
PMID- 35991858
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220823
IS  - 2561-4444 (Electronic)
IS  - 2561-4444 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Spring
TI  - Strategies to achieve population control of HCV infection: results of a
      multidisciplinary focus group.
PG  - 224-231
LID - 10.3138/canlivj-2019-0017 [doi]
AB  - Background: To meet the World Health Organization's ambitious target to eradicate
      hepatitis C virus (HCV) by 2030, a comprehensive strategy is needed in Canada to 
      ensure everyone infected with HCV is identified, diagnosed, and treated. The
      purpose of this study was to highlight the barriers to any strategy aimed at
      achieving this goal. Methods: A focus group was formed (N = 11) that consisted of
      clinicians, patients, drug program budget managers, industry representatives, and
      individuals from provincial public health and federal agencies in Canada. The
      group met in person for a half-day focus group session. Two discussions were
      held: one on future barriers related to HCV treatment and one related to HCV
      screening. A grounded theory approach was used to elicit key themes from the
      day's discussion. Results: Nine themes were identified. Four themes related to
      HCV screening: public awareness and engagement, resource infrastructure and
      capacity, heterogeneity between provinces, and mechanisms of screening. Three
      themes related to HCV treatment: access to treatment and illicit drug use,
      linkage to care, and predicting post-treatment outcomes. Two overarching themes
      that contributed to most discussions were a focus on baby boomers versus persons 
      who inject drugs and the need for further education and training. Conclusion: The
      views and findings extracted from this qualitative research complement proposals 
      of national strategies from organizations such as the Canadian Network on
      Hepatitis C. This work highlights the financial, logistical, and ethical
      constraints that need to be tackled to make HCV elimination proposals a reality.
CI  - Copyright (c) 2020 Canadian Association for the Study of the Liver.
FAU - Haines, Alexander G
AU  - Haines AG
AD  - Toronto Health Economics and Technology Assessment Collaborative, Toronto,
      Ontario, Canada.
FAU - Mendlowitz, Andrew B
AU  - Mendlowitz AB
AD  - Toronto Health Economics and Technology Assessment Collaborative, Toronto,
      Ontario, Canada.
AD  - University of Toronto, Toronto, Ontario, Canada.
FAU - Wong, William Wl
AU  - Wong WW
AD  - School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
FAU - Krahn, Murray
AU  - Krahn M
AD  - Toronto Health Economics and Technology Assessment Collaborative, Toronto,
      Ontario, Canada.
AD  - University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - Canada
TA  - Can Liver J
JT  - Canadian liver journal
JID - 101778326
PMC - PMC9202787
OTO - NOTNLM
OT  - HCV
OT  - focus group
OT  - implementation
OT  - policy
OT  - screening
COIS- Dr Wong reports grants from the Canadian Liver Foundation and the Ontario
      Ministry of Research, Innovation, and Science Early Researcher Award during the
      conduct of the study; Mr Mendlowitz reports grants from the Canadian Liver
      Foundation, an Ontario Early Researcher Award, and a Tier 1 CRC Chair in Health
      Technology Assessment during the conduct of the study; Dr Krahn reports a grant
      from the Canadian Liver Foundation and a Tier 1 CRC Chair in Health Technology
      Assessment during the conduct of the study; Mr Haines reports grants from the
      Canadian Liver Foundation, and Ontario Early Researcher Award, and a from Tier 1 
      CRC Chair in Health Technology Assessment, during the conduct of the study.
EDAT- 2020/06/04 00:00
MHDA- 2020/06/04 00:01
CRDT- 2022/08/22 04:17
PHST- 2019/07/05 00:00 [received]
PHST- 2019/11/11 00:00 [accepted]
PHST- 2022/08/22 04:17 [entrez]
PHST- 2020/06/04 00:00 [pubmed]
PHST- 2020/06/04 00:01 [medline]
AID - 10.3138/canlivj-2019-0017 [doi]
PST - epublish
SO  - Can Liver J. 2020 Jun 4;3(2):224-231. doi: 10.3138/canlivj-2019-0017. eCollection
      2020 Spring.


PMID- 35519823
OWN - NLM
STAT- MEDLINE
DCOM- 20220509
LR  - 20220716
IS  - 2399-4908 (Electronic)
IS  - 2399-4908 (Linking)
VI  - 5
IP  - 3
DP  - 2020
TI  - Participant acceptability of digital footprint data collection strategies: an
      exemplar approach to participant engagement and involvement in the ALSPAC birth
      cohort study.
PG  - 1728
LID - 10.23889/ijpds.v7i1.1728 [doi]
AB  - Introduction: Digital footprint records - the tracks and traces amassed by
      individuals as a result of their interactions with the internet, digital devices 
      and services - can provide ecologically valid data on individual behaviours.
      These could enhance longitudinal population study databanks; but few UK
      longitudinal studies are attempting this. When using novel sources of data, study
      managers must engage with participants in order to develop ethical data
      processing frameworks that facilitate data sharing whilst safeguarding
      participant interests. Objectives: This paper aims to summarise the participant
      involvement approach used by the ALSPAC birth cohort study to inform the
      development of a framework for using linked participant digital footprint data,
      and provide an exemplar for other data linkage infrastructures. Methods: The
      paper synthesises five qualitative forms of inquiry. Thematic analysis was used
      to code transcripts for common themes in relation to conditions associated with
      the acceptability of sharing digital footprint data for longitudinal research.
      Results: We identified six themes: participant understanding; sensitivity of
      location data; concerns for third parties; clarity on data granularity;
      mechanisms of data sharing and consent; and trustworthiness of the organisation. 
      For cohort members to consider the sharing of digital footprint data acceptable, 
      they require information about the value, validity and risks; control over
      sharing elements of the data they consider sensitive; appropriate mechanisms to
      authorise or object to their records being used; and trust in the organisation.
      Conclusion: Realising the potential for using digital footprint records within
      longitudinal research will be subject to ensuring that this use of personal data 
      is acceptable; and that rigorously controlled population data science benefiting 
      the public good is distinguishable from the misuse and lack of personal control
      of similar data within other settings. Participant co-development informs the
      ethical-governance framework for these novel linkages in a manner which is
      acceptable and does not undermine the role of the trusted data custodian.
FAU - Shiells, Kate
AU  - Shiells K
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, University of
      Bristol, Bristol, UK.
AD  - Alan Turing Institute, London, UK.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Di Cara, Nina
AU  - Di Cara N
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Skatova, Anya
AU  - Skatova A
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, University of
      Bristol, Bristol, UK.
AD  - Alan Turing Institute, London, UK.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Davis, Oliver S P
AU  - Davis OSP
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, University of
      Bristol, Bristol, UK.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Haworth, Claire M A
AU  - Haworth CMA
AD  - Alan Turing Institute, London, UK.
AD  - School of Psychological Science, University of Bristol, Bristol, UK.
FAU - Skinner, Andy L
AU  - Skinner AL
AD  - Medical Research Council (MRC) Integrative Epidemiology Unit, University of
      Bristol, Bristol, UK.
AD  - Integrative Cancer Epidemiology Programme, University of Bristol, Bristol, UK.
FAU - Thomas, Richard
AU  - Thomas R
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Tanner, Alastair R
AU  - Tanner AR
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Macleod, John
AU  - Macleod J
AD  - Avon Longitudinal Study of Parents and Children, Population Health Sciences,
      Bristol Medical School, University of Bristol, Bristol, UK.
AD  - NIHR Applied Research Collaboration West, Bristol, UK.
FAU - Timpson, Nicholas J
AU  - Timpson NJ
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
AD  - Avon Longitudinal Study of Parents and Children, Population Health Sciences,
      Bristol Medical School, University of Bristol, Bristol, UK.
FAU - Boyd, Andy
AU  - Boyd A
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
AD  - Avon Longitudinal Study of Parents and Children, Population Health Sciences,
      Bristol Medical School, University of Bristol, Bristol, UK.
AD  - CLOSER longitudinal study consortium, University College London, London, UK.
LA  - eng
GR  - 217065/Z/19/Z/WT_/Wellcome Trust/United Kingdom
GR  - WT086118/Z/08/Z/WT_/Wellcome Trust/United Kingdom
GR  - 202802/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - MC_UU_00011/6/MRC_/Medical Research Council/United Kingdom
GR  - C18281/A19169 /CRUK_/Cancer Research UK/United Kingdom
GR  - C18281/A29019/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220316
PL  - Wales
TA  - Int J Popul Data Sci
JT  - International journal of population data science
JID - 101737740
SB  - IM
MH  - *Birth Cohort
MH  - Cohort Studies
MH  - Data Collection
MH  - Humans
MH  - *Information Dissemination
MH  - Qualitative Research
PMC - PMC9053133
OTO - NOTNLM
OT  - *ALSPAC
OT  - *attitudes
OT  - *co-development
OT  - *data linkage
OT  - *digital footprint data
OT  - *engagement
OT  - *longitudinal research
OT  - *participant involvement
OT  - *safeguards
COIS- Statement of conflicts of interests: None to be declared.
EDAT- 2022/05/07 06:00
MHDA- 2022/05/10 06:00
CRDT- 2022/05/06 06:08
PHST- 2022/05/06 06:08 [entrez]
PHST- 2022/05/07 06:00 [pubmed]
PHST- 2022/05/10 06:00 [medline]
AID - 10.23889/ijpds.v7i1.1728 [doi]
AID - S2399490821017286 [pii]
PST - epublish
SO  - Int J Popul Data Sci. 2022 Mar 16;5(3):1728. doi: 10.23889/ijpds.v7i1.1728.
      eCollection 2020.


PMID- 34935894
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 0272-9490 (Print)
IS  - 0272-9490 (Linking)
VI  - 74
IP  - Supplement_3
DP  - 2020 Nov 1
TI  - AOTA 2020 Occupational Therapy Code of Ethics.
PG  - 7413410005p1-7413410005p13
LID - 10.5014/ajot.2020.74S3006 [doi]
AB  - The 2020 Occupational Therapy Code of Ethics (the Code) of the American
      Occupational Therapy Association (AOTA) is designed to reflect the dynamic nature
      of the occupational therapy profession, the evolving health care environment, and
      emerging technologies that can present potential ethical concerns in practice,
      research, education, and policy. AOTA members are committed to promoting
      inclusion, participation, safety, and well-being for all recipients of service in
      various stages of life, health, and illness and to empowering all beneficiaries
      of service to meet their occupational needs. Recipients of services may be
      persons, groups, families, organizations, communities, or populations (AOTA,
      2020).
CI  - Copyright (c) 2020 by the American Occupational Therapy Association, Inc.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Occup Ther
JT  - The American journal of occupational therapy : official publication of the
      American Occupational Therapy Association
JID - 7705978
SB  - IM
MH  - Codes of Ethics
MH  - Humans
MH  - *Occupational Therapy
MH  - Organizations
MH  - United States
EDAT- 2021/12/23 06:00
MHDA- 2021/12/25 06:00
CRDT- 2021/12/22 12:46
PHST- 2021/12/22 12:46 [entrez]
PHST- 2021/12/23 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
AID - 6691 [pii]
AID - 10.5014/ajot.2020.74S3006 [doi]
PST - ppublish
SO  - Am J Occup Ther. 2020 Nov 1;74(Supplement_3):7413410005p1-7413410005p13. doi:
      10.5014/ajot.2020.74S3006.


PMID- 34935892
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 0272-9490 (Print)
IS  - 0272-9490 (Linking)
VI  - 74
IP  - Supplement_3
DP  - 2020 Nov 1
TI  - Guidelines for Reentry Into the Field of Occupational Therapy.
PG  - 7413410010p1-7413410010p3
LID - 10.5014/ajot.2020.74S3003 [doi]
AB  - These guidelines are designed to assist occupational therapists and occupational 
      therapy assistants who have left the field of occupational therapy for 24 months 
      or more and have chosen to return to the profession and deliver occupational
      therapy services. The guidelines represent minimum recommendations only and are
      designed to support practitioners in meeting their ethical obligation to maintain
      high standards of competence and to provide guidance to regulatory bodies.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Occup Ther
JT  - The American journal of occupational therapy : official publication of the
      American Occupational Therapy Association
JID - 7705978
SB  - IM
MH  - Humans
MH  - Occupational Therapists
MH  - *Occupational Therapy
EDAT- 2021/12/23 06:00
MHDA- 2021/12/25 06:00
CRDT- 2021/12/22 12:46
PHST- 2021/12/22 12:46 [entrez]
PHST- 2021/12/23 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
AID - 6688 [pii]
AID - 10.5014/ajot.2020.74S3003 [doi]
PST - ppublish
SO  - Am J Occup Ther. 2020 Nov 1;74(Supplement_3):7413410010p1-7413410010p3. doi:
      10.5014/ajot.2020.74S3003.


PMID- 34756222
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220531
IS  - 2214-5532 (Electronic)
IS  - 2214-5524 (Linking)
VI  - 27
DP  - 2020 Nov
TI  - Population analysis of space travelers.
PG  - 1-5
LID - S2214-5524(20)30044-4 [pii]
LID - 10.1016/j.lssr.2020.06.003 [doi]
AB  - Although many space missions have been completed in the last 60 years, space
      exploration is still technologically and medically challenging. While large-scale
      medical studies are impossible in space travelers, meta-analysis allows combining
      data from small crews that participated in space missions over several decades.
      Our primary objective was to examine space-travelers' sociodemographic
      characteristics and spaceflight activities, and their changes with time from the 
      first spaceflight. Our secondary objective was to evaluate the publication
      practices to assess data availability for health-related meta-analytic studies.
      Based on state-funded space agencies used as primary sources, and third-party
      websites used as secondary sources, 565 humans (501 males/64 females) have
      currently completed spaceflight. The average age of space-travelers increased
      from 34+/-4 in the 1960s to 45+/-4 in the 2010s. While the duration of space
      missions has increased consistently, the number of missions per year varied in
      correlation with technological events. Using papers identified in the systematic 
      review of bone health in astronauts, we examined the changes in reporting
      practices with time. The reported sample size varied from 1 to 58 people, in
      total providing data for 148 individuals. Data confidentiality significantly
      improved with time; however, the corresponding decrease in the availability of
      individual parameters did not allow stratification even by age, sex, and mission 
      duration. Thus, space travelers represent a diverse population suitable for
      comparative studies, however, it is important to develop reporting practices that
      ensure consistent, transparent, and ethical presentation of outcomes to support
      meta-analyses that are critical for understanding the scope of
      spaceflight-induced health issues.
CI  - Copyright (c) 2020 The Committee on Space Research (COSPAR). Published by
      Elsevier Ltd. All rights reserved.
FAU - Corlett, Tatsuya
AU  - Corlett T
AD  - Shriners Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, QC H4A
      0A9, Canada. Electronic address: tatsuya.corlett@mail.mcgill.ca.
FAU - Stavnichuk, Mariya
AU  - Stavnichuk M
AD  - Shriners Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, QC H4A
      0A9, Canada; Department of Biomedical Engineering, McGill University, Montreal,
      QC, Canada. Electronic address: mariya.stavnichuk@mail.mcgill.ca.
FAU - Komarova, Svetlana V
AU  - Komarova SV
AD  - Shriners Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, QC H4A
      0A9, Canada; Department of Biomedical Engineering, McGill University, Montreal,
      QC, Canada; Faculty of Dentistry, McGill University, Montreal, QC, Canada.
      Electronic address: svetlana.komarova@mcgill.ca.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - Netherlands
TA  - Life Sci Space Res (Amst)
JT  - Life sciences in space research
JID - 101632373
SB  - IM
MH  - *Astronauts
MH  - Female
MH  - Humans
MH  - Male
MH  - *Space Flight
OTO - NOTNLM
OT  - Astronauts
OT  - Cosmonauts
OT  - Demographics
OT  - History
OT  - Population
OT  - Space flight
EDAT- 2021/11/11 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/11/10 13:16
PHST- 2020/01/20 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/06/13 00:00 [accepted]
PHST- 2021/11/10 13:16 [entrez]
PHST- 2021/11/11 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - S2214-5524(20)30044-4 [pii]
AID - 10.1016/j.lssr.2020.06.003 [doi]
PST - ppublish
SO  - Life Sci Space Res (Amst). 2020 Nov;27:1-5. doi: 10.1016/j.lssr.2020.06.003. Epub
      2020 Jun 16.


PMID- 34752527
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211111
IS  - 8755-1225 (Print)
IS  - 1549-4810 (Linking)
VI  - 36
IP  - 5
DP  - 2020 Oct
TI  - Evaluation of the Management of Acute Exacerbations of Chronic Obstructive
      Pulmonary Disease in Hospitalized Patients.
PG  - 187-195
LID - 10.1177/8755122520942762 [doi]
AB  - Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
      are estimated to cost $1.5 billion annually in Canada. Previous studies have
      shown that barely half of all patients receive ideal care in hospitals.
      Deviations from guideline-defined optimal care lead to longer hospital stays,
      readmissions, and increased mortality. Objective: To determine the proportion of 
      patients admitted to hospital for AECOPD who received treatment adherent to
      guidelines. Methods: A retrospective cohort study was conducted with ethics
      approval from the University of British Columbia Clinical Research Ethics Board. 
      Patients hospitalized for >/=24 hours with an AECOPD at a tertiary care center
      and a community hospital were assessed. Guideline-adherent treatment was defined 
      as appropriate use of supplemental oxygen, inhaled bronchodilators, systemic
      corticosteroids, antibiotics, venous thromboembolism prophylaxis,
      initiation/continuation of nicotine replacement therapy for current smokers, and 
      vaccination optimization, reflecting international standards of care. Outcomes
      were assessed using descriptive statistics. Results: A random sample of 210
      patients were selected of which 99 met inclusion criteria. Only 4% received
      therapy that met all recommendations. Differences in management were found
      between sites, specifically the appropriate use of bronchodilators,
      corticosteroids, antibiotics, and supplemental oxygen. Venous thromboembolism
      prophylaxis and smoking cessation rates were 97% and 94%, respectively, at the
      tertiary care center, compared with 73% and 100% at the community hospital.
      Additionally, less than half of all patients had their immunization history
      verified. Conclusion: Gaps in the inpatient management of AECOPD continue to
      exist. Initiatives must be targeted to optimize management and reduce the burden 
      of the disease.
CI  - (c) The Author(s) 2020.
FAU - Kumar, Jessica
AU  - Kumar J
AD  - University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Sy, Isabelle
AU  - Sy I
AD  - University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Wei, Felix
AU  - Wei F
AD  - University of British Columbia, Vancouver, British Columbia, Canada.
FAU - de Lemos, Jane
AU  - de Lemos J
AD  - Richmond Hospital, Vancouver Coastal Health, Richmond, British Columbia, Canada.
FAU - Loh, Gabriel
AU  - Loh G
AD  - Richmond Hospital, Vancouver Coastal Health, Richmond, British Columbia, Canada.
FAU - Harbin, Megan
AU  - Harbin M
AD  - Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British
      Columbia, Canada.
FAU - Dahri, Karen
AU  - Dahri K
AUID- ORCID: https://orcid.org/0000-0001-5653-6056
AD  - University of British Columbia, Vancouver, British Columbia, Canada.
AD  - Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British
      Columbia, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - United States
TA  - J Pharm Technol
JT  - The Journal of pharmacy technology : jPT : official publication of the
      Association of Pharmacy Technicians
JID - 8504643
PMC - PMC7453477
OTO - NOTNLM
OT  - COPD
OT  - acute exacerbations of COPD
OT  - guideline adherence
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2021/11/10 06:00
MHDA- 2021/11/10 06:01
CRDT- 2021/11/09 17:30
PHST- 2021/11/09 17:30 [entrez]
PHST- 2021/11/10 06:00 [pubmed]
PHST- 2021/11/10 06:01 [medline]
AID - 10.1177/8755122520942762 [doi]
AID - 10.1177_8755122520942762 [pii]
PST - ppublish
SO  - J Pharm Technol. 2020 Oct;36(5):187-195. doi: 10.1177/8755122520942762. Epub 2020
      Aug 26.


PMID- 34737680
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
IS  - 1542-5177 (Print)
IS  - 1542-5177 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Dec
TI  - A New Governance Approach to Regulating Human Genome Editing.
PG  - 107-141
AB  - For years, genomic medicine-medicine based on the growing understanding of the
      genetic contribution to many diseases and conditions-has been hailed as the
      future of medical treatment, but it has thus far had limited effect on day-to-day
      medical practice. The ultimate goal of genomic medicine has always been the
      ability not just to identify dangerous gene mutations, but to fix them. Now
      CRISPR and related genome-editing technologies may have the potential to provide 
      a safe and effective way to repair dangerous mutations. In the wake of ethically 
      dubious experiments with human embryos in China, the international governance of 
      human genome editing is emerging as an urgent topic for scientists, regulators,
      and the public. Efforts to develop a governance model are underway at national
      and international levels. These efforts are the subject of multiple initiatives
      by national and international health and science organizations and are topics of 
      discussion at scientific conferences, summits, and meetings. This Article reports
      on the Authors' multi-year, interdisciplinary project to identify and investigate
      the practical, ethical, and policy considerations that are emerging as the
      greatest concerns about human genome editing, and ultimately to develop policy
      options. The project involves monitoring the discussions of groups, both
      government-sponsored and private, that are considering how genome editing should 
      be governed; observing conferences where the topic is discussed; analyzing
      emerging policy reports by national and international bodies; and interviewing a 
      wide range of stakeholders, including scientists, ethicists, and those who make
      and comment on public policy. The Article identifies several stakeholder concerns
      that are especially prominent in the research to date and begins to explore the
      implications of these concerns for alternative models of governance. There are
      current indications that, for practical purposes, a focus on "soft," hybrid forms
      of governance based on networks of multiple public and private stakeholders may
      turn out to be the most promising course to pursue. The "new governance" paradigm
      developed in the corporate and financial sectors offers a useful model for
      understanding the dynamics of this approach.
FAU - Conley, John M
AU  - Conley JM
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Davis, Arlene M
AU  - Davis AM
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Henderson, Gail E
AU  - Henderson GE
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Juengst, Eric T
AU  - Juengst ET
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Meagher, Karen M
AU  - Meagher KM
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Walker, Rebecca L
AU  - Walker RL
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Waltz, Margaret
AU  - Waltz M
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
FAU - Cadigan, Jean
AU  - Cadigan J
AD  - John M. Conley is the William Rand Kenan, Junior Professor at the University of
      North Carolina School of Law, and the corresponding author for this
      Article.Arlene M. Davis is an Associate Professor of Social Medicine at the
      University of North Carolina School of Medicine. Gail E. Henderson is the
      Director of the Center for Genomic and Society, and a professor in in the
      Department of Social Medicine at the University of North Carolina School of
      Medicine. Eric T. Juengst is the Director of the Center for Bioethics, a
      Professor of Social Medicine, and a Professor of Genetics in the University of
      North Carolina School of Medicine. Karen M. Meagher is an Assistant Professor in 
      the Biomedical Ethics Research Program at the Mayo Clinic. Rebecca L. Walker is a
      professor in the Department of Social Medicine, Department of Philosophy, and
      Center for Bioethics at the University of North Carolina at Chapel Hill.
      Margarete Waltz is a Research Assistant in the Department of Social Medicine at
      University of North Carolina School of Medicine. Jean Cadigan is an Associate
      Professor in the Department of Social Medicine, and a part of the core faculty at
      the Center for Bioethics at the University of North Carolina at Chapel Hill.
LA  - eng
GR  - R01 HG010661/HG/NHGRI NIH HHS/United States
GR  - UL1 TR002489/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - N C J Law Technol
JT  - North Carolina journal of law & technology
JID - 101641147
PMC - PMC8565716
MID - NIHMS1748795
EDAT- 2021/11/06 06:00
MHDA- 2021/11/06 06:01
CRDT- 2021/11/05 06:47
PHST- 2021/11/05 06:47 [entrez]
PHST- 2021/11/06 06:00 [pubmed]
PHST- 2021/11/06 06:01 [medline]
PST - ppublish
SO  - N C J Law Technol. 2020 Dec;22(2):107-141.


PMID- 34723107
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2524-5309 (Electronic)
IS  - 2524-5295 (Linking)
VI  - 3
IP  - 4
DP  - 2020
TI  - Aligning AI Optimization to Community Well-Being.
PG  - 443-463
LID - 10.1007/s42413-020-00086-3 [doi]
AB  - This paper investigates incorporating community well-being metrics into the
      objectives of optimization algorithms and the teams that build them. It documents
      two cases where a large platform appears to have modified their system to this
      end. Facebook incorporated "well-being" metrics in 2017, while YouTube began
      integrating "user satisfaction" metrics around 2015. Metrics tied to community
      well-being outcomes could also be used in many other systems, such as a news
      recommendation system that tries to increase exposure to diverse views, or a
      product recommendation system that opstimizes for the carbon footprint of
      purchased products. Generalizing from these examples and incorporating insights
      from participatory design and AI governance leads to a proposed process for
      integrating community well-being into commercial AI systems: identify and involve
      the affected community, choose a useful metric, use this metric as a managerial
      performance measure and/or an algorithmic objective, and evaluate and adapt to
      outcomes. Important open questions include the best approach to community
      participation and the uncertain business effects of this process.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Stray, Jonathan
AU  - Stray J
AUID- ORCID: https://orcid.org/0000-0003-4467-1239
AD  - Partnership on AI, San Francisco, CA USA.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - Switzerland
TA  - Int J Community Wellbeing
JT  - International journal of community well-being
JID - 9918284170606676
PMC - PMC7610010
OTO - NOTNLM
OT  - AI ethics
OT  - Artificial intelligence
OT  - Community well-being
OT  - Corporate social responsibility
OT  - Optimization
COIS- Conflict of InterestThe author declares that they have no conflicts of interest.
EDAT- 2021/11/02 06:00
MHDA- 2021/11/02 06:01
CRDT- 2021/11/01 09:32
PHST- 2020/02/07 00:00 [received]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2021/11/02 06:01 [medline]
PHST- 2021/11/01 09:32 [entrez]
AID - 10.1007/s42413-020-00086-3 [doi]
AID - 86 [pii]
PST - ppublish
SO  - Int J Community Wellbeing. 2020;3(4):443-463. doi: 10.1007/s42413-020-00086-3.
      Epub 2020 Nov 4.


PMID- 34713062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211208
IS  - 2673-253X (Electronic)
IS  - 2673-253X (Linking)
VI  - 2
DP  - 2020
TI  - Toward an Ethical Framework for the Text Mining of Social Media for Health
      Research: A Systematic Review.
PG  - 592237
LID - 10.3389/fdgth.2020.592237 [doi]
AB  - Background: Text-mining techniques are advancing all the time and vast corpora of
      social media text can be analyzed for users' views and experiences related to
      their health. There is great promise for new insights into health issues such as 
      drug side effects and spread of disease, as well as patient experiences of health
      conditions and health care. However, this emerging field lacks ethical consensus 
      and guidance. We aimed to bring together a comprehensive body of opinion, views, 
      and recommendations in this area so that academic researchers new to the field
      can understand relevant ethical issues. Methods: After registration of a protocol
      in PROSPERO, three parallel systematic searches were conducted, to identify
      academic articles comprising commentaries, opinion, and recommendations on
      ethical practice in social media text mining for health research and gray
      literature guidelines and recommendations. These were integrated with social
      media users' views from qualitative studies. Papers and reports that met the
      inclusion criteria were analyzed thematically to identify key themes, and an
      overarching set of themes was deduced. Results: A total of 47 reports and
      articles were reviewed, and eight themes were identified. Commentators suggested 
      that publicly posted social media data could be used without consent and formal
      research ethics approval, provided that the anonymity of users is ensured,
      although we note that privacy settings are difficult for users to navigate on
      some sites. Even without the need for formal approvals, we note ethical issues:
      to actively identify and minimize possible harms, to conduct research for public 
      benefit rather than private gain, to ensure transparency and quality of data
      access and analysis methods, and to abide by the law and terms and conditions of 
      social media sites. Conclusion: Although social media text mining can often
      legally and reasonably proceed without formal ethics approvals, we recommend
      improving ethical standards in health-related research by increasing transparency
      of the purpose of research, data access, and analysis methods; consultation with 
      social media users and target groups to identify and mitigate against potential
      harms that could arise; and ensuring the anonymity of social media users.
CI  - Copyright (c) 2021 Ford, Shepherd, Jones and Hassan.
FAU - Ford, Elizabeth
AU  - Ford E
AD  - Department of Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, United Kingdom.
FAU - Shepherd, Scarlett
AU  - Shepherd S
AD  - Department of Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, United Kingdom.
FAU - Jones, Kerina
AU  - Jones K
AD  - Population Data Science, Medical School, Swansea University, Swansea, United
      Kingdom.
FAU - Hassan, Lamiece
AU  - Hassan L
AD  - Division of Informatics, Imaging & Data Sciences, University of Manchester,
      Manchester, United Kingdom.
LA  - eng
GR  - MR/S004025/1/MRC_/Medical Research Council/United Kingdom
PT  - Systematic Review
DEP - 20210126
PL  - Switzerland
TA  - Front Digit Health
JT  - Frontiers in digital health
JID - 101771889
PMC - PMC8521805
OTO - NOTNLM
OT  - ethics
OT  - health research
OT  - natural language processing
OT  - social media
OT  - text-mining
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/10/30 06:00
MHDA- 2021/10/30 06:01
CRDT- 2021/10/29 06:34
PHST- 2020/08/06 00:00 [received]
PHST- 2020/12/18 00:00 [accepted]
PHST- 2021/10/29 06:34 [entrez]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2021/10/30 06:01 [medline]
AID - 10.3389/fdgth.2020.592237 [doi]
PST - epublish
SO  - Front Digit Health. 2021 Jan 26;2:592237. doi: 10.3389/fdgth.2020.592237.
      eCollection 2020.


PMID- 34713030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211030
IS  - 2673-253X (Electronic)
IS  - 2673-253X (Linking)
VI  - 2
DP  - 2020
TI  - Real-Time Assessment of Stress and Stress Response Using Digital Phenotyping: A
      Study Protocol.
PG  - 544418
LID - 10.3389/fdgth.2020.544418 [doi]
AB  - Background: Stress is a complex phenomenon that may have a negative influence on 
      health and well-being; consequently, it plays a pivotal role in mental health.
      Although the incidence of mental disorders has been continuously rising,
      development of prevention and treatment methods has been rather slow. Through the
      ubiquitous presence of smartphones and wearable devices, people can monitor
      stress parameters in everyday life. However, the reliability and validity of such
      monitoring are still unsatisfactory. Methods: The aim of this trial is to find a 
      relationship between psychological stress and saliva cortisol levels on the one
      hand and physiological parameters measured by smartphones in combination with a
      commercially available wearable device on the other. Participants include cohorts
      of individuals with and without a psychiatric disorder. The study is conducted in
      two settings: one naturalistic and one a controlled laboratory environment,
      combining ecological momentary assessment (EMA) and digital phenotyping (DP). EMA
      is used for the assessment of challenging and stressful situations coincidentally
      happening during a whole observation week. DP is used during a controlled stress 
      situation with the Trier Social Stress Test (TSST) as a standardized
      psychobiological paradigm. Initially, participants undergo a complete
      psychological screening and profiling using a standardized psychometric test
      battery. EMA uses a smartphone application, and the participants keep a diary
      about their daily routine, activities, well-being, sleep, and difficult and
      stressful situations they may encounter. DP is conducted through wearable devices
      able to continuously monitor physiological parameters (i.e., heart rate, heart
      rate variability, skin conductivity, temperature, movement and acceleration).
      Additionally, saliva cortisol samples are repeatedly taken. The TSST is conducted
      with continuous measurement of the same parameters measured during the EMA.
      Discussion: We aim to identify valid and reliable digital biomarkers for stress
      and stress reactions. Furthermore, we expect to find a way of early detection of 
      psychological stress in order to evolve new opportunities for interventions
      reducing stress. That may allow us to find new ways of treating and preventing
      mental disorders. Trial Registration: The competing ethics committee of the
      Canton of Zurich, Switzerland, approved the study protocol V05.1 May 28, 2019
      [BASEC: 2019-00814]; the trial was registered at ClinicalTrials.gov [NCT04100213]
      on September 19, 2019.
CI  - Copyright (c) 2020 Egger, Knorr, Bobes, Bernstein, Seifritz and Vetter.
FAU - Egger, Stephan T
AU  - Egger ST
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, 
      Psychiatric University Hospital of Zurich, University of Zurich, Zurich,
      Switzerland.
AD  - Department of Psychiatry, Faculty of Medicine, University of Oviedo, CIBERSAM,
      Oviedo, Spain.
FAU - Knorr, Marius
AU  - Knorr M
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, 
      Psychiatric University Hospital of Zurich, University of Zurich, Zurich,
      Switzerland.
FAU - Bobes, Julio
AU  - Bobes J
AD  - Department of Psychiatry, Faculty of Medicine, University of Oviedo, CIBERSAM,
      Oviedo, Spain.
FAU - Bernstein, Abraham
AU  - Bernstein A
AD  - Department of Informatics, University of Zurich, Zurich, Switzerland.
FAU - Seifritz, Erich
AU  - Seifritz E
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, 
      Psychiatric University Hospital of Zurich, University of Zurich, Zurich,
      Switzerland.
FAU - Vetter, Stefan
AU  - Vetter S
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, 
      Psychiatric University Hospital of Zurich, University of Zurich, Zurich,
      Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04100213
PT  - Journal Article
DEP - 20201015
PL  - Switzerland
TA  - Front Digit Health
JT  - Frontiers in digital health
JID - 101771889
PMC - PMC8521792
OTO - NOTNLM
OT  - cortisol
OT  - digital phenotyping
OT  - ecological moment assessment
OT  - stress
OT  - trier social stress test
EDAT- 2021/10/30 06:00
MHDA- 2021/10/30 06:01
CRDT- 2021/10/29 06:34
PHST- 2020/03/20 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2021/10/29 06:34 [entrez]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2021/10/30 06:01 [medline]
AID - 10.3389/fdgth.2020.544418 [doi]
PST - epublish
SO  - Front Digit Health. 2020 Oct 15;2:544418. doi: 10.3389/fdgth.2020.544418.
      eCollection 2020.


PMID- 34691512
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211026
IS  - 2053-714X (Electronic)
IS  - 2053-714X (Linking)
VI  - 7
IP  - 11
DP  - 2020 Nov
TI  - Research ethics: a safeguard for advanced technologies.
PG  - 1787-1792
LID - 10.1093/nsr/nwz133 [doi]
AB  - With the fast development of cutting-edge technologies and their greater
      integration into human life, more ethical challenges emerge. The problem became
      more salient when the world's first genetically edited babies were born in China 
      in violation of existing ethical rules. Although the responsible researcher He
      Jiankui was sentenced for imprisonment for three years last December, it is still
      necessary to examine the current status of research ethics and the challenges in 
      China. Has China set up a sophisticated research ethics system? For research
      ethics and their implementation in China, are there unique national
      characteristics? Can the dominant ethics principles primarily developed from life
      science research be equally adopted in the emerging artificial intelligence
      research and development? At an online forum organized by National Science Review
      (NSR) and through subsequent correspondences among forum participants, NSR
      Executive Editor-in-Chief Mu-ming Poo and guest moderator Hepeng Jia asked three 
      scientists and three bioethicists or philosophers of science and technology in
      the field to examine the dynamic development of research ethics in China. Weiwen 
      DuanPhilosopher of Science and Technology at Chinese Academy of Social Sciences, 
      Beijing, China Junjiu HuangLife scientist focused on genetics at Sun Yat-sen
      University, Guangzhou, China Renzong QiuBioethicist at Chinese Academy of Social 
      Sciences, Beijing, China Qiang SunLife scientist and the principal investigator
      (PI) of clone monkey program at Shanghai Institute of Neuroscience, Chinese
      Academy of Sciences, Shanghai, China Yi ZengArtificial intelligence scientist at 
      Institute of Automation, Chinese Academy of Sciences, Beijing, China Xiaomei
      ZhaiBioethicist at Chinese Academy of Medical Sciences/Peking Union Medical
      College, Beijing, China Mu-ming Poo (Chair)Neurobiologist at Center for
      Excellence in Brain Science and Intelligence Technology, Chinese Academy of
      Sciences, Shanghai, China Hepeng Jia (Co-chair)Professor of Science Communication
      at Soochow University, Suzhou, China.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of China
      Science Publishing & Media Ltd.
FAU - Jia, Hepeng
AU  - Jia H
AD  - Professor of science communication, Soochow University and a freelancing science 
      writer for NSR.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - China
TA  - Natl Sci Rev
JT  - National science review
JID - 101633095
PMC - PMC8290955
EDAT- 2021/10/26 06:00
MHDA- 2021/10/26 06:01
CRDT- 2021/10/25 06:30
PHST- 2021/10/25 06:30 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2021/10/26 06:01 [medline]
AID - 10.1093/nsr/nwz133 [doi]
AID - nwz133 [pii]
PST - epublish
SO  - Natl Sci Rev. 2020 Oct 16;7(11):1787-1792. doi: 10.1093/nsr/nwz133. eCollection
      2020 Nov.


PMID- 34676086
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211023
IS  - 2053-714X (Electronic)
IS  - 2053-714X (Linking)
VI  - 7
IP  - 12
DP  - 2020 Dec
TI  - Yi Zeng: promoting good governance of artificial intelligence.
PG  - 1954-1956
LID - 10.1093/nsr/nwaa255 [doi]
AB  - Artificial intelligence (AI) has developed quickly in recent years, with
      applications expanding from automatic driving and smart manufacturing to personal
      healthcare and algorithm-based social media utilization. During the COVID-19
      pandemic, AI has played an essential role in identifying suspected infections,
      ensuring epidemic surveillance and quickening drug screening. However, many
      questions accompanied AI's development. How to protect citizens' privacy and
      national information security? What measures can help AI learn and practice good 
      human behaviors and avoid unethical use of AI technologies? To answer these
      questions, Nation Science Review (NSR) interviewed Yi Zeng, Professor and Deputy 
      Director at the Research Center for Brain-inspired Artificial Intelligence at the
      Institute of Automation, Chinese Academy of Sciences (CAS). He is a board member 
      for the National Governance Committee of Next-Generation Artificial Intelligence 
      affiliated to the Ministry of Science and Technology of China (MOST). Zeng is
      also in AI ethics expert groups at the World Health Organization and the United
      Nations Educational, Scientific, and Cultural Organization (UNESCO). He jointly
      led the drafting of Beijing AI Principles (2019) and the National Governance
      Principles of New Generation AI of China (GPNGAI, 2019).
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of China
      Science Publishing & Media Ltd.
FAU - Jia, Hepeng
AU  - Jia H
AD  - Science Communication at Soochow University and a freelancing science writer for 
      NSR.
LA  - eng
PT  - Journal Article
DEP - 20201024
PL  - China
TA  - Natl Sci Rev
JT  - National science review
JID - 101633095
PMC - PMC7665600
EDAT- 2021/10/23 06:00
MHDA- 2021/10/23 06:01
CRDT- 2021/10/22 06:50
PHST- 2021/10/22 06:50 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/10/23 06:01 [medline]
AID - 10.1093/nsr/nwaa255 [doi]
AID - nwaa255 [pii]
PST - epublish
SO  - Natl Sci Rev. 2020 Oct 24;7(12):1954-1956. doi: 10.1093/nsr/nwaa255. eCollection 
      2020 Dec.


PMID- 34660847
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211023
IS  - 2332-2136 (Print)
VI  - 6
IP  - 3
DP  - 2020 Sep
TI  - Leading the people and leading the work: Practical considerations for ethical
      research.
PG  - 257-270
LID - 10.1037/tps0000260 [doi]
AB  - Scientific work is demanding and complex, requiring those leading research to be 
      simultaneously innovative and ethical in their work. Along with this, those
      leading scientific teams need to be able to influence both the work being done
      and lab members doing the work. Thus, both leadership and management skills are
      necessary to navigating the organizational, social, and ethical components of the
      research process in order to do rigorous, ethical, and high-quality scientific
      work. This paper recommends a number of practices that leaders of research teams 
      should engage in, including management behaviors for "leading the work" and
      leadership behaviors for "leading the people" that foster excellence and
      integrity in research labs. Researchers can take an intentional approach to
      leadership and management to create a robust environment for ethical research.
      Overall, a researcher's routine behaviors as leaders of their labs should
      establish a healthy work environment and promote effective interpersonal
      interactions among lab members. Further, the lab requires routine procedures and 
      structure to provide adequate oversight of the research. This paper also
      addresses challenges that may arise when implementing leadership and management
      practices, along with strategies for overcoming these strategies. Avenues for
      future research and policy development related to leadership and management in
      scientific contexts are discussed.
FAU - McIntosh, Tristan
AU  - McIntosh T
AUID- ORCID: 0000-0002-1931-4793
AD  - Bioethics Research Center, Division of General Medical Sciences, Washington
      University School of Medicine, St. Louis, MO.
FAU - Sanders, Chanda
AU  - Sanders C
AD  - University of Oklahoma, Department of Psychology, Norman, OK.
FAU - Antes, Alison L
AU  - Antes AL
AUID- ORCID: 0000-0002-2632-7701
AD  - Bioethics Research Center, Division of General Medical Sciences, Washington
      University School of Medicine, St. Louis, MO.
LA  - eng
GR  - K01 HG008990/HG/NHGRI NIH HHS/United States
GR  - UL1 TR002345/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Transl Issues Psychol Sci
JT  - Translational issues in psychological science
JID - 101645472
PMC - PMC8519508
MID - NIHMS1738365
OTO - NOTNLM
OT  - Ethics
OT  - Leadership
OT  - Management
OT  - Research Ethics
OT  - Research Integrity
OT  - Research Labs
EDAT- 2021/10/19 06:00
MHDA- 2021/10/19 06:01
CRDT- 2021/10/18 09:10
PHST- 2021/10/18 09:10 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2021/10/19 06:01 [medline]
AID - 10.1037/tps0000260 [doi]
PST - ppublish
SO  - Transl Issues Psychol Sci. 2020 Sep;6(3):257-270. doi: 10.1037/tps0000260.


PMID- 34567535
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20210930
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Impact of COVID-19 on utilization of maternal, newborn and child health services 
      in Nigeria: protocol for a country-level mixed-methods study.
PG  - 1106
LID - 10.12688/f1000research.26283.2 [doi]
AB  - Background: Battling with COVID-19 and providing essential services along the
      continuum of care could be challenging. This study will evaluate the impact of
      COVID-19 on utilization of maternal, newborn and child health (MNCH) services in 
      Nigeria and explore the barriers being experienced by women and their families in
      getting access to MNCH services, as well as other contextual factors that may
      have shaped the utilization of MNCH services during the COVID-19 pandemic.
      Methods and analysis: The study will adopt an observational mixed-methods study
      design involving 18 health care facilities delivering MNCH services in six
      selected states across six geopolitical zones of Nigeria. We will retrieve
      longitudinal data on MNCH services from all selected hospitals six months before 
      and after the first recorded case of COVID-19 in Nigeria. Qualitative data will
      be collected using in-depth interviews conducted via mobile phones or ZOOM
      meeting platforms among stakeholder participants (users of MNCH services, health 
      workers and policymakers) to ascertain their perceptions on how COVID-19 has
      shaped the utilization of MNCH services. We will triangulate quantitative and
      qualitative data to better understand the impact of COVID-19 on the utilization
      of MNCH services in Nigeria. Ethics and dissemination: Ethics approvals have been
      obtained from the Health Research Ethics Committee of the tertiary hospitals
      involved in the study. Our findings will provide the first evidence from an
      African setting on the impact of COVID-19 on the utilization of MNCH services
      using a mixed-methods study design for policy formulation towards sustained MNCH 
      service delivery.
CI  - Copyright: (c) 2021 Akaba G et al.
FAU - Akaba, Godwin
AU  - Akaba G
AUID- ORCID: https://orcid.org/0000-0002-8149-5492
AD  - College of Health Sciences, Department of Obstetrics and Gynaecology, University 
      of Abuja, Abuja, Nigeria.
FAU - Dirisu, Osasuyi
AU  - Dirisu O
AD  - Department of Research, Population Council, Abuja, Nigeria.
FAU - Okunade, Kehinde
AU  - Okunade K
AUID- ORCID: https://orcid.org/0000-0002-0957-7389
AD  - Department of Obstetrics and Gynaecology, College of Medicine, University of
      Lagos, Lagos, Nigeria.
FAU - Adams, Eseoghene
AU  - Adams E
AD  - Research Hub Africa, Abuja, Nigeria.
FAU - Ohioghame, Jane
AU  - Ohioghame J
AD  - Research and Statistics, Lifesworth- Research Lab II, Abuja, Nigeria.
FAU - Obikeze, Obioma
AU  - Obikeze O
AD  - Department of Community Medicine/Public Health, Federal Medical Centre, Yenagoa, 
      Bayelsa, Nigeria.
FAU - Izuka, Emmanuel
AU  - Izuka E
AD  - Department of Obstetrics and Gynaecology, University of Nigeria, Abuja, Nigeria.
FAU - Sulieman, Maryam
AU  - Sulieman M
AD  - Department of Obstetrics and Gynaecology, Muhammad Abdullahi Wase Teaching
      Hospital, Kano, Nigeria.
FAU - Edeh, Michael
AU  - Edeh M
AD  - Department of Obstetrics and Gynaecology, General Hospital, Takum, Taraaba,
      Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - *COVID-19
MH  - Child
MH  - *Child Health Services
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Maternal Health Services
MH  - Nigeria
MH  - Pandemics
MH  - Pregnancy
MH  - SARS-CoV-2
PMC - PMC8422339
OTO - NOTNLM
OT  - Africa
OT  - COVID-19
OT  - Healthcare
OT  - Impact
OT  - MNCH
OT  - Nigeria
OT  - Services
OT  - Utilization
COIS- No competing interests were disclosed.
EDAT- 2021/09/29 06:00
MHDA- 2021/10/01 06:00
CRDT- 2021/09/28 06:41
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/09/28 06:41 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
AID - 10.12688/f1000research.26283.2 [doi]
PST - epublish
SO  - F1000Res. 2020 Sep 9;9:1106. doi: 10.12688/f1000research.26283.2. eCollection
      2020.


PMID- 34554513
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20220121
IS  - 2676-8607 (Electronic)
IS  - 2676-8607 (Linking)
VI  - 71
IP  - 3
DP  - 2020 Sep
TI  - Generation of periodontal ligament stem cells from human iPSCs with a chemically 
      defined condition.
PG  - 241-248
LID - 10.1007/s42977-020-00022-8 [doi]
AB  - Human periodontal ligament stem cells (PDLSCs) play an important role in
      periodontal tissue regeneration. The generation of PDLSCs from human induced
      pluripotent stem cells (iPSCs) by simulating the development pattern of PDLSCs in
      vivo provided a new way to obtain a large and stable source of PDLSCs. However,
      animal-derived components were still necessary for current differentiation
      protocols, which could cause safety and ethical problems and hinder the clinical 
      application of iPSCs-derived PDLSCs. Here, we established a novel protocol to
      induce iPSCs into PDLSCs by chemically defined conditions. We first induced iPSCs
      into neural crest-like cells by inhibiting TGF-beta pathway, BMP pathway and
      Notch pathway using SB431542, LDN and DAPT, respectively. The iPSC-induced neural
      crest-like cells were further cultured in chemically defined medium containing
      recombinant human bFGF as well as the rho-associated protein kinase inhibitor
      Y27632 to generate PDLSCs. The characteristics of iPSCs-derived PDLSCs and the
      bi-potentiality of osteogenesis and adipogenesis differentiation were verified in
      vitro. The establishment of the chemically defined differentiation system breaks 
      through the limitation brought from animal-derived components and enables us to
      obtain a large number of PDLSCs, which holds a significant value to the research 
      and treatment of periodontal diseases.
CI  - (c) 2020. Akademiai Kiado Zrt.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Orthodontics, School of Stomatology, Shanghai Engineering Research 
      Center of Tooth Restoration and Regeneration, Tongji University, Shanghai, China.
FAU - Hua, Yongmei
AU  - Hua Y
AD  - Department of Orthodontics, School of Stomatology, Shanghai Engineering Research 
      Center of Tooth Restoration and Regeneration, Tongji University, Shanghai, China.
      yongmeihua@tongji.edu.cn.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200730
PL  - Switzerland
TA  - Biol Futur
JT  - Biologia futura
JID - 101738236
SB  - IM
MH  - *Cell Culture Techniques
MH  - *Cell Differentiation
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*physiology
MH  - Periodontal Ligament/*cytology
OTO - NOTNLM
OT  - Chemically defined differentiation system
OT  - Induced pluripotent stem cells
OT  - Periodontal ligament stem cells
EDAT- 2021/09/24 06:00
MHDA- 2022/01/22 06:00
CRDT- 2021/09/23 12:31
PHST- 2019/03/12 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2021/09/23 12:31 [entrez]
PHST- 2021/09/24 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
AID - 10.1007/s42977-020-00022-8 [doi]
AID - 10.1007/s42977-020-00022-8 [pii]
PST - ppublish
SO  - Biol Futur. 2020 Sep;71(3):241-248. doi: 10.1007/s42977-020-00022-8. Epub 2020
      Jul 30.


PMID- 34506431
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Histopathological Spectrum of Non-Neoplastic and Neoplastic Lesions of Thyroid: A
      Descriptive Cross-sectional Study.
PG  - 856-861
LID - 10.31729/jnma.5038 [doi]
AB  - INTRODUCTION: Thyroid gland lesions are the most common endocrine disorders
      encountered globally. Diseases of the thyroid gland present with either an
      alteration of hormone secretion or as an enlargement of the thyroid gland. The
      objective of the study is to find the frequency of different thyroid lesions.
      METHODS: A descriptive cross-sectional study was conducted at Manipal Teaching
      Hospital, Pokhara from Jan 2005 to Jan 2020. Ethical approval was taken from the 
      Institutional Review Committee (Ref: 330). Patients who had undergone
      thyroidectomy procedures for both non-neoplastic and neoplastic thyroid lesions
      were enrolled. Convenient sampling was done. IBM Statistical Package for Social
      Sciences version 21 and Microsoft Excel were used. RESULTS: Out of 345
      thyroidectomy specimens, 246 (71.3%) cases of non-neoplastic lesions, and 99
      (28.69%) cases of neoplastic lesions were present. There were 54 males and 291
      females with a male to female ratio of 1:5.4. The age ranged from 9 to 76 years
      with a mean age of 43.67 years. In non-neoplastic lesions, the predominant lesion
      was the colloid goiter with 205 (83.33%) cases followed by Grave's disease and
      lymphocytic thyroiditis with 14 (5.69%) cases each. In neoplastic lesions,
      papillary carcinoma was the commonest lesion with 56 (56.56%) cases followed by
      follicular carcinoma with 14 (14.14%) cases and follicular adenoma with 13
      (13.13%) cases. There were also 9 (9.09%) cases of anaplastic carcinoma in
      neoplastic lesions. CONCLUSIONS: Colloid goiter and papillary carcinoma was the
      most commonly encountered non-neoplastic and neoplastic lesion with a female
      predominance. Rare tumors like anaplastic carcinoma, papillary carcinoma, and
      follicular carcinoma with anaplastic transformation were also encountered.
FAU - Ghartimagar, Dilasma
AU  - Ghartimagar D
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Ghosh, Arnab
AU  - Ghosh A
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Shrestha, Manish Kiran
AU  - Shrestha MK
AD  - Department of Radiology, Charak Memorial Hospital, Pokhara, Nepal.
FAU - Thapa, Sushma
AU  - Thapa S
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Talwar, Om Prakash
AU  - Talwar OP
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Thyroid Neoplasms/epidemiology
MH  - Thyroidectomy
MH  - Young Adult
PMC - PMC7775000
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/05/23 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5038 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):856-861. doi: 10.31729/jnma.5038.


PMID- 34506425
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Study of Antibiotic Susceptibility among Bacterial Isolates in Neonatal Intensive
      Care Unit of a Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 893-899
LID - 10.31729/jnma.5216 [doi]
AB  - INTRODUCTION: Neonatal sepsis is a major cause of neonatal morbidity and
      mortality worldwide, especially in developing countries like Nepal. Antibiotic
      resistance among microorganisms poses new challenges in the treatment of neonatal
      sepsis. The present study is conducted with the objectives of determining
      clinico-bacteriological profile and antibiotic susceptibility among isolated
      bacteria in a neonatal intensive care unit. METHODS: A descriptive
      cross-sectional study was conducted from January 1, 2017, to December 31, 2019,
      in the neonatal intensive care unit of a tertiary care hospital after obtaining
      ethical clearance from Institutional Review Committee (Reference Number:
      2020-064). The sample size was calculated and 77 neonates with culture-proven
      sepsis were included in the study. The antibiotic susceptibility tests of the
      isolates were done by Kirby-Bauer disc diffusion method. Data entry was done in
      Statistical Packages for the Social Sciences version 20. RESULTS: Of the 841
      specimens (blood, cerebrospinal fluid, urine, tracheal aspirate and pus)
      processed for culture, bacteria were isolated in 84 (10.0%) specimens. Among the 
      84, gram-negative bacilli were the predominant isolates 76 (90.5%); of which
      Acinetobacter baumannii was the most common 27 (32.1%). Both the Gram-negative
      and the Gram-positive bacteria showed high resistance to Penicillin and
      Cephalosporins. Gram-negative bacteria showed maximum sensitivity to Colistin,
      Carbapenems, Tigecycline and Fluoroquinolones. Gram-positive bacteria showed
      maximum susceptibility to Amikacin, Vancomycin and Carbapenems. CONCLUSIONS:
      Judicious use of antibiotics based on the updated knowledge of prevalent
      organisms in the local hospital setting and their antibiotic sensitivity pattern 
      is of utmost importance for the effective treatment of neonatal sepsis.
FAU - Chaudhary, Brajesh Raj
AU  - Chaudhary BR
AD  - Department of Pediatrics, College of Medical Sciences and Teaching Hospital,
      Bharatpur, Nepal.
FAU - Malla, Kalpana Karmacharya
AU  - Malla KK
AD  - Department of Pediatrics, College of Medical Sciences and Teaching Hospital,
      Bharatpur, Nepal.
FAU - Poudel, Sajan
AU  - Poudel S
AD  - Department of Pediatrics, College of Medical Sciences and Teaching Hospital,
      Bharatpur, Nepal.
FAU - Jha, Brajesh Kumar
AU  - Jha BK
AD  - Department of Microbiology, College of Medical Sciences and Teaching Hospital,
      Bharatpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - *Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Infant, Newborn
MH  - *Intensive Care Units, Neonatal
MH  - Microbial Sensitivity Tests
MH  - Tertiary Care Centers
PMC - PMC7775007
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/07/20 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5216 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):893-899. doi: 10.31729/jnma.5216.


PMID- 34506424
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Prevalence of Aeroallergens in Allergic Rhinitis in a Tertiary Care Hospital.
PG  - 866-870
LID - 10.31729/jnma.5218 [doi]
AB  - INTRODUCTION: The prevalence of allergic rhinitis has increased significantly
      globally over the last two decades. Detection of sensitizing aeroallergens plays 
      a crucial role in the diagnosis and management of this troublesome disease. This 
      study aims to investigate the spectrum of aeroallergens sensitization in patients
      with allergic rhinitis in a tertiary care hospital. METHODS: A descriptive
      cross-sectional study conducted in the Department of Otorhinolaryngology of our
      hospital between January 2016 to December 2019. Ethical approval was taken from
      the Institutional Review Committee (No: 210/19). Patients diagnosed with allergic
      rhinitis were enrolled using the convenience sampling technique. Data entry and
      analysis was done using IBM Statistical Package for Social Sciences version 20.0.
      RESULTS: Among 170 patients, altogether 103 (60.6%) patients yielded positive
      responses on the skin prick test. The most prevalent aeroallergens were
      Lepidoglyphus 86 (50.60%), Dermatophagoides pteronyssinus 85 (50%),
      Dermatophagoides farina 82 (48.20%), Thyrophagus 50 (29.40%), Blomia 46 (27.10%),
      Acarus 43 (25.30%), cat dander 26 (15.30%), dog dander 24 (14.10%), cow and
      buffalo dander 20 (11.8%), ragweed 20 (11.8%), grass pollen 18 (10.60%) and
      mugwort 17 (10%). CONCLUSIONS: This study highlights that the frequency of
      aeroallergens based on skin prick test in patients presenting to a tertiary care 
      hospital which showed the dominance of house dust mites, dog and cat hair,
      pollen, and grasses. Reduced exposure and training of patients about protection
      against these agents will possibly help in controlling the severity of allergic
      rhinitis in this region.
FAU - Pokharel, Monika
AU  - Pokharel M
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Kathmandu University
      School of Medical Sciences Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
FAU - Shrestha, Bikash Lal
AU  - Shrestha BL
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Kathmandu University
      School of Medical Sciences Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
FAU - Karn, Dharmendra
AU  - Karn D
AD  - Department of Dermatology, Kathmandu University School of Medical Sciences
      Dhulikhel Hospital, Dhulikhel, Kavre, Nepal. monikapokharel@hotmail.com.
FAU - Dhakal, Ashish
AU  - Dhakal A
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Kathmandu University
      School of Medical Sciences Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
FAU - Kc, Abha Kiran
AU  - Kc AK
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Kathmandu University
      School of Medical Sciences Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
FAU - Shrestha, Krishna Sundar
AU  - Shrestha KS
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Kathmandu University
      School of Medical Sciences Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
FAU - Shakya, Sushan
AU  - Shakya S
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Kathmandu University
      School of Medical Sciences Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Animals
MH  - *Cat Diseases
MH  - Cats
MH  - Cattle
MH  - Cross-Sectional Studies
MH  - *Dog Diseases
MH  - Dogs
MH  - Female
MH  - Humans
MH  - Prevalence
MH  - *Rhinitis, Allergic/epidemiology
MH  - Tertiary Care Centers
PMC - PMC7775014
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/07/20 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5218 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):866-870. doi: 10.31729/jnma.5218.


PMID- 34506423
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Bacteriological Profile of Urine in Patients with Different Types of Kidney
      Stones in a Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 871-874
LID - 10.31729/jnma.5226 [doi]
AB  - INTRODUCTION: The association of bacteriology in the pathogenesis of urolithiasis
      is a known and fact. The urinary tract stones being the most common problem that 
      brings the patient to the surgical outpatient department; it is important to know
      the relation between the types of stone and the organism isolated from the urine 
      for better management of the patient. The aim of this study was to find out the
      urine bacteriological profile of patients with kidney stones. METHODS: This is a 
      descriptive cross-sectional study done over 18 months in a tertiary care hospital
      in Nepal. Ethical clearance was taken from the Institutional Review Committee
      (No: 03/16). Preoperative urine cultures were done routinely in all the patients 
      who agreed to take participate in the study. The biochemical stone analysis was
      done. Urinary microbial floras and stone composition were noted. Data entry and
      analysis was done using Statistical Package for the Social Sciences version 25.0.
      RESULTS: Among 107 patients, kidney stones were more common in males and most of 
      the patients were in their 2nd to 4th decade. Female patients 45 (42.05%) had
      more predilections towards the urinary tract infection. Among 15 (14.01%)
      positive cultures, Escherichia coli 10 (67%) was the most common organism
      isolated followed by Klebsiella; 4 (27%), and Pseudomonas; 1 (6%). CONCLUSIONS:
      Thus, we would like to state that Escherichia coli, though being a non-urease
      producing organism, is a major organism isolated in the preoperative culture of
      urine in a patient with kidney stones.
FAU - Ranjit, Srijana
AU  - Ranjit S
AD  - Department of Microbiology, Kathmandu University School of Medical Sciences
      Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
FAU - Singh, Amit Kumar
AU  - Singh AK
AD  - Department of General Surgery, Kathmandu University School of Medical Sciences
      Dhulikhel Hospital, Dhulikhel, Kavre, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Escherichia coli
MH  - Female
MH  - Humans
MH  - *Kidney Calculi/epidemiology
MH  - Male
MH  - Tertiary Care Centers
MH  - *Urinary Tract Infections/epidemiology
PMC - PMC7775010
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/07/22 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5226 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):871-874. doi: 10.31729/jnma.5226.


PMID- 34506422
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Prevalence of Acute Pediatric Burns in a Tertiary Care Hospital.
PG  - 862-865
LID - 10.31729/jnma.5233 [doi]
AB  - INTRODUCTION: Burn injury is an important cause of mortality and morbidity in
      children worldwide. Mortality is higher in developing countries than in developed
      ones. Most of them occur in predictable domestic settings and can be prevented.
      The objective of this study was to find out the prevalence of acute pediatric
      burns in a hospital setting. METHODS: A descriptive cross-sectional study was
      conducted by reviewing the secondary data of burn cases admitted during the years
      2016 AD to 2018 AD in a tertiary care hospital after taking ethical clearance
      from the Institutional Review Committee (IRC No. 016-2019). The sample size was
      calculated and systematic random sampling was done. Data analysis was done using 
      Statistical Package for the Social Sciences, version 23. Point estimate at 95%
      Confidence Interval was calculated along with frequency and proportion for binary
      data. RESULTS: The prevalence of acute pediatric burns at the hospital was found 
      to be 101 (29.71%) (24.85-34.57 at 95% Confidence Interval). The majority of them
      were males 54 (53.47%) and toddlers 39 (38.61%). Scalding 54 (53.47%) was the
      main etiology. Most of the burn injuries occurred inside the house 76 (75.25%)
      and on November 11 (10.9%). The mortality rate was 11 (10.89%). CONCLUSIONS: The 
      prevalence of acute pediatric burns in a hospital setting was lower than most
      other countries but mortality was higher. The majority of the burn injuries
      occurred inside the house. Therefore, special focus should be done on prevention 
      at the household level. Adequate medical services for emergency management of
      childhood burns should be available in different parts of the country.
FAU - Nakarmi, Kiran Kishor
AU  - Nakarmi KK
AD  - Department of Burns, Plastic and Reconstructive Surgery, Kirtipur Hospital,
      Kathmandu, Nepal.
FAU - Pathak, Bishnu Deep
AU  - Pathak BD
AD  - Nepalese Army Institute of Health Sciences, Bhandarkhal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Burns/epidemiology/etiology
MH  - Child
MH  - Cross-Sectional Studies
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC7775026
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/07/26 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5233 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):862-865. doi: 10.31729/jnma.5233.


PMID- 34506418
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Knowledge of COVID-19 among Health Care Workers at a Tertiary Care Hospital of
      Nepal: A Descriptive Cross-sectional Study.
PG  - 905-910
LID - 10.31729/jnma.5266 [doi]
AB  - INTRODUCTION: Health care workers are at higher risk of infection with the
      coronavirus disease as they are directly involved in the treatment of infected
      patients and perform aerosol-generating procedures. Proper knowledge of this
      disease can influence the positive attitude, good practices and enhance their
      safety. We aim to study the knowledge of COVID-19 among health care workers of
      the tertiary care hospital of Nepal. METHODS: A descriptive cross-sectional study
      was conducted among health care workers of Shahid Gangalal National Heart Centre 
      from May 20 to June 19, 2020. Ethical approval was taken from the Institutional
      Review Board (IRB No: 4-2020). Written informed consent was taken from all
      respondents. Correct answers were summated to reflect the mean knowledge,
      expressed as a percentage. Data analysis was done using Statistical Package for
      the Social Sciences version 21. RESULTS: The mean general knowledge score was
      95.7%. The mean medical knowledge score was 70.5%. Only 42 (56.8%) of physicians 
      and 103 (53.6%) of nurses had a higher level of medical knowledge regarding
      COVID-19. Likewise, very few lab technicians 7 (21.9%) and none of the
      pharmacists had a higher level of medical knowledge. CONCLUSIONS: The healthcare 
      workers of this centre have adequate knowledge regarding COVID-19. However,
      periodic training for all workers, especially the nurses and allied workers, may 
      help to update the knowledge and hence enhance their safety and that of their
      patients.
FAU - Bhandari, Sandip
AU  - Bhandari S
AD  - Department of Anaesthesiology, Shahid Gangalal National Heart Centre, Kathmandu, 
      Nepal.
FAU - Sharma, Medha
AU  - Sharma M
AD  - Visible Impact, Kathmandu, Nepal.
FAU - Shrestha, Gentle Sundar
AU  - Shrestha GS
AD  - Department of Anaesthesiology, Tribhuvan University Teaching Hospital,
      Maharajgunj, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Personnel
MH  - Humans
MH  - Nepal
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
PMC - PMC7775016
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/09 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5266 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):905-910. doi: 10.31729/jnma.5266.


PMID- 34506417
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Prevalence of Misuse of Topical Corticosteroid among Dermatology Outpatients.
PG  - 834-838
LID - 10.31729/jnma.5271 [doi]
AB  - INTRODUCTION: Topical corticosteroids misuse has become one of the burning issues
      in many countries across the globe. They are known to cause a myriad of adverse
      effects which include local effects commonly and systemic effects rarely. In
      dermatology practice, one of the common problems we see these days are
      steroid-induced and steroid aggravated dermatoses. So, this study was done to
      find the prevalence of misuse of topical corticosteroid among dermatology
      outpatients. METHODS: A descriptive cross-sectional study was done in the
      outpatient department of dermatology at atertiary care hospital for 18 months.
      Ethical clearance was obtained from the Institutional Review Committee of NMCTH
      (Reference no. 029-076/077). Convenient sampling was done. Statistical Package
      for the Social Sciences (SPSS) version 16 was used to tabulate the data and
      analyze the results. Point estimate at 95% Confidence Interval was calculated
      along with frequency and proportion for binary data. RESULTS: Out of 19464
      patients, 614 (3.15%) (2.91%-3.39% at 95% Confidence Interval) gave a history of 
      applying steroid containing creams. Among them, 220 (35.8%) belonged to the age
      group 21-30 years. Dermatophytoses were the skin disease where TCS was most
      commonly misused followed by melasma in 425 (69.2%) and 115 (18.7%) respectively.
      Beclomethasone was the steroid preparation that was misused in the maximum number
      of patients in 271 (44.1%). Some form of adverse effects was seen in 554 (88.6%) 
      patients. CONCLUSIONS: Non-prescription sale of topical corticosteroids is the
      major cause of topical corticosteroids abuse in Nepal. Creating awareness among
      the prescribers as well as the patients is the current need.
FAU - Shrestha, Shristi
AU  - Shrestha S
AD  - Department of Dermatology, Nepal Medical College and Teaching Hospital,
      Attarkhel, Kathmandu, Nepal.
FAU - Joshi, Smita
AU  - Joshi S
AD  - Department of Dermatology, Nepal Medical College and Teaching Hospital,
      Attarkhel, Kathmandu, Nepal.
FAU - Bhandari, Sajana
AU  - Bhandari S
AD  - Department of Dermatology, Nepal Medical College and Teaching Hospital,
      Attarkhel, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Adrenal Cortex Hormones/adverse effects
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Dermatology
MH  - Humans
MH  - *Outpatients
MH  - Prevalence
MH  - Young Adult
PMC - PMC7775011
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/11 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5271 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):834-838. doi: 10.31729/jnma.5271.


PMID- 34506414
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Anatomical Position of Lower Third Molar in Relation to Mandibular Canal on
      Cone-Beam Computed Tomography Images in A Tertiary Care Hospital: A Descriptive
      Cross-sectional Study.
PG  - 879-883
LID - 10.31729/jnma.5314 [doi]
AB  - INTRODUCTION: The positional relationship between the mandibularcanal with
      impacted mandibular third molar is the main factor of inferior alveolar nerve
      injury. The purpose of this study wasto classify the anatomical three dimensional
      relationship between the proximity of impacted mandibular third molars to the
      inferior alveolar canal. METHODS: The descriptive cross-sectional study was
      conducted inthe Department of Oral and Maxillofacial Surgery of a tertiary care
      hospital from July 2020 to August 2020 after obtaining ethical approval from the 
      Institutional Review Committee (Reference number 2506202001). Cone-beam computed 
      tomography images of 200 patient's mandibular third molars were used. A
      convenient sampling method was used. Data were analyzed using Statistical package
      for the Social Sciences. RESULTS: Mandibular canal relative to the roots of the
      mandibular third molar was observed on the apical side in 104 (52.0%) and 173
      (86.5%) third molars had direct contact with the mandibular canal. About 36
      (97.3%) lingually placed mandibular third molars had contact with the mandibular 
      canal. CONCLUSIONS: The findings of the study conclude that most of the
      mandibular third molars situated lingually had a higher occurrence of mandibular 
      nerve involvement. The anatomic structures of the mandibular third molar and the 
      mandibular canal may be helpful to draw upon the adequate surgical plan to
      avoidor reduce nerve involvement.
FAU - Chaudhary, Bikash
AU  - Chaudhary B
AD  - Department of Oral and Maxillofacial Surgery, Kathmandu Medical College and
      Teaching Hospital, Bhaktapur, Nepal.
FAU - Joshi, Ujjwal
AU  - Joshi U
AD  - Department of Oral Medicine and Radiology, Kathmandu Medical College and Teaching
      Hospital,Bhaktapur,Nepal.
FAU - Dahal, Sirjana
AU  - Dahal S
AD  - Department of Oral and Maxillofacial Surgery, Kathmandu Medical College and
      Teaching Hospital, Bhaktapur, Nepal.
FAU - Sagtani, Alok
AU  - Sagtani A
AD  - Department of Oral and Maxillofacial Surgery, Kathmandu Medical College and
      Teaching Hospital, Bhaktapur, Nepal.
FAU - Khanal, Pranaya
AU  - Khanal P
AD  - Department of Community and Public Health Dentistry, Kathmandu Medical College
      and Teaching Hospital, Bhaktapur, Nepal.
FAU - Bhattarai, Niroj
AU  - Bhattarai N
AD  - Department of Oral and Maxillofacial Surgery, Kathmandu Medical College and
      Teaching Hospital, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cone-Beam Computed Tomography
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Mandible/diagnostic imaging
MH  - *Molar, Third/diagnostic imaging/surgery
MH  - Tertiary Care Centers
PMC - PMC7775019
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/24 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5314 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):879-883. doi: 10.31729/jnma.5314.


PMID- 34506412
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Hypocalcemia in Elderly Population in a Tertiary Care Hospital: A Descriptive
      Cross-sectional Study.
PG  - 843-846
LID - 10.31729/jnma.5324 [doi]
AB  - INTRODUCTION: As the medical facilities are improving, the life expectancy is
      increasing which has led to rapid rise in elderly population. The epidemiology of
      many diseases in elderly has been modified, including calcium imbalance. This
      study aims to know the prevalence of hypocalcemia in elderly population visiting 
      a tertiary care center of Kathmandu. METHODS: A descriptive cross-sectional study
      was conducted in a tertiary care center of Kathmandu from March to July 2020
      after obtaining ethical clearance (Ref: 2003202007). Total 402 participants at or
      above 60 years of age groups visiting outpatient departments were included in the
      study by convenience sampling method excluding those under vitamin D and calcium 
      supplements. Serum total calcium level was measured using standard routine method
      and corrected with albumin. The serum calcium value less than 8 mg/dl was
      considered as hypocalcemia in accordance with the reference range of our
      laboratory. Data analysis for calculation of frequency and proportion was done in
      Statistical Package of Social Sciences. RESULTS: The prevalence of hypocalcaemia 
      in elderly was found to be 97 (24.1%). Out of 286 participants of age group 60-74
      years, hypocalcemia was seen in 75 (26.2%) and among 116 participants of age
      group >74 years, 22 (19%) were hypocalcemic. Among 181 male participants, 44
      (24.3%) had hypocalcemia and out of 221 female participants, 53 (24%) had
      hypocalcemia. CONCLUSIONS: The finding of present study suggests that
      hypocalcemia is common among elderly which can be life threatening. Therefore,
      regular monitoring of serum calcium is recommended for this age group.
FAU - Thapa, Sangita
AU  - Thapa S
AD  - Department of Biochemistry, Kathmandu Medical College Teaching Hospital, Duwakot,
      Bhaktapur, Nepal.
FAU - Rayamajhi, Rabindra Jang
AU  - Rayamajhi RJ
AD  - Department of Internal Medicine, Shree Birendra Hospital, Chhauni, Kathmandu,
      Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 1406-16-2 (Vitamin D)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aged
MH  - Calcium
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Hypocalcemia/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Tertiary Care Centers
MH  - Vitamin D
PMC - PMC7775006
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/28 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5324 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):843-846. doi: 10.31729/jnma.5324.


PMID- 34506411
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Professional Quality of Life among Medical Doctors Working in Kathmandu: A
      Descriptive Cross-sectional Study.
PG  - 900-904
LID - 10.31729/jnma.5330 [doi]
AB  - INTRODUCTION: The practice of medicine is an honorable profession besides being
      accompanied by a demanding environment. This study aimed to find out the
      professional quality of life of medical doctors working in Kathmandu valley.
      METHODS: A descriptive cross-sectional study was conducted among 174 Nepalese
      medical doctors working in different hospitals of Kathmandu valley. Ethical
      approval was taken from the Ethical Review Board of the Nepal Health Research
      Council (Reference Number: 830). The data collection tool used in the study was
      WHO Professional Quality of Life Scale-5 to collect data about Compassion
      satisfaction, Burnout and Secondary traumatic stress among medical doctors
      working in Kathmandu valley. Data analysis was done in the Statistical Package
      for the Social Sciences version 16.0. RESULTS: Out of 174 participants, 101
      (58%), 126 (72.4%) and 135 (77.6%) were found to have moderate level of
      Compassion satisfaction, Burnout and Secondary Traumatic Stress respectively.
      CONCLUSIONS: More than half, nearly two-third, and more than two-third
      participants had moderate levels of Compassion satisfaction, Burnout and
      Secondary Traumatic Stress respectively. The overall study findings reflected
      good balance between Compassion satisfaction and Compassion fatigue (burnout and 
      secondary traumatic stress) among the Nepalese medical doctors. Further
      assessment of professional quality of life of doctors as well as other health
      care workers via Multifaceted and large-scale study is recommended.
FAU - Vaidya, Anju
AU  - Vaidya A
AD  - Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal.
FAU - Karki, Shristi
AU  - Karki S
AD  - Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal.
FAU - Dhimal, Meghnath
AU  - Dhimal M
AD  - Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal.
FAU - Gyanwali, Pradip
AU  - Gyanwali P
AD  - Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal.
FAU - Baral, Dibash
AU  - Baral D
AD  - Public Health Promotion and Development Organization, Chandole, Kathmandu, Nepal.
FAU - Pandey, Ashok
AU  - Pandey A
AD  - Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal.
FAU - Jha, Anjani Kumar
AU  - Jha AK
AD  - Nepal Health Research Council, Ramshah Path, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Burnout, Professional/epidemiology
MH  - *Compassion Fatigue
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Job Satisfaction
MH  - Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC7775029
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/09/03 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5330 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):900-904. doi: 10.31729/jnma.5330.


PMID- 34506406
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Normal Anatomy and Variants of Renal Vasculature with Multidetector Computed
      Tomography in a Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 911-914
LID - 10.31729/jnma.5615 [doi]
AB  - INTRODUCTION: Preoperative multisection computed tomography evaluation can
      provide necessary anatomic information in minimally invasive surgeries. This
      study was done to estimate the preva-lence and pattern of variations of renal
      vasculature through contrast-enhanced computed tomogra-phy in patients referred
      to the radiology department of a tertiary care hospital. METHODS: A descriptive
      cross-sectional study was conducted from 6th April 2016 to 6th April 2017.
      Ethical approval was taken. The triple-phase contrast-enhanced computed
      tomography was per-formed on 188 patients enrolled through convenient sampling.
      The images were evaluated in un-enhanced, arterial, and venous phases for the
      vascular variants. Data were analyzed based on the anatomical types of variations
      and descriptive statistics such as frequency and percentage using the Statistical
      Package for the Social Sciences. RESULTS: Out of the 188 patients, 60 (31.9%) had
      accessory renal arteries. The most common variant was hilar arteries which
      comprised 38 cases (20.2%) whereas polar arteries were present in 21 (11.1%)cases
      and the capsular artery was present in one (0.5%) case. Early bifurcation of the 
      renal artery was noted in 15 (8%) cases with 10 (5.3%) on the right and 5 (2.7%) 
      on the left side. Twelve (6.3%) cases of the double right renal vein were noted
      whereas retroaortic left renal vein was noted in only 4(2.1%) cases. CONCLUSIONS:
      Based on our study, almost one in three patients had accessory renal arteries and
      eighty-five out of a thousand patients had variants of renal veins.
FAU - Regmi, Pradeep Raj
AU  - Regmi PR
AD  - Department of Radiology and Imaging, University Hospital of Ioannina, Ioannina,
      Greece.
FAU - Amatya, Isha
AU  - Amatya I
AD  - Department of Community Medicine, Kathmandu Medical College and Teaching
      Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Kayastha, Prakash
AU  - Kayastha P
AD  - Department of Radiology and Imaging, Tribhuvan University Teaching Hospital,
      Maharajgunj, Kathmandu, Nepal.
FAU - Paudel, Sharma
AU  - Paudel S
AD  - Department of Radiology and Imaging, Tribhuvan University Teaching Hospital,
      Maharajgunj, Kathmandu, Nepal.
FAU - Suwal, Sundar
AU  - Suwal S
AD  - Department of Radiology and Imaging, Tribhuvan University Teaching Hospital,
      Maharajgunj, Kathmandu, Nepal.
FAU - Ghimire, Ram Kumar
AU  - Ghimire RK
AD  - Department of Radiology and Imaging, Nepal Mediciti
      Hospital,Karyabinayak,Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Kidney/diagnostic imaging
MH  - *Multidetector Computed Tomography
MH  - Renal Veins/diagnostic imaging
MH  - Tertiary Care Centers
PMC - PMC7775024
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/11/03 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5615 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):911-914. doi: 10.31729/jnma.5615.


PMID- 34506404
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - Vitamin D Deficiency among Patients Visiting a Tertiary Care Hospital: A
      Descriptive Cross-sectional Study.
PG  - 839-842
LID - 10.31729/jnma.5645 [doi]
AB  - INTRODUCTION: Vitamin D deficiency is a common condition prevalent among both
      developed and developing countries where it is seen mostly in females. It has
      been linked to various skeletal and non-skeletal diseases. This study was done to
      find out the prevalence of Vitamin D deficiency and clinical features of
      deficient patients attending the outpatient department of a tertiary care
      hospital. METHODS: This descriptive cross-sectional study was done among the
      patients attending the outpatient department of a tertiary care hospital in
      Kathmandu, Nepal. The study was conducted from May 2019 to July 2019. The ethical
      approval was taken from the Institutional Review Committee (ref no. 310520113).
      Convenient sampling was done. The collected data was entered in Microsoft Excel
      and was analyzed in the Statistical Package for the Social Sciences (SPSS)
      version 26. RESULTS: Out of 481 participants, the prevalence of vitamin D
      deficiency was 335 (69.6%). Severe vitamin D deficiency was seen in 78 (16.2%)
      and insufficient vitamin D in 77 (16%) of the patients. The mean serum vitamin D 
      concentration by gender was 22.38+/-17.07 ng/ml in males and 18.89+/-15.25 ng/ml 
      in females. A total of 263 (54.6%) females and 72 (14.97%) males had vitamin D
      deficiency. The most common symptoms found in vitamin D deficiency patients were 
      fatigue 187(55.8%), muscle cramps 131(39.1%), generalized myalgia 125(37.31%),
      bone and joint pain 111(33.13%). CONCLUSIONS: Vitamin D deficiency was prevalent 
      especially in females and elderly people. Fatigability was present in more than
      half of the vitamin D deficient patients.
FAU - Poudel, Nimesh
AU  - Poudel N
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Dhakal, Subodh Sagar
AU  - Dhakal SS
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Sukhupayo, Renu
AU  - Sukhupayo R
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Karki, Dambar Bahadur
AU  - Karki DB
AD  - Department of Cardiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Prevalence
MH  - Tertiary Care Centers
MH  - Vitamin D
MH  - *Vitamin D Deficiency/epidemiology
PMC - PMC7775021
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/11/09 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5645 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):839-842. doi: 10.31729/jnma.5645.


PMID- 34506401
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 231
DP  - 2020 Nov 22
TI  - A Study on the Clinical and Hormonal Profile of Polycystic Ovarian Syndrome
      Patients Attending a Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 875-888
LID - 10.31729/jnma.5694 [doi]
AB  - INTRODUCTION: Polycystic ovarian syndrome is the most common endocrinological
      disorder in women of reproductive age and has a considerable metabolic,
      reproductive, and cardiovascular consequences. This study was designed to provide
      an overview of the presentation of he clinical profile and hormonal presentation 
      of the patients with polycystic ovarian syndrome attending a tertiary care
      hospital. METHODS: A descriptive cross-sectional study was conducted between
      September 14, 2019 to October 16, 2019 on patients presenting to a tertiary care 
      hospital, after obtaining ethical clearance from Institutional Review Committee
      (Dated 03/09/2019) and informed consent from the patient or patient relatives.
      Data entry and analysis were done in Microsoft Excel 10. The data was
      statistically analysed using Statistical Package for the Social Sciences (SPSS)
      version 20.0. RESULTS: The study included 100 PCOS patients. The mean age of the 
      patients was 24.9+/-4.52 years and the most common group was 26-34 years. The
      most common presenting symptom was menstrual irregularity which was seen in 86
      (86%) of the patients, followed by weight gain in 55 (55%) of the patients.
      Thirty percent (30 in number) of the patients were overweight, while eleven (11%)
      of the patients had grade I obesity. LH/FSH ratio was more than or equal to 2 in 
      eighty-three percent 83 (83%) of the patients. CONCLUSIONS: Polycystic ovarian
      syndrome has varying clinical manifestations, most commonly affecting the young
      women of reproductive age group. The commonest presenting complaint in the
      current study was menstrual abnormality. Majority of the patients had deranged
      hormonal profile which can lead to an increased risk of cardiovascular disease
      and type 2 DM. Thus, awareness regarding PCOS is important for early diagnosis
      and to prevent its sequalae to various complications.
FAU - Vaidya, Achala
AU  - Vaidya A
AD  - Department of Obstetrics and Gynaecology, Norvic International Hospital,
      Kathmandu, Nepal.
FAU - Yadav, Sweta
AU  - Yadav S
AD  - Department of Obstetrics and Gynaecology, Norvic International Hospital,
      Kathmandu, Nepal.
FAU - Vaidya, Anshu
AU  - Vaidya A
AD  - Department of Obstetrics and Gynaecology, Norvic International Hospital,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Menstruation Disturbances/epidemiology/etiology
MH  - *Polycystic Ovary Syndrome/diagnosis/epidemiology
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7775009
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/11/20 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5694 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Nov 22;58(231):875-888. doi: 10.31729/jnma.5694.


PMID- 34506394
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Prevalence of Colistin-resistant Gram-negative Isolates Carrying the mcr-1 Gene
      among Patients Visiting a Tertiary Care Center.
PG  - 983-997
LID - 10.31729/jnma.5246 [doi]
AB  - INTRODUCTION: Gram-negative isolates harboring mobilized colistin resistance
      (mcr-1) gene are a great threat to human health. They have been reported
      worldwide among various bacterial isolates. This work aimed to study the
      prevalence of colistin resistance among Gram-negative bacteria and the incidence 
      of mcr-1 gene among these isolates. METHODS: A descriptive cross-sectional study 
      was done at a tertiary care center from June 2016 to February 2017. An ethical
      approval was taken from review board of the Nepal Health Research Council (Reg.
      no: 274/2016). Convenience sampling was used. The data was collected and analyzed
      using Microsoft Excel 2010 and Statistical Package for Social Sciences (SPSS)
      Version 16 . Point estimate at 95% Confidence Interval was calculated along with 
      frequency and proportion for binary data. RESULTS: Among 485 gram-negative
      isolates, only 13 (2.68%) (1.26-6.62 at 95% Confidence Interval) isolates were
      colistin-resistant and mcr-1 was present in two isolates. Predominant
      colistin-resistant isolates were E. coli 6 (4.1%), Enterobacter spp 2 (2.81%),
      and Acinetobacter spp 2 (2.81%). A high level of colistin-resistance was noted in
      4 (30.7%) isolates as indicated by the very high value of colistin MIC (>256
      mug/ml). ICU was the major site of isolation of colistin-resistant and mcr-1
      positive pathogens. The majority of colistin-resistant isolates were highly
      drug-resistant and were sensitive only to polymyxin B. Antibiotics like imipenem,
      amikacin, gentamicin, aztreonam, ciprofloxacin, and piperacillin-tazobactam were 
      effective for few of these isolates. CONCLUSIONS: Though the prevalence of mcr-1 
      gene was low among colistin-resistant gram-negative isolates, the resistant
      pattern was quite alarming as these isolates were highly drug-resistant.
FAU - Paudel, Ashmita
AU  - Paudel A
AD  - Department of Microbiology, Regional College of Health Science and Technology,
      Pokhara, Nepal.
FAU - Devkota, Surya Prasad
AU  - Devkota SP
AD  - Department of Microbiology, Pokhara Bigyan Tatha Prabidhi Campus, Pokhara, Nepal 
      .
FAU - Shrestha, Anima
AU  - Shrestha A
AD  - Department of Microbiology, Saint Xavier's College, Maitighar, Kathmandu, Nepal.
FAU - Shah, Anil Kumar
AU  - Shah AK
AD  - Annapurna Research center, Maitighar, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Escherichia coli Proteins)
RN  - 0 (MCR-1 protein, E coli)
RN  - Z67X93HJG1 (Colistin)
SB  - IM
MH  - Anti-Bacterial Agents/pharmacology
MH  - *Colistin/pharmacology
MH  - Cross-Sectional Studies
MH  - Drug Resistance, Bacterial/genetics
MH  - Escherichia coli
MH  - *Escherichia coli Proteins
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC8028535
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/02 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5246 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):983-997. doi: 10.31729/jnma.5246.


PMID- 34506393
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Psychiatric Morbidities in Patients with Non-communicable Diseases among
      Inpatients of Medicine Department in a Tertiary Care Hospital: A Descriptive
      Cross-sectional Study.
PG  - 1005-1010
LID - 10.31729/jnma.5255 [doi]
AB  - INTRODUCTION: Psychiatric morbidities are common among patients with chronic
      non-communicable diseases. These diseases have high morbidity, mortality, and
      higher health costs. However, psychiatric conditions are often underdiagnosed and
      undertreated in our country. This study aimed to find out the psychiatric
      morbidities among patients with non-communicable diseases admitted in inpatients 
      units of the medicine department. METHODS: A descriptive cross-sectional study
      was conducted in the inpatients of the medicine department of a tertiary care
      hospital among 926 patients with chronic non-communicable diseases. Ethical
      approval was obtained from the Chitwan Medical College Institutional Review
      Committee (Ref.No.IRC:2074/75:38). A convenient sampling technique was used.
      Patients were interviewed using the Patients Health Questionnaire. Data analysis 
      was performed using Statistical Package for Social Sciences version 16. RESULTS: 
      Among 926 non-communicable disease patients, psychiatric morbidities observed
      were somatization 612 (66.1%) anxiety 319 (34.4%), and depression 379 (40.9%).
      Patients with multiple non-communicable diseases had higher psychiatric
      morbidities compared to patients with a single disease. CONCLUSIONS: Psychiatric 
      morbidities are common among admitted patients suffering from non-communicable
      diseases in Nepal. Hence, regular screening services are needed in all levels of 
      health care centers to identify and treat the risk groups on time.
FAU - Sharma, Kalpana
AU  - Sharma K
AD  - Department of Adult Health Nursing, Chitwan Medical College, Bharatpur, Chitwan, 
      Nepal.
FAU - Dhungana, Govinda
AU  - Dhungana G
AD  - Department of Statistics, Birendra Multiple Campus, Bharatpur, Chitwan, Nepal.
FAU - Adhikari, Shailendra
AU  - Adhikari S
AD  - Department of Psychiatry, Chitwan Medical College, Bharatpur, Chitwan, Nepal.
FAU - Pandey, Archana Bista
AU  - Pandey AB
AD  - Department of Women Health and Development, Institute of Medicine, Kathmandu,
      Nepal.
FAU - Sharma, Muna
AU  - Sharma M
AD  - Department of Adult Health Nursing, Institute of Medicine, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Inpatients
MH  - Morbidity
MH  - *Noncommunicable Diseases/epidemiology
MH  - Tertiary Care Centers
PMC - PMC8028527
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/06 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5255 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1005-1010. doi: 10.31729/jnma.5255.


PMID- 34506392
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Washing Hands according to the WHO Guideline since the COVID-19 Outbreak in the
      Context of Medical Undergraduates at a Tertiary Care Center: A Descriptive
      Cross-sectional Study.
PG  - 1018-1023
LID - 10.31729/jnma.5259 [doi]
AB  - INTRODUCTION: Hand washing is an important preventive measure to avoid
      transmission of Coronavirus Disease of 2019. Medical students should be
      acquainted with the World Health Organization's hand-washing guidelines and
      should follow them to break the chain of spread of the virus. This study aims to 
      find the acquaintance of medical undergraduates with the guidelines and to find
      out if they have started implementing these guidelines since the corona-virus
      outbreak. METHODS: This is a descriptive cross-sectional study, conducted among
      MBBS, BSc, and PCL nursing students in their first year to the internship of a
      tertiary care hospital from May 2020 to August 2020, and ethical clearance was
      received from the Institutional Review Committee (ref no: IRC-LMC 11-D/020) of
      Lumbini Medical College and Teaching Hospital. Data collection was done through
      online questionnaires. Data analysis of the obtained information was done in
      Microsoft-excel. Point estimate at 95% Confidence Interval was calculated along
      with frequency and proportion for binary data. RESULTS: Of 462 respondents, 265
      (57.4%) (52.9-61.9 at 95% Confidence Interval) respondents followed the World
      Health Organization hand-washing guidelines during every hand wash. Among them
      172 (37.2%) participants had learned the guidelines through awareness programs.
      The majority of respondents belonged to 20-25 age groups, 275 (59.5%), and the
      majority were pursuing an MBBS degree, 360 (77.9%). CONCLUSIONS: We conclude that
      a notable number of medical undergraduates have been acquainted with standard
      hand-washing guidelines since the corona-virus outbreak, but some of them still
      do not follow the guidelines practically. Therefore, effective and impactful
      awareness programs need to be launched to improve hand hygiene practices.
FAU - Khadka, Anuska
AU  - Khadka A
AD  - Lumbini Medical College and Teaching Hospital, Palpa, Nepal.
FAU - Dani, Saurav
AU  - Dani S
AD  - Lumbini Medical College and Teaching Hospital, Palpa, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - Disease Outbreaks/prevention & control
MH  - Humans
MH  - SARS-CoV-2
MH  - *Students, Medical
MH  - Tertiary Care Centers
MH  - World Health Organization
PMC - PMC8028522
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/07 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5259 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1018-1023. doi: 10.31729/jnma.5259.


PMID- 34506391
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Isolated Gall Bladder Perforation in a Tertiary Care Hospital in Eastern Nepal: A
      Descriptive Cross-sectional Study.
PG  - 988-991
LID - 10.31729/jnma.5267 [doi]
AB  - INTRODUCTION: Cholelithiasisis is a common surgical problem worldwide. Gall
      bladder perforation is a rare life-threatening complication with considerable
      mortality. This study aims to find the etiology, demography, type of perforation,
      and outcome of gall bladder perforation. METHODS: This descriptive
      cross-sectional study was done on patients above 18 years of age visiting the
      department of surgery of B. P. Koirala Institute of Health Sciences (BPKIHS) who 
      were diagnosed with isolated gall bladder perforation. The study was done from
      1st January 2006 till 30 December 2016. Ethical approval was obtained from the
      Institutional Review Committee (reference number. 34/074/075). The convenient
      sampling method was used. Data were entered in excel sheets and analyzed.
      RESULTS: Out of 49 patients included in the study, 28 (57.14%) were females and
      the commonest age group was 36 to 50 years 22 (44.9%) followed by 51 to 65 years 
      16 (32.6%). Most of the patients presented in emergency with pain in their
      abdomen. Diabetes mellitus was the commonest co-morbidity present in 10 (20.41%) 
      patients. Operative management was done in 45 (91.84%) of the patient and
      conservative management in 4 (8.16%). After surgery of 45 patients, 43 (95.56%)
      improved and 2 (4.44%) expired. The most common type of perforation was Niemeier 
      Type I in 21 (46.67%) followed by Type III 14 (31.11%). The most common
      histopathological diagnosis was acute cholecystitis 20 (44.44%). CONCLUSIONS:
      Isolated gall bladder perforation is not an uncommon complication. The most
      common etiological factor was acute cholecystitis with a slight female
      predominance. Most of the patients needed surgical intervention and they had good
      outcomes when diagnosed and managed on time.
FAU - Joshi, Brikh Raj
AU  - Joshi BR
AD  - Department of Surgery, Lumbini Provincial Hospital, Butwal, Rupendehi, Nepal.
FAU - Gautam, Swotantra
AU  - Gautam S
AD  - B. P. Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Adhikari Yadav, Saroj
AU  - Adhikari Yadav S
AD  - Patan Academy of Health Sciences, Patan, Nepal.
FAU - Dhakal, Sushil
AU  - Dhakal S
AD  - Department of Pathology, Maya Metro Hospital, Dhangadi, Nepal.
FAU - Thapaliya, Rasmita
AU  - Thapaliya R
AD  - Department of Nursing, Sanjjevani College of Medical Sciences, Rupendehi, Nepal.
FAU - Gupta, Rakesh Kumar
AU  - Gupta RK
AD  - Department of Surgery, B. P. Koirala Institute of Health Sciences, Dharan, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Gallbladder Diseases/epidemiology/surgery
MH  - Humans
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - Tertiary Care Centers
PMC - PMC8028541
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/09 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5267 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):988-991. doi: 10.31729/jnma.5267.


PMID- 34506389
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Prevalence of Self Induced Abortion by Self-Administration of Abortive Pills
      among Abortion-related Admissions in a Tertiary Care Centre.
PG  - 971-975
LID - 10.31729/jnma.5287 [doi]
AB  - INTRODUCTION: Each year, unsafe medical abortion costs the lives of thousands
      worldwide. Despite the legalization of abortion in Nepal in 2002, many still seek
      services from unauthorized sources. This has led to grave consequences including 
      death. Our objective is to find out the prevalence of self-induced abortion by
      self-administration of abortive pills and related complications. METHODS: It is a
      descriptive cross-sectional study carried out among abortion-related admissions
      in a tertiary care center from June 15 2018 to March 15, 2020. Ethical approval
      was taken from the institutional review committee (076/077/51). Data was
      collected using pre-designed proforma and analyzed in Statistical Package for the
      Social Sciences version 26. Point estimate at 95% Confidence Interval (CI) was
      calculated along with frequency and proportion for binary data. RESULTS: Out of
      223 cases enrolled, 37 (16.6%) (9.6-23.6 at 95% Confidence Interval) were
      self-induced abortion cases by self-administration of abortion pills. The mean
      gestational age at the time of intake of pills was 7+6+/-3+1 week of gestation.
      The majority were diagnosed with incomplete abortion 14 (37.8%) followed by
      septic abortion 8 (21.6%). A surgical evacuation was performed in 25 (67.6%).
      Anemia was observed in 19 (51.3%) with severe anemia in 4 (10.8%). Blood
      transfusion was carried out in 14 (37.8%). Post abortive contraception was
      accepted by only 16 (42.3%). CONCLUSIONS: Medical abortion is safe if done under 
      supervision but self-induced abortion by self-administration of abortion pills
      has a high complication rate. Therefore, further studies exploring a different
      dimension of the serious issue is the need of time.
FAU - Thapa, Bibechan
AU  - Thapa B
AD  - Department of Gynaecology and Obstetrics, KIST Medical College and Teaching
      Hospital, Mahalaxmi-1, Lalitpur, Nepal.
FAU - Sharma, Nisha
AU  - Sharma N
AD  - Department of Gynaecology and Obstetrics, KIST Medical College and Teaching
      Hospital, Mahalaxmi-1, Lalitpur, Nepal.
FAU - Dwa, Yam Prasad
AU  - Dwa YP
AD  - Department of Gynaecology and Obstetrics, KIST Medical College and Teaching
      Hospital, Mahalaxmi-1, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Abortion, Induced
MH  - Contraception
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC8028532
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/15 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5287 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):971-975. doi: 10.31729/jnma.5287.


PMID- 34506388
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Blood Donation Practice among Undergraduate Students in a Tertiary Care Hospital:
      A Descriptive Cross-sectional Study.
PG  - 998-1004
LID - 10.31729/jnma.5288 [doi]
AB  - INTRODUCTION: Voluntary blood donation is a reliable source of increasing the
      demand for blood transfusion. Medical students are the potential pool of blood
      donors. This study aims to find the prevalence of blood donation practice among
      medical students of a medical college in Nepal. METHODS: This is a descriptive
      cross-sectional study conducted in a medical college of Nepal among students
      studying from the first year to final year MBBS. Ethical approval was obtained
      from the Institutional Review Committee of the Nepalese Army Institute of Health 
      Sciences (Ref no. 245). A stratified random sampling technique was used to
      collect data. A self-administered pre-tested questionnaire was used to collect
      data. Data were analyzed using Microsoft Excel 2016. RESULTS: The prevalence of
      blood donation practice among medical students of the medical college is 41
      (22.20%) (17.35-27.05 at 95% Confidence Interval). The practice of blood donation
      is seen more among students of the final year 15 (35.71%) and the least among
      first year 3 (8.57%). Most of the donors, 24 (58.54%), have donated blood only
      once before. The most common reasons for donating and not donating blood before
      are 'behavior of altruism' 12 (29.27%) and 'I am not fit/disapproved' 44 (30.56%)
      respectively. CONCLUSIONS: This study shows less prevalence of blood donation
      practice among medical students. It points to the need for more extensive studies
      to explore the factors deterring medical students from donating blood. Definitive
      strategies are also needed to encourage medical students to increased voluntary
      participation in blood donation.
FAU - Dawadi, Pravakar
AU  - Dawadi P
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Khadka, Sabina
AU  - Khadka S
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Khanal, Milan Chandra
AU  - Khanal MC
AD  - Shepherd College, New Baneshwor, Kathmandu, Nepal.
FAU - Thapa, Raj Kumar
AU  - Thapa RK
AD  - Department of Internal Medicine, Shree Birendra Hospital, Chhauni, Kathmandu,
      Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Blood Donors
MH  - Cross-Sectional Studies
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Students, Medical
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
PMC - PMC8028513
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/16 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5288 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):998-1004. doi: 10.31729/jnma.5288.


PMID- 34506387
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Oct 2
TI  - Prevalence of Hypertension in a Community.
PG  - 1011-1017
LID - 10.31729/jnma.5316 [doi]
AB  - INTRODUCTION: Hypertension is one of the leading risk factors for the global
      burden of disease and is of rising public health concerns in the developing world
      including Nepal. However, few studies have focused on awareness, treatment, and
      control of hypertension among people living with this condition. In this
      scenario, this study aimed to find out the prevalence of hypertension and its
      awareness, treatment, and control among hypertensive patients residing in
      different parts of Kaski district, Nepal. METHODS: A descriptive cross-sectional 
      study was performed among 977 family members of 290 households from August to
      December 2017. Ethical approval was taken from the Institutional Review Committee
      (reference number:73/074/75) of the Pokhara University Research Center. Simple
      random sampling was done. Hypertension screening was performed through averaging 
      three values obtained by standardized aneroid sphygmomanometer in three
      observations. Primary data was collected through self-administered questionnaires
      and face-to-face interviews based on the participant's preferences. Collected
      data were analyzed using Statistical Package for the Social Sciences version 20. 
      Point estimate at 95% Confidence Interval was calculated along with frequency and
      proportion for binary data. RESULTS: Out Of total 997 family members screened,
      294 (29.49%) (26.66-32.32 at 95% confidence interval) had hypertension whereas
      only 127 (43.2%) were completely aware of their disease condition. 279 (94.9%)
      were taking antihypertensive medication and 201 (68.4%) had their blood pressure 
      controlled. CONCLUSIONS: We found that almost one-fourth of the adult population 
      in the community suffered from hypertension but less than half of the
      hypertensive patients are aware of their conditions.
FAU - Paudel, Pradeep
AU  - Paudel P
AD  - Faculty of Health Sciences, School of Health and Allied Sciences, Pokhara
      University, Kaski, Nepal.
FAU - Chalise, Samir
AU  - Chalise S
AD  - Faculty of Health Sciences, School of Health and Allied Sciences, Pokhara
      University, Kaski, Nepal.
FAU - Neupane, Dinesh Raj
AU  - Neupane DR
AD  - Faculty of Health Sciences, School of Health and Allied Sciences, Pokhara
      University, Kaski, Nepal.
FAU - Adhikari, Narayan
AU  - Adhikari N
AD  - Faculty of Health Sciences, School of Health and Allied Sciences, Pokhara
      University, Kaski, Nepal.
FAU - Paudel, Shishir
AU  - Paudel S
AD  - Department of Public Health, Manmohan Memorial Institute of Health Sciences,
      Kathmandu, Nepal.
FAU - Dangi, Nim Bahadur
AU  - Dangi NB
AD  - Faculty of Health Sciences, School of Health and Allied Sciences, Pokhara
      University, Kaski, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Pressure
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Hypertension/drug therapy/epidemiology
MH  - Prevalence
PMC - PMC8028540
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/24 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5316 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 2;58(232):1011-1017. doi: 10.31729/jnma.5316.


PMID- 34506386
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Prevalence of Hysterectomy among Gynecological Surgeries in a Tertiary Care
      Hospital.
PG  - 965-970
LID - 10.31729/jnma.5315 [doi]
AB  - INTRODUCTION: Hysterectomy is the most common gynecological procedure. Over the
      last decade, the minimally invasive approach has been practiced more frequently. 
      Fibroid uterus being the most common indication for hysterectomy justifies this
      minimal approach, however, whenever feasible, vaginal hysterectomy can be the
      preferred route. The objective of this study was to find out the prevalence and
      indication of hysterectomy among major gynecological surgeries in a tertiary care
      hospital. METHODS: A descriptive cross-sectional study was done at a tertiary
      care hospital among 1912 patients who had major gynecological surgeries from
      January 2017 to December 2019. Ethical clearance was obtained from the
      institutional review committee (ref. no. ACD 935/076/077). Convenient sampling
      was used. Statistical analysis was done using Statistical Package for Social
      Sciences version 21.0. Point estimate at 95% Confidence Interval was calculated
      along with frequency and proportion for binary data. RESULTS: During the study
      period, there were 1,912 major gynecological surgeries and the prevalence of
      hysterectomy was 1,131 (59.15%) (56.94-61.35 at 95% Confidence Interval). Fibroid
      uterus was the most common clinical indication for hysterectomy which was done in
      397 (35.10%) patients, followed by uterovaginal prolapse in 254 (22.46) patients,
      adnexal mass in 210 (18.56%), and abnormal uterine bleeding in 117 (10.34%)
      patients. CONCLUSIONS: Hysterectomy, being the most common gynecological surgery,
      selection of the most appropriate route is of paramount importance. As for any
      other surgery, it is not without complication and hysterectomy should always be
      justified. With the advancement in the conservative approaches, these
      organ-preserving options should be explored rigorously before opting for
      hysterectomy.
FAU - Manandhar, Tara
AU  - Manandhar T
AD  - Department of Obstetrics and Gynecology, B. P. Koirala Institute of Health
      Sciences, Dharan, Nepal.
FAU - Sitaula, Sarita
AU  - Sitaula S
AD  - Department of Obstetrics and Gynecology, B. P. Koirala Institute of Health
      Sciences, Dharan, Nepal.
FAU - Thapa, Baburam Dixit
AU  - Thapa BD
AD  - Department of Obstetrics and Gynecology, B. P. Koirala Institute of Health
      Sciences, Dharan, Nepal.
FAU - Agrawal, Ajay
AU  - Agrawal A
AD  - Department of Obstetrics and Gynecology, B. P. Koirala Institute of Health
      Sciences, Dharan, Nepal.
FAU - Thakur, Achala
AU  - Thakur A
AD  - Department of Obstetrics and Gynecology, B. P. Koirala Institute of Health
      Sciences, Dharan, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Gynecologic Surgical Procedures
MH  - Humans
MH  - *Hysterectomy
MH  - Hysterectomy, Vaginal
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC8028525
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/08/24 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5315 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):965-970. doi: 10.31729/jnma.5315.


PMID- 34506384
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Cases of Left Against Medical Advice from the Emergency Department of a Tertiary 
      Care Hospital in Kathmandu: A Descriptive Cross-Sectional Study.
PG  - 992-997
LID - 10.31729/jnma.5411 [doi]
AB  - INTRODUCTION: Left against medical advice is a worldwide phenomenon. Patients
      leaving against Left against medical advice do not provide the health
      professionals with legal impunity. A well-informed consent should be present with
      surety that they are well understood by the patient before they leave. The study 
      was undertaken to study the prevalence of patients that leave against medical
      advice. METHODS: This is a descriptive cross-sectional study done in the
      emergency department of a tertiary care hospital from 1st February 2020 to 31
      July 2020. Ethical approval was taken from the Institutional Review Committee
      (ref. no. 130120205). The sample size was calculated and the convenient sampling 
      method was used. Data were analyzed in the Statistical Package of the Social
      Sciences version 22. Point estimate at 95% Confidence Interval was calculated
      along with frequency and proportion for binary data. RESULTS: Out of 5834 visits,
      332 (5.96%) (4.70-7.22 at 95% Confidence Interval) patients left against medical 
      advice. The mean age was 36.48 years (3 days-91 years) and males 173 (52.3%) were
      prone to leave than females. Only 50 (15.1%) cases had well-informed consent with
      complications documented. Hundred (30.5%) patients had wanted to come on follow
      up the next day in the out-patient department while 41 (12.4%) had to leave
      because of financial reasons. Only seven (2.9%) of well-oriented patients gave
      their consent and the remaining 233 (97.1%) were by the kin present. Only 76
      (23%) patients were sent home with a well-documented medicine prescription.
      CONCLUSIONS: The proportion of patients who left against medical advice was more 
      than the studies done in a similar setting.
FAU - Pant, Manish Nath
AU  - Pant MN
AD  - Departent of General Practice and Emergency Medicine, Kathmandu Medical College
      and Teaching Hospital.
FAU - Jha, Saswat Kumar
AU  - Jha SK
AD  - Jyoti Hospital, Kalimati, Kathmandu, Nepal.
FAU - Shrestha, Sauravi
AU  - Shrestha S
AD  - Nepal Korea Friendship Municipality Hospital, Madhyapur Thimi, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Emergency Service, Hospital
MH  - Female
MH  - Humans
MH  - *Informed Consent
MH  - Male
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC8028538
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/09/21 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5411 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):992-997. doi: 10.31729/jnma.5411.


PMID- 34506383
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Out of pocket Expenditure on Health Service Delivery at a Tertiary Care Women's
      Hospital: A Descriptive Cross-sectional Study.
PG  - 1024-1027
LID - 10.31729/jnma.5433 [doi]
AB  - INTRODUCTION: Institutional delivery in Nepal is increasing in the past decades
      and has been the priority program of the government of Nepal. However, due to the
      hidden costs related to institutional deliveries, the financial burden remains
      unacceptably high for poor households. The study aimed to find out the major out 
      of pocket expenditure on health service delivery at a tertiary care hospital in
      Kathmandu, Nepal. METHODS: A descriptive cross-sectional study was carried out at
      a tertiary care hospital from December 2018 to May 2019. Ethical approval was
      taken from Nepal Health Research Council (ref. no. 2087) and permission was taken
      from the hospital. Informed consent was taken from the participants. Convenient
      sampling was done. A semi-structured questionnaire was used as a tool for the
      interview. Data was entered into Epidata and analyzed using the Statistical
      Package of the Social Sciences version 23. Descriptive analysis was done using
      mean, median, standard deviation, inter-quartile range, frequency, and
      percentage. RESULTS: The median out of pocket expenditure of the participants to 
      maternal delivery was NRs. 11720 (7610-20263). The median expenditure was found
      highest for food and drinking NRs. 2500 (1500-5550) and transportation NRs. 2150 
      (1400-4543) respectively. CONCLUSIONS: Indirect expenditures were found to be
      higher than direct medical expenditures. Accessibility of the birthing centers
      and health insurance may reduce the costs related to maternal deliveries.
FAU - Gartaula, Puja
AU  - Gartaula P
AD  - Department of Public Health, Little Buddha College of Health Sciences, New
      Baneshwar, Kathmandu, Nepal.
FAU - Neupane, Shristi
AU  - Neupane S
AD  - Department of Public Health, Little Buddha College of Health Sciences, New
      Baneshwar, Kathmandu, Nepal.
FAU - Thakur, Dip Narayan
AU  - Thakur DN
AD  - Nepal Public Health Research and Development Center, New Baneshwar, Kathmandu,
      Nepal.
FAU - Sangroula, Raj Kumar
AU  - Sangroula RK
AD  - Department of Public Health, Little Buddha College of Health Sciences, New
      Baneshwar, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Health Expenditures
MH  - *Health Services
MH  - Hospitals
MH  - Humans
MH  - Tertiary Healthcare
PMC - PMC8028534
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/09/26 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5433 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1024-1027. doi: 10.31729/jnma.5433.


PMID- 34506382
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Use of Statins as Lipid Lowering Agent in Hypercholesterolemia in a Tertiary Care
      Hospital: A Descriptive Cross-sectional Study.
PG  - 1031-1035
LID - 10.31729/jnma.5444 [doi]
AB  - INTRODUCTION: Lipids contribute to atherosclerosis and obesity that can lead to
      different cardiovascular diseases. Statins are hydroxymethylglutaryl reductase
      inhibitors that effectively lower the cholesterol level. It is widely prescribed 
      in the treatment of hypercholesterolemia. Thus it optimizes the lipoprotein
      profile. The selection of a particular drug by the practitioner should be
      primarily based on clinical outcome. This study was conducted to find the type of
      statins that are most preferred by the doctors for treating dyslipidemia and
      preferred the fixed-dose in a tertiary care hospital. METHODS: This was a
      descriptive cross-sectional study conducted among the practicing doctors of
      Kathmandu Medical College from July to August 2020. Ethical approval was taken
      from the Institutional Review Committee of the college (Ref: 207202006).
      Convenient sampling was done. A semi-structured questionnaire was used with
      consent. The data were analyzed with Social Statistical Package for the Social
      Sciences version 20. RESULTS: Statins, with the score 4.25 was accounted for most
      preferred for the treatment of dyslipidemia. Among different statins,
      atorvastatin with a score of 4.48 was most popular followed by rosuvastatin 2.9
      score and simvastatin 2.1 scores. CONCLUSIONS: Statins were the most preferred
      agents for the treatment of dyslipidemia. Although different types of statins
      ought to have similar efficacy in treating dyslipidemia, atorvastatin was found
      to be popular and the most commonly prescribed one. The most common side effect
      reported with statins was myopathy.
FAU - Bhattarai, Aashish Kumar
AU  - Bhattarai AK
AD  - Department of Pharmacology, Kathmandu Medical College, Duwakot, Bhaktapur, Nepal.
FAU - Acharya, Anna
AU  - Acharya A
AD  - Department of Pharmacology, Kathmandu Medical College, Duwakot, Bhaktapur, Nepal.
FAU - Karki, Prabin Kumar
AU  - Karki PK
AD  - Department of Physiology, Kathmandu Medical College, Duwakot, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
SB  - IM
MH  - Cholesterol, LDL
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *Hypercholesterolemia/drug therapy/epidemiology
MH  - Lipids
MH  - Tertiary Care Centers
PMC - PMC8028536
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/09/28 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5444 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1031-1035. doi: 10.31729/jnma.5444.


PMID- 34506376
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Prevalence of Type II Diabetes Mellitus Among Adult Population in Medical
      Department of A Tertiary Care Centre.
PG  - 1028-1030
LID - 10.31729/jnma.5647 [doi]
AB  - INTRODUCTION: Diabetes mellitus is a chronic metabolic disease that is mainly
      associated with a number of lifestyle behaviors. There is a high discrepancy
      among urban and rural populations with the prevalence of diabetes in rural areas 
      as 2.5% and a high prevalence of 14.6% in urban areas. Type 2 diabetes mellitus
      accounts for the majority of all diabetes cases with a number of chronic effects 
      that include cardiovascular disease, kidney disease, blindness, and disability.
      This study is done to determine the prevalence of Type II Diabetes Mellitus among
      the adult population in the medical department of a tertiary care center.
      METHODS: A descriptive cross-sectional study was done in a medical department of 
      a tertiary care center of Himal Hospital Private Limited from March to April
      2020. Ethical approval was taken from the Ethical Review Board of NHRC (Reference
      Number 752). All the data of the last two years from the medical record section
      were included in the study. The convenience sampling technique was followed.
      Descriptive statistical analysis was done. RESULTS: The study showed the
      prevalence of Type II Diabetes Mellitus among the adult population to be 23.93 % 
      (0.23) (C.I= 0.20-0.26). CONCLUSIONS: The prevalence of Type II Diabetes Mellitus
      was found to be higher than the previous study done in similar settings.
FAU - Karki, Lochan
AU  - Karki L
AD  - Department of Medicine, Himal Hospital Private Limited, Kathmandu, Nepal.
FAU - Rana, Krishna
AU  - Rana K
AD  - Deurali Primary Health Centre, Nuwakot, Nepal.
FAU - Shahi, Manisha
AU  - Shahi M
AD  - Himal Hospital Private Limited, Kathmandu, Nepal.
FAU - Pradhan, Anjila
AU  - Pradhan A
AD  - Himal Hospital Private Limited, Kathmandu, Nepal.
FAU - Thapa, Roshina
AU  - Thapa R
AD  - Tribhuwan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal.
FAU - Yogi, Prajwala
AU  - Yogi P
AD  - Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Niroula, Aliska
AU  - Niroula A
AD  - Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Humans
MH  - Prevalence
MH  - Rural Population
MH  - Tertiary Care Centers
PMC - PMC8028515
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/11/09 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5647 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1028-1030. doi: 10.31729/jnma.5647.


PMID- 34506372
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Changes and Compromises in Health Choices during COVID-19 Lockdown in Kathmandu
      Valley: A Descriptive Cross-sectional Study.
PG  - 1046-1051
LID - 10.31729/jnma.5790 [doi]
AB  - INTRODUCTION: Nepal government enforced a lockdown as a social distancing measure
      to curb the COVID-19 pandemic. The lockdown has led to compromises in day to day 
      choices like food, exercise, sleep, self-care routines and utilization of
      healthcare facilities - directly and indirectly influencing aspects of health.
      Identification of compromised health choices can assist in better planning of
      inevitable future crises. METHODS: This is a cross-sectional descriptive study
      based on an online self -administered questionnaire, done using CHERRIES
      criteria, conducted from March 30, 2020, to July 31, 2020. Ethical approval for
      the study was obtained from the Institutional Review Committee of Nepal Health
      Research Council (Registration number: 2119; 300/2020 P). Descriptive statistics 
      was used for analysis. RESULTS: Our study had 340 (51%) female and 325 (48.7%)
      male participants. A total of 112 (67.9%) reported decreased consumption of
      tobacco and 178 (53.6%) reported decreased consumption of alcohol during the
      lockdown period. Participants who reported that they would have visited a
      hospital if they had a flu-like illness increased from 151 (22.6%) pre-pandemic
      to 391 (58.6%) post-pandemic. Increase in news consumption was reported by 528
      (79.2%). Out of 43 (6.4%) participants with a chronic condition, 30 (69.8%)
      reported having missed follow up due to the lockdown. CONCLUSIONS: The health of 
      an individual is determined by various choices s/he makes on a day to day basis. 
      Many of those choices are in turn influenced by the availability and
      accessibility of commodities. Lessons learned from the affected lives due to
      COVID-19 can be used in proper planning of inevitable future crises.
FAU - Shrestha, Carmina
AU  - Shrestha C
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Acharya, Sajan
AU  - Acharya S
AD  - New York Medical College/Metropolitan Hospital Center, New York, USA.
FAU - Sharma, Raksha
AU  - Sharma R
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Khanal, Roja
AU  - Khanal R
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Joshi, Jasmin
AU  - Joshi J
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Ghimire, Calvin
AU  - Ghimire C
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Bhandari, Prakriti
AU  - Bhandari P
AD  - Tesla Diagnostic Clinic, Kathmandu, Nepal.
FAU - Agrawal, Aditi
AU  - Agrawal A
AD  - Annapurna Neurological Institute and Allied Sciences, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *COVID-19
MH  - Communicable Disease Control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - *Pandemics
MH  - SARS-CoV-2
PMC - PMC8028530
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/12/09 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5790 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1046-1051. doi: 10.31729/jnma.5790.


PMID- 34506371
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Success Rate of Endoscopic Sphenopalatine Artery Ligation for the Management of
      Refractory Posterior Epistaxis Patients in a Tertiary Care Hospital: A
      Descriptive Cross-sectional Study.
PG  - 1056-1060
LID - 10.31729/jnma.5855 [doi]
AB  - INTRODUCTION: Epistaxis is a common medical emergency with 5% to 15% of patients 
      admitted for epistaxis will require surgical management as nasal packing has high
      failure rates. A modern endoscopic technique like Endoscopic Sphenopalatine
      Artery Ligation has increased in popularity for managing intractable posterior
      epistaxis. It has less complication and a high success rate. The study conducted 
      to estimate the success rate of Endoscopic Sphenopalatine Artery Ligation of
      refractory posterior epistaxis among admitted patients in a tertiary care
      hospital. METHODS: This is a descriptive cross-sectional study conducted from
      June 2019 to June 2020 at the Department of Otorhinolaryngology, Nobel Medical
      College and Teaching Hospital among the patient with refractory posterior
      epistaxis with the help of retrospective data. A convenient sampling method was
      used. These patients underwent endoscopic sphenopalatine artery cauterization for
      recurrent/intractable posterior epistaxis. Ethical clearance was taken from the
      Institutional Review Board. Data were analyzed in Statistical Package for the
      Social Sciences. RESULTS: Out of the total patient with refractory posterior
      epistaxis who underwent Endoscopic Sphenopalatine Artery Ligation, the overall
      success rate was 39 (95.12%). Among them, 25 (60.97%) males and 16 (39.02%)
      females underwent endoscopic sphenopalatine artery ligation. Twenty (48.78%) of
      them were unilateral whilst 21 (51.21%) were bilateral disease. About 2 (4.8%)
      cases had re-bleeding within 48 hours which was managed conservatively.
      Hypertension was found to be the most common comorbid condition followed by
      diabetes, chronic kidney. CONCLUSIONS: From our study, we conclude that the
      success rate for Endoscopic Sphenopalatine Artery Ligation in a patient with
      refractory posterior epistaxis was high.
FAU - Basnet, Meenakshi
AU  - Basnet M
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Nobel Medical
      College and Teaching Hospital, Biratnagar, Nepal.
FAU - Ghimire, Bibek
AU  - Ghimire B
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Nobel Medical
      College and Teaching Hospital, Biratnagar, Nepal.
FAU - Shrestha, Akriti
AU  - Shrestha A
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Nobel Medical
      College and Teaching Hospital, Biratnagar, Nepal.
FAU - Aryal, Gyan Raj
AU  - Aryal GR
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Nobel Medical
      College and Teaching Hospital, Biratnagar, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Arteries
MH  - Cross-Sectional Studies
MH  - *Epistaxis/etiology/surgery
MH  - Female
MH  - Humans
MH  - Ligation
MH  - Male
MH  - *Maxillary Artery
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - Treatment Outcome
PMC - PMC8028521
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/12/21 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5855 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1056-1060. doi: 10.31729/jnma.5855.


PMID- 34506370
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Surgical Emergencies among Gynecological Surgeries in a Tertiary Care Center: A
      Descriptive Cross-sectional Study.
PG  - 1052-1055
LID - 10.31729/jnma.5888 [doi]
AB  - INTRODUCTION: The management of gynecological emergencies is essential for the
      preservation of the life of affected woman, her sexual functions and fertility
      particularly in disease conditions that threaten her life. The main objective of 
      the study is to determine the proportion of the surgical emergencies among
      gynecological surgeries in a tertiary care center. METHODS: This is a descriptive
      cross-sectional study conducted in the department of gynecology and obstetrics in
      Shree Birendra Hospital, Kathmandu, Nepal from April 2013 till March 2017.
      Ethical approval was taken from the Institutional Review Committee (IRC) in
      November 2019. This study was conducted among 515 gynecological surgeries by
      using convenience sampling methods. Point estimate at 95% Confidence Interval was
      calculated along with frequency and proportion for binary data. Data were
      analyzed using Excel software. RESULTS: In our study, the proportion of surgical 
      emergencies among total gynecological surgeries performed in the department of
      gynecology and obstetrics in Shree Birendra Hospital was 120 (23.30%). The
      highest number of surgical emergencies was observed in the age group of 20-29
      years old, followed by less than 19 years of old age group. Ectopic pregnancy
      accounting for 85 (70.83%) is found to be the most common surgical emergencies in
      our study. Out of all surgical emergency cases, most of them underwent
      salpingectomy 65 (54.16%) followed by salpingectomy with tubal ligation 20
      (16.16%). CONCLUSIONS: Surgical emergencies among gynecological surgeries are
      found to be in greater proportion in the department of gynecology and obstetrics 
      in Shree Birendra Hospital. Ectopic pregnancy accounted for more than half of the
      diagnoses in this study.
FAU - Acharya, Indira
AU  - Acharya I
AD  - Department of Gynecology and Obstetrics, Shree Birendra Hospital, Chhauni,
      Kathmandu, Nepal.
FAU - Thapa, Sumana
AU  - Thapa S
AD  - Department of Gynecology and Obstetrics, Shree Birendra Hospital, Chhauni,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Emergencies
MH  - Emergency Service, Hospital
MH  - Female
MH  - *Gynecologic Surgical Procedures
MH  - Humans
MH  - Pregnancy
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC8028531
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/12/28 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5888 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1052-1055. doi: 10.31729/jnma.5888.


PMID- 34506369
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 232
DP  - 2020 Dec 31
TI  - Anatomical Variations in Circle of Willis in Patients Undergoing CT Cerebral
      Angiography in a Tertiary Hospital in Nepal: A Descriptive Cross-sectional Study.
PG  - 1065-1068
LID - 10.31729/jnma.5893 [doi]
AB  - INTRODUCTION: Variation in Circle of Willis is a commonly encountered entity in
      patients undergoing computed tomography angiography, identification of which is
      crucial in the management of patients with vascular pathologies. The aim of the
      study was to find out the anatomical variations in the Circle of Willis in
      patients undergoing Computed Tomography cerebral angiography in a tertiary
      hospital in Nepal. METHODS: This is a descriptive cross-sectional study involving
      95 patients using convenient sampling techniques who were sent to the Department 
      of Radiology and Imaging, Tribhuvan University Teaching hospital, for further
      evaluation of suspected vascular pathologies in the brain from April 2017 to
      September 2017. Ethical approval was taken from the Institutional Review
      Committee of the Institute of Medicine with reference number 326 (6-11-E). CT
      angiographic images of these patients were evaluated for the presence of
      variations in Circle of Willis, aneurysms, and other vascular pathologies. Data
      were analyzed using SPSS. RESULTS: Among 95 subjects included in the study, the
      anatomical variations in the arteries of Circle of Willis was seen in 52 (54.7%) 
      patients, hypoplastic posterior communicating artery being the most common
      variation 33 (34.7%). The aneurysm was seen in 22 (23.2%) of cases. CONCLUSIONS: 
      CT Angiography is a commonly performed imaging modality for suspected cases of
      cerebral aneurysms and various other vascular pathologies. Multidetector computed
      tomography can effectively detect variations in arteries of Circle of Willis,
      recognition of which is crucial in operative management of vascular pathologies.
FAU - Dhakal, Prajwal
AU  - Dhakal P
AD  - Department of Radiology and Imaging, HAMS hospital, Kathmandu, Nepal.
FAU - Kayastha, Prakash
AU  - Kayastha P
AD  - Department of Radiology and Imaging, Tribhuvan University Teaching Hospital,
      Kathmandu, Nepal.
FAU - Paudel, Sharma
AU  - Paudel S
AD  - Department of Radiology and Imaging, Tribhuvan University Teaching Hospital,
      Kathmandu, Nepal.
FAU - Suwal, Sundar
AU  - Suwal S
AD  - Department of Radiology and Imaging, Tribhuvan University Teaching Hospital,
      Kathmandu, Nepal.
FAU - Sharma, Mohan Raj
AU  - Sharma MR
AD  - Department of Neurosurgery, Tribhuvan University Teaching Hospital, Kathmandu,
      Nepal.
FAU - Ghimire, Ram Kumar
AU  - Ghimire RK
AD  - Department of Radiology, Nepal Mediciti Hospital, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cerebral Angiography
MH  - *Circle of Willis/diagnostic imaging
MH  - *Computed Tomography Angiography
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Nepal
MH  - Tertiary Care Centers
MH  - Tomography, X-Ray Computed
PMC - PMC8028512
EDAT- 2021/09/11 06:00
MHDA- 2021/09/15 06:00
CRDT- 2021/09/10 17:18
PHST- 2020/12/28 00:00 [received]
PHST- 2021/09/10 17:18 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
AID - 10.31729/jnma.5893 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):1065-1068. doi: 10.31729/jnma.5893.


PMID- 34504380
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Histopathologic Profile of Salivary Gland Tumors among Specimens from a Tertiary 
      Care Hospital: A Descriptive Cross-sectional Study.
PG  - 729-735
LID - 10.31729/jnma.4898 [doi]
AB  - INTRODUCTION: Salivary gland tumors are rare, comprising about 3% of all head and
      neck neoplasms. About 80% of the tumors are in parotids, 10% in submandibular
      glands and the remainders are distributed in sublingual and minor salivary
      glands. This study was conducted to evaluate the relative frequencies, types,
      site of distribution and the histopathological features of salivary gland tumors.
      METHODS: A descriptive cross-sectional study was conducted in the Department of
      Pathology, Manipal College of Medical Sciences, Pokhara from January 2011 to
      December 2019. Ethical approval was taken from the institutional review committee
      of Manipal College of Medical Sciences (Ref: 314). Convenient sampling was done
      among specimen. Data were entered in Microsoft Excel and analyzed using
      Statistical Package for the Social Sciences version 21. RESULTS: Among the 130
      specimens, the patients' age ranged from 6 to 78 years with a mean age of 37.26
      years for benign tumors and 48.45 years for malignant tumors. There was female
      predominance with a male to female ratio of 1:1.36. There were 98 cases of benign
      tumors, commonest being pleomorphic adenoma with 82 (83.67%) cases which was
      noticed more frequently in fourth decade of life. Among the 32 malignant tumors, 
      mucoepidermoid carcinoma was the commonest tumor 20 (62.5%), followed by adenoid 
      cystic carcinoma 7 (23.33%). CONCLUSIONS: Benign salivary gland tumors were more 
      common than malignant tumors and the most common site of location was the parotid
      for both the benign and malignant tumors. Female outnumbered the male population 
      in benign tumors whereas males were slightly more than females in malignant
      tumors. This study corroborated well with other previously published studies.
FAU - Ghartimagar, Dilasma
AU  - Ghartimagar D
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Ghosh, Arnab
AU  - Ghosh A
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Shrestha, Manish Kiran
AU  - Shrestha MK
AD  - Department of Radiology, Charak Memorial Hospital , Pokhara, Nepal.
FAU - Thapa, Sushma
AU  - Thapa S
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Talwar, Om Prakash
AU  - Talwar OP
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Adenoma, Pleomorphic/epidemiology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Salivary Gland Neoplasms/epidemiology
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7654487
OTO - NOTNLM
OT  - mucoepidermoid carcinoma;pleomorphic adenoma;salivary gland;tumor.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/03/31 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.4898 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):729-735. doi: 10.31729/jnma.4898.


PMID- 34504378
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20220531
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Dental Practice during COVID-19 in Nepal: A Descriptive Cross-sectional Study.
PG  - 764-769
LID - 10.31729/jnma.5022 [doi]
AB  - INTRODUCTION: Currently, coronavirus disease (COVID-19) has become pandemic and
      spread globally. In Nepal, the number of COVID-19 is increasing day-by-day. This 
      research was done to find out the impact of COVID-19 on dentists, patients, and
      dental practice in Nepal. METHODS: This study is a cross-sectional study
      conducted using an online survey from May 10 to17, 2020. A questionnaire was
      designed and uploaded in Freeonlinesurveys.com. Following ethical approval, the
      questionnaire was distributed among 500 dentists, and 406 dentists participated
      in the study. The survey link was dispersed to the Nepali dentists through social
      media and e-mail, and the results of the responses were received online. The
      questionnaire consisted of a total of 34 closed-ended questions containing three 
      parts; demographic details, knowledge of dentists on COVID-19, and the impact of 
      COVID-19 on dentists, patients, and dental treatments. RESULTS: It showed that
      majority of the participants were females 243 (60%) of the age group 25-29 years 
      with the clinic as the workplace. Patients receive dental treatments only from 40
      (10%) of the dentist. A high number of dentists: 284 (70%) were severely affected
      by the financial burden and were not receiving a salary during this lockdown.
      About 349(86%) of the dentist think they should do regular dental treatments, but
      only 101 (25%) think the dentist should do only dental emergency treatments for
      COVID-19 infected cases. CONCLUSIONS: Dentists, patients, and dental practice are
      severely affected by the COVID-19.The majority of the dentists have faced
      financial burdens. The dental treatments should be done with high standards of
      care and infection control following proper recommendations.
FAU - Humagain, Manoj
AU  - Humagain M
AD  - Department of Periodontology and Oral Implantology, Kathmandu University School
      of Medical Sciences, Dhulikhel, Nepal.
FAU - Humagain, Rashmi
AU  - Humagain R
AD  - Dental Doctor Clinic, Kathmandu, Nepal.
FAU - Rokaya, Dinesh
AU  - Rokaya D
AD  - Department of Clinical Dentistry, Walailak University International College of
      Dentistry, Walailak University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - *Dentists
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Infection Control
MH  - Male
MH  - Nepal/epidemiology
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
PMC - PMC7654486
OTO - NOTNLM
OT  - coronavirus;COVID-19;dentistry;dentists;knowledge.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/05/20 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5022 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):764-769. doi: 10.31729/jnma.5022.


PMID- 34504374
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Information about COVID-19 among Selected Population of Eastern Nepal: A
      Descriptive Cross-sectional Study.
PG  - 770-774
LID - 10.31729/jnma.5096 [doi]
AB  - INTRODUCTION: Rapid spread of COVID-19 has become a major concern worldwide.
      Strong adherence to preventive measures can help to break the chain of the spread
      of coronavirus. We conducted this study to find out the extent of information
      general people of Eastern Nepal have regarding COVID-19 and their attitude and
      practice towards preventing its spread. METHODS: A descriptive cross-sectional
      online study was done among the people of Eastern Nepal on knowledge, attitude,
      and practice related to COVID-19 from May 1st to May 15th after obtaining ethical
      clearance from the ethical review board (ERB) (ref no. 319/2020 P). A 20 item
      survey instrument was adapted using WHO course materials on an emerging COVID-19.
      A convenience sample method was used. Data were collected and entered in
      Statistical Packages for Social Services version 11.5. Point estimate at 95%
      Confidence Interval was calculated along with frequency and proportion for binary
      data. RESULTS: Among 1069 respondents, the correct answer on the COVID-19 related
      knowledge questionnaire was 958 (89.61%), 487 (93.11%) were health professionals,
      and 471 (86.26%) non-health professionals. Preventive measures were strictly
      followed by 1044 (97.66%) participants. A wrong perception about the disease was 
      present in 390 (36.48%). Health ministry website 356 (33.30%) followed by news
      media 309 (29%) was the major source of information among the people.
      CONCLUSIONS: Knowledge regarding COVID-19 among people the selected population of
      eastern is satisfactory which was similar to other studies done. However, people 
      still have misperceptions regarding the disease and do not strictly follow the
      preventive measures.
FAU - Chapagain, Kumud
AU  - Chapagain K
AD  - Department of Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of
      Health Sciences, Dharan, Nepal.
FAU - Rauniyar, Gajendra Prasad
AU  - Rauniyar GP
AD  - Department of Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of
      Health Sciences, Dharan, Nepal.
FAU - Pokharel, Rais
AU  - Pokharel R
AD  - Department of Otorhinolaryngology, Purbanchal University College of Medical
      Sciences, Gothgaun, Morang, Nepal.
FAU - Bhattarai, Abhisekh
AU  - Bhattarai A
AD  - Purbanchal University School of Engineering and Technology, Morang, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *COVID-19
MH  - Cross-Sectional Studies
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Nepal/epidemiology
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
PMC - PMC7654481
OTO - NOTNLM
OT  - COVID-19;eastern Nepal;information.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/06/08 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5096 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):770-774. doi: 10.31729/jnma.5096.


PMID- 34504373
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Computer Vision Syndrome among Patients Attending the Outpatient Department of
      Ophthalmology in a Tertiary Care Centre: A Descriptive Cross-sectional Study.
PG  - 721-724
LID - 10.31729/jnma.5123 [doi]
AB  - INTRODUCTION: Computers and digital electronic devices have become an integral
      part of life. These devices have adverse effects and nowadays are considered
      leading occupational hazards. Computer vision syndrome comprises of all the
      ocular, visual and musculoskeletal symptoms secondary to long term computer use. 
      The objective of this study is to determine the prevalence of computer vision
      syndrome among people attending the outpatient department of ophthalmology in the
      tertiary care center in Nepal. METHODS: A descriptive cross-sectional study was
      done among 70 patients in a tertiary care hospital from January 2017 to June 2017
      after obtaining ethical approval from the institutional review committee (Ref:
      12042017). Convenient sampling method was applied and the point estimate at 95%
      confidence interval was calculated along with frequency and proportion for binary
      data. Patients using computers for more than one hour were included in the study.
      All data were entered in Microsoft Excel and analyzed using statistical package
      for social sciences version 20. RESULTS: Among 70 patients, 67 (95.7%) (87.9-99.1
      at 95% confidence interval) had one or more symptoms on computer use. The mean
      duration of computer use was 7.5A+/-5.4 years and average hours of computer use
      among computer users were 6.9A+/-3 hours. The most common symptom among computer 
      users was headache seen in 46 (62.2%) patients. CONCLUSIONS: Our study showed
      that a significant number of people using a computer develop one or more symptoms
      on the long-term use of the computer. Therefore, it is very important to create
      awareness regarding computer vision syndrome and methods to prevent it among
      computer users.
FAU - Shrestha, Priyanka
AU  - Shrestha P
AD  - Department of Ophthalmology, Kathmandu Medical College Teaching Hospital,
      Kathmandu, Nepal.
FAU - Pradhan, Pranil Man Singh
AU  - Pradhan PMS
AD  - Department of Community Medicine, Institute of Medicine, Tribhuvan University,
      Kathmandu, Nepal.
FAU - Malla, Om Krishna
AU  - Malla OK
AD  - Department of Ophthalmology, Kathmandu Medical College Teaching Hospital,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Computers
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Outpatients
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC7654495
OTO - NOTNLM
OT  - computer;vision syndrome;ergonomics.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/06/21 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5123 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):721-724. doi: 10.31729/jnma.5123.


PMID- 34504371
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Functional Outcomes of Capitellum Fractures Treated by Open Reduction and
      Internal Fixation with Herbert Screw: A Descriptive Cross-sectional Study.
PG  - 775-779
LID - 10.31729/jnma.5188 [doi]
AB  - INTRODUCTION: Based on the complex intra-articular nature of capitellum
      fractures, it has been sometimes difficult to formulate a universally accepted
      method of surgical treatment. The purpose of this study is to present the
      functional outcomes of capitellum fractures after fixation with Herbert screw
      including the safety and tips of the surgical approach. METHODS: This descriptive
      cross-sectional study was done from December 2014 to November 2019. Ethical
      approval was taken. The study included 22 capitellum fractures treated by open
      reduction and internal fixation with Herbert screws either lateral or
      anterolateral approach. Functional outcomes were assessed with Mayo elbow
      performance index scores at the latest follow-up visit. Convenient sampling was
      done. Data entry was done using the Statistical Package for the Social Sciences
      (version16.0). RESULTS: Out of 22 surgeries, the average time to unite the
      fracture was 11.13+/-1.20 weeks (range 9 to 15). The mean range of movement for
      flexion and extension was 138.41+/-8.22 degree while the mean supination and
      pronation range was 161.59+/-6.79 degree. The average time of follow-up in this
      series was 37.45+/-9.43 weeks (range 22 to 58 weeks). Similarly, the mean Mayo
      elbow performance index score at the latest follow-up was 90.22+/-8.65 (range 70 
      to 100). CONCLUSIONS: Careful assessment and radiological evaluation, anatomical 
      reduction, and stable fixation with Herbert screws maintaining the minimal damage
      to the articular cartilage can maximize the functional outcomes and minimize the 
      incidence of complications.
FAU - K C, Kapil Mani
AU  - K C KM
AD  - Department of Orthopedics, Civil Service Hospital, Minbhawan, Kathmandu, Nepal.
FAU - Acharya, Parimal
AU  - Acharya P
AD  - Department of Orthopedics, Civil Service Hospital, Minbhawan, Kathmandu, Nepal.
FAU - Marahatta, Suman Babu
AU  - Marahatta SB
AD  - Department of Orthopedics, Civil Service Hospital, Minbhawan, Kathmandu, Nepal.
FAU - Sigdel, Arun
AU  - Sigdel A
AD  - Department of Orthopedics, Civil Service Hospital, Minbhawan, Kathmandu, Nepal.
FAU - K C, Amuda
AU  - K C A
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepa.
FAU - Dahal, Sudip Chandra
AU  - Dahal SC
AD  - Civil Service Hospital, Minbhawan, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Bone Screws
MH  - Cross-Sectional Studies
MH  - *Elbow Joint/diagnostic imaging/surgery
MH  - Fracture Fixation, Internal
MH  - Humans
MH  - *Humeral Fractures
MH  - Open Fracture Reduction/adverse effects
MH  - Range of Motion, Articular
MH  - Treatment Outcome
PMC - PMC7654489
OTO - NOTNLM
OT  - fracture;surgery;treatment.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/07/14 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5188 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):775-779. doi: 10.31729/jnma.5188.


PMID- 34504370
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Study of Menopausal Symptoms using Menopause Rating Scale at a Tertiary Care
      Center: A Descriptive Cross-sectional Study.
PG  - 725-728
LID - 10.31729/jnma.5200 [doi]
AB  - INTRODUCTION: Menopause is the permanent cessation of menstruation for more than 
      a year resulting from the loss of follicular activity of the ovaries. It is
      manifested by vasomotor, psychological, and urogenital symptoms which can be
      assessed by an internationally accepted scale known as Menopause Rating Scale.
      This study was conducted to find out the issues of perimenopausal women and
      proceed for management and proper counseling. METHODS: A descriptive
      cross-sectional study was conducted among women visiting the gynecological
      outpatient department of a tertiary care hospital from June 2017 to May 2018
      using the Menopause Rating Scale. Ethical approval was taken from the
      Institutional Review Committee (reference number: 20122016). Convenient sampling 
      was done. Statistical Package for the Social Sciences version 20.0 was used for
      data analysis. Point estimate at 90% confidence interval was calculated along
      with frequency and proportion for binary data. RESULTS: Out of 189 perimenopausal
      women interviewed, the mean age of menopause was found to be 50.2+/-2.1 years.
      The most common gynecological symptoms among the study population was abnormal
      uterine bleeding 66 (34.9%) followed by abnormal vaginal discharge 50 (26.5%).
      Among symptoms in Menopause Rating Scale, the depressive mood was found in 99
      (52.4%) cases followed by joint and muscular discomfort 88 (46.6%) and bladder
      problems in 87 (46%). None of the women had a score on the Menopause Rating Scale
      more than 16 and did not require management for their problem. CONCLUSIONS: Most 
      of the women didn't know menopausal symptoms. However, none required intervention
      from gynecologists for their problems reflecting better quality of life.
FAU - Pandey, Asmita
AU  - Pandey A
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Karki, Chanda
AU  - Karki C
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Shrivastava, Veena Rani
AU  - Shrivastava VR
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Shrestha, Dipty
AU  - Shrestha D
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Gautam, Pratigyan
AU  - Gautam P
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Hot Flashes/epidemiology
MH  - Humans
MH  - Menopause
MH  - Middle Aged
MH  - *Quality of Life
MH  - Tertiary Care Centers
PMC - PMC7654501
OTO - NOTNLM
OT  - menopause;quality of life;questionnaire.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/07/17 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5200 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):725-728. doi: 10.31729/jnma.5200.


PMID- 34504369
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Health Co-morbidities and Early Marriage in Women of a Rural Area of Nepal: A
      Descriptive Cross-Sectional Study.
PG  - 780-783
LID - 10.31729/jnma.5205 [doi]
AB  - INTRODUCTION: Early marriage is defined as the marriage of a young person less
      than 18 years. Early marriage is more prevalent in South Asia as more than half
      of all child marriage occurs here. Thirtyseven percent of girls in Nepal marry
      before age 18 years. This study was done to find out the health consequences of
      early marriage in women of a rural area of Nepal. METHODS: A descriptive
      cross-sectional study was conducted from 10th to 15th Feb 2020 February in 358
      women from Panauti, Kavrepalchowk. The convenient sampling method was used.
      Ethical approval was taken from the Institutional Review Committee. Economic
      status was assessed by using Kuppuswamyaeuros socioeconomic scale. The collected 
      data were analyzed using the Statistical Package for Social Science version 20.
      Point estimate at 95% confidence interval was calculated along with frequency and
      proportion for binary data. RESULTS: The prevalence of early marriage was 187
      (52.2%) (47.03 to 57.37 at 95% confidence interval). One hundred sixteen (62%)
      early marriage women had gynecological problems followed by depression problem 85
      (45.5%) and miscarriage 32 (17.1%). The mean age of marriage was 17.2 years. The 
      majority, i.e. 167 (89.3%) of respondents who married earlier were Hindu by
      religion. Early marriage was observed in 104 (55.6 %) of illiterate women.
      CONCLUSIONS: The prevalence of early marriage was high. Early married women had a
      lower level of socio-economic status, lower level of education, which harmed the 
      participants' health status.
FAU - Manandhar, Naresh
AU  - Manandhar N
AD  - Department of Community Medicine, Kathmandu Medical College, Sinamangal.
FAU - Joshi, Sunil Kumar
AU  - Joshi SK
AD  - Department of Community Medicine, Kathmandu Medical College, Sinamangal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Cross-Sectional Studies
MH  - Educational Status
MH  - Female
MH  - Humans
MH  - Morbidity
MH  - Nepal/epidemiology
MH  - *Rural Population
MH  - Socioeconomic Factors
PMC - PMC7654477
OTO - NOTNLM
OT  - depression;early marriage;gynaecological;haemorrhage;miscarriage.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/07/19 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5205 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):780-783. doi: 10.31729/jnma.5205.


PMID- 34504368
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Prevalence of Psychoactive Drug Use among Medical Students in a Medical College
      of Nepal.
PG  - 717-720
LID - 10.31729/jnma.5237 [doi]
AB  - INTRODUCTION: Psychoactive drug is a worrisome and emerging global problem. This 
      is a disturbing matter, especially in the case of medical students, as it affects
      not only their health and academic performance alone but their clinical
      efficiency as well. This study aims to determine the prevalence of psychoactive
      drug use among medical students in a medical college in Nepal. METHODS: A
      descriptive cross-sectional study was conducted after receiving ethical clearance
      from the Institutional Review Committee (Ref: 258/19) among undergraduate medical
      students from December 2019 to June 2020. Convenience sampling was used to
      collect data. Data analysis was done in the Statistical Package for Social
      Sciences. Point estimate at 95% confidence interval was calculated along with
      frequency and proportion for binary data. RESULTS: The prevalence of psychoactive
      drug abuse was found to be 76 (44.2%) [CI= 43.6%aeuro"44.8%]. The study showed
      males 59 (59%) were more indulged in abuse than females 17 (23.6%). Alcohol 72
      (41.86%) was the most commonly used, then was tobacco 24 (13.95%) followed by
      cannabis 17(9.88%). Only two students were sedative and opioid abusers. Pleasure 
      38 (31.70%) and experimentation 29 (24.20%) were the two major causes of
      substance abuse. Tobacco was used more frequently 14 (58.33%) used daily and
      found to have more financial and health-related issues in the last three months. 
      CONCLUSIONS: Even almost half of the students were using some form of
      psychoactive drugs, the majority of them were occasional users. Proper counseling
      needs to be done to address this problem. Further study should be conducted to
      address the influencing factors and adverse outcomes.
FAU - Shrestha, Jyoti Tara Manandhar
AU  - Shrestha JTM
AD  - Department of Pharmacology, Kathmandu University School of Medical Sciences,
      Dhulikhel, Nepal.
FAU - Tiwari, Saurabh
AU  - Tiwari S
AD  - Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
FAU - Kushwaha, Dilip Kumar
AU  - Kushwaha DK
AD  - Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
FAU - Bhattarai, Pratigya
AU  - Bhattarai P
AD  - Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
FAU - Raj, Risu
AU  - Raj R
AD  - Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - Psychotropic Drugs
MH  - *Students, Medical
MH  - *Substance-Related Disorders/epidemiology
MH  - Surveys and Questionnaires
PMC - PMC7654497
OTO - NOTNLM
OT  - alchohol;medical students;psychoactive drugs;substance abuse.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/07/27 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5237 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):717-720. doi: 10.31729/jnma.5237.


PMID- 34504366
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20220531
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Prevalence of Laryngomalacia among Young Children Presenting with Stridor in a
      Tertiary Care Hospital.
PG  - 712-716
LID - 10.31729/jnma.5244 [doi]
AB  - INTRODUCTION: Laryngomalacia is one of the most common causes of stridor in young
      children. It can be a serious concern to both parents and caregivers. The main
      objective of this study is to find the prevalence of laryngomalacia among young
      children presenting with stridor in a tertiary care hospital in central Nepal.
      METHODS: A descriptive cross-sectional study was carried out form 1st December
      2017 to 1st May 2020 in children less than two years of age in a tertiary care
      hospital. Ethical approval was taken from the Institutional Review Committee of
      the hospital (reference number: 2020/23). Convenient sampling was done. Detailed 
      demography, clinical examination, and video laryngoscopy findings were evaluated 
      to find the prevalence of laryngomalacia among all children with stridor. Data
      were analyzed by using Statistical Package for the Social Sciences version 20.
      Point estimate at 95% confidence interval was calculated along with frequency and
      proportion for binary data. RESULTS: Out of 430 participants who presented with
      stridor, the laryngomalacia was found in 234 (66%) (58.7-74.07) cases at a 95%
      confidence interval. The male: female ratio was 1.7:1. Most children, 192
      (67.6%), presented with a milder form of laryngomalacia. The most common type was
      a mixed type of laryngomalacia in 159 (56%). Sleep-disordered breathing was seen 
      in 113 (39.79%) of children diagnosed with laryngomalacia. CONCLUSIONS: Our study
      concluded that laryngomalacia was the most common cause of stridor in children
      less than two years of age. However, in most cases, the problem is not serious
      and a regular follow-up with weight monitoring is warranted.
FAU - Pokharel, Apar
AU  - Pokharel A
AD  - Department of Ear, Nose, and Throat, and Head and Neck Surgery, College of
      Medical Sciences, Bharatpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Laryngomalacia/complications/diagnosis/epidemiology
MH  - Male
MH  - Prevalence
MH  - Respiratory Sounds/etiology
MH  - Tertiary Care Centers
PMC - PMC7654493
OTO - NOTNLM
OT  - laryngomalacia;Nepal;stridor.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/07/30 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5244 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):712-716. doi: 10.31729/jnma.5244.


PMID- 34504365
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Knowledge, Attitude and Practices among Mothers of Children 6 to 24 months of Age
      Regarding Complementary Feeding.
PG  - 758-763
LID - 10.31729/jnma.5274 [doi]
AB  - INTRODUCTION: Complementary foods fill the gap between the total nutritional
      needs of the child and the amounts provided by breast milk. Inappropriate feeding
      practices are a major cause of the onset of malnutrition in young children. The
      objective of this study was to assess the knowledge, attitude, and practices of
      mothers of children between 6 to 24 months of age regarding complementary
      feeding. METHODS: This Knowledge, Attitude, and Practice Study was conducted
      among 250 mothers in Kathmandu Medical College and Teaching Hospital from June
      2019 to November 2019 after obtaining ethical approval from the institutional
      review committee (Ref no. 150320199). Convenient sampling method was applied. The
      mothers of children between 6 to 24 months were interviewed using a structured
      questionnaire to ascertain the knowledge, attitude, and practices regarding
      complementary feeding. Statistical analysis was done using SPSS version 20.
      RESULTS: Two hundred and fifty mothers were interviewed. 151 (60.4%) mothers knew
      initiation of breastfeeding soon after birth and 179 (71.6%) were knowledgeable
      about exclusive breastfeeding for 6 months. 161 (64.4%) mothers knew the proper
      age of initiating complementary feeding but only 139 (55.6%) mothers practiced
      it. Early initiation of complementary feeding was done by 87 (34.8%) mothers
      while 24 (9.6%) mothers delayed it beyond 6 months. CONCLUSIONS: There was a gap 
      in knowledge and practice among mothers regarding adequate age of initiation of
      complementary feeding, complementary foods, preparation, and practices.
FAU - Shrestha, Sabina
AU  - Shrestha S
AD  - Department of Pediatrics, Kathmandu Medical College and Teaching Hospital,
      Kathmandu, Nepal.
FAU - Pokhrel, Manoj
AU  - Pokhrel M
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College and Teaching 
      Hospital, Kathmandu, Nepal.
FAU - Mathema, Smriti
AU  - Mathema S
AD  - Department of Pediatrics, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Breast Feeding
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Infant
MH  - Infant Nutritional Physiological Phenomena
MH  - *Mothers
MH  - Surveys and Questionnaires
PMC - PMC7654499
OTO - NOTNLM
OT  - attitude;complementary feeding;knowledge.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/08/12 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5274 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):758-763. doi: 10.31729/jnma.5274.


PMID- 34504361
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Patterns of Rheumatic Heart Disease and Treatment Practices at Tertiary Care
      Center in Nepal: A Descriptive Cross-sectional Study.
PG  - 784-788
LID - 10.31729/jnma.5405 [doi]
AB  - INTRODUCTION: Rheumatic heart disease is a sequel of rheumatic fever which causes
      heart valve damage. This study was conducted to look at the pattern of valve
      lesions and treatment practices in patients with rheumatic heart disease.
      METHODS: A cross-sectional study conducted at the tertiary care center with a
      diagnosis of rheumatic heart disease from July 2018 to January 2020 by convenient
      sampling. Ethical clearance was obtained from the Institutional Review Committee 
      (ref no. 55/2018). Data were analyzed by using Statistical package for social
      sciences version 20. RESULTS: Out of 600 patients, 428 (71.3%) were female. The
      mean age was 44.24A+/-14.24 years. The isolated mitral valve was affected in 280 
      (46.6%). Dual involvement of mitral and aortic valve was present in 294 (49%).
      Only 14 (2.3%) had involvement of isolated aortic valve involvement. Overall,
      mitral stenosis was the most common abnormality 508 (84.6%) followed by mitral
      regurgitation 418 (69.6%), aortic regurgitation 320 (53.3%), and aortic stenosis 
      63 (10.5%). Assessment of the severity of lesions showed that 247 (41.2%)
      patients had severe mitral stenosis, 119 (19.8%) severe mitral regurgitation, 14 
      (2.3%) severe aortic stenosis, and 11 (1.8%) severe aortic regurgitation.
      Majority 493 (82.2%) were treated with medical therapies. Surgical procedures
      were performed in 51 (8.5%). The use of anticoagulation was in 212 (35.3%) of
      eligible patients. CONCLUSIONS: Mitral valve was affected commonly both in
      isolation and combination. The majority of patients who were eligible for cardiac
      interventions were treated medically with suboptimal use of anticoagulation and
      secondary prophylaxis.
FAU - Nepal, Rajesh
AU  - Nepal R
AD  - Department of Internal Medicine and Cardiology Unit, Nobel Medical College
      Teaching Hospital, Biratnagar, Nepal.
FAU - Bista, Madhab
AU  - Bista M
AD  - Department of Internal Medicine and Cardiology Unit, Nobel Medical College
      Teaching Hospital, Biratnagar, Nepal.
FAU - Dhungana, Sahadeb Prasad
AU  - Dhungana SP
AD  - Department of Internal Medicine and Cardiology Unit, Nobel Medical College
      Teaching Hospital, Biratnagar, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Mitral Valve Stenosis/epidemiology/etiology
MH  - Nepal/epidemiology
MH  - *Rheumatic Heart Disease/epidemiology/therapy
MH  - Tertiary Care Centers
PMC - PMC7654488
OTO - NOTNLM
OT  - rheumatic heart disease;spectrum analysis;treatment.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/09/18 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5405 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):784-788. doi: 10.31729/jnma.5405.


PMID- 34504359
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Mental Wellbeing during the Lockdown Period following the COVID-19 Pandemic in
      Nepal: A Descriptive Cross-sectional Study.
PG  - 744-750
LID - 10.31729/jnma.5498 [doi]
AB  - INTRODUCTION: COVID-19 pandemic has profoundly affected all aspects of society,
      including mental and physical health. Often missed is the fact that the pandemic 
      is occurring against the backdrop of a very high prevalence of mental health
      issues. Protecting the mental health of people and healthcare workers is
      important for long-term positive health outcomes and proper control of the
      outbreak. METHODS: This is a descriptive cross-sectional, questionnaire-based,
      online survey by convenience sampling. Ethical approval was obtained from the
      institutional review committee of Nepal Health Research Council (reference no.
      2467). Open access, pre-validated questionnaires were used. Participants with
      significantly poor Mental wellbeing were identified using the WHO well-being
      index threshold score. Descriptive statistical analysis was carried out. RESULTS:
      Five hundred and fifty-six participants were included in the analysis. Forty
      percent of the participants reported a WHO well-being index score of below 13,
      indicative of poor mental wellbeing and a need for further assessment for
      depression. Poor Mental wellbeing was more prevalent among participants less than
      30 years of age, female gender, never married, diagnosed mental disorder, living 
      alone and those using informal sources for COVID-19 related information. More
      participants with lower sleep quality score and higher perceived stress score
      reported poor Mental wellbeing. CONCLUSIONS: Combating this challenge requires
      integration across disciplines. One potential part of the solution is
      psychological intervention teams. An emerging positive connotation to the
      pandemic is that it needs to be harnessed as a tool for improving health
      facilities, community participation, and fighting misinformation.
FAU - Shrestha, Carmina
AU  - Shrestha C
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Ghimire, Calvin
AU  - Ghimire C
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Acharya, Sajan
AU  - Acharya S
AD  - New York Medical College/Metropolitan Hospital Center, New York, USA.
FAU - Kc, Prabhat
AU  - Kc P
AD  - Patan Academy of Health Sciences-School of Medicine, Lalitpur, Nepal.
FAU - Singh, Swarndeep
AU  - Singh S
AD  - Department of Psychiatry, All India Institute of Medical Sciences, New Delhi,
      India.
FAU - Sharma, Pawan
AU  - Sharma P
AD  - Department of Psychiatry, Patan Academy of Health Sciences-School of Medicine,
      Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *COVID-19
MH  - Communicable Disease Control
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Nepal/epidemiology
MH  - *Pandemics
MH  - SARS-CoV-2
PMC - PMC7654491
OTO - NOTNLM
OT  - COVID-19;lockdown;mental well being;Nepal;pandemic.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/10/06 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5498 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):744-750. doi: 10.31729/jnma.5498.


PMID- 34504357
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 230
DP  - 2020 Oct 15
TI  - Medical Induction for Mid trimester Abortion: A Hospital-based Descriptive
      Cross-sectional Study.
PG  - 794-797
LID - 10.31729/jnma.5502 [doi]
AB  - INTRODUCTION: Second trimester abortion is known as termination of pregnancy from
      13- 28 weeks of gestation which can be further divided into early second
      trimester as 13-22 weeks and late as 23-28 weeks. In our study we have limited up
      to early second trimester. We intend to see the success rate of combination of
      mifepristone and misoprostol for medical induction, median time required for
      expulsion, complication and need of dilation and evacuation in some cases. This
      study also aims to give a review of current literature in mid trimester abortion 
      with respect to efficacy, complication and also to provide evidencebase
      recommendation for safe regimens for mid trimester pregnancy termination.
      METHODS: This was hospital-based descriptive cross-sectional study conducted
      among 40 pregnant women at second trimester admitted for termination of pregnancy
      in Kathmandu medical collage teaching hospital for the period of six month.
      Ethical approval was taken from the Institutional Review Committee of Kathmandu
      Medical College (Ref: 2207202002). Convenient sampling was done. All the pregnant
      women who need to terminate their pregnancy at second trimester (13-22 weeks)
      were admitted at Kathmandu Medical College Teaching hospital for termination of
      pregnancy were included in the study. RESULTS: Among the 40 women, who had
      termination of pregnancy at second trimester 37 (92.5%) had successful medical
      termination whereas 3 (7.5%) needed dilatation and evacuation. CONCLUSIONS: The
      combination of Mifepristone and Misoprostol have excellent result for termination
      of pregnancy if appropriately used after evaluating the patient with minimal
      complications.
FAU - Sharma, Jyotshna
AU  - Sharma J
AD  - Department of Obstetrics and Gyanecology, Kathmandu Medical College-Teaching
      Hospital, Kathmandu, Nepal.
FAU - Tiwari, Sanjeeb
AU  - Tiwari S
AD  - Department of General Practice and Emergency Medicine, Maharajgunj Medical
      Campus, Institute of Medicine, T.U., Maharajgunj, Kathmandu, Nepal.
FAU - Pokhrel, Manoj
AU  - Pokhrel M
AD  - epartment of Obstetrics and Gyanecology, Kathmandu Medical College-Teaching
      Hospital, Kathmandu, Nepal.
FAU - Lama, Lhakpa
AU  - Lama L
AD  - Department of Obstetrics and Gyanecology, Kathmandu Medical College-Teaching
      Hospital, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201015
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Abortifacient Agents, Nonsteroidal)
RN  - 0E43V0BB57 (Misoprostol)
RN  - 320T6RNW1F (Mifepristone)
SB  - IM
MH  - *Abortifacient Agents, Nonsteroidal
MH  - *Abortion, Induced
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Mifepristone
MH  - *Misoprostol
MH  - Pregnancy
MH  - Pregnancy Trimester, Second
PMC - PMC7654484
OTO - NOTNLM
OT  - abortion;dilation and evacuation;medical induction.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/09/10 06:57
PHST- 2020/10/07 00:00 [received]
PHST- 2021/09/10 06:57 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.31729/jnma.5502 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Oct 15;58(230):794-797. doi: 10.31729/jnma.5502.


PMID- 34497404
OWN - NLM
STAT- Publisher
LR  - 20210909
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Sep 9
TI  - A new way to cool computer chips - from within.
LID - 10.1038/d41586-020-02595-9 [doi]
FAU - Bundell, Shamini
AU  - Bundell S
FAU - Howe, Nick
AU  - Howe N
LA  - eng
PT  - News
DEP - 20200909
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Engineering
OT  - Ethics
EDAT- 2021/09/10 06:00
MHDA- 2021/09/10 06:00
CRDT- 2021/09/09 06:45
PHST- 2021/09/09 06:45 [entrez]
PHST- 2021/09/10 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
AID - 10.1038/d41586-020-02595-9 [doi]
AID - 10.1038/d41586-020-02595-9 [pii]
PST - aheadofprint
SO  - Nature. 2020 Sep 9. pii: 10.1038/d41586-020-02595-9. doi:
      10.1038/d41586-020-02595-9.


PMID- 34457775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2156-8650 (Electronic)
IS  - 2156-8650 (Linking)
VI  - 30
IP  - 3
DP  - 2020 Sep
TI  - Comparison of Objective Structured Practical Examination (OSPE) Versus
      Conventional Pathology Practical Examination Methods Among the Second-Year
      Medical Students-a Cross-sectional Study.
PG  - 1131-1135
LID - 10.1007/s40670-020-01025-9 [doi]
AB  - INTRODUCTION: The medical education in India is moving towards competency-based
      medical education (CBME) with many cognitive and psychomotor skills needed to be 
      taught and assessed in the various subjects of the undergraduate medical
      curriculum. In the Pathology subject, psychomotor skills such as haemoglobin
      estimation, blood grouping, urine examination, liver function test/cerebrospinal 
      fluid interpretation, histopathology and haematology slide interpretation are
      taught and assessed for many years. Skill assessment by the conventional method, 
      which is followed since many years, is subjective in nature and lack of scope for
      direct observation of the performance of skills. Objective structured practical
      examination (OSPE) is one of the methods to minimize the variations in
      subjectivity, thus enhancing the objectivity. Due to a technicality and labour
      intensity, it is implemented only in a few medical colleges and universities
      across India. Because of CBME curriculum on the roll, the assessment of practical
      skills in medical education needs to be shifted from conventional subjective
      methods to more objective OSPE methods. MATERIAL AND METHODS: After institutional
      ethical clearance, the second-year medical students appearing for practical in
      Pathology were selected for the study. Practical skills of the students were
      assessed by both the conventional way and OSPE after obtaining the written
      consent. Among 104 students, 89 students were assessed by both methods. Adequate 
      instructions about the pattern of the examination were given in both assessment
      methods. For the OSPE group, specific instructions about the role of observer,
      response stations and method of scoring were given. Practical performance of
      haemoglobin estimation and blood grouping by slide method was assessed, and
      scores were compared. Student and faculty perception regarding OSPE was assessed 
      by a prevalidated questionnaire. RESULTS: In the conventional group, the mean
      score of 6.91 +/- 1.08 was obtained, while in OSPE, it was 8.43 +/- 1.41. In
      comparing both, a p value of > 0.001 was obtained, which is found to be
      significant. Student's perceptions appeared to favour the OSPE format rather than
      the traditional examination. CONCLUSION: This study showed a significant
      difference in scores obtained by OSPE in comparison with conventional practical
      examination. Thus, this information suggests that OSPE format was perceived
      better by the students, and resulted in a higher average score. Hence, the use of
      OSPE as a formative assessment tool will help in modifying teaching-learning
      strategies so that it is beneficial to students and teachers.
CI  - (c) International Association of Medical Science Educators 2020.
FAU - Prasad, H L Kishan
AU  - Prasad HLK
AD  - Department of Pathology, K S Hegde Medical Academy of Nitte (Deemed to be
      University), Mangaluru, 575018 India.grid.414809.00000 0004 1765 9194
FAU - Prasad, H V Krishna
AU  - Prasad HVK
AD  - Department of Pathology, K S Hegde Medical Academy of Nitte (Deemed to be
      University), Mangaluru, 575018 India.grid.414809.00000 0004 1765 9194
FAU - Sajitha, K
AU  - Sajitha K
AD  - Department of Pathology, K S Hegde Medical Academy of Nitte (Deemed to be
      University), Mangaluru, 575018 India.grid.414809.00000 0004 1765 9194
FAU - Bhat, Shubha
AU  - Bhat S
AD  - Department of Pathology, K S Hegde Medical Academy of Nitte (Deemed to be
      University), Mangaluru, 575018 India.grid.414809.00000 0004 1765 9194
FAU - Shetty, K Jayaprakash
AU  - Shetty KJ
AD  - Department of Pathology, K S Hegde Medical Academy of Nitte (Deemed to be
      University), Mangaluru, 575018 India.grid.414809.00000 0004 1765 9194
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - United States
TA  - Med Sci Educ
JT  - Medical science educator
JID - 101625548
PMC - PMC8368153
OTO - NOTNLM
OT  - Conventional
OT  - OSPE
OT  - Pathology
OT  - Perception
OT  - Practical
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2021/08/31 06:00
MHDA- 2021/08/31 06:01
CRDT- 2021/08/30 05:57
PHST- 2021/08/30 05:57 [entrez]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2021/08/31 06:01 [medline]
AID - 10.1007/s40670-020-01025-9 [doi]
AID - 1025 [pii]
PST - epublish
SO  - Med Sci Educ. 2020 Jul 10;30(3):1131-1135. doi: 10.1007/s40670-020-01025-9.
      eCollection 2020 Sep.


PMID- 34447707
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211008
IS  - 2239-9747 (Print)
IS  - 2239-9747 (Linking)
VI  - 23
DP  - 2020 Sep
TI  - Saving Limited Resources During Covid-19 Pandemic.
PG  - 20-21
LID - 10.37825/2239-9747.1003 [doi]
FAU - Piazza, O
AU  - Piazza O
AD  - Department of Medicine, Surgery, Dentistry, University of Salerno, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Italy
TA  - Transl Med UniSa
JT  - Translational medicine @ UniSa
JID - 101588308
PMC - PMC8370519
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - ICU
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
CRDT- 2021/08/27 06:57
PHST- 2021/08/27 06:57 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
AID - 10.37825/2239-9747.1003 [doi]
AID - tmj-23-04-020 [pii]
PST - epublish
SO  - Transl Med UniSa. 2020 Oct 1;23:20-21. doi: 10.37825/2239-9747.1003. eCollection 
      2020 Sep.


PMID- 34447702
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210827
IS  - 2239-9747 (Print)
IS  - 2239-9747 (Linking)
VI  - 23
DP  - 2020 Sep
TI  - The Iterative Model of Ethical Analysis for Large-Scale Implementation Of ICT
      Solutions.
PG  - 1-9
LID - 10.37825/2239-9747.1023 [doi]
AB  - This manuscript presents a model and the methodology to understand and define the
      ethical management of the large-scale implementation of ICT solutions for Active 
      and Healthy Ageing. Based on project expertise, including experience from the
      Pharaon project Horizon 2020, this model includes an understanding of the main
      ethical challenges and the development of the necessary guidelines, measures, and
      tools for different stakeholder profiles. This model extends beyond conventional 
      ethical guidelines, providing a methodology to actively discuss ethical and
      societal challenges within a project based on interactive and iterative dialogue 
      between the entire value-chain of stakeholders. One of the cornerstones in the
      analysis of challenges is focused attention on policy and societal issues that
      emerge during a project. Accordingly, the model includes targeted reflections and
      tools delivered in the context of the recent Covid-19 pandemic. The tools
      developed in this process are organised in a guide that can be actively used
      throughout large-scale implementation projects related to ICT solutions.
FAU - Dantas, C
AU  - Dantas C
AD  - Innovation Department, Caritas Diocesana de Coimbra, Portugal.
FAU - Machado, N
AU  - Machado N
AD  - Innovation Department, Caritas Diocesana de Coimbra, Portugal.
FAU - Ortet, S
AU  - Ortet S
AD  - Innovation Department, Caritas Diocesana de Coimbra, Portugal.
FAU - Leandro, F
AU  - Leandro F
AD  - Innovation Department, Caritas Diocesana de Coimbra, Portugal.
FAU - Burnard, M
AU  - Burnard M
AD  - InnoRenew CoE, Slovenia University of Primorska, Andrej Marusic Institute,
      Slovenia.
FAU - Grunloh, C
AU  - Grunloh C
AD  - eHealth Group, Roessingh Research and Development, Enschede, The Netherlands
      Biomedical Signals and Systems Group, University of Twente, Enschede, The
      Netherlands.
FAU - Grguric, A
AU  - Grguric A
AD  - Ericsson Nikola Tesla d.d., Croatia.
FAU - Hormann, V
AU  - Hormann V
AD  - AGE Platform Europe, Belgium.
FAU - Fiorini, L
AU  - Fiorini L
AD  - The BioRobotics Institute, Scuola Superiore Sant'Anna, Italy. Department of
      Excellence in Robotics & AI, Scuola Superiore Sant'Anna, Italy.
FAU - Cavallo, F
AU  - Cavallo F
AD  - The BioRobotics Institute, Scuola Superiore Sant'Anna, Italy. Department of
      Excellence in Robotics & AI, Scuola Superiore Sant'Anna, Italy.
AD  - Department of Industrial Engineering, University of Florence, Italy.
FAU - Rovini, E
AU  - Rovini E
AD  - The BioRobotics Institute, Scuola Superiore Sant'Anna, Italy. Department of
      Excellence in Robotics & AI, Scuola Superiore Sant'Anna, Italy.
FAU - Scano, R
AU  - Scano R
AD  - UNINFO - Associazione di Normazione Informatica, Italy.
FAU - Pocs, M
AU  - Pocs M
AD  - Stelar Security Technology Law Research, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Italy
TA  - Transl Med UniSa
JT  - Translational medicine @ UniSa
JID - 101588308
PMC - PMC8370527
OTO - NOTNLM
OT  - Active and Healthy Ageing
OT  - Covid-19
OT  - Ethics Model
OT  - ICT solutions
OT  - large-scale implementation
OT  - pilots
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
CRDT- 2021/08/27 06:57
PHST- 2021/08/27 06:57 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
AID - 10.37825/2239-9747.1023 [doi]
AID - tmj-23-04-123 [pii]
PST - epublish
SO  - Transl Med UniSa. 2020 Oct 1;23:1-9. doi: 10.37825/2239-9747.1023. eCollection
      2020 Sep.


PMID- 34422289
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2055-7647 (Print)
IS  - 2055-7647 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - A blood biomarker and clinical correlation cohort study protocol to diagnose
      sports-related concussion and monitor recovery in elite rugby.
PG  - e000948
LID - 10.1136/bmjsem-2020-000948 [doi]
AB  - INTRODUCTION: In professional rugby, sports-related concussion (SRC) remains the 
      most frequent time loss injury. Therefore, accurately diagnosing SRC and
      monitoring player recovery, through a multi-modal assessment process, is critical
      to SRC management. In this protocol study, we aim to assess SRC over multiple
      time points post-injury to determine the value of multi-modal assessments to
      monitor player recovery. This is of significance to minimise premature
      return-to-play and, ultimately, to reduce the long-term effects associated with
      SRC. The study will also establish the logistics of implementing such a study in 
      a professional setting to monitor a player's SRC recovery. METHODS AND ANALYSIS: 
      All players from the participating professional rugby club within the Irish Rugby
      Football Union are invited to participate in the current study. Player assessment
      includes head injury assessment (HIA), neuropsychometric assessment (ImPACT),
      targeted biomarker analysis and untargeted biomarker analysis. Baseline HIA,
      ImPACT, and blood draws are performed prior to the start of playing season.
      During the baseline tests, player's complete consent forms and an SRC history
      questionnaire. Subsequently, any participant that enters the HIA process over the
      playing season due to a suspected SRC will be clinically assessed (HIA and
      ImPACT) and their blood will be drawn within 3 days of injury, 6 days
      post-injury, and 13 days post-injury. ETHICS AND DISSEMINATION: Ethical approval 
      was attained from the Science and Engineering Research Ethics Committee,
      University of Limerick (Approval Code: 2018_06_11_S&E). On completion of the
      study, further manuscripts will be published to present the results of the tests 
      and their ability to measure player recovery from SRC. TRIAL REGISTRATION NUMBER:
      NCT04485494.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kearns, Jamie
AU  - Kearns J
AD  - Munster Rugby Club, High Performance Centre, Limerick, Ireland.
FAU - Ross, Aisling M
AU  - Ross AM
AD  - School of Engineering, University of Limerick, Limerick, Ireland.
FAU - Walsh, Darragh R
AU  - Walsh DR
AD  - School of Engineering, University of Limerick, Limerick, Ireland.
FAU - Cahalane, Rachel M
AU  - Cahalane RM
AD  - School of Engineering, University of Limerick, Limerick, Ireland.
FAU - Hinchion, Rita
AU  - Hinchion R
AD  - Clinical Research Support Unit, University Hospital Limerick, Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
FAU - Ryan, Maria C
AU  - Ryan MC
AD  - Clinical Research Support Unit, University Hospital Limerick, Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
FAU - Conway, Elaine
AU  - Conway E
AD  - Clinical Research Support Unit, University Hospital Limerick, Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
FAU - Comyns, Tom M
AU  - Comyns TM
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
FAU - Kenny, Ian C
AU  - Kenny IC
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
AD  - Physical Education and Sport Sciences, University of Limerick, Limerick, Ireland.
FAU - O'Connor, Eibhlis M
AU  - O'Connor EM
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
AD  - Biological Sciences, University of Limerick, Limerick, Ireland.
AD  - Bernal Institute, University of Limerick, Limerick, Ireland.
FAU - McGourty, Kieran D
AU  - McGourty KD
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
AD  - Bernal Institute, University of Limerick, Limerick, Ireland.
AD  - Chemical Sciences, University of Limerick, Limerick, Ireland.
FAU - Mulvihill, John Joseph Eugene
AU  - Mulvihill JJE
AUID- ORCID: 0000-0003-0437-0351
AD  - School of Engineering, University of Limerick, Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, Ireland.
AD  - Bernal Institute, University of Limerick, Limerick, Ireland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04485494
PT  - Journal Article
DEP - 20201126
PL  - England
TA  - BMJ Open Sport Exerc Med
JT  - BMJ open sport & exercise medicine
JID - 101681007
PMC - PMC8323462
OTO - NOTNLM
OT  - Biochemistry
OT  - Brain
OT  - Concussion
OT  - Recovery
OT  - Rugby
COIS- Competing interests: None declared.
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:01
CRDT- 2021/08/23 06:31
PHST- 2020/08/31 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2021/08/23 06:31 [entrez]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:01 [medline]
AID - 10.1136/bmjsem-2020-000948 [doi]
AID - bmjsem-2020-000948 [pii]
PST - epublish
SO  - BMJ Open Sport Exerc Med. 2020 Nov 26;6(1):e000948. doi:
      10.1136/bmjsem-2020-000948. eCollection 2020.


PMID- 34422285
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2055-7647 (Print)
IS  - 2055-7647 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - The Biathlon Injury and Illness Surveillance (BIIS) project protocol: a
      prospective cohort study across two World Cup seasons.
PG  - e000862
LID - 10.1136/bmjsem-2020-000862 [doi]
AB  - INTRODUCTION: Reliably and accurately establishing injury and illness
      epidemiology in biathletes will provide insight into seasonal changes, provide
      potential to better embed innovative prevention strategies and advance sports
      medicine through the provision of effective healthcare to biathletes. The main
      objective of the Biathlon Injury and Illness Study (BIIS) is to provide the first
      comprehensive epidemiological profile of injury and illness in biathlon athletes 
      during two consecutive Biathlon World Cup seasons over 2-years. METHODS: The BIIS
      study methodology is established in line with the International Olympic Committee
      (IOC) injury and illness surveillance protocols using a biathlon-specific injury 
      and illness report form. Team medical staff will provide weekly data using injury
      and illness definitions of any injury or illness that receives medical attention 
      regardless of time loss. Injuries or illness must be diagnosed and reported by a 
      qualified medical professional (eg, team physician, physiotherapist) to ensure
      accurate and reliable diagnoses. Descriptive statistics will be used to identify 
      the type, body region and nature of the injury or illness and athlete
      demographics such as age and gender. Summary measures of injury and illnesses per
      1000 athlete-days will be calculated whereby the total number of athletes will be
      multiplied by the number of days in the season to calculate athlete-days. ETHICS 
      AND DISSEMINATION: This study has been approved by the Bellbery Human Research
      Ethics Committee (HREC reference: 2017-10-757). Results will be published
      irrespective of negative or positive outcomes and disseminated through different 
      platforms to reach a wide range of stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fitzpatrick, Jane
AU  - Fitzpatrick J
AUID- ORCID: 0000-0002-9578-026X
AD  - Centre for Health and Exercise Sports Medicine, The University of Melbourne
      Faculty of Medicine Dentistry and Health Sciences, Melbourne, Australia.
AD  - Research Committee, Australasian College of Sport and Exercise Physicians,
      Melbourne, Australia.
FAU - Panagodage Perera, Nirmala
AU  - Panagodage Perera N
AUID- ORCID: 0000-0001-6110-8945
AD  - Unit of Physiotherapy, Department of Health, Medicine and Caring Sciences (HMV), 
      Linkoping University Department of Medical and Health Sciences, Linkoping,
      Sweden.
AD  - Centre for Sport, Exercise and Osteoarthritis Research versus Arthritis, Oxford
      University, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - England
TA  - BMJ Open Sport Exerc Med
JT  - BMJ open sport & exercise medicine
JID - 101681007
PMC - PMC8323460
OTO - NOTNLM
OT  - Biathlon
OT  - Epidemiology
OT  - Illness
OT  - Injury
OT  - Surveillance
COIS- Competing interests: NPP declares no competing interests. JF is the Medical
      Director for the Australian Biathlon Association and has previously served as a
      member of the Medical Committee for the International Biathlon Unio.
EDAT- 2021/08/24 06:00
MHDA- 2021/08/24 06:01
CRDT- 2021/08/23 06:31
PHST- 2020/06/10 00:00 [received]
PHST- 2020/09/04 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2021/08/23 06:31 [entrez]
PHST- 2021/08/24 06:00 [pubmed]
PHST- 2021/08/24 06:01 [medline]
AID - 10.1136/bmjsem-2020-000862 [doi]
AID - bmjsem-2020-000862 [pii]
PST - epublish
SO  - BMJ Open Sport Exerc Med. 2020 Nov 26;6(1):e000862. doi:
      10.1136/bmjsem-2020-000862. eCollection 2020.


PMID- 34406963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210825
IS  - 2562-7600 (Electronic)
IS  - 2562-7600 (Linking)
VI  - 3
IP  - 1
DP  - 2020 Dec 17
TI  - Predicted Influences of Artificial Intelligence on the Domains of Nursing:
      Scoping Review.
PG  - e23939
LID - 10.2196/23939 [doi]
AB  - BACKGROUND: Artificial intelligence (AI) is set to transform the health system,
      yet little research to date has explored its influence on nurses-the largest
      group of health professionals. Furthermore, there has been little discussion on
      how AI will influence the experience of person-centered compassionate care for
      patients, families, and caregivers. OBJECTIVE: This review aims to summarize the 
      extant literature on the emerging trends in health technologies powered by AI and
      their implications on the following domains of nursing: administration, clinical 
      practice, policy, and research. This review summarizes the findings from 3
      research questions, examining how these emerging trends might influence the roles
      and functions of nurses and compassionate nursing care over the next 10 years and
      beyond. METHODS: Using an established scoping review methodology, MEDLINE,
      CINAHL, EMBASE, PsycINFO, Cochrane Database of Systematic Reviews, Cochrane
      Central, Education Resources Information Center, Scopus, Web of Science, and
      ProQuest databases were searched. In addition to the electronic database
      searches, a targeted website search was performed to access relevant gray
      literature. Abstracts and full-text studies were independently screened by 2
      reviewers using prespecified inclusion and exclusion criteria. Included articles 
      focused on nursing and digital health technologies that incorporate AI. Data were
      charted using structured forms and narratively summarized. RESULTS: A total of
      131 articles were retrieved from the scoping review for the 3 research questions 
      that were the focus of this manuscript (118 from database sources and 13 from
      targeted websites). Emerging AI technologies discussed in the review included
      predictive analytics, smart homes, virtual health care assistants, and robots.
      The results indicated that AI has already begun to influence nursing roles,
      workflows, and the nurse-patient relationship. In general, robots are not viewed 
      as replacements for nurses. There is a consensus that health technologies powered
      by AI may have the potential to enhance nursing practice. Consequently, nurses
      must proactively define how person-centered compassionate care will be preserved 
      in the age of AI. CONCLUSIONS: Nurses have a shared responsibility to influence
      decisions related to the integration of AI into the health system and to ensure
      that this change is introduced in a way that is ethical and aligns with core
      nursing values such as compassionate care. Furthermore, nurses must advocate for 
      patient and nursing involvement in all aspects of the design, implementation, and
      evaluation of these technologies. INTERNATIONAL REGISTERED REPORT IDENTIFIER
      (IRRID): RR2-10.2196/17490.
CI  - (c)Christine Buchanan, M Lyndsay Howitt, Rita Wilson, Richard G Booth, Tracie
      Risling, Megan Bamford. Originally published in JMIR Nursing Informatics
      (https://nursing.jmir.org), 17.12.2020.
FAU - Buchanan, Christine
AU  - Buchanan C
AUID- ORCID: https://orcid.org/0000-0001-5053-0737
AD  - Registered Nurses' Association of Ontario, Toronto, ON, Canada.
FAU - Howitt, M Lyndsay
AU  - Howitt ML
AUID- ORCID: https://orcid.org/0000-0002-6424-2290
AD  - Registered Nurses' Association of Ontario, Toronto, ON, Canada.
FAU - Wilson, Rita
AU  - Wilson R
AUID- ORCID: https://orcid.org/0000-0003-3461-736X
AD  - Registered Nurses' Association of Ontario, Toronto, ON, Canada.
FAU - Booth, Richard G
AU  - Booth RG
AUID- ORCID: https://orcid.org/0000-0002-0300-9954
AD  - Arthur Labatt Family School of Nursing, Western University, London, ON, Canada.
FAU - Risling, Tracie
AU  - Risling T
AUID- ORCID: https://orcid.org/0000-0002-4235-4785
AD  - College of Nursing, University of Saskatchewan, Saskatoon, SK, Canada.
FAU - Bamford, Megan
AU  - Bamford M
AUID- ORCID: https://orcid.org/0000-0002-2346-1606
AD  - Registered Nurses' Association of Ontario, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201217
PL  - Canada
TA  - JMIR Nurs
JT  - JMIR nursing
JID - 101771299
PMC - PMC8373374
OTO - NOTNLM
OT  - artificial intelligence
OT  - machine learning
OT  - nursing
OT  - patient-centered care
OT  - review
OT  - robotics
EDAT- 2021/08/19 06:00
MHDA- 2021/08/19 06:01
CRDT- 2021/08/18 17:18
PHST- 2020/09/11 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/11/05 00:00 [revised]
PHST- 2021/08/18 17:18 [entrez]
PHST- 2021/08/19 06:00 [pubmed]
PHST- 2021/08/19 06:01 [medline]
AID - v3i1e23939 [pii]
AID - 10.2196/23939 [doi]
PST - epublish
SO  - JMIR Nurs. 2020 Dec 17;3(1):e23939. doi: 10.2196/23939.


PMID- 34405159
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2666-6235 (Electronic)
IS  - 2666-6235 (Linking)
VI  - 1-2
DP  - 2020
TI  - Migrant women and sexual and gender-based violence at the Colombia-Venezuela
      border: A qualitative study.
PG  - 100003
LID - 10.1016/j.jmh.2020.100003 [doi]
AB  - BACKGROUND: Sexual and Gender-Based Violence (SGBV) affects women and girls in
      multiple ways. During migration and within humanitarian settings, migrant women
      and girls are exposed to different forms of SGBV and to higher vulnerabilities
      compared with those men encounter. Survivors of this kind of violence face
      challenges in accessing healthcare for reasons that not only include legal
      status, language barriers, discrimination, misinformation on the availability of 
      healthcare services, but also the growing spread of conservative views regarding 
      sexual and reproductive health which pose a considerable threat to human rights. 
      This study was guided by the question of how humanitarian emergency preparedness 
      and response initiatives within four cities at the Colombo-Venezuelan border are 
      addressing SGBV. The goal of this research was threefold: first, to explain the
      level of implementation of the second goal of the MISP, which is to prevent and
      respond to the consequences of sexual violence; second, to assess the
      availability of services for migrants who have experienced some type of sexual
      violence; and third, to understand the perceptions of migrants regarding sexual
      and gender-based violence. METHODS AND FINDINGS: This study assessed the degree
      of implementation of the Minimal Initial Service Package (MISP) using a set of
      tools developed by the Inter-Agency Working Group on Reproductive Health in
      Crises. This study combined the use of different qualitative methods: i) a
      literature review; ii) 23 interviews with key informants on sexual and
      reproductive health; iii) an assessment of 21 health institutions which provide
      services to migrants; and iv) 24 focus groups with migrants between the ages of
      14 to 49 years old (241 participants, of which 121 were women and 120 were men). 
      This research was conducted in four cities at the Colombo-Venezuelan border where
      there was the highest concentration of migrants. Ethical approval was granted by 
      Profamilia s Advisory Committee on Research Ethics. Although preventing and
      managing the consequences of sexual violence is the second objective of the MISP,
      this study found several barriers for the guarantee of comprehensive healthcare
      for survivors: Venezuelan migrants do not usually consider that healthcare is a
      need for them after they have survived sexual violence; SGBV during migration is 
      a common occurrence according to key informants; in three out of four cities
      there were existing organizations working on SGBV, but not all of them could
      offer comprehensive healthcare services in response to sexual violence.
      CONCLUSIONS: In this study, we observed that migrants tend to be more exposed to 
      Sexual and Gender-Based Violence due to the normalization of such forms of
      violence in the Colombian and Venezuelan cultures. Findings suggest that
      Venezuelan migrants are facing complex SGBV issues during the humanitarian
      emergency at the Colombia-Venezuela border. Recommendations include local health 
      systems response teams, governments and host communities working together to
      address early access to prevention, healthcare, and protection services for the
      survivors of SGBV; eliminating barriers in access to essential and comprehensive 
      equity-oriented healthcare services; developing the skills and capacities of
      healthcare services professionals around the proper management of SGBV; and
      countering misinformation, lowering the stigma associated with migrants in host
      communities, and broadening migrant s perceptions of SGBV, gender roles, and
      xenophobia.
CI  - (c) 2020 The Authors. Published by Elsevier Ltd.
FAU - Calderon-Jaramillo, Mariana
AU  - Calderon-Jaramillo M
AD  - Asociacion Profamilia, Calle 34 No. 14 - 52, Teusaquillo, Bogota, DC, Colombia.
FAU - Parra-Romero, Diana
AU  - Parra-Romero D
AD  - Bogota Mayoralty, Bogota, DC, Colombia.
FAU - Forero-Martinez, Luz Janeth
AU  - Forero-Martinez LJ
AD  - Bogota Mayoralty, Bogota, DC, Colombia.
FAU - Royo, Marta
AU  - Royo M
AD  - Asociacion Profamilia, Calle 34 No. 14 - 52, Teusaquillo, Bogota, DC, Colombia.
FAU - Rivillas-Garcia, Juan Carlos
AU  - Rivillas-Garcia JC
AD  - Asociacion Profamilia, Calle 34 No. 14 - 52, Teusaquillo, Bogota, DC, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - J Migr Health
JT  - Journal of migration and health
JID - 101774615
PMC - PMC8352007
OTO - NOTNLM
OT  - Health systems
OT  - Migrants
OT  - Sexual and gender-based violence
OT  - Sexual and reproductive health
OT  - Vulnerable population
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2021/08/19 06:00
MHDA- 2021/08/19 06:01
CRDT- 2021/08/18 06:33
PHST- 2020/04/30 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2021/08/18 06:33 [entrez]
PHST- 2021/08/19 06:00 [pubmed]
PHST- 2021/08/19 06:01 [medline]
AID - 10.1016/j.jmh.2020.100003 [doi]
AID - S2666-6235(20)30003-9 [pii]
PST - epublish
SO  - J Migr Health. 2020 Sep 29;1-2:100003. doi: 10.1016/j.jmh.2020.100003.
      eCollection 2020.


PMID- 34404976
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210818
IS  - 0143-6503 (Print)
IS  - 0143-6503 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Winter
TI  - Pater Knows Best: Withdrawal of Medical Treatment from Infants in Scotland.
PG  - 682-707
LID - 10.1093/ojls/gqaa019 [doi]
AB  - The cases of Charlie Gard and Alfie Evans placed the withdrawal of treatment from
      terminally ill infants at the forefront of medical law and ethics. In the
      medico-legal context, Scottish court procedures materially differ from those in
      England. This article considers these differences in light of the possibility
      that a similar case might soon be called before the Scottish courts. The Court of
      Session would then be required to consider whether to utilise its parens patriae 
      jurisdiction to consent to the withdrawal of treatment as if it were the parent
      of the infant. The operation of this jurisdiction is such that the outcome of any
      Scottish case cannot be said to be certain, as the Scottish courts are bound to
      pay more heed to parental autonomy than their English counterparts do.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Brown, Jonathan
AU  - Brown J
FAU - Christie, Sarah
AU  - Christie S
AUID- ORCID: 0000-0002-5951-9398
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - Oxf J Leg Stud
JT  - Oxford journal of legal studies
JID - 100973094
PMC - PMC8362623
OTO - NOTNLM
OT  - Scots law
OT  - best interests
OT  - infants
OT  - medical treatment
OT  - parens patriae
OT  - withdrawal
EDAT- 2021/08/19 06:00
MHDA- 2021/08/19 06:01
CRDT- 2021/08/18 06:30
PHST- 2021/08/18 06:30 [entrez]
PHST- 2021/08/19 06:00 [pubmed]
PHST- 2021/08/19 06:01 [medline]
AID - 10.1093/ojls/gqaa019 [doi]
AID - gqaa019 [pii]
PST - epublish
SO  - Oxf J Leg Stud. 2020 Sep 3;40(4):682-707. doi: 10.1093/ojls/gqaa019. eCollection 
      2020 Winter.


PMID- 34395922
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210817
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Making sense of it all: Ethical reflections on the conditions surrounding the
      first genome-edited babies.
PG  - 216
LID - 10.12688/wellcomeopenres.16295.2 [doi]
AB  - In November 2018 the birth of the first genome-edited human beings was announced 
      by Chinese scientist, He Jiankui. The ensuing ethical controversy, institutional 
      investigations and legal proceedings led to the revision of standards, rules and 
      procedures at many levels. Arguably, however, these developments have not
      fundamentally changed the conditions or the culture that nourished He Jiankui's
      vaulting ambition in the first place and enabled it to find expression. In this
      paper we explore the clinical, regulatory and societal circumstances of the
      'gene-edited baby' case, the political, cultural and economic conditions that
      created a radical and dangerous climate for biotechnology innovation, and the
      responsibilities of the international research community, many of whose members
      were apprised of Dr He's intentions. The aim is not to heap anathemas on the
      heads of implicated individuals but to draw attention to the need for different
      communities (researchers, authorities and domestic publics) to play a part
      actively in the governance of biomedical innovation and for research to be
      bridled by human values.
CI  - Copyright: (c) 2021 Chen Q et al.
FAU - Chen, Qi
AU  - Chen Q
AD  - Centre for Bioethics, Medical School, Xiamen University, Xiamen, 361102, China.
FAU - Ma, Yonghui
AU  - Ma Y
AUID- ORCID: https://orcid.org/0000-0001-5787-8445
AD  - Centre for Bioethics, Medical School, Xiamen University, Xiamen, 361102, China.
FAU - Labude, Markus
AU  - Labude M
AD  - Centre for Biomedical Ethics, National University of Singapore, Singapore,
      117597, Singapore.
FAU - Schaefer, G Owen
AU  - Schaefer GO
AD  - Centre for Biomedical Ethics, National University of Singapore, Singapore,
      117597, Singapore.
FAU - Xafis, Vicki
AU  - Xafis V
AUID- ORCID: https://orcid.org/0000-0002-5104-9686
AD  - Centre for Biomedical Ethics, National University of Singapore, Singapore,
      117597, Singapore.
FAU - Mills, Peter
AU  - Mills P
AUID- ORCID: https://orcid.org/0000-0002-2080-8424
AD  - Nuffield Council on Bioethics, London, WC1B 3JS, UK.
LA  - eng
PT  - Journal Article
DEP - 20210623
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8340653
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - Gene editing
OT  - HIV
OT  - He Jiankui
OT  - Human germline genome editing
OT  - Research ethics
OT  - Research governance
OT  - Twins/genetics
COIS- No competing interests were disclosed.
EDAT- 2021/08/18 06:00
MHDA- 2021/08/18 06:01
CRDT- 2021/08/17 07:33
PHST- 2021/06/09 00:00 [accepted]
PHST- 2021/08/17 07:33 [entrez]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2021/08/18 06:01 [medline]
AID - 10.12688/wellcomeopenres.16295.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2021 Jun 23;5:216. doi: 10.12688/wellcomeopenres.16295.2.
      eCollection 2020.


PMID- 34395923
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210825
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - A study protocol for quantifying patient preferences in neuromuscular disorders: 
      a case study of the IMI PREFER Project.
PG  - 253
LID - 10.12688/wellcomeopenres.16116.1 [doi]
AB  - Objectives: Patient preference studies are increasingly used to inform
      decision-making during the medical product lifecycle but are rarely used to
      inform early stages of drug development. The primary aim of this study is to
      quantify treatment preferences of patients with neuromuscular disorders, which
      represent serious and debilitating conditions with limited or no treatment
      options available. Methods: This quantitative patient preferences study was
      designed as an online survey, with a cross-over design. This study will target
      two different diseases from the neuromuscular disorders disease group, myotonic
      dystrophy type 1 (DM1) and mitochondrial myopathies (MM). Despite having
      different physio-pathological pathways both DM1 and MM manifest in a clinically
      similar manner and may benefit from similar treatment options. The sample will be
      stratified into three subgroups: two patient groups differentiated by age of
      symptom onset and one caregivers group. Each subgroup will be randomly assigned
      to complete two of three different preference elicitation methods at two
      different time points: Q-methodology survey, discrete choice experiment, and
      best-worst scaling type 2, allowing cross-comparisons of the results across each 
      study time within participants and within elicitation methods. Additional
      variables such as sociodemographic, clinical and health literacy will be
      collected to enable analysis of potential heterogeneity. Ethics and
      Dissemination: This study protocol has undergone ethical review and approval by
      the Newcastle University R&D Ethics Committee (Ref: 15169/2018). All participants
      will be invited to give electronic informed consent to take part in the study
      prior accessing the online survey. All electronic data will be anonymised prior
      analysis. This study is part of the Patient Preferences in Benefit-Risk
      Assessments during the Drug Life Cycle (IMI-PREFER) project, a public-private
      collaborative research project aiming to develop expert and evidence-based
      recommendations on how and when patient preferences can be assessed and used to
      inform medical product decision making.
CI  - Copyright: (c) 2020 Jimenez-Moreno AC et al.
FAU - Jimenez-Moreno, Aura Cecilia
AU  - Jimenez-Moreno AC
AUID- ORCID: https://orcid.org/0000-0002-0488-9631
AD  - Wellcome Centre for Mitochondrial Research, Newcastle University,
      Newcastle-Upon-Tyne, NE2 4HH, UK.
AD  - Patient Centered Research, Evidera, London, W6 8BJ, UK.
FAU - Pinto, Cathy Anne
AU  - Pinto CA
AD  - Pharmacoepidemiology Department, Centre for Observational and Realworld Evidence,
      Merck & Co, Inc., Rahway, NJ, USA.
FAU - Levitan, Bennett
AU  - Levitan B
AD  - Department of Epidemiology, Janssen Research & Development, Titusville, NJ, USA.
FAU - Whichello, Chiara
AU  - Whichello C
AD  - Erasmus School of Health Policy & Management and Erasmus Choice Modelling Centre,
      Erasmus University Rotterdam, Rotterdam, The Netherlands.
FAU - Dyer, Christine
AU  - Dyer C
AD  - Wellcome Centre for Mitochondrial Research, Newcastle University,
      Newcastle-Upon-Tyne, NE2 4HH, UK.
FAU - Van Overbeeke, Eline
AU  - Van Overbeeke E
AD  - Department of Clinical Pharmacology and Pharmacotherapy, University of Leuven,
      Leuven, Belgium.
FAU - de Bekker-Grob, Esther
AU  - de Bekker-Grob E
AD  - Erasmus School of Health Policy & Management and Erasmus Choice Modelling Centre,
      Erasmus University Rotterdam, Rotterdam, The Netherlands.
FAU - Smith, Ian
AU  - Smith I
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Huys, Isabelle
AU  - Huys I
AD  - Department of Clinical Pharmacology and Pharmacotherapy, University of Leuven,
      Leuven, Belgium.
FAU - Viberg Johansson, Jennifer
AU  - Viberg Johansson J
AUID- ORCID: https://orcid.org/0000-0001-9533-9274
AD  - Centre for Research Ethics & Bioethics, Uppsala universitet, Uppsala, 75122,
      Sweden.
FAU - Adcock, Kate
AU  - Adcock K
AD  - Muscular Dystrophy UK, London, UK.
FAU - Bullock, Kristin
AU  - Bullock K
AUID- ORCID: https://orcid.org/0000-0001-6039-4222
AD  - Global Patient Safety Department, Eli Lilly & Co., Indianapolis, IN, 46205, USA.
FAU - Soekhai, Vikas
AU  - Soekhai V
AD  - Erasmus School of Health Policy & Management and Erasmus Choice Modelling Centre,
      Erasmus University Rotterdam, Rotterdam, The Netherlands.
FAU - Yuan, Zhong
AU  - Yuan Z
AD  - Department of Epidemiology, Janssen Research & Development, Titusville, NJ, USA.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada.
FAU - de Wit, Ardine
AU  - de Wit A
AUID- ORCID: https://orcid.org/0000-0002-1375-7657
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Gorman, Grainne S
AU  - Gorman GS
AD  - Wellcome Centre for Mitochondrial Research, Newcastle University,
      Newcastle-Upon-Tyne, NE2 4HH, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20201023
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8356266
OTO - NOTNLM
OT  - Best Worst Scaling
OT  - Discrete Choice Experiment
OT  - IMI-PREFER
OT  - Myotonic Dystrophy
OT  - Q-methodology
OT  - mitochondrial disease
OT  - patient preferences
OT  - risk tolerance
OT  - treatment preferences.
COIS- No competing interests were disclosed.
EDAT- 2021/08/17 06:00
MHDA- 2021/08/17 06:01
CRDT- 2021/08/16 06:06
PHST- 2020/08/24 00:00 [accepted]
PHST- 2021/08/16 06:06 [entrez]
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2021/08/17 06:01 [medline]
AID - 10.12688/wellcomeopenres.16116.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Oct 23;5:253. doi: 10.12688/wellcomeopenres.16116.1.
      eCollection 2020.


PMID- 34394695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1744-988X (Electronic)
IS  - 1744-9871 (Linking)
VI  - 25
IP  - 8
DP  - 2020 Dec
TI  - The effectiveness of empathy training on the empathy skills of nurses working in 
      intensive care units.
PG  - 722-731
LID - 10.1177/1744987120902827 [doi]
AB  - BACKGROUND: Empathy is an essential condition for effective nursing care. An
      empathetic relationship between the nurse and the patient leads to positive
      therapeutic outcomes, increases nurses' adjustment in educational and therapeutic
      environments and influences their ethical sensitivities. AIMS: The current study 
      aimed to determine the effectiveness of empathy training on the empathy skills of
      nurses working in intensive care units of Shahid Bahonar Hospital in Kerman,
      Iran. METHODS: This experimental study was conducted on nurses working in
      intensive care units of Shahid Bahonar Hospital affiliated to Kerman University
      of Medical Sciences in Iran. All nurses working in intensive care units of Shahid
      Bahonar Hospital were selected by randomised sampling. Data were collected by the
      Davis Empathy Scale (possible range 0-105) and analysed using descriptive
      statistics and analysis of variance. RESULTS: Comparison of the mean empathy
      scores showed the mean scores of empathy skills in the control group were 63.45
      +/- 8.102 and 63.54 +/- 8.05 in the pre- and post-test, respectively, which was
      not significantly different. But the mean scores of empathy skills in the
      Experimental group were 63.40 +/- 8.136 and 67.7 +/- 9.027 in the pre- and
      post-test, respectively, which showed a significant increase (p < 0.05).
      CONCLUSIONS: The present intervention showed the effectiveness of empathy
      training on the empathy skills of nurses. Empathy can be acquired and learned.
CI  - (c) The Author(s) 2020.
FAU - Mirzaei Maghsud, Azam
AU  - Mirzaei Maghsud A
AUID- ORCID: https://orcid.org/0000-0001-7365-5866
AD  - Clinical and research nurse, Shahid Bahonar Hospital, Kerman, Iran; MSc in
      Nursing, School of Nursing and Midwifery, Kerman University of Medical Sciences, 
      Iran.
FAU - Abazari, Farrokh
AU  - Abazari F
AD  - Assistant Professor, Faculty of Nursing, Department of Community Health, School
      of Nursing and Midwifery, Kerman University of Medical Sciences, Iran.
FAU - Miri, Sakineh
AU  - Miri S
AD  - Nursing Instructor, Faculty of Nursing, Department of Community Health, School of
      Nursing and Midwifery, Kerman University of Medical Sciences, Iran.
FAU - Sadat Nematollahi, Monir
AU  - Sadat Nematollahi M
AD  - Assistant Professor, Faculty of Nursing, Department of Community Health, School
      of Nursing and Midwifery, Kerman University of Medical Sciences, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - England
TA  - J Res Nurs
JT  - Journal of research in nursing : JRN
JID - 101234311
PMC - PMC7932470
OTO - NOTNLM
OT  - empathy skills
OT  - empathy training
OT  - intensive care unit
OT  - nurses
COIS- Declaration of conflicting interest: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2021/08/17 06:00
MHDA- 2021/08/17 06:01
CRDT- 2021/08/16 05:52
PHST- 2021/08/16 05:52 [entrez]
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2021/08/17 06:01 [medline]
AID - 10.1177/1744987120902827 [doi]
AID - 10.1177_1744987120902827 [pii]
PST - ppublish
SO  - J Res Nurs. 2020 Dec;25(8):722-731. doi: 10.1177/1744987120902827. Epub 2020 Oct 
      12.


PMID- 34394270
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20220425
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Dec
TI  - Self-reported halitosis and oral health related quality of life in adolescent
      students from a suburban community in Nigeria.
PG  - 2044-2049
LID - 10.4314/ahs.v20i4.62 [doi]
AB  - BACKGROUND: Halitosis is an important cause of impaired quality of life in
      adolescents. Little is known about the prevalence of self-reported halitosis in
      adolescents in Nigeria and the extent to which self-reported halitosis impairs
      their oral health related quality of life. OBJECTIVES: To determine the
      prevalence and impact of self-reported halitosis on the oral health related
      quality of life of adolescent students in a suburban community in Nigeria.
      METHODS: An analytical cross-sectional study. Pre-tested self-administered
      pro-forma was used to obtain the adolescents' demographic data and their
      self-perception of halitosis. The Oral Health Impact Profile (OHIP-14) was used
      to assess the adolescents' OHRQoL. The Mann-Whitney U test was used to compare
      the median OHIP-14 scores between adolescents who reported halitosis and those
      who did not. The level of significance was set at p < 0.05. Ethics approval for
      this study was obtained from the Health Research and Ethics Committee of the
      Lagos University Teaching Hospital. RESULTS: A total of 361 adolescents aged 10 -
      19 years (mean age 14.1 +/- 1.79 years) took part in the study. Of these, 32.7%
      (n=118) had self-reported halitosis. The median OHIP-14 score among adolescents
      with self-reported halitosis was 3 (0-9) while those who did not report halitosis
      had a median OHIP-14 score of 0 (0 - 5). This difference was statistically
      significant (p < 0.0001). CONCLUSION: Self-reported halitosis significantly
      impaired the oral health related quality of life of the adolescents.
CI  - (c) 2020 Alade O et al.
FAU - Alade, Omolola
AU  - Alade O
AD  - Obafemi Awolowo University, Department of Preventive and Community Dentistry.
FAU - Ajoloko, Ebenezer
AU  - Ajoloko E
AD  - Lagos University Teaching Hospital, Department of Oral & Maxillofacial Surgery.
FAU - Dedeke, Aderonke
AU  - Dedeke A
AD  - University of Lagos College of Medicine, Department of Preventive Dentistry.
FAU - Uti, Omolara
AU  - Uti O
AD  - University of Lagos College of Medicine, Department of Preventive Dentistry.
FAU - Sofola, Oyinkansola
AU  - Sofola O
AD  - University of Lagos College of Medicine, Department of Preventive Dentistry.
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Halitosis/*epidemiology/psychology
MH  - Humans
MH  - Male
MH  - Nigeria/epidemiology
MH  - Oral Health/ethnology/*statistics & numerical data
MH  - Prevalence
MH  - Quality of Life/*psychology
MH  - Self Report
MH  - Students/*psychology
MH  - Suburban Population
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC8351855
OTO - NOTNLM
OT  - Halitosis
OT  - adolescent
OT  - oral health
OT  - quality of life
EDAT- 2021/08/17 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/08/16 05:49
PHST- 2021/08/16 05:49 [entrez]
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.4314/ahs.v20i4.62 [doi]
AID - jAFHS.v20.i4.pg2044 [pii]
PST - ppublish
SO  - Afr Health Sci. 2020 Dec;20(4):2044-2049. doi: 10.4314/ahs.v20i4.62.


PMID- 34394258
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20220425
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Dec
TI  - Management of spinal-induced hypotension for elective caesarean section: A survey
      of practices among anesthesiologists from a developing country.
PG  - 1918-1926
LID - 10.4314/ahs.v20i4.50 [doi]
AB  - BACKGROUND: In developing countries, more than half of the anesthesia-related
      maternal deaths are related to spinal hypotension. OBJECTIVE: To explore the
      practices of management of spinal induced hypotension with respect to fluid and
      vasopressor administration among anesthesiologists from a developing country.
      METHODS: After approval from institutional ethics committee, an online
      questionnaire was sent to anesthesiologists registered with Pakistan Society of
      Anesthesiologists between July and August 2018 to determine management strategies
      for prevention and treatment of spinal-induced hypotension. RESULTS: The response
      rate was 36% (156/433), majority from academic institution (62.8%) with equal
      representation from attending and trainee anesthesiologist. For prophylaxis 39.1%
      respondents did not use vasopressors, 32.7% used fluid preloading with
      crystalloids (54.7%) as fluid of choice followed by combination of co-loading and
      vasopressor(22.4%). Phenylephrine was the vasopressor of choice for both
      prophylaxis (33.1%) and treatment (57%). Attending anesthesiologist used a
      combination of fluid co-loading and vasopressors for prophylaxis as compared to
      trainee anesthesiologists (37.2% vs. 17.9%; P=0.035) and selected vasopressors
      according to patient's heart rate (33.3% vs. 19.5%; p=0.05). Prophylactic
      phenylephrine was used more by respondents from the academic institution
      (p=0.023). Fluid co-loading was used more by respondents with <30 % compared to
      those with > 30% of clinical responsibility to obstetric anesthesia (P<0.05).
      CONCLUSION: Phenylephrine as the vasopressor of choice indicates growing
      awareness of management strategies among anesthesiologists from developing
      countries but there is a need to increase its use for prophylaxis. Some variation
      in practice according to the level of anesthesiologist, practice type and
      responsibilities to obstetric anesthesia are evident.
CI  - (c) 2020 Ismail S et al.
FAU - Ismail, Samina
AU  - Ismail S
AD  - Aga Khan University Hospital, Anaesthesiology.
FAU - Sohaib, Muhammad
AU  - Sohaib M
AD  - Aga Khan University Hospital, Anaesthesiology.
FAU - Farrukh, Fatima
AU  - Farrukh F
AD  - Aga Khan University, Medical College.
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
RN  - 0 (Crystalloid Solutions)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Vasoconstrictor Agents)
RN  - 1WS297W6MV (Phenylephrine)
RN  - GN83C131XS (Ephedrine)
SB  - IM
MH  - Anesthesia, Obstetrical/adverse effects/*methods
MH  - Anesthesia, Spinal/adverse effects/*methods
MH  - Anesthesiologists/*psychology
MH  - Blood Pressure/drug effects
MH  - Cesarean Section/*methods
MH  - Crystalloid Solutions/administration & dosage/therapeutic use
MH  - Ephedrine/administration & dosage/adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Hypotension/etiology/*prevention & control
MH  - Hypotension, Controlled
MH  - Isotonic Solutions/therapeutic use
MH  - Pakistan
MH  - Phenylephrine/administration & dosage/therapeutic use
MH  - Pregnancy
MH  - Surveys and Questionnaires
MH  - Vasoconstrictor Agents/*administration & dosage
PMC - PMC8351839
OTO - NOTNLM
OT  - Cesarean delivery
OT  - Hypotension
OT  - Spinal anesthesia
OT  - Vasopressors
EDAT- 2021/08/17 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/08/16 05:49
PHST- 2021/08/16 05:49 [entrez]
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.4314/ahs.v20i4.50 [doi]
AID - jAFHS.v20.i4.pg1918 [pii]
PST - ppublish
SO  - Afr Health Sci. 2020 Dec;20(4):1918-1926. doi: 10.4314/ahs.v20i4.50.


PMID- 34349330
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Oct-Dec
TI  - Diagnostic Accuracy of Various Biomarkers of Sepsis (Serum Pro-Calcitonin,
      High-Sensitivity C-reactive Protein, and C-reactive Protein) and Band Cell
      Percentage in Critically lll Patients: A Prospective, Observational, Cohort
      Study.
PG  - 615-619
LID - 10.4103/aer.AER_3_21 [doi]
AB  - BACKGROUND: Despite the advances in medical sciences, the morbidity and mortality
      due to sepsis in critically ill medical or surgical patients remains high, hence 
      the need for an early and accurate diagnosis. In the current armamentarium, we
      have various biomarkers such as procalcitonin (PCT), high-sensitivity C-reactive 
      protein (hs-CRP), CRP, and band cell percentage for an early clue. AIMS: This
      study explores the accuracy of these markers in distinguishing sepsis from
      systemic inflammatory response syndrome (SIRS) and their correlation with
      sequential organ failure assessment (SOFA) scoring in critically ill patients.
      MATERIALS AND METHODS: After ethical committee approval and written informed
      consent from guardians, 180 consecutive patients, with clinically suspected
      infection from any source fulfilling at least two criteria of SIRS, were enrolled
      and 150 eligible patients were investigated and analyzed prospectively in one
      cohort, which was later subdivided into two different groups (Group A and Group
      B) based on microbiology reports, as having SIRS or sepsis, respectively. Samples
      for cultures (blood, tracheal, or urine as required), biomarkers such as PCT,
      hs-CRP, and CRP, and band cell percentage were sent from each patient on days 1, 
      2, 3, and 5 and whenever there were fever spikes. Clinical follow-up was done for
      28 days, and demographics, ventilator days, duration of intensive care unit (ICU)
      stay, and the survival rates were noted. STATISTICAL ANALYSIS: Receiver operating
      characteristics, area under curve (AUC-ROC) was used for each of the biomarker
      variables to decide the cutoff values and performance. Correlation coefficient
      was also seen for each of the biomarkers with SOFA scoring. RESULTS: Attributes
      of performance for all the biomarkers were satisfactory but was best for PCT
      (AUC-ROC of 0.987) followed by band cell percentage (0.881). SOFA scoring could
      also be used with good diagnostic accuracy (AUC-ROC of 0.920). SOFA score
      correlated best with PCT among the four biomarkers in diagnosing sepsis
      (Spearman's coefficient of + 0.734). Band cell percentage was significantly
      higher in the expired group of sepsis patients than survived patients (P = 0.02) 
      and correlated well with ICU stay and 28-day mortality than rest (Spearman's
      coefficient of - 0.54). CONCLUSIONS: The addition of PCT to the standard workup
      of critically ill patients with suspected sepsis increases diagnostic certainty
      and generates improved patient management. Band cell percentage also provides a
      cost-effective alternative to PCT with an analogous diagnostic performance.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Gupta, Bikram Kumar
AU  - Gupta BK
AD  - Department of Anaesthesiology, Division of Critical Care Medicine, Institute of
      Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
FAU - Das, Badri Prasad
AU  - Das BP
AD  - Department of Anaesthesiology, Institute of Medical Sciences, Banaras Hindu
      University, Varanasi, Uttar Pradesh, India.
FAU - Mhaske, Vanita Ramesh
AU  - Mhaske VR
AD  - Department of Obstetrics and Gynaecology, Institute of Medical Sciences, Banaras 
      Hindu University, Varanasi, Uttar Pradesh, India.
FAU - Tomar, Shubham
AU  - Tomar S
AD  - Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, 
      Varanasi, Uttar Pradesh, India.
FAU - Rastogi, Kapil
AU  - Rastogi K
AD  - Department of Anaesthesiology, Integral Institute of Medical Sciences and
      Research, Lucknow, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20210527
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8294415
OTO - NOTNLM
OT  - Band cell percentage
OT  - C-reactive protein
OT  - high-sensitivity C-reactive protein
OT  - procalcitonin
OT  - sepsis
OT  - sequential organ failure assessment score
COIS- There are no conflicts of interest.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
CRDT- 2021/08/05 06:20
PHST- 2021/01/05 00:00 [received]
PHST- 2021/01/11 00:00 [revised]
PHST- 2021/02/13 00:00 [accepted]
PHST- 2021/08/05 06:20 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
AID - 10.4103/aer.AER_3_21 [doi]
AID - AER-14-615 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Oct-Dec;14(4):615-619. doi: 10.4103/aer.AER_3_21. Epub
      2021 May 27.


PMID- 34349325
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Oct-Dec
TI  - A Comparative Study of Modulation of Neuroendocrine Stress Response by
      Dexmedetomidine versus Fentanyl Premedication during Laparoscopic
      Cholecystectomy.
PG  - 589-593
LID - 10.4103/aer.AER_22_21 [doi]
AB  - INTRODUCTION: Surgical stress is the systemic response to surgical injury.
      Analyzing these surgical stress responses and pharmacologically modulating them
      can be of immense use to an anesthetist for optimal patient care. AIM: The aim of
      the present study was to investigate the influence of dexmedetomidine and
      fentanyl premedication on the modulation of neuroendocrine stress response during
      laparoscopic cholecystectomy under general anesthesia. METHODS: After obtaining
      approval from the institutional ethical committee [Date - 05/11/2020, Ethical
      Clearence Number - 133/2018], 60 patients undergoing laparoscopic cholecystectomy
      under general anesthesia were randomized into three study groups of 20 patients
      each. Group D patients were given intravenous (i.v.) dexmedetomidine 1
      mug.kg(-1), Group F patients fentanyl 2 mug.kg(-1) and Group C patients 10 mL of 
      normal saline. All patients received the same anesthetic drugs and surgical
      procedure. Patients were assessed for changes in hemodynamic parameters such as
      heart rate (H) and mean arterial pressure (MAP). Blood samples were analyzed for 
      glucose, serum albumin, C-reactive protein (CRP), and serum cortisol levels at
      various time intervals. RESULTS: H and MAP differed among the groups after
      intubation, 5 min after pneumoperitoneum (POT), and 10 min after POT. The
      increase in these parameters from their baseline values was less in the
      dexmedetomidine group when compared to other groups. Among the biological
      markers, the increase in serum cortisol levels and decrease in albumin levels
      could be detected 6 h after induction while blood glucose levels rose immediately
      after the incision. CRP levels started significantly rising only after 24 h of
      induction. All these changes were much less pronounced in patients receiving
      dexmedetomidine premedication as compared to other groups. CONCLUSION: i.v.
      dexmedetomidine 1 mug.kg(-1) is better than injection fentanyl 2 mug.kg(-1), in
      the modulation of neuroendocrine response in patients undergoing laparoscopic
      cholecystectomy under general anesthesia.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Shukla, Usha
AU  - Shukla U
AD  - Department of Anaesthesiology, Uttar Pradesh University of Medical Sciences,
      Etawah, Uttar Pradesh, India.
FAU - Kumar, Manoj
AU  - Kumar M
AD  - Department of Anaesthesiology, Uttar Pradesh University of Medical Sciences,
      Etawah, Uttar Pradesh, India.
FAU - Srivastava, Saumya
AU  - Srivastava S
AD  - Department of Anaesthesiology, Uttar Pradesh University of Medical Sciences,
      Etawah, Uttar Pradesh, India.
FAU - Srivastava, Swati
AU  - Srivastava S
AD  - Department of Anaesthesiology, Uttar Pradesh University of Medical Sciences,
      Etawah, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20210527
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8294409
OTO - NOTNLM
OT  - C-reactive protein
OT  - Cortisol
OT  - dexmedetomidine
OT  - fentanyl
OT  - laparoscopic cholecystectomy
OT  - stress response
COIS- There are no conflicts of interest.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
CRDT- 2021/08/05 06:20
PHST- 2021/02/25 00:00 [received]
PHST- 2021/03/05 00:00 [revised]
PHST- 2021/03/16 00:00 [accepted]
PHST- 2021/08/05 06:20 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
AID - 10.4103/aer.AER_22_21 [doi]
AID - AER-14-589 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Oct-Dec;14(4):589-593. doi: 10.4103/aer.AER_22_21. Epub
      2021 May 27.


PMID- 34349318
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Oct-Dec
TI  - A Comparative Study of Periarticular Infiltration with Dexmedetomidine versus
      Ketorolac as an Additive to Ropivacaine after Total Knee Arthroplasty: A
      Prospective, Randomized Double-Blind Study.
PG  - 550-554
LID - 10.4103/aer.AER_18_21 [doi]
AB  - BACKGROUND: Periarticular infiltration (PAI) analgesia has been found to be an
      effective analgesia modality after total knee arthroplasty (TKA). Dexmedetomidine
      has many beneficial effects on postoperative analgesia by different routes, but
      studies on PAI are lagging. AIMS AND OBJECTIVES: In this study, we compared
      postoperative analgesia after PAI with dexmedetomidine versus ketorolac as an
      additive to ropivacaine after TKA. SETTING AND DESIGN: This is a prospective,
      randomized, double-blind study conducted on 75 patients belonging to American
      Society of Anesthesiologists I to III, undergoing total knee arthroplasty, of
      either gender, belonging to American Society of Anesthesiologists I to III.
      MATERIALS AND METHODS: After institutional ethics committee approval and written 
      informed consent, patients were randomly allocated into three groups. Group C (n 
      = 25) received cocktail of 60 mL ropivacaine (0.25%) infiltration with adrenaline
      5 mL (0.1 mg.mL(-1)), Group D (n = 25) received additive dexmedetomidine 1
      ug.kg(-1) to above cocktail, and Group K (n = 25) received ketorolac 30 mg.
      Postoperatively pain by Visual Analog Scale, vitals, total duration of analgesia,
      need for rescue analgesia, sedation, patient satisfaction, mobilization time, and
      complications were recorded. STATISTICAL ANALYSIS: The Statistical Package for
      the Social Sciences version 20 was used for statistical analysis. Analysis of
      variance has been used to find the significance of study parameters between the
      three groups of patients. P < 0.05 was considered statistically significant.
      RESULTS: Postoperative pain score was lesser in the ketorolac group (1.52 +/-
      0.71, P = 0.001) than the other two groups. Duration of analgesia was more with
      ketorolac (343.00 +/- 144.45, P < 0.001) compared with the other two groups, and 
      epidural activation timings (462 +/- 235.84) were significantly delayed in Group 
      K compared to Group C and Group D. There was no significant difference in
      mobilization time, patient satisfaction, and complications between the three
      groups. CONCLUSION: Ketorolac was a better additive to ropivacaine than
      dexmedetomidine for postoperative analgesia after TKA.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Nikhar, Sapna Annaji
AU  - Nikhar SA
AD  - Department of Anaesthesiology and Intensive Care, Nizam's Institute of Medical
      Sciences, Hyderabad, Telangana, India.
FAU - Yadav, Monu
AU  - Yadav M
AD  - Department of Anaesthesiology and Intensive Care, Nizam's Institute of Medical
      Sciences, Hyderabad, Telangana, India.
FAU - Damera, Shashi
AU  - Damera S
AD  - Department of Anaesthesiology and Intensive Care, Nizam's Institute of Medical
      Sciences, Hyderabad, Telangana, India.
FAU - Mohan, Lalith
AU  - Mohan L
AD  - Department of Orthopedics, Nizam's Institute of Medical Sciences, Hyderabad,
      Telangana, India.
FAU - Ch, V Jyotsna
AU  - Ch VJ
AD  - Department of Anaesthesiology and Intensive Care, Nizam's Institute of Medical
      Sciences, Hyderabad, Telangana, India.
FAU - Ramachandran, Gopinath
AU  - Ramachandran G
AD  - Department of Anesthesiology, ESIC Medical College and Hospital, Sanath Nagar,
      Hyderabad, Telangana, India.
LA  - eng
PT  - Journal Article
DEP - 20210527
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8294412
OTO - NOTNLM
OT  - Dexmedetomidine
OT  - ketorolac
OT  - knee arthroplasty
OT  - periarticular infiltration
COIS- There are no conflicts of interest.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
CRDT- 2021/08/05 06:20
PHST- 2021/02/10 00:00 [received]
PHST- 2021/02/11 00:00 [revised]
PHST- 2021/02/26 00:00 [accepted]
PHST- 2021/08/05 06:20 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
AID - 10.4103/aer.AER_18_21 [doi]
AID - AER-14-550 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Oct-Dec;14(4):550-554. doi: 10.4103/aer.AER_18_21. Epub
      2021 May 27.


PMID- 34345714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220324
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Perspectives on public health interventions in the management of the COVID-19
      pandemic in Thailand.
PG  - 245
LID - 10.12688/wellcomeopenres.16293.3 [doi]
AB  - Background: Any government needs to react quickly to a pandemic and make
      decisions on healthcare interventions locally and internationally with little
      information regarding the perceptions of people and the reactions they may
      receive during the implementation of restrictions. Methods: We report an
      anonymous online survey in Thailand conducted in May 2020 to assess public
      perceptions of three interventions in the Thai context: isolation, quarantine and
      social distancing. A total of 1,020 participants, of whom 52% were women,
      responded to the survey. Results: Loss of income was the main concern among
      respondents (>80% for all provinces in Thailand). Traditional media and social
      media were important channels for communication during the pandemic. A total of
      92% of respondents reported that they changed their social behaviour even before 
      the implementation of government policy with 94% reporting they performed social 
      distancing, 97% reported using personal protective equipment such as masks and
      95% reported using sanitizer products. Conclusions: This study showed a high
      level of compliance from individuals with government enforced or voluntarily
      controls such as quarantine, isolation and social distancing in Thailand. The
      findings from this study can be used to inform future government measures to
      control the pandemic and to shape communication strategies.
CI  - Copyright: (c) 2021 Pan-ngum W et al.
FAU - Pan-Ngum, Wirichada
AU  - Pan-Ngum W
AUID- ORCID: https://orcid.org/0000-0002-9839-5359
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University,
      Bangkok, 10400, Thailand.
FAU - Poomchaichote, Tassawan
AU  - Poomchaichote T
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Peerawaranun, Pimnara
AU  - Peerawaranun P
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Kulpijit, Natinee
AU  - Kulpijit N
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Osterrieder, Anne
AU  - Osterrieder A
AUID- ORCID: https://orcid.org/0000-0003-3378-4211
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Waithira, Naomi
AU  - Waithira N
AUID- ORCID: https://orcid.org/0000-0002-2267-9347
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Mukaka, Mavuto
AU  - Mukaka M
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Naemiratch, Bhensri
AU  - Naemiratch B
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Chanviriyavuth, Rita
AU  - Chanviriyavuth R
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Asarath, Supa-At
AU  - Asarath SA
AUID- ORCID: https://orcid.org/0000-0002-4337-6599
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Ruangkajorn, Supanat
AU  - Ruangkajorn S
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Kannika, Noppadon
AU  - Kannika N
AD  - SUPER POLL, Research Institute for Community Happiness and Leadership, Mahidol
      University, Bangkok, 10400, Thailand.
AD  - UCSI Poll Research Centre, Faculty of Business and Information Science, UCSI
      University, Kuala Lumpur, Malaysia.
FAU - Cheah, Phaik Yeong
AU  - Cheah PY
AUID- ORCID: https://orcid.org/0000-0001-6327-3266
AD  - Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
AD  - The Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      Oxford, UK.
LA  - eng
GR  - 210599/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20210715
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8283548
OTO - NOTNLM
OT  - COVID-19
OT  - Thailand
OT  - behavioural
OT  - ethical
OT  - isolation
OT  - pandemic
OT  - public health
OT  - quarantine
OT  - social
OT  - social distancing
OT  - survey
COIS- No competing interests were disclosed.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
CRDT- 2021/08/05 06:32
PHST- 2021/07/13 00:00 [accepted]
PHST- 2021/08/05 06:32 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
AID - 10.12688/wellcomeopenres.16293.3 [doi]
PST - epublish
SO  - Wellcome Open Res. 2021 Jul 15;5:245. doi: 10.12688/wellcomeopenres.16293.3.
      eCollection 2020.


PMID- 34341216
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 0970-258X (Print)
IS  - 0970-258X (Linking)
VI  - 33
IP  - 6
DP  - 2020 Nov-Dec
TI  - Effectiveness and perceptions of MBBS students about process-oriented guided
      inquiry learning in biochemistry.
PG  - 362-365
LID - 10.4103/0970-258X.321143 [doi]
AB  - Background: On reviewing our teaching methods through students' feedback, we
      realized they were dissatisfied with the present teaching methodology of lectures
      in terms of knowledge retention and problem-solving. This issue was addressed
      using student-centred and cooperative learning methodology, i.e. process-oriented
      guided inquiry learning (POGIL) where pre-designed questions guide students to
      enquire concepts, with reflection writing exercise helping students to strengthen
      their concepts. This study analysed the effectiveness and perceptions of POGIL
      sessions conducted after lectures. Methods: The study was approved by the
      institutional ethical committee. A total of 42 (7 groups; each group with 6
      members of high, low and average achievers) consented and POGIL-sensitized MBBS
      phase I students were part of the study. One-hour POGIL sessions were conducted a
      week after lecturing with reading material. Pre-, post- and retention test
      multiple-choice questions (MCQs) were administered for assessment of
      effectiveness and a close-ended questionnaire for recording perception. Results: 
      Post-test and retention test MCQ scores were statistically higher than pre-test
      scores both in all participants and low achievers (p<0.05). Around 60% of the
      students felt that the POGIL activities and working in teams helped them to
      understand concepts. Reflection analysis revealed the best and least understood
      concept and students came up with memory aids to remember complex metabolic
      regulation. Conclusion: POGIL might be a promising reinforcement strategy to
      lectures in biochemistry and preferred tool to address the issue of low achievers
      in the class.
FAU - Sonoli, Smita S
AU  - Sonoli SS
AD  - Department of Biochemistry, K.L.E. Academy of Higher Education (KAHER) Jawaharlal
      Nehru Medical College, Belagavi, Karnataka, India.
FAU - Sankanagoudar, Shrimanjunath
AU  - Sankanagoudar S
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur
      342005, Rajasthan, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Natl Med J India
JT  - The National medical journal of India
JID - 8809315
SB  - IM
MH  - Curriculum
MH  - *Educational Measurement
MH  - Humans
MH  - *Learning
MH  - Perception
MH  - Students
COIS- None
EDAT- 2021/08/04 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/08/03 05:51
PHST- 2021/08/03 05:51 [entrez]
PHST- 2021/08/04 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - NatlMedJIndia_2020_33_6_362_321143 [pii]
AID - 10.4103/0970-258X.321143 [doi]
PST - ppublish
SO  - Natl Med J India. 2020 Nov-Dec;33(6):362-365. doi: 10.4103/0970-258X.321143.


PMID- 34337480
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2666-1683 (Electronic)
IS  - 2666-1683 (Linking)
VI  - 22
DP  - 2020 Dec
TI  - Scheduling Appointments for Postvasectomy Semen Analysis Has No Impact on
      Compliance.
PG  - 74-78
LID - 10.1016/j.euros.2020.10.006 [doi]
AB  - BACKGROUND: A postvasectomy semen analysis (PVSA) is recommended 8-16 wk after
      vasectomy to ensure azoospermia. Patient compliance with submitting a semen
      sample for PVSA has historically been low. To increase patient compliance, a
      policy change was made to schedule patients for PVSA appointments instead of a
      previous "drop-in" option. OBJECTIVE: To compare patient compliance for PVSA when
      scheduling appointments as opposed to a "drop-in" appointment 8-16 wk after the
      procedure. DESIGN SETTING AND PARTICIPANTS: Ethical approval was obtained to
      retrospectively evaluate patients undergoing vasectomy. A total of 400 patients
      were evaluated, 200 consecutive patients before and 200 after the policy change. 
      Patients were excluded from analysis if they had other surgeries at the same time
      of vasectomy or if the vasectomy was a repeat procedure. OUTCOME MEASUREMENTS AND
      STATISTICAL ANALYSIS: Percent of patients attending PVSA and time to PVSA were
      assessed. Nominal data were compared using chi-square analysis and interval data 
      were compared using Student unpaired t test. RESULTS AND LIMITATIONS: Thirteen
      patients were excluded from analysis: six before and seven after the policy
      change. Compliance rates were similar before and after the policy change (144/194
      [74%] and 154/193 [80%], p = 0.19). There was no difference in the time from
      vasectomy to PVSA between groups (before: mean [standard deviation] 69 [55] d vs 
      after: 74 (63) d, p = 0.44). This study is limited by its retrospective design.
      CONCLUSIONS: Scheduling appointments for PVSA has no impact on compliance rates
      or the time between vasectomy and semen analysis when compared with "drop-in"
      appointments. PATIENT SUMMARY: Sterility after a vasectomy is guaranteed by
      delivering a semen sample. Many men do not deliver this sample, and sterility
      cannot be guaranteed. This study found that scheduling appointments did not
      increase the number of men who delivered a semen sample compared with "drop-in"
      appointments.
CI  - (c) 2020 The Author(s).
FAU - Jacobsen, Frederik M
AU  - Jacobsen FM
AD  - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Jensen, Christian Fuglesang S
AU  - Jensen CFS
AD  - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen,
      Copenhagen, Denmark.
AD  - Department of Urology, University of Michigan, Ann Arbor, MI, USA.
FAU - Fode, Mikkel
AU  - Fode M
AD  - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Sonksen, Jens
AU  - Sonksen J
AD  - Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Ohl, Dana A
AU  - Ohl DA
AD  - Department of Urology, University of Michigan, Ann Arbor, MI, USA.
CN  - CopMich Collaborative
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Netherlands
TA  - Eur Urol Open Sci
JT  - European urology open science
JID - 101771568
PMC - PMC8317907
OTO - NOTNLM
OT  - Fertility
OT  - Patient compliance
OT  - Postvasectomy semen analysis
OT  - Semen analysis
OT  - Vasectomy
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
CRDT- 2021/08/02 06:16
PHST- 2020/10/21 00:00 [accepted]
PHST- 2021/08/02 06:16 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
AID - 10.1016/j.euros.2020.10.006 [doi]
AID - S2666-1683(20)36362-X [pii]
PST - epublish
SO  - Eur Urol Open Sci. 2020 Nov 20;22:74-78. doi: 10.1016/j.euros.2020.10.006.
      eCollection 2020 Dec.


PMID- 34337475
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2666-1683 (Electronic)
IS  - 2666-1683 (Linking)
VI  - 22
DP  - 2020 Dec
TI  - Utilising an Accelerated Delphi Process to Develop Guidance and Protocols for
      Telepresence Applications in Remote Robotic Surgery Training.
PG  - 23-33
LID - 10.1016/j.euros.2020.09.005 [doi]
AB  - CONTEXT: The role of robot-assisted surgery continues to expand at a time when
      trainers and proctors have travel restrictions during the coronavirus disease
      2019 (COVID-19) pandemic. OBJECTIVE: To provide guidance on setting up and
      running an optimised telementoring service that can be integrated into current
      validated curricula. We define a standardised approach to training candidates in 
      skill acquisition via telepresence technologies. We aim to describe an approach
      based on the current evidence and available technologies, and define the key
      elements within optimised telepresence services, by seeking consensus from an
      expert committee comprising key opinion leaders in training. EVIDENCE
      ACQUISITION: This project was carried out in phases: a systematic review of the
      current literature, a teleconference meeting, and then an initial survey were
      conducted based on the current evidence and expert opinion, and sent to the
      committee. Twenty-four experts in training, including clinicians, academics, and 
      industry, contributed to the Delphi process. An accelerated Delphi process
      underwent three rounds and was completed within 72 h. Additions to the second-
      and third-round surveys were formulated based on the answers and comments from
      the previous rounds. Consensus opinion was defined as >/=80% agreement. EVIDENCE 
      SYNTHESIS: There was 100% consensus regarding an urgent need for international
      agreement on guidance for optimised telepresence. Consensus was reached in
      multiple areas, including (1) infrastructure and functionality; (2) definitions
      and terminology; (3) protocols for training, communication, and safety issues;
      and (4) accountability including ethical and legal issues. The resulting
      formulated guidance showed good internal consistency among experts, with a
      Cronbach alpha of 0.90. CONCLUSIONS: Using the Delphi methodology, we achieved
      international consensus among experts for development and content validation of
      optimised telepresence services for robotic surgery training. This guidance lays 
      the foundation for launching telepresence services in robotic surgery. This
      guidance will require further validation. PATIENT SUMMARY: Owing to travel
      restrictions during the coronavirus disease 2019 (COVID-19) pandemic, development
      of remote training and support via telemedicine is becoming increasingly
      important. We report a key opinion leader consensus view on a standardised
      approach to telepresence.
CI  - Crown Copyright (c) 2020 Published by Elsevier B.V. on behalf of European
      Association of Urology.
FAU - Collins, Justin W
AU  - Collins JW
AD  - Division of Surgery and Interventional Science, Research Department of Targeted
      Intervention, University College London, London, UK.
AD  - Department of Uro-Oncology, University College London Hospital, London, UK.
AD  - Wellcome/ESPRC Centre for Interventional and Surgical Sciences (WEISS),
      University College London, London, UK.
FAU - Ghazi, Ahmed
AU  - Ghazi A
AD  - University of Rochester Medical Center, Rochester, NY, USA.
FAU - Stoyanov, Danail
AU  - Stoyanov D
AD  - Wellcome/ESPRC Centre for Interventional and Surgical Sciences (WEISS),
      University College London, London, UK.
FAU - Hung, Andrew
AU  - Hung A
AD  - Keck School of Medicine of USC, Los Angeles, CA, USA.
FAU - Coleman, Mark
AU  - Coleman M
AD  - Plymouth Hospitals NHS Trust, Plymouth, UK.
FAU - Cecil, Tom
AU  - Cecil T
AD  - Hampshire Hospitals NHS Foundation Trust, Hampshire, UK.
FAU - Ericsson, Anders
AU  - Ericsson A
AD  - Department of Psychology, Florida State University, Tallahassee, FL, USA.
FAU - Anvari, Mehran
AU  - Anvari M
AD  - Department of Surgery, St. Joseph's Healthcare, McMaster University, Hamilton,
      Ontario, Canada.
FAU - Wang, Yulun
AU  - Wang Y
AD  - InTouch Health, Santa Barbara, CA, USA.
FAU - Beaulieu, Yanick
AU  - Beaulieu Y
AD  - Division of Cardiology and Critical Care, Sacre-Coeur Hospital, University of
      Montreal, Montreal, Quebec, Canada.
FAU - Haram, Nadine
AU  - Haram N
AD  - Department of Plastic Surgery, Royal Free London NHS Foundation Trust, London,
      UK.
FAU - Sridhar, Ashwin
AU  - Sridhar A
AD  - Division of Surgery and Interventional Science, Research Department of Targeted
      Intervention, University College London, London, UK.
AD  - Department of Uro-Oncology, University College London Hospital, London, UK.
FAU - Marescaux, Jacques
AU  - Marescaux J
AD  - IRCAD, Research Institute Against Digestive Cancer, Strasbourg, France.
FAU - Diana, Michele
AU  - Diana M
AD  - IRCAD, Research Institute Against Digestive Cancer, Strasbourg, France.
FAU - Marcus, Hani J
AU  - Marcus HJ
AD  - Wellcome/ESPRC Centre for Interventional and Surgical Sciences (WEISS),
      University College London, London, UK.
FAU - Levy, Jeffrey
AU  - Levy J
AD  - Institute for Surgical Excellence, Philadelphia, PA, USA.
FAU - Dasgupta, Prokar
AU  - Dasgupta P
AD  - MRC Centre for Transplantation, Kings College London, London, UK.
FAU - Stefanidis, Dimitrios
AU  - Stefanidis D
AD  - Indiana University School of Medicine, Indianapolis, IN, USA.
FAU - Martino, Martin
AU  - Martino M
AD  - University of Southern Florida, Tampa, FL, USA.
FAU - Feins, Richard
AU  - Feins R
AD  - Division of C Surgery, University of North Carolina, Chapel Hill, NC, USA.
FAU - Patel, Vipul
AU  - Patel V
AD  - Global Robotics Institute, Celebration, FL, USA.
FAU - Slack, Mark
AU  - Slack M
AD  - Department of Obstetrics and Gynaecology, Addenbrooke's Hospital, Cambridge, UK.
FAU - Satava, Richard M
AU  - Satava RM
AD  - University of Washington Medical Center, Seattle, WA, USA.
FAU - Kelly, John D
AU  - Kelly JD
AD  - Division of Surgery and Interventional Science, Research Department of Targeted
      Intervention, University College London, London, UK.
AD  - Department of Uro-Oncology, University College London Hospital, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201106
PL  - Netherlands
TA  - Eur Urol Open Sci
JT  - European urology open science
JID - 101771568
PMC - PMC8317899
OTO - NOTNLM
OT  - Communication
OT  - Curriculum development
OT  - Deliberate practice
OT  - Patient safety
OT  - Robotic-assisted surgery
OT  - Surgical education
OT  - Telementoring
OT  - Telepresence
OT  - Telesurgery
OT  - Training protocol
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
CRDT- 2021/08/02 06:16
PHST- 2020/09/28 00:00 [accepted]
PHST- 2021/08/02 06:16 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
AID - 10.1016/j.euros.2020.09.005 [doi]
AID - S2666-1683(20)35831-6 [pii]
PST - epublish
SO  - Eur Urol Open Sci. 2020 Nov 6;22:23-33. doi: 10.1016/j.euros.2020.09.005.
      eCollection 2020 Dec.


PMID- 34337453
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2666-1683 (Electronic)
IS  - 2666-1683 (Linking)
VI  - 19
DP  - 2020 Jul
TI  - A Prospective, Observational, Multicentre Study Concerning Nontechnical Skills in
      Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy.
PG  - 37-44
LID - 10.1016/j.euros.2020.05.003 [doi]
AB  - INTRODUCTION AND HYPOTHESES: valuation of surgical skills, both technical and
      nontechnical, is possible through observations and video analysis. Besides
      technical failures, adverse outcomes in surgery can also be related to hampered
      communication, moderate teamwork, lack of leadership, and loss of situational
      awareness. Even though some surgeons are convinced about nontechnical skills
      being an important part of their professionalisation, there is paucity of data
      about a possible relationship between nontechnical skills and surgical outcome.
      In robot-assisted surgery, the surgeon sits behind the console and is at a remote
      position from the surgical field and team, making communication more important
      than in open surgery and conventional laparoscopy. A lack of structured research 
      makes it difficult to assess the value of the different analysis methods for
      nontechnical skills, particularly in robot-assisted surgery. Our hypothesis
      includes the following: (1) introduction of robot-assisted surgery leads to an
      initial decay in nontechnical skills behaviour during the learning curve of the
      team, (2) nontechnical skills behaviour is more explicitly expressed in
      experienced robot-assisted surgery teams than in experienced open surgery teams, 
      and (3) introduction of robot-assisted surgery leads to the development of
      different forms of nontechnical skills behaviour compared with open surgery.
      DESIGN: This study is a prospective, observational, multicentre, nonrandomised,
      case-control study including bladder cancer patients undergoing either an open
      radical cystectomy or a robot-assisted radical cystectomy at the Catharina
      Hospital Eindhoven, the Netherlands, or at the Netherlands Cancer Institute,
      Antoni van Leeuwenhoek Hospital Amsterdam. All patients are eligible for
      inclusion; there are no exclusion criteria. The Catharina Hospital Eindhoven, the
      Netherlands, performs on average 35 radical cystectomies a year. The Netherlands 
      Cancer Institute, Antoni van Leeuwenhoek Hospital Amsterdam, performs on average 
      100 radical cystectomies a year. PROTOCOL OVERVIEW: The choice of treatment is at
      the discretion of the patient and the surgeon. Patient results will be obtained
      prospectively. Pathology results as well as complications occurring within 90 d
      following surgery will be registered. Surgical complications will be registered
      according to the Clavien-Dindo system. MEASUREMENTS: Nontechnical skills will be 
      observed using five different methods: (1) NOTSS: Nontechnical Skills for
      Surgeons; (2) Oxford NOTECHS II: a modified theatre team nontechnical skills
      scoring system; (3) OTAS: Observational Teamwork Assessment for Surgery; (4)
      Interpersonal and Cognitive Assessment for Robotic Surgery (ICARS): evaluation of
      nontechnical skills in robotic surgery; and (5) analysis of human factors.
      Technical skills in robot-assisted radical cystectomy will be analysed using two 
      different methods: (1) GEARS: Global Evaluative Assessment of Robotic Skill and
      (2) GERT: Generic Error Rating Tool. SAFETY CRITERIA AND REPORTING: Formal
      ethical approval has been provided by Medical research Ethics Committees United
      (MEC-U), The Netherlands (reference number W19.048). We hope to present the
      results of this study to the scientific community at conferences and in
      peer-reviewed journals. STATISTICAL ANALYSIS: Frequency statistics will be
      calculated for patient demographical data, and a Shapiro-Wilk test with p > 0.05 
      will be used to define normal distribution. Univariate analysis will be conducted
      to test for statistically significant differences in observation scores between
      open radical cystectomy and robot-assisted radical cystectomy cohorts across all 
      variables, using independent sample t tests and Mann-Whitney U testing, as
      appropriate. A variable-selection strategy will be used to create multivariate
      models. Binary logistic regression will be conducted to calculate odds ratios and
      95% confidence intervals for significant predictors on univariate analysis and
      clinically relevant covariates. Statistical significance is set at p < 0.05 based
      on a two-tailed comparison. SUMMARY: This study uses a structured approach to the
      analysis of nontechnical skills using extracorporeal videos of both open radical 
      cystectomy and robot-assisted radical cystectomy surgeries, in order to obtain
      detailed data on nontechnical skills during open and minimally invasive
      surgeries. The results of this study could possibly be used to develop
      team-training programmes, specifically for the introduction of the surgical robot
      in relation to changes in nontechnical skills. Additional analysis of technical
      skills using the intracorporeal footage of the surgical robot will be used to
      elucidate the role of surgical skills and surgical events in nontechnical skills.
CI  - (c) 2020 The Author(s).
FAU - Beulens, Alexander J W
AU  - Beulens AJW
AD  - Netherlands Institute for Health Services Research (NIVEL), Utrecht, The
      Netherlands.
AD  - Department of Urology, Catharina Hospital, Eindhoven, The Netherlands.
FAU - Brinkman, Willem M
AU  - Brinkman WM
AD  - Department of Oncological Urology, University Medical Centre Utrecht, Utrecht,
      The Netherlands.
FAU - Koldewijn, Evert L
AU  - Koldewijn EL
AD  - Department of Urology, Catharina Hospital, Eindhoven, The Netherlands.
FAU - Hendrikx, Ad J M
AU  - Hendrikx AJM
AD  - Department of Urology, Catharina Hospital, Eindhoven, The Netherlands.
FAU - van Basten, Jean Paul A
AU  - van Basten JPA
AD  - Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
FAU - van Merrienboer, Jeroen J G
AU  - van Merrienboer JJG
AD  - School of Health Professions Education, Maastricht University, Maastricht, The
      Netherlands.
FAU - Van der Poel, Henk G
AU  - Van der Poel HG
AD  - Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek
      Hospital, Amsterdam, The Netherlands.
FAU - Bangma, Chris H
AU  - Bangma CH
AD  - Department of Urology, Erasmus University Medical Centre, Rotterdam, The
      Netherlands.
FAU - Wagner, Cordula
AU  - Wagner C
AD  - Netherlands Institute for Health Services Research (NIVEL), Utrecht, The
      Netherlands.
AD  - Amsterdam Public Health Research Institute, Amsterdam UMC, Location VUmc,
      Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - Netherlands
TA  - Eur Urol Open Sci
JT  - European urology open science
JID - 101771568
PMC - PMC8317860
OTO - NOTNLM
OT  - Cystectomy
OT  - Nontechnical skills
OT  - Outcome
OT  - Robot-assisted surgery
OT  - Surgical skills
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
CRDT- 2021/08/02 06:16
PHST- 2020/03/21 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2021/08/02 06:16 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
AID - 10.1016/j.euros.2020.05.003 [doi]
AID - S2666-1683(20)35110-7 [pii]
PST - epublish
SO  - Eur Urol Open Sci. 2020 Jul 3;19:37-44. doi: 10.1016/j.euros.2020.05.003.
      eCollection 2020 Jul.


PMID- 34321640
OWN - NLM
STAT- Publisher
LR  - 20210729
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Nov 18
TI  - The troubling rise of facial recognition technology.
LID - 10.1038/d41586-020-03271-8 [doi]
FAU - Thompson, Benjamin
AU  - Thompson B
FAU - Van Noorden, Richard
AU  - Van Noorden R
LA  - eng
PT  - News
DEP - 20201118
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Computer science
OT  - Ethics
OT  - Information technology
OT  - Machine learning
EDAT- 2021/07/30 06:00
MHDA- 2021/07/30 06:00
CRDT- 2021/07/29 06:42
PHST- 2021/07/29 06:42 [entrez]
PHST- 2021/07/30 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - 10.1038/d41586-020-03271-8 [doi]
AID - 10.1038/d41586-020-03271-8 [pii]
PST - aheadofprint
SO  - Nature. 2020 Nov 18. pii: 10.1038/d41586-020-03271-8. doi:
      10.1038/d41586-020-03271-8.


PMID- 34316723
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220803
IS  - 2662-2416 (Electronic)
IS  - 2662-2416 (Linking)
VI  - 1
IP  - 4
DP  - 2020 Dec
TI  - Fifty Years of Research on Prenatal Substances: Lessons Learned for the Opioid
      Epidemic.
PG  - 223-234
LID - 10.1007/s42844-020-00021-7 [doi]
AB  - Current efforts to design research on developmental effects of prenatal opioid
      exposure can benefit from knowledge gained from 50 years of studies of fetal
      alcohol and prenatal drug exposures such as cocaine. Scientific advances in
      neurobiology, developmental psychopathology, infant assessments, genetics, and
      imaging support the principles of developmental neurotoxicology that guide
      research in prenatal exposures. Important to research design is accurate
      assessment of amount, frequency, and timing of exposure which benefits from
      accurate self-report and biomarkers of exposure. Identifying and control of pre- 
      and postnatal factors that impact development are difficult and dependent on
      appropriate research design and selection of comparison groups and measurement of
      confounding, mediating, and moderating variables. Polysubstance exposure has
      increased due to the number of prescribed and nonprescribed substances used by
      pregnant women and varying combinations of drugs may have differential effects on
      the outcome. Multiple experimental and clinical assessments of infant behavior
      have been developed but predicting outcome before 18-24 months of age remains
      difficult. With some exceptions, prenatal substance exposure effect sizes have
      been small, and cognitive and behavioral effects tend to be specific rather than 
      global. Studies require large sample sizes, adequate retention, and support for
      social services in at-risk samples. The ethical and legal contexts and stigma
      associated with drug/alcohol use disorder should be considered in order to
      prevent harm to families in research programs. Recognition of the pervasive use
      of addictive substances in this nation should lead to broad scientific efforts to
      understand how substances affect child outcomes and to initiate prevention and
      intervention where needed.
FAU - Singer, Lynn T
AU  - Singer LT
AUID- ORCID: 0000-0003-2950-9460
AD  - School of Medicine, Case Western Reserve University, WG49, Cleveland, OH
      44106-7001, USA.
FAU - Chambers, Christina
AU  - Chambers C
AD  - Health Sciences, University of California, San Diego, San Diego, CA, USA.
FAU - Coles, Claire
AU  - Coles C
AD  - Psychiatry and Behavioral Sciences and Pediatrics, Emory University, Atlanta, GA,
      USA.
FAU - Kable, Julie
AU  - Kable J
AD  - Psychiatry and Behavioral Sciences and Pediatrics, Emory University, Atlanta, GA,
      USA.
LA  - eng
GR  - R34 DA050340/DA/NIDA NIH HHS/United States
GR  - R34 DA050341/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20201027
PL  - Switzerland
TA  - Advers Resil Sci
JT  - Adversity and resilience science
JID - 101768799
PMC - PMC8312986
MID - NIHMS1648880
OTO - NOTNLM
OT  - Alcohol
OT  - Drugs
OT  - Opioid crisis
OT  - Prenatal substance exposure
OT  - Research design
COIS- Conflict of Interest The authors declare that they have no conflict of interest.
EDAT- 2021/07/29 06:00
MHDA- 2021/07/29 06:01
CRDT- 2021/07/28 06:36
PHST- 2021/07/28 06:36 [entrez]
PHST- 2021/07/29 06:00 [pubmed]
PHST- 2021/07/29 06:01 [medline]
AID - 10.1007/s42844-020-00021-7 [doi]
PST - ppublish
SO  - Advers Resil Sci. 2020 Dec;1(4):223-234. doi: 10.1007/s42844-020-00021-7. Epub
      2020 Oct 27.


PMID- 34287420
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210723
IS  - 2056-4740 (Print)
IS  - 2056-4740 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Aug
TI  - 'Who are you today?' Problems of identity in psychiatry.
PG  - 60-62
LID - 10.1192/bji.2020.6 [doi]
AB  - Our attributes change. Sometimes they are changed so dramatically (for instance
      by organic brain disease, traumatic brain injury or psychiatric disease) that it 
      is hard to see any significant continuity with the premorbid person. Sometimes
      this can have important ethical and legal consequences, but the problems are
      often ignored. This article highlights some of the difficulties.
CI  - (c) The Author 2020.
FAU - Foster, Charles
AU  - Foster C
AUID- ORCID: https://orcid.org/0000-0002-7678-4441
AD  - Visiting Professor, Faculty of Law, University of Oxford, UK. Email:
      charles.foster@law.ox.ac.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJPsych Int
JT  - BJPsych international
JID - 101654173
PMC - PMC8280790
OTO - NOTNLM
OT  - Dementia
OT  - dissociative disorders
OT  - ethics
OT  - psychiatry and law
COIS- Conflicts of interest: None.
EDAT- 2021/07/22 06:00
MHDA- 2021/07/22 06:01
CRDT- 2021/07/21 12:53
PHST- 2019/12/10 00:00 [received]
PHST- 2020/01/27 00:00 [accepted]
PHST- 2021/07/21 12:53 [entrez]
PHST- 2021/07/22 06:00 [pubmed]
PHST- 2021/07/22 06:01 [medline]
AID - 10.1192/bji.2020.6 [doi]
AID - S2056474020000069 [pii]
PST - ppublish
SO  - BJPsych Int. 2020 Aug;17(3):60-62. doi: 10.1192/bji.2020.6.


PMID- 34283778
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 84
IP  - 12
DP  - 2020 Dec
TI  - Harnessing Placebo Responses to Improve Health Outcomes.
PG  - 8184
LID - 10.5688/ajpe8184 [doi]
AB  - Variations in the psychosocial aspects of the provision of health care treatments
      can measurably affect the health outcomes resulting from the use of such
      treatments. These benefits (or harms) in outcomes result from processes beyond
      the specific physiological mechanisms induced by the treatments. Such phenomena
      can be most clearly seen when physiological improvements are induced by
      administering inert placebo medications in the same manner as if they were actual
      medications. By logic, these physiological improvements should also occur during 
      the provision of actual medications and potentiate the latter's effectiveness.
      There are likely many manipulations of the patient-clinician interaction that can
      positively or negatively affect therapeutic outcomes for many conditions.
      Clinicians should thus be able to make choices in their behavior that optimize
      any possible increases in drug effectiveness resulting from placebo responses.
      This commentary makes the assertion that pharmacists are ethically obligated to
      learn and practice techniques that maximize placebo responses and that it is
      incumbent upon the Academy to explore and understand such techniques and
      effectively teach them to students.
CI  - (c) 2020 American Association of Colleges of Pharmacy.
FAU - McCarter, Gordon
AU  - McCarter G
AD  - Touro University California College of Pharmacy, Vallejo, California
      gordon.mccarter@tu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
MH  - *Education, Pharmacy
MH  - Humans
MH  - Learning
MH  - Outcome Assessment, Health Care
PMC - PMC7779879
OTO - NOTNLM
OT  - *affective skills
OT  - *major depression
OT  - *pain
OT  - *placebo response
EDAT- 2021/07/21 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/07/20 17:20
PHST- 2020/05/22 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2021/07/20 17:20 [entrez]
PHST- 2021/07/21 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - ajpe8184 [pii]
AID - 10.5688/ajpe8184 [doi]
PST - ppublish
SO  - Am J Pharm Educ. 2020 Dec;84(12):8184. doi: 10.5688/ajpe8184. Epub 2020 Sep 18.


PMID- 34283748
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 84
IP  - 11
DP  - 2020 Nov
TI  - Incorporating Ethics Content Throughout an Integrated Pharmacy Curriculum.
PG  - 7865
LID - 10.5688/ajpe7865 [doi]
AB  - Objective. To incorporate ethics content into nine courses across three years of 
      the didactic pharmacy curriculum and in introductory and advanced pharmacy
      practice experiences to ensure Doctor of Pharmacy (PharmD) students are prepared 
      to address ethical issues.Methods. A free-standing, one-credit ethics course from
      the existing curriculum was eliminated. Partnering with course directors from
      nine required PharmD courses across all three years of the didactic curriculum
      and with the Office of Experiential Education, an Integrated Ethics syllabus was 
      created that provided each class of approximately 170 students with at least one 
      credit of didactic ethics instruction and added ethics activities to the
      experiential curriculum. Learning approaches included lecture, case analysis, and
      discussion with preceptors. Assessment approaches included written case analyses,
      tests with multiple-choice and true/false questions, case vignette-based
      short-answer essay questions, and student discussions with preceptors.Results.
      The newly integrated curriculum provided students with opportunities to discuss
      and apply ethics concepts several times throughout their coursework. The
      integration also ensured that ethics topics were relevant to the material
      students were learning in the host course at the time. The majority of students
      consistently rated the ethics sessions as useful, but some found the repeated
      application of the ethics problem-solving framework to be tedious and
      duplicative.Conclusion. It is possible to embed ethics topics within different
      courses in the PharmD curriculum rather than offering a stand-alone ethics course
      at a single point in the curriculum. Challenges remain to assessing students'
      ability to apply ethics principles once they are presented.
CI  - (c) 2020 American Association of Colleges of Pharmacy.
FAU - Stratton, Timothy P
AU  - Stratton TP
AD  - University of Minnesota, College of Pharmacy, Duluth, Minnesota
      tstratto@d.umn.edu.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
MH  - Curriculum
MH  - *Education, Pharmacy
MH  - Humans
MH  - *Pharmaceutical Services
MH  - *Pharmacy
MH  - *Students, Pharmacy
PMC - PMC7712732
OTO - NOTNLM
OT  - *curriculum
OT  - *education
OT  - *ethics
EDAT- 2021/07/21 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/07/20 17:20
PHST- 2019/09/26 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2021/07/20 17:20 [entrez]
PHST- 2021/07/21 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - ajpe7865 [pii]
AID - 10.5688/ajpe7865 [doi]
PST - ppublish
SO  - Am J Pharm Educ. 2020 Nov;84(11):7865. doi: 10.5688/ajpe7865. Epub 2020 Jul 9.


PMID- 34263212
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210723
IS  - 2687-6442 (Electronic)
IS  - 2687-6442 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Oct
TI  - Organizational Citizenship Behavior among Nurses: The Influence of Organizational
      Trust and Job Satisfaction.
PG  - 333-340
LID - 10.5152/FNJN.2020.19108 [doi]
AB  - AIM: This study was conducted to determine the relationship between nurses'
      organizational citizenship behavior organizational citizenship behavior and
      organizational trust and job satisfaction. METHOD: This descriptive study was
      carried out in March and April 2014 among 429 nurses working in a private
      hospital which had an International Joint Commission International Accreditation 
      Certificate. "A Descriptive Information Form", "Organizational Citizenship
      Behavior Scale", "Organizational Trust Inventory" and "Minnesota Job Satisfaction
      Scale" were used in data collection. The required permissions and approvals were 
      obtained from the authors of the scales, the ethics committee and the
      institution. Frequency, percentage, Pearson Correlation and multiple regression
      analysis were used in the analysis of the data. RESULTS: In this study, it was
      determined that organizational citizenship behavior levels of nurses were high
      (M=5.45+/-0.59). It was determined that the nurses demonstrated the highest
      organizational citizenship behavior with regard to conscientiousness
      (M=6.10+/-0.56), and they demonstrated the lowest organizational citizenship
      behavior with regard to courtesy (M= 4.54+/-0.69). It was determined that
      organizational citizenship behavior had a significant positive relationship with 
      organizational trust and job satisfaction (p<0.001). According to the regression 
      analysis, it was determined that organizational trust was explained with 13.5% of
      the nurses' organizational citizenship behavior levels while job satisfaction was
      related to 80.9% of the nurses' organizational citizenship behavior levels.
      CONCLUSION: As a result of this study, it was found that organizational trust and
      job satisfaction influenced organizational citizenship behavior. Nursing managers
      should encourage improvements and make plans to teach nurses behaviors beyond
      those normally expected.
CI  - Copyright (c) 2020 Florence Nightingale Journal of Nursing.
FAU - Ozluk, Bilgen
AU  - Ozluk B
AUID- ORCID: 0000-0002-2560-4199
AD  - Department of Nursing Management, Necmettin Erbakan University Faculty of
      Nursing, Konya, Turkey.
FAU - Baykal, Ulku
AU  - Baykal U
AUID- ORCID: 0000-0001-5790-5992
AD  - Department of Nursing Management, Istanbul University-Cerrahpasa Florence
      Nightingale Faculty of Nursing, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Turkey
TA  - Florence Nightingale J Nurs
JT  - Florence Nightingale journal of nursing
JID - 101770108
PMC - PMC8134014
OTO - NOTNLM
OT  - Job satisfaction
OT  - nursing
OT  - organizational citizenship behavior
OT  - organizational trust
COIS- Conflict of Interest: The authors have no conflict of interest to declare.
EDAT- 2021/07/16 06:00
MHDA- 2021/07/16 06:01
CRDT- 2021/07/15 06:27
PHST- 2019/07/12 00:00 [received]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2021/07/15 06:27 [entrez]
PHST- 2021/07/16 06:00 [pubmed]
PHST- 2021/07/16 06:01 [medline]
AID - 10.5152/FNJN.2020.19108 [doi]
AID - fnjn-28-3-333 [pii]
PST - epublish
SO  - Florence Nightingale J Nurs. 2020 Oct 26;28(3):333-340. doi:
      10.5152/FNJN.2020.19108. eCollection 2020 Oct.


PMID- 34249349
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - XENOBREAST Trial: A prospective study of xenografts establishment from surgical
      specimens of patients with triple negative or luminal b breast cancer.
PG  - 1219
LID - 10.12688/f1000research.26873.3 [doi]
AB  - Introduction: Patient-derived xenografts (PDX) can be used to explore tumour
      pathophysiology and could be useful to better understand therapeutic response in 
      breast cancer. PDX from mammary tumours are usually made from metastatic tumours.
      Thus, PDX from primary mammary tumours or after neoadjuvant treatment are still
      rare. This study aims to assess the feasibility to establish xenografts from
      tumour samples of patients with triple negative or luminal B breast cancer in
      neoadjuvant, adjuvant or metastatic setting. Methods: XENOBREAST is a
      single-centre and prospective study. This feasibility pilot trial aims to produce
      xenografts from tumour samples of patients with triple negative or luminal B
      breast cancer. Patient enrolment is expected to take 3 years: 85 patients will be
      enrolled and followed for 28 months. Additional blood samples will be taken as
      part of the study. Surgical specimens from post-NAC surgery, primary surgery or
      surgical excision of the metastases will be collected to establish PDX.
      Histomolecular characteristics of the established PDX will be investigated and
      compared with the initial histomolecular profile of the collected tumours to
      ensure that they are well-established. Ethics and dissemination: XENOBREAST
      belongs to category 2 interventional research on the human person. This study has
      been approved by the Sud Mediterranee IV - Montpellier ethics committee. It is
      conducted notably in accordance with the Declaration of Helsinki and General Data
      Protection Regulation (GDPR). Study data and findings will be published in
      peer-reviewed medical journals. We also plan to present the study and all data at
      national congresses and conferences. Registration: ClinicalTrials.gov ID
      NCT04133077; registered on October 21, 2019.
CI  - Copyright: (c) 2021 Veyssiere H et al.
FAU - Veyssiere, Hugo
AU  - Veyssiere H
AUID- ORCID: 0000-0003-2202-7362
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
FAU - Passildas, Judith
AU  - Passildas J
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
FAU - Ginzac, Angeline
AU  - Ginzac A
AUID- ORCID: 0000-0002-5614-0876
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
FAU - Lusho, Sejdi
AU  - Lusho S
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
FAU - Bidet, Yannick
AU  - Bidet Y
AUID- ORCID: 0000-0002-9624-8195
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Departement d'oncogenetique, Laboratoire d'Oncologie Moleculaire, Centre Jean
      Perrin, Clermont-Ferrand, 63011, France.
FAU - Molnar, Ioana
AU  - Molnar I
AUID- ORCID: 0000-0001-5114-2648
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
FAU - Bernadach, Maureen
AU  - Bernadach M
AUID- ORCID: 0000-0002-7185-0809
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
AD  - Departement d'Oncologie Medicale, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
FAU - Cavaille, Mathias
AU  - Cavaille M
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Departement d'oncogenetique, Laboratoire d'Oncologie Moleculaire, Centre Jean
      Perrin, Clermont-Ferrand, 63011, France.
FAU - Radosevic-Robin, Nina
AU  - Radosevic-Robin N
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Departement d'anatomie et de cytologie pathologiques, Centre Jean Perrin,
      Clermont-Ferrand, 63011, France.
FAU - Durando, Xavier
AU  - Durando X
AUID- ORCID: 0000-0001-6035-3172
AD  - Universite Clermont Auvergne, INSERM UMR 1240 << Imagerie Moleculaire et
      Strategies Theranostiques >>, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
AD  - Division de Recherche Clinique, Delegation Recherche Clinique & Innovation,
      Centre Jean Perrin, Clermont-Ferrand, 63011, France.
AD  - Centre d'Investigation Clinique, UMR501, F-63001, Clermont-Ferrand, 63011,
      France.
AD  - Departement d'Oncologie Medicale, Centre Jean Perrin, Clermont-Ferrand, 63011,
      France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04133077
PT  - Journal Article
DEP - 20201009
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - *Breast Neoplasms/surgery
MH  - Female
MH  - Heterografts
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Prospective Studies
PMC - PMC8258709
OTO - NOTNLM
OT  - *Interventional research
OT  - *Luminal B breast cancer
OT  - *Patient-Derived Xenografts
OT  - *Triple negative breast cancer
COIS- No competing interests were disclosed.
EDAT- 2021/07/14 06:00
MHDA- 2021/07/24 06:00
CRDT- 2021/07/13 06:28
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/07/13 06:28 [entrez]
PHST- 2021/07/14 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
AID - 10.12688/f1000research.26873.3 [doi]
PST - epublish
SO  - F1000Res. 2020 Oct 9;9:1219. doi: 10.12688/f1000research.26873.3. eCollection
      2020.


PMID- 34095505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210710
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Engagement and social acceptance in genome editing for human benefit: Reflections
      on research and practice in a global context.
PG  - 244
LID - 10.12688/wellcomeopenres.16260.2 [doi]
AB  - While there are both practical and ethical reasons for public engagement in
      science and innovation, real-world detailed examples of engagement practice and
      the lessons to come from these are still hard to find. This paper showcases three
      contextually diverse case studies of engagement practice. Case 1 recounts the
      experiences of a government-funded initiative to involve scientists and policy
      makers as science communicators for the purpose of engaging the Argentine public 
      on gene editing. Case 2 describes the research methodologies used to elicit
      diverse stakeholder views in the face of political uncertainty and institutional 
      distrust in India. Finally, case 3 unpacks the tensions and gaps with existing
      international guidelines for ensuring local voices are respected in community
      decision-making in Burkina Faso. Each case shares its own compelling rationale
      for selecting the engagement method chosen and details the challenges encountered
      along the way. Each case shares its vision for creating legitimate opportunities 
      for broader societal involvement in the planning, conduct and delivery of
      responsible science. These cases demonstrate the nuances, sensitivities and
      challenges of engaging with publics and broader stakeholders in discussions about
      genome editing for human benefit.
CI  - Copyright: (c) 2021 Barbosa S et al.
FAU - Barbosa, Sebastian
AU  - Barbosa S
AUID- ORCID: https://orcid.org/0000-0002-6624-2323
AD  - Ministry of Science, Technology and Innovation, Buenos Aires, Argentina.
FAU - Pare Toe, Lea
AU  - Pare Toe L
AD  - Institut de Recherche en Sciences de la Sante, Ouagadougou, Burkina Faso.
FAU - Thizy, Delphine
AU  - Thizy D
AUID- ORCID: https://orcid.org/0000-0003-2606-1584
AD  - Imperial College London, London, UK.
FAU - Vaz, Manjulika
AU  - Vaz M
AUID- ORCID: https://orcid.org/0000-0001-5867-1665
AD  - St John's Research Institute, St John's Medical College, Bengaluru, India.
FAU - Carter, Lucy
AU  - Carter L
AUID- ORCID: https://orcid.org/0000-0003-2606-1584
AD  - CSIRO Land and Water, Brisbane, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20210702
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8142603.2
OTO - NOTNLM
OT  - Public engagement
OT  - gene drives
OT  - genome editing
OT  - social acceptance
COIS- No competing interests were disclosed.
EDAT- 2021/07/10 06:00
MHDA- 2021/07/10 06:01
CRDT- 2021/07/09 07:02
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/09 07:02 [entrez]
PHST- 2021/07/10 06:00 [pubmed]
PHST- 2021/07/10 06:01 [medline]
AID - 10.12688/wellcomeopenres.16260.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2021 Jul 2;5:244. doi: 10.12688/wellcomeopenres.16260.2.
      eCollection 2020.


PMID- 34235110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210709
IS  - 2278-330X (Print)
IS  - 2278-330X (Linking)
VI  - 9
IP  - 4
DP  - 2020 Oct
TI  - Marathi Translation and Linguistic Validation of an Updated European Organization
      for Research and Treatment of Cancer Quality of Life Module for Head and Neck.
PG  - 199-203
LID - 10.1055/s-0041-1729444 [doi]
AB  - Aim This study was aimed to translate an updated European Organization for
      Research and Treatment of Cancer (EORTC) quality of life module for head and neck
      (EORTC QLQ-H&N43) in grammatically and conceptually acceptable Marathi language
      and its linguistic validation. Materials and Methods Approval was obtained from
      the Institutional Ethics Committee. The permission for translation was obtained
      from the EORTC translation unit (TU). The EORTC guidelines for the translation
      were followed to form a translation for pilot testing which was administered to
      10 Marathi speaking head and neck squamous cell cancer (HNSCC) patients who gave 
      informed written consent for the participation in the study. Patients were
      interviewed personally. The final Marathi translation was prepared and sent to
      EORTC TU for approval. Statistical analysis was performed using SYSTAT version 12
      by Cranes software, Bengaluru, Karnataka, India. Results After getting
      permission, the translation files were received from EORTC TU, including Marathi 
      EORTC QLQ-H&N35 for reference. Two forward translations, reconciled translation, 
      back translations, first interim translation, translation for proof editing, and 
      second interim translation (SIT) were prepared. This SIT was pilot tested in 10
      Marathi-speaking HNSCC patients. Each patient was interviewed regarding
      difficulty in answering, confusing or offensive word, and reframing sentence. The
      questionnaire was well understood by patients reflecting its linguistic validity.
      After incorporating the changes as per the patient's interview, updated
      translation was prepared and sent to EORTC TU which was accepted and approved by 
      EORTC. The psychometric analysis of pilot testing showed that the questionnaire
      is acceptable. Conclusion Marathi translation of EORTC QLQ-H&N43 is well accepted
      and understandable. It can be used for future studies.
CI  - MedIntel Services Pvt Ltd. This is an open access article published by Thieme
      under the terms of the Creative Commons
      Attribution-NonDerivative-NonCommercial-License, permitting copying and
      reproduction so long as the original work is given appropriate credit. Contents
      may not be used for commercial purposes, or adapted, remixed, transformed or
      built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Waghmare, Chaitali M
AU  - Waghmare CM
AD  - Department of Radiation Oncology, RMC and PRH, PMTPIMS, Loni, Maharashtra, India.
FAU - Pawar, Hemant J
AU  - Pawar HJ
AD  - Department of Medical Statistics, PMTPIMS, PRH, Loni, Maharashtra, India.
FAU - Jain, Vandana S
AU  - Jain VS
AD  - Department of Radiation Oncology, RMC and PRH, PMTPIMS, Loni, Maharashtra, India.
FAU - Bhanu, Arya
AU  - Bhanu A
AD  - Department of Radiation Oncology, RMC and PRH, PMTPIMS, Loni, Maharashtra, India.
FAU - Thakur, Pradeep K
AU  - Thakur PK
AD  - Department of Radiation Oncology, RMC and PRH, PMTPIMS, Loni, Maharashtra, India.
FAU - Nirmal, Padmini H
AU  - Nirmal PH
AD  - Department of Radiation Oncology, RMC and PRH, PMTPIMS, Loni, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20210704
PL  - India
TA  - South Asian J Cancer
JT  - South Asian journal of cancer
JID - 101618774
PMC - PMC8255102
OTO - NOTNLM
OT  - European Organization for Research and Treatment of Cancer QLQ-H&N43
OT  - Marathi translation
OT  - head and neck cancer
OT  - quality of life
COIS- Conflict of InterestFinancial Support and Sponsorship There are no conflict of
      interest to declare. Nil.
EDAT- 2021/07/09 06:00
MHDA- 2021/07/09 06:01
CRDT- 2021/07/08 06:44
PHST- 2021/07/08 06:44 [entrez]
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/07/09 06:01 [medline]
AID - 10.1055/s-0041-1729444 [doi]
AID - SAJC28819 [pii]
PST - ppublish
SO  - South Asian J Cancer. 2020 Oct;9(4):199-203. doi: 10.1055/s-0041-1729444. Epub
      2021 Jul 4.


PMID- 34223490
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2689-2820 (Electronic)
IS  - 2689-2820 (Linking)
VI  - 1
IP  - 1
DP  - 2020
TI  - Student-Reported Attitudes during an Interprofessional Palliative Care Learning
      Experience: Implications for Dual-Professional Identity, Interdisciplinary Bias, 
      and Patient Outcomes.
PG  - 307-313
LID - 10.1089/pmr.2020.0096 [doi]
AB  - Background: The geriatric population in the United States is in need of
      palliative care (PC), yet it is not consistently established in the curriculum
      across health care training programs. There is a clarion call to reform the
      education of health care students using interprofessional education (IPE). The
      Joint Commission reported that communication errors represent two-thirds of the
      causes behind provider sentinel events in health care. Objective: The purpose of 
      this study was to design, implement, and assess an IPE curriculum on PC to
      understand interprofessional student attitudes. Design/Setting: Three professors 
      conducted a mixed-methods study at a California university involving an IPE PC
      event for 40 nursing and speech-language pathology students, and administered the
      Interprofessional Attitudes Survey (IPAS) and reflective questions. Results:
      Qualitative findings indicated that students increased their knowledge about PC
      and the purpose/value of IPE. Four out of the five IPAS subscales had positive
      outcomes: teamwork and roles/responsibilities, patient-centeredness,
      diversity/ethics, and community-centeredness. Interprofessional-biases subscale
      revealed that 33% of the participants reported biases toward students from other 
      health care disciplines, and 35% reported that students from other health care
      disciplines held similar biases toward them. However, only 25% did not believe
      that the interdisciplinary biases interfered with patient outcomes. Conclusion:
      The study identified the existence of interprofessional biases and prejudices
      that may impede collaboration among health care professionals resulting in
      reduced health care outcomes. Faculty and health educators are encouraged to
      embed IPE into a multidisciplinary curriculum that dismantles preexisting
      interdisciplinary biases and stereotypes, and constructs dual-professional
      identity. IRB ID #904203-1.
CI  - (c) Nassrine Noureddine et al., 2020; Published by Mary Ann Liebert, Inc.
FAU - Noureddine, Nassrine
AU  - Noureddine N
AD  - School of Nursing, California State University Sacramento, Sacramento,
      California, USA.
FAU - Hagge, Darla K
AU  - Hagge DK
AD  - Department of Communication Sciences and Disorders, California State University
      Sacramento, Sacramento, California, USA.
FAU - Kashkouli, Pouria
AU  - Kashkouli P
AD  - Hospital Medicine and Palliative Care, University of California, Department of
      Internal Medicine, Davis Medical Center, Sacramento, California, USA.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - United States
TA  - Palliat Med Rep
JT  - Palliative medicine reports
JID - 101770666
PMC - PMC8241387
OTO - NOTNLM
OT  - dual-professional identity
OT  - end of life
OT  - interdisciplinary bias
OT  - interprofessional education
OT  - multidisciplinary education
OT  - palliative care
COIS- No competing financial interests exist.
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
CRDT- 2021/07/05 10:25
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/07/05 10:25 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
AID - 10.1089/pmr.2020.0096 [doi]
AID - 10.1089/pmr.2020.0096 [pii]
PST - epublish
SO  - Palliat Med Rep. 2020 Dec 11;1(1):307-313. doi: 10.1089/pmr.2020.0096.
      eCollection 2020.


PMID- 34223476
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2689-2820 (Electronic)
IS  - 2689-2820 (Linking)
VI  - 1
IP  - 1
DP  - 2020
TI  - Intensity of Predeath Grief and Postdeath Grief of Family Caregivers in
      Palliative Care in Relation to Preparedness for Caregiving, Caregiver Burden, and
      Social Support.
PG  - 191-200
LID - 10.1089/pmr.2020.0033 [doi]
AB  - Background: The intensity of predeath grief is associated with postdeath grief in
      family caregivers of patients in palliative care. Different factors during
      caregiving may influence this association. Objective: To examine (1) the
      intensity of grief in relation to preparedness for caregiving, caregiver burden, 
      and social support, and (2) if these variables moderate associations between
      predeath and postdeath grief. Methods: This prospective correlational study used 
      unpaired t-test to compare grief in relation to preparedness for caregiving,
      caregiver burden, and social support. Hierarchical multiple linear regression
      analysis investigated moderation effects. Family caregivers were recruited from
      10 palliative homecare facilities. The Anticipatory Grief Scale, Texas Revised
      Inventory of Grief, Preparedness for Caregiving Scale, Caregiver Burden Scale,
      and Multidimensional Scale of Perceived Social Support were used. Ethical
      approval for the study was granted by the Regional Ethical Review Board in
      Stockholm, Sweden. Results: In total, 128 family caregivers participated. Those
      with high caregiver burden scored significantly higher intensity of predeath but 
      not postdeath grief. Caregiver burden and social support moderated the
      association between intensity of predeath grief and postdeath grief. There was a 
      stronger association between predeath and postdeath grief among caregivers with
      low caregiver burden or low social support. Preparedness for caregiving had no
      moderating effect. Discussion: Attention should be directed to caregiver burden
      and social support during family caregiving, as these variables seem to be
      significant for the intensity of grief before and after the patient's death.
      Acknowledging predeath grief during caregiving and recognizing pre- and postdeath
      grief as parts of the same process are of importance in clinical practice and
      when designing supportive interventions.
CI  - (c) Lena Axelsson et al., 2020; Published by Mary Ann Liebert, Inc.
FAU - Axelsson, Lena
AU  - Axelsson L
AD  - Department of Nursing Science, Sophiahemmet University, Stockholm, Sweden.
FAU - Alvariza, Anette
AU  - Alvariza A
AD  - Department of Health Care Sciences/Palliative Research Centre, Ersta Skondal
      Bracke University College, Stockholm, Sweden.
AD  - Capio Palliative Care, Dalen Hospital, Stockholm, Sweden.
FAU - Holm, Maja
AU  - Holm M
AD  - Department of Nursing Science, Sophiahemmet University, Stockholm, Sweden.
FAU - Arestedt, Kristofer
AU  - Arestedt K
AD  - Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden.
AD  - The Research Section, Region Kalmar County, Kalmar, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - United States
TA  - Palliat Med Rep
JT  - Palliative medicine reports
JID - 101770666
PMC - PMC8241336
OTO - NOTNLM
OT  - burden
OT  - family caregiver
OT  - grief
OT  - moderation
OT  - palliative care
OT  - preparedness
COIS- No competing financial interests exist.
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
CRDT- 2021/07/05 10:25
PHST- 2020/08/17 00:00 [accepted]
PHST- 2021/07/05 10:25 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
AID - 10.1089/pmr.2020.0033 [doi]
AID - 10.1089/pmr.2020.0033 [pii]
PST - epublish
SO  - Palliat Med Rep. 2020 Sep 9;1(1):191-200. doi: 10.1089/pmr.2020.0033. eCollection
      2020.


PMID- 34223459
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2689-2820 (Electronic)
IS  - 2689-2820 (Linking)
VI  - 1
IP  - 1
DP  - 2020
TI  - Advances in Cardiopulmonary Life-Support Change the Meaning of What It Means to
      be Resuscitated.
PG  - 67-71
LID - 10.1089/pmr.2020.0002 [doi]
AB  - As options for advanced cardiopulmonary support proliferate, the use of
      mechanical circulatory support, such as left ventricular assist device as
      destination therapy (LVAD-DT), is becoming increasingly commonplace. In the
      current case, a patient was hospitalized for complications related to his LVAD-DT
      requests "full code" status, despite a clinician's warning that performing chest 
      compressions may damage the LVAD device or vascular structures leading to poor
      outcome. This discussion explores the ethical and legal considerations regarding 
      a patient request for cardiopulmonary resuscitation when limited options for
      survival or further treatment are available.
CI  - (c) Leslie C. Avant et al., 2020; Published by Mary Ann Liebert, Inc.
FAU - Avant, Leslie C
AU  - Avant LC
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama,
      USA.
FAU - Kezar, Carolyn E
AU  - Kezar CE
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama,
      USA.
AD  - Department of Medicine, Division of Gerontology, Geriatrics, and Palliative
      Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
AD  - Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA.
FAU - Swetz, Keith M
AU  - Swetz KM
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama,
      USA.
AD  - Department of Medicine, Division of Gerontology, Geriatrics, and Palliative
      Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
AD  - Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA.
LA  - eng
PT  - Case Reports
DEP - 20200601
PL  - United States
TA  - Palliat Med Rep
JT  - Palliative medicine reports
JID - 101770666
PMC - PMC8241316
OTO - NOTNLM
OT  - end of life
OT  - palliative care
OT  - patient-physician relationship
OT  - withdrawing
OT  - withholding
COIS- No competing financial interests exist.
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
CRDT- 2021/07/05 10:25
PHST- 2020/05/04 00:00 [accepted]
PHST- 2021/07/05 10:25 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
AID - 10.1089/pmr.2020.0002 [doi]
AID - 10.1089/pmr.2020.0002 [pii]
PST - epublish
SO  - Palliat Med Rep. 2020 Jun 1;1(1):67-71. doi: 10.1089/pmr.2020.0002. eCollection
      2020.


PMID- 34221429
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Dec
TI  - What guidance does HIPAA offer to providers considering familial risk
      notification and cascade genetic testing?
PG  - lsaa071
LID - 10.1093/jlb/lsaa071 [doi]
AB  - BACKGROUND: It is unclear how the Health Insurance Portability and Accountability
      Act (HIPAA) should be interpreted in the context of sharing of genomic
      information between family members. METHODS: The authors analyzed the HIPAA
      Privacy Rule, reviewed the literature and constructed a clinical scenario to
      inform how HIPAA can be interpreted for multiple forms of patient- and
      provider-mediated genetic risk notification. RESULTS: Under HIPAA, healthcare
      providers can lawfully notify relatives to recommend genetic risk assessment
      using multiple approaches, including supporting the patient telling their own
      relatives, contacting relatives directly with the patient's authorization, or
      contacting a relative's provider directly. CONCLUSIONS: Multiple forms of
      patient- or provider-mediated contact of relatives are already legally
      permissible under HIPAA, are consistent with ethical obligations of care to
      patients and their families, and could result in improved population health
      through identification of clinically actionable disease risk. Unanswered
      questions remain about implementation and impacts of provider-mediated programs.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Henrikson, Nora B
AU  - Henrikson NB
AUID- ORCID: 0000-0002-3459-7787
AD  - Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
FAU - Wagner, Jennifer K
AU  - Wagner JK
AD  - Geisinger Health System, Danville, PA, USA.
FAU - Hampel, Heather
AU  - Hampel H
AD  - Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA.
FAU - DeVore, Christopher
AU  - DeVore C
AD  - Asian Pacific American Institute for Congressional Studies, Washington DC, USA.
FAU - Shridhar, Nirupama
AU  - Shridhar N
AD  - Washington State Department of Health, Tumwater, WA USA.
FAU - Williams, Janet L
AU  - Williams JL
AD  - Geisinger Health System, Danville, PA, USA.
FAU - Donohue, Katherine E
AU  - Donohue KE
AD  - The Icahn School of Medicine at Mount Sinai, New York, NY.
FAU - Kullo, Iftikhar
AU  - Kullo I
AD  - Mayo Clinic, Rochester, MN, USA.
FAU - Prince, Anya E R
AU  - Prince AER
AD  - University of Iowa, College of Law, Iowa City, IA, USA.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC8249115
OTO - NOTNLM
OT  - HIPAA
OT  - familial implications
OT  - genetic testing
OT  - genomics
OT  - physician duty
OT  - privacy
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
CRDT- 2021/07/05 10:07
PHST- 2019/11/25 00:00 [received]
PHST- 2020/08/14 00:00 [revised]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2021/07/05 10:07 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
AID - 10.1093/jlb/lsaa071 [doi]
AID - lsaa071 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Dec 11;7(1):lsaa071. doi: 10.1093/jlb/lsaa071. eCollection
      2020 Jan-Dec.


PMID- 34221420
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Dec
TI  - 'Digital pills' for mental diseases: an ethical and social analysis of the issues
      behind the concept.
PG  - lsaa040
LID - 10.1093/jlb/lsaa040 [doi]
AB  - Recently, the US Food and Drug Administration has given a landmark approval to
      the very first digital pill with a sensor embedded in the inside. These are
      complex systems that include a drug and an electronic tracker that is activated
      when the patient takes the pill. Accordingly, they might be an excellent tool for
      monitoring and potentially improving patients' adherence to prescriptions. This
      would serve well to avoid unnecessary healthcare costs and reduce the anxiety of 
      patients and their relatives. However, digital pills might also diminish patient 
      autonomy, reduce privacy, or promote inadequate use of pharmaceutical resources. 
      This article is aimed at contributing to adequate use of this new tool by showing
      the main ethical and social issues they involve and proposing measures meant to
      address them. Finally, we conclude by defending the idea that these new systems
      should be seen as means of complementing traditional strategies to promote
      adherence to treatment, and not as substitutes.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - de Miguel Beriain, Inigo
AU  - de Miguel Beriain I
AUID- ORCID: 0000-0002-2650-5280
AD  - Derecho Publico. University of the Basque Country, Leioa, Spain, and IKERBASQUE, 
      Basque Foundation for Science. Bilbao. Spain.
FAU - Morla Gonzalez, Marina
AU  - Morla Gonzalez M
AD  - Departamento de Derecho Publico, Universidad de Leon, Area de Derecho
      Eclesiastico, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC8249108
OTO - NOTNLM
OT  - Digital health
OT  - adherence
OT  - data protection and privacy
OT  - digital pills
OT  - ingestible sensor
OT  - patient autonomy
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
CRDT- 2021/07/05 10:07
PHST- 2021/07/05 10:07 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
AID - 10.1093/jlb/lsaa040 [doi]
AID - lsaa040 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jul 27;7(1):lsaa040. doi: 10.1093/jlb/lsaa040. eCollection
      2020 Jan-Dec.


PMID- 34221418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Dec
TI  - Human cerebral organoids as a new legal and ethical challenge.
PG  - lsaa005
LID - 10.1093/jlb/lsaa005 [doi]
AB  - Human cerebral organoids (HCOs) are miniature brains cultivated in a dish using
      pluripotent human cells that, thanks to advanced technologies, tend to reproduce 
      the development path of the brain of an embryo in the mother's uterus. Recent
      data from studies carried out in different laboratories have indicated that HCOs 
      show complex electrical activity, are receptive to light stimuli, and can command
      a muscle connected to them. The presence of the main neuronal structures in them 
      suggests that, despite currently lacking vascularization and sensory exchanges
      with the outside world, more developed HCOs could exhibit some rudimentary form
      of consciousness, specifically a minimal sentience with respect to the basic
      experiences of pain and pleasure. Faced with this possibility, which for many
      scientists is still a long way off, we have begun to reflect on how we could
      empirically investigate the presence of consciousness. If we were certain or had 
      a reasonable belief that some types of HCOs are sentient, what kind of entity
      would we judge them to be? Would they have specific legal protection? Should they
      be attributed to a moral status? This article tries to give an initial answer to 
      these two questions. On the one side, it seems that no special rights can be
      claimed for HCOs other than those relating to human biological material. On the
      other side, instead, a sentient HCO could aspire to having its moral status
      recognized. If this were the case, the law may have to adapt to this
      unprecedented situation.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Lavazza, Andrea
AU  - Lavazza A
FAU - Pizzetti, Federico Gustavo
AU  - Pizzetti FG
LA  - eng
PT  - Journal Article
DEP - 20200609
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC8248991
OTO - NOTNLM
OT  - brain activity
OT  - consciousness
OT  - integrated information theory
OT  - legal protection
OT  - moral status
OT  - neuroethics
OT  - personhood
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
CRDT- 2021/07/05 10:07
PHST- 2019/09/09 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2021/07/05 10:07 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
AID - 10.1093/jlb/lsaa005 [doi]
AID - lsaa005 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 9;7(1):lsaa005. doi: 10.1093/jlb/lsaa005. eCollection 2020
      Jan-Dec.


PMID- 34212006
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210703
IS  - 2296-9144 (Electronic)
IS  - 2296-9144 (Linking)
VI  - 7
DP  - 2020
TI  - Risk of Injury in Moral Dilemmas With Autonomous Vehicles.
PG  - 572529
LID - 10.3389/frobt.2020.572529 [doi]
AB  - As autonomous machines, such as automated vehicles (AVs) and robots, become
      pervasive in society, they will inevitably face moral dilemmas where they must
      make decisions that risk injuring humans. However, prior research has framed
      these dilemmas in starkly simple terms, i.e., framing decisions as life and death
      and neglecting the influence of risk of injury to the involved parties on the
      outcome. Here, we focus on this gap and present experimental work that
      systematically studies the effect of risk of injury on the decisions people make 
      in these dilemmas. In four experiments, participants were asked to program their 
      AVs to either save five pedestrians, which we refer to as the utilitarian choice,
      or save the driver, which we refer to as the nonutilitarian choice. The results
      indicate that most participants made the utilitarian choice but that this choice 
      was moderated in important ways by perceived risk to the driver and risk to the
      pedestrians. As a second contribution, we demonstrate the value of formulating AV
      moral dilemmas in a game-theoretic framework that considers the possible
      influence of others' behavior. In the fourth experiment, we show that
      participants were more (less) likely to make the utilitarian choice, the more
      utilitarian (nonutilitarian) other drivers behaved; furthermore, unlike the
      game-theoretic prediction that decision-makers inevitably converge to
      nonutilitarianism, we found significant evidence of utilitarianism. We discuss
      theoretical implications for our understanding of human decision-making in moral 
      dilemmas and practical guidelines for the design of autonomous machines that
      solve these dilemmas while, at the same time, being likely to be adopted in
      practice.
CI  - Copyright (c) 2021 De Melo, Marsella and Gratch.
FAU - de Melo, Celso M
AU  - de Melo CM
AD  - CCDC US Army Research Laboratory, Playa Vista, CA, United States.
FAU - Marsella, Stacy
AU  - Marsella S
AD  - College of Computer and Information Science, Northeastern University, Boston, MA,
      United States.
FAU - Gratch, Jonathan
AU  - Gratch J
AD  - Institute for Creative Technologies, University of Southern, Playa Vista, CA,
      United States.
LA  - eng
PT  - Journal Article
DEP - 20210120
PL  - Switzerland
TA  - Front Robot AI
JT  - Frontiers in robotics and AI
JID - 101749350
PMC - PMC8239464
OTO - NOTNLM
OT  - automated vehicles
OT  - ethics
OT  - moral dilemma
OT  - risk of injury
OT  - utilitarian choice
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
CRDT- 2021/07/02 06:43
PHST- 2020/06/14 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/07/02 06:43 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
AID - 10.3389/frobt.2020.572529 [doi]
AID - 572529 [pii]
PST - epublish
SO  - Front Robot AI. 2021 Jan 20;7:572529. doi: 10.3389/frobt.2020.572529. eCollection
      2020.


PMID- 34192280
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2644-1276 (Electronic)
IS  - 2644-1276 (Linking)
VI  - 1
DP  - 2020
TI  - COVID-19 Antibody Test/Vaccination Certification: There's an App for That.
PG  - 148-155
LID - 10.1109/OJEMB.2020.2999214 [doi]
AB  - Goal: As the Coronavirus Pandemic of 2019/2020 unfolds, a COVID-19 'Immunity
      Passport' has been mooted as a way to enable individuals to return back to work. 
      While the quality of antibody testing, the availability of vaccines, and the
      likelihood of even attaining COVID-19 immunity continue to be researched, we
      address the issues involved in providing tamper-proof and privacy-preserving
      certification for test results and vaccinations. Methods: We developed a
      prototype mobile phone app and requisite decentralized server architecture that
      facilitates instant verification of tamper-proof test results. Personally
      identifiable information is only stored at the user's discretion, and the app
      allows the end-user selectively to present only the specific test result with no 
      other personal information revealed. The architecture, designed for scalability, 
      relies upon (a) the 2019 World Wide Web Consortium standard called 'Verifiable
      Credentials', (b) Tim Berners-Lee's decentralized personal data platform 'Solid',
      and (c) a Consortium Ethereum-based blockchain. Results: Our mobile phone app and
      decentralized server architecture enable the mixture of verifiability and privacy
      in a manner derived from public/private key pairs and digital signatures,
      generalized to avoid restrictive ownership of sensitive digital keys and/or data.
      Benchmark performance tests show it to scale linearly in the worst case, as
      significant processing is done locally on each app. For the test certificate
      Holder, Issuer (e.g. healthcare staff, pharmacy) and Verifier (e.g. employer), it
      is 'just another app' which takes only minutes to use. Conclusions: The app and
      decentralized server architecture offer a prototype proof of concept that is
      readily scalable, applicable generically, and in effect 'waiting in the wings'
      for the biological issues, plus key ethical issues raised in the discussion
      section, to be resolved.
CI  - This work is licensed under a Creative Commons Attribution 4.0 License. For more 
      information, see https://creativecommons.org/licenses/by/4.0/.
FAU - Eisenstadt, Marc
AU  - Eisenstadt M
AD  - Knowledge Media InstituteThe Open UniversityMiltonKeynesMK7 6AAU.K.5488
FAU - Ramachandran, Manoharan
AU  - Ramachandran M
AD  - Knowledge Media InstituteThe Open UniversityMiltonKeynesMK7 6AAU.K.5488
FAU - Chowdhury, Niaz
AU  - Chowdhury N
AD  - Knowledge Media InstituteThe Open UniversityMiltonKeynesMK7 6AAU.K.5488
FAU - Third, Allan
AU  - Third A
AD  - Knowledge Media InstituteThe Open UniversityMiltonKeynesMK7 6AAU.K.5488
FAU - Domingue, John
AU  - Domingue J
AD  - Knowledge Media InstituteThe Open UniversityMiltonKeynesMK7 6AAU.K.5488
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - IEEE Open J Eng Med Biol
JT  - IEEE open journal of engineering in medicine and biology
JID - 101766631
PMC - PMC8043425
OTO - NOTNLM
OT  - Blockchain
OT  - COVID-19
OT  - coronavirus
OT  - decentralized
OT  - immunity certification
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:01
CRDT- 2021/06/30 17:33
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/22 00:00 [revised]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2021/06/30 17:33 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:01 [medline]
AID - 10.1109/OJEMB.2020.2999214 [doi]
PST - epublish
SO  - IEEE Open J Eng Med Biol. 2020 Jun 1;1:148-155. doi: 10.1109/OJEMB.2020.2999214. 
      eCollection 2020.


PMID- 34192172
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Out-of-hospital deaths among children during COVID-19 pandemic: indicator of
      collateral damage?
PG  - e000763
LID - 10.1136/bmjpo-2020-000763 [doi]
AB  - We aimed to investigate the out-of-hospital mortality, and the actual prevalence 
      of COVID-19 in children requiring paediatric emergency department (ED) care for
      infectious symptoms. There were four emergency medical services (EMS) responses
      concerning children (age 0-15 years) leading to death on-scene in 2 months during
      the pandemic, and eight during the previous 12 months in the Helsinki University 
      Hospital area, although the number of EMS missions decreased by 18%. The
      prevalence of COVID-19 in children contacting a paediatric ED for any infectious 
      symptoms during the epidemic peak was only 2.7%.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Harve-Rytsala, Heini
AU  - Harve-Rytsala H
AUID- ORCID: 0000-0002-0104-4553
AD  - Emergency Medicine and Services, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
FAU - Puhakka, Laura
AU  - Puhakka L
AD  - New Children's Hospital, University of Helsinki and Helsinki University Hospital,
      Helsinki, Uusimaa, Finland.
FAU - Kuisma, Markku
AU  - Kuisma M
AD  - Emergency Medicine and Services, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
FAU - Kuitunen, Mikael
AU  - Kuitunen M
AD  - New Children's Hospital, University of Helsinki and Helsinki University Hospital,
      Helsinki, Uusimaa, Finland.
FAU - Oulasvirta, Jelena
AU  - Oulasvirta J
AUID- ORCID: 0000-0001-6750-4615
AD  - Helsingin ja Uudenmaan Sairaanhoitopiiri, Helsinki, Uusimaa, Finland.
AD  - Faculty of Medicine, The University of Helsinki, Helsinki, Uusimaa, Finland.
AD  - Division of Anaesthesiology, Department of Anaesthesiology, Intensive Care and
      Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki,
      Uusimaa, Finland.
FAU - Salmi, Heli
AU  - Salmi H
AD  - New Children's Hospital, University of Helsinki and Helsinki University Hospital,
      Helsinki, Uusimaa, Finland.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7430182
OTO - NOTNLM
OT  - ethics
OT  - health services research
OT  - mortality
COIS- Competing interests: None declared.
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:01
CRDT- 2021/06/30 17:31
PHST- 2020/06/11 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2021/06/30 17:31 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:01 [medline]
AID - 10.1136/bmjpo-2020-000763 [doi]
AID - bmjpo-2020-000763 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Aug 13;4(1):e000763. doi: 10.1136/bmjpo-2020-000763.
      eCollection 2020.


PMID- 34192167
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Healthcare access for migrant children in England during the COVID-19 pandemic.
PG  - e000705
LID - 10.1136/bmjpo-2020-000705 [doi]
FAU - Wood, Laura C N
AU  - Wood LCN
AUID- ORCID: 0000-0001-8947-2677
AD  - Sociology, Lancaster University, Lancaster, Lancashire, UK.
FAU - Devakumar, Delanjathan
AU  - Devakumar D
AD  - Centre for the Health of Women, Children and Adolescents, Institute for Global
      Health, University College London, London, UK.
LA  - eng
PT  - Editorial
DEP - 20200716
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7372171
OTO - NOTNLM
OT  - ethics
COIS- Competing interests: LCNW: (non-financial association) is the Child & Family
      Modern Slavery Lead for VITA, an organisation seeking to advance the public
      health response to modern slavery.
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:01
CRDT- 2021/06/30 17:31
PHST- 2020/05/03 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2021/06/30 17:31 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:01 [medline]
AID - 10.1136/bmjpo-2020-000705 [doi]
AID - bmjpo-2020-000705 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Jul 16;4(1):e000705. doi: 10.1136/bmjpo-2020-000705.
      eCollection 2020.


PMID- 34192005
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2054-4642 (Print)
IS  - 2054-4650 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Oct
TI  - The Psychological Consequences of the COVID-19 on Residents and Staff in Nursing 
      Homes.
PG  - 254-259
LID - 10.1093/workar/waaa021 [doi]
AB  - In this commentary, we overview the existing research on psychological
      consequences caused by COVID-19 for both residents and staff in the nursing
      homes. We identify loneliness and emotional anxiety as main psychological
      consequences for nursing home residents, whereas uncertainty, hopelessness, work 
      overload, and role conflicts are the most salient psychological challenges for
      the staff in the nursing homes during the pandemic. We then summarize the
      existing strategies and interventions responsive to the above challenges. We
      suggest that this overview may help nursing home managers understand what are the
      key psychological challenges and how to deal with them during a crisis period.
      Finally, we also encourage future research to pay more attention to exploring
      interventions specifically designed for vulnerable older people, understanding
      the role of the nursing home leader team in managing emotional and ethical
      challenges in organizations, and developing community-wide collaboration with
      multiple external stakeholders.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. For permissions
      please e-mail: journals.permissions@oup.com.
FAU - Mo, Shenjiang
AU  - Mo S
AD  - Zhejiang University, Hangzhou, China.
FAU - Shi, Junqi
AU  - Shi J
AUID- ORCID: 0000-0002-1116-5017
AD  - Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - England
TA  - Work Aging Retire
JT  - Work, aging and retirement
JID - 101708619
PMC - PMC7665707
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:01
CRDT- 2021/06/30 17:29
PHST- 2021/06/30 17:29 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:01 [medline]
AID - 10.1093/workar/waaa021 [doi]
AID - waaa021 [pii]
PST - ppublish
SO  - Work Aging Retire. 2020 Oct;6(4):254-259. doi: 10.1093/workar/waaa021. Epub 2020 
      Oct 8.


PMID- 34191974
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 1946-6315 (Print)
IS  - 1946-6315 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Aug 17
TI  - Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and 
      Interpretability of Clinical Trials.
PG  - 419-426
LID - 10.1080/19466315.2020.1788984 [doi]
AB  - Abstract-The COVID-19 pandemic has a global impact on the conduct of clinical
      trials of medical products. This article discusses implications of the COVID-19
      pandemic on clinical research methodology aspects and provides points to consider
      to assess and mitigate the risk of seriously compromising the integrity and
      interpretability of clinical trials. The information in this article will support
      discussions that need to occur cross-functionally on an ongoing basis to
      "integrate all available knowledge from the ethical, the medical, and the
      methodological perspective into decision making." This article aims at
      facilitating: (i) risk assessments of the impact of the pandemic on trial
      integrity and interpretability; (ii) identification of the relevant data and
      information related to the impact of the pandemic on the trial that needs to be
      collected; (iii) short-term decision making impacting ongoing trial operations;
      (iv) ongoing monitoring of the trial conduct until completion, including the
      possible involvement of data monitoring committees, and adequately documenting
      all measures taken to secure trial integrity throughout and after the pandemic,
      and (v) proper analysis and interpretation of the eventual interim or final trial
      data.
CI  - (c) 2020 American Statistical Association.
FAU - Akacha, Mouna
AU  - Akacha M
AD  - Clinical Development & Analytics, Novartis Pharma, Basel, Switzerland.
FAU - Branson, Janice
AU  - Branson J
AD  - Clinical Development & Analytics, Novartis Pharma, Basel, Switzerland.
FAU - Bretz, Frank
AU  - Bretz F
AD  - Clinical Development & Analytics, Novartis Pharma, Basel, Switzerland.
AD  - Section for Medical Statistics, Medical University of Vienna, Vienna, Austria.
FAU - Dharan, Bharani
AU  - Dharan B
AD  - Clinical Development & Analytics, Novartis Pharmaceuticals, East Hanover, NJ.
FAU - Gallo, Paul
AU  - Gallo P
AD  - Clinical Development & Analytics, Novartis Pharmaceuticals, East Hanover, NJ.
FAU - Gathmann, Insa
AU  - Gathmann I
AD  - Clinical Development & Analytics, Novartis Pharma, Basel, Switzerland.
FAU - Hemmings, Robert
AU  - Hemmings R
AD  - CONSILIUM Salmonson & Hemmings, London, UK.
FAU - Jones, Julie
AU  - Jones J
AD  - Clinical Development & Analytics, Novartis Pharma, Basel, Switzerland.
FAU - Xi, Dong
AU  - Xi D
AUID- ORCID: https://orcid.org/0000-0003-1482-234X
AD  - Clinical Development & Analytics, Novartis Pharmaceuticals, East Hanover, NJ.
FAU - Zuber, Emmanuel
AU  - Zuber E
AD  - Clinical Development & Analytics, Novartis Pharma, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - United States
TA  - Stat Biopharm Res
JT  - Statistics in biopharmaceutical research
JID - 101507745
PMC - PMC8011599
OTO - NOTNLM
OT  - Adherence
OT  - Estimand
OT  - Intercurrent event
OT  - Missing data
OT  - Protocol deviations
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:01
CRDT- 2021/06/30 17:29
PHST- 2021/06/30 17:29 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:01 [medline]
AID - 10.1080/19466315.2020.1788984 [doi]
AID - 1788984 [pii]
PST - epublish
SO  - Stat Biopharm Res. 2020 Aug 17;12(4):419-426. doi: 10.1080/19466315.2020.1788984.


PMID- 34191197
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2510-3636 (Electronic)
IS  - 2510-3636 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Dec 9
TI  - Artificial intelligence and hybrid imaging: the best match for personalized
      medicine in oncology.
PG  - 24
LID - 10.1186/s41824-020-00094-8 [doi]
AB  - Artificial intelligence (AI) refers to a field of computer science aimed to
      perform tasks typically requiring human intelligence. Currently, AI is recognized
      in the broader technology radar within the five key technologies which emerge for
      their wide-ranging applications and impact in communities, companies, business,
      and value chain framework alike. However, AI in medical imaging is at an early
      phase of development, and there are still hurdles to take related to reliability,
      user confidence, and adoption. The present narrative review aimed to provide an
      overview on AI-based approaches (distributed learning, statistical learning,
      computer-aided diagnosis and detection systems, fully automated image analysis
      tool, natural language processing) in oncological hybrid medical imaging with
      respect to clinical tasks (detection, contouring and segmentation, prediction of 
      histology and tumor stage, prediction of mutational status and molecular
      therapies targets, prediction of treatment response, and outcome). Particularly, 
      AI-based approaches have been briefly described according to their purpose and,
      finally lung cancer-being one of the most extensively malignancy studied by
      hybrid medical imaging-has been used as illustrative scenario. Finally, we
      discussed clinical challenges and open issues including ethics, validation
      strategies, effective data-sharing methods, regulatory hurdles, educational
      resources, and strategy to facilitate the interaction among different
      stakeholders. Some of the major changes in medical imaging will come from the
      application of AI to workflow and protocols, eventually resulting in improved
      patient management and quality of life. Overall, several time-consuming tasks
      could be automatized. Machine learning algorithms and neural networks will permit
      sophisticated analysis resulting not only in major improvements in disease
      characterization through imaging, but also in the integration of multiple-omics
      data (i.e., derived from pathology, genomic, proteomics, and demographics) for
      multi-dimensional disease featuring. Nevertheless, to accelerate the transition
      of the theory to practice a sustainable development plan considering the
      multi-dimensional interactions between professionals, technology, industry,
      markets, policy, culture, and civil society directed by a mindset which will
      allow talents to thrive is necessary.
FAU - Sollini, Martina
AU  - Sollini M
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), 
      Italy.
AD  - Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
FAU - Bartoli, Francesco
AU  - Bartoli F
AD  - Regional Center of Nuclear Medicine, Department of Translational Research and New
      Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
FAU - Marciano, Andrea
AU  - Marciano A
AD  - Regional Center of Nuclear Medicine, Department of Translational Research and New
      Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
FAU - Zanca, Roberta
AU  - Zanca R
AD  - Regional Center of Nuclear Medicine, Department of Translational Research and New
      Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
FAU - Slart, Riemer H J A
AU  - Slart RHJA
AD  - University Medical Center Groningen, Medical Imaging Center, University of
      Groningen, Groningen, The Netherlands.
AD  - Faculty of Science and Technology, Biomedical Photonic Imaging, University of
      Twente, Enschede, The Netherlands.
FAU - Erba, Paola A
AU  - Erba PA
AUID- ORCID: http://orcid.org/0000-0003-0058-7377
AD  - Regional Center of Nuclear Medicine, Department of Translational Research and New
      Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
      paola.erba@unipi.it.
AD  - University Medical Center Groningen, Medical Imaging Center, University of
      Groningen, Groningen, The Netherlands. paola.erba@unipi.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201209
PL  - England
TA  - Eur J Hybrid Imaging
JT  - European journal of hybrid imaging
JID - 101724113
PMC - PMC8218106
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Computer-aided diagnosis systems
OT  - Deep learning
OT  - Distributed learning
OT  - Hybrid imaging
OT  - Imaging biomarkers
OT  - Machine learning
OT  - Natural language processing
OT  - PET/CT
OT  - Radiomics
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:01
CRDT- 2021/06/30 12:35
PHST- 2020/09/14 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2021/06/30 12:35 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:01 [medline]
AID - 10.1186/s41824-020-00094-8 [doi]
AID - 10.1186/s41824-020-00094-8 [pii]
PST - epublish
SO  - Eur J Hybrid Imaging. 2020 Dec 9;4(1):24. doi: 10.1186/s41824-020-00094-8.


PMID- 34187159
OWN - NLM
STAT- Publisher
LR  - 20210630
IS  - 1868-1891 (Electronic)
IS  - 1868-1883 (Linking)
DP  - 2020 Dec 17
TI  - Fertility preservation in women with early ovarian cancer.
LID - 10.1515/hmbci-2020-0026 [doi]
AB  - Fertility preservation is an important option to consider for young women with
      low-grade early ovarian cancer. Fertility-sparing surgery ("FSS") permits the
      conservation of the uterus and one of the ovaries. This technique is considered
      safe for stages IA G1, G2 and probably safe for IC G1 epithelial and
      non-epithelial ovarian cancers. There are still uncertainties and FSS is not
      fully accepted for stage IC G1, G2 and clear cell carcinoma. The difficulty in
      choosing the best option lies in the fact that there is a lack of prospective
      randomized studies, due to ethical and organizational issues. Retrospective
      studies and reviews showed reassuring results for FSS in terms of relapse and
      long term survival. The spontaneous pregnancy rate seems to decrease after FSS,
      but chemotherapy does not seem to have an impact on fertility rates. Compared
      with the general population, assisted reproductive techniques are considered safe
      and with similar fertility results.
CI  - (c) 2020 Walter de Gruyter GmbH, Berlin/Boston.
FAU - Necula, Daniel
AU  - Necula D
AD  - Obstetrics and Gynecology Unit, Biel Hospital, Biel, Switzerland.
FAU - Istrate, Daria
AU  - Istrate D
AD  - Genentech, San Francisco, CA, USA.
FAU - Mathis, Jerome
AU  - Mathis J
AD  - Obstetrics and Gynecology Unit, Biel Hospital, Biel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201217
PL  - Germany
TA  - Horm Mol Biol Clin Investig
JT  - Hormone molecular biology and clinical investigation
JID - 101538885
SB  - IM
OTO - NOTNLM
OT  - assisted reproductive techniques
OT  - early ovarian cancer
OT  - fertility preservation
OT  - fertility sparing surgery
OT  - oncological safety
EDAT- 2021/07/01 06:00
MHDA- 2021/07/01 06:00
CRDT- 2021/06/30 03:38
PHST- 2020/04/26 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2021/06/30 03:38 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - hmbci-2020-0026 [pii]
AID - 10.1515/hmbci-2020-0026 [doi]
PST - aheadofprint
SO  - Horm Mol Biol Clin Investig. 2020 Dec 17. pii: hmbci-2020-0026. doi:
      10.1515/hmbci-2020-0026.


PMID- 34173537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210628
IS  - 2590-3322 (Electronic)
IS  - 2590-3322 (Linking)
VI  - 3
IP  - 3
DP  - 2020 Sep 18
TI  - Informal Work and Sustainable Cities: From Formalization to Reparation.
PG  - 290-299
LID - 10.1016/j.oneear.2020.08.012 [doi]
AB  - Informal workers produce economic, social, and environmental value for cities.
      Too often, policy elites, including those promoting sustainable cities, overlook 
      this value, proposing formalization and relying on deficit-based framings of
      informal work. In this perspective piece, we bring critical research and
      community-produced knowledge about informal work to sustainability scholarship.
      We challenge the dominant, deficit-based frame of informal work, which can
      dispossess workers, reduce their collective power, and undercut the social and
      environmental value their work generates. Instead, thinking historically,
      relationally, and spatially clarifies the essential role of informal work for
      urban economies and highlights their potential for promoting sustainable cities. 
      It also reveals how growth-oriented economies reproduce environmental
      destruction, income inequality, and poverty, the very conditions impelling many
      to informal work. Rather than formalization, we propose reparation, an ethic and 
      practice promoting ecological regeneration, while redressing historic wrongs and 
      redistributing resources and social power to workers and grassroots social
      movements.
CI  - (c) 2020 Elsevier Inc.
FAU - Tucker, Jennifer L
AU  - Tucker JL
AD  - Community and Regional Planning, University of New Mexico, University of New
      Mexico, Albuquerque, NM 87131, USA.
FAU - Anantharaman, Manisha
AU  - Anantharaman M
AD  - Justice Community and Leadership, Saint Mary's College of California, Moraga CA
      94575, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - One Earth
JT  - One earth (Cambridge, Mass.)
JID - 101772818
PMC - PMC7500398
OTO - NOTNLM
OT  - decent work
OT  - development
OT  - economic imaginaries
OT  - formalization
OT  - informal
OT  - pro-poor
OT  - street vendors
OT  - sustainable cities
OT  - urban
OT  - waste pickers
EDAT- 2021/06/27 06:00
MHDA- 2021/06/27 06:01
CRDT- 2021/06/26 08:35
PHST- 2021/06/26 08:35 [entrez]
PHST- 2021/06/27 06:00 [pubmed]
PHST- 2021/06/27 06:01 [medline]
AID - 10.1016/j.oneear.2020.08.012 [doi]
AID - S2590-3322(20)30421-8 [pii]
PST - ppublish
SO  - One Earth. 2020 Sep 18;3(3):290-299. doi: 10.1016/j.oneear.2020.08.012.


PMID- 34165103
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 72
DP  - 2020 Oct.-Dec.
TI  - Research during COVID-19 Pandemic: Perspectives from the Ethics Committees of a
      Lower Middle Income Country.
PG  - 420-422
AB  - The pandemic of Coronavirus Disease 2019 (COVID-19) has created paradoxically a
      good opportunity globally to conduct research in the field of health and social
      science, and a Lower Middle-Income Country (LMIC) like Nepal is not an exception 
      in this regard. During this ongoing pandemic, the Ethical Review Board (ERB) of
      Nepal Health Research Council (NHRC) has received numerous research proposals
      regarding COVID-19. As its main responsibility is to ensure participants' safety,
      at the same time maintaining the scientific standard of research, the ERB has
      meticulously gone through all the proposals received so far. During this
      situation of a health emergency, the ERB of NHRC has had a different experience
      compared to the usual time. Its strength, weakness, opportunities, and threats
      have been like never before.
FAU - Ghimire, N
AU  - Ghimire N
AD  - Nepal Health Research Council, Ram Shah Path, Kathmandu, Nepal.
FAU - Panthee, A
AU  - Panthee A
AD  - Nepal Health Research Council, Ram Shah Path, Kathmandu, Nepal.
FAU - Sharma, M R
AU  - Sharma MR
AD  - Nepal Health Research Council, Ram Shah Path, Kathmandu, Nepal.
FAU - Adhikari, R K
AU  - Adhikari RK
AD  - Nepal Health Research Council, Ram Shah Path, Kathmandu, Nepal.
FAU - Gyanwali, P
AU  - Gyanwali P
AD  - Nepal Health Research Council, Ram Shah Path, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
SB  - IM
MH  - *COVID-19
MH  - Ethics Committees
MH  - Humans
MH  - Nepal/epidemiology
MH  - *Pandemics
MH  - SARS-CoV-2
EDAT- 2021/06/25 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/06/24 09:33
PHST- 2021/06/24 09:33 [entrez]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 Oct.-Dec.;18(72):420-422.


PMID- 34165092
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20220531
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 72
DP  - 2020 Oct.-Dec.
TI  - Knowledge, Attitude and Practice of Hepatitis B Vaccination among Health Care
      Workers at Manipal Teaching Hospital.
PG  - 256-259
AB  - Background Hepatitis B vaccine is the single most effective and safest strategy
      for the prevention of the disease among health care workers. Despite the
      knowledge, higher occupational risk among themselves and increasing prevalence of
      hepatitis B virus worldwide, there is scanty information on knowledge, attitude
      and practice (KAP) concerning HBV vaccination among health care workers in our
      country. Objective To understand the knowledge, attitude and practice of
      hepatitis B vaccination among health care workers at Manipal Teaching Hospital at
      Pokhara, Gandaki Province in Nepal. Method Four hundred and eight health care
      workers were enrolled for an observational, cross-sectional study at Manipal
      Teaching Hospital, Gandaki Province, Nepal after obtaining ethical clearance from
      Institutional Review Committee. Pre-tested questionnaire including knowledge,
      attitude and practice regarding hepatitis B vaccination were studied. Result All 
      participants demonstrated good knowledge and positive attitude towards Hepatitis 
      B infection and vaccination. However many had risky practice towards it. Only
      about half (51.7%) of these participants were completely vaccinated. The most
      common reason for non vaccination was negligence. Conclusion Despite good
      knowledge and positive attitude towards hepatitis B infection and vaccination,
      low rates of vaccination and risky practice was observed among HCW. Various
      occupational, behavioural, economical and psychological factors associated with
      it must be explored. Easy availability of vaccine, regular hepatitis B campaigns 
      must be conducted and policy guidelines need to be formulated by the government
      to manage all aspects of knowledge, attitude and practice of HCWs regarding
      hepatitis B vaccination.
FAU - Bhattarai, S
AU  - Bhattarai S
AD  - Department of Medicine, Manipal College of Medical Sciences and Teaching
      Hospital, Pokhara, Nepal.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel
MH  - *Hepatitis B/prevention & control
MH  - Hospitals, Teaching
MH  - Humans
MH  - Nepal
MH  - Surveys and Questionnaires
MH  - Vaccination
EDAT- 2021/06/25 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/06/24 09:33
PHST- 2021/06/24 09:33 [entrez]
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 Oct.-Dec.;18(72):256-259.


PMID- 34161058
STAT- Publisher
DA  - 20210624
PB  - Swedish Agency for Health Technology Assessment and Assessment of Social Services
      (SBU)
CTI - Swedish Agency for Health Technology Assessment and Assessment of Social Services
      (SBU): SBU Systematic Review Summaries
DP  - 2020 Nov 27
BTI - Treatment of depression with transcranial magnetic stimulation using an H-coil
      (dTMS): A systematic review and assessment of medical, economic, social and
      ethical aspects. An HTA Report
AB  - This report is part of a government assignment regarding mental illnesses and
      consists of a systematic review of therapeutic effects and adverse events in the 
      treatment of depression with deep transcranial magnetic stimulation (dTMS), which
      is a variant of repetitive transcranial magnetic stimulation (rTMS).
CI  - Copyright (c) 2020 by SBU - Swedish Agency for Health Technology Assessment and
      Assessment of Social Services.
LA  - eng
PT  - Review
PT  - Book
PL  - Stockholm
EDAT- 2021/06/24 06:01
MHDA- 2021/06/24 06:01
CDAT- 2021/06/24 06:01
AID - NBK571286 [bookaccession]


PMID- 34158433
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 71
DP  - 2020 Jul-Sept.
TI  - Localization of Mental Foramen in Panoramic Radiographs of 18-30 Year Olds: A
      Hospital Based Study.
PG  - 260-265
AB  - Background The position of the mental foramen demonstrates anatomical variations,
      although typically it is reported to be either between the apices of the first
      and second premolars or below the apex of the second premolar. Objective To
      determine the radiographic position of mental foramen in relation to Premolar
      crown and apex, in panoramic radiographs. Method Following ethical approval a
      retrospective study was conducted in 510 panoramic radiographs of 18-30 year olds
      from archives of Department of Oral Medicine and Radiology. The position of
      mental foramen was scored using crown and apex scores according to scoring
      criteria given by Jasser and Nwoku, 1998. Descriptive statistics was calculated
      and Chi-square test was applied to assess variation in position of mental foramen
      between genders and right and left side of mandible. Kappa statistics was applied
      to assess intra-observer reliability. Result The most common scoring for position
      of mental foramen on right side crown and apex was 3 (49.4%) followed by 4
      (45.9%). Similarly, on left side the most common score for crown and apex was 3
      (50.8%) followed by 4 (44.3%). There was no statistically significant difference 
      in position between the genders. Comparing the right and left sides, the position
      was symmetrical in 83.3% for crown and apex scores. The Kappa values indicated
      good agreement for intraobserver reliability. Conclusion The most common position
      for the mental foramen is between the first and second premolar teeth; though,
      anatomical variations are seen.
FAU - Luitel, A
AU  - Luitel A
AD  - Department of Dentistry, Mechi Zonal Hospital, Bhadrapur, Jhapa, Nepal.
FAU - Rimal, J
AU  - Rimal J
AD  - College of Dental Surgery, BP Koirala Institue of Health Sciences, Dharan, Nepal.
FAU - Maharjan, I K
AU  - Maharjan IK
AD  - College of Dental Surgery, BP Koirala Institue of Health Sciences, Dharan, Nepal.
FAU - Shrestha, A
AU  - Shrestha A
AD  - College of Dental Surgery, BP Koirala Institue of Health Sciences, Dharan, Nepal.
FAU - Tamang, R
AU  - Tamang R
AD  - Department of General Surgery, Koshi Zonal Hospital, Biratnagar, Morang, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
SB  - IM
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - *Mental Foramen
MH  - Radiography, Panoramic
MH  - Reproducibility of Results
MH  - Retrospective Studies
EDAT- 2021/06/24 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/06/23 06:42
PHST- 2021/06/23 06:42 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 Jul-Sept.;18(71):260-265.


PMID- 34158432
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 71
DP  - 2020 Jul-Sept.
TI  - Clinical Profile of Patients Presenting with Gallstone Disease in University
      Hospital of Nepal.
PG  - 256-259
AB  - Background Gallstone disease is one of the most common surgical problem
      throughout the world. The rise in gallstone disease burden and its wide spectrum 
      of non-specific presentation makes the disease more challenging. Objective To
      know the various modes of presentation, socio-demographic details of the patients
      with gallstone disease, any associated factors and its treatment options. Method 
      This is a prospective descriptive study in the patients presenting to Dhulikhel
      Hospital Kathmandu University Hospital diagnosed with gallstone during May 2018
      to April 2020. After receiving ethical clearance from institutional Review
      committee, the informed consent was taken from all patient involved in the study.
      The presence of gallstone was confirmed by abdominal ultrasonography (USG). This 
      study included total of 202 patients with gallstone disease. Result A total of
      202 individuals with gallstone were included in the study; 48 males (24%) and 154
      females (76%). The disease condition was common in age group 31-40 years
      (26.24%). Majority of the study population consumed mixed diet (92.57%). Out of
      202 patients; 52 patients (25.74%) were overweight. In this study series 185
      patients (91.58%) were symptomatic. Pain abdomen was one of the commonest
      symptoms (97.84%) followed by Nausea (28.11%), Dyspepsia (28.11%), Vomiting
      (18.38%), Fever (1.62) and Jaundice (1.08%). All cases were planned for
      laparoscopic cholecystectomy however 4 cases had to be converted to open surgery 
      for completion. Conclusion Gallstone disease is a common surgical problem in
      Female population that presents most commonly with pain abdomen. Laparoscopic
      cholecystectomy can be easily performed in all cases of gallstone disease.
FAU - Joshi, H N
AU  - Joshi HN
AD  - Department of Surgery, Dhulikhel Hospital, Kathmandu University Hospital,
      Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
FAU - Singh, A K
AU  - Singh AK
AD  - Department of Surgery, Dhulikhel Hospital, Kathmandu University Hospital,
      Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
FAU - Shrestha, D
AU  - Shrestha D
AD  - Department of Surgery, Dhulikhel Hospital, Kathmandu University Hospital,
      Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
FAU - Shrestha, I
AU  - Shrestha I
AD  - Department of Surgery, Dhulikhel Hospital, Kathmandu University Hospital,
      Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
FAU - Karmacharya, R M
AU  - Karmacharya RM
AD  - Department of Surgery, Dhulikhel Hospital, Kathmandu University Hospital,
      Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
SB  - IM
MH  - Adult
MH  - *Cholecystectomy, Laparoscopic
MH  - Female
MH  - *Gallstones/epidemiology/surgery
MH  - Hospitals, University
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Prospective Studies
EDAT- 2021/06/24 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/06/23 06:42
PHST- 2021/06/23 06:42 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 Jul-Sept.;18(71):256-259.


PMID- 34158428
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 71
DP  - 2020 Jul-Sept.
TI  - Factors Influencing Male Participation in Maternal Health Care among Married
      Couples in Nepal: A Population-based Cross-sectional Study.
PG  - 228-234
AB  - Background The male involvement in maternal health care is essential to reduce
      obstetric complications. However, there is little known about factors
      contributing to male participation in maternal health in Nepal. Objective To
      assess predisposing, enabling and reinforcing factors contributing male
      participation in maternal health care in Nepal. Method A population based
      cross-sectional study was conducted among 374 married couples. Ethical approval
      was obtained from Institutional Review Board of Kathmandu Medical College
      Teaching Hospital. The data was collected, using modified Safe Motherhood and
      Partnership Family Approach Model. Multivariable logistic regression was applied 
      to account associated paternal factors. Concentration curve and concentration
      index were computed to measure equity gap between lowest and highest quintiles.
      Result While four out of ten husbands reported high level of their involvement in
      maternal health care practices, wives reported relatively less involvement of
      their husbands. Logistic regression showed that husband having low family income,
      knows about immunization, contact with family planning providers were more likely
      to participate. In contrary, according to wives, husbands' who have ever been to 
      health facility, discuss family planning with others, contact with family
      planning providers and who knows about exclusive breast feeding were less likely 
      to participate. The study also showed that socio-economic factors play a
      significant role. Conclusion Male involvement in maternal health care practices
      is low. Predisposing, enabling and reinforcing factors play a significant role;
      however, some contradictions among husbands' and wives' perspectives provide
      strong evidence on significance of communication within partners on maternal
      health care issues.
FAU - Sharma, S
AU  - Sharma S
AD  - Department of Nursing, Kathmandu Medical College Teaching Hospital, Sinamangal,
      Kathmandu, Nepal.
FAU - Aryal, U R
AU  - Aryal UR
AD  - Researcher/Senior Statistician, Public Health and Environment Research Center and
      Leaders, Kathmandu, Nepal.
FAU - Shrestha, A
AU  - Shrestha A
AD  - Department of Community Programs, Kathmandu University School of Medical
      Sciences, Dhulikhel, Kavre, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Maternal Health
MH  - *Maternal Health Services
MH  - Nepal
MH  - Pregnancy
MH  - *Spouses
EDAT- 2021/06/24 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/06/23 06:42
PHST- 2021/06/23 06:42 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 Jul-Sept.;18(71):228-234.


PMID- 34136136
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Evaluating adults' health-related values and preferences about unprocessed red
      meat and processed meat consumption: protocol for a cross-sectional mixed-methods
      study.
PG  - 346
LID - 10.12688/f1000research.23593.2 [doi]
AB  - Background: People need to choose from a wide range of foods, and in addition to 
      availability and accessibility, people's values and preferences largely determine
      their daily food choices. Given the potential adverse health consequences of red 
      and processed meat and the limited knowledge on individuals' health-related
      values and preferences on the topic, such data would be useful in the development
      of recommendations regarding meat consumption. Methods and analysis: We will
      perform a cross-sectional mixed methods study. The study population will consist 
      of adult omnivores currently consuming a minimum of three weekly servings of
      either unprocessed red meat or processed meat. We will explore participants'
      willingness to stop or reduce their unprocessed red meat, or their processed meat
      consumption through a direct-choice exercise. This exercise will consist of
      presenting a scenario tailored to each individual's average weekly consumption.
      That is, based on a systematic review and meta-analysis of the best estimate of
      the risk reduction in overall cancer incidence and cancer mortality, we will ask 
      participants if they would stop their consumption, and/or reduce their average
      consumption. We will also present the corresponding certainty of the evidence for
      the potential risk reductions. Finally, we will measure their meat consumption
      three months after the interview and determine if they have made any changes to
      their average consumption. Ethics and dissemination: The research protocol was
      approved by the ethics committees in Canada (Research Ethics Board, Dalhousie
      University), Spain (Comite Etic d'Investigacio Clinica de l'IDIAP Jordi Gol),
      Poland (The Bioethics Committee of the Jagiellonian University), and Brazil
      (National Research Ethics Commission). The study is based on voluntary
      participation and informed written consent. Results from this project will be
      disseminated through publications and presentations.
CI  - Copyright: (c) 2021 Valli C et al.
FAU - Valli, Claudia
AU  - Valli C
AUID- ORCID: 0000-0002-4393-3690
AD  - Department of Paediatrics, Obstetrics, Gynaecology and Preventive Medicine,
      Universidad Autonoma de Barcelona, Barcelona, Spain.
AD  - Iberoamerican Cochrane Centre, Biomedical Research Institute San Pau (IIB Sant
      Pau), Barcelona, Spain.
FAU - Howatt, Victoria
AU  - Howatt V
AD  - Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Prokop-Dorner, Anna
AU  - Prokop-Dorner A
AUID- ORCID: 0000-0003-3575-469X
AD  - Department of Medical Sociology, Chair of Epidemiology and Preventive Medicine,
      Jagiellonian University Medical College, Krakow, Poland.
FAU - Rabassa, Montserrat
AU  - Rabassa M
AD  - Iberoamerican Cochrane Centre, Biomedical Research Institute San Pau (IIB Sant
      Pau), Barcelona, Spain.
FAU - Johnston, Bradley C
AU  - Johnston BC
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Department of Community Health and Epidemiology, Dalhousie University, Halifax,
      Nova Scotia, Canada.
AD  - Department of Nutrition, Texas A&M University, College Station, Texas, USA.
FAU - Zajac, Joanna
AU  - Zajac J
AD  - Department of Hygiene and Dietetics, Chair of Epidemiology and Preventive
      Medicine, Jagiellonian University Medical College, Krakow, Poland.
FAU - Han, Mi Ah
AU  - Han MA
AD  - Department of Preventive Medicine, College of Medicine, Chosun University,
      Gwangju, South Korea.
FAU - Kenji Nampo, Fernando
AU  - Kenji Nampo F
AUID- ORCID: 0000-0001-6411-6131
AD  - Latin-American Institute of Life and Nature Sciences, Federal University of
      Latin-American Integration, Evidence-Based Public Health Research Group, Foz do
      Iguassu, Brazil.
FAU - Guyatt, Gordon H
AU  - Guyatt GH
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Bala, Malgorzata M
AU  - Bala MM
AUID- ORCID: 0000-0003-1978-7264
AD  - Chair of Epidemiology and Preventive Medicine, Department of Hygiene and
      Dietetics, Jagiellonian University Medical College, Krakow, Poland.
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
AD  - Iberoamerican Cochrane Centre, Biomedical Research Institute San Pau (IIB Sant
      Pau), Barcelona, Spain.
AD  - CIBER de Epidemiologia y Salud Publica, (CIBERESP), Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - Adult
MH  - Brazil
MH  - Canada
MH  - Cross-Sectional Studies
MH  - Diet
MH  - Humans
MH  - Meat
MH  - *Meat Products
MH  - Meta-Analysis as Topic
MH  - *Red Meat
MH  - Systematic Reviews as Topic
PMC - PMC8176263
OTO - NOTNLM
OT  - *cross-sectional study
OT  - *health
OT  - *mixed methods
OT  - *processed meat
OT  - *red meat
OT  - *values and preferences
COIS- Competing interests: MR is funded by a Sara Borrell post-doctoral contract
      (CD16/00157) from the Carlos III Institute of Health and the European Social Fund
      (ESF). BCJ has received a grant from Texas A&M AgriLife Research to fund
      investigator-initiated research related to saturated and polyunsaturated fats.
      The grant was from Texas A&M AgriLife institutional funds from interest and
      investment earnings, not a sponsoring organization, industry, or company. The
      rest of the authors conducted this study independently without involvement of the
      funder. No further competing interests were disclosed. The authors declared that 
      no funding grants were involved in supporting this work.
EDAT- 2021/06/19 06:00
MHDA- 2021/07/09 06:00
CRDT- 2021/06/18 06:44
PHST- 2021/05/07 00:00 [accepted]
PHST- 2021/06/18 06:44 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
AID - 10.12688/f1000research.23593.2 [doi]
PST - epublish
SO  - F1000Res. 2020 May 11;9:346. doi: 10.12688/f1000research.23593.2. eCollection
      2020.


PMID- 34124576
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210721
IS  - 2515-9321 (Electronic)
IS  - 2515-9321 (Linking)
VI  - 3
DP  - 2020
TI  - Continuous research monitoring improves the quality of research conduct and
      compliance among research trainees: internal evaluation of a monitoring
      programme.
PG  - 57
LID - 10.12688/aasopenres.13117.1 [doi]
AB  - Background: Research site monitoring (RSM) is an effective way to ensure
      compliance with Good Clinical Practice (GCP). However, RSM is not offered to
      trainees (investigators) at African Institutions routinely. The Makerere
      University/Uganda Virus Research Institute Centre of Excellence in Infection and 
      Immunity Research and Training (MUII-Plus) introduced internal monitoring to
      promote the quality of trainees' research projects. Here, we share our monitoring
      model, experiences and achievements, and challenges encountered. Methods: We
      analysed investigators' project reports from monitoring visits undertaken from
      April 2017 to December 2019. Monitors followed a standard checklist to review
      investigator site files and record forms, and toured site facilities. We planned 
      four monitoring visits for each trainee: one at site initiation, two interim, and
      a closeout monitoring visit. A team of two monitors conducted the visits.
      Results: We monitored 25 out of the 26 research projects in progress between
      April 2017 and December 2019. Compliance with protocols, standard operating
      procedures, GCP, and GCLP improved with each monitoring visit. Median (IQR)
      compliance rate was 43% (31%, 44%) at site initiation visit for different
      monitoring items, 70% (54%, 90%) at the 1st interim monitoring visit, 100% (92%, 
      100%) at 2nd interim monitoring visit and all projects achieved 100% compliance
      at site closeout. All investigators had good work ethics and practice, and
      appropriate facilities. Initially, some investigators' files lacked essential
      documents, and informed consent processes needed to be improved. We realized that
      non-compliant investigators had not received prior training in GCP/GCLP, so we
      offered them this training. Conclusions: Routine monitoring helps identify
      non-compliance early and improves the quality of research. We recommend
      continuous internal monitoring for all research studies. Investigators conducting
      research involving human subjects should receive GCP/GCLP training before
      commencing their projects. Institutional higher degrees and research ethics
      committees should enforce this as a requirement for project approvals.
CI  - Copyright: (c) 2020 Akello M et al.
FAU - Akello, Mirriam
AU  - Akello M
AUID- ORCID: https://orcid.org/0000-0002-5660-2874
AD  - Medical Research Council/Uganda Virus Research Institute and London School
      Hygiene Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
FAU - Coutinho, Sarah
AU  - Coutinho S
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
FAU - N-Mboowa, Mary Gorrethy
AU  - N-Mboowa MG
AUID- ORCID: https://orcid.org/0000-0003-2587-011X
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
FAU - Bukirwa, Victoria D
AU  - Bukirwa VD
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
FAU - Natukunda, Agnes
AU  - Natukunda A
AD  - Medical Research Council/Uganda Virus Research Institute and London School
      Hygiene Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
FAU - Lubyayi, Lawrence
AU  - Lubyayi L
AD  - Medical Research Council/Uganda Virus Research Institute and London School
      Hygiene Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
FAU - Nabakooza, Grace
AU  - Nabakooza G
AUID- ORCID: https://orcid.org/0000-0003-4565-3227
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
AD  - Department of Immunology and Molecular Biology, Makerere University, Kampala,
      Uganda.
AD  - Centre for Computational Biology, Uganda Christian University, Mukono, Uganda.
FAU - Cose, Stephen
AU  - Cose S
AUID- ORCID: https://orcid.org/0000-0002-5156-037X
AD  - Medical Research Council/Uganda Virus Research Institute and London School
      Hygiene Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Elliott, Alison M
AU  - Elliott AM
AUID- ORCID: https://orcid.org/0000-0003-2818-9549
AD  - Medical Research Council/Uganda Virus Research Institute and London School
      Hygiene Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
AD  - Makerere University/ Uganda Virus Research Institute Centre of Excellence in
      Infection and Immunity Research and Training (MUII-Plus), Uganda Virus Research
      Institute, Entebbe, Uganda.
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
LA  - eng
GR  - MC_UU_00027/5/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - AAS Open Res
JT  - AAS open research
JID - 101740247
PMC - PMC8170533
OTO - NOTNLM
OT  - Africa
OT  - Good Clinical Research Practice
OT  - Internal monitoring
OT  - Uganda
OT  - research quality
OT  - trainees or investigators
COIS- Competing interests: With the exception of LL and AN, the authors are members of 
      the MUII-plus executive.
EDAT- 2021/06/15 06:00
MHDA- 2021/06/15 06:01
CRDT- 2021/06/14 09:56
PHST- 2020/11/13 00:00 [accepted]
PHST- 2021/06/14 09:56 [entrez]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/06/15 06:01 [medline]
AID - 10.12688/aasopenres.13117.1 [doi]
PST - epublish
SO  - AAS Open Res. 2020 Nov 25;3:57. doi: 10.12688/aasopenres.13117.1. eCollection
      2020.


PMID- 33501381
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220323
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Fostering global data sharing: highlighting the recommendations of the Research
      Data Alliance COVID-19 working group.
PG  - 267
LID - 10.12688/wellcomeopenres.16378.2 [doi]
AB  - The systemic challenges of the COVID-19 pandemic require cross-disciplinary
      collaboration in a global and timely fashion. Such collaboration needs open
      research practices and the sharing of research outputs, such as data and code,
      thereby facilitating research and research reproducibility and timely
      collaboration beyond borders. The Research Data Alliance COVID-19 Working Group
      recently published a set of recommendations and guidelines on data sharing and
      related best practices for COVID-19 research. These guidelines include
      recommendations for clinicians, researchers, policy- and decision-makers,
      funders, publishers, public health experts, disaster preparedness and response
      experts, infrastructure providers from the perspective of different domains
      (Clinical Medicine, Omics, Epidemiology, Social Sciences, Community
      Participation, Indigenous Peoples, Research Software, Legal and Ethical
      Considerations), and other potential users. These guidelines include
      recommendations for researchers, policymakers, funders, publishers and
      infrastructure providers from the perspective of different domains (Clinical
      Medicine, Omics, Epidemiology, Social Sciences, Community Participation,
      Indigenous Peoples, Research Software, Legal and Ethical Considerations). Several
      overarching themes have emerged from this document such as the need to balance
      the creation of data adherent to FAIR principles (findable, accessible,
      interoperable and reusable), with the need for quick data release; the use of
      trustworthy research data repositories; the use of well-annotated data with
      meaningful metadata; and practices of documenting methods and software. The
      resulting document marks an unprecedented cross-disciplinary, cross-sectoral, and
      cross-jurisdictional effort authored by over 160 experts from around the globe.
      This letter summarises key points of the Recommendations and Guidelines,
      highlights the relevant findings, shines a spotlight on the process, and suggests
      how these developments can be leveraged by the wider scientific community.
CI  - Copyright: (c) 2021 Austin CC et al.
FAU - Austin, Claire C
AU  - Austin CC
AUID- ORCID: https://orcid.org/0000-0001-9138-5986
AD  - Environment and Climate Change Canada, 351 boul. St-Joseph, Gatineau, Quebec, K1A
      0H3, Canada.
FAU - Bernier, Alexander
AU  - Bernier A
AUID- ORCID: https://orcid.org/0000-0001-8615-8375
AD  - Centre of Genomics and Policy, McGill University, 740, avenue Dr. Penfield, suite
      5200, Montreal, Quebec, Canada.
FAU - Bezuidenhout, Louise
AU  - Bezuidenhout L
AUID- ORCID: https://orcid.org/0000-0003-4328-3963
AD  - Institute for Science, Innovation and Society, University of Oxford, 64 Banbury
      Road, Oxford, OX2 6PN, UK.
FAU - Bicarregui, Juan
AU  - Bicarregui J
AUID- ORCID: https://orcid.org/0000-0001-5250-7653
AD  - UKRI-STFC Rutherford Appleton Laboratory, Harwell Campus, Didcot, OX11 0QX, UK.
FAU - Biro, Timea
AU  - Biro T
AUID- ORCID: https://orcid.org/0000-0002-8900-8978
AD  - Digital Repository of Ireland, Royal Irish Academy, 19 Dawson St, Dublin 2, D02
      HH58, Ireland.
FAU - Cambon-Thomsen, Anne
AU  - Cambon-Thomsen A
AUID- ORCID: https://orcid.org/0000-0001-8793-3644
AD  - CNRS, Inserm and University Toulouse III Paul Sabatier, Toulouse, France.
FAU - Carroll, Stephanie Russo
AU  - Carroll SR
AUID- ORCID: https://orcid.org/0000-0002-8996-8071
AD  - Native Nations Institute at the Udall Center for Studies in Public Policy and the
      College of Public Health, University of Arizona, 803 E First ST, Tucson, AZ,
      85719, USA.
FAU - Cournia, Zoe
AU  - Cournia Z
AUID- ORCID: https://orcid.org/0000-0001-9287-364X
AD  - Biomedical Research Foundation, Academy of Athens, 4 Soranou Ephessiou, Athens,
      11527, Greece.
FAU - Dabrowski, Piotr Wojciech
AU  - Dabrowski PW
AUID- ORCID: https://orcid.org/0000-0003-4893-805X
AD  - HTW Berlin University of Applied Science, Wilhelminenhofstrasse 75A, Berlin,
      12459, Germany.
FAU - Diallo, Gayo
AU  - Diallo G
AD  - BPH INSERM1219 & LaBRI, Univ. Bordeaux, 146 rue Leo Saignat, F-33000, Bordeaux,
      France.
FAU - Duflot, Thomas
AU  - Duflot T
AUID- ORCID: https://orcid.org/0000-0002-8730-284X
AD  - Normandie Univ, UNIROUEN, CHU Rouen, Department of Clinical Research, Rouen
      University Hospital, 1 Rue de Germont, Rouen Cedex, 76031, France.
FAU - Garcia, Leyla
AU  - Garcia L
AUID- ORCID: https://orcid.org/0000-0003-3986-0510
AD  - ZB MED Information Centre for Life Sciences, Gleueler Str 60, Cologne, 50931,
      Germany.
FAU - Gesing, Sandra
AU  - Gesing S
AD  - University of Notre Dame Center for Research Computing, 814 Flanner Hall, Notre
      Dame, IN, 46556, USA.
FAU - Gonzalez-Beltran, Alejandra
AU  - Gonzalez-Beltran A
AUID- ORCID: https://orcid.org/0000-0003-3499-8262
AD  - UKRI-STFC Rutherford Appleton Laboratory, Harwell Campus, Didcot, OX11 0QX, UK.
FAU - Gururaj, Anupama
AU  - Gururaj A
AUID- ORCID: https://orcid.org/0000-0002-4221-4379
AD  - National Institute of Allergy and Infectious Diseases, National Institutes of
      Health, 5601 Fishers Lane, Rockville, MD, 20852, USA.
FAU - Harrower, Natalie
AU  - Harrower N
AUID- ORCID: https://orcid.org/0000-0002-7487-4881
AD  - Digital Repository of Ireland, Royal Irish Academy, 19 Dawson St, Dublin 2, D02
      HH58, Ireland.
FAU - Lin, Dawei
AU  - Lin D
AD  - National Institute of Allergy and Infectious Diseases, National Institutes of
      Health, 5601 Fishers Lane, Rockville, MD, 20852, USA.
FAU - Medeiros, Claudia
AU  - Medeiros C
AUID- ORCID: https://orcid.org/0000-0003-1908-4753
AD  - Institute of Computing, University of Campinas, Av Albert Einstein 1251,
      Campinas, Sao Paulo, 13082-853, Brazil.
FAU - Mendez, Eva
AU  - Mendez E
AUID- ORCID: https://orcid.org/0000-0002-5337-4722
AD  - Universidad Carlos III de Madrid, C/ Madrid, 128, Getafe (Madrid), 28903, Spain.
FAU - Meyers, Natalie
AU  - Meyers N
AUID- ORCID: https://orcid.org/0000-0001-6441-6716
AD  - 250D Navari Center for Digital Scholarship, Hesburgh Library, University of Notre
      Dame, Notre Dame, IN, 46556, USA.
FAU - Mietchen, Daniel
AU  - Mietchen D
AUID- ORCID: https://orcid.org/0000-0001-9488-1870
AD  - School of Data Science, University of Virginia, P.O. Box 400249, Charlottesville,
      VA, 22904, USA.
FAU - Nagrani, Rajini
AU  - Nagrani R
AUID- ORCID: https://orcid.org/0000-0002-1708-2319
AD  - Leibniz Institute for Prevention Research and Epidemiology, Achterstrasse 30,
      Bremen, 28359, Germany.
FAU - Nilsonne, Gustav
AU  - Nilsonne G
AUID- ORCID: https://orcid.org/0000-0001-5273-0150
AD  - Karolinska Institutet & Swedish National Data Service, Nobels vag 9, Stockholm,
      17177, Sweden.
FAU - Parker, Simon
AU  - Parker S
AD  - Cancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
FAU - Pickering, Brian
AU  - Pickering B
AUID- ORCID: https://orcid.org/0000-0002-6815-2938
AD  - University of Southampton, University Road, Southampton, SO17 1BJ, UK.
FAU - Pienta, Amy
AU  - Pienta A
AD  - ICPSR, University of Michigan, P.O. Box 1248, Ann Arbor, MI, 48106-1248, USA.
FAU - Polydoratou, Panayiota
AU  - Polydoratou P
AUID- ORCID: https://orcid.org/0000-0002-7551-8002
AD  - OpenEdition/Department of Library Science, Archives and Information Systems,
      International Hellenic University, P.O. Box 141, Thessaloniki, 57400, Greece.
FAU - Psomopoulos, Fotis
AU  - Psomopoulos F
AUID- ORCID: https://orcid.org/0000-0002-0222-4273
AD  - Institute of Applied Biosciences (INAB), Centre for Research and Technology
      Hellas (CERTH), Thessaloniki, 57001, Greece.
FAU - Rennes, Stephanie
AU  - Rennes S
AUID- ORCID: https://orcid.org/0000-0003-1458-7773
AD  - INRAE National Research Institute for Agriculture, Food and Environment, 147 Rue 
      de l'Universite, Paris, 75007, France.
FAU - Rowe, Robyn
AU  - Rowe R
AUID- ORCID: https://orcid.org/0000-0003-0591-6213
AD  - Laurentian University, Ontario, P3E 2C6, Canada.
FAU - Sansone, Susanna-Assunta
AU  - Sansone SA
AUID- ORCID: https://orcid.org/0000-0001-5306-5690
AD  - Oxford e-Research Centre, Department of Engineering Science, University of
      Oxford, 7 Keble Road, Oxford, OX1 3QG, UK.
FAU - Shanahan, Hugh
AU  - Shanahan H
AUID- ORCID: https://orcid.org/0000-0003-1374-6015
AD  - Department of Computer Science, Royal Holloway, University of London, Bedford
      Building, Egham, TW20 0EX, UK.
FAU - Sitz, Lina
AU  - Sitz L
AUID- ORCID: https://orcid.org/0000-0002-6333-4986
AD  - Indepedent Researcher, Strada Costiera, Trieste, 34151, Italy.
FAU - Stocks, Joanne
AU  - Stocks J
AUID- ORCID: https://orcid.org/0000-0002-7800-6002
AD  - Division of Rheumatology, Orthopedics and Dermatology, School of Medicine,
      University of Nottingham, Queens Medical Centre, Nottingham, NG7 2UH, UK.
FAU - Tovani-Palone, Marcos Roberto
AU  - Tovani-Palone MR
AD  - Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.
AD  - Modestum Ltd, Hilton, Derbyshire, UK.
FAU - Uhlmansiek, Mary
AU  - Uhlmansiek M
AUID- ORCID: https://orcid.org/0000-0002-7949-2057
AD  - Research Data Alliance - US Region (RDA-US), c/o Ronin Institute, 127 Haddon
      Place, Montclair, NJ, 07043, USA.
CN  - Research Data Alliance
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 75N95019C00017/DA/NIDA NIH HHS/United States
GR  - BB/E025080/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
DEP - 20210526
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7808050.2
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical Research
OT  - Epidemiology
OT  - FAIR and CARE principles
OT  - Omics
OT  - Open science
OT  - Sharing research outputs in pandemics caused by infectious diseases
OT  - Social Science
COIS- No competing interests were disclosed.
EDAT- 2021/06/11 06:00
MHDA- 2021/06/11 06:01
CRDT- 2021/06/10 06:48
PHST- 2021/04/08 00:00 [accepted]
PHST- 2021/06/10 06:48 [entrez]
PHST- 2021/06/11 06:00 [pubmed]
PHST- 2021/06/11 06:01 [medline]
AID - 10.12688/wellcomeopenres.16378.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2021 May 26;5:267. doi: 10.12688/wellcomeopenres.16378.2.
      eCollection 2020.


PMID- 34106835
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20211220
IS  - 1878-0415 (Electronic)
IS  - 0737-6146 (Linking)
VI  - 38
DP  - 2020 Dec
TI  - Emergency Anesthesia in Resource-Limited Areas.
PG  - 209-227
LID - S0737-6146(20)30015-0 [pii]
LID - 10.1016/j.aan.2020.09.005 [doi]
AB  - Anesthesia providers play a critical role in the gap between unmet surgical need 
      and access to safe surgical care. Providers from high-income countries can help
      fill this gap, particularly during crises, but it is critical to provide care
      responsibly and ethically. Most unmet surgical need is in low-income and
      middle-income countries where limited infrastructural, human, and material
      resources pose significant challenges. Anesthesia providers must recognize these 
      difficulties as they apply to the local context and plan accordingly. This
      article outlines some of the unique issues and provides a framework of
      considerations for safe and responsible anesthesia delivery in resource-limited
      areas.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Lee, Seung
AU  - Lee S
AD  - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University
      School of Medicine, 1800 Orleans Street, 6222 Charlotte R. Bloomberg, Baltimore, 
      MD 21287, USA.
FAU - Onye, Azuka
AU  - Onye A
AD  - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University
      School of Medicine, 1800 Orleans Street, 9137 Sheikh Zayed Building, Baltimore,
      MD 21287, USA.
FAU - Latif, Asad
AU  - Latif A
AD  - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University
      School of Medicine, Armstrong Institute for Patient Safety and Quality, Johns
      Hopkins Medicine, 600 North Wolfe Street, Meyer 297A, Baltimore, MD 21287, USA.
      Electronic address: alatif1@jhmi.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Anesth
JT  - Advances in anesthesia
JID - 8409340
SB  - IM
MH  - Anesthesia/*statistics & numerical data
MH  - *Developing Countries
MH  - Emergencies
MH  - Health Resources/*statistics & numerical data
MH  - Health Services Accessibility/*statistics & numerical data
MH  - Humans
OTO - NOTNLM
OT  - *Disaster settings
OT  - *Emergency anesthesia
OT  - *Global anesthesia
OT  - *Global surgery
OT  - *Resource-limited settings
COIS- Disclosure The authors have no real or potential commercial or financial
      conflicts of interest to report.
EDAT- 2021/06/10 06:00
MHDA- 2021/12/21 06:00
CRDT- 2021/06/09 17:21
PHST- 2021/06/09 17:21 [entrez]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
AID - S0737-6146(20)30015-0 [pii]
AID - 10.1016/j.aan.2020.09.005 [doi]
PST - ppublish
SO  - Adv Anesth. 2020 Dec;38:209-227. doi: 10.1016/j.aan.2020.09.005.


PMID- 34093727
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210608
IS  - 1751-1437 (Print)
IS  - 1751-1437 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Nov
TI  - Evaluating the clinical and cost-effectiveness of permissive hypotension in
      critically ill patients aged 65 years or over with vasodilatory hypotension:
      Protocol for the 65 randomised clinical trial.
PG  - 281-282
LID - 10.1177/1751143720971433 [doi]
AB  - Vasodilatory shock is common in critically ill patients and vasopressors are a
      mainstay of therapy. A meta-analysis suggested that use of a higher, as opposed
      to a lower, mean arterial pressure target to guide titration of vasopressor
      therapy, could be associated with a higher risk of death in older critically ill 
      patients. The 65 trial is a pragmatic, multi-centre, parallel-group, open-label, 
      randomised clinical trial of permissive hypotension (a mean arterial pressure
      target of 60 -65 mmHg during vasopressor therapy) versus usual care in critically
      ill patients aged 65 years or over with vasodilatory hypotension. The trial is
      conducted in 2600 patients from 65 United Kingdom adult, general critical care
      units. The primary outcome is all-cause mortality at 90 days. An economic
      evaluation is embedded. The 65 trial received favourable ethical opinion from the
      South Central - Oxford C Research Ethics Committee and approval from the Health
      Research Authority. The results will be presented at national and international
      conferences and published in peer-reviewed medical journals. Trial registration: 
      ISRCTN10580502.
CI  - (c) The Intensive Care Society 2020.
FAU - Richards-Belle, Alvin
AU  - Richards-Belle A
AD  - Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC),
      London, UK.
FAU - Mouncey, Paul R
AU  - Mouncey PR
AD  - Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC),
      London, UK.
FAU - Grieve, Richard D
AU  - Grieve RD
AD  - Department of Health Services Research and Policy, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Harrison, David A
AU  - Harrison DA
AD  - Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC),
      London, UK.
FAU - Sadique, M Zia
AU  - Sadique MZ
AD  - Department of Health Services Research and Policy, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Henry, Doreen
AU  - Henry D
AD  - Patient Representative, UK.
FAU - Whitman, Chris
AU  - Whitman C
AD  - Patient Representative, UK.
FAU - Camsooksai, Julie
AU  - Camsooksai J
AD  - Critical Care, Poole Hospital NHS Foundation Trust, Dorset, UK.
FAU - Gordon, Anthony C
AU  - Gordon AC
AD  - Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College
      London, London, UK.
AD  - Intensive Care Unit, Imperial College Healthcare NHS Trust, St Mary's Hospital,
      London, UK.
FAU - Young, J Duncan
AU  - Young JD
AD  - Kadoorie Centre for Critical Care Research and Education, University of Oxford,
      John Radcliffe Hospital, Oxford, UK.
FAU - Rowan, Kathryn M
AU  - Rowan KM
AD  - Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC),
      London, UK.
FAU - Lamontagne, Francois
AU  - Lamontagne F
AD  - Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke et Faculte 
      de medecine et des sciences de la sante, Universite de Sherbrooke, Sherbrooke,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - England
TA  - J Intensive Care Soc
JT  - Journal of the Intensive Care Society
JID - 101538668
PMC - PMC8142090
OTO - NOTNLM
OT  - Vasopressors, mean arterial pressure, critical care, intensive care, clinical
      trial
COIS- Declaration of conflicting interests: The author(s) declared the following
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: ACG reports that outside of this work he has
      received speaker fees from Orion Corporation, Orion Pharma and Amomed Pharma. He 
      has consulted for Ferring Pharmaceuticals, Tenax Therapeutics, Baxter Healthcare,
      Bristol-Myers Squibb and GSK, and received grant support from Orion Corporation, 
      Orion Pharma, Tenax Therapeutics and HCA International with funds paid to his
      institution. All other authors declare no conflicts of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
CRDT- 2021/06/07 05:52
PHST- 2021/06/07 05:52 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
AID - 10.1177/1751143720971433 [doi]
AID - 10.1177_1751143720971433 [pii]
PST - ppublish
SO  - J Intensive Care Soc. 2020 Nov;21(4):281-282. doi: 10.1177/1751143720971433. Epub
      2020 Dec 8.


PMID- 34092864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jul-Sep
TI  - Comparison of Different Doses of Clonidine as an Additive to Intrathecal Isobaric
      Levobupivacaine in Patients Undergoing Infraumbilical Surgeries.
PG  - 492-496
LID - 10.4103/aer.AER_57_20 [doi]
AB  - BACKGROUND: Spinal anesthesia is a safe, reliable, and inexpensive technique with
      the advantage of providing surgical anesthesia and prolonged postoperative pain
      relief, and it also blunts autonomic, somatic, and endocrine responses to
      surgical stimulus. AIM: The aim of this study was to assess the efficacy 15 mug
      and 30 mug of intrathecal clonidine along with 3 mL of 0.5% isobaric
      levobupivacaine in comparison with plain 0.5% isobaric levobupivacaine. SETTING
      AND DESIGN: The prospective, interventional, randomized, comparative,
      double-blinded study was conducted after obtaining approval from the
      institutional ethical committee. MATERIALS AND METHODS: Seventy-five patients
      posted for elective lower-limb orthopedic surgeries were randomly divided into
      three groups with 25 patients in each group as L (levobupivacaine 0.5%), LC-15
      (levobupivacaine 0.5% + clonidine 15 mug), and LC-30 (levobupivacaine 0.5% +
      clonidine 30 mug). All the patients were given spinal anesthesia using the study 
      drugs, and various parameters were monitored. STATISTICAL ANALYSIS: The three
      groups were compared statistically using analysis of variance and Student's
      t-test (independent samples t-test). P < 0.05 was considered statistically
      significant. RESULTS: There was a statistically significant difference among the 
      three groups with respect to the onset of time for maximum sensory blockade and
      duration of analgesia. A statistically significant difference was noted among the
      three groups with respect to the onset of time for maximum motor blockade.
      CONCLUSION: Both doses of clonidine produced prolonged sensory block compared to 
      the control. It has been found that 30 mug of clonidine as an adjuvant has
      produced faster onset and prolonged duration sensory block compared to 15 mug of 
      clonidine.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Krishna, K
AU  - Krishna K
AD  - Department of Anaesthesiology, Mandya Institute of Medical Sciences, Mandya,
      Karnataka, India.
FAU - Muralidhara, K S
AU  - Muralidhara KS
AD  - Department of Anaesthesiology, Mandya Institute of Medical Sciences, Mandya,
      Karnataka, India.
FAU - Santhosh, M C B
AU  - Santhosh MCB
AD  - Department of Anaesthesiology, Mandya Institute of Medical Sciences, Mandya,
      Karnataka, India.
FAU - Shivakumar, G
AU  - Shivakumar G
AD  - Department of Anaesthesiology, Mandya Institute of Medical Sciences, Mandya,
      Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20210322
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8159055
OTO - NOTNLM
OT  - Clonidine
OT  - duration of analgesia
OT  - levobupivacaine
OT  - spinal anesthesia
COIS- There are no conflicts of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
CRDT- 2021/06/07 05:42
PHST- 2020/06/19 00:00 [received]
PHST- 2020/06/20 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2021/06/07 05:42 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
AID - 10.4103/aer.AER_57_20 [doi]
AID - AER-14-492 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jul-Sep;14(3):492-496. doi: 10.4103/aer.AER_57_20. Epub
      2021 Mar 22.


PMID- 34092860
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jul-Sep
TI  - Effect of Two Regimens of Fluid Administration on Airway Edema in Prone-Position 
      Surgery.
PG  - 467-473
LID - 10.4103/aer.AER_89_20 [doi]
AB  - BACKGROUND: Surgeries in prone position expose a patient to multitude of
      complications including laryngeal edema which may be related to the volume of
      fluid administered. Administering larger volumes of fluid intraoperatively may
      contribute to significant tissue edema, leading many anesthesiologists to
      practice a restrictive fluid infusion strategy. Although previous studies have
      compared fluid infusion strategies, changes in airway dimensions leading to
      airway edema have not been extensively investigated. Here, we compared two fluid 
      infusion regimens in patients undergoing spine surgery in the prone position, and
      assessed their association with airway edema by means of the cuff leak test
      (CLT). AIMS: The aim of this study was to test the hypothesis whether a larger
      volume of crystalloid administration in spine surgeries performed in prone
      position would result in greater chances of airway edema, than would a restricted
      infusion policy, utilizing the CLT. MATERIALS AND METHODS: After ethical
      committee approval, thirty patients, aged 21-60 years, American Society of
      Anesthesiologists Status I or II, scheduled for elective spine surgery in the
      prone position, were selected. Group 1 (restrictive group) received 3 mL.kg (-
      1).h (- 1), whereas Group 2 (permissive group) received 5 mL.kg (- 1).h (- 1) of 
      crystalloids plus urine output replacement. The airway edema was assessed by CLT 
      which was performed soon after intubation (T1) and before extubation (T2). Cuff
      leak volume (CLV) was calculated from the difference in tidal volumes before (VT 
      i) and after cuff deflation (VT e). Airway edema was evaluated by calculating the
      differences in the CLV at T1 and T2 (DeltaCLV); the more the value of Delta CLV
      which means greater difference between these two points, the more the decrease in
      laryngeal lumen, signifying an increased risk of airway edema. RESULTS: Decrease 
      in laryngeal lumen was observed in patients who received permissive fluid regimen
      than that of the restrictive group, signifying more chances of airway edema in
      the former group. In addition, a poor correlation was found between the duration 
      of anesthesia and development of airway edema in our study group. CONCLUSIONS:
      Because surgeries in the prone position are at risk of airway edema, restrictive 
      fluid regimen strategy should be preferred over the liberal one as there are more
      chances of reduction in laryngeal lumen dimensions with permissive fluid
      infusions.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Jan, Ravees
AU  - Jan R
AD  - Department of Anesthesiology and Perioperative Medicine, King Fahad Medical City,
      Riyadh, Kingdom of Saudi Arabia.
FAU - Alahdal, Ayman
AU  - Alahdal A
AD  - Department of Anesthesiology and Perioperative Medicine, King Fahad Medical City,
      Riyadh, Kingdom of Saudi Arabia.
FAU - Bithal, Parmod Kumar
AU  - Bithal PK
AD  - Department of Anesthesiology and Perioperative Medicine, King Fahad Medical City,
      Riyadh, Kingdom of Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20210322
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8159037
OTO - NOTNLM
OT  - Airway edema
OT  - cuff-leak test
OT  - prone position
OT  - spine surgery
COIS- There are no conflicts of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
CRDT- 2021/06/07 05:42
PHST- 2020/09/24 00:00 [received]
PHST- 2020/11/03 00:00 [revised]
PHST- 2020/11/29 00:00 [accepted]
PHST- 2021/06/07 05:42 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
AID - 10.4103/aer.AER_89_20 [doi]
AID - AER-14-467 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jul-Sep;14(3):467-473. doi: 10.4103/aer.AER_89_20. Epub
      2021 Mar 22.


PMID- 34092851
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jul-Sep
TI  - Comparison of Oral Clonidine and Gabapentin Premedication for Attenuation of
      Pressor Response to Laryngoscopy and Endotracheal Intubation.
PG  - 412-419
LID - 10.4103/aer.AER_114_20 [doi]
AB  - BACKGROUND: During the administration of general anesthesia, direct laryngoscopy 
      and endotracheal intubation cause an increase in heart rate, arterial pressure,
      and dysrhythmias in upto 90% of patients. These changes can be particularly
      hazardous for patients with cerebral or coronary diseases. Both clonidine and
      gabapentin have been used for anesthetic effects, but a better drug for
      controlling hemodynamic parameters is being investigated. AIMS: The study was
      done to evaluate and compare the efficacy of oral clonidine 0.3 mg and oral
      gabapentin 900 mg as a premedication for attenuation of pressor response to
      laryngoscopy and endotracheal intubation. MATERIALS AND METHODS: After obtaining 
      approval from the ethics committee, 75 patients, American Society of
      Anesthesiologists physical status classes I and II between the ages of 18 and 60 
      years scheduled to undergo elective noncardiac surgical procedure were enrolled
      in the study. Patients were randomized into three groups of 25 each who received 
      0.3 mg clonidine, 900 mg gabapentin, and placebo. The hemodynamic parameters were
      recorded at various time intervals along with any adverse effects. STATISTICAL
      ANALYSIS: Quantitative variables were compared using unpaired t-test between the 
      two groups and ANOVA for three groups. Qualitative variables were compared using 
      the Chi-square test/Fisher's exact test. P < 0.05 was considered statistically
      significant. RESULTS: In our study, we found that both clonidine and gabapentin
      are effective premedicants by oral route 2 h before induction of anesthesia to
      blunt the hemodynamic response to laryngoscopy and intubation as compared to
      placebo. Between clonidine and gabapentin, clonidine was found to be more
      effective with respect to blunting of systolic blood pressure (SBP), diastolic
      blood pressure (DBP), and mean arterial pressure (MAP), although found to be
      statistically significant only at 15 min with respect to SBP and DBP. CONCLUSION:
      Using clonidine or gabapentin, one can effectively provide stable hemodynamic
      conditions during laryngoscopy and endotracheal intubation, but more so with
      clonidine.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Sharma, Vaishali
AU  - Sharma V
AD  - Batra Hospital and Medical Research Centre, New Delhi, India.
FAU - Fotedar, Kamal
AU  - Fotedar K
AD  - Batra Hospital and Medical Research Centre, New Delhi, India.
FAU - Goel, Ravi
AU  - Goel R
AD  - Batra Hospital and Medical Research Centre, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20210322
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8159057
OTO - NOTNLM
OT  - Clonidine
OT  - endotracheal intubation
OT  - gabapentin
OT  - hemodynamic changes
OT  - pressor response to laryngoscopy
COIS- There are no conflicts of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
CRDT- 2021/06/07 05:42
PHST- 2020/12/23 00:00 [received]
PHST- 2021/01/17 00:00 [revised]
PHST- 2021/01/20 00:00 [accepted]
PHST- 2021/06/07 05:42 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
AID - 10.4103/aer.AER_114_20 [doi]
AID - AER-14-412 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jul-Sep;14(3):412-419. doi: 10.4103/aer.AER_114_20. Epub 
      2021 Mar 22.


PMID- 34092843
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210608
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jul-Sep
TI  - Preparing Intensive Care Unit in Resource-Constraint Setting Amid COVID-19
      Pandemic: Our Experience and Review.
PG  - 366-369
LID - 10.4103/aer.AER_86_20 [doi]
AB  - COVID-19 pandemic is an emerging, rapidly evolving public health emergency where 
      a nation's health-care system can face a marked surge in demand for intensive
      care unit (ICU) beds and organ support. In regions with insufficient medical
      resources, it may further aggravate the existing shortage, limiting an ICU's
      ability to provide the normal standard of care. It can present ethically or
      legally demanding questions about how to prioritize the allocation of life-saving
      medical resources. In developing countries like India, still many hospitals are
      challenged by competing priorities and remain underprepared. In the wake of
      COVID-19 pandemic, to guide the intensive care disaster planners in regions with 
      low resources and to ensure ICU readiness, this review shares our experience and 
      strategies for preparing ICU with existing and alternative resources, focusing on
      space, equipment, and health-care workers' safety and training.
CI  - Copyright: (c) 2021 Anesthesia: Essays and Researches.
FAU - Kajal, Kamal
AU  - Kajal K
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Naik, B Naveen
AU  - Naik BN
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Singh, Ajay
AU  - Singh A
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Soni, Shiv Lal
AU  - Soni SL
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Hazarika, Amarjyoti
AU  - Hazarika A
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Saini, Kulbhushan
AU  - Saini K
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Jaswal, Sanjay
AU  - Jaswal S
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Meena, Shyam Charan
AU  - Meena SC
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
FAU - Pandey, Naveen
AU  - Pandey N
AD  - Department of Hospital Administration, Post Graduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Puri, G D
AU  - Puri GD
AD  - Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical 
      Education and Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210322
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC8159056
OTO - NOTNLM
OT  - COVID-19
OT  - intensive care unit
OT  - pandemic
OT  - resource
COIS- There are no conflicts of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
CRDT- 2021/06/07 05:42
PHST- 2020/09/10 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2021/06/07 05:42 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
AID - 10.4103/aer.AER_86_20 [doi]
AID - AER-14-366 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jul-Sep;14(3):366-369. doi: 10.4103/aer.AER_86_20. Epub
      2021 Mar 22.


PMID- 34092344
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20210927
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Oct
TI  - Participant-funded clinical trials on rare diseases.
PG  - 267.e1-267.e9
LID - S2341-2879(20)30178-2 [pii]
LID - 10.1016/j.anpede.2020.03.005 [doi]
AB  - The development of medicines for certain rare diseases can be cut short by lack
      of funding. In certain cases the patients themselves, or their relatives,
      occasionally fund the clinical trial in which they will be treated with the
      investigational medicine. There are three models of self-funded clinical
      research: two of them, 'pay to try' and 'pay to participate', have already been
      put into practice. The third, the 'plutocratic' proposal, which has been recently
      put forward is still a theoretical model. In this work the scientific, social and
      ethical benefits and risks of the two clinical research models, 'pay to
      participate and the 'plutocratic' proposal, are reviewed. Patient-funded clinical
      trials are frequently performed through crowdfunding. The most controversial
      aspects of this funding modality are also addressed in this article from several 
      perspectives. Finally, a future scenario that would allow the launching of
      self-funded clinical trials in Spain by the 'plutocratic' proposal is proposed.
CI  - Copyright (c) 2020 Asociacion Espanola de Pediatria. Published by Elsevier
      Espana, S.L.U. All rights reserved.
FAU - Dal-Re, Rafael
AU  - Dal-Re R
AD  - Unidad de Epidemiologia, Instituto de Investigacion Sanitaria, Hospital
      Universitario Fundacion Jimenez Diaz, IIS-UAM, Universidad Autonoma de Madrid,
      Madrid, Spain. Electronic address: Rafael.dalre@quironsalud.es.
FAU - Palau, Francesc
AU  - Palau F
AD  - Servicio de Medicina Genetica y Molecular, Instituto Pediatrico de Enfermedades
      Raras (IPER), Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu,
      Esplugues de Llobregat, Barcelona, Spain; Institut Clinic de Medicina i
      Dermatologia, Hospital Clinic, Barcelona, Spain; Unidad de Pediatria, Facultat de
      Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain;
      CIBER de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.
FAU - Guillen-Navarro, Encarna
AU  - Guillen-Navarro E
AD  - CIBER de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain; Seccion de Genetica
      Medica, Servicio de Pediatria, Hospital Clinico Universitario Virgen de la
      Arrixaca, Instituto Murciano de Investigacion Biosanitaria (IMIB-Arrixaca),
      Facultad de Medicina, Universidad de Murcia, Murcia, Spain.
FAU - Ayuso, Carmen
AU  - Ayuso C
AD  - CIBER de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain; Departamento de
      Genetica y Genomica, Instituto de Investigacion Sanitaria, Hospital Universitario
      Fundacion Jimenez Diaz, IIS-UAM, Universidad Autonoma de Madrid, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201010
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - *Biomedical Research/economics
MH  - Clinical Trials as Topic/*economics
MH  - Drugs, Investigational/*therapeutic use
MH  - Humans
MH  - *Rare Diseases/drug therapy
MH  - Spain
OTO - NOTNLM
OT  - Autofinanciacion
OT  - Clinical trials
OT  - Crowdfunding
OT  - Enfermedades raras
OT  - Ensayos clinicos
OT  - Medicamentos huerfanos
OT  - Microfinanciacion
OT  - Micromecenazgo
OT  - Orphan drugs
OT  - Patient-Funded
OT  - Rare diseases
OT  - Self-Funded
EDAT- 2021/06/08 06:00
MHDA- 2021/09/28 06:00
CRDT- 2021/06/07 05:29
PHST- 2020/02/12 00:00 [received]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2021/06/07 05:29 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
AID - S2341-2879(20)30178-2 [pii]
AID - 10.1016/j.anpede.2020.03.005 [doi]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Oct;93(4):267.e1-267.e9. doi:
      10.1016/j.anpede.2020.03.005. Epub 2020 Oct 10.


PMID- 34092333
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Oct
TI  - Clinical research in rare diseases: New challenges, opportunities and ethical
      issues.
PG  - 219-221
LID - S2341-2879(20)30179-4 [pii]
LID - 10.1016/j.anpede.2020.06.001 [doi]
FAU - Alfonso Farnos, Iciar
AU  - Alfonso Farnos I
AD  - Comite de Etica de la Investigacion con medicamentos de Euskadi, Vitoria-Gasteiz,
      Spain. Electronic address: iciar.alfonso@hotmail.com.
FAU - Alcalde Bezhold, Guillermo
AU  - Alcalde Bezhold G
AD  - Comite de Etica de la Investigacion del Hospital Universitario Araba,
      Vitoria-Gasteiz, Spain.
LA  - eng
PT  - Editorial
PT  - Comment
DEP - 20201002
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
SB  - IM
CON - An Pediatr (Engl Ed). 2020 Oct;93(4):219-221. PMID: 32921623
MH  - Humans
MH  - *Rare Diseases/therapy
EDAT- 2021/06/08 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/06/07 05:29
PHST- 2020/06/24 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2021/06/07 05:29 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S2341-2879(20)30179-4 [pii]
AID - 10.1016/j.anpede.2020.06.001 [doi]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Oct;93(4):219-221. doi: 10.1016/j.anpede.2020.06.001. 
      Epub 2020 Oct 2.


PMID- 34077101
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1118-4841 (Print)
IS  - 1118-4841 (Linking)
VI  - 24
IP  - 2
DP  - 2020 Jun
TI  - Can Women's Lives be saved from Hypertensive Disorders during Pregnancy?
      Experiences of South African Midwives.
PG  - 152-163
LID - 10.29063/ajrh2020/v24i2.15 [doi]
AB  - A qualitative, descriptive phenomenological research design was conducted to
      explore and describe the experiences of midwives on the management of women
      diagnosed with hypertensive disorders during pregnancy in rural areas of Limpopo 
      Province, South Africa. Non-probability sampling was used to select eighteen (18)
      midwives from primary health care facilities of Mopani and Vhembe districts in
      Limpopo Province. Data was collected through in-depth interview and analysed
      using eight steps of Tesch's open coding method. Ethical considerations were
      adhered to by ensuring confidentiality, anonymity, privacy and signing of
      informed consent by participants. Measures to ensure trustworthiness;
      credibility, transferability, dependability and lastly, confirmability were
      ensured. Findings of this study revealed three themes (with sub-themes) namely;
      management of pregnant women diagnosed with hypertensive disorders, support
      experienced when managing complications, challenges experienced by midwives when 
      managing hypertensive disorders during pregnancy. In conclusion, poor support
      came up very strongly as a factor influencing good management of hypertensive
      disorders in pregnancy. Recruitment of more midwives that will support each other
      during management of pregnant women with hypertensive disorders is recommended.
FAU - Ramavhoya, Irene T
AU  - Ramavhoya IT
AD  - Department of Nursing Science, University of Pretoria, South Africa.
FAU - Maputle, Maria S
AU  - Maputle MS
AD  - Department of Advance Nursing Science, University of Venda, Private Bag X5050,
      Thohoyandou 0950, South Africa.
FAU - Lebese, Rachel T
AU  - Lebese RT
AD  - Department of Advance Nursing Science, University of Venda, Private Bag X5050,
      Thohoyandou 0950, South Africa.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Afr J Reprod Health
JT  - African journal of reproductive health
JID - 9712263
SB  - IM
MH  - Adult
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*prevention & control
MH  - Interviews as Topic
MH  - Maternal Death/*prevention & control
MH  - Middle Aged
MH  - Midwifery
MH  - Nurse Midwives/*psychology
MH  - Pregnancy
MH  - Pregnant Women/*psychology
MH  - Qualitative Research
MH  - *Quality of Health Care
MH  - South Africa
OTO - NOTNLM
OT  - Hypertensive disorders in pregnancy
OT  - South Africa
OT  - maternal death
OT  - midwives
EDAT- 2021/06/03 06:00
MHDA- 2021/06/12 06:00
CRDT- 2021/06/02 12:36
PHST- 2021/06/02 12:36 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
AID - 10.29063/ajrh2020/v24i2.15 [doi]
PST - ppublish
SO  - Afr J Reprod Health. 2020 Jun;24(2):152-163. doi: 10.29063/ajrh2020/v24i2.15.


PMID- 34077073
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1118-4841 (Print)
IS  - 1118-4841 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Dec
TI  - Regulating assisted reproductive technologies (ART) in Nigeria: lessons from
      Australia and the United Kingdom.
PG  - 82-93
LID - 10.29063/ajrh2020/v24i4.9 [doi]
AB  - Assisted reproductive technologies (ART), are innovative, non-coital medical
      procreative procedures, that have brought respite to a number of childless
      persons and couples, just as it also raises a number of ethical and medico-legal 
      issues. A number of countries including Nigeria, are still struggling to find the
      appropriate legal framework to provide guidelines for this reproductive process
      to curtail inherent unethical practices associated with that development. The
      paper explores the available regulatory instruments in Nigeria and in cognate
      jurisdictions such as Australia and the United Kingdom, through a comparative
      study to ascertain the efficacy of the existing instruments in ensuring that
      unethical practices and abuses associated with ART are eradicated. The findings
      indicate that the regulatory instrument in Nigeria requires significant
      improvement in line with the legal frameworks in operation in the cognate
      jurisdictions to effectively guard against potential unethical practices and
      abuses associated with the application of ART.
FAU - Ekechi-Agwu, Chinelo A
AU  - Ekechi-Agwu CA
AD  - Department of Sociology, University of Lagos, Nigeria.
FAU - Nwafor, Anthony O
AU  - Nwafor AO
AD  - School of Law, University of Venda, South Africa.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Afr J Reprod Health
JT  - African journal of reproductive health
JID - 9712263
SB  - IM
MH  - Adult
MH  - Australia
MH  - Fertilization in Vitro/*ethics
MH  - Guideline Adherence
MH  - Humans
MH  - Nigeria
MH  - Practice Guidelines as Topic
MH  - Reproductive Health Services/*ethics
MH  - Reproductive Techniques, Assisted/*ethics/*legislation & jurisprudence
MH  - United Kingdom
OTO - NOTNLM
OT  - Assisted reproduction
OT  - Australia
OT  - Nigeria
OT  - United Kingdom
OT  - ethics
OT  - law
EDAT- 2021/06/03 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/06/02 12:36
PHST- 2021/06/02 12:36 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.29063/ajrh2020/v24i4.9 [doi]
PST - ppublish
SO  - Afr J Reprod Health. 2020 Dec;24(4):82-93. doi: 10.29063/ajrh2020/v24i4.9.


PMID- 34077050
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 1118-4841 (Print)
IS  - 1118-4841 (Linking)
VI  - 24
IP  - s1
DP  - 2020 Jun
TI  - Who Gets Scarce Medical Resources during a COVID-19 Pandemic? Let's not beat
      about the Bush.
PG  - 32-40
LID - 10.29063/ajrh2020/v24i2s.5 [doi]
AB  - Except for such rare situations where it might be determined absence of
      physician's imputability, physicians cannot save the most lives while respecting 
      the legal rights of the patient' without violating the overarching principle
      every human life has equal value'. Arguing to the contrary is a conscious
      hypocritical attitude, or in other words, a fiction. Medical law and ethics long 
      since carry with its various fictions. Furthermore, in a public health emergency 
      such as the current COVID-19 crisis, medical law and ethics change and shift the 
      focus from the patient-centered model towards the public health-centered model.
      Under these particular circumstances, this fiction becomes striking, and it can
      no longer be swept under the rug. As health emergencies can happen anywhere,
      anytime, the patient prioritization in circumstances of limited resources should 
      be accepted. Medical law and ethics should back away from strict commitment to
      placing paramount emphasis on the value of human life. It is time for medical law
      and ethics to leave taboo-related hypocritical attitudes, and venture to make a
      historic compromise. To do so, three principles should be met: subsidiarity,
      proportionality, and consensus and social proof.
FAU - Voultsos, Polychronis P
AU  - Voultsos PP
AD  - Laboratory of Legal Medicine & Toxicology (Medical Law and Ethics), Department of
      Medicine, School of Health Sciences, Aristotle University of Thessaloniki,
      Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Afr J Reprod Health
JT  - African journal of reproductive health
JID - 9712263
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Health Care Rationing/*ethics/*legislation & jurisprudence
MH  - Humans
MH  - Pandemics
MH  - Public Health/*ethics/*legislation & jurisprudence
MH  - Respiration, Artificial/ethics
MH  - SARS-CoV-2
MH  - Withholding Treatment/ethics/legislation & jurisprudence
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - conflict of duties
OT  - human life
OT  - imputability
OT  - scarce resources
OT  - tragic dilemma
OT  - withdrawal of ventilator
EDAT- 2021/06/03 06:00
MHDA- 2021/06/16 06:00
CRDT- 2021/06/02 12:36
PHST- 2021/06/02 12:36 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 10.29063/ajrh2020/v24i2s.5 [doi]
PST - ppublish
SO  - Afr J Reprod Health. 2020 Jun;24(s1):32-40. doi: 10.29063/ajrh2020/v24i2s.5.


PMID- 34057357
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 0167-9228 (Print)
IS  - 0167-9228 (Linking)
VI  - 51
IP  - 4
DP  - 2020 Dec 10
TI  - [Care for delirium superimposed on dementia at an early stage].
LID - 10.36613/tgg.1875-6832/2020.04.02 [doi]
AB  - Delirium is a common serious complication in dementia that is associated with
      poor prognosis and a high burden on caregivers and healthcare professionals.
      Appropriate care is therefore important at an early stage for patients with
      delirium superimposed on dementiaTo gain insight into the care of six patients
      with delirium superimposed on dementia, 19 semi-structured interviews were
      conducted focused on the experiences of caregivers and professionals. The
      interviews revealed four themes that appeared to play a role: 1. experiences with
      and views on behavioral problems of these patients, 2. recognition and diagnosis 
      of delirium in dementia, 3. views on good care and 4. organizational aspects.
      Knowledge gaps about delirium in dementia, as well as ethical considerations,
      play an important role in organizing timely and adequate care for patients with
      delirium superimposed on dementia.
FAU - Oudewortel, Letty
AU  - Oudewortel L
AD  - Parnassia Groep, Ouderenkliniek, Opname Psychogeriatrie.
FAU - Gool, Willem A van
AU  - Gool WAV
AD  - Parnassia Groep, Ouderenkliniek, Opname Psychogeriatrie.
LA  - dut
PT  - Journal Article
TT  - Zorg in de vroege fase van een delier bij dementie.
DEP - 20201210
PL  - Netherlands
TA  - Tijdschr Gerontol Geriatr
JT  - Tijdschrift voor gerontologie en geriatrie
JID - 8210346
SB  - IM
MH  - Caregivers
MH  - *Delirium/diagnosis/therapy
MH  - *Dementia/complications
MH  - Humans
OTO - NOTNLM
OT  - Behavioral problems
OT  - Community-dwelling
OT  - Delirium superimposed on dementia
OT  - Diagnosis of delirium superimposed on dementia
OT  - Long-term care facility
EDAT- 2021/06/01 06:00
MHDA- 2021/06/03 06:00
CRDT- 2021/05/31 11:45
PHST- 2021/05/31 11:45 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
AID - 10.36613/tgg.1875-6832/2020.04.02 [doi]
PST - epublish
SO  - Tijdschr Gerontol Geriatr. 2020 Dec 10;51(4). doi:
      10.36613/tgg.1875-6832/2020.04.02. eCollection 2020 Dec 10.


PMID- 34056534
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210601
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Dietary interventions with or without omega-3 supplementation for the management 
      of rheumatoid arthritis: a systematic review protocol.
PG  - 72
LID - 10.12688/hrbopenres.13136.1 [doi]
AB  - Background: Rheumatoid arthritis (RA) is an autoimmune disease characterised by
      swollen and painful joints. It is hypothesised that changes in lifestyle factors 
      such as consuming a healthier diet may reduce the severity of RA symptoms. People
      living with RA commonly make alterations to their dietary intake with the hope of
      improving their symptoms. This systematic review aims to discuss the effects of
      dietary interventions with and without omega-3 supplementation for the management
      of rheumatoid arthritis. Methods: A systematic review of randomised controlled
      trials (RCTs) and non-randomised controlled trials (NRCTs) will be conducted.
      MEDLINE, EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews,
      Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology
      Register) and CINAHL will be searched from inception without using date
      restrictions. Primary outcomes will include measures of disease activity,
      inflammation and quality of life among adults living with RA. Study selection
      will follow the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses (PRISMA) guidelines, and the methodological appraisal of the
      studies will be assessed independently by two different reviewers (TR and AG)
      using the Cochrane Risk-of-Bias Tool for RCTs, and Risk-of-Bias In Non-Randomised
      Studies Tool for NRCTs. Ethics and dissemination: Ethical approval is not
      required for this systematic review. Only publically available data from
      previously published studies will be used. The findings of this systematic review
      will be submitted for publication in a peer-reviewed journal and presented at
      relevant conferences. PROSPERO registration: CRD42020147415 (11/02/2020).
CI  - Copyright: (c) 2020 Raad T et al.
FAU - Raad, Tala
AU  - Raad T
AUID- ORCID: https://orcid.org/0000-0002-2261-9061
AD  - Discipline of Dietetics, School of Allied Health, Faculty of Education and Health
      Sciences and Health Implementation Science and Technology Centre, Health Research
      Institute, University of Limerick, Limerick, Ireland.
FAU - George, Elena
AU  - George E
AUID- ORCID: https://orcid.org/0000-0002-1385-2371
AD  - Deakin University, Institute for Physical Activity and Nutrition (IPAN), School
      of Exercise and Nutrition Sciences, Geelong, Victoria, 3220, Australia.
FAU - Griffin, Anne
AU  - Griffin A
AUID- ORCID: https://orcid.org/0000-0002-1581-2998
AD  - Discipline of Dietetics, School of Allied Health, Faculty of Education and Health
      Sciences and Health Implementation Science and Technology Centre, Health Research
      Institute, University of Limerick, Limerick, Ireland.
FAU - Larkin, Louise
AU  - Larkin L
AUID- ORCID: https://orcid.org/0000-0001-9646-3947
AD  - Discipline of Physiotherapy, School of Allied Health, Faculty of Education and
      Health Sciences, Implementation Science and Technology Centre, Health Research
      Institute, University of Limerick, Limerick, Ireland.
FAU - Fraser, Alexander
AU  - Fraser A
AD  - Department of Rheumatology, University Hospital Limerick, Limerick, Ireland.
AD  - Graduate Entry Medical School, Faculty of Education and Health Sciences,
      University of Limerick, Limerick, Ireland.
FAU - Kennedy, Norelee
AU  - Kennedy N
AUID- ORCID: https://orcid.org/0000-0001-6047-1240
AD  - Discipline of Physiotherapy, School of Allied Health, Faculty of Education and
      Health Sciences, Implementation Science and Technology Centre, Health Research
      Institute, University of Limerick, Limerick, Ireland.
FAU - Tierney, Audrey
AU  - Tierney A
AUID- ORCID: https://orcid.org/0000-0001-8562-2877
AD  - Discipline of Dietetics, School of Allied Health, Faculty of Education and Health
      Sciences and Health Implementation Science and Technology Centre, Health Research
      Institute, University of Limerick, Limerick, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC8138488
OTO - NOTNLM
OT  - Rheumatoid arthritis
OT  - diet
OT  - non-randomised controlled trial
OT  - omega-3
OT  - protocol
OT  - randomised controlled trials
OT  - systematic review
COIS- No competing interests were disclosed.
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:23
PHST- 2020/09/25 00:00 [accepted]
PHST- 2021/05/31 06:23 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.12688/hrbopenres.13136.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Oct 2;3:72. doi: 10.12688/hrbopenres.13136.1. eCollection
      2020.


PMID- 34056121
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2392-7518 (Print)
IS  - 2392-7518 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Jul
TI  - Epidural Naloxone Attenuates Fentanyl Induced PONV in Patients Undergoing Lower
      Limb Orthopaedic Surgeries. a Prospective Randomized Double-Blind Comparative
      Study.
PG  - 23-28
LID - 10.2478/rjaic-2020-0009 [doi]
AB  - BACKGROUND AND AIM: Epidural administration of opioids with local anaesthetics is
      a popular choice for perioperative pain relief. But opioid induced side effects
      limit their use for postoperative analgesia. Hence, this study was designed to
      evaluate the effectiveness of epidural naloxone, an opioid receptor antagonist,
      in reducing PONV in patients receiving epidural fentanyl. METHODS: After
      obtaining the Institutional Ethics Committee approval and written informed
      consent, 46 patients, between 18-80 years, of either sex, with ASA physical
      status 1-3, undergoing lower limb orthopaedic surgeries were enlisted for this
      prospective, randomized, double blind comparative study. Subjects were allocated 
      to one of the two groups and received epidurally, either fentanyl with
      bupivacaine (Group C, n = 23) or fentanyl with bupivacaine and naloxone 2 mcg
      (Group N, n = 25), for reducing postoperative pain. PONV score and Wong Bakers
      Scale (WBS) for pain score were recorded at 6, 12 and 18hrs, postoperatively.
      RESULTS: All patients were comparable with respect to age, gender, ASA PS,
      height, body weight as well as duration of surgery. A statistically significant
      decrease in PONV score was observed in Group N at 6 and 12 hours,
      postoperatively. The patients who required rescue antiemetic were also
      significantly lower in Group N at 6 and 12 hours. The mean WBS score for pain
      also showed significant reduction in Group N at 6 hours, postoperatively.
      CONCLUSION: Concomitant use of low dose epidural naloxone and fentanyl is
      effective in attenuating PONV, besides enhancing analgesia in the
      earlypostoperative period.
CI  - (c) 2020 Zabrin Nimeeliya et al., published by Sciendo.
FAU - Nimeeliya, Zabrin
AU  - Nimeeliya Z
AD  - Azeezia Institute of Medical Sciences & Research, Kollam, Kerala, India.
FAU - Derlin, Thomas
AU  - Derlin T
AD  - Azeezia Institute of Medical Sciences & Research, Kollam, Kerala, India.
FAU - Kundil Alungal, Sabah Rahman
AU  - Kundil Alungal SR
AD  - Azeezia Institute of Medical Sciences & Research, Kollam, Kerala, India.
FAU - Kanjirathummoottil, George
AU  - Kanjirathummoottil G
AD  - Azeezia Institute of Medical Sciences & Research, Kollam, Kerala, India.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - Romania
TA  - Rom J Anaesth Intensive Care
JT  - Romanian journal of anaesthesia and intensive care
JID - 101681752
PMC - PMC8158304
OTO - NOTNLM
OT  - Epidural
OT  - Fentanyl
OT  - Naloxone
OT  - PONV
OT  - Wong Bakers Scale
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:21
PHST- 2021/05/31 06:21 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.2478/rjaic-2020-0009 [doi]
AID - rjaic-2020-0009 [pii]
PST - ppublish
SO  - Rom J Anaesth Intensive Care. 2020 Jul;27(1):23-28. doi: 10.2478/rjaic-2020-0009.
      Epub 2020 Aug 10.


PMID- 34055246
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210601
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Ethical communication to patient & society: a critical responsibility in COVID-19
      pandemic.
PG  - 30
LID - 10.18502/jmehm.v13i30.5047 [doi]
FAU - Chatterjee, Saptarshi
AU  - Chatterjee S
AD  - Assistant Professor, Department of Microbiology, School of Life Science &
      Biotechnology, Adamas University, West Bengal, India.
LA  - eng
PT  - Journal Article
DEP - 20201227
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC8141207
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:12
PHST- 2020/06/14 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2021/05/31 06:12 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.18502/jmehm.v13i30.5047 [doi]
AID - JMEHM-13-30 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 27;13:30. doi: 10.18502/jmehm.v13i30.5047.
      eCollection 2020.


PMID- 34055244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210601
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Health lag: medical philosophy reflects on COVID-19 pandemic.
PG  - 28
LID - 10.18502/jmehm.v13i28.5045 [doi]
AB  - In this paper, we reflect on the COVID-19 pandemic based on medical philosophy. A
      critical examination of the Corona crisis uncovers that in order to understand
      and explain the unpreparedness of the health systems, we need a new conceptual
      framework. This helps us to look at this phenomenon in a new way, address new
      problems, and come up with creative solutions. Our proposal is that "health lag" 
      is a concept that could help frame and explain this unpreparedness and
      unreadiness. The term "health lag" refers to the failure of health systems to
      keep up with clinical medicine. In other words, health issues in most situations 
      fall behind clinical medicine, leading to social, cultural, and economic
      problems. In the first step to define health lag, we have to explain the
      distinction between clinical medicine and health and address the role of
      individual health, public health, and epidemic in this dichotomy. Thereafter, the
      reasons behind health lag will be analyzed in three levels: theoretical,
      practical, and institutional. In the third step, we will point out the most
      important consequences of health lag: the medicalization of health, the
      inconsistency of biopolitics, inadequate ethical frameworks, and public sphere
      vulnerabilities. Finally, we try to come up with a set of recommendations based
      on this philosophical-conceptual analysis.
CI  - Copyright (c) 2020 Tehran University of Medical Sciences.
FAU - Monajemi, Alireza
AU  - Monajemi A
AD  - Assistant Professor, Department of Philosophy of Science and Technology,
      Institute for Humanities and Cultural Studies, Tehran, Iran.
FAU - Namazi, Hamidreza
AU  - Namazi H
AD  - Assistant Professor, Department of Medical Ethics, School of Medicine, Tehran
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC8141206
OTO - NOTNLM
OT  - COVID-19
OT  - Medical humanities
OT  - Medical philosophy
OT  - Medicalization
OT  - Pandemics.
OT  - Public health
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:12
PHST- 2020/11/01 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/05/31 06:12 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.18502/jmehm.v13i28.5045 [doi]
AID - JMEHM-13-28 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 23;13:28. doi: 10.18502/jmehm.v13i28.5045.
      eCollection 2020.


PMID- 34055243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210601
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Confidentiality challenges surrounding plasma therapy during the COVID-19
      pandemic: a case discussion in Iran.
PG  - 27
LID - 10.18502/jmehm.v13i27.5044 [doi]
AB  - Maintaining confidentiality, both in national and international codes of ethics, 
      is considered an important principle in healthcare and the medical profession for
      both patients and physicians. This case-report article focused on a real case.
      Based on the request of the Iranian Blood Transfusion Organization (IBTO) for
      plasma donation from recovered COVID-19 patients, we asked the names and personal
      information of those patients from hospitals affiliated with Iran University of
      Medical Sciences (IUMS) and arranged for the subjects to be referred to the
      Medical Ethics Department of IUMS for consultation during the COVID-19 pandemic. 
      Various ethical and legal aspects of this case were discussed in a special
      meeting, and practical solutions were then provided considering the limits of
      confidentiality and conditions for ethical access to patients' information during
      a pandemic. Since plasma therapy is not a definitive cure for COVID-19 and
      considering the ethical and legal points presented in this article, it is not
      recommended to announce the names of patients in the early stages. Given the
      potential impacts of the procedure and the possibility of patients being cured,
      however, their consent should be obtained in different situations and, if
      necessary, providing information to patients or educating them should be
      considered.
CI  - Copyright (c) 2020 Tehran University of Medical Sciences.
FAU - Saeedi Tehrani, Saeedeh
AU  - Saeedi Tehrani S
AD  - Assistant Professor, Department of Medical Ethics, School of Medicine, Iran
      University of Medical Sciences, Tehran, Iran.
FAU - Hashemi, Akram
AU  - Hashemi A
AD  - Assistant Professor, Department of Medical Ethics, School of Medicine, Iran
      University of Medical Sciences, Tehran, Iran.
FAU - Madani, Mansureh
AU  - Madani M
AD  - Researcher, PhD in Medical Ethics.
FAU - Forouzandeh, Mina
AU  - Forouzandeh M
AD  - Assistant Professor, Department of Medical Ethics, School of Medicine, Iran
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Case Reports
DEP - 20201221
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC8141205
OTO - NOTNLM
OT  - COVID- 19
OT  - Confidentiality
OT  - Confidentiality breach
OT  - Plasma therapy.
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:12
PHST- 2020/10/25 00:00 [received]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2021/05/31 06:12 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.18502/jmehm.v13i27.5044 [doi]
AID - JMEHM-13-27 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 21;13:27. doi: 10.18502/jmehm.v13i27.5044.
      eCollection 2020.


PMID- 34055241
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210601
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Virtual learning for teaching medical ethics during COVID-19 pandemic.
PG  - 25
LID - 10.18502/jmehm.v13i25.4956 [doi]
FAU - Mobasher, Mina
AU  - Mobasher M
AD  - Assistant Professor, Department of Medical Ethics and History of Medicine, School
      of Traditional Medicine, Kerman University of Medical Sciences, Kerman, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201219
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC8141210
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:12
PHST- 2020/10/02 00:00 [received]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2021/05/31 06:12 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.18502/jmehm.v13i25.4956 [doi]
AID - JMEHM-13-25 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 19;13:25. doi: 10.18502/jmehm.v13i25.4956.
      eCollection 2020.


PMID- 34055240
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210601
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - COVID-19 pandemic and the ethical challenges in patient care.
PG  - 24
LID - 10.18502/jmehm.v13i24.4955 [doi]
FAU - Sahebi, Ali
AU  - Sahebi A
AD  - PhD Candidate in Health in Emergencies and Disasters, Department of Health in
      Emergencies and Disasters, School of Public Health and Safety, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Moayedi, Siamak
AU  - Moayedi S
AD  - Assistant Professor, Department of Emergency Medicine, University of Maryland
      School of Medicine, Baltimore, USA.
FAU - Golitaleb, Mohamad
AU  - Golitaleb M
AD  - Instructor, Department of Nursing, School of Nursing, Arak University of Medical 
      Sciences, Arak, Iran .
LA  - eng
PT  - Journal Article
DEP - 20201219
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC8141212
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:12
PHST- 2020/10/08 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2021/05/31 06:12 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.18502/jmehm.v13i24.4955 [doi]
AID - JMEHM-13-24 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 19;13:24. doi: 10.18502/jmehm.v13i24.4955.
      eCollection 2020.


PMID- 34055239
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211217
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Nurses' perception of ethical challenges in caring for patients with COVID-19: a 
      qualitative analysis.
PG  - 23
LID - 10.18502/jmehm.v13i23.4954 [doi]
AB  - Nurses face several challenges in providing care for patients with coronavirus
      disease in 2019 (COVID-19). The study aimed to explain the nurses' perception of 
      ethical challenges in this regard. The qualitative study was carried out using a 
      content analysis method. Individual and semi-structured interviews were conducted
      with 24 nurses. Inductive content analysis was used to categorize the data.
      Nurses' narratives indicated that ethical challenges in caring for patients with 
      COVID-19 included threats to professional values and the absence of a holistic
      COVID-19 care approach. The first category was subcategorized into the risk of
      declining quality of patient care and a stigmatized public image about COVID-19
      care. The second category was divided into poor spiritual care, poor
      compassionate care, and lack of family-centered care. Health care managers must
      develop protocols for nurses that address these issues to alleviate the ethical
      challenges of COVID-19 care.
CI  - Copyright (c) 2020 Tehran University of Medical Sciences.
FAU - Rezaee, Nasrin
AU  - Rezaee N
AD  - Associate Professor, Community Nursing Research Center, Department of Psychiatric
      Nursing, Zahedan University of Medical Sciences, Zahedan, Iran.
FAU - Mardani-Hamooleh, Marjan
AU  - Mardani-Hamooleh M
AD  - Associate Professor, Nursing Care Research Center, Department of Psychiatric
      Nursing, Iran University of Medical Sciences, Tehran, Iran.
FAU - Seraji, Maryam
AU  - Seraji M
AD  - Assistant Professor, Department of Health Education & Health Promotion, Zahedan
      University of Medical Sciences, Zahedan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201219
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC8141204
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Ethical challenges
OT  - Nursing ethics
OT  - Qualitative study.
EDAT- 2021/06/01 06:00
MHDA- 2021/06/01 06:01
CRDT- 2021/05/31 06:12
PHST- 2020/10/21 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2021/05/31 06:12 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/06/01 06:01 [medline]
AID - 10.18502/jmehm.v13i23.4954 [doi]
AID - JMEHM13-23 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 19;13:23. doi: 10.18502/jmehm.v13i23.4954.
      eCollection 2020.


PMID- 34025797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1828-8936 (Print)
IS  - 1828-8928 (Linking)
VI  - 15
IP  - 3
DP  - 2020 Sep-Dec
TI  - Exploring the Ethics of Stature Lengthening as Treatment for Height Dysphoria.
PG  - 163-168
LID - 10.5005/jp-journals-10080-1502 [doi]
AB  - AIM: To promote a discussion on the ethics and justifications of stature
      lengthening in patients without skeletal deformity. BACKGROUND: Stature
      lengthening for height gain in patients without skeletal deformity has stirred
      controversy within the orthopedic community. However, current literature does not
      delineate the ethical issues surrounding this procedure. Improvements in the
      techniques, technology, and safety profile of stature lengthening warrant an
      ethical discussion to challenge, justify, and guide the use of this surgical
      procedure. REVIEW RESULTS: Examination of ethical issues leads to the distinction
      between the dual roles of stature lengthening as a treatment vs an enhancement.
      The primary focus on stature lengthening as treatment allows for exploration of
      "height dysphoria"-a psychological burden caused by a dissatisfaction with one's 
      height-as the primary pathology that may justify surgical intervention.
      CONCLUSION: In our opinion, additional work is required to establish "height
      dysphoria" as a true pathology in order to ethically justify stature lengthening 
      as a legitimate form of treatment. Further discussion is needed to address the
      ethics of stature lengthening as an enhancement. CLINICAL SIGNIFICANCE: This
      paper addresses salient ethical issues of stature lengthening in patients without
      skeletal deformity by exploring historical, contemporary, and comparative
      contexts. HOW TO CITE THIS ARTICLE: Lee RC, Aulisio M, Liu RW. Exploring the
      Ethics of Stature Lengthening as Treatment for Height Dysphoria. Strategies
      Trauma Limb Reconstr 2020;15(3):163-168.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Lee, Richard C
AU  - Lee RC
AD  - Department of Bioethics, Case Western Reserve University School of Medicine,
      Cleveland, Ohio, United States.
FAU - Aulisio, Mark
AU  - Aulisio M
AD  - Department of Bioethics, Case Western Reserve University School of Medicine,
      Cleveland, Ohio, United States.
FAU - Liu, Raymond W
AU  - Liu RW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Strategies Trauma Limb Reconstr
JT  - Strategies in trauma and limb reconstruction
JID - 101299515
PMC - PMC8121106
OTO - NOTNLM
OT  - Enhancement
OT  - Ethics
OT  - Height dysphoria
OT  - Stature lengthening
OT  - Treatment
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2021/05/25 06:00
MHDA- 2021/05/25 06:01
CRDT- 2021/05/24 08:05
PHST- 2021/05/24 08:05 [entrez]
PHST- 2021/05/25 06:00 [pubmed]
PHST- 2021/05/25 06:01 [medline]
AID - 10.5005/jp-journals-10080-1502 [doi]
PST - ppublish
SO  - Strategies Trauma Limb Reconstr. 2020 Sep-Dec;15(3):163-168. doi:
      10.5005/jp-journals-10080-1502.


PMID- 34018959
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 4
DP  - 2020 Oct-Dec
TI  - Burnout among healthcare providers during COVID-19: Challenges and evidence-based
      interventions.
PG  - 1-6
LID - 10.20529/IJME.2020.73 [doi]
AB  - Burnout is a major occupational problem among healthcare providers, especially
      during the Covid-19 pandemic. The frontline health workforce is experiencing a
      high workload and multiple psychosocial stressors which may affect their mental
      and emotional health, leading to burnout symptoms. Moreover, sleep deprivation
      and a critical lack of psychosocial support may aggravate such symptoms amidst
      Covid-19. From an ethical viewpoint, healthcare providers may experience moral
      distress while safeguarding patient welfare and autonomy. Moreover, social
      injustice and structural inequities may affect their emotional health while
      tackling a high volume of new cases and mortality. Global evidence indicates the 
      need for adopting multipronged evidence-based approaches to address burnout
      during this pandemic, which may include increasing the awareness of work-related 
      stress and burnout, promoting mindfulness and self-care practices for promoting
      mental wellbeing, ensuring optimal mental health services, using digital
      technologies to address workplace stress and deliver mental health interventions,
      and improving organisational policies and practices focusing on burnout among
      healthcare providers.
FAU - Sultana, Abida
AU  - Sultana A
AD  - Gazi Medical College, Khulna, BANGLADESH.
FAU - Sharma, Rachit
AU  - Sharma R
AD  - The INCLEN Trust, New Delhi, INDIA.
FAU - Hossain, Md Mahbub
AU  - Hossain MM
AD  - Texas A&M School of Public Health, TX 77843, USA.
FAU - Bhattacharya, Sudip
AU  - Bhattacharya S
AD  - Department of Community Medicine, HIMS, Dehradun, INDIA.
FAU - Purohit, Neetu
AU  - Purohit N
AD  - The IIHMR University, Jaipur, Rajasthan, INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Burnout, Psychological/epidemiology/*prevention & control
MH  - COVID-19/*psychology
MH  - Health Personnel/*psychology
MH  - Humans
MH  - SARS-CoV-2
EDAT- 2021/05/22 06:00
MHDA- 2021/06/08 06:00
CRDT- 2021/05/21 12:18
PHST- 2021/05/21 12:18 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
AID - 10.20529/IJME.2020.73 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Oct-Dec;V(4):1-6. doi: 10.20529/IJME.2020.73.


PMID- 34018958
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 4
DP  - 2020 Oct-Dec
TI  - Moving from clinical to pragmatic equipoise in health policy and systems
      research.
PG  - 1-6
LID - 10.20529/IJME.2020.77 [doi]
AB  - Health policy and systems research refers to the research conducted on the
      formulation, impact, organisation and functioning of health policies, and how to 
      optimise the functioning of health systems and policies towards achieving health 
      for all. There is emerging scholarship on the ethics of conducting such health
      policy and systems research. Ethics of health policy and systems research, though
      similar to the ethics of traditional clinical research in many ways, has several 
      important distinctions. In traditional clinical research on human participants,
      where two treatments or interventions are compared, clinical equipoise is an
      important ethical consideration. This refers to the genuine uncertainty among
      professional peers on whether one of the interventions is better than the other. 
      This uncertainty is in the biomedical efficacy of the intervention. Unless such
      equipoise exists, clinical research is said to be unethical from the benefit-risk
      balance and justice perspectives. In health policy and systems research, the
      question of clinical equipoise is often not relevant. This article will describe 
      the condition of clinical equipoise in health policy and systems research, its
      applications and challenges.
FAU - Gopichandran, Vijayaprasad
AU  - Gopichandran V
AD  - Assistant Professor, Department of Community Medicine, ESIC Medical College and
      PGIMSR, KK Nagar, Chennai 600 078 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - *Ethics, Research
MH  - *Health Policy
MH  - Humans
MH  - Research Design
MH  - Risk Assessment
MH  - *Therapeutic Equipoise
MH  - Uncertainty
EDAT- 2021/05/22 06:00
MHDA- 2021/08/04 06:00
CRDT- 2021/05/21 12:18
PHST- 2021/05/21 12:18 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
AID - 10.20529/IJME.2020.77 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Oct-Dec;V(4):1-6. doi: 10.20529/IJME.2020.77.


PMID- 34018957
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 4
DP  - 2020 Oct-Dec
TI  - Nipah outbreak in Kerala, South India: Ethical challenges in the deployment of
      healthcare workers.
PG  - 1-9
LID - 10.20529/IJME.2020.078 [doi]
AB  - A highly fatal emerging zoonotic virus, Nipah Virus (NiV), identified as a
      potential threat to global health security and declared as a candidate for
      bioterrorism by the World Health Organization (WHO) was first reported in the
      South Indian district of Kozhikode, Kerala, on May 20, 2018. Following the
      declaration of an outbreak, emergency control measures, contact tracing,
      isolation, and barrier nursing were implemented by the state health department.
      Since no prophylactic drugs or vaccines are available to prevent further
      transmission, the healthcare teams responded by initiating contact tracing and
      isolation, the only measures available. There were 2642 contacts that included
      40% hospital contacts (185 doctors, 476 nurses, 344 other hospital staff).
      Quarantine and isolation of healthy persons, especially healthcare workers,
      involve certain ethical issues. We present an ethical analysis and discussion of 
      contact tracing during the Nipah outbreak in Kerala, based on six principles of
      public health ethics, namely justice, beneficence and utility, respect for
      persons, reciprocity and solidarity. Several knowledge gaps and ethical issues
      that arose should be understood and addressed in future outbreaks. Setting up
      decision making systems and procedures in advance is the best way to ensure that 
      ethically appropriate decisions will be made during such future outbreaks.
FAU - Thayyil, Jayakrishnan
AU  - Thayyil J
AD  - Additional Professor, Department of Community Medicine, and Head, UNESCO
      Bioethics Chair Unit , Government Medical College, Kozhikode, Kerala, INDIA.
FAU - Padmanabhan, Aparna
AU  - Padmanabhan A
AD  - Junior Resident,, Department of Community Medicine, Government Medical College,
      Kozhikode, Kerala, INDIA.
FAU - Gangadharan, Alan
AU  - Gangadharan A
AD  - Junior Resident, Department of Community Medicine, Government Medical College,
      Kozhikode, Kerala, INDIA.
FAU - Salim, Sreya
AU  - Salim S
AD  - Intern, Department of Community Medicine, Government Medical College, Kozhikode, 
      Kerala, INDIA.
FAU - Jayakrishnan, Thejus
AU  - Jayakrishnan T
AD  - Resident Physician, Department Of Internal Medicine, Allegheny Health Network,
      Pittsburg, PA, USA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Disease Outbreaks
MH  - Health Personnel/*psychology
MH  - Henipavirus Infections/*epidemiology
MH  - Humans
MH  - India/epidemiology
MH  - *Nipah Virus
MH  - Resource Allocation/*ethics
EDAT- 2021/05/22 06:00
MHDA- 2021/08/04 06:00
CRDT- 2021/05/21 12:18
PHST- 2021/05/21 12:18 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
AID - 10.20529/IJME.2020.078 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Oct-Dec;V(4):1-9. doi: 10.20529/IJME.2020.078.


PMID- 34018953
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 4
DP  - 2020 Oct-Dec
TI  - Cerebral palsy litigation after fifty years: A hoax on you.
PG  - 1-15
LID - 10.20529/IJME.2020.093 [doi]
AB  - The worldwide cerebral palsy (CP) litigation crisis is predicated on the hoax
      that electronic foetal monitoring (EFM) predicts and prevents CP. There are
      decades of research disproving this hoax, yet EFM continues to be performed in
      the vast majority of labours in developed countries with resultant harm to
      mothers and babies alike through unnecessary caesarean sections with all of the
      attendant complications and ramifications of that procedure. This article reviews
      the history and evolution of EFM, explores the reasons for its misuse, discusses 
      how obstetricians have abandoned their ethical mandate by failing to obtain
      informed consent for EFM, and proposes a realistic, practical solution that would
      effectively change the standard of care.
FAU - Sartwelle, Thomas P
AU  - Sartwelle TP
AD  - Hicks Davis Wynn, P.C, Houston, Texas, USA.
FAU - Johnston, James C
AU  - Johnston JC
AD  - Consultant Neurologist, Global Neurology Consultants, San Antonio, Texas, USA and
      Auckland, NEW ZEALAND.
FAU - Arda, Berna
AU  - Arda B
AD  - Professor and Chair, Department of Medical Ethics, Ankara University, TURKEY.
FAU - Zebenigus, Mehila
AU  - Zebenigus M
AD  - Professor, Department of Neurology, Addis Ababa University, ETHIOPIA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Bioethics
MH  - *Cardiotocography/ethics
MH  - *Cerebral Palsy
MH  - Cesarean Section
MH  - Deception
MH  - *Ethics, Medical
MH  - Female
MH  - *Fetal Monitoring/adverse effects
MH  - Humans
MH  - Infant
MH  - Informed Consent
MH  - *Malpractice
MH  - Pregnancy
EDAT- 2021/05/22 06:00
MHDA- 2021/08/07 06:00
CRDT- 2021/05/21 12:18
PHST- 2021/05/21 12:18 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
AID - 10.20529/IJME.2020.093 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Oct-Dec;V(4):1-15. doi: 10.20529/IJME.2020.093.


PMID- 34018950
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 4
DP  - 2020 Oct-Dec
TI  - Forging an ethical pathway: Disability accommodation, diverse voices, and
      standards of care.
PG  - 1-9
LID - 10.20529/IJME.2020.109 [doi]
AB  - The opening quote by Alexandra Adams, the first deaf-blind medical student in the
      United Kingdom, is a response to naysayers on her decision to join medicine. The 
      cover page of this issue of IJME also highlights the underrepresented in
      medicine: portraying a healthcare professional with an acquired visual impairment
      who works with full professional rigour and dedication.
FAU - Singh, Satendra
AU  - Singh S
AD  - Associate Professor, Dept of Physiology, and Health Humanities Group, University 
      College of Medical Sciences, Delhi, INDIA.
FAU - Meeks, Lisa M
AU  - Meeks LM
AD  - Assistant Professor of Family Medicine, University of Michigan Medical School,
      Michigan, and Researcher, Center for a Diverse Healthcare Workforce, University
      of California, Davis School of Medicine, California, USA.
FAU - Dhaliwal, Upreet
AU  - Dhaliwal U
AD  - Former Director-Professor, Dept of Ophthalmology, and Health Humanities Group,
      University College of Medical Sciences, Delhi, INDIA.
LA  - eng
PT  - Editorial
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - *Disabled Persons
MH  - Female
MH  - Humans
MH  - Morals
MH  - *Standard of Care/ethics
MH  - *Students, Medical
MH  - Students, Nursing/*psychology
MH  - United Kingdom
EDAT- 2021/05/22 06:00
MHDA- 2021/08/07 06:00
CRDT- 2021/05/21 12:18
PHST- 2021/05/21 12:18 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
AID - 10.20529/IJME.2020.109 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Oct-Dec;V(4):1-9. doi: 10.20529/IJME.2020.109.


PMID- 34007881
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2399-4908 (Electronic)
IS  - 2399-4908 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Oct 2
TI  - Guidance for researchers wanting to link NHS data using non-consent approaches: a
      thematic analysis of feedback from the Health Research Authority Confidentiality 
      Advisory Group.
PG  - 1355
LID - 10.23889/ijpds.v5i1.1355 [doi]
AB  - INTRODUCTION: The use of linked data and non-consent methodologies is a rapidly
      growing area of health research due to the increasing detail, availability and
      scope of routinely collected electronic health records data. However, gaining the
      necessary legal and governance approvals to undertake data linkage is a complex
      process in England. OBJECTIVES: We reflect on our own experience of establishing 
      lawful basis for data linkage through Section 251 approval, with the intention to
      build a knowledgebase of practical advice for future applicants. METHODS:
      Thematic analysis was conducted on a corpus of Section 251 feedback reports from 
      the NHS Health Research Authority Confidentiality Advisory Group. RESULTS: Four
      themes emerged from the feedback. These were: (a) Patient and Public Involvement,
      (b) Establishing Rationale, (c) Data maintenance and contingency, and the need to
      gain (d) Further Permissions from external authorities prior to full approval.
      CONCLUSIONS: Securing Section 251 approval poses ethical, practical and
      governance challenges. However, through a comprehensive, planned approach Section
      251 approval is possible, enabling researchers to unlock the potential of linked 
      data for the purposes of health research.
FAU - Cross, Lauren
AU  - Cross L
AD  - Department of Psychological Medicine, King's College London, Strand, London WC2R 
      2LS, UK.
FAU - Carson, Lauren Emma
AU  - Carson LE
AD  - Department of Psychological Medicine, King's College London, Strand, London WC2R 
      2LS, UK.
FAU - Jewell, Amelia
AU  - Jewell A
AD  - South London and Maudsley NHS Foundation Trust, National Institute for Health
      Research (NIHR), Maudsley Biomedical Research Centre, Denmark Hill, London, SE5
      8AF, UK.
FAU - Heslin, Margaret
AU  - Heslin M
AD  - Department of Health Services & Population Research, King's College London,
      Strand, London WC2R 2LS, UK.
FAU - Osborn, David
AU  - Osborn D
AD  - Division of Psychiatry, University College London, Maple House, 149 Tottenham
      Court Rd, Bloomsbury, London W1T 7BN, UK.
FAU - Downs, Johnny
AU  - Downs J
AD  - Department of Psychological Medicine, King's College London, Strand, London WC2R 
      2LS, UK.
FAU - Stewart, Robert
AU  - Stewart R
AD  - Department of Psychological Medicine, King's College London, Strand, London WC2R 
      2LS, UK.
LA  - eng
GR  - CS-2018-18-ST2-014/DH_/Department of Health/United Kingdom
GR  - MR/L017105/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20201002
PL  - Wales
TA  - Int J Popul Data Sci
JT  - International journal of population data science
JID - 101737740
PMC - PMC8110887
OTO - NOTNLM
OT  - data linkage
OT  - non-consent approaches
OT  - section 251
OT  - thematic analysis
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
CRDT- 2021/05/19 06:53
PHST- 2021/05/19 06:53 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
AID - 10.23889/ijpds.v5i1.1355 [doi]
AID - S2399490820013555 [pii]
PST - epublish
SO  - Int J Popul Data Sci. 2020 Oct 2;5(1):1355. doi: 10.23889/ijpds.v5i1.1355.


PMID- 34007654
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2155-0417 (Electronic)
IS  - 2155-0417 (Linking)
VI  - 11
IP  - 4
DP  - 2020
TI  - Integration of the Saline Process on Holistic Patient Care to Improve Student
      Understanding of Interprofessional Team Roles, Values, and Ethics.
LID - 10.24926/iip.v11i4.3271 [doi]
AB  - DESCRIPTION OF THE PROBLEM: Healthcare practitioner students currently report
      feeling underprepared to provide holistic and spiritual care to their patients
      upon transitioning into practice, and there is currently little data on the
      efficacy of holistic care-focused interventions on interprofessional outcomes.
      The goal of this research was to assess the impact of an interprofessional
      training session on holistic care on student perceptions of interprofessional 1) 
      roles/responsibilities and 2) values/ethics. THE INNOVATION: A live, interactive 
      interprofessional training session to address holistic patient care was
      implemented in fall of 2017. Students' pre- and post-training perceptions of
      their confidence in study outcomes were assessed using a survey instrument.
      CRITICAL ANALYSIS: Significant positive changes were seen in students' perceived 
      ability to participate in team discussions and clarify misconceptions regarding
      their role in healthcare following the training. Students had high confidence in 
      interacting ethically at pre-test and sustained that confidence. NEXT STEPS:
      Live, interactive educational interventions with skills practice and group
      discussions can help to increase students' awareness of team roles and
      responsibilities, as well as expand their understanding of the values and ethics 
      within healthcare professions.
CI  - (c) Individual authors.
FAU - Laswell, Emily M
AU  - Laswell EM
AD  - Cedarville University School of Pharmacy.
FAU - Wicker, Emily
AU  - Wicker E
AD  - Cedarville University School of Pharmacy.
FAU - Keib, Carrie N
AU  - Keib CN
AD  - Cedarville University School of Pharmacy.
FAU - Younkin, Felisha
AU  - Younkin F
AD  - Cedarville University Department of Psychology.
FAU - Sled, Elizabeth
AU  - Sled E
AD  - Cedarville University Department of Kinesiology and Allied Health.
FAU - Coe, Kristi
AU  - Coe K
AD  - Cedarville University School of Nursing.
FAU - Lefever, Suzanne
AU  - Lefever S
AD  - Cedarville University School of Nursing.
FAU - Chen, Aleda M H
AU  - Chen AMH
AD  - Cedarville University School of Pharmacy.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - United States
TA  - Innov Pharm
JT  - Innovations in pharmacy
JID - 101574764
PMC - PMC8127116
OTO - NOTNLM
OT  - holistic patient care
OT  - interprofessional education
OT  - student perceptions
OT  - team roles
OT  - values and ethics
COIS- Conflicts of Interest: None
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
CRDT- 2021/05/19 06:50
PHST- 2021/05/19 06:50 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
AID - 10.24926/iip.v11i4.3271 [doi]
PST - epublish
SO  - Innov Pharm. 2020 Oct 28;11(4). doi: 10.24926/iip.v11i4.3271. eCollection 2020.


PMID- 34007642
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210520
IS  - 2155-0417 (Electronic)
IS  - 2155-0417 (Linking)
VI  - 11
IP  - 4
DP  - 2020
TI  - Rational Prescription and Cost-Effective Medication: Challenges and Opportunities
      in Pakistan.
LID - 10.24926/iip.v11i4.1613 [doi]
AB  - Pakistan is one of the countries with the highest number of medications filled
      per prescription due to overly prescribed antibiotics and injectable drugs. This 
      is due to a lack of ethical practices in prescribing because doctors
      aresignificantly influenced by lucrative financial incentives of pharmaceutical
      companies rather than clinical findings. This immoral activity has become
      significantly amplified over the past few years and continues to be a challenge
      in Pakistan. Currently, there is no code of ethics for marketing and promotional 
      activities of pharmaceutical companies. This year, authorities have step up and
      are in the process of creating policies to regulate companies and practitioners. 
      Implementation of these new policies needs vigilance from health officials,
      strong professional commitment and institutional collaboration. If executed
      correctly, these polices should create an environment of professionalism within
      the healthcare sector.
CI  - (c) Individual authors.
FAU - Aslam, Fahmida
AU  - Aslam F
AD  - International Food and Drug Policy Law and Research Centre, School of Business
      Administration; Shenyang Pharmaceutical University, China.
FAU - Khan, Faiz Ullah
AU  - Khan FU
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy
      Xi'an Jiaotong University, Xi'an, China.
AD  - Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an,
      China.
AD  - The Global Health Institute, Xi'an Jiaotong University, Xi'an, China.
AD  - Shaanxi Centre for Health Reform and Development Research, Xi'an, China.
FAU - Yue, Yang
AU  - Yue Y
AD  - International Food and Drug Policy Law and Research Centre, School of Business
      Administration; Shenyang Pharmaceutical University, China.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - United States
TA  - Innov Pharm
JT  - Innovations in pharmacy
JID - 101574764
PMC - PMC8127104
OTO - NOTNLM
OT  - Brands names
OT  - Generic names
OT  - Pakistan
OT  - Rational prescription
OT  - cost-effective medication
COIS- Conflicts of interest/Competing interests:The authors declare that there is no
      conflict of interest.
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
CRDT- 2021/05/19 06:50
PHST- 2021/05/19 06:50 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
AID - 10.24926/iip.v11i4.1613 [doi]
PST - epublish
SO  - Innov Pharm. 2020 Oct 22;11(4). doi: 10.24926/iip.v11i4.1613. eCollection 2020.


PMID- 33997297
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220211
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study
      protocol.
PG  - 200
LID - 10.12688/wellcomeopenres.16228.2 [doi]
AB  - Background: England, UK has one of the highest rates of confirmed COVID-19
      mortality globally. Until recently, testing for the SARS-CoV-2 virus focused
      mainly on healthcare and care home settings. As such, there is far less
      understanding of community transmission. Protocol: The REal-time Assessment of
      Community Transmission (REACT) programme is a major programme of home testing for
      COVID-19 to track progress of the infection in the community. REACT-1 involves
      cross-sectional surveys of viral detection (virological swab for RT-PCR) tests in
      repeated samples of 100,000 to 150,000 randomly selected individuals across
      England. This examines how widely the virus has spread and how many people are
      currently infected. The age range is 5 years and above. Individuals are sampled
      from the England NHS patient list. REACT-2 is a series of five sub-studies
      towards establishing the seroprevalence of antibodies to SARS-CoV-2 in England as
      an indicator of historical infection. The main study (study 5) uses the same
      design and sampling approach as REACT-1 using a self-administered lateral flow
      immunoassay (LFIA) test for IgG antibodies in repeated samples of 100,000 to
      200,000 adults aged 18 years and above. To inform study 5, studies 1-4 evaluate
      performance characteristics of SARS-CoV-2 LFIAs (study 1) and different aspects
      of feasibility, usability and application of LFIAs for home-based testing in
      different populations (studies 2-4). Ethics and dissemination: The study has
      ethical approval. Results are reported using STROBE guidelines and disseminated
      through reports to public health bodies, presentations at scientific meetings and
      open access publications. Conclusions: This study provides robust estimates of
      the prevalence of both virus (RT-PCR, REACT-1) and seroprevalence (antibody,
      REACT-2) in the general population in England. We also explore acceptability and 
      usability of LFIAs for self-administered testing for SARS-CoV-2 antibody in a
      home-based setting, not done before at such scale in the general population.
CI  - Copyright: (c) 2021 Riley S et al.
FAU - Riley, Steven
AU  - Riley S
AD  - School of Public Health, Imperial College London, London, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, School of Public Health,
      Imperial College London, London, UK.
FAU - Atchison, Christina
AU  - Atchison C
AUID- ORCID: https://orcid.org/0000-0001-8304-7389
AD  - School of Public Health, Imperial College London, London, UK.
AD  - Patient Experience Research Centre, School of Public Health, Imperial College
      London, London, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
FAU - Ashby, Deborah
AU  - Ashby D
AD  - School of Public Health, Imperial College London, London, UK.
FAU - Donnelly, Christl A
AU  - Donnelly CA
AUID- ORCID: https://orcid.org/0000-0002-0195-2463
AD  - School of Public Health, Imperial College London, London, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, School of Public Health,
      Imperial College London, London, UK.
AD  - Department of Statistics, University of Oxford, Oxford, UK.
FAU - Barclay, Wendy
AU  - Barclay W
AD  - Department of Statistics, University of Oxford, Oxford, UK.
FAU - Cooke, Graham S
AU  - Cooke GS
AUID- ORCID: https://orcid.org/0000-0001-6475-5056
AD  - Imperial College Healthcare NHS Trust, London, UK.
AD  - Department of Infectious Disease, Imperial College London, London, UK.
AD  - National Institute for Health Research Imperial Biomedical Research Centre,
      Imperial College London, London, UK.
FAU - Ward, Helen
AU  - Ward H
AUID- ORCID: https://orcid.org/0000-0001-8238-5036
AD  - School of Public Health, Imperial College London, London, UK.
AD  - Patient Experience Research Centre, School of Public Health, Imperial College
      London, London, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
AD  - National Institute for Health Research Imperial Biomedical Research Centre,
      Imperial College London, London, UK.
FAU - Darzi, Ara
AU  - Darzi A
AD  - Imperial College Healthcare NHS Trust, London, UK.
AD  - National Institute for Health Research Imperial Biomedical Research Centre,
      Imperial College London, London, UK.
AD  - Institute of Global Health Innovation, Imperial College London, London, UK.
FAU - Elliott, Paul
AU  - Elliott P
AUID- ORCID: https://orcid.org/0000-0002-7511-5684
AD  - School of Public Health, Imperial College London, London, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
AD  - National Institute for Health Research Imperial Biomedical Research Centre,
      Imperial College London, London, UK.
AD  - MRC Centre for Environment and Health, School of Public Health, Imperial College 
      London, London, UK.
CN  - REACT study group
LA  - eng
GR  - MR/L01341X/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S019669/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20210421
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8095190
OTO - NOTNLM
OT  - COVID-19
OT  - PCR
OT  - SARS-CoV-2
OT  - antibody
OT  - lateral flow immunoassay
OT  - point-of-care diagnostics
OT  - prevalence
OT  - virus
COIS- No competing interests were disclosed.
EDAT- 2021/05/19 06:00
MHDA- 2021/05/19 06:01
CRDT- 2021/05/18 07:09
PHST- 2021/04/09 00:00 [accepted]
PHST- 2021/05/18 07:09 [entrez]
PHST- 2021/05/19 06:00 [pubmed]
PHST- 2021/05/19 06:01 [medline]
AID - 10.12688/wellcomeopenres.16228.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2021 Apr 21;5:200. doi: 10.12688/wellcomeopenres.16228.2.
      eCollection 2020.


PMID- 33987512
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2474-0527 (Electronic)
IS  - 2474-0527 (Linking)
VI  - 4
IP  - 3
DP  - 2020 Sep 24
TI  - "It's like she's talking about me" - Exploring the value and potential impact of 
      a YouTube film presenting a qualitative evidence synthesis about chronic pain: An
      analysis of online comments.
PG  - 61-70
LID - 10.1080/24740527.2020.1785853 [doi]
AB  - BACKGROUND: There is very limited research exploring the value and impact of
      qualitative research in chronic pain despite the large volume of research. AIMS: 
      The aim of this study was to find out whether viewers' comments in response to a 
      YouTube film, portraying findings from a qualitative evidence synthesis about
      living with pain, revealed any potential value or impact to viewers. METHODS: We 
      collected online data posted in response to the film Struggling to Be Me. We used
      themes from a large review of qualitative research as an a priori analytic
      framework. We used inductive thematic analysis to distil the essence of data that
      did not fit this framework. A thematic analysis of online comments to evaluate
      the impact of an arts-based health research film on people living with chronic
      pain is presented. RESULTS: We developed two inductive themes that explored the
      value and potential impact of watching the film online: (1) It has given voice to
      our suffering and (2) it makes me feel that I am not alone. Two subthemes added
      insight to the a priori framework: First, I have had enough of me added insight
      to the theme my life is impoverished and confined; second, I am treated like a
      criminal because I take opioids added insight to the theme lost personal
      credibility. CONCLUSIONS: Our findings indicate that watching the YouTube film
      has potential value and impact, giving voice to suffering and making people feel 
      that they are not alone. There are specific ethical challenges relating to
      internet-mediated research.
CI  - (c) 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Toye, Francine
AU  - Toye F
AD  - Physiotherapy Research Unit, Oxford University Hospitals NHS Foundation Trust,
      Oxford, UK.
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Seers, Kate
AU  - Seers K
AD  - Warwick Research in Nursing, Warwick Medical School, University of Warwick,
      Coventry, UK.
FAU - Barker, Karen
AU  - Barker K
AUID- ORCID: https://orcid.org/0000-0001-9363-0383
AD  - Physiotherapy Research Unit, Oxford University Hospitals NHS Foundation Trust,
      Oxford, UK.
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
LA  - eng
GR  - 09/2001/09/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200924
PL  - United States
TA  - Can J Pain
JT  - Canadian journal of pain = Revue canadienne de la douleur
JID - 101720589
PMC - PMC7942787
OTO - NOTNLM
OT  - YouTube
OT  - arts-based health research
OT  - chronic pain
OT  - film
OT  - impact
OT  - internet
OT  - qualitative evidence synthesis
OT  - qualitative research
COIS- Francine Toye does not have any conflicts of interest. Kate Seers does not have
      any conflicts of interest. Karen Barker does not have any conflicts of interest.
EDAT- 2021/05/15 06:00
MHDA- 2021/05/15 06:01
CRDT- 2021/05/14 07:04
PHST- 2021/05/14 07:04 [entrez]
PHST- 2021/05/15 06:00 [pubmed]
PHST- 2021/05/15 06:01 [medline]
AID - 10.1080/24740527.2020.1785853 [doi]
AID - 1785853 [pii]
PST - epublish
SO  - Can J Pain. 2020 Sep 24;4(3):61-70. doi: 10.1080/24740527.2020.1785853.


PMID- 33981989
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210514
IS  - 2624-8212 (Electronic)
IS  - 2624-8212 (Linking)
VI  - 3
DP  - 2020
TI  - Addressing Fairness, Bias, and Appropriate Use of Artificial Intelligence and
      Machine Learning in Global Health.
PG  - 561802
LID - 10.3389/frai.2020.561802 [doi]
AB  - In Low- and Middle- Income Countries (LMICs), machine learning (ML) and
      artificial intelligence (AI) offer attractive solutions to address the shortage
      of health care resources and improve the capacity of the local health care
      infrastructure. However, AI and ML should also be used cautiously, due to
      potential issues of fairness and algorithmic bias that may arise if not applied
      properly. Furthermore, populations in LMICs can be particularly vulnerable to
      bias and fairness in AI algorithms, due to a lack of technical capacity, existing
      social bias against minority groups, and a lack of legal protections. In order to
      address the need for better guidance within the context of global health, we
      describe three basic criteria (Appropriateness, Fairness, and Bias) that can be
      used to help evaluate the use of machine learning and AI systems: 1)
      APPROPRIATENESS is the process of deciding how the algorithm should be used in
      the local context, and properly matching the machine learning model to the target
      population; 2) BIAS is a systematic tendency in a model to favor one demographic 
      group vs another, which can be mitigated but can lead to unfairness; and 3)
      FAIRNESS involves examining the impact on various demographic groups and choosing
      one of several mathematical definitions of group fairness that will adequately
      satisfy the desired set of legal, cultural, and ethical requirements. Finally, we
      illustrate how these principles can be applied using a case study of machine
      learning applied to the diagnosis and screening of pulmonary disease in Pune,
      India. We hope that these methods and principles can help guide researchers and
      organizations working in global health who are considering the use of machine
      learning and artificial intelligence.
CI  - Copyright (c) 2021 Fletcher, Nakeshimana and Olubeko.
FAU - Fletcher, Richard Ribon
AU  - Fletcher RR
AD  - Massachusetts Institute of Technology, Cambridge, MA, United States.
AD  - University of Massachusetts Medical School, Worcester, MA, United States.
FAU - Nakeshimana, Audace
AU  - Nakeshimana A
AD  - Massachusetts Institute of Technology, Cambridge, MA, United States.
FAU - Olubeko, Olusubomi
AU  - Olubeko O
AD  - Massachusetts Institute of Technology, Cambridge, MA, United States.
LA  - eng
PT  - Editorial
DEP - 20210415
PL  - Switzerland
TA  - Front Artif Intell
JT  - Frontiers in artificial intelligence
JID - 101770551
PMC - PMC8107824
OTO - NOTNLM
OT  - appropriate use
OT  - artificial intelligence
OT  - bias
OT  - ethics
OT  - fairness
OT  - global health
OT  - machine learning
OT  - medicine
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/05/14 06:00
MHDA- 2021/05/14 06:01
CRDT- 2021/05/13 06:33
PHST- 2020/05/13 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/05/13 06:33 [entrez]
PHST- 2021/05/14 06:00 [pubmed]
PHST- 2021/05/14 06:01 [medline]
AID - 10.3389/frai.2020.561802 [doi]
AID - 561802 [pii]
PST - epublish
SO  - Front Artif Intell. 2021 Apr 15;3:561802. doi: 10.3389/frai.2020.561802.
      eCollection 2020.


PMID- 33981059
OWN - NLM
STAT- Publisher
LR  - 20210513
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 May 13
TI  - Podcast: The super-sleuth who spots trouble in science papers.
LID - 10.1038/d41586-020-01431-4 [doi]
LA  - eng
PT  - News
DEP - 20200513
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Atmospheric science
OT  - Ethics
OT  - Peer review
EDAT- 2021/05/14 06:00
MHDA- 2021/05/14 06:00
CRDT- 2021/05/13 06:21
PHST- 2021/05/13 06:21 [entrez]
PHST- 2021/05/14 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.1038/d41586-020-01431-4 [doi]
AID - 10.1038/d41586-020-01431-4 [pii]
PST - aheadofprint
SO  - Nature. 2020 May 13. pii: 10.1038/d41586-020-01431-4. doi:
      10.1038/d41586-020-01431-4.


PMID- 33975375
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20210722
IS  - 2511-705X (Electronic)
IS  - 0026-1270 (Linking)
VI  - 59
IP  - 6
DP  - 2020 Dec
TI  - Evidence-Based Health Informatics as the Foundation for the COVID-19 Response: A 
      Joint Call for Action.
PG  - 183-192
LID - 10.1055/s-0041-1726414 [doi]
AB  - BACKGROUND: As a major public health crisis, the novel coronavirus disease 2019
      (COVID-19) pandemic demonstrates the urgent need for safe, effective, and
      evidence-based implementations of digital health. The urgency stems from the
      frequent tendency to focus attention on seemingly high promising digital health
      interventions despite being poorly validated in times of crisis. AIM: In this
      paper, we describe a joint call for action to use and leverage evidence-based
      health informatics as the foundation for the COVID-19 response and public health 
      interventions. Tangible examples are provided for how the working groups and
      special interest groups of the International Medical Informatics Association
      (IMIA) are helping to build an evidence-based response to this crisis. METHODS:
      Leaders of working and special interest groups of the IMIA, a total of 26 groups,
      were contacted via e-mail to provide a summary of the scientific-based efforts
      taken to combat COVID-19 pandemic and participate in the discussion toward the
      creation of this manuscript. A total of 13 groups participated in this
      manuscript. RESULTS: Various efforts were exerted by members of IMIA including
      (1) developing evidence-based guidelines for the design and deployment of digital
      health solutions during COVID-19; (2) surveying clinical informaticians
      internationally about key digital solutions deployed to combat COVID-19 and the
      challenges faced when implementing and using them; and (3) offering necessary
      resources for clinicians about the use of digital tools in clinical practice,
      education, and research during COVID-19. DISCUSSION: Rigor and evidence need to
      be taken into consideration when designing, implementing, and using digital tools
      to combat COVID-19 to avoid delays and unforeseen negative consequences. It is
      paramount to employ a multidisciplinary approach for the development and
      implementation of digital health tools that have been rapidly deployed in
      response to the pandemic bearing in mind human factors, ethics, data privacy, and
      the diversity of context at the local, national, and international levels. The
      training and capacity building of front-line workers is crucial and must be
      linked to a clear strategy for evaluation of ongoing experiences.
CI  - The Author(s). This is an open access article published by Thieme under the terms
      of the Creative Commons Attribution-NonDerivative-NonCommercial License,
      permitting copying and reproduction so long as the original work is given
      appropriate credit. Contents may not be used for commercial purposes, or adapted,
      remixed, transformed or built upon.
      (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Fernandez-Luque, Luis
AU  - Fernandez-Luque L
AD  - Adhera Health Inc., Palo Alto, California, United States.
FAU - Kushniruk, Andre W
AU  - Kushniruk AW
AD  - School of Health Information Science, University of Victoria, Victoria, Canada.
FAU - Georgiou, Andrew
AU  - Georgiou A
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie, New
      South Wales, Australia.
FAU - Basu, Arindam
AU  - Basu A
AD  - School of Health Sciences, University of Canterbury, Christchurch, New Zealand.
FAU - Petersen, Carolyn
AU  - Petersen C
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester,
      Minnesota, United States.
FAU - Ronquillo, Charlene
AU  - Ronquillo C
AD  - Daphne Cockwell School of Nursing, Ryerson University, Ryerson, Toronto, Canada.
FAU - Paton, Chris
AU  - Paton C
AD  - Department of Information Science, University of Otago, Dunedin, New Zealand.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
FAU - Nohr, Christian
AU  - Nohr C
AD  - Centre for Health Informatics and Technology, Maersk McKinney Moller Institute,
      University of Southern Denmark, Denmark.
FAU - Kuziemsky, Craig E
AU  - Kuziemsky CE
AD  - Office of Research Services, MacEwan University, Edmonton, AB, Canada.
FAU - Alhuwail, Dari
AU  - Alhuwail D
AD  - Department of Information Science, Kuwait University, Kuwait.
AD  - Health Informatics Unit, Dasman Diabetes Institute, Kuwait.
FAU - Skiba, Diane
AU  - Skiba D
AD  - University of Colorado, Denver, Colorado, United States.
FAU - Huesing, Elaine
AU  - Huesing E
AD  - IMIA CEO.
FAU - Gabarron, Elia
AU  - Gabarron E
AD  - Norwegian Centre for E-health Research, University Hospital of North Norway,
      Tromso, Norway.
FAU - Borycki, Elizabeth M
AU  - Borycki EM
AD  - School of Health Information Science, University of Victoria, Victoria, Canada.
FAU - Magrabi, Farah
AU  - Magrabi F
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie, New
      South Wales, Australia.
FAU - Denecke, Kerstin
AU  - Denecke K
AD  - Institute for Medical Informatics, Bern University of Applied Sciences, Bern,
      Switzerland.
FAU - Peute, Linda W P
AU  - Peute LWP
AD  - Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The
      Netherlands.
FAU - Topaz, Max
AU  - Topaz M
AD  - Columbia University Medical Center, Data Science Institute, Columbia University, 
      Columbia, United States.
FAU - Al-Shorbaji, Najeeb
AU  - Al-Shorbaji N
AD  - Amman, Jordan.
FAU - Lacroix, Paulette
AU  - Lacroix P
AD  - University of Victoria, Victoria, Canada.
FAU - Marcilly, Romaric
AU  - Marcilly R
AD  - Univ. Lille, Inserm, CHU Lille, ULR 2694 - METRICS: Evaluation des technologies
      de sante et des pratiques medicales, F-59000 Lille, France.
FAU - Cornet, Ronald
AU  - Cornet R
AD  - Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The
      Netherlands.
FAU - Gogia, Shashi B
AU  - Gogia SB
AD  - Society for Administration of Telemedicine and Healthcare Informatics, New Delhi,
      India.
FAU - Kobayashi, Shinji
AU  - Kobayashi S
AD  - National Institute of Public Health, Japan.
FAU - Iyengar, Sriram
AU  - Iyengar S
AD  - The University of Arizona, Arizona, United States.
FAU - Deserno, Thomas M
AU  - Deserno TM
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Braunschweig, Germany.
FAU - Mettler, Tobias
AU  - Mettler T
AD  - Swiss Graduate School of Public Administration, University of Lausanne, Lausanne,
      Switzerland.
FAU - Vimarlund, Vivian
AU  - Vimarlund V
AD  - Department of Computer and Information Science (IDA), School of Engineering and
      Technology, Linkoping University, Linkoping, Sweden.
FAU - Zhu, Xinxin
AU  - Zhu X
AD  - Center for Biomedical Data Science, Yale University, New Haven, Connecticut,
      United States.
LA  - eng
PT  - Journal Article
DEP - 20210511
PL  - Germany
TA  - Methods Inf Med
JT  - Methods of information in medicine
JID - 0210453
SB  - IM
MH  - *COVID-19
MH  - Cooperative Behavior
MH  - *Evidence-Based Practice
MH  - Humans
MH  - *Medical Informatics
MH  - Pandemics
MH  - Public Health
MH  - Qualitative Research
MH  - SARS-CoV-2
PMC - PMC8279811
COIS- L.F.L. is Chief Scientific Officer and shareholder at Adhera Health Inc (USA).
      All the other authors report no conflict of interest.
EDAT- 2021/05/12 06:00
MHDA- 2021/07/23 06:00
CRDT- 2021/05/11 20:33
PHST- 2021/05/12 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
PHST- 2021/05/11 20:33 [entrez]
AID - 10.1055/s-0041-1726414 [doi]
PST - ppublish
SO  - Methods Inf Med. 2020 Dec;59(6):183-192. doi: 10.1055/s-0041-1726414. Epub 2021
      May 11.


PMID- 33967512
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 0973-029X (Print)
IS  - 0973-029X (Linking)
VI  - 24
IP  - 3
DP  - 2020 Sep-Dec
TI  - Immunohistochemical analysis and correlation of cyclooxygenase-2 expression
      status with clinicopathological parameters in head and neck squamous cell
      carcinomas: An Indian perspective.
PG  - 583
LID - 10.4103/jomfp.JOMFP_128_20 [doi]
AB  - CONTEXT: Head and neck squamous cell carcinoma (HNSCC) poses a major health
      problem and despite the advancements in its diagnosis and management the overall 
      survival has not improved significantly. A search for newer diagnostic and
      prognostic markers along with fresh molecular targets is required for its
      prevention and cure. AIMS: The study aims to study the expression of
      cyclooxygenase-2 (COX-2) in HNSCCs and investigate its correlation with the
      clinicopathological profile of these cases. This study was performed to determine
      the significance of COX-2 expression in the Indian context. SETTINGS AND DESIGN: 
      This study incorporated 90 cases of HNSCCs; both prospectively and
      retrospectively in a tertiary care center. MATERIALS AND METHODS: Expression of
      COX-2 on immunohistochemistry (IHC) was evaluated in correlation with the
      histological grade, maximum tumor size, tumor depth, nodal status and
      lymphovascular/perineural invasion (lvi/pni). The study received a waiver from
      the institutional ethics committee. STATISTICAL ANALYSIS USED: Statistical
      analysis of the data was done using SPSS software. RESULTS: COX-2 expression was 
      found in 97.8% of the cases. A statistically significant correlation of COX-2
      immunopositivity was found with the histological grade, clinical staging (tumor
      size and nodal status), maximum tumor depth and lvi/pni in our study (P < 0.05). 
      CONCLUSIONS: COX-2 is expressed by most of the cases in this study. Its
      expression is related to tumor growth, differentiation and aggressiveness and
      therefore can be used as a good independent prognostic marker in HNSCCs. There is
      also possible scope of using it for targeted therapy in HNSCCs.
CI  - Copyright: (c) 2021 Journal of Oral and Maxillofacial Pathology.
FAU - Chadha, Prerna
AU  - Chadha P
AD  - Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow,
      Uttar Pradesh, India.
FAU - Ranjan, Richa
AU  - Ranjan R
AD  - Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow,
      Uttar Pradesh, India.
FAU - Kumar, Nikhilesh
AU  - Kumar N
AD  - Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow,
      Uttar Pradesh, India.
FAU - Vardhan, Rig
AU  - Vardhan R
AD  - Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow,
      Uttar Pradesh, India.
FAU - Sengupta, Prashant
AU  - Sengupta P
AD  - Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow,
      Uttar Pradesh, India.
FAU - Negi, Rakhi
AU  - Negi R
AD  - Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow,
      Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20210109
PL  - India
TA  - J Oral Maxillofac Pathol
JT  - Journal of oral and maxillofacial pathology : JOMFP
JID - 101227995
PMC - PMC8083447
OTO - NOTNLM
OT  - Cyclooxygenase-2
OT  - head and neck squamous cell carcinoma
OT  - immunohistochemistry
COIS- There are no conflicts of interest.
EDAT- 2021/05/11 06:00
MHDA- 2021/05/11 06:01
CRDT- 2021/05/10 06:17
PHST- 2020/04/01 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2021/05/10 06:17 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/11 06:01 [medline]
AID - 10.4103/jomfp.JOMFP_128_20 [doi]
AID - JOMFP-24-583 [pii]
PST - ppublish
SO  - J Oral Maxillofac Pathol. 2020 Sep-Dec;24(3):583. doi:
      10.4103/jomfp.JOMFP_128_20. Epub 2021 Jan 9.


PMID- 33967499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 0973-029X (Print)
IS  - 0973-029X (Linking)
VI  - 24
IP  - 3
DP  - 2020 Sep-Dec
TI  - Estimation of postmortem death interval from autopsied tongue tissue: A
      cross-sectional study.
PG  - 568-571
LID - 10.4103/jomfp.jomfp_479_20 [doi]
AB  - CONTEXT: Estimation of time since death is the preliminary step in any postmortem
      examination. Although there are various physiological methods to conclude the
      postmortem, interval histological changes can be applied to obtain precision.
      However, the utility of oral tissues for such an event is still evolving. AIMS:
      The present study was conducted to assess the efficacy of postmortem histological
      changes that occur in tongue to conclude the postmortem interval (PMI). MATERIALS
      AND METHODS: After obtaining institutional human ethical committee, tongue tissue
      was collected for during routine autopsy procedure. The study comprised twelve
      autopsied tongue tissues. The tissue specimens were subjected to routine
      laboratory tissue processing procedure and the histological changes were
      evaluated. CONCLUSION: This is the first study of this kind in the scientific
      literature to explore the tongue tissue to estimate the PMI. There were definite 
      changes in the epithelium and the connective tissue of the tongue, and these
      features were highly remarkable at various postmortem time intervals.
CI  - Copyright: (c) 2021 Journal of Oral and Maxillofacial Pathology.
FAU - Rajkumari, S
AU  - Rajkumari S
AD  - Department of Oral Pathology and Microbiology, Sree Balaji Dental College and
      Hospital, Bharath Institute of Higher Education and Research, Chennai, Tamil
      Nadu, India.
FAU - Mensudar, R
AU  - Mensudar R
AD  - Department of Conservative and Endodontics, Sree Balaji Dental College and
      Hospital, Chennai, Tamil Nadu, India.
FAU - Naveen, N
AU  - Naveen N
AD  - Department of Forensic Medicine, Government Thiruvarur Medical College,
      Thiruvarur, Tamil Nadu, India.
FAU - Thayumanavan, B
AU  - Thayumanavan B
AD  - Department of Oral Pathology and Microbiology, Sathyabama Dental College and
      Hospital, Chennai, Tamil Nadu, India.
FAU - Thammaiah, Smitha
AU  - Thammaiah S
AD  - Department of Oral Pathology and Microbiology, V. S. Dental College and Hospital,
      Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20210109
PL  - India
TA  - J Oral Maxillofac Pathol
JT  - Journal of oral and maxillofacial pathology : JOMFP
JID - 101227995
PMC - PMC8083394
OTO - NOTNLM
OT  - Death interval
OT  - histology
OT  - oral autopsy
OT  - postmortem
OT  - time since death
OT  - tongue
COIS- There are no conflicts of interest.
EDAT- 2021/05/11 06:00
MHDA- 2021/05/11 06:01
CRDT- 2021/05/10 06:17
PHST- 2020/11/24 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2021/05/10 06:17 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/11 06:01 [medline]
AID - 10.4103/jomfp.jomfp_479_20 [doi]
AID - JOMFP-24-568 [pii]
PST - ppublish
SO  - J Oral Maxillofac Pathol. 2020 Sep-Dec;24(3):568-571. doi:
      10.4103/jomfp.jomfp_479_20. Epub 2021 Jan 9.


PMID- 33967478
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210513
IS  - 0973-029X (Print)
IS  - 0973-029X (Linking)
VI  - 24
IP  - 3
DP  - 2020 Sep-Dec
TI  - Effect of COVID-19 on oral research in Indian scenario: An observation.
PG  - 446-450
LID - 10.4103/jomfp.jomfp_480_20 [doi]
AB  - COVID-19 pandemic is an event to remember; it has unequivocally affected every
      part of our lives both ways. It has opened up numerous research areas with
      abundant funding opportunities and avenues; oral research is just a small part of
      this research world. In this review, we look into oral research in the COVID-19
      era and India's position in COVID-19 research. The salient features of the
      National Guidelines for Ethics Committee Reviewing Biomedical and Health Research
      during the COVID-19 pandemic have been described. Some possible research topics
      in dentistry during COVID-19 and the need for the impetus to the dental community
      for oral research have been discussed.
CI  - Copyright: (c) 2021 Journal of Oral and Maxillofacial Pathology.
FAU - Sundaragiri, Krishna Sireesha
AU  - Sundaragiri KS
AD  - Department of Oral Pathology, RUHS College of Dental Sciences, Jaipur, Rajasthan,
      India.
FAU - Panda, Abikshyeet
AU  - Panda A
AD  - Department of Oral and Maxillofacial Pathology, Kalinga Institute of Dental
      Sciences, KIIT Deemed to be University, Bhubaneswar, Odisha, India.
LA  - eng
PT  - Journal Article
DEP - 20210109
PL  - India
TA  - J Oral Maxillofac Pathol
JT  - Journal of oral and maxillofacial pathology : JOMFP
JID - 101227995
PMC - PMC8083428
OTO - NOTNLM
OT  - COVID-19
OT  - Indian Council of Medical Research
OT  - oral research
OT  - research grants
COIS- There are no conflicts of interest.
EDAT- 2021/05/11 06:00
MHDA- 2021/05/11 06:01
CRDT- 2021/05/10 06:17
PHST- 2020/10/12 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2021/05/10 06:17 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/11 06:01 [medline]
AID - 10.4103/jomfp.jomfp_480_20 [doi]
AID - JOMFP-24-446 [pii]
PST - ppublish
SO  - J Oral Maxillofac Pathol. 2020 Sep-Dec;24(3):446-450. doi:
      10.4103/jomfp.jomfp_480_20. Epub 2021 Jan 9.


PMID- 33954264
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210728
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Practical and ethical complexities of MAiD: Examples from Quebec.
PG  - 227
LID - 10.12688/wellcomeopenres.16306.2 [doi]
AB  - Background: Legally practiced assisted dying is an ethically complex area in need
      of empirical and conceptual work. International research suggests that providing 
      assisted dying may be experienced as rewarding and meaningful but also
      emotionally and psychologically taxing, associated with feelings of loss and
      loneliness. Yet little research has been published to date, which attends to the 
      long-term effects of providing assisted dying. In this article, I contribute to
      filling this gap in the literature using the Canadian province Quebec as an
      illustrative case. Medical aid in dying (MAiD) in the form of physician provided 
      euthanasia has been a lawful end of life healthcare option in Quebec since
      December 2015 and significant research is currently emerging from this
      jurisdiction. Methods: In this article, I draw on nine in-depth interviews with
      Quebec physicians, all of whom engaged with end of life care in different ways.
      Results: Four of the interviewed physicians provided medical aid in dying (MAiD) 
      and five did not. The major themes of MAiD in relation to aggressive treatment,
      conscientious objection and uneven distribution of work emerge, and it appeared
      clearly that MAiD was experienced and thought of as qualitatively different to
      other end of life procedures. Conclusions: Our findings expose a complexity and
      contentiousness within the practice, which remains under researched and
      underreported and indicate avenues where more research is needed.
CI  - Copyright: (c) 2020 Koksvik G.
FAU - Koksvik, Gitte
AU  - Koksvik G
AUID- ORCID: https://orcid.org/0000-0003-1233-4887
AD  - Department of Philosophy and Religious Studies, Programme for Applied Ethics,
      Norwegian University of Science and Technology, Trondheim, Norway.
AD  - End of Life Studies Group, School of Interdisciplinary Studies, University of
      Glasgow, Dumfries, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8063540
OTO - NOTNLM
OT  - Assisted dying
OT  - Canada
OT  - Conscientious objection
OT  - Ethics
OT  - Euthanasia
OT  - MAiD
OT  - Medical Aid In Dying
OT  - Quebec
COIS- No competing interests were disclosed.
EDAT- 2021/05/11 06:00
MHDA- 2021/05/11 06:01
CRDT- 2021/05/10 06:31
PHST- 2020/11/17 00:00 [accepted]
PHST- 2021/05/10 06:31 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/11 06:01 [medline]
AID - 10.12688/wellcomeopenres.16306.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Nov 23;5:227. doi: 10.12688/wellcomeopenres.16306.2.
      eCollection 2020.


PMID- 33953753
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210508
IS  - 1687-966X (Print)
VI  - 2020
DP  - 2020
TI  - Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation.
PG  - 8837654
LID - 10.1155/2020/8837654 [doi]
AB  - Mesenchymal stem/progenitor cells (MSCs) are key players in regenerative
      medicine, relying principally on their differentiation/regeneration potential,
      immunomodulatory properties, paracrine effects, and potent homing ability with
      minimal if any ethical concerns. Even though multiple preclinical and clinical
      studies have demonstrated remarkable properties for MSCs, the clinical
      applicability of MSC-based therapies is still questionable. Several challenges
      exist that critically hinder a successful clinical translation of MSC-based
      therapies, including but not limited to heterogeneity of their populations,
      variability in their quality and quantity, donor-related factors, discrepancies
      in protocols for isolation, in vitro expansion and premodification, and
      variability in methods of cell delivery, dosing, and cell homing. Alterations of 
      MSC viability, proliferation, properties, and/or function are also affected by
      various drugs and chemicals. Moreover, significant safety concerns exist due to
      possible teratogenic/neoplastic potential and transmission of infectious
      diseases. Through the current review, we aim to highlight the major challenges
      facing MSCs' human clinical translation and shed light on the undergoing
      strategies to overcome them.
CI  - Copyright (c) 2020 Dina Rady et al.
FAU - Rady, Dina
AU  - Rady D
AUID- ORCID: https://orcid.org/0000-0002-9672-6935
AD  - Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.
AD  - Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
FAU - Abbass, Marwa M S
AU  - Abbass MMS
AUID- ORCID: https://orcid.org/0000-0002-6455-7516
AD  - Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.
AD  - Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
FAU - El-Rashidy, Aiah A
AU  - El-Rashidy AA
AUID- ORCID: https://orcid.org/0000-0002-4475-0837
AD  - Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
AD  - Biomaterials Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.
FAU - El Moshy, Sara
AU  - El Moshy S
AUID- ORCID: https://orcid.org/0000-0002-2860-8523
AD  - Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.
AD  - Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
FAU - Radwan, Israa Ahmed
AU  - Radwan IA
AUID- ORCID: https://orcid.org/0000-0001-8262-5941
AD  - Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.
AD  - Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
FAU - Dorfer, Christof E
AU  - Dorfer CE
AD  - Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, 
      Christian Albrechts University, Kiel, Germany.
FAU - Fawzy El-Sayed, Karim M
AU  - Fawzy El-Sayed KM
AUID- ORCID: https://orcid.org/0000-0002-6261-3609
AD  - Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
AD  - Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, 
      Christian Albrechts University, Kiel, Germany.
AD  - Oral Medicine and Periodontology Department, Faculty of Dentistry, Cairo
      University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200811
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC8063852
COIS- All authors declare that they do not have any conflict of interest related to
      this work.
EDAT- 2021/05/07 06:00
MHDA- 2021/05/07 06:01
CRDT- 2021/05/06 07:03
PHST- 2020/04/27 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2021/05/06 07:03 [entrez]
PHST- 2021/05/07 06:00 [pubmed]
PHST- 2021/05/07 06:01 [medline]
AID - 10.1155/2020/8837654 [doi]
PST - epublish
SO  - Stem Cells Int. 2020 Aug 11;2020:8837654. doi: 10.1155/2020/8837654. eCollection 
      2020.


PMID- 33952141
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 1745-8315 (Electronic)
IS  - 0020-7578 (Linking)
VI  - 101
IP  - 5
DP  - 2020 Oct
TI  - The working of values in ethics and religion.
PG  - 992-1013
LID - 10.1080/00207578.2020.1776618 [doi]
AB  - This paper attempts to understand further the working of values in ethics and
      religion. Its premise is that the psyche is organized by its internal objects,
      and that understanding the effective working of values therefore requires
      understanding the relevant internal objects. It begins with a brief outline of
      the history of internal objects in the thought of Freud, Klein, Fairbairn,
      Winnicott and Loewald, and suggests that they are best thought of as
      "phenomenological" in nature, meaning that, whether conscious or unconscious,
      they appear in the mind without an enduring substrate. Using the thought of
      Loewald and of the philosopher Emmanuel Levinas in particular, it suggests that
      the functioning of "allegory" offers an important avenue to understanding how
      certain internal objects act to organize the psyche hierarchically on a basis of 
      values including ethical ones. "Religious objects" may then be understood as a
      subclass of "allegorical objects", acting analogously to Levinas's "face of the
      other" and experienced as giving access to "transcendent" (commanding) values.
      Such values are not adequately described by traditional accounts of a superego
      and require a deepening of the psychoanalytic dialogue with philosophy.
FAU - Black, David M
AU  - Black DM
AD  - British Psychoanalytical Society, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200904
PL  - England
TA  - Int J Psychoanal
JT  - The International journal of psycho-analysis
JID - 2985179R
SB  - IM
MH  - Humans
MH  - *Morals
MH  - *Philosophy
MH  - Religion
MH  - Superego
OTO - NOTNLM
OT  - Dante
OT  - Ethics
OT  - Levinas
OT  - Loewald
OT  - allegorical objects
OT  - internal objects
EDAT- 2021/05/07 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/05/06 05:40
PHST- 2021/05/06 05:40 [entrez]
PHST- 2021/05/07 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.1080/00207578.2020.1776618 [doi]
PST - ppublish
SO  - Int J Psychoanal. 2020 Oct;101(5):992-1013. doi: 10.1080/00207578.2020.1776618.
      Epub 2020 Sep 4.


PMID- 33950608
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 8756-8160 (Print)
IS  - 8756-8160 (Linking)
VI  - 35
IP  - 1
DP  - 2020 Spring
TI  - Human Fetal Tissue from Elective Abortions in Research and Medicine: Science,
      Ethics, and the Law.
PG  - 3-61
AB  - Since the U.S. Supreme Court issued its landmark decision in 1973 to legalize
      abortion, over 60 million preborn have been killed by elective abortion. While
      alive in the womb, these preborn are abandoned and not protected under current
      law. But once aborted, their body parts are a highly esteemed and prized
      commodity amongst certain members of the scientific community. Moral discourse is
      disregarded for the sake of science. The public have been lulled and lured into
      believing that this practice must continue in order to understand and develop
      cures for some of the most debilitating diseases of our day. But they are
      mistaken. This practice is not necessary, especially in light of numerous
      noncontroversial alternatives. Here, we expose and consider the false and
      misleading claims regarding human fetal tissue (HFT) in research from scientific,
      legal, and ethical points of view. We endeavor deeply to understand the depth of 
      the injustice in this practice and what forces promote and maintain it; and by
      revealing and understanding these forces, we set forth how these inhumane
      practices can be ended. An accurate portrayal of the history of HFT use in
      research is provided, along with a close examination of the current state of this
      practice under existing laws. The serious societal implications are also
      discussed, which will worsen beyond comprehension if these practices are allowed 
      to continue. The timeliness of this information cannot be overstated, and a
      thorough understanding is paramount for anyone who desires to know the facts
      about HFT in research and medicine and its detrimental impact for humanity.
CI  - Copyright (c) 2020 by the National Legal Center for the Medically Dependent and
      Disabled, Inc.
FAU - Lee, Tara Sander
AU  - Lee TS
AD  - Charlotte Lozier Institute, Arlington, VA.
FAU - Feeney, Maria B
AU  - Feeney MB
AD  - Charlotte Lozier Institute, Arlington, VA.
FAU - Schmainda, Kathleen M
AU  - Schmainda KM
AD  - Charlotte Lozier Institute, Arlington, VA.
FAU - Sherley, James L
AU  - Sherley JL
AD  - Charlotte Lozier Institute, Arlington, VA, Asymmetrex, LLC, Boston, MA.
FAU - Prentice, David A
AU  - Prentice DA
AD  - Charlotte Lozier Institute, Arlington, VA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Issues Law Med
JT  - Issues in law & medicine
JID - 8511295
SB  - IM
MH  - *Abortion, Induced
MH  - Abortion, Legal
MH  - Female
MH  - Fetus
MH  - Humans
MH  - *Medicine
MH  - Morals
MH  - Pregnancy
MH  - United States
EDAT- 2021/05/06 06:00
MHDA- 2021/07/21 06:00
CRDT- 2021/05/05 12:46
PHST- 2021/05/05 12:46 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PST - ppublish
SO  - Issues Law Med. 2020 Spring;35(1):3-61.


PMID- 33950600
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 8756-8160 (Print)
IS  - 8756-8160 (Linking)
VI  - 35
IP  - 2
DP  - 2020 Fall
TI  - Abortion and Infertility.
PG  - 173-195
AB  - The purpose of this article is to examine one potential factor that might
      negatively impact female fertility, namely induced abortion. While there appears 
      to be a general consensus that there is no association between abortion and
      infertility, amongst the publications that do exist there is nevertheless
      evidence to the contrary. Moreover, given the variety of reasonable grounds for a
      link, and the insufficient attention to the subject by researchers, a
      re-examination of the field is warranted. Abortion, whether surgical or medical, 
      is one of the most common medical procedures undertaken by women, so even a small
      effect could influence large numbers of women, and therefore couples. If it were 
      known that abortion was an underlying cause of infertility, it would be an
      ethical and legal requirement for medical professionals to inform women before
      consent is obtained. A case could even be made that if research were
      inconclusive, inadequate or preliminary, women should nevertheless be informed.
CI  - Copyright (c) 2020 by the National Legal Center for the Medically Dependent and
      Disabled, Inc.
FAU - Pike, Gregory K
AU  - Pike GK
AD  - Senior Research Fellow, Bios Centre, London. Bachelor of Sciences with Honors in 
      Physiology; Doctor of Philosophy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Issues Law Med
JT  - Issues in law & medicine
JID - 8511295
SB  - IM
MH  - *Abortion, Induced
MH  - Female
MH  - Humans
MH  - *Infertility
MH  - Morals
MH  - Pregnancy
EDAT- 2021/05/06 06:00
MHDA- 2021/07/21 06:00
CRDT- 2021/05/05 12:46
PHST- 2021/05/05 12:46 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PST - ppublish
SO  - Issues Law Med. 2020 Fall;35(2):173-195.


PMID- 33950597
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 8756-8160 (Print)
IS  - 8756-8160 (Linking)
VI  - 35
IP  - 2
DP  - 2020 Fall
TI  - The Prioritization of Life-Saving Resources in a Pandemic Surge Crisis.
PG  - 99-116
AB  - The COVID-19 pandemic has engendered a national discussion regarding scarce
      life-saving medical resources. These discussions often turn on allocation,
      reconfiguration, and reallocation of resources during the surge crisis of a
      declared emergency. Protocols to address these issues are being widely
      promulgated. From the standpoint of biomedical ethics, the principal concerns in 
      these discussions should center on duty, justification, legality, and underlying 
      moral standards. In this article the author explores general concepts of
      prioritization and crisis standards of care, physician duties and the conflict of
      those duties, the problematic nature of reallocation, and legitimate responses to
      the extreme absolute scarcity of surge crisis.
CI  - Copyright (c) 2020 by the National Legal Center for the Medically Dependent and
      Disabled, Inc.
FAU - White, Frederick J 3rd
AU  - White FJ 3rd
AD  - Past-Chair, Institutional Ethics Committee, Willis-Knighton Health System;
      Physician, Willis-Knighton Cardiology. M.D., Louisiana State University Health
      Sciences Center School of Medicine, 1982.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Issues Law Med
JT  - Issues in law & medicine
JID - 8511295
SB  - IM
MH  - *Bioethics
MH  - COVID-19
MH  - *Educational Personnel
MH  - Humans
MH  - *Pandemics
MH  - SARS-CoV-2
EDAT- 2021/05/06 06:00
MHDA- 2021/07/21 06:00
CRDT- 2021/05/05 12:46
PHST- 2021/05/05 12:46 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PST - ppublish
SO  - Issues Law Med. 2020 Fall;35(2):99-116.


PMID- 33948255
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 2059-8661 (Electronic)
IS  - 2059-8661 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Aug 19
TI  - EHR phenotyping for research recruitment: Researcher, IRB, and physician
      perspectives on approaches to contacting patients.
PG  - e32
LID - 10.1017/cts.2020.524 [doi]
AB  - INTRODUCTION: Failure to achieve accrual goals is a common problem in
      health-related research. Electronic health records represent a promising
      resource, offering the ability to identify a precisely defined cohort of patients
      who meet inclusion/exclusion criteria. However, challenges associated with the
      recruitment process remain and institutional policies vary. METHODS: We
      interviewed researchers, institutional review board chairs, and primary care
      physicians in North Carolina and Tennessee. Questions focused on strategies for
      initiating contact with potentially eligible patients, as well as recruitment
      letters asking recipients to opt in versus opt out of further communication.
      RESULTS: When we asked about initiating contact with prospective participants,
      qualitative themes included trust, credibility, and established relationships;
      research efficiency and validity; privacy and autonomy; the intersection between 
      research and clinical care; and disruption to physician-researcher and
      physician-patient relationships. All interviewees said it was acceptable for
      researchers to contact patients through their physicians; most said it was
      acceptable for researchers to contact patients directly. Over half chose contact 
      through physicians as more appropriate. Regarding recruitment letters,
      qualitative themes included the quality of the participant pool; privacy and
      control; research efficiency and representativeness; and patients' opportunity to
      make their own decisions. All interviewees said asking recipients to opt in to
      further communication was acceptable; nearly all said opt out was acceptable.
      Similar proportions chose each approach as more appropriate. CONCLUSIONS:
      Comparing these results to our previous research with patients reveals potential 
      differences in stakeholder perspectives. We offer suggestions for developing
      balanced approaches that respect patients and facilitate the advancement of
      science.
CI  - (c) The Association for Clinical and Translational Science 2020.
FAU - Beskow, Laura M
AU  - Beskow LM
AUID- ORCID: https://orcid.org/0000-0002-9314-1915
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN.
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN.
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - England
TA  - J Clin Transl Sci
JT  - Journal of clinical and translational science
JID - 101689953
PMC - PMC8057488
OTO - NOTNLM
OT  - Electronic health records
OT  - physician-patient relationship
OT  - research ethics
OT  - research subject recruitment
OT  - stakeholder perspectives
OT  - trust
COIS- This research was supported by a grant from NIH. The funders had no role in the
      design of the study; the collection, analysis, or interpretation of data; the
      writing of this manuscript; or the decision to submit this manuscript for
      publication.
EDAT- 2021/05/06 06:00
MHDA- 2021/05/06 06:01
CRDT- 2021/05/05 06:25
PHST- 2021/05/05 06:25 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/05/06 06:01 [medline]
AID - 10.1017/cts.2020.524 [doi]
AID - S2059866120005245 [pii]
PST - epublish
SO  - J Clin Transl Sci. 2020 Aug 19;5(1):e32. doi: 10.1017/cts.2020.524.


PMID- 33948251
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 2059-8661 (Electronic)
IS  - 2059-8661 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Aug 7
TI  - Assessing clinical investigators' perceptions of relevance and competency of
      clinical trials skills: An international AIDS Malignancy Consortium (AMC) study.
PG  - e28
LID - 10.1017/cts.2020.520 [doi]
AB  - INTRODUCTION: The AIDS Malignancy Consortium (AMC) conducts clinical trials of
      therapeutic and prevention strategies for cancer in people living with HIV. With 
      its recent expansion to Sub-Saharan Africa and Latin America, there was a need to
      increase the competence of clinical investigators (CIs) to implement clinical
      trials in these regions. METHODS: AMC CIs were invited to complete a survey to
      assess role-relevance and self-perceived competence based on the Joint Task Force
      for Clinical Trials Competency domains. RESULTS: A total of 40 AMC CIs were
      invited to complete the questionnaire and 35 responded to the survey. The data
      management and informatics and engaging with communities' domains were lowest in 
      the average proportion of CIs rating themselves high (scores of 3-4) for
      self-perceived competency (46.6% and 44.2%) and role-relevance (61.6% and 67.5%),
      whereas, the ethical and participant safety considerations domain resulted in the
      highest score for competency (86.6%) and role-relevance (93.3%). In the
      scientific concepts and research design domain, a high proportion rated for
      competency in evaluating study designs and scientific literature (71.4% and
      74.3%) but a low proportion for competency for designing trials and specimen
      collection protocols (51.4% and 54.3%). CONCLUSIONS: Given the complexity of AMC 
      clinical research, these results provide evidence of the need to develop training
      for clinical research professionals across domains where self-perceived
      competence is low. This assessment will be used to tailor and prioritize the AMC 
      Training Program in clinical trial development and management for AMC CIs.
CI  - (c) The Association for Clinical and Translational Science 2020.
FAU - Lee, Jeannette Y
AU  - Lee JY
AD  - University of Arkansas for Medical Sciences, Little Rock, AR, USA.
FAU - Lensing, Shelly V
AU  - Lensing SV
AD  - University of Arkansas for Medical Sciences, Little Rock, AR, USA.
FAU - Botello-Harbaum, Maria T
AU  - Botello-Harbaum MT
AD  - The Emmes Company, LLC, Rockville, MD, USA.
FAU - Medina, Rebecca
AU  - Medina R
AD  - The Emmes Company, LLC, Rockville, MD, USA.
FAU - Zozus, Meredith
AU  - Zozus M
AD  - University of Texas Health Sciences Center, San Antonio, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - England
TA  - J Clin Transl Sci
JT  - Journal of clinical and translational science
JID - 101689953
PMC - PMC8057474
OTO - NOTNLM
OT  - HIV malignancies
OT  - clinical trial needs assessment
OT  - core competency framework
OT  - learning objectives
OT  - training
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/05/06 06:00
MHDA- 2021/05/06 06:01
CRDT- 2021/05/05 06:25
PHST- 2021/05/05 06:25 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/05/06 06:01 [medline]
AID - 10.1017/cts.2020.520 [doi]
AID - S2059866120005208 [pii]
PST - epublish
SO  - J Clin Transl Sci. 2020 Aug 7;5(1):e28. doi: 10.1017/cts.2020.520.


PMID- 33948243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210625
IS  - 2059-8661 (Electronic)
IS  - 2059-8661 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Jul 16
TI  - Enhancing reproducibility using interprofessional team best practices.
PG  - e20
LID - 10.1017/cts.2020.512 [doi]
AB  - The pervasive problem of irreproducibility of preclinical research represents a
      substantial threat to the translation of CTSA-generated health interventions. Key
      stakeholders in the research process have proposed solutions to this challenge to
      encourage research practices that improve reproducibility. However, these
      proposals have had minimal impact, because they either 1. take place too late in 
      the research process, 2. focus exclusively on the products of research instead of
      the processes of research, and/or 3. fail to take into account the driving
      incentives in the research enterprise. Because so much clinical and translational
      science is team-based, CTSA hubs have a unique opportunity to leverage Science of
      Team Science research to implement and support innovative, evidence-based,
      team-focused, reproducibility-enhancing activities at a project's start, and
      across its evolution. Here, we describe the impact of irreproducibility on
      clinical and translational science, review its origins, and then describe
      stakeholders' efforts to impact reproducibility, and why those efforts may not
      have the desired effect. Based on team-science best practices and principles of
      scientific integrity, we then propose ways for Translational Teams to build
      reproducible behaviors. We end with suggestions for how CTSAs can leverage
      team-based best practices and identify observable behaviors that indicate a
      culture of reproducible research.
CI  - (c) The Association for Clinical and Translational Science 2020.
FAU - Rolland, Betsy
AU  - Rolland B
AUID- ORCID: https://orcid.org/0000-0002-4947-988X
AD  - Institute for Clinical and Translational Research, School of Medicine and Public 
      Health, University of Wisconsin-Madison, Madison, WI, USA.
AD  - Carbone Cancer Center, School of Medicine and Public Health, University of
      Wisconsin-Madison, Madison, WI, USA.
FAU - Burnside, Elizabeth S
AU  - Burnside ES
AD  - Institute for Clinical and Translational Research, School of Medicine and Public 
      Health, University of Wisconsin-Madison, Madison, WI, USA.
AD  - Carbone Cancer Center, School of Medicine and Public Health, University of
      Wisconsin-Madison, Madison, WI, USA.
AD  - Radiology, School of Medicine and Public Health, University of Wisconsin-Madison,
      Madison, WI, USA.
FAU - Voils, Corrine I
AU  - Voils CI
AD  - Institute for Clinical and Translational Research, School of Medicine and Public 
      Health, University of Wisconsin-Madison, Madison, WI, USA.
AD  - Surgery, School of Medicine and Public Health, University of Wisconsin-Madison,
      Madison, WI, USA.
AD  - William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
FAU - Shah, Manish N
AU  - Shah MN
AD  - Institute for Clinical and Translational Research, School of Medicine and Public 
      Health, University of Wisconsin-Madison, Madison, WI, USA.
AD  - Emergency Medicine and Internal Medicine, School of Medicine and Public Health,
      University of Wisconsin-Madison, Madison, WI, USA.
AD  - Internal Medicine, School of Medicine and Public Health, University of
      Wisconsin-Madison, Madison, WI, USA.
FAU - Brasier, Allan R
AU  - Brasier AR
AD  - Institute for Clinical and Translational Research, School of Medicine and Public 
      Health, University of Wisconsin-Madison, Madison, WI, USA.
AD  - Internal Medicine, School of Medicine and Public Health, University of
      Wisconsin-Madison, Madison, WI, USA.
LA  - eng
GR  - UL1 TR002373/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200716
PL  - England
TA  - J Clin Transl Sci
JT  - Journal of clinical and translational science
JID - 101689953
PMC - PMC8057443
OTO - NOTNLM
OT  - Team science
OT  - ethics
OT  - interprofessional teams
OT  - reproducibility
OT  - translational teams
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/05/06 06:00
MHDA- 2021/05/06 06:01
CRDT- 2021/05/05 06:25
PHST- 2021/05/05 06:25 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/05/06 06:01 [medline]
AID - 10.1017/cts.2020.512 [doi]
AID - S2059866120005129 [pii]
PST - epublish
SO  - J Clin Transl Sci. 2020 Jul 16;5(1):e20. doi: 10.1017/cts.2020.512.


PMID- 33948232
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210507
IS  - 2059-8661 (Electronic)
IS  - 2059-8661 (Linking)
VI  - 4
IP  - 6
DP  - 2020 Jun 19
TI  - Workshop on reproducibility in research.
PG  - 562-564
LID - 10.1017/cts.2020.496 [doi]
AB  - In recent years, concern about research reproducibility has increased
      dramatically for scientists, funders of research, and the general public. With a 
      view to explicitly address what is often called a reproducibility crisis and
      putting the focus on research being done by individual trainees, a two-hour
      workshop was developed and introduced into six courses at UC San Diego.
      Participation in the workshop resulted in a statistically significant increase in
      the number of different types of strategies identified by the trainees for
      fostering reproducibility. The findings are consistent with having increased
      awareness of strategies to promote reproducibility.
CI  - (c) The Association for Clinical and Translational Science 2020.
FAU - Kalichman, Michael
AU  - Kalichman M
AUID- ORCID: https://orcid.org/0000-0002-4268-1188
AD  - Research Ethics Program, University of California San Diego, La Jolla, CA, USA.
FAU - Mills, Paul J
AU  - Mills PJ
AD  - Family Medicine and Public Health, University of California San Diego, La Jolla, 
      CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - England
TA  - J Clin Transl Sci
JT  - Journal of clinical and translational science
JID - 101689953
PMC - PMC8057479
OTO - NOTNLM
OT  - Reproducibility
OT  - education
OT  - good practices of research
OT  - research ethics
OT  - responsible conduct of research
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/05/06 06:00
MHDA- 2021/05/06 06:01
CRDT- 2021/05/05 06:25
PHST- 2021/05/05 06:25 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/05/06 06:01 [medline]
AID - 10.1017/cts.2020.496 [doi]
AID - S2059866120004963 [pii]
PST - epublish
SO  - J Clin Transl Sci. 2020 Jun 19;4(6):562-564. doi: 10.1017/cts.2020.496.


PMID- 33939352
STAT- Publisher
DA  - 20210504
PB  - Swedish Agency for Health Technology Assessment and Assessment of Social Services
      (SBU)
CTI - Swedish Agency for Health Technology Assessment and Assessment of Social Services
      (SBU): SBU Systematic Review Summaries
DP  - 2020 Sep 3
BTI - Pharmacological treatment of common pain conditions in older persons: A
      systematic review and assessment of medical, economic, social and ethical aspects
AB  - Several common pain drugs may not be suitable for the treatment of older persons 
      (65 years and older) due to an increased risk of adverse events, which in some
      cases may be serious. In the light of this problem, long-term pain conditions are
      the focus of this evaluation. In addition, several problems and shortcomings have
      been identified in the care of pain in older persons. The purpose of this report 
      has been to evaluate the efficacy and risk of common adverse events of drugs in
      common and long-term pain conditions in older persons, the risk of rare but
      potentially serious adverse events of these drugs, and experiences in the care of
      pain in older persons, both in patients and health care professionals. The aim
      has also been to highlight the health-economic and ethical aspects of the area
      and to include a practice survey of the prescription patterns in the field.
CI  - Copyright (c) 2020 by SBU - Swedish Agency for Health Technology Assessment and
      Assessment of Social Services.
LA  - eng
PT  - Review
PT  - Book
PL  - Stockholm
EDAT- 2021/05/04 06:01
MHDA- 2021/05/04 06:01
CDAT- 2021/05/04 06:01
AID - NBK570090 [bookaccession]


PMID- 33936301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 1817-1745 (Print)
IS  - 1817-1745 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct-Dec
TI  - Acute Symptomatic Seizures in Critically Ill Children: Frequency, Etiology and
      Outcomes.
PG  - 375-378
LID - 10.4103/jpn.JPN_140_19 [doi]
AB  - BACKGROUND: Critically ill individuals have an increased risk of acute
      symptomatic seizures secondary to systemic illnesses; unrecognized or untreated
      seizures can quickly convert into status epilepticus, which is associated with
      high morbidity and mortality. OBJECTIVE: The aim of this study was to determine
      frequency, etiology, and outcome of seizures in critical ill children admitted in
      intensive care unit of a tertiary care hospital. MATERIALS AND METHODS:
      Retrospective review of medical records of all children admitted in pediatric
      intensive care unit (PICU) of the Aga Khan University from January 2016 to
      December 2018 and who had a new-onset seizure irrespective of underlying
      diagnosis was carried out after ethical review committee approval. Data were
      collected on a structured proforma; it included demographic information as well
      as relevant clinical and outcome information. The data were analyzed on
      Statistical Package for the Social Sciences (SPSS) software program, version
      19.0. The descriptive statistics frequency and percentage was computed for
      qualitative variable. Mean and standard deviation were computed for quantitative 
      variable, and univariate analysis was performed. RESULTS: During the study
      period, a total 2053 patients were admitted in the PICU. One hundred six (5%) had
      seizure. Sixty-three (59.5%) were males. Meningitis 21 (20%), sepsis 21 (20%),
      complicated pneumonia 18 (17%) were the major primary diagnosis in these
      children. Mean age of the study population was 75 months (standard deviation [SD]
      +/- 54.4) and 72 (68%) were <5 years of age, whereas 63 (59.5%) were males. The
      seizures lasted >10min in 10 (10%) and were associated with high had neurological
      deficit (P = 0.001). We did not observe any correlation with electrolyte
      imbalance, renal failure, need of ventilator support with duration of seizure,
      and type of seizure (P > 0.005). CONCLUSION: Infection was the most common
      etiology associated with a new-onset seizure in children admitted in our PICU.
      Seizures lasting for >10min were observed with high neurological deficit. We did 
      not find any association of mortality with seizure duration.
CI  - Copyright: (c) 2021 Journal of Pediatric Neurosciences.
FAU - Rajper, Sanam B
AU  - Rajper SB
AD  - Department of Pediatrics and Child Health, Aga Khan University Karachi, Karachi, 
      Pakistan.
FAU - Moazzam, Mujtaba
AU  - Moazzam M
AD  - Medical College, Aga Khan University Karachi, Karachi, Pakistan.
FAU - Zeeshan, Arsheen
AU  - Zeeshan A
AD  - Department of Pediatrics and Child Health, Aga Khan University Karachi, Karachi, 
      Pakistan.
FAU - Abbas, Qalab
AU  - Abbas Q
AD  - Department of Pediatrics and Child Health, Aga Khan University Karachi, Karachi, 
      Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20210119
PL  - India
TA  - J Pediatr Neurosci
JT  - Journal of pediatric neurosciences
JID - 101273794
PMC - PMC8078641
OTO - NOTNLM
OT  - Acute symptomatic seizure
OT  - antiepileptic drug (AEDs)
OT  - critical ill children
COIS- There are no conflicts of interest.
EDAT- 2021/05/04 06:00
MHDA- 2021/05/04 06:01
CRDT- 2021/05/03 06:13
PHST- 2019/10/25 00:00 [received]
PHST- 2020/01/15 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2021/05/03 06:13 [entrez]
PHST- 2021/05/04 06:00 [pubmed]
PHST- 2021/05/04 06:01 [medline]
AID - 10.4103/jpn.JPN_140_19 [doi]
AID - JPN-15-375 [pii]
PST - ppublish
SO  - J Pediatr Neurosci. 2020 Oct-Dec;15(4):375-378. doi: 10.4103/jpn.JPN_140_19. Epub
      2021 Jan 19.


PMID- 33936300
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 1817-1745 (Print)
IS  - 1817-1745 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct-Dec
TI  - Cerebral Venous Sinus Thrombosis in Children: A Study from a Tertiary Care
      Hospital of Eastern India.
PG  - 370-374
LID - 10.4103/jpn.JPN_133_19 [doi]
AB  - CONTEXT: Cerebral venous sinus (sinovenous) thrombosis (CVST) in childhood is a
      rare, but under recognized, disorder, typically of multifactorial etiology, with 
      neurologic sequelae apparent in up to 40% of survivors and mortality approaching 
      10%. AIM: The aim of this study was to enlist the patients diagnosed as CVST
      younger than 14 years of age and to diagnose the etiology along with radiological
      correlation. SETTINGS AND DESIGN: This prospective clinical study was conducted
      for 2 years in the Department of Neurology, Srirama Chandra Bhanja Medical
      College & Hospital (SCBMCH), Cuttack, Odisha, India. MATERIALS AND METHODS: All
      the patients were enlisted in a prestructured format with detailed
      clinico-radiological evaluation. Treatment was performed according to recent
      guidelines. Outcome after 3 months was analyzed. Ethical clearance was obtained
      from institutional ethics committee. STATISTICAL ANALYSIS: Data were
      statistically analyzed using IBM SPSS Statistics for Windows, version 20 (IBM
      Corp., Armonk, N.Y., USA). RESULTS: The total number of patients included in the 
      study was 30. Of them, six were neonates. The most common provocative factor was 
      tuberculous meningitis. Phototherapy after neonatal hyperbilirubinemia was
      prominent cause in neonatal age group. Multiple sinus involvement was seen in
      most of the patients. Transverse sinus was the most common sinus to be involved. 
      CONCLUSION: CVST is an underdiagnosed but important cause of stroke in childhood,
      occurring most often in the neonatal period. Mortality and morbidity are
      significant. Infections hyper coagulative disorders are the two primary
      associations. Magnetic resonance venography is the investigation of choice. Early
      diagnosis with management along with plan for secondary prevention can save from 
      catastrophic consequences.
CI  - Copyright: (c) 2021 Journal of Pediatric Neurosciences.
FAU - Mishra, Shubhankar
AU  - Mishra S
AD  - Department of Neurology, Srirama Chandra Bhanja Medical College & Hospital
      (SCBMCH), Cuttack, Odisha, India.
FAU - Mallick, Ashok K
AU  - Mallick AK
AD  - Department of Neurology, Srirama Chandra Bhanja Medical College & Hospital
      (SCBMCH), Cuttack, Odisha, India.
FAU - Mohanty, Geeta
AU  - Mohanty G
AD  - Department of Neurology, Srirama Chandra Bhanja Medical College & Hospital
      (SCBMCH), Cuttack, Odisha, India.
FAU - Nayak, Priyabrata
AU  - Nayak P
AD  - Department of Neurology, Srirama Chandra Bhanja Medical College & Hospital
      (SCBMCH), Cuttack, Odisha, India.
LA  - eng
PT  - Journal Article
DEP - 20210119
PL  - India
TA  - J Pediatr Neurosci
JT  - Journal of pediatric neurosciences
JID - 101273794
PMC - PMC8078633
OTO - NOTNLM
OT  - Cerebral venous sinus thrombosis
OT  - phototherapy
OT  - post-infective
OT  - transverse sinus
COIS- There are no conflicts of interest.
EDAT- 2021/05/04 06:00
MHDA- 2021/05/04 06:01
CRDT- 2021/05/03 06:13
PHST- 2019/10/14 00:00 [received]
PHST- 2020/01/16 00:00 [accepted]
PHST- 2021/05/03 06:13 [entrez]
PHST- 2021/05/04 06:00 [pubmed]
PHST- 2021/05/04 06:01 [medline]
AID - 10.4103/jpn.JPN_133_19 [doi]
AID - JPN-15-370 [pii]
PST - ppublish
SO  - J Pediatr Neurosci. 2020 Oct-Dec;15(4):370-374. doi: 10.4103/jpn.JPN_133_19. Epub
      2021 Jan 19.


PMID- 33927913
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210503
IS  - 2157-3883 (Print)
IS  - 2157-3891 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Apr
TI  - Best Practices in Global Mental Health: An Exploratory Study of Recommendations
      for Psychologists.
PG  - 67-83
LID - 10.1037/ipp0000125 [doi]
AB  - Recommendations for best practice are useful in guiding the ethical and effective
      practice of psychology. Global mental health (GMH), which works to improve mental
      health treatment and access on a worldwide scale, is a growing field with many
      opportunities for psychologists, though such best practice recommendations have
      not been articulated. Using a grounded theory approach, this qualitative study
      recruited and interviewed psychologists identified as leaders in the field.
      Findings included broad categories of recommendations related to overarching
      variables (consideration of cultural/contextual variables; collaboration),
      program level characteristics (sustainability; formative and summative
      evaluation; flexibility; attention to systems; multidisciplinary teams; clinical 
      knowledge and perspective; attention to spectrum of mental health), and
      individual level characteristics (perseverance; ongoing mentorship/supervision;
      self-awareness; boundary setting). Future directions include recommendations to
      recreate this study with a more geographically diverse sample, as well as with
      community members and service users of global mental heath projects. Increased
      attention to individual level competencies that impact global mental health
      projects are warranted. Recommendations for best practice and implications for
      training are also considered.
FAU - Hook, Kimberly
AU  - Hook K
AD  - Boston University School of Medicine/Boston Medical Center.
FAU - Vera, Elizabeth
AU  - Vera E
AD  - Loyola University Chicago.
LA  - eng
GR  - T32 MH116140/MH/NIMH NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Int Perspect Psychol
JT  - International perspectives in psychology : research, practice, consultation
JID - 101580720
PMC - PMC8080059
MID - NIHMS1694268
OTO - NOTNLM
OT  - best practices
OT  - cross-cultural
OT  - global mental health
OT  - international
OT  - training
COIS- Competing interests: The authors declare that they have no competing interests or
      disclosures.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
CRDT- 2021/04/30 06:54
PHST- 2021/04/30 06:54 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
AID - 10.1037/ipp0000125 [doi]
PST - ppublish
SO  - Int Perspect Psychol. 2020 Apr;9(2):67-83. doi: 10.1037/ipp0000125.


PMID- 33911770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 2005-3894 (Electronic)
IS  - 1013-9087 (Linking)
VI  - 32
IP  - 5
DP  - 2020 Oct
TI  - Correlation of Plasma Level of Insulin-Like Growth Factor-1 (IGF-1) with
      Bacterial Index on Leprosy Patients in Bali.
PG  - 370-374
LID - 10.5021/ad.2020.32.5.370 [doi]
AB  - BACKGROUND: Leprosy is an infection by Mycobacterium leprae, which influenced by 
      cellular immunity. Leprosy tends to occur in low socio-economic and nutrition
      groups. Researchers try to prove the role of nutrition in the pathogenesis of
      leprosy. Insulin-like growth factor-1 (IGF-1) as a marker of nutritional status
      shown to play a role in cellular immunity. OBJECTIVE: To evaluate the correlation
      between IGF-1 with bacterial index (BI) on leprosy patients in Bali. METHODS:
      Cross-sectional study in Sanglah Public General Hospital, Denpasar of patients
      with paucibacillary (PB) and multibacillary (MB) leprosy were assessed for BI
      using slit-skin smear. All patients were tested for plasma IGF-1 using
      chemiluminescent immunometric assay Immulite. All data were analyzed using IBM
      SPSS ver. 24.0. The study has been approved by local Institutional Review Board
      with ethical clearance number 2017.02.1.0356. RESULTS: Our study involved 44 MB
      and 2 PB leprosy. The common age group affected was between 31~40 years old
      (23.9%), male (60.9%), and normal body mass index (BMI) (65.2%). Mean plasma
      IGF-1 level in PB leprosy was higher (91.07+/-0.74 ng/ml) than MB (82.74+/-6.44
      ng/ml). The mean IGF-1 level decreases as BI increases in both groups (CI
      95%=81.16~85.04; p<0.001). Pearson correlation test shows strong negative
      correlation (Pearson r=-0.976; p<0.001) with determinant coefficient (R2) showing
      95.2% (p<0.001). CONCLUSION: In Balinese leprosy patients, severity of disease
      status measured by BI were found to be strongly correlated with the plasma IGF-1 
      level which may help preventing transmission in household contacts by improving
      nutritional status.
CI  - Copyright (c) 2020 The Korean Dermatological Association and The Korean Society
      for Investigative Dermatology.
FAU - Santosa, Calvin
AU  - Santosa C
AUID- ORCID: https://orcid.org/0000-0002-0979-6522
AD  - Department of Dermatovenereology, Sanglah General Public Hospital, Udayana
      University, Bali, Indonesia.
FAU - Rusyati, Luh Made Mas
AU  - Rusyati LMM
AUID- ORCID: https://orcid.org/0000-0002-6986-5438
AD  - Department of Dermatovenereology, Sanglah General Public Hospital, Udayana
      University, Bali, Indonesia.
FAU - Adiguna, Made Swastika
AU  - Adiguna MS
AUID- ORCID: https://orcid.org/0000-0003-4097-8989
AD  - Department of Dermatovenereology, Sanglah General Public Hospital, Udayana
      University, Bali, Indonesia.
FAU - Praharsini, Igaa
AU  - Praharsini I
AUID- ORCID: https://orcid.org/0000-0003-0600-3029
AD  - Department of Dermatovenereology, Sanglah General Public Hospital, Udayana
      University, Bali, Indonesia.
FAU - Wiraguna, Aagp
AU  - Wiraguna A
AUID- ORCID: https://orcid.org/0000-0002-7459-9103
AD  - Department of Dermatovenereology, Sanglah General Public Hospital, Udayana
      University, Bali, Indonesia.
FAU - Wardhana, Made
AU  - Wardhana M
AUID- ORCID: https://orcid.org/0000-0003-1161-0421
AD  - Department of Dermatovenereology, Sanglah General Public Hospital, Udayana
      University, Bali, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - Korea (South)
TA  - Ann Dermatol
JT  - Annals of dermatology
JID - 8916577
PMC - PMC7992574
OTO - NOTNLM
OT  - Bacterial index
OT  - Insulin like growth factor 1
OT  - Leprosy
COIS- CONFLICTS OF INTEREST: The authors have nothing to disclose.
EDAT- 2021/04/30 06:00
MHDA- 2021/04/30 06:01
CRDT- 2021/04/29 06:22
PHST- 2019/11/04 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2021/04/29 06:22 [entrez]
PHST- 2021/04/30 06:00 [pubmed]
PHST- 2021/04/30 06:01 [medline]
AID - 10.5021/ad.2020.32.5.370 [doi]
PST - ppublish
SO  - Ann Dermatol. 2020 Oct;32(5):370-374. doi: 10.5021/ad.2020.32.5.370. Epub 2020
      Sep 29.


PMID- 33911768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210430
IS  - 2005-3894 (Electronic)
IS  - 1013-9087 (Linking)
VI  - 32
IP  - 5
DP  - 2020 Oct
TI  - How Annals of Dermatology Has Improved the Scientific Quality and Ethical
      Standards of its Articles in the Two-Year Period since October 2018.
PG  - 353-359
LID - 10.5021/ad.2020.32.5.353 [doi]
AB  - Annals of Dermatology has not been deposited in PubMed Central (PMC) since
      October 2018 due to inadequate scientific quality, including the absence of
      informed consent in three case reports with patients' photos. This study examined
      the readiness of Annals of Dermatology to be deposited in PMC again by analyzing 
      the 13 issues published from October 2018 to August 2020. The journal's
      scientific quality and ethical standards were assessed, and adherence to these
      standards was documented. In total, 259 articles were analyzed for ethical
      standards, including institutional review board (IRB) approval, an informed
      consent statement, and disclosure of conflicts of interest. Scientific quality
      was also checked for each article. Of the 129 original articles or brief reports 
      presenting research on human subjects or human-derived materials, 111 studies
      received IRB approval and/or obtained informed consent. The other seven studies
      were data analyses or studies of purchased cultured cells. One study that used a 
      post-circumcision foreskin sample contained no statement describing permission
      from the patient's family, but the researchers were found to have obtained
      informed consent. In all 152 case presentations, the authors obtained informed
      consent. All seven animal experiments received Institutional Animal Care and Use 
      Committee approval. One review article did not disclose conflicts of interest,
      but this was an editorial error. Two systematic reviews adopted the PRISMA
      guidelines. In conclusion, the present publication policies, scientific quality, 
      and ethical standards of the journal are top-tier internationally. Annals of
      Dermatology may be ready to apply to PMC again.
CI  - Copyright (c) 2020 The Korean Dermatological Association and The Korean Society
      for Investigative Dermatology.
FAU - Huh, Sun
AU  - Huh S
AUID- ORCID: https://orcid.org/0000-0002-8559-8640
AD  - Department of Parasitology and Institute of Medical Education, College of
      Medicine, Hallym University, Chuncheon, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200929
PL  - Korea (South)
TA  - Ann Dermatol
JT  - Annals of dermatology
JID - 8916577
PMC - PMC7992585
OTO - NOTNLM
OT  - Conflict of interest
OT  - Dermatology
OT  - Disclosure
OT  - Informed consent
OT  - Research design
OT  - Research ethics committees
COIS- CONFLICTS OF INTEREST: The author has nothing to disclose.
EDAT- 2021/04/30 06:00
MHDA- 2021/04/30 06:01
CRDT- 2021/04/29 06:22
PHST- 2020/09/04 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2021/04/29 06:22 [entrez]
PHST- 2021/04/30 06:00 [pubmed]
PHST- 2021/04/30 06:01 [medline]
AID - 10.5021/ad.2020.32.5.353 [doi]
PST - ppublish
SO  - Ann Dermatol. 2020 Oct;32(5):353-359. doi: 10.5021/ad.2020.32.5.353. Epub 2020
      Sep 29.


PMID- 33898717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2352-6475 (Print)
IS  - 2352-6475 (Linking)
VI  - 6
IP  - 5
DP  - 2020 Dec
TI  - Ethical concerns in caring for active duty service members who may be seeking
      dermatologic care outside the military soon.
PG  - 445-447
LID - 10.1016/j.ijwd.2020.07.001 [doi]
FAU - Dodd, Jacob G
AU  - Dodd JG
AD  - San Antonio Uniformed Services Health Education Consortium Wilford Hall
      Ambulatory Surgical Center, Lackland, TX, United States.
FAU - Grant-Kels, Jane M
AU  - Grant-Kels JM
AD  - University of Connecticutm, Department of Dermatology, Farmington, CT, United
      States.
LA  - eng
PT  - Editorial
DEP - 20200710
PL  - United States
TA  - Int J Womens Dermatol
JT  - International journal of women's dermatology
JID - 101654170
PMC - PMC8060680
OTO - NOTNLM
OT  - Autonomy
OT  - BCC
OT  - Deployment
OT  - Ethics
OT  - Military
OT  - Paternalism
EDAT- 2021/04/27 06:00
MHDA- 2021/04/27 06:01
CRDT- 2021/04/26 05:59
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2021/04/26 05:59 [entrez]
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/04/27 06:01 [medline]
AID - 10.1016/j.ijwd.2020.07.001 [doi]
AID - S2352-6475(20)30113-1 [pii]
PST - epublish
SO  - Int J Womens Dermatol. 2020 Jul 10;6(5):445-447. doi: 10.1016/j.ijwd.2020.07.001.
      eCollection 2020 Dec.


PMID- 33898098
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2158-8333 (Print)
IS  - 2158-8333 (Linking)
VI  - 17
IP  - 10-12
DP  - 2020 Oct-Dec
TI  - Ethical Challenges Posed by Big Data.
PG  - 24-30
AB  - Big Data is a term that refers to tremendously large data sets intended for
      computational analysis that can be used to advance research through revealing
      trends and associations. Innovative research that leverages Big Data can
      dramatically advance the fields of medicine and public health but can also raise 
      new ethical challenges. This paper explores these challenges, and how they might 
      be addressed such that individuals are optimally protected. Key ethical concerns 
      raised by Big Data research include respecting patient's autonomy via provision
      of adequate consent, ensuring equity, and respecting participants' privacy.
      Examples of actions that could be taken to address these key concerns on a
      broader regulatory level, as well as on a case specific level, are presented. Big
      Data research offers enormous potential, but due to its widespread influence, it 
      also introduces the potential for extensive harm. It is imperative to consider
      and account for the risks associated with this research.
CI  - Copyright (c) 2020. Matrix Medical Communications. All rights reserved.
FAU - Howe Iii, Edmund G
AU  - Howe Iii EG
AD  - Dr. Howe is a Professor of Psychiatry and Medicine, Director of Medical School
      Programs in Ethics, and Senior Scientist at Uniformed Services University of the 
      Health Sciences in Bethesda, Maryland.
FAU - Elenberg, Falicia
AU  - Elenberg F
AD  - Dr. Howe is a Professor of Psychiatry and Medicine, Director of Medical School
      Programs in Ethics, and Senior Scientist at Uniformed Services University of the 
      Health Sciences in Bethesda, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - Innov Clin Neurosci
JT  - Innovations in clinical neuroscience
JID - 101549695
PMC - PMC7819582
OTO - NOTNLM
OT  - Big Data
OT  - artificial intelligence
OT  - data privacy
OT  - ethics
OT  - healthcare
COIS- FUNDING:No funding was provided for this study. DISCLOSURES:The opinions or
      assertions contained herein are the private views of the authors and are not
      necessarily those of the AFRRI, USUHS, or the Department of Defense.
EDAT- 2021/04/27 06:00
MHDA- 2021/04/27 06:01
CRDT- 2021/04/26 05:54
PHST- 2021/04/26 05:54 [entrez]
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/04/27 06:01 [medline]
PST - epublish
SO  - Innov Clin Neurosci. 2020 Oct 1;17(10-12):24-30. eCollection 2020 Oct-Dec.


PMID- 33896978
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 0019-5545 (Print)
IS  - 0019-5545 (Linking)
VI  - 62
IP  - 6
DP  - 2020 Nov-Dec
TI  - Comparison of maternal stress and psychiatric morbidity among mothers of children
      having psychiatric disorders and those of typically developing children.
PG  - 707-712
LID - 10.4103/psychiatry.IndianJPsychiatry_733_19 [doi]
AB  - INTRODUCTION: Motherhood is regarded to be stressful, but when the child has a
      psychiatric illness, the mother is affected more than the father since she is the
      primary caregiver. She gets affected not only emotionally but also
      psychologically. Increasing severity of stress in mothers may lead to negative
      outcome on a child's care. AIMS: The aim of this study was to evaluate the stress
      levels in mothers of children diagnosed with psychiatric disorder and to study
      the association between children having a psychiatric disorder and the
      psychiatric morbidity in their mothers. MATERIALS AND METHODS: This was a
      case-control study with a total of 150 participants, in which 75 consecutive
      mothers of children were diagnosed with any psychiatric illness using ICD-10
      criteria and compared to 75 mothers of typically developing children. The study
      was approved by the Institutional Ethics Committee. The Parental Stress Scale and
      the Mini-International Neuropsychiatric Interview-Plus questionnaire were used
      for assessments. RESULTS: The study showed statistically significant stress
      scores (49.54) in mothers having children diagnosed with psychiatric illnesses as
      compared to scores (30.98) in mothers of normally developing children.
      Psychiatric morbidity in cases (n = 58; 77.3%) was statistically significant as
      compared to controls (n = 23; 30.6%). Depression and anxiety were among the most 
      common psychiatric morbidities evaluated, and the highest was for mothers having 
      children with severe mental retardation. CONCLUSION: In all children with
      psychiatric disorders, mothers have to be screened for psychiatric morbidity to
      prevent, detect, and manage it at the earliest.
CI  - Copyright: (c) 2020 Indian Journal of Psychiatry.
FAU - Mahatme, Nupur Shashank
AU  - Mahatme NS
AD  - Department of Psychiatry, Yenepoya Medical College, Yenepoya (Deemed to be
      University), Mangalore, Karnataka, India.
FAU - Kakunje, Anil
AU  - Kakunje A
AD  - Department of Psychiatry, Yenepoya Medical College, Yenepoya (Deemed to be
      University), Mangalore, Karnataka, India.
FAU - Karkal, Ravichandra
AU  - Karkal R
AD  - Department of Psychiatry, Yenepoya Medical College, Yenepoya (Deemed to be
      University), Mangalore, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201212
PL  - India
TA  - Indian J Psychiatry
JT  - Indian journal of psychiatry
JID - 0013255
PMC - PMC8052877
OTO - NOTNLM
OT  - Child care
OT  - mothers
OT  - psychiatric morbidity
OT  - stress
COIS- There are no conflicts of interest.
EDAT- 2021/04/27 06:00
MHDA- 2021/04/27 06:01
CRDT- 2021/04/26 05:42
PHST- 2019/11/29 00:00 [received]
PHST- 2020/02/07 00:00 [revised]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2021/04/26 05:42 [entrez]
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/04/27 06:01 [medline]
AID - 10.4103/psychiatry.IndianJPsychiatry_733_19 [doi]
AID - IJPsy-62-707 [pii]
PST - ppublish
SO  - Indian J Psychiatry. 2020 Nov-Dec;62(6):707-712. doi:
      10.4103/psychiatry.IndianJPsychiatry_733_19. Epub 2020 Dec 12.


PMID- 33888958
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 0974-777X (Print)
IS  - 0974-777X (Linking)
VI  - 12
IP  - 4
DP  - 2020 Oct-Dec
TI  - Incidence, Risk Factors and Clinical Outcomes of Patients with Hypermucoviscoid
      Klebsiella in a Tertiary Intensive Care Unit.
PG  - 202-207
LID - 10.4103/jgid.jgid_145_19 [doi]
AB  - BACKGROUND AND OBJECTIVES: Hypermucoviscoid Klebsiella(hvKP), a dreaded variant
      of Klebsiella, so far, fewer cases were reported from the community. This study
      was designed to evaluate the incidence of hvKP isolates, risk factors for hvKP
      infections, antibiotic sensitivity pattern and clinical outcome including
      morbidity and mortality. PATIENTS AND SETTING: Patients who have got admitted
      under medical intensive care unit (MICU) and had positive culture of Klebsiella
      infections. MATERIALS AND METHODS: This study was conducted at department of MICU
      at a tertiary care hospital between January 2018 and December 2018. A
      standardized proforma was prepared and data was collected, which includes basic
      demographics of the patients, co-morbidities, clinical details and mortality.
      This study was approved by the Institutional Review Board and Ethics Committee.
      RESULTS: A total of 165 patients (males, 123; 74.5%) had Klebsiella pneumoniae
      infection during the study period, out of whom 32 was hvKP (19.4%). The mean age 
      was 53.1 +/- 16.8 years. Among the 32 hvKP patients, 22 (68.8%) were hospital
      acquired infection (HAI) and 10 were (31.2%) community acquired infection. The
      overall mortality rate of hvKP infection was 56.2% (18/32). The incidence of
      mortality rate was similar in patients having pan-drug sensitive and in patients 
      with extreme drug-resistance (61.9% vs. 66.7%; P = 0.831). HAI is significantly
      associated with multi drug resistance of hvKP (odds ratio [OR], 7.917; P < 0.05) 
      and diabetes is associated with increased risk of hvKP related mortality (OR,
      5.250; P = 0.054). CONCLUSIONS: Our study results showed, increased incidence of 
      HAI with hvKP predominantly associated with pneumonia and increase in trend of
      drug resistance with two cases being pan resistant. More number of studies are
      required to evaluate the existing antibiotics strategy and steps to curb the
      spread of this dreaded infection.
CI  - Copyright: (c) 2020 Journal of Global Infectious Diseases.
FAU - Bhardwaj, Vimal
AU  - Bhardwaj V
AD  - Department of Critical Care Medicine, Mazumdar Shaw Medical Center, Narayana
      Health City, Bengaluru, Karnataka, India.
FAU - Annapandian, Vellaichamy Muthupandi
AU  - Annapandian VM
AD  - Department of Pharmacology, Narayana Hrudayalaya Foundations, Bengaluru,
      Karnataka, India.
FAU - Sinazer, Annie Rofeena
AU  - Sinazer AR
AD  - Department of Microbiology, Narayana Health City, Bengaluru, Karnataka, India.
FAU - Alva, Arjun
AU  - Alva A
AD  - Department of Critical Care Medicine, Mazumdar Shaw Medical Center, Narayana
      Health City, Bengaluru, Karnataka, India.
FAU - Prasad, Shiva
AU  - Prasad S
AD  - Department of Critical Care Medicine, Mazumdar Shaw Medical Center, Narayana
      Health City, Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - India
TA  - J Glob Infect Dis
JT  - Journal of global infectious diseases
JID - 101521436
PMC - PMC8045536
OTO - NOTNLM
OT  - Community acquired infection
OT  - Klebsiella
OT  - hospital acquired infection
OT  - hvKP
OT  - hypermucoviscoid Klebsiella
COIS- There are no conflicts of interest.
EDAT- 2021/04/24 06:00
MHDA- 2021/04/24 06:01
CRDT- 2021/04/23 06:21
PHST- 2019/11/02 00:00 [received]
PHST- 2019/12/07 00:00 [revised]
PHST- 2020/02/20 00:00 [accepted]
PHST- 2021/04/23 06:21 [entrez]
PHST- 2021/04/24 06:00 [pubmed]
PHST- 2021/04/24 06:01 [medline]
AID - 10.4103/jgid.jgid_145_19 [doi]
AID - JGID-12-202 [pii]
PST - epublish
SO  - J Glob Infect Dis. 2020 Nov 30;12(4):202-207. doi: 10.4103/jgid.jgid_145_19.
      eCollection 2020 Oct-Dec.


PMID- 33883771
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20220422
IS  - 2616-163X (Electronic)
IS  - 0016-9560 (Linking)
VI  - 54
IP  - 4
DP  - 2020 Dec
TI  - Assessment of patients waiting and service times in the ophthalmology clinic of a
      public tertiary hospital in Nigeria.
PG  - 231-237
LID - 10.4314/gmj.v54i4.5 [doi]
AB  - INTRODUCTION: Long waiting time in the out-patient clinic is a major cause of
      dissatisfaction in Eye care services. This study aimed to assess patients'
      waiting and service times in the out-patient Ophthalmology clinic of UITH.
      METHODS: This was a descriptive cross-sectional study conducted in March and
      April 2019. A multi-staged sampling technique was used. A timing chart was used
      to record the time in and out of each service station. An experiencebased exit
      survey form was used to assess patients' experience at the clinic. The frequency 
      and mean of variables were generated. Student t-test and Pearson's correlation
      were used to establish the association and relationship between the total clinic,
      service, waiting, and clinic arrival times. Ethical approval was granted by the
      Ethical Review Board of the UITH. RESULT: Two hundred and twenty-six patients
      were sampled. The mean total waiting time was 180.3+/- 84.3 minutes, while the
      mean total service time was 63.3+/-52.0 minutes. Patient's average total clinic
      time was 243.7+/-93.6 minutes. Patients' total clinic time was determined by the 
      patients' clinic status and clinic arrival time. Majority of the patients (46.5%)
      described the time spent in the clinic as long but more than half (53.0%)
      expressed satisfaction at the total time spent at the clinic. CONCLUSION:
      Patients' clinic and waiting times were long, however, patients expressed
      satisfaction with the clinic times. FUNDING: Self-funded.
CI  - Copyright (c) The Author(s).
FAU - Olokoba, Lateefat B
AU  - Olokoba LB
AD  - Department of Ophthalmology, University of Ilorin Teaching Hospital, Ilorin,
      Kwara State, Nigeria.
FAU - Durowade, Kabir A
AU  - Durowade KA
AD  - Department of Community Medicine, Afe Babalola University, Ado-Ekiti, Nigeria.
FAU - Adepoju, Feyi G
AU  - Adepoju FG
AD  - Department of Ophthalmology, University of Ilorin Teaching Hospital, Ilorin,
      Kwara State, Nigeria.
FAU - Olokoba, Abdulfatai B
AU  - Olokoba AB
AD  - Department of Medicine, University of Ilorin Teaching Hospital, Ilorin, Kwara
      State, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Ghana
TA  - Ghana Med J
JT  - Ghana medical journal
JID - 0073210
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care/*organization & administration
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria
MH  - *Ophthalmology
MH  - *Patient Satisfaction
MH  - *Quality of Health Care
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
MH  - *Waiting Lists
PMC - PMC8042814
OTO - NOTNLM
OT  - Service time
OT  - ophthalmology clinic
OT  - waiting time
COIS- Conflict of interest: None declared
EDAT- 2021/04/23 06:00
MHDA- 2021/07/20 06:00
CRDT- 2021/04/22 06:41
PHST- 2021/04/22 06:41 [entrez]
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
AID - 10.4314/gmj.v54i4.5 [doi]
AID - jGMJ.v54.i4.pg231 [pii]
PST - ppublish
SO  - Ghana Med J. 2020 Dec;54(4):231-237. doi: 10.4314/gmj.v54i4.5.


PMID- 33883763
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20220422
IS  - 2616-163X (Electronic)
IS  - 0016-9560 (Linking)
VI  - 54
IP  - 3
DP  - 2020 Sep
TI  - Patterns of ethical issues and decision-making challenges in clinical practice
      among Ghanaian physiotherapists.
PG  - 179-185
LID - 10.4314/gmj.v54i3.9 [doi]
AB  - OBJECTIVES: To determine the patterns of ethical issues and decision-making
      challenges encountered by practicing physiotherapists in Ghana. DESIGN: This is a
      cross-sectional study in which the stratified sampling technique was adopted to
      sample the participants. SETTING: The study involved physiotherapists at the
      private healthcare setting and from different levels of public healthcare
      facilities. PARTICIPANTS: Eighty-two duly registered physiotherapists who were
      practising in Ghana participated in the study. INTERVENTIONS: Participants
      completed a 30-item questionnaire related to ethical issues and challenges
      encountered in making ethical decisions. Data analysis was premised on the
      frequency of occurrence of ethical tensions and difficulty in decision making
      which were dichotomized as 'high' and 'low' issues, and 'extreme' and 'low'
      difficult decisions, respectively. RESULTS: The age range of the participants was
      21-49 years (mean 31.5 +/- 1.4years). 18 (22%), 31 (37.8%) and 33 (40.2%)
      physiotherapists practice in the primary, secondary and tertiary healthcare
      settings respectively. 56 (68.3%) and 43 (52.4%) of the participants affirmed
      that 'establishing priorities for patient's treatment amidst limited time
      resources' was the most frequently encountered and the most extremely difficult
      ethical issue to make a decision on respectively. Whereas, limiting physical
      therapy services for personal or organizational gains sub-theme was the least
      occurred issue which was also the least difficult to make a decision on as
      indicated by the respective 16 (19.5%) and 18 (22.0%) physiotherapists.
      CONCLUSION: A wide range of primary and secondary ethical issues were reported by
      the sampled physiotherapists, which tend to pose difficulty during the
      decision-making process in practice. FUNDING: The research work was self-funded
      by the authors.
CI  - Copyright (c) The Author(s).
FAU - Nyante, Gifty G
AU  - Nyante GG
AD  - Department of Physiotherapy, School of Biomedical and Allied Health Sciences,
      College of Health Sciences, University of Ghana.
FAU - Andoh, Caleb K
AU  - Andoh CK
AD  - Department of Physiotherapy, School of Biomedical and Allied Health Sciences,
      College of Health Sciences, University of Ghana.
FAU - Bello, Ajediran I
AU  - Bello AI
AD  - Department of Physiotherapy, School of Biomedical and Allied Health Sciences,
      College of Health Sciences, University of Ghana.
LA  - eng
PT  - Journal Article
PL  - Ghana
TA  - Ghana Med J
JT  - Ghana medical journal
JID - 0073210
SB  - IM
MH  - Adult
MH  - Codes of Ethics
MH  - Cross-Sectional Studies
MH  - *Decision Making
MH  - Ethics
MH  - Female
MH  - Ghana
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Therapists/*ethics/*psychology
MH  - Physical Therapy Specialty/*ethics
MH  - Professional-Patient Relations/ethics
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC8042790
OTO - NOTNLM
OT  - Ethical issues
OT  - code of ethics
OT  - decision making
OT  - ethical judgement
OT  - physiotherapy practice
COIS- Conflict of interest: None declared
EDAT- 2021/04/23 06:00
MHDA- 2021/07/21 06:00
CRDT- 2021/04/22 06:41
PHST- 2021/04/22 06:41 [entrez]
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
AID - 10.4314/gmj.v54i3.9 [doi]
AID - jGMJ.v54.i3.pg179 [pii]
PST - ppublish
SO  - Ghana Med J. 2020 Sep;54(3):179-185. doi: 10.4314/gmj.v54i3.9.


PMID- 33883713
OWN - NLM
STAT- Publisher
LR  - 20210929
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Sep 29
TI  - Attention science: some people have only one name.
LID - 10.1038/d41586-020-02761-z [doi]
FAU - Sheherazade
AU  - Sheherazade
FAU - Ardiantiono
AU  - Ardiantiono
LA  - eng
PT  - News
DEP - 20200929
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Careers
OT  - Ethics
OT  - Publishing
EDAT- 2021/04/23 06:00
MHDA- 2021/04/23 06:00
CRDT- 2021/04/22 06:38
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PHST- 2021/04/22 06:38 [entrez]
AID - 10.1038/d41586-020-02761-z [doi]
AID - 10.1038/d41586-020-02761-z [pii]
PST - aheadofprint
SO  - Nature. 2020 Sep 29. pii: 10.1038/d41586-020-02761-z. doi:
      10.1038/d41586-020-02761-z.


PMID- 33870059
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210421
IS  - 2504-0537 (Electronic)
IS  - 2504-0537 (Linking)
VI  - 5
DP  - 2020
TI  - Mitigating Biases in CORD-19 for Analyzing COVID-19 Literature.
PG  - 596624
LID - 10.3389/frma.2020.596624 [doi]
AB  - On the behest of the Office of Science and Technology Policy in the White House, 
      six institutions, including ours, have created an open research dataset called
      COVID-19 Research Dataset (CORD-19) to facilitate the development of
      question-answering systems that can assist researchers in finding relevant
      research on COVID-19. As of May 27, 2020, CORD-19 includes more than 100,000 open
      access publications from major publishers and PubMed as well as preprint articles
      deposited into medRxiv, bioRxiv, and arXiv. Recent years, however, have also seen
      question-answering and other machine learning systems exhibit harmful behaviors
      to humans due to biases in the training data. It is imperative and only ethical
      for modern scientists to be vigilant in inspecting and be prepared to mitigate
      the potential biases when working with any datasets. This article describes a
      framework to examine biases in scientific document collections like CORD-19 by
      comparing their properties with those derived from the citation behaviors of the 
      entire scientific community. In total, three expanded sets are created for the
      analyses: 1) the enclosure set CORD-19E composed of CORD-19 articles and their
      references and citations, mirroring the methodology used in the renowned "A
      Century of Physics" analysis; 2) the full closure graph CORD-19C that recursively
      includes references starting with CORD-19; and 3) the inflection closure
      CORD-19I, that is, a much smaller subset of CORD-19C but already appropriate for 
      statistical analysis based on the theory of the scale-free nature of the citation
      network. Taken together, all these expanded datasets show much smoother trends
      when used to analyze global COVID-19 research. The results suggest that while
      CORD-19 exhibits a strong tilt toward recent and topically focused articles, the 
      knowledge being explored to attack the pandemic encompasses a much longer time
      span and is very interdisciplinary. A question-answering system with such
      expanded scope of knowledge may perform better in understanding the literature
      and answering related questions. However, while CORD-19 appears to have topical
      coverage biases compared to the expanded sets, the collaboration patterns,
      especially in terms of team sizes and geographical distributions, are captured
      very well already in CORD-19 as the raw statistics and trends agree with those
      from larger datasets.
CI  - Copyright (c) 2020 Kanakia, Wang, Dong, Xie, Lo, Shen, Wang, Huang, Eide,
      Kohlmeier and Wu.
FAU - Kanakia, Anshul
AU  - Kanakia A
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Wang, Kuansan
AU  - Wang K
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Dong, Yuxiao
AU  - Dong Y
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Xie, Boya
AU  - Xie B
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Lo, Kyle
AU  - Lo K
AD  - Allen Institute for Artificial Intelligence, Seattle, WA, United States.
FAU - Shen, Zhihong
AU  - Shen Z
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Wang, Lucy Lu
AU  - Wang LL
AD  - Allen Institute for Artificial Intelligence, Seattle, WA, United States.
FAU - Huang, Chiyuan
AU  - Huang C
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Eide, Darrin
AU  - Eide D
AD  - Microsoft Research, Redmond, WA, United States.
FAU - Kohlmeier, Sebastian
AU  - Kohlmeier S
AD  - Allen Institute for Artificial Intelligence, Seattle, WA, United States.
FAU - Wu, Chieh-Han
AU  - Wu CH
AD  - Microsoft Research, Redmond, WA, United States.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - Switzerland
TA  - Front Res Metr Anal
JT  - Frontiers in research metrics and analytics
JID - 101718019
PMC - PMC8025972
OTO - NOTNLM
OT  - CORD-19
OT  - Microsoft Academic Services
OT  - citation analysis
OT  - closure graph
OT  - data biases
OT  - scientometrics
COIS- Authors AK, KW, YD, BX, ZS, CH, DE and C-HW are employed by Microsoft Research.
      The remaining authors declare that the research was conducted in the absence of
      any commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/04/20 06:00
MHDA- 2021/04/20 06:01
CRDT- 2021/04/19 06:39
PHST- 2020/08/19 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2021/04/19 06:39 [entrez]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/04/20 06:01 [medline]
AID - 10.3389/frma.2020.596624 [doi]
AID - 596624 [pii]
PST - epublish
SO  - Front Res Metr Anal. 2020 Nov 23;5:596624. doi: 10.3389/frma.2020.596624.
      eCollection 2020.


PMID- 33870042
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210421
IS  - 2504-0537 (Electronic)
IS  - 2504-0537 (Linking)
VI  - 5
DP  - 2020
TI  - Language Bias in Health Research: External Factors That Influence Latent Language
      Patterns.
PG  - 4
LID - 10.3389/frma.2020.00004 [doi]
AB  - Background: Concerns with problematic research are primarily attributed to
      statistics and methods used to support data. Language, as an extended component
      of problematic research in published work, is rarely given the same attention
      despite language's equally important role in shaping the discussion and framings 
      of presented data. Purpose: This study uses a topic modeling approach to study
      language as a predictor of potential bias among collected publication histories
      of several health research areas. Methods: We applied Latent Dirichlet Allocation
      (LDA) topic models to dissect publication histories disaggregated by three
      factors commonly cited as language influencers: (1) time, to study ADHD
      pharmacotherapy; (2) funding source, to study sugar consumption; and (3) nation
      of origin, to study Pediatric Highly-Active Anti-Retroviral Therapy (P-HAART).
      Results: We found that, for each factor, there were notable differences in
      language among each corpus when disaggregated by each factor. For time, article
      content changed to reflect new trends and research practices for the commonly
      prescribed ADHD medication, Ritalin. For funding source, industry and federally
      funded studies had differing foci, despite testing the same hypothesis. For
      nation of origin, regulatory structures between the United States and Europe
      seemingly influenced the direction of research. Conclusion: This work presents
      two contributions to ethics research: (1) language and language framing should be
      studied as carefully as numeric data among studies of rigor, reproducibility, and
      transparency; and (2) the scientific community should continue to apply topic
      models as mediums to answer hypothesis-driven research questions.
CI  - Copyright (c) 2020 Valdez and Goodson.
FAU - Valdez, Danny
AU  - Valdez D
AD  - Department of Applied Health Science, Indiana University School of Public Health,
      Bloomington, IN, United States.
FAU - Goodson, Patricia
AU  - Goodson P
AD  - Department of Health and Kinesiology, Texas A&M University, College Station, TX, 
      United States.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - Switzerland
TA  - Front Res Metr Anal
JT  - Frontiers in research metrics and analytics
JID - 101718019
PMC - PMC8028389
OTO - NOTNLM
OT  - ethics
OT  - language framing
OT  - publication history
OT  - reviews
OT  - topic models
EDAT- 2021/04/20 06:00
MHDA- 2021/04/20 06:01
CRDT- 2021/04/19 06:39
PHST- 2020/04/21 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2021/04/19 06:39 [entrez]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/04/20 06:01 [medline]
AID - 10.3389/frma.2020.00004 [doi]
PST - epublish
SO  - Front Res Metr Anal. 2020 Aug 20;5:4. doi: 10.3389/frma.2020.00004. eCollection
      2020.


PMID- 33867754
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210421
IS  - 0974-0333 (Print)
IS  - 0974-0333 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Sep-Dec
TI  - Ethics of Glaucoma Widgets.
PG  - 77-80
LID - 10.5005/jp-journals-10078-1288 [doi]
AB  - How to cite this article: Dada T, Ramesh P, Sethi A, et al. Ethics of Glaucoma
      Widgets. J Curr Glaucoma Pract 2020;14(3):77-80.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Dada, Tanuj
AU  - Dada T
AD  - Department of Ophthalmology, Dr RP Centre for Ophthalmic Sciences, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Ramesh, Priyanka
AU  - Ramesh P
AD  - Department of Ophthalmology, Dr RP Centre for Ophthalmic Sciences, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Sethi, Anin
AU  - Sethi A
AD  - Department of Ophthalmology, Dr RP Centre for Ophthalmic Sciences, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Bhartiya, Shibal
AU  - Bhartiya S
AD  - Glaucoma Services, Department of Ophthalmology, Fortis Memorial Research
      Institute, Gurugram, Haryana, India.
LA  - eng
PT  - Editorial
PL  - India
TA  - J Curr Glaucoma Pract
JT  - Journal of current glaucoma practice
JID - 101492611
PMC - PMC8028034
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2021/04/20 06:00
MHDA- 2021/04/20 06:01
CRDT- 2021/04/19 06:17
PHST- 2021/04/19 06:17 [entrez]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/04/20 06:01 [medline]
AID - 10.5005/jp-journals-10078-1288 [doi]
PST - ppublish
SO  - J Curr Glaucoma Pract. 2020 Sep-Dec;14(3):77-80. doi:
      10.5005/jp-journals-10078-1288.


PMID- 33861188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210610
IS  - 2056-4694 (Print)
IS  - 2056-4694 (Linking)
VI  - 44
IP  - 3
DP  - 2020 Jun
TI  - A day in the life of a psychiatrist in 2050: where will the algorithm take us?
PG  - 121-123
LID - 10.1192/bjb.2020.22 [doi]
AB  - Digital phenotyping (such as using live data from personal digital devices on
      sleep, activity and social media interactions) to monitor and interpret people's 
      current mental state is a newly emerging development in psychiatry. This article 
      offers an imaginary insight into its future potential for both psychiatrist and
      patient.
FAU - Gillett, George
AU  - Gillett G
AUID- ORCID: https://orcid.org/0000-0002-0270-9369
AD  - Oxford University Clinical Academic Graduate School, UK.
AD  - Department of Psychiatry, University of Oxford, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJPsych Bull
JT  - BJPsych bulletin
JID - 101650950
PMC - PMC8170007
OTO - NOTNLM
OT  - Information technologies
OT  - bipolar affective disorders
OT  - ethics
OT  - risk assessment
OT  - schizophrenia
EDAT- 2021/04/17 06:00
MHDA- 2021/04/17 06:01
CRDT- 2021/04/16 12:11
PHST- 2021/04/16 12:11 [entrez]
PHST- 2021/04/17 06:00 [pubmed]
PHST- 2021/04/17 06:01 [medline]
AID - 10.1192/bjb.2020.22 [doi]
AID - S2056469420000224 [pii]
PST - ppublish
SO  - BJPsych Bull. 2020 Jun;44(3):121-123. doi: 10.1192/bjb.2020.22.


PMID- 33858526
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210418
IS  - 2056-4694 (Print)
IS  - 2056-4694 (Linking)
VI  - 44
IP  - 2
DP  - 2020 Apr
TI  - Assessing asylum seekers, refugees and undocumented migrants.
PG  - 75-80
LID - 10.1192/bjb.2019.67 [doi]
AB  - Identifying the causes of psychiatric and physical symptoms in asylum seekers,
      refugees and other migrants and making definitive diagnoses can be challenging.
      Ethical and legal challenges in the UK include the likely deterrent effects of
      upfront charging for National Health Service (NHS) services. This paper focuses
      on the fictitious case of an asylum seeker presenting to a mental health service 
      in England, highlighting some of the difficulties in assessing and treating this 
      patient group and providing advice to clinicians on clinical and practical
      management. Current NHS entitlements for migrants are summarised and a list is
      presented in the online supplement of non-governmental organisations that can
      provide further support.
FAU - Waterman, Lauren Z
AU  - Waterman LZ
AUID- ORCID: https://orcid.org/0000-0002-9963-4008
AD  - South London and Maudsley NHS Foundation Trust, UK.
FAU - Katona, Cara
AU  - Katona C
AD  - Camden and Islington Mental Health NHS Trust, UK.
FAU - Katona, Cornelius
AU  - Katona C
AD  - Helen Bamber Foundation, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJPsych Bull
JT  - BJPsych bulletin
JID - 101650950
PMC - PMC7283125
OTO - NOTNLM
OT  - Education and training
OT  - PTSD
OT  - health inequalities
OT  - migrant
OT  - refugee
EDAT- 2021/04/17 06:00
MHDA- 2021/04/17 06:01
CRDT- 2021/04/16 05:41
PHST- 2021/04/16 05:41 [entrez]
PHST- 2021/04/17 06:00 [pubmed]
PHST- 2021/04/17 06:01 [medline]
AID - 10.1192/bjb.2019.67 [doi]
AID - S2056469419000676 [pii]
PST - ppublish
SO  - BJPsych Bull. 2020 Apr;44(2):75-80. doi: 10.1192/bjb.2019.67.


PMID- 33855271
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210416
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - The future of genomics in Ireland - focus on genomics for health.
PG  - 89
LID - 10.12688/hrbopenres.13187.1 [doi]
AB  - Genomics is revolutionizing biomedical research, medicine and healthcare globally
      in academic, public and industry sectors alike. Concrete examples around the
      world show that huge benefits for patients, society and economy can be accrued
      through effective and responsible genomic research and clinical applications.
      Unfortunately, Ireland has fallen behind and needs to act now in order to catch
      up. Here, we identify key issues that have resulted in Ireland lagging behind,
      describe how genomics can benefit Ireland and its people and outline the measures
      needed to make genomics work for Ireland and Irish patients. There is now an
      urgent need for a national genomics strategy that enables an effective,
      collaborative, responsible, well-regulated, and patient centred environment where
      genome research and clinical genomics can thrive. We present eight
      recommendations that could be the pillars of a national genomics health strategy.
CI  - Copyright: (c) 2020 Seoighe C et al.
FAU - Seoighe, Cathal
AU  - Seoighe C
AD  - National University of Ireland Galway, Galway, H91 TK33, Ireland.
FAU - Bracken, Adrian P
AU  - Bracken AP
AD  - Trinity College Dublin, Dublin, 2, Ireland.
FAU - Buckley, Patrick
AU  - Buckley P
AD  - Genuity Science (Ireland) Ltd., Dublin, D18 K7W4, Ireland.
FAU - Doran, Peter
AU  - Doran P
AD  - University College Dublin, Dublin, 4, Ireland.
AD  - Mater Misericordiae University Hospital, Dublin, 7, Ireland.
FAU - Green, Robert
AU  - Green R
AD  - Brigham Health, Broad Institute, Ariadne Labs, Harvard Medical School, Boston,
      MA, 02115, USA.
FAU - Healy, Sandra
AU  - Healy S
AD  - National University of Ireland Galway, Galway, H91 TK33, Ireland.
FAU - Kavanagh, David
AU  - Kavanagh D
AD  - Genuity Science (Ireland) Ltd., Dublin, D18 K7W4, Ireland.
FAU - Kenny, Elaine
AU  - Kenny E
AD  - Trinity College Dublin, Dublin, 2, Ireland.
AD  - ELDA Biotech, Trinity Translational Medicine Institute, St James's Hospital,
      Dublin, D08 W9RT, Ireland.
FAU - Lawler, Mark
AU  - Lawler M
AD  - Queen's University Belfast, Belfast, Northern Ireland, BT7 1NN, Ireland.
FAU - Lowery, Maeve
AU  - Lowery M
AD  - Trinity College Dublin, Dublin, 2, Ireland.
AD  - Saint James' Hospital, Dublin, D08 NHY1, Ireland.
FAU - Morris, Derek
AU  - Morris D
AD  - National University of Ireland Galway, Galway, H91 TK33, Ireland.
FAU - Morrissey, Darrin
AU  - Morrissey D
AD  - National Institute for Bioprocessing Research and Training, Blackrock, A94 X099, 
      Ireland.
FAU - O'Byrne, James J
AU  - O'Byrne JJ
AD  - Mater Misericordiae University Hospital, Dublin, 7, Ireland.
FAU - Shields, Denis
AU  - Shields D
AD  - University College Dublin, Dublin, 4, Ireland.
FAU - Smith, Owen
AU  - Smith O
AD  - University College Dublin, Dublin, 4, Ireland.
AD  - Children's Health Ireland, Crumlin, Dublin, D12 N512, Ireland.
FAU - Steward, Charles A
AU  - Steward CA
AUID- ORCID: https://orcid.org/0000-0001-8829-5349
AD  - Congenica, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR, UK.
FAU - Sweeney, Brian
AU  - Sweeney B
AD  - University College Cork, Cork, T12 YN60, Ireland.
FAU - Kolch, Walter
AU  - Kolch W
AUID- ORCID: https://orcid.org/0000-0001-5777-5016
AD  - National University of Ireland Galway, Galway, H91 TK33, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7993626
OTO - NOTNLM
OT  - Genomics
OT  - ethics of genome research
OT  - genome research
OT  - health-economic assessment of clinical genomics
OT  - national genomics strategy
OT  - patient involvement
OT  - precision/personalized medicine
OT  - societal and economic aspects of genome research
COIS- Competing interests: RG receives compensation for advising the following
      companies: AIA, SavvySherpa, Verily, Wamberg; and is co-founder of Genome
      Medical, Inc, a technology and services company providing genetics expertise to
      patients, providers, employers and care systems. EK is the CEO of ELDA Biotech, a
      company providing genomics consultancy and sequencing services. DK and PB are
      employees of Genuity Science (Ireland) Ltd, a genomics company carrying out
      population sequencing studies. WK and ML receive co-funding for specific projects
      from Genuity Science, and WK receives co-funding from Astra Zeneca and the
      National Children's Research Centre through the Precision Oncology Ireland -
      Science Foundation Strategic Partnership grant 18/SPP/3522. MLowery is
      Chairperson of the Cancer Molecular Diagnostics Advisory Group of the National
      Cancer Control Program in Ireland. MLawler is supported by an unrestricted
      educational grant from Pfizer, for research unrelated to this work. MLawler has
      received honoraria from Pfizer, EMD Serono, Roche and BMS for presentations
      unrelated to this work; and is engaged in two separate research projects (with
      IQVIA and Diaceutics respectively) which receive funding through public research 
      funding organisations but which are unrelated to this work. MLawler is on the
      Scientific Board of Genomics England but does not receive remuneration for this
      position. CSeoighe is Scientific Advisor (unpaid) on Genomics for Orreco and
      Director of the SFI Centre for Research Training in Genomics Data Science, which 
      lists Genuity Science as a Partner Organization that has committed to providing
      co-funding for genomics PhD students. OS is member of the Strategic Advisory
      Board for Genuity Science (Ireland) Ltd.. CSteward is the Patient Advocacy and
      Engagement Lead at Congenica, UK, and is a member of the Genomics England
      Participant Panel, UK and the Simons Searchlight Community Advisory Committee,
      USA. The views expressed in this article are the independent opinions of the
      authors and do not reflect the views or interests of the organisations disclosed 
      here. The other authors disclose no competing interests.
EDAT- 2021/04/16 06:00
MHDA- 2021/04/16 06:01
CRDT- 2021/04/15 07:26
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/04/15 07:26 [entrez]
PHST- 2021/04/16 06:00 [pubmed]
PHST- 2021/04/16 06:01 [medline]
AID - 10.12688/hrbopenres.13187.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Dec 4;3:89. doi: 10.12688/hrbopenres.13187.1. eCollection
      2020.


PMID- 33852259
STAT- Publisher
DA  - 20210415
PB  - European Observatory on Health Systems and Policies
CTI - European Observatory Policy Briefs
DP  - 2020
BTI - Regulating the unknown: A guide to regulating genomics for health policy-makers
AB  - Genomics can improve individual and population health outcomes, but making
      genomic data widely available creates ethical, legal and social challenges.
      Genomics reveals sensitive personal and familial information. This may improve
      prevention and treatment but means that, without regulation and other measures,
      at risk individuals can be discriminated against; or that those at low risk may
      opt out of public protection. This endangers the equity and solidarity that
      underpin European health systems. The possibility of data being misused by
      insurers, employers or others makes it essential that there is strong regulation 
      of genomic data in research, in health care and more widely. Regulation needs to 
      be proportionate to balance privacy and data security against the benefits of
      scientific advances and their translation into clinical practice. The 2018
      European Union General Data Protection Regulation (GDPR) has transformed the way 
      genomic data are processed and will impact research, clinical practice and
      national regulators, even beyond the EU. The benefits of genomics can only be
      realized if, in addition to effective regulation: -There is broad societal trust 
      built by active dialogue and engagement. -All stakeholders, including industry
      are involved so that genomic initiatives engender confidence and align with
      societal values. -Wider information infrastructure and digitalization strategies 
      are in place so that genomic data can be linked to other information without
      breaching public trust. -Policy makers are able to manage the costs of
      genomics-driven innovation and ensure that benefits give value for money, improve
      health and are fairly distributed.
CI  - (c) World Health Organization 2020 (acting as the host organization for, and
      secretariat of, the European Observatory on Health Systems and Policies).
FAU - Williams, Gemma A
AU  - Williams GA
FAU - Liede, Sandra
AU  - Liede S
FAU - Fahy, Nick
AU  - Fahy N
FAU - Aittomaki, Kristiina
AU  - Aittomaki K
FAU - Perola, Markus
AU  - Perola M
FAU - Helander, Tuula
AU  - Helander T
FAU - McKee, Martin
AU  - McKee M
FAU - Sagan, Anna
AU  - Sagan A
LA  - eng
PT  - Review
PT  - Book
PL  - Copenhagen (Denmark)
OTO - NLM
OT  - Genomics
OT  - Health Information Management
OT  - Health Policy
OT  - Legislation
OT  - Ethics
OT  - Public Health
EDAT- 2021/04/15 06:01
MHDA- 2021/04/15 06:01
CDAT- 2021/04/15 06:01
AID - NBK569507 [bookaccession]


PMID- 33851094
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210416
IS  - 2588-9567 (Electronic)
IS  - 2588-9559 (Linking)
VI  - 2
IP  - 2
DP  - 2020 Oct
TI  - Ethical and Welfare Implications of Genetically Altered Non-Human Primates for
      Biomedical Research.
PG  - 151-176
LID - 10.1163/25889567-BJA10002 [doi]
AB  - Breakthroughs in gene editing technologies have made it feasible to create
      genetically altered (GA) non-human primate (NHP) models of disease. This area of 
      research is accelerating, particularly in China, Japan and the USA, and could
      lead to an increase in NHP use globally. The hope is that genetic models in
      animal species closely related to humans will significantly improve understanding
      of neurological diseases and validation of potential therapeutic interventions,
      for which there is a dire need. However, the creation and use of GA NHPS raises
      serious animal welfare and ethical issues, which are highlighted here. It
      represents a step change in how these highly sentient animals are used in
      biomedical research, because of the large numbers required, inherent wastage and 
      the sum of the harms caused to the animals involved. There is little evidence of 
      these important issues being addressed alongside the rapidly advancing science.
      We are still learning about how gene editing tools work in NHPS, and significant 
      added scientific and medical benefit from GA NHP models has yet to be
      demonstrated. Together, this suggests that current regulatory and review
      frameworks, in some jurisdictions at least, are not adequately equipped to deal
      with this emerging, complex area of NHP use.
FAU - Prescott, Mark J
AU  - Prescott MJ
AD  - National Centre for the Replacement, Refinement and Reduction of Animals in
      Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - Netherlands
TA  - J Appl Anim Ethics Res
JT  - Journal of applied animal ethics research
JID - 101777223
PMC - PMC7610575
MID - EMS117800
OTO - NOTNLM
OT  - animal welfare
OT  - ethics
OT  - gene editing
OT  - genetically modified
OT  - macaque
OT  - marmoset
OT  - transgenesis
OT  - transgenic
EDAT- 2021/04/15 06:00
MHDA- 2021/04/15 06:01
CRDT- 2021/04/14 06:37
PHST- 2021/04/14 06:37 [entrez]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2021/04/15 06:01 [medline]
AID - 10.1163/25889567-BJA10002 [doi]
PST - ppublish
SO  - J Appl Anim Ethics Res. 2020 Oct;2(2):151-176. doi: 10.1163/25889567-BJA10002.
      Epub 2020 May 26.


PMID- 33850609
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 2008-126X (Print)
IS  - 2008-126X (Linking)
VI  - 11
IP  - 6
DP  - 2020 Nov-Dec
TI  - Experimental Models of Absence Epilepsy.
PG  - 715-726
LID - 10.32598/bcn.11.6.731.1 [doi]
AB  - INTRODUCTION: Absence epilepsy is a brief non-convulsive seizure associated with 
      sudden abruptness in consciousness. Because of the unpredictable occurrence of
      absence seizures and the ethical issues of human investigation on the
      pathogenesis and drug assessment, researchers tend to study animal models. This
      paper aims to review the advantages and disadvantages of several animal models of
      nonconvulsive induced seizure. METHODS: The articles that were published since
      1990 were assessed. The publications that used genetic animals were analyzed,
      too. Besides, we reviewed possible application methods of each model, clinical
      types of seizures induced, purposed mechanism of epileptogenesis, their validity,
      and relevance to the absence epileptic patients. RESULTS: The number of studies
      that used genetic models of absence epilepsy from years of 2000 was noticeably
      more than pharmacological models. Genetic animal models have a close correlation 
      of electroencephalogram features and epileptic behaviors to the human condition. 
      CONCLUSION: The validity of genetic models of absence epilepsy would motivate the
      researchers to focus on genetic modes in their studies. As there are some
      differences in the pathophysiology of absence epilepsy between animal models and 
      humans, the development of new animal models is necessary to understand better
      the epileptogenic process and, or discover novel therapies for this disorder.
CI  - Copyright(c) 2020 Iranian Neuroscience Society.
FAU - Jafarian, Maryam
AU  - Jafarian M
AUID- ORCID: https://orcid.org/0000-0001-6016-6094
AD  - Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran
      University of Mdical Sciences, Tehran, Iran.
AD  - Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran.
FAU - Esmaeil Alipour, Mohammad
AU  - Esmaeil Alipour M
AUID- ORCID: https://orcid.org/0000-0001-5251-1193
AD  - Department of Neurosciences and Addiction Studies, School of Advanced
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Karimzadeh, Fariba
AU  - Karimzadeh F
AUID- ORCID: https://orcid.org/0000-0002-8805-3486
AD  - Cellular and Molecular Research Center, Iran University of Medical Sciences,
      Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201101
PL  - Iran
TA  - Basic Clin Neurosci
JT  - Basic and clinical neuroscience
JID - 101575211
PMC - PMC8019851
OTO - NOTNLM
OT  - Absence
OT  - Animal models
OT  - Epilepsy
OT  - Genetic models
OT  - Seizures
COIS- Conflict of interest The authors declared no conflicts of interest.
EDAT- 2021/04/15 06:00
MHDA- 2021/04/15 06:01
CRDT- 2021/04/14 06:33
PHST- 2019/01/21 00:00 [received]
PHST- 2019/03/10 00:00 [revised]
PHST- 2019/11/30 00:00 [accepted]
PHST- 2021/04/14 06:33 [entrez]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2021/04/15 06:01 [medline]
AID - 10.32598/bcn.11.6.731.1 [doi]
AID - bcn-11-715 [pii]
PST - ppublish
SO  - Basic Clin Neurosci. 2020 Nov-Dec;11(6):715-726. doi: 10.32598/bcn.11.6.731.1.
      Epub 2020 Nov 1.


PMID- 33844774
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 11
DP  - 2020 Nov
TI  - [Ethical tribulations of COVID-19: the sinister ominous, existential
      responsibility and Medice, Cura Te Ipsum].
PG  - 1668-1673
LID - S0034-98872020001101668 [pii]
LID - 10.4067/S0034-98872020001101668 [doi]
AB  - The COVID-19 pandemic revealed the vulnerability of the human being in their
      existential and medical fields. A feeling of uncertainty of an overwhelming and
      ominous nature indicates that dying is inherent for the human condition, a
      feeling that is daily hidden behind the mask of a casual, unexpected, random
      event. The possibility of dying from the viral disease revealed that the essence 
      of man as being-in-the-world is ethical or self-assumption and is expressed
      through an original rather than a moral conscience, which calls for authenticity,
      to listen to its nihility as being-referred-to-death. The medical ethical
      principles based on rights and duties need to be perfected by the ethics of
      virtues in accordance with the current challenges, requiring a transformation of 
      the moral self of the doctor. A moral failure of duty is inevitable for medicine,
      it will never reach its final realization.
FAU - Figueroa, Gustavo
AU  - Figueroa G
AD  - Departamento de Psiquiatria, Escuela de Medicina, Universidad de Valparaiso,
      Valparaiso, Chile.
LA  - spa
PT  - Journal Article
TT  - Tribulaciones eticas del COVID-19: lo sobrecogedor siniestro, la responsabilidad 
      existencial y Medice, Cura Te Ipsum.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - *COVID-19
MH  - Ethics, Medical
MH  - Humans
MH  - Moral Obligations
MH  - Morals
MH  - *Pandemics
MH  - SARS-CoV-2
MH  - Virtues
EDAT- 2021/04/13 06:00
MHDA- 2021/04/15 06:00
CRDT- 2021/04/12 17:18
PHST- 2020/08/28 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/04/12 17:18 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - S0034-98872020001101668 [pii]
AID - 10.4067/S0034-98872020001101668 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Nov;148(11):1668-1673. doi: 10.4067/S0034-98872020001101668.


PMID- 33844742
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 12
DP  - 2020 Dec
TI  - [A survey among patients about physician virtues that they value].
PG  - 1767-1772
LID - S0034-98872020001201767 [pii]
LID - 10.4067/S0034-98872020001201767 [doi]
AB  - BACKGROUND: Theoretically, the exercise of good medicine requires physicians who 
      possess and practice virtues. There are good reasons to believe that virtue
      ethics would be highly appreciated by patients. AIM: To determine the importance 
      that patients attribute to the possession virtues among physicians. MATERIAL AND 
      METHODS: Patients hospitalized in a private and a public hospital were invited to
      answer a three-question survey. The questions were: first, what do you expect of 
      a good physician? Second, please evaluate, in a scale from 1 to 5, the importance
      of physician virtues to consider him a good doctor (fidelity to trust given by
      the patient, benevolence, postponement of self-interests, compassion,
      intellectual honesty, justice and prudence). Third, among the seven former
      virtues, select the three more important, and then the most important of all.
      RESULTS: Most patients responded that they valued that a good physician should
      have good communication skills, a cordial relationship, commitment to the patient
      and knowledge. All virtues studied were considered important or very important by
      almost all patients. The virtues considered the most important were intellectual 
      honesty and fidelity to trust given by the patient. CONCLUSIONS: These results
      support the theoretical argument that, for patients, the practice of virtue
      ethics is essential for a good medical practice.
FAU - Carvajal, Sergio
AU  - Carvajal S
AD  - Centro de Bioetica, Facultad de Medicina Clinica Alemana, Universidad del
      Desarrollo, Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Virtudes del medico: inverted question markque importancia le atribuyen los
      pacientes?
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Empathy
MH  - Ethics, Medical
MH  - Humans
MH  - Male
MH  - *Medicine
MH  - Physician-Patient Relations
MH  - *Physicians
MH  - Surveys and Questionnaires
MH  - Virtues
EDAT- 2021/04/13 06:00
MHDA- 2021/04/15 06:00
CRDT- 2021/04/12 17:18
PHST- 2020/06/05 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2021/04/12 17:18 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - S0034-98872020001201767 [pii]
AID - 10.4067/S0034-98872020001201767 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Dec;148(12):1767-1772. doi: 10.4067/S0034-98872020001201767.


PMID- 33844726
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 10
DP  - 2020 Oct
TI  - [Ethical arguments for and against the participation of the medical profession in
      assisted death].
PG  - 1520-1521
LID - S0034-98872020001001520 [pii]
LID - 10.4067/S0034-98872020001001520 [doi]
FAU - Ortiz Pommier, Armando
AU  - Ortiz Pommier A
AD  - Academico Departamento de Bioetica y Humanidades medicas, Facultad de Medicina,
      Universidad de Chile, Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Argumentos eticos a favor y en contra de la participacion del profesional medico 
      en la muerte asistida.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Dissent and Disputes
MH  - Ethics, Medical
MH  - Humans
MH  - *Medicine
MH  - Morals
MH  - *Suicide, Assisted
EDAT- 2021/04/13 06:00
MHDA- 2021/05/12 06:00
CRDT- 2021/04/12 17:18
PHST- 2021/04/12 17:18 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - S0034-98872020001001520 [pii]
AID - 10.4067/S0034-98872020001001520 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Oct;148(10):1520-1521. doi: 10.4067/S0034-98872020001001520.


PMID- 33844719
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 10
DP  - 2020 Oct
TI  - [Proposal on the principles that should guide the ethical responsibilities of the
      state during the COVID-19 pandemic].
PG  - 1481-1488
LID - S0034-98872020001001481 [pii]
LID - 10.4067/S0034-98872020001001481 [doi]
AB  - On March 11, 2020, the World Health Organization (WHO) stated that the number of 
      cases of COVID-19 multiplied by 13 outside China, with a threefold increase in
      the number of affected countries. The WHO expressed its concern about the
      alarming levels of spread and severity of the outbreak, declaring the pandemic.
      This pandemic context is generating a social pact that seeks to ensure collective
      protection over individual freedoms. To meet the challenge, Governments must make
      decisions based on the principles that govern the State- These should consider
      the differences and particularities of those affected, without diverting
      attention from collective social protection. The following is a proposal on the
      ethical principles that should guide a State that makes decisions in public
      health emergencies.
FAU - Paredes E, Maria Cristina
AU  - Paredes E MC
AD  - Centro Integrativo de Biologia y Quimica Aplicada, Escuela de Enfermeria,
      Universidad Bernardo O`Higgins, Santiago, Chile.
FAU - Pesse-Sorensen, Karen
AU  - Pesse-Sorensen K
AD  - Facultad de Medicina, Pontificia Universidad Catolica del Ecuador, Quito,
      Ecuador.
FAU - Barros Rubio, Ximena
AU  - Barros Rubio X
AD  - Escuela de Salud Publica, Facultad de Medicina, Universidad de Chile, Santiago,
      Chile.
LA  - spa
PT  - Journal Article
TT  - Etica de la Salud Publica: propuesta sobre los principios fundamentales que guian
      las responsabilidades eticas del estado en el contexto pandemia COVID-19.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - *COVID-19
MH  - Humans
MH  - *Pandemics/prevention & control
MH  - Public Health
MH  - Public Policy
MH  - SARS-CoV-2
EDAT- 2021/04/13 06:00
MHDA- 2021/04/15 06:00
CRDT- 2021/04/12 17:18
PHST- 2020/06/08 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2021/04/12 17:18 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - S0034-98872020001001481 [pii]
AID - 10.4067/S0034-98872020001001481 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Oct;148(10):1481-1488. doi: 10.4067/S0034-98872020001001481.


PMID- 33842695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210414
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Health on the Move (HOME) Study: Using a smartphone app to explore the health and
      wellbeing of migrants in the United Kingdom.
PG  - 268
LID - 10.12688/wellcomeopenres.16348.1 [doi]
AB  - Background/Aim: We have a limited understanding of the broader determinants of
      health of international migrants and how these change over time since migration
      to the United Kingdom (UK). To address this knowledge gap, we aim to conduct a
      prospective cohort study with data acquisition via a smartphone application
      (app). In this pilot study, we aim to 1) determine the feasibility of the use of 
      an app for data collection in international migrants, 2) optimise app engagement 
      by quantifying the impact of specific design features on the completion rates of 
      survey questionnaires and on study retention, 3) gather preliminary profile
      health status data, to begin to examine how risk factors for health are
      distributed among migrants. Methods: We will recruit 275 participants through a
      social media campaign and through third sector organisations that work with or
      support migrants in the UK. Following consent and registration, data will be
      collected via surveys. To optimise app engagement and study retention, we will
      quantify the impact of specific design features (i.e. the frequency of survey
      requests, the time of day for app notifications, the frequency of notifications, 
      and the wording of notifications) via micro-randomised process evaluations. The
      primary outcome for this study is survey completion rates with numerator as the
      number of surveys completed and denominator as the total number of available
      surveys. Secondary outcomes are study retention rates and ratings of interest
      after app usage. Ethics and dissemination: We have obtained approval to use
      consented patient identifiable data from the University College London Ethics
      Committee. Improving engagement with the app and gathering preliminary health
      profile data will help us identify accessibility and usability issues and other
      barriers to app and study engagement prior to moving to a larger study.
CI  - Copyright: (c) 2020 Aldridge RW et al.
FAU - Aldridge, Robert W
AU  - Aldridge RW
AUID- ORCID: https://orcid.org/0000-0003-0542-0816
AD  - UCL Public Health Data Science Research Group, Institute of Health Informatics,
      University College London, London, Camden, NW1 2DA, UK.
FAU - Burns, Rachel
AU  - Burns R
AUID- ORCID: https://orcid.org/0000-0002-9559-2867
AD  - UCL Public Health Data Science Research Group, Institute of Health Informatics,
      University College London, London, Camden, NW1 2DA, UK.
FAU - Kirkby, Victoria
AU  - Kirkby V
AUID- ORCID: https://orcid.org/0000-0003-0610-2318
AD  - UCL Public Health Data Science Research Group, Institute of Health Informatics,
      University College London, London, Camden, NW1 2DA, UK.
FAU - Elsay, Nadia
AU  - Elsay N
AD  - UCL Public Health Data Science Research Group, Institute of Health Informatics,
      University College London, London, Camden, NW1 2DA, UK.
FAU - Murray, Elizabeth
AU  - Murray E
AD  - Primary Care & Population Health, Institute of Epidemiology & Health Care,
      University College London, London, NW3 2PF, UK.
FAU - Perski, Olga
AU  - Perski O
AD  - Behavioural Science and Health, Faculty of Population Health Sciences, Institute 
      of Epidemiology & Health Care, University College London, London, WC1E 6BT, UK.
FAU - Navaratnam, Annalan M
AU  - Navaratnam AM
AUID- ORCID: https://orcid.org/0000-0002-8141-5923
AD  - UCL Public Health Data Science Research Group, Institute of Health Informatics,
      University College London, London, Camden, NW1 2DA, UK.
FAU - Williamson, Elizabeth J
AU  - Williamson EJ
AUID- ORCID: https://orcid.org/0000-0001-6905-876X
AD  - Faculty of Epidemiology & Population Health, London School of Hygiene and
      Tropical Medicine, London, WC1E 7HT, UK.
FAU - Nieto-Martinez, Ramfis
AU  - Nieto-Martinez R
AUID- ORCID: https://orcid.org/0000-0002-0575-7534
AD  - LifeDoc Health, Memphis, TN, 38119, USA.
FAU - Miranda, J Jaime
AU  - Miranda JJ
AUID- ORCID: https://orcid.org/0000-0002-4738-5468
AD  - Faculty of Epidemiology & Population Health, London School of Hygiene and
      Tropical Medicine, London, WC1E 7HT, UK.
AD  - CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano
      Heredia, Lima, Peru.
AD  - The George Institute for Global Health, UNSW, Sydney, Australia.
FAU - Hugenholtz, Greg C G
AU  - Hugenholtz GCG
AD  - UCL Public Health Data Science Research Group, Institute of Health Informatics,
      University College London, London, Camden, NW1 2DA, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20201111
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC8008349
OTO - NOTNLM
OT  - App
OT  - health
OT  - healthcare access
OT  - mhealth
OT  - migrant
OT  - migration
OT  - occupational health
OT  - refugee
OT  - smartphone application
OT  - wellbeing.
COIS- No competing interests were disclosed.
EDAT- 2021/04/13 06:00
MHDA- 2021/04/13 06:01
CRDT- 2021/04/12 06:26
PHST- 2020/10/15 00:00 [accepted]
PHST- 2021/04/12 06:26 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/13 06:01 [medline]
AID - 10.12688/wellcomeopenres.16348.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Nov 11;5:268. doi: 10.12688/wellcomeopenres.16348.1.
      eCollection 2020.


PMID- 33840939
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 0970-9185 (Print)
IS  - 0970-9185 (Linking)
VI  - 36
IP  - 4
DP  - 2020 Oct-Dec
TI  - Quantitative rise in intraocular pressure in patients undergoing robotic surgery 
      in steep Trendelenburg position: A prospective observational study.
PG  - 546-551
LID - 10.4103/joacp.JOACP_96_20 [doi]
AB  - BACKGROUND AND AIMS: Raised intraocular pressure (IOP) is one of the known causes
      of anterior ischemic optic neuropathy. In the case of robotic
      urological-gynecological surgeries, patient is kept in steep Trendelenburg
      supine-lithotomy position. Aim of this study was to observe the quantitative rise
      in IOP in steep Trendelenburg position (>45 degrees ) in robotic-assisted
      prostatectomy and hysterectomy. MATERIAL AND METHODS: After institutional ethical
      clearance and written informed consent, 100 patients undergoing robotic surgeries
      in steep Trendelenburg position were recruited for the study. IOP was measured at
      different time intervals in steep Trendelenburg position using Schiotz tonometer:
      Post intubation (T1), post pneumoperitoneum (T2), post steep Trendelenburg (T3), 
      and rest readings were taken 30 min apart. T9 was taken 10 min after patient is
      made supine and parallel to the ground. Mean arterial pressure (MAP), positive
      inspiratory pressure (PIP), and end-tidal carbon dioxide (EtCO2) values were
      recorded at different time points. Descriptive analysis, linear regression
      analysis, and Freidman's nonparametric tests were used to analyze the results.
      RESULTS: Ninety-five patients were included for statistical analysis as five
      patients were excluded due to intraoperative interventions leading to alteration 
      of results. Mean IOP at T1 was 19.181/18.462 mmHg in L/R eye. A gradual rise in
      IOP was observed with every time point while patient was in steep Trendelenburg
      position which reverts back to near normal values once the patient is changed to 
      normal position 21.419/20.671: Left/right eye in mm of Hg. Uni and multiple
      regression analysis showed insignificant P value, thus no correlation between
      MAP, PIP, and EtCO2 with IOP. CONCLUSION: Steep Trendelenburg position for
      prolong duration leads to significant rise in intraocular pressure.
CI  - Copyright: (c) 2021 Journal of Anaesthesiology Clinical Pharmacology.
FAU - Goel, Nitesh
AU  - Goel N
AD  - Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre,
      Sec-5, Rohini, New Delhi, India.
FAU - Chowdhury, Itee
AU  - Chowdhury I
AD  - Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre,
      Sec-5, Rohini, New Delhi, India.
FAU - Dubey, Jitendra
AU  - Dubey J
AD  - Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre,
      Sec-5, Rohini, New Delhi, India.
FAU - Mittal, Amit
AU  - Mittal A
AD  - Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre,
      Sec-5, Rohini, New Delhi, India.
FAU - Pathak, Soumi
AU  - Pathak S
AD  - Department of Anaesthesia, Rajiv Gandhi Cancer Institute and Research Centre,
      Sec-5, Rohini, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20210118
PL  - India
TA  - J Anaesthesiol Clin Pharmacol
JT  - Journal of anaesthesiology, clinical pharmacology
JID - 9516972
PMC - PMC8022061
OTO - NOTNLM
OT  - Aqueous humor
OT  - Robotic surgery
OT  - Schiotz tonometer
OT  - intraocular pressure
OT  - ocular tonometry
OT  - pneumoperitoneum
OT  - steep Trendelenburg position
COIS- There are no conflicts of interest.
EDAT- 2021/04/13 06:00
MHDA- 2021/04/13 06:01
CRDT- 2021/04/12 06:13
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2021/04/12 06:13 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/13 06:01 [medline]
AID - 10.4103/joacp.JOACP_96_20 [doi]
AID - JOACP-36-546 [pii]
PST - ppublish
SO  - J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):546-551. doi:
      10.4103/joacp.JOACP_96_20. Epub 2021 Jan 18.


PMID- 33840938
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 0970-9185 (Print)
IS  - 0970-9185 (Linking)
VI  - 36
IP  - 4
DP  - 2020 Oct-Dec
TI  - A comparative study of desflurane versus sevoflurane in obese patients: Effect on
      recovery profile.
PG  - 541-545
LID - 10.4103/joacp.JOACP_307_19 [doi]
AB  - BACKGROUND AND AIMS: Anesthesia in obese patients is difficult due to associated 
      comorbidities and altered physiology. Desflurane and sevoflurane have a low
      fat-blood solubility coefficient and are better suited in these patients to
      achieve a rapid emergence. We studied BIS guided drug titration to compare the
      postoperative recovery characteristics and cognitive function of desflurane
      versus sevoflurane in obese patients undergoing laparoscopic abdominal surgeries.
      MATERIAL AND METHODS: After institutional ethics committee approval and written
      informed consent, sixty obese patients (BMI >/=30 kg/m(2)) were randomized to
      receive either BIS guided desflurane or sevoflurane. Recovery was assessed by
      time taken for eye opening on verbal command, sustained head lift for 5 s, and
      extubation and orientation to time, place, and person after discontinuation of
      volatile anesthetic agent. For cognitive function, time taken to complete Mini
      mental state examination (MMSE) score to baseline was compared in both study
      groups. RESULTS: Difference of time taken for eye opening on verbal command,
      sustained head lift for 5 s, and extubation and orientation to time, place, and
      person was not significant between both anesthetic groups. Patients in
      sevoflurane group took significantly (P-value = 0.001) less time (40.07 +/- 13
      min) to achieve preoperative MMSE score than desflurane group (51.2 +/- 11.7
      min). CONCLUSION: Both desflurane and sevoflurane have similar recovery profile
      in obese patients when anesthetic concentration is carefully titrated. Reversal
      of cognitive function is significantly earlier in obese patients anesthetized
      with sevoflurane.
CI  - Copyright: (c) 2021 Journal of Anaesthesiology Clinical Pharmacology.
FAU - Bansal, Tania
AU  - Bansal T
AD  - Department of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana,
      Punjab, India.
FAU - Garg, Kamakshi
AU  - Garg K
AD  - Department of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana,
      Punjab, India.
FAU - Katyal, Sunil
AU  - Katyal S
AD  - Department of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana,
      Punjab, India.
FAU - Sood, Dinesh
AU  - Sood D
AD  - Department of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana,
      Punjab, India.
FAU - Grewal, Anju
AU  - Grewal A
AD  - Department of Anaesthesiology, Dayanand Medical College and Hospital, Ludhiana,
      Punjab, India.
FAU - Kumar, Arvind
AU  - Kumar A
AD  - Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20210118
PL  - India
TA  - J Anaesthesiol Clin Pharmacol
JT  - Journal of anaesthesiology, clinical pharmacology
JID - 9516972
PMC - PMC8022057
OTO - NOTNLM
OT  - Anesthesia for obese
OT  - desflurane
OT  - inhalational agents
OT  - recovery characteristics
OT  - sevoflurane
COIS- There are no conflicts of interest.
EDAT- 2021/04/13 06:00
MHDA- 2021/04/13 06:01
CRDT- 2021/04/12 06:13
PHST- 2019/09/15 00:00 [received]
PHST- 2020/03/03 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2021/04/12 06:13 [entrez]
PHST- 2021/04/13 06:00 [pubmed]
PHST- 2021/04/13 06:01 [medline]
AID - 10.4103/joacp.JOACP_307_19 [doi]
AID - JOACP-36-541 [pii]
PST - ppublish
SO  - J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):541-545. doi:
      10.4103/joacp.JOACP_307_19. Epub 2021 Jan 18.


PMID- 33835003
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1847-6538 (Electronic)
IS  - 1330-027X (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - A Case of Dominant Dystrophic Epidermolysis Bullosa with a G2043R Mutation in the
      Type VII Collagen Gene.
PG  - 251-252
AB  - Dear Editor, Dystrophic epidermolysis bullosa (DEB) is a subepidermal bulla,
      characterized by severe itching, lichenoid or nodular prurigo-like lesions, skin 
      erosion, scars, milia, and nail dystrophy, resulting from COL7A1 mutation.
      Herein, we report a case of dominant DEB with a G2043R mutation in COL7A1.
      A-25-year-old Japanese woman was referred to our clinic for recurrent intense
      pruritis and hypertrophic scars on the abdomen (Figure 1, a). She presented with 
      paper-like scars on her forehead, breast, back, buttock, and extremities (Figure 
      1, b) with mild toenail hypoplasia (Figure 1, c), but no symptoms on the
      fingernails, hair, teeth, or esophagus. She had developed erosions at the ankle
      joint a few days after birth. Her parents and four siblings had no related
      symptoms. She had been diagnosed with DEB at 11 months based on clinical and
      histopathological findings. Erythema, bullae, and skin ulcers had healed with
      scarring on the extensor surface of the lower legs at 7 years (Figure 1, d).
      Histopathological findings revealed subepidermal bulla with lymphocyte and
      eosinophil infiltration in the upper dermis (Figure 1, e). Immunofluorescence
      staining with type VII collagen antibody showed uneven faint localization at the 
      basement membrane zone (Figure 1, f). Electron microscopy showed scanty and
      hypoplastic anchoring fibrils (Figure 1, g). Following ethical approval, informed
      consent was obtained in compliance with the Declaration of Helsinki guidelines,
      DNA was extracted from peripheral blood lymphocytes of the patient, and exome
      sequence analysis was performed. A heterozygous single nucleotide substitution
      c.6127G>A in exon 73 of COL7A1 was found, which converts glycine to arginine
      residue, designated p. G2043R. Since COL7A1 is a giant gene with 118 exons and
      9276 base pairs, exome sequencing is convenient to determine the mutated gene. In
      dominant DEB, pathogenic mutations usually occur in glycine substitutions within 
      the type VII collagen triple helix (1). The mutation impedes the trimer formation
      of collagen and disrupts the normal location of anchoring fibril. The particular 
      localization of mutated collagen VII protein could vary based on the position of 
      mutated glycine residue. In our patient, the mutated collagens were observed
      sparsely and unevenly at the basement membrane, but can accumulate granularly
      within the basal keratinocytes (2,3). G2043R mutation such as in the present case
      has been previously described with dominant DEB in Italian, Hungarian, Norwegian,
      Mexican, Scottish, Finnish, American, Chinese, and Japanese cases (1). Given the 
      widespread geographical distribution of this mutation and its occurrence as a de 
      novo event like in our case, G2043R can be one of the mutational hotspots in
      dominant DEB (1). Symptom severity in dominant DEB varies in the same mutation or
      intra-familial cases, and symptoms regress with age (4). The patient had severe
      blisters on her legs in early childhood; however, as her age increased, the
      hypertrophic or atrophic scars on the lower abdomen and extensor surface of her
      lower legs became the primary skin symptoms. It is presumed that some factor will
      compensate for the vulnerabilities.
FAU - Komatsu, Kotaro
AU  - Komatsu K
FAU - Yamaguchi, Sayaka
AU  - Yamaguchi S
AD  - Sayaka Yamaguchi, MD, PhD, Department of Dermatology Graduate School and
      Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0125,
      Japan; sayaka-y@med.u-ryukyu.ac.jp.
FAU - Utsumi, Daisuke
AU  - Utsumi D
FAU - Yamamoto, Ichi
AU  - Yamamoto I
FAU - Takahashi, Kenzo
AU  - Takahashi K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Croatia
TA  - Acta Dermatovenerol Croat
JT  - Acta dermatovenerologica Croatica : ADC
JID - 9433781
RN  - 0 (COL7A1 protein, human)
RN  - 0 (Collagen Type VII)
SB  - IM
MH  - Child, Preschool
MH  - *Collagen Type VII/genetics
MH  - *Epidermolysis Bullosa Dystrophica/genetics
MH  - Exons
MH  - Female
MH  - Humans
MH  - Mutation
MH  - Pedigree
EDAT- 2021/04/10 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/04/09 12:25
PHST- 2021/04/09 12:25 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PST - ppublish
SO  - Acta Dermatovenerol Croat. 2020 Dec;28(4):251-252.


PMID- 33834162
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210411
IS  - 2590-0978 (Electronic)
IS  - 2590-0978 (Linking)
VI  - 6
DP  - 2020 Dec
TI  - Fecal microbiota transplantation: Uses, questions, and ethics.
LID - 100027 [pii]
LID - 10.1016/j.medmic.2020.100027 [doi]
AB  - Fecal microbiota transplantation (FMT) has rapidly grown in notoriety and
      popularity worldwide as a treatment for both recurrent and refractory C.
      difficile infection (CDI), as well as for a myriad of other indications, with
      varying levels of evidence to justify its use. At present, FMT use in the U.S.
      has not received marketing approval from the U.S. Food and Drug Administration
      (FDA), but is permitted under "enforcement discretion" for CDI not responding to 
      standard therapy. Meanwhile, the rising interest in the gut microbiome throughout
      mainstream media has paved the way for "do-it-yourself" (DIY) adaptations of the 
      procedure. This access and unregulated use, often outside any clinical
      supervision, has quickly outpaced the medical community's research and regulatory
      efforts. While some studies have been able to demonstrate the success of FMT in
      treating conditions other than CDI-studies on ulcerative colitis have been
      particularly promising-little is still known about the treatmen's mechanism of
      action or long-term side effects. Likewise, screening of donor stool is in its
      early stages in terms of protocol standardization. In this paper, we explore the 
      regulatory and ethical concerns that arise from the need to balance access to a
      nascent but promising innovative treatment with the need for research into its
      efficacy, risk profile, and long-term impact.
FAU - Grigoryan, Zoya
AU  - Grigoryan Z
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman
      School of Medicine, 462 First Avenue, 10E1, New York, NY, 10016, USA.
FAU - Shen, Michael J
AU  - Shen MJ
AD  - Division of Medical Ethics, Department of Population Health, NYU Grossman School 
      of Medicine, 550 First Avenue, New York, NY, 10016, USA.
FAU - Twardus, Shaina W
AU  - Twardus SW
AD  - Division of Gastroenterology, Massachusetts General Hospital, 165 Cambridge St
      Floor 9, Boston, MA 02114; Center for Computational and Integrative Biology,
      Massachusetts General Hospital, 185 Cambridge St Floor 7, Boston, MA, 02114, USA.
FAU - Beuttler, Marc M
AU  - Beuttler MM
AD  - Division of Medical Ethics, Department of Population Health, NYU Grossman School 
      of Medicine, 550 First Avenue, New York, NY, 10016, USA.
AD  - Department of Dermatology, Louisiana State University School of Medicine, 1542
      Tulane Ave, New Orleans, LA, 70112, USA.
FAU - Chen, Lea Ann
AU  - Chen LA
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman
      School of Medicine, 462 First Avenue, 10E1, New York, NY, 10016, USA.
FAU - Bateman-House, Alison
AU  - Bateman-House A
AD  - Division of Medical Ethics, Department of Population Health, NYU Grossman School 
      of Medicine, 550 First Avenue, New York, NY, 10016, USA.
LA  - eng
GR  - K23 DK119544/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20201020
PL  - Netherlands
TA  - Med Microecol
JT  - Medicine in microecology
JID - 101777407
PMC - PMC8026161
MID - NIHMS1685380
OTO - NOTNLM
OT  - Bioethics
OT  - C. difficile
OT  - Expanded access
OT  - Gastrointestinal microbiome
OT  - Investigational drugs
OT  - Regulation
EDAT- 2021/04/10 06:00
MHDA- 2021/04/10 06:01
CRDT- 2021/04/09 06:32
PHST- 2021/04/09 06:32 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/04/10 06:01 [medline]
AID - 10.1016/j.medmic.2020.100027 [doi]
PST - ppublish
SO  - Med Microecol. 2020 Dec;6. doi: 10.1016/j.medmic.2020.100027. Epub 2020 Oct 20.


PMID- 33824129
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 33
IP  - 5
DP  - 2020 Sep
TI  - Observation on China's efficient mobilization and external dependencies in
      COVID-19 detection reagents, vaccines and drugs development.
PG  - 2193-2198
AB  - Respiratory infectious diseases had happened in China in recent years, and the
      outbreak of Corona Virus Disease 2019(COVID-19) had drawn worldwide attention. In
      order to control such high-mortality infectious diseases, the work of the Chinese
      government and the medical community in detection reagents, drugs, and vaccines
      had been speeded up. This research extensively searched the medical data of
      drugs, vaccines and kits development, the company's business report and the
      government's policy documents and conducted case analysis. We found some national
      mobilization measures had been put on the agenda and some special marketing
      authorization measures had been adopted. Due to the limitations of biotechnology 
      research and the pharmaceutical industry, some key technologies and drugs still
      had a high external dependence. In the process of development, it was necessary
      to attach importance to scientific, ethical, and safety construction, and to
      strengthen international cooperation.
FAU - Yu, Xiang
AU  - Yu X
AD  - Public Affairs at Fujian Jiangxia University, 2st Xiyuangong Road, Fuzhou,
      Fujian, China.
FAU - Li, Na
AU  - Li N
AD  - Law at Ningbo University, 818st Fenghua Road, Ningbo Zhejiang, China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (Indicators and Reagents)
SB  - IM
MH  - COVID-19/*diagnosis
MH  - COVID-19 Testing/*methods
MH  - China
MH  - Community-Institutional Relations
MH  - *Efficiency, Organizational
MH  - Government
MH  - Health Policy
MH  - Humans
MH  - Indicators and Reagents/*chemistry
MH  - International Cooperation
EDAT- 2021/04/08 06:00
MHDA- 2021/04/15 06:00
CRDT- 2021/04/07 05:57
PHST- 2021/04/07 05:57 [entrez]
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2020 Sep;33(5):2193-2198.


PMID- 33815718
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210406
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 11
DP  - 2020
TI  - Mapping the Age of Laboratory Rabbit Strains to Human.
PG  - 194
LID - 10.4103/ijpvm.IJPVM_530_18 [doi]
AB  - Rabbit strains find immense application in biomedical research with every strain 
      having their discrete advantage in specific research endeavor. Acceptability of
      rabbit strains as laboratory animals owes to their breeding ease, availability,
      cost-effectiveness, ethical conveniences, larger size, compared to rats and mice,
      and responsiveness. With respect to different life phases, the article displays
      that one human year is equivalent to: (1) in developmental phase, 56.77 days for 
      New Zealand White (NZW) and New Zealand Red (NZR) rabbits, 71.01 days for Dutch
      belted and Polish rabbits, and 85.28 days for Californian rabbits; (2) in the
      prepubertal phase, 13.04 days for NZW and Dutch belted, 15.65 days for NZR and
      Californian, and 10.43 days for Polish rabbits; (3) in the adult phase, 18.25
      days for NZW and Californian rabbits, 22.75 days for NZR, and 12 days for Dutch
      Belted and Polish rabbits; (4) during reproductive senescence, 42.94 days for
      NZW, NZR and Californian rabbits, 28.62 days for Dutch belted, and 25.05 days for
      Polish rabbits; (5) in the post-senescence phase, 50.34 days for NZW, 25.17 days 
      for NZR, Dutch Belted and Californian and 31.46 days for Polish rabbits. The
      laboratory rabbit strains differ in various physiological, developmental and
      genetic make-ups, which also reflect upon the correlation of their age at
      different life stages with that of a human. The present article aids selection of
      laboratory rabbit strain of accurate age as per experimental need, by precisely
      relating the same with age of human considering different life stages.
CI  - Copyright: (c) 2019 International Journal of Preventive Medicine.
FAU - Sengupta, Pallav
AU  - Sengupta P
AD  - Department of Physiology, Faculty of Medicine, MAHSA University, Malaysia.
FAU - Dutta, Sulagna
AU  - Dutta S
AD  - Department of Oral Biology and Biomedical Sciences, Faculty of Dentistry, MAHSA
      University, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201211
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC8000163
OTO - NOTNLM
OT  - Aging
OT  - animal models
OT  - physiology
OT  - rabbits
COIS- There are no conflicts of interest.
EDAT- 2021/04/06 06:00
MHDA- 2021/04/06 06:01
CRDT- 2021/04/05 06:01
PHST- 2018/11/24 00:00 [received]
PHST- 2019/05/24 00:00 [accepted]
PHST- 2021/04/05 06:01 [entrez]
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/04/06 06:01 [medline]
AID - 10.4103/ijpvm.IJPVM_530_18 [doi]
AID - IJPVM-11-194 [pii]
PST - epublish
SO  - Int J Prev Med. 2020 Dec 11;11:194. doi: 10.4103/ijpvm.IJPVM_530_18. eCollection 
      2020.


PMID- 33797331
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1521-057X (Electronic)
IS  - 0194-7648 (Linking)
VI  - 40
IP  - 3-4
DP  - 2020 Jul-Dec
TI  - Thinking Outside the Silos: Information Sharing in Medical-Legal Partnerships.
PG  - 369-389
LID - 10.1080/01947648.2020.1854135 [doi]
AB  - Medical-legal partnerships (MLPs) allow providers to address patients'
      health-harming legal needs through partnerships with lawyers. MLPs are most
      successful in addressing the complex needs of vulnerable populations when
      clinicians, social workers, and other care team members regularly communicate
      with the MLP lawyer. Privacy laws and professional rules of conduct governing
      patient/client confidentiality, however, potentially hinder this exchange of
      patient-client information. MLP attorneys may be reluctant to share relevant
      information about a client with the medical partner for fear that doing so would 
      breach client confidentiality or result in an ill-advised waiver of
      attorney-client privilege. Similarly, privacy concerns may lead providers to
      limit MLP attorneys' access to patients' medical information.Drawing on the
      real-world experiences of MLP professionals, this article explores whether legal 
      and ethical obligations impede the sharing of patient-client information between 
      MLPs' medical and legal partners. Our research indicates that at present
      patient/client confidentiality rules generally do not pose a significant barrier 
      to doing so. However, current legal and professional standards may frustrate
      emerging advanced care coordination models that pair MLPs with care teams that
      comprehensively address a broad range of social, economic, and behavioral health 
      needs. We therefore recommend continued monitoring and discussion of the issue.
FAU - Mantel, Jessica
AU  - Mantel J
FAU - Fowler, Leah
AU  - Fowler L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Leg Med
JT  - The Journal of legal medicine
JID - 8000151
SB  - IM
MH  - Confidentiality/*standards
MH  - Disclosure/*standards
MH  - Health Personnel/standards
MH  - Humans
MH  - Information Dissemination/*legislation & jurisprudence
MH  - *Interprofessional Relations
MH  - *Intersectoral Collaboration
MH  - Lawyers/standards
MH  - Patient Care Team/*organization & administration
MH  - Policy
MH  - *Professional-Patient Relations
EDAT- 2021/04/03 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/04/02 12:14
PHST- 2021/04/02 12:14 [entrez]
PHST- 2021/04/03 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.1080/01947648.2020.1854135 [doi]
PST - ppublish
SO  - J Leg Med. 2020 Jul-Dec;40(3-4):369-389. doi: 10.1080/01947648.2020.1854135.


PMID- 33791440
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220129
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Concurrent adult pulmonary tuberculosis prevalence survey using digital
      radiography and Xpert MTB/RIF Ultra and child interferon-gamma release assay
      Mycobacterium tuberculosis infection survey in Karachi, Pakistan: a study
      protocol.
PG  - 159
LID - 10.12688/wellcomeopenres.15963.1 [doi]
AB  - Background: Assessment of the effectiveness of tuberculosis control strategies
      requires the periodic measurement of M. tuberculosis transmission in populations,
      which is notoriously difficult. One well-established method is to measure the
      prevalence of infectious pulmonary tuberculosis in the population which is then
      repeated at a second time point after a period of 'intervention', such as scale
      up of the Search-Treat-Prevent strategy of the Zero TB Cities initiative,
      allowing for a 'before and after' comparison. Protocol: The concurrent adult
      pulmonary tuberculosis prevalence survey (using digital radiography and Xpert
      MTB/RIF Ultra) and child M. tuberculosis infection survey (using
      QuantiFERON-TB(R) Gold Plus) will primarily provide a baseline measure of the
      burden of adult infectious tuberculosis in Karachi and assess whether a
      large-scale interferon gamma release assay survey in children aged 2 to 4 years
      is feasible. The target population for the prevalence survey is comprised of a
      stratified random sample of all adults aged 15 years and above and all children
      aged 2 to 4 years resident in four districts in Karachi. The survey procedures
      and analyses to estimate pulmonary tuberculosis prevalence are based on the World
      Health Organization methodology for tuberculosis prevalence surveys. Ethics and
      dissemination: The study protocol has been approved by the Interactive Research
      Development / The Indus Hospital Research Centre Research Ethics Committee in
      Karachi, Pakistan and the London School of Hygiene & Tropical Medicine Research
      Ethics Committee. Due to non-representative sampling in this setting, where a
      large proportion of the population are illiterate and are reluctant to provide
      fingerprints due to concerns about personal security, verbal informed consent
      will be obtained from each eligible participant or guardian. Results will be
      submitted to international peer-reviewed journals, presented at international
      conferences and shared with participating communities and with the Provincial and
      National TB programme.
CI  - Copyright: (c) 2020 Khan PY et al.
FAU - Khan, Palwasha Y
AU  - Khan PY
AUID- ORCID: https://orcid.org/0000-0002-0873-8355
AD  - Interactive Research and Development, Karachi, Pakistan.
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
AD  - TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
FAU - Paracha, M Shariq
AU  - Paracha MS
AD  - Interactive Research and Development, Karachi, Pakistan.
FAU - Grundy, Chris
AU  - Grundy C
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Saeed, Saadia
AU  - Saeed S
AD  - Interactive Research and Development, Karachi, Pakistan.
FAU - Dojki, Maqboola
AU  - Dojki M
AD  - The Indus Health Network, Karachi, Pakistan.
FAU - Madhani, Falak
AU  - Madhani F
AD  - The Indus Health Network, Karachi, Pakistan.
FAU - Page-Shipp, Liesl
AU  - Page-Shipp L
AD  - Interactive Research and Development Global, Singapore, Singapore.
FAU - Khursheed, Nazia
AU  - Khursheed N
AD  - The Indus Health Network, Karachi, Pakistan.
FAU - Rabbani, Waleed
AU  - Rabbani W
AD  - Interactive Research and Development, Karachi, Pakistan.
FAU - Riaz, Najam
AU  - Riaz N
AD  - The Indus Health Network, Karachi, Pakistan.
FAU - Khowaja, Saira
AU  - Khowaja S
AD  - Interactive Research and Development, Karachi, Pakistan.
AD  - The Indus Health Network, Karachi, Pakistan.
FAU - Hussain, Owais
AU  - Hussain O
AD  - Interactive Health Solutions, Karachi, Pakistan.
FAU - Habib, Ali
AU  - Habib A
AD  - Interactive Health Solutions, Karachi, Pakistan.
FAU - Khan, Uzma
AU  - Khan U
AD  - Interactive Research and Development Global, Dubai, United Arab Emirates.
FAU - Kranzer, Katharina
AU  - Kranzer K
AD  - TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Ferrand, Rashida A
AU  - Ferrand RA
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Lewis, James J
AU  - Lewis JJ
AD  - Y Lab - the Public Services Innovation Lab for Wales, Cardiff University,
      Cardiff, UK.
FAU - Khan, Aamir J
AU  - Khan AJ
AD  - The Indus Health Network, Karachi, Pakistan.
AD  - Interactive Research and Development Global, Singapore, Singapore.
FAU - Fielding, Katherine L
AU  - Fielding KL
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
AD  - TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - MR/K007467/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7968470
OTO - NOTNLM
OT  - Karachi
OT  - M. tuberculosis transmission
OT  - infectious tuberculosis
OT  - tuberculosis prevalence
COIS- No competing interests were disclosed.
EDAT- 2021/04/02 06:00
MHDA- 2021/04/02 06:01
CRDT- 2021/04/01 06:32
PHST- 2020/06/16 00:00 [accepted]
PHST- 2021/04/01 06:32 [entrez]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/04/02 06:01 [medline]
AID - 10.12688/wellcomeopenres.15963.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Jul 6;5:159. doi: 10.12688/wellcomeopenres.15963.1.
      eCollection 2020.


PMID- 33778637
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2638-6135 (Electronic)
IS  - 2638-6135 (Linking)
VI  - 2
IP  - 6
DP  - 2020 Dec
TI  - Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores.
PG  - e200022
LID - 10.1148/ryct.2020200022 [doi]
AB  - PURPOSE: To develop radiomics-based CT scores for assessing lung disease severity
      and exacerbation risk in adult patients with cystic fibrosis (CF). MATERIALS AND 
      METHODS: This two-center retrospective observational study was approved by an
      institutional ethics committee, and the need for patient consent was waived. A
      total of 215 outpatients with CF referred for unenhanced follow-up chest CT were 
      evaluated in two different centers between January 2013 and December 2016. After 
      lung segmentation, chest CT scans from center 1 (training cohort, 162 patients
      [median age, 29 years; interquartile range {IQR}, 24-36 years; 84 men]) were used
      to build CT scores from 38 extracted CT features, using five different machine
      learning techniques trained to predict a clinical prognostic score, the Nkam
      score. The correlations between the developed CT scores, two different clinical
      prognostic scores (Liou and CF-ABLE), forced expiratory volume in 1 second
      (FEV1), and risk of respiratory exacerbations were evaluated in the test cohort
      (center 2, 53 patients [median age, 27 years; IQR, 22-35 years; 34 men]) using
      the Spearman rank coefficient. RESULTS: In the test cohort, all radiomics-based
      CT scores showed moderate to strong correlation with the Nkam score (R = 0.57 to 
      0.63, P < .001) and Liou scores (R = -0.55 to -0.65, P < .001), whereas the
      correlation with CF-ABLE score was weaker (R = 0.28 to 0.38, P = .005 to .048).
      The developed CT scores showed strong correlation with predicted FEV1 (R = -0.62 
      to -0.66, P < .001) and weak to moderate correlation with the number of pulmonary
      exacerbations to occur in the 12 months after the CT examination (R = 0.38 to
      0.55, P < .001 to P = .006). CONCLUSION: Radiomics can be used to build automated
      CT scores that correlate to clinical severity and exacerbation risk in adult
      patients with CF.Supplemental material is available for this article.See also the
      commentary by Elicker and Sohn in this issue.(c) RSNA, 2020.
CI  - 2020 by the Radiological Society of North America, Inc.
FAU - Chassagnon, Guillaume
AU  - Chassagnon G
AUID- ORCID: 0000-0003-1487-7922
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Zacharaki, Evangelia I
AU  - Zacharaki EI
AUID- ORCID: 0000-0001-8228-0437
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Bommart, Sebastien
AU  - Bommart S
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Burgel, Pierre-Regis
AU  - Burgel PR
AUID- ORCID: 0000-0003-0903-9828
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Chiron, Raphael
AU  - Chiron R
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Dangeard, Severine
AU  - Dangeard S
AUID- ORCID: 0000-0002-6503-7336
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Paragios, Nikos
AU  - Paragios N
AUID- ORCID: 0000-0002-9668-4763
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Martin, Clemence
AU  - Martin C
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
FAU - Revel, Marie-Pierre
AU  - Revel MP
AD  - Department of Radiology (G.C., S.D., M.P.R.) and Respiratory Medicine and
      National Cystic Reference Center (P.R.B.), Groupe Hospitalier Cochin-Hotel Dieu, 
      AP-HP, Universite Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris,
      France; Center for Visual Computing, Ecole CentraleSupelec, Grande Voie des
      Vignes, Chatenay Malabry, France (G.C., E.I.Z., N.P.); U1016 Inserm, Institut
      Cochin, Paris, France (G.C., P.R.B., C.M., M.P.R.); Radiology Department (S.B.)
      and Pulmonary Department (R.C.), Hopital Arnaud de Villeneuve, CHU de
      Montpellier, Universite de Montpellier, Montpellier, France; ERN-Lung CF Network,
      France (P.R.B., C.M.); and TheraPanacea, Paris-Biotech-Sante, Paris, France
      (N.P.).
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - United States
TA  - Radiol Cardiothorac Imaging
JT  - Radiology. Cardiothoracic imaging
JID - 101748663
CIN - Radiol Cardiothorac Imaging. 2020 Dec 17;2(6):e200589. PMID: 33779641
PMC - PMC7977785
COIS- Disclosures of Conflicts of Interest: G.C. disclosed no relevant relationships.
      E.I.Z. disclosed no relevant relationships. S.B. Activities related to the
      present article: disclosed no relevant relationships. Activities not related to
      the present article: disclosed money paid to author's institution from
      AstraZeneca for research protocol on chest CT to predict response to
      Benralizumab; disclosed money paid to author from Boehringer Ingelheim,
      AstraZeneca, and GSK for lectures, including service on speakers bureaus;
      disclosed money paid to author from Boehringer Ingelheim for
      travel/accommodations/meeting expenses unrelated to activities listed. Other
      relationships: disclosed no relevant relationships. P.R.B. Activities related to 
      the present article: disclosed no relevant relationships. Activities not related 
      to the present article: disclosed money paid to author from Vertex and
      AstraZeneca for board membership; disclosed money paid to author from
      AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Insmed, Novartis, Pfizer, Teva,
      Vertex, and Zambon for consultancy. Other relationships: disclosed no relevant
      relationships. R.C. disclosed no relevant relationships. S.D. disclosed no
      relevant relationships. N.P. Activities related to the present article: disclosed
      no relevant relationships. Activities not related to the present article:
      disclosed money paid to author from Artredrone and Easyrescue for board
      membership; disclosed money paid to author from AstraZeneca and Ipsen for
      consultancy; disclosed money paid to author from TheraPanacea for employment.
      Other relationships: disclosed no relevant relationships. C.M. Activities related
      to the present article: disclosed no relevant relationships. Activities not
      related to the present article: disclosed money paid to author from Zambon for
      consultancy; disclosed money paid to author from Chiesi, Vertex, Novartis, ALK,
      Zambon, and Sunpharma for lectures, including service on speakers bureaus. Other 
      relationships: disclosed no relevant relationships. M.P.R. disclosed no relevant 
      relationships.
EDAT- 2021/03/30 06:00
MHDA- 2021/03/30 06:01
CRDT- 2021/03/29 06:44
PHST- 2020/01/31 00:00 [received]
PHST- 2020/09/10 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2021/03/29 06:44 [entrez]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/03/30 06:01 [medline]
AID - 10.1148/ryct.2020200022 [doi]
PST - epublish
SO  - Radiol Cardiothorac Imaging. 2020 Dec 17;2(6):e200022. doi:
      10.1148/ryct.2020200022. eCollection 2020 Dec.


PMID- 33761497
OWN - NLM
STAT- MEDLINE
DCOM- 20211223
LR  - 20211223
IS  - 1422-6421 (Electronic)
IS  - 1422-6405 (Linking)
VI  - 209
IP  - 4-6
DP  - 2020
TI  - Ethical Aspects of Human Embryo Collections: A Historically Grounded Approach to 
      the Blechschmidt Collection at the University of Gottingen.
PG  - 189-199
LID - 10.1159/000513176 [doi]
AB  - Human body donation and tissue collections are nowadays grounded on a legal
      framework centered around the concept of informed consent in most countries.
      Comparable regulations did not exist prior to the second half of the 20th
      century, when several of the most important collections of human embryos were
      established. As a particularly prominent example, the Human Embryology Collection
      ("Blechschmidt Collection") at the Center of Anatomy, University Medical Center
      Gottingen, Germany, is described here with regard to how to approach a human
      specimen collection from the perspective of both collection ethics and the
      history of science. The methods and concepts used as well as the outcome in terms
      of historical and ethical knowledge will be discussed as a model for future
      projects of similar scope at other collection sites. It it also shown that
      general ethical recommendations published by museum and collection experts are of
      value only if they are related to profound knowledge about the history of the
      particular collection in focus.
CI  - (c) 2021 The Author(s) Published by S. Karger AG, Basel.
FAU - Markert, Michael
AU  - Markert M
AD  - Professur fur Materialitat des Wissens, Kunstgeschichtliches Seminar, Universitat
      Gottingen, Gottingen, Germany, michael.markert@uni-goettingen.de.
LA  - eng
PT  - Journal Article
DEP - 20210324
PL  - Switzerland
TA  - Cells Tissues Organs
JT  - Cells, tissues, organs
JID - 100883360
SB  - IM
MH  - *Embryo, Mammalian
MH  - Germany
MH  - Humans
OTO - NOTNLM
OT  - *Collection ethics
OT  - *History of embryology
OT  - *Human remains
OT  - *Tissue collections
EDAT- 2021/03/25 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/03/24 20:22
PHST- 2020/04/27 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/03/24 20:22 [entrez]
AID - 000513176 [pii]
AID - 10.1159/000513176 [doi]
PST - ppublish
SO  - Cells Tissues Organs. 2020;209(4-6):189-199. doi: 10.1159/000513176. Epub 2021
      Mar 24.


PMID- 33747873
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2229-5070 (Print)
IS  - 2229-5070 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Jul-Dec
TI  - A study on intestinal parasitic infections among school children in Karaikal.
PG  - 79-85
LID - 10.4103/tp.TP_42_19 [doi]
AB  - INTRODUCTION: Intestinal parasitic infections (IPIs) play a major role in global 
      disease burden with significant morbidity. The most vulnerable age group was
      school going children and is transmitted through soil. About 90% of infected
      individuals remain asymptomatic. The present study was designed to screen for IPI
      among school children in Karaikal, to identify the asymptomatic infections and to
      assess the type and occurrence of IPIs. METHODOLOGY: A cross-sectional study was 
      carried out from July to September 2018 among school children in the age group of
      6-14 years after getting ethical clearance. A total of 335 single stool samples
      were collected. The samples were subjected to macroscopic examination,
      microscopic examination and subjected to concentration techniques such as salt
      floatation and formal ether sedimentation technique. Two separate fresh stool
      smears were made on the microscopic slides for trichrome and modified acid-fast
      staining. The results were calculated as percentage, frequency/proportion, and
      Chi-square test using IBM SPSS software version 19. RESULTS: Only 90 (28%) out of
      324 stool samples were positive for the presence of intestinal parasites. The
      sensitivity of formal ether sedimentation technique (58%) was higher than other
      techniques. None of the ova of helminths detected. Modified acid-fast staining
      was negative for coccidian parasites. CONCLUSIONS: The low prevalence of
      protozoan parasites and total absence of helminths in the study revealed the
      effective role of nationwide deworming program and Swachh Bharat Abhiyan program.
      However, anthelminthic does not cover the protozoan parasites and it exists among
      asymptomatic healthy population.
CI  - Copyright: (c) 2021 Tropical Parasitology.
FAU - Teja, S Sai
AU  - Teja SS
AD  - Department of Microbiology, JIPMER, Karaikal, India.
FAU - Swarna, S R
AU  - Swarna SR
AD  - Department of Microbiology, JIPMER, Karaikal, India.
FAU - Jeyakumari, D
AU  - Jeyakumari D
AD  - Department of Microbiology, JIPMER, Karaikal, India.
FAU - Kanna, Vignesh
AU  - Kanna V
AD  - Department of Microbiology, JIPMER, Karaikal, India.
LA  - eng
PT  - Journal Article
DEP - 20210125
PL  - India
TA  - Trop Parasitol
JT  - Tropical parasitology
JID - 101580198
PMC - PMC7951065
OTO - NOTNLM
OT  - Children
OT  - helminths
OT  - parasitic intestinal diseases
OT  - protozoan
COIS- There are no conflicts of interest.
EDAT- 2021/03/23 06:00
MHDA- 2021/03/23 06:01
CRDT- 2021/03/22 08:20
PHST- 2019/07/09 00:00 [received]
PHST- 2020/03/21 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2021/03/22 08:20 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/03/23 06:01 [medline]
AID - 10.4103/tp.TP_42_19 [doi]
AID - TP-10-79 [pii]
PST - ppublish
SO  - Trop Parasitol. 2020 Jul-Dec;10(2):79-85. doi: 10.4103/tp.TP_42_19. Epub 2021 Jan
      25.


PMID- 33747872
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2229-5070 (Print)
IS  - 2229-5070 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Jul-Dec
TI  - Prevalence and the factors influencing soil-transmitted helminths among school
      age children (5-14 years age) in a rural area of Coimbatore district.
PG  - 74-78
LID - 10.4103/tp.TP_33_19 [doi]
AB  - CONTEXT: Highest intensity of soil-transmitted helminthiasis (STH) is seen among 
      school age children. AIMS: The aim of this study is to find out the prevalence
      and factors associated with soil-transmitted helminthic infection among school
      age children (5-14 years) in a rural area of Coimbatore district. SETTINGS AND
      DESIGN: The study was conducted in the field practice area of the Rural Health
      Training Centre (RHTC) Vedapatti, Coimbatore. RHTC caters to a total population
      of 23,841 distributed in 14 villages. After getting ethical clearance, five of
      the 14 villages of Vedapatti were selected by the cluster sampling method.
      Totally, 819 participated in the survey conducted between November 2015 and July 
      2016 in the field practice area. SUBJECTS AND METHODS: Structured questionnaire
      was used to collect the information. Consent from parents and assent from child
      were obtained. Totally, 610 gave one adequate stool sample. Early morning samples
      were collected and transported to the laboratory within four hours. Formal ether 
      concentration method was performed, and examination was done. STATISTICAL
      ANALYSIS USED: Data analysis was performed with the SPSS version 19 software. The
      prevalence is expressed in percentage with 95% confidence interval (CI).
      Univariate and multivariate analyses were performed. Strength of association was 
      expressed in terms of odds ratio (OR) and adjusted OR with 95% CI. P < 0.05 was
      considered as statistically significant. RESULTS: The prevalence of STH was 7.70%
      (95% CI: 5.58-9.82). Ascaris lumbricoides was highly prevalent 6.9% (4.89%-8.91%)
      followed by Hook worm 0.7% (0.04%-1.36%), and Trichuris trichura 0.2%
      (0.15%-0.55%). Mulitivariate logistic regression analysis showed that pucca
      houses offered protection against STH. CONCLUSIONS: The prevalence of STH in a
      rural area of Coimbatore is 7.7% (95% CI: 5.58-9.82), and is continuing as a
      public health problem.
CI  - Copyright: (c) 2021 Tropical Parasitology.
FAU - Christu Rajan, V Xavier
AU  - Christu Rajan VX
AD  - Institute of Community Medicine, Madras Medical College, Chennai, Tamil Nadu,
      India.
FAU - Sivamani, M
AU  - Sivamani M
AD  - Department of Community Medicine, PSG Institute of Medical Sciences and Research,
      Coimbatore, Tamil Nadu, India.
FAU - Appalaraju, B
AU  - Appalaraju B
AD  - Department of Microbiology, PSG Institute of Medical Sciences and Research,
      Coimbatore, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
DEP - 20210125
PL  - India
TA  - Trop Parasitol
JT  - Tropical parasitology
JID - 101580198
PMC - PMC7951075
OTO - NOTNLM
OT  - Coimbatore
OT  - prevalence
OT  - school age children
OT  - soil-transmitted helminthiasis
COIS- There are no conflicts of interest.
EDAT- 2021/03/23 06:00
MHDA- 2021/03/23 06:01
CRDT- 2021/03/22 08:20
PHST- 2019/05/22 00:00 [received]
PHST- 2019/11/16 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2021/03/22 08:20 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/03/23 06:01 [medline]
AID - 10.4103/tp.TP_33_19 [doi]
AID - TP-10-74 [pii]
PST - ppublish
SO  - Trop Parasitol. 2020 Jul-Dec;10(2):74-78. doi: 10.4103/tp.TP_33_19. Epub 2021 Jan
      25.


PMID- 33747844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1735-9066 (Print)
IS  - 1735-9066 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Nov-Dec
TI  - The Association between Moral Distress and Moral Courage in Nurses: A
      Cross-Sectional Study in Iran.
PG  - 533-538
LID - 10.4103/ijnmr.IJNMR_156_19 [doi]
AB  - BACKGROUND: Moral distress and moral courage among healthcare professionals have 
      received considerable attention in recent years. However, there is a paucity of
      studies investigating these topics among nurses. Thus, the present study aimed to
      evaluate the association between moral distress and moral courage among nurses in
      an Iranian sample population. MATERIALS AND METHODS: The present cross-sectional 
      study was conducted during February-December 2018. Corley's Moral Distress
      (MDS-R) and Sekerka's moral courage scales were used to collect the data. MDS-R
      is a 21-items scale which includes frequency and intensity ranges from 0 (never) 
      to 4 (very frequently) and 0 (none) to 4 (great extent), respectively. In
      addition, the moral courage scale contains 15 items ranging from "never true" (1 
      point) to "always true" (7 points). In total, 225 eligible nurses were entered
      into this study. Finally, SPSS-16 was used for statistical analysis at the alpha 
      = 0.05 level. RESULTS: The mean scores of the frequency and intensity of moral
      distress and moral courage were 45.41 (95% CI = 43.37-47.45), 44.24 (95% CI =
      42.98-45.42), and 59.63 (95% CI = 58.50-60.87), respectively. Eventually, a
      significant relationship was found between the moral courage and frequency of
      moral distress (r = 0.46, p < 0.001) and the intensity of moral distress (r =
      0.73, p < 0.001). CONCLUSIONS: In general, encouraging healthcare managers and
      administrators is considered as crucial for developing supportive structures and 
      highly sensitive management which promotes moral courage while reducing moral
      distress in nurses' work setting.
CI  - Copyright: (c) 2020 Iranian Journal of Nursing and Midwifery Research.
FAU - Safarpour, Hamid
AU  - Safarpour H
AD  - Department of Nursing, Faculty of Nursing and Midwifery, Ilam University of
      Medical Sciences, Ilam, Iran.
FAU - Ghazanfarabadi, Mohammad
AU  - Ghazanfarabadi M
AD  - Department of Nursing, School of Nursing and Midwifery, Bam University of Medical
      Sciences, Bam, Iran.
FAU - Varasteh, Saeideh
AU  - Varasteh S
AD  - Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Bazyar, Jafar
AU  - Bazyar J
AD  - Department of Nursing, Faculty of Nursing and Midwifery, Ilam University of
      Medical Sciences, Ilam, Iran.
FAU - Fuladvandi, Masoumeh
AU  - Fuladvandi M
AD  - Department of Nursing, School of Nursing and Midwifery, Bam University of Medical
      Sciences, Bam, Iran.
FAU - Malekyan, Leila
AU  - Malekyan L
AD  - Clinical Research Center, Pastor Educational Hospital, Bam University of Medical 
      Sciences, Bam, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - India
TA  - Iran J Nurs Midwifery Res
JT  - Iranian journal of nursing and midwifery research
JID - 101558775
PMC - PMC7968592
OTO - NOTNLM
OT  - Ethics
OT  - Iran
OT  - nursing
OT  - quality of health care
COIS- Nothing to declare.
EDAT- 2021/03/23 06:00
MHDA- 2021/03/23 06:01
CRDT- 2021/03/22 08:20
PHST- 2019/12/01 00:00 [received]
PHST- 2020/08/15 00:00 [revised]
PHST- 2020/09/19 00:00 [accepted]
PHST- 2021/03/22 08:20 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/03/23 06:01 [medline]
AID - 10.4103/ijnmr.IJNMR_156_19 [doi]
AID - IJNMR-25-533 [pii]
PST - epublish
SO  - Iran J Nurs Midwifery Res. 2020 Nov 7;25(6):533-538. doi:
      10.4103/ijnmr.IJNMR_156_19. eCollection 2020 Nov-Dec.


PMID- 33747839
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1735-9066 (Print)
IS  - 1735-9066 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Nov-Dec
TI  - The Impact of Open versus Closed Catheter Access System of Central Venous
      Catheter on Infection Prevention in Critically Ill Patients: A Comparative
      Evaluation.
PG  - 497-501
LID - 10.4103/ijnmr.IJNMR_34_19 [doi]
AB  - BACKGROUND: Use of Central Venous Catheters (CVC) can be associated with
      increased incidence of Catheter-Related Bloodstream Infections (CRBSIs). The
      present study assessed the impact of open versus closed catheter access system of
      CVC on infection prevention in critically sick patients admitted in the Intensive
      Care Unit (ICU). MATERIALS AND METHODS: After obtaining ethical clearance and
      consent of relatives of the patients admitted in ICU of our institute, the
      present study was carried out as a randomized, prospective, double-blind trial
      with parallel group design (of 200 patients in each group). In study group (Group
      I), closed catheter access system (Luer access split septum) was used, while open
      access (three-way) system was used in the control group. Among clinical
      parameters, if any patient developed fever, his/her blood, urine, and tracheal
      secretions were sent for culture and sensitivity. Collected data were analyzed
      using descriptive and inferential statistics. RESULTS: Demographic profile was
      similar in both the groups. Significant clinical and statistical differences were
      observed in blood culture values (chi(2) = 58.30, df = 1, p < 0.001) as well as
      Total Leukocyte Counts (TLC) on day 1, 4, and 8 (F2,260= 80.61, p < 0.001).
      However, no statistically significant (t390= 0.90, p = 0.367) difference was
      found in the duration of hospital stay among patients in both the groups despite 
      significant differences in various clinical parameter. CONCLUSION: Luer access
      split septum connectors along with appropriate training of the nursing personals 
      decrease CRBSI.
CI  - Copyright: (c) 2020 Iranian Journal of Nursing and Midwifery Research.
FAU - Kaur, Davinder
AU  - Kaur D
AD  - Principal, Gian Sagar College of Nursing, RamNagar, Patiala, Punjab, India.
FAU - Jaspal, Surinder
AU  - Jaspal S
AD  - Principal, Guru Nanak College of Nursing, Dahan Kaleran, SBS Nagar, Punjab,
      India.
FAU - Bajwa, Sukhminderjit Singh
AU  - Bajwa SS
AD  - Professor & HOD, Anaesthesiology and Intensive Care Medicine, Gian Sagar Medical 
      College and Hospital, RamNagar, Patiala, Punjab, India.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - India
TA  - Iran J Nurs Midwifery Res
JT  - Iranian journal of nursing and midwifery research
JID - 101558775
PMC - PMC7968585
OTO - NOTNLM
OT  - Bacteremia
OT  - catheter-related infections
OT  - central venous catheters
OT  - intensive care units
COIS- Nothing to declare.
EDAT- 2021/03/23 06:00
MHDA- 2021/03/23 06:01
CRDT- 2021/03/22 08:20
PHST- 2019/03/05 00:00 [received]
PHST- 2019/06/12 00:00 [revised]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2021/03/22 08:20 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/03/23 06:01 [medline]
AID - 10.4103/ijnmr.IJNMR_34_19 [doi]
AID - IJNMR-25-497 [pii]
PST - epublish
SO  - Iran J Nurs Midwifery Res. 2020 Nov 7;25(6):497-501. doi:
      10.4103/ijnmr.IJNMR_34_19. eCollection 2020 Nov-Dec.


PMID- 33732439
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Perceptions of Surrogacy Within the Yoruba Socio-Cultural Context of Ado-Ekiti,
      Nigeria.
PG  - 103
LID - 10.12688/f1000research.20999.3 [doi]
AB  - Background: Surrogacy might be a reproductive process that brings joy and
      fulfilment to many but it also brings with it numerous ethical and legal
      concerns; it raises questions about the fundamental human rights, welfare and
      wellbeing of women and infants especially within a context where it is barely
      regulated. This article examines the perception of surrogacy within the Yoruba
      socio-cultural context in Ado-Ekiti, Nigeria. It brings to the fore various
      socio-cultural concerns that questions the influence of surrogacy as a
      reproductive process on womanhood, motherhood and parenthood. It discusses by
      analysing the narratives of participants how surrogacy process is a dereliction
      of the sacredness and cultural sanctity of the family system, most especially in 
      an African context. Methods: 15 stakeholders (traditional birth attendants and
      gynaecologists) were engaged in an in-depth interview to unravel the challenges
      surrogacy might or is encountering within the socio-cultural context of
      Ado-Ekiti. Results: There are various social, cultural and religious beliefs that
      police the reproductive sphere of the Yoruba socio-cultural group, which has
      grave implications on fertility treatment. These socio-cultural and religious
      factors do not provide a fertile ground for surrogacy to thrive within the study 
      location. Hence, it is important that the socio-cultural framing of reproduction 
      within this cultural context become receptive to medical reproductive solutions
      and innovations if at all the processes are to thrive or at least become less
      stigmatised. Conclusions: The process of surrogacy is very complex and people's
      attitude towards the practice is greatly influenced by their culture, religion
      and social belief systems about what is considered appropriate for procreation.
      Also, it is important to have clear-cut policy regulating surrogacy and all forms
      of ARTs in Nigeria, as this will protect women and infants, as well as, ensure
      that they are not to exposed abuse, commercialization and exploitation.
CI  - Copyright: (c) 2021 Alabi OJ.
FAU - Alabi, Oluwatobi Joseph
AU  - Alabi OJ
AUID- ORCID: 0000-0003-1220-760X
AD  - Department of Sociology, University of Johannesburg, Johannesburg, Gauteng, 2006,
      South Africa.
LA  - eng
SI  - figshare/10.6084/m9.figshare.11120891.v1
SI  - figshare/10.6084/m9.figshare.10264904.v1
PT  - Journal Article
DEP - 20200211
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Attitude
MH  - *Culture
MH  - Doulas
MH  - Female
MH  - *Fertility
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria
MH  - Physicians
MH  - *Religion
MH  - *Surrogate Mothers
PMC - PMC7921890.3
OTO - NOTNLM
OT  - *Surrogacy
OT  - *culture
OT  - *infertility
OT  - *religion.
OT  - *reproduction
COIS- No competing interests were disclosed.
EDAT- 2021/03/23 06:00
MHDA- 2021/04/15 06:00
CRDT- 2021/03/22 08:14
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/03/22 08:14 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - 10.12688/f1000research.20999.3 [doi]
PST - epublish
SO  - F1000Res. 2020 Feb 11;9:103. doi: 10.12688/f1000research.20999.3. eCollection
      2020.


PMID- 33739645
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 10
DP  - 2020 Dec
TI  - [Clinical management of intersex conditions in France].
PG  - 1069-1075
AB  - Clinical management of intersex conditions in france. Although a better
      understanding of the nuances of the spectrum linking the normal to the
      pathological seems to be acquired today, some situations such as intersexuality
      remain problematic and impose legitimate questions about intervention modalities 
      by medical profession. It is characterized by variations in sexual development
      both in the genital organs and overall sexual characteristics. Since the 1950s,
      its clinical management has been based on heavy medical procedures in the first
      years of life and throughout childhood and adolescence. These procedures such as 
      repeated surgical operations, hormonal treatments and vaginal dilations are often
      not agreed by the child. In the early 2000s, there was an emergence of
      associations promoting interests of intersex people and a dissemination of
      intersex testimonies. They aiming to alert the public opinion by showing
      consequences and limitations of early systematic sexual conformation. These
      procedures, practiced and defended today by some specialists, are a subject of
      debate. Therefore, we propose an analysis of ethical stakes of this situation,
      which is part of the current debate on patient care modalities. A reorganisation 
      of care pathway based on a well-reasoned and supervised bio-psycho-social
      approach would therefore emerge. This approach avoids systematic interventionism 
      and allows patients to make free choices.
FAU - Thibault, Lea
AU  - Thibault L
AD  - Espace de reflexion ethique de Normandie, CHU de Caen, Normandie Universite,
      Caen, France.
FAU - Boisgontier, Audrey
AU  - Boisgontier A
AD  - Centre de recherches et d'etudes sur les droits fondamentaux, Universite Paris
      Nanterre, Nanterre, France.
FAU - Charvin, Maud
AU  - Charvin M
AD  - Espace de reflexion ethique de Normandie, CHU de Caen, Normandie Universite,
      Caen, France.
AD  - ANTICIPE, Normandie Universite, Unicaen, Inserm, Caen, France.
FAU - Grandazzi, Guillaume
AU  - Grandazzi G
AD  - Espace de reflexion ethique de Normandie, CHU de Caen, Normandie Universite,
      Caen, France.
AD  - Centre de recherche Risques et vulnerabilites EA 3918, Caen, France.
FAU - Moutel, Gregoire
AU  - Moutel G
AD  - Espace de reflexion ethique de Normandie, CHU de Caen, Normandie Universite,
      Caen, France.
AD  - ANTICIPE, Normandie Universite, Unicaen, Inserm, Caen, France.
LA  - fre
PT  - Journal Article
TT  - Prise en charge de l'intersexuation en France.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Disorders of Sex Development/diagnosis/epidemiology/therapy
MH  - Female
MH  - France/epidemiology
MH  - Genitalia
MH  - Humans
MH  - Sexual Behavior
OTO - NOTNLM
OT  - Case Management
OT  - Disorders of Sex Development
OT  - Ethics, Clinical
COIS- A. Boisgontier, M. Charvin, G. Grandazzi et L. Thibault declarent n'avoir aucun
      lien d'interets. G. Moutel declare etre expert judiciaire pres la cours d'appel
      de Caen.
EDAT- 2021/03/20 06:00
MHDA- 2021/03/24 06:00
CRDT- 2021/03/19 12:36
PHST- 2021/03/19 12:36 [entrez]
PHST- 2021/03/20 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Dec;70(10):1069-1075.


PMID- 33737776
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 0971-3026 (Print)
IS  - 0970-2016 (Linking)
VI  - 30
IP  - 4
DP  - 2020 Oct-Dec
TI  - Native T1 mapping in diffuse myocardial diseases using 3-Tesla MRI: An
      institutional experience.
PG  - 465-472
LID - 10.4103/ijri.IJRI_326_20 [doi]
AB  - AIMS: Newer cardiac magnetic resonance techniques like native T1 mapping are
      being used increasingly as an adjunct to diagnose myocardial diseases with
      fibrosis. However, its full clinical utility has not been tested extensively,
      especially in the Indian population. The purpose of this study was to find native
      T1 values in healthy individuals without cardiac disease in our 3-Tesla MRI
      system and examine whether native myocardial T1 values can be used to
      differentiate between normal and diffuse myocardial disease groups. SUBJECTS AND 
      METHODS: After approval from the institutional ethics committee, native T1
      mapping was performed in 12 healthy individuals without cardiac disease who
      served as controls and in 26 patients with diffuse myocardial diseases (acute
      myocarditis (n = 5), hypertrophic cardiomyopathy (HCM) (n = 8), nonischemic
      dilated cardiomyopathy (DCM) (n = 7), restrictive cardiomyopathy (RCM) due to
      amyloidosis (n = 6)) in a 3-Tesla MRI system in short axis slices and
      four-chamber view using a modified Look-Locker inversion recovery sequence. The
      mean native T1 values and standard deviations were calculated for control and
      disease groups and compared. The ability of native myocardial T1 mapping to
      differentiate between normal and diffuse myocardial disease groups was assessed. 
      One-way ANOVA with Tukey's Post-Hoc test was used to find significant difference 
      in the multivariate analysis and Chi-Square test was used to find the
      significance in categorical data. RESULTS: The native T1 values for the healthy
      group in our 3-Tesla MRI system was 1186.47 +/- 45.67 ms. The mean T1 values of
      the groups acute myocarditis (1418.68 +/- 8.62 ms), HCM (1355.86 +/- 44.67 ms),
      nonischemic DCM (1341.31 +/- 41.48 ms), and RCM due to amyloidosis (1370.37 +/-
      90.14 ms) were significantly higher (P = 0.0005) than that of the healthy control
      group. CONCLUSION: Native myocardial T1 mapping is a promising tool for
      differentiating between healthy and diffuse myocardial disease groups.
CI  - Copyright: (c) 2021 Indian Journal of Radiology and Imaging.
FAU - Mondy, Vimal Chacko
AU  - Mondy VC
AD  - Barnard Institute of Radiology, Madras Medical College, Chennai, Tamil Nadu,
      India.
FAU - Peter, S Babu
AU  - Peter SB
AD  - Barnard Institute of Radiology, Madras Medical College, Chennai, Tamil Nadu,
      India.
FAU - Ravi, R
AU  - Ravi R
AD  - Barnard Institute of Radiology, Madras Medical College, Chennai, Tamil Nadu,
      India.
LA  - eng
PT  - Journal Article
DEP - 20210113
PL  - Germany
TA  - Indian J Radiol Imaging
JT  - The Indian journal of radiology & imaging
JID - 8503873
PMC - PMC7954171
OTO - NOTNLM
OT  - Cardiac magnetic resonance
OT  - cardiomyopathy
OT  - diffuse myocardial disease
OT  - modified look-locker inversion recovery
OT  - native T1 mapping
COIS- There are no conflicts of interest.
EDAT- 2021/03/20 06:00
MHDA- 2021/03/20 06:01
CRDT- 2021/03/19 07:19
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/14 00:00 [revised]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2021/03/19 07:19 [entrez]
PHST- 2021/03/20 06:00 [pubmed]
PHST- 2021/03/20 06:01 [medline]
AID - 10.4103/ijri.IJRI_326_20 [doi]
AID - IJRI-30-465 [pii]
PST - ppublish
SO  - Indian J Radiol Imaging. 2020 Oct-Dec;30(4):465-472. doi:
      10.4103/ijri.IJRI_326_20. Epub 2021 Jan 13.


PMID- 33735015
OWN - NLM
STAT- Publisher
LR  - 20210525
IS  - 2530-3120 (Electronic)
IS  - 2530-3120 (Linking)
DP  - 2020 Nov 12
TI  - Effectiveness of Brief Counseling in a Hospital Setting for Smoking Cessation and
      Risky Alcohol Drinking Reduction: Randomized Clinical Trial Protocol.
LID - S0034-7450(20)30085-8 [pii]
LID - 10.1016/j.rcp.2020.06.005 [doi]
AB  - INTRODUCTION: Chronic diseases are a public health problem, and 80% of them are
      related to modifiable risk factors such as unhealthy diet, physical inactivity,
      smoking, and risky alcohol consumption. Although the intervention in smoking and 
      hazardous alcohol drinking has proven to be effective in Primary Care, it is
      unknown whether it works in the same way in the hospital setting. OBJECTIVE: To
      evaluate the effectiveness of brief counselling in order to modify the stage of
      change in smokers and at-risk drinkers treated in a high complexity hospital.
      METHODS: A Randomised controlled trial to be conducted, in which an evaluation is
      made of four brief counselling strategies for smoking cessation and risky alcohol
      consumption compared to usual care, selected according to the patient's stage of 
      change. The primary result will be the proportion of patients in each of the
      groups (intervention and control) with identified progress in the stage of
      change. The reduction of consumption will be also be analysed. Protocol
      registered at ClinicalTrials.gov (NCT03521622). RESULTS: The results will be
      published in scientific journals, and its application aims to generate
      behavioural intervention protocols for modifiable risk factors in high complexity
      hospitals. The trial was presented and approved by the Ethics and Research
      Committee of the Pontificia Universidad Javeriana and Hospital Universitario de
      San Ignacio, Bogota, Colombia (Approval 01/2018).
CI  - Copyright (c) 2020 Asociacion Colombiana de Psiquiatria. Publicado por Elsevier
      Espana, S.L.U. All rights reserved.
FAU - Almonacid, Ingrid
AU  - Almonacid I
AD  - Departamento de Medicina Preventiva y Social. Pontificia Universidad Javeriana.
      Hospital Universitario de San Ignacio, Bogota, Colombia.
FAU - Olaya, Lina
AU  - Olaya L
AD  - Departamento de Medicina Preventiva y Social. Pontificia Universidad Javeriana.
      Hospital Universitario de San Ignacio, Bogota, Colombia.
FAU - Cuevas, Virginia
AU  - Cuevas V
AD  - Departamento de Medicina Preventiva y Social. Pontificia Universidad Javeriana.
      Hospital Universitario de San Ignacio, Bogota, Colombia.
FAU - Castillo, Juan Sebastian
AU  - Castillo JS
AD  - Departamento de Medicina Preventiva y Social. Pontificia Universidad Javeriana.
      Hospital Universitario de San Ignacio, Bogota, Colombia.
FAU - Becerra, Nelci
AU  - Becerra N
AD  - Departamento de Medicina Preventiva y Social. Pontificia Universidad Javeriana.
      Hospital Universitario de San Ignacio, Bogota, Colombia.
FAU - Delgado, Jimena
AU  - Delgado J
AD  - Programa de promocion y prevencion, Hospital Universitario de San Ignacio,
      Bogota, Colombia.
FAU - Canas, Alejandra
AU  - Canas A
AD  - Departamento de Medicina Interna, Hospital Universitario de San
      Ignacio-Pontificia Universidad Javeriana, Bogota, Colombia.
FAU - Alba, Luz Helena
AU  - Alba LH
AD  - Departamento de Medicina Preventiva y Social. Pontificia Universidad Javeriana.
      Hospital Universitario de San Ignacio, Bogota, Colombia. Electronic address:
      lalba@javeriana.edu.co.
LA  - eng
LA  - spa
SI  - ClinicalTrials.gov/NCT03521622
PT  - Journal Article
TT  - Efectividad de la consejeria breve en el ambito hospitalario para la cesacion del
      tabaquismo y la disminucion del consumo riesgoso de alcohol: Protocolo de un
      experimento clinico aleatorizado.
DEP - 20201112
PL  - Spain
TA  - Rev Colomb Psiquiatr (Engl Ed)
JT  - Revista Colombiana de psiquiatria (English ed.)
JID - 101778593
SB  - IM
OTO - NOTNLM
OT  - Alcohol drinking
OT  - Behaviour
OT  - Comportamiento
OT  - Consejeria medica
OT  - Consumo de bebidas alcoholicas
OT  - Counselling
OT  - Hospitales
OT  - Hospitals
OT  - Tabaquismo
OT  - Tobacco use disorder
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:00
CRDT- 2021/03/18 17:25
PHST- 2019/11/13 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2021/03/18 17:25 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - S0034-7450(20)30085-8 [pii]
AID - 10.1016/j.rcp.2020.06.005 [doi]
PST - aheadofprint
SO  - Rev Colomb Psiquiatr (Engl Ed). 2020 Nov 12. pii: S0034-7450(20)30085-8. doi:
      10.1016/j.rcp.2020.06.005.


PMID- 33734995
OWN - NLM
STAT- Publisher
LR  - 20210525
IS  - 2530-3120 (Electronic)
IS  - 2530-3120 (Linking)
DP  - 2020 Dec 14
TI  - Futility and Palliative Psychiatry in Mental Health: New Clinical and Ethical
      Challenges.
LID - S0034-7450(20)30097-4 [pii]
LID - 10.1016/j.rcp.2020.10.002 [doi]
FAU - Ramos Pozon, Sergio
AU  - Ramos Pozon S
AD  - Escuela de Enfermeria, Universidad de Barcelona, Barcelona, Espana. Electronic
      address: sergioramos@ub.edu.
LA  - eng
LA  - spa
PT  - Letter
TT  - Futilidad y psiquiatria paliativa en salud mental: nuevos desafios clinicos y
      eticos.
DEP - 20201214
PL  - Spain
TA  - Rev Colomb Psiquiatr (Engl Ed)
JT  - Revista Colombiana de psiquiatria (English ed.)
JID - 101778593
SB  - IM
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:00
CRDT- 2021/03/18 17:25
PHST- 2020/09/02 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2021/03/18 17:25 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - S0034-7450(20)30097-4 [pii]
AID - 10.1016/j.rcp.2020.10.002 [doi]
PST - aheadofprint
SO  - Rev Colomb Psiquiatr (Engl Ed). 2020 Dec 14. pii: S0034-7450(20)30097-4. doi:
      10.1016/j.rcp.2020.10.002.


PMID- 33733215
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210320
IS  - 2624-8212 (Electronic)
IS  - 2624-8212 (Linking)
VI  - 3
DP  - 2020
TI  - AI Data-Driven Personalisation and Disability Inclusion.
PG  - 571955
LID - 10.3389/frai.2020.571955 [doi]
AB  - This study aims to help people working in the field of AI understand some of the 
      unique issues regarding disabled people and examines the relationship between the
      terms "Personalisation" and "Classification" with regard to disability inclusion.
      Classification using big data struggles to cope with the individual uniqueness of
      disabled people, and whereas developers tend to design for the majority so
      ignoring outliers, designing for edge cases would be a more inclusive approach.
      Other issues that are discussed in the study include personalising mobile
      technology accessibility settings with interoperable profiles to allow ubiquitous
      accessibility; the ethics of using genetic data-driven personalisation to ensure 
      babies are not born with disabilities; the importance of including disabled
      people in decisions to help understand AI implications; the relationship between 
      localisation and personalisation as assistive technologies need localising in
      terms of language as well as culture; the ways in which AI could be used to
      create personalised symbols for people who find it difficult to communicate in
      speech or writing; and whether blind or visually impaired person will be
      permitted to "drive" an autonomous car. This study concludes by suggesting that
      the relationship between the terms "Personalisation" and "Classification" with
      regards to AI and disability inclusion is a very unique one because of the
      heterogeneity in contrast to the other protected characteristics and so needs
      unique solutions.
CI  - Copyright (c) 2021 Wald.
FAU - Wald, Mike
AU  - Wald M
AD  - University of Southampton, Southampton, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20210118
PL  - Switzerland
TA  - Front Artif Intell
JT  - Frontiers in artificial intelligence
JID - 101770551
PMC - PMC7861332
OTO - NOTNLM
OT  - artificial intelligence
OT  - classification-
OT  - disability
OT  - localisation
OT  - personalisation
COIS- The author declares that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:01
CRDT- 2021/03/18 06:57
PHST- 2020/06/12 00:00 [received]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2021/03/18 06:57 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:01 [medline]
AID - 10.3389/frai.2020.571955 [doi]
AID - 571955 [pii]
PST - epublish
SO  - Front Artif Intell. 2021 Jan 18;3:571955. doi: 10.3389/frai.2020.571955.
      eCollection 2020.


PMID- 33733202
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220322
IS  - 2624-8212 (Electronic)
IS  - 2624-8212 (Linking)
VI  - 3
DP  - 2020
TI  - Artificial Intelligence, Big Data, and mHealth: The Frontiers of the Prevention
      of Violence Against Children.
PG  - 543305
LID - 10.3389/frai.2020.543305 [doi]
AB  - Violence against children is a global public health threat of considerable
      concern. At least half of all children worldwide experience violence every year; 
      globally, the total number of children between the ages of 2 and 17 years who
      have experienced violence in any given year is one billion. Based on a review of 
      the literature, we argue that there is substantial potential for AI (and
      associated machine learning and big data), and mHealth approaches to be utilized 
      to prevent and address violence at a large scale. This potential is particularly 
      marked in low- and middle-income countries (LMIC), although whether it could
      translate into effective solutions at scale remains unclear. We discuss possible 
      entry points for Artificial Intelligence (AI), big data, and mHealth approaches
      to violence prevention, linking these to the World Health Organization's seven
      INSPIRE strategies. However, such work should be approached with caution. We
      highlight clear directions for future work in technology-based and
      technology-enabled violence prevention. We argue that there is a need for good
      agent-based models at the level of entire cities where and when violence can
      occur, where local response systems are. Yet, there is a need to develop common, 
      reliable, and valid population- and individual/family-level data on predictors of
      violence. These indicators could be integrated into routine health or other
      information systems and become the basis of Al algorithms for violence prevention
      and response systems. Further, data on individual help-seeking behavior, risk
      factors for child maltreatment, and other information which could help us to
      identify the parameters required to understand what happens to cause, and in
      response to violence, are needed. To respond to ethical issues engendered by
      these kinds of interventions, there must be concerted, meaningful efforts to
      develop participatory and user-led work in the AI space, to ensure that the
      privacy and profiling concerns outlined above are addressed explicitly going
      forward. Finally, we make the case that developing AI and other technological
      infrastructure will require substantial investment, particularly in LMIC.
CI  - Copyright (c) 2020 Hunt, Tomlinson, Sikander, Skeen, Marlow, du Toit and Eisner.
FAU - Hunt, Xanthe
AU  - Hunt X
AD  - Department of Global Health, Institute for Life Course Health Research,
      Stellenbosch University, Stellenbosch, South Africa.
FAU - Tomlinson, Mark
AU  - Tomlinson M
AD  - Department of Global Health, Institute for Life Course Health Research,
      Stellenbosch University, Stellenbosch, South Africa.
AD  - School of Nursing and Midwifery, Queens University Belfast, Belfast, United
      Kingdom.
FAU - Sikander, Siham
AU  - Sikander S
AD  - Global Health Department, Health Services Academy, Islamabad, Pakistan.
FAU - Skeen, Sarah
AU  - Skeen S
AD  - Department of Global Health, Institute for Life Course Health Research,
      Stellenbosch University, Stellenbosch, South Africa.
FAU - Marlow, Marguerite
AU  - Marlow M
AD  - Department of Global Health, Institute for Life Course Health Research,
      Stellenbosch University, Stellenbosch, South Africa.
FAU - du Toit, Stefani
AU  - du Toit S
AD  - Department of Global Health, Institute for Life Course Health Research,
      Stellenbosch University, Stellenbosch, South Africa.
FAU - Eisner, Manuel
AU  - Eisner M
AD  - Institute of Criminology, University of Cambridge, Cambridge, United Kingdom.
LA  - eng
GR  - K43 TW010399/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201022
PL  - Switzerland
TA  - Front Artif Intell
JT  - Frontiers in artificial intelligence
JID - 101770551
PMC - PMC7861328
OTO - NOTNLM
OT  - LMIC
OT  - artificial intelligence
OT  - big data
OT  - child abuse
OT  - mHealth
OT  - machine learning
OT  - violence
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:01
CRDT- 2021/03/18 06:57
PHST- 2020/03/16 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2021/03/18 06:57 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:01 [medline]
AID - 10.3389/frai.2020.543305 [doi]
PST - epublish
SO  - Front Artif Intell. 2020 Oct 22;3:543305. doi: 10.3389/frai.2020.543305.
      eCollection 2020.


PMID- 33733154
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210320
IS  - 2624-8212 (Electronic)
IS  - 2624-8212 (Linking)
VI  - 3
DP  - 2020
TI  - The Moral Choice Machine.
PG  - 36
LID - 10.3389/frai.2020.00036 [doi]
AB  - Allowing machines to choose whether to kill humans would be devastating for world
      peace and security. But how do we equip machines with the ability to learn
      ethical or even moral choices? In this study, we show that applying machine
      learning to human texts can extract deontological ethical reasoning about "right"
      and "wrong" conduct. We create a template list of prompts and responses, such as 
      "Should I [action]?", "Is it okay to [action]?", etc. with corresponding answers 
      of "Yes/no, I should (not)." and "Yes/no, it is (not)." The model's bias score is
      the difference between the model's score of the positive response ("Yes, I
      should") and that of the negative response ("No, I should not"). For a given
      choice, the model's overall bias score is the mean of the bias scores of all
      question/answer templates paired with that choice. Specifically, the resulting
      model, called the Moral Choice Machine (MCM), calculates the bias score on a
      sentence level using embeddings of the Universal Sentence Encoder since the moral
      value of an action to be taken depends on its context. It is objectionable to
      kill living beings, but it is fine to kill time. It is essential to eat, yet one 
      might not eat dirt. It is important to spread information, yet one should not
      spread misinformation. Our results indicate that text corpora contain recoverable
      and accurate imprints of our social, ethical and moral choices, even with context
      information. Actually, training the Moral Choice Machine on different temporal
      news and book corpora from the year 1510 to 2008/2009 demonstrate the evolution
      of moral and ethical choices over different time periods for both atomic actions 
      and actions with context information. By training it on different cultural
      sources such as the Bible and the constitution of different countries, the
      dynamics of moral choices in culture, including technology are revealed. That is 
      the fact that moral biases can be extracted, quantified, tracked, and compared
      across cultures and over time.
CI  - Copyright (c) 2020 Schramowski, Turan, Jentzsch, Rothkopf and Kersting.
FAU - Schramowski, Patrick
AU  - Schramowski P
AD  - Department of Computer Science, Darmstadt University of Technology, Darmstadt,
      Germany.
FAU - Turan, Cigdem
AU  - Turan C
AD  - Department of Computer Science, Darmstadt University of Technology, Darmstadt,
      Germany.
FAU - Jentzsch, Sophie
AU  - Jentzsch S
AD  - Department of Computer Science, Darmstadt University of Technology, Darmstadt,
      Germany.
AD  - German Aerospace Center (DLR), Institute for Software Technology, Cologne,
      Germany.
FAU - Rothkopf, Constantin
AU  - Rothkopf C
AD  - Institute of Psychology, Darmstadt University of Technology, Darmstadt, Germany.
AD  - Centre for Cognitive Science, Darmstadt University of Technology, Darmstadt,
      Germany.
FAU - Kersting, Kristian
AU  - Kersting K
AD  - Department of Computer Science, Darmstadt University of Technology, Darmstadt,
      Germany.
AD  - Centre for Cognitive Science, Darmstadt University of Technology, Darmstadt,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Switzerland
TA  - Front Artif Intell
JT  - Frontiers in artificial intelligence
JID - 101770551
PMC - PMC7861227
OTO - NOTNLM
OT  - AI
OT  - fairness in machine learning
OT  - machine learning
OT  - moral bias
OT  - natural language processing
OT  - text-embedding models
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:01
CRDT- 2021/03/18 06:57
PHST- 2019/12/02 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2021/03/18 06:57 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:01 [medline]
AID - 10.3389/frai.2020.00036 [doi]
PST - epublish
SO  - Front Artif Intell. 2020 May 20;3:36. doi: 10.3389/frai.2020.00036. eCollection
      2020.


PMID- 33733152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210320
IS  - 2624-8212 (Electronic)
IS  - 2624-8212 (Linking)
VI  - 3
DP  - 2020
TI  - On Consequentialism and Fairness.
PG  - 34
LID - 10.3389/frai.2020.00034 [doi]
AB  - Recent work on fairness in machine learning has primarily emphasized how to
      define, quantify, and encourage "fair" outcomes. Less attention has been paid,
      however, to the ethical foundations which underlie such efforts. Among the
      ethical perspectives that should be taken into consideration is consequentialism,
      the position that, roughly speaking, outcomes are all that matter. Although
      consequentialism is not free from difficulties, and although it does not
      necessarily provide a tractable way of choosing actions (because of the combined 
      problems of uncertainty, subjectivity, and aggregation), it nevertheless provides
      a powerful foundation from which to critique the existing literature on machine
      learning fairness. Moreover, it brings to the fore some of the tradeoffs
      involved, including the problem of who counts, the pros and cons of using a
      policy, and the relative value of the distant future. In this paper we provide a 
      consequentialist critique of common definitions of fairness within machine
      learning, as well as a machine learning perspective on consequentialism. We
      conclude with a broader discussion of the issues of learning and randomization,
      which have important implications for the ethics of automated decision making
      systems.
CI  - Copyright (c) 2020 Card and Smith.
FAU - Card, Dallas
AU  - Card D
AD  - Computer Science Department, Stanford University, Stanford, CA, United States.
FAU - Smith, Noah A
AU  - Smith NA
AD  - Paul G. Allen School of Computer Science & Engineering, University of Washington,
      Seattle, WA, United States.
AD  - Allen Institute for AI, Seattle, WA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200508
PL  - Switzerland
TA  - Front Artif Intell
JT  - Frontiers in artificial intelligence
JID - 101770551
PMC - PMC7861221
OTO - NOTNLM
OT  - consequentialism
OT  - ethics
OT  - fairness
OT  - machine learning
OT  - randomization
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:01
CRDT- 2021/03/18 06:57
PHST- 2020/01/13 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2021/03/18 06:57 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:01 [medline]
AID - 10.3389/frai.2020.00034 [doi]
PST - epublish
SO  - Front Artif Intell. 2020 May 8;3:34. doi: 10.3389/frai.2020.00034. eCollection
      2020.


PMID- 33733146
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210320
IS  - 2624-8212 (Electronic)
IS  - 2624-8212 (Linking)
VI  - 3
DP  - 2020
TI  - Digital Normativity: A Challenge for Human Subjectivation.
PG  - 27
LID - 10.3389/frai.2020.00027 [doi]
FAU - Fourneret, Eric
AU  - Fourneret E
AD  - Inserm and Univ Grenoble Alpes, BrainTech Lab U1205, Gieres, France.
FAU - Yvert, Blaise
AU  - Yvert B
AD  - Inserm and Univ Grenoble Alpes, BrainTech Lab U1205, Gieres, France.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - Switzerland
TA  - Front Artif Intell
JT  - Frontiers in artificial intelligence
JID - 101770551
PMC - PMC7861289
OTO - NOTNLM
OT  - agency
OT  - artificial intelligence
OT  - education
OT  - ethics
OT  - free will (freedom)
OT  - governance
OT  - machine learning
OT  - normativity
EDAT- 2021/03/19 06:00
MHDA- 2021/03/19 06:01
CRDT- 2021/03/18 06:57
PHST- 2019/10/14 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2021/03/18 06:57 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/03/19 06:01 [medline]
AID - 10.3389/frai.2020.00027 [doi]
PST - epublish
SO  - Front Artif Intell. 2020 Apr 28;3:27. doi: 10.3389/frai.2020.00027. eCollection
      2020.


PMID- 33724753
STAT- Publisher
DA  - 20210317
ISBN- 9780367338312
ISBN- 9780367503253
ISBN- 9780429322297
ISBN- 9781000073768
ISBN- 9781000073805
ISBN- 9781000073782
PB  - Routledge
CTI - Wellcome Trust-Funded Monographs and Book Chapters
DP  - 2020 Jun
TI  - Understanding empathy through a study of autistic life writing: On the importance
      of neurodivergent morality
BTI - Neurodiversity Studies: A New Critical Paradigm
PG  - 108-124
LID - 10.4324/9780429322297 [doi]
CP  - Chapter 7
AB  - This chapter provides a critique of medical and literary writing about autism
      that maintains it is characterised by empathy deficits and, as a result, leads to
      morally challenged lives, both for the autistic person and those around them. It 
      draws on a sample of writings by autistic authors, which shows both that autistic
      individuals recognise themselves to be capable of empathy, and, that their moral 
      lives are represented as equally rich and complex as those of any other group of 
      humans. This contrasts with dominant science writing on autism and empathy, which
      relies on a foreshortened sense of the latter and implies that there is a
      benchmark psychological makeup that is both morally valuable and commonplace -
      and of which autistic people are commonly assumed to fall short. This epistemic
      assumption is questioned. While I focus on moral considerations, what I say has
      implications for the ethics of conventional autism theory. Psychologists who
      reinforce an essentialist idea of autism in relation to supposed empathy deficits
      obscure the broader social and environmental contexts in which different
      configurations of empathy occur in all humans. This recentring of autistic - and 
      neurodivergent - morality, is an essential next step for the neurodiversity
      paradigm.
CI  - (c) 2020 selection and editorial matter, Hanna Bertilsdotter Rosqvist, Nick Chown
      and Anna Stenning; individual chapters, the contributors.
FED - Rosqvist, Hanna Bertilsdotter
ED  - Rosqvist HB
FED - Chown, Nick
ED  - Chown N
FED - Stenning, Anna
ED  - Stenning A
FAU - Stenning, Anna
AU  - Stenning A
LA  - eng
GR  - 218124/Wellcome Trust/United Kingdom
PT  - Review
PT  - Book Chapter
PL  - London
EDAT- 2021/03/17 06:01
MHDA- 2021/03/17 06:01
CDAT- 2021/03/17 06:01
AID - NBK568484 [bookaccession]
AID - 10.4324/9780429322297-11 [doi]


PMID- 33723955
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 32
IP  - 5
DP  - 2020 September December
TI  - [Moving beyond the ethical tension of caesarean section on maternal request].
PG  - 497-505
LID - 10.3917/spub.205.0497 [doi]
AB  - INTRODUCTION: In a legal context focused on the right and autonomy of the
      patient, some women wish to be able to choose their mode of childbirth. As
      midwives are primary care-givers for pregnant women with a physiological
      pregnancy, we wanted to find out whether it was ethically acceptable for them to 
      accompany a woman in her decision to have a caesarean section.Purpose of
      research: This survey is an ancillary study of the CESARIA research program
      validated by the Comit&#233; de Protection des Personnes Sud
      M&#233;diterran&#233;e IV and declared to the CNIL. Thirty-seven semi-directive
      interviews were conducted with midwives and women. RESULTS: The majority of women
      and midwives share a vision of childbirth as &#8220;natural&#8221; and consider
      the request for caesarean section as a pathology. When formulated, this request
      places midwives in a situation of ethical tension. On the one hand, midwives wish
      to refer women to vaginal birth as the norm, and this choice embodies the ethical
      principles of beneficence and non-maleficence. On the other hand, midwives
      express a desire to respect patient choice and freedom, illustrating the ethical 
      principle of respect for autonomy. CONCLUSIONS: The ethical issue of caesarean
      section on demand lies not so much in the decision to accept or not to accept a
      caesarean section but rather in listening to the request. Taking into
      consideration a medical indication more broadly than the simple obstetrical
      indication makes it possible to ethically support these requests while respecting
      the pregnant woman&#8217;s autonomy.
FAU - Schantz, Clemence
AU  - Schantz C
FAU - Lhotte, Marie
AU  - Lhotte M
FAU - Pantelias, Anne-Charlotte
AU  - Pantelias AC
LA  - fre
PT  - Journal Article
TT  - Depasser la tension ethique de la cesarienne sur demande maternelle.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - Cesarean Section
MH  - Delivery, Obstetric
MH  - Female
MH  - Humans
MH  - *Midwifery
MH  - *Obstetrics
MH  - Parturition
MH  - Pregnancy
EDAT- 2021/03/17 06:00
MHDA- 2021/03/18 06:00
CRDT- 2021/03/16 07:37
PHST- 2021/03/16 07:37 [entrez]
PHST- 2021/03/17 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.3917/spub.205.0497 [doi]
PST - ppublish
SO  - Sante Publique. 2020 September December;32(5):497-505. doi:
      10.3917/spub.205.0497.


PMID- 33720006
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220502
IS  - 0269-8897 (Print)
IS  - 0269-8897 (Linking)
VI  - 33
IP  - 2
DP  - 2020 Jun
TI  - Why they shared: recovering early arguments for sharing social scientific data.
PG  - 101-119
LID - 10.1017/S0269889720000204 [doi]
AB  - Most social scientists today think of data sharing as an ethical imperative
      essential to making social science more transparent, verifiable, and replicable. 
      But what moved the architects of some of the U.S.'s first university-based social
      scientific research institutions, the University of Michigan's Institute for
      Social Research (ISR), and its spin-off, the Inter-university Consortium for
      Political and Social Research (ICPSR), to share their data? Relying primarily on 
      archived records, unpublished personal papers, and oral histories, I show that
      Angus Campbell, Warren Miller, Philip Converse, and others understood sharing
      data not as an ethical imperative intrinsic to social science but as a useful
      means to the diverse ends of financial stability, scholarly and institutional
      autonomy, and epistemological reproduction. I conclude that data sharing must be 
      evaluated not only on the basis of the scientific ideals its supporters affirm,
      but also on the professional objectives it serves.
FAU - Hauptmann, Emily
AU  - Hauptmann E
AUID- ORCID: 0000-0002-2838-1752
AD  - Western Michigan University E-mail: emily.hauptmann@wmich.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Sci Context
JT  - Science in context
JID - 8904113
MH  - *Dissent and Disputes
MH  - Humans
MH  - *Information Dissemination
MH  - Morals
OTO - NOTNLM
OT  - *Angus Campbell
OT  - *Data sharing
OT  - *Institute for Social Research (ISR)
OT  - *Interuniversity Consortium for Political and Social Research (ICPSR)
OT  - *University of Michigan
OT  - *Warren Miller
OT  - *political science
OT  - *social science history
EDAT- 2021/03/16 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/03/15 12:51
PHST- 2021/03/15 12:51 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
AID - S0269889720000204 [pii]
AID - 10.1017/S0269889720000204 [doi]
PST - ppublish
SO  - Sci Context. 2020 Jun;33(2):101-119. doi: 10.1017/S0269889720000204.


PMID- 33719884
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1087-0415 (Electronic)
IS  - 1081-0730 (Linking)
VI  - 25
IP  - 10
DP  - 2020 Oct 2
TI  - Communication, Health Literacy and a Systems Approach for Mitigating the COVID-19
      Pandemic: The Case for Massive Vaccine Roll-out in Israel.
PG  - 816-818
LID - 10.1080/10810730.2021.1884773 [doi]
AB  - COVID-19 has created global challenges that only an effective vaccine,
      apparently, can lead the citizens of the world back to a sense of normalcy. While
      safe vaccines were developed, tested and approved at an extraordinary pace,
      concerns were raised regarding the public's response in accepting the vaccine on 
      the population level. Israel was among the first countries to roll out a massive 
      national campaign for COVID-19 vaccination, positioning Israel as the global lead
      in vaccine uptake. Priority for vaccination was given to high-risk groups: older 
      and middle-age adults, healthcare workers, senior home residents and caregivers, 
      people with chronic conditions, followed by teachers and soldiers. Contributing
      to the success of the operation thus far has been a systems approach beyond
      nationwide accessibility: building public trust through an integrated and
      familiar health system, a familiar technology (vaccine), transparency regarding
      vaccine safety information, culturally appropriate messages in digital and
      offline media, acknowledging diverse health literacy needs, and active
      participation and role-modeling by political/religious opinion leaders. Vaccine
      resistance and hesitancy may be encountered as the campaign progresses, and
      younger groups targeted. Future considerations include perceived benefits offered
      to people with vaccination and the role of health/digital literacy in
      preparedness policies. Ethical issues regarding the rights of those vaccinated,
      as well as those who have not, are explored.
FAU - Levin-Zamir, Diane
AU  - Levin-Zamir D
AD  - Department of Health Education and Promotion, Clalit Health Services, Tel Aviv,
      Israel.
AD  - School of Public Health, University of Haifa, Haifa, Israel.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Health Commun
JT  - Journal of health communication
JID - 9604100
RN  - 0 (COVID-19 Vaccines)
MH  - COVID-19/*prevention & control
MH  - COVID-19 Vaccines/*therapeutic use
MH  - Culture
MH  - *Health Communication
MH  - *Health Literacy
MH  - Health Personnel/organization & administration/psychology
MH  - Health Priorities
MH  - Health Promotion
MH  - Humans
MH  - Israel
MH  - Leadership
MH  - Middle Aged
MH  - Patient Acceptance of Health Care
MH  - *Systems Analysis
EDAT- 2021/03/16 06:00
MHDA- 2021/04/02 06:00
CRDT- 2021/03/15 12:46
PHST- 2021/03/15 12:46 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
AID - 10.1080/10810730.2021.1884773 [doi]
PST - ppublish
SO  - J Health Commun. 2020 Oct 2;25(10):816-818. doi: 10.1080/10810730.2021.1884773.


PMID- 33717344
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211203
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - Socio-ethical Dimension of COVID-19 Prevention Mechanism-The Triumph of Care
      Ethics.
PG  - 539-550
LID - 10.1007/s41649-020-00143-1 [doi]
AB  - The psycho-social day-to-day experience of COVID-19 pandemic has shone some light
      on the wider scope of health vulnerability and has correspondingly enlarged the
      ethical debate surrounding the social implications of health and healthcare. This
      emerging paradigm is neither a single-handed problem of biomedical scientists nor
      of social analysts. It instead needs a strategically oriented collaborative and
      interdisciplinary preventive effort. To that effect, this article presents some
      socio-ethical reflections underscoring the judicious use of the insight from care
      ethics as an asset in minimizing the possible propagation of the COVID-19 virus
      and the escalation of its vulnerability in the day-to-day human interaction. It
      further emphasizes that if this insight is overlooked, the effects of the diverse
      facets of the "shadow pandemics" of COVID-19-fallouts on both the affected and
      the infected-may equally be deadly.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Dine, Charles Biradzem
AU  - Dine CB
AUID- ORCID: https://orcid.org/0000-0002-1884-0812
AD  - Applied Human Sciences, University of Montreal, Montreal,
      Canada.grid.14848.310000 0001 2292 3357
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747343
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - Care ethics
OT  - Stigmatization
OT  - Vulnerability
COIS- Conflict of interestThe author declares that he has no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00143-1 [doi]
AID - 143 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 12;12(4):539-550. doi: 10.1007/s41649-020-00143-1.
      eCollection 2020 Dec.


PMID- 33717343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211203
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - Ethical Pricing: a Confucian Perspective.
PG  - 419-433
LID - 10.1007/s41649-020-00146-y [doi]
AB  - Based on an analysis of a landmark case Lim Mey Lee Susan v Singapore Medical
      Council in Singapore where a doctor was professionally disciplined for
      over-charging a wealthy patient, a judgement upheld by the Singapore High Court, 
      this paper will discuss the notion of an 'ethical price' (EP) and its
      determination with respect to the provision of healthcare services. It will first
      examine the limitations of a legal approach for setting an ethical limit to
      pricing. From there, it will argue that Confucian philosophy provides a useful
      ethical framework to explore EP, with focus on the context of Singapore. The
      following question is addressed: What is an ethical pricing standard for medical 
      practice from a Confucian perspective? The strengths and limitations of a
      Confucian value base as regards the determination of an objective EP will be
      analysed through an examination of the shortcomings of the doctor's behaviour in 
      the Susan Lim case as well as other case scenarios. The paper will conclude with 
      some practical suggestions on how Confucian-based ideas can be applied to
      decision-making on pricing and the importance of this for medical professionalism
      and ethics teaching.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Wong, Gabriel Hong Zhe
AU  - Wong GHZ
AUID- ORCID: 0000-0003-0002-3598
AD  - Yong Loo Lin School of Medicine, National University of Singapore,
      Singapore.grid.4280.e0000 0001 2180 6431
LA  - eng
PT  - Journal Article
DEP - 20201017
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747314
OTO - NOTNLM
OT  - Confucianism
OT  - Ethical pricing
OT  - Singapore
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/06/29 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00146-y [doi]
AID - 146 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Oct 17;12(4):419-433. doi: 10.1007/s41649-020-00146-y.
      eCollection 2020 Dec.


PMID- 33717342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211203
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - The Pitfalls of Overtreatment: Why More Care is not Necessarily Beneficial.
PG  - 399-417
LID - 10.1007/s41649-020-00145-z [doi]
AB  - Overtreatment refers to interventions that do not benefit the patient, or where
      the risk of harm from the intervention is likely to outweigh any benefit the
      patient will receive. It can account for up to 30% of health care costs, and is
      increasingly recognised as a widespread problem across nations and within
      clinical and scientific communities. There are a number of inter-related factors 
      that drive overtreatment including the expanding definition of diseases,
      advertising and the influence of the pharmaceutical industry, how doctors are
      trained and remunerated, demands from patients (and their families) and the fear 
      of complaints leading doctors to practise defensively. This paper discusses a
      number of ethical and practical issues arising from overtreatment that doctors
      and patients should be aware of. It also considers the flow-on effects of
      overtreatment such as the increased cost of care, increase in work load for
      health professionals, and wastage as resources are diverted from more genuine and
      pressing needs. In addition, there are references to a number of Medical Council 
      of New Zealand statements about what good medical practice means in an
      environment of resource limitation. The paper concludes with a few measures that 
      doctors and patients could take to reduce overtreatment but acknowledges that
      health care is extremely complex so it would be unrealistic to eliminate
      overtreatment entirely.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Ooi, Kanny
AU  - Ooi K
AUID- ORCID: https://orcid.org/0000-0002-2549-6036
AD  - Medical Council of New Zealand, Wellington, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747436
OTO - NOTNLM
OT  - Best practice
OT  - Doctors
OT  - Medical Council of New Zealand
OT  - Overtreatment
OT  - Patients
OT  - Uncertainty
COIS- Conflict of InterestI have been a Senior Policy Adviser and Researcher with the
      Medical Council of New Zealand (MCNZ) since December 2014. MCNZ is responsible
      for registering doctors who practise in New Zealand, and setting standards for
      the way our doctors practise. A large part of my role involves researching and
      writing those standards which are used to assess a doctor's conduct and
      competence. I am often contacted by doctors, patients and members of the public
      about our standards and how they apply to a particular situation. I also
      facilitate consumer panel discussions about our standards so that the needs and
      perspectives of consumers are reflected in the standards we set. In addition, I
      am part of MCNZ's Triage Team that makes initial decisions on how complaints
      about doctors should be handled. I researched and wrote the following MCNZ
      statements mentioned in my paper: * Advertising * Safe practice in an environment
      of resource limitation * Informed consent: helping patients make informed
      decisions about their care. MCNZ endorses Choosing Wisely's campaign, and a
      number of its principles are reflected in our statements including Safe practice 
      in an environment of resource limitation, and Informed consent: helping patients 
      make informed decisions about their care. I was a member of the Editorial Board
      of Cole's medical practice in New Zealand when it was updated in 2017. (Cole's is
      a handbook published by MCNZ for new doctors and doctors new to medical practice 
      in New Zealand.) While my paper references two chapters from Cole's and a number 
      of MCNZ statements, the views expressed in my paper are my own, and are not to be
      attributed to MCNZ.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00145-z [doi]
AID - 145 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 19;12(4):399-417. doi: 10.1007/s41649-020-00145-z.
      eCollection 2020 Dec.


PMID- 33717341
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211203
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - Knowledge, Awareness, Attitudes, and Practices towards Research Ethics and
      Research Ethics Committees among Myanmar Post-graduate Students.
PG  - 379-398
LID - 10.1007/s41649-020-00148-w [doi]
AB  - Health research has increased during the last decade, which has enhanced the
      importance of research ethics. However, little is known regarding the knowledge, 
      awareness, attitudes, and practices of investigators in Myanmar. To assess
      awareness, knowledge, and attitudes of post-graduates regarding research ethics
      and research ethics committees (RECs) and their informed consent practices and to
      determine the association between their responses and certain independent
      factors. We conducted a cross-sectional study using a questionnaire that was
      distributed to a convenience sample of post-graduates at the Defence Services
      Medical Academy in Myanmar. We used descriptive, t test, and chi-square
      statistics to analyze the data. Significance was set at p < 0.05. We obtained
      surveys from 204 participants, which included 177 MSc and 27 PhDs of whom 63.6%
      had performed research and 86.5% had prior ethics training. Regarding awareness, 
      92.2% were aware of an REC at their academy, but only 47.1% were "fully aware" of
      the functions of an REC and only 52.9% stated they were familiar with ethical
      principles that govern human subject research. More than 90% thought that
      research involving human subjects should be submitted to an REC and that
      post-graduates should have training on research ethics. However, several of their
      attitudes were sub-optimal; for example, 20.2% said that informed consent is only
      necessary from the community leader of a village rather than from the individual,
      32.8% agreed it is acceptable to fabricate research data, and 33.0% believed that
      ethical review of research should be restricted to international collaborative
      research. Calculated mean total attitude scores were statistically significantly 
      higher in post-graduates with PhDs compared with those with MSc and higher in
      those with knowledge of research ethics principles compared with those lacking
      such knowledge. Significant gaps exist among post-graduates regarding their
      knowledge, awareness, and attitudes regarding research ethics and RECs. We
      recommend that post-graduates receive further training in research ethics to
      ensure the ethical conduct of research. Further studies should be performed to
      determine the generalizability of our findings to other institutions in Myanmar.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Than, Mo Mo
AU  - Than MM
AD  - Department of Biochemistry, Defence Services Medical Academy, Yangon, Myanmar.
FAU - Htike, Hein
AU  - Htike H
AD  - Department of Biochemistry, Defence Services Medical Academy, Yangon, Myanmar.
FAU - Silverman, Henry J
AU  - Silverman HJ
AUID- ORCID: 0000-0003-3320-4328
AD  - University of Maryland Baltimore School of Medicine, Baltimore, MD
      USA.grid.411024.20000 0001 2175 4264
LA  - eng
GR  - R25 TW010516/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200926
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747287
OTO - NOTNLM
OT  - Myanmar
OT  - Post-graduates
OT  - Research ethics
OT  - Research ethics committees
COIS- Conflict of InterestAll authors declare that they have no competing interests.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2020/07/31 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00148-w [doi]
AID - 148 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Sep 26;12(4):379-398. doi: 10.1007/s41649-020-00148-w.
      eCollection 2020 Dec.


PMID- 33717340
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210903
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Sep
TI  - Framing Ethical Concerns and Attitudes towards Human Gene Patents in the Chinese 
      Press.
PG  - 307-323
LID - 10.1007/s41649-020-00136-0 [doi]
AB  - This study examines the representations of human gene patents in Chinese
      newspapers. We conducted a qualitative content analysis of news articles
      published between 2006 and 2017 to identify the major themes in media coverage,
      ethical considerations, perceptions of risks and benefits, and attitudes towards 
      the patentability of human genes. The results show that two key ethical concerns 
      were expressed by journalists: (1) that it is morally wrong to own or patent
      human genes and (2) that gene patents could potentially impede patients' access
      to healthcare services. Nonetheless, the press coverage has tended to be largely 
      favorable (57.8%), rather than opposed (17.8%) to human gene patenting. There
      were no normative claims that human genes should not be patentable in China,
      which indicates a generally positive attitude towards patentability in media
      discourse. Most articles that expressed criticism toward gene patenting discussed
      challenges in other countries, with significant attention given to the United
      States Supreme Court's ruling in the Myriad case that invalidated Myriad
      Genetics' patents on the BRCA1 and BRCA2 genes. Overall, the newspapers were
      uncritical of the Chinese gene patenting regime. News reporting on the issue was 
      highly suggestive of a strong pro-commercialization stance, although some
      discussions emphasized potential risks over benefits. Our analysis highlights the
      need for balanced media reporting on human gene patents in China and a top-down
      approach to engage the public in substantive discussions on the ethical and
      societal implications of the existing patent regime.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Du, Li
AU  - Du L
AUID- ORCID: https://orcid.org/0000-0003-0463-5241
AD  - Faculty of Law, University of Macau, Taipa, Macau SAR.
FAU - Lin, Sijie
AU  - Lin S
AD  - Faculty of Law, University of Macau, Taipa, Macau SAR.
AD  - C&C Lawyers & Notaries, Macau, Macau SAR.
FAU - Kamenova, Kalina
AU  - Kamenova K
AUID- ORCID: https://orcid.org/0000-0003-2894-388X
AD  - Canadian Institute for Genomics and Society, Toronto, Ontario Canada.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747419
OTO - NOTNLM
OT  - Chinese newspapers
OT  - Content analysis
OT  - Human gene patents
OT  - Patentability
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00136-0 [doi]
AID - 136 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 1;12(3):307-323. doi: 10.1007/s41649-020-00136-0.
      eCollection 2020 Sep.


PMID- 33717338
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210903
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Sep
TI  - Post-mortem Reproduction from a Vietnamese Perspective-an Analysis and
      Commentary.
PG  - 257-288
LID - 10.1007/s41649-020-00137-z [doi]
AB  - Post-mortem reproduction is a complex and contested matter attracting attention
      from a diverse group of scholars and resulting in various responses from a range 
      of countries. Vietnam has been reluctant to deal directly with this matter and
      has, accordingly, permitted post-mortem reproduction implicitly. First, by
      analysing Vietnam's post-mortem reproduction cases, this paper reflects on the
      manner in which Vietnamese authorities have handled each case in the context of
      the contemporary legal framework, and it reveals the moral questions arising
      therefrom. The article then offers an account of Vietnamese social norms as an
      explanation for the tendency to conduct post-mortem reproduction. In arguing that
      a deeper and more thorough examination of the moral and ethical reasoning is
      required, the paper advocates in favour of supportive post-mortem reproduction
      regulation. In doing so, the paper seeks to reconcile the Vietnamese legal
      framework and post-mortem reproduction experiences of other countries. The
      article concludes that Vietnam and countries sharing the similar cultural traits 
      should permit post-mortem reproduction explicitly. This would require full
      engagement with the ethical and legal issues arising, and careful promulgation of
      regulations and guidelines based on comparative experiences of a range of
      countries in handling this matter.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Doan, Hai Thanh
AU  - Doan HT
AUID- ORCID: https://orcid.org/0000-0002-1365-0761
AD  - University of Economics and Law, Vietnam National University Ho Chi Minh, Ho Chi 
      Minh, Vietnam.grid.444808.40000 0001 2037 434X
FAU - Doan, Diep Thi Phuong
AU  - Doan DTP
AD  - University of Economics and Law, Vietnam National University Ho Chi Minh, Ho Chi 
      Minh, Vietnam.grid.444808.40000 0001 2037 434X
FAU - Duong, Nguyen Kim The
AU  - Duong NKT
AD  - University of Economics Ho Chi Minh, Ho Chi Minh, Vietnam.grid.444827.90000 0000 
      9009 5680
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747272
OTO - NOTNLM
OT  - Confucianism
OT  - Post-mortem reproduction
OT  - Post-mortem sperm retrieval
OT  - Vietnamese indigenous belief
OT  - Vietnamese legal system
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00137-z [doi]
AID - 137 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 6;12(3):257-288. doi: 10.1007/s41649-020-00137-z.
      eCollection 2020 Sep.


PMID- 33717337
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - An Ethical Analysis of the 'Ayushman Bharat-Pradhan Mantri Jan Arogya Yojna
      (PM-JAY)' Scheme using the Stakeholder Approach to Universal Health Care in
      India.
PG  - 195-203
LID - 10.1007/s41649-020-00121-7 [doi]
AB  - This paper analyses the ethical considerations using the stakeholder theory on
      two specific domains of the newly implemented 'Ayushman Bharat-Pradhan Mantri Jan
      Arogya Yojna (PM-JAY)' scheme by the Government of India. The paper recommends a 
      solidarity-based approach over an entitlement based one that focuses on
      out-of-pocket expenses for the most vulnerable and a stewardship role from the
      private sector to ensure equity, accountability, and sustainability of PM-JAY
      scheme.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Dholakia, Saumil
AU  - Dholakia S
AUID- ORCID: https://orcid.org/0000-0003-2445-1466
AD  - Geriatric Clinical Psychopharmacology and Geriatric Psychiatry, GeriMedRisk, St. 
      Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON
      Canada.grid.25073.330000 0004 1936 8227
AD  - Joint Centre for Bioethics, Dalla Lana School of Public Health, University of
      Toronto, Toronto, ON Canada.grid.17063.330000 0001 2157 2938
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747257
OTO - NOTNLM
OT  - Health System
OT  - India
OT  - PM-JAY
OT  - Stake-holder approach
OT  - Universal Health Care
COIS- Conflict of InterestThe author declares that he has no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/07/29 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00121-7 [doi]
AID - 121 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 27;12(2):195-203. doi: 10.1007/s41649-020-00121-7.
      eCollection 2020 Jun.


PMID- 33717336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - What Does It Mean for a Case to be 'Local'?: the Importance of Local Relevance
      and Resonance for Bioethics Education in the Asia-Pacific Region.
PG  - 173-194
LID - 10.1007/s41649-020-00120-8 [doi]
AB  - Contemporary bioethics education has been developed predominately within
      Euro-American contexts, and now, other global regions are increasingly joining
      the field, leading to a richer global understanding. Nevertheless, many standard 
      bioethics curriculum materials retain a narrow geographic focus. The purpose of
      this article is to use local cases from the Asia-Pacific region as examples for
      exploring questions such as 'what makes a case or example truly local, and why?',
      'what topics have we found to be best explained through local cases or
      examples?', and 'how does one identify a relevant local case?' Furthermore, we
      consider the global application of local cases to help extend the possible scope 
      of the discussion, opening new avenues for the development of practical bioethics
      educational materials. We begin with a background description and discussion of
      why local cases enhance bioethics education, move to an overview of what is
      currently available and what is not for the region, and then outline a discussion
      of what it means to be local using example cases drawn from Hong Kong, Australia,
      Pakistan, and Malaysia. We are not creating a casebook but rather constructing by
      example a toolbox for designing active and dynamic learning cases using regional 
      diversity as contextualised cases with generalised principles.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Bergstresser, Sara M
AU  - Bergstresser SM
AUID- ORCID: https://orcid.org/0000-0001-7667-2426
AD  - Office of Medical Education, Faculty of Medicine, The Chinese University of Hong 
      Kong, Hong Kong SAR.
AD  - Columbia University, New York, NY United States of
      America.grid.21729.3f0000000419368729
FAU - Ghias, Kulsoom
AU  - Ghias K
AD  - Department of Biological and Biomedical Sciences, Medical College, Aga Khan
      University, Karachi, Pakistan.grid.7147.50000 0001 0633 6224
FAU - Lane, Stuart
AU  - Lane S
AD  - Sydney Medical School, University of Sydney, Sydney, NSW
      Australia.grid.1013.30000 0004 1936 834X
FAU - Lau, Wee-Ming
AU  - Lau WM
AD  - Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia,
      Bandar Sunway, Selangor Malaysia.grid.440425.3
FAU - Hwang, Isabel S S
AU  - Hwang ISS
AD  - School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong
      SAR.
FAU - Ngan, Olivia M Y
AU  - Ngan OMY
AD  - Office of Medical Education, Faculty of Medicine, The Chinese University of Hong 
      Kong, Hong Kong SAR.
AD  - CUHK Centre for Bioethics, Faculty of Medicine, The Chinese University of Hong
      Kong, Hong Kong SAR.
FAU - Klitzman, Robert L
AU  - Klitzman RL
AD  - Columbia University, New York, NY United States of
      America.grid.21729.3f0000000419368729
FAU - Ng, Ho Keung
AU  - Ng HK
AD  - Office of Medical Education, Faculty of Medicine, The Chinese University of Hong 
      Kong, Hong Kong SAR.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747335
OTO - NOTNLM
OT  - Australia
OT  - Hong Kong
OT  - Malaysia
OT  - Pakistan
OT  - Teaching ethics
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/08/29 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00120-8 [doi]
AID - 120 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 30;12(2):173-194. doi: 10.1007/s41649-020-00120-8.
      eCollection 2020 Jun.


PMID- 33717334
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - Non-commercial Surrogacy in Thailand: Ethical, Legal, and Social Implications in 
      Local and Global Contexts.
PG  - 135-147
LID - 10.1007/s41649-020-00126-2 [doi]
AB  - In this paper, the ethical, legal, and social implications of Thailand's
      surrogacy regulations from both domestic and global perspectives are explored.
      Surrogacy tourism in Thailand has expanded since India strengthened its visa
      regulations in 2012. In 2015, in the wake of a major scandal surrounding the
      abandonment of a surrogate child by its foreign intended parents, a law
      prohibiting the practice of surrogacy for commercial purposes was enacted.
      Consequently, a complete ban on surrogacy tourism was imposed. However, some Thai
      physicians and surrogate mothers cross into neighboring countries to provide
      foreign clients with the commercial surrogacy services that are forbidden in
      Thailand. Under this legislation, the needs of Thai couples who are unable to
      conceive are accommodated by legally accessible, non-commercial surrogacy
      services; however, there is currently no provision in place aimed at protecting
      the rights and interests of surrogate mothers and children. It is widely believed
      that the abolition of surrogacy tourism, an industry that give rise to several
      major scandals, and legal access to surrogacy by Thai couples were the Thai
      government's primary goal in implementing this legislation.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Hibino, Yuri
AU  - Hibino Y
AUID- ORCID: https://orcid.org/0000-0002-9492-5375
AD  - Department of Medical Science, Environmental and Preventive Medicine, Kanazawa
      University, Kanazawa City, Japan.grid.9707.90000 0001 2308 3329
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747428
OTO - NOTNLM
OT  - ELSI
OT  - Global
OT  - Local
OT  - Surrogacy
OT  - Thailand
COIS- Conflict of interestThe author declares that she has no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/03/09 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00126-2 [doi]
AID - 126 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 29;12(2):135-147. doi: 10.1007/s41649-020-00126-2.
      eCollection 2020 Jun.


PMID- 33717333
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - Will Confucian Values Help or Hinder the Crisis of Elder Care in Modern
      Singapore?
PG  - 117-134
LID - 10.1007/s41649-020-00123-5 [doi]
AB  - The unique mix of modern Western and traditional Confucian values in Singapore
      presents young people with contradictory views on duties to aging parents. It
      remains to be seen whether the changing demands of modern life will result in new
      generations giving up Confucian family ethics or whether the Confucian dynamic
      will find a way to adapt to the new pressures. It is the opinion of this author
      that the Confucian family structure has mixed potential for the growing crisis of
      elder care. Alone, both Confucian traditions and typical Western institutional
      approaches toward elder care fall short of what is necessary for
      intergenerational social justice, yet a hybrid of the two has great potential for
      the growing aging crisis. To demonstrate this, I first give a brief account of
      the history of filial piety in Confucianism as well as the social environment
      from which it originated. Then I turn my attention to the present issues of an
      aging population and elder care that face much of the developed world in the
      twenty-first century. Finally, I show how adherence to Confucian filial
      traditions can both help to address many of these issues and how it can
      potentially leave unjust gaps in elder care. Ultimately, I conclude that the
      crisis of elder care may be best dealt with through a hybrid of Confucian values 
      and Western approaches.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Muyskens, Kathryn
AU  - Muyskens K
AUID- ORCID: https://orcid.org/0000-0001-8506-0659
AD  - Nanyang Technological University, Singapore, Singapore.grid.59025.3b0000 0001
      2224 0361
LA  - eng
PT  - Journal Article
DEP - 20200524
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747315
OTO - NOTNLM
OT  - Elder care
OT  - Filial piety
OT  - Singapore
OT  - Social justice
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/07/14 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00123-5 [doi]
AID - 123 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 24;12(2):117-134. doi: 10.1007/s41649-020-00123-5.
      eCollection 2020 Jun.


PMID- 33717332
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - The Ethics of the Reuse of Disposable Medical Supplies.
PG  - 103-116
LID - 10.1007/s41649-020-00114-6 [doi]
AB  - The use of single-use items (SUDs) is now ubiquitous in medical practice. Because
      of the high costs of these items, the practice of reusing them after
      sterilisation is also widespread especially in resource-poor economies. However, 
      the ethics of reusing disposable items remain unclear. There are several
      analogous conditions, which could shed light on the ethics of reuse of
      disposables. These include the use of restored kidney transplantation and the use
      of generic drugs etc. The ethical issues include the question of patient safety
      and the possibility of infection. It is also important to understand the role (or
      otherwise) of informed consent before reuse of disposables. The widespread
      practice of reuse may bring down high healthcare costs and also reduce the huge
      amount of hospital waste that is generated. The reuse of disposables can be
      justified on various grounds including the safety and the cost effectiveness of
      this practice.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Das, Anjan Kumar
AU  - Das AK
AUID- ORCID: https://orcid.org/0000-0001-6318-4669
AD  - School of Medicine, Faculty of Health and Medical Sciences, Taylor's University, 
      Subang Jaya, Selangor Malaysia.grid.452879.50000 0004 0647 0003
FAU - Okita, Taketoshi
AU  - Okita T
AUID- ORCID: https://orcid.org/0000-0002-0233-6451
AD  - Department of Medical Ethics, Tohoku University Graduate School of Medicine
      Sendai, Sendai, Japan.grid.69566.3a0000 0001 2248 6943
FAU - Enzo, Aya
AU  - Enzo A
AUID- ORCID: https://orcid.org/0000-0002-2359-9111
AD  - Department of Medical Ethics, Tohoku University Graduate School of Medicine
      Sendai, Sendai, Japan.grid.69566.3a0000 0001 2248 6943
FAU - Asai, Atsushi
AU  - Asai A
AD  - Department of Medical Ethics, Tohoku University Graduate School of Medicine
      Sendai, Sendai, Japan.grid.69566.3a0000 0001 2248 6943
LA  - eng
PT  - Journal Article
DEP - 20200412
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747311
OTO - NOTNLM
OT  - Disposables reuse
OT  - Health inequality
OT  - Healthcare cost
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2018/12/18 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00114-6 [doi]
AID - 114 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Apr 12;12(2):103-116. doi: 10.1007/s41649-020-00114-6.
      eCollection 2020 Jun.


PMID- 33717331
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - Ethical Practices and Legal Challenges in Mental Health Research.
PG  - 87-102
LID - 10.1007/s41649-020-00116-4 [doi]
AB  - Considerations of justice and concern for well-being support conducting mental
      health research and addressing ethical concerns specific to mental health
      research are critical. We discuss these concerns, provide recommendations to
      enable the ethical conduct of mental health research, and argue that
      participants' interests should be given primary weight in resolving apparent
      dilemmas. We also comment on provisions of two legislative actions in India
      relevant to mental health research: Rights of Persons with Disability Act 2016
      and the Mental Health Care Act 2017. Both conform to the 2006 United Nations
      Convention on Rights of Persons with Disabilities of which India is a signatory. 
      Both provide protections and enumerate rights relevant to people with mental
      health conditions but with differing focus. The commonalities and differences
      between the three are discussed in the background of international literature on 
      research in mental health conditions. Studies involving deception and future
      directions for ethical requirements regarding genetic research are discussed.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Deshpande, Smita N
AU  - Deshpande SN
AUID- ORCID: 0000-0001-7770-9657
AD  - Centre of Excellence in Mental Health, Atal Bihari Vajpayee Institute of Medical 
      Sciences, Dr. Ram Manohar Lohia Hospital, New Delhi, India.grid.414117.60000 0004
      1767 6509
AD  - Department of Psychiatry, Centre of Excellence in Mental Health, Atal Bihari
      Vajpayee Institute of Medical Sciences, Dr. Ram Manohar Lohia Hospital, New
      Delhi, India.grid.414117.60000 0004 1767 6509
FAU - Nimgaonkar, Vishwajit L
AU  - Nimgaonkar VL
AD  - Program for Genetics and Psychosis, Department of Psychiatry and Department of
      Genetics, University of Pittsburgh, Pittsburgh, PA USA.grid.21925.3d0000 0004
      1936 9000
FAU - Bhatia, Triptish
AU  - Bhatia T
AD  - Indo-US Projects, Centre of Excellence in Mental Health, Atal Bihari Vajpayee
      Institute of Medical Sciences, Dr. Ram Manohar Lohia Hospital, New Delhi,
      India.grid.414117.60000 0004 1767 6509
FAU - Mishra, Nagendra Narayan
AU  - Mishra NN
AD  - Department of Psychology, Langat Singh College, Muzaffarpur, Bihar
      India.grid.459403.f0000 0004 1803 2406
FAU - Nagpal, Rajesh
AU  - Nagpal R
AD  - Manobal Klinik, New Delhi, India.
FAU - Parker, Lisa S
AU  - Parker LS
AD  - Center for Bioethics & Health Law, University of Pittsburgh, Pittsburgh, PA
      USA.grid.21925.3d0000 0004 1936 9000
LA  - eng
GR  - D43 TW006167/TW/FIC NIH HHS/United States
GR  - D43 TW009114/TW/FIC NIH HHS/United States
GR  - R01 TW008289/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200525
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747337
OTO - NOTNLM
OT  - Decisional capacity
OT  - Mental health care
OT  - Mental health condition
OT  - Mental health research
OT  - Rights of persons with disability
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/05/09 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00116-4 [doi]
AID - 116 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 25;12(2):87-102. doi: 10.1007/s41649-020-00116-4.
      eCollection 2020 Jun.


PMID- 33717329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Mar
TI  - Some Unresolved Ethical Challenges in Healthcare Decision-Making: Navigating
      Family Involvement.
PG  - 27-36
LID - 10.1007/s41649-020-00111-9 [doi]
AB  - Family involvement in healthcare decision-making for competent patients occurs to
      varying degrees in many communities around the world. There are different
      attitudes about who should make treatment decisions, how and why. Legal and
      professional ethics codes in most jurisdictions reflect and support the idea that
      competent patients should be enabled to make their own treatment decisions, even 
      if others, including their healthcare professionals, disagree with them. This way
      of thinking contrasts with some cultural norms that put more emphasis on the
      family as a decision-making entity, in some circumstances to the exclusion of a
      competent patient. Possible tensions may arise between various combinations of
      patient, family members and healthcare professionals, and healthcare
      professionals must tread a careful path in navigating family involvement in the
      decision-making process. These tensions may be about differences of opinion about
      which treatment option is best and/or on who should have a say or influence in
      the decision-making process. While some relevant cultural, legal and policy
      considerations vary from community to community, there are ethical issues that
      healthcare professionals need to grapple with in balancing the laws and
      professional codes on decision-making and the ethical principle of respecting
      patients and their autonomy. This paper will highlight and propose that a partial
      resolution to these issues may lie in relational understandings of autonomy,
      which in principle justify interventions by healthcare professionals and family
      that support patients in decision-making.
CI  - (c) The Author(s) 2020.
FAU - Menon, Sumytra
AU  - Menon S
AUID- ORCID: https://orcid.org/0000-0001-9129-4072
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Entwistle, Vikki A
AU  - Entwistle VA
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Campbell, Alastair V
AU  - Campbell AV
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - van Delden, Johannes J M
AU  - van Delden JJM
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, Netherlands.grid.7692.a0000000090126352
LA  - eng
PT  - Journal Article
DEP - 20200305
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747266
OTO - NOTNLM
OT  - Competent patient
OT  - Decision-making
OT  - Family involvement
OT  - Relational autonomy
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00111-9 [doi]
AID - 111 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Mar 5;12(1):27-36. doi: 10.1007/s41649-020-00111-9.
      eCollection 2020 Mar.


PMID- 33717328
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Mar
TI  - Why have Non-communicable Diseases been Left Behind?
PG  - 5-25
LID - 10.1007/s41649-020-00112-8 [doi]
AB  - Non-communicable diseases are no longer largely limited to high-income countries 
      and the elderly. The burden of non-communicable diseases is rising across all
      country income categories, in part because these diseases have been relatively
      overlooked on the global health agenda. Historically, communicable diseases have 
      been prioritized in many countries as they were perceived to constitute the
      greatest disease burden, especially among vulnerable and poor populations, and
      strategies for prevention and treatment, which had been successful in high-income
      settings, were considered feasible and often affordable in low-income settings.
      This prioritization has reduced the communicable diseases burden globally but has
      left non-communicable diseases largely neglected. A new approach is urgently
      needed to tackle non-communicable diseases. Based on an analysis of potential
      features which may have underlain the different approaches to non-communicable
      diseases and communicable diseases until now, including acuity of disease,
      potential for control or cure, cost, infectiousness, blaming of individuals and
      logistical barriers, little ethical or rational justification can be found to
      support continued neglect of non-communicable diseases. Justice demands access to
      quality and affordable care for all. An equitable approach to non-communicable
      diseases is therefore strongly mandated on medical, ethical, economic, and public
      health grounds. Funding must not however be diverted away from communicable
      diseases, which continue to require attention-but concomitantly, funding for
      non-communicable diseases must be increased. International and multi-sectoral
      action is required to accelerate progress towards true universal health coverage 
      and towards achievement of all of the sustainable development goals, such that
      prevention and access to care for non-communicable disease can become a global
      reality.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Luna, Florencia
AU  - Luna F
AD  - Programa de Bioetica, Area Etica, Derechos y Bienes Publicos Globales, Facultad
      Latinoamericana de Ciencias Sociales (FLACSO), Buenos Aires,
      Argentina.grid.466676.30000 0001 2292 6259
FAU - Luyckx, Valerie A
AU  - Luyckx VA
AD  - Institute for Biomedical Ethics and the History of Medicine, University of
      Zurich, Zurich, Switzerland.grid.7400.30000 0004 1937 0650
AD  - Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 
      USA.grid.38142.3c000000041936754X
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747415
OTO - NOTNLM
OT  - Equity
OT  - Ethics
OT  - Justice
OT  - Non-communicable diseases
OT  - Public health
COIS- Competing InterestsThe authors declare that they have no competing interests.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
CRDT- 2021/03/15 07:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2021/03/15 07:00 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
AID - 10.1007/s41649-020-00112-8 [doi]
AID - 112 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Mar 20;12(1):5-25. doi: 10.1007/s41649-020-00112-8.
      eCollection 2020 Mar.


PMID- 33708381
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Effective image visualization for publications - a workflow using open access
      tools and concepts.
PG  - 1373
LID - 10.12688/f1000research.27140.2 [doi]
AB  - Today, 25% of figures in biomedical publications contain images of various types,
      e.g. photos, light or electron microscopy images, x-rays, or even sketches or
      drawings. Despite being widely used, published images may be ineffective or
      illegible since details are not visible, information is missing or they have been
      inappropriately processed. The vast majority of such imperfect images can be
      attributed to the lack of experience of the authors as undergraduate and graduate
      curricula lack courses on image acquisition, ethical processing, and
      visualization. Here we present a step-by-step image processing workflow for
      effective and ethical image presentation. The workflow is aimed to allow novice
      users with little or no prior experience in image processing to implement the
      essential steps towards publishing images. The workflow is based on the open
      source software Fiji, but its principles can be applied with other software
      packages. All image processing steps discussed here, and complementary
      suggestions for image presentation, are shown in an accessible "cheat
      sheet"-style format, enabling wide distribution, use, and adoption to more
      specific needs.
CI  - Copyright: (c) 2021 Schmied C and Jambor HK.
FAU - Schmied, Christopher
AU  - Schmied C
AUID- ORCID: 0000-0003-2058-1124
AD  - Leibniz-Forschungsinstitut fur Molekulare Pharmakologie im Forschungsverbund
      Berlin e.V. (FMP), Berlin, Germany.
FAU - Jambor, Helena Klara
AU  - Jambor HK
AUID- ORCID: 0000-0003-3397-1842
AD  - Mildred-Scheel Early Career Center, Medical Faculty, Technische Universitat
      Dresden, Dresden, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - *Access to Information
MH  - Fiji
MH  - *Image Processing, Computer-Assisted
MH  - Software
MH  - Workflow
PMC - PMC7931257.2
OTO - NOTNLM
OT  - *Beginner's workflow
OT  - *FIJI
OT  - *Good principles of figure design
OT  - *Image Publication
OT  - *Image analysis
OT  - *Image processing
OT  - *Visualization
OT  - *open source
COIS- No competing interests were disclosed.
EDAT- 2021/03/16 06:00
MHDA- 2021/05/18 06:00
CRDT- 2021/03/15 07:01
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/03/15 07:01 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.12688/f1000research.27140.2 [doi]
PST - epublish
SO  - F1000Res. 2020 Nov 26;9:1373. doi: 10.12688/f1000research.27140.2. eCollection
      2020.


PMID- 33704183
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Dec 25
TI  - Catching the Wave: Quantifying the Impact of COVID on Radiotherapy Delivery.
PG  - 152-158
LID - 10.3390/curroncol28010018 [doi]
AB  - The novel coronavirus of 2019 has had a broad impact of the delivery of
      healthcare, including cancer care. We chose to quantify the impact in the
      radiation oncology department of the largest academic center in the hardest hit
      city in Canada. With the approval of our ethics review board, data on each
      patient treated from March 13, 2020 to August 10, 2020 were compared to patients 
      treated during the same period in 2019. We compared the case mix, delay from
      treatment decision to treatment start, and number of fractions per patient. We
      reviewed prospectively collected information regarding deviations from our usual 
      practice. During the pandemic the caseload was reduced by 12%; this was more
      pronounced in prostate and CNS tumors. The average number of fractions per
      patient was reduced from 12.3 to 10.9. This reduction was most marked in
      prostate, breast, gastro-intestinal, and palliative cases. When physicians were
      questioned, they reported that 17% of treatment plans deviated from their usual
      practice because of the pandemic. The most common deviations were related to
      changes in department policies (77%) vs. patient-specific deviations (20%) or
      changes requested by the patient (3%). Rare deviations were due to patients
      contracting COVID-19 (2 patients). At its worse, the wait list contained 27% of
      patients who had a delay to radiotherapy of more than 28 days. However, the
      average wait time increased little (19.6 days vs. 18.2 days) as more pressing
      cases were prioritized. In an unprecedented health crisis, our radiation oncology
      department was able to reduce resource utilization, notably by decreasing the
      number of fractions per patient. It will be important to follow these patients'
      health outcomes for insight into these practices. More quantitative tools to
      simulate and plan future practice changes in response to resource constraints
      will be implemented.
FAU - Roberge, David
AU  - Roberge D
AUID- ORCID: 0000-0001-8747-648X
AD  - Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal 
      (CHUM), Montreal, QC H2X 0C1, Canada.
FAU - Delouya, Guila
AU  - Delouya G
AD  - Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal 
      (CHUM), Montreal, QC H2X 0C1, Canada.
FAU - Bohigas, Alexandra
AU  - Bohigas A
AD  - Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal 
      (CHUM), Montreal, QC H2X 0C1, Canada.
FAU - Michalowski, Stefan
AU  - Michalowski S
AD  - Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal 
      (CHUM), Montreal, QC H2X 0C1, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201225
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - COVID-19/epidemiology/*prevention & control/virology
MH  - Canada
MH  - Delivery of Health Care/methods/*statistics & numerical data/trends
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/classification/*radiotherapy
MH  - Pandemics
MH  - Radiation Oncology/methods/*statistics & numerical data/trends
MH  - SARS-CoV-2/*isolation & purification/physiology
PMC - PMC7816192
OTO - NOTNLM
OT  - *SARS-CoV-2
OT  - *radiation oncology
OT  - *wait times
EDAT- 2021/03/12 06:00
MHDA- 2021/03/30 06:00
CRDT- 2021/03/11 12:32
PHST- 2020/08/25 00:00 [received]
PHST- 2020/12/15 00:00 [revised]
PHST- 2020/12/22 00:00 [accepted]
PHST- 2021/03/11 12:32 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - curroncol28010018 [pii]
AID - 10.3390/curroncol28010018 [doi]
PST - epublish
SO  - Curr Oncol. 2020 Dec 25;28(1):152-158. doi: 10.3390/curroncol28010018.


PMID- 33693425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 2624-909X (Electronic)
IS  - 2624-909X (Linking)
VI  - 3
DP  - 2020
TI  - A Policy and Practice Review of Consumer Protections and Their Application to
      Hospital-Sourced Data Aggregation and Analytics by Third-Party Companies.
PG  - 603044
LID - 10.3389/fdata.2020.603044 [doi]
AB  - The Office of the National Coordinator for Health Information Technology
      estimates that 96% of all U.S. hospitals use a basic electronic health record,
      but only 62% are able to exchange health information with outside providers.
      Barriers to information exchange across EHR systems challenge data aggregation
      and analysis that hospitals need to evaluate healthcare quality and safety. A
      growing number of hospital systems are partnering with third-party companies to
      provide these services. In exchange, companies reserve the rights to sell the
      aggregated data and analyses produced therefrom, often without the knowledge of
      patients from whom the data were sourced. Such partnerships fall in a regulatory 
      grey area and raise new ethical questions about whether health, consumer, or
      health and consumer privacy protections apply. The current opinion probes this
      question in the context of consumer privacy reform in California. It analyzes
      protections for health information recently expanded under the California
      Consumer Privacy Act ("CA Privacy Act") in 2020 and compares them to protections 
      outlined in the Health Information Portability and Accountability Act ("Federal
      Privacy Rule"). Four perspectives are considered in this ethical analysis: 1)
      standards of data deidentification; 2) rights of patients and consumers in
      relation to their health information; 3) entities covered by the CA Privacy Act; 
      4) scope and complementarity of federal and state regulations. The opinion
      concludes that the CCPA is limited in its application when health information is 
      processed by a third-party data aggregation company that is contractually
      designated as a business associate; when health information is deidentified; and 
      when hospital data are sourced from publicly owned and operated hospitals.
      Lastly, the opinion offers practical recommendations for facilitating parity
      between state and federal health data privacy laws and for how a more equitable
      distribution of informational risks and benefits from the sale of aggregated
      hospital data could be fostered and presents ways both for-profit and nonprofit
      hospitals can sustain patient trust when negotiating partnerships with
      third-party data aggregation companies.
CI  - Copyright (c) 2021 Rahimzadeh.
FAU - Rahimzadeh, Vasiliki
AU  - Rahimzadeh V
AD  - Stanford Center for Biomedical Ethics, Stanford University, Stanford, CA, United 
      States.
LA  - eng
PT  - Journal Article
DEP - 20210212
PL  - Switzerland
TA  - Front Big Data
JT  - Frontiers in big data
JID - 101770603
PMC - PMC7931961
OTO - NOTNLM
OT  - California Consumer Privacy Act
OT  - EHR
OT  - HIPAA
OT  - Proposition 24
OT  - data aggregation
OT  - privacy
COIS- The author declares that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/12 06:00
MHDA- 2021/03/12 06:01
CRDT- 2021/03/11 06:41
PHST- 2020/09/04 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/03/11 06:41 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/12 06:01 [medline]
AID - 10.3389/fdata.2020.603044 [doi]
AID - 603044 [pii]
PST - epublish
SO  - Front Big Data. 2021 Feb 12;3:603044. doi: 10.3389/fdata.2020.603044. eCollection
      2020.


PMID- 33693418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 2624-909X (Electronic)
IS  - 2624-909X (Linking)
VI  - 3
DP  - 2020
TI  - Interdisciplinary Research in Artificial Intelligence: Challenges and
      Opportunities.
PG  - 577974
LID - 10.3389/fdata.2020.577974 [doi]
AB  - The use of artificial intelligence (AI) in a variety of research fields is
      speeding up multiple digital revolutions, from shifting paradigms in healthcare, 
      precision medicine and wearable sensing, to public services and education offered
      to the masses around the world, to future cities made optimally efficient by
      autonomous driving. When a revolution happens, the consequences are not obvious
      straight away, and to date, there is no uniformly adapted framework to guide AI
      research to ensure a sustainable societal transition. To answer this need, here
      we analyze three key challenges to interdisciplinary AI research, and deliver
      three broad conclusions: 1) future development of AI should not only impact other
      scientific domains but should also take inspiration and benefit from other fields
      of science, 2) AI research must be accompanied by decision explainability,
      dataset bias transparency as well as development of evaluation methodologies and 
      creation of regulatory agencies to ensure responsibility, and 3) AI education
      should receive more attention, efforts and innovation from the educational and
      scientific communities. Our analysis is of interest not only to AI practitioners 
      but also to other researchers and the general public as it offers ways to guide
      the emerging collaborations and interactions toward the most fruitful outcomes.
CI  - Copyright (c) 2020 Kusters, Misevic, Berry, Cully, Cunff, Dandoy, Diaz-Rodriguez,
      Ficher, Grizou, Othmani, Palpanas, Komorowski, Loiseau, Frier, Nanini, Quercia,
      Sebag, Fogelman, Taleb, Tupikina, Sahu, Vie and Wehbi.
FAU - Kusters, Remy
AU  - Kusters R
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Misevic, Dusan
AU  - Misevic D
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Berry, Hugues
AU  - Berry H
AD  - Inria, Villeurbanne, France.
FAU - Cully, Antoine
AU  - Cully A
AD  - Imperial College London, London, United Kingdom.
FAU - Le Cunff, Yann
AU  - Le Cunff Y
AD  - University of Rennes, Rennes, France.
FAU - Dandoy, Loic
AU  - Dandoy L
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Diaz-Rodriguez, Natalia
AU  - Diaz-Rodriguez N
AD  - Inria Flowers, Paris and Bordeaux, France.
AD  - ENSTA Paris, Institut Polytechnique Paris, Paris, France.
FAU - Ficher, Marion
AU  - Ficher M
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Grizou, Jonathan
AU  - Grizou J
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Othmani, Alice
AU  - Othmani A
AD  - Universite Paris-Est, LISSI, Vitry sur Seine, France.
FAU - Palpanas, Themis
AU  - Palpanas T
AD  - Universite de Paris, France and French University Institute (IUF), Paris, France.
FAU - Komorowski, Matthieu
AU  - Komorowski M
AD  - Imperial College London, London, United Kingdom.
FAU - Loiseau, Patrick
AU  - Loiseau P
AD  - Universite Grenoble Alpes, Inria, CNRS, Grenoble INP, LIG, Grenoble, France.
FAU - Moulin Frier, Clement
AU  - Moulin Frier C
AD  - Inria Flowers, Paris and Bordeaux, France.
FAU - Nanini, Santino
AU  - Nanini S
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Quercia, Daniele
AU  - Quercia D
AD  - Nokia Bell Labs, Cambridge, United Kingdom.
FAU - Sebag, Michele
AU  - Sebag M
AD  - TAU, LRI-CNRS-INRIA, Universite Paris-Saclay, France.
FAU - Soulie Fogelman, Francoise
AU  - Soulie Fogelman F
AD  - Hub France Intelligence Artificielle, Paris, France.
FAU - Taleb, Sofiane
AU  - Taleb S
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Tupikina, Liubov
AU  - Tupikina L
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
AD  - Nokia Bell Labs, Paris, France.
FAU - Sahu, Vaibhav
AU  - Sahu V
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
FAU - Vie, Jill-Jenn
AU  - Vie JJ
AD  - Inria, Lille, France.
FAU - Wehbi, Fatima
AU  - Wehbi F
AD  - INSERM U1284, Universite de Paris, Center for Research and Interdisciplinarity
      (CRI), Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - Switzerland
TA  - Front Big Data
JT  - Frontiers in big data
JID - 101770603
PMC - PMC7931862
OTO - NOTNLM
OT  - artificial intelligence
OT  - auditability
OT  - education
OT  - ethics
OT  - interdisciplinary science
OT  - interpretability
COIS- Authors LT and DQ are employed by the company Nokia Bell Labs. The remaining
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of
      interest.
EDAT- 2021/03/12 06:00
MHDA- 2021/03/12 06:01
CRDT- 2021/03/11 06:41
PHST- 2020/06/30 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2021/03/11 06:41 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/12 06:01 [medline]
AID - 10.3389/fdata.2020.577974 [doi]
AID - 577974 [pii]
PST - epublish
SO  - Front Big Data. 2020 Nov 23;3:577974. doi: 10.3389/fdata.2020.577974. eCollection
      2020.


PMID- 33693406
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 2624-909X (Electronic)
IS  - 2624-909X (Linking)
VI  - 3
DP  - 2020
TI  - Perspective: Acknowledging Data Work in the Social Media Research Lifecycle.
PG  - 509954
LID - 10.3389/fdata.2020.509954 [doi]
AB  - This perspective article suggests considering the everyday research data
      management work required to accomplish social media research along different
      phases in a data lifecycle to inform the ongoing discussion of social media
      research data's quality and validity. Our perspective is informed by practical
      experience of archiving social media data, by results from a series of
      qualitative interviews with social media researchers, as well as by recent
      literature in the field. We emphasize how social media researchers are entangled 
      in complexities between social media platform providers, social media users,
      other actors, as well as legal and ethical frameworks, that all affect their
      everyday research practices. Research design decisions are made iteratively at
      different stages, involving many decisions that may potentially impact the
      quality of research. We show that these decisions are often hidden, but that
      making them visible allows us to better understand what drives social media
      research into specific directions. Consequently, we argue that untangling and
      documenting choices during the research lifecycle, especially when researchers
      pursue specific approaches and may have actively decided against others (often
      due to external factors) is necessary and will help to spot and address
      structural challenges in the social media research ecosystem that go beyond
      critiques of individual opportunistic approaches to easily accessible data.
CI  - Copyright (c) 2020 Kinder-Kurlanda and Weller.
FAU - Kinder-Kurlanda, Katharina E
AU  - Kinder-Kurlanda KE
AD  - CAIS - Center for Advanced Internet Studies, Bochum, Germany.
FAU - Weller, Katrin
AU  - Weller K
AD  - Computational Social Science Department, GESIS - Leibniz Institute for the Social
      Sciences, Cologne, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - Switzerland
TA  - Front Big Data
JT  - Frontiers in big data
JID - 101770603
PMC - PMC7931894
OTO - NOTNLM
OT  - data archiving
OT  - data lifecycle
OT  - digital trace data
OT  - epistemology
OT  - methodology
OT  - research data management
OT  - social media research
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/12 06:00
MHDA- 2021/03/12 06:01
CRDT- 2021/03/11 06:41
PHST- 2019/11/04 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2021/03/11 06:41 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/12 06:01 [medline]
AID - 10.3389/fdata.2020.509954 [doi]
AID - 509954 [pii]
PST - epublish
SO  - Front Big Data. 2020 Dec 10;3:509954. doi: 10.3389/fdata.2020.509954. eCollection
      2020.


PMID- 33693398
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 2624-909X (Electronic)
IS  - 2624-909X (Linking)
VI  - 3
DP  - 2020
TI  - Considerations for a More Ethical Approach to Data in AI: On Data Representation 
      and Infrastructure.
PG  - 25
LID - 10.3389/fdata.2020.00025 [doi]
AB  - Data shapes the development of Artificial Intelligence (AI) as we currently know 
      it, and for many years centralized networking infrastructures have dominated both
      the sourcing and subsequent use of such data. Research suggests that centralized 
      approaches result in poor representation, and as AI is now integrated more in
      daily life, there is a need for efforts to improve on this. The AI research
      community has begun to explore managing data infrastructures more democratically,
      finding that decentralized networking allows for more transparency which can
      alleviate core ethical concerns, such as selection-bias. With this in mind,
      herein, we present a mini-survey framed around data representation and data
      infrastructures in AI. We outline four key considerations (auditing,
      benchmarking, confidence and trust, explainability and interpretability) as they 
      pertain to data-driven AI, and propose that reflection of them, along with
      improved interdisciplinary discussion may aid the mitigation of data-based AI
      ethical concerns, and ultimately improve individual wellbeing when interacting
      with AI.
CI  - Copyright (c) 2020 Baird and Schuller.
FAU - Baird, Alice
AU  - Baird A
AD  - Chair of Embedded Intelligence for Health Care and Wellbeing, University of
      Augsburg, Augsburg, Germany.
FAU - Schuller, Bjorn
AU  - Schuller B
AD  - Chair of Embedded Intelligence for Health Care and Wellbeing, University of
      Augsburg, Augsburg, Germany.
AD  - Group on Language, Audio & Music, Imperial College London, London, United
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200902
PL  - Switzerland
TA  - Front Big Data
JT  - Frontiers in big data
JID - 101770603
PMC - PMC7931893
OTO - NOTNLM
OT  - artificial intelligence
OT  - decentralization
OT  - ethical AI
OT  - machine learning
OT  - selection-bias
EDAT- 2021/03/12 06:00
MHDA- 2021/03/12 06:01
CRDT- 2021/03/11 06:41
PHST- 2020/01/16 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2021/03/11 06:41 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/12 06:01 [medline]
AID - 10.3389/fdata.2020.00025 [doi]
PST - epublish
SO  - Front Big Data. 2020 Sep 2;3:25. doi: 10.3389/fdata.2020.00025. eCollection 2020.


PMID- 33693390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 2624-909X (Electronic)
IS  - 2624-909X (Linking)
VI  - 3
DP  - 2020
TI  - Variational Autoencoder Modular Bayesian Networks for Simulation of Heterogeneous
      Clinical Study Data.
PG  - 16
LID - 10.3389/fdata.2020.00016 [doi]
AB  - In the area of Big Data, one of the major obstacles for the progress of
      biomedical research is the existence of data "silos" because legal and ethical
      constraints often do not allow for sharing sensitive patient data from clinical
      studies across institutions. While federated machine learning now allows for
      building models from scattered data of the same format, there is still the need
      to investigate, mine, and understand data of separate and very differently
      designed clinical studies that can only be accessed within each of the
      data-hosting organizations. Simulation of sufficiently realistic virtual patients
      based on the data within each individual organization could be a way to fill this
      gap. In this work, we propose a new machine learning approach [Variational
      Autoencoder Modular Bayesian Network (VAMBN)] to learn a generative model of
      longitudinal clinical study data. VAMBN considers typical key aspects of such
      data, namely limited sample size coupled with comparable many variables of
      different numerical scales and statistical properties, and many missing values.
      We show that with VAMBN, we can simulate virtual patients in a sufficiently
      realistic manner while making theoretical guarantees on data privacy. In
      addition, VAMBN allows for simulating counterfactual scenarios. Hence, VAMBN
      could facilitate data sharing as well as design of clinical trials.
CI  - Copyright (c) 2020 Gootjes-Dreesbach, Sood, Sahay, Hofmann-Apitius and Frohlich.
FAU - Gootjes-Dreesbach, Luise
AU  - Gootjes-Dreesbach L
AD  - UCB Pharma (UCB Celltech Ltd.), Slough, United Kingdom.
FAU - Sood, Meemansa
AU  - Sood M
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for IT, University of Bonn, Bonn, Germany.
FAU - Sahay, Akrishta
AU  - Sahay A
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Sankt Augustin, Germany.
FAU - Hofmann-Apitius, Martin
AU  - Hofmann-Apitius M
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for IT, University of Bonn, Bonn, Germany.
FAU - Frohlich, Holger
AU  - Frohlich H
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for IT, University of Bonn, Bonn, Germany.
AD  - UCB Pharma (UCB Biosciences GmbH), Monheim am Rhein, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - Switzerland
TA  - Front Big Data
JT  - Frontiers in big data
JID - 101770603
PMC - PMC7931863
OTO - NOTNLM
OT  - Bayesian Networks
OT  - autoencoders
OT  - clinical study simulation
OT  - longitudinal data
OT  - time series data
EDAT- 2021/03/12 06:00
MHDA- 2021/03/12 06:01
CRDT- 2021/03/11 06:41
PHST- 2019/10/10 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2021/03/11 06:41 [entrez]
PHST- 2021/03/12 06:00 [pubmed]
PHST- 2021/03/12 06:01 [medline]
AID - 10.3389/fdata.2020.00016 [doi]
PST - epublish
SO  - Front Big Data. 2020 May 28;3:16. doi: 10.3389/fdata.2020.00016. eCollection
      2020.


PMID- 33688417
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 1995-705X (Print)
IS  - 1995-705X (Linking)
VI  - 21
IP  - 3
DP  - 2020 Jul-Sep
TI  - Racing for COVID-19 Vaccine and Cure: Lessons and Tragedies in Human Subject
      Research.
PG  - 229-234
LID - 10.4103/HEARTVIEWS.HEARTVIEWS_144_20 [doi]
AB  - Pressured by the enormous human and economic costs of the COVID-19 pandemic,
      certain countries and political figures have advocated the use of drugs and
      vaccines that did not go through the required regulatory stages of the
      development. Although the reason for bypassing these stages in a race to produce 
      a treatment and vaccine for the COVID-19 patients could have been caused by good 
      intentions to stop the human suffering from the pandemic, nonetheless, history
      has taught us that the results of this action could be catastrophic. In this
      article, we briefly review the lessons and tragedies in the evolution of human
      subject research regulations emphasizing the need for the proper evaluation of
      drugs and vaccines for COVID-19.
CI  - Copyright: (c) 2020 Heart Views.
FAU - Salam, Amar M
AU  - Salam AM
AD  - Department of Cardiology, Al-Khor Hospital, Hamad Medical Corporation, Doha,
      Qatar.
AD  - College of Medicine, QU Health, Qatar University, Doha, Qatar.
AD  - College of Medicine, Weill Cornell Medical College, New York, NY, USA.
FAU - Carr, Alison S
AU  - Carr AS
AD  - College of Medicine, QU Health, Qatar University, Doha, Qatar.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - India
TA  - Heart Views
JT  - Heart views : the official journal of the Gulf Heart Association
JID - 101316474
PMC - PMC7899008
OTO - NOTNLM
OT  - COVID-19
OT  - ethics
OT  - human subjects
OT  - regulations
OT  - research
COIS- There are no conflicts of interest.
EDAT- 2021/03/11 06:00
MHDA- 2021/03/11 06:01
CRDT- 2021/03/10 08:20
PHST- 2020/08/15 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2021/03/10 08:20 [entrez]
PHST- 2021/03/11 06:00 [pubmed]
PHST- 2021/03/11 06:01 [medline]
AID - 10.4103/HEARTVIEWS.HEARTVIEWS_144_20 [doi]
AID - HV-21-229 [pii]
PST - ppublish
SO  - Heart Views. 2020 Jul-Sep;21(3):229-234. doi:
      10.4103/HEARTVIEWS.HEARTVIEWS_144_20. Epub 2020 Oct 13.


PMID- 33679611
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - Massively Parallel Sequencing for Rare Genetic Disorders: Potential and Pitfalls.
PG  - 628946
LID - 10.3389/fendo.2020.628946 [doi]
AB  - There have been two major eras in the history of gene discovery. The first was
      the era of linkage analysis, with approximately 1,300 disease-related genes
      identified by positional cloning by the turn of the millennium. The second era
      has been powered by two major breakthroughs: the publication of the human genome 
      and the development of massively parallel sequencing (MPS). MPS has greatly
      accelerated disease gene identification, such that disease genes that would have 
      taken years to map previously can now be determined in a matter of weeks.
      Additionally, the number of affected families needed to map a causative gene and 
      the size of such families have fallen: de novo mutations, previously intractable 
      by linkage analysis, can be identified through sequencing of the parent-child
      trio, and genes for recessive disease can be identified through MPS even of a
      single affected individual. MPS technologies include whole exome sequencing
      (WES), whole genome sequencing (WGS), and panel sequencing, each with their
      strengths. While WES has been responsible for most gene discoveries through MPS, 
      WGS is superior in detecting copy number variants, chromosomal rearrangements,
      and repeat-rich regions. Panels are commonly used for diagnostic purposes as they
      are extremely cost-effective and generate manageable quantities of data, with no 
      risk of unexpected findings. However, in instances of diagnostic uncertainty, it 
      can be challenging to choose the right panel, and in these circumstances WES has 
      a higher diagnostic yield. MPS has ethical, social, and legal implications, many 
      of which are common to genetic testing generally but amplified due to the
      magnitude of data (e.g., relationship misattribution, identification of variants 
      of uncertain significance, and genetic discrimination); others are unique to WES 
      and WGS technologies (e.g., incidental or secondary findings). Nonetheless, MPS
      is rapidly translating into clinical practice as an extremely useful part of the 
      clinical armamentarium.
CI  - Copyright (c) 2021 McInerney-Leo and Duncan.
FAU - McInerney-Leo, Aideen M
AU  - McInerney-Leo AM
AD  - Dermatology Research Centre, University of Queensland Diamantina Institute, The
      University of Queensland, Brisbane, QLD, Australia.
FAU - Duncan, Emma L
AU  - Duncan EL
AD  - Department of Twin Research & Genetic Epidemiology, Faculty of Life Sciences and 
      Medicine, School of Life Course Sciences, King's College London, London, United
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210219
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Animals
MH  - DNA Copy Number Variations/genetics
MH  - Genetic Diseases, Inborn/diagnosis/*genetics
MH  - Genetic Testing/*methods/trends
MH  - Genome, Human/genetics
MH  - High-Throughput Nucleotide Sequencing/*methods/trends
MH  - Humans
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Rare Diseases/diagnosis/*genetics
MH  - Sequence Analysis, DNA/*methods/trends
PMC - PMC7933540
OTO - NOTNLM
OT  - *gene discovery
OT  - *massively parallel sequencing
OT  - *rare genetic bone disorder
OT  - *skeletal dysplasias
OT  - *whole exome sequencing
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/09 06:00
MHDA- 2021/05/27 06:00
CRDT- 2021/03/08 05:50
PHST- 2020/11/13 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/03/08 05:50 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
AID - 10.3389/fendo.2020.628946 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2021 Feb 19;11:628946. doi:
      10.3389/fendo.2020.628946. eCollection 2020.


PMID- 33679200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210420
IS  - 1321-8719 (Print)
IS  - 1321-8719 (Linking)
VI  - 27
IP  - 4
DP  - 2020
TI  - Absence of insight as a catch-all extra-legislative factor in Swedish mental
      health law proceedings.
PG  - 601-619
LID - 10.1080/13218719.2020.1739577 [doi]
AB  - Previous research indicates that insight is frequently used but rarely defined in
      mental health proceedings. This article examines how participants in Swedish
      administrative court proceedings use the concept of insight when discussing
      decisions regarding involuntary psychiatric care. Open-ended qualitative
      interviews were conducted with professional mental health court participants. The
      results show that lack of insight is used by the informants as an argument for
      all three legal criteria for involuntary psychiatric care in Sweden, as well as
      the criterion for release from forensic psychiatric care. It is concluded that
      there are troublesome legal and ethical implications of courts relying on a
      poorly defined concept such as insight in their rulings.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Radovic, Susanna
AU  - Radovic S
AUID- ORCID: https://orcid.org/0000-0003-4062-5761
AD  - Department of Philosophy, Linguistics and Theory of Science, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Ethics, Law and Mental Health, University of Gothenburg, Gothenburg,
      Sweden.
FAU - Eriksson, Lena
AU  - Eriksson L
AD  - Department of Philosophy, Linguistics and Theory of Science, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Ethics, Law and Mental Health, University of Gothenburg, Gothenburg,
      Sweden.
FAU - Dahlin, Moa Kindstrom
AU  - Dahlin MK
AD  - Department of Law, Uppsala University, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Psychiatr Psychol Law
JT  - Psychiatry, psychology, and law : an interdisciplinary journal of the Australian 
      and New Zealand Association of Psychiatry, Psychology and Law
JID - 9433511
PMC - PMC7901691
OTO - NOTNLM
OT  - civil commitment
OT  - compliance
OT  - conceptual analysis
OT  - ethics
OT  - insight
OT  - involuntary psychiatric care
OT  - mental health court
EDAT- 2021/03/09 06:00
MHDA- 2021/03/09 06:01
CRDT- 2021/03/08 05:48
PHST- 2021/03/08 05:48 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/03/09 06:01 [medline]
AID - 10.1080/13218719.2020.1739577 [doi]
AID - 1739577 [pii]
PST - epublish
SO  - Psychiatr Psychol Law. 2020 Apr 20;27(4):601-619. doi:
      10.1080/13218719.2020.1739577. eCollection 2020.


PMID- 33678857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210310
IS  - 0019-5545 (Print)
IS  - 0019-5545 (Linking)
VI  - 62
IP  - 5
DP  - 2020 Sep-Oct
TI  - Coronavirus disease 2019 pandemic: Ethical concerns for the treatment of
      individuals with substance use disorders in India.
PG  - 606-607
LID - 10.4103/psychiatry.IndianJPsychiatry_376_20 [doi]
FAU - Mahintamani, Tathagata
AU  - Mahintamani T
AD  - Department of Psychiatry, Drug De-addiction and Treatment Centre, Postgraduate
      Institute of Medical Education and Research, Chandigarh, India. E-mail:
      ghoshabhishek12@gmail.com.
FAU - Ghosh, Abhishek
AU  - Ghosh A
AD  - Department of Psychiatry, Drug De-addiction and Treatment Centre, Postgraduate
      Institute of Medical Education and Research, Chandigarh, India. E-mail:
      ghoshabhishek12@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201010
PL  - India
TA  - Indian J Psychiatry
JT  - Indian journal of psychiatry
JID - 0013255
PMC - PMC7909028
COIS- There are no conflicts of interest.
EDAT- 2021/03/09 06:00
MHDA- 2021/03/09 06:01
CRDT- 2021/03/08 05:47
PHST- 2020/04/21 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2021/03/08 05:47 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/03/09 06:01 [medline]
AID - 10.4103/psychiatry.IndianJPsychiatry_376_20 [doi]
AID - IJPsy-62-606 [pii]
PST - ppublish
SO  - Indian J Psychiatry. 2020 Sep-Oct;62(5):606-607. doi:
      10.4103/psychiatry.IndianJPsychiatry_376_20. Epub 2020 Oct 10.


PMID- 33665213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210306
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - A Review of Recent Advances in 3D Bioprinting With an Eye on Future Regenerative 
      Therapies in Veterinary Medicine.
PG  - 584193
LID - 10.3389/fvets.2020.584193 [doi]
AB  - 3D bioprinting is a rapidly evolving industry that has been utilized for a
      variety of biomedical applications. It differs from traditional 3D printing in
      that it utilizes bioinks comprised of cells and other biomaterials to allow for
      the generation of complex functional tissues. Bioprinting involves computational 
      modeling, bioink preparation, bioink deposition, and subsequent maturation of
      printed products; it is an intricate process where bioink composition,
      bioprinting approach, and bioprinter type must be considered during construct
      development. This technology has already found success in human studies, where a 
      variety of functional tissues have been generated for both in vitro and in vivo
      applications. Although the main driving force behind innovation in 3D bioprinting
      has been utility in human medicine, recent efforts investigating its veterinary
      application have begun to emerge. To date, 3D bioprinting has been utilized to
      create bone, cardiovascular, cartilage, corneal and neural constructs in animal
      species. Furthermore, the use of animal-derived cells and various animal models
      in human research have provided additional information regarding its capacity for
      veterinary translation. While these studies have produced some promising results,
      technological limitations as well as ethical and regulatory challenges have
      impeded clinical acceptance. This article reviews the current understanding of 3D
      bioprinting technology and its recent advancements with a focus on recent
      successes and future translation in veterinary medicine.
CI  - Copyright (c) 2021 Jamieson, Keenan, Kirkwood, Oji, Webster, Russell and Koch.
FAU - Jamieson, Colin
AU  - Jamieson C
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
FAU - Keenan, Patrick
AU  - Keenan P
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
FAU - Kirkwood, D'Arcy
AU  - Kirkwood D
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
FAU - Oji, Saba
AU  - Oji S
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
FAU - Webster, Caroline
AU  - Webster C
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
FAU - Russell, Keith A
AU  - Russell KA
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
FAU - Koch, Thomas G
AU  - Koch TG
AD  - Reproductive Health and Biotechnology Lab, Department of Biomedical Science,
      University of Guelph, Guelph, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210216
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7921312
OTO - NOTNLM
OT  - 3D print
OT  - additive manufacturing
OT  - bioprint
OT  - regenerative medicine
OT  - tissue engineering
OT  - veterinary
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/06 06:00
MHDA- 2021/03/06 06:01
CRDT- 2021/03/05 06:07
PHST- 2020/07/16 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2021/03/05 06:07 [entrez]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/03/06 06:01 [medline]
AID - 10.3389/fvets.2020.584193 [doi]
PST - epublish
SO  - Front Vet Sci. 2021 Feb 16;7:584193. doi: 10.3389/fvets.2020.584193. eCollection 
      2020.


PMID- 33652410
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Mar 4
TI  - Late Termination of Pregnancy in Belgium: Exploring Its Legality and Scope.
PG  - 9-34
LID - 10.1163/15718093-12271451 [doi]
AB  - Termination of pregnancy when the foetus is considered viable remains a legal and
      ethical challenge for lawmakers and society. In Belgium, the lawfulness of late
      termination of pregnancy is contested by legal scholars up until today. Through
      statutory interpretation, this analysis demonstrates that this controversy is
      unwarranted and that termination of pregnancy for particularly severe and
      incurable foetal abnormality or for serious threats to the health of the pregnant
      person is also permitted after foetal viability. Nonetheless, by using open terms
      the Belgian Act on the Voluntary Termination of Pregnancy creates considerable
      legal uncertainty. Drawing on a comparison with the regulatory frameworks of the 
      Netherlands and the United Kingdom, this article underlines the need for
      increased multidisciplinary debate, medical guidance, and scientific research on 
      late termination of pregnancy in Belgium.
FAU - De Meyer, Fien
AU  - De Meyer F
AD  - PhD Candidate, Faculty of Law, University of Antwerp Antwerp Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200304
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - Abortion, Legal/*legislation & jurisprudence
MH  - Belgium
MH  - Female
MH  - *Fetal Viability
MH  - Humans
MH  - Netherlands
MH  - Pregnancy
MH  - Pregnancy Trimester, Second
MH  - Pregnancy Trimester, Third
MH  - United Kingdom
EDAT- 2021/03/03 06:00
MHDA- 2021/07/21 06:00
CRDT- 2021/03/02 20:15
PHST- 2021/03/02 20:15 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
AID - 10.1163/15718093-12271451 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 Mar 4;27(1):9-34. doi: 10.1163/15718093-12271451.


PMID- 33652400
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20211204
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 3
DP  - 2020 May 18
TI  - Ethical, Legal and Regulatory Issues of Paediatric Translational Research. Call
      for an Adequate Model of Governance.
PG  - 213-231
LID - 10.1163/15718093-BJA10010 [doi]
AB  - The lack of paediatric medicines, including innovative and advanced ones, is a
      long-lasting and well-known problem at European and international levels. Despite
      the existing legal frameworks and incentives, children remain deprived of many
      kinds of therapy because of challenges faced in appropriately study and tailoring
      medicinal and other products for them. In this context, the necessity to foster
      paediatric research addressing unsolved and uncovered issues within a
      'translational approach' has appeared. This article, after having clarified the
      concept of translational research in the perspective of the establishment of a
      European paediatric research infrastructure (RI), will identify and point out
      ethical, legal and regulatory issues particularly relevant in a children's rights
      perspective. It concludes asking for the setting up of an adequate model of
      governance within a future RI, including adequate and independent ethical
      oversight and a pluridisciplinary common service dealing with ethical, legal and 
      societal issues relevant for children.
FAU - Altavilla, Annagrazia
AU  - Altavilla A
AD  - Espace Ethique Mediterraneen/PACA-Corse, Assistance Publique Hopitaux de
      Marseille/Aix-Marseille Universite Marseille France TEDDYChair.
AD  - TEDDY (European Network of Excellence for Paediatric Research) Pavia Italy.
FAU - Giannuzzi, Viviana
AU  - Giannuzzi V
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi onlus Bari Italy.
AD  - TEDDY (European Network of Excellence for Paediatric Research) Pavia Italy.
FAU - Lupo, Mariangela
AU  - Lupo M
AD  - TEDDY (European Network of Excellence for Paediatric Research) Pavia Italy.
FAU - Bonifazi, Donato
AU  - Bonifazi D
AD  - TEDDY (European Network of Excellence for Paediatric Research) Pavia Italy.
AD  - Consorzio per Valutazioni Biologiche e Farmacologiche Bari Italy Coordinator,
      European Paediatric Translational Research Infrastructure (EPTRI).
FAU - Ceci, Adriana
AU  - Ceci A
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi onlus Bari Italy.
AD  - TEDDY (European Network of Excellence for Paediatric Research) Pavia Italy.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - Child
MH  - Confidentiality/ethics/legislation & jurisprudence
MH  - Europe
MH  - Gene Editing/ethics/legislation & jurisprudence
MH  - Humans
MH  - *Minors
MH  - *Patient Rights
MH  - *Pediatrics
MH  - Right to Health
MH  - Therapies, Investigational/*standards
MH  - Translational Research, Biomedical/*ethics/*legislation &
      jurisprudence/organization & administration
EDAT- 2021/03/03 06:00
MHDA- 2021/08/21 06:00
CRDT- 2021/03/02 20:15
PHST- 2021/03/02 20:15 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
AID - 10.1163/15718093-BJA10010 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 May 18;27(3):213-231. doi: 10.1163/15718093-BJA10010.


PMID- 33652397
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 3
DP  - 2020 May 19
TI  - Machine Learning Systems Applied to Health Data and System.
PG  - 242-258
LID - 10.1163/15718093-BJA10009 [doi]
AB  - The use of machine learning (ML) in medicine is becoming increasingly fundamental
      to analyse complex problems by discovering associations among different types of 
      information and to generate knowledge for medical decision support. Many
      regulatory and ethical issues should be considered. Some relevant EU provisions, 
      such as the General Data Protection Regulation, are applicable. However, the
      regulatory framework for developing and marketing a new health technology
      implementing ML may be quite complex. Other issues include the legal liability
      and the attribution of negligence in case of errors. Some of the above-mentioned 
      concerns could be, at least partially, resolved in case the ML software is
      classified as a 'medical device', a category covered by EU/national provisions.
      Concluding, the challenge is to understand how sustainable is the regulatory
      system in relation to the ML innovation and how legal procedures should be
      revised in order to adapt them to the current regulatory framework.
FAU - Bonifazi, Fedele
AU  - Bonifazi F
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus Bari Italy.
FAU - Volpe, Elisabetta
AU  - Volpe E
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus Bari Italy.
FAU - Digregorio, Giuseppe
AU  - Digregorio G
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus Bari Italy.
FAU - Giannuzzi, Viviana
AU  - Giannuzzi V
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus Bari Italy.
FAU - Ceci, Adriana
AU  - Ceci A
AD  - Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus Bari Italy.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - Bias
MH  - Confidentiality/legislation & jurisprudence
MH  - Decision Making/ethics
MH  - Drug Development
MH  - Drug Discovery
MH  - Humans
MH  - Machine Learning/*ethics/*legislation & jurisprudence/*standards
MH  - Malpractice
MH  - Medical Device Legislation
MH  - *Medical Informatics
MH  - Precision Medicine
MH  - Risk Management
MH  - Safety/legislation & jurisprudence
MH  - *Software
MH  - Trust
EDAT- 2021/03/03 06:00
MHDA- 2021/08/21 06:00
CRDT- 2021/03/02 20:15
PHST- 2021/03/02 20:15 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
AID - 10.1163/15718093-BJA10009 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 May 19;27(3):242-258. doi: 10.1163/15718093-BJA10009.


PMID- 33652394
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Jun 15
TI  - Models of Governance for Innovation in Medicine and Health Research.
PG  - 324-334
LID - 10.1163/15718093-BJA10022 [doi]
AB  - Personalised medicine, digital innovations, and neuro-technologies all offer
      significant potential benefit for human health and welfare, but also raise
      complex governance challenges. A variety of approaches have been adopted in the
      governance of innovative medicines and health technologies, including risk
      assessment, ethics and self-governance. Recently anticipatory or 'upstream' modes
      of governance have garnered favour. Anticipatory regulation demands a closer
      relationship between regulators and innovators, to shape the trajectories of the 
      technology. In the EU context, responsible research and innovation has emerged as
      a key mechanism of governance. This is linked but distinct from a human rights
      governance which has the advantage of exerting both legal and moral force. What
      is needed in the healthcare context are governance models which ensure human
      rights considerations are taken into account from the earliest stages of
      innovation, to maximise the likelihood that developments are from the outset
      beneficial and oriented towards protecting ethical values.
FAU - O'Sullivan, Siobhan
AU  - O'Sullivan S
AD  - Royal College of Surgeons of Ireland Dublin Ireland.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - Biomedical Technology/*legislation & jurisprudence
MH  - European Union
MH  - Human Rights/*ethics
MH  - Humans
MH  - Inventions/*legislation & jurisprudence
MH  - Social Values
MH  - Stakeholder Participation
EDAT- 2021/03/03 06:00
MHDA- 2021/08/21 06:00
CRDT- 2021/03/02 20:15
PHST- 2021/03/02 20:15 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
AID - 10.1163/15718093-BJA10022 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 Jun 15;27(3):324-334. doi: 10.1163/15718093-BJA10022.


PMID- 33652389
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Oct 8
TI  - The Underappreciated Role of Advance Directives: How the Pandemic Revitalises
      Advance Care Planning Actions.
PG  - 451-475
LID - 10.1163/15718093-BJA10029 [doi]
AB  - Covid-19 continues to alter our way of living and dying. Much attention has
      focused on how to resolve pressing issues surrounding resource allocation and
      competing public health ethics. While these are important discussions, the legal 
      and ethical dilemmas of treatment decisions remain highly critical. The urgency
      to ensure that life and death affairs are in order is magnified due to the
      possibility of becoming infected with Covid-19. However, many people continue to 
      face challenges in organising their future medical care and treatment. This
      article explores how the pandemic affects advance care planning through the
      lenses of law and ethics. The range of Covid-19 implications on advance care
      planning demonstrates a paradigm shift from a primarily elective function to an
      essential role in healthcare delivery. This renewed appreciation to advance care 
      planning offers the opportunity to support and sustain the important role that it
      could play during ordinary and extraordinary times.
FAU - Chan, Hui Yun
AU  - Chan HY
AD  - University of Huddersfield Huddersfield United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - Advance Care Planning/*ethics/*legislation & jurisprudence
MH  - *Advance Directives
MH  - *COVID-19
MH  - Decision Making
MH  - Family Conflict
MH  - Health Equity
MH  - Humans
MH  - *Pandemics
EDAT- 2021/03/03 06:00
MHDA- 2021/03/17 06:00
CRDT- 2021/03/02 20:15
PHST- 2021/03/02 20:15 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
AID - 10.1163/15718093-BJA10029 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 Oct 8;27(5):451-475. doi: 10.1163/15718093-BJA10029.


PMID- 33652387
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Oct 21
TI  - Conducting Non-COVID-19 Clinical Trials during the Pandemic: Can Today's Learning
      Impact Framework Efficiency?
PG  - 425-450
LID - 10.1163/15718093-BJA10031 [doi]
AB  - The COVID-19 pandemic has severely disrupted non-coronavirus clinical trials. In 
      the case of life-threatening diseases, such as cancer, this is particularly
      dangerous, as treatment cannot simply be stopped. In the EU, guidelines for the
      management of ongoing studies were issued; however, national coordination is
      still lacking. This article aims to raise awareness on the struggle of managing
      ongoing clinical trials in the EU during the pandemic. The goals are to bring
      attention, from a legal and regulatory point of view to the difficulties faced by
      those involved in clinical research, and to critically position the current
      hurdles against the backdrop of the existing legal and ethical framework. We
      investigated the EU guidance and the national approaches of all EU/EEA Member
      States, and critically discussed selected issues. We argue that the crisis may be
      an opportunity to foresee meaningful changes in the EU clinical trials framework 
      post-COVID-19.
FAU - Lalova, Teodora
AU  - Lalova T
AD  - Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology 
      and Pharmacotherapy, KU Leuven Leuven Belgium.
AD  - Centre for IT & IP Law (CiTiP), KU Leuven Leuven Belgium.
FAU - Negrouk, Anastassia
AU  - Negrouk A
AD  - European Organisation for Research and Treatment of Cancer Brussels Belgium.
FAU - Deleersnijder, Angelique
AU  - Deleersnijder A
AD  - European Organisation for Research and Treatment of Cancer Brussels Belgium.
FAU - Valcke, Peggy
AU  - Valcke P
AD  - Centre for IT & IP Law (CiTiP), KU Leuven Leuven Belgium.
FAU - Huys, Isabelle
AU  - Huys I
AD  - Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology 
      and Pharmacotherapy, KU Leuven Leuven Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - COVID-19/prevention & control
MH  - Clinical Trials as Topic/*legislation & jurisprudence/*organization &
      administration
MH  - Ethics, Research
MH  - European Union
MH  - Humans
MH  - *Pandemics
MH  - Research/*legislation & jurisprudence/*organization & administration
MH  - Research Design/*standards
EDAT- 2021/03/03 06:00
MHDA- 2021/03/17 06:00
CRDT- 2021/03/02 20:15
PHST- 2021/03/02 20:15 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
AID - 10.1163/15718093-BJA10031 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 Oct 21;27(5):425-450. doi: 10.1163/15718093-BJA10031.


PMID- 33651936
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1708-3923 (Electronic)
IS  - 0383-6320 (Linking)
VI  - 45
IP  - 2
DP  - 2020 Fall
TI  - [Life Satisfaction, Perceived Discrimination, Religiosity, and Mental Health in
      Sufism: a Perspective from Montreal].
PG  - 125-145
AB  - Objective The central objective of this paper is to explore the dynamic
      interactions between 5 sets of variables, which are Sociodemographic
      Characteristics, Satisfaction with Life, Perceived Discrimination, Religiosity
      and Emotional Distress within Montreal's Tariqa Qadiriya Boudchichiya, a Muslim
      Sufi way whose origins are Moroccan and date back to the 18th century. Method As 
      a method, we considered psychological distress as the dependent variable and
      performed univariate descriptive statistical analyzes, bivariate correlation
      analyzes (Pearson correlation), one-way ANOVA analyzes, and multivariate analyzes
      (linear regressions). Results Our results, although preliminary due to a
      relatively small sample (n = 56), allow us to put forward a new hypothesis
      suggesting that the intense spiritual practice that characterizes the Tariqa,
      would allow "a work of the self on self" through a set of "techniques of the
      self" (Foucault) that contribute to a certain emotional well-being, if not to
      mental health. Conclusion Our conclusion underlines the importance of
      investigating more in depth the possible contribution of religiosity to the
      subject's capacity to act on oneself in order to emerge as a spiritual, ethical
      and political subject.
FAU - Mekki-Berrada, Abdelwahed
AU  - Mekki-Berrada A
AD  - Departement d'anthropologie, Universite Laval, Quebec Qc., Canada.
FAU - Ben Driss, Karim
AU  - Ben Driss K
AD  - Directeur de l'Institut soufi de Montreal, Montreal Qc., Canada.
LA  - fre
PT  - Journal Article
TT  - Satisfaction a l'egard de la vie, discrimination percue, religiosite et sante
      mentale dans l'islam soufi : une perspective montrealaise.
PL  - Canada
TA  - Sante Ment Que
JT  - Sante mentale au Quebec
JID - 9424773
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Female
MH  - Humans
MH  - Islam/*psychology
MH  - Linear Models
MH  - Male
MH  - *Mental Health
MH  - Middle Aged
MH  - *Personal Satisfaction
MH  - Preliminary Data
MH  - *Psychological Distress
MH  - Quebec
MH  - *Social Discrimination
MH  - Spirituality
MH  - Surveys and Questionnaires
MH  - Young Adult
EDAT- 2021/03/03 06:00
MHDA- 2021/10/08 06:00
CRDT- 2021/03/02 17:09
PHST- 2021/03/02 17:09 [entrez]
PHST- 2021/03/03 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
AID - 1075392ar [pii]
PST - ppublish
SO  - Sante Ment Que. 2020 Fall;45(2):125-145.


PMID- 33647107
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1943-6270 (Electronic)
IS  - 8756-971X (Linking)
VI  - 36
IP  - 4
DP  - 2020 Dec 1
TI  - Artificial Bloodfeeder Glytube: Evaluating Different Types of Membranes and Blood
      Sources for Feeding Aedes aegypti and Aedes albopictus.
PG  - 233-239
LID - 10.2987/20-6930.1 [doi]
AB  - Mosquito colony maintenance in the laboratory is essential for research but
      presents logistical and ethical problems with the use of live animals for
      bloodfeeding. The Glytube is an artificial bloodfeeding system for mosquitoes
      that uses Parafilm-M(R) membrane and human blood to feed Aedes aegypti. This
      study evaluated the efficiency of Glytube with different types of membranes and
      chicken blood to feed Ae. aegypti and Ae. albopictus. We evaluated 2 artificial
      (thread seal tape [TST], Parafilm-M) and 2 natural membranes (pork, sheep
      intestine). The results for Ae. aegypti suggest that TST was the best membrane
      because it presented a high percentage of fed females (63%), a high average
      number of eggs per female (54.65), and an egg viability rate significantly
      similar to control (mouse). For Ae. albopictus, there was no significant
      difference between the membranes and the control; however, the use of TST is
      suggested due to the low cost and easy manipulation. The treatments that used
      chicken blood did not present significant differences in the egg viability when
      compared with the control. The Glytube functionality can be increased by
      replacing the Parafilm-M membrane by TST and human to chicken blood.
CI  - Copyright (c) 2020 by The American Mosquito Control Association, Inc.
FAU - de Almeida Costa, Kelion
AU  - de Almeida Costa K
FAU - Garcia Rosario, Ingrid N
AU  - Garcia Rosario IN
FAU - Eiras, Alvaro E
AU  - Eiras AE
FAU - da Silva, Ivoneide Maria
AU  - da Silva IM
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Mosq Control Assoc
JT  - Journal of the American Mosquito Control Association
JID - 8511299
RN  - 0 (Membranes, Artificial)
SB  - IM
MH  - *Aedes
MH  - Animal Husbandry
MH  - Animals
MH  - Blood
MH  - Entomology/*instrumentation
MH  - Feeding Behavior
MH  - Membranes, Artificial
MH  - Sheep
MH  - Swine
OTO - NOTNLM
OT  - * Aedes aegypti
OT  - * Aedes albopictus
OT  - *Culicidae
OT  - *artificial bloodfeeder
OT  - *maintenance of mosquito colonies
EDAT- 2021/03/02 06:00
MHDA- 2021/05/22 06:00
CRDT- 2021/03/01 17:10
PHST- 2021/03/01 17:10 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - 461479 [pii]
AID - 10.2987/20-6930.1 [doi]
PST - ppublish
SO  - J Am Mosq Control Assoc. 2020 Dec 1;36(4):233-239. doi: 10.2987/20-6930.1.


PMID- 33644162
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2297-900X (Electronic)
IS  - 2297-900X (Linking)
VI  - 5
DP  - 2020 Nov
TI  - Digitized HIV/AIDS Treatment Adherence Interventions: A Review of Recent
      SMS/Texting Mobile Health Applications and Implications for Theory and Practice.
LID - 530164 [pii]
LID - 10.3389/fcomm.2020.530164 [doi]
AB  - BACKGROUND: Mobile health technologies (mHealth) are efficacious along the
      continuum of HIV/AIDS-from prevention of HIV transmission to those at the highest
      risk of acquiring infection, to adherence to HIV medical care, for those living
      with the disease-decreasing the public health burden of the disease. HIV/AIDS is 
      a complex condition, as certain population subgroups are disproportionately
      affected. Furthermore, barriers experienced at the individual level (e.g., HIV
      stigma) and at the systems level (i.e., access to care) contribute to these
      disparities. Low cost, high penetration rates and ease of use mean mHealth
      SMS/texting solutions hold the biggest promise for curbing the global HIV/AIDS
      epidemic; yet these technologies have their own challenges. Our primary objective
      was to assess interventions that promote adherence, which are delivered via
      SMS/texting, and important design and ethical considerations of these
      technologies. Specifically, we evaluated the underlying frameworks underpinning
      intervention design, strategies to safeguard privacy and confidentiality, and
      measures taken to ensure equity and equitable access across different subgroups
      of persons living with HIV (PLWH). We also synthesized study outcomes,
      barriers/facilitators to adherence, and barriers/facilitators of technology to
      support HIV adherence. METHODS: A scoping review methodology was utilized,
      searching the Medline database for recently published articles (January 2017 to
      June 2019). Two reviewers independently screened titles and abstracts for
      relevancy using the following eligibility criteria: (a) original research or
      protocol; (b) inclusion of persons living with HIV; (c) intervention delivery via
      SMS/text messaging; and, (d) intervention included HIV care adherence. RESULTS:
      Seven (7) of the 134 articles met full criteria. The great majority (n = 6) did
      not report whether the interventions were developed under established behavioral 
      change models or frameworks. Strategies to address privacy, confidentiality and
      equity/equitable access were taken in four (n = 4) studies. CONCLUSION: Our mixed
      methods review determined that privacy and confidentiality remain a concern for
      PLWH. Provisions to accommodate literacy, infrastructure, technology and other
      challenges (e.g., access to smartphones and Wifi) are important ethical
      considerations that guarantee equity and equitable access. Further investigation 
      will determine the contexts within which theoretical models and frameworks remain
      relevant in the rapidly evolving field of digitized interventions that support
      adherence.
FAU - Duthely, Lunthita M
AU  - Duthely LM
AD  - Obstetrics, Gynecology and Reproductive Sciences, Division of Research and
      Special Projects, University of Miami Miller School of Medicine, Miami, FL,
      United States.
FAU - Sanchez-Covarrubias, Alex P
AU  - Sanchez-Covarrubias AP
AD  - Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic
      Oncology, University of Miami Miller School of Medicine, Miami, FL, United
      States.
LA  - eng
GR  - KL2 TR002737/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20201110
PL  - Switzerland
TA  - Front Commun (Lausanne)
JT  - Frontiers in communication
JID - 101714787
PMC - PMC7909469
MID - NIHMS1671354
OTO - NOTNLM
OT  - HIV/AIDS
OT  - access to healthcare
OT  - health disparities in HIV/AIDS
OT  - intervention - behavioral
OT  - mHealth
OT  - mHealth ethics
OT  - minorities
COIS- Conflict of Interest: The authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a
      potential conflict of interest.
EDAT- 2021/03/02 06:00
MHDA- 2021/03/02 06:01
CRDT- 2021/03/01 05:39
PHST- 2021/03/01 05:39 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/03/02 06:01 [medline]
AID - 10.3389/fcomm.2020.530164 [doi]
PST - ppublish
SO  - Front Commun (Lausanne). 2020 Nov;5. doi: 10.3389/fcomm.2020.530164. Epub 2020
      Nov 10.


PMID- 33644087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210701
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - The Role of DICOM in Artificial Intelligence for Skin Disease.
PG  - 619787
LID - 10.3389/fmed.2020.619787 [doi]
AB  - There is optimism that artificial intelligence (AI) will result in positive
      clinical outcomes, which is driving research and investment in the use of AI for 
      skin disease. At present, AI for skin disease is embedded in research and
      development and not practiced widely in clinical dermatology. Clinical
      dermatology is also undergoing a technological transformation in terms of the
      development and adoption of standards that optimizes the quality use of imaging. 
      Digital Imaging and Communications in Medicine (DICOM) is the international
      standard for medical imaging. DICOM is a continually evolving standard. There is 
      considerable effort being invested in developing dermatology-specific extensions 
      to the DICOM standard. The ability to encode relevant metadata and afford
      interoperability with the digital health ecosystem (e.g., image repositories,
      electronic medical records) has driven the initial impetus in the adoption of
      DICOM for dermatology. DICOM has a dedicated working group whose role is to
      develop a mechanism to support AI workflows and encode AI artifacts. DICOM can
      improve AI workflows by encoding derived objects (e.g., secondary images, visual 
      explainability maps, AI algorithm output) and the efficient curation of
      multi-institutional datasets for machine learning training, testing, and
      validation. This can be achieved using DICOM mechanisms such as standardized
      image formats and metadata, metadata-based image retrieval, and de-identification
      protocols. DICOM can address several important technological and workflow
      challenges for the implementation of AI. However, many other technological,
      ethical, regulatory, medicolegal, and workforce barriers will need to be
      addressed before DICOM and AI can be used effectively in dermatology.
CI  - Copyright (c) 2021 Caffery, Rotemberg, Weber, Soyer, Malvehy and Clunie.
FAU - Caffery, Liam J
AU  - Caffery LJ
AD  - Centre for Online, Centre for Health Services Research, The University of
      Queensland, Brisbane, QLD, Australia.
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      The University of Queensland, Brisbane, QLD, Australia.
FAU - Rotemberg, Veronica
AU  - Rotemberg V
AD  - Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer
      Center, New York, NY, United States.
FAU - Weber, Jochen
AU  - Weber J
AD  - Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer
      Center, New York, NY, United States.
FAU - Soyer, H Peter
AU  - Soyer HP
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      The University of Queensland, Brisbane, QLD, Australia.
AD  - Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
FAU - Malvehy, Josep
AU  - Malvehy J
AD  - Department of Dermatology, Institut d'Investigacions Biomediques August Pi i
      Sunyer, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
FAU - Clunie, David
AU  - Clunie D
AD  - PixelMed Publishing, Bangor, PA, United States.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20210210
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7902872
OTO - NOTNLM
OT  - DICOM
OT  - artificial intelligence
OT  - dermatology
OT  - imaging
OT  - standards
COIS- HS is a shareholder of MoleMap NZ Limited and e-derm consult GmbH, and undertakes
      regular teledermatological reporting for both companies. HS also provides medical
      consultant services for Canfield Scientific Inc., First Derm by iDoc24 Inc, and
      Revenio Research Oy. DC provides consultancy to: MITA (editor of DICOM standard),
      Canfield Scientific, Philips Algotec, Essex Leidos CBIIT NCI, Brigham and Women's
      Hospital NCI Imaging Data Commons (IDC), University of Leeds Northern Pathology
      Imaging Co-operative (NPIC) and is on the advisory board of maiData. The
      remaining authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/02 06:00
MHDA- 2021/03/02 06:01
CRDT- 2021/03/01 05:39
PHST- 2020/10/21 00:00 [received]
PHST- 2020/12/31 00:00 [accepted]
PHST- 2021/03/01 05:39 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/03/02 06:01 [medline]
AID - 10.3389/fmed.2020.619787 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Feb 10;7:619787. doi: 10.3389/fmed.2020.619787.
      eCollection 2020.


PMID- 33643109
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210303
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Creating a Compassionate World: Addressing the Conflicts Between Sharing and
      Caring Versus Controlling and Holding Evolved Strategies.
PG  - 582090
LID - 10.3389/fpsyg.2020.582090 [doi]
AB  - For thousands of years, various spiritual traditions and social activists have
      appealed to humans to adopt compassionate ways of living to address the suffering
      of life. Yet, along with our potential for compassion and self-sacrifice, the
      last few thousand years of wars, slavery, tortures, and holocausts have shown
      humans can be extraordinarily selfish, callous, vicious, and cruel. While there
      has been considerable engagement with these issues, particularly in the area of
      moral psychology and ethics, this paper explores an evolutionary analysis
      relating to evolved resource-regulation strategies that can be called "care and
      share" versus "control and hold." Control and hold are typical of primates that
      operate through intimidatory social hierarchies. Care and share are less common
      in non-human primates, but evolved radically in humans during our hunter-gatherer
      stage when our ancestors lived in relatively interdependent, small, mobile
      groups. In these groups, individualistic, self-focus, and self-promoting control 
      and hold strategies (trying to secure and accumulate more than others) were
      shunned and shamed. These caring and sharing hunter-gatherer lifestyles also
      created the social contexts for the evolution of new forms of childcare and
      complex human competencies for language, reasoning, planning, empathy, and
      self-awareness. As a result of our new 'intelligence', our ancestors developed
      agriculture that reduced mobility, increased group size, resource availability
      and storage, and resource competition. These re-introduced competing for, rather 
      than sharing of, resources and advantaged those who now pursue (often
      aggressively) control and hold strategies. Many of our most typical forms of
      oppressive and anti-compassionate behavior are the result of these strategies.
      Rather than (just) thinking about individuals competing with one another, we can 
      also consider these different resource regulation strategies as competing within 
      populations shaping psychophysiological patterns; both wealth and poverty change 
      the brain. One of the challenges to creating a more compassionate society is to
      find ways to create the social and economic conditions that regulate control and 
      hold strategies and promote care and share. No easy task.
CI  - Copyright (c) 2021 Gilbert.
FAU - Gilbert, Paul
AU  - Gilbert P
AD  - Centre for Compassion Research and Training, College of Health and Social Care
      Research Centre, University of Derby, Derby, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210210
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7902494
OTO - NOTNLM
OT  - caring
OT  - compassion
OT  - competitive
OT  - evolution
OT  - strategies
COIS- The author declares that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/03/02 06:00
MHDA- 2021/03/02 06:01
CRDT- 2021/03/01 05:35
PHST- 2020/07/29 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2021/03/01 05:35 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/03/02 06:01 [medline]
AID - 10.3389/fpsyg.2020.582090 [doi]
PST - epublish
SO  - Front Psychol. 2021 Feb 10;11:582090. doi: 10.3389/fpsyg.2020.582090. eCollection
      2020.


PMID- 33638531
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 187
IP  - 1
DP  - 2020 Jul
TI  - Evaluating the use of cytosine arabinoside for treatment for recurrent canine
      steroid-responsive meningitis-arteritis.
PG  - e7
LID - 10.1136/vr.105683 [doi]
AB  - BACKGROUND: Relapses in steroid-responsive meningitis-arteritis (SRMA) are
      frequently observed but specific treatment protocols to address this problem are 
      sparsely reported. Standard treatment includes prolonged administration of
      glucocorticoids as monotherapy or in combination with immunosuppressive drugs.
      The aim of this study was to assess the safety and efficacy of cytosine
      arabinoside (CA) in combination with glucocorticoids for treatment of SRMA
      relapses in 12 dogs on a retrospective basis. METHODS: Dogs with recurrent
      episodes of SRMA and treated with a combination of CA and prednisolone were
      included. Information about clinical course, treatment response and adverse
      events was collected from medical records. Ethical approval was not required for 
      this study. RESULTS: Ten dogs (10/12) responded well to the treatment with
      clinical signs being completely controlled. One dog is in clinical remission, but
      still under treatment. One dog (8%) showed further relapse. Mean treatment period
      was 51 weeks. Adverse events of variable severity (grade 1-4/5) were documented
      in all dogs during treatment according to the veterinary cooperative oncology
      group grading. Three dogs developed severe adverse events. Laboratory findings
      showed marked changes up to grade 4. Diarrhoea and anaemia were the most often
      observed adverse events (6), followed by dermatitis (4), alopecia (3) and
      pneumonia (3). Including blood chemistry changes (13), 50 adverse events were
      found in total. CONCLUSION: Treatment with CA and glucocorticoids resulted in
      clinical remission in 10/12 dogs, but a high incidence of adverse events occurred
      requiring additional measures. All adverse events could be managed successfully
      in all cases.
CI  - (c) British Veterinary Association 2020.
FAU - Gunther, Christian
AU  - Gunther C
AUID- ORCID: 0000-0001-8999-1223
AD  - Clinic of Small Animal Surgery/Neurology, Vetsuisse Faculty, University of
      Zurich, Zurich, Switzerland.
FAU - Steffen, Frank
AU  - Steffen F
AD  - Clinic of Small Animal Surgery/Neurology, Vetsuisse Faculty, University of
      Zurich, Zurich, Switzerland.
FAU - Alder, Daniela S
AU  - Alder DS
AD  - Clinic of Small Animal Surgery/Neurology, Vetsuisse Faculty, University of
      Zurich, Zurich, Switzerland.
AD  - Neurology/Neurosurgery, Southern Counties Veterinary Specialists LLP, Ringwood,
      Hampshire, UK.
FAU - Beatrice, Laura
AU  - Beatrice L
AD  - Department fur Kleintiere, Oncology, Universitat Zurich, Zurich, Switzerland.
FAU - Geigy, Caroline
AU  - Geigy C
AD  - Department fur Kleintiere, Oncology, Universitat Zurich, Zurich, Switzerland.
AD  - Departmend of Internal Medicine, Marigin - Zentrum fur Tiermedizin, Feusisberg,
      Switzerland.
FAU - Beckmann, Katrin
AU  - Beckmann K
AD  - Clinic of Small Animal Surgery/Neurology, Vetsuisse Faculty, University of
      Zurich, Zurich, Switzerland.
AD  - Department fur Kleintiere, Oncology, Universitat Zurich, Zurich, Switzerland.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
RN  - 0 (Glucocorticoids)
RN  - 04079A1RDZ (Cytarabine)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Animals
MH  - Arteritis/drug therapy/*veterinary
MH  - Cytarabine/adverse effects/*therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Drug Therapy, Combination/veterinary
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Male
MH  - Meningitis/drug therapy/*veterinary
MH  - Prednisolone/therapeutic use
MH  - Recurrence
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7456679
OTO - NOTNLM
OT  - *adverse events
OT  - *cytosine arabinoside
OT  - *dogs
OT  - *recurrence
OT  - *relaps
OT  - *steroid responsive meningitis-arteritis
EDAT- 2021/02/28 06:00
MHDA- 2021/04/21 06:00
CRDT- 2021/02/27 08:35
PHST- 2019/08/14 00:00 [received]
PHST- 2019/10/17 00:00 [revised]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2021/02/27 08:35 [entrez]
PHST- 2021/02/28 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - 10.1136/vr.105683 [doi]
PST - ppublish
SO  - Vet Rec. 2020 Jul;187(1):e7. doi: 10.1136/vr.105683.


PMID- 33638519
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 187
IP  - 1
DP  - 2020 Jul
TI  - Is it ethical to continue to race horses?
PG  - 38
LID - 10.1136/vr.m2778 [doi]
FAU - Williams, David
AU  - Williams D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
SB  - IM
MH  - Animal Welfare/standards
MH  - Animals
MH  - Horses/*injuries
MH  - Running/*ethics/injuries
MH  - United Kingdom/epidemiology
MH  - Wounds and Injuries/mortality/*veterinary
PMC - PMC7456692
EDAT- 2021/02/28 06:00
MHDA- 2021/04/21 06:00
CRDT- 2021/02/27 08:35
PHST- 2021/02/27 08:35 [entrez]
PHST- 2021/02/28 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - 10.1136/vr.m2778 [doi]
PST - ppublish
SO  - Vet Rec. 2020 Jul;187(1):38. doi: 10.1136/vr.m2778.


PMID- 33635761
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20220213
IS  - 1552-5775 (Electronic)
IS  - 1552-5767 (Linking)
VI  - 25
DP  - 2020 Dec
TI  - Interfaith Dialogue and Sir William Osler.
PG  - 1
LID - 10.7812/TPP/20.045 [doi]
AB  - None: In recent years, the US has become extensively polarized across social,
      political, and religious divides. As the cultural, political, and social divides 
      continue to grow, the medical establishment has shown similar divisions between
      clinicians and patients. However, an inclusive dialogue that recognizes the
      intellectual and interpersonal boundaries of opposing groups and traditions would
      provide an avenue toward mutual understanding and further collaboration toward a 
      common goal and solution. One such method for building bridges between opposing
      groups can be found in interfaith dialogue. The goal of interfaith dialogue is
      not merely to exchange pleasantries but also to develop a mutual collaboration
      addressing moral and ethical issues with a unified voice. This is achieved
      through moving beyond separation and suspicion, inquiring more deeply, sharing
      both the easy and the difficult parts, moving beyond safe territory, and
      exploring spiritual practices from other traditions. A physician who exemplified 
      many aspects interfaith dialogue in his clinical practice was the late Sir
      William Osler. Through examining Osler's application of interfaith dialogue, we
      may develop a framework by which clinicians can actively build new bridges and
      dialogue between their patients and society.
CI  - Copyright (c) 2020 The Permanente Press. All rights reserved.
FAU - Kopel, Jonathan
AU  - Kopel J
AD  - Texas Tech University Health Sciences Center, Lubbock, TX.
FAU - Webb, Mark
AU  - Webb M
AD  - Philosophy Department, Texas Tech University, Lubbock, TX.
FAU - Gorga, Carmine
AU  - Gorga C
AD  - Somist Institute, Gloucester, MA.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Perm J
JT  - The Permanente journal
JID - 9800474
SB  - IM
MH  - History, 20th Century
MH  - Humans
MH  - Morals
MH  - Motivation
MH  - *Physicians
PMC - PMC8803255
EDAT- 2021/02/27 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/02/26 17:08
PHST- 2021/02/26 17:08 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.7812/TPP/20.045 [doi]
PST - ppublish
SO  - Perm J. 2020 Dec;25:1. doi: 10.7812/TPP/20.045.


PMID- 33634661
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1744-9219 (Electronic)
IS  - 1744-9200 (Linking)
VI  - 16
IP  - 3
DP  - 2020 May 4
TI  - The priority health issues and key health determinants of detained Filipino
      children.
PG  - 281-302
LID - 10.1108/IJPH-09-2019-0052 [doi]
AB  - PURPOSE: Rising societal pressures for the Filipino urban poor population -
      precipitating increased crime - alongside widespread corruption, have led to many
      children being both lawfully and unlawfully detained in child rehabilitation
      centres. Far from rehabilitating, detained children live in prisonlike
      conditions, despite the illegality of child imprisonment in the country. Their
      human rights disregarded; they suffer from abuse, neglect and a multitude of
      health issues, with no access to healthcare. This study aims to explore the
      experiences and perceptions of formerly detained looked-after adolescents and
      their carers, on the priority health issues and key health determinants of
      detained Filipino children. DESIGN/METHODOLOGY/APPROACH: A qualitative study was 
      conducted in June 2019 in a Filipino children's home for previously detained
      children. In total, 18 semi-structured interviews, using photo-elicitation, were 
      conducted to retrospectively explore the experiences of formerly detained
      children and their carers, who were purposively sampled. Data were transcribed
      and thematically analysed. Ethical approval was granted by the University of
      Leeds. FINDINGS: Adolescents and carers commonly reported eight key health issues
      in detained children, namely, most frequently skin disease, mental health issues 
      and malnutrition, then additionally wounds, respiratory disease, dental problems,
      sexual health issues and gastrointestinal issues. Six determinants of health in
      detainment centres were identified as follows: hygiene, food, weather,
      overcrowding, facilities and safeguarding issues. ORIGINALITY/VALUE: The
      illegality and corruption associated with child detention centres mean the
      situation of detained Filipino children is difficult to assess directly. This
      study combats this by exploring the experiences of formerly detained children and
      their carers, to retrospectively assess the health of illegally detained Filipino
      Children.
CI  - (c) Emerald Publishing Limited.
FAU - Blount, Rosie
AU  - Blount R
AD  - Department of Medicine and Health, University of Leeds, Leeds, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Prison Health
JT  - International journal of prisoner health
JID - 101255940
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Child Abuse
MH  - Human Rights
MH  - Humans
MH  - Qualitative Research
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *Child prisoner
OT  - *Childhood abuse
OT  - *Infectious disease
OT  - *Juvenile offenders
OT  - *Overcrowding
OT  - *Young offenders
EDAT- 2021/02/27 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/02/26 06:10
PHST- 2021/02/26 06:10 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.1108/IJPH-09-2019-0052 [doi]
PST - ppublish
SO  - Int J Prison Health. 2020 May 4;16(3):281-302. doi: 10.1108/IJPH-09-2019-0052.


PMID- 33634047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210227
IS  - 2279-9028 (Print)
IS  - 2279-9028 (Linking)
VI  - 9
IP  - Suppl 1
DP  - 2020 Nov 17
TI  - Work environment during the COVID-19 pandemic in Saudi Arabia.
PG  - 1968
LID - 10.4081/jphr.2020.1968 [doi]
AB  - Background: COVID-19 is affecting all spheres of life. As of 8 September 2020,
      there have been 321,595 confirmed cases of COVID-19 and 4,107 deaths in Saudi
      Arabia. The concerns regarding work from offices and contacting others is a
      global concern during this pandemic. Most of workers are mainly concerns about
      getting infected and spread it to their families. Therefore, to cope with the
      COVID-19 pandemic, architects, urban planners, and designers have already
      switched their attention to visualizing the post-pandemic era; however, there are
      inadequate studies on how the antivirus-built environment will look. Accordingly,
      this study aims to reflect on perceptions of the work environment during the
      COVID-19 pandemic in Saudi Arabia. Design and Methods: An online questionnaire
      consisting of five questions was designed to collect the data and was distributed
      via SurveyMonkey in August 2020. Research ethics approval was sought from the
      institutional review board. A total of 87 respondents participated in this study.
      Results: The result shows that 57.83% of respondents were female and 42.17% were 
      male. The majority of the respondents were from the public sector (49.40% -
      public sector, 43.37% - private sector, and 7.23% - other sectors). Overall,
      female participants were more concerned about work environments during the
      pandemic. Most of the participants were working in individual offices.
      Conclusion: The virus does not discriminate by gender. In order to respond
      effectively to the crisis, we need a whole-society approach to understand its
      differential impact on women and men. The findings will encourage policymakers
      and business owners to respond to the areas highlighted in this study as causing 
      concern such as elevators, restrooms, and common areas.
CI  - (c)Copyright: the Author(s).
FAU - Aburas, Rehab
AU  - Aburas R
AD  - Interior Design Engineering Department, College of Architecture and Design,
      Prince Sultan University, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20210208
PL  - United States
TA  - J Public Health Res
JT  - Journal of public health research
JID - 101580775
PMC - PMC7883107
OTO - NOTNLM
OT  - COVID-19
OT  - Saudi Arabia
OT  - work environment
EDAT- 2021/02/27 06:00
MHDA- 2021/02/27 06:01
CRDT- 2021/02/26 06:04
PHST- 2020/09/27 00:00 [received]
PHST- 2021/01/09 00:00 [accepted]
PHST- 2021/02/26 06:04 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/02/27 06:01 [medline]
AID - 10.4081/jphr.2020.1968 [doi]
PST - epublish
SO  - J Public Health Res. 2021 Feb 8;9(Suppl 1):1968. doi: 10.4081/jphr.2020.1968.
      eCollection 2020 Nov 17.


PMID- 33633695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210227
IS  - 1664-302X (Print)
IS  - 1664-302X (Linking)
VI  - 11
DP  - 2020
TI  - Translating New Synthetic Biology Advances for Biosensing Into the Earth and
      Environmental Sciences.
PG  - 618373
LID - 10.3389/fmicb.2020.618373 [doi]
AB  - The rapid diversification of synthetic biology tools holds promise in making some
      classically hard-to-solve environmental problems tractable. Here we review
      longstanding problems in the Earth and environmental sciences that could be
      addressed using engineered microbes as micron-scale sensors (biosensors).
      Biosensors can offer new perspectives on open questions, including understanding 
      microbial behaviors in heterogeneous matrices like soils, sediments, and
      wastewater systems, tracking cryptic element cycling in the Earth system, and
      establishing the dynamics of microbe-microbe, microbe-plant, and microbe-material
      interactions. Before these new tools can reach their potential, however, a suite 
      of biological parts and microbial chassis appropriate for environmental
      conditions must be developed by the synthetic biology community. This includes
      diversifying sensing modules to obtain information relevant to environmental
      questions, creating output signals that allow dynamic reporting from
      hard-to-image environmental materials, and tuning these sensors so that they
      reliably function long enough to be useful for environmental studies. Finally,
      ethical questions related to the use of synthetic biosensors in environmental
      applications are discussed.
CI  - Copyright (c) 2021 Del Valle, Fulk, Kalvapalle, Silberg, Masiello and Stadler.
FAU - Del Valle, Ilenne
AU  - Del Valle I
AD  - Systems, Synthetic, and Physical Biology Graduate Program, Rice University,
      Houston, TX, United States.
FAU - Fulk, Emily M
AU  - Fulk EM
AD  - Systems, Synthetic, and Physical Biology Graduate Program, Rice University,
      Houston, TX, United States.
FAU - Kalvapalle, Prashant
AU  - Kalvapalle P
AD  - Systems, Synthetic, and Physical Biology Graduate Program, Rice University,
      Houston, TX, United States.
FAU - Silberg, Jonathan J
AU  - Silberg JJ
AD  - Department of BioSciences, Rice University, Houston, TX, United States.
AD  - Department of Bioengineering, Rice University, Houston, TX, United States.
AD  - Department of Chemical and Biomolecular Engineering, Rice University, Houston,
      TX, United States.
FAU - Masiello, Caroline A
AU  - Masiello CA
AD  - Department of BioSciences, Rice University, Houston, TX, United States.
AD  - Department of Earth, Environmental and Planetary Sciences, Rice University,
      Houston, TX, United States.
AD  - Department of Chemistry, Rice University, Houston, TX, United States.
FAU - Stadler, Lauren B
AU  - Stadler LB
AD  - Department of Civil and Environmental Engineering, Rice University, Houston, TX, 
      United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210204
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC7901896
OTO - NOTNLM
OT  - biogeochemistry
OT  - biosensor
OT  - cell-free sensors
OT  - environmental microbiology
OT  - marine
OT  - soil
OT  - synthetic biology
OT  - wastewater
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/27 06:00
MHDA- 2021/02/27 06:01
CRDT- 2021/02/26 06:03
PHST- 2020/10/16 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/02/26 06:03 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/02/27 06:01 [medline]
AID - 10.3389/fmicb.2020.618373 [doi]
PST - epublish
SO  - Front Microbiol. 2021 Feb 4;11:618373. doi: 10.3389/fmicb.2020.618373.
      eCollection 2020.


PMID- 33631901
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2448-9190 (Electronic)
IS  - 0002-5151 (Linking)
VI  - 67
IP  - 4
DP  - 2020 Oct-Dec
TI  - [The prevalence of allergic diseases in children with short bowel syndrome].
PG  - 329-337
LID - 10.29262/ram.v67i4.801 [doi]
AB  - BACKGROUND: Short bowel syndrome is the result of an extensive surgical resection
      that leaves the length of the small intestine at a critical value for the proper 
      nutritional absorption. An increased risk of food allergy has been described in
      patients who suffer from this condition. OBJECTIVE: To describe the prevalence of
      allergic diseases in a group of patients with short bowel syndrome. METHODS: A
      descriptive, cross-sectional, and ambispective study was carried out; it included
      patients with short bowel syndrome who had attended the nephrology service of the
      National Institute of Pediatrics in a period of 18 months. Information about
      medical records, surgery history, diet history, and food tolerance was collected 
      with prior authorization of parents or legal guardians. Likewise, there was
      questioning about history of atopy, and validated questionnaires for allergic
      diseases were applied in Spanish. The following tests were carried out: skin
      tests with allergen extracts, determination of four foods specific immunoglobulin
      E, patch test, and open oral food challenge. The protocol was authorized by the
      research ethics committee. RESULTS: Fifteen patients with a median age of 44
      months (range of 8-128 months) and with a male/female ratio of 2:1 were included.
      The most common causes of SBS were necrotizing enterocolitis and intestinal
      atresia. 27% of the patients had a family history of atopy and 40 % of the
      patients had a personal history that suggested an allergy to cow's milk in
      infancy. Allergic diseases were found in 40 %. CONCLUSIONS: Allergic diseases
      seem to have high prevalence in patients with SBS. More studies in large
      populations are required in order to confirm this discovery.
FAU - Morfin-Maciel, Blanca Maria
AU  - Morfin-Maciel BM
AD  - Instituto Nacional de Pediatria, Servicio de Nefrologia, Ciudad de Mexico,
      Mexico. blancammorfin@gmail.com.
FAU - Garcia-de la Puente, Silvestre
AU  - Garcia-de la Puente S
FAU - Huante-Anaya, Alfonso
AU  - Huante-Anaya A
FAU - Bojorquez-Ochoa, Aurora
AU  - Bojorquez-Ochoa A
LA  - spa
PT  - Journal Article
TT  - Prevalencia de enfermedades alergicas en ninos con sindrome de intestino corto.
PL  - Mexico
TA  - Rev Alerg Mex
JT  - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
JID - 9438824
SB  - IM
MH  - Animals
MH  - Cattle
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Food Hypersensitivity/diagnosis/epidemiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - *Milk Hypersensitivity
MH  - Prevalence
MH  - *Short Bowel Syndrome/epidemiology
MH  - Skin Tests
OTO - NOTNLM
OT  - Atopy
OT  - Childhood
OT  - Food allergy
OT  - Sensitization
OT  - Short bowel syndrome
EDAT- 2021/02/27 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/02/26 03:05
PHST- 2021/02/26 03:05 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 10.29262/ram.v67i4.801 [doi]
PST - ppublish
SO  - Rev Alerg Mex. 2020 Oct-Dec;67(4):329-337. doi: 10.29262/ram.v67i4.801.


PMID- 33629030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210226
IS  - 2515-9321 (Electronic)
IS  - 2515-9321 (Linking)
VI  - 3
DP  - 2020
TI  - The nexus between improved water supply and water-borne diseases in urban areas
      in Africa: a scoping review protocol.
PG  - 12
LID - 10.12688/aasopenres.13063.2 [doi]
AB  - Introduction: Currently, an estimated two thirds of the world population is water
      insufficient. As of 2015, one out of every five people in developing countries do
      not have access to clean sufficient drinking water. In an attempt to share the
      limited resource, water has been distributed at irregular intervals in cities in 
      developing countries. Residents in these cities seek alternative water sources to
      supplement the inadequate water supplied. Some of these alternative sources of
      water are unsafe for human consumption, leading to an increased risk in
      water-borne diseases. Africa contributes to 53% of the diarrheal cases reported
      globally, with contaminated drinking water being the main source of transmission.
      Water-borne diseases like diarrhea, cholera, typhoid, amoebiasis, dysentery,
      gastroenteritis, cryptosporidium, cyclosporiasis, giardiasis, guinea worm and
      rotavirus are a major public health concern. The main objective of this scoping
      review is to map the available evidence to understand the sources of water among 
      residents in cities in Africa and the relationship between clean water
      sufficiency and water-borne diseases in urban Africa. Methods and analysis: The
      search strategy will identify studies published in scientific journals and
      reports that are directly relevant to African cities that have a population of
      more than half a million residents as of 2014 AND studies on the ten emerging
      water-borne diseases, which are diarrhea, cholera, typhoid, amoebiasis,
      dysentery, gastroenteritis, cryptosporidium, cyclosporiasis, giardiasis, guinea
      worm and rotavirus. Ethics and dissemination: This scoping review did not require
      any formal ethical approval. The findings will be published in a peer-reviewed
      journal.
CI  - Copyright: (c) 2020 Mutono N et al.
FAU - Mutono, Nyamai
AU  - Mutono N
AUID- ORCID: https://orcid.org/0000-0002-7378-0007
AD  - Wangari Maathai Institute for Peace and Environmental Studies, University of
      Nairobi, Nairobi, Kenya.
AD  - Washington State University Global Health - Kenya, Nairobi, Kenya.
FAU - Wright, James
AU  - Wright J
AD  - Geography and Environmental Science, University of Southampton, Southampton, UK.
FAU - Mutembei, Henry
AU  - Mutembei H
AD  - Wangari Maathai Institute for Peace and Environmental Studies, University of
      Nairobi, Nairobi, Kenya.
AD  - Department of Clinical Studies, Faculty of Veterinary Medicine, University of
      Nairobi, Nairobi, Kenya.
FAU - Muema, Josphat
AU  - Muema J
AUID- ORCID: https://orcid.org/0000-0001-5894-5136
AD  - Washington State University Global Health - Kenya, Nairobi, Kenya.
AD  - Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi,
      Kenya.
FAU - Thomas, Mair
AU  - Thomas M
AUID- ORCID: https://orcid.org/0000-0003-1899-2434
AD  - Geography and Environmental Science, University of Southampton, Southampton, UK.
FAU - Mutunga, Mumbua
AU  - Mutunga M
AD  - Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi,
      Kenya.
FAU - Thumbi, Samuel Mwangi
AU  - Thumbi SM
AUID- ORCID: https://orcid.org/0000-0002-5754-0556
AD  - Wangari Maathai Institute for Peace and Environmental Studies, University of
      Nairobi, Nairobi, Kenya.
AD  - Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi,
      Kenya.
AD  - Paul G Allen School for Global Animal Health, Washington State University,
      Pullman, USA.
AD  - Institute of Immunology and Infection Research, University of Edinburgh,
      Edinburgh, UK.
AD  - NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA),
      University of Edinburgh, Edinburgh, UK.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - England
TA  - AAS Open Res
JT  - AAS open research
JID - 101740247
PMC - PMC7883317
OTO - NOTNLM
OT  - African cities
OT  - Water-borne diseases
OT  - scoping review
OT  - water insufficiency
OT  - water supply
COIS- No competing interests were disclosed.
EDAT- 2021/02/27 06:00
MHDA- 2021/02/27 06:01
CRDT- 2021/02/26 06:05
PHST- 2020/12/04 00:00 [accepted]
PHST- 2021/02/26 06:05 [entrez]
PHST- 2021/02/27 06:00 [pubmed]
PHST- 2021/02/27 06:01 [medline]
AID - 10.12688/aasopenres.13063.2 [doi]
PST - epublish
SO  - AAS Open Res. 2020 Dec 8;3:12. doi: 10.12688/aasopenres.13063.2. eCollection
      2020.


PMID- 33628955
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2421-4248 (Electronic)
IS  - 1121-2233 (Linking)
VI  - 61
IP  - 4
DP  - 2020 Dec
TI  - Universal Health Coverage to counteract the economic impact of the COVID-19
      infection: current practices and ethical challenges.
PG  - E520-E524
LID - 10.15167/2421-4248/jpmh2020.61.4.1581 [doi]
AB  - In late December 2019, the first case of an emerging coronavirus was identified
      in the city of Wuhan, Hubei province, in mainland China. The novel virus appears 
      to be highly contagious and is rapidly spreading worldwide, becoming a pandemic. 
      The disease is causing a high toll of deaths. Effective public health responses
      to a new infectious disease are expected to mitigate and counteract its negative 
      impact on the population. However, time and economic-financial constraints, as
      well as uncertainty, can jeopardize the answer. The aim of the present paper was 
      to discuss the role of Universal Health Coverage to counteract the economic
      impact of the COVID-19 infection. Appropriate financing of the health system and 
      ensuring equitable access to health services for all can, indeed, protect
      individuals against high medical costs, which is one of the most important goals 
      of any health system. Financing profoundly affects the performance of the health 
      system, and any policy that the health system decides to implement or not
      directly depends on the amount of available funding. Developed countries are
      injecting new funding to cope with the disease and prevent its further
      transmission. In addition to psychological support and increased societal
      engagement for the prevention, control, and treatment of COVID-19, extensive
      financial support to governments by the community should be considered. Developed
      and rich countries should support countries that do not have enough financial
      resources. This disease cannot be controlled and contained without international 
      cooperation. The experience of the COVID-19 should be a lesson for further
      establishing and achieving universal health coverage in all countries. In
      addition to promoting equity in health, appropriate infrastructure should be
      strengthened to address these crises. Governments should make a stronger
      political commitment to fully implement this crucial set of policies and plans.
CI  - (c)2020 Pacini Editore SRL, Pisa, Italy.
FAU - Behzadifar, Masoud
AU  - Behzadifar M
AD  - Social Determinants of Health Research Center, Lorestan University of Medical
      Sciences, Khorramabad, Iran.
FAU - Imani-Nasab, Mohammad-Hasan
AU  - Imani-Nasab MH
AD  - Social Determinants of Health Research Center, Lorestan University of Medical
      Sciences, Khorramabad, Iran.
FAU - Martini, Mariano
AU  - Martini M
AD  - Department of Health Sciences, University of Genoa, Italy.
FAU - Ghanbari, Mahboubeh Khaton
AU  - Ghanbari MK
AD  - Health Management and Economics Research Center, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Bakhtiari, Ahad
AU  - Bakhtiari A
AD  - Department of Health Management and Economics, School of Public Health, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Bragazzi, Nicola Luigi
AU  - Bragazzi NL
AD  - Department of Mathematics and Statistics, York University, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20210114
PL  - Italy
TA  - J Prev Med Hyg
JT  - Journal of preventive medicine and hygiene
JID - 9214440
SB  - IM
MH  - COVID-19/*economics/epidemiology
MH  - Developing Countries/economics
MH  - Global Health/*economics
MH  - Health Services Accessibility/*economics
MH  - Humans
MH  - International Cooperation
MH  - Pandemics/economics
MH  - Public Health/economics
MH  - Universal Health Insurance/*economics
PMC - PMC7888394
OTO - NOTNLM
OT  - COVID-19
OT  - Economic crisis
OT  - Ethical issues
OT  - Health crisis
OT  - Health financing
OT  - Health policy
OT  - Universal health coverage
EDAT- 2021/02/26 06:00
MHDA- 2021/03/05 06:00
CRDT- 2021/02/25 05:47
PHST- 2020/05/14 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2021/02/25 05:47 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - 10.15167/2421-4248/jpmh2020.61.4.1581 [doi]
PST - epublish
SO  - J Prev Med Hyg. 2021 Jan 14;61(4):E520-E524. doi:
      10.15167/2421-4248/jpmh2020.61.4.1581. eCollection 2020 Dec.


PMID- 33628190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210225
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Corrigendum: Linking the Declarations of Helsinki and of Taipei: Critical
      Challenges of Future-Oriented Research Ethics.
PG  - 637775
LID - 10.3389/fphar.2020.637775 [doi]
AB  - [This corrects the article DOI: 10.3389/fphar.2020.579714.].
CI  - Copyright (c) 2021 Kurihara, Baroutsou, Becker, Brun, Franke-Bray, Carlesi, Chan,
      Collia, Kleist, Laranjeira, Matsuyama, Naseem, Schenk, Silva and Kerpel-Fronius.
FAU - Kurihara, Chieko
AU  - Kurihara C
AD  - National Institutes for Quantum and Radiological Science and Technology, Chiba,
      Japan.
FAU - Baroutsou, Varvara
AU  - Baroutsou V
AD  - Independent Medical Consultant, and Consultant, Pharmaceutical Medicine, Athens, 
      Greece.
FAU - Becker, Sander
AU  - Becker S
AD  - Consultants in Pharmaceutical Medicine, Dover Heights, Australia.
FAU - Brun, Johan
AU  - Brun J
AD  - LIF, Stockholm, Sweden.
FAU - Franke-Bray, Brigitte
AU  - Franke-Bray B
AD  - Independent Consultant, Basel, Switzerland.
FAU - Carlesi, Roberto
AU  - Carlesi R
AD  - Independent Researcher, Bellagio, Italy.
FAU - Chan, Anthony
AU  - Chan A
AD  - Pfizer Biopharmaceuticals Group, Dublin, Ireland.
FAU - Collia, Luis Francisco
AU  - Collia LF
AD  - Craveri Pharma, Buenos Aires, Argentina.
FAU - Kleist, Peter
AU  - Kleist P
AD  - Cantonal Ethics Committee, Zurich, Switzerland.
FAU - Laranjeira, Luis Filipe
AU  - Laranjeira LF
AD  - Eli Lilly & Co., Lisbon, Portugal.
FAU - Matsuyama, Kotone
AU  - Matsuyama K
AD  - Nippon Medical School, Tokyo, Japan.
FAU - Naseem, Shehla
AU  - Naseem S
AD  - Ferozsons Laboratories Ltd, Karachi, Pakistan.
FAU - Schenk, Johanna
AU  - Schenk J
AD  - PPH Plus GmbH & Co. KG, Hochheim am Main, Germany.
FAU - Silva, Honorio
AU  - Silva H
AD  - IFAPP Academy, New York, NY, United States.
FAU - Kerpel-Fronius, Sandor
AU  - Kerpel-Fronius S
AD  - Semmelweis University, Budapest, Hunbary.
CN  - Working Group on Ethics of the International Federation of Associations of
      Pharmaceutical Physicians and Pharmaceutical Medicine
LA  - eng
PT  - Published Erratum
DEP - 20210208
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
EFR - Front Pharmacol. 2020 Oct 29;11:579714. PMID: 33324212
PMC - PMC7897664
OTO - NOTNLM
OT  - data science
OT  - data sharing
OT  - declaration of Helsinki
OT  - declaration of Taipei
OT  - medicines development
OT  - privacy protection
OT  - research ethics
COIS- JB is an employee of LIF; AC is an employee of Pfizer Biopharmaceuticals Group;
      LC is an employee of Craveri Pharma; LF is an employee of Eli Lilly & Co.; SN is 
      an employee of Ferozsons Laboratories Ltd.; JS is an executive consultant of PPH 
      plus GmbH & Co. KG, Hochheim am Main. The remaining authors declare that the
      research was conducted in the absence of any commercial or financial
      relationships that could be construed as a potential conflict of interest.
EDAT- 2021/02/26 06:00
MHDA- 2021/02/26 06:01
CRDT- 2021/02/25 05:44
PHST- 2020/12/04 00:00 [received]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/02/25 05:44 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/02/26 06:01 [medline]
AID - 10.3389/fphar.2020.637775 [doi]
AID - 637775 [pii]
PST - epublish
SO  - Front Pharmacol. 2021 Feb 8;11:637775. doi: 10.3389/fphar.2020.637775.
      eCollection 2020.


PMID- 33627982
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0974-1208 (Print)
IS  - 1998-4766 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Oct-Dec
TI  - Emotional Impact of Delay in Fertility Treatment due to COVID-19 Pandemic.
PG  - 317-322
LID - 10.4103/jhrs.JHRS_144_20 [doi]
AB  - BACKGROUND: COVID-19 pandemic is an unprecedented public health emergency. When
      the pandemic started in our country fertility treatment was suspended for
      sometimes following national and international guidelines. This has led to delay 
      in fertility treatment for some couples which was emotionally upsetting.
      METHODOLOGY AND DESIGN: This study was done on the patients enrolled at our
      various fertility units across India. The survey questionnaire was sent to
      patients during the month of first May to June 15, 2020, when COVID-19 pandemic
      was active across the country, and fertility units were just resuming the
      services back. The questionnaire was distributed to 100 patients who were
      currently under treatment and their response was recorded. Ethical committee
      approval was not taken as surveys are exempted from IRB. RESULTS: This survey was
      undertaken to understand the emotional impact of delay/cancelation in the
      fertility treatment during the COVID-19 pandemic. The survey revealed that
      majority (95%) of couples felt cancelation of cycles as upsetting and 16%
      reporting it to be extremely upsetting. The impact was seen in the form of mood
      disturbances, anxiety, sleep disturbances, and depressive ideas. Almost half of
      the couples (49.4%) were desirous to start the fertility treatment immediately.
      Their knowledge regarding COVID-19 and pregnancy and future child was limited.
      CONCLUSION: COVID-19 has had impact on every sphere of life. Delay in treatment
      and cancelation of cycles were emotionally upsetting to majority of couples and
      they were keen to restart the treatment sooner than later.
CI  - Copyright: (c) 2020 Journal of Human Reproductive Sciences.
FAU - Kaur, Harpreet
AU  - Kaur H
AD  - Milann Fertility Center, Chandigarh, India.
FAU - Pranesh, Gautham T
AU  - Pranesh GT
AD  - Milann Fertility Center, Bengaluru, Karnataka, India.
FAU - Rao, Kamini A
AU  - Rao KA
AD  - Milann Fertility Center, Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201228
PL  - India
TA  - J Hum Reprod Sci
JT  - Journal of human reproductive sciences
JID - 101473512
PMC - PMC7879841
OTO - NOTNLM
OT  - COVID-19
OT  - delay in fertility treatment
OT  - emotional impact
COIS- There are no conflicts of interest.
EDAT- 2021/02/26 06:00
MHDA- 2021/02/26 06:01
CRDT- 2021/02/25 05:43
PHST- 2020/08/04 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2021/02/25 05:43 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/02/26 06:01 [medline]
AID - 10.4103/jhrs.JHRS_144_20 [doi]
AID - JHRS-13-317 [pii]
PST - ppublish
SO  - J Hum Reprod Sci. 2020 Oct-Dec;13(4):317-322. doi: 10.4103/jhrs.JHRS_144_20. Epub
      2020 Dec 28.


PMID- 33627922
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0353-8109 (Print)
IS  - 0353-8109 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - Guidelines for Editing Biomedical Journals: Recommended by Academy of Medical
      Sciences of Bosnia and Herzegovina.
PG  - 232-236
LID - 10.5455/aim.2020.28.232-236 [doi]
AB  - BACKGROUND: Enormous number of medical journals published around the globe
      requires standardization of editing practice. OBJECTIVE: The aim of this article 
      was to enlist main principles of editing biomedical scientific journals adopted
      at annual meeting of Academy of Medical Sciences of Bosnia & Herzegovina
      (AMSB&H). METHODS: The evidence for writing this Guideline was systematically
      searched for during September 2020 in the PUBMED and GOOGLE SCHOLAR databases.
      The inclusion criteria were: original studies, systematic reviews, invited expert
      opinions, guidelines and editorials. The exclusion criteria were narrative
      reviews and uninvited opinion articles. The retrieved evidence was analyzed by
      members of the AMSB&H, then discussed at 2020 annual meeting of the AMSB&H and
      adopted by nominal group technique. RESULTS: In total 14 recommendations were
      made, based on A to C class of evidence. The editors should educate potential
      authors and instruct them how to structure their manuscript, how to write every
      segment of the manuscript, and take care about correct use of statistical tests. 
      Plagiarism detection softwares should be used regularly, and statistical and
      technical editing should be rigorous and thorough. International standards of
      reporting specific types of studies should be followed, and principles of ethical
      and responsible behavior of editors, reviewers and authors should be published on
      the journal's web site. The editors should insist on registration of clinical
      studies before submission, and check whether non-essential personal information
      is removed from the articles; when essential personal information has to be
      included, an article should not be published without signed informed consent by
      the patient to whom these information relate. CONCLUSIONS: Principles of editing 
      biomedical scientific journals recommended in this guideline should serve as one 
      of the means of improving medical journals' quality.
CI  - (c) 2020 Izet Masic, Slobodan M. Jankovic, Asim Kurjak, Doncho M. Donev, Muharem 
      Zildzic, Osman Sinanovic, Izet Hozo, Snjezana Milicevic, Sefik Hasukic, Emir
      Mujanovic, Kenan Arnautovic, Senaid Trnacevic, Enisa Mesic, Mirza Biscevic,
      Mustafa Sefic, Vjekoslav Gerc, Abdulah Kucukalic, Zlatko Hrgovic, Jacob
      Bergsland, Mirko Grujic.
FAU - Masic, Izet
AU  - Masic I
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - World Academy of Art and Science, Washington, USA.
AD  - International Academy of Health Science Informatics, Geneva, Switzerland.
FAU - Jankovic, Slobodan M
AU  - Jankovic SM
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
FAU - Kurjak, Asim
AU  - Kurjak A
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - World Academy of Art and Science, Washington, USA.
AD  - European Academy of Sciences and Arts, Salzburg, Austria.
AD  - International Academy of Perinatal medicine, Zagreb, Croatia.
AD  - Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.
FAU - Donev, Doncho M
AU  - Donev DM
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - European Academy of Sciences and Arts, Salzburg, Austria.
AD  - Faculty of Medicine, Ss Cyril and Methodius University, Skopje, R.N. Macedonia.
FAU - Zildzic, Muharem
AU  - Zildzic M
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
FAU - Sinanovic, Osman
AU  - Sinanovic O
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.
FAU - Hozo, Izet
AU  - Hozo I
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Faculty of Medicine, University of Split, Split, Croatia.
FAU - Milicevic, Snjezana
AU  - Milicevic S
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and
      Herzegovina.
FAU - Hasukic, Sefik
AU  - Hasukic S
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Department of Surgery, University Clinical Center Tuzla, Tuzla, Bosnia and
      Herzegovina.
FAU - Mujanovic, Emir
AU  - Mujanovic E
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Medical center Bayer, Tuzla, Tuzla, Bosnia and Herzegovina.
FAU - Arnautovic, Kenan
AU  - Arnautovic K
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - Semmes Murphey Leaders in Brain and Spine Care, Memphis, Tennessee, USA.
FAU - Trnacevic, Senaid
AU  - Trnacevic S
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
FAU - Mesic, Enisa
AU  - Mesic E
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
FAU - Biscevic, Mirza
AU  - Biscevic M
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - General Hospital "Prim. Dr. Abdulah Nakas", Sarajevo, Bosnia and Herzegovina.
FAU - Sefic, Mustafa
AU  - Sefic M
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
FAU - Gerc, Vjekoslav
AU  - Gerc V
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
FAU - Kucukalic, Abdulah
AU  - Kucukalic A
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
FAU - Hrgovic, Zlatko
AU  - Hrgovic Z
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
FAU - Bergsland, Jacob
AU  - Bergsland J
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
AD  - University Hospital Oslo, Oslo, Norway.
FAU - Grujic, Mirko
AU  - Grujic M
AD  - Academy of Medical Sciences of Bosnia and Herzegovina, Sarajevo, Bosnia and
      Herzegovina.
LA  - eng
PT  - Editorial
PL  - Bosnia and Herzegovina
TA  - Acta Inform Med
JT  - Acta informatica medica : AIM : journal of the Society for Medical Informatics of
      Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH
JID - 101147064
PMC - PMC7879445
OTO - NOTNLM
OT  - editing
OT  - evidence-based
OT  - medical journals
OT  - recommendations
COIS- None declared.
EDAT- 2021/02/26 06:00
MHDA- 2021/02/26 06:01
CRDT- 2021/02/25 05:43
PHST- 2021/02/25 05:43 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/02/26 06:01 [medline]
AID - 10.5455/aim.2020.28.232-236 [doi]
AID - AIM-28-232 [pii]
PST - ppublish
SO  - Acta Inform Med. 2020 Dec;28(4):232-236. doi: 10.5455/aim.2020.28.232-236.


PMID- 33623619
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1937-8688 (Electronic)
VI  - 35
IP  - Suppl 2
DP  - 2020
TI  - Ethical issues in the COVID-19 pandemic control preparedness in a developing
      economy.
PG  - 95
LID - 10.11604/pamj.supp.2020.35.23121 [doi]
AB  - Adequate preparation for highly pathogenic infectious disease pandemic can reduce
      the incidence, prevalence and burden of diseases like COVID-19 pandemic. An
      antidote to the spread of the disease is adequate preparation for its control
      since there is no proven curative measure yet. Effective management of identified
      cases, social distancing, contact tracing and provision of basic infrastructure
      to facilitate compliance with preventive measures, testing are proven management 
      strategies. Although these measures seem to be the best options presently, it is 
      important to pay attention to ethical issues arising from the implementation
      process to ensure best practice. While disease epidemic is not alien to human
      societies, lessons from previous outbreaks are vital for addressing future
      outbreaks. For effective control of this pandemic, there should be a clear
      definition of social distancing in terms of distance and space in line with the
      WHO definition, adequate provision of basic amenities, screening and testing with
      specific criteria for selecting those to be screened. Also, there should be a
      free testing procedure, access to treatment opportunities for those who test
      positive, ethical free contact tracing practice, respect for the autonomy of
      those to be tested, and global best practice of open science, open data and data 
      sharing practices. In conclusion, a framework/guideline for epidemic/pandemic
      ethics guidance should be developed while an ethical sensitive communication
      manual should be prepared for public engagement on epidemic and pandemic.
CI  - (c) Ayodele Jegede et al.
FAU - Jegede, Ayodele
AU  - Jegede A
AD  - Department of Sociology, Faculty of the Social Sciences, University of Ibadan,
      Ibadan, Nigeria.
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
FAU - Ajayi, IkeOluwapo
AU  - Ajayi I
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Epidemiology and Medical Statistics, Faculty of Public Health,
      College of Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Akintola, Simisola
AU  - Akintola S
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Public Law, Faculty of Law, University of Ibadan, Ibadan, Nigeria.
FAU - Falade, Catherine
AU  - Falade C
AD  - Department of Pharmacology and Therapeutics, Institute for Advanced Medical
      Research and Training, College of Medicine, University of Ibadan, Ibadan,
      Nigeria.
FAU - Dipeolu, Isaac Oluwafemi
AU  - Dipeolu IO
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Health Promotion and Education, Faculty of Public Health, College
      of Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Cadmus, Simeon
AU  - Cadmus S
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Veterinary Public Health and Preventive Medicine, Faculty of
      Veterinary Medicine, University of Ibadan, Ibadan, Nigeria.
FAU - Aderemi, Ajala
AU  - Aderemi A
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Archaeology and Anthropology, University of Ibadan, Ibadan,
      Nigeria.
FAU - Olaifa, Abayomi
AU  - Olaifa A
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine,
      University of Ibadan, Ibadan, Nigeria.
FAU - Olatoye, Olufemi
AU  - Olatoye O
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Pharmacology and Therapeutics, Institute for Advanced Medical
      Research and Training, College of Medicine, University of Ibadan, Ibadan,
      Nigeria.
FAU - Akinyemi, Odunayo
AU  - Akinyemi O
AD  - Ethics Sub-committee of the Coronavirus Pandemic Response Committee, University
      of Ibadan, Ibadan, Nigeria.
AD  - Department of Epidemiology and Medical Statistics, Faculty of Public Health,
      College of Medicine, University of Ibadan, Ibadan, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - COVID-19/diagnosis/*prevention & control
MH  - *COVID-19 Testing
MH  - Contact Tracing/ethics
MH  - Developing Countries
MH  - Disease Outbreaks/ethics/*prevention & control
MH  - Health Services Accessibility
MH  - Humans
MH  - Mass Screening/*methods
MH  - Physical Distancing
PMC - PMC7875799
OTO - NOTNLM
OT  - Pandemic preparedness
OT  - disease control
OT  - ethics
COIS- The authors declare no competing interests.
EDAT- 2021/02/25 06:00
MHDA- 2021/03/03 06:00
CRDT- 2021/02/24 05:44
PHST- 2020/04/27 00:00 [received]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2021/02/24 05:44 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
AID - 10.11604/pamj.supp.2020.35.23121 [doi]
AID - PAMJ-SUPP-35-2-95 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Jun 29;35(Suppl 2):95. doi: 10.11604/pamj.supp.2020.35.23121.
      eCollection 2020.


PMID- 33623552
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1937-8688 (Electronic)
VI  - 35
IP  - Suppl 2
DP  - 2020
TI  - Managing cancer care during the COVID-19 pandemic-experience at a cancer
      department in a tertiary hospital in Antigua and Barbuda.
PG  - 27
LID - 10.11604/pamj.supp.2020.35.2.23092 [doi]
AB  - The emergence of corona virus disease 2019 (COVID-19) has caused a global public 
      health emergency and the pandemic has forced the healthcare givers to organise
      their work differently to provide the same level of care to their patients.
      Meticulous planning and implementation of robust infection control, proper triage
      of patients, patient education and awareness and establishment of good command
      structure has become the norm. In this article we illustrate how the COVID-19
      pandemic has affected the oncology department in a tertiary centre in the
      Caribbean country of Antigua & Barbuda. We describe the changes in treatment
      decisions for outpatient and inpatient services along with a look at the ethical 
      considerations and the well-being of the oncology team.
CI  - (c)Nandan Maruti Shanbhag et al.
FAU - Shanbhag, Nandan Maruti
AU  - Shanbhag NM
AD  - Department of Oncology, Mount Saint John s Medical Centre, Antigua and Barbuda.
FAU - Phillip, Joycelyn Condace
AU  - Phillip JC
AD  - Department of Oncology, Mount Saint John s Medical Centre, Antigua and Barbuda.
FAU - Duncan, Albert
AU  - Duncan A
AD  - Department of Oncology, Mount Saint John s Medical Centre, Antigua and Barbuda.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Antigua and Barbuda
MH  - COVID-19/*prevention & control
MH  - Humans
MH  - Infection Control/*methods
MH  - Neoplasms/*therapy
MH  - Patient Care Team/ethics/*organization & administration
MH  - Patient Education as Topic/methods
MH  - Tertiary Care Centers
MH  - Triage/methods
PMC - PMC7875731
OTO - NOTNLM
OT  - COVID-19
OT  - cancer
OT  - challenges
COIS- The authors declare no competing interests.
EDAT- 2021/02/25 06:00
MHDA- 2021/03/02 06:00
CRDT- 2021/02/24 05:43
PHST- 2020/04/25 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2021/02/24 05:43 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 10.11604/pamj.supp.2020.35.2.23092 [doi]
AID - PAMJ-SUPP-35-2-27 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 May 7;35(Suppl 2):27. doi:
      10.11604/pamj.supp.2020.35.2.23092. eCollection 2020.


PMID- 33623316
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0973-1075 (Print)
IS  - 0973-1075 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Oct-Dec
TI  - To assess the Prevalence and Predictors of Cancer-related Fatigue and its Impact 
      on Quality of Life in Advanced Cancer Patients Receiving Palliative Care in a
      Tertiary Care Hospital: A Cross-sectional Descriptive Study.
PG  - 523-527
LID - 10.4103/IJPC.IJPC_223_19 [doi]
AB  - INTRODUCTION: Cancer-related fatigue (CRF) is one of the adverse outcomes of
      cancer and its treatment. Despite its high prevalence; the data are scarce from
      the Indian population on the prevalence of CRF and its predictors in advanced
      cancer patients. Hence, we aim to find the prevalence of the fatigue, its impact 
      of fatigue on quality of life (QOL), and possible predictors. METHODS: This study
      was conducted after approval of the ethical committee in adult patients of
      advanced cancer receiving palliative care. The data collected included
      demographic details, nutritional status, any comorbidities involving
      cardiorespiratory, renal, pulmonary, and neurological system, type and stage of
      cancer, site of metastasis, any previous or ongoing chemotherapy or radiotherapy,
      history of drug intake, hemoglobin, and albumin. The study parameters included
      assessment of fatigue, QOL, and symptom assessment as per the validated tools.
      The primary objective of the study was to find the prevalence of fatigue in
      advanced cancer patients receiving palliative care. The secondary objectives were
      to find predictive factors of fatigue, its impact on QOL of patients, and the
      relation between the fatigue and QOL receiving palliative care. The correlation
      between fatigue score and QOL was analyzed using Pearson's correlation
      coefficient. Multiple linear regression analysis was performed for identifying
      the predictors of CRF. RESULTS: The fatigue was observed in all 110 patients in
      this study. Of these, severe fatigue was seen in 97 patients (Functional
      Assessment of Chronic Illness Therapy [FACIT]-F < 30). The median (interquartile 
      range [IQR]) FACIT-F score was 14 (8-23). The median (IQR) of the overall QOL was
      16.66 (16.6-50). The correlation between the fatigue (FACIT-F) and QOL was + 0.64
      (P < 0.001). The predictors of fatigue included pain, physical functioning,
      Eastern Cooperative Oncology Group, tiredness, and the level of albumin.
      CONCLUSION: We conclude that the prevalence of fatigue in Indian patients with
      advanced cancer receiving palliative care was high and it has a negative impact
      on QOL. Pain, physical functioning, performance status, and albumin were found to
      be independent predictors of CRF.
CI  - Copyright: (c) 2020 Indian Journal of Palliative Care.
FAU - Agarwal, Shilpi
AU  - Agarwal S
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Garg, Rakesh
AU  - Garg R
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Minhas, Varnika
AU  - Minhas V
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Bhatnagar, Sushma
AU  - Bhatnagar S
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Mishra, Seema
AU  - Mishra S
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Kumar, Vinod
AU  - Kumar V
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Bharati, Sachidanand Jee
AU  - Bharati SJ
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Gupta, Nishkarsh
AU  - Gupta N
AD  - Departments of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Khan, Maroof Ahmad
AU  - Khan MA
AD  - Department of Biostatistics, AIIMS, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - United States
TA  - Indian J Palliat Care
JT  - Indian journal of palliative care
JID - 101261221
PMC - PMC7888426
OTO - NOTNLM
OT  - Albumin
OT  - cancer
OT  - fatigue
OT  - pain
OT  - palliative care
OT  - predictors
OT  - quality of life
COIS- There are no conflicts of interest.
EDAT- 2021/02/25 06:00
MHDA- 2021/02/25 06:01
CRDT- 2021/02/24 05:42
PHST- 2019/12/16 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2021/02/24 05:42 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/02/25 06:01 [medline]
AID - 10.4103/IJPC.IJPC_223_19 [doi]
AID - IJPC-26-523 [pii]
PST - ppublish
SO  - Indian J Palliat Care. 2020 Oct-Dec;26(4):523-527. doi: 10.4103/IJPC.IJPC_223_19.
      Epub 2020 Nov 19.


PMID- 33623300
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0973-1075 (Print)
IS  - 0973-1075 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Oct-Dec
TI  - Perception and Quality of Life in Family Caregivers of Cancer Patients.
PG  - 415-420
LID - 10.4103/IJPC.IJPC_225_19 [doi]
AB  - INTRODUCTION: Cancer has been most feared among all the significantly increasing 
      chronic diseases, and is widely assumed to be fatal. The quality of life (QOL) of
      the patient pertaining to physical, psychological, social, and spiritual
      well-being is altered, which ultimately affects the QOL of the family caregivers.
      The study was conducted to assess the QOL among family caregivers of cancer
      patients and how cancer changes and alters the vision about life for the patient 
      as well as the family caregivers. OBJECTIVE: The objective was to assess the QOL 
      among family caregivers of the cancer patients. METHODOLOGY: A cross-sectional,
      questionnaire-based study was conducted after the protocol was approved by the
      institutional ethics committee and obtaining written informed consent from the
      participants. Two sets of validated questionnaire were used to assess the
      awareness and QOL of the family caregivers of the cancer patients. The filled
      questionnaires were received from the participants, and data were analyzed using 
      descriptive statistics. RESULTS: Nearly 74% (148/200) of the participants
      responded, with majority of the caregivers being females (71.62%). Majority
      (72.9%) expressed that cancer cannot spread from one person to another and were
      positive (70.9%) toward cancer cure. The caregivers (76.3%) opined that the
      diagnosis of cancer should be informed to the family members. Approximately 50%
      of the participants were aware that environmental toxins and tobacco would
      predispose to cancer. Although most of them (87.8%) believed that the cancer
      treatment cause ill effects, they (93.2%) were satisfied with the hospital
      facilities. Among the QOL parameters, most of the participants had complaint of
      decreased general physical health, difficulty to cope, reduced concentration,
      anguish over the first treatment, disease, and interference in household
      activities. Among the spiritual parameters, the participants expressed sufficient
      support from religious activities, prayer, and general spiritual well-being.
      CONCLUSION: Majority of the caregivers had awareness regarding the cancer and
      carcinogens from the environmental toxins. The QOL among caregivers of cancer
      patients is affected in all dimensions of life, with more emphasis on the social 
      and psychological dimensions.
CI  - Copyright: (c) 2020 Indian Journal of Palliative Care.
FAU - Nidhi, Vidya
AU  - Nidhi V
AD  - Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and 
      Research, Kolar, Karnataka, India.
FAU - Basavareddy, Asha
AU  - Basavareddy A
AD  - Department of Pharmacology, Sri Devaraj Urs Medical College, Sri Devaraj Urs
      Academy of Higher Education and Research, Kolar, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - United States
TA  - Indian J Palliat Care
JT  - Indian journal of palliative care
JID - 101261221
PMC - PMC7888413
OTO - NOTNLM
OT  - Cancer caregivers
OT  - perception
OT  - quality of life
COIS- There are no conflicts of interest.
EDAT- 2021/02/25 06:00
MHDA- 2021/02/25 06:01
CRDT- 2021/02/24 05:42
PHST- 2019/12/17 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2021/02/24 05:42 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/02/25 06:01 [medline]
AID - 10.4103/IJPC.IJPC_225_19 [doi]
AID - IJPC-26-415 [pii]
PST - ppublish
SO  - Indian J Palliat Care. 2020 Oct-Dec;26(4):415-420. doi: 10.4103/IJPC.IJPC_225_19.
      Epub 2020 Nov 19.


PMID- 33623212
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0970-0218 (Print)
IS  - 0970-0218 (Linking)
VI  - 45
IP  - 4
DP  - 2020 Oct-Dec
TI  - Study to Assess Birth Preparedness and Complication Readiness to Promote Safe
      Motherhood among Women from a Rural Area of Western Maharashtra.
PG  - 511-515
LID - 10.4103/ijcm.IJCM_4_20 [doi]
AB  - BACKGROUND: Promotion of maternal health should be an integrated approach
      comprising adequate planning of pregnancy coupled with the awareness of the
      available maternal and child health services and its utilization. OBJECTIVES: The
      aim of this study is to determine birth preparedness and complication readiness
      (BPACR) among antenatal and postnatal women and to assess the factors related to 
      it. MATERIALS AND METHODS: This hospital-based cross-sectional study was
      conducted on 400 antenatal and postnatal women attending a tertiary care hospital
      of Karad. Antenatal women in their third trimester and postnatal women up to
      Postnatal day-7 were included. Institutional ethical clearance was obtained
      before the commencement of the study. All the women were interviewed after their 
      informed consent using the appropriately validated and modified BPACR tool
      developed with respect to the Indian setup. Chi-square and multivariate logistic 
      regression analysis were carried out to determine the various associated factors 
      with BPACR. RESULTS: The study population comprised 55.5% antenatal mothers and
      44.5% postnatal mothers. The BPACR index was found to be 59.56, and the maximum
      had a good BPACR 208 (52%). There was poor knowledge regarding blood transfusion,
      danger signs, and available community resources. A higher level of education had 
      a statistically significant association with BPACR (46.2%) in women educated
      above high school). Women belonging to the upper class had two times, and
      postnatal women had 2.02 times increased chances for a good BPACR. CONCLUSION: An
      inclusion of components related to BPACR during pregnancy will improve timely and
      adequate access to healthcare, better management of complications, and thereby
      improve both maternal and fetal outcomes.
CI  - Copyright: (c) 2020 Indian Journal of Community Medicine.
FAU - Viswanathan, Viyusha T
AU  - Viswanathan VT
AD  - Department of Community Medicine, Krishna Institute of Medical Sciences Deemed to
      be University, Karad, Maharashtra, India.
FAU - Patil, Supriya S
AU  - Patil SS
AD  - Department of Community Medicine, Krishna Institute of Medical Sciences Deemed to
      be University, Karad, Maharashtra, India.
FAU - Joshi, Radhika N
AU  - Joshi RN
AD  - Krishna Hospital and Medical Research Centre, Karad, Maharashtra, India.
FAU - Durgawale, Prakash M
AU  - Durgawale PM
AD  - Department of Community Medicine, Krishna Institute of Medical Sciences Deemed to
      be University, Karad, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - India
TA  - Indian J Community Med
JT  - Indian journal of community medicine : official publication of Indian Association
      of Preventive & Social Medicine
JID - 9315574
PMC - PMC7877419
OTO - NOTNLM
OT  - Antenatal
OT  - birth
OT  - complication
OT  - signs
OT  - tool
COIS- There are no conflicts of interest.
EDAT- 2021/02/25 06:00
MHDA- 2021/02/25 06:01
CRDT- 2021/02/24 05:42
PHST- 2020/01/02 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2021/02/24 05:42 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/02/25 06:01 [medline]
AID - 10.4103/ijcm.IJCM_4_20 [doi]
AID - IJCM-45-511 [pii]
PST - ppublish
SO  - Indian J Community Med. 2020 Oct-Dec;45(4):511-515. doi: 10.4103/ijcm.IJCM_4_20. 
      Epub 2020 Oct 28.


PMID- 33623200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0970-0218 (Print)
IS  - 0970-0218 (Linking)
VI  - 45
IP  - 4
DP  - 2020 Oct-Dec
TI  - Impact of Community Defluoridation on a Village Endemic for Hydric Fluorosis in
      Rural Karnataka, India.
PG  - 454-457
LID - 10.4103/ijcm.IJCM_489_19 [doi]
AB  - INTRODUCTION: Excessive intake of fluorides can lead to the development of
      fluorosis, a serious public health issue in India. The objective of this study
      was to assess the impact of community defluoridation in preventing fluorosis in
      Kaiwara village. METHODOLOGY: This community interventional trial was conducted
      in Kaiwara village, Karnataka, after obtaining ethical clearance. The study
      included 903 participants; preintervention data were collected by recording the
      required parameters. The postinterventional study was carried out 2 years after
      installing the reverse osmosis plant. Data from pre- and post-intervention study 
      were compared. RESULTS: Dean's index showed no significant change in the pre- and
      post-intervention period for its various categories (P = 0.543). However, the
      mean urine fluoride levels were found to be decreased significantly (Wilcoxon
      Signed-Rank test, P < 0.001). CONCLUSION: This study demonstrates the importance 
      of providing defluorinated water to the village population as a potential
      solution for fluorosis.
CI  - Copyright: (c) 2020 Indian Journal of Community Medicine.
FAU - Isaac, Arjunan
AU  - Isaac A
AD  - Department of Community Medicine, MS Ramaiah Medical College, Bengaluru,
      Karnataka, India.
FAU - Pruthvish, S
AU  - Pruthvish S
AD  - Department of Community Medicine, MS Ramaiah Medical College, Bengaluru,
      Karnataka, India.
FAU - Haridas, Radhika
AU  - Haridas R
AD  - Department of Biostatistics, MS Ramaiah Medical College, Bengaluru, Karnataka,
      India.
FAU - Murthy, N S
AU  - Murthy NS
AD  - Department of Biostatistics, MS Ramaiah Medical College, Bengaluru, Karnataka,
      India.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - India
TA  - Indian J Community Med
JT  - Indian journal of community medicine : official publication of Indian Association
      of Preventive & Social Medicine
JID - 9315574
PMC - PMC7877423
OTO - NOTNLM
OT  - Community health services
OT  - fluorides
OT  - fluorosis
OT  - public health
OT  - reverse osmosis
COIS- There are no conflicts of interest.
EDAT- 2021/02/25 06:00
MHDA- 2021/02/25 06:01
CRDT- 2021/02/24 05:42
PHST- 2019/11/29 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2021/02/24 05:42 [entrez]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/02/25 06:01 [medline]
AID - 10.4103/ijcm.IJCM_489_19 [doi]
AID - IJCM-45-454 [pii]
PST - ppublish
SO  - Indian J Community Med. 2020 Oct-Dec;45(4):454-457. doi:
      10.4103/ijcm.IJCM_489_19. Epub 2020 Oct 28.


PMID- 33620069
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220716
IS  - 1930-6180 (Electronic)
IS  - 1084-2020 (Linking)
VI  - 61
IP  - 2-3
DP  - 2020 Dec 31
TI  - Marmosets: Welfare, Ethical Use, and IACUC/Regulatory Considerations.
PG  - 167-178
LID - 10.1093/ilar/ilab003 [doi]
AB  - Use of marmosets in biomedical research has increased dramatically in recent
      years due, in large part, to their suitability for transgenic applications and
      utility as models for neuroscience investigations. This increased use includes
      the establishment of new colonies and involvement of people new to marmoset
      research. To facilitate the use of the marmoset as a research model, we provide
      an overview of issues surrounding the ethics and regulations associated with
      captive marmoset research, including discussion of the history of marmosets in
      research, current uses of marmosets, ethical considerations related to marmoset
      use, issues related to importation of animals, and recommendations for regulatory
      oversight of gene-edited marmosets. To understand the main concerns that
      oversight bodies have regarding captive biomedical research with marmosets, we
      developed a brief, 15-question survey that was then sent electronically to
      academic and biomedical research institutions worldwide that were believed to
      house colonies of marmosets intended for biomedical research. The survey included
      general questions regarding the individual respondent's colony, status of
      research use of the colony and institutional oversight of both the colony itself 
      and the research use of the colony. We received completed surveys from a total of
      18 institutions from North America, Europe, and Asia. Overall, there appeared to 
      be no clear difference in regulatory oversight body concerns between
      countries/regions. One difference that we were able to appreciate was that while 
      biomedical research with marmosets was noted to be either stable or decreasing in
      Europe, use was clearly increasing elsewhere.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the
      National Academies of Sciences, Engineering, and Medicine. All rights reserved.
      For permissions, please email: journals.permissions@oup.com.
FAU - Colman, Ricki J
AU  - Colman RJ
AD  - Department of Cell and Regenerative Biology, School of Medicine and Public
      Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
AD  - Wisconsin National Primate Research Center, University of Wisconsin-Madison,
      Madison, Wisconsin, USA.
FAU - Capuano, Saverio
AU  - Capuano S
AD  - Wisconsin National Primate Research Center, University of Wisconsin-Madison,
      Madison, Wisconsin, USA.
FAU - Bakker, Jaco
AU  - Bakker J
AD  - Biomedical Primate Research Centre, Rijswijk, the Netherlands.
FAU - Keeley, Jo
AU  - Keeley J
AD  - University of Cambridge, Cambridge, United Kingdom.
FAU - Nakamura, Katsuki
AU  - Nakamura K
AD  - Primate Research Institute, Kyoto University, Kyoto, Japan.
FAU - Ross, Corinna
AU  - Ross C
AD  - Department of Life Sciences, Texas A&M University, San Antonio, Texas, USA; and
      Population Health, Texas Biomedical Research Institute, San Antonio, Texas, USA.
LA  - eng
GR  - P51 OD011106/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - ILAR J
JT  - ILAR journal
JID - 9516416
SB  - IM
MH  - *Animal Care Committees
MH  - Animals
MH  - Animals, Genetically Modified
MH  - *Biomedical Research
MH  - Callithrix
PMC - PMC9214643
OTO - NOTNLM
OT  - *biomedical research
OT  - *gene-edited
OT  - *marmoset
OT  - *neuroscience
OT  - *regulatory oversight
OT  - *transgenic
OT  - *welfare
EDAT- 2021/02/24 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/02/23 08:38
PHST- 2020/05/15 00:00 [received]
PHST- 2020/11/13 00:00 [revised]
PHST- 2020/12/20 00:00 [accepted]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2021/02/23 08:38 [entrez]
AID - 6146826 [pii]
AID - 10.1093/ilar/ilab003 [doi]
PST - ppublish
SO  - ILAR J. 2020 Dec 31;61(2-3):167-178. doi: 10.1093/ilar/ilab003.


PMID- 33615295
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2676-296X (Electronic)
IS  - 2676-296X (Linking)
VI  - 17
IP  - 19
DP  - 2020 Aug
TI  - Effect of an Oral Health Promotion Program Including Supervised Toothbrushing on 
      6 to 7-Year-Old School Children: A Randomized Controlled Trial.
PG  - 1-9
LID - 10.18502/fid.v17i19.4313 [doi]
AB  - OBJECTIVES: The purpose was to evaluate the impact of an oral health promotion
      program including supervised toothbrushing and educational packages for parents
      on parent's knowledge and oral health status of 6- to 7-year-old schoolchildren. 
      MATERIALS AND METHODS: A multi-stage cluster random sampling method was applied, 
      and schools were allocated to intervention and control groups. After ethical
      clearance and baseline evaluation, an intervention package consisting of
      supervised toothbrushing at the school setting, an educational package for
      parents, and a home package containing toothbrush and fluoridated toothpaste
      (1000 parts-per-million) were delivered. A post-intervention evaluation was
      performed after one month on parents' oral health knowledge and oral hygiene of
      children using the Oral Hygiene Index Simplified (OHI-S). Schools were considered
      as a unit of randomization, and a generalized estimating equation (GEE) analysis 
      was performed to apply the cluster effect. Descriptive and analytical analyses
      were performed using SPSS 22 software. RESULTS: Overall, 701 subjects were
      re-examined (response rate of 95%). At the one-month follow-up, being in the
      intervention group (P<0.001, B=-0.028, 95% confidence interval (CI)= -0.33,
      -0.23) and having higher socioeconomic status [P=0.01, B=-0.12, 95% CI=-0.22,
      -0.03) were significantly associated with improved oral hygiene status. In the
      post-test evaluation, parents' knowledge improvement score regarding oral health 
      in the intervention group was not statistically different from that of the
      controls (0.51 vs. 0.23). However, the DeltaOHI-S improved in the post-test
      evaluation (-0.27+/-0.02 vs. 0.02+/-0.02; P<0.001). CONCLUSION: Children showed
      improved oral hygiene status, as measured by the OHI-S, after the program
      consisting of supervised toothbrushing.
CI  - (c) 2020 The Authors. Published by Tehran University of Medical Sciences.
FAU - Babaei, Azadeh
AU  - Babaei A
AD  - Department of Community Oral Health, School of Dentistry, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Pakdaman, Afsaneh
AU  - Pakdaman A
AD  - Department of Community Oral Health, School of Dentistry, Tehran University of
      Medical Sciences, Tehran, Iran.
AD  - Research Center for Caries Prevention, Dentistry Research Institute, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Hessari, Hossein
AU  - Hessari H
AD  - Research Center for Caries Prevention, Dentistry Research Institute, Tehran
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200830
PL  - Iran
TA  - Front Dent
JT  - Frontiers in dentistry
JID - 101747773
PMC - PMC7883658
OTO - NOTNLM
OT  - Child
OT  - Dental
OT  - Health Education
OT  - Schools
OT  - Toothbrushing
COIS- CONFLICT OF INTEREST STATEMENT None declared
EDAT- 2021/02/23 06:00
MHDA- 2021/02/23 06:01
CRDT- 2021/02/22 06:00
PHST- 2019/12/22 00:00 [received]
PHST- 2020/07/19 00:00 [accepted]
PHST- 2021/02/22 06:00 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/02/23 06:01 [medline]
AID - 10.18502/fid.v17i19.4313 [doi]
AID - FID-17-19 [pii]
PST - ppublish
SO  - Front Dent. 2020 Aug;17(19):1-9. doi: 10.18502/fid.v17i19.4313. Epub 2020 Aug 30.


PMID- 33614546
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210223
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Case Report: Intact Survival of a Marginally Viable Male Infant Born Weighing 268
      Grams at 24 Weeks Gestation.
PG  - 628362
LID - 10.3389/fped.2020.628362 [doi]
AB  - We report the case of a preterm small for gestational age male infant born at 24 
      weeks of gestation with a birth weight of 268 g who was discharged from our
      hospital without the requirement for home oxygen therapy or tube feeding. He did 
      not experience severe intraventricular hemorrhage, periventricular leukomalacia, 
      hearing disability, or any other serious complications. At that time (February
      2019), according to the University of Iowa's Tiniest Babies Registry, he was the 
      tiniest male infant in the world to survive without any serious complications
      other than severe retinopathy of prematurity that required laser therapy.
      Although the survival rate of infants with extremely low birth weight is
      improving worldwide, a high mortality rate and incidence of severe complications 
      remain common for infants weighing <300 g at birth, particularly in male infants.
      In recent years, there have been frequent discussions regarding the ethical and
      social issues involved in treating extremely preterm infants weighing <400 g.
      Despite the challenges, reports of such infants surviving are increasing.
      Neonatal medicine has already achieved great success in treating infants weighing
      400 g or more at birth. However, lack of evidence and experience may make
      physicians reluctant to treat infants weighing less than this. The present case
      demonstrates that intact survival of a marginally viable male infant with a birth
      weight of <300 g is possible with minimal handling and family involvement
      beginning shortly after birth. Our detailed description of the clinical course of
      this case should provide invaluable information to physicians around the world
      who treat such infants. This report will aid in the progress of neonatal medicine
      and help to address many of the social and ethical issues surrounding their care.
CI  - Copyright (c) 2021 Arimitsu, Wakabayashi, Tamaoka, Takahashi, Hida and Takahashi.
FAU - Arimitsu, Takeshi
AU  - Arimitsu T
AD  - Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
FAU - Wakabayashi, Daiki
AU  - Wakabayashi D
AD  - Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
FAU - Tamaoka, Satoshi
AU  - Tamaoka S
AD  - Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
FAU - Takahashi, Mona
AU  - Takahashi M
AD  - Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
FAU - Hida, Mariko
AU  - Hida M
AD  - Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
FAU - Takahashi, Takao
AU  - Takahashi T
AD  - Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Case Reports
DEP - 20210203
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7888275
OTO - NOTNLM
OT  - birth weight of 268 g
OT  - extremely low birth weight
OT  - family involvement
OT  - intact survival
OT  - male
OT  - marginally viable infant
OT  - minimal handling
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/23 06:00
MHDA- 2021/02/23 06:01
CRDT- 2021/02/22 05:57
PHST- 2020/11/11 00:00 [received]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/02/22 05:57 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/02/23 06:01 [medline]
AID - 10.3389/fped.2020.628362 [doi]
PST - epublish
SO  - Front Pediatr. 2021 Feb 3;8:628362. doi: 10.3389/fped.2020.628362. eCollection
      2020.


PMID- 33613536
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node
      Activation Measured by (18)F-FDG- and (11)C-PBR28-PET/CT Imaging, and Whole Blood
      and Muscle Transcriptomics After Immunization of Healthy Humans With Adjuvanted
      and Unadjuvanted Vaccines.
PG  - 613496
LID - 10.3389/fimmu.2020.613496 [doi]
AB  - Systems vaccinology has been applied to detect signatures of human vaccine
      induced immunity but its ability, together with high definition in vivo clinical 
      imaging is not established to predict vaccine reactogenicity. Within two European
      Commission funded high impact programs, BIOVACSAFE and ADITEC, we applied high
      resolution positron emission tomography/computed tomography (PET/CT) scanning
      using tissue-specific and non-specific radioligands together with transcriptomic 
      analysis of muscle biopsies in a clinical model systematically and prospectively 
      comparing vaccine-induced immune/inflammatory responses. 109 male participants
      received a single immunization with licensed preparations of either
      AS04-adjuvanted hepatitis B virus vaccine (AHBVV); MF59C-adjuvanted (ATIV) or
      unadjuvanted seasonal trivalent influenza vaccine (STIV); or
      alum-OMV-meningococcal B protein vaccine (4CMenB), followed by a PET/CT scan (n =
      54) or an injection site muscle biopsy (n = 45). Characteristic kinetics was
      observed with a localized intramuscular focus associated with increased tissue
      glycolysis at the site of immunization detected by (18)F-fluorodeoxyglucose (FDG)
      PET/CT, peaking after 1-3 days and strongest and most prolonged after 4CMenB,
      which correlated with clinical experience. Draining lymph node activation peaked 
      between days 3-5 and was most prominent after ATIV. Well defined uptake of the
      immune cell-binding radioligand (11)C-PBR28 was observed in muscle lesions and
      draining lymph nodes. Kinetics of muscle gene expression module upregulation
      reflected those seen previously in preclinical models with a very early (~6hrs)
      upregulation of monocyte-, TLR- and cytokine/chemokine-associated modules after
      AHBVV, in contrast to a response on day 3 after ATIV, which was bracketed by
      whole blood responses on day 1 as antigen presenting, inflammatory and innate
      immune cells trafficked to the site of immunization, and on day 5 associated with
      activated CD4+ T cells. These observations confirm the use of PET/CT, including
      potentially tissue-, cell-, or cytokine/chemokine-specific radioligands, is a
      safe and ethical quantitative technique to compare candidate vaccine formulations
      and could be safely combined with biopsy to guide efficient collection of samples
      for integrated whole blood and tissue systems vaccinology in small-scale but
      intensive human clinical models of immunization and to accelerate clinical
      development and optimisation of vaccine candidates, adjuvants, and formulations.
CI  - Copyright (c) 2021 Win, Weiner 3rd, Listanco, Patel, Sharma, Greenwood,
      Maertzdorf, Mollenkopf, Pizzoferro, Cole, Bodinham, Kaufmann, Denoel, Del Giudice
      and Lewis.
FAU - Win, Zarni
AU  - Win Z
AD  - Department of Nuclear Medicine and Radiological Sciences Unit, Imperial College
      Healthcare NHS Trust (ICHNT), London, United Kingdom.
FAU - Weiner Rd, January
AU  - Weiner Rd J
AD  - Department for Immunology, Max Planck Institute for Infection Biology, Berlin,
      Germany.
AD  - Core Unit for Bioinformatics (CUBI), Berlin Institute of Health, Berlin, Germany.
FAU - Listanco, Allan
AU  - Listanco A
AD  - National Institute for Health Research (NIHR) Imperial Clinical Research Facility
      (NICRF), Imperial College Healthcare NHS Trust, London, United Kingdom.
FAU - Patel, Neva
AU  - Patel N
AD  - Department of Nuclear Medicine and Radiological Sciences Unit, Imperial College
      Healthcare NHS Trust (ICHNT), London, United Kingdom.
FAU - Sharma, Rohini
AU  - Sharma R
AD  - Department of Surgery & Cancer, Imperial College London (ICL), London, United
      Kingdom.
FAU - Greenwood, Aldona
AU  - Greenwood A
AD  - Surrey Clinical Research Centre, University of Surrey, Guildford, United Kingdom.
FAU - Maertzdorf, Jeroen
AU  - Maertzdorf J
AD  - Department for Immunology, Max Planck Institute for Infection Biology, Berlin,
      Germany.
FAU - Mollenkopf, Hans-Joachim
AU  - Mollenkopf HJ
AD  - Department for Immunology, Max Planck Institute for Infection Biology, Berlin,
      Germany.
FAU - Pizzoferro, Kat
AU  - Pizzoferro K
AD  - Surrey Clinical Research Centre, University of Surrey, Guildford, United Kingdom.
FAU - Cole, Thomas
AU  - Cole T
AD  - National Institute for Health Research (NIHR) Imperial Clinical Research Facility
      (NICRF), Imperial College Healthcare NHS Trust, London, United Kingdom.
FAU - Bodinham, Caroline L
AU  - Bodinham CL
AD  - Surrey Clinical Research Centre, University of Surrey, Guildford, United Kingdom.
FAU - Kaufmann, Stefan H E
AU  - Kaufmann SHE
AD  - Department for Immunology, Max Planck Institute for Infection Biology, Berlin,
      Germany.
FAU - Denoel, Philippe
AU  - Denoel P
AD  - External R&D, GSK, Rixenstart, Belgium and Siena, Italy.
FAU - Del Giudice, Giuseppe
AU  - Del Giudice G
AD  - External R&D, GSK, Rixenstart, Belgium and Siena, Italy.
FAU - Lewis, David J M
AU  - Lewis DJM
AD  - National Institute for Health Research (NIHR) Imperial Clinical Research Facility
      (NICRF), Imperial College Healthcare NHS Trust, London, United Kingdom.
AD  - Surrey Clinical Research Centre, University of Surrey, Guildford, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210205
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cytokines)
RN  - 0 (Vaccines)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adjuvants, Immunologic/*metabolism
MH  - Adolescent
MH  - Adult
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism
MH  - Cytokines/immunology
MH  - Female
MH  - Fluorodeoxyglucose F18/*metabolism
MH  - Humans
MH  - Immunization/methods
MH  - Kinetics
MH  - Lymph Nodes/immunology/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Muscles/immunology/*metabolism
MH  - Positron Emission Tomography Computed Tomography/methods
MH  - Transcriptome/*immunology
MH  - Vaccination/methods
MH  - Vaccines/immunology/*metabolism
MH  - Young Adult
PMC - PMC7893084
OTO - NOTNLM
OT  - *PET/CT (positron emission tomography/computed tomography)
OT  - *TSPO (18kda translocator protein)
OT  - *fluorodeoxyglucose (F-FDG) 18
OT  - *muscle
OT  - *reactogenicity
OT  - *systems vaccinology
OT  - *transcriptomics
COIS- PD and GG are employees of the GSK group of companies, and report receiving
      restricted shares of the company. The remaining authors declare that the research
      was conducted in the absence of any commercial or financial relationships that
      could be construed as a potential conflict of interest.
EDAT- 2021/02/23 06:00
MHDA- 2021/06/23 06:00
CRDT- 2021/02/22 05:53
PHST- 2020/10/02 00:00 [received]
PHST- 2020/12/24 00:00 [accepted]
PHST- 2021/02/22 05:53 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
AID - 10.3389/fimmu.2020.613496 [doi]
PST - epublish
SO  - Front Immunol. 2021 Feb 5;11:613496. doi: 10.3389/fimmu.2020.613496. eCollection 
      2020.


PMID- 33613349
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210223
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Ethical Climate(s), Distributed Leadership, and Work Outcomes: The Mediating Role
      of Organizational Identification.
PG  - 564112
LID - 10.3389/fpsyg.2020.564112 [doi]
AB  - Organizational identification (OI) has increasingly attracted scholarly attention
      as a key factor in understanding organizational processes and in fostering
      efficient human resource (HR) management. Available evidence shows that
      organizational ethical climate crucially predicts OI, a key determinant of both
      employees' attitudes and behaviors. In the present paper, we examined the
      relationship between two specific ethical climates (self-interest vs.
      friendship), distributed leadership (DL), and employees' attitudes and behaviors,
      incorporating OI as a core underlying mechanism driving these relationships.
      Three hundred and forty-two employees filled out questionnaires to examine
      ethical climate, DL, OI, and a series of measures concerning attitudes and
      behaviors toward the organization. Structural equation modeling confirmed that a 
      perception of an ethical climate of friendship (but not self-interest) fostered
      OI, which elicited higher commitment, perceived trust and recommendation, and
      lower turnover intention. Perception of DL further contributed to increasing OI. 
      Our findings suggest that HR practices should carefully consider employee
      perceptions of a collectivistic (vs. individualistic) ethical climate, together
      with perceptions of DL, as key determinants of positive organizational outcomes. 
      We discuss results in light of the social identity approach and present practical
      implications for HR management.
CI  - Copyright (c) 2021 Barattucci, Teresi, Pietroni, Iacobucci, Lo Presti and
      Pagliaro.
FAU - Barattucci, Massimiliano
AU  - Barattucci M
AD  - Department of Psychology, eCampus University, Novedrate, Italy.
FAU - Teresi, Manuel
AU  - Teresi M
AD  - Department of Neurosciences, Imaging and Clinical Sciences, University of Studies
      G. d'Annunzio Chieti-Pescara, Chieti, Italy.
FAU - Pietroni, Davide
AU  - Pietroni D
AD  - Department of Neurosciences, Imaging and Clinical Sciences, University of Studies
      G. d'Annunzio Chieti-Pescara, Chieti, Italy.
FAU - Iacobucci, Serena
AU  - Iacobucci S
AD  - Department of Neurosciences, Imaging and Clinical Sciences, University of Studies
      G. d'Annunzio Chieti-Pescara, Chieti, Italy.
FAU - Lo Presti, Alessandro
AU  - Lo Presti A
AD  - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta,
      Italy.
FAU - Pagliaro, Stefano
AU  - Pagliaro S
AD  - Department of Neurosciences, Imaging and Clinical Sciences, University of Studies
      G. d'Annunzio Chieti-Pescara, Chieti, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210204
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7889511
OTO - NOTNLM
OT  - distributed leadership
OT  - ethical climate
OT  - identification
OT  - outcomes
OT  - work outcomes
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/23 06:00
MHDA- 2021/02/23 06:01
CRDT- 2021/02/22 05:53
PHST- 2020/05/20 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/02/22 05:53 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/02/23 06:01 [medline]
AID - 10.3389/fpsyg.2020.564112 [doi]
PST - epublish
SO  - Front Psychol. 2021 Feb 4;11:564112. doi: 10.3389/fpsyg.2020.564112. eCollection 
      2020.


PMID- 33612617
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1881-7742 (Electronic)
IS  - 0301-4800 (Linking)
VI  - 66
IP  - Supplement
DP  - 2020
TI  - What We Eat and Where We Work Is What We Become: Worksite Food Environment
      Exposure and Cardio-Metabolic Health among Employed Adults of Urban Delhi, India.
PG  - S32-S35
LID - 10.3177/jnsv.66.S32 [doi]
AB  - The incidence of metabolic syndrome (MS) which is a predictor of increasing CVD
      is on the rise among adults in urban India. The present study was designed to
      measure the prevalence of cardio metabolic risk (CMR) as per MS among employed
      adults in Delhi, India. Study design was cross-sectional. Anthropometric and
      biochemical measurements were carried out using standard techniques on apparently
      healthy males and females (n=455) working in various government and private
      organisations in Delhi, India after obtaining ethical permissions. It was found
      that more than one-third of the study population had MS (43.8%). A significant
      difference in the prevalence of MS was seen among males (34.7%) and females
      (57.5%, p<0.05). The prevalence of MS components was: abdominal obesity (54.3%), 
      hypertriglyceridemia (61.9%), hypertension (56.6%), hypertriglyceridemia (27.4%),
      low HDL-c levels (63.7%). CMR (assessed from 0-5, where 0 means no MS). It was
      found that CMR increased with age (beta: 0.01; 95% CI: 0.009,0.01; p=0.000)
      especially among females (beta: 0.29; 95% CI: 0.19,0.38; p=0.000) who were
      consuming frequent non-vegetarian foods (beta: 0.04; 95% CI: 0.01,0.09; p=0.07), 
      had family history of diseases (beta: 0.08; 95% CI: 0.01,0.18; p=0.09) and were
      sedentary workers (beta: 0.05; 95% CI: 0.00,0.10; p=0.06). Unhealthy worksite
      food environment characterised by high fast food outlet density (beta: 0.003; 95%
      CI: 0.00,0.007; p=0.04) in close proximity (beta: 0.17; 95% CI: 0.36,0.00;
      p=0.05) to worksite were also associated with MS. There is a high prevalence of
      individual components of MS and overall prevalence of MS. Food environment and
      physical inactivity were two paramount factors resulting in increased CMR among
      the study population.
FAU - Shokeen, Deepa
AU  - Shokeen D
AD  - Department of Food and Nutrition, Institute of Home Economics, University of
      Delhi.
FAU - Aeri, Bani Tamber
AU  - Aeri BT
AD  - Department of Food and Nutrition, Institute of Home Economics, University of
      Delhi.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Nutr Sci Vitaminol (Tokyo)
JT  - Journal of nutritional science and vitaminology
JID - 0402640
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - India/epidemiology
MH  - Male
MH  - *Metabolic Syndrome/epidemiology
MH  - Prevalence
MH  - Risk Factors
MH  - *Workplace
OTO - NOTNLM
OT  - cardio-metabolic risk
OT  - food environment
OT  - metabolic syndrome
OT  - obesity
EDAT- 2021/02/23 06:00
MHDA- 2021/09/01 06:00
CRDT- 2021/02/22 05:50
PHST- 2021/02/22 05:50 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
AID - 10.3177/jnsv.66.S32 [doi]
PST - ppublish
SO  - J Nutr Sci Vitaminol (Tokyo). 2020;66(Supplement):S32-S35. doi:
      10.3177/jnsv.66.S32.


PMID- 33611306
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 73
IP  - 12 cz 2
DP  - 2020
TI  - ALCOHOLISM AS A PROFESSIONAL DISEASE OF THE REPRESENTATIVES OF JUSTICE.
PG  - 2934-2939
AB  - OBJECTIVE: The aim: The purpose of the research is to summarize the leading
      experience of European countries on the protection and prevention of the
      alcoholism problem among judges, attorneys and prosecutors as representatives of 
      justice. PATIENTS AND METHODS: Materials and methods: The subject under
      discussion has been considered based on sources on this issue (scientific
      publications, legal acts, decisions of judicial and quasijudicial institutions), 
      using the method of content analysis, comparative and contrastive, analytical and
      biblio-semantic methods. CONCLUSION: Conclusions: Analysis of existing statistics
      as well as decisions of the disciplinary bodies of justice indicates the
      predisposition of justice representatives to alcohol dependency, which is caused 
      by a number of reasons. Based on medical research, it is substantiated that
      stress is the determining factor in prompting a justice officer to use alcohol as
      a means capable of exerting an antidepressant effect. But in addition to quickly 
      de-stress, alcohol is attractive for its availability. We refer such availability
      as: financial, social and psychological, corporate, territorial, legislative one.
      It is argued that among the representatives of justice alcoholism has a harmful
      effect not only on their health. It has a negative impact on professional
      discipline and is fraught with de-ethicalization of representatives' of justice
      behavior. The alcohol dependence of justice officials can cause doubts on their
      competence, hold them accountable and undermine public confidence in the
      credibility of justice.
FAU - Khotynska-Nor, Oksana Z
AU  - Khotynska-Nor OZ
AD  - Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
FAU - Moskvych, Lidiya capital EM, Cyrillic
AU  - Moskvych Lcapital EM, Cyrillic
AD  - Yaroslav Mudryi National Law University, Kharkiv, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
SB  - IM
MH  - *Alcoholism
MH  - Europe
MH  - Humans
MH  - Social Justice
OTO - NOTNLM
OT  - alcohol addiction
OT  - alcoholism
OT  - justice
OT  - litigation stress
EDAT- 2021/02/22 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/21 20:39
PHST- 2021/02/21 20:39 [entrez]
PHST- 2021/02/22 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2020;73(12 cz 2):2934-2939.


PMID- 33611291
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20220531
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 73
IP  - 12 cz 2
DP  - 2020
TI  - CONTRACTUAL REGISTRATION OF ORGANIZATIONAL AND LEGAL RELATIONS BETWEEN SUBJECTS
      INVOLVED IN THE CONDUCT OF CLINICAL TRIALS OF MEDICINAL PRODUCTS.
PG  - 2840-2847
AB  - OBJECTIVE: The aim: Determination of features of contractual registration of
      organizational and legal relations between the subjects involved in carrying out 
      clinical trials of medicinal products; justification of proposals on improvement 
      of law enforcement practice in this field. PATIENTS AND METHODS: Materials and
      methods: This research is based on the analysis of the norms of international law
      and legislation of particular states, practice of contractual registration of
      organizational and legal relations between the subjects of clinical trials of
      medicinal products. The research was carried out using the methods of dialectical
      and formal logic, general scientific and special legal research methods.
      CONCLUSION: Conclusions: Two models of contractual registration of organizational
      and legal relations between the subjects involved in clinical trials of medicinal
      products were justified, and law enforcement recommendations for the contractual 
      registration of such relationships, ensuring that the clinical trial is in
      compliance with international regulations and ethics in this field, were given.
FAU - Antoniuk, Olena I
AU  - Antoniuk OI
AD  - Supreme Court, Kyiv, Ukraine, Ukrainian Association for Clinical Research, Kyiv, 
      Ukraine.
FAU - Pavliuchenko, Yuliia M
AU  - Pavliuchenko YM
AD  - Vasyl' Stus Donetsk National University, Vinnytsia, Ukraine.
FAU - Vyshnyvetskyy, Ivan I
AU  - Vyshnyvetskyy II
AD  - Bogomolets National Medical University, Ukrainian Association for Clinical
      Research, Kyiv, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
SB  - IM
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *International Law
OTO - NOTNLM
OT  - CRO
OT  - SMO
OT  - hospital
OT  - researcher
OT  - sponsor
EDAT- 2021/02/22 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/21 20:39
PHST- 2021/02/21 20:39 [entrez]
PHST- 2021/02/22 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2020;73(12 cz 2):2840-2847.


PMID- 33611285
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 73
IP  - 12 cz 2
DP  - 2020
TI  - LEGAL REGULATION OF BIOETHICAL ISSUES IN THE LIGHT OF MEDICAL SCIENCE
      ACHIEVEMENTS.
PG  - 2804-2809
AB  - OBJECTIVE: The aim: To identify issues of legal support for the use of genetics' 
      advances in medicine, reproductive technologies, etc. and to identify criteria
      for admissibility of safe and ethical implementation of scientific results.
      PATIENTS AND METHODS: Materials and methods: The analysis of international acts, 
      legislation of European countries, scientific reports on the results of
      achievements in medicine, in particular, the study and modification of DNA.
      Decisions of the European Court of Human Rights and a sample survey were used.
      The study is based on a combination of philosophical approaches, theoretical
      (dialectical, logical, historical, analysis and synthesis), specific legal and
      sociological methods of scientific knowledge. CONCLUSION: Conclusions: It is
      necessary to adopt at the UN level the Convention on the Control of Genetic
      Programming, to clearly define international cooperation in the field of
      prevention and counteraction to experiments on editing the genome of the "best
      man". Governments should adopt regulations based on certain standards of
      "preservation of human genetic identity", to establish the order of location of
      laboratories or other institutions on the territory of the states conducting
      research with genetic material.
FAU - Akhtyrska, Nataliia M
AU  - Akhtyrska NM
AD  - Institute of Law of Taras Shevchenko National University of Kyiv, Ukriane.
FAU - Kostiuchenko, Olena Yu
AU  - Kostiuchenko OY
AD  - Institute of Law of Taras Shevchenko National University of Kyiv, Ukriane.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
SB  - IM
MH  - *Bioethical Issues
MH  - Europe
MH  - Human Rights
MH  - Humans
MH  - International Cooperation
MH  - Male
MH  - *Medicine
OTO - NOTNLM
OT  - DNA
OT  - genome
OT  - germ cells
EDAT- 2021/02/22 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/21 20:39
PHST- 2021/02/21 20:39 [entrez]
PHST- 2021/02/22 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2020;73(12 cz 2):2804-2809.


PMID- 33611272
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20220531
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 73
IP  - 12 cz 2
DP  - 2020
TI  - ARTIFICIAL INTELLIGENCE IN MEDICAL PRACTICE: REGULATIVE ISSUES AND PERSPECTIVES.
PG  - 2722-2727
AB  - OBJECTIVE: The aim of the research is to identify specific of AI in healthcare,
      its nature, and specifics and to establish complexities of AI implementation in
      healthcare and to propose ways to eliminate them. PATIENTS AND METHODS: Materials
      and methods: This study was conducted during June-October of 2020. Through a
      broad literature review, analysis of EU, USA regulation acts, scientific
      researches and opinions of progressive-minded people in this sphere this paper
      provide a guide to understanding the essence of AI in healthcare and specifics of
      its regulation. It is based on dialectical, comparative, analytic, synthetic and 
      comprehensive methods. RESULTS: Results: One of the first broad definitions of AI
      sounded like "Artificial Intelligence is the study of ideas which enable
      computers to do the things that make people seem intelligent ... The central
      goals of Artificial Intelligence are to make computers more useful and to
      understand the principles which make intelligence possible." There are two
      approaches to name this technology - "Artificial intelligence" and "Augmented
      Intelligence." We prefer to use a more common category of "Artificial
      intelligence" rather than "Augmented Intelligence" because the last one, from our
      point of view, leaves much space for "human supervision" meaning, and that will
      limit the sense of AI while it will undoubtedly develop in future. AI in current 
      practice is interpreted in three forms, they are: AI as a simple electronic tool 
      without any level of autonomy (like electronic assistant, "calculator"), AI as an
      entity with some level of autonomy, but under human control, and AI as an entity 
      with broad autonomy, substituting human's activity wholly or partly, and we have 
      to admit that the first one cannot be considered as AI at all in current
      conditions of science development. Description of AI often tends to operate with 
      big technological products like DeepMind (by Google), Watson Health (by IBM),
      Healthcare's Edison (by General Electric), but in fact, a lot of smaller
      technologies also use AI in the healthcare field - smartphone applications,
      wearable health devices and other examples of the Internet of Things. At the
      current stage of development AI in medical practice is existing in three
      technical forms: software, hardware, and mixed forms using three main
      scientific-statistical approaches - flowchart method, database method, and
      decision-making method. All of them are useable, but they are differently suiting
      for AI implementation. The main issues of AI implementation in healthcare are
      connected with the nature of technology in itself, complexities of legal support 
      in terms of safety and efficiency, privacy, ethical and liability concerns.
      CONCLUSION: Conclusion: The conducted analysis makes it possible to admit a
      number of pros and cons in the field of AI using in healthcare. Undoubtedly this 
      is a promising area with a lot of gaps and grey zones to fill in. Furthermore,
      the main challenge is not on technology itself, which is rapidly growing,
      evolving, and uncovering new areas of its use, but rather on the legal framework 
      that is clearly lacking appropriate regulations and some political, ethical, and 
      financial transformations. Thus, the core questions regarding is this technology 
      by its nature is suitable for healthcare at all? Is the current legislative
      framework looking appropriate to regulate AI in terms of safety, efficiency,
      premarket, and postmarked monitoring? How the model of liability with connection 
      to AI technology using in healthcare should be constructed? How to ensure privacy
      without the restriction of AI technology use? Should intellectual privacy rights 
      prevail over public health concerns? Many questions to address in order to move
      in line with technology development and to get the benefits of its practical
      implementation.
FAU - Pashkov, Vitalii M
AU  - Pashkov VM
AD  - Poltava Law Institute of Yaroslav Mudryi National Law University, Poltava,
      Ukraine.
FAU - Harkusha, Andrii O
AU  - Harkusha AO
AD  - Laboratory for the Study of National Security Problems in the Field of Public
      Health of capital A, Cyrilliccademician Stashis Scientific Research Institute for
      the Study of Crime Problems, Kharkiv, Ukraine.
FAU - Harkusha, Yevheniia O
AU  - Harkusha YO
AD  - Laboratory for the Study of National Security Problems in the Field of Public
      Health of capital A, Cyrilliccademician Stashis Scientific Research Institute for
      the Study of Crime Problems, Kharkiv, Ukraine.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
SB  - IM
MH  - *Artificial Intelligence
MH  - *Delivery of Health Care
MH  - Humans
MH  - Morals
MH  - Software
MH  - Technology
OTO - NOTNLM
OT  - AI
OT  - Artificial Intelligence
OT  - Healthcare
OT  - Medical devices
OT  - Software
EDAT- 2021/02/22 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/21 20:39
PHST- 2021/02/21 20:39 [entrez]
PHST- 2021/02/22 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2020;73(12 cz 2):2722-2727.


PMID- 33605236
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20220531
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 70
DP  - 2020 COVID-19 SPECIAL ISSUE
TI  - Sensitivity and Specificity of Lateral Flow Antigen Test Kits for COVID-19 in
      Asymptomatic Population of Quarantine Centre of Province 3.
PG  - 36-39
AB  - Background Nearly after 6 months of the spread of Corona Virus Disease 19, along 
      with the world Nepal is still trying to control the spread and prevent general
      population from acquiring it. With limited resources in manpower, technology and 
      evidence it has been a difficult battle. But with time and more understanding of 
      the virus new technology to detect the virus are coming up. It is a major
      breakthrough in the diagnostic field as this helps us in not only detecting the
      virus but also helps us to mobilize our human resources. This comes in a time
      where the cases are increasing at an alarming rate. Although numbers of
      Polymerase Chain Reaction testing have increased but due to the time consuming
      and the cost wise, we need a faster and equally reliable alternative. Antigen
      test approved by different countries can be used for point of care, screening and
      surveillance depending upon the requirements after calculating its sensitivity,
      specificity and accuracy. Objective To find out sensitivity and specificity of
      the Antigen test kit for COVID-19. Method Antigen tests were compared with
      Reverse Transcription Polymerase Chain Reaction as a reference standard in
      calculated sample size of 113 subjects in a high risk population. Both Reverse
      Transcription Polymerase Chain Reaction and antigen test were performed in a same
      subject with in maximum of 2 days' interval. Convenience sampling technique was
      used to select the subjects. Ethical approval was taken from Nepal Health
      Research Council before data collection. Study was done from August to September 
      2020 from Quarantine center of Province 3. Result There were total of 113 test
      carried out, among those 47 were positive and 66 were negative in Reverse
      Transcription Polymerase Chain Reaction. After preparing two by two table,
      Sensitivity and specificity of the tested was calculated which came out to be 85%
      and 100% respectively, with accuracy of 93.80%. Conclusion Even though the
      sensitivity and specificity came to be higher, this test should be interpreted
      cautiously depending upon the prevalence of Corona Virus Disease 19 in that
      particular community and the clinical and epidemiological context of the person
      who has been tested. When in doubt by clinical correlation should be confirmed
      with Reverse Transcription Polymerase Chain Reaction.
FAU - Shrestha, B
AU  - Shrestha B
AD  - Nepalese Army Institute of Health Sciences, Kathmandu, Nepal.
FAU - Neupane, A K
AU  - Neupane AK
AD  - Nepalese Army Institute of Health Sciences, Kathmandu, Nepal.
FAU - Pant, S
AU  - Pant S
AD  - Nepal Health Research Council, Kathmandu, Nepal.
FAU - Shrestha, A
AU  - Shrestha A
AD  - Patan Academy of Health Science, Lalitpur, Patan, Nepal.
FAU - Bastola, A
AU  - Bastola A
AD  - Shukraraaj Tropical and Infectious Disease Hospital, Kathmandu, Nepal.
FAU - Rajbhandari, B
AU  - Rajbhandari B
AD  - Nepal Police Hospital, Kathmandu, Nepal.
FAU - Thapa, A
AU  - Thapa A
AD  - Nepal Armed Police Force Hospital, Kathmandu, Nepal.
FAU - Singh, A
AU  - Singh A
AD  - Nepalese Army Institute of Health Sciences, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - *Antibodies, Viral
MH  - *COVID-19
MH  - COVID-19 Testing
MH  - Humans
MH  - Nepal
MH  - Quarantine
MH  - SARS-CoV-2
MH  - Sensitivity and Specificity
MH  - Serologic Tests
EDAT- 2021/02/20 06:00
MHDA- 2021/02/23 06:00
CRDT- 2021/02/19 08:39
PHST- 2021/02/19 08:39 [entrez]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 COVID-19 SPECIAL ISSUE;18(70):36-39.


PMID- 33603982
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210220
IS  - 2008-3009 (Print)
IS  - 2008-2207 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Oct 1
TI  - Identifying Barriers to Umbilical Cord Blood Banking in Jordan: A Cross-Sectional
      Survey of Obstetricians.
PG  - 213-225
LID - 10.18502/ijhoscr.v14i4.4474 [doi]
AB  - Background: The expansion of umbilical cord blood (UCB) banking necessitates a
      greater understanding among obstetricians in order to responsibly inform parents 
      about UCB collection and storage. Gaps in knowledge can compromise public UCB
      banking efforts and result in missed opportunities and public misguidance about
      UCB banking. Materials and Methods: A cross-sectional survey was disseminated
      among obstetricians in Amman, Jordan. The questionnaire aimed to evaluate
      obstetricians' knowledge of and attitude toward UCB storage and applications, as 
      well as current practice patterns. Results: Ninety-six obstetricians responded
      (55% response rate), most of whom were Jordanian (71%), female (83%), resident
      physicians (59%), and working in either private (43%) or public (42%) hospitals, 
      with an average of 6.5 years in practice. Only 26% had personal experience in UCB
      collection, and 20% had received education on UCB collection. Nearly 75% said
      their hospitals lacked standard operating procedures, guidelines, or infectious
      disease screening for UCB units. Overall knowledge about UCB was moderate, and
      the internet was the most common information source (54%). Overall attitudes were
      positive, especially in desire to expand personal knowledge about UCB, integrate 
      information into medical residency curricula, and establish a public UCB bank in 
      Jordan. However, many believed that ethical (61%) and religious (56%)
      controversies surround UCB donation. Conclusion: This study identifies
      deficiencies in quality control and experience in UCB collection in Jordan, as
      well as areas of inadequate knowledge and ethical controversies among
      obstetricians. These issues contribute to public misinformation and limit public 
      UCB donation programs, and requires improved medical education on this topic.
CI  - Copyright (c) 2020 Tehran University of Medical Sciences.
FAU - Abdulrazeq, Fayez
AU  - Abdulrazeq F
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
FAU - Matsumoto, Monica M
AU  - Matsumoto MM
AD  - Pritzker School of Medicine, University of Chicago, 924 E. 57 Street, Suite 104, 
      Chicago, IL, 60637, USA.
FAU - Abduljabbar, Reem
AU  - Abduljabbar R
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
FAU - Al-Hajj, Amira
AU  - Al-Hajj A
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
FAU - Alayash, Melad
AU  - Alayash M
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
FAU - Ballourah, Rahaf
AU  - Ballourah R
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
FAU - Issak, Sumayya
AU  - Issak S
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
FAU - Issak, Zubeida
AU  - Issak Z
AD  - Community Medicine and Public Health Department, Faculty of Medicine, Yemen's
      University of Science and Technology-Jordan Branch, Farid Abu Minnah Street,
      Amman, Jordan.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Hematol Oncol Stem Cell Res
JT  - International journal of hematology-oncology and stem cell research
JID - 101511150
PMC - PMC7876430
OTO - NOTNLM
OT  - Attitudes
OT  - Jordan
OT  - Knowledge
OT  - Obstetricians
OT  - Umbilical cord blood banking
EDAT- 2021/02/20 06:00
MHDA- 2021/02/20 06:01
CRDT- 2021/02/19 06:06
PHST- 2021/02/19 06:06 [entrez]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2021/02/20 06:01 [medline]
AID - 10.18502/ijhoscr.v14i4.4474 [doi]
AID - IJHOSCR-14-213 [pii]
PST - ppublish
SO  - Int J Hematol Oncol Stem Cell Res. 2020 Oct 1;14(4):213-225. doi:
      10.18502/ijhoscr.v14i4.4474.


PMID- 33597882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210219
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Guidance for Demonstrating the Societal Value of new Antibiotics.
PG  - 618238
LID - 10.3389/fphar.2020.618238 [doi]
AB  - Given that antibiotic use is associated with externalities, standard economic
      evaluation which considers costs and health gains accruing to patients
      under-values antibiotics. Informed by a scoping review, this discussion paper
      aims to identify the societal value elements of antibiotics and to provide
      guidance on how these value elements can be incorporated in economic evaluation. 
      With a view to appropriately quantify the societal value of antibiotics, there is
      a need for good practice guidelines on the methodology of economic evaluation for
      such products. We argue that it is important to assess antibiotics at population 
      level to account for their transmission, diversity, insurance, spectrum, novel
      action and enablement values. In addition to the value of antibiotics to infected
      patients, economic evaluations need to use modeling approaches to explore the
      impact of different modes of employing new and existing antibiotics (for example,
      as last resort treatment) on disease transmission and resistance development in
      current and future patients. Hence, assessing the value of antibiotics also
      involves an ethical dimension. Further work is required about how the multiple
      value elements of antibiotics are linked to each other and how they can be
      aggregated.
CI  - Copyright (c) 2021 Simoens and Spriet.
FAU - Simoens, Steven
AU  - Simoens S
AD  - KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven,
      Belgium.
FAU - Spriet, Isabel
AU  - Spriet I
AD  - KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven,
      Belgium.
AD  - Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210201
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7882732
OTO - NOTNLM
OT  - antibiotic
OT  - economic evaluation
OT  - resistance
OT  - transmission
OT  - value
COIS- SS has carried out health economic studies of antibiotics funded by
      Sanofi-Aventis, Bayer, TEVA, and the Belgian National Institute for Health and
      Disability Insurance. IS received unrestricted research grants from Pfizer and
      Merck, and travel support from Pfizer, Merck and Gilead.
EDAT- 2021/02/19 06:00
MHDA- 2021/02/19 06:01
CRDT- 2021/02/18 06:10
PHST- 2020/10/16 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/02/18 06:10 [entrez]
PHST- 2021/02/19 06:00 [pubmed]
PHST- 2021/02/19 06:01 [medline]
AID - 10.3389/fphar.2020.618238 [doi]
AID - 618238 [pii]
PST - epublish
SO  - Front Pharmacol. 2021 Feb 1;11:618238. doi: 10.3389/fphar.2020.618238.
      eCollection 2020.


PMID- 33597799
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210628
LR  - 20220420
IS  - 2532-179X (Electronic)
IS  - 1124-0490 (Linking)
VI  - 37
IP  - 4
DP  - 2020
TI  - Predictive value of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte
      ratio in patients with hypersensitivity pneumonia.
PG  - e2020012
LID - 10.36141/svdld.v37i4.9966 [doi]
AB  - AIM: To evaluate Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte 
      Ratio (NLR) in patients with HP. METHOD: A sample of 140 total patients, 50
      having chronic HP and 20 having acute HP, and a control group of 70 more patients
      were included in this retrospective study conducted with hospital Ethical
      Committee approval. RESULTS: PLR and NLR values were significantly higher in all 
      HP patients than in the control group ( p <0.001). In addition, these biomarkers 
      were significantly higher in patients with acute HP than in the chronic HP group 
      (p = 0.017 and p = 0.044, respectively). The cutoff values for PLR and NLR were: 
      (1) 177 (p = 0.020) and 2.76 (p <0.0001) between the HP patients and the control 
      group, and, (2) 110 (p = 0.0054) and 2.15 (p = 0.03), between the acute and
      chronic HP groups. CONCLUSION: PLR and NLR values are inexpensive and easy
      parameters that can guide in diagnosing hypersensitivity pneumonia in combination
      with clinical, radiological and pathology findings.and the acute-chronic
      differentiation of the disease. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (4): 
      e2020012).
CI  - Copyright: (c) 2020 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.
FAU - Ucsular, Fatma
AU  - Ucsular F
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Polat, Gulru
AU  - Polat G
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Karadeniz, Gulistan
AU  - Karadeniz G
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Ayranci, Aysu
AU  - Ayranci A
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Keskin, Merve
AU  - Keskin M
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Buyuksirin, Melih
AU  - Buyuksirin M
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Guldaval, Filiz
AU  - Guldaval F
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
FAU - Yalniz, Enver
AU  - Yalniz E
AD  - Department of Pulmonology, Health Siences University Dr. Suat Seren Chest
      Diseases and Surgery Training and Research Hospital, Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - Italy
TA  - Sarcoidosis Vasc Diffuse Lung Dis
JT  - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
JID - 9610928
PMC - PMC7883515
OTO - NOTNLM
OT  - acute/chronic hypersensitivity pneumonia
OT  - neutrophil-to-lymphocyte ratio
OT  - platelet-to-lymphocyte ratio
EDAT- 2021/02/19 06:00
MHDA- 2021/02/19 06:01
CRDT- 2021/02/18 06:09
PHST- 2020/05/31 00:00 [received]
PHST- 2020/11/15 00:00 [accepted]
PHST- 2021/02/18 06:09 [entrez]
PHST- 2021/02/19 06:00 [pubmed]
PHST- 2021/02/19 06:01 [medline]
AID - 10.36141/svdld.v37i4.9966 [doi]
AID - SVDLD-37-12 [pii]
PST - ppublish
SO  - Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(4):e2020012. doi:
      10.36141/svdld.v37i4.9966. Epub 2020 Dec 16.


PMID- 33590742
OWN - NLM
STAT- Publisher
LR  - 20210216
IS  - 2322-5939 (Electronic)
IS  - 2322-5939 (Linking)
DP  - 2020 Dec 30
TI  - Towards Core Competencies for Health Policy and Systems Research (HPSR) Training:
      Results From a Global Mapping and Consensus-Building Process.
LID - 10.34172/ijhpm.2020.258 [doi]
AB  - BACKGROUND: As the field of health policy and systems research (HPSR) continues
      to grow, there is a recognition of the need for training in HPSR. This aspiration
      has translated into a multitude of teaching programmes of variable scope and
      quality, reflecting a lack of consensus on the skills and practices required for 
      rigorous HPSR. The purpose of this paper is to identify an agreed set of core
      competencies for HPSR researchers, building on the previous work by the Health
      Systems Global (HSG) Thematic Working Group on Teaching & Learning. METHODS: Our 
      methods involved an iterative approach of four phases including a literature
      review, key informant interviews and group discussions with HPSR educators, and
      webinars with pre-post surveys capturing views among the global HPSR community.
      The phased discussions and consensus-building contributed to the evolution of the
      HPSR competency domains and competencies framework. RESULTS: Emerging domains
      included understanding health systems complexity, assessing policies and
      programs, appraising data and evidence, ethical reasoning and practice, leading
      and mentoring, building partnerships, and translating and utilizing knowledge and
      HPSR evidence. The development of competencies and their application were often
      seen as a continuous process spanning evidence generation, partnering,
      communicating and helping to identify new critical health systems questions.
      CONCLUSION: The HPSR competency set can be seen as a useful reference point in
      the teaching and practice of high-quality HPSR and can be adapted based on
      national priorities, the particularities of local contexts, and the needs of
      stakeholders (HPSR researchers and educators), as well as practitioners and
      policy-makers. Further research is needed in using the core competency set to
      design national training programmes, develop locally relevant benchmarks and
      assessment methods, and evaluate their use in different settings.
CI  - (c) 2020 The Author(s); Published by Kerman University of Medical Sciences. This 
      is an open-access article distributed under the terms of the Creative Commons
      Attribution License (http://creativecommons.org/ licenses/by/4.0), which permits 
      unrestricted use, distribution, and reproduction in any medium, provided the
      original work is properly cited.
FAU - Schleiff, Meike J
AU  - Schleiff MJ
AUID- ORCID: 0000-0001-6492-3718
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
FAU - Rangnekar, Avanti
AU  - Rangnekar A
AUID- ORCID: 0000-0002-9825-1582
AD  - University of Tennessee, Knoxville, TN, USA.
FAU - Oviedo Gomez, Francisco
AU  - Oviedo Gomez F
AD  - Ministry of Health, San Jose, Costa Rica.
AD  - School of Public Health, University of Costa Rica, San Jose, Costa Rica.
FAU - Teddy, Gina
AU  - Teddy G
AUID- ORCID: 0000-0001-9747-2685
AD  - Center for Health Systems and Policy Research at GIMPA, Accra, Ghana.
FAU - Peters, David H
AU  - Peters DH
AUID- ORCID: 0000-0001-8377-3444
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
FAU - Balabanova, Dina
AU  - Balabanova D
AUID- ORCID: 0000-0001-7163-3428
AD  - London School of Hygiene and Tropical Medicine, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20201230
PL  - Iran
TA  - Int J Health Policy Manag
JT  - International journal of health policy and management
JID - 101619905
SB  - IM
OTO - NOTNLM
OT  - Competency Based Education
OT  - Health Systems Research
OT  - Stakeholder Engagement
OT  - Workforce
EDAT- 2021/02/17 06:00
MHDA- 2021/02/17 06:00
CRDT- 2021/02/16 06:30
PHST- 2020/07/09 00:00 [received]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2021/02/16 06:30 [entrez]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - 10.34172/ijhpm.2020.258 [doi]
PST - aheadofprint
SO  - Int J Health Policy Manag. 2020 Dec 30. doi: 10.34172/ijhpm.2020.258.


PMID- 33585598
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210216
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Resource, Collaborator, or Individual Cow? Applying Q Methodology to Investigate 
      Austrian Farmers' Viewpoints on Motivational Aspects of Improving Animal Welfare.
PG  - 607925
LID - 10.3389/fvets.2020.607925 [doi]
AB  - One keystone to successful welfare improvement endeavors is a respected
      cooperation between farmer and advisor (e.g., veterinarian), which requires a
      thorough understanding of what motivates farmer behavior. In this respect, Q
      methodology offers a promising approach in investigating individual motivational 
      patterns and to discriminate between and describe typologies of farmers. In our
      study we explored, based on a sample of 34 Austrian dairy farmers, how 39
      potentially motivating statements regarding the improvement of dairy cow health
      and welfare were assessed. We were able to identify and describe four different
      viewpoints, explaining 47% of total study variance. All four viewpoints have in
      common that pride in a healthy herd is motivating to work toward improved animal 
      health and welfare to a certain extent, but meeting legal requirements is rather 
      not. Viewpoint 1 acknowledges welfare for economic performance, ease of work and 
      short working hours but does not make allowance for outside interference.
      Participants loading on Viewpoint 2 also show a focus on economic aspects but,
      keep close track of the animal welfare debate recognizing its potential to
      improve the public image of dairy farming. Even though they cautiously criticize 
      an exploitative application of dairy farming, they do not want to be understood
      as role models. With regards to animal welfare, farmers sharing Viewpoint 3
      perceive themselves as superior to and show little reluctance of comparison with 
      mainstream farming. For them, the animal as sentient being itself owns some
      intrinsic value and it is necessary to strike a balance between economic and
      other, ethical considerations. Viewpoint 4 perceives cows as equal collaborators 
      who deserve to be treated with respect and appreciation and is willing to accept 
      certain economic losses in order to maintain high standards regarding animal
      health and welfare. Using Q methodology, we have been able to draw high
      resolution images of different farmer typologies, enabling advisors to tailor
      intervention strategies specifically addressing leverage points with a high
      chance of farmer compliance.
CI  - Copyright (c) 2021 Maurer, Schenkenfelder and Winckler.
FAU - Maurer, Lorenz
AU  - Maurer L
AD  - Division of Livestock Sciences, Department of Sustainable Agricultural Systems,
      University of Natural Resources and Life Sciences, Vienna, Austria.
FAU - Schenkenfelder, Josef
AU  - Schenkenfelder J
AD  - Division of Livestock Sciences, Department of Sustainable Agricultural Systems,
      University of Natural Resources and Life Sciences, Vienna, Austria.
FAU - Winckler, Christoph
AU  - Winckler C
AD  - Division of Livestock Sciences, Department of Sustainable Agricultural Systems,
      University of Natural Resources and Life Sciences, Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20210112
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7873868
OTO - NOTNLM
OT  - Q methodology
OT  - cow
OT  - dairy
OT  - farmer
OT  - improvement
OT  - motivation
OT  - viewpoint
OT  - welfare
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:11
PHST- 2020/09/18 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/02/15 06:11 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
AID - 10.3389/fvets.2020.607925 [doi]
PST - epublish
SO  - Front Vet Sci. 2021 Jan 12;7:607925. doi: 10.3389/fvets.2020.607925. eCollection 
      2020.


PMID- 33585179
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Hypercholesterolemia Is an Associated Factor for Risk of Differentiated Thyroid
      Cancer in Chinese Population.
PG  - 508126
LID - 10.3389/fonc.2020.508126 [doi]
AB  - BACKGROUND: Hyperlipidemia has been hypothesized as a risk factor for thyroid
      cancer. However, the association between hypercholesterolemia and thyroid cancer 
      is unclear, especially in Chinese population without available published data. We
      conducted this study to investigate the relationship between hypercholesterolemia
      and differentiated thyroid cancer (DTC) in Chinese population. METHODS: Three
      thousand seven hundred forty-eight patients were enrolled in the study, including
      2,021 DTC patients and 1,727 benign subjects with benign thyroid nodules.
      Demographic characteristics, medical history, and clinical hematological
      examination were collected. Stratified analyses of association between
      hypercholesterolemia and risk of DTC were done. Multivariable logistic regression
      models were used to estimate the association between hypercholesterolemia and the
      risk of thyroid nodules being malignant. This study protocol was approved by the 
      ethics committee of Shandong Provincial Qianfoshan Hospital and assigned in
      ClinicalTrials.gov protocol registration and results system (NCT03006289,
      https://clinicaltrials.gov/ct2/show/NCT03006289). RESULTS: The level of serum
      total cholesterol in patients with DTC is higher than that in benign subjects (P 
      < 0.001). After adjusting hypercholesterolemia, age (P < 0.001), triglyceride (P 
      = 0.003), and thyroid stimulating hormone (TSH) (P < 0.001) are found to be
      confounding factors. The risk of DTC in patients younger than 45 years old is
      2.08 times than that of patients older than 45 years old (odds ratio = 0.48, 95% 
      CI (0.38, 0.61), P < 0.001). A high TSH level is highly associated with the
      increased risk of DTC (P < 0.001). The multivariable logistic regression analysis
      revealed that the absence of hypercholesterolemia could reduce the risk of
      thyroid nodules being malignant (odds ratio = -0.75, 95% CI (-1.39, -0.12), P =
      0.02). Comparing to the higher level of serum total cholesterol (>5.7 mmol/L),
      the closer the serum total cholesterol level is to normal (3.17-5.7 mmol/L), the 
      less the risk of thyroid nodules being malignant is, and this difference is
      statistically significant (odds ratio = -0.67, 95% CI (-1.31, -0.03), P = 0.040).
      However, this difference is not found in the group of patients with lower level
      of total cholesterol (<3.17 mmol/L, odds ratio = 0.43, 95% CI (-1.22, 2.09), P = 
      0.068), suggesting that hypocholesterolemia is not a protective factor in the
      risk of thyroid nodules being malignant. CONCLUSIONS: Hypercholesterolemia is an 
      associated factor for risk of DTC in Chinese population.
CI  - Copyright (c) 2021 Zhao, Tian, Yao, Gu, Zhang, Wang, Liao and Dong.
FAU - Zhao, Junyu
AU  - Zhao J
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of
      Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,
      Jinan, China.
AD  - Department of Endocrinology and Metabology, Shandong Provincial Qianfoshan
      Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Tian, Yutian
AU  - Tian Y
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of
      Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,
      Jinan, China.
AD  - Department of Endocrinology and Metabology, Shandong Provincial Qianfoshan
      Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Yao, Jinming
AU  - Yao J
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of
      Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,
      Jinan, China.
AD  - Department of Endocrinology and Metabology, Shandong Provincial Qianfoshan
      Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Gu, He
AU  - Gu H
AD  - Department of Thyroid & Breast Surgery, The First Affiliated Hospital of Shandong
      First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong
      University, Jinan, China.
AD  - Department of Thyroid & Breast Surgery, Shandong Provincial Qianfoshan Hospital, 
      Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of Endocrinology and Metabology, Qilu Hospital of Shandong University,
      Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Wang, Huanjun
AU  - Wang H
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of
      Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,
      Jinan, China.
AD  - Department of Endocrinology and Metabology, Shandong Provincial Qianfoshan
      Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Liao, Lin
AU  - Liao L
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of
      Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,
      Jinan, China.
AD  - Department of Endocrinology and Metabology, Shandong Provincial Qianfoshan
      Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
FAU - Dong, Jianjun
AU  - Dong J
AD  - Department of Endocrinology and Metabology, Qilu Hospital of Shandong University,
      Cheeloo College of Medicine, Shandong University, Jinan, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03006289
PT  - Journal Article
DEP - 20210128
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7876371
OTO - NOTNLM
OT  - clinical study
OT  - differentiated thyroid cancer
OT  - hypercholesterolemia
OT  - thyroid nodule
OT  - total cholesterol
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:10
PHST- 2019/10/29 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/02/15 06:10 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
AID - 10.3389/fonc.2020.508126 [doi]
PST - epublish
SO  - Front Oncol. 2021 Jan 28;10:508126. doi: 10.3389/fonc.2020.508126. eCollection
      2020.


PMID- 33584507
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210216
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Triage and Allocation of Neurocritical Care Resources During the COVID 19
      Pandemic - A National Survey.
PG  - 609227
LID - 10.3389/fneur.2020.609227 [doi]
AB  - Objective: In light of the ongoing COVID-19 pandemic and the associated
      hospitalization of an overwhelming number of ventilator-dependent patients,
      medical and/or ethical patient triage paradigms have become essential. While
      guidelines on the allocation of scarce resources do exist, such work within the
      subdisciplines of intensive care (e.g., neurocritical care) remains limited.
      Methods: A 16-item questionnaire was developed that sought to explore/quantify
      the expert opinions of German neurointensivists with regard to triage decisions. 
      The anonymous survey was conducted via a web-based platform and in total, 96
      members of the Initiative of German Neurointensive Trial Engagement
      (IGNITE)-study group were contacted via e-mail. The IGNITE consortium consists of
      an interdisciplinary panel of specialists with expertise in neuro-critical care
      (i.e., anesthetists, neurologists and neurosurgeons). Results: Fifty members of
      the IGNITE consortium responded to the questionnaire; in total the respondents
      were in charge of more than 500 Neuro ICU beds throughout Germany. Common
      determinants reported which affected triage decisions included known patient
      wishes (98%), the state of health before admission (96%), SOFA-score (85%) and
      patient age (69%). Interestingly, other principles of allocation, such as a
      treatment of "youngest first" (61%) and members of the healthcare sector (50%)
      were also noted. While these were the most accepted parameters affecting the
      triage of patients, a "first-come, first-served" principle appeared to be more
      accepted than a lottery for the allocation of ICU beds which contradicts much of 
      what has been reported within the literature. The respondents also felt that at
      least one neurointensivist should serve on any interdisciplinary triage team.
      Conclusions: The data gathered in the context of this survey reveal the
      estimation/perception of triage algorithms among neurointensive care specialists 
      facing COVID-19. Further, it is apparent that German neurointensivists strongly
      feel that they should be involved in any triage decisions at an institutional
      level given the unique resources needed to treat patients within the Neuro ICU.
CI  - Copyright (c) 2021 Gessler, Lehmann, Bosel, Fuhrer, Neugebauer, Wartenberg, Wolf,
      Bernstock, Niesen and Schuss.
FAU - Gessler, Florian
AU  - Gessler F
AD  - Department of Neurosurgery, University Hospital Frankfurt, Frankfurt, Germany.
FAU - Lehmann, Felix
AU  - Lehmann F
AD  - Department of Anesthesiology and Intensive Care Medicine, University Hospital
      Bonn, Bonn, Germany.
FAU - Bosel, Julian
AU  - Bosel J
AD  - Department of Neurology, Kassel General Hospital, Kassel, Germany.
FAU - Fuhrer, Hannah
AU  - Fuhrer H
AD  - Department of Neurology, University Hospital Freiburg, Freiburg, Germany.
FAU - Neugebauer, Hermann
AU  - Neugebauer H
AD  - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Wartenberg, Katja E
AU  - Wartenberg KE
AD  - Department of Neurology, University Hospital Leipzig, Leipzig, Germany.
FAU - Wolf, Stefan
AU  - Wolf S
AD  - Department of Neurosurgery, Charite University Hospital Berlin, Berlin, Germany.
FAU - Bernstock, Joshua D
AU  - Bernstock JD
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United
      States.
AD  - Harvard Medical School, Harvard University, Boston, MA, United States.
FAU - Niesen, Wolf-Dirk
AU  - Niesen WD
AD  - Department of Neurology, University Hospital Freiburg, Freiburg, Germany.
FAU - Schuss, Patrick
AU  - Schuss P
AD  - Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210106
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7874200
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV
OT  - neurocritical care
OT  - pandemic
OT  - patient triage
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:08
PHST- 2020/09/22 00:00 [received]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2021/02/15 06:08 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
AID - 10.3389/fneur.2020.609227 [doi]
PST - epublish
SO  - Front Neurol. 2021 Jan 6;11:609227. doi: 10.3389/fneur.2020.609227. eCollection
      2020.


PMID- 33584427
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210216
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Traditional Sports and Games: Intercultural Dialog, Sustainability, and
      Empowerment.
PG  - 590301
LID - 10.3389/fpsyg.2020.590301 [doi]
AB  - From Traditional Sports and Games (TSG) we have not only learned different ways
      of living time as well as inhabit space and a particular mode of practicing
      sports and games from distinct cultures, but also promoting universal dialog
      among people. TSG presents sustainable and ecological references for living
      needed even before the advent of the COVID-19 pandemic. Nowadays, environmentally
      friendly policies and production methods must be taken more seriously. TSG may
      reveal a path to sustainable development, considering our corporeality and
      cultural diversity. TSG are expressions of human groups that historically
      reproduce their way of life-based on modes of social cooperation and specific
      forms of relationship with nature, traditionally characterized by sustained
      environmental management. The purpose of this article is to discuss how TSG
      promotes intercultural dialog with a focus on sustainability, and how it empowers
      people and creates equality among its players. We understand that TSG can break
      socio-cultural barriers. For this study, we considered data from a Brazilian
      experience of TSG's Festival held at a public school in the city of Sao Paulo
      (Brazil), organized in collaboration with our study group. Data consists of
      observations recorded in pictures and films during the processes of organization,
      preparation, implementation, and evaluation of a TSG Festival, held in a public
      school in Sao Paulo, Brazil from the years of 2017 and 2018, with the
      participation of 800 students from the first to the ninth grade of elementary
      school, aged between 7 and 17 years. The first step in our analysis is taken from
      a dynamic called "Talking Circles," where researchers registered dialog about
      experiences and used specific literature about TSG, from a philosophical
      perspective. The team and students from our study group that organized these
      events were invited to participate in four different Talking Circles.
      Approximately 20 people participated in each one of these meetings. Recurrences
      that emerged from these Talking Circles are presented in the results and explored
      afterward. What does this experience-from bodies in movement, artistic or
      sporting, or both-teach about intercultural dialog and empowerment? Such gestures
      indicate a cultural heritage and corporeal wisdom that allows humans to face new 
      encounters and understanding in peace, recognizing humanity common to all of us, 
      regardless of our origins. Ethical and aesthetical results of such dialog reveal 
      possibilities to be explored in our relationship with different cultures and the 
      environment, providing points of sustainable development through TSG.
CI  - Copyright (c) 2021 Saura and Zimmermann.
FAU - Saura, Soraia Chung
AU  - Saura SC
AD  - Center for Cultural Studies on the Human Movement, Department of Pedagogy of the 
      Human Body Movement, School of Physical Education and Sport, University of Sao
      Paulo, Sao Paulo, Brazil.
FAU - Zimmermann, Ana Cristina
AU  - Zimmermann AC
AD  - Center for Cultural Studies on the Human Movement, Department of Pedagogy of the 
      Human Body Movement, School of Physical Education and Sport, University of Sao
      Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20210122
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7873946
OTO - NOTNLM
OT  - dialog
OT  - festival
OT  - phenomenology
OT  - philosophy
OT  - traditional sports and games
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:07
PHST- 2020/07/31 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2021/02/15 06:07 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
AID - 10.3389/fpsyg.2020.590301 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 22;11:590301. doi: 10.3389/fpsyg.2020.590301. eCollection
      2020.


PMID- 33584422
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210216
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Study Protocol for the Evaluation of Individual Psychological Interventions for
      Family Caregivers of Advanced Cancer Patients.
PG  - 587627
LID - 10.3389/fpsyg.2020.587627 [doi]
AB  - Background: Both anxiety and depression in family caregivers (FCs) of advanced
      cancer patients are common, and they have a negative influence on both the FCs
      and the patients. Some studies suggested that a variety of interventions could
      alleviate the psychological symptoms of FCs. However, there is no consensus on
      much more effective methods for intervention, and relatively high-quality
      research is blank in psychological problems of these population in China. The
      validity of mindfulness-based stress reduction (MBSR) and psychological
      consultation guided by the needs assessment tool (NST) in the psychological
      status of caregivers will be compared in this study to select a more suitable
      intervention for the FCs of advanced cancer patients in China. Methods and
      Analysis: A randomized N-of-1 trial would be conducted at the Cancer Hospital,
      Chinese Academy of Medical Sciences. Fifty eligible FCs of advanced cancer
      patients will be recruited, and all will receive three cycles of psychological
      intervention treatment, with each cycle including both of MBSR and psychological 
      consultation guided by the NST. MBSR and psychological consultation guided by the
      NST will be compared with each other in each cycle, and the intervention sequence
      will be based on the random number table generated after the informed consent has
      been completed. Each treatment period is 2 weeks, and the interval between
      different treatment cycles or treatment periods is 1 week. The self-reported
      scales are measured at the beginning and end of each treatment period, including 
      the Self-Rating Anxiety Scale (SAS), the Self-Rating Depression Scale (SDS),
      Distress Thermometer (DT), Zarit Burden Interview (ZBI), Chinese version of the
      Medical Outcomes Study 12-item Short Form (C-SF-12), and Family Carer
      Satisfaction with Palliative Care scale (FAMCARE-2). Dissemination: The protocol 
      of the study was approved by the Institutional Review Board of the Ethical
      Committee of the Cancer Hospital, Chinese Academic of Medical Science. The
      results will be published in a peer-reviewed medical journal. The study is
      registered at Chinese Clinical Trials Registry with the trial registration number
      chiCTR2000033707. This study employs an innovative methodological approach on the
      effectiveness of MBSR and psychological consultation guided by the NST for
      psychological status of FCs of advanced cancer patients. The findings of the
      study will be helpful to provide high-quality evidence-based medical data for
      psychological intervention of FCs of advanced cancer patients, and guide
      clinicians on best quality treatment recommendations.
CI  - Copyright (c) 2021 Yang, Sun, Wang, Xu, Zou, Yang, Cong, Zheng, Yu, Ma, Qiu and
      Li.
FAU - Yang, Min
AU  - Yang M
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Sun, Rui
AU  - Sun R
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Wang, Yanfeng
AU  - Wang Y
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Xu, Haiyan
AU  - Xu H
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Zou, Baohua
AU  - Zou B
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Yang, Yanmin
AU  - Yang Y
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Cong, Minghua
AU  - Cong M
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Zheng, Yadi
AU  - Zheng Y
AD  - Office of Cancer Screening, National Cancer Center/National Clinical Research
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
      Union Medical College, Beijing, China.
FAU - Yu, Lei
AU  - Yu L
AD  - Department of Comprehensive Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Ma, Fei
AU  - Ma F
AD  - Department of Internal Medicine, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Qiu, Tinglin
AU  - Qiu T
AD  - Division of Medical Services, National Cancer Center/National Clinical Research
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
      Union Medical College, Beijing, China.
FAU - Li, Jiang
AU  - Li J
AD  - Office of Cancer Screening, National Cancer Center/National Clinical Research
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
      Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210120
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7873877
OTO - NOTNLM
OT  - N-of-1 trial
OT  - advanced cancer patients
OT  - family caregivers
OT  - individual effectiveness
OT  - psychological intervention
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:07
PHST- 2020/07/27 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2021/02/15 06:07 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
AID - 10.3389/fpsyg.2020.587627 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 20;11:587627. doi: 10.3389/fpsyg.2020.587627. eCollection
      2020.


PMID- 33584171
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210216
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Electrical Characterisation of Adelta-Fibres Based on Human in vivo
      Electrostimulation Threshold.
PG  - 588056
LID - 10.3389/fnins.2020.588056 [doi]
AB  - Electrical stimulation of small fibres is gaining attention in the diagnosis of
      peripheral neuropathies, such as diabetes mellitus, and pain research. However,
      it is still challenging to characterise the electrical characteristics of axons
      in small fibres (Adelta and C fibres). In particular, in vitro measurement for
      human Adelta-fibre is difficult due to the presence of myelin and ethical reason.
      In this study, we investigate the in vivo electrical characteristics of the human
      Adelta-fibre to derive strength-duration (S-D) curves from the measurement. The
      Adelta-fibres are stimulated using coaxial planar electrodes with intraepidermal 
      needle tip. For human volunteer experiments, the S-D curve of Adelta-fibre is
      obtained in terms of injected electrical current. With the computational
      analysis, the standard deviation of the S-D curve is mostly attributed to the
      thickness of the stratum corneum and depth of the needle tip, in addition to the 
      fibre thickness. Then, we derive electrical parameters of the axon in the
      Adelta-fibre based on a conventional fibre model. The parameters derived here
      would be important in exploring the optimal stimulation condition of
      Adelta-fibres.
CI  - Copyright (c) 2021 Tanaka, Gomez-Tames, Wasaka, Inui, Ueno and Hirata.
FAU - Tanaka, Shota
AU  - Tanaka S
AD  - Department of Electrical and Mechanical Engineering, Nagoya Institute of
      Technology, Nagoya, Japan.
FAU - Gomez-Tames, Jose
AU  - Gomez-Tames J
AD  - Department of Electrical and Mechanical Engineering, Nagoya Institute of
      Technology, Nagoya, Japan.
AD  - Center of Biomedical Physics and Information Technology, Nagoya Institute of
      Technology, Nagoya, Japan.
FAU - Wasaka, Toshiaki
AU  - Wasaka T
AD  - Department of Electrical and Mechanical Engineering, Nagoya Institute of
      Technology, Nagoya, Japan.
AD  - Center of Biomedical Physics and Information Technology, Nagoya Institute of
      Technology, Nagoya, Japan.
FAU - Inui, Koji
AU  - Inui K
AD  - Department of Functioning and Disability, Institute for Developmental Research,
      Aichi Developmental Disability Center, Kasugai, Japan.
AD  - Department of Integrative Physiology, National Institute for Physiological
      Sciences, Okazaki, Japan.
FAU - Ueno, Shoogo
AU  - Ueno S
AD  - Center of Biomedical Physics and Information Technology, Nagoya Institute of
      Technology, Nagoya, Japan.
AD  - Department of Biomedical Engineering, Graduate School of Medicine, The University
      of Tokyo, Tokyo, Japan.
FAU - Hirata, Akimasa
AU  - Hirata A
AD  - Department of Electrical and Mechanical Engineering, Nagoya Institute of
      Technology, Nagoya, Japan.
AD  - Center of Biomedical Physics and Information Technology, Nagoya Institute of
      Technology, Nagoya, Japan.
AD  - Frontier Research Institute for Information Science, Nagoya Institute of
      Technology, Nagoya, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210105
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7873976
OTO - NOTNLM
OT  - electrical analysis in biological tissues
OT  - electrical stimulation
OT  - extracellular electric field
OT  - selective stimulation of small fibres
OT  - strength duration curve
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:07
PHST- 2020/07/28 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2021/02/15 06:07 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
AID - 10.3389/fnins.2020.588056 [doi]
PST - epublish
SO  - Front Neurosci. 2021 Jan 5;14:588056. doi: 10.3389/fnins.2020.588056. eCollection
      2020.


PMID- 33584094
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
IS  - 1119-5096 (Print)
IS  - 1119-5096 (Linking)
VI  - 23
IP  - Suppl 2
DP  - 2020 Dec
TI  - Protocol and Researcher's Relationship with Institutional Review Board.
PG  - 15-20
AB  - The document of ethical approval is an important official requirement for
      research involving human participants worldwide. It is the process whereby an
      investigator submits the full research proposal and related documents including
      detailed informed consent process to an independent Institutional Review Board
      (IRB) for scrutiny. The process of seeking review and approval is necessary to
      ensure adequate measure are in place to safeguard and protect research
      participants as entrenched in the principles of The Declaration of Helsinki and
      The Belmont Report. It is the responsibility of every clinical researcher to
      obtain ethical approval, therefore, their obligation to understand the process of
      review and establish relationship with local IRB in order to enhance smooth
      review and approval. This article, therefore, explains clinical research and
      distinguishes between research and clinical care, clarifies briefly what
      constitutes a study protocol and describes the researchers' relationship with
      IRB.
FAU - Orimadegun, A E
AU  - Orimadegun AE
AD  - Institute of Child Health, College of Medicine, University of Ibadan. Ibadan,
      Nigeria.
LA  - eng
GR  - D71 TW010876/TW/FIC NIH HHS/United States
PT  - Journal Article
PL  - Nigeria
TA  - Afr J Biomed Res
JT  - African journal of biomedical research : AJBR
JID - 101214362
PMC - PMC7876614
MID - NIHMS1662742
OTO - NOTNLM
OT  - Clinical research
OT  - clinical practice
OT  - ethical approval
OT  - institutional review board
OT  - study protocol
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
CRDT- 2021/02/15 06:06
PHST- 2021/02/15 06:06 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
PST - ppublish
SO  - Afr J Biomed Res. 2020 Dec;23(Suppl 2):15-20.


PMID- 33583857
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 3
DP  - 2020
TI  - Two Cases of Pregnancy Following Uterine Transplant: An Ethical Analysis.
PG  - 263-268
LID - 10.1353/nib.2020.0074 [doi]
AB  - Uterine factor infertility (UFI) affects 1-5% of women of reproductive age, and
      uterus transplantation is the only option available to these women for carrying a
      pregnancy. The ethical analysis of uterus transplantation focuses on the value
      and experience of pregnancy in recipients; to date, however, no personal
      experiences with pregnancy after uterus transplantation have been published. The 
      authors share the stories of two of our uterus transplant recipients, obtained
      through semi-structured, in-person interviews. The interview questions focused on
      the recipients' experiences during pregnancy. We report the cases as the
      interwoven narratives of the two women's pregnancies and their perceptions of the
      value of gestation.
FAU - Wall, Anji E
AU  - Wall AE
FAU - Johannesson, Liza
AU  - Johannesson L
FAU - Testa, Giuliano
AU  - Testa G
FAU - Warren, Ann Marie
AU  - Warren AM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - Ethical Analysis
MH  - Female
MH  - Humans
MH  - Narration
MH  - Pregnancy/ethics/physiology/*psychology
MH  - Transplant Recipients/*psychology
MH  - Uterus/*transplantation
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:00
CRDT- 2021/02/15 06:05
PHST- 2021/02/15 06:05 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - S2157174020300178 [pii]
AID - 10.1353/nib.2020.0074 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(3):263-268. doi: 10.1353/nib.2020.0074.


PMID- 33583856
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 3
DP  - 2020
TI  - A Qualitative Study of the Views of Individuals With Type 1 Diabetes on the
      Ethical Considerations Raised by the Artificial Pancreas.
PG  - 237-261
LID - 10.1353/nib.2020.0072 [doi]
AB  - Type 1 diabetes management requires regular blood glucose measurements and
      tailored insulin administration to prevent its complications. An artificial
      pancreas is developed to automate insulin therapy, thereby improving its safety
      and effectiveness. Despite its benefits compared to conventional approaches, the 
      artificial pancreas raises ethical considerations which could impact its uptake
      and user satisfaction. The objective of this qualitative study was to understand 
      the ethical considerations associated with the artificial pancreas of
      significance to individuals with type 1 diabetes. Sixteen interviews were
      conducted with these stakeholders. Qualitative content analysis was conducted on 
      interview transcriptions. Five categories of ethical considerations were
      identified: (1) contextualized autonomy and control in diabetes management; (2)
      relational autonomy, identity, and relationships; (3) safety, privacy, and
      confidentiality; (4) public and private coverage; and (5) justice and patient
      selection criteria. These issues need to be addressed in the development of the
      artificial pancreas, clinical practice, and coverage policies.
FAU - Quintal, Ariane
AU  - Quintal A
FAU - Messier, Virginie
AU  - Messier V
FAU - Rabasa-Lhoret, Remi
AU  - Rabasa-Lhoret R
FAU - Racine, Eric
AU  - Racine E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - Adult
MH  - Aged
MH  - Confidentiality/ethics
MH  - Diabetes Mellitus, Type 1/*therapy
MH  - Female
MH  - Humans
MH  - *Insulin Infusion Systems
MH  - Insurance Coverage/ethics
MH  - Male
MH  - Middle Aged
MH  - Pancreas, Artificial/*ethics
MH  - Patient Selection/ethics
MH  - Personal Autonomy
MH  - Privacy
MH  - Qualitative Research
MH  - Quebec/epidemiology
MH  - Relational Autonomy
MH  - Self Concept
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:00
CRDT- 2021/02/15 06:05
PHST- 2021/02/15 06:05 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - S2157174020300154 [pii]
AID - 10.1353/nib.2020.0072 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(3):237-261. doi: 10.1353/nib.2020.0072.


PMID- 33583844
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 3
DP  - 2020
TI  - What is Ethical Discharge? Turning the Negatives into Positives.
PG  - 192-195
LID - 10.1353/nib.2020.0065 [doi]
FAU - Griffin, Leslie C
AU  - Griffin LC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - Humans
MH  - *Patient Discharge
EDAT- 2021/02/16 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/02/15 06:05
PHST- 2021/02/15 06:05 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - S2157174020300087 [pii]
AID - 10.1353/nib.2020.0065 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(3):192-195. doi: 10.1353/nib.2020.0065.


PMID- 33583839
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 3
DP  - 2020
TI  - Ethical Challenges in Discharge Planning: Stories from Patients.
PG  - 183-186
LID - 10.1353/nib.2020.0070 [doi]
AB  - This symposium includes twelve personal narratives from patients and their
      caregivers who have navigated challenges in planning for discharge from the
      hospital and transition to care at home, a rehabilitation facility, long-term
      care facility, or hospice. Three commentaries on these narratives are also
      included, authored by experts and scholars in the fields of medicine, bioethics, 
      and health policy with particular interest in vulnerable populations. The goal of
      this symposium is to call attention to the experiences of patients during
      transitions in care and to enrich discussions of ethical issues in discharge
      planning.
FAU - Pendo, Elizabeth
AU  - Pendo E
LA  - eng
PT  - Introductory Journal Article
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - Authorship
MH  - *Ethics
MH  - Humans
MH  - *Patient Discharge
MH  - *Patient Transfer
MH  - Periodicals as Topic
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:00
CRDT- 2021/02/15 06:05
PHST- 2021/02/15 06:05 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - S2157174020300130 [pii]
AID - 10.1353/nib.2020.0070 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(3):183-186. doi: 10.1353/nib.2020.0070.


PMID- 33582686
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1812-2078 (Electronic)
IS  - 1812-2027 (Linking)
VI  - 18
IP  - 69
DP  - 2020 Jan.-Mar
TI  - Risk of Diabetic Foot in Diabetic Patients with Peripheral Arterial Disease.
PG  - 38-41
AB  - Background The prevalence of peripheral arterial disease is higher in diabetic
      patients. And 11.6% of the patients with diabetic foot ulcer have associated
      peripheral arterial disease. Objective The main objective of the study is to
      assess the risk of diabetic foot in diabetic patients with peripheral arterial
      disease. Method This was a case control study conducted in Bir Hospital, National
      Academy of Medical Sciences (NAMS). The sample size was 173 out of which cases
      (diabetic foot) and unmatched controls (diabetics without diabetic foot) were
      divided in the ratio of 1:2. The Odds Ratio (OR) of peripheral arterial disease
      in diabetic foot was calculated. The study was conducted after taking ethical
      clearance from Institutional Review Board of National Academy of Medical
      Sciences. Result There were 173 participants enrolled in the study. Four were
      excluded, 55 participants were cases of diabetic foot (cases) and 114
      participants were diabetics without diabetic foot (controls). The odds of
      diabetic foot in patients with peripheral arterial disease was 4.12, p < 0.001.
      Conclusion The risk of diabetic foot in diabetic patients with peripheral
      arterial disease was higher as compared to diabetic patients without peripheral
      arterial disease.
FAU - Joshi, A
AU  - Joshi A
AD  - Department of Surgery, Bir Hospital, National Academy of Medical Sciences,
      Mahaboudha, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - Kathmandu Univ Med J (KUMJ)
JT  - Kathmandu University medical journal (KUMJ)
JID - 101215359
SB  - IM
MH  - Case-Control Studies
MH  - *Diabetes Mellitus
MH  - *Diabetic Foot/epidemiology
MH  - Humans
MH  - *Peripheral Arterial Disease/complications/epidemiology
MH  - Prevalence
EDAT- 2021/02/15 06:00
MHDA- 2021/02/17 06:00
CRDT- 2021/02/14 20:36
PHST- 2021/02/14 20:36 [entrez]
PHST- 2021/02/15 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PST - ppublish
SO  - Kathmandu Univ Med J (KUMJ). 2020 Jan.-Mar;18(69):38-41.


PMID- 33580801
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1526-4637 (Electronic)
IS  - 1526-2375 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Nov 1
TI  - Pain in the Pandemic: Ethical Approaches During COVID-19.
PG  - 2629-2633
LID - 10.1093/pm/pnaa222 [doi]
FAU - House, L McLean
AU  - House LM
AD  - Anesthesia & Perioperative Care, University of California, San Francisco, San
      Francisco, California.
FAU - Tabari, Kayla N
AU  - Tabari KN
AD  - Harvard Center for Bioethics, Harvard Medical School, Boston, Massachusetts.
FAU - Rieder, Travis N
AU  - Rieder TN
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland.
FAU - McCormick, Zachary L
AU  - McCormick ZL
AD  - Physical Medicine and Rehabilitation, University of Utah School of Medicine, Salt
      Lake City, Utah, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Pain Med
JT  - Pain medicine (Malden, Mass.)
JID - 100894201
SB  - IM
MH  - Aged
MH  - COVID-19/epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - Injections, Epidural/ethics
MH  - Low Back Pain/diagnosis/*therapy
MH  - Male
MH  - Nerve Block/ethics
MH  - Pain Management/*ethics/methods
MH  - Pandemics/*ethics
MH  - Phantom Limb/diagnosis/*therapy
MH  - Radiculopathy/diagnosis/*therapy
PMC - PMC7499699
EDAT- 2021/02/14 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/02/13 12:04
PHST- 2021/02/13 12:04 [entrez]
PHST- 2021/02/14 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - 5901366 [pii]
AID - 10.1093/pm/pnaa222 [doi]
PST - ppublish
SO  - Pain Med. 2020 Nov 1;21(11):2629-2633. doi: 10.1093/pm/pnaa222.


PMID- 33575673
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210213
IS  - 2032-0418 (Print)
IS  - 2032-0418 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Jan 8
TI  - WHO fact sheet on infertility gives hope to millions of infertile couples
      worldwide.
PG  - 249-251
AB  - Although the consequences of infertility are often severe in LMIC (Low and Middle
      Income Countries), national and international health strategies have always
      focussed on reducing total fertility rates while infertility care has received no
      attention at all. Access to infertility care can only be achieved when good
      quality but affordable infertility care is linked to more effective family
      planning programmes. Only a global project with respect to socio-cultural,
      ethical, economical and political differences can be successful. The 2020 WHO
      fact sheet on infertility cannot be misunderstood; global access to high-quality 
      services for family planning including fertility care is one of the core elements
      of reproductive health. Different strategies are presented.
CI  - Copyright (c) 2020 Facts, Views & Vision.
FAU - Ombelet, Willem
AU  - Ombelet W
AD  - Genk Institute for Fertility Technology, ZOL Hospitals, Schiepse Bos 6, 3600
      Genk, Belgium.
LA  - eng
PT  - Editorial
DEP - 20200108
PL  - Belgium
TA  - Facts Views Vis Obgyn
JT  - Facts, views & vision in ObGyn
JID - 101578773
PMC - PMC7863696
OTO - NOTNLM
OT  - LMIC
OT  - WHO
OT  - equity
OT  - fact sheet
OT  - infertility
OT  - low and middle income countries
OT  - reproductive rights
OT  - universal access
EDAT- 2021/02/13 06:00
MHDA- 2021/02/13 06:01
CRDT- 2021/02/12 06:10
PHST- 2021/02/12 06:10 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/02/13 06:01 [medline]
PST - epublish
SO  - Facts Views Vis Obgyn. 2020 Jan 8;12(4):249-251.


PMID- 33574590
OWN - NLM
STAT- Publisher
LR  - 20210212
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Feb 13
TI  - Stop making graduate students pay up front for conferences.
LID - 10.1038/d41586-020-00421-w [doi]
FAU - Malloy, John
AU  - Malloy J
LA  - eng
PT  - News
DEP - 20200213
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Careers
OT  - Conferences and meetings
OT  - Ethics
EDAT- 2021/02/13 06:00
MHDA- 2021/02/13 06:00
CRDT- 2021/02/12 06:02
PHST- 2021/02/12 06:02 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - 10.1038/d41586-020-00421-w [doi]
AID - 10.1038/d41586-020-00421-w [pii]
PST - aheadofprint
SO  - Nature. 2020 Feb 13. pii: 10.1038/d41586-020-00421-w. doi:
      10.1038/d41586-020-00421-w.


PMID- 33569366
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - COVID-19 and Teleneurology in Sub-Saharan Africa: Leveraging the Current
      Exigency.
PG  - 574505
LID - 10.3389/fpubh.2020.574505 [doi]
AB  - Africa has over 1.3 billion inhabitants, with over 60% of this population
      residing in rural areas that have poor access to medical experts. Despite having 
      a ridiculously huge, underserved population, very few African countries currently
      have any form of sustained and organized telemedicine practice, and even fewer
      have dedicated tele-neurology services. The ongoing COVID-19 pandemic has proved 
      to be one of the most significant disruptors of vital sectors of human endeavor
      in modern times. In the healthcare sector, there is an increasing advocacy to
      deliver non-urgent care via telemedicine. This paper examined the current state
      of tele-neurology practice and infrastructural preparedness in sub-Saharan
      Africa. Currently, there is over 70% mobile phone penetration in most of the
      countries and virtually all of them have mobile internet services of different
      technologies and generations. Although the needed infrastructure is increasingly 
      available, it should be improved upon. We have proposed the access, costs,
      ethics, and support (ACES) model as a bespoke, holistic strategy for the
      successful implementation and advancement of tele-neurology in sub-Saharan
      Africa.
CI  - Copyright (c) 2021 Adebayo, Oluwole and Taiwo.
FAU - Adebayo, Philip Babatunde
AU  - Adebayo PB
AD  - Neurology Section, Department of Internal Medicine, Aga Khan University, Dar es
      Salaam, Tanzania.
FAU - Oluwole, Olusegun John
AU  - Oluwole OJ
AD  - Department of Neurology, King's College Hospital, Dubai, United Arab Emirates.
FAU - Taiwo, Funmilola Tolulope
AU  - Taiwo FT
AD  - Department of Neurology, University College Hospital, Ibadan, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20210125
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - COVID-19/*diagnosis/epidemiology/*therapy
MH  - *Cell Phone
MH  - Humans
MH  - Neurology/*standards
MH  - Pandemics
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Telemedicine/*standards
PMC - PMC7868436
OTO - NOTNLM
OT  - *Africa
OT  - *COVID-19
OT  - *coronavirus
OT  - *telehealth
OT  - *teleneurology
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/12 06:00
MHDA- 2021/02/20 06:00
CRDT- 2021/02/11 05:54
PHST- 2020/06/20 00:00 [received]
PHST- 2020/12/30 00:00 [accepted]
PHST- 2021/02/11 05:54 [entrez]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - 10.3389/fpubh.2020.574505 [doi]
PST - epublish
SO  - Front Public Health. 2021 Jan 25;8:574505. doi: 10.3389/fpubh.2020.574505.
      eCollection 2020.


PMID- 33569177
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - The promise of direct-to-consumer COVID-19 testing: ethical and regulatory
      issues.
PG  - lsaa069
LID - 10.1093/jlb/lsaa069 [doi]
AB  - Widespread diagnostic and serological (antibody) testing is one key to mitigating
      the COVID-19 pandemic. While at first, the majority of COVID-19 diagnostic
      testing in the USA took place in healthcare settings, quickly a
      direct-to-consumer (DTC) testing market also emerged. In these DTC provision
      models, the test is initiated by a consumer and the sample collection occurs at
      home or in a commercial laboratory. Although the provision of DTC tests has
      potential benefits-such as expanding access to testing and reducing the risk of
      exposure for consumers and medical personnel-it also raises significant ethical
      and regulatory concerns. This article reviews these challenges and shows how they
      parallel and also diverge from prior concerns raised in the DTC health testing
      arena. The first part of this paper provides an overview of the landscape of
      diagnostic and serological tests for COVID-19, anticipating how provision models 
      are likely to evolve in the future. The second part discusses five primary issues
      for DTC COVID-19 tests: test accuracy; potential misinterpretation of results;
      misleading claims and other misinformation; privacy concerns; and fair allocation
      of scarce resources. We conclude with recommendations for regulators and
      companies that aim to ensure ethically marketed DTC COVID-19 tests.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Kalokairinou, Louiza
AU  - Kalokairinou L
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Zettler, Patricia J
AU  - Zettler PJ
AD  - Moritz College of Law and The James Comprehensive Cancer Center, The Ohio State
      University, Columbus, OH 43210, USA.
FAU - Nagappan, Ashwini
AU  - Nagappan A
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Kyweluk, Moira A
AU  - Kyweluk MA
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Wexler, Anna
AU  - Wexler A
AUID- ORCID: 0000-0002-6723-9038
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA 19104, USA.
LA  - eng
GR  - DP5 OD026420/OD/NIH HHS/United States
GR  - T32 HG009496/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20200923
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7543538
OTO - NOTNLM
OT  - Diagnostic COVID-19 tests
OT  - direct-to-consumer tests
OT  - misinformation
OT  - privacy
OT  - regulation
OT  - serological COVID-19 tests
EDAT- 2021/02/12 06:00
MHDA- 2021/02/12 06:01
CRDT- 2021/02/11 05:54
PHST- 2020/05/22 00:00 [received]
PHST- 2020/08/07 00:00 [revised]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2021/02/11 05:54 [entrez]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/02/12 06:01 [medline]
AID - 10.1093/jlb/lsaa069 [doi]
AID - lsaa069 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Sep 23;7(1):lsaa069. doi: 10.1093/jlb/lsaa069. eCollection
      2020 Jan-Jun.


PMID- 33569176
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210211
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - COVID-19 emergency measures and the impending authoritarian pandemic.
PG  - lsaa064
LID - 10.1093/jlb/lsaa064 [doi]
AB  - COVID-19 has brought the world grinding to a halt. As of early August 2020, the
      greatest public health emergency of the century thus far has registered almost 20
      million infected people and claimed over 730,000 lives across all inhabited
      continents, bringing public health systems to their knees, and causing shutdowns 
      of borders and lockdowns of cities, regions, and even nations unprecedented in
      the modern era. Yet, as this Article demonstrates-with diverse examples drawn
      from across the world-there are unmistakable regressions into authoritarianism in
      governmental efforts to contain the virus. Despite the unprecedented nature of
      this challenge, there is no sound justification for systemic erosion of
      rights-protective democratic ideals and institutions beyond that which is
      strictly demanded by the exigencies of the pandemic. A Wuhan-inspired
      all-or-nothing approach to viral containment sets a dangerous precedent for
      future pandemics and disasters, with the global copycat response indicating an
      impending 'pandemic' of a different sort, that of authoritarianization. With a
      gratuitous toll being inflicted on democracy, civil liberties, fundamental
      freedoms, healthcare ethics, and human dignity, this has the potential to unleash
      humanitarian crises no less devastating than COVID-19 in the long run.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Thomson, Stephen
AU  - Thomson S
AD  - School of Law, City University of Hong Kong.
FAU - Ip, Eric C
AU  - Ip EC
AUID- ORCID: 0000-0001-9832-0288
AD  - Centre for Medical Ethics and Law, University of Hong Kong.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7543595
OTO - NOTNLM
OT  - COVID-19
OT  - Democracy
OT  - Emergency Powers
OT  - Governance
OT  - Human Rights
OT  - Regulation
EDAT- 2021/02/12 06:00
MHDA- 2021/02/12 06:01
CRDT- 2021/02/11 05:54
PHST- 2020/05/01 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2021/02/11 05:54 [entrez]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/02/12 06:01 [medline]
AID - 10.1093/jlb/lsaa064 [doi]
AID - lsaa064 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Sep 29;7(1):lsaa064. doi: 10.1093/jlb/lsaa064. eCollection
      2020 Jan-Jun.


PMID- 33568618
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 1526-3711 (Electronic)
IS  - 1526-3711 (Linking)
VI  - 21
IP  - 8
DP  - 2020 Aug 1
TI  - Dental Care Implications in Coronavirus Disease-19 Scenario: Perspectives.
PG  - 935-941
AB  - AIM: The aim of this review is to discuss the implications of COVID-19 on various
      aspects of dental care. BACKGROUND: The COVID-19 pandemic had suspended dental
      practice globally for over 3 months. While dental practice is being resumed
      cautiously, standard infection control protocols that were traditionally
      overlooked are now being strictly implemented. Post-COVID-19, dental care is
      expected to see a drastic change in the way it is practiced. REVIEW RESULTS: With
      a view on the natural history and disease dynamics of COVID-19, this review
      reports various aspects of dental care, viz., patient triaging, engineering and
      work practice controls, and administrative, financial, and ethical aspects of
      dental care during and after COVID-19 pandemic. Current evidence-based
      recommendations with regard to infection-control practices are discussed. A call 
      for universal oral health care with suggestions regarding integration of medical 
      and health care is also proposed. CONCLUSION: COVID-19 is expected to be a
      watershed moment in the field of dentistry. While we expect to see positive
      changes in safe delivery of dental care, an increase in cost of availing care is 
      imminent. CLINICAL SIGNIFICANCE: The practice of dentistry and dental infection
      control has undergone dimensional changes due to bloodborne infectious diseases
      such as hepatitis B virus infections and human immunodeficiency virus epidemic.
      Due to these pandemics, many regulatory organizations have provided safety
      recommendations and guidelines that impact the dental practice. Currently, we are
      faced with a highly infective disease with a high mortality rate among people
      with comorbidities and of predominantly droplet transmission and no concrete
      safety recommendations and guidelines. This manuscript addresses multiple issues,
      gaps, and pragmatic solutions in controlling transmission of SARS-CoV-2 in dental
      settings, during and after the pandemic.
FAU - Janakiram, Chandrashekar
AU  - Janakiram C
AD  - Department of Public Health Dentistry, Amrita School of Dentistry, Amrita Vishwa 
      Vidyapeetham, Kochi, Kerala, India.
FAU - Nayar, Suresh
AU  - Nayar S
AD  - Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Faculty 
      of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada;
      Clinics, Institute for Reconstructive Sciences in Medicine, Edmonton, Alberta,
      Canada.
FAU - Varma, Balagopal
AU  - Varma B
AD  - Department of Pedodontics and Preventive Dentistry, Amrita School of Dentistry,
      Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
FAU - Ramanarayanan, Venkitachalam
AU  - Ramanarayanan V
AD  - Department of Public Health Dentistry, Amrita School of Dentistry, Amrita Vishwa 
      Vidyapeetham, Kochi, Kerala, India.
FAU - Mathew, Anil
AU  - Mathew A
AD  - Department of Prosthodontics, Amrita School of Dentistry, Amrita Vishwa
      Vidyapeetham, Kochi, Kerala, India.
FAU - Suresh, Rakesh
AU  - Suresh R
AD  - Department of Oral Pathology, Amrita School of Dentistry, Amrita Vishwa
      Vidyapeetham, Kochi, Kerala, India.
FAU - Puttaiah, Raghunath
AU  - Puttaiah R
AD  - OSHA4 Dental LLC, Murphy, Texas, USA, Phone: +14698795003, e-mail:
      osha4dental@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200801
PL  - India
TA  - J Contemp Dent Pract
JT  - The journal of contemporary dental practice
JID - 101090552
SB  - IM
MH  - *COVID-19
MH  - Dental Care
MH  - Humans
MH  - Infection Control
MH  - *Pandemics
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - Dental care
OT  - Ethics
OT  - Infection control Occupational safety.
EDAT- 2021/02/12 06:00
MHDA- 2021/02/13 06:00
CRDT- 2021/02/11 05:45
PHST- 2021/02/11 05:45 [entrez]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - 1526-3711-2651 [pii]
PST - epublish
SO  - J Contemp Dent Pract. 2020 Aug 1;21(8):935-941.


PMID- 33564745
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210211
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Quality care process metrics (QCP-Ms) in nursing and midwifery care processes: a 
      rapid realist review (RRR) protocol.
PG  - 85
LID - 10.12688/hrbopenres.13120.2 [doi]
AB  - Background: In 2018, the Office of the Nursing and Midwifery Services Director
      (ONMSD) completed phase one of work which culminated in the development and
      launch of seven research reports with defined suites of quality care process
      metrics (QCP-Ms) and respective indicators for the practice areas - acute care,
      midwifery, children's, public health nursing, older persons, mental health and
      intellectual disability nursing in Ireland. This paper presents a rapid realist
      review protocol that will systematically review the literature that examines
      QCP-Ms in practice; what worked, or did not work for whom, in what contexts, to
      what extent, how and why? Methods : The review will explore if there are benefits
      of using the QCP-Ms and what are the contexts in which these mechanisms are
      triggered. The essence of this rapid realist review is to ascertain how a change 
      in context generates a particular mechanism that produces specific outcomes. A
      number of steps will occur including locating existing theories on implementation
      of quality care metrics, searching the evidence, selecting relevant documents,
      data extraction, validation of findings, synthesising and refining programme
      theory. This strategy may help to describe potential consequences resulting from 
      changes in context and their interactions with mechanisms. Initial theories will 
      be refined throughout the process by the local reference panel, comprised of
      eight key intervention stakeholders, knowledge users such as healthcare
      professionals and an expert panel. Ethical approval is not required for this
      rapid realist review. Conclusion: It is anticipated that the final programme
      theory will help to explain how QCP-Ms work in practice; for whom, why and in
      what circumstances. Findings of this review could help to give insights into the 
      use of a rapid realist review as a framework and how nursing and midwifery QCP-Ms
      have been implemented previously.
CI  - Copyright: (c) 2021 O'Connor L et al.
FAU - O'Connor, Laserina
AU  - O'Connor L
AUID- ORCID: https://orcid.org/0000-0003-3020-9246
AD  - School of Nursing Midwifery & Health Systems, University College Dublin, Dublin, 
      Ireland.
FAU - Coffey, Alice
AU  - Coffey A
AUID- ORCID: https://orcid.org/0000-0002-5178-6723
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Lambert, Veronica
AU  - Lambert V
AUID- ORCID: https://orcid.org/0000-0003-4396-5462
AD  - School of Nursing, Psychotherapy and Community Health, Dublin City University,
      Dublin, Ireland.
FAU - Casey, Mary
AU  - Casey M
AUID- ORCID: https://orcid.org/0000-0003-3305-0074
AD  - School of Nursing Midwifery & Health Systems, University College Dublin, Dublin, 
      Ireland.
FAU - McNamara, Martin
AU  - McNamara M
AD  - School of Nursing Midwifery & Health Systems, University College Dublin, Dublin, 
      Ireland.
FAU - Teeling, Sean Paul
AU  - Teeling SP
AUID- ORCID: https://orcid.org/0000-0002-4102-7280
AD  - School of Nursing Midwifery & Health Systems, University College Dublin, Dublin, 
      Ireland.
FAU - O'Doherty, Jane
AU  - O'Doherty J
AUID- ORCID: https://orcid.org/0000-0002-7972-8883
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Barnard, Marlize
AU  - Barnard M
AUID- ORCID: https://orcid.org/0000-0002-5125-8648
AD  - School of Nursing Midwifery & Health Systems, University College Dublin, Dublin, 
      Ireland.
FAU - Corcoran, Yvonne
AU  - Corcoran Y
AD  - School of Nursing, Psychotherapy and Community Health, Dublin City University,
      Dublin, Ireland.
FAU - Davies, Carmel
AU  - Davies C
AD  - UCD Health Sciences Centre, University College Dublin, Dublin, Ireland.
FAU - Doody, Owen
AU  - Doody O
AUID- ORCID: https://orcid.org/0000-0002-3708-1647
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Frawley, Timothy
AU  - Frawley T
AUID- ORCID: https://orcid.org/0000-0002-2108-005X
AD  - UCD Health Sciences Centre, University College Dublin, Dublin, Ireland.
FAU - O'Brien, Denise
AU  - O'Brien D
AUID- ORCID: https://orcid.org/0000-0003-1434-4069
AD  - UCD Health Sciences Centre, University College Dublin, Dublin, Ireland.
FAU - Redmond, Catherine
AU  - Redmond C
AUID- ORCID: https://orcid.org/0000-0002-7778-489X
AD  - UCD Health Sciences Centre, University College Dublin, Dublin, Ireland.
FAU - Smith, Rita
AU  - Smith R
AUID- ORCID: https://orcid.org/0000-0002-9090-9642
AD  - UCD Health Sciences Centre, University College Dublin, Dublin, Ireland.
FAU - Somanadhan, Suja
AU  - Somanadhan S
AUID- ORCID: https://orcid.org/0000-0002-0590-0126
AD  - School of Nursing Midwifery & Health Systems, University College Dublin, Dublin, 
      Ireland.
FAU - Noonan, Maria
AU  - Noonan M
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Bradshaw, Carmel
AU  - Bradshaw C
AUID- ORCID: https://orcid.org/0000-0003-1272-3823
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Tuohy, Dympna
AU  - Tuohy D
AUID- ORCID: https://orcid.org/0000-0001-6240-0315
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Gallen, Anne
AU  - Gallen A
AD  - Director of Nursing and Midwifery Planning and Development Unit (NMPDU), Health
      Service Executive North West, Donegal, Ireland.
LA  - eng
SI  - figshare/10.6084/m9.figshare.13040333
PT  - Journal Article
DEP - 20210128
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7848854
OTO - NOTNLM
OT  - care processes
OT  - quality care metrics
OT  - quality indicators
OT  - rapid realist review
COIS- No competing interests were disclosed.
EDAT- 2021/02/12 06:00
MHDA- 2021/02/12 06:01
CRDT- 2021/02/11 05:55
PHST- 2021/01/20 00:00 [accepted]
PHST- 2021/02/11 05:55 [entrez]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/02/12 06:01 [medline]
AID - 10.12688/hrbopenres.13120.2 [doi]
PST - epublish
SO  - HRB Open Res. 2021 Jan 28;3:85. doi: 10.12688/hrbopenres.13120.2. eCollection
      2020.


PMID- 33565451
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Nov-Dec
TI  - Attitude and levels of awareness toward organ donation and transplantation among 
      healthcare providers: A cross-sectional study.
PG  - 1388-1394
LID - 10.4103/1319-2442.308351 [doi]
AB  - End-stage organ damage is the major cause of death worldwide. The number of
      donors is low, and one of the challenging phases in organ donation is the
      availability of organ donors. There are many studies that suggest a strong
      correlation between knowledge and beliefs toward organ donation. A study
      conducted among Health-Care Providers in the Intensive Care Units at a Tertiary
      Center at Riyadh reported that only 57% of the health-care providers in the
      Intensive Care Unit were willing to donate their organs. The objective of our
      study was to evaluate the knowledge, attitude, and awareness of organ donation
      and transplantation among health-care providers at different hospitals around the
      Kingdom of Saudi Arabia. The data of this cross-sectional descriptive study were 
      collected between February and July 2018 in different hospitals all around the
      Kingdom of Saudi Arabia. The investigators formulated a questionnaire based on
      several published studies. Ethical approval was obtained from the Unit of
      Biomedical Ethics, Research Committee at King Abdul Aziz University. Of the 241
      participants, 130 (53.9%) were female. In addition, 110 (45.6%) of them were
      medical residents. Moreover, 224 (92.9%) participants were aware of the concept
      of organ donation. The overall level of knowledge is good (55.2%).The study
      showed 62.2% have participated in the organ donation program for their close
      relatives only. In conclusion, the level of perception and knowledge about organ 
      donation among health-care providers was inadequate, although they showed
      positive attitudes toward this issue.
FAU - Mortada, Hatan
AU  - Mortada H
AD  - Plastic Surgery Division, Department of Surgery, King Saud University Medical
      City (KSUMC), King Saud University, Riyadh, Saudi Arabia.
FAU - Alharbi, Nawal Mashni
AU  - Alharbi NM
AD  - Medical student, King Faisal University, Alhasa, Saudi Arabia.
FAU - Alsuhaibani, Marya Abdullah
AU  - Alsuhaibani MA
AD  - General Surgery Department, Prince Sultan Military Medical City, Riyadh, Saudi
      Arabia.
FAU - Buhlagah, Rawan Abdullah
AU  - Buhlagah RA
AD  - Medical student, King Faisal University, Alhasa, Saudi Arabia.
FAU - Mohamed, Yasmina Nezar
AU  - Mohamed YN
AD  - Medical student, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi
      Arabia.
FAU - Alharbi, Amjad
AU  - Alharbi A
AD  - Pathology Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
FAU - Safdar, Osama Y
AU  - Safdar OY
AD  - Pediatric Department, Faculty of Medicine, King Abdul Aziz University, Jeddah,
      Saudi Arabia.
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Organ Transplantation
MH  - Saudi Arabia
MH  - Surveys and Questionnaires
MH  - *Tissue and Organ Procurement
MH  - Young Adult
EDAT- 2021/02/11 06:00
MHDA- 2021/10/28 06:00
CRDT- 2021/02/10 08:38
PHST- 2021/02/10 08:38 [entrez]
PHST- 2021/02/11 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
AID - SaudiJKidneyDisTranspl_2020_31_6_1388_308351 [pii]
AID - 10.4103/1319-2442.308351 [doi]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2020 Nov-Dec;31(6):1388-1394. doi:
      10.4103/1319-2442.308351.


PMID- 33564725
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2424-810X (Electronic)
IS  - 2382-6533 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Dec 11
TI  - Human umbilical cord-derived mesenchymal stem cells induce tissue repair and
      regeneration in collagen-induced arthritis in rats.
PG  - 203-216
AB  - The immunosuppressive and anti-inflammatory properties of mesenchymal
      stem/stromal cells (MSCs) have prompted their therapeutic application in several 
      autoimmune diseases, including rheumatoid arthritis (RA). MSCs derived from bone 
      marrow and adipose tissue has earlier been tried with limited success. However,
      Wharton's jelly present in human umbilical cord is discarded after delivery which
      makes a rich source of MSCs with least ethical issues. The immunomodulatory
      properties of human umbilical cord-derived MSCs (UC-MSCs) were evaluated in-vitro
      on the mononuclear cells from synovial fluid (SF) and peripheral blood of RA
      patients. The therapeutic potential of UC-MSCs was checked by transplanting the
      cells in rats with collagen-induced arthritis (CIA). MSCs isolated from Wharton's
      Jelly significantly suppressed the proliferation and activation of lymphocytes
      from both peripheral blood as well as SF of RA patients, down-modulated the
      functions of activated CD4+, CD8+ T-cells, suppressed the secretion of
      pro-inflammatory cytokines, and induced the expansion of T-regulatory cells.
      Xenotransplantation of UC-MSCs in CIA rats clearly indicated a sustained impact
      in terms of slowing down the progression of disease activity and reversal of
      arthritic processes along with triggering of joint tissue repair mechanisms,
      which could be observed till 6 weeks post-transplantation. The results from the
      current study suggest that human umbilical cord is a rich source of MSCs for
      allotransplantation. The UC-MSCs may be used successfully as a cell-based
      therapeutic option either in isolation or in conjunction with existing
      therapeutic drugs not only to relieve the joint inflammation but also regenerate 
      the damaged bone and cartilage tissues in arthritis. RELEVANCE TO PATIENTS: The
      current study highlights the potential use of MSCs as a cell-based therapeutic
      option for the treatment of inflammatory RA.
CI  - Copyright: (c) Whioce Publishing Pte. Ltd.
FAU - Vohra, Mehak
AU  - Vohra M
AD  - Department of Immunopathology, Post Graduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Sharma, Aman
AU  - Sharma A
AD  - Department of Internal Medicine (Rheumatology), Post Graduate Institute of
      Medical Education and Research, Chandigarh, India.
FAU - Bagga, Rashmi
AU  - Bagga R
AD  - Department of Obstetrics and Gynaecology Post Graduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Arora, Sunil K
AU  - Arora SK
AD  - Department of Immunopathology, Post Graduate Institute of Medical Education and
      Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - Singapore
TA  - J Clin Transl Res
JT  - Journal of clinical and translational research
JID - 101667205
PMC - PMC7868118
OTO - NOTNLM
OT  - collagen-induced arthritis
OT  - immunomodulation
OT  - regeneration
OT  - rheumatoid arthritis
OT  - stem cells
OT  - umbilical cord-derived mesenchymal
EDAT- 2021/02/11 06:00
MHDA- 2021/02/11 06:01
CRDT- 2021/02/10 05:57
PHST- 2020/08/14 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2021/02/10 05:57 [entrez]
PHST- 2021/02/11 06:00 [pubmed]
PHST- 2021/02/11 06:01 [medline]
AID - jctres.06.202006.003 [pii]
PST - epublish
SO  - J Clin Transl Res. 2020 Dec 11;6(6):203-216. eCollection 2020 Dec 11.


PMID- 33561075
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Dec 30
TI  - Protocol for a Trial Assessing the Impacts of School-Based WaSH Interventions on 
      Children's Health Literacy, Handwashing, and Nutrition Status in Low- and
      Middle-Income Countries.
LID - 226 [pii]
LID - 10.3390/ijerph18010226 [doi]
AB  - Diarrhea, soil-transmitted helminth infection and malnutrition are leading causes
      of child mortality in low- and middle-income countries (LMICs). To reduce the
      prevalence of these diseases, effective interventions for adequate water,
      sanitation, and hygiene (WaSH) should be implemented. This paper describes the
      design of a cluster-randomized controlled trial that will compare the efficacy of
      four school-based WaSH interventions for improving children's health literacy,
      handwashing, and nutrition. Interventions consisted of (1) WaSH policy
      reinforcement; (2) low-, medium-, or high-volume health education; (3) hygiene
      supplies; and (4) WaSH facilities (e.g., toilets, urinals, handwashing basins)
      improvements. We randomly allocated school clusters from the intervention arm to 
      one of four groups to compare with schools from the control arm. Primary outcomes
      were: children's health literacy, physical growth, nutrition status, and
      handwashing prevalence. Secondary outcomes were: children's self-reported health 
      status and history of extreme hunger, satisfaction with WaSH facilities, and
      school restrooms' WaSH adequacy. We will measure differences in pre- and
      post-intervention outcomes and compare these differences between control and
      intervention arms. This research protocol can be a blueprint for future
      school-based WaSH intervention studies to be conducted in LMICs. Study protocols 
      were approved by the ethics committees of the University of Bonn, Germany, and
      the University of the Philippines Manila. This trial was retroactively
      registered, ID number: DRKS00021623.
FAU - Sangalang, Stephanie O
AU  - Sangalang SO
AD  - Center for Development Research, University of Bonn, 53113 Bonn, Germany.
FAU - Medina, Shelley Anne J
AU  - Medina SAJ
AD  - College of Social Work and Community Development, University of the Philippines
      Diliman, Quezon City 1101, Philippines.
FAU - Ottong, Zheina J
AU  - Ottong ZJ
AD  - Marine Science Institute, University of the Philippines Diliman, Quezon City
      1101, Philippines.
AD  - School of Earth Sciences and Environmental Engineering, Gwangju Institute of
      Science and Technology, Gwangju 61005, Korea.
FAU - Lemence, Allen Lemuel G
AU  - Lemence ALG
AUID- ORCID: 0000-0003-3717-5202
AD  - National Graduate School of Engineering, College of Engineering, University of
      the Philippines Diliman, Quezon City 1101, Philippines.
FAU - Totanes, Donrey
AU  - Totanes D
AD  - College of Mass Communication, University of the Philippines Diliman, Quezon City
      1101, Philippines.
FAU - Valencia, John Cedrick
AU  - Valencia JC
AD  - National College of Public Administration and Governance, University of the
      Philippines Diliman, Quezon City 1101, Philippines.
FAU - Singson, Patricia Andrea A
AU  - Singson PAA
AD  - School of Social Sciences, Ateneo de Manila University, Quezon City 1800,
      Philippines.
FAU - Olaguera, Mikaela
AU  - Olaguera M
AD  - College of Mass Communication, University of the Philippines Diliman, Quezon City
      1101, Philippines.
FAU - Prado, Nelissa O
AU  - Prado NO
AD  - Kashiwa Campus, University of Tokyo, Chiba 277-0882, Japan.
FAU - Ocana, Roezel Mari Z
AU  - Ocana RMZ
AD  - School of Medicine, Far Eastern University, Nicanor Reyes Medical Foundation,
      Quezon City 1118, Philippines.
FAU - Canja, Rovin James F
AU  - Canja RJF
AD  - National College of Public Administration and Governance, University of the
      Philippines Diliman, Quezon City 1101, Philippines.
FAU - Benolirao, Alfem John T
AU  - Benolirao AJT
AD  - College of Business Administration, Adamson University, Manila 1000, Philippines.
FAU - Mariano, Shyrill Mae F
AU  - Mariano SMF
AD  - Marine Science Institute, University of the Philippines Diliman, Quezon City
      1101, Philippines.
FAU - Gavieres, Jergil Gyle
AU  - Gavieres JG
AD  - Department of Sociology, College of Social Sciences and Philosophy, University of
      the Philippines Dili-man, Quezon City 1101, Philippines.
FAU - Aquino, Clarisse P
AU  - Aquino CP
AD  - Department of Sociology, College of Social Sciences and Philosophy, University of
      the Philippines Dili-man, Quezon City 1101, Philippines.
FAU - Latag, Edison C
AU  - Latag EC
AD  - College of Engineering, Technological University of the Philippines, Manila 1008,
      Philippines.
FAU - Anglo, Maria Vianca Jasmin C
AU  - Anglo MVJC
AD  - Department of Psychology, College of Social Sciences and Philosophy, University
      of the Philippines Diliman, Quezon City 1101, Philippines.
FAU - Borgemeister, Christian
AU  - Borgemeister C
AUID- ORCID: 0000-0001-8067-0335
AD  - Center for Development Research, University of Bonn, 53113 Bonn, Germany.
FAU - Kistemann, Thomas
AU  - Kistemann T
AD  - Center for Development Research, University of Bonn, 53113 Bonn, Germany.
AD  - Institute of Hygiene and Public Health, University of Bonn, 53127 Bonn, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201230
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Child
MH  - Child Health/statistics & numerical data
MH  - *Developing Countries
MH  - Female
MH  - *Hand Disinfection
MH  - Health Impact Assessment/methods
MH  - *Health Literacy/statistics & numerical data
MH  - Humans
MH  - Hygiene
MH  - Male
MH  - *Nutritional Status
MH  - *Preventive Health Services/standards
MH  - *Sanitation
MH  - *Schools
PMC - PMC7795080
OTO - NOTNLM
OT  - *and hygiene
OT  - *children's health
OT  - *health literacy
OT  - *malnutrition
OT  - *sanitation
OT  - *water
EDAT- 2021/02/10 06:00
MHDA- 2021/02/18 06:00
CRDT- 2021/02/09 17:11
PHST- 2020/11/02 00:00 [received]
PHST- 2020/12/14 00:00 [revised]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/02/09 17:11 [entrez]
PHST- 2021/02/10 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - ijerph18010226 [pii]
AID - 10.3390/ijerph18010226 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 30;18(1). pii: ijerph18010226. doi:
      10.3390/ijerph18010226.


PMID- 33561056
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 22
DP  - 2020 Nov 12
TI  - Study Protocol for Two-Steps Parallel Randomized Controlled Trial: Pre-Clinical
      Usability Tests for a New Double-Chamber Syringe.
LID - 8376 [pii]
LID - 10.3390/ijerph17228376 [doi]
AB  - A new double-chamber syringe (DUO Syringe) was developed for intravenous drug
      administration and catheter flushing. This study presents a protocol for
      pre-clinical usability tests to validate the golden prototype of this new device,
      performed in a high-fidelity simulation lab by nurses. A two-steps parallel
      randomized controlled trial with two arms was designed (with standard syringes
      currently used in clinical practice and with the DUO Syringe). After
      randomization, eligible and consented participants will be requested to perform, 
      individually, intravenous drug administration and flushing, following the arm
      that has been allocated. The procedure will be video-recorded for posterior
      analyses. After the completion of the tasks, nurses will be asked to answer a
      demographic survey, as well as an interview about their qualitative assessment of
      the device. A final focus group with all participants will also be conducted.
      Primary outcomes will concern the DUO Syringe's effectiveness, efficiency, and
      safety, while secondary outcomes will focus on nurses' satisfaction and intention
      of use. The pre-clinical protocol was defined according to the legal requirements
      and ISO norms and was reviewed and approved by the Ethics Committee of the Health
      Sciences Research Unit: Nursing of the Nursing School of Coimbra.
FAU - Parreira, Pedro
AU  - Parreira P
AUID- ORCID: 0000-0002-3880-6590
AD  - The Health Sciences Research Unit, Nursing, Nursing School of Coimbra, 3004-011
      Coimbra, Portugal.
FAU - Sousa, Liliana B
AU  - Sousa LB
AUID- ORCID: 0000-0002-8914-6975
AD  - The Health Sciences Research Unit, Nursing, Nursing School of Coimbra, 3004-011
      Coimbra, Portugal.
FAU - Marques, Ines A
AU  - Marques IA
AD  - The Health Sciences Research Unit, Nursing, Nursing School of Coimbra, 3004-011
      Coimbra, Portugal.
AD  - Biophysics Institute, Coimbra Institute for Clinical and Biomedical Research
      (iCBR) Area of CIMAGO, Faculty of Medicine, CIBB, University of Coimbra, 3000-354
      Coimbra, Portugal.
FAU - Santos-Costa, Paulo
AU  - Santos-Costa P
AUID- ORCID: 0000-0003-0761-6548
AD  - The Health Sciences Research Unit, Nursing, Nursing School of Coimbra, 3004-011
      Coimbra, Portugal.
FAU - Cortez, Sara
AU  - Cortez S
AUID- ORCID: 0000-0002-2794-084X
AD  - Muroplas-Plastic Engineering Industry, 4745-334 Muro, Portugal.
FAU - Carneiro, Filipa
AU  - Carneiro F
AUID- ORCID: 0000-0002-4439-4166
AD  - PIEP-Innovation in Polymer Engineering, Guimaraes, 4800-058 Braga, Portugal.
FAU - Cruz, Armenio
AU  - Cruz A
AUID- ORCID: 0000-0003-3254-3176
AD  - The Health Sciences Research Unit, Nursing, Nursing School of Coimbra, 3004-011
      Coimbra, Portugal.
FAU - Salgueiro-Oliveira, Anabela
AU  - Salgueiro-Oliveira A
AUID- ORCID: 0000-0002-8231-8279
AD  - The Health Sciences Research Unit, Nursing, Nursing School of Coimbra, 3004-011
      Coimbra, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Administration, Intravenous/*instrumentation
MH  - Equipment Design
MH  - Humans
MH  - Pharmaceutical Preparations/*administration & dosage
MH  - *Randomized Controlled Trials as Topic
MH  - Syringes/*adverse effects
MH  - Treatment Outcome
PMC - PMC7696070
OTO - NOTNLM
OT  - *medical devices
OT  - *nursing research
OT  - *usability tests
EDAT- 2021/02/10 06:00
MHDA- 2021/02/17 06:00
CRDT- 2021/02/09 17:11
PHST- 2020/09/29 00:00 [received]
PHST- 2020/11/06 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2021/02/09 17:11 [entrez]
PHST- 2021/02/10 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - ijerph17228376 [pii]
AID - 10.3390/ijerph17228376 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 12;17(22). pii: ijerph17228376. doi:
      10.3390/ijerph17228376.


PMID- 33561032
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 19
DP  - 2020 Oct 2
TI  - Cross-Sectional Seroepidemiologic Study of Coronavirus Disease 2019 (COVID-19)
      among Close Contacts, Children, and Migrant Workers in Shanghai.
LID - 7223 [pii]
LID - 10.3390/ijerph17197223 [doi]
AB  - (1) Background: Along with an increasing risk caused by migrant workers returning
      to the urban areas for the resumption of work and production and growing
      epidemiological evidence of possible transmission during the incubation period, a
      study of Coronavirus Disease 2019 (COVID-19) is warranted among key populations
      to determine the serum antibody against the SARS-CoV-2 and the carrying status of
      SARS-CoV-2 to identify potential asymptomatic infection and to explore the risk
      factors. (2) Method: This is a cross-sectional seroepidemiologic study. Three
      categories of targeted populations (close contacts, migrant workers who return to
      urban areas for work, and school children) will be included in this study as they
      are important for case identification in communities. A multi-stage sampling
      method will be employed to acquire an adequate sample size. Assessments that
      include questionnaires and blood, nasopharyngeal specimens, and feces collection 
      will be performed via home-visit survey. (3) Ethics and Dissemination: The study 
      was approved by the Institute Review Board of School of Public Health, Fudan
      University (IRB#2020-04-0818). Before data collection, written informed consent
      will be obtained from all participants. The manuscripts from this work will be
      submitted for publication in quality peer-reviewed journals and presented at
      national or international conferences.
FAU - Xu, Shuang-Fei
AU  - Xu SF
AD  - Department of Epidemiology, School of Public Health, Fudan University, Shanghai
      200032, China.
FAU - Lu, Yi-Han
AU  - Lu YH
AUID- ORCID: 0000-0003-4651-9433
AD  - Department of Epidemiology, School of Public Health, Fudan University, Shanghai
      200032, China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Epidemiology, School of Public Health, Fudan University, Shanghai
      200032, China.
FAU - Xiong, Hai-Yan
AU  - Xiong HY
AD  - Department of Epidemiology, School of Public Health, Fudan University, Shanghai
      200032, China.
FAU - Wang, Wei-Bing
AU  - Wang WB
AUID- ORCID: 0000-0002-4497-5251
AD  - Department of Epidemiology, School of Public Health, Fudan University, Shanghai
      200032, China.
LA  - eng
GR  - INV-006277/Bill and Melinda Gates Foundation
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201002
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - COVID-19/blood/*epidemiology
MH  - COVID-19 Serological Testing
MH  - Child
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Research Design
MH  - Sample Size
MH  - *Seroepidemiologic Studies
MH  - *Transients and Migrants
PMC - PMC7579139
OTO - NOTNLM
OT  - *Coronavirus Disease 2019 (COVID-19)
OT  - *Shanghai
OT  - *seroepidemiologic study
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/10 06:00
MHDA- 2021/02/13 06:00
CRDT- 2021/02/09 17:11
PHST- 2020/08/25 00:00 [received]
PHST- 2020/09/27 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2021/02/09 17:11 [entrez]
PHST- 2021/02/10 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - ijerph17197223 [pii]
AID - 10.3390/ijerph17197223 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 2;17(19). pii: ijerph17197223. doi:
      10.3390/ijerph17197223.


PMID- 33553293
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Modeling the Ruminant Placenta-Pathogen Interactions in Apicomplexan Parasites:
      Current and Future Perspectives.
PG  - 634458
LID - 10.3389/fvets.2020.634458 [doi]
AB  - Neospora caninum and Toxoplasma gondii are one of the main concerns of the
      livestock sector as they cause important economic losses in ruminants due to the 
      reproductive failure. It is well-known that the interaction of these parasites
      with the placenta determines the course of infection, leading to fetal death or
      parasite transmission to the offspring. However, to advance the development of
      effective vaccines and treatments, there are still important gaps on knowledge on
      the placental host-parasite interactions that need to be addressed. Ruminant
      animal models are still an indispensable tool for providing a global view of the 
      pathogenesis, lesions, and immune responses, but their utilization embraces
      important economic and ethics restrictions. Alternative in vitro systems based on
      caruncular and trophoblast cells, the key cellular components of placentomes,
      have emerged in the last years, but their use can only offer a partial view of
      the processes triggered after infection as they cannot mimic the complex
      placental architecture and neglect the activity of resident immune cells. These
      drawbacks could be solved using placental explants, broadly employed in human
      medicine, and able to preserve its cellular architecture and function. Despite
      the availability of such materials is constrained by their short shelf-life, the 
      development of adequate cryopreservation protocols could expand their use for
      research purposes. Herein, we review and discuss existing (and potential) in
      vivo, in vitro, and ex vivo ruminant placental models that have proven useful to 
      unravel the pathogenic mechanisms and the host immune responses responsible for
      fetal death (or protection) caused by neosporosis and toxoplasmosis.
CI  - Copyright (c) 2021 Pastor-Fernandez, Collantes-Fernandez, Jimenez-Pelayo,
      Ortega-Mora and Horcajo.
FAU - Pastor-Fernandez, Ivan
AU  - Pastor-Fernandez I
AD  - Animal Health and Zoonoses (SALUVET) Group, Animal Health Department, Faculty of 
      Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
FAU - Collantes-Fernandez, Esther
AU  - Collantes-Fernandez E
AD  - Animal Health and Zoonoses (SALUVET) Group, Animal Health Department, Faculty of 
      Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
FAU - Jimenez-Pelayo, Laura
AU  - Jimenez-Pelayo L
AD  - Animal Health and Zoonoses (SALUVET) Group, Animal Health Department, Faculty of 
      Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
FAU - Ortega-Mora, Luis Miguel
AU  - Ortega-Mora LM
AD  - Animal Health and Zoonoses (SALUVET) Group, Animal Health Department, Faculty of 
      Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
FAU - Horcajo, Pilar
AU  - Horcajo P
AD  - Animal Health and Zoonoses (SALUVET) Group, Animal Health Department, Faculty of 
      Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210121
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7859336
OTO - NOTNLM
OT  - ex vivo models
OT  - in vitro models
OT  - in vivo models
OT  - neosporosis
OT  - placenta
OT  - ruminants
OT  - toxoplasmosis
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:47
PHST- 2020/11/27 00:00 [received]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/02/08 05:47 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fvets.2020.634458 [doi]
PST - epublish
SO  - Front Vet Sci. 2021 Jan 21;7:634458. doi: 10.3389/fvets.2020.634458. eCollection 
      2020.


PMID- 33553276
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Social Preference Tests in Zebrafish: A Systematic Review.
PG  - 590057
LID - 10.3389/fvets.2020.590057 [doi]
AB  - The use of animal models in biology research continues to be necessary for the
      development of new technologies and medicines, and therefore crucial for
      enhancing human and animal health. In this context, the need to ensure the
      compliance of research with the principles Replacement, Reduction and Refinement 
      (the 3 Rs), which underpin the ethical and human approach to husbandry and
      experimental design, has become a central issue. The zebrafish (Danio rerio) is
      becoming a widely used model in the field of behavioral neuroscience. In
      particular, studying zebrafish social preference, by observing how an individual 
      fish interacts with conspecifics, may offer insights into several
      neuropsychiatric and neurodevelopmental disorders. The main aim of this review is
      to summarize principal factors affecting zebrafish behavior during social
      preference tests. We identified three categories of social research using
      zebrafish: studies carried out in untreated wild-type zebrafish, in
      pharmacologically treated wild-type zebrafish, and in genetically engineered
      fish. We suggest guidelines for standardizing social preference testing in the
      zebrafish model. The main advances gleaned from zebrafish social behavior testing
      are discussed, together with the relevance of this method to scientific research,
      including the study of behavioral disorders in humans. The authors stress the
      importance of adopting an ethical approach that considers the welfare of animals 
      involved in experimental procedures. Ensuring a high standard of animal welfare
      is not only good for the animals, but also enhances the quality of our science.
CI  - Copyright (c) 2021 Ogi, Licitra, Naef, Marchese, Fronte, Gazzano and Santorelli.
FAU - Ogi, Asahi
AU  - Ogi A
AD  - Neurobiology and Molecular Medicine, Istituto di Ricovero e Cura a Carattere
      Scientifico Stella Maris, Pisa, Italy.
AD  - Department of Veterinary Sciences, University of Pisa, Pisa, Italy.
FAU - Licitra, Rosario
AU  - Licitra R
AD  - Neurobiology and Molecular Medicine, Istituto di Ricovero e Cura a Carattere
      Scientifico Stella Maris, Pisa, Italy.
FAU - Naef, Valentina
AU  - Naef V
AD  - Neurobiology and Molecular Medicine, Istituto di Ricovero e Cura a Carattere
      Scientifico Stella Maris, Pisa, Italy.
FAU - Marchese, Maria
AU  - Marchese M
AD  - Neurobiology and Molecular Medicine, Istituto di Ricovero e Cura a Carattere
      Scientifico Stella Maris, Pisa, Italy.
FAU - Fronte, Baldassare
AU  - Fronte B
AD  - Department of Veterinary Sciences, University of Pisa, Pisa, Italy.
FAU - Gazzano, Angelo
AU  - Gazzano A
AD  - Department of Veterinary Sciences, University of Pisa, Pisa, Italy.
FAU - Santorelli, Filippo M
AU  - Santorelli FM
AD  - Neurobiology and Molecular Medicine, Istituto di Ricovero e Cura a Carattere
      Scientifico Stella Maris, Pisa, Italy.
LA  - eng
PT  - Systematic Review
DEP - 20210122
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7862119
OTO - NOTNLM
OT  - animal welfare
OT  - disease model
OT  - oxytocin
OT  - social behavior
OT  - social preference test
OT  - zebrafish
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:47
PHST- 2020/07/31 00:00 [received]
PHST- 2020/12/24 00:00 [accepted]
PHST- 2021/02/08 05:47 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fvets.2020.590057 [doi]
PST - epublish
SO  - Front Vet Sci. 2021 Jan 22;7:590057. doi: 10.3389/fvets.2020.590057. eCollection 
      2020.


PMID- 33553091
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - COVID-19 and Italian Healthcare Workers From the Initial Sacrifice to the mRNA
      Vaccine: Pandemic Chrono-History, Epidemiological Data, Ethical Dilemmas, and
      Future Challenges.
PG  - 591900
LID - 10.3389/fpubh.2020.591900 [doi]
AB  - On March 11, 2020, the World Health Organization (WHO) declared the coronavirus
      disease 2019 (COVID-19) outbreak a pandemic. Simultaneously, in Italy, in which
      the first case had occurred on February 18, the rigid phase of the lockdown
      began. The country has attracted worldwide attention, becoming at the same time a
      field of study both concerning the spread of the pandemic and advanced
      assessments of the effectiveness of political, public health, and therapeutic
      measures. The protagonists of the Italian crisis were the healthcare workers
      (HCWs) who were exposed to severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) without having any perception of what they were facing, courageously
      contributing to the containment of the epidemic to be defined by the media as
      "heroes." However, in the first phase of the pandemic (March-May 2020), the price
      that the Italian Public Health System had to pay both in terms of the number of
      positive virus cases and deaths among the HCWs was beyond and represented a
      peculiarity compared to what happened in other countries. In the current study,
      after a summary of the evolution of the pandemic in Italy, we offer an analysis
      of the statistical data concerning contagions and deaths among healthcare workers
      (physicians in particular). In conclusion, we describe the critical issues that
      still need to be resolved and the future challenges facing healthcare workers and
      the general population.
CI  - Copyright (c) 2021 Nioi, Napoli, Lobina, Fossarello and d'Aloja.
FAU - Nioi, Matteo
AU  - Nioi M
AD  - Department of Medical Sciences and Public Health, Forensic Medicine Unit,
      University of Cagliari, Cagliari, Italy.
FAU - Napoli, Pietro Emanuele
AU  - Napoli PE
AD  - Department of Surgical Science, Eye Clinic, University of Cagliari, Cagliari,
      Italy.
FAU - Lobina, Jessica
AU  - Lobina J
AD  - Department of Medical Sciences and Public Health, Forensic Medicine Unit,
      University of Cagliari, Cagliari, Italy.
FAU - Fossarello, Maurizio
AU  - Fossarello M
AD  - Department of Surgical Science, Eye Clinic, University of Cagliari, Cagliari,
      Italy.
FAU - d'Aloja, Ernesto
AU  - d'Aloja E
AD  - Department of Medical Sciences and Public Health, Forensic Medicine Unit,
      University of Cagliari, Cagliari, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210121
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - *COVID-19/epidemiology/mortality
MH  - *COVID-19 Vaccines
MH  - *Communicable Disease Control
MH  - Health Personnel/ethics/*statistics & numerical data
MH  - Humans
MH  - Italy/epidemiology
MH  - Middle Aged
MH  - Personal Protective Equipment
MH  - Public Health
MH  - *RNA, Messenger
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
PMC - PMC7859528
OTO - NOTNLM
OT  - COVID-19
OT  - COVID-19 HCWs deaths
OT  - COVID-19 Italian physician's positivities and deaths
OT  - COVID-19 ethical dilemmas
OT  - COVID-19 future challenges
OT  - COVID-19 healthcare workers
OT  - COVID-19 mRNA vaccine
OT  - COVID-19: specialties of dead doctors
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/25 06:00
CRDT- 2021/02/08 05:45
PHST- 2020/08/05 00:00 [received]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2021/02/08 05:45 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
AID - 10.3389/fpubh.2020.591900 [doi]
PST - epublish
SO  - Front Public Health. 2021 Jan 21;8:591900. doi: 10.3389/fpubh.2020.591900.
      eCollection 2020.


PMID- 33553084
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Influence of Empathy Disposition and Risk Perception on the Psychological Impact 
      of Lockdown During the Coronavirus Disease Pandemic Outbreak.
PG  - 567337
LID - 10.3389/fpubh.2020.567337 [doi]
AB  - During the current COVID-19 pandemic, and especially in the absence of
      availability of an effective treatment or a vaccine, the main health measure is
      neither chemical nor biological, but behavioral. To reduce the exponential growth
      of infections due to the new coronavirus (SARS-CoV-2) and the resulting
      overburdening of the healthcare system, many European Countries, parts of the US 
      and Switzerland gradually implemented measures of quarantine and isolation
      defined as lockdown. This consideration leads to the need to understand how
      individuals are motivated to protect themselves and others. Recent research
      suggested that prosocial mental dispositions, such as empathy, might promote
      adherence to social norms of distancing. Other research conducted during the
      COVID-19 outbreak indicates, however, that empathy levels might fluctuate
      according to anxiety linked to the risk of death, and this negatively predicted
      prosocial willingness. The present protocol proposes a study on whether people's 
      empathic dispositions, interacting with the levels of risk, influence the
      psychological impact of lockdown. The rationale is that emphatic dispositions,
      encouraging the acceptance of the lockdown, determine a better psychological
      adaptation and less distress. One retrospective study will be developed in
      Switzerland and, if the pandemic conditions force a new wave of lockdown on the
      population, one prospective study as well. A total of 120 participants will be
      involved, distinguished by their level of objective risk: (1) high objective risk
      (COVID-19 positive patients, hospitalized in isolation in post-acute phase); (2) 
      moderate objective risk (COVID-19 positive patients, isolated at home); (3)
      minimum objective risk (non-positive adults, in lockdown). Measures of perceived 
      risk of being contagious for third parties, empathic dispositions and acceptance 
      of lockdown will be collected. The expected results provide important answers
      related to the immediate impact of empathic dispositions, effective risk and risk
      perception on the psychological impact of lockdown during a pandemic outbreak.
      Data gathered from this study could inform policy makers and public health
      managers about the best communication strategies that will take into account the 
      various stages of health risk and, in particular, to modulate messages to the
      population aimed at inducing self-isolation behaviors.
CI  - Copyright (c) 2021 Grignoli, Petrocchi, Bernardi, Massari, Traber, Malacrida and 
      Gabutti.
FAU - Grignoli, Nicola
AU  - Grignoli N
AD  - Consultation-Liaison Psychiatry Service, Organizzazione Sociopsichiatrica
      Cantonale, Mendrisio, Switzerland.
AD  - Department of Internal Medicine and Nephrology, Regional Hospital of Bellinzona
      and Valli, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
FAU - Petrocchi, Serena
AU  - Petrocchi S
AD  - Institute of Communication and Health, Universita della Svizzera Italiana,
      Lugano, Switzerland.
FAU - Bernardi, Sheila
AU  - Bernardi S
AD  - Sasso Corbaro Medical Humanities Foundation, Bellinzona, Switzerland.
FAU - Massari, Ilaria
AU  - Massari I
AD  - Consultation-Liaison Psychiatry Service, Organizzazione Sociopsichiatrica
      Cantonale, Mendrisio, Switzerland.
FAU - Traber, Rafael
AU  - Traber R
AD  - Consultation-Liaison Psychiatry Service, Organizzazione Sociopsichiatrica
      Cantonale, Mendrisio, Switzerland.
FAU - Malacrida, Roberto
AU  - Malacrida R
AD  - Sasso Corbaro Medical Humanities Foundation, Bellinzona, Switzerland.
FAU - Gabutti, Luca
AU  - Gabutti L
AD  - Department of Internal Medicine and Nephrology, Regional Hospital of Bellinzona
      and Valli, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210120
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - *Adaptation, Psychological
MH  - COVID-19/*prevention & control
MH  - *Empathy
MH  - Humans
MH  - *Perception
MH  - Prospective Studies
MH  - Psychological Distress
MH  - *Quarantine
MH  - Retrospective Studies
MH  - Risk Reduction Behavior
MH  - Surveys and Questionnaires
PMC - PMC7855966
OTO - NOTNLM
OT  - *COVID-19
OT  - *empathy
OT  - *ethics
OT  - *isolation
OT  - *lockdown
OT  - *prosocial
OT  - *psychological distress
OT  - *risk
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/25 06:00
CRDT- 2021/02/08 05:45
PHST- 2020/05/29 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/02/08 05:45 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
AID - 10.3389/fpubh.2020.567337 [doi]
PST - epublish
SO  - Front Public Health. 2021 Jan 20;8:567337. doi: 10.3389/fpubh.2020.567337.
      eCollection 2020.


PMID- 33552455
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Euthanasia and physician-assisted suicide: a systematic review of medical
      students' attitudes in the last 10 years.
PG  - 22
LID - 10.18502/jmehm.v13i22.4864 [doi]
AB  - This study aimed at examining the approval rate of the medical students'
      regarding active euthanasia, passive euthanasia, and physician-assisted-suicide
      over the last ten years. To do so, the arguments and variables affecting
      students' choices were examined and a systematic review was conducted, using
      PubMed and Web of Science databases, including articles from January 2009 to
      December 2018. From 135 identified articles, 13 met the inclusion criteria. The
      highest acceptance rates for euthanasia and physician-assisted suicide were from 
      European countries. The most common arguments supporting euthanasia and
      physician-assisted suicide were the followings: (i) patient's autonomy (n = 6),
      (ii) relief of suffering (n = 4), and (ii) the thought that terminally-ill
      patients are additional burden (n = 2). The most common arguments against
      euthanasia were as follows: (i) religious and personal beliefs (n = 4), (ii) the 
      "slippery slope" argument and the risk of abuse (n = 4), and (iii) the
      physician's role in preserving life (n = 2). Religion (n = 7), religiosity (n =
      5), and the attributes of the medical school of origin (n = 3) were the most
      significant variables to influence the students' attitude. However, age, previous
      academic experience, family income, and place of residence had no significant
      impact. Medical students' opinions on euthanasia and physician-assisted suicide
      should be appropriately addressed and evaluated because their moral compass,
      under the influence of such opinions, will guide them in solving future ethical
      and therapeutic dilemmas in the medical field.
CI  - (c) 2020 Tehran University of Medical Sciences.
FAU - Gutierrez-Castillo, Alejandro
AU  - Gutierrez-Castillo A
AD  - Researcher, School of Medicine, Monterrey Institute of Technology and Higher
      Education, Nuevo Leon Mexico, Mexico.
FAU - Gutierrez-Castillo, Javier
AU  - Gutierrez-Castillo J
AD  - Researcher, School of Medicine, Monterrey Institute of Technology and Higher
      Education, Nuevo Leon Mexico, Mexico.
FAU - Guadarrama-Conzuelo, Francisco
AU  - Guadarrama-Conzuelo F
AD  - Researcher, School of Medicine, Monterrey Institute of Technology and Higher
      Education, Nuevo Leon Mexico, Mexico.
FAU - Jimenez-Ruiz, Amado
AU  - Jimenez-Ruiz A
AD  - Neurology Resident, Department of Neurology, National Institute of Medical
      Science and Nutrition Salvador Zubiran, Ciudad de Mexico, Mexico.
FAU - Ruiz-Sandoval, Jose Luis
AU  - Ruiz-Sandoval JL
AD  - Professor, Department of Neurology, Civil Hospital of Guadalajara "Fray Antonio
      Alcalde", Jalisco, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20201212
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7839145
OTO - NOTNLM
OT  - Euthanasia
OT  - Medical ethics
OT  - Medical students
OT  - Physician-assisted Suicide
OT  - Religion.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:37
PHST- 2019/12/25 00:00 [received]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2021/02/08 05:37 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.18502/jmehm.v13i22.4864 [doi]
AID - JMEHM-13-22 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 12;13:22. doi: 10.18502/jmehm.v13i22.4864.
      eCollection 2020.


PMID- 33552452
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Neonatal end-of-life decisions and ethical perspectives.
PG  - 19
LID - 10.18502/jmehm.v13i19.4827 [doi]
AB  - End-of-life decisions are usually required when a neonate is at high risk of
      disability or death, and such decisions involve many legal and ethical
      challenges. This article reviewed the processes of ethical decision-making for
      severely ill or terminal neonates, considering controversial issues including the
      followings: (i) identifying primary decision makers, (ii) the role of law and
      guidelines, and (iii) changes in treatment controversy, law and regulations over 
      twenty years in several European countries such as Switzerland, Germany, Italy,
      United Kingdom, France, the Netherlands, Sweden, and Spain. This review study
      conducted on accessible articles from PubMed, Google Scholar, Web of Science and 
      Scopus databases. Based on two studies in 2016 and 1996, neonatologists reported 
      that withholding intensive care, withdrawing mechanical ventilation or
      life-saving drugs, and involvement of parents in decision-makings have become
      more acceptable as time passes, indicative of trend change. Trend of physicians
      on how end the life of neonates, at risk of death, varies in different countries,
      and cultural factors, parents' involvement in decisions and gestational age are
      factors considered in end-of-life decision-making. Future investigations
      continuously need to identify upcoming ethical aspects of proper decision-making.
CI  - (c) 2020 Tehran University of Medical Sciences.
FAU - Soltani Gerdfaramarzi, Madjid
AU  - Soltani Gerdfaramarzi M
AD  - PhD Candidate of Medical Ethics, Medical Ethics Department, School of Traditional
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Bazmi, Shabnam
AU  - Bazmi S
AD  - Associate professor, Medical Ethics Department, School of Traditional Medicine,
      Shahid Beheshti University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201205
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7838882
OTO - NOTNLM
OT  - Decision-making
OT  - End-of-life
OT  - Ethics
OT  - Law.
OT  - Neonatal intensive care
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:37
PHST- 2020/01/04 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2021/02/08 05:37 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.18502/jmehm.v13i19.4827 [doi]
AID - JMEHM-13-19 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Dec 5;13:19. doi: 10.18502/jmehm.v13i19.4827.
      eCollection 2020.


PMID- 33552370
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210818
IS  - 1937-8688 (Electronic)
VI  - 37
IP  - Suppl 1
DP  - 2020
TI  - COVID-19 infection in pediatric subjects: study of 36 cases in Conakry.
PG  - 42
LID - 10.11604/pamj.supp.2020.37.42.26573 [doi]
AB  - The aim of this study was to evaluate the main clinical and evolutionary features
      of SARS-CoV-2 infection in children aged 0-18 years who were suspected and
      diagnosed for COVID-19 during routine consultations in the pediatric ward of the 
      Ignace Deen National Hospital in Conakry. This retrospective study targeted all
      children admitted to the Pediatrics Department during the study period and
      focused on children whose clinical examination and/or history indicated a
      suspicion of SARS-CoV-2 infection. Only children with a positive reverse
      transcriptase-polymerase chain reaction (RT-PCR) test were included. Clinical and
      paraclinical data were rigorously analyzed. Anonymity and respect for ethical
      rules were the norm. Medical records were used as the data source and a
      questionnaire was developed for collection. The analysis was done using STATA/SE 
      version 11.2 software. The mean age of the patients observed was 9.66+/-1.32
      years, with a sex ratio of 1.25. The history of the patients found that 36.11 had
      already been in contact with a COVID-19 positive subject, of which 8 or 22 had
      close relatives treated for COVID-19 and 5 had been with classmates treated for
      COVID-19. Fever and physical asthenia, runny nose and throat pain were
      respectively found in 58.33%, 50% and 30.55% of patients with irritability in
      25%. Asymptomatic children were 30.55%. The diagnosis was confirmed after a
      positive RT-PCR test. Thoracic computed tomography (CT) scan was normal in 80.55%
      of the children. They were given mostly azithromycin 15mg/kg, zinc and
      chloroquine sulfate 5mg/kg. The mean age of the patients observed was 9.66 years,
      with a sex ratio of 1.25. The history of the patients found that 36.11 had
      already been in contact with a COVID-19 positive subject, of which 8 or 22 had
      close relatives treated for COVID-19 and 5 had been with classmates treated for
      COVID-19. Fever and physical asthenia, runny nose and throat pain were
      respectively found in 58.33%, 50% and 30.55% of patients with irritability in
      25%. Asymptomatic children were 30.55%. The diagnosis was confirmed after a
      positive RT-PCR test. Thoracic computed tomography (CT) scan was normal in 80.55%
      of the children. They were given mostly azithromycin 15mg/kg, zinc and
      chloroquine sulfate 5mg/kg.
CI  - Copyright: Hugues Ghislain Atakla et al.
FAU - Atakla, Hugues Ghislain
AU  - Atakla HG
AD  - Neurology Department, University Hospital Center Hubert Koutoukou MAGA, Cotonou, 
      Benin.
AD  - Laboratory of Noncommunicable and Neurologic Diseases Epidemiology, Faculty of
      Health Science, University of Abomey-Calavi, Cotonou, Benin.
FAU - Noudohounsi, Mahugnon Maurel Ulrich Denis
AU  - Noudohounsi MMUD
AD  - Monitoring and Evaluation/WHO AFRO, Research Project Manager, Brazzaville, Congo.
FAU - Salami, Aichat Yabo
AU  - Salami AY
AD  - Microbiology Laboratory, University Hospital Center Hubert Koutoukou MAGA,
      Cotonou, Benin.
FAU - Sacca, Helene
AU  - Sacca H
AD  - Laboratory of Noncommunicable and Neurologic Diseases Epidemiology, Faculty of
      Health Science, University of Abomey-Calavi, Cotonou, Benin.
FAU - Houinato, Axel Gael
AU  - Houinato AG
AD  - Laboratory of Noncommunicable and Neurologic Diseases Epidemiology, Faculty of
      Health Science, University of Abomey-Calavi, Cotonou, Benin.
FAU - Barry, Mamadou Cire
AU  - Barry MC
AD  - Pediatric Department, Ignace Deen University Hospital Center, Conakry, Guinea.
FAU - Othon, Guelngar Carlos
AU  - Othon GC
AD  - Pediatric Department, Ignace Deen University Hospital Center, Conakry, Guinea.
FAU - Adjadi, Ayeratou Abebi
AU  - Adjadi AA
AD  - Pediatric Department, Ignace Deen University Hospital Center, Conakry, Guinea.
FAU - Houinato, Dismand Stephan
AU  - Houinato DS
AD  - Neurology Department, University Hospital Center Hubert Koutoukou MAGA, Cotonou, 
      Benin.
AD  - Laboratory of Noncommunicable and Neurologic Diseases Epidemiology, Faculty of
      Health Science, University of Abomey-Calavi, Cotonou, Benin.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
RN  - 83905-01-5 (Azithromycin)
RN  - 886U3H6UFF (Chloroquine)
RN  - J41CSQ7QDS (Zinc)
SB  - IM
MH  - Adolescent
MH  - Asymptomatic Infections/*epidemiology
MH  - Azithromycin/administration & dosage
MH  - COVID-19/diagnosis/*epidemiology/physiopathology
MH  - *COVID-19 Testing
MH  - Child
MH  - Child, Preschool
MH  - Chloroquine/administration & dosage
MH  - Female
MH  - Guinea
MH  - *Hospitalization
MH  - Humans
MH  - Infant
MH  - Male
MH  - Retrospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tomography, X-Ray Computed
MH  - Zinc/administration & dosage
PMC - PMC7846264
OTO - NOTNLM
OT  - Conakry
OT  - RT-PCR
OT  - SARS-CoV-2
OT  - pediatric
COIS- The authors declare no competing interests.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/16 06:00
CRDT- 2021/02/08 05:37
PHST- 2020/10/18 00:00 [received]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2021/02/08 05:37 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - 10.11604/pamj.supp.2020.37.42.26573 [doi]
AID - PAMJ-SUPP-37-1-42 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Dec 8;37(Suppl 1):42. doi:
      10.11604/pamj.supp.2020.37.42.26573. eCollection 2020.


PMID- 33551909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Sports and Functional Training Improve a Subset of Obesity-Related Health
      Parameters in Adolescents: A Randomized Controlled Trial.
PG  - 589554
LID - 10.3389/fpsyg.2020.589554 [doi]
AB  - To investigate the effects of two different modes of physical activity on body
      composition, physical fitness, cardiometabolic risk, and psychological responses 
      in female adolescents participating in a multi-disciplinary program. The 12-week 
      randomized intervention included 25-adolescents with overweight divided into two 
      groups: sports practice-SPG and functional training-FTG. The SPG intervention was
      divided into three sports: basketball, handball, and futsal. SPG participants
      performed one sport 3-times/week, over the course of 1 month. The FTG performed
      concurrent exercises 3-times/week. This study was registered in Clinical Trials
      Registry Platform under number: RBR-45ywtg and registered in Local Ethics
      Committee number: 2,505.200/2018. The intensity of physical exercises-PE was
      matched between groups by the rating of perceived exertion. The primary outcome
      was body composition, and secondary outcomes were physical fitness,
      cardiometabolic risk, and psychological responses. There was a significant
      time-effect for body mass, body mass index, and low-density lipoprotein (LDL-c), 
      all being reduced. There were increases over time for musculoskeletal mass,
      aerobic fitness, and high-density lipoprotein (HDL-c) (p < 0.05). There was a
      group time interaction with body fat percentage being lower post-intervention in 
      the SPG (p < 0.05). No significant differences were observed for the other
      variables. Both physical activity models were effective in improving a subset of 
      obesity-related health parameters. The findings should be extended by further
      investigation using more sophisticated measures of energy expenditure. Clinical
      Trial Registration: https://ensaiosclinicos.gov.br/, identifier: RBR-45ywtg.
CI  - Copyright (c) 2021 Branco, Mariano, de Oliveira, Bertolini, de Oliveira, Araujo
      and Adamo.
FAU - Branco, Braulio Henrique Magnani
AU  - Branco BHM
AD  - Research Group in Physical Education, Physiotherapy, Sports, Nutrition and
      Performance, Unicesumar University, Maringa, Brazil.
AD  - Graduate Program in Health Promotion, Unicesumar University, Maringa, Brazil.
AD  - Faculty of Health Sciences, School of Human Kinetics, University of Ottawa,
      Ottawa, ON, Canada.
FAU - Mariano, Isabela Ramos
AU  - Mariano IR
AD  - Research Group in Physical Education, Physiotherapy, Sports, Nutrition and
      Performance, Unicesumar University, Maringa, Brazil.
AD  - Graduate Program in Biological Sciences, State University of Maringa, Maringa,
      Brazil.
FAU - de Oliveira, Leonardo Pestillo
AU  - de Oliveira LP
AD  - Graduate Program in Health Promotion, Unicesumar University, Maringa, Brazil.
FAU - Bertolini, Sonia Maria Marques Gomes
AU  - Bertolini SMMG
AD  - Graduate Program in Health Promotion, Unicesumar University, Maringa, Brazil.
FAU - de Oliveira, Fabiano Mendes
AU  - de Oliveira FM
AD  - Research Group in Physical Education, Physiotherapy, Sports, Nutrition and
      Performance, Unicesumar University, Maringa, Brazil.
AD  - Graduate Program in Health Promotion, Unicesumar University, Maringa, Brazil.
FAU - Araujo, Cynthia Gobbi Alves
AU  - Araujo CGA
AD  - Research Group in Physical Education, Physiotherapy, Sports, Nutrition and
      Performance, Unicesumar University, Maringa, Brazil.
FAU - Adamo, Kristi
AU  - Adamo K
AD  - Faculty of Health Sciences, School of Human Kinetics, University of Ottawa,
      Ottawa, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20210121
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7859634
OTO - NOTNLM
OT  - adolescent health
OT  - cardiometabolic risk in adolescents
OT  - exercise physiology
OT  - multi-professional research
OT  - psychophysiological habituation
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:35
PHST- 2020/07/31 00:00 [received]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2021/02/08 05:35 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fpsyg.2020.589554 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 21;11:589554. doi: 10.3389/fpsyg.2020.589554. eCollection
      2020.


PMID- 33551904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The Impact of Complexity on Methods and Findings in Psychological Science.
PG  - 580111
LID - 10.3389/fpsyg.2020.580111 [doi]
AB  - The study of human behavior is severely hampered by logistical problems, ethical 
      and legal constraints, and funding shortfalls. However, the biggest difficulty of
      conducting social and behavioral research is the extraordinary complexity of the 
      study phenomena. In this article, we review the impact of complexity on research 
      design, hypothesis testing, measurement, data analyses, reproducibility, and the 
      communication of findings in psychological science. The systematic investigation 
      of the world often requires different approaches because of the variability in
      complexity. Confirmatory testing, multi-factorial designs, survey methods, large 
      samples, and modeling are frequently needed to study complex social and
      behavioral topics. Complexity impedes the measurement of general constructs, the 
      reproducibility of results and scientific reporting, and the general rigor of
      research. Many of the benchmarks established by classic work in physical science 
      are not attainable in studies of more complex phenomena. Consequently, the
      standards used to evaluate scientific research should be tethered to the
      complexity of the study topic.
CI  - Copyright (c) 2021 Sanbonmatsu, Cooley and Butner.
FAU - Sanbonmatsu, David M
AU  - Sanbonmatsu DM
AD  - Department of Psychology, University of Utah, Salt Lake City, UT, United States.
FAU - Cooley, Emily H
AU  - Cooley EH
AD  - Department of Psychology, University of Utah, Salt Lake City, UT, United States.
FAU - Butner, Jonathan E
AU  - Butner JE
AD  - Department of Psychology, University of Utah, Salt Lake City, UT, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210121
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7859482
OTO - NOTNLM
OT  - complexity
OT  - measurement
OT  - methods
OT  - reproduction
OT  - scientific rigor
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:35
PHST- 2020/07/04 00:00 [received]
PHST- 2020/12/22 00:00 [accepted]
PHST- 2021/02/08 05:35 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fpsyg.2020.580111 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 21;11:580111. doi: 10.3389/fpsyg.2020.580111. eCollection
      2020.


PMID- 33551883
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Psychiatric Advance Directives and Artificial Intelligence: A Conceptual
      Framework for Theoretical and Ethical Principles.
PG  - 622506
LID - 10.3389/fpsyt.2020.622506 [doi]
AB  - The patient's decision-making abilities are often altered in psychiatric
      disorders. The legal framework of psychiatric advance directives (PADs) has been 
      made to provide care to patients in these situations while respecting their free 
      and informed consent. The implementation of artificial intelligence (AI) within
      Clinical Decision Support Systems (CDSS) may result in improvements for complex
      decisions that are often made in situations covered by PADs. Still, it raises
      theoretical and ethical issues this paper aims to address. First, it goes through
      every level of possible intervention of AI in the PAD drafting process, beginning
      with what data sources it could access and if its data processing competencies
      should be limited, then treating of the opportune moments it should be used and
      its place in the contractual relationship between each party (patient,
      caregivers, and trusted person). Second, it focuses on ethical principles and how
      these principles, whether they are medical principles (autonomy, beneficence,
      non-maleficence, justice) applied to AI or AI principles (loyalty and vigilance) 
      applied to medicine, should be taken into account in the future of the PAD
      drafting process. Some general guidelines are proposed in conclusion: AI must
      remain a decision support system as a partner of each party of the PAD contract; 
      patients should be able to choose a personalized type of AI intervention or no AI
      intervention at all; they should stay informed, i.e., understand the functioning 
      and relevance of AI thanks to educational programs; finally, a committee should
      be created for ensuring the principle of vigilance by auditing these new tools in
      terms of successes, failures, security, and relevance.
CI  - Copyright (c) 2021 Mouchabac, Adrien, Falala-Sechet, Bonnot, Maatoug, Millet,
      Peretti, Bourla and Ferreri.
FAU - Mouchabac, Stephane
AU  - Mouchabac S
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Saint-Antoine,
      Paris, France.
AD  - Sorbonne Universite, iCRIN Psychiatry (Infrastructure of Clinical Research In
      Neurosciences - Psychiatry), Brain and Spine Institute (ICM), INSERM, CNRS,
      Paris, France.
FAU - Adrien, Vladimir
AU  - Adrien V
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Saint-Antoine,
      Paris, France.
AD  - Sorbonne Universite, iCRIN Psychiatry (Infrastructure of Clinical Research In
      Neurosciences - Psychiatry), Brain and Spine Institute (ICM), INSERM, CNRS,
      Paris, France.
FAU - Falala-Sechet, Clara
AU  - Falala-Sechet C
AD  - Laboratory of Psychopathology and Health Processes, EA 4057, Institute of
      Psychology, University of Paris, Paris, France.
FAU - Bonnot, Olivier
AU  - Bonnot O
AD  - CHU de Nantes, Department of Child and Adolescent Psychiatry, Nantes, France.
AD  - Pays de la Loire Psychology Laboratory, EA 4638, Nantes, France.
FAU - Maatoug, Redwan
AU  - Maatoug R
AD  - Sorbonne Universite, iCRIN Psychiatry (Infrastructure of Clinical Research In
      Neurosciences - Psychiatry), Brain and Spine Institute (ICM), INSERM, CNRS,
      Paris, France.
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Millet, Bruno
AU  - Millet B
AD  - Sorbonne Universite, iCRIN Psychiatry (Infrastructure of Clinical Research In
      Neurosciences - Psychiatry), Brain and Spine Institute (ICM), INSERM, CNRS,
      Paris, France.
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Peretti, Charles-Siegfried
AU  - Peretti CS
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Saint-Antoine,
      Paris, France.
FAU - Bourla, Alexis
AU  - Bourla A
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Saint-Antoine,
      Paris, France.
AD  - Jeanne d'Arc Hospital, INICEA Group, Saint-Mande, France.
FAU - Ferreri, Florian
AU  - Ferreri F
AD  - Sorbonne Universite, AP-HP Department of Psychiatry, Hopital Saint-Antoine,
      Paris, France.
AD  - Sorbonne Universite, iCRIN Psychiatry (Infrastructure of Clinical Research In
      Neurosciences - Psychiatry), Brain and Spine Institute (ICM), INSERM, CNRS,
      Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210122
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7862130
OTO - NOTNLM
OT  - artificial intelligence
OT  - clinical decision support system
OT  - joint crisis plan
OT  - medical ethics
OT  - predictive medicine
OT  - psychiatric advance directives
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:35
PHST- 2020/10/28 00:00 [received]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2021/02/08 05:35 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fpsyt.2020.622506 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Jan 22;11:622506. doi: 10.3389/fpsyt.2020.622506.
      eCollection 2020.


PMID- 33551882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Right to Life or Right to Die in Advanced Dementia: Physician-Assisted Dying.
PG  - 622446
LID - 10.3389/fpsyt.2020.622446 [doi]
FAU - Jakhar, Jitender
AU  - Jakhar J
AD  - Department of Psychiatry, Govind Ballabh Pant Institute of Postgraduate Medical
      Education and Research, University of Delhi, New Delhi, India.
FAU - Ambreen, Saaniya
AU  - Ambreen S
AD  - Department of Psychiatry, Govind Ballabh Pant Institute of Postgraduate Medical
      Education and Research, University of Delhi, New Delhi, India.
FAU - Prasad, Shiv
AU  - Prasad S
AD  - Faculty of Medical Sciences, Lady Hardinge Medical College, University of Delhi, 
      New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20210121
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7858261
OTO - NOTNLM
OT  - advanced dementia
OT  - burden
OT  - ethical
OT  - physician assisted dying
OT  - psychiatry
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:35
PHST- 2020/10/28 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/02/08 05:35 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fpsyt.2020.622446 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Jan 21;11:622446. doi: 10.3389/fpsyt.2020.622446.
      eCollection 2020.


PMID- 33551782
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1662-5188 (Print)
IS  - 1662-5188 (Linking)
VI  - 14
DP  - 2020
TI  - BCNNM: A Framework for in silico Neural Tissue Development Modeling.
PG  - 588224
LID - 10.3389/fncom.2020.588224 [doi]
AB  - Cerebral ("brain") organoids are high-fidelity in vitro cellular models of the
      developing brain, which makes them one of the go-to methods to study isolated
      processes of tissue organization and its electrophysiological properties,
      allowing to collect invaluable data for in silico modeling neurodevelopmental
      processes. Complex computer models of biological systems supplement in vivo and
      in vitro experimentation and allow researchers to look at things that no
      laboratory study has access to, due to either technological or ethical
      limitations. In this paper, we present the Biological Cellular Neural Network
      Modeling (BCNNM) framework designed for building dynamic spatial models of neural
      tissue organization and basic stimulus dynamics. The BCNNM uses a convenient
      predicate description of sequences of biochemical reactions and can be used to
      run complex models of multi-layer neural network formation from a single initial 
      stem cell. It involves processes such as proliferation of precursor cells and
      their differentiation into mature cell types, cell migration, axon and dendritic 
      tree formation, axon pathfinding and synaptogenesis. The experiment described in 
      this article demonstrates a creation of an in silico cerebral organoid-like
      structure, constituted of up to 1 million cells, which differentiate and
      self-organize into an interconnected system with four layers, where the spatial
      arrangement of layers and cells are consistent with the values of analogous
      parameters obtained from research on living tissues. Our in silico organoid
      contains axons and millions of synapses within and between the layers, and it
      comprises neurons with high density of connections (more than 10). In sum, the
      BCNNM is an easy-to-use and powerful framework for simulations of neural tissue
      development that provides a convenient way to design a variety of tractable in
      silico experiments.
CI  - Copyright (c) 2021 Bozhko, Galumov, Polovian, Kolchanova, Myrov, Stelmakh and
      Schioth.
FAU - Bozhko, Dmitrii V
AU  - Bozhko DV
AD  - JetBrains Research Department, Space Office Center, Saint Petersburg, Russia.
FAU - Galumov, Georgii K
AU  - Galumov GK
AD  - JetBrains Research Department, Space Office Center, Saint Petersburg, Russia.
FAU - Polovian, Aleksandr I
AU  - Polovian AI
AD  - JetBrains Research Department, Space Office Center, Saint Petersburg, Russia.
FAU - Kolchanova, Sofiia M
AU  - Kolchanova SM
AD  - JetBrains Research Department, Space Office Center, Saint Petersburg, Russia.
AD  - Department of Biology, University of Puerto Rico at Mayaguez, Mayaguez, PR,
      United States.
AD  - Theodosius Dobzhansky Center for Genome Bioinformatics, St. Petersburg State
      University, Saint Petersburg, Russia.
FAU - Myrov, Vladislav O
AU  - Myrov VO
AD  - Neuroscience Center, Helsinki Institute of Life Science, University of Helsinki, 
      Helsinki, Finland.
AD  - Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo,
      Finland.
FAU - Stelmakh, Viktoriia A
AU  - Stelmakh VA
AD  - JetBrains Research Department, Space Office Center, Saint Petersburg, Russia.
AD  - Skolkovo Institute of Science and Technology, Center of Life Sciences, Moscow,
      Russia.
FAU - Schioth, Helgi B
AU  - Schioth HB
AD  - Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala,
      Sweden.
AD  - Institute for Translational Medicine and Biotechnology, Sechenov First Moscow
      State Medical University, Moscow, Russia.
LA  - eng
PT  - Journal Article
DEP - 20210120
PL  - Switzerland
TA  - Front Comput Neurosci
JT  - Frontiers in computational neuroscience
JID - 101477956
PMC - PMC7855713
OTO - NOTNLM
OT  - axon guidance
OT  - brain organoid
OT  - neurogenesis
OT  - neuronal connectivity
OT  - simulation
OT  - tissue development
COIS- DB, GG, AP, VS, and SK were employed by legal entities which are a part of
      JetBrains group of companies. The remaining authors declare that the research was
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:35
PHST- 2020/07/28 00:00 [received]
PHST- 2020/12/18 00:00 [accepted]
PHST- 2021/02/08 05:35 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fncom.2020.588224 [doi]
PST - epublish
SO  - Front Comput Neurosci. 2021 Jan 20;14:588224. doi: 10.3389/fncom.2020.588224.
      eCollection 2020.


PMID- 33551729
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Interaction Between Mesenchymal Stem Cells and Retinal Degenerative
      Microenvironment.
PG  - 617377
LID - 10.3389/fnins.2020.617377 [doi]
AB  - Retinal degenerative diseases (RDDs) are a group of diseases contributing to
      irreversible vision loss with yet limited therapies. Stem cell-based therapy is a
      promising novel therapeutic approach in RDD treatment. Mesenchymal stromal/stem
      cells (MSCs) have emerged as a leading cell source due to their neurotrophic and 
      immunomodulatory capabilities, limited ethical concerns, and low risk of tumor
      formation. Several pre-clinical studies have shown that MSCs have the potential
      to delay retinal degeneration, and recent clinical trials have demonstrated
      promising safety profiles for the application of MSCs in retinal disease.
      However, some of the clinical-stage MSC therapies have been unable to meet
      primary efficacy end points, and severe side effects were reported in some
      retinal "stem cell" clinics. In this review, we provide an update of the
      interaction between MSCs and the RDD microenvironment and discuss how to balance 
      the therapeutic potential and safety concerns of MSCs' ocular application.
CI  - Copyright (c) 2021 Lin, Ren, Chen and Chen.
FAU - Lin, Yu
AU  - Lin Y
AD  - The Research Laboratory of Ophthalmology and Vision Sciences, State Key
      Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu,
      China.
AD  - The Department of Ophthalmology, West China Hospital, Sichuan University,
      Chengdu, China.
FAU - Ren, Xiang
AU  - Ren X
AD  - The Research Laboratory of Ophthalmology and Vision Sciences, State Key
      Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu,
      China.
AD  - The Department of Ophthalmology, West China Hospital, Sichuan University,
      Chengdu, China.
FAU - Chen, Yongjiang
AU  - Chen Y
AD  - The School of Optometry and Vision Science, University of Waterloo, Waterloo, ON,
      Canada.
FAU - Chen, Danian
AU  - Chen D
AD  - The Research Laboratory of Ophthalmology and Vision Sciences, State Key
      Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu,
      China.
AD  - The Department of Ophthalmology, West China Hospital, Sichuan University,
      Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210121
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7859517
OTO - NOTNLM
OT  - immunomodulation
OT  - inflammation
OT  - interaction
OT  - licensing
OT  - mesenchymal stem cells
OT  - retinal degenerative diseases
OT  - trophic
OT  - tunneling nanotubes
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
CRDT- 2021/02/08 05:35
PHST- 2020/10/14 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/02/08 05:35 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
AID - 10.3389/fnins.2020.617377 [doi]
PST - epublish
SO  - Front Neurosci. 2021 Jan 21;14:617377. doi: 10.3389/fnins.2020.617377.
      eCollection 2020.


PMID- 33544699
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 73
IP  - 1
DP  - 2020 May 7
TI  - Bioethics in Medical Care Rationing During the Coronavirus Disease-19 Pandemic.
PG  - 1-5
LID - 10.24875/RIC.20000385 [doi]
AB  - BACKGROUND: Coronavirus (CoV) disease (COVID)-19 poses difficult situations in
      which the ethical course of action is not clear, or choices are made between
      equally unacceptable responses. METHODS: A web search was performed using the
      terms "bioethics; COVID-19; ethics; severe acute respiratory syndrome CoV-2;
      emergent care; pandemic; and public health emergencies." RESULTS: Protection from
      COVID-19 has resulted in the cancellation of necessary medical interventions,
      lengthened suffering, and potential non-COVID-19 deaths. Prolonged lockdown
      reduced well-being, triggering or aggravating mental illnesses and violence, and 
      escalated medical risks. Collateral damage includes restrictions on visitations
      to hospitals, alienation from the deceased relative, or lack of warm caring of
      patients. Finally, in a public health crisis, public health interest overrides
      individual rights if it results in severe harm to the community. CONCLUSION:
      Balancing ethical dilemmas are one more challenge in the COVID-19 pandemic.
FAU - Gonzalez-Duarte, Alejandra
AU  - Gonzalez-Duarte A
AD  - Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran (INCMyNSZ), Mexico City, Mexico.
FAU - Kaufer-Horwitz, Martha
AU  - Kaufer-Horwitz M
AD  - Department of Endocrinology, Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran, Mexico City, Mexico.
FAU - Gamba, Gerardo
AU  - Gamba G
AD  - Direction of Research, Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran (INCMyNSZ), Mexico City; Molecular Physiology Unit, Instituto de
      Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City;
      Mexico.
FAU - Rivera-Moscoso, Raul
AU  - Rivera-Moscoso R
AD  - Direction of Strategic Planning, Instituto Nacional de Ciencias Medicas y
      Nutricion Salvador Zubiran (INCMyNSZ), Mexico City, Mexico.
FAU - Aguilar-Salinas, Carlos A
AU  - Aguilar-Salinas CA
AD  - Direction of Nutrition; Metabolic Diseases Research Unit,and Department of
      Endocrinology and Metabolism, INCMNSZ, Mexico City; School of Medicine and Health
      Sciences, Tecnologico de Monterrey, Monterrey, N.L., Mexico.
LA  - eng
PT  - Journal Article
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la
      Nutricion
JID - 9421552
SB  - IM
MH  - COVID-19/*epidemiology/prevention & control/psychology
MH  - Cost of Illness
MH  - Ethics, Research
MH  - Health Care Rationing/*ethics
MH  - *Health Policy
MH  - Health Services Accessibility
MH  - Humans
MH  - Interpersonal Relations
MH  - Mental Disorders/epidemiology/etiology
MH  - Pandemics/*ethics/prevention & control
MH  - Professional-Patient Relations
MH  - *Public Health
MH  - Quality of Life
MH  - Quarantine
MH  - *SARS-CoV-2
MH  - Social Isolation
MH  - Telemedicine
EDAT- 2021/02/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2021/02/05 17:11
PHST- 2021/02/05 17:11 [entrez]
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.24875/RIC.20000385 [doi]
PST - ppublish
SO  - Rev Invest Clin. 2020 May 7;73(1):1-5. doi: 10.24875/RIC.20000385.


PMID- 33543151
OWN - NLM
STAT- MEDLINE
DCOM- 20211209
LR  - 20211214
IS  - 2208-7958 (Electronic)
VI  - 49
DP  - 2020 Dec 18
TI  - Communicable disease outbreaks: Ethics in an outbreak.
LID - 10.31128/AJGP-COVID-42 [doi]
AB  - This fifth article in a series on communicable disease outbreaks explores ethical
      aspects of public health action, information disclosure and research in an
      epidemic.
FAU - Ward, Jeanette E
AU  - Ward JE
AD  - MBBS, MHPEd, PhD, FAFPHM, FACHSM, FAICD, Adjunct Professor, Nulungu Research
      Institute, University of Notre Dame, WA.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - Australia
TA  - Aust J Gen Pract
JT  - Australian journal of general practice
JID - 101718099
SB  - IM
MH  - *Communicable Diseases/epidemiology
MH  - *Disease Outbreaks
MH  - Humans
MH  - Public Health
EDAT- 2021/02/06 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/02/05 06:00
PHST- 2021/02/05 06:00 [entrez]
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.31128/AJGP-COVID-42 [doi]
PST - epublish
SO  - Aust J Gen Pract. 2020 Dec 18;49. doi: 10.31128/AJGP-COVID-42.


PMID- 33543120
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2651-2823 (Electronic)
IS  - 2651-2823 (Linking)
VI  - 54
IP  - 3
DP  - 2020 Sep 1
TI  - The effect of pain intensity levels and clinical symptoms on the treatment
      preferences of patients with endodontically involved teeth: A preliminary
      cross-sectional study.
PG  - 142-147
LID - 10.26650/eor.20200043 [doi]
AB  - PURPOSE: This study aimed to evaluate the effect of pain intensity levels and
      clinical symptoms on the treatment preferences of patients with endodontically
      involved teeth in a local Turkish population. SUBJECTS AND METHODS: A total of 30
      patients with symptomatic teeth requiring non-surgical root canal treatment were 
      included in the study. The patients' demographic (age, gender, and education
      level) and diagnostic data (tooth type, pain intensity, response to percussion
      and palpation, presence of referred pain, and diagnosis) were analyzed. Data on
      the patients' explicit preferences (requested treatment, whether they are willing
      to accept a proposed extraction, choice of treatment if an anterior tooth was
      involved, and choice of treatment if the pain was not severe) as well as previous
      root canal treatment experiences were also analyzed. Pain intensity levels were
      evaluated using the Visual Analog Scale. RESULTS: Pain intensity levels had a
      significant effect on the treatment requested by the patient (p=0.001). Among the
      patients who requested extraction upon referral to the clinic, the rate of those 
      who reported that they would not accept extraction if the pain was located in an 
      anterior tooth was significantly lower than that of patients stating that they
      would refuse (p=0.039). The presence of referred pain also had a significant
      effect on the requested treatment (p=0.001). CONCLUSION: The intensity of pain
      and the presence of referred pain influence patients' treatment preferences.
CI  - Copyright (c) 2020 European Oral Research.
FAU - Eyuboglu, Tan Firat
AU  - Eyuboglu TF
AD  - Department of Endodontics, Istanbul Medipol University,Faculty of Dentistry,
      Istanbul,Turkey.
FAU - Gonenc, Fulya Ilcin
AU  - Gonenc FI
AD  - Department of Endodontics, Istanbul Medipol University,Faculty of Dentistry,
      Istanbul,Turkey.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Eur Oral Res
JT  - European oral research
JID - 101738487
PMC - PMC7837708
OTO - NOTNLM
OT  - Decision-making
OT  - Dental pain
OT  - Ethics
OT  - Informed consent
OT  - Treatment preference
EDAT- 2021/02/06 06:00
MHDA- 2021/02/06 06:01
CRDT- 2021/02/05 06:00
PHST- 2021/02/05 06:00 [entrez]
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/02/06 06:01 [medline]
AID - 10.26650/eor.20200043 [doi]
AID - eor-54-3-2019-0043 [pii]
PST - ppublish
SO  - Eur Oral Res. 2020 Sep 1;54(3):142-147. doi: 10.26650/eor.20200043.


PMID- 33542578
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 12
DP  - 2020 Dec
TI  - Sham block in a randomised controlled trial: Is it ethical?
PG  - 1082-1083
LID - 10.4103/ija.IJA_836_20 [doi]
FAU - Nair, Abhijit
AU  - Nair A
AD  - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and
      Research Institute, Hyderabad, Telangana, India.
FAU - Diwan, Sandeep
AU  - Diwan S
AD  - Department of Anaesthesia, Sancheti Hospital, Pune, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20201212
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7852443
COIS- There are no conflicts of interest.
EDAT- 2021/02/06 06:00
MHDA- 2021/02/06 06:01
CRDT- 2021/02/05 05:58
PHST- 2020/06/24 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2021/02/05 05:58 [entrez]
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/02/06 06:01 [medline]
AID - 10.4103/ija.IJA_836_20 [doi]
AID - IJA-64-1082 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Dec;64(12):1082-1083. doi: 10.4103/ija.IJA_836_20. Epub
      2020 Dec 12.


PMID- 33541488
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 2095-4352 (Print)
VI  - 32
IP  - 12
DP  - 2020 Dec
TI  - [First aid spirit and first aid thinking should be established in saving lives in
      new epidemic of coronavirus disease 2019].
PG  - 1414-1415
LID - 10.3760/cma.j.cn121430-20201211-00764 [doi]
AB  - Saving lives is the bounden glorious mission and sacred duty of medical staff. As
      the front-line and cutting-edge, the emergency department and prehospital
      first-aid personnel have a deeper understanding and feeling. In the face of all
      kinds of patients and coming critical patients, as well as potential, suspected
      and even clearly diagnosed infectious diseases, the first-aid personnel of the
      emergency department performed their duties without hesitation, saved countless
      lives, and composed a song of life praise. In order to better carry forward and
      inherit this kind of boundless love, life-saving professional ethics and
      revolutionary spirit, this paper proposes to establish and uphold the first aid
      spirit in the industry and cultivate first aid thinking.
FAU - Wu, Xiukun
AU  - Wu X
AD  - Pingdingshan City Emergency Command Centre, Pingdingshan 467000, Henan, China.
      Corresponding author: Wu Xiukun, Email: pdsjjwxk@163.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
JT  - Zhonghua wei zhong bing ji jiu yi xue
JID - 101604552
SB  - IM
MH  - *COVID-19
MH  - Emergency Service, Hospital
MH  - *Epidemics
MH  - First Aid
MH  - Humans
MH  - SARS-CoV-2
EDAT- 2021/02/06 06:00
MHDA- 2021/02/09 06:00
CRDT- 2021/02/05 05:40
PHST- 2021/02/05 05:40 [entrez]
PHST- 2021/02/06 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.3760/cma.j.cn121430-20201211-00764 [doi]
PST - ppublish
SO  - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Dec;32(12):1414-1415. doi:
      10.3760/cma.j.cn121430-20201211-00764.


PMID- 33537150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210204
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - The impact of the COVID-19 pandemic on medical assistance in dying in Canada and 
      the relationship of public health laws to private understandings of the legal
      order.
PG  - lsaa087
LID - 10.1093/jlb/lsaa087 [doi]
AB  - Drawing on interviews we conducted with 15 medical assistance in dying (MAiD)
      providers from across Canada, we examine how physicians and nurse practitioners
      reconcile respect for the new, changing rules brought upon by the coronavirus
      disease 2019 (COVID-19) pandemic, along with their existing legal obligations and
      ethical commitments as health care professionals and MAiD providers. Our
      respondents reported situations where they did not follow or did not insist on
      others following the applicable public health rules. We identify a variety of
      techniques that they deployed either to minimize, rationalize, justify or excuse 
      deviations from the relevant public health rules. They implicitly invoked the
      exceptionality and emotionality of the MAiD context, especially in the time of
      COVID, when offering their accounts and explanations. What respondents relate
      about their experiences providing MAiD during the COVID pandemic offers occasion 
      to reflect on the role actors themselves play in giving meaning (if not
      coherence) to the potentially conflicting normative expectations to which they
      are subject.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Tremblay-Huet, Sabrina
AU  - Tremblay-Huet S
AD  - Faculty of Law, University of Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - McMorrow, Thomas
AU  - McMorrow T
AD  - Faculty of Social Science and Humanities, Ontario Tech University, Oshawa,
      Ontario, Canada.
FAU - Wiebe, Ellen
AU  - Wiebe E
AD  - Department of Family Practice, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Kelly, Michaela
AU  - Kelly M
AD  - London School of Hygiene and Tropical Medicine, University of London, London, UK.
FAU - Hennawy, Mirna
AU  - Hennawy M
AD  - Department of Family Practice, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Sum, Brian
AU  - Sum B
AD  - Department of Family Practice, University of British Columbia, Vancouver, British
      Columbia, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7799035
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - Canada
OT  - Medical Aid in Dying
OT  - professional ethics
OT  - public health
EDAT- 2021/02/05 06:00
MHDA- 2021/02/05 06:01
CRDT- 2021/02/04 05:51
PHST- 2020/07/17 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2021/02/04 05:51 [entrez]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/02/05 06:01 [medline]
AID - 10.1093/jlb/lsaa087 [doi]
AID - lsaa087 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Dec 11;7(1):lsaa087. doi: 10.1093/jlb/lsaa087. eCollection
      2020 Jan-Jun.


PMID- 33536954
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210204
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Corrigendum: Sharing Clinical Notes in Psychotherapy: A New Tool to Strengthen
      Patient Autonomy.
PG  - 636411
LID - 10.3389/fpsyt.2020.636411 [doi]
AB  - [This corrects the article DOI: 10.3389/fpsyt.2020.527872.].
CI  - Copyright (c) 2021 Blease, Walker, Torous and O'Neill.
FAU - Blease, Charlotte R
AU  - Blease CR
AD  - OpenNotes, General Medicine and Primary Care Research, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, MA, United States.
FAU - Walker, Jan
AU  - Walker J
AD  - OpenNotes, General Medicine and Primary Care Research, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, MA, United States.
FAU - Torous, John
AU  - Torous J
AD  - Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard
      Medical School, Boston, MA, United States.
FAU - O'Neill, Stephen
AU  - O'Neill S
AD  - OpenNotes, General Medicine and Primary Care Research, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, MA, United States.
LA  - eng
PT  - Published Erratum
DEP - 20210118
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
EFR - Front Psychiatry. 2020 Oct 28;11:527872. PMID: 33192647
PMC - PMC7849277
OTO - NOTNLM
OT  - electronic health records
OT  - evidence-based practice
OT  - informed consent
OT  - open notes
OT  - patient autonomy
OT  - psychotherapy
OT  - psychotherapy ethics
EDAT- 2021/02/05 06:00
MHDA- 2021/02/05 06:01
CRDT- 2021/02/04 05:51
PHST- 2020/12/01 00:00 [received]
PHST- 2020/12/09 00:00 [accepted]
PHST- 2021/02/04 05:51 [entrez]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/02/05 06:01 [medline]
AID - 10.3389/fpsyt.2020.636411 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Jan 18;11:636411. doi: 10.3389/fpsyt.2020.636411.
      eCollection 2020.


PMID- 33536947
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - A German Version of the Staff Attitude to Coercion Scale. Development and
      Empirical Validation.
PG  - 573240
LID - 10.3389/fpsyt.2020.573240 [doi]
AB  - Background: Individual staff factors, such as personality traits and attitudes,
      are increasingly seen as an important factor in the reduction of coercion in
      mental health services. At the same time, only a few validated instruments exist 
      to measure those factors and examine their influence on the use of coercion. Aim:
      The present study aimed to develop and validate a German version of the Staff
      Attitude to Coercion Scale (SACS). Methods: The original English version of the
      SACS published was translated into German. Subsequently, it was empirically
      validated on a sample of N = 209 mental health professionals by conducting an
      exploratory factor analysis. Results: The three-factor structure in the original 
      version of the SACS, consisting of critical, pragmatic and positive attitudes
      toward the use of coercion, could not be replicated. Instead, the German version 
      revealed one factor ranging from rejecting to approving the use of coercion.
      Conclusion: The SACS is one of the first instruments created to assess staff
      attitudes toward coercion in a validated way. The version of the instrument
      developed in this study allows for a validated assessment of those attitudes in
      German. Our results highlight the ethical importance of using validated
      measurements in studies on the role of staff factors in the reduction of
      coercion.
CI  - Copyright (c) 2021 Efkemann, Scholten, Bottlender, Juckel and Gather.
FAU - Efkemann, Simone A
AU  - Efkemann SA
AD  - Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University
      Hospital, Ruhr University Bochum, Bochum, Germany.
FAU - Scholten, Matthe
AU  - Scholten M
AD  - Institute for Medical Ethics and History of Medicine, Ruhr University Bochum,
      Bochum, Germany.
FAU - Bottlender, Ronald
AU  - Bottlender R
AD  - Klinik fur Psychiatrie und Psychotherapie, Klinikum Ludenscheid, Markische
      Klinken, Ludenscheid, Germany.
FAU - Juckel, Georg
AU  - Juckel G
AD  - Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University
      Hospital, Ruhr University Bochum, Bochum, Germany.
FAU - Gather, Jakov
AU  - Gather J
AD  - Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University
      Hospital, Ruhr University Bochum, Bochum, Germany.
AD  - Institute for Medical Ethics and History of Medicine, Ruhr University Bochum,
      Bochum, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210118
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7847975
OTO - NOTNLM
OT  - attitudes research
OT  - coercive measures
OT  - compulsory treatment
OT  - involuntary admission
OT  - mental health care
OT  - psychiatry
OT  - test adaptation
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/05 06:00
MHDA- 2021/02/05 06:01
CRDT- 2021/02/04 05:50
PHST- 2020/06/16 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2021/02/04 05:50 [entrez]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/02/05 06:01 [medline]
AID - 10.3389/fpsyt.2020.573240 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Jan 18;11:573240. doi: 10.3389/fpsyt.2020.573240.
      eCollection 2020.


PMID- 33536676
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20220420
IS  - 2616-163X (Electronic)
IS  - 0016-9560 (Linking)
VI  - 54
IP  - 2
DP  - 2020 Jun
TI  - Patients' satisfaction with ophthalmic counselling services in a tertiary
      hospital in Calabar, South-South Nigeria.
PG  - 76-81
LID - 10.4314/gmj.v54i2.4 [doi]
AB  - OBJECTIVE: To assess the level of satisfaction of patients who access the
      Ophthalmic counselling services anchored by trained social workers of the
      University of Calabar Teaching Hospital, Calabar, Nigeria. METHODS: A
      cross-sectional study of serial consenting participants was done. Ethical
      approval was obtained from the University of Calabar Teaching hospitals' ethics
      committee. Data was obtained using a semi-structured interviewer-administered
      questionnaire. Data were collated and analyzed using the SPSS for Windows
      (version 20, SPSS inc. Chicago, IL, USA). Modified Likert scale (very satisfied, 
      satisfied and not satisfied) was used to rate the satisfaction level. RESULTS: A 
      total of 120 respondents met the inclusion criteria and were enrolled into the
      study. Majority of the respondents (60%) were male with an overall mean age of
      45.32+/- 1.82. Over a quarter (28.3%) of the respondents were in the age bracket 
      of 41-50. Glaucoma (48.3%) was the most common eye condition of the respondents. 
      Seventy-five percent of the respondents were satisfied with the average time
      spent for the counselling services while 76.7% were satisfied with the overall
      ophthalmic counselling services they received with 46.7% believing that the
      service was provided by a social worker. CONCLUSION: Majority of the Patients
      were satisfied with the Ophthalmic counselling services mainly anchored by social
      workers. Training and retraining of allied support staff to render ophthalmic
      counselling services in order to ease the workload of the Ophthalmologist should 
      be encouraged in resource-limited settings. FUNDING: None declared.
CI  - Copyright (c) The Author(s).
FAU - Etim, Bassey A
AU  - Etim BA
AD  - Department of Ophthalmology, University of Calabar and University of Calabar
      Teaching Hospital, Calabar, Nigeria.
FAU - Ibanga, Affiong A
AU  - Ibanga AA
AD  - Department of Ophthalmology, University of Calabar and University of Calabar
      Teaching Hospital, Calabar, Nigeria.
FAU - Udoh, Martha-Mary E
AU  - Udoh ME
AD  - Department of Ophthalmology, University of Calabar Teaching Hospital, Calabar,
      Nigeria.
FAU - Nkanga, Elizabeth D
AU  - Nkanga ED
AD  - Department of Ophthalmology, University of Calabar and University of Calabar
      Teaching Hospital, Calabar, Nigeria.
FAU - Utam, Utam A
AU  - Utam UA
AD  - Department of Ophthalmology, University of Calabar Teaching Hospital, Calabar,
      Nigeria.
FAU - Okwejie, John A
AU  - Okwejie JA
AD  - Department of Ophthalmology, University of Calabar Teaching Hospital, Calabar,
      Nigeria.
LA  - eng
PT  - Journal Article
PL  - Ghana
TA  - Ghana Med J
JT  - Ghana medical journal
JID - 0073210
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Counseling/*statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hospitals, Teaching
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria
MH  - *Ophthalmology
MH  - Patient Satisfaction/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7829054
OTO - NOTNLM
OT  - Nigeria
OT  - Patients satisfaction
OT  - ophthalmic counselling service
COIS- Conflict of interest: None declared
EDAT- 2021/02/05 06:00
MHDA- 2021/06/24 06:00
CRDT- 2021/02/04 05:50
PHST- 2021/02/04 05:50 [entrez]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
AID - 10.4314/gmj.v54i2.4 [doi]
AID - jGMJ.v54.i2.pg76 [pii]
PST - ppublish
SO  - Ghana Med J. 2020 Jun;54(2):76-81. doi: 10.4314/gmj.v54i2.4.


PMID- 33536223
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210625
IS  - 2375-2548 (Electronic)
IS  - 2375-2548 (Linking)
VI  - 7
IP  - 6
DP  - 2020 Feb
TI  - Vaccine optimization for COVID-19: Who to vaccinate first?
LID - eabf1374 [pii]
LID - 10.1126/sciadv.abf1374 [doi]
AB  - Vaccines, when available, will likely become our best tool to control the
      COVID-19 pandemic. Even in the most optimistic scenarios, vaccine shortages will 
      likely occur. Using an age-stratified mathematical model paired with optimization
      algorithms, we determined optimal vaccine allocation for four different metrics
      (deaths, symptomatic infections, and maximum non-ICU and ICU hospitalizations)
      under many scenarios. We find that a vaccine with effectiveness >/=50% would be
      enough to substantially mitigate the ongoing pandemic, provided that a high
      percentage of the population is optimally vaccinated. When minimizing deaths, we 
      find that for low vaccine effectiveness, irrespective of vaccination coverage, it
      is optimal to allocate vaccine to high-risk (older) age groups first. In
      contrast, for higher vaccine effectiveness, there is a switch to allocate vaccine
      to high-transmission (younger) age groups first for high vaccination coverage.
      While there are other societal and ethical considerations, this work can provide 
      an evidence-based rationale for vaccine prioritization.
CI  - Copyright (c) 2021 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0
      (CC BY-NC).
FAU - Matrajt, Laura
AU  - Matrajt L
AUID- ORCID: 0000-0003-4495-7245
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA, USA. laurama@fredhutch.org.
FAU - Eaton, Julia
AU  - Eaton J
AUID- ORCID: 0000-0002-1687-5042
AD  - University of Washington, Tacoma, WA, USA.
FAU - Leung, Tiffany
AU  - Leung T
AUID- ORCID: 0000-0002-9075-4134
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA, USA.
FAU - Brown, Elizabeth R
AU  - Brown ER
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA, USA.
AD  - Department of Biostatistics, University of Washington, Seattle, WA, USA.
LA  - eng
GR  - S10 OD028685/OD/NIH HHS/United States
GR  - UM1 AI148684/AI/NIAID NIH HHS/United States
GR  - 1 UM1 AI148684-01/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210203
PL  - United States
TA  - Sci Adv
JT  - Science advances
JID - 101653440
RN  - 0 (COVID-19 Vaccines)
SB  - IM
UOF - medRxiv. 2020 Dec 15;:. PMID: 32817963
MH  - Age Factors
MH  - Algorithms
MH  - COVID-19/epidemiology/pathology/*prevention & control/virology
MH  - COVID-19 Vaccines/*immunology
MH  - Epidemics
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Models, Biological
MH  - Pandemics/*prevention & control
MH  - Risk
MH  - SARS-CoV-2/isolation & purification
MH  - Vaccination/*methods
PMC - PMC8128110
EDAT- 2021/02/05 06:00
MHDA- 2021/02/16 06:00
CRDT- 2021/02/04 05:40
PHST- 2020/10/06 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/02/04 05:40 [entrez]
PHST- 2021/02/05 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - 7/6/eabf1374 [pii]
AID - 10.1126/sciadv.abf1374 [doi]
PST - epublish
SO  - Sci Adv. 2021 Feb 3;7(6). pii: 7/6/eabf1374. doi: 10.1126/sciadv.abf1374. Print
      2020 Feb.


PMID- 33532046
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Nurses' perspectives regarding the relationship between professional ethics and
      organizational commitment in healthcare organizations.
PG  - 17
LID - 10.18502/jmehm.v13i17.4658 [doi]
AB  - Nurses' professional and ethical performances are influenced by the health
      organizations' environment, and high quality and holistic care can only be
      provided by observing the principles of professional ethics and organizational
      commitment. Therefore, this study aimed at investigating the relationship between
      professional ethics and organizational commitment in nurses. This
      descriptive-analytic study was conducted in hospitals affiliated to Shiraz
      University of Medical Sciences (SUMS) in 2019 in Iran. The study participants
      included 210 public ward nurses selected using the stratified random sampling
      method. Data were collected using Petty Professional Ethics and Allen-Meyer
      Organizational Commitment questionnaires, and then analyzed by SPSS V.25. Both
      the mean score of the nurses' professional ethics (102.21 +/- 10.89) and the mean
      score of the nurses' organizational commitment (95.30 +/- 16.54) were at high
      levels. Moreover, a direct and significant relationship was found between
      professional ethics and organizational commitment (P= 0.009, r = 0.179). In other
      words, a positive correlation was found between professional ethics and
      organizational commitment. Considering the relationship between professional
      ethics and organizational commitment in nurses, managers should enhance nurses'
      level of adherence to ethical principles, organizational commitment and
      organizational attachment. Additionally, training courses can help improve
      nurses' professional capabilities, and hence enhancing the quality of providing
      healthcare services.
CI  - (c) 2020 Tehran University of Medical Sciences.
FAU - Torkaman, Mahya
AU  - Torkaman M
AD  - PhD Candidate in Nursing, Department of Nursing, School of Nursing and Midwifery,
      Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Heydari, Naval
AU  - Heydari N
AD  - PhD Candidate in Nursing, Department of Nursing, School of Nursing and Midwifery,
      Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Torabizadeh, Camellia
AU  - Torabizadeh C
AD  - Associate Professor, Community Based Psychiatric Care Research Center, Shiraz
      University of Medical Sciences, Shiraz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201108
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7816541
OTO - NOTNLM
OT  - Ethics
OT  - Nursing.
OT  - Organizational commitment
OT  - Organizational culture
EDAT- 2021/02/04 06:00
MHDA- 2021/02/04 06:01
CRDT- 2021/02/03 05:58
PHST- 2020/04/18 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2021/02/03 05:58 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/02/04 06:01 [medline]
AID - 10.18502/jmehm.v13i17.4658 [doi]
AID - JMEHM-13-17 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Nov 8;13:17. doi: 10.18502/jmehm.v13i17.4658.
      eCollection 2020.


PMID- 33532045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - White lies in pediatric care: a qualitative study from nurses' perspective.
PG  - 16
LID - 10.18502/jmehm.v13i16.4414 [doi]
AB  - Communication and sharing information with ill children are challenging. To
      protect a child from the bitter reality, sometimes use of well-intended untruths,
      or white lies is necessary. This research aimed at studying the experiences of
      nurses about the use of white lies in in pediatric clinical setting. In this
      qualitative, content-analysis study, 24 on-duty pediatric nurses were interviewed
      in 2019. Data were collected through purposeful sampling using semi-structured
      interviews, and the collected data were analyzed according to Granheim and
      Landman's method using MAXQDA-10 software. Eighteen female and six male nurses
      with the mean age of 42 +/- 3/7 years and mean work experience of 16 +/- 4/1
      years were selected to participate in this study. Data analysis showed that use
      of white lies depends on both situation and several other factors classified into
      five general categories: nature of data, childhood characteristics, family norms,
      treatment team's capabilities and organization policies. Treatment team members
      need to improve their communication skills to convey therapeutic information to
      the ill child's family appropriately. To do so, special guidelines should be
      prepared for healthcare staff in pediatric clinical setting.
CI  - (c) 2020 Tehran University of Medical Sciences.
FAU - Shali, Mahboobeh
AU  - Shali M
AD  - Reseacher, Department of Critical Care Nursing and Management, School of Nursing 
      and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Joolaee, Soodabeh
AU  - Joolaee S
AD  - Professor, Nursing Care Research Center, Iran University of Medical Sciences,
      Tehran, Iran; Researcher, Center for Health Evaluation & Outcome Sciences
      (CHEOS), University of British Columbia (UBC), Vancouver, BC, Canada.
FAU - Navab, Elham
AU  - Navab E
AD  - Associate Professor, Department of Critical Care Nursing and Management, School
      of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Esmaeili, Maryam
AU  - Esmaeili M
AD  - Researcher, Nursing Care Research Center, School of Nursing and Midwifery, Tehran
      University of Medical Sciences, Tehran, Iran; Associate Professor, Department of 
      Critical Care Nursing and Management, School of Nursing and Midwifery, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Nikbakht Nasrabadi, Alireza
AU  - Nikbakht Nasrabadi A
AD  - Professor, Department of Medical Surgical Nursing, School of Nursing and
      Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201018
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7816540
OTO - NOTNLM
OT  - Content analysis.
OT  - Ethics
OT  - Pediatrics
OT  - Truth-telling
EDAT- 2021/02/04 06:00
MHDA- 2021/02/04 06:01
CRDT- 2021/02/03 05:58
PHST- 2020/03/29 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2021/02/03 05:58 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/02/04 06:01 [medline]
AID - 10.18502/jmehm.v13i16.4414 [doi]
AID - JMEHM-13-16 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Oct 18;13:16. doi: 10.18502/jmehm.v13i16.4414.
      eCollection 2020.


PMID- 33532044
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Rate and causes of discharge against medical advice from a university hospital
      emergency department in Iran: an ethical perspective.
PG  - 15
LID - 10.18502/jmehm.v13i15.4391 [doi]
AB  - Discharge against medical advice (DAMA) is a common problem in the health-care
      system. It imposes risks to both patients and medical staff and could be the
      subject of ethical deliberation. This cross-sectional study was conducted in 2017
      on 400 patients who were discharged against medical advice from the emergency
      ward of Shariati Hospital, Tehran, Iran. Patients' information was collected
      using clinical records and telephone calls. The collected data were analyzed
      using STATA software. DAMA rate was 12% in the emergency department of Shariati
      Hospital. Male gender was found to be a risk factor for DAMA (OR: 1.90; CI (95%):
      1.44 - 2.52; P < 0.0001). In addition, younger patients were more likely to leave
      hospital against medical advice (p-value: 0.04). The more common reasons for DAMA
      were feeling better, long delay in diagnostic and therapeutic procedures and the 
      hectic ambience of the emergency ward. Patients' self-discharge is a
      multi-dimensional phenomenon that is affected by patients' characteristics,
      medical conditions and hospital circumstances. It raises some ethical concerns,
      mainly due to a conflict between patients' autonomy and beneficence. It is
      helpful for the medical staff to create an effective relationship with patients
      who are at higher risk of DAMA, in order to increase their compliance and prevent
      the consequences of leaving hospital against medical advice.
CI  - (c) 2020 Tehran University of Medical Sciences.
FAU - Rouhbakhsh Halvaei, Sanaz
AU  - Rouhbakhsh Halvaei S
AD  - Medical Student, School of Medicine, Tehran University of Medical Sciences,
      Tehran, Iran.
FAU - Sheikh Motahar Vahedi, Hojat
AU  - Sheikh Motahar Vahedi H
AD  - Associate Professor, Shariati Hospital, School of Medicine, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Ahmadi, Ayat
AU  - Ahmadi A
AD  - Assistant Professor, Knowledge Utilization Research Center, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Mousavi, Maryam Sadat
AU  - Mousavi MS
AD  - Medical Ethics Supervisor, Medical Ethics and Professionalism Office, Shariati
      Hospital, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Parsapoor, Alireza
AU  - Parsapoor A
AD  - Assistant Professor, Medical Ethics and History of Medicine Research Center,
      Tehran University of Medical Sciences, Tehran, Iran; Department of Medical
      Ethics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sima, Ali Reza
AU  - Sima AR
AD  - Assistant Professor, Digestive Diseases Research Center, Digestive Diseases
      Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Shojaei, Amir Ahmad
AU  - Shojaei AA
AD  - Assistant Professor, Medical Ethics and History of Medicine Research Center,
      Tehran University of Medical Sciences, Tehran, Iran; Department of Medical
      Ethics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Shamsi-Gooshki, Ehsan
AU  - Shamsi-Gooshki E
AD  - Assistant Professor, Medical Ethics and History of Medicine Research Center,
      Tehran University of Medical Sciences, Tehran, Iran; Department of Medical
      Ethics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7816543
OTO - NOTNLM
OT  - Discharge against medical advice (DAMA)
OT  - Emergency department
OT  - Iran
OT  - Medical ethics.
EDAT- 2021/02/04 06:00
MHDA- 2021/02/04 06:01
CRDT- 2021/02/03 05:58
PHST- 2020/01/27 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2021/02/03 05:58 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/02/04 06:01 [medline]
AID - 10.18502/jmehm.v13i15.4391 [doi]
AID - JMEHM-13-15 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Sep 28;13:15. doi: 10.18502/jmehm.v13i15.4391.
      eCollection 2020.


PMID- 33529283
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 2391-5854 (Electronic)
IS  - 0033-2674 (Linking)
VI  - 54
IP  - 5
DP  - 2020 Oct 31
TI  - Kazimierz Filip Wize (1873 - 1953) - a psychiatrist, a biologist, and a
      philosopher.
PG  - 1025-1035
LID - 105213 [pii]
LID - 10.12740/PP/OnlineFirst/105213 [doi]
AB  - Kazimierz Filip Wize (1873-1953) was a Polish multidisciplinary scholar, a
      microbiologist, a lepidopterologist, a psychiatrist, and a philosopher. He was an
      avid promoter of care of the mentally ill. After defending a Ph.D. in medicine in
      Munich (Germany) in 1899, Wize specialized in bacteriology at the Pasteur
      Institute in Paris. In 1907 he defended his second Ph.D. in philosophy in
      Leipzig. Soon, Wize became an internationally active scholar and a prolific
      writer, working especially on esthetics and the philosophy of medicine. For Wize,
      philosophy of action was a bridge between abstract academic philosophy, practical
      ethics, and the philosophy of medicine understood as an art and a science. Later 
      in his life, Wize moved back to practicing medicine, and in the 1930s he
      specialized in psychiatry. The new field enabled him to apply his esthetic
      concepts to the treatment of patients and become a pioneer of art therapy. Music,
      painting, and dance, Wize argued, are a means to achieve serenity and freedom and
      play an important part in the process of recovery. Much later, Wize witnessed the
      extermination of psychiatric patients in Poland during a Nazi T4 action.
FAU - Czekajewska, Justyna
AU  - Czekajewska J
AD  - Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra Nauk
      Spolecznych i Humanistycznych.
FAU - Moskalewicz, Marcin
AU  - Moskalewicz M
AD  - Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra Nauk
      Spolecznych i Humanistycznych.
FAU - Zamojski, Jan
AU  - Zamojski J
AD  - Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra Nauk
      Spolecznych i Humanistycznych.
FAU - Musielak, Michal
AU  - Musielak M
AD  - Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra Nauk
      Spolecznych i Humanistycznych.
LA  - eng
LA  - pol
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Review
TT  - Kazimierz Filip Wize (1873 - 1953) - psychiatra, biolog i filozof.
DEP - 20201031
PL  - Poland
TA  - Psychiatr Pol
JT  - Psychiatria polska
JID - 0103314
SB  - IM
MH  - Ethics, Medical/*history
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Poland
MH  - Psychiatry/*history
MH  - Psychology/*history
PS  - Wize KF
FPS - Wize, Kazimierz Filip
OTO - NOTNLM
OT  - art therapy
OT  - history of medicine
OT  - philosophy of medicine
EDAT- 2021/02/03 06:00
MHDA- 2021/08/31 06:00
CRDT- 2021/02/02 17:14
PHST- 2021/02/02 17:14 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
AID - 105213 [pii]
AID - 10.12740/PP/OnlineFirst/105213 [doi]
PST - ppublish
SO  - Psychiatr Pol. 2020 Oct 31;54(5):1025-1035. doi: 10.12740/PP/OnlineFirst/105213. 
      Epub 2020 Oct 31.


PMID- 33527111
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 1930-613X (Electronic)
IS  - 0026-4075 (Linking)
VI  - 185
IP  - 5-6
DP  - 2020 Jun 8
TI  - Strategic Orthopedic Evacuations to the Spanish Role 4 During a Decade
      (2009-2018).
PG  - e734-e741
LID - 10.1093/milmed/usz354 [doi]
AB  - INTRODUCTION: Casualty evacuation is a key point in medical support to military
      operations, sometimes being necessary to transfer them to National Territory for 
      a definitive diagnosis and treatment. The aim of this work is to analyze the
      patients evacuated from Areas of Operations to the Orthopedic Surgery and
      Traumatology Unit of the Spanish Role 4 Medical Treatment Facility in the last 10
      years. MATERIAL AND METHODS: A cross-sectional, descriptive, and retrospective
      study carried out in the period between January 1, 2009 and December 31, 2018.
      The study population was all personnel evacuated from the Area of Operations to
      Spanish Role 4. For categorical variables, absolute and relative percent
      frequencies were used. Spanish military authorization was obtained to perform
      this study. This study has been approved by the Ethics and Clinical Research
      Committee of the Defense Central Hospital "Gomez Ulla" (code 12/17). RESULTS: A
      total of 520 medical evacuations have been performed on Role 4, of which 227 were
      on the Orthopedic Surgery and Traumatology Unit. Seven percent of the evacuees
      were categorized as "combat" casualties. The areas of operations from which more 
      patients have been evacuated were Afghanistan and Lebanon, 30.39% and 19.38%,
      respectively. The most frequent lesion pattern was the fracture affecting the
      extremities. Accidents (n = 98, 43.17%) and sport (n = 57; 25.3%) were the main
      causes of injury. Sixty-seven (29.51%) patients were treated surgically in Role
      4. No deaths were recorded among patients in this series. CONCLUSION: Evacuations
      because of trauma cause more than half of the medical repatriations carried out
      on the National Territory, of which the majority are due to fractures affecting
      the limbs, especially the bones of the hand. Sport was the first preventable
      cause of injury among evacuated patients. Our results are similar to the
      experience obtained by other allied armed forces. It is a moral imperative and a 
      fundamental necessity for the Spanish military medical services to promote and
      maintain the Spanish Role 4 Medical Treatment Facility as an indispensable
      element in medical support for international missions.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the
      Association of Military Surgeons of the United States. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Canas, Rafael Garcia
AU  - Canas RG
AD  - Orthopedic Surgery and Traumatology Unit, Defense Central Hospital "Gomez Ulla", 
      Glorieta del Ejercito 1. 28047, Madrid, Spain.
FAU - Suay, Ricardo Navarro
AU  - Suay RN
AD  - Anesthesiology, Reanimation and Pain Treatment Unit, Defense Central Hospital
      "Gomez Ulla", Glorieta del Ejercito 1. 28047, Madrid, Spain.
FAU - Moro, Carlos Rodriguez
AU  - Moro CR
AD  - Orthopedic Surgery and Traumatology Unit, Defense Central Hospital "Gomez Ulla", 
      Glorieta del Ejercito 1. 28047, Madrid, Spain.
FAU - Martin, Daniel Aedo
AU  - Martin DA
AD  - Orthopedic Surgery and Traumatology Unit, University Hospital del Henares, Av. de
      Marie Curie, 0, 28822 Coslada, Madrid, Spain.
FAU - Bariain, Rafael Tamburri
AU  - Bariain RT
AD  - Medical Services of the Spanish Royal Guard, Guardia Real espanola. Paseo del
      Pardo, 43, 28048 El Pardo, Madrid, Spain.
FAU - Jimenez, Javier Areta
AU  - Jimenez JA
AD  - Orthopedic Surgery and Traumatology Unit, Defense Central Hospital "Gomez Ulla", 
      Glorieta del Ejercito 1. 28047, Madrid, Spain.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
SB  - IM
MH  - Accidents
MH  - Adult
MH  - Afghan Campaign 2001-
MH  - Afghanistan
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Military Medicine
MH  - *Military Personnel
MH  - *Orthopedics
MH  - Retrospective Studies
MH  - *Wounds and Injuries/therapy
EDAT- 2021/02/03 06:00
MHDA- 2021/03/06 06:00
CRDT- 2021/02/02 06:11
PHST- 2021/02/02 06:11 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - 5610396 [pii]
AID - 10.1093/milmed/usz354 [doi]
PST - ppublish
SO  - Mil Med. 2020 Jun 8;185(5-6):e734-e741. doi: 10.1093/milmed/usz354.


PMID- 33525297
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20220716
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 4
DP  - 2020 Oct 7
TI  - Study, conservation and exhibition of human remains: the need of a bioethical
      perspective.
PG  - e2020110
LID - 10.23750/abm.v91i4.9674 [doi]
AB  - Today, the recovery, study and exposition of archaeological human remains are
      subjected to new discussions. Human remains preserve a clear record of past life 
      to later generations. These remains, even if dated hundreds or thousands of years
      ago, maintain their human dignity and force the community to reflect on the
      ethical issues related to their analysis, curation and display. Such a topic
      stimulate a continuous dialogue between the different actors of the
      bioarchaeological/osteoarchaeological/anthropological (physical and forensic)
      field: archaeologists, anthropologists, bioethicists, museum curators and other
      figures in order to give voice to a broad range of approaches and identify shared
      paths on the management of human remains that respect human dignity and different
      cultural values of community. As a "culturally sensitive material", human remains
      collections must be acquired and handled with respect regardless of their age and
      legitimacy of provenance. The opening up to disciplines quite far from the
      expertize of museum curators is an essential prerequisite to increase awareness
      towards ethical issues and to develop guidelines that take into account the
      dignity of the person and the cultural values of community to whom human remains 
      belonged. Accordingly, the authors stimulate the increase of the discussion and
      try to identify solutions sensitive to the issue.
FAU - Licata, Marta
AU  - Licata M
AD  - . marta.licata@uninsubria.it.
FAU - Bonsignore, Alessandro
AU  - Bonsignore A
AD  - . alessandro.bonsignore@unige.it.
FAU - Boano, Rosa
AU  - Boano R
AD  - . rosa.boano@unito.it.
FAU - Monza, Francesca
AU  - Monza F
AD  - . francesca.monza@unich.it.
FAU - Fulcheri, Ezio
AU  - Fulcheri E
AD  - . ezio.fulcheri@unige.it.
FAU - Ciliberti, Rosagemma
AU  - Ciliberti R
AD  - . rosellaciliberti@yahoo.it.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - *Anthropology
MH  - *Body Remains
MH  - Humans
MH  - Museums
PMC - PMC7927479
EDAT- 2021/02/03 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/02/02 01:03
PHST- 2020/05/01 00:00 [received]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2021/02/02 01:03 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.23750/abm.v91i4.9674 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Oct 7;91(4):e2020110. doi: 10.23750/abm.v91i4.9674.


PMID- 33525278
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20220716
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 4
DP  - 2020 Nov 10
TI  - Pattern of pediatric skin disorders in Murtala Muhammad Specialist Hospital Kano,
      Nigeria.
PG  - e2020184
LID - 10.23750/abm.v91i4.8727 [doi]
AB  - BACKGROUND: Skin disorders are very common in children. Wide spectrum of skin
      disorders is seen among children. The spectrum of skin disorders seen in children
      vary from region to region. AIM OF THE WORK: The study is aimed to determine the 
      pattern of skin disorders among children in Pediatric dermatology clinic of
      Murtala Muhammad Specialist Hospital, Kano, Nigeria. Methods: It was a
      descriptive cross-sectional study. Subjects were consecutively recruited. Using a
      semi-structured questionnaire, demographic history of the subjects and history of
      skin disorders were obtained from all the subjects and detailed physical
      examination was carried out with particular emphasis on skin lesion examination
      after obtaining an informed consent. Ethical clearance was obtained from Ethical 
      committee of the hospital. Data obtained was analyzed using SPSS version 24.
      RESULTS: A total of 338 subjects were recruited. One hundred and seventy-three
      (51.2%) were males and 165 (48.8%) were females. There were 35 specific types of 
      skin disorders observed. Infections and infestations were the commonest category 
      of skin disorders seen among 47% of the children followed by inflammatory skin
      disorders observed among 36.9% of the subjects. Tinea capitis was the commonest
      type of skin disorder observed among 15.5% of the subjects followed by atopic
      eczema (13.0%). Tinea capitis was significantly commoner among male children aged
      6-10 years (p<0.01) and Miliaria was significantly commoner among children aged
      less than 2years (p=0.04). CONCLUSION: Wide spectrum of skin disorders was seen
      among children in this environment and infections and infestations were the
      commonest category of skin disorders seen.
FAU - Yahya, Aishatu
AU  - Yahya A
AD  - Array. aishayahya35@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - Nigeria/epidemiology
MH  - *Skin Diseases/epidemiology
PMC - PMC7927560
EDAT- 2021/02/03 06:00
MHDA- 2021/06/24 06:00
CRDT- 2021/02/02 01:03
PHST- 2019/07/29 00:00 [received]
PHST- 2019/11/24 00:00 [accepted]
PHST- 2021/02/02 01:03 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
AID - 10.23750/abm.v91i4.8727 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Nov 10;91(4):e2020184. doi: 10.23750/abm.v91i4.8727.


PMID- 33525236
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20220716
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 4
DP  - 2020 Nov 10
TI  - Triage protocol for allocation of critical health resources during Covid-19
      pandemic and public health emergencies. A narrative review.
PG  - e2020162
LID - 10.23750/abm.v91i4.10393 [doi]
AB  - BACKGROUND AND AIM OF THE WORK: Triage during the Covid-19 pandemic can impose
      difficult allocation decisions when demand for mechanical ventilation or
      intensive care beds greatly exceeds available resources. Triage criteria should
      be objective, ethical, transparent, applied equitably and publically disclosed.
      The aim of this review is to describe the triage tools and process for critical
      care resources in a pandemic health emergency. METHODS: A narrative review was
      conducted of the literature on five electronic databases, namely PubMed, CINHAL, 
      Web of Science, Cochrane and Embase, searching for studies published from 2006 to
      June 2020. RESULTS: The results describe different triage tools. A gold standard 
      of triage does not exist for the adult or paediatric population. Using
      probability of short-term survival as the sole allocation principle is
      problematic. In general, each triage protocol should be applied with a specific
      ethical justification, including transparency, duty to care, duty to steward
      resources, duty to plan, and distributive justice. CONCLUSIONS: Clinical triage
      decisions based on clinical judgment alone are prone to inconsistent application 
      by triage officers in a pandemic. An ethical framework can inform decision-making
      and improve accountability. It remains difficult to connect clinical criteria and
      ethical criteria, because of the models on offer for health services.
FAU - Iacorossi, Laura
AU  - Iacorossi L
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      laura.iacorossi@iss.it.
FAU - Fauci, Alice J
AU  - Fauci AJ
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      alice.fauci@iss.it.
FAU - Napoletano, Antonello
AU  - Napoletano A
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      antonello.napoletano@iss.it.
FAU - D'Angelo, Daniela
AU  - D'Angelo D
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      daniela.dangelo@iss.it.
FAU - Salomone, Katia
AU  - Salomone K
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      katia.salomone@iss.it.
FAU - Latina, Roberto
AU  - Latina R
AD  - Array. roblatina@gmail.com.
FAU - Coclite, Daniela
AU  - Coclite D
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      daniela.coclite@iss.it.
FAU - Iannone, Primiano
AU  - Iannone P
AD  - National Center for Clinical Excellence, Quality and Safety of Care (CNEC),
      Istituto Superiore di Sanita, Via Giano della Bella, 34, 00162 Rome, Italy.
      primiano.iannone@iss.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201110
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - *COVID-19/therapy
MH  - *Critical Care
MH  - Emergencies
MH  - Humans
MH  - Public Health
MH  - Resource Allocation/*standards
MH  - Triage/ethics/*standards
PMC - PMC7927504
EDAT- 2021/02/03 06:00
MHDA- 2021/03/09 06:00
CRDT- 2021/02/02 01:03
PHST- 2020/08/03 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2021/02/02 01:03 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - 10.23750/abm.v91i4.10393 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Nov 10;91(4):e2020162. doi: 10.23750/abm.v91i4.10393.


PMID- 33525224
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 4
DP  - 2020 Nov 10
TI  - Medicine and humanism in the time of COVID-19. Ethical choices.
PG  - e2020167
LID - 10.23750/abm.v91i4.10569 [doi]
AB  - The Covid-19 pandemic has been the most defining event of our era. The world of
      healthcare has experienced first-hand the dramatic situation of treating patients
      in the face of the dangers of contagion and limited resources. Difficult choices 
      have everywhere been made alongside ethical reflection. Now that, at least in our
      part of the world, viral infection seems to be broadly on the decline, there is
      an urgent need for fresh, anthropological, ethical reflection. It is important to
      avoid being unprepared in the event of further occasions, but above all, to now
      think in global terms. This is because the pandemic has forced us to recognise
      the urgency of building alliance in healthcare and a balanced relationship with
      the environment.
FAU - Doldi, Marco
AU  - Doldi M
AD  - Facolta Teologica dell'Italia Settentrionale, Sezione di Genova, Genoa, Italy.
      dm.doldi@gmail.com.
FAU - Moscatelli, Andrea
AU  - Moscatelli A
AD  - IRCCS Istituto Giannina Gaslini, Centro di Terapia intensiva Neonatale e
      Pediatrica, Dipartimento Integrato di Alta Intensita di Cura e Chirurgia, Genoa, 
      Italy. andreamoscatelli@gaslini.org.
FAU - Ravelli, Angelo
AU  - Ravelli A
AD  - IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, and
      Universita degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione,
      Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy..
      angeloravelli@gaslini.org.
FAU - Spiazzi, Raffaele
AU  - Spiazzi R
AD  - IRCCS Istituto Giannina Gaslini, Direzione Sanitaria, Genoa, Italy.
      raffaelespiazzi@gaslini.org.
FAU - Petralia, Paolo
AU  - Petralia P
AD  - IRCCS Istituto Giannina Gaslini, Direzione Generale, Genoa, Italy.
      paolopetralia@gaslini.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201110
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - Bioethical Issues
MH  - *COVID-19
MH  - *Ethics, Medical
MH  - Forecasting
MH  - *Humanism
MH  - Humans
PMC - PMC7927485
EDAT- 2021/02/03 06:00
MHDA- 2021/03/09 06:00
CRDT- 2021/02/02 01:02
PHST- 2020/09/07 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2021/02/02 01:02 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - 10.23750/abm.v91i4.10569 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Nov 10;91(4):e2020167. doi: 10.23750/abm.v91i4.10569.


PMID- 33523713
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 0261-1929 (Print)
IS  - 0261-1929 (Linking)
VI  - 48
IP  - 5-6
DP  - 2020 Sep-Nov
TI  - The Implementation of the Three Rs in Regulatory Toxicity and Biosafety
      Assessment: The Indian Perspective.
PG  - 234-251
LID - 10.1177/0261192920986811 [doi]
AB  - Animal models have long served as a basis for scientific experimentation,
      biomedical research, drug development and testing, disease modelling and toxicity
      studies, as they are widely thought to provide meaningful, human-relevant
      predictions. However, many of these systems are resource intensive and
      time-consuming, have low predictive value and are associated with great social
      and ethical dilemmas. Often drugs appear to be effective and safe in these
      classical animal models, but later prove to be ineffective and/or unsafe in
      clinical trials. These issues have paved the way for a paradigm shift from the
      use of in vivo approaches, toward the 'science of alternatives'. This has fuelled
      several research and regulatory initiatives, including the ban on the testing of 
      cosmetics on animals. The new paradigm has been shifted toward increasing the
      relevance of the models for human predictivity and translational efficacy, and
      this has resulted in the recent development of many new methodologies, from 3-D
      bio-organoids to bioengineered 'human-on-a-chip' models. These improvements have 
      the potential to significantly advance medical research globally. This paper
      offers a stance on the existing strategies and practices that utilise
      alternatives to animals, and outlines progress on the incorporation of these
      models into basic and applied research and education, specifically in India. It
      also seeks to provide a strategic roadmap to streamline the future directions for
      the country's policy changes and investments. This strategic roadmap could be a
      useful resource to guide research institutions, industries, regulatory agencies, 
      contract research organisations and other stakeholders in transitioning toward
      modern approaches to safety and risk assessment that could replace or reduce the 
      use of animals without compromising the safety of humans or the environment.
FAU - Pant, Aditya B
AU  - Pant AB
AD  - System Toxicology and Health Risk Assessment Group, 538266Council of Scientific
      and Industrial Research-Indian Institute of Toxicology Research (CSIR-IITR),
      Lucknow, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20210201
PL  - England
TA  - Altern Lab Anim
JT  - Alternatives to laboratory animals : ATLA
JID - 8110074
SB  - IM
MH  - *Animal Testing Alternatives
MH  - Animals
MH  - Containment of Biohazards
MH  - India
MH  - Models, Animal
MH  - Toxicity Tests
OTO - NOTNLM
OT  - 3Rs
OT  - animal alternatives
OT  - experimental models
OT  - in vitro toxicity testing
OT  - regulatory toxicology
EDAT- 2021/02/02 06:00
MHDA- 2021/03/02 06:00
CRDT- 2021/02/01 17:10
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2021/02/01 17:10 [entrez]
AID - 10.1177/0261192920986811 [doi]
PST - ppublish
SO  - Altern Lab Anim. 2020 Sep-Nov;48(5-6):234-251. doi: 10.1177/0261192920986811.
      Epub 2021 Feb 1.


PMID- 33521761
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210924
IS  - 2666-6758 (Electronic)
IS  - 2666-6758 (Linking)
VI  - 1
IP  - 2
DP  - 2020 Aug 28
TI  - Patients' Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation.
PG  - 100028
LID - 10.1016/j.xinn.2020.100028 [doi]
AB  - Since the outbreak of COVID-19, many randomized controlled trials have been
      launched to test the efficacy of promising treatments. These trials will offer
      great promise for future treatment. However, a public health emergency calls for 
      a balance between gathering sound evidence and granting therapeutic access to
      promising trial drugs as widely as possible. In an electronic survey, we found
      that 3.9% of the participants preferred to receive an unproven trial drug
      directly in the hypothetical scenario of mild COVID-19 infection. This percentage
      increased drastically to 31.1% and 54.2% in the hypothetical scenario of severe
      and extremely severe infection, respectively. Our survey indicates a likelihood
      of substantial receptivity of trial drugs among actual patients in severe
      conditions. From the perspective of deontological ethics, a trial can only be
      approved when potential benefits of the investigational treatment are presumed to
      outweigh risks, so compassionate or off-label use of investigational therapies
      merits evaluation.
CI  - (c) 2020.
FAU - Li, Hong-Tian
AU  - Li HT
AD  - Institute of Reproductive and Child Health, National Health Commission Key
      Laboratory of Reproductive Health, Peking University Health Science Center, No
      38, Xueyuan Road, Haidian District, Beijing 100191, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Cheng, Zhi-Hao
AU  - Cheng ZH
AD  - Institute of Reproductive and Child Health, National Health Commission Key
      Laboratory of Reproductive Health, Peking University Health Science Center, No
      38, Xueyuan Road, Haidian District, Beijing 100191, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Huang, Yong-Ying
AU  - Huang YY
AD  - Institute of Reproductive and Child Health, National Health Commission Key
      Laboratory of Reproductive Health, Peking University Health Science Center, No
      38, Xueyuan Road, Haidian District, Beijing 100191, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Lv, Xi-Lin
AU  - Lv XL
AD  - Institute of Reproductive and Child Health, National Health Commission Key
      Laboratory of Reproductive Health, Peking University Health Science Center, No
      38, Xueyuan Road, Haidian District, Beijing 100191, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Zhou, Yu-Bo
AU  - Zhou YB
AD  - Institute of Reproductive and Child Health, National Health Commission Key
      Laboratory of Reproductive Health, Peking University Health Science Center, No
      38, Xueyuan Road, Haidian District, Beijing 100191, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University Health Science Center, Beijing 100191, China.
FAU - Dong, Erdan
AU  - Dong E
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University
      Third Hospital, Beijing 100191, China.
AD  - National Health Commission Key Laboratory of Cardiovascular Molecular Biology and
      Regulatory Peptides, Peking University Third Hospital, Beijing 100191, China.
AD  - Key Laboratory of Molecular Cardiovascular Science, Ministry of Education,
      Beijing 100191, China.
AD  - Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University
      Third Hospital, Beijing 100191, China.
FAU - Liu, Jian-Meng
AU  - Liu JM
AD  - Institute of Reproductive and Child Health, National Health Commission Key
      Laboratory of Reproductive Health, Peking University Health Science Center, No
      38, Xueyuan Road, Haidian District, Beijing 100191, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University Health Science Center, Beijing 100191, China.
LA  - eng
PT  - News
DEP - 20200731
PL  - United States
TA  - Innovation (Camb)
JT  - Innovation (Cambridge (Mass.))
JID - 101771342
EIN - Innovation (N Y). 2020 Nov 25;1(3):100046. PMID: 33016958
PMC - PMC7836536
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:03
PHST- 2021/02/01 06:03 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.1016/j.xinn.2020.100028 [doi]
AID - S2666-6758(20)30028-X [pii]
PST - ppublish
SO  - Innovation (Camb). 2020 Aug 28;1(2):100028. doi: 10.1016/j.xinn.2020.100028. Epub
      2020 Jul 31.


PMID- 33521539
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2516-5542 (Electronic)
IS  - 2516-5542 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Dec
TI  - Perfluoroalkyl substances (PFASs) and mercury in never-pregnant women of fertile 
      age: association with fish consumption and unfavorable lipid profile.
PG  - 277-284
LID - 10.1136/bmjnph-2020-000131 [doi]
AB  - OBJECTIVES: To examine concentrations of perfluoroalkyl substances (PFASs) and
      lifestyle factors that may contribute to higher levels of pollutants in
      never-pregnant women of fertile age. DESIGN: Observational cross-sectional study.
      SETTING: Participants were recruited among employees and students at Haukeland
      University Hospital and the University of Bergen, Norway. PARTICIPANTS: Healthy, 
      never-pregnant Norwegian women (n=158) of fertile age (18-39 years). OUTCOMES:
      Concentrations of 20 different PFASs, mercury (Hg), lead, cadmium, total,
      high-density lipoprotein and low-density lipoprotein (LDL) cholesterol, in
      addition to self-reported data on dietary intake. RESULTS: Seven PFASs were
      detected in more than 95% of the women. Women aged 30-39 years had higher
      concentrations of sum PFAS compared with younger women. Serum PFASs were
      significantly intercorrelated (rho: 0.34-0.98, p<0.001) and six of them were
      significantly correlated to whole blood Hg (rho: 0.21-0.74, p<0.01). Fish
      consumption was the strongest predictor for most serum PFASs and for whole blood 
      Hg. Fish consumption and serum perfluorooctanesulfonic acid (PFOS) concentrations
      were both positively associated with serum total and LDL cholesterol, established
      risk factors for cardiovascular disease. CONCLUSIONS: The majority of Norwegian
      never-pregnant women of fertile age had a mixture of seven different PFASs and Hg
      detected in their blood. PFAS concentrations were higher in older women and
      associated with fish intake. As the mean age of women at first birth is
      increasing, several factors require further consideration including diet, as this
      may influence the burden of PFAS to the next generation. TRIAL REGISTRATION
      NUMBER: ClinicalTrials.gov ID: NCT03272022, Unique Protocol ID: 2011/2447,
      Regional Committee for Medical Research Ethics West (2011/2447), 12 January 2012.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bjorke-Monsen, Anne-Lise
AU  - Bjorke-Monsen AL
AUID- ORCID: 0000-0002-9232-2503
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway.
AD  - Department of Medical Biochemistry and Pharmacology, Haukeland University
      Hospital, Bergen, Norway.
FAU - Varsi, Kristin
AU  - Varsi K
AD  - Department of Medical Biochemistry and Pharmacology, Haukeland University
      Hospital, Bergen, Norway.
FAU - Averina, Maria
AU  - Averina M
AD  - Department of Laboratory Medicine, University Hospital of North Norway, Tromso,
      Norway.
AD  - Department of Community Medicine, UiT The Arctic University of Norway, Tromso,
      Norway.
FAU - Brox, Jan
AU  - Brox J
AD  - Department of Laboratory Medicine, University Hospital of North Norway, Tromso,
      Norway.
AD  - Department of Community Medicine, UiT The Arctic University of Norway, Tromso,
      Norway.
FAU - Huber, Sandra
AU  - Huber S
AD  - Department of Laboratory Medicine, University Hospital of North Norway, Tromso,
      Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT03272022
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - BMJ Nutr Prev Health
JT  - BMJ nutrition, prevention & health
JID - 101769223
PMC - PMC7841832
OTO - NOTNLM
OT  - dietary patterns
COIS- Competing interests: None declared.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:02
PHST- 2020/06/22 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2021/02/01 06:02 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.1136/bmjnph-2020-000131 [doi]
AID - bmjnph-2020-000131 [pii]
PST - epublish
SO  - BMJ Nutr Prev Health. 2020 Nov 4;3(2):277-284. doi: 10.1136/bmjnph-2020-000131.
      eCollection 2020 Dec.


PMID- 33521536
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2516-5542 (Electronic)
IS  - 2516-5542 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Dec
TI  - Responsibility for vitamin D supplementation of elderly care home residents in
      England: falling through the gap between medicine and food.
PG  - 256-262
LID - 10.1136/bmjnph-2020-000129 [doi]
AB  - INTRODUCTION: Daily vitamin D supplements are recommended for elderly care home
      residents; however, they are rarely given and vitamin D deficiency in care homes 
      is widespread. This study aimed to understand the determinants of current
      practice and perceived responsibility for the vitamin D status of residents.
      METHODS: Thirteen semi-structured interviews were conducted with key informants
      in two areas of Southern England including care home managers, general
      practitioners (GPs) and public health professionals. Interviews were audio
      recorded and transcribed verbatim. RESULTS: Inductive thematic analysis
      identified four themes: framing of vitamin D supplements as medicines;
      professional and sector boundaries whereby GPs are perceived as responsible for
      the vitamin D status of residents and care home managers felt unable to
      administer over-the-counter vitamin tablets; low awareness of national guidance; 
      and ethical and practical issues. This results in vitamin D supplements requiring
      prescription by medical professionals and few residents receiving them.
      CONCLUSION: The medical framing of vitamin D supplements in care homes is a
      practical barrier to implementation of longstanding nutrition guidelines. A
      paradigm shift is needed so that vitamin D is understood as a protective nutrient
      as well as a medicine, and a public health as well as a medical responsibility.
      Vitamin D is important for musculoskeletal health. Possible links with COVID-19
      are still being investigated. The pandemic has drawn attention to conditions in
      care homes and there is an opportunity to revise current guidance on vitamin D
      supplementation which will have lasting benefit for this vulnerable group.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Williams, Joseph
AU  - Williams J
AD  - Department of Medical Education, Brighton and Sussex Medical School, Brighton,
      UK.
FAU - Williams, Carol
AU  - Williams C
AUID- ORCID: 0000-0003-1735-2523
AD  - School of Health Sciences, University of Brighton, Brighton, UK.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - England
TA  - BMJ Nutr Prev Health
JT  - BMJ nutrition, prevention & health
JID - 101769223
PMC - PMC7841808
OTO - NOTNLM
OT  - malnutrition
OT  - nutrient deficiencies
COIS- Competing interests: None declared.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:02
PHST- 2020/06/21 00:00 [received]
PHST- 2020/08/16 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2021/02/01 06:02 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.1136/bmjnph-2020-000129 [doi]
AID - bmjnph-2020-000129 [pii]
PST - epublish
SO  - BMJ Nutr Prev Health. 2020 Oct 12;3(2):256-262. doi: 10.1136/bmjnph-2020-000129. 
      eCollection 2020 Dec.


PMID- 33521064
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 2297-055X (Print)
IS  - 2297-055X (Linking)
VI  - 7
DP  - 2020
TI  - Ethical Challenges With Smartwatch-Based Screening for Atrial Fibrillation:
      Putting Users at Risk for Marketing Purposes?
PG  - 615927
LID - 10.3389/fcvm.2020.615927 [doi]
AB  - Background: Atrial fibrillation is the most common persistent arrhythmia. It is
      associated with increased mortality and morbidity such as stroke. The early
      detection of atrial fibrillation can significantly reduce the risk of stroke
      through preventive anticoagulation. Smartwatches offer the opportunity to screen 
      for atrial fibrillation in the general population. This paper aims to analyze the
      ethical challenges associated with screening for atrial fibrillation using
      smartwatches. Methods: This is an ethical analysis. The methodology is based on
      the principle-orientated approach of Beauchamp and Childress. The principles of
      beneficence, non-maleficence, justice, and autonomy have to be guaranteed given
      the influence of private companies, privacy protection, liability and
      doctor-patient-relationship. The work is based on a systematic literature
      research. Results: There is currently no evidence that screening for atrial
      fibrillation with smartwatches improves the outcome and reduces the number of
      adverse events. The high number of false-positive results can lead to harm. The
      principle of non-maleficence is violated. The over-reliance on and the lack of
      adequate education by smartwatches can worsen the doctor-patient relationship.
      However, the relationship can also be improved by the proactive participation of 
      the patient, which leads to greater autonomy, compliance and in the end
      beneficence. Since smartwatches are consumer goods, there is a risk for greater
      disparities in the poor and rich population. There is also a risk of
      discrimination against ethnic minorities due to underrepresentation in training
      data and study cohorts. The principle of justice is violated. The storage of
      sensitive medical data by private companies also raises many ethical and legal
      concerns. Conclusion: This analysis has shown that the use of smartwatches to
      detect atrial fibrillation is currently in an ethical perspective problematic.
      The lack of evidence and the high number of false-positive results can lead to
      harm. As smartwatches provide only little information about the possible
      consequences, informed consent cannot be assumed. Ethical implementation could be
      archived if doctors provide smartwatches to patients who have been shown to
      benefit from them. The implementation and education should be managed by the
      doctor.
CI  - Copyright (c) 2021 Predel and Steger.
FAU - Predel, Christopher
AU  - Predel C
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University, Ulm,
      Germany.
FAU - Steger, Florian
AU  - Steger F
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University, Ulm,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20210115
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC7843431
OTO - NOTNLM
OT  - artificial intelligence
OT  - atrial fibrillation
OT  - autonomy
OT  - ethics
OT  - justice
OT  - smartwatch
OT  - wearable
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:00
PHST- 2020/10/10 00:00 [received]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2021/02/01 06:00 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fcvm.2020.615927 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Jan 15;7:615927. doi: 10.3389/fcvm.2020.615927.
      eCollection 2020.


PMID- 33521054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 2296-889X (Print)
IS  - 2296-889X (Linking)
VI  - 7
DP  - 2020
TI  - Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint
      Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory
      Hepatocellular Carcinoma: A Retrospective Study.
PG  - 609322
LID - 10.3389/fmolb.2020.609322 [doi]
AB  - Purpose: The study aims to retrospectively investigate the efficacy and safety of
      sorafenib combined with transarterial chemoembolization (TACE) (TACE+Sor) vs.
      TACE combined with sorafenib plus immune checkpoint inhibitors (TACE+Sor+ICIs) in
      treating intermediate and advanced TACE-refractory hepatocellular carcinoma
      (HCC). Materials and Methods: This study was approved by the ethics committee of 
      Lisui Hospital, Zhejiang University, China. From January 2016 to June 2020, 51
      eligible patients with intermediate or advanced TACE-refractory HCC received
      TACE+Sor (n = 29) or TACE+Sor+ICIs (n = 22). The differences in tumor response,
      adverse events (AEs), progression-free survival (PFS), and overall survival (OS) 
      were compared between the two groups. Factors affecting PFS and OS were
      determined by Cox regression. Results: The disease control rate was higher in the
      TACE+Sor+ICIs group than in the TACE+Sor group (81.82 vs. 55.17%, P = 0.046).
      Compared with the TACE+Sor group, PFS and OS were prolonged in the TACE+Sor+ICIs 
      group (median PFS: 16.26 vs. 7.30 months, P < 0.001; median OS: 23.3 vs. 13.8
      months, P = 0.012). Multivariate analysis showed that BCLC stage,
      alpha-fetoprotein and treatment were independent factors of PFS; BCLC, Child-Pugh
      class, ablation after disease progression and treatment were independent
      predictive factors of OS. Four patients in the TACE+Sor+ICIs group and three
      patients in the TACE+Sor group suffered from dose reduction or interruption
      (18.18 vs. 10.34%, P = 0.421). The incidence of ICI-related AEs in the
      TACE+Sor+ICIs group was well-controlled. Conclusion: The therapeutic schedule of 
      TACE+Sor+ICIs demonstrated efficacy and safety in intermediate and advanced
      TACE-refractory HCC.
CI  - Copyright (c) 2021 Zheng, Fang, Wu, Chen, Chen, Weng, Wu, Song, Zhao and Ji.
FAU - Zheng, Liyun
AU  - Zheng L
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Fang, Shiji
AU  - Fang S
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Wu, Fazong
AU  - Wu F
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Chen, Weiqian
AU  - Chen W
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Chen, Minjiang
AU  - Chen M
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Weng, Qiaoyou
AU  - Weng Q
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Wu, Xulu
AU  - Wu X
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Song, Jingjing
AU  - Song J
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Zhao, Zhongwei
AU  - Zhao Z
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Ji, Jiansong
AU  - Ji J
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
LA  - eng
PT  - Journal Article
DEP - 20210115
PL  - Switzerland
TA  - Front Mol Biosci
JT  - Frontiers in molecular biosciences
JID - 101653173
PMC - PMC7843459
OTO - NOTNLM
OT  - TACE-refractory
OT  - adverse events
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
OT  - overall survival
OT  - progression-free survival
OT  - sorafenib
OT  - transarterial chemoembolization
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:00
PHST- 2020/09/23 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/02/01 06:00 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fmolb.2020.609322 [doi]
PST - epublish
SO  - Front Mol Biosci. 2021 Jan 15;7:609322. doi: 10.3389/fmolb.2020.609322.
      eCollection 2020.


PMID- 33521023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Allocation of the "Already" Limited Medical Resources Amid the COVID-19 Pandemic,
      an Iterative Ethical Encounter Including Suggested Solutions From a Real Life
      Encounter.
PG  - 616277
LID - 10.3389/fmed.2020.616277 [doi]
AB  - The shortage of healthcare providers is well-documented in low-income countries
      (LIC) prior to COVID-19, due to various causes including the migration to
      developed countries, scarcity of supplies, poor healthcare infrastructure,
      limited ICU facilities, and lack of access to guidelines and protocols. One of
      the important hitches in LIC is the insufficient testing capacity that precluded 
      accurate assessment of disease burden and subsequently resource allocations.
      Trying to adhere to the principles of bioethics including respect to others,
      beneficence, and justice should be applied on the ground in the particular
      setting of the LIC. Solutions should be tailored to the tangible needs and
      possibility of implementation in real life in the face of the "already" limited
      resources by making use of simple, yet plausible, measures. Implementing
      guidelines and frameworks that were set to work in the better-resourced nations
      is a call for futility. The adoption of novel solutions to overcome the unique
      challenges in the LIC is exigent. These include the use of automated screening
      algorithms and virtual video clinics. Moreover, integrating electronic intensive 
      care unit (e-ICU) software may allow for remote monitoring of multiple patients
      simultaneously. Telemedicine could help in getting consultations worldwide. It
      can also enhance healthcare workers' knowledge and introduce new skills through
      teleconferences, e-workshops, and free webinars. Healthcare workers can be
      remotely trained to enhance their skills. Agencies, such as the WHO, should
      develop comprehensive programs to tackle different health issues in LIC in
      collaboration with major institutions and experts around the world.
CI  - Copyright (c) 2021 Alhalaseh, Elshabrawy, Erashdi, Shahait, Abu-Humdan and
      Al-Hussaini.
FAU - Alhalaseh, Yazan Nedal
AU  - Alhalaseh YN
AD  - Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
FAU - Elshabrawy, Hatem A
AU  - Elshabrawy HA
AD  - Department of Molecular and Cellular Biology, College of Osteopathic Medicine,
      Sam Houston State University, Conroe, TX, United States.
FAU - Erashdi, Madiha
AU  - Erashdi M
AD  - Department of Pathology and Laboratory Medicine, King Hussein Cancer Center,
      Amman, Jordan.
FAU - Shahait, Mohammed
AU  - Shahait M
AD  - Department of Surgery, King Hussein Cancer Center, Amman, Jordan.
FAU - Abu-Humdan, Abdulrahman Mohammad
AU  - Abu-Humdan AM
AD  - Independent Researcher, Amman, Jordan.
FAU - Al-Hussaini, Maysa
AU  - Al-Hussaini M
AD  - Department of Pathology and Laboratory Medicine, King Hussein Cancer Center,
      Amman, Jordan.
AD  - Human Research Protection Program Office, King Hussein Cancer Center, Amman,
      Jordan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210114
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7840687
OTO - NOTNLM
OT  - COVID-19
OT  - challenges
OT  - low-income countries
OT  - resources
OT  - solutions
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:00
PHST- 2020/10/11 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/02/01 06:00 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fmed.2020.616277 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Jan 14;7:616277. doi: 10.3389/fmed.2020.616277.
      eCollection 2020.


PMID- 33520956
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Comparative Analysis of Mesenchymal Stem Cell Cultivation in Fetal Calf Serum,
      Human Serum, and Platelet Lysate in 2D and 3D Systems.
PG  - 598389
LID - 10.3389/fbioe.2020.598389 [doi]
AB  - In vitro two-dimensional (2D) and three-dimensional (3D) cultivation of mammalian
      cells requires supplementation with serum. Mesenchymal stem cells (MSCs) are
      widely used in clinical trials for bioregenerative medicine and in most cases, in
      vitro expansion and differentiation of these cells are required before
      application. Optimized expansion and differentiation protocols play a key role in
      the treatment outcome. 3D cell cultivation systems are more comparable to in vivo
      conditions and can provide both, more physiological MSC expansion and a better
      understanding of intercellular and cell-matrix interactions. Xeno-free
      cultivation conditions minimize risks of immune response after implantation.
      Human platelet lysate (hPL) appears to be a valuable alternative to widely used
      fetal calf serum (FCS) since no ethical issues are associated with its harvest,
      it contains a high concentration of growth factors and cytokines and it can be
      produced from expired platelet concentrate. In this study, we analyzed and
      compared proliferation, as well as osteogenic and chondrogenic differentiation of
      human adipose tissue-derived MSCs (hAD-MSC) using three different supplements:
      FCS, human serum (HS), and hPL in 2D. Furthermore, online monitoring of
      osteogenic differentiation under the influence of different supplements was
      performed in 2D. hPL-cultivated MSCs exhibited a higher proliferation and
      differentiation rate compared to HS- or FCS-cultivated cells. We demonstrated a
      fast and successful chondrogenic differentiation in the 2D system with the
      addition of hPL. Additionally, FCS, HS, and hPL were used to formulate
      Gelatin-methacryloyl (GelMA) hydrogels in order to evaluate the influence of the 
      different supplements on the cell spreading and proliferation of cells growing in
      3D culture. In addition, the hydrogel constructs were cultivated in media
      supplemented with three different supplements. In comparison to FCS and HS, the
      addition of hPL to GelMA hydrogels during the encapsulation of hAD-MSCs resulted 
      in enhanced cell spreading and proliferation. This effect was promoted even
      further by cultivating the hydrogel constructs in hPL-supplemented media.
CI  - Copyright (c) 2021 Kirsch, Rach, Handke, Seltsam, Pepelanova, Strauss, Vogt,
      Scheper and Lavrentieva.
FAU - Kirsch, Marline
AU  - Kirsch M
AD  - Institute of Technical Chemistry, Leibniz University Hannover, Hanover, Germany.
FAU - Rach, Jessica
AU  - Rach J
AD  - German Red Cross Blood Service NSTOB, Institute Springe, Springe, Germany.
FAU - Handke, Wiebke
AU  - Handke W
AD  - Bavarian Red Cross Blood Service, Institute Nuremberg, Nuremberg, Germany.
FAU - Seltsam, Axel
AU  - Seltsam A
AD  - Bavarian Red Cross Blood Service, Institute Nuremberg, Nuremberg, Germany.
FAU - Pepelanova, Iliyana
AU  - Pepelanova I
AD  - Institute of Technical Chemistry, Leibniz University Hannover, Hanover, Germany.
FAU - Strauss, Sarah
AU  - Strauss S
AD  - Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover
      Medical School, Hanover, Germany.
FAU - Vogt, Peter
AU  - Vogt P
AD  - Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover
      Medical School, Hanover, Germany.
FAU - Scheper, Thomas
AU  - Scheper T
AD  - Institute of Technical Chemistry, Leibniz University Hannover, Hanover, Germany.
FAU - Lavrentieva, Antonina
AU  - Lavrentieva A
AD  - Institute of Technical Chemistry, Leibniz University Hannover, Hanover, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210115
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7844400
OTO - NOTNLM
OT  - differentiation
OT  - fetal calf serum
OT  - gelatin methacryloyl (GelMA)
OT  - human serum
OT  - hydrogel
OT  - medium supplements
OT  - mesenchymal stem cells
OT  - platelet lysate
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 06:00
PHST- 2020/08/24 00:00 [received]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2021/02/01 06:00 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fbioe.2020.598389 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2021 Jan 15;8:598389. doi: 10.3389/fbioe.2020.598389.
      eCollection 2020.


PMID- 33520918
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Face Masks During the COVID-19 Pandemic: A Simple Protection Tool With Many
      Meanings.
PG  - 606635
LID - 10.3389/fpubh.2020.606635 [doi]
AB  - Wearing face masks is recommended as part of personal protective equipment and as
      a public health measure to prevent the spread of coronavirus disease 2019
      (COVID-19) pandemic. Their use, however, is deeply connected to social and
      cultural practices and has acquired a variety of personal and social meanings.
      This article aims to identify the diversity of sociocultural, ethical, and
      political meanings attributed to face masks, how they might impact public health 
      policies, and how they should be considered in health communication. In May 2020,
      we involved 29 experts of an interdisciplinary research network on health and
      society to provide their testimonies on the use of face masks in 20 European and 
      2 Asian countries (China and South Korea). They reflected on regulations in the
      corresponding jurisdictions as well as the personal and social aspects of face
      mask wearing. We analyzed those testimonies thematically, employing the method of
      qualitative descriptive analysis. The analysis framed the four dimensions of the 
      societal and personal practices of wearing (or not wearing) face masks:
      individual perceptions of infection risk, personal interpretations of
      responsibility and solidarity, cultural traditions and religious imprinting, and 
      the need of expressing self-identity. Our study points to the importance for an
      in-depth understanding of the cultural and sociopolitical considerations around
      the personal and social meaning of mask wearing in different contexts as a
      necessary prerequisite for the assessment of the effectiveness of face masks as a
      public health measure. Improving the personal and collective understanding of
      citizens' behaviors and attitudes appears essential for designing more effective 
      health communications about COVID-19 pandemic or other global crises in the
      future. To wear a face mask or not to wear a face mask? Nowadays, this question
      has been analogous to the famous line from Shakespeare's Hamlet: "To be or not to
      be, that is the question." This is a bit allegorical, but certainly not far from 
      the current circumstances where a deadly virus is spreading amongst us... Vanja
      Kopilas, Croatia.
CI  - Copyright (c) 2021 Martinelli, Kopilas, Vidmar, Heavin, Machado, Todorovic,
      Buzas, Pot, Prainsack and Gajovic.
FAU - Martinelli, Lucia
AU  - Martinelli L
AD  - MUSE - Science Museum, Trento, Italy.
FAU - Kopilas, Vanja
AU  - Kopilas V
AD  - Faculty of Croatian Studies, University of Zagreb, Zagreb, Croatia.
AD  - Croatian Institute for Brain Research, University of Zagreb School of Medicine,
      Zagreb, Croatia.
FAU - Vidmar, Matjaz
AU  - Vidmar M
AD  - Institute for the Study of Science, Technology and Innovation, The University of 
      Edinburgh, Edinburgh, United Kingdom.
FAU - Heavin, Ciara
AU  - Heavin C
AD  - Business Information Systems, Cork University Business School, University College
      Cork, Cork, Ireland.
FAU - Machado, Helena
AU  - Machado H
AD  - Communication and Society Research Centre, University of Minho, Braga, Portugal.
FAU - Todorovic, Zoran
AU  - Todorovic Z
AD  - University Hospital Medical Center "Bezanijska kosa", and University of Belgrade 
      Faculty of Medicine, Belgrade, Serbia.
FAU - Buzas, Norbert
AU  - Buzas N
AD  - Department of Health Economics, Faculty of Medicine, University of Szeged,
      Szeged, Hungary.
FAU - Pot, Mirjam
AU  - Pot M
AD  - Department of Political Science, Centre for the Study of Contemporary Solidarity 
      (CeSCoS), University of Vienna, Vienna, Austria.
FAU - Prainsack, Barbara
AU  - Prainsack B
AD  - Department of Political Science, Centre for the Study of Contemporary Solidarity 
      (CeSCoS), University of Vienna, Vienna, Austria.
AD  - Department of Global Health & Social Medicine, King's College London, London,
      United Kingdom.
FAU - Gajovic, Srecko
AU  - Gajovic S
AD  - Croatian Institute for Brain Research, University of Zagreb School of Medicine,
      Zagreb, Croatia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210113
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Attitude to Health
MH  - COVID-19/*prevention & control/*psychology
MH  - Europe
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Masks/*statistics & numerical data
MH  - Middle Aged
MH  - Pandemics/*prevention & control
MH  - Personal Protective Equipment/*statistics & numerical data
MH  - *Public Opinion
MH  - SARS-CoV-2
PMC - PMC7838459
OTO - NOTNLM
OT  - *COVID-19
OT  - *face mask
OT  - *health communication
OT  - *personal protecting equipment
OT  - *physical distancing
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/13 06:00
CRDT- 2021/02/01 06:00
PHST- 2020/09/15 00:00 [received]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2021/02/01 06:00 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - 10.3389/fpubh.2020.606635 [doi]
PST - epublish
SO  - Front Public Health. 2021 Jan 13;8:606635. doi: 10.3389/fpubh.2020.606635.
      eCollection 2020.


PMID- 33520415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2163-0402 (Print)
IS  - 2163-0402 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Dec
TI  - Neurology clinicians' views on palliative care communication: "How do you frame
      this?"
PG  - 527-534
LID - 10.1212/CPJ.0000000000000794 [doi]
AB  - BACKGROUND: The communication process of preparing patients and families facing
      progressive neurodegenerative diseases for future illness has not been
      empirically elucidated; the goal of this qualitative study was to explore
      neurology interdisciplinary health professionals' communication experiences,
      including current approaches, facilitators, and challenges. METHODS: Three focus 
      groups were conducted with 22 clinicians representing a range of health
      professions from several multidisciplinary neurology outpatient clinics at a
      large academic medical center. A thematic analysis approach was used to develop a
      coding structure and identify overarching themes. RESULTS: Neurology clinicians
      highlighted that in their practice, (1) conversations are triggered by acute
      events and practical needs; (2) conversations occur routinely but are rarely
      documented; (3) loss of patient capacity and resultant surrogate decision-making 
      can be ethically fraught, especially in times of family conflict; (4) prognostic 
      uncertainty, unfamiliarity with disease trajectories, and patient or surrogate
      avoidance pose communication challenges; and (5) generalist- and specialty-level 
      palliative care roles should be better defined. CONCLUSIONS: There is a need for 
      a systematic, structured approach to communication that can be applied early in
      the disease trajectory and considered when developing integrated neuro-palliative
      care programs.
CI  - (c) 2019 American Academy of Neurology.
FAU - Zehm, April
AU  - Zehm A
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
FAU - Hazeltine, Amanda M
AU  - Hazeltine AM
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
FAU - Greer, Joseph A
AU  - Greer JA
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
FAU - Traeger, Lara
AU  - Traeger L
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
FAU - Nelson-Lowe, Margaret
AU  - Nelson-Lowe M
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
FAU - Brizzi, Kate
AU  - Brizzi K
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
FAU - Jacobsen, Juliet
AU  - Jacobsen J
AD  - Division of Palliative Care and Geriatric Medicine (AZ, AMH, KB, JJ), Department 
      of Medicine, Massachusetts General Hospital; Harvard Medical School (AZ, JAG, LT,
      KB, JJ); Department of Psychiatry (JAG, LT, MN-L), Massachusetts General
      Hospital, Boston.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurol Clin Pract
JT  - Neurology. Clinical practice
JID - 101577149
PMC - PMC7837442
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 05:58
PHST- 2019/09/05 00:00 [received]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2021/02/01 05:58 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.1212/CPJ.0000000000000794 [doi]
AID - NEURCLINPRACT2019045336 [pii]
PST - ppublish
SO  - Neurol Clin Pract. 2020 Dec;10(6):527-534. doi: 10.1212/CPJ.0000000000000794.


PMID- 33519994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210203
IS  - 1857-7881 (Print)
VI  - 16
IP  - 36
DP  - 2020 Dec 31
TI  - Proposed Design of a Real-Time COVID-19 Pandemic Contact Tracing Using Mobile
      Phone.
PG  - 1-7
LID - 10.19044/esj.2020.v16n36p1 [doi]
AB  - As the virus that causes COVID-19 continues to spread from person to persons in
      communities and rampaging the world, the need for an effective real-time
      surveillance system becomes paramount. Advance contact tracing and detection of
      the persons with the virus represents one of the main strategies to prevent
      transmission. Although COVID-19 surveillance systems such as contact tracing
      mobile apps have improved the administration and management of virus, there are
      still challenges such as privacy, cost and ethical issues, the adoption of new
      technologies, standardized cases, and validly diagnosed case and validity.
      However, the current mobile apps contact tracing system adopted by different
      nations has complemented conventional tracing effort in fighting the virus. This 
      proposal is a model for an interactive computer system using mobile phones and
      the internet for real-time collection and transmission of events related to
      COVID-19. It will aid the administration and presumptive management of COVID-19
      in the world, especially in rural areas. This proposal shows that a sophisticated
      COVID-19 surveillance system can be build using mobile phones with the right
      telecommunication technology partner.
FAU - Nwawudu, Ezenwa
AU  - Nwawudu E
AD  - Global Needs Institute,Saint Etienne,France.
FAU - Ikwu, Amanze
AU  - Ikwu A
AD  - Cardiology Department University Hospitals Plymouth NHS Trust,Plymouth,United
      Kingdom.
FAU - Ikwu, Ugochi
AU  - Ikwu U
AD  - Senior Enterprise Engineer, Allergan USA. New Jersey,USA.
FAU - Oparah, Nneoma
AU  - Oparah N
AD  - Argon Medical Devices, Plano,Texas,USA.
FAU - Nnorom, Stanley
AU  - Nnorom S
AD  - Educational Management and Policy Faculty of Education Nnamdi Azikiwe University,
      Awka,Nigeria.
LA  - eng
GR  - CR200027/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PL  - France
TA  - Eur Sci J
JT  - European scientific journal
JID - 101668676
PMC - PMC7842268
MID - NIHMS1659231
OTO - NOTNLM
OT  - COVID-19
OT  - Contact tracing
OT  - Mobile phone
OT  - Pandemic
OT  - Real-time
COIS- Conflict of Interest: The authors declare no conflict of interest
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 05:56
PHST- 2021/02/01 05:56 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.19044/esj.2020.v16n36p1 [doi]
PST - ppublish
SO  - Eur Sci J. 2020 Dec 31;16(36):1-7. doi: 10.19044/esj.2020.v16n36p1.


PMID- 33519695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - A Mobile Phone App-Based Tai Chi Training in Parkinson's Disease: Protocol for a 
      Randomized Controlled Study.
PG  - 615861
LID - 10.3389/fneur.2020.615861 [doi]
AB  - Introduction: With an increasing number of China's aging population, Parkinson's 
      disease (PD) increases year by year. Persons with PD exhibit abnormal balance
      functions, leading to motor skills difficulties, such as unstable walking or even
      falling. Therefore, activities of daily living and quality of life are affected. 
      This study aims to explore the effectiveness of Tai Chi training based on the
      mobile phone app in improving the balance ability of persons with PD. Methods and
      Analysis: A randomized, single-blind, parallel controlled trial will be conducted
      in this study. One hundred forty-four persons with PD who meet the inclusion
      criteria will be randomly divided into a 1:1:1 ratio: (1) control group, (2)
      basic experimental group (basic app with no Tai Chi training features), and (3)
      balanced-enhanced experimental group (basic app with Tai Chi training features). 
      Individuals with PD will be evaluated on balance and motor function outcomes. The
      primary outcome measure is the limits of stability (including the maximum
      excursion and direction control); the secondary outcome measures include the
      Unified Parkinson's Disease Rating Scale III (UPDRS-III), Berg Balance Scale
      (BBS), Functional Reach Test (FRT), Timed Up & Go (TUG), 6-Minute Walk Test
      (6MWT), and 39-item Parkinson's Disease Questionnaire (PDQ-39). Each group of
      patients will go through an assessment at baseline, 17 and 33 weeks. Discussion: 
      This study will evaluate the effectiveness of the mobile phone app Tai Chi
      training on the balance function of persons with PD. We assume that a challenging
      Tai Chi project based on a mobile phone app will improve balance in the short and
      long term. As walking stability progresses, it is expected that daily activities 
      and quality of life improve. These findings will be used to improve the
      effectiveness of future home management measures for persons with PD. Ethics and 
      Dissemination: This study has been approved by the ethical review committee of
      the Shanghai University of Sport (approval number: 102772019RT056). Informed
      consent will be obtained from all participants or their guardians. The authors
      intend to submit the study findings to peer-reviewed journals or academic
      conferences to be published. Clinical Trial Registration: Chinese Clinical Trial 
      Registry (ChiCTR2000029135).
CI  - Copyright (c) 2021 Gao, Kaudimba, Cai, Tong, Tian, Liu, Liu, Chen and Wang.
FAU - Gao, Song
AU  - Gao S
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
FAU - Kaudimba, Keneilwe Kenny
AU  - Kaudimba KK
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
FAU - Cai, Jiaxin
AU  - Cai J
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
FAU - Tong, Yao
AU  - Tong Y
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
AD  - Institute of Sport Science, Shenyang Sport University, Shenyang, China.
FAU - Tian, Qianqian
AU  - Tian Q
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
FAU - Liu, Peize
AU  - Liu P
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
FAU - Liu, Tiemin
AU  - Liu T
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
AD  - State Key Laboratory of Genetic Engineering, Department of Endocrinology and
      Metabolism, School of Life Sciences, Institute of Metabolism and Integrative
      Biology, Human Phenome Institute, Zhongshan Hospital, Fudan University, Shanghai,
      China.
FAU - Chen, Peijie
AU  - Chen P
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
FAU - Wang, Ru
AU  - Wang R
AD  - Shanghai Key Laboratory for Human Athletic Ability Development and Support,
      School of Kinesiology, Shanghai University of Sport, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20210113
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7838616
OTO - NOTNLM
OT  - Parkinson's disease
OT  - Tai Chi training
OT  - balance ability
OT  - mobile phone app
OT  - randomized controlled trial
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 05:55
PHST- 2020/10/10 00:00 [received]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2021/02/01 05:55 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fneur.2020.615861 [doi]
PST - epublish
SO  - Front Neurol. 2021 Jan 13;11:615861. doi: 10.3389/fneur.2020.615861. eCollection 
      2020.


PMID- 33519669
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210831
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Telemedicine Guidelines in South East Asia-A Scoping Review.
PG  - 581649
LID - 10.3389/fneur.2020.581649 [doi]
AB  - Background: Telemedicine is a useful tool to deliver healthcare to communities in
      low- to high-income countries, especially in the coronavirus disease 2019
      pandemic era. Guidelines on telemedicine would assist healthcare providers in
      delivering healthcare services based on local circumstances. Objective: To
      explore and compare guidelines on telehealth and telemedicine in South East Asian
      countries. Methods: Electronic databases such as Google, PubMed, and Cochrane
      reviews were searched for articles using keywords such as "telemedicine" OR
      "telehealth" OR "eHealth" OR "telemedis" AND "guidelines" AND "South East Asia"
      OR "Malaysia" OR "Singapore" OR "Indonesia" OR "Thailand" OR "Vietnam" published 
      up to 2020. Inclusion criteria were full articles and gray materials (i.e.,
      policy statements, advisories, blueprints, executive summaries, and circulars)
      related to telemedicine guidelines. No language restrictions were imposed. Only
      the first 100 Google searches were included for eligibility based on its
      relevance to telemedicine guidelines. Exclusion criteria were abstracts,
      duplicate publications, blogs, news articles, promotional brochures, conference
      proceedings, and telemedicine projects unrelated to telemedicine guidelines.
      Results: A total of 62,300 articles were identified through the search engines
      (Google 62,203, PubMed 77, and Cochrane 20) and six articles from additional
      sources. Sixty-eight full-text articles fulfilled the inclusion criteria, but
      only 24 articles contained some form of guidelines on telemedicine: Indonesia
      (nine), Malaysia (seven), Singapore (five), Thailand (two), and Vietnam (one).
      There were six laws, six advisory guidelines, five policy statements, and two
      circulars (regulations) issued by either the Ministry of Communication and
      Multimedia, Ministry of Health, or Medical Councils from the respective
      countries. Issues addressed were clinical governance (100%); information and
      communication technology infrastructure (83.3%); privacy, storage, and
      record-keeping (77.8%, respectively); ethics and legal (77.8%); security and
      safety (72.2%); definitions and applications of telemedicine (72.2%);
      confidentiality (66.7%); licensing (66.7%); identification (55.6%); cost of
      information and communication technology infrastructure (55.6%); reimbursement
      (16.7%); mobile applications (11.1%); and feedback and choices (5.6%). The
      Singapore National Telemedicine Guidelines contained the most domains compared
      with other guidelines from South East Asia. Conclusions: Although there can be no
      "one-size-fits-all" telemedicine guideline, there should be a comprehensive and
      universal telemedicine guideline for any country to adapt based on the local
      context. Details on patient-identification, data ownership, back-up, and
      disposal; transregional cybersecurity laws and ways to overcome the limitations
      of telemedicine compared with face-to-face consultations should be outlined
      clearly to ensure uniformity of telemedicine service and patient safety.
CI  - Copyright (c) 2021 Intan Sabrina and Defi.
FAU - Intan Sabrina, Mohamad
AU  - Intan Sabrina M
AD  - Neurorehabilitation Unit, Department of Rehabilitation Medicine, Hospital
      Rehabilitasi Cheras, Kuala Lumpur, Malaysia.
AD  - Tung Shin Hospital, Kuala Lumpur, Malaysia.
FAU - Defi, Irma Ruslina
AU  - Defi IR
AD  - Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran,
      Bandung, Indonesia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210113
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
CIN - Res Social Adm Pharm. 2021 Oct;17(10):1860-1862. PMID: 34272201
PMC - PMC7838484
OTO - NOTNLM
OT  - South East Asia
OT  - guidelines
OT  - low to high income countries
OT  - telemedicine
OT  - universal
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 05:55
PHST- 2020/07/09 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/02/01 05:55 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fneur.2020.581649 [doi]
PST - epublish
SO  - Front Neurol. 2021 Jan 13;11:581649. doi: 10.3389/fneur.2020.581649. eCollection 
      2020.


PMID- 33519434
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Effects of Guanxinshutong Capsules as Complementary Treatment in Patients With
      Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial.
PG  - 571106
LID - 10.3389/fphar.2020.571106 [doi]
AB  - Chronic heart failure (CHF) is a common cardiovascular disease with high
      mortality and a poor prognosis, which places heavy burdens upon society and
      families. Traditional Chinese medicine (TCM) has been used extensively as
      complementary treatment for CHF. Guanxinshutong (GXST) capsules are used commonly
      for the treatment of coronary heart disease (CHD). Experimental research and
      small-sample clinical trials have shown that GXST can attenuate CHF. However, the
      effects of GXST as complementary medicine in CHF treatment lack high-quality
      clinical evidence. We have designed a multicenter, randomized, double-blind,
      placebo-controlled clinical trial that explores the efficacy and safety of using 
      GXST compared with placebo for patients with CHF with reduced left ventricular
      ejection fraction (LVEF). A total of 480 participants will be assigned randomly
      to the GXST group or placebo group at a 2:1 ratio. GXST and placebo will be added
      to standard treatment for 12 weeks, and then followed up for another 40 weeks.
      The primary outcome is the improvement value of 6-min walk distance, and the
      secondary outcomes include plasma levels of N-terminal pro-B-type natriuretic
      peptide, New York Heart Association classification, Minnesota Living with Heart
      Failure Questionnaire scores, echocardiographic parameters, and clinical endpoint
      events. Adverse events will be monitored throughout the trial. Data will be
      analyzed following a predefined statistical analysis plan. This study will show
      the effects of the specific use of GXST in CHF patients with reduced LVEF. The
      Research Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese
      Medical University has approved this study (2019-Y-003-02). Written informed
      consent of patients will be required. This trial is registered in the Chinese
      Clinical Trial Registry (ChiCTR1900023877). Our results will be disseminated to
      the public through peer-reviewed journals, academic conferences, and the
      Internet.
CI  - Copyright (c) 2021 Wang, Xu, Yang, Zhang, Pan, Dou, Zhou, Xu, Li, He, Zhou, Yu,
      Chen, Huang, Fu and Wan.
FAU - Wang, Yu
AU  - Wang Y
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Xu, Jiaping
AU  - Xu J
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Yang, Jiehong
AU  - Yang J
AD  - School of Basic Medicine and Public Health, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Pan, Yuanjiang
AU  - Pan Y
AD  - Department of Chemistry, Zhejiang University, Hangzhou, China.
FAU - Dou, Liping
AU  - Dou L
AD  - Department of Cardiology, Second Affiliated Hospital of Zhejiang Chinese Medical 
      University, Hangzhou, China.
FAU - Zhou, Peng
AU  - Zhou P
AD  - Institute of Brain and Heart CO Treatment, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Xu, Yizhou
AU  - Xu Y
AD  - Department of Cardiology, Hangzhou First People's Hospital, Hangzhou, China.
FAU - Li, Chang
AU  - Li C
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - He, Yu
AU  - He Y
AD  - School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Zhou, Huifen
AU  - Zhou H
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Yu, Li
AU  - Yu L
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Chen, Jingwen
AU  - Chen J
AD  - Department of Cardiology, Second Affiliated Hospital of Zhejiang Chinese Medical 
      University, Hangzhou, China.
FAU - Huang, Shuwei
AU  - Huang S
AD  - Department of Cardiology, Second Affiliated Hospital of Zhejiang Chinese Medical 
      University, Hangzhou, China.
FAU - Fu, Wei
AU  - Fu W
AD  - Department of Cardiac-Cerebral Diseases, Yinchuan Cardiac-Cerebral Treatment
      Internet Hospital, Yinchuan, China.
FAU - Wan, Haitong
AU  - Wan H
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210114
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7840487
OTO - NOTNLM
OT  - Guanxinshutong (GXST)
OT  - clinical trial
OT  - complementary medicine
OT  - heart failure
OT  - traditional Chinese medicine (TCM)
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 05:54
PHST- 2020/06/09 00:00 [received]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2021/02/01 05:54 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.3389/fphar.2020.571106 [doi]
AID - 571106 [pii]
PST - epublish
SO  - Front Pharmacol. 2021 Jan 14;11:571106. doi: 10.3389/fphar.2020.571106.
      eCollection 2020.


PMID- 33518955
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210201
IS  - 0262-4079 (Print)
IS  - 0262-4079 (Linking)
VI  - 248
IP  - 3305
DP  - 2020 Oct 24
TI  - Intentional infections.
PG  - 7
LID - 10.1016/S0262-4079(20)31860-1 [doi]
AB  - A plan to give the coronavirus to volunteers may help us test potential vaccines,
      if it gets ethical approval, says Michael Le Page.
CI  - (c) 2020.
FAU - Le Page, Michael
AU  - Le Page M
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - England
TA  - New Sci
JT  - New scientist (1971)
JID - 9815377
PMC - PMC7833448
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
CRDT- 2021/02/01 05:52
PHST- 2021/02/01 05:52 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
AID - 10.1016/S0262-4079(20)31860-1 [doi]
AID - S0262-4079(20)31860-1 [pii]
PST - ppublish
SO  - New Sci. 2020 Oct 24;248(3305):7. doi: 10.1016/S0262-4079(20)31860-1. Epub 2020
      Oct 23.


PMID- 33518548
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1080-6571 (Electronic)
IS  - 0278-9671 (Linking)
VI  - 38
IP  - 2
DP  - 2020
TI  - Accounting for Dignity in the Iliad, Ajax, Electra, and the Clinical Encounter:
      Debating the "End" of Life.
PG  - 375-398
LID - 10.1353/lm.2020.0026 [doi]
AB  - This essay explores as "dignity-denuding" case studies Greek tragic protagonists 
      in order to discuss the ethical problematics involved in "accounting for" such
      figures: i.e. both diagnosing them and constructing (broken) narratives into
      which they are fitted. Starting with epic's positive constructions of "aidos"
      (shame), it contrasts Ajax and Phaedra-each deprived of their dignity by what one
      psychiatrist called a "violent storm"-as seeking to construct a restorative story
      of self after trauma. Finally, it argues that Sophocles's Electra's presentation 
      of her "shameful" state has been misread, by both psychiatrists and dramaturgs
      seeking, perhaps needing?, to impose an inappropriate closure on both her and the
      play. It is suggestive and significant that this so-called "hysteric" should
      attract accounts which so impose a diagnosis, impose an "end." The essay
      concludes that such imposition on anyone who has had their dignity taken away,
      whether protagonist or patient, is the final indignity.
FAU - Parker, Jan
AU  - Parker J
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Lit Med
JT  - Literature and medicine
JID - 8309346
SB  - IM
MH  - *Death
MH  - Drama/*history
MH  - History, Ancient
MH  - Humans
MH  - Medicine in Literature
MH  - *Respect
MH  - Shame
MH  - Social Identification
EDAT- 2021/02/02 06:00
MHDA- 2021/10/05 06:00
CRDT- 2021/02/01 05:49
PHST- 2021/02/01 05:49 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - S1080657120200124 [pii]
AID - 10.1353/lm.2020.0026 [doi]
PST - ppublish
SO  - Lit Med. 2020;38(2):375-398. doi: 10.1353/lm.2020.0026.


PMID- 33518542
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1080-6571 (Electronic)
IS  - 0278-9671 (Linking)
VI  - 38
IP  - 2
DP  - 2020
TI  - Introduction: Dignity in Literature and Medical Ethics.
PG  - 255-261
LID - 10.1353/lm.2020.0020 [doi]
AB  - It was during the sixteenth and seventeenth centuries that the concept of human
      dignity began to pivot more firmly towards the notion of egalitarian moral worth 
      that it now represents. This essay focuses on the relationship between the
      generations as an important place to look for markers of societal attitudes about
      the meaning of dignity or its absence. A valuable site of discovery is the early 
      modern letter of advice, passed between parents and children or, in some cases,
      across three generations. The category of intergenerational relationship analysis
      is increasingly an important focus of study within the health humanities, a
      category of particular use in improving social cohesion and wellbeing and,
      therefore, community flourishing.
FAU - Harris, Johanna
AU  - Harris J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lit Med
JT  - Literature and medicine
JID - 8309346
SB  - IM
MH  - *Ethics, Medical
MH  - Humanities
MH  - *Medicine in Literature
MH  - *Respect
EDAT- 2021/02/02 06:00
MHDA- 2021/10/05 06:00
CRDT- 2021/02/01 05:49
PHST- 2021/02/01 05:49 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - S1080657120200069 [pii]
AID - 10.1353/lm.2020.0020 [doi]
PST - ppublish
SO  - Lit Med. 2020;38(2):255-261. doi: 10.1353/lm.2020.0020.


PMID- 33511283
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2392-1099 (Print)
IS  - 2392-1099 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Dec
TI  - Whole exome sequencing analysis for mutations in isolated type III biliary
      atresia patients.
PG  - 347-353
LID - 10.5114/ceh.2020.102156 [doi]
AB  - AIM OF THE STUDY: Biliary atresia is an idiopathic, destructive disease that
      affects both extrahepatic and intrahepatic bile ducts with severe inflammation
      and manifests as progressive jaundice within the first few months of life. In
      this study, we aimed to investigate the significance of genetic mutations in the 
      onset of biliary atresia disease. MATERIAL AND METHODS: With the approval of the 
      ethics committee and parental consent, blood was taken from patients to obtain
      their DNA, and the study commenced. In this prospective study, we examined the
      DNA of 10 patients with no disease other than biliary atresia, and an exome
      sequence analysis was performed with the new-generation DNA sequencing method.
      The genetic structure of biliary atresia disease was examined by statistical
      analysis of the mutations, which were determined according to the reference DNA
      sequencing. RESULTS: In the exome sequence analysis, the number of mutations
      detected among the patients changed significantly; the lowest number was 12,591, 
      and the maximum was 19,863. By examining these mutations, we identified the
      mutated genes that were common to all patients. CONCLUSIONS: In this study, the
      highest mutation rates were detected in the PRIM2 and MAP2K3 genes. These genes
      have not previously been associated with biliary atresia.
CI  - Copyright: (c) 2020 Clinical and Experimental Hepatology.
FAU - Gurunluoglu, Kubilay
AU  - Gurunluoglu K
AD  - Department of Pediatric Surgery, Faculty of Medicine, Inonu University, Malatya, 
      Turkey.
FAU - Koc, Ahmet
AU  - Koc A
AD  - Department of Medical Genetics, Faculty of Medicine, Inonu University, Malatya,
      Turkey.
FAU - Durmus, Kubra
AU  - Durmus K
AD  - Department of Medical Genetics, Faculty of Medicine, Inonu University, Malatya,
      Turkey.
FAU - Gozukara Bag, Harika
AU  - Gozukara Bag H
AD  - Department of Biostatistics and Medical Informatics, Faculty of Medicine, Inonu
      University, Malatya, Turkey.
FAU - Ceran, Canan
AU  - Ceran C
AD  - Department of Pediatric Surgery, Faculty of Medicine, Inonu University, Malatya, 
      Turkey.
FAU - Gurunluoglu, Semra
AU  - Gurunluoglu S
AD  - Pathology Laboratory, Education and Research Hospital, Malatya, Turkey.
FAU - Yildiz, Turan
AU  - Yildiz T
AD  - Department of Pediatric Surgery, Faculty of Medicine, Inonu University, Malatya, 
      Turkey.
FAU - Gul, Mehmet
AU  - Gul M
AD  - Department of Histology and Embryology, Faculty of Medicine, Inonu University,
      Malatya, Turkey.
FAU - Demircan, Mehmet
AU  - Demircan M
AD  - Department of Pediatric Surgery, Faculty of Medicine, Inonu University, Malatya, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201230
PL  - Poland
TA  - Clin Exp Hepatol
JT  - Clinical and experimental hepatology
JID - 101703431
PMC - PMC7816631
OTO - NOTNLM
OT  - DNA
OT  - biliary atresia
OT  - exome sequencing analysis
OT  - genetic
OT  - mutation
COIS- The authors declare no conflict of interest.
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
CRDT- 2021/01/29 05:57
PHST- 2020/07/23 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2021/01/29 05:57 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
AID - 10.5114/ceh.2020.102156 [doi]
AID - 42841 [pii]
PST - ppublish
SO  - Clin Exp Hepatol. 2020 Dec;6(4):347-353. doi: 10.5114/ceh.2020.102156. Epub 2020 
      Dec 30.


PMID- 33511090
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210130
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Improving Informed Consent for Novel Vaccine Research in a Pediatric Hospital
      Setting Using a Blended Research-Design Approach.
PG  - 520803
LID - 10.3389/fped.2020.520803 [doi]
AB  - It is necessary to conduct Clinical Trials in children, including for novel
      vaccines. Children cannot legally provide valid consent, but can assent to
      research participation. Informed consent and assent communications are frequently
      criticized for their lack of comprehensibility and often, researchers do not
      involve patients in informed consent design. We tested a blended research-design 
      approach to co-design multimedia informed consent prototypes for experimental
      vaccine studies targeted at the pediatric population. We report details on the
      methodology utilized, and the insights, ideas, and prototype solutions we
      generated using social media data analysis, a survey, and workshops. A survey of 
      clinical trial researchers indicated that while the most did not use technology
      for informed consent, they considered its utilization favorable. Social media
      analysis enabled researchers to quickly understand where community perspectives
      were concordant and discordant and build their understanding of the types of
      topics that they may want to focus on during the design workshops. Participatory 
      design workshops for children and their families reaped insights, ideas, and
      prototypes for a range of tools including apps and websites. Participants felt
      that the prototypes were better able to communicate necessary content than the
      original text document format. We propose using a participatory, mixed-methods
      approach to design informed consent so that it is better adapted to patients'
      needs. Such an approach would be helpful in better addressing the needs of
      different segments of the populations involved in clinical trials. Further
      evidence should be gained about the impact of this strategy in improving
      recruitment, decreasing withdrawals and litigations, and improving patient
      satisfaction during clinical trials.
CI  - Copyright (c) 2021 Jackson, Daverio, Perez, Gesualdo and Tozzi.
FAU - Jackson, Sally M
AU  - Jackson SM
AD  - Multifactorial and Complex Diseases Research Area, Bambino Gesu Children's
      Hospital IRCCS, Rome, Italy.
FAU - Daverio, Margherita
AU  - Daverio M
AD  - Libera Universita Maria SS. Assunta, Rome, Italy.
FAU - Perez, Silvia Lorenzo
AU  - Perez SL
AD  - AND Consulting Group, Brussels, Belgium.
FAU - Gesualdo, Francesco
AU  - Gesualdo F
AD  - Multifactorial and Complex Diseases Research Area, Bambino Gesu Children's
      Hospital IRCCS, Rome, Italy.
FAU - Tozzi, Alberto E
AU  - Tozzi AE
AD  - Multifactorial and Complex Diseases Research Area, Bambino Gesu Children's
      Hospital IRCCS, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210112
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7835206
OTO - NOTNLM
OT  - clinical research
OT  - design thinking (DT)
OT  - ethics
OT  - inclusion
OT  - informed consent
OT  - mixed-methods
OT  - natural language processing (nlp)
OT  - vaccination
COIS- SLP was employed by the company AND Consulting Group. The remaining authors
      declare that the research was conducted in the absence of any commercial or
      financial relationships that could be construed as a potential conflict of
      interest.
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
CRDT- 2021/01/29 05:57
PHST- 2019/12/16 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2021/01/29 05:57 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
AID - 10.3389/fped.2020.520803 [doi]
PST - epublish
SO  - Front Pediatr. 2021 Jan 12;8:520803. doi: 10.3389/fped.2020.520803. eCollection
      2020.


PMID- 33510656
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210130
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Assessing the Mental Health of Fathers, Other Co-parents, and Partners in the
      Perinatal Period: Mixed Methods Evidence Synthesis.
PG  - 585479
LID - 10.3389/fpsyt.2020.585479 [doi]
AB  - Introduction: Five to 10 percentage of fathers experience perinatal depression
      and 5-15% experience perinatal anxiety, with rates increasing when mothers are
      also experiencing perinatal mental health disorders. Perinatal mental illness in 
      either parent contributes to adverse child and family outcomes. While there are
      increasing calls to assess the mental health of both parents, universal services 
      (e.g., maternity) and specialist perinatal mental health services usually focus
      on the mother (i.e., the gestational parent). The aim of this review was to
      identify and synthesize evidence on the performance of mental health screening
      tools and the acceptability of mental health assessment, specifically in relation
      to fathers, other co-parents and partners in the perinatal period. Methods: A
      systematic search was conducted using electronic databases (MEDLINE, PsycINFO,
      Maternity, and Infant Care Database and CINAHL). Articles were eligible if they
      included expectant or new partners, regardless of the partner's gender or
      relationship status. Accuracy was determined by comparison of screening tool with
      diagnostic interview. Acceptability was predominantly assessed through parents'
      and health professionals' perspectives. Narrative synthesis was applied to all
      elements of the review, with thematic analysis applied to the acceptability
      studies. Results: Seven accuracy studies and 20 acceptability studies were
      included. The review identified that existing evidence focuses on resident
      fathers and assessing depression in universal settings. All accuracy studies
      assessed the Edinburgh Postnatal Depression Scale but with highly varied results.
      Evidence on acceptability in practice is limited to postnatal settings. Amongst
      both fathers and health professionals, views on assessment are mixed. Identified 
      challenges were categorized at the individual-, practitioner- and service-level. 
      These include: gendered perspectives on mental health; the potential to
      compromise support offered to mothers; practitioners' knowledge, skills, and
      confidence; service culture and remit; time pressures; opportunity for contact;
      and the need for tools, training, supervision and onward referral routes.
      Conclusion: There is a paucity of published evidence on assessing the mental
      health of fathers, co-mothers, step-parents and other partners in the perinatal
      period. Whilst practitioners need to be responsive to mental health needs,
      further research is needed with stakeholders in a range of practice settings,
      with attention to ethical and practical considerations, to inform the
      implementation of evidence-based assessment.
CI  - Copyright (c) 2021 Darwin, Domoney, Iles, Bristow, Siew and Sethna.
FAU - Darwin, Zoe
AU  - Darwin Z
AD  - School of Human and Health Sciences, University of Huddersfield, Huddersfield,
      United Kingdom.
FAU - Domoney, Jill
AU  - Domoney J
AD  - Section of Women's Mental Health, Health Service and Population Research
      Department, Institute of Psychiatry, Psychology & Neuroscience, King's College
      London, London, United Kingdom.
FAU - Iles, Jane
AU  - Iles J
AD  - Department of Psychology, University of Surrey, Surrey, United Kingdom.
FAU - Bristow, Florence
AU  - Bristow F
AD  - Community Perinatal Mental Health Service for Croydon, South London and Maudsley 
      NHS Foundation Trust, London, United Kingdom.
FAU - Siew, Jasmine
AU  - Siew J
AD  - Department of Experimental Clinical and Health Psychology, Research in
      Developmental Disorders Lab, Ghent University, Ghent, Belgium.
AD  - Department of Forensic and Neurodevelopmental Sciences, Sackler Institute for
      Translational Neurodevelopment, Institute of Psychiatry, Psychology &
      Neuroscience, King's College London, London, United Kingdom.
FAU - Sethna, Vaheshta
AU  - Sethna V
AD  - Department of Forensic and Neurodevelopmental Sciences, Sackler Institute for
      Translational Neurodevelopment, Institute of Psychiatry, Psychology &
      Neuroscience, King's College London, London, United Kingdom.
LA  - eng
PT  - Systematic Review
DEP - 20210112
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7835428
OTO - NOTNLM
OT  - acceptability
OT  - diagnostic test accuracy
OT  - evidence synthesis
OT  - fathers
OT  - partners
OT  - paternal depression
OT  - perinatal mental health
OT  - screening
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
CRDT- 2021/01/29 05:55
PHST- 2020/07/20 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2021/01/29 05:55 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
AID - 10.3389/fpsyt.2020.585479 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Jan 12;11:585479. doi: 10.3389/fpsyt.2020.585479.
      eCollection 2020.


PMID- 33510652
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210130
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Perceived Burdensomeness and the Wish for Hastened Death in Persons With Severe
      and Persistent Mental Illness.
PG  - 532817
LID - 10.3389/fpsyt.2020.532817 [doi]
AB  - Background: In several European countries, medical assistance in dying (MAID) is 
      no longer confined to persons with a terminal prognosis but is also available to 
      those suffering from persistent and unbearable mental illness. To date, scholarly
      discourse on MAID in this population has been dominated by issues such as
      decision-making capacity, uncertainty as to when a disease is incurable,
      stigmatization, isolation, and loneliness. However, the issue of perceived
      burdensomeness has received little attention. Objective: The study explores the
      possible impact of perceived burdensomeness on requests for MAID among persons
      with severe and persistent mental illness (SPMI). Method: Using the method of
      ethical argumentation, we discuss the issue of access to MAID for persons with
      SPMI and perceived burdensomeness. Conclusion: Perceived burdensomeness may be a 
      contributing factor in the wish for hastened death among persons with SPMI. MAID 
      is ethically unsupportable if SPMI causes the individual to make an unrealistic
      assessment of burdensomeness, indicating a lack of decision-making capacity in
      the context of that request. However, the possibility that some individuals with 
      SPMI may perceive burdensomeness does not mean that they should be routinely
      excluded from MAID. For SPMI patients with intact decision-making capacity who
      feel their life is not worth living, perceived burdensomeness as a component of
      this intolerable suffering is not a sufficient reason to deny access to MAID.
CI  - Copyright (c) 2021 Stoll, Ryan and Trachsel.
FAU - Stoll, Julia
AU  - Stoll J
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Zurich, Switzerland.
FAU - Ryan, Christopher James
AU  - Ryan CJ
AD  - Discipline of Psychiatry, Westmead Clinical School and Sydney Health Ethics,
      University of Sydney, Sydney, NSW, Australia.
FAU - Trachsel, Manuel
AU  - Trachsel M
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Zurich, Switzerland.
AD  - Clinical Ethics Unit, University Hospital Basel and University Psychiatric
      Clinics Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20210112
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7835407
OTO - NOTNLM
OT  - anorexia nervosa
OT  - autonomy
OT  - depression
OT  - ethics
OT  - euthanasia
OT  - mental competency
OT  - schizophrenia
OT  - suicide
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
CRDT- 2021/01/29 05:55
PHST- 2020/02/12 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2021/01/29 05:55 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
AID - 10.3389/fpsyt.2020.532817 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Jan 12;11:532817. doi: 10.3389/fpsyt.2020.532817.
      eCollection 2020.


PMID- 33505948
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Stakeholder Recommendations to Increase the Accessibility of Online Health
      Information for Adults Experiencing Concussion Symptoms.
PG  - 557814
LID - 10.3389/fpubh.2020.557814 [doi]
AB  - Background: Concussion is a global public health problem. In Canada, concussion
      is among the top five reasons for workplace time-loss. Concussion results in
      physical, cognitive, and/or emotional symptoms that temporarily worsen with
      physical and mental exertion, such as viewing electronic screens. The Internet is
      the primary source of consumer health information. Studies on the end-user needs 
      of adults with brain injuries in regards to digital health technologies largely
      focus on informational content. There is little to no research on the
      accessibility of screen-based informational websites and smartphone applications 
      among this population. Objective: The aim of this research was to involve
      stakeholders in the design of a comprehensive educational resource to guide
      concussion recognition, recovery, and return-to-work, called the Concussion
      Awareness Training Tool for Workers and Workplaces (CATT WW). In order to ensure 
      both relevant content and appropriate delivery of the information to the target
      groups, participants were asked whether adaptations could increase the
      accessibility of online health information for the general adult population
      experiencing concussion symptoms. Methods: Data have been generated through
      semi-structured in-depth interviews and focus groups with participants from
      across British Columbia (BC): workers from various industries who were in the
      concussion recovery process or had returned to work (n = 31); and healthcare or
      workplace professionals who support concussion diagnosis, recovery, and
      return-to-work (n = 16). Data were analyzed using NVivo 12. Before commencing
      data collection, ethical permission was granted by the University of British
      Columbia Research Ethics Board (H18-00604), and approval was received from
      WorkSafeBC Research Services. Results: Participants (n = 47) recommended twenty
      adaptations or supplements to electronic screen-based digital health
      technologies. Conclusion: Given the high prevalence of concussion among the
      working adult population, the symptom exacerbation commonly caused by prolonged
      use of electronic screens, and the demand for online educational resources, these
      findings can guide clinicians, researchers, technology developers, employers, and
      occupational health and safety committees to further support adults in concussion
      recovery and return-to-work.
CI  - Copyright (c) 2021 Beaton, Hadly and Babul.
FAU - Beaton, M Denise
AU  - Beaton MD
AD  - British Columbia Injury Research and Prevention Unit, British Columbia Children's
      Hospital Research Institute, Vancouver, BC, Canada.
AD  - British Columbia Centre for Disease Control, Population and Public Health,
      Provincial Health Services Authority, Vancouver, BC, Canada.
FAU - Hadly, Gabrielle
AU  - Hadly G
AD  - British Columbia Injury Research and Prevention Unit, British Columbia Children's
      Hospital Research Institute, Vancouver, BC, Canada.
AD  - School of Population and Public Health, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Babul, Shelina
AU  - Babul S
AD  - British Columbia Injury Research and Prevention Unit, British Columbia Children's
      Hospital Research Institute, Vancouver, BC, Canada.
AD  - Department of Paediatrics, University of British Columbia, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210111
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Adult
MH  - *Brain Concussion/diagnosis
MH  - British Columbia
MH  - Delivery of Health Care
MH  - Humans
MH  - Return to Work
MH  - Workplace
PMC - PMC7829503
OTO - NOTNLM
OT  - *accessibility
OT  - *concussion
OT  - *digital health
OT  - *mild traumatic brain injuries
OT  - *online resources
OT  - *technology
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/28 05:44
PHST- 2020/04/30 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2021/01/28 05:44 [entrez]
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.3389/fpubh.2020.557814 [doi]
PST - epublish
SO  - Front Public Health. 2021 Jan 11;8:557814. doi: 10.3389/fpubh.2020.557814.
      eCollection 2020.


PMID- 33502000
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210819
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 8
DP  - 2020 Aug 18
TI  - Digital contact tracing technologies in epidemics: a rapid review.
PG  - CD013699
LID - 10.1002/14651858.CD013699 [doi]
AB  - BACKGROUND: Reducing the transmission of severe acute respiratory syndrome
      coronavirus 2 (SARS-CoV-2) is a global priority. Contact tracing identifies
      people who were recently in contact with an infected individual, in order to
      isolate them and reduce further transmission. Digital technology could be
      implemented to augment and accelerate manual contact tracing. Digital tools for
      contact tracing may be grouped into three areas: 1) outbreak response; 2)
      proximity tracing; and 3) symptom tracking. We conducted a rapid review on the
      effectiveness of digital solutions to contact tracing during infectious disease
      outbreaks. OBJECTIVES: To assess the benefits, harms, and acceptability of
      personal digital contact tracing solutions for identifying contacts of an
      identified positive case of an infectious disease. SEARCH METHODS: An information
      specialist searched the literature from 1 January 2000 to 5 May 2020 in CENTRAL, 
      MEDLINE, and Embase. Additionally, we screened the Cochrane COVID-19 Study
      Register. SELECTION CRITERIA: We included randomised controlled trials (RCTs),
      cluster-RCTs, quasi-RCTs, cohort studies, cross-sectional studies and modelling
      studies, in general populations. We preferentially included studies of contact
      tracing during infectious disease outbreaks (including COVID-19, Ebola,
      tuberculosis, severe acute respiratory syndrome virus, and Middle East
      respiratory syndrome) as direct evidence, but considered comparative studies of
      contact tracing outside an outbreak as indirect evidence. The digital solutions
      varied but typically included software (or firmware) for users to install on
      their devices or to be uploaded to devices provided by governments or third
      parties. Control measures included traditional or manual contact tracing,
      self-reported diaries and surveys, interviews, other standard methods for
      determining close contacts, and other technologies compared to digital solutions 
      (e.g. electronic medical records). DATA COLLECTION AND ANALYSIS: Two review
      authors independently screened records and all potentially relevant full-text
      publications. One review author extracted data for 50% of the included studies,
      another extracted data for the remaining 50%; the second review author checked
      all the extracted data. One review author assessed quality of included studies
      and a second checked the assessments. Our outcomes were identification of
      secondary cases and close contacts, time to complete contact tracing,
      acceptability and accessibility issues, privacy and safety concerns, and any
      other ethical issue identified. Though modelling studies will predict estimates
      of the effects of different contact tracing solutions on outcomes of interest,
      cohort studies provide empirically measured estimates of the effects of different
      contact tracing solutions on outcomes of interest. We used GRADE-CERQual to
      describe certainty of evidence from qualitative data and GRADE for modelling and 
      cohort studies. MAIN RESULTS: We identified six cohort studies reporting
      quantitative data and six modelling studies reporting simulations of digital
      solutions for contact tracing. Two cohort studies also provided qualitative data.
      Three cohort studies looked at contact tracing during an outbreak, whilst three
      emulated an outbreak in non-outbreak settings (schools). Of the six modelling
      studies, four evaluated digital solutions for contact tracing in simulated
      COVID-19 scenarios, while two simulated close contacts in non-specific outbreak
      settings. Modelling studies Two modelling studies provided low-certainty evidence
      of a reduction in secondary cases using digital contact tracing (measured as
      average number of secondary cases per index case - effective reproductive number 
      (R eff)). One study estimated an 18% reduction in R eff with digital contact
      tracing compared to self-isolation alone, and a 35% reduction with manual
      contact-tracing. Another found a reduction in R eff for digital contact tracing
      compared to self-isolation alone (26% reduction) and a reduction in R eff for
      manual contact tracing compared to self-isolation alone (53% reduction). However,
      the certainty of evidence was reduced by unclear specifications of their models, 
      and assumptions about the effectiveness of manual contact tracing (assumed 95% to
      100% of contacts traced), and the proportion of the population who would have the
      app (53%). Cohort studies Two cohort studies provided very low-certainty evidence
      of a benefit of digital over manual contact tracing. During an Ebola outbreak,
      contact tracers using an app found twice as many close contacts per case on
      average than those using paper forms. Similarly, after a pertussis outbreak in a 
      US hospital, researchers found that radio-frequency identification identified 45 
      close contacts but searches of electronic medical records found 13. The certainty
      of evidence was reduced by concerns about imprecision, and serious risk of bias
      due to the inability of contact tracing study designs to identify the true number
      of close contacts. One cohort study provided very low-certainty evidence that an 
      app could reduce the time to complete a set of close contacts. The certainty of
      evidence for this outcome was affected by imprecision and serious risk of bias.
      Contact tracing teams reported that digital data entry and management systems
      were faster to use than paper systems and possibly less prone to data loss. Two
      studies from lower- or middle-income countries, reported that contact tracing
      teams found digital systems simpler to use and generally preferred them over
      paper systems; they saved personnel time, reportedly improved accuracy with large
      data sets, and were easier to transport compared with paper forms. However,
      personnel faced increased costs and internet access problems with digital
      compared to paper systems. Devices in the cohort studies appeared to have privacy
      from contacts regarding the exposed or diagnosed users. However, there were risks
      of privacy breaches from snoopers if linkage attacks occurred, particularly for
      wearable devices. AUTHORS' CONCLUSIONS: The effectiveness of digital solutions is
      largely unproven as there are very few published data in real-world outbreak
      settings. Modelling studies provide low-certainty evidence of a reduction in
      secondary cases if digital contact tracing is used together with other public
      health measures such as self-isolation. Cohort studies provide very low-certainty
      evidence that digital contact tracing may produce more reliable counts of
      contacts and reduce time to complete contact tracing. Digital solutions may have 
      equity implications for at-risk populations with poor internet access and poor
      access to digital technology. Stronger primary research on the effectiveness of
      contact tracing technologies is needed, including research into use of digital
      solutions in conjunction with manual systems, as digital solutions are unlikely
      to be used alone in real-world settings. Future studies should consider access to
      and acceptability of digital solutions, and the resultant impact on equity.
      Studies should also make acceptability and uptake a primary research question, as
      privacy concerns can prevent uptake and effectiveness of these technologies.
CI  - Copyright (c) 2020 The Cochrane Collaboration. Published by John Wiley & Sons,
      Ltd.
FAU - Anglemyer, Andrew
AU  - Anglemyer A
AD  - Department of Preventive and Social Medicine, Dunedin School of Medicine,
      University of Otago, Dunedin, New Zealand.
AD  - Methods Support Unit, Editorial Methods Department, London, UK.
FAU - Moore, Theresa Hm
AU  - Moore TH
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
AD  - Methods Support Unit, Editorial Methods Department, London, UK.
AD  - NIHR ARC West, Bristol, UK.
FAU - Parker, Lisa
AU  - Parker L
AD  - Sydney School of Pharmacy, The University of Sydney, Sydney, Australia.
FAU - Chambers, Timothy
AU  - Chambers T
AD  - Department of Public Health, University of Otago, Wellington, Wellington, New
      Zealand.
FAU - Grady, Alice
AU  - Grady A
AD  - School of Medicine and Public Health, Faculty of Health and Medicine, University 
      of Newcastle, Callaghan, Australia.
FAU - Chiu, Kellia
AU  - Chiu K
AD  - Charles Perkins Centre and School of Pharmacy, The University of Sydney, Sydney, 
      Australia.
FAU - Parry, Matthew
AU  - Parry M
AD  - Department of Mathematics and Statistics, University of Otago, Dunedin, New
      Zealand.
FAU - Wilczynska, Magdalena
AU  - Wilczynska M
AD  - School of Medicine and Public Health, University of Newcastle, Callaghan,
      Australia.
FAU - Flemyng, Ella
AU  - Flemyng E
AD  - Editorial and Methods Department, Cochrane, London, UK.
FAU - Bero, Lisa
AU  - Bero L
AD  - Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health,
      The University of Sydney, Camperdown, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200818
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
SB  - IM
MH  - Botswana/epidemiology
MH  - COVID-19/epidemiology/prevention & control
MH  - Cohort Studies
MH  - Contact Tracing/instrumentation/*methods
MH  - Coronavirus Infections/epidemiology
MH  - Disease Outbreaks/*prevention & control
MH  - Hemorrhagic Fever, Ebola/epidemiology/prevention & control
MH  - Humans
MH  - Mobile Applications/*statistics & numerical data
MH  - Models, Theoretical
MH  - Patient Isolation/statistics & numerical data
MH  - Privacy
MH  - Quarantine/statistics & numerical data
MH  - Secondary Prevention/methods/statistics & numerical data
MH  - Sierra Leone/epidemiology
MH  - Tuberculosis/epidemiology/prevention & control
MH  - United States/epidemiology
MH  - Whooping Cough/epidemiology/prevention & control
PMC - PMC8241885
EDAT- 2021/01/28 06:00
MHDA- 2021/02/04 06:00
CRDT- 2021/01/27 08:38
PHST- 2021/01/27 08:38 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
AID - 10.1002/14651858.CD013699 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2020 Aug 18;8:CD013699. doi:
      10.1002/14651858.CD013699.


PMID- 33501361
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210127
IS  - 2296-9144 (Electronic)
IS  - 2296-9144 (Linking)
VI  - 7
DP  - 2020
TI  - Editorial: Towards Real World Impacts: Design, Development, and Deployment of
      Social Robots in the Wild.
PG  - 600830
LID - 10.3389/frobt.2020.600830 [doi]
FAU - Park, Chung Hyuk
AU  - Park CH
AD  - Department of Biomedical Engineering, School of Engineering and Applied Science, 
      The George Washington University, Washington, DC, United States.
FAU - Ros, Raquel
AU  - Ros R
AD  - Grup de Tecnologies Media, La Salle-Universitat Ramon Llull, Barcelona, Spain.
FAU - Kwak, Sonya S
AU  - Kwak SS
AD  - Center for Intelligent and Interactive Robotics, Korea Institute of Science and
      Technology (KIST), Seoul, South Korea.
FAU - Huang, Chien-Ming
AU  - Huang CM
AD  - Department of Computer Science, Johns Hopkins University, Baltimore, MD, United
      States.
FAU - Lemaignan, Severin
AU  - Lemaignan S
AD  - Bristol Robotics Laboratory, Bristol, United Kingdom.
LA  - eng
PT  - Editorial
DEP - 20201203
PL  - Switzerland
TA  - Front Robot AI
JT  - Frontiers in robotics and AI
JID - 101749350
PMC - PMC7805884
OTO - NOTNLM
OT  - HRI computational modeling
OT  - HRI in healthcare and special education
OT  - HRI theories
OT  - emotions and ethics in HRI
OT  - large-group HRI
OT  - longitudinal HRI
OT  - social robots in the wild
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/28 06:00
MHDA- 2021/01/28 06:01
CRDT- 2021/01/27 05:53
PHST- 2020/08/31 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2021/01/27 05:53 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/01/28 06:01 [medline]
AID - 10.3389/frobt.2020.600830 [doi]
PST - epublish
SO  - Front Robot AI. 2020 Dec 3;7:600830. doi: 10.3389/frobt.2020.600830. eCollection 
      2020.


PMID- 33501324
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210129
IS  - 2296-9144 (Electronic)
IS  - 2296-9144 (Linking)
VI  - 7
DP  - 2020
TI  - Kinesthetic Device vs. Keyboard/Mouse: A Comparison in Home Care
      Telemanipulation.
PG  - 561015
LID - 10.3389/frobt.2020.561015 [doi]
AB  - Ensuring care is one of the biggest humanitarian challenges of the future since
      an acute shortage in nursing staff is expected. At the same time, this offers the
      opportunity for new technologies in nursing, as the use of robotic systems. One
      potential use case is outpatient care, which nowadays involves traveling long
      distances. Here, the use of telerobotics could provide a major relief for the
      nursing staff, as it could spare them many of those-partially far-journeys. Since
      autonomous robotic systems are not desired at least in Germany for ethical
      reasons, this paper evaluates the design of a telemanipulation system consisting 
      of off-the-shelf components for outpatient care. Furthermore, we investigated the
      suitability of two different input devices for control, a kinesthetic device, and
      a keyboard plus mouse. We conducted the investigations in a laboratory study.
      This laboratory represents a realistic environment of an elderly home and a
      remote care service center. It was carried out with 25 nurses. Tasks common in
      outpatient care, such as handing out things (manipulation) and examining body
      parts (set camera view), were used in the study. After a short training period,
      all nurses were able to control a manipulator with the two input devices and
      perform the two tasks. It was shown that the Falcon leads to shorter execution
      times (on average 0:54.82 min, compared to 01:10.92 min with keyboard and mouse),
      whereby the participants were more successful with the keyboard plus mouse, in
      terms of task completion. There is no difference in usability and cognitive load.
      Moreover, we pointed out, that the access to this kind of technology is
      desirable, which is why we identified further usage scenarios.
CI  - Copyright (c) 2020 Gliesche, Krick, Pfingsthorn, Drolshagen, Kowalski and Hein.
FAU - Gliesche, Pascal
AU  - Gliesche P
AD  - R&D Division Health, OFFIS-Institute for Information Technology, Oldenburg,
      Germany.
FAU - Krick, Tobias
AU  - Krick T
AD  - SOCIUM Research Center on Inequality and Social Policy, University of Bremen,
      Bremen, Germany.
AD  - High-Profile Area of Health Sciences, University of Bremen, Bremen, Germany.
FAU - Pfingsthorn, Max
AU  - Pfingsthorn M
AD  - R&D Division Production, OFFIS-Institute for Information Technology, Oldenburg,
      Germany.
FAU - Drolshagen, Sandra
AU  - Drolshagen S
AD  - R&D Division Production, OFFIS-Institute for Information Technology, Oldenburg,
      Germany.
FAU - Kowalski, Christian
AU  - Kowalski C
AD  - R&D Division Health, OFFIS-Institute for Information Technology, Oldenburg,
      Germany.
FAU - Hein, Andreas
AU  - Hein A
AD  - R&D Division Health, OFFIS-Institute for Information Technology, Oldenburg,
      Germany.
AD  - Assistance Systems and Medical Device Technology, Department of Health Services
      Research, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - Switzerland
TA  - Front Robot AI
JT  - Frontiers in robotics and AI
JID - 101749350
PMC - PMC7805703
OTO - NOTNLM
OT  - human-robot interface
OT  - input device
OT  - outpatient care
OT  - telecare
OT  - telemanipulation
OT  - teleoperation systems
OT  - telerobotics
EDAT- 2021/01/28 06:00
MHDA- 2021/01/28 06:01
CRDT- 2021/01/27 05:53
PHST- 2020/05/11 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2021/01/27 05:53 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/01/28 06:01 [medline]
AID - 10.3389/frobt.2020.561015 [doi]
PST - epublish
SO  - Front Robot AI. 2020 Nov 4;7:561015. doi: 10.3389/frobt.2020.561015. eCollection 
      2020.


PMID- 33501297
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210130
IS  - 2296-9144 (Electronic)
IS  - 2296-9144 (Linking)
VI  - 7
DP  - 2020
TI  - Virtual Reality and Empathy Enhancement: Ethical Aspects.
PG  - 506984
LID - 10.3389/frobt.2020.506984 [doi]
AB  - The history of humankind is full of examples that indicate a constant desire to
      make human beings more moral. Nowadays, technological breakthroughs might have a 
      significant impact on our moral character and abilities. This is the case of
      Virtual Reality (VR) technologies. The aim of this paper is to consider the
      ethical aspects of the use of VR in enhancing empathy. First, we will offer an
      introduction to VR, explaining its fundamental features, devices and concepts.
      Then, we will approach the characterization of VR as an "empathy machine,"
      showing why this medium has aroused so much interest and why, nevertheless, we do
      not believe it is the ideal way to enhance empathy. As an alternative, we will
      consider fostering empathy-related abilities through virtual embodiment in
      avatars. In the conclusion, however, we will examine some of the serious concerns
      related to the ethical relevance of empathy and will defend the philosophical
      case for a reason-guided empathy, also suggesting specific guidelines for
      possible future developments of empathy enhancement projects through VR embodied 
      experiences.
CI  - Copyright (c) 2020 Rueda and Lara.
FAU - Rueda, Jon
AU  - Rueda J
AD  - FiloLab Scientific Unit of Excellence, Department of Philosophy, University of
      Granada, Granada, Spain.
FAU - Lara, Francisco
AU  - Lara F
AD  - FiloLab Scientific Unit of Excellence, Department of Philosophy, University of
      Granada, Granada, Spain.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20201109
PL  - Switzerland
TA  - Front Robot AI
JT  - Frontiers in robotics and AI
JID - 101749350
PMC - PMC7805945
OTO - NOTNLM
OT  - applied ethics
OT  - empathy
OT  - empathy enhancement
OT  - moral enhancement
OT  - moral psychology
OT  - neuroethics
OT  - virtual embodiment
OT  - virtual reality
EDAT- 2021/01/28 06:00
MHDA- 2021/01/28 06:01
CRDT- 2021/01/27 05:53
PHST- 2019/10/30 00:00 [received]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2021/01/27 05:53 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/01/28 06:01 [medline]
AID - 10.3389/frobt.2020.506984 [doi]
PST - epublish
SO  - Front Robot AI. 2020 Nov 9;7:506984. doi: 10.3389/frobt.2020.506984. eCollection 
      2020.


PMID- 33501191
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210129
IS  - 2296-9144 (Electronic)
IS  - 2296-9144 (Linking)
VI  - 7
DP  - 2020
TI  - A Self-Guiding Tool to Conduct Research With Embodiment Technologies Responsibly.
PG  - 22
LID - 10.3389/frobt.2020.00022 [doi]
AB  - The extension of the sense of self to the avatar during experiences of avatar
      embodiment requires thorough ethical and legal consideration, especially in light
      of potential scenarios involving physical or psychological harm caused to, or by,
      embodied avatars. We provide researchers and developers working in the field of
      virtual and robot embodiment technologies with a self-guidance tool based on the 
      principles of Responsible Research and Innovation (RRI). This tool will help them
      engage in ethical and responsible research and innovation in the area of
      embodiment technologies in a way that guarantees all the rights of the embodied
      users and their interactors, including safety, privacy, autonomy, and dignity.
CI  - Copyright (c) 2020 Aymerich-Franch and Fosch-Villaronga.
FAU - Aymerich-Franch, Laura
AU  - Aymerich-Franch L
AD  - Communication Department, Pompeu Fabra University, Barcelona, Spain.
FAU - Fosch-Villaronga, Eduard
AU  - Fosch-Villaronga E
AD  - eLaw - Center for Law and Digital Technologies, Leiden University, Leiden,
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200221
PL  - Switzerland
TA  - Front Robot AI
JT  - Frontiers in robotics and AI
JID - 101749350
PMC - PMC7805620
OTO - NOTNLM
OT  - avatars
OT  - body ownership
OT  - embodiment
OT  - embodiment technologies
OT  - ethics
OT  - responsible research & innovation (RRI)
OT  - social robots
OT  - virtual reality
EDAT- 2021/01/28 06:00
MHDA- 2021/01/28 06:01
CRDT- 2021/01/27 05:53
PHST- 2019/08/14 00:00 [received]
PHST- 2020/02/06 00:00 [accepted]
PHST- 2021/01/27 05:53 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/01/28 06:01 [medline]
AID - 10.3389/frobt.2020.00022 [doi]
PST - epublish
SO  - Front Robot AI. 2020 Feb 21;7:22. doi: 10.3389/frobt.2020.00022. eCollection
      2020.


PMID- 33501170
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210129
IS  - 2296-9144 (Electronic)
IS  - 2296-9144 (Linking)
VI  - 7
DP  - 2020
TI  - Designing Ethical Social Robots-A Longitudinal Field Study With Older Adults.
PG  - 1
LID - 10.3389/frobt.2020.00001 [doi]
AB  - Emotional deception and emotional attachment are regarded as ethical concerns in 
      human-robot interaction. Considering these concerns is essential, particularly as
      little is known about longitudinal effects of interactions with social robots. We
      ran a longitudinal user study with older adults in two retirement villages, where
      people interacted with a robot in a didactic setting for eight sessions over a
      period of 4 weeks. The robot would show either non-emotive or emotive behavior
      during these interactions in order to investigate emotional deception.
      Questionnaires were given to investigate participants' acceptance of the robot,
      perception of the social interactions with the robot and attachment to the robot.
      Results show that the robot's behavior did not seem to influence participants'
      acceptance of the robot, perception of the interaction or attachment to the
      robot. Time did not appear to influence participants' level of attachment to the 
      robot, which ranged from low to medium. The perceived ease of using the robot
      significantly increased over time. These findings indicate that a robot showing
      emotions-and perhaps resulting in users being deceived-in a didactic setting may 
      not by default negatively influence participants' acceptance and perception of
      the robot, and that older adults may not become distressed if the robot would
      break or be taken away from them, as attachment to the robot in this didactic
      setting was not high. However, more research is required as there may be other
      factors influencing these ethical concerns, and support through other
      measurements than questionnaires is required to be able to draw conclusions
      regarding these concerns.
CI  - Copyright (c) 2020 van Maris, Zook, Caleb-Solly, Studley, Winfield and
      Dogramadzi.
FAU - van Maris, Anouk
AU  - van Maris A
AD  - Bristol Robotics Laboratory, University of the West of England, Bristol, United
      Kingdom.
FAU - Zook, Nancy
AU  - Zook N
AD  - Department of Health and Social Sciences, University of the West of England,
      Bristol, United Kingdom.
FAU - Caleb-Solly, Praminda
AU  - Caleb-Solly P
AD  - Bristol Robotics Laboratory, University of the West of England, Bristol, United
      Kingdom.
FAU - Studley, Matthew
AU  - Studley M
AD  - Bristol Robotics Laboratory, University of the West of England, Bristol, United
      Kingdom.
FAU - Winfield, Alan
AU  - Winfield A
AD  - Bristol Robotics Laboratory, University of the West of England, Bristol, United
      Kingdom.
FAU - Dogramadzi, Sanja
AU  - Dogramadzi S
AD  - Bristol Robotics Laboratory, University of the West of England, Bristol, United
      Kingdom.
AD  - Department of Automatic Control and Systems Engineering, The University of
      Sheffield, Sheffield, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200124
PL  - Switzerland
TA  - Front Robot AI
JT  - Frontiers in robotics and AI
JID - 101749350
PMC - PMC7805906
OTO - NOTNLM
OT  - attachment
OT  - deception
OT  - ethics
OT  - longitudinal study
OT  - older adults
OT  - social robots
EDAT- 2021/01/28 06:00
MHDA- 2021/01/28 06:01
CRDT- 2021/01/27 05:53
PHST- 2019/07/15 00:00 [received]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2021/01/27 05:53 [entrez]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/01/28 06:01 [medline]
AID - 10.3389/frobt.2020.00001 [doi]
PST - epublish
SO  - Front Robot AI. 2020 Jan 24;7:1. doi: 10.3389/frobt.2020.00001. eCollection 2020.


PMID- 33497095
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1538-8689 (Electronic)
IS  - 0360-4039 (Linking)
VI  - 50
IP  - 12
DP  - 2020 Dec 1
TI  - Ethical tipping point: Nurses' presence on social media.
PG  - 52-54
LID - 10.1097/01.NURSE.0000694768.02007.f1 [doi]
AB  - ABSTRACT: This article discusses ethical concerns surrounding social media
      content posted by nurses; specifically, how these posts may violate public trust.
      It also summarizes considerations for nurses to contemplate before posting to
      social media and provides examples of positive uses of social media.
CI  - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Steers, Mai-Ly N
AU  - Steers MN
AD  - Mai-Ly N. Steers and Sarah F. Gallups are assistant professors at Duquesne
      University in Pittsburgh, Pa.
FAU - Gallups, Sarah F
AU  - Gallups SF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nursing
JT  - Nursing
JID - 7600137
MH  - *Ethics, Nursing
MH  - Humans
MH  - Social Media/*ethics
EDAT- 2021/01/27 06:00
MHDA- 2021/02/03 06:00
CRDT- 2021/01/26 13:50
PHST- 2021/01/26 13:50 [entrez]
PHST- 2021/01/27 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - 10.1097/01.NURSE.0000694768.02007.f1 [doi]
AID - 00152193-202012000-00014 [pii]
PST - ppublish
SO  - Nursing. 2020 Dec 1;50(12):52-54. doi: 10.1097/01.NURSE.0000694768.02007.f1.


PMID- 33496252
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1646-0758 (Electronic)
IS  - 0870-399X (Linking)
VI  - 33
IP  - 12
DP  - 2020 Dec 2
TI  - [A New Paradigm in Health Research: FAIR Data (Findable, Accessible,
      Interoperable, Reusable)].
PG  - 828-834
LID - 10.20344/amp.12910 [doi]
AB  - The digital era, that we are living nowadays, is transforming health, health care
      models and services, and the role of society in this new reality. We currently
      have a large amount of stored health data, including clinical, biometric, and
      scientific research data. Nonetheless, its potential is not being fully
      exploited. It is essential to foster the sharing and reuse of this data not only 
      in research but also towards the development of health technologies in order to
      improve health care efficiency, as well as products, services or digital health
      apps, to promote preventive and individualized medicine and to empower citizens
      in health literacy and self-management. In this sense, the FAIR concept has
      emerged, which implies that health data is findable, accessible, shared and
      reusable, facilitating interoperability between systems, ensuring the protection 
      of personal and sensitive data. In this paper we review the FAIR concept,
      'FAIRification' process, FAIR data versus open access data, ethical issues and
      the general data protection regulation, and digital health and citizen science.
FAU - Almada, Marta
AU  - Almada M
AD  - UCIBIO/REQUIMTE. Faculty of Pharmacy and Competences Centre on Active and Healthy
      Ageing (Porto4Ageing). University of Porto. Porto. Portugal.
FAU - Midao, Luis
AU  - Midao L
AD  - UCIBIO/REQUIMTE. Faculty of Pharmacy and Competences Centre on Active and Healthy
      Ageing (Porto4Ageing). University of Porto. Porto. Portugal.
FAU - Portela, Diana
AU  - Portela D
AD  - Agrupamentos de Centros de Saude Entre Douro e Vouga I. Feira Arouca. Santa Maria
      da Feira. Centre for Health Technology and Services Research (CINTESIS). Faculty 
      of Medicine. University of Porto. Porto. Portugal.
FAU - Dias, Ines
AU  - Dias I
AD  - UCIBIO/REQUIMTE. Faculty of Pharmacy and Competences Centre on Active and Healthy
      Ageing (Porto4Ageing). University of Porto. Porto. Portugal.
FAU - Nunez-Benjumea, Francisco J
AU  - Nunez-Benjumea FJ
AD  - Group of Research and Innovation in Biomedical Informatics, Biomedical
      Engineering and Health Economy. Institute of Biomedicine of Seville. IBiS /
      Virgen del Rocio University Hospital / CSIC / University of Seville. Seville.
      Spain. Espanha.
FAU - Parra-Calderon, Carlos L
AU  - Parra-Calderon CL
AD  - Group of Research and Innovation in Biomedical Informatics, Biomedical
      Engineering and Health Economy. Institute of Biomedicine of Seville. IBiS /
      Virgen del Rocio University Hospital / CSIC / University of Seville. Seville.
      Spain. Espanha.
FAU - Costa, Elisio
AU  - Costa E
AD  - UCIBIO/REQUIMTE. Faculty of Pharmacy and Competences Centre on Active and Healthy
      Ageing (Porto4Ageing). University of Porto. Porto. Biochemistry Laboratory.
      Biological Sciences Department. Faculty of Pharmacy. University of Porto. Porto. 
      Portugal.
LA  - por
PT  - Journal Article
PT  - Review
TT  - Um Novo Paradigma em Investigacao em Saude: Dados FAIR (Localizaveis, Acessiveis,
      Interoperaveis, Reutilizaveis).
DEP - 20201202
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
SB  - IM
MH  - *Access to Information
MH  - *Biomedical Research
MH  - *Data Management/ethics
MH  - *Databases, Factual
MH  - *Health Information Interoperability
MH  - Humans
OTO - NOTNLM
OT  - Databases, Factual
OT  - Health Information Management
OT  - Health Information Systems
OT  - Information Dissemination
OT  - Metadata
OT  - Research
EDAT- 2021/01/27 06:00
MHDA- 2021/03/12 06:00
CRDT- 2021/01/26 08:36
PHST- 2019/10/04 00:00 [received]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2019/12/02 00:00 [revised]
PHST- 2021/01/26 08:36 [entrez]
PHST- 2021/01/27 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - 10.20344/amp.12910 [doi]
PST - ppublish
SO  - Acta Med Port. 2020 Dec 2;33(12):828-834. doi: 10.20344/amp.12910. Epub 2020 Dec 
      2.


PMID- 33490861
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Implementing a National Approach to Research Ethics Review during a Pandemic -
      the Irish Experience.
PG  - 63
LID - 10.12688/hrbopenres.13146.2 [doi]
AB  - The surge of coronavirus disease 2019 (COVID-19) research studies involving human
      participants in response to the pandemic has meant that research ethics
      committees across the world have been challenged to adapt their processes to meet
      demand while retaining high standards of review. Ethics review during this
      pandemic remains essential to ensure the safety, dignity and well-being of
      research participants, however research ethics committees are now faced with new,
      and often complex, ethics considerations and logistical challenges. This Open
      Letter looks specifically at the Irish experience of establishing a national
      approach to research ethics review amidst a global pandemic. This represents
      Ireland's first National Research Ethics Committee, which provided the research
      community with an expedited and 'single national opinion' for ethics review for
      COVID-related research. The insights gleaned and lessons learned from the Irish
      experience may inform emergency responses to future pandemics or public health
      emergencies.
CI  - Copyright: (c) 2020 Sheehy A et al.
FAU - Sheehy, Aileen
AU  - Sheehy A
AD  - National Office for Research Ethics Committees, Dublin, Ireland.
FAU - Ralph James, Jennifer
AU  - Ralph James J
AD  - National Office for Research Ethics Committees, Dublin, Ireland.
FAU - Horgan, Mary
AU  - Horgan M
AD  - Royal College of Physicians of Ireland, Dublin, Ireland.
AD  - School of Medicine, University College Cork, Cork, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7797935
OTO - NOTNLM
OT  - COVID-19
OT  - National Research Ethics Committees
OT  - Research Ethics
OT  - Research Integrity
COIS- No competing interests were disclosed.
EDAT- 2021/01/27 06:00
MHDA- 2021/01/27 06:01
CRDT- 2021/01/26 05:49
PHST- 2020/11/09 00:00 [accepted]
PHST- 2021/01/26 05:49 [entrez]
PHST- 2021/01/27 06:00 [pubmed]
PHST- 2021/01/27 06:01 [medline]
AID - 10.12688/hrbopenres.13146.2 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Nov 16;3:63. doi: 10.12688/hrbopenres.13146.2. eCollection
      2020.


PMID- 33490011
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Collision of Fundamental Human Rights and the Right to Health Access During the
      Novel Coronavirus Pandemic.
PG  - 570243
LID - 10.3389/fpubh.2020.570243 [doi]
AB  - Introduction: COVID-19 requires governmental measures to protect healthcare
      system access for people. In this process, the collision of fundamental rights
      emerges as a crucial challenge for decision-making. Policy Options and
      Implications: This policy review analyzes selected articles by the PubMed
      searcher about extreme measures taken in several countries during precedent
      pandemics and the current pandemic, and selects hard decisions relating to the
      exceptional measures taken by judicial departments in Brazil, connecting them to 
      the "collision of fundamental rights and law principles." The collision of rights
      and principles imposed on decision makers a duty to provide balanced rights, and 
      to adopt the enforcement of some rights prioritization. Ethical concerns were
      also verified in this field involving rights limitations. During a pandemic, the 
      importance of extreme measures to protect health rights and healthcare systems is
      instrumental for focused, fast, and correct decision making to avoid loss of life
      and the collapse of healthcare systems. The main goals of this research are to
      discuss the implications and guidelines for public health decision making, the
      indispensable ethical and legal aspects for safeguarding health systems and the
      lives of people, and the respect of the Justice principle and of fundamental
      health and dignity rights. We conclude that COVID-19 justifies the prioritization
      of collective and individual health access rights. Acceptable standards of
      fundamental rights restrictions are established at the constitutional and
      international levels and must be enforced by rules and governmental action, to
      ensure fast and accurate decision making during a pandemic. Freedom rights
      exercises must be linked to solidarity for the realization of social welfare, for
      the health rights of all individuals and for health systems to function well
      during a pandemic. Actionable Recommendations: All individuals are free and
      equal, therefore social exclusion is prohibited. Institutions must consider
      social inequalities when discussing public health measures and be guided by
      ethical standards, by law principles, and rules recognized by constitutional and 
      international law for the benefit of all during a health pandemic. Conclusions:
      Collective and individual health rights prevail over the collision of rights when
      facing pandemic occurrences, case by case, in health systems protection, based on
      the literature, on precedent pandemics and on legitimate Public Health efforts.
CI  - Copyright (c) 2021 dos Santos, Stein Messetti, Adami, Bezerra, Maia,
      Tristan-Cheever and Abreu.
FAU - Dos Santos, Jose Luiz Gondim
AU  - Dos Santos JLG
AD  - Laboratorio de Delineamento de Estudos e de Escrita Cientifica, Centro
      Universitario Saude ABC Faculdade de Medicina do ABC (FMABC), Santo Andre,
      Brazil.
FAU - Stein Messetti, Paulo Andre
AU  - Stein Messetti PA
AD  - Laboratorio de Delineamento de Estudos e de Escrita Cientifica, Centro
      Universitario Saude ABC Faculdade de Medicina do ABC (FMABC), Santo Andre,
      Brazil.
FAU - Adami, Fernando
AU  - Adami F
AD  - Laboratorio de Delineamento de Estudos e de Escrita Cientifica, Centro
      Universitario Saude ABC Faculdade de Medicina do ABC (FMABC), Santo Andre,
      Brazil.
FAU - Bezerra, Italla Maria Pinheiro
AU  - Bezerra IMP
AD  - Laboratorio de Delineamento de Estudos e de Escrita Cientifica, Centro
      Universitario Saude ABC Faculdade de Medicina do ABC (FMABC), Santo Andre,
      Brazil.
FAU - Maia, Paula Christianne G G Souto
AU  - Maia PCGGS
AD  - Laboratorio de Delineamento de Estudos e de Escrita Cientifica, Centro
      Universitario Saude ABC Faculdade de Medicina do ABC (FMABC), Santo Andre,
      Brazil.
FAU - Tristan-Cheever, Elisa
AU  - Tristan-Cheever E
AD  - Cambridge Health Alliance, Cambridge, MA, United States.
AD  - Programa de Pos-Graduacao em Ciencias Medicas, Faculdade de Medicina da
      Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - de Abreu, Luiz Carlos
AU  - de Abreu LC
AD  - Laboratorio de Delineamento de Estudos e de Escrita Cientifica, Centro
      Universitario Saude ABC Faculdade de Medicina do ABC (FMABC), Santo Andre,
      Brazil.
AD  - Programa de Pos-Graduacao em Ciencias Medicas, Faculdade de Medicina da
      Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - School of Medicine, University of Limerick, Limerick, Ireland.
AD  - Federal University of Espirito Santo, Vitoria, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20210108
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Brazil
MH  - *COVID-19
MH  - Decision Making
MH  - *Health Services Accessibility
MH  - Human Rights/*ethics
MH  - Humans
MH  - Public Health
MH  - *Public Policy
MH  - *Right to Health
PMC - PMC7820746
OTO - NOTNLM
OT  - coronavirus infections
OT  - court decisions
OT  - human rights abuses
OT  - jurisprudence
OT  - right to health
EDAT- 2021/01/26 06:00
MHDA- 2021/02/03 06:00
CRDT- 2021/01/25 05:44
PHST- 2020/06/06 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2021/01/25 05:44 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - 10.3389/fpubh.2020.570243 [doi]
PST - epublish
SO  - Front Public Health. 2021 Jan 8;8:570243. doi: 10.3389/fpubh.2020.570243.
      eCollection 2020.


PMID- 33489836
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2229-3485 (Print)
IS  - 2229-3485 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Consent concerns in clinical trials of investigational therapies for COVID-19:
      Vulnerability versus voluntariness.
PG  - 174-177
LID - 10.4103/picr.PICR_271_20 [doi]
AB  - Obtaining informed consent from vulnerable patients participating in clinical
      trials of investigational therapies for COVID-19 is a major ethical challenge.
      Ethical and operational considerations - voluntariness, waiver, timing, time,
      documentation, and responsibilities of the sponsor, the investigator, and the
      ethics committee - are discussed briefly.
CI  - Copyright: (c) 2020 Perspectives in Clinical Research.
FAU - Bhatt, Arun
AU  - Bhatt A
AD  - Consultant - Clinical Research and Drug Development, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - India
TA  - Perspect Clin Res
JT  - Perspectives in clinical research
JID - 101551517
PMC - PMC7819368
OTO - NOTNLM
OT  - Consent
OT  - screening
OT  - vulnerability
OT  - waiver
COIS- There are no conflicts of interest.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:44
PHST- 2020/08/17 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2021/01/25 05:44 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.4103/picr.PICR_271_20 [doi]
AID - PCR-11-174 [pii]
PST - ppublish
SO  - Perspect Clin Res. 2020 Oct-Dec;11(4):174-177. doi: 10.4103/picr.PICR_271_20.
      Epub 2020 Oct 6.


PMID- 33489806
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2218-6751 (Print)
IS  - 2218-6751 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Dec
TI  - Treatment patterns, clinical outcomes, and healthcare resource use associated
      with advanced/metastatic lung cancer in China: protocol for a retrospective
      observational study.
PG  - 2460-2468
LID - 10.21037/tlcr-20-1269 [doi]
AB  - BACKGROUND: Lung cancer (LC) is the most common cancer worldwide. The prevalence 
      of LC and rate of associated mortality are high and increasing faster in China
      than in Western countries. Non-small cell lung cancer (NSCLC) accounts for most
      LCs. This study aims to be the first large, multi-center, non-interventional
      retrospective study of treatment patterns (type/duration, number of lines,
      completion rate), real-world outcomes, and medical costs among Chinese patients
      with advanced/metastatic NSCLC (IIIb/IV) or extensive-stage small cell LC
      (ES-SCLC). METHODS: This study will enroll 8,800 patients (>/=18 years, with a
      diagnosis of advanced/metastatic NSCLC made between 1 December 2013 to 30
      November 2014) from 35 to 50 Chinese sites. Hospital information systems (HIS)
      and electronic medical records will be retrospectively reviewed, in adherence
      with regulatory and ethical requirements. Early-stage treatment (starting from 1 
      December 2010) of patients with recurrent disease or early disease progression
      will be examined. Data will be collected at baseline (diagnosis) and 6 and 12
      months after this. Observation will end after 3 years or death. Data will be
      stratified by histology, staging, age, region, health insurance, and epidermal
      growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) mutation status.
      Treatment duration and overall survival will be estimated using Kaplan-Meier
      curves. Descriptive statistics will be used for disease characteristics and
      patient demographics. Cox-proportional hazards models will be used to examine the
      impact of demographics/treatment on survival. Treatment patterns and outcome
      predictors will be explored using multivariate logistic regression. DISCUSSION:
      This protocol describes the methodology for collecting real-world data to guide
      evidence-based clinical practice and inform unmet needs in NSCLC treatment, with 
      potential to identify gaps between guidelines and current practice. TRIAL
      REGISTRATION: NCT03505515; data registered on ClinicalTrials.gov: 12h Apr., 2018.
CI  - 2020 Translational Lung Cancer Research. All rights reserved.
FAU - Qiu, Bin
AU  - Qiu B
AD  - Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Li, Gaofeng
AU  - Li G
AD  - Yunnan Cancer Hospital, Kunming, China.
FAU - Luo, Feng
AU  - Luo F
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Cai, Xiaohong
AU  - Cai X
AD  - Sichuan Cancer Hospital & Institute, Chengdu, China.
FAU - Wu, Lin
AU  - Wu L
AD  - Hunan Cancer Hospital, Changsha, China.
FAU - Chen, Jianhua
AU  - Chen J
AD  - Hunan Cancer Hospital, Changsha, China.
FAU - Hu, Yanping
AU  - Hu Y
AD  - Hubei Cancer Hospital, Hubei, China.
FAU - Tang, Zhiliu
AU  - Tang Z
AD  - Bristol-Myers Squibb, Shanghai, China (was with BMS at the time when the research
      and the manuscript were conducted).
FAU - Yang, Shuo
AU  - Yang S
AD  - Bristol-Myers Squibb, Shanghai, China.
FAU - He, Jie
AU  - He J
AD  - Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03505515
PT  - Journal Article
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC7815359
OTO - NOTNLM
OT  - China
OT  - clinical protocol
OT  - lung neoplasms
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/tlcr-20-1269). ZT was employed by
      Bristol-Myers Squibb at the time the manuscript was prepared, and SY is employed 
      by Bristol-Myers Squibb. The other authors have no conflicts of interest to
      declare.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:43
PHST- 2021/01/25 05:43 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.21037/tlcr-20-1269 [doi]
AID - tlcr-09-06-2460 [pii]
PST - ppublish
SO  - Transl Lung Cancer Res. 2020 Dec;9(6):2460-2468. doi: 10.21037/tlcr-20-1269.


PMID- 33489548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 18
TI  - Lateral Arm Flap: Its Usage as Pedicle and Free Flap.
PG  - e12136
LID - 10.7759/cureus.12136 [doi]
AB  - Introduction The lateral arm flap is an excellent flap for both local and
      microvascular reconstruction. For local reconstruction on the upper extremity or 
      as a distant microvascular flap, its advantages include short operation time,
      thin pliable tissue, non-dominant vessel, and minimal donor site morbidity.
      Moreover, it fulfills the goal of optimal reconstruction of form, function, and
      aesthetics. The objective is to share our experience of using the lateral arm
      flap, both as a free flap and as a pedicled flap. Methods After taking exemption 
      from the ethical review committee (ERC) of Aga Khan University Hospital, a
      retrospective data analysis of patients who had undergone lateral arm flap at the
      Plastic and Reconstructive Surgery department of the Aga Khan University Hospital
      was carried out from January 2012 to December 2019. The data examined included
      the patient's age, gender, diagnosis, location of the defect, size of the flap,
      and outcome of the flap at three weeks post-operation. For free flaps, data of
      the recipient artery used for anastomosis and the number of veins anastomosed
      were also included. Results Over a period of eight years, 33 lateral arm flaps
      were performed, including 23 free flaps and 10 pedicled flaps. The average size
      of the free flap was 12x6 cm and that of the pedicled flap was 8x5 cm. In the
      free-flap group, there was a failure in three flaps, two of which were due to
      arterial anastomosis in the zone of injury. There were no failures in the
      pedicled flap group. Conclusion The lateral arm flap is a reliable flap, with
      consistent anatomy, which can be used for coverage in different parts of the
      body.
CI  - Copyright (c) 2020, Ullah et al.
FAU - Ullah, Sami
AU  - Ullah S
AD  - Plastic and Reconstructive Surgery, Shaukat Khanum Memorial Cancer Hospital and
      Research Centre, Lahore, PAK.
FAU - Asif, Muhammad
AU  - Asif M
AD  - Plastic Surgery, Cancer Foundation Hospital, Karachi, PAK.
AD  - Community Health Sciences, Aga Khan University, Karachi, PAK.
FAU - Ubaid, Muhammad
AU  - Ubaid M
AD  - Plastic and Reconstructive Surgery, Aga Khan University Hospital, Karachi, PAK.
FAU - Khalid, Amna
AU  - Khalid A
AD  - Plastic and Reconstructive Surgery, Aga Khan University Hospital, Karachi, PAK.
FAU - Khan, Majid
AU  - Khan M
AD  - Plastic and Reconstructive Surgery, Aga Khan University Hospital, Karachi, PAK.
FAU - Rahman, Mohammad Fazlur
AU  - Rahman MF
AD  - Plastic and Reconstructive Surgery, Aga Khan University Hospital, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7811680
OTO - NOTNLM
OT  - extended lateral arm flap (elaf)
OT  - free lateral arm flap (flaf)
OT  - pedicle lateral arm flap (plaf)
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:43
PHST- 2021/01/25 05:43 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.7759/cureus.12136 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 18;12(12):e12136. doi: 10.7759/cureus.12136.


PMID- 33489547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 17
TI  - Role, Effectiveness, and Outcome of Decompressive Craniectomy for Cerebral Venous
      and Dural Sinus Thrombosis (CVST): Is Surgery Really an Option?
PG  - e12135
LID - 10.7759/cureus.12135 [doi]
AB  - Cerebral venous and dural sinus thrombosis (CVST) is predominantly a disease of
      young people. It accounts for 0.5% of all strokes, and patients usually have good
      outcomes. However, a minority of patients may present with elevated intracranial 
      pressure characteristics in a serious illness type and may die from brain
      herniation if not treated promptly. Decompressive craniectomy (DC) is the only
      treatment modality that can prevent death in such cases of imminent brain
      herniation. Unfortunately, due to the condition's rarity and ethical concerns,
      randomized controlled trials are not available. This review assessed the
      available literature on cerebral venous and dural sinus thrombosis in different
      age groups and decompressive craniectomy in cerebral venous and dural sinus
      thrombosis. It revealed that decompressive surgery is extremely effective when
      done early and for the correct indications with patients achieving excellent
      functional outcomes post-surgery. Decompressive surgery is recommended in rapidly
      deteriorating patients with computed tomography (CT) scan evidence of basal
      cisterns effacement, a mass effect from haemorrhage and/or infarction, and
      significant midline shift.
CI  - Copyright (c) 2020, Mohamed et al.
FAU - Mohamed, Mohamed Wael F
AU  - Mohamed MWF
AD  - Neurological Surgery, Royal London Hospital, London, GBR.
FAU - Aung, Su Sandi
AU  - Aung SS
AD  - Medicine and Surgery, University of Medicine 1, Yangon, MMR.
FAU - Mereddy, Nakul
AU  - Mereddy N
AD  - Medicine and Surgery, Bhaskar Medical College, Hyderabad, IND.
FAU - Ramanan, Sruthi Priyavadhana
AU  - Ramanan SP
AD  - Medicine and Surgery, Saveetha Medical College, Chennai, IND.
FAU - Hamid, Pousette
AU  - Hamid P
AD  - Neurology, California Institute of Behavioral Neurosciences and Psychology,
      Fairfield, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201217
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7811578
OTO - NOTNLM
OT  - brain herniation
OT  - cerebral venous and dural sinus thrombosis
OT  - decompressive craniectomy
OT  - outcome
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:43
PHST- 2021/01/25 05:43 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.7759/cureus.12135 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 17;12(12):e12135. doi: 10.7759/cureus.12135.


PMID- 33489454
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2160-1992 (Print)
IS  - 2160-1992 (Linking)
VI  - 10
IP  - 6
DP  - 2020
TI  - Al-hijamah (the triple S treatment of prophetic medicine) exerts
      cardioprotective, tissue-protective and immune potentiating effects in
      thalassemic children: a pilot clinical trial.
PG  - 447-458
AB  - Thalassemia is a major health problem in affected children due to iron overload, 
      increased oxidative stress, atherogenic lipid profile and tissue-damage. This
      study aims at investigating the cardioprotective and tissue-protective benefits
      of Al-hijamah and their impact on cell-mediated immunity for treating thalassemic
      children. This study aimed also at investigating the tissue-clearance principle
      of Taibah mechanism: whenever pathological substances are to be cleared from the 
      human body, Al-hijamah is indicated. Al-hijamah was done to thalassemic children 
      (15 males and 5 females having a mean age of 9.07 +/- 4.26 years) using sterile
      disposable sets in a complete aseptic hospital environment. Prior ethical
      committee agreement (in addition to written patient's consents) was obtained from
      Tanta Faculty of Medicine, Egypt. Twenty thalassemic children received iron
      chelation therapy plus Al-hijamah for one session (30-60 minutes) versus an age
      and sex-matched thalassemic control group treated with iron chelation therapy
      only. Al-hijamah is a quite safe outpatient hematological procedure that
      significantly decreased serum cholesterol (from 129.75 +/- 3.67 to 103.5 +/- 4.18
      mg/dl) and decreased serum triglycerides (from 109.25 +/- 8.96 to 91.95 +/- 7.22 
      mg/dl). Interestingly, Al-hijamah exerted significant tissue-protective effects
      (it decreased serum GPT from 98.65 +/- 12.27 to 71.65 +/- 32.78 U/L and serum GOT
      from 96.35 +/- 14.33 to 69.35 +/- 34.37 U/L). Al-hijamah-induced ferritin
      excretion caused decreased serum ferritin (high serum ferritin negatively
      correlated with cell mediated immunity). Al-hijamah exerted cardioprotective and 
      tissue-protective and hypolipidemic effects. Al-hijamah decreased serum
      cholesterol and is cardioprotective for thalassemic patients as it protects
      against atherogenesis and atherosclerosis. Medical practice of Al-hijamah is
      strongly recommended in hospitals. Al-hijamah cleared blood significantly from
      causative pathological substances e.g. serum ferritin resulting in enhanced
      cell-mediated immunity (in agreement with the evidence-based Taibah mechanism).
CI  - AJBR Copyright (c) 2020.
FAU - El-Shanshory, Mohamed
AU  - El-Shanshory M
AD  - Prophetic Medicine Course and Research Group, Taibah College of Medicine
      Al-Madinah Al-Munawwarah, Saudi Arabia.
AD  - Department of Pediatrics, Tanta University Faculty of Medicine Tanta, Gharbia,
      Egypt.
FAU - Hablas, Nahed Mohammed
AU  - Hablas NM
AD  - Department of Pediatrics, Tanta University Faculty of Medicine Tanta, Gharbia,
      Egypt.
FAU - Shebel, Yasmin
AU  - Shebel Y
AD  - Department of Pediatrics, Tanta University Faculty of Medicine Tanta, Gharbia,
      Egypt.
FAU - Alhadramy, Osama
AU  - Alhadramy O
AD  - Division of Cardiology, Department of Medicine, Taibah College of Medicine,
      Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - El-Tahlawi, Rehab
AU  - El-Tahlawi R
AD  - Department of Microbiology, College of Medicine, Taibah University Saudi Arabia.
AD  - Department of Microbiology, Faculty of Medicine, Zagazig University Egypt.
FAU - Aboonq, Moutasem Salih
AU  - Aboonq MS
AD  - Department of Medical Physiology, Taibah College of Medicine, Taibah University
      Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Soliman, Tamer M
AU  - Soliman TM
AD  - Department of Clinical Pathology, Sohag Faculty of Medicine, Sohag University
      Sohag, Egypt.
FAU - Abdel-Gawad, Abdelhady Ragab
AU  - Abdel-Gawad AR
AD  - Department of Clinical Pathology, Sohag Faculty of Medicine, Sohag University
      Sohag, Egypt.
FAU - El Sayed, Sayed Mostafa
AU  - El Sayed SM
AD  - Department of Anatomy, Faculty of Medicine, Ain Shams University Egypt.
AD  - Department of Anatomy, Taibah Faculty of Medicine, Taibah University Al-Madinah
      Al-Munawwarah, Saudi Arabia.
FAU - Abdallah, Hesham I
AU  - Abdallah HI
AD  - Department of Anatomy, Faculty of Medicine, Ain Shams University Egypt.
AD  - Department of Anatomy, Taibah Faculty of Medicine, Taibah University Al-Madinah
      Al-Munawwarah, Saudi Arabia.
FAU - Mahmoud, Hany Salah
AU  - Mahmoud HS
AD  - Center of Scientific Foundation for Experimental Studies and Research Ismailia,
      Egypt.
FAU - El-Allaf, Hassan
AU  - El-Allaf H
AD  - Department of Medical Physiology, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - El-Sawy, Samer
AU  - El-Sawy S
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Yousef, Reda S
AU  - Yousef RS
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Abu-El Naga, Mostafa
AU  - Abu-El Naga M
AD  - Department of Anatomy, College of Medicine, Al-Rayyan National Colleges
      Al-Madinah, Saudi Arabia.
AD  - Department of Anatomy, Faculty of Medicine, New Damietta, Al-Azhar University
      Egypt.
FAU - Mariah, Reham A
AU  - Mariah RA
AD  - Department of Medical Biochemistry, Tanta Faculty of Medicine, Tanta University
      Tanta, Egypt.
FAU - Nabo, Manal Mohamed Helmy
AU  - Nabo MMH
AD  - Division of Pediatric Cardiology, Pediatrics Department, Maternity and Children
      Hospital Hail, Saudi Arabia.
AD  - Division of Pediatric Cardiology, Pediatrics Department, Sohag Teaching Hospital,
      Ministry of Health Sohag, Egypt.
FAU - Abdel-Haleem, Mohamed
AU  - Abdel-Haleem M
AD  - Department of Ear, Nose and Throat, Taibah Faculty of Medicine, Taibah University
      Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Mahmoud, Ahmed Alamir
AU  - Mahmoud AA
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Hassan, Mohammad Ahmad
AU  - Hassan MA
AD  - Department of Pediatrics, Sohag Faculty of Medicine Sohag, Egypt.
FAU - Al Arabi, Areej Hesham
AU  - Al Arabi AH
AD  - Department of Cardiology, Governorate of Health, Uhud Hospital Al-Madinah
      Al-Munawwarah, Saudi Arabia.
FAU - Alnakhli, Abdullah Ahmed
AU  - Alnakhli AA
AD  - Department of Cardiology, Governorate of Health, Uhud Hospital Al-Madinah
      Al-Munawwarah, Saudi Arabia.
FAU - El Sayed, Salah Mohamed
AU  - El Sayed SM
AD  - Prophetic Medicine Course and Research Group, Taibah College of Medicine
      Al-Madinah Al-Munawwarah, Saudi Arabia.
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
AD  - Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of
      Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20201215
PL  - United States
TA  - Am J Blood Res
JT  - American journal of blood research
JID - 101569577
PMC - PMC7811902
OTO - NOTNLM
OT  - Al-hijamah
OT  - Al-hijamah indices
OT  - Thalassemia
OT  - cholesterol
OT  - clearance
OT  - iron chelation therapy
OT  - liver functions
COIS- None.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:42
PHST- 2020/05/12 00:00 [received]
PHST- 2020/10/24 00:00 [accepted]
PHST- 2021/01/25 05:42 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
PST - epublish
SO  - Am J Blood Res. 2020 Dec 15;10(6):447-458. eCollection 2020.


PMID- 33489449
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2160-1992 (Print)
IS  - 2160-1992 (Linking)
VI  - 10
IP  - 6
DP  - 2020
TI  - TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid 
      reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and 
      treatment of COVID-19 pandemic.
PG  - 397-406
AB  - Public prophylaxis to decrease the emergence of new daily COVID-19 cases is
      vital. Adjuvant TaibUVID nutritional supplements are promising home-made or
      hospital-made supplements suggested for rapidly preventing and treating COVID-19 
      pandemic. We report here a 44 years old male physician who caught COVID-19
      infection at hospital in Egypt with confirmed positive nasopharyngeal swab PCR.
      Ethical committee approval and informed patient's consent were gained before
      performing this study. Chest X-ray revealed increased bronchovascular markings.
      Close follow-up was done with no treatment given and he was sent for home
      isolation. Few days later, he developed progressive non-productive cough and a
      sense of difficult breathing with no associated fever or chest pain. An
      antitussive drug was given to him. The patient read about TaibUVID supplements
      from social media and started to feel improvement after TaibUVID inhalation
      therapy (using the heated solution of nigella sativa and chamomile five times a
      day). He also received a home-made TaibUVID nutritional supplement (nigella
      sativa, chamomile and natural honey) five times daily for four consecutive days. 
      The next day, he was quite better with mild symptoms. Two days later,
      nasopharyngeal swab PCR was negative while other patients still had positive
      nasopharyngeal swabs. As few attacks of mild cough and breathing difficulty
      existed, he was admitted to hospital. A nasopharyngeal swab PCR was done for him 
      again and the result was negative also. Blood gases were normal. He had
      lymphocytosis (possibly due to TaibUVID effects) that counteract lymphopenia seen
      in COVID-19 patients. Biochemical and hematological evaluation were quite normal 
      apart from increased serum chloride and lactate dehydrogenase. There was a mild
      decrease in serum CO2 and alkaline phosphatase. Chest CT report revealed
      symmetrically inflated both lungs with non-specific focal nodular infiltrates
      (scattered in basal and medial lung segments) in left lower lobes with faint
      ground glass opacities. He was discharged home. Few days later, he was quite
      improved with no symptoms and returned to his work comfortably. In conclusion,
      TaibUVID nutritional supplements may be effective in rapidly changing the
      nasopharyngeal swab PCR from positive to negative. TaibUVID nutritional
      supplements are advisable as a natural, safe and effective prophylaxis to stop
      COVID-19 infectiousness, transmission and emergence of new cases. Clinical
      studies to investigate TaibUVID nutritional benefits are strongly recommended.
      TaibUVID may be promising and recommended for public prophylaxis to decrease
      emergence of new COVID-19 cases.
CI  - AJBR Copyright (c) 2020.
FAU - El Sayed, Salah Mohamed
AU  - El Sayed SM
AD  - Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of
      Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
AD  - Prophetic Medicine Course and Research, Taibah Faculty of Medicine, Taibah
      University Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Aboonq, Moutasem Salih
AU  - Aboonq MS
AD  - Department of Medical Physiology, Taibah Faculty of Medicine, Taibah University
      Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Aljehani, Yasmeen Talal
AU  - Aljehani YT
AD  - Director of The Research and Studies Department of Health Affairs in Al-Madinah
      Region, Consultant Family Medicine and Trainer in Family Medicine Program for
      Postgraduate Studies Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Hassan, Mohammad Ahmad
AU  - Hassan MA
AD  - Department of Pediatrics, Sohag Faculty of Medicine, Sohag Univerity Egypt.
FAU - Abou El-Magd, Rabab M
AU  - Abou El-Magd RM
AD  - Department of Psychiatry, Faculty of Medicine and Dentistry, University of
      Alberta Canada.
AD  - Institute of Genetic Engineering, City for Scientific Research and Technological 
      Applications Alexandria, Egypt.
FAU - Abdelrahman, Abdelrahman I
AU  - Abdelrahman AI
AD  - Department of Diagnostic Radiology, Zagazig Faculty of Medicine, Zagazig
      University Egypt.
FAU - El-Tahlawi, Rehab
AU  - El-Tahlawi R
AD  - Department of Microbiology, College of Medicine, Taibah University Saudi Arabia.
AD  - Department of Microbiology, Faculty of Medicine, Zagazig University Egypt.
FAU - Nabo, Manal Mohamed Helmy
AU  - Nabo MMH
AD  - Division of Pediatric Cardiology, Pediatrics Department, Maternity and Children
      Hospital Hail, Saudi Arabia.
FAU - Yousef, Reda S
AU  - Yousef RS
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Mahmoud, Ahmed Alamir
AU  - Mahmoud AA
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Elsayed, Yasser Yahia
AU  - Elsayed YY
AD  - Department of Neonatology Maternity Hospital Kuwait, Kuait.
FAU - Abu-Elnaga, Mostafa
AU  - Abu-Elnaga M
AD  - Department of Anatomy, College of Medicine, Al-Rayyan Medical Colleges
      Al-Madinah, Saudi Arabia.
AD  - Department of Anatomy, College of Medicine, Al-Azhar University Egypt.
FAU - Soliman, Tamer M
AU  - Soliman TM
AD  - Department of Clinical Pathology, Faculty of Medicine, Sohag University Sohag,
      Egypt.
FAU - Abdel-Gawad, Abdelhady Ragab
AU  - Abdel-Gawad AR
AD  - Department of Clinical Pathology, Faculty of Medicine, Sohag University Sohag,
      Egypt.
FAU - Elshazley, Momen
AU  - Elshazley M
AD  - Department of Medicine, Taibah Faculty of Medicine, Taibah University Al-Madinah 
      Al-Munawwarah, Saudi Arabia.
AD  - Department of Occupational Diseases and Toxigenomics, Sohag Faculty of Medicine, 
      Sohag University Egypt.
FAU - Baghdadi, Hussam
AU  - Baghdadi H
AD  - Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of
      Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - El-Sawy, Samer
AU  - El-Sawy S
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Mahmoud, Hany Salah
AU  - Mahmoud HS
AD  - Center of Scientific Foundation for Experimental Studies and Research Ismailia,
      Egypt.
FAU - El-Anzi, Mariam E
AU  - El-Anzi ME
AD  - Diabetic Center in King Fahd Hospital & Sayed Al-Shohada Primary Health Care
      Center Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Alharbi, Mansour Barakah
AU  - Alharbi MB
AD  - Head of Training and Academic Affairs and Designated Institutional Official
      (DIO), King Fahad Hospital, Al-Madinah and Leader of Training and Academic
      Affairs Taskforce Al-Madinah Al-Munawwarah, Saudi Arabia.
LA  - eng
PT  - Case Reports
DEP - 20201215
PL  - United States
TA  - Am J Blood Res
JT  - American journal of blood research
JID - 101569577
PMC - PMC7811903
OTO - NOTNLM
OT  - COVID-19
OT  - TaibUVID
OT  - chamomile
OT  - nasopharyngeal swab PCR
OT  - natural honey
OT  - nigella sativa
COIS- None.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:42
PHST- 2020/05/16 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2021/01/25 05:42 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
PST - epublish
SO  - Am J Blood Res. 2020 Dec 15;10(6):397-406. eCollection 2020.


PMID- 33489448
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2160-1992 (Print)
IS  - 2160-1992 (Linking)
VI  - 10
IP  - 6
DP  - 2020
TI  - Zamzam water is pathogen-free, uricosuric, hypolipidemic and exerts
      tissue-protective effects: relieving BBC concerns.
PG  - 386-396
AB  - Zamzam water is the most frequently used drinking water by millions of people in 
      Saudi Arabia. It is carried all the time by millions of pilgrims to their home
      countries as gifts to close and near relatives and friends. Safety of
      constituents of Zamzam water is a vital health topic. British Broadcasting
      Corporation (BBC) raised many health concerns regarding the high serum arsenic
      and nitrate contents in Zamzam water that may cause cancer. It is role of
      scientific research to present scientific facts to relieve such concerns. Arsenic
      is a carcinogen while nitrate causes methemogloinemia that affect oxygen carriage
      by haemoglobin. An ethical committee approval was obtained. Eighteen white albino
      mice (40-45 g) were used in this study. Three experimental groups were allocated 
      (six mice per group): tap water group, distilled water group and Zamzam water
      group. Our data revealed that Zamzam water exerts tissue-protective effects that 
      contradict malignancy. Our data proved that Zamzam water is pathogen-free causing
      no bacterial growth on CLED agar colonies. Zamzam water consumption for three
      consecutive months in mice was quite safe for the general health and
      significantly decreased serum uric acid (p < 0.05) (possibly due to
      Zamzam-induced urine alkalinisation facilitating uric acid excretion). Regular
      Zamzam water consumption significantly decreased serum cholesterol (p < 0.05) and
      serum triglycerides (p < 0.05). Hypolipidemic effects of Zamzam water may be due 
      to its high mineral content facilitating increased lipids metabolism. Our data
      confirmed safety of prolonged use of Zamzam water comparable to other drinking
      water types regarding the metabolic and synthetic functions of the liver.
      Nitrates in Zamzam water are thought to be an original constituent that may be
      useful (exerting vasodilation, antithrombotic, and immunoregulatory effects) and 
      not harmless. This may occur due to high Zamzam content of calcium, magnesium and
      selenium. Histologically, our data confirmed that Zamzam water was quite safe to 
      renal parenchyma and comparable to other types of drinking water. In conclusion, 
      health concerns raised by BBC regarding Zamzam water safety were a good chance
      for fruitful scientific research investigations that confirmed safety and
      beneficial effects of Zamzam water for human health.
CI  - AJBR Copyright (c) 2020.
FAU - Mahmoud, Hany Salah
AU  - Mahmoud HS
AD  - Prophetic Medicine Course and Research, Taibah College of Medicine, Taibah
      University Al-Madinah Al-Munawwarah, Saudi Arabia.
AD  - Center of Scientific Foundation for Experimental Studies and Research Ismailia,
      Egypt.
FAU - Eltahlawi, Rehab A
AU  - Eltahlawi RA
AD  - Department of Microbiology and Immunology, Faculty of Medicine, Zagazig
      University Zagazig, Egypt.
AD  - Department of Microbiology and Immunology, Taibah College of Medicine, Taibah
      University Saudi Arabia.
FAU - Jan, Abdulhalem Abdulsamad
AU  - Jan AA
AD  - Laboratory and Blood Bank General Director, King Fahad Hospital Al-Madinah
      Al-Munawwarah, Saudi Arabia.
FAU - Alhadramy, Osama
AU  - Alhadramy O
AD  - Division of Cardiology, Department of Medicine, Taibah College of Medicine,
      Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Soliman, Tamer M
AU  - Soliman TM
AD  - Department of Clinical Pathology, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - El Sayed, Sayed Mostafa
AU  - El Sayed SM
AD  - Anatomy and Embryology Department, Faculty of Medicine, Taibah University Saudi
      Arabia.
AD  - Anatomy and Embryology Department, Faculty of Medicine-Ain Shams University
      Egypt.
FAU - Abdallah, Hesham I
AU  - Abdallah HI
AD  - Anatomy and Embryology Department, Faculty of Medicine, Taibah University Saudi
      Arabia.
AD  - Anatomy and Embryology Department, Faculty of Medicine-Ain Shams University
      Egypt.
FAU - El-Shazley, Momen
AU  - El-Shazley M
AD  - Department of Medicine, Taibah College of Medicine, Taibah University Al-Madinah 
      Al-Munawwarah, Saudi Arabia.
AD  - Department of Occupational Diseases and Toxigenomics, Sohag Faculty of Medicine, 
      Sohag University Egypt.
FAU - Shafik, Noha M
AU  - Shafik NM
AD  - Department of Biochemistry, Tanta Faculty of Medicine, Tanta University Egypt.
FAU - Mariah, Reham A
AU  - Mariah RA
AD  - Department of Biochemistry, Tanta Faculty of Medicine, Tanta University Egypt.
FAU - El-Dabie, Noha
AU  - El-Dabie N
AD  - Department of Pathology, Faculty of Medicine, Sohag University Egypt.
FAU - Abdel-Haleem, Mohamed
AU  - Abdel-Haleem M
AD  - Department of Ear, Nose and Throat, College of Medicine, Taibah University Saudi 
      Arabia.
FAU - Hassan, Shaima Mohamed Abdelfattah
AU  - Hassan SMA
AD  - Department of Histology and Cell Biology, Faculty of Medicine, Menoufia
      University Egypt.
FAU - Nabo, Manal Mohamed Helmy
AU  - Nabo MMH
AD  - Division of Pediatric Cardiology, Department of Pediatrics, Maternity and
      Children Hospital Hail, Saudi Arabia.
FAU - El-Alaf, Hassan
AU  - El-Alaf H
AD  - Department of Medical Physiology, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Baghdadi, Hussam
AU  - Baghdadi H
AD  - Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of
      Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
FAU - Yousef, Reda S
AU  - Yousef RS
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Mahmoud, Ahmed Alamir
AU  - Mahmoud AA
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - El Sayed, Salah Mohamed
AU  - El Sayed SM
AD  - Prophetic Medicine Course and Research, Taibah College of Medicine, Taibah
      University Al-Madinah Al-Munawwarah, Saudi Arabia.
AD  - Department of Clinical Biochemistry and Molecular Medicine, Taibah Faculty of
      Medicine, Taibah University Al-Madinah Al-Munawwarah, Saudi Arabia.
AD  - Department of Medical Biochemistry, Sohag Faculty of Medicine, Sohag University
      Egypt.
FAU - Amer, Soliman M
AU  - Amer SM
AD  - Family and Community Medicine Department, Taibah University Al-Medinah, Saudi
      Arabia.
AD  - Public Health and Community Medicine Department, Faculty of Medicine, Al-Azhar
      University New Damietta, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20201215
PL  - United States
TA  - Am J Blood Res
JT  - American journal of blood research
JID - 101569577
PMC - PMC7811908
OTO - NOTNLM
OT  - BBC concerns
OT  - Zamzam water
OT  - histology
OT  - kidney functions
OT  - liver functions
OT  - uric acid
COIS- None.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:42
PHST- 2020/06/28 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2021/01/25 05:42 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
PST - epublish
SO  - Am J Blood Res. 2020 Dec 15;10(6):386-396. eCollection 2020.


PMID- 33488459
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Court-Mandated Patients' Perspectives on the Psychotherapist's Dual Loyalty
      Conflict - Between Ally and Enemy.
PG  - 592638
LID - 10.3389/fpsyg.2020.592638 [doi]
AB  - BACKGROUND: Mental health professionals working in correctional contexts engage a
      double role to care and control. This dual loyalty conflict has repeatedly been
      criticized to impede the development of a high-quality alliance. As therapeutic
      alliance is a robust predictor of outcome measures of psychotherapy, it is
      essential to investigate the effects of this ethical dilemma. METHODS: This
      qualitative interview study investigates patients' perceptions of their
      therapists' dual role conflict in court-mandated treatment settings. We
      interviewed 41 older incarcerated persons using a semi-structured interview
      guide, the interviews were subsequently analyzed following thematic analysis.
      RESULTS: We first present the patients' perceptions of their treating
      psychotherapist's dual loyalty conflict, which was linked to their overall
      treatment experience. In a second step, we outline the study participants'
      reasons for this judgment, which were most commonly linked to feelings of trust
      or betrayal. More specifically, they named certain therapist characteristics and 
      activities that enabled them to develop a trustful therapeutic alliance, which we
      grouped into four topics: (1) respecting the patient's pace and perceived
      coercion; (2) patient health needs to be first priority; (3) clarity in roles and
      responsibilities; and (4) the art of communication - between transparency and
      unchecked information sharing. DISCUSSION: Developing a high quality alliance in 
      mandatory offender treatment is central due to its relationship with recovery and
      desistance. Our findings show that some therapists' characteristics and
      activities attenuate the negative impact of their double role on the development 
      and maintenance of the alliance. To increase the effectiveness of court-mandated 
      treatments, we need to support clinicians in dealing with their dual role to
      allow the formation of a high quality therapeutic alliance. Our qualitative
      interview study contributed to this much-needed empirical research on therapist' 
      characteristics promoting a trustful relationship in correctional settings.
CI  - Copyright (c) 2021 Merkt, Wangmo, Pageau, Liebrenz, Devaud Cornaz and Elger.
FAU - Merkt, Helene
AU  - Merkt H
AD  - Insitute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Wangmo, Tenzin
AU  - Wangmo T
AD  - Department of Forensic Psychiatry, Institute of Forensic Medicine, University of 
      Bern, Bern, Switzerland.
FAU - Pageau, Felix
AU  - Pageau F
AD  - Insitute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Liebrenz, Michael
AU  - Liebrenz M
AD  - Department of Forensic Psychiatry, Institute of Forensic Medicine, University of 
      Bern, Bern, Switzerland.
FAU - Devaud Cornaz, Corinne
AU  - Devaud Cornaz C
AD  - Unite Therapeutique, Centre de Psychiatrie Forensique, Reseau Fribourgeois de
      Sante Mentale, Fribourg, Switzerland.
FAU - Elger, Bernice
AU  - Elger B
AD  - Insitute for Biomedical Ethics, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20210106
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7815763
OTO - NOTNLM
OT  - coercion
OT  - dual loyalty
OT  - dual role
OT  - limited confidentiality
OT  - offender
OT  - prison
OT  - therapeutic alliance
OT  - triangular relationship
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:38
PHST- 2020/08/07 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2021/01/25 05:38 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.3389/fpsyg.2020.592638 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 6;11:592638. doi: 10.3389/fpsyg.2020.592638. eCollection 
      2020.


PMID- 33488436
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The Trickle-Down Effect of Authoritarian Leadership on Unethical Employee
      Behavior: A Cross-Level Moderated Mediation Model.
PG  - 550082
LID - 10.3389/fpsyg.2020.550082 [doi]
AB  - Authoritarian leadership is of great significance to eastern countries, including
      China. Meanwhile, unethical employee behavior also exists in all types of social 
      organizations. The relationship between authoritarian leadership and unethical
      employee behavior is worth studying. Senior leaders (managers) often do not have 
      a direct influence on employees except for through their immediate supervisors.
      The leadership style of senior leaders also influences the leadership style of
      their subordinates (employees' direct supervisors). This paper studies how
      authoritarian manager leadership trickles down to unethical employee behavior
      through authoritarian supervisor leadership (through social learning theory and
      ASA theory) and discusses the moderating effect of leader member exchange (LMX)
      and an ethical climate. Through a questionnaire survey of 406 pairs of leaders,
      supervisors, and employees, the research results of the multilevel model show
      that (1) authoritarian supervisor leadership is positively related to unethical
      employee behavior, (2) authoritarian supervisor leadership mediates the
      relationship between authoritarian manager leadership and unethical employee
      behavior, (3) LMX positively moderates the relationship between authoritarian
      manager leadership and authoritarian supervisor leadership and moderates the
      mediating effect of authoritarian supervisor leadership, and (4), that an ethical
      climate negatively moderates the relationship between authoritarian supervisor
      leadership and unethical employee behavior and moderates the mediating effect of 
      authoritarian supervisor leadership.
CI  - Copyright (c) 2021 Rui and Qi.
FAU - Rui, Jiang
AU  - Rui J
AD  - Business School, Hohai University, Nanjing, China.
FAU - Qi, Lin Xin
AU  - Qi LX
AD  - School of Labor and Human Resources, Renmin University of China, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210106
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7815699
OTO - NOTNLM
OT  - LMX
OT  - authoritarian leadership
OT  - ethical climate
OT  - trickle-down effect
OT  - unethical employee behavior
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:38
PHST- 2020/04/09 00:00 [received]
PHST- 2020/10/31 00:00 [accepted]
PHST- 2021/01/25 05:38 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.3389/fpsyg.2020.550082 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 6;11:550082. doi: 10.3389/fpsyg.2020.550082. eCollection 
      2020.


PMID- 33487935
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 0971-9261 (Print)
IS  - 0971-9261 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Nov-Dec
TI  - Ethics in Research and Publication.
PG  - 349-351
LID - 10.4103/jiaps.JIAPS_219_19 [doi]
AB  - Published articles in scientific journals are a key method for knowledge-sharing.
      Researchers can face the pressures to publish and this can sometimes lead to a
      breach of ethical values, whether consciously or unconsciously. The prevention of
      such practices is achieved by the application of strict ethical guidelines
      applicable to experiments involving human subjects or biological tissues. Editors
      too are faced with ethical problems, including how best to handle peer-review
      bias, and find reviewers with experience, probity, and professionalism. This
      article emphasizes that authors and their sponsoring organizations need to be
      informed of the importance of upholding the guidelines in research and ethical
      rules when disclosing scientific work.
CI  - Copyright: (c) 2020 Journal of Indian Association of Pediatric Surgeons.
FAU - Pan, Pradyumna
AU  - Pan P
AD  - Ashish Hospital and Research Centre, Pediatric Surgery Unit, Jabalpur, Madhya
      Pradesh, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201027
PL  - India
TA  - J Indian Assoc Pediatr Surg
JT  - Journal of Indian Association of Pediatric Surgeons
JID - 101179870
PMC - PMC7815037
OTO - NOTNLM
OT  - Ethics
OT  - guidelines
OT  - medical research
OT  - scientific misconduct
COIS- There are no conflicts of interest.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:36
PHST- 2019/12/16 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2021/01/25 05:36 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.4103/jiaps.JIAPS_219_19 [doi]
AID - JIAPS-25-349 [pii]
PST - ppublish
SO  - J Indian Assoc Pediatr Surg. 2020 Nov-Dec;25(6):349-351. doi:
      10.4103/jiaps.JIAPS_219_19. Epub 2020 Oct 27.


PMID- 33487823
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 2
DP  - 2020 Apr-Jun
TI  - Comparison of Ultrasoundguided Ilioinguinal Iliohypogastric Nerve Block with
      Wound Infiltration during Pediatric Herniotomy Surgeries.
PG  - 243-247
LID - 10.4103/aer.AER_22_20 [doi]
AB  - BACKGROUND AND AIMS: The purpose of this study was to compare the analgesic
      efficacy of the ilioinguinal-iliohypogastric nerve block (II/IH) with local wound
      infiltration in children undergoing herniotomy surgeries. METHODS: After ethics
      committee approval and informed consent, 100 children aged 6 months-7 years
      posted for herniotomy surgeries were randomly divided into Group B and Group W.
      Local wound infiltration was performed in Group W by the surgeon at the time of
      port placement and the end of the surgery with 0.2 mL.kg(-1) of 0.25%
      bupivacaine. Ipsilateral II/IH was performed in Group B at the end of the
      surgery, under ultrasonographic guidance with a Sonosite portable ultrasound unit
      and a linear 5-10 MHz probe with a 22G hypodermic needle, and 0.2 mL.kg(-1) of
      0.25% bupivacaine was used on each side. The parameters recorded were
      postoperative hemodynamics, paracetamol and opioid requirements, postoperative
      pain scores, postoperative nausea vomiting, and the need for rescue analgesia in 
      the first 6 h postoperatively. RESULTS: The median pain scores were significantly
      lower in the II/IH group than the local wound infiltration group at 10 min (2
      [0-2.5] compared to 2 [3-4]; P = 0.011), 30 min (1.5 [0-3] compared to 3 [2-5]; P
      < 0.001), 1 h (1.5 [0-2] compared to 2 [2-3]; P < 0.001) and 2 h (2 [0-2]
      compared to 2 [1.5-2.5]; P = 0.010) postoperatively. The need for postoperative
      opioids and rescue analgesia was also significantly lower in the II/IH group (P <
      0.001). CONCLUSION: II/IH is superior to local wound infiltration for
      postoperative analgesia in pediatric herniotomy surgeries.
CI  - Copyright: (c) 2020 Anesthesia: Essays and Researches.
FAU - Karim, Wahaja A
AU  - Karim WA
AD  - Department of Anaesthesia, VMMC and Safdarjung Hospital, Delhi, India.
FAU - Bathla, Sapna
AU  - Bathla S
AD  - Department of Anaesthesia, VMMC and Safdarjung Hospital, Delhi, India.
FAU - Malik, Shraddha
AU  - Malik S
AD  - Department of Anaesthesia, Rajiv Gandhi Super Speciality Hospital, Delhi, India.
FAU - Arora, Deep
AU  - Arora D
AD  - Department of Anaesthesia, Medanta Medicity, Gurugram, Haryana, India.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC7819410
OTO - NOTNLM
OT  - Herniotomy
OT  - ilioinguinal iliohypogastric block
OT  - pediatric
COIS- There are no conflicts of interest.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:36
PHST- 2020/03/10 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2021/01/25 05:36 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.4103/aer.AER_22_20 [doi]
AID - AER-14-243 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Apr-Jun;14(2):243-247. doi: 10.4103/aer.AER_22_20. Epub
      2020 Oct 12.


PMID- 33487807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 6 Suppl
DP  - 2020 Dec
TI  - Community-Based Rehabilitation for Persons with Severe Mental Illness in a Rural 
      Community of Karnataka: Methodology of a Randomized Controlled Study.
PG  - S73-S79
LID - 10.1177/0253717620971203 [doi]
AB  - BACKGROUND: Task shifting has been recommended as a strategy to reach out to
      persons with mental illness and bridge the treatment gap. There is a need to
      explore task-shifting using existing health staff like Accredited Social Health
      Activists (ASHAs). AIM AND CONTEXT: ASHAs are involved in ongoing community-based
      rehabilitation (CBR) program run with a public-private partnership over the last 
      5 years at Jagaluru Taluk (an administrative block) in Davanagere district
      (Karnataka, India). This article aims to summarize a randomized controlled trial 
      (RCT) to examine whether CBR delivered by ASHAs is more effective than treatment 
      as usual (TAU) control group in reducing disability associated with severe mental
      illness (SMI). METHOD: A group of proactive ASHAs is already working with us for 
      a follow-up of persons with SMI. For the study, we would allocate areas that are 
      currently not being covered proactively by ASHAs randomly in a 1:1 ratio via
      computer-generated randomization list to receive either ASHAs delivered CBR arm
      or TAU control group. A sample size of about 100 in each arm is enough to
      identify an effect size of 0.5 in total IDEAS score between the intervention and 
      control arms with a power of 90% and an alpha of 0.05. We use the SPIRIT
      (Standard Protocol Items: Recommendations for Interventional Trials) statement to
      describe the methods of the trial. RESULT: The study has been approved by the
      institute ethics committee and registered with CTRI (CTRI/2019/08/020585 dated
      6th August 2019). The recruitment of subjects is ongoing. The patients will be
      followed up for 1 year and assessed. The trial is funded by the Indian Council of
      Medical Research, Government of India. DISCUSSION: The results of the study will 
      be helpful from a public health perspective in delivering cost-effective and
      replicable CBR for persons with SMI through ASHAs. If the model turns successful,
      this could be expanded throughout the state/country. This would go a long way in 
      bridging the huge treatment gap.
CI  - (c) 2020 Indian Psychiatric Society - South Zonal Branch.
FAU - Sivakumar, Thanapal
AU  - Sivakumar T
AUID- ORCID: https://orcid.org/0000-0002-9498-9424
AD  - Psychiatric Rehabilitation Services, Dept. of Psychiatry, National Institute of
      Mental Health and Neurosciences, Bengaluru, Karnataka, India.
FAU - Thirthalli, Jagadisha
AU  - Thirthalli J
AD  - Psychiatric Rehabilitation Services, Dept. of Psychiatry, National Institute of
      Mental Health and Neurosciences, Bengaluru, Karnataka, India.
FAU - Kumar, C Naveen
AU  - Kumar CN
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neurosciences,
      Bengaluru, Karnataka, India.
FAU - Basavarajappa, Chethan
AU  - Basavarajappa C
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neurosciences,
      Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201207
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7802032
OTO - NOTNLM
OT  - ASHA
OT  - Community-based rehabilitation
OT  - India
OT  - rural
OT  - severe mental illness
OT  - task-shifting
COIS- We declare that we have not submitted this article in any other journal.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:36
PHST- 2021/01/25 05:36 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.1177/0253717620971203 [doi]
AID - 10.1177_0253717620971203 [pii]
PST - ppublish
SO  - Indian J Psychol Med. 2020 Dec;42(6 Suppl):S73-S79. doi:
      10.1177/0253717620971203. Epub 2020 Dec 7.


PMID- 33487797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 6 Suppl
DP  - 2020 Dec
TI  - Protocol for a Coordinated Approach for Building Capacity of Mental Health
      Researchers in India.
PG  - S5-S14
LID - 10.1177/0253717620969063 [doi]
AB  - INTRODUCTION: India's National Mental Health Programme (NMHP) was initiated in
      1982. In 2016, the Indian Council of Medical Research (ICMR) organized a
      Brainstorming Meeting on Prioritization of Mental Health Research. Recognizing
      the need for improving mental healthcare by building a cadre of mental health
      researchers based on focus areas of the NMHP, the ICMR organized a research
      training cum capacity building workshop in collaboration with the
      Cross-Fertilized Research Training Programme (funded by Fogarty International
      Centre, NIH, USA) in 2016. The workshop successfully prepared and reviewed 12
      single and multicenter research proposals in priority areas of mental health
      research, which were awarded by the ICMR to middle- and junior-level research
      faculty and NGO. METHODS: A National Coordination Unit (NCU) was set up to mentor
      investigators and to coordinate, train, and monitor the progress of their
      projects. Investigators were paired with senior mentors and also participated in 
      four capacity building workshops focusing on proposal-writing, evaluation, and
      process tracking. RESULTS: Following discussions with ICMR program officers, the 
      NCU formulated standard operating procedures for ethical conduct, data
      collection, data sharing, progress reporting procedures, and manuscript
      preparation for all research projects. Regularly scheduled long-distance
      communications with investigators using social media and group communications
      were planned. NCU partnered with the ICMR Database Management Unit to build a
      shared online platform for real-time data entry and storage, and organized two
      project review meetings where it also coordinated with US faculty to organize
      public workshops on manuscript writing and qualitative research. CONCLUSIONS: The
      NCU will ensure timely completion of research projects, data entry and analysis, 
      and reports and project publications. It is feasible to evaluate progress with
      the NMHP through coordinated multisite research that also enables research
      capacity building. Results from these projects will help in formulating policies 
      by the Ministry of Health Government of India for achieving objectives of the
      NMHP.
CI  - (c) 2020 Indian Psychiatric Society - South Zonal Branch.
FAU - Deshpande, Smita N
AU  - Deshpande SN
AD  - Dept. of Psychiatry, Centre of Excellence in Mental Health, Atal Bihari Vajpayee 
      Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, Delhi,
      India.
FAU - Singh, Ravinder
AU  - Singh R
AD  - Division of Non-Communicable Disease, Indian Council of Medical Research, New
      Delhi, Delhi, India.
FAU - Bhatia, Triptish
AU  - Bhatia T
AD  - Indo-US Projects and National Coordination Unit-Indian Council of Medical
      Research, Dept. of Psychiatry and De-addiction, Centre of Excellence in Mental
      Health, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar
      Lohia Hospital, New Delhi, Delhi, India.
FAU - Shah, Gyan D
AU  - Shah GD
AD  - Indo-US Projects and National Coordination Unit-Indian Council of Medical
      Research, Dept. of Psychiatry and De-addiction, Centre of Excellence in Mental
      Health, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar
      Lohia Hospital, New Delhi, Delhi, India.
FAU - Singh, Harpreet
AU  - Singh H
AD  - Data Management Unit, Indian Council for Medical Research, New Delhi, Delhi,
      India.
FAU - Hawk, Mary
AU  - Hawk M
AD  - Evaluation Institute for Public Health, Centre for LGBT Health Research,
      University of Pittsburgh Graduate School of Public Health Behavioural and
      Community Health Sciences, Pittsburgh, Pennsylvania, USA.
FAU - Nimgaonkar, Vishwajit L
AU  - Nimgaonkar VL
AD  - Dept. of Psychiatry and Dept. of Human Genetics, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
LA  - eng
GR  - D43 TW006167/TW/FIC NIH HHS/United States
GR  - D43 TW008302/TW/FIC NIH HHS/United States
GR  - D43 TW009114/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20201208
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7802036
OTO - NOTNLM
OT  - Capacity building
OT  - coordination
OT  - mental health research
OT  - multi centric data collection
OT  - software
COIS- The authors declared no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
CRDT- 2021/01/25 05:36
PHST- 2021/01/25 05:36 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
AID - 10.1177/0253717620969063 [doi]
AID - 10.1177_0253717620969063 [pii]
PST - ppublish
SO  - Indian J Psychol Med. 2020 Dec;42(6 Suppl):S5-S14. doi: 10.1177/0253717620969063.
      Epub 2020 Dec 8.


PMID- 33476114
STAT- Publisher
DA  - 20210122
CTDT- 20201027
PB  - Springer
CTI - Wellcome Trust-Funded Monographs and Book Chapters
DP  - 2020
TI  - Moral Responsibility and the Justification of Policies to Preserve Antimicrobial 
      Effectiveness
BTI - Ethics and Drug Resistance: Collective Responsibility for Global Public Health
PG  - 141-154
LID - 10.1007/978-3-030-27874-8 [doi]
CP  - Chapter 9
AB  - Restrictive policies that limit antimicrobial consumption, including
      therapeutically justified use, might be necessary to tackle the problem of
      antimicrobial resistance. We argue that such policies would be ethically
      justified when forgoing antimicrobials constitutes a form of easy rescue for an
      individual. These are cases of mild and self-limiting infections in otherwise
      healthy patients whose overall health is not significantly compromised by the
      infection. In such cases, restrictive policies would be ethically justified
      because they would coerce individuals into fulfilling a moral obligation they
      independently have. However, to ensure that such justification is the strongest
      possible, states also have the responsibility to ensure that forgoing
      antimicrobials is as easy as possible for patients by implementing adequate
      compensation measures.
CI  - Copyright 2020, The Author(s).
FED - Jamrozik, Euzebiusz
ED  - Jamrozik E
FED - Selgelid, Michael
ED  - Selgelid M
FAU - Giubilini, Alberto
AU  - Giubilini A
FAU - Savulescu, J.
AU  - Savulescu J
LA  - eng
GR  - 104848/Wellcome Trust/United Kingdom
PT  - Review
PT  - Book Chapter
PL  - Cham (CH)
OTO - NLM
OT  - Bioethics
OT  - Public health ethics
OT  - Antimicrobial resistance
OT  - Collective responsibility
OT  - Easy rescue
EDAT- 2021/01/22 06:01
MHDA- 2021/01/22 06:01
CDAT- 2021/01/22 06:01
AID - NBK566842 [bookaccession]
AID - 10.1007/978-3-030-27874-8_9 [doi]


PMID- 33475599
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 12(A)
DP  - 2020 Dec
TI  - Perception on service quality in old age homes: A qualitative study in Karachi,
      Pakistan.
PG  - 2205-2209
LID - 10.47391/JPMA.606 [doi]
AB  - OBJECTIVE: The growing number of older people due to demographic transition is
      paving the way for nongovernmental organizations and the private sector for
      mushrooming of old age homes (OAHs). These homes function either free or fee for 
      services and the services provided at these OAHs determines the quality of life
      of older people. The aim of the study was to explore the stakeholders' perception
      on the quality of services offered to people living in OAHs. METHODS: A
      descriptive qualitative study design was used to explore stakeholders' perception
      of elderly living experiences in old age homes. Three OAH were selected through
      purposive sampling for the study. Data collected from February-March 2015 through
      the structured interview guide. Participants' for FGDs were recruited through
      universal sampling, while purposive sampling was used for KIIs selection.
      Researcher ensured all ethical considerations for the entire study period.
      RESULTS: Two major themes were drawn including the reasons and experiences of
      older people living in OAH, secondly the need for caregivers' academic
      competencies. Majority of KIIs and FGDs reported common responses under the two
      themes. Also the elderly experiences varied from living comfortably to being
      depressed. KIIs and caregivers' FGD participants' strongly urged the need for
      caregivers' training and institutional accreditation. CONCLUSIONS: The results of
      the study on the older people's experiences and challenges of living in OAHs,
      strongly propose community support system and credentialing of the caregivers for
      age appropriate care. Moreover the capacity building of academia for offering
      specialized training in gerontology and geriatrics is also highlighted.
FAU - Vertejee, Samina
AU  - Vertejee S
AD  - Aga Khan University School of Nursing and Midwifery (AKU-SONAM), Karachi,
      Pakistan.
FAU - Allana, Saleema
AU  - Allana S
AD  - University of Alberta, Canada.
FAU - Somani, Rozina
AU  - Somani R
AD  - University of Toronto, Canada.
FAU - Aijaz, Saher
AU  - Aijaz S
AD  - Aga Khan University School of Nursing and Midwifery, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Caregivers
MH  - *Homes for the Aged
MH  - Humans
MH  - Pakistan
MH  - Perception
MH  - Qualitative Research
MH  - *Quality of Life
OTO - NOTNLM
OT  - Caregivers; Elderly; Institutionalization; Old Age Homes, Geriatric health and
      wellbeing
EDAT- 2021/01/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/21 12:17
PHST- 2021/01/21 12:17 [entrez]
PHST- 2021/01/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10270 [pii]
AID - 10.47391/JPMA.606 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Dec;70(12(A)):2205-2209. doi: 10.47391/JPMA.606.


PMID- 33475584
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 12(A)
DP  - 2020 Dec
TI  - Association of apoptotic marker cytokeratin18 with blood pressure in nonalcoholic
      fatty liver disease patients.
PG  - 2128-2131
LID - 10.47391/JPMA.689 [doi]
AB  - OBJECTIVE: Non Alcoholic fatty liver disease (NAFLD) associated with hypertension
      (HTN) is an emerging health issue globally. It is associated with increased
      levels of apoptotic marker CK18. Main objective of this study was to explore
      association of cytokeratin18 (CK18) with hypertension (HTN) in NAFLD patients.
      METHODS: Descriptive cross sectional study was conducted in Mayo hospital Lahore.
      Hundred NAFLD subjects were enrolled from OPD of radiology department after
      approval from ethical review committee. Anthropometric measurements were taken
      and blood pressure (BP) was measured by mercury sphygmomanometer. Blood samples
      were drawn from each patient for CK18 levels with ELISA. Data was analyzed by
      SPSS 20. Continuous variables were presented as mean+/- SD. Association between
      CK18 and HTN were analyzed by regression analysis and results were presented as
      beta coefficient. P <0.05 was taken as significant. RESULTS: Mean age of studied 
      subjects was 43.8+/-5.34 with height (m), weight (kg) and BMI 1.59+/-0.063 m,
      78.2+/-11.17 kg, 30.5+/-4.07kg/m2 respectively. Systolic and diastolic blood
      pressures were 106+/-12.8, 72+/- 12.8mmHg. CK 18 was not significantly associated
      with systolic (P value 0.55) and diastolic BP (P value 0.37) most probably due to
      small size of study. CONCLUSIONS: Most of the NAFLD patients were hypertensive
      and have raised CK18 levels than normotensive subjects. So, raised levels of CK18
      in NAFLD subjects might be helpful in early screening of HTN. However,
      significant association was not observed probably due to small sample size.
FAU - Altaf, Benash
AU  - Altaf B
AD  - Department of Physiology, Aziz Fatimah Medical and Dental College, Faisalabad,
      Pakistan.
FAU - Jawed, Shireen
AU  - Jawed S
AD  - Department of Physiology, Aziz Fatima Medical College, Faisalabad, Pakistan.
FAU - Tahir Salam, Rana Muhammad
AU  - Tahir Salam RM
AD  - Department of Sonology, Aziz Fatimah Hospital, Faisalabad, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Blood Pressure
MH  - Body Weight
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Hypertension/epidemiology
MH  - *Non-alcoholic Fatty Liver Disease
OTO - NOTNLM
OT  - CVS, CK18, DBP, HTN, MS, NAFLD, SBP.
EDAT- 2021/01/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/21 12:17
PHST- 2021/01/21 12:17 [entrez]
PHST- 2021/01/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10239 [pii]
AID - 10.47391/JPMA.689 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Dec;70(12(A)):2128-2131. doi: 10.47391/JPMA.689.


PMID- 33475560
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 12(B)
DP  - 2020 Dec
TI  - Resolving mystery behind autonomous retrogression of low-grade gliomas: A
      systematic review.
PG  - 2441-2448
LID - 10.47391/JPMA.581 [doi]
AB  - OBJECTIVE: To review evidence-based data on spontaneous retrogression of
      low-grade gliomas with respect to interval till regression, type of glioma and
      patient outcome. METHODS: The systematic review comprised medical literature in
      English language published from January 1997 to January 2017 on Scopus, PubMed
      and Google Scholar databases to establish consensus about the possible mechanism 
      of spontaneous regression, the role of therapeutic intervention and failure of
      management strategies in low-grade gliomas. Preferred Reporting Items for
      Systematic Reviews and Meta-Analysis guidelines were followed during the review. 
      RESULTS: Of the 176 articles identified, 73(41.5%) were shortlisted for detailed 
      assessment. Of them, 10(13.7%) were included; 5(50%) case reports and 5(50%) case
      series. There were 23 cases of spontaneous regression; 15(65.2%) males and
      8(34.7%) females. The interval of regression varied from 3 months to 15.5 years, 
      and the most commonly presenting low-grade glioma type was optic pathway glioma
      11(47.4%). CONCLUSIONS: The phenomenon of regression was most evident in optic
      pathway glioma. Literature suggested that low-grade gliomas should undergo serial
      imaging before implying any therapeutic intervention. However, the evidencebased 
      proof, large-scale experimental studies and ethical considerations are still
      required to standardise this strategy.
FAU - Ahmed, Syed Ijlal
AU  - Ahmed SI
AD  - Liaquat National Hospital and Medical College, Karachi.
FAU - Bareeqa, Syeda Beenish
AU  - Bareeqa SB
AD  - Jinnah Medical and Dental College, Karachi, Pakistan.
FAU - Samar, Syeda Sana
AU  - Samar SS
AD  - Jinnah Sindh Medical University, Karachi.
FAU - Jilanee, Syed Daniyal Ahmed
AU  - Jilanee SDA
AD  - Liaquat National Hospital and Medical College, Karachi, Pakistan.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - *Astrocytoma
MH  - *Brain Neoplasms/epidemiology
MH  - Consensus
MH  - Female
MH  - *Glioma/epidemiology
MH  - Humans
MH  - Language
MH  - Male
OTO - NOTNLM
OT  - Pilocytic astrocytomas, Desmoplastic infantile ganglioglioma, DIG, Desmoplastic
      infantile astrocytomas, DIA, Diffuse astrocytoma, Spontaneous regression.
EDAT- 2021/01/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/21 12:17
PHST- 2021/01/21 12:17 [entrez]
PHST- 2021/01/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10324 [pii]
AID - 10.47391/JPMA.581 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Dec;70(12(B)):2441-2448. doi: 10.47391/JPMA.581.


PMID- 33475548
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 12(B)
DP  - 2020 Dec
TI  - Physicians' job satisfaction, ethics and burnout in Makkah, Saudi Arabia.
PG  - 2383-2389
LID - 10.47391/JPMA.401 [doi]
AB  - OBJECTIVE: To investigate the frequency of job satisfaction, burnout and ethics
      among physicians across specialties with varied levels of experience and
      seniority, in hospitals in Makkah, Saudi Arabia. METHODS: From April-May 2016,
      job satisfaction, burnout and ethics were assessed in 136 physicians across
      specialties from six government hospitals in Makkah. Data collection was via a
      self administered questionnaire. SPSS was used to obtain the likelihood ratio
      chi-square for all categorical bivariate statistical analyses. P-value <0.05 was 
      considered significant. RESULTS: A total of 136 physicians participated in the
      study. Ninety five (70%) physicians were male and 41(30%) were female. Medical
      specialties varied between genders. There was no significant difference by
      gender, in job satisfaction among sphysicians (p-value 0.99). However, a high
      level of burnout was statistically significant among physicians (51%, p-value
      <0.001) and the level of burnout was significantly higher among physicians
      willing to change their specialty compared to those willing to repeat it (50% vs.
      24%, p-value 0.02). Physicians dissatisfied with their salary had double the
      scores of ethics compared to satisfied physicians. Female physicians were better 
      at resolving ethical dilemmas. CONCLUSIONS: :This study provided the first
      evidence of high frequency of burnout and career choice regret among physicians
      working in Makkah, Saudi Arabia. Preventing physician burnout not only improves
      the quality of healthcare but also ensures patient safety.
FAU - Baghdadi, Leena Rashad
AU  - Baghdadi LR
AD  - Department of Family and Community Medicine, College of Medicine, King Saud
      University, Riyadh, Saudi Arabia.
FAU - Baghdadi, Razan Rashad
AU  - Baghdadi RR
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Kamal, Ruqayyah Sami
AU  - Kamal RS
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Obaid, Elaf Faisal
AU  - Obaid EF
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Aloqalaa, Maryam Farraj
AU  - Aloqalaa MF
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Rambo, Tharaa Waleed
AU  - Rambo TW
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Al-Fahmi, Julnar Ayman
AU  - Al-Fahmi JA
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Almasaoudi, Bayan Mutlaq
AU  - Almasaoudi BM
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Bin Afeef, Shahad Fuad
AU  - Bin Afeef SF
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
FAU - Abusalamah, Maryam Talal
AU  - Abusalamah MT
AD  - 7th Year MBBS Student, Umm Al Qura University, Makkah, Saudi Arabia.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - *Burnout, Professional/epidemiology
MH  - Career Choice
MH  - Female
MH  - Humans
MH  - Job Satisfaction
MH  - Male
MH  - *Physicians
MH  - Saudi Arabia/epidemiology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Physician satisfaction, ethics, burnout, work stress, loss of enthusiasm
EDAT- 2021/01/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/21 12:17
PHST- 2021/01/21 12:17 [entrez]
PHST- 2021/01/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10311 [pii]
AID - 10.47391/JPMA.401 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Dec;70(12(B)):2383-2389. doi: 10.47391/JPMA.401.


PMID- 33471559
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1746-076X (Electronic)
IS  - 1746-0751 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Breeding brains? Patients' and laymen's perspectives on cerebral organoids.
PG  - 2351-2360
LID - 10.2217/rme-2020-0108 [doi]
AB  - Aim: To explore the perspectives of patients and laymen with regard to the
      development, use and storage of cerebral organoids, in order to contribute to the
      ethical debate about this technology. Materials & methods: In depth
      semi-structured interviews with 28 patients and laymen were conducted. A
      qualitative thematic analysis was undertaken using a constant comparative method.
      Results: Three interrelated themes emerged from the empirical material: moral
      value; willingness to donate; and elements of good governance. Conclusion:
      Patients and laymen are most concerned about cerebral organoids potentially
      developing consciousness and potential misuse. They support the use of cerebral
      organoids under the conditions that donors are adequately informed and that there
      will be good governance. Perspectives of patients and laymen are helpful to
      enable responsible development and use of cerebral organoids in practice.
FAU - Haselager, Dolly R
AU  - Haselager DR
AD  - Department of Medical Humanities, Julius Center for Health Sciences & Primary
      Care, University Medical Center Utrecht, Utrecht 3584CG, The Netherlands.
FAU - Boers, Sarah N
AU  - Boers SN
AD  - Department of Medical Humanities, Julius Center for Health Sciences & Primary
      Care, University Medical Center Utrecht, Utrecht 3584CG, The Netherlands.
FAU - Jongsma, Karin R
AU  - Jongsma KR
AD  - Department of Medical Humanities, Julius Center for Health Sciences & Primary
      Care, University Medical Center Utrecht, Utrecht 3584CG, The Netherlands.
FAU - Vinkers, Christiaan H
AU  - Vinkers CH
AD  - Department of Psychiatry, Amsterdam University Medical Center & Department of
      Anatomy & Neurosciences, Amsterdam University Medical Center, Amsterdam 1081HV,
      The Netherlands.
FAU - Broekman, Marike L
AU  - Broekman ML
AD  - Department of Neurosurgery, Haaglanden Medical Center, 2501CK The Hague & Leiden 
      University Medical Center, Leiden University, Leiden 2333ZA, The Netherlands.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AD  - Department of Medical Humanities, Julius Center for Health Sciences & Primary
      Care, University Medical Center Utrecht, Utrecht 3584CG, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210120
PL  - England
TA  - Regen Med
JT  - Regenerative medicine
JID - 101278116
SB  - IM
MH  - *Brain
MH  - Breeding
MH  - Humans
MH  - *Organoids
MH  - Tissue Donors
OTO - NOTNLM
OT  - *brain
OT  - *empirical research
OT  - *interview
OT  - *organoid
OT  - *research ethics
OT  - *translational research
EDAT- 2021/01/21 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/01/20 17:08
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2021/01/20 17:08 [entrez]
AID - 10.2217/rme-2020-0108 [doi]
PST - ppublish
SO  - Regen Med. 2020 Dec;15(12):2351-2360. doi: 10.2217/rme-2020-0108. Epub 2021 Jan
      20.


PMID- 33470990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210122
IS  - 2409-9279 (Electronic)
IS  - 2409-9279 (Linking)
VI  - 3
IP  - 4
DP  - 2020 Dec 6
TI  - A Personalized Patient-Centered Intervention to Empower through Physical Activity
      the Patient in the Dialysis Center: Study Protocol for a Pragmatic Nonrandomized 
      Clinical Trial.
LID - E83 [pii]
LID - 10.3390/mps3040083 [doi]
AB  - Sedentariness of patients affected by end-stage kidney disease (ESKD) expose them
      to high risk of unfavorable clinical outcomes. Exercise training is effective in 
      improving physical function, quality of life (QoL) and long-term outcomes.
      However, the existing barriers related to patients, programs and dialysis staff
      limit patient participation and call for new strategies. This pragmatic
      nonrandomized trial will test the impact on ESKD population of an intervention
      proposed by an exercise facilitator regularly present in a dialysis center. The
      patient will be free to choose among three-month walking and/or resistance
      low-intensity training programs: (a) guided physical activity increase; (b)
      home-based exercise; (c) in-hospital (pre/post dialysis) supervised exercise; (d)
      performance assessment only. The first phase will define feasibility and the
      characteristics and preference of responders. The second phase will evaluate
      safety and patients' adherence. Outcome measures will be collected at baseline,
      after three-month and at six-month follow-up. They will include: aerobic
      capacity, QoL, gait speed, strength, depression and long-term clinical outcomes
      (hospitalization and mortality). The trial was approved by the Area-Vasta
      Emilia-Romagna Centro Ethics Committee with approval number 48/2019. Written
      informed consent will be obtained from all participants. The results of the study
      will be presented in international congresses, published in peer-reviewed
      journals and communicated to the patient community. Registration details:
      Clinicaltrials.gov NCT04282616 [Registered:24/02/2020].
FAU - Manfredini, Fabio
AU  - Manfredini F
AD  - Department of Neuroscience and Rehabilitation, Section of Sports Sciences,
      University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
AD  - Unit of Physical Medicine and Rehabilitation, University Hospital of Ferrara, Via
      Aldo Moro 8, 44124 Ferrara, Italy.
FAU - Lamberti, Nicola
AU  - Lamberti N
AUID- ORCID: 0000-0001-5763-3069
AD  - Department of Neuroscience and Rehabilitation, Section of Sports Sciences,
      University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
FAU - Battaglia, Yuri
AU  - Battaglia Y
AUID- ORCID: 0000-0003-3947-1814
AD  - Unit of Nephrology and Dialysis, University Hospital of Ferrara, Via Aldo Moro 8,
      44124 Ferrara, Italy.
FAU - Straudi, Sofia
AU  - Straudi S
AD  - Unit of Physical Medicine and Rehabilitation, University Hospital of Ferrara, Via
      Aldo Moro 8, 44124 Ferrara, Italy.
FAU - Belvederi Murri, Martino
AU  - Belvederi Murri M
AUID- ORCID: 0000-0002-7262-3528
AD  - Institute of Psychiatry, Department of Neuroscience and Rehabilitation,
      University of Ferrara, Via Fossato di Mortara 64, 44121 Ferrara, Italy.
FAU - Donadi, Maria
AU  - Donadi M
AD  - Unit of Nephrology and Dialysis, University Hospital of Ferrara, Via Aldo Moro 8,
      44124 Ferrara, Italy.
FAU - Piva, Giovanni
AU  - Piva G
AD  - Department of Neuroscience and Rehabilitation, Section of Sports Sciences,
      University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
FAU - Fabbian, Fabio
AU  - Fabbian F
AUID- ORCID: 0000-0001-5189-3695
AD  - Department of Medical Sciences, University of Ferrara, Via Aldo Moro 8, 44124
      Ferrara, Italy.
FAU - Lopez-Soto, Pablo Jesus
AU  - Lopez-Soto PJ
AD  - Department of Nursing, Maimonides Biomedical Research Institute of Cordoba
      (IMIBIC), University of Cordoba, Reina Sofia University Hospital, 14004 Cordoba, 
      Spain.
FAU - Grassi, Luigi
AU  - Grassi L
AD  - Institute of Psychiatry, Department of Neuroscience and Rehabilitation,
      University of Ferrara, Via Fossato di Mortara 64, 44121 Ferrara, Italy.
FAU - Manfredini, Roberto
AU  - Manfredini R
AUID- ORCID: 0000-0002-8364-2601
AD  - Department of Medical Sciences, University of Ferrara, Via Aldo Moro 8, 44124
      Ferrara, Italy.
FAU - Basaglia, Nino
AU  - Basaglia N
AD  - Unit of Physical Medicine and Rehabilitation, University Hospital of Ferrara, Via
      Aldo Moro 8, 44124 Ferrara, Italy.
FAU - Storari, Alda
AU  - Storari A
AD  - Unit of Nephrology and Dialysis, University Hospital of Ferrara, Via Aldo Moro 8,
      44124 Ferrara, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT04282616
PT  - Journal Article
DEP - 20201206
PL  - Switzerland
TA  - Methods Protoc
JT  - Methods and protocols
JID - 101720073
PMC - PMC7768449
OTO - NOTNLM
OT  - chronic kidney disease
OT  - depression
OT  - exercise
OT  - exercise testing
OT  - rehabilitation
OT  - risk factors
EDAT- 2021/01/21 06:00
MHDA- 2021/01/21 06:01
CRDT- 2021/01/20 12:20
PHST- 2020/11/11 00:00 [received]
PHST- 2020/12/02 00:00 [revised]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2021/01/20 12:20 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/21 06:01 [medline]
AID - mps3040083 [pii]
AID - 10.3390/mps3040083 [doi]
PST - epublish
SO  - Methods Protoc. 2020 Dec 6;3(4). pii: mps3040083. doi: 10.3390/mps3040083.


PMID- 33469543
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210122
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Mixed Method Study to Explore Ethical Dilemmas and Health Care Workers'
      Willingness to Work Amid COVID-19 Pandemic in Palestine.
PG  - 576820
LID - 10.3389/fmed.2020.576820 [doi]
AB  - Background: The high potential risks involved in working in a healthcare setting 
      during a pandemic and the associated fear that may affect health care workers'
      (HCWs') willingness to work are important to understand to eliminate potential
      barriers to working. This study aimed to assess Palestinian HCWs' willingness to 
      work and the related factors as well as to explore their ethical dilemmas during 
      the coronavirus disease 2019 (COVID-19) pandemic. Materials and Methods:
      Quantitative (survey questionnaire) and qualitative (semi-structured interviews) 
      data were collected. Frontline HCWs (n = 550) received an online survey link via 
      closed institutional networks. Frequencies summarized the data, and chi-square
      compared variables and outcomes. Odds ratios (ORs) and multivariable analysis
      examined predictors for willingness to work. Fifteen HCWs (physicians, nurses,
      and lab and radiology technicians) were purposefully sampled and agreed to
      interviews to explore their thoughts, motivations, and worries. Thematic analysis
      focused on ethical dilemmas to enhance the breadth and the depth of the study.
      Results: Almost 25% of surveyed HCWs were not willing to work during the
      pandemic. Logistic model results showed that physicians and nurses had higher
      willingness to work than others (p = 0.004, Adj. OR = 3.5). Lower stress levels
      and longer professional experience were predictors of more willing to work (p =
      0.03, Adj. OR = 2.5; p = 0.03, Adj. OR = 2.6, respectively). Interviews showed
      that willingness to work did not preclude HCWs from fulfilling their duties
      despite grueling workloads and grave fears about safety and security. HCWs felt
      poorly prepared, unappreciated, and frustrated by unfair work distribution. The
      occupation presented additional safety issues. Conclusion: Physicians and nurses 
      were more likely to comply with a commitment to their professional ethics and the
      duty or obligation to work. Stress levels could be mitigated in the future with
      better leadership, adding supports to address mental health and psychosocial
      challenges to enhance HCWs' well-being and improve quality of care. The realities
      of the occupation added additional threats and uncertainty.
CI  - Copyright (c) 2021 Maraqa, Nazzal and Zink.
FAU - Maraqa, Beesan
AU  - Maraqa B
AD  - Primary Health Directorate, Ministry of Health, Ramallah, Palestine.
AD  - Family Medicine Residency Program, Faculty of Graduate Studies, An-Najah National
      University, Nablus, Palestine.
FAU - Nazzal, Zaher
AU  - Nazzal Z
AD  - Department of Family and Community Medicine, Faculty of Medicine and Health
      Sciences, An-Najah National University, Nablus, Palestine.
FAU - Zink, Therese
AU  - Zink T
AD  - Department of Family Medicine & School of Public Health, Brown University,
      Providence, RI, United States.
LA  - eng
PT  - Journal Article
DEP - 20210105
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7813812
OTO - NOTNLM
OT  - COVID 19
OT  - Palestine
OT  - duty to work
OT  - ethical dilemmas
OT  - health care workers
OT  - willingness to work
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/21 06:00
MHDA- 2021/01/21 06:01
CRDT- 2021/01/20 05:54
PHST- 2020/06/27 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2021/01/20 05:54 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/21 06:01 [medline]
AID - 10.3389/fmed.2020.576820 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Jan 5;7:576820. doi: 10.3389/fmed.2020.576820.
      eCollection 2020.


PMID- 33469440
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210122
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Editorial: Perceptions of Human-Animal Relationships and Their Impacts on Animal 
      Ethics, Law and Research.
PG  - 631238
LID - 10.3389/fpsyg.2020.631238 [doi]
FAU - Pele, Marie
AU  - Pele M
AD  - Anthropo-Lab, ETHICS EA7446, Lille Catholic University, Lille, France.
FAU - Georges, Jean-Yves
AU  - Georges JY
AD  - Universite de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
FAU - Matsuzawa, Tetsuro
AU  - Matsuzawa T
AD  - Kyoto University Institute for Advanced Study, Kyoto, Japan.
FAU - Sueur, Cedric
AU  - Sueur C
AD  - Universite de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
AD  - Centre Europeen d'Enseignement et de recherche en Ethique, Strasbourg, France.
AD  - Institut Universitaire de France, Paris, France.
LA  - eng
PT  - Editorial
DEP - 20210105
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7813984
OTO - NOTNLM
OT  - animal consciousness
OT  - animal conservation
OT  - animal ethics
OT  - animal law
OT  - animalism
OT  - cognitive bias
OT  - one-health
OT  - speciesism
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/21 06:00
MHDA- 2021/01/21 06:01
CRDT- 2021/01/20 05:54
PHST- 2020/11/19 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2021/01/20 05:54 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/21 06:01 [medline]
AID - 10.3389/fpsyg.2020.631238 [doi]
PST - epublish
SO  - Front Psychol. 2021 Jan 5;11:631238. doi: 10.3389/fpsyg.2020.631238. eCollection 
      2020.


PMID- 33469436
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - A Good Night's Sleep: Learning About Sleep From Autistic Adolescents' Personal
      Accounts.
PG  - 583868
LID - 10.3389/fpsyg.2020.583868 [doi]
AB  - BACKGROUND: Sleep is a strong predictor of quality of life and has been related
      to cognitive and behavioral functioning. However, research has shown that most
      autistic people experience sleep problems throughout their life. The most common 
      sleep problems include sleep onset delay, frequent night-time wakings and shorter
      total sleep time. Despite the importance of sleep on many domains, it is still
      unclear from first-hand accounts what helps autistic people to sleep. The purpose
      of this study is to explore together with autistic adolescents their
      sleep-related practices before bedtime and during the day which contribute to a
      good night's sleep. METHODS: Fifty-four autistic adolescents collaborated with an
      academic researcher in a novel adapted photo-elicitation methodology, rooted in a
      Lifeworld framework. The adolescents were invited to collect and analyze their
      data. The data were also presented in a community knowledge exchange event.
      RESULTS: Several self-reported practices that facilitate better nocturnal sleep
      were identified. Those were organized into two thematics: Evening/bedtime factors
      and Day time factors. These included practices such as personalized sensory and
      relaxation tools before bed and during night-time, engaging in a range of
      physical activities during daytime and accommodating personal time to engage with
      highly preferred and intense focus activities and hobbies. It also included
      spending time in predictable and fun ways with family members before bedtime.
      CONCLUSION: This is the first time that a study uses a novel methodological
      approach based on personal accounts elicited by photos rooted in a Lifeworld
      framework to describe personal sleep-related practices before bedtime and during 
      the day to identify a "good night of sleep" in autistic adolescents. The outcomes
      from the current study showed that sleep facilitating factors are in a direct
      contrast to the sleep hygiene recommendations. Therefore, it is thus important
      for the sleep practitioners and healthcare providers to move beyond providing
      standardized sleep hygiene interventions. A Lifeworld led care model that pays
      attention to personal experiences, promotes sense of agency, evaluates both
      autism-specific strengths and struggles could and should complement biomedical
      approaches. LAY SUMMARY: This is the first study to examine autistic adolescents'
      self-reported sleep habits and factors which facilitate autistic adolescents'
      sleep by employing adapted photo-elicitation interviews. This study is innovative
      in at least three ways. First, it examines the factors that may facilitate a good
      night's sleep through personal accounts of autistic adolescents. Second, this is 
      the first sleep study to adopt a collaborative, flexible approach to
      understanding positive sleep factors in the lives of autistic adolescents. This
      study employed a personalized approach into collecting, categorizing, coding, and
      analyzing qualitative data allowing autistic adolescents and the researcher to
      work together across key stages of data collection and data analysis. Third, we
      adopted a theoretical framework that allows us to consider autistic adolescents
      in both agency and vulnerability positions when it comes to their sleep
      difficulties. Our results highlight that sleep should be treated individually and
      in relation to the environmental and personal factors that affect each autistic
      person. Hence, researchers and professionals may benefit from working
      collaboratively with autistic adolescents with the aim to identify individual
      strengths and adopt a positive narrative around sleep. Furthermore, it is
      important to further examine both the daytime and evening factors that may affect
      bedtime and the quality and quantity of sleep as well as the role of intense
      focused interests and physical activities that cultivate positive feelings and
      help autistic people to relax before bedtime.
CI  - Copyright (c) 2020 Pavlopoulou.
FAU - Pavlopoulou, Georgia
AU  - Pavlopoulou G
AD  - Department of Psychology and Human Development, Institute of Education,
      University College London, London, United Kingdom.
AD  - Anna Freud National Centre for Children and Families, London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201222
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
EIN - Front Psychol. 2021 Apr 07;12:657385. PMID: 33897566
PMC - PMC7814098
OTO - NOTNLM
OT  - adolescence
OT  - autism (ASD)
OT  - autistic wellbeing
OT  - mental health - related quality of life
OT  - phenomenology and care ethics
OT  - sleep
COIS- The author declares that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/21 06:00
MHDA- 2021/01/21 06:01
CRDT- 2021/01/20 05:54
PHST- 2020/07/15 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2021/01/20 05:54 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/21 06:01 [medline]
AID - 10.3389/fpsyg.2020.583868 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 22;11:583868. doi: 10.3389/fpsyg.2020.583868. eCollection
      2020.


PMID- 33467258
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210122
IS  - 2411-5142 (Electronic)
IS  - 2411-5142 (Linking)
VI  - 5
IP  - 2
DP  - 2020 Jun 10
TI  - Research and Publication Ethics in Journal of Functional Morphology and
      Kinesiology.
LID - E42 [pii]
LID - 10.3390/jfmk5020042 [doi]
AB  - Research is required to minimize uncertainty and to be reproducible, that is, the
      design, implementation, evaluation, interpretation, and reporting of the
      presented data, must follow a good practice. An appropriate experimental design, 
      an accurate execution of the study, a strict criticism of the obtained data while
      avoiding overestimation, as well as a suitable interpretation of main outcomes,
      represent key aspects in reporting and disseminating research to the scientific
      community. Furthermore, author contribution, responsibility, funding,
      acknowledgement, and adequately declaring any conflict of interest play important
      roles in science. The Journal of Functional Morphology and Kinesiology (JFMK), a 
      member of the Committee on Publication Ethics (COPE), is committed to the highest
      scientific and ethical standards and encourages all authors to take into account 
      and to comply, as much as possible, with the contents and issues reported in this
      technical note. This could be useful to improve the quality of the manuscripts
      and avoid misconduct, as well as to stimulate interest and debate, reflecting
      upon uses and misuses within our disciplines belonging to the medicine area
      (sports medicine and movement sciences) categories: anatomy, histology,
      orthopedics and sports medicine, rheumatology, sports sciences, physical therapy,
      sports therapy, and rehabilitation.
FAU - Maugeri, Grazia
AU  - Maugeri G
AD  - Department of Biomedical and Biotechnological Sciences, Human, Histology and
      Movement Science Section, University of Catania, Via S. Sofia n degrees 87, 95123
      Catania, Italy.
FAU - Musumeci, Giuseppe
AU  - Musumeci G
AUID- ORCID: 0000-0002-8260-8890
AD  - Department of Biomedical and Biotechnological Sciences, Human, Histology and
      Movement Science Section, University of Catania, Via S. Sofia n degrees 87, 95123
      Catania, Italy.
AD  - Research Center on Motor Activities (CRAM), University of Catania, Via S. Sofia n
      degrees 97, 95123 Catania, Italy.
AD  - Department of Biology, Sbarro Institute for Cancer Research and Molecular
      Medicine, College of Science and Technology, Temple University, Philadelphia, PA 
      19122, USA.
LA  - eng
PT  - Editorial
DEP - 20200610
PL  - Switzerland
TA  - J Funct Morphol Kinesiol
JT  - Journal of functional morphology and kinesiology
JID - 101712257
PMC - PMC7739350
OTO - NOTNLM
OT  - author contributions
OT  - best practice
OT  - conflict of interest
OT  - design
OT  - ethical standard
OT  - experimental approach
OT  - funding
OT  - performance indicators
OT  - plagiarism
OT  - reliability of the measures
OT  - sample size
OT  - statement
OT  - statistical analysis
EDAT- 2021/01/21 06:00
MHDA- 2021/01/21 06:01
CRDT- 2021/01/20 01:08
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2021/01/20 01:08 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/21 06:01 [medline]
AID - jfmk5020042 [pii]
AID - 10.3390/jfmk5020042 [doi]
PST - epublish
SO  - J Funct Morphol Kinesiol. 2020 Jun 10;5(2). pii: jfmk5020042. doi:
      10.3390/jfmk5020042.


PMID- 33463969
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1940-4379 (Electronic)
IS  - 1050-6934 (Linking)
VI  - 30
IP  - 3
DP  - 2020
TI  - Crestal Bone Loss in Implants Postloading and Its Association with Age, Gender,
      and Implant Site: A Retrospective Study.
PG  - 205-211
LID - 10.1615/JLongTermEffMedImplants.2020035936 [doi]
AB  - We evaluate crestal bone loss in implants after loading and bone loss associated 
      with age, gender, and implant site. This retrospective study was conducted in the
      Department of Prosthodontics, Saveetha Dental College, India. We obtained ethical
      clearance from the Scientific Review Board at the college. Data were collected
      from 86,000 patients who visited Saveetha Dental College between June 2019 and
      March 2020. From these, we retrieved data from 335 patients, in whom implants
      were placed during this time frame. We tabulated data using the Statistical
      Package for the Social Sciences (IBM; Armonk, NY), ver. 20 for Windows.
      Chi-squared tests determined association among bone density, implant site,
      crestal implant position, and primary implant stability. We observed significant 
      correlation between age and crestal bone loss (p = 0.019), but not between gender
      (p = 0.792) nor implant site (p = 0.223) with crestal bone loss.
FAU - Devi, Sanjana
AU  - Devi S
AD  - Department of Prosthodontics, Saveetha Dental College, Saveetha Institute of
      Medical and Technical Science, Saveetha University, Chennai 600077, Tamil Nadu,
      India.
FAU - Duraisamy, Revathi
AU  - Duraisamy R
AD  - Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha
      Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077,
      Tamil Nadu, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Long Term Eff Med Implants
JT  - Journal of long-term effects of medical implants
JID - 9110830
RN  - 0 (Dental Implants)
MH  - *Alveolar Bone Loss/epidemiology/etiology
MH  - Bone Density
MH  - Dental Implantation, Endosseous
MH  - *Dental Implants/adverse effects
MH  - Dental Prosthesis Design
MH  - Humans
MH  - Prostheses and Implants
MH  - Retrospective Studies
EDAT- 2021/01/20 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/01/19 08:45
PHST- 2021/01/19 08:45 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 324bc17a1849e338,4912f0b9249a02e0 [pii]
AID - 10.1615/JLongTermEffMedImplants.2020035936 [doi]
PST - ppublish
SO  - J Long Term Eff Med Implants. 2020;30(3):205-211. doi:
      10.1615/JLongTermEffMedImplants.2020035936.


PMID- 33463925
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1940-4379 (Electronic)
IS  - 1050-6934 (Linking)
VI  - 30
IP  - 4
DP  - 2020
TI  - Three-Dimensional (3D) Printing in Orthopedics Education.
PG  - 255-258
LID - 10.1615/JLongTermEffMedImplants.2020036911 [doi]
AB  - Three-dimensional (3D) printing is a newly established concept in orthopedics
      compared with other industries. Surgical applications of 3D printing and tissue
      engineering have been investigated since the early 2000s, almost two decades
      after Charles Hull had patented the first device currently in use for additive
      manufacturing, also known as rapid prototyping or more commonly 3D printing, and 
      whose initial formal appellation was stereolithography (SLA). Despite
      technological progress, substantial principles have largely remained unaltered.
      Training directly on patients and on cadavers is considered the "gold standard"
      for learning and developing suitable surgical qualifications. However,
      restrictions concerning patient safety, ethical dilemmas, lack of availability,
      etc., have to be taken into account. Thus, 3D representations can be utilized as 
      an educational tool both for patients to improve their understanding of their
      condition and also medical students, residents, and surgeons to comprehend
      complex anatomical structures and practice their surgical maneuvers to be
      prepared and more confident in theater.
FAU - Maglara, Elli
AU  - Maglara E
AD  - School of Medicine, National and Kapodistrian University of Athens, Greece.
FAU - Angelis, Stavros
AU  - Angelis S
AD  - Department of Anatomy, School of Medicine, National and Kapodistrian University
      of Athens, Greece; Trauma and Orthopaedic Department, "Korgialenio-Benakio"
      Hellenic Red Cross Hospital, Athens, Greece.
FAU - Solia, Eirini
AU  - Solia E
AD  - School of Medicine, National and Kapodistrian University of Athens, Greece.
FAU - Apostolopoulos, Alexandros P
AU  - Apostolopoulos AP
AD  - Trauma and Orthopaedic Department, "Korgialenio-Benakio" Hellenic Red Cross
      Hospital, Athens, Greece; Trauma and Orthopaedic Department, Ealing Hospital,
      North West University Healthcare NHS Trust, London, United Kingdom.
FAU - Tsakotos, Georgios
AU  - Tsakotos G
AD  - Department of Anatomy, School of Medicine, National and Kapodistrian University
      of Athens, Greece.
FAU - Vlasis, Konstantinos
AU  - Vlasis K
AD  - Department of Anatomy, School of Medicine, National and Kapodistrian University
      of Athens, Greece.
FAU - Katsimantas, Antonios
AU  - Katsimantas A
AD  - Department of Urology, General Military Hospital of Athens, Athens, Greece;
      Department of Urology, Mediterraneo Hospital, Glyfada, Greece; Department of
      Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian
      University of Athens, Athens, Greece.
FAU - Filippou, Dimitrios K
AU  - Filippou DK
AD  - Department of Anatomy and Surgical Anatomy, Medical School, National and
      Kapodistrian University of Athens, Athens, Greece; National Organization for
      Medicines (EOF), Athens, Greece.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Long Term Eff Med Implants
JT  - Journal of long-term effects of medical implants
JID - 9110830
MH  - Humans
MH  - *Orthopedics
MH  - Printing, Three-Dimensional
EDAT- 2021/01/20 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/01/19 08:45
PHST- 2021/01/19 08:45 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 798d10cb46b67ba2,0c8f7e522043e4b8 [pii]
AID - 10.1615/JLongTermEffMedImplants.2020036911 [doi]
PST - ppublish
SO  - J Long Term Eff Med Implants. 2020;30(4):255-258. doi:
      10.1615/JLongTermEffMedImplants.2020036911.


PMID- 33463869
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 1099-1611 (Electronic)
IS  - 1057-9249 (Linking)
VI  - 29
IP  - 10
DP  - 2020 Oct
TI  - Clinical correlates of the ability to consent to research participation in brain 
      metastasis.
PG  - 1655-1661
LID - 10.1002/pon.5487 [doi]
AB  - OBJECTIVE: Impairment in the ability to provide informed consent is common in
      persons with brain metastasis. However, little is known about what factors
      contribute to this impairment in the patient group. Our objective is to determine
      if the associations between demographic, cognitive, and clinical variables
      correlate with the ability to provide informed consent in persons with brain
      metastasis. METHODS: We administered a comprehensive neuropsychological battery
      to a group of 61 persons with brain metastasis. Demographic and clinical
      information was also collected. All diagnoses were made by board-certified
      oncologists and were verified histologically. Statistical analyses included
      Pearson's product-moment correlations, point biserial correlations, and linear
      regression. RESULTS: Results indicated that combinations of education, verbal
      memory, executive function, whole brain radiation therapy, and chemotherapy
      affected various aspects of the ability to provide informed consent. Subsequent
      regression models demonstrated that these variables contributed a significant
      amount of shared variance to the ability to provide informed consent. CONCLUSION:
      We found that the ability of persons with brain metastasis to provide informed
      consent is a cognitively complex ability that is also affected by education and
      treatment variables. This information can help clinical researchers in
      identifying persons with brain metastasis at risk of an impaired ability to
      provide informed consent and aid in the consenting process.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Gerstenecker, Adam
AU  - Gerstenecker A
AUID- ORCID: 0000-0003-2696-5380
AD  - Department of Neurology, Division of Neuropsychology, University of Alabama,
      Birmingham, Alabama, USA.
AD  - Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham,
      Birmingham, Alabama, USA.
AD  - Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham,
      Alabama, USA.
FAU - Gammon, Meredith
AU  - Gammon M
AD  - Department of Neurology, Division of Neuropsychology, University of Alabama,
      Birmingham, Alabama, USA.
FAU - Marotta, Dario
AU  - Marotta D
AUID- ORCID: 0000-0002-0852-2327
AD  - Department of Neurology, Division of Neuropsychology, University of Alabama,
      Birmingham, Alabama, USA.
FAU - Fiveash, John
AU  - Fiveash J
AD  - O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham,
      Birmingham, Alabama, USA.
AD  - Department of Radiation Oncology, University of Alabama at Birmingham,
      Birmingham, Alabama, USA.
FAU - Nabors, Burt
AU  - Nabors B
AD  - Department of Neurology, Division of Neuropsychology, University of Alabama,
      Birmingham, Alabama, USA.
AD  - O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham,
      Birmingham, Alabama, USA.
FAU - Mulhauser, Kyler
AU  - Mulhauser K
AUID- ORCID: 0000-0003-2755-0451
AD  - Department of Neurology, Division of Neuropsychology, University of Alabama,
      Birmingham, Alabama, USA.
FAU - Triebel, Kristen
AU  - Triebel K
AD  - Department of Neurology, Division of Neuropsychology, University of Alabama,
      Birmingham, Alabama, USA.
AD  - Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham,
      Birmingham, Alabama, USA.
AD  - O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham,
      Birmingham, Alabama, USA.
LA  - eng
GR  - 5R25CA076023/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*pathology/secondary/therapy
MH  - Cognition Disorders/*psychology
MH  - Decision Making
MH  - Ethics, Medical
MH  - Executive Function/*physiology
MH  - Female
MH  - Humans
MH  - Informed Consent/*ethics/psychology
MH  - Male
MH  - Memory/physiology
MH  - Mental Competency/psychology
MH  - Middle Aged
MH  - Patient Participation/*psychology
MH  - Patient Selection/ethics
MH  - Research Subjects/psychology
OTO - NOTNLM
OT  - *brain metastasis
OT  - *cancer
OT  - *cognition
OT  - *informed consent
OT  - *medical ethics
OT  - *oncology
EDAT- 2021/01/20 06:00
MHDA- 2021/03/27 06:00
CRDT- 2021/01/19 08:44
PHST- 2020/03/14 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2021/01/19 08:44 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - 10.1002/pon.5487 [doi]
PST - ppublish
SO  - Psychooncology. 2020 Oct;29(10):1655-1661. doi: 10.1002/pon.5487. Epub 2020 Aug
      11.


PMID- 33462980
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20211204
IS  - 1399-3062 (Electronic)
IS  - 1398-2273 (Linking)
VI  - 22
IP  - 5
DP  - 2020 Oct
TI  - Seroprevalence of Torque Teno Virus in hemodialysis and renal transplant patients
      in Australia: A cross-sectional study.
PG  - e13400
LID - 10.1111/tid.13400 [doi]
AB  - INTRODUCTION: Torque teno virus (TTV) is a non-pathogenic anellovirus commonly
      found in the blood of human beings. Emerging data suggest that TTV viral load is 
      proportional to the degree of immunosuppression, but its seroprevalence is
      unknown in Australia. We aimed to determine the seroprevalence of TTV in an
      Australian population of renal patients. METHODS: We developed a real-time PCR to
      measure TTV viral load, using the TaqMan platform and previously published
      primers and probes. Following ethics approval and informed consent, we collected 
      blood from hemodialysis patients not receiving immunosuppression, and renal
      transplant patients. All patients were recruited from a single teaching hospital 
      in New South Wales. RESULTS: We enrolled 50 hemodialysis and 30 renal transplant 
      patients. 56 (70%) were males, and the mean (sd) age was 61 (16) years. TTV was
      detectable in plasma of 40/50 (80%) of hemodialysis patients and 28/30 (93%) of
      transplant patients. The mean TTV viral load was higher in transplant patients
      than in dialysis patients (6.3 log versus 5.0 log copies/ml, P = .001).
      CONCLUSIONS: Torque teno virus is prevalent in Australian renal patients and thus
      may be a useful novel marker to help tailor immunosuppressive therapy in renal
      transplant patients. Further work is needed to establish TTV seroprevalence in
      other regions and patient groups, and to investigate whether there is correlation
      with clinically important events (infection and rejection episodes) in
      longitudinal studies.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Davis, Joshua S
AU  - Davis JS
AUID- ORCID: https://orcid.org/0000-0001-9864-5699
AD  - Department of Immunology and Infectious Diseases, John Hunter Hospital,
      Newcastle, NSW, Australia.
AD  - School of Medicine and Public Health, University of Newcastle, Newcastle, NSW,
      Australia.
AD  - Menzies School of Health Research, Darwin, NT, Australia.
FAU - Chu, Ginger
AU  - Chu G
AD  - Department of Nephrology, John Hunter Hospital, Newcastle, NSW, Australia.
FAU - Pathinayake, Prabuddhua
AU  - Pathinayake P
AD  - School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine,
      Hunter Medical Research Institute, University of Newcastle, NSW, Australia.
FAU - Jones, Denise
AU  - Jones D
AD  - Department of Nephrology, John Hunter Hospital, Newcastle, NSW, Australia.
FAU - Giffard, Phil
AU  - Giffard P
AD  - Menzies School of Health Research, Darwin, NT, Australia.
FAU - Macera, Lisa
AU  - Macera L
AD  - Department of Translational Research, University of Pisa, Pisa, Italy.
FAU - Choi, Peter
AU  - Choi P
AD  - Department of Nephrology, John Hunter Hospital, Newcastle, NSW, Australia.
FAU - Bartlett, Nathan W
AU  - Bartlett NW
AD  - School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine,
      Hunter Medical Research Institute, University of Newcastle, NSW, Australia.
LA  - eng
GR  - #1160331/National Health and Medical Research Council
GR  - Hunter Transplant Research Foundation
PT  - Journal Article
DEP - 20200727
PL  - Denmark
TA  - Transpl Infect Dis
JT  - Transplant infectious disease : an official journal of the Transplantation
      Society
JID - 100883688
RN  - 0 (Biomarkers)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Aged
MH  - Australia/epidemiology
MH  - Biomarkers/blood
MH  - Cross-Sectional Studies
MH  - DNA Virus Infections/blood/*epidemiology/virology
MH  - DNA, Viral/*blood
MH  - Female
MH  - Humans
MH  - Immunosuppression Therapy
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Real-Time Polymerase Chain Reaction
MH  - *Renal Dialysis
MH  - Seroepidemiologic Studies
MH  - Torque teno virus/genetics/*isolation & purification
MH  - Viral Load
OTO - NOTNLM
OT  - Australia
OT  - Torque teno virus
OT  - hemodialysis
OT  - immunosuppression
OT  - kidney transplantation
EDAT- 2021/01/20 06:00
MHDA- 2021/04/27 06:00
CRDT- 2021/01/19 06:04
PHST- 2020/02/18 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2021/01/19 06:04 [entrez]
PHST- 2021/01/20 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
AID - 10.1111/tid.13400 [doi]
PST - ppublish
SO  - Transpl Infect Dis. 2020 Oct;22(5):e13400. doi: 10.1111/tid.13400. Epub 2020 Jul 
      27.


PMID- 33459944
OWN - NLM
STAT- MEDLINE
DCOM- 20210916
LR  - 20210916
IS  - 1573-0980 (Electronic)
IS  - 1386-7415 (Linking)
VI  - 41
IP  - 5-6
DP  - 2020 Dec
TI  - The ethics of innovation for Alzheimer's disease: the risk of overstating
      evidence for metabolic enhancement protocols.
PG  - 223-237
LID - 10.1007/s11017-020-09536-7 [doi]
AB  - Medical practice is ideally based on robust, relevant research. However, the lack
      of disease-modifying treatments for Alzheimer's disease has motivated "innovative
      practice" to improve patients' well-being despite insufficient evidence for the
      regular use of such interventions in health systems treating millions of
      patients. Innovative or new non-validated practice poses at least three distinct 
      ethical questions: first, about the responsible application of new non-validated 
      practice to individual patients (clinical ethics); second, about the way in which
      data from new non-validated practice are communicated via the scientific and lay 
      press (scientific communication ethics); and third, about the prospect of making 
      new non-validated interventions widely available before more definitive testing
      (public health ethics). We argue that the authors of metabolic enhancement
      protocols for Alzheimer's disease have overstated the evidence in favor of these 
      interventions within the scientific and lay press, failing to communicate
      weaknesses in their data and uncertainty about their conclusions. Such unmeasured
      language may create false hope, cause financial harm, undermine informed consent,
      and frustrate the production of generalizable knowledge necessary to face the
      societal problems posed by this devastating disease. We therefore offer more
      stringent guidelines for responsible innovation in the treatment of Alzheimer's
      disease.
FAU - Daly, Timothy
AU  - Daly T
AUID- ORCID: 0000-0003-1650-242X
AD  - Sorbonne University, Paris, France. timothy.daly@paris-sorbonne.fr.
FAU - Mastroleo, Ignacio
AU  - Mastroleo I
AUID- ORCID: 0000-0002-8243-9943
AD  - National Scientific and Technical Research Council, Buenos Aires, Argentina.
FAU - Gorski, David
AU  - Gorski D
AUID- ORCID: 0000-0002-9805-6699
AD  - Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
FAU - Epelbaum, Stephane
AU  - Epelbaum S
AUID- ORCID: 0000-0003-4059-2891
AD  - Institut du Cerveau et de la Moelle epiniere (Brain and Spine Institute), Paris, 
      France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210118
PL  - Netherlands
TA  - Theor Med Bioeth
JT  - Theoretical medicine and bioethics
JID - 9805378
SB  - IM
MH  - Alzheimer Disease/*therapy
MH  - Biomedical Research/ethics
MH  - Humans
MH  - Inventions/*ethics/trends
MH  - Research/*standards/trends
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *Biomedical ethics
OT  - *Clinical ethics
OT  - *Dementia
OT  - *Diffusion of innovation
OT  - *Innovation
OT  - *Integrative medicine
EDAT- 2021/01/19 06:00
MHDA- 2021/09/18 06:00
CRDT- 2021/01/18 12:16
PHST- 2020/12/07 00:00 [accepted]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2021/01/18 12:16 [entrez]
AID - 10.1007/s11017-020-09536-7 [doi]
AID - 10.1007/s11017-020-09536-7 [pii]
PST - ppublish
SO  - Theor Med Bioeth. 2020 Dec;41(5-6):223-237. doi: 10.1007/s11017-020-09536-7. Epub
      2021 Jan 18.


PMID- 33458358
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2405-6316 (Electronic)
IS  - 2405-6316 (Linking)
VI  - 16
DP  - 2020 Oct
TI  - Machine learning applications in radiation oncology: Current use and needs to
      support clinical implementation.
PG  - 144-148
LID - 10.1016/j.phro.2020.11.002 [doi]
AB  - BACKGROUND AND PURPOSE: The use of artificial intelligence (AI)/ machine learning
      (ML) applications in radiation oncology is emerging, however no clear guidelines 
      on commissioning of ML-based applications exist. The purpose of this study was
      therefore to investigate the current use and needs to support implementation of
      ML-based applications in routine clinical practice. MATERIALS AND METHODS: A
      survey was conducted among medical physicists in radiation oncology, consisting
      of four parts: clinical applications (1), model training, acceptance and
      commissioning (2), quality assurance (QA) in clinical practice and General Data
      Protection Regulation (GDPR) (3), and need for education and guidelines (4).
      Survey answers of medical physicists of the same radiation oncology centre were
      treated as a separate unique responder in case reporting on different AI
      applications. RESULTS: In total, 213 medical physicists from 202 radiation
      oncology centres were included in the analysis. Sixty-nine percent (1 4 7) was
      using (37%) or preparing (32%) to use ML in clinic, mostly for contouring and
      treatment planning. In 86%, human observers were still involved in daily clinical
      use for quality check of the output of the ML algorithm. Knowledge on ethics,
      legislation and data sharing was limited and scattered among responders. Besides 
      the need for (implementation) guidelines, training of medical physicists and
      larger databases containing multicentre data was found to be the top priority to 
      accommodate the further introduction of ML in clinical practice. CONCLUSION: The 
      results of this survey indicated the need for education and guidelines on the
      implementation and quality assurance of ML-based applications to benefit clinical
      introduction.
CI  - (c) 2020 The Author(s).
FAU - Brouwer, Charlotte L
AU  - Brouwer CL
AD  - University of Groningen, University Medical Center Groningen, Department of
      Radiation Oncology, Groningen, The Netherlands.
FAU - Dinkla, Anna M
AU  - Dinkla AM
AD  - Department of Radiation Oncology, Amsterdam University Medical Center, VU
      University, The Netherlands.
FAU - Vandewinckele, Liesbeth
AU  - Vandewinckele L
AD  - Department Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, 
      Belgium.
AD  - Radiation Oncology, UZ Leuven, Leuven, Belgium.
FAU - Crijns, Wouter
AU  - Crijns W
AD  - Department Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, 
      Belgium.
AD  - Radiation Oncology, UZ Leuven, Leuven, Belgium.
FAU - Claessens, Michael
AU  - Claessens M
AD  - Iridium Network, Wilrijk (Antwerp), Belgium.
AD  - Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
FAU - Verellen, Dirk
AU  - Verellen D
AD  - Iridium Network, Wilrijk (Antwerp), Belgium.
AD  - Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
FAU - van Elmpt, Wouter
AU  - van Elmpt W
AD  - Department of Radiation Oncology (MAASTRO), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - Netherlands
TA  - Phys Imaging Radiat Oncol
JT  - Physics and imaging in radiation oncology
JID - 101704276
PMC - PMC7807598
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Clinical implementation
OT  - Commissioning
OT  - Machine learning
OT  - Quality assurance
OT  - Radiotherapy
OT  - Survey
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2021/01/19 06:00
MHDA- 2021/01/19 06:01
CRDT- 2021/01/18 05:35
PHST- 2020/07/13 00:00 [received]
PHST- 2020/11/08 00:00 [revised]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2021/01/18 05:35 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/19 06:01 [medline]
AID - 10.1016/j.phro.2020.11.002 [doi]
AID - S2405-6316(20)30073-7 [pii]
PST - epublish
SO  - Phys Imaging Radiat Oncol. 2020 Nov 30;16:144-148. doi:
      10.1016/j.phro.2020.11.002. eCollection 2020 Oct.


PMID- 33457522
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210119
IS  - 2374-3735 (Print)
IS  - 2374-3735 (Linking)
VI  - 7
IP  - 6
DP  - 2020 Dec
TI  - Challenges of Patient Engagement in an HIV Clinical Research Program: A
      Qualitative Analysis of Stakeholder Accounts.
PG  - 925-930
LID - 10.1177/2374373520975728 [doi]
AB  - Patient engagement (PE) promotes collaboration between stakeholders (researchers,
      patients, clinicians, etc). It often faces challenges due to tensions between its
      ethical/political and scientific underpinnings. This article explores how
      stakeholders applied the guiding principles of a PE project ("co-build," "support
      and mutual respect," and "inclusiveness") for an HIV clinical research program
      initiated in January 2016. Three researchers/clinicians, a PE agent, and 2
      patients held 3 meetings (June-October 2018) to discuss challenges faced and how 
      these impacted their approach to PE. Regular stakeholder discussions about PE in 
      clinical research could be documented and help guide PE to better meet
      stakeholder needs.
CI  - (c) The Author(s) 2020.
FAU - Lessard, David
AU  - Lessard D
AUID- ORCID: https://orcid.org/0000-0002-1151-3763
AD  - Chronic and Viral Illness Service (CVIS), McGill University Health Centre (MUHC),
      Montreal, Canada.
AD  - Centre for Health Outcomes Research and Evaluation (CORE), Research Institute of 
      the McGill University Health Centre (RI-MUHC), Montreal, Canada.
AD  - Canadian Institutes of Health Research Strategy for Patient-Oriented Research
      (CIHR/SPOR) Mentorship Chair in Innovative Clinical Trials in HIV, Montreal,
      Canada.
FAU - Engler, Kim
AU  - Engler K
AD  - Chronic and Viral Illness Service (CVIS), McGill University Health Centre (MUHC),
      Montreal, Canada.
AD  - Centre for Health Outcomes Research and Evaluation (CORE), Research Institute of 
      the McGill University Health Centre (RI-MUHC), Montreal, Canada.
AD  - Canadian Institutes of Health Research Strategy for Patient-Oriented Research
      (CIHR/SPOR) Mentorship Chair in Innovative Clinical Trials in HIV, Montreal,
      Canada.
FAU - Vicente, Serge
AU  - Vicente S
AD  - Canadian Institutes of Health Research Strategy for Patient-Oriented Research
      (CIHR/SPOR) Mentorship Chair in Innovative Clinical Trials in HIV, Montreal,
      Canada.
AD  - Department of Mathematics and Statistics, Universite de Montreal, Montreal,
      Canada.
FAU - Bilodeau, Martin
AU  - Bilodeau M
AD  - Canadian Institutes of Health Research Strategy for Patient-Oriented Research
      (CIHR/SPOR) Mentorship Chair in Innovative Clinical Trials in HIV, Montreal,
      Canada.
AD  - Ontario AIDS Network, Positive Leadership Development Institute (PLDI), Toronto, 
      Canada.
FAU - Lebouche, Bertrand
AU  - Lebouche B
AD  - Chronic and Viral Illness Service (CVIS), McGill University Health Centre (MUHC),
      Montreal, Canada.
AD  - Centre for Health Outcomes Research and Evaluation (CORE), Research Institute of 
      the McGill University Health Centre (RI-MUHC), Montreal, Canada.
AD  - Canadian Institutes of Health Research Strategy for Patient-Oriented Research
      (CIHR/SPOR) Mentorship Chair in Innovative Clinical Trials in HIV, Montreal,
      Canada.
AD  - Department of Family Medicine, McGill University, Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - United States
TA  - J Patient Exp
JT  - Journal of patient experience
JID - 101688338
PMC - PMC7786743
OTO - NOTNLM
OT  - Patient Advisory Councils
OT  - methods
OT  - patient engagement
OT  - patient perspectives/narratives
OT  - qualitative
OT  - team communication
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2021/01/19 06:00
MHDA- 2021/01/19 06:01
CRDT- 2021/01/18 05:33
PHST- 2021/01/18 05:33 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/19 06:01 [medline]
AID - 10.1177/2374373520975728 [doi]
AID - 10.1177_2374373520975728 [pii]
PST - ppublish
SO  - J Patient Exp. 2020 Dec;7(6):925-930. doi: 10.1177/2374373520975728. Epub 2020
      Nov 25.


PMID- 33457317
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210829
IS  - 2239-9747 (Print)
IS  - 2239-9747 (Linking)
VI  - 23
DP  - 2020 Dec
TI  - Saving Limited Resources During Covid-19 Pandemic.
PG  - 20-21
FAU - Piazza, O
AU  - Piazza O
AD  - Department of Medicine, Surgery, Dentistry, University of Salerno, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Italy
TA  - Transl Med UniSa
JT  - Translational medicine @ UniSa
JID - 101588308
PMC - PMC7789931
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - ICU
EDAT- 2021/01/19 06:00
MHDA- 2021/01/19 06:01
CRDT- 2021/01/18 05:32
PHST- 2021/01/18 05:32 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/19 06:01 [medline]
AID - tm-23-020 [pii]
PST - epublish
SO  - Transl Med UniSa. 2020 Dec 31;23:20-21. eCollection 2020 Dec.


PMID- 33456547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Mar
TI  - Assessing Research Ethics Committees in Myanmar: Results of a Self-Assessment
      Tool.
PG  - 37-49
LID - 10.1007/s41649-020-00113-7 [doi]
AB  - BACKGROUND: Human subject research has increased in Myanmar since 2010 and
      accordingly, the establishment of research ethics committees (RECs) have
      increased to review these research studies. However, characteristics that reflect
      the operations of RECs in Myanmar have not been assessed. OBJECTIVES: To assess
      the structures and processes of RECs at Medical Institutions in Myanmar. METHODS:
      We used a self-assessment tool for RECs operating in low and middle-income
      countries. This tool consists of the following ten domains: organizational
      aspects, membership and ethics training, submission arrangements and materials,
      meeting minutes, policies referring to review procedures, review of specific
      protocol and informed consent items, communication a decision, continuing review,
      REC resources, and institutional commitment. We distributed this
      self-administered questionnaire to RECs from 15 Medical Institutions in Myanmar
      and one representative from each REC completed this questionnaire and returned it
      anonymously. We used descriptive, bivariate, and multivariate statistics to
      analyse the data. RESULTS: Out of maximum 200 points, the total mean score for
      Myanmar Medical Institutions was 112.6 +/- 12.77, which is lower compared to the 
      aggregate mean score of 137.4 +/- 35.8 obtained from RECs in other countries.
      Domains in which the average percentage score was less than 60% included
      organizational commitment, membership and ethics training, continuing review and 
      REC resources. Many RECs have a diverse membership and appropriate gender balance
      but, lacked essential policies. CONCLUSION: The results show that for Myanmar
      RECs there is significant room for improvement in their "structures and
      processes" as well as the extent of institutionl commitment. The self-assessment 
      tool proved to be valuable method to assess the quality of RECs.
FAU - Oo, Zaw Zaw
AU  - Oo ZZ
AD  - University of Medicine 2, Yangon, Ministry of Health and Sports, Yangon, Myanmar.
FAU - Wun, Min
AU  - Wun M
AD  - Department of Medical Research, Myanmar Ministry of Health and Sports, Yangon,
      Myanmar.
FAU - Oo, Yin Thet Nu
AU  - Oo YTN
AD  - Department of Medical Research, Myanmar Ministry of Health and Sports, Yangon,
      Myanmar.
FAU - Mya, Kyaw Swa
AU  - Mya KS
AD  - University of Public Health, Ministry of Health and Sports, Yangon, Myanmar.
FAU - Silverman, Henry J
AU  - Silverman HJ
AD  - Department of Medicine, University of Maryland School of Medicine, Baltimore,
      USA.
LA  - eng
GR  - R25 TW010516/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200317
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7747290
MID - NIHMS1577470
OTO - NOTNLM
OT  - Institutional Review Committees
OT  - Myanmar
OT  - Research
OT  - Research Ethics
OT  - Research Ethics Committees
COIS- Conflicts of interest/Competing interests: All authors declare the non-existence 
      of any financial or non-financial competing interests.
EDAT- 2021/01/19 06:00
MHDA- 2021/01/19 06:01
CRDT- 2021/01/18 05:29
PHST- 2021/01/18 05:29 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/19 06:01 [medline]
AID - 10.1007/s41649-020-00113-7 [doi]
PST - ppublish
SO  - Asian Bioeth Rev. 2020 Mar;12(1):37-49. doi: 10.1007/s41649-020-00113-7. Epub
      2020 Mar 17.


PMID- 33456076
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210119
IS  - 0034-6233 (Print)
IS  - 0034-6233 (Linking)
VI  - 58
IP  - 6
DP  - 2020
TI  - Scientific authorship: a primer for researchers.
PG  - 345-349
LID - 10.5114/reum.2020.101999 [doi]
AB  - The International Committee of Medical Journal Editors (ICMJE) proposed the
      authorship criteria which can be employed by medics and allied specialists.
      Scholars who substantively contribute to research and writing, revise, approve
      final drafts for target journal submissions, and take responsibility for all
      aspects of the work deserve authorship. Increasing awareness of the ICMJE
      criteria, incorporating related points in journal instructions, and enforcing
      them in daily practice may have positive impact for healthcare. Instances of
      inappropriate authorship are ethical transgressions which can be avoided by
      editors employing strategies of author profile evaluations. There are several
      platforms for recording author accomplishments which may improve the
      discoverability of scholarly works and prevent unethical conduct. Most publishers
      advise authors to submit their Open Researcher and Contributor IDs (ORCID) at the
      manuscript submission. Other identifiers, such as Twitter handles, are also
      emerging as tools to stimulate post-publication communication and increase
      authors' accountability for published articles.
CI  - Copyright: (c) 2020 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w
      Warszawie.
FAU - Zimba, Olena
AU  - Zimba O
AD  - Department of Internal Medicine No. 2, Danylo Halytsky Lviv National Medical
      University, Lviv, Ukraine.
FAU - Gasparyan, Armen Yuri
AU  - Gasparyan AY
AD  - Departments of Rheumatology and Research and Development, Dudley Group NHS
      Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells
      Hall Hospital, Dudley, West Midlands, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - Poland
TA  - Reumatologia
JT  - Reumatologia
JID - 20130190R
PMC - PMC7792538
OTO - NOTNLM
OT  - authorship
OT  - publication ethics
OT  - publishing
OT  - rheumatology
COIS- The authors declare no conflict of interest.
EDAT- 2021/01/19 06:00
MHDA- 2021/01/19 06:01
CRDT- 2021/01/18 05:27
PHST- 2020/11/25 00:00 [received]
PHST- 2020/12/02 00:00 [accepted]
PHST- 2021/01/18 05:27 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/19 06:01 [medline]
AID - 10.5114/reum.2020.101999 [doi]
AID - 42769 [pii]
PST - ppublish
SO  - Reumatologia. 2020;58(6):345-349. doi: 10.5114/reum.2020.101999. Epub 2020 Dec
      23.


PMID- 33448422
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Toward Fair and Humane Pain Policy.
PG  - 33-36
LID - 10.1002/hast.1170 [doi]
AB  - Pain policy is not drug policy. If society wants to improve the lives of people
      in pain and compress the terrible inequalities in its diagnosis and treatment, we
      have to tailor policy to the root causes driving our problems in treating pain
      humanely and equitably. In the United States, we do not. Instead, we have
      proceeded to conflate drug policy with pain policy, relying on arguably magical
      thinking for the conclusion that by addressing the drug overdose crisis, we are
      simultaneously addressing the pain crisis. This is a category error, decades of
      commitment to which have resulted mostly in a worsening of both public health
      problems. Disentangling our problems in treating pain fairly and equitably from
      our problems with drugs and substance use is the only path to humane and ethical 
      policy for each.
CI  - (c) 2020 The Hastings Center.
FAU - Goldberg, Daniel S
AU  - Goldberg DS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/therapeutic use
MH  - *Chronic Pain/drug therapy
MH  - *Drug Overdose/drug therapy
MH  - Health Policy
MH  - Humans
MH  - Public Health
MH  - Public Policy
MH  - United States
OTO - NOTNLM
OT  - drugs
OT  - inequalities
OT  - overdose
OT  - pain
OT  - policy
OT  - substance misuse
EDAT- 2021/01/16 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/01/15 08:44
PHST- 2021/01/15 08:44 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1170 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):33-36. doi: 10.1002/hast.1170.


PMID- 33448415
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Solving the Opioid Crisis Isn't Just a Public Health Challenge-It's a Bioethics
      Challenge.
PG  - 24-32
LID - 10.1002/hast.1169 [doi]
AB  - Among those who discuss America's opioid crisis, it is popular to claim that we
      know what we, as a society, ought to do to solve the problem-we simply don't want
      it badly enough. We don't lack knowledge; we lack the will to act and to fund the
      right policies. In fact, I've heard two versions of this. Among those who focus
      on prescription opioids, it is clear that we ought to stop prescribing so many
      powerful opioid painkillers. And among my public health colleagues focusing on
      illicit drug use, it is clear that we ought to expand addiction treatment and
      harm-reduction services. The problem, however, is that the second claim is not
      obvious (and, indeed, is denied by many Americans), and the first claim probably 
      isn't even true (at least, not in so crude a form). In short, the opioid crisis
      presents not only a problem of political will but also one of ethics. It will
      take work to discover or justify our normative claims in this arena.
CI  - (c) 2020 The Hastings Center.
FAU - Rieder, Travis N
AU  - Rieder TN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/adverse effects
MH  - *Bioethics
MH  - Harm Reduction
MH  - Humans
MH  - *Opioid Epidemic
MH  - Public Health
MH  - United States
OTO - NOTNLM
OT  - addiction
OT  - bioethics
OT  - harm reduction
OT  - opioid crisis
OT  - overdose
OT  - responsibility
EDAT- 2021/01/16 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/01/15 08:43
PHST- 2021/01/15 08:43 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1169 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):24-32. doi: 10.1002/hast.1169.


PMID- 33448410
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220531
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - The Ethical Limits of Children's Participation in Clinical Research.
PG  - 12-13
LID - 10.1002/hast.1167 [doi]
AB  - This essay reflects on arguments by Paul Ramsey, in The Patient as Person:
      Explorations in Medical Ethics (1970) and elsewhere, that continue to challenge
      policy-makers and those doing clinical and translational research involving
      children. Ramsey argued that parents cannot morally authorize their child's
      participation in research unless the research is designed to benefit the child.
      He acknowledged that abiding by this position could have adverse impacts on
      improving child health, and he concluded, in a 1976 Hastings Center Report piece,
      that researchers must "sin bravely." Many philosophers and theologians, including
      Richard McCormick, have argued against Ramsey. The Ramsey-McCormick debate played
      out in the bioethics literature and, by invitation, at the deliberations of the
      National Commission for the Protection of Human Subjects of Biomedical and
      Behavioral Research, which was tasked with developing an ethics framework and
      policies for human subjects protections. Although in its final recommendations,
      the commission sided with McCormick, the strict limitations on risks and harms to
      which a child can be exposed were clearly influenced by Ramsey.
CI  - (c) 2020 The Hastings Center.
FAU - Ross, Lainie Friedman
AU  - Ross LF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Bioethics
MH  - Biomedical Research/*ethics
MH  - *Child
MH  - Decision Making
MH  - Dissent and Disputes
MH  - Family
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - Morals
MH  - Parents
MH  - *Patient Participation
MH  - Research Subjects
OTO - NOTNLM
OT  - human subjects protections
OT  - informed consent
OT  - minimal risk
OT  - minors
OT  - parental autonomy
OT  - parent-child relationship
OT  - pediatric research
OT  - proxy decision-making
EDAT- 2021/01/16 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/01/15 08:43
PHST- 2021/01/15 08:43 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1167 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):12-13. doi: 10.1002/hast.1167.


PMID- 33448404
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Patients Left Behind: Ethical Challenges in Caring for Indirect Victims of the
      Covid-19 Pandemic.
PG  - 19-23
LID - 10.1002/hast.1168 [doi]
AB  - In response to the Covid-19 pandemic, health care systems worldwide canceled or
      delayed elective surgeries, outpatient procedures, and clinic appointments.
      Although such measures may have been necessary to preserve medical resources and 
      to prevent potential exposures early in the pandemic, moving forward, the
      indirect effects of such an extensive medical shutdown must not outweigh the
      direct harms of Covid-19. In this essay, we argue for the reopening of
      evidence-based health care with assurance provided to patients about the safety
      and necessity of high-value vaccinations, screenings, therapeutics, and
      procedures. To ensure that virtually all non-Covid-related services do not come
      to a halt again, health care systems and physician practices must preemptively
      increase their capacity, secure adequate personal protective equipment to
      safeguard health care personnel, and develop a measured approach to reclosing
      such routine health care, should it become necessary in the future.
CI  - (c) 2020 The Hastings Center.
FAU - Bruno, Bethany
AU  - Bruno B
FAU - Rose, Susannah
AU  - Rose S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Delivery of Health Care/*ethics
MH  - *Ethics, Institutional
MH  - Evidence-Based Medicine
MH  - *Health Facility Closure
MH  - Humans
MH  - Occupational Health/ethics
MH  - Pandemics
MH  - Personal Protective Equipment
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Covid-19 pandemic
OT  - *coronavirus
OT  - *health care
OT  - *medical outcomes
OT  - *reopening
OT  - *risk-benefit analysis
EDAT- 2021/01/16 06:00
MHDA- 2021/01/22 06:00
CRDT- 2021/01/15 08:43
PHST- 2021/01/15 08:43 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - 10.1002/hast.1168 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):19-23. doi: 10.1002/hast.1168.


PMID- 33448401
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Dueling Definitions of Abortifacient: How Cultural, Political, and Religious
      Values Affect Language in the Contraception Debate.
PG  - 14-19
LID - 10.1002/hast.1161 [doi]
AB  - Contraception works by preventing fertilization of an egg or preventing
      implantation of a fertilized embryo. For those who believe pregnancy begins at
      implantation, contraceptives preventing implantation are not abortifacient.
      However, for those who assert that pregnancy begins at fertilization, any agent
      causing the intentional loss of an embryo, even prior to implantation, is
      abortifacient, both morally and for lack of a different term to describe the
      postfertilization, preimplantation loss. In the debate on this topic, much of the
      discourse on both sides wrongly focuses on the opposing side's perceived
      ignorance in denying scientifically proven definitions rather than on the
      substance of the conflict. Indeed, both sides accuse the other of prioritizing
      its "subjective" views over "objective" facts. In this essay, we unpack the
      scientific, cultural, and religious factors that underlie this debate. We argue
      that the only way to move forward is to clarify our terminology and engage with
      the substance of the argument, rather than merely the rhetoric.
CI  - (c) 2020 The Hastings Center.
FAU - Horner, Claire
AU  - Horner C
FAU - Campo-Engelstein, Lisa
AU  - Campo-Engelstein L
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
RN  - 0 (Abortifacient Agents)
SB  - IM
MH  - *Abortifacient Agents
MH  - Contraception
MH  - Female
MH  - Fertilization
MH  - Humans
MH  - *Language
MH  - Pregnancy
OTO - NOTNLM
OT  - abortifacient
OT  - contraception
OT  - embryo
OT  - pregnancy
OT  - reproductive ethics
EDAT- 2021/01/16 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/01/15 08:43
PHST- 2021/01/15 08:43 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1161 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):14-19. doi: 10.1002/hast.1161. Epub 2020 Jul
      17.


PMID- 33448397
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 5
DP  - 2020 Sep
TI  - Sexual misconduct by health professionals in Australia, 2011-2016: a
      retrospective analysis of notifications to health regulators.
PG  - 218-224
LID - 10.5694/mja2.50706 [doi]
AB  - OBJECTIVES: To assess the numbers of notifications to health regulators alleging 
      sexual misconduct by registered health practitioners in Australia, by health care
      profession. DESIGN, SETTING: Retrospective cohort study; analysis of Australian
      Health Practitioner Regulation Agency and NSW Health Professional Councils
      Authority data on notifications of sexual misconduct during 2011-2016.
      PARTICIPANTS: All registered practitioners in 15 health professions. MAIN OUTCOME
      MEASURES: Notification rates (per 10 000 practitioner-years) and adjusted rate
      ratios (aRRs) by age, sex, profession, medical specialty, and practice location. 
      RESULTS: Regulators received 1507 sexual misconduct notifications for 1167 of 724
      649 registered health practitioners (0.2%), including 208 practitioners (18%) who
      were the subjects of more than one report during 2011-2016; 381 notifications
      (25%) alleged sexual relationships, 1126 (75%) sexual harassment or assault.
      Notifications regarding sexual relationships were more frequent for psychiatrists
      (15.2 notifications per 10 000 practitioner-years), psychologists (5.0 per 10 000
      practitioner-years), and general practitioners (6.4 per 10 000
      practitioner-years); the rate was higher for regional/rural than metropolitan
      practitioners (aRR, 1.73; 95% CI, 1.31-2.30). Notifications of sexual harassment 
      or assault more frequently named male than female practitioners (aRR, 37.1; 95%
      CI, 26.7-51.5). A larger proportion of notifications of sexual misconduct than of
      other forms of misconduct led to regulatory sanctions (242 of 709 closed cases
      [34%] v 5727 of 23 855 [24%]). CONCLUSIONS: While notifications alleging sexual
      misconduct by health practitioners are rare, such misconduct has serious
      consequences for patients, practitioners, and the community. Further efforts are 
      needed to prevent sexual misconduct in health care and to ensure thorough
      investigation of alleged misconduct.
CI  - (c) 2020 AMPCo Pty Ltd.
FAU - Bismark, Marie M
AU  - Bismark MM
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, VIC.
FAU - Studdert, David M
AU  - Studdert DM
AD  - Center for Health Policy, Freeman Spogli Institute for International Studies,
      Stanford University, Stanford, CA, United States of America.
FAU - Morton, Katinka
AU  - Morton K
AD  - Perth Children's Hospital, Perth, WA.
FAU - Paterson, Ron
AU  - Paterson R
AD  - The University of Auckland, Auckland, New Zealand.
FAU - Spittal, Matthew J
AU  - Spittal MJ
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, VIC.
FAU - Taouk, Yamna
AU  - Taouk Y
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, VIC.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia
MH  - Data Collection
MH  - Female
MH  - Health Occupations/*legislation & jurisprudence
MH  - Health Personnel/*legislation & jurisprudence
MH  - Humans
MH  - Male
MH  - *Mandatory Reporting
MH  - Middle Aged
MH  - Professional Misconduct/*statistics & numerical data
MH  - Retrospective Studies
MH  - Sexual Harassment/*statistics & numerical data
OTO - NOTNLM
OT  - *Ethics, professional
OT  - *Medical misconduct
OT  - *Professional misconduct
OT  - *Sex offenses
OT  - *Sexual harassment in medicine
EDAT- 2021/01/16 06:00
MHDA- 2021/02/03 06:00
CRDT- 2021/01/15 08:43
PHST- 2019/11/05 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2021/01/15 08:43 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - 10.5694/mja2.50706 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Sep;213(5):218-224. doi: 10.5694/mja2.50706. Epub 2020 Jul 27.


PMID- 33448391
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - A Futile Use of Futility.
PG  - 4-5
LID - 10.1002/hast.1166 [doi]
AB  - As the rates of intravenous opioid use have increased, so have its associated
      medical complications, such as endocarditis, and known interventions, such as
      heart-valve replacements. For many patients, including Jacob, whose case was
      brought to my psychiatric consult service and to my colleagues in the clinical
      ethics service, relapse increases the risk of repeat endocarditis and the need
      for repeat surgical interventions. Previous works have posed the bioethical
      quandary regarding the responsibilities of a surgeon in these repeat procedures
      and whether a surgeon may ethically refuse to perform a repeat intervention in a 
      patient who has relapsed. Notions of futility are commonly used to navigate this 
      complex terrain, and they were the focus of the ethics consideration given to
      Jacob's case, in which surgeons were reluctant to perform valve replacements. In 
      this narrative essay, I interrogate the concept of futility by appealing to its
      history and variable meanings, and I argue against its relevance in cases like
      Jacob's. I propose that a more suitable bioethical approach in such cases would
      consider resource allocation, the sociocultural stigma of addiction, and the
      interpersonal and narrative factors that make each case unique.
CI  - (c) 2020 The Hastings Center.
FAU - Goldberg, Aryeh
AU  - Goldberg A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - *Medical Futility
MH  - Resource Allocation
OTO - NOTNLM
OT  - addiction
OT  - futility
OT  - narrative ethics
OT  - opioid use
OT  - stigma
OT  - substance use
EDAT- 2021/01/16 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/01/15 08:43
PHST- 2021/01/15 08:43 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1166 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):4-5. doi: 10.1002/hast.1166.


PMID- 33447654
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 2333-3936 (Electronic)
IS  - 2333-3936 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - The Care Ethics of Child Health Nurses in Danish Asylum Centers: An Ethnographic 
      Study.
PG  - 2333393620984141
LID - 10.1177/2333393620984141 [doi]
AB  - Child health nurses play an important role in promoting the health and well-being
      of children and families seeking asylum. However, little is known about how they 
      establish caring partnerships with families in asylum centers. In this article,
      we examine the ethical care practices that child health nurses within Danish
      asylum centers adopt to overcome barriers, related to culture, language and
      migration history, in delivering care. We conducted ethnographic fieldwork in
      four Danish Red Cross asylum centers, involving participant observation and
      individual interviews with 20 families and six child health nurses. A thematic
      analysis of the material reveals five ethical care practices; compassionate care,
      humanitarian care, flexible care, collaborative care, and supportive care. We
      show how the confluence of these types of care enables child health nurses to
      promote health and well-being of children seeking asylum, and discuss the
      enabling role of the humanitarian culture that prevails within the asylum
      centers.
CI  - (c) The Author(s) 2020.
FAU - Barghadouch, Amina
AU  - Barghadouch A
AUID- ORCID: https://orcid.org/0000-0002-0683-7093
AD  - University of Copenhagen, Denmark.
FAU - Norredam, Marie
AU  - Norredam M
AD  - University of Copenhagen, Denmark.
FAU - Skovdal, Morten
AU  - Skovdal M
AD  - University of Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20201227
PL  - United States
TA  - Glob Qual Nurs Res
JT  - Global qualitative nursing research
JID - 101666563
PMC - PMC7780172
OTO - NOTNLM
OT  - Denmark
OT  - asylum-seeking children
OT  - care ethics
OT  - child health nurse
OT  - cultural humility
OT  - family-centered care
OT  - parallel humanitarian system
COIS- Declaration of Conflicting Interests: The authors declared no potential conflicts
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:01
PHST- 2020/04/13 00:00 [received]
PHST- 2020/12/03 00:00 [revised]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2021/01/15 06:01 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.1177/2333393620984141 [doi]
AID - 10.1177_2333393620984141 [pii]
PST - epublish
SO  - Glob Qual Nurs Res. 2020 Dec 27;7:2333393620984141. doi:
      10.1177/2333393620984141. eCollection 2020 Jan-Dec.


PMID- 33447603
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211203
IS  - 2297-4725 (Print)
IS  - 2297-4725 (Linking)
VI  - 36
IP  - 6
DP  - 2020 Dec
TI  - Artificial Intelligence in Visceral Medicine.
PG  - 471-475
LID - 10.1159/000512440 [doi]
FAU - Wilhelm, Dirk
AU  - Wilhelm D
AD  - Department of Surgery, Faculty of Medicine, Technical University of Munich,
      Munich, Germany.
FAU - Bouarfa, Loubna
AU  - Bouarfa L
AD  - CEO at Okra Technologies and Member of the European Commission's High Level
      Expert Group for Artificial Intelligence, London, United Kingdom.
FAU - Navab, Nassir
AU  - Navab N
AD  - Chair for Computer Aided Medical Procedures and Augmented Reality, Faculty of
      Informatics, Technical University of Munich, Munich, Germany.
FAU - Meining, Alexander
AU  - Meining A
AD  - Center for Internal Medicine (ZIM), Medical Department II, University Hospital of
      Wurzburg, Wurzburg, Germany.
FAU - Muller-Stich, Beat
AU  - Muller-Stich B
AD  - Department of General, Visceral, and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
FAU - Jarc, Anthony
AU  - Jarc A
AD  - Director of Research and Data Science, Intuitive Surgical, Inc., Norcross,
      Georgia, USA.
FAU - Padoy, Nicolas
AU  - Padoy N
AD  - ICube, University of Strasbourg, CNRS, IHU Strasbourg, Strasbourg, France.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - Switzerland
TA  - Visc Med
JT  - Visceral medicine
JID - 101681546
PMC - PMC7768142
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Digitalization
OT  - Ethics
OT  - Explainable artificial intelligence
OT  - Smart technology
COIS- Authors D. Wilhelm, N. Padoy, A. Meining, B. Muller-Stich, and N. Navab have no
      conflicts of interest to declare. L. Bouarfa is the founder and CEO of OKRA
      Technologies. A. Jarc is an employee and the director of Research and Data
      Science at Intuitive Surgical, Inc.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:01
PHST- 2020/09/27 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2021/01/15 06:01 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.1159/000512440 [doi]
AID - vis-0036-0471 [pii]
PST - ppublish
SO  - Visc Med. 2020 Dec;36(6):471-475. doi: 10.1159/000512440. Epub 2020 Nov 4.


PMID- 33447311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 1918-3003 (Print)
IS  - 1918-3003 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec
TI  - Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative
      Medicine.
PG  - 780-786
LID - 10.14740/jocmr3964 [doi]
AB  - Recently, the design and development of a modern health policy in the field of
      regenerative medicine leads to the formation of a new and integrated cognitive
      field, which requires systematic research and study in order to produce
      innovative answers and best practices. Advanced therapy medicinal products
      (ATMPs) is a new product category, which is at the heart of concern since it has 
      to deal with diseases in which traditional medicine has proven to be ineffective 
      so far. The aim of this review is to provide evidence for the state of the art
      ATMPs and their modern applications in the field of regenerative medicine. The
      ATMPs are characterized by a great heterogeneity and variation in methods of
      isolation, which cover the entire spectrum from a single intravenous injection to
      a surgical placement. Clinical development of ATMP encounters specific challenges
      due to the nature of the product and the limited availability of non-clinical
      data. The gold standard of a controlled, randomized, clinical trial may not be
      feasible or ethically justified for all indications, particularly in
      life-threatening diseases, where there is no satisfactory standard of care.
      Therefore, the European Commission (EC) took initiatives in order to set
      standards and operating rules concerning authorization and supervision of ATMPs
      and on pharmacovigilance in relation to them. The European Union (EU) Regulation 
      1394/2007 provides the possibility of exceptions. In particular, the "hospital
      exemption" allows for the administration of an ATMP without a license on certain 
      conditions. Although the Regulation 1394/2007 has led to the commercial
      exploitation of ATMPs, the reality today, 11 years after its first
      implementation, is completely different. While the Committee for Advanced
      Therapies (CAT) has already registered 285 products as ATMPs, only 10 licenses
      were granted which only remained six (the rest related to products withdrawn).
      The key players in the development and delivery of ATMPs still remain the
      academic/research centers and small and medium-sized enterprises; while the
      involvement of pharmaceutical companies is focusing on recent developments in the
      treatment of oncological incidents with in vitro modified cytotoxic T
      lymphocytes, and chimeric antigen receptor (CAR)-T cells.
CI  - Copyright 2020, Goula et al.
FAU - Goula, Aspasia
AU  - Goula A
AD  - Business Administration-Health and Welfare Management, University of West Attica,
      Egaleo, Greece.
FAU - Gkioka, Vasiliki
AU  - Gkioka V
AD  - Biomedical Research Foundation Academy of Athens, 4th Soranou Efessiou Str.,
      11527 Athens, Greece.
FAU - Michalopoulos, Efstathios
AU  - Michalopoulos E
AD  - Biomedical Research Foundation Academy of Athens, 4th Soranou Efessiou Str.,
      11527 Athens, Greece.
FAU - Katsimpoulas, Michalis
AU  - Katsimpoulas M
AD  - Biomedical Research Foundation Academy of Athens, 4th Soranou Efessiou Str.,
      11527 Athens, Greece.
FAU - Noutsias, Michel
AU  - Noutsias M
AD  - Mid-German Heart Center, Department of Internal Medicine III, Division of
      Cardiology, Angiology and Intensive Medical Care, University Hospital Halle,
      Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, D-06120 Halle 
      (Saale), Germany.
FAU - Sarri, Eirini Faidra
AU  - Sarri EF
AD  - Biomedical Research Foundation Academy of Athens, 4th Soranou Efessiou Str.,
      11527 Athens, Greece.
FAU - Stavropoulos, Catherine
AU  - Stavropoulos C
AD  - Biomedical Research Foundation Academy of Athens, 4th Soranou Efessiou Str.,
      11527 Athens, Greece.
FAU - Kostakis, Alkiviadis
AU  - Kostakis A
AD  - Biomedical Research Foundation Academy of Athens, 4th Soranou Efessiou Str.,
      11527 Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201218
PL  - Canada
TA  - J Clin Med Res
JT  - Journal of clinical medicine research
JID - 101538301
PMC - PMC7781285
OTO - NOTNLM
OT  - Advanced therapy medicinal products
OT  - CAT
OT  - EU regulation
OT  - Quality and safety standards
OT  - Randomize clinical trial
COIS- MN has received grants by the Deutsche Forschungsgemeinschaft (DFG) through the
      Sonderforschungsbereich Transregio 19 "Inflammatory Cardiomyopathy" (SFB TR19)
      (TP B2), and by the University Hospital Giessen and Marburg Foundation Grant "T
      cell functionality" (UKGM 10/2009). MN has been consultant to the IKDT (Institute
      for Cardiac Diagnosis and Therapy GmbH, Berlin) 2004 - 2008, and has received
      honoraria for presentations and/or participated in advisory boards from Abiomed, 
      AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Fresenius,
      Miltenyi Biotech, Novartis, Pfizer and Zoll. All other authors declare no
      potential conflict of interest.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:00
PHST- 2020/08/26 00:00 [received]
PHST- 2020/09/19 00:00 [accepted]
PHST- 2021/01/15 06:00 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.14740/jocmr3964 [doi]
PST - ppublish
SO  - J Clin Med Res. 2020 Dec;12(12):780-786. doi: 10.14740/jocmr3964. Epub 2020 Dec
      18.


PMID- 33447299
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 1849-5435 (Electronic)
IS  - 1849-5435 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Effect of intracellular uptake of nanoparticle-encapsulated trehalose on the
      hemocompatibility of allogeneic valves in the VS83 vitrification protocol.
PG  - 1849543520983173
LID - 10.1177/1849543520983173 [doi]
AB  - Trehalose is a disaccharide molecule consisting of two molecules of glucose.
      Industrially, trehalose is derived from corn starch and utilized as a drug. This 
      study aims to examine whether the integration of nanoparticle-encapsulated
      trehalose to the Ice-Free Cryopreservation (IFC) method for preserving heart
      valves has better cell viability, benefits to protect the extracellular matrix
      (ECM), and reduce immune response after storage. For the experiment to be carried
      out, we obtained materials, and the procedures were carried out in the following 
      manner. The initial step was the preparation of hydroxyapatite nanoparticles,
      followed by precipitation to acquire Apatite colloidal suspensions. Animals were 
      obtained, and their tissue isolation and grouping were done ethically. All
      samples were then divided into four groups, Control group, Conventional Frozen
      Cryopreservation (CFC) group, IFC group, and IFC + T (IFC with the addition of
      0.2 M nanoparticle-encapsulated Trehalose) group. Histological analysis was
      carried out via H&E staining, ECM components were stained with Modified Weigert
      staining, and the Gomori Ammonia method was used to stain reticular fibers.
      Alamar Blue assay was utilized to assess cell viability. Hemocompatibility was
      evaluated, and samples were processed for immunohistochemistry (TNFalpha and
      IL-10). Hemocompatibility was quantified using Terminal Complement Complex (TCC) 
      and Neutrophil elastase (NE) as an indicator. The results of the H&E staining
      revealed less formation of extracellular ice crystals and intracellular vacuoles 
      in the IFC + T group compared with all other groups. The CFC group's cell
      viability showed better viability than the IFC group, but the highest viability
      was exhibited in the IFC + T group (70.96 +/- 2.53, P < 0.0001, n = 6). In
      immunohistochemistry, TNFalpha levels were lowest in both IFC and IFC + T group, 
      and IL-10 expression had significantly reduced in IFC and IFC + T group. The
      results suggested that the nanoparticle encapsulated trehalose did not show
      significant hemocompatibility issues on the cryopreserved heart valves.
CI  - (c) The Author(s) 2020.
FAU - Vasudevan, Balamurugan
AU  - Vasudevan B
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Chang, Qing
AU  - Chang Q
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Wang, Bin
AU  - Wang B
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Huang, Siyang
AU  - Huang S
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Sui, Yulong
AU  - Sui Y
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Zhu, Wenjie
AU  - Zhu W
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Fan, Qing
AU  - Fan Q
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
FAU - Song, Yisheng
AU  - Song Y
AD  - Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.235960
LA  - eng
PT  - Journal Article
DEP - 20201229
PL  - England
TA  - Nanobiomedicine (Rij)
JT  - Nanobiomedicine
JID - 101667896
PMC - PMC7780325
OTO - NOTNLM
OT  - Homograft valve
OT  - VS83
OT  - apatite
OT  - ice-free cryopreservation
OT  - immunogenicity
OT  - nanoparticle
OT  - trehalose
COIS- Declaration of conflicting interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:00
PHST- 2019/07/02 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2021/01/15 06:00 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.1177/1849543520983173 [doi]
AID - 10.1177_1849543520983173 [pii]
PST - epublish
SO  - Nanobiomedicine (Rij). 2020 Dec 29;7:1849543520983173. doi:
      10.1177/1849543520983173. eCollection 2020 Jan-Dec.


PMID- 33447237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1661-3791 (Print)
IS  - 1661-3791 (Linking)
VI  - 15
IP  - 6
DP  - 2020 Dec
TI  - Subsequent Marking under Ultrasound Guidance of Vacuum-Assisted Breast Biopsy
      Areas after Receipt of Histology: A Feasibility Study of a New Technique.
PG  - 628-634
LID - 10.1159/000506069 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the feasibility and the accuracy
      of a secondary, metachronous ultrasound (US)-guided marking of the stereotactic
      vacuum-assisted breast biopsy (ST-VABB) area. MATERIALS AND METHODS: The
      institutional ethics committee approved the study. The retrospective study
      included 98 patients. In ST-VABB of 45 women, no tissue markers were deployed at 
      the biopsy site, even if no residual calcifications remained. After histology
      proved the necessity for a subsequent operation, the biopsy site was marked under
      US guidance using a coil marker. All interventions were technically successful.
      No complications occurred. Mammography was done to visualize the coil deployment.
      The distances from the center of the lesion and the biopsy cavity to the coil
      location were measured in both planes to evaluate the accuracy of the marking
      procedure. RESULTS: In 24 of the 46 cases, the whole lesion was biopsied without 
      residual elements. The mean time between ST-VABB and sonographic marking of the
      lesion was 9.7 days (median 6.5). The biopsy cavity could be detected in 40 (87%)
      cases and thus marked exactly. The mean time of US-guided marking was 12.5 min.
      The mean distance between the coil and the target lesion was 0.6 +/- 1.5 cm in
      the craniocaudal (cc) view and 0.5 +/- 1.5 cm in the mediolateral (ml) view for
      all markings. The mean delta value from the distance nipple-original lesion and
      from the distance nipple-coil was 0.85 +/- 1.2 cm (median 0.5) in the cc view and
      0.88 +/- 1.2 cm (median 0.6) in the ml view for all cases. Clip migration was not
      observed. CONCLUSION: Our study demonstrates the feasibility and the technical
      success of secondary metachronous coil marking of the biopsy site under US
      guidance after receipt of histology. This approach seems to be a cost-effective
      alternative to the standard procedure of the primary coil marking especially in
      all completely removed lesions. It may offer advantages for allergic patients.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Park, Clara
AU  - Park C
AD  - Institute for Diagnostic and Interventional Radiology, Frankfurt University
      Hospital, Frankfurt am Main, Germany.
FAU - Chevalier, Frauke
AU  - Chevalier F
AD  - Department of Radiology, Municipal Clinics Frankfurt/Main-Hoechst, Frankfurt am
      Main, Germany.
FAU - Mobus, Volker
AU  - Mobus V
AD  - Department of Gynaecology, Municipal Clinics Frankfurt/Main-Hoechst, Frankfurt am
      Main, Germany.
FAU - Hoedl, Petra
AU  - Hoedl P
AD  - Department of Pathology, Municipal Clinics Frankfurt/Main-Hoechst, Frankfurt am
      Main, Germany.
FAU - Engelmann, Kerstin
AU  - Engelmann K
AD  - Breast Screening Centre Turmcarree, Frankfurt am Main, Germany.
FAU - Falk, Stephan
AU  - Falk S
AD  - OptiPath, Pathology Associates, Frankfurt am Main, Germany.
FAU - Leithner, Doris
AU  - Leithner D
AD  - Institute for Diagnostic and Interventional Radiology, Frankfurt University
      Hospital, Frankfurt am Main, Germany.
FAU - Kaltenbach, Benjamin
AU  - Kaltenbach B
AD  - Institute for Diagnostic and Interventional Radiology, Frankfurt University
      Hospital, Frankfurt am Main, Germany.
FAU - Vogl, Thomas J
AU  - Vogl TJ
AD  - Institute for Diagnostic and Interventional Radiology, Frankfurt University
      Hospital, Frankfurt am Main, Germany.
FAU - Muller-Schimpfle, Markus
AU  - Muller-Schimpfle M
AD  - Department of Radiology, Municipal Clinics Frankfurt/Main-Hoechst, Frankfurt am
      Main, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200221
PL  - Switzerland
TA  - Breast Care (Basel)
JT  - Breast care (Basel, Switzerland)
JID - 101254060
PMC - PMC7768143
OTO - NOTNLM
OT  - Breast cancer
OT  - Diagnostic markers
OT  - Stereotactic vacuum biopsy
OT  - Ultrasound
COIS- Prof. Markus Muller-Schimpfle receives a royalty of Cook Medical, Bloomington,
      IN, USA, for the co-development of the MReye(R) breast localization coil. The
      other authors have no conflicts of interest to declare.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:00
PHST- 2019/07/24 00:00 [received]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2021/01/15 06:00 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.1159/000506069 [doi]
AID - brc-0015-0628 [pii]
PST - ppublish
SO  - Breast Care (Basel). 2020 Dec;15(6):628-634. doi: 10.1159/000506069. Epub 2020
      Feb 21.


PMID- 33447190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1658-354X (Print)
VI  - 14
IP  - 4
DP  - 2020 Oct-Dec
TI  - Postoperative analgesic efficacy of fluoroscopy-guided erector spinae plane block
      after percutaneous nephrolithotomy (PCNL): A randomized controlled study.
PG  - 480-486
LID - 10.4103/sja.SJA_26_20 [doi]
AB  - BACKGROUND: Percutaneous nephrolithotomy (PCNL) a minimally invasive method for
      the removal of renal calculi and is associated with significant pain in
      postoperative period. Conventionally, intravenous opioids, local anesthetic
      infiltration, and regional blocks (intercostal/paravertebral blocks) have been
      tried with less efficacy to control postoperative pain. The present study is
      conducted to assess the effectiveness of erector spinae plane block (ESPB)
      performed under fluoroscopy guidance for postoperative analgesia during PCNL.
      SUBJECTS AND METHODS: After obtaining ethical clearance, the study was conducted 
      on 61 American Society of Anaesthesiologists (ASA) I and II patients aged between
      18-65 years admitted for PCNL. Group I (n = 30) did not receive ESPB while Group 
      II (n = 31) received ESPB under fluoroscopy guidance and 20 ml of 0.375%
      ropivacaine was administered after PCNL. Patient-reported pain intensity using
      visual analogue scale (VAS) was considered as a primary outcome. The hemodynamic 
      variables (heart rate, systolic, diastolic, and mean blood pressure) was
      considered as a secondary outcome. Statistical analysis was performed using
      Student's t-test and Mann-Whitney U test. Data analysis was performed using the
      Statistical Package for the Social Sciences version 23.0. RESULTS:
      Postoperatively VAS score was significantly lower in Group II at 0, 1, 2, 3, 4,
      6, 12, 18, and 24 hours after PCNL (P < 0.001). Dose of rescue analgesia
      significantly decreased in Group II compared to Group I. CONCLUSION: ESPB
      performed under fluoroscopic guidance is a simple and effective technique and it 
      provides significantly better postoperative pain relief.
CI  - Copyright: (c) 2020 Saudi Journal of Anesthesia.
FAU - Prasad, Mukesh K
AU  - Prasad MK
AD  - Department of Anaesthesia and Pain, Teerthankar Mahaveer Medical College,
      Moradbad, Uttar Pradesh, India.
FAU - Varshney, Rohit K
AU  - Varshney RK
AD  - Department of Anaesthesia and Pain, Teerthankar Mahaveer Medical College,
      Moradbad, Uttar Pradesh, India.
FAU - Jain, Payal
AU  - Jain P
AD  - Department of Anaesthesia and Pain, Teerthankar Mahaveer Medical College,
      Moradbad, Uttar Pradesh, India.
FAU - Choudhary, Amit K
AU  - Choudhary AK
AD  - Consultant Anaesthesiologist, Indra Memorial Hospital, Patna, Bihar, India.
FAU - Khare, Aditi
AU  - Khare A
AD  - Department of Anaesthesia and Pain, Teerthankar Mahaveer Medical College,
      Moradbad, Uttar Pradesh, India.
FAU - Jheetay, Gurdeep S
AU  - Jheetay GS
AD  - Department of Anaesthesia and Pain, Teerthankar Mahaveer Medical College,
      Moradbad, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - India
TA  - Saudi J Anaesth
JT  - Saudi journal of anaesthesia
JID - 101500601
PMC - PMC7796763
OTO - NOTNLM
OT  - Erector spinae plane block
OT  - postoperative analgesia
OT  - ropivacaine
COIS- There are no conflicts of interest.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/02/15 00:00 [accepted]
PHST- 2021/01/15 06:00 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.4103/sja.SJA_26_20 [doi]
AID - SJA-14-480 [pii]
PST - ppublish
SO  - Saudi J Anaesth. 2020 Oct-Dec;14(4):480-486. doi: 10.4103/sja.SJA_26_20. Epub
      2020 Sep 24.


PMID- 33447187
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1658-354X (Print)
VI  - 14
IP  - 4
DP  - 2020 Oct-Dec
TI  - Attitudes and knowledge of anesthesiology trainees to radiation exposure in a
      Tertiary care hospital.
PG  - 459-463
LID - 10.4103/sja.SJA_659_19 [doi]
AB  - BACKGROUND AND AIMS: Ionizing radiation procedures are indispensable in medical
      clinical practice. Exposure to radiation at any dose could have serious adverse
      effects. Anesthesiologists working in interventional radiology suites are at a
      higher risk of radiation exposure than other personnel. The aim of this study was
      to assess the knowledge and attitude of anesthesiology trainees towards the
      radiation hazards and current safety practices. METHODS: This prospective
      cross-sectional survey was conducted at the department of anesthesiology at Aga
      Khan University. All anesthesiology trainees working in the department were given
      a 12-question paper-based survey after getting ethical review committee approval 
      and informed consent. The questionnaire contained requests for personal
      demographic data and specific questions regarding radiation protection. RESULTS: 
      A total of 54 participants were included in this survey. Thirty-two (59.3%) were 
      male, and 22 (40.7%) were female. The average year of experience working in
      anesthesia of the participants was 2.8 +/- 1.65 years (range, one to eight
      years). Frequency of radiation exposure of 32 (59.3%) participants was 1-5 times 
      per week. Approximately 68.5% (37/54) of participants believed they took adequate
      precautions for protection against radiation. Only 20.4% (11/54) used both a lead
      apron and a thyroid shield for prevention of radiation exposure. Most
      participants using the radiation shield or clothing (70.4%; 38/54) cited concerns
      about cancer. CONCLUSIONS: A lack of knowledge persists among anesthesiology
      trainees in our institute regarding the risks associated with ionizing radiation.
      This study also serves to highlight the need for anesthesiology trainees to
      protect themselves properly. Radiation dose, hazards, and protection strategies
      must be included in the basic curriculum of medical colleges.
CI  - Copyright: (c) 2020 Saudi Journal of Anesthesia.
FAU - Ali, Mohammad Asghar
AU  - Ali MA
AD  - Department of Anesthesiology, Aga Khan University, Karachi, Pakistan.
FAU - Salim, Bushra
AU  - Salim B
AD  - Department of Anesthesiology, Aga Khan University, Karachi, Pakistan.
FAU - Siddiqui, Khalid Maudood
AU  - Siddiqui KM
AD  - Department of Anesthesiology, Aga Khan University, Karachi, Pakistan.
FAU - Khan, Muhammad Faisal
AU  - Khan MF
AD  - Department of Anesthesiology, Aga Khan University, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - India
TA  - Saudi J Anaesth
JT  - Saudi journal of anaesthesia
JID - 101500601
PMC - PMC7796730
OTO - NOTNLM
OT  - Knowledge
OT  - radiation
OT  - trainees
COIS- There are no conflicts of interest.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:00
PHST- 2019/10/16 00:00 [received]
PHST- 2019/11/26 00:00 [revised]
PHST- 2019/10/29 00:00 [accepted]
PHST- 2021/01/15 06:00 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.4103/sja.SJA_659_19 [doi]
AID - SJA-14-459 [pii]
PST - ppublish
SO  - Saudi J Anaesth. 2020 Oct-Dec;14(4):459-463. doi: 10.4103/sja.SJA_659_19. Epub
      2020 Sep 24.


PMID- 33447141
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 1394-195X (Print)
IS  - 1394-195X (Linking)
VI  - 27
IP  - 6
DP  - 2020 Dec
TI  - Be Honest: Individuals' Moral Responsibility within the COVID-19 Context.
PG  - 144-147
LID - 10.21315/mjms2020.27.6.13 [doi]
AB  - We recognise that people lie to health professionals for several reasons.
      However, these incidents endanger the well-being of the professionals and bring
      us to the question of whether people have an exclusive moral duty to always
      profess the truth about their health and other facts, particularly in a pandemic 
      crisis. This review argues that an honest patient is a key to undertaking their
      roles as health professionals and delivering the best services possible to meet
      the needs of the patient. Greater awareness and comprehension of the potential
      ramifications of dishonesty, not only helps establish the moral obligation, to
      tell the truth, particularly in a pandemic situation, but also translates into a 
      better relationship with health professionals. It also enforces an ethical
      solidarity on every single of us to show tangible moral response to ensure that
      those most vulnerable to risks from the pandemic illness such as health
      professionals are protected as far as possible.
CI  - (c) Penerbit Universiti Sains Malaysia, 2020.
FAU - Zolkefli, Yusrita
AU  - Zolkefli Y
AD  - PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei
      Darussalam.
LA  - eng
PT  - Journal Article
DEP - 20201229
PL  - Malaysia
TA  - Malays J Med Sci
JT  - The Malaysian journal of medical sciences : MJMS
JID - 101126308
PMC - PMC7785260
OTO - NOTNLM
OT  - COVID-19
OT  - health professionals
OT  - pandemic
OT  - patients
OT  - truth
COIS- Conflict of Interest None.
EDAT- 2021/01/16 06:00
MHDA- 2021/01/16 06:01
CRDT- 2021/01/15 06:00
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2021/01/15 06:00 [entrez]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/01/16 06:01 [medline]
AID - 10.21315/mjms2020.27.6.13 [doi]
AID - 13mjms27062020_sc1 [pii]
PST - ppublish
SO  - Malays J Med Sci. 2020 Dec;27(6):144-147. doi: 10.21315/mjms2020.27.6.13. Epub
      2020 Dec 29.


PMID- 33444218
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Predicting dementia diagnosis from cognitive footprints in electronic health
      records: a case-control study protocol.
PG  - e043487
LID - 10.1136/bmjopen-2020-043487 [doi]
AB  - INTRODUCTION: Dementia is a group of disabling disorders that can be devastating 
      for persons living with it and for their families. Data-informed decision-making 
      strategies to identify individuals at high risk of dementia are essential to
      facilitate large-scale prevention and early intervention. This population-based
      case-control study aims to develop and validate a clinical algorithm for
      predicting dementia diagnosis, based on the cognitive footprint in personal and
      medical history. METHODS AND ANALYSIS: We will use territory-wide electronic
      health records from the Clinical Data Analysis and Reporting System (CDARS) in
      Hong Kong between 1 January 2001 and 31 December 2018. All individuals who were
      at least 65 years old by the end of 2018 will be identified from CDARS. A random 
      sample of control individuals who did not receive any diagnosis of dementia will 
      be matched with those who did receive such a diagnosis by age, gender and index
      date with 1:1 ratio. Exposure to potential protective/risk factors will be
      included in both conventional logistic regression and machine-learning models.
      Established risk factors of interest will include diabetes mellitus, midlife
      hypertension, midlife obesity, depression, head injuries and low education.
      Exploratory risk factors will include vascular disease, infectious disease and
      medication. The prediction accuracy of several state-of-the-art machine-learning 
      algorithms will be compared. ETHICS AND DISSEMINATION: This study was approved by
      Institutional Review Board of The University of Hong Kong/Hospital Authority Hong
      Kong West Cluster (UW 18-225). Patients' records are anonymised to protect
      privacy. Study results will be disseminated through peer-reviewed publications.
      Codes of the resulted dementia risk prediction algorithm will be made publicly
      available at the website of the Tools to Inform Policy: Chinese Communities'
      Action in Response to Dementia project (https://www.tip-card.hku.hk/).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Luo, Hao
AU  - Luo H
AUID- ORCID: 0000-0003-4261-3414
AD  - Department of Social Work and Social Administration, University of Hong Kong,
      Hong Kong, China haoluo@hku.hk.
AD  - Department of Computer Science, University of Hong Kong, Hong Kong, China.
FAU - Lau, Kui Kai
AU  - Lau KK
AD  - Department of Medicine, University of Hong Kong, Hong Kong, China.
FAU - Wong, Gloria H Y
AU  - Wong GHY
AUID- ORCID: 0000-0002-1331-942X
AD  - Department of Social Work and Social Administration, University of Hong Kong,
      Hong Kong, China.
FAU - Chan, Wai-Chi
AU  - Chan WC
AD  - Department of Psychiatry, University of Hong Kong, Hong Kong, China.
FAU - Mak, Henry K F
AU  - Mak HKF
AD  - Department of Diagnostic Radiology, University of Hong Kong, Hong Kong, China.
FAU - Zhang, Qingpeng
AU  - Zhang Q
AD  - School of Data Science, City University of Hong Kong, Hong Kong, China.
FAU - Knapp, Martin
AU  - Knapp M
AD  - Care Policy and Evaluation Centre (CPEC), The London School of Economics and
      Political Science, London, UK.
FAU - Wong, Ian C K
AU  - Wong ICK
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, University of Hong Kong, Hong Kong, China.
AD  - Research Department of Practice and Policy, University College London School of
      Pharmacy, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Cognition
MH  - *Dementia/diagnosis/epidemiology
MH  - *Electronic Health Records
MH  - Female
MH  - Hong Kong/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC7678375
OTO - NOTNLM
OT  - *dementia
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: KKL has received grant support from Health and Medical
      Research Fund, Hong Kong Government Food & Health Bureau, Amgen, Boehringer
      Ingelheim, Eisai, Pfizer and Sanofi; as well as honorarium from Boehringer
      Ingelheim and Sanofi. All of which are not related to the current paper.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-043487 [pii]
AID - 10.1136/bmjopen-2020-043487 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e043487. doi: 10.1136/bmjopen-2020-043487.


PMID- 33444217
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Understanding public preferences and trade-offs for government responses during a
      pandemic: a protocol for a discrete choice experiment in the UK.
PG  - e043477
LID - 10.1136/bmjopen-2020-043477 [doi]
AB  - INTRODUCTION: Social distancing and lockdown measures are among the main
      government responses to the COVID-19 pandemic. These measures aim to limit the
      COVID-19 infection rate and reduce the mortality rate of COVID-19. Given we are
      likely to see local lockdowns until a treatment or vaccine for COVID-19 is
      available, and their effectiveness depends on public acceptability, it is
      important to understand public preference for government responses. METHODS AND
      ANALYSIS: Using a discrete choice experiment (DCE), this study will investigate
      the public's preferences for pandemic responses in the UK. Attributes (and
      levels) are based on: (1) lockdown measures described in policy documents; (2)
      literature on preferences for lockdown measures and (3) a social media analysis. 
      Attributes include: lockdown type; lockdown length; postponement of usual
      non-urgent medical care; number of excess deaths; number of infections; impact on
      household spending and job losses. We will prepilot the DCE using virtual think
      aloud interviews with respondents recruited via Facebook. We will collect
      preference data using an online survey of 4000 individuals from across the four
      UK countries (1000 per country). We will estimate the relative importance of the 
      attributes, and the trade-offs individuals are willing to make between
      attributes. We will test if respondents' preferences differ based on moral
      attitudes (using the Moral Foundation Questionnaire), socioeconomic circumstances
      (age, education, economic insecurity, health status), country of residence and
      experience of COVID-19. ETHICS AND DISSEMINATION: The University of Aberdeen's
      College Ethics Research Board (CERB) has approved the study (reference:
      CERB/2020/6/1974). We will seek CERB approval for major changes from the
      developmental and pilot work. Peer-reviewed papers will be submitted, and results
      will be presented at public health and health economic conferences nationally and
      internationally. A lay summary will be published on the Health Economics Research
      Unit blog.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Genie, Mesfin G
AU  - Genie MG
AUID- ORCID: 0000-0002-1744-4666
AD  - Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
      mesfin.genie@abdn.ac.uk.
FAU - Loria-Rebolledo, Luis Enrique
AU  - Loria-Rebolledo LE
AD  - Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.
FAU - Paranjothy, Shantini
AU  - Paranjothy S
AD  - Health Data Science Research Centre, University of Aberdeen, Aberdeen, UK.
FAU - Powell, Daniel
AU  - Powell D
AUID- ORCID: 0000-0003-4995-6057
AD  - Health Psychology, University of Aberdeen, Aberdeen, UK.
FAU - Ryan, Mandy
AU  - Ryan M
AD  - Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.
FAU - Sakowsky, Ruben Andreas
AU  - Sakowsky RA
AUID- ORCID: 0000-0002-6893-9220
AD  - Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.
FAU - Watson, Verity
AU  - Watson V
AUID- ORCID: 0000-0002-3824-5076
AD  - Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.
LA  - eng
GR  - HERU1/CSO_/Chief Scientist Office/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/epidemiology/*prevention & control
MH  - Communicable Disease Control/*organization & administration
MH  - *Government Programs
MH  - Humans
MH  - Pandemics
MH  - Physical Distancing
MH  - *Public Opinion
MH  - Quarantine
MH  - Social Media
MH  - Socioeconomic Factors
MH  - United Kingdom/epidemiology
PMC - PMC7682450
OTO - NOTNLM
OT  - *COVID-19
OT  - *health economics
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/01/22 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - bmjopen-2020-043477 [pii]
AID - 10.1136/bmjopen-2020-043477 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e043477. doi: 10.1136/bmjopen-2020-043477.


PMID- 33444214
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Effects of smart garments on the well-being of athletes: a scoping review
      protocol.
PG  - e042127
LID - 10.1136/bmjopen-2020-042127 [doi]
AB  - INTRODUCTION: With the advancements in wearable electronics, electronically
      integrated smart garments started to transpire in our daily lives. Smart garment 
      technologies are incorporated into sportswear applications to enhance the
      well-being and performance of athletes. Smart garments applications in the sports
      sector are increasing, and the variety of smart garment applications available in
      the literature is overwhelming. Therefore, it is essential to compare the vast
      array of technologies incorporated in smart garments for athletes to understand
      the knowledge gaps for future studies. The protocol paper aims to examine the
      smart garments used in the sports domain to enhance the health and well-being of 
      athletes. METHODS AND ANALYSIS: Relevant studies will be retrieved using
      predefined search terms from Scopus, Web of Science, Science Direct, PubMed and
      IEEE Xplore. The retrieved articles will be eliminated in two phases: title and
      abstract screening and full-text screening. The included articles will be primary
      studies published in the English language within the last 10 years. Subsequently,
      the included articles will be further studied to extract data using a data
      extraction form. The extracted data will undergo a thematic analysis. Also,
      quantitative analysis will be carried out using descriptive statistics. ETHICS
      AND DISSEMINATION: The results of this review will provide a comprehensive
      understanding of smart garment concepts used in the sports domain. The findings
      of this scoping review will be shared through a journal publication and a
      conference presentation. Ethical approval is not needed for this scoping review. 
      PROTOCOL REGISTRATION NUMBER: DOI 10.17605/OSF.IO/34MF2 (https://osf.io/34mf2).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Al Mahmud, Abdullah
AU  - Al Mahmud A
AUID- ORCID: 0000-0002-2801-723X
AD  - School of Design; Centre for Design Innovation, Swinburne University of
      Technology, Melbourne, Victoria, Australia aalmahmud@swin.edu.au.
FAU - Wickramarathne, Tharushi Indeewari
AU  - Wickramarathne TI
AUID- ORCID: 0000-0002-8040-4579
AD  - School of Design; Centre for Design Innovation, Swinburne University of
      Technology, Melbourne, Victoria, Australia.
FAU - Kuys, Blair
AU  - Kuys B
AUID- ORCID: 0000-0001-9857-0439
AD  - School of Design; Centre for Design Innovation, Swinburne University of
      Technology, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Athletes
MH  - Clothing
MH  - Humans
MH  - Technology
PMC - PMC7678371
OTO - NOTNLM
OT  - *health informatics
OT  - *information management
OT  - *information technology
OT  - *world wide web technology
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-042127 [pii]
AID - 10.1136/bmjopen-2020-042127 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e042127. doi: 10.1136/bmjopen-2020-042127.


PMID- 33444212
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Seroprevalence of SARS-CoV-2 antibodies in children of United Kingdom healthcare 
      workers: a prospective multicentre cohort study protocol.
PG  - e041661
LID - 10.1136/bmjopen-2020-041661 [doi]
AB  - BACKGROUND: A novel coronavirus SARS-CoV-2 has been responsible for a worldwide
      pandemic. Children typically have very mild, or no, symptoms of infection. This
      makes estimations of seroprevalence in children difficult. Research is therefore 
      required to determine the seroprevalence of SARS-CoV-2 antibodies in children.
      The primary objective of this study is to report the seroprevalence of SARS-CoV-2
      IgM and/or IgG antibodies in healthy children at baseline, 2 months and 6 months.
      This is the only longitudinal UK study of seroprevalence in an exclusively
      paediatric population. Determining the changing seroprevalence is of vital public
      health importance and can help inform decisions around the lifting of paediatric 
      specific social distancing measures such as school closures and the cancellation 
      of routine paediatric hospital services. METHODS AND ANALYSIS: 1000 healthy
      children of healthcare workers aged between 2 and 15 years will be recruited from
      five UK sites (Belfast, Cardiff, Glasgow, London and Manchester). The children
      will undergo phlebotomy at baseline, 2 months and 6 months to measure IgM and/or 
      IgG positivity to SARS-CoV-2. A sample size of 675 patients is required to detect
      a 5% change in seroprevalence at each time point assuming an alpha of 0.05 and a 
      beta of 0.2. Adjusted probabilities for the presence of IgG and/or IgM antibodies
      and of SARS-CoV-2 infection will be reported using logistic regression models
      where appropriate. ETHICS AND DISSEMINATION: Ethical approval was obtained from
      the London - Chelsea Research Ethics Committee (REC Reference-20/HRA/1731) and
      the Belfast Health & Social Care Trust Research Governance (Reference
      19147TW-SW). Results of this study will be made available as preprints and
      submitted for publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT0434740; Results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Corr, Michael
AU  - Corr M
AUID- ORCID: 0000-0001-9272-2323
AD  - Department of Nephrology, Belfast Health and Social Care Trust, Belfast, United
      Kingdom.
FAU - Christie, Sharon
AU  - Christie S
AD  - Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children,
      Belfast, United Kingdom.
FAU - Watson, Chris
AU  - Watson C
AD  - Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast-
      School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK.
FAU - Maney, Julieann
AU  - Maney J
AD  - Emergency Department, Royal Belfast Hospital for Sick Children, Belfast, United
      Kingdom.
FAU - Fairley, Derek
AU  - Fairley D
AD  - Regional Virus Laboratory, Belfast Health and Social Care Trust, Belfast, United 
      Kingdom.
FAU - Ladhani, Shamez N
AU  - Ladhani SN
AD  - Immunisation and Countermeasures Division, Public Health England, London, UK.
FAU - Lyttle, Mark David
AU  - Lyttle MD
AUID- ORCID: 0000-0002-8634-7210
AD  - Emergency Department, Bristol Royal Hospital for Children, Bristol, UK.
AD  - Faculty of Health and Applied Science, University of the West of England,
      Bristol, UK.
FAU - McFetridge, Lisa
AU  - McFetridge L
AD  - Mathematical Sciences Research Centre, Queen's University Belfast School of
      Mathematics and Physics, Belfast, UK.
FAU - Mitchell, Hannah
AU  - Mitchell H
AD  - Mathematical Sciences Research Centre, Queen's University Belfast School of
      Mathematics and Physics, Belfast, UK.
FAU - Shields, Michael David
AU  - Shields MD
AD  - Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast-
      School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK.
FAU - McGinn, Claire
AU  - McGinn C
AD  - General Paediatrics, Belfast Health and Social Care Trust, Belfast, UK.
FAU - McKenna, James
AU  - McKenna J
AD  - Regional Virus Laboratory, Belfast Health and Social Care Trust, Belfast, United 
      Kingdom.
FAU - Mallett, Peter
AU  - Mallett P
AD  - General Paediatrics, Belfast Health and Social Care Trust, Belfast, UK.
FAU - Ferris, Kathryn
AU  - Ferris K
AD  - General Paediatrics, Belfast Health and Social Care Trust, Belfast, UK.
FAU - Rowe-Setz, Gala
AU  - Rowe-Setz G
AD  - General Paediatrics, Belfast Health and Social Care Trust, Belfast, UK.
FAU - Moore, Rebecca
AU  - Moore R
AD  - General Paediatrics, Belfast Health and Social Care Trust, Belfast, UK.
FAU - Foster, Steven
AU  - Foster S
AD  - Emergency Department, Royal Hospital for Children, Glasgow, UK.
FAU - Evans, Jennifer
AU  - Evans J
AD  - Paediatric Infectious Disease and Immunology, Cardiff and Vale University Health 
      Board, Cardiff, UK.
FAU - Waterfield, Tom
AU  - Waterfield T
AD  - Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast-
      School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK
      t.waterfield@qub.ac.uk.
AD  - Emergency Department, Children's Health Ireland, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Viral/*blood
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - *Health Personnel
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Pandemics
MH  - Prospective Studies
MH  - SARS-CoV-2/*immunology
MH  - *Seroepidemiologic Studies
MH  - United Kingdom/epidemiology
PMC - PMC7678379
OTO - NOTNLM
OT  - *infectious diseases
OT  - *paediatric infectious disease & immunisation
OT  - *paediatrics
COIS- Competing interests: JMK holds share options in Hibergene Diagnostics Ltd,
      Sandyford, Dublin, Republic of Ireland. DF is a non-executive director, advisory 
      board member and shareholder in Hibergene Diagnostics Ltd, Sandyford, Dublin,
      Republic of Ireland.
EDAT- 2021/01/15 06:00
MHDA- 2021/01/22 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - bmjopen-2020-041661 [pii]
AID - 10.1136/bmjopen-2020-041661 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e041661. doi: 10.1136/bmjopen-2020-041661.


PMID- 33444208
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Effectiveness, cost-effectiveness and safety of gabapentin versus placebo as an
      adjunct to multimodal pain regimens in surgical patients: protocol of a placebo
      controlled randomised controlled trial with blinding (GAP study).
PG  - e041176
LID - 10.1136/bmjopen-2020-041176 [doi]
AB  - INTRODUCTION: Gabapentin is an antiepileptic drug currently licensed to treat
      epilepsy and neuropathic pain but has been used off-label to treat acute
      postoperative pain. The GAP study will compare the effectiveness,
      cost-effectiveness and safety of gabapentin as an adjunct to standard multimodal 
      analgesia versus placebo for the management of pain after major surgery. METHODS 
      AND ANALYSIS: The GAP study is a multicentre, double-blind, randomised controlled
      trial in patients aged 18 years and over, undergoing different types of major
      surgery (cardiac, thoracic or abdominal). Patients will be randomised in a 1:1
      ratio to receive either gabapentin (600 mg just before surgery and 600 mg/day for
      2 days after surgery) or placebo in addition to usual pain management for each
      type of surgery. Patients will be followed up daily until hospital discharge and 
      then at 4 weeks and 4 months after surgery. The primary outcome is length of
      hospital stay following surgery. Secondary outcomes include pain, total opioid
      use, adverse health events, health related quality of life and costs. ETHICS AND 
      DISSEMINATION: This study has been approved by the Research Ethics Committee .
      Findings will be shared with participating hospitals and disseminated to the
      academic community through peer-reviewed publications and presentation at
      national and international meetings. Patients will be informed of the results
      through patient organisations and participant newsletters. TRIAL REGISTRATION
      NUMBER: ISRCTN63614165.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Baos, Sarah
AU  - Baos S
AUID- ORCID: 0000-0003-2039-8768
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK sarah.baos@bristol.ac.uk.
FAU - Rogers, Chris A
AU  - Rogers CA
AUID- ORCID: 0000-0002-9624-2615
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - Abbadi, Reyad
AU  - Abbadi R
AUID- ORCID: 0000-0002-5334-5227
AD  - Department of Surgery, University Hospitals Bristol and Weston NHS Foundation
      Trust, Bristol, UK.
FAU - Alzetani, Aiman
AU  - Alzetani A
AUID- ORCID: 0000-0002-3373-6714
AD  - Department of Surgery, University Hospital Southampton NHS Foundation Trust,
      Southampton, UK.
FAU - Casali, Gianluca
AU  - Casali G
AD  - Department of Surgery, University Hospitals Bristol and Weston NHS Foundation
      Trust, Bristol, UK.
FAU - Chauhan, Nilesh
AU  - Chauhan N
AUID- ORCID: 0000-0002-2307-9204
AD  - Department of Anaesthesia, University Hospitals Bristol and Weston NHS Foundation
      Trust, Bristol, UK.
FAU - Collett, Laura
AU  - Collett L
AUID- ORCID: 0000-0002-6681-2146
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - Culliford, Lucy
AU  - Culliford L
AUID- ORCID: 0000-0002-9255-6617
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - de Jesus, Samantha E
AU  - de Jesus SE
AUID- ORCID: 0000-0002-9905-2737
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - Edwards, Mark
AU  - Edwards M
AUID- ORCID: 0000-0002-5048-1784
AD  - Department of Anaesthesia, University Hospital Southampton NHS FoundationTrust,
      Southampton, UK.
AD  - Acute, Critical & Perioperative Care Research Group, NIHR Biomedical Research
      Centre, University Hospital Southampton NHS Foundation Trust/University of
      Southampton, Southampton, UK.
FAU - Goddard, Nicholas
AU  - Goddard N
AD  - Department of Anaesthesia, University Hospital Southampton NHS FoundationTrust,
      Southampton, UK.
FAU - Lamb, Jennifer
AU  - Lamb J
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - McKeon, Holly
AU  - McKeon H
AUID- ORCID: 0000-0002-0220-503X
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - Molyneux, Mat
AU  - Molyneux M
AD  - Department of Anaesthesia, University Hospitals Bristol and Weston NHS Foundation
      Trust, Bristol, UK.
FAU - Stokes, Elizabeth A
AU  - Stokes EA
AUID- ORCID: 0000-0002-4179-1369
AD  - Health Economics Research Centre, University of Oxford, Oxford, UK.
FAU - Wordsworth, Sarah
AU  - Wordsworth S
AUID- ORCID: 0000-0002-2361-3040
AD  - Health Economics Research Centre, University of Oxford, Oxford, UK.
FAU - Gibbison, Ben
AU  - Gibbison B
AUID- ORCID: 0000-0003-3635-6212
AD  - Department of Anaesthesia, University Hospitals Bristol and Weston NHS Foundation
      Trust, Bristol, UK.
AD  - Bristol Medical School, University of Bristol, Bristol, UK.
FAU - Pufulete, Maria
AU  - Pufulete M
AUID- ORCID: 0000-0002-1775-1949
AD  - Bristol Trials Centre, Clinical Trials and Evaluation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
LA  - eng
SI  - ISRCTN/ISRCTN63614165
GR  - 15/101/16/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 6CW7F3G59X (Gabapentin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cost-Benefit Analysis
MH  - Double-Blind Method
MH  - Gabapentin/therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Pain, Postoperative/drug therapy
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7682449
OTO - NOTNLM
OT  - *clinical trials
OT  - *pain management
OT  - *surgery
COIS- Competing interests: No competing interests are declared. At the time that the
      work was carried out, GC was employed by the University Hospitals Bristol NHS
      Foundation Trust, Bristol, UK. GC is currently the Medical Director Johnson and
      Johnson Medical Devices UK and Ireland. GC has no competing interests to declare.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-041176 [pii]
AID - 10.1136/bmjopen-2020-041176 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e041176. doi: 10.1136/bmjopen-2020-041176.


PMID- 33444206
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Effectiveness and cost-effectiveness of personalised dietary advice aiming at
      increasing protein intake on physical functioning in community-dwelling older
      adults with lower habitual protein intake: rationale and design of the PROMISS
      randomised controlled trial.
PG  - e040637
LID - 10.1136/bmjopen-2020-040637 [doi]
AB  - INTRODUCTION: Short-term metabolic and observational studies suggest that protein
      intake above the recommended dietary allowance of 0.83 g/kg body weight (BW)/day 
      may support preservation of lean body mass and physical function in old age, but 
      evidence from randomised controlled trials is inconclusive. METHODS AND ANALYSIS:
      The PRevention Of Malnutrition In Senior Subjects in the EU (PROMISS) trial
      examines the effect of personalised dietary advice aiming at increasing protein
      intake with or without advice regarding timing of protein intake to close
      proximity of usual physical activity, on change in physical functioning after 6
      months among community-dwelling older adults (>/=65 years) with a habitual
      protein intake of <1.0 g/kg adjusted (a)BW/day. Participants (n=264) will be
      recruited in Finland and the Netherlands, and will be randomised into three
      groups; two intervention groups and one control group. Intervention group 1
      (n=88) receives personalised dietary advice and protein-enriched food products in
      order to increase their protein intake to at least 1.2 g/kg aBW/day. Intervention
      group 2 (n=88) receives the same advice as described for intervention group 1,
      and in addition advice to consume 7.5-10 g protein through protein-(en)rich(ed)
      foods within half an hour after performing usual physical activity. The control
      group (n=88) receives no intervention. All participants will be invited to attend
      lectures not related to health. The primary outcome is a 6-month change in
      physical functioning measured by change in walk time using a 400 m walk test.
      Secondary outcomes are: 6-month change in the Short Physical Performance Battery 
      score, muscle strength, body composition, self-reported mobility limitations,
      quality of life, incidence of frailty, incidence of sarcopenia risk and incidence
      of malnutrition. We also investigate cost-effectiveness by change in healthcare
      costs. DISCUSSION: The PROMISS trial will provide evidence whether increasing
      protein intake, and additionally optimising the timing of protein intake, has a
      positive effect on the course of physical functioning after 6 months among
      community-dwelling older adults with a habitual protein intake of <1.0 g/kg
      aBW/day. ETHICS AND DISSEMINATION: The study has been approved by the Ethics
      Committee of the Helsinki University Central Hospital, Finland (ID of the
      approval: HUS/1530/2018) and The Medical Ethical Committee of the Amsterdam UMC, 
      location VUmc, Amsterdam, the Netherlands (ID of the approval: 2018.399). All
      participants provided written informed consent prior to being enrolled onto the
      study. Results will be submitted for publication in peer-reviewed journals and
      will be made available to stakeholders (ie, older adults, healthcare
      professionals and industry). TRIAL REGISTRATION NUMBER: ClinicalTrials.gov
      Registry (NCT03712306).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Reinders, Ilse
AU  - Reinders I
AUID- ORCID: 0000-0003-2156-4254
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands ilse.reinders@vu.nl.
FAU - Wijnhoven, Hanneke A H
AU  - Wijnhoven HAH
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Jyvakorpi, Satu K
AU  - Jyvakorpi SK
AD  - Department of General Practice and Primary Health Care, University of Helsinki,
      Helsinki, Finland.
AD  - Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki,
      Finland.
FAU - Suominen, Merja H
AU  - Suominen MH
AD  - Department of General Practice and Primary Health Care, University of Helsinki,
      Helsinki, Finland.
AD  - Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki,
      Finland.
FAU - Niskanen, Riikka
AU  - Niskanen R
AD  - Department of General Practice and Primary Health Care, University of Helsinki,
      Helsinki, Finland.
AD  - Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki,
      Finland.
FAU - Bosmans, Judith E
AU  - Bosmans JE
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Brouwer, Ingeborg A
AU  - Brouwer IA
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Fluitman, Kristien S
AU  - Fluitman KS
AD  - Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam,
      Amsterdam Public Health research institute, Amsterdam UMC, Amsterdam, The
      Netherlands.
AD  - Wallenburg Laboratory, Department of Molecular and Clinical Medicine, Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Klein, Michel C A
AU  - Klein MCA
AD  - Department of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Kuijper, Lothar D
AU  - Kuijper LD
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - van der Lubbe, Laura M
AU  - van der Lubbe LM
AD  - Department of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Olthof, Margreet R
AU  - Olthof MR
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Pitkala, Kaisu H
AU  - Pitkala KH
AD  - Department of General Practice and Primary Health Care, University of Helsinki,
      Helsinki, Finland.
AD  - Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki,
      Finland.
FAU - Vijlbrief, Rachel
AU  - Vijlbrief R
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Visser, Marjolein
AU  - Visser M
AD  - Department of Health Sciences, Faculty of Science, and the Amsterdam Public
      Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03712306
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Cost-Benefit Analysis
MH  - Finland
MH  - Humans
MH  - *Independent Living
MH  - *Malnutrition
MH  - Netherlands
MH  - Quality of Life
PMC - PMC7682452
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-040637 [pii]
AID - 10.1136/bmjopen-2020-040637 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e040637. doi: 10.1136/bmjopen-2020-040637.


PMID- 33444204
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Acute Rehabilitation following Traumatic anterior shoulder dISlocAtioN (ARTISAN):
      protocol for a multicentre randomised controlled trial.
PG  - e040623
LID - 10.1136/bmjopen-2020-040623 [doi]
AB  - INTRODUCTION: First-time traumatic anterior shoulder dislocation (TASD) is
      predominantly managed non-operatively. People sustaining TASD have ongoing pain, 
      disability and future risk of redislocation. There are no published randomised
      controlled trials (RCTs) comparing different non-operative rehabilitation
      strategies to ascertain the optimum clinically effective approach after TASD.
      METHODS AND ANALYSIS: In this multicentre adaptive RCT, with internal pilot,
      adults with a radiologically confirmed first time TASD treated non-surgically
      will be screened at a minimum of 30 sites. People with neurovascular
      complications, bilateral dislocations or are unable to attend physiotherapy will 
      be excluded.Randomisation will be on a 1:1 treatment allocation, stratified by
      age, hand dominance and site. Participants will receive a single session of
      advice; or a single session of advice plus offer of further physiotherapy
      (maximum 4 months). The primary analysis will be the difference in Oxford
      Shoulder Instability Score at 6 months. A sample size of a minimum of 478
      participants will allow us to show a four point difference with 90% power.An
      embedded qualitative study will explore the participants' experiences of the
      trial interventions. ETHICS, REGISTRATION AND DISSEMINATION: Funded by NIHR HTA
      (16/167/56), 1 June 2018; National Research Ethic Committee approved
      (18/WA/0236), 26 July 2018. First site opened 5 November 2018 and final results
      will be updated on trial registries and submitted to a peer-reviewed journal and 
      will inform rehabilitation strategies after a TASD. Study Within A Trial (SWAT)
      funded by MRC (MR/R013748/1), 1 May 2019; registered on the MRC-HTMR All-Ireland 
      Hub (reference number SWAT 121). TRIAL REGISTRATION NUMBER: ISRCTN63184243.
      (Trial stage: Pre-results).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kearney, Rebecca Samantha
AU  - Kearney RS
AUID- ORCID: 0000-0002-8010-164X
AD  - Warwick Medical School, University of Warwick, Coventry, UK
      R.S.Kearney@Warwick.ac.uk.
FAU - Dhanjal, Gurmit
AU  - Dhanjal G
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Parsons, Nicholas
AU  - Parsons N
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Ellard, David
AU  - Ellard D
AUID- ORCID: 0000-0002-2992-048X
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Parsons, Helen
AU  - Parsons H
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Haque, Aminul
AU  - Haque A
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Karasouli, Eleni
AU  - Karasouli E
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Mason, James
AU  - Mason J
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Nwankwo, Henry
AU  - Nwankwo H
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Brown, Jaclyn
AU  - Brown J
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Liew, ZiHeng
AU  - Liew Z
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Drew, Stephen
AU  - Drew S
AD  - Trauma and Orthopaedics, University Hospitals Coventry and Warwickshire NHS
      Trust, Coventry, UK.
FAU - Modi, Chetan
AU  - Modi C
AD  - Trauma and Orthopaedics, University Hospitals Coventry and Warwickshire NHS
      Trust, Coventry, UK.
FAU - Bush, Howard
AU  - Bush H
AD  - Trauma and Orthopaedics, University Hospitals Coventry and Warwickshire NHS
      Trust, Coventry, UK.
FAU - Torgerson, David
AU  - Torgerson D
AD  - York Clinical Trials Unit, The University of York, York, UK.
FAU - Underwood, Martin
AU  - Underwood M
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
LA  - eng
SI  - ISRCTN/ISRCTN63184243
GR  - 16/167/56/DH_/Department of Health/United Kingdom
GR  - MR/R013748/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - Adult
MH  - Aged
MH  - Humans
MH  - Ireland
MH  - *Joint Instability
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Shoulder Dislocation
MH  - Surveys and Questionnaires
PMC - PMC7678365
OTO - NOTNLM
OT  - *clinical trials
OT  - *rehabilitation medicine
OT  - *shoulder
COIS- Competing interests: RSK is a member of the UK NIHR HTA CET board, NIHR ICA
      Doctoral panel and previous member of the NIHR RfPB board. RSK, NP, DRE, HP, JM, 
      MU, SD, CM and DT have all been awarded current and previous NIHR research
      grants. JB, GD, ZHL, AH, HN, EK and HB have none to declare. MU has received
      travel expenses for speaking at conferences from the professional organisations
      hosting the conferences. He is a director and shareholder of Clinvivo Ltd that
      provides electronic data collection for health services research. He is part of
      an academic partnership with Serco. He was an editor of the NIHR journal series
      for which he received a fee.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-040623 [pii]
AID - 10.1136/bmjopen-2020-040623 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e040623. doi: 10.1136/bmjopen-2020-040623.


PMID- 33444199
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated
      SubSegmental Pulmonary Embolism: protocol for a multicentre randomised
      placebo-controlled non-inferiority trial (SAFE-SSPE).
PG  - e040151
LID - 10.1136/bmjopen-2020-040151 [doi]
AB  - INTRODUCTION: The clinical significance of subsegmental pulmonary embolism (SSPE)
      is currently unclear. Although growing evidence from observational studies
      suggests that withholding anticoagulant treatment may be a safe option in
      selected patients with isolated SSPE, most patients with this condition receive
      anticoagulant treatment, which is associated with a 90-day risk of recurrent
      venous thromboembolism (VTE) of 0.8% and major bleeding of up to 5%. Given the
      ongoing controversy concerning the risk-benefit ratio of anticoagulation for
      isolated SSPE and the lack of evidence from randomised-controlled studies, the
      aim of this clinical trial is to evaluate the efficacy and safety of clinical
      surveillance without anticoagulation in low-risk patients with isolated SSPE.
      METHODS AND ANALYSIS: SAFE-SSPE (Surveillance vs. Anticoagulation For low-risk
      patiEnts with isolated SubSegmental Pulmonary Embolism, a multicentre randomised 
      placebo-controlled non-inferiority trial) is an international, multicentre,
      placebo-controlled, double-blind, parallel-group non-inferiority trial conducted 
      in Switzerland, the Netherlands and Canada. Low-risk patients with isolated SSPE 
      are randomised to receive clinical surveillance with either placebo (no
      anticoagulation) or anticoagulant treatment with rivaroxaban. All patients
      undergo bilateral whole-leg compression ultrasonography to exclude concomitant
      deep vein thrombosis before enrolment. Patients are followed for 90 days. The
      primary outcome is symptomatic recurrent VTE (efficacy). The secondary outcomes
      include clinically significant bleeding and all-cause mortality (safety). The
      ancillary outcomes are health-related quality of life, functional status and
      medical resource utilisation. ETHICS AND DISSEMINATION: The local ethics
      committees in Switzerland have approved this protocol. Submission to the Ethical 
      Committees in the Netherlands and Canada is underway. The results of this trial
      will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      NCT04263038.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Baumgartner, Christine
AU  - Baumgartner C
AUID- ORCID: 0000-0003-2296-9632
AD  - Department of General Internal Medicine, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland Christine.Baumgartner@insel.ch.
FAU - Klok, Frederikus A
AU  - Klok FA
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - Carrier, Marc
AU  - Carrier M
AD  - Department of Medicine, The Ottawa Hospital Research Institute at the University 
      of Ottawa, Ottawa, Ontario, Canada.
FAU - Limacher, Andreas
AU  - Limacher A
AD  - CTU Bern, University of Bern, Bern, Switzerland.
FAU - Moor, Jeanne
AU  - Moor J
AD  - Department of General Internal Medicine, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland.
FAU - Righini, Marc
AU  - Righini M
AD  - Division of Angiology and Haemostasis, Geneva University Hospital, University of 
      Geneva, Geneva, Switzerland.
FAU - Beer, Jurg-Hans
AU  - Beer JH
AD  - Department of Internal Medicine, Cantonal Hospital of Baden, Baden, Switzerland.
FAU - Peluso, Martina
AU  - Peluso M
AD  - Department of General Internal Medicine, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland.
FAU - Rakovic, Damiana
AU  - Rakovic D
AD  - Department of General Internal Medicine, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland.
FAU - Huisman, Menno V
AU  - Huisman MV
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - Aujesky, Drahomir
AU  - Aujesky D
AD  - Department of General Internal Medicine, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04263038
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Adult
MH  - Anticoagulants/adverse effects
MH  - Canada
MH  - Double-Blind Method
MH  - Humans
MH  - Netherlands
MH  - *Pulmonary Embolism/drug therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Switzerland
MH  - *Venous Thromboembolism/drug therapy/prevention & control
PMC - PMC7678381
OTO - NOTNLM
OT  - *anticoagulation
OT  - *randomised clinical trialx
OT  - *subsegmental pulmonary embolism
COIS- Competing interests: MC reports grants from Leo Pharma, BMS, Pfizer, personal
      fees from Bayer, BMS, Pfizer, Sanofi, Leo Pharma, Servier, outside the submitted 
      work. All other authors declare that they have no competing interest with regard 
      to the intellectual concern and proprietary of affairs. The funding source had no
      role in the design of this study and does not have any role in the conduct, the
      collection, management, analysis and interpretation of the data, the writing of
      the manuscript or the decision to submit the results for publication.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-040151 [pii]
AID - 10.1136/bmjopen-2020-040151 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e040151. doi: 10.1136/bmjopen-2020-040151.


PMID- 33444198
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Assessing the efficacy and impact of a personalised smoking cessation
      intervention among type 2 diabetic smokers: study protocol for an open-label
      randomised controlled trial (DISCGO-RCT).
PG  - e040117
LID - 10.1136/bmjopen-2020-040117 [doi]
AB  - INTRODUCTION: Few studies have assessed the efficacy of smoking cessation
      interventions in individuals with type 2 diabetes, but interventions adapted to
      the specific needs of this population are warranted. The aim of this study is to 
      assess the efficacy of a smoking cessation intervention in a population of
      smokers with type 2 diabetes and to measure the metabolic impact of smoking
      cessation. METHODS AND ANALYSIS: The study is an open-label, randomised control
      trial. Participants recruited from a sanitary region of Switzerland will be
      randomly allocated to either the intervention or the control arm. The
      intervention group will have four individual counselling sessions over 12 weeks. 
      Trained research nurses will conduct the behavioural intervention, using
      motivational interviews and addressing diabetes and gender specificities. The
      control group will have one short counselling session at baseline and will be
      given written information on smoking cessation. Both groups will have a follow-up
      visit at 26 and 52 weeks. Demographic and medical data will be collected at
      baseline and follow-up, along with blood and urine samples. The primary study
      outcome is continuous smoking abstinence validated by expired-air carbon monoxide
      from week 12 to week 52. Secondary study outcomes are continuous and 7-day point 
      prevalence smoking abstinence at 12 and 26 weeks; change in motivation to quit
      and cigarette consumption; and change in glycosylated haemoglobin levels, body
      weight, waist circumference and renal function after smoking cessation. In a
      subsample of 80 participants, change in stool microbiota from baseline will be
      measured at 3, 8 and 26 weeks after smoking cessation. ETHICS AND DISSEMINATION: 
      Ethical approval has been obtained by the competent ethics committee (Commission 
      cantonale d'ethique de la recherche sur l'etre humain, CER-VD 2017-00812). The
      results of the study will be disseminated through publications in peer-reviewed
      journals and conference presentations. TRIAL REGISTRATION NUMBERS:
      ClinicalTrials.gov NCT03426423 and SNCTP000002762; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Clair, Carole
AU  - Clair C
AUID- ORCID: 0000-0001-5281-0943
AD  - Department of Training, Research and Innovation, Center for Primary Care and
      Public Health, Lausanne, Vaud, Switzerland carole.clair@unisante.ch.
AD  - Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
FAU - Augsburger, Aurelie
AU  - Augsburger A
AUID- ORCID: 0000-0002-8121-665X
AD  - Department of Training, Research and Innovation, Center for Primary Care and
      Public Health, Lausanne, Vaud, Switzerland.
FAU - Birrer, Priska
AU  - Birrer P
AD  - Department of Training, Research and Innovation, Center for Primary Care and
      Public Health, Lausanne, Vaud, Switzerland.
AD  - Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
FAU - Locatelli, Isabella
AU  - Locatelli I
AD  - Department of Training, Research and Innovation, Center for Primary Care and
      Public Health, Lausanne, Vaud, Switzerland.
AD  - Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
FAU - Schwarz, Joelle
AU  - Schwarz J
AD  - Department of Training, Research and Innovation, Center for Primary Care and
      Public Health, Lausanne, Vaud, Switzerland.
FAU - Greub, Gilbert
AU  - Greub G
AD  - Center for Research on Intracellular Bacteria, Institute of Microbiology,
      University Hospital of Lausanne, Lausanne, Switzerland.
FAU - Zanchi, Anne
AU  - Zanchi A
AD  - Service of Nephrology and Hypertension, Service of Endocrinology, Diabetes and
      Metabolism, University Hospital of Lausanne Department of Medicine, Lausanne,
      Switzerland.
FAU - Jacot-Sadowski, Isabelle
AU  - Jacot-Sadowski I
AD  - Department of Health Promotion and Prevention, Center for Primary Care and Public
      Health, Lausanne, Vaud, Switzerland.
FAU - Puder, Jardena J
AU  - Puder JJ
AD  - Service of Obstetrics, Department Woman Mother Child, University Hospital of
      Lausanne, Lausanne, Vaud, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03426423
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Behavior Therapy
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Smokers
MH  - *Smoking Cessation
MH  - Switzerland
PMC - PMC7678377
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *general medicine (see internal medicine)
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-040117 [pii]
AID - 10.1136/bmjopen-2020-040117 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e040117. doi: 10.1136/bmjopen-2020-040117.


PMID- 33444196
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Specialised orthotic care to improve functioning in adults with neuromuscular
      disorders: protocol of a prospective randomised open-label blinded end-point
      study.
PG  - e039683
LID - 10.1136/bmjopen-2020-039683 [doi]
AB  - INTRODUCTION: People suffering from leg muscle weakness caused by neuromuscular
      disorders (NMDs) are often provided with leg orthoses to reduce walking problems 
      such as increased walking effort, diminished walking speed, reduced balance and
      falls. However, evidence for the effectiveness of leg orthoses to improve walking
      in this patient group is limited and there is an absence of standardised practice
      in orthotic prescription. In 2012 a Dutch multidisciplinary guideline was
      developed aimed to standardise the orthotic treatment process in NMD. Although
      application of the guideline in expert centres (specialised orthotic care) seems 
      beneficial regarding clinical effectiveness, larger studies are necessary to
      confirm results and investigate cost-effectiveness. Therefore, this study aims to
      examine the effectiveness and cost-effectiveness of specialised orthotic care
      compared with usual orthotic care in adults with slowly progressive NMD. METHODS 
      AND ANALYSIS: A prospective randomised open-label blinded end-point study will be
      performed, in which 70 adults with slowly progressive NMD are randomly assigned
      to specialised orthotic care (intervention) or usual orthotic care (control).
      Outcome measures are assessed at baseline and at 3 and 6 months follow-up. The
      primary endpoints are gross walking energy cost (J/kg/m) assessed during a 6 min 
      walk test and achievement of personal goals, measured with the Goal Attainment
      Scale. Secondary endpoints include walking speed, gait biomechanics, stability,
      physical functioning, falls and fear of falling, perceived fatigue and
      satisfaction. For the economic evaluation, societal costs and health-related
      quality of life will be assessed using cost questionnaires and the 5-Level
      version of EuroQol 5 Dimension, retrospectively. ETHICS AND DISSEMINATION: The
      study is registered in the Dutch trial register (NL 7511) and the protocol has
      been approved by the Medical Ethics Committee of the Academic Medical Center in
      Amsterdam. Results will be presented at national and international scientific
      conferences and disseminated through peer-reviewed journals and media aimed at a 
      broad audience including patients.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - van Duijnhoven, Elza
AU  - van Duijnhoven E
AUID- ORCID: 0000-0002-7876-046X
AD  - Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam
      UMC, University of Amsterdam, Amsterdam, The Netherlands
      e.vanduijnhoven@amsterdamumc.nl.
FAU - Koopman, Fieke Sophia
AU  - Koopman FS
AD  - Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam
      UMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Tuijtelaars, Jana Antonius Maria
AU  - Tuijtelaars JAM
AD  - Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam
      UMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Altmann, Viola
AU  - Altmann V
AD  - Klimmendaal Rehabilitation Center, Arnhem, The Netherlands.
FAU - Lagrand, Rimke
AU  - Lagrand R
AD  - Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam
      UMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - van Dongen, Johanna Maria
AU  - van Dongen JM
AD  - Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, 
      Amsterdam, The Netherlands.
FAU - Nollet, Frans
AU  - Nollet F
AD  - Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam
      UMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Brehm, Merel-Anne
AU  - Brehm MA
AD  - Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam
      UMC, University of Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Accidental Falls/prevention & control
MH  - Adult
MH  - Fear
MH  - Humans
MH  - *Neuromuscular Diseases
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
PMC - PMC7678344
OTO - NOTNLM
OT  - *neuromuscular disease
OT  - *protocols & guidelines
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-039683 [pii]
AID - 10.1136/bmjopen-2020-039683 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e039683. doi: 10.1136/bmjopen-2020-039683.


PMID- 33444195
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Evaluating the impact of the Bolsa Familia conditional cash transfer program on
      premature cardiovascular and all-cause mortality using the 100 million Brazilian 
      cohort: a natural experiment study protocol.
PG  - e039658
LID - 10.1136/bmjopen-2020-039658 [doi]
AB  - INTRODUCTION: Brazil's Bolsa Familia Program (BFP) is the world's largest
      conditional cash transfer scheme. We shall use a large cohort of applicants for
      different social programmes to evaluate the effect of BFP receipt on premature
      all-cause and cardiovascular mortality. METHODS AND ANALYSIS: We will identify
      BFP recipients and non-recipients among new applicants from 2004 to 2015 in the
      100 Million Brazilian Cohort, a database of 114 million individuals containing
      sociodemographic and mortality information of applicants to any Brazilian social 
      programme. For individuals applying from 2011, when we have better recorded
      income data, we shall compare premature (age 30-69) cardiovascular and all-cause 
      mortality among BFP recipients and non-recipients using regression discontinuity 
      design (RDD) with household monthly per capita income as the forcing variable.
      Effects will be estimated using survival models accounting for individuals
      follow-up. To test the sensitivity of our findings, we will estimate models with 
      different bandwidths, include potential confounders as covariates in the survival
      models, and restrict our data to locations with the most reliable data. In
      addition, we will estimate the effect of BFP on studied outcomes using propensity
      score risk-set matching, separately for individuals that applied </=2010 and
      >2011, allowing comparability with RDD. Analyses will be stratified by
      geographical region, gender, race/ethnicity and socioeconomic position. We will
      investigate differential impacts of BFP and the presence of effect modification
      for a combination of characteristics, including gender and race/ethnicity. ETHICS
      AND DISSEMINATION: The study was approved by the ethics committees of Oswaldo
      Cruz Foundation and the University of Glasgow College of Medicine and Veterinary 
      Life Sciences. The deidentified dataset will be provided to researchers, and data
      analysis will be performed in a safe computational environment without internet
      access. Study findings will be published in high quality peer-reviewed research
      articles. The published results will be disseminated in the social media and to
      policy-makers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Pescarini, Julia M
AU  - Pescarini JM
AUID- ORCID: 0000-0001-8711-9589
AD  - Centro de Integracao de Dados e Conhecimentos para Saude (Cidacs), Fundacao
      Oswaldo Cruz, Salvador, Brazil juliapescarini@gmail.com.
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Craig, Peter
AU  - Craig P
AD  - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow,
      Glasgow, UK.
FAU - Allik, Mirjam
AU  - Allik M
AD  - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow,
      Glasgow, UK.
FAU - Amorim, Leila
AU  - Amorim L
AD  - Instituto de Matematica e Estatistica, Universidade Federal da Bahia, Salvador,
      Brazil.
FAU - Ali, Sanni
AU  - Ali S
AD  - Centro de Integracao de Dados e Conhecimentos para Saude (Cidacs), Fundacao
      Oswaldo Cruz, Salvador, Brazil.
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Smeeth, Liam
AU  - Smeeth L
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
AD  - Health Data Research (HDR), London, UK.
FAU - Barreto, Mauricio L
AU  - Barreto ML
AD  - Centro de Integracao de Dados e Conhecimentos para Saude (Cidacs), Fundacao
      Oswaldo Cruz, Salvador, Brazil.
AD  - Instituto de Saude Coletiva, Universidade Federal da Bahia, Salvador, Brazil.
FAU - Leyland, Alastair H
AU  - Leyland AH
AD  - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow,
      Glasgow, UK.
FAU - Aquino, Estela M L
AU  - Aquino EML
AD  - Centro de Integracao de Dados e Conhecimentos para Saude (Cidacs), Fundacao
      Oswaldo Cruz, Salvador, Brazil.
AD  - Instituto de Saude Coletiva, Universidade Federal da Bahia, Salvador, Brazil.
FAU - Katikireddi, Srinivasa Vittal
AU  - Katikireddi SV
AUID- ORCID: 0000-0001-6593-9092
AD  - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow,
      Glasgow, UK.
LA  - eng
GR  - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom
GR  - SCAF/15/02/CSO_/Chief Scientist Office/United Kingdom
GR  - 202912/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - MC_UU_12017/13/MRC_/Medical Research Council/United Kingdom
GR  - SPHSU17/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brazil/epidemiology
MH  - Cardiovascular Diseases
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - *Income
MH  - Male
MH  - Middle Aged
MH  - Premature Birth
MH  - Propensity Score
PMC - PMC7682454
OTO - NOTNLM
OT  - *Health policy
OT  - *cardiac epidemiology
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-039658 [pii]
AID - 10.1136/bmjopen-2020-039658 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e039658. doi: 10.1136/bmjopen-2020-039658.


PMID- 33444194
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Valuing health-related quality of life among the Indian population: a protocol
      for the Development of an EQ-5D Value set for India using an Extended design
      (DEVINE) Study.
PG  - e039517
LID - 10.1136/bmjopen-2020-039517 [doi]
AB  - INTRODUCTION: Quality-adjusted life year (QALY) has been recommended by the
      government as preferred outcome measure for Health Technology Assessment (HTA) in
      India. As country-specific health-related quality of life tariff values are
      essential for accurate measurement of QALYs, the government of India has
      commissioned the present study. The aim of this paper is to describe the methods 
      for the Development of an EQ-5D Value set for India using an Extended design
      (DEVINE) Study. Additionally, this study aspires to establish if the design of
      10-time trade-off (TTO) blocks is enough to generate valid value sets. METHODS
      AND ANALYSIS: A cross-sectional survey using the EuroQol Group's Valuation
      Technology (EQ-VT) will be undertaken in a sample of 2700 respondents selected
      from six different states of India using a multistage stratified random sampling 
      technique. The participants will be interviewed using computer-assisted personal 
      interviewing technique. The TTO valuation will be done using 10 composite TTO
      (c-TTO) tasks and 7 discrete choice experiment (DCE) tasks. Hybrid modelling
      approach using both c-TTO and DCE data to estimate the potential value set will
      be applied. Values of all 3125 health states will be predicted using both the
      conventional EQ-VT design of 10 blocks of 10 TTO tasks, and an extended design of
      18 blocks of 10 TTO tasks. The potential added value of the eight additional
      blocks in overall validity will be tested. The study will deliver value set for
      India and assess the adequacy of existing 10-blocks design to be able to
      correctly predict the values of all 3125 health states. ETHICS AND DISSEMINATION:
      The ethical approval has been obtained from Institutional Ethics Committee of
      PGIMER, Chandigarh, India. The anonymised EQ-5D-5L value set will be available
      for general use and in the HTAs commissioned by India's central HTA Agency.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jyani, Gaurav
AU  - Jyani G
AUID- ORCID: 0000-0003-3787-2446
AD  - Department of Community Medicine and School of Public Health, Postgraduate
      Institute of Medical Education and Research, Chandigarh, India.
FAU - Prinja, Shankar
AU  - Prinja S
AUID- ORCID: 0000-0001-7719-6986
AD  - Department of Community Medicine and School of Public Health, Postgraduate
      Institute of Medical Education and Research, Chandigarh, India
      shankarprinja@gmail.com.
FAU - Kar, Sitanshu Sekhar
AU  - Kar SS
AD  - Department of Preventive and Social Medicine, Jawaharlal Institute of
      Postgraduate Medical Education and Research, Puducherry, Tamil Nadu, India.
FAU - Trivedi, Mayur
AU  - Trivedi M
AD  - Indian Institute of Public Health, Gandhinagar, Gujarat, India.
FAU - Patro, Binod
AU  - Patro B
AD  - Department of Community Medicine and Family Medicine, All India Institute of
      Medical Sciences, Bhubaneswar, Odisha, India.
FAU - Purba, Fredrick
AU  - Purba F
AD  - Department of Developmental Psychology, Universitas Padjadjaran, Jatinangor, West
      Jawa, Indonesia.
FAU - Pala, Star
AU  - Pala S
AD  - Department of Community Medicine, North Eastern Indira Gandhi Regional Institute 
      of Health and Medical Sciences, Shillong, Meghalaya, India.
FAU - Raman, Swati
AU  - Raman S
AD  - Academy of Management Sciences, Lucknow, Uttar Pradesh, India.
FAU - Sharma, Atul
AU  - Sharma A
AD  - Department of Community Medicine and School of Public Health, Postgraduate
      Institute of Medical Education and Research, Chandigarh, India.
FAU - Jain, Shalu
AU  - Jain S
AD  - Department of Health Research, Ministry of Health and Family Welfare, Government 
      of India, New Delhi, India.
FAU - Kaur, Manmeet
AU  - Kaur M
AD  - Department of Community Medicine and School of Public Health, Postgraduate
      Institute of Medical Education and Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Health Status
MH  - Humans
MH  - India
MH  - *Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC7682473
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-039517 [pii]
AID - 10.1136/bmjopen-2020-039517 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e039517. doi: 10.1136/bmjopen-2020-039517.


PMID- 33444192
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Active and passive work breaks during simulated laparoscopy among laparoscopic
      surgeons: study protocol for a controlled, randomised cross-over laboratory
      trial.
PG  - e038952
LID - 10.1136/bmjopen-2020-038952 [doi]
AB  - INTRODUCTION: Laparoscopy has partially replaced open surgery due to the lower
      infection rate for the patient and hence better and shorter recovery. However,
      the surgeon's physical load is higher due to longer duration static and awkward
      body postures, increasing the risk for developing work-related musculoskeletal
      disorders. Interventions of an organisational nature are work breaks, being
      either passive or active. The primary objectives of this study are to determine
      whether passive and active work breaks lead to less discomfort than no work
      breaks and whether active work breaks lead to less discomfort than passive work
      breaks. METHODS AND ANALYSIS: A controlled, randomised cross-over trial will be
      performed in the laboratory, of which its protocol is described here according to
      the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
      2013 Statement. Recruitment of 21 laparoscopic surgeons started in April 2019 and
      the study is ongoing. The participating surgeons will perform three 1.5 hour
      experimental conditions, one without work breaks, one with 2.5 min passive work
      breaks including rest, and one with 2.5 min active work breaks including mobility
      and stretching exercises. The work breaks will be taken after 30 and 60 min of
      work. During the experiments, outcomes will be recorded. The primary outcome is
      rating of perceived discomfort measured on an 11-point numeric rating scale. The 
      secondary outcomes are performance, muscle activity of selected muscles, upper
      body angles, heart rate, workload and subjective evaluation of both
      interventions. The collected data will be tested using a one-way or two-factorial
      repeated-measures analysis of variance. ETHICS AND DISSEMINATION: Ethical
      approval of the study protocol was received by the local medical ethical
      committee of the University of Tubingen in February 2019 (no 618/2018BO2). The
      results of this study will be presented at national and international
      conferences, submitted for publications in peer-reviewed journals and serve as
      the starting point for a feasibility study. TRIAL REGISTRATION NUMBER:
      NCT03715816.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Luger, Tessy
AU  - Luger T
AUID- ORCID: 0000-0001-5718-251X
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital of Tubingen, Tubingen, Germany
      tessy.luger@med.uni-tuebingen.de.
FAU - Rieger, Monika A
AU  - Rieger MA
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital of Tubingen, Tubingen, Germany.
FAU - Bonsch, Rosina
AU  - Bonsch R
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital of Tubingen, Tubingen, Germany.
FAU - Kramer, Bernhard
AU  - Kramer B
AD  - Department of Gynecology, University Hospital of Tubingen, Tubingen, Germany.
FAU - Seibt, Robert
AU  - Seibt R
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital of Tubingen, Tubingen, Germany.
FAU - Steinhilber, Benjamin
AU  - Steinhilber B
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital of Tubingen, Tubingen, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03715816
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19
MH  - Cross-Over Studies
MH  - Humans
MH  - Laboratories
MH  - *Laparoscopy
MH  - SARS-CoV-2
MH  - Surgeons
PMC - PMC7678387
OTO - NOTNLM
OT  - *minimally invasive surgery
OT  - *occupational & industrial medicine
OT  - *physiology
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-038952 [pii]
AID - 10.1136/bmjopen-2020-038952 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e038952. doi: 10.1136/bmjopen-2020-038952.


PMID- 33444190
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Use of dating sites and applications by women and their risk of sexually
      transmitted infections: a systematic review and meta-analysis protocol.
PG  - e038738
LID - 10.1136/bmjopen-2020-038738 [doi]
AB  - INTRODUCTION: The use of social networks has been increasing worldwide. Mobile
      websites and applications (apps) allow people to network more quickly and have
      more partners for sex. This can facilitate risky sexual behaviours, such as
      having multiple partners and unprotected sex, which can lead to a higher
      incidence of sexually transmitted infections. This systematic
      review/meta-analysis will assess the effects of the use of dating sites and apps 
      by women on their level of engagement in risky sexual behaviours and their
      incidence of sexually transmitted infections. METHODS AND ANALYSIS: The Cochrane 
      Central Controlled Trials Registry, ClinicalTrials.gov, MEDLINE, Embase, SciELO, 
      Web of Science, Scopus and Cumulative Index to Nursing & Allied Health Literature
      will be searched for cross-sectional studies, clinical trials and observational
      studies published between January 1990 and July 2020. This systematic review and 
      meta-analysis will include studies investigating the use of mobile apps by women,
      risky sexual behaviour and sexually transmitted infections. The outcome will be
      an increase in new cases of sexually transmitted infections and HIV among women
      using dating sites and apps. Three independent reviewers will select the studies 
      and extract data from the original articles. The risk of bias will be assessed
      using the Cochrane risk of bias tool and Risk Of Bias in Non-randomized Studies
      of Interventions. Data synthesis will be performed using Review Manager software 
      (RevMan V.5.2.3). To assess heterogeneity, we will compute the I(2) statistic. In
      addition, a quantitative synthesis will be carried out if the included studies
      are sufficiently homogeneous. ETHICS AND DISSEMINATION: This study will be a
      review of the published data, and thus ethical approval is not required. The
      findings of this systematic review will be published in a peer-reviewed journal. 
      PROSPERO REGISTRATION NUMBER: CRD42019120494.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Queiroz, Janice Franca
AU  - Queiroz JF
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Medeiros, Kleyton Santos
AU  - Medeiros KS
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Sarmento, Ayane Cristine Alves
AU  - Sarmento ACA
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Monteiro, Michelly Nobrega
AU  - Monteiro MN
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Cobucci, Ricardo Ney
AU  - Cobucci RN
AD  - Postgraduate Program in Woman Health, MEJC/EBSERH, Natal, Brazil.
FAU - Stransky, Beatriz
AU  - Stransky B
AD  - Department of Biomedical Engineering, Federal University of Rio Grande do Norte, 
      Natal, Brazil.
FAU - Goncalves, Ana Katherine
AU  - Goncalves AK
AUID- ORCID: 0000-0002-8351-5119
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil anakatherine_ufrnet@yahoo.com.br.
AD  - Department of Gynecology and Obstetrics, Federal University of Rio Grande do
      Norte, Natal, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (DAT1 protein, S cerevisiae)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Saccharomyces cerevisiae Proteins)
SB  - IM
MH  - Cross-Sectional Studies
MH  - DNA-Binding Proteins
MH  - Female
MH  - *HIV Infections
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Mobile Applications
MH  - Saccharomyces cerevisiae Proteins
MH  - Sexual Behavior
MH  - *Sexually Transmitted Diseases/epidemiology
PMC - PMC7678376
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *gynaecology
OT  - *health informatics
OT  - *infectious diseases
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-038738 [pii]
AID - 10.1136/bmjopen-2020-038738 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e038738. doi: 10.1136/bmjopen-2020-038738.


PMID- 33444189
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - GlutenSpA trial: protocol for a randomised double-blind placebo-controlled trial 
      of the impact of a gluten-free diet on quality of life in patients with axial
      spondyloarthritis.
PG  - e038715
LID - 10.1136/bmjopen-2020-038715 [doi]
AB  - INTRODUCTION: Subclinical intestinal inflammation and gut dysbiosis have been
      reported in patients with spondyloarthritis (SpA). In common practice,
      rheumatologists are increasingly confronted with patients with inflammatory
      rheumatism who are on gluten-free diets (GFDs), despite the lack of reliable data
      from controlled studies. This study aims to determine the impact of a GFD on the 
      quality of life of patients with axial SpA. METHODS AND ANALYSIS: The GlutenSpA
      study is a 24-week, randomised, double-blinded, placebo-controlled, multicentre
      trial. Patients with axial SpA (n=200) will follow a 16-week GFD and be randomly 
      assigned (1:1) to an experimental or control arm. In the experimental arm with
      receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta 
      per week + 6 rice flavour capsules per day. The control arm will receive at least
      6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per
      week + 6 vital gluten-containing capsules per day. The primary end-point is the
      variation in Assessment of SpondyloArthritis International Society-Health Index
      (ASAS-HI) questionnaire between week 16 and baseline. A second open-label period 
      of 8 weeks will follow the intervention period, during which the patient will be 
      free to decide whether they will follow the GFD. The secondary outcomes comprise 
      several patient-reported outcomes (SpA activity (Bath Ankylosing Spondylitis
      Disease Activity Index)), fatigue (Functional Assessment of Chronic Illness
      Therapy), depression (Hospital Anxiety and Depression Scale), functional
      disability index (Bath Ankylosing Spondylitis Functional Index)), variations in
      body mass index and Homeostasis Model Assessment Index and variations in the
      abundance and type of bacterial species found in the gut microbiota for a
      subgroup of patients (n=40). The data will be analysed using the
      intention-to-treat principle.The regional ethics committee (CPP Nord-ouest IV)
      has approved the study (IDRCB 2018-A00309-46). The results of the trial will be
      submitted for publication in peer-reviewed journals. The authors have no
      relationship that may have influenced the submitted work. TRIAL REGISTRATION
      NUMBER: NCT04274374.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Couderc, Marion
AU  - Couderc M
AUID- ORCID: 0000-0002-2001-1132
AD  - Rheumatology, CHU Clermont-Ferrand, Clermont-Ferrand, France
      mcouderc@chu-clermontferrand.fr.
FAU - Pereira, Bruno
AU  - Pereira B
AD  - Biostatistical Unit, CHU Clermont-Ferrand, Clermont-Ferrand, France.
FAU - Schaeverbeke, Thierry
AU  - Schaeverbeke T
AD  - Rheumatology, CHU de Bordeaux, Bordeaux, Aquitaine, France.
FAU - Thomas, Thierry
AU  - Thomas T
AD  - Rheumatology, CHU ST ETIENNE, Saint Etienne, France.
FAU - Chapurlat, Roland
AU  - Chapurlat R
AD  - Rheumatology, CHU Lyon, Lyon, Auvergne-Rhone-Alpes, France.
FAU - Gaudin, Philippe
AU  - Gaudin P
AD  - Rheumatology, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Morel, Jacques
AU  - Morel J
AD  - Rheumatology, CHU Montpellier, Montpellier, Languedoc-Roussillon, France.
FAU - Dougados, Maxime
AU  - Dougados M
AD  - Rheumatology, Cochin Institute, Paris, Ile-de-France, France.
FAU - Soubrier, Martin
AU  - Soubrier M
AD  - Rheumatology, CHU Clermont-Ferrand, Clermont-Ferrand, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04274374
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Diet, Gluten-Free
MH  - Double-Blind Method
MH  - Humans
MH  - *Quality of Life
MH  - *Spondylarthritis/drug therapy
MH  - Treatment Outcome
PMC - PMC7682451
OTO - NOTNLM
OT  - *inflammatory bowel disease
OT  - *nutrition & dietetics
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-038715 [pii]
AID - 10.1136/bmjopen-2020-038715 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e038715. doi: 10.1136/bmjopen-2020-038715.


PMID- 33444188
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Effect of spironolactone on cardiovascular morbidity and mortality in patients
      with hypertension and glucose metabolism disorders (ESCAM): a study protocol for 
      a pragmatic randomised controlled trial.
PG  - e038694
LID - 10.1136/bmjopen-2020-038694 [doi]
AB  - INTRODUCTION: Hypertension combined with diabetes and hypokalemia is more likely 
      to develop hyperaldosteronism and is at higher risk of cardiovascular events.
      There is evidence that activation of aldosterone and mineralocorticoid receptors 
      may play a significant role in the occurrence of cardiovascular events in
      patients with hypertension and diabetes. Clinical studies have demonstrated that 
      spironolactone can reduce the incidence of cardiovascular events in patients with
      chronic kidney diseases or severe heart failure. However, the effect of
      spironolactone on cardiovascular risk in patients with hypertension and glucose
      metabolism disorders (GMD) and low potassium has been scarcely studied.
      Therefore, this study aims to evaluate whether add-on spironolactone
      (conventional antihypertensive drugs alone vs conventional antihypertensive
      drugs+spironolactone) can reduce the morbidity and mortality of cardiovascular
      events in this population. METHODS AND ANALYSIS: In this multicentre, randomised,
      parallel-controlled study, a total of 7140 hypertensive patients aged 45-75 years
      with GMD and low potassium will be randomised in a 1:1 manner to the control or
      the spironolactone group (20 mg/day or with a maximum dose of 40 mg). The primary
      objective is to estimate the difference in the HR of composite cardiovascular
      events between the two groups. We will also assess the effects of spironolactone 
      on individual cardiovascular events and the progression of diabetes and renal
      dysfunction. ETHICS AND DISSEMINATION: This protocol was approved by the
      Independent Ethics Committee of People's Hospital of Xinjiang Uygur Autonomous
      Region (no. 2020020618). The results will be disseminated in peer-reviewed
      journals and at scientific conferences. TRIAL REGISTRATION NUMBER:
      ChiCTR2000028909.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Nanfang
AU  - Li N
AUID- ORCID: 0000-0003-1505-8566
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China lnanfang2016@sina.com.
FAU - Lin, Mengyue
AU  - Lin M
AUID- ORCID: 0000-0002-0389-0331
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
AD  - Xinjiang Medical University, Urumqi, China.
FAU - Heizhati, Mulalibieke
AU  - Heizhati M
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
FAU - Wang, Lin
AU  - Wang L
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
AD  - Xinjiang Medical University, Urumqi, China.
FAU - Luo, Qin
AU  - Luo Q
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
FAU - Li, Yuanyuan
AU  - Li Y
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
FAU - Yili, Jina
AU  - Yili J
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
FAU - Hong, Jing
AU  - Hong J
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
FAU - Yao, Xiaoguang
AU  - Yao X
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
FAU - Zhu, Qing
AU  - Zhu Q
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region,
      Xinjiang Hypertension Institute, National Health Committee Key Laboratory of
      Hypertension Clinical Research, Urumqi, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 268B43MJ25 (Uric Acid)
RN  - 27O7W4T232 (Spironolactone)
SB  - IM
MH  - Aged
MH  - Female
MH  - *Glucose Metabolism Disorders/drug therapy
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Pragmatic Clinical Trials as Topic
MH  - Spironolactone/*adverse effects/*therapeutic use
MH  - Uric Acid
PMC - PMC7678363
OTO - NOTNLM
OT  - *cardiology
OT  - *clinical trials
OT  - *diabetes & endocrinology
OT  - *hypertension
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-038694 [pii]
AID - 10.1136/bmjopen-2020-038694 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e038694. doi: 10.1136/bmjopen-2020-038694.


PMID- 33444185
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Mental health recovery for survivors of modern slavery: grounded theory study
      protocol.
PG  - e038583
LID - 10.1136/bmjopen-2020-038583 [doi]
AB  - INTRODUCTION: Slavery and human trafficking are crimes involving the violation of
      human rights and refer to exploitative situations where an individual cannot
      refuse or leave due to threats, coercion or abuse of power. Activities involving 
      slavery include forced labour exploitation, forced sexual exploitation, forced
      marriage and servitude. Epidemiological studies show high levels of mental health
      need and poor provision of appropriate support for survivors. What mental health 
      recovery means to victims/survivors and how it could be promoted is
      under-researched. METHODS AND ANALYSIS: A grounded theory study based on
      individual interviews will be undertaken. Survivors across the UK will be
      identified and recruited from non-governmental organisations and via social
      media. As per grounded theory methodology, data collection and analysis will be
      undertaken concurrently and recruitment will continue until theoretical
      saturation is reached. It is anticipated that approximately 30 participants will 
      be recruited. Interviews will be audio recorded, transcribed verbatim and
      uploaded to NVivo V.11. The constant comparative method will be used to analyse
      the data, in order to produce a theoretical framework for mental health recovery 
      that is grounded in the experiences of survivors. ETHICS AND DISSEMINATION:
      Ethical approval has been obtained from the Faculty of Medicine and Health
      Sciences Ethics Committee at the University of Nottingham. The findings of the
      study will be disseminated to academic, professional and survivor-based audiences
      to inform future policy developments and the provision of mental health recovery 
      support to this population.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Wright, Nicola
AU  - Wright N
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK
      nicola.wright@nottingham.ac.uk.
FAU - Hadziosmanovic, Emina
AU  - Hadziosmanovic E
AUID- ORCID: 0000-0001-5154-0136
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK.
FAU - Dang, Minh
AU  - Dang M
AD  - School of Politics and International Relations, University of Nottingham,
      Nottingham, UK.
AD  - Survivor Alliance, Birmingham, UK.
FAU - Bales, Kevin
AU  - Bales K
AD  - School of Politics and International Relations, University of Nottingham,
      Nottingham, UK.
FAU - Brookes, Caroline
AU  - Brookes C
AD  - Emergency Preparedness Resilience & Response (EPRR), Nottinghamshire Healthcare
      NHS Foundation Trust, Nottingham, UK.
FAU - Jordan, Melanie
AU  - Jordan M
AD  - School of Sociology and Social Policy, University of Nottingham, Nottingham, UK.
FAU - Slade, Mike
AU  - Slade M
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK.
CN  - Lived Experience Research Advisory Board
LA  - eng
GR  - PB-PG-1217-20036/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Enslavement
MH  - Female
MH  - Grounded Theory
MH  - Humans
MH  - *Mental Health Recovery
MH  - Qualitative Research
MH  - Survivors
PMC - PMC7678374
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *anxiety disorders
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-038583 [pii]
AID - 10.1136/bmjopen-2020-038583 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e038583. doi: 10.1136/bmjopen-2020-038583.


PMID- 33444183
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Longitudinal study of symptom burden in outpatients with advanced cancers based
      on electronic Patient-Reported Outcome (ePRO) platform: a single institution,
      prospective study protocol.
PG  - e038223
LID - 10.1136/bmjopen-2020-038223 [doi]
AB  - INTRODUCTION: An electronic Patient-Reported Outcome (ePRO) platform is needed
      for implementing evidence-based symptom management in outpatients with advanced
      cancer. We describe the overall protocol and the methodology for measuring
      symptom burden, to provide critical parameters needed to implement symptom
      management on the ePRO platform. METHODS AND ANALYSIS: The study focusses on
      patients with advanced lung cancer, stomach cancer, oesophagus cancer, liver
      cancer, colorectal cancer or breast cancer. The primary outcome is the change of 
      symptom burden. MD Anderson Symptom Inventory, and other PRO instruments
      (Insomnia Severity Index, Hospital Anxiety and Depression Scale, 9-item Patient
      Health Questionnaire and EuroQol-5 dimensions-5 levels version) were used. The
      secondary outcomes include feasibility of using ePRO, symptom-related quality of 
      life, reasons for no improvement of symptoms, defining frequency of PRO
      assessments and cut-points, items for screening and management of comorbidity and
      satisfaction with ePRO platform in patients and health providers. After initial
      outpatient visit for baseline assessment, ePRO system will automatically send
      follow-up notification seven times over 4 weeks to patients. The characteristics 
      and changing trajectory of symptoms of patients will be described. Parameters for
      using PROs, such as optimal time points for follow-up and cut-off point for alert
      will be determined. The feasibility of ePRO platform to track the changes of
      target symptoms in outpatients will be evaluated. ETHICS AND DISSEMINATION: The
      study protocol and related documents were approved by the Institutional Research 
      Board (IRB) of Peking University Cancer Hospital on 13 February 2019 (2019YJZ07).
      The results of this study will be disseminated through academic workshops,
      peer-reviewed publications and conferences. TRIAL REGISTRATION NUMBER:
      ChiCTR1900023560.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tang, Lili
AU  - Tang L
AUID- ORCID: 0000-0003-1524-4617
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China tanglili_cpos@126.com.
FAU - Pang, Ying
AU  - Pang Y
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - He, Yi
AU  - He Y
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Shi, Qiuling
AU  - Shi Q
AD  - School of Public Health and Management, Chongqing Medical University, Chongqing, 
      Sichuan, China.
FAU - Han, Xinkun
AU  - Han X
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Li, Zimeng
AU  - Li Z
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Zhou, Chengcheng
AU  - Zhou C
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Zhou, Yuhe
AU  - Zhou Y
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - He, Shuangzhi
AU  - He S
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Zhang, Yening
AU  - Zhang Y
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Song, Lili
AU  - Song L
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Wang, Bingmei
AU  - Wang B
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
FAU - Li, Xiumin
AU  - Li X
AD  - Department of Psycho-Oncology, Peking University Cancer Hospital & Institute, Key
      laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Electronics
MH  - Humans
MH  - Longitudinal Studies
MH  - Neoplasms/therapy
MH  - *Outpatients
MH  - Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC7682447
OTO - NOTNLM
OT  - *adult oncology
OT  - *adult palliative care
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-038223 [pii]
AID - 10.1136/bmjopen-2020-038223 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e038223. doi: 10.1136/bmjopen-2020-038223.


PMID- 33444182
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Using nudges to promote physical activity and to reduce sedentary behaviour in
      the workplace: a scoping review protocol.
PG  - e038205
LID - 10.1136/bmjopen-2020-038205 [doi]
AB  - INTRODUCTION: Physical inactivity and sedentary behaviour are associated with
      numerous health problems and increasing risks of premature morbidity and
      mortality. Workplace health promotion with a focus on increasing physical
      activity (PA) and reducing sedentary behaviour is of growing interest. The
      concept of choice architecture with the use of nudges is a promising approach to 
      influence decision making regarding health behaviours. It can help to understand 
      why people often fail to act in their best interest, to follow well-informed
      preferences or to achieve their set goals. Nudges, the way the choice is
      presented, can help to overcome these challenges by using the same habits, biases
      or boundaries to alter our decision-making in favour of the more preferred
      behaviour. Aims of the scoping review will be to analyse (a) to what extent the
      concept of choice architecture is used in workplace health promotion to promote
      PA and/or to reduce sedentary behaviour and (b) which instruments (nudges) are
      used to archive that. METHODS AND ANALYSES: Medline, PsychInfo, Web of Science
      and CINHAL will be searched from 2009 until June 2020. Applying a two-level
      screening process, title and abstracts will be screened according to a set of
      predetermined inclusion and exclusion criteria. Included articles will be
      screened a second time to determine the extent to which choice architecture has
      been used. Analyses for publication year, location, setting and target group will
      be provided. Interventions will be analysed presenting the instruments used,
      number of studies per instrument, combinations of instruments and alteration of
      the environment. Outcome measures and results will be reported as they occur.
      ETHICS AND DISSEMINATION: Due to the nature of the scoping review, ethical
      concerns are minimal. No patient data will be included. Results are published in 
      peer-review journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Forberger, Sarah
AU  - Forberger S
AUID- ORCID: 0000-0002-7169-675X
AD  - Prevention and Evaluation, Leibniz Institute for Prevention Research and
      Epidemiology-BIPS, Bremen, Germany forberger@leibniz-bips.de.
FAU - Wichmann, Frauke
AU  - Wichmann F
AD  - Prevention and Evaluation, Leibniz Institute for Prevention Research and
      Epidemiology-BIPS, Bremen, Germany.
FAU - Comito, Chiara Nicoletta Nicoletta
AU  - Comito CNN
AUID- ORCID: 0000-0003-0487-6539
AD  - Faculty of Sport and Exercise Sciences, University of Rome 'Foro Italico', Roma, 
      Lazio, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Exercise
MH  - Habits
MH  - Health Promotion
MH  - Humans
MH  - *Sedentary Behavior
MH  - Workplace
PMC - PMC7678358
OTO - NOTNLM
OT  - *choice architecture
OT  - *nudges
OT  - *physical activity
OT  - *sedentary behaviour
OT  - *workplace health promotion
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-038205 [pii]
AID - 10.1136/bmjopen-2020-038205 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e038205. doi: 10.1136/bmjopen-2020-038205.


PMID- 33444178
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210831
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Protocol for the REPAT study: role of emotional processing in art therapy for
      breast cancer palliative care patients.
PG  - e037521
LID - 10.1136/bmjopen-2020-037521 [doi]
AB  - INTRODUCTION: Patients with breast cancer (BC) cope with depression which is
      linked to functional limitations in survivorship and to physical symptoms. Pain
      and fatigue are prominent symptoms that affect the well-being of cancer
      survivors. Emotional processing has been associated with improved physical and
      psychological health in survivors. Art therapy is a form of psychotherapy that
      involves the use of visual art-making for expression and communication. It
      encourages emotional processing and has been linked to symptom reduction in
      patients with cancer. This protocol is designed to examine two mechanistic
      changes: emotional processing (awareness, expression and acceptance) and
      cholinergic anti-inflammatory processes (heart rate variability and cytokine
      expression) through which an art therapy intervention may reduce depression, pain
      and fatigue. In addition, we will examine ethnocultural differences in the effect
      of art therapy in women from different ethnocultural backgrounds. METHODS AND
      ANALYSIS: A randomised controlled study with careful controls will randomise 240 
      patient with BC (50% Jewish and 50% Arab) to an 8-week group art therapy
      intervention or an 8-week Mandala colouring comparison group. This design will
      test the mechanisms of art therapy on the targeted outcomes beyond the effects of
      time with a group, focus on a task and engagement with art materials. We will
      examine two potential mechanisms: emotional processing and cholinergic
      anti-inflammatory processes; of the intervention effects on depression, pain and 
      fatigue and compare these effects in Arab versus Jewish women. ETHICS AND
      DISSEMINATION: Participants will sign informed consent before participation and
      will be informed that they can leave the study at any point in time without
      effect on their medical treatment. The Helsinki committees of each participating 
      hospital have approved the study. Data collected in this study will be published 
      in peer-review journals, and we will use the platform of the study website
      (http://repat.haifa.ac.il/en/) for further dissemination to the general public.
      TRIAL REGISTRATION NUMBER: The study is registered in ClinicalTrials.gov:
      NCT03377816; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Czamanski-Cohen, Johanna
AU  - Czamanski-Cohen J
AUID- ORCID: 0000-0003-3980-6848
AD  - School of Creative Arts Therapies, University of Haifa, Haifa, Israel
      joczamanski@gmail.com.
AD  - Emili Sagol Creative Arts Therapies Research Center, University of Haifa Faculty 
      of Social Welfare and Health Sciences, Haifa, Israel.
FAU - Wiley, Joshua
AU  - Wiley J
AD  - Turner Institute for Brain and Mental Health, School of Psychological Sciences,
      Monash University, Clayton, Victoria, Australia.
FAU - Weihs, K L
AU  - Weihs KL
AD  - The Department of Psychiatry College of Medicine, University of Arizona, Tucson, 
      Arizona, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03377816
GR  - R03 CA137975/CA/NCI NIH HHS/United States
GR  - R01 MH040859/MH/NIMH NIH HHS/United States
GR  - R01 CA133081/CA/NCI NIH HHS/United States
GR  - R01 MH073712/MH/NIMH NIH HHS/United States
GR  - R01 NR017186/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Art Therapy
MH  - *Breast Neoplasms/therapy
MH  - Emotions
MH  - Fatigue/therapy
MH  - Female
MH  - Humans
MH  - Palliative Care
PMC - PMC7678396
OTO - NOTNLM
OT  - *adult palliative care
OT  - *breast tumours
OT  - *cancer pain
OT  - *complementary medicine
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-037521 [pii]
AID - 10.1136/bmjopen-2020-037521 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e037521. doi: 10.1136/bmjopen-2020-037521.


PMID- 33444177
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES
      Trial): protocol of a prospective, multicentre observational trial.
PG  - e037267
LID - 10.1136/bmjopen-2020-037267 [doi]
AB  - INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with
      an overall 5-year survival of approximately 8%. The success in reducing the
      mortality rate of PDAC is related to the discovery of new therapeutic agents, and
      to a significant extent to the development of early detection and prevention
      programmes. Patients with new-onset diabetes mellitus (DM) represent a high-risk 
      group for PDAC as they have an eightfold higher risk of PDAC than the general
      population. The proposed screening programme may allow the detection of PDAC in
      the early, operable stage. Diagnosing more patients in the curable stage might
      decrease the morbidity and mortality rates of PDAC and additionally reduce the
      burden of the healthcare. METHODS AND ANALYSIS: This is a prospective,
      multicentre observational cohort study. Patients >/=60 years old diagnosed with
      new-onset (</=6 months) diabetes will be included. Exclusion criteria are (1)
      Continuous alcohol abuse; (2) Chronic pancreatitis; (3) Previous pancreas
      operation/pancreatectomy; (4) Pregnancy; (5) Present malignant disease and (6)
      Type 1 DM. Follow-up visits are scheduled every 6 months for up to 36 months.
      Data collection is based on questionnaires. Clinical symptoms, body weight and
      fasting blood will be collected at each, carbohydrate antigen 19-9 and blood to
      biobank at every second visit. The blood samples will be processed to plasma and 
      analysed with mass spectrometry (MS)-based metabolomics. The metabolomic data
      will be used for biomarker validation for early detection of PDAC in the
      high-risk group patients with new-onset diabetes. Patients with worrisome
      features will undergo MRI or endoscopic ultrasound investigation, and surgical
      referral depending on the radiological findings. One of the secondary end points 
      is the incidence of PDAC in patients with newly diagnosed DM. ETHICS AND
      DISSEMINATION: The study has been approved by the Scientific and Research Ethics 
      Committee of the Hungarian Medical Research Council (41085-6/2019). We plan to
      disseminate the results to several members of the healthcare system includining
      medical doctors, dietitians, nurses, patients and so on. We plan to publish the
      results in a peer-reviewed high-quality journal for professionals. In addition,
      we also plan to publish it for lay readers in order to maximalise the
      dissemination and benefits of this trial. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov NCT04164602.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Illes, Dora
AU  - Illes D
AUID- ORCID: 0000-0003-3138-8039
AD  - First Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
      Hungary.
FAU - Ivany, Emese
AU  - Ivany E
AD  - First Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
      Hungary.
FAU - Holzinger, Gabor
AU  - Holzinger G
AD  - First Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
      Hungary.
FAU - Kosar, Klara
AU  - Kosar K
AD  - First Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
      Hungary.
FAU - Adam, M Gordian
AU  - Adam MG
AD  - Tegeler Weg 33, 10589, Metanomics Health GmbH, Berlin, Germany.
FAU - Kamlage, Beate
AU  - Kamlage B
AD  - Tegeler Weg 33, 10589, Metanomics Health GmbH, Berlin, Germany.
FAU - Zsori, Gabor
AU  - Zsori G
AD  - First Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
      Hungary.
FAU - Tajti, Mate
AU  - Tajti M
AD  - First Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
      Hungary.
FAU - Svebis, Mark M
AU  - Svebis MM
AD  - Department of Internal Medicine, Semmelweis University of Medicine, Budapest,
      Hungary.
FAU - Horvath, Viktor
AU  - Horvath V
AD  - Department of Internal Medicine, Semmelweis University of Medicine, Budapest,
      Hungary.
FAU - Olah, Ilona
AU  - Olah I
AD  - Ilona Toth Outpatient Clinic, Budapest, Hungary.
FAU - Marta, Katalin
AU  - Marta K
AD  - Institute for Translational Medicine, University of Pecs Medical School, Pecs,
      Hungary.
AD  - Janos Szentagothai Research Center, University of Pecs, Pecs, Hungary.
FAU - Vancsa, Szilard
AU  - Vancsa S
AD  - Institute for Translational Medicine, University of Pecs Medical School, Pecs,
      Hungary.
AD  - Janos Szentagothai Research Center, University of Pecs, Pecs, Hungary.
FAU - Zadori, Noemi
AU  - Zadori N
AD  - Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos
      Orvostudomanyi Kar, Pecs, Hungary.
FAU - Szentesi, Andrea
AU  - Szentesi A
AD  - Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos
      Orvostudomanyi Kar, Pecs, Hungary.
AD  - MTA-SZTE Translational Gastroenterology Research Group, Szegedi Tudomanyegyetem, 
      Szeged, Hungary.
FAU - Czako, Balint
AU  - Czako B
AD  - Medical School, University of Szeged Faculty of Medicine, Szeged, Hungary.
FAU - Hegyi, Peter
AU  - Hegyi P
AUID- ORCID: 0000-0002-7035-941X
AD  - Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos
      Orvostudomanyi Kar, Pecs, Hungary.
FAU - Czako, Laszlo
AU  - Czako L
AUID- ORCID: 0000-0002-6331-0802
AD  - First Department of Medicine, University of Szeged, Szeged, Hungary
      czako.laszlo@med.u-szeged.hu.
LA  - eng
SI  - ClinicalTrials.gov/NCT04164602
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Carcinoma, Pancreatic Ductal/diagnosis
MH  - Diabetes Mellitus
MH  - Early Detection of Cancer
MH  - Humans
MH  - Hungary
MH  - Middle Aged
MH  - *Pancreatic Neoplasms/diagnosis
MH  - Prospective Studies
PMC - PMC7678370
OTO - NOTNLM
OT  - *general diabetes
OT  - *pancreatic disease
OT  - *preventive medicine
OT  - *protocols & guidelines
COIS- Competing interests: BK and AMG are employees of Metanomics Health GmbH, Germany.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-037267 [pii]
AID - 10.1136/bmjopen-2020-037267 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e037267. doi: 10.1136/bmjopen-2020-037267.


PMID- 33444176
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Characteristics and trends of clinical studies primarily sponsored by China in
      WHO primary registries between 2009 and 2018: a cross-sectional survey.
PG  - e037262
LID - 10.1136/bmjopen-2020-037262 [doi]
AB  - OBJECTIVES: To analyse characteristics and developmental trends of clinical study
      registration primarily sponsored by China's institutions during 2009-2018.
      SETTING: Registration information registered prior to 31 December 2018 was
      obtained from the International Clinical Trials Registry Platform (ICTRP) source 
      registries, including Chinese Clinical Trial Registry, ClinicalTrials.gov,
      Australian New Zealand Clinical Trials Registry and International Standard
      Randomised Controlled Trial Number. Registration information on other ICTRP
      source registries was collected from the ICTRP. DESIGN: A cross-sectional
      analysis was performed. The studies sponsored by mainland China's institutions
      (not including institutions in Hong Kong SAR, Macau SAR or Taiwan of China) as of
      31 December 2018 were filtered. For duplicate registrations, only the records
      with the earliest registration date were included. Global registrations were
      summarised for comparison. RESULTS: A total of 32 557 China-sponsored studies and
      478 261 global studies were included. The registered China-sponsored studies,
      increased from a cumulative number of 1333 in 2009 to 32 557 in 2018, were less
      likely to have industry involvement (14% vs 30%) and more likely to be registered
      prospectively (63% vs 45%) than the global registrations during 2009-2018. The
      top three most studied health conditions were lung cancer (4.2%), diabetes (3.8%)
      and ischaemic heart disease (3.2%). Depression and depressive disorders and
      chronic obstructive pulmonary disease (COPD) each represented 1.1% of registered 
      China-sponsored studies. Phase 2 and phase 3 trials together accounted for 30%,
      notably lower than the global level (53%). The registered studies responding to
      an individual participant data (IPD) sharing plan had increased since 2016, but
      the proportions of studies indicating 'yes' were still at a low level and
      accounted for 5% of the registered China-sponsored studies and global
      registrations. CONCLUSIONS: Clinical study registration activity in China has
      been substantial during 2009-2018. Some diseases with a high disease burden in
      China (depression and depressive disorders and COPD) were underrepresented by the
      proportion of registered studies. The accessibility of IPD merits improvement.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Yang
AU  - Xu Y
AUID- ORCID: 0000-0002-8897-3872
AD  - Huaxi Medical Journal Press, West China Hospital, Sichuan University, Chengdu,
      China.
FAU - Dong, Min
AU  - Dong M
AD  - Huaxi Medical Journal Press, West China Hospital, Sichuan University, Chengdu,
      China.
FAU - Liu, Xuemei
AU  - Liu X
AD  - Huaxi Medical Journal Press, West China Hospital, Sichuan University, Chengdu,
      China liuxuemei@wchscu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Trials as Topic
MH  - Cross-Sectional Studies
MH  - Databases, Factual
MH  - Humans
MH  - Registries
MH  - *World Health Organization
PMC - PMC7682458
OTO - NOTNLM
OT  - *health informatics
OT  - *health policy
OT  - *medical ethics
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-037262 [pii]
AID - 10.1136/bmjopen-2020-037262 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e037262. doi: 10.1136/bmjopen-2020-037262.


PMID- 33444175
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210616
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Protocol for an economic analysis of the randomised controlled trial of Improving
      the Well-being of people with Opioid Treated CHronic pain: I-WOTCH Study.
PG  - e037243
LID - 10.1136/bmjopen-2020-037243 [doi]
AB  - INTRODUCTION: Over the last two decades, the use of opioids for the treatment of 
      chronic pain in England has steadily increased despite lack of evidence of both
      long-term effectiveness in pain relief and significant, well-documented physical 
      and mental adverse events. Guidelines recommend tapering when harms outweigh
      benefits, but the addictive nature of opioids hinders simple dose-reduction
      strategies. Improving the Well-being of people with Opioid Treated CHronic pain
      (I-WOTCH) trial tests a multicomponent self-management intervention aimed to help
      patients with chronic non-malignant pain taper opioid doses. This paper outlines 
      the methods to be used for the economic analysis of the I-WOTCH intervention
      compared with the best usual care. METHODS AND ANALYSIS: Economic evaluation
      alongside the I-WOTCH study, prospectively designed to identify, measure and
      value key healthcare resource use and outcomes arising from the treatment
      strategies being compared. A within-trial cost-consequences analysis and a
      model-based long-term cost-effectiveness analysis will be conducted from the
      National Health Service and Personal Social Service perspective in England. The
      former will quantify key parameters to populate a Markov model designed to
      estimate the long-term cost and quality-adjusted life years of the I-WOTCH
      intervention against best usual care. Regression equations will be used to
      estimate parameters such as transition probabilities, utilities, and costs
      associated with the model's states and events. Probabilistic sensitivity analysis
      will be used to assess the impact of parameter uncertainty onto the predicted
      costs and health outcomes, and the resulting value for money assessment of the
      I-WOTCH intervention. ETHICS AND DISSEMINATION: Full ethics approval was granted 
      by Yorkshire & The Humber-South Yorkshire Research Ethics Committee on 13
      September 2016 (16/YH/0325). Current protocol: V.1.7, date 31 July 2019. Findings
      will be disseminated in peer-reviewed journals, scientific conferences,
      newsletters and websites. TRIAL REGISTRATION NUMBER: International Standard
      Randomised Controlled Trial Number (49 470 934); Pre-result.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Manchira Krishnan, Sheeja
AU  - Manchira Krishnan S
AUID- ORCID: 0000-0001-8574-695X
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Gc, Vijay Singh
AU  - Gc VS
AUID- ORCID: 0000-0003-0365-2605
AD  - Centre for Health Economics, University of York, York, UK.
FAU - Sandhu, Harbinder Kaur
AU  - Sandhu HK
AUID- ORCID: 0000-0003-1522-8078
AD  - Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick,
      Coventry, West Midlands, UK.
FAU - Underwood, Martin
AU  - Underwood M
AUID- ORCID: 0000-0002-0309-1708
AD  - Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick,
      Coventry, West Midlands, UK.
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
FAU - Eldabe, Sam
AU  - Eldabe S
AUID- ORCID: 0000-0002-9250-1886
AD  - Pain Department, James Cook University Hospital, Middlesbrough, UK.
FAU - Manca, Andrea
AU  - Manca A
AUID- ORCID: 0000-0001-8342-8421
AD  - Centre for Health Economics, University of York, York, UK.
FAU - Iglesias Urrutia, Cynthia P
AU  - Iglesias Urrutia CP
AUID- ORCID: 0000-0002-3426-0930
AD  - Department of Health Sciences, University of York, York, UK
      cynthia.iglesias@york.ac.uk.
AD  - Danish Center for Healthcare Improvements, Aalborg University, Aalborg, Denmark.
CN  - I-WOTCH team
LA  - eng
GR  - 14/224/04/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Activities of Daily Living
MH  - *Analgesics, Opioid
MH  - *Chronic Pain/drug therapy
MH  - Cost-Benefit Analysis
MH  - England
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
PMC - PMC7682467
OTO - NOTNLM
OT  - *health economics
OT  - *pain management
OT  - *protocols & guidelines
COIS- Competing interests: MU was the chair of the NICE accreditation advisory
      committee until March 2017 for which he received a fee. He is the chief
      investigator or co-investigator on multiple previous and current research grants 
      from the UK National Institute for Health Research, Arthritis Research UK, and is
      a co-investigator on grants funded by the Australian NHMRC. MU is an NIHR senior 
      investigator and has received travel expenses for speaking at conferences from
      the professional organisations hosting the conferences. He is a director and
      shareholder of Clinvivo that provides electronic data collection for health
      services research. MU is part of an academic partnership with Serco related to
      return to work initiatives. He is a co-investigator on a study receiving support 
      in kind from Stryker. MU has accepted honoraria for teaching/lecturing from the
      consortium for advanced research training in Africa. He is an editor of the NIHR 
      journal series, and a member of the NIHR Journal Editors Group, for which he
      receives a fee. SE is an investigator on number of NIHR and industry-sponsored
      studies. SE received travel expenses for speaking at conferences from the
      professional organisations organising these conferences. SE attended advisory
      boards and provided consultancy services for Medtronic, Abbott, Boston
      Scientific, and Mainstay Medical, none in relation to opioids. SE's department
      has received research funding from Medtronic. HS is the director of Health
      Psychology Services, providing psychological services for a range of
      health-related conditions. AM has received consultancy fees for participating in 
      Pharmaceutical and Medical Device Industry Advisory Boards in the area of
      musculoskeletal pain. AM is a member of the NICE Technology Appraisal Committee. 
      CPIU is a member of the NICE Medical Technologies Advisory Committee.
IR  - Sandhu HK
FIR - Sandhu, Harbinder Kaur
IR  - Eldabe S
FIR - Eldabe, Sam
IR  - Abraham C
FIR - Abraham, Charles
IR  - Alleyne S
FIR - Alleyne, Sharisse
IR  - Balasubramanian S
FIR - Balasubramanian, Shyam
IR  - Betteley L
FIR - Betteley, Lauren
IR  - Booth K
FIR - Booth, Katie
IR  - Carnes D
FIR - Carnes, Dawn
IR  - Furlan AD
FIR - Furlan, Andrea Dompieri
IR  - Haywood K
FIR - Haywood, Kirstie
IR  - Hill M
FIR - Hill, Maddy
IR  - Lall R
FIR - Lall, Ranjit
IR  - Manca A
FIR - Manca, Andrea
IR  - Mistry D
FIR - Mistry, Dipesh
IR  - Nichols V
FIR - Nichols, Vivien
IR  - Noyes J
FIR - Noyes, Jennifer
IR  - Rahman A
FIR - Rahman, Anisur
IR  - Seers K
FIR - Seers, Kate
IR  - Shaw J
FIR - Shaw, Jane
IR  - Tang N
FIR - Tang, Nicole
IR  - Taylor S
FIR - Taylor, Stephanie
IR  - Tysall C
FIR - Tysall, Colin
IR  - Underwood M
FIR - Underwood, Martin
IR  - Withers E
FIR - Withers, Emma
IR  - Urrutia C
FIR - Urrutia, Cynthia
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2020-037243 [pii]
AID - 10.1136/bmjopen-2020-037243 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e037243. doi: 10.1136/bmjopen-2020-037243.


PMID- 33444174
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Studying Accompaniment model Feasibility and Effectiveness (SAFE) Study: study
      protocol for a prospective observational cohort study of the effectiveness of
      self-managed medication abortion.
PG  - e036800
LID - 10.1136/bmjopen-2020-036800 [doi]
AB  - INTRODUCTION: A range of barriers deter or prevent people from accessing
      facility-based abortion care. As a result, people are obtaining and using
      abortifacient medications to end their pregnancies outside of the formal
      healthcare system, without clinical supervision. One model of self-managed
      abortion has come to be known as the 'accompaniment' model, in which grassroots
      organisations provide pregnant people with evidence-based counselling and support
      through the medication abortion process. Data are needed to understand the safety
      and effectiveness of this increasingly common model of abortion care. METHODS AND
      ANALYSIS: This is a large, prospective, observational study in Argentina and
      Nigeria. All people who contact one of two accompaniment groups seeking
      information for their own self-managed medication abortion, are ages 13 years and
      older, have no contraindications for medication abortion, are within the
      gestational range supported by the group (up to 12 weeks' gestation for the
      primary outcome) and are willing to be contacted for follow-up will be recruited.
      Participants will respond to an interviewer-administered baseline survey at
      enrolment, and 1-4 additional surveys over 6 weeks to ascertain whether they
      obtain medications for abortion, dosing and route of administration of
      medications, physical and emotional experience of medication abortion
      self-management, and effectiveness and safety outcomes. Analyses will include
      estimates of the primary outcome: the proportion of participants that report a
      complete abortion without surgical intervention at last recorded follow-up; as
      well as secondary outcomes including a pseudo-experimental test of
      non-inferiority of the effectiveness of self-managed medication abortion as
      compared with clinical medication abortion. ETHICS AND DISSEMINATION: We describe
      the ethical considerations and protections for this study, as well the creation
      of a study-specific Data Monitoring and Oversight Committee. We describe
      dissemination plans to ensure that study results are shared widely with all
      relevant audiences, particularly researchers, advocates, policymakers and
      clinicians. TRIAL REGISTRATION NUMBER: ISRCTN95769543.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Moseson, Heidi
AU  - Moseson H
AUID- ORCID: 0000-0002-2488-2429
AD  - Ibis Reproductive Health, Oakland, California, USA
      hmoseson@ibisreproductivehealth.org.
FAU - Keefe-Oates, Brianna
AU  - Keefe-Oates B
AD  - Ibis Reproductive Health, Cambridge, Massachusetts, USA.
FAU - Jayaweera, Ruvani T
AU  - Jayaweera RT
AD  - Ibis Reproductive Health, Oakland, California, USA.
FAU - Filippa, Sofia
AU  - Filippa S
AD  - Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
FAU - Motana, Relebohile
AU  - Motana R
AD  - Ibis Reproductive Health, Johannesburg, Gauteng, South Africa.
FAU - Bercu, Chiara
AU  - Bercu C
AD  - Ibis Reproductive Health, Oakland, California, USA.
FAU - Egwuatu, Ijeoma
AU  - Egwuatu I
AD  - Generation Initiative for Women and Youth Nigeria, Lagos, Nigeria.
FAU - Grosso, Belen
AU  - Grosso B
AD  - Colectiva Feminista La Revuelta, Neuquen, Argentina.
FAU - Kristianingrum, Ika Ayu
AU  - Kristianingrum IA
AD  - Samsara, Yogyakarta, Indonesia.
FAU - Nmezi, Sybil
AU  - Nmezi S
AD  - Generation Initiative for Women and Youth Nigeria, Lagos, Nigeria.
FAU - Zurbriggen, Ruth
AU  - Zurbriggen R
AD  - Colectiva Feminista La Revuelta, Neuquen, Argentina.
FAU - Friedman, Emmeline
AU  - Friedman E
AD  - Icahn School of Medicine at Mount Sinai, New York, New York, USA.
FAU - Gerdts, Caitlin
AU  - Gerdts C
AD  - Ibis Reproductive Health, Oakland, California, USA.
LA  - eng
SI  - ANZCTR/ISRCTN95769543
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Abortion, Induced
MH  - *Abortion, Spontaneous
MH  - Adolescent
MH  - Argentina
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Nigeria
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7678383
OTO - NOTNLM
OT  - *abortion
OT  - *accompaniment
OT  - *medication abortion
OT  - *mifepristone
OT  - *misoprostol
OT  - *self-managed abortion
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-036800 [pii]
AID - 10.1136/bmjopen-2020-036800 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e036800. doi: 10.1136/bmjopen-2020-036800.


PMID- 33444172
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Diagnostic accuracy of an app-guided, self-administered test for influenza among 
      individuals presenting to general practice with influenza-like illness: study
      protocol.
PG  - e036298
LID - 10.1136/bmjopen-2019-036298 [doi]
AB  - INTRODUCTION: Diagnostic tests for influenza in Australia are currently only
      authorised for use in clinical settings. At-home diagnostic testing for influenza
      could reduce the need for patient contact with healthcare services, which
      potentially could contribute to symptomatic improvement and reduced spread of
      influenza. We aim to determine the accuracy of an app-guided nasal self-swab
      combined with a lateral flow immunoassay for influenza conducted by individuals
      with influenza-like illness (ILI). METHODS AND ANALYSIS: Adults (>/=18 years)
      presenting with ILI will be recruited by general practitioners (GP) participating
      in Australian Sentinel Practices Research Network. Eligible participants will
      have a nasal swab obtained by their GP for verification of influenza A/B status
      using reverse transcription polymerase chain reaction (RT-PCR) test at an
      accredited laboratory. Participants will receive an influenza test kit and will
      download an app that collects self-reported symptoms and influenza risk factors, 
      then instructs them in obtaining a low-nasal self-swab, running a QuickVue
      influenza A+B lateral flow immunoassay (Quidel Corporation) and interpreting the 
      results. Participants will also interpret an enhanced image of the test strip in 
      the app. The primary outcome will be the accuracy of participants' test
      interpretation compared with the laboratory RT-PCR reference standard. Secondary 
      analyses will include accuracy of the enhanced test strip image, accuracy of an
      automatic test strip reader algorithm and validation of prediction rules for
      influenza based on self-reported symptoms. A post-test survey will be used to
      obtain participant feedback on self-test procedures. ETHICS AND DISSEMINATION:
      The study was approved by the Human Research and Ethic Committee (HREC) at the
      University of Adelaide (H-2019-116). Protocol details and any amendments will be 
      reported to https://www.tga.gov.au/. Results will be published in the
      peer-reviewed literature, and shared with stakeholders in the primary care and
      diagnostics communities. TRIAL REGISTRATION NUMBER: Australia New Zealand
      Clinical Trial Registry (U1111-1237-0688).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lyon, Victoria
AU  - Lyon V
AUID- ORCID: 0000-0001-5669-1099
AD  - Family Medicine, University of Washington, Seattle, Washington, USA vlyon@uw.edu.
FAU - Zigman Suchsland, Monica
AU  - Zigman Suchsland M
AUID- ORCID: 0000-0001-7007-6973
AD  - Family Medicine, University of Washington, Seattle, Washington, USA.
FAU - Chilver, Monique
AU  - Chilver M
AD  - Discipline of General Practice, University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - Stocks, Nigel
AU  - Stocks N
AUID- ORCID: 0000-0002-9018-0361
AD  - Discipline of General Practice, University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - Lutz, Barry
AU  - Lutz B
AD  - Bioengineering, University of Washington, Seattle, Washington, USA.
FAU - Su, Philip
AU  - Su P
AD  - Audere, Seattle, Washington, USA.
FAU - Cooper, Shawna
AU  - Cooper S
AD  - Audere, Seattle, Washington, USA.
FAU - Park, Chunjong
AU  - Park C
AD  - Computer Science, University of Washington, Seattle, Washington, USA.
FAU - Lavitt, Libby Rose
AU  - Lavitt LR
AD  - Computer Science, University of Washington, Seattle, Washington, USA.
FAU - Mariakakis, Alex
AU  - Mariakakis A
AD  - Computer Science, University of Washington, Seattle, Washington, USA.
FAU - Patel, Shwetak
AU  - Patel S
AD  - Computer Science, University of Washington, Seattle, Washington, USA.
FAU - Graham, Chelsey
AU  - Graham C
AD  - Brotman Bay Institute for Precision Medicine, University of Washington, Seattle, 
      Washington, USA.
FAU - Rieder, Mark
AU  - Rieder M
AD  - Brotman Bay Institute for Precision Medicine, University of Washington, Seattle, 
      Washington, USA.
FAU - LeRouge, Cynthia
AU  - LeRouge C
AD  - College of Business, Florida International University, Miami, Florida, USA.
FAU - Thompson, Matthew
AU  - Thompson M
AUID- ORCID: 0000-0003-0256-8444
AD  - Family Medicine, University of Washington, Seattle, Washington, USA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - *General Practice
MH  - Humans
MH  - Influenza Vaccines
MH  - *Influenza, Human/diagnosis
MH  - *Mobile Applications
MH  - Prospective Studies
MH  - Registries
PMC - PMC7678361
OTO - NOTNLM
OT  - *Infection control
OT  - *biotechnology & bioinformatics
OT  - *molecular diagnostics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2019-036298 [pii]
AID - 10.1136/bmjopen-2019-036298 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e036298. doi: 10.1136/bmjopen-2019-036298.


PMID- 33444169
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 20
TI  - Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth
      factor receptor-2 positive early breast cancer: protocol for a network
      meta-analysis of randomised controlled trials.
PG  - e035802
LID - 10.1136/bmjopen-2019-035802 [doi]
AB  - INTRODUCTION: Controversy regarding optimum duration of trastuzumab treatment
      remains in patients with human epidermal growth factor receptor-2 (HER2) positive
      early breast cancer. The objective of applying network meta-analysis (NMA) is to 
      integrate existing evidence based on direct and indirect comparisons of efficacy 
      and safety, and then to determine the duration of trastuzumab treatments with the
      greatest impact on therapeutic outcomes in HER2-positive early breast cancers.
      METHODS AND ANALYSIS: Electronic searching of trastuzumab treatments for early
      breast cancer by titles and abstracts will be conducted for the period from
      inception to 16 June 2019 in PubMed, Cochrane Library, Embase and
      ClinicalTrils.gov, as well as the annual meetings of San Antonio Breast Cancer
      Symposium (SABCS), European Society of Medical Oncology (ESMO) and American
      Society of Clinical Oncology (ASCO) online archives. The outcomes of interest are
      overall survival, disease-free survival, acceptability, cardiotoxicities and
      grade 3 to 4 non-haematological toxicities. Two independent reviewers will screen
      and extract eligible data based on the inclusion and exclusion criteria, and then
      assess the risk of bias and evidence quality of individual studies using Cochrane
      Collaboration's tool and Grades of Recommendation, Assessment, Development and
      Evaluation (GRADE). The heterogeneity, transitivity and inconsistency of NMA will
      be evaluated. In addition, we will perform subgroup and sensitivity analyses to
      assess the robustness and reliability of findings in our NMA. ETHICS AND
      DISSEMINATION: Ethics approval is not required for our NMA. Findings from our NMA
      will be submitted as peer-reviewed journal manuscripts and international
      conference reports. TRIAL REGISTRATION NUMBER: CRD42019139109.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hu, Qiancheng
AU  - Hu Q
AD  - Department of Abdominal Oncology, Cancer Center, Sichuan University West China
      Hospital, Chengdu, Sichuan, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Abdominal Oncology, Cancer Center, Sichuan University West China
      Hospital, Chengdu, Sichuan, China.
FAU - Chen, Ye
AU  - Chen Y
AD  - Department of Abdominal Oncology, Cancer Center, Sichuan University West China
      Hospital, Chengdu, Sichuan, China.
FAU - Li, Xiaofen
AU  - Li X
AD  - Department of Abdominal Oncology, Cancer Center, Sichuan University West China
      Hospital, Chengdu, Sichuan, China.
FAU - Luo, Ting
AU  - Luo T
AD  - Breast Medical Oncology, Clinical Research Center for Breast, Sichuan University 
      West China Hospital, Chengdu, Sichuan, China caodan316@163.com tina621@163.com.
FAU - Cao, Dan
AU  - Cao D
AUID- ORCID: 0000-0002-6709-4932
AD  - Department of Abdominal Oncology, Cancer Center, Sichuan University West China
      Hospital, Chengdu, Sichuan, China caodan316@163.com tina621@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Biosimilar Pharmaceuticals
MH  - *Breast Neoplasms/drug therapy
MH  - Chemotherapy, Adjuvant
MH  - ErbB Receptors
MH  - Humans
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - Trastuzumab/*therapeutic use
PMC - PMC7682472
OTO - NOTNLM
OT  - *breast tumours
OT  - *gene therapy
OT  - *pharmacology
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at http://www.icmje.org/coi_disclosure.pdf and stated that there is no
      organisation to support the submission; no organisation is interested in the
      submitted work; no other relationships or activities effect the submitted work.
EDAT- 2021/01/15 06:00
MHDA- 2021/03/20 06:00
CRDT- 2021/01/14 17:09
PHST- 2021/01/14 17:09 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - bmjopen-2019-035802 [pii]
AID - 10.1136/bmjopen-2019-035802 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 20;10(11):e035802. doi: 10.1136/bmjopen-2019-035802.


PMID- 33443759
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 0303-7339 (Print)
IS  - 0303-7339 (Linking)
VI  - 62
IP  - 12
DP  - 2020
TI  - [Autism spectrum disorder diagnosis in young children: a clinical-ethical study
      on the experiences of parents and physicians].
PG  - 1059-1066
AB  - BACKGROUND After decades of research and clinical experience, autism spectrum
      disorder (ASD) turns out to be heterogeneous in every sense, including phenotype 
      and etiology. How is this heterogeneous view translated in information that is
      useful and significant to parents and clinicians?<br/> AIM: To formulate
      recommendations with regard to clinical ASD care in young children.<br/> METHOD: 
      We conducted in-depth interviews on how parents (11 mothers and 6 fathers of 11
      children) and physicians (n = 16) view and experience a young child's ASD
      diagnosis. The interviews were analysed in Nvivo 11 according to the guidelines
      of interpretative phenomenological analysis.<br/> RESULTS: The interviewed
      parents and physicians addressed psycho-relational implications of an ASD
      diagnosis as much as treatment-oriented implications. Twelve months after their
      child got an ASD diagnosis, some disappointment regarding these implications led 
      parents to a pragmatic understanding of an ASD diagnosis.<br/> CONCLUSION: Our
      results may be useful to both clinicians and policy makers with regard to
      clinical ASD care in young children. An ASD diagnosis in itself may be of limited
      help to parents and clinicians but can be of use if it is embedded in a
      request-oriented diagnostic process guided by a communication model of shared
      decision making and aimed at elaborating a treatment-oriented profile of the
      child.
FAU - Jacobs, D
AU  - Jacobs D
FAU - Steyaert, J
AU  - Steyaert J
FAU - Dierickx, K
AU  - Dierickx K
FAU - Hens, K
AU  - Hens K
LA  - dut
PT  - Journal Article
TT  - Hoe ouders en hulpverleners een diagnose autismespectrumstoornis van een jong
      kind ervaren: een klinisch-ethische studie.
PL  - Netherlands
TA  - Tijdschr Psychiatr
JT  - Tijdschrift voor psychiatrie
JID - 0423731
SB  - IM
MH  - *Autism Spectrum Disorder/diagnosis
MH  - Child
MH  - Child, Preschool
MH  - Fathers
MH  - Female
MH  - Humans
MH  - Male
MH  - Mothers
MH  - Parents
MH  - *Physicians
EDAT- 2021/01/15 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/01/14 12:12
PHST- 2021/01/14 12:12 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - TVPart_12421 [pii]
PST - ppublish
SO  - Tijdschr Psychiatr. 2020;62(12):1059-1066.


PMID- 33443749
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 0303-7339 (Print)
IS  - 0303-7339 (Linking)
VI  - 62
IP  - 11
DP  - 2020
TI  - [You should exercise a bit more - The ethics of lifestyle and mental health].
PG  - 976-980
AB  - BACKGROUND: The fact that environmental factors and lifestyle play a role in
      mental health is well known. In the last decades more research has gone into the 
      link between environment and genetics: epigenetics has shown us the molecular
      link between these two, and the influence of the microbiome on mental health has 
      demonstrated the importance of food. Still, ethical questions remain about how
      lifestyle advice can be integrated in clinical practice in an ethical way.<br/>
      AIM: To describe the normative import of our view on biology and individual
      responsibility and the place of lifestyle in the debate.<br/> METHOD: A
      consideration of ethical aspects of lifestyle and lifestyle advice.<br/> RESULTS:
      The normative import of our view on biology and individual responsibility and the
      place of lifestyle in the debate is described. It is argued that lifestyle has a 
      unique place between biological and psychosocial concepts. Finally, the pitfalls 
      and opportunities of introducing lifestyle in clinical practice are shown.<br/>
      CONCLUSION: Lifestyle is conceptually situated between the biological and the
      psychosocial, and sheds new light on the importance of certain explanations for
      recovery, and the relation with specific treatments. Lifestyle advice can only be
      used optimally in therapy if mental health care professionals also include a
      dialogue about assumptions and expectations.
FAU - Hens, K
AU  - Hens K
LA  - dut
PT  - Journal Article
TT  - 'Je zou wat meer moeten sporten'; de ethiek van leefstijl en geestelijke
      gezondheid.
PL  - Netherlands
TA  - Tijdschr Psychiatr
JT  - Tijdschrift voor psychiatrie
JID - 0423731
SB  - IM
MH  - Health Personnel
MH  - Humans
MH  - *Life Style
MH  - *Mental Health
MH  - Morals
EDAT- 2021/01/15 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/01/14 12:12
PHST- 2021/01/14 12:12 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - TVPart_12417 [pii]
PST - ppublish
SO  - Tijdschr Psychiatr. 2020;62(11):976-980.


PMID- 33443118
OWN - NLM
STAT- Publisher
LR  - 20210114
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 21
TI  - Capturing and promoting the autonomy of capacitous vulnerable adults.
LID - medethics-2020-106835 [pii]
LID - 10.1136/medethics-2020-106835 [doi]
AB  - According to the High Court in England and Wales, the primary purpose of legal
      interventions into the lives of vulnerable adults with mental capacity should be 
      to allow the individuals concerned to regain their autonomy of decision-making.
      However, recent cases of clinical decision-making involving capacitous vulnerable
      adults have shown that, when it comes to medical law, medical ethics and clinical
      practice, vulnerability is typically conceived as opposed to autonomy. The first 
      aim of this paper is to detail the problems that arise when the courts and
      healthcare practitioners respond to the vulnerability of capacitous adults on the
      basis of such an opposition. It will be shown that not only does the common law
      approach to vulnerability fail to adequately capture the autonomy of capacitous
      vulnerable adults, the conception of vulnerability and autonomy in oppositional
      terms leads to objectionably paternalistic healthcare responses that undermine
      the autonomy of vulnerable patients as well as clinical and legal interventions
      that violate their autonomy. In response, the second aim of this paper is to show
      that the concepts of autonomy and vulnerability are necessarily entwined and, on 
      that basis, the focus should be on promoting the autonomy of capacitous
      vulnerable adults where possible In order to make this case, the paper explains
      the limitations of standard approaches to the autonomy of vulnerable adults and, 
      in their place, offers a conception of legitimate, self-authorised autonomy that 
      is fundamentally dependent on intersubjective practices of recognition.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Lewis, Jonathan
AU  - Lewis J
AUID- ORCID: http://orcid.org/0000-0001-8342-1051
AD  - Institute of Ethics, Dublin City University, Dublin, Ireland
      jonathan.lewis@dcu.ie.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - autonomy
OT  - capacity
OT  - decision-making
OT  - informed consent
OT  - legal aspects
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/01/15 06:00
CRDT- 2021/01/14 08:47
PHST- 2020/08/29 00:00 [received]
PHST- 2020/10/27 00:00 [revised]
PHST- 2020/11/21 00:00 [accepted]
PHST- 2021/01/14 08:47 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - medethics-2020-106835 [pii]
AID - 10.1136/medethics-2020-106835 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 21. pii: medethics-2020-106835. doi:
      10.1136/medethics-2020-106835.


PMID- 33443116
OWN - NLM
STAT- Publisher
LR  - 20210114
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 21
TI  - Conflicts of interest in clinical ethics consults.
LID - medethics-2020-106725 [pii]
LID - 10.1136/medethics-2020-106725 [doi]
AB  - Although there is wide agreement that ethics consults are at risk for conflicts
      of interest (COIs), ethics consultants (ECs) have limited guidance with regard to
      how to identify and approach COIs. We aim to address these concerns and provide
      practical guidance. We will define and consider four categories of COIs: consult 
      type, team composition, dual clinical roles and other concerns. We will define
      and consider six actions available for ECs to take in response to COIs: no
      action, disclosure only, obtaining a second opinion, referring to another EC,
      referring to an institutional ethics committee or seeking an outside consult. We 
      will then propose a points-based algorithm for ECs to use to determine the
      appropriate response to COI. Finally, we will discuss the strengths and
      limitations of our proposed algorithm.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Weiss, Elliott Mark
AU  - Weiss EM
AUID- ORCID: http://orcid.org/0000-0003-2473-9638
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle,
      Washington, USA emweiss@uw.edu.
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
FAU - Wightman, Aaron
AU  - Wightman A
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle,
      Washington, USA.
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
FAU - Webster, Laura
AU  - Webster L
AD  - Department of Hospital Consultative Services, Virginia Mason Medical Center,
      Seattle, Washington, USA.
AD  - Department of Bioethics and Humanities, University of Washington School of
      Medicine, Seattle, WA, USA.
FAU - Diekema, Douglas
AU  - Diekema D
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle,
      Washington, USA.
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - ethics committees/consultation
COIS- Competing interests: None declared.
EDAT- 2021/01/15 06:00
MHDA- 2021/01/15 06:00
CRDT- 2021/01/14 08:47
PHST- 2020/07/25 00:00 [received]
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/11/15 00:00 [accepted]
PHST- 2021/01/14 08:47 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - medethics-2020-106725 [pii]
AID - 10.1136/medethics-2020-106725 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 21. pii: medethics-2020-106725. doi:
      10.1136/medethics-2020-106725.


PMID- 33442468
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210115
IS  - 2045-452X (Print)
IS  - 2045-452X (Linking)
VI  - 9
IP  - 6
DP  - 2020 Dec
TI  - Justification for species selection for pharmaceutical toxicity studies.
PG  - 758-770
LID - 10.1093/toxres/tfaa081 [doi]
AB  - Toxicity studies using mammalian species are generally required to provide safety
      data to support clinical development and licencing registration for potential new
      pharmaceuticals. International regulatory guidelines outline recommendations for 
      the order (rodent and/or non-rodent) and number of species, retaining flexibility
      for development of a diverse range of drug modalities in a manner relevant for
      each specific new medicine. Selection of the appropriate toxicology species
      involves consideration of scientific, ethical and practical factors, with
      individual companies likely having different perspectives and preferences
      regarding weighting of various aspects dependent upon molecule characteristics
      and previous experience of specific targets or molecule classes. This article
      summarizes presentations from a symposium at the 2019 Annual Congress of the
      British Toxicology Society on the topic of species selection for pharmaceutical
      toxicity studies. This symposium included an overview of results from a National 
      Centre for the Replacement, Refinement and Reduction of Animals in Research
      (NC3Rs) and Association of British Pharmaceutical Industry (ABPI) international
      collaboration that reviewed the use of one or two species in regulatory
      toxicology studies and justification for the species selected within each
      programme. Perspectives from two pharmaceutical companies described their
      processes for species selection for evaluation of biologics, and justification
      for selection of the minipig as a toxicological species for small molecules. This
      article summarizes discussions on the scientific justification and other
      considerations taken into account to ensure the most appropriate animal species
      are used for toxicity studies to meet regulatory requirements and to provide the 
      most value for informing project decisions.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Prior, Helen
AU  - Prior H
AUID- ORCID: 0000-0002-8700-7226
AD  - National Centre for the Replacement, Refinement and Reduction of Animals in
      Research (NC3Rs), 215 Euston Rd, London, NW1 2BE, UK.
FAU - Haworth, Richard
AU  - Haworth R
AD  - GlaxoSmithKline R&D, Park Road, Ware, SG12 0DP, UK.
FAU - Labram, Briony
AU  - Labram B
AD  - National Centre for the Replacement, Refinement and Reduction of Animals in
      Research (NC3Rs), 215 Euston Rd, London, NW1 2BE, UK.
FAU - Roberts, Ruth
AU  - Roberts R
AUID- ORCID: 0000-0002-7763-7558
AD  - ApconiX, Alderley Park, Alderley Edge, SK10 4TG, UK.
FAU - Wolfreys, Alison
AU  - Wolfreys A
AD  - UCB Biopharma, Bath Rd, Slough, SL1 3WE, UK.
FAU - Sewell, Fiona
AU  - Sewell F
AD  - National Centre for the Replacement, Refinement and Reduction of Animals in
      Research (NC3Rs), 215 Euston Rd, London, NW1 2BE, UK.
LA  - eng
PT  - Journal Article
DEP - 20201124
PL  - England
TA  - Toxicol Res (Camb)
JT  - Toxicology research
JID - 101587950
PMC - PMC7786171
OTO - NOTNLM
OT  - 3Rs
OT  - dog
OT  - drug development
OT  - minipig
OT  - non-rodent
OT  - rat
OT  - rodent
OT  - safety assessment
OT  - toxicology
EDAT- 2021/01/15 06:00
MHDA- 2021/01/15 06:01
CRDT- 2021/01/14 05:47
PHST- 2020/08/17 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2021/01/14 05:47 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/01/15 06:01 [medline]
AID - 10.1093/toxres/tfaa081 [doi]
AID - tfaa081 [pii]
PST - epublish
SO  - Toxicol Res (Camb). 2020 Nov 24;9(6):758-770. doi: 10.1093/toxres/tfaa081.
      eCollection 2020 Dec.


PMID- 33442166
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210115
IS  - 0857-1074 (Print)
IS  - 0857-1074 (Linking)
VI  - 35
IP  - 1
DP  - 2020
TI  - Research in the Time of COVID-19: Challenges of Research Ethics Committees.
PG  - 29-32
LID - 10.15605/jafes.035.01.07 [doi]
AB  - Compliance with ethics guidelines for research are even more critical in the time
      of emergency public health situations such as a pandemic. Underpinned by the
      principles laid out in the 1979 Belmont report, conduct of research at any time
      should focus on respect for persons, beneficence and justice. Certain Standard
      Operating Procedures (SOPs) in research ethics committees may be revised to
      provide a quicker turn-around and timely review. Key elements in effective review
      of studies include rigorousness, responsiveness and timeliness. It is crucial to 
      recognize that ethics review committees share responsibility with researchers and
      its institutions, funding agencies and regulatory agencies for upholding ethical 
      principles in research at all times.
CI  - (c) 2020 Journal of the ASEAN Federation of Endocrine Societies.
FAU - Reyes, Marita
AU  - Reyes M
AD  - National Ethics Committee.
LA  - eng
PT  - Journal Article
DEP - 20200523
PL  - Thailand
TA  - J ASEAN Fed Endocr Soc
JT  - Journal of the ASEAN Federation of Endocrine Societies
JID - 8608483
PMC - PMC7784177
OTO - NOTNLM
OT  - ethical standards
OT  - ethics review
OT  - global health emergencies
OT  - health research
OT  - research ethics
EDAT- 2021/01/15 06:00
MHDA- 2021/01/15 06:01
CRDT- 2021/01/14 05:46
PHST- 2020/05/20 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2021/01/14 05:46 [entrez]
PHST- 2021/01/15 06:00 [pubmed]
PHST- 2021/01/15 06:01 [medline]
AID - 10.15605/jafes.035.01.07 [doi]
AID - JAFES-35-1-029 [pii]
PST - ppublish
SO  - J ASEAN Fed Endocr Soc. 2020;35(1):29-32. doi: 10.15605/jafes.035.01.07. Epub
      2020 May 23.


PMID- 33437878
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210114
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Informed consent for neonatal trials: practical points to consider and a check
      list.
PG  - e000847
LID - 10.1136/bmjpo-2020-000847 [doi]
AB  - Obtaining informed consent from parents of critically ill neonates can be
      challenging. The parental decision-making process is influenced by the severity
      of the child's condition, the benefit-risk balance, their emotional state and the
      quality of the relationship with the clinical team. Independent of local
      legislation, parents may prefer that consent is sought from both. Misconceptions 
      about the absence of risks or unrealistic expectations about benefits should be
      openly addressed to avoid misunderstandings which may harm the relationship with 
      the clinical team. Continuous consent can be sought where it is unclear whether
      the free choice of parental consent has been compromised. Obtaining informed
      consent is a dynamic process building on trusting relationships. It should
      include open and honest discussions about benefits and risks. Investigators may
      benefit from training in effective communication. Finally, involving parents in
      neonatal research including the development of the informed consent form and the 
      process of obtaining consent should be considered standard practice.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aurich, Beate
AU  - Aurich B
AUID- ORCID: 0000-0002-8830-023X
AD  - Department of Paediatric Clinical Pharmacology and Pharmacogenetics, Robert Debre
      Hospital, 48 Boulevard Serurier, Institut National de la Sante et de la Recherche
      Medicale (INSERM), Paris, France.
FAU - Vermeulen, Eric
AU  - Vermeulen E
AD  - Dutch patient association for rare and genetic diseases (VSOP), Soest, The
      Netherlands.
FAU - Elie, Valery
AU  - Elie V
AD  - Department of Paediatric Clinical Pharmacology and Pharmacogenetics, Robert Debre
      Hospital, 48 Boulevard Serurier, Institut National de la Sante et de la Recherche
      Medicale (INSERM), Paris, France.
FAU - Driessens, Mariette H E
AU  - Driessens MHE
AD  - Dutch patient association for rare and genetic diseases (VSOP), Soest, The
      Netherlands.
FAU - Kubiak, Christine
AU  - Kubiak C
AD  - The European Clinical Research Infrastructure Network (ECRIN), 5-7 Rue Watt,
      Paris, France.
FAU - Bonifazi, Donato
AU  - Bonifazi D
AD  - Consorzio per le Valutazioni Biologiche e Farmacologiche, Via Nicolo Putignani,
      Bari, Italy.
AD  - TEDDY European Network of Excellence for Paediatric Research, Via Luigi Porta 14,
      Pavia, Italy.
FAU - Jacqz-Aigrain, Evelyne
AU  - Jacqz-Aigrain E
AD  - Department of Paediatric Clinical Phramcology and Pharmacogenetics, Robert Debre 
      Hospital, APHP, 48 Boulevard Serurier, Paris, France.
AD  - Paris University, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201229
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7778778
OTO - NOTNLM
OT  - ethics
OT  - neonatology
COIS- Competing interests: BA has worked for GlaxoSmithKline between October 2006 and
      September 2009 and holds company shares. Between October 2009 and May 2015, she
      has worked for Novartis.
EDAT- 2021/01/14 06:00
MHDA- 2021/01/14 06:01
CRDT- 2021/01/13 06:13
PHST- 2020/08/20 00:00 [received]
PHST- 2020/11/23 00:00 [revised]
PHST- 2020/11/29 00:00 [accepted]
PHST- 2021/01/13 06:13 [entrez]
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/01/14 06:01 [medline]
AID - 10.1136/bmjpo-2020-000847 [doi]
AID - bmjpo-2020-000847 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Dec 29;4(1):e000847. doi: 10.1136/bmjpo-2020-000847.
      eCollection 2020.


PMID- 33437823
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 2305-5839 (Print)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 23
DP  - 2020 Dec
TI  - Sharing of decision-making for infective endocarditis surgery: a narrative review
      of clinical and ethical implications.
PG  - 1624
LID - 10.21037/atm-20-4626 [doi]
AB  - Infective endocarditis (IE) is nowadays one of the most challenging disease in
      cardiac surgery because of its multifaceted clinical and anatomical presentation.
      Despite the many clinical and surgical advances achieved in the past 60 years,
      there is a lack of evidence regarding the ideal strategy. The present review aims
      to investigate and highlight two main novel concepts for the decision-making of
      the best substitute. Firstly, the concept of an "endocarditis team": a
      coordinated multidisciplinary effort in the diagnostic work-up, especially in
      conditions of high risk of embolization or clinical deterioration. A good
      "endocarditis team" has the role to overcome such problem, in order to ensure a
      prompt and balanced strategy. Secondly, which ethical considerations are required
      to drive the choice of valvular substitute. The choice of best valve substitute
      is a relevant issue of debate, not only with operative but also prognostic and
      accordingly ethical aftermaths. Many different solutions have been developed to
      substitute the infected valve. Among these: mechanical prosthesis (MP),
      biological stented prosthesis (BP), sutureless bioprosthesis and cryopreserved
      homografts (CHs). Patients need to be informed in detail about the technical
      issues pertaining the use of these valve substitute. We will discuss the
      evidences regarding the risk of recurrent infections or future potentially severe
      calcification of aortic homograft valve and wall (in other words, the failure of 
      the homograft) and the difficulties in managing the reoperation.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Pollari, Francesco
AU  - Pollari F
AD  - Department of Cardiac Surgery, Klinikum Nurnberg-Paracelsus Medical University,
      Nuremberg, Germany.
FAU - Spadaccio, Cristiano
AU  - Spadaccio C
AD  - Department of Cardiac Surgery, Golden Jubilee National Hospital, Glasgow, UK.
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.
FAU - Cuomo, Michela
AU  - Cuomo M
AD  - Division of Pediatric Cardiac Surgery, University of Erlangen, Erlangen, Germany.
FAU - Chello, Massimo
AU  - Chello M
AD  - Department of Cardiovascular Surgery, University Campus Bio-Medico of Rome, Rome,
      Italy.
FAU - Nenna, Antonio
AU  - Nenna A
AD  - Department of Cardiovascular Surgery, University Campus Bio-Medico of Rome, Rome,
      Italy.
FAU - Fischlein, Theodor
AU  - Fischlein T
AD  - Department of Cardiac Surgery, Klinikum Nurnberg-Paracelsus Medical University,
      Nuremberg, Germany.
FAU - Nappi, Francesco
AU  - Nappi F
AD  - Department of Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis,
      Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7791252
OTO - NOTNLM
OT  - Multidisciplinary decision-making
OT  - aortic homograft
OT  - infective endocarditis (IE)
OT  - pulmonary autograft
OT  - structural valve deterioration (SVD)
COIS- Conflicts of Interest: The authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/atm-20-4626). The series "Infective
      Endocarditis in the 21st Century" was commissioned by the editorial office
      without any funding or sponsorship. FN served as the unpaid Guest Editor of the
      series and serves as an unpaid editorial board member of Annals of Translational 
      Medicine from Feb 2019 to Jan 2021. CS served as the unpaid Guest Editor of the
      series. Dr. TF reports other from LivaNova, outside the submitted work. The other
      authors have no conflicts of interest to declare.
EDAT- 2021/01/14 06:00
MHDA- 2021/01/14 06:01
CRDT- 2021/01/13 06:13
PHST- 2021/01/13 06:13 [entrez]
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/01/14 06:01 [medline]
AID - 10.21037/atm-20-4626 [doi]
AID - atm-08-23-1624 [pii]
PST - ppublish
SO  - Ann Transl Med. 2020 Dec;8(23):1624. doi: 10.21037/atm-20-4626.


PMID- 33437071
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 10
DP  - 2020 Oct
TI  - Comparison of effects of volume-controlled and pressure-controlled mode of
      ventilation on endotracheal cuff pressure and respiratory mechanics in
      laparoscopic cholecystectomies: A randomised controlled trial.
PG  - 842-848
LID - 10.4103/ija.IJA_949_19 [doi]
AB  - BACKGROUND AND AIMS: One of the pathophysiological consequences of
      pneumoperitoneum is variations in endotracheal cuff pressure (ETTc).
      Volume-controlled mode and pressure-controlled mode of ventilation being two
      modes of ventilatory strategies; we intended to find out variations in ETTc
      governed by respiratory mechanics between these two modes during laparoscopic
      cholecystectomies. METHODS: After obtaining ethics committee approval, this
      randomised (1:1), active-controlled, parallel-assigned study was done on 60
      patients undergoing laparoscopic cholecystectomies. These patients were allocated
      into two groups by computer-generated randomisation: Volume-controlled mode (V)
      and pressure-controlled mode (P). We observed for variations in ETTc which was
      the primary aim and haemodynamic parameters; respiratory mechanics at baseline
      (T1), at pneumoperitoneum (T2), after 10 min (T3), 20 min (T4) of
      pneumoperitoneum and at desufflation (T5). Post-operative laryngotracheal
      co-morbidities were also observed. Analysis was done using Statistical Package
      for the Social Sciences version 16.0 (IBM SPSS Statistics, Somers NY, USA).
      RESULTS: No statistically significant difference was found in both groups either 
      concerning ETTc, haemodynamic parameters or complications. In both groups, ETTc
      variation was statistically significant when compared from baseline to
      desufflation (T1 versus T5) and in group V additionally from baseline to time of 
      pneumoperitoneum (T1 versus T2). Group P showed lower peak airway pressure at
      desufflation and higher mean airway pressure throughout at all the time
      intervals. CONCLUSIONS: There is no variation in ETTc between the two modes.
      Group P appears to be better in terms of lower Ppeak and better Pmean.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Nethra, S S
AU  - Nethra SS
AD  - Department of Anaesthesia, Bangalore Medical College and Research Institute,
      Bengaluru, Karnataka, India.
FAU - Nagaraja, Swathi
AU  - Nagaraja S
AD  - Department of Anaesthesia, Bangalore Medical College and Research Institute,
      Bengaluru, Karnataka, India.
FAU - Sudheesh, K
AU  - Sudheesh K
AD  - Department of Anaesthesia, Bangalore Medical College and Research Institute,
      Bengaluru, Karnataka, India.
FAU - Duggappa, Devika Rani
AU  - Duggappa DR
AD  - Department of Anaesthesia, Bangalore Medical College and Research Institute,
      Bengaluru, Karnataka, India.
FAU - Sanket, Bhargavi
AU  - Sanket B
AD  - Department of Anaesthesia, Bangalore Medical College and Research Institute,
      Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7791417
OTO - NOTNLM
OT  - Endotracheal tube cuff pressure
OT  - laparoscopic surgery
OT  - respiratory mechanicsKey messages:
COIS- There are no conflicts of interest.
EDAT- 2021/01/14 06:00
MHDA- 2021/01/14 06:01
CRDT- 2021/01/13 06:11
PHST- 2019/12/29 00:00 [received]
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2021/01/13 06:11 [entrez]
PHST- 2021/01/14 06:00 [pubmed]
PHST- 2021/01/14 06:01 [medline]
AID - 10.4103/ija.IJA_949_19 [doi]
AID - IJA-64-842 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Oct;64(10):842-848. doi: 10.4103/ija.IJA_949_19. Epub 2020
      Oct 1.


PMID- 33427692
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 19
TI  - Containment of Antibiotic REsistance-measures to improve antibiotic use in
      pregnancy, childbirth and young children (CAREChild): a protocol of a
      prospective, quasiexperimental interventional study in Lao PDR.
PG  - e040334
LID - 10.1136/bmjopen-2020-040334 [doi]
AB  - INTRODUCTION: Antibiotics are essential to treat infections during pregnancy and 
      to reduce both maternal and infant mortality. Overall use, but especially
      non-indicated use, and misuse of antibiotics are drivers of antibiotic resistance
      (ABR). High non-indicated use of antibiotics for uncomplicated vaginal deliveries
      is widespread in many parts of the world. Similarly, irrational use of
      antibiotics is reported for children. There is scarcity of evidence regarding
      antibiotic use and ABR in Lao PDR (Laos). The overarching aim of this project is 
      to fill those knowledge gaps and to evaluate a quality improvement intervention. 
      The primary objective is to estimate the proportion of uncomplicated vaginal
      deliveries where antibiotics are used and to compare its trend before and after
      the intervention. METHODS AND ANALYSIS: This 3-year, prospective,
      quasiexperimental study without comparison group includes a formative and
      interventional phase. Data on antibiotic use during delivery will be collected
      from medical records. Knowledge, attitudes and reported practices on antibiotic
      use in pregnancy, during delivery and for children, will be collected from women 
      through questionnaires. Healthcare providers' knowledge, attitudes and practices 
      of antibiotics administration for pregnant women, during delivery and for
      children, will be collected via adapted questionnaires. Perceptions regarding
      antibiotics will be explored through focus group discussions with women and
      individual interviews with key stakeholders. Faecal samples for culturing of
      Escherichia coli and Klebsiella spp. and antibiotic susceptibility testing will
      be taken before, during and 6 months after delivery to determine colonisation of 
      resistant strains. The planned intervention will comprise training workshops,
      educational materials and social media campaign and will be evaluated using
      interrupted time series analysis. ETHICS AND DISSEMINATION: The project received 
      ethical approval from the National Ethics Committee for Health Research, Ministry
      of Health, Laos. The results will be disseminated via scientific publications,
      conference presentations and communication with stakeholders. TRAIL REGISTRATION 
      NUMBER: ISRCTN16217522; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Machowska, Anna
AU  - Machowska A
AUID- ORCID: 0000-0002-4675-2908
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden Anna.machowska@ki.se.
FAU - Sihavong, Amphoy
AU  - Sihavong A
AD  - Vientiane Capital Health Department, Lao Ministry of Health, Vientiane, Lao
      People's Democratic Republic.
FAU - Eriksen, Jaran
AU  - Eriksen J
AUID- ORCID: 0000-0003-1146-5615
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden.
AD  - Department of Infectious Diseases/Venhalsan, Stockholm South General Hospital,
      Stockholm, Sweden.
FAU - Vongsouvath, Manivanh
AU  - Vongsouvath M
AD  - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology
      Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.
FAU - Marrone, Gaetano
AU  - Marrone G
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden.
FAU - Sychareun, Vanphanom
AU  - Sychareun V
AD  - Faculty of Postgraduate Studies, Lao University of Health Sciences, Vientiane,
      Lao People's Democratic Republic.
FAU - Hanson, Claudia
AU  - Hanson C
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden.
FAU - Keohavong, Bounxou
AU  - Keohavong B
AD  - Food and Drug Department, Lao Ministry of Health, Vientiane, Lao People's
      Democratic Republic.
FAU - Brauner, Annelie
AU  - Brauner A
AD  - Department of Microbiology, Tumor and Cell Biology, Karolinska Institute,
      Stockholm, Sweden.
FAU - Mayxay, Mayfong
AU  - Mayxay M
AD  - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology
      Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.
AD  - Institute of Research and Education Development (IRED), Lao University of Health 
      Sciences, Vientiane, Lao People's Democratic Republic.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, United Kingdom.
FAU - Kounnavong, Sengchanh
AU  - Kounnavong S
AD  - Lao Tropical and Public Health Institute, Lao Ministry of Health, Vientiane, Lao 
      People's Democratic Republic.
FAU - Lundborg, Cecilia Stalsby
AU  - Lundborg CS
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden.
LA  - eng
SI  - ISRCTN/ISRCTN16217522
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - *Drug Resistance, Microbial
MH  - Female
MH  - Humans
MH  - Laos
MH  - Parturition
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7678367
OTO - NOTNLM
OT  - *gynaecology
OT  - *microbiology
OT  - *obstetrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/12 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/01/11 12:16
PHST- 2021/01/11 12:16 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - bmjopen-2020-040334 [pii]
AID - 10.1136/bmjopen-2020-040334 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 19;10(11):e040334. doi: 10.1136/bmjopen-2020-040334.


PMID- 33427418
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1728-2985 (Print)
IS  - 1728-2985 (Linking)
IP  - 6
DP  - 2020 Dec
TI  - [Flexible ureteroscopy for lower pole renal stones: novel superpulse thulium (TM)
      fiber laser lithotripsy].
PG  - 89-92
AB  - INTRODUCTION: The SuperPulse Thulium (Tm) fiber laser (wavelength of 1.94 m) has 
      been recently introduced as a directed-energy source for urology. Preclinical
      studies have shown a significant potential of the SuperPulse Tm fiber laser (SP
      TFL) for lithotripsy. However, clinical reports of using SP TFL to treat
      urolithiasis are still few and limited. Of special interest are challenging
      cases, e.g., lower pole stones, when extreme deflection of the instrument is
      required. OBJECTIVE: To evaluate the effectiveness of the SuperPulse Tm fiber
      laser in the management of lower pole small calyceal stones during flexible
      ureteroscopy (F-URS). METHOD: s. The SuperPulse Tm fiber laser device (Urolase 2,
      IRE Polus, Fryazino, Russia) has been cleared for clinical use by the Ministry of
      Health of Russian Federation. Study protocol has been approved by the Ethical
      Review Committee. Between January 2018 and February 2019, 130 patients with
      kidney stones have undergone Thulium fiber laser lithotripsy during F-URS. We
      retrospectively analyzed 15 of this patients with a single radiopaque lower pole 
      calculus that were included in the present study. Stone size, stone density,
      lithotripsy time (from the first to last footswitch press) and "lasering" (laser 
      emission) time were measured. The SP TFL was used for stone disintegration with
      different settings in dusting and fragmentation modes (0.1 - 4J, 7-300Hz, 6-40W) 
      via a fiber with a 200-m core diameter. Low dose CT scanning was performed on POD
      90 to assess SFR. RESULTS: Stone size ranged from 4 to 17 mm and stone density
      varied from 350 to 1459 HU. The average lithotripsy time was 12 min (3-30 min).
      The average "lasering" time was 1.3 min (0.4-2.5 min) and the mean hospital stay 
      was 1.1+/-0.3 days. In all cases we reached the lower pole stone containing calyx
      with a laser fiber. The complication rates were evaluated by using the
      Clavien-Dindo grading system and did not exceed GII (6.6%). SFR on POD 90 was
      achieved in 86.6% of cases. CONCLUSIONS: F-URS with SuperPulse Tm fiber laser is 
      safe and effective option in the management of lower pole small calyceal stones. 
      The possibility of using small laser fibers gives better instrument deflection
      which make possible to reach lower pole calyceal stones even with acute lower
      pole infundibulopelvic angle (IPA).
FAU - Rapoport, L M
AU  - Rapoport LM
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Gazimiev, M A
AU  - Gazimiev MA
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Korolev, D O
AU  - Korolev DO
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Tsarichenko, D G
AU  - Tsarichenko DG
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Svetikova, Y U A
AU  - Svetikova YUA
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Enikeev, M E
AU  - Enikeev ME
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Akopyan, G N
AU  - Akopyan GN
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Chinenov, D V
AU  - Chinenov DV
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Taratkin, M S
AU  - Taratkin MS
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
FAU - Enikeev, D V
AU  - Enikeev DV
AD  - Institute for Urology and Reproductive Health, Sechenov University, Moscow,
      Russia.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Urologiia
JT  - Urologiia (Moscow, Russia : 1999)
JID - 100900900
RN  - 8RKC5ATI4P (Thulium)
SB  - IM
MH  - Humans
MH  - *Kidney Calculi/therapy
MH  - *Lithotripsy
MH  - *Lithotripsy, Laser
MH  - Retrospective Studies
MH  - Russia
MH  - Thulium
MH  - Treatment Outcome
MH  - Ureteroscopy
OTO - NOTNLM
OT  - F-URS
OT  - flexible ureteroscopy
OT  - kidney stones
OT  - laser lithotripsy
OT  - lower pole stone
OT  - thulium fiber laser
OT  - urolithiasis
EDAT- 2021/01/12 06:00
MHDA- 2021/01/13 06:00
CRDT- 2021/01/11 08:44
PHST- 2021/01/11 08:44 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PST - ppublish
SO  - Urologiia. 2020 Dec;(6):89-92.


PMID- 33426996
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220531
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 37
IP  - 3
DP  - 2020 Dec
TI  - Clinical treatment of intra-epithelia cervical neoplasia with photodynamic
      therapy.
PG  - 50-58
LID - 10.1080/02656736.2020.1804077 [doi]
AB  - OBJECTIVES: This clinical study was developed to primarily evaluate the Complete 
      Cytopathological Response Rate of Cervical Intraepithelial Neoplasms to PDT using
      chitosan nanocapsules containing Chlorocyan-aluminum phthalocyanine as a
      photoactive agent. Analyses of the Free Recurrence Interval, toxicity profile
      (immediate and late), and complications (immediate and late), were secondarily
      analyzed. METHODS: This study was previously approved by the National Council of 
      Ethics in Research of Brazil (CONEP), on May 28, 2014, under case number
      19182113.4.0000.5009. On the surface of the cervix of each selected patient was
      applied one mL of the formulated gel, and after 30 min, the light was applied.
      Reports or the identification of adverse effects and/or complications were
      observed in follow-up visits, in addition to the collection of cervical oncotic
      cytology. RESULTS: Out of the total group, 11 (91.7%) primarily treated patients 
      evolved with negative cervical oncotic cytology as soon as in the first
      evaluation following treatment, and one did not achieve any therapeutic benefit, 
      even after reapplication. Two patients with initially positive response presented
      cytological recurrence determined by histopathology. A new round of PDT was
      developed, and both evolved with cytological remission three weeks later,
      remaining negative until the last follow-up. No important side effects were
      observed in all the patients. CONCLUSIONS: Our trial demonstrates that treatment 
      of CIN 1 and 2 lesions using our PDT formulation is feasible and safe. Large
      randomized clinical trials are required to establish efficacy.
FAU - Vendette, Antonio Carlos Figueiredo
AU  - Vendette ACF
AD  - Institute of Biological Science, University of Brasilia, Brasilia, Brazil.
FAU - Piva, Henrique Luis
AU  - Piva HL
AD  - Department of Chemistry, Center of Nanotechnology and Tissue Engineering -
      Photobiology and Photomedicine Research Group, Faculty of Philosophy, Science and
      Letters of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, Brazil.
FAU - Muehlmann, Luis Alexandre
AU  - Muehlmann LA
AD  - Laboratory of Nanoscience and Immunology, Faculty of Ceilandia, University of
      Brasilia, Brasilia, Brazil.
FAU - de Souza, Delfrank Ananias
AU  - de Souza DA
AD  - Acre State Oncology Control Center (CECON), Acre, Brazil.
FAU - Tedesco, Antonio Claudio
AU  - Tedesco AC
AD  - Department of Chemistry, Center of Nanotechnology and Tissue Engineering -
      Photobiology and Photomedicine Research Group, Faculty of Philosophy, Science and
      Letters of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, Brazil.
FAU - Azevedo, Ricardo Bentes
AU  - Azevedo RB
AUID- ORCID: 0000-0002-2137-9588
AD  - Institute of Biological Science, University of Brasilia, Brasilia, Brazil.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
SB  - IM
MH  - *Cervical Intraepithelial Neoplasia
MH  - Female
MH  - Humans
MH  - Neoplasm Recurrence, Local
MH  - *Papillomavirus Infections
MH  - *Photochemotherapy
MH  - *Uterine Cervical Neoplasms/drug therapy
OTO - NOTNLM
OT  - *PDT
OT  - *cancer
OT  - *cervical neoplasia
OT  - *chitosan nanocapsules
OT  - *clinical trial
EDAT- 2021/01/12 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/01/11 08:41
PHST- 2021/01/11 08:41 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1080/02656736.2020.1804077 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2020 Dec;37(3):50-58. doi: 10.1080/02656736.2020.1804077.


PMID- 33426482
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2575-7873 (Electronic)
IS  - 2575-7873 (Linking)
VI  - 4
DP  - 2020
TI  - Association Between Family Medicine Residents' Mindsets and In-Training Exam
      Scores.
PG  - 33
LID - 10.22454/PRiMER.2020.796230 [doi]
AB  - INTRODUCTION: In medical practice, a mastery mindset is important for engaging in
      lifelong learning. The objective of this study was to examine the association
      between family medicine residents' scores on mindset measures and their
      performance on in-training examinations (ITE). METHODS: This was a secondary data
      analysis of a cohort of family medicine residents. Following ethics approval,
      residents' ITE scores from each of the 2 years of residency were linked with
      residents' responses to a mindsets survey that they had taken at the midpoint of 
      residency training. Multiple regression analysis was used to investigate the
      relationship between residents' mindset scores and their ITE scores. Of 85
      residents, 46 (54%) had complete data for the three data collection points.
      RESULTS: Residents' ITE scores in year 1 were most predictive of their ITE scores
      in year 2 (beta=0.72; P<.001). Mastery mindset scores were negatively associated 
      with residents' performance on the ITE in year 2 (beta=-0.29; P=.004).
      CONCLUSION: While the observed negative relationship between residents' mastery
      mindset scores and their ITE performance may be disconcerting, it is not
      surprising. In clinical settings, residents are individually coached by
      preceptors and provided with specific, actionable feedback to support their
      learning. With respect to formative assessments, residents likely require
      explicit training on how to use their assessment results (ITE scores) to support 
      their self-directed learning. This finding has practical implications for
      residency programs in using ITEs as formative assessments.
CI  - (c) 2021 by the Society of Teachers of Family Medicine.
FAU - Sloychuk, Janelle
AU  - Sloychuk J
AD  - Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
FAU - Szafran, Olga
AU  - Szafran O
AD  - Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
FAU - Duerksen, Kimberley
AU  - Duerksen K
AD  - Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
FAU - Babenko, Oksana
AU  - Babenko O
AD  - Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - United States
TA  - PRiMER
JT  - PRiMER (Leawood, Kan.)
JID - 101726396
PMC - PMC7789880
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:44
PHST- 2021/01/11 05:44 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.22454/PRiMER.2020.796230 [doi]
AID - primer-4-33 [pii]
PST - epublish
SO  - PRiMER. 2020 Nov 2;4:33. doi: 10.22454/PRiMER.2020.796230. eCollection 2020.


PMID- 33426130
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Academic procrastination and self-efficacy among a group of dental undergraduate 
      students in Malaysia.
PG  - 326
LID - 10.4103/jehp.jehp_195_20 [doi]
AB  - BACKGROUND: Undergraduate dental students have to do multiple tasks as part of
      their extensive curriculum in order to achieve the proficiencies expected of
      them. During the course of their study, a tendency to procrastinate and question 
      their self-efficacy is detrimental for the students. The aim of this study was to
      evaluate the level of procrastination and self-efficacy and its related factors
      among dental undergraduate students. SUBJECTS AND METHODS: This cross-sectional
      study was conducted among all (n = 361) consented dental undergraduate students
      of our dental school. A twenty-item Lay's Procrastination Scale for student
      population and a ten-item General Self-Efficacy Scale were used for the study
      after getting institutional ethical approval. The quantitative data were
      explained using descriptive statistics. Independent sample t-test and ANOVA were 
      used to determine the association between self-efficacy, academic
      procrastination, and genders and academic years. Pearson correlation coefficient 
      was used to determine the association between self-efficacy and procrastination. 
      Multiple linear regression analysis was performed to determine the related
      factors to academic procrastination. RESULTS: High procrastination (score >/=62) 
      was seen among 28.5% of students. The mean self-efficacy score was 29.5. There
      was no significant difference between genders for procrastination scores (P =
      0.835) and between academic years (P = 0.226). Males showed significantly more
      self-efficacy (P < 0.001), and self-efficacy did not show any significant
      difference (P = 0.204) between academic years though a tendency for year 5
      students to have lower self-efficacy scores was observed. Academic
      procrastination was negatively correlated with self-efficacy (r = -0.238 and P < 
      0.001). CONCLUSIONS: For dental undergraduates who have cognitive load as well as
      work associated with patients, procrastination and self-efficacy are negatively
      correlated.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Uma, Eswara
AU  - Uma E
AD  - Department of Pediatric Dentistry, Faculty of Dentistry, Melaka Manipal Medical
      College, MAHE, Manipal, Melaka, Malaysia.
FAU - Lee, Chia Hua
AU  - Lee CH
AD  - Former Undergraduate Student, Faculty of Dentistry, Melaka Manipal Medical
      College, MAHE, Manipal, Melaka, Malaysia.
FAU - Shapiai, Siti Nor Hidayu Binti Mohd
AU  - Shapiai SNHBM
AD  - Former Undergraduate Student, Faculty of Dentistry, Melaka Manipal Medical
      College, MAHE, Manipal, Melaka, Malaysia.
FAU - Binti Mat Nor, Anis Nabila
AU  - Binti Mat Nor AN
AD  - Former Undergraduate Student, Faculty of Dentistry, Melaka Manipal Medical
      College, MAHE, Manipal, Melaka, Malaysia.
FAU - Soe, Htoo Htoo Kyaw
AU  - Soe HHK
AD  - Department of Community Medicine, Faculty of Medicine, Research Methodology and
      Biostatistics Unit, Melaka Manipal Medical College, MAHE, Melaka, Malaysia.
FAU - Varghese, Eby
AU  - Varghese E
AD  - Department of Pediatric Dentistry, Faculty of Dentistry, Melaka Manipal Medical
      College, MAHE, Manipal, Melaka, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7774631
OTO - NOTNLM
OT  - Dental students
OT  - procrastination
OT  - self-efficacy
OT  - undergraduates
COIS- There are no conflicts of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:43
PHST- 2020/03/05 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2021/01/11 05:43 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.4103/jehp.jehp_195_20 [doi]
AID - JEHP-9-326 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Nov 26;9:326. doi: 10.4103/jehp.jehp_195_20.
      eCollection 2020.


PMID- 33426112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Designing a truth-based communication model in patient ethical care process.
PG  - 308
LID - 10.4103/jehp.jehp_405_20 [doi]
AB  - INTRODUCTION: Providing information based on truth is very important in patients'
      treatment-related decisions and reduces emotional and physical sufferings as well
      as patient costs. The aim of this study was to design a model that is based on
      the culture and health-care context of Iran in order to establish a truth-based
      communication and provide accurate information to patient. MATERIALS AND METHODS:
      This qualitative study was conducted in 2019. Data were collected through
      semi-structured interviews with 18 nurses who had been selected by purposeful
      sampling method. Data analysis was performed in two steps. In the first step, the
      participants' experiences were determined using the grounded theory approach. In 
      the next step, using Walker and Evant's (2011) method, the concepts and
      statements were combined and presented in a central concept. RESULTS: The central
      concept in this study was "an attempt to establish a truth-based communication
      with patient," and then, a truth-based communication model was presented. The
      components of the model were presented in three parts: improving patient
      communication skills, managing the situation in which the truth is presented, and
      the patient's participation in decision-making. CONCLUSION: To present the truth 
      of the treatment, which can sometimes be unpleasant and bitter, it is very
      important to improve communication skills and choose an effective communication
      strategy. To establish a truth-based communication, it is necessary to create a
      suitable ground for communication, which should be provided in clinical setting
      and community.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Nasrabadi, Alireza Nikbakht
AU  - Nasrabadi AN
AD  - Department of Medical Surgical Nursing and, School of Nursing and Midwifery,
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Joolaee, Soodabeh
AU  - Joolaee S
AD  - Center of Health Evaluation and Outcome Sciences, Vancouver, BC, Canada.
AD  - Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
FAU - Navab, Elham
AU  - Navab E
AD  - Department of Critical Care Nursing and Management, School of Nursing and
      Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Esmaeilie, Maryam
AU  - Esmaeilie M
AD  - Department of Critical Care Nursing and Management, Nursing Care Research Center,
      School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran,
      Iran.
FAU - Shali, Mahboobeh
AU  - Shali M
AD  - Department of Critical Care Nursing and Management, School of Nursing and
      Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sheikhzakaryaee, Neda
AU  - Sheikhzakaryaee N
AD  - Department of Pediatric Nursing, School of Nursing and Midwifery, Kurdistan
      University of Medical Sciences, Sanandaj, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7774625
OTO - NOTNLM
OT  - Care
OT  - ethics
OT  - grounded theory
OT  - model
OT  - truth-telling
COIS- There are no conflicts of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:43
PHST- 2020/04/25 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2021/01/11 05:43 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.4103/jehp.jehp_405_20 [doi]
AID - JEHP-9-308 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Nov 26;9:308. doi: 10.4103/jehp.jehp_405_20.
      eCollection 2020.


PMID- 33425952
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader
      Cooperation Between the Pharmaceutical Industry and Society.
PG  - 608249
LID - 10.3389/fmed.2020.608249 [doi]
AB  - Gene therapy orphan medicinal products constitute a unique group of new drugs
      which in case of hereditary diseases are usually administered only once at an
      early age, in the hope to provide sufficient gene product to last for the entire 
      life of the patients. The combination of an exceptionally large single payment
      and the life-long clinical follow-up needed for understanding the long-term
      benefits and safety of gene therapy, represent new types of scientific,
      financial, social and ethical challenges for the pharmaceutical industry,
      regulators and society. With special consideration of the uniqueness and
      importance of gene therapy, the authors propose a three points plan for a close
      cooperation between the pharmaceutical industry and society to develop orphan
      gene therapy. (1) In fully transparent health technology negotiations a close and
      long-lasting, contractually fixed cooperation should be established between the
      manufacturers and local health-care stakeholders for sharing the medical and
      scientific benefits, the financial risks as well as the burdens of the
      post-authorization clinical and regulatory development. (2) The parties should
      agree on a fair, locally affordable drug price without the usually very high
      premium price calculated to compensate for the low number of patients. In case of
      high manufacturing costs, the companies should offer prolonged, 15-20 years long 
      payment by installment with risk-sharing, especially considering that the late
      outcome of the treatment is unknown. Society should assist scientifically and
      financially organizing a specific patient registry, treatment in specialized
      hospitals and adequate long-term follow-up of patients, the coordinated
      management of financial transactions related to the risk sharing program. (3) The
      post-authorization treatment and prolonged observation of additional new cases
      coordinated by society should provide real world data needed for the modern
      complex regulatory evaluation of gene therapy products by the competent
      authorities. We assume that fair sharing of the benefits and risks as well as a
      well-organized cooperation of society with the industry in collecting real world 
      evidence might result in better drug evaluation and improved accessibility due to
      lower prices. The outlined concept might support gene therapy more efficiently
      than the presently requested outstandingly high prices.
CI  - Copyright (c) 2020 Kerpel-Fronius, Baroutsou, Becker, Carlesi, Collia,
      Franke-Bray, Kleist, Kurihara, Laranjeira, Matsuyama, Naseem, Schenk and Silva.
FAU - Kerpel-Fronius, Sandor
AU  - Kerpel-Fronius S
AD  - Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, 
      Hungary.
FAU - Baroutsou, Varvara
AU  - Baroutsou V
AD  - Independent Medical Consultant & Pharmaceutical Medicine Consultant, Athens,
      Greece.
FAU - Becker, Sander
AU  - Becker S
AD  - Consultants in Pharmaceutical Medicine, Dover Heights, NSW, Australia.
FAU - Carlesi, Roberto
AU  - Carlesi R
AD  - Independent Researcher, Bellagio, Italy.
FAU - Collia, Luis
AU  - Collia L
AD  - Craveri Pharma, Buenos Aires, Argentina.
FAU - Franke-Bray, Brigitte
AU  - Franke-Bray B
AD  - Independent Consultant, Basel, Switzerland.
FAU - Kleist, Peter
AU  - Kleist P
AD  - Cantonal Ethics Committee, Zurich, Switzerland.
FAU - Kurihara, Chieko
AU  - Kurihara C
AD  - Quality Assurance and Audit Office, Quantum Medical Science Directorate, National
      Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
FAU - Laranjeira, Luis Filipe
AU  - Laranjeira LF
AD  - Eli Lilly & Co., Lisbon, Portugal.
FAU - Matsuyama, Kotone
AU  - Matsuyama K
AD  - Nippon Medical School, Tokyo, Japan.
FAU - Naseem, Shehla
AU  - Naseem S
AD  - Ferozsons Laboratories Ltd., Karachi, Pakistan.
FAU - Schenk, Johanna
AU  - Schenk J
AD  - PPH Plus GmbH & Co. KG, Hochheim am Main, Germany.
FAU - Silva, Honorio
AU  - Silva H
AD  - IFAPP Academy, New York, NY, United States.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7785873
OTO - NOTNLM
OT  - accelerated approval
OT  - drug pricing
OT  - ethics
OT  - gene therapy
OT  - health care
OT  - orphan drugs
OT  - rare diseases
OT  - spinal muscular atrophy
COIS- LL was employed by Eli Lilly & Co. LC was employed by Craveri Pharma. SN was
      employed by Ferozsons Laboratories Ltd. JS was employed by PPH plus GmbH & Co.
      KG. BF-B is a consultant affiliated with IFAPP and IFAPP Academy. The remaining
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of
      interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:42
PHST- 2020/09/19 00:00 [received]
PHST- 2020/12/02 00:00 [accepted]
PHST- 2021/01/11 05:42 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fmed.2020.608249 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Dec 23;7:608249. doi: 10.3389/fmed.2020.608249.
      eCollection 2020.


PMID- 33425945
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Obstacles and Considerations Related to Clinical Trial Research During the
      COVID-19 Pandemic.
PG  - 598038
LID - 10.3389/fmed.2020.598038 [doi]
AB  - The response to the COVID-19 pandemic from the research and science community has
      been vigorous, with information being released faster than that of any other
      event in human history. Articles related to the virus were being rapidly
      published by January 2020. A small fraction of these publications comprised
      reports of prospective clinical trials (0.25%), and many of these trials have
      imparted conflicting conclusions, leading to confusion among the public and the
      scientific community. Additionally, the pandemic has raised many serious
      scientific and ethical concerns related to clinical research. In this review, we 
      divided the conduct of clinical research trials into three steps and critically
      reviewed each step, along with the challenges and obstacles arising amid the
      ongoing crisis. The clinical research steps we reviewed include (1) clinical
      trial design factors such as social and scientific value, feasibility, single vs.
      multicenter trials, randomization, control groups, endpoints, off-label and
      compassionate use of medications, data analysis, and verifying the integrity of
      data; (2) ethical issues such as committee approvals, efficiency, virtual visits 
      and remote monitoring, informed consent, shipping investigational products, and
      external monitoring and audits; and (3) publication and sharing of preprints,
      press releases, social media, and misinformation. The COVID-19 pandemic is
      adversely affecting existing clinical trials for other ailments and diseases,
      including cancer, with most trials being delayed or deferred. Although urgency is
      needed to communicate effective treatment and prevention strategies for COVID-19,
      research efforts should maintain the same high-quality core ethical principles
      that governed human subject research before the pandemic. Despite the
      catastrophic devastation caused by the pandemic, the adoption of more flexible,
      cost-effective methods of conducting clinical trials (without compromising
      ethical conduct, safety, or data integrity, while maintaining research
      efficiency) represents a potential silver lining. Streamlining clinical research 
      will help to congruently address other important health issues, despite the
      ongoing COVID-19 crisis.
CI  - Copyright (c) 2020 Hashem, Abufaraj, Tbakhi and Sultan.
FAU - Hashem, Hasan
AU  - Hashem H
AD  - Division of Pediatric Hematology Oncology, Department of Pediatrics, King Hussein
      Cancer Center (KHCC), Amman, Jordan.
FAU - Abufaraj, Mohammad
AU  - Abufaraj M
AD  - Division of Urology, Department of Special Surgery, Jordan University Hospital,
      Amman, Jordan.
FAU - Tbakhi, Abdelghani
AU  - Tbakhi A
AD  - Department of Cellular Therapy and Applied Genomics, King Hussein Cancer Center
      (KHCC), Amman, Jordan.
FAU - Sultan, Iyad
AU  - Sultan I
AD  - Division of Pediatric Hematology Oncology, Department of Pediatrics, King Hussein
      Cancer Center (KHCC), Amman, Jordan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201223
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7785796
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - clinical research
OT  - clinical trials
OT  - ethics
OT  - misinformation
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:42
PHST- 2020/08/23 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2021/01/11 05:42 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fmed.2020.598038 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Dec 23;7:598038. doi: 10.3389/fmed.2020.598038.
      eCollection 2020.


PMID- 33425755
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Cancer During Pregnancy: How to Handle the Bioethical Dilemmas?-A Scoping Review 
      With Paradigmatic Cases-Based Analysis.
PG  - 598508
LID - 10.3389/fonc.2020.598508 [doi]
AB  - Ethical issues that arise during the care of a pregnant woman with cancer are
      challenging to physicians, policymakers, lawyers, and the bioethics community.
      The main purpose of this scoping review is to summarize existing literature
      regarding the bioethical dilemmas when a conflict arises in the maternal-fetus
      dyad, like the one related to cancer and pregnancy outcomes. Moreover, we
      illustrate the decision-making process of real-life case reports. Published data 
      were searched through the PubMed and Google Scholar databases, as well as in grey
      literature, using appropriate controlled keywords in English and Portuguese.
      After identification, screening, eligibility and data extraction from the
      articles, a total of 50 was selected. There are several established ethical
      frameworks for conflict resolution and decision-making. Pragmatic theoretical
      approaches include case-based analysis, the ethics of care, feminist theory, and 
      traditional ethical principlism that scrutinizes the framework of autonomy,
      justice, beneficence, and non-maleficence. In addition, society and practitioner 
      values could mediate this complex ethical interplay. The physician must balance
      autonomy and beneficence-based obligations to the pregnant woman with cancer,
      along with beneficence-based obligations to the fetus. Ethical challenges have
      received less attention in the literature, particularly before the third
      trimester of pregnancy. Best, unbiased and balanced information must be granted
      both to the patient and to the family, regarding the benefits and harms for the
      woman herself as well as for the fetal outcome. Based on a previously validated
      method for analyzing and working up clinical ethical problems, we suggest an
      adaptation of an algorithm for biomedical decision-making in cancer during
      pregnancy, including recommendations that can facilitate counseling and help
      reduce the suffering of the patient and her family.
CI  - Copyright (c) 2020 Alpuim Costa, Nobre, de Almeida, Ferreira, Goncalves, Braga
      and Pais.
FAU - Alpuim Costa, Diogo
AU  - Alpuim Costa D
AD  - CUF Oncologia, Haematology and Oncology Department, Lisbon, Portugal.
AD  - NOVA Medical School, Faculdade de Ciencias Medicas, Lisbon, Portugal.
FAU - Nobre, Jose Guilherme
AU  - Nobre JG
AD  - Universidade de Lisboa, Faculdade de Medicina, Lisbon, Portugal.
FAU - de Almeida, Susana Baptista
AU  - de Almeida SB
AD  - Hospital Professor Doutor Fernando Fonseca EPE, Oncology Department, Amadora,
      Portugal.
FAU - Ferreira, Marisa Horta
AU  - Ferreira MH
AD  - Universidade da Beira Interior, Faculdade de Ciencias da Saude, Covilha,
      Portugal.
FAU - Goncalves, Ines
AU  - Goncalves I
AD  - Hospital CUF Almada, Emergency Department, Almada, Portugal.
FAU - Braga, Sofia
AU  - Braga S
AD  - CUF Oncologia, Haematology and Oncology Department, Lisbon, Portugal.
AD  - NOVA Medical School, Faculdade de Ciencias Medicas, Lisbon, Portugal.
AD  - Hospital Professor Doutor Fernando Fonseca EPE, Oncology Department, Amadora,
      Portugal.
FAU - Pais, Diogo
AU  - Pais D
AD  - Ethics Department, NOVA Medical School, Faculdade de Ciencias Medicas, Lisbon,
      Portugal.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201223
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7787159
OTO - NOTNLM
OT  - cancer
OT  - carcinoma
OT  - ethical
OT  - ethics
OT  - gestation
OT  - neoplasm
OT  - pregnancy
OT  - pregnant
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:41
PHST- 2020/08/24 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2021/01/11 05:41 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fonc.2020.598508 [doi]
PST - epublish
SO  - Front Oncol. 2020 Dec 23;10:598508. doi: 10.3389/fonc.2020.598508. eCollection
      2020.


PMID- 33425729
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection:
      Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE
      Monotherapy.
PG  - 574668
LID - 10.3389/fonc.2020.574668 [doi]
AB  - This study aims to compare the effectiveness and complications of transarterial
      chemoembolization (TACE) combined with sorafenib (S-TACE) and TACE monotherapy in
      HCC patients with diffuse recurrence (DR). This retrospective study was approved 
      by our hospital ethics committee, and all patients provided informed consent. We 
      retrospectively enrolled 356 DR patients from January 2005 to December 2014, who 
      underwent either S-TACE or TACE monotherapy. Treatment complications, overall
      survival (OS) and progression-free survival (PFS) were evaluated. Survival curves
      were constructed using the Kaplan-Meier method and compared using a log-rank
      test. Our results found a significant difference between S-TACE and TACE
      monotherapy in the PFS and OS of HCC patients with early diffuse recurrence (EDR)
      (p=0.011 and 0.049, respectively). Patients with late diffuse recurrence (LDR)
      who underwent S-TACE had longer OS (median 24.0 vs. 16.0 months; p=0.044)
      compared with those in the TACE monotherapy group. Subgroup analysis revealed
      that S-TACE therapy resulted in higher OS of EDR patients with tumors > 5 cm and 
      HBV-DNA >100 (p=0.036 and 0.035, respectively), compared with patients given TACE
      monotherapy. S-TACE therapy also resulted in better OS in LDR patients with
      AFP>/=400 ng/ml, AFP<400 ng/ml, TB<28 g/L, TB>28 g/L, and a maximum tumor
      diameter < 5 cm (p=<0.001, 0.042, <0.001, <0.001, and <0.001, respectively). The 
      rate of major complications in patients who underwent S-TACE was not
      significantly different to those who underwent TACE monotherapy (33.5% vs. 28.2%,
      p= 0.69). Overall, patients given S-TACE had better OS in both EDR and LDR
      patients, but only EDR patients had better PFS.
CI  - Copyright (c) 2020 Yao, Xue, Lu, Wang, Zhao, Wu, Fan and Li.
FAU - Yao, Wang
AU  - Yao W
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
FAU - Xue, Miao
AU  - Xue M
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
FAU - Lu, Mingjian
AU  - Lu M
AD  - Department of Radiology, Affiliated Cancer Hospital & Institute of Guangzhou
      Medical University, Guangzhou, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
FAU - Zhao, Yue
AU  - Zhao Y
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
FAU - Wu, Yanqin
AU  - Wu Y
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
FAU - Fan, Wenzhe
AU  - Fan W
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
FAU - Li, Jiaping
AU  - Li J
AD  - Department of Interventional Oncology, the First Affiliated Hospital of Sun
      Yat-Sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7793644
OTO - NOTNLM
OT  - diffuse recurrence
OT  - hepatocellular carcinoma
OT  - liver resection
OT  - sorafenib
OT  - transarterial chemoembolization
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:41
PHST- 2020/06/22 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2021/01/11 05:41 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fonc.2020.574668 [doi]
PST - epublish
SO  - Front Oncol. 2020 Dec 17;10:574668. doi: 10.3389/fonc.2020.574668. eCollection
      2020.


PMID- 33425166
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20220419
IS  - 1937-8688 (Electronic)
VI  - 37
DP  - 2020
TI  - Nuances of reproductive decisions by women in a rural community of Lagos,
      Nigeria.
PG  - 133
LID - 10.11604/pamj.2020.37.133.18235 [doi]
AB  - INTRODUCTION: inadequate utilization of maternal health services due to limited
      reproductive decision-making capacity could be contributory to high maternal
      mortality in developing countries. This study sought to assess nuances of
      reproductive decisions by women in a rural community of Lagos, Nigeria. METHODS: 
      this descriptive, cross-sectional house to house survey was part of a study
      conducted in April 2015 on females selected from 298 households chosen based on
      geographical clusters by simple random sampling. The study instrument was adapted
      from a USAID-funded project and was interviewer-administered. Data entry and
      analysis were performed with the aid of Epi-info 7.0.8.3 statistical software and
      ethical approval was obtained for the study. RESULTS: spousal age difference was 
      less than 10 years for about half (51.3%) of the respondents. The majority
      (91.6%) of the respondents had received antenatal care during pregnancy and
      jointly decided with their spouses on place of care. The most commonly used
      contraceptives were the pills (23.5%), injectables (16.8%) and condoms (13.8%).
      Spousal disapproval regarding the use of family planning was almost nil at 1%.
      Employment status as a socio-economic factor did not significantly affect
      respondents involvement in decision-making. However, there were statistically
      significant associations between spousal age differences and some indicators of
      autonomy such as respondents involvement in health care decisions and the
      determinant on choice of antenatal care provider. CONCLUSION: women s
      reproductive independence and involvement in health decisions could result in
      reduction of maternal ill-health and mortality whilst promoting higher male
      involvement and better maternal health.
CI  - Copyright: Kikelomo Ololade Wright et al.
FAU - Wright, Kikelomo Ololade
AU  - Wright KO
AD  - Department of Community Health and Primary Health Care, Lagos State University
      College of Medicine, Ikeja, Lagos, Nigeria.
FAU - Bakare, Omowunmi
AU  - Bakare O
AD  - Department of Community Health and Primary Health Care, Lagos State University
      College of Medicine, Ikeja, Lagos, Nigeria.
FAU - Adeniran, Adeyinka
AU  - Adeniran A
AD  - Department of Community Health and Primary Health Care, Lagos State University
      College of Medicine, Ikeja, Lagos, Nigeria.
FAU - Akinyinka, Modupe
AU  - Akinyinka M
AD  - Department of Community Health and Primary Health Care, Lagos State University
      College of Medicine, Ikeja, Lagos, Nigeria.
FAU - Kuyinu, Yetunde
AU  - Kuyinu Y
AD  - Department of Community Health and Primary Health Care, Lagos State University
      College of Medicine, Ikeja, Lagos, Nigeria.
FAU - Goodman, Olayinka
AU  - Goodman O
AD  - Department of Community Health and Primary Health Care, Lagos State University
      College of Medicine, Ikeja, Lagos, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Contraception/methods/*statistics & numerical data
MH  - Cross-Sectional Studies
MH  - *Decision Making
MH  - Family Planning Services/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Maternal Health Services/*statistics & numerical data
MH  - Maternal Mortality
MH  - Middle Aged
MH  - Nigeria
MH  - Personal Autonomy
MH  - Prenatal Care/statistics & numerical data
MH  - Rural Population
MH  - Spouses/statistics & numerical data
MH  - Young Adult
PMC - PMC7757217
OTO - NOTNLM
OT  - Reproductive health
OT  - decision-making
OT  - maternal health
OT  - spouse
COIS- The authors declare no competing interests.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/20 06:00
CRDT- 2021/01/11 05:39
PHST- 2019/01/22 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2021/01/11 05:39 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.11604/pamj.2020.37.133.18235 [doi]
AID - PAMJ-37-133 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Oct 6;37:133. doi: 10.11604/pamj.2020.37.133.18235.
      eCollection 2020.


PMID- 33425139
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20220419
IS  - 1937-8688 (Electronic)
VI  - 37
DP  - 2020
TI  - Emergency hysterectomy in a tertiary care hospital: indications, surgical
      outcomes and challenges: a 2-year retrospective descriptive cross-sectional
      study.
PG  - 106
LID - 10.11604/pamj.2020.37.106.25393 [doi]
AB  - INTRODUCTION: emergency hysterectomy (EH) remains a life-saving procedure in
      cases of life-threatening obstetric hemorrhage and other gynaecological
      emergencies. We aim to determine the indications, surgical outcomes and
      challenges of EH in our tertiary centre. METHODS: an ethically approved
      retrospective descriptive cross-sectional study on all EHs performed at a
      tertiary hospital during the period of 1(st) January 2018 to 31(st) December 2019
      was conducted. Medical records of eligible patients were retrieved, reviewed and 
      analysed using frequencies and percentages and then summarized in tables.
      RESULTS: there were 146 EHs over the two year period. The age of participants
      ranged from 19 to 59 years, with a mean of 34.3 years (SD = 6.06). SD: standard
      deviation.The main indication for EH was primary postpartum haemorrhage (PPH):
      73.28% (n = 110/146). The other indications were uterine perforation with
      necrosis: 8.9% (n = 13/146), secondary postpartum haemorrhage: 4.8% (n = 7/146), 
      choriocarcinoma and pelvic abscess: 2.74% (n = 4/146) each and broad ligament
      haematoma: 2.06% (n = 3/146). There were 3.42% (n = 5/146) which were classified 
      as 'others **': two cases of ovarian cyst torsion; one case of placental site
      tumour; one case of incomplete septic abortion; one case of bulky multinodular
      fibroid uterus with severe unremitting lower abdominal pain.The most common
      indication for the subgroup of hysterectomy due to PPH was uterine atony 54.20%
      (n = 60/110), followed by ruptured uterus20.56% (n = 23/110) and then, morbidly
      adherent placenta 14.95% (n = 16/110). Placenta accreta constituted 62.5% (n =
      10/16) of the morbidly adherent placenta.There were 91.78% (n=134/146) total
      abdominal hysterectomies and 8.22% (n = 12/146) subtotalhysterectomies. About
      eighty percent 79.45% (n = 116/146) of the surgeries required general
      anaesthesia, 15.07% (n = 22/146) required regional anaesthesia whilst 5.48% (n = 
      8/146) were started as regional anaesthesia but were converted to general
      anaesthesia.There were no associated intraoperative complications in 96.60%
      (141/146) of the cases. The most frequent intraoperative complications included
      bowel injury 2.04% (3/146), bladder injury 0.68% (1/146) and maternal death 0.68%
      (1/146).Twoof the three bowel injuries required bowel resection and anastomosis. 
      Most of the surgeries 89.73% (n = 131/146) were performed by skilled doctors
      above the level of a Specialist. Major challenges faced include delayed referral 
      of patients to the tertiary centre for prompt management and lack of quick access
      to blood products. CONCLUSION: emergency hysterectomy is performed in women who
      are relatively young with primary postpartum haemorrhage as the commonest
      indication but there are other non-obstetric indications for this emergency
      surgery. Though a challenging procedure, it is safe in the hands of a skilled
      surgical team.
CI  - Copyright: John Jude Kweku Annan et al.
FAU - Annan, John Jude Kweku
AU  - Annan JJK
AD  - Department of Obstetrics and Gynaecology, Komfo Anokye Teaching Hospital, Kumasi,
      Ghana.
AD  - School of Medicine and Dentistry, Kwame Nkrumah University of Science and
      Technology, Kumasi, Ghana.
FAU - Konney, Thomas Opkoti
AU  - Konney TO
AD  - Department of Obstetrics and Gynaecology, Komfo Anokye Teaching Hospital, Kumasi,
      Ghana.
AD  - School of Medicine and Dentistry, Kwame Nkrumah University of Science and
      Technology, Kumasi, Ghana.
FAU - Sam-Awortwi, Wilfred
AU  - Sam-Awortwi W
AD  - Department of Anaesthesiology and Intensive Care, Komfo Anokye Teaching Hospital,
      Kumasi, Ghana.
FAU - Darkwa, Kwasi Ampem
AU  - Darkwa KA
AD  - Directorate of Obstetrics and Gynaecology, Komfo Anokye Teaching Hospital,
      Kumasi, Ghana.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adult
MH  - Anesthesia, Conduction/statistics & numerical data
MH  - Anesthesia, General/statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Emergencies
MH  - Female
MH  - Humans
MH  - Hysterectomy/*methods/statistics & numerical data
MH  - Middle Aged
MH  - Postpartum Hemorrhage/*surgery
MH  - Referral and Consultation/*statistics & numerical data
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7757309
OTO - NOTNLM
OT  - Emergency hysterectomy
OT  - massive obstetric hemorrhage
OT  - placenta previa
OT  - uterine atony
OT  - uterine rupture
COIS- The authors declare no competing interests.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/20 06:00
CRDT- 2021/01/11 05:38
PHST- 2020/08/06 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2021/01/11 05:38 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.11604/pamj.2020.37.106.25393 [doi]
AID - PAMJ-37-106 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Oct 1;37:106. doi: 10.11604/pamj.2020.37.106.25393.
      eCollection 2020.


PMID- 33424727
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The Importance of WE in POWER: Integrating Police Wellness and Ethics.
PG  - 614995
LID - 10.3389/fpsyg.2020.614995 [doi]
AB  - In this article, the authors introduce the POWER perspective of police wellness
      and ethics. POWER stands for Police Officer Wellness, Ethics, and Resilience. The
      perspective represents the view that wellness and ethics cannot be discussed
      separately; they are inextricably connected to each other. Initiatives to address
      one should always, simultaneously, include the other. Although there is a need
      for wellness and ethics to be addressed on an organizational level, the present
      article emphasizes the importance of POWER for individual police officers. The
      authors make the argument that officers need to expand the way in which they
      conceptualize their own wellness to include efforts to maintain ethical
      decision-making. Specifically, officers will remain psychologically healthier
      when they take active steps to stay steadfastly committed to their ethical
      principles. Likewise, officers who utilize a comprehensive wellness program,
      including strategies to boost resilience, will be far less likely to experience
      lapses in ethical decision-making. Further recommendations for action and
      implication of this matter in law enforcement are presented and discussed.
CI  - Copyright (c) 2020 Blumberg, Papazoglou and Schlosser.
FAU - Blumberg, Daniel M
AU  - Blumberg DM
AD  - California School of Professional Psychology, Alliant International
      University-San Diego, San Diego, CA, United States.
FAU - Papazoglou, Konstantinos
AU  - Papazoglou K
AD  - Department of Criminal Justice, New Jersey City University, New Jersey, NJ,
      United States.
FAU - Schlosser, Michael D
AU  - Schlosser MD
AD  - Police Training Institute, University of Illinois at Urbana-Champaign, Champaign,
      IL, United States.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7793676
OTO - NOTNLM
OT  - ethics
OT  - law enforcement
OT  - moral risks
OT  - resilience
OT  - training
OT  - wellness
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:36
PHST- 2020/10/07 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/01/11 05:36 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fpsyg.2020.614995 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 18;11:614995. doi: 10.3389/fpsyg.2020.614995. eCollection
      2020.


PMID- 33424704
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Does the Use of Social Media Tools in Classrooms Increase Student Commitment to
      Corporate Social Responsibility?
PG  - 589250
LID - 10.3389/fpsyg.2020.589250 [doi]
AB  - There is an increasing demand for ethical and Corporate Social Responsibility
      (CSR) practices by companies. This competence has to be introduced in students'
      training in business degree programs, and a check must then be done to determine 
      if the students have come to appreciate the importance of CSR commitments. Using 
      the framework of Stakeholders Theory, this work aims to examine students'
      perceptions of ethical and CSR practices and commitment to different
      stakeholders, as well as the factors that lead students to act in a socially
      responsible way. Furthermore, we hope to identify how the perception of CSR can
      be improved when Web 2.0 and social media tools that have proven effective in
      transmitting emotions and values are used in classrooms to teach these ideas. To 
      this end, a survey was carried out in the year 2019 with 1,030 first-year
      students; it was administered at the beginning of the semester and also at the
      end of the semester after the training activities had been carried out. The main 
      finding of the research is that students start with the belief that ethics and
      CSR are developed for reasons of image and legitimacy; however, after receiving
      training on these topics through tools that take into account emotions and
      values, they start to value the importance of the company as an agent of social
      change. The main practical and managerial implication is that methods based on
      Web 2.0 and social media tools are useful to teach ethics and CSR; the
      theoretical contribution is that students take into account the welfare of
      others. This finding contributes to Stakeholder Theory in a higher education
      context.
CI  - Copyright (c) 2020 Rodriguez-Gomez, Garde-Sanchez, Arco-Castro and Lopez-Perez.
FAU - Rodriguez-Gomez, Sara
AU  - Rodriguez-Gomez S
AD  - Departamento de Economia Financiera y Contabilidad, Facultad de Ciencias
      Economicas y Empresariales, Universidad de Granada, Granada, Spain.
FAU - Garde-Sanchez, Raquel
AU  - Garde-Sanchez R
AD  - Departamento de Economia Financiera y Contabilidad, Facultad de Ciencias
      Economicas y Empresariales, Universidad de Granada, Granada, Spain.
FAU - Arco-Castro, Maria Lourdes
AU  - Arco-Castro ML
AD  - Departamento de Economia Financiera y Contabilidad, Facultad de Ciencias
      Economicas y Empresariales, Universidad de Granada, Granada, Spain.
FAU - Lopez-Perez, Maria Victoria
AU  - Lopez-Perez MV
AD  - Departamento de Economia Financiera y Contabilidad, Facultad de Ciencias
      Economicas y Empresariales, Universidad de Granada, Granada, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7786309
OTO - NOTNLM
OT  - Corporative Social Responsibility
OT  - business ethics
OT  - digital technologies
OT  - higher education
OT  - social media
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest. The handling Editor declared a shared affiliation with one 
      of the authors with the authors at the time of review.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:36
PHST- 2020/08/28 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2021/01/11 05:36 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fpsyg.2020.589250 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 23;11:589250. doi: 10.3389/fpsyg.2020.589250. eCollection
      2020.


PMID- 33424679
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Character Strengths Profiles in Medical Professionals and Their Impact on
      Well-Being.
PG  - 566728
LID - 10.3389/fpsyg.2020.566728 [doi]
AB  - Character strengths profiles in the specific setting of medical professionals are
      widely unchartered territory. This paper focused on an overview of character
      strengths profiles of medical professionals (medical students and physicians)
      based on literature research and available empirical data illustrating their
      impact on well-being and work engagement. A literature research was conducted and
      the majority of peer-reviewed considered articles dealt with theoretical or
      conceptually driven 'virtues' associated with medical specialties or questions of
      ethics in patient care (e.g., professionalism, or what makes a good physician).
      The virtues of compassion, courage, altruism, and benevolence were described most
      often. Only a limited number of papers addressed character strengths of medical
      students or physicians according to the VIA-classification. Those articles showed
      that the VIA-character strengths fairness, honesty, kindness, and teamwork were
      considered most often by respondents to be particularly important for the medical
      profession. Available cross-sectional (time span: six years) and longitudinal
      (time span: three years) data regarding VIA-character strengths profiles of
      medical professionals were analyzed (N = 584 medical students, 274 physicians).
      These profiles were quite homogenous among both groups. The character strengths
      fairness, honesty, judgment, kindness, and love had the highest means in both
      samples. Noteworthy differences appeared when comparing medical specialties, in
      particular concerning general surgeons and psychiatrists, with the former
      reporting clearly higher levels of e.g., honesty (d = 1.02) or prudence (d =
      1.19). Long-term results revealed significant positive effects of character
      strengths on well-being and work engagement (e.g., perseverance on physicians'
      work engagement) but also significant negative effects (e.g., appreciation of
      beauty and excellence on students' well-being). Further, hope was significantly
      associated both positively with physicians' well-being and negatively with
      students' work engagement, possibly indicating specific issues concerning medical
      education or hospital working conditions. According to the modern-day physician's
      pledge, medical professionals should pay attention to their own well-being and
      health. Therefore, promoting self-awareness and character building among medical 
      professionals could be a beneficial strategy.
CI  - Copyright (c) 2020 Huber, Strecker, Kachel, Hoge and Hofer.
FAU - Huber, Alexandra
AU  - Huber A
AD  - Department of Medical Psychology, Medical University of Innsbruck, Innsbruck,
      Austria.
FAU - Strecker, Cornelia
AU  - Strecker C
AD  - Institute of Psychology, University of Innsbruck, Innsbruck, Austria.
FAU - Kachel, Timo
AU  - Kachel T
AD  - Institute of Psychology, University of Innsbruck, Innsbruck, Austria.
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital
      of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
FAU - Hoge, Thomas
AU  - Hoge T
AD  - Institute of Psychology, University of Innsbruck, Innsbruck, Austria.
FAU - Hofer, Stefan
AU  - Hofer S
AD  - Department of Medical Psychology, Medical University of Innsbruck, Innsbruck,
      Austria.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7786021
OTO - NOTNLM
OT  - VIA-classification
OT  - character strengths profiles
OT  - medical students
OT  - physicians
OT  - well-being
OT  - work engagement
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:36
PHST- 2020/05/28 00:00 [received]
PHST- 2020/12/04 00:00 [accepted]
PHST- 2021/01/11 05:36 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fpsyg.2020.566728 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 23;11:566728. doi: 10.3389/fpsyg.2020.566728. eCollection
      2020.


PMID- 33424563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Linking)
VI  - 14
DP  - 2020
TI  - Researcher Perspectives on Data Sharing in Deep Brain Stimulation.
PG  - 578687
LID - 10.3389/fnhum.2020.578687 [doi]
AB  - The expansion of research on deep brain stimulation (DBS) and adaptive DBS (aDBS)
      raises important neuroethics and policy questions related to data sharing.
      However, there has been little empirical research on the perspectives of experts 
      developing these technologies. We conducted semi-structured, open-ended
      interviews with aDBS researchers regarding their data sharing practices and their
      perspectives on ethical and policy issues related to sharing. Researchers
      expressed support for and a commitment to sharing, with most saying that they
      were either sharing their data or would share in the future and that doing so was
      important for advancing the field. However, those who are sharing reported a
      variety of sharing partners, suggesting heterogeneity in sharing practices and
      lack of the broad sharing that would reflect principles of open science.
      Researchers described several concerns and barriers related to sharing, including
      privacy and confidentiality, the usability of shared data by others, ownership
      and control of data (including potential commercialization), and limited
      resources for sharing. They also suggested potential solutions to these
      challenges, including additional safeguards to address privacy issues,
      standardization and transparency in analysis to address issues of data usability,
      professional norms and heightened cooperation to address issues of ownership and 
      control, and streamlining of data transmission to address resource limitations.
      Researchers also offered a range of views on the sensitivity of neural activity
      data (NAD) and data related to mental health in the context of sharing. These
      findings are an important input to deliberations by researchers, policymakers,
      neuroethicists, and other stakeholders as they navigate ethics and policy
      questions related to aDBS research.
CI  - Copyright (c) 2020 Zuk, Sanchez, Kostick, Torgerson, Munoz, Hsu, Kalwani,
      Sierra-Mercado, Robinson, Outram, Koenig, Pereira, McGuire and Lazaro-Munoz.
FAU - Zuk, Peter
AU  - Zuk P
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Sanchez, Clarissa E
AU  - Sanchez CE
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Kostick, Kristin
AU  - Kostick K
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Torgerson, Laura
AU  - Torgerson L
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Munoz, Katrina A
AU  - Munoz KA
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Hsu, Rebecca
AU  - Hsu R
AD  - Evans School of Public Policy and Governance, University of Washington, Seattle, 
      WA, United States.
FAU - Kalwani, Lavina
AU  - Kalwani L
AD  - Department of Biosciences, Rice University, Houston, TX, United States.
FAU - Sierra-Mercado, Demetrio
AU  - Sierra-Mercado D
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
AD  - Department of Anatomy and Neurobiology, School of Medicine, University of Puerto 
      Rico, San Juan, Puerto Rico.
FAU - Robinson, Jill O
AU  - Robinson JO
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Outram, Simon
AU  - Outram S
AD  - Program in Bioethics, University of California, San Francisco, San Francisco, CA,
      United States.
FAU - Koenig, Barbara A
AU  - Koenig BA
AD  - Program in Bioethics, University of California, San Francisco, San Francisco, CA,
      United States.
FAU - Pereira, Stacey
AU  - Pereira S
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - McGuire, Amy L
AU  - McGuire AL
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Lazaro-Munoz, Gabriel
AU  - Lazaro-Munoz G
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC7793701
OTO - NOTNLM
OT  - closed-loop
OT  - commercialization
OT  - data sharing
OT  - deep brain stimulation
OT  - mental health data
OT  - neural activity data
OT  - neuroethics
OT  - neuromodulation
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:36
PHST- 2020/06/30 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/01/11 05:36 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fnhum.2020.578687 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2020 Dec 17;14:578687. doi: 10.3389/fnhum.2020.578687.
      eCollection 2020.


PMID- 33424534
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Monitoring of Heart Rate and Activity Using Telemetry Allows Grading of
      Experimental Procedures Used in Neuroscientific Rat Models.
PG  - 587760
LID - 10.3389/fnins.2020.587760 [doi]
AB  - In animal experimentation, welfare and severity assessments of all procedures
      applied to animals are necessary to meet legal and ethical requirements, as well 
      as public interests. So far, the methods suggested for this purpose are time
      consuming and personnel intensive. Also, evidence-based biostatistical methods
      for this purpose are still rare. We here tested whether the classification of
      heart rate (HR) and activity (Act) data monitored by telemetry in the home cage
      by unsupervised k-means-based class-labeling and subsequent Support Vector
      Machine (SVM) analysis allows severity assessment and grading of experimental
      procedures of different domains, including surgery, injection, behavioral
      testing, and routine handling for maintenance. Telemetric devices were
      subcutaneously implanted in young adult male Crl:CD(SD) and BDIX/UImHanZtm rats. 
      After recovery, rats were randomly subjected to different experimental
      procedures, i.e., handling and cage change as routine maintenance, Rat Grimace
      Scale, burrowing, and social interaction for welfare assessment, as well as
      repeated subcutaneous injections. Thereafter, rats were either intracranially
      implanted with electrodes or injected with tumor cells. Directly after each
      procedure, HR and Act were monitored by telemetry in the home cage for 4 h.
      Application of k-means and SVM algorithms on the obtained data sets from baseline
      (as no stress), cage change (exploratory Act), and intracranial surgery (as
      burden) measurements computed three classes described as low HR/low Act, high
      HR/high Act, and high HR/low Act, respectively. Validation of the SVM model by
      entering data from all procedures confirmed the allocation to the high HR/low Act
      class (burden) after surgery, which lasted longer after subcutaneous transmitter 
      implantation than after intracranial surgery. The majority of data points from
      repeated injections, behavioral testing, and maintenance handling were allocated 
      to the low HR/low Act and high HR/high Act classes. Overall, the SVM model based 
      on HR and Act data monitored in home cage after procedures may be useful for the 
      classification and grading of experimental procedures of different domains.
CI  - Copyright (c) 2020 Wassermann, Helgers, Riedesel, Talbot, Bleich, Schwabe and
      Hager.
FAU - Wassermann, Laura
AU  - Wassermann L
AD  - Institute for Laboratory Animal Science, Hannover Medical School, Hanover,
      Germany.
FAU - Helgers, Simeon O A
AU  - Helgers SOA
AD  - Department of Neurosurgery, Hannover Medical School, Hanover, Germany.
FAU - Riedesel, Ann-Kristin
AU  - Riedesel AK
AD  - Department of Neurosurgery, Hannover Medical School, Hanover, Germany.
FAU - Talbot, Steven R
AU  - Talbot SR
AD  - Institute for Laboratory Animal Science, Hannover Medical School, Hanover,
      Germany.
FAU - Bleich, Andre
AU  - Bleich A
AD  - Institute for Laboratory Animal Science, Hannover Medical School, Hanover,
      Germany.
FAU - Schwabe, Kerstin
AU  - Schwabe K
AD  - Department of Neurosurgery, Hannover Medical School, Hanover, Germany.
FAU - Hager, Christine
AU  - Hager C
AD  - Institute for Laboratory Animal Science, Hannover Medical School, Hanover,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7793729
OTO - NOTNLM
OT  - behavior
OT  - injection
OT  - intracranial surgery
OT  - k-means and SVM algorithms
OT  - telemetry
OT  - welfare
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:36
PHST- 2020/08/05 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2021/01/11 05:36 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.3389/fnins.2020.587760 [doi]
PST - epublish
SO  - Front Neurosci. 2020 Dec 17;14:587760. doi: 10.3389/fnins.2020.587760.
      eCollection 2020.


PMID- 33424257
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1319-0164 (Print)
IS  - 1319-0164 (Linking)
VI  - 28
IP  - 12
DP  - 2020 Dec
TI  - Perceptions regarding antimicrobial use and resistance among adult hospital
      patients in Saudi Arabian Ministry of Health (MOH) hospitals.
PG  - 1648-1654
LID - 10.1016/j.jsps.2020.10.011 [doi]
AB  - BACKGROUND: Education, a key strategy within antimicrobial stewardship programmes
      (ASPs), has been mainly directed towards healthcare professionals and prescribers
      more than hospitalised patients. AIM: To examine patients' knowledge and
      perceptions of antibiotic use and resistance, while evaluating the institutional 
      role of patient education on antibiotic use in two Saudi Arabian hospitals, one
      with an implemented ASP and one without an ASP. METHOD: A cross-sectional
      self-administered survey was developed and piloted. A total of 400 surveys were
      distributed, 200 within the hospital with an ASP and another 200 within the
      hospital without an ASP. Data were coded and analysed. Ethical approval was
      obtained before the start of the study. FINDINGS: 176 patients responded to the
      survey with 150 surveys completed and analysed. 78% of patients agreed that they 
      should only take an antibiotic when prescribed by the doctor, however they still 
      tended to keep left over antibiotics for future use. 84% of patients were unaware
      'antibiotic resistance', with 48% believing that antibiotics help them get better
      quicker when they had a 'cold'. Information on antibiotic use and resistance were
      provided to patients in the hospital with an ASP in contrast to the hospital
      without an ASP. CONCLUSION: Overall there are poor perceptions regarding
      antibiotic use and resistance among hospital patients in Saudi Arabia. Patients
      in the hospital with ASP demonstrated greater knowledge during their
      hospitalisation. ASPs should not only focus on educating healthcare professionals
      but should involve the patients and seize the opportunity to educate them while
      hospitalised.
CI  - (c) 2020 The Author(s).
FAU - Alghamdi, Saleh
AU  - Alghamdi S
AD  - Department of Clinical Pharmacy, Faculty of Clinical Pharmacy, Albaha University,
      Albaha, Saudi Arabia.
FAU - Berrou, Ilhem
AU  - Berrou I
AD  - Faculty of Health & Applied Sciences, University of the West of England, Staple
      Hill, Bristol, UK.
FAU - Aslanpour, Zoe
AU  - Aslanpour Z
AD  - Department of Clinical, Pharmaceutical and Biological Sciences, School of Life
      and Medical Sciences, University of Hertfordshire, Hatfield, UK.
FAU - Bajnaid, Eshtyag
AU  - Bajnaid E
AD  - Department of Clinical Pharmacy, Pharmaceutical Services Administration, King
      Abdullah Medical City, Makkah, Saudi Arabia.
FAU - Alzahrani, Abdulhakim
AU  - Alzahrani A
AD  - Pharmaceutical Care Department, King Fahad Hospital, Ministry of Health, Albaha, 
      Saudi Arabia.
FAU - Shebl, Nada Atef
AU  - Shebl NA
AD  - Department of Clinical, Pharmaceutical and Biological Sciences, School of Life
      and Medical Sciences, University of Hertfordshire, Hatfield, UK.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi
      Pharmaceutical Society
JID - 9705695
PMC - PMC7783113
OTO - NOTNLM
OT  - Antimicrobials
OT  - Inpatients
OT  - Knowledge
OT  - Perceptions
OT  - Resistance
OT  - Stewardship programmes
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:35
PHST- 2020/05/09 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2021/01/11 05:35 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.1016/j.jsps.2020.10.011 [doi]
AID - S1319-0164(20)30246-2 [pii]
PST - ppublish
SO  - Saudi Pharm J. 2020 Dec;28(12):1648-1654. doi: 10.1016/j.jsps.2020.10.011. Epub
      2020 Oct 29.


PMID- 33424256
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1319-0164 (Print)
IS  - 1319-0164 (Linking)
VI  - 28
IP  - 12
DP  - 2020 Dec
TI  - Assessment of beverage consumption by young adults in Saudi Arabia.
PG  - 1635-1647
LID - 10.1016/j.jsps.2020.10.010 [doi]
AB  - OBJECTIVE: The primary objective was to assess beverage consumption pattern and
      calorie intake among undergraduate students on weekly and daily basis. Secondary 
      objectives were to determine the relationship between demographic variables and
      beverage intake, assess mean differences in calorie intake between students'
      groups and, report the predictors of beverage consumption. METHODS: A
      cross-sectional study was conducted for 3 months (January-March 2019) among
      currently enrolled undergraduate students studying in 8 colleges of a public
      sector university in Dammam, Saudi Arabia. The study used the Arabic version of
      Beverage Frequency Questionnaire (BFQ) and collected data through purposive
      stratified sampling. Total intake in ml and calories in kcals were calculated.
      Data was analyzed through SPSS version 23 and the study was approved from ethics 
      committee of the university (IRB-2019-05-021). RESULTS: A total of 507 students
      responded to the survey. The average volume of sugar sweetened beverages (SSBs), 
      caffeine containing beverage (CCBs) and carbonated beverages (CarBs) consumed was
      4.2 L, 4 L and 1.5 L per week and 650.6 ml, 575.2 ml and 224.6 ml per day,
      respectively. Average daily calorie intake from SSBs, CCBs and CarBs was 187.6
      kcals, 87.6 kcals and 52.5 kcals, respectively. Body mass index (BMI) was
      significantly related to CCB (rho = 0.130) and CarBs (rho = 0.100) intake (mL) (p
      < 0.05). Mean difference in calorie intake was mostly significant (p < 0.05) when
      accounted for students' demographics, gender, BMI, residence, illness and,
      examination time, in case of SSBs, CCBs, CarBs and, all beverages. Averge %
      contribution towards total daily energy expenditure (TDEE) for SSBs, CCBs and
      CarBs were 10.2%, 6.3% and 2.8%, respectively. Year of study, BMI, residence and 
      illness were predictors of SSBs consumption while BMI, residence and examination 
      time were predictors of CCBs consumption. Gender and BMI were predictors of CarBs
      intake. CONCLUSION: There was a high consumption of beverages in students that
      was related to their demographic characteristics. There is a need to create
      awareness among the students regarding the detrimental effects of chronic
      consumption of these beverages.
CI  - (c) 2020 The Authors.
FAU - Islam, Md Ashraful
AU  - Islam MA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Al-Karasneh, Aseel Fuad
AU  - Al-Karasneh AF
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Hussain, Ahmed Bin
AU  - Hussain AB
AD  - College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam,
      Saudi Arabia.
FAU - Muhanna, Ali
AU  - Muhanna A
AD  - College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam,
      Saudi Arabia.
FAU - Albu-Hulayqah, Taher
AU  - Albu-Hulayqah T
AD  - College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam,
      Saudi Arabia.
FAU - Naqvi, Atta Abbas
AU  - Naqvi AA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Iqbal, Muhammad Shahid
AU  - Iqbal MS
AD  - Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdul
      Aziz University, Alkharj, Saudi Arabia.
FAU - Farooqui, Maryam
AU  - Farooqui M
AD  - Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, 
      Qassim, Saudi Arabia.
FAU - Elrggal, Mahmoud E
AU  - Elrggal ME
AD  - Pharmaceutical Research Center, Deanship of Scientific Research, Umm Al Qura
      University, Makkah, Saudi Arabia.
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Mahmoud, Mansour Adam
AU  - Mahmoud MA
AD  - Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah
      University, Al-Madinah Al-Munawarah, Saudi Arabia.
FAU - Haseeb, Abdul
AU  - Haseeb A
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi
      Pharmaceutical Society
JID - 9705695
PMC - PMC7783230
OTO - NOTNLM
OT  - Beverage consumption
OT  - Caffeine
OT  - Carbonated drinks
OT  - Energy drinks
OT  - SSBs
OT  - Saudi Arabia
OT  - Undergraduate student
COIS- The authors declare that they have no competing interests. No funding was
      obtained for this study.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
CRDT- 2021/01/11 05:35
PHST- 2020/05/26 00:00 [received]
PHST- 2020/10/18 00:00 [accepted]
PHST- 2021/01/11 05:35 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
AID - 10.1016/j.jsps.2020.10.010 [doi]
AID - S1319-0164(20)30245-0 [pii]
PST - ppublish
SO  - Saudi Pharm J. 2020 Dec;28(12):1635-1647. doi: 10.1016/j.jsps.2020.10.010. Epub
      2020 Oct 22.


PMID- 33419505
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 12
DP  - 2020 Dec 1
TI  - What Should We Do About the Mismatch Between Legal Criteria for Death and How
      Brain Death Is Diagnosed?
PG  - E1038-1046
LID - amajethics.2020.1038 [pii]
LID - 10.1001/amajethics.2020.1038 [doi]
AB  - Mismatch between whole-brain death criteria embedded in statutes and accepted
      tests physicians use to diagnose brain death have clinical and ethical
      implications that could undermine public trust in death pronouncements. We
      consider merits and drawbacks of 4 ways to address this problem.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Robbins, Nathaniel M
AU  - Robbins NM
AD  - Assistant professor of neurology at the Dartmouth College Geisel School of
      Medicine in Hanover, New Hampshire.
FAU - Bernat, James L
AU  - Bernat JL
AD  - Professor emeritus of neurology and medicine at the Dartmouth College Geisel
      School of Medicine in Hanover, New Hampshire.
LA  - eng
GR  - UL1 TR001086/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201201
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Brain Death
MH  - Humans
MH  - *Trust
EDAT- 2021/01/10 06:00
MHDA- 2021/07/29 06:00
CRDT- 2021/01/09 05:26
PHST- 2021/01/09 05:26 [entrez]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.1038 [pii]
AID - 10.1001/amajethics.2020.1038 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Dec 1;22(12):E1038-1046. doi: 10.1001/amajethics.2020.1038.


PMID- 33419502
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 12
DP  - 2020 Dec 1
TI  - AMA Code of Medical Ethics' Opinions About End-of-Life Care and Death.
PG  - E1025-1026
LID - amajethics.2020.1025 [pii]
LID - 10.1001/amajethics.2020.1025 [doi]
AB  - Death determination is fraught with clinical, cultural, and ethics questions.
      This article considers relevant history that informs the AMA Code of Medical
      Ethics opinions about neurological criteria for death.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Chaet, Danielle Hahn
AU  - Chaet DH
AD  - Research associate for the American Medical Association Council on Ethical and
      Judicial Affairs in Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *American Medical Association
MH  - Codes of Ethics
MH  - Ethics, Medical
MH  - Humans
MH  - *Terminal Care
MH  - United States
EDAT- 2021/01/10 06:00
MHDA- 2021/07/29 06:00
CRDT- 2021/01/09 05:26
PHST- 2021/01/09 05:26 [entrez]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.1025 [pii]
AID - 10.1001/amajethics.2020.1025 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Dec 1;22(12):E1025-1026. doi: 10.1001/amajethics.2020.1025.


PMID- 33419501
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 12
DP  - 2020 Dec 1
TI  - Reexamining the Flawed Legal Basis of the "Dead Donor Rule" as a Foundation for
      Organ Donation Policy.
PG  - E1019-1024
LID - amajethics.2020.1019 [pii]
LID - 10.1001/amajethics.2020.1019 [doi]
AB  - The legal basis of what's known as the "dead donor rule" (DDR), which requires
      that donors must be dead according to legal criteria, is rooted in physicians'
      fears of civil and criminal liability for participating in organ retrieval and
      donation. This article suggests that one reason to revisit the DDR is to help
      illuminate possible legal ways to retrieve and donate organs. Specifically, this 
      article considers one of these: medically justifiable homicide, which is legally 
      and ethically distinct from murder and wrongful death.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Schweikart, Scott J
AU  - Schweikart SJ
AD  - Senior research associate for the American Medical Association Council on Ethical
      and Judicial Affairs in Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Brain Death
MH  - Death
MH  - Humans
MH  - *Organ Transplantation
MH  - Policy
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
EDAT- 2021/01/10 06:00
MHDA- 2021/07/29 06:00
CRDT- 2021/01/09 05:26
PHST- 2021/01/09 05:26 [entrez]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.1019 [pii]
AID - 10.1001/amajethics.2020.1019 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Dec 1;22(12):E1019-1024. doi: 10.1001/amajethics.2020.1019.


PMID- 33419499
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 12
DP  - 2020 Dec 1
TI  - Should a Patient Who Is Pregnant and Brain Dead Receive Life Support, Despite
      Objection From Her Appointed Surrogate?
PG  - E1004-1009
LID - amajethics.2020.1004 [pii]
LID - 10.1001/amajethics.2020.1004 [doi]
AB  - This article considers whether and when a physician is obligated to offer life
      support to the point of fetal viability to a patient who is brain dead and
      pregnant. Lack of ethical, legal, and clinical consensus about best practice in
      managing this kind of case; a poor clinical evidence base; and the fact that
      offering life support violates the patient's autonomy and human dignity, as
      expressed in her advance directive, are sources of ethical, legal, and clinical
      complexity analyzed here.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Sperling, Daniel
AU  - Sperling D
AD  - Associate professor in bioethics in the Department of Nursing at the University
      of Haifa in Israel.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Advance Directives
MH  - *Brain Death
MH  - Female
MH  - Humans
MH  - Morals
MH  - Personal Autonomy
MH  - Pregnancy
EDAT- 2021/01/10 06:00
MHDA- 2021/07/29 06:00
CRDT- 2021/01/09 05:26
PHST- 2021/01/09 05:26 [entrez]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.1004 [pii]
AID - 10.1001/amajethics.2020.1004 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Dec 1;22(12):E1004-1009. doi: 10.1001/amajethics.2020.1004.


PMID- 33416806
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 4
DP  - 2020
TI  - Tragic Realism: Reading Simon Critchley for Bioethics.
PG  - 695-707
LID - 10.1353/pbm.2020.0056 [doi]
AB  - The essay explores how Simon Critchley's critique of philosophy and understanding
      of tragedy might affect bioethics and health-care practice. What I playfully call
      the Critchley Doctrine begins with a rejection of philosophy's aspiration to a
      non-contradictory life and its premise that humans act on rational deliberation. 
      This rejection opens us to a recognition of the uncontainable that is expressed
      in tragedy, and that speaks to what is inexplicable about the suffering of
      illness. Critchley advocates an ethics of heteronomy or hetero-affectivity rather
      than autonomy, but his version is distinguished by its recognition of how
      crushing the demands of the other can be. Tragedy and humor offer what he calls
      aesthetic reparation. A tragic medicine balances grieving with humor and seeks
      above all honesty in communication.
FAU - Frank, Arthur W
AU  - Frank AW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - *Bioethics
MH  - Delivery of Health Care/organization & administration
MH  - Humans
MH  - *Life Change Events
MH  - *Philosophy, Medical
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:12
PHST- 2021/01/08 12:12 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520400079 [pii]
AID - 10.1353/pbm.2020.0056 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(4):695-707. doi: 10.1353/pbm.2020.0056.


PMID- 33416799
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 4
DP  - 2020
TI  - Biomarkers Can't Bypass the Mouth of a Wound.
PG  - 602-615
LID - 10.1353/pbm.2020.0049 [doi]
AB  - This article critiques the idealization of a biomarker-based "objective pain
      scale" in order to argue for increased investment in communication-centric
      approaches to chronic pain diagnosis and treatment. Although new technological
      advances and the rise of big data have revived old fantasies of objective pain
      measures, scholars have long affirmed the dangers of converting human experience 
      into numbers, as well as the fundamental impossibility of reducing pain to
      physiology. Biomarkers can certainly be useful tools, but investments must also
      be made in fostering the "strong objectivity" that feminist scholars have
      advocated for and that the incorporation of narrative-driven initiatives can
      provide. Because expressing pain is notoriously difficult, doing this creative,
      communication-driven work well requires substantial effort, time, and training.
      Engaging with chronic pain from a feminist standpoint-one that affirms
      individuals' situated experiences as valuable data and that attends to the rich
      multi-modal vocabularies emerging on social media-can pave the way to a more
      equitable, ethical, and effective future of pain care.
FAU - Greene, Amanda K
AU  - Greene AK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
RN  - 0 (Biomarkers)
SB  - IM
MH  - *Biomarkers
MH  - Chronic Pain/*metabolism
MH  - Communication
MH  - Feminism
MH  - Humans
MH  - Pain Management/*methods
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:12
PHST- 2021/01/08 12:12 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520400006 [pii]
AID - 10.1353/pbm.2020.0049 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(4):602-615. doi: 10.1353/pbm.2020.0049.


PMID- 33416659
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - International Clinical Research and Justice in the Belmont Report.
PG  - 374-388
LID - 10.1353/pbm.2020.0025 [doi]
AB  - The Belmont Report was written by a US Commission charged by the US Congress to
      advise on research supported by the US government. Its focus was understandably
      domestic. In the 40 years since its publication, clinical research has become
      increasingly international. Many clinical trials have sites in multiple
      countries, and many of the host countries are relatively impoverished. Such
      research raises some distinctive ethical issues. This paper outlines some of the 
      key ethical challenges that have been raised by clinical research conducted in
      low- and middle-income countries (LMICs) and sponsored by high-income country
      (HIC) institutions. It then considers whether the Belmont Report has the
      resources to address these problems and argues that it does not. The article
      closes by noting some parallels between this international research and domestic 
      US research, which suggest that the US might benefit from the discussions abroad.
FAU - Millum, Joseph
AU  - Millum J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Biomedical Research/ethics
MH  - Clinical Trials as Topic/*ethics/*standards
MH  - *Developing Countries
MH  - Drug Industry/ethics/standards
MH  - Ethics, Research
MH  - Human Experimentation/*ethics/*standards
MH  - Humans
MH  - Internationality
MH  - Multicenter Studies as Topic/ethics/standards
MH  - *Poverty
MH  - United States
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200099 [pii]
AID - 10.1353/pbm.2020.0025 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):374-388. doi: 10.1353/pbm.2020.0025.


PMID- 33416658
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Informed Consent, Therapeutic Misconception, and Unrealistic Optimism.
PG  - 359-373
LID - 10.1353/pbm.2020.0024 [doi]
AB  - The Belmont Report attested to the cardinal importance of informed consent for
      ethical research on human subjects. Important challenges to securing informed
      consent have emerged since its publication more than 40 years ago. Among some of 
      the most significant of these challenges are those that highlight social
      psychological factors that have the potential to impair the appreciation of
      relevant information disclosed in the informed consent process. Responding to
      these challenges requires us to think harder about the content of the principle
      of informed consent and the demands that it imposes on investigators. This
      article focuses on two challenges in particular, that presented by the so-called 
      therapeutic misconception, and that presented by the psychological bias of
      unrealistic optimism. After outlining an account of the principle of informed
      consent as it applies to the research context, the article briefly reviews the
      empirical literature on the therapeutic misconception and the bias of unrealistic
      optimism. It then relates these phenomena to the principle of informed consent,
      paying special attention to the ethical demands they impose on investigators. The
      article concludes by considering how recent trends to integrate research and
      clinical care affect the main points it has advanced.
FAU - Jansen, Lynn A
AU  - Jansen LA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Biomedical Research/ethics/*standards
MH  - Comprehension
MH  - Ethics, Research
MH  - Human Experimentation/ethics/standards
MH  - Humans
MH  - Informed Consent/ethics/*standards
MH  - Optimism/*psychology
MH  - Research Subjects/*psychology
MH  - Therapeutic Misconception/ethics/*psychology
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200087 [pii]
AID - 10.1353/pbm.2020.0024 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):359-373. doi: 10.1353/pbm.2020.0024.


PMID- 33416657
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Minimizing Risks Is Not Enough: The Relevance of Benefits to Protecting Research 
      Participants.
PG  - 346-358
LID - 10.1353/pbm.2020.0023 [doi]
AB  - Forty years ago, the Belmont Report counseled that a "systematic, nonarbitrary
      analysis of risks and benefits" is vital to ensuring the ethical appropriateness 
      of research with human subjects. Since then, research ethics has devoted
      considerable attention to the first half of this advice, emphasizing the ethical 
      importance of assessing and minimizing the risks of research with human subjects.
      Significantly less attention has been devoted to a systematic assessment of the
      potential benefits of research participation. To the extent that benefits for
      individual participants are considered at all, commentators tend to focus on
      their potential to undermine the goal of minimizing risks. A chance for clinical 
      benefit may obscure the fact that research poses risks not present in clinical
      care, while an offer of financial compensation or ancillary care may induce
      individuals to accept risks that conflict with their long-term interests. This
      article argues that, while undoubtedly important, minimizing risks fails to offer
      sufficient protection for research participants, especially those who cannot
      consent, because it neither ensures that the risks of research are justified nor 
      protects participants from exploitation. Belmont's advice to develop systematic
      and nonarbitrary ways to ensure that research participants receive appropriate
      benefits needs to be heeded as well.
FAU - Wendler, David
AU  - Wendler D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Biomedical Research/*ethics/*standards
MH  - Ethics, Research
MH  - Guidelines as Topic
MH  - Human Experimentation/*ethics/*standards
MH  - Humans
MH  - Informed Consent/*ethics/*standards
MH  - Research Subjects/psychology
MH  - Risk Assessment
MH  - Social Values
MH  - Socioeconomic Factors
MH  - World Health Organization
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200075 [pii]
AID - 10.1353/pbm.2020.0023 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):346-358. doi: 10.1353/pbm.2020.0023.


PMID- 33416656
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Towards Identifying an Upper Limit of Risk: A Persistent Area of Controversy in
      Research Ethics.
PG  - 327-345
LID - 10.1353/pbm.2020.0022 [doi]
AB  - Whether there is an upper limit of net risk that volunteers can consent to in
      research, and what that limit happens to be, has been the subject of persistent
      controversy in research ethics. This article defends the concept of an upper
      limit of risk in research against recent critics and supports the most promising 
      approach for identifying this limit, that of finding comparator activities that
      are generally accepted in society and pose high levels of risk. However,
      high-risk activities that have been proposed as relevant comparators involve more
      certain benefits and confer considerable social esteem to those who take on the
      risks. This suggests that developing a robust approach to identifying social
      value, whether by developing a procedural safeguard or a systematic framework,
      could more effectively identify research with sufficient social value to justify 
      high net risk. Additionally, the social status of research participants should be
      elevated to be more on par with others who laudably take on high risk for the
      benefit of others. By attending to the benefits necessary for the justification
      of high-risk research, the level of allowable risk will no longer be so
      controversial.
FAU - Paquette, Erin T
AU  - Paquette ET
FAU - Shah, Seema K
AU  - Shah SK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Biomedical Research/*ethics/*standards
MH  - Ethics, Research
MH  - Guidelines as Topic
MH  - Human Experimentation/*ethics/*standards
MH  - Humans
MH  - Informed Consent/*ethics/*standards
MH  - Research Subjects/psychology
MH  - Risk Assessment
MH  - Social Values
MH  - Socioeconomic Factors
MH  - World Health Organization
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200063 [pii]
AID - 10.1353/pbm.2020.0022 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):327-345. doi: 10.1353/pbm.2020.0022.


PMID- 33416655
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - The Belmont Report and Innovative Practice.
PG  - 313-326
LID - 10.1353/pbm.2020.0021 [doi]
AB  - One of the Belmont Report's most important contributions was the clear and
      serviceable distinction it drew between standard medical practice and biomedical 
      research. A less well-known achievement of the Report was its conceptualization
      of innovative practice, a type of medical practice that is often mistaken for
      research because it is new, untested, or experimental. Although the discussion of
      innovative practice in Belmont is brief and somewhat cryptic, this does not
      reflect the significant progress its authors made in understanding innovative
      practice and the distinctive ethical issues it raises. This article explores the 
      history and broader context of Belmont's conception of innovative practice, its
      strengths and weaknesses, and its contemporary relevance for scholars working in 
      bioethics and health policy. While this conception of innovative practice
      deserves our attention, it is inherently limited in some important ways.
FAU - Earl, Jake
AU  - Earl J
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Bioethics/*history/trends
MH  - Biomedical Research/*ethics/history
MH  - Ethics, Research
MH  - *Health Policy
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Human Experimentation/ethics/history
MH  - Humans
MH  - Inventions/*ethics/history
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200051 [pii]
AID - 10.1353/pbm.2020.0021 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):313-326. doi: 10.1353/pbm.2020.0021.


PMID- 33416654
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Judging the Social Value of Health-Related Research: Current Debate and Open
      Questions.
PG  - 293-312
LID - 10.1353/pbm.2020.0020 [doi]
AB  - On the occasion of the 40th anniversary of the Belmont Report-one of the
      foundational documents of modern research ethics-this article reviews the ethical
      debate about the social value of health-related research with human participants.
      It shows that the Belmont Report discusses the social value of research only
      cursorily, much like most of the research ethics literature until recently. The
      article then reviews the current debate and open questions about the social value
      of health-related research, organized around three questions: (1) is social value
      a necessary ethical requirement for health-related research with human
      participants? (2) if so, how should a social value requirement should be
      specified? and (3) how should such a requirement be implemented in practice?
FAU - Rid, Annette
AU  - Rid A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Biomedical Research/*ethics/*organization & administration
MH  - Community Participation
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - Philosophy
MH  - Public Health/ethics
MH  - *Social Values
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S152987952020004X [pii]
AID - 10.1353/pbm.2020.0020 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):293-312. doi: 10.1353/pbm.2020.0020.


PMID- 33416653
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Revisiting the Distinction and the Connection Between Research and Practice.
PG  - 277-292
LID - 10.1353/pbm.2020.0019 [doi]
AB  - The Belmont Report addresses the distinction between practice and research as
      guidance for which activities should be evaluated prospectively by a research
      ethics committee. This essay argues that the distinction between clinical
      practice and clinical research has a more fundamental significance for
      understanding the ethics of clinical research. After discussing the important
      connections between clinical research and clinical practice, the essay examines
      in detail ethically significant differences between these two sorts of
      activities. This sets the stage for a critique of clinical equipoise, widely
      regarded as a fundamental principle of clinical research ethics.
FAU - Miller, Franklin G
AU  - Miller FG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Behavioral Research/ethics
MH  - Biomedical Research/*ethics/standards
MH  - *Ethics, Medical
MH  - *Ethics, Research
MH  - Humans
MH  - Philosophy
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200038 [pii]
AID - 10.1353/pbm.2020.0019 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):277-292. doi: 10.1353/pbm.2020.0019.


PMID- 33416652
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Belmont in Europe: A Mostly Indirect Influence.
PG  - 262-276
LID - 10.1353/pbm.2020.0018 [doi]
AB  - This paper traces the reception of the Belmont Report in Europe and its influence
      on the development of European research ethics thinking and European research
      ethics systems. It is very difficult to trace a clear, linear reception history
      because it is difficult to disentangle the influence of the Report from the
      influence of concurrent developments, such as the 1975 revision of the World
      Medical Association Declaration of Helsinki and the requirement for research
      ethics review in the Vancouver Group's 1978 "Uniform Requirements for Manuscript 
      Submission." The Report's insistence that the focus of research ethics should be 
      the rights and interests of the individual research subject, and the use of an
      ethical framework and not ethical theory as the basis of analysis and
      justification of recommendations, were nevertheless very important for the
      development of research ethics. The divergence between Europe and the US in the
      governance of non-biomedical research can at least partly be explained by the
      absence of strong drivers for the introduction of research ethics committees
      outside of biomedicine in Europe, and by the ability of non-biomedical
      researchers to mobilize effectively against the introduction of such committees.
FAU - Holm, Soren
AU  - Holm S
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Behavioral Research/ethics/standards
MH  - Biomedical Research/*ethics/history
MH  - Ethical Theory
MH  - Ethics Committees, Research/standards
MH  - *Ethics, Research
MH  - Europe
MH  - History, 20th Century
MH  - Human Experimentation/*ethics/history
MH  - Humans
MH  - Informed Consent/history/*standards
MH  - Philosophy
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200026 [pii]
AID - 10.1353/pbm.2020.0018 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):262-276. doi: 10.1353/pbm.2020.0018.


PMID- 33416649
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 2
DP  - 2020
TI  - Belmont in Context.
PG  - 220-239
LID - 10.1353/pbm.2020.0028 [doi]
AB  - Given its outsized influence as a core document in bioethics, it is worth
      reminding ourselves of the historical context in which the Belmont Report came to
      be. This article examines the societal forces that helped bring about the Belmont
      Report and that shaped its conception of ethical research. A product of a public 
      investigation that included many nonscientists and espoused philosophical
      principles, the Report internalized a growing call in the late 1960s for
      oversight over the research enterprise, which had long been the private realm of 
      physician-investigators. Belmont helped bring about a regulatory and oversight
      apparatus to the research enterprise, as well as a language and discipline of
      bioethics that added a multidisciplinary set of voices and decision-makers to
      discussions of what constitutes ethical research. Because it reflected the spirit
      of protectionism engendered by events of the 1960s and 1970s, Belmont also helped
      emphasize the importance of informed consent and the protection of vulnerable
      populations. But because the Report was a product of its time, contingent on
      historical developments and highly publicized events, it is not necessarily
      responsive to new factors that now condition the research enterprise.
FAU - Schupmann, Will
AU  - Schupmann W
FAU - Moreno, Jonathan D
AU  - Moreno JD
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Biomedical Research/*ethics/*history
MH  - Ethics, Research/*history
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Human Experimentation/*ethics/*history
MH  - Humans
MH  - Informed Consent/standards
MH  - National Institutes of Health (U.S.)/standards
MH  - United States
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520200129 [pii]
AID - 10.1353/pbm.2020.0028 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(2):220-239. doi: 10.1353/pbm.2020.0028.


PMID- 33416634
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 3
DP  - 2020
TI  - The Advent of the Professional Ethicist: Moral Expertise and Health-Care Ethics
      Certification.
PG  - 570-588
LID - 10.1353/pbm.2020.0048 [doi]
AB  - With the Healthcare Ethics Consultant Certification (HEC-C) offered through the
      American Society for Bioethics and Humanities (ASBH), the practice of clinical
      ethics has taken a decisive step into professionalization. But without an
      unambiguous sense of what clinical ethicists can contribute to the clinical
      environment, it is unclear what the HEC-C ensures clinical ethicists can do.
      Though the ASBH enumerates a set of core competencies, many disagree over what
      role those competencies empower ethicists to serve. Two recent publications are
      notable for advocating conflicting positions on the question of ethicists'
      competence: "Ethics Expertise: What It Is, How to Get It, and What to Do with It"
      by Christopher Meyers (2018) and Rethinking Health Care Ethics by Stephen Scher
      and Kasia Kozlowska (2018). In response to Scher and Kozlowska's argument that
      the primary role of ethicists is to create space to engage clinician's moral
      intuitions, this analysis follows Meyers in contending that ethicists can also
      contribute a kind of moral expertise. However, acquiring moral expertise is no
      easy task, and it is unlikely to be substantiated by a certification exam. This
      analysis draws on research from the psychology of expertise to outline the sort
      of training needed to cultivate and enhance moral expertise.
FAU - Watson, Jamie Carlin
AU  - Watson JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Bioethics/*education/trends
MH  - Certification/*standards
MH  - Ethicists/*education/*standards
MH  - Humans
MH  - Professional Competence/standards
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520300193 [pii]
AID - 10.1353/pbm.2020.0048 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(3):570-588. doi: 10.1353/pbm.2020.0048.


PMID- 33416633
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 3
DP  - 2020
TI  - Covert Consciousness and Covert Ethics.
PG  - 553-569
LID - 10.1353/pbm.2020.0047 [doi]
AB  - Rights Come to Mind: Brain Injury, Ethics, and the Struggle for Consciousness
      (2015) by Joseph J. Fins offers rich narratives of families and patients who
      experience disorders of consciousness in flawed health-care systems that are not 
      clinically, structurally, financially, or ethically prepared to respond to the
      inherent complexities of these conditions. In 2018, only a few years after the
      publication of this book, the medical guidelines for these disorders officially
      changed with key publications in Neurology. Fins has called on bioethicists to
      respond to these significant developments, and this paper serves as a response to
      that call. This article offers a critical analysis of a couple of Fins's
      arguments. But it also emphasizes the importance of these developments and Fins's
      work for thinking through bedside and organizational ethics issues that arise in 
      advocating for patients with disorders of consciousness.
FAU - Guidry-Grimes, Laura
AU  - Guidry-Grimes L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Brain Injuries/*epidemiology
MH  - Decision Support Techniques
MH  - Hospital Administration
MH  - Humans
MH  - Long-Term Care/organization & administration
MH  - Persistent Vegetative State/*psychology
MH  - Prognosis
MH  - Withholding Treatment/*ethics
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520300181 [pii]
AID - 10.1353/pbm.2020.0047 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(3):553-569. doi: 10.1353/pbm.2020.0047.


PMID- 33416624
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 3
DP  - 2020
TI  - The Congress "Yes to Life": A Hand Offered in Dialogue.
PG  - 506-508
LID - 10.1353/pbm.2020.0038 [doi]
AB  - The Congress "Yes to Life," devoted to the ethical problems in perinatology, has 
      been an important carrefour for the intercultural dialogue on these themes. This 
      paper describes the aim of the Congress and why it was proposed.
FAU - Bellieni, Carlo V
AU  - Bellieni CV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Congresses as Topic
MH  - Female
MH  - Global Health
MH  - Hospice Care/*organization & administration
MH  - Humans
MH  - Perinatology/*organization & administration
MH  - Pregnancy
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520300090 [pii]
AID - 10.1353/pbm.2020.0038 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(3):506-508. doi: 10.1353/pbm.2020.0038.


PMID- 33416622
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 3
DP  - 2020
TI  - Life After the Storm: Surviving COVID-19.
PG  - 494-501
LID - 10.1353/pbm.2020.0036 [doi]
AB  - This article highlights the outcomes of COVID-19, from the perspective of
      surviving patients, health-care systems, and societies. It draws on first-person 
      experience of what it is to go through and survive acute respiratory distress
      syndrome (ARDS) and multiple organ failure. It summarizes the research on the
      short- and long-term outcomes for critically ill patients. The physical,
      cognitive, and emotional sequalae are staggering. Health-care professionals and
      systems will have to step up to meet the challenge of caring for large numbers of
      COVID-19 patients after discharge. And societies will have to step up to the
      ethical questions that the pandemic has made so stark. What kind of societies do 
      we want to be, in terms of guarding the welfare of our most vulnerable citizens?
FAU - Misak, Cheryl
AU  - Misak C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
RN  - postintensive care syndrome
SB  - IM
MH  - *COVID-19/therapy
MH  - Critical Illness/psychology/rehabilitation
MH  - Health Personnel
MH  - Humans
MH  - Intensive Care Units
MH  - *Quality of Life
MH  - Respiration, Artificial/adverse effects/*psychology
MH  - Socioeconomic Factors
MH  - Survivors
EDAT- 2021/01/09 06:00
MHDA- 2021/01/15 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - S1529879520300077 [pii]
AID - 10.1353/pbm.2020.0036 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(3):494-501. doi: 10.1353/pbm.2020.0036.


PMID- 33416618
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 3
DP  - 2020
TI  - When Physicians Don't Know.
PG  - 444-457
LID - 10.1353/pbm.2020.0032 [doi]
AB  - Given the boundless amount of scientific information, clinical skills, and
      interventional techniques present in biomedicine today, it is impossible for
      individual physicians and clinicians to have absolute medical knowledge. Further,
      ambiguity in the interpretation and treatment of illness can lead to significant 
      uncertainty. Despite the inevitability of not knowing in biomedicine, however,
      there is relatively little academic discussion about how physicians are
      socialized to address ignorance, how clinicians experience gaps in knowledge as
      practitioners, or the various forms that not knowing takes in professional
      health-care practice and education. This article seeks to invigorate new
      discussions on the role of ignorance and "non-knowledge" in biomedical practice
      and training. The article critically examines the predominant focus on medical
      knowledge in the sociological literature and presents a new anthropological
      framework for the relationship between knowing and not knowing in medicine,
      called "sufficient knowledge." The author posits that future social and
      humanistic examinations of biomedicine should seriously consider the ways that
      physicians navigate ignorance, uncertainty, and not knowing, and that scientists,
      clinicians, social scientists, and ethicists all have valuable disciplinary
      perspectives to bring to the conversation around medical ignorance.
FAU - Knopes, Julia
AU  - Knopes J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Anthropology
MH  - Education, Medical/organization & administration
MH  - Humans
MH  - *Knowledge
MH  - Medicine/*standards
MH  - Philosophy, Medical
MH  - Physicians/*psychology
MH  - Uncertainty
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S152987952030003X [pii]
AID - 10.1353/pbm.2020.0032 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(3):444-457. doi: 10.1353/pbm.2020.0032.


PMID- 33416616
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1529-8795 (Electronic)
IS  - 0031-5982 (Linking)
VI  - 63
IP  - 3
DP  - 2020
TI  - Three Kinds of Humility in Bioethics Certification.
PG  - 420-428
LID - 10.1353/pbm.2020.0030 [doi]
AB  - The author's skepticism about certifying bioethicists has a 20-year history. The 
      hazards of certification include doubts about whether an online, multiple-choice 
      exam measures what is important in bioethical deliberation. Other worries include
      the potential neglect of informal reasoning processes used by patients and
      families, the creation of a false sense of expertise, and how certification can
      disenfranchise lay members of ethics committees. This essay does not seek to
      reverse the growing trend toward certification but urges humility both in the
      process of certification and in interpreting the results. Humility is here
      defined through the works of Judith Andre and Jack Coulehan. Three kinds of
      humility are described as important for bioethics work: epistemic, moral, and
      ontological. The current qualifications for taking the certification exam are
      discussed, and suggestions for a better approach are offered.
FAU - Churchill, Larry R
AU  - Churchill LR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perspect Biol Med
JT  - Perspectives in biology and medicine
JID - 0401132
SB  - IM
MH  - Bioethics
MH  - Certification/*standards
MH  - Ethicists/*psychology/*standards
MH  - Humans
MH  - Intelligence
MH  - Morals
MH  - *Personality
MH  - Professional Competence
EDAT- 2021/01/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1529879520300016 [pii]
AID - 10.1353/pbm.2020.0030 [doi]
PST - ppublish
SO  - Perspect Biol Med. 2020;63(3):420-428. doi: 10.1353/pbm.2020.0030.


PMID- 33416597
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 1080-6571 (Electronic)
IS  - 0278-9671 (Linking)
VI  - 38
IP  - 1
DP  - 2020
TI  - Clinical Empathy and the Ethics of "Detached Concern" in Mid-Twentieth-Century
      British Literature.
PG  - 113-140
LID - 10.1353/lm.2020.0005 [doi]
AB  - This article explores the cultural reception of the medical ethic of "detached
      concern" as represented in mid-twentieth-century British literature. Although
      empathy is a crucial aspect of effective medical care, daily exposure to the pain
      and suffering of others can lead to professional distress and burnout. In
      response, medical practitioners developed an emotionless conception of
      professional empathy, namely "detached concern," which equates the detachment
      required to dissect a cadaver to the stance needed to listen empathically without
      becoming emotionally involved. Mid-century British novels by Stanley Winchester, 
      Margaret Drabble, Anthony Burgess, and A. J. Cronin offer privileged insight into
      the values British physicians and patients attached to empathy. These texts lead 
      readers to question whether "detached concern" necessarily leads to empathy and
      offer insight into the lived experience of doctor-patient relations during a
      period of radical change and innovation in healthcare practices.
FAU - Matthews, Graham
AU  - Matthews G
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Lit Med
JT  - Literature and medicine
JID - 8309346
SB  - IM
MH  - *Empathy
MH  - *Ethics, Medical
MH  - History, 20th Century
MH  - Humans
MH  - *Medicine in Literature
MH  - *Physician-Patient Relations
MH  - United Kingdom
EDAT- 2021/01/09 06:00
MHDA- 2021/10/27 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
AID - S1080657120100055 [pii]
AID - 10.1353/lm.2020.0005 [doi]
PST - ppublish
SO  - Lit Med. 2020;38(1):113-140. doi: 10.1353/lm.2020.0005.


PMID- 33416589
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1086-3249 (Electronic)
IS  - 1054-6863 (Linking)
VI  - 30
IP  - 2
DP  - 2020
TI  - Research and Responsibility in Global Health: An Analysis of the Joining Forces
      Study in Ghana.
PG  - 111-139
LID - 10.1353/ken.2020.0008 [doi]
AB  - We explore conceptions of responsibility and integrity in global health research 
      and practice as it is being carried out in the academic setting. Our specific
      motivation derives from the recent publication of a study by a clinical research 
      team involving the delivery of mental health care services in a Ghanaian prayer
      camp. The study was controversial on account of the prayer camp's history of
      human rights abuses and therefore was met with several high-profile critiques. We
      offer a more charitable evaluation of the Joining Forces study. Our analysis has 
      three primary goals. First, we respond to criticism suggesting that the Joining
      Forces research team needed to maintain some form of morally "clean hands" in
      relation to the human rights abuses at Mount Horeb prayer camp. We argue that,
      for academic global health practitioners working under severe resource
      constraints, what is reasonable and responsible to pursue is a complex
      proposition without a one-size-fits-all ethical answer. Second, we offer an
      explanation for why the Joining Forces study team designed the project as they
      did in spite of their obvious vulnerability to ethical concern. We argue that the
      Joining Forces study was a morally risky, but ethically earnest effort to reach a
      neglected patient population and promote behavior change in prayer camp staff.
      Third, we identify an open ethical question born of the researchers' commitment
      to pragmatism that, to our knowledge, has not been previously addressed in
      published discussion of the Joining Forces project. Namely, was the incomplete
      disclosure of information to prayer camp staff defensible? We close with a
      broader reflection on the notion of moral integrity in the pursuit of the
      salutary aims of global health.
FAU - Taylor, Lauren
AU  - Taylor L
FAU - Sayeed, Sadath
AU  - Sayeed S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kennedy Inst Ethics J
JT  - Kennedy Institute of Ethics journal
JID - 9109135
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - *Ethics, Research
MH  - Ghana/epidemiology
MH  - Global Health
MH  - Human Rights Abuses
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - Psychotropic Drugs/*therapeutic use
MH  - *Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - Research Personnel/ethics
MH  - Restraint, Physical
MH  - Spiritual Therapies/*methods
EDAT- 2021/01/09 06:00
MHDA- 2021/08/06 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - S108632492020003X [pii]
AID - 10.1353/ken.2020.0008 [doi]
PST - ppublish
SO  - Kennedy Inst Ethics J. 2020;30(2):111-139. doi: 10.1353/ken.2020.0008.


PMID- 33416586
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 2
DP  - 2020
TI  - How Should Physicians Manage Neuroprognosis with ECPR?
PG  - 173-182
LID - 10.1353/nib.2020.0046 [doi]
AB  - Rapidly advancing technologies in the field of extracorporeal cardiopulmonary
      resuscitation (ECPR) have presented a new challenge in accurate
      neuroprognostication following cardiac arrest. Determination of brain state
      informs the prognostic picture and allows providers to begin effective
      communication regarding likelihood of meaningful neurological recovery as defined
      by patients or family members. The evolving role of sedation during ECPR and its 
      impacts on ethical tension in decision-making is reviewed. Work surrounding the
      advancing field of neuroprognostication after cardiac arrest and hypothermia is
      summarized and implications of premature withdrawal of life-sustaining treatments
      are discussed. Advances that improve predictive value for neurological recovery
      are utilized in affirming and discussing the implications for end-of-life wishes 
      of individuals in the setting of intensive resuscitative therapies.
FAU - McCurry, Ian J
AU  - McCurry IJ
FAU - Han, Jason
AU  - Han J
FAU - Courtwright, Andrew
AU  - Courtwright A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - Cardiopulmonary Resuscitation/*methods
MH  - Clinical Decision-Making/*ethics
MH  - Decision Making/*ethics
MH  - Extracorporeal Membrane Oxygenation/*methods
MH  - Female
MH  - Heart Arrest/*therapy
MH  - Humans
MH  - Hypoxia-Ischemia, Brain/*diagnosis
MH  - Middle Aged
MH  - Prognosis
MH  - Withholding Treatment/ethics
EDAT- 2021/01/09 06:00
MHDA- 2021/09/22 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
AID - S215717402020019X [pii]
AID - 10.1353/nib.2020.0046 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(2):173-182. doi: 10.1353/nib.2020.0046.


PMID- 33416585
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 2
DP  - 2020
TI  - An Ethics of Unknowing: Discerning Ethical Patient-Provider Interactions in
      Clinical Decision-Making.
PG  - 159-172
LID - 10.1353/nib.2020.0045 [doi]
AB  - There is an irreducible amount of uncertainty in clinical decision-making. Both
      health care providers and patients experience anxiety elicited by clinical
      uncertainty, and this can lead to missed opportunities for healthy shared
      decision-making. In order to improve the patient-provider relationship and the
      ethical qualities of decision-making, the provider first needs to recognize where
      his/her "unknowing" exists. This article presents a model for a unique ethics of 
      unknowing by identifying three levels at which the provider's knowledge or lack
      thereof impacts clinical decision-making. The model illuminates ethical choices
      that providers can make to promote healthy patient-provider relationships. The
      means by which an ethics of unknowing informs shared decision-making in patient
      care will be exemplified through a case study of one patient's encounters with
      several physicians while making difficult decisions throughout her breast cancer 
      journey.
FAU - Kasman, Deborah L
AU  - Kasman DL
LA  - eng
PT  - Journal Article
PT  - Personal Narrative
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Breast Neoplasms/*therapy
MH  - Clinical Decision-Making/*ethics
MH  - *Decision Making, Shared
MH  - Female
MH  - Humans
MH  - Physician-Patient Relations/*ethics
MH  - *Uncertainty
EDAT- 2021/01/09 06:00
MHDA- 2021/09/22 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
AID - S2157174020200188 [pii]
AID - 10.1353/nib.2020.0045 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(2):159-172. doi: 10.1353/nib.2020.0045.


PMID- 33416531
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 2157-1740 (Electronic)
IS  - 2157-1740 (Linking)
VI  - 10
IP  - 1
DP  - 2020
TI  - Reanimated: Navigating Life After a Near-Death Experience.
PG  - 1-4
LID - 10.1353/nib.2020.0024 [doi]
AB  - This symposium includes twelve personal narratives from individuals who have had 
      a near-death experience (NDE) in medical or surgical settings. It also includes
      three commentaries on these narratives by experts in NDEs, healthcare ethics,
      spiritual counseling, and chaplaincy. The stories and commentaries highlight how 
      healthcare workers' reactions to NDEs may have long-term positive or negative
      effects on patients and their families. The symposium identifies gaps in care and
      provides a road map for nonjudgmental and supportive responses to NDEs.
FAU - DuBois, James M
AU  - DuBois JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Narrat Inq Bioeth
JT  - Narrative inquiry in bioethics
JID - 101603418
SB  - IM
MH  - *Death
MH  - Ethics, Clinical
MH  - Humans
MH  - *Narration
MH  - Pastoral Care
MH  - Surveys and Questionnaires
EDAT- 2021/01/09 06:00
MHDA- 2021/09/02 06:00
CRDT- 2021/01/08 12:11
PHST- 2021/01/08 12:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - S2157174020100241 [pii]
AID - 10.1353/nib.2020.0024 [doi]
PST - ppublish
SO  - Narrat Inq Bioeth. 2020;10(1):1-4. doi: 10.1353/nib.2020.0024.


PMID- 33415906
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 28
IP  - 1
DP  - 2020 Dec
TI  - Don Chalmers: His Contributions to Legal Research and Education, Health Law, and 
      Research Ethics, Locally and Globally.
PG  - 289-297
AB  - Distinguished Professor Don Chalmers retired from the Law Faculty at the
      University of Tasmania on Friday 10 July 2020. This article is dedicated to Don, 
      providing a brief account and acknowledgment of his fine contributions to legal
      research and education and law reform, particularly in the field of health and
      medical law, research ethics and policy reform. He has been an excellent
      colleague, mentor, leader, teacher, and researcher. He deserves to enjoy a long
      and rewarding retirement, though we, and many others, will not allow him to slip 
      entirely out of the limelight. Don is still much needed, and still has so much to
      give in our ongoing quest to ensure that legal, research ethics and policy
      responses are adequate in reaping the benefits and responding to the challenges
      of biomedical advances.
FAU - Nicol, Dianne
AU  - Nicol D
AD  - Professor of Law and Director of the Centre for Law and Genetics, Law Faculty,
      University of Tasmania.
FAU - Joly, Yann
AU  - Joly Y
AD  - Professor of Law and member of the Centre of Genomics and Policy, McGill
      University, Canada.
FAU - Kaye, Jane
AU  - Kaye J
AD  - Professor of Law and Director, Centre for Health, Law and Emerging Technologies
      University of Oxford and Centre for Health, Law and Emerging Technologies,
      Melbourne Law School, University of Melbourne.
FAU - Knoppers, Bartha
AU  - Knoppers B
AD  - Professor of Law and Director of the Centre of Genomics and Policy, McGill
      University, Canada.
FAU - Meslin, Eric M
AU  - Meslin EM
AD  - President and CEO, Council of Canadian Academies; former Executive Director, US
      National Bioethics Advisory Commission; Adjunct Professor, Dalla Lana School of
      Public Health, University of Toronto, Canada.
FAU - Nielsen, Jane
AU  - Nielsen J
AD  - Associate Professor of Law and member of the Centre for Law and Genetics, Law
      Faculty, University of Tasmania.
FAU - Otlowski, Margaret
AU  - Otlowski M
AD  - Professor of Law and Deputy Director of the Centre for Law and Genetics, Law
      Faculty and Pro Vice Chancellor (Culture, Wellbeing and Sustainability)
      University of Tasmania.
FAU - Warner, Kate
AU  - Warner K
AD  - Emeritus Professor of Law, University of Tasmania and Governor, State of
      Tasmania.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - *Ethics, Research
MH  - *Health Education
MH  - Male
OTO - NOTNLM
OT  - Don Chalmers
OT  - education
OT  - law reform
OT  - legal research
EDAT- 2021/01/09 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/08 06:21
PHST- 2021/01/08 06:21 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Dec;28(1):289-297.


PMID- 33415903
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 28
IP  - 1
DP  - 2020 Dec
TI  - In Whose Interest? Recent Developments in Regulatory Immediate Action against
      Medical Practitioners in Australia.
PG  - 244-269
AB  - "Immediate action" is a powerful regulatory tool available to Medical Boards. It 
      protects the public from harm by restricting a medical practitioner's
      registration after allegations have been made, but before wrongdoing is proven.
      This article charts the development of these coercive powers in Australia and
      examines the legal, socio-political and ethical justification for supplementing a
      well-defined "public risk" test with a broad and controversial "public interest" 
      test that leaves medical practitioners vulnerable to inconsistent
      decision-making. Compared to overseas jurisdictions, immediate action powers in
      Australia offer fewer procedural protections. The regulatory response to
      perceived threats to public trust and confidence in the medical profession needs 
      to be proportionate, transparent, effective, and consistent, to protect the
      public while also being fair to practitioners.
FAU - Bradfield, Owen M
AU  - Bradfield OM
AD  - PhD Candidate, Melbourne School of Population and Global Health, University of
      Melbourne.
FAU - Spittal, Matthew J
AU  - Spittal MJ
AD  - Associate Professor, Melbourne School of Population and Global Health.
FAU - Bismark, Marie M
AU  - Bismark MM
AD  - Associate Professor and Head, Law and Public Health Unit, Melbourne School of
      Population and Global Health.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Australia
MH  - *Health Personnel
MH  - Humans
OTO - NOTNLM
OT  - Medical regulation
OT  - immediate action
OT  - patient safety
OT  - public interest
COIS- The authors have previously conducted research in partnership with AHPRA.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/08 06:21
PHST- 2021/01/08 06:21 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Dec;28(1):244-269.


PMID- 33415893
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220531
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 28
IP  - 1
DP  - 2020 Dec
TI  - Clinical Research without Consent: Challenges for COVID-19 Research.
PG  - 90-106
AB  - The imperatives generated by the need for research into efficacious forms of
      treatment for COVID-19 have shone a fresh light upon the criteria for inclusion
      in clinical trials of persons unable to provide informed consent by reason of a
      number of factors including the seriousness of their illness symptomatology. This
      column identifies diversity in European, United States and Australian legislative
      and other guidance on the ethical issues that arise in respect of clinical
      research to which participants are not able to consent. It reviews the
      decision-making by the New South Wales Civil and Administrative Tribunal in a
      2020 case in which permission was sought to conduct a clinical trial into a drug,
      STC 3141, designed by researchers as a potential treatment for patients with
      Adult Respiratory Distress Syndrome arising from COVID-19. It outlines the
      reasoning of the Tribunal in the context of debates about the balance to be
      struck between clinically useful medication trials and the need to avoid
      exploitation of vulnerable persons not able to provide their own consent, be that
      by virtue of disabilities such as acuteness of illness or dementia
      symptomatology. It contends that the decision illustrates the potential for
      research to be undertaken safely and ethically, utilising subjects in an
      intensive care unit who are unable to provide consent.
FAU - Freckelton, Ian
AU  - Freckelton I
AD  - Barrister, Castan Chambers, Melbourne; Judge, Supreme Court of the Republic of
      Nauru; Professorial Fellow of Law and Psychiatry, University of Melbourne;
      Adjunct Professor of Forensic Medicine, Monash University; Adjunct Professor,
      Australian Centre for Health Law Research, Queensland University of Technology;
      Adjunct Professor, Johns Hopkins University, Baltimore, Maryland, United States.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Adult
MH  - Australia
MH  - Biomedical Research
MH  - *COVID-19
MH  - *Clinical Trials as Topic
MH  - Humans
MH  - *Informed Consent
MH  - New South Wales
MH  - SARS-CoV-2
MH  - United States
OTO - NOTNLM
OT  - COVID-19
OT  - NHMRC guidance
OT  - clinical research
OT  - consent
OT  - ethics
OT  - external oversight
OT  - patients unable to give consent
OT  - surrogate decision-making
COIS- None.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/08 06:21
PHST- 2021/01/08 06:21 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Dec;28(1):90-106.


PMID- 33415888
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 28
IP  - 1
DP  - 2020 Dec
TI  - Embracing the Future: Using Artificial Intelligence in Australian Health
      Practitioner Regulation.
PG  - 21-44
AB  - Artificial intelligence (AI) - computerised technology that imitates aspects of
      human intelligence - is developing at a rapid pace. It is increasingly used to
      improve the efficiency and effectiveness of multifarious processes in private
      industry and public administration. Among the statutory authorities that have
      begun to explore the potential for AI to assist them are regulators of
      Australia's health professions. Protection of the public is a chief objective of 
      this area of administrative law. This section considers some possible uses of AI 
      - and particularly its capacities to analyse and draw inferences from data, make 
      predictions and decisions, and automate tasks - that might help regulators
      achieve this goal. The section also contemplates the implications of AI
      involvement in the regulation of health practitioners for the rule of law and
      human rights it protects and recommends measures that might be taken to mitigate 
      risks of their infringement.
FAU - Wolf, Gabrielle
AU  - Wolf G
AD  - Associate Professor, School of Law, Faculty of Business & Law, Deakin University.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - *Artificial Intelligence
MH  - Australia
MH  - *Human Rights
MH  - Humans
OTO - NOTNLM
OT  - artificial intelligence
OT  - bias
OT  - ethical safeguards
OT  - health technology
OT  - privacy protection
OT  - regulation of health practitioners
COIS- None.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/08 06:21
PHST- 2021/01/08 06:21 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Dec;28(1):21-44.


PMID- 33415306
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2382-1205 (Print)
IS  - 2382-1205 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Addressing the Needs of Migrant Workers in ICUs in Singapore.
PG  - 2382120520977190
LID - 10.1177/2382120520977190 [doi]
AB  - BACKGROUND: With nearly 400 000 migrant workers in Singapore, many from
      Bangladesh, India and Myanmar, language and cultural barriers posed a great many 
      challenges during the COVID-19 pandemic. This was especially so as majority of
      the COVID-19 clusters in Singapore emerged from their communal dormitories. With 
      concerns arising as to how this minority group could be best cared for in the
      intensive care units, the need for medical interpreters became clear. MAIN: In
      response, the Communication and Supportive Care (CSC) workgroup at the Singapore 
      General Hospital developed the 'Medical Interpreters Training for ICU
      Conversations' program. Led by a medical social worker-cum-ethicist and 2
      palliative care physicians, twenty volunteers underwent training. The program
      comprised of 4 parts. Firstly, volunteers were provided with an overview of
      challenges within the COVID-19 isolation ICU environment. Discussed in detail
      were common issues between patients and families, forms of distress faced by
      healthcare workers, family communication modality protocols, and the
      sociocultural demographics of Singapore's migrant worker population. Secondly,
      key practice principles and 'Do's/Don'ts' in line with the ethical principles of 
      medical interpretation identified by the California Healthcare Interpreters
      Association were shared. Thirdly, practical steps to consider before, during and 
      at the end of each interpretation session were foregrounded. Lastly, a focus
      group discussion on the complexities of ICU cases and their attending issues was 
      conducted. Targeted support was further provided in response to participant
      feedback and specific issues raised. CONCLUSION: As a testament to its efficacy, 
      the program has since been extended to the general wards and the Ministry of
      Health in Singapore has further commissioned similar programs in various
      hospitals. In-depth training on the fundamentals of medical terminology, language
      and cultural competency should be provided to all pertinent healthcare workers
      and hospitals should consider hiring medical interpreters in permanent positions.
CI  - (c) The Author(s) 2020.
FAU - Lim, Crystal
AU  - Lim C
AD  - Medical Social Services, Singapore General Hospital, Singapore.
FAU - Zhou, Jamie Xuelian
AU  - Zhou JX
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
AD  - Academic Clinical Programme, SingHealth Duke-NUS Academic Medical Centre,
      Singapore.
AD  - Lien Center for Palliative Care, Duke-NUS Graduate Medical School, Singapore.
FAU - Woong, Natalie Liling
AU  - Woong NL
AD  - Department of Internal Medicine, Singapore General Hospital, Singapore.
FAU - Chiam, Min
AU  - Chiam M
AD  - Division of Cancer Education, National Cancer Centre Singapore, Singapore.
FAU - Krishna, Lalit Kumar Radha
AU  - Krishna LKR
AUID- ORCID: https://orcid.org/0000-0002-7350-8644
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
AD  - Division of Cancer Education, National Cancer Centre Singapore, Singapore.
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, Cancer Research Centre, University of Liverpool, UK.
AD  - Centre for Biomedical Ethics, National University of Singapore, Singapore.
AD  - PalC, The Palliative Care Centre for Excellence in Research and Education,
      Singapore.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - United States
TA  - J Med Educ Curric Dev
JT  - Journal of medical education and curricular development
JID - 101690298
PMC - PMC7750748
OTO - NOTNLM
OT  - COVID-19
OT  - Intensive care units
OT  - emigrants and immigrants
OT  - medical interpretation
OT  - medical translation
OT  - migrant community
OT  - training support
OT  - translations
COIS- Declaration of conflicting Interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:13
PHST- 2020/09/23 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2021/01/08 06:13 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - 10.1177/2382120520977190 [doi]
AID - 10.1177_2382120520977190 [pii]
PST - epublish
SO  - J Med Educ Curric Dev. 2020 Dec 18;7:2382120520977190. doi:
      10.1177/2382120520977190. eCollection 2020 Jan-Dec.


PMID- 33415279
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2377-9608 (Electronic)
IS  - 2377-9608 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Strengthening Perceptions of Ethical Competence Among Nursing Students and
      Graduates.
PG  - 2377960820924170
LID - 10.1177/2377960820924170 [doi]
AB  - INTRODUCTION: Ethical competence is part of all health-care professionals'
      general competence. It relates to moral issues and is based on the professionals'
      knowledge, skills, and attitudes for coping with ethical dilemmas. Ethics
      education aims to increase nursing students' and nursing graduates' ethical
      self-confidence. Previous research has found many gaps in ethical education
      content and poor understanding of how these gaps affect graduates. OBJECTIVES:
      This study aims to evaluate an advanced education workshop held in the nursing
      department in Max Stern Yezreel Valley College aimed at strengthening the
      self-perceptions of ethical competence, to address the above gap, by raising
      students' self-efficacy when coping with ethical dilemmas. METHODS: The
      effectiveness of the workshop for nursing students was evaluated using the
      Generalized Self-Efficacy Scale and at three points in time: before the workshop,
      after the workshop, and after graduation. RESULTS: Statistically significant
      differences were found in overall self-efficacy: before the workshop (mean of
      2.42), after the workshop (mean of 2.13), and for graduates (mean of 1.58) with p
      < .000 on a scale ranging from 1 to 5 (1 indicating high self-efficacy). Mean
      scores for students' evaluation after the workshop and for graduates were 7.8 and
      7.25, respectively, on a scale ranging from 1 to 10, where 10 indicates high
      self-efficacy. Graduates presented a high mean score regarding their ability to
      cope with ethical dilemmas when compared with other nurses working with them
      (mean of 7.4, on a scale ranging from 1 to 10). CONCLUSION: Levels of
      self-efficacy with regard to coping with ethical dilemmas increased over time,
      suggesting that the workshop strengthened the self-perception of ethical
      competence for nursing students and graduates.
CI  - (c) The Author(s) 2020.
FAU - Obeid, Samira
AU  - Obeid S
AUID- ORCID: https://orcid.org/0000-0002-1028-1729
AD  - Department of Nursing, Max Stern Yezreel Valley College, Israel.
FAU - Man, Michal
AU  - Man M
AD  - Department of Nursing, Max Stern Yezreel Valley College, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - United States
TA  - SAGE Open Nurs
JT  - SAGE open nursing
JID - 101724853
PMC - PMC7774371
OTO - NOTNLM
OT  - ethical dilemma
OT  - ethics education
OT  - graduates
OT  - nursing students
OT  - self-efficacy
COIS- All authors have read and approved this manuscript and participated in collecting
      the data and analyzing it.The author(s) declared no potential conflicts of
      interest with respect to the research, authorship, and/or publication of this
      article.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:13
PHST- 2019/07/02 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2021/01/08 06:13 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - 10.1177/2377960820924170 [doi]
AID - 10.1177_2377960820924170 [pii]
PST - epublish
SO  - SAGE Open Nurs. 2020 May 12;6:2377960820924170. doi: 10.1177/2377960820924170.
      eCollection 2020 Jan-Dec.


PMID- 33415274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2377-9608 (Electronic)
IS  - 2377-9608 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Nurses' Perception of the Bed Alarm System in Acute-Care Hospitals.
PG  - 2377960820916252
LID - 10.1177/2377960820916252 [doi]
AB  - INTRODUCTION: In hospitals, the nurse uses the bed alarm system for patients'
      safety, which may have some forms of physical restraints included, depending on
      the situation. However, the nurses' perceptions of the bed alarm system with
      reference to restraints are yet to be clarified. Moreover, there were no reports 
      that can shed light upon the factors that relate to nurses' perceptions about the
      bed alarm system in Japan. The objective of this study is to investigate the
      nurses' perception on whether the bed alarm can be considered as a form of
      physical restraint and to elucidate the factors that pertain to the nurses'
      perceptions regarding the bed alarm. METHODS: This study conducted a quantitative
      cross-sectional survey. We used bivariate logistic regression analyses to
      investigate the nurses' perception and the factors affecting these perception.
      Ethical approval was obtained from the research ethics committee of the Kyoto
      University. Participants opted for answering the questionnaire voluntarily.
      RESULTS: The sample population comprised of 289 nurses from 10 acute-care
      hospitals. Out of these, 214 (74.0%) nurses considered the bed alarm system as a 
      form of restraint, and 75 nurses (26.0%) did not. Furthermore, the nurses'
      perception was relevant to the hospitals that they belonged to, their years of
      experience, and the content of education. It was especially interesting that the 
      group of nurses with little experience had the consciousness of being considered 
      the bed alarm as restraint compared with nurses with many years of experience.
      CONCLUSION: The alarm systems are gradually being considered to be classified as 
      a restraint. Hospitals should ensure providing an ethically sensitive climate and
      appropriate educational opportunities to help nurses build these perceptions for 
      patient care. An ethically sensitive climate and appropriate educational
      opportunities would lead to an environment that nurtures nurses with the ability 
      to recognize problems in daily care.
CI  - (c) The Author(s) 2020.
FAU - Okumoto, Ayaka
AU  - Okumoto A
AUID- ORCID: https://orcid.org/0000-0001-8056-3978
AD  - School of Human Health Sciences, Kyoto University Graduate School of Medicine,
      Kyoto, Japan.
FAU - Miyata, Chiharu
AU  - Miyata C
AD  - Course of Nursing, Mie University Graduate School of Medicine, Mie, Japan.
FAU - Yoneyama, Satoko
AU  - Yoneyama S
AD  - School of Human Health Sciences, Kyoto University Graduate School of Medicine,
      Kyoto, Japan.
AD  - Department of Neuropsychiatry, Kanazawa Medical University, Ishikawa, Japan.
FAU - Kinoshita, Ayae
AU  - Kinoshita A
AD  - School of Human Health Sciences, Kyoto University Graduate School of Medicine,
      Kyoto, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200405
PL  - United States
TA  - SAGE Open Nurs
JT  - SAGE open nursing
JID - 101724853
PMC - PMC7774491
OTO - NOTNLM
OT  - acute hospital
OT  - bed alarm
OT  - nursing ethics
OT  - organizational climate
OT  - physical restraint
COIS- The author(s) declared no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:13
PHST- 2019/11/23 00:00 [received]
PHST- 2020/02/09 00:00 [revised]
PHST- 2020/03/08 00:00 [accepted]
PHST- 2021/01/08 06:13 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - 10.1177/2377960820916252 [doi]
AID - 10.1177_2377960820916252 [pii]
PST - epublish
SO  - SAGE Open Nurs. 2020 Apr 5;6:2377960820916252. doi: 10.1177/2377960820916252.
      eCollection 2020 Jan-Dec.


PMID- 33415264
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 2377-9608 (Electronic)
IS  - 2377-9608 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Living With Obesity: Expressions of Longing.
PG  - 2377960819901193
LID - 10.1177/2377960819901193 [doi]
AB  - Those who are obese experience complex moral distress. The norm in Western
      societies is to be slim, and people living with obesity experience challenges
      under the gaze of society. They feel great vulnerability and the available
      treatments seldom meet individual needs. New concepts of embodiment need to be
      developed to include phenomenological investigations. There is limited knowledge 
      about longing among those suffering from obesity. A deeper understanding of
      longing from an individual perspective is required to improve treatment. The aim 
      of this study was to gain an in-depth understanding of the experiences of longing
      by those suffering from obesity. The research was approved by the Norwegian
      Regional Committees for Medical and Health Research Ethics. An explorative
      phenomenological-hermeneutical design was used. Qualitative interviews were
      conducted with 18 participants, all with body mass indexes in the range of 30 to 
      45, which were then analyzed using a phenomenological-hermeneutical approach.
      Three main dimensions of longing were revealed: longing for normality, longing
      for what was lost, and longing for simplicity in life. The health service needs
      to understand better the longings of obese individuals to help them live their
      lives in greater freedom, based on their own longings and self-care. Focusing on 
      longing may reveal a person's true desires, and the longing may be a form of
      resistance to the disciplination of society.
CI  - (c) The Author(s) 2020.
FAU - Ueland, Venke
AU  - Ueland V
AUID- ORCID: https://orcid.org/0000-0001-5600-3348
AD  - Faculty of Health Sciences, University of Stavanger, Stavanger, Norway.
FAU - Dysvik, Elin
AU  - Dysvik E
AD  - Faculty of Health Sciences, University of Stavanger, Stavanger, Norway.
FAU - Furnes, Bodil
AU  - Furnes B
AD  - Faculty of Health Sciences, University of Stavanger, Stavanger, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200122
PL  - United States
TA  - SAGE Open Nurs
JT  - SAGE open nursing
JID - 101724853
PMC - PMC7774488
OTO - NOTNLM
OT  - Foucault
OT  - body
OT  - disciplination
OT  - heterotopic spaces
OT  - longing
OT  - obesity
OT  - self-care
COIS- The author(s) declared no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:13
PHST- 2019/07/05 00:00 [received]
PHST- 2019/10/27 00:00 [revised]
PHST- 2019/12/23 00:00 [accepted]
PHST- 2021/01/08 06:13 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - 10.1177/2377960819901193 [doi]
AID - 10.1177_2377960819901193 [pii]
PST - epublish
SO  - SAGE Open Nurs. 2020 Jan 22;6:2377960819901193. doi: 10.1177/2377960819901193.
      eCollection 2020 Jan-Dec.


PMID- 33415057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 4
TI  - Resuscitative Thoracotomy for Multiple Gunshot Wounds With Cardiac Tamponade
      Despite Pericardial Window.
PG  - e11907
LID - 10.7759/cureus.11907 [doi]
AB  - This report reviews the indications and complications of resuscitative
      thoracotomy in the trauma patient as seen with the clinical course of a
      19-year-old male who experienced postoperative pericardial tamponade after a
      bilateral resuscitative thoracotomy with pericardiotomy. This patient presented
      to the hospital in critical condition with 31 gunshot wounds (GSWs) distributed
      over the chest, abdomen, and extremities. After undergoing an initially
      successful resuscitative thoracotomy, the patient continued to bleed into his
      chest at a greater rate than the chest tubes were able to adequately evacuate.
      Despite the presence of a large pericardial window, clotted blood led to cardiac 
      tamponade. Subsequent bedside reopening of thoracotomy under conscious sedation
      (ketamine, fentanyl, and midazolam) was required to evacuate the clots and
      stabilize the patient. This case provides the opportunity to discuss several
      interesting points for managing the traumatized patient, including indications
      for resuscitative thoracotomy, use of conscious sedation for bedside major
      surgery, and complications of clamshell thoracotomy, and ethics of resource
      allocation.
CI  - Copyright (c) 2020, Kostick et al.
FAU - Kostick, Nathan
AU  - Kostick N
AD  - Medicine, University of Central Florida College of Medicine, Orlando, USA.
FAU - Gray, Sanjiv
AU  - Gray S
AD  - Surgery, University of Central Florida College of Medicine, Orlando, USA.
FAU - Huynh, Dustin
AU  - Huynh D
AD  - Trauma and Acute Care Surgery, Osceola Regional Medical Center, Kissimmee, USA.
LA  - eng
PT  - Case Reports
DEP - 20201204
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7781870
OTO - NOTNLM
OT  - coagulopathy of trauma
OT  - emergency medicine
OT  - gsw
OT  - tamponade
OT  - thoracic surgery
OT  - thoracotomy
OT  - trauma
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:12
PHST- 2021/01/08 06:12 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - 10.7759/cureus.11907 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 4;12(12):e11907. doi: 10.7759/cureus.11907.


PMID- 33414932
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 2075-0528 (Electronic)
IS  - 2075-051X (Linking)
VI  - 20
IP  - 4
DP  - 2020 Nov
TI  - Towards Culture-Oriented Medical Philosophy, Education, Research and Practice.
PG  - e290-e295
LID - 10.18295/squmj.2020.20.04.003 [doi]
AB  - Medicine is a sociotechnical system wherein culture manifests itself in all its
      aspects. Culture, however, is often intangible and is frequently neglected in
      formal healthcare education, research and practice. This sounding board article
      attempts to generate interest in making culture a serious component of healthcare
      systems at different levels, including its founding philosophical underpinnings, 
      educational systems, research activities and clinical practice. It is recommended
      that a framework of culture-oriented medical philosophy, education, research and 
      practice be implemented. Each component of this framework is briefly discussed in
      relation to healthcare. Culture should be reflected explicitly in healthcare
      through research activities, medical humanities, cultural competence,
      communication and ethics.
CI  - (c) Copyright 2020, Sultan Qaboos University Medical Journal, All Rights
      Reserved.
FAU - Al-Azri, Nasser Hammad
AU  - Al-Azri NH
AD  - Department of Emergency Medicine, Ibri Hospital, Ministry of Health, Ibri, Oman.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - Oman
TA  - Sultan Qaboos Univ Med J
JT  - Sultan Qaboos University medical journal
JID - 101519915
SB  - IM
MH  - *Bioethics
MH  - *Education, Medical
MH  - Ethics, Medical
MH  - Humans
MH  - Interdisciplinary Communication
MH  - Interprofessional Relations
MH  - Philosophy
MH  - Philosophy, Medical
MH  - *Physicians
MH  - Social Values
PMC - PMC7757935
OTO - NOTNLM
OT  - Bioethics
OT  - Biomedical Research
OT  - Communication
OT  - Culture
OT  - Medical Education
OT  - Medical Philosophy
OT  - Medicine
OT  - Policy Making
EDAT- 2021/01/09 06:00
MHDA- 2021/09/18 06:00
CRDT- 2021/01/08 06:12
PHST- 2020/02/24 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2021/01/08 06:12 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - 10.18295/squmj.2020.20.04.003 [doi]
AID - squmj2011-e290-295 [pii]
PST - ppublish
SO  - Sultan Qaboos Univ Med J. 2020 Nov;20(4):e290-e295. doi:
      10.18295/squmj.2020.20.04.003. Epub 2020 Dec 21.


PMID- 33414861
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1939-795X (Print)
IS  - 1939-795X (Linking)
VI  - 13
IP  - 1
DP  - 2020
TI  - The Effects of Concurrent Activation Potentiation on Bat Swing Velocity of
      Division II College Softball Athletes.
PG  - 1630-1637
AB  - As an ethical and practical ergogenic strategy, concurrent activation
      potentiation (CAP), achieved by remote voluntary contractions (RVC) such as jaw
      clenching, has been proposed to acutely enhance muscular and athletic performance
      characteristics. The effects of CAP on bat swing velocity (BSV), an important
      component for successful hitting in sports such as baseball and softball has yet 
      to be reported in the literature. The purpose of this research was to examine the
      effects of maximal jaw clenching on BSV in collegiate division II softball
      players. Thirteen (n = 13) division II softball athletes volunteered to
      participate in this study. Subjects completed five maximal effort swings
      targeting a softball on a tee during two experimental conditions: jaw musculature
      maximally clenched and relaxed jaw musculature. An inertial measurement unit
      (Zepp Sensor, Zepp Labs, Inc.) attached to the knob of the bat recorded BSV and
      all trials for each experimental condition were averaged for analysis. Paired
      sample t-tests were used to determine differences between the two conditions.
      Mean BSV was 28.02 m/s (62.68 mph) for the jaw relaxed condition and 29.42 m/s
      (65.82 mph) for the jaw clenched condition, producing a statistically significant
      mean difference of 1.4 m/s (3.14 mph) (p = 0.003). Maximal jaw clenching is an
      effective strategy to improve BSV in division II college softball players.
FAU - Mace, Alexis P
AU  - Mace AP
AD  - Exercise Science Program, Florida Southern College, Lakeland, FL, USA.
FAU - Allen, Charles R
AU  - Allen CR
AD  - Exercise Science Program, Florida Southern College, Lakeland, FL, USA.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - Int J Exerc Sci
JT  - International journal of exercise science
JID - 101513127
PMC - PMC7745898
OTO - NOTNLM
OT  - Batting
OT  - ergogenic strategy
OT  - female
OT  - hitting
OT  - jaw clenching
OT  - performance
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:11
PHST- 2021/01/08 06:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - ijes-13-1-1630 [pii]
PST - epublish
SO  - Int J Exerc Sci. 2020 Dec 1;13(1):1630-1637. eCollection 2020.


PMID- 33414849
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1759-720X (Print)
IS  - 1759-720X (Linking)
VI  - 12
DP  - 2020
TI  - Evaluation of osteoarthritis knee and hip quality of life (OAKHQoL): adaptation
      and validation of the questionnaire in the Hungarian population.
PG  - 1759720X20959570
LID - 10.1177/1759720X20959570 [doi]
AB  - BACKGROUND: At least 17% of the population suffers from osteoarthritis (OA) in
      Hungary, according to the European Health Interview Survey. In Hungary, until now
      there was no OA-specific questionnaire available for the lower limb, in order to 
      monitor the health-related quality of life (HRQoL). This gap gave the relevance
      of this research. The aim of the study was to perform the Hungarian
      cross-cultural adaptation and validation of the French-developed Osteoarthritis
      Knee and Hip Quality of Life (OAKHQoL) questionnaire. METHODS: The five-step
      translation procedure of the original OAKHQoL was performed by the expert panel
      and the translators. The created Hungarian version (OAKHQoL-HUN) was tested in
      six different geographical areas of Hungary. The validity and the reliability of 
      this adapted tool was analyzed by our research group. RESULTS: A total of 99
      patients completed the questionnaires (78 women and 21 men), with the average age
      of 66.6 years (standard deviation (SD) 12.1), living with OA for more than 10
      years. Excellent internal consistency was observed in the following domains:
      physical activity (alpha = 0.93), mental health (alpha = 0.91) and pain (alpha = 
      0.89). Good correlation was determined between physical subscales (r =
      0.615-0.676) and mental subscales (r = 0.633-0.643) compared to generic quality
      of life instruments (World Health Organization Quality of life - BREF
      questionnaire and EQ-5D-3L). CONCLUSION: The OAKHQoL-HUN is the first valid and
      reliable tool for measuring the Hungarian lower limb OA patients' quality of
      life. TRIAL REGISTRATION: This study is registered (24950-3/2016/EKU) by the
      National Ethics Committee: the Hungarian Medical Research Council.
CI  - (c) The Author(s), 2020.
FAU - Fekete, Helga
AU  - Fekete H
AD  - Institute of Pharmaceutical Technology and Regulatory Affairs, University of
      Szeged, Faculty of Pharmacy, Szeged, Hungary.
FAU - Guillemin, Francis
AU  - Guillemin F
AD  - University of Lorraine, University Paris Descartes, Nancy, France.
FAU - Pallagi, Edina
AU  - Pallagi E
AD  - Institute of Pharmaceutical Technology and Regulatory Affairs, University of
      Szeged, Faculty of Pharmacy, Szeged, Hungary.
FAU - Fekete, Robert
AU  - Fekete R
AD  - County Hospital, Kiskunfelegyhaza Municipal Hospital and Polyclinic -
      Musculoskeletal Rehabilitation Unit, Kiskunfelegyhaza, Hungary.
FAU - Lippai, Zoltan
AU  - Lippai Z
AD  - Hospital - Musculoskeletal Rehabilitation Unit, Budapest, Hungary.
FAU - Luteran, Ferenc
AU  - Luteran F
AD  - Teaching Hospital Musculoskeletal Rehabilitation Unit, Gyor, Hungary.
FAU - Toth, Istvan
AU  - Toth I
AD  - II. Rakoczi Ferenc Hospital, Szikszo, Musculoskeletal Rehabilitation Unit,
      Szikszo, Hungary.
FAU - Toth, Kalman
AU  - Toth K
AD  - Department of Orthopaedics, University of Szeged, Faculty of Medicine, Szeged,
      Hungary.
FAU - Vallata, Amandine
AU  - Vallata A
AD  - Centre d'investigation Clinique - Epidemiologie Clinique CIC 1433, Institute
      national de la sante et de la recherche medicale, rue du Morvan, Vandoeuvre -
      les-Nancy, France.
FAU - Varju, Cecilia
AU  - Varju C
AD  - Department of Rheumatology and Immunology, University of Pecs, Medical School,
      Pecs, Hungary.
FAU - Csoka, Ildiko
AU  - Csoka I
AUID- ORCID: https://orcid.org/0000-0003-0807-2781
AD  - Institute of Pharmaceutical Technology and Regulatory Affairs, University of
      Szeged, Faculty of Pharmacy, Eotvos u. 6., Szeged 6720, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - England
TA  - Ther Adv Musculoskelet Dis
JT  - Therapeutic advances in musculoskeletal disease
JID - 101517322
PMC - PMC7750574
OTO - NOTNLM
OT  - adaptation
OT  - osteoarthritis
OT  - osteoarthritis knee and hip quality of life questionnaire
OT  - patient-reported outcome
OT  - quality of life
OT  - validation
COIS- Conflict of interest: The authors declare that there is no conflict of interest.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/09 06:01
CRDT- 2021/01/08 06:11
PHST- 2019/10/14 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2021/01/08 06:11 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/09 06:01 [medline]
AID - 10.1177/1759720X20959570 [doi]
AID - 10.1177_1759720X20959570 [pii]
PST - epublish
SO  - Ther Adv Musculoskelet Dis. 2020 Dec 17;12:1759720X20959570. doi:
      10.1177/1759720X20959570. eCollection 2020.


PMID- 33412801
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210301
IS  - 1120-9763 (Print)
IS  - 1120-9763 (Linking)
VI  - 44
IP  - 5-6 Suppl 2
DP  - 2020 Sep-Dec
TI  - Ethics committees in the time of COVID-19.
PG  - 113-118
LID - 10.19191/EP20.5-6.S2.109 [doi]
AB  - BACKGROUND: ethics committees (ECs) protect the rights, safety, and well-being of
      research participants and ensure the scientific correctness of clinical research.
      COVID-19 pandemic and the lockdown from 9 March to 16 May 2020 have potentially
      influenced several activities, including ECs. OBJECTIVES: to assess the impact of
      COVID-19 outbreak on Italian ECs and their performance during the lockdown.
      DESIGN: cross-sectional survey. SETTING AND PARTICIPANTS: the survey was
      conducted in mid-June 2020 in Italy contacting all the 90 local ECs. MAIN OUTCOME
      MEASURES: amount and kind of activities performed during the lockdown,
      characteristics of submitted studies and adoption of standard protocols of
      evaluation of research applications during the pandemic. Chi-square test was used
      to estimate the differences between territories with higher incidence (HI) and
      lower incidence (LI) of COVID-19. RESULTS: 258 questionnaires were collected from
      46 ECs that participated in the study. Ten were excluded due to missing
      substantial data. Responses were divided into two groups according to location of
      EC: the HI (125 responses) and the LI (123 responses). Seventy-five percent of
      the HI describe an increase in the number of studies submitted, while 53% of the 
      LI does not (p=0.001). Due to the pandemic and its effects on research, the 15%
      of participants belonging to HI territories reported that consideration and
      respect of research-related and general ethical principles could have decreased, 
      as well the adoption of standard protocols of evaluation of research
      applications. EC secretariats located in HI Regions moved to smart working more
      than in LI ones (75% vs 59%; p=0.001). Where the EC workload increased
      significantly, it was reported that it was impossible to perform an accurate
      analysis of the submitted documentation, with the effect of providing a favorable
      opinion to studies of not excellent quality, though always ensuring the respect
      of ethical principles and patients' safety. CONCLUSIONS: COVID-19 impact on ECs
      has been heavier in HI territories, but smart working has been effective in
      ensuring EC activities and the subsequent activation of clinical studies
      potentially useful to face the pandemic. Clear differences arise between ECs
      belonging to the Italian Regions that have recorded a HI of COVID-19 cases
      compared to those located in Regions with a LI of cases. In some EC members'
      perception, the high number of studies in the most affected Regions together with
      the emergency experienced during the lockdown may have exposed ECs to the risk of
      decreasing the adoption of ethical principles and standard protocols of
      evaluation of research applications.
FAU - Monaco, Eleonora
AU  - Monaco E
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua 
      (Italy).
FAU - Pisano, Lorenza
AU  - Pisano L
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua 
      (Italy).
FAU - Nasato, Laura
AU  - Nasato L
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua 
      (Italy).
FAU - Lorenzoni, Giulia
AU  - Lorenzoni G
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua 
      (Italy).
FAU - Gregori, Dario
AU  - Gregori D
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua 
      (Italy).
FAU - Martinato, Matteo
AU  - Martinato M
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua 
      (Italy); matteo.martinato@unipd.it.
LA  - eng
PT  - Journal Article
PT  - Validation Study
TT  - I comitati etici al tempo del COVID-19.
PL  - Italy
TA  - Epidemiol Prev
JT  - Epidemiologia e prevenzione
JID - 8902507
SB  - IM
MH  - *COVID-19/epidemiology/prevention & control
MH  - *Ethics Committees/statistics & numerical data
MH  - Ethics Committees, Research
MH  - Ethics, Research
MH  - Health Care Surveys
MH  - Humans
MH  - Italy/epidemiology
MH  - Outcome Assessment, Health Care
MH  - *Pandemics
MH  - Physical Distancing
MH  - *Quarantine
MH  - *SARS-CoV-2
MH  - Workload
OTO - NOTNLM
OT  - *ethics committees
OT  - *pandemic COVID-19.
EDAT- 2021/01/09 06:00
MHDA- 2021/01/20 06:00
CRDT- 2021/01/08 04:07
PHST- 2021/01/08 04:07 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.19191/EP20.5-6.S2.109 [doi]
AID - 5119 [pii]
PST - ppublish
SO  - Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):113-118. doi:
      10.19191/EP20.5-6.S2.109.


PMID- 33411435
STAT- Publisher
DA  - 20210108
ISBN- 9780309682633
ISBN- 0309682630
PB  - National Academies Press (US)
DP  - 2020 Oct 29
BTI - Examining the Use of Biomarkers in Establishing the Presence and Severity of
      Impairments: Proceedings of a Workshop
LID - 10.17226/25926 [doi]
AB  - As part of the overall disability determination process, the Social Security
      Administration uses a step-by-step approach to understand how severe an
      individual's condition is and whether it meets program criteria for disability.
      The use of various types of biomarkers has been suggested as a way to strengthen 
      the amount and quality of objective evidence available to the review process. At 
      the request of the Social Security Administration, the National Academies of
      Sciences, Engineering, and Medicine's Board on Health Care Services organized a
      virtual workshop on July 21, 2020, titled The State of the Science of the Use of 
      Biomarkers to Establish the Presence and Severity of Impairments. Workshop
      discussions focused on the current and potential uses for biomarkers; explored
      legal and ethical implications associated with biomarker use in clinical decision
      making; and considered the possible uses of nongenetic biomarkers as tools for
      the diagnosis or prognosis of the severity of specific physical and mental
      impairments. This publication summarizes the presentations and discussion of the 
      workshop.
CI  - Copyright 2020 by the National Academy of Sciences. All rights reserved.
CN  - National Academies of Sciences, Engineering, and Medicine; Health and Medicine
      Division; Board on Health Care Services
FED - Trang, Cyndi
ED  - Trang C
FED - Lustig, Tracy A.
ED  - Lustig TA
FED - Snair, Megan
ED  - Snair M
LA  - eng
PT  - Review
PT  - Book
PL  - Washington (DC)
EDAT- 2021/01/08 06:01
MHDA- 2021/01/08 06:01
CDAT- 2021/01/08 06:01
AID - NBK566347 [bookaccession]
AID - 10.17226/25926 [doi]


PMID- 33411651
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1446-1242 (Print)
IS  - 1446-1242 (Linking)
VI  - 29
IP  - 2
DP  - 2020 Jul
TI  - When open source design is vital: critical making of DIY healthcare equipment
      during the COVID-19 pandemic.
PG  - 158-167
LID - 10.1080/14461242.2020.1784772 [doi]
AB  - Shortages of personal protective equipment (PPE) and medical devices needed
      during the COVID-19 pandemic were widely reported in early 2020. In response,
      civic DIY volunteers explored how they could produce the required equipment.
      Members of communities such as hacker- and makerspaces employed their skills and 
      tools to manufacture, for example, face shields and masks. The article discusses 
      these civic innovation practices and their broader social implications by
      relating them to critical making theory. Methodologically, it is based on a
      digital ethnography approach, focusing on hacker and maker communities in the UK.
      Communities' DIY initiatives display characteristics of critical making and
      'craftivism', as they assessed and counteracted politicised healthcare supply
      shortages. It is argued that their manufacturing activities during the COVID
      pandemic relate to UK austerity politics' effects on healthcare and government
      failure to ensure medical crisis supplies. Facilitated by open source design,
      communities' innovation enabled healthcare emergency equipment. At the same time,
      their DIY manufacturing raises practical as well as ethical issues concerning,
      among other things, efficacy and safety of use.
FAU - Richterich, Annika
AU  - Richterich A
AD  - School of Media, Film and Music, University of Sussex, Brighton, UK.
AD  - Faculty of Arts & Social Sciences, Maastricht University, Maastricht,
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - United States
TA  - Health Sociol Rev
JT  - Health sociology review : the journal of the Health Section of the Australian
      Sociological Association
JID - 101156268
SB  - IM
MH  - COVID-19/*prevention & control
MH  - Equipment Design
MH  - Humans
MH  - Masks/standards/*supply & distribution
MH  - Personal Protective Equipment/standards/*supply & distribution
MH  - Private Sector
MH  - *Protective Devices
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *COVID-19
OT  - *DIY communities
OT  - *critical making
OT  - *hacking
OT  - *healthcare equipment
OT  - *open source
EDAT- 2021/01/08 06:00
MHDA- 2021/01/27 06:00
CRDT- 2021/01/07 17:13
PHST- 2021/01/07 17:13 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.1080/14461242.2020.1784772 [doi]
PST - ppublish
SO  - Health Sociol Rev. 2020 Jul;29(2):158-167. doi: 10.1080/14461242.2020.1784772.
      Epub 2020 Jul 10.


PMID- 33409179
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct
TI  - Oral hygiene habits amongst chromium mine workers-A cross sectional study.
PG  - 5148-5151
LID - 10.4103/jfmpc.jfmpc_551_20 [doi]
AB  - BACKGROUND: Oral health means much more than just having healthy teeth. Various
      oral diseases have significant side effects on general health; also systemic
      diseases can show a reciprocal effect on oral health. So oral health needs to be 
      regarded by multi-professional approaches and should be combined into
      comprehensive health-promotion strategies and actions. The present study aimed to
      determine oral hygiene habits amongst chromium mine workers. MATERIALS AND
      METHODS: The present observational, cross-sectional study was conducted for a
      period of 4 months from April to October 2017. The present study evaluated the
      oral hygiene habits amongst the chromium mine workers of Odisha. A total of 1140 
      males were enrolled in the study. The study was conducted after the institutional
      ethical board clearance and informed written consent for participation in the
      study and written consent was obtained from all in their vernacular language.
      Data were entered using MS-EXCEL 2016 and the statistical analysis was done using
      SPSS software. RESULTS: There were 91.9% of subjects who brushed once a day, 6.9%
      brushed twice a day and 1.1% brushed after every meal. The results of the study
      showed that 75.9% and 8.1% of subjects used tooth paste and tooth powder
      respectively for brushing there teeth regularly.the results of this study also
      showed that 11.9% of study participants used indigenous means (other means) as an
      aid to tooth brushing. CONCLUSION: There is a lack of awareness and education
      about oral hygiene practices amongst mine workers due to which they do not resort
      to good oral hygiene practices.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Priyaranjan
AU  - Priyaranjan
AD  - Lecturer, Department of Public Health Dentistry, Kalinga Institute of Dental
      Sciences, KIIT University, Bhubaneswar, Odisha, India.
FAU - Barman, Diplina
AU  - Barman D
AD  - Department of Public Health Dentistry, Kalinga Institute of Dental Sciences, KIIT
      University, BBSR, Ranchi, Jharkhand, India.
FAU - Kumar, Sandeep
AU  - Kumar S
AD  - Department of Public Health Dentistry, Dental Institute RIMS, Ranchi, Jharkhand, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7773098
OTO - NOTNLM
OT  - Brushing
OT  - chromium mine workers
OT  - health
OT  - hygiene
OT  - oral
COIS- There are no conflicts of interest.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
CRDT- 2021/01/07 06:08
PHST- 2020/04/05 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2021/01/07 06:08 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_551_20 [doi]
AID - JFMPC-9-5148 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Oct 30;9(10):5148-5151. doi:
      10.4103/jfmpc.jfmpc_551_20. eCollection 2020 Oct.


PMID- 33409089
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 2
TI  - Teaching Without Harm: The Ethics of Performing Posthumous Procedures on the
      Newly Deceased.
PG  - e11855
LID - 10.7759/cureus.11855 [doi]
AB  - Physicians must be proficient in and efficient at various lifesaving and
      life-sustaining procedures. Multiple methods exist to teach these skills to
      inexperienced medical professionals, ranging from lectures to practical models to
      live patients. Proficiency and prior knowledge are especially important when
      novice medical trainees first perform these procedures because of the increased
      risk of harm in these high-stakes scenarios. To mitigate inherent risks, many
      medical centers controversially advocate and allow the use of newly deceased
      patients to practice, teach, and perfect these procedures. As a result, this type
      of experience facilitates medical training and competency while simultaneously
      avoiding physical harm to living patients. Nonetheless, it raises numerous
      ethical and legal considerations, including concerns of damage to the
      doctor-patient relationship. This manuscript aims to comprehensively review the
      ethicality of practicing postmortem procedures and its current debate regarding
      the role and type of consent. This is followed by examining scenarios where the
      prior patient or postmortem surrogate consent is required for procedures that do 
      not benefit the patient, including organ donation, cadaver donation, and brain
      tissue donation. Using these scenarios as a framework, best practices for gaining
      permission to use the newly deceased for medical training purposes are offered.
      Procedures on deceased patients should always be done under competent supervision
      in a structured manner, with comprehensive explanations to encourage
      accountability and professionalism and prevent misuse. Informed consent for all
      educational procedures must be obtained by individuals separate from the
      treatment team. However, exceptions to this standard could be made in pediatrics 
      (especially in the neonatal intensive care unit) given the intimate relationship 
      between providers and parents. Depending on the situation, consent should be
      obtained from the patient and/or their family, with separate documentation
      provided to create awareness. All relative parties should be consented after
      receiving appropriate time to process to prevent further emotional compromise. If
      there are concerns about jeopardizing the family and creating further burdens,
      they should not be approached.
CI  - Copyright (c) 2020, Rajagopal et al.
FAU - Rajagopal, Aarabhi S
AU  - Rajagopal AS
AD  - Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA.
AD  - Institute for Bioethics and Health Policy, University of Miami Miller School of
      Medicine, Miami, USA.
FAU - Champney, Thomas H
AU  - Champney TH
AD  - Cell Biology, University of Miami Miller School of Medicine, Miami, USA.
AD  - Institute for Bioethics and Health Policy, University of Miami Miller School of
      Medicine, Miami, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201202
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7781543
OTO - NOTNLM
OT  - attitude to death
OT  - cadaver
OT  - death
OT  - donation
OT  - ethics
OT  - informed consent
OT  - medical education
OT  - nearly dead
OT  - teaching
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
CRDT- 2021/01/07 06:07
PHST- 2021/01/07 06:07 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
AID - 10.7759/cureus.11855 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 2;12(12):e11855. doi: 10.7759/cureus.11855.


PMID- 33409070
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 1
TI  - "Near-Miss" Obstetric Events and Maternal Deaths in a Rural Tertiary Care Center 
      in North India.
PG  - e11828
LID - 10.7759/cureus.11828 [doi]
AB  - Introduction Maternal near-miss and maternal mortality cases have common
      characters, especially in terms of risk factors. Both of them are indicators of
      the quality of health care services provided to pregnant women. Our center is a
      tertiary care center in a rural area of western Uttar Pradesh (U.P.) so we get a 
      large number of referred cases from most of the rural areas of western U.P. and
      the adjoining areas of other states too, which sometimes end up in mortality.
      Thus this study was planned to find out the incidence of maternal near-miss
      events and compare the nature of near-miss events with maternal mortality. Goal
      and objectives The main objectives of the study were to determine the frequency
      of maternal near-miss events, observe the trend of near-miss events, and compare 
      the nature of near-miss events with maternal mortality. Materials and methods It 
      was a retrospective study conducted in the department of obstetrics and
      gynecology at Uttar Pradesh University of Medical Sciences (UPUMS), Saifai,
      Etawah, from July 2018 - June 2019, over a period of one year. Potentially
      life-threatening conditions and maternal mortalities were noted from the records 
      of the hospital after taking ethical clearance from the institute. Near-miss
      cases were noted based on the Health and Family Welfare Government of India
      guidelines 2014. Data were collected and statistical analysis was performed using
      the Statistical Package of the Social Sciences (SPSS) version 21 (IBM Corp.,
      Armonk, NY). Results The maternal near-miss incidence ratio was 16.6/1000 live
      births, the maternal near-miss to mortality ratio was 1.9:1, and the mortality
      index was 0.34%. Hypertensive disorders of pregnancy were the most common causes 
      of near-miss events (45.8%) followed by hemorrhage (23.6%) in this study.
      Conclusions Hypertensive disorders in pregnancy and hemorrhage were the two
      leading causes of near-miss events and mortality followed by sepsis. As the
      near-miss analysis indicates, the quality of health care and causes are almost
      similar to maternal mortality, so its registry should be done along with maternal
      mortality.
CI  - Copyright (c) 2020, Verma et al.
FAU - Verma, Vandana
AU  - Verma V
AD  - Obstetrics and Gynecology, Uttar Pradesh University of Medical Sciences, Etawah, 
      IND.
FAU - Kanti, Vaibhav
AU  - Kanti V
AD  - Obstetrics and Gynecology, Uttar Pradesh University of Medical Sciences, Etawah, 
      IND.
FAU - Vishwakarma, Soniya
AU  - Vishwakarma S
AD  - Obstetrics and Gynecology, Uttar Pradesh University of Medical Sciences, Etawah, 
      IND.
FAU - Gupta, Umesh K
AU  - Gupta UK
AD  - Pediatric Surgery, Uttar Pradesh University of Medical Sciences, Etawah, IND.
FAU - Shree, Pragya
AU  - Shree P
AD  - Obstetrics and Gynecology, Kanti Devi (KD) Medical College, Hospital and Research
      Center, Mathura, IND.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7781506
OTO - NOTNLM
OT  - haemorrhage in pregnancy
OT  - mortality index
OT  - quality of health care
OT  - severe acute maternal morbidity
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
CRDT- 2021/01/07 06:07
PHST- 2021/01/07 06:07 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
AID - 10.7759/cureus.11828 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 1;12(12):e11828. doi: 10.7759/cureus.11828.


PMID- 33409063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 1
TI  - Analysis of Transitional Milk of Post-Natal Cases in Non-Anaemic Mothers and Its 
      Comparison With Anaemic Mothers in Rural Western Uttar Pradesh.
PG  - e11818
LID - 10.7759/cureus.11818 [doi]
AB  - AIM: Present study is aimed at determining the analysis of transitional milk of
      post-natal non-anaemic mothers and its comparison with anaemic mothers in rural
      Uttar Pradesh. METHODS: Totally, 132 post-natal cases were enrolled for the
      study. After taking ethical committee approval, breast milk samples were
      collected from day 4 to 11. We measured the following important parameters in
      breast milk (fat, density, carbohydrates, solid not fat [SNF], protein and added 
      water). Data were analysed by using SPSS-24 software (IBM Corp., Armonk, NY).
      Tests used in our study were the analysis of variance (ANOVA) test, Chi-square
      test and independent T-test. RESULT: In our study, it was found that severe
      anaemia causes significant changes in fat, lactose and protein content of breast 
      milk. We found that there are no significant changes in breast milk composition
      with age. Our study shows statistically no association between residence and
      breast milk content. CONCLUSION: As the severity of anaemia increases, protein
      and fat content in breast milk decreases, lactose content on the contrary follows
      a reverse relationship with maternal haemoglobin. Maternal anaemia not only
      affects the macronutrients in breast milk but also decreases the density of
      breast milk.
CI  - Copyright (c) 2020, Divedi et al.
FAU - Divedi, Pragati
AU  - Divedi P
AD  - Obstetrics and Gynaecology, Santosh Medical College and Hospital, Ghaziabad, IND.
FAU - Maheshwari, Parul
AU  - Maheshwari P
AD  - Obstetrics and Gynaecology, Uttar Pradesh University of Medical Sciences, Saifai,
      IND.
FAU - Seth, Shikha
AU  - Seth S
AD  - Obstetrics and Gynaecology, Government Institute of Medical Sciences, Greater
      Noida, IND.
FAU - Mishra, Archana
AU  - Mishra A
AD  - Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung
      Hospital, New Delhi, IND.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7781501
OTO - NOTNLM
OT  - anaemic mothers
OT  - non-anaemic mothers
OT  - post-natal
OT  - transitional milk
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
CRDT- 2021/01/07 06:07
PHST- 2021/01/07 06:07 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
AID - 10.7759/cureus.11818 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 1;12(12):e11818. doi: 10.7759/cureus.11818.


PMID- 33408758
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1757-1774 (Print)
IS  - 1757-1782 (Linking)
VI  - 21
IP  - 6
DP  - 2020 Nov
TI  - Barriers associated with mandatory influenza vaccination policies for healthcare 
      workers: an integrative review.
PG  - 212-220
LID - 10.1177/1757177420935629 [doi]
AB  - BACKGROUND: Uptake of influenza vaccination reduces staff absenteeism as well as 
      mortality of patients and healthcare workers (HCWs); however, adherence of HCWs
      to annual influenza vaccination is poor and some healthcare facilities are now
      considering mandatory influenza vaccination policies. AIM: The purpose of this
      study was to identify the perceived and reported barriers to the implementation
      of a mandatory influenza vaccination policy for HCWs. METHODS: An integrative
      review of the literature was conducted. Databases including CINAHL, Cochrane
      Library, Medline and PubMed were searched using key terms. The quality of papers 
      was assessed utilising the Standard Quality Assessment Criteria for Evaluating
      Primary Research papers for a Variety of Fields which consisted of 10 questions
      with a possible total score of 20. PRISMA guidelines were used to report the
      search outcomes. RESULTS: A total of 68 papers were identified from the database 
      search. Seven papers were relevant, following screening. The quality scores of
      these were in the range of 15-20. A number of barriers are reported to prevent
      the effective implementation of mandatory influenza vaccination policies
      including ethical and legal considerations, logistics, healthcare burden,
      leadership and management, and human factors such as HCWs' perspectives.
      CONCLUSIONS: By comprehensively identifying these, barriers can be addressed to
      allow effective implementation of such policies in healthcare facilities to
      ensure improved outcomes. The results of the review indicated the need for
      further research to ensure that barriers are addressed cohesively.
CI  - (c) 2020 The Author(s).
FAU - Short, Erica
AU  - Short E
AUID- ORCID: https://orcid.org/0000-0003-4998-6029
AD  - Griffith University, Logan Campus, Brisbane, Australia.
FAU - Zimmerman, Peta-Anne
AU  - Zimmerman PA
AUID- ORCID: https://orcid.org/0000-0003-3764-1277
AD  - Graduate Infection Prevention and Control Program, School of Nursing and
      Midwifery, Menzies Health Institute, Gold Coast Hospital and Health Services,
      Griffith University, Southport, QLD, Australia.
FAU - van de Mortel, Thea
AU  - van de Mortel T
AD  - School of Nursing and Midwifery, Griffith University, Southport, QLD, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200727
PL  - England
TA  - J Infect Prev
JT  - Journal of infection prevention
JID - 101469725
PMC - PMC7745584
OTO - NOTNLM
OT  - Immunisation
OT  - infection control
OT  - infection prevention
OT  - influenza
OT  - vaccination
COIS- Declaration of conflicting interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
CRDT- 2021/01/07 06:06
PHST- 2019/10/08 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2021/01/07 06:06 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
AID - 10.1177/1757177420935629 [doi]
AID - 10.1177_1757177420935629 [pii]
PST - ppublish
SO  - J Infect Prev. 2020 Nov;21(6):212-220. doi: 10.1177/1757177420935629. Epub 2020
      Jul 27.


PMID- 33408668
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Cognitive Interaction Technology in Sport-Improving Performance by Individualized
      Diagnostics and Error Prediction.
PG  - 597913
LID - 10.3389/fpsyg.2020.597913 [doi]
AB  - The interdisciplinary research area Cognitive Interaction Technology (CIT) aims
      to understand and support interactions between human users and other elements of 
      socio-technical systems. Important reasons for the new interest in understanding 
      CIT in sport psychology are the impressive development of cognitive robotics and 
      advanced technologies such as virtual or augmented reality systems, cognitive
      glasses or neurotechnology settings. The present article outlines this area of
      research, addresses ethical issues, and presents an empirical study in the
      context of a new measurement and assessment system for training in karate. Recent
      advances in the field of cognitive assistance systems enabled largely automatized
      assessments of individual mental representation structures for action sequences, 
      such as choreographed movement patterns in dance or martial arts. Empirical
      investigations with karate practitioners of different skill levels demonstrate
      that advanced software-based survey and algorithmic analysis procedures based on 
      cognitive models generate individualized performance predictions for a movement
      sequence from the Kanku-dai kata (a pre-defined karate movement sequence), which 
      correlated significantly not only with formal expertise (kyu/dan rank) but also
      with the actual likelihood of mistakes in action execution. This information
      could prospectively be used to define individual training goals for deliberate
      practice and incorporated into cognitive interaction technology to provide
      appropriate feedback. We argue that the development of cognitive interaction
      systems for sport should explicitly take ethical issues into consideration and
      present a particular developed engineering approach. The potential benefits of
      such an assistance system for intermediate and advanced practitioners include
      more effective and flexible practice, as well as supportive effects, and more
      flexible training schedules. Furthermore, we argue that researchers from the
      field of sport psychology can benefit from advances in technological systems that
      enhance the understanding of mental and motor control in skilled voluntary
      action.
CI  - Copyright (c) 2020 Strenge, Koester and Schack.
FAU - Strenge, Benjamin
AU  - Strenge B
AD  - Neurocognition and Action Group, Faculty of Psychology and Sports Science, Center
      for Cognitive Interaction Technology (CITEC), Bielefeld University, Bielefeld,
      Germany.
FAU - Koester, Dirk
AU  - Koester D
AD  - Sport Psychology, Faculty Business and Management, BSP Business School Berlin,
      Berlin, Germany.
FAU - Schack, Thomas
AU  - Schack T
AD  - Neurocognition and Action Group, Faculty of Psychology and Sports Science, Center
      for Cognitive Interaction Technology (CITEC), Bielefeld University, Bielefeld,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7779401
OTO - NOTNLM
OT  - SDA-M
OT  - cognitive assistance systems
OT  - ethical issue recognition
OT  - karate athletes/performance
OT  - karate kata
OT  - mental representation structures
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/08 06:00
MHDA- 2021/01/08 06:01
CRDT- 2021/01/07 06:05
PHST- 2020/08/22 00:00 [received]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2021/01/07 06:05 [entrez]
PHST- 2021/01/08 06:00 [pubmed]
PHST- 2021/01/08 06:01 [medline]
AID - 10.3389/fpsyg.2020.597913 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 21;11:597913. doi: 10.3389/fpsyg.2020.597913. eCollection
      2020.


PMID- 33406166
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Linking)
VI  - 44
DP  - 2020
TI  - The landscape of COVID-19 clinical trials in Latin America and the Caribbean:
      assessment and challenges.
PG  - e177
LID - 10.26633/RPSP.2020.177 [doi]
AB  - A considerable number of clinical trials is being conducted globally in response 
      to the COVID-19 pandemic, including in low- and middle-income countries such as
      those in the Latin America and Caribbean region (LAC). Yet, an abundance of
      studies does not necessarily shorten the path to find safe and efficacious
      interventions for COVID-19. We analyze the trials for COVID-19 treatment and
      prevention that are registered from LAC countries in the International Clinical
      Trials Registry Platform, and identify a trend towards small repetitive
      non-rigorous studies that duplicate efforts and drain limited resources without
      producing meaningful conclusions on the safety and efficacy of the interventions 
      being tested. We further assess the challenges to conducting scientifically sound
      and socially valuable research in the LAC region in order to inform
      recommendations to encourage clinical trials that are most likely to produce
      robust evidence during the pandemic.
FAU - Carracedo, Sarah
AU  - Carracedo S
AD  - Pan American Health Organization Washington, DC United States of America Pan
      American Health Organization, Washington, DC, United States of America.
FAU - Palmero, Ana
AU  - Palmero A
AD  - Pan American Health Organization Washington, DC United States of America Pan
      American Health Organization, Washington, DC, United States of America.
FAU - Neil, Marcie
AU  - Neil M
AD  - Pan American Health Organization Washington, DC United States of America Pan
      American Health Organization, Washington, DC, United States of America.
FAU - Hasan-Granier, Anisa
AU  - Hasan-Granier A
AD  - Pan American Health Organization Washington, DC United States of America Pan
      American Health Organization, Washington, DC, United States of America.
FAU - Saenz, Carla
AU  - Saenz C
AD  - Pan American Health Organization Washington, DC United States of America Pan
      American Health Organization, Washington, DC, United States of America.
FAU - Reveiz, Ludovic
AU  - Reveiz L
AD  - Pan American Health Organization Washington, DC United States of America Pan
      American Health Organization, Washington, DC, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - United States
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC7758055
OTO - NOTNLM
OT  - Caribbean Region
OT  - Coronavirus infections
OT  - Latin America
OT  - clinical trial
OT  - ethics, research
OT  - public health policy
EDAT- 2021/01/07 06:00
MHDA- 2021/01/07 06:01
CRDT- 2021/01/06 17:13
PHST- 2020/10/15 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2021/01/06 17:13 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/07 06:01 [medline]
AID - 10.26633/RPSP.2020.177 [doi]
AID - RPSP.2020.177 [pii]
PST - epublish
SO  - Rev Panam Salud Publica. 2020 Dec 23;44:e177. doi: 10.26633/RPSP.2020.177.
      eCollection 2020.


PMID- 33404344
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - The Health Reframing of Climate Change and the Poverty of Narrow Bioethics.
PG  - 705-717
LID - 10.1177/1073110520979381 [doi]
AB  - We must resist thoroughly reframing climate change as a health issue. For human
      health-centric ethical frameworks omit dimensions of value that we must duly
      consider. We need a new, an environmental, research ethic, one that we can use to
      more completely and impartially evaluate proposed research on mitigation and
      adaptation strategies.
FAU - Ferguson, Kyle
AU  - Ferguson K
AD  - Kyle Ferguson, Ph.D., is a postdoctoral fellow in the Division of Medical Ethics 
      at NYU Grossman School of Medicine and an adjunct professor in the Department of 
      Environmental Studies at NYU.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - *Bioethics
MH  - *Climate Change
MH  - Ecosystem
MH  - Environmental Health/*ethics
MH  - *Ethical Analysis
MH  - *Ethics, Research
MH  - Humans
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979381 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):705-717. doi: 10.1177/1073110520979381.


PMID- 33404343
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - Introduction Climate Change and the Legal, Ethical, and Health Issues Facing
      Healthcare and Public Health Systems.
PG  - 636-642
LID - 10.1177/1073110520979370 [doi]
FAU - Ganesh, Chandra
AU  - Ganesh C
AD  - Chandra Ganesh, Ph.D., is an Associate Professor of Health Sciences at Cal State 
      East Bay in Hayward, CA. Michael Schmeltz, M.S., Dr.P.H., is an Assistant
      Professor in the Department of Health Sciences at Cal State East Bay. Jason
      Smith, J.D., is an Associate Professor of Health Sciences and Chair of the
      Department of Health Sciences at Cal State East Bay in Hayward, CA.
FAU - Schmeltz, Michael
AU  - Schmeltz M
AD  - Chandra Ganesh, Ph.D., is an Associate Professor of Health Sciences at Cal State 
      East Bay in Hayward, CA. Michael Schmeltz, M.S., Dr.P.H., is an Assistant
      Professor in the Department of Health Sciences at Cal State East Bay. Jason
      Smith, J.D., is an Associate Professor of Health Sciences and Chair of the
      Department of Health Sciences at Cal State East Bay in Hayward, CA.
FAU - Smith, Jason
AU  - Smith J
AD  - Chandra Ganesh, Ph.D., is an Associate Professor of Health Sciences at Cal State 
      East Bay in Hayward, CA. Michael Schmeltz, M.S., Dr.P.H., is an Assistant
      Professor in the Department of Health Sciences at Cal State East Bay. Jason
      Smith, J.D., is an Associate Professor of Health Sciences and Chair of the
      Department of Health Sciences at Cal State East Bay in Hayward, CA.
LA  - eng
PT  - Introductory Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - COVID-19/epidemiology
MH  - *Climate Change
MH  - Delivery of Health Care/*standards
MH  - *Global Warming
MH  - Humans
MH  - Natural Disasters
MH  - *Public Health
MH  - *Public Policy
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979370 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):636-642. doi: 10.1177/1073110520979370.


PMID- 33404339
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210622
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - An Ethicolegal Analysis of Involuntary Treatment for Opioid Use Disorders.
PG  - 735-740
LID - 10.1177/1073110520979383 [doi]
AB  - Supply-side interventions such as prescription drug monitoring programs, "pill
      mill" laws, and dispensing limits have done little to quell the burgeoning opioid
      crisis. An increasingly popular demand-side alternative to these measures - now
      adopted by 38 jurisdictions in the USA and 7 provinces in Canada - is
      court-mandated involuntary commitment and treatment. In Massachusetts, for
      example, Part I, Chapter 123, Section 35 of the state's General Laws allows
      physicians, spouses, relatives, and police officers to petition a court to
      involuntarily commit and treat a person whose alcohol or drug abuse poses a
      likelihood of serious harm. This paper explores the ethical underpinnings of this
      law as a case study for others. First, we highlight the procedural and
      substantive standards of Section 35 and evaluate the application of the law in
      practice, including the frequency with which it has been invoked and outcomes. We
      then use this background to inform an ethical critique of the law. Specifically, 
      we argue that the infringement of autonomy and privacy associated with
      involuntary intervention under Section 35 is not currently justified on the
      grounds of a lack of evidenced benefits and a risk of significant of harm.
      Further ethical concerns also arise from a lack of standard of care provided
      under the Section 35 pathway. Based on this analysis, we advance four
      recommendations for change to mitigate these ethical shortcomings.
FAU - Udwadia, Farhad R
AU  - Udwadia FR
AD  - Farhad R. Udwadia, MBE, is affiliated with Neuroethics Canada, Division of
      Neurology, Department of Medicine, at the University of British Columbia in
      Vancouver, and completed this work while at the Center for Bioethics at Harvard
      Medical School. Judy Illes, C.M., Ph.D., is affiliated with Neuroethics Canada,
      Division of Neurology, Department of Medicine, at the University of British
      Columbia in Vancouver.
FAU - Illes, Judy
AU  - Illes J
AD  - Farhad R. Udwadia, MBE, is affiliated with Neuroethics Canada, Division of
      Neurology, Department of Medicine, at the University of British Columbia in
      Vancouver, and completed this work while at the Center for Bioethics at Harvard
      Medical School. Judy Illes, C.M., Ph.D., is affiliated with Neuroethics Canada,
      Division of Neurology, Department of Medicine, at the University of British
      Columbia in Vancouver.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2020 Dec;48(4):741-743. PMID: 33404332
MH  - Humans
MH  - Involuntary Commitment/*ethics/*legislation & jurisprudence
MH  - Involuntary Treatment/*ethics/*legislation & jurisprudence
MH  - Massachusetts/epidemiology
MH  - Opioid-Related Disorders/*prevention & control
MH  - Personal Autonomy
MH  - Privacy
MH  - Standard of Care
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979383 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):735-740. doi: 10.1177/1073110520979383.


PMID- 33404337
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210622
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - Perceived Benefits and Harms of Involuntary Civil Commitment for Opioid Use
      Disorder.
PG  - 718-734
LID - 10.1177/1073110520979382 [doi]
AB  - Involuntary civil commitment (ICC) to treatment for opioid use disorder (OUD)
      prevents imminent overdose, but also restricts autonomy and raises other ethical 
      concerns. Using the Kass Public Health Ethics Framework, we identified ICC
      benefits and harms. Benefits include: protection of vulnerable, underserved
      patients; reduced legal consequences; resources for families; and "on-demand"
      treatment access. Harms include: stigmatizing and punitive experiences;
      heightened family conflict and social isolation; eroded patient
      self-determination; limited or no provision of OUD medications; and long-term
      overdose risk. To use ICC ethically, it should be recognized as comprising
      vulnerable patients worthy of added protections; be a last resort option; utilize
      consensual, humanizing processes; provide medications and other
      evidence-based-treatment; integrate with existing healthcare systems; and
      demonstrate effective outcomes before diffusion. ICC to OUD treatment carries
      significant potential harms that, if unaddressed, may outweigh its benefits.
      Findings can inform innovations for ensuring that ICC is used in an ethically
      responsible way.
FAU - Evans, Elizabeth A
AU  - Evans EA
AD  - Elizabeth A. Evans, Ph.D., M.A., is an Associate Professor of public health at
      the University of Massachusetts Amherst. She received her B.A. from the
      University of California San Diego, her M.A. from Indiana University,
      Bloomington, and her Ph.D. from the University of California Los Angeles Fielding
      School of Public Health. Dr. Evans researches how health care systems and public 
      policies can better promote health and wellness particularly among individuals at
      risk for opioid and substance use disorders, mental illness, and infectious
      diseases. Calla Harrington, M.P.H., M.S.W., L.C.S.W., is a Research Fellow in the
      Department of Health Policy and Promotion at the University of Massachusetts
      Amherst. Calla received her M.P.H. in Epidemiology from UMass Amherst, her
      clinical M.S.W. from Boston University, M.A., and her B.S.W. from Eastern
      University in St. Davids, PA. Robert Roose, M.D., M.P.H., F.A.S.A.M., is the
      Chief Medical Officer for Mercy Medical Center and affiliates. Dr. Roose received
      his M.D. and M.P.H. from the George Washington University School of Medicine and 
      Health Sciences in Washington, DC. He received his B.S. from the University of
      Illinois at Urbana-Champaign, IL. He serves on the Quality Improvement Council of
      the American Society of Addiction Medicine and is a key contributor to opioid
      task forces in Massachusetts. Susan Lemere, M.S.W., L.I.C.S.W., received her
      M.S.W. from Smith College in Northampton, MA, a M.F.A. from Pine Manor College in
      Brookline, MA, and a B.A. at UMass Amherst. Currently, she is pursuing her Ph.D. 
      in public health at UMass Amherst. David Buchanan, Dr.P.H., Professor Emeritus at
      UMass Amherst, received his B.A., his M.P.H., and his Dr.PH., from University of 
      California Berkeley. He is a prominent expert in public health ethics.
FAU - Harrington, Calla
AU  - Harrington C
AD  - Elizabeth A. Evans, Ph.D., M.A., is an Associate Professor of public health at
      the University of Massachusetts Amherst. She received her B.A. from the
      University of California San Diego, her M.A. from Indiana University,
      Bloomington, and her Ph.D. from the University of California Los Angeles Fielding
      School of Public Health. Dr. Evans researches how health care systems and public 
      policies can better promote health and wellness particularly among individuals at
      risk for opioid and substance use disorders, mental illness, and infectious
      diseases. Calla Harrington, M.P.H., M.S.W., L.C.S.W., is a Research Fellow in the
      Department of Health Policy and Promotion at the University of Massachusetts
      Amherst. Calla received her M.P.H. in Epidemiology from UMass Amherst, her
      clinical M.S.W. from Boston University, M.A., and her B.S.W. from Eastern
      University in St. Davids, PA. Robert Roose, M.D., M.P.H., F.A.S.A.M., is the
      Chief Medical Officer for Mercy Medical Center and affiliates. Dr. Roose received
      his M.D. and M.P.H. from the George Washington University School of Medicine and 
      Health Sciences in Washington, DC. He received his B.S. from the University of
      Illinois at Urbana-Champaign, IL. He serves on the Quality Improvement Council of
      the American Society of Addiction Medicine and is a key contributor to opioid
      task forces in Massachusetts. Susan Lemere, M.S.W., L.I.C.S.W., received her
      M.S.W. from Smith College in Northampton, MA, a M.F.A. from Pine Manor College in
      Brookline, MA, and a B.A. at UMass Amherst. Currently, she is pursuing her Ph.D. 
      in public health at UMass Amherst. David Buchanan, Dr.P.H., Professor Emeritus at
      UMass Amherst, received his B.A., his M.P.H., and his Dr.PH., from University of 
      California Berkeley. He is a prominent expert in public health ethics.
FAU - Roose, Robert
AU  - Roose R
AD  - Elizabeth A. Evans, Ph.D., M.A., is an Associate Professor of public health at
      the University of Massachusetts Amherst. She received her B.A. from the
      University of California San Diego, her M.A. from Indiana University,
      Bloomington, and her Ph.D. from the University of California Los Angeles Fielding
      School of Public Health. Dr. Evans researches how health care systems and public 
      policies can better promote health and wellness particularly among individuals at
      risk for opioid and substance use disorders, mental illness, and infectious
      diseases. Calla Harrington, M.P.H., M.S.W., L.C.S.W., is a Research Fellow in the
      Department of Health Policy and Promotion at the University of Massachusetts
      Amherst. Calla received her M.P.H. in Epidemiology from UMass Amherst, her
      clinical M.S.W. from Boston University, M.A., and her B.S.W. from Eastern
      University in St. Davids, PA. Robert Roose, M.D., M.P.H., F.A.S.A.M., is the
      Chief Medical Officer for Mercy Medical Center and affiliates. Dr. Roose received
      his M.D. and M.P.H. from the George Washington University School of Medicine and 
      Health Sciences in Washington, DC. He received his B.S. from the University of
      Illinois at Urbana-Champaign, IL. He serves on the Quality Improvement Council of
      the American Society of Addiction Medicine and is a key contributor to opioid
      task forces in Massachusetts. Susan Lemere, M.S.W., L.I.C.S.W., received her
      M.S.W. from Smith College in Northampton, MA, a M.F.A. from Pine Manor College in
      Brookline, MA, and a B.A. at UMass Amherst. Currently, she is pursuing her Ph.D. 
      in public health at UMass Amherst. David Buchanan, Dr.P.H., Professor Emeritus at
      UMass Amherst, received his B.A., his M.P.H., and his Dr.PH., from University of 
      California Berkeley. He is a prominent expert in public health ethics.
FAU - Lemere, Susan
AU  - Lemere S
AD  - Elizabeth A. Evans, Ph.D., M.A., is an Associate Professor of public health at
      the University of Massachusetts Amherst. She received her B.A. from the
      University of California San Diego, her M.A. from Indiana University,
      Bloomington, and her Ph.D. from the University of California Los Angeles Fielding
      School of Public Health. Dr. Evans researches how health care systems and public 
      policies can better promote health and wellness particularly among individuals at
      risk for opioid and substance use disorders, mental illness, and infectious
      diseases. Calla Harrington, M.P.H., M.S.W., L.C.S.W., is a Research Fellow in the
      Department of Health Policy and Promotion at the University of Massachusetts
      Amherst. Calla received her M.P.H. in Epidemiology from UMass Amherst, her
      clinical M.S.W. from Boston University, M.A., and her B.S.W. from Eastern
      University in St. Davids, PA. Robert Roose, M.D., M.P.H., F.A.S.A.M., is the
      Chief Medical Officer for Mercy Medical Center and affiliates. Dr. Roose received
      his M.D. and M.P.H. from the George Washington University School of Medicine and 
      Health Sciences in Washington, DC. He received his B.S. from the University of
      Illinois at Urbana-Champaign, IL. He serves on the Quality Improvement Council of
      the American Society of Addiction Medicine and is a key contributor to opioid
      task forces in Massachusetts. Susan Lemere, M.S.W., L.I.C.S.W., received her
      M.S.W. from Smith College in Northampton, MA, a M.F.A. from Pine Manor College in
      Brookline, MA, and a B.A. at UMass Amherst. Currently, she is pursuing her Ph.D. 
      in public health at UMass Amherst. David Buchanan, Dr.P.H., Professor Emeritus at
      UMass Amherst, received his B.A., his M.P.H., and his Dr.PH., from University of 
      California Berkeley. He is a prominent expert in public health ethics.
FAU - Buchanan, David
AU  - Buchanan D
AD  - Elizabeth A. Evans, Ph.D., M.A., is an Associate Professor of public health at
      the University of Massachusetts Amherst. She received her B.A. from the
      University of California San Diego, her M.A. from Indiana University,
      Bloomington, and her Ph.D. from the University of California Los Angeles Fielding
      School of Public Health. Dr. Evans researches how health care systems and public 
      policies can better promote health and wellness particularly among individuals at
      risk for opioid and substance use disorders, mental illness, and infectious
      diseases. Calla Harrington, M.P.H., M.S.W., L.C.S.W., is a Research Fellow in the
      Department of Health Policy and Promotion at the University of Massachusetts
      Amherst. Calla received her M.P.H. in Epidemiology from UMass Amherst, her
      clinical M.S.W. from Boston University, M.A., and her B.S.W. from Eastern
      University in St. Davids, PA. Robert Roose, M.D., M.P.H., F.A.S.A.M., is the
      Chief Medical Officer for Mercy Medical Center and affiliates. Dr. Roose received
      his M.D. and M.P.H. from the George Washington University School of Medicine and 
      Health Sciences in Washington, DC. He received his B.S. from the University of
      Illinois at Urbana-Champaign, IL. He serves on the Quality Improvement Council of
      the American Society of Addiction Medicine and is a key contributor to opioid
      task forces in Massachusetts. Susan Lemere, M.S.W., L.I.C.S.W., received her
      M.S.W. from Smith College in Northampton, MA, a M.F.A. from Pine Manor College in
      Brookline, MA, and a B.A. at UMass Amherst. Currently, she is pursuing her Ph.D. 
      in public health at UMass Amherst. David Buchanan, Dr.P.H., Professor Emeritus at
      UMass Amherst, received his B.A., his M.P.H., and his Dr.PH., from University of 
      California Berkeley. He is a prominent expert in public health ethics.
LA  - eng
GR  - UG3 DA044830/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2020 Dec;48(4):741-743. PMID: 33404332
MH  - Adult
MH  - Aged
MH  - Caregivers/*psychology
MH  - Female
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Involuntary Commitment/*ethics/legislation & jurisprudence
MH  - Male
MH  - Massachusetts/epidemiology
MH  - Middle Aged
MH  - Opioid-Related Disorders/*prevention & control
MH  - Patients/*psychology
MH  - Public Health/*ethics
MH  - Qualitative Research
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979382 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):718-734. doi: 10.1177/1073110520979382.


PMID- 33404332
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - Neither Ethical Nor Effective: The False Promise of Involuntary Commitment to
      Address the Overdose Crisis.
PG  - 741-743
LID - 10.1177/1073110520979384 [doi]
FAU - Sinha, Michael S
AU  - Sinha MS
AD  - Michael S. Sinha, M.D., J.D., M.P.H., is a Research Fellow at the Harvard-MIT
      Center for Regulatory Science at Harvard Medical School, an Affiliated Researcher
      at the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and
      Women's Hospital, and a Visiting Scholar at the Center for Health Policy and Law 
      at Northeastern University School of Law, all in Boston, Massachusetts, United
      States. John C. Messinger, B.S., is a Medical Student at Harvard Medical School
      in Boston, Massachusetts, United States. Leo Beletsky, J.D., M.P.H., is a
      Professor of Law and Health Sciences at Northeastern University, Boston,
      Massachusetts, United States, where he also directs the Health in Justice Action 
      Lab. He is also an Associate Adjunct Professor in the Division of Infectious
      Disease and Global Public Health at UC San Diego School of Medicine, La Jolla,
      California, United States.
FAU - Messinger, John C
AU  - Messinger JC
AD  - Michael S. Sinha, M.D., J.D., M.P.H., is a Research Fellow at the Harvard-MIT
      Center for Regulatory Science at Harvard Medical School, an Affiliated Researcher
      at the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and
      Women's Hospital, and a Visiting Scholar at the Center for Health Policy and Law 
      at Northeastern University School of Law, all in Boston, Massachusetts, United
      States. John C. Messinger, B.S., is a Medical Student at Harvard Medical School
      in Boston, Massachusetts, United States. Leo Beletsky, J.D., M.P.H., is a
      Professor of Law and Health Sciences at Northeastern University, Boston,
      Massachusetts, United States, where he also directs the Health in Justice Action 
      Lab. He is also an Associate Adjunct Professor in the Division of Infectious
      Disease and Global Public Health at UC San Diego School of Medicine, La Jolla,
      California, United States.
FAU - Beletsky, Leo
AU  - Beletsky L
AD  - Michael S. Sinha, M.D., J.D., M.P.H., is a Research Fellow at the Harvard-MIT
      Center for Regulatory Science at Harvard Medical School, an Affiliated Researcher
      at the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and
      Women's Hospital, and a Visiting Scholar at the Center for Health Policy and Law 
      at Northeastern University School of Law, all in Boston, Massachusetts, United
      States. John C. Messinger, B.S., is a Medical Student at Harvard Medical School
      in Boston, Massachusetts, United States. Leo Beletsky, J.D., M.P.H., is a
      Professor of Law and Health Sciences at Northeastern University, Boston,
      Massachusetts, United States, where he also directs the Health in Justice Action 
      Lab. He is also an Associate Adjunct Professor in the Division of Infectious
      Disease and Global Public Health at UC San Diego School of Medicine, La Jolla,
      California, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CON - J Law Med Ethics. 2020 Dec;48(4):718-734. PMID: 33404337
CON - J Law Med Ethics. 2020 Dec;48(4):735-740. PMID: 33404339
MH  - Commitment of Mentally Ill
MH  - *Drug Overdose
MH  - Humans
MH  - *Involuntary Commitment
MH  - Morals
EDAT- 2021/01/07 06:00
MHDA- 2021/06/23 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
AID - 10.1177/1073110520979384 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):741-743. doi: 10.1177/1073110520979384.


PMID- 33404329
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210622
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - Legal and Ethical Analysis of Advertising for Elective Egg Freezing.
PG  - 748-764
LID - 10.1177/1073110520979386 [doi]
AB  - This paper reviews common advertising claims by egg freezing companies and
      evaluates the medical evidence behind those claims. It then surveys legal
      standards for truth in advertising, including FTC and FDA regulations and the
      First Amendment right to free speech. Professional standards for medical
      advertising, such as guidelines published by the American Society for
      Reproductive Medicine (ASRM), the American College of Obstetricians and
      Gynecologists (ACOG), and the American Medical Association (AMA), are also
      summarized. A number of claims, many of which relate to the targeting of younger 
      women for eOC, are found to breach legal and ethical standards for truth in
      advertising. The ethical implications of misleading advertising claims are also
      discussed, and the central narrative woven by OC ads - that egg freezing is
      empowering to women - is examined. The paper concludes that a more balanced
      approach to the risks and benefits of OC is necessary to truly respect women's
      autonomy. Moreover, justice requires us to look beyond a medical procedure
      accessible only to a minority of women in order to address inequities in the
      workplace.
FAU - Bayefsky, Michelle J
AU  - Bayefsky MJ
AD  - Michelle Bayefsky, B.A., is a fourth-year medical student at Harvard Medical
      School (Boston, Massachusetts). Previously she was a post-baccalaureate fellow in
      the Department of Bioethics of the National Institutes of Health, where her work 
      focused on topics related to reproduction, genomics policy, and public health.
      Ms. Bayefsky graduated summa cum laude from Yale College (New Haven, Connecticut)
      with a Bachelor of Arts in ethics, politics and economics.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2020 Dec;48(4):765-767. PMID: 33404330
MH  - Advertising/*ethics/*legislation & jurisprudence/standards
MH  - *Cryopreservation
MH  - Female
MH  - Government Regulation
MH  - Guidelines as Topic
MH  - Humans
MH  - *Ovum
MH  - Societies, Medical
MH  - United States
MH  - United States Federal Trade Commission
MH  - United States Food and Drug Administration
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979386 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):748-764. doi: 10.1177/1073110520979386.


PMID- 33404327
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - "Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical
      Considerations for Children with Cancer.
PG  - 778-783
LID - 10.1177/1073110520979389 [doi]
FAU - Knapp, Esther
AU  - Knapp E
AD  - Esther Knapp, M.D., M.B.E., is with the Division of Pediatric
      Hematology/Oncology, Department of Pediatrics at University of Louisville/Norton 
      Children's Hospital.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Child
MH  - *Genetic Predisposition to Disease
MH  - Genetic Testing/*ethics/methods
MH  - Genomics/*ethics/methods
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Medical Oncology/methods
MH  - Neoplasms/*diagnosis/*genetics
MH  - Precision Medicine/ethics
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979389 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):778-783. doi: 10.1177/1073110520979389.


PMID- 33404326
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - How Should Ethics Consultants Weigh the Law (and other Authoritative Directives)?
PG  - 768-777
LID - 10.1177/1073110520979388 [doi]
AB  - In the continuing debate about the role of the Clinical Ethics Consultant in
      performing clinical ethics consultations, it is often assumed that consultants
      should operate within ethical and legal standards. Recent scholarship has focused
      primarily on clarifying the consultant's role with respect to the ethical
      standards that serve as parameters of consulting. In the following, however, I
      wish to address the question of how the ethics consultant should weigh legal
      standards and, more broadly, how consultants might weigh authoritative
      directives, whether legal, institutional, or professional, against other
      normative considerations. I argue that consultants should reject the view that
      authoritative directives carry exclusionary reason for actions and, further,
      ethicists should interpret directives as lacking any moral weight qua
      authoritative directive. I then identify both implications and limitations of
      this view with respect to the evolving role of the ethics consultant in an
      institutional setting, and in doing so propose the kinds of considerations the
      ethicist should weigh when presented with an authoritative directive.
FAU - Koch, Peter
AU  - Koch P
AD  - Peter Koch, Ph.D., is an assistant professor of philosophy at Villanova
      University. His research interests include clinical and biomedical ethics,
      philosophy of law, and philosophy of medicine. Along with experience as a
      clinical ethics consultant, Peter has published on a range of topics, including
      patient welfare, the metaphysics of brain death, medical professionalism, and
      harm in medicine.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Codes of Ethics
MH  - Ethicists/*legislation & jurisprudence/*standards
MH  - Ethics Consultation/*legislation & jurisprudence/*standards
MH  - Humans
MH  - Moral Obligations
MH  - Professional Role
EDAT- 2021/01/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/1073110520979388 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4):768-777. doi: 10.1177/1073110520979388.


PMID- 33404307
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 4_suppl
DP  - 2020 Dec
TI  - The "Rules of the Road": Ethics, Firearms, and the Physician's "Lane".
PG  - 142-145
LID - 10.1177/1073110520979415 [doi]
AB  - Physicians play a critical role in preventing and treating firearm injury,
      although the scope of that role remains contentious and lacks systematic
      definition. This piece aims to utilize the fundamental principles of medical
      ethics to present a framework for physician involvement in firearm violence.
      Physicians' agency relationship with their patients creates ethical obligations
      grounded on three principles of medical ethics - patient autonomy, beneficence,
      and nonmaleficence. Taken together, they suggest that physicians ought to engage 
      in clinical screening and treatment related to firearm violence. The principle of
      beneficence also applies more generally, but more weakly, to relations between
      physicians and society, creating nonobligatory moral ideals. Balanced against
      physicians' primary obligations to patient agency relationships, general
      beneficence suggests that physicians may engage in public advocacy to address gun
      violence, although they are not ethically obligated to do so. A fourth
      foundational principle - justice - requires that clinicians attempt to ensure
      that the benefits and burdens of healthcare are distributed fairly.
FAU - Shultz, Blake N
AU  - Shultz BN
AD  - Blake N. Shultz is a sixth-year medical student at Yale School of Medicine and a 
      third-year law student at Yale Law School in New Haven, CT. He is also a fellow
      at the Solomon Center for Health Law and Policy at Yale Law School. He received
      his B.A. from Cornell University (2015) in Ithaca, NY. Benjamin Tolchin, M.D.,
      M.S., is an Assistant Professor of Neurology at Yale School of Medicine and an
      Attending Physician at Yale New Haven Hospital and at the West Haven VA Medical
      Center. Katherine L. Kraschel, J.D., is the Executive Director of the Solomon
      Center for Health Law and Policy as well as a Lecturer in Law, Clinical Lecturer 
      in Law, and Research Scholar in Law at Yale Law School. She received her J.D.
      from Harvard Law School, and her B.A. from Mount Holyoke College.
FAU - Tolchin, Benjamin
AU  - Tolchin B
AD  - Blake N. Shultz is a sixth-year medical student at Yale School of Medicine and a 
      third-year law student at Yale Law School in New Haven, CT. He is also a fellow
      at the Solomon Center for Health Law and Policy at Yale Law School. He received
      his B.A. from Cornell University (2015) in Ithaca, NY. Benjamin Tolchin, M.D.,
      M.S., is an Assistant Professor of Neurology at Yale School of Medicine and an
      Attending Physician at Yale New Haven Hospital and at the West Haven VA Medical
      Center. Katherine L. Kraschel, J.D., is the Executive Director of the Solomon
      Center for Health Law and Policy as well as a Lecturer in Law, Clinical Lecturer 
      in Law, and Research Scholar in Law at Yale Law School. She received her J.D.
      from Harvard Law School, and her B.A. from Mount Holyoke College.
FAU - Kraschel, Katherine L
AU  - Kraschel KL
AD  - Blake N. Shultz is a sixth-year medical student at Yale School of Medicine and a 
      third-year law student at Yale Law School in New Haven, CT. He is also a fellow
      at the Solomon Center for Health Law and Policy at Yale Law School. He received
      his B.A. from Cornell University (2015) in Ithaca, NY. Benjamin Tolchin, M.D.,
      M.S., is an Assistant Professor of Neurology at Yale School of Medicine and an
      Attending Physician at Yale New Haven Hospital and at the West Haven VA Medical
      Center. Katherine L. Kraschel, J.D., is the Executive Director of the Solomon
      Center for Health Law and Policy as well as a Lecturer in Law, Clinical Lecturer 
      in Law, and Research Scholar in Law at Yale Law School. She received her J.D.
      from Harvard Law School, and her B.A. from Mount Holyoke College.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Beneficence
MH  - *Ethics, Medical
MH  - Firearms/*ethics
MH  - Humans
MH  - Patient Advocacy/*standards
MH  - Personal Autonomy
MH  - Physician-Patient Relations/ethics
MH  - Public Health/*standards
MH  - Social Justice
MH  - *Wounds, Gunshot
EDAT- 2021/01/07 06:00
MHDA- 2021/07/08 06:00
CRDT- 2021/01/06 12:14
PHST- 2021/01/06 12:14 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
AID - 10.1177/1073110520979415 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Dec;48(4_suppl):142-145. doi: 10.1177/1073110520979415.


PMID- 33404001
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 2078-5135 (Electronic)
VI  - 111
IP  - 1
DP  - 2020 Dec 14
TI  - Do COVID-19 patients needing extended care in an intensive care unit fall under
      the 'emergency medical treatment' provisions of the South African Constitution?
PG  - 23-25
LID - 10.7196/SAMJ.2020.v111i1.15424 [doi]
AB  - Whether COVID-19 patients in need of extended care in an intensive care unit
      qualify for 'emergency medical treatment' is answered by considering the
      Constitution, the meaning of emergency medical treatment, and whether such
      patients are in an incurable chronic condition. Considering ethical guidelines
      for the withholding and withdrawal of treatment may assist a court in determining
      whether a healthcare practitioner has acted with the degree of skill and care
      required of a reasonably competent practitioner in his or her branch of the
      profession.
FAU - McQuoid-Mason, D J
AU  - McQuoid-Mason DJ
AD  - Centre for Socio-Legal Studies, University of KwaZulu-Natal, Durban, South
      Africa. mcquoidm@ukzn.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19/*therapy
MH  - Chronic Disease/legislation & jurisprudence
MH  - *Constitution and Bylaws
MH  - Critical Care/ethics/*legislation & jurisprudence
MH  - Emergency Treatment/ethics
MH  - Health Services Accessibility/ethics/*legislation & jurisprudence
MH  - Humans
MH  - Intensive Care Units
MH  - Jurisprudence
MH  - Respiration, Artificial
MH  - SARS-CoV-2
MH  - South Africa
MH  - Withholding Treatment/ethics/*legislation & jurisprudence
EDAT- 2021/01/07 06:00
MHDA- 2021/01/16 06:00
CRDT- 2021/01/06 08:41
PHST- 2020/12/14 00:00 [received]
PHST- 2021/01/06 08:41 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.7196/SAMJ.2020.v111i1.15424 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Dec 14;111(1):23-25. doi: 10.7196/SAMJ.2020.v111i1.15424.


PMID- 33403961
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210119
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 12
DP  - 2020 Nov 5
TI  - Critical care triage during the COVID-19 pandemic in South Africa: A
      constitutional imperative!
PG  - 1176-1179
LID - 10.7196/SAMJ.2020.v110i12.15411 [doi]
AB  - Triage and rationing of scarce intensive care unit (ICU) resources are an
      unavoidable necessity. In routine circumstances, ICU triage is premised on the
      best interests of an individual patient; however, when increased demand exceeds
      capacity, as during an infectious disease outbreak, healthcare providers need to 
      make difficult decisions to benefit the broader community while still respecting 
      individual interests. We are currently living through an unprecedented period,
      with South Africa (SA) facing the challenges of the global COVID-19 pandemic. The
      Critical Care Society of Southern Africa (CCSSA) expedited the development of a
      triage guidance document to inform the appropriate and fair use of scarce ICU
      resources during this pandemic. Triage decision-making is based on the clinical
      odds of a positive ICU outcome, balanced against the risk of mortality and
      longer-term morbidity affecting quality of life. Factors such as age and comorbid
      conditions are considered for their potential impact on clinical outcome, but are
      never the sole criteria for denying ICU-level care. Arbitrary, unfair
      discrimination is never condoned. The CCSSA COVID-19 triage guideline is aligned 
      with SA law and international ethical standards, and upholds respect for all
      persons. The Bill of Rights, however, does not mandate the level of care
      enshrined in the constitutional right to healthcare. ICU admission is not always 
      appropriate, available or feasible for every person suffering critical illness or
      injury; however, everyone has the right to receive appropriate healthcare at
      another level. If ICU resources are used for people who do not stand to benefit, 
      this effectively denies others access to potentially life-saving healthcare.
      Appropriate triaging can therefore be considered a constitutional imperative.
FAU - Morrow, B M
AU  - Morrow BM
AD  - Department of Paediatrics and Child Health, Faculty of Health Sciences,
      University of Cape Town, South Africa. brenda.morrow@uct.ac.za.
FAU - Gopalan, P D
AU  - Gopalan PD
FAU - Joubert, I
AU  - Joubert I
FAU - Paruk, F
AU  - Paruk F
FAU - Pope, A
AU  - Pope A
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20201105
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
CON - S Afr Med J. 2020 Nov 05;110(12):1172-1175. PMID: 33403960
MH  - Africa, Southern
MH  - *COVID-19
MH  - Critical Care
MH  - Health Care Rationing
MH  - Humans
MH  - Intensive Care Units
MH  - *Pandemics
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - South Africa
MH  - Triage
EDAT- 2021/01/07 06:00
MHDA- 2021/01/20 06:00
CRDT- 2021/01/06 08:40
PHST- 2020/11/05 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2021/01/06 08:40 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i12.15411 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Nov 5;110(12):1176-1179. doi: 10.7196/SAMJ.2020.v110i12.15411.


PMID- 33403364
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2666-5204 (Electronic)
IS  - 2666-5204 (Linking)
VI  - 4
DP  - 2020 Dec
TI  - Sub30: Protocol for the Sub30 feasibility study of a pre-hospital Extracorporeal 
      membrane oxygenation (ECMO) capable advanced resuscitation team at achieving
      blood flow within 30 min in patients with refractory out-of-hospital cardiac
      arrest.
PG  - 100029
LID - 10.1016/j.resplu.2020.100029 [doi]
AB  - BACKGROUND: Out-of-hospital cardiac arrest carries a poor prognosis with survival
      less than 10% in many patient cohorts. Survival is inversely associated with
      duration of resuscitation as external chest compressions do not provide
      sufficient blood flow to prevent irreversible organ damage during a prolonged
      resuscitation. Extracorporeal membrane oxygenation (ECMO) instituted during
      cardiac arrest can provide normal physiological blood flows and is termed
      Extracorporeal Cardio-Pulmonary Resuscitation (ECPR). ECPR may improve survival
      when used with in-hospital cardiac arrests. This possible survival benefit has
      not been replicated in trials of out-of-hospital cardiac arrests, possibly
      because of the additional time it takes to transport the patient to hospital and 
      initiate ECPR. Pre-hospital ECPR may shorten the time between cardiac arrest and 
      physiological blood flows, potentially improving survival. It may also mitigate
      some of the neurological injury that many survivors suffer. METHODS: Sub30 is a
      prospective six patient feasibility study. The primary aim is to test whether it 
      is possible to institute ECPR within 30 min of collapse in adult patients with
      refractory out of hospital cardiac arrest (OHCA). The secondary aims are to
      gather preliminary data on clinical outcomes, resource utilisation, and health
      economics associated with rapid ECPR delivery in order to plan any subsequent
      clinical investigation or clinical service. On study days a dedicated
      fast-response vehicle with ECPR capability will be tasked to out-of-hospital
      cardiac arrests in an area of London served by Barts Heart Centre. If patients
      suffer a cardiac arrest refractory to standard advanced resuscitation and meet
      eligibility criteria, ECPR will be started in the pre-hospital environment.
      DISCUSSION: Delivering pre-hospital ECPR within 30 min of an out-of-hospital
      cardiac arrest presents significant ethical, clinical, governance and logistical 
      challenges. Prior to conducting an efficacy study of ECPR the feasibility of
      timely and safe application must be demonstrated first. Extensive planning,
      multiple high-fidelity multiagency simulations and a unique collaboration between
      pre-hospital and in-hospital institutions will allow us to test the feasibility
      of this intervention in London. The study has been reviewed, refined and endorsed
      by the International ECMO Network (ECMONet). TRIAL REGISTRATION: Clinicaltrials. 
      gov NCT03700125, prospectively registered October 9, 2018.
CI  - Crown Copyright (c) 2020 Published by Elsevier B.V.
FAU - Singer, Ben
AU  - Singer B
AD  - St Bartholomew's Hospital, London, UK.
AD  - London's Air Ambulance, UK.
FAU - Reynolds, Joshua C
AU  - Reynolds JC
AD  - Michigan State University, USA.
FAU - Davies, Gareth E
AU  - Davies GE
AD  - London's Air Ambulance, UK.
FAU - Wrigley, Fenella
AU  - Wrigley F
AD  - London Ambulance Service, UK.
FAU - Whitbread, Mark
AU  - Whitbread M
AD  - University of Sussex, UK.
FAU - Faulkner, Mark
AU  - Faulkner M
AD  - London Ambulance Service, UK.
FAU - O'Brien, Ben
AU  - O'Brien B
AD  - St Bartholomew's Hospital, London, UK.
FAU - Proudfoot, Alastair G
AU  - Proudfoot AG
AD  - St Bartholomew's Hospital, London, UK.
FAU - Mathur, Anthony
AU  - Mathur A
AD  - St Bartholomew's Hospital, London, UK.
FAU - Evens, Thomas
AU  - Evens T
AD  - London's Air Ambulance, UK.
FAU - Field, Jane
AU  - Field J
AD  - Barts Cardiovascular Clinical Trials Unit, London, UK.
FAU - Monk, Vivienne
AU  - Monk V
AD  - Barts Cardiovascular Clinical Trials Unit, London, UK.
FAU - Finney, Simon J
AU  - Finney SJ
AD  - St Bartholomew's Hospital, London, UK.
CN  - International ECMO Network (ECMONet)
LA  - eng
SI  - ClinicalTrials.gov/NCT03700125
PT  - Journal Article
DEP - 20201008
PL  - Netherlands
TA  - Resusc Plus
JT  - Resuscitation plus
JID - 101774410
PMC - PMC7543759
OTO - NOTNLM
OT  - Cardiac arrest
OT  - Extra-corporeal cardiopulmonary resuscitation
OT  - Extracorporeal membrane oxygenation
OT  - Pre-hospital medical care
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2021/01/07 06:00
MHDA- 2021/01/07 06:01
CRDT- 2021/01/06 05:54
PHST- 2020/07/02 00:00 [received]
PHST- 2020/09/12 00:00 [revised]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2021/01/06 05:54 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/07 06:01 [medline]
AID - 10.1016/j.resplu.2020.100029 [doi]
AID - S2666-5204(20)30029-1 [pii]
PST - ppublish
SO  - Resusc Plus. 2020 Dec;4:100029. doi: 10.1016/j.resplu.2020.100029. Epub 2020 Oct 
      8.


PMID- 33402975
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20220419
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Sep
TI  - Determination of expression profile of p53 gene in different grades of breast
      cancer tissues by real time PCR.
PG  - 1273-1282
LID - 10.4314/ahs.v20i3.32 [doi]
AB  - BACKGROUND: Pakistan has a high incidence of breast cancer in Asia, where
      annually 16,232 deaths are reported. There are many exogenous and endogenous risk
      factors that affect the tumor suppressor genes and oncogenes. The p53 gene is a
      tumor suppressor gene and it has a role to protect the whole genome from external
      and internal stresses, which causes damages to the genome. OBJECTIVE: The aim of 
      the current study was to investigate the p53 gene expression by using the
      real-time PCR technique in different grades of breast cancer as compared to the
      normal tissue. METHODS: Fresh Modified Radical Mastectomy (MRM) samples
      (grade1-grade3) were collected from different hospitals of the Lahore. The
      project was approved by an ethical review committee of Jinnah Hospital, Lahore.
      And before sampling an informed consent was obtained from patients and
      clinicians. RNA from fresh biopsies was extracted by Qiagen extraction kit and
      cDNA was formed. Real time PCR performed by using SYBR green master mix (ABI) and
      the data was evaluated by using Livak method. Statistical analysis was done by
      using Microsoft Excel. RESULTS: There was an abnormal gene expression of p53 in
      all grades of the breast tumors. Non-significant (p>0.05) difference of down and 
      up regulation of p53 in different grades of breast tumor was found. However, as a
      whole up-regulation was more than down-regulation with significant difference
      (p<0.0011). CONCLUSION: The abnormal expression of p53 shows that there are some 
      genetic and epigenetic factors which are the primal cause of an abnormal gene
      expression. It is recommended that perform next generation sequencing (NGS) of
      the gene to find out the mutations causing the abnormal behavior of p53 gene.
CI  - (c) 2020 Sadia H et al.
FAU - Sadia, Haleema
AU  - Sadia H
AD  - Department of Biotechnology, Balochistan University of Information Technology,
      Engineering and Management Sciences, Quetta, Pakistan.
AD  - Center for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
FAU - Bhinder, Munir Ahmad
AU  - Bhinder MA
AD  - Department of Human Genetics and Molecular Biology, University of Health
      Sciences, Lahore, Pakistan.
FAU - Irshad, Asma
AU  - Irshad A
AD  - Department of Life Sciences, University of Management and Technology (UMT)
      Lahore, Pakistan.
FAU - Zahid, Beenish
AU  - Zahid B
AD  - Department of Pathology, UVAS, Narowal, Pakistan.
FAU - Ahmed, Rais
AU  - Ahmed R
AD  - Department of Microbiology, Cholistan University of Veterinary and Animal
      Sciences CUVAS, Cholistan, Pakistan.
FAU - Ashiq, Sana
AU  - Ashiq S
AD  - Center for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
FAU - Malik, Kausar
AU  - Malik K
AD  - National Centre of Excellence in Molecular Biology, University of the Punjab,
      Lahore, Pakistan.
FAU - Riaz, Muhammad
AU  - Riaz M
AD  - Department of Allied Health Sciences, University of Sargodha, Sargodha Pakistan.
FAU - Nadeem, Tariq
AU  - Nadeem T
AD  - National Centre of Excellence in Molecular Biology, University of the Punjab,
      Lahore, Pakistan.
FAU - Ashiq, Kanwal
AU  - Ashiq K
AD  - Faculty of Pharmaceutical Sciences, Superior University Lahore, Pakistan.
FAU - Akbar, Ali
AU  - Akbar A
AD  - Department of Microbiology, University of Balochistan, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Breast Neoplasms/*genetics/pathology/surgery
MH  - Down-Regulation
MH  - Female
MH  - Genes, p53
MH  - Humans
MH  - Mastectomy
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Pakistan
MH  - Real-Time Polymerase Chain Reaction
MH  - Tumor Suppressor Protein p53/*genetics/metabolism
MH  - Up-Regulation
PMC - PMC7751535
OTO - NOTNLM
OT  - Breast cancer
OT  - Pakistan
OT  - Punjab
OT  - down-regulation
OT  - p53 gene
OT  - real-time PCR
OT  - up-regulation
EDAT- 2021/01/07 06:00
MHDA- 2021/07/01 06:00
CRDT- 2021/01/06 05:53
PHST- 2021/01/06 05:53 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 10.4314/ahs.v20i3.32 [doi]
AID - jAFHS.v20.i3.pg1273 [pii]
PST - ppublish
SO  - Afr Health Sci. 2020 Sep;20(3):1273-1282. doi: 10.4314/ahs.v20i3.32.


PMID- 33402898
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20220419
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Mar
TI  - Chronic HIV infection and health related quality of life in resource poor
      settings-an assessment from South East Nigeria.
PG  - 102-113
LID - 10.4314/ahs.v20i1.15 [doi]
AB  - BACKGROUND: Health-related quality of life reflects a patient's general
      subjective perception of the effect of an illness or intervention on physical,
      psychological and social aspects of daily life. HIV infection is a major public
      health problem especially in developing countries where poor health
      infrastructure and poverty are prevalent. This paper addresses the quality of
      life in patients with chronic HIV infection in South East Nigeria and addresses
      issues that may help improve the current situation. METHODS: A cross-sectional
      survey was carried out at the University of Nigeria Teaching Hospital, Enugu, to 
      assess patients with HIV receiving antiretroviral therapy (ART) using a validated
      structured questionnaire (WHOQoL-BREF). Ethical clearance for the study was
      obtained. Study period was from October - December, 2017. Data obtained was
      analysed. RESULTS: A total of 389 HIV patients consented to the study. Over 70%
      were aged 18- 45 years and majority were females. Females had a higher quality of
      life score with respect to the domain of psychological health while males had a
      higher score with respect to the environmental domain. Older age and presence of 
      co-morbidities were significantly associated with affectation of physical health 
      while younger age was associated with affectation of psychological health domain.
      CONCLUSION: HIV impairs the quality of life for affected individuals in South
      East Nigeria especially across the domains of physical and psychological health. 
      No age group is spared. The presence of co-morbidities significantly reduces
      quality of life in these patients. Younger patients may require mental health
      services in the management of their disease.
CI  - (c) 2020 Onyekonwu CL et al.
FAU - Onyekonwu, Chinwe Laura
AU  - Onyekonwu CL
AD  - Sub-Department of Dermatology, College of Medicine, University of Nigeria,
      Ituku-Ozalla Campus, Enugu, Nigeria.
FAU - Onyeka, Tonia Chinyelu
AU  - Onyeka TC
AD  - Department of Anaesthesia/Pain and palliative Care Unit, Multidisciplinary
      Oncology Center, College of Medicine, UNTH, Ituku-Ozalla Campus, Enugu, Nigeria.
FAU - Brenda, Nwatu Chidimma
AU  - Brenda NC
AD  - Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla 
      Campus, Enugu, Nigeria.
FAU - Ijoma, Uchenna Nkemdilim
AU  - Ijoma UN
AD  - Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla 
      Campus, Enugu, Nigeria.
FAU - Unaogu, Ngozichukwu Nneka
AU  - Unaogu NN
AD  - Federal Neuropsychiatric Hospital, Enugu, Nigeria.
FAU - Onwuekwe, Ikenna Obinwanne
AU  - Onwuekwe IO
AD  - Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla 
      Campus, Enugu, Nigeria.
FAU - Ugwumba, Fred
AU  - Ugwumba F
AD  - Urology Unit, Department of Surgery, College of Medicine, University of Nigeria, 
      Ituku-Ozalla Campus, Enugu, Nigeria.
FAU - Nwutobo, Chidimma Rhoda
AU  - Nwutobo CR
AD  - Department of Medicine, University of Nigeria Teaching Hospital, Ituku-Ozalla.
FAU - Nwachukwu, Chioma Victoria
AU  - Nwachukwu CV
AD  - Department of Medical Physiology, College of Medicine, University of Nigeria,
      Enugu Campus, Enugu, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Chronic Disease/epidemiology/*psychology
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/drug therapy/epidemiology/*psychology
MH  - *Health Status
MH  - Humans
MH  - Interpersonal Relations
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - Quality of Life/*psychology
MH  - Socioeconomic Factors
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7750088
OTO - NOTNLM
OT  - HIV
OT  - South East Nigeria
OT  - quality of life
EDAT- 2021/01/07 06:00
MHDA- 2021/02/13 06:00
CRDT- 2021/01/06 05:52
PHST- 2021/01/06 05:52 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - 10.4314/ahs.v20i1.15 [doi]
AID - jAFHS.v20.i1.pg102 [pii]
PST - ppublish
SO  - Afr Health Sci. 2020 Mar;20(1):102-113. doi: 10.4314/ahs.v20i1.15.


PMID- 33402807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Jul
TI  - Processes for Scientific and Ethical Approval of Research Proposals: Better
      Oversight May Be Necessary.
PG  - 403
LID - 10.1177/0253717620928251 [doi]
FAU - Andrade, Chittaranjan
AU  - Andrade C
AD  - Dept. of Clinical Psychopharmacology and Neurotoxicology, National Institute of
      Mental Health and Neurosciences, Bangalore, Karnataka, India.
FAU - Harshe, Devavrat
AU  - Harshe D
AD  - Dept. of Psychiatry, Dr D. Y. Patil Medical College, Hospital and Research
      Centre, Kolhapur, Maharashtra, India.
FAU - Bhise, Manik
AU  - Bhise M
AD  - Dept. of Psychiatry, MGM Medical College, Aurangabad, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7746899
EDAT- 2021/01/07 06:00
MHDA- 2021/01/07 06:01
CRDT- 2021/01/06 05:52
PHST- 2021/01/06 05:52 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/07 06:01 [medline]
AID - 10.1177/0253717620928251 [doi]
AID - 10.1177_0253717620928251 [pii]
PST - epublish
SO  - Indian J Psychol Med. 2020 Jul 13;42(4):403. doi: 10.1177/0253717620928251.
      eCollection 2020 Jul.


PMID- 33402798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Jul
TI  - Ethical Considerations of Mental Health Research Amidst COVID-19 Pandemic:
      Mitigating the Challenges.
PG  - 379-381
LID - 10.1177/0253717620929097 [doi]
FAU - Choudhury, Shinjini
AU  - Choudhury S
AD  - All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
FAU - Ghosh, Abhishek
AU  - Ghosh A
AD  - (Addiction Psychiatry), Postgraduate Institute of Medical Education & Research,
      Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7746900
EDAT- 2021/01/07 06:00
MHDA- 2021/01/07 06:01
CRDT- 2021/01/06 05:52
PHST- 2021/01/06 05:52 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/01/07 06:01 [medline]
AID - 10.1177/0253717620929097 [doi]
AID - 10.1177_0253717620929097 [pii]
PST - epublish
SO  - Indian J Psychol Med. 2020 Jul 6;42(4):379-381. doi: 10.1177/0253717620929097.
      eCollection 2020 Jul.


PMID- 33400057
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20220218
IS  - 1573-0980 (Electronic)
IS  - 1386-7415 (Linking)
VI  - 41
IP  - 4
DP  - 2020 Aug
TI  - What we talk about when we talk about pediatric suffering.
PG  - 143-163
LID - 10.1007/s11017-020-09535-8 [doi]
AB  - In this paper I aim to show why pediatric suffering must be understood as a
      judgment or evaluation, rather than a mental state. To accomplish this task,
      first I analyze the various ways that the label of suffering is used in pediatric
      practice. Out of this analysis emerge what I call the twin poles of pediatric
      suffering. At one pole sits the belief that infants and children with severe
      cognitive impairment cannot suffer because they are nonverbal or lack subjective 
      life experience. At the other pole exists the idea that once child suffering
      reaches some threshold it is ethical to eliminate the sufferer. Concerningly, at 
      both poles, any particular child vanishes from view. Second, in an attempt to
      identify a theory of suffering inclusive of children, I examine two prominent
      so-called experiential accounts of suffering. I find them both wanting on account
      of their absurd entailments and their flawed assumptions regarding the subjective
      experiences of people who cannot communicate expressively. Finally, I extend
      arguments found in Alastair MacIntyre's Dependent Rational Animals to argue that 
      child suffering can be understood only as a set of absences-absences of
      conditions such as love, warmth, and freedom from pain. An evaluation of these
      absences reveals the exquisite dependency of children. It also discloses why
      pediatric suffering is necessarily a social and political event. Unlike adults,
      children will never be either the authors or the mitigators of their own
      suffering. Rather, children must rely wholly on others in order to resist
      suffering, grow, and flourish.
FAU - Tate, Tyler
AU  - Tate T
AD  - Oregon Health and Science University, Portland, OR, USA. tatety@ohsu.edu.
LA  - eng
PT  - Journal Article
DEP - 20210105
PL  - Netherlands
TA  - Theor Med Bioeth
JT  - Theoretical medicine and bioethics
JID - 9805378
SB  - IM
MH  - Humans
MH  - Pain/*psychology
MH  - Pediatrics/*ethics/trends
PMC - PMC7784220
OTO - NOTNLM
OT  - *Disability
OT  - *Pediatric ethics
OT  - *Quality of life
OT  - *Suffering
OT  - *Withholding/withdrawing treatment
EDAT- 2021/01/06 06:00
MHDA- 2021/09/09 06:00
CRDT- 2021/01/05 12:16
PHST- 2020/12/05 00:00 [accepted]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2021/01/05 12:16 [entrez]
AID - 10.1007/s11017-020-09535-8 [doi]
AID - 10.1007/s11017-020-09535-8 [pii]
PST - ppublish
SO  - Theor Med Bioeth. 2020 Aug;41(4):143-163. doi: 10.1007/s11017-020-09535-8. Epub
      2021 Jan 5.


PMID- 33399798
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 37
IP  - 5
DP  - 2020 Nov
TI  - [Case fatality rate-related factors in patients with bacteremia hospitalized due 
      medical conditions in an institution of third level in Colombia, 2014-2016].
PG  - 515-522
LID - S0716-10182020000500515 [pii]
LID - 10.4067/S0716-10182020000500515 [doi]
AB  - BACKGROUND: Bloodstream infections are an increasing problem and currently
      represent a threat to public health, overcoming diseases such as HIV. Bacteremia 
      accounts for approximately 15% of all nosocomial infections and affects 1% of all
      hospitalized patients. AIM: To describe the clinical, epidemiological and
      microbiological characteristic of episodes of nosocomial bacteremia occurring in 
      a Colombian hospital. METHODS: Retrospective, observational, cross-sectional
      study including adult patients, hospitalized in the internal medicine unit at the
      University Hospital of Santander, Bucaramanga, Colombia, during years 2014 to
      2016, who met the criteria of the CDC for bloodstream infection. The protocol was
      approved by the Hospital Ethics Committee and by the Research Ethics Committee of
      the Industrial University of Santander. RESULTS: We reviewed 450 clinical records
      with 148 patients and 182 microbiological isolates. 53% were male. The most
      frequent comorbidities were: high blood pressure (46.6%), HIV infection (29.7%). 
      The vascular and urinary systems were the most frequent anatomical sites as the
      source of the infection (respectively 37.3% and 38.3%). Case fatality rate was
      29%. The pathogens most frequently isolated were: Klebsiella pneumoniae,
      Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa (globally:
      49.8%) and Staphylococcus aureus 12.1%. The multivariate analysis showed a
      relationship between anemia and in-hospital mortality (OR = 17.3, 95%CI
      2.95-102.0). CONCLUSIONS: Bacteremia is a frequent infection during hospital care
      that presents high mortality. It is noteworthy the predominance of
      Enterobacteriaceae isolates with broad profiles of resistance. The history of HIV
      infection is one of the most frequent which deserves to be evaluated as a risk
      group.
FAU - Sanchez-Pardo, Santiago
AU  - Sanchez-Pardo S
AD  - Hospital Universitario de Santander, Universidad Industrial de Santander,
      Bucaramanga, Santander, Colombia.
FAU - Ochoa-Diaz, Andres Felipe
AU  - Ochoa-Diaz AF
AD  - Escuela de Medicina, Universidad Industrial de Santander, Bucaramanga, Santander,
      Colombia.
FAU - Rodriguez-Amaya, Reynaldo Mauricio
AU  - Rodriguez-Amaya RM
AD  - Hospital Universitario de Santander, Universidad Industrial de Santander,
      Bucaramanga, Santander, Colombia.
FAU - Rojas-Garrido, Elsa Marina
AU  - Rojas-Garrido EM
AD  - Hospital Universitario de Santander, Universidad Industrial de Santander,
      Bucaramanga, Santander, Colombia.
FAU - Rodriguez-Morales, Alfonso J
AU  - Rodriguez-Morales AJ
AD  - Facultad de Ciencias de la Salud, Universidad Tecnologica de Pereira, Pereira,
      Risaralda, Colombia.
LA  - spa
PT  - Journal Article
PT  - Observational Study
TT  - Factores relacionados con letalidad en pacientes con bacteriemia hospitalizados
      por patologia medica en una institucion de tercer nivel en Colombia, 2014-2016.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de
      Infectologia
JID - 9305754
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Bacteremia/drug therapy/epidemiology
MH  - Colombia/epidemiology
MH  - *Cross Infection/drug therapy/epidemiology
MH  - Female
MH  - HIV Infections/drug therapy
MH  - Humans
MH  - Male
MH  - Retrospective Studies
EDAT- 2021/01/06 06:00
MHDA- 2021/03/05 06:00
CRDT- 2021/01/05 12:13
PHST- 2018/10/07 00:00 [received]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - S0716-10182020000500515 [pii]
AID - 10.4067/S0716-10182020000500515 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2020 Nov;37(5):515-522. doi:
      10.4067/S0716-10182020000500515.


PMID- 33399762
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 5
DP  - 2020 May
TI  - [Moral judgment of physicians is insufficient as a framework for medical ethics].
PG  - 684-688
LID - S0034-98872020000500684 [pii]
LID - 10.4067/S0034-98872020000500684 [doi]
AB  - Physicians values are largely supported by a socio-cultural moral basis, also
      known as "classical utilitarianism". Technological advances and social questions 
      to physicians show their paucity of an ethical conceptualization in medicine. A
      new way of approaching ethical conflicts in medicine should be constructed.
      Training should promote ethical reflection about these conflicts and about the
      actions of physicians. Ontogenetic and phylogenetic research on human nature, and
      the advances in moral psychology, could allow us to understand the construction
      of our judgment of values. An introspective emotional and rational effort to
      understand "how we are" and from there, to "how we act" lacks among physicians.
      This issue is even more complex in a political-social model which does not
      stimulate this type of analysis. The university space is a privileged opportunity
      to educate. The student must be envisioned as a human being whose professional
      acts should consider the needs of our society, aiming at a new ethical
      conceptualization in medicine.
FAU - Navarrete R, Gonzalo
AU  - Navarrete R G
AD  - Departamento de Psiquiatria y Salud Mental, Facultad de Medicina, Universidad de 
      Concepcion, Concepcion, Chile.
LA  - spa
PT  - Journal Article
TT  - inverted question markEs suficiente la base moral de los medicos?
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - *Ethics, Medical/education
MH  - Humans
MH  - *Judgment/ethics
MH  - *Morals
MH  - *Physicians/psychology
EDAT- 2021/01/06 06:00
MHDA- 2021/01/29 06:00
CRDT- 2021/01/05 12:13
PHST- 2019/08/14 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
AID - S0034-98872020000500684 [pii]
AID - 10.4067/S0034-98872020000500684 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 May;148(5):684-688. doi: 10.4067/S0034-98872020000500684.


PMID- 33399760
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 5
DP  - 2020 May
TI  - [Legalization of medically assisted death: its potential impact on the
      development of palliative care].
PG  - 665-673
LID - S0034-98872020000500665 [pii]
LID - 10.4067/S0034-98872020000500665 [doi]
AB  - In Chile, there are four bills to legalize euthanasia, an act which public
      surveys report as supported by most of the population. At the legislative,
      healthcare and social level, there is an active debate about euthanasia, the
      rights of terminally ill patients and the context of Palliative Care (PC) in the 
      country. Chilean literature on euthanasia focuses mainly on the ethical analysis 
      of the act itself but does not address the moral legitimacy of the legalization
      of this practice. This distinction is relevant since the probity of a particular 
      action does not determine the moral legitimacy of its implementation at a public 
      policy level. One aspect of this dimension is the potential negative impact of
      the legalization of physician-assisted death (PAD) on the development of PC
      services. This issue is particularly relevant in Chile, where PC provision is
      currently suboptimal and mostly restricted to cancer patients. This paper
      analyses available evidence on the potential impairment of PC development after
      PAD legalization. Although the analysis of evidence has some limitations, this
      concern is not supported by the available evidence. However, any project about
      PAD legalization must contemplate a factual commitment with the development of
      minimum PC provision, according to international recommendations.
FAU - Dittborn B, Mariana
AU  - Dittborn B M
AD  - Facultad de Medicina, Clinica Alemana, Universidad del Desarrollo, Santiago,
      Chile.
FAU - Micolich V, Constanza
AU  - Micolich V C
AD  - Unidad de Alivio del Dolor y Cuidados Paliativos, Hospital de Angol, Angol,
      Chile.
LA  - spa
PT  - Journal Article
TT  - Legalizacion de muerte medicamente asistida: discusion sobre el potencial impacto
      en el desarrollo de cuidados paliativos.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Chile
MH  - Humans
MH  - *Palliative Care/organization & administration
MH  - *Suicide, Assisted/legislation & jurisprudence
EDAT- 2021/01/06 06:00
MHDA- 2021/01/29 06:00
CRDT- 2021/01/05 12:13
PHST- 2019/05/22 00:00 [received]
PHST- 2020/01/17 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
AID - S0034-98872020000500665 [pii]
AID - 10.4067/S0034-98872020000500665 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 May;148(5):665-673. doi: 10.4067/S0034-98872020000500665.


PMID- 33399734
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 0717-6228 (Electronic)
IS  - 0370-4106 (Linking)
VI  - 91
IP  - 4
DP  - 2020 Aug
TI  - [Importance of early detection of hemoglobinopathies in the pediatric population 
      in developing countries].
PG  - 568-572
LID - S0370-41062020005001105 [pii]
LID - 10.32641/rchped.vi91i4.1438 [doi]
AB  - OBJECTIVE: The objective of this study is to spread awareness among health
      personnel about the importance of early detection of hemoglobinopathies since it 
      is the most frequent monogenic recessive disorder worldwide. PATIENTS AND METHOD:
      Retrospective study of the results of capillary electropho resis (CE) of 152
      patients aged between 0 and 18 years who were evaluated in 2017 due to suspected 
      hemoglobinopathies in a University Hospital in Colombia. The information was
      collected from me dical records and the Hematology and Hemostasis Laboratory,
      ensuring data privacy and approved by the local Ethics Committee. RESULTS: Of 152
      patients, 48.6% were aged between 7 and 18. The frequency of hemoglobinopathies
      was 42.7%. The most frequent hemoglobin variant was the sickle cell trait (Hb S) 
      with 14.5%. The hematologist was the professional who most frequently requested
      CE. DISCUSSION: We found that hemoglobinopathies are usually diagnosed late in
      pediatric patients. This may favor complications and progression of the disease
      and increase healthcare costs. More information and education are required for
      general physicians and pediatricians in order to achieve early diagnosis.
FAU - Aguirre, Marisol
AU  - Aguirre M
AD  - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Cali, Colombia.
FAU - Medina, Diego
AU  - Medina D
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Colombia.
FAU - Araujo, Maria Valeria
AU  - Araujo MV
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Colombia.
FAU - Campo, Maria Alejandra
AU  - Campo MA
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Colombia.
FAU - Castro, Andres
AU  - Castro A
AD  - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Cali, Colombia.
FAU - Fernandez-Trujillo, Liliana
AU  - Fernandez-Trujillo L
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Colombia.
FAU - Alcala, Mercedes
AU  - Alcala M
AD  - Departamento de Patologia y Medicina de Laboratorio, Fundacion Valle del Lili,
      Cali, Colombia.
FAU - Sua, Luz Fernanda
AU  - Sua LF
AD  - Facultad de Ciencias de la Salud, Universidad Icesi, Colombia.
LA  - spa
PT  - Journal Article
TT  - Importancia de la deteccion temprana de hemoglobinopatias en la poblacion
      pediatrica en paises en desarrollo.
DEP - 20200823
PL  - Chile
TA  - Rev Chil Pediatr
JT  - Revista chilena de pediatria
JID - 0404261
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Colombia/epidemiology
MH  - Delayed Diagnosis/*statistics & numerical data
MH  - Developing Countries
MH  - Early Diagnosis
MH  - Electrophoresis, Capillary
MH  - Female
MH  - Hemoglobinopathies/*diagnosis/epidemiology
MH  - Hospitals, University
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Prognosis
MH  - Quality of Life
MH  - Retrospective Studies
EDAT- 2021/01/06 06:00
MHDA- 2021/08/25 06:00
CRDT- 2021/01/05 12:13
PHST- 2019/09/23 00:00 [received]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
AID - S0370-41062020005001105 [pii]
AID - 10.32641/rchped.vi91i4.1438 [doi]
PST - ppublish
SO  - Rev Chil Pediatr. 2020 Aug;91(4):568-572. doi: 10.32641/rchped.vi91i4.1438. Epub 
      2020 Aug 23.


PMID- 33399724
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 0717-6228 (Electronic)
IS  - 0370-4106 (Linking)
VI  - 91
IP  - 4
DP  - 2020 Aug
TI  - [Ethical aspects of the COVID-19 pandemic in pediatrics].
PG  - 495-499
LID - S0370-41062020005001307 [pii]
LID - 10.32641/rchped.vi91i4.2466 [doi]
AB  - The COVID-19 pandemic has highlighted different ethical dilemmas inday-to-day
      patient care. We analyzed the crisis caused by the pandemic and evaluate general 
      aspects of ethical analysis in clinical practice and the context of the health
      crisis. In addition, we review some relevant ethical aspects related to the
      proportionality of the implemented measures, the palliative care management, and 
      the challenges generated due to the lack of resources and professional duties, in
      relation to patients infected with COVID-19 and those chronic patients whose
      outpatient control is delayed.
FAU - Vega Toro, Sebastian
AU  - Vega Toro S
AD  - Hospital Carlos Van Buren, Chile.
FAU - Novoa Sotta, Fernando
AU  - Novoa Sotta F
AD  - Departamento de Pediatria, Universidad de Valparaiso, Chile.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Aspectos eticos de la pandemia por COVID-19 en pediatria.
DEP - 20200912
PL  - Chile
TA  - Rev Chil Pediatr
JT  - Revista chilena de pediatria
JID - 0404261
SB  - IM
MH  - Ambulatory Care/organization & administration
MH  - COVID-19/*epidemiology/therapy
MH  - Child
MH  - *Ethics, Medical
MH  - Humans
MH  - Patient Care/*ethics
MH  - Pediatrics/ethics
EDAT- 2021/01/06 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/05 12:13
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - S0370-41062020005001307 [pii]
AID - 10.32641/rchped.vi91i4.2466 [doi]
PST - ppublish
SO  - Rev Chil Pediatr. 2020 Aug;91(4):495-499. doi: 10.32641/rchped.vi91i4.2466. Epub 
      2020 Sep 12.


PMID- 33399654
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 37
IP  - 4
DP  - 2020 Aug
TI  - [Antibiotic escalation with the inclusion of a checklist in the pediatric
      intensive care unit].
PG  - 349-355
LID - S0716-10182020000400349 [pii]
LID - 10.4067/S0716-10182020000400349 [doi]
AB  - BACKGROUND: Antibiotic surveillance improves the appropriate antibiotic therapy. 
      AIM: To decrease the antibiotic scaling, 48 hours after starting prescription in 
      the pediatric intensive care unit (PICU). METHODS: A ambispective cohort study
      was performed in the PICU including patients admitted in whom antibiotic therapy 
      was started and a checklist was applied prospectively. They were compared with a 
      historical cohort, prior the checklist. The main outcome was the antibiotic
      scaling 48 hours after starting and the secondary endpoints were consultation
      with infectious diseases (ID) specialist and vancomycin prescription. To compare 
      the variables between the two cohorts, the chi2 test, Fischer test and U
      Mann-Whitney test were used. The results of the main variables were expressed in 
      RR and RAR. The study was approved by the institution's Ethics Committee.
      RESULTS: 70 patients were admitted in the checklist cohort and they were compared
      with 124 patients of the historical cohort. The checklist implementation
      decreased the antibiotic scaling at 48 h after starting from 56.4 to 21.4% (p <
      0.0001) ARR = 35% and vancomycin prescription from 64.5 to 40% (p < 0.001) ARR
      =24.5%. The consultation with ID specialist increased from 9.6 to 32.8% (p <
      0.0001). There were no differences in mortality and duration of antibiotic
      therapy at 10 days of hospitalization. CONCLUSION: The checklist implementation
      decreased the antibiotic scaling,48 hs after starting and the vancomycin
      prescription while the ID specialist consultation increased.
FAU - Mesquita, Mirta N
AU  - Mesquita MN
AD  - Hospital General Pediatrico Ninos de Acosta Nu, San Lorenzo, Paraguay.
FAU - Godoy, Laura E
AU  - Godoy LE
AD  - Hospital General Pediatrico Ninos de Acosta Nu, San Lorenzo, Paraguay.
FAU - Kabboutt, Hayat A
AU  - Kabboutt HA
AD  - Hospital General Pediatrico Ninos de Acosta Nu, San Lorenzo, Paraguay.
FAU - Servin, Maria L
AU  - Servin ML
AD  - Hospital General Pediatrico Ninos de Acosta Nu, San Lorenzo, Paraguay.
LA  - spa
PT  - Journal Article
TT  - Escalamiento de antimicrobianos con la inclusion de una lista de verificacion en 
      la unidad de cuidados intensivos pediatricos.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de
      Infectologia
JID - 9305754
RN  - 0 (Anti-Bacterial Agents)
RN  - 6Q205EH1VU (Vancomycin)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Checklist
MH  - Child
MH  - Cohort Studies
MH  - Humans
MH  - Intensive Care Units, Pediatric
MH  - Retrospective Studies
MH  - Vancomycin
EDAT- 2021/01/06 06:00
MHDA- 2021/03/09 06:00
CRDT- 2021/01/05 12:13
PHST- 2019/10/10 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - S0716-10182020000400349 [pii]
AID - 10.4067/S0716-10182020000400349 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2020 Aug;37(4):349-355. doi:
      10.4067/S0716-10182020000400349.


PMID- 33399646
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 0717-6228 (Electronic)
IS  - 0370-4106 (Linking)
VI  - 91
IP  - 5
DP  - 2020 Oct
TI  - [The responsible use and dissemination of information in a pandemic: an ethical
      imperative].
PG  - 794-799
LID - S0370-41062020005001406 [pii]
LID - 10.32641/rchped.vi91i5.2420 [doi]
AB  - The current COVID-19 pandemic is producing an unprecedented impact in the
      different spheres of life, at the same time that it has highlighted the
      importance that the Bioethics discipline has in analyzing and deliberating of
      emerging ethical challenges, before making reasonable and prudent decisions. The 
      management and communication of information on this crisis has not been properly 
      addressed, where it is considered that its negative effects may lead not only to 
      interfere with the communication channels with citizens but also affect the
      expected adherence of the population to the indications that they need to follow.
      This issue is especially complex when experiencing a period of information
      explosion, a phenomenon called 'infodemic' by the World Health Organization. This
      article, claiming the ethical and legal imperative to act responsibly in
      collecting, using, and disse minating the information that helps any authority
      that plays a social function, proposes a series of recommendations to achieve its
      effectiveness in practice.
FAU - Borquez P, Blanca
AU  - Borquez P B
AD  - Departamento Bioetica y Humanidades Medicas, Facultad de Medicina, Universidad de
      Chile, Santiago, Chile.
FAU - Luengo-Charath, M Ximena
AU  - Luengo-Charath MX
AD  - Universidad Autonoma de Chile, Santiago, Chile.
FAU - Anguita M, Veronica
AU  - Anguita M V
AD  - Universidad Alberto Hurtado, Santiago, Chile.
FAU - Bascunan R, M Luz
AU  - Bascunan R ML
AD  - Departamento de Bioetica y Humanidades Medicas, Facultad de Medicina, Universidad
      de Chile, Santiago, Chile.
FAU - Pacheco M, Isabel M
AU  - Pacheco M IM
AD  - aff7, Chile.
FAU - Michaud Ch, Patricio
AU  - Michaud Ch P
AD  - Ministerio de Salud, Santiago, Chile.
FAU - Vacarezza Y, Ricardo
AU  - Vacarezza Y R
AD  - Ministerio de Salud, Santiago, Chile.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Uso y difusion responsable de la informacion en pandemia: un imperativo etico.
PL  - Chile
TA  - Rev Chil Pediatr
JT  - Revista chilena de pediatria
JID - 0404261
SB  - IM
MH  - *Bioethical Issues
MH  - Bioethics
MH  - *COVID-19
MH  - Communication
MH  - Decision Making
MH  - Humans
MH  - Information Dissemination/*ethics/legislation & jurisprudence
EDAT- 2021/01/06 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/05 12:13
PHST- 2020/05/05 00:00 [received]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2021/01/05 12:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - S0370-41062020005001406 [pii]
AID - 10.32641/rchped.vi91i5.2420 [doi]
PST - ppublish
SO  - Rev Chil Pediatr. 2020 Oct;91(5):794-799. doi: 10.32641/rchped.vi91i5.2420.


PMID- 33396951
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Dec 30
TI  - The Chick Chorioallantoic Membrane Model: A New In Vivo Tool to Evaluate Breast
      Cancer Stem Cell Activity.
LID - E334 [pii]
LID - 10.3390/ijms22010334 [doi]
AB  - The high plasticity of cancer stem-like cells (CSCs) allows them to differentiate
      and proliferate, specifically when xenotransplanted subcutaneously into
      immunocompromised mice. CSCs are highly tumorigenic, even when inoculated in
      small numbers. Thus, in vivo limiting dilution assays (LDA) in mice are the
      current gold standard method to evaluate CSC enrichment and activity. The chick
      embryo chorioallantoic membrane (CAM) is a low cost, naturally immune-incompetent
      and reproducible model widely used to evaluate the spontaneous growth of human
      tumor cells. Here, we established a CAM-LDA assay able to rapidly reproduce tumor
      specificities-in particular, the ability of the small population of CSCs to form 
      tumors. We used a panel of organotropic metastatic breast cancer cells, which
      show an enrichment in a stem cell gene signature, enhanced CD44(+)/CD24(-/low)
      cell surface expression and increased mammosphere-forming efficiency (MFE). The
      size of CAM-xenografted tumors correlate with the number of inoculated cancer
      cells, following mice xenograft growth pattern. CAM and mice tumors are
      histologically comparable, displaying both breast CSC markers CD44 and CD49f.
      Therefore, we propose a new tool for studying CSC prevalence and function-the
      chick CAM-LDA-a model with easy handling, accessibility, rapid growth and the
      absence of ethical and regulatory constraints.
FAU - Pinto, Marta Teixeira
AU  - Pinto MT
AUID- ORCID: 0000-0002-8521-2904
AD  - i3S-Institute of Investigation and Innovation in Health, 4200-135 Porto,
      Portugal.
AD  - Ipatimup, Institute of Molecular Pathology and Immunology, University of Porto,
      4200-135 Porto, Portugal.
FAU - Ribeiro, Ana Sofia
AU  - Ribeiro AS
AUID- ORCID: 0000-0002-9698-9233
AD  - i3S-Institute of Investigation and Innovation in Health, 4200-135 Porto,
      Portugal.
AD  - Ipatimup, Institute of Molecular Pathology and Immunology, University of Porto,
      4200-135 Porto, Portugal.
FAU - Conde, Ines
AU  - Conde I
AD  - i3S-Institute of Investigation and Innovation in Health, 4200-135 Porto,
      Portugal.
AD  - Ipatimup, Institute of Molecular Pathology and Immunology, University of Porto,
      4200-135 Porto, Portugal.
FAU - Carvalho, Rita
AU  - Carvalho R
AD  - i3S-Institute of Investigation and Innovation in Health, 4200-135 Porto,
      Portugal.
AD  - Ipatimup, Institute of Molecular Pathology and Immunology, University of Porto,
      4200-135 Porto, Portugal.
FAU - Paredes, Joana
AU  - Paredes J
AD  - i3S-Institute of Investigation and Innovation in Health, 4200-135 Porto,
      Portugal.
AD  - Ipatimup, Institute of Molecular Pathology and Immunology, University of Porto,
      4200-135 Porto, Portugal.
AD  - Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
LA  - eng
GR  - Pest-C/SAU/LA0003/2013/Fundacao para a Ciencia e a Tecnologia
GR  - NORTE-01-0145-FEDER-000029/Fundacao para a Ciencia e a Tecnologia
GR  - SAICTPAC/0022/2015/Fundacao para a Ciencia e a Tecnologia
GR  - FCT/02/SAICT/2017/030625/Fundacao para a Ciencia e a Tecnologia
GR  - SFRH/BD/135831/2018/Fundacao para a Ciencia e a Tecnologia
PT  - Evaluation Study
PT  - Journal Article
DEP - 20201230
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Breast Neoplasms/metabolism/*pathology
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Chick Embryo
MH  - *Chorioallantoic Membrane
MH  - Female
MH  - Humans
MH  - Hyaluronan Receptors/metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Neoplastic Stem Cells/metabolism/*pathology
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC7795925
OTO - NOTNLM
OT  - cancer stem cells
OT  - chicken chorioallantoic membrane
OT  - in vivo model
OT  - limiting dilution assay
EDAT- 2021/01/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2021/01/05 01:19
PHST- 2020/11/23 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2020/12/25 00:00 [accepted]
PHST- 2021/01/05 01:19 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - ijms22010334 [pii]
AID - 10.3390/ijms22010334 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Dec 30;22(1). pii: ijms22010334. doi: 10.3390/ijms22010334.


PMID- 33396444
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210124
IS  - 2304-8158 (Print)
IS  - 2304-8158 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Dec 31
TI  - Discrete Choice Analysis of Consumer Preferences for Meathybrids-Findings from
      Germany and Belgium.
LID - E71 [pii]
LID - 10.3390/foods10010071 [doi]
AB  - High levels of meat consumption are increasingly being criticised for ethical,
      environmental and social reasons. Plant-based meat substitutes have been
      identified as healthy sources of protein that, in comparison to meat, offer a
      number of social, environmental and health benefits and may play a role in
      reducing meat consumption. However, there has been a lack of research on the role
      they can play in the policy agenda and how specific meat substitute attributes
      can influence consumers to partially replace meat in their diets. This paper is
      focused on consumers' preferences for so-called meathybrid or plant-meathybrid
      products. In meathybrids, only a fraction of the meat product (e.g., 20% to 50%) 
      is replaced with plant-based proteins. Research demonstrates that in many
      countries, consumers are highly attached to meat and consider it as an essential 
      and integral element of their daily diet. For these consumers that are not
      interested in vegan or vegetarian alternatives as meat substitutes, meathybrids
      could be a low-threshold option for a more sustainable food consumption
      behaviour. In this paper, the results of an online survey with 500 German and 501
      Belgian consumers are presented. The results show that more than fifty percent of
      consumers substitute meat at least occasionally. Thus, about half of the
      respondents reveal an eligible consumption behaviour with respect to
      sustainability and healthiness, at least sometimes. The applied discrete choice
      experiment demonstrated that the analysed meat products are the most preferred by
      consumers. Nonetheless, the tested meathybrid variants with different shares of
      plant-based proteins took the second position followed by the vegetarian-based
      alternatives. Therefore, meathybrids could facilitate the diet transition of
      meat-eaters in the direction toward a more healthy and sustainable consumption.
      The analysed consumer segment is more open-minded to the meathybrid concept in
      comparison to the vegetarian substitutes.
FAU - Profeta, Adriano
AU  - Profeta A
AUID- ORCID: 0000-0002-9207-8029
AD  - DIL e.V.-German Institute of Food Technology, Prof.-von-Klitzing-Strasse 7, 49610
      D-Quakenbruck, Germany.
FAU - Baune, Marie-Christin
AU  - Baune MC
AUID- ORCID: 0000-0003-0869-1320
AD  - DIL e.V.-German Institute of Food Technology, Prof.-von-Klitzing-Strasse 7, 49610
      D-Quakenbruck, Germany.
FAU - Smetana, Sergiy
AU  - Smetana S
AUID- ORCID: 0000-0002-5471-0521
AD  - DIL e.V.-German Institute of Food Technology, Prof.-von-Klitzing-Strasse 7, 49610
      D-Quakenbruck, Germany.
FAU - Broucke, Keshia
AU  - Broucke K
AD  - Institute for Agricultural and Fisheries Research (ILVO), Brusselsesteenweg, 370,
      9090 Melle, Belgium.
FAU - Royen, Geert Van
AU  - Royen GV
AUID- ORCID: 0000-0001-6818-8896
AD  - Institute for Agricultural and Fisheries Research (ILVO), Brusselsesteenweg, 370,
      9090 Melle, Belgium.
FAU - Weiss, Jochen
AU  - Weiss J
AUID- ORCID: 0000-0003-1669-1507
AD  - Institute of Food Science and Biotechnology, Department of Food Structure and
      Functionality, University of Hohenheim, Garbenstrasse 21/25, 70599 Stuttgart,
      Germany.
FAU - Heinz, Volker
AU  - Heinz V
AD  - DIL e.V.-German Institute of Food Technology, Prof.-von-Klitzing-Strasse 7, 49610
      D-Quakenbruck, Germany.
FAU - Terjung, Nino
AU  - Terjung N
AD  - DIL e.V.-German Institute of Food Technology, Prof.-von-Klitzing-Strasse 7, 49610
      D-Quakenbruck, Germany.
LA  - eng
GR  - AiF 196 EN/Forschungskreis der Ernahrungsindustrie
PT  - Journal Article
DEP - 20201231
PL  - Switzerland
TA  - Foods
JT  - Foods (Basel, Switzerland)
JID - 101670569
PMC - PMC7823736
OTO - NOTNLM
OT  - consumer preference
OT  - meat substitute
OT  - meathybrid
OT  - plant-based proteins
EDAT- 2021/01/06 06:00
MHDA- 2021/01/06 06:01
CRDT- 2021/01/05 01:13
PHST- 2020/12/09 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2020/12/25 00:00 [accepted]
PHST- 2021/01/05 01:13 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/01/06 06:01 [medline]
AID - foods10010071 [pii]
AID - 10.3390/foods10010071 [doi]
PST - epublish
SO  - Foods. 2020 Dec 31;10(1). pii: foods10010071. doi: 10.3390/foods10010071.


PMID- 33396356
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1424-8220 (Electronic)
IS  - 1424-8220 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Dec 31
TI  - Human-Robot Interaction and Sexbots: A Systematic Literature Review.
LID - E216 [pii]
LID - 10.3390/s21010216 [doi]
AB  - At present, sexual robots have become a new paradigm of social robots. In this
      paper, we developed a systematic literature review about sexual robots (sexbots).
      To do this, we used the Scopus and WoS databases to answer different research
      questions regarding the design, interaction, and gender and ethical approaches
      from 1980 until 2020. In our review, we found a male bias in this discipline, and
      in recent years, articles have shown that user opinion has become more relevant. 
      Some insights and recommendations on gender and ethics in designing sexual robots
      were also made.
FAU - Gonzalez-Gonzalez, Carina Soledad
AU  - Gonzalez-Gonzalez CS
AUID- ORCID: 0000-0001-5939-9544
AD  - Departamento de Ingenieria Informatica y de Sistemas, Escuela de Ingenieria y
      Tecnologia, Universidad de La Laguna, 38204 La Laguna, Spain.
FAU - Gil-Iranzo, Rosa Maria
AU  - Gil-Iranzo RM
AUID- ORCID: 0000-0001-6304-9635
AD  - Departamento de Informatica e Ingenieria Industrial, Escuela Politecnica
      Superior, Universitat de Lleida, 25001 LLeida, Spain.
FAU - Paderewski-Rodriguez, Patricia
AU  - Paderewski-Rodriguez P
AUID- ORCID: 0000-0001-6626-9633
AD  - Departmento de Lenguajes y Sistemas Informaticos, Escuela Tecnica Superior de
      Ingenierias Informatica y de Telecomunicacion, Universidad de Granada, 18071
      Granada, Spain.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201231
PL  - Switzerland
TA  - Sensors (Basel)
JT  - Sensors (Basel, Switzerland)
JID - 101204366
SB  - IM
MH  - Attitude
MH  - Humans
MH  - *Robotics
MH  - *Sexual Behavior
PMC - PMC7795467
OTO - NOTNLM
OT  - ethics
OT  - gender
OT  - human-robot interaction
OT  - sexbots
OT  - sexual robots
OT  - social robots
EDAT- 2021/01/06 06:00
MHDA- 2021/04/10 06:00
CRDT- 2021/01/05 01:12
PHST- 2020/10/21 00:00 [received]
PHST- 2020/12/13 00:00 [revised]
PHST- 2020/12/26 00:00 [accepted]
PHST- 2021/01/05 01:12 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - s21010216 [pii]
AID - 10.3390/s21010216 [doi]
PST - epublish
SO  - Sensors (Basel). 2020 Dec 31;21(1). pii: s21010216. doi: 10.3390/s21010216.


PMID- 33396206
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Dec 31
TI  - Effect of Ethics Seminar on Moral Sensitivity and Ethical Behavior of Clinical
      Nurses.
LID - E241 [pii]
LID - 10.3390/ijerph18010241 [doi]
AB  - While nursing is an ethical profession, unethical behavior among nurses is
      increasing worldwide. This study examined the effects of an ethics seminar on
      nurses' moral sensitivity and ethical behavior. A total of 35 nurses (17
      experimental, 18 control) were recruited. The ethics seminar was held over a
      six-month period from May to October 2018 and comprised six sessions held once a 
      month for two hours. Moral sensitivity and unethical behavior were measured at
      the start and end of the seminar. Moral sensitivity and unethical behavior showed
      a negative correlation (r = -0.400, p < 0.05). After the ethics seminar, the
      experimental group's moral sensitivity was not significantly increased (t =
      -1.039, p = 0.314). The experimental group's mean scores of unethical behavior at
      pre- and posttest were 12.59 and 9.47, respectively, indicating a statistically
      significant difference (t = 3.363, p = 0.004). There was no statistically
      significant difference in the mean score in both moral sensitivity and unethical 
      behavior at pre- and posttest in the control group. Thus, ethics seminars can
      reduce the risk of unethical behavior among nurses. Regular ethics seminars and
      training must be provided to nurses as part of their curriculum/practice.
FAU - Lee, Chunbok
AU  - Lee C
AD  - Institute for Historical Studies, Chung-Ang University, 84 Heukseok-ro,
      Dongjak-gu, Seoul 06974, Korea.
FAU - Kim, Sunman
AU  - Kim S
AD  - Chung-Ang University Hospital, 102 Heukseok-ro Dongjak-gu, Seoul 06973, Korea.
FAU - Choe, Kwisoon
AU  - Choe K
AUID- ORCID: 0000-0001-7889-8760
AD  - Department of Nursing, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul
      06974, Korea.
FAU - Kim, Sunghee
AU  - Kim S
AUID- ORCID: 0000-0001-6964-6158
AD  - Department of Nursing, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul
      06974, Korea.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Curriculum
MH  - *Education, Nursing
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Morals
MH  - *Nurses
MH  - Surveys and Questionnaires
PMC - PMC7795744
OTO - NOTNLM
OT  - *ethics seminar
OT  - *moral sensitivity
OT  - *nurse
OT  - *unethical behavior
EDAT- 2021/01/06 06:00
MHDA- 2021/02/23 06:00
CRDT- 2021/01/05 01:10
PHST- 2020/12/01 00:00 [received]
PHST- 2020/12/18 00:00 [revised]
PHST- 2020/12/28 00:00 [accepted]
PHST- 2021/01/05 01:10 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - ijerph18010241 [pii]
AID - 10.3390/ijerph18010241 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 31;18(1). pii: ijerph18010241. doi:
      10.3390/ijerph18010241.


PMID- 33392440
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - COVID-19 IDD: A global survey exploring family members' and paid staff's
      perceptions of the impact of COVID-19 on individuals with intellectual and
      developmental disabilities and their caregivers.
PG  - 39
LID - 10.12688/hrbopenres.13077.2 [doi]
AB  - Background: This protocol outlines research to explore family members' and paid
      staff's perceptions of the impact of COVID-19 on individuals with intellectual
      and developmental disabilities and their caregivers. Evidence suggests that
      people with intellectual and developmental disabilities experience disparities in
      healthcare access and utilisation. This disparity was evident early in the
      pandemic when discussions arose regarding the potential exclusion of this
      population to critical care. Methods: An anonymous online survey will be
      conducted with caregivers, both family members and paid staff, to explore their
      perceptions of the impact of COVID-19 in terms of demographics, living
      arrangements, access to services, social distancing, and carer wellbeing. The
      survey will be developed by the research team, many of whom are experts in
      intellectual disability within their own jurisdictions. Using back-translation
      our team will translate the survey for distribution in 18 countries worldwide for
      international comparison. The survey team have extensive personal and
      professional networks and will promote the survey widely on social media with the
      support of local disability and advocacy agencies. Statistical descriptive and
      comparative analyses will be conducted. Ethical approval has been obtained for
      this study from University College Dublin's Human Research Ethics Committee
      (HS-20-28-Linehan). Dissemination: Study findings will be prepared in a number of
      formats in order to meet the needs of different audiences. Outputs will include
      academic papers, lessons learned paper, practice guidelines, reports,
      infographics and video content. These outputs will be directed to families,
      frontline and management delivering disability services, national-level policy
      makers, healthcare quality and delivery authorities, national pandemic
      organisations and international bodies.
CI  - Copyright: (c) 2020 Linehan C et al.
FAU - Linehan, Christine
AU  - Linehan C
AUID- ORCID: https://orcid.org/0000-0002-9083-3457
AD  - UCD Centre for Disability Studies, University College Dublin, Belfield, Dublin,
      Dublin 4, Ireland.
FAU - Araten-Bergam, Tal
AU  - Araten-Bergam T
AUID- ORCID: https://orcid.org/0000-0003-4915-2729
AD  - Living with Disability Research Centre, School of Allied Health, Human Services &
      Sport, La Trobe University, Bundoora, Victoria, 3086, Australia.
FAU - Baumbusch, Jennifer
AU  - Baumbusch J
AD  - Canadian Institute for Inclusion and Citizenship, University of British Columbia,
      2080 West Mall, Vancouver, BC Canada, V6T 1Z2, Canada.
FAU - Beadle-Brown, Julie
AU  - Beadle-Brown J
AD  - Tizard Centre, University of Kent, Canterbury, Kent, CT2 7NZ, UK.
FAU - Bigby, Christine
AU  - Bigby C
AUID- ORCID: https://orcid.org/0000-0001-7001-8976
AD  - Living with Disability Research Centre, School of Allied Health, Human Services &
      Sport, La Trobe University, Bundoora, Victoria, 3086, Australia.
FAU - Birkbeck, Gail
AU  - Birkbeck G
AD  - Business Information Systems, University College Cork, O'Rahilly Building, Cork, 
      Ireland.
FAU - Bradley, Valerie
AU  - Bradley V
AD  - Human Services Research Institute, 2336 Massachusetts Ave, Cambridge, MA 02140,
      USA.
FAU - Brown, Michael
AU  - Brown M
AUID- ORCID: https://orcid.org/0000-0003-3230-401X
AD  - School of Nursing and Midwifery, Queen's University, 97 Lisburn Road, Medical
      Biology Centre, Belfast, BT9 7BL, UK.
FAU - Bredewold, Femmianne
AU  - Bredewold F
AUID- ORCID: https://orcid.org/0000-0002-6231-8263
AD  - University of Humanistic Studies, Kromme Nieuwegracht 29, Utrecht, 3512 HD, The
      Netherlands.
FAU - Chirwa, Masauso
AU  - Chirwa M
AUID- ORCID: https://orcid.org/0000-0002-6293-5034
AD  - School of Humanities and Social Sciences, Department of Social Work and
      Sociology, University of Zambia, Great East Road Campus P.O Box 32379, Lusaka,
      10101, Zambia.
FAU - Cui, Jialiang
AU  - Cui J
AUID- ORCID: https://orcid.org/0000-0001-8708-1947
AD  - Department of Social Work, The Chinese University of Hong Kong, Shatin, New
      Territories, Hong Kong, China.
FAU - Godoy Gimenez, Marta
AU  - Godoy Gimenez M
AD  - Department of Psychology, University of Almeria, La Canada de San Urbano, 04120, 
      Almeria, Spain.
FAU - Gomiero, Tiziano
AU  - Gomiero T
AUID- ORCID: https://orcid.org/0000-0002-2931-9571
AD  - ANFFAS Trentino Onlus DAD(c) Project Group, via Giambattista Unterveger, 38121
      Trento Trentino,, Italy.
FAU - Kanova, Sarka
AU  - Kanova S
AD  - Department of Education, University of West Bohemia, Univerzitni 2732/8, Plzen 3,
      301 00, Czech Republic.
FAU - Kroll, Thilo
AU  - Kroll T
AUID- ORCID: https://orcid.org/0000-0003-2082-5117
AD  - School of Nursing, Midwifery and Health Systems, University College Dublin,
      Belfield, Dublin, 4, Ireland.
FAU - MacLachlan, Mac
AU  - MacLachlan M
AD  - School of Psychology, Maynooth University, Maynooth, Ireland.
FAU - Mirfin-Veitch, Brigit
AU  - Mirfin-Veitch B
AD  - Donald Beasley Institute, 248 Cumberland Street, Dunedin Central, Dunedin 9016,
      New Zealand.
FAU - Narayan, Jayanthi
AU  - Narayan J
AUID- ORCID: https://orcid.org/0000-0001-5125-0227
AD  - Inclusive Education at Faculty of Health, Education and Society, University of
      Northampton, Northampton, UK.
FAU - Nearchou, Finiki
AU  - Nearchou F
AUID- ORCID: https://orcid.org/0000-0002-2018-9096
AD  - UCD School of Psychology, University College Dublin, Belfield, Dublin, 4,
      Ireland.
FAU - Nolan, Adam
AU  - Nolan A
AD  - UCD Centre for Disability Studies, University College Dublin, Belfield, Dublin,
      Dublin 4, Ireland.
FAU - O'Donovan, Mary-Ann
AU  - O'Donovan MA
AD  - Centre for Disability Studies, Sydney Medical School, Faculty of Medicine and
      Health, University of Sydney, 92-94 Parramatta Rd, Camperdown, Sydney, NSW 2050, 
      Australia.
FAU - Santos, Flavia H
AU  - Santos FH
AUID- ORCID: https://orcid.org/0000-0003-2592-9038
AD  - UCD School of Psychology, University College Dublin, Belfield, Dublin, 4,
      Ireland.
FAU - Siska, Jan
AU  - Siska J
AUID- ORCID: https://orcid.org/0000-0003-2379-2285
AD  - Department of Special Education, Charles University, Magdaleny Rettigove 4, Praha
      1, 116 39, Czech Republic.
FAU - Stainton, Tim
AU  - Stainton T
AUID- ORCID: https://orcid.org/0000-0002-5146-2497
AD  - Canadian Institute for Inclusion and Citizenship, University of British Columbia,
      2080 West Mall, Vancouver, BC Canada, V6T 1Z2, Canada.
FAU - Tideman, Magnus
AU  - Tideman M
AUID- ORCID: https://orcid.org/0000-0002-7519-6488
AD  - Department of Social Sciences, Ersta Skondal Bracke University, Box 441, Skondal,
      SE-128 06, Sweden.
AD  - School of Health and Welfare, Halmstad University, Box 823, Halmstad, SE 301 18, 
      Sweden.
FAU - Tossebro, Jan
AU  - Tossebro J
AD  - Department of Social Work, Norwegian University of Science and Technology,
      Trondheim, NO-7491, Norway.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7745183
OTO - NOTNLM
OT  - COVID-19
OT  - Caregivers Carers
OT  - Coronavirus
OT  - Health Disparity
OT  - Intellectual Disability
OT  - Intellectual and Developmental Disability
OT  - Pandemic
COIS- No competing interests were disclosed.
EDAT- 2021/01/06 06:00
MHDA- 2021/01/06 06:01
CRDT- 2021/01/05 06:26
PHST- 2020/10/06 00:00 [accepted]
PHST- 2021/01/05 06:26 [entrez]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/01/06 06:01 [medline]
AID - 10.12688/hrbopenres.13077.2 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Dec 3;3:39. doi: 10.12688/hrbopenres.13077.2. eCollection
      2020.


PMID- 33395664
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 308
DP  - 2020 Nov
TI  - [SEPARATE LEGAL AND MEDICAL AND SOCIAL ASPECTS OF POSTTHEAL TRANSPLANTATION IN
      UKRAINE].
PG  - 180-185
AB  - Organ donation is one of the topical issues in the field of medicine around the
      world. Although the practice of transplantation exists in most countries of the
      world, there are still many unresolved issues. One of them is the issues related 
      to postmortem organ transplantation in Ukraine. Despite the significant increase 
      in the scale of transplantation of human organs, tissues and cells, today there
      is a need to improve the mechanism of organ transplantation from deceased
      persons, both at the legal level and in the provision of medical services. The
      purpose of the study is to consider problematic issues related to posthumous
      transplantation, in particular its legal support, ethical aspects, medical
      opportunities for improving the procedure for providing organs to the recipient, 
      as well as looking for prospects for their resolution. To achieve this goal, an
      analysis of the existing regulatory framework in the field of transplantation was
      carried out, the experience of Ukraine and foreign countries on the issue under
      study was analyzed, the following methods were used: comparative legal,
      statistical, induction, analysis, synthesis. Based on the study, the authors
      conclude that the regulation of transplantation in Ukraine should be not only at 
      a high legal level, but also implemented in practice into the Unified State
      Information System for Organ and Tissue Transplantation, which will allow timely 
      and efficient provision of organs to the recipient.
FAU - Baluk, B
AU  - Baluk B
AD  - 1Yaroslav Mudryi National Law University, Kharkov, Ukraine.
FAU - Grynko, L
AU  - Grynko L
AD  - 2Poltava Law Institute Yaroslav Mudryi National Law University, Ukraine.
FAU - Domashenko, A
AU  - Domashenko A
AD  - 1Yaroslav Mudryi National Law University, Kharkov, Ukraine.
FAU - Ostapenko, I
AU  - Ostapenko I
AD  - 1Yaroslav Mudryi National Law University, Kharkov, Ukraine.
FAU - Zadykhaylo, D
AU  - Zadykhaylo D
AD  - 1Yaroslav Mudryi National Law University, Kharkov, Ukraine.
LA  - rus
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
SB  - IM
MH  - Humans
MH  - Internationality
MH  - Motivation
MH  - *Organ Transplantation
MH  - *Tissue and Organ Procurement
MH  - Ukraine
EDAT- 2021/01/05 06:00
MHDA- 2021/01/07 06:00
CRDT- 2021/01/04 20:06
PHST- 2021/01/04 20:06 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2020 Nov;(308):180-185.


PMID- 33395662
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 308
DP  - 2020 Nov
TI  - TOPICAL ISSUES OF COPD MANAGEMENT IN GEORGIA.
PG  - 171-175
AB  - Chronic obstructive pulmonary disease (COPD) is the major cause of chronic
      morbidity and mortality throughout the world. USAID Health Care Improvement
      Project (HCI) had collaborated with the Ministry of Labor, Healthcare and Social 
      Affairs of Georgia in 2012-2014 to improve quality of care for high-burden and
      under-diagnosed diseases, including asthma and COPD. The Aim of the study was to 
      evaluate the effectiveness (quality, consistency and continuity) of medical care 
      in COPD patients in one of the regions of Georgia after 5 years from the ending
      of the project. The received results of our research were compared to the data
      from USAID HCI Project. In order to evaluate the effectiveness of medical care, 7
      rural primary care units and 1 hospital have been selected. Information was
      gathered with standardized questionnaires: from providers, patients and medical
      records: 42 physicians and 83 patients were interviewed, 152 medical records were
      reviewed. Research period was defined from March 2017 till March 2019. Research
      protocol is approved by an Ethical Committee Review Board at ATSU. All indicators
      showing the quality and effectiveness of COPD management (prescription of COPD
      controller medications, bronchodilators, documented procedures, etc) are
      improved. Improvement tendency is obvious in all aspects of treatment/management,
      except spirometry results recorded, which is 4% less compared to the project
      results. Documentation from the primary care units showed decreased indicator of 
      counseling provided for smoking cessation by 9%. Based on our data the
      sustainability in the treatment and management of COPD is still in progress. Two 
      main areas need to be paid special attention to: patient consultation/education
      and timely diagnosis of the disease.
FAU - Pkhakadze, I
AU  - Pkhakadze I
AD  - 1Akaki Tsereteli State University, Georgia.
FAU - Ekaladze, E
AU  - Ekaladze E
AD  - 2Tbilisi State Medical University; Georgia.
FAU - Jugheli, K
AU  - Jugheli K
AD  - 3Kutaisi D. Nazarishvili Family Medicine Regional Training Center, Georgia.
FAU - Abashishvili, L
AU  - Abashishvili L
AD  - 2Tbilisi State Medical University; Georgia.
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
SB  - IM
MH  - *Asthma
MH  - Georgia (Republic)
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive/drug therapy
MH  - *Smoking Cessation
MH  - Spirometry
EDAT- 2021/01/05 06:00
MHDA- 2021/01/07 06:00
CRDT- 2021/01/04 20:06
PHST- 2021/01/04 20:06 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2020 Nov;(308):171-175.


PMID- 33392510
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211211
IS  - 2637-3726 (Electronic)
IS  - 2637-3726 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Jul-Dec
TI  - Patients as partners in readiness for COVID-19: using 'live simulation' to
      implement infection prevention and control procedures in the maternity operating 
      theatre.
PG  - 191-195
LID - 10.1002/anr3.12086 [doi]
AB  - Insitu simulation can be used to improve care within a particular setting and has
      specific value in developing and testing guidelines and procedures. However, it
      can be challenging to undertake simulation when clinical work is ongoing.
      Responding to the need to develop infection prevention and control procedures for
      coronavirus disease 2019 in the obstetric operating theatre, we asked three
      patients who required operative intervention to consent to be managed according
      to preliminary standard operating procedures as if they were severe acute
      respiratory syndrome-coronavirus-2 positive. With this method, we were able to
      run scenarios in real-time without interrupting clinical work. As well as
      allowing us to develop and refine procedures, these 'live simulations' provided
      staff training and highlighted system problems that needed to be addressed as the
      first wave of the pandemic approached. In this case series, we describe our
      procedure for live simulation, report the learning points that this approach
      yielded, present the feedback from patient participants and reflect on the
      ethical implications of this technique.
CI  - (c) 2020 Association of Anaesthetists.
FAU - Cegielski, D
AU  - Cegielski D
AUID- ORCID: https://orcid.org/0000-0003-0698-0372
AD  - Wythenshawe Hospital Manchester University NHS Foundation Trust Southmoor Rd
      Manchester UK.
FAU - Darling, C
AU  - Darling C
AD  - Wythenshawe Hospital Manchester University NHS Foundation Trust Southmoor Rd
      Manchester UK.
AD  - University of Salford The Crescent Salford UK.
FAU - Noor, C
AU  - Noor C
AD  - Wythenshawe Hospital Manchester University NHS Foundation Trust Southmoor Rd
      Manchester UK.
FAU - Shelton, C L
AU  - Shelton CL
AD  - Wythenshawe Hospital Manchester University NHS Foundation Trust Southmoor Rd
      Manchester UK.
AD  - Lancaster Medical School Faculty of Health and Medicine Lancaster University
      Lancaster UK.
FAU - Parry, Z
AU  - Parry Z
AD  - Wythenshawe Hospital Manchester University NHS Foundation Trust Southmoor Rd
      Manchester UK.
LA  - eng
PT  - Case Reports
DEP - 20201208
PL  - England
TA  - Anaesth Rep
JT  - Anaesthesia reports
JID - 101759073
PMC - PMC7772639
OTO - NOTNLM
OT  - anesthesia
OT  - education
OT  - obstetrics
OT  - pandemics
OT  - safety
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:32
PHST- 2020/11/06 00:00 [accepted]
PHST- 2021/01/04 05:32 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.1002/anr3.12086 [doi]
AID - ANR312086 [pii]
PST - epublish
SO  - Anaesth Rep. 2020 Dec 8;8(2):191-195. doi: 10.1002/anr3.12086. eCollection 2020
      Jul-Dec.


PMID- 33392425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 2475-0360 (Electronic)
IS  - 2475-0360 (Linking)
VI  - 3
IP  - 4
DP  - 2020 Dec
TI  - Ethical guidance for geriatric clinical research in China.
PG  - 218-223
LID - 10.1002/agm2.12138 [doi]
AB  - In China, the population is aging rapidly, and the elderly have enormous medical 
      needs. However, the elderly are underrepresented in clinical research,
      potentially forcing them to use medical devices and treatments that may be not
      suitable for them. Elderly patients are characterized by multiple comorbidities, 
      concomitant treatments, and high incidence of cognitive impairment, and
      consequently are at increased risk of participating in clinical research. To
      reduce the risks involved with the elderly participating in clinical research,
      guidance on the ethical review of geriatric research is necessary. Based on a
      literature review and panel discussion, we have developed the Ethical Guidance
      for Geriatric Clinical Research, aiming to provide guidance on the ethical review
      of geriatric clinical research.
CI  - (c) 2020 The Authors. Aging Medicine published by Beijing Hospital and John Wiley
      & Sons Australia, Ltd.
FAU - Yu, Lingling
AU  - Yu L
AUID- ORCID: https://orcid.org/0000-0002-9363-2802
AD  - Scientific Research Administration Department Beijing Hospital, National Center
      of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical
      Sciences Beijing China.
FAU - Li, Xiaoling
AU  - Li X
AD  - Ethics Committee Xuanwu Hospital Capital Medical University National Center for
      Clinical Research on Geriatric Diseases Beijing China.
FAU - Zhang, Pengjun
AU  - Zhang P
AD  - Scientific Research Administration Department Beijing Hospital, National Center
      of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical
      Sciences Beijing China.
FAU - Zhang, Guojun
AU  - Zhang G
AD  - Ethics Committee Xuanwu Hospital Capital Medical University National Center for
      Clinical Research on Geriatric Diseases Beijing China.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - Australia
TA  - Aging Med (Milton)
JT  - Aging medicine (Milton (N.S.W))
JID - 101741954
PMC - PMC7771564
OTO - NOTNLM
OT  - clinical research
OT  - ethics
OT  - geriatrics
COIS- Nothing to disclose.
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:31
PHST- 2020/11/18 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2021/01/04 05:31 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.1002/agm2.12138 [doi]
AID - AGM212138 [pii]
PST - epublish
SO  - Aging Med (Milton). 2020 Dec 21;3(4):218-223. doi: 10.1002/agm2.12138.
      eCollection 2020 Dec.


PMID- 33391957
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 22
TI  - Clinical Profile and Prognosis of Cerebral Venous Sinus Thrombosis.
PG  - e12221
LID - 10.7759/cureus.12221 [doi]
AB  - Introduction Cerebral venous sinus thrombosis (CVST) is an acute cerebrovascular 
      disease diagnosed nowadays more frequently. Magnetic resonance venogram (MRV) is 
      the modality of choice for accurate diagnosis. Young females in their
      childbearing age are prone to develop CVST. Clinical presentation is mainly with 
      headache, focal neurologic deficits, and seizures. Around one third of the
      patients have altered sensorium at presentation. Prognosis of CVST is good if
      diagnosed and treated early. Long-term deficits may remain in one quarter of
      patients. The aim of our study was to do clinical profiling and prognosis of CVST
      patients. Materials and methods This is a descriptive study conducted at the
      department of Neurology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan.
      Study duration was one year. Patients fulfilling inclusion and exclusion criteria
      were included in the study. Patients confirmed to have CVST on magnetic resonance
      imaging (MRI)/MRV were included in final analysis. Ethical approval was taken
      from the Institutional Review Board. Results Thirty three out of 54 patients were
      included in the final analysis. Out of them, 29 (87.8%) were females and four
      (12.1%) were males. The mean age at the time of presentation was 31.36 +/- 9.61. 
      Of the 29 females, only three were pregnant and 26 were in the postpartum period 
      at the time of presentation. Twelve (41.4%) females were primigravida. Focal
      deficits were present in 30 (90.9%) patients; headache was present in 26 (78.8%) 
      patients; seizures were present in 24 (72.7%) patients on presentation; and
      anemia was present in 20 (60.6%) patients. Conclusion CVST is an important cause 
      of intracranial hypertension, seizures, and stroke in young people. Clinical
      presentation is extremely variable, and a high index of suspicion is needed.
      Magnetic resonance imaging brain with MRV is the current diagnostic modality of
      choice. Medical management with anticoagulants and supportive measures has
      excellent clinical outcomes.
CI  - Copyright (c) 2020, Khan et al.
FAU - Khan, Muhammad Wazir Ali
AU  - Khan MWA
AD  - Department of Neurology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan,
      PAK.
FAU - Zeeshan, Hafiz Muhammad
AU  - Zeeshan HM
AD  - Department of Neurology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan,
      PAK.
FAU - Iqbal, Sehar
AU  - Iqbal S
AD  - Department of Obstetrics and Gynecology, Sheikh Zayed Medical College/Hospital,
      Rahim Yar Khan, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201222
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7767834
OTO - NOTNLM
OT  - cerebral venous sinus thrombosis (cvst)
OT  - peripartum
OT  - prognosis
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:29
PHST- 2021/01/04 05:29 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.7759/cureus.12221 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 22;12(12):e12221. doi: 10.7759/cureus.12221.


PMID- 33391827
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2071-9736 (Electronic)
IS  - 1025-9848 (Linking)
VI  - 25
DP  - 2020
TI  - Understanding how young people become motivated to take their human
      immunodeficiency virus medication (antiretroviral therapy) and how the need for
      adherence is communicated.
PG  - 1458
LID - 10.4102/hsag.v25i0.1458 [doi]
AB  - BACKGROUND: Antiretroviral therapy (ART), the only effective treatment for human 
      immunodeficiency virus (HIV), requires excellent long-term compliance. Poor
      levels of adherence to ART, especially amongst adolescents and young adults in
      South Africa, have been reported. AIM: This study aimed to explore how young
      people become motivated to take their HIV medication (ART) and how the need for
      adherence is communicated. SETTING: The study was conducted in a peri-urban
      township in the Western Cape, South Africa. METHODS: A qualitative grounded
      theory approach was employed. Eighty young people were purposively recruited.
      Participant observation, focus groups and semi-structured interviews were
      utilised to explore how effective ART adherence messages are in motivating
      adherence amongst young people and how they would like ART adherence to be
      communicated to them. All interviews and focus groups were transcribed and
      analysed by using cross-comparison analysis. Measures to ensure trustworthiness
      were established and ethical considerations were adhered to. RESULTS: Young
      people's adherence motivation was an outcome of reconnecting to one or more
      trusted significant other(s) from within their belonging group, who accepted and 
      supported them, which in turn affirmed their prior belonging identities of son,
      daughter, other family member or close friend. This facilitated reconnection to
      their present and future hopes, which in turn increased their motivation to live 
      and to adhere to treatment. CONCLUSION: The findings highlight the need for the
      development of more effective communication strategies, which facilitate and
      support young people's reconnection to trusted members of their belonging groups,
      and also help belonging group members to accept, affirm and support adherence.
CI  - (c) 2020. The Authors.
FAU - Hickson, Warren
AU  - Hickson W
AUID- ORCID: https://orcid.org/0000-0002-9425-4671
AD  - Department of Public Health and Family Medicine, Faculty of Health Sciences,
      University of Cape Town, Cape Town, South Africa.
FAU - Mayers, Pat M
AU  - Mayers PM
AUID- ORCID: https://orcid.org/0000-0002-2622-1624
AD  - Department of Health and Rehabilitation Sciences, Faculty of Health Sciences,
      University of Cape Town, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - South Africa
TA  - Health SA
JT  - Health SA = SA Gesondheid
JID - 101213385
PMC - PMC7756603
OTO - NOTNLM
OT  - ART adherence
OT  - HIV
OT  - South Africa
OT  - adolescents
OT  - health communication
OT  - young people
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:29
PHST- 2020/03/25 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2021/01/04 05:29 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.4102/hsag.v25i0.1458 [doi]
AID - HSAG-25-1458 [pii]
PST - epublish
SO  - Health SA. 2020 Dec 14;25:1458. doi: 10.4102/hsag.v25i0.1458. eCollection 2020.


PMID- 33391826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2071-9736 (Electronic)
IS  - 1025-9848 (Linking)
VI  - 25
DP  - 2020
TI  - Towards community-based nursing: Mothers' experiences caring for their preterm
      infants in an informal settlement, Gauteng.
PG  - 1437
LID - 10.4102/hsag.v25i0.1437 [doi]
AB  - BACKGROUND: Pregnant women who experience preterm labour rush to public hospitals
      closest to the informal settlement in which they reside. Preterm infants are
      discharged when they reach a certain weight. Mothers take their preterm infants
      to their homes inside the informal settlements. Yet, preterm infants have special
      needs and require specific management. Research confirmed that nurses working in 
      community clinics near informal settlements are unaware of the challenges faced
      by such mothers. Community nurses are at the heart of nursing, they work closest 
      to the community and have a distinct opportunity to provide contextual,
      community-based care and support to these mothers, to promote good health and
      prevent diseases. AIM: This article aims to enhance community nurses' insight
      about the mothers' experiences in caring for their preterm infants
      post-hospitalisation. SETTING: The study was conducted in an informal settlement 
      in Midvaal, Gauteng. METHODS: A qualitative, exploratory, descriptive and
      contextual research design was used. In-depth, phenomenological interviews were
      conducted with 10 purposefully sampled mothers to explore their experiences in
      caring for their preterm infants in an informal settlement. Data were analysed
      using Giorgi's coding method. Ethical approval was received from the University
      of Johannesburg. Measures were applied to ensure trustworthiness. RESULTS: Three 
      themes emerged: mothers experienced intrapersonal responses, interpersonal
      responses and numerous physical challenges in taking care of their preterm
      infants. CONCLUSION: Study findings revealed that mothers experienced several
      responses in caring for their preterm infants. Sharing their experiences can
      enhance community clinic nurses' insight to provide contextual health education.
CI  - (c) 2020. The Authors.
FAU - du Plessis-Faurie, Alida S
AU  - du Plessis-Faurie AS
AUID- ORCID: 0000-0002-0407-0634
AD  - Department of Nursing Sciences, Faculty of Health, University of Johannesburg,
      Johannesburg, South Africa.
FAU - Poggenpoel, Marie
AU  - Poggenpoel M
AUID- ORCID: https://orcid.org/0000-0001-7515-8695
AD  - Department of Nursing Sciences, Faculty of Health, University of Johannesburg,
      Johannesburg, South Africa.
FAU - Myburgh, Chris P H
AU  - Myburgh CPH
AUID- ORCID: https://orcid.org/0000-0003-4182-4244
AD  - Department of Nursing Sciences, Faculty of Health, University of Johannesburg,
      Johannesburg, South Africa.
FAU - Jacobs, Wanda O
AU  - Jacobs WO
AUID- ORCID: https://orcid.org/0000-0003-0864-5834
AD  - Department of Nursing Sciences, Faculty of Health, University of Johannesburg,
      Johannesburg, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - South Africa
TA  - Health SA
JT  - Health SA = SA Gesondheid
JID - 101213385
PMC - PMC7756596
OTO - NOTNLM
OT  - Community clinic nurses
OT  - Experiences
OT  - Informal settlement
OT  - Mothers
OT  - Preterm infants
COIS- The authors declare that they have no financial or personal relationships that
      may have inappropriately influenced them in writing this research article.
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:29
PHST- 2020/02/29 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2021/01/04 05:29 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.4102/hsag.v25i0.1437 [doi]
AID - HSAG-25-1437 [pii]
PST - epublish
SO  - Health SA. 2020 Dec 11;25:1437. doi: 10.4102/hsag.v25i0.1437. eCollection 2020.


PMID- 33391393
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210104
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Nov
TI  - Corrigendum: Scraping the Web for Public Health Gains: Ethical Considerations
      from a 'Big Data' Research Project on HIV and Incarceration.
PG  - 314
LID - 10.1093/phe/phaa018 [doi]
AB  - [This corrects the article DOI: 10.1093/phe/phaa006.][This corrects the article
      DOI: 10.1093/phe/phaa006.].
CI  - (c) The Author(s) 2020. Published by Oxford University Press. Available online at
      www.phe.oxfordjournals.org.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - UNC Bioethics Center, Department of Social Medicine, University of North Carolina
      at Chapel Hill.
FAU - Buchbinder, Mara
AU  - Buchbinder M
AD  - UNC Bioethics Center, Department of Social Medicine, University of North Carolina
      at Chapel Hill.
FAU - Juengst, Eric
AU  - Juengst E
AD  - UNC Bioethics Center, Department of Social Medicine, University of North Carolina
      at Chapel Hill.
FAU - Brinkley-Rubinstein, Lauren
AU  - Brinkley-Rubinstein L
AD  - Center for Health Equity, Department of Social Medicine, University of North
      Carolina at Chapel Hill.
FAU - Rosen, Colleen Blue And David L
AU  - Rosen CBADL
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill.
LA  - eng
PT  - Published Erratum
DEP - 20200504
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
EFR - Public Health Ethics. 2020 Mar 11;13(1):111-121. PMID: 32765647
PMC - PMC7765631
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:27
PHST- 2021/01/04 05:27 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.1093/phe/phaa018 [doi]
AID - phaa018 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 May 4;13(3):314. doi: 10.1093/phe/phaa018. eCollection
      2020 Nov.


PMID- 33391392
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Nov
TI  - What High-Income States Should Do to Address Industrial Antibiotic Pollution.
PG  - 275-287
LID - 10.1093/phe/phaa020 [doi]
AB  - Antibiotic resistance is widely recognized as a major threat to public health and
      healthcare systems worldwide. Recent research suggests that pollution from
      antibiotics manufacturing is an important driver of resistance development. Using
      Sweden as an example, this article considers how industrial antibiotic pollution 
      might be addressed by public actors who are in a position to influence the
      distribution and use of antibiotics in high-income countries with publicly funded
      health systems. We identify a number of opportunities for these actors to
      incentivize industry to increase sustainability in antibiotics production.
      However, we also show that each alternative would create tensions with other
      significant policy goals, necessitating trade-offs. Since justifiable trade-offs 
      require ethical consideration, we identify and explore the main underlying
      normative issues, namely, the weighing of local versus global health interests,
      the weighing of present versus future health interests, and the role of
      individualistic constraints on the pursuit of collective goals. Based on this
      analysis, we conclude that the actors have weighty principled reasons for
      prioritizing the goal of addressing pollution, but that translating this stance
      into concrete policy requires accommodating significant pragmatic challenges.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Malmqvist, Erik
AU  - Malmqvist E
AUID- ORCID: 0000-0003-3071-9609
AD  - University of Gothenburg.
FAU - Munthe, Christian
AU  - Munthe C
AUID- ORCID: 0000-0003-0761-960X
AD  - University of Gothenburg.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7765630
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:27
PHST- 2021/01/04 05:27 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.1093/phe/phaa020 [doi]
AID - phaa020 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Sep 2;13(3):275-287. doi: 10.1093/phe/phaa020.
      eCollection 2020 Nov.


PMID- 33391102
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210908
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - How Dogs Perceive Humans and How Humans Should Treat Their Pet Dogs: Linking
      Cognition With Ethics.
PG  - 584037
LID - 10.3389/fpsyg.2020.584037 [doi]
AB  - Humans interact with animals in numerous ways and on numerous levels. We are
      indeed living in an "animal"s world,' in the sense that our lives are very much
      intertwined with the lives of animals. This also means that animals, like those
      dogs we commonly refer to as our pets, are living in a "human's world" in the
      sense that it is us, not them, who, to a large degree, define and manage the
      interactions we have with them. In this sense, the human-animal relationship is
      nothing we should romanticize: it comes with clear power relations and thus with 
      a set of responsibilities on the side of those who exercise this power. This
      holds, despite the fact that we like to think about our dogs as human's best
      friend. Dogs have been part of human societies for longer than any other domestic
      species. Like no other species they exemplify the role of companion animals.
      Relationships with pet dogs are both very widespread and very intense, often
      leading to strong attachments between owners or caregivers and animals and to a
      treatment of these dogs as family members or even children. But how does this
      relationship look from the dogs' perspective? How do they perceive the humans
      they engage with? What responsibilities and duties arise from the kind of mutual 
      understanding, attachment, and the supposedly "special" bonds we form with them? 
      Are there ethical implications, maybe even ethical implications beyond animal
      welfare? The past decades have seen an upsurge of research from comparative
      cognition on pet dogs' cognitive and social skills, especially in comparison with
      and reference to humans. We will therefore set our discussion about the nature
      and ethical dimensions of the human-dog relationship against the background of
      the current empirical knowledge on dog (social) cognition. This allows us to
      analyze the human-dog relationship by applying an interdisciplinary approach that
      starts from the perspective of the dog to ultimately inform the perspective of
      humans. It is our aim to thereby identify ethical dimensions of the human-dog
      relationship that have been overlooked so far.
CI  - Copyright (c) 2020 Benz-Schwarzburg, Monso and Huber.
FAU - Benz-Schwarzburg, Judith
AU  - Benz-Schwarzburg J
AD  - Unit of Ethics and Human-Animal Studies, Messerli Research Institute, Vetmeduni
      Vienna, University of Vienna, Medical University of Vienna, Vienna, Austria.
FAU - Monso, Susana
AU  - Monso S
AD  - Unit of Ethics and Human-Animal Studies, Messerli Research Institute, Vetmeduni
      Vienna, University of Vienna, Medical University of Vienna, Vienna, Austria.
FAU - Huber, Ludwig
AU  - Huber L
AD  - Unit of Comparative Cognition, Messerli Research Institute, Vetmeduni Vienna,
      University of Vienna, Medical University of Vienna, Vienna, Austria.
LA  - eng
GR  - M 2518/FWF_/Austrian Science Fund FWF/Austria
PT  - Journal Article
PT  - Review
DEP - 20201216
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7772310
OTO - NOTNLM
OT  - animal cognition
OT  - animal ethics
OT  - human-animal interactions
OT  - positive duties
OT  - social cognition
OT  - trust
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest. The handling editor declared a past co-authorship with one 
      of the authors JB-S.
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:26
PHST- 2020/07/16 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2021/01/04 05:26 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.3389/fpsyg.2020.584037 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 16;11:584037. doi: 10.3389/fpsyg.2020.584037. eCollection
      2020.


PMID- 33391072
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Understanding Independence: Board of Directors and CSR.
PG  - 552152
LID - 10.3389/fpsyg.2020.552152 [doi]
AB  - On August Business Roundtable (2019), the Business Roundtable redefined the
      purpose and social responsibility of the corporation. Yet, this statement must be
      followed by substantial changes in the business models of corporations for it to 
      avoid becoming empty rhetoric. We believe that the figure of the independent
      director may be one of the catalysts needed for this change of paradigm for
      corporations. In spite of the positive correlation between Corporate Social
      Responsibility (CSR) and board independence, the development of the independence 
      of boards during the last decade has not lead to the expected CSR results.
      Academics and regulators point to a weak definition and the non-standardized
      measurement of both independence and board independence (BI) as one possible
      explanation, and agree that a broader definition is needed. This paper aims to
      contribute to this debate. We develop a second-generation definition of
      independence based on a positive approximation to the concept by integrating an
      Aristotelian perspective of virtue ethics with the best practices of corporate
      governance. Thus, we define independence as a virtue guided by practical wisdom, 
      that implies autonomy and autarky and which enables a person to act with
      integrity, fairness and truthfulness. In the context of corporate governance,
      independence is associated with an honest disposition to serve. Our proposal has 
      political implications for supervisors that make decisions relating to the
      suitability of board members.
CI  - Copyright (c) 2020 Calderon, Pinero and Redin.
FAU - Calderon, Reyes
AU  - Calderon R
AD  - Universidad de Navarra and Universidad Francisco de Vitoria, Madrid, Spain.
FAU - Pinero, Ricardo
AU  - Pinero R
AD  - Department of Business, University of Navarra, Pamplona, Spain.
FAU - Redin, Dulce M
AU  - Redin DM
AD  - Department of Business, University of Navarra, Pamplona, Spain.
AD  - School of Economics and Business of the University of Navarra, Pamplona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7774598
OTO - NOTNLM
OT  - CSR
OT  - board independence
OT  - corporate governance
OT  - independent director
OT  - integrity
OT  - practical wisdom
OT  - virtue ethics
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:26
PHST- 2020/04/15 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2021/01/04 05:26 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.3389/fpsyg.2020.552152 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 17;11:552152. doi: 10.3389/fpsyg.2020.552152. eCollection
      2020.


PMID- 33390892
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Beyond Technologies of Electroencephalography-Based Brain-Computer Interfaces: A 
      Systematic Review From Commercial and Ethical Aspects.
PG  - 611130
LID - 10.3389/fnins.2020.611130 [doi]
AB  - The deployment of electroencephalographic techniques for commercial applications 
      has undergone a rapid growth in recent decades. As they continue to expand in the
      consumer markets as suitable techniques for monitoring the brain activity, their 
      transformative potential necessitates equally significant ethical inquiries. One 
      of the main questions, which arises then when evaluating these kinds of
      applications, is whether they should be aligned or not with the main ethical
      concerns reported by scholars and experts. Thus, the present work attempts to
      unify these disciplines of knowledge by performing a comprehensive scan of the
      major electroencephalographic market applications as well as their most relevant 
      ethical concerns arising from the existing literature. In this literature review,
      different databases were consulted, which presented conceptual and empirical
      discussions and findings about commercial and ethical aspects of
      electroencephalography. Subsequently, the content was extracted from the articles
      and the main conclusions were presented. Finally, an external assessment of the
      outcomes was conducted in consultation with an expert panel in some of the topic 
      areas such as biomedical engineering, biomechatronics, and neuroscience. The
      ultimate purpose of this review is to provide a genuine insight into the
      cutting-edge practical attempts at electroencephalography. By the same token, it 
      seeks to highlight the overlap between the market needs and the ethical standards
      that should govern the deployment of electroencephalographic consumer-grade
      solutions, providing a practical approach that overcomes the engineering myopia
      of certain ethical discussions.
CI  - Copyright (c) 2020 Fontanillo Lopez, Li and Zhang.
FAU - Fontanillo Lopez, Cesar Augusto
AU  - Fontanillo Lopez CA
AD  - KU-Leuven Center for IT & IP Law, KU-Leuven, Leuven, Belgium.
FAU - Li, Guangye
AU  - Li G
AD  - The Robotics Institute, School of Mechanical Engineering, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Zhang, Dingguo
AU  - Zhang D
AD  - The Department of Electronic and Electrical Engineering, University of Bath,
      Bath, United Kingdom.
LA  - eng
PT  - Systematic Review
DEP - 20201217
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7773904
OTO - NOTNLM
OT  - EEG
OT  - brain-computer interface
OT  - commercial aspects
OT  - electroencephalography
OT  - ethical aspects
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:25
PHST- 2020/09/28 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2021/01/04 05:25 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.3389/fnins.2020.611130 [doi]
PST - epublish
SO  - Front Neurosci. 2020 Dec 17;14:611130. doi: 10.3389/fnins.2020.611130.
      eCollection 2020.


PMID- 33390735
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210105
IS  - 1205-7088 (Print)
IS  - 1205-7088 (Linking)
VI  - 25
IP  - 1
DP  - 2020 Feb
TI  - Discharge against medical advice (DAMA) in paediatrics: An approach to promote
      safety and ethics.
PG  - 12-15
LID - 10.1093/pch/pxz052 [doi]
AB  - Requests for discharge against medical advice are often challenging for
      clinicians to navigate, especially when the patient is a child. An informed,
      standardized approach to managing situations where children and their families
      are requesting to leave against medical advice is essential to maximizing safety 
      and ethics for patients and staff, yet such situations are often not handled this
      way. Paediatric discharge against medical advice (DAMA) requests are best managed
      when clinicians ensure the patient's best interests are met, understand and act
      upon their professional obligations, and engage in guided discussion with
      patients and families that involves both shared and informed decision-making
      strategies. A process map can capture these criteria and readily provide
      clinicians with a bedside reference tool when managing paediatric DAMA requests.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the
      Canadian Paediatric Society. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Kavanagh, Aifric
AU  - Kavanagh A
AD  - Department of Bioethics, The Hospital for Sick Children, Toronto, Ontario.
FAU - Ostrow, Olivia
AU  - Ostrow O
AD  - Division of Pediatric Emergency Medicine, The Hospital for Sick Children,
      Toronto, Ontario.
AD  - Department of Paediatrics, University of Toronto, Toronto, Ontario.
FAU - Zlotnik Shaul, Randi
AU  - Zlotnik Shaul R
AD  - Department of Bioethics, The Hospital for Sick Children, Toronto, Ontario.
AD  - Department of Paediatrics, University of Toronto, Toronto, Ontario.
LA  - eng
PT  - Journal Article
DEP - 20190418
PL  - England
TA  - Paediatr Child Health
JT  - Paediatrics & child health
JID - 9815960
PMC - PMC7757767
OTO - NOTNLM
OT  - Best interests
OT  - Bioethics
OT  - Capacity
OT  - DAMA
OT  - Decision making
OT  - Discharge
OT  - Patient safety
EDAT- 2021/01/05 06:00
MHDA- 2021/01/05 06:01
CRDT- 2021/01/04 05:25
PHST- 2021/01/04 05:25 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/01/05 06:01 [medline]
AID - 10.1093/pch/pxz052 [doi]
AID - pxz052 [pii]
PST - ppublish
SO  - Paediatr Child Health. 2020 Feb;25(1):12-15. doi: 10.1093/pch/pxz052. Epub 2019
      Apr 18.


PMID- 33390689
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2150-4113 (Electronic)
IS  - 1079-0969 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Dec
TI  - Human Rights and Digital Health Technologies.
PG  - 21-32
AB  - Digital health technologies have been heralded as a critical solution to
      challenges and gaps in the delivery of quality health care and essential to
      achieving the Sustainable Development Goals. Yet they also present threats to
      privacy and confidentiality, which can lead to discrimination and violence,
      resulting in violations of the rights to health, housing, employment, freedom of 
      assembly, expression, protection from arbitrary detention, bodily autonomy, and
      security. More broadly, without proper planning and safeguards, digital health
      technologies can contribute to expanding health inequity, widening the "digital
      divide" that separates those who can and cannot access such interventions. This
      article outlines key harms related to digital technologies for health, as well as
      ethical and human rights standards relevant to their use. It also presents
      several strategies for mitigating risks from digital health technologies and
      reviews mechanisms of accountability, including recent judicial rulings.
CI  - Copyright (c) 2020 Sun, Esom, Dhaliwal, and Amon.
FAU - Sun, Nina
AU  - Sun N
AD  - Deputy Director of Global Health and Assistant Clinical Professor in the
      Department of Community Health and Prevention, Dornsife School of Public Health
      at Drexel University, Philadelphia, USA.
FAU - Esom, Kenechukwu
AU  - Esom K
AD  - Policy Specialist with the HIV, Health and Development Group of the United
      Nations Development Programme's Bureau for Policy and Programme Support, New
      York, USA.
FAU - Dhaliwal, Mandeep
AU  - Dhaliwal M
AD  - Director of the HIV, Health and Development Group of the United Nations
      Development Programme's Bureau for Policy and Programme Support, New York, USA.
FAU - Amon, Joseph J
AU  - Amon JJ
AD  - Director of Global Health and Clinical Professor in the Department of Community
      Health and Prevention, Dornsife School of Public Health, Drexel University,
      Philadelphia, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Health Hum Rights
JT  - Health and human rights
JID - 9502498
SB  - IM
MH  - *Confidentiality
MH  - Freedom
MH  - *Human Rights
MH  - Humans
MH  - Privacy
PMC - PMC7762914
COIS- Competing interests: None declared.
EDAT- 2021/01/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2021/01/04 05:25
PHST- 2021/01/04 05:25 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - hhr-22-02-021 [pii]
PST - ppublish
SO  - Health Hum Rights. 2020 Dec;22(2):21-32.


PMID- 33389944
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2149-8709 (Electronic)
IS  - 2149-8709 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Dec 29
TI  - Reply to Letter to the Editor.
PG  - 393
LID - 10.4274/tjo.galenos.2020.11455 [doi]
FAU - Keskinbora, Kadircan H
AU  - Keskinbora KH
AUID- ORCID: 0000-0003-1940-1026
AD  - Bahcesehir University Faculty of Medicine, Department of Ophthalmology;
      Bahcesehir University Faculty of Medicine, Department of Medical Ethics and
      History of Medicine, Istanbul, Turkey.
FAU - Guven, Fatih
AU  - Guven F
AUID- ORCID: 0000-0003-3587-7403
AD  - University of Health Sciences Turkey, Bakirkoy Training and Research Hospital,
      Clinic of Ophthalmology, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - Turkey
TA  - Turk J Ophthalmol
JT  - Turkish journal of ophthalmology
JID - 101686048
SB  - IM
CON - Turk J Ophthalmol. 2020 Jun 27;50(3):133-142. PMID: 32630999
CON - Turk J Ophthalmol. 2020 Dec 29;50(6):390-391. PMID: 33389942
MH  - Artificial Intelligence
MH  - *Cataract
MH  - *Dry Eye Syndromes
MH  - Humans
MH  - Machine Learning
MH  - Risk Factors
PMC - PMC7802098
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *machine learning
OT  - *medical ethics
OT  - *ophthalmology
EDAT- 2021/01/05 06:00
MHDA- 2021/03/04 06:00
CRDT- 2021/01/04 01:50
PHST- 2021/01/04 01:50 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - 10.4274/tjo.galenos.2020.11455 [doi]
PST - ppublish
SO  - Turk J Ophthalmol. 2020 Dec 29;50(6):393. doi: 10.4274/tjo.galenos.2020.11455.


PMID- 33389943
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2149-8709 (Electronic)
IS  - 2149-8709 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Dec 29
TI  - Comment on: "Artificial Intelligence and Ophthalmology".
PG  - 392
LID - 10.4274/tjo.galenos.2020.98354 [doi]
FAU - Dos Santos Martins, Thiago Goncalves
AU  - Dos Santos Martins TG
AUID- ORCID: 0000-0002-3878-8564
AD  - Federal University of Sao Paulo, Department of Ophthalmology, Brazil.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - Turkey
TA  - Turk J Ophthalmol
JT  - Turkish journal of ophthalmology
JID - 101686048
SB  - IM
CON - Turk J Ophthalmol. 2020 Mar 05;50(1):37-43. PMID: 32167262
MH  - *Artificial Intelligence
MH  - Humans
MH  - Machine Learning
MH  - *Ophthalmology
PMC - PMC7802103
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *deep learning
OT  - *machine learning
OT  - *medical ethics
OT  - *ophthalmology
EDAT- 2021/01/05 06:00
MHDA- 2021/03/04 06:00
CRDT- 2021/01/04 01:48
PHST- 2021/01/04 01:48 [entrez]
PHST- 2021/01/05 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - 10.4274/tjo.galenos.2020.98354 [doi]
PST - ppublish
SO  - Turk J Ophthalmol. 2020 Dec 29;50(6):392. doi: 10.4274/tjo.galenos.2020.98354.


PMID- 33389845
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 2155-7780 (Electronic)
IS  - 2155-7780 (Linking)
VI  - 23
IP  - 1
DP  - 2020 Dec 31
TI  - Possible Ethical Issues of Digital Mental Health Education During and After the
      COVID-19 Pandemic and How to Prevent Them.
LID - 10.4088/PCC.20com02818 [doi]
LID - 20com02818 [pii]
FAU - Curkovic, Marko
AU  - Curkovic M
AD  - University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10090 Zagreb, Croatia.
      markocurak@gmail.com.
AD  - University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10 090 Zagreb,
      Croatia.
AD  - School of Medicine, University of Zagreb, Salata 2, 10 000 Zagreb, Croatia.
FAU - Savic, Aleksandar
AU  - Savic A
AD  - University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10 090 Zagreb,
      Croatia.
AD  - School of Medicine, University of Zagreb, Salata 2, 10 000 Zagreb, Croatia.
FAU - Brecic, Petrana
AU  - Brecic P
AD  - University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10 090 Zagreb,
      Croatia.
AD  - School of Medicine, University of Zagreb, Salata 2, 10 000 Zagreb, Croatia.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - United States
TA  - Prim Care Companion CNS Disord
JT  - The primary care companion for CNS disorders
JID - 101547532
SB  - IM
MH  - *COVID-19
MH  - Education, Distance/*ethics/methods/standards
MH  - Education, Medical/*ethics/methods/standards
MH  - Humans
MH  - Mental Health/*education
EDAT- 2021/01/04 06:00
MHDA- 2021/01/13 06:00
CRDT- 2021/01/03 20:44
PHST- 2021/01/03 20:44 [entrez]
PHST- 2021/01/04 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.4088/PCC.20com02818 [doi]
PST - epublish
SO  - Prim Care Companion CNS Disord. 2020 Dec 31;23(1). doi: 10.4088/PCC.20com02818.


PMID- 33389828
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 29
IP  - 12
DP  - 2020 Dec
TI  - Determinants of moral attitudes toward stem cells.
PG  - 1379-1387
LID - 10.17219/acem/127678 [doi]
AB  - BACKGROUND: The paper presents an analysis of opinions concerning the use of stem
      cells (SCs), using tools developed in the field of moral psychology. OBJECTIVES: 
      To determine the factors that affect beliefs regarding the status of SCs and to
      evaluate the impact of these factors. The paper investigated whether factors of a
      moral nature prevail over the knowledge that makes it possible to use SCs in
      practice. MATERIAL AND METHODS: The analysis of psychological perception is based
      on a study carried out on a group of 172 Polish and 161 English-speaking
      first-year medical students. The study was conducted between 2005 and 2007, and
      in 2019 at the Poznan University of Medical Sciences (Poland). RESULTS: Knowledge
      is not the main factor that differentiates approaches towards the use of SCs. The
      importance of religion in the lives of the respondents has a significant impact
      on the perception of the use of SCs, and is associated with indications of
      ethically saturated terms. Focusing on the usefulness of cells is associated with
      lesser significance of religion and greater value placed on scientific knowledge.
      CONCLUSIONS: Although the research results indicate a correlation between
      religiousness and the respondents' perception of the use of SCs, further research
      is needed into the relationship between the influence of scientific knowledge on 
      views related to SCs.
FAU - Zok, Agnieszka
AU  - Zok A
AD  - Division of Philosophy of Medicine and Bioethics, Poznan University of Medical
      Sciences, Poland.
FAU - Wiertlewska-Bielarz, Jadwiga
AU  - Wiertlewska-Bielarz J
AD  - Department of Social Sciences and Humanities, Poznan University of Medical
      Sciences, Poland.
FAU - Baum, Ewa
AU  - Baum E
AD  - Division of Philosophy of Medicine and Bioethics, Poznan University of Medical
      Sciences, Poland.
AD  - Department of Social Sciences and Humanities, Poznan University of Medical
      Sciences, Poland.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical
      University
JID - 101138582
SB  - IM
MH  - *Attitude
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Morals
MH  - Poland
MH  - Religion
MH  - Stem Cells
OTO - NOTNLM
OT  - bioethics
OT  - education
OT  - medical ethics
OT  - moral psychology
OT  - stem cells
EDAT- 2021/01/04 06:00
MHDA- 2021/02/07 06:00
CRDT- 2021/01/03 20:44
PHST- 2021/01/03 20:44 [entrez]
PHST- 2021/01/04 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - 10.17219/acem/127678 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2020 Dec;29(12):1379-1387. doi: 10.17219/acem/127678.


PMID- 33386719
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 2391-5854 (Electronic)
IS  - 0033-2674 (Linking)
VI  - 54
IP  - 4
DP  - 2020 Aug 31
TI  - Euthanasia and assisted suicide in the context of psychiatric disorders: sharing 
      experiences from the Low Countries.
PG  - 661-672
LID - 124078 [pii]
LID - 10.12740/PP/124078 [doi]
AB  - Euthanasia and physician assisted suicide (E/PAS) in the context of unbearable
      psychological or emotional suffering related to psychiatric disorders
      (psychiatric E/PAS) is ahighly debated topic. In Belgium and The Netherlands, the
      law allows for psychiatric E/PAS since 2002. The aim of this article is to give
      an overview of the Belgian and Dutch experiences and the questions raised during 
      the last decade of real-life experiences with psychiatric E/PAS. We use the
      available national data on psychiatric E/PAS to present a quantitative overview
      of the current situation. In addition, we identified different challenges; i.e.
      ethical, medicalpsychiatric and legal, that increasingly impact and change the
      attitudes within the medical and psychiatric professional community towards
      psychiatric E/PAS.
FAU - Dom, Geert
AU  - Dom G
AD  - Collaborative Antwerp Psychiatric Research Institute, Antwerp University,
      Belgium.
FAU - Stoop, Heidi
AU  - Stoop H
AD  - PC Multiversum, Boechout, Belgium.
FAU - Haekens, An
AU  - Haekens A
AD  - Zorggroep Alexianen, Tienen, Belgium.
FAU - Sterckx, Sigrid
AU  - Sterckx S
AD  - Bioethics Institute Ghent and End-of-Life Care Research Group Ghent University,
      Belgium.
LA  - eng
LA  - pol
PT  - Journal Article
PT  - Review
TT  - Eutanazja i wspomagane samobojstwo w kontekscie zaburzen psychicznych w krajach
      niderlandzkich: doswiadczenie poparte praktyka.
DEP - 20200831
PL  - Poland
TA  - Psychiatr Pol
JT  - Psychiatria polska
JID - 0103314
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Euthanasia, Active, Voluntary/*ethics/legislation &
      jurisprudence/psychology/*statistics & numerical data
MH  - Humans
MH  - Mental Disorders/psychology/*therapy
MH  - Mentally Ill Persons
MH  - Netherlands
MH  - Suicide, Assisted/*ethics/legislation & jurisprudence/psychology/*statistics &
      numerical data
OTO - NOTNLM
OT  - euthanasia
OT  - physician assisted suicide
OT  - psychiatric disorder
EDAT- 2021/01/03 06:00
MHDA- 2021/07/30 06:00
CRDT- 2021/01/02 08:32
PHST- 2021/01/02 08:32 [entrez]
PHST- 2021/01/03 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - 124078 [pii]
AID - 10.12740/PP/124078 [doi]
PST - ppublish
SO  - Psychiatr Pol. 2020 Aug 31;54(4):661-672. doi: 10.12740/PP/124078. Epub 2020 Aug 
      31.


PMID- 33384627
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210308
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Acceleration of Anxiety, Depression, and Suicide: Secondary Effects of Economic
      Disruption Related to COVID-19.
PG  - 592467
LID - 10.3389/fpsyt.2020.592467 [doi]
AB  - The SARS-CoV-2 (COVID-19) pandemic has contributed to increasing levels of
      anxiety, depression and other symptoms of stress around the globe. Reasons for
      this increase are understandable in the context of individual level factors such 
      as self-isolation, lockdown, grief, survivor guilt, and other factors but also
      broader social and economic factors such as unemployment, insecure employment and
      resulting poverty, especially as the impacts of 2008 recession are still being
      felt in many countries further accompanied by social isolation. For those who are
      actively employed a fear of job and income loss and those who have actually
      become ill and recovered or those who have lost family and friends to illness, it
      is not surprising that they are stressed and feeling the psychological impact.
      Furthermore, multiple uncertainties contribute to this sense of anxiety. These
      fears and losses are major immediate stresses and undoubtedly can have long-term 
      implications on mental health. Economic uncertainty combined with a sense of
      feeling trapped and resulting lack of control can contribute to helplessness and 
      hopelessness where people may see suicide as a way out. Taking a macro view, we
      present a statistical model of the impact of unemployment, and national income
      declines, on suicide, separately for males and females over the life cycle in
      developed countries. This impact may reflect a potent combination of social
      changes and economic factors resulting in anomie. The governments and
      policymakers have a moral and ethical obligation to ensure the physical health
      and well-being of their populations. While setting in place preventive measures
      to avoid infections and then subsequent mortality, the focus on economic and
      social recovery is crucial. A global pandemic requires a global response with a
      clear inter-linked strategy for health as well as economic solutions. The models 
      we have constructed represent predictions of suicide rates among the 38 highly
      industrialized OECD countries over a period of 18 years (2000-2017). Unemployment
      has a major effect on increasing suicide, especially in middle-aged groups.
      However, the impact of economic decline through losses of national income (GDP
      per capita) are substantially greater than those of unemployment and influence
      suicide throughout the life course, especially at the oldest ages.
CI  - Copyright (c) 2020 Brenner and Bhugra.
FAU - Brenner, M Harvey
AU  - Brenner MH
AD  - School of Public Health, Health Policy and Management, Johns Hopkins University
      Bloomberg, Baltimore, MD, United States.
AD  - University of North Texas Health Science Center, Fort Worth, TX, United States.
FAU - Bhugra, Dinesh
AU  - Bhugra D
AD  - Medizinische Hochschule Hannover, Hannover, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201215
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
EIN - Front Psychiatry. 2021 Feb 19;12:660659. PMID: 33679494
PMC - PMC7771384
OTO - NOTNLM
OT  - COVID-19
OT  - Great Recession
OT  - depression
OT  - economy
OT  - national income loss
OT  - recession
OT  - suicide
OT  - unemployment
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2021/01/02 06:00
MHDA- 2021/01/02 06:01
CRDT- 2021/01/01 05:21
PHST- 2020/08/07 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/01/01 05:21 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/01/02 06:01 [medline]
AID - 10.3389/fpsyt.2020.592467 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Dec 15;11:592467. doi: 10.3389/fpsyt.2020.592467.
      eCollection 2020.


PMID- 33384402
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Measuring the Outcomes of Maternal COVID-19-related Prenatal Exposure (MOM-COPE):
      study protocol for a multicentric longitudinal project.
PG  - e044585
LID - 10.1136/bmjopen-2020-044585 [doi]
AB  - INTRODUCTION: COVID-19 is a highly infectious respiratory disease that rapidly
      emerged as an unprecedented epidemic in Europe, with a primary hotspot in
      Northern Italy during the first months of 2020. Its high infection rate and rapid
      spread contribute to set the risk for relevant psychological stress in citizens. 
      In this context, mother-infant health is at risk not only because of potential
      direct exposure to the virus but also due to high levels of stress experienced by
      mothers from conception to delivery. Prenatal stress exposure associates with
      less-than-optimal child developmental outcomes, and specific epigenetic
      mechanisms (eg, DNA methylation) may play a critical role in mediating this
      programming association. METHODS AND ANALYSIS: We present the methodological
      protocol for a longitudinal, multicentric study on the behavioural and epigenetic
      effects of COVID-19-related prenatal stress in a cohort of mother-infant dyads in
      Northern Italy. The dyads will be enrolled at 10 facilities in Northern Italy.
      Saliva samples will be collected at birth to assess the methylation status of
      specific genes linked with stress regulation in mothers and newborns. Mothers
      will provide retrospective data on COVID-19-related stress during pregnancy. At
      3, 6 and 12 months, mothers will provide data on child behavioural and
      socioemotional outcomes, their own psychological status (stress, depressive and
      anxious symptoms) and coping strategies. At 12 months, infants and mothers will
      be videotaped during semistructured interaction to assess maternal sensitivity
      and infant's relational functioning. ETHICS AND DISSEMINATION: This study was
      approved by the Ethics Committee (Pavia). Results will be published in
      peer-reviewed journals and presented at national and international scientific
      conferences. TRIAL REGISTRATION NUMBER: NCT04540029; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Provenzi, Livio
AU  - Provenzi L
AUID- ORCID: 0000-0001-7424-8744
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy
      livio.provenzi@mondino.it.
FAU - Grumi, Serena
AU  - Grumi S
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
FAU - Giorda, Roberto
AU  - Giorda R
AD  - Biology Lab, Scientific Institute, IRCCS E. Medea, Bosisi Parini, Italy.
FAU - Biasucci, Giacomo
AU  - Biasucci G
AD  - Pediatrics & Neonatology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy.
FAU - Bonini, Renza
AU  - Bonini R
AD  - Pediatrics & Neonatology Unit, Guglielmo da Saliceto Hospital, Piacenza, Italy.
FAU - Cavallini, Anna
AU  - Cavallini A
AD  - Child and Adolescent Mental Health, San Gerardo Hospital, Monza, Italy.
FAU - Decembrino, Lidia
AU  - Decembrino L
AD  - Pediatric Unit and Neonatal Unit, Ospedale Civile di Vigevano, ASST di Pavia,
      Vigevano, Italy.
FAU - Drera, Bruno
AU  - Drera B
AD  - Neonatal Intensive Care Unit, Azienda Istituti Ospitalieri di Cremona, Cremona,
      Italy.
FAU - Falcone, Rossana
AU  - Falcone R
AD  - Pediatric Unit and Neonatal Unit, Ospedale Civile di Vigevano, ASST di Pavia,
      Vigevano, Italy.
FAU - Fazzi, Elisa
AU  - Fazzi E
AD  - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,
      Italy.
AD  - Unit of Child and Adolescence Neuropsychiatry, Azienda Ospedaliera Spedali Civili
      di Brescia, Brescia, Italy.
FAU - Gardella, Barbara
AU  - Gardella B
AD  - Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo,
      Pavia, Italy.
FAU - Giacchero, Roberta
AU  - Giacchero R
AD  - Department of Pediatrics, Lodi Hospital, Lodi, Italy.
FAU - Nacinovich, Renata
AU  - Nacinovich R
AD  - Child and Adolescent Mental Health, San Gerardo Hospital, Monza, Italy.
AD  - School of Medicine and Surgery and Milan Center for Neuroscience, University of
      Milano Bicocca, Milano, Italy.
FAU - Pisoni, Camilla
AU  - Pisoni C
AD  - Neonatal Intensive Care Unit, IRCCS Foundation Policlinico San Matteo, Pavia,
      Italy.
FAU - Prefumo, Federico
AU  - Prefumo F
AD  - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,
      Italy.
FAU - Scelsa, Barbara
AU  - Scelsa B
AD  - Unit of Pediatric Neurology, Buzzi Children's Hospital, Milano, Italy.
FAU - Sparta, Maria Valentina
AU  - Sparta MV
AD  - Department of Pediatrics, Lodi Hospital, Lodi, Italy.
FAU - Veggiotti, Pierangelo
AU  - Veggiotti P
AD  - Unit of Pediatric Neurology, Buzzi Children's Hospital, Milano, Italy.
AD  - Biomedical and Clinical Science Department, University of Milano, Milano, Italy.
FAU - Orcesi, Simona
AU  - Orcesi S
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
AD  - Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
FAU - Borgatti, Renato
AU  - Borgatti R
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
AD  - Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
CN  - MOM-COPE Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT04540029
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *COVID-19/epidemiology/prevention & control/psychology
MH  - Child Development/physiology
MH  - DNA Methylation
MH  - Female
MH  - Humans
MH  - Infant
MH  - Italy
MH  - Longitudinal Studies
MH  - Maternal Exposure/*prevention & control
MH  - Maternal-Fetal Relations/physiology/psychology
MH  - Mothers/*psychology
MH  - Multicenter Studies as Topic
MH  - Outcome Assessment, Health Care
MH  - Pregnancy
MH  - *Pregnancy Complications/diagnosis/physiopathology
MH  - Research Design
MH  - SARS-CoV-2
MH  - *Stress, Psychological/complications/diagnosis/psychology
PMC - PMC7780424
OTO - NOTNLM
OT  - *COVID-19
OT  - *mental health
OT  - *perinatology
COIS- Competing interests: None declared.
IR  - Accorsi P
FIR - Accorsi, Patrizia
IR  - Bucci R
FIR - Bucci, Rossana
IR  - Cavalleri E
FIR - Cavalleri, Elisa
IR  - Malerba L
FIR - Malerba, Laura
IR  - Martelli P
FIR - Martelli, Paola
IR  - Motta M
FIR - Motta, Mario
IR  - Zatti S
FIR - Zatti, Sonia
IR  - Bertazzoli E
FIR - Bertazzoli, Emanuela
IR  - Centinaio G
FIR - Centinaio, Giovanna
IR  - Longo MR
FIR - Longo, Maria Roberta
IR  - Pietra BC
FIR - Pietra, Benedetta Chiara
IR  - Sabatini C
FIR - Sabatini, Caterina
IR  - Chiara A
FIR - Chiara, Alberto
IR  - Campo GD
FIR - Campo, Giuliana Del
IR  - Magnani L
FIR - Magnani, Luisa
IR  - Pantaleo D
FIR - Pantaleo, Dario
IR  - Spinillo A
FIR - Spinillo, Arsenio
IR  - Zecca M
FIR - Zecca, Marco
IR  - Bensi G
FIR - Bensi, Giulia
IR  - Grossi E
FIR - Grossi, Elena
IR  - Pavesi C
FIR - Pavesi, Cristiana
IR  - Russo D
FIR - Russo, Daniela
IR  - Kullmann G
FIR - Kullmann, Gaia
EDAT- 2021/01/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2021/01/01 05:17
PHST- 2021/01/01 05:17 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - bmjopen-2020-044585 [pii]
AID - 10.1136/bmjopen-2020-044585 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e044585. doi: 10.1136/bmjopen-2020-044585.


PMID- 33384397
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Risk of colectomy after conservative treatment of diverticulitis of the left
      hemicolon complicated by abdominal or pelvic abscess: protocol of a systematic
      review and meta-analysis.
PG  - e042350
LID - 10.1136/bmjopen-2020-042350 [doi]
AB  - INTRODUCTION: Acute diverticulitis of the sigmoid colon is increasingly treated
      by a non-operative approach. The need for colectomy after recovery from a flare
      of acute diverticulitis of the left colon, complicated diverticular abscess is
      still controversial. The primary aim of this study is to assess the risk of
      interval emergency surgery by systematic review and meta-analysis. METHODS AND
      ANALYSIS: The systematic review and meta-analysis will be conducted in accordance
      to the Preferred Reporting Items for Systematic Review and Meta-Analysis
      Protocols statement. PubMed/MEDLINE, Cochrane Central Register of Controlled
      Trials and EMBASE will be screened for the predefined searching term:
      (Diverticulitis OR Diverticulum) AND (Abscess OR pelvic abscess OR pericolic
      abscess OR intraabdominal abscess) AND (surgery OR operation OR sigmoidectomy OR 
      drainage OR percutaneous drainage OR conservative therapy OR watchful waiting).
      All studies published in an English or German-speaking peer-reviewed journal will
      be suitable for this analysis. Case reports, case series of less than five
      patients, studies without follow-up information, systematic and non-systematic
      reviews and meta-analyses will be excluded. Primary endpoint is the rate of
      interval emergency surgery. Using the Review Manager Software (Review
      Manager/RevMan, V.5.3, Copenhagen, The Nordic Cochrane Centre, The Cochrane
      Collaboration, 2012) meta-analysis will be pooled using the Mantel-Haenszel
      method for random effects. The Risk of Bias in Non-randomized Studies of
      Interventions tool will be used to assess methodological quality of
      non-randomised studies. Risk of bias in randomised studies will be assessed using
      the Cochrane developed RoB 2-tool. ETHICS AND DISSEMINATION: As no new data are
      being collected, ethical approval is exempt for this study. This systematic
      review is to provide a new insight on the need for surgical treatment after a
      first attack of acute diverticulitis, complicated by intra-abdominal or pelvic
      abscesses. The results of this study will be presented at national and
      international meetings and published in a peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42020164813.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sohn, Maximilian
AU  - Sohn M
AUID- ORCID: 0000-0003-2434-2366
AD  - Department of General-, Abdominal-, Endocrine- and Minimally Invasive Surgery,
      Munchen Klinik Bogenhausen, Munchen, Germany
      maximilian.sohn@klinikum-muenchen.de.
FAU - Agha, Ayman
AU  - Agha A
AD  - Department of General-, Abdominal-, Endocrine- and Minimally Invasive Surgery,
      Munchen Klinik Bogenhausen, Munchen, Germany.
FAU - Iesalnieks, Igors
AU  - Iesalnieks I
AD  - Department of General-, Abdominal-, Endocrine- and Minimally Invasive Surgery,
      Munchen Klinik Bogenhausen, Munchen, Germany.
FAU - Tiefes, Anna
AU  - Tiefes A
AD  - Department of General-, Abdominal-, Endocrine- and Minimally Invasive Surgery,
      Munchen Klinik Bogenhausen, Munchen, Germany.
FAU - Hochrein, Alfred
AU  - Hochrein A
AD  - OCM Clinic, Munich, Germany.
FAU - Friess, Helmut
AU  - Friess H
AD  - Department of Surgery, Technical University Munich Faculty of Medicine, Munchen, 
      Germany.
FAU - Wilhelm, Dirk
AU  - Wilhelm D
AD  - Department of Surgery, Technical University Munich Faculty of Medicine, Munchen, 
      Germany.
FAU - Schorn, Stephan
AU  - Schorn S
AD  - Department of Surgery, Technical University Munich Faculty of Medicine, Munchen, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Abscess/complications/surgery
MH  - *Colectomy
MH  - Colon
MH  - Conservative Treatment
MH  - *Diverticulitis/complications/surgery
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7780530
OTO - NOTNLM
OT  - *adult surgery
OT  - *colorectal surgery
OT  - *gastrointestinal infections
COIS- Competing interests: None declared.
EDAT- 2021/01/02 06:00
MHDA- 2021/03/27 06:00
CRDT- 2021/01/01 05:17
PHST- 2021/01/01 05:17 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-042350 [pii]
AID - 10.1136/bmjopen-2020-042350 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e042350. doi: 10.1136/bmjopen-2020-042350.


PMID- 33384394
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Searching for the erosion of empathy in medical undergraduate students: a
      longitudinal study.
PG  - e041810
LID - 10.1136/bmjopen-2020-041810 [doi]
AB  - OBJECTIVE: To analyse the trajectory of empathy throughout the degree programme
      of medicine in a Spanish school of medicine. DESIGN: Longitudinal, prospective
      5-year study, between October 2014 and June 2019. SETTING: Students from a
      Spanish university of medicine. PARTICIPANTS: Two voluntary cohorts of
      undergraduate medical students from two different school years were invited to
      participate (n=135 (cohort 1, C1) and 106 (cohort 2, C2) per school year).
      Finally, a total number of 174 students (102 (C1, 71.6% women) and 72 (C2, 70.8% 
      women) students, respectively) were monitored for 5 years. Each cohort was
      divided in two subcohorts of paired and unpaired students that were analysed to
      check possible social desirability bias. PRIMARY OUTCOME MEASURE: The Jefferson
      Scale of Empathy (JSE). RESULTS: The cohort of 102 students (C1) monitored
      between their first and fifth years of study (71.6% women) showed an improvement 
      among paired women of 2.15 points in total JSE score (p=0.01) and 2.39 points in 
      cognitive empathy (p=0.01); in the unpaired female cohort the increase was of
      2.32 points (cognitive empathy) (p=0.02). The cohort of 72 students (C2)
      monitored between their second and sixth years of study (70.8% women) displayed a
      cognitive empathy increase of 2.32 points (p=0.04) in the paired group of women. 
      There were no significant differences between paired and unpaired results for
      either cohort. Empathy scores among men did not decrease. CONCLUSIONS: The
      empathy of medical students at our school did not decline along grade years. In
      fact, it improved slightly, particularly cognitive empathy, among women. This
      paper contributes to enlarge data from Europe, where longitudinal studies are
      scarce. It supports the idea that there may be global geo-sociocultural
      differences; however, more studies comparing different school settings are
      needed.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Blanco, Jose Manuel
AU  - Blanco JM
AD  - School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
AD  - Valle de la Oliva Healthcare Centre, Madrid, Spain.
FAU - Caballero, Fernando
AU  - Caballero F
AD  - School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
FAU - Alvarez, Santiago
AU  - Alvarez S
AD  - School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.
FAU - Plans, Mercedes
AU  - Plans M
AD  - Valle de la Oliva Healthcare Centre, Madrid, Spain.
FAU - Monge, Diana
AU  - Monge D
AUID- ORCID: 0000-0002-3593-1820
AD  - School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
      d.monge@ufv.es.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Education, Medical, Undergraduate
MH  - *Empathy
MH  - Europe
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Prospective Studies
MH  - *Students, Medical/psychology
PMC - PMC7780525
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *ethics (see medical ethics)
OT  - *medical education & training
COIS- Competing interests: None declared.
EDAT- 2021/01/02 06:00
MHDA- 2021/03/27 06:00
CRDT- 2021/01/01 05:16
PHST- 2021/01/01 05:16 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-041810 [pii]
AID - 10.1136/bmjopen-2020-041810 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e041810. doi: 10.1136/bmjopen-2020-041810.


PMID- 33384393
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Impact of the COVID-19 pandemic on mental health and well-being of communities:
      an exploratory qualitative study protocol.
PG  - e041641
LID - 10.1136/bmjopen-2020-041641 [doi]
AB  - INTRODUCTION: The COVID-19 pandemic has certainly resulted in an increased level 
      of anxiety and fear in communities in terms of disease management and infection
      spread. Due to fear and social stigma linked with COVID-19, many individuals in
      the community hide their disease and do not access healthcare facilities in a
      timely manner. In addition, with the widespread use of social media, rumours,
      myths and inaccurate information about the virus are spreading rapidly, leading
      to intensified irritability, fearfulness, insomnia, oppositional behaviours and
      somatic complaints. Considering the relevance of all these factors, we aim to
      explore the perceptions and attitudes of community members towards COVID-19 and
      its impact on their daily lives and mental well-being. METHODS AND ANALYSIS: This
      formative research will employ an exploratory qualitative research design using
      semistructured interviews and a purposive sampling approach. The data collection 
      methods for this formative research will include indepth interviews with
      community members. The study will be conducted in the Karimabad Federal B Area
      and in the Garden (East and West) community settings in Karachi, Pakistan. The
      community members of these areas have been selected purposively for the
      interview. Study data will be analysed thematically using NVivo V.12 Plus
      software. ETHICS AND DISSEMINATION: Ethical approval for this study has been
      obtained from the Aga Khan University Ethical Review Committee (2020-4825-10599).
      The results of the study will be disseminated to the scientific community and to 
      the research subjects participating in the study. The findings will help us
      explore the perceptions and attitudes of different community members towards the 
      COVID-19 pandemic and its impact on their daily lives and mental well-being.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shahil Feroz, Anam
AU  - Shahil Feroz A
AUID- ORCID: 0000-0003-0180-0213
AD  - Community Health Sciences, Aga Khan University, Karachi, Pakistan
      anam.sahyl@gmail.com.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Akber Ali, Naureen
AU  - Akber Ali N
AD  - School of Nursing and Midwifery, Aga Khan University, Karachi, Pakistan.
FAU - Akber Ali, Noshaba
AU  - Akber Ali N
AD  - Community Health Sciences, Aga Khan University, Karachi, Pakistan.
FAU - Feroz, Ridah
AU  - Feroz R
AD  - Aga Khan University Institute for Educational Development, Karachi, Pakistan.
FAU - Nazim Meghani, Salima
AU  - Nazim Meghani S
AD  - Community Health Sciences, Aga Khan University, Karachi, Pakistan.
FAU - Saleem, Sarah
AU  - Saleem S
AD  - Community Health Sciences, Aga Khan University, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Anxiety/diagnosis/etiology
MH  - Attitude to Health
MH  - *COVID-19/epidemiology/prevention & control/psychology
MH  - Community Medicine/methods
MH  - Fear
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Health/statistics & numerical data/trends
MH  - Middle Aged
MH  - Pakistan/epidemiology
MH  - Population Surveillance
MH  - Qualitative Research
MH  - Research Design
MH  - SARS-CoV-2
MH  - Social Perception/*psychology
MH  - *Social Stigma
MH  - *Stress, Psychological/diagnosis/epidemiology/etiology/psychology
PMC - PMC7780420
OTO - NOTNLM
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2021/01/01 05:16
PHST- 2021/01/01 05:16 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - bmjopen-2020-041641 [pii]
AID - 10.1136/bmjopen-2020-041641 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e041641. doi: 10.1136/bmjopen-2020-041641.


PMID- 33384392
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Risk of infections and cardiovascular and venous thromboembolic events associated
      with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews 
      and network meta-analyses.
PG  - e041420
LID - 10.1136/bmjopen-2020-041420 [doi]
AB  - INTRODUCTION: Janus kinases (JAK) inhibitors demonstrated to be effective in the 
      treatment of adult patients with moderate-to-severe active rheumatoid arthritis
      (RA) but have been associated with serious cardiovascular and serious events. Two
      systematic reviews and network meta-analyses will be carried aiming to compare
      the relative safety of the different JAK inhibitors with regard to the risk of
      (1) cardiovascular and thromboembolic events and (2) serious infections in
      patients with RA. METHODS AND ANALYSIS: PUBMED, Embase, Cochrane Controlled
      Register of Trials and ClinicalTrials.gov will be searched in order to identify
      randomised controlled trials evaluating the efficacy and safety of JAK inhibitors
      in patients with RA. The following events will be assessed: (1) any
      cardiovascular event; major adverse cardiovascular events and venous
      thromboembolism and (2) any infection; serious infections; herpes zoster
      infection and tuberculosis. Search terms will comprise RA and drugs names,
      including the thesaurus terms and the International Nonproprietary Names. The
      assessment of the methodological quality of the included studies will be
      performed through the RoB 2 tool: a revised Cochrane risk of bias tool for
      randomised trials. Network meta-analyses will be performed using STATA V.13.0.
      For each outcome, treatments will be ranked according to the probability of being
      the safest (best) alternative using the surface under the cumulative ranking
      curve. ETHICS AND DISSEMINATION: Ethical approval is not required as no primary
      data are collected. This systematic review will be disseminated through
      peer-reviewed publications and at conference meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alves, Carlos
AU  - Alves C
AUID- ORCID: 0000-0002-2061-4718
AD  - Faculty of Pharmacy, Laboratory of Social Pharmacy and Public Health, University 
      of Coimbra, Coimbra, Portugal carlosmiguel.costaalves@gmail.com.
AD  - Coimbra Regional Pharmacovigilance Unit-UFC, Centre for Health Technology
      Assessment and Drug Research-CHAD, Association for Innovation and Biomedical
      Research on Light and Image-AIBILI, Coimbra, Portugal.
FAU - Penedones, Ana
AU  - Penedones A
AUID- ORCID: 0000-0002-2061-4718
AD  - Coimbra Regional Pharmacovigilance Unit-UFC, Centre for Health Technology
      Assessment and Drug Research-CHAD, Association for Innovation and Biomedical
      Research on Light and Image-AIBILI, Coimbra, Portugal.
FAU - Mendes, Diogo
AU  - Mendes D
AD  - Coimbra Regional Pharmacovigilance Unit-UFC, Centre for Health Technology
      Assessment and Drug Research-CHAD, Association for Innovation and Biomedical
      Research on Light and Image-AIBILI, Coimbra, Portugal.
FAU - Batel-Marques, Francisco
AU  - Batel-Marques F
AD  - Faculty of Pharmacy, Laboratory of Social Pharmacy and Public Health, University 
      of Coimbra, Coimbra, Portugal.
AD  - Coimbra Regional Pharmacovigilance Unit-UFC, Centre for Health Technology
      Assessment and Drug Research-CHAD, Association for Innovation and Biomedical
      Research on Light and Image-AIBILI, Coimbra, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Janus Kinase Inhibitors)
SB  - IM
MH  - Adult
MH  - *Arthritis, Rheumatoid/complications/drug therapy
MH  - Humans
MH  - *Janus Kinase Inhibitors/adverse effects
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
MH  - *Venous Thromboembolism
MH  - *Venous Thrombosis
PMC - PMC7780510
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *epidemiology
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2021/01/02 06:00
MHDA- 2021/03/27 06:00
CRDT- 2021/01/01 05:16
PHST- 2021/01/01 05:16 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-041420 [pii]
AID - 10.1136/bmjopen-2020-041420 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e041420. doi: 10.1136/bmjopen-2020-041420.


PMID- 33384390
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical 
      treatment of bladder cancer in a multicentre phase II randomised controlled trial
      (RAIDER): radiotherapy planning and delivery guidance.
PG  - e041005
LID - 10.1136/bmjopen-2020-041005 [doi]
AB  - INTRODUCTION: Daily radiotherapy delivered with radiosensitisation offers
      patients with muscle invasive bladder cancer (MIBC) comparable outcomes to
      cystectomy with functional organ preservation. Most recurrences following
      radiotherapy occur within the bladder. Increasing the delivered radiotherapy dose
      to the tumour may further improve local control. Developments in image-guided
      radiotherapy have allowed bladder tumour-focused 'plan of the day' radiotherapy
      delivery. We aim to test within a randomised multicentre phase II trial whether
      this technique will enable dose escalation with acceptable rates of toxicity.
      METHODS AND ANALYSIS: Patients with T2-T4aN0M0 unifocal MIBC will be randomised
      (1:1:2) between standard/control whole bladder single plan radiotherapy, standard
      dose adaptive tumour-focused radiotherapy or dose-escalated adaptive
      tumour-focused radiotherapy (DART). Adaptive tumour-focused radiotherapy will use
      a library of three plans (small, medium and large) for treatment. A cone beam CT 
      taken prior to each treatment will be used to visualise the anatomy and inform
      selection of the most appropriate plan for treatment.Two radiotherapy
      fractionation schedules (32f and 20f) are permitted. A minimum of 120
      participants will be randomised in each fractionation cohort (to ensure 57
      evaluable DART patients per cohort).A comprehensive radiotherapy quality
      assurance programme including pretrial and on-trial components is instituted to
      ensure standardisation of radiotherapy planning and delivery.The trial has a
      two-stage non-comparative design. The primary end point of stage I is the
      proportion of patients meeting predefined normal tissue constraints in the DART
      group. The primary end point of stage II is late Common Terminology Criteria for 
      Adverse Events grade 3 or worse toxicity aiming to exclude a rate of >20% (80%
      power and 5% alpha, one sided) in each DART fractionation cohort. Secondary end
      points include locoregional MIBC control, progression-free survival overall
      survival and patient-reported outcomes. ETHICS AND DISSEMINATION: This clinical
      trial is approved by the London-Surrey Borders Research Ethics Committee
      (15/LO/0539). The results when available will be disseminated via peer-reviewed
      scientific journals, conference presentations and submission to regulatory
      authorities. TRIAL REGISTRATION NUMBER: NCT02447549; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Hafeez, Shaista
AU  - Hafeez S
AUID- ORCID: 0000-0002-2057-0946
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
      shaista.hafeez@icr.ac.uk.
AD  - Radiotherapy Department, The Royal Marsden NHS Foundation Trust, London, UK.
FAU - Webster, Amanda
AU  - Webster A
AD  - National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon
      Hospital, Northwood, UK.
FAU - Hansen, Vibeke N
AU  - Hansen VN
AD  - Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark.
FAU - McNair, Helen A
AU  - McNair HA
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
AD  - Radiotherapy Department, The Royal Marsden NHS Foundation Trust, London, UK.
FAU - Warren-Oseni, Karole
AU  - Warren-Oseni K
AD  - Joint Department of Physics, The Institute of Cancer Research and The Royal
      Marsden NHS Foundation Trust, London, UK.
FAU - Patel, Emma
AU  - Patel E
AD  - National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon
      Hospital, Northwood, UK.
FAU - Choudhury, Ananya
AU  - Choudhury A
AD  - Division of Cancer Studies, The University of Manchester, Manchester, UK.
AD  - Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.
FAU - Creswell, Joanne
AU  - Creswell J
AD  - Department of Urology, James Cook University Hospital, Middlesbrough, UK.
FAU - Foroudi, Farshad
AU  - Foroudi F
AD  - Department of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia.
FAU - Henry, Ann
AU  - Henry A
AD  - Leeds Institute of Medical Research, University of Leeds, Leeds, West Yorkshire, 
      UK.
AD  - Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Kron, Tomas
AU  - Kron T
AD  - Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - McLaren, Duncan B
AU  - McLaren DB
AD  - Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
FAU - Mitra, Anita V
AU  - Mitra AV
AD  - Cancer Services, University College London Hospitals NHS Foundation Trust,
      London, UK.
FAU - Mostafid, Hugh
AU  - Mostafid H
AD  - The Stokes Centre for Urology, Royal Surrey Hospital NHS Foundation Trust,
      Guildford, Surrey, UK.
FAU - Saunders, Daniel
AU  - Saunders D
AD  - Department of Clinical Oncology, Nottingham University Hospitals NHS Trust,
      Nottingham, UK.
FAU - Miles, Elizabeth
AU  - Miles E
AD  - National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon
      Hospital, Northwood, UK.
FAU - Griffin, Clare
AU  - Griffin C
AD  - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London,
      UK.
FAU - Lewis, Rebecca
AU  - Lewis R
AD  - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London,
      UK.
FAU - Hall, Emma
AU  - Hall E
AD  - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London,
      UK.
FAU - Huddart, Robert
AU  - Huddart R
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
AD  - Radiotherapy Department, The Royal Marsden NHS Foundation Trust, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02447549
GR  - CRUK/14/016/CRUK_/Cancer Research UK/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cystectomy
MH  - Dose Fractionation, Radiation
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local/radiotherapy
MH  - Randomized Controlled Trials as Topic
MH  - *Urinary Bladder Neoplasms/radiotherapy/surgery
PMC - PMC7780718
OTO - NOTNLM
OT  - *clinical trials
OT  - *oncology
OT  - *radiotherapy
OT  - *urological tumours
COIS- Competing interests: SH reports non-financial support from Elekta (Elekta AB,
      Stockholm, Sweden), non-financial support from Merck Sharp & Dohme (MSD),
      personal fees and non-financial support from Roche outside the submitted work; AC
      reports grants from National Institute of Health Research Manchester Biomedical
      Research Centre, grants from Cancer Research, UK, grants from Medical Research
      Council, UK, grants from Prostate Cancer, UK, grants from Bayer, UK, personal
      fees from Janssen Pharmaceutical, non-financial support from ASCO, grants and
      non-financial support from Elekta AB, outside the submitted work; AH reports
      grants from CRUK, grants from MRC, grants from NIHR, outside the submitted work; 
      TK reports reports grants from Cancer Australia, during the conduct of the study;
      and his group has a research collaborative agreement with Varian Medical System
      not related to this project; EH reports grants from Cancer Research UK during the
      conduct of the study; grants from Accuray Inc., grants from Varian Medical
      Systems Inc., outside the submitted work; RH reports non-financial support from
      Janssen, grants and personal fees from MSD, personal fees from Bristol Myers
      Squibb, grants from Cancer Research UK, other from Nektar Therapeutics, personal 
      fees and non-financial support from Roche outside the submitted work.
EDAT- 2021/01/02 06:00
MHDA- 2021/03/27 06:00
CRDT- 2021/01/01 05:16
PHST- 2021/01/01 05:16 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-041005 [pii]
AID - 10.1136/bmjopen-2020-041005 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e041005. doi: 10.1136/bmjopen-2020-041005.


PMID- 33384389
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 31
TI  - Cost-effectiveness of prehabilitation prior to elective surgery compared to usual
      preoperative care: protocol for a systematic review of economic evaluations.
PG  - e040262
LID - 10.1136/bmjopen-2020-040262 [doi]
AB  - INTRODUCTION: Preoperative functional capacity is an important predictor of
      postoperative outcomes. Prehabilitation aims to optimise patients' functional
      capacity before surgery to improve postoperative outcomes. As prolonged hospital 
      stay and postoperative complications present an avoidable use of healthcare
      resources, prehabilitation might also save costs.The aim of this systematic
      review is to investigate the cost-effectiveness of prehabilitation programmes for
      patients awaiting elective surgery compared with usual preoperative care. The
      results will be useful to inform decisions about the implementation of
      prehabilitation programmes and the design of future economic evaluations of
      prehabilitation programmes. METHODS AND ANALYSIS: We will search PubMed, Embase, 
      the Centre for Reviews and Dissemination Database, the WHO International Clinical
      Trials Registry Platform and ClinicalTrials.gov for full or partial economic
      evaluations of preoperative prehabilitation programmes conducted in any
      population compared with usual preoperative care. Studies will be included
      regardless of the type, design and perspective of the economic evaluation, and
      their publication year, language or status. Initial searches were performed
      between 30 April and 4 May 2020.Study selection, data extraction and assessment
      of the included studies' risk of bias and methodological quality will initially
      be performed by two independent reviewers and, if agreement was sufficiently
      high, by one reviewer. We will extract data regarding the included studies' basic
      characteristics, economic evaluation methods and cost-effectiveness results.A
      narrative synthesis will be performed. The primary endpoint will be
      cost-effectiveness based on cost-utility analyses. We will discuss heterogeneity 
      between the studies and assess the risk of publication bias. The certainty of the
      evidence will be determined using the Grading of Recommendations, Assessment,
      Development and Evaluation approach. ETHICS AND DISSEMINATION: Ethics approval is
      not required as the systematic review will not involve human participants. We
      plan to present our findings at scientific conferences, pass them on to relevant 
      stakeholder organisations and publish them in a peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42020182813.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rombey, Tanja
AU  - Rombey T
AD  - Department of Health Care Management, Technische Universitat Berlin, Berlin,
      Berlin, Germany tanja.rombey@tu-berlin.de.
FAU - Eckhardt, Helene
AU  - Eckhardt H
AD  - Department of Health Care Management, Technische Universitat Berlin, Berlin,
      Berlin, Germany.
FAU - Quentin, Wilm
AU  - Quentin W
AD  - Department of Health Care Management, Technische Universitat Berlin, Berlin,
      Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201231
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Postoperative Complications/prevention & control
MH  - *Preoperative Care
MH  - *Preoperative Exercise
PMC - PMC7780539
OTO - NOTNLM
OT  - *health economics
OT  - *rehabilitation medicine
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2021/01/02 06:00
MHDA- 2021/03/18 06:00
CRDT- 2021/01/01 05:16
PHST- 2021/01/01 05:16 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040262 [pii]
AID - 10.1136/bmjopen-2020-040262 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 31;10(12):e040262. doi: 10.1136/bmjopen-2020-040262.


PMID- 33384319
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210930
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 12
DP  - 2020 Dec
TI  - Towards inclusionary and diversity-sensitive public health: the consequences of
      exclusionary othering in public health using the example of COVID-19 management
      in German reception centres and asylum camps.
LID - e003789 [pii]
LID - 10.1136/bmjgh-2020-003789 [doi]
AB  - The German government's response to the COVID-19 pandemic has been predominantly 
      considered wellfounded. Still, the practice of mass quarantine in reception
      centres and asylum camps has been criticised for its discrimination of refugees
      and asylum seekers. Building on the concept of othering, this article argues that
      processes of othering are structurally anchored in German asylum regulations and 
      they have further pervaded public health measures against COVID-19. The practice 
      of mass quarantine made the negative consequences of exclusionary othering for
      public health particularly noticeable. In the light of recent data indicating
      this measure to be epidemiologically, legally and ethically insufficient, we
      apply the concept of othering to public health and discuss (1) exclusionary, (2) 
      inclusionary and (3) diversity-sensitive approaches to public health. We finally 
      conclude that a shift of perspective from exclusion to inclusion, from
      subordination to empowerment and from silencing to participation is urgently
      required.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tallarek, Marie
AU  - Tallarek M
AUID- ORCID: 0000-0002-5349-7378
AD  - Department of Public Health, Brandenburg University of Technology
      Cottbus-Senftenberg, Senftenberg, Germany marie.tallarek@b-tu.de.
FAU - Bozorgmehr, Kayvan
AU  - Bozorgmehr K
AD  - Department of Population Medicine and Health Services Research, School of Public 
      Health, Bielefeld University, Bielefeld, Nordrhein-Westfalen, Germany.
AD  - Section for Health Equity Studies & Migration, Department of General Practice and
      Health Services Research, University Hospital Heidelberg, Heidelberg,
      Baden-Wurttemberg, Germany.
FAU - Spallek, Jacob
AU  - Spallek J
AD  - Department of Public Health, Brandenburg University of Technology
      Cottbus-Senftenberg, Senftenberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *COVID-19
MH  - Communicable Disease Control
MH  - Germany
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Public Health/*ethics
MH  - *Refugees
MH  - SARS-CoV-2
MH  - *Social Isolation
PMC - PMC7780422
OTO - NOTNLM
OT  - *SARS
OT  - *control strategies
OT  - *health policy
OT  - *prevention strategies
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/02 06:00
MHDA- 2021/01/12 06:00
CRDT- 2021/01/01 05:16
PHST- 2020/08/21 00:00 [received]
PHST- 2020/12/10 00:00 [revised]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2021/01/01 05:16 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - bmjgh-2020-003789 [pii]
AID - 10.1136/bmjgh-2020-003789 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Dec;5(12). pii: bmjgh-2020-003789. doi:
      10.1136/bmjgh-2020-003789.


PMID- 33383867
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Dec 29
TI  - Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?
LID - E186 [pii]
LID - 10.3390/ijerph18010186 [doi]
AB  - Biologic reference drugs and their copies, biosimilars, have a complex structure.
      Biosimilars need to demonstrate their biosimilarity during development but
      unpredictable variations can remain, such as micro-heterogeneity. The healthcare 
      community may raise questions regarding the clinical outcomes induced by this
      micro-heterogeneity. Indeed, unwanted immune reactions may be induced for
      numerous reasons, including product variations. However, it is challenging to
      assess these unwanted immune reactions because of the multiplicity of causes and 
      potential delays before any reaction. Moreover, safety assessments as part of
      preclinical studies and clinical trials may be of limited value with respect to
      immunogenicity assessments because they are performed on a standardised
      population during a limited period. Real-life data could therefore supplement the
      assessments of clinical trials by including data on the real-life use of
      biosimilars, such as switches. Furthermore, real-life data also include any
      economic incentives to prescribe or use biosimilars. This article raises the
      question of relevance of automating real life data processing regarding
      Biosimilars. The objective is to initiate a discussion about different approaches
      involving Machine Learning. So, the discussion is established regarding
      implementation of Neural Network model to ensure safety of biosimilars subject to
      economic incentives. Nevertheless, the application of Machine Learning in the
      healthcare field raises ethical, legal and technical issues that require further 
      discussion.
FAU - Perpoil, Antoine
AU  - Perpoil A
AD  - Compliance Department, Amgen SAS, 92100 Paris, France.
FAU - Grimandi, Gael
AU  - Grimandi G
AD  - Faculty of Pharmaceutical and Biological Sciences, University of Nantes, 44035
      Nantes, France.
AD  - University of Nantes, INSERM UMR1229, RMeS, Regenerative Medicine and Skeleton,
      ONIRIS, 44322 Nantes, France.
AD  - Central Pharmacy, University Public Hospitals of Nantes, 44093 Nantes, France.
FAU - Birkle, Stephane
AU  - Birkle S
AD  - Faculty of Pharmaceutical and Biological Sciences, University of Nantes, 44035
      Nantes, France.
AD  - Universite de Nantes, CRCINA, F-44000 Nantes, France.
FAU - Simonet, Jean-Francois
AU  - Simonet JF
AD  - Compliance Department, Amgen SAS, 92100 Paris, France.
FAU - Chiffoleau, Anne
AU  - Chiffoleau A
AD  - Sponsor Department, University Public Hospitals of Nantes, 44093 Nantes, France.
FAU - Bocquet, Francois
AU  - Bocquet F
AD  - Law and Social Change Laboratory, Faculty of Law and Political Sciences,
      University of Nantes, CNRS UMR6297, 44300 Nantes, France.
AD  - Oncology Data Factory and Analytics Department, Institut de Cancerologie de
      l'Ouest, 44800 Nantes-Angers, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201229
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Biosimilar Pharmaceuticals)
SB  - IM
MH  - Biosimilar Pharmaceuticals/*standards
MH  - Follow-Up Studies
MH  - Humans
MH  - Machine Learning
MH  - Neural Networks, Computer
MH  - *Public Health
PMC - PMC7796345
OTO - NOTNLM
OT  - *biosimilars
OT  - *economic incentives
OT  - *immunogenicity
OT  - *machine learning
OT  - *safety
EDAT- 2021/01/02 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/01/01 01:05
PHST- 2020/11/21 00:00 [received]
PHST- 2020/12/17 00:00 [revised]
PHST- 2020/12/19 00:00 [accepted]
PHST- 2021/01/01 01:05 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - ijerph18010186 [pii]
AID - 10.3390/ijerph18010186 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 29;18(1). pii: ijerph18010186. doi:
      10.3390/ijerph18010186.


PMID- 33383732
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Dec 29
TI  - Workshops as Tools for Developing Collaborative Practice across Professional
      Social Worlds in Telemonitoring.
LID - E181 [pii]
LID - 10.3390/ijerph18010181 [doi]
AB  - BACKGROUND: Lately, patients suffering from chronic obstructive pulmonary disease
      use telemonitoring services from home. We discuss three professional groups' idea
      of good care in terms of living as a chronically ill patient. METHODS: We
      scrutinize a workshop consisting of the following: (1) presentation of
      pre-workshop interviews focusing on good patient flows; (2) presentation of the
      participants' photos illustrating their idea of the good life with
      telemonitoring; (3) discussion of what the three social worlds of care can do
      together. We understand workshops as learning events founded on the symbolic
      interactionist idea of learning as reflexism. That is, the process where
      participants make joint action an object of attention. RESULTS: We propose that
      not only people, but also objects such as applications, gold standards, and
      financial arrangement are actively involved in hampering collaboration across
      social worlds. The contribution is a discussion of the contemporary challenges of
      technological intensification into healthcare processes seen as a learning event.
      CONCLUSION: Workshops constitute useful tools to understand more of how
      professional groups seek to adopt new technologies and learn about the larger
      structure of telemonitoring. Developing joint action among social worlds appears 
      to be one of the main challenges of technologically driven innovation in
      healthcare.
FAU - Nickelsen, Niels Christian Mossfeldt
AU  - Nickelsen NCM
AD  - School of Education, Aarhus University, 2400 NV Copenhagen, Denmark.
FAU - Bal, Roland
AU  - Bal R
AD  - Health Care Governance, Erasmus University, 3000 DR Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201229
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Denmark
MH  - Health Services
MH  - Humans
MH  - Monitoring, Physiologic/*methods
MH  - Nurses
MH  - Physicians
MH  - Pilot Projects
MH  - Pulmonary Disease, Chronic Obstructive/*diagnosis
MH  - *Telemedicine
PMC - PMC7795852
OTO - NOTNLM
OT  - *COPD
OT  - *care ethics
OT  - *collaborative practice
OT  - *joint action
OT  - *learning
OT  - *social world analysis
OT  - *telemonitoring
OT  - *workshops
EDAT- 2021/01/02 06:00
MHDA- 2021/02/24 06:00
CRDT- 2021/01/01 01:05
PHST- 2020/10/30 00:00 [received]
PHST- 2020/12/08 00:00 [revised]
PHST- 2020/12/22 00:00 [accepted]
PHST- 2021/01/01 01:05 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - ijerph18010181 [pii]
AID - 10.3390/ijerph18010181 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 29;18(1). pii: ijerph18010181. doi:
      10.3390/ijerph18010181.


PMID- 33382922
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1471-8847 (Electronic)
IS  - 1471-8731 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Dec
TI  - Access to mental health care - a profound ethical problem in the global south.
PG  - 174
LID - 10.1111/dewb.12300 [doi]
FAU - Schuklenk, Udo
AU  - Schuklenk U
LA  - eng
PT  - Editorial
PL  - England
TA  - Dev World Bioeth
JT  - Developing world bioethics
JID - 101120122
SB  - IM
MH  - Culture
MH  - Delivery of Health Care/*ethics
MH  - Developing Countries
MH  - *Global Health
MH  - Health Services Accessibility/*ethics
MH  - *Human Rights
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - *Mental Health
MH  - *Mental Health Services
MH  - Vulnerable Populations
EDAT- 2021/01/01 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/12/31 17:11
PHST- 2020/12/31 17:11 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - 10.1111/dewb.12300 [doi]
PST - ppublish
SO  - Dev World Bioeth. 2020 Dec;20(4):174. doi: 10.1111/dewb.12300.


PMID- 33382835
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Do people have an ethical obligation to share their health information? Comparing
      narratives of altruism and health information sharing in a nationally
      representative sample.
PG  - e0244767
LID - 10.1371/journal.pone.0244767 [doi]
AB  - BACKGROUND: With the emergence of new health information technologies, health
      information can be shared across networks, with or without patients' awareness
      and/or their consent. It is often argued that there can be an ethical obligation 
      to participate in biomedical research, motivated by altruism, particularly when
      risks are low. In this study, we explore whether altruism contributes to the
      belief that there is an ethical obligation to share information about one's
      health as well as how other health care experiences, perceptions, and concerns
      might be related to belief in such an obligation. METHODS: We conducted an online
      survey using the National Opinion Research Center's (NORC) probability-based,
      nationally representative sample of U.S. adults. Our final analytic sample
      included complete responses from 2069 participants. We used multivariable
      logistic regression to examine how altruism, together with other knowledge,
      attitudes, and experiences contribute to the belief in an ethical obligation to
      allow health information to be used for research. RESULTS: We find in
      multivariable regression that general altruism is associated with a higher
      likelihood of belief in an ethical obligation to allow one's health information
      to be used for research (OR = 1.22, SE = 0.14, p = 0.078). Trust in the health
      system and in care providers are both associated with a significantly higher
      likelihood of believing there is an ethical obligation to allow health
      information to be used (OR = 1.48, SE = 0.76, p<0.001; OR = 1.58, SE = 0.26,
      p<0.01, respectively). CONCLUSIONS: Belief that there is an ethical obligation to
      allow one's health information to be used for research is shaped by altruism and 
      by one's experience with, and perceptions of, health care and by general concerns
      about the use of personal information. Altruism cannot be assumed and researchers
      must recognize the ways encounters with the health care system influence
      (un)willingness to share one's health information.
FAU - Raj, Minakshi
AU  - Raj M
AUID- ORCID: 0000-0002-1457-7850
AD  - Department of Kinesiology and Community Health, University of Illinois at Urbana 
      Champaign, Champaign, IL, United States of America.
FAU - De Vries, Raymond
AU  - De Vries R
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann
      Arbor, MI, United States of America.
FAU - Nong, Paige
AU  - Nong P
AUID- ORCID: 0000-0002-2849-9005
AD  - Department of Health Management and Policy, University of Michigan School of
      Public Health, Ann Arbor, MI, United States of America.
FAU - Kardia, Sharon L R
AU  - Kardia SLR
AD  - Department of Epidemiology, University of Michigan School of Public Health, Ann
      Arbor, MI, United States of America.
FAU - Platt, Jodyn E
AU  - Platt JE
AD  - Department of Learning Health Sciences, University of Michigan Medical School,
      Ann Arbor, MI, United States of America.
LA  - eng
GR  - R01 CA214829/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201231
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Altruism
MH  - *Attitude
MH  - Female
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - Male
MH  - Middle Aged
MH  - *Moral Obligations
MH  - Motivation
MH  - Surveys and Questionnaires
MH  - Truth Disclosure/*ethics
PMC - PMC7774955
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/01 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/12/31 17:10
PHST- 2020/09/18 00:00 [received]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2020/12/31 17:10 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - 10.1371/journal.pone.0244767 [doi]
AID - PONE-D-20-29473 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 31;15(12):e0244767. doi: 10.1371/journal.pone.0244767.
      eCollection 2020.


PMID- 33382683
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210310
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Perspectives of Singaporean biomedical researchers and research support staff on 
      actual and ideal IRB review functions and characteristics: A quantitative
      analysis.
PG  - e0241783
LID - 10.1371/journal.pone.0241783 [doi]
AB  - BACKGROUND: Biomedical research is overseen by numerous Institutional Review
      Boards (IRBs) in Singapore but there has been no research that examines how the
      research review process is perceived by the local research community nor is there
      any systematic data on perceptions regarding the review process or other research
      ethics processes and IRB characteristics. The aim of this study was to ascertain 
      general views regarding the overall perceived value of ethics review processes;
      to measure perceptions about local IRB functions and characteristics; to identify
      IRB functions and characteristics viewed as important; and to compare these views
      with those of other international studies. METHODS: An online survey was used
      with the main component being the IRB-Researcher Assessment Tool (IRB-RAT), a
      validated tool, to evaluate perceptions of ideal and actual IRB functions and
      characteristics held by Singaporean researchers and research support staff. Data 
      were analysed descriptively first, with mean and SD of each item of IRB-RAT
      questionnaire reported, excluding the respondents whose answers were unknown or
      not applicable. The Wilcoxon Sign Rank test was used to compare the ideal and
      actual ratings of each IRB-RAT item, while the Mann-Whitney U test was used to
      compare the ratings of each IRB-RAT item between respondents with different
      characteristics. The Z-test was used to compare the mean ratings of our cohort
      with the mean ratings reported in the literature. The correlation between our
      mean ideal scores and those of two international studies also employing the
      IRB-RAT was examined. RESULTS: Seventy-one respondents completed the survey. This
      cohort generally held positive views of the impact of the ethics review process
      on: the quality of research; establishing and maintaining public trust in
      research; the protection of research participants; and on the scientific validity
      of research. The most important ideal IRB characteristics were timeliness,
      upholding participants' rights while also facilitating research, working with
      investigators to find solutions when there are disagreements, and not allowing
      biases to affect reviews. For almost all 45 IRB-RAT statements, the rating of the
      importance of the characteristic was higher than the rating of how much that
      characteristic was descriptive of IRBs the respondents were familiar with. There 
      was a significant strong correlation between our study's scores on the ideal IRB 
      characteristics and those of the first and largest published study that employed 
      the IRB-RAT, the US National Validation (USNV) sample in Keith-Spiegel et al.
      [19]. CONCLUSIONS: An understanding of the perceptions held by Singaporean
      researchers and research support staff on the value that the ethics review
      process adds, their perceptions of actual IRB functions and characteristics as
      well as what they view as central to high functioning IRBs is the first step to
      considering the aspects of the review process that might benefit from
      improvements. This study provides insight into how our cohort compares to others 
      internationally and highlights strengths and areas for improvement of Singapore
      IRBs as perceived by a small sample of the local research community. Such
      insights provide a springboard for additional research and may assist in further 
      enhancing good relations so that both are working towards the same end.
FAU - Labude, Markus K
AU  - Labude MK
AUID- ORCID: 0000-0002-5352-3986
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
FAU - Shen, Liang
AU  - Shen L
AD  - Biostatistics Unit, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore, Singapore.
FAU - Zhu, Yujia
AU  - Zhu Y
AUID- ORCID: 0000-0003-4388-6457
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
FAU - Schaefer, G Owen
AU  - Schaefer GO
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
FAU - Ong, Catherine
AU  - Ong C
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore, Singapore.
AD  - Division of Infectious Diseases, University Medicine Cluster, National University
      Health System, Singapore, Singapore.
FAU - Xafis, Vicki
AU  - Xafis V
AUID- ORCID: 0000-0002-5104-9686
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
LA  - eng
SI  - figshare/10.6084/m9.figshare.13093466
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201231
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EIN - PLoS One. 2021 Mar 10;16(3):e0248613. PMID: 33690709
MH  - Adult
MH  - Biomedical Research/*ethics
MH  - Ethics Committees, Research/*ethics
MH  - Ethics, Research
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Research Personnel/*psychology
MH  - Singapore
MH  - Social Perception/*psychology
MH  - Surveys and Questionnaires
PMC - PMC7774925
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/01 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/31 17:09
PHST- 2020/06/19 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/31 17:09 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1371/journal.pone.0241783 [doi]
AID - PONE-D-20-18824 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 31;15(12):e0241783. doi: 10.1371/journal.pone.0241783.
      eCollection 2020.


PMID- 33381691
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210101
IS  - 2536-4553 (Electronic)
IS  - 2536-4553 (Linking)
VI  - 7
IP  - 6
DP  - 2020
TI  - The urine foaming test in COVID-19 as a useful tool in diagnosis, prognosis and
      follow-up: Preliminary results.
PG  - 534-540
LID - 10.14744/nci.2020.42027 [doi]
AB  - OBJECTIVE: We aimed to develop a simple, rapid urine test based on the level of
      foaming that occurs in the urine sample due to the excretion of peptide
      structures containing amino acids specific to the antigenic structure of
      COVID-19. In this study, we present the preliminary results of the first clinical
      study with a newly developed urine foaming test (UFT). METHODS: This study was
      conducted in a tertiary hospital in Istanbul. After obtaining the approval of the
      ethics committee, urine samples were taken from three groups of patients whose
      informed consent was obtained. The groups were created according to the COVID-19 
      Diagnostic Guide of Ministry of Health: A: outpatients with suspected COVID-19,
      B: inpatients for follow-up and treatment, C: patients treated in intensive care 
      unit (ICU). Also, 30 healthy volunteers were included as the control group D.
      Urine samples taken from all groups were delivered to the laboratory. 2.5 ml
      urine sample was added to the test tube and shaken for 15 seconds and the level
      of foam formed was visually evaluated according to the color scale. Other data of
      the patients were obtained from the hospital information management system and
      the physician caring for the patient. The clinical status, PCR test results,
      computed tomography (CT), if any, laboratory tests, and UFT results were compared
      and the level of statistical significance was expressed as p</=0.05 in the 95%
      confidence intervals (CI). Performance characteristics, such as sensitivity,
      specificity, positive and negative predictive value of the UFT, were
      statistically calculated according to the RT-PCR result and/or CT. RESULTS: A
      statistically significant difference was observed between UFT distributions of
      the control, outpatient, inpatient and ICU patients (p=0.0001). The results of
      UFT orange and red in inpatients and ICU patients were statistically
      significantly higher than in the control and outpatient groups. The diagnostic
      accuracy of UFT was detected in all group, the pooled sensitivity was 92% (95%
      CI: 87-95%) and specificity was 89% (95% CI: 80-98%). CONCLUSION: Our preliminary
      results suggest that the UFT is useful, particularly in predicting the clinical
      severity of COVID-19. The UFT could be recommended as a point of care test, rapid
      and non-invasive method in the diagnosis and follow-up of COVID-19.
CI  - Copyright: (c) 2020 by Istanbul Northern Anatolian Association of Public
      Hospitals.
FAU - Kurtulmus, Mehmet Serhan
AU  - Kurtulmus MS
AD  - Department of Physical Therapy and Rehabilitation, Memorial Hospital Group,
      Istanbul, Turkey.
FAU - Kazezoglu, Cemal
AU  - Kazezoglu C
AD  - Department of Medical Biochemistry, University of Health Science, Kanuni Sultan
      Suleyman Training and Research Hospital, Istanbul, Turkey.
FAU - Cakiroglu, Busra
AU  - Cakiroglu B
AD  - Department of Infectious Diseases and Clinical Microbiology, University of Health
      Science, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.
FAU - Yilmaz, Habip
AU  - Yilmaz H
AD  - Specialist of Anesthesiology and Reanimation, TR Ministry of Health, Istanbul
      Provincial Health Directorate, Public Hospitals Services Presidency-3, Istanbul, 
      Turkey.
FAU - Guner, Abdullah Emre
AU  - Guner AE
AD  - Public Health Specialist, TR Ministry of Health, Istanbul Provincial Health
      Directorate, Head of Public Health Services, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - Turkey
TA  - North Clin Istanb
JT  - Northern clinics of Istanbul
JID - 101684520
PMC - PMC7754871
OTO - NOTNLM
OT  - COVID-19
OT  - prognostic predictive value
OT  - urine foaming test
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2021/01/01 06:00
MHDA- 2021/01/01 06:01
CRDT- 2020/12/31 05:27
PHST- 2020/11/03 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/31 05:27 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/01 06:01 [medline]
AID - 10.14744/nci.2020.42027 [doi]
AID - NCI-7-534 [pii]
PST - epublish
SO  - North Clin Istanb. 2020 Nov 30;7(6):534-540. doi: 10.14744/nci.2020.42027.
      eCollection 2020.


PMID- 33381649
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211212
IS  - 2688-4887 (Print)
IS  - 2380-193X (Linking)
VI  - 5
IP  - 4
DP  - 2020
TI  - Ethical Considerations of Fertility Preservation for Transmasculine and Nonbinary
      Youth.
PG  - 201-204
LID - 10.1089/trgh.2020.0004 [doi]
AB  - An increasing number of young adolescents who identify as transgender or
      nonbinary are presenting to the health care system for gender affirmation therapy
      before the full progression of puberty. Gender-affirming therapy may impair
      future fertility, but options exist for fertility preservation. This perspective 
      reviews these options for transmasculine and nonbinary youth, and explores
      related ethical considerations. The authors support the right of transgender and 
      nonbinary youth to utilize available reproductive technologies, provide
      recommendations for treating health professionals, and advocate for increased
      research efforts and tools to aid patient decision making.
CI  - Copyright 2020, Mary Ann Liebert, Inc., publishers.
FAU - Katabi, Leila J
AU  - Katabi LJ
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Ng, Henry H
AU  - Ng HH
AD  - Center for LGBT Health, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
AD  - Public Health and Science Department, Baldwin Wallace University, Berea, Ohio,
      USA.
FAU - Streed, Carl G Jr
AU  - Streed CG Jr
AD  - Department of Medicine, Boston University School of Medicine, Boston,
      Massachusetts, USA.
AD  - Center for Transgender Medicine and Surgery, Boston Medical Center, Boston,
      Massachusetts, USA.
FAU - Arora, Kavita S
AU  - Arora KS
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland,
      Ohio, USA.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - United States
TA  - Transgend Health
JT  - Transgender health
JID - 101691357
PMC - PMC7759263
OTO - NOTNLM
OT  - adolescents
OT  - ethics
OT  - fertility preservation
OT  - infertility
OT  - transgender
COIS- No competing financial interests exist.
EDAT- 2021/01/01 06:00
MHDA- 2021/01/01 06:01
CRDT- 2020/12/31 05:27
PHST- 2020/12/31 05:27 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/01 06:01 [medline]
AID - 10.1089/trgh.2020.0004 [doi]
AID - 10.1089/trgh.2020.0004 [pii]
PST - epublish
SO  - Transgend Health. 2020 Dec 11;5(4):201-204. doi: 10.1089/trgh.2020.0004.
      eCollection 2020.


PMID- 33380970
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1556-3316 (Print)
IS  - 1556-3316 (Linking)
VI  - 16
IP  - Suppl 2
DP  - 2020 Dec
TI  - The Clavicle Continues to Grow During Adolescence and Early Adulthood.
PG  - 372-377
LID - 10.1007/s11420-020-09754-8 [doi]
AB  - BACKGROUND: As more adults undergo surgical fixation of clavicle fractures with
      improved outcomes, interest is renewed in managing clavicle fractures in
      adolescents. The medial clavicular physis does not fuse until 23 to 25 years of
      age, but studies report minimal clavicular growth during adolescence-studies that
      employed cross-sectional methodologies, which cannot not capture growth in
      patients over time. The assumption that clavicle length at each stage is uniform,
      as is the final overall length, may not be accurate if the age groups studied
      comprise various ethnicities, socioeconomic status, or height.
      QUESTIONS/PURPOSES: We sought to quantify longitudinal clavicular growth on
      serial radiographs in adolescents and young adults. Our hypothesis was that
      substantial clavicular growth would be seen beyond the age of 12 years. METHODS: 
      We conducted a longitudinal case series of non-syndromic patients in a single
      orthopedic clinic and analyzed serial radiographic images of the clavicles. For
      ethical reasons, only patients with non-neuromuscular scoliosis and kyphosis (in 
      whom the existing standard of care includes serial thoracic radiographs) were
      considered for inclusion. Patients ages 10 to 25 years old were included in the
      study if three or more serial thoracic radiographs over a minimum 5 years were
      available that captured the entire length of at least one non-rotated clavicle.
      Three types of radiographs were included for analysis: digital low-dose-radiation
      stereoradiographic (EOS Imaging, Paris, France), non-EOS digital, and non-EOS
      printed. The overall longitudinal growth, yearly growth, and the yearly growth
      percentage were calculated for each clavicle. RESULTS: Fifty-seven patients (22
      male and 35 female) met the inclusion criteria. In male patients, at ages 12 to
      15 years, the clavicular growth was 4.9 mm/year, or 4%/year; at ages 16 to 19
      years, growth was 3.2 mm/year, or 2.4%/year; and at ages 20 to 25 years, growth
      was 1.7 mm/year, or 1.1%/year. In female patients, at ages 12 to 15 years, growth
      was 4.7 mm/year, or 4%/year; at 16 to 19 years, growth was 2.2 mm/year, or
      1.7%/year; and at ages 20 to 25 years, growth was 0.2 mm/year or 0.1%/year. We
      could not detect the age of terminal growth in either sex because growth was
      ongoing in most patients in the oldest group. CONCLUSION: We found substantial
      clavicular growth potential after age 18 years, when growth is thought to be
      nearly finished, as well as remodeling potential even up to age 25 years. Further
      research is needed, but our findings suggest that strategies for managing
      clavicle fracture in adults may not be applied universally to adolescents and
      young adults.
CI  - (c) Hospital for Special Surgery 2020.
FAU - Hughes, Jessica L
AU  - Hughes JL
AD  - Baylor Scott & White Medical Center, Temple, TX USA.grid.508013.f
FAU - Newton, Peter O
AU  - Newton PO
AD  - Rady Children's Hospital-San Diego, MD 3020 Children's Way, MC 5062, San Diego,
      CA 92123 USA.grid.286440.c0000 0004 0383 2910
AD  - University of California San Diego, San Diego, CA USA.grid.266100.30000 0001 2107
      4242
FAU - Bastrom, Tracey
AU  - Bastrom T
AD  - Rady Children's Hospital-San Diego, MD 3020 Children's Way, MC 5062, San Diego,
      CA 92123 USA.grid.286440.c0000 0004 0383 2910
FAU - Fabricant, Peter D
AU  - Fabricant PD
AD  - Hospital for Special Surgery, New York, NY USA.grid.239915.50000 0001 2285 8823
FAU - Pennock, Andrew T
AU  - Pennock AT
AUID- ORCID: https://orcid.org/0000-0002-8628-5603
AD  - Rady Children's Hospital-San Diego, MD 3020 Children's Way, MC 5062, San Diego,
      CA 92123 USA.grid.286440.c0000 0004 0383 2910
AD  - University of California San Diego, San Diego, CA USA.grid.266100.30000 0001 2107
      4242
LA  - eng
PT  - Journal Article
DEP - 20200426
PL  - United States
TA  - HSS J
JT  - HSS journal : the musculoskeletal journal of Hospital for Special Surgery
JID - 101273938
PMC - PMC7749897
OTO - NOTNLM
OT  - adolescents
OT  - clavicle
OT  - fracture
OT  - remodeling
OT  - trauma
COIS- Conflict of InterestTracey Bastrom, MS, declares no conflicts of interest.
      Jessica L. Hughes, MD, reports personal fees or other material support from Depuy
      Synthes, Medical Device Business Services, Axogen, Stryker, Globus Medical, and
      Sanofi-Aventis, outside the submitted work. Peter O. Newton, MD, reports personal
      fees or other material support from Nuvasive, Zimmer Biomet, K2M, Medtronic USA, 
      Merck Sharp & Dohme Corp., Globus Medical, Ethicon, and Depuy Synthes, outside
      the submitted work. Peter D. Fabricant, MD, MPH, reports personal fees or other
      material or nonfinancial support from Smith & Nephew, Medical Device Business
      Services, and Arthrex, and personal fees and board membership from Clinical
      Orthopedics and Related Research, Pediatric Orthopedic Society of North America, 
      Pediatric Research in Sports Medicine Society, and Research in OsteoChondritis of
      the Knee (ROCK), outside the submitted work. Andrew T. Pennock, MD, reports
      personal fees or other material support from Stryker, Sportstek Medical,
      Orthopediatrics, Smith & Nephew; personal fees and board membership from American
      Orthopedic Society for Sports Medicine and Pediatric Orthopedic Society of North 
      America; and stock or stock options from Imagen, outside the submitted work.
EDAT- 2021/01/01 06:00
MHDA- 2021/01/01 06:01
CRDT- 2020/12/31 05:24
PHST- 2019/08/06 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/12/31 05:24 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/01 06:01 [medline]
AID - 10.1007/s11420-020-09754-8 [doi]
AID - 9754 [pii]
PST - ppublish
SO  - HSS J. 2020 Dec;16(Suppl 2):372-377. doi: 10.1007/s11420-020-09754-8. Epub 2020
      Apr 26.


PMID- 33380909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211102
IS  - 1535-2188 (Print)
IS  - 1535-2188 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Nov
TI  - Facial Transplantation: Complications, Outcomes, and Long-Term Management
      Strategies.
PG  - 245-253
LID - 10.1055/s-0040-1721760 [doi]
AB  - Within the past two decades, vascularized facial composite allotransplantation
      has evolved into a viable option in the reconstructive surgeons' armamentarium
      for patients with extensive facial disfigurements. As it has expanded the
      frontiers of microsurgical reconstructive techniques, facial transplantation has 
      come to garner widespread interest within both the medical community and the
      general public. The procedure has established itself as an amalgamation of the
      forefronts of reconstructive microsurgery, immunology, and transplantation
      science. Therein too lies its complexity as multifaceted scientific developments 
      are met with ethical and social issues. Both patients and physicians are faced
      with the everlasting challenges of immunosuppression regimens and their inherent 
      complications, long-term aesthetic and functional considerations, the role of
      revision procedures, and the inevitable psychosocial implications. This article
      reflects on the medical and surgical advancements in facial transplantation
      surgery and highlights anticipated future challenges. It aims to encourage
      discussion regarding anticipated barriers to current practice and suggest future 
      directions as we transition into the next phase of facial allograft
      transplantation.
CI  - Thieme. All rights reserved.
FAU - Shokri, Tom
AU  - Shokri T
AD  - Otolaryngology and Facial Plastic Surgery Associates, Fort Worth, Texas.
FAU - Saadi, Robert
AU  - Saadi R
AD  - Department of Otolaryngology - Head & Neck Surgery, Penn State Health, Hershey,
      Pennsylvania.
FAU - Wang, Weitao
AU  - Wang W
AD  - Otolaryngology and Facial Plastic Surgery Associates, Fort Worth, Texas.
FAU - Reddy, Likith
AU  - Reddy L
AD  - Department of Oral and Maxillofacial Surgery, Texas A&M College of Dentistry,
      Dallas, Texas.
FAU - Ducic, Yadranko
AU  - Ducic Y
AD  - Otolaryngology and Facial Plastic Surgery Associates, Fort Worth, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201224
PL  - United States
TA  - Semin Plast Surg
JT  - Seminars in plastic surgery
JID - 101131275
PMC - PMC7759434
OTO - NOTNLM
OT  - composite tissue allotransplantation
OT  - ethics
OT  - facial transplantation
OT  - immunosuppression
OT  - microvascular surgery
COIS- Conflict of Interest None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/01/01 06:01
CRDT- 2020/12/31 05:24
PHST- 2020/12/31 05:24 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/01 06:01 [medline]
AID - 10.1055/s-0040-1721760 [doi]
AID - 01270 [pii]
PST - ppublish
SO  - Semin Plast Surg. 2020 Nov;34(4):245-253. doi: 10.1055/s-0040-1721760. Epub 2020 
      Dec 24.


PMID- 33380585
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - A randomized single-blinded, parallel-arm group feasibility trial evaluating role
      of pectoral nerve block on serum vascular endothelial growth factor levels in
      patients undergoing unilateral modified radical mastectomy.
PG  - 179-184
LID - 10.4103/2045-9912.299465 [doi]
AB  - Metastatic breast cancer cells carry adult and neonatal variants of NaV1.5
      voltage-gated activated Na(+) channels involved in cell invasion. We hypothesize 
      that instilling lignocaine near the surgical field to anesthetize the pectoral
      nerves for analgesia will decrease angiogenesis by blocking voltage-gated
      activated Na(+) channels. Twenty patients undergoing unilateral modified radical 
      mastectomy were randomized in a single-blinded, parallel-arm group feasibility
      pilot study in two groups. In Group I a catheter was placed between the
      pectoralis major and minor muscle under direct vision before skin closure. Ten
      milliliters of 2% lignocaine was given as an initial bolus followed by 10 mL of
      2% lignocaine every 8 hours up to 24 hours. Group II did not receive any regional
      block. Primary measure outcomes were pre and postoperative changes in levels of
      vascular endothelial growth factor. Secondary outcomes were postoperative pain
      scores and total rescue analgesia used. Nine patients in each group were
      analyzed. Baseline demographic data of all females were similar with respect to
      age, body mass, height and duration of anesthesia. Postoperative mean serum
      levels of vascular endothelial growth factor were decreased by 46.60% from
      baseline in Group I, while were increased by 84.27% as compared to preoperative
      values in Group II. Postoperative average pain scores were less in Group I.
      Postoperative rescue analgesia in 24 hours in Group I was lower than that in
      Group II. There was no postoperative adverse event related to catheter or
      lignocaine administration at given doses. Instilling lignocaine to block pectoral
      nerves provides better postoperative analgesia and decreases a marker of
      angiogenesis. The study protocol was approved by the Institutional Ethical
      Committee of the Tertiary Centre (All India Institute of Medical Sciences
      Rishikesh India) (No. AIIMS/IEC/19/1002) on August 9, 2019, and the larger
      expansion trial was prospectively registered on Clinical Trial Registry India
      (No. CTRI/2020/01/022784) on January 15, 2020.
FAU - Govil, Nishith
AU  - Govil N
AD  - Department of Anaesthesiology, Shri Guru Ram Rai Institute of Medical & Health
      Sciences, Dehradun, India.
FAU - Naithani, Manisha
AU  - Naithani M
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh,
      India.
FAU - Ravi, Bina
AU  - Ravi B
AD  - Department of Breast Cancer Surgery, All India Institute of Medical Sciences,
      Rishikesh, India.
FAU - Sharda, Prateek
AU  - Sharda P
AD  - Department of Surgery, All India Institute of Medical Sciences, Rishikesh, India.
FAU - Tripathi, Mukesh
AU  - Tripathi M
AD  - All India Institute of Medical Sciences, Mangalagiri, India.
FAU - Bhardwaj, Bharat Bhushan
AU  - Bhardwaj BB
AD  - Department of Emergency Medicine, All India Institute of Medical Sciences,
      Rishikesh, India.
LA  - eng
SI  - CTRI/CTRI/2020/01/022784
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adult
MH  - Breast Neoplasms/blood/surgery
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - *Mastectomy
MH  - Middle Aged
MH  - Nerve Block/*methods
MH  - Thoracic Nerves/*surgery
MH  - Vascular Endothelial Growth Factor A/*blood
PMC - PMC8092146
OTO - NOTNLM
OT  - *analgesia
OT  - *angiogenesis
OT  - *lignocaine
OT  - *modified radical mastectomy
OT  - *nerve block
OT  - *pectoral nerve
OT  - *vascular endothelial growth factor
OT  - *voltage-gated sodium channel
COIS- None
EDAT- 2021/01/01 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/31 05:20
PHST- 2020/12/31 05:20 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - MedGasRes_2020_10_4_179_300911 [pii]
AID - 10.4103/2045-9912.299465 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Oct-Dec;10(4):179-184. doi: 10.4103/2045-9912.299465.


PMID- 33380584
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210507
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Role of methemoglobin and carboxyhemoglobin levels in predicting COVID-19
      prognosis: an observational study.
PG  - 174-178
LID - 10.4103/2045-9912.304224 [doi]
AB  - World Health Organization has declared coronavirus disease-19 (COVID-19) as a
      pandemic. Although there are studies about this novel virus, our knowledge is
      still limited. There is limited information about its diagnosis, treatment and
      prognosis. We aimed to investigate the effect of methemoglobin and
      carboxyhemoglobin levels on the prognosis of COVID-19. In this observational
      study, patients who were diagnosed with COVID-19 during March 1-April 31, 2020 in
      a secondary-level state hospital in Turkey were included in the study. COVID-19
      diagnosis was confirmed with reverse transcription polymerase chain reaction
      method, with nasal, oral or sputum specimens. During the period this study was
      performed, 3075 patients were tested for COVID-19 and 573 of them were
      hospitalized. Among the hospitalised patients, 23.2% (133) of them had a positive
      polymerase chain reaction result for COVID-19. A total of 125 patients, 66
      (52.8%) males and 59 (47.2%) females, with an average age of 50.2 +/- 19.8 years,
      were included in the study. The most common findings in chest radiogram were
      ground-glass areas and consolidations, while one-third of the patients had a
      normal chest radiogram. Computed thorax tomography was performed for 77.6%
      (97/125) of the patients. The 24.7% of computed tomographies (24/97) did not
      reveal any pathological findings, and the most common findings were ground-glass 
      appearance and consolidation. Those who needed intensive care had statistically
      significantly lower platelet count (P = 0.011) and higher lactate dehydrogenase
      levels (P < 0.001). No statistically significant difference was found in
      carboxyhemoglobin (P = 0.395) and methemoglobin (P = 1.000) levels. We found that
      carboxyhemoglobin and methemoglobin levels had no effect on COVID-19 prognosis,
      but low platelet level played a role in predicting COVID-19 prognosis. This study
      was approved by the Ethical Committee of Harran University Faculty of Medicine on
      May 11, 2020 with approval No. 09.
FAU - Oktem, Begum
AU  - Oktem B
AD  - Department of Emergency Medicine, Kastamonu State Hospital, Kastamonu, Turkey.
FAU - Uzer, Fatih
AU  - Uzer F
AD  - Department of Pulmonology, Kastamonu State Hospital, Kastamonu, Turkey.
FAU - Kukul Guven, Fatma Mutlu
AU  - Kukul Guven FM
AD  - Department of Emergency Medicine, Kastamonu State Hospital, Kastamonu, Turkey.
FAU - Kirhan, Idris
AU  - Kirhan I
AD  - Department of Internal Medicine, Harran University Faculty of Medicine,
      Sanliurfa, Turkey.
FAU - Topal, Mehmet
AU  - Topal M
AD  - Department of Biostatistics, Kastamonu University Faculty of Medicine, Kastamonu,
      Turkey.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Biomarkers)
RN  - 9008-37-1 (Methemoglobin)
RN  - 9061-29-4 (Carboxyhemoglobin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - COVID-19/*blood/*diagnostic imaging/epidemiology
MH  - Carboxyhemoglobin/*metabolism
MH  - Female
MH  - Hospitalization/trends
MH  - Humans
MH  - Male
MH  - Methemoglobin/*metabolism
MH  - Middle Aged
MH  - Platelet Count/methods
MH  - Predictive Value of Tests
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Turkey/epidemiology
PMC - PMC8092149
OTO - NOTNLM
OT  - *COVID-19
OT  - *carboxyhemoglobin
OT  - *methemoglobin
OT  - *pandemic
OT  - *prognosis
COIS- None
EDAT- 2021/01/01 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/12/31 05:20
PHST- 2020/12/31 05:20 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - MedGasRes_2020_10_4_174_304224 [pii]
AID - 10.4103/2045-9912.304224 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Oct-Dec;10(4):174-178. doi: 10.4103/2045-9912.304224.


PMID- 33380582
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Two-week continuous supplementation of hydrogenrich water increases peak oxygen
      uptake during an incremental cycling exercise test in healthy humans: a
      randomized, single-blinded, placebo-controlled study.
PG  - 163-169
LID - 10.4103/2045-9912.304223 [doi]
AB  - The various beneficial effects of the intake of molecular hydrogen (H2) have been
      demonstrated in the field of sports science. Although supplementation of H2 has
      been reported to increase mitochondrial metabolism in animal studies, the effects
      of the administration of H2 on aerobic capacity during exercise in humans are
      still not clear. We investigated whether a single or 2-week continuous intake of 
      H2-rich water (HW) enhanced the aerobic capacity during incremental exercise in
      healthy humans. In this randomized, single-blinded, placebo-controlled
      experimental study, the participants performed an incremental cycling exercise to
      measure peak oxygen uptake and peak load before and after a single (500 mL) or a 
      2-week supplementation (total 5 L) of HW. In the latter experiment, the
      participants drank the 500 mL of HW on all weekdays (i.e., 10 times). The single 
      intake of HW did not significantly increase peak oxygen uptake and peak load, and
      did not significantly alter the responses in oxidative stress, antioxidant
      activity, and lactate levels. However, importantly, the 2-week continuous
      consumption of HW significantly augmented peak oxygen uptake and tended to
      increase the peak load without any significant changes in lactate levels,
      oxidative stress, and antioxidant responses. In conclusion, the continuous
      supplementation of HW potentially augments the aerobic capacity, implying that
      continuous supplementation of H2 might help improve aerobic exercise performance 
      and physical health. This study protocol was approved by the Ethical Committee of
      Chubu University (approval No. 260086-2) on March 29, 2018.
FAU - Hori, Amane
AU  - Hori A
AD  - Graduate School of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Sobue, Sayaka
AU  - Sobue S
AD  - College of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Kurokawa, Ryosuke
AU  - Kurokawa R
AD  - MiZ Company Limited, Kamakura, Japan.
FAU - Hirano, Shin-Ichi
AU  - Hirano SI
AD  - MiZ Company Limited, Kamakura, Japan.
FAU - Ichihara, Masatoshi
AU  - Ichihara M
AD  - Graduate School of Life and Health Sciences; College of Life and Health Sciences,
      Chubu University, Kasugai, Japan.
FAU - Hotta, Norio
AU  - Hotta N
AD  - Graduate School of Life and Health Sciences; College of Life and Health Sciences,
      Chubu University, Kasugai, Japan.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Placebos)
RN  - 059QF0KO0R (Water)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Adult
MH  - Bicycling/*physiology
MH  - Biological Transport/drug effects
MH  - Double-Blind Method
MH  - *Exercise
MH  - Healthy Volunteers
MH  - Humans
MH  - Hydrogen/*analysis
MH  - Male
MH  - Oxygen/*metabolism
MH  - Placebos
MH  - Water/*chemistry/*pharmacology
MH  - Young Adult
PMC - PMC8092150
OTO - NOTNLM
OT  - *aerobic capacity
OT  - *antioxidant activity
OT  - *blood lactate
OT  - *mitochondrial metabolism
OT  - *molecular hydrogen
OT  - *oxidative phosphorylation
OT  - *oxidative stress
OT  - *reactive oxygen species
COIS- None
EDAT- 2021/01/01 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/31 05:20
PHST- 2020/12/31 05:20 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - MedGasRes_2020_10_4_163_304223 [pii]
AID - 10.4103/2045-9912.304223 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Oct-Dec;10(4):163-169. doi: 10.4103/2045-9912.304223.


PMID- 33380581
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Impact of hydrogen-rich gas mixture inhalation through nasal cannula during
      post-exercise recovery period on subsequent oxidative stress, muscle damage, and 
      exercise performances in men.
PG  - 155-162
LID - 10.4103/2045-9912.304222 [doi]
AB  - Molecular hydrogen has been suggested to have a cytoprotective effect on the
      whole body and to enhance exercise performances. However, the effect of
      hydrogen-rich gas mixture (HG) inhalation on physiological responses has been
      poorly investigated. We examined the impact of acute HG inhalation on subsequent 
      oxidative stress, muscle damage, and exercise performances during the recovery
      period after a strenuous exercise. This is a two-trial, double-blind, crossover, 
      repeated measures study. Eight physically active male volunteers inhaled HG
      (estimated fraction of inspired oxygen and hydrogen were 21.57 and 4.08% at most,
      respectively) or normal gas (placebo, ambient air 400 m above sea level) during a
      60-minute recovery phase after oxidative stress-inducing exercise) completion
      comprising 30-minute treadmill running at an intensity corresponding to 75% of
      maximal oxygen uptake and squat jumps (5 sets x 10 repetitions). Before oxidative
      stress-inducing exercise and 10 minutes after the post-exercise gas inhalation,
      blood and urine samples were obtained and exercise performances (jumping ability;
      pedaling power output; muscle strength) were evaluated. Post-exercise HG
      inhalation attenuated the increase in urinary 8-hydroxydeoxyguanosine excretion
      rate (P < 0.05), a DNA oxidation marker, and the reduction in the countermovement
      jump height (P < 0.05), compared with Placebo inhalation. Other exercise
      performances and blood oxidative stress and muscle damage markers did not differ 
      between HG and Placebo inhalation. Moreover, the increase in urinary
      8-hydroxydeoxyguanosine excretion rate was significantly associated with
      countermovement jump performance reduction (r = -0.78, P < 0.01). These findings 
      suggested that HG inhalation during post-exercise recovery period might improve
      exercise performance via reducing systemic oxidative damage. The study was
      approved by the Human Research Ethics Committee of the University of Yamanashi
      (approval No. H29-006) on June 28, 2017.
FAU - Shibayama, Yudai
AU  - Shibayama Y
AD  - Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences,
      University of Yamanashi, Yamanashi, Japan.
FAU - Dobashi, Shohei
AU  - Dobashi S
AD  - Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences,
      University of Yamanashi, Yamanashi; Institute of Health and Sports Science &
      Medicine, Juntendo University, Chiba, Japan.
FAU - Arisawa, Takaaki
AU  - Arisawa T
AD  - Helix Japan Co., Ltd., Tokyo, Japan.
FAU - Fukuoka, Tamotsu
AU  - Fukuoka T
AD  - Helix Japan Co., Ltd., Tokyo, Japan.
FAU - Koyama, Katsuhiro
AU  - Koyama K
AD  - Graduate School Department of Interdisciplinary Research, University of
      Yamanashi, Yamanashi, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 7YNJ3PO35Z (Hydrogen)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Exercise/*physiology
MH  - Humans
MH  - Hydrogen/*administration & dosage/*pharmacology
MH  - Male
MH  - Muscle Strength
MH  - Muscles/*drug effects/physiology
MH  - *Nose
MH  - Oxidative Stress/*drug effects
PMC - PMC8092152
OTO - NOTNLM
OT  - *8-hydroxydeoxyguanosine
OT  - *endurance running
OT  - *inhalation
OT  - *molecular hydrogen
OT  - *muscle fatigue
OT  - *oxidative stress
OT  - *sprint cycling
OT  - *squat jumps
EDAT- 2021/01/01 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/31 05:20
PHST- 2020/12/31 05:20 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - MedGasRes_2020_10_4_155_304222 [pii]
AID - 10.4103/2045-9912.304222 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Oct-Dec;10(4):155-162. doi: 10.4103/2045-9912.304222.


PMID- 33380580
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Two weeks of hydrogen inhalation can significantly reverse adaptive and innate
      immune system senescence patients with advanced non-small cell lung cancer: a
      self-controlled study.
PG  - 149-154
LID - 10.4103/2045-9912.304221 [doi]
AB  - Following standard treatments, the traditional model for enhancing anti-tumor
      immunity involves performing immune reconstitution (e.g., adoptive immune cell
      therapies or immunoenhancing drugs) to prevent recurrence. For patients with
      advanced non-small cell lung cancer, we report here on two objectives, the
      immunosenescence for advanced non-small cell lung cancer and hydrogen gas
      inhalation for immune reconstitution. From July 1(st) to September 25(th), 2019, 
      20 non-small cell lung cancer patients were enrolled to evaluate the
      immunosenescence of peripheral blood lymphocyte subsets, including T cell,
      natural killer/natural killer T cell and gamma delta T cell. Two weeks of
      hydrogen inhalation was performed during the waiting period for treatment-related
      examination. All patients inhaled a mixture of hydrogen (66.7%) and oxygen
      (33.3%) with a gas flow rate of 3 L/min for 4 hours each day. None of the
      patients received any standard treatment during the hydrogen inhalation period.
      After pretreatment testing, major indexes of immunosenescence were observed. The 
      abnormally higher indexes included exhausted cytotoxic T cells, senescent
      cytotoxic T cells, and killer Vdelta1 cells. After 2 weeks of hydrogen therapy,
      the number of exhausted and senescent cytotoxic T cells decreased to within the
      normal range, and there was an increase in killer Vdelta1 cells. The abnormally
      lower indexes included functional helper and cytotoxic T cells, Th1, total
      natural killer T cells, natural killer, and Vdelta2 cells. After 2 weeks of
      hydrogen therapy, all six cell subsets increased to within the normal range. The 
      current data indicate that the immunosenescence of advanced non-small cell lung
      cancer involves nearly all lymphocyte subsets, and 2 weeks of hydrogen treatment 
      can significantly improve most of these indexes. The study was approved by the
      Ethics Committee of Fuda Cancer Hospital, Jinan University in China (approval No.
      Fuda20181207) on December 7(th), 2018, and was registered on ClinicalTrials.gov
      (ID: NCT03818347) on January 24(th), 2019.
FAU - Chen, Ji-Bing
AU  - Chen JB
AD  - Fuda Cancer Hospital of Jinan University; Fuda Cancer Institute, Guangzhou,
      Guangdong Province, China.
FAU - Kong, Xiao-Feng
AU  - Kong XF
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
FAU - Qian, Wei
AU  - Qian W
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
FAU - Mu, Feng
AU  - Mu F
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
FAU - Lu, Tian-Yu
AU  - Lu TY
AD  - Fuda Cancer Hospital of Jinan University; Fuda Cancer Institute, Guangzhou,
      Guangdong Province, China.
FAU - Lu, You-Yong
AU  - Lu YY
AD  - Central Laboratory, Peking University Cancer Hospital, Beijing, China.
FAU - Xu, Ke-Cheng
AU  - Xu KC
AD  - Fuda Cancer Hospital of Jinan University; Fuda Cancer Institute, Guangzhou,
      Guangdong Province, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03818347
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 7YNJ3PO35Z (Hydrogen)
SB  - IM
MH  - Adaptive Immunity/*drug effects
MH  - Administration, Inhalation
MH  - Carcinoma, Non-Small-Cell Lung/*immunology/pathology
MH  - Female
MH  - Humans
MH  - Hydrogen/*administration & dosage/*pharmacology
MH  - Immunity, Innate/*drug effects
MH  - Lung Neoplasms/*immunology/pathology
MH  - Male
MH  - Middle Aged
PMC - PMC8092147
OTO - NOTNLM
OT  - *T cell
OT  - *adaptive and innate immune system
OT  - *gamma delta T cell
OT  - *hydrogen inhalation
OT  - *immunosenescence
OT  - *natural killer T cell
OT  - *natural killer cell
OT  - *non-small cell lung cancer
COIS- None
EDAT- 2021/01/01 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/31 05:20
PHST- 2020/12/31 05:20 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - MedGasRes_2020_10_4_149_304221 [pii]
AID - 10.4103/2045-9912.304221 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Oct-Dec;10(4):149-154. doi: 10.4103/2045-9912.304221.


PMID- 33380579
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Change in saturation oxygen and hemodynamic responses by adding intrathecal
      dexmedetomidine vs. sufentanil to bupivacaine in patients undergoing dynamic hip 
      screw operation: a randomized clinical trial.
PG  - 144-148
LID - 10.4103/2045-9912.304220 [doi]
AB  - Sufentanil (SUF) and dexmedetomidine (DEX) are used as bupivacaine in the spinal 
      technique that providing stable hemodynamic conditions with least side effects.
      This study aimed to compare the change in saturation oxygen and hemodynamic
      responses after intrathecal DEX and SUF as adjuvants to bupivacaine in patients
      undergoing dynamic hip screw. This clinical trial was conducted with 80 patients 
      referring to Valiasr Hospital, Arak, Iran, who were randomly assigned to two
      groups (n = 40): DEX group (8 mg bupivacaine with 5 mug DEX) and SUF group (8 mg 
      bupivacaine with 2.5 mug SUF). The pain severity was lower in DEX group at
      different hours and the systolic pressure and diastolic blood pressure were lower
      in DEX group than in SUF group after surgery. Saturation oxygen was generally
      lower and more stable in DEX group but there was no significant difference
      between two groups. The incidence of sensory and motor block was lower in DEX
      group than in SUF group, but the duration of assessment of sensory block was
      lower in SUF group than in DEX group. DEX relieves pain up to 24 hours
      postoperatively. Nevertheless, Care should be taken to avoid the DEX induced
      shivering in patients. The study was approved by Ethical Committee of Arak
      University of Medical Sciences by IR.ARAKMU.REC.1395.32 code on April 25, 2016
      and was registered in Iranian Registry of Clinical Trials by code number:
      IRCT2017050220258N45 on August 4, 2017.
FAU - Yazdi, Bijan
AU  - Yazdi B
AD  - Department of Anesthesiology and Critical Care, Arak University of Medical
      Sciences, Arak, Iran.
FAU - Modir, Hesameddin
AU  - Modir H
AD  - Department of Anesthesiology and Critical Care, Arak University of Medical
      Sciences, Arak, Iran.
FAU - Kamali, Alireza
AU  - Kamali A
AD  - Department of Anesthesiology and Critical Care, Arak University of Medical
      Sciences, Arak, Iran.
FAU - Masouri, Hanieh
AU  - Masouri H
AD  - Students Research Committee, Arak University of Medical Sciences, Arak, Iran.
LA  - eng
SI  - IRCT/IRCT2017050220258N45
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 67VB76HONO (Dexmedetomidine)
RN  - AFE2YW0IIZ (Sufentanil)
RN  - S88TT14065 (Oxygen)
RN  - Y8335394RO (Bupivacaine)
SB  - IM
MH  - Adult
MH  - *Bone Screws
MH  - Bupivacaine/*pharmacology
MH  - Dexmedetomidine/administration & dosage/*pharmacology
MH  - Double-Blind Method
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Hip/*surgery
MH  - Humans
MH  - Male
MH  - Oxygen/*metabolism
MH  - Sufentanil/administration & dosage/*pharmacology
PMC - PMC8092148
OTO - NOTNLM
OT  - *adjuvants
OT  - *bupivacaine
OT  - *dexmedetomidine
OT  - *intravenous
OT  - *spinal anesthesia
OT  - *sufentanil
EDAT- 2021/01/01 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/31 05:20
PHST- 2020/12/31 05:20 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - MedGasRes_2020_10_4_144_304220 [pii]
AID - 10.4103/2045-9912.304220 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Oct-Dec;10(4):144-148. doi: 10.4103/2045-9912.304220.


PMID- 33380487
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Incidence and risk factors of delirium after percutaneous coronary intervention
      in individuals hospitalised for acute myocardial infarction: protocol for a
      systematic review and meta-analysis.
PG  - e044564
LID - 10.1136/bmjopen-2020-044564 [doi]
AB  - INTRODUCTION: Delirium in the postoperative period is a wide-reaching problem
      that affects important clinical outcomes. The incidence and risk factors of
      delirium in individuals with acute myocardial infarction (AMI) after primary
      percutaneous coronary intervention (PCI) has not been completely determined and
      no relevant systematic review and meta-analysis of incidence or risk factors
      exists. Hence, we aim to conduct a systematic review and meta-analysis to
      ascertain the incidence and risk factors of delirium among AMI patients
      undergoing PCI. METHODS AND ANALYSES: We will undertake a comprehensive
      literature search among PubMed, EMBASE, Cochrane Library, PsycINFO, CINAHL and
      Google Scholar from their inception to the search date. Prospective cohort and
      cross-sectional studies that described the incidence or at least one risk factor 
      of delirium will be eligible for inclusion. The primary outcome will be the
      incidence of postoperative delirium. The quality of included studies will be
      assessed using a risk of bias tool for prevalence studies and the Cochrane
      guidelines. Heterogeneity of the estimates across studies will be assessed.
      Incidence and risk factors associated with delirium will be extracted. Incidence 
      data will be pooled. Each risk factor reported in the included studies will be
      recorded together with its statistical significance; narrative and
      meta-analytical approaches will be employed. The systematic review and
      meta-analysis will be presented according to the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses. ETHICS AND DISSEMINATION: This proposed
      systematic review and meta-analysis is based on published data, and thus there is
      no requirement for ethics approval. The study will provide an up to date and
      accurate incidence and risk factors of delirium after PCI among patients with
      AMI, which is necessary for future research in this area. The findings of this
      study will be disseminated through publication in a peer-reviewed journal.
      PROSPERO REGISTRATION NUMBER: CRD42020184388.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huang, Kaizhuang
AU  - Huang K
AUID- ORCID: 0000-0002-2740-1387
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Lu, Jiaying
AU  - Lu J
AD  - Department of Gastroenterology, The Fifth Affiliated Hospital, Sun Yat-Sen
      University, Zhuhai 519000, China.
FAU - Zhu, Yaoli
AU  - Zhu Y
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Cheng, Tao
AU  - Cheng T
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Du, Dahao
AU  - Du D
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Qian, Xueqin
AU  - Qian X
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Pan, Haiyan
AU  - Pan H
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Wang, Xiaohua
AU  - Wang X
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Yang, Hong
AU  - Yang H
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China.
FAU - Lou, Shaofei
AU  - Lou S
AD  - Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai 519000, China loushaofei0459@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Delirium/epidemiology/etiology
MH  - Humans
MH  - Incidence
MH  - Meta-Analysis as Topic
MH  - *Myocardial Infarction/epidemiology/therapy
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Prospective Studies
MH  - Research Design
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7780515
OTO - NOTNLM
OT  - *coronary intervention
OT  - *delirium & cognitive disorders
OT  - *myocardial infarction
COIS- Competing interests: None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-044564 [pii]
AID - 10.1136/bmjopen-2020-044564 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e044564. doi: 10.1136/bmjopen-2020-044564.


PMID- 33380486
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20220323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Study protocol: a mixed-methods realist evaluation of the Universal Health
      Visiting Pathway in Scotland.
PG  - e042305
LID - 10.1136/bmjopen-2020-042305 [doi]
AB  - INTRODUCTION: The growing political emphasis on the early years reflects the
      importance of these formative years of life. Health visitors in the UK are
      uniquely positioned to improve health outcomes for children and families and to
      reduce health inequalities. Recently, there has been a policy change in Scotland 
      in an attempt to enhance the delivery of the universal health visiting service.
      This study aims to examine the extent to which the enhanced Universal Health
      Visiting Pathway is implemented and delivered across Scotland and to assess any
      associated impacts. METHODS AND ANALYSIS: A mixed-methods study incorporating
      four methodological components and uses realist evaluation as the overall
      conceptual framework. It comprises three phases (1) initial programme theory
      development; (2) programme theory validation and (3) programme theory refinement.
      The programme theory validation will use interview and focus group data of
      parents and health visitors, and conduct a case note review at five study sites. 
      It also involves a national survey of parents and health visitors and routine
      data analysis of existing secondary data. The analyses of the ensuing qualitative
      and quantitative data will be carried out using a convergent mixed-methods
      approach to ensure continuous triangulation of multiple data. The findings of the
      evaluation will provide contextually relevant understanding of how the Universal 
      Health Visiting Pathway works and evidence the impact of increased investments in
      health visiting in Scotland. ETHICS AND DISSEMINATION: This protocol has been
      approved by the School of Health in Social Science Research Ethics Committee,
      University of Edinburgh. Additional approvals have been granted/will be sought
      from the Public Benefit and Privacy Panel for health and social care in Scotland 
      for the case note review,survey and routine data analysis elements of the
      evaluation. The findings will be prepared as reports to the funders and presented
      at conferences. It will be submitted for publication in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Doi, Lawrence
AU  - Doi L
AUID- ORCID: 0000-0001-6853-5050
AD  - Scottish Collaboration for Public Health Research and Policy, School of Health in
      Social Science, The University of Edinburgh, Edinburgh, UK larry.doi@ed.ac.uk.
FAU - Morrison, Kathleen
AU  - Morrison K
AD  - Scottish Collaboration for Public Health Research and Policy, School of Health in
      Social Science, The University of Edinburgh, Edinburgh, UK.
FAU - Astbury, Ruth
AU  - Astbury R
AD  - School of Health and Life Science, University of the West of Scotland, Paisley,
      Renfrewshire, UK.
FAU - Eunson, Jane
AU  - Eunson J
AD  - Ipsos MORI Scotland, Edinburgh, Lothian, UK.
FAU - Horne, Margaret A
AU  - Horne MA
AD  - Centre for Population Health Sciences, The University of Edinburgh, Edinburgh,
      UK.
FAU - Jepson, Ruth
AU  - Jepson R
AD  - Scottish Collaboration for Public Health Research and Policy, School of Health in
      Social Science, The University of Edinburgh, Edinburgh, UK.
FAU - Marryat, Louise
AU  - Marryat L
AUID- ORCID: 0000-0002-6093-4679
AD  - Salvensen Mindroom Research Centre, The University of Edinburgh, Edinburgh, UK.
FAU - Ormston, Rachel
AU  - Ormston R
AD  - Ipsos MORI Scotland, Edinburgh, Lothian, UK.
FAU - Wood, Rachael
AU  - Wood R
AUID- ORCID: 0000-0003-4453-623X
AD  - Information Services Division, NHS Scotland National Services Division,
      Edinburgh, UK.
AD  - Child Life and Health, The University of Edinburgh, Edinburgh, UK.
LA  - eng
GR  - MR/K023209/1/MRC_/Medical Research Council/United Kingdom
GR  - CSO_/Chief Scientist Office/United Kingdom
GR  - MR/KO 023209/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Focus Groups
MH  - *Health Services
MH  - Humans
MH  - Program Evaluation
MH  - Research Design
MH  - Scotland
PMC - PMC7780504
OTO - NOTNLM
OT  - *community child health
OT  - *health policy
OT  - *maternal medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-042305 [pii]
AID - 10.1136/bmjopen-2020-042305 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e042305. doi: 10.1136/bmjopen-2020-042305.


PMID- 33380484
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Role of occupational therapy in musicians' health: a scoping review protocol.
PG  - e040922
LID - 10.1136/bmjopen-2020-040922 [doi]
AB  - REVIEW QUESTION/OBJECTIVE: The purpose of this proposed review is twofold: first,
      to understand the role of occupational therapy presented in the musicians' health
      literature; and second, to explore the potential for this role. INTRODUCTION: The
      intense movement, awkward postures, concentration and emotional communication
      required of musicians can place them at increased risk of music-related health
      conditions, such as musculoskeletal disorders and performance anxiety. The
      development of music-related health conditions can be emotionally and financially
      devastating. The role of occupational therapy in musicians' health has been
      previously discussed; however, no rigorous reviews of the scholarly literature
      have been published. We will, therefore, undertake a scoping review with the
      following research questions: (1) what is known about the role of occupational
      therapy in instrumental musicians' health? and (2) what is the potential role of 
      occupational therapy in musicians' health? METHODS AND ANALYSIS: A preliminary
      search of Medline, CINAHL, SCOPUS and Web of Science was previously undertaken by
      the first author to determine the extent of the research on this topic and to
      confirm that no other reviews have been conducted or are in progress. Study
      selection and analysis will follow the Joanna Briggs Institute and the Preferred 
      Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping
      reviews guidelines for conducting a scoping review. ETHICS AND DISSEMINATION:
      Formal ethics approval is not required at our institution for a review of
      published literature. The results of this review will be shared through
      peer-reviewed publications, conference presentations and traditional and social
      media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Villas, Bethany
AU  - Villas B
AD  - Occupational Therapy, University of Alberta, Edmonton, Alberta, Canada.
FAU - Duarte Wisnesky, Uira
AU  - Duarte Wisnesky U
AD  - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
FAU - Campbell, Sandra
AU  - Campbell S
AD  - University of Alberta Libraries, University of Alberta, Edmonton, Alberta,
      Canada.
FAU - Slavik, Lauren
AU  - Slavik L
AD  - Occupational Therapy, University of Alberta, Edmonton, Alberta, Canada.
FAU - Mevawala, Amynah S
AU  - Mevawala AS
AD  - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
FAU - Handl, Melisa N
AU  - Handl MN
AD  - Faculty of Law, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Guptill, Christine
AU  - Guptill C
AUID- ORCID: 0000-0002-5080-2672
AD  - Faculty of Health Sciences School of rehabilitation sciences, University of
      Ottawa, Ottawa, Ontario, Canada cguptill@uottawa.ca.
LA  - eng
PT  - Journal Article
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Emotions
MH  - Humans
MH  - *Musculoskeletal Diseases
MH  - *Music
MH  - *Occupational Therapy
MH  - Social Media
PMC - PMC7780529
OTO - NOTNLM
OT  - *occupational & industrial medicine
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040922 [pii]
AID - 10.1136/bmjopen-2020-040922 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e040922. doi: 10.1136/bmjopen-2020-040922.


PMID- 33380482
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Guided relaxation-based virtual reality versus distraction-based virtual reality 
      or passive control for postoperative pain management in children and adolescents 
      undergoing Nuss repair of pectus excavatum: protocol for a prospective,
      randomised, controlled trial (FOREVR Peds trial).
PG  - e040295
LID - 10.1136/bmjopen-2020-040295 [doi]
AB  - INTRODUCTION: Virtual reality (VR) offers an innovative method to deliver
      non-pharmacological pain management. Distraction-based VR (VR-D) using immersive 
      games to redirect attention has shown short-term pain reductions in various
      settings. To create lasting pain reduction, VR-based strategies must go beyond
      distraction. Guided relaxation-based VR (VR-GR) integrates pain-relieving
      mind-body based guided relaxation with VR, a novel therapy delivery mechanism.
      The primary aim of this study is to assess the impact of daily VR-GR, VR-D and
      360 video (passive control) on pain intensity. We will also assess the impact of 
      these interventions on pain unpleasantness, anxiety and opioid and benzodiazepine
      consumption. The secondary aim of this study will assess the impact of
      psychological factors (anxiety sensitivity and pain catastrophising) on pain
      following VR. METHODS AND ANALYSIS: This is a single centre, prospective,
      randomised, clinical trial. Ninety children/adolescents, aged 8-18 years,
      presenting for Nuss repair of pectus excavatum will be randomised to 1 of 3 study
      arms (VR-GR, VR-D and 360 video). Patients will use the Starlight Xperience
      (Google Daydream) VR suite for 10 min. Patients randomised to VR-GR (n=30) will
      engage in guided relaxation/mindfulness with the Aurora application. Patients
      randomised to VR-D (n=30) will play 1 of 3 distraction-based games, and those
      randomised to the 360 video (n=30) will watch the Aurora application without
      audio instructions or sound. Primary outcome is pain intensity. Secondary
      outcomes include pain unpleasantness, anxiety and opioid and benzodiazepine
      consumption. ETHICS AND DISSEMINATION: This study follows Standard Protocol
      Items: Recommendations for Interventional Trials guidelines. The protocol was
      approved by the Cincinnati Children's Hospital Medical Center's institutional
      review board. Patient recruitment began in July 2020. Written informed consent
      will be obtained for all participants. All information acquired will be
      disseminated via scientific meetings and published in peer-reviewed journals.
      TRIAL REGISTRATION NUMBER: NCT04351776.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Olbrecht, Vanessa A
AU  - Olbrecht VA
AUID- ORCID: 0000-0001-9110-0282
AD  - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA vanessa.olbrecht@cchmc.org.
FAU - Williams, Sara E
AU  - Williams SE
AD  - Division of Behavioral Medicine and Clinical Psychology, Department of
      Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
FAU - O'Conor, Keith T
AU  - O'Conor KT
AD  - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA.
FAU - Boehmer, Chloe O
AU  - Boehmer CO
AD  - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA.
FAU - Marchant, Gilbert W
AU  - Marchant GW
AD  - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA.
FAU - Glynn, Susan M
AU  - Glynn SM
AD  - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA.
FAU - Geisler, Kristie J
AU  - Geisler KJ
AD  - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA.
FAU - Ding, Lili
AU  - Ding L
AD  - Divsion of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati
      Children's Hospital Medical Center, Cincinnati, OH, USA.
FAU - Yang, Gang
AU  - Yang G
AD  - Divsion of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati
      Children's Hospital Medical Center, Cincinnati, OH, USA.
FAU - King, Christopher D
AU  - King CD
AD  - Division of Behavioral Medicine and Clinical Psychology, Department of
      Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04351776
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Funnel Chest/surgery
MH  - Humans
MH  - Pain, Postoperative
MH  - Practice Guidelines as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - *Virtual Reality
PMC - PMC7780540
OTO - NOTNLM
OT  - *clinical trials
OT  - *complementary medicine
OT  - *paediatric anaesthesia
OT  - *paediatric thoracic surgery
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040295 [pii]
AID - 10.1136/bmjopen-2020-040295 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e040295. doi: 10.1136/bmjopen-2020-040295.


PMID- 33380481
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Patterns and predictors of high-cost users of the health system: a data linkage
      protocol to combine a cohort study and randomised controlled trial of adults with
      a history of homelessness.
PG  - e039966
LID - 10.1136/bmjopen-2020-039966 [doi]
AB  - INTRODUCTION: Homelessness is a global issue with a detrimental impact on health.
      Individuals who experience homelessness are often labelled as frequent healthcare
      users; yet it is a small group of individuals who disproportionately use the
      majority of services. This protocol outlines the approach to combine survey data 
      from a prospective cohort study and randomised controlled trial with
      administrative healthcare data to characterise patterns and predictors of
      healthcare utilisation among a group of adults with a history of homelessness.
      METHODS AND ANALYSIS: This cohort study will apply survey data from the Health
      and Housing in Transition study and the At Home/Chez Soi study linked with
      administrative healthcare databases in Ontario, Canada. We will use count models 
      to quantify the associations between baseline predisposing, enabling, and need
      factors and hospitalisations, emergency department visits and physician visits in
      the following year. Subsequently, we will identify individuals who are high-cost 
      users of the health system (top 5%) and characterise their patterns of healthcare
      utilisation. Logistic regression will be applied to develop a set of models to
      predict who will be high-cost users over the next 5 years based on predisposing, 
      enabling and need factors. Calibration and discrimination will be estimated with 
      bootstrapped optimism (bootstrap performance-test performance) to ensure the
      model performance is not overestimated. ETHICS AND DISSEMINATION: This study is
      approved by the St Michael's Hospital Research Ethics Board and the University of
      Toronto Research Ethics Board. Findings will be disseminated through publication 
      in peer-reviewed journals, presentations at research conferences and brief
      reports made available to healthcare professionals and the general public. TRIAL 
      REGISTRATION NUMBER: This is a secondary data analysis of a cohort study and
      randomized trial. The At Home/Chez Soi study has been registered with the
      International Standard Randomised Control Trial Number Register and assigned
      ISRCTN42520374.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wiens, Kathryn
AU  - Wiens K
AUID- ORCID: 0000-0003-3451-6788
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada kathryn.wiens@mail.utoronto.ca.
AD  - MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St
      Michael's Hospital, Toronto, Ontario, Canada.
FAU - Rosella, Laura C
AU  - Rosella LC
AUID- ORCID: 0000-0003-4867-869X
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Kurdyak, Paul
AU  - Kurdyak P
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Hwang, Stephen W
AU  - Hwang SW
AD  - MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St
      Michael's Hospital, Toronto, Ontario, Canada.
AD  - Division of General Internal Medicine, Department of Medicine, University of
      Toronto, Toronto, Ontario, Canada.
LA  - eng
SI  - ISRCTN/ISRCTN42520374
GR  - MOP-130405/Canadian Institute of Health Research/International
GR  - FDN-167263/Canadian Institute of Health Research/International
GR  - HOA-80066/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Alcoholism
MH  - Cohort Studies
MH  - *Homeless Persons
MH  - Humans
MH  - Information Storage and Retrieval
MH  - Ontario
MH  - Prospective Studies
PMC - PMC7780507
OTO - NOTNLM
OT  - *epidemiology
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-039966 [pii]
AID - 10.1136/bmjopen-2020-039966 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e039966. doi: 10.1136/bmjopen-2020-039966.


PMID- 33380479
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Double-task exercise programmes to strengthen cognitive and vascular health in
      older adults at risk of cognitive decline: protocol for a randomised clinical
      trial.
PG  - e039723
LID - 10.1136/bmjopen-2020-039723 [doi]
AB  - INTRODUCTION: Cognitive and physical declines are frequent causes of disability
      among older adults (OAs) in Mexico that imposes significant burden on the health 
      system and OAs' families. Programmes to prevent or delay OAs' cognitive and
      physical decline are scarce. METHODS AND ANALYSIS: A double-blind randomised
      clinical trial will be conducted. The study will aim to evaluate two 24-week
      double-task (aerobic and cognitive) square-stepping exercise programmes for OAs
      at risk of cognitive decline-one programme with and another without caregiver
      participation-and to compare these with an aerobic-balance-stretching exercise
      programme (control group). 300 OAs (100 per group) affiliated with the Mexican
      Institute of Social Security (IMSS) between 60 and 65 years of age with
      self-reported cognitive concerns will participate. They will be stratified by
      education level and randomly allocated to the groups. The intervention will last 
      24 weeks, and the effect of each programme will be evaluated 12, 24 and 52 weeks 
      after the intervention. Participants' demographic and clinical characteristics
      will be collected at baseline. The outcomes will include: (1) general cognitive
      function; (2) specific cognitive functions; (3) dual-task gait; (4) blood
      pressure; (5) carotid intima-media thickness; (6) OAs' health-related quality of 
      life; and (7) caregiver burden. The effects of the interventions on each outcome 
      variable will be examined using a repeated-measures analysis of variance (ANOVA),
      with study groups as the between-subjects variable and time as the within-subject
      variable. ETHICS AND DISSEMINATION: The study was approved by the IMSS Ethics and
      Research Committees (registration number: 2018-785-095). All participants will
      sign a consent form prior to their participation. The study results will be
      disseminated to the IMSS authorities, healthcare providers and the research
      community. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT04068376).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sanchez-Arenas, Rosalinda
AU  - Sanchez-Arenas R
AD  - Epidemiology and Health Services Research Unit CMN Siglo XXI, Mexican Institute
      of Social Security, Mexico City, Mexico.
FAU - Doubova, Svetlana V
AU  - Doubova SV
AUID- ORCID: 0000-0002-0521-7095
AD  - Epidemiology and Health Services Research Unit CMN Siglo XXI, Mexican Institute
      of Social Security, Mexico City, Mexico svetlana.doubova@gmail.com.
FAU - Bernabe-Garcia, Mariela
AU  - Bernabe-Garcia M
AD  - Medical Research Unit in Nutrition, Pediatrics Hospital, National Medical Center 
      Century XXI, Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Gregory, Michel A
AU  - Gregory MA
AD  - School of Rehabilitation Sciences, Faculty of Health Sciences, McMaster
      University, Hamilton, Ontario, Canada.
FAU - Mejia-Alonso, Laura Alejandra
AU  - Mejia-Alonso LA
AD  - Rehabilitation Service, Specialty Hospital, National Medical Center Century XXI, 
      Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Orihuela-Rodriguez, Oscar
AU  - Orihuela-Rodriguez O
AD  - Cardiology Service, Specialty Hospital, National Medical Center Century XXI,
      Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Paredes-Manjarrez, Carlos
AU  - Paredes-Manjarrez C
AD  - Image Service, Specialty Hospital, National Medical Center Century XXI, Mexican
      Institute of Social Security, Mexico City, Mexico.
FAU - Colin-Martinez, Tania
AU  - Colin-Martinez T
AD  - Continuous Admission Service, Specialty Hospital, National Medical Center Century
      XXI, Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Mujica-Morales, Irene
AU  - Mujica-Morales I
AD  - Division of Occupational Risk Prevention. Occupational Health Coordination,
      Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Grijalva-Otero, Israel
AU  - Grijalva-Otero I
AD  - Medical Research Unit in Neurological Diseases, National Medical Center Century
      XXI, Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Basurto-Acevedo, Lourdes
AU  - Basurto-Acevedo L
AD  - Research Unit in Endocrine Diseases, National Medical Center Century XXI, Mexican
      Institute of Social Security, Mexico City, Mexico.
FAU - Manuel-Apolinar, Leticia
AU  - Manuel-Apolinar L
AD  - Research Unit in Endocrine Diseases, National Medical Center Century XXI, Mexican
      Institute of Social Security, Mexico City, Mexico.
FAU - Cuadros-Moreno, Juan
AU  - Cuadros-Moreno J
AD  - Coordination of Health Education, Mexican Institute of Social Security, Mexico
      City, Mexico.
FAU - Bernal-Diaz, Arcelia
AU  - Bernal-Diaz A
AD  - Aragon School of Higher Education, National Autonomous University of Mexico,
      Mexico City, Mexico.
FAU - Shigematsu, Ryosuke
AU  - Shigematsu R
AD  - Faculty of Education, Mie University, Tsu, Mie, Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT04068376
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Carotid Intima-Media Thickness
MH  - Cognition
MH  - *Cognitive Dysfunction/prevention & control
MH  - Double-Blind Method
MH  - Exercise
MH  - Exercise Therapy
MH  - Humans
MH  - Mexico
MH  - *Quality of Life
PMC - PMC7780518
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *mental health
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2021/01/01 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-039723 [pii]
AID - 10.1136/bmjopen-2020-039723 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e039723. doi: 10.1136/bmjopen-2020-039723.


PMID- 33380478
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 30
TI  - Natural history of glaucomatous optic neuropathy in highly myopic Chinese: study 
      protocol for a registry cohort study.
PG  - e039183
LID - 10.1136/bmjopen-2020-039183 [doi]
AB  - INTRODUCTION: Myopic maculopathy and glaucoma belong to the most common causes of
      irreversible blindness worldwide and, having an ocular axial elongation as one of
      their main risk factors, can occur together. The detection of glaucomatous optic 
      neuropathy (GON) in highly myopic eyes is clinically and technically difficult,
      and there is no information available, neither about the natural course of GON or
      about the course of GON under intraocular pressure-lowering therapy. We therefore
      designed this study to explore the natural course of GON in highly myopic eyes.
      METHODS AND ANALYSIS: In this single-centred longitudinal registry cohort study, 
      813 highly myopic individuals will be recruited and undergo detailed ophthalmic
      examinations. High myopia is defined by a myopic refractive error of >/=-6 D or
      an axial length of >/=26.5 mm. GON is defined by a glaucomatous appearance of the
      optic nerve head or glaucomatous visual field (VF) defects. GON progression is
      defined by either change of the optic disc or VF. ETHICS AND DISSEMINATION:
      Ethical approval has been obtained from the ethical committee of the Zhongshan
      Ophthalmic Center (ZOC), Sun Yat-sen University, China (ID: 2019KYPJ079). All the
      participants are required to provide informed consents. Results will be
      disseminated through scientific meetings and published in peer-reviewed journals.
      The data will be deposited at the clinical research centre in ZOC using
      electronic data capture system, and a copy of paper files will also be kept. Only
      members of the project team will have access to these data. TRIAL REGISTRATION
      NUMBER: NCT04302220.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Song, Yunhe
AU  - Song Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Wang, Wei
AU  - Wang W
AUID- ORCID: 0000-0002-5273-3332
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Lin, Fengbin
AU  - Lin F
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Chen, Shida
AU  - Chen S
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Jin, Ling
AU  - Jin L
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Li, Fei
AU  - Li F
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Gao, Kai
AU  - Gao K
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Cheng, Weijing
AU  - Cheng W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Xiong, Jian
AU  - Xiong J
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Zhou, Rouxi
AU  - Zhou R
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Chen, Meiling
AU  - Chen M
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Liang, Jiaen
AU  - Liang J
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Zhang, Jiani
AU  - Zhang J
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Jonas, Jost B
AU  - Jonas JB
AUID- ORCID: 0000-0003-2972-5227
AD  - Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University,
      Heidelberg, Baden-Wurttemberg, Germany.
FAU - Zhang, Xiulan
AU  - Zhang X
AUID- ORCID: 0000-0003-1522-2653
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China zhangxl2@mail.sysu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT04302220
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201230
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - Cohort Studies
MH  - *Glaucoma
MH  - Humans
MH  - Intraocular Pressure
MH  - *Myopia/complications
MH  - *Optic Nerve Diseases/etiology
MH  - Registries
MH  - Retrospective Studies
PMC - PMC7780524
OTO - NOTNLM
OT  - *glaucoma
OT  - *medical retina
OT  - *ophthalmology
COIS- Competing interests: JBJ: Patent application: Europaische Patentanmeldung 16 720 
      043.5 and Patent application US 2019 0085065 A1, agents for use in the
      therapeutic or prophylactic treatment of myopia or hyperopia.
EDAT- 2021/01/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/31 05:19
PHST- 2020/12/31 05:19 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039183 [pii]
AID - 10.1136/bmjopen-2020-039183 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 30;10(12):e039183. doi: 10.1136/bmjopen-2020-039183.


PMID- 33380128
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210101
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 66
IP  - 7
DP  - 2020 Fall
TI  - Ethical connotations of the treatment of COVID-19 disease.
PG  - 8-12
AB  - The current situation of the COVID-19 pandemic has brought entirely new
      challenges to the health care professionals as well as to the general public, and
      together with them a number of new problems that the society needs to deal with. 
      One of the groups of new challenges are undoubtedly ethical issues. For
      physicians in their daily practice, it is important to realize the significant
      role of ethical aspects during an epidemic or pandemic. The article aims to
      acquaint health care professionals with ethical principles in general, with their
      distinctiveness and application in the course of infectious diseases, and with
      the main ethical aspects of the COVID-19 treatment during the pandemic. One of
      the most important topics of the subject-matter experts discussions, which took
      place in connection with preparation of recommendations for the allocation
      criteria of scarce resources in the provision of health care services in the
      context of the COVID-19 pandemic, is particularly the allocation of scarce
      resources based on age and discrimination. The intention of the article is to
      support healthcare professionals to fulfil their responsibilities in providing
      health care services in a professional and equitable way that does not conflict
      with any legal obligations.
FAU - Jedlickova, Anetta
AU  - Jedlickova A
LA  - eng
PT  - Journal Article
TT  - Eticke konotace le&#269;by onemocn&#283;ni covid-19.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - COVID-19 drug treatment
SB  - IM
MH  - *COVID-19/drug therapy
MH  - *Coronavirus Infections/epidemiology
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - age discrimination
OT  - allocation of scarce resources
OT  - ethical aspects
OT  - ethical dilemmas
OT  - ethical principles
OT  - medical ethics
EDAT- 2021/01/01 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/12/31 05:17
PHST- 2020/12/31 05:17 [entrez]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
AID - 125196 [pii]
PST - ppublish
SO  - Vnitr Lek. 2020 Fall;66(7):8-12.


PMID- 33378833
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 0254-6450 (Print)
IS  - 0254-6450 (Linking)
VI  - 41
IP  - 12
DP  - 2020 Dec 10
TI  - [Application of healthy big data in prevention and control of chronic diseases].
PG  - 2163-2168
LID - 10.3760/cma.j.cn112338-20191119-00815 [doi]
AB  - With the continuous development of informatization, big data has been
      increasingly used in the prevention and control of chronic diseases, which has a 
      significant and considerable influence on public health. This paper briefly
      introduces the definition, characteristics and classification of big data and
      healthy big data, focusing on the analysis methods and their applications in
      tertiary prevention, as well as the challenges in technology, data management,
      sharing and quality, ethics and privacy, with the aim of providing more research 
      approaches for healthy big data application in chronic disease prevention and
      control.
FAU - Liu, Y
AU  - Liu Y
AD  - National Center for Chronic and Non-communicable Disease Control and Prevention, 
      Chinese Center for Disease Control and Prevention, Beijing 100050, China; Tobacco
      Control office, Chinese Center for Disease Control and Prevention, Beijing
      100050, China.
FAU - Li, H
AU  - Li H
AD  - Ningbo Prefectural Center for Disease Control and Prevention, Ningbo 315010,
      China.
FAU - Zeng, X Y
AU  - Zeng XY
AD  - Tobacco Control office, Chinese Center for Disease Control and Prevention,
      Beijing 100050, China.
FAU - Dong, W L
AU  - Dong WL
AD  - National Center for Chronic and Non-communicable Disease Control and Prevention, 
      Chinese Center for Disease Control and Prevention, Beijing 100050, China.
FAU - Liu, S W
AU  - Liu SW
AD  - National Center for Chronic and Non-communicable Disease Control and Prevention, 
      Chinese Center for Disease Control and Prevention, Beijing 100050, China; Tobacco
      Control office, Chinese Center for Disease Control and Prevention, Beijing
      100050, China.
LA  - chi
GR  - 2017YFC1310902/National Key R&D Program of China
GR  - 81872721/National Natural Science Foundation of China
PT  - Journal Article
PL  - China
TA  - Zhonghua Liu Xing Bing Xue Za Zhi
JT  - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
JID - 8208604
SB  - IM
MH  - *Big Data
MH  - *Chronic Disease/prevention & control
MH  - Humans
OTO - NOTNLM
OT  - Chronic disease
OT  - Healthy big data
OT  - Tertiary prevention
EDAT- 2020/12/31 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/12/30 22:17
PHST- 2020/12/30 22:17 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - 10.3760/cma.j.cn112338-20191119-00815 [doi]
PST - ppublish
SO  - Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Dec 10;41(12):2163-2168. doi:
      10.3760/cma.j.cn112338-20191119-00815.


PMID- 33377830
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1750-8460 (Print)
IS  - 1750-8460 (Linking)
VI  - 81
IP  - 12
DP  - 2020 Dec 2
TI  - Managing the overlap between mental and physical health.
PG  - 1-2
LID - 10.12968/hmed.2020.0487 [doi]
AB  - The interface between the Mental Capacity Act 2005 and the Mental Health Act 1983
      can be complex, particularly in patients with co-existing mental and physical
      illnesses. The management of these patients requires the involvement of patients,
      relatives and multidisciplinary teams. This article presents four illustrative
      patient cases, all of whom suffered from co-existing mental and physical
      illnesses. In managing these cases, dilemmas had arisen in the provision of
      treatment encompassing both legal frameworks. These cases helped to emphasise the
      decision-specific and time-specific nature of assessment of mental capacity,
      requiring clinicians to assess on a case-by-case basis over a suitable period.
      Often, principles from both legal frameworks may be applied by the treatment
      team. These cases help to highlight the significant overlap between mental and
      physical health, which often cannot be managed independently. This may call for
      the need to better integrate the current legal frameworks, and the optimal
      involvement of specialists across both settings.
FAU - Chen, Fangyue
AU  - Chen F
AD  - Department of General Medicine, Peterborough City Hospital, Peterborough, UK.
FAU - Ruiz-Mendoza, Eladia
AU  - Ruiz-Mendoza E
AD  - Department of General Medicine, Peterborough City Hospital, Peterborough, UK.
FAU - Essem, Julius
AU  - Essem J
AD  - Older People's Mental Health, Cavell Centre, Edith Cavell Hospital, Peterborough,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - England
TA  - Br J Hosp Med (Lond)
JT  - British journal of hospital medicine (London, England : 2005)
JID - 101257109
SB  - IM
MH  - Health Status
MH  - Humans
MH  - *Mental Competency
MH  - *Mental Health
OTO - NOTNLM
OT  - Best interest
OT  - Consent to treatment
OT  - Legal framework
OT  - Mental health ethics
OT  - Physical health
EDAT- 2020/12/31 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/12/30 12:16
PHST- 2020/12/30 12:16 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.12968/hmed.2020.0487 [doi]
PST - ppublish
SO  - Br J Hosp Med (Lond). 2020 Dec 2;81(12):1-2. doi: 10.12968/hmed.2020.0487. Epub
      2020 Dec 16.


PMID- 33377374
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220531
IS  - 1440-6047 (Electronic)
IS  - 0964-7058 (Linking)
VI  - 29
IP  - 4
DP  - 2020
TI  - Birth anthropometry from a tertiary care hospital in Sri Lanka: Differs from the 
      WHO growth standards.
PG  - 795-802
LID - 10.6133/apjcn.202012_29(4).0015 [doi]
AB  - BACKGROUND AND OBJECTIVES: The nutritional status of infants is assessed using
      the WHO growth references, based on the Multicenter Growth Reference Study (MGRS)
      in many countries including Sri Lanka. Birth parameters define infant growth
      curves. The aim of this study was to compare the birth anthropometric data of a
      healthy population of babies born in Colombo, Sri Lanka with the WHO MGRS birth
      data and determine its suitability for assessment of growth in this population.
      METHODS AND STUDY DESIGN: Birth data were obtained as part of a study on
      longitudinal infant body composition from birth to 2 years from 2015-2019.
      Healthy babies, born to non-smoking mothers, >18 years old, with a singleton
      pregnancy at term, living in the study area and intending to breastfeed, were
      recruited. The Ethical Review Committee of the Faculty of Medicine, University of
      Colombo, approved the study. RESULTS: Compared to WHO data, the mean birth weight
      (2.9+/-0.4 kg), length (48.2+/-2.7 cm) and head circumference (33.6+/-1.2 cm) of 
      our study population (n=337) was significantly lower with a left shift in the z
      score distribution. This was despite similar background characteristics except
      for significantly lower income (USD 200) and lower maternal (154.2+/-9.0 cm) and 
      paternal height (165+/-11.6 cm) in our study population. A significant change in 
      birth parameters was only seen with maternal height when disaggregated.
      CONCLUSIONS: WHO birth parameters were significantly higher and underestimated
      the growth of healthy babies in Sri Lanka.
FAU - Lucas, Marianne Nishani
AU  - Lucas MN
AD  - Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo,
      Sri Lanka. Email: nishani@pdt.cmb.ac.lk, nishrockpoly@gmail.com.
FAU - Lanerolle, Pulani
AU  - Lanerolle P
AD  - Department of Biochemistry and Molecular Biology, University of Colombo, Colombo,
      Sri Lanka.
FAU - Senarath, Upul
AU  - Senarath U
AD  - Department of Community Medicine, University of Colombo, Colombo, Sri Lanka.
FAU - Hills, Andrew Peter
AU  - Hills AP
AD  - School of Health Sciences, College of Health and Medicine, University of
      Tasmania, Australia.
FAU - Wickramasinghe, Vithanage Pujitha
AU  - Wickramasinghe VP
AD  - Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo,
      Sri Lanka.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Australia
TA  - Asia Pac J Clin Nutr
JT  - Asia Pacific journal of clinical nutrition
JID - 9440304
SB  - IM
MH  - Anthropometry
MH  - *Birth Weight
MH  - *Body Height
MH  - *Child Development
MH  - Female
MH  - Humans
MH  - Infant
MH  - Nutritional Status
MH  - Pregnancy
MH  - Sri Lanka/epidemiology
MH  - Tertiary Care Centers
MH  - World Health Organization
EDAT- 2020/12/31 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/30 07:45
PHST- 2020/12/30 07:45 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.6133/apjcn.202012_29(4).0015 [doi]
PST - ppublish
SO  - Asia Pac J Clin Nutr. 2020;29(4):795-802. doi: 10.6133/apjcn.202012_29(4).0015.


PMID- 33376744
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20220419
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Morocco's First Biobank: Establishment, Ethical Issues, Biomedical Research
      Opportunities, and Challenges.
PG  - 8812609
LID - 10.1155/2020/8812609 [doi]
AB  - BACKGROUND: Biobanks are highly organized infrastructures that allow the storage 
      of human biological specimens associated with donors' personal and clinical data.
      These infrastructures play a key role in the development of translational medical
      research. In this context, we launched, in November 2015, the first biobank in
      Morocco (BRO Biobank) in order to promote biomedical research and provide
      opportunities to include Moroccan and North African ethnic groups in
      international biomedical studies. Here, we present the setup and the sample
      characteristics of BRO Biobank. METHODS: Patients were recruited at several
      departments of two major health-care centers in the city of Oujda. Healthy donors
      were enrolled during blood donation campaigns all over Eastern Morocco. From each
      participant, personal, clinical, and biomedical data were collected, and several 
      biospecimens were stored. Standard operating procedures have been established in 
      accordance with international guidelines on human biobanks. RESULTS: Between
      November 2015 and July 2020, 2446 participants were recruited into the BRO
      Biobank, of whom 2013 were healthy donors, and 433 were patients. For healthy
      donors, the median age was 35 years with a range between 18 and 65 years and the 
      consanguinity rate was 28.96%. For patients, the median age was 11 years with a
      range between 1 day and 83 years. Among these patients, 55% had rare diseases
      (hemoglobinopathies, intellectual disabilities, disorders of sex differentiation,
      myopathies, etc.), 13% had lung cancer, 4% suffered from hematological neoplasms,
      3% were from the kidney transplantation project, and 25% had unknown diagnoses.
      The BRO Biobank has collected 5092 biospecimens, including blood, white blood
      cells, plasma, serum, urine, frozen tissue, FFPE tissue, and nucleic acids. A
      sample quality control has been implemented and suggested that samples of the BRO
      Biobank are of high quality and therefore suitable for high-throughput nucleic
      acid analysis. CONCLUSIONS: The BRO Biobank is the largest sample collection in
      Morocco, and it is ready to provide samples to national and international
      research projects. Therefore, the BRO Biobank is a valuable resource for
      advancing translational medical research.
CI  - Copyright (c) 2020 Saida Lhousni et al.
FAU - Lhousni, Saida
AU  - Lhousni S
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Belmokhtar, Karam Yahya
AU  - Belmokhtar KY
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Belmokhtar, Ihab
AU  - Belmokhtar I
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Elidrissi Errahhali, Mounia
AU  - Elidrissi Errahhali M
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Elidrissi Errahhali, Manal
AU  - Elidrissi Errahhali M
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Boulouiz, Redouane
AU  - Boulouiz R
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
AD  - Higher Institute of Nursing Professions and Health Technologies, Oujda, Morocco.
FAU - Tajir, Mariam
AU  - Tajir M
AD  - Medical Genetics Unit, Central Laboratory, Mohammed VI University Hospital,
      Faculty of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Charif, Majida
AU  - Charif M
AD  - Genetics, and Immuno-Cell Therapy Team, Faculty of Sciences, University Mohammed 
      Premier, Oujda, Morocco.
FAU - Zerrouki, Khawla
AU  - Zerrouki K
AD  - Medical Genetics Unit, Central Laboratory, Mohammed VI University Hospital,
      Faculty of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Benajiba, Noufissa
AU  - Benajiba N
AD  - Department of Pediatrics, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Rkain, Maria
AU  - Rkain M
AD  - Department of Pediatrics, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Babakhouya, Abdeladim
AU  - Babakhouya A
AD  - Department of Pediatrics, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Kouismi, Hatim
AU  - Kouismi H
AD  - Department of Pulmonology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Thouil, Afaf
AU  - Thouil A
AD  - Department of Pulmonology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Latrach, Hanane
AU  - Latrach H
AD  - Department of Endocrinology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Amrani, Rim
AU  - Amrani R
AD  - Department of Neonatology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Messaoudi, Sahar
AU  - Messaoudi S
AD  - Department of Neonatology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Ayyad, Anass
AU  - Ayyad A
AD  - Department of Neonatology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Sidqi, Zaina
AU  - Sidqi Z
AD  - Transfusion Regional Centre, Oujda, Morocco.
FAU - Andaloussi Serraj, Khalid
AU  - Andaloussi Serraj K
AD  - Department of Internal Medicine, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Hamaz, Siham
AU  - Hamaz S
AD  - Department of Internal Medicine, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Alaoui, Habiba
AU  - Alaoui H
AD  - Department of Internal Medicine, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Bachir, Houda
AU  - Bachir H
AD  - Department of Internal Medicine, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Bentata, Yassamine
AU  - Bentata Y
AD  - Nephrology and Kidney Transplantation Unit, Mohammed VI Faculty of Medicine and
      Pharmacy, University Hospital, University Mohammed Premier, Oujda, Morocco.
FAU - Haddiya, Intissar
AU  - Haddiya I
AD  - Nephrology and Kidney Transplantation Unit, Mohammed VI Faculty of Medicine and
      Pharmacy, University Hospital, University Mohammed Premier, Oujda, Morocco.
FAU - Choukri, Mohammed
AU  - Choukri M
AD  - Biochemistry Unit, Central Laboratory, Mohammed VI University Hospital, Faculty
      of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Seddik, Rachid
AU  - Seddik R
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
AD  - Hematology Unit, Central Laboratory, Mohammed VI University Hospital, Faculty of 
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Bennani, Amal
AU  - Bennani A
AD  - Pathology Unit, Central Laboratory, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Dikhaye, Siham
AU  - Dikhaye S
AD  - Department of Dermatology, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Oneib, Bouchra
AU  - Oneib B
AD  - Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Elghazouani, Fatima
AU  - Elghazouani F
AD  - Department of Psychiatry, Mohammed VI University Hospital, Faculty of Medicine
      and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - El Mahi, Omar
AU  - El Mahi O
AD  - Department of Vascular Surgery, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Benzirar, Adnane
AU  - Benzirar A
AD  - Department of Vascular Surgery, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Oufkir, Ayat Allah
AU  - Oufkir AA
AD  - Department of Plastic Surgery, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Housni, Brahim
AU  - Housni B
AD  - Department of Anesthesiology and Reanimation, Mohammed VI University Hospital,
      Faculty of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Mimouni, Ahmed
AU  - Mimouni A
AD  - Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Faculty
      of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Saadi, Hanane
AU  - Saadi H
AD  - Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Faculty
      of Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Belahcen, Mohammed
AU  - Belahcen M
AD  - Department of Pediatrics Surgery, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - El Harroudi, Tijani
AU  - El Harroudi T
AD  - Department of Surgical Oncology, Mohammed VI University Hospital, Faculty of
      Medicine and Pharmacy, University Mohammed Premier, Oujda, Morocco.
FAU - Ouarzane, Meryem
AU  - Ouarzane M
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
AD  - Faculty of Sciences, University Mohammed Premier, Oujda, Morocco.
FAU - Bellaoui, Mohammed
AU  - Bellaoui M
AUID- ORCID: https://orcid.org/0000-0001-7508-4550
AD  - Genetics Unit, Medical Sciences Research Laboratory, Faculty of Medicine and
      Pharmacy, University Mohammed Premier, Oujda, Morocco.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biological Specimen Banks/*ethics/*standards
MH  - Biomedical Research/*standards
MH  - Blood Donors/ethics
MH  - Child
MH  - Child, Preschool
MH  - Consanguinity
MH  - Ethnicity
MH  - Female
MH  - Geography
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Morocco
MH  - Quality Control
MH  - Specimen Handling/*ethics/*standards
MH  - Translational Research, Biomedical
MH  - Young Adult
PMC - PMC7738781
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/12/31 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/12/30 05:22
PHST- 2020/08/26 00:00 [received]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/12/30 05:22 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
AID - 10.1155/2020/8812609 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Dec 8;2020:8812609. doi: 10.1155/2020/8812609. eCollection
      2020.


PMID- 33376703
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2229-516X (Print)
IS  - 2229-516X (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - A Cross-Sectional Study to Evaluate Cardiovascular Risk Score in Type 2 Diabetes 
      Mellitus.
PG  - 276-279
LID - 10.4103/ijabmr.IJABMR_45_20 [doi]
AB  - BACKGROUND: Cardiovascular disease is the leading cause of mortality worldwide,
      including in low- and middle-income countries. Cardiovascular risk assessment is 
      essential to prevent the mortality caused by diabetes. AIM: The current study was
      conducted to assess the prevalence of cardiovascular risk factors in type 2
      diabetes and to compare the United Kingdom Prospective Diabetes Study (UKPDS) and
      World Health Organization (WHO)/International Society of Hypertension (ISH) chart
      in assessing cardiovascular risk score. MATERIALS AND METHODS: Cardiac risk
      assessments were done in fifty patients attending the medicine outpatient
      department in an institutional hospital after ethical clearance and taking
      informed consent from patients. Two assessment tools were applied on the same
      patient. RESULTS: Overall, 10% of people were obese (body mass index >30).
      Smoking was prevalent in 20% (10/50) of patients. Hypertension was observed in
      60% (30/50) of patients. Raised total cholesterol (TC) was the most common lipid 
      abnormality affecting 94% of patients. The WHO/ISH prediction charts identified
      14% and 10% of patients with cardiovascular risk category <10 and 10-20, whereas 
      the UKPDS engine predicted 24% and 38% in the same category. In high-risk
      categories 30-40 and >40, the WHO/ISH score predicted a higher proportion of
      patients (18% and 32%) than the UKPDS engine (8% and 4%, respectively). Kappa
      value was calculated to calculate the degree of agreement between two tools, and 
      it was found to be 0.781 (P < 0.01). CONCLUSION: Raised TC and hypertension were 
      the most prevalent risk factors. There was no significant discrepancy between two
      assessment tools in predicting cardiovascular risk score among type 2 diabetes
      mellitus patients in our study.
CI  - Copyright: (c) 2020 International Journal of Applied and Basic Medical Research.
FAU - Sehgal, Arshiya
AU  - Sehgal A
AD  - Department of Pharmacology, Government Medical College, Rajindra Hospital,
      Patiala, Punjab, India.
FAU - Sibia, Rps
AU  - Sibia R
AD  - Department of Medicine, Rajindra Hospital, Patiala, Punjab, India.
FAU - Kaur, Jasleen
AU  - Kaur J
AD  - Department of Pharmacology, Government Medical College, Rajindra Hospital,
      Patiala, Punjab, India.
FAU - Bhajni, Ena
AU  - Bhajni E
AD  - Department of Pharmacology, Government Medical College, Rajindra Hospital,
      Patiala, Punjab, India.
FAU - Sehgal, Vijay Kumar
AU  - Sehgal VK
AD  - Department of Pharmacology, Government Medical College, Rajindra Hospital,
      Patiala, Punjab, India.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - India
TA  - Int J Appl Basic Med Res
JT  - International journal of applied & basic medical research
JID - 101579831
PMC - PMC7758795
OTO - NOTNLM
OT  - Cardiovascular risk score
OT  - International Society of Hypertension
OT  - United Kingdom Prospective Diabetes Study
OT  - type 2 diabetes mellitus
COIS- There are no conflicts of interest.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:22
PHST- 2020/01/29 00:00 [received]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/12/30 05:22 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - 10.4103/ijabmr.IJABMR_45_20 [doi]
AID - IJABMR-10-276 [pii]
PST - ppublish
SO  - Int J Appl Basic Med Res. 2020 Oct-Dec;10(4):276-279. doi:
      10.4103/ijabmr.IJABMR_45_20. Epub 2020 Oct 7.


PMID- 33376683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2229-5151 (Print)
IS  - 2229-5151 (Linking)
VI  - 10
IP  - Suppl 1
DP  - 2020 Sep
TI  - The prognostic value of neutrophil gelatinase-associated lipocalin in
      sepsis-associated acute kidney injury: A prospective observational study.
PG  - 6-10
LID - 10.4103/IJCIIS.IJCIIS_80_19 [doi]
AB  - BACKGROUND: Sepsis is one of the most common triggering factors for acute kidney 
      injury (AKI). The aim of the study is to evaluate the outcome in sepsis with AKI 
      and determine the prognostic value of urinary neutrophil gelatinase-associated
      lipocalin (NGAL) in septicemic AKI. MATERIALS AND METHODS: This prospective
      follow-up study was carried out over a period of 1 year after ethical clearance
      from the Institutional Ethics committee, a total 165 cases of septicemia were
      recruited, of which 15 patients were dropped out, 150 patients were identified
      suffering from septicemia defined as per the organ dysfunction criteria
      (according to third international consensus 2016) and patients of AKI defined as 
      per the Kidney Disease Improving Global Outcomes 2012 criteria). RESULTS: Out of 
      150 patients of septicemia enrolled in the study, only 38 (25.33%) suffering from
      AKI were classified as Group I and rest 112 (74.67%) patients of septicemia not
      suffering from AKI were classified as Group II. In total, 60.0% (90) patients
      were discharged from the hospital, rest of the patients (40%) expired. Mean
      duration of survival was higher in Group II (21.29 +/- 1.89 days) as compared to 
      Group I (13.67 +/- 1.06 days). Cases with >/=121.90 urine NGAL, rate of mortality
      (41.7%), were higher as compared to alive patients discharged (34.4%).
      CONCLUSION: Sequential organ failure assessment score, hospital stay, and
      mortality were high in septicemic patients with AKI as compared to sepsis without
      AKI. Survival of patients also not good with septic AKI, those patients who had
      high NGAL value had poor prognosis.
CI  - Copyright: (c) 2020 International Journal of Critical Illness and Injury Science.
FAU - Shyam, Radhey
AU  - Shyam R
AD  - Department of Geriatric Intensive Care Unit (Anaesthesiology) DGMH, King George's
      Medical University, Lucknow, Uttar Pradesh, India.
FAU - Patel, Munna Lal
AU  - Patel ML
AD  - Department of Internal Medicine, King George's Medical University, Lucknow, Uttar
      Pradesh, India.
FAU - Kumar, Dhananjay
AU  - Kumar D
AD  - Department of Internal Medicine, King George's Medical University, Lucknow, Uttar
      Pradesh, India.
FAU - Sachan, Rekha
AU  - Sachan R
AD  - Department of Obstetrics and Gynaecology, King George's Medical University,
      Lucknow, Uttar Pradesh, India.
FAU - Chaudhary, Shyam Chand
AU  - Chaudhary SC
AD  - Department of Internal Medicine, King George's Medical University, Lucknow, Uttar
      Pradesh, India.
FAU - Gupta, K K
AU  - Gupta KK
AD  - Department of Internal Medicine, King George's Medical University, Lucknow, Uttar
      Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - India
TA  - Int J Crit Illn Inj Sci
JT  - International journal of critical illness and injury science
JID - 101571136
PMC - PMC7759065
OTO - NOTNLM
OT  - Acute kidney injury
OT  - mortality
OT  - sepsis
OT  - sequential organ failure assessment score
OT  - survival
COIS- There are no conflicts of interest.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:22
PHST- 2019/09/22 00:00 [received]
PHST- 2019/01/18 00:00 [revised]
PHST- 2019/11/01 00:00 [accepted]
PHST- 2020/12/30 05:22 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - 10.4103/IJCIIS.IJCIIS_80_19 [doi]
AID - IJCIIS-10-6 [pii]
PST - ppublish
SO  - Int J Crit Illn Inj Sci. 2020 Sep;10(Suppl 1):6-10. doi:
      10.4103/IJCIIS.IJCIIS_80_19. Epub 2020 Sep 16.


PMID- 33376647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 22
TI  - The Frequency of Catamenial Epilepsy in Female Epileptic Patients of Reproductive
      Age Group Presented to the Tertiary Care Hospital.
PG  - e11635
LID - 10.7759/cureus.11635 [doi]
AB  - Background and aim Catamenial epilepsy is the type of seizures during the
      reproductive phase of menstruation due to hormonal changes during the different
      phases of menstruation. This study aims to evaluate the frequency of epileptic
      seizures in women during the menstruation cycle and its management. Material and 
      methods This study was conducted at the neurology department of Jinnah
      Postgraduate Medical Centre (JPMC), Karachi, Pakistan. The study's duration was
      six months, from the 22(nd) of January 2020 to the 22(nd) of July 2020. The
      sample size for catamenial epilepsy in female epileptic patients of reproductive 
      age was 78%. After approval by the ethical committee of JPMC, data collection
      started. Data was collected and analyzed in the Statistical Package for the
      Social Sciences (SPSS, version 22; IBM Inc., Armonk, USA). Mean, and the standard
      deviation was calculated for age, duration of epilepsy, duration of
      antiepileptic, and antiepileptic drug. A Chi-square test was applied, and
      p</=0.05 was considered a statistically significant difference. Results A total
      of 184 female patients of reproductive age were selected for this study. The mean
      duration of epilepsy was 15.96 +/- 8.85 months. The mean duration of
      antiepileptic drugs was 11.16 +/- 7.53 months. In 73 patients (39.7%), EEG showed
      increased seizure activity during particular phases of the menstrual cycle.
      Catamenial epilepsy was seen in 73 patients (39.7%). The stratification according
      to age, duration of epilepsy, duration of antiepileptic drugs, the antiepileptic 
      drug was done to observe the effect of these modifiers on catamenial epilepsy.
      Conclusion Catamenial epilepsy is relatively common epilepsy. The physician
      should evaluate patients when the seizures are refractory to the treatment. The
      females should manage a seizure diary, which will be beneficial in the management
      of epilepsy. In women with epilepsy, catamenial epilepsy should be considered in 
      the diagnosis when the seizures are refractory to optimal treatment.
CI  - Copyright (c) 2020, Kumar et al.
FAU - Kumar, Deepak
AU  - Kumar D
AD  - Neurology, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
FAU - Iltaf, Samar Sr
AU  - Iltaf S Sr
AD  - Neurology, Dow University of Health Sciences, Karachi, PAK.
FAU - Umer, Anila
AU  - Umer A
AD  - Neurology, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Fatima, Meraj
AU  - Fatima M
AD  - Neurology, Dow University of Health Sciences, Dow International Medical College, 
      Karachi, PAK.
FAU - Zaheer, Muhammad
AU  - Zaheer M
AD  - Neurology, Lady Reading Hospital Peshawar, Peshawar, PAK.
FAU - Waqar, Kiran
AU  - Waqar K
AD  - Neurology, Fazia Ruth Pfau Medical College Karachi, Karachi, PAK.
FAU - Girdhari, Komal
AU  - Girdhari K
AD  - Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201122
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7755724
OTO - NOTNLM
OT  - antiepileptic drugs
OT  - carbamazepine
OT  - catamenial epilepsy
OT  - levetiracetam
OT  - reproductive age
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:22
PHST- 2020/12/30 05:22 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - 10.7759/cureus.11635 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 22;12(11):e11635. doi: 10.7759/cureus.11635.


PMID- 33376598
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2055-7647 (Print)
IS  - 2055-7647 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - Effects of a single bout of walking on postprandial triglycerides in men of
      Chinese, European and Japanese descent: a multisite randomised crossover trial.
PG  - e000928
LID - 10.1136/bmjsem-2020-000928 [doi]
AB  - INTRODUCTION: Elevated non-fasting triglyceride (TG) concentrations are a risk
      factor for cardiovascular diseases but can be reduced after acute exercise.
      Ethnic-based differences in the magnitude of postprandial lipaemia and the extent
      that acute exercise reduces postprandial TG are poorly characterised across some 
      ethnicities including those of East Asian origin. This paper describes the
      protocol of a multisite randomised crossover study comparing the effect of acute 
      walking on postprandial TG in two groups of East Asian men with European men.
      METHODS AND ANALYSIS: Twenty Japanese, 20 Singaporean Chinese and 20 white
      British healthy men (21-39 years) recruited from Japan, Singapore and the UK,
      respectively, will complete two, 2-day trials. Fasted and postprandial venous
      blood samples and arterial blood pressure measurements will be taken over 6 hours
      the day after either: (1) 60-min treadmill walking; or (2) a rest day of normal
      living. The primary outcome is the difference in postprandial TG among ethnic
      groups after rest and walking. Secondary outcomes include cholesterol, glucose,
      insulin, ketone bodies, preheparin lipoprotein lipase, C-reactive protein and
      systolic/diastolic blood pressure. ETHICS AND DISSEMINATION: The study was
      approved by the Ethics Review Committee on Research with Human Subjects of Waseda
      University and the Nanyang Technological University Institutional Review Board.
      Relevant approval will be obtained from the UK site. Research findings will be
      disseminated through peer-reviewed journal publication and health conferences.
      TRIAL REGISTRATION NUMBER: UMIN000038625.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nagayama, Chihiro
AU  - Nagayama C
AUID- ORCID: 0000-0002-2098-3484
AD  - Graduate School of Sport Sciences, Waseda University, Tokorozawa, Japan.
FAU - Burns, Stephen F
AU  - Burns SF
AUID- ORCID: 0000-0001-7192-4735
AD  - Physical Education and Sports Science Academic Group, National Institute of
      Education, Nanyang Technological University, Singapore.
FAU - Stensel, David J
AU  - Stensel DJ
AUID- ORCID: 0000-0001-9119-8590
AD  - School of Sport, Exercise and Health Sciences, Loughborough University,
      Loughborough, UK.
AD  - National Institute for Health Research (NIHR) Leicester Biomedical Research
      Centre, University Hospitals of Leicester NHS and University of Leicester,
      Leicester, UK.
FAU - Thackray, Alice E
AU  - Thackray AE
AUID- ORCID: 0000-0002-7800-3207
AD  - School of Sport, Exercise and Health Sciences, Loughborough University,
      Loughborough, UK.
AD  - National Institute for Health Research (NIHR) Leicester Biomedical Research
      Centre, University Hospitals of Leicester NHS and University of Leicester,
      Leicester, UK.
FAU - Takahashi, Masaki
AU  - Takahashi M
AUID- ORCID: 0000-0002-4038-8164
AD  - Comprehensive Research Organization, Waseda University, Singapore.
FAU - Miyashita, Masashi
AU  - Miyashita M
AUID- ORCID: 0000-0002-7656-641X
AD  - Faculty of Sport Sciences, Waseda University, Tokorozawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - England
TA  - BMJ Open Sport Exerc Med
JT  - BMJ open sport & exercise medicine
JID - 101681007
PMC - PMC7745685
OTO - NOTNLM
OT  - cardiovascular
OT  - exercise physiology
OT  - lipids
OT  - physical activity
OT  - postprandial lipaemia
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - 10.1136/bmjsem-2020-000928 [doi]
AID - bmjsem-2020-000928 [pii]
PST - epublish
SO  - BMJ Open Sport Exerc Med. 2020 Dec 16;6(1):e000928. doi:
      10.1136/bmjsem-2020-000928. eCollection 2020.


PMID- 33376574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Linking)
VI  - 13
IP  - 12
DP  - 2020 Dec
TI  - Consensus on DEfinition of Food Allergy SEverity (DEFASE): Protocol for a
      systematic review.
PG  - 100493
LID - 10.1016/j.waojou.2020.100493 [doi]
AB  - BACKGROUND AND AIMS: The term "Food Allergy" refers to a complex global health
      problem with a wide spectrum of severity. However, a uniform definition of severe
      food allergy is currently missing. This systematic review is the preliminary step
      towards a state-of-the-art synopsis of the current evidence relating to the
      severity of IgE-mediated food allergy; it will inform attempts to develop a
      consensus to define food allergy severity by clinicians and other stakeholders.
      METHODS: We will undertake a systematic review, which will involve searching
      international biomedical databases for published studies. Studies will be
      independently screened against pre-defined eligibility criteria and critically
      appraised by established instruments. Data will be descriptively and, if possible
      and applicable, quantitatively synthesised. ETHICS AND DISSEMINATION: This study 
      does not require any specific ethical approval since it is a systematic review.
      We plan to report results from this systematic review in a peer reviewed journal.
      These results will be used to inform the development of an international
      consensus to define severe food allergy. Author's potential conflicts of interest
      are clearly stated. PROSPERO REGISTRATION NUMBER: CRD42020183103.
CI  - (c) 2020 Published by Elsevier Inc. on behalf of World Allergy Organization.
FAU - Arasi, Stefania
AU  - Arasi S
AD  - Predictive and Preventive Medicine Research Unit, Multifactorial and Systemic
      Diseases Research Area, Pediatric Allergology Unit, Bambino Gesu Children's
      Hospital IRCCS, Rome, Italy.
FAU - Nurmatov, Ulugbek
AU  - Nurmatov U
AD  - Division of Population Medicine, School of Medicine, Cardiff University, Wales,
      UK.
FAU - Turner, Paul J
AU  - Turner PJ
AD  - National Heart & Lung Institute, Imperial College London, London, UK.
AD  - Discipline of Paediatrics and Child Health, School of Medicine, University of
      Sydney, Sydney, Australia.
FAU - Ansotegui, Ignacio J
AU  - Ansotegui IJ
AD  - Dept. Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.
FAU - Daher, Shahd
AU  - Daher S
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Radcliffe Observatory Quarter, England, UK.
FAU - Dunn-Galvin, Audrey
AU  - Dunn-Galvin A
AD  - Applied Psychology and Paediatrics and Child Health, University College Cork,
      Cork, Ireland.
FAU - Ebisawa, Motohiro
AU  - Ebisawa M
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara National
      Hospital, Kanagawa, Japan.
FAU - Eigenmann, Philippe
AU  - Eigenmann P
AD  - Pediatric Allergy Unit, Department of Women-Children-Teenagers Pediatrics,
      University Hospitals of Geneva, Geneva, Switzerland.
FAU - Fernandez-Rivas, Montserrat
AU  - Fernandez-Rivas M
AD  - Servicio de Alergia, Hospital Clinico San Carlos, UCM, IdISSC, ARADyAL, Madrid,
      Spain.
FAU - Gupta, Ruchi
AU  - Gupta R
AD  - Center for Food Allergy and Asthma Research (CFAAR), Northwestern University
      Feinberg School of Medicine; Department of Pediatrics & Medicine, Ann & Robert H.
      Lurie Children's Hospital of Chicago, USA.
FAU - Nowak-Wegrzyn, Anna
AU  - Nowak-Wegrzyn A
AD  - Allergy and Immunology, Department of Pediatrics, New York University School of
      Medicine, Langone Health, New York, NY, USA.
AD  - Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum,
      University of Warmia and Mazury, Olsztyn, Poland.
FAU - Petrou, Stavros
AU  - Petrou S
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Radcliffe Observatory Quarter, England, UK.
FAU - Roberts, Graham
AU  - Roberts G
AD  - NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS 
      Foundation Trust, Southampton, UK.
AD  - Clinical and Experimental Sciences and Human Development in Health, Faculty of
      Medicine, University of Southampton, Southampton, UK.
AD  - The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of
      Wight, UK.
FAU - Sanchez Borges, Mario A
AU  - Sanchez Borges MA
AD  - Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad,
      Caracas, Venezuela.
FAU - Sindher, Sayantani B
AU  - Sindher SB
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of
      Medicine, Stanford University, Stanford, CA, USA.
AD  - Sean N. Parker Center for Allergy and Asthma Research at Stanford University,
      Stanford University, Stanford, CA, USA.
FAU - Tanno, Luciana Kase
AU  - Tanno LK
AD  - Hospital Sirio Libanes, Sao Paulo, Brazil.
AD  - University Hospital of Montpellier; Sorbonne Universites, Paris, Montpellier,
      France.
FAU - Vazquez-Ortiz, Marta
AU  - Vazquez-Ortiz M
AD  - Department of Paediatrics, Imperial College, London, United Kingdom.
FAU - Vickery, Brian P
AU  - Vickery BP
AD  - Department of Pediatrics, Emory University, Atlanta, GA, USA.
FAU - Wong, Gary Wing-Kin
AU  - Wong GW
AD  - Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales
      Hospital, Shatin, Hong Kong, China.
FAU - Fiocchi, Alessandro
AU  - Fiocchi A
AD  - Predictive and Preventive Medicine Research Unit, Multifactorial and Systemic
      Diseases Research Area, Pediatric Allergology Unit, Bambino Gesu Children's
      Hospital IRCCS, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201219
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC7753945
OTO - NOTNLM
OT  - CASP, Critical Appraisal Skills Programme
OT  - CBA, controlled before after studies
OT  - CCT, controlled clinical trials
OT  - CHEERS, Consolidated Health Economic Evaluation Reporting Standards
OT  - CI, confidential interval
OT  - Classification
OT  - Definition
OT  - FAIM, food allergy independent measure
OT  - FAQL, food allergy quality of life
OT  - FARE, Food Allergy Research & Education
OT  - Food allergy
OT  - GRADE, Grading of Recommendations Assessment, Development and Evaluation
OT  - ITS, interrupted time series
OT  - PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
OT  - PROSPERO, Prospective Register of Systematic Reviews
OT  - RCT, randomized controlled trials
OT  - Severity
OT  - WAO, World Allergy Organization
COIS- The following authors declared no potential interests: Ignacio J Ansotegui;
      Stefania Arasi; Shahd Daher; Alessandro Fiocchi; Ulugbek Nurmatov; Stavros
      Petrou; Graham Roberts; Mario Sanchez-Borges; Luciana Kase Tanno; Marta Vazquez
      Ortiz; Gary Wing-Kin Wong. Some of the authors have professional affiliations
      related to the content of the systematic review as set out below: Audrey
      Dunn-Galvin: consultancy fee from Aimmune and DBV; Motohiro Ebisawa: lecture
      fees: DBV technologies and Mylan; Philippe Eigenmann: Research grants and
      support: Ulrich Muller Gierock Foundation, 10.13039/100011033ThermoFisher
      Scientific; Consultant: DBV technologies, Neste, Danone, Novartis, Abbott;
      Speaking engagements: ThermoFisher Scientific, ALK, Abbott; Stock options: DBV
      technologies; Montserrat Fernandez-Rivas: research grants from the Spanish
      Government (10.13039/501100003329MINECO, 10.13039/501100004587ISCIII) for the
      projectos SOLMILK, ARADyAL network and PI19/01095; consultancy fees from Aimmune,
      DBV, Novartis, SPRIM; lecture fees from ALK, Allergy Therapeutics, Diater, GSK,
      HAL Allergy, Thermofisher Scientific. Ruchi Gupta: grants from
      10.13039/100000002The National Institute of Health (NIH) (R21 ID # AI135705, R01 
      ID# AI130348, U01 ID # AI138907), Rho Inc., Stanford Sean N. Parker Center for
      Allergy Research, UnitedHealth Group, 10.13039/100011033Thermo Fisher Scientific,
      10.13039/100004328Genentech, and the National Confectioners Association (NCA); is
      employed by Ann & Robert H. Lurie Children's Hospital of Chicago; is a Professor 
      of Pediatrics at Northwestern University; and serves as a medical
      consultant/advisor for Before Brands, Kaleo Inc., Genentech, ICER, FARE, Aimmune 
      TherapeuticsAimmune Therapeutics, and DBV Technologies; Anna Nowak-Wegrzyn:
      Grant/Research/Clinical Trial Support: DBV Technologies;
      10.13039/100000060ITN/NIAID; 10.13039/100004324Astellas Pharmaceutical;
      Sanofi-Aventis [Future therapies for food allergy]. International FPIES
      Association [FPIES, unpaid advisor]. Consultant/Advisory Boards: Gerber Nutrition
      Institute; Merck. Speaking engagements: Nestle, Thermofisher Scientific;
      Sayantani B Sindher: supported by 10.13039/100000002NIH grants. Involved in
      clinical trials with Regeneron, Aimmune Therapeutics, DBV Technologies, Adare
      Pharmaceuticals, Sanofi, Novartis; Paul J Turner: grants from UK Medical Research
      Council, NIHR/Imperial BRC, JM Charitable Foundation and UK Food Standards
      Agency; personal fees fromUK Food Standards Agency, DBV Technologies, ILSI Europe
      and Allergenis, non-financial support from Aimmune Therapeutics; Brian P Vickery:
      Employment: Pediatric Institute of Emory University + Children's Healthcare of
      Atlant; Consultant/Advisor: Aimmune Therapeutics; AllerGenis, LLC; Food Allergy
      Research and Education (FARE); Reacta Biosciences; Grant support: Immune
      Tolerance Network; 10.13039/100000060NIH-NIAID; 10.13039/100006423FARE;
      10.13039/100004328Genentech; Clinical investigator: Aimmune; DBV Technologies;
      Regeneron.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/08/06 00:00 [received]
PHST- 2020/10/27 00:00 [revised]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - 10.1016/j.waojou.2020.100493 [doi]
AID - S1939-4551(20)30396-3 [pii]
PST - epublish
SO  - World Allergy Organ J. 2020 Dec 19;13(12):100493. doi:
      10.1016/j.waojou.2020.100493. eCollection 2020 Dec.


PMID- 33376573
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Linking)
VI  - 13
IP  - 12
DP  - 2020 Dec
TI  - Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with 
      allergic rhinitis and asthma in UK primary care.
PG  - 100490
LID - 10.1016/j.waojou.2020.100490 [doi]
AB  - BACKGROUND: MP-AzeFlu (Dymista(R); spray of azelastine/fluticasone propionate) is
      the most effective allergic rhinitis (AR) treatment available. Its effect on
      asthma outcomes in patients with AR and asthma is unknown. METHODS: This pre-post
      historical cohort study, using the Optimum Patient Care Research Database,
      included patients aged >/=12 years, from UK general practice with active asthma
      (defined as a recorded diagnosis, with >/=1 prescription for reliever or
      controller inhaler) in the year before or at the initiation date. The primary
      study outcome was change in number of acute respiratory events (i.e. exacerbation
      or antibiotic course for a respiratory event) between baseline and outcome years.
      The effect size of MP-AzeFlu was quantified as the difference in % of patients
      that improved and worsened. RESULTS: Of the 1,188 patients with AR and asthma
      included, many had a record of irreversible obstruction (67%), and uncontrolled
      asthma (70.4%), despite high mean daily doses of reliever/controller therapy and 
      acute oral corticosteroid use, in the year pre-MP-AzeFlu initiation. MP-AzeFlu
      initiation was associated with fewer acute respiratory events (effect size (e) = 
      5.8%, p = 0.0129) and a reduction in daily use of short-acting beta2-agonists,
      with fewer patients requiring >2 SABA puffs/week (e = 7.7% p < 0.0001). More
      patients had well-controlled asthma 1-year post-MP-AzeFlu initiation (e = 4.1%; p
      = 0.0037), despite a reduction in inhaled corticosteroids (e = 4.8%; p = 0.0078).
      CONCLUSIONS: This study provides the first direct evidence of the beneficial
      effect of MP-AzeFlu on asthma outcomes in co-morbid patients in primary care in
      the United Kingdom. TRIAL REGISTRATION: EUPAS30940. Registered August 13, 2019.
CI  - (c) 2020 The Authors.
FAU - De Jong, Hilda J I
AU  - De Jong HJI
AD  - Observational and Pragmatic Research Institute, Singapore.
FAU - Voorham, Jaco
AU  - Voorham J
AD  - Observational and Pragmatic Research Institute, Singapore.
FAU - Scadding, Glenis K
AU  - Scadding GK
AD  - Royal National Throat, Nose and Ear Hospital, University College London School of
      Medicine, London, UK.
FAU - Bachert, Claus
AU  - Bachert C
AD  - Ghent University Hospital, Ghent, Belgium.
FAU - Canonica, Giorgio Walter
AU  - Canonica GW
AD  - Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research
      Hospital, SANI-Severe Asthma Network, Milan, Italy.
FAU - Smith, Peter
AU  - Smith P
AD  - Griffith University, Southport, QLD, Australia.
FAU - Wahn, Ulrich
AU  - Wahn U
AD  - Charite Medical University, Berlin, Germany.
FAU - Ryan, Dermot
AU  - Ryan D
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK.
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Castillo, Jose A
AU  - Castillo JA
AD  - Hospital Universitari Quiron Dexeus, Barcelona, Spain.
FAU - Carter, Victoria A
AU  - Carter VA
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Murray, Ruth B
AU  - Murray RB
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Price, David B
AU  - Price DB
AD  - Observational and Pragmatic Research Institute, Singapore.
AD  - Optimum Patient Care, Cambridge, UK.
AD  - Academic Primary Care, University of Aberdeen, Aberdeen, UK.
LA  - eng
PT  - Journal Article
DEP - 20201219
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC7753940
OTO - NOTNLM
OT  - ADEPT, Anonymized data ethics & protocol transparency
OT  - AR, Allergic rhinitis
OT  - ATS, American Thoracic society
OT  - BEC, Blood eosinophil count
OT  - CRS, Chronic rhinosinusitis
OT  - Control
OT  - ERS, European respiratory society
OT  - Exacerbations
OT  - FEV1, forced expiratory volume in 1 s
OT  - FVC, Forced vital capacity
OT  - GERD, Gastroesophageal reflux disease
OT  - GINA, Global initiative for asthma
OT  - ICS, Inhaled corticosteroid
OT  - INS, Intranasal corticosteroid
OT  - NP, Nasal polyps
OT  - OAC, Overall asthma control
OT  - OAH, Oral anti-histamine
OT  - OCS, Oral corticosteroid
OT  - OPCRD, Optimum patient care research database
OT  - OTC, Over the counter
OT  - PEF, Peak expiratory flow rate
OT  - RCT, Randomized controlled trial
OT  - RDAC, Risk domain asthma control
OT  - Rescue medication
OT  - SABA, Short-acting beta2-agonist
OT  - SMD, Standardised mean difference
OT  - UK, United Kingdom
COIS- Hilda J.I. De Jong, Jaco Voorham, and Victoria A. Carter are employees of the
      Observational and Pragmatic Research Institute (OPRI). Glenis K.Scadding has
      received funding for talks and for advice from Mylan, GSK, ALK-Abello, Sanofi and
      Stallergenes. She chaired the BSACI Rhinitis Guidelines and chairs the EAACI
      Ethics Committee. Claus Bachert has received fees for lectures, advisory board
      meetings or search grants from Sanofi-Aventis, Novartis, GSK, Astra-Zeneca,
      Genzyme, Regeneron, Mylan, Uriach, ALK, Asit Biotech and Stallergenes. Giorgio
      Walter Canonica has received research grants, as well as lecture or advisory
      board fees from A. Menarini, Alk-Abello, Allergy Therapeutics, Anallergo,
      AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia,
      Danone, Faes, Genentech, Guidotti-Malesci, GlaxoSmithKline, Hal Allergy, Merck,
      MSD, Mundipharma, Novartis, Orion, Sanofi-Aventis, Sanofi, Genzyme/Regeneron,
      Stallergenes, UCB Pharma, Uriach Pharma, Teva, Thermo Fisher, and Valeas. Peter
      Smith has received an investigator initiated grant and funding for talks and
      advice from Mylan, has done talks for GSK, AZ, Novartis, Bayer, and Abbott, and
      has been on advisory boards for Nestle and Seqirus. Ulrich Wahn received
      honoraria for consultation and lectures from ALK, Stallergenes, Allergopharma,
      Novartis, Sanofi-Aventis, Roxall, Pfizer, UCB, Biomay, Berlin-Chemie. Dermot Ryan
      has (in the last 3 years) lectured on behalf of, received sponsorship from, or
      acted as a paid advisor to Mylan, AZ, Chiesi, Novartis, GSK, Boehringer Ingelheim
      and Regeneron. Jose A. Castillo reports receipt of fees for lectures, advisory
      board meetings or research grants from MSD, ALK, AstraZeneca,
      Boehringer-Ingelheim, Uriach, GSK, Leti and ALK. He has chaired the Normativa
      SEPAR on Asthma, Rhinitis and Nasal Polyp Multimorbidities and chairs The
      Rhinitis Committee in Asthma Area from SEPAR. Ruth B. Murray reports no conflict 
      of interest. David B. Price has board membership with Amgen, AstraZeneca,
      Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron 
      Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy 
      agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi,
      GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals,
      Theravance; grants and unrestricted funding for investigator-initiated studies
      (conducted through Observational and Pragmatic Research Institute Pte Ltd) from
      AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma,
      Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group,
      Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service;
      payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim,
      Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron
      Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the
      development of educational materials from Mundipharma, Novartis; payment for
      travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim,
      Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or
      completion of research from Novartis; stock/stock options from AKL Research and
      Development Ltd which produces phytopharmaceuticals; owns 74% of the social
      enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational
      and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in
      Timestamp which develops adherence monitoring technology; is peer reviewer for
      grant committees of the Efficacy and Mechanism Evaluation programme, and Health
      Technology Assessment; and was an expert witness for GlaxoSmithKline.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/06/08 00:00 [received]
PHST- 2020/10/30 00:00 [revised]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - 10.1016/j.waojou.2020.100490 [doi]
AID - S1939-4551(20)30393-8 [pii]
PST - epublish
SO  - World Allergy Organ J. 2020 Dec 19;13(12):100490. doi:
      10.1016/j.waojou.2020.100490. eCollection 2020 Dec.


PMID- 33376472
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - How does the MedTech Europe Code of Ethical Business Practice Affect the
      Activities of Professional Societies in Laboratory Medicine?
PG  - 320-325
AB  - The MedTech Europe Code of Ethical Business Practice came into effect on 1
      January 2018. It was created by the medical technology industry. It addresses the
      importance of fair management of educational grants: public disclosure of
      provided educational grants, compliance of conferences with the Conference
      Vetting System; allocation of grants to healthcare organizations (HCOs) but not
      to the healthcare professionals (HCPs); the need for written contracts with HCOs,
      etc. As a National Society and member of IFCC and EFLM, the Lithuanian Society of
      Laboratory Medicine (LLMD) has created a fund dedicated to the continuous
      professional development of LLMD member HCPs. The fund, as an instrument for the 
      ethical use of money, corresponds to the principles of the MedTech Code of
      Ethical Business Practice and is an example on how HCOs can implement it to
      ensure ethical communication between the IVD (In Vitro Diagnostics) industry,
      HCOs and their member HCPs. Scarce data exists on the level of MedTech acceptance
      and implementation among HCOs and HCPs, thus more effort has to be made to better
      communicate and consequently improve fair use of the funds received from the
      industry, and to improve the ethical behavior of HCPs.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Banys, Valdas
AU  - Banys V
AD  - Vilnius University, Faculty of Medicine, Institute of Biomedical Sciences,
      Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine,
      Vilnius, Lithuania.
AD  - Vilnius University Hospital Santaros Klinikos, Center of Laboratory Medicine,
      Vilnius, Lithuania.
AD  - Lithuanian Society of Laboratory Medicine.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745294
OTO - NOTNLM
OT  - MedTech Europe
OT  - continuous professional development
OT  - laboratory medicine
OT  - the Code of Ethical Business Practice
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-320 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):320-325. eCollection 2020 Nov.


PMID- 33376471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - Ethics and the Electronic Health Record: Description of An Integrating System of 
      Electronic Health Records in Argentina and a Proposal to Shift Towards a
      Patient-Centered Conception.
PG  - 310-319
AB  - The Electronic Health Record (EHR) constitutes a complete information system
      useful for patient care, epidemiological studies and public health policies
      development. We describe the Integrating System of EHRs of the Autonomous City of
      Buenos Aires (CABA), established by Law 5669, of 2016. Although we consider the
      Integrating System of EHRs implemented by CABA very appropriate, we propose,
      first, that health services no longer store comprehensive EHRs. Instead, complete
      information would reside in one or several servers sheltered by civil society.
      Second, information would become integrated only when patients require it and
      grant access. The patient would now be in a position of strength (complete
      autonomy). Instead of asking for his data he would be asked for them. In this
      sense, the patient will have to exercise the emerging responsibility of
      reciprocity to the benefit of his own care and the care of others.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Verona, Julian
AU  - Verona J
AD  - Central Laboratory, Hospital Dr. Felipe A. Fossati, Balcarce, Argentina.
AD  - Confederacion Unificada Bioquimica de la Republica Argentina, CUBRA.
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
LA  - eng
PT  - Case Reports
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745301
OTO - NOTNLM
OT  - bioethical principles
OT  - patient-centered electronic health record
OT  - patient`s rights
OT  - reciprocity
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-310 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):310-319. eCollection 2020 Nov.


PMID- 33376470
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - A Framework to Ethically Approach Incidental Findings in Genetic Research.
PG  - 302-309
AB  - With the advancement of science in the area of genetics and genomics, special
      ethical considerations should be taken in addition to the general ethical
      framework followed in research. Genetic research can reveal information about the
      susceptibility of an individual to disease and hence about his/her future health.
      Such information may be of interest and benefit to research participants,
      especially if preventive strategies exist. It may also expose them to other risks
      or anxieties when incidental findings that were not the primary scope of the
      study are found. Ethical guidelines acknowledge the duty of researchers to
      disclose incidental findings (IFs) to participants. In this review, we recommend 
      four steps approach that researchers can use to disclose incidental findings:
      plan for IFs, discuss IFs in informed consent, identify and disclose IFs.
      Verification and identification of IFs should follow a categorical stratification
      based on the importance of the findings and the presence of a beneficial
      intervention to the participants.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Beshir, Lamis
AU  - Beshir L
AD  - Department of Clinical Immunology, Sudan Medical Specialization Board, Khartoum, 
      Sudan.
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745305
OTO - NOTNLM
OT  - genetic research
OT  - genomics
OT  - incidental findings
OT  - research ethics
OT  - unsolicited findings
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-302 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):302-309. eCollection 2020 Nov.


PMID- 33376469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - Conflicts of Interest and An Approach to Managing Them.
PG  - 292-301
AB  - Conflicts of interest (COI) exist in every step of life, including in medicine
      and science. Professionals who work in different areas of Health systems, such as
      physicians in care patient, in pharmaceutical and biomedical devices industries, 
      in management positions, in teaching or in research, all must apply rigid ethical
      principles. It is possible with these actions that COI were detected in several
      circumstances such as in the prescribing therapy, in production or employment of 
      technology in services of Health system, in article publications, and in
      decision-making for those who have decided to occupy positions of responsibility 
      in scientific and healthcare institutions, in industry or professional
      associations, among others. These actions must be consistent with the essential
      principles of Bioethics. At present, COI disclosure has been irreversibly
      installed in Medicine. A detailed description of the classification of conflicts 
      of interest and its ethical and legal implications in the practice of health
      sciences such as those that appear in the practice of clinical and laboratory
      medicine, pharmaceutical industry and also, research and publications are
      included. Final considerations on the management of COI are also included.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Fink, Nilda E
AU  - Fink NE
AD  - PROES Program, Biochemical Foundation of Argentina.
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745299
OTO - NOTNLM
OT  - conflict of interest
OT  - disclosure
OT  - ethics
OT  - management
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-292 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):292-301. eCollection 2020 Nov.


PMID- 33376468
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - Research Ethics Committees in Laboratory Medicine.
PG  - 282-291
AB  - Biomedical research that involves human subjects requires compliance with ethical
      principles and guidelines. The ethical and scientific standards of research have 
      been thoroughly discussed by international ethical guidelines and declarations.
      Compliance with these ensures the autonomy, dignity and well-being of research
      subjects; as well as the integrity and credibility of research results. Research 
      ethics committees (RECs) are mandated to ensure that research proposals are
      scientifically sound and ethical. In this review, we define RECs in laboratory
      medicine and describe their role based on the examination of the requirements of 
      ethical research; discuss particular ethical issues that arise in laboratory
      medicine research using biological samples, what challenges they face and how
      they can ensure the quality of their review. RECs need to be put into a broader
      framework that ensures institutional governance with continuous evaluation and
      auditing that ensure the quality of ethical review.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Beshir, Lamis
AU  - Beshir L
AD  - Department of Clinical Immunology, Sudan Medical Specialization Board, Khartoum, 
      Sudan.
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745300
OTO - NOTNLM
OT  - autonomy
OT  - beneficence
OT  - biological samples
OT  - informed consent
OT  - institutional review boards
OT  - justice
OT  - laboratory medicine
OT  - non-maleficence
OT  - research ethics
OT  - research ethics committees
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-282 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):282-291. eCollection 2020 Nov.


PMID- 33376467
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201230
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - Ethics in Laboratory Medicine: Perspectives and Challenges in Resource Limited
      Settings.
PG  - 274-281
AB  - Currently diagnosis and management of patients in Clinical Practice is very much 
      dependent on laboratory diagnostics. Laboratory Medicine, like any other branch
      of Medicine, is therefore, mandated with ethical usage of materials and data
      obtained from patients. Several countries, professional societies and the have
      developed policies and guidance materials on ethical issues related to laboratory
      medicine. However, ethical standards and practices vary between different
      cultures, geographies, legal architecture and according to available resources.
      In this article, we try to understand the challenges presented in terms of
      Ethics, where there are constraints of resources.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Datta, Sudip Kumar
AU  - Datta SK
AD  - Department of Lab Medicine, All India Institute of Medical Sciences, New Delhi,
      India.
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745303
OTO - NOTNLM
OT  - challenges
OT  - ethics
OT  - laboratory medicine
OT  - perspectives
OT  - resource-limited
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-274 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):274-281. eCollection 2020 Nov.


PMID- 33376466
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - Codes of Ethics for Laboratory Medicine: Definition, Structure and Procedures - A
      Narrative Review Based on Existing National Codes.
PG  - 262-273
AB  - BACKGROUND: It behoves every national society of clinical laboratory medicine to 
      have a well formulated and publicly accessible policy concerning the morally
      acceptable way in which its members should practise their profession; such a
      policy is published as a Code of Ethics.This Code assists its members in the
      performance of their duties in relation to the patients they share with other
      clinicians, within their own particular professional environment and, at large,
      to the rest of their national society. METHODS AND RESULT: The International
      Federation of Clinical Chemistry and Laboratory Medicine's (IFCC) Task Force on
      Ethics here examines a curated selection of extant Codes and provides guidance at
      the level of definition, structure and procedures to assist national societies
      and their clinical chemistry and laboratory medicine professionals in the task of
      crafting their own Ethics Code.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Davey, Richard X
AU  - Davey RX
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745304
OTO - NOTNLM
OT  - clinical laboratory
OT  - ethics code
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-262 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):262-273. eCollection 2020 Nov.


PMID- 33376465
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Nov
TI  - Foreword: Ethics in Laboratory Medicine.
PG  - 260-261
FAU - Fink, Nilda E
AU  - Fink NE
AD  - On behalf of the IFCC Task Force on Ethics (TF-E).
AD  - PROES Program, Biochemical Foundation of Argentina.
LA  - eng
PT  - Editorial
DEP - 20201120
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7745295
OTO - NOTNLM
OT  - MedTech Europe Code
OT  - autonomy
OT  - beneficence
OT  - bioethical principles
OT  - biological samples
OT  - clinical laboratory
OT  - conflict of interest
OT  - continuous professional development
OT  - disclosure
OT  - ethics
OT  - ethics code
OT  - incidental findings
OT  - informed consent
OT  - justice
OT  - laboratory medicine
OT  - management
OT  - non-maleficence
OT  - patient-centered electronic health record
OT  - research ethics
OT  - research ethics committees
OT  - resource limited settings
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 05:21
PHST- 2020/12/30 05:21 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - ejifcc-31-260 [pii]
PST - epublish
SO  - EJIFCC. 2020 Nov 20;31(4):260-261. eCollection 2020 Nov.


PMID- 33376186
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Masculinising testosterone treatment and effects on preclinical cardiovascular
      disease, muscle strength and power, aggression, physical fitness and respiratory 
      function in transgender men: protocol for a 10-year, prospective, observational
      cohort study in Denmark at the Body Identity Clinic (BIC).
PG  - e045714
LID - 10.1136/bmjopen-2020-045714 [doi]
AB  - INTRODUCTION: The number of individuals with gender dysphoria seeking
      gender-affirming treatment is increasing. The short-term and long-term effects of
      masculinising treatment with testosterone are debated as serum testosterone
      increases up to 20-fold compared with cisgender women. We will investigate
      short-term and long-term effects of masculinising testosterone treatment on
      preclinical and clinical coronary disease, muscle strength and power, oxygen
      consumption (VO2) max, cardiac and respiratory function and quality of life
      including aggression in transgender men. METHODS AND ANALYSES: Prospective,
      single-centre, observational cohort study at the Body Identity Clinic (BIC),
      Odense University Hospital, Denmark. Investigations are performed at inclusion
      and following 1, 3, 5 and 10 years of testosterone therapy. Non-calcified
      coronary plaque volume and calcium score are estimated by coronary CT
      angiography. CT is only performed at inclusion and following 1 and 10 years.
      Upper body muscle strength and power are measured by a 'low row' weight stack
      resisted exercise machine. Evaluation of aggression and quality of life is
      assessed by questionnaires, VO2 max is estimated by maximal testing on bike
      ergometer, and cardiac and respiratory functions are measured by echocardiography
      and spirometry, respectively. Markers of cardiovascular risk and inflammation and
      also cortisol and cortisone are assessed in blood, diurnal urine and/or hair
      samples. Our cohort (BIC), including dropouts, will be an embedded subcohort in a
      future national registry study in all individuals with gender dysphoria and
      controls. Data are available on International Statistical Classification of
      Diseases and Related Health Problems 10(th) version diagnostic codes,
      prescriptions, socioeconomics and causes of death. ETHICS AND DISSEMINATION: The 
      Regional Committee on Health Research Ethics for Southern Denmark (S-20190108)
      and the Danish Data Protection Agency (19/27572) approved the study. Signed
      informed consent will be obtained from all participants. All findings will be
      published in peer-reviewed journals or at scientific conferences. TRIAL
      REGISTRATION NUMBER: NCT04254354.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lehmann Christensen, Louise
AU  - Lehmann Christensen L
AUID- ORCID: 0000-0001-6489-7054
AD  - Body Identity Clinic, Department of Endocrinology, Odense University Hospital,
      Odense, Denmark louise.lehmann.christensen@rsyd.dk.
AD  - Odense University Hospital Department of Endocrinology, Odense, Denmark.
FAU - Glintborg, Dorte
AU  - Glintborg D
AUID- ORCID: 0000-0002-8338-8025
AD  - Body Identity Clinic, Department of Endocrinology, Odense University Hospital,
      Odense, Denmark.
FAU - Taulbjerg Kristensen, Tine
AU  - Taulbjerg Kristensen T
AUID- ORCID: 0000-0002-0730-6120
AD  - Body Identity Clinic, Department of Endocrinology, Odense University Hospital,
      Odense, Denmark.
FAU - Diederichsen, Axel
AU  - Diederichsen A
AUID- ORCID: 0000-0002-1285-4826
AD  - Department of Cardiology, Odense University Hospital, Odense, Denmark.
FAU - T'Sjoen, Guy
AU  - T'Sjoen G
AUID- ORCID: 0000-0003-0457-9673
AD  - Department of Endocrinology, University Hospital Ghent, Gent, Belgium.
FAU - Frystyk, Jan
AU  - Frystyk J
AUID- ORCID: 0000-0002-5379-0961
AD  - Body Identity Clinic, Department of Endocrinology, Odense University Hospital,
      Odense, Denmark.
AD  - Odense University Hospital Department of Endocrinology, Odense, Denmark.
FAU - Skovsager Andersen, Marianne
AU  - Skovsager Andersen M
AUID- ORCID: 0000-0002-4603-9504
AD  - Body Identity Clinic, Department of Endocrinology, Odense University Hospital,
      Odense, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04254354
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Aggression
MH  - Body Image
MH  - *Cardiovascular Diseases
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscle Strength
MH  - Observational Studies as Topic
MH  - Physical Fitness
MH  - Prospective Studies
MH  - Quality of Life
MH  - Testosterone
MH  - *Transgender Persons
PMC - PMC7778784
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *general endocrinology
OT  - *sex steroids & HRT
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-045714 [pii]
AID - 10.1136/bmjopen-2020-045714 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e045714. doi: 10.1136/bmjopen-2020-045714.


PMID- 33376184
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Exercise training modalities for heart transplant recipients: a systematic review
      and network meta-analysis protocol.
PG  - e044975
LID - 10.1136/bmjopen-2020-044975 [doi]
AB  - INTRODUCTION: Heart transplantation is the gold standard treatment for selected
      patients with end-stage heart failure. Although this procedure can improve
      quality and prolong life expectancy, several of these patients persist with
      decreased exercise tolerance. Evidence suggests that exercise training can bring 
      multifactorial benefits to heart transplant (HTx) recipients. However, it is
      unclear that exercise modality should be preferred. Therefore, the aim of this
      systematic review and network meta-analysis is to compare the efficacy and safety
      of different training modalities in HTx recipients. METHODS AND ANALYSIS: We will
      perform a comprehensive literature search in PubMed/MEDLINE, Embase, The Cochrane
      Library, CINAHL, Scopus, SportDISCUS, Web of Science Core Collection and PEDro
      from inception until November 2020. Two registries (ClinicalTrials.gov and REBEC)
      will also be searched for potential results in unpublished studies. There will be
      no restriction on language, date of publication, publication status or sample
      size. We will include randomised controlled trials enrolling adult HTx recipients
      with the presence of at least one exercise training group, which might be
      compared with another training modality and/or a non-exercise control group for a
      minimum of 4 weeks of intervention. The primary outcomes will be peak oxygen
      consumption and occurrence of adverse events. As secondary outcomes, the
      interaction between pulmonary ventilation, pulmonary perfusion and cardiac
      output, oxygen uptake efficiency slope, heart rate response, oxygen pulse, peak
      blood pressure and peak subjective perception of effort. In addition, we will
      evaluate the 6 min walking distance, health-related quality of life, endothelial 
      function, muscle strength, body fat percentage and lean mass. Risk of bias will
      be assessed using the Cochrane RoB V.2.0 tool, and we plan to use the Confidence 
      in Network Meta-Analysis tool to assess confidence in the results. All materials 
      (raw data, processed data, statistical code and outputs) will be shared in a
      public repository. ETHICS AND DISSEMINATION: Given the nature of this study, no
      ethical approval will be required. We believe that the findings of this study may
      show which is the most efficacious and safe physical training modality for HTx
      recipients. The completed systematic review and network meta-analysis will be
      submitted to a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020191192.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Lima, Juliana Beust
AU  - de Lima JB
AUID- ORCID: 0000-0002-5408-2457
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS,
      Brazil julianabeustdelima@gmail.com.
AD  - Exercise Cardiology Research Group, Universidade Federal do Rio Grande do Sul,
      Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
FAU - Soares, Douglas Dos Santos
AU  - Soares DDS
AUID- ORCID: 0000-0002-9166-7614
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS,
      Brazil.
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
FAU - Ferrari, Filipe
AU  - Ferrari F
AUID- ORCID: 0000-0001-6929-8392
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS,
      Brazil.
AD  - Exercise Cardiology Research Group, Universidade Federal do Rio Grande do Sul,
      Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
FAU - Carvas Junior, Nelson
AU  - Carvas Junior N
AUID- ORCID: 0000-0003-2168-8927
AD  - Department of Evidence-Based Health, Brazilian Cochrane Center, Universidade
      Federal de Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Carvalho, Gabriel
AU  - Carvalho G
AUID- ORCID: 0000-0001-7792-826X
AD  - Exercise Cardiology Research Group, Universidade Federal do Rio Grande do Sul,
      Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
FAU - Tobar Leitao, Santiago Alonso
AU  - Tobar Leitao SA
AUID- ORCID: 0000-0002-4163-7783
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS,
      Brazil.
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
FAU - Goldraich, Livia Adams
AU  - Goldraich LA
AUID- ORCID: 0000-0002-1523-4286
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
AD  - Heart Failure and Cardiac Transplant Unit, Cardiology Division, Hospital das
      Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
FAU - Clausell, Nadine
AU  - Clausell N
AUID- ORCID: 0000-0003-4207-3809
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS,
      Brazil.
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
AD  - Heart Failure and Cardiac Transplant Unit, Cardiology Division, Hospital das
      Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
AD  - Associate Professor, School of Medicine, Universidade Federal do Rio Grande do
      Sul, Porto Alegre, RS, Brazil.
FAU - Stein, Ricardo
AU  - Stein R
AUID- ORCID: 0000-0003-2357-5176
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS,
      Brazil.
AD  - Exercise Cardiology Research Group, Universidade Federal do Rio Grande do Sul,
      Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
AD  - Interdisciplinary Research Group in Translational Cardiology, Clinical Research
      Center, Hospital das Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.
AD  - Associate Professor, School of Medicine, Universidade Federal do Rio Grande do
      Sul, Porto Alegre, RS, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Exercise
MH  - Exercise Therapy
MH  - *Heart Transplantation
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - *Quality of Life
MH  - Systematic Reviews as Topic
PMC - PMC7778772
OTO - NOTNLM
OT  - *cardiorespiratory fitness
OT  - *exercise training
OT  - *health-related quality of life
OT  - *heart rate
OT  - *heart transplantation
OT  - *safety
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-044975 [pii]
AID - 10.1136/bmjopen-2020-044975 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e044975. doi: 10.1136/bmjopen-2020-044975.


PMID- 33376181
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort
      study to examine if medical cannabis reduces opioid use among adults with chronic
      pain.
PG  - e043400
LID - 10.1136/bmjopen-2020-043400 [doi]
AB  - INTRODUCTION: In the USA, opioid analgesic use and overdoses have increased
      dramatically. One rapidly expanding strategy to manage chronic pain in the
      context of this epidemic is medical cannabis. Cannabis has analgesic effects, but
      it also has potential adverse effects. Further, its impact on opioid analgesic
      use is not well studied. Managing pain in people living with HIV is particularly 
      challenging, given the high prevalence of opioid analgesic and cannabis use. This
      study's overarching goal is to understand how medical cannabis use affects opioid
      analgesic use, with attention to Delta9-tetrahydrocannabinol and cannabidiol
      content, HIV outcomes and adverse events. METHODS AND ANALYSES: We are conducting
      a cohort study of 250 adults with and without HIV infection with (a) severe or
      chronic pain, (b) current opioid use and (c) who are newly certified for medical 
      cannabis in New York. Over 18 months, we collect data via in-person visits every 
      3 months and web-based questionnaires every 2 weeks. Data sources include:
      questionnaires; medical, pharmacy and Prescription Monitoring Program records;
      urine and blood samples; and physical function tests. Using marginal structural
      models and comparisons within participants' 2-week time periods (unit of
      analysis), we will examine how medical cannabis use (primary exposure) affects
      (1) opioid analgesic use (primary outcome), (2) HIV outcomes (HIV viral load, CD4
      count, antiretroviral adherence, HIV risk behaviours) and (3) adverse events
      (cannabis use disorder, illicit drug use, diversion, overdose/deaths,
      accidents/injuries, acute care utilisation). ETHICS AND DISSEMINATION: This study
      is approved by the Montefiore Medical Center/Albert Einstein College of Medicine 
      institutional review board. Findings will be disseminated through conferences,
      peer-reviewed publications and meetings with medical cannabis stakeholders. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03268551); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cunningham, Chinazo O
AU  - Cunningham CO
AUID- ORCID: 0000-0002-7930-313X
AD  - Division of General Internal Medicine, Montefiore Health System, Bronx, New York,
      USA chinazo.cunningham@einsteinmed.org.
FAU - Starrels, Joanna L
AU  - Starrels JL
AD  - Division of General Internal Medicine, Montefiore Health System, Bronx, New York,
      USA.
FAU - Zhang, Chenshu
AU  - Zhang C
AD  - Division of General Internal Medicine, Montefiore Health System, Bronx, New York,
      USA.
FAU - Bachhuber, Marcus A
AU  - Bachhuber MA
AD  - Section of Community and Population Medicine, Louisiana State University Health
      Sciences Center, New Orleans, Louisiana, USA.
FAU - Sohler, Nancy L
AU  - Sohler NL
AD  - School of Medicine, City University of New York, New York, New York, USA.
FAU - Levin, Frances R
AU  - Levin FR
AD  - Department of Psychiatry, Columbia University Irving Medical Center, New York,
      New York, USA.
FAU - Minami, Haruka
AU  - Minami H
AD  - Psychology Department, Fordham University, Bronx, New York, USA.
FAU - Slawek, Deepika E
AU  - Slawek DE
AD  - Division of General Internal Medicine, Montefiore Health System, Bronx, New York,
      USA.
FAU - Arnsten, Julia H
AU  - Arnsten JH
AD  - Division of General Internal Medicine, Montefiore Health System, Bronx, New York,
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03268551
GR  - K24 DA036955/DA/NIDA NIH HHS/United States
GR  - K24 DA046309/DA/NIDA NIH HHS/United States
GR  - P30 AI124414/AI/NIAID NIH HHS/United States
GR  - R01 DA044171/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Medical Marijuana)
SB  - IM
MH  - Adult
MH  - Analgesics, Opioid/adverse effects
MH  - *Chronic Pain/drug therapy/epidemiology
MH  - Cohort Studies
MH  - *HIV Infections/complications/drug therapy
MH  - Humans
MH  - Longitudinal Studies
MH  - *Medical Marijuana/therapeutic use
MH  - New York
PMC - PMC7778768
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *complementary medicine
OT  - *pain management
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043400 [pii]
AID - 10.1136/bmjopen-2020-043400 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e043400. doi: 10.1136/bmjopen-2020-043400.


PMID- 33376179
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Biomarkers for length of hospital stay, changes in muscle mass, strength and
      physical function in older medical patients: protocol for the Copenhagen PROTECT 
      study-a prospective cohort study.
PG  - e042786
LID - 10.1136/bmjopen-2020-042786 [doi]
AB  - INTRODUCTION: Sarcopenia is generally used to describe the age-related loss of
      muscle mass and strength believed to play a major role in the pathogenesis of
      physical frailty and functional impairment that may occur with old age. The
      knowledge surrounding the prevalence and determinants of sarcopenia in older
      medical patients is scarce, and it is unknown whether specific biomarkers can
      predict physical deconditioning during hospitalisation. We hypothesise that a
      combination of clinical, functional and circulating biomarkers can serve as a
      risk stratification tool and can (i) identify older acutely ill medical patients 
      at risk of prolonged hospital stays and (ii) predict changes in muscle mass,
      muscle strength and function during hospitalisation. METHOD AND ANALYSIS: The
      Copenhagen PROTECT study is a prospective cohort study consisting of acutely ill 
      older medical patients admitted to the acute medical ward at Copenhagen
      University Hospital, Bispebjerg and Frederiksberg, Denmark. Assessments are
      performed within 24 hours of admission and include blood samples, body
      composition, muscle strength, physical function and questionnaires. A subgroup of
      patients transferred to the Geriatric Department are included in a smaller
      geriatric cohort and have additional assessments at discharge to evaluate the
      relative change in circulating biomarker concentrations, body composition, muscle
      strength and physical function during hospitalisation. Enrolment commenced 4
      November 2019, and proceeds until August 2021. ETHICS AND DISSEMINATION: The
      study protocol has been approved by the local ethics committee of Copenhagen and 
      Frederiksberg (H-19039214) and the Danish Data Protection Agency (P-2019-239) and
      all experimental procedures were performed in accordance with the Declaration of 
      Helsinki. Findings from the project, regardless of the outcome, will be published
      in relevant peer-reviewed scientific journals in online (www.clinicaltrials.gov).
      TRIAL REGISTRATION NUMBER: NCT04151108.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kamper, Rikke S
AU  - Kamper RS
AUID- ORCID: 0000-0002-1927-9078
AD  - Geriatric Research Unit, Department of Geriatric and Palliative Medicine,
      Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
      rikke.stefan.kamper.01@regionh.dk.
AD  - CopenAge; Copenhagen Center for Clinical Age Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Schultz, Martin
AU  - Schultz M
AD  - Geriatric Research Unit, Department of Medicine, Copenhagen University Hospital, 
      Herlev and Gentofte, Herlev, Denmark.
AD  - CopenAge; Copenhagen Center for Clinical Age Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Hansen, Sofie K
AU  - Hansen SK
AD  - Geriatric Research Unit, Department of Geriatric and Palliative Medicine,
      Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen,
      Denmark.
AD  - CopenAge; Copenhagen Center for Clinical Age Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Andersen, Helle
AU  - Andersen H
AD  - Department of Occupational and Physiotherapy, Copenhagen University Hospital,
      Bispebjerg and Frederiksberg, Copenhagen, Denmark.
AD  - CopenAge; Copenhagen Center for Clinical Age Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Ekmann, Anette
AU  - Ekmann A
AD  - Geriatric Research Unit, Department of Geriatric and Palliative Medicine,
      Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen,
      Denmark.
AD  - CopenAge; Copenhagen Center for Clinical Age Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Nygaard, Hanne
AU  - Nygaard H
AD  - Department of Emergency Medicine, Copenhagen University Hospital, Bispebjerg and 
      Frederiksberg, Copenhagen, Denmark.
AD  - CopenAge; Copenhagen Center for Clinical Age Research, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Helland, Fredrik
AU  - Helland F
AD  - Department of Geriatric and Palliative Medicine, Copenhagen University Hospital, 
      Bispebjerg and Frederiksberg, Copenhagen, Denmark.
FAU - Wejse, Miriam R
AU  - Wejse MR
AD  - Department of Geriatric and Palliative Medicine, Copenhagen University Hospital, 
      Bispebjerg and Frederiksberg, Copenhagen, Denmark.
FAU - Rahbek, Camilla B
AU  - Rahbek CB
AD  - Geriatric Research Unit, Department of Geriatric and Palliative Medicine,
      Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen,
      Denmark.
FAU - Noerst, Tim
AU  - Noerst T
AD  - Geriatric Research Unit, Department of Geriatric and Palliative Medicine,
      Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen,
      Denmark.
FAU - Pressel, Eckart
AU  - Pressel E
AD  - Department of Geriatric and Palliative Medicine, Copenhagen University Hospital, 
      Bispebjerg and Frederiksberg, Copenhagen, Denmark.
FAU - Nielsen, Finn Erland
AU  - Nielsen FE
AD  - Department of Emergency Medicine, Copenhagen University Hospital, Bispebjerg and 
      Frederiksberg, Copenhagen, Denmark.
AD  - Copenhagen Center for Translational Research, Copenhagen University Hospital,
      Bispebjerg and Frederiksberg, Copenhagen, Denmark.
FAU - Suetta, Charlotte
AU  - Suetta C
AD  - Geriatric Research Unit, Department of Geriatric and Palliative Medicine,
      Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen,
      Denmark.
AD  - Geriatric Research Unit, Department of Medicine, Copenhagen University Hospital, 
      Herlev and Gentofte, Herlev, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04151108
PT  - Journal Article
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
SB  - IM
MH  - Aged
MH  - Biomarkers
MH  - Cohort Studies
MH  - Humans
MH  - Length of Stay
MH  - *Muscle Strength
MH  - *Muscles
MH  - Prospective Studies
PMC - PMC7778767
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *risk management
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042786 [pii]
AID - 10.1136/bmjopen-2020-042786 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e042786. doi: 10.1136/bmjopen-2020-042786.


PMID- 33376177
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Implementing telehealth support to increase physical activity in girls and women 
      with Rett syndrome-ActivRett: protocol for a waitlist randomised controlled
      trial.
PG  - e042446
LID - 10.1136/bmjopen-2020-042446 [doi]
AB  - INTRODUCTION: Individuals with Rett syndrome (RTT) experience impaired gross
      motor skills, limiting their capacity to engage in physical activities and
      participation in activities. There is limited evidence of the effectiveness of
      supported physical activity interventions. This study aims to evaluate the
      effects of a telehealth-delivered physical activity programme on physical
      activity, sedentary behaviour and quality of life in RTT. METHODS AND ANALYSIS:
      This is a multicentre study, conducted in Australia, Denmark and Israel. It is a 
      randomised waitlist-controlled trial comparing an intervention to support
      physical activity with usual care. Participants are children and adults with RTT,
      recruited from the Australian Rett Syndrome Database, the Danish Center for Rett 
      Syndrome and the Rett Syndrome Association of Israel. The intervention duration
      is 12 weeks, including fortnightly telephone contact to plan, monitor and develop
      individual activity programmes. Outcomes are measured at baseline, at 13 weeks
      and then at 25 weeks. The primary outcomes are sedentary behaviour assessed with 
      an activPAL accelerometer and the number of daily steps measured with a StepWatch
      Activity Monitor. Secondary outcomes include sleep, behaviour and quality of
      life. Caregiver experiences will be assessed immediately after the intervention
      using a satisfaction questionnaire. Group differences for each outcome will be
      evaluated with analysis of covariance, adjusting for baseline values on an
      intention-to-treat basis. ETHICS AND DISSEMINATION: Ethics approval has been
      obtained in Western Australia from the Child and Adolescent Health Services
      (RGS3371), in Denmark from the Capital Region Ethics Committee (H-19040514) and
      in Israel from the Ariel University Institutional Review Board
      (AU-HEA-ML-20190331). Manuscripts on the development of the intervention from
      pilot work and the results of the intervention will be submitted to peer-reviewed
      journals. Results will be presented at conferences and consumer forums. We will
      develop an online resource documenting the physical activity programme and
      available supporting evidence. TRIAL REGISTRATION NUMBER: NCT04167059;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Downs, Jenny
AU  - Downs J
AUID- ORCID: 0000-0001-7358-9037
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia Jenny.Downs@telethonkids.org.au.
AD  - School of Physiotherapy and Exercise Science, Curtin University, Perth, Western
      Australia, Australia.
FAU - Lotan, Meir
AU  - Lotan M
AD  - Department of Physiotherapy, Ariel University, Ariel, Israel.
FAU - Elefant, Cochavit
AU  - Elefant C
AD  - School of Creative Arts Therapies, University of Haifa, Haifa, Israel.
FAU - Leonard, Helen
AU  - Leonard H
AUID- ORCID: 0000-0001-6405-5834
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia.
FAU - Wong, Kingsley
AU  - Wong K
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia.
FAU - Buckley, Nicholas
AU  - Buckley N
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia.
AD  - School of Physiotherapy and Exercise Science, Curtin University, Perth, Western
      Australia, Australia.
FAU - Stahlhut, Michelle
AU  - Stahlhut M
AD  - Department of Paediatrics and Adolescent Medicine, Center for Rett Syndrome,
      Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04167059
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - Child
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Israel
MH  - Multicenter Studies as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Rett Syndrome
MH  - *Telemedicine
MH  - Western Australia
PMC - PMC7778785
OTO - NOTNLM
OT  - *community child health
OT  - *developmental neurology & neurodisability
OT  - *paediatric neurology
COIS- Competing interests: JD is employed at Telethon Kids Institute where she is
      program head of Child Disability. The protocol for this study was developed for
      this grant received from Rettsyndrome.org. The authors do not have competing
      interests to declare in relation to this study.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042446 [pii]
AID - 10.1136/bmjopen-2020-042446 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e042446. doi: 10.1136/bmjopen-2020-042446.


PMID- 33376176
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Randomised placebo-controlled multicentre effectiveness trial of adjunct
      betamethasone therapy in hospitalised children with community-acquired pneumonia:
      a trial protocol for the KIDS-STEP trial.
PG  - e041937
LID - 10.1136/bmjopen-2020-041937 [doi]
AB  - INTRODUCTION: Community-acquired pneumonia (CAP) causes around 10
      hospitalisations per 1000 child-years, each associated with an average 13
      non-routine days experienced and more than 4 parent workdays lost. In adults,
      steroid treatment shortens time to clinical stabilisation without an increase in 
      complications in patients with CAP. However, despite promising data from
      observational studies, there is a lack of high-quality evidence for the use of
      steroids. METHODS AND ANALYSIS: The KIDS-STEP trial is a multicentre, randomised,
      double-blind, placebo-controlled superiority trial of betamethasone treatment on 
      outcome of hospitalised children with CAP. Children are enrolled in paediatric
      emergency departments of hospitals across Switzerland and randomised to adjunct
      oral betamethasone for 2 days or matching placebo in addition to standard of care
      treatment. The co-primary outcomes are the proportion of children clinically
      stable 48 hours after randomisation and the proportion of children with
      CAP-related readmission within 28 days after randomisation. Secondary outcomes
      include length of hospital stay, time away from routine childcare and healthcare 
      utilisation and total antibiotic prescriptions within 28 days from
      randomisation.Each of the co-primary outcomes will be analysed separately. We
      will test clinical stability rates using a proportion test; to test
      non-inferiority in readmission rates, we will construct 1-alpha % CI of the
      estimated difference and test if it contains the pre-defined margin of 7%.
      Success is conditional on both tests. A simulation-based sample size estimation
      determined that recruiting 700 patients will ensure a power of 80% for the study.
      ETHICS AND DISSEMINATION: The trial protocol and materials were approved by
      ethics committees in Switzerland (lead: Ethikkommission Nordwest und
      Zentralschweiz) and the regulatory authority Swissmedic. Participants and
      caregivers provide informed consent prior to study procedures commencing. The
      trial results will be published in peer-reviewed journals and at national and
      international conferences. Key messages will also be disseminated via press and
      social media where appropriate. TRIAL REGISTRATION NUMBER: NCT03474991 and
      SNCTP000002864.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kohns Vasconcelos, Malte
AU  - Kohns Vasconcelos M
AUID- ORCID: 0000-0002-6207-9442
AD  - Department of Paediatric Pharmacology, University of Basel Children's Hospital
      (UKBB), Basel, Switzerland malte.kohns@ukbb.ch.
AD  - Institute for Medical Microbiology and Hospital Hygiene, Heinrich Heine
      University Dusseldorf, Dusseldorf, Germany.
FAU - Meyer Sauteur, Patrick M
AU  - Meyer Sauteur PM
AUID- ORCID: 0000-0002-4312-9803
AD  - Department of Paediatric Infectious Diseases and Hospital Epidemiology,
      University Children's Hospital Zurich, Zurich, Switzerland.
FAU - Santoro, Regina
AU  - Santoro R
AD  - Ambulatory Study Centre, University of Basel Children's Hospital (UKBB), Basel,
      Switzerland.
FAU - Coslovsky, Michael
AU  - Coslovsky M
AD  - Clinical Trial Unit, University of Basel, Basel, Switzerland.
FAU - Lura, Marco
AU  - Lura M
AD  - Division of Paediatric Pulmonology, Children's Hospital Lucerne, Lucerne,
      Switzerland.
FAU - Keitel, Kristina
AU  - Keitel K
AD  - Paediatric Emergency Department, University Children's Hospital, Inselspital,
      University of Bern, Bern, Switzerland.
AD  - Swiss Tropical and Public Health Institute, University of Basel, Basel,
      Switzerland.
FAU - Wachinger, Tanja
AU  - Wachinger T
AD  - Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.
FAU - Beglinger, Svetlana
AU  - Beglinger S
AD  - Paediatric Emergency Unit, University of Basel Children's Hospital (UKBB), Basel,
      Switzerland.
FAU - Heininger, Ulrich
AU  - Heininger U
AD  - Department of Infectious Diseases and Vaccinology, University of Basel Children's
      Hospital (UKBB), Basel, Switzerland.
FAU - van den Anker, Johannes
AU  - van den Anker J
AD  - Department of Paediatric Pharmacology, University of Basel Children's Hospital
      (UKBB), Basel, Switzerland.
FAU - Bielicki, Julia Anna
AU  - Bielicki JA
AD  - Department of Paediatric Pharmacology, University of Basel Children's Hospital
      (UKBB), Basel, Switzerland.
AD  - Department of Infectious Diseases and Vaccinology, University of Basel Children's
      Hospital (UKBB), Basel, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03474991
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9842X06Q6M (Betamethasone)
SB  - IM
MH  - Adult
MH  - Betamethasone
MH  - *COVID-19
MH  - Child
MH  - Child, Hospitalized
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Pneumonia/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Switzerland
MH  - Treatment Outcome
PMC - PMC7778765
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *paediatric A&E and ambulatory care
OT  - *paediatric infectious disease & immunisation
OT  - *paediatric thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041937 [pii]
AID - 10.1136/bmjopen-2020-041937 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e041937. doi: 10.1136/bmjopen-2020-041937.


PMID- 33376175
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Systematic examination of preprint platforms for use in the medical and
      biomedical sciences setting.
PG  - e041849
LID - 10.1136/bmjopen-2020-041849 [doi]
AB  - OBJECTIVES: The objective of this review is to identify all preprint platforms
      with biomedical and medical scope and to compare and contrast the key
      characteristics and policies of these platforms. STUDY DESIGN AND SETTING:
      Preprint platforms that were launched up to 25 June 2019 and have a biomedical
      and medical scope according to MEDLINE's journal selection criteria were
      identified using existing lists, web-based searches and the expertise of both
      academic and non-academic publication scientists. A data extraction form was
      developed, pilot tested and used to collect data from each preprint platform's
      webpage(s). RESULTS: A total of 44 preprint platforms were identified as having
      biomedical and medical scope, 17 (39%) were hosted by the Open Science Framework 
      preprint infrastructure, 6 (14%) were provided by F1000 Research (the Open
      Research Central infrastructure) and 21 (48%) were other independent preprint
      platforms. Preprint platforms were either owned by non-profit academic groups,
      scientific societies or funding organisations (n=28; 64%), owned/partly owned by 
      for-profit publishers or companies (n=14; 32%) or owned by individuals/small
      communities (n=2; 5%). Twenty-four (55%) preprint platforms accepted content from
      all scientific fields although some of these had restrictions relating to funding
      source, geographical region or an affiliated journal's remit. Thirty-three (75%) 
      preprint platforms provided details about article screening (basic checks) and 14
      (32%) of these actively involved researchers with context expertise in the
      screening process. Almost all preprint platforms allow submission to any
      peer-reviewed journal following publication, have a preservation plan for read
      access and most have a policy regarding reasons for retraction and the
      sustainability of the service. CONCLUSION: A large number of preprint platforms
      exist for use in biomedical and medical sciences, all of which offer researchers 
      an opportunity to rapidly disseminate their research findings onto an open-access
      public server, subject to scope and eligibility.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kirkham, Jamie J
AU  - Kirkham JJ
AUID- ORCID: 0000-0003-2579-9325
AD  - Centre for Biostatistics, Manchester Academic Health Science Centre, University
      of Manchester, Manchester, UK jamie.kirkham@manchester.ac.uk.
FAU - Penfold, Naomi C
AU  - Penfold NC
AUID- ORCID: 0000-0003-0568-1194
AD  - ASAPbio, San Francisco, California, USA.
FAU - Murphy, Fiona
AU  - Murphy F
AD  - Murphy Mitchell Consulting Ltd, Chichester, UK.
FAU - Boutron, Isabelle
AU  - Boutron I
AD  - Universite de Paris, Centre of Research in Epidemiology and Statistics (CRESS),
      Inserm, Paris, France.
FAU - Ioannidis, John P
AU  - Ioannidis JP
AD  - Meta-Research Innovation Center at Stanford (METRICS) and Departments of
      Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and 
      of Statistics, Stanford University, Stanford, California, USA.
FAU - Polka, Jessica
AU  - Polka J
AD  - ASAPbio, San Francisco, California, USA.
FAU - Moher, David
AU  - Moher D
AUID- ORCID: 0000-0003-2434-4206
AD  - Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research 
      Institute, Ottawa, Ontario, Canada.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - MRC_/Medical Research Council/United Kingdom
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Biomedical Research
MH  - Humans
MH  - *Peer Review
MH  - Research Personnel
MH  - Societies, Scientific
PMC - PMC7778769
OTO - NOTNLM
OT  - *medical ethics
OT  - *medical journalism
OT  - *statistics & research methods
COIS- Competing interests: JP is executive director of ASAPbio.
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041849 [pii]
AID - 10.1136/bmjopen-2020-041849 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e041849. doi: 10.1136/bmjopen-2020-041849.


PMID- 33376166
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Metabolomics for prediction of hypertension in pregnancy: a systematic review and
      meta-analysis protocol.
PG  - e040652
LID - 10.1136/bmjopen-2020-040652 [doi]
AB  - INTRODUCTION: Hypertension is a very important cause of maternal morbidity and
      mortality worldwide, despite efforts on prevention. The lack of a tool to provide
      effective and early prediction of hypertension for a high-risk group may
      contribute to improving maternal and fetal outcomes. Metabolomics has figured out
      as a promised technology to contribute to the improvement of hypertension in
      pregnancy prediction. METHODS AND ANALYSIS: Our primary outcome is hypertensive
      disorders of pregnancy. A detailed systematic literature search will be performed
      in electronic databases PubMed, EMBASE, Scopus, Web of Science, Latin America and
      Caribbean Health Sciences Literature, Scientific Electronic Library Online,
      Health Technology Assessment and Database of Abstracts of Reviews of Effects
      using controlled terms 'pre-eclampsia', 'hypertensive disorders', 'metabolomics' 
      and 'prediction' (and their variations). Studies from the latest 20 years will be
      included, except case reports, reviews, cross-sectional studies, letter to
      editors, expert opinions, commentaries papers or non-human research. If possible,
      we will perform a meta-analysis. Two peer-reviewers will independently perform
      the search and in cases of discordance, a third reviewer will be consulted.
      ETHICS AND DISSEMINATION: As a systematic review, ethics approval is not
      required. The results of this review will present the current use and performance
      of metabolomics for predicting gestational hypertension. Such data could
      potentially guide future studies and interventions to improve existing prediction
      models. PROSPERO REGISTRATION NUMBER: CRD42018097409.
CI  - (c)World Health Organization 2020. Licensee BMJ.
FAU - Mayrink, Jussara
AU  - Mayrink J
AD  - Department of Gynecology and Obstetrics, State University of Campinas, Campinas, 
      Brazil.
FAU - Leite, Debora Farias Batista
AU  - Leite DFB
AUID- ORCID: 0000-0001-8839-3934
AD  - Department of Gynecology and Obstetrics, State University of Campinas, Campinas, 
      Brazil.
AD  - Department of Maternal and Child Health, Federal University of Pernambuco,
      Recife, Brazil.
FAU - Costa, Maria Laura
AU  - Costa ML
AD  - Department of Gynecology and Obstetrics, State University of Campinas, Campinas, 
      Brazil.
FAU - Cecatti, Jose Guilherme
AU  - Cecatti JG
AUID- ORCID: 0000-0003-1285-8445
AD  - Department of Gynecology and Obstetrics, State University of Campinas, Campinas, 
      Brazil cecatti@unicamp.br.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Caribbean Region
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced/diagnosis
MH  - Latin America
MH  - Metabolomics
MH  - Pregnancy
MH  - Research Design
PMC - PMC7778786
OTO - NOTNLM
OT  - *epidemiology
OT  - *hypertension
OT  - *prenatal diagnosis
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040652 [pii]
AID - 10.1136/bmjopen-2020-040652 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e040652. doi: 10.1136/bmjopen-2020-040652.


PMID- 33376164
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 29
TI  - Poor treatment outcomes of children on highly active antiretroviral therapy:
      protocol for a systematic review and meta-analysis.
PG  - e040161
LID - 10.1136/bmjopen-2020-040161 [doi]
AB  - INTRODUCTION: While access to highly active antiretroviral therapy (HAART) for
      children with HIV has expanded and the use of HAART has substantially reduced the
      morbidity and mortality of children due to HIV, poor treatment outcomes among
      children with HIV are still a major public health problem globally. The aim of
      this systematic review and meta-analysis is to quantify treatment outcomes among 
      children with HIV. METHODS AND ANALYSIS: Systematic searches will be conducted in
      three electronic databases (PubMed, SCOPUS and Web of Science) for recent studies
      published from 01 Jan 2000 up to 28 October 2020, without geographical
      restriction. The primary outcomes of the study will be poor treatment outcomes,
      which include death, treatment failure and loss to follow-up. We will include
      quantitative studies that report treatment outcomes among children under the age 
      of 18 years with HIV. Studies will be excluded if they are case report, case
      series, conducted among adults only or do not provide data on treatment outcomes 
      for children. Two researchers will screen the titles and abstracts of all
      citations identified in our search, then review the full text of the remaining
      papers to identify those that meet the inclusion criteria. The Newcastle-Ottawa
      Scale will be used for quality assessment. A random-effects meta-analysis will be
      used to obtain pooled estimates of the proportion of poor treatment outcomes. The
      heterogeneity between studies will be checked visually by using forest plots and 
      quantitatively measured by the index of heterogeneity (I(2)). Pooled estimates of
      poor treatment outcomes will be calculated with a random-effects model. Subgroup 
      analysis will be conducted by study settings, treatment regimen, comorbidity
      (such as tuberculosis), study period and HIV type (HIV-1 and HIV-2). ETHICS AND
      DISSEMINATION: Ethical approval will not be required for this study as it will be
      based on published papers. The final report of this review will be published in a
      peer-reviewed scientific journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Atalell, Kendalem Asmare
AU  - Atalell KA
AUID- ORCID: 0000-0003-1127-3592
AD  - Department of Pediatrics and Child Health Nursing, School of Nursing,College of
      Medicine and Health Sciences, University of Gondar, Gondar, Amhara, Ethiopia
      kedasmar@gmail.com.
FAU - Alene, Kefyalew Addis
AU  - Alene KA
AUID- ORCID: 0000-0002-1904-4682
AD  - Faculty of Health Sciences, Curtin University, Bentley Campus, Perth, Western
      Australia, Australia.
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Perth, Western Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201229
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Antiretroviral Therapy, Highly Active
MH  - Child
MH  - Comorbidity
MH  - Female
MH  - *HIV Infections/drug therapy/epidemiology
MH  - *HIV-1
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Treatment Outcome
PMC - PMC7778777
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *infectious diseases
COIS- Competing interests: None declared.
EDAT- 2020/12/31 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/30 05:18
PHST- 2020/12/30 05:18 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040161 [pii]
AID - 10.1136/bmjopen-2020-040161 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 29;10(12):e040161. doi: 10.1136/bmjopen-2020-040161.


PMID- 33375807
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 103
DP  - 2020 Sep-Dec
TI  - [Case: bioethical disputes of the donations of the pharmaceutical companies to
      the health centers].
PG  - 423-427
LID - 10.30444/CB.80 [doi]
AB  - The interaction between doctors and pharmaceutical companies has been and is
      common, occurs in multiple ways and has proven, in many cases, to be necessary
      for the development of medicine. However, some of the sales techniques of the
      pharmaceutical industry are not ethically acceptable and can compromise the
      independence of physicians. An ethical dilemma arises from a real case in which
      the search for vulnerability in prescription based on a donation by a
      pharmaceutical company was not easy to identify.
FAU - Gonzalez-Gonzalez, Abel
AU  - Gonzalez-Gonzalez A
AD  - Seccion de Endocrinologia y Nutricion. Hospital General Universitario de Ciudad
      Real. Avda/ Obispo Rafael Torija, s/n. 13005 Ciudad Real. Tfno: 926 278000.
      Extension: 77437. abelg@sescam.jccm.es.
LA  - spa
PT  - Case Reports
PT  - English Abstract
TT  - Caso: controversias bioeticas de las donaciones de las companias farmaceuticas a 
      los centros sanitarios.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Capital Financing/ethics
MH  - Crime
MH  - Drug Industry/*ethics/legislation & jurisprudence
MH  - Endocrinology
MH  - Gift Giving/*ethics
MH  - Hospital Departments
MH  - Hospitals, General
MH  - Hospitals, University
MH  - Humans
MH  - Marketing/*ethics/legislation & jurisprudence
MH  - Nutritional Sciences
MH  - Patient Care Team/economics/organization & administration
MH  - Persuasive Communication
MH  - Physicians/*ethics
MH  - Practice Patterns, Physicians'/ethics
MH  - *Professional Autonomy
EDAT- 2020/12/31 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/12/30 05:15
PHST- 2018/11/10 00:00 [received]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2020/12/30 05:15 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.30444/CB.80 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 Sep-Dec;31(103):423-427. doi: 10.30444/CB.80.


PMID- 33375805
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 103
DP  - 2020 Sep-Dec
TI  - [From transgenesis to gene edition. Bioethical and applied considerations].
PG  - 387-401
LID - 10.30444/CB.78 [doi]
AB  - Transgenesis is a parcel of biotechnology that allows the introduction of genetic
      information not proper to the genome of living beings, apart from the mechanisms 
      of natural genetic exchange. This made possible to address important applications
      in bacteria, animals and plants with significant benefits in health, food and
      environmental aspects. Since its origin, the production of genetically modified
      organisms (GMOs) caused some controversy due to the possible negative influence
      of these organisms or their derived products on health and the environment. Over 
      time, genetic modification techniques have renewed, giving way to others of
      greater precision, simplicity and safety. Currently the CRISPR-Cas9 technique is 
      widely used, which allows to edit, modify or eliminate specific DNA sequences,
      with multiple applications in the same fields of transgenesis, but adding greater
      simplicity, security and lower cost. This work presents the main techniques,
      applications and ethical implications of using these methods and their
      perspectives in an ever-evolving world. The bacteria for obtaining products of
      pharmacological interest, new varieties of cultivated plants of higher
      production, more resistance to growth limiting agents and better nutritional
      quality and domestic animals modified genetically, offer a set of advantages
      needed to address the global challenges that affect the lives of many people
      around the world.
FAU - Jouve de la Barreda, Nicolas
AU  - Jouve de la Barreda N
AD  - Departamento de Biotecnologia y Biomedicina, Universidad de Alcala, Alcala de
      Henares (Madrid), Espana. nicolas.jouve@uah.es.
LA  - spa
PT  - Journal Article
TT  - De la transgenesis a la edicion genica. Aplicaciones y consideraciones bioeticas.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Agriculture/methods
MH  - Animal Husbandry/methods
MH  - Animals
MH  - Bacteriological Techniques
MH  - CRISPR-Cas Systems
MH  - Environment
MH  - Food Safety
MH  - Food Security
MH  - Gene Editing/*ethics/legislation & jurisprudence
MH  - Gene Transfer Techniques/*ethics
MH  - Genetic Enhancement/ethics/legislation & jurisprudence
MH  - Global Health
MH  - Humans
MH  - *Organisms, Genetically Modified
MH  - Risk Assessment
EDAT- 2020/12/31 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/12/30 05:15
PHST- 2019/12/26 00:00 [received]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/12/30 05:15 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.30444/CB.78 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 Sep-Dec;31(103):387-401. doi: 10.30444/CB.78.


PMID- 33375803
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 103
DP  - 2020 Sep-Dec
TI  - [Map of ethics conflicts in chronic patient's hospitalization].
PG  - 367-375
LID - 10.30444/CB.76 [doi]
AB  - The identification, priorization and anticipation of the ethics conflicts, allow 
      the Healthcare Ethics Committees (HEC) a better approach to them, as well as the 
      adoption of measures to prevent its appearance and/or its mitigation. For this
      purpose, we set ourselves the objective of knowing what they are in the present, 
      how important they are, and what would be the future scenario to face. An
      qualitative structure research was made whit two focal groups whit the
      participation of nurses, nurse auxiliary and doctors from the hospitalization
      area, they also answer a future ethics conflicts Decalogue. The results were
      tested after by their importance level (Relevance-Frequency-Consistency). The
      medium age of the participants was 34,7 +- 15,4, whit a medium experience at work
      of 11,7 +- 15,4 years. A total of 40 ethics conflicts was identify grouped in 5
      risk areas: professional, assistance, social, organizational and legal. From
      there 21 results the more important, between them we find patient abandonment,
      inexistence of internal performance protocols, patient and relatives false
      expectations waiting for non-assistance care, unnecessary care at the end of the 
      life, lack of rules for family / caregivers, and ignorance of legality. The more 
      important ethical dilemmas for the future identified by the personal will be
      patients in abandonment, the lack of sociohealth resources, conflicts with family
      / caregivers situation and lack of information for decision making at the end of 
      the life. The ethical conflicts between the personal from a chronic patients
      hospital and the relatives/caregivers was identifying, the most important were
      prioritized, and futures were anticipated. In these scenarios, we highlight
      abandonment as the most important. A map of ethics conflicts is a good tool to
      identify risk areas for ethics conflicts, we see the difference between the
      ethics conflicts found in other kind of hospitals. The map of ethics conflicts
      need to be update periodically to keep the validity.
FAU - Camacho, Francisco
AU  - Camacho F
AD  - Unidad de Hospitalizacion. Hospital Bernal. Calle del Dr. Robles sin numero,
      Caravaca de la Cruz, Murcia, Espana. drfjct@gmail.com.
FAU - Lopez-Soriano, Francisco
AU  - Lopez-Soriano F
AD  - Unidad de Hospitalizacion. Hospital Bernal. Calle del Dr. Robles sin numero,
      Caravaca de la Cruz, Murcia, Espana.
FAU - Martinez, Ricardo
AU  - Martinez R
AD  - Unidad de Hospitalizacion. Hospital Bernal. Calle del Dr. Robles sin numero,
      Caravaca de la Cruz, Murcia, Espana.
LA  - spa
PT  - Journal Article
TT  - Mapa de conflictos eticos en hospitalizacion de pacientes cronicos.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Chronic Disease
MH  - Dissent and Disputes
MH  - *Ethics Committees, Clinical
MH  - Female
MH  - Focus Groups
MH  - *Hospitalization
MH  - Hospitals, Private
MH  - Human Rights Abuses/ethics
MH  - Humans
MH  - Interprofessional Relations
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - *Negotiating
MH  - Professional-Family Relations
MH  - Refusal to Treat/ethics
MH  - Risk Factors
MH  - Spain
MH  - Terminal Care/ethics
MH  - Unnecessary Procedures/ethics
MH  - Young Adult
EDAT- 2020/12/31 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/12/30 05:15
PHST- 2019/02/22 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/12/30 05:15 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.30444/CB.76 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 Sep-Dec;31(103):367-375. doi: 10.30444/CB.76.


PMID- 33375802
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 103
DP  - 2020 Sep-Dec
TI  - [Knowledge of the Assistance Bioethics Committee (ABC) between the general
      hospital health professionals].
PG  - 357-366
LID - 10.30444/CB.75 [doi]
AB  - To show hospital health professionals' knowledge on ABC. Observational,
      descriptive, transversal and analytical research using questionnaires designed ad
      hoc. Comparative statistical analysis applying Ji-square by Pearson and Fisher
      tests. Binary logistic regression model to determine the odd ratios (O.R) having 
      education level and sex as independent variables. A 4% accuracy was accepted, as 
      well as a confidence Interval of 95% and a p value inferior to 0.05. The data was
      processed by IBM SPSS Statistics v.20 software. Required sample of 351
      professionals (108 doctors and other related graduate; 144 nurses and 99 clinical
      assistants (TCAE)). 276 participants (78,6%; IC95%: 74,0-82,2); of which 84
      doctors (77,8%; IC95%: 68,8-85,2); 120 nurses (83,3%; IC95%: 76,2-89,0) y 71 TCAE
      (71,7%; IC95%: 61,7-80,3), predominantly women (194, 70,3%). 228 (82,6%) were
      aware of the existence of ABC. Both doctors and nurses had more knowledge of ABC 
      than clinical assistants (p 0,0001 for both), however there was not significative
      difference between doctors and nurses (p=0,836; OR:0,901; IC95%: 0,334-2,228).
      124 (45,1%) knew the functions of ABC, with doctors displaying more knownledge
      than both nurses and clinical assistants (p=0,002 and p 0,0001 respectively) and 
      nurses showing more familiarity than clinical assistants (p=0,008). 129(47,6%)
      communicated ethical conflicts, showing no significative difference between
      doctors and nurses (p=0,119). However, clinical assistants displayed different
      behabiour than the other two groups in this regard (p 0,0001 and p=0,001
      respectively). Of all, 47 (22,4%) communicated they had ethical conflicts
      regarding the beginning and end of life. The knowledge on the existence of the
      ABC is high, however there is poor knowledge around its functions. Among health
      professionals, doctors and nurses know him better than TCAE. Matters related with
      the beginning and end of life cause most of ethical conflicts.
FAU - Pons Valls, Francisco
AU  - Pons Valls F
AD  - Comite de Bioetica Asistencial. Departamento de Salud de Castellon.
FAU - Marcos Gonzalez, Eufemia
AU  - Marcos Gonzalez E
AD  - Comite de Bioetica Asistencial. Departamento de Salud de Castellon.
FAU - Vera-Remartinez, Enrique
AU  - Vera-Remartinez E
AD  - Centro Penitenciario de Castellon I.
FAU - Bernat Adell, M Desamparados
AU  - Bernat Adell MD
AD  - Comite de Bioetica Asistencial. Departamento de Salud de Castellon.
FAU - Garcia-Guerrero, Julio
AU  - Garcia-Guerrero J
AD  - Comite de Bioetica Asistencial. Departamento de Salud de Castellon.
      garciaj@comcas.es.
CN  - Comite de Bioetica Asistencial del Departamento de Salud de Castellon
AD  - Comite de Bioetica Asistencial. Departamento de Salud de Castellon.
CN  - Comite de Bioetica Asistencial del Departamento de Salud de Castellon
LA  - spa
PT  - Journal Article
PT  - Observational Study
TT  - Conocimiento del Comite de Etica Asistencial (CEA) entre profesionales sanitarios
      de un hospital general.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Educational Status
MH  - *Ethics Committees, Clinical
MH  - Female
MH  - Hospitals, General
MH  - Hospitals, University
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Odds Ratio
MH  - Personnel, Hospital/*psychology
MH  - Spain
MH  - Surveys and Questionnaires
IR  - Fabra Gil D
FIR - Fabra Gil, Domingo
IR  - Vidal Tegedor B
FIR - Vidal Tegedor, Barbara
IR  - Calvo Cabezas P
FIR - Calvo Cabezas, Patrici
IR  - Martin Parra B
FIR - Martin Parra, Belen
IR  - Garcia Marza D
FIR - Garcia Marza, Domingo
IR  - Rius Peris A
FIR - Rius Peris, Asuncion
IR  - Morales Ventura E
FIR - Morales Ventura, Encarna
IR  - Izquierdo Izquierdo E
FIR - Izquierdo Izquierdo, Esther
IR  - Fabregat Navarro L
FIR - Fabregat Navarro, Laura
IR  - Ferrando Piqueras R
FIR - Ferrando Piqueras, Raul
IR  - Martinez Rodenas Y C
FIR - Martinez Rodenas Y, Carmen
IR  - Moliner Monedero Natalia A
FIR - Moliner Monedero Natalia, Ana
EDAT- 2020/12/31 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/12/30 05:15
PHST- 2020/02/23 00:00 [received]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/12/30 05:15 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.30444/CB.75 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 Sep-Dec;31(103):357-366. doi: 10.30444/CB.75.


PMID- 33375798
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 103
DP  - 2020 Sep-Dec
TI  - [Action before ethical dilemmas in the consultation after divorce. Role of the
      minor according to age and level of maturity].
PG  - 309-317
LID - 10.30444/CB.71 [doi]
AB  - Lately, number of divorces is increasing, nevertheless, a parents' divorce can
      become a traumatic problem for paediatric patients. Consequently, the aim of this
      study was to analyze the ethical conflicts that appear in the relationship
      between physician/parents/son/daughter, and more specifically those that a
      divorce generates. A descriptive study was developed through a survey composed by
      39 items. Previously, an exhaustive bibliographic analysis was carried out. Our
      results show that only 35% of paediatricians interviewed have been educated in
      bioethics although this issue is important in daily practice. Other items show
      that 57,5% would not cancel a pharmacological treatment in order to improve
      quality of life. Also, they would react against a wrong parents' decision
      (82,5%). They give low value to the minor`s decision (6,05%), and rarely inform
      exclusively to adolescents (5%). In contrast, paediatricians sometimes ask to
      adolescents (20%) in first place and involved them to decide in 90% of cases.
      Besides, there are differences in the relation with fathers and mothers, 17,5% of
      mothers are informed exclusively, a fact that never happens with fathers. Ethics 
      has an intrinsic value very important in daily clinical decisions in order to
      respect the rules and to adapt them to the situation of every paediatric patient.
      When an important ethical conflict become, as a divorce is, it is essential to
      know who must be informed and the rights everyone has to make a decision. It is
      complicated to the paediatricians yet to develop 41/2002 law for Patient's
      autonomy.
FAU - Leal Hernandez, Mariano
AU  - Leal Hernandez M
AD  - Area de Medicina Legal y Forense, Departamento de Ciencias Sociosanitarias,
      Universidad de Murcia.
FAU - Navarro-Zaragoza, Javier
AU  - Navarro-Zaragoza J
AD  - Dpto. Farmacologia. CP 30100, Facultad de Medicina, Universidad de Murcia.
FAU - Falcon, Maria
AU  - Falcon M
AD  - Area de Medicina Legal y Forense, Departamento de Ciencias Sociosanitarias,
      Universidad de Murcia.
FAU - Carrillo Navarro, Francisco
AU  - Carrillo Navarro F
AD  - Area de Medicina Legal y Forense, Departamento de Ciencias Sociosanitarias,
      Universidad de Murcia.
FAU - Luna, Aurelio
AU  - Luna A
AD  - Area de Medicina Legal y Forense, Departamento de Ciencias Sociosanitarias,
      Universidad de Murcia.
LA  - spa
PT  - Journal Article
TT  - Actuacion ante los dilemas eticos en la consulta tras divorcio. Papel del menor
      segun edad y nivel de madurez.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Bioethics/education
MH  - Child
MH  - Child Custody/ethics
MH  - Civil Rights
MH  - Clinical Decision-Making
MH  - Divorce/*ethics/legislation & jurisprudence
MH  - Education, Medical
MH  - Fathers
MH  - Female
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - Mothers
MH  - *Negotiating
MH  - Pediatricians/education
MH  - Physician's Role
MH  - Professional-Family Relations
MH  - Psychology, Adolescent
MH  - Psychology, Child
MH  - Third-Party Consent/ethics/legislation & jurisprudence
MH  - Truth Disclosure/ethics
EDAT- 2020/12/31 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/12/30 05:15
PHST- 2020/04/24 00:00 [received]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/12/30 05:15 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.30444/CB.71 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 Sep-Dec;31(103):309-317. doi: 10.30444/CB.71.


PMID- 33375544
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210218
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Dec 25
TI  - Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the
      Italian National Health Service from a Medico-Legal Point of View.
LID - 17 [pii]
LID - 10.3390/healthcare9010017 [doi]
AB  - The World Health Organization (WHO) declared the outbreak of the Coronavirus
      disease-2019 (COVID-19) infection a pandemic on 11 March 2020. As of the end of
      October 2020, there were 50 million cases of infection and over one million
      deaths recorded worldwide, over 45,000 of which occurred in Italy. In Italy, the 
      demand for intensive care over the course of this pandemic crisis has been
      exceptionally high, resulting in a severe imbalance between the demand for and
      availability of the necessary resources. This paper focuses on elements of
      preventive medicine and medical treatments in emergency and non-emergency
      situations which, based on the international scientific literature, may prove to 
      be useful to physicians on a behavioral level and avert professional liability
      problems. In order to achieve this objective, we have performed a search on
      MEDLINE to find published articles related to the risks associated with the
      pandemic that contain useful suggestions and strategies for mitigating risks and 
      protecting the safety of the population. The results have been collocated in line
      with these specific study areas.
FAU - Bolcato, Matteo
AU  - Bolcato M
AUID- ORCID: 0000-0002-8784-8463
AD  - Legal Medicine, Department of Molecular Medicine, University of Padua, 35121
      Padova, Italy.
FAU - Aurilio, Marco Trabucco
AU  - Aurilio MT
AD  - Department of Medicine and Health Sciences "V. Tiberio", University of Molise,
      86100 Campobasso, Italy.
FAU - Aprile, Anna
AU  - Aprile A
AD  - Legal Medicine, Department of Molecular Medicine, University of Padua, 35121
      Padova, Italy.
FAU - Di Mizio, Giulio
AU  - Di Mizio G
AUID- ORCID: 0000-0001-7279-3693
AD  - Forensic Medicine, Department of Law, "Magna Graecia" University of Catanzaro,
      88100 Catanzaro, Italy.
FAU - Della Pietra, Bruno
AU  - Della Pietra B
AD  - Department Experimental Medicine, University of Campania "Luigi Vanvitelli",
      80138 Naples, Italy.
FAU - Feola, Alessandro
AU  - Feola A
AUID- ORCID: 0000-0002-9666-2636
AD  - Department Experimental Medicine, University of Campania "Luigi Vanvitelli",
      80138 Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201225
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7824087
OTO - NOTNLM
OT  - COVID-19
OT  - clinical risk management
OT  - ethics
OT  - medical liability
OT  - medico-legal evaluation
OT  - patient blood management
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 01:04
PHST- 2020/11/24 00:00 [received]
PHST- 2020/12/18 00:00 [revised]
PHST- 2020/12/22 00:00 [accepted]
PHST- 2020/12/30 01:04 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - healthcare9010017 [pii]
AID - 10.3390/healthcare9010017 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Dec 25;9(1). pii: healthcare9010017. doi:
      10.3390/healthcare9010017.


PMID- 33374855
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2304-8158 (Print)
IS  - 2304-8158 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Dec 23
TI  - A Critical Appraisal of the Evidence Supporting Consumer Motivations for
      Alternative Proteins.
LID - E24 [pii]
LID - 10.3390/foods10010024 [doi]
AB  - Alternative proteins are receiving increased global attention. This burgeoning
      interest in plants (especially plant-based meat alternatives), insects, algae,
      and cultured meat has been attributed to their reported health benefits, lower
      environmental impact and improved animal welfare compared to conventional
      animal-based meat. Food producers and the media are promoting acceptance of these
      products, claiming superior nutritional, environmental and ethical credentials
      and a desirable novel sensory experience. However, the evidence supporting these 
      claims remains unclear. In this review, we summarise the main evidence underlying
      the nutritional, sensorial, economical, ethical, and environmental reasons
      reported for the rise in consumer demand for alternative proteins. We found many 
      of these reasons to lack a strong evidence base. For instance, evidence is
      emerging for the nutritional benefits of plant-based meat alternatives, but
      present claims are largely based on established evidence for plant-based diets.
      Significant research gaps remain, especially longitudinal evidence on the
      sustained effects of replacing conventional animal-based proteins with
      alternative sources. For many alternative proteins, challenges exist in achieving
      desirable sensory properties akin to animal-based meat to promote their
      acceptance by consumers. Overall, fundamental shifts in the food system are
      required to create a culture in which healthful and sustainable food choices are 
      the norm.
FAU - Tso, Rachel
AU  - Tso R
FAU - Lim, Amanda JiaYing
AU  - Lim AJ
FAU - Forde, Ciaran G
AU  - Forde CG
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201223
PL  - Switzerland
TA  - Foods
JT  - Foods (Basel, Switzerland)
JID - 101670569
PMC - PMC7823589
OTO - NOTNLM
OT  - acceptance
OT  - animal welfare
OT  - consumer behaviour
OT  - food choice
OT  - health
OT  - meat
OT  - plant-based meat
OT  - sensory
OT  - sustainable
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
CRDT- 2020/12/30 01:02
PHST- 2020/11/27 00:00 [received]
PHST- 2020/12/17 00:00 [revised]
PHST- 2020/12/18 00:00 [accepted]
PHST- 2020/12/30 01:02 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
AID - foods10010024 [pii]
AID - 10.3390/foods10010024 [doi]
PST - epublish
SO  - Foods. 2020 Dec 23;10(1). pii: foods10010024. doi: 10.3390/foods10010024.


PMID- 33373997
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Addressing the drug-resistant tuberculosis challenge through implementing a mixed
      model of care in Uganda.
PG  - e0244451
LID - 10.1371/journal.pone.0244451 [doi]
AB  - Worldwide, Drug-resistant Tuberculosis (DR-TB) remains a big problem; the
      diagnostic capacity has superseded the clinical management capacity thereby
      causing ethical challenges. In Sub-Saharan Africa, treatment is either inadequate
      or lacking and some diagnosed patients are on treatment waiting lists. In Uganda,
      various health system challenges impeded scale-up of DR-TB care in 2012; only
      three treatment initiation facilities existed, with only 41 of the estimated 1010
      RR-TB/MDR-TB cases enrolled on treatment yet 300 were on the waiting list and
      there was no DR-TB treatment scale-up plan. To scale up care, the National TB and
      leprosy Program (NTLP) with partners rolled out a DR-TB mixed model of care. In
      this paper, we share achievements and outcomes resulting from the implementation 
      of this mixed Model of DR-TB care. Routine NTLP DR-TB program data on treatment
      initiation site, number of patients enrolled, their demographic characteristics, 
      patient category, disease classification (based on disease site and human
      immunodeficiency virus (HIV) status), on co-trimoxazole preventive therapy (CPT) 
      and antiretroviral therapy (ART) statuses, culture results, smear results and
      treatment outcomes (6, 12, and 24 months) from 2012 to 2017 RR-TB/MDR-TB cohorts 
      were collected from all the 15 DR-TB treatment initiation sites and descriptive
      analysis was done using STATA version 14.2. We presented outcomes as the number
      of patient backlog cleared, DR-TB initiation sites, RR-TB/DR-TB cumulative
      patients enrolled, percentage of co-infected patients on the six, twelve interim 
      and 24 months treatment outcomes as per the Uganda NTLP 2016 Programmatic
      Management of drug-resistant Tuberculosis (PMDT) guidelines (NTLP, 2016). Over
      the period 2013-2015, the RR-TB/MDR-TB Treatment success rate (TSR) was sustained
      between 70.1% and 74.1%, a performance that is well above the global TSR average 
      rate of 50%. Additionally, the cure rate increased from 48.8% to 66.8% (P =
      0.03). The Uganda DR-TB mixed model of care coupled with early application of
      continuous improvement approaches, enhanced cohort reviews and use of
      multi-disciplinary teams allowed for rapid DR-TB program expansion, rapid
      clearance of patient backlog, attainment of high cumulative enrollment and high
      treatment success rates. Sustainability of these achievements is needed to
      further reduce the DR-TB burden in the country. We highly recommend this mixed
      model of care in settings with similar challenges.
FAU - Kasozi, Samuel
AU  - Kasozi S
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Kirirabwa, Nicholas Sebuliba
AU  - Kirirabwa NS
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Kimuli, Derrick
AU  - Kimuli D
AUID- ORCID: 0000-0002-5302-7077
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Luwaga, Henry
AU  - Luwaga H
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Kizito, Enock
AU  - Kizito E
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Turyahabwe, Stavia
AU  - Turyahabwe S
AD  - National Tuberculosis and Leprosy Program, Ministry of Health, Kampala, Uganda.
FAU - Lukoye, Deus
AU  - Lukoye D
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Byaruhanga, Raymond
AU  - Byaruhanga R
AD  - TRACK TB Project, Management Sciences for Health, Kampala, Uganda.
FAU - Chen, Lisa
AU  - Chen L
AD  - Curry International Tuberculosis Center (UCSF/CITC), University of California,
      San Francisco, San Francisco, California, United States of America.
FAU - Suarez, Pedro
AU  - Suarez P
AD  - Management Sciences for Health, Arlington, Virginia, United States of America.
LA  - eng
GR  - 623-A-13-00003/PEPFAR/PEPFAR/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201229
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Antitubercular Agents)
RN  - 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aftercare/organization & administration/statistics & numerical data
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Antitubercular Agents/pharmacology/therapeutic use
MH  - Chemoprevention/methods
MH  - Cohort Studies
MH  - Coinfection/*drug therapy/microbiology
MH  - Delivery of Health Care/methods/*organization & administration/statistics &
      numerical data
MH  - Drug Resistance, Multiple, Bacterial
MH  - Female
MH  - HIV Infections/*drug therapy/virology
MH  - *Health Plan Implementation
MH  - Humans
MH  - Leprosy/*drug therapy/microbiology
MH  - Male
MH  - Middle Aged
MH  - Models, Organizational
MH  - Mycobacterium leprae/isolation & purification
MH  - Mycobacterium tuberculosis/isolation & purification
MH  - Patient Care Team/organization & administration/statistics & numerical data
MH  - Treatment Outcome
MH  - Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
MH  - Tuberculosis, Multidrug-Resistant/*drug therapy/microbiology
MH  - Uganda
MH  - Young Adult
PMC - PMC7772013
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/20 06:00
CRDT- 2020/12/29 20:14
PHST- 2020/05/17 00:00 [received]
PHST- 2020/12/09 00:00 [accepted]
PHST- 2020/12/29 20:14 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - 10.1371/journal.pone.0244451 [doi]
AID - PONE-D-20-14673 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 29;15(12):e0244451. doi: 10.1371/journal.pone.0244451.
      eCollection 2020.


PMID- 33372927
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 156
IP  - 5
DP  - 2020
TI  - Great personalities of medicine, great lessons.
PG  - 465-472
LID - 10.24875/GMM.M20000448 [doi]
AB  - The analysis of three characters corresponding to different spaces and times
      shows the close link between literature and the history of medicine. On one hand,
      Don Quixote of La Mancha, who reflects the thought of the last years of the
      Renaissance and that has been assimilated in contemporary Mexico. On the other
      hand, Doctors Miguel Francisco Jimenez and Rita Levi Montalcini, who lived in the
      19th and 20th centuries, respectively. Despite the years that separate these
      three personalities, many elements in common are observed that do not lose their 
      validity: the value that is given to health, ethics, tenacity and experience to
      attain successful results. All three characters refer to the medicine of their
      time, their achievements and the promotion of humanism, always inherent to
      medicine.
CI  - Copyright: (c) 2019 Permanyer.
FAU - Ruelas-Barajas, Enrique
AU  - Ruelas-Barajas E
AD  - Medical School, Universidad Panamericana. Mexico City, Mexico.
FAU - Rodriguez-Perez, Martha E
AU  - Rodriguez-Perez ME
AD  - Faculty of Medicine, Department of History and Philosophy of Medicine,
      Universidad Nacional Autonoma de Mexico. Mexico City, Mexico.
FAU - Romo, Ana C Rodriguez-de
AU  - Romo ACR
AD  - Faculty of Medicine, Department of History and Philosophy of Medicine,
      Universidad Nacional Autonoma de Mexico. Mexico City, Mexico.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
TT  - Grandes personajes de la medicina, grandes lecciones.
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Italy
MH  - Medicine in Literature/*history
MH  - Mexico
MH  - Nerve Growth Factor/history
MH  - *Nobel Prize
PS  - Jimenez MF
FPS - Jimenez, Miguel Francisco
PS  - Levi Montalcini R
FPS - Levi Montalcini, Rita
OTO - NOTNLM
OT  - 19th century medicine
OT  - Medicina del Renacimiento
OT  - Medicina del siglo XIX
OT  - Medicine of the Renaissance
OT  - Nobel Prize in Medicine
OT  - Premio Nobel de Medicina
EDAT- 2020/12/30 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/12/29 12:08
PHST- 2020/12/29 12:08 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - j156/5/465 [pii]
AID - 10.24875/GMM.M20000448 [doi]
PST - ppublish
SO  - Gac Med Mex. 2020;156(5):465-472. doi: 10.24875/GMM.M20000448.


PMID- 33372926
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 156
IP  - 5
DP  - 2020
TI  - Recommendations for the sale and promotion of dermocosmetic treatments at the
      office.
PG  - 458-459
LID - 10.24875/GMM.M20000450 [doi]
AB  - A novel chapter in current medical settings is the promotion and attention of
      esthetic aspects rather than health issues by health professionals. The human
      aspiration related to the search for personal beauty has generated new scenarios 
      in medical practice. The Committee on Ethics and Transparency in the
      Physician-Industry Relationship (CETREMI) of the National Academy of Medicine of 
      Mexico has analyzed this phenomenon and has issued recommendations directed both 
      to medical professionals and to producers and potential consumers of esthetic
      procedures.
CI  - Copyright: (c) 2019 Permanyer.
FAU - Dominguez, Judith
AU  - Dominguez J
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Verastegui, Emma
AU  - Verastegui E
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Arrieta, Oscar
AU  - Arrieta O
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Burgos, Ruben
AU  - Burgos R
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Campillo, Carlos
AU  - Campillo C
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Celis, Miguel A
AU  - Celis MA
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Llata, Manuel De la
AU  - Llata M
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Halabe, Jose
AU  - Halabe J
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Islas, Sergio
AU  - Islas S
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Jasso, Luis
AU  - Jasso L
FAU - Lifshitz, Alberto
AU  - Lifshitz A
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Moreno, Mucio
AU  - Moreno M
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Plancarte, Ricardo
AU  - Plancarte R
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Reyes-Sanchez, Alejandro
AU  - Reyes-Sanchez A
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Ruiz-Arguelles, Guillermo
AU  - Ruiz-Arguelles G
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Soda, Antonio
AU  - Soda A
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
FAU - Sotelo, Julio
AU  - Sotelo J
AD  - Comite de Etica y Transparencia en la Relacion Medico-Industria (CETREMI),
      Academia Nacional de Medicina de Mexico, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
TT  - Recomendaciones para la venta y promocion en el consultorio de tratamientos
      dermocosmeticos.
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Cosmetics)
SB  - IM
MH  - Advisory Committees
MH  - Beauty Culture/*ethics
MH  - Commerce/*ethics
MH  - *Cosmetics
MH  - Dermatologists/*ethics
MH  - *Guidelines as Topic
MH  - Humans
MH  - Marketing/ethics
MH  - Mexico
MH  - Surgery, Plastic/*ethics
OTO - NOTNLM
OT  - Dermocosmetic products
OT  - Dermocosmeticos
OT  - Esthetics medicine
OT  - Medicina estetica
OT  - Sale at doctors'
OT  - Venta en consultorios
OT  - offices
EDAT- 2020/12/30 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/12/29 12:08
PHST- 2020/12/29 12:08 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - j156/5/458 [pii]
AID - 10.24875/GMM.M20000450 [doi]
PST - ppublish
SO  - Gac Med Mex. 2020;156(5):458-459. doi: 10.24875/GMM.M20000450.


PMID- 33372921
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20220419
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 156
IP  - 5
DP  - 2020
TI  - Towards medicine of excellence in Mexico: the "Codigo Infarto" protocol, a view
      from the perspective of translational bioethics.
PG  - 366-372
LID - 10.24875/GMM.M20000423 [doi]
AB  - INTRODUCTION: Mexico is the country with the highest mortality due to
      ST-elevation acute myocardial infarction (STEMI), and the IMSS has therefore
      developed the protocol of care for emergency departments called Codigo Infarto
      (Infarction Code). In this article, aspects of translational medicine are
      discussed with a bioethical and comprehensive perspective. OBJECTIVE: To analyze 
      the Codigo Infarto protocol from the perspective of translational bioethics.
      METHOD: A problem-centered approach was carried out through reflective
      equilibrium (or Rawls' method), as well as by applying the integral method for
      ethical discernment. RESULTS: The protocol of care for emergency services Codigo 
      Infarto is governed by evidence-based medicine and value-based medicine; it is
      guided by a principle of integrity that considers six dimensions of quality for
      the care of patients with STEMI. CONCLUSION: The protocol overcomes some adverse 
      social determinants that affect STEMI medical care, reduces mortality and global 
      economic disease burden, and develops medicine of excellence with high social
      reach.
CI  - Copyright: (c) 2019 Permanyer.
FAU - Borrayo-Sanchez, Gabriela
AU  - Borrayo-Sanchez G
AD  - A Todo Corazon, Codigo Infarto Program. Centro Medico Nacional Siglo XXI,
      Instituto Mexicano del Seguro Social, Mexico City, Mexico.
FAU - Flores-Morales, Abelardo
AU  - Flores-Morales A
AD  - Cardiology Hospital. Centro Medico Nacional Siglo XXI, Instituto Mexicano del
      Seguro Social, Mexico City, Mexico.
FAU - Salas-Collado, Leonardo
AU  - Salas-Collado L
AD  - Cardiology Hospital. Centro Medico Nacional Siglo XXI, Instituto Mexicano del
      Seguro Social, Mexico City, Mexico.
FAU - Altamirano-Bustamante, Myriam M
AU  - Altamirano-Bustamante MM
AD  - Metabolic Diseases Research Unit, Clinical Ethics Trans-functional Group. Centro 
      Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City,
      Mexico.
LA  - eng
PT  - Journal Article
TT  - Hacia una medicina de excelencia en Mexico: el protocolo Codigo Infarto, una
      vision desde la bioetica traslacional.
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - *Bioethical Issues
MH  - *Clinical Protocols
MH  - Emergency Service, Hospital/*ethics
MH  - Evidence-Based Medicine
MH  - Fibrinolytic Agents/administration & dosage
MH  - Humans
MH  - Mexico
MH  - Myocardial Reperfusion/*ethics/methods/statistics & numerical data
MH  - Reproducibility of Results
MH  - ST Elevation Myocardial Infarction/*diagnosis/mortality/*therapy
MH  - Stakeholder Participation
MH  - Time-to-Treatment
MH  - Translational Research, Biomedical/*ethics
OTO - NOTNLM
OT  - Acute myocardial infarction
OT  - Bioetica traslacional
OT  - Codigo Infarto
OT  - Dilemas eticos
OT  - Ethical dilemmas
OT  - Infarto agudo de miocardio
OT  - Translational bioethics
EDAT- 2020/12/30 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/12/29 12:08
PHST- 2020/12/29 12:08 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - j156/5/366 [pii]
AID - 10.24875/GMM.M20000423 [doi]
PST - ppublish
SO  - Gac Med Mex. 2020;156(5):366-372. doi: 10.24875/GMM.M20000423.


PMID- 33372103
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2054-4774 (Print)
IS  - 2054-4774 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Dec
TI  - Prevention of hepatic encephalopathy by administration of rifaximin and lactulose
      in patients with liver cirrhosis undergoing placement of a transjugular
      intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, 
      placebo controlled trial (PEARL trial).
LID - e000531 [pii]
LID - 10.1136/bmjgast-2020-000531 [doi]
AB  - INTRODUCTION: Cirrhotic patients with portal hypertension can suffer from
      variceal bleeding or refractory ascites and can benefit from a transjugular
      intrahepatic portosystemic shunt (TIPS). Post-TIPS hepatic encephalopathy (HE) is
      a common (20%-54%) and often severe complication. A prophylactic strategy is
      lacking. METHODS AND ANALYSIS: The Prevention of hepatic Encephalopathy by
      Administration of Rifaximin and Lactulose in patients with liver cirrhosis
      undergoing placement of a TIPS (PEARL) trial, is a multicentre randomised, double
      blind, placebo controlled trial. Patients undergoing covered TIPS placement are
      prescribed either rifaximin 550 mg two times per day and lactulose 25 mL two
      times per day (starting dose) or placebo 550 mg two times per day and lactulose
      25 mL two times per day from 72 hours before and until 3 months after TIPS
      placement. Primary endpoint is the development of overt HE (OHE) within 3 months 
      (according to West Haven criteria). Secondary endpoints include 90-day mortality;
      development of a second episode of OHE; time to development of episode(s) of OHE;
      development of minimal HE; molecular changes in peripheral and portal blood
      samples; quality of life and cost-effectiveness. The total sample size is 238
      patients and recruitment period is 3 years in six hospitals in the Netherlands
      and one in Belgium. ETHICS AND DISSEMINATION: This study protocol was approved in
      the Netherlands by the Medical Research Ethics Committee of the Academic Medical 
      Centre, Amsterdam (2018-332), in Belgium by the Ethics Committee Research UZ/KU
      Leuven (S62577) and competent authorities. This study will be conducted in
      accordance with Good Clinical Practice guidelines and the principles of the
      Declaration of Helsinki. Study results will be submitted for publication in a
      peer-reviewed journal. TRIAL REGISTRATION NUMBERS: ClinicalTrials.gov
      (NCT04073290) and EudraCT database (2018-004323-37).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - de Wit, K
AU  - de Wit K
AUID- ORCID: 0000-0001-8472-8549
AD  - Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam,
      Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
FAU - Schaapman, J J
AU  - Schaapman JJ
AD  - Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Nevens, F
AU  - Nevens F
AD  - Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
FAU - Verbeek, J
AU  - Verbeek J
AD  - Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium.
FAU - Coenen, S
AU  - Coenen S
AD  - Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam,
      Rotterdam, The Netherlands.
FAU - Cuperus, F J C
AU  - Cuperus FJC
AD  - Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, 
      The Netherlands.
FAU - Kramer, M
AU  - Kramer M
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine,
      Maastricht University Medical Center, Maastricht, The Netherlands.
FAU - Tjwa, E T T L
AU  - Tjwa ETTL
AD  - Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The
      Netherlands.
FAU - Mostafavi, N
AU  - Mostafavi N
AD  - Biostatistics Unit, Department of Gastroenterology and Hepatology, Amsterdam UMC,
      University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism,
      Amsterdam, The Netherlands.
FAU - Dijkgraaf, M G W
AU  - Dijkgraaf MGW
AD  - Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam,
      The Netherlands.
FAU - van Delden, O M
AU  - van Delden OM
AD  - Interventional Radiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The 
      Netherlands.
FAU - Beuers, U H W
AU  - Beuers UHW
AD  - Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam,
      Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
FAU - Coenraad, M J
AU  - Coenraad MJ
AD  - Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Takkenberg, R B
AU  - Takkenberg RB
AD  - Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam,
      Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands
      r.b.takkenberg@amsterdamumc.nl.
LA  - eng
SI  - ClinicalTrials.gov/NCT04073290
SI  - EudraCT/2018-004323-37
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Gastroenterol
JT  - BMJ open gastroenterology
JID - 101660690
RN  - 4618-18-2 (Lactulose)
RN  - L36O5T016N (Rifaximin)
SB  - IM
MH  - *Esophageal and Gastric Varices
MH  - Gastrointestinal Hemorrhage
MH  - *Hepatic Encephalopathy/etiology
MH  - Humans
MH  - Lactulose/therapeutic use
MH  - Liver Cirrhosis/complications
MH  - *Portasystemic Shunt, Transjugular Intrahepatic
MH  - Quality of Life
MH  - Rifaximin/therapeutic use
PMC - PMC7783616
OTO - NOTNLM
OT  - *hepatic encephalopathy
OT  - *liver cirrhosis
OT  - *portal hypertension
COIS- Competing interests: MK: lecture fees from Norgine. BT: grant from Netherlands
      Organisation for Health Research and Development; advisory board member of
      Norgine. UB: grants from Dr Falk Pharma and Intercept for investigator-initiated 
      studies; lecture fees from Abbvie, Falk Foundation, Gilead, Intercept.
EDAT- 2020/12/30 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/08/28 00:00 [received]
PHST- 2020/11/12 00:00 [revised]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - bmjgast-2020-000531 [pii]
AID - 10.1136/bmjgast-2020-000531 [doi]
PST - ppublish
SO  - BMJ Open Gastroenterol. 2020 Dec;7(1). pii: bmjgast-2020-000531. doi:
      10.1136/bmjgast-2020-000531.


PMID- 33372102
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 2053-3624 (Print)
IS  - 2053-3624 (Linking)
VI  - 7
IP  - 2
DP  - 2020 Dec
TI  - Clinical governance programme in patients with acute coronary syndrome: design
      and methodology of a quality improvement initiative.
LID - e001415 [pii]
LID - 10.1136/openhrt-2020-001415 [doi]
AB  - INTRODUCTION: Despite the availability of diverse evidence-based diagnostic and
      treatment options, many patients with acute coronary syndrome (ACS) still fail to
      receive effective, safe and timely diagnoses and therapies. The Association of
      Acute CardioVascular Care of the European Society of Cardiology has proposed and 
      retrospectively validated a set of ACS-specific quality indicators. Combining
      these indicators with the principles of clinical governance-a holistic,
      patient-centred approach intended to promote continuous quality improvement-we
      designed the clinical governance programme in patients with ACS. METHODS AND
      ANALYSIS: This is a multicentre quality improvement initiative exploring multiple
      dimensions of care, including diagnosis, therapy, patient satisfaction, centre
      organisation and efficiency in all comers patients with ACS.The study will enrol 
      approximately 5000 patients prospectively (ie, at the time of the first objective
      qualifying ACS criterion) with a 1-year follow-up. Consecutive inclusion will be 
      promoted by a simplified informed consent process and quantified by the
      concordance with corresponding hospital administrative records using
      diagnosis-related group codes of ACS.Coprimary outcome measures are (1) timely
      reperfusion in patients with ST-elevation ACS and (2) optimal medical therapy at 
      discharge in patients with confirmed acute myocardial infarction. Secondary
      outcomes broadly include multiple indicators of the process of care. Clinical
      endpoints (ie, death, myocardial infarction, stroke and bleeding) will be
      adjudicated by a clinical event committee according to predefined criteria.
      ETHICS AND DISSEMINATION: The study has been approved by local ethics committee
      of all study sites. As a quality improvement initiative and to promote
      consecutive inclusion of the population of interest, a written informed consent
      will be requested only to patients who are discharged alive. Dissemination will
      be actively promoted by (1) the registration site (ClinicalTrials.Gov ID
      NCT04255537), (2) collaborations with investigators through open data access and 
      sharing.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Leonardi, Sergio
AU  - Leonardi S
AUID- ORCID: 0000-0002-4800-6132
AD  - Cardiology, University of Pavia, Pavia, Lombardia, Italy
      s.leonardi@smatteo.pv.it.
AD  - Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy.
FAU - Montalto, Claudio
AU  - Montalto C
AD  - Cardiology, University of Pavia, Pavia, Lombardia, Italy.
FAU - Casella, Gianni
AU  - Casella G
AD  - Maggiore Hospital Carlo Alberto Pizzardi, Bologna, Emilia-Romagna, Italy.
FAU - Grosseto, Daniele
AU  - Grosseto D
AD  - Ospedale degli Infermi di Rimini, Rimini, Emilia-Romagna, Italy.
FAU - Repetto, Alessandra
AU  - Repetto A
AD  - Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy.
FAU - Portolan, Monica
AU  - Portolan M
AD  - Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy.
FAU - Fortuni, Federico
AU  - Fortuni F
AD  - Cardiology, University of Pavia, Pavia, Lombardia, Italy.
FAU - Ottani, Filippo
AU  - Ottani F
AD  - Ospedale Morgagni-Pierantoni, Forli, Emilia-Romagna, Italy.
FAU - Galvani, Marcello
AU  - Galvani M
AD  - Ospedale Morgagni-Pierantoni, Forli, Emilia-Romagna, Italy.
FAU - Cardelli, Laura Sofia
AU  - Cardelli LS
AD  - Maria Cecilia Hospital SpA, Cotignola, Emilia-Romagna, Italy.
AD  - UO Cardiologia, Azienda Ospedaliero Universitaria di Ferrara Arcispedale
      Sant'Anna, Cona, Italy.
FAU - De Servi, Stefano
AU  - De Servi S
AD  - Cardiology, University of Pavia, Pavia, Lombardia, Italy.
AD  - IRCCS MultiMedica, Sesto San Giovanni, Lombardia, Italy.
FAU - Rubboli, Andrea
AU  - Rubboli A
AD  - Ospedale Santa Maria delle Croci, Ravenna, Emilia-Romagna, Italy.
FAU - De Ferrari, Gaetano Maria
AU  - De Ferrari GM
AD  - Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino,
      Torino, Piemonte, Italy.
FAU - Oltrona Visconti, Luigi
AU  - Oltrona Visconti L
AD  - Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy.
FAU - Campo, Gianluca
AU  - Campo G
AUID- ORCID: 0000-0002-5150-188X
AD  - UO Cardiologia, Azienda Ospedaliero Universitaria di Ferrara Arcispedale
      Sant'Anna, Cona, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT04255537
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Open Heart
JT  - Open heart
JID - 101631219
SB  - IM
MH  - Acute Coronary Syndrome/diagnosis/*therapy
MH  - Clinical Governance/*standards
MH  - Follow-Up Studies
MH  - Humans
MH  - *Practice Guidelines as Topic
MH  - Prospective Studies
MH  - *Quality Improvement
MH  - Risk Assessment/*methods
PMC - PMC7768950
OTO - NOTNLM
OT  - *acute coronary syndrome
OT  - *myocardial ischaemia and infarction (IHD)
OT  - *quality of care and outcomes
COIS- Competing interests: SL reports personal fees for advisory board participation
      from AstraZeneca, Chiesi, BMS/Pfizer, Novo Nordisk, and The Medicine Company,
      outside the submitted work.
EDAT- 2020/12/30 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
AID - openhrt-2020-001415 [pii]
AID - 10.1136/openhrt-2020-001415 [doi]
PST - ppublish
SO  - Open Heart. 2020 Dec;7(2). pii: openhrt-2020-001415. doi:
      10.1136/openhrt-2020-001415.


PMID- 33372080
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Clinical outcomes and cost-utility of rotator cuff repair surgery by open and
      arthroscopic techniques: study protocol for a randomised clinical trial.
PG  - e043126
LID - 10.1136/bmjopen-2020-043126 [doi]
AB  - INTRODUCTION: Rotator cuff injuries account for up to 70% of pain in the
      shoulder. However, there remains no consensus on the best surgical treatment for 
      patients with rotator cuff injuries, in terms of the cost-effectiveness and
      cost-utility of open and arthroscopic methods for rotator cuff repair. The
      objective of this trial is to compare the efficacy, cost-effectiveness and
      cost-utility of open and arthroscopic procedures for rotator cuff repair. METHODS
      AND ANALYSIS: The trial is a two-group, parallel-design, randomised controlled
      trial. A total of 100 patients with symptomatic rotator cuff lesions will be
      allocated in either open or arthroscopic technique in a 1:1 ratio, considering
      smoking (yes or no), lesion size (</=3 cm or >3 cm) and diabetes (present or
      absent) as stratification factors. All patients will be included in the same
      rehabilitation programme after the intervention. The primary outcome measure will
      be the Constant-Murley Score and the EuroQol-5D-3L score at 48 weeks postsurgery.
      Secondary outcomes include cost-effectiveness, cost-utility, pain, complications 
      and clinical analysis, using the Simple Shoulder Test, Visual Analogue Pain Scale
      (VAS), integrity of the repair evaluated through MRI, and complications and
      failures of the proposed methods. For the cost-effectiveness analysis, we will
      use the VAS and the Constant-Murley Score as measures of effectiveness. For the
      cost-utility analysis, we will use the EuroQol-5D-3L as a measure of utility in
      terms of incremental cost per quality-adjusted life-years. ETHICS AND
      DISSEMINATION: The study has been approved by the local research ethics committee
      of both institutions: Hospital Israelita Albert Einstein and Hospital Alvorada
      Moema/Hospital Pro-Cardiaco. The results will be published in a peer-reviewed,
      open access journal. TRIAL REGISTRATION NUMBER: NCT04146987.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pierami, Rafael
AU  - Pierami R
AUID- ORCID: 0000-0002-1745-4362
AD  - Departamento de Ortopedia, Grupo de Ombro e Cotovelo do Hospital Alvorada Moema, 
      Sao Paulo, Sao Paulo, Brazil rafael_pierami@hotmail.com.
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Antonioli, Eliane
AU  - Antonioli E
AUID- ORCID: 0000-0002-8563-877X
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Oliveira, Isadora
AU  - Oliveira I
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Castro, Isabela Queiros
AU  - Castro IQ
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Manente, Felipe
AU  - Manente F
AD  - Faculdade Israelita de Ciencias da Saude Albert Einstein, Sao Paulo, SP, Brazil.
FAU - Fairbanks, Paula
AU  - Fairbanks P
AD  - Faculdade Israelita de Ciencias da Saude Albert Einstein, Sao Paulo, SP, Brazil.
FAU - Carrera, Eduardo da Frota
AU  - Carrera EDF
AD  - Departamento de Ortopedia, Grupo de Ombro e Cotovelo do Hospital Alvorada Moema, 
      Sao Paulo, Sao Paulo, Brazil.
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Matsumura, Bruno Akio
AU  - Matsumura BA
AD  - Departamento de Ortopedia, Grupo de Ombro e Cotovelo do Hospital Alvorada Moema, 
      Sao Paulo, Sao Paulo, Brazil.
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Lenza, Mario
AU  - Lenza M
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
AD  - Faculdade Israelita de Ciencias da Saude Albert Einstein, Sao Paulo, SP, Brazil.
LA  - eng
SI  - ClinicalTrials.gov/NCT04146987
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arthroscopy
MH  - Humans
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - *Rotator Cuff/surgery
MH  - *Rotator Cuff Injuries/surgery
MH  - Shoulder
MH  - Treatment Outcome
PMC - PMC7772301
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *elbow & shoulder
OT  - *musculoskeletal disorders
OT  - *orthopaedic sports trauma
OT  - *shoulder
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043126 [pii]
AID - 10.1136/bmjopen-2020-043126 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e043126. doi: 10.1136/bmjopen-2020-043126.


PMID- 33372078
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - What is spiritual care? Professional perspectives on the concept of spiritual
      care identified through group concept mapping.
PG  - e042142
LID - 10.1136/bmjopen-2020-042142 [doi]
AB  - OBJECTIVES: The overall study aim was to synthesise understandings and
      experiences regarding the concept of spiritual care (SC). More specifically, to
      identify, organise and prioritise experiences with the way SC is conceived and
      practised by professionals in research and the clinic. DESIGN: Group concept
      mapping (GCM). SETTING: The study was conducted within a university setting in
      Denmark. PARTICIPANTS: Researchers, students and clinicians working with SC on a 
      daily basis in the clinic and/or through research participated in brainstorming
      (n=15), sorting (n=15), rating and validation (n=13). RESULTS: Applying GCM,
      ideas were identified, organised and prioritised online. A total of 192 unique
      ideas of SC were identified and organised into six clusters. The results were
      discussed and interpreted at a validation meeting. Based on input from the
      validation meeting a conceptual model was developed. The model highlights three
      overall themes: (1) 'SC as an integral but overlooked aspect of healthcare'
      containing the two clusters SC as a part of healthcare and perceived
      significance; (2) 'delivering SC' containing the three clusters quality in
      attitude and action, relationship and help and support, and finally (3) 'the role
      of spirituality' containing a single cluster. CONCLUSION: Because spirituality is
      predominantly seen as a fundamental aspect of each individual human being,
      particularly important during suffering, SC should be an integral aspect of
      healthcare, although it is challenging to handle. SC involves paying attention to
      patients' values and beliefs, requires adequate skills and is realised in a
      relationship between healthcare professional and patient founded on trust and
      confidence.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hvidt, Niels Christian
AU  - Hvidt NC
AUID- ORCID: 0000-0002-6311-9784
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark nchvidt@health.sdu.dk.
AD  - Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital,
      Odense, Denmark.
FAU - Nielsen, Kristina Tomra
AU  - Nielsen KT
AUID- ORCID: 0000-0002-4944-9453
AD  - Department of Occupational Therapy, University College of Northern Denmark (UCN),
      Aalborg, Denmark.
AD  - The ADL Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg
      and Frederiksberg, Denmark.
FAU - Korup, Alex K
AU  - Korup AK
AUID- ORCID: 0000-0002-1926-9435
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
AD  - Department of Mental Health Service Kolding-Vejle, Region of Southern Denmark,
      Vejle, Denmark.
FAU - Prinds, Christina
AU  - Prinds C
AUID- ORCID: 0000-0002-2070-4641
AD  - Clinical Institute, Syddansk Universitet Det Sundhedsvidenskabelige Fakultet,
      Odense, Denmark.
AD  - Research, University College South - Campus Haderslev, Haderslev, Denmark.
FAU - Hansen, Dorte Gilsa
AU  - Hansen DG
AUID- ORCID: 0000-0002-5946-9968
AD  - IRS, Center for Shared Decision Making, Lillebaelt Hospital, University of
      Southern Denmark, Vejle, Denmark.
FAU - Viftrup, Dorte Toudal
AU  - Viftrup DT
AUID- ORCID: 0000-0002-8254-6001
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Assing Hvidt, Elisabeth
AU  - Assing Hvidt E
AUID- ORCID: 0000-0003-3762-8478
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Hammer, Elisabeth Rokkjaer
AU  - Hammer ER
AUID- ORCID: 0000-0002-1101-1472
AD  - Research Unit of General Practice, Institute of Public Health, SDU, Odense,
      Syddanmark, Denmark.
FAU - Falko, Erik
AU  - Falko E
AUID- ORCID: 0000-0002-7421-084X
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Locher, Flemming
AU  - Locher F
AUID- ORCID: 0000-0003-4378-5779
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, JELLING, Denmark.
FAU - Boelsbjerg, Hanne Bess
AU  - Boelsbjerg HB
AUID- ORCID: 0000-0002-1235-0206
AD  - Interacting Minds Centre, Department of Clinical Medicine, Aarhus Universitet,
      Aarhus, Denmark.
AD  - Elective Surgery Center, Silkeborg Regional Hospital, Silkeborg, Midtjylland,
      Denmark.
FAU - Wallin, Johan Albert
AU  - Wallin JA
AUID- ORCID: 0000-0002-8225-7285
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Thomsen, Karsten Flemming
AU  - Thomsen KF
AUID- ORCID: 0000-0002-9151-209X
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Schroder, Katja
AU  - Schroder K
AUID- ORCID: 0000-0002-9100-7237
AD  - Department of Public Health, Syddansk Universitet, Odense, Denmark.
FAU - Moestrup, Lene
AU  - Moestrup L
AUID- ORCID: 0000-0002-0978-664X
AD  - Health Science Research Center, University College Lillebaelt - Campus Odense,
      Odense, Denmark.
FAU - Nissen, Ricko Damberg
AU  - Nissen RD
AUID- ORCID: 0000-0001-5590-374X
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Stewart-Ferrer, Sif
AU  - Stewart-Ferrer S
AUID- ORCID: 0000-0002-4350-0051
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Stripp, Tobias Kvist
AU  - Stripp TK
AUID- ORCID: 0000-0001-7271-3411
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Steenfeldt, Vibeke Ostergaard
AU  - Steenfeldt VO
AUID- ORCID: 0000-0002-2724-6815
AD  - Center for Nursing, University College Absalon Campus Roskilde, Roskilde,
      Sjaelland, Denmark.
FAU - Sondergaard, Jens
AU  - Sondergaard J
AUID- ORCID: 0000-0002-1629-1864
AD  - Research Unit of General Practice, Institute of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Waehrens, Eva Ejlersen
AU  - Waehrens EE
AUID- ORCID: 0000-0002-0846-1659
AD  - The Research Initiative for Activity studies and Occupational Therapy, Research
      Unit of User Perspectives, Institute of Public Health, University of Southern
      Denmark, Odense, Denmark.
AD  - The ADL unit, Frederiksberg Hospital Parker Institute, Frederiksberg,
      Hovedstaden, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Spiritual Therapies
MH  - *Spirituality
PMC - PMC7772306
OTO - NOTNLM
OT  - *medical ethics
OT  - *palliative care
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-042142 [pii]
AID - 10.1136/bmjopen-2020-042142 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e042142. doi: 10.1136/bmjopen-2020-042142.


PMID- 33372075
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Investigating associations between physical activity and presenteeism: a scoping 
      review protocol.
PG  - e040740
LID - 10.1136/bmjopen-2020-040740 [doi]
AB  - INTRODUCTION: Considering that physical activity plays a key role in the health
      of workers, a growing number of researchers are studying its relationship with
      various workplace outcomes, such as presenteeism. Numerous scientists recognise
      the relevance of further studying this relationship in order to improve our
      understanding of it. However, studies about the association between physical
      activity and presenteeism show some discrepancy in the results obtained.
      Disparity in the way of measuring presenteeism makes it even more challenging to 
      compare results. In addition, it remains difficult to determine the optimal
      frequency, intensity, duration and type of physical activity to increase the
      productivity benefits of physical activity. In light of these issues,
      clarification through a scoping review of the literature on the subject is
      warranted. METHOD AND ANALYSIS: A search strategy will be conducted in six
      scientific databases: MEDLINE, CINAHL, PsycINFO, ABI Inform Global, Web of
      Science and Business Source Premier. A screening process by two independent
      reviewers will lead to study selection. Quantitative and qualitative studies
      written in English about the relation between physical activity and presenteeism 
      will be considered for inclusion. Data on the definition and measurement of
      presenteeism as well as the measurement of physical activity will be extracted.
      Additional data will be extracted to provide a descriptive overview of studies
      that have examined the relationship between presenteeism and physical activity.
      ETHICS AND DISSEMINATION: As this study will be based only on published studies, 
      ethics approval is not required. Through the manner in which the included studies
      will be presented (categorised by their approach to presenteeism), this scoping
      review has the potential to improve our understanding of some of the
      inconsistencies observed in the literature. This review can also identify gaps in
      the existing evidence base and lead to new avenues of research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hervieux, Valerie
AU  - Hervieux V
AUID- ORCID: 0000-0001-8003-2560
AD  - Management, Laval University Faculty of Business Administration, Quebec, Quebec
      City, Canada valerie.hervieux.1@ulaval.ca.
AD  - Center of Expertise in Occupational Health and Safety Management, Laval
      University, Quebec, Quebec City, Canada.
AD  - VITAM Research Center on Sustainable Health, Quebec Integrated University Health 
      and Social Services Center, Quebec, Quebec City, Canada.
FAU - Biron, Caroline
AU  - Biron C
AD  - Management, Laval University Faculty of Business Administration, Quebec, Quebec
      City, Canada.
AD  - Center of Expertise in Occupational Health and Safety Management, Laval
      University, Quebec, Quebec City, Canada.
AD  - VITAM Research Center on Sustainable Health, Quebec Integrated University Health 
      and Social Services Center, Quebec, Quebec City, Canada.
FAU - Dima, Justine
AU  - Dima J
AD  - Management, Laval University Faculty of Business Administration, Quebec, Quebec
      City, Canada.
AD  - Center of Expertise in Occupational Health and Safety Management, Laval
      University, Quebec, Quebec City, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Child
MH  - Efficiency
MH  - Exercise
MH  - Humans
MH  - *Presenteeism
MH  - Research Design
MH  - Workplace
PMC - PMC7772325
OTO - NOTNLM
OT  - *preventive medicine
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040740 [pii]
AID - 10.1136/bmjopen-2020-040740 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e040740. doi: 10.1136/bmjopen-2020-040740.


PMID- 33372072
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Protocol to assess the efficacy of carnosine supplementation in mitigating the
      adverse cardiovascular responses to particulate matter (PM) exposure: the
      Nucleophilic Defense Against PM Toxicity (NEAT) trial.
PG  - e039118
LID - 10.1136/bmjopen-2020-039118 [doi]
AB  - INTRODUCTION: Exposure to airborne particulate matter (PM) is associated with
      cardiovascular disease. These outcomes are believed to originate from pulmonary
      oxidative stress and the systemic delivery of oxidised biomolecules (eg,
      aldehydes) generated in the lungs. Carnosine is an endogenous di-peptide
      (beta-alanine-L-histidine) which promotes physiological homeostasis in part by
      conjugating to and neutralising toxic aldehydes. We hypothesise that an increase 
      of endogenous carnosine by dietary supplementation would mitigate the adverse
      cardiovascular outcomes associated with PM exposure in humans. METHODS AND
      ANALYSIS: To test this, we designed the Nucleophilic Defense Against PM Toxicity 
      trial. This trial will enroll 240 participants over 2 years and determine if
      carnosine supplementation mitigates the adverse effects of PM inhalation. The
      participants will have low levels of endogenous carnosine to facilitate
      identification of supplementation-specific outcomes. At enrollment, we will
      measure several indices of inflammation, preclinical cardiovascular disease and
      physical function. Participants will be randomly allocated to carnosine or
      placebo groups and instructed to take their oral supplement for 12 weeks with two
      return clinical visits and repeated assessments during times of peak PM exposure 
      (June-September) in Louisville, Kentucky, USA. Statistical modelling approaches
      will be used to assess the efficacy of carnosine supplementation in mitigating
      adverse outcomes. ETHICS AND DISSEMINATION: This study protocol has been approved
      by the Institutional Review Board at the University of Louisville. Results from
      this study will be disseminated at scientific conferences and in peer-reviewed
      publications.Trial registration: NCT03314987; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - O'Toole, Timothy E
AU  - O'Toole TE
AUID- ORCID: 0000-0003-1773-1523
AD  - Division of Environmental Medicine, Christina Lee Brown Envirome Institute,
      University of Louisville, Louisville, Kentucky, USA teotoo01@louisville.edu.
FAU - Amraotkar, Alok A
AU  - Amraotkar AA
AD  - Division of Environmental Medicine, Christina Lee Brown Envirome Institute,
      University of Louisville, Louisville, Kentucky, USA.
AD  - Division of Cardiovascular Medicine, University of Louisville, Louisville,
      Kentucky, USA.
FAU - DeFilippis, Andrew P
AU  - DeFilippis AP
AD  - Department of Medicine, Vanderbilt University, Nashville, TN, USA.
FAU - Rai, Shesh N
AU  - Rai SN
AD  - Department of Biostatistics and Bioinfomatics, University of Louisville,
      Louisville, Kentucky, USA.
FAU - Keith, Rachel J
AU  - Keith RJ
AD  - Division of Environmental Medicine, Christina Lee Brown Envirome Institute,
      University of Louisville, Louisville, Kentucky, USA.
FAU - Baba, Shahid P
AU  - Baba SP
AD  - Division of Environmental Medicine, Christina Lee Brown Envirome Institute,
      University of Louisville, Louisville, Kentucky, USA.
FAU - Lorkiewicz, Pawel
AU  - Lorkiewicz P
AD  - Division of Environmental Medicine, Christina Lee Brown Envirome Institute,
      University of Louisville, Louisville, Kentucky, USA.
AD  - Department of Chemistry, University of Louisville, Louisville, KY, USA.
FAU - Crandell, Catherine E
AU  - Crandell CE
AD  - Department of Physical Therapy, Bellarmine University, Louisville, Kentucky, USA.
FAU - Pariser, Gina L
AU  - Pariser GL
AD  - Department of Physical Therapy, Bellarmine University, Louisville, Kentucky, USA.
FAU - Wingard, Christopher J
AU  - Wingard CJ
AD  - Department of Physical Therapy, Bellarmine University, Louisville, Kentucky, USA.
FAU - Pope Iii, C Arden
AU  - Pope Iii CA
AD  - Department of Economics, Brigham Young University, Provo, Utah, USA.
FAU - Bhatnagar, Aruni
AU  - Bhatnagar A
AD  - Division of Environmental Medicine, Christina Lee Brown Envirome Institute,
      University of Louisville, Louisville, Kentucky, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03314987
GR  - P30 ES030283/ES/NIEHS NIH HHS/United States
GR  - R01 ES012917/ES/NIEHS NIH HHS/United States
GR  - R01 ES019217/ES/NIEHS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Particulate Matter)
RN  - 8HO6PVN24W (Carnosine)
SB  - IM
MH  - *Cardiovascular Diseases/chemically induced/prevention & control
MH  - *Carnosine
MH  - Dietary Supplements
MH  - Humans
MH  - Kentucky
MH  - Particulate Matter/toxicity
PMC - PMC7772308
OTO - NOTNLM
OT  - *cardiology
OT  - *clinical trials
OT  - *toxicology
OT  - *vascular medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039118 [pii]
AID - 10.1136/bmjopen-2020-039118 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e039118. doi: 10.1136/bmjopen-2020-039118.


PMID- 33372071
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Which psychotherapy is effective in panic disorder? And which delivery formats
      are supported by the evidence? Study protocol for two systematic reviews and
      network meta-analyses.
PG  - e038909
LID - 10.1136/bmjopen-2020-038909 [doi]
AB  - INTRODUCTION: Panic disorder is among the most prevalent anxiety diseases.
      Although psychotherapy is recommended as first-line treatment for panic disorder,
      little is known about the relative efficacy of different types of
      psychotherapies. Moreover, there is little evidence concerning the effectiveness 
      of different formats of major psychotherapeutic types, such as
      cognitive-behavioural therapy (CBT). In this protocol, we present an overarching 
      project consisting of two systematic reviews and network meta-analyses (NMA) to
      shed light on which psychotherapy (NMA-1), and specifically, which CBT delivery
      format (NMA-2) should be considered most effective for adults suffering from
      panic disorder with or without agoraphobia. METHODS AND ANALYSES: Starting from a
      common pool of data, we will conduct two systematic reviews and NMA of randomised
      controlled trials examining panic disorder. A comprehensive search will be
      performed in electronic databases MEDLINE, Embase, PsycINFO and the Cochrane
      Register of Controlled Trials-CENTRAL from database inception to 1 January 2021
      to identify relevant studies. A systematic approach to searching, screening,
      reviewing and data extraction will be applied. Titles, abstract and-whenever
      necessary-full texts will be examined independently by at least two reviewers.
      The quality of the included studies will be assessed using the revised Cochrane
      risk of bias tool V.2. The primary efficacy outcome will be anxiety symptoms at
      study endpoint. The primary acceptability outcome will be all-cause
      discontinuation, as measured by the proportion of patients who had discontinued
      treatment for any reason at endpoint. Data will be pooled using a random-effects 
      model. Pairwise and NMA will be conducted. ETHICS AND DISSEMINATION: No ethical
      approval is necessary for these two studies, as there will be no collection of
      primary data. The results will be disseminated through peer-reviewed publications
      and presentations at national and international conferences and meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Papola, Davide
AU  - Papola D
AUID- ORCID: 0000-0001-6482-8593
AD  - WHO Collaborating Centre for Research and Training in Mental Health and Service
      Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences;
      Section of Psychiatry, University of Verona, Verona, Italy candido09@hotmail.it.
FAU - Ostuzzi, Giovanni
AU  - Ostuzzi G
AD  - WHO Collaborating Centre for Research and Training in Mental Health and Service
      Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences;
      Section of Psychiatry, University of Verona, Verona, Italy.
FAU - Gastaldon, Chiara
AU  - Gastaldon C
AD  - WHO Collaborating Centre for Research and Training in Mental Health and Service
      Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences;
      Section of Psychiatry, University of Verona, Verona, Italy.
FAU - Purgato, Marianna
AU  - Purgato M
AD  - WHO Collaborating Centre for Research and Training in Mental Health and Service
      Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences;
      Section of Psychiatry, University of Verona, Verona, Italy.
FAU - Del Giovane, Cinzia
AU  - Del Giovane C
AD  - Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
FAU - Pompoli, Alessandro
AU  - Pompoli A
AD  - Psychiatric Rehabilitation Clinic Villa San Pietro, Trento, Italy.
FAU - Karyotaki, Eirini
AU  - Karyotaki E
AUID- ORCID: 0000-0002-0071-2599
AD  - Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public
      Health research institute, Vrije Universiteit, Amsterdam, the Netherlands.
FAU - Sijbrandij, Marit
AU  - Sijbrandij M
AD  - Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public
      Health research institute, Vrije Universiteit, Amsterdam, the Netherlands.
FAU - Furukawa, Toshi A
AU  - Furukawa TA
AD  - Departments of Health Promotion and Human Behavior, Kyoto University Graduate
      School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan.
FAU - Cuijpers, Pim
AU  - Cuijpers P
AUID- ORCID: 0000-0001-5497-2743
AD  - Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public
      Health research institute, Vrije Universiteit, Amsterdam, the Netherlands.
FAU - Barbui, Corrado
AU  - Barbui C
AD  - WHO Collaborating Centre for Research and Training in Mental Health and Service
      Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences;
      Section of Psychiatry, University of Verona, Verona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Agoraphobia
MH  - Anxiety Disorders
MH  - Humans
MH  - Network Meta-Analysis
MH  - *Panic Disorder/therapy
MH  - Psychotherapy
MH  - Systematic Reviews as Topic
PMC - PMC7772327
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *anxiety disorders
OT  - *epidemiology
COIS- Competing interests: TAF reports personal fees from Mitsubishi-Tanabe, MSD and
      Shionogi, and a grant from Mitsubishi-Tanabe, outside the submitted work; TAF has
      a patent 2018-1 77 688 pending.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038909 [pii]
AID - 10.1136/bmjopen-2020-038909 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e038909. doi: 10.1136/bmjopen-2020-038909.


PMID- 33372070
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Effectiveness and cost-effectiveness of a lifestyle modification programme in the
      prevention and treatment of subclinical, mild and moderate depression in primary 
      care: a randomised clinical trial protocol.
PG  - e038457
LID - 10.1136/bmjopen-2020-038457 [doi]
AB  - INTRODUCTION: Major depression is a highly prevalent pathology that is currently 
      the second most common cause of disease-induced disability in our society. The
      onset and continuation of depression may be related to a wide variety of
      biological and psychosocial factors, many of which are linked to different
      lifestyle aspects. Therefore, health systems must design and implement health
      promotion and lifestyle modification programmes (LMPs), taking into account
      personal factors and facilitators. The main objective of this protocol is to
      analyse the clinical effectiveness, cost-effectiveness and cost utility of an LMP
      and an LMP with information and communication technologies (ICTs) as adjunctive
      treatment for depression in primary care patients. The secondary objectives are
      to analyse the clinical effectiveness in the subgroup that presents comorbidity
      and to analyse the correlation between personal factors on health behaviour and
      lifestyle patterns. METHODS AND ANALYSIS: A randomised, multicenter pragmatic
      clinical trial with three parallel groups consisting of primary healthcare
      patients suffering from subclinical, mild or moderate depression. The following
      interventions will be used: (1) Usual antidepressant treatment with psychological
      advice and/or psychotropic drugs prescribed by the general practitioner
      (treatment as usual (TAU)). (2) TAU+LMP. A programme to be imparted in six weekly
      90-minute group sessions, intended to improve the following aspects: behavioural 
      activation+daily physical activity+adherence to the Mediterranean diet
      pattern+sleep hygiene+careful exposure to sunlight. (3) TAU+LMP+ICTs: healthy
      lifestyle recommendations (TAU+LMP)+monitoring using ICTs (a wearable
      smartwatch). The primary outcome will be the depressive symptomatology and the
      secondary outcomes will be the quality of life, the use of health and social
      resources, personal factors on health behaviour, social support, lifestyle
      patterns and chronic comorbid pathology. Data will be collected before and after 
      the intervention, with 6-month and 12-month follow-ups. ETHICS AND DISSEMINATION:
      This study has been approved by the Clinical Research Ethics Committee of Aragon 
      (approval number: C.P.-C.I. PI18/286) and the Research Ethics Committee of the
      Balearic Islands (IB3950/19 PI). Data distribution will be anonymous. Results
      will be disseminated via conferences and papers published in peer-reviewed,
      open-access journals. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry
      (NCT03951350).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aguilar-Latorre, Alejandra
AU  - Aguilar-Latorre A
AUID- ORCID: 0000-0003-2683-7346
AD  - Primary Health Care Research Group of Aragon (GAIAP), Institute for Health
      Research Aragon (IIS Aragon), Zaragoza, Spain.
FAU - Navarro, Capilla
AU  - Navarro C
AD  - Department of Psychology, University of the Balearic Islands, Palma de Mallorca, 
      Spain.
FAU - Olivan-Blazquez, Barbara
AU  - Olivan-Blazquez B
AD  - Primary Health Care Research Group of Aragon (GAIAP), Institute for Health
      Research Aragon (IIS Aragon), Zaragoza, Spain barbaraolivan@gmail.com.
AD  - Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain.
FAU - Gervilla, Elena
AU  - Gervilla E
AD  - Department of Psychology, University of the Balearic Islands, Palma de Mallorca, 
      Spain.
AD  - Statistic and psychometric procedures implemented in Health Sciences Research
      Group, Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca,
      Spain.
FAU - Magallon Botaya, Rosa
AU  - Magallon Botaya R
AD  - Primary Health Care Research Group of Aragon (GAIAP), Institute for Health
      Research Aragon (IIS Aragon), Zaragoza, Spain.
AD  - Department of Medicine, Psychiatry and Dermatology, University of Zaragoza,
      Zaragoza, Spain.
FAU - Calafat-Villalonga, Catalina
AU  - Calafat-Villalonga C
AD  - Department of Psychology, University of the Balearic Islands, Palma de Mallorca, 
      Spain.
FAU - Garcia-Toro, Mauro
AU  - Garcia-Toro M
AD  - Mental disorders of high prevalence Research Group (TRAMAP), Balearic Islands
      Health Research Institute (IdISBa), Palma de Mallorca, Spain.
AD  - Department of Medicine, University of the Balearic Islands, Palma de Mallorca,
      Spain.
FAU - Boira, Santiago
AU  - Boira S
AD  - Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain.
FAU - Serrano-Ripoll, Maria Jesus
AU  - Serrano-Ripoll MJ
AD  - Department of Psychology, University of the Balearic Islands, Palma de Mallorca, 
      Spain.
AD  - Research in Preventive Activities and Promotion and in Cancer Illes Balears
      (GRAPP-CAIB), Balearic Islands Health Research Institute (IdISBa), Palma de
      Mallorca, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03951350
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - *Depression/prevention & control
MH  - Humans
MH  - Life Style
MH  - Multicenter Studies as Topic
MH  - Primary Health Care
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Spain
PMC - PMC7772323
OTO - NOTNLM
OT  - *clinical trials
OT  - *depression & mood disorders
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038457 [pii]
AID - 10.1136/bmjopen-2020-038457 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e038457. doi: 10.1136/bmjopen-2020-038457.


PMID- 33372068
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Risk factors for mental illness in adults with atopic eczema or psoriasis:
      protocol for a systematic review.
PG  - e038324
LID - 10.1136/bmjopen-2020-038324 [doi]
AB  - INTRODUCTION: Evidence indicates that people with the common inflammatory skin
      diseases atopic eczema or psoriasis are at increased risk of mental illness.
      However, the reasons for the relationship between skin disease and common mental 
      disorders (ie, depression and anxiety) or severe mental illnesses (ie,
      schizophrenia, bipolar disorder and other psychoses) are unclear. Therefore, we
      aim to synthesise the available evidence regarding the risk factors for mental
      illness in adults with atopic eczema or psoriasis. METHODS AND ANALYSIS: We will 
      conduct a systematic review of randomised controlled trials, cohort, case-control
      and cross-sectional studies. We will search the following databases from
      inception to March 2020: Medline, Embase, Global Health, Scopus, the Cochrane
      Library, Web of Science, Base, PsycInfo, the Global Resource of Eczema Trials,
      and the grey literature databases Open Grey, PsycExtra and the New York Academy
      of Medicine Grey Literature Report. We will also search the bibliographies of
      eligible studies and relevant systematic reviews to identify additional relevant 
      studies. Citation searching of large summary papers will be used to further
      identify relevant publications. Two reviewers will initially review study titles 
      and abstracts for eligibility, followed by full text screening. We will extract
      data using a standardised data extraction form. We will assess the risk of bias
      of included studies using the Quality in Prognosis Studies tool. We will
      synthesise data narratively, and if studies are sufficiently homogenous, we will 
      consider a meta-analysis. We will assess the quality of the evidence using the
      Grading of Recommendations, Assessment, Development and Evaluation framework.
      ETHICS AND DISSEMINATION: Ethical approval is not required for a systematic
      review. Results of the review will be published in a peer-reviewed journal and
      disseminated through conferences. PROSPERO REGISTRATION NUMBER: CRD42020163941.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Adesanya, Elizabeth I
AU  - Adesanya EI
AUID- ORCID: 0000-0002-8912-7520
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK elizabeth.adesanya@lshtm.ac.uk.
FAU - Schonmann, Yochai
AU  - Schonmann Y
AD  - Siaal Research Center for Family Medicine and Primary Care, Faculty of Health
      Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
AD  - Department of Quality Measurements and Research, Clalit Health Services, Tel
      Aviv, Israel.
FAU - Hayes, Joseph F
AU  - Hayes JF
AD  - Division of Psychiatry, University College London, London, UK.
FAU - Mathur, Rohini
AU  - Mathur R
AUID- ORCID: 0000-0002-3817-8790
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Mulick, Amy R
AU  - Mulick AR
AUID- ORCID: 0000-0002-4009-2080
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Rayner, Lauren
AU  - Rayner L
AD  - Department of Psychological Medicine, Institute of Psychiatry, Psychology, and
      Neuroscience, King's College London, London, UK.
FAU - Smeeth, Liam
AU  - Smeeth L
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Smith, Catherine H
AU  - Smith CH
AD  - St John's Institute of Dermatology, Guys and St Thomas' Foundation Trust and
      King's College London, London, UK.
FAU - Langan, Sinead M
AU  - Langan SM
AUID- ORCID: 0000-0002-7022-7441
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
AD  - Health Data Research UK, London, UK.
FAU - Mansfield, Kathryn E
AU  - Mansfield KE
AUID- ORCID: 0000-0002-2551-410X
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene &
      Tropical Medicine, London, UK.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - PB-PG-0418-20025/DH_/Department of Health/United Kingdom
GR  - 205039/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Dermatitis, Atopic/epidemiology
MH  - Humans
MH  - *Mental Disorders/epidemiology
MH  - Meta-Analysis as Topic
MH  - New York
MH  - *Psoriasis/epidemiology
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7772326
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *eczema
OT  - *mental health
OT  - *psoriasis
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038324 [pii]
AID - 10.1136/bmjopen-2020-038324 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e038324. doi: 10.1136/bmjopen-2020-038324.


PMID- 33372067
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 28
TI  - Study protocol epidemiology of inflammatory bowel disease in childhood and
      adolescence: a systematic review.
PG  - e037669
LID - 10.1136/bmjopen-2020-037669 [doi]
AB  - INTRODUCTION: The incidence and prevalence of chronic inflammatory bowel diseases
      in childhood and adolescence is increasing and varies internationally. The
      systematic literature review aims to describe international epidemiological
      trends of chronic inflammatory bowel diseases in the child and adolescence age. A
      period from 1970 to 2019 will be taken into account when searching for suitable
      studies as well as geographical differences in the development of incidences will
      be presented. METHODS AND ANALYSIS: The literature databases PubMed and Embase
      will be searched for the period from 01 January 1970 to 31 December 2019 using
      linked keywords. A manual search in bibliographies of already published and
      relevant systematic reviews will complete the systematic literature search. The
      included studies will be combined in a qualitative and quantitative synthesis and
      statistically evaluated. ETHICS AND DISSEMINATION: Ethical approval is not
      required for this study as it is a systematicreview. The results will be
      submitted to peer-reviewed journals and presented in national andinternational
      meetings. This research received no specific grant from any funding agency inthe 
      public, commercial or not-for-profit sectors. This systematic review protocol was
      registeredwith the International Prospective Register of Systematic Reviews
      (PROSPERO-NR:CRD42020168644).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Weidner, Jens
AU  - Weidner J
AUID- ORCID: 0000-0003-4373-8147
AD  - Faculty of Medicine "Carl Gustav Carus", Health Sciences/ Public Health,
      Technische Universitat Dresden, Dresden, Germany jens.weidner@tu-dresden.de.
FAU - Kern, Ivana
AU  - Kern I
AD  - Faculty of Medicine "Carl Gustav Carus", Health Sciences/ Public Health,
      Technische Universitat Dresden, Dresden, Germany.
FAU - Manuwald, Ulf
AU  - Manuwald U
AD  - Faculty of Medicine "Carl Gustav Carus", Health Sciences/ Public Health,
      Technische Universitat Dresden, Dresden, Germany.
FAU - Kugler, Joachim
AU  - Kugler J
AD  - Faculty of Medicine "Carl Gustav Carus", Health Sciences/ Public Health,
      Technische Universitat Dresden, Dresden, Germany.
FAU - Rothe, Ulrike
AU  - Rothe U
AUID- ORCID: 0000-0001-9779-7260
AD  - Faculty of Medicine "Carl Gustav Carus", Health Sciences/ Public Health,
      Technische Universitat Dresden, Dresden, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201228
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - Incidence
MH  - *Inflammatory Bowel Diseases/epidemiology
MH  - Prevalence
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7772290
OTO - NOTNLM
OT  - *community child health
OT  - *inflammatory bowel disease
OT  - *paediatric gastroenterology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 06:01
PHST- 2020/12/29 06:01 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037669 [pii]
AID - 10.1136/bmjopen-2020-037669 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 28;10(12):e037669. doi: 10.1136/bmjopen-2020-037669.


PMID- 33371878
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20210101
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 28
TI  - The impact of death and dying on the personhood of medical students: a systematic
      scoping review.
PG  - 516
LID - 10.1186/s12909-020-02411-y [doi]
AB  - BACKGROUND: The re-introduction of medical students into healthcare systems
      struggling with the COVID-19 pandemic raises concerns as to whether they will be 
      supported when confronted with death and dying patients in resource-limited
      settings and with reduced support from senior clinicians. Better understanding of
      how medical students respond to death and dying will inform educationalists and
      clinicians on how to best support them. METHODS: We adopt Krishna's Systematic
      Evidence Based Approach to carry out a Systematic Scoping Review (SSR in SEBA) on
      the impact of death and dying on medical students. This structured search process
      and concurrent use of thematic and directed content analysis of data from six
      databases (Split Approach) enhances the transparency and reproducibility of this 
      review. RESULTS: Seven thousand six hundred nineteen were identified, 149
      articles reviewed and 52 articles included. The Split Approach revealed similar
      themes and categories that correspond to the Innate, Individual, Relational and
      Societal domains in the Ring Theory of Personhood. CONCLUSION: Facing death and
      dying amongst their patients affect how medical students envisage their
      personhood. This underlines the need for timely, holistic and longitudinal
      support systems to ensure that problems faced are addressed early. To do so,
      there must be effective training and a structured support mechanism.
FAU - Ho, Chong Yao
AU  - Ho CY
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Kow, Cheryl Shumin
AU  - Kow CS
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Chia, Chin Howe Joshua
AU  - Chia CHJ
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Low, Jia Ying
AU  - Low JY
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Lai, Yong Hao Melvin
AU  - Lai YHM
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Lauw, Sarah-Kei
AU  - Lauw SK
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - How, Ashley Ern Hui
AU  - How AEH
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, 59 Nanyang
      Dr, Experimental Medicine Building, Singapore, 636921, Singapore.
FAU - Tan, Lorraine Hui En
AU  - Tan LHE
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Ngiam, Xin Ling Lisa
AU  - Ngiam XLL
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Chan, Natalie Pei Xin
AU  - Chan NPX
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Kuek, Tze Yin Joshua
AU  - Kuek TYJ
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Kamal, Nur Haidah Ahmad
AU  - Kamal NHA
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Chia, Jeng Long
AU  - Chia JL
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Abdurrahman, Ahmad Bin Hanifah Marican
AU  - Abdurrahman ABHM
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Chiam, Min
AU  - Chiam M
AD  - Division of Cancer Education, National Cancer Centre Singapore, Level 4, 11
      Hospital Crescent, Singapore, 169610, Singapore.
FAU - Ong, Yun Ting
AU  - Ong YT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
FAU - Chin, Annelissa Mien Chew
AU  - Chin AMC
AD  - Medical Library, National University of Singapore Libraries, Blk MD6, Centre, 14 
      Medical Dr, #05-01 for Translational Medicine, Singapore, 117599, Singapore.
FAU - Toh, Ying Pin
AU  - Toh YP
AD  - Star PALS (Paediatric Advanced Life Support), HCA Hospice Care, Kwong Wai Shiu
      Hospital Singapore, 705 Serangoon Road, Block A #03-01, Singapore, 328127,
      Singapore.
AD  - Department of Family Medicine, Yong Loo Lin School of Medicine, National
      University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 11,
      Singapore, 119228, Singapore.
FAU - Mason, Stephen
AU  - Mason S
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, University of Liverpool, Cancer Research Centre, University of Liverpool,
      200 London Road, Liverpool, L3 9TA, UK.
FAU - Krishna, Lalit Kumar Radha
AU  - Krishna LKR
AUID- ORCID: http://orcid.org/0000-0002-7350-8644
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Crescent, Singapore, 169610, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - Division of Cancer Education, National Cancer Centre Singapore, Level 4, 11
      Hospital Crescent, Singapore, 169610, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, University of Liverpool, Cancer Research Centre, University of Liverpool,
      200 London Road, Liverpool, L3 9TA, UK. lalit.radha-krishna@liverpool.ac.uk.
AD  - Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - Centre of Biomedical Ethics, National University of Singapore, Blk MD11, 10
      Medical Drive, #02-03, Singapore, 117597, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - PalC, The Palliative Care Centre for Excellence in Research and Education, PalC
      c/o Dover Park Hospice, 10 Jalan Tan Tock Seng, Singapore, 308436, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201228
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - COVID-19/mortality
MH  - Curriculum
MH  - *Death
MH  - Humans
MH  - Pandemics
MH  - *Personhood
MH  - Research Design
MH  - SARS-CoV-2
MH  - Schools, Medical/organization & administration
MH  - Social Support
MH  - Students, Medical/*psychology
PMC - PMC7768997
OTO - NOTNLM
OT  - Dying patients
OT  - Medical schools
OT  - Medical student
OT  - Organisational ethics
OT  - Personhood
OT  - Resilience
OT  - Ring theory of personhood
OT  - Undergraduate medical education
EDAT- 2020/12/30 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/12/29 05:30
PHST- 2020/05/21 00:00 [received]
PHST- 2020/12/02 00:00 [accepted]
PHST- 2020/12/29 05:30 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1186/s12909-020-02411-y [doi]
AID - 10.1186/s12909-020-02411-y [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Dec 28;20(1):516. doi: 10.1186/s12909-020-02411-y.


PMID- 33371172
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Modular transitional nursing intervention improves pain-related self-management
      for cancer patients: Study protocol for a randomized controlled trial.
PG  - e23867
LID - 10.1097/MD.0000000000023867 [doi]
AB  - OBJECTIVE: To explore the effect of modular transitional nursing intervention on 
      the improvement of self-management of the patients with cancer pain. METHOD: This
      study will be conducted from March 2021 to May 2022 at Affiliated Hospital of
      Beihua University. The experiment was granted through the Research Ethics
      Committee of Affiliated Hospital of Beihua University (4348-019). Eighty patients
      are analyzed in our study. The patients will be included if they are between 18
      and 70 years old and are diagnosed with cancer, the pain intensity score on
      moderate level, the pain lasts for more than 3 days, and the patients who have
      signed the written informed consent. While the patients will be excluded if they 
      have a documented history of drug or alcohol abuse, and patients with limited
      performance, and patients have a surgery in the past 3 days. The primary result
      mainly expresses as intergroup differences in self-management disorders (Barriers
      Questionnaire-II) associated with the cancer pain. And the secondary results
      include the quality of life (QOL) and pain intensity. All the analyses are
      implemented with SPSS for Windows Version 20.0. RESULTS: Table 1 will show the
      clinical outcomes between the 2 groups. CONCLUSION: A modular transitional
      nursing intervention appears to reduce pain in cancer patients. TRIAL
      REGISTRATION NUMBER: researchregistry6262.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Miao, Beibei
AU  - Miao B
AD  - School of nursing, Beihua University, Jilin, China.
FAU - Sun, Yali
AU  - Sun Y
FAU - Gong, Ling
AU  - Gong L
FAU - Liu, Wei
AU  - Liu W
LA  - eng
GR  - JJKH20200080KJ/Science and Technology Planning Project of Jilin Education Bureau
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Clinical Protocols
MH  - Humans
MH  - Neoplasms/*nursing/psychology
MH  - Nursing Care/methods/*standards
MH  - Pain Management/methods/psychology/*standards
MH  - Self-Management/methods/*psychology
MH  - Treatment Outcome
PMC - PMC7748349
COIS- All of the authors approved the article and there is no conflict of interest.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/19 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1097/MD.0000000000023867 [doi]
AID - 00005792-202012180-00120 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23867. doi:
      10.1097/MD.0000000000023867.


PMID- 33371169
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Herbal medicine for cervicogenic dizziness: A protocol for a systematic review
      and meta-analysis.
PG  - e23852
LID - 10.1097/MD.0000000000023852 [doi]
AB  - BACKGROUND: Herbal medicines are empirically used to treat cervicogenic
      dizziness. However, till date there have been no systematic review to evaluate
      the efficacy and safety of these medicines. Therefore, this study protocol
      describes the methods for evaluating the efficacy and safety of herbal medicine
      for cervicogenic dizziness. METHODS AND ANALYSIS: The following electronic
      academic databases will be searched up to December 2019 without language or
      publication status restrictions: Medical Literature Analysis and Retrieval System
      Online (MEDLINE), Excerpta Medica database (EMBASE), and the Cochrane Central
      Register of Controlled Trials (CENTRAL), together with Korean, Chinese, and
      Japanese databases. Any randomized controlled trials related to herbal medicine
      for cervicogenic dizziness will be included. The functional outcomes and the
      vertebrobasilar artery hemodynamic states will be evaluated as primary outcomes. 
      The total effective rate, hematological conditions, and adverse events will be
      assessed as secondary outcomes. Study selection, data extraction, quality
      assessment of studies, and qualitative evaluation of clinical evidence will be
      performed by 2 independent reviewers. The methodological quality of the included 
      studies will be evaluated using a revised Cochrane risk-of-bias tool for
      randomized trials. The strength of evidence from the included data will be
      evaluated using the Grading of Recommendations Assessment, Development, and
      Evaluation approach. Data synthesis will be performed as either a fixed-effects
      or a random-effects model using Review Manager software version 5.3. The results 
      will be reported as a risk ratio for dichotomous outcomes and as a mean
      difference or standardized mean difference for continuous outcomes. ETHICS AND
      DISSEMINATION: No ethical approval is required since the individual clinical
      information of the patient is not used. The findings of this systematic review
      will be disseminated through the peer-reviewed publications or conference
      presentations. REVIEW REGISTRY UNIQUE IDENTIFYING NUMBER: reviewregistry1036.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Oh, Hyunjoo
AU  - Oh H
AD  - Department of Clinical Korean Medicine, Graduate School, Kyung Hee University,
      Seoul, Republic of Korea.
FAU - Shin, Seungwon
AU  - Shin S
AD  - National Agency for Development of Innovative Technologies in Korean Medicine,
      National Development Institute of Korean Medicine, Seoul, Republic of Korea,
      Department of Clinical Korean Medicine, Graduate School, Kyung Hee University.
FAU - Lee, Euiju
AU  - Lee E
AUID- ORCID: 0000-0002-3860-0533
AD  - Department of Sasang Constitutional Medicine, College of Korean Medicine, Kyung
      Hee University, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, Republic of Korea.
LA  - eng
GR  - None (scholarship)/Kyung Hee University
GR  - HB16C0010/Ministry of Health and Welfare
GR  - 2020R1F1A1068808/National Research Foundation (KR)
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Clinical Protocols
MH  - Dizziness/*drug therapy
MH  - Herbal Medicine/methods/*standards
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Phytotherapy/methods/standards
MH  - Post-Traumatic Headache/*drug therapy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7748346
COIS- The authors declare no conflicts of interest regarding the publication of this
      article.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/18 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1097/MD.0000000000023852 [doi]
AID - 00005792-202012180-00117 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23852. doi:
      10.1097/MD.0000000000023852.


PMID- 33371168
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Efficacy and safety of Tian moxibustion in treating allergic rhinitis: A protocol
      for a systematic review and meta-analysis.
PG  - e23848
LID - 10.1097/MD.0000000000023848 [doi]
AB  - BACKGROUND: Allergic rhinitis, abbreviated AR, modern medicine considers AR to be
      a chronic inflammatory reactive disease of the nasal mucosa mediated by exposure 
      to allergens such as pollen and mites immunoglobulin E. AR not only affects
      patients' daily life, sleep, work, and study, but also brings huge economic
      burden to patients and society. At present, desensitization therapy, antiallergic
      drugs, antihistamines, hormones, and other drugs are used to improve symptoms or 
      immune regulation, but the clinical short-term and long-term efficacy is general,
      the symptoms are easy to be repeated after drug withdrawal, and the long-term
      toxicity and side effects of drugs are obviously insufficient. Tian moxibustion
      therapy has a good effect on AR. Therefore, this paper will carry out a
      systematic evaluation and meta-analysis of the efficacy and safety of moxibustion
      in the treatment of allergic rhinitis. METHODS: Eight electronic databases will
      be searched, including PubMed, Embase, Web of Science, Cochrane Library, the
      China National Knowledge Infrastructure (CNKI), Chinese Science and Technology
      Periodical Database (VIP), Wanfang Database (WF), and Chinese Biomedical
      Literature Database (CBM). We will search above electronic databases from the
      beginning to November 2020, without any language restriction, but involving only 
      the human subjects. Clinical efficacy, including total effective rate or cure
      rate, and recurrence rate will be accepted as the primary outcomes. The
      Rhinoconjunctivitis quality of life questionaire (RQLQ) score, symptom score
      (nasal congestion, snot, continuous sneezing) will be used as secondary outcomes.
      The Cochrane Handbook of Systematic Review (5.3.0) randomized controlled trials
      (RCT) risk assessment tool will be used to evaluate the risk of bias by 2
      independent researchers. RESULTS: After the completion of this study, the results
      will be reported, so it is not possible to give accurate results at present.
      CONCLUSIONS: The results of this study will provide reliable evidence for the
      efficacy and safety of Tian moxibustion in the treatment of allergic rhinitis.
      ETHICS AND DISSEMINATION: This paper does not need to be approved by the Ethics
      Committee, because this paper is a systematic review and quality evaluation of
      relevant literature. The results of this study will be disseminated in the form
      of a paper to help better guide the clinical practice of Tian moxibustion in the 
      treatment of allergic rhinitis. INPLASY REGISTRATION NUMBER: INPLASY2020110058.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Deng, Gen
AU  - Deng G
AD  - College of Acupuncture and Massage, Jiangxi University of Traditional Chinese
      Medicine.
FAU - Wan, Qun
AU  - Wan Q
AD  - College of Acupuncture and Massage, Jiangxi University of Traditional Chinese
      Medicine.
FAU - Wang, Jinlong
AU  - Wang J
AD  - College of Acupuncture and Massage, Jiangxi University of Traditional Chinese
      Medicine.
FAU - Ye, Wenguo
AU  - Ye W
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang, China.
LA  - eng
GR  - No .190687/Jiangxi Provincial Department of Science and Technology
GR  - YC2019-S366/Project of Jiangxi Provincial Graduate Innovation Special Fund
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (tian-xian)
SB  - IM
MH  - *Clinical Protocols
MH  - Drugs, Chinese Herbal/*standards/therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Moxibustion/methods/*standards
MH  - Rhinitis, Allergic/*drug therapy/physiopathology
MH  - Systematic Reviews as Topic
PMC - PMC7748347
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/20 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1097/MD.0000000000023848 [doi]
AID - 00005792-202012180-00116 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23848. doi:
      10.1097/MD.0000000000023848.


PMID- 33371158
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - The comparison of the effectiveness and safety of drospirone ethinyl estradiol
      and ethinyl estradiol cyproterone in the treatment of polycystic ovarian
      syndrome: A protocol for systematic review and meta-analysis.
PG  - e23811
LID - 10.1097/MD.0000000000023811 [doi]
AB  - BACKGROUND: Polycystic ovarian syndrome (PCOS) is an endocrine disorder syndrome 
      with reproductive dysfunction and abnormal glucose metabolism. Persistent
      non-ovulation, excessive androgens and insulin resistance are important features 
      and they are the most common causes of menstrual disorders in women during
      childbearing years. At present, the cause of PCOS is not clinically clear.
      Current studies suggest that it may be due to the interaction of certain genetic 
      genes with environmental factors. It is an important cause of infertility or
      early miscarriage with the characteristics of various causes and complex clinical
      manifestations. At present, for the treatment of PCOS patients, clinical
      treatment mainly includes hypoglycemia, insulin and menstrual regulation and
      other symptomatic and supportive treatment. Drospirone ethinyl estradiol and
      ethinyl estradiol cyproterone are 2 of the most commonly used drugs in clinical
      treatment of PCOS, but there is lack of the evidence of evidence-based medicine. 
      Therefore, this study systematically evaluates the therapeutic effect and safety 
      of PCOS patients with 2 short-acting oral contraceptives, drospirone ethinyl
      estradiol and ethinyl estradiol cyproterone, which provides the guidance for
      clinically selecting the appropriate drug to treat PCOS. METHODS: Searching CNKI,
      WanFang Data, VIP, SinoMed, PubMed, EMbase, Web of Science, and The Cochrane
      Library database by computer, collecting the randomized controlled studies of DEE
      and EEC in the treatment of PCOS. The retrieval time limit is from the
      establishment of each database to July 1, 2020. In addition, tracing the
      references incorporated into the literature to supplement to the relevant
      literature. Using the retrieval method by combining the free words and the
      subject words, and the individual search of different databases is carried out.
      Meta-analysis is performed using RevMan 5.3 software after 2 researchers
      independently screens the literature, extracts the data, and evaluates the bias
      risk included in the study. RESULTS: This study will systematically evaluate the 
      DEE and EEC in the treatment of PCOS by collecting the required evidence to
      understand the effects of the 2 drugs on hypersotrophicemia, insulin resistance, 
      lipid metabolism, and the safety during drug use in patients of this class, and
      the results will be published in highly influential academic journals.
      CONCLUSION: The results of this study will provide theoretical basis for the drug
      treatment of polycystic ovarian syndrome and provide help in the decision-making 
      of clinical treatment of the disease. ETHICS AND DISSEMINATION: In this study,
      meta-analysis was used to conduct a second study on the published literature.
      Therefore, this type of systematic review research does not need to be approved
      by ethics. OSF REGISTRATION DOI: 10.17605/OSF.IO/8GW9M.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Liu, Zhimin
AU  - Liu Z
AD  - Department of Reproductive Medicine, Wenchang People's Hospital, No. 42 Wenqing
      Avenue, Wencheng Town, Wenchang City.
FAU - Song, Ying
AU  - Song Y
AD  - Department of Gynecology Clinic, Hainan Modern Women & Infants Hospital, NO. 16
      Jinyu East Road, Longhua District, Haikou City.
FAU - Xu, Yuanfang
AU  - Xu Y
AD  - Department of Gynecology, People's Hospital of Wanning, No. 1 Huanshi 3rd East
      Road, Wancheng Town, Wanning City.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Gynecology, Hainan Modern Women & Infants Hospital, NO. 16 Jinyu
      East Road, Longhua District, Haikou City.
FAU - Hu, Hongyuan
AU  - Hu H
AD  - Department of Obstetrics.
FAU - Weng, Yingchun
AU  - Weng Y
AUID- ORCID: 0000-0002-5866-9829
AD  - Department of Obstetrics, People's Hospital of Wanning, No. 1 Huanshi 3rd East
      Road, Wancheng Town, Wanning City, Hainan Province, PR China.
LA  - eng
GR  - 19A200103/Scientific Research Projects of Health and Family Planning Industry in 
      Hainan Province
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Androstenes)
RN  - 0 (Contraceptives, Oral)
RN  - 0 (drospirenone and ethinyl estradiol combination)
RN  - 423D2T571U (Ethinyl Estradiol)
SB  - IM
MH  - Adult
MH  - Androstenes/*standards/therapeutic use
MH  - Contraceptives, Oral/standards/therapeutic use
MH  - Ethinyl Estradiol/*standards/therapeutic use
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Polycystic Ovary Syndrome/*drug therapy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7748340
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/17 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1097/MD.0000000000023811 [doi]
AID - 00005792-202012180-00106 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23811. doi:
      10.1097/MD.0000000000023811.


PMID- 33371156
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Clinical efficacy of Qi Di laxative decoction in the treatment of functional
      constipation: A protocol for systematic review and meta-analysis.
PG  - e23806
LID - 10.1097/MD.0000000000023806 [doi]
AB  - BACKGROUND: Functional constipation (FC) is a common gastrointestinal disorder
      characterized by slow bowel movement and defecation difficulties, significantly
      impacting patients' quality of life and exerting heavy financial burden to whole 
      society. However, more than 50% FC patients are not completely satisfied with
      current therapies and alternative therapies are urgently required. Increasing
      evidences have demonstrated that traditional Chinese medicine has a good
      therapeutic effect on FC, which is well known for its multitarget and multimode
      effects on diverse diseases as well as less side effects. Furthermore, studies
      proved that Qi Di Laxative Decoction was an effective treatment for FC. Its
      safety and effectiveness should be verified by further studies. METHODS: We will 
      search the following electronic databases for randomized controlled trials to
      evaluate the clinical efficacy of Qi Di Laxative Decoction in treating FC:
      Wanfang and Pubmed Database, China National Knowledge Infrastructure Database,
      Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and
      Allied Health Literature, and Excerpta Medica database. Each database will be
      searched from inception to November 2020. The entire process will include study
      selection, data extraction, risk of bias assessment, and meta-analyses. RESULTS: 
      This proposed study will evaluate the clinical efficacy of Qi Di Laxative
      Decoction for patients with FC. The outcomes will include changes in FC relief
      and adverse effect. CONCLUSION: This proposed systematic review will evaluate the
      existing evidence on the clinical efficacy of Qi Di Laxative Decoction in
      treating FC. DISSEMINATION AND ETHICS: The results of this review will be
      disseminated through peer-reviewed publication. Because all of the data used in
      this systematic review and meta-analysis has been published, this review does not
      require ethical approval. Furthermore, all data will be analyzed anonymously
      during the review process. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/M2ESR.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Jian-Fang
AU  - Wang JF
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Sun, Zhong-Mei
AU  - Sun ZM
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Li, Jun-Xiang
AU  - Li JX
AUID- ORCID: 0000-0001-7418-7080
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
LA  - eng
GR  - JJ-2020-37/Beijing Traditional Chinese Medicine Technology Development Fund
      Project
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Laxatives)
SB  - IM
MH  - *Clinical Protocols
MH  - Constipation/*drug therapy
MH  - Humans
MH  - Laxatives/*standards/therapeutic use
MH  - Medicine, Chinese Traditional/methods/*standards
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7748364
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/15 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1097/MD.0000000000023806 [doi]
AID - 00005792-202012180-00104 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23806. doi:
      10.1097/MD.0000000000023806.


PMID- 33371155
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Effect of acupuncture treatment on post-stroke cognitive impairment: A randomized
      controlled trial.
PG  - e23803
LID - 10.1097/MD.0000000000023803 [doi]
AB  - INTRODUCTION: Post-stroke cognitive impairment (PSCI), which has a high
      morbidity, is closely associated with the recurrence and rehabilitation of
      ischemic stroke. There are 2 different stages of PSCI, including post-stroke
      cognitive impairment with no dementia (PSCIND) and post-stroke dementia (PSD).
      The latter has a significantly higher mortality rate than the previous one.
      Therefore, preventing the onset of PSD is of vital importance. However, there is 
      no unequivocally effective prevention or treatment for PSCI, except intensive
      secondary prevention of stroke. The primary aim of this protocol is to explore
      whether acupuncture can improve cognitive function of patients with PSCIND and
      reduce the chances of developing PSD. On this bias, we also want to explore its
      possible mechanisms. METHODS AND ANALYSIS: A prospective, multicenter, large
      sample, randomized controlled trial will be conducted. A total of 360 eligible
      patients will be recruited from 5 different hospitals and randomly allocated into
      the acupuncture group (AG), sham acupuncture group (NAG), and waiting-list group 
      (WLG) in a 1:1:1 ratio. The intervention period of NAG and AG will last 3 months 
      (30 minutes per day, 3 times per week). Primary and secondary outcomes will be
      measured at baseline, 12 weeks (at the end of the intervention), 24 weeks (after 
      the 12-week follow-up period), and 36 weeks (after the 24-week follow-up period).
      Resting-state and task-state functional MRI will be conducted at baseline and 12 
      weeks. ETHICS AND DISSEMINATION: The ethic committee of First Teaching Hospital
      of University of Traditional Chinese Medicine approved the study. Study results
      will be first informed to each participant and later disseminated to researchers,
      and the general public through courses, presentations and the internet,
      regardless of the magnitude or direction of effect. The results will also be
      documented in a published peer-reviewed academic journal. REGISTRATION: We have
      registered at ClinicalTrials.gov(ChiCTR2000033801).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Du, Yuzheng
AU  - Du Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Zhang, Lili
AU  - Zhang L
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Liu, Wei
AU  - Liu W
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Rao, Chang
AU  - Rao C
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Li, Boxuan
AU  - Li B
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Nan, Xi
AU  - Nan X
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Li, Zefang
AU  - Li Z
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Jiang, Hailun
AU  - Jiang H
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
LA  - eng
GR  - 18PTLCSY00060/Tianjin Science and Technology Project
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Placebos)
SB  - IM
MH  - Acupuncture Therapy/methods/*standards/statistics & numerical data
MH  - China
MH  - Cognitive Dysfunction/etiology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Prospective Studies
MH  - Statistics, Nonparametric
MH  - Stroke/*complications/therapy
MH  - Stroke Rehabilitation/methods
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7748352
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/15 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1097/MD.0000000000023803 [doi]
AID - 00005792-202012180-00103 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23803. doi:
      10.1097/MD.0000000000023803.


PMID- 33371136
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Acupuncture and related therapies for stable angina pectoris: A protocol for
      network meta-analysis.
PG  - e23756
LID - 10.1097/MD.0000000000023756 [doi]
AB  - BACKGROUND: Stable angina pectoris (SAP) is one of the important causes and
      harbingers of disability and mortality worldwide in the cardiovascular diseases. 
      Acupuncture has been widely applied in the treatment and prevention of
      cardiovascular diseases in recent years. This systematic review protocol aims to 
      analyze different acupuncture and related therapies to treat SAP, with a view to 
      providing an evidence-based basis for clinical implementation of treatment for
      patients with SAP. METHODS AND ANALYSIS: The electronic databases of PubMed,
      EMBASE, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI),
      Wanfang database, Chinese Science and Technology Periodical Database (VIP), and
      China Biology Medicine Database (CBM) will be searched from inception to November
      2020. The outcome measures were angina attack frequency, ECG changes, angina pain
      intensity, performance on the Six-Minute Walk Test (6-MWT) and reported adverse
      events. Study inclusion, data extraction and quality assessment will be performed
      independently by 2 reviewers. STATA 14.0 will be used to perform pairwise
      meta-analysis. STATA 13.0 and WinBUGS 1.4.3 will be used to perform pairwise
      meta-analysis and will be used to conduct network meta-analyses. RESULTS: The
      results of this review will generate a comprehensive review of current evidence
      and be published on a peer-reviewed journal. CONCLUSIONS: The result of this
      network meta-analysis is expected to provide a possible ranking for acupuncture
      treatment methods of stable angina pectoris and offer better options for patients
      with stable angina pectoris. ETHICS AND DISSEMINATION: Ethical approval is not
      necessary since this protocol is only for systematic review and does not involve 
      privacy data or conduct an animal experiment. This protocol will be disseminated 
      by a peer-review journal or conference presentation. TRIAL REGISTRATION NUMBER:
      INPLASY2020110035.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Xue, Yixuan
AU  - Xue Y
AUID- ORCID: 0000-0002-2630-4892
AD  - College of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese 
      Medicine, The Co-innovation Center for Preventive Treatment of Disease of
      Acupuncture-moxibustion in Hubei Province.
FAU - Zhang, Xiaolei
AU  - Zhang X
AD  - College of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese 
      Medicine, The Co-innovation Center for Preventive Treatment of Disease of
      Acupuncture-moxibustion in Hubei Province.
FAU - Yang, Qiqi
AU  - Yang Q
AD  - College of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese 
      Medicine, The Co-innovation Center for Preventive Treatment of Disease of
      Acupuncture-moxibustion in Hubei Province.
FAU - Zhang, Yanji
AU  - Zhang Y
AD  - College of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese 
      Medicine, The Co-innovation Center for Preventive Treatment of Disease of
      Acupuncture-moxibustion in Hubei Province.
FAU - Liu, Zhenzhen
AU  - Liu Z
AD  - College of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese 
      Medicine, The Co-innovation Center for Preventive Treatment of Disease of
      Acupuncture-moxibustion in Hubei Province.
FAU - Lu, Wei
AU  - Lu W
AD  - College of Acupuncture-Moxibustion and Orthopaedics, Hubei University of Chinese 
      Medicine, The Co-innovation Center for Preventive Treatment of Disease of
      Acupuncture-moxibustion in Hubei Province.
FAU - Huang, Wei
AU  - Huang W
AUID- ORCID: 0000-0003-1885-2087
AD  - First Clinical College, Hubei University of Chinese Medicine, Hubei Provincial
      Hospital of Traditional Chinese Medicine, Wuhan, China.
LA  - eng
GR  - Document No. 284 (2018)/Qihuang Engineering Project of National Administration of
      Traditional Chinese Medicine)
GR  - no. 81704142/Youth Fund Project of National Natural Science Foundation of China
GR  - Document No. 2019XZZX-ZJ006/Evidence-based research on acupuncture treatment of
      dominant diseases
GR  - Health Commission of Hubei Province Notice No.[2019]47/The 2nd Hubei Province's
      Outstanding Medical Academic Leader Program
GR  - HBPCIC-2020-11/2020 Project in the Co-innovation Center for Preventive Treatment 
      of Disease of Acupuncture-moxibustion in Hubei Province
GR  - no. 2017QNRC001/China Association of Science and Technology Youth Talents
      Invitation Project
GR  - no. 116, family planning tong [2018]/Wuhan young and middle-aged medical backbone
      talents (sixth batch)
GR  - Hubei traditional Chinese medicine yard: [2018] no. 72/Hubei hospital of
      traditional Chinese medicine, the first Tanhualin famous doctor, student training
      project
GR  - no. 47 [2019]/Hubei Provincial Second Medical Leading Talent Project Training
      Object and Hubei Famous Medical Studio Project
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/adverse effects/*methods
MH  - Angina, Stable/*therapy
MH  - Electrocardiography
MH  - Humans
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Severity of Illness Index
MH  - Walk Test
PMC - PMC7748164
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/16 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023756 [doi]
AID - 00005792-202012180-00084 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23756. doi:
      10.1097/MD.0000000000023756.


PMID- 33371135
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - The effect of acupuncture on emotional disorders in patients with insomnia: A
      protocol for systemic review and meta-analysis.
PG  - e23754
LID - 10.1097/MD.0000000000023754 [doi]
AB  - BACKGROUND: Insomnia with high incidence is usually accompanied by many other
      diseases, especially mental disorders with the under-diagnosis and
      under-treatment. Some studies demonstrated that acupuncture may be effective for 
      emotional disorders accompanied by insomnia. The systematic review protocol is
      designed to guiding analysis the effectiveness and safety of acupuncture for
      emotional disorders in patients with insomnia. METHODS: Seven databases, Cochrane
      central register of controlled trials, Medline, Embase, China National Knowledge 
      Infrastructure, Chinese Biomedical Literature database, VIP database and Wanfang 
      database, will be searched from initial to December 2020. Randomized controlled
      trials (RCTs) of acupuncture for insomnia with emotional disorders (depression
      and anxiety) outcomes, which were reported in Chinese or English, will be
      included. The primary outcome is the change of degree of anxiety and depression. 
      Study selection, data extraction and assessment of the risk of bias will be
      performed independently by 2 or more reviewers. Available data will be
      synthesized and statistically analyzed in RevMan V.5.3. The model of fixed
      effects will be used for the pooled data when the heterogeneity tests show little
      or no statistical heterogeneity (I2 < 50%). The random-effects model will be
      taken with heterogeneous data (50% </= I2 < 75%). RESULTS: The effect of
      acupuncture on emotional disorders in patients with insomnia will be assessed on 
      Hamilton anxiety Scale, Hamilton anxiety Scale, Pittsburgh Sleep Quality Index,
      Insomnia Severity Index, Self-rating Anxiety Scale, Self-rating Depressive Scale 
      and the number of participants secede and the number of patients reported adverse
      events. CONCLUSION: the emotional disorders interaction with insomnia and the
      increase of risk on disease evolving and insomnia-related burden, it is so
      momentous to know that the role of insomnia treatment on comorbidities. We should
      concern about the management of emotional disorders when treat insomnia, and
      acupuncture treatment anxiety and depression caused by insomnia may be effective.
      ETHICS AND DISSEMINATION: Ethics approval is not be needed because the data will 
      not contain individual patient data, and there are no concerns about privacy. The
      results of this meta-analysis will be disseminated through publication in a
      peer-reviewed academic journal or relevant conference. INPLASY REGISTRATION
      NUMBER: INPLASY2020100115.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Huang, Bi-Qing
AU  - Huang BQ
AUID- ORCID: 0000-0002-2998-1709
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Xu, Gu-Xing
AU  - Xu GX
FAU - Luo, Ling
AU  - Luo L
LA  - eng
GR  - 81873240/the National Natural Science Foundation of China
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/adverse effects/*methods
MH  - Anxiety Disorders/epidemiology/*therapy
MH  - Depressive Disorder/epidemiology/*therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Severity of Illness Index
MH  - Sleep
MH  - Sleep Initiation and Maintenance Disorders/epidemiology/*therapy
PMC - PMC7748192
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/14 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023754 [doi]
AID - 00005792-202012180-00083 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23754. doi:
      10.1097/MD.0000000000023754.


PMID- 33371133
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Comparative efficacy and safety of traditional Chinese patent medicine in the
      treatment of Mycoplasma pneumoniae pneumonia in children: A protocol for
      systematic review and meta-analysis.
PG  - e23747
LID - 10.1097/MD.0000000000023747 [doi]
AB  - BACKGROUND: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory disease
      in children. Its incidence rate is increasing year by year. The drug resistance
      rate of macrolide antibiotics and other conventional treatment methods is higher,
      and there are limitations in clinical application. Traditional Chinese patent
      medicine (TCPM) is a powerful weapon to treat this disease. At present, there is 
      no comparison of the safety and effectiveness of multiple TCPMs in the treatment 
      of MPP in children. Therefore, we take the method of network meta-analysis to
      systematically compare the efficacy of various TCPMs in the treatment of this
      disease. METHODS: We will conduct comprehensive searches of Cochrane Library,
      PubMed, Web of Science, Clinical Trials, China National Knowledge Infrastructure,
      Chinese Scientific Journals Database, Chinese BioMedical Literature, Wanfang
      Database, and other electronic databases. The time frame is set from the
      establishment of the database to October 2020. All randomized controlled trials
      that meet the inclusion criteria will be included in this study. The 2
      researchers will independently screen the literature according to the inclusion
      criteria, extract the data, and assess the bias risk of the included study. We
      will evaluate all the obtained data and evidence through Bayesian network
      meta-analysis, and use Stata 15.0 to process and analyze the data. RESULTS:
      Through this study, we will evaluate the efficacy and safety of a variety of
      TCPMs for the treatment of MPP in children. CONCLUSION: The purpose of this study
      is to provide a strong reference for clinical application of TCPMs in the
      treatment of MPP in children, and to provide an important basis for clinicians to
      make correct judgments and put forward accurate treatment plans. ETHICS AND
      DISSEMINATION: This review does not involve any human or animal experiments and
      therefore does not require ethical approval. INPLASY REGISTRATION NUMBER: INPLASY
      2020100108.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - He, Hongan
AU  - He H
AD  - The First College of Clinical Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Wang, Xiao
AU  - Wang X
AD  - The First College of Clinical Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Xiao, Yanyan
AU  - Xiao Y
AD  - The First College of Clinical Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Zheng, Jialin
AU  - Zheng J
AD  - The First College of Clinical Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Wang, Jinjuan
AU  - Wang J
AD  - The First College of Clinical Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Zhang, Baoqing
AU  - Zhang B
AUID- ORCID: 0000-0002-7166-1864
AD  - The Affiliated Hospital of Shandong University of Traditional Chinese Medicine,
      Jinan, Shandong Province, China.
LA  - eng
GR  - 2019XZZX-EK004/TCM Evidence-based Capacity
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Macrolides)
SB  - IM
MH  - Adolescent
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Infant
MH  - Macrolides/adverse effects/*therapeutic use
MH  - Male
MH  - Mycoplasma pneumoniae
MH  - Network Meta-Analysis
MH  - Pneumonia, Mycoplasma/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7748181
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/13 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023747 [doi]
AID - 00005792-202012180-00081 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23747. doi:
      10.1097/MD.0000000000023747.


PMID- 33371125
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - The relationship between quantitative epicardial adipose tissue based on CT and
      coronary artery disease: A protocol for systematic review and meta-analysis.
PG  - e23729
LID - 10.1097/MD.0000000000023729 [doi]
AB  - BACKGROUND: Epicardial adipose tissue (EAT) is a kind of visceral adipose tissue 
      with close proximity to coronary artery and myocardium, which can secrete cell
      factor, and influence the physiological function and pathophysiological process
      of myocardium and coronary artery. Clinical imaging diagnosis showed that the
      volume and thickness of EAT exists a certain relevance with coronary artery
      disease, but it lacked evidence of evidence-based medicine. The research on the
      implementation of this program will systematically evaluate the relationship of
      computed tomography (CT) quantitative EAT and coronary artery disease. METHOD:
      The English databases (Embase, PubMed, the Cochrane Library, Web of Science) and 
      Chinese database (CNKI, Wanfang, China biomedical database, VIP) of computer
      retrieval has collected the case control clinical study of relationship between
      EAT and coronary artery disease from the establishment of the database to October
      2020, which was conducted extraction and quality evaluation by 2 researchers
      independently for data included in the study, and was conducted Meta-analysis for
      the included literature by adopting RevMan5.3 software. RESULT: The research
      evaluated the correlation between EAT and coronary artery disease through the EAT
      thickness, EAT volume, and other indexes. CONCLUSION: The research has provided
      reliable evidence-based evidence for the correlation between CT EAT
      quantification and coronary artery disease. ETHICS AND DISSEMINATION: We will not
      publish private information from individuals. This kind of systematic review does
      not involve harming the rights of participants. No ethical approval was required.
      The results can be published in peer-reviewed journals or at relevant
      conferences. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/DVQNE.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wu, Baohua
AU  - Wu B
AD  - Baoji Central Hospital, Baoji 721000, Shaanxi Province.
FAU - Ren, Zhuanqin
AU  - Ren Z
AD  - Baoji Central Hospital, Baoji 721000, Shaanxi Province.
FAU - Du, Zhengang
AU  - Du Z
AD  - Gansu gem flower hospital, Lanzhou 730060, Gansu Province.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Baoji hi-tech people's hospital, Baoji 721013, Shaanxi Province, China.
FAU - Hou, Bin
AU  - Hou B
AUID- ORCID: 0000-0001-7571-6757
AD  - Gansu gem flower hospital, Lanzhou 730060, Gansu Province.
LA  - eng
GR  - No. CZK-2012-22/the Research project of Gansu Administration of Traditional
      Chinese Medicine
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adipose Tissue/diagnostic imaging/*pathology
MH  - Case-Control Studies
MH  - Coronary Artery Disease/*pathology
MH  - Humans
MH  - Pericardium/diagnostic imaging/*pathology
MH  - Research Design
MH  - Tomography, X-Ray Computed
PMC - PMC7748182
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/12 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023729 [doi]
AID - 00005792-202012180-00073 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23729. doi:
      10.1097/MD.0000000000023729.


PMID- 33371124
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Acupoint catgut embedding for obesity: A protocol of systematic review.
PG  - e23728
LID - 10.1097/MD.0000000000023728 [doi]
AB  - BACKGROUND: Obesity is a chronic metabolic disease in which patients are
      overweight due to the excessive accumulation of fat in the body. As a subtype of 
      acupuncture, catgut embedding at acupoints has increased in clinical application 
      for obesity. The aim of this study is to evaluate the effectiveness and safety of
      acupoint catgut embedding therapy for simple obesity. METHODS AND ANALYSIS:
      Electronic searches of the Cochrane Library, PubMed, Springer Medline, EMBASE,
      Web of Science, China National Knowledge Infrastructure (CNKI), Wan-Fang Data
      (WANFANG), Chinese Biomedical Literature Database (CBM), and Chinese Scientific
      Journal Database (VIP databases) will be performed. The Chinese Clinical Trial
      Registry Center and the ClinicalTrials.gov registry will also be searched for
      ongoing trials. Databases will be searched from inception to August
      2020.Randomized controlled clinical trials (RCTs) will be included if acupoint
      catgut embedding was evaluated as the sole treatment (diet or exercise therapy as
      the control group will be allowed) for simple obesity. The primary outcomes will 
      consist of the improvement rate and reduction in body weight (BW). The secondary 
      outcomes will include body mass index (BMI), waist circumference (WC), fat
      percentage (F %) and adverse effects. Two reviewers will undertake the study
      selection, data extraction and assessments of study quality. After screening the 
      studies, the quality of the included studies will be assessed according to the
      quality criteria specified by the Cochrane Handbook for Systematic Reviews of
      Interventions (version 5.1.0). Meta-analysis will be performed by RevMan 5.3
      software. RESULTS: According to the data of improvement rate and reduction in BW,
      BMI, WC, and F %, this study will provide an evidence-based review of acupoint
      catgut embedding therapy for simply. CONCLUSIONS: This systematic review will
      present the current evidence for acupoint catgut embedding therapy for obesity.
      ETHICS AND DISSEMINATION: Ethical approval is not necessary since this protocol
      is only for systematic review and does not involve privacy data. The findings of 
      this study will be disseminated electronically through a peer-review publication 
      or presented at a relevant conference. TRIAL REGISTRATION NUMBER:
      INPLASY2020110045.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Huang, Wei
AU  - Huang W
AD  - Hubei University of Chinese Medicine/The Co-innovation Center for Preventive
      Treatment of Disease of Acupuncture-moxibustion in Hubei Province.
AD  - Department of Acupuncture, Hubei Provincial Hospital of Traditional Chinese
      Medicine, Wuhan, China.
FAU - Chen, Xia
AU  - Chen X
AD  - Department of Acupuncture, Hubei Provincial Hospital of Traditional Chinese
      Medicine, Wuhan, China.
FAU - Zhang, Yanji
AU  - Zhang Y
AD  - Hubei University of Chinese Medicine/The Co-innovation Center for Preventive
      Treatment of Disease of Acupuncture-moxibustion in Hubei Province.
FAU - Wang, Lihua
AU  - Wang L
AD  - Hubei University of Chinese Medicine/The Co-innovation Center for Preventive
      Treatment of Disease of Acupuncture-moxibustion in Hubei Province.
FAU - Wang, Jiajie
AU  - Wang J
AD  - Department of Acupuncture, Hubei Provincial Hospital of Traditional Chinese
      Medicine, Wuhan, China.
FAU - Zhang, Yingrong
AU  - Zhang Y
AD  - Hubei University of Chinese Medicine/The Co-innovation Center for Preventive
      Treatment of Disease of Acupuncture-moxibustion in Hubei Province.
FAU - Wei, Dan
AU  - Wei D
AD  - Department of Acupuncture, Hubei Provincial Hospital of Traditional Chinese
      Medicine, Wuhan, China.
FAU - Zhou, Zhongyu
AU  - Zhou Z
AD  - Department of Acupuncture, Hubei Provincial Hospital of Traditional Chinese
      Medicine, Wuhan, China.
LA  - eng
GR  - 201507003/2015 Special Project in TCM Industry of State of Administration of
      Traditional Chinese Medicine of the People's Republic of China
GR  - 81674081, 81704142/National Natural Science Foundation of China
GR  - Health Commission of Hubei Province Notice No.[2019]47/The 2nd Hubei Province's
      Outstanding Medical Academic Leader Program
GR  - (Hubei traditional Chinese medicine yard: [2018] no. 72/Hubei hospital of
      traditional Chinese medicine, the first Tanhualin famous doctor, student training
      project
GR  - Document No. 284 (2018)/Qihuang Engineering Project of National Administration of
      Traditional Chinese Medicine
GR  - no. 116, family planning tong [2018]/Wuhan young and middle-aged medical backbone
      talents (sixth batch)
GR  - Health Commission of Hubei Province bulletin No. 15 (2018)/The Project of Hubei
      Famous Doctor of Traditional Chinese Medicine Studio
GR  - Document No. 2019XZZX-ZJ006/Evidence-based research on acupuncture treatment of
      dominant diseases
GR  - HBPCIC-2020-11/2020 Project in the Co-innovation Center for Preventive Treatment 
      of Disease of Acupuncture-moxibustion in Hubei Province
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Body Mass Index
MH  - Body Weights and Measures
MH  - *Catgut
MH  - Humans
MH  - Obesity/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Weight Loss
PMC - PMC7748162
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/12 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023728 [doi]
AID - 00005792-202012180-00072 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23728. doi:
      10.1097/MD.0000000000023728.


PMID- 33371115
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Acupuncture and related therapies for treating stable angina pectoris: A protocol
      of an overview of systematic reviews and meta-analysis.
PG  - e23701
LID - 10.1097/MD.0000000000023701 [doi]
AB  - BACKGROUND: Stable angina pectoris (SAP) is a global health challenge. Multiple
      previous systematic reviews (SRs) have been conducted to assess the effectiveness
      of acupuncture and related therapies on SAP. We will carry out a comprehensive
      overview to map, synthesize, and assess the all the available evidence of
      acupuncture and related therapies on SAP. METHODS: We will search 7 databases,
      including China National Knowledge Infrastructure (CNKI) and Chinese Biomedical
      Literature Database (CBM), WanFang Database, the Cochrane Library, PubMed,
      EMbase, MEDLINE. SRs and meta-analyses (MAs) of acupuncture and related therapies
      on SAP will be screened for eligibility. Systematic reviews, qualification
      evaluation, data extraction, methodological quality, and evidence quality
      evaluation will be conducted in pairs. The outcomes of interest include:
      frequency of angina attack, changes in nitroglycerin use, intensity of anginal
      pain, depression assessment, changes of the electrocardiogramme (ECG), anxiety
      assessment, results of the Six-Minute Walk Test (6-MWT), overall effectiveness,
      the Seattle Angina Questionnaire (SAQ), and adverse events. Where appropriate,
      the evidence will be synthesized based on the outcomes and patient subgroups.
      RESULTS: This overview will be published in a peer-reviewed journal. CONCLUSION: 
      This overview is expected to provide a reliable and valuable evidence of
      acupuncture for treating SAP. ETHICS AND COMMUNICATION: Given that this is an
      overview of published research, patient consent and ethical approval are not
      needed. The findings of this study will be disseminated through conference
      presentations and publication in peer-reviewed journals. PROSPERO REGISTRATION
      NUMBER: CRD42020164466.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Sun, Haiju
AU  - Sun H
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou City, Zhejiang Province.
FAU - Li, Xiaoyu
AU  - Li X
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou City, Zhejiang Province.
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      China.
FAU - Lou, Jiali
AU  - Lou J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou City, Zhejiang Province.
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      China.
FAU - Zhang, Yajun
AU  - Zhang Y
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou City, Zhejiang Province.
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      China.
FAU - Jiang, Yongliang
AU  - Jiang Y
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou City, Zhejiang Province.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou City, Zhejiang Province.
LA  - eng
GR  - NO.2018YFC1704600/the National Key R&amp;D Program of China
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Angina, Stable/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7748361
EDAT- 2020/12/30 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/13 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1097/MD.0000000000023701 [doi]
AID - 00005792-202012180-00063 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23701. doi:
      10.1097/MD.0000000000023701.


PMID- 33371109
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Evaluation of a web-based intervention in patients with chronic human
      immunodeficiency virus infection: Protocol for a randomized controlled trial.
PG  - e23683
LID - 10.1097/MD.0000000000023683 [doi]
AB  - BACKGROUND: The infection of human immunodeficiency virus (HIV) is 1 of the major
      causes of morbidity and mortality in the world. People with chronic diseases have
      a higher risk of depression. The HIV people are more likely to suffer from
      depression. Appropriate psychosocial interventions are effective, but their
      accessibility is limited by the resources needed for their transmission. Thus, it
      makes sense to develop more cost-effective alternatives, for instance the
      web-based intervention (WBI), which may be effective for the well-being and
      depression. The aim of our program is to explore the effects of a WBI on
      depressive symptoms and well-being in HIV-infected patients. METHOD: It is a
      randomized controlled experiment to be conducted from February 2021 to July 2021.
      It was permitted through the Ethics Committee of Changshan County People's
      Hospital (no.60928376). This study includes 100 HIV patients. Inclusion criteria:
      (1)18 + years, on effective antiretroviral therapy>/= 1 year before inclusion.
      Exclusion criteria: patients with severe kidney, liver, lung, and heart diseases.
      Patients are divided randomly into the study group and control group, each group 
      is assigned 50. The primary results are subjective well-being and depressive
      symptoms, while the secondary result involves the patients' satisfaction with
      life. RESULTS: The following Table 1 will exhibit the comparison of outcomes
      between 2 groups. CONCLUSION: HIV infected patients can benefit from WBI, which
      can be utilized as an adjunct to medical treatment. TRIAL REGISTRATION NUMBER:
      researchregistry6215.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Mao, Meihua
AU  - Mao M
AUID- ORCID: 0000-0002-4951-9693
AD  - Department of infectious disease, Changshan County People's Hospital, Zhejiang,
      China.
FAU - Jiang, Gongying
AU  - Jiang G
FAU - Jiang, Qiaofei
AU  - Jiang Q
LA  - eng
GR  - 20189089/Zhejiang Natural Science Foundation
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Depression/*prevention & control
MH  - HIV Infections/*psychology
MH  - Humans
MH  - *Internet-Based Intervention
MH  - Randomized Controlled Trials as Topic
PMC - PMC7748183
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/11 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1097/MD.0000000000023683 [doi]
AID - 00005792-202012180-00057 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23683. doi:
      10.1097/MD.0000000000023683.


PMID- 33371108
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - The effect of enhancing quality of life in patients intervention for advanced
      lung cancer: Protocol for a randomized clinical study.
PG  - e23682
LID - 10.1097/MD.0000000000023682 [doi]
AB  - OBJECTIVE: The objective of this present research is to evaluate the effect of
      the intervention of enhancing quality of life in patients in patients with
      advanced lung cancer. METHODS: Our research is carried out as a randomized
      clinical trial which will be implemented from December 2020 to October 2021. It
      was approved by the Ethics Committee of People's Hospital of Chengyang District
      (03982790). This study includes 90 patients with advanced lung cancer. Patients
      diagnosed at our oncology clinic are eligible if they are diagnosed within 8
      weeks of a novel diagnosis of stage 3 or stage 4 lung cancer. Patients with
      hepatic insufficiency, renal failure, and respiratory and heart failure, as well 
      as a series of severe mental illness are excluded from our research. Patients are
      divided randomly into the intervention group and control group, each group is
      assigned 45 patients. Through utilizing functional assessment of cancer
      therapy-lung, the measurement of life quality is conducted. And the measurement
      of mood is carried out with Hospital Anxiety and Depression Scale. RESULTS: Table
      1 indicates the patient's life quality and Hospital Anxiety and Depression Scale 
      in both groups. CONCLUSION: Enhancing quality of life in patient intervention may
      be beneficial to improve the life quality in advanced lung cancer patients.Trial 
      registration: The protocol was registered in Research Registry
      (researchregistry6243).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Li, Xianhong
AU  - Li X
AD  - Department of Urology.
FAU - Qin, Ke
AU  - Qin K
AD  - Department of Urology.
FAU - Yuan, Chunyan
AU  - Yuan C
AD  - Department of Rehabilitation Medicine, People's Hospital of Chengyang District,
      Qingdao, China.
FAU - Song, Shiqiang
AU  - Song S
AUID- ORCID: 0000-0003-0314-7852
AD  - Department of Urology.
LA  - eng
GR  - 10-1-12-sh/Qingdao Chengyang District Science and Technology Project
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Lung Neoplasms/*nursing/psychology
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7748172
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/10 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1097/MD.0000000000023682 [doi]
AID - 00005792-202012180-00056 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23682. doi:
      10.1097/MD.0000000000023682.


PMID- 33371107
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for
      patients with myasthenia gravis: Study protocol for a series of randomized,
      controlled N-of-1 trials.
PG  - e23679
LID - 10.1097/MD.0000000000023679 [doi]
AB  - INTRODUCTION: Myasthenia gravis (MG) is an autoimmune disease in which antibodies
      directly target components of the neuromuscular junction, causing neuromuscular
      conduction damage that leads to muscle weakness. The current pharmaceutical
      treatment for MG is still not ideal to address the problems of disease
      progression, high recurrence rate, and drug side effects. Clinical observations
      suggest that traditional Chinese medicine (TCM) can strengthen immunity and
      improve symptoms of MG patients, delay the progression of the disease, reduce or 
      even prevent the need for immunosuppressive therapy when used in combination with
      acetylcholinesterase inhibitors or low-dose prednisone, as well as improve the
      quality of life of patients. The Qiangji Jianli Capsule (QJC) is a combination of
      medicinal herbs which is used in traditional Chinese medicine. Since MG is a rare
      disorder, randomized controlled trials comparing large cohorts are difficult to
      conduct. Therefore, we proposed to aggregate data from a small series of N-of-1
      trials to assess the effect of the Chinese medical prescription QJC, which
      strengthens the spleen and nourishes Qi, as an add-on treatment for MG with
      spleen and stomach Qi deficiency syndrome. METHODS AND ANALYSIS: Single-center,
      randomized, double-blind, multiple crossover N-of-1 studies will compare QJC
      versus placebo in 5 adult MG patients with spleen and stomach Qi deficiency
      syndrome. Patients will undergo 3 cycles of two 4-week intervention periods.
      According to the treatment schedule, patients will continue to be treated with
      pyridine bromide tablets, prednisone acetate, tablets and/or tacrolimus capsules 
      throughout the entire trial. Each period consisting of 4-week oral add-on
      treatment with QJC will be compared with 4-week add-on treatment with a placebo. 
      The primary endpoints are quantitative myasthenia gravis (QMG) test; measurement 
      of the amount of Treg cells and cytokines such as interferon-gamma (IFN-gamma),
      interleukin-4 (IL-4), interleukin-17A (IL-17A), and transforming growth
      factor-beta (TGF-beta); and corticosteroid or immunosuppressive agent dosage.
      Secondary outcome measures: Clinical: Evaluation of the effect of TCM syndromes; 
      MG-activities of daily living (MG-ADL) scales; adverse events. ETHICS AND
      DISSEMINATION: This study was approved by The First Affiliated Hospital of
      Guangzhou University of Chinese Medicine (GZUCM), No. ZYYECK[2019]038. The
      results will be published in a peer-reviewed publication. Regulatory stakeholders
      will comment on the suitability of the trial for market authorization and
      reimbursement purposes. Trial registration: Chinese Clinical Trial Register, ID: 
      ChiCTR2000033516. Registered on 3 June 2020,
      http://www.chictr.org.cn/showprojen.aspx?proj=54618.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Weng, Senhui
AU  - Weng S
AUID- ORCID: 0000-0003-2116-2845
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Fan, Zhixin
AU  - Fan Z
AD  - Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Qiu, Guoyu
AU  - Qiu G
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Liu, Fengbin
AU  - Liu F
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Huang, Linwen
AU  - Huang L
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Li, Jinghao
AU  - Li J
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Jiang, Xiaotao
AU  - Jiang X
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Song, Zhixuan
AU  - Song Z
AD  - Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Gao, Yuxia
AU  - Gao Y
AD  - Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Zhong, Zhuotai
AU  - Zhong Z
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - He, Long
AU  - He L
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Kang, Liping
AU  - Kang L
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
FAU - Wu, Yunlong
AU  - Wu Y
AD  - Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Chen, Benshu
AU  - Chen B
AD  - Guangzhou University of Chinese Medicine, Guangzhou, China.
FAU - Jiang, Qilong
AU  - Jiang Q
AD  - Department of Spleen-Stomach, First Affiliated Hospital of Guangzhou University
      of Chinese Medicine.
LA  - eng
GR  - 1,000,000yuan/The Scientific Research Team Training Project Of Guangzhou
      University of Chinese Medicine (2019KYTD101)
GR  - 50,000yuan/The Youth Innovation Scientific Research Project Of The First
      Affiliated Hospital of Guangzhou University of Chinese Medicine (2019QN28)
GR  - 210,000yuan/The National Natural Science Foundation of China(NSFC) (81904133)
GR  - self-finance/The Scientific Research Of Traditional Chinese Medicine Bureau Of
      Guangdong Province (20192022)
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (qiangji jianli)
SB  - IM
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Myasthenia Gravis/*drug therapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7748195
EDAT- 2020/12/30 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/09 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1097/MD.0000000000023679 [doi]
AID - 00005792-202012180-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23679. doi:
      10.1097/MD.0000000000023679.


PMID- 33371097
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Effects of houttuynia cordata thunb. on rhinosinusitis by nasal irrigation: A
      protocol for systematic review and meta-analysis.
PG  - e23634
LID - 10.1097/MD.0000000000023634 [doi]
AB  - BACKGROUND: The herba Houttuynia cordata Thunb. (HC) has anti-inflammatory,
      antibacterial and antiviral effects. Through nasal irrigation, the related
      preparation of HC is beneficial for treating rhinosinusitis or promoting recovery
      after an endoscopic sinus surgery. However, it remains controversial whether
      nasal irrigation with HC preparation can provide evidence-based clinical benefits
      for rhinosinusitis patients. METHODS: With reference to the Preferred Reporting
      Items for Systematic Reviews and Meta-Analyses (PRISMA), 8 databases are perused 
      to perform a methodical investigation of nasal irrigation with HC preparation and
      health-related results amongst rhinosinusitis patients. The main research purpose
      is to determine the influence of PRISMA standards on medical results pertaining
      to rhinosinusitis patients, including quantitative symptom recording and
      effective rate. With reference to the Cochrane Handbook, quality assessment of
      qualified papers is conducted using the Cochrane Risk Assessment Tool. RESULTS:
      The results will be publicised through a peer-reviewed journal publication.
      CONCLUSION: The results of the systematic review will summarise evidences for the
      efficacy of nasal irrigation with HC preparation in rhinosinusitis treatment.
      ETHICS AND DISSEMINATION: Since this study involves a methodical investigation of
      issued medical papers, ethical authorisation and informed patient consent are not
      necessary.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Dandan
AU  - Wang D
AUID- ORCID: 0000-0003-0537-061
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Tian, Tian
AU  - Tian T
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Jinniu District, Chengdu,
      Sichuan Province, PR China.
FAU - Liao, Chao
AU  - Liao C
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Jinniu District, Chengdu,
      Sichuan Province, PR China.
FAU - Liu, Ting
AU  - Liu T
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Tang, Guangjun
AU  - Tang G
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Jinniu District, Chengdu,
      Sichuan Province, PR China.
FAU - Tian, Li
AU  - Tian L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
GR  - project number: 2019YFC1712500, subject number:2019YFC1712502/The 2019 National
      Key R&amp;D Program of the Ministry of Science and Technology "Modernization
      Research of TCM"
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Houttuynia cordata extract)
SB  - IM
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - *Houttuynia
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Nasal Lavage
MH  - *Phytotherapy
MH  - Rhinitis/*drug therapy
MH  - Sinusitis/*drug therapy
MH  - Systematic Reviews as Topic
PMC - PMC7748356
COIS- The authors report no conflicts of interest.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/06 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1097/MD.0000000000023634 [doi]
AID - 00005792-202012180-00045 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23634. doi:
      10.1097/MD.0000000000023634.


PMID- 33371086
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Efficacy of Omaha system-based nursing management on nutritional status in
      patients undergoing peritoneal dialysis: A randomized controlled trial protocol.
PG  - e23572
LID - 10.1097/MD.0000000000023572 [doi]
AB  - ABSTRACT: The chronic kidney disease (CKD) patients may have a variety of
      complications during receiving peritoneal dialysis (PD). The malnutrition in CKD 
      patients is related to their lower life quality, higher hospitalization rates,
      and higher risk of cardiovascular disease, as well as the increased morbidity and
      mortality. Hence, it is very important to monitor and then manage the nutritional
      status of CKD patients. Thus, we perform this randomized controlled study
      protocol to introduce a continuing nursing program based on Omaha system (OS) for
      the patients with CKD receiving PD treatment.The randomized trial will be
      implemented from November 2020 to May 2021 and was granted through the Research
      Ethics Committee of Wuhan No.1 Hospital (2020003281). Two hundred patients meet
      inclusion criteria and exclusion criteria are included.Patients who meet the
      following criteria will be selected: voluntary participation, aged 20 to 60;
      undergoing the regular PD treatment for at least 3 months. Patients will be
      excluded if the patients are in unstable status, or experience the intermittent
      PD or some other kinds of dialysis mode, have severe cachexia, infection, or
      malnutrition, or if they have mental disorders. In control group, patients are
      given routine treatment, containing general guidance associated with PD and the
      outpatient telephone calls from the clinical nurses during follow-up. In study
      group, the patients are given the continuous nursing treatment scheme based on
      OS. The clinical results are the biochemical parameters after intervention,
      anthropometry, as well as the subjective global assessment.Table 1 reveals the
      clinical endpoints between the 2 groups.This protocol can guide nurses to develop
      a nursing program based on evidence for patients with CKD receiving PD. TRIAL
      REGISTRATION: This study protocol was registered in Research Registry
      (researchregistry6202).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Peng, Liqing
AU  - Peng L
AD  - Department of Critical Care Medicine, Wuhan No.1 Hospital, Hubei, China.
FAU - Gao, Yuanyuan
AU  - Gao Y
FAU - Lu, Rong
AU  - Lu R
FAU - Zhou, Ruixiang
AU  - Zhou R
AUID- ORCID: 0000-0002-5022-1181
LA  - eng
GR  - 2016032101/Natural Science Foundation of Hubei
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Body Mass Index
MH  - Body Weights and Measures
MH  - Diet/*standards
MH  - Female
MH  - Hand Strength
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nutritional Status
MH  - Patient Care Planning/*organization & administration
MH  - Patient Education as Topic/*organization & administration
MH  - Peritoneal Dialysis/*nursing
MH  - Renal Insufficiency, Chronic/*therapy
MH  - Young Adult
PMC - PMC7748208
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/03 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023572 [doi]
AID - 00005792-202012180-00034 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23572. doi:
      10.1097/MD.0000000000023572.


PMID- 33371080
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Guizhi Fuling wan for chronic pelvic inflammatory disease protocol: A protocol
      for systematic review and meta analysis.
PG  - e23549
LID - 10.1097/MD.0000000000023549 [doi]
AB  - BACKGROUND: Chronic pelvic inflammatory disease (CPID) is one of common diseases 
      of department of gynaecology, point to female inside genital and circumferential 
      organization to suffer from infection of all sorts of pathogenic bacteria and
      cause chronic inflammation sex disease, also cause one of main factors of
      infertile of female of childbearing age period. Due to its insidious onset, it is
      not easy to find out in the early stage. Therefore, it is difficult to obtain
      satisfactory curative effect by taking routine treatment with antibiotics. In
      recent years, TCM has made great strides in the treatment of chronic pelvic
      inflammation, a number of clinical studies have shown that Guizhi Fuling wan
      combined with antibiotics can significantly improve the clinical symptoms and
      enhance the therapeutic effect. Therefore, we intend to conduct a system review
      and meta-analysis to further clarify the effectiveness and safety of GZFLW for
      CPID. METHODS: We will search each database from the built-in until
      September2020.The English literature mainly searches Cochrane Library, PubMed,
      EMBASE, and Web of Science, while the Chinese literature comes from CNKI, CBM,
      VIP, and Wangfang database. Simultaneously we will retrieval clinical
      registration tests and grey literatures. This study only screens the clinical
      randomized controlled trials (RCTs) about GZFLW for CPID to assess its efficacy
      and safety. The 2 researchers worked independently on literature selection, data 
      extraction, and quality assessment. The dichotomous data is represented by
      relative risk (RR), and the continuous is expressed by mean difference (MD) or
      standard mean difference (SMD), eventually the data is synthesized using a fixed 
      effect model (FEM) or a random effect model (REM) depending on whether or not
      heterogeneity exists. The clinical efficacy, pelvic effusion and mass were
      evaluated as the main outcomes. The serum interleukin-6 (IL-6), C-reactive
      protein (CRP), tumor necrosis factor (TNF)-alpha, erythrocyte sedimentation rate 
      (ESR), erythrocyte specific volume was secondary outcomes. Finally, meta-analysis
      was conducted by RevMan software version 5.3. RESULTS: This study will provide
      high-quality evidence for treatment of CPID with GZFLW in terms of effectiveness 
      and safety. CONCLUSION: This systematic review aims to provide new options for
      GZFLW treatment of CPID in terms of its efficacy and safety. ETHICS AND
      DISSEMINATION: This study does not require ethical approval. We will disseminate 
      our findings by publishing results in a peer-reviewed journal. OSF REGISTRATION
      NUMBER: DOI 10.17605 / OSF.IO / R9NVT.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Chunrong
AU  - Wang C
AD  - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Chen, Jingyun
AU  - Chen J
FAU - Xiao, Yanling
AU  - Xiao Y
FAU - Shen, Qilin
AU  - Shen Q
AUID- ORCID: 0000-0002-0643-4892
LA  - eng
GR  - (No. 201926/State Administration of Traditional Chinese Medicine of the People's 
      Republic of China
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Inflammation Mediators)
RN  - 0 (guizhi-fuling)
SB  - IM
MH  - Blood Sedimentation/drug effects
MH  - Chronic Disease
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Pelvic Inflammatory Disease/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7748215
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/04 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023549 [doi]
AID - 00005792-202012180-00028 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23549. doi:
      10.1097/MD.0000000000023549.


PMID- 33371076
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Is acupuncture effective and safe for prophylaxis of vestibular migraine?: A
      protocol for systematic review and meta analysis.
PG  - e23533
LID - 10.1097/MD.0000000000023533 [doi]
AB  - BACKGROUND: Increasing studies indicate that acupuncture can be used for treating
      vestibular migraine (VM), but current evidence remains inconclusive. Thus, this
      protocol aims to evaluate the evidence regarding the efficacy and safety of
      acupuncture for VM prophylaxis by conducting a systematic review and
      meta-analysis. METHODS: Studies will be retrieved by searching electronic
      databases from their inception to December 2020, including EMBASE, PubMed, Web of
      Science, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI),
      Chinese BioMedical Literature Database (CBM), and Chinese Science and Technology 
      Periodical Database (VIP). Eligible randomized controlled trials involving
      acupuncture for VM prophylaxis will be included. Study screening, data
      collection, and assessment for risk of bias will be executed by 2 independent
      reviewers. Meta-analyses will be conducted, followed by subgroup analysis if
      significant heterogeneity is detected. Sensitivity analysis and summary of the
      strength of the evidence will also be performed. RESULTS: The results of the
      present systematic review and meta-analysis will verify the efficacy and safety
      of acupuncture for VM prophylaxis. CONCLUSION: This review will determine the
      efficacy and safety of acupuncture on VM prophylaxis. The findings are expected
      to verified whether acupuncture can be an alternative treatment for VM
      prophylaxis. ETHICS AND DISSEMINATION: Given that a systematic review and
      meta-analysis will not involve private information of individuals, ethical
      approval is not required. Relevant results and findings will be submitted to an
      academic journal for peer reviews. PROSPERO REGISTRATION NUMBER: CRD42020202588.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Hu, Tianye
AU  - Hu T
AD  - Department of Traditional Chinese Medicine and Acupuncture.
FAU - Zhang, Aijun
AU  - Zhang A
AD  - Department of Traditional Chinese Medicine and Acupuncture.
FAU - Jiang, Bin
AU  - Jiang B
AD  - Department of Traditional Chinese Medicine and Acupuncture.
FAU - Shen, Fengfei
AU  - Shen F
AD  - Department of Traditional Chinese Medicine and Acupuncture.
FAU - Hu, Jin
AU  - Hu J
AUID- ORCID: 0000-0003-4579-0432
AD  - Department of Neurology, The First Affiliated Hospital of Jiaxing University,
      Jiaxing 314001, Zhejiang Province, China.
LA  - eng
GR  - 2021ZQ084/Project of Zhejiang Administration of Traditional Chinese Medicine
GR  - 201906-202207/Key Discipline of Traditional Chinese Medicine of Jiaxing
GR  - 201904-202203/13th Five-Year Key Specialty of Traditional Chinese Medicine of
      Zhejiang Province
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/adverse effects/*methods
MH  - Combined Modality Therapy
MH  - Humans
MH  - Migraine Disorders/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7748202
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/10/31 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023533 [doi]
AID - 00005792-202012180-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23533. doi:
      10.1097/MD.0000000000023533.


PMID- 33371074
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Efficacy of different plant extracts in the prevention of radiation dermatitis in
      radiotherapy patients with nasopharyngeal carcinoma: A protocol for a Bayesian
      network meta-analysis.
PG  - e23523
LID - 10.1097/MD.0000000000023523 [doi]
AB  - BACKGROUND: Radiation dermatitis is a common complication in patients with
      nasopharyngeal carcinoma (NPC) when treated with radiotherapy. Plant extracts
      have good effects on the prevention of radiation dermatitis in patients with NPC 
      when treated with radiotherapy. However, there is insufficient comparison among
      the currently used plant extracts. Therefore, the purpose of this study was to
      explore the efficacy of different plant extracts in the prevention of radiation
      dermatitis in patients with NPC by Bayesian network meta-analysis. METHODS: We
      searched Chinese and English databases to collect all randomized controlled
      trials (RCT) of plant extracts for the prevention of radiation dermatitis in NPC 
      patients who underwent radiotherapy up to October 2020. Two researchers then
      independently screened articles, extracted data and evaluated the quality
      selected literatures. All data were processed by Stata 14.0 and WinBUGS V.1.4.3. 
      RESULTS: We applied Bayesian statistical model for network meta-analysis, ranked 
      the effects of various plant extracts, and adopted GRADE method to explain the
      results. CONCLUSION: Our study is expected to provide high-quality evidence-based
      medicine advice for the prevention of radiation dermatitis in patients suffering 
      from NPC undergoing radiotherapy. ETHICS AND DISSEMINATION: Ethical approval was 
      not required for this study. The systematic review will be published in a
      peer-reviewed journal, presented at conferences, and will be shared on social
      media platforms. This review would be disseminated in a peer-reviewed journal or 
      conference presentations. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/6SV45.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Yi, Yi
AU  - Yi Y
AUID- ORCID: 0000-0002-9538-3192
AD  - Department of Otolaryngology, The Second Branch of Chongqing Ninth People's
      Hospital.
FAU - You, Xingli
AU  - You X
AD  - Department of Medical Insurance, Chongqing Fifth People's Hospital.
FAU - Long, Ying
AU  - Long Y
AD  - Department of Medical Insurance, Chongqing Fifth People's Hospital.
FAU - Huang, Ya
AU  - Huang Y
AD  - Department of Oncology, Chongqing Ninth People's Hospital, Chongqing, China.
LA  - eng
GR  - 2018-25/Beibei District, Chongqing, Applied development Plan project
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Bayes Theorem
MH  - Humans
MH  - Nasopharyngeal Carcinoma/*radiotherapy
MH  - Nasopharyngeal Neoplasms/*radiotherapy
MH  - Network Meta-Analysis
MH  - Plant Extracts/*administration & dosage
MH  - Radiodermatitis/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7748178
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/11/04 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023523 [doi]
AID - 00005792-202012180-00022 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23523. doi:
      10.1097/MD.0000000000023523.


PMID- 33371066
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 51
DP  - 2020 Dec 18
TI  - Quantitative assessment-based nursing intervention improves bowel function in
      patients with neurogenic bowel dysfunction after spinal cord injury: Study
      protocol for a randomized controlled study.
PG  - e23354
LID - 10.1097/MD.0000000000023354 [doi]
AB  - BACKGROUND: The neurogenic bowel dysfunction is a kind of familiar sequelae of
      the spinal cord injury (SCI), occurring in 70 to 80 percent of the SCI patients. 
      The nursing intervention based on quantitative evaluation is to fully consider
      and assess the disease condition of patients, implement the personalized programs
      of nursing intervention, meet the patient's nursing needs to the maximum extent, 
      improve the quality of nursing, and then facilitate the rehabilitation of
      patients. Our aim is to implement this program to evaluate the impact of this
      nursing intervention based on quantitative evaluation on the quality of life and 
      bowel function in the neurogenic bowel dysfunction patients after SCI. METHODS:
      The experiment is a randomized clinical research which will be implemented from
      May 2021 to October 2021 at the First Affiliated Hospital of Soochow University. 
      The experiment was granted through the Research Ethics Committee of the First
      Affiliated Hospital of Soochow University (No.100238765). Fifty neurogenic bowel 
      dysfunction patients after SCI confirmed via the imaging are included in this
      study. The patients with the history of bowel diseases or patients who are
      unwilling to cooperate with the evaluation will be excluded. The primary outcomes
      are bowel function recovery and satisfaction of the patients. The secondary
      outcomes are quality of life evaluated by SF-36 questionnaire. The questionnaire 
      involves physical pain, role physiology, physiological functions, social
      functions, vitality, general health, mental health and role-motional. RESULTS:
      Comparison of clinical parameters between the 2 groups will be shown in Table 1. 
      CONCLUSION: Nursing intervention based on the quantitative evaluation can improve
      the quality of life and recovery of intestinal function for the neurogenic
      intestinal dysfunction patients after SCI. TRIAL REGISTRATION NUMBER:
      researchregistry6143.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Yin, Qionghua
AU  - Yin Q
AD  - Department of Intensive Care Unit, The First Affiliated Hospital of Soochow
      University, Jiangsu, China.
FAU - Wang, Can
AU  - Wang C
FAU - Yu, Jianhong
AU  - Yu J
FAU - Zhang, Qiufang
AU  - Zhang Q
AUID- ORCID: 0000-0001-5729-0895
LA  - eng
GR  - 2019128763/Jiangsu Natural Science Foundation
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Neurogenic Bowel/etiology/*nursing/physiopathology/*therapy
MH  - Patient Care Planning/*organization & administration/standards
MH  - Quality of Health Care
MH  - Quality of Life
MH  - Research Design
MH  - Severity of Illness Index
MH  - Spinal Cord Injuries/complications/rehabilitation
PMC - PMC7748302
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/10/20 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000023354 [doi]
AID - 00005792-202012180-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 18;99(51):e23354. doi:
      10.1097/MD.0000000000023354.


PMID- 33371052
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 21
TI  - Evaluation of the effectiveness of behavioural economic incentive programmes for 
      the promotion of a healthy diet and physical activity: a protocol for a
      systematic review and network meta-analysis.
PG  - e046035
LID - 10.1136/bmjopen-2020-046035 [doi]
AB  - INTRODUCTION: Obesity and being overweight are major risk factors for metabolic
      syndrome and non-communicable diseases. Despite the recommendation that a healthy
      diet and physical activity can reduce the severity of these diseases, many fail
      to adhere to these measures. From a behavioural economic perspective, adherence
      to such measures can be encouraged through financial incentives. However,
      additional related behavioural economic approaches may improve the effectiveness 
      of an incentive programme. As such, we have developed a protocol for a systematic
      review and network meta-analysis to summarise the current evidence from financial
      incentive programmes with and without behavioural economic insights for promoting
      healthy diet and physical activity. METHODS AND ANALYSIS: Previous systematic
      reviews, meta-analyses and individual studies were identified from Medline and
      Scopus in June 2020 and will be updated until December 2020. Individual studies
      will be selected and data extracted by two reviewers. Disagreement will be
      resolved by consensus or adjudicated by a third reviewer. A descriptive analysis 
      will summarise the effectiveness of behavioural economic incentive programmes for
      promoting healthy diet and physical activity. Moreover, individual studies will
      be pooled using network meta-analyses where possible. I(2) statistics and
      Cochran's Q test will be used to assess heterogeneity. Risk of bias and
      publication bias, if appropriate, will be evaluated, as well as the overall
      strength of the evidence. ETHICS AND DISSEMINATION: Ethics approval for a
      systematic review and meta-analysis is not required. The findings will be
      published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020198024.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Boonmanunt, Suparee
AU  - Boonmanunt S
AD  - Department of Clinical Epidemiology and Biostatistics, Mahidol University,
      Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand.
FAU - Pattanaprateep, Oraluck
AU  - Pattanaprateep O
AUID- ORCID: 0000-0001-9570-2635
AD  - Department of Clinical Epidemiology and Biostatistics, Mahidol University,
      Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand
      oraluck.pat@mahidol.edu.
FAU - Ongphiphadhanakul, Boonsong
AU  - Ongphiphadhanakul B
AD  - Department of Medicine, Mahidol University Faculty of Medicine Ramathibodi
      Hospital, Bangkok, Thailand.
FAU - McKay, Gareth
AU  - McKay G
AUID- ORCID: 0000-0001-8197-6280
AD  - Centre for Public Health, Queen's University Belfast Faculty of Medicine Health
      and Life Sciences, Belfast, UK.
FAU - Attia, John
AU  - Attia J
AUID- ORCID: 0000-0001-9800-1308
AD  - Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
AD  - School of Medicine and Public Health, The University of Newcastle, Newcastle, New
      South Wales, Australia.
FAU - Thakkinstian, Ammarin
AU  - Thakkinstian A
AD  - Department of Clinical Epidemiology and Biostatistics, Mahidol University,
      Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Diet, Healthy
MH  - Economics, Behavioral
MH  - Exercise
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Motivation
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
PMC - PMC7754655
OTO - NOTNLM
OT  - *behavioural economic
OT  - *change management
OT  - *health economics
OT  - *incentive programmes
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-046035 [pii]
AID - 10.1136/bmjopen-2020-046035 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 21;10(12):e046035. doi: 10.1136/bmjopen-2020-046035.


PMID- 33371050
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220201
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Psychosocial and health behavioural impacts of COVID-19 pandemic on adults in the
      USA: protocol for a longitudinal cohort study.
PG  - e044642
LID - 10.1136/bmjopen-2020-044642 [doi]
AB  - INTRODUCTION: Although social distancing may help contain the spread of COVID-19,
      the social isolation and loneliness it causes can heighten stress, contribute to 
      unhealthy lifestyle behaviours and have deleterious effects on social
      relationships. This ongoing longitudinal cohort study aims to (1) characterise
      the psychological, social and health behavioural impacts of the COVID-19 pandemic
      over a 12-month period in the USA; (2) determine whether these impacts differ for
      certain subgroups based on sociodemographics and other individual-level factors; 
      and (3) explore whether there are modifiable factors (eg, coping, social support)
      that moderate the effects of the pandemic over time. METHODS AND ANALYSIS: Adults
      (aged >/=18 years) who were fluent in either English or Spanish were recruited
      via social media and invited to complete an online survey during the 8-week
      period from 13 April to 8 June 2020 (baseline). Follow-up surveys will be
      conducted 6 and 12 months after baseline. Data transformations, non-parametric
      tests or other alternative methods will be used when appropriate. Descriptive
      statistics and cross-sectional analyses will be performed. Longitudinal
      associations will be analysed using multilevel modelling with time-variant and
      time-invariant predictors of change in trajectory over the study period. ETHICS
      AND DISSEMINATION: Research ethics approval was received from the Baylor College 
      of Medicine Institutional Review Board (H-47505). Overall, this study will
      provide timely information that can be used to inform public health messaging
      strategies and guide development of assessment tools and interventions to support
      vulnerable individuals dealing with the long-term impacts of the COVID-19
      pandemic.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Badr, Hoda
AU  - Badr H
AUID- ORCID: 0000-0002-4549-9111
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA hoda.badr@bcm.edu.
FAU - Oluyomi, Abiodun
AU  - Oluyomi A
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
FAU - Adel Fahmideh, Maral
AU  - Adel Fahmideh M
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
AD  - Center for Epidemiology and Population Health, Department of Pediatrics, Baylor
      College of Medicine, Houston, Texas, USA.
FAU - Raza, Syed Ahsan
AU  - Raza SA
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
FAU - Zhang, Xiaotao
AU  - Zhang X
AUID- ORCID: 0000-0002-3968-5030
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
AD  - Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - El-Mubasher, Ola
AU  - El-Mubasher O
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
FAU - Amos, Christopher
AU  - Amos C
AD  - Section of Epidemiology and Population Sciences, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
LA  - eng
GR  - P30 CA125123/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *COVID-19/epidemiology/prevention & control/psychology
MH  - Cohort Studies
MH  - Communicable Disease Control/*methods
MH  - Female
MH  - *Health Behavior
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Mental Health/*trends
MH  - *Psychosocial Functioning
MH  - Research Design
MH  - SARS-CoV-2
MH  - Social Isolation/*psychology
MH  - Surveys and Questionnaires
MH  - United States/epidemiology
PMC - PMC7757396
OTO - NOTNLM
OT  - *COVID-19
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - bmjopen-2020-044642 [pii]
AID - 10.1136/bmjopen-2020-044642 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e044642. doi: 10.1136/bmjopen-2020-044642.


PMID- 33371049
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Implementing large-system, value-based healthcare initiatives: a realist study
      protocol for seven natural experiments.
PG  - e044049
LID - 10.1136/bmjopen-2020-044049 [doi]
AB  - INTRODUCTION: Value-based healthcare delivery models have emerged to address the 
      unprecedented pressure on long-term health system performance and sustainability 
      and to respond to the changing needs and expectations of patients. Implementing
      and scaling the benefits from these care delivery models to achieve large-system 
      transformation are challenging and require consideration of complexity and
      context. Realist studies enable researchers to explore factors beyond 'what
      works' towards more nuanced understanding of 'what tends to work for whom under
      which circumstances'. This research proposes a realist study of the
      implementation approach for seven large-system, value-based healthcare
      initiatives in New South Wales, Australia, to elucidate how different
      implementation strategies and processes stimulate the uptake, adoption, fidelity 
      and adherence of initiatives to achieve sustainable impacts across a variety of
      contexts. METHODS AND ANALYSIS: This exploratory, sequential, mixed methods
      realist study followed RAMESES II (Realist And Meta-narrative Evidence Syntheses:
      Evolving Standards) reporting standards for realist studies. Stage 1 will
      formulate initial programme theories from review of existing literature, analysis
      of programme documents and qualitative interviews with programme designers,
      implementation support staff and evaluators. Stage 2 envisages testing and
      refining these hypothesised programme theories through qualitative interviews
      with local hospital network staff running initiatives, and analyses of
      quantitative data from the programme evaluation, hospital administrative systems 
      and an implementation outcome survey. Stage 3 proposes to produce generalisable
      middle-range theories by synthesising data from context-mechanism-outcome
      configurations across initiatives. Qualitative data will be analysed
      retroductively and quantitative data will be analysed to identify relationships
      between the implementation strategies and processes, and implementation and
      programme outcomes. Mixed methods triangulation will be performed. ETHICS AND
      DISSEMINATION: Ethical approval has been granted by Macquarie University (Project
      ID 23816) and Hunter New England (Project ID 2020/ETH02186) Human Research Ethics
      Committees. The findings will be published in peer-reviewed journals. Results
      will be fed back to partner organisations and roundtable discussions with other
      health jurisdictions will be held, to share learnings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sarkies, Mitchell N
AU  - Sarkies MN
AUID- ORCID: 0000-0001-7318-3598
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia Mitchell.sarkies@mq.edu.au.
FAU - Francis-Auton, Emilie
AU  - Francis-Auton E
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Long, Janet C
AU  - Long JC
AUID- ORCID: 0000-0002-0553-682X
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Partington, Andrew
AU  - Partington A
AD  - Centre for the Health Economy, Macquarie University, Macquarie Park, New South
      Wales, Australia.
FAU - Pomare, Chiara
AU  - Pomare C
AUID- ORCID: 0000-0002-9118-7207
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Nguyen, Hoa Mi
AU  - Nguyen HM
AUID- ORCID: 0000-0002-8431-9160
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Wu, Wendy
AU  - Wu W
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Westbrook, Johanna
AU  - Westbrook J
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Day, Richard O
AU  - Day RO
AUID- ORCID: 0000-0002-6045-6937
AD  - Clinical Pharmacology, St Vincents Hospital Sydney, Darlinghurst, New South
      Wales, Australia.
AD  - Pharmacology, University of New South Wales, Kensington, New South Wales,
      Australia.
FAU - Levesque, Jean-Frederic
AU  - Levesque JF
AD  - Bureau of Health Information, St Leonards, New South Wales, Australia.
AD  - Centre for Primary Health Care and Equity, University of New South Wales,
      Kensington, New South Wales, Australia.
FAU - Mitchell, Rebecca
AU  - Mitchell R
AUID- ORCID: 0000-0003-1939-1761
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Rapport, Frances
AU  - Rapport F
AUID- ORCID: 0000-0002-4428-2826
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Cutler, Henry
AU  - Cutler H
AD  - Centre for the Health Economy, Macquarie University, Macquarie Park, New South
      Wales, Australia.
FAU - Tran, Yvonne
AU  - Tran Y
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Clay-Williams, Robyn
AU  - Clay-Williams R
AUID- ORCID: 0000-0002-6107-7445
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Watson, Diane E
AU  - Watson DE
AD  - Bureau of Health Information, St Leonards, New South Wales, Australia.
FAU - Arnolda, Gaston
AU  - Arnolda G
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Hibbert, Peter D
AU  - Hibbert PD
AUID- ORCID: 0000-0001-7865-343X
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
AD  - University of South Australia Division of Health Sciences, Adelaide, South
      Australia, Australia.
FAU - Lystad, Reidar
AU  - Lystad R
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Mumford, Virginia
AU  - Mumford V
AUID- ORCID: 0000-0001-7915-0615
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
FAU - Leipnik, George
AU  - Leipnik G
AD  - New South Wales Ministry of Health, St Leonards, New South Wales, Australia.
FAU - Sutherland, Kim
AU  - Sutherland K
AD  - New South Wales Agency for Clinical Innovation, St Leonards, New South Wales,
      Australia.
FAU - Hardwick, Rebecca
AU  - Hardwick R
AUID- ORCID: 0000-0002-2488-829X
AD  - Medical School, University of Exeter, Exeter, Devon, UK.
FAU - Braithwaite, Jeffrey
AU  - Braithwaite J
AUID- ORCID: 0000-0003-0296-4957
AD  - Australian Institute of Health Innovation, Macquarie University, Macquarie Park, 
      New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Delivery of Health Care
MH  - Humans
MH  - New England
MH  - New South Wales
MH  - Program Evaluation
PMC - PMC7757496
OTO - NOTNLM
OT  - *bone diseases
OT  - *diabetic foot
OT  - *end stage renal failure
OT  - *general diabetes
OT  - *health services administration & management
OT  - *heart failure
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-044049 [pii]
AID - 10.1136/bmjopen-2020-044049 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e044049. doi: 10.1136/bmjopen-2020-044049.


PMID- 33371048
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Financial Incentives and Nurse Coaching to Enhance Diabetes Outcomes
      (FINANCE-DM): a trial protocol.
PG  - e043760
LID - 10.1136/bmjopen-2020-043760 [doi]
AB  - INTRODUCTION: Given the burden of diabetes in ethnic minorities and emerging data
      on the efficacy of financial incentives in type 2 diabetes mellitus (T2DM), it is
      critical to examine the efficacy of financial incentives across and within
      racial/ethnic groups. METHODS AND ANALYSIS: This trial is an ongoing 5-year,
      randomised clinical trial designed to test the efficacy of a Financial Incentives
      And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM) intervention
      composed of (1) nurse education, (2) home telemonitoring and (3) structured
      financial incentives; compared with an active control group (nurse education and 
      home telemonitoring alone). The study also will evaluate whether intervention
      effects are sustained 6 months after the financial incentives are withdrawn (ie, 
      18 months post-randomisation) and whether the intervention is differentially
      efficacious across racial/ethnic groups. Participants will include 450 adults
      with a clinical diagnosis of T2DM and HbA1c of 8% or higher who self-identify as 
      White, African American or Hispanic. Participants will be randomised to one of
      two groups: the FINANCE intervention or Active Control. The location and setting 
      of this study include primary care clinics at the Medical College of Wisconsin
      (MCW) in Milwaukee, WI and community partner sites affiliated with the Center for
      Advancing Population Science at MCW. ETHICS AND DISSEMINATION: This trial was
      approved by IRB at MCW under PRO00033788. TRIAL REGISTRATION NUMBER: Registration
      for this trial on the United States National Institute of Health Clinical Trials 
      Registry can be found under ID: NCT04203173 and online
      (https://clinicaltrials.gov/ct2/show/NCT04203173?id=NCT04203173&draw=2&rank=1).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Egede, Leonard E
AU  - Egede LE
AUID- ORCID: 0000-0003-1546-1515
AD  - Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA legede@mcw.edu.
AD  - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee,
      Wisconsin, USA.
FAU - Walker, Rebekah
AU  - Walker R
AD  - Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
AD  - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee,
      Wisconsin, USA.
FAU - Williams, Joni S
AU  - Williams JS
AD  - Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
AD  - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee,
      Wisconsin, USA.
FAU - Knapp, Rebecca
AU  - Knapp R
AD  - Department of Public Health Sciences, Medical University of South Carolina,
      Charleston, South Carolina, USA.
FAU - Dismuke, Clara Elizabeth
AU  - Dismuke CE
AD  - VA Palo Alto Health Care System, Palo Alto, California, USA.
FAU - Davidson, Tatiana
AU  - Davidson T
AD  - College of Nursing, Medical University of South Carolina, Charleston, South
      Carolina, USA.
FAU - Campbell, Jennifer A
AU  - Campbell JA
AD  - Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
AD  - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee,
      Wisconsin, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04203173
GR  - R01 DK120861/DK/NIDDK NIH HHS/United States
GR  - R01 DK118038/DK/NIDDK NIH HHS/United States
GR  - K24 DK093699/DK/NIDDK NIH HHS/United States
GR  - R01 MD013826/MD/NIMHD NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Humans
MH  - *Mentoring
MH  - Minority Groups
MH  - Motivation
MH  - Randomized Controlled Trials as Topic
MH  - Wisconsin
PMC - PMC7757449
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *general diabetes
OT  - *health economics
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043760 [pii]
AID - 10.1136/bmjopen-2020-043760 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e043760. doi: 10.1136/bmjopen-2020-043760.


PMID- 33371047
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Practicability of lower extremity functional performance tests and their
      measurement properties in elite athletes: protocol for a systematic review.
PG  - e042975
LID - 10.1136/bmjopen-2020-042975 [doi]
AB  - INTRODUCTION: Lower extremity injury (LEI) is highly prevalent and its occurrence
      increases the risk of future injury in athletic populations. Identifying athletes
      at risk of injury is the key to target injury-prevention programmes. Functional
      performance tests (FPT) assess an athlete's ability to produce and accept forces 
      during movement tasks reflective of those experienced in sport, and are used to
      identify deficits in physical qualities or neuromuscular control. This review
      aims to identify FPT which have potential to predict LEI and assess their
      measurement properties associated with reliability, validity, responsiveness and 
      practicability (interpretability and feasibility). METHODS/ANALYSIS: This
      protocol will be reported using the Preferred Reporting Items for Systematic
      Review and Meta-Analysis Protocol and the COnsensus-based Standards for the
      selection of health Measurement INstruments Methodology. The search strategy has 
      two stages: stage 1 will identify lower limb FPT used in athletic populations;
      and stage 2 will assess the measurement properties of the identified FPT. A
      sensitive search strategy will use MEDLINE, EMBASE, CINHAL and SPORTdiscus
      databases; from inception to June 2020. Hand searching reference lists, key
      journals and grey literature will be completed. One reviewer will complete search
      1 and data extraction. Two reviewers will complete the search, data extraction
      and risk-of-bias assessment for search 2. Evidence will be pooled or summarised
      by individual measurement property by each individual study and grouped by FPT.
      Meta-analysis using a random effects model with subgroup analysis will be
      performed where possible. Pooled or summarised results for each FPT in relation
      to each measurement property will be rated against the criteria for good
      measurement properties. Two reviewers will assess the overall body of evidence
      per measurement property per FPT using the modified Grading of Recommendations,
      Assessment, Development and Evaluation guidelines. This review will enable
      clinicians to make an informed choice when selecting FPT. ETHICS AND
      DISSEMINATION: No ethical approval is required for this review and the results
      will be disseminated through peer-reviewed publications and submitted for
      conference presentation. PROSPERO REGISTRATION NUMBER: CRD42020188932.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cooke, Rosalyn
AU  - Cooke R
AUID- ORCID: 0000-0003-2784-9365
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences,
      University of Birmingham, Birmingham, UK rcc004@student.bham.ac.uk.
FAU - Rushton, Alison
AU  - Rushton A
AUID- ORCID: 0000-0001-8114-7669
AD  - School of Physical Therapy, Faculty of Health Sciences, Western University,
      London, Ontario, Canada.
FAU - Martin, James
AU  - Martin J
AUID- ORCID: 0000-0002-6949-4200
AD  - Institute of Applied Health Research, Public Health Building, College of Medical 
      and Dental Sciences, University of Birmingham, Birmingham, West Midlands, UK.
FAU - Herrington, Lee
AU  - Herrington L
AUID- ORCID: 0000-0003-4732-1955
AD  - School of Health and Society, University of Salford, Salford, UK.
FAU - Heneghan, Nicola R
AU  - Heneghan NR
AUID- ORCID: 0000-0001-7599-3674
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences,
      University of Birmingham, Birmingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Athletes
MH  - Humans
MH  - Lower Extremity
MH  - Meta-Analysis as Topic
MH  - Physical Functional Performance
MH  - Reproducibility of Results
MH  - *Research Design
MH  - Review Literature as Topic
PMC - PMC7757441
OTO - NOTNLM
OT  - *orthopaedic sports trauma
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:03
PHST- 2020/12/29 01:03 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042975 [pii]
AID - 10.1136/bmjopen-2020-042975 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e042975. doi: 10.1136/bmjopen-2020-042975.


PMID- 33371044
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 21
TI  - TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2
      inhibitor and thiazolidinedione as second-line or third-line therapy in patients 
      with type 2 diabetes who have suboptimal glycaemic control on metformin treatment
      with or without a sulfonylurea-a MASTERMIND study protocol.
PG  - e042784
LID - 10.1136/bmjopen-2020-042784 [doi]
AB  - INTRODUCTION: Pharmaceutical treatment options for patients with type 2 diabetes 
      mellitus (T2DM) have increased to include multiple classes of oral
      glucose-lowering agents but without accompanying guidance on which of these may
      most benefit individual patients. Clinicians lack information for treatment
      intensification after first-line metformin therapy. Stratifying patients by
      simple clinical characteristics may improve care by targeting treatment options
      to those in whom they are most effective. This academically designed and run
      three-way crossover trial aims to test a stratification approach using three
      standard oral glucose-lowering agents. METHODS AND ANALYSIS: TriMaster is a
      randomised, double-blind, crossover trial taking place at up to 25 clinical sites
      across England, Scotland and Wales. 520 patients with T2DM treated with either
      metformin alone, or metformin and a sulfonylurea who have glycated haemoglobin
      (HbA1c) >58 mmol/mol will be randomised to receive 16 weeks each of a dipeptidyl 
      peptidase-4 inhibitor, sodium-glucose co-transporter-2 inhibitor and
      thiazolidinedione in random order. Participants will be assessed at the end of
      each treatment period, providing clinical and biochemical data, and their
      experience of side effects. Participant preference will be assessed on completion
      of all three treatments. The primary endpoint is HbA1c after 4 months of therapy 
      (allowing a range of 12-18 weeks for analysis). Secondary endpoints include
      participant-reported preference between the three treatments, tolerability and
      prevalence of side effects. ETHICAL APPROVAL: This study was approved by National
      Health Service Health Research Authority Research Ethics Committee South
      Central-Oxford A, study 16/SC/0147. Written informed consent will be obtained
      from all participants. Results will be submitted to a peer-reviewed journal and
      presented at relevant scientific meetings. A lay summary of results will be made 
      available to all participants. TRIAL REGISTRATION NUMBERS: 12039221;
      2015-002790-38 and NCT02653209.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Angwin, Catherine
AU  - Angwin C
AUID- ORCID: 0000-0002-0935-5284
AD  - Institute of Biomedical and Clinical Science, University of Exeter Medical
      School, University of Exeter, Exeter, Devon, UK.
FAU - Jenkinson, Caroline
AU  - Jenkinson C
AD  - Institute of Biomedical and Clinical Science, University of Exeter Medical
      School, University of Exeter, Exeter, Devon, UK.
FAU - Jones, Angus
AU  - Jones A
AUID- ORCID: 0000-0002-0883-7599
AD  - Institute of Biomedical and Clinical Science, University of Exeter Medical
      School, University of Exeter, Exeter, Devon, UK.
FAU - Jennison, Christopher
AU  - Jennison C
AD  - Department of Mathematical Sciences, University of Bath, Bath, Somerset, UK.
FAU - Henley, William
AU  - Henley W
AD  - Health Statistics Group, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Farmer, Andrew
AU  - Farmer A
AUID- ORCID: 0000-0002-6170-4402
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Sattar, Naveed
AU  - Sattar N
AUID- ORCID: 0000-0002-1604-2593
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      UK.
FAU - Holman, Rury R
AU  - Holman RR
AD  - Radcliffe Department of Medicine, University of Oxford Medical Sciences Division,
      Oxford, UK.
FAU - Pearson, Ewan
AU  - Pearson E
AD  - University of Dundee, Dundee, Dundee, UK.
FAU - Shields, Beverley
AU  - Shields B
AUID- ORCID: 0000-0003-3785-327X
AD  - Institute of Biomedical and Clinical Science, University of Exeter Medical
      School, University of Exeter, Exeter, Devon, UK b.shields@exeter.ac.uk.
FAU - Hattersley, Andrew
AU  - Hattersley A
AD  - Institute of Biomedical and Clinical Science, University of Exeter Medical
      School, University of Exeter, Exeter, Devon, UK.
CN  - MASTERMIND consortium
LA  - eng
SI  - ClinicalTrials.gov/NCT02653209
GR  - MR/N00633X/1/MRC_/Medical Research Council/United Kingdom
GR  - 102820/Z/13/Z/WT_/Wellcome Trust/United Kingdom
GR  - 098395/Z/12/Z/WT_/Wellcome Trust/United Kingdom
GR  - RE/18/6/34217/BHF_/British Heart Foundation/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201221
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Cross-Over Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dipeptidyl Peptidase 4/therapeutic use
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - England
MH  - Glycated Hemoglobin A/analysis
MH  - Glycemic Control
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Metformin/therapeutic use
MH  - *Pharmaceutical Preparations
MH  - Randomized Controlled Trials as Topic
MH  - Scotland
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - State Medicine
MH  - *Thiazolidinediones/therapeutic use
MH  - Treatment Outcome
MH  - Wales
PMC - PMC7754630
OTO - NOTNLM
OT  - *clinical trials
OT  - *diabetes & endocrinology
OT  - *therapeutics
COIS- Competing interests: EP has received Honoraria from Lilly. NS has consulted for
      Amgen, Astrazeneca, Boehringer Ingelheim, Eli-Lilly, Napp, NovoNordisk, Sanofi
      and Pfizer and received grant funding from Boehringer Ingelheim. RRH reports
      research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal
      fees from Bayer, Intarcia, Merck Sharp & Dohme, Novartis and Novo Nordisk outside
      the submitted work. CJ has consulted for AstraZeneca, Boehringer Ingelheim,
      NovoNordisk and Sanofi. WH has received grant funding from IQVIA and travel funds
      from Eisai.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042784 [pii]
AID - 10.1136/bmjopen-2020-042784 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 21;10(12):e042784. doi: 10.1136/bmjopen-2020-042784.


PMID- 33371043
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 21
TI  - Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen 
      for the treatment of rifampicin-resistant tuberculosis from the STREAM trial.
PG  - e042390
LID - 10.1136/bmjopen-2020-042390 [doi]
AB  - INTRODUCTION: A December 2019 WHO rapid communication recommended the use of
      9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB).
      Besides the clinical benefits, they are thought to be less costly than the
      injectable-containing regimens, for both the patient and the health system.
      STREAM is the first randomised controlled trial with an economical evaluation to 
      compare all-oral and injectable-containing 9-11-month MDR-TB treatment regimens. 
      METHODS AND ANALYSIS: Health system costs of delivering a 9-month
      injectable-containing regimen and a 9-month all-oral bedaquiline-containing
      regimen will be collected in Ethiopia, India, Moldova and Uganda, using
      'bottom-up' and 'top-down' costing approaches. Patient costs will be collected
      using questionnaires that have been developed based on the STOP-TB questionnaire.
      The primary objective of the study is to estimate the cost utility of the two
      regimens, from a health system perspective. Secondary objectives include
      estimating the cost utility from a societal perspective as well as evaluating the
      cost-effectiveness of the regimens, using both health system and societal
      perspectives. The effect measure for the cost-utility analysis will be the
      quality-adjusted life years (QALY), while the effect measure for the
      cost-effectiveness analysis will be the efficacy outcome from the clinical trial.
      ETHICS AND DISSEMINATION: The study has been evaluated and approved by the Ethics
      Advisory Group of the International Union Against Tuberculosis and Lung Disease
      and also approved by ethics committees in all participating countries. All
      participants have provided written informed consent. The results of the economic 
      evaluation will be published in a peer-reviewed journal. TRIAL REGISTRATION
      NUMBER: ISRCTN18148631.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Rosu, Laura
AU  - Rosu L
AUID- ORCID: 0000-0003-1172-0962
AD  - Centre for Applied Health Research and Delivery & Department of Clinical
      Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
      laura.rosu@lstmed.ac.uk.
FAU - Madan, Jason
AU  - Madan J
AUID- ORCID: 0000-0003-4316-1480
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Worrall, Eve
AU  - Worrall E
AUID- ORCID: 0000-0001-9147-3388
AD  - Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool,
      UK.
FAU - Tomeny, Ewan
AU  - Tomeny E
AUID- ORCID: 0000-0003-4547-2389
AD  - Centre for Applied Health Research and Delivery & Department of Clinical
      Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
FAU - Squire, Bertel
AU  - Squire B
AUID- ORCID: 0000-0001-7173-9038
AD  - Centre for Applied Health Research and Delivery & Department of Clinical
      Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
CN  - STREAM Study Health Economic Evaluation Collaborators
LA  - eng
SI  - ISRCTN/ISRCTN18148631
GR  - MC_UU_12023/27/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201221
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antitubercular Agents)
RN  - 0 (Diarylquinolines)
RN  - 78846I289Y (bedaquiline)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Antitubercular Agents/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Diarylquinolines
MH  - Ethiopia
MH  - Humans
MH  - India
MH  - Moldova
MH  - *Myocardial Infarction/drug therapy
MH  - Rifampin
MH  - Tuberculosis, Multidrug-Resistant/drug therapy
MH  - Uganda
PMC - PMC7754660
OTO - NOTNLM
OT  - *economics
OT  - *health economics
OT  - *tuberculosis
COIS- Competing interests: None declared.
IR  - Girma M
FIR - Girma, Mamo
IR  - Patel V
FIR - Patel, Vanita
IR  - Mukesh M
FIR - Mukesh, Makwana
IR  - Muniyandi M
FIR - Muniyandi, Malaisamy
IR  - Kumar S
FIR - Kumar, Shravan
IR  - Subramani S
FIR - Subramani, Sangeetha
IR  - Ahmad S
FIR - Ahmad, Saleem
IR  - Nidoi J
FIR - Nidoi, Jasper
IR  - Pirlog I
FIR - Pirlog, Irina
IR  - Macarie M
FIR - Macarie, Mariana
IR  - Rusen ID
FIR - Rusen, I D
IR  - Bronson G
FIR - Bronson, Gay
IR  - Gurumurthy M
FIR - Gurumurthy, Meera
IR  - Sanders K
FIR - Sanders, Karen
IR  - Meredith S
FIR - Meredith, Sarah
IR  - Nunn A
FIR - Nunn, Andrew
IR  - Ben Spittle WD
FIR - Ben Spittle, Wendy Dodds
IR  - Henry-Cockles R
FIR - Henry-Cockles, Robyn
IR  - Bennett R
FIR - Bennett, Rachel
IR  - Giallongo E
FIR - Giallongo, Elisa
IR  - Maas D
FIR - Maas, Danni
IR  - Bennett R
FIR - Bennett, Rachel
IR  - Goodall R
FIR - Goodall, Ruth
IR  - Ahmed S
FIR - Ahmed, Saiam
IR  - Cook C
FIR - Cook, Claire
IR  - Bellenger K
FIR - Bellenger, Katharine
IR  - Narendran G
FIR - Narendran, Gopalan
IR  - Kirenga B
FIR - Kirenga, Bruce
IR  - Tudor E
FIR - Tudor, Elena
IR  - Solanki R
FIR - Solanki, Rajesh
IR  - Meressa D
FIR - Meressa, Daniel
IR  - Bayissa A
FIR - Bayissa, Adamu
IR  - Bhatnagar A
FIR - Bhatnagar, Anuj
EDAT- 2020/12/30 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-042390 [pii]
AID - 10.1136/bmjopen-2020-042390 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 21;10(12):e042390. doi: 10.1136/bmjopen-2020-042390.


PMID- 33371042
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 18
TI  - Efficacy and safety of mesenchymal stem cells for the treatment of patients
      infected with COVID-19: a systematic review and meta-analysis protocol.
PG  - e042085
LID - 10.1136/bmjopen-2020-042085 [doi]
AB  - INTRODUCTION: To date, no specific antivirus drugs or vaccines have been
      available to prevent or treat the COVID-19 pandemic. Mesenchymal stem cell (MSC) 
      therapy may be a promising therapeutic approach that reduces the high mortality
      in critical cases. This protocol is proposed for a systematic review and
      meta-analysis that aims to evaluate the efficacy and safety of MSC therapy on
      patients with COVID-19. METHODS AND ANALYSIS: Ten databases including PubMed,
      EMBASE, Cochrane Library, CINAHL, Web of Science, Chinese National Knowledge
      Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang
      database, China Biomedical Literature Database (CBM) and Chinese Biomedical
      Literature Service System (SinoMed) will be searched from inception to 1 December
      2020. All published randomised controlled trials, clinical controlled trials and 
      case series that meet the prespecified eligibility criteria will be included. The
      primary outcomes include mortality, incidence and severity of adverse events,
      respiratory improvement, days from ventilator, duration of fever, progression
      rate from mild or moderate to severe, improvement of such serious symptoms as
      difficulty breathing or shortness of breath, chest pain or pressure, and loss of 
      speech or movement, biomarkers of laboratory examination and changes in CT. The
      secondary outcomes include dexamethasone doses and quality of life. Two reviewers
      will independently perform study selection, data extraction and assessment of
      bias risk. Data synthesis will be conducted using RevMan software (V.5.3.5). If
      necessary, subgroup and sensitivity analysis will be performed. Grading of
      Recommendations Assessment, Development and Evaluation system will be used to
      assess the strength of evidence. ETHICS AND DISSEMINATION: Ethical approval is
      not necessary since no individual patient or privacy data have been collected.
      The results of this review will be disseminated in a peer-reviewed journal or an 
      academic conference presentation. PROSPERO REGISTRATION NUMBER: CRD42020190079.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Yunhui
AU  - Chen Y
AUID- ORCID: 0000-0002-3555-8018
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zhang, Qing
AU  - Zhang Q
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Peng, Wei
AU  - Peng W
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Liu, Dan
AU  - Liu D
AD  - West China Hospital, Sichuan University, Chengdu, China.
FAU - You, Yanyan
AU  - You Y
AD  - West China Hospital, Sichuan University, Chengdu, China.
FAU - Liu, Xinglong
AU  - Liu X
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Tang, Songqi
AU  - Tang S
AD  - Hainan Medical University, Haikou, China tangsongqi@foxmail.com
      zhte2003@cdutcm.edu.cn.
FAU - Zhang, Tiane
AU  - Zhang T
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China
      tangsongqi@foxmail.com zhte2003@cdutcm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201218
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/*therapy
MH  - Humans
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - SARS-CoV-2/isolation & purification
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7750871
OTO - NOTNLM
OT  - *cell biology
OT  - *immunology
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - bmjopen-2020-042085 [pii]
AID - 10.1136/bmjopen-2020-042085 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 18;10(12):e042085. doi: 10.1136/bmjopen-2020-042085.


PMID- 33371041
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210920
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Prediction of outcomes after acute kidney injury in hospitalised patients:
      protocol for a systematic review.
PG  - e042035
LID - 10.1136/bmjopen-2020-042035 [doi]
AB  - INTRODUCTION: Acute kidney injury (AKI) is common and is associated with negative
      long-term outcomes. Given the heterogeneity of the syndrome, the ability to
      predict outcomes of AKI may be beneficial towards effectively using resources and
      personalising AKI care. This systematic review will identify, describe and assess
      current models in the literature for the prediction of outcomes in hospitalised
      patients with AKI. METHODS AND ANALYSIS: Relevant literature from a comprehensive
      search across six databases will be imported into Covidence. Abstract screening
      and full-text review will be conducted independently by two team members, and any
      conflicts will be resolved by a third member. Studies to be included are cohort
      studies and randomised controlled trials with at least 100 subjects, adult
      hospitalised patients, with AKI. Only those studies evaluating multivariable
      predictive models reporting a statistical measure of accuracy (area under the
      receiver operating curve or C-statistic) and predicting resolution of AKI,
      progression of AKI, subsequent dialysis and mortality will be included. Data
      extraction will be performed independently by two team members, with a third
      reviewer available to resolve conflicts. Results will be reported using Preferred
      Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Risk of bias
      will be assessed using Prediction model Risk Of Bias ASsessment Tool. ETHICS AND 
      DISSEMINATION: We are committed to open dissemination of our results through the 
      registration of our systematic review on PROSPERO and future publication. We hope
      that our review provides a platform for future work in realm of using artificial 
      intelligence to predict outcomes of common diseases. PROSPERO REGISTRATION
      NUMBER: CRD42019137274.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arora, Tanima
AU  - Arora T
AUID- ORCID: 0000-0003-4918-5352
AD  - Clinical and Translational Research Accelerator, Yale School of Medicine, New
      Haven, Connecticut, USA tanima.arora@yale.edu.
FAU - Martin, Melissa
AU  - Martin M
AD  - Clinical and Translational Research Accelerator, Yale School of Medicine, New
      Haven, Connecticut, USA.
FAU - Grimshaw, Alyssa
AU  - Grimshaw A
AD  - Harvey Cushing Library, Yale University School of Medicine, New Haven,
      Connecticut, USA.
FAU - Mansour, Sherry
AU  - Mansour S
AD  - Clinical and Translational Research Accelerator, Yale School of Medicine, New
      Haven, Connecticut, USA.
FAU - Wilson, Francis P
AU  - Wilson FP
AUID- ORCID: 0000-0002-2633-2412
AD  - Clinical and Translational Research Accelerator, Yale School of Medicine, New
      Haven, Connecticut, USA.
AD  - Yale University.
LA  - eng
GR  - P30 DK079310/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
GR  - R01 DK113191/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acute Kidney Injury/diagnosis/therapy
MH  - Adult
MH  - *Artificial Intelligence
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Renal Dialysis
MH  - Systematic Reviews as Topic
PMC - PMC7757434
OTO - NOTNLM
OT  - *acute renal failure
OT  - *adult nephrology
OT  - *dialysis
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042035 [pii]
AID - 10.1136/bmjopen-2020-042035 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e042035. doi: 10.1136/bmjopen-2020-042035.


PMID- 33371037
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - How to improve emergency care to adults discharged within 24 hours? Acute Care
      planning in Emergency departments (The ACE study): a protocol of a participatory 
      design study.
PG  - e041743
LID - 10.1136/bmjopen-2020-041743 [doi]
AB  - INTRODUCTION: The development of acute symptoms or changes in diseases led to
      feelings of fear and vulnerability and the need for health professional support. 
      Therefore, the care provided in the acute medical and surgical areas of the
      emergency department (ED) is highly important as it influences the confidence of 
      patients and families in managing everyday life after discharge. There is an
      increase in short-episode (<24 hours) hospital admissions, related to demographic
      changes and a focus on outpatient care. Clear discharge information and inclusion
      in treatment decisions increase the patient's and family's ability to understand 
      and manage health needs after discharge, reduces the risk of readmission. This
      study aims to identify the needs for ED care and develop a solution to improve
      outcomes of patients discharged within 24 hours of admission. METHODS AND
      ANALYSIS: The study comprises the three phases of a participatory design (PD).
      Phase 1 aims to understand and identify patient and family needs when discharged 
      within 24 hours of admission. A qualitative observational study will be conducted
      in two different EDs, followed by 20 joint interviews with patients and their
      families. Four focus group interviews with healthcare professionals will provide 
      understanding of the short pathways. Findings from phase 1 will inform phase 2,
      which aims to develop a solution to improve patient outcomes. Three workshops
      gathering relevant stakeholders are arranged in the design plus development of a 
      solution with specific outcomes. The solution will be implemented and tested in
      phase 3. Here we report the study protocol of phase 1 and 2. ETHICS AND
      DISSEMINATION: The study is registered with the Danish Data Protection Agency
      (19/22672). Approval of the project has been granted by the Regional Committees
      on Health Research Ethics for Southern Denmark (S-20192000-111). Findings will be
      published in suitable international journals and disseminated through
      conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ostervang, Christina
AU  - Ostervang C
AUID- ORCID: 0000-0001-5990-0167
AD  - Department of Emergency Medicine, Odense Universitetshospital, Odense, Denmark
      christina.oestervang.nielsen@rsyd.dk.
AD  - Clinical Institute, University of Southern Denmark Faculty of Health Sciences,
      Odense, Denmark.
FAU - Lassen, Annmarie Touborg
AU  - Lassen AT
AUID- ORCID: 0000-0003-4942-6152
AD  - Department of Emergency Medicine, Odense Universitetshospital, Odense, Denmark.
AD  - Clinical Institute, University of Southern Denmark Faculty of Health Sciences,
      Odense, Denmark.
FAU - Jensen, Charlotte Myhre
AU  - Jensen CM
AUID- ORCID: 0000-0002-7058-4641
AD  - Clinical Institute, University of Southern Denmark Faculty of Health Sciences,
      Odense, Denmark.
AD  - Department of Orthopedics Surgery and Traumatology, Odense Universitetshospital, 
      Odense, Denmark.
FAU - Coyne, Elisabeth
AU  - Coyne E
AUID- ORCID: 0000-0001-8511-600X
AD  - Clinical Institute, University of Southern Denmark Faculty of Health Sciences,
      Odense, Denmark.
AD  - School of Nursing and Midwifery, Logan Campus, Griffith University Faculty of
      Health, Brisbane, Queensland, Australia.
FAU - Dieperink, Karin Brochstedt
AU  - Dieperink KB
AUID- ORCID: 0000-0003-4766-3242
AD  - Clinical Institute, University of Southern Denmark Faculty of Health Sciences,
      Odense, Denmark.
AD  - Department of Oncology, Odense University Hospital, Odense, Denmark.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Emergency Medical Services
MH  - Emergency Service, Hospital
MH  - Hospitalization
MH  - Humans
MH  - Observational Studies as Topic
MH  - *Patient Discharge
MH  - Qualitative Research
PMC - PMC7757437
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health services administration & management
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041743 [pii]
AID - 10.1136/bmjopen-2020-041743 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e041743. doi: 10.1136/bmjopen-2020-041743.


PMID- 33371036
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Transition from child to adult health services for young people with cerebral
      palsy in Ireland: a mixed-methods study protocol.
PG  - e041425
LID - 10.1136/bmjopen-2020-041425 [doi]
AB  - INTRODUCTION: The transition from child to adult health services is a challenging
      and complex process for young people with cerebral palsy (CP). Poorly managed
      transition is associated with deterioration in health, increased hospitalisations
      and reduced quality of life. While international research identifies key
      practices that can improve the experience and outcomes of transition, there is a 
      paucity of data in the Irish context. This research study aims to gain an insight
      into the experience of transition for young people with CP in Ireland. METHODS
      AND ANALYSIS: A convergent parallel mixed-methods design will be used to collect,
      analyse and interpret quantitative and qualitative data. Participants will be
      young people aged 16-22 years with CP, their parent(s)/carer(s) and service
      providers. Quantitative and qualitative data will be collected through
      questionnaires and interviews, respectively. Quantitative data will be reported
      using descriptive statistics. Where sufficient data are collected, we will
      examine associations between the experience of transition practices and
      sociodemographic and CP-related factors, respectively, using appropriate
      regression models. Associations between service provider characteristics and
      provision of key transition practices may also be explored using appropriate
      regression models. Qualitative data will be analysed using the Framework Method. 
      A coding matrix based on key transitional practices identified from the
      literature will be used to identify convergence and divergence across study
      components at the integration stage. ETHICS AND DISSEMINATION: The study has been
      approved by the RCSI University of Medicine and Health Sciences Research Ethics
      Committee (REC201911010). Results will be presented to non-academic stakeholders 
      through a variety of knowledge translation activities. Results will be published 
      in open access, peer-reviewed journals and presented at national and
      international scientific conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ryan, Jennifer M
AU  - Ryan JM
AD  - Department of Public Health and Epidemiology, RCSI University of Medicine and
      Health Sciences, Dublin, Ireland jenniferryan@rcsi.ie.
FAU - Fortune, Jennifer
AU  - Fortune J
AUID- ORCID: 0000-0001-8971-1236
AD  - Department of Public Health and Epidemiology, RCSI University of Medicine and
      Health Sciences, Dublin, Ireland.
FAU - Walsh, Aisling
AU  - Walsh A
AUID- ORCID: 0000-0002-5312-5101
AD  - Department of Public Health and Epidemiology, RCSI University of Medicine and
      Health Sciences, Dublin, Ireland.
FAU - Norris, Meriel
AU  - Norris M
AD  - College of Health, Medicine and Life Sciences, Brunel University London,
      Uxbridge, UK.
FAU - Kerr, C
AU  - Kerr C
AD  - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
FAU - Hensey, Owen
AU  - Hensey O
AD  - Medical Department, Central Remedial Clinic, Dublin, Ireland.
FAU - Kroll, Thilo
AU  - Kroll T
AD  - School of Nursing, Midwifery and Health Systems, University College Dublin,
      Dublin, UK.
FAU - Lavelle, Grace
AU  - Lavelle G
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, UK.
FAU - Owens, Mary
AU  - Owens M
AD  - Physiotherapy Department, Central Remedial Clinic, Dublin, Ireland.
FAU - Byrne, M
AU  - Byrne M
AD  - National Disability Children & Families Team, Social Care Division, Health
      Service Executive, Dublin, Ireland.
FAU - Walsh, Michael
AU  - Walsh M
AD  - Office of the Chief Clinical Officer, Health Service Executive, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Cerebral Palsy/therapy
MH  - Child
MH  - Humans
MH  - Ireland
MH  - Quality of Life
MH  - Surveys and Questionnaires
MH  - *Transition to Adult Care
MH  - Young Adult
PMC - PMC7757447
OTO - NOTNLM
OT  - *adult neurology
OT  - *developmental neurology & neurodisability
OT  - *neurology
OT  - *paediatric neurology
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041425 [pii]
AID - 10.1136/bmjopen-2020-041425 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e041425. doi: 10.1136/bmjopen-2020-041425.


PMID- 33371034
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 21
TI  - Using qualitative and co-design methods to inform the development of an
      intervention to support and improve physical activity in childhood cancer
      survivors: a study protocol for BEing Active after ChildhOod caNcer (BEACON).
PG  - e041073
LID - 10.1136/bmjopen-2020-041073 [doi]
AB  - INTRODUCTION: Childhood cancer survivors (CCSs) treated with cardiotoxic cancer
      treatments are at increased risk of developing cardiometabolic complications.
      This risk is further exacerbated by poor health behaviours. In particular, CCSs
      are less active than non-cancer comparators. Existing interventions aiming to
      improve physical activity (PA) levels in CCSs are methodologically weak. The aim 
      of this study is to rigorously and systematically develop an evidence-based and
      theoretically-informed intervention to promote, support, improve and sustain PA
      levels in CCSs, with the long-term goal of reducing CCSs' cardiovascular
      morbidity and mortality. METHODS AND ANALYSIS: The BEing Active after ChildhOod
      caNcer (BEACON) study involves two workpackages at two National Health Service
      sites in England, UK.Participants will be CCSs and their parents, and healthcare 
      professionals (HCPs) involved in their care.Workpackage one (WP1) will use
      qualitative methods to explore and understand the barriers and facilitators to PA
      in CCSs. Two sets of semistructured interviews will be conducted with (1) CCSs
      (aged 10-24 years) and (2) parents of CCSs. WP2 will use co-design methods to
      bring together stakeholders (CCSs; their parents; HCPs; researchers) to develop a
      prototype intervention. Where possible, all data will be audio recorded and
      transcribed.Data from WP1 will be analysed using a thematic approach. Analysis of
      WP2 data will involve content analysis, and analysis of formative output and
      procedures. ETHICS AND DISSEMINATION: The study was approved by North East-Tyne &
      Wear South Research Ethics Committee (REC ref: 18/NE/0274). Research findings
      will be disseminated primarily via national and international conferences and
      publication in peer-reviewed journals. Patient and public involvement will inform
      further dissemination activities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Brown, Morven C
AU  - Brown MC
AUID- ORCID: 0000-0003-2501-0670
AD  - Newcastle University Centre for Cancer, Newcastle University, Newcastle upon
      Tyne, UK.
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Araujo-Soares, Vera
AU  - Araujo-Soares V
AD  - Newcastle University Centre for Cancer, Newcastle University, Newcastle upon
      Tyne, UK.
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Skinner, Roderick
AU  - Skinner R
AD  - Newcastle University Centre for Cancer, Newcastle University, Newcastle upon
      Tyne, UK.
AD  - Department of Paediatric and Adolescent Haematology and Oncology, Great North
      Children's Hospital, Newcastle upon Tyne, UK.
FAU - Glaser, Adam W
AU  - Glaser AW
AD  - Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
AD  - Department of Paediatric Oncology, Leeds Children's Hospital, Leeds, UK.
FAU - Sarwar, Naseem
AU  - Sarwar N
AD  - Department of Paediatric Oncology, Leeds Children's Hospital, Leeds, UK.
FAU - Saxton, John M
AU  - Saxton JM
AD  - Department of Sport, Exercise and Rehabilitation, Faculty of Health and Life
      Sciences, Northumbria University, Newcastle upon Tyne, UK.
FAU - Montague, Kyle
AU  - Montague K
AD  - OpenLab, Newcastle University, Newcastle upon Tyne, UK.
FAU - Hall, Jamie
AU  - Hall J
AD  - Newcastle upon Tyne, UK.
FAU - Burns, Olivia
AU  - Burns O
AD  - Newcastle upon Tyne, UK.
FAU - Sharp, Linda
AU  - Sharp L
AD  - Newcastle University Centre for Cancer, Newcastle University, Newcastle upon
      Tyne, UK linda.sharp@ncl.ac.uk.
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201221
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Cancer Survivors
MH  - Child
MH  - England
MH  - Exercise
MH  - Humans
MH  - *Neoplasms
MH  - State Medicine
MH  - Young Adult
PMC - PMC7754664
OTO - NOTNLM
OT  - *paediatric oncology
OT  - *protocols & guidelines
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-041073 [pii]
AID - 10.1136/bmjopen-2020-041073 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 21;10(12):e041073. doi: 10.1136/bmjopen-2020-041073.


PMID- 33371027
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210920
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 21
TI  - Multilevel mobile health approach to improve cardiovascular health in
      resource-limited communities with Step It Up: a randomised controlled trial
      protocol targeting physical activity.
PG  - e040702
LID - 10.1136/bmjopen-2020-040702 [doi]
AB  - INTRODUCTION: Although physical activity (PA) reduces cardiovascular disease
      (CVD) risk, physical inactivity remains a pressing public health concern,
      especially among African American (AA) women in the USA. PA interventions focused
      on AA women living in resource-limited communities with scarce PA infrastructure 
      are needed. Mobile health (mHealth) technology can increase access to PA
      interventions. We describe the development of a clinical protocol for a
      multilevel, community-based, mHealth PA intervention for AA women. METHODS AND
      ANALYSIS: An mHealth intervention targeting AA women living in resource-limited
      Washington, DC communities was developed based on the socioecological framework
      for PA. Over 6 months, we will use a Sequential Multi-Assignment, Randomized
      Trial approach to compare the effects on PA of location-based remote messaging
      (named 'tailored-to-place') to standard remote messaging in an mHealth
      intervention. Participants will be randomised to a remote messaging intervention 
      for 3 months, at which point the intervention strategy will adapt based on
      individuals' PA levels. Those who do not meet the PA goal will be rerandomised to
      more intensive treatment. Participants will be followed for another 3 months to
      determine the contribution of each mHealth intervention to PA level. This
      protocol will use novel statistical approaches to account for the adaptive
      strategy. Finally, effects of PA changes on CVD risk biomarkers will be
      characterised. ETHICS AND DISSEMINATION: This protocol has been developed in
      partnership with a Washington, DC-area community advisory board to ensure
      feasibility and acceptability to community members. The National Institutes of
      Health Intramural IRB approved this research and the National Heart, Lung, and
      Blood Institute provided funding. Once published, results of this work will be
      disseminated to community members through presentations at community advisory
      board meetings and our quarterly newsletter. TRIAL REGISTRATION NUMBER:
      NCT03288207.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tamura, Kosuke
AU  - Tamura K
AUID- ORCID: 0000-0002-4920-2856
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Vijayakumar, Nithya P
AU  - Vijayakumar NP
AUID- ORCID: 0000-0002-8231-5713
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Troendle, James F
AU  - Troendle JF
AD  - Office of Biostatistics Research, Division of Cardiovascular Sciences, National
      Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda,
      Maryland, USA.
FAU - Curlin, Kaveri
AU  - Curlin K
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Neally, Sam J
AU  - Neally SJ
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Mitchell, Valerie M
AU  - Mitchell VM
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Collins, Billy S
AU  - Collins BS
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Baumer, Yvonne
AU  - Baumer Y
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Gutierrez-Huerta, Cristhian A
AU  - Gutierrez-Huerta CA
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Islam, Rafique
AU  - Islam R
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Turner, Briana S
AU  - Turner BS
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Andrews, Marcus R
AU  - Andrews MR
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Ceasar, Joniqua N
AU  - Ceasar JN
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Claudel, Sophie E
AU  - Claudel SE
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Tippey, Kathryn G
AU  - Tippey KG
AD  - University of North Carolina, Nutrition Obesity Research Center, Lineberger
      Comprehensive Cancer Center, Connected Health Applications and Interventions
      (CHAI) Core, Chapel Hill, North Carolina, USA.
FAU - Giuliano, Shayne
AU  - Giuliano S
AD  - University of North Carolina, Nutrition Obesity Research Center, Lineberger
      Comprehensive Cancer Center, Connected Health Applications and Interventions
      (CHAI) Core, Chapel Hill, North Carolina, USA.
FAU - McCoy, Regina
AU  - McCoy R
AD  - University of North Carolina, Nutrition Obesity Research Center, Lineberger
      Comprehensive Cancer Center, Connected Health Applications and Interventions
      (CHAI) Core, Chapel Hill, North Carolina, USA.
FAU - Zahurak, Jessica
AU  - Zahurak J
AD  - University of North Carolina, Nutrition Obesity Research Center, Lineberger
      Comprehensive Cancer Center, Connected Health Applications and Interventions
      (CHAI) Core, Chapel Hill, North Carolina, USA.
FAU - Lambert, Sharon
AU  - Lambert S
AD  - Department of Psychological and Brain Sciences, George Washington University,
      Washington, District of Columbia, USA.
FAU - Moore, Philip J
AU  - Moore PJ
AD  - Department of Psychological and Brain Sciences, George Washington University,
      Washington, District of Columbia, USA.
FAU - Douglas-Brown, Mary
AU  - Douglas-Brown M
AD  - Health Ministry, Pilgrim Rest Baptist Church, Washington, DC, USA.
FAU - Wallen, Gwenyth R
AU  - Wallen GR
AD  - National Institutes of Health Clinical Center, Nursing Department, Bethesda,
      Maryland, USA.
FAU - Dodge, Tonya
AU  - Dodge T
AD  - Department of Psychological and Brain Sciences, George Washington University,
      Washington, District of Columbia, USA.
FAU - Powell-Wiley, Tiffany M
AU  - Powell-Wiley TM
AUID- ORCID: 0000-0001-9488-4131
AD  - Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular
      Branch, Division of Intramural Research, National Heart, Lung, and Blood
      Institute, National Institutes of Health, Bethesda, Maryland, USA
      tiffany.powell@nih.gov.
AD  - Intramural Research Program, National Institute on Minority Health and Health
      Disparities, National Institutes of Health, Bethesda, Maryland, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03288207
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
GR  - ZIA HL006168/ImNIH/Intramural NIH HHS/United States
GR  - ZIJ MD000010/ImNIH/Intramural NIH HHS/United States
GR  - P30 CA016086/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201221
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Mobile Applications
MH  - Pregnancy
MH  - Prospective Studies
MH  - *Telemedicine
MH  - Treatment Outcome
PMC - PMC7754642
OTO - NOTNLM
OT  - *cardiology
OT  - *health informatics
OT  - *protocols & guidelines
OT  - *public health
OT  - *social medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040702 [pii]
AID - 10.1136/bmjopen-2020-040702 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 21;10(12):e040702. doi: 10.1136/bmjopen-2020-040702.


PMID- 33371022
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Multimodal prehabilitation as strategy for reduction of postoperative
      complications after cardiac surgery: a randomised controlled trial protocol.
PG  - e039885
LID - 10.1136/bmjopen-2020-039885 [doi]
AB  - INTRODUCTION: Prehabilitation programmes that combine exercise training,
      nutritional support and emotional reinforcement (multimodal prehabilitation) have
      demonstrated efficacy reducing postoperative complications in the context of
      abdominal surgery. However, such programmes have seldom been studied in cardiac
      surgery, one of the surgeries associated with higher postoperative morbidity and 
      mortality. This trial will assess the feasibility and efficacy in terms of
      reduction of postoperative complications and cost-effectiveness of a multimodal
      prehabilitation programme comparing to the standard of care in cardiac surgical
      patients. METHODS AND ANALYSIS: This is a single-centre, randomised, open-label, 
      controlled trial with a 1:1 ratio. Consecutive 160 elective valve replacement
      and/or coronary revascularisation surgical patients will be randomised to either 
      standard of care or 4-6 weeks of multimodal prehabilitation that will consist in 
      (1) two times/week supervised endurance and strength exercise training sessions, 
      (2) promotion of physical activity and healthy lifestyle, (3) respiratory
      physiotherapy, (4) nutrition counselling and supplementation if needed, and (5)
      weekly mindfulness sessions. Baseline, preoperative and 3-month postoperative
      data will be collected by an independent blinded evaluator. The primary outcome
      of this study will be the incidence of postoperative complications. ETHICS AND
      DISSEMINATION: This study has been approved by the Ethics Committee of Clinical
      investigation of Hospital Clinic de Barcelona (HCB/2017/0708). The results will
      be disseminated in a peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      NCT03466606.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Coca-Martinez, Miquel
AU  - Coca-Martinez M
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Lopez-Hernandez, Antonio
AU  - Lopez-Hernandez A
AUID- ORCID: 0000-0002-5310-030X
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Montane-Muntane, Mar
AU  - Montane-Muntane M
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Arguis, Maria Jose
AU  - Arguis MJ
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
AD  - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalunya,
      Spain.
FAU - Gimeno-Santos, Elena
AU  - Gimeno-Santos E
AD  - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalunya,
      Spain.
AD  - Prehabilitation Unit, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
FAU - Navarro-Ripoll, Ricard
AU  - Navarro-Ripoll R
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Perdomo, Juan
AU  - Perdomo J
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Lopez-Baamonde, Manuel
AU  - Lopez-Baamonde M
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Rios, Jose
AU  - Rios J
AD  - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalunya,
      Spain.
AD  - Biostatistics Unit, Universitat Autonoma de Barcelona Facultat de Medicina,
      Bellaterra, Catalunya, Spain.
FAU - Moises, Jorge
AU  - Moises J
AD  - Respiratory Medicine, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
FAU - Sanz de la Garza, Maria
AU  - Sanz de la Garza M
AD  - Department of Cardiology, Cardiovascular Institute, Hospital Clinic de Barcelona,
      Barcelona, Catalunya, Spain.
FAU - Sandoval, Elena
AU  - Sandoval E
AD  - Department of Cardiac Surgery, Cardiovascular Institute, Hospital Clinic de
      Barcelona, Barcelona, Catalunya, Spain.
FAU - Romano, Barbara
AU  - Romano B
AD  - Nutrition and Clinical Dietetics, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain.
FAU - Sebio, Raquel
AU  - Sebio R
AD  - Prehabilitation Unit, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
FAU - Dana, Fernando
AU  - Dana F
AD  - Prehabilitation Unit, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
FAU - Martinez-Palli, Graciela
AU  - Martinez-Palli G
AD  - Anaesthesiology and Intensive Care, Hospital Clinic de Barcelona, Barcelona,
      Catalunya, Spain GMARTIN@clinic.cat.
AD  - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalunya,
      Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03466606
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiac Surgical Procedures/adverse effects
MH  - Elective Surgical Procedures
MH  - Humans
MH  - *Postoperative Complications/prevention & control
MH  - Preoperative Care
MH  - *Preoperative Exercise
PMC - PMC7757458
OTO - NOTNLM
OT  - *anaesthesia in cardiology
OT  - *cardiac surgery
OT  - *protocols & guidelines
OT  - *sports medicine
COIS- Competing interests: All researchers and authors of this protocol declare that
      they have no conflict of interest.
EDAT- 2020/12/30 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-039885 [pii]
AID - 10.1136/bmjopen-2020-039885 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e039885. doi: 10.1136/bmjopen-2020-039885.


PMID- 33371021
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Inflammatory bowel disease in sub-Saharan Africa: a protocol of a prospective
      registry with a nested case-control study.
PG  - e039456
LID - 10.1136/bmjopen-2020-039456 [doi]
AB  - INTRODUCTION: The epidemiology of inflammatory bowel disease (IBD) in sub-Saharan
      Africa is poorly documented. We have started a registry to determine the burden, 
      phenotype, risk factors, disease course and outcomes of IBD in Zimbabwe. METHODS 
      AND ANALYSIS: A prospective observational registry with a nested case-control
      study has been established at a tertiary hospital in Harare, Zimbabwe. The
      registry is recruiting confirmed IBD cases from the hospital, and other
      facilities throughout Zimbabwe. Demographic and clinical data are obtained at
      baseline, 6 months and annually. Two age and sex-matched non-IBD controls per
      case are recruited-a sibling or second-degree relative, and a randomly selected
      individual from the same neighbourhood. Cases and controls are interviewed for
      potential risk factors of IBD, and dietary intake using a food frequency
      questionnaire. Stool is collected for 16S rRNA-based microbiota profiling, and
      along with germline DNA from peripheral blood, is being biobanked. The estimated 
      sample size is 86 cases and 172 controls, and the overall registry is anticipated
      to run for at least 5 years. Descriptive statistics will be used to describe the 
      demographic and phenotypic characteristics of IBD, and incidence and prevalence
      will be estimated for Harare. Risk factors for IBD will be analysed using
      conditional logistic regression. For microbial analysis, alpha diversity and beta
      diversity will be compared between cases and controls, and between IBD
      phenotypes. Mann-Whitney U tests for alpha diversity and Adonis (Permutational
      Multivariate Analysis of Variance) for beta diversity will be computed. ETHICS
      AND DISSEMINATION: Ethical approval has been obtained from the Parirenyatwa
      Hospital's and University of Zimbabwe's research ethics committee and the Medical
      Research Council of Zimbabwe. Findings will be discussed with patients, and the
      Zimbabwean Ministry of Health. Results will be presented at scientific meetings, 
      published in peer reviewed journals, and on social media. TRIAL REGISTRATION
      NUMBER: NCT04178408.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Katsidzira, Leolin
AU  - Katsidzira L
AUID- ORCID: 0000-0003-4815-5207
AD  - Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of
      Zimbabwe, Harare, Zimbabwe lkatsidzira@hotmail.com.
FAU - Mudombi, Wisdom F
AU  - Mudombi WF
AD  - Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of
      Zimbabwe, Harare, Zimbabwe.
FAU - Makunike-Mutasa, Rudo
AU  - Makunike-Mutasa R
AD  - Histopathology Unit, Faculty of Medicine and Heath Sciences, University of
      Zimbabwe, Harare, Zimbabwe.
FAU - Yilmaz, Bahtiyar
AU  - Yilmaz B
AUID- ORCID: 0000-0003-1888-9226
AD  - Maurice Muller Laboratories, Department for Biomedical Research, University of
      Bern, Bern, Switzerland.
AD  - Department of Visceral Surgery and Medicine, Inselspital Bern and Bern
      University, Bern, Switzerland.
FAU - Blank, Annika
AU  - Blank A
AD  - Institute of Pathology, University of Bern, Bern, Switzerland.
FAU - Rogler, Gerhard
AU  - Rogler G
AD  - Department of Gastroenterology and Hepatology, University Hospital Zurich,
      Zurich, Switzerland.
FAU - Macpherson, Andrew
AU  - Macpherson A
AD  - Maurice Muller Laboratories, Department for Biomedical Research, University of
      Bern, Bern, Switzerland.
AD  - Department of Visceral Surgery and Medicine, Inselspital Bern and Bern
      University, Bern, Switzerland.
FAU - Vavricka, Stephan
AU  - Vavricka S
AD  - Department of Gastroenterology and Hepatology, University Hospital Zurich,
      Zurich, Switzerland.
FAU - Gangaidzo, Innocent
AU  - Gangaidzo I
AD  - Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of
      Zimbabwe, Harare, Zimbabwe.
FAU - Misselwitz, Benjamin
AU  - Misselwitz B
AD  - Maurice Muller Laboratories, Department for Biomedical Research, University of
      Bern, Bern, Switzerland.
AD  - Department of Visceral Surgery and Medicine, Inselspital Bern and Bern
      University, Bern, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04178408
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (RNA, Ribosomal, 16S)
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - Case-Control Studies
MH  - Humans
MH  - *Inflammatory Bowel Diseases/epidemiology
MH  - Observational Studies as Topic
MH  - RNA, Ribosomal, 16S
MH  - Registries
MH  - Zimbabwe
PMC - PMC7757438
OTO - NOTNLM
OT  - *adult gastroenterology
OT  - *inflammatory bowel disease
OT  - *tropical medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039456 [pii]
AID - 10.1136/bmjopen-2020-039456 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e039456. doi: 10.1136/bmjopen-2020-039456.


PMID- 33371019
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Effectiveness of workplace exercise interventions in the treatment of
      musculoskeletal disorders in office workers: a protocol of a systematic review.
PG  - e038854
LID - 10.1136/bmjopen-2020-038854 [doi]
AB  - INTRODUCTION: Physical inactivity due to changes in our society towards more
      sedentary behaviours is leading to health problems. Increasing physical activity 
      might be a good strategy to improve physical strength and reduce the prevalence
      of illnesses associated with prolonged sitting. Office workers exhibit a
      sedentary lifestyle with short rest periods or even without pauses during the
      workday. It is important to perform workplace interventions to treat
      musculoskeletal disorders caused by prolonged sitting and lack of movement
      adopted on the office setting. This article describes a protocol for a systematic
      review to evaluate the effectiveness of exercise interventions on office workers 
      in their work environment. METHODS AND ANALYSIS: A literature search will be
      performed in the PubMed, CINAHL Plus, Cochrane Library, Scopus, ISI WoS and PeDRO
      databases for randomised controlled trials and studies published from 1 January
      2010 to 31 July 2020 in English or Spanish. The participants will be office
      workers who spend most of their work time in a sitting position. The
      interventions performed will include any type of exercise intervention in the
      workplace. The outcome measures will vary in accordance with the aim of the
      intervention observed. The results of the review and the outcomes from the
      studies reviewed will be summarised with a narrative synthesis. The review
      protocol was developed according to the Preferred Reporting Items for Systematic 
      Review and Meta-Analysis Protocols guidelines. ETHICS AND DISSEMINATION: Ethical 
      approval is not required. The review outcomes and the additional data obtained
      will be disseminated through publications and in scientific conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020177462.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tersa-Miralles, Carlos
AU  - Tersa-Miralles C
AUID- ORCID: 0000-0001-7037-5033
AD  - Department of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
FAU - Pastells-Peiro, Roland
AU  - Pastells-Peiro R
AUID- ORCID: 0000-0002-9561-9038
AD  - Department of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
AD  - Grup de Recerca de Cures en Salut, IRBLleida, Lleida Institute for Biomedical
      Research Dr. Pifarre Foundation, Lleida, Spain.
FAU - Rubi-Carnacea, Francesc
AU  - Rubi-Carnacea F
AUID- ORCID: 0000-0002-0162-3950
AD  - Department of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
AD  - Grup de Recerca de Cures en Salut, IRBLleida, Lleida Institute for Biomedical
      Research Dr. Pifarre Foundation, Lleida, Spain.
AD  - Grupo de Estudios Sociedad, Salud, Educacion y Cultura, University of Lleida,
      Lleida, Spain.
FAU - Bellon, Filip
AU  - Bellon F
AUID- ORCID: 0000-0003-4880-9207
AD  - Department of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
AD  - Grup de Recerca de Cures en Salut, IRBLleida, Lleida Institute for Biomedical
      Research Dr. Pifarre Foundation, Lleida, Spain.
FAU - Rubinat Arnaldo, Esther
AU  - Rubinat Arnaldo E
AUID- ORCID: 0000-0003-0232-9777
AD  - Department of Nursing and Physiotherapy, University of Lleida, Lleida, Spain
      esther.rubinat@udl.cat.
AD  - Grup de Recerca de Cures en Salut, IRBLleida, Lleida Institute for Biomedical
      Research Dr. Pifarre Foundation, Lleida, Spain.
AD  - Grupo de Estudios Sociedad, Salud, Educacion y Cultura, University of Lleida,
      Lleida, Spain.
AD  - Center for Biomedical Research on Diabetes and Associated Metabolic Diseases,
      Instituto de Salud Carlos III, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Exercise
MH  - Exercise Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Musculoskeletal Diseases/therapy
MH  - Sedentary Behavior
MH  - Systematic Reviews as Topic
MH  - *Workplace
PMC - PMC7757473
OTO - NOTNLM
OT  - *medical education & training
OT  - *occupational & industrial medicine
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038854 [pii]
AID - 10.1136/bmjopen-2020-038854 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e038854. doi: 10.1136/bmjopen-2020-038854.


PMID- 33371017
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 18
TI  - Acupuncture for neck pain caused by cervical spondylosis: a systematic review and
      meta-analysis protocol.
PG  - e038455
LID - 10.1136/bmjopen-2020-038455 [doi]
AB  - INTRODUCTION: Neck pain causes serious social and economic burden. Research on
      the use of acupuncture for managing cervical spondylosis has increased over time,
      with the quality of studies showing an improved trend. The present study seeks to
      use a systematic review approach to understand efficacy and safety of acupuncture
      for treatment of neck pain caused by cervical spondylosis. METHODS AND ANALYSIS: 
      We will search PubMed, Web of Science, Cochrane Library, Embase, China National
      Knowledge Infrastructure, Chinese BioMedical Literature, Wanfang database and VIP
      databases, from their inception to July 2020, to identify and retrieve all
      randomised controlled trials, describing the use of acupuncture for treatment of 
      cervical spondylosis. Thereafter, two reviewers will independently select the
      studies, extract data and assess the risk of bias. Any disagreements, between
      them, will be resolved through a discussion with a third reviewer. Data synthesis
      and statistical analyses will be performed using the Revman V.5.3 software.
      Specifically, data will be synthesised by either fixed-effects (heterogeneity
      less than 50%) or random-effects models, following a heterogeneity test, with
      outcome measures focusing on pain intensity, functional disability, psychological
      improvements and adverse events. In cases where no considerable heterogeneity is 
      detected, a meta-analysis will be conducted. ETHICS AND DISSEMINATION: No ethical
      approval will be required for this study, since it does not infringe on anyone's 
      interests. The findings will be published in a peer-reviewed journal or
      disseminated through conferences. PROSPERO REGISTRATION NUMBER: CRD42020152379.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gao, Zhen
AU  - Gao Z
AUID- ORCID: 0000-0001-8410-8630
AD  - Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine, Chengdu, China.
FAU - Liu, Gao-Feng
AU  - Liu GF
AD  - Graduate Faculty, Tianjin University of Traditional Chinese Medicine, Tianjin,
      China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of acupuncture, Affiliated Hospital of Shanxi University of
      Traditional Chinese Medicine, Taiyuan, China.
FAU - Ji, Lai-Xi
AU  - Ji LX
AD  - The 3rd Teaching Hospital, Shanxi University of Traditional Chinese Medicine,
      Jinzhong, China tyjilaixi@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201218
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - China
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neck Pain/etiology/therapy
MH  - Research Design
MH  - *Spondylosis/complications/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7751201
OTO - NOTNLM
OT  - *bone diseases
OT  - *complementary medicine
OT  - *musculoskeletal disorders
OT  - *pain management
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038455 [pii]
AID - 10.1136/bmjopen-2020-038455 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 18;10(12):e038455. doi: 10.1136/bmjopen-2020-038455.


PMID- 33371015
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 18
TI  - Screening test accuracy to improve detection of precancerous lesions of the
      cervix in women living with HIV: a study protocol.
PG  - e037955
LID - 10.1136/bmjopen-2020-037955 [doi]
AB  - INTRODUCTION: The simplest and cheapest method for cervical cancer screening is
      visual inspection after application of acetic acid (VIA). However, this method
      has limitations for correctly identifying precancerous cervical lesions
      (sensitivity) and women free from these lesions (specificity). We will assess
      alternative screening methods that could improve sensitivity and specificity in
      women living with humanimmunodeficiency virus (WLHIV) in Southern Africa. METHODS
      AND ANALYSIS: We will conduct a paired, prospective, screening test accuracy
      study among consecutive, eligible women aged 18-65 years receiving treatment for 
      HIV/AIDS at Kanyama Hospital, Lusaka, Zambia. We will assess a portable
      magnification device (Gynocular, Gynius Plus AB, Sweden) based on the Swede score
      assessment of the cervix, test for high-risk subtypes of human papillomavirus
      (HR-HPV, GeneXpert, Cepheid, USA) and VIA. All study participants will receive
      all three tests and the reference standard at baseline and at six-month
      follow-up. The reference standard is histological assessment of two to four
      biopsies of the transformation zone. The primary histological endpoint is
      cervical intraepithelial neoplasia grade two and above (CIN2+). Women who are
      VIA-positive or have histologically confirmed CIN2+ lesions will be treated as
      per national guidelines. We plan to enrol 450 women. Primary outcome measures for
      test accuracy include sensitivity and specificity of each stand-alone test. In
      the secondary analyses, we will evaluate the combination of tests. Pre-planned
      additional studies include use of cervigrams to test an automated visual
      assessment tool using image pattern recognition, cost-analysis and associations
      with trichomoniasis. ETHICS AND DISSEMINATION: Ethical approval was obtained from
      the University of Zambia Biomedical Research Ethics Committee, Zambian National
      Health Regulatory Authority, Zambia Medicines Regulatory Authority, Swissethics
      and the International Agency for Research on Cancer Ethics Committee. Results of 
      the study will be submitted for publication in a peer-reviewed journal. TRIAL
      REGISTRATION NUMBER: NCT03931083; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Taghavi, Katayoun
AU  - Taghavi K
AUID- ORCID: 0000-0003-0812-0069
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland katayoun.taghavi@ispm.unibe.ch.
AD  - Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern,
      Switzerland.
FAU - Moono, Misinzo
AU  - Moono M
AD  - Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
FAU - Mwanahamuntu, Mulindi
AU  - Mwanahamuntu M
AD  - Obstetrics and Gynaecology, University Teaching Hospital, Lusaka, Zambia.
AD  - Women and Newborn health, Levy Mwanawasa Medical University Hospital, Lusaka,
      Zambia.
FAU - Basu, Partha
AU  - Basu P
AD  - International Agency for Research on Cancer (IARC), World Health Organization,
      Lyon, France.
FAU - Limacher, Andreas
AU  - Limacher A
AD  - CTU Bern, University of Bern, Bern, Switzerland.
FAU - Tembo, Taniya
AU  - Tembo T
AD  - Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
FAU - Kapesa, Herbert
AU  - Kapesa H
AD  - Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
FAU - Hamusonde, Kalongo
AU  - Hamusonde K
AD  - Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
FAU - Asangbeh, Serra
AU  - Asangbeh S
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
AD  - Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern,
      Switzerland.
FAU - Sznitman, Raphael
AU  - Sznitman R
AD  - ARTORG Center for Biomedical Engineering Research, University of Bern, Bern,
      Switzerland.
FAU - Low, Nicola
AU  - Low N
AUID- ORCID: 0000-0003-4817-8986
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
FAU - Manasyan, Albert
AU  - Manasyan A
AD  - Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
AD  - University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA.
FAU - Bohlius, Julia
AU  - Bohlius J
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03931083
GR  - U01 AI069924/AI/NIAID NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201218
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cervix Uteri
MH  - Colposcopy
MH  - Early Detection of Cancer
MH  - Female
MH  - *HIV Infections/diagnosis
MH  - Humans
MH  - Mass Screening
MH  - Middle Aged
MH  - Papillomaviridae
MH  - *Papillomavirus Infections/diagnosis
MH  - *Precancerous Conditions/diagnosis
MH  - Prospective Studies
MH  - *Uterine Cervical Neoplasms/diagnosis
MH  - Vaginal Smears
MH  - Young Adult
MH  - Zambia
PMC - PMC7751198
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *gynaecology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037955 [pii]
AID - 10.1136/bmjopen-2020-037955 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 18;10(12):e037955. doi: 10.1136/bmjopen-2020-037955.


PMID- 33371014
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 22
TI  - Individual interventions to improve adherence to pharmaceutical treatment, diet
      and physical activity among adults with primary hypertension. A systematic review
      protocol.
PG  - e037920
LID - 10.1136/bmjopen-2020-037920 [doi]
AB  - INTRODUCTION: Hypertension is a chronic disease with 31% worldwide prevalence in 
      adults. It has been associated with non-adherence to therapeutic regime with a
      negative impact on the prognosis of the disease and healthcare-associated costs. 
      So, it is necessary to identify effective interventions to improve adherence
      among the afflicted population. The objective of this protocol is to describe the
      methods for a systematic review that will evaluate the effect of individual
      interventions so as to improve adherence to the prescribed pharmacological
      treatment, as well as to prescribed diet and physical activity in adults with
      primary hypertension. METHODS AND ANALYSIS: A systematic search of studies will
      be conducted in PubMed/MEDLINE, BVS, CINAHL, Embase, Cochrane and Scopus
      databases. Randomised and non-randomised clinical studies conducted in human
      beings, published from 1 January 2009 to 13 December 2019, are to be included, in
      any language. Adherence to pharmacological treatment, diet and physical activity,
      measured by direct and indirect methods, will be the primary outcome. Two
      independent reviewers will select relevant studies and will extract the data
      following the Cochrane's Handbook for Systematic Reviews of Approach and the
      Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols.
      Methodological quality will be evaluated using the risk-of-bias (RoB) 2 and Risk 
      of Bias in Non-randomised Studies - of Interventions (ROBINS-I) tools. Risk of
      bias will also be evaluated, and if the criteria are met, a meta-analysis will be
      finally performed. ETHICS AND DISSEMINATION: Information to be analysed is of a
      grouped nature, and given that its sources are published studies, no ethics
      committee approval is required. Results will be published in scientific journals,
      and in conferences, seminars and symposiums. Copyrights will be addressed by
      giving due credit through bibliographic references. PROSPERO REGISTRATION NUMBER:
      CRD42020147655.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Parra, Dora Ines
AU  - Parra DI
AUID- ORCID: 0000-0003-1527-973X
AD  - Nursing School, Universidad Industrial de Santander, Bucaramanga, Colombia
      doiparra@uis.edu.co.
AD  - Clinical and Community Nursing Doctoral student, Universitat de Valencia,
      Valencia, Spain.
FAU - Trapero Gimeno, Isabel
AU  - Trapero Gimeno I
AUID- ORCID: 0000-0001-7531-6825
AD  - Faculty of Nursing and Podology, Universitat de Valencia, Valencia, Spain.
FAU - Sanchez Rodriguez, Javier Mauricio
AU  - Sanchez Rodriguez JM
AUID- ORCID: 0000-0001-9580-2724
AD  - Faculty of Nursing, Fundacion Universitaria Sanitas, Bogota, Colombia.
FAU - Rodriguez Corredor, Lizeth Catherine
AU  - Rodriguez Corredor LC
AUID- ORCID: 0000-0002-1338-3405
AD  - Research Division, Instituto Neumologico del Oriente, Bucaramanga, Colombia.
AD  - Public Health Department, Universidad Industrial de Santander, Bucaramanga,
      Colombia.
FAU - Hernandez Vargas, Juliana Alexandra
AU  - Hernandez Vargas JA
AUID- ORCID: 0000-0001-6183-252X
AD  - Colombian High Cost Diseases Fund, Bogota, Colombia.
FAU - Lopez Romero, Luis Alberto
AU  - Lopez Romero LA
AUID- ORCID: 0000-0002-7698-7900
AD  - Research Institute, Fundacion Cardiovascular de Colombia, Floridablanca,
      Colombia.
FAU - Garcia Lopez, Fernando J
AU  - Garcia Lopez FJ
AUID- ORCID: 0000-0002-4802-2650
AD  - Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Escudero-Gomez, Cristina
AU  - Escudero-Gomez C
AUID- ORCID: 0000-0002-7333-8673
AD  - Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
FAU - Trujillo-Caceres, Silvia Juliana
AU  - Trujillo-Caceres SJ
AUID- ORCID: 0000-0002-7626-3822
AD  - Colombian High Cost Diseases Fund, Bogota, Colombia.
FAU - Serrano-Gallardo, Pilar
AU  - Serrano-Gallardo P
AUID- ORCID: 0000-0002-5163-6821
AD  - Department of Nursing, School of Medicine, Universidad Autonoma de Madrid/IDIPHIM
      / INAECU, Madrid, Spain.
FAU - Vera-Cala, Lina M
AU  - Vera-Cala LM
AUID- ORCID: 0000-0003-3174-8153
AD  - Public Health Department, Universidad Industrial de Santander, Bucaramanga,
      Colombia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201222
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Adult
MH  - Diet
MH  - Essential Hypertension
MH  - Exercise
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Meta-Analysis as Topic
MH  - *Pharmaceutical Preparations
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7757507
OTO - NOTNLM
OT  - *epidemiology
OT  - *hypertension
OT  - *nutrition & dietetics
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/29 01:02
PHST- 2020/12/29 01:02 [entrez]
PHST- 2020/12/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037920 [pii]
AID - 10.1136/bmjopen-2020-037920 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 22;10(12):e037920. doi: 10.1136/bmjopen-2020-037920.


PMID- 35079657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220127
IS  - 2413-1067 (Electronic)
IS  - 2412-8058 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Dec 30
TI  - Ethical Telemedicine for Honduras in times of COVID-19.
PG  - 38-45
LID - 10.5377/rcfh.v6i2.10716 [doi]
AB  - In Honduras and in the rest of the world, we are going through a public health
      challenge due to the COVID-19 pandemic. Therefore, the need to implement
      telehealth has arisen, considering the deontological and ethical principles that 
      govern the medical profession. It is important to break paradigms in the
      incorporation of information and communication technologies in health systems. We
      must expand our vision for the benefit of people's health, taking into account
      that it is and will always be, appropriate and unavoidable to question the
      innovations, to analyze and reflect on the ethical and legal aspects of their
      implementation and guarantee that what is implemented represents a direct benefit
      for the users. From this approach, it was reflected on the need to implement an
      ethical telemedicine, humanistic, whose main purpose is to preserve life,
      confidentiality, patient safety, as well as the quality and continuity of medical
      care.
FAU - Moya Diaz, Geovanna Michele
AU  - Moya Diaz GM
AUID- ORCID: 0000-0003-1555-7904
AD  - Facultad de Ciencias Medicas, Universidad Nacional Autonoma de Honduras.
LA  - eng
GR  - R25 TW001605/TW/FIC NIH HHS/United States
PT  - Journal Article
PL  - Honduras
TA  - Rev Cienc Forenses Honduras
JT  - Revista de ciencias forenses de Honduras
JID - 9918300981606676
PMC - PMC8785975
MID - NIHMS1760388
OTO - NOTNLM
OT  - Information Technologies in health
OT  - Information and Communication Technologies
OT  - Medical ethics
OT  - Telehealth
OT  - Telemedicine
COIS- ASPECTOS ETICOS El autor declara que no hubo conflicto de interes en la
      preparacion de este articulo.
EDAT- 2020/12/30 00:00
MHDA- 2020/12/30 00:01
CRDT- 2022/01/26 05:31
PHST- 2022/01/26 05:31 [entrez]
PHST- 2020/12/30 00:00 [pubmed]
PHST- 2020/12/30 00:01 [medline]
AID - 10.5377/rcfh.v6i2.10716 [doi]
PST - ppublish
SO  - Rev Cienc Forenses Honduras. 2020 Dec 30;6(2):38-45. doi:
      10.5377/rcfh.v6i2.10716.


PMID- 33355741
STAT- Publisher
DA  - 20201229
CTDT- 20200709
ISBN- 9783030414368
ISBN- 9783030414375
PB  - Palgrave Macmillan
CTI - Wellcome Trust-Funded Monographs and Book Chapters
DP  - 2020
TI  - Understanding the Social Care Crisis in England Through Older People's Lived
      Experiences
BTI - Care Ethics, Democratic Citizenship and the State
PG  - 219-239
LID - 10.1007/978-3-030-41437-5 [doi]
CP  - Chapter 11
AB  - How is knowledge about care produced? The 'epistemological dimension' of care is 
      recognised in the concept of 'responsiveness' in which attention to the
      care-receiver's experience informs the care process at the micro level. What
      counts as 'knowledge' about care in political processes is also highly
      significant yet a further dimension of exclusion from participation operates
      here. Most knowledge about care is produced without the inclusion of
      care-receivers and without regard to their lived experiences of care. This
      chapter explores this using empirical research that was co-produced with older
      people about lived experiences of care within the English social care system.
      Within the current neoliberal context, measurement-based knowledge is more highly
      valued and recognised. The lived experiences of care under neoliberalism directly
      challenge the assumptions underpinning the consumer choice rationale of the
      marketisation of care. The authors argue that building knowledge based on the
      lived experiences of care with those who have direct experience is necessary for 
      'caring democracy'. The chapter is available open access under a CC BY 4.0
      license.
CI  - Copyright 2020, The Author(s).
FED - Urban, Petr
ED  - Urban P
FED - Ward, Lizzie
ED  - Ward L
FAU - Ward, Lizzie
AU  - Ward L
FAU - Ray, Mo
AU  - Ray M
FAU - Tanner, Denise
AU  - Tanner D
LA  - eng
GR  - 203363/Wellcome Trust/United Kingdom
PT  - Review
PT  - Book Chapter
PL  - Cham (CH)
OTO - NLM
OT  - Older people
OT  - Social care
OT  - Lived experience
OT  - Epistemological dimension
OT  - Neoliberalism
OT  - Open access
EDAT- 2020/12/29 06:01
MHDA- 2020/12/29 06:01
CDAT- 2020/12/29 06:01
AID - NBK565989 [bookaccession]
AID - 10.1007/978-3-030-41437-5_11 [doi]


PMID- 33370519
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1488-2353 (Electronic)
IS  - 0147-958X (Linking)
VI  - 43
IP  - 4
DP  - 2020 Dec 27
TI  - International training considerations of Canadian Clinician-Scientist Trainees - 
      A national survey.
PG  - E2-7
LID - 10.25011/cim.v43i4.35003 [doi]
AB  - PURPOSE: Canadian clinician-scientist trainees enrolled in dual degree programs
      often pursue an extended training route following completion of MD and MSc or PhD
      degrees. However, the proportion, plans and reasoning of trainees who intend to
      pursue training internationally following dual degree completion has not been
      investigated. In this study, we assessed the international training
      considerations of current clinician-scientist trainees. METHODS: We designed an
      11-question survey, which was sent out by program directors to all current MDPhD 
      program and Clinician Investigator Program (CIP) trainees. Responses were
      collected from July 8, 2019 to August 8, 2019. RESULTS: We received a total of
      191 responses, with representation from every Canadian medical school and both
      MD-PhD program and CIP trainees. The majority of trainees are considering
      completing additional training outside Canada, most commonly post-doctoral and/or
      clinical fellowships. The most common reasons for considering international
      training include those related to quality and prestige of training programs. In
      contrast, the most common reasons for considering staying in Canada for
      additional training are related to personal and ethical reasons. Irrespective of 
      intentions to pursue international training, the majority of trainees ultimately 
      intend to establish a career in Canada. CONCLUSION: While most trainees are
      considering additional training outside of Canada due to prestige and quality of 
      training, the majority of trainees intend to pursue a career as a
      clinician-scientist back in Canada. Trainees would likely benefit from improved
      guidance and mentorship on the value of international training, as well as
      enhanced support in facilitating cross-border mobility.
FAU - Pietrobon, Adam
AU  - Pietrobon A
AD  - Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
FAU - Cook, Elina K
AU  - Cook EK
AD  - School of Medicine, Queen's University, Kingston, ON, Canada.
FAU - Yin, Charles
AU  - Yin C
AD  - Schulich School of Medicine and Dentistry, Western University, London, ON,
      Canada.
FAU - Chan, Derek C H
AU  - Chan DCH
AD  - Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster
      University, Hamilton, ON, Canada.
FAU - Marvasti, Tina B
AU  - Marvasti TB
AD  - Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
      tina.bineshmarvasti@mail.utoronto.ca.
LA  - eng
PT  - Journal Article
DEP - 20201227
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
SB  - IM
MH  - *Biomedical Research
MH  - Canada
MH  - Education, Graduate
MH  - Humans
MH  - Mentors
MH  - Research Personnel
OTO - NOTNLM
OT  - *clinician-scientist training
OT  - *trainee survey
OT  - *international training
OT  - *MD-PhD programs
OT  - *clinician investigator programs
EDAT- 2020/12/29 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/12/28 18:25
PHST- 2020/10/28 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/12/28 18:25 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.25011/cim.v43i4.35003 [doi]
PST - epublish
SO  - Clin Invest Med. 2020 Dec 27;43(4):E2-7. doi: 10.25011/cim.v43i4.35003.


PMID- 33370340
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Social exclusion and the perspectives of health care providers on migrants in
      Gauteng public health facilities, South Africa.
PG  - e0244080
LID - 10.1371/journal.pone.0244080 [doi]
AB  - BACKGROUND: Universal health coverage (UHC) for all people, regardless of
      citizenship, is a global priority. Health care providers are central to the
      achievement of UHC, and their attitudes and behaviour could either advance or
      impede UHC for migrants. Using a social exclusion conceptual framework, this
      study examined the perspectives of health care providers on delivering health
      services to migrants in public health facilities in Gauteng Province, South
      Africa. METHODS: We used stratified, random sampling to select 13 public health
      facilities. All health care providers working in ambulatory care were invited to 
      complete a self-administered questionnaire. In addition to socio-demographic
      information, the questionnaire asked health care providers if they had witnessed 
      discrimination against migrants at work, and measured their perspectives on
      social exclusionary views and practices. Multiple regression analysis was used to
      identify predictors of more exclusionary perspectives for each item. RESULTS: 277
      of 308 health care providers participated in the study-a response rate of 90%.
      The participants were predominantly female (77.6%) and nurses (51.9%), and had
      worked for an average of 6.8 years in their facilities. 19.2% of health care
      providers reported that they had witnessed discrimination against migrants, while
      20.0% reported differential treatment of migrant patients. Exclusionary
      perspectives varied across the different items, and for different provider
      groups. Enrolled nurses and nursing assistants were significantly more
      exclusionary on a number of items, while the opposite was found for providers
      born outside South Africa. For some questions, female providers held more
      exclusionary perspectives and this was also the case for providers from higher
      levels of care. CONCLUSION: Health care providers are critical to inclusive UHC. 
      Social exclusionary views or practices must be addressed through enabling health 
      policies; training in culture-sensitivity, ethics and human rights; and advocacy 
      to ensure that health care providers uphold their professional obligations to all
      patients.
FAU - White, Janine A
AU  - White JA
AUID- ORCID: 0000-0001-8547-2012
AD  - School of Public Health, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
FAU - Blaauw, Duane
AU  - Blaauw D
AD  - Centre for Health Policy, School of Public Health, Faculty of Health Sciences,
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Rispel, Laetitia C
AU  - Rispel LC
AD  - Centre for Health Policy & South African Research Chairs Initiative, School of
      Public Health, Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201228
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Female
MH  - *Health Personnel
MH  - *Health Services Accessibility
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Social Isolation
MH  - South Africa
MH  - *Surveys and Questionnaires
MH  - *Transients and Migrants
MH  - *Universal Health Insurance
PMC - PMC7769451
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/29 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/12/28 17:10
PHST- 2019/12/09 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/12/28 17:10 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
AID - 10.1371/journal.pone.0244080 [doi]
AID - PONE-D-19-34029 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 28;15(12):e0244080. doi: 10.1371/journal.pone.0244080.
      eCollection 2020.


PMID- 33370298
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Directions in abusive language training data, a systematic review: Garbage in,
      garbage out.
PG  - e0243300
LID - 10.1371/journal.pone.0243300 [doi]
AB  - Data-driven and machine learning based approaches for detecting, categorising and
      measuring abusive content such as hate speech and harassment have gained traction
      due to their scalability, robustness and increasingly high performance. Making
      effective detection systems for abusive content relies on having the right
      training datasets, reflecting a widely accepted mantra in computer science:
      Garbage In, Garbage Out. However, creating training datasets which are large,
      varied, theoretically-informed and that minimize biases is difficult, laborious
      and requires deep expertise. This paper systematically reviews 63 publicly
      available training datasets which have been created to train abusive language
      classifiers. It also reports on creation of a dedicated website for cataloguing
      abusive language data hatespeechdata.com. We discuss the challenges and
      opportunities of open science in this field, and argue that although more dataset
      sharing would bring many benefits it also poses social and ethical risks which
      need careful consideration. Finally, we provide evidence-based recommendations
      for practitioners creating new abusive content training datasets.
FAU - Vidgen, Bertie
AU  - Vidgen B
AD  - The Alan Turing Institute, London, United Kingdom.
FAU - Derczynski, Leon
AU  - Derczynski L
AUID- ORCID: 0000-0002-8656-3431
AD  - Department of Computer Science, IT University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201228
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Databases, Factual
MH  - *Hate
MH  - Humans
MH  - *Language
MH  - *Machine Learning
PMC - PMC7769249
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/29 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/28 17:10
PHST- 2020/05/27 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/12/28 17:10 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1371/journal.pone.0243300 [doi]
AID - PONE-D-20-15800 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 28;15(12):e0243300. doi: 10.1371/journal.pone.0243300.
      eCollection 2020.


PMID- 33369306
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 12
DP  - 2020 Dec
TI  - [LEGAL ASPECTS OF TELEMEDICINE].
PG  - 898-902
AB  - BACKGROUND: This article describes the COVID19 effects on telehealth, which is
      becoming an integral part of medical treatment. In telehealth, healthcare
      personnel are required to follow the legislation which applies to more
      traditional medical encounters. We review the unique implementation of these
      legal requirements, in the novel digital setting. We further scrutinize the
      Ministry of Health's Director General's ordinance on telehealth, and related
      ethical rules. We focus on informed consent, medical confidentiality and privacy,
      documentation and liability. Finally, we raise the issue of artificial
      intelligence in telehealth and resulting future legal challenges.
FAU - Tavory, Tamar
AU  - Tavory T
AD  - Digital Health, Yigal Arnon.
AD  - Co. Law Firm, Tel Aviv University.
LA  - heb
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - Artificial Intelligence
MH  - *COVID-19
MH  - Confidentiality
MH  - Humans
MH  - Informed Consent
MH  - SARS-CoV-2
MH  - *Telemedicine
EDAT- 2020/12/29 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/12/28 12:46
PHST- 2020/12/28 12:46 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Dec;159(12):898-902.


PMID- 33369302
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210101
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 12
DP  - 2020 Dec
TI  - [Ethical rules for Remote Medical Treatment].
PG  - 882
FAU - Karni, Tami
AU  - Karni T
AD  - Comprehensive Breast Care Institute, Department of Surgery, Shamir Medical
      Center.
AD  - Chairwoman of the Ethics Bureau, Israeli Medical Association.
LA  - heb
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - *Morals
EDAT- 2020/12/29 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/12/28 12:46
PHST- 2020/12/28 12:46 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Dec;159(12):882.


PMID- 33368122
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1098-8793 (Electronic)
IS  - 0736-6825 (Linking)
VI  - 36
IP  - 6
DP  - 2020 Dec
TI  - Practical Considerations in Adopting New Technology for Facial Cosmetic
      Procedures.
PG  - 684-687
LID - 10.1055/s-0040-1721104 [doi]
AB  - The field of facial plastic and reconstructive surgery encompasses both surgical 
      and nonsurgical facets, creating a supplemental level of care and an additional
      layer of complexity. Determining the "best course of care" can be very difficult 
      in experienced situations, but even more so when considering adopting an emerging
      technology. A basic and practical method of analyzing a new technology requires
      investigating the risk-to-benefit assessment, the utility and clinical outcomes
      compared with other treatment options, and an introspective ethical appraisal of 
      whether the technology is foremost for patient care purposes. Even after
      employing a new technology, constant monitoring and reevaluation of the results
      is necessary to determine if it should be continued or altered.
CI  - Thieme. All rights reserved.
FAU - Rousso, Joseph J
AU  - Rousso JJ
AD  - Manhatten Facial Plastic Surgery and ENT, New York, New York.
AD  - Department of Otolaryngology - Head & Neck Surgery, Icahn School of Medicine at
      Mount Sinai, New York, New York.
LA  - eng
PT  - Journal Article
DEP - 20201224
PL  - United States
TA  - Facial Plast Surg
JT  - Facial plastic surgery : FPS
JID - 8405303
MH  - *Cosmetic Techniques
MH  - Face/surgery
MH  - Humans
MH  - Patient Satisfaction
MH  - *Reconstructive Surgical Procedures
MH  - *Surgery, Plastic
MH  - Technology
COIS- None declared.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/12/28 12:22
PHST- 2020/12/28 12:22 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 10.1055/s-0040-1721104 [doi]
PST - ppublish
SO  - Facial Plast Surg. 2020 Dec;36(6):684-687. doi: 10.1055/s-0040-1721104. Epub 2020
      Dec 24.


PMID- 33368069
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210106
IS  - 1305-7456 (Print)
VI  - 14
IP  - S 01
DP  - 2020 Dec
TI  - Association of Personal Protective Equipment with De Novo Headaches in Frontline 
      Healthcare Workers during COVID-19 Pandemic: A Cross-Sectional Study.
PG  - S79-S85
LID - 10.1055/s-0040-1721904 [doi]
AB  - OBJECTIVES: This study aimed to determine the association of personal protective 
      equipment (PPE) usage with new-onset headaches and exacerbation of pre-existing
      headache disorders among healthcare workers at the frontlines during coronavirus 
      disease 2019 (COVID-19) pandemic. MATERIALS AND METHODS: A descriptive
      cross-sectional survey was conducted across Pakistan in June-July 2020. The study
      was approved by Ethical Committee, Armed Forces Institute of Dentistry,
      Rawalpindi (IRB form no.905/Trg-ABP 1K2). A qualitative questionnaire was
      developed and was shared via different social networks. The questionnaire was
      closed when 241 responses were received. STATISTICAL ANALYSIS: Descriptive
      analysis was performed on demographic data. Chi-squared analysis was performed
      between demographic data and PPE-usage patterns among participants with or
      without de novo headaches. Univariable and multivariable logistic regression
      models were used to compare variables with the development of new-onset
      headaches. Chi-squared test was also performed between demographic data and other
      factors that may be causing new-onset headaches. A p-value < 0.05 was considered 
      significant. RESULTS: A total of 241 healthcare workers participated, of which 68
      participants (28.2%) reported de novo headaches since the start of the pandemic. 
      Incidence of pre-existing headaches (odds ratio [OR] = 1.91; 95% confidence
      interval [CI]: 0.99-0.37; p = 0.049) was associated with new-onset headaches.
      Post hoc multivariable logistic regression analysis stated that incidence of
      pre-existing headaches (OR = 1.88; 95% CI: 0.94-3.78; p = 0.75) and age (OR =
      2.21; 95% CI: 0.47-10.33; p = 0.36) was independently associated with new-onset
      PPE-induced headaches but was not statistically significant. Chi-squared analysis
      showed a statistically significant relationship between other factors (sleep
      deprivation, emotional stress, etc.) and department of activity, gender, and
      occupation (p < 0.05). CONCLUSION: Healthcare workers with previous history of
      pre-existing headaches were found to be more susceptible to PPE-induced headaches
      during COVID-19 pandemic. However, age and the department where the healthcare
      workers performed may also be risk factors.
CI  - European Journal of Dentistry. This is an open access article published by Thieme
      under the terms of the Creative Commons
      Attribution-NonDerivative-NonCommercial-License, permitting copying and
      reproduction so long as the original work is given appropriate credit. Contents
      may not be used for commercial purposes, or adapted, remixed, transformed or
      built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Zaheer, Rumeesha
AU  - Zaheer R
AD  - Orthodontics Department, Armed Forces Institute of Dentistry, Combined Military
      Hospital, Rawalpindi, Pakistan.
FAU - Khan, Maheen
AU  - Khan M
AD  - Prosthodontics Department, Khyber College of Dentistry, Peshawar, Pakistan.
FAU - Tanveer, Ahmed
AU  - Tanveer A
AD  - National University of Medical Sciences, Rawalpindi, Pakistan.
FAU - Farooq, Amal
AU  - Farooq A
AD  - National University of Medical Sciences, Rawalpindi, Pakistan.
FAU - Khurshid, Zohaib
AU  - Khurshid Z
AUID- ORCID: 0000-0001-7998-7335
AD  - Department of Prosthodontics and Dental Implantology, College of Dentistry, King 
      Faisal University, Al Ahsa, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20201226
PL  - Germany
TA  - Eur J Dent
JT  - European journal of dentistry
JID - 101303672
PMC - PMC7775222
COIS- None declared.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:22
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
PHST- 2020/12/28 12:22 [entrez]
AID - 10.1055/s-0040-1721904 [doi]
PST - ppublish
SO  - Eur J Dent. 2020 Dec;14(S 01):S79-S85. doi: 10.1055/s-0040-1721904. Epub 2020 Dec
      26.


PMID- 33367770
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1465-3648 (Electronic)
IS  - 0268-1153 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Dec 23
TI  - Teachers' professional identities in the context of school-based sexuality
      education in Uganda-a qualitative study.
PG  - 553-563
LID - 10.1093/her/cyaa044 [doi]
AB  - School-based sexuality education makes teachers important gatekeepers of
      students' access to information about sexual and reproductive health and rights. 
      The school setting has the potential to reach large numbers of students. However,
      teachers' professional identities may go beyond, differ from or even conflict
      with the qualities required of sexuality educators. To gain a better
      understanding of the role of professional identity in the delivery of
      school-based sexuality education, this study used cultural schema theory to study
      teachers' professional identities, and how these motivate them to provide
      sexuality education. In-depth interviews were conducted with 40 sexuality
      education teachers at secondary schools in Kampala, the capital of Uganda.
      Sexuality education lessons were observed to validate the findings from the
      interviews. Results identified five cultural schemas of professional identity:
      (i) upholder of ethics and regulations; (ii) authority figure; (iii) counsellor
      and guide; (iv) role model; and (v) guardian. The study concludes that teachers' 
      cultural schemas of professional identity motivate them to adhere to moral
      discourses of abstinence and sexual innocence. To support teachers in taking more
      comprehensive approaches to sexuality education, it is important that they
      receive adequate teacher training and support from the Ugandan government, the
      school administration and the wider community.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - de Haas, Billie
AU  - de Haas B
AD  - Population Research Centre, Faculty of Spatial Sciences, University of Groningen,
      P.O. Box 800, 9700 AV Groningen, The Netherlands.
FAU - Hutter, Inge
AU  - Hutter I
AD  - International Institute of Social Studies, Erasmus University Rotterdam, P.O. Box
      29776, 2502 LT The Hague, The Netherlands.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Health Educ Res
JT  - Health education research
JID - 8608459
MH  - Humans
MH  - School Teachers
MH  - *Schools
MH  - *Sex Education
MH  - Sexual Behavior
MH  - Sexuality
MH  - Uganda
PMC - PMC7768668
EDAT- 2020/12/29 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/12/28 12:17
PHST- 2019/05/15 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/12/28 12:17 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 6046287 [pii]
AID - 10.1093/her/cyaa044 [doi]
PST - ppublish
SO  - Health Educ Res. 2020 Dec 23;35(6):553-563. doi: 10.1093/her/cyaa044.


PMID- 33367154
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2455-5568 (Electronic)
IS  - 2455-5568 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Apr-Jun
TI  - A personalized Institutional Review Board Liaison Service: Evaluation over its
      initial 30 months.
PG  - 96-102
AB  - BACKGROUND: The aim of this study is to evaluate whether a dedicated
      Institutional Review Board (IRB) Liaison Service situated at our Institute's
      central location could provide additional useful staff support to the
      investigator community for interactions with the IRB at various levels of
      protocol submission and review. MATERIALS AND METHODS: Over a period of 2(1/2)
      years, from January 2015 to June 2017, a total of 501 in-person consultations
      were performed during office hours, usually 25-30 per month. Most requests
      concerned new protocol development, IRB policy questions, and strategies for
      compliance or assistance in addressing IRB comments on returned protocols. We
      analyzed the results of a user evaluation survey for in-person consults and
      performed a focused in-depth analysis of the impact of the IRB Liaison Service.
      RESULTS: Survey response rate was 43%. Results of 215 completed satisfaction
      surveys were 100% positive. Users were primarily study coordinators and
      investigators. Of a randomly selected sample of consultations analyzed in-depth
      for 67 unique protocols, 73% were subsequently approved within 14 days.
      CONCLUSION: National concerns about IRB-related research delays have led to the
      re-assessment of IRB review processes at institutional levels. Overall, we have
      found the Liaison Service to be a popular, useful addition to research support
      for a meaningful number of researchers, enhancing our already research-friendly
      environment. We plan to continue the service and the evaluation going forward. We
      will focus in the next phase on exploring whether the Liaison Service can reduce 
      IRB approval times for protocols using its services and on providing support for 
      the use of single IRBs for multi-site studies. THE FOLLOWING CORE COMPETENCIES
      ARE ADDRESSED IN THIS ARTICLE: Practice-based learning and improvement.
FAU - Abedin, Zainab
AU  - Abedin Z
AD  - Evaluation and Continuous Improvement Resource of the Irving Institute for
      Clinical and Translation Research, Columbia University, New York, USA.
FAU - Teller, Alan
AU  - Teller A
AD  - Institutional Review Board of the Human Research Protection Office, Columbia
      University, New York, USA.
FAU - Ruotolo, Brenda
AU  - Ruotolo B
AD  - Institutional Review Board of the Human Research Protection Office, Columbia
      University, New York, USA.
FAU - Muhammad, Kawthar
AU  - Muhammad K
AD  - Evaluation and Continuous Improvement Resource of the Irving Institute for
      Clinical and Translation Research, Columbia University, New York, USA.
FAU - Stiles, Deborah F
AU  - Stiles DF
AD  - Office of Vice President for Research, Columbia University, New York, USA.
FAU - Ferreira, Rui
AU  - Ferreira R
AD  - Institutional Review Board of the Human Research Protection Office, Columbia
      University, New York, USA.
FAU - Green, Nancy
AU  - Green N
AD  - Regulatory Knowledge and Ethics Support (RKSER) of the Irving Institute for
      Clinical and Translation Research, Columbia University, New York, USA.
AD  - Department of Pediatrics, Columbia University, New York, USA.
LA  - eng
GR  - UL1 TR001873/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200629
PL  - India
TA  - Int J Acad Med
JT  - International journal of academic medicine
JID - 101706449
PMC - PMC7755161
MID - NIHMS1653719
OTO - NOTNLM
OT  - Ethics
OT  - Institutional Review Board
OT  - research support
OT  - translational research
COIS- Conflicts of interest There are no conflicts of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:11
PHST- 2020/12/28 12:11 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
PST - ppublish
SO  - Int J Acad Med. 2020 Apr-Jun;6(2):96-102. Epub 2020 Jun 29.


PMID- 33365216
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 18
TI  - COVID-19: The First 30 Days at a UK Level 1 Trauma Centre and Lessons Learnt.
PG  - e11547
LID - 10.7759/cureus.11547 [doi]
AB  - Aims To analyse the learning points from the first 30 days of the COVID-19
      lockdown at our institution. Patients & methods Following ethical approval, data 
      were collected prospectively on all patients admitted under orthopaedics between 
      March 23, 2020, and April 22, 2020. This included baseline demographics (sex,
      age), biochemical (blood tests), radiological (chest X-ray (CXR), computed
      tomography (CT)), nature and mechanism of injury, comorbidities, regular
      medication, observations, specific respiratory symptoms of COVID-19, management, 
      operations, time to theatre, and outcome including mortality incidence. The
      nature of injury and operations performed were compared to the same period of the
      previous year (2019). Results During the study period, 162 (74 males) patients
      were admitted, with a mean age of 60.7 (range 1-101, SD 2.1). On admission, 66
      (41%) patients were tested for COVID, out of which eight (13.7%) patients tested 
      positive. Subsequently, another four patients tested positive, who developed
      symptoms after admission. Four out 12 (33%) confirmed COVID patients died. During
      this period, 4/150 other patients also died of other causes (mortality incidence 
      2.6%). The average ages of COVID non-survivors vs survivors were 88, SD 1, vs 76,
      SD 12, respectively; 2/4 had concurrent diabetes and cancer, another cancer
      alone, and another complex autoimmune disease managed by immunosuppressive
      medication. Overall admissions significantly reduced by almost 50% compared with 
      the previous year (162 vs 373, p=<0.05), including cases of polytrauma (15 vs
      33). Time to surgery was increased by an average of one day, mainly due to time
      taken for COVID-19 swab results to come back, and in positive patients, this was 
      an average of 2.75 days (0-13). Lymphopenia was a useful biomarker of COVID, with
      levels significantly different between groups (p=<0.05). Of the clinical symptoms
      assessed, 8/12 patients experienced positive chest symptoms or pyrexia but only
      four had positive CXR changes. Discussion & lessons learnt Eight out of 12
      patients who contracted COVID-19 survived without needing intensive care.
      Non-survivors were older with significant comorbidities. Lymphopenia is a good
      biomarker of the disease, but suspicious CXR was not sensitive for excluding it. 
      Trauma volume reduced. We have highlighted significant changes to expect should
      there be a second wave of the virus. Key lessons learnt were that reduction in
      trauma volume and cessation of elective operating allowed for redeployment,
      including taking over the minor injury unit; more senior, consultant
      decision-makers 'at the front door' reduced unnecessary admissions. Increased use
      of conservative practice was effective at reducing operations required. Expedited
      COVID swab test processing allowed early de-escalation of isolation, reducing
      time to surgery. We expect approximately 12% of the typical orthopaedic
      population to be admitted with COVID, and up to 33% of these patients to die
      within 28 days of contracting the virus. The vast majority of patients, however, 
      can be managed appropriately with ward-level care. An early decision on
      escalation and resuscitation status in the emergency department improves patient 
      flow significantly. Remote working was effective and could be extended in the
      future. We have highlighted the significant changes to expect should there be a
      second wave of the virus and effective solutions for managing the problems that
      arise, which could be useful for other units.
CI  - Copyright (c) 2020, Andrzejowski et al.
FAU - Andrzejowski, Paul A
AU  - Andrzejowski PA
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Howard, Anthony
AU  - Howard A
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Vun, James Shen Hwa
AU  - Vun JSH
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Manzoor, Nauman
AU  - Manzoor N
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Patsiogiannis, Nikolaos
AU  - Patsiogiannis N
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Kanakaris, Nikolaos K
AU  - Kanakaris NK
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Giannoudis, Peter V
AU  - Giannoudis PV
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7748575
OTO - NOTNLM
OT  - biomarker
OT  - covid-19
OT  - hospital epidemiology
OT  - lessons learnt
OT  - orthopedics and trauma
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:06
PHST- 2020/12/28 12:06 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.7759/cureus.11547 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 18;12(11):e11547. doi: 10.7759/cureus.11547.


PMID- 33365035
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Prenatal Diagnosis for Primary Immunodeficiency Disorders-An Overview of the
      Indian Scenario.
PG  - 612316
LID - 10.3389/fimmu.2020.612316 [doi]
AB  - Prenatal Diagnosis (PND) forms an important part of primary preventive management
      for families having a child affected with primary immunodeficiency. Although
      individually sparse, collectively this group of genetic disorders represents a
      significant burden of disease. This paper discusses the prenatal services
      available for affected families at various centers across the country and the
      challenges and ethical considerations associated with genetic counseling.
      Mutation detection in the index case and analysis of chorionic villous sampling
      or amniocentesis remain the preferred procedures for PND and phenotypic analysis 
      of cordocentesis sample is reserved for families with well-characterized index
      case seeking PND in the latter part of the second trimester of pregnancy. A total
      of 112 families were provided PND services in the last decade and the presence of
      an affected fetus was confirmed in 32 families. Post-test genetic counseling
      enabled the affected families to make an informed decision about the current
      pregnancy.
CI  - Copyright (c) 2020 Yadav, Gupta, Dalvi, Bargir, Hule, Shabrish, Aluri, Kulkarni, 
      Kambli, Uppuluri, Seshadri, Jagadeesh, Suresh, Raja, Taur, Malaischamy, Ghosh,
      Mahalingam, Kadam, Lashkari, Tamhankar, Tamhankar, Mithbawkar, Bhattad, Jhawar,
      Makam, Bansal, Prasad, Govindaraj, Guhan, Bharadwaj Tallapaka, Desai, Raj and
      Madkaikar.
FAU - Yadav, Reetika Malik
AU  - Yadav RM
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Gupta, Maya
AU  - Gupta M
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Dalvi, Aparna
AU  - Dalvi A
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Bargir, Umair Ahmed
AU  - Bargir UA
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Hule, Gouri
AU  - Hule G
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Shabrish, Snehal
AU  - Shabrish S
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Aluri, Jahnavi
AU  - Aluri J
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Kulkarni, Manasi
AU  - Kulkarni M
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Kambli, Priyanka
AU  - Kambli P
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
FAU - Uppuluri, Ramya
AU  - Uppuluri R
AD  - Department of Pediatric Hematology-Oncology, Blood Marrow Transplantation, Apollo
      Hospitals, Chennai, India.
FAU - Seshadri, Suresh
AU  - Seshadri S
AD  - Department of Clinical Genetics & Genetic Counseling, Mediscan Systems, Chennai, 
      India.
FAU - Jagadeesh, Sujatha
AU  - Jagadeesh S
AD  - Department of Clinical Genetics & Genetic Counseling, Mediscan Systems, Chennai, 
      India.
FAU - Suresh, Beena
AU  - Suresh B
AD  - Department of Clinical Genetics & Genetic Counseling, Mediscan Systems, Chennai, 
      India.
FAU - Raja, Jayarekha
AU  - Raja J
AD  - Department of Clinical Genetics & Genetic Counseling, Mediscan Systems, Chennai, 
      India.
FAU - Taur, Prasad
AU  - Taur P
AD  - Department of Immunology and Department of Pediatric Hemato-Oncology, Bai Jerbai 
      Wadia Hospital for Children, Mumbai, India.
FAU - Malaischamy, Sivasankar
AU  - Malaischamy S
AD  - MedGenome Labs Private Limited, Bangalore, India.
FAU - Ghosh, Priyanka
AU  - Ghosh P
AD  - MedGenome Labs Private Limited, Bangalore, India.
FAU - Mahalingam, Shweta
AU  - Mahalingam S
AD  - MedGenome Labs Private Limited, Bangalore, India.
FAU - Kadam, Priya
AU  - Kadam P
AD  - MedGenome Labs Private Limited, Bangalore, India.
FAU - Lashkari, Harsha Prasada
AU  - Lashkari HP
AD  - Department of Pediatrics, Kasturba Medical College Hospital, Manipal Academy of
      Higher Education, Mangalore, India.
FAU - Tamhankar, Parag
AU  - Tamhankar P
AD  - Centre for Medical Genetics, Mumbai, India.
FAU - Tamhankar, Vasundhara
AU  - Tamhankar V
AD  - Centre for Medical Genetics, Mumbai, India.
FAU - Mithbawkar, Shilpa
AU  - Mithbawkar S
AD  - Centre for Medical Genetics, Mumbai, India.
FAU - Bhattad, Sagar
AU  - Bhattad S
AD  - Division of Pediatric Immunology and Rheumatology, Department of Pediatrics,
      Aster CMI Hospital, Bangalore, India.
FAU - Jhawar, Prerna
AU  - Jhawar P
AD  - Department of Fetal Medicine, Motherhood Hospital, Bangalore, India.
FAU - Makam, Adinarayan
AU  - Makam A
AD  - Department of Fetal Medicine, Adi Advanced Centre for Fetal Care, Bangalore,
      India.
FAU - Bansal, Vandana
AU  - Bansal V
AD  - Fetal Medicine Department Surya Hospitals, Mumbai, India.
FAU - Prasad, Malathi
AU  - Prasad M
AD  - Fetal Medicine Centre, Trichy, India.
FAU - Govindaraj, Geeta
AU  - Govindaraj G
AD  - Department of Pediatrics, Government Medical College, Kozhikode, Calicut, India.
FAU - Guhan, Beena
AU  - Guhan B
AD  - Department of Pediatrics, Government Medical College, Kozhikode, Calicut, India.
FAU - Bharadwaj Tallapaka, Karthik
AU  - Bharadwaj Tallapaka K
AD  - CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, India.
FAU - Desai, Mukesh
AU  - Desai M
AD  - Department of Immunology and Department of Pediatric Hemato-Oncology, Bai Jerbai 
      Wadia Hospital for Children, Mumbai, India.
FAU - Raj, Revathi
AU  - Raj R
AD  - Department of Pediatric Hematology-Oncology, Blood Marrow Transplantation, Apollo
      Hospitals, Chennai, India.
FAU - Madkaikar, Manisha Rajan
AU  - Madkaikar MR
AD  - Center of Excellence for PIDs, Department of Pediatric Immunology and Leucocyte
      Biology, ICMR-National Institute of Immunohaematology, Mumbai, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201207
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Amniocentesis/methods
MH  - Female
MH  - Genetic Diseases, Inborn/diagnosis/genetics
MH  - Genetic Testing/methods
MH  - Humans
MH  - India
MH  - Mutation/genetics
MH  - Pregnancy
MH  - Prenatal Diagnosis/methods
MH  - Primary Immunodeficiency Diseases/*diagnosis/genetics
PMC - PMC7750517
OTO - NOTNLM
OT  - *chorionic villus sampling
OT  - *cordocentesis
OT  - *flow cytometry
OT  - *maternal contamination
OT  - *prenatal diagnosis
OT  - *variants of unknown significance
COIS- SMal, PG, SMah, and PKad were employed by the company MedGenome Labs Private
      Limited. SJ, BS, and JR were employed by the company Mediscan Systems. The
      remaining authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/12/28 12:05
PHST- 2020/09/30 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/12/28 12:05 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
AID - 10.3389/fimmu.2020.612316 [doi]
PST - epublish
SO  - Front Immunol. 2020 Dec 7;11:612316. doi: 10.3389/fimmu.2020.612316. eCollection 
      2020.


PMID- 33364885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1302-7123 (Print)
IS  - 1302-7123 (Linking)
VI  - 54
IP  - 4
DP  - 2020
TI  - Can Bispectral Index Monitoring (EEG) be an Early Predictor of Respiratory
      Depression under Deep Sedation during Endoscopic Retrograde
      Cholangiopancreatography?
PG  - 444-450
LID - 10.14744/SEMB.2020.10476 [doi]
AB  - OBJECTIVES: The more often the endoscopy sedation is performed, the more the risk
      of adverse events, and therefore, advanced monitoring becomes more and more
      essential in endoscopy units. The present study aims to evaluate whether the
      Bispectral Index (BIS) monitoring is an early predictor of respiratory depression
      and to determine the compliance between commonly used clinical sedation score.
      METHODS: This study was approved by the ethics committee. The sample consisted of
      60 patients aged 18 to 50 years with an American Society of Anesthesiologists
      (ASA) physical status of I scheduled for endoscopic retrograde
      cholangiopancreatography (ERCP). All patients received propofol mediated
      sedation. Ramsay sedation score (RSS) was used as a clinical sedation score to
      assess the depth of sedation. Participants were attached to a BIS monitor.
      Perioperative hemodynamics, BIS values, the mean dose of propofol, procedure
      duration, apnea, frequency of oxygen desaturation and airway-related
      interventions, as well as demographic parameters, were recorded. BIS scores were 
      blinded to RSS data. RESULTS: The study sample consisted of 60 patients (36
      females) aged 18 to 50 years (mean: 36.10+/-8.02). The mean procedure time and
      the dose of propofol were 32.70+/-1.79 min and 287.17+/-59.66 mg, respectively.
      The cut-off values for respiratory depression were as follows. At the 15th min of
      measurement, the BIS score of 60 had 96.2% sensitivity and 42.9% specificity. At 
      the 20th min of measurement, the BIS score of 59.50 had 98.2% sensitivity and
      100.0% specificity. At the 25th min of measurement, the BIS score of 59.00 had
      98.3% sensitivity and 50.0% specificity. Regression analysis showed that the mean
      BIS score (p=0.000, 95%CI-0.110-0.043) increased by 0.076 with a unit increase in
      the RSS. CONCLUSION: BIS was highly correlated with RSS, and therefore, can be
      used to avoid respiratory depression during sedation.
CI  - Copyright: (c) 2020 by The Medical Bulletin of Sisli Etfal Hospital.
FAU - Kilic, Ebru Tarikci
AU  - Kilic ET
AD  - Department of Anesthesiology and Perioperative Medicine, Umraniye Training and
      Research Hospital, Istanbul, Turkey.
FAU - Sayar, Suleyman
AU  - Sayar S
AD  - Department of Gastroenterology, Umraniye Training and Research Hospital,
      Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - Turkey
TA  - Sisli Etfal Hastan Tip Bul
JT  - Sisli Etfal Hastanesi tip bulteni
JID - 9424130
PMC - PMC7751237
OTO - NOTNLM
OT  - Bispectral index
OT  - continuous monitoring
OT  - respiratory depression
OT  - sedation
COIS- Conflict of Interest: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:04
PHST- 2020/06/06 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/12/28 12:04 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.14744/SEMB.2020.10476 [doi]
AID - MBSEH-54-444 [pii]
PST - epublish
SO  - Sisli Etfal Hastan Tip Bul. 2020 Dec 11;54(4):444-450. doi:
      10.14744/SEMB.2020.10476. eCollection 2020.


PMID- 33364873
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1179-9927 (Electronic)
IS  - 1179-9927 (Linking)
VI  - 11
DP  - 2020
TI  - Magnitude and Factors Associated with Preoperative Anxiety Among Pediatric
      Patients: Cross-Sectional Study.
PG  - 485-494
LID - 10.2147/PHMT.S288077 [doi]
AB  - BACKGROUND: Anesthesia and surgery are common sources of anxiety and stressful
      experiences in children. This unpleasant sensation depends on several factors.
      This study aimed to determine the magnitude of preoperative anxiety and
      associated factors in pediatrics patients at the University of Gondar
      Comprehensive Specialized Hospital North West Ethiopia 2020. METHODS: An
      institutional-based cross-sectional observational study was conducted from March 
      to September 2020 at the University of Gondar Comprehensive Specialized Hospital.
      After obtaining ethical approval from the institutional review board. All
      consecutive ASA physical status I & II boys and girls with the age of 2-12 years 
      scheduled for a variety of elective (general, urologic, ENT, ophthalmic and other
      surgical) operations were included. The level of anxiety was measured using the
      Modified Yale Preoperative Anxiety Scale short form (m-YPAS-SF) observational
      tool. Parental anxiety was assessed using Spielberger's short version of
      state-trait anxiety. Binary logistic regression analysis was performed to
      identify the association between preoperative children's anxiety and independent 
      variables. The strength of the association was present by adjusted odds ratios.
      RESULTS: The magnitude of preoperative anxiety in children in the operation room 
      was 75.44% (95% confidence interval (CI): 68.36, 81.34). Age (AOR: 3.83; 95% CI: 
      1.58, 9.30), previous surgery and anesthesia (AOR: 6.73, 95% CI: 1.25, 36.19),
      outpatient surgery (AOR: 5.16, 95% CI: 1.32, 20.23) and parental anxiety (AOR:
      3.26, 95% CI: 1.30, 20.23) were significantly associated with preoperative
      children anxiety. CONCLUSION: The magnitude of preoperative anxiety in pediatric 
      patients was considerably high in our setup. Younger age, previous surgery and
      anesthesia, outpatient surgical setting, and parental anxiety were the
      independent risk factors for preoperative anxiety. Therefore, the operating staff
      should assess the child's anxiety and should consider appropriate anxiety
      reduction methods during the preoperative visit of pediatric patients and their
      families.
CI  - (c) 2020 Getahun et al.
FAU - Getahun, Amare Belete
AU  - Getahun AB
AD  - Department of Anaesthesia, School of Medicine, College of Medicine and Health
      Science, University of Gondar, Gondar, Ethiopia.
FAU - Endalew, Nigussie Simeneh
AU  - Endalew NS
AUID- ORCID: 0000-0001-7632-5707
AD  - Department of Anaesthesia, School of Medicine, College of Medicine and Health
      Science, University of Gondar, Gondar, Ethiopia.
FAU - Mersha, Abraham Tarekegn
AU  - Mersha AT
AUID- ORCID: 0000-0002-5548-0289
AD  - Department of Anaesthesia, School of Medicine, College of Medicine and Health
      Science, University of Gondar, Gondar, Ethiopia.
FAU - Admass, Biruk Adie
AU  - Admass BA
AD  - Department of Anaesthesia, School of Medicine, College of Medicine and Health
      Science, University of Gondar, Gondar, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - New Zealand
TA  - Pediatric Health Med Ther
JT  - Pediatric health, medicine and therapeutics
JID - 101655856
PMC - PMC7751437
OTO - NOTNLM
OT  - anesthesia
OT  - anxiety
OT  - children
OT  - preoperative
OT  - surgery
COIS- The authors report no conflicts of interest for this work.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:04
PHST- 2020/10/27 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2020/12/28 12:04 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.2147/PHMT.S288077 [doi]
AID - 288077 [pii]
PST - epublish
SO  - Pediatric Health Med Ther. 2020 Dec 16;11:485-494. doi: 10.2147/PHMT.S288077.
      eCollection 2020.


PMID- 33364733
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210106
IS  - 1108-4189 (Print)
IS  - 1108-4189 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Jan-Mar
TI  - Translation and cultural adaptation of the Greek version of the confusion
      assessment method diagnostic algorithm and the nursing delirium screening scale
      and their inter-rater reliability: A prospective cohort study.
PG  - 8-14
AB  - AIM: The lack of standardized tools limits the diagnosis omicronf postoperative
      delirium (POD) in the Greek population. Our aim was the translation and the
      cultural adaptation of the confusion assessment method (CAM) diagnostic algorithm
      and the nursing delirium screening scale (nu-DESC) in the Greek surgical
      population, and the determination of their inter-rater reliability. METHODS:
      After Ethical approval and registration as a clinical trial (NCT04154176), a
      prospective cohort study was conducted in the Department of Anesthesiology,
      University Hospital of Larissa, Greece. Patients at least 60 years old,
      undergoing elective non-cardiac surgery, under general anesthesia were included. 
      RESULTS: Data from 60 patients, 180 records in total, were analyzed. There was an
      "almost perfect agreement" between the raters with the use of CAM (Cohen's Kappa 
      estimate: 0.960; 95 % CI: 0.905-1.000) and nu-DESC (Cohen's Kappa estimate:
      0.981; 95 % CI: 0.944-1.000). The agreement on each specific question of CAM and 
      nu-DESC ranged from "substantial" to "almost perfect agreement". Based on the
      CAM, the sensitivity and specificity of nu-DESC were 0.97 (95 % CI: 0.82-1.00)
      and 0.99 (95 % CI: 0.96-1.00), respectively. The Greek versions of CAM and
      nu-DESC showed a high inter-rater agreement. CONCLUSION: With the translation,
      the cultural adaptation, and the determination of their inter-rater agreement,
      the CAM diagnostic algorithm and the nu-DESC may serve as reliable instruments
      for the detection of POD in the Greek population. HIPPOKRATIA 2020, 24(1): 8-14.
CI  - Copyright 2020, Hippokratio General Hospital of Thessaloniki.
FAU - Ntalouka, M P
AU  - Ntalouka MP
AD  - Department of Anesthesiology, Faculty of Medicine, School of Health Sciences,
      University of Thessaly, Larissa, Greece.
FAU - Bareka, M
AU  - Bareka M
AD  - Department of Anesthesiology, Faculty of Medicine, School of Health Sciences,
      University of Thessaly, Larissa, Greece.
FAU - Brotis, A G
AU  - Brotis AG
AD  - Department of Neurosurgery, University Hospital of Larissa, Thessaly, Greece.
FAU - Chalkias, A
AU  - Chalkias A
AD  - Department of Anesthesiology, Faculty of Medicine, School of Health Sciences,
      University of Thessaly, Larissa, Greece.
FAU - Stamoulis, K
AU  - Stamoulis K
AD  - Department of Anesthesiology, Faculty of Medicine, School of Health Sciences,
      University of Thessaly, Larissa, Greece.
FAU - Flossos, A
AU  - Flossos A
AD  - Department of Anesthesiology, Faculty of Medicine, School of Health Sciences,
      University of Thessaly, Larissa, Greece.
FAU - Tzimas, P
AU  - Tzimas P
AD  - Department of Anesthesiology and Postoperative Intensive Care, Faculty of
      Medicine, School of Health Sciences, University of Ioannina, Epirus, Greece.
FAU - Arnaoutoglou, E
AU  - Arnaoutoglou E
AD  - Department of Anesthesiology, Faculty of Medicine, School of Health Sciences,
      University of Thessaly, Larissa, Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hippokratia
JT  - Hippokratia
JID - 101296613
PMC - PMC7733361
OTO - NOTNLM
OT  - *Delirium
OT  - *Greece
OT  - *anesthesia
OT  - *confusion assessment method
OT  - *diagnosis
OT  - *general
OT  - *humans
OT  - *neuropsychological tests
OT  - *nursing delirium screening scale
OT  - *reproducibility of results
COIS- Authors declare no conflict of interest and not receiving any specific grant from
      any funding agency in the public, commercial, or not-for-profit sectors.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:04
PHST- 2020/12/28 12:04 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 111540327 [pii]
PST - ppublish
SO  - Hippokratia. 2020 Jan-Mar;24(1):8-14.


PMID- 33364548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Developing an open educational resource for open research: Protocol for the PaPOR
      TRAIL project.
PG  - 84
LID - 10.12688/hrbopenres.13171.1 [doi]
AB  - Background: Open research involves actions at all stages of the research cycle to
      make the research process and outputs more transparent and accessible. Though a
      number of initiatives exist for researchers at PhD, post-doctoral and more senior
      levels, there remains a critical need for educational resources for research
      students at earlier career stages and across disciplines. The aim of the
      Principles and Practices of Open Research: Teaching, Research, Impact, and
      Learning (PaPOR TRaIL) project is to develop an open educational resource (OER)
      on the principles and practice of open research for undergraduate and master's
      students. Methods: In stage 1, interviews and surveys of students and supervisors
      are being conducted to explore students' and supervisors' knowledge, attitudes,
      and experiences of open research, in addition to needs and preferences for the
      content and delivery of the OER. Stage 2 involves development of the OER content 
      and delivery, based on Stage 1 engagement and national and international guidance
      on best practice in conducting and teaching open research. In Stage 3, students
      and supervisors will evaluate the developed OER and provide feedback in terms of 
      OER usability, learning experience and learning outcomes. This feedback will
      guide revisions and finalisation of the OER content, format and learning
      activities. Discussion: The PaPOR TRaIL project will develop an evidence-based
      OER that provides a foundation in all aspects of open research theory & practice.
      Teaching undergraduate and master's students open research will promote
      development of core research values and equip them with transferable competencies
      and skills, including how to conduct and use research in a trustworthy and
      ethical manner within and beyond academia. Enhancing teaching and learning of
      open research will promote better teaching and research outcomes that will
      benefit individuals, universities, and science more broadly.
CI  - Copyright: (c) 2020 Egan S et al.
FAU - Egan, Sophia
AU  - Egan S
AD  - School of Public Health, University College Cork, Cork, Ireland.
FAU - Tobin, Mary
AU  - Tobin M
AD  - School of Public Health, University College Cork, Cork, Ireland.
FAU - Palmer, Brendan
AU  - Palmer B
AD  - School of Public Health, University College Cork, Cork, Ireland.
AD  - Health Research Board Clinical Research Facility Cork, University College Cork,
      Cork, Ireland.
FAU - Coffey, Aoife
AU  - Coffey A
AUID- ORCID: https://orcid.org/0000-0001-5008-3711
AD  - UCC Library, University College Cork, Cork, Ireland.
FAU - Dahly, Darren
AU  - Dahly D
AD  - School of Public Health, University College Cork, Cork, Ireland.
AD  - Health Research Board Clinical Research Facility Cork, University College Cork,
      Cork, Ireland.
FAU - Houghton, Catherine
AU  - Houghton C
AUID- ORCID: https://orcid.org/0000-0003-3740-1564
AD  - School of Nursing and Midwifery, National University of Ireland, Galway, Galway, 
      Ireland.
FAU - O Carragain, Eoghan
AU  - O Carragain E
AD  - UCC Library, University College Cork, Cork, Ireland.
FAU - Toomey, Elaine
AU  - Toomey E
AUID- ORCID: https://orcid.org/0000-0001-5941-0838
AD  - School of Allied Health, University of Limerick, Limerick, Ireland.
FAU - Dockray, Samantha
AU  - Dockray S
AD  - School of Applied Psychology, University College Cork, Cork, Ireland.
FAU - Matvienko-Sikar, Karen
AU  - Matvienko-Sikar K
AUID- ORCID: https://orcid.org/0000-0003-2777-6581
AD  - School of Public Health, University College Cork, Cork, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7737705
OTO - NOTNLM
OT  - Open Educational Resource
OT  - Open Research
COIS- No competing interests were disclosed.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:03
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/12/28 12:03 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.12688/hrbopenres.13171.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Nov 12;3:84. doi: 10.12688/hrbopenres.13171.1. eCollection
      2020.


PMID- 33364366
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 2366-5017 (Electronic)
IS  - 2366-5017 (Linking)
VI  - 37
IP  - 7
DP  - 2020
TI  - Retrospective investigation of organization and examination results of the state 
      examination in restorative dentistry, endodontology and periodontology under
      simulated conditions in times of Covid-19 compared to standard conditions when
      treating patients.
PG  - Doc87
LID - 10.3205/zma001380 [doi]
AB  - Objective: Primary outcome of this retrospective study was the comparison of
      state examination results under simulated treatment conditions in times of
      Covid-19 versus patient treatment under non-pandemic conditions. Additionally,
      correlation analysis was performed between students' self- and examiners'
      assessment of the treatment results. Methods: Within 4 hours, 22 examinees each
      had to place a multi-surface adhesive anterior and posterior restoration,
      performed an endodontic treatment on a maxillary premolar and a periodontal
      debridement of one quadrant. All treatments were performed on a model fixed in a 
      phantom head. Compliance with the prescribed hygiene and social distancing
      guidelines and self-assessment of the practical performance was part of the
      practical examination as well. One examiner per examination part evaluated
      anonymously the final results. The historical control was based on the exam
      results of a cohort from 2019. Mean values (standard deviation), non-parametric
      correlations (Spearman's Rho) and group comparisons (Mann-Whitney) were
      calculated for statistical analysis. Results: Examination results under simulated
      treatment conditions were significantly worse (p<0.05) than in the cohort that
      took their state exam in patients, with exception of the endodontic partial exam.
      The overall scores in restorative dentistry and periodontology of both groups,
      which include a structured theoretical examination, did not differ. The majority 
      of the candidates rated their performance worse than the examiners, and there was
      no correlation between self- and third-party assessment. Conclusion: In the
      comparison of two years, a simulated practical examination without patients in
      restorative dentistry, endodontics and periodontology resulted in matchable
      results compared with an examination on patients. Equal conditions for the
      candidates resulting in better comparability and avoidance of ethical dilemmas of
      patient treatment under examination conditions could also be arguments towards a 
      state examination under phantom conditions in the future.
CI  - Copyright (c) 2020 Wicht et al.
FAU - Wicht, Michael J
AU  - Wicht MJ
AD  - Uniklinik Koln, Zentrum fur Zahn-, Mund und Kieferheilkunde, Poliklinik fur
      Zahnerhaltung und Parodontologie, Cologne, Germany.
FAU - Hofer, Karolin
AU  - Hofer K
AD  - Uniklinik Koln, Zentrum fur Zahn-, Mund und Kieferheilkunde, Poliklinik fur
      Zahnerhaltung und Parodontologie, Cologne, Germany.
FAU - Derman, Sonja H M
AU  - Derman SHM
AD  - Uniklinik Koln, Zentrum fur Zahn-, Mund und Kieferheilkunde, Poliklinik fur
      Zahnerhaltung und Parodontologie, Cologne, Germany.
FAU - Noack, M J
AU  - Noack MJ
AD  - Uniklinik Koln, Zentrum fur Zahn-, Mund und Kieferheilkunde, Poliklinik fur
      Zahnerhaltung und Parodontologie, Cologne, Germany.
FAU - Barbe, A Greta
AU  - Barbe AG
AD  - Uniklinik Koln, Zentrum fur Zahn-, Mund und Kieferheilkunde, Poliklinik fur
      Zahnerhaltung und Parodontologie, Cologne, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - Germany
TA  - GMS J Med Educ
JT  - GMS journal for medical education
JID - 101676086
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Dentists/education
MH  - Education, Dental/*organization & administration/standards
MH  - Education, Distance/*organization & administration/standards
MH  - Educational Measurement/standards/*statistics & numerical data
MH  - Endodontics/education
MH  - Humans
MH  - Models, Anatomic
MH  - Pandemics
MH  - SARS-CoV-2
MH  - Self-Assessment
MH  - Students, Dental
PMC - PMC7740043
OTO - NOTNLM
OT  - *Covid-19
OT  - *dentistry
OT  - *simulated treatment
OT  - *state examination
COIS- The authors declare that they have no competing interests.
EDAT- 2020/12/29 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/28 12:02
PHST- 2020/07/28 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/12/28 12:02 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.3205/zma001380 [doi]
AID - zma001380 [pii]
PST - epublish
SO  - GMS J Med Educ. 2020 Dec 3;37(7):Doc87. doi: 10.3205/zma001380. eCollection 2020.


PMID- 33364359
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 2366-5017 (Electronic)
IS  - 2366-5017 (Linking)
VI  - 37
IP  - 7
DP  - 2020
TI  - Can we adequately teach ethics and ethical decision making via distant learning? 
      A pandemic pilot.
PG  - Doc80
LID - 10.3205/zma001373 [doi]
AB  - The Corona virus pandemic rendered most live education this spring term
      impossible. Other formats and new ideas were needed to offer students the
      opportunity to learn unchanged learning content and outcomes. To replace our
      module on ethics and ethical decision making in emergency medicine with
      simulation patients we developed an e-learning module consisting of a case,
      trigger questions and literature for self-study. This was followed by a Microsoft
      Teams seminar in which the students discussed their questions in subgroups on the
      basis of their reading and developed a team product they then presented to the
      other team. Students valued this module as enabling a safe space for their
      beliefs and views. A vast majority deemed the topics as relevant, two thirds
      would retake the seminar. Despite a productive online discourse, this format
      should not be used as sole module under normal conditions since it lacks the
      (simulation) patient interaction but it can prove to be a valuable addendum to
      live teaching.
CI  - Copyright (c) 2020 Gintrowicz et al.
FAU - Gintrowicz, Robert
AU  - Gintrowicz R
AD  - Charite Universitatsmedizin Berlin, Prodekanat fur Studium und Lehre, Berlin,
      Germany.
FAU - Pawloy, Klemens
AU  - Pawloy K
AD  - Charite Universitatsmedizin Berlin, Prodekanat fur Studium und Lehre, Berlin,
      Germany.
FAU - Richter, Julius
AU  - Richter J
AD  - Charite Universitatsmedizin Berlin, Prodekanat fur Studium und Lehre, Berlin,
      Germany.
FAU - Degel, Antje
AU  - Degel A
AD  - Charite Universitatsmedizin Berlin, Prodekanat fur Studium und Lehre, Berlin,
      Germany.
AD  - Charite Universitatsmedizin Berlin, Med. Klinik fur Kardiologie, Campus Benjamin 
      Franklin, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - Germany
TA  - GMS J Med Educ
JT  - GMS journal for medical education
JID - 101676086
SB  - IM
MH  - *Decision Making/ethics
MH  - *Education, Distance/standards
MH  - Education, Medical/methods/standards
MH  - *Ethics
MH  - Humans
MH  - Pandemics
PMC - PMC7740007
OTO - NOTNLM
OT  - *corona virus
OT  - *distant learning
OT  - *emergency medicine
OT  - *ethical decision making
OT  - *ethics course
OT  - *pandemic
OT  - *undergraduate medical education
COIS- The authors declare that they have no competing interests.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/28 12:02
PHST- 2020/07/31 00:00 [received]
PHST- 2020/10/17 00:00 [revised]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/12/28 12:02 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.3205/zma001373 [doi]
AID - zma001373 [pii]
PST - epublish
SO  - GMS J Med Educ. 2020 Dec 3;37(7):Doc80. doi: 10.3205/zma001373. eCollection 2020.


PMID- 33364358
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 2366-5017 (Electronic)
IS  - 2366-5017 (Linking)
VI  - 37
IP  - 7
DP  - 2020
TI  - How to achieve quality assurance, shared ethics and efficient teambuilding?
      Lessons learned from interprofessional collaboration during the COVID-19
      pandemic.
PG  - Doc79
LID - 10.3205/zma001372 [doi]
AB  - Objective: Against the background of the current pandemic crisis, this case
      report presents the experiences made from interprofessional teamwork with group
      members from different medical qualification levels. Our objectives were to
      identify areas of shared knowledge regarding efficient collaboration; to improve 
      effective teamwork based on mutual respect; to develop innovative teaching
      methods tailored to the needs of COVID-19 interprofessional response teams.
      Methods: Field notes from numerous team discussions and improvised internal
      training sessions were compiled into a checklist. Each author edited and revised 
      the checklist and a consensus has been reached after an in-person discussion.
      Feedback from an academic expert in emergency services has been incorporated into
      the final version of the checklist. Results: Three main topics were identified:
      the need for quality-assured professional training, the clarification of role
      expectations including assigned responsibilities, opportunities to contribute and
      participate in the team building process, and the development of area-related
      ethical competence in the sense of shared moral public health literacy. Hence, we
      developed the following ad - hoc teaching methods: use of online teaching videos,
      practical exercises on intubation models and the collective development of an
      annotated, detailed checklist for all relevant work processes of the mobile
      corona unit based on everyday debriefings. Summary: The need for
      interprofessional team building in the context of the current health crisis
      provides a beneficial learning environment for all participants. We propose to
      conceptually refine this approach into a cross-professional, innovative method of
      teaching.
CI  - Copyright (c) 2020 Hunger et al.
FAU - Hunger, Jonathan
AU  - Hunger J
AD  - Maastricht University, Maastricht, The Netherlands.
FAU - Schumann, Heiko
AU  - Schumann H
AD  - Otto-von-Guericke- Universitat Magdeburg, Medizinische Fakultat, Bereich
      Arbeitsmedizin, Magdeburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - Germany
TA  - GMS J Med Educ
JT  - GMS journal for medical education
JID - 101676086
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Cooperative Behavior
MH  - Education, Medical/*organization & administration
MH  - Ethics, Medical/*education
MH  - Group Processes
MH  - Humans
MH  - Interprofessional Relations
MH  - Organizational Case Studies
MH  - Patient Care Team/*organization & administration
MH  - Physician's Role
MH  - Quality Assurance, Health Care/*organization & administration
MH  - SARS-CoV-2
PMC - PMC7740004
OTO - NOTNLM
OT  - *COVID-19
OT  - *interprofessional cooperation
OT  - *mobile corona unit
OT  - *pandemic
OT  - *public health ethics
OT  - *quality assurance
OT  - *training
COIS- The authors declare that they have no competing interests.
EDAT- 2020/12/29 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/28 12:02
PHST- 2020/08/08 00:00 [received]
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/12/28 12:02 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.3205/zma001372 [doi]
AID - zma001372 [pii]
PST - epublish
SO  - GMS J Med Educ. 2020 Dec 3;37(7):Doc79. doi: 10.3205/zma001372. eCollection 2020.


PMID- 33364323
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2352-8532 (Electronic)
IS  - 2352-8532 (Linking)
VI  - 12
DP  - 2020 Dec
TI  - Medication-assisted treatment vs. detoxification for women who misuse opioids in 
      pregnancy: Associations with dropout, relapse, neonatal opioid withdrawal
      syndrome (NOWS), and childhood sexual abuse.
PG  - 100315
LID - 10.1016/j.abrep.2020.100315 [doi]
AB  - The American College of Obstetricians and Gynecologists recommends
      medication-assisted treatment (MAT) for pregnant women who misuse opioids rather 
      than detoxification because of possible relapse and dropout from treatment (ACOG,
      2017). In a prospective study, fifty-five pregnant women with an opioid use
      disorder were offered a choice of MAT or detoxification. Ethical concerns
      precluded random assignment. We assessed dropout, treatment outcome, relapse,
      other illicit drug use, infant neonatal opioid withdrawal syndrome (NOWS), and
      childhood sexual abuse. Of 55 women, 13 initially chose MAT and 42 women chose
      detoxification. All women received behavioral support. No one dropped out of
      treatment prior to delivery. All women who chose MAT initially remained on MAT.
      Of women who chose detoxification, 23% switched to MAT, 30% tapered below initial
      MAT doses, and 45% fully detoxified by delivery. There was a significant
      difference in opioid relapse between women on MAT (26%) and those who detoxified 
      (0%), but no differences for other illicit drug use. Infants of women on MAT were
      more likely to have neonatal NOWS (91%) than infants of women who tapered below
      initial MAT doses but did not fully detoxify (62%). Infants of mothers who
      tapered (62%) were more likely to have NOWS than infants of women who fully
      detoxified (0%). Women on MAT reported significantly lower sexual abuse severity 
      than did women who tapered or detoxified. It is critical to replicate the current
      findings and to follow up with mothers and their infants postpartum to ascertain 
      the long-term impact of tapering or detoxification during pregnancy.
CI  - (c) 2020 The Authors.
FAU - Macfie, Jenny
AU  - Macfie J
AD  - Psychology Department, University of Tennessee Knoxville, Knoxville, TN
      37996-0900, United States.
FAU - Towers, Craig V
AU  - Towers CV
AD  - High Risk Obstetrical Consultants, Knoxville, TN, United States.
FAU - Fortner, Kimberly B
AU  - Fortner KB
AD  - Department of Obstetrics and Gynecology, University of Tennessee Medical Center, 
      Knoxville, TN, United States.
FAU - Stuart, Gregory L
AU  - Stuart GL
AD  - Psychology Department, University of Tennessee Knoxville, Knoxville, TN
      37996-0900, United States.
FAU - Zvara, Bharathi J
AU  - Zvara BJ
AD  - Gillings School of Global Public Health, University of North Carolina, United
      States.
FAU - Kurdziel-Adams, Gretchen
AU  - Kurdziel-Adams G
AD  - Cambridge Health Alliance, Harvard Medical School, Boston, MA, United States.
FAU - Kors, Stephanie B
AU  - Kors SB
AD  - Psychology Department, University of Tennessee Knoxville, Knoxville, TN
      37996-0900, United States.
FAU - Noose, Samantha K
AU  - Noose SK
AD  - Psychology Department, University of Tennessee Knoxville, Knoxville, TN
      37996-0900, United States.
FAU - Gorrondona, Andrea M
AU  - Gorrondona AM
AD  - Psychology Department, University of Tennessee Knoxville, Knoxville, TN
      37996-0900, United States.
FAU - Cohen, Chloe T
AU  - Cohen CT
AD  - Psychology Department, University of Tennessee Knoxville, Knoxville, TN
      37996-0900, United States.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - Netherlands
TA  - Addict Behav Rep
JT  - Addictive behaviors reports
JID - 101656077
PMC - PMC7752716
OTO - NOTNLM
OT  - Detoxification
OT  - Medication-assisted treatment
OT  - Opioid use
OT  - Pregnancy
OT  - Sexual abuse
COIS- The authors declared that there is no conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 12:02
PHST- 2020/06/30 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/12/28 12:02 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.1016/j.abrep.2020.100315 [doi]
AID - S2352-8532(20)30130-9 [pii]
PST - epublish
SO  - Addict Behav Rep. 2020 Nov 12;12:100315. doi: 10.1016/j.abrep.2020.100315.
      eCollection 2020 Dec.


PMID- 33363483
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable
      Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective 
      Observational Study (ARIDE).
PG  - 580863
LID - 10.3389/fpsyt.2020.580863 [doi]
AB  - Introduction: Once-weekly or once-monthly injectable depot buprenorphine is a new
      opioid substitution treatment (OST) medication that provides clinically relevant 
      plasma concentrations without daily peaks. Together with a high tolerability and 
      acceptance reported by patients, the prolonged release of injectable depot
      buprenorphine might have beneficial implications on the patients' quality of life
      and social participation. The primary objective of this prospective
      non-interventional observational study is to evaluate the effects of subcutaneous
      injectable depot buprenorphine on the quality of life of patients in routine OST 
      care in Germany. Secondary outcomes like illicit substance use, psychological
      distress, social participation and activity are assessed to provide an overall
      evaluation toward addiction recovery. Methods and Analysis: The present study is 
      a non-randomized prospective observational study with a control group
      (treatment-as-usual). To ensure comparability between both patient groups,
      suitable control patients (n = 213) from the same OST unit will be matched
      pairwise to each patient treated with injectable depot buprenorphine (n = 213).
      Matching variables are gender, duration of OST, take-home prescription and
      psychosocial functioning (according to the Global Assessment of Functioning
      scale). Primary study endpoint is the difference of change in quality of life,
      assessed with the recently developed Opioid Substitution Treatment Quality of
      Life scale (OSTQOL), within the depot buprenorphine group between baseline and
      month 12. The primary analysis will be carried out according to the
      intention-to-treat principle (ITT) by comparing OSTQOL mean scores using
      dependent t-tests. For secondary analyses, group comparisons will be done by
      mixed model approaches with baseline OSTQOL score and the (pairwise) cluster term
      as covariates. Discussion: The study combines clinical, routine OST care data
      with relevant patient reported outcome data. The pairwise matching allows
      conclusions on effects of different OST medications. The study findings will
      provide new insights in the addiction recovery processes of OST patients treated 
      with depot buprenorphine. Ethics and Dissemination: The study protocol has been
      approved by the Ethics Committee of the Hamburg Chamber of Physicians
      (Arztekammer Hamburg) (reference number: PV7078). The study results will be
      disseminated through peer-reviewed publications and presentations on scientific
      conferences. Clinical Trial Registration: German Clinical Trials Register
      DRKS-ID: DRKS00020797.
CI  - Copyright (c) 2020 Schulte, Lehmann, Schmidt, Ruhling, Weber, Schafer, Reimer and
      Verthein.
FAU - Schulte, Bernd
AU  - Schulte B
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
FAU - Lehmann, Kirsten
AU  - Lehmann K
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
FAU - Schmidt, Christiane Sybille
AU  - Schmidt CS
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
FAU - Ruhling, Elke
AU  - Ruhling E
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
FAU - Weber, Bernd
AU  - Weber B
AD  - Praxiszentrum Friedrichsplatz, Competence Center for Addiction Medicine, Kassel, 
      Germany.
FAU - Schafer, Ingo
AU  - Schafer I
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
FAU - Reimer, Jens
AU  - Reimer J
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
AD  - Gesundheit Nord, Bremen, Germany.
FAU - Verthein, Uwe
AU  - Verthein U
AD  - Department of Psychiatry, Centre for Interdisciplinary Addiction Research of
      Hamburg University (ZIS), University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7752950
OTO - NOTNLM
OT  - addiction recovery
OT  - injectable depot buprenorphine
OT  - opioid substitution treatment (OST)
OT  - quality of life
OT  - social participation
COIS- BS had received an unrestricted educational grant from Camurus. UV received
      speaker's honoraria and traveling expenses from Mundipharma and received
      traveling expenses from Camurus. JR had served as consultant for Camurus,
      Indivior, Mundipharma, Sanofi-Aventis, was member of the speakers bureau for
      Camurus, Hexal, Indivior, and received unrestricted educational grants from
      Mundipharma. The remaining authors declare that the research was conducted in the
      absence of any commercial or financial relationships that could be construed as a
      potential conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:59
PHST- 2020/07/07 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/12/28 11:59 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.3389/fpsyt.2020.580863 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Dec 8;11:580863. doi: 10.3389/fpsyt.2020.580863.
      eCollection 2020.


PMID- 33363426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1179-7258 (Print)
IS  - 1179-7258 (Linking)
VI  - 11
DP  - 2020
TI  - Knowledge and Attitudes Towards Abortion and Euthanasia Among Health Students in 
      Papua New Guinea.
PG  - 977-987
LID - 10.2147/AMEP.S281199 [doi]
AB  - PURPOSE: The purpose of this study was to explore knowledge and attitudes of
      health program students towards ethical issues pertaining to the beginning and
      the end of human life, and associations between these attitudes and demographic
      variables. PARTICIPANTS AND METHODS: The study took a mixed-method approach with 
      self-administered survey questionnaires and in-depth interviews. A total of 88
      students participated in the survey, and 10 students participated in interviews. 
      The study was conducted among students in the Health Extension Program at a
      Christian university in Papua New Guinea. RESULTS: Students showed a higher
      acceptance of abortion than euthanasia. More year-4 students presented
      significantly deeper knowledge of euthanasia and abortion compared to year-1
      students. There were no gender differences regarding knowledge and attitude
      towards these two bioethical issues. The majority of students opposed the idea of
      women's right to abortion, which is attributed mainly to socio-cultural reasons. 
      The qualitative analysis indicated a very strong perception that having children 
      'defines' womanhood and also revealed general disapproval of any form of
      euthanasia. A low level of acceptance of various forms of euthanasia is
      associated with a respect for older people in Melanesian society and beliefs that
      ancestors' support is required for achieving prosperity in life. CONCLUSION: The 
      study offered a comprehensive description and analysis of students' knowledge and
      attitudes towards ethical issues pertaining to the beginning and the end of human
      life. Presented a low level of knowledge towards bioethical issues, together with
      a small proportion of the knowledge gained from lectures and tutorials, indicated
      inadequate teaching of bioethics and calls for further improvement. In the
      perspective of rapid social and cultural changes in the Papua New Guinea society,
      further studies on changing attitudes towards bioethics issues would be valuable.
CI  - (c) 2020 Kolodziejczyk and Kuzma.
FAU - Kolodziejczyk, Iwona
AU  - Kolodziejczyk I
AUID- ORCID: 0000-0003-2401-7221
AD  - Centre for Learning and Teaching, Divine Word University, Madang, Papua New
      Guinea.
FAU - Kuzma, Jerzy
AU  - Kuzma J
AD  - Medical Department, Divine Word University, Madang, Papua New Guinea.
LA  - eng
PT  - Journal Article
DEP - 20201215
PL  - New Zealand
TA  - Adv Med Educ Pract
JT  - Advances in medical education and practice
JID - 101562700
PMC - PMC7753174
OTO - NOTNLM
OT  - abortion
OT  - bioethics education
OT  - developing country
OT  - euthanasia
OT  - health students
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:59
PHST- 2020/09/09 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/28 11:59 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.2147/AMEP.S281199 [doi]
AID - 281199 [pii]
PST - epublish
SO  - Adv Med Educ Pract. 2020 Dec 15;11:977-987. doi: 10.2147/AMEP.S281199.
      eCollection 2020.


PMID- 33363361
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1177-889X (Print)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study
      from Jordan.
PG  - 2451-2458
LID - 10.2147/PPA.S284385 [doi]
AB  - PURPOSE: The development and production of novel vaccine to prevent COVID-19 is
      an international imperative to human lives. For that purpose, clinical trials
      have to be carried out as per international ethical standards. The current study 
      was undertaken to examine the willingness to participate in COVID-19 vaccine
      clinical trials and to determine factors that might affect their decision to
      participate. PATIENTS AND METHODS: A cross-sectional survey study was carried out
      among the public in Jordan. During the study period, a convenience sample of
      adults (aged 18 years or above) were asked to participate via an online
      self-administered survey that was designed to evaluate the willingness to
      participate in COVID-19 vaccine clinical trials and to determine factors
      affecting their decision to participate. RESULTS: Results showed that, among
      participants (n=1,287), 36.1% reported to be willing to participate in clinical
      trials of the vaccine. Additionally, a lower percentage (18.1%) were willing to
      allow their children to participate. Motivators that encourage participation were
      the desire to return to normal life (73.2%), followed by the desire to help in
      finding a treatment for COVID-19 infection (68.1%). Barriers towards the
      participation were not wanting to be challenged by the virus (54.7%), fear
      (40.7%), lack of time (40.4%), and mistrust in pharmaceutical companies (38.9%). 
      Finally, results showed that higher educational level was associated with lower
      willingness to participate (P=0.001), whereas having a previous participation in 
      clinical studies is associated with a significantly higher willingness to
      participate in COVID-19 vaccine clinical trials (P<0.001). CONCLUSION: A good
      portion of Jordanians are positive regarding participation in clinical studies of
      COVID-19 vaccine. Educational level and previous participation in clinical
      studies were among the determinants of such willingness. In addition, fear and
      lack of time were among the barriers of participation.
CI  - (c) 2020 Abu-Farha et al.
FAU - Abu-Farha, Rana K
AU  - Abu-Farha RK
AUID- ORCID: 0000-0001-8298-4071
AD  - Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied
      Science Private University, Amman, Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AUID- ORCID: 0000-0002-2808-5099
AD  - Department of Clinical Pharmacy, Jordan University of Science and Technology,
      Irbid 22110, Jordan.
FAU - Khabour, Omar F
AU  - Khabour OF
AUID- ORCID: 0000-0002-3006-3104
AD  - Department of Medical Laboratory Sciences, Jordan University of Science and
      Technology, Irbid 22110, Jordan.
LA  - eng
GR  - R25 TW010026/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20201214
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7754261
OTO - NOTNLM
OT  - COVID-19
OT  - Jordan
OT  - clinical trials
OT  - participation
OT  - willingness
COIS- The authors report no conflicts of interest for this work.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:59
PHST- 2020/10/02 00:00 [received]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/28 11:59 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.2147/PPA.S284385 [doi]
AID - 284385 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2020 Dec 14;14:2451-2458. doi: 10.2147/PPA.S284385.
      eCollection 2020.


PMID- 33363321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 0972-8988 (Print)
IS  - 0972-8988 (Linking)
VI  - 13
IP  - 11
DP  - 2020 Nov
TI  - Genetic characterization and phylogenetic study of Indonesian cuscuses from
      Maluku and Papua Island based on 16S rRNA gene.
PG  - 2319-2325
LID - 10.14202/vetworld.2020.2319-2325 [doi]
AB  - BACKGROUND AND AIM: Indonesian cuscuses are now becoming scarce because of the
      reduction of habitat and poaching. Further, molecular characterization of
      Indonesian cuscuses is still very lacking. This study aimed to determine genetic 
      markers and phylogenetic relationships of Indonesian cuscuses based on 16S rRNA
      gene sequences. MATERIALS AND METHODS: This study used 21 cuscuses caught from
      two provinces and 16 islands: 13 from Maluku and eight from Papua. Cuscus samples
      were taken by biopsy following ethics guidelines for animals. The genome
      isolation was done using gSYNC DNA Mini Kit (Geneaid Biotech Ltd., Taiwan). The
      16S rRNA gene was amplified by primers (16SKUSAF and 16SKUSAR), and the
      polymerase chain reaction product obtained was 1875 base pair (bp). The analysis 
      of genetic characterization and the phylogenetic relationship was performed
      usingMEGA version X software (https://www.megasoftware.net/). RESULTS: 16S rRNA
      gene sequencing attained 1598 bp for all samples. Based on the 16S rRNA
      nucleotide sequences, cuscuses from Papua and Maluku belong to the genus
      Phalanger and Spilocuscus. Phalanger spp. and Spilocuscus spp. from Papua can be 
      distinguished from Phalanger and Spilocuscus from Maluku, except Spilocuscus from
      Ternate has a very close relationship with cuscus from Sentani, Papua.
      CONCLUSION: Indonesian cuscuses were derived into two clades based on 16S rRNA
      gene sequence, one group to genus Phalanger and another group to Spilocuscus.
CI  - Copyright: (c) Widayanti, et al.
FAU - Widayanti, Rini
AU  - Widayanti R
AD  - Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine,
      Universitas Gadjah Mada, Yogyakarta, Indonesia.
FAU - Pradana, Richo Apriladi Bagas
AU  - Pradana RAB
AD  - Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine,
      Universitas Gadjah Mada, Yogyakarta, Indonesia.
FAU - Kunda, Rony Marsyal
AU  - Kunda RM
AD  - Biology Study Program, Faculty of Mathematics and Natural Sciences, Universitas
      Pattimura, Ambon, Indonesia.
FAU - Pakpahan, Suhendra
AU  - Pakpahan S
AD  - Research Center for Biology, Indonesian Institute of Sciences (LIPI), Cibinong,
      West Java, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - India
TA  - Vet World
JT  - Veterinary world
JID - 101504872
PMC - PMC7750240
OTO - NOTNLM
OT  - Indonesian cuscuses
OT  - Maluku
OT  - Papua
OT  - Phalanger
OT  - Spilocuscus
OT  - phylogeny
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:59
PHST- 2020/06/04 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/12/28 11:59 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.14202/vetworld.2020.2319-2325 [doi]
AID - Vetworld-13-2319 [pii]
PST - ppublish
SO  - Vet World. 2020 Nov;13(11):2319-2325. doi: 10.14202/vetworld.2020.2319-2325. Epub
      2020 Nov 4.


PMID- 33363084
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - General Public Preferences for Allocating Scarce Medical Resources During
      COVID-19.
PG  - 587423
LID - 10.3389/fpubh.2020.587423 [doi]
AB  - COVID-19 has overwhelmed healthcare systems across the globe with an
      unprecedented surge in the demand for hospitalizations. Consequently, many
      hospitals are facing precarious conditions due to limited capacity, especially in
      the provision of ventilators. The governing ethical principles of medical
      practice delineated in (1) favor prioritizing younger patients, largely because
      of their relatively higher expected life years. We conduct a survey of the
      general public in the United States to elicit their preferences for the
      allocation of a limited number of ventilators. The results show that the general 
      public views align with the established ethical principles, which favor younger
      patients. JEL Classification: C91.
CI  - Copyright (c) 2020 Huseynov, Palma and Nayga.
FAU - Huseynov, Samir
AU  - Huseynov S
AD  - Texas A&M University, College Station, TX, United States.
FAU - Palma, Marco A
AU  - Palma MA
AD  - Texas A&M University, College Station, TX, United States.
FAU - Nayga, Rodolfo M Jr
AU  - Nayga RM Jr
AD  - University of Arkansas, Fayetteville, AR, United States.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Adult
MH  - *COVID-19
MH  - Female
MH  - Health Care Rationing/*ethics
MH  - *Hospitalization
MH  - Humans
MH  - Male
MH  - *Prognosis
MH  - Quality-Adjusted Life Years
MH  - *Resource Allocation
MH  - Triage/*ethics
MH  - United States
MH  - Ventilators, Mechanical/supply & distribution
PMC - PMC7759519
OTO - NOTNLM
OT  - *ethics
OT  - *principles
OT  - *scarce
OT  - *triage
OT  - *ventilators
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/12/28 11:57
PHST- 2020/07/26 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/28 11:57 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
AID - 10.3389/fpubh.2020.587423 [doi]
PST - epublish
SO  - Front Public Health. 2020 Dec 11;8:587423. doi: 10.3389/fpubh.2020.587423.
      eCollection 2020.


PMID- 33363065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Appendicitis in Children in a Large Italian COVID-19 Pandemic Area.
PG  - 600320
LID - 10.3389/fped.2020.600320 [doi]
AB  - Introduction: The coronavirus disease 2019 (COVID-19) pandemic has dramatically
      changed the routine activities of pediatric surgical centers, and it determined
      the reduction of admissions in the pediatric emergency departments (PED). We
      reviewed the records of patients affected by acute appendicitis (AA) during the
      COVID-19 pandemic period in a large Italian COVID-19 pandemic area. Methods: Data
      regarding demographics, age, macroscopic and microscopic findings, and time
      between symptom onset and PED admission of patients affected by confirmed AA in
      the period between March and April 2020 were considered. The data were compared
      with those obtained during the same period of 2019, 2018, and 2017 in the
      included centers. Data were quoted as median (range) or absolute number.
      Non-parametric statistical tests were used to compare groups. A p </= 0.05 was
      regarded as significant. Since only anonymous data have been used and the data
      storage meets current data protection regulations, ethical committee approval was
      not required for this study. Results: Eighty-six patients underwent surgical
      appendectomy for AA between February 20th, 2020 and April 20th, 2020; 32.5% were 
      complicated appendicitis and 67.5% were uncomplicated. Fifty-three patients were 
      males and 33 were females. Patients' age ranged from 3 to 17 years and the median
      age was 10 years. The median time between the onset of symptoms and the admission
      in PED was 1.85 days. The average time between the symptom onset and PED
      admission was 1.8 days. Conclusions: Although fear from the COVID-19 pandemic
      determined a delayed diagnosis of serious pediatric diseases, the increasing
      prevalence and severity of AA were not demonstrated in the most COVID-19-affected
      areas of Italy.
CI  - Copyright (c) 2020 La Pergola, Sgro, Rebosio, Vavassori, Fava, Codrich,
      Montanaro, Leva, Schleef, Cheli, Pelizzo, Gamba, Alberti and Betalli.
FAU - La Pergola, Enrico
AU  - La Pergola E
AD  - Paediatric Surgery Unit, Ospedale dei Bambini V. Buzzi, Milan, Italy.
FAU - Sgro, Alberto
AU  - Sgro A
AD  - Paediatric Surgery Unit, Department of Women's and Children's Health, University 
      of Padova, Padova, Italy.
FAU - Rebosio, Federico
AU  - Rebosio F
AD  - Paediatric Surgery Unit, Ospedale dei Bambini V. Buzzi, Milan, Italy.
AD  - Department of Paediatric Surgery, "Spedali Civili" Children's Hospital, Brescia, 
      Italy.
FAU - Vavassori, Daniele
AU  - Vavassori D
AD  - Department of Paediatric Surgery, Papa Giovanni XXIII, Bergamo, Italy.
FAU - Fava, Giorgio
AU  - Fava G
AD  - Department of Pediatric Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore
      Policlinico, Milan, Italy.
FAU - Codrich, Daniela
AU  - Codrich D
AD  - Department of Paediatric Surgery, Institute for Maternal and Child Health, IRCCS 
      Burlo Garofolo, Trieste, Italy.
FAU - Montanaro, Beatrice
AU  - Montanaro B
AD  - Department of Paediatric Surgery, "Spedali Civili" Children's Hospital, Brescia, 
      Italy.
FAU - Leva, Ernesto
AU  - Leva E
AD  - Department of Pediatric Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore
      Policlinico, Milan, Italy.
FAU - Schleef, Jurgen
AU  - Schleef J
AD  - Department of Paediatric Surgery, Institute for Maternal and Child Health, IRCCS 
      Burlo Garofolo, Trieste, Italy.
FAU - Cheli, M
AU  - Cheli M
AD  - Department of Paediatric Surgery, Papa Giovanni XXIII, Bergamo, Italy.
FAU - Pelizzo, Gloria
AU  - Pelizzo G
AD  - Paediatric Surgery Unit, Ospedale dei Bambini V. Buzzi, Milan, Italy.
FAU - Gamba, Piergiorgio
AU  - Gamba P
AD  - Paediatric Surgery Unit, Department of Women's and Children's Health, University 
      of Padova, Padova, Italy.
FAU - Alberti, Daniele
AU  - Alberti D
AD  - Department of Paediatric Surgery, "Spedali Civili" Children's Hospital, Brescia, 
      Italy.
FAU - Betalli, Pietro
AU  - Betalli P
AD  - Department of Paediatric Surgery, Papa Giovanni XXIII, Bergamo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7755995
OTO - NOTNLM
OT  - COVID-19
OT  - appendicitis
OT  - children
OT  - incidence of a disease
OT  - pediatric surgery
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:57
PHST- 2020/08/29 00:00 [received]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/12/28 11:57 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.3389/fped.2020.600320 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Dec 9;8:600320. doi: 10.3389/fped.2020.600320. eCollection
      2020.


PMID- 33362936
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2054-670X (Electronic)
IS  - 0033-2879 (Linking)
VI  - 60
IP  - 1
DP  - 2020 Dec 14
TI  - A Stakeholder Perspective on Ethical Leadership in Sport: Bridging the Gap
      Between the Normative and Descriptive Lines of Inquiry.
PG  - 381-395
LID - 10.5334/pb.543 [doi]
AB  - This critical PhD review paper examines existing scholarship on ethical
      leadership in sport. Following a general trend in business ethics and related
      fields, ethical leadership has gained considerable research attention in sport
      over the last decades. Within this growing body of literature, ethical leadership
      is often presented as part of the desired strategic response of sport
      organizations to tackle the so-called dark side of sport (i.e., formed by such
      ethical issues as abuse, violence, management fraud, match-fixing, and doping).
      However, this critical PhD review paper argues that the current body of
      literature on ethical leadership in sport has matured along two strongly related 
      yet quite isolated lines of inquiry: a normative (i.e., philosophical) and a
      descriptive (i.e., empirical) line. While the normative line of inquiry focuses
      on what ethical leadership in sport should look like based on moral reasoning,
      the descriptive line examines how ethical leadership in sport is perceived in
      practice and how it relates to certain antecedents and outcomes. As both lines
      offer complementary insights, we advocate future research to bridge this gap to
      come to an improved understanding of ethical leadership in sport. To this aim, we
      propose a broad stakeholder perspective on ethical leadership in sport, in which 
      necessary attention is given to how all involved stakeholders make sense of
      ethical leadership as a socially constructed and context-dependent phenomenon.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Constandt, Bram
AU  - Constandt B
AD  - Department of Movement and Sports Sciences, Ghent University, BE.
FAU - Heres, Leonie
AU  - Heres L
AD  - Utrecht University School of Governance, Utrecht University, NL.
FAU - Marlier, Mathieu
AU  - Marlier M
AD  - Department of International Sport Management, LUNEX University, LU.
FAU - Willem, Annick
AU  - Willem A
AD  - Department of Movement and Sports Sciences, Ghent University, BE.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - England
TA  - Psychol Belg
JT  - Psychologica Belgica
JID - 0067335
PMC - PMC7747760
OTO - NOTNLM
OT  - descriptive leadership
OT  - ethical leadership
OT  - normative leadership
OT  - sport ethics
OT  - sport integrity
OT  - stakeholder perspective
COIS- The authors have no competing interests to declare.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:57
PHST- 2020/12/28 11:57 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.5334/pb.543 [doi]
PST - epublish
SO  - Psychol Belg. 2020 Dec 14;60(1):381-395. doi: 10.5334/pb.543.


PMID- 33362850
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Reporting Genetic Findings to Individual Research Participants: Guidelines From
      the Swiss Personalized Health Network.
PG  - 585820
LID - 10.3389/fgene.2020.585820 [doi]
AB  - In 2017 the Swiss federal government established the Swiss Personalized Health
      Network (SPHN), a nationally coordinated data infrastructure for genetic
      research. The SPHN advisory group on Ethical, Legal, and Social Implications
      (ELSI) was tasked with the creation of a recommendation to ensure ethically
      responsible reporting of genetic research findings to research participants in
      SPHN-funded studies. Following consultations with expert stakeholders, including 
      geneticists, pediatricians, sociologists, university hospitals directors, patient
      representatives, consumer protection associations, and insurers, the ELSI
      advisory group issued its recommendation on "Reporting actionable genetic
      findings to research participants" in May 2020. In this paper we outline the
      development of this recommendation and the provisions it contains. In particular,
      we discuss some of its key features, namely: (1) that participation in
      SPHN-funded studies as a research subject is conditional to accepting that
      medically relevant genetic research findings will be reported; (2) that a
      Multidisciplinary Expert Panel (MEP) should be created to support researchers'
      decision-making processes about reporting individual genetic research findings;
      (3) that such Multidisciplinary Expert Panel will make case-by-case decisions
      about whether to allow reporting of genetic findings, instead of relying on a
      pre-defined list of medically relevant variants; (4) that research participants
      shall be informed of the need to disclose genetic mutations when applying for
      private insurance, which may influence individual decisions about participation
      in research. By providing an account of the procedural background and
      considerations leading to the SPHN recommendation on "Reporting actionable
      genetic findings to research participants," we seek to promote a better
      understanding of the proposed guidance, as well as to contribute to the global
      dialog on the reporting of genetic research findings.
CI  - Copyright (c) 2020 Blasimme, Brall and Vayena.
FAU - Blasimme, Alessandro
AU  - Blasimme A
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Zurich, Switzerland.
FAU - Brall, Caroline
AU  - Brall C
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Zurich, Switzerland.
AD  - Ethical, Legal, and Social Implications (ELSI) Advisory Group, Swiss Personalized
      Health Network (SPHN), Bern, Switzerland.
FAU - Vayena, Effy
AU  - Vayena E
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Zurich, Switzerland.
AD  - Ethical, Legal, and Social Implications (ELSI) Advisory Group, Swiss Personalized
      Health Network (SPHN), Bern, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7759560
OTO - NOTNLM
OT  - Switzerland
OT  - ethical recommendations
OT  - expert stakeholder consultation
OT  - genetic research findings
OT  - reporting
OT  - return of results
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:56
PHST- 2020/07/21 00:00 [received]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/28 11:56 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.3389/fgene.2020.585820 [doi]
PST - epublish
SO  - Front Genet. 2020 Dec 11;11:585820. doi: 10.3389/fgene.2020.585820. eCollection
      2020.


PMID- 33362708
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - Prevalence of Diabetes and Its Determinants in the Young Adults Indian
      Population-Call for Yoga Intervention.
PG  - 507064
LID - 10.3389/fendo.2020.507064 [doi]
AB  - Background: The young Indian population, which constitutes 65% of the country, is
      fast adapting to a new lifestyle, which was not known earlier. They are at a high
      risk of the increasing burden of diabetes and associated complications. The new
      evolving lifestyle is not only affecting people's health but also mounting the
      monetary burden on a developing country such as India. Aim: We aimed to collect
      information regarding the prevalence of risk of diabetes in young adults (<35
      years) in the 29 most populous states and union territories (7 zones) of India,
      using a validated questionnaire. Methods: A user-friendly questionnaire-based
      survey using a mobile application was conducted on all adults in the 29 most
      populous states/union territories of India, after obtaining ethical clearance for
      the study. Here, we report the estimation of the prevalence of the risk of
      diabetes and self-reported diabetes on 58,821 young individuals below the age of 
      35 years. Risk for diabetes was assessed using a standardized instrument, the
      Indian diabetes risk score (IDRS), that has 4 factors (age, family history of
      diabetes, waist circumference, and physical activity). Spearman's correlation
      coefficient was used to check the correlations. Results: The prevalence of high
      (IDRS score > 60), moderate (IDRS score 30-50), and low (IDRS < 30) diabetes risk
      in young adults (<35 years) was 10.2%, 33.1%, and 56.7%, respectively. Those with
      high-risk scores were highest (14.4%) in the Jammu zone and lowest (4.1%) in the 
      central zone. The prevalence of self-reported diabetes was 1.8% with a small
      difference between men (1.7%) and women (1.9%), and the highest (8.4%) in those
      with a parental history of diabetes. The south zone had the highest (2.5%), and
      the north west zone had the lowest (4.4%) prevalence. Conclusions: Indian youth
      are at high risk for diabetes, which calls for an urgent action plan through
      intensive efforts to promote lifestyle behavior modifications during the
      pandemics of both communicable and noncommunicable diseases.
CI  - Copyright (c) 2020 Nagarathna, Bali, Anand, Srivastava, Patil, Sharma, Manasa,
      Pannu, Singh and Nagendra.
FAU - Nagarathna, Raghuram
AU  - Nagarathna R
AD  - Vivekananda Yoga Anusandhana Samsthana, Bengaluru, India.
FAU - Bali, Parul
AU  - Bali P
AD  - Department of Biophysics, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Anand, Akshay
AU  - Anand A
AD  - Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of
      Medical Education and Research, Chandigarh, India.
FAU - Srivastava, Vinod
AU  - Srivastava V
AD  - College of Social Work, University of Kentucky, Lexington, KY, United States.
FAU - Patil, Suchitra
AU  - Patil S
AD  - Department of Yoga and Life Science, Swami Vivekananda Yoga Anusandhana
      Samsthana, Bengaluru, India.
FAU - Sharma, Guruprasad
AU  - Sharma G
AD  - Department of Yoga and Life Science, Swami Vivekananda Yoga Anusandhana
      Samsthana, Bengaluru, India.
FAU - Manasa, Krishna
AU  - Manasa K
AD  - Department of Yoga and Life Science, Swami Vivekananda Yoga Anusandhana
      Samsthana, Bengaluru, India.
FAU - Pannu, Viraaj
AU  - Pannu V
AD  - Government Medical College and Hospital Sector 32, Chandigarh, India.
FAU - Singh, Amit
AU  - Singh A
AD  - Department of Yoga and Life Science, Swami Vivekananda Yoga Anusandhana
      Samsthana, Bengaluru, India.
FAU - Nagendra, Hongasandra R
AU  - Nagendra HR
AD  - Department of Yoga and Life Science, Swami Vivekananda Yoga Anusandhana
      Samsthana, Bengaluru, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201211
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Adult
MH  - Diabetes Mellitus/*epidemiology/*prevention & control
MH  - Female
MH  - Humans
MH  - India/epidemiology
MH  - Life Style
MH  - Male
MH  - Prevalence
MH  - Risk Factors
MH  - Surveys and Questionnaires
MH  - *Yoga
MH  - Young Adult
PMC - PMC7759624
OTO - NOTNLM
OT  - *IDRs
OT  - *diabetes
OT  - *lifestyle - related disease
OT  - *prevalence
OT  - *young adult Indian population
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/12/28 11:56
PHST- 2019/10/24 00:00 [received]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/12/28 11:56 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
AID - 10.3389/fendo.2020.507064 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Dec 11;11:507064. doi:
      10.3389/fendo.2020.507064. eCollection 2020.


PMID- 33362662
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Can Psychodynamically Oriented Early Prevention for "Children-at-Risk" in Urban
      Areas With High Social Problem Density Strengthen Their Developmental Potential? 
      A Cluster Randomized Trial of Two Kindergarten-Based Prevention Programs.
PG  - 599477
LID - 10.3389/fpsyg.2020.599477 [doi]
AB  - Children who live on the margins of society are disadvantaged in achieving their 
      developmental potential because of the lack of a necessary stable environment and
      nurturing care. Many early prevention programs aim at mitigating such effects,
      but often the evaluation of their long-term effect is missing. The aim of the
      study presented here was to evaluate such long-term effects in two prevention
      programs for children-at-risk growing up in deprived social environments focusing
      on child attachment representation as the primary outcome as well as on
      self-reflective capacities of teachers taking care of these children. The latter 
      was a key component for promoting resilient behavior in children. Five hundred
      and twenty-six children aged 36 to 60 months at risk due to immigration status,
      low family socio-economic status and child behavior were examined in a
      cluster-randomized study comparing two preventions, the psychodynamic,
      attachment-based holistic approach EARLY STEPS (ES) with the classroom based
      FAUSTLOS (FA) for their efficacy. Primary outcome was the child attachment
      representation measured by the Manchester Child Attachment Story Task (MCAST).
      Secondary outcomes were derived from (a) the Caregiver-Teacher Report Form
      (C-TRF: problem behaviors, including anxiety/depressive symptoms,
      emotional-reactive and somatic problems, social withdrawal, aggressive behavior, 
      and attention deficit), from (b) the Strength and Difficulties Questionnaire
      (SDQ, parent version: resilience and wellbeing) and (c) Self-Reflective Scales
      for teachers (SRS: self-reflective capacities of teachers). Compared to baseline,
      attachment and behavioral problems improved in both programs. ES led to more
      secure and more organized attachment representations (medium effect sizes).
      Aggressive behavior and externalizing problems were reduced in the FA group
      compared with ES, particularly in boys (medium effect sizes). Self-reflective
      capacities of the teachers increased only in the ES group. High correlation
      between children's attachment type with the number of social risk factors and the
      increase of problematic social behavior strongly indicate that an increase in
      teachers' self-reflective capacities helps to change children's attachment
      patterns which thus strengthens the resilience of these children-at-risk [An
      ethical vote from LPPKJP 2009-02-25 was obtained and the trial registered;
      Clinical trial registration information: The trial was registered 14.02.2012
      (DRKS00003500; https://www.drks.de)].
CI  - Copyright (c) 2020 Fischmann, Asseburg, Green, Hug, Neubert, Wan and
      Leuzinger-Bohleber.
FAU - Fischmann, Tamara
AU  - Fischmann T
AD  - International Psychoanalytic University Berlin, Berlin, Germany.
AD  - Sigmund-Freud-Institut, Frankfurt am Main, Germany.
FAU - Asseburg, Lorena K
AU  - Asseburg LK
AD  - Sigmund-Freud-Institut, Frankfurt am Main, Germany.
FAU - Green, Jonathan
AU  - Green J
AD  - The University of Manchester, Manchester, United Kingdom.
FAU - Hug, Felicitas
AU  - Hug F
AD  - Sigmund-Freud-Institut, Frankfurt am Main, Germany.
FAU - Neubert, Verena
AU  - Neubert V
AD  - Sigmund-Freud-Institut, Frankfurt am Main, Germany.
FAU - Wan, Ming
AU  - Wan M
AD  - The University of Manchester, Manchester, United Kingdom.
FAU - Leuzinger-Bohleber, Marianne
AU  - Leuzinger-Bohleber M
AD  - Sigmund-Freud-Institut, Frankfurt am Main, Germany.
AD  - University Medicine Johannes-Gutenberg-University, Mainz, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7759147
OTO - NOTNLM
OT  - children at risk
OT  - object attachment
OT  - prevention program evaluation
OT  - randomized controlled trial
OT  - resilience
OT  - risk/protective factor
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:56
PHST- 2020/08/27 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/12/28 11:56 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.3389/fpsyg.2020.599477 [doi]
PST - epublish
SO  - Front Psychol. 2020 Dec 10;11:599477. doi: 10.3389/fpsyg.2020.599477. eCollection
      2020.


PMID- 33362514
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1662-6575 (Print)
IS  - 1662-6575 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Sep-Dec
TI  - Gender Dysphoria Disrupting the Course of Treatment of a Recurrent Juvenile
      Granulosa Cell Tumor in an Adolescent Female: A Case Report.
PG  - 1330-1336
LID - 10.1159/000510810 [doi]
AB  - We present the case of an adolescent female patient with gender dysphoria (GD)
      who was diagnosed with a recurrent ovarian neoplasm - juvenile granulosa cell
      tumor (JGCT). The 17-year-old female patient presented multiple endocrine
      pathologies and a recurrent JGCT. During the surgery qualification process, the
      patient admitted having identified herself as a male. The patient reported being 
      uncomfortable with her body and with the expected roles of her assigned gender.
      Due to that, the patient requested a total hysterectomy with a bilateral
      salpingo-oophorectomy. As a minor, she required the permission of her parents,
      which was not granted. The patient underwent several specialist consultations,
      after which she agreed to the unilateral removal of tumor-changed pathologies and
      additional hormonal, psychological, and psychiatric diagnostics. To the best of
      our knowledge, this is the first detailed report of co-occurrence of GD spectrum 
      disorders and JGCT in an adolescent female. This case contains many therapeutic
      and ethical problems regarding both physical and mental health. It should be
      noted that adolescents with GD spectrum rarely develop persistent transsexuality.
      Modulations from developmental psychology, psychotherapy, family dynamics,
      hormonal treatment, and the removal of JGCT in the presented case may have
      potential therapeutic implications for GD.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Kwiatkowska, Agnieszka
AU  - Kwiatkowska A
AD  - Ist Chair and Department of Gynaecologial Oncology and Gynaecology, Medical
      University of Lublin, Lublin, Poland.
FAU - Kulak, Krzysztof
AU  - Kulak K
AD  - Ist Chair and Department of Gynaecologial Oncology and Gynaecology, Medical
      University of Lublin, Lublin, Poland.
FAU - Wertel, Iwona
AU  - Wertel I
AD  - Independent Laboratory of Cancer Diagnostics and Immunology, Ist Chair and
      Department of Oncological Gynaecology and Gynaecology, Medical University of
      Lublin, Lublin, Poland.
LA  - eng
PT  - Case Reports
DEP - 20201110
PL  - Switzerland
TA  - Case Rep Oncol
JT  - Case reports in oncology
JID - 101517601
PMC - PMC7747049
OTO - NOTNLM
OT  - Ethical issues
OT  - Gender dysphoria
OT  - Juvenile granulosa cell tumor
OT  - Therapeutic difficulties
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:55
PHST- 2020/08/07 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/12/28 11:55 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.1159/000510810 [doi]
AID - cro-0013-1330 [pii]
PST - epublish
SO  - Case Rep Oncol. 2020 Nov 10;13(3):1330-1336. doi: 10.1159/000510810. eCollection 
      2020 Sep-Dec.


PMID- 33362347
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 0915-5287 (Print)
IS  - 0915-5287 (Linking)
VI  - 32
IP  - 12
DP  - 2020 Dec
TI  - An epidemic of new-born photography poses: the potential dangers of passive end
      range positioning during induced sleep in 0-14-day-old neonates: a scoping
      review.
PG  - 788-794
LID - 10.1589/jpts.32.788 [doi]
AB  - [Purpose] In the photography of new-borns, there is an epidemic trend in the
      posing of 0-14-day-old neonates that induces ethical and competence issues. The
      aim of this study is to map the key concepts underpinning the contraindications
      of this type of passive positioning of the new-borns. [Methods] During the search
      for literature, the following keywords were used in the PubMed database:
      neonates; new-born; neck position; hyperextension; rotation; atlanto-occipital
      joint; sudden infant death; prone sleeping position; white noise; and pain
      perception. [Results] The white noise applied has been described as a pain
      perception modulator and an alternative pain reducing method in new-born care.
      There is evidence warning of the potential danger of passively produced cervical 
      spine positions, considering the primary unstable atlanto-occipital joint during 
      early infancy, the possible compression on vertebral arteries, and the intradural
      diameter decreasing the effect of extension. These factors may have an impact on 
      healthy motor and cognitive development. [Conclusion] This perspective suggests
      that a wider debate should be called for concerning the role of medical
      professions to control this very dangerous practice, and that future cohort
      studies are necessary to monitor and follow up on the potential negative effects 
      of this current trend.
CI  - 2020(c)by the Society of Physical Therapy Science. Published by IPEC Inc.
FAU - Nagy, Edit
AU  - Nagy E
AD  - Department of Physiotherapy, University of Szeged, Faculty of Health and Social
      Sciences: Temesvari krt 31 Szeged Csongrad 6726, Hungary.
FAU - Finta, Regina
AU  - Finta R
AD  - Department of Physiotherapy, University of Szeged, Faculty of Health and Social
      Sciences: Temesvari krt 31 Szeged Csongrad 6726, Hungary.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201211
PL  - Japan
TA  - J Phys Ther Sci
JT  - Journal of physical therapy science
JID - 9105359
PMC - PMC7758610
OTO - NOTNLM
OT  - Induced sleep
OT  - Neonates
OT  - Passive position
COIS- Regina Finta owns the copyrights of the drawings. Edit Nagy is a hobby
      photographer and restored the pictures into digital format.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:54
PHST- 2019/12/07 00:00 [received]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/12/28 11:54 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.1589/jpts.32.788 [doi]
AID - 2019-246 [pii]
PST - ppublish
SO  - J Phys Ther Sci. 2020 Dec;32(12):788-794. doi: 10.1589/jpts.32.788. Epub 2020 Dec
      11.


PMID- 33362325
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220220
IS  - 0264-3758 (Print)
IS  - 0264-3758 (Linking)
VI  - 37
IP  - 4
DP  - 2020 Aug
TI  - No Blame No Gain? From a No Blame Culture to a Responsibility Culture in
      Medicine.
PG  - 646-660
LID - 10.1111/japp.12433 [doi]
AB  - Healthcare systems need to consider not only how to prevent error, but how to
      respond to errors when they occur. In the United Kingdom's National Health
      Service, one strand of this latter response is the 'No Blame Culture', which
      draws attention from individuals and towards systems in the process of
      understanding an error. Defences of the No Blame Culture typically fail to
      distinguish between blaming someone and holding them responsible. This article
      argues for a 'responsibility culture', where healthcare professionals are held
      responsible in cases of foreseeable and avoidable errors. We demonstrate how
      healthcare professionals can justifiably be held responsible for their errors
      even though they work in challenging circumstances. We then review the idea of
      'responsibility without blame', applying this to cases of error in healthcare.
      Sensitive to the undesirable effects of blaming healthcare professionals and to
      the moral significance of holding individuals accountable, we argue that a
      responsibility culture has significant advantages over a No Blame Culture due to 
      its capacity to enhance patient safety and support medical professionals in
      learning from their mistakes, while also recognising and validating the
      legitimate sense of responsibility that many medical professionals feel following
      avoidable error, and motivating medical professionals to report errors.
CI  - (c) 2020 The Authors. Journal of Applied Philosophy published by John Wiley &
      Sons Ltd on behalf of Society for Applied Philosophy.
FAU - Parker, Joshua
AU  - Parker J
AD  - Wythenshawe Hospital Southmoor Road Wythenshawe Manchester M23 9LT UK.
FAU - Davies, Ben
AU  - Davies B
AUID- ORCID: https://orcid.org/0000-0003-4612-7894
AD  - Uehiro Centre for Practical Ethics University of Oxford Littlegate House, St
      Ebbe's Street Oxford OX1 1PT UK.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200510
PL  - England
TA  - J Appl Philos
JT  - Journal of applied philosophy
JID - 100971946
PMC - PMC7750815
OTO - NOTNLM
OT  - Responsibility
OT  - blame
OT  - liability
OT  - medical ethics
OT  - professional ethics
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
CRDT- 2020/12/28 11:54
PHST- 2019/06/28 00:00 [received]
PHST- 2020/02/13 00:00 [revised]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/12/28 11:54 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
AID - 10.1111/japp.12433 [doi]
AID - JAPP12433 [pii]
PST - ppublish
SO  - J Appl Philos. 2020 Aug;37(4):646-660. doi: 10.1111/japp.12433. Epub 2020 May 10.


PMID- 33361756
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20220419
IS  - 0717-6384 (Electronic)
IS  - 0717-6384 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Dec 17
TI  - Mortality after hip or knee arthroplasty for osteoarthritis in Chile: A survival 
      analysis.
PG  - e8089
LID - 10.5867/medwave.2020.11.8088 [doi]
AB  - BACKGROUND: The purpose of this study is to determine if patients with
      osteoarthritis that undergo hip or knee arthroplasty jeopardize their life
      expectancy in Chile. METHODS: A survival analysis study was designed and approved
      by our institutional ethics review board. Patients were included if they
      underwent surgery for hip or knee osteoarthritis and were 50 years or older at
      the time of surgery. Patients were excluded if arthroplasty was performed for
      fracture, hemophilia arthropathy, or tumor. A multiparametric Weibull regression 
      was estimated, and the hazard ratio was reported. For internal validity, a
      bootstrap of 200 repetitions was performed. RESULTS: A total of 4 094
      arthroplasties were included. The Kaplan-Meier curve estimates a higher survival 
      than the general population up to 12 years, after which the median survival is
      less than the general population. The bootstrap multiparametric Weibull
      regression estimated a hazard ratio of 1.53 (95% confidence interval: 1.27 to
      1.84) for women, 1.09 (1.08 to 1.10) for every year older, and 1.29 (1.07 to
      1.53) for hip arthroplasty patients. CONCLUSION: Mortality after hip and knee
      arthroplasty in Chile follows a bimodal behavior similar to reports from the
      United States and Europe. At first, mortality is lower than the general
      population but worsens after 12 to 15 years of surgery.
FAU - Barahona, Maximiliano
AU  - Barahona M
AD  - Departamento de Ortopedia y Traumatologia en Hospital Clinico Universidad de
      Chile, Santiago, Chile. Adress: Santos Dumont 999, 3rd Floor, office 351, Postal 
      code 8380456, Independencia, Santiago, Chile. Email:
      maxbarahonavasquez@gmail.com. ORCID: 0000-0001-7878-8625.
FAU - Barrientos, Cristian
AU  - Barrientos C
AD  - Departamento de Ortopedia y Traumatologia en Hospital Clinico Universidad de
      Chile, Santiago, Chile; Departamento de Ortopedia y Traumatologia en Hospital San
      Jose, Santiago, Chile. ORCID: 0000-0001-9674-0553.
FAU - Martinez, Alvaro
AU  - Martinez A
AD  - Departamento de Ortopedia y Traumatologia en Hospital San Jose, Santiago, Chile. 
      ORCID: 0000-0002-8541-0839.
FAU - Branes, Julian
AU  - Branes J
AD  - Departamento de Ortopedia y Traumatologia en Hospital Clinico Universidad de
      Chile, Santiago, Chile; Departamento de Ortopedia y Traumatologia en Hospital San
      Jose, Santiago, Chile. ORCID: 0000-0003-3494-9778.
FAU - Prieto, Juan Pablo
AU  - Prieto JP
AD  - Departamento de Ortopedia y Traumatologia en Hospital Clinico Universidad de
      Chile, Santiago, Chile. ORCID: 0000-0003-4373-4939.
FAU - Hinzpeter, Jaime
AU  - Hinzpeter J
AD  - Departamento de Ortopedia y Traumatologia en Hospital Clinico Universidad de
      Chile, Santiago, Chile. ORCID: 0000-0003-1693-9808.
LA  - eng
PT  - Journal Article
TT  - Mortalidad de los pacientes intervenidos de artroplastia de rodilla y cadera en
      Chile: analisis de sobrevida.
DEP - 20201217
PL  - Chile
TA  - Medwave
JT  - Medwave
JID - 101581949
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Hip/*mortality
MH  - Arthroplasty, Replacement, Knee/*mortality
MH  - Chile/epidemiology
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Osteoarthritis, Hip/mortality/*surgery
MH  - Osteoarthritis, Knee/mortality/*surgery
MH  - Postoperative Complications
MH  - Survival Analysis
MH  - United States
OTO - NOTNLM
OT  - epidemiology
OT  - knee arthroplasty
OT  - osteoarthritis
OT  - survival analysis
OT  - hip arthroplasty
EDAT- 2020/12/29 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/12/28 11:45
PHST- 2020/07/11 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/12/28 11:45 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - e8089 [pii]
AID - 10.5867/medwave.2020.11.8088 [doi]
PST - epublish
SO  - Medwave. 2020 Dec 17;20(11):e8089. doi: 10.5867/medwave.2020.11.8088.


PMID- 33361396
OWN - NLM
STAT- Publisher
LR  - 20210112
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 23
TI  - Implementation of the EU clinical trial regulation transforms the ethics
      committee systems and endangers ethical standards.
LID - medethics-2020-106757 [pii]
LID - 10.1136/medethics-2020-106757 [doi]
AB  - The upcoming Regulation (EU) No 536/2014 on clinical trials on medicinal products
      for human use (Regulation), which will replace the current Clinical Trial
      Directive at the end of 2021, has triggered a significant reform of research
      ethics committee systems in Europe. Changes related to ethics review of clinical 
      trials in the EU were considered to be essential to create a more favourable
      environment to conduct clinical trials in the EU. The concern is, however, that
      the role of the research ethics committees will weaken in at least some of the
      Member States because the new Regulation allows narrowing down the scope of
      ethics review as compared with the currently valid Clinical Trial Directive.
      Although the new Regulation may lead to faster approval procedures for clinical
      trials, which is especially relevant in the context of pandemics, high-quality
      ethics reviews integrating methodological aspects of a clinical trial should
      nevertheless be ensured. To maintain high research ethics standards as well as to
      foster measures to mitigate potential negative consequences of the reform, it is 
      therefore of vital importance to start debating and sharing the reflections about
      the potential consequences of these transformations and trends as soon as
      possible.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Lukaseviciene, Vilma
AU  - Lukaseviciene V
AUID- ORCID: http://orcid.org/0000-0001-8277-7603
AD  - Centre for Health Ethics, Law and History, Vilnius University Faculty of
      Medicine, Vilnius, Lithuania vilma.lukaseviciene@gmail.com.
FAU - Hasford, Joerg
AU  - Hasford J
AUID- ORCID: http://orcid.org/0000-0002-9685-4769
AD  - Institut fur Med. Informationsverarbeitung, Biometrie und Epidemiologie, LMU
      Munchen, Munchen, Germany.
AD  - Association of Medical Ethics Committees in Germany, Berlin, Germany.
FAU - Lanzerath, Dirk
AU  - Lanzerath D
AD  - German Reference Centre for Ethics in the Life Sciences, University of Bonn,
      Bonn, Germany.
FAU - Gefenas, Eugenijus
AU  - Gefenas E
AD  - Centre for Health Ethics, Law and History, Vilnius University Faculty of
      Medicine, Vilnius, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical trials
OT  - research ethics
COIS- Competing interests: DL is Secretary General and Eugenijus Gefenas is a vice
      chair of the European Network of Research Ethics Committees (EUREC). EUREC serves
      as a platform for the exchange of information between European Ethics Committees.
      VL is employed at the Lithuanian Bioethics Committee and JH is a chairman of the 
      Arbeitskreis Medizinischer Ethik-Kommissionen in der Bundesrepublik Deutschland
      (Association of Medical Ethics Committees in Germany).
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/28 11:42
PHST- 2020/07/30 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/12/28 11:42 [entrez]
AID - medethics-2020-106757 [pii]
AID - 10.1136/medethics-2020-106757 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 23. pii: medethics-2020-106757. doi:
      10.1136/medethics-2020-106757.


PMID- 33361395
OWN - NLM
STAT- Publisher
LR  - 20210112
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 23
TI  - COVID-19 ventilator rationing protocols: why we need to know more about the views
      of those with most to lose.
LID - medethics-2020-106948 [pii]
LID - 10.1136/medethics-2020-106948 [doi]
AB  - Withholding or withdrawing life-saving ventilators can become necessary when
      resources are insufficient. With rising cases in many countries, and likely
      further peaks in the coming colder seasons, ventilator triage guidance remains a 
      central part of the COVID-19 policy response. The dominant model in ventilator
      triage guidelines prioritises the ethical principles of saving the most lives and
      saving the most life-years. We sought to ascertain to what extent this focus
      aligns, or conflicts, with the preferences of disadvantaged minority populations.
      We conducted a bibliographical search of PubMed and Google Scholar and reviewed
      all ventilator rationing guidelines included in major recent systematic reviews, 
      yielding 589 studies before screening. Post screening, we found six studies
      comprising a total of 10 591 participants, with 1247 from disadvantaged
      populations. Three studies reported findings stratified by race and age, two of
      which stratified by income. Studies included two to seven principles; all
      included 'save the most lives'. Involvement of disadvantaged minority populations
      in eliciting preferences is very limited; few studies capture race and income.
      This is concerning, as despite relatively small numbers and framing effects there
      is an observable and plausible trend suggesting that disadvantaged groups worry
      that dominant principles reduce their chances of receiving a ventilator. To avoid
      compounding prior historical and structural disadvantage, policy makers need to
      engage more fully with these populations in designing and justifying ventilator
      rationing guidance and review their adequacy. Likewise, clinicians need to be
      aware that their implementation of dominant triage guidelines is viewed with
      higher levels of concern by minority populations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kerr, Whitney
AU  - Kerr W
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA wjea@sas.upenn.edu.
FAU - Schmidt, Harald
AU  - Schmidt H
AUID- ORCID: http://orcid.org/0000-0003-4806-8816
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20201223
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - COVID-19
OT  - allocation of health care resources
OT  - distributive justice
OT  - ethics
OT  - resource allocation
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/28 11:42
PHST- 2020/09/26 00:00 [received]
PHST- 2020/11/22 00:00 [revised]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/12/28 11:42 [entrez]
AID - medethics-2020-106948 [pii]
AID - 10.1136/medethics-2020-106948 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 23. pii: medethics-2020-106948. doi:
      10.1136/medethics-2020-106948.


PMID- 33361170
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 23
TI  - Feasibility and acceptability of personalised breast cancer screening (DECIDO
      study): protocol of a single-arm proof-of-concept trial.
PG  - e044597
LID - 10.1136/bmjopen-2020-044597 [doi]
AB  - INTRODUCTION: Personalised cancer screening aims to improve benefits, reduce
      harms and being more cost-effective than age-based screening. The objective of
      the DECIDO study is to assess the acceptability and feasibility of offering
      risk-based personalised breast cancer screening and its integration in regular
      clinical practice in a National Health System setting. METHODS AND ANALYSIS: The 
      study is designed as a single-arm proof-of-concept trial. The study sample will
      include 385 women aged 40-50 years resident in a primary care health area in
      Spain. The study intervention consists of (1) a baseline visit; (2) breast cancer
      risk estimation; (3) a second visit for risk communication and screening
      recommendations based on breast cancer risk and (4) a follow-up to obtain the
      study outcomes.A polygenic risk score (PRS) will be constructed as a composite
      likelihood ratio of 83 single nucleotide polymorphisms. The Breast Cancer
      Surveillance Consortium risk model, including age, race/ethnicity, family history
      of breast cancer, benign breast disease and breast density will be used to
      estimate a preliminary 5-year absolute risk of breast cancer. A Bayesian approach
      will be used to update this risk with the PRS value.The primary outcome measures 
      will be attitude towards, intention to participate in and satisfaction with
      personalised breast cancer screening. Secondary outcomes will include the
      proportions of women who accept to participate and who complete the different
      phases of the study. The exact binomial and the Student's t-test will be used to 
      obtain 95% CIs. ETHICS AND DISSEMINATION: The study protocol was approved by the 
      Drug Research Ethics Committee of the University Hospital Arnau de Vilanova. The 
      trial will be conducted in compliance with this study protocol, the Declaration
      of Helsinki and Good Clinical Practice.The results will be published in
      peer-reviewed scientific journals and disseminated in scientific conferences and 
      media. TRIAL REGISTRATION NUMBER: NCT03791008.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pons-Rodriguez, Anna
AU  - Pons-Rodriguez A
AD  - Eixample Basic Health Area, Catalan Institute of Health, Lleida, Spain.
AD  - Health PhD Program, University of Lleida, Lleida, Spain.
FAU - Forne Izquierdo, Carles
AU  - Forne Izquierdo C
AUID- ORCID: 0000-0002-8133-3274
AD  - Basic Medical Sciences, University of Lleida, Lleida, Spain.
AD  - Research Group on Statistics and Economic Evaluation in Health (GRAEES),
      University of Lleida, Lleida, Spain.
FAU - Vilaplana-Mayoral, Jordi
AU  - Vilaplana-Mayoral J
AD  - Department of Computing and Industrial Engineering, University of Lleida, Lleida,
      Spain.
FAU - Cruz-Esteve, Ines
AU  - Cruz-Esteve I
AD  - Primer de Maig Basic Health Area, Catalan Institute of Health, Lleida, Spain.
FAU - Sanchez-Lopez, Isabel
AU  - Sanchez-Lopez I
AD  - Proteomics and Genomics Service, University of Lleida, Lleida, Spain.
FAU - Rene-Rene, Merce
AU  - Rene-Rene M
AD  - Radiology Department, Arnau de Vilanova University Hospital, Lleida, Spain.
FAU - Cazorla, Cristina
AU  - Cazorla C
AD  - Primer de Maig Basic Health Area, Catalan Institute of Health, Lleida, Spain.
FAU - Hernandez-Andreu, Marta
AU  - Hernandez-Andreu M
AD  - Primer de Maig Basic Health Area, Catalan Institute of Health, Lleida, Spain.
FAU - Galindo-Ortego, Gisela
AU  - Galindo-Ortego G
AD  - Primer de Maig Basic Health Area, Catalan Institute of Health, Lleida, Spain.
FAU - Llorens Gabande, Montserrat
AU  - Llorens Gabande M
AD  - Breast Cancer Screening Program, Catalan Institute of Health, Lleida, Spain.
FAU - Laza-Vasquez, Celmira
AU  - Laza-Vasquez C
AD  - Health PhD Program, University of Lleida, Lleida, Spain.
FAU - Balaguer-Llaquet, Pau
AU  - Balaguer-Llaquet P
AD  - IRBLleida, Lleida, Spain.
FAU - Martinez-Alonso, Montserrat
AU  - Martinez-Alonso M
AD  - Basic Medical Sciences, University of Lleida, Lleida, Spain.
AD  - Research Group on Statistics and Economic Evaluation in Health (GRAEES),
      University of Lleida, Lleida, Spain.
AD  - IRBLleida, Lleida, Spain.
FAU - Rue, Montserrat
AU  - Rue M
AUID- ORCID: 0000-0002-7862-9365
AD  - Basic Medical Sciences, University of Lleida, Lleida, Spain
      montserrat.rue@udl.cat.
AD  - Research Group on Statistics and Economic Evaluation in Health (GRAEES),
      University of Lleida, Lleida, Spain.
AD  - IRBLleida, Lleida, Spain.
CN  - DECIDO Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03791008
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201223
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Bayes Theorem
MH  - *Breast Neoplasms/diagnosis/genetics
MH  - *Early Detection of Cancer
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Spain
PMC - PMC7759966
OTO - NOTNLM
OT  - *breast tumours
OT  - *epidemiology
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
IR  - Balaguer-Llaquet P
FIR - Balaguer-Llaquet, Pau
IR  - Benitez ID
FIR - Benitez, Ivan-David
IR  - Bertran A
FIR - Bertran, Alexandra
IR  - Cardona A
FIR - Cardona, Angels
IR  - Carles-Lavila M
FIR - Carles-Lavila, Misericordia
IR  - Cazorla-Sanchez C
FIR - Cazorla-Sanchez, Cristina
IR  - Codern N
FIR - Codern, Nuria
IR  - Cruz-Esteve I
FIR - Cruz-Esteve, Ines
IR  - Forne-Izquierdo C
FIR - Forne-Izquierdo, Carles
IR  - Hernandez-Andreu MJ
FIR - Hernandez-Andreu, Maria Jose
IR  - Iglesias E
FIR - Iglesias, Edelmir
IR  - Galindo-Ortego G
FIR - Galindo-Ortego, Gisela
IR  - Hernandez M
FIR - Hernandez, Marta
IR  - Laza-Vasquez C
FIR - Laza-Vasquez, Celmira
IR  - Llorens-Gabande M
FIR - Llorens-Gabande, Montserrat
IR  - Martinez-Alonso M
FIR - Martinez-Alonso, Montserrat
IR  - Perez-Lacasta MJ
FIR - Perez-Lacasta, Maria Jose
IR  - Perpinan H
FIR - Perpinan, Hector
IR  - Pons-Rodriguez A
FIR - Pons-Rodriguez, Anna
IR  - Rue M
FIR - Rue, Montserrat
IR  - Sanchez-Lopez I
FIR - Sanchez-Lopez, Isabel
IR  - Vilaplana-Mayoral J
FIR - Vilaplana-Mayoral, Jordi
IR  - Rene-Rene M
FIR - Rene-Rene, Merce
EDAT- 2020/12/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-044597 [pii]
AID - 10.1136/bmjopen-2020-044597 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 23;10(12):e044597. doi: 10.1136/bmjopen-2020-044597.


PMID- 33361167
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210929
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 23
TI  - Prevalence of hospital-acquired infections (HAIs) and associated factors in
      Ethiopia: a systematic review and meta-analysis protocol.
PG  - e042111
LID - 10.1136/bmjopen-2020-042111 [doi]
AB  - INTRODUCTION: Hospital-acquired infections (HAIs) are public health problems of
      global concern and are notably prevalent in developing countries. The prevalence 
      of HAI and its associated factors are not well described in the context of
      Ethiopia. Currently, the nationwide prevalence of HAI and its corresponding
      associated factors have not been formally reported in Ethiopia. This review will 
      provide an estimate of the prevalence of HAI and its associated factors. METHODS:
      Scholarly articles will be selected from the Embase, PubMed, Cochrane library,
      Hinary, Scopus, Web of Science and Google Scholar databases. Articles within the 
      timeline of January 2000 to December 2020 will be included for review.
      Observational studies, randomised trials, surveys, surveillance reports,
      published and grey literature that reported the prevalence of HAI or factors
      associated with HAI reported as OR (95% CI) with no language restriction will be 
      included in the analysis. Screening and selection of articles will be done using 
      web-based Covidence software. The article's quality and risk of bias will be
      critically appraised using Johanna Briggs Institute quality appraisal checklist. 
      Random effects model using the inverse variance method will be conducted to
      estimate the prevalence of HAI. To examine heterogeneity, the Q statistics and
      I(2) statistics will be conducted. Publication bias will be investigated using
      Begg's correlation method and Egger's weighted regression test. All analyses will
      be performed with STATA (V.14) software. ETHICS AND DISSEMINATION: Ethical
      approval is not required for meta-analysis reviews as participants are not
      included. The review will be submitted for publication in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gebregiorgis, Birhan Gebresillassie
AU  - Gebregiorgis BG
AUID- ORCID: 0000-0002-6886-5145
AD  - Nursing, Debre Berhan University, Debre Berhan, Amhara, Ethiopia
      birhan1475@gmail.com.
FAU - Takele, Goitom Molalign
AU  - Takele GM
AD  - Nursing, Mekelle University, Mekelle, Tigray, Ethiopia.
FAU - Ayenew, Kassahun Dires
AU  - Ayenew KD
AD  - Pharmacy, Debre Berhan University, Debre Berhan, Amhara, Ethiopia.
FAU - Amare, Yosef Eshetie
AU  - Amare YE
AD  - Biomedical Science, Debre Berhan University, Debre Berhan, Amhara, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201223
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Databases, Factual
MH  - Ethiopia/epidemiology
MH  - *Hospitals
MH  - Humans
MH  - Prevalence
MH  - *Research Design
PMC - PMC7759952
OTO - NOTNLM
OT  - *EPIDEMIOLOGY
OT  - *HEALTH SERVICES ADMINISTRATION & MANAGEMENT
OT  - *INFECTIOUS DISEASES
OT  - *Infectious diseases & infestations
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-042111 [pii]
AID - 10.1136/bmjopen-2020-042111 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 23;10(12):e042111. doi: 10.1136/bmjopen-2020-042111.


PMID- 33361166
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 23
TI  - Combination of InnoSEAL plus TR band compared with TR band alone for radial
      artery outcomes in patients undergoing transradial coronary intervention
      (InnoSEAL-II): an open-label randomised controlled trial (protocol).
PG  - e042101
LID - 10.1136/bmjopen-2020-042101 [doi]
AB  - INTRODUCTION: About 2%-30% of cardiac catheterisation procedures get complicated 
      by radial artery occlusion (RAO). Ensuring patent haemostasis appears to be an
      important factor in reducing RAO. Currently employed method is a radial
      compression device (RCD) such as transradial band (TRB) that take hours to
      achieve haemostasis and cause discomfort to the patients. Haemostatic pads offer 
      an alternative to RCD with reduced time to achieve haemostasis. Our trial aims to
      determine the non-inferiority of the catecholamine chitosan-based pad (InnoSEAL
      haemostatic pad) used in conjunction with TRB (InnoSEAL +TRB) when compared with 
      the TRB alone in reducing composite adverse access site outcomes. METHODS AND
      ANALYSIS: It will be an open-label, parallel, randomised controlled trial on 714 
      adult patients (325 in each arm) undergoing coronary procedure using transradial 
      approach at a cardiac health facility over 7 months duration. InnoSEAL patch
      along with TRB will be used to control bleeding in intervention arm and TRB alone
      in control arm, which is the standard practice. Study primary outcomes include
      RAO and haematoma; secondary outcomes are compression time, patient discomfort,
      time to discharge and ease of use of the intervention technique by the healthcare
      staff. chi(2) test will be used to compare the categorical outcomes between two
      arms and student's t-test for continuous outcomes. A p value of <0.05 will be
      considered significant. ETHICS AND DISSEMINATION: Ethical approval for the study 
      has been obtained from the Institutional Review Board of Tabba Heart Institute
      number IORG0007863. Findings will be disseminated through seminars and scientific
      publications. TRIAL REGISTRATION NUMBER: NCT04380883; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aijaz, Saba
AU  - Aijaz S
AD  - Department of Cardiology, Tabba Heart Institute, Karachi, Sindh, Pakistan.
FAU - Sheikh, Sana
AU  - Sheikh S
AUID- ORCID: 0000-0001-7981-2957
AD  - Clinical Research Department, Tabba Heart Institute, Karachi, Sindh, Pakistan.
FAU - Pathan, Asad
AU  - Pathan A
AD  - Department of Cardiology, Tabba Heart Institute, Karachi, Sindh, Pakistan
      asadzpathan@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04380883
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201223
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Female
MH  - Heparin
MH  - Humans
MH  - Male
MH  - *Percutaneous Coronary Intervention
MH  - Prospective Studies
MH  - *Radial Artery/surgery
MH  - Treatment Outcome
PMC - PMC7759964
OTO - NOTNLM
OT  - *adult cardiology
OT  - *coronary heart disease
OT  - *coronary intervention
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-042101 [pii]
AID - 10.1136/bmjopen-2020-042101 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 23;10(12):e042101. doi: 10.1136/bmjopen-2020-042101.


PMID- 33361164
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 23
TI  - Implementation of C-reactive protein point of care testing to improve antibiotic 
      targeting in respiratory illness in Vietnamese primary care (ICAT): a study
      protocol for a cluster randomised controlled trial.
PG  - e040977
LID - 10.1136/bmjopen-2020-040977 [doi]
AB  - INTRODUCTION: C-reactive protein (CRP), a biomarker of infection, has been used
      widely in high-income settings to guide antibiotic treatment in patients
      presenting with respiratory illnesses in primary care. Recent trials in low- and 
      middle-income countries showed that CRP testing could safely reduce antibiotic
      use in patients with non-severe acute respiratory infections (ARIs) and fever in 
      primary care. The studies, however, were conducted in a research-oriented
      context, with research staff closely monitoring healthcare behaviour thus
      potentially influencing healthcare workers' prescribing practices. For
      policy-makers to consider wide-scale roll-out, a pragmatic implementation study
      of the impact of CRP point of care (POC) testing in routine care is needed.
      METHODS AND ANALYSIS: A pragmatic, cluster-randomised controlled trial, with two 
      study arms, consisting of 24 commune health centres (CHC) in the intervention arm
      (provision of CRP tests with additional healthcare worker guidance) and 24
      facilities acting as controls (routine care). Comparison between the treatment
      arms will be through logistic regression, with the treatment assignment as a
      fixed effect, and the CHC as a random effect. With 48 clusters, an average of 10 
      consultations per facility per week will result in approximately 520 over 1 year,
      and 24 960 in total (12 480 per arm). We will be able to detect a reduction of
      12% to 23% or more in immediate antibiotic prescription as a result of the CRP
      POC intervention. The primary endpoint is the proportion of patient consultations
      for ARI resulting in immediate antibiotic prescription. Secondary endpoints
      include the proportion of all patients receiving an antibiotic prescription
      regardless of ARI diagnosis, frequency of re-consultation, subsequent antibiotic 
      use when antibiotics are not prescribed, referral and hospitalisation. ETHICS AND
      DISSEMINATION: The study protocol was approved by the Oxford University Tropical 
      Research Ethics Committee (OxTREC, Reference: 53-18), and the ethical committee
      of the National Hospital for Tropical Diseases in Vietnam
      (Reference:07/HDDD-NDTW/2019). Results from this study will be disseminated via
      meetings with stakeholders, conferences and publications in peer-reviewed
      journals. Authorship and reporting of this work will follow international
      guidelines. TRIAL REGISTRATION DETAILS: NCT03855215; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Thi Thuy Do, Nga
AU  - Thi Thuy Do N
AUID- ORCID: 0000-0002-3435-1402
AD  - Oxford University Clinical Research Unit, Hanoi, Vietnam ngadtt@oucru.org.
FAU - Greer, Rachel Claire
AU  - Greer RC
AUID- ORCID: 0000-0001-9327-0234
AD  - Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Lubell, Yoel
AU  - Lubell Y
AD  - Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Dittrich, Sabine
AU  - Dittrich S
AUID- ORCID: 0000-0002-4522-2788
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
AD  - Malaria/Fever Program, Foundation for Innovative New Diagnostics (FIND), Geneva, 
      Switzerland.
FAU - Vandendorpe, Maida
AU  - Vandendorpe M
AD  - Malaria/Fever Program, Foundation for Innovative New Diagnostics (FIND), Geneva, 
      Switzerland.
FAU - Nguyen, Van Anh
AU  - Nguyen VA
AD  - Foundation for Innovative New Diagnostics (FIND), Hanoi, Vietnam.
FAU - Ngoc Thach, Pham
AU  - Ngoc Thach P
AD  - National Hospital of Tropical Diseases, Hanoi, Vietnam.
FAU - Thi Dieu Ngan, Ta
AU  - Thi Dieu Ngan T
AD  - National Hospital of Tropical Diseases, Hanoi, Vietnam.
FAU - Van Kinh, Nguyen
AU  - Van Kinh N
AD  - National Hospital of Tropical Diseases, Hanoi, Vietnam.
FAU - Hung Thai, Cao
AU  - Hung Thai C
AD  - Medical Services Administration, Ministry of Health, Hanoi, Vietnam.
FAU - Dung, Le Thi Kim
AU  - Dung LTK
AD  - Medical Services Administration, Ministry of Health, Hanoi, Vietnam.
FAU - Nguyen Thi Cam, Tu
AU  - Nguyen Thi Cam T
AD  - Oxford University Clinical Research Unit, Hanoi, Vietnam.
FAU - Nguyen, Thanh Ha
AU  - Nguyen TH
AD  - Oxford University Clinical Research Unit, Hanoi, Vietnam.
FAU - Nadjm, Behzad
AU  - Nadjm B
AD  - Oxford University Clinical Research Unit, Hanoi, Vietnam.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
AD  - University College London Hospitals NHS Foundation Trust, London, UK.
AD  - Clinical Services Department, MRC Unit The Gambia at The London School of
      Hygiene, Banjul, Gambia.
FAU - van Doorn, H Rogier
AU  - van Doorn HR
AD  - Oxford University Clinical Research Unit, Hanoi, Vietnam.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Lewycka, Sonia
AU  - Lewycka S
AUID- ORCID: 0000-0002-5923-9468
AD  - Oxford University Clinical Research Unit, Hanoi, Vietnam.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
AD  - University of Auckland, Auckland, New Zealand.
LA  - eng
SI  - ClinicalTrials.gov/NCT03855215
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201223
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Asians
MH  - C-Reactive Protein/analysis
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Middle Aged
MH  - Point-of-Care Testing
MH  - Pregnancy
MH  - Primary Health Care
MH  - *Respiratory Tract Infections/diagnosis/drug therapy
MH  - Vietnam
MH  - Young Adult
PMC - PMC7759760
OTO - NOTNLM
OT  - *infectious diseases
OT  - *public health
OT  - *respiratory infections
COIS- Competing interests: We declare no competing interests. Neither Medix Biochemica 
      nor any of its distributors, have had involvement with the funding or design of
      this study. The investigators have no financial connection to this or any other
      CRP test manufacturer or distributor.
EDAT- 2020/12/29 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040977 [pii]
AID - 10.1136/bmjopen-2020-040977 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 23;10(12):e040977. doi: 10.1136/bmjopen-2020-040977.


PMID- 33361163
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 23
TI  - Role of contextual and compositional characteristics of schools for health
      inequalities in childhood and adolescence: protocol for a scoping review.
PG  - e038999
LID - 10.1136/bmjopen-2020-038999 [doi]
AB  - INTRODUCTION: Childhood and adolescence are crucial life stages for health
      trajectories and the development of health inequalities in later life. The
      relevance of schools for health and well-being of children and adolescents has
      long been recognised, and there is some research regarding the association of
      contextual and compositional characteristics of schools and classes with health, 
      health behaviour and well-being in this population. Little is known about the
      role of meso-level characteristics in relation to health inequalities. The aim of
      this scoping review is to retrieve and synthesise evidence about the mediating or
      moderating role of compositional or contextual characteristics of schools for the
      association between students' socioeconomic position and health in primary and
      secondary education. METHODS AND ANALYSIS: We will conduct a systematic search of
      electronic databases in PubMed/Medline, Web of Science and Education Resources
      Information Center. Studies must meet the following inclusion criteria: (1) The
      population must be students attending primary or secondary schools in developed
      economies. (2) The outcomes must include at least one indicator for individual
      health, health behaviour or well-being. (3) The study must include at least one
      contextual or compositional characteristic of the school context and one
      individual determinant of socioeconomic position. (4) The study must also examine
      the mediating or moderating role of the contextual or compositional
      characteristic of the school context for the associations between socioeconomic
      position and health, health behaviour or well-being. (5) The study must be
      published since 1 January 2000 in English or German language. We will provide a
      narrative synthesis of findings. ETHICS AND DISSEMINATION: We will not collect
      primary data and only include secondary data derived from previously published
      studies. Therefore, ethical approval is not required. We intend to publish our
      findings in an international peer-reviewed journal and to present them at
      national and international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Herke, Max
AU  - Herke M
AUID- ORCID: 0000-0001-6425-4366
AD  - Institute of Medical Sociology, Medical Faculty, Martin-Luther-University
      Halle-Wittenberg, Halle (Saale), Germany max.herke@medizin.uni-halle.de.
FAU - Moor, Irene
AU  - Moor I
AUID- ORCID: 0000-0003-3245-5176
AD  - Institute of Medical Sociology, Medical Faculty, Martin-Luther-University
      Halle-Wittenberg, Halle (Saale), Germany.
FAU - Winter, Kristina
AU  - Winter K
AD  - Institute of Medical Sociology, Medical Faculty, Martin-Luther-University
      Halle-Wittenberg, Halle (Saale), Germany.
FAU - Hoffmann, Stephanie
AU  - Hoffmann S
AD  - Department of Public Health, Faculty for Social Work, Health, and Music,
      Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
FAU - Spallek, Jacob
AU  - Spallek J
AD  - Department of Public Health, Faculty for Social Work, Health, and Music,
      Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
FAU - Hilger-Kolb, Jennifer
AU  - Hilger-Kolb J
AUID- ORCID: 0000-0003-0347-1900
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Pischke, Claudia
AU  - Pischke C
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
FAU - Dragano, Nico
AU  - Dragano N
AUID- ORCID: 0000-0002-0378-0757
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
FAU - Novelli, Anna
AU  - Novelli A
AUID- ORCID: 0000-0002-4600-0183
AD  - Department of Health Services Management, Ludwig-Maximilians-University Munich,
      Munich, Germany.
FAU - Richter, Matthias
AU  - Richter M
AD  - Institute of Medical Sociology, Medical Faculty, Martin-Luther-University
      Halle-Wittenberg, Halle (Saale), Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201223
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Health Status Disparities
MH  - Humans
MH  - *Research Design
MH  - Review Literature as Topic
MH  - Schools
MH  - Students
PMC - PMC7759761
OTO - NOTNLM
OT  - *community child health
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038999 [pii]
AID - 10.1136/bmjopen-2020-038999 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 23;10(12):e038999. doi: 10.1136/bmjopen-2020-038999.


PMID- 33361162
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 23
TI  - Effects of multisession transcranial direct current stimulation as an
      augmentation to cognitive tasks in patients with neurocognitive disorders in
      Japan: a study protocol for a randomised controlled trial.
PG  - e037654
LID - 10.1136/bmjopen-2020-037654 [doi]
AB  - INTRODUCTION: Transcranial direct current stimulation (tDCS) is a potentially
      novel strategy for cognitive enhancement in patients with disorders. We present a
      study protocol for a randomised controlled trial designed to evaluate the safety 
      and efficacy of tDCS combined with cognitive tasks on cognition in such patients.
      METHOD AND ANALYSIS: This is a two-arm, parallel-design, randomised,
      sham-controlled trial, in which participants and raters will be blinded at a
      single centre. Stratified randomisation will be conducted, and a randomisation
      sequence will be generated through the Electronic Data Capture system. Patients
      who met the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for 
      neurocognitive disorders will be recruited and randomised to receive either
      active (2 mA for 20 min) or sham (stimulation ramped up and down for 1 min)
      stimulation in 10 sessions over five consecutive days. A direct current will be
      transferred by a 35 cm(2) saline-soaked sponge electrode. An anode will be placed
      over the left dorsolateral prefrontal cortex, and a cathode will be placed over
      the right supraorbital cortex. Calculation tasks will be conducted in both arms
      as a cognitive task for 20 min during the stimulation. This task consists of
      basic arithmetic questions, such as single-digit addition, subtraction,
      multiplication and division. The primary outcome will be the mean change in the
      Alzheimer Disease Assessment Scale-cognition at Day 5 after baseline. Depressive 
      symptoms, as measured by the geriatric depression scale, and quality of life, as 
      measured by the Medical Outcomes Study 36-item Short-Form Health Survey, will
      also be assessed. Data will be collected at baseline, within 3 days following the
      final stimulation and 1 month thereafter. The estimated sample size is 46 per
      group based on the assumptions that an estimated mean difference is -1.61 and SD 
      is 2.7. Mixed models for repeated measures will be used for the statistical
      analysis. ETHICS AND DISSEMINATION: The National Center of Neurology and the
      Psychiatry Clinical Research Review Board (CRB3180006) approved this study. The
      results of this study will be published in a scientific peer-reviewed journal.
      TRIAL REGISTRATION DETAILS: Japan Registry of Clinical Trials jRCTs032180016.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Inagawa, Takuma
AU  - Inagawa T
AUID- ORCID: 0000-0001-6147-5008
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan tinagawa@ncnp.go.jp.
FAU - Yokoi, Yuma
AU  - Yokoi Y
AUID- ORCID: 0000-0002-4405-8322
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Yamada, Yuji
AU  - Yamada Y
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Miyagawa, Nozomi
AU  - Miyagawa N
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Otsuka, Takeshi
AU  - Otsuka T
AD  - Department of Behavioral Medicine, National Center of Neurology and Psychiatry,
      Kodaira, Tokyo, Japan.
FAU - Yasuma, Naonori
AU  - Yasuma N
AUID- ORCID: 0000-0002-1216-7639
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Bunkyo-ku, Japan.
FAU - Omachi, Yoshie
AU  - Omachi Y
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Tsukamoto, Tadashi
AU  - Tsukamoto T
AD  - Department of Neurology, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Takano, Harumasa
AU  - Takano H
AD  - Department of Clinical Neuroimaging, Integrative Brain Imaging Center, National
      Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Sakata, Masuhiro
AU  - Sakata M
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Maruo, Kazushi
AU  - Maruo K
AD  - Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba,
      Ibaraki, Japan.
FAU - Matsui, Mie
AU  - Matsui M
AD  - Clinical Cognitive Neuroscience, Kanazawa University Graduate School of Medical
      Sciences, Kanazawa, Ishikawa, Japan.
FAU - Nakagome, Kazuyuki
AU  - Nakagome K
AD  - Department of Psychiatry, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201223
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Cognition
MH  - Double-Blind Method
MH  - Humans
MH  - Japan
MH  - Neurocognitive Disorders
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Transcranial Direct Current Stimulation
MH  - Treatment Outcome
PMC - PMC7759995
OTO - NOTNLM
OT  - *dementia
OT  - *neurophysiology
OT  - *old age psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037654 [pii]
AID - 10.1136/bmjopen-2020-037654 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 23;10(12):e037654. doi: 10.1136/bmjopen-2020-037654.


PMID- 33361082
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 24
TI  - Glenoid failure after total shoulder arthroplasty with cemented all-polyethylene 
      versus metal-backed implants: a systematic review protocol.
PG  - e043449
LID - 10.1136/bmjopen-2020-043449 [doi]
AB  - INTRODUCTION: Anatomical total shoulder arthroplasty (TSA) is an effective
      treatment adopted for patients with glenohumeral osteoarthritis (OA). The glenoid
      component failure is the main risk that occurs in this therapeutic choice;
      however, doubts remain regarding the selection of the best implant for avoiding
      complication. This systematic review aims to evaluate the glenoid component in
      TSA by comparing the complications of different types of implants. METHODS AND
      ANALYSIS: A systematic review of randomised clinical trials or quasi-randomised
      trials will be performed by applying the Preferred Reporting Items for Systematic
      Review and Meta-Analysis protocols and comparing polyethylene (keeled and pegged)
      versus metal-backed implants in adult patients with glenohumeral OA. Our search
      strategy will be performed using MEDLINE, PubMed, Cochrane Central Register of
      Controlled Trials, EMBASE and Web of Science. Data management and extraction will
      be performed using a data withdrawal form and by analysing study method
      characteristics, participant characteristics, intervention characteristics,
      results and methodological domains. The database search will be performed by
      February 2021. The Grading of Recommendations Assessment, Development and
      Evaluation will be used for assessing the quality of evidence of each study
      selected; however, some critical and important outcomes were determined such as
      the shoulder function through functional scores (Constant-Murley and American
      Shoulder and Elbow Surgeons), complications represented by pain (Visual Analogue 
      Scale), surgical revision, radiograph radiolucency and loosening. The confidence 
      in estimated effects for these outcomes will be applied as the overall
      confidence. The outcomes will be defined as early or late, according to the
      postoperative follow-up of less than or greater than 1 year, respectively, for
      complications and radiographs. For the shoulder function, follow-ups will be
      divided into 6, 12 and 24 months. Heterogeneity is expected in systematic
      reviews; therefore, the selection of outcomes, as well as the sample size, and
      specific statistical analysis can lead to meta-analysis; however, if it fails,
      narrative evidence synthesis will be conducted. Other analyses such as
      descriptive, subgroup and sensitivity analyses will be performed whenever
      possible. This systematic review will, therefore, provide evidence concerning the
      best clinical practice for avoiding complications. ETHICS AND DISSEMINATION: This
      study has been approved by the Institutional Review Board of Universidade Federal
      de Sao Paulo (protocols 0725/2017, 2.157.415 and 70473017.5.0000.5505), and the
      findings will be disseminated through peer-reviewed publication and conference
      presentations. PROSPERO REGISTRATION NUMBER: CRD42018079537.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zan, Renato Aroca Aroca
AU  - Zan RAA
AUID- ORCID: 0000-0001-9289-7983
AD  - Orthopedics and Traumatology-Division of Hand surgery and Upper Limb,
      Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
      re_zan@hotmail.com.
FAU - Lazarini, Rafael Fuchs
AU  - Lazarini RF
AD  - Department of Orthopaedics and Traumatology, Hospital Felicio Rocho, Belo
      Horizonte, Minas Gerais, Brazil.
FAU - Matsunaga, Fabio Teruo
AU  - Matsunaga FT
AD  - Orthopedics and Traumatology-Division of Hand surgery and Upper Limb,
      Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
FAU - Netto, Nicola Archetti
AU  - Netto NA
AD  - Orthopedics and Traumatology-Division of Hand surgery and Upper Limb,
      Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
FAU - Belloti, Joao Carlos
AU  - Belloti JC
AD  - Orthopedics and Traumatology-Division of Hand surgery and Upper Limb,
      Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
AD  - Universidade Federal de Sao Paulo Escola Paulista de Medicina, Sao Paulo, Brazil.
FAU - Tamaoki, Marcel Jun Sugawara
AU  - Tamaoki MJS
AD  - Orthopedics and Traumatology-Division of Hand surgery and Upper Limb,
      Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20201224
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9002-88-4 (Polyethylene)
SB  - IM
MH  - Adult
MH  - *Arthroplasty, Replacement/adverse effects
MH  - *Arthroplasty, Replacement, Shoulder/adverse effects
MH  - Brazil
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Polyethylene
MH  - Prosthesis Design
MH  - *Shoulder Joint/surgery
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7768953
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *elbow & shoulder
OT  - *radiology & imaging
OT  - *shoulder
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043449 [pii]
AID - 10.1136/bmjopen-2020-043449 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 24;10(12):e043449. doi: 10.1136/bmjopen-2020-043449.


PMID- 33361080
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 24
TI  - Global impact of tobacco control policies on smokeless tobacco use: a systematic 
      review protocol.
PG  - e042860
LID - 10.1136/bmjopen-2020-042860 [doi]
AB  - INTRODUCTION: Smokeless tobacco (ST) was consumed by 356 million people globally 
      in 2017. Recent evidence shows that ST consumption is responsible for an
      estimated 652 494 all-cause deaths across the globe annually. The WHO Framework
      Convention on Tobacco Control (FCTC) was negotiated in 2003 and ratified in 2005 
      to implement effective tobacco control measures. While the policy measures
      enacted through various tobacco control laws have been effective in reducing the 
      incidence and prevalence of smoking, the impact of ST-related policies (within
      WHO FCTC and beyond) on ST use is under-researched and not collated. METHODS AND 
      ANALYSIS: A systematic review will be conducted to collate all available
      ST-related policies implemented across various countries and assess their impact 
      on ST use. The following databases will be searched: Medline, EMBASE, PsycINFO,
      Cumulative Index to Nursing and Allied Health Literature, Scopus, EconLit, ISI
      Web of Science, Cochrane Library (CENTRAL), African Index Medicus, LILACS,
      Scientific Electronic Library Online, Index Medicus for the Eastern Mediterranean
      Region, Index Medicus for South-East Asia Region, Western Pacific Region Index
      Medicus and WHO Library Database, as well as Google search engine and
      country-specific government websites. All ST-related policy documents (FCTC and
      non-FCTC) will be included. Results will be limited to literature published since
      2005 in English and regional languages (Bengali, Hindi and Urdu). Two reviewers
      will independently employ two-stage screening to determine inclusion. The
      Effective Public Health Practice Project's 'Quality Assessment Tool for
      Quantitative Studies' will be used to record ratings of quality and risk of bias 
      among studies selected for inclusion. Data will be extracted using a standardised
      form. Meta-analysis and narrative synthesis will be used. ETHICS AND
      DISSEMINATION: Permission for ethics exemption of the review was obtained from
      the Centre for Chronic Disease Control's Institutional Ethics Committee, India
      (CCDC_IEC_06_2020; dated 16 April 2020). The results will be disseminated through
      publications in a peer-reviewed journal and will be presented in national and
      international conferences. PROSPERO REGISTRATION NUMBER: CRD42020191946.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Arora, Monika
AU  - Arora M
AUID- ORCID: 0000-0001-9987-3933
AD  - HRIDAY, New Delhi, India.
AD  - Health Promotion Division, Public Health Foundation of India, Gurugram, Haryana, 
      India.
FAU - Chugh, Aastha
AU  - Chugh A
AUID- ORCID: 0000-0002-6669-3394
AD  - HRIDAY, New Delhi, India.
FAU - Jain, Neha
AU  - Jain N
AUID- ORCID: 0000-0002-5449-5980
AD  - Health Promotion Division, Public Health Foundation of India, Gurugram, Haryana, 
      India.
FAU - Mishu, Masuma
AU  - Mishu M
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Boeckmann, Melanie
AU  - Boeckmann M
AUID- ORCID: 0000-0001-5909-5508
AD  - School of Public Health, Bielefeld University, Bielefeld, Germany
      boeckmannmelanie@gmail.com.
FAU - Dahanayake, Suranji
AU  - Dahanayake S
AD  - Department of Health Sciences, University of York, York, UK.
AD  - Ministry of Health, Nutrition and Indigenous Medicine, Colombo, Sri Lanka.
FAU - Eckhardt, Jappe
AU  - Eckhardt J
AD  - Department of Politics, University of York, York, UK.
FAU - Forberger, Sarah
AU  - Forberger S
AUID- ORCID: 0000-0002-7169-675X
AD  - Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany.
FAU - Huque, Rumana
AU  - Huque R
AD  - University of Dhaka, Dhaka, Bangladesh.
FAU - Kanaan, Mona
AU  - Kanaan M
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Khan, Zohaib
AU  - Khan Z
AUID- ORCID: 0000-0002-1885-8254
AD  - Khyber Medical University, Peshawar, Pakistan.
FAU - Mehrotra, Ravi
AU  - Mehrotra R
AD  - Indian Council of Medical Research, India Cancer Research Consortium, New Delhi, 
      India.
FAU - Rahman, Muhammad Aziz
AU  - Rahman MA
AD  - School of Health, Federation University Australia, Berwick, Victoria, Australia.
AD  - La Trobe University, Melbourne, Victoria, Australia.
FAU - Readshaw, Anne
AU  - Readshaw A
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Sheikh, Aziz
AU  - Sheikh A
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK.
FAU - Siddiqi, Kamran
AU  - Siddiqi K
AUID- ORCID: 0000-0003-1529-7778
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Vidyasagaran, Aishwarya
AU  - Vidyasagaran A
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Dogar, Omara
AU  - Dogar O
AD  - Department of Health Sciences, University of York, York, UK.
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201224
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - Humans
MH  - India
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
MH  - Tobacco
MH  - Tobacco Use
MH  - *Tobacco, Smokeless
PMC - PMC7768955
OTO - NOTNLM
OT  - *health policy
OT  - *international health services
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042860 [pii]
AID - 10.1136/bmjopen-2020-042860 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 24;10(12):e042860. doi: 10.1136/bmjopen-2020-042860.


PMID- 33361078
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210112
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 24
TI  - Clinico-epidemiological characteristics of Kawasaki-like disease in paediatric
      patients with COVID-19: a protocol for rapid living systematic review.
PG  - e041160
LID - 10.1136/bmjopen-2020-041160 [doi]
AB  - INTRODUCTION: The COVID-19 outbreak has posed a major challenge to healthcare
      providers. Due to its communicable nature, very stringent public health
      interventions have been put in place worldwide; yet, it still poses new emerging 
      challenges, one of the most recent being a multisystem inflammatory condition
      with clinical features resembling Kawasaki-like disease and toxic shock syndrome 
      in children and adolescents. The data on this novel condition are scarce which
      need to be reported to identify its clinico-epidemiological and geographical
      distribution. There is an urgent need to generate evidence for diagnosis and
      management of this condition in the midst of a pandemic. METHODS AND ANALYSIS:
      This systematic review will be conducted using Medline database searched through 
      PubMed, Embase, Ovid; and Google Scholar, ProQuest and EBSCO databases will also 
      be searched along with grey literature with the aim to identify the clinical
      features, aetiopathology, laboratory findings, treatment modes and outcomes of
      Kawasaki-like disease among paediatric patients suffering from COVID-19. Original
      articles reporting Kawasaki-like disease in paediatric patients with COVID-19
      will be retrieved after screening by two independent reviewers. Data will be
      extracted in a specially designed form and studies will be assessed independently
      for risk of bias. Data will be extracted for the following: author, journal
      title, publication year, study design, study setting, demographic
      characteristics, sample size, clinical features, aetiopathology, laboratory
      findings, modes and doses of treatment given, strength and weakness of studies. A
      descriptive and quantitative analysis will be completed. ETHICS AND
      DISSEMINATION: This is a literature-based review study with no ethical concerns. 
      We will publish the results in a peer-reviewed journal and present at a
      conference. PROSPERO REGISTRATION NUMBER: CRD42020187427.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sinha, Abhinav
AU  - Sinha A
AUID- ORCID: http://orcid.org/0000-0001-7702-3671
AD  - ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
FAU - Nayak, Swetalina
AU  - Nayak S
AD  - ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.
FAU - Dehuri, Priyadarshini
AU  - Dehuri P
AD  - Department of Pathology, Institute of Medical Sciences and SUM Hospital,
      Bhubaneswar, Odisha, India.
FAU - Kanungo, Srikanta
AU  - Kanungo S
AD  - ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India
      drsanghamitra12@gmail.com srikantak109@gmail.com.
FAU - Pati, Sanghamitra
AU  - Pati S
AD  - ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India
      drsanghamitra12@gmail.com srikantak109@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201224
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Child
MH  - *Clinical Protocols
MH  - Comorbidity
MH  - Global Health
MH  - Humans
MH  - Mass Screening/*methods
MH  - Mucocutaneous Lymph Node Syndrome/*epidemiology
MH  - *Pandemics
MH  - *Public Health
MH  - *SARS-CoV-2
PMC - PMC7768614
OTO - NOTNLM
OT  - *COVID-19
OT  - *community child health
OT  - *infectious diseases
OT  - *paediatrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - bmjopen-2020-041160 [pii]
AID - 10.1136/bmjopen-2020-041160 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 24;10(12):e041160. doi: 10.1136/bmjopen-2020-041160.


PMID- 33361077
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 24
TI  - Measurement of violence against women and disability: protocol for a scoping
      review.
PG  - e040104
LID - 10.1136/bmjopen-2020-040104 [doi]
AB  - INTRODUCTION: Violence against women is a serious threat to women's health and
      human rights globally. Disability has been associated with increased risk of
      exposure to different forms of violence, however, there are questions concerning 
      how best to measure this association. Research on understanding the association
      between violence and disability among women has included incorporating short
      disability measures into violence against women prevalence surveys. The potential
      to improve understanding of interconnections between violence and disability by
      measuring violence within disability-focused research is underexplored. The
      scoping review described here focuses on three areas of measurement of violence
      against women and disability: (1) measurement of violence within the context of
      disability-focused research, (2) measurement in research focused on the
      intersection of disability and violence and (3) measurement of disability in the 
      context of research focused on violence against women. Specifically, we aim to
      map definitions, measures and methodologies in these areas, globally. METHODS AND
      ANALYSIS: For our scoping review, we will conduct searches for quantitative
      studies of disability-focused research which use measures of violence against
      women, and measures of disability in research focused on violence against women, 
      in 11 online databases. Two authors will independently review titles and
      abstracts retrieved through the search strategy. We will search for grey
      literature, search the websites of National Statistics Offices for all countries 
      to identify any national or subnational disability research and consult with
      experts for input. Data extraction will be conducted independently by one author 
      and reviewed by another author, and data will be analysed and synthesised using a
      thematic synthesis approach. ETHICS AND DISSEMINATION: Ethics approval was not
      sought as no primary data is being collected. Findings will be disseminated
      through a publication in a peer-reviewed journal, through coordinated
      dissemination to researchers, practitioners, data users and generators and
      through various working groups and networks on violence against women and
      disability.
CI  - (c)World Health Organization 2020.
FAU - Meyer, Sarah R
AU  - Meyer SR
AUID- ORCID: 0000-0001-8595-2358
AD  - Department of Sexual and Reproductive Health and Research, WHO, Geneva,
      Switzerland.
FAU - Lasater, Molly E
AU  - Lasater ME
AD  - Department of Mental Health, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, Maryland, USA.
FAU - Lee, Lindsay
AU  - Lee L
AD  - Department of Noncommunicable Diseases, WHO, Geneva, Switzerland.
FAU - Garcia-Moreno, Claudia
AU  - Garcia-Moreno C
AD  - Department of Sexual and Reproductive Health and Research, WHO, Geneva,
      Switzerland garciamorenoc@who.int.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201224
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Disabled Persons
MH  - Humans
MH  - Prevalence
MH  - Reproducibility of Results
MH  - Research Design
MH  - *Violence
PMC - PMC7768952
OTO - NOTNLM
OT  - *public health
OT  - *sexual medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040104 [pii]
AID - 10.1136/bmjopen-2020-040104 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 24;10(12):e040104. doi: 10.1136/bmjopen-2020-040104.


PMID- 33361075
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 24
TI  - Effects of dry cupping on pain, function and quality of life in women with knee
      osteoarthritis: a protocol for a sham-controlled randomised trial.
PG  - e039857
LID - 10.1136/bmjopen-2020-039857 [doi]
AB  - INTRODUCTION: Knee osteoarthritis (KOA) is the most common cause of pain and
      disability worldwide. Dry cupping has been used as non-pharmacological approach
      to control pain and improve physical function. However, there is a lack of
      high-quality scientific evidence regarding its effects on this condition. This
      protocol describes a sham-controlled, randomised and simple blind study that aims
      to evaluate the effect of dry cupping on pain, function and quality of life in
      women with KOA. METHODS AND ANALYSIS: Sixty-two women diagnosed with KOA, based
      on American College of Rheumatology clinical criteria, and aged from 50 to 75
      years, will be randomly distributed into two groups (31 per group): real and sham
      dry cupping. Both applications will occur with acrylic cups around the knee. The 
      intervention will last 15 min, two times a week over six consecutive weeks, for a
      total of 12 sessions. Both groups will be assessed at four different times:
      before the intervention (T0), after 3 weeks intervention (T3), at the end of the 
      protocol (T6) and 4 weeks after the interventions (follow-up: T10). The primary
      outcome will be pain intensity (Numerical Pain Rating Scale), and secondary
      outcomes will be knee-related health status (Western Ontario and McMaster
      Universities Osteoarthritis Index), functional capacity (8-step stair climb test,
      40-metre fast-paced walk test and 30-second chair stand test), quality of life
      (Short-Form 36) and global perceived effect. ETHICS AND DISSEMINATION: This
      protocol was approved by the UFRN/FACISA Ethics Committee (number 3.737.688). The
      study results will be disseminated to the participants and submitted to a
      peer-reviewed journal and scientific meetings. TRIAL REGISTRATION NUMBER:
      NCT04331158.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pontes, Nayara Silva
AU  - Pontes NS
AUID- ORCID: 0000-0002-4955-5563
AD  - Postgraduate Program in Rehabilitation Sciences, Faculty of Health Sciences of
      Trairi, Federal University of Rio Grande do Norte (UFRN/FACISA), Santa Cruz,
      Brazil.
FAU - Barbosa, Germanna Medeiros
AU  - Barbosa GM
AUID- ORCID: 0000-0002-1094-334X
AD  - Faculty of Health Sciences of Trairi, Federal University of Rio Grande do Norte
      (UFRN/FACISA), Santa Cruz, Brazil.
FAU - Almeida Silva, Hugo Jario
AU  - Almeida Silva HJ
AUID- ORCID: 0000-0003-2185-4059
AD  - Postgraduate Program in Rehabilitation Sciences, Faculty of Health Sciences of
      Trairi, Federal University of Rio Grande do Norte (UFRN/FACISA), Santa Cruz,
      Brazil.
FAU - Scattone Silva, Rodrigo
AU  - Scattone Silva R
AUID- ORCID: 0000-0002-7973-188X
AD  - Postgraduate Program in Rehabilitation Sciences, Faculty of Health Sciences of
      Trairi, Federal University of Rio Grande do Norte (UFRN/FACISA), Santa Cruz,
      Brazil.
FAU - Souza, Clecio Gabriel
AU  - Souza CG
AUID- ORCID: 0000-0001-9005-7956
AD  - Postgraduate Program in Rehabilitation Sciences, Faculty of Health Sciences of
      Trairi, Federal University of Rio Grande do Norte (UFRN/FACISA), Santa Cruz,
      Brazil.
FAU - Lins, Caio Alano de Almeida
AU  - Lins CAA
AUID- ORCID: 0000-0001-6424-3114
AD  - Postgraduate Program in Rehabilitation Sciences, Faculty of Health Sciences of
      Trairi, Federal University of Rio Grande do Norte (UFRN/FACISA), Santa Cruz,
      Brazil.
FAU - de Souza, Marcelo Cardoso
AU  - de Souza MC
AUID- ORCID: 0000-0002-9268-8353
AD  - Postgraduate Program in Rehabilitation Sciences, Faculty of Health Sciences of
      Trairi, Federal University of Rio Grande do Norte (UFRN/FACISA), Santa Cruz,
      Brazil marcellogv@hotmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04331158
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201224
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Knee
MH  - Knee Joint
MH  - Middle Aged
MH  - *Osteoarthritis, Knee/therapy
MH  - Pain
MH  - *Quality of Life
MH  - Treatment Outcome
PMC - PMC7768956
OTO - NOTNLM
OT  - *knee
OT  - *rehabilitation medicine
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-039857 [pii]
AID - 10.1136/bmjopen-2020-039857 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 24;10(12):e039857. doi: 10.1136/bmjopen-2020-039857.


PMID- 33361074
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210112
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 24
TI  - Clinical, laboratory and imaging predictors for critical illness and mortality in
      patients with COVID-19: protocol for a systematic review and meta-analysis.
PG  - e039813
LID - 10.1136/bmjopen-2020-039813 [doi]
AB  - INTRODUCTION: With the threat of a worldwide pandemic of COVID-19, it is
      important to identify the prognostic factors for critical conditions among
      patients with non-critical COVID-19. Prognostic factors and models may assist
      front-line clinicians in rapid identification of high-risk patients, early
      management of modifiable factors, appropriate triaging and optimising the use of 
      limited healthcare resources. We aim to systematically assess the clinical,
      laboratory and imaging predictors as well as prediction models for severe or
      critical illness and mortality in patients with COVID-19. METHODS AND ANALYSIS:
      All peer-reviewed and preprint primary articles with a longitudinal design that
      focused on prognostic factors or models for critical illness and mortality
      related to COVID-19 will be eligible for inclusion. A systematic search of 11
      databases including PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, VIP, 
      Wanfang Data, SinoMed, bioRxiv, Arxiv and MedRxiv will be conducted. Study
      selection will follow the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses guidelines. Data extraction will be performed using the modified
      version of the Critical Appraisal and Data Extraction for Systematic Reviews of
      Prediction Modelling Studies checklist and quality will be evaluated using the
      Newcastle-Ottawa Scale and the Quality In Prognosis Studies tool. The association
      between prognostic factors and outcomes of interest will be synthesised and a
      meta-analysis will be conducted with three or more studies reporting a particular
      factor in a consistent manner. ETHICS AND DISSEMINATION: Ethical approval was not
      required for this systematic review. We will disseminate our findings through
      publication in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD
      42020178798.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lai, Xinxing
AU  - Lai X
AUID- ORCID: http://orcid.org/0000-0003-1916-3953
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Institute for TCM-X, MOE Key Laboratory of Bioinformatics/Bioinformatics
      Division, BNRIST, Department of Automation, Tsinghua University, Beijing, China.
AD  - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing,
      China.
FAU - Liu, Jian
AU  - Liu J
AD  - Department of TCM Pulmonary Diseases, Center of Respiratory Medicine, China-Japan
      Friendship Hospital, Beijing, China.
FAU - Zhang, Tianyi
AU  - Zhang T
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Feng, Luda
AU  - Feng L
AUID- ORCID: http://orcid.org/0000-0002-7259-4421
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Jiang, Ping
AU  - Jiang P
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Kang, Ligaoge
AU  - Kang L
AD  - Department of Emergency, Fangshan Hospital, Beijing University of Chinese
      Medicine, Beijing, China.
FAU - Liu, Qiang
AU  - Liu Q
AD  - Center for Evidence-based Medicine, World Federation of Chinese Medicine
      Societies, Beijing, China.
FAU - Gao, Ying
AU  - Gao Y
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
      gaoying973@163.com.
AD  - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing,
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201224
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/*diagnosis/epidemiology
MH  - *Clinical Laboratory Services
MH  - Critical Illness/*epidemiology
MH  - Diagnostic Imaging/*methods
MH  - Global Health
MH  - Humans
MH  - Morbidity/trends
MH  - *Pandemics
MH  - Prognosis
MH  - SARS-CoV-2
MH  - Survival Rate/trends
PMC - PMC7768616
OTO - NOTNLM
OT  - *COVID-19
OT  - *adult intensive & critical care
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/29 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - bmjopen-2020-039813 [pii]
AID - 10.1136/bmjopen-2020-039813 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 24;10(12):e039813. doi: 10.1136/bmjopen-2020-039813.


PMID- 33361014
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1950-6112 (Electronic)
IS  - 0003-3898 (Linking)
VI  - 78
IP  - 6
DP  - 2020 Dec 1
TI  - [Dental stem cells: myth or hope in neuroregenerative medicine?]
PG  - 593-603
LID - 10.1684/abc.2020.1611 [doi]
AB  - The use of dental stem cells has raised many hopes in the development of new
      treatments for neurodegenerative diseases. According to current statistics, about
      1 in 6 people in the world would be affected by a neurological disease. This
      number continues to increase as the world's population ages, making
      neurodegenerative diseases probably the one of the major challenges of public
      health in the 21st century. Neurodegenerative diseases are characterized mainly
      by a progressive loss of cognitive abilities and patient autonomy related to loss
      and degeneration of neurons in brain structures. Unfortunately, today, the only
      treatments available for this type of disease do only relieve the symptoms, they 
      do not treat them, and few clinical trials have been truly convincing to date.
      Hence, hope lies for these diseases in the development of other therapeutic
      approaches. As such, dental stem cells could be a promising area of research
      because of their rapid growth, their great capacity for differentiation into
      different types of cells (among neuronal ones for some of them) and how easy they
      can be obtained, without raising ethical issues as for example for embryonic stem
      cells.
FAU - Dimassi, Syrine
AU  - Dimassi S
AD  - DERBS, Univ Montpellier, Faculte d'odontologie, Montpellier, France, IRMB, Univ
      Montpellier, Inserm, CHU Montpellier, CNRS, Montpellier, France.
FAU - Relano-Gines, Aroa
AU  - Relano-Gines A
AD  - DERBS, Univ Montpellier, Faculte d'odontologie, Montpellier, France, IRMB, Univ
      Montpellier, Inserm, CHU Montpellier, CNRS, Montpellier, France.
FAU - Hirtz, Christophe
AU  - Hirtz C
AD  - DERBS, Univ Montpellier, Faculte d'odontologie, Montpellier, France, IRMB, Univ
      Montpellier, Inserm, CHU Montpellier, CNRS, Montpellier, France.
FAU - Lehmann, Sylvain
AU  - Lehmann S
AD  - IRMB, Univ Montpellier, Inserm, CHU Montpellier, CNRS, Montpellier, France.
FAU - Deville de Periere, Dominique
AU  - Deville de Periere D
AD  - DERBS, Univ Montpellier, Faculte d'odontologie, Montpellier, France, IRMB, Univ
      Montpellier, Inserm, CHU Montpellier, CNRS, Montpellier, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Cellules souches dentaires : mythe ou espoir en medecine neuroregeneratrice ?
PL  - France
TA  - Ann Biol Clin (Paris)
JT  - Annales de biologie clinique
JID - 2984690R
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Humans
MH  - Nerve Regeneration/physiology
MH  - Neural Stem Cells/cytology/*physiology
MH  - Neurodegenerative Diseases/*therapy
MH  - Neurogenesis/physiology
MH  - Regenerative Medicine/methods/*trends
MH  - Stem Cell Transplantation/methods/trends
MH  - Stem Cells/cytology/*physiology
MH  - Tissue Banks/trends
MH  - Tissue Culture Techniques/methods/trends
MH  - Tooth/*cytology
OTO - NOTNLM
OT  - cellular therapy
OT  - dental stem cells
OT  - mesenchymal stem cells
OT  - neurodegenerative diseases
EDAT- 2020/12/29 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/28 11:40
PHST- 2020/12/28 11:40 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - abc.2020.1611 [pii]
AID - 10.1684/abc.2020.1611 [doi]
PST - ppublish
SO  - Ann Biol Clin (Paris). 2020 Dec 1;78(6):593-603. doi: 10.1684/abc.2020.1611.


PMID- 33357666
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 331
DP  - 2020 Nov-Dec
TI  - [Ethical support units: benefits and limits of externalised ethics in times of
      crisis].
PG  - 34-38
LID - S0241-6972(20)30124-9 [pii]
LID - 10.1016/S0241-6972(20)30124-9 [doi]
AB  - This health crisis has revealed the difficulties, but also the creativity of the 
      caregiving teams. In this context, assisting health professionals through the
      creation of an ethical support unit is valuable. However, the implementation of
      such a unit requires reflection with the definition of the resulting limits. Two 
      questions are raised: is it really possible to externalise ethical reflection? Is
      there such a thing as ethics of crisis?
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Bemben, Lucas
AU  - Bemben L
AD  - Foyer d'accueil medicalise, Appartements de coordination therapeutique,
      association Accueil et reinsertion sociale, 12 boulevard Jean-Jaures, 54000
      Nancy, France. Electronic address: lucas@psymas.fr.
LA  - fre
PT  - Journal Article
TT  - "Cellules ethiques de soutien", apports et limites d'une ethique externalisee en 
      temps de crise.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - *Ethical Theory
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Morals
OTO - NOTNLM
OT  - cellule ethique de soutien
OT  - crise sanitaire
OT  - deontological ethics
OT  - ethical support unit
OT  - health crisis
OT  - teleological ethics
OT  - ethique deontologique
OT  - ethique teleologique
EDAT- 2020/12/29 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/12/28 10:20
PHST- 2020/12/28 10:20 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - S0241-6972(20)30124-9 [pii]
AID - 10.1016/S0241-6972(20)30124-9 [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 Nov-Dec;41(331):34-38. doi: 10.1016/S0241-6972(20)30124-9.


PMID- 33357611
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
VI  - 65
IP  - 849
DP  - 2020 Oct
TI  - [Crisis management in the face of SARS-CoV-2: management and leadership in health
      care].
PG  - 12-17
LID - S0038-0814(20)30237-1 [pii]
LID - 10.1016/S0038-0814(20)30237-1 [doi]
AB  - The coronavirus SARS-CoV-2 pandemic has forced frontline health care teams to
      make radical and rapid adjustments. Aside from the danger of catalysing and
      integrating, the crisis provides an opportunity to rediscover the very essence of
      the art of caring: an ability to be present for oneself, for others and for the
      world. This pandemic is shattering everyone's comfort zones, on the social,
      professional, psychological and ethical level. It is reviving our profound
      humanity, imposing with humility coordinated actions, while allowing a degree of 
      subsidiarity in the adjustments.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Lefort, Hugues
AU  - Lefort H
AD  - Hopital d'instruction des armees Legouest, 27 avenue de Plantieres, BP 90001,
      57077 Metz cedex 3, France. Electronic address: lefort.hugues@gmail.com.
FAU - Psiuk, Therese
AU  - Psiuk T
AD  - 38 rue des Tours, Lille, France.
FAU - Nonin, Danielle
AU  - Nonin D
AD  - Hopital d'instruction des armees Legouest, 27 avenue de Plantieres, BP 90001,
      57077 Metz cedex 3, France.
FAU - Voirgard, Carole
AU  - Voirgard C
AD  - Hopital d'instruction des armees Legouest, 27 avenue de Plantieres, BP 90001,
      57077 Metz cedex 3, France.
FAU - Epifanie, Sandie
AU  - Epifanie S
AD  - Hopital d'instruction des armees Legouest, 27 avenue de Plantieres, BP 90001,
      57077 Metz cedex 3, France.
LA  - fre
PT  - Journal Article
TT  - La gestion de crise face au Sars-CoV-2 : management et leadership dans les soins.
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
MH  - *COVID-19
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Leadership
MH  - *Pandemics
OTO - NOTNLM
OT  - COVID-19
OT  - Covid-19
OT  - behaviour
OT  - crisis management
OT  - gestion de crise
OT  - leadership
OT  - management
OT  - posture
OT  - team building
OT  - travail en equipe
EDAT- 2020/12/29 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/12/28 10:20
PHST- 2020/12/28 10:20 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - S0038-0814(20)30237-1 [pii]
AID - 10.1016/S0038-0814(20)30237-1 [doi]
PST - ppublish
SO  - Soins. 2020 Oct;65(849):12-17. doi: 10.1016/S0038-0814(20)30237-1.


PMID- 33357599
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1769-664X (Electronic)
IS  - 0929-693X (Linking)
VI  - 27
IP  - 7S
DP  - 2020 Dec
TI  - Ethical aspects in the care of a child with infantile spinal muscular atrophy
      (SMA).
PG  - 7S50-7S53
LID - S0929-693X(20)30278-5 [pii]
LID - 10.1016/S0929-693X(20)30278-5 [doi]
AB  - The pediatrician has a privileged relationship with a child with infantile spinal
      muscular atrophy (SMA). At all times, he/she must be the child's mentor,
      promoting a comprehensive approach and support in order to ensure the best
      possible solution for the patient's autonomy. In all circumstances, an ethical
      stance is essential. After a reminder on the notions of ethics of care, we will
      address various ethical questions encountered through three critical situations
      during the care of a child with infantile spinal muscular atrophy: the
      announcement of the diagnosis, the transmission of information on innovative
      therapies, and palliative care and end-of-life support. (c) 2020 French Society
      of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
CI  - Copyright (c) 2020 French Society of Pediatrics. Published by Elsevier Masson
      SAS. All rights reserved.
FAU - Chabrol, B
AU  - Chabrol B
AD  - Centre de reference des maladies neuromusculaires de l'Enfant, Neuromuscular
      Commission of French Society of Pediatric Neurology, Filiere FINELMUS, Hopital
      d'Enfants, CHU Timone, 13385 Marseille cedex 5. Electronic address:
      bchabrol@ap-hm.fr.
FAU - Desguerre, I
AU  - Desguerre I
AD  - Centre de reference des maladies neuromusculaires de l'Enfant, Neuromuscular
      Commission of French Society of Pediatric Neurology, Filiere FINELMUS, Hopital
      Necker, rue de Sevres, 75015 Paris.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Arch Pediatr
JT  - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
JID - 9421356
SB  - IM
MH  - Adolescent
MH  - Beneficence
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Informed Consent/ethics
MH  - Palliative Care/*ethics/psychology
MH  - Patient Education as Topic/ethics
MH  - Pediatrics/ethics
MH  - Personal Autonomy
MH  - Physician-Patient Relations/*ethics
MH  - Professional-Family Relations/*ethics
MH  - Spinal Muscular Atrophies of Childhood/diagnosis/psychology/*therapy
MH  - Terminal Care/*ethics/psychology
MH  - Therapies, Investigational/*ethics/psychology
MH  - Truth Disclosure/*ethics
OTO - NOTNLM
OT  - Announcement of the diagnosis
OT  - End of life
OT  - Ethical aspects
OT  - Infantile spinal muscular atrophy
OT  - Innovative therapies
OT  - Palliative care
OT  - SMA
EDAT- 2020/12/29 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/12/28 10:20
PHST- 2020/12/28 10:20 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - S0929-693X(20)30278-5 [pii]
AID - 10.1016/S0929-693X(20)30278-5 [doi]
PST - ppublish
SO  - Arch Pediatr. 2020 Dec;27(7S):7S50-7S53. doi: 10.1016/S0929-693X(20)30278-5.


PMID- 33357365
OWN - NLM
STAT- MEDLINE
DCOM- 20211006
LR  - 20220419
IS  - 2105-0686 (Electronic)
IS  - 2105-0678 (Linking)
VI  - 214
IP  - 3-4
DP  - 2020
TI  - [Spyridon Kanellis, a 19th century daring plagiarist].
PG  - 85-90
LID - 10.1051/jbio/2020009 [doi]
AB  - In 1883, a case of daring plagiarism was revealed during a session of the Biology
      Society in Paris. This article discusses the details of this plagiarism and the
      identity of its perpetrator, a physician by the name of Spiridion Kanellis.
CI  - (c) Societe de Biologie, 2020.
FAU - Gautron, Laurent
AU  - Gautron L
AD  - Center for Hypothalamic Research and Department of Internal Medicine, The
      University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, 
      Texas 75390, USA.
LA  - fre
PT  - Historical Article
PT  - Journal Article
TT  - Spiridion Kanellis, un plagiaire audacieux du XIX(e) siecle*.
DEP - 20201224
PL  - France
TA  - Biol Aujourdhui
JT  - Biologie aujourd'hui
JID - 101544020
SB  - IM
MH  - History, 19th Century
MH  - *Plagiarism
OTO - NOTNLM
OT  - ethics
OT  - histoire
OT  - history
OT  - medicine
OT  - medecine
OT  - plagiarism
OT  - plagiat
OT  - ethique
EDAT- 2020/12/29 06:00
MHDA- 2021/10/07 06:00
CRDT- 2020/12/28 10:15
PHST- 2020/09/03 00:00 [received]
PHST- 2020/12/28 10:15 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/10/07 06:00 [medline]
AID - 10.1051/jbio/2020009 [doi]
AID - jbio200009 [pii]
PST - ppublish
SO  - Biol Aujourdhui. 2020;214(3-4):85-90. doi: 10.1051/jbio/2020009. Epub 2020 Dec
      24.


PMID- 35837660
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2096-112X (Electronic)
IS  - 2096-112X (Linking)
VI  - 1
IP  - 1
DP  - 2020
TI  - Hyaluronic acid-based hydrogels with tobacco mosaic virus containing cell
      adhesive peptide induce bone repair in normal and osteoporotic rats.
PG  - 89-98
LID - 10.3877/cma.j.issn.2096-112X.2020.01.009 [doi]
AB  - Tobacco mosaic virus (TMV) has been studied as a multi-functional agent for bone 
      tissue engineering. An osteo-inductive effect of wild-type TMV has been reported,
      as it can significantly enhance the bone differentiation potential of bone marrow
      stromal cells both on a two-dimensional substrate and in a three-dimensional (3D)
      hydrogel system. A TMV mutant (TMV-RGD1) was created which featured the adhesion 
      peptide arginyl-glycyl-aspartic acid (RGD), the most common peptide motif
      responsible for cell adhesion to the extracellular matrix, on the surface of the 
      virus particle to enhance the bio-functionality of the scaffold material. We
      hypothesised that the incorporation of either wild-type TMV or TMV-RGD1 in the 3D
      hydrogel scaffold would induce bone healing in critical size defects of the
      cranial segmental bone. We have previously tested the virus-functionalised
      scaffolds, in vitro, with a hyaluronic acid-based system as an in-situ hydrogel
      platform for 3D cell encapsulation, culture, and differentiation. The results of 
      these experiments suggested the potential of the virus-functionalised hydrogel to
      promote in vitro stem cell differentiation. The hydrogel-forming system we
      employed was shown to be safe and biocompatible in vivo. Here, we further
      explored the physiological responses regarding bone regeneration of a calvarial
      defect in both normal and osteoporotic ovariectomized rat models. Our results,
      based on histological analysis in both animal models, suggested that both
      wild-type TMV and TMV-RGD1 functionalised hydrogels could accelerate bone
      regeneration, without systemic toxicity, evaluated by blood counts. New bone
      formation was intensified by the incorporation of the RGD-mutant viral particles.
      This finding increased the potential for use of the rod-shaped plant virus as a
      platform for the addition of powerful biofunctionality for tissue engineering
      applications. This study was approved by the Ethics Committee on Animal Use of
      the Zhenjiang Affiliated First People's Hospital affiliated to Jiangsu
      University.
FAU - Yuan, Jishan
AU  - Yuan J
AD  - Department of Orthopaedic Surgery, the Affiliated First People's Hospital to
      Jiangsu University, Zhenjiang, Jiangsu Province, China.
FAU - Maturavongsadit, Panita
AU  - Maturavongsadit P
AD  - Department of Chemistry and Biochemistry, University of South Carolina, Columbia,
      SC, USA.
AD  - Joint Department of Biomedical Engineering, North Carolina State University and
      The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Zhou, Zhihui
AU  - Zhou Z
AD  - Department of Orthopaedic Surgery, the Affiliated First People's Hospital to
      Jiangsu University, Zhenjiang, Jiangsu Province, China.
FAU - Lv, Bin
AU  - Lv B
AD  - Department of Orthopaedic Surgery, the Affiliated First People's Hospital to
      Jiangsu University, Zhenjiang, Jiangsu Province, China.
FAU - Lin, Yuan
AU  - Lin Y
AD  - The State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of
      Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin Province, China.
FAU - Yang, Jia
AU  - Yang J
AD  - Department of Chemistry and Biochemistry, University of South Carolina, Columbia,
      SC, USA.
FAU - Luckanagul, Jittima Amie
AU  - Luckanagul JA
AD  - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical
      Sciences, Chulalongkorn University, Bangkok, Thailand.
AD  - Research Unit for Plant-produced Pharmaceuticals, Chulalongkorn University,
      Bangkok, Thailand.
FAU - JYuan
AU  - JYuan
FAU - Jal
AU  - Jal
FAU - JYuan
AU  - JYuan
FAU - Jal
AU  - Jal
FAU - Pm
AU  - Pm
FAU - JYuan
AU  - JYuan
FAU - Zz
AU  - Zz
FAU - Bl
AU  - Bl
FAU - JYang
AU  - JYang
FAU - Zz
AU  - Zz
FAU - Bl
AU  - Bl
FAU - Yl
AU  - Yl
FAU - JYuan
AU  - JYuan
FAU - Jal
AU  - Jal
FAU - JYuan
AU  - JYuan
FAU - JYang
AU  - JYang
FAU - Pm
AU  - Pm
FAU - JYuan
AU  - JYuan
FAU - Jal
AU  - Jal
FAU - Yl
AU  - Yl
FAU - Pm
AU  - Pm
FAU - Jal
AU  - Jal
FAU - Pm
AU  - Pm
FAU - Jal
AU  - Jal
FAU - JYuan
AU  - JYuan
FAU - Zz
AU  - Zz
FAU - Bl
AU  - Bl
FAU - JYang
AU  - JYang
FAU - JYuan
AU  - JYuan
FAU - Yl
AU  - Yl
FAU - Jal
AU  - Jal
LA  - eng
PT  - Journal Article
DEP - 20201228
PL  - China
TA  - Biomater Transl
JT  - Biomaterials translational
JID - 9918351163606676
PMC - PMC9255816
OTO - NOTNLM
OT  - bone regeneration
OT  - calvarial defect
OT  - hydrogel
OT  - osteoporosis
OT  - tobacco mosaic virus
COIS- Conflicts of interest statement: The authors declare no conflict of interest.
EDAT- 2020/12/28 00:00
MHDA- 2020/12/28 00:01
CRDT- 2022/07/15 02:45
PHST- 2020/09/11 00:00 [received]
PHST- 2020/10/13 00:00 [revised]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2022/07/15 02:45 [entrez]
PHST- 2020/12/28 00:00 [pubmed]
PHST- 2020/12/28 00:01 [medline]
AID - 10.3877/cma.j.issn.2096-112X.2020.01.009 [doi]
PST - epublish
SO  - Biomater Transl. 2020 Dec 28;1(1):89-98. doi:
      10.3877/cma.j.issn.2096-112X.2020.01.009. eCollection 2020.


PMID- 35837657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2096-112X (Electronic)
IS  - 2096-112X (Linking)
VI  - 1
IP  - 1
DP  - 2020
TI  - Three-dimensional biofabrication of an aragonite-enriched self-hardening bone
      graft substitute and assessment of its osteogenicity in vitro and in vivo.
PG  - 69-81
LID - 10.3877/cma.j.issn.2096-112X.2020.01.007 [doi]
AB  - A self-hardening three-dimensional (3D)-porous composite bone graft consisting of
      65 wt% hydroxyapatite (HA) and 35 wt% aragonite was fabricated using a
      3D-Bioplotter((R)). New tetracalcium phosphate and dicalcium phosphate
      anhydrous/aragonite/gelatine paste formulae were developed to overcome the phase 
      separation of the liquid and solid components. The mechanical properties,
      porosity, height and width stability of the end products were optimised through a
      systematic analysis of the fabrication processing parameters including printing
      pressure, printing speed and distance between strands. The resulting 3D-printed
      bone graft was confirmed to be a mixture of HA and aragonite by X-ray
      diffraction, Fourier transform infrared spectroscopy and energy dispersive X-ray 
      spectroscopy. The compression strength of HA/aragonite was between 0.56 and 2.49 
      MPa. Cytotoxicity was assessed using the
      3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in
      vitro. The osteogenicity of HA/aragonite was evaluated in vitro by alkaline
      phosphatase assay using human umbilical cord matrix mesenchymal stem cells, and
      in vivo by juxtapositional implantation between the tibia and the anterior
      tibialis muscle in rats. The results showed that the scaffold was not toxic and
      supported osteogenic differentiation in vitro. HA/aragonite stimulated new bone
      formation that bridged host bone and intramuscular implants in vivo. We conclude 
      that HA/aragonite is a biodegradable and conductive bone formation biomaterial
      that stimulates bone regeneration. Since this material is formed near 37 degrees 
      C, it will have great potential for incorporating bioactive molecules to suit
      personalised application; however, further study of its biodegradation and
      osteogenic capacity is warranted. The study was approved by the Animal Ethical
      Committee at Tongji Medical School, Huazhong University of Science and Technology
      (IACUC No. 738) on October 1, 2017.
FAU - Shi, Yunsong
AU  - Shi Y
AD  - Union Hospital affiliated to Tongji Medical College of Huazhong University of
      Science and Technology, Wuhan, Hubei Province, China.
AD  - Centre for Nanohealth, Swansea University Medical School, Swansea, UK.
FAU - He, Ruijun
AU  - He R
AD  - Union Hospital affiliated to Tongji Medical College of Huazhong University of
      Science and Technology, Wuhan, Hubei Province, China.
FAU - Deng, Xiangyu
AU  - Deng X
AD  - Union Hospital affiliated to Tongji Medical College of Huazhong University of
      Science and Technology, Wuhan, Hubei Province, China.
FAU - Shao, Zengwu
AU  - Shao Z
AD  - Union Hospital affiliated to Tongji Medical College of Huazhong University of
      Science and Technology, Wuhan, Hubei Province, China.
FAU - Deganello, Davide
AU  - Deganello D
AD  - Centre for Nanohealth, Faculty of Science and Engineering, Swansea University,
      Swansea, UK.
FAU - Yan, Chunze
AU  - Yan C
AD  - State Key Laboratory of Materials Processing and Die & Mould Technology, Huazhong
      University of Science and Technology, Wuhan, Hubei Province, China.
FAU - Xia, Zhidao
AU  - Xia Z
AD  - Centre for Nanohealth, Swansea University Medical School, Swansea, UK.
FAU - Ys
AU  - Ys
FAU - Rh
AU  - Rh
FAU - Xd
AU  - Xd
FAU - Rh
AU  - Rh
FAU - Xd
AU  - Xd
FAU - Zs
AU  - Zs
FAU - Dd
AU  - Dd
FAU - Dd
AU  - Dd
FAU - Cy
AU  - Cy
FAU - Zx
AU  - Zx
FAU - Cy
AU  - Cy
FAU - Zx
AU  - Zx
FAU - Cy
AU  - Cy
FAU - Zx
AU  - Zx
FAU - Ys
AU  - Ys
FAU - Zx
AU  - Zx
FAU - Zx
AU  - Zx
LA  - eng
PT  - Journal Article
DEP - 20201228
PL  - China
TA  - Biomater Transl
JT  - Biomaterials translational
JID - 9918351163606676
PMC - PMC9255821
OTO - NOTNLM
OT  - biofabrication
OT  - cytotoxicity
OT  - hydroxyapatite/aragonite
OT  - osteogenesis
COIS- Conflicts of interest statement: The authors declare that they have no competing 
      financial interests or personal relationships that could have appeared to
      influence the work reported in this study.
EDAT- 2020/12/28 00:00
MHDA- 2020/12/28 00:01
CRDT- 2022/07/15 02:45
PHST- 2020/09/02 00:00 [received]
PHST- 2020/10/02 00:00 [revised]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2022/07/15 02:45 [entrez]
PHST- 2020/12/28 00:00 [pubmed]
PHST- 2020/12/28 00:01 [medline]
AID - 10.3877/cma.j.issn.2096-112X.2020.01.007 [doi]
PST - epublish
SO  - Biomater Transl. 2020 Dec 28;1(1):69-81. doi:
      10.3877/cma.j.issn.2096-112X.2020.01.007. eCollection 2020.


PMID- 33355266
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20220725
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 12
DP  - 2020 Dec
TI  - Contextual equipoise: a novel concept to inform ethical implications for
      implementation research in low-income and middle-income countries.
LID - e003456 [pii]
LID - 10.1136/bmjgh-2020-003456 [doi]
AB  - The call for universal health coverage requires the urgent implementation and
      scale-up of interventions that are known to be effective, in resource-poor
      settings. Achieving this objective requires high-quality implementation research 
      (IR) that evaluates the complex phenomenon of the influence of context on the
      ability to effectively deliver evidence-based practice. Nevertheless, IR for
      global health is failing to apply a robust, theoretically driven approach,
      leading to ethical concerns associated with research that is not methodologically
      sound.Inappropriate methods are often used in IR to address and report on
      context. This may result in a lack in understanding of how to effectively adapt
      the intervention to the new setting and a lack of clarity in conceptualising
      whether there is sufficient evidence to generalise findings from previous IR to a
      new setting, or if a randomised controlled trial (RCT) is needed. Some of the
      ethical issues arising from this shortcoming include poor-quality research that
      may needlessly expose vulnerable participants to research that has not been
      adapted to suit local needs and priorities, and the inappropriate use of RCTs
      that denies participants in the control arm access to treatment that is effective
      within the local context.To address these concerns, we propose a complementary
      approach to clinical equipoise for IR, known as contextual equipoise We discuss
      challenges in the evaluation of context and also with assessing the certainty of 
      evidence to justify an RCT. Finally, we describe methods that can be applied to
      improve the evaluation and reporting of context and to help understand if
      contextual equipoise can be justified or if significant adaptations are required.
      We hope our analysis offers helpful insight to better understand and ensure that 
      the ethical principle of beneficence is upheld in the real-world contexts of IR
      in low-resource settings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Seward, Nadine
AU  - Seward N
AUID- ORCID: 0000-0002-4821-9437
AD  - Centre for Implementation Science, Department of Health Service and Population
      Research, King's College London, London, UK nadine.seward@kcl.ac.uk.
FAU - Hanlon, Charlotte
AU  - Hanlon C
AUID- ORCID: 0000-0002-7937-3226
AD  - Institute of Psychiatry, Psychology and Neuroscience, Centre for Global Mental
      Health, King's College London, London, UK.
AD  - Centre for Innovative Drug Development and Therapeutic Trials for Africa
      (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa,
      Ethiopia.
AD  - Health Service and Population Research Department, King's College London, London,
      UK.
FAU - Murdoch, Jamie
AU  - Murdoch J
AUID- ORCID: 0000-0002-9021-3629
AD  - Norwich Medical School, Faculty of Medicine and Health Sciences, University of
      East Anglia Faculty of Medicine and Health Sciences, Norwich, UK.
FAU - Colbourn, Tim
AU  - Colbourn T
AUID- ORCID: 0000-0002-6917-6552
AD  - Institute of Global Health, University College London, London, UK.
FAU - Prince, Martin James
AU  - Prince MJ
AUID- ORCID: 0000-0003-1379-7146
AD  - Health Service and Population Research Department, King's College London, London,
      UK.
FAU - Venkatapuram, Sridhar
AU  - Venkatapuram S
AUID- ORCID: 0000-0003-3076-0783
AD  - King's College London, London, UK.
FAU - Sevdalis, Nick
AU  - Sevdalis N
AD  - Health Service and Population Research Department, King's College London, London,
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *Developing Countries
MH  - *Ethics, Research
MH  - Humans
MH  - *Income
MH  - Randomized Controlled Trials as Topic
MH  - Therapeutic Equipoise
PMC - PMC7757476
OTO - NOTNLM
OT  - *health policy
OT  - *other study design
OT  - *public health
OT  - *randomised control trial
COIS- Competing interests: None declared.
EDAT- 2020/12/24 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/12/23 08:41
PHST- 2020/07/15 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/12/23 08:41 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - bmjgh-2020-003456 [pii]
AID - 10.1136/bmjgh-2020-003456 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Dec;5(12). pii: bmjgh-2020-003456. doi:
      10.1136/bmjgh-2020-003456.


PMID- 33355165
OWN - NLM
STAT- Publisher
LR  - 20201223
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 Dec 21
TI  - Duration of palliative care involvement and cancer care aggressiveness near the
      end of life.
LID - bmjspcare-2020-002641 [pii]
LID - 10.1136/bmjspcare-2020-002641 [doi]
AB  - OBJECTIVES: Previous studies have found an association between aggressive cancer 
      care and lower quality end of life. Despite international recommendations, late
      or very late referral to palliative care seems frequent. This study aimed to
      evaluate the association between the duration of involvement of a palliative care
      team (PCT), and aggressive cancer care, and to identify factors associated with
      aggressive cancer care. METHODS: We performed an observational retrospective
      study in a single academic teaching hospital. In total, 561 inpatients with solid
      tumours or haematological malignancies were included. Patients followed by a PCT 
      for at least 1 month before death were classified in the palliative care group.
      Aggressive cancer care was defined as: hospitalisations and/or a new line of
      chemotherapy within the last month of life, location of death, the use of
      chemotherapy in the last 2 weeks and hospice admissions within the last 3 days of
      life. RESULTS: Among the 561 patients, 241 (43%) were referred to the PCT; 89
      (16%) were followed by the PCT for a month or more before death. In the last 2
      weeks of life, 124 (22%) patients received chemotherapy, 110 (20%) died in an
      acute care unit. At least one criterion of aggressive cancer care was found in
      395 patients overall (71%). Aggressive cancer care was significantly less
      frequent when the PCT referral occurred >1 month before death (p<0.0001).
      CONCLUSION: More studies are needed to understand reasons for late referrals
      despite international recommendations encouraging integrative palliative care.
      ETHICS APPROVAL: The study was approved by the Grenoble Teaching Hospital ethics 
      committee, and by the CNIL (French national commission for data privacy;
      Commission Nationale de l'Informatique et des Libertes) under the number 1987785 
      v 0. Due to ethical and legal restrictions, data are only available on request.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Monier, Pierre Antoine
AU  - Monier PA
AD  - Department of Supportive and Palliative Care, Centre Hospitalo-Universitaire de
      Grenoble, Grenoble, France.
FAU - Chrusciel, Jan
AU  - Chrusciel J
AD  - Department of Public Health and Performance, Hopitaux Champagne Sud, Troyes,
      France.
FAU - Ecarnot, Fiona
AU  - Ecarnot F
AD  - Department of Cardiology, University Hospital Besancon, Besancon, France.
AD  - EA3920, University of Burgundy Franche-Comte, Besancon, France.
FAU - Bruera, Eduardo
AU  - Bruera E
AUID- ORCID: http://orcid.org/0000-0002-8745-0412
AD  - Department of Palliative, Rehabilitation, and Integrative Medicine, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Sanchez, Stephane
AU  - Sanchez S
AD  - Department of Public Health and Performance, Hopitaux Champagne Sud, Troyes,
      France.
FAU - Barbaret, Cecile
AU  - Barbaret C
AUID- ORCID: http://orcid.org/0000-0001-7144-7115
AD  - Department of Supportive and Palliative Care, Centre Hospitalo-Universitaire de
      Grenoble, Grenoble, France cbarbaret@chu-grenoble.fr.
AD  - Laboratoire ThEMAS (Techniques pour l'evaluation et la Modelisation des Actions
      de Sante) TIMC-IMAG (Technique de l'Ingenierie Medicale et de la
      Complexite-Informatique, Mathematiques et Applications, Grenoble), Grenoble,
      France.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - cancer
OT  - end of life care
OT  - quality of life
OT  - terminal care
COIS- Competing interests: None declared.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:00
CRDT- 2020/12/23 08:40
PHST- 2020/08/17 00:00 [received]
PHST- 2020/11/05 00:00 [revised]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/23 08:40 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:00 [medline]
AID - bmjspcare-2020-002641 [pii]
AID - 10.1136/bmjspcare-2020-002641 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 Dec 21. pii: bmjspcare-2020-002641. doi:
      10.1136/bmjspcare-2020-002641.


PMID- 33355021
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1945-7243 (Electronic)
IS  - 0046-9580 (Linking)
VI  - 57
DP  - 2020 Jan-Dec
TI  - What Makes Some Diseases More Typical than Others? A Survey on the Impact of
      Disease Characteristics and Professional Background on Disease Typicality.
PG  - 46958020972813
LID - 10.1177/0046958020972813 [doi]
AB  - Health professionals tend to perceive some diseases as more typical than others. 
      If disease typicalities have implications for health professionals or health
      policy makers' handling of different diseases, then it is of great social,
      epistemic, and ethical interest. Accordingly, it is important to find out what
      makes health professionals rank diseases as more or less typical. This study
      investigates the impact of various factors on how typical various diseases are
      perceived to be by health professionals. In particular, we study the influence of
      broad disease categories, such as somatic versus psychological/behavioral
      conditions, and a wide range of more specific disease characteristics, as well as
      the health professional's own background. We find that professional background
      strongly impacted disease typicality. All professionals (MD, RN, physiotherapists
      and psychologists) considered somatic conditions to be more typical than
      psychological/behavioral. As expected, psychologists also found
      psychological/behavioral conditions to be more typical than did other groups.
      Professions of respondents could be well predicted from their individual
      typicality judgments, with the exception of physiotherapists and nurses who had
      very similar judgment profiles. We also demonstrate how various disease
      characteristics impact typicality for the different professionals. Typicality
      showed moderate to strong positive correlations with condition severity and
      mortality, and only non-severe conditions were rated as atypical. Hence, studying
      how different disease characteristics and occupational background influences
      health professionals' perception of disease typicality is the first and important
      step toward a more general study of how typicality influences disease handling.
FAU - Hofstad, Tore
AU  - Hofstad T
AUID- ORCID: 0000-0003-0718-7931
AD  - The University of Oslo, Oslo, Norway.
FAU - Hampton, James A
AU  - Hampton JA
AUID- ORCID: 0000-0002-0363-8232
AD  - City, University of London, England.
FAU - Hofmann, Bjorn
AU  - Hofmann B
AUID- ORCID: 0000-0001-6709-4265
AD  - The University of Oslo, Oslo, Norway.
AD  - The Norwegian University of Science and Technology (NTNU), Gjovik, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Inquiry
JT  - Inquiry : a journal of medical care organization, provision and financing
JID - 0171671
SB  - IM
MH  - *Health Personnel
MH  - Humans
MH  - Surveys and Questionnaires
PMC - PMC7873920
OTO - NOTNLM
OT  - *disease
OT  - *disease characteristics
OT  - *ethics
OT  - *health policy
OT  - *judgment
OT  - *profession
OT  - *respondents
OT  - *severity
OT  - *survey
OT  - *typical
EDAT- 2020/12/24 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/12/23 08:39
PHST- 2020/12/23 08:39 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.1177/0046958020972813 [doi]
PST - ppublish
SO  - Inquiry. 2020 Jan-Dec;57:46958020972813. doi: 10.1177/0046958020972813.


PMID- 33354875
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 12
DP  - 2020 Dec
TI  - Ethics of information-gathering interventions in innovative practice.
PG  - 1583-1587
LID - 10.1111/imj.15117 [doi]
AB  - Innovative practice involves medical interventions that deviate from standard
      practice in significant ways. For many patients, innovative practice offers the
      best chance of successful treatment. Because little is known about most
      innovative treatments, clinicians who engage in innovative practice might
      consider including extra procedures, such as scans or blood draws, to gather
      information about the innovation. Such information-gathering interventions can
      yield valuable information for modifying the innovation to benefit future
      patients and for designing scientific studies of the innovation. However,
      existing guidelines do not say when or whether it is appropriate to add
      potentially risky information-gathering interventions for these purposes. As a
      result, clinicians may assume that information-gathering interventions are
      ethically inappropriate and should not be used in innovative practice. This
      assumption can lead to seriously negative consequences, such as increasing the
      likelihood that harmful or ineffective innovations will be adopted and creating
      new barriers to the development of genuinely beneficial treatments. We argue that
      health care institutions need to promote the responsible use of
      information-gathering interventions as an adjunct to innovative practice, and
      that these interventions are not clinical research and should not be subject to
      research oversight.
CI  - (c) 2020 Royal Australasian College of Physicians. This article has been
      contributed to by US Government employees and their work is in the public domain 
      in the USA.
FAU - Earl, Jake
AU  - Earl J
AUID- ORCID: https://orcid.org/0000-0003-3001-7885
AD  - Center for Clinical and Organizational Ethics, Inova Health System, Falls Church,
      Virginia, USA.
FAU - Wendler, David
AU  - Wendler D
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Bethesda,
      Maryland, USA.
LA  - eng
GR  - NIH Clinical Center
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
OTO - NOTNLM
OT  - innovative practice
OT  - medical ethics
OT  - research ethics
EDAT- 2020/12/24 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/12/23 05:53
PHST- 2019/09/08 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/12/23 05:53 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1111/imj.15117 [doi]
PST - ppublish
SO  - Intern Med J. 2020 Dec;50(12):1583-1587. doi: 10.1111/imj.15117.


PMID- 33354370
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2090-0023 (Print)
IS  - 2090-0023 (Linking)
VI  - 2020
DP  - 2020
TI  - The Role of Sex in Malaria-COVID19 Coinfection and Some Associated Factors in
      Rivers State, Nigeria.
PG  - 8829848
LID - 10.1155/2020/8829848 [doi]
AB  - OBJECTIVES: Data on the coinfection of malaria and COVID-19 is highly limited
      especially in Africa due to the novel nature of the pandemic COVID-19. Malaria
      and COVID-19 share striking similarities in their symptoms. A cross-sectional
      randomized study was conducted to investigate the role of sex in the coinfection 
      of malaria and COVID-19 as well as some associated factors in Rivers State,
      Nigeria. METHODS: Ethical approval was obtained from the Rivers State Health and 
      Ethics Committee before the commencement of this study, and the study was
      conducted at the COVID-19 Treatment Center Medical Laboratory, Rivers State,
      Nigeria. Intravenous blood samples from three hundred randomly selected
      consenting study participants were examined for Plasmodium species using Giemsa
      microscopy, while pretested questionnaires were used to obtain data on sex, risk 
      factors, and symptoms. All data generated were analyzed statistically using the
      Chi-square test with a P < 0.05 value considered significant. RESULTS: All study 
      participants had Plasmodium species (100% prevalence) with varying parasite
      loads, and P. falciparum was the only species observed. Study participants
      (irrespective of sex) with low and high parasitaemia had the highest and least
      prevalence, respectively (P > 0.05). Male study participants experienced more
      symptoms than females (P > 0.05) except for sore throat which had an equal value 
      among males and females. Travel history was the only risk factor that showed
      significant association with sex, and males had a higher value than females (P < 
      0.05). CONCLUSION: Malaria and COVID-19 are major public health issues in
      Nigeria; more researches on these diseases especially in epidemiology, pathology,
      diagnosis, treatment, and vaccine production are vital.
CI  - Copyright (c) 2020 E. O. Onosakponome and M. N. Wogu.
FAU - Onosakponome, E O
AU  - Onosakponome EO
AD  - Department of Medical Laboratory Science, PAMO University of Medical Sciences,
      Port Harcourt, Nigeria.
FAU - Wogu, M N
AU  - Wogu MN
AUID- ORCID: https://orcid.org/0000-0002-4189-0826
AD  - Department of Animal and Environmental Biology, University of Port Harcourt,
      Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - United States
TA  - J Parasitol Res
JT  - Journal of parasitology research
JID - 101526294
PMC - PMC7737434
COIS- The authors declare that there is no competing interest in this study.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 05:49
PHST- 2020/08/31 00:00 [received]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/23 05:49 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - 10.1155/2020/8829848 [doi]
PST - epublish
SO  - J Parasitol Res. 2020 Dec 2;2020:8829848. doi: 10.1155/2020/8829848. eCollection 
      2020.


PMID- 33354128
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201223
IS  - 1300-0667 (Print)
IS  - 1300-0667 (Linking)
VI  - 57
IP  - 4
DP  - 2020 Dec
TI  - A Bridge Between in vitro and in vivo Studies in Neuroscience: Organotypic Brain 
      Slice Cultures.
PG  - 333-337
LID - 10.29399/npa.26139 [doi]
AB  - In vitro and in vivo models are efficiently used systems in neuroscience research
      to study the brain in normal or pathological conditions. There are many
      advantages to these systems, yet they also have significant limitations. In vitro
      cell cultures offer the opportunity to investigate the cell basics or primary
      response of a cell population against any treatment. However, these models do not
      always predict in vivo behavior. In vivo animal studies constitute the most
      realistic platform for research and therapeutic approaches, yet they are
      laborious, open to secondary complications and painful or stressful for the
      animals from an ethical point of view. Organotypic brain slice cultures provide
      an in vivo-like environment since they maintain three-dimensional
      cytoarchitecture of the brain thus enable to study many cell types in one system 
      and allow precise control of the microenvironment. In this review, we will focus 
      on the history and key features of organotypic brain slice cultures as well as
      its preparation.
CI  - Copyright: (c) 2020 Turkish Neuropsychiatric Society.
FAU - AlaylioGlu, Merve
AU  - AlaylioGlu M
AD  - Brain and Neurodegenerative Disorders Research Laboratory, Department of Medical 
      Biology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa,
      Istanbul, Turkey.
FAU - Dursun, Erdinc
AU  - Dursun E
AD  - Brain and Neurodegenerative Disorders Research Laboratory, Department of Medical 
      Biology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa,
      Istanbul, Turkey.
AD  - Department of Neuroscience, Institute of Neurological Sciences, Istanbul
      University-Cerrahpasa, Istanbul, Turkey.
FAU - Yilmazer, Selma
AU  - Yilmazer S
AD  - Department of Medical Biology, School of Medicine, Altinbas University, Istanbul,
      Turkey.
FAU - Ak, Duygu Gezen
AU  - Ak DG
AD  - Brain and Neurodegenerative Disorders Research Laboratory, Department of Medical 
      Biology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa,
      Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200921
PL  - Turkey
TA  - Noro Psikiyatr Ars
JT  - Noro psikiyatri arsivi
JID - 9426194
PMC - PMC7735142
OTO - NOTNLM
OT  - Organotypic brain slice culture
OT  - membrane interface method
OT  - whole-brain slice culture
COIS- Conflict of Interest: The authors declare that they have no conflict of interest.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 05:48
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/12/23 05:48 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - 10.29399/npa.26139 [doi]
AID - archneuro-57-333 [pii]
PST - epublish
SO  - Noro Psikiyatr Ars. 2020 Sep 21;57(4):333-337. doi: 10.29399/npa.26139.
      eCollection 2020 Dec.


PMID- 33354067
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201223
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 5 Suppl
DP  - 2020 Oct
TI  - Ethical and Legal Aspects of Telepsychiatry.
PG  - 63S-69S
LID - 10.1177/0253717620962033 [doi]
AB  - Ethical and legal frameworks are essential components in mental health care, due 
      to inherent nature of illnesses and practice modules. These serve to safeguard
      rights and privileges of patients and mental health professional. Gradual
      evolution of technology and its' application in assessments and interventions is 
      making it as an essential part of mental health care delivery. This transition
      will bring innovative challenges for mental health care delivery in terms of
      practice, ethical and legal aspects. Existing ethical and legal frameworks are
      time tested for real time/face to face delivery of mental health care. Ongoing
      pandemic provided opportunity and necessitated use of technology for delivering
      health care needs. Newer operational and practice guidelines have emerged for
      practice of telemedicine in general and telepsychiatry in specific. These are in 
      lines with existing ethical and legal frameworks. However, additional frameworks 
      with specific definitions about what constitutes consultation, assessment
      methods, prescription modes and contents of prescription, documentation,
      certification, eligible platforms for telepsychiatry, need to be incorporated and
      observed. The article addresses these ethical and legal aspects in telepsychiatry
      practice with the background of existing practice guidelines and rules.
CI  - (c) 2020 Indian Psychiatric Society - South Zonal Branch.
FAU - Raveesh, Bevinahalli Nanjegowda
AU  - Raveesh BN
AD  - Dept. of Psychiatry, Mysore Medical College & Research Institute, Mysore,
      Karnataka, India.
AD  - Legal Subcommittee, Indian Psychiatry Society (National).
FAU - Munoli, Ravindra Neelakanthappa
AU  - Munoli RN
AD  - Dept. of Psychiatry, Kasturba Medical College, Manipal, Manipal Academy of Higher
      Education, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7736742
OTO - NOTNLM
OT  - Cyberpsychiatry
OT  - ethics
OT  - review
OT  - telemedicine/telecare
COIS- The authors declared no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 05:48
PHST- 2020/12/23 05:48 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - 10.1177/0253717620962033 [doi]
AID - 10.1177_0253717620962033 [pii]
PST - epublish
SO  - Indian J Psychol Med. 2020 Nov 1;42(5 Suppl):63S-69S. doi:
      10.1177/0253717620962033. eCollection 2020 Oct.


PMID- 33354064
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201223
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 5 Suppl
DP  - 2020 Oct
TI  - Setting Up and Providing Telepsychiatry Services in India.
PG  - 4S-10S
LID - 10.1177/0253717620959783 [doi]
AB  - The exponential growth of technology in the past few decades has benefitted the
      healthcare sector. Telemedicine is a newer advancement which is making healthcare
      affordable and more accessible to the needy in recent times. This article
      discusses how to set up telepsychiatry services, the procedure of telepsychiatry 
      consultation, how to record and maintain the electronic health records, the
      potential challenges, ethical and legal aspects concerning telepsychiatry while
      ensuring the good practice guidelines, medical ethics, patient rights, and the
      minimum requirements as established by the Information Technology Act and the
      telemedicine practice guidelines (TPG) 2020 issued by the Indian Medical Council.
CI  - (c) 2020 Indian Psychiatric Society - South Zonal Branch.
FAU - Ali, Furkhan
AU  - Ali F
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neurosciences
      (NIMHANS), Bengaluru, Karnataka, India.
FAU - Kamila, Vachana
AU  - Kamila V
AD  - Spandana Health Care, Bengaluru, Karnataka, India.
FAU - Gowda, Mahesh R
AU  - Gowda MR
AD  - Spandana Health Care, Bengaluru, Karnataka, India.
FAU - Srinivasa, Preeti
AU  - Srinivasa P
AD  - Spandana Health Care, Bengaluru, Karnataka, India.
FAU - Gowda, Guru S
AU  - Gowda GS
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neurosciences
      (NIMHANS), Bengaluru, Karnataka, India.
FAU - Math, Suresh Bada
AU  - Math SB
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neurosciences
      (NIMHANS), Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7736744
OTO - NOTNLM
OT  - India
OT  - Telepsychiatry
OT  - telemedicine
OT  - telepsychiatry setup
COIS- The authors declared no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 05:48
PHST- 2020/12/23 05:48 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - 10.1177/0253717620959783 [doi]
AID - 10.1177_0253717620959783 [pii]
PST - epublish
SO  - Indian J Psychol Med. 2020 Oct 7;42(5 Suppl):4S-10S. doi:
      10.1177/0253717620959783. eCollection 2020 Oct.


PMID- 33354057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201223
IS  - 0253-7176 (Print)
IS  - 0253-7176 (Linking)
VI  - 42
IP  - 5 Suppl
DP  - 2020 Oct
TI  - Approach to Informed Consent in Telepsychiatric Service: Indian Perspective.
PG  - 16S-22S
LID - 10.1177/0253717620959781 [doi]
AB  - Consent is an essential and important medico-legal prerequisite for a patient's
      treatment. This necessitates the service provider to participate in the informed 
      consent process and discuss the risk-benefit of the proposed treatment, the best 
      available treatment, engage in shared decision-making process, opportunity to
      convey their view and thereby limit chances of legal liability for all parties.
      The clinician should have ample knowledge and skill pertaining to the informed
      consent process and also have adequate understanding of medical ethics and law.
      This article provides an overview on informed consent pertaining to
      telepsychiatric services in India.
CI  - (c) 2020 Indian Psychiatric Society - South Zonal Branch.
FAU - Gowda, Guru S
AU  - Gowda GS
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neuro Sciences
      (NIMHANS), Bengaluru, Karnataka, India.
FAU - Enara, Arun
AU  - Enara A
AD  - Hertfordshire Partnership University, NHS Foundation Trust, Hertfordshire, UK.
FAU - Ali, Furkhan
AU  - Ali F
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neuro Sciences
      (NIMHANS), Bengaluru, Karnataka, India.
FAU - Gowda, Mahesh R
AU  - Gowda MR
AD  - Spandana Health Care, Bengaluru, Karnataka, India.
FAU - Basavarajappa, Chethan
AU  - Basavarajappa C
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neuro Sciences
      (NIMHANS), Bengaluru, Karnataka, India.
FAU - Kumar, Channaveerachari Naveen
AU  - Kumar CN
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neuro Sciences
      (NIMHANS), Bengaluru, Karnataka, India.
FAU - Math, Suresh Bada
AU  - Math SB
AD  - Dept. of Psychiatry, National Institute of Mental Health and Neuro Sciences
      (NIMHANS), Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - United States
TA  - Indian J Psychol Med
JT  - Indian journal of psychological medicine
JID - 7910727
PMC - PMC7736733
OTO - NOTNLM
OT  - India
OT  - Psychiatry
OT  - consent
OT  - telepsychiatry
COIS- The authors declared the following potential conflicts of interest with respect
      to the research, authorship, and/or publication of this article: Suresh Bada
      Math, Channaveerachari Naveen Kumar, and Chethan Basavarajappa are the authors of
      Telepsychiatry Operational Guidelines, 2020.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 05:48
PHST- 2020/12/23 05:48 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - 10.1177/0253717620959781 [doi]
AID - 10.1177_0253717620959781 [pii]
PST - epublish
SO  - Indian J Psychol Med. 2020 Oct 14;42(5 Suppl):16S-22S. doi:
      10.1177/0253717620959781. eCollection 2020 Oct.


PMID- 33354009
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 0970-0218 (Print)
IS  - 0970-0218 (Linking)
VI  - 45
IP  - 3
DP  - 2020 Jul-Sep
TI  - Pulmonary Functions and Respiratory Symptoms of the Women Exposed to Mine
      Tailings.
PG  - 311-314
LID - 10.4103/ijcm.IJCM_313_19 [doi]
AB  - INTRODUCTION: Impact of mining on environmental degradation affecting water,
      soil, and air is established. With the recognition that air pollution is the most
      important cause for noncommunicable cause for mortality and women as a gender at 
      higher susceptibility to lung dysfunction, it was necessary to make a start to
      understand the detrimental effect of mine tailing on ambient air pollution almost
      two decades after closure and its effect on the vulnerable women residents.
      MATERIALS AND METHODS: After institutional ethical clearance and informed
      consent, 258 females between the age of 18 and 60 years living in the gold mining
      town for over 3 years were selected. Respiratory symptoms were assessed using the
      American Thoracic Society questionnaire and lung functions of forced vital
      capacity (FVC), forced expiratory volume in 1 s (FEV1), peak expiratory flow rate
      (PEFR), and FEV1/FVC% using computerized spirometer. Dust samples were analyzed
      for particulate matter concentration (PM) by gravimetric method. RESULTS: The
      average PM concentration in the mining area was 1.491+/-0.737 mg/m. Of the
      respiratory symptoms, complaints of cough were 34%, breathlessness 31%, phlegm
      30%, and asthma 20%. FVC, FEV1, and PEFR were 1.3157 +/- 0.487 L/s, 1.2500 +/-
      0.4850 L/s, and 2.611 +/- 1.185 L/s, respectively. FEV/FEV1 was 93.650 +/-
      9.2733%. CONCLUSION: Mine tailing contributed to ambient air pollution, which has
      significantly decreased lung functions in the local women residents and produced 
      the restrictive type of lung abnormality.
CI  - Copyright: (c) 2020 Indian Journal of Community Medicine.
FAU - Shenoy, Usha G
AU  - Shenoy UG
AD  - Department of Physiology, Sri Devaraj Urs Medical College, Sri Devaraj Urs
      Academy of Higher Education and Research, Kolar, Karnataka, India.
FAU - Kutty, Karthiyanee
AU  - Kutty K
AD  - Department of Physiology, Sri Devaraj Urs Medical College, Sri Devaraj Urs
      Academy of Higher Education and Research, Kolar, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - India
TA  - Indian J Community Med
JT  - Indian journal of community medicine : official publication of Indian Association
      of Preventive & Social Medicine
JID - 9315574
PMC - PMC7745820
OTO - NOTNLM
OT  - Lung functions
OT  - Mine tailings
OT  - particulate matter
OT  - women
COIS- There are no conflicts of interest.
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 05:48
PHST- 2019/08/01 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/12/23 05:48 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - 10.4103/ijcm.IJCM_313_19 [doi]
AID - IJCM-45-311 [pii]
PST - ppublish
SO  - Indian J Community Med. 2020 Jul-Sep;45(3):311-314. doi:
      10.4103/ijcm.IJCM_313_19. Epub 2020 Sep 1.


PMID- 33353603
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 330
DP  - 2020 Sep-Oct
TI  - [Ethics: supporting the sexuality of people with a mental disability in an
      institution].
PG  - 23-26
LID - S0241-6972(20)30102-X [pii]
LID - 10.1016/S0241-6972(20)30102-X [doi]
AB  - The question of the sexuality of people with a disability in an institution
      touches on two sensitive aspects: sexuality, between taboo and unknown, and
      disability-related particularities. Within the microsociety of an institution,
      the protocols, daily living rules and therapeutic framework guide institutional
      life, and caregivers are sometimes helpless. An ethical perspective can help
      professionals support people with a mental disability with regard to their
      emotional and sexual life.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Paris, Pierre
AU  - Paris P
AD  - Maison d'accueil specialisee, La Valette, 12780 Saint-Leons, France; Fondation
      Opteo, 82 route de Saint-Mayme, 12850 Onet-le-Chateau, France. Electronic
      address: pierre-marie.paris@fondationopteo.fr.
FAU - Blanchard, Melodie
AU  - Blanchard M
AD  - Maison d'accueil specialisee, La Valette, 12780 Saint-Leons, France; Fondation
      Opteo, 82 route de Saint-Mayme, 12850 Onet-le-Chateau, France.
LA  - fre
PT  - Journal Article
TT  - Ethique : accompagner la sexualite des personnes atteintes de handicap en
      institution.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - Caregivers/psychology
MH  - Humans
MH  - *Institutionalization
MH  - *Intellectual Disability
MH  - *Professional-Patient Relations/ethics
MH  - *Sexuality
OTO - NOTNLM
OT  - consent
OT  - consentement
OT  - disability
OT  - ethics
OT  - handicap
OT  - institution
OT  - intimacy
OT  - intimite
OT  - sexuality
OT  - sexualite
OT  - ethique
EDAT- 2020/12/24 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/23 05:33
PHST- 2020/12/23 05:33 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - S0241-6972(20)30102-X [pii]
AID - 10.1016/S0241-6972(20)30102-X [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 Sep-Oct;41(330):23-26. doi: 10.1016/S0241-6972(20)30102-X.


PMID- 33353186
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 24
DP  - 2020 Dec 18
TI  - Xenogeneic and Stem Cell-Based Therapy for Cardiovascular Diseases: Genetic
      Engineering of Porcine Cells and Their Applications in Heart Regeneration.
LID - E9686 [pii]
LID - 10.3390/ijms21249686 [doi]
AB  - Cardiovascular diseases represent a major health concern worldwide with few
      therapy options for ischemic injuries due to the limited regeneration potential
      of affected cardiomyocytes. Innovative cell replacement approaches could
      facilitate efficient regenerative therapy. However, despite extensive attempts to
      expand primary human cells in vitro, present technological limitations and the
      lack of human donors have so far prevented their broad clinical use. Cell
      xenotransplantation might provide an ethically acceptable unlimited source for
      cell replacement therapies and bridge the gap between waiting recipients and
      available donors. Pigs are considered the most suitable candidates as a source
      for xenogeneic cells and tissues due to their anatomical and physiological
      similarities with humans. The potential of porcine cells in the field of stem
      cell-based therapy and regenerative medicine is under intensive investigation.
      This review outlines the current progress and highlights the most promising
      approaches in xenogeneic cell therapy with a focus on the cardiovascular system.
FAU - Galow, Anne-Marie
AU  - Galow AM
AUID- ORCID: 0000-0002-7968-3152
AD  - Institute of Genome Biology, Leibniz Institute for Farm Animal Biology, 18196
      Dummerstorf, Germany.
FAU - Goldammer, Tom
AU  - Goldammer T
AUID- ORCID: 0000-0003-1215-5504
AD  - Institute of Genome Biology, Leibniz Institute for Farm Animal Biology, 18196
      Dummerstorf, Germany.
AD  - Molecular Biology and Fish Genetics Unit, Faculty of Agriculture and
      Environmental Sciences, University of Rostock, 18059 Rostock, Germany.
FAU - Hoeflich, Andreas
AU  - Hoeflich A
AUID- ORCID: 0000-0003-2018-2836
AD  - Institute of Genome Biology, Leibniz Institute for Farm Animal Biology, 18196
      Dummerstorf, Germany.
LA  - eng
GR  - ESF /14-BM-A55-0028/18/EU Social Fund
PT  - Journal Article
PT  - Review
DEP - 20201218
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/*therapy
MH  - *Genetic Engineering
MH  - Humans
MH  - Myocytes, Cardiac/*cytology
MH  - *Regenerative Medicine
MH  - Stem Cell Transplantation/*methods
MH  - Stem Cells/*cytology
MH  - Swine
MH  - *Transplantation, Heterologous
PMC - PMC7766969
OTO - NOTNLM
OT  - CRISPR/Cas
OT  - cell transplantation
OT  - genome editing
OT  - graft rejection
OT  - iPSCs
OT  - mesenchymal stem cells
OT  - myocardial infarction
OT  - triple knockout pigs
EDAT- 2020/12/24 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/12/23 01:03
PHST- 2020/11/18 00:00 [received]
PHST- 2020/12/11 00:00 [revised]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2020/12/23 01:03 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - ijms21249686 [pii]
AID - 10.3390/ijms21249686 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Dec 18;21(24). pii: ijms21249686. doi: 10.3390/ijms21249686.


PMID- 33352950
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 18
TI  - Head-Only Stunning of Turkeys Part 1: The Minimum Voltage Necessary to Break Down
      the Inherent High Resistance.
LID - E2427 [pii]
LID - 10.3390/ani10122427 [doi]
AB  - Pre-slaughter stunning is required for humane slaughter. For turkeys, head-only
      electrical stunning is most often used by small scale producers. To ensure
      immediate and effective stunning, the impedance (resistance) of the tissue of the
      head of the animal situated between the two electrodes needs to be overcome
      swiftly. The impedance is a function of the voltage and decreases non-linearly
      with increasing voltage. In this paper, we describe a method to assess the
      minimum voltage needed at which the impedance no longer decreases, that is likely
      to produce an effective stun. For ethical reasons, gas stunned, electrically
      naive turkeys were used to measure impedance at various levels of voltage and
      current. Several combinations of voltage and frequency, alternate current (AC),
      direct current (DC) and pulsed DC, were identified that would be sufficient to
      achieve the maximum decrease in the impedance, and therefore would allow the
      highest current and the most effective stun. A minimum, expressed as Root Mean
      Squared voltage, of 150 V and 50 Hz. would be required in AC, 175 V in pulsed DC 
      at 30% cycle (150 at 50% cycle), and 225 V if voltage spikes of very short
      duration were used. Sinusoidal AC applied at 150 V, 50 Hz was selected for
      further testing.
FAU - Wotton, Steve
AU  - Wotton S
AUID- ORCID: 0000-0002-9855-0267
AD  - Bristol Veterinary School, University of Bristol, Bristol BS40 5DU, UK.
FAU - Grist, Andrew
AU  - Grist A
AD  - Bristol Veterinary School, University of Bristol, Bristol BS40 5DU, UK.
FAU - O'Callaghan, Mike
AU  - O'Callaghan M
AD  - Bristol Veterinary School, University of Bristol, Bristol BS40 5DU, UK.
FAU - van Klink, Ed
AU  - van Klink E
AUID- ORCID: 0000-0002-3175-5823
AD  - Bristol Veterinary School, University of Bristol, Bristol BS40 5DU, UK.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7766315
OTO - NOTNLM
OT  - electrical stunning
OT  - impedance
OT  - turkeys
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 01:02
PHST- 2020/11/06 00:00 [received]
PHST- 2020/12/16 00:00 [revised]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2020/12/23 01:02 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - ani10122427 [pii]
AID - 10.3390/ani10122427 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Dec 18;10(12). pii: ani10122427. doi: 10.3390/ani10122427.


PMID- 33352906
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 18
TI  - Quality Outcomes in Appendicitis Care: Identifying Opportunities to Improve Care.
LID - E358 [pii]
LID - 10.3390/life10120358 [doi]
AB  - INTRODUCTION: Appendicitis is one of the most common causes of acute abdominal
      pain requiring surgical intervention, but the variability of diagnosis and
      management continue to challenge the surgeons. Aim: This study assessed patients 
      undergoing appendectomy to identify opportunities to improve diagnostic accuracy 
      and outcomes. METHODS: An ethically approved retrospective cohort study was
      undertaken between March 2016 and March 2017 at a single university hospital of
      all consecutive adult and paediatric patients undergoing appendectomy.
      Demographic data including age, gender, co-morbidities, presentation and triage
      timings along with investigation, imaging and operative data were analysed.
      Appendicitis was defined as acute based on histology coupled with intraoperative 
      grading with the American Association for the Surgery of Trauma (AAST) grades.
      Complications using the Clavien-Dindo classification along with 30-day
      re-admission rates and the negative appendectomy rates (NAR) were recorded and
      categorised greater and less than 25%. The use of scoring systems was assessed,
      and retrospective scoring performed to compare the Alvarado, Adult Appendicitis
      Score (AAS) and the Appendicitis Inflammatory Response (AIR) score. Results: A
      total of 201 patients were studied, 115 male and 86 females, of which 136/201
      (67.6%) were adults and 65/201 (32.3%) paediatric. Of the adult group, 83 were
      male and 53 were female, and of the paediatric group, 32 were male and 33 were
      female. Median age was 20 years (range: 5 years to 81 years) and no patient below
      the age of 5 years had an appendectomy during our study period. All patients were
      admitted via the emergency department and median time from triage to surgical
      review was 2 h and 38 min, (range: 10 min to 26 h and 10 min). Median time from
      emergency department review to surgical review, 55 min (range: 5 min to 6 h and
      43 min). Median time to operating theatre was 21 h from admission (range: 45 min 
      to 140 h and 30 min). Out of the total patients, 173 (86.1%) underwent
      laparoscopic approach, 28 (13.9%) had an open approach and 12 (6.9%) of the 173
      were converted to open. Acute appendicitis occurred in 166/201 (82.6%). There was
      no significant association between grade of appendicitis and surgeons'
      categorical NAR rate (p = 0.07). Imaging was performed in 118/201 (58.7%);
      abdominal ultrasound (US) in 53 (26.4%), abdominal computed tomography (CT) in 59
      (29.2%) and both US and CT in 6 (3%). The best cut-off point was 4 (sensitivity
      84.3% and specificity of 65.7%) for AIR score, 9 (sensitivity of 74.7% and
      specificity of 68.6%) for AAS, and 7 (sensitivity of 77.7% and specificity of
      71.4%) for the Alvarado score. Twenty-four (11.9%) were re-admitted, due to pain 
      in 16 (58.3%), collections in 3 (25%), 1 (4.2%) wound abscess, 1 (4.2%) stump
      appendicitis, 1 (4.2%) small bowel obstruction and 1 (4.2%) fresh rectal
      bleeding. CT guided drainage was performed in 2 (8.3%). One patient had release
      of wound collection under general anaesthetic whereas another patient had
      laparoscopic drain placement. A laparotomy was undertaken in 3 (12.5%) patients
      with division of adhesions in 1, the appendicular stump removed in 1 and 1 had
      multiple collections drained. CONCLUSION: The negative appendectomy and
      re-admission rates were unacceptably high and need to be reduced. Minimising
      surgical variance with use of scoring systems and introduction of pathways may be
      a strategy to reduce NAR. New systems of feedback need to be introduced to
      improve outcomes.
FAU - Kabir, Syed Mohammad Umar
AU  - Kabir SMU
AD  - Donegal Clinical Research Academy and Department of Surgery Letterkenny
      University Hospital, Letterkeny, Co. F92 AE81 Donegal, Ireland.
FAU - Bucholc, Magda
AU  - Bucholc M
AD  - Intelligent Systems Research Centre, University of Ulster, Magee Campus,
      Londonderry BT48 7JL, UK.
FAU - Walker, Carol-Ann
AU  - Walker CA
AD  - EU INTERREG Emergency Surgery Outcome Advancement Project, Centre for
      Personalised Medicine, X728 HG Letterkenny, Ireland.
FAU - Sogaolu, Opeyemi O
AU  - Sogaolu OO
AD  - Donegal Clinical Research Academy and Department of Surgery Letterkenny
      University Hospital, Letterkeny, Co. F92 AE81 Donegal, Ireland.
FAU - Zeeshan, Saqib
AU  - Zeeshan S
AD  - Donegal Clinical Research Academy and Department of Surgery Letterkenny
      University Hospital, Letterkeny, Co. F92 AE81 Donegal, Ireland.
FAU - Sugrue, Michael
AU  - Sugrue M
AD  - Donegal Clinical Research Academy and Department of Surgery Letterkenny
      University Hospital, Letterkeny, Co. F92 AE81 Donegal, Ireland.
AD  - EU INTERREG Emergency Surgery Outcome Advancement Project, Centre for
      Personalised Medicine, X728 HG Letterkenny, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC7767194
OTO - NOTNLM
OT  - Adult Appendicitis Score
OT  - Alvarado score
OT  - Appendicitis Inflammatory Response score
OT  - appendectomy
OT  - appendicitis
OT  - negative appendectomy rate
OT  - re-admission
EDAT- 2020/12/24 06:00
MHDA- 2020/12/24 06:01
CRDT- 2020/12/23 01:02
PHST- 2020/11/18 00:00 [received]
PHST- 2020/12/07 00:00 [revised]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2020/12/23 01:02 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2020/12/24 06:01 [medline]
AID - life10120358 [pii]
AID - 10.3390/life10120358 [doi]
PST - epublish
SO  - Life (Basel). 2020 Dec 18;10(12). pii: life10120358. doi: 10.3390/life10120358.


PMID- 33351304
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1009-3591 (Print)
IS  - 1009-3591 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Apr
TI  - [Stem cell therapy for non-obstructive azoospermia].
PG  - 351-356
AB  - Non-obstructive azoospermia (NOA) is an important factor that causes male
      infertility. Stem cells are a group of cells capable of self-renewal and
      multi-directional differentiation, and embryonic stem cells and induced
      pluripotent stem cells can generate spermatozoa through differentiation, which,
      however, is confronted with ethical constraints and the risk of tumorigenesis.
      Spermatogonial stem cells can produce haploid gametes by differentiation but
      human spermatogonial stem cells are difficult to be cultured in vitro.
      Mesenchymal stem cells promote spermatogenesis through paracrine activity, and
      Leydig stem cells act on sperm production by secreting testosterone. 2D
      co-culture of multiple stem cells and 3D testicular organ culture can promote
      spermatogenesis by simulating a better spermatogenic microenvironment of the
      testis. Some progress has been achieved in the treatment of NOA by stem cell
      therapy despite existing problems and difficulties. This review summarizes the
      advances in the studies of stem cell therapy for NOA and introduces its
      application prospects and existing problems so as to provide some reference for
      the relevant researches and application.
FAU - Deng, Cun-Can
AU  - Deng CC
AD  - Center of Reproduction, The Sixth Hospital of Sun Yat-sen University, Guangzhou, 
      Guangdong 510620, China.
AD  - Family Planning Research Institute of Guangdong Province, Guangzhou, Guangdong
      510600, China.
FAU - Liu, Gui-Hua
AU  - Liu GH
AD  - Center of Reproduction, The Sixth Hospital of Sun Yat-sen University, Guangzhou, 
      Guangdong 510620, China.
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Nan Ke Xue
JT  - Zhonghua nan ke xue = National journal of andrology
JID - 101093592
SB  - IM
MH  - *Azoospermia/therapy
MH  - Humans
MH  - Male
MH  - Organ Culture Techniques
MH  - Spermatogenesis
MH  - Spermatozoa
MH  - *Stem Cell Transplantation
MH  - Testis
OTO - NOTNLM
OT  - differentiation
OT  - non-obstructive azoospermia
OT  - paracrine
OT  - spermatogenic microenvironment
OT  - stem cell
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 12:42
PHST- 2020/12/22 12:42 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nan Ke Xue. 2020 Apr;26(4):351-356.


PMID- 33351183
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1543-5865 (Print)
IS  - 1543-5865 (Linking)
VI  - 18
IP  - 7
DP  - 2020
TI  - Canadian emergency medicine and critical care physician perspectives on pandemic 
      triage in COVID-19.
PG  - 31-35
LID - jem.2020.0484 [pii]
LID - 10.5055/jem.2020.0484 [doi]
AB  - INTRODUCTION: Local and regional policies to guide the allocation of scarce
      critical care resources have been developed, but the views of prospective users
      are not understood. We sought to investigate the perspectives of Canadian acute
      care physicians toward triaging scarce critical care resources in the COVID-19
      pandemic. METHODS: We rapidly deployed a brief survey to Canadian emergency and
      critical care physicians in April 2020 to investigate current attitudes toward
      triaging scarce critical care resources and identify subsequent areas for
      improvement. Descriptive and between-group analyses along with thematic coding
      were used. RESULTS: The survey was completed by 261 acute care physicians.
      Feelings of anxiety related to the pandemic were common (65 percent), as well as 
      fears of psychological distress if required to triage scarce resources (77
      percent). Only 49 percent of respondents felt confident in making resource
      allocation decisions. Both critical care and emergency physicians favored
      multidisciplinary teams over single physicians to allocate scarce critical care
      resources. Critical care physicians were supportive of decision making by teams
      not involved in patient care (3.4/5 versus 2.9/5 p = 0.04), whereas emergency
      physicians preferred to maintain their involvement in such decisions (3.4/5
      versus 4.0/5 p = 0.007). Free text responses identified five themes for
      subsequent action including the need for further guidance on existing triage
      policies, ethical support in decision making, medicolegal protection, additional 
      tools for therapeutic communications, and healthcare provider psychological
      support. CONCLUSION: There is an urgent need for collaboration between
      policymakers and frontline physicians to develop critical care resource triage
      policies that wholly consider the diversity of provider perspectives across
      practice environments.
FAU - Mulla, Ali
AU  - Mulla A
AD  - Emergency Medicine Physician, Trillium Health Partners, Mississauga, Ontario;
      Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Bigham, Blair L
AU  - Bigham BL
AD  - Emergency Medicine Physician, Critical Care Fellow, Stanford University,
      Stanford, California; Stanford University Medical Centre, Palo Alto, California.
FAU - Frolic, Andrea
AU  - Frolic A
AD  - Director of the Program for Ethics and Ecologies of Care, Hamilton Health
      Sciences, Hamilton, Canada; Assistant Professor, Department of Family Medicine,
      McMaster University, Hamilton, Canada.
FAU - Christian, Michael D
AU  - Christian MD
AD  - Research & Clinical Effectiveness Lead, London's Air Ambulance, Barts NHS Health 
      Trust, London, United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Emerg Manag
JT  - Journal of emergency management (Weston, Mass.)
JID - 101284695
SB  - IM
MH  - *COVID-19
MH  - Canada
MH  - Critical Care
MH  - *Emergency Medicine
MH  - Humans
MH  - Pandemics
MH  - *Physicians
MH  - Prospective Studies
MH  - SARS-CoV-2
MH  - Triage
EDAT- 2020/12/23 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/12/22 12:39
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/12/22 12:39 [entrez]
AID - jem.2020.0484 [pii]
AID - 10.5055/jem.2020.0484 [doi]
PST - ppublish
SO  - J Emerg Manag. 2020;18(7):31-35. doi: 10.5055/jem.2020.0484.


PMID- 33350794
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Intravenous vs intraosseous adrenaline administration in cardiac arrest: A
      protocol for systematic review and meta-analysis.
PG  - e23917
LID - 10.1097/MD.0000000000023917 [doi]
AB  - INTRODUCTION: Cardiac arrest refers to the sudden termination of cardiac ejection
      function due to various causes. Adrenaline is an important component of
      resuscitation among individuals experiencing cardiac arrest. The adrenaline
      delivery method chiefly involved intraosseous infusion and intravenous access.
      However, the impact of different adrenaline delivery methods on cardiac arrest
      has been unclear in previous research. Thus, the present study aimed to
      synthesize the available evidence regarding intravenous vs intraosseous
      adrenaline administration in cardiac arrest. METHODS AND ANALYSIS: We will search
      PubMed, EMBASE, Cochrane Library, Wanfang, and China National Knowledge
      Infrastructure. As per the inclusion criteria, randomized controlled trials
      (RCTs) on adrenaline administration in cardiac arrest were selected. The primary 
      outcome was prehospital restoration of spontaneous circulation (ROSC); the
      secondary endpoints were survival, favorable neurological outcome at discharge,
      and poor neurological outcome at >/=3 mon.We plan to use the Cochrane
      Collaboration's tool for assessing the bias risk for RCTs. The Grading of
      Recommendations Assessment, Development and Evaluation approach will grade the
      certainty of the evidence for all the outcome measures across studies. RevMan
      5.3.5 will be used for meta-analysis. If the heterogeneity tests show slight or
      no statistical heterogeneity, the fixed effects model will be used, in other
      cases, the random effect model will be used for data synthesis. RESULTS AND
      CONCLUSION: This protocol will determine which epinephrine delivery method is the
      optimal in the management of cardiac arrest. Our findings will help clinicians
      and health professionals in making accurate clinical decisions about adrenaline
      administrations in cardiac arrest. ETHICS AND DISSEMINATION: Ethical approval was
      not required because this study was planned as a secondary analysis. The results 
      will be disseminated in peer-reviewed publications, journals, and academic.
      INPLASY REGISTRATION NUMBER: INPLASY202090100 (DOI:10.37766/inplasy2020.9.0100).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zhang, Wei
AU  - Zhang W
AUID- ORCID: 0000-0002-8326-8496
AD  - Department of Emergency Medicine, Laboratory of Emergency Medicine, West China
      Hospital, and Disaster Medical Center.
AD  - School of Nursing.
FAU - Liu, Yi
AU  - Liu Y
AD  - Department of Emergency Medicine, Laboratory of Emergency Medicine, West China
      Hospital, and Disaster Medical Center.
AD  - School of Nursing.
FAU - Yu, Jing
AU  - Yu J
AD  - School of Nursing.
FAU - Li, Dongze
AU  - Li D
AD  - Department of Emergency Medicine, Laboratory of Emergency Medicine, West China
      Hospital, and Disaster Medical Center.
FAU - Jia, Yu
AU  - Jia Y
AD  - Department of Emergency Medicine, Laboratory of Emergency Medicine, West China
      Hospital, and Disaster Medical Center.
FAU - Zhang, Qin
AU  - Zhang Q
AD  - Department of Emergency Medicine, Laboratory of Emergency Medicine, West China
      Hospital, and Disaster Medical Center.
AD  - School of Nursing.
FAU - Gao, Yongli
AU  - Gao Y
AD  - Department of Emergency Medicine, Laboratory of Emergency Medicine, West China
      Hospital, and Disaster Medical Center.
AD  - School of Nursing.
FAU - Liao, Xiaoyang
AU  - Liao X
AD  - Department of General Practice and National Clinical Research Center for
      Geriatrics, International Medical Center, West China Hospital, Sichuan
      University, Chengdu, China.
LA  - eng
GR  - 20SYSX0293/Sichuan Science and Technology Program
GR  - 2020YFS0154/Sichuan Science and Technology Program
GR  - 2019JDRC0105/Sichuan Science and Technology Program
GR  - Z20191009/National Clinical Research Centre for Geriatrics
GR  - 2018HXFH001/Sichuan University West China Hospital
GR  - 2018HXFH027/Sichuan University West China Hospital
GR  - 20HXFH050/Sichuan University West China Hospital
GR  - 2020YFSY0014/Sichuan Science and Technology Program
GR  - HXHL19023/West China School of Nursing, Sichuan University
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Vasoconstrictor Agents)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Epinephrine/*administration & dosage
MH  - Heart Arrest/*drug therapy
MH  - Humans
MH  - Infusions, Intraosseous/*methods
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Vasoconstrictor Agents/administration & dosage
PMC - PMC7769335
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/28 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1097/MD.0000000000023917 [doi]
AID - 00005792-202012240-00076 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23917. doi:
      10.1097/MD.0000000000023917.


PMID- 33350793
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Herbal medicines for anorexia in lung cancer: A protocol for systematic review
      and meta-analysis.
PG  - e23913
LID - 10.1097/MD.0000000000023913 [doi]
AB  - INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide.
      Anorexia is the most common cause of malnutrition in lung cancer patients as well
      as an independent prognostic factor for cancer survival. This review will deal
      with the clinical evidence of herbal medicine use for reducing anorexia in lung
      cancer patients. METHODS AND ANALYSIS: Fourteen electronic databases will be
      searched from inception until October 2020. We will include randomized controlled
      trials (RCTs) assessing herbal medicines for anorexia in lung cancer patients.
      Interventions of any herbal medicines will be included. The methodological
      qualities of the included RCTs will be assessed via the Cochrane Collaboration
      tool for assessing the risk of bias. The Grading of Recommendations Assessment,
      Development, and Evaluation (GRADE) instrument will be used to evaluate the
      confidence in the cumulative evidence. ETHICS AND DISSEMINATION: This systematic 
      literature review does not require an ethics review. This review will be
      published in a peer-reviewed journal and disseminated electronically and in
      print. The review will be updated to inform and guide healthcare practices.
      REGISTRATION NUMBER: reviewregistry1038.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Lee, Ju Ah
AU  - Lee JA
AD  - Hwapyeong Institute of Integrative Medicine.
FAU - Kim, Kyun Ha
AU  - Kim KH
AD  - National Clinical Research Center for Korean Medicine, Korean Medicine Hospital
      of Pusan National University.
FAU - Ko, Geum Young
AU  - Ko GY
AD  - National Clinical Research Center for Korean Medicine, Korean Medicine Hospital
      of Pusan National University.
FAU - Yoo, Hwa-Seung
AU  - Yoo HS
AD  - East West Cancer Center, Seoul Korean Medicine Hospital of Daejeon University.
FAU - Choi, Jun-Yong
AU  - Choi JY
AUID- ORCID: 0000-0002-2854-3862
AD  - National Clinical Research Center for Korean Medicine, Korean Medicine Hospital
      of Pusan National University.
AD  - Department of Internal Medicine, Korean Medicine Hospital of Pusan National
      University.
AD  - School of Korean Medicine, Pusan National University, Republic of Korea.
LA  - eng
GR  - HI19C1046/Ministry of Health and Welfare
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Anorexia/etiology/therapy
MH  - Humans
MH  - Lung Neoplasms/*complications
MH  - *Malnutrition/etiology/prevention & control
MH  - Medicine, Traditional/methods
MH  - Meta-Analysis as Topic
MH  - Phytotherapy/*methods
MH  - Plants, Medicinal
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7769363
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/27 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1097/MD.0000000000023913 [doi]
AID - 00005792-202012240-00075 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23913. doi:
      10.1097/MD.0000000000023913.


PMID- 33350786
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Psychometric properties of quality of life questionnaires for patients with
      breast cancer-related lymphedema: A protocol for a systematic review.
PG  - e23897
LID - 10.1097/MD.0000000000023897 [doi]
AB  - BACKGROUND: Breast-cancer related lymphedema (BCRL) is a common condition among
      breast cancer survivors that could impact the quality of life (QoL) of patients. 
      Exploring the QoL of the patients with BCRL using valid and reliable QoL is
      crucial to capture the status of this important aspect hence appropriate
      intervention could be implement to patient. However, so far no scientific review 
      is available, which reports the psychometric properties of the QoL questionnaires
      used in BCRL. The purpose of this systematic review is to comprehensively assess 
      the psychometric properties of QoL questionnaires in patients with BCRL. METHODS:
      We will perform comprehensive searches of published studies in electronic
      databases such as Medline (via Ovid), EBSCOhost, PubMed, Scopus, and Web of
      Science by using the following search terms: "quality of life"; "breast cancer"; 
      "upper limb"; "lymphedema"; "questionnaire"; and "measurement properties." Only
      full-text articles in English language are included. Two reviewers will
      independently conduct the article selection, data extraction, and quality
      assessment. Any possible conflict between the 2 reviewers is going to be solved
      with the help of a third reviewer. The Consensus-based Standards for the
      Selection of Health Measurement Instrument (COSMIN) checklist and manual will be 
      used to assess the selected study quality. RESULTS: This review will provide an
      updated overview of available lymphedema-specific questionnaires used in BCRL
      population and then recommend the most valid and reliable QoL questionnaire for
      clinical and research use in patients with BCRL. CONCLUSION: This review may help
      the clinician and researcher to find an updated overview of various
      questionnaires used to assess BCRL patients' QoL. ETHICS AND DISSEMINATION: This 
      review will use data from published studies. Therefore, ethical approval is not
      required prior to this review. The results of this review will be published in a 
      peer-reviewed journal or presented at conferences. STUDY REGISTRATION: OSF
      osf.io/8xwym.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Meilani, Estu
AU  - Meilani E
AD  - Physiotherapy Programme, Centre for Rehabilitation and Special Needs Studies,
      Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Malaysia.
FAU - Zanudin, Asfarina
AU  - Zanudin A
AUID- ORCID: 0000-0001-6187-1019
FAU - Nordin, Nor Azlin Mohd
AU  - Nordin NAM
LA  - eng
GR  - NN-2020-087/UKM UNIPEQ Sdn Bhd
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Breast Cancer Lymphedema/*psychology
MH  - Female
MH  - Humans
MH  - Psychometrics/*methods
MH  - *Quality of Life
MH  - Research Design
MH  - Surveys and Questionnaires
MH  - Systematic Reviews as Topic
PMC - PMC7769337
COIS- The authors declares no conflicts of interests.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/25 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1097/MD.0000000000023897 [doi]
AID - 00005792-202012240-00068 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23897. doi:
      10.1097/MD.0000000000023897.


PMID- 33350776
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Nursing case management for people with hypertension: A randomized controlled
      trial protocol.
PG  - e23850
LID - 10.1097/MD.0000000000023850 [doi]
AB  - OBJECTIVE: To explore the effect of management of nursing case on blood pressure 
      control in hypertension patients. METHOD: This is a randomized controlled study
      which will be carried out from May 2021 to May 2022. The experiment was granted
      through the Research Ethics Committee of the People's Hospital of Chengyang
      District (03982808). Our research includes 200 patients. Patients who meet the
      following conditions will be included in this experiment: the patients aged 18 to
      60 years; the patients had the diagnosis of hypertension; and the urban
      residents. While patients with the following conditions will be excluded: having 
      renal failure, liver failure, heart and respiratory failure; and known pregnancy.
      Primary result is blood pressure, while secondary results are treatment
      compliance, waist circumference, body mass index (BMI), type and number of
      antihypertensive agents used, and the existence of metabolic and cardiovascular
      comorbidities. RESULTS: Table 1 shows the clinical outcomes between the two
      groups. CONCLUSION: Nursing case management is effective to improve the prognosis
      of hypertension patients.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Song, Chunjing
AU  - Song C
AD  - Department of Urology, People's Hospital of Chengyang District, Qingdao, China.
FAU - Li, Xianhong
AU  - Li X
FAU - Ning, Xueling
AU  - Ning X
FAU - Song, Shiqiang
AU  - Song S
AUID- ORCID: 0000-0002-1890-5452
LA  - eng
GR  - 2013-WSZD120/Qingdao Health Bureau project
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Case Management/*organization & administration
MH  - China
MH  - Humans
MH  - *Hypertension/diagnosis/nursing
MH  - Nursing Care/*methods
MH  - Outcome and Process Assessment, Health Care
MH  - Practice Patterns, Nurses'
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
PMC - PMC7769350
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/17 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1097/MD.0000000000023850 [doi]
AID - 00005792-202012240-00058 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23850. doi:
      10.1097/MD.0000000000023850.


PMID- 33350773
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Clinical therapeutic effects of lidocaine combination with flurbiprofen axetil
      for reducing propofol-induced pain in adults: A protocol for systematic review
      and meta-analysis.
PG  - e23844
LID - 10.1097/MD.0000000000023844 [doi]
AB  - BACKGROUND: Pain on injection is a well-recognized adverse event of propofol
      administration for the stimulation of general anesthesia. Pre-treatment with
      lidocaine or flurbiprofen axetil has proven to be effectual in the reduction
      propofol-induced pain in adults. Nonetheless, only few studies have evaluated the
      clinical therapeutic effects of lidocaine combination with flurbiprofen axetil to
      prevent pain on injection of propofol. The current study aims to evaluate the
      clinical therapeutic effects of lidocaine combination with flurbiprofen axetil to
      reduce pain on injection of propofol among adult patients. METHODS: The
      literature search will be conducted from their inception to November 2020 from
      MEDLINE, EMBASE, Web of Science, and Cochrane Library databases without date or
      geographical restrictions. However, language will be restricted to publications
      in English and Chinese. Two authors will independently screen abstracts and
      titles of all papers to determine whether to include or exclude them. The authors
      will also study characteristic and outcomes of data extraction and carry out risk
      of bias assessment. We plan to use either a fixed-effects or random-effects model
      to estimate the risk ratios (RR) or mean difference (MD) or standardized mean
      difference (SMD) together with 95% confidence interval (CI). RESULTS: This study 
      will provide high-quality evidence for the clinical therapeutic effects of
      lidocaine combination with flurbiprofen axetil for reducing pain on injection of 
      propofol in adult patients. CONCLUSION: This study will summarize current
      evidence for the management of pain on injection of propofol in adult patients
      and provide guidance for both intervention and future research. ETHICS AND
      DISSEMINATION: Since no data collection will be involved, there is no need for an
      ethics approval. REGISTRATION NUMBER: November 17, 2020.osf.io/72tpj/.
      (https://osf.io/72tpj/).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Sun, Weiqiang
AU  - Sun W
AD  - Pain Management, Maternal and Child Health Hospital of Hubei Province, Wuhan,
      Hubei, PR China.
FAU - Yu, Jinfen
AU  - Yu J
FAU - Lu, Gang
AU  - Lu G
FAU - Ye, Xiaofeng
AU  - Ye X
AUID- ORCID: 0000-0002-8896-145
FAU - Fu, Jun
AU  - Fu J
LA  - eng
GR  - WJ2019H302/Joint Foundation of Health Commission of Hubei Province
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anesthetics, Intravenous)
RN  - 0 (Anesthetics, Local)
RN  - 5GRO578KLP (Flurbiprofen)
RN  - 98PI200987 (Lidocaine)
RN  - I0OU31PUI5 (flurbiprofen axetil)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Adult
MH  - Anesthetics, Intravenous/administration & dosage/adverse effects
MH  - Anesthetics, Local/pharmacology
MH  - Drug Therapy, Combination/methods
MH  - Flurbiprofen/*analogs & derivatives/pharmacology
MH  - Humans
MH  - Lidocaine/*pharmacology
MH  - Meta-Analysis as Topic
MH  - *Pain, Procedural/etiology/prevention & control
MH  - Propofol/administration & dosage/*adverse effects
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7769353
COIS- The authors report no conflicts of interest.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/18 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1097/MD.0000000000023844 [doi]
AID - 00005792-202012240-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23844. doi:
      10.1097/MD.0000000000023844.


PMID- 33350772
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A
      protocol for systematic review and meta analysis.
PG  - e23841
LID - 10.1097/MD.0000000000023841 [doi]
AB  - BACKGROUND: Previous studies have showed that the high expression of urokinase
      plasminogen activator (uPA) in pathology and serology is closely related to the
      progression of hepatocellular carcinoma (HCC). However, there are no systematic
      reviews for these evidence, and the association between uPA and HCC is still not 
      completely understood. Therefore, we will undertake a systematic review of the
      literature to summarize previous evidence regarding this topic, in order to
      clarify the prognostic significance of uPA in HCC. METHODS AND ANALYSIS: Studies 
      comparing the HCC patients with high and low expression of uPA on the
      clinicopathological features and the prognosis are eligible for this review.
      Outcomes include all endpoints about survival and clinicopathological features.
      Prospective or retrospective primary studies which published in English will be
      included. Four databases of Medline, EMBASE, Web of Science, and the Cochrane
      Library will be systematically searched from their inception to Mar 2021 to
      retrieve relevant studies. Reference lists of included studies will be manually
      reviewed and grey literatures will be identified by Google Scholar. Two reviewers
      will independently screen the records and extract the information and data of the
      included studies. The Newcastle-Ottawa Scale will be used to assess the quality
      of included studies. Hazard ratio and 95% confidence interval will be pooled to
      assess the association between uPA expression and the prognosis. Pooled odds
      ratio and 95% confidence interval will be used for other outcomes. Heterogeneity 
      will be assessed using the Cochrane Q test and I2 statistic, and a subgroup
      analysis will be performed if necessary. Grades of Recommendation, Assessment,
      Development and Evaluation method will be applied to assess the certainty of
      evidence. ETHICS AND DISSEMINATION: This protocol required information extracted 
      from previously published articles. So, there is no ethical problem in this
      study. We plan to publish our findings in peer-reviewed journals and relevant
      conference proceedings. SYSTEMATIC REVIEW REGISTRATION: This study has been
      registered with the International Prospective Register of Systematic Reviews
      database (no.CRD42020150340).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Tao, Pengxian
AU  - Tao P
AD  - The Department of Tumor Surgery, Lanzhou University Second Hospital.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou.
FAU - Gao, Lei
AU  - Gao L
AD  - The Department of Tumor Surgery, Lanzhou University Second Hospital.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou.
FAU - Li, Haiyuan
AU  - Li H
AD  - The Department of Tumor Surgery, Lanzhou University Second Hospital.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou.
FAU - Wang, Bofang
AU  - Wang B
AD  - The Department of Tumor Surgery, Lanzhou University Second Hospital.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou.
FAU - Li, Xuemei
AU  - Li X
AD  - The Department of Tumor Surgery, Lanzhou University Second Hospital.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Department of Laboratory Medicine, the First Medical Centre, Chinese PLA General 
      Hospital, Beijing, China.
FAU - Chen, Hao
AU  - Chen H
AD  - The Department of Tumor Surgery, Lanzhou University Second Hospital.
LA  - eng
GR  - 81470791, 81376597, 81670594/National Nature Science Foundation of China
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - *Carcinoma, Hepatocellular/metabolism/pathology
MH  - Humans
MH  - *Liver Neoplasms/metabolism/pathology
MH  - Meta-Analysis as Topic
MH  - Prognosis
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Urokinase-Type Plasminogen Activator/*analysis
PMC - PMC7769352
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/18 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1097/MD.0000000000023841 [doi]
AID - 00005792-202012240-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23841. doi:
      10.1097/MD.0000000000023841.


PMID- 33350758
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Chinese herbal medicine for small cell lung cancer patients: A protocol for a
      systematic review and meta-analysis.
PG  - e23746
LID - 10.1097/MD.0000000000023746 [doi]
AB  - BACKGROUND: Small cell lung cancer (SCLC) is an aggressive disease. Chemotherapy 
      is the standard treatment for SCLC, but the resistance and the adverse effects of
      Chemotherapy still remains a major problem. Although Chinese herbal medicine
      (traditional Chinese medicine) is wildly applied for patients with SCLC in China,
      the evidence of traditional Chinese medicine in the treatment for SCLC is
      limited. METHOD: We conducted a systematic search of PubMed, EMBASE, the Chinese 
      National Knowledge Infrastructure, the VIP Information Database, and the Wanfang 
      Database for relevant studies. Only randomized controlled trials were included.
      Two investigators independently reviewed the included studies and extracted
      relevant data. The effect estimate of interest was the relative risk or mean
      difference with 95% confidence intervals. ETHICS AND DISSEMINATION: Ethical
      approval is not required, as this study is based on the review of published
      research. This review will be published in a peer-reviewed journal and
      disseminated both electronically and in print. INPLASY REGISTRATION NUMBER:
      INPLASY2020110055.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Mi, Xue
AU  - Mi X
AUID- ORCID: 0000-0001-7265-5477
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
AD  - Shaanxi University of Traditional Chinese Medicine, Xi'an.
FAU - Zhang, Xiwen
AU  - Zhang X
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
FAU - He, Shulin
AU  - He S
AD  - Xichengqu Guangwai Hospital.
FAU - Zhang, Zhenhua
AU  - Zhang Z
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
FAU - Qi, Runzhi
AU  - Qi R
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
FAU - Jiang, Juling
AU  - Jiang J
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
FAU - Chen, Shuntai
AU  - Chen S
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zheng, Honggang
AU  - Zheng H
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
FAU - Hua, Baojin
AU  - Hua B
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences, Beijing.
LA  - eng
GR  - 81774294/National Natural Science Foundation of China
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Medicine, Chinese Traditional
MH  - Small Cell Lung Carcinoma/*drug therapy
PMC - PMC7769348
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/14 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1097/MD.0000000000023746 [doi]
AID - 00005792-202012240-00040 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23746. doi:
      10.1097/MD.0000000000023746.


PMID- 33350755
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Hemostasis after percutaneous transfemoral access: A protocol for systematic
      review.
PG  - e23731
LID - 10.1097/MD.0000000000023731 [doi]
AB  - BACKGROUND: Access site hemostasis after percutaneous procedures done in the
      catheterization laboratory still needs to be better studied in relation to such
      aspects as the different results achieved with different hemostasis strategies,
      the impact of different introducer sheath sizes, and arterial versus venous
      access. The objective of this review is to synthesize the available scientific
      evidence regarding different techniques for hemostasis of femoral access sites
      after percutaneous diagnostic and therapeutic procedures. METHODS: This review is
      being reported in accordance with the Preferred Reporting Items for Systematic
      Review and Meta-Analysis Protocols (PRISMA-P). The primary outcomes will include 
      the following vascular complications: hematoma, pseudoaneurysm, bleeding, minor, 
      and major vascular complications. The secondary outcomes will include the
      following: time to hemostasis, repetition of manual compression, and device
      failure. A structured strategy will be used to search the PubMed/ MEDLINE,
      Embase, CINAHL, and CENTRAL databases. In addition, a handsearch of the reference
      lists of selected studies will be conducted. The ERIC research database will be
      queried for the gray literature and ClinicalTrials.gov, for potential results not
      yet published in indexed journals. Two reviewers will independently screen
      citations and abstracts, identify full-text articles for inclusion, extract data,
      and appraise the quality and risk of bias of included studies. If possible, a
      meta-analysis will be carried out. All estimations will be made using Review
      Manager 5.3. Statistical heterogeneity will be assessed by considering the I2
      proxy, accompanied with qualitative indicators such as differences in procedures,
      interventions, and outcomes among the studies. If synthesis proves inappropriate,
      a narrative review will be undertaken. RESULTS: This protocol adheres to the
      PRISMA-P guideline to ensure clarity and completeness of reporting at all phases 
      of the systematic review. CONCLUSION: This study will provide synthesized
      information on different methods used to achieve hemostasis after femoral access.
      ETHICS AND DISSEMINATION: Ethical approval number CAAE 19713219700005327. The
      results of the systematic review will be disseminated via publication in a
      peer-reviewed journal and through conference presentations. SYSTEMATIC REVIEW
      REGISTRATION: PROSPERO CRD42019140794.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Reich, Rejane
AU  - Reich R
AUID- ORCID: 0000-0002-7238-3800
AD  - Graduate Program in Nursing, Universidade Federal do Rio Grande do Sul.
AD  - Hospital de Clinicas de Porto Alegre.
FAU - Helal, Lucas
AU  - Helal L
AD  - Graduate Program in Cardiology and Cardiovascular Sciences, Universidade Federal 
      do Rio Grande do Sul, Porto Alegre.
AD  - Universidade Federal do Extremo Sul Catarinense, Criciuma.
FAU - Mantovani, Vanessa Monteiro
AU  - Mantovani VM
AD  - Graduate Program in Nursing, Universidade Federal do Rio Grande do Sul.
FAU - Rabelo-Silva, Eneida Rejane
AU  - Rabelo-Silva ER
AD  - Hospital de Clinicas de Porto Alegre.
AD  - Graduate Program in Nursing and Graduate Program in Cardiology and Cardiovascular
      Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Coronary Artery Disease/*surgery
MH  - *Femoral Artery
MH  - *Hemostasis
MH  - Humans
MH  - *Percutaneous Coronary Intervention
PMC - PMC7769327
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/14 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1097/MD.0000000000023731 [doi]
AID - 00005792-202012240-00037 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23731. doi:
      10.1097/MD.0000000000023731.


PMID- 33350753
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Correlation between tumor marker CA72-4 and prognosis of patients with gastric
      cancer: A protocol for systematic review and meta-analysis.
PG  - e23723
LID - 10.1097/MD.0000000000023723 [doi]
AB  - BACKGROUND: Gastric cancer is one of the common gastrointestinal tumors, with
      high recurrence and metastasis rates. Tumor marker tumor marker carbohydrate
      antigen 72-4 (CA72-4) has been used in the screening and diagnosis of gastric
      cancer, but whether it can be used as an indicator to monitor the prognosis of
      gastric cancer remains a great controversy. The purpose of this study was to
      systematically evaluate the correlation between tumor marker CA72-4 and prognosis
      of gastric cancer patients. METHODS: A systematic search was performed by
      retrieving on English databases (PubMed, Embase, Web of Science, the Cochrane
      Library) and Chinese databases (China Knowledge Network, Wanfang, Weipu (VIP
      Information Chinese Journal Service Platform), CBM) of clinical study on the
      correlation between tumor marker CA72-4 and prognosis of gastric cancer patients.
      The retrieval time limit was from the establishment of the database to October
      2020. Two researchers independently extracted and evaluated the quality of the
      data in the included study. A meta-analysis was performed using Stata12.0 and
      RevMan5.3 software. CONCLUSIONS: This study will compare the correlation between 
      tumor marker CA72-4 and prognosis of gastric cancer patients, so as to provide
      evidence-based basis for clinicians to select prognostic indicators of gastric
      cancer. ETHICS AND DISSEMINATION: Private information from individuals will not
      be published. This systematic review also does not involve endangering
      participant rights. Ethical approval was not required. The results may be
      published in a peer-reviewed journal or disseminated at relevant conferences. OSF
      REGISTRATION NUMBER: DOI: 10.17605 / OSF.IO / B3AMN.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Li, Minxia
AU  - Li M
AD  - The People's Hospital of Danyang city, Danyang, Jiangsu Province.
FAU - Xue, Fei
AU  - Xue F
AD  - Dongchang Fu People's Hospital, Liaocheng, Shandong Province.
FAU - Yang, Jie
AU  - Yang J
AD  - Central Laboratory, Danyang People's Hospital of Jiangsu Province, Danyang,
      Jiangsu Province.
FAU - Pan, Xiaodong
AU  - Pan X
AUID- ORCID: 0000-0001-9810-8105
AD  - Zhangye People's Hospital Affiliated to Hexi University, Zhangye, Gansu Province,
      China.
LA  - eng
GR  - No.FZ2019006/Social Development Guide Project of Zhenjiang
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antigens, Tumor-Associated, Carbohydrate)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-72-4 antigen)
SB  - IM
MH  - Antigens, Tumor-Associated, Carbohydrate/*blood
MH  - Biomarkers, Tumor/blood
MH  - Humans
MH  - Neoplasm Recurrence, Local/blood/*mortality
MH  - Prognosis
MH  - Stomach Neoplasms/blood/*mortality
PMC - PMC7769321
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/13 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1097/MD.0000000000023723 [doi]
AID - 00005792-202012240-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23723. doi:
      10.1097/MD.0000000000023723.


PMID- 33350741
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Long-term outcomes of single stenting compared with double stenting strategy for 
      unprotected left main coronary artery disease: A protocol for systematic review
      and meta-analysis.
PG  - e23639
LID - 10.1097/MD.0000000000023639 [doi]
AB  - BACKGROUND: The optimal interventions for unprotected left main coronary artery
      (ULMCA) disease have long been debated, and long-term clinical studies comparing 
      single stenting to double stenting strategies for ULMCA are currently lacking.
      METHODS: We plan to perform a systematic review and meta-analysis of clinical
      trials comparing single stenting with double stents strategy for ULMCA disease.
      We will search PubMed, EMBASE, Web of science and Cochrane Library using a
      comprehensive strategy. The related conference proceedings and reference lists of
      the included studies will also be checked to identify additional studies. Two
      reviewers will screen retrieved records, extract information and assess the risk 
      of bias independently. STATA software will be used to conduct data synthesis.
      There is no requirement of ethical approval and informed consent. RESULTS: This
      study will be submitted to a peer-reviewed journal for publication. CONCLUSION:
      We hope it will provide a relatively comprehensive reference for clinical
      practice and future relevant clinical trials. ETHICS AND DISSEMINATION: Ethics
      approval and patient consent are not required, as this study is a systematic
      review and meta-analysis. INPLASY REGISTRATION NUMBER: INPLASY2020110030.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Jia-Jie
AU  - Wang JJ
AD  - The first clinical medical college, Lanzhou University.
AD  - Department of Cardiology, the first hospital of Lanzhou University, Lanzhou,
      China.
FAU - Li, Xin
AU  - Li X
AD  - The first clinical medical college, Lanzhou University.
FAU - Yan, Dong-Dong
AU  - Yan DD
AD  - The first clinical medical college, Lanzhou University.
FAU - Zhang, Zheng
AU  - Zhang Z
AUID- ORCID: 0000-0003-3810-8562
AD  - The first clinical medical college, Lanzhou University.
AD  - Department of Cardiology, the first hospital of Lanzhou University, Lanzhou,
      China.
LA  - eng
GR  - GSXZYZH2018001/Laboratory of Intelligent Medical Engineering of Gansu Province
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Coronary Artery Disease/*surgery
MH  - Humans
MH  - *Stents
PMC - PMC7769356
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/08 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1097/MD.0000000000023639 [doi]
AID - 00005792-202012240-00023 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23639. doi:
      10.1097/MD.0000000000023639.


PMID- 33350738
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Efficacy and safety of intravenous thrombolysis with alteplase for treating acute
      ischemic stroke at different time windows: A protocol for systematic review and
      meta-analysis.
PG  - e23620
LID - 10.1097/MD.0000000000023620 [doi]
AB  - BACKGROUND: As the priority drug for treating acute ischemic stroke (AIS),
      alteplase is a thrombolytic drug with strong fibrin specificity. It can obviously
      treat AIS with high safety. However, the validity of its time window is
      controversial. This study focus on the efficacy and safety of intravenous
      thrombolysis with alteplase for treating AIS at different time windows. METHODS: 
      Retrieval of English database (PubMed, Embase, Web of Science, the Cochrane
      Library) and Chinese database was conducted (China National Knowledge
      Infrastructure, WAN FANG, VIP, China Biology Medicine disc) by computers. From
      the establishment of the database to October 2020, a retrospective study and
      case-control study on intravenous thrombolysis at different time windows for
      treating AIS were conducted. Two researchers independently conducted data
      extraction and quality evaluation of literature on the included studies, and
      RevMan5.3 was used for Meta-analysis on the included literature. RESULTS: This
      study aims to evaluate the efficacy and safety of intravenous thrombolysis with
      alteplase at different time windows for treating AIS by National Institutes of
      Health Stroke Scale score, modified Rankin Scale rating scale, spontaneous
      intracerebral hemorrhage incidence rate, All-cause mortality, and so on.
      CONCLUSIONS: This study will provide an evidence-based basis for the clinical
      efficacy of alteplase for treating AIS by thrombolytic therapy at different time 
      windows. ETHICS AND DISSEMINATION: Private information from individuals will not 
      be published. This systematic review also does not involve endangering
      participant rights. Ethical approval was not required. The results may be
      published in a peer-reviewed journal or disseminated at relevant conferences. OSF
      REGISTRATION NUMBER: DOI 10.17605 / OSF.IO / K7PHB.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Huang, Baogang
AU  - Huang B
AUID- ORCID: 0000-0002-7544-7208
AD  - First People's Hospital of Qujing City, Qujing, Yunnan province, China.
FAU - Qian, Fang
AU  - Qian F
FAU - Fan, Xijun
AU  - Fan X
FAU - Guan, Shaoyong
AU  - Guan S
FAU - Zheng, Yan
AU  - Zheng Y
FAU - Yang, Junsu
AU  - Yang J
FAU - Xu, Fengming
AU  - Xu F
LA  - eng
GR  - No .2019017/Special Fund for Agro-scientific Research in the Public Interest
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Fibrinolytic Agents)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Acute Disease
MH  - Administration, Intravenous
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Humans
MH  - Ischemic Stroke/*drug therapy
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic/*methods
MH  - *Thrombolytic Therapy/adverse effects/methods
MH  - Time Factors
MH  - Tissue Plasminogen Activator/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC7769329
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/05 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1097/MD.0000000000023620 [doi]
AID - 00005792-202012240-00020 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23620. doi:
      10.1097/MD.0000000000023620.


PMID- 33350735
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Massage treatment of hyperplasia of mammary glands: A protocol for a systematic
      review and meta-analysis.
PG  - e23601
LID - 10.1097/MD.0000000000023601 [doi]
AB  - BACKGROUND: With the accelerated pace of life, the problems of residence, diet,
      and environment have occurred frequently in recent years. External factors are
      easily to cause endocrine disorders and hormone sensitivity of breast tissue,
      which can lead to mammary hyperplasia. The incidence rate of hyperplasia of
      mammary glands is increasing year by year, and the age of onset is also getting
      lower and lower. If not treated in time, there is a crisis of breast
      cancer.Clinical studies have found that massage is widely used in clinical
      treatment of mammary hyperplasia recently, but the efficacy of massage in the
      treatment of mammary hyperplasia has not been systematically reviewed. The
      purpose of this study is to explore the efficacy, safety and effectiveness of
      massage in the treatment of hyperplasia of mammary glands. METHODS: We will
      search PubMed, Cochrane Central Register of controlled trials (central),
      ScienceNet, EMBASE, CBM, CNKI, VIP and Wanfang databases. The retrieval date was 
      October 20, 2020. RevMan 5.3 software was used to evaluate the quality and risk
      of included studies. The efficacy, recurrence rate, and symptom score of breast
      hyperplasia were analyzed, and the results were observed and measured. RESULTS:
      This study will be from the clinical efficiency, improvement rate, pain symptoms 
      disappear rate, tumor size improvement rate and other aspects of the existing
      evidence for a high quality synthesis, as well as massage adverse events.
      CONCLUSION: the conclusion of this review will provide the basis for judging
      whether massage is safe and effective in the treatment of hyperplasia of mammary 
      glands. ETHICS AND DISSEMINATION: This systematic will evaluate the effectiveness
      and safety of massage in the treatment of hyperplasia of mammary glands. As all
      data used in this systematic review and meta-analysis have been published,
      ethical approval is not required for this review. PROTOCOL REGISTRATION NUMBER:
      INPLASY2020100066.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Ma, Dehui
AU  - Ma D
AUID- ORCID: 0000-0002-3204-4847
AD  - Changchun University of Chinese Medicine.
FAU - Liu, Guochao
AU  - Liu G
AD  - The Changchun Hospital of TCM, Changchun, Jilin, China.
FAU - Zhang, Xiaolin
AU  - Zhang X
AD  - Changchun University of Chinese Medicine.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Changchun University of Chinese Medicine.
FAU - Gao, Tianjiao
AU  - Gao T
AD  - Changchun University of Chinese Medicine.
FAU - Liu, Mingjun
AU  - Liu M
AD  - Changchun University of Chinese Medicine.
LA  - eng
GR  - 86174092/National Natural Science Foundation of China
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Female
MH  - Humans
MH  - Hyperplasia/therapy
MH  - Mammary Glands, Human/*pathology
MH  - *Massage
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic/*methods
PMC - PMC7769290
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/11/06 00:00 [received]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1097/MD.0000000000023601 [doi]
AID - 00005792-202012240-00017 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23601. doi:
      10.1097/MD.0000000000023601.


PMID- 33350731
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Vitamin D supplementation for improving children with bone mineral density: A
      protocol for systematic review and meta-analysis.
PG  - e23475
LID - 10.1097/MD.0000000000023475 [doi]
AB  - BACKGROUND: Osteoporosis is usually one of the less perceived complications of
      chronic illness among children. Previous studies have shown that vitamin D
      supplementation may be valuable to bone density, especially among children with a
      deficiency of vitamin D. Yet, the results often remain inconsistent. Therefore,
      the present study investigates the clinical therapeutic effects of vitamin D
      supplementation to enhance children with bone mineral density. METHODS: We will
      search the randomised controlled experiment literature of vitamin D
      supplementation for bone mineral density, focusing on children, in 3 distinct
      English databases (EMBASE, MEDLINE via PubMed, and Cochrane Library) and 2
      specific Chinese databases (China National Knowledge Infrastructure (CNKI) and
      WanFang databases). Additionally, we intend to explore the Clinical Trials.gov,
      reference lists of identified publication and the grey literature. Accordingly,
      we will use 2 independent authors to screen the literature, extract data, and
      research quality assessment. We will carry out all statistical analyses using
      RevMan 5.3 software. RESULTS: We will systematically evaluate the clinical
      therapeutic effects of vitamin D supplementation to enhance children with bone
      mineral density. CONCLUSION: The present study will summarise the currently
      published pieces of evidence of vitamin D supplementation for bone mineral
      density in children to further comprehend its promotion and application. ETHICS
      AND DISSEMINATION: The present study is a systematic review and meta-analysis
      founded upon existing or published studies; therefore, ethical approval is not
      applicable. OSF REGISTRATION NUMBER: October 24, 2020. osf.io/7vtey.
      (https://osf.io/7vtey/).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Yuan, Chengcheng
AU  - Yuan C
AD  - Affiliated Maternity and Child Health Care Hospital of Nantong University,
      Nantong, China.
FAU - Qu, Chunyan
AU  - Qu C
AUID- ORCID: 0000-0001-8069-2729
FAU - Ji, Weigang
AU  - Ji W
LA  - eng
GR  - MS2018008/Nantong Municipal Science and Technology
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Bone Density/*drug effects
MH  - Child
MH  - *Dietary Supplements
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic/*methods
MH  - Vitamin D/pharmacology/*therapeutic use
PMC - PMC7769342
COIS- The authors report no conflicts of interest.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/10/25 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1097/MD.0000000000023475 [doi]
AID - 00005792-202012240-00013 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23475. doi:
      10.1097/MD.0000000000023475.


PMID- 33350726
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Conservative versus surgical treatment for Garden I hip fracture: A randomized
      controlled trial protocol.
PG  - e23378
LID - 10.1097/MD.0000000000023378 [doi]
AB  - BACKGROUND: A femoral neck fracture (FNF) is one of the most destructive and
      familiar injuries encountered via the orthopedic surgeons. However, this is no
      guideline for the treatment of the Garden I hip fractures because the current
      evidence is limited from the poor study design and small sample size. The
      objective of our research is to compare the safety and effectiveness of the
      surgical treatment and conservative treatment in the non-displaced FNFs. METHODS:
      This is a randomized trial, which will be implemented from December 2020 to
      December 2021. The experiment was granted through the Research Ethics Committee
      of the Zhenhai District People's Hospital of Ningbo (2014005). Hundred patients
      meet inclusion criteria and exclusion criteria are included. Patients who are
      eligible for the following conditions will be included: those over 75 years old
      with Garden I hip fractures diagnosed by CT or X-ray. Patients with the following
      conditions will be excluded: patients age under 75 years old, the avascular
      necrosis of the femoral head, pathological fracture, infection, former
      symptomatic hip pathology, the history of hip fracture, as well as the lower limb
      deformity. The primary outcome contains pain at 1 month, 3 months and 6 months
      and hip function at 1 month, 3 months and 6 months. Secondary outcome includes
      the life quality, mortality rate, complications such as deep venous thrombosis,
      pulmonary embolism. RESULTS: Comparison of outcome indicators in 2 groups after
      conservative treatment or surgical treatment (Table). CONCLUSION: The current
      trial will offer better evidence for the future treatment selection for Garden 1 
      FNFs for patients older than 75years old. TRIAL REGISTRATION NUMBER:
      researchregistry6147.
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Orthopaedics, Zhenhai District People's Hospital of Ningbo,
      Zhejiang.
FAU - Xu, Fangzhu
AU  - Xu F
AD  - Department of Orthopaedics, Zhenhai District People's Hospital of Ningbo,
      Zhejiang.
FAU - Luo, Jianguang
AU  - Luo J
AD  - Department of Orthopaedics, Zhenhai District People's Hospital of Ningbo,
      Zhejiang.
FAU - Zhu, Liping
AU  - Zhu L
AUID- ORCID: 0000-0002-6776-6508
AD  - Department of Orthopaedics, the First People's Hospital of Jingzhou, Hubei,
      China.
LA  - eng
GR  - 2010A1056/Zhenhai Medical Science and Technology Project
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - *Conservative Treatment
MH  - *Hemiarthroplasty
MH  - Hip Fractures/surgery/*therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic/*methods
PMC - PMC7769300
COIS- The authors report no conflicts of interest.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/10/22 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1097/MD.0000000000023378 [doi]
AID - 00005792-202012240-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23378. doi:
      10.1097/MD.0000000000023378.


PMID- 33350725
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 52
DP  - 2020 Dec 24
TI  - Evaluation on curative effects of ethylene diamine tetra-acetic acid chelation
      therapy in treating with atherosclerotic cardiovascular disease: A protocol for
      systematic review and meta-analysis.
PG  - e23346
LID - 10.1097/MD.0000000000023346 [doi]
AB  - BACKGROUND: Ethylene diamine tetra-acetic acid (EDTA) is a chelating agent which 
      attach to metals such as calcium and enables their elimination. In particular,
      some researchers suggest chelation with EDTA to treat cardiovascular disease with
      the hypothesis of moderating calcium to decrease atherosclerotic calcification of
      arteries. However, chelation with EDTA therapeutic effects in atherosclerotic
      cardiovascular disease is still unclear. Therefore, we propose to undertake a
      meta-analysis to assess the curative effects of EDTA chelation therapy in
      patients with atherosclerotic cardiovascular disease. METHODS: In the current
      study, we set to perform a systematic literature search using the electronic
      databases of 4 most commonly used English databases (EMBASE, MEDLINE, Cochrane
      Library, and ClinicalTrials.gov trials register), as well as 3 most commonly
      employed Chinese databases (China Nation Knowledge Infrastructure, Wan Fang, and 
      VIP), from the date of database inception until September 30, 2020 to identify
      relevant randomized controlled studies of the evaluation on curative effects of
      EDTA chelation therapy in patients with atherosclerotic cardiovascular disease.
      In the study, 2 authors worked independently to screen search results, chose
      studies for inclusion, then they extracted pertinent data to evaluate and study
      quality based on Cochrane Risk of Bias Tool V.2.0. Additionally, we will address 
      discrepancies by consultation with a third author. We also intend to use pooled
      risk ratio (RR) and pooled mean difference (MD) or pooled standardized mean
      difference (SMD) with 95% confidence intervals (CI) to approximate the relative
      strength of curative effects of EDTA chelation therapy in patients with
      atherosclerotic cardiovascular disease. RESULTS: The results of the current study
      will systematically assess curative effects of EDTA chelation therapy in patients
      with atherosclerotic cardiovascular disease. CONCLUSION: The study will infer the
      currently published evidence to evaluate curative effects of EDTA chelation
      therapy in patients with atherosclerotic cardiovascular disease, which might be
      beneficial to these patients. ETHICS AND DISSEMINATION: The present study is a
      systematic review, hence the pooled results are founded upon the published
      evidence. Therefore, ethical approval is not necessary for the study. OPEN
      SCIENCE FRAMEWORK REGISTRATION NUMBER: October 20, 2020.osf.io/tvmk8.
      (https://osf.io/tvmk8/).
CI  - Copyright (c) 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Song, Tao
AU  - Song T
AD  - Department of Cardiology, People's Hospital of Lanling County, Linyi, Shandong.
FAU - Zhang, Daimin
AU  - Zhang D
AUID- ORCID: 0000-0001-8303-9039
AD  - Department of Cardiology, Nanjing First Hospital, Nanjing Medical University,
      Nanjing, Jiangsu, China.
LA  - eng
GR  - BE2018611/Jiangsu Provincial Key Research and Development Program
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 9G34HU7RV0 (Edetic Acid)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Atherosclerosis/*drug therapy
MH  - *Calcium
MH  - Chelation Therapy/*methods
MH  - Edetic Acid/*therapeutic use
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic/*methods
PMC - PMC7769341
COIS- The authors report no conflicts of interest.
EDAT- 2020/12/23 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/12/22 11:22
PHST- 2020/10/20 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/12/22 11:22 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1097/MD.0000000000023346 [doi]
AID - 00005792-202012240-00007 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 24;99(52):e23346. doi:
      10.1097/MD.0000000000023346.


PMID- 33350374
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20220209
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 104
IP  - 3
DP  - 2020 Dec 21
TI  - Application of the Relationship-Based Model to Engagement for Field Trials of
      Genetically Engineered Malaria Vectors.
PG  - 805-811
LID - 10.4269/ajtmh.20-0868 [doi]
LID - tpmd200868 [pii]
AB  - The transition of new technologies for public health from laboratory to field is 
      accompanied by a broadening scope of engagement challenges. Recent developments
      of vector control strategies involving genetically engineered mosquitoes with
      gene drives to assist in the eradication of malaria have drawn significant
      attention. Notably, questions have arisen surrounding community and regulatory
      engagement activities and of the need for examples of models or frameworks that
      can be applied to guide engagement. A relationship-based model (RBM) provides a
      framework that places stakeholders and community members at the center of
      decision-making processes, rather than as recipients of predetermined strategies,
      methods, and definitions. Successful RBM application in the transformation of
      healthcare delivery has demonstrated the importance of open dialogue and
      relationship development in establishing an environment where individuals are
      actively engaged in decision-making processes regarding their health. Although
      guidelines and recommendations for engagement for gene drives have recently been 
      described, we argue here that communities and stakeholders should lead the
      planning, development, and implementation phases of engagement. The RBM provides 
      a new approach to the development of ethical, transparent, and effective
      engagement strategies for malaria control programs.
FAU - Kormos, Ana
AU  - Kormos A
AD  - 1Vector Genetics Laboratory, University of California, Davis, California.
FAU - Lanzaro, Gregory C
AU  - Lanzaro GC
AD  - 1Vector Genetics Laboratory, University of California, Davis, California.
FAU - Bier, Ethan
AU  - Bier E
AD  - 2Section of Cell and Developmental Biology, University of California, San Diego, 
      California.
AD  - 3Tata Institute for Genetics and Society (TIGS)-UCSD, San Diego, California.
FAU - Dimopoulos, George
AU  - Dimopoulos G
AD  - 4Department of Molecular Microbiology and Immunology, Malaria Research Institute 
      (JHMRI), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, 
      Maryland.
FAU - Marshall, John M
AU  - Marshall JM
AD  - 5Division of Epidemiology and Biostatistics, School of Public Health, University 
      of California, Berkeley, California.
AD  - 6Innovative Genomics Institute, Berkeley, California.
FAU - Pinto, Joao
AU  - Pinto J
AD  - 7Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical,
      Universidade Nova de Lisboa, Lisbon, Portugal.
FAU - Aguiar Dos Santos, Adionilde
AU  - Aguiar Dos Santos A
AD  - 8Ministerio da Saude, Delegacia de Saude Distrital de Agua Grande, Cidade de Sao 
      Tome, Sao Tome and Principe.
FAU - Bacar, Affane
AU  - Bacar A
AD  - 9Ministry of Health, Programme Nationale de Lutte Contre le Paludisme, Moroni,
      Union of the Comoros.
FAU - Sousa Pontes Sacramento Rompao, Herodes
AU  - Sousa Pontes Sacramento Rompao H
AD  - 10Ministerio da Saude, Programa Nacional de Luta Contra o Paludismo, Cidade de
      Sao Tome, Sao Tome and Principe.
FAU - James, Anthony A
AU  - James AA
AD  - 11Department of Microbiology and Molecular Genetics, University of California,
      Irvine, California.
AD  - 12Department of Molecular Biology and Biochemistry, University of California,
      Irvine, California.
LA  - eng
GR  - R01 GM117321/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201221
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
SB  - IM
MH  - Animals
MH  - Culicidae/*genetics
MH  - *Genetic Engineering
MH  - Malaria/*transmission
MH  - *Models, Biological
MH  - Mosquito Vectors/*genetics
PMC - PMC7941841
EDAT- 2020/12/23 06:00
MHDA- 2022/02/10 06:00
CRDT- 2020/12/22 08:43
PHST- 2020/07/16 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2020/12/22 08:43 [entrez]
AID - tpmd200868 [pii]
AID - 10.4269/ajtmh.20-0868 [doi]
PST - epublish
SO  - Am J Trop Med Hyg. 2020 Dec 21;104(3):805-811. doi: 10.4269/ajtmh.20-0868.


PMID- 33349774
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201223
IS  - 1923-1202 (Print)
IS  - 1923-1202 (Linking)
VI  - 11
IP  - 6
DP  - 2020 Dec
TI  - The role of medical students in the COVID-19 pandemic response: A call for
      ethical guidelines.
PG  - e176-e178
LID - 10.36834/cmej.70307 [doi]
FAU - Kitching, George T
AU  - Kitching GT
AD  - Schulich School of Medicine and Dentistry, Western University, Ontario, Canada.
FAU - Zhong, Adrina
AU  - Zhong A
AD  - Schulich School of Medicine and Dentistry, Western University, Ontario, Canada.
FAU - Kogel, Emily
AU  - Kogel E
AD  - Schulich School of Medicine and Dentistry, Western University, Ontario, Canada.
FAU - Wilson, Krista
AU  - Wilson K
AD  - Schulich School of Medicine and Dentistry, Western University, Ontario, Canada.
FAU - Letourneau, Sasha
AU  - Letourneau S
AD  - School of Medicine, Queen's University, Ontario, Canada.
FAU - Ge, Yipeng
AU  - Ge Y
AD  - Faculty of Medicine, University of Ottawa, Ontario, Canada.
FAU - Sayed, Celine
AU  - Sayed C
AD  - Faculty of Medicine, University of Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201207
PL  - Canada
TA  - Can Med Educ J
JT  - Canadian medical education journal
JID - 101560935
PMC - PMC7749677
COIS- Conflicts of interest: None to declare.
EDAT- 2020/12/23 06:00
MHDA- 2020/12/23 06:01
CRDT- 2020/12/22 05:46
PHST- 2020/12/22 05:46 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2020/12/23 06:01 [medline]
AID - 10.36834/cmej.70307 [doi]
AID - CMEJ-11-e176 [pii]
PST - epublish
SO  - Can Med Educ J. 2020 Dec 7;11(6):e176-e178. doi: 10.36834/cmej.70307. eCollection
      2020 Dec.


PMID- 33349757
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1923-1202 (Print)
IS  - 1923-1202 (Linking)
VI  - 11
IP  - 6
DP  - 2020 Dec
TI  - Medical Assistance in Dying in health sciences curricula: A qualitative
      exploratory study.
PG  - e79-e89
LID - 10.36834/cmej.69325 [doi]
AB  - BACKGROUND: This paper offers insight into (1) the driving and restraining forces
      impacting the inclusion of medical assistance in dying (MAID) in health sciences 
      curricula, (2) the required resources for teaching MAID, and (3) the current
      placement of MAID in health sciences curricula in relation to end-of-life care
      concepts. METHOD: We conducted a qualitative exploratory study in a Canadian
      province using Interpretive Description, Force Field Analysis, and Change as
      Three Steps. We interviewed ten key informants (KI), representing the provincial 
      health sciences programs of medicine, nursing, pharmacy, and social work. KIs
      held various roles, including curriculum coordinator, associate dean, or
      lecturing faculty. Data were analyzed via the comparative method using NVivo12.
      RESULTS: Curriculum delivery structures, resources, faculty comfort and practice 
      context, and uncertainty of the student scope of practice influenced MAID
      inclusion. Medical and pharmacy students were consistently exposed to MAID,
      whereas MAID inclusion in nursing and social work was determined by faculty in
      consideration with the pre-existing course objectives. The theoretical and legal 
      aspects of MAID were more consistently taught than clinical care when faculty did
      not have a current practice context. Care pathways, accreditation standards,
      practice experts, peer-reviewed evidence, and local statistics were identified as
      the required resources to support student learning. MAID was delivered in
      conjunction with palliative care and ethics, legalities, and professional
      regulation courses. CONCLUSION: The addition of MAID in health sciences curricula
      is crucial to support students in this new practice context. Identifying the
      drivers and restrainers influencing the inclusion of MAID in health sciences
      curricula is critical to support the comprehensiveness of end-of-life education
      for all students.
CI  - (c) 2020 Brown, Goodridge, Thorpe; licensee Synergies Partners.
FAU - Brown, Janine
AU  - Brown J
AD  - College of Medicine, University of Saskatchewan, Saskatchewan, Canada.
AD  - Faculty of Nursing, University of Regina, Saskatchewan, Canada.
FAU - Goodridge, Donna
AU  - Goodridge D
AD  - College of Medicine, University of Saskatchewan, Saskatchewan, Canada.
FAU - Thorpe, Lilian
AU  - Thorpe L
AD  - Department of Community Health & Epidemiology, University of Saskatchewan,
      Saskatchewan, Canada.
AD  - Department of Psychiatry, University of Saskatchewan, Saskatchewan, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201207
PL  - Canada
TA  - Can Med Educ J
JT  - Canadian medical education journal
JID - 101560935
PMC - PMC7749690
COIS- Conflicts of interest: The authors do not have any conflicts to declare.
EDAT- 2020/12/23 06:00
MHDA- 2020/12/23 06:01
CRDT- 2020/12/22 05:46
PHST- 2020/12/22 05:46 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2020/12/23 06:01 [medline]
AID - 10.36834/cmej.69325 [doi]
AID - CMEJ-11-e079 [pii]
PST - epublish
SO  - Can Med Educ J. 2020 Dec 7;11(6):e79-e89. doi: 10.36834/cmej.69325. eCollection
      2020 Dec.


PMID- 33349044
OWN - NLM
STAT- Publisher
LR  - 20201222
IS  - 1741-2889 (Electronic)
IS  - 1367-4935 (Linking)
DP  - 2020 Dec 21
TI  - Children's assent within clinical care: A concept analysis.
PG  - 1367493520976300
LID - 10.1177/1367493520976300 [doi]
AB  - Seeking children's assent has been put forward as a way to foster children's
      involvement in the healthcare decision-making process. However, the functions of 
      the concept of assent within clinical care are manifold, and methods used to
      recognize children's capacities and promote their involvement in their care
      remain debated. We performed an instrumentalist concept analysis of assent, with 
      58 included articles. Final themes were jointly identified through a deliberative
      process. Two distinct perspectives of assent were predominant: as an affirmative 
      agreement for a specific decision and as part of a continuous, interactive
      process of care. Differing standards were provided as to how and when to apply
      the concept of assent. The concept of dissent was largely omitted from
      conceptions of assent, especially in situations for which children's refusal
      would lead to severe health consequences. Ethical implications included fostering
      autonomy, reducing physical/psychological harm to the child, respecting the child
      as a human being, and fulfilling the universal rights of the child. There remain 
      important gaps in the theory of assent and its desirable and possible practical
      implications. Practical standards are largely missing, and evidence supporting
      the claims made in the literature requires further investigation.
FAU - Montreuil, Marjorie
AU  - Montreuil M
AUID- ORCID: https://orcid.org/0000-0002-0238-025X
AD  - Ingram School of Nursing, McGill University, Canada.
FAU - Fortin, Justine
AU  - Fortin J
AD  - Pragmatic Health Ethics Research Unit, 225598Institut de recherches cliniques de 
      Montreal, Canada.
FAU - Racine, Eric
AU  - Racine E
AD  - Pragmatic Health Ethics Research Unit, 225598Institut de recherches cliniques de 
      Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - England
TA  - J Child Health Care
JT  - Journal of child health care : for professionals working with children in the
      hospital and community
JID - 9806360
OTO - NOTNLM
OT  - Assent
OT  - children
OT  - concept analysis
OT  - health care
OT  - patient engagement
EDAT- 2020/12/23 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/12/22 05:31
PHST- 2020/12/22 05:31 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.1177/1367493520976300 [doi]
PST - aheadofprint
SO  - J Child Health Care. 2020 Dec 21:1367493520976300. doi: 10.1177/1367493520976300.


PMID- 33347241
STAT- Publisher
DA  - 20201222
CTDT- 20200811
ISBN- 9783030470692
ISBN- 9783030470708
PB  - Springer
DP  - 2020
TI  - Charting Spiritual Care: Ethical Perspectives
BTI - Charting Spiritual Care: The Emerging Role of Chaplaincy Records in Global Health
      Care
PG  - 199-211
LID - 10.1007/978-3-030-47070-8 [doi]
AB  - The introduction of electronic health records (EHRs) into clinical practice
      appears to be irreversible. Where EHRs are used, chaplains have cooperated
      willingly with this way of reporting and sharing information with other members
      of the care team. They will have to, as a result, adapt their own note-taking
      practices to ensure effective, relevant and meaningful communication as part of
      the joint decision-making process. Although the specialized literature has
      addressed some of the "classic" ethical issues raised by EHRs, in particular
      those in connection with confidentiality and access, other questions, no less
      crucial, have received less attention and are addressed here. They include
      questions about the recognition of all players in the care relationship (both
      patients and caregivers) as subjects, and the communication of "non-generic"
      information about emotions, values, life history, etc. The fact that chaplains
      contribute to EHRs is both a sign of and a vector for recognition of their work
      within healthcare institutions - yet a recognition that could involve a price to 
      pay for chaplains and patients.
CI  - Copyright 2020, The Author(s).
FED - Peng-Keller, Simon
ED  - Peng-Keller S
FED - Neuhold, David
ED  - Neuhold D
FAU - Jobin, Guy
AU  - Jobin G
LA  - eng
PT  - Review
PT  - Book Chapter
PL  - Cham (CH)
OTO - NLM
OT  - Clinical judgment
OT  - Confidentiality
OT  - Deontology
OT  - Ethics
OT  - Relationship
OT  - Recognition
EDAT- 2020/12/22 06:01
MHDA- 2020/12/22 06:01
CDAT- 2020/12/22 06:01
AID - NBK565693 [bookaccession]
AID - 10.1007/978-3-030-47070-8_12 [doi]


PMID- 33347993
OWN - NLM
STAT- Publisher
LR  - 20201221
IS  - 1532-8414 (Electronic)
IS  - 1071-9164 (Linking)
DP  - 2020 Dec 18
TI  - Social Media as Ethical Obligation.
LID - S1071-9164(20)31582-7 [pii]
LID - 10.1016/j.cardfail.2020.12.010 [doi]
FAU - Timimi, Farris K
AU  - Timimi FK
AD  - Department of Cardiovascular Diseases, Mayo Clinic, Rochester MN. Electronic
      address: Timimi.farris@mayo.edu.
LA  - eng
PT  - Editorial
DEP - 20201218
PL  - United States
TA  - J Card Fail
JT  - Journal of cardiac failure
JID - 9442138
SB  - IM
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/21 20:10
PHST- 2020/12/14 00:00 [received]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2020/12/21 20:10 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - S1071-9164(20)31582-7 [pii]
AID - 10.1016/j.cardfail.2020.12.010 [doi]
PST - aheadofprint
SO  - J Card Fail. 2020 Dec 18. pii: S1071-9164(20)31582-7. doi:
      10.1016/j.cardfail.2020.12.010.


PMID- 33347460
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210121
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Situation analysis for delivering integrated comprehensive sexual and
      reproductive health services for displaced population of Kasai, Democratic
      Republic of Congo: Protocol for a mixed method study.
PG  - e0242046
LID - 10.1371/journal.pone.0242046 [doi]
AB  - INTRODUCTION: Delivering integrated sexual and reproductive health services
      (SRHS) in emergencies is important in order to save lives of the most vulnerable 
      as well as to combat poverty, reduce inequities and social injustice. More than
      60% of preventable maternal deaths occur in conflict areas and especially among
      the internally displaced persons (IDP). Between 2016 and 2018, unprecedented
      violence erupted in the Kasai's region, in the Democratic Republic of Congo
      (DRC), called the Kamuina Nsapu Insurgency. During that period, an estimated
      three million of adolescent girls and women were forced to flee; and have faced
      growing threat to their health, safety, security, and well-being including
      significant sexual and reproductive health challenges. Between August 2016 and
      May 2017, the "Sous-Cluster sur les violences basees sur le genre (SC-VBG)" in
      DRC (2017) reported 1,429 Gender Based Violence (GBV) incidents in the 49 service
      delivery points in the provinces of Kasai, Kasai Central and Kasai Oriental. Rape
      cases represented 79% of reported incidents whereas sexual assault and forced
      marriage accounted for respectively 11% and 4% of Gender Based Violence (GBV)
      among women and adolescent girls. This study aims to assess the availability of
      SRHS in the displaced camps in Kasai; to evaluate the SRHS needs of young girls
      and women in the reproductive age (12-49). Studies of sexual and reproductive
      health (SRH) in the Democratic Republic of Congo (DRC) have often included
      adolescent girls under the age of 15 because of high prevalence of child marriage
      and early onset of childbearing, especially in the humanitarian context.
      According to the 2013 Demographic and Health Survey (DHS), about 16% of surveyed 
      women got married by age 14 while the prevalence of early child marriage
      (marriage by 15) was estimated at 30%; to assess the use of SRHS services and
      identify barriers as well as challenges for SRH service delivery and use.
      Findings from this study will help provide evidence to inform towards more
      needs-based and responsive SRH service delivery. This is hoped for ultimately
      improve the quality and effectiveness of services, when considering service
      delivery and response in humanitarian settings. DATA AND METHODS: We will conduct
      a mixed-methods study design, which will combine quantitative and qualitative
      approaches. Based on the estimation of the sample size, quantitative data will be
      drawn from the community-based survey (500 women of reproductive age per site)
      and health facility assessments will include assessments of 45 health facilities 
      and 135 health providers' interviews. Qualitative data will comprise materials
      from 30 Key Informant Interviews (KII) and 24 Focus Group Discussions (FGDs),
      which are believed to achieve the needed saturation levels. Data analysis will
      include thematic and content analysis for the KIIs and FGDs using ATLAS.ti
      software for the qualitative arm. For the quantitative arm, data analysis will
      combine frequency and bivariate chi-square analysis, coupled with multi-level
      regression models, using Stata 15 software. Statistic differences will be
      established at the significance level of 0.05. We submitted this protocol to the 
      national ethical committee of the ministry of health in September 2019 and it was
      approved in January 2020. It needs further approval from the Scientific Oversee
      Committee (SOC) and the Provincial Ministry of Health. Prior to data collection, 
      informed consents will be obtained from all respondents.
FAU - Emina, Jacques B O
AU  - Emina JBO
AUID- ORCID: 0000-0003-3709-1121
AD  - Population and Health Research Institute, Kinshasa, Democratic Republic of Congo 
      (DRC).
AD  - Department of Population and Development Studies, University of Kinshasa,
      Kinshasa, Democratic Republic of Congo (DRC).
FAU - Gahungu, Parfait
AU  - Gahungu P
AD  - Programme National de Sante des Adolescents (PNSA), Kinshasa, Democratic Republic
      of Congo (DRC).
FAU - Iyese, Francis
AU  - Iyese F
AD  - Population and Health Research Institute, Kinshasa, Democratic Republic of Congo 
      (DRC).
FAU - Etinkum, Rinelle
AU  - Etinkum R
AD  - Population and Health Research Institute, Kinshasa, Democratic Republic of Congo 
      (DRC).
FAU - Kini, Brigitte
AU  - Kini B
AD  - WHO National Office, Kinshasa, Democratic Republic of Congo (DRC).
FAU - Mobolua, Joseph Fataki
AU  - Mobolua JF
AD  - Projet SR en situation d'urgence dans la Region du Kasai, WHO- DRC, Kinshasa,
      Democratic Republic of Congo (DRC).
FAU - Boboeva, Mohira
AU  - Boboeva M
AD  - Global Health Cluster, Emergency Operations Department, Health Emergencies
      Program, World Health Organization (HQ), Geneva, Switzerland.
FAU - Kobeissi, Loulou
AU  - Kobeissi L
AD  - Department of Sexual and Reproductive Health and Research (SRH), including the
      UNDP/UNFPA/UNICEF/WHO/World/Bank Special program of research, development and
      research training in human reproduction (HRP), World Health Organization (HQ),
      Geneva, Switzerland.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201221
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Delivery of Health Care, Integrated/*organization & administration
MH  - Democratic Republic of the Congo
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Refugees/*psychology
MH  - Reproductive Health
MH  - Reproductive Health Services/*organization & administration
MH  - Sexual Health
MH  - *Women's Health
MH  - Young Adult
PMC - PMC7751877
COIS- The authors have declared that no competing interests exist. The authors alone
      are responsible for the views expressed in this article and they do not
      necessarily represent the views, decisions or policies of the funding bodies or
      institutions with which they are affiliated.
EDAT- 2020/12/22 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/21 17:12
PHST- 2020/04/17 00:00 [received]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/12/21 17:12 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1371/journal.pone.0242046 [doi]
AID - PONE-D-20-10507 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 21;15(12):e0242046. doi: 10.1371/journal.pone.0242046.
      eCollection 2020.


PMID- 33346175
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211204
IS  - 2384-8553 (Electronic)
IS  - 0021-2571 (Linking)
VI  - 56
IP  - 4
DP  - 2020 Oct-Dec
TI  - A few ethical issues in translational research for medicinal products discovery
      and development.
PG  - 487-491
LID - 10.4415/ANN_20_04_11 [doi]
AB  - The results obtained with basic research showing significant therapeutic promise 
      are often not translated into clinical applications. The purpose of translational
      research is to favour the transition of basic research to application at the
      patient's bedside, and from here to routine clinical practice (without excluding 
      the opposite pathway, in which the evidence generated by clinical practice helps 
      to guide research). Although translational research can provide patients with
      valuable therapeutic resources, it is not risk-free. The most significant ethical
      issues in translational research on medicinal products derive from the risk of
      the intention to shorten the timeframes for the application of the results of the
      research making the scientific methods adopted and the regulatory requisites to
      be satisfied along the long path from the bench to the patient's bedside less
      rigorous. This is also relevant during pandemics when shortening the timeline
      from basic research to bedside is even more crucial. It is therefore necessary to
      establish defined and agreed requisites in order to guarantee the ethicality of
      translational research, by promoting the good of individuals and minimising the
      risks.
FAU - Petrini, Carlo
AU  - Petrini C
AD  - Unita di Bioetica, Istituto Superiore di Sanita, Rome, Italy.
FAU - Minghetti, Luisa
AU  - Minghetti L
AD  - Servizio di Coordinamento e Supporto alla Ricerca, Istituto Superiore di Sanita, 
      Rome, Italy.
FAU - Brusaferro, Silvio
AU  - Brusaferro S
AD  - President, Istituto Superiore di Sanita, Rome, Italy.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Ann Ist Super Sanita
JT  - Annali dell'Istituto superiore di sanita
JID - 7502520
SB  - IM
MH  - *Bioethical Issues
MH  - Drug Development/*ethics
MH  - Drug Discovery/*ethics
MH  - Humans
MH  - Translational Research, Biomedical/*ethics
EDAT- 2020/12/22 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/12/21 08:45
PHST- 2020/12/21 08:45 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.4415/ANN_20_04_11 [doi]
PST - ppublish
SO  - Ann Ist Super Sanita. 2020 Oct-Dec;56(4):487-491. doi: 10.4415/ANN_20_04_11.


PMID- 33344911
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211009
IS  - 2575-9108 (Electronic)
IS  - 2575-9108 (Linking)
VI  - 3
IP  - 6
DP  - 2020 Dec 11
TI  - Locusts: A Model to Investigate Human Disease and Sickness Behavior.
PG  - 1423-1424
LID - 10.1021/acsptsci.0c00151 [doi]
AB  - Traditionally, vertebrate models have been utilized and are viewed as more
      pertinent; however, we propose the application of an invertebrate model such as
      locusts to study human disease and sickness behavior at an early phase of
      research. This model has numerous benefits, namely, expense, swiftness,
      procedural convenience, and ethical acceptance. For example, the injection of
      immunogen-induced anorexia behavior in rats and locusts in vivo are analogous.
      Moreover, the presence of a brain barrier in locusts reveals remarkable
      similarities in molecular methods utilized by E. coli K1 to traverse the central 
      nervous system of rats and locusts, consequently providing a worthwhile model to 
      investigate pathogenesis. The presence of cytokines in these insects and presence
      of a brain barrier (which is physiologically relevant to human blood-brain
      barrier) makes it a relevant model in determining disease mechanisms and invasion
      of the brain by central nervous system pathogens.
CI  - (c) 2020 American Chemical Society.
FAU - Siddiqui, Ruqaiyyah
AU  - Siddiqui R
AD  - Department of Biology, Chemistry and Environmental Sciences, College of Arts and 
      Sciences, American University of Sharjah, PO Box 26666, University City, Sharjah,
      United Arab Emirates.
FAU - Khan, Naveed Ahmed
AU  - Khan NA
AD  - Department of Biology, Chemistry and Environmental Sciences, College of Arts and 
      Sciences, American University of Sharjah, PO Box 26666, University City, Sharjah,
      United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - United States
TA  - ACS Pharmacol Transl Sci
JT  - ACS pharmacology & translational science
JID - 101721411
PMC - PMC7737313
COIS- The authors declare no competing financial interest.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:10
PHST- 2020/09/26 00:00 [received]
PHST- 2020/12/21 06:10 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1021/acsptsci.0c00151 [doi]
PST - epublish
SO  - ACS Pharmacol Transl Sci. 2020 Oct 8;3(6):1423-1424. doi:
      10.1021/acsptsci.0c00151. eCollection 2020 Dec 11.


PMID- 33344785
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Nairobi Early Childcare in Slums (NECS) Study Protocol: a mixed-methods
      exploration of paid early childcare in Mukuru slum, Nairobi.
PG  - e000822
LID - 10.1136/bmjpo-2020-000822 [doi]
AB  - INTRODUCTION: The early years are critical. Early nurturing care can lay the
      foundation for human capital accumulation with lifelong benefits. Conversely,
      early adversity undermines brain development, learning and future earning.Slums
      are among the most challenging places to spend those early years and are
      difficult places to care for a child. Shifting family and work structures mean
      that paid, largely informal, childcare seems to be becoming the 'new normal' for 
      many preschool children growing up in rapidly urbanising Africa. However, little 
      is known about the quality of this childcare. AIMS: To build a rigorous
      understanding what childcare strategies are used and why in a typical Nairobi
      slum, with a particular focus on provision and quality of paid childcare. Through
      this, to inform evaluation of quality and design and implementation of
      interventions with the potential to reach some of the most vulnerable children at
      the most critical time in the life course. METHODS AND ANALYSIS: Mixed methods
      will be employed. Qualitative research (in-depth interviews and focus group
      discussions) with parents/carers will explore need for and decision-making about 
      childcare. A household survey (of 480 households) will estimate the use of
      different childcare strategies by parents/carers and associated parent/carer
      characteristics. Subsequently, childcare providers will be mapped and surveyed to
      document and assess quality of current paid childcare. Semistructured
      observations will augment self-reported quality with observable
      characteristics/practices. Finally, in-depth interviews and focus group
      discussions with childcare providers will explore their behaviours and
      motivations. Qualitative data will be analysed through thematic analysis and
      triangulation across methods. Quantitative and spatial data will be analysed
      through epidemiological methods (random effects regression modelling and spatial 
      statistics). ETHICS AND DISSEMINATION: Ethical approval has been granted in the
      UK and Kenya. Findings will be disseminated through journal publications,
      community and government stakeholder workshops, policy briefs and social media
      content.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hughes, Robert C
AU  - Hughes RC
AUID- ORCID: 0000-0002-1345-3063
AD  - Department of Population Health, London School of Hygiene and Tropical Medicine
      Faculty of Epidemiology and Population Health, London, UK.
FAU - Kitsao-Wekulo, Patricia
AU  - Kitsao-Wekulo P
AD  - Maternal and Child Wellbeing Unit, African Population and Health Research Center,
      Nairobi, Kenya.
FAU - Bhopal, Sunil
AU  - Bhopal S
AD  - Department of Population Health, London School of Hygiene and Tropical Medicine
      Faculty of Epidemiology and Population Health, London, UK.
AD  - Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle
      University, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Kimani-Murage, Elizabeth W
AU  - Kimani-Murage EW
AD  - Maternal and Child Wellbeing Unit, African Population and Health Research Center,
      Nairobi, Kenya.
FAU - Hill, Zelee
AU  - Hill Z
AD  - Epidemiology and Public Health, Institute of Global Health, University College
      London, London, UK.
FAU - Kirkwood, Betty R
AU  - Kirkwood BR
AD  - Department of Population Health, London School of Hygiene and Tropical Medicine
      Faculty of Epidemiology and Population Health, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7716665
OTO - NOTNLM
OT  - epidemiology
COIS- Competing interests: There are no competing interests.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:10
PHST- 2020/07/31 00:00 [received]
PHST- 2020/08/12 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/12/21 06:10 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1136/bmjpo-2020-000822 [doi]
AID - bmjpo-2020-000822 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Dec 3;4(1):e000822. doi: 10.1136/bmjpo-2020-000822.
      eCollection 2020.


PMID- 33344779
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210616
IS  - 2397-7000 (Electronic)
IS  - 2397-7000 (Linking)
VI  - 5
IP  - 1
DP  - 2020
TI  - Advances in engineering CRISPR-Cas9 as a molecular Swiss Army knife.
PG  - ysaa021
LID - 10.1093/synbio/ysaa021 [doi]
AB  - The RNA-guided endonuclease system CRISPR-Cas9 has been extensively modified
      since its discovery, allowing its capabilities to extend far beyond
      double-stranded cleavage to high fidelity insertions, deletions and single base
      edits. Such innovations have been possible due to the modular architecture of
      CRISPR-Cas9 and the robustness of its component parts to modifications and the
      fusion of new functional elements. Here, we review the broad toolkit of
      CRISPR-Cas9-based systems now available for diverse genome-editing tasks. We
      provide an overview of their core molecular structure and mechanism and distil
      the design principles used to engineer their diverse functionalities. We end by
      looking beyond the biochemistry and toward the societal and ethical challenges
      that these CRISPR-Cas9 systems face if their transformative capabilities are to
      be deployed in a safe and acceptable manner.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Meaker, Grace A
AU  - Meaker GA
AUID- ORCID: 0000-0003-4705-3137
AD  - School of Biological Sciences, University of Bristol, Bristol BS8 1TQ, UK.
AD  - School of Biosciences, Cardiff University, Cardiff CF10 3AT, UK.
FAU - Hair, Emma J
AU  - Hair EJ
AD  - School of Biological Sciences, University of Bristol, Bristol BS8 1TQ, UK.
FAU - Gorochowski, Thomas E
AU  - Gorochowski TE
AUID- ORCID: 0000-0003-1702-786X
AD  - School of Biological Sciences, University of Bristol, Bristol BS8 1TQ, UK.
AD  - BrisSynBio, University of Bristol, Bristol BS8 1TQ, UK.
LA  - eng
GR  - BB/L01386X/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
PT  - Review
DEP - 20201024
PL  - England
TA  - Synth Biol (Oxf)
JT  - Synthetic biology (Oxford, England)
JID - 101728857
PMC - PMC7737000
OTO - NOTNLM
OT  - CRISPR
OT  - Cas9
OT  - ethics
OT  - genome editing
OT  - synthetic biology
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:10
PHST- 2020/07/15 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/12/21 06:10 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1093/synbio/ysaa021 [doi]
AID - ysaa021 [pii]
PST - epublish
SO  - Synth Biol (Oxf). 2020 Oct 24;5(1):ysaa021. doi: 10.1093/synbio/ysaa021.
      eCollection 2020.


PMID- 33344477
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Mandating the Use of Proximity Tracking Apps During Coronavirus Disease 2019:
      Ethical Justifications.
PG  - 590265
LID - 10.3389/fmed.2020.590265 [doi]
AB  - The rise of the coronavirus disease 2019 (COVID-19) in a digital world has
      expectedly called upon technologies, such as wearables and mobile devices, to
      work in conjunction with public health interventions to tackle the pandemic. One 
      significant example of this integration is the deployment of proximity tracking
      apps on smartphones to enhance traditional contact tracing methods. Many
      countries have adopted proximity tracking apps; however, there is a large degree 
      of global differentiation in the voluntariness of the apps. Further, the concept 
      of a mandatory policy-forcing individuals to use the apps-has been met with
      ethical concerns (e.g., privacy and liberty). While ethical considerations
      surrounding deployment have been put forth, such as by the World Health
      Organization, ethical justifications for a mandatory policy are lacking. Here, we
      use the Faden-Shebaya framework, which was formed to justify public health
      interventions, to determine if the compulsory use of proximity tracking apps is
      ethically appropriate. We show that while theoretically justified, due to the
      current state of proximity tracking applications and societal factors, it is
      difficult to defend a mandatory policy in practice.
CI  - Copyright (c) 2020 Dave and Gupta.
FAU - Dave, Riya
AU  - Dave R
AD  - Cognitive and Behavioural Neuroscience Laboratory, Department of Humanities and
      Social Sciences, Indian Institute of Technology Bombay, Mumbai, India.
FAU - Gupta, Rashmi
AU  - Gupta R
AD  - Cognitive and Behavioural Neuroscience Laboratory, Department of Humanities and
      Social Sciences, Indian Institute of Technology Bombay, Mumbai, India.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7738463
OTO - NOTNLM
OT  - COVID-19
OT  - contact tracing
OT  - digital health
OT  - ethical framework
OT  - ethics
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:08
PHST- 2020/07/31 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/12/21 06:08 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.3389/fmed.2020.590265 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Dec 2;7:590265. doi: 10.3389/fmed.2020.590265.
      eCollection 2020.


PMID- 33344387
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Summary of the Key Concepts on How to Develop a Perinatal Palliative Care
      Program.
PG  - 596744
LID - 10.3389/fped.2020.596744 [doi]
AB  - Purpose of review: The aim of this study is to assess the most significant
      Perinatal Palliative Care (PnPC) development projects in the literature and
      summarize the shared key principles. Recent findings: PnPC is a new concept in
      neonatal intensive care approach. Advancements in perinatal diagnostics and
      medical technology have changed the landscape of the perinatal world. The
      threshold of viability continues to decrease, and diagnostic information is
      available earlier in pregnancy and more rapidly at the bedside; overall outcomes 
      continue to improve. This rapid technological improvement brings ethical debates 
      on the quality of life of patients with life-limiting and life-threatening
      conditions and the need to involve the family in the decision-making process,
      according to their wishes and cultural beliefs. Although the Perinatal Hospice
      concept was developed in the 1980s in the US, the first recommendations on how to
      develop a PnPC pathway were published in the early 2000s. We considered the most 
      relevant position statements or guidelines on PnPC published in the last two
      decades. Some of them were more pertinent to pediatrics but still useful for the 
      fundamental concepts and PnPC project's development. Summary: Health care
      providers and institutions are encouraged to develop PnPC programs, which have
      the goal of maximizing the quality of life of infants with non-curable
      conditions. These may generally include the following: a formal prenatal
      consultation; development of a coordinated birth plan between obstetrician,
      newborn care, and family; access to other neonatal and pediatric specialties, as 
      needed; comfort palliative care during the prenatal, birth, and postnatal
      periods; and psychosocial and spiritual support for families, siblings, and
      staff.
CI  - Copyright (c) 2020 Lago, Cavicchiolo, Rusalen and Benini.
FAU - Lago, Paola
AU  - Lago P
AD  - Neonatal Intensive Care Unit, Ca' Foncello Hospital, Treviso, Italy.
FAU - Cavicchiolo, Maria Elena
AU  - Cavicchiolo ME
AD  - Department of Woman and Child Health, Neonatal Intensive Care Unit, University of
      Padua, Padua, Italy.
FAU - Rusalen, Francesca
AU  - Rusalen F
AD  - Department of Woman and Child Health, Paediatric Pain and Palliative Care
      Service, University of Padua, Padua, Italy.
FAU - Benini, Franca
AU  - Benini F
AD  - Department of Woman and Child Health, Paediatric Pain and Palliative Care
      Service, University of Padua, Padua, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201203
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7744474
OTO - NOTNLM
OT  - life-limiting condition
OT  - life-threatening condition
OT  - limit of viability
OT  - perinatal palliative care
OT  - program
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:08
PHST- 2020/09/23 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/12/21 06:08 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.3389/fped.2020.596744 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Dec 3;8:596744. doi: 10.3389/fped.2020.596744. eCollection
      2020.


PMID- 33343774
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1885-642X (Print)
IS  - 1885-642X (Linking)
VI  - 18
IP  - 4
DP  - 2020 Oct-Dec
TI  - Primary health care policy and vision for community pharmacy and pharmacists in
      Jordan.
PG  - 2184
LID - 10.18549/PharmPract.2020.4.2184 [doi]
AB  - Jordan is considered a low middle-income country with a population of 9.956
      million in 2018. It is considered the training center for healthcare professions 
      in the region, as the Jordanian healthcare sector has seen remarkable
      development. In 2017, the expenditure on health as a percentage of Gross Domestic
      Product (GDP) was estimated to be around 8%. The healthcare sector is divided
      into two main sectors; the public and the private sector with both including
      hospitals, primary care clinics and pharmacies. The Jordanian government has a
      strong commitment to health and educational programs; hence, an increase in the
      number of pharmacy schools and pharmacy graduates has occurred in the past few
      years. Health authorities, such as the Jordan Food and Drug Association (JFDA)
      and the Jordan Pharmaceutical Association (JPA) have played an important role in 
      ensuring the availability and affordability of medications, and has influenced
      the practice of pharmacists. Protecting the pharmaceutical market and
      professional interests, preserving pharmacists' rights, building needed
      cooperation with the internal federation, and maintaining professional ethics are
      some of the objectives for the JPA. Hence, the integration of community
      pharmacists into the primary healthcare system is considered vital to the
      different health authorities in Jordan, emphasizing the fact that community
      pharmacists are the most trusted, accessible, and affordable healthcare providers
      in the country. There have been many developments in the pharmacy practice in the
      past recent years, including the establishment of 'Good Pharmacy Practice', new
      curricular development based on the international accreditation (the ACPE), a new
      immunization program, and health services research aimed to save patients' lives,
      influence expenses, and improve patients' quality of life. Although these
      developments in pharmacy practice are promising, challenges continue to exist,
      specifically the establishment of an evidence base for pharmaceutical care
      services such as the medication management review service.
CI  - Copyright: (c) Pharmacy Practice and the Authors.
FAU - Basheti, Iman A
AU  - Basheti IA
AUID- ORCID: https://orcid.org/
AD  - PhD. Professor in Clinical Pharmacy. Department of Clinical Pharmacy and
      Therapeutics, Faculty of Pharmacy, Applied Sciences Private University. Amman
      (Jordan). dr_iman@asu.edu.jo.
FAU - Mhaidat, Nizar M
AU  - Mhaidat NM
AUID- ORCID: https://orcid.org/
AD  - PhD. Director of Jordan Food and Drug administration. Professor in Oncology,
      Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of
      Science and Technology. Irbid (Jordan). nizarm@just.edu.jo.
FAU - Alqudah, Rajaa
AU  - Alqudah R
AUID- ORCID: https://orcid.org/
AD  - MSc. Clinical Lecturer, Department of Clinical Pharmacy and Therapeutics, Faculty
      of Pharmacy, Applied Sciences Private University. Amman (Jordan).
      ra_alqudah@asu.edu.jo.
FAU - Nassar, Razan
AU  - Nassar R
AUID- ORCID: https://orcid.org/
AD  - MSc. Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy,
      Applied Science Private University. Amman (Jordan). Razanassar@outlook.com.
FAU - Othman, Bayan
AU  - Othman B
AUID- ORCID: https://orcid.org/
AD  - MSc. Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy,
      Applied Science Private University. Amman (Jordan). b_othman@asu.edu.jo.
FAU - Mukattash, Tareq L
AU  - Mukattash TL
AUID- ORCID: https://orcid.org/
AD  - PhD. Professor in Clinical Pharmacy, Department of Clinical Pharmacy, Faculty of 
      Pharmacy, Jordan University of Science and Technology. Amman (Jordan).
      tlmukattash@just.edu.jo.
LA  - eng
PT  - Journal Article
DEP - 20201205
PL  - Spain
TA  - Pharm Pract (Granada)
JT  - Pharmacy practice
JID - 101530029
PMC - PMC7732212
OTO - NOTNLM
OT  - Ambulatory Care
OT  - Community Health Services
OT  - Community Pharmacy Services
OT  - Delivery of Health Care, Integrated
OT  - Jordan
OT  - Pharmacies
OT  - Pharmacists
OT  - Primary Health Care
OT  - Professional Practice
COIS- CONFLICT OF INTEREST None.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:05
PHST- 2020/12/21 06:05 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.18549/PharmPract.2020.4.2184 [doi]
AID - pharmpract-18-2184 [pii]
PST - ppublish
SO  - Pharm Pract (Granada). 2020 Oct-Dec;18(4):2184. doi:
      10.18549/PharmPract.2020.4.2184. Epub 2020 Dec 5.


PMID- 33343701
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1754-6605 (Print)
IS  - 1754-6605 (Linking)
VI  - 14
DP  - 2020
TI  - Trends in the crossover of patients in phase III oncology clinical trials in the 
      USA.
PG  - 1142
LID - 10.3332/ecancer.2020.1142 [doi]
AB  - BACKGROUND: The incorporation of crossover in randomised controlled trials is
      accepted as an ethical obligation, especially in cancer clinical trials. The more
      common type of crossover is crossover allowance, which allows patients assigned
      to one arm to switch to another arm if there is an established benefit in the
      crossover arm. In contrast, crossover-designed studies involve switching patients
      from all arms to a different arm as part of the study design. Crossover allowance
      may have advantages in patient recruitment and incorporating crossover after
      initial positive results fulfil ethical requirements. However, crossover can also
      contribute to confounding major endpoints of studies, such as overall survival or
      the second progression-free survival interval. For this reason, it is important
      to investigate and identify potential trends of crossover in clinical trials
      testing novel therapies. METHODS: Data about cancer clinical trials were
      extracted from clinicaltrials.gov. The search query was limited to completed
      phase III studies in adult populations. Location was limited to the USA. Date
      range extended from 1990 to 2019. Search query included the terms: cancer;
      completed- recruitment status; age: 18-65+ years; sex: all; location: USA; and
      study phase: phase 3. Studies were then excluded if they were not randomised
      controlled trials (RCTs) with the primary purpose of treatment and if they did
      not test cancer-related interventions. RESULTS: A total of 744 clinical trials
      were identified. There were 459 RCTs aimed at treatment, and of those, 35
      utilised crossover. The start dates of these crossover trials ranged from 1997 to
      2012. Thirty studies utilised crossover allowance. Prostate, breast and
      gastrointestinal stromal tumour cancers were the most represented cancer types in
      crossover studies. Among the 30 studies, the median proportion of patients who
      crossed over relative to the original arm assignment ranged from 2% to 88%, with 
      a median of 57.5%. CONCLUSIONS: The proportion of identified clinical trials with
      crossover compared to those without is extremely small. Crossover in clinical
      trials studying cancer treatment does not appear to be a widespread practice.
      Even though statistical approaches to mitigate confounding exist, crossover can
      still skew accurate reporting of the impact of experimental therapies on overall 
      survival.
CI  - (c) the authors; licensee ecancermedicalscience.
FAU - Yeh, Justin
AU  - Yeh J
AD  - Medical College of Georgia, Augusta University, Augusta, GA 30909, USA.
FAU - Gupta, Shruti
AU  - Gupta S
AD  - Medical College of Georgia, Augusta University, Augusta, GA 30909, USA.
FAU - Patel, Sunny J
AU  - Patel SJ
AD  - Medical College of Georgia, Augusta University, Augusta, GA 30909, USA.
FAU - Kota, Vamsi
AU  - Kota V
AD  - Division of Hematology/Oncology, Georgia Cancer Center, Augusta University,
      Augusta, GA 30909, USA.
FAU - Guddati, Achuta K
AU  - Guddati AK
AD  - Division of Hematology/Oncology, Georgia Cancer Center, Augusta University,
      Augusta, GA 30909, USA.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - England
TA  - Ecancermedicalscience
JT  - Ecancermedicalscience
JID - 101392236
PMC - PMC7738270
OTO - NOTNLM
OT  - cancer
OT  - controlled trials
OT  - crossover
OT  - randomised
COIS- None.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:05
PHST- 2020/02/28 00:00 [received]
PHST- 2020/12/21 06:05 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.3332/ecancer.2020.1142 [doi]
AID - can-14-1142 [pii]
PST - epublish
SO  - Ecancermedicalscience. 2020 Nov 13;14:1142. doi: 10.3332/ecancer.2020.1142.
      eCollection 2020.


PMID- 33343657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1687-6415 (Print)
IS  - 1687-6415 (Linking)
VI  - 2020
DP  - 2020
TI  - The Recent Progress and Applications of Digital Technologies in Healthcare: A
      Review.
PG  - 8830200
LID - 10.1155/2020/8830200 [doi]
AB  - BACKGROUND: The implementation of medical digital technologies can provide better
      accessibility and flexibility of healthcare for the public. It encompasses the
      availability of open information on the health, treatment, complications, and
      recent progress on biomedical research. At present, even in low-income countries,
      diagnostic and medical services are becoming more accessible and available.
      However, many issues related to digital health technologies remain unmet,
      including the reliability, safety, testing, and ethical aspects. PURPOSE: The aim
      of the review is to discuss and analyze the recent progress on the application of
      big data, artificial intelligence, telemedicine, block-chain platforms, smart
      devices in healthcare, and medical education. Basic Design. The publication
      search was carried out using Google Scholar, PubMed, Web of Sciences, Medline,
      Wiley Online Library, and CrossRef databases. The review highlights the
      applications of artificial intelligence, "big data," telemedicine and block-chain
      technologies, and smart devices (internet of things) for solving the real
      problems in healthcare and medical education. Major Findings. We identified 252
      papers related to the digital health area. However, the number of papers
      discussed in the review was limited to 152 due to the exclusion criteria. The
      literature search demonstrated that digital health technologies became highly
      sought due to recent pandemics, including COVID-19. The disastrous dissemination 
      of COVID-19 through all continents triggered the need for fast and effective
      solutions to localize, manage, and treat the viral infection. In this regard, the
      use of telemedicine and other e-health technologies might help to lessen the
      pressure on healthcare systems. Summary. Digital platforms can help optimize
      diagnosis, consulting, and treatment of patients. However, due to the lack of
      official regulations and recommendations, the stakeholders, including private and
      governmental organizations, are facing the problem with adequate validation and
      approbation of novel digital health technologies. In this regard, proper
      scientific research is required before a digital product is deployed for the
      healthcare sector.
CI  - Copyright (c) 2020 Maksut Senbekov et al.
FAU - Senbekov, Maksut
AU  - Senbekov M
AD  - S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
FAU - Saliev, Timur
AU  - Saliev T
AD  - S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
FAU - Bukeyeva, Zhanar
AU  - Bukeyeva Z
AD  - NJSC "Astana Medical University", Nur-Sultan, Kazakhstan.
FAU - Almabayeva, Aigul
AU  - Almabayeva A
AD  - NJSC "Astana Medical University", Nur-Sultan, Kazakhstan.
FAU - Zhanaliyeva, Marina
AU  - Zhanaliyeva M
AD  - NJSC "Astana Medical University", Nur-Sultan, Kazakhstan.
FAU - Aitenova, Nazym
AU  - Aitenova N
AD  - NJSC "Astana Medical University", Nur-Sultan, Kazakhstan.
FAU - Toishibekov, Yerzhan
AU  - Toishibekov Y
AD  - Institute of Experimental Biology, Almaty, Kazakhstan.
FAU - Fakhradiyev, Ildar
AU  - Fakhradiyev I
AUID- ORCID: https://orcid.org/0000-0003-0528-3874
AD  - S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201203
PL  - Egypt
TA  - Int J Telemed Appl
JT  - International journal of telemedicine and applications
JID - 101467196
PMC - PMC7732404
COIS- The authors have no competing interests to declare.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:05
PHST- 2020/08/14 00:00 [received]
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/21 06:05 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1155/2020/8830200 [doi]
PST - epublish
SO  - Int J Telemed Appl. 2020 Dec 3;2020:8830200. doi: 10.1155/2020/8830200.
      eCollection 2020.


PMID- 33343254
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211002
IS  - 1541-4094 (Print)
IS  - 1541-4094 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Oct
TI  - Ethical Issues in Schizophrenia.
PG  - 428-431
LID - 10.1176/appi.focus.20200030 [doi]
FAU - Beck, Nataly S
AU  - Beck NS
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, 
      CA.
FAU - Ballon, Jacob S
AU  - Ballon JS
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, 
      CA.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - United States
TA  - Focus (Am Psychiatr Publ)
JT  - Focus (American Psychiatric Publishing)
JID - 101156081
PMC - PMC7725160
COIS- The authors report no financial relationships with commercial interests.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:03
PHST- 2020/12/21 06:03 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1176/appi.focus.20200030 [doi]
PST - ppublish
SO  - Focus (Am Psychiatr Publ). 2020 Oct;18(4):428-431. doi:
      10.1176/appi.focus.20200030. Epub 2020 Nov 5.


PMID- 33343193
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Feb 23
TI  - Informed consent in genomic research and biobanking: taking feedback of findings 
      seriously.
PG  - 200-215
LID - 10.1080/11287462.2020.1717896 [doi]
AB  - Genomic research and biobanking present several ethical, social and cultural
      challenges, particularly when conducted in settings with limited scientific
      research capacity. One of these challenges is determining the model of consent
      that should support the sharing of human biological samples and data in the
      context of international collaborative research. In this paper, we report on the 
      views of key research stakeholders in Ghana on what should count as good ethical 
      practice when seeking consent for genomic research and biobanking in Africa. This
      study was part of a multi-country qualitative case study conducted in three
      African countries: Ghana, Uganda and Zambia under the auspices of the Human
      Heredity and Health in Africa initiative (H3Africa). Our study suggests that
      while participants are willing to give consent for their samples and associated
      data to be used for future research purposes, they expect to receive feedback
      about the progress of the research and about the kinds of research being
      undertaken on their samples and data. These expectations need to be anticipated
      and discussed during the consent process which should be seen as part of an
      ongoing communication process throughout the research process.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Tindana, Paulina
AU  - Tindana P
AUID- ORCID: https://orcid.org/0000-0002-9171-2083
AD  - Department of Health Policy, Planning and Management, University of Ghana School 
      of Public Health, Accra, Ghana.
FAU - Depuur, Cornelius
AU  - Depuur C
AUID- ORCID: https://orcid.org/0000-0003-0968-5280
AD  - Navrongo Health Research Centre, Navrongo, Ghana.
FAU - de Vries, Jantina
AU  - de Vries J
AD  - University of Cape Town, Cape Town, South Africa.
FAU - Seeley, Janet
AU  - Seeley J
AUID- ORCID: https://orcid.org/0000-0002-0583-5272
AD  - MRC/UVRI Uganda Research Unit on Aids, Kampala, Uganda.
FAU - Parker, Michael
AU  - Parker M
AD  - University of Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20200223
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7734033
OTO - NOTNLM
OT  - Africa
OT  - Broad consent
OT  - data sharing
OT  - genomic research feedback of findings
OT  - sample sharing
COIS- No potential conflict of interest was reported by the authors.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:03
PHST- 2020/12/21 06:03 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1080/11287462.2020.1717896 [doi]
AID - 1717896 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Feb 23;31(1):200-215. doi: 10.1080/11287462.2020.1717896.


PMID- 33343190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Dec 9
TI  - Editorial - ethical practice and genomic research.
PG  - 164-168
LID - 10.1080/11287462.2020.1855712 [doi]
FAU - Seeley, Janet
AU  - Seeley J
AD  - London School of Hygiene and Tropical Medicine, London, United Kingdom.
FAU - Parker, Michael
AU  - Parker M
AUID- ORCID: https://orcid.org/0000-0002-7054-4711
AD  - Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      United Kingdom.
LA  - eng
PT  - Editorial
DEP - 20201209
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7734112
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:03
PHST- 2020/12/21 06:03 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1080/11287462.2020.1855712 [doi]
AID - 1855712 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Dec 9;31(1):164-168. doi: 10.1080/11287462.2020.1855712.


PMID- 33343189
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220107
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Dec 2
TI  - Assessing training needs in health research ethics: a case study from the
      University of Zambia School of Medicine.
PG  - 155-163
LID - 10.1080/11287462.2020.1853001 [doi]
AB  - In many settings, and perhaps especially in low-middle income countries, training
      institutions do not adequately prepare their students for the ethical challenges 
      that confront them in professional life. We conducted a survey to assess the
      training needs in research ethics among the faculty at the University of Zambia, 
      School of Medicine (UNZASoM) using a structured questionnaire distributed to
      faculty members in January 2015. The study was approved by the University of
      Zambia Biomedical Research Ethics Committee. Seventy-five faculty members of
      various ranks completed the questionnaire. It was found that 31% of the faculty
      had not received any research ethics training. Of those who had received
      training, most of them had received it through short workshops of five days or
      less (57.4%, n = 31), while only 27.7% received ethics training as a component of
      an academic degree and 22.2% obtained it through electronic web-based courses.
      While most faculty (70.7%) reported being well-prepared to guide their students
      in developing a research methods section of a research protocol, only 25.3% felt 
      they were well-prepared to guide on ethical considerations. This study has
      demonstrated gaps in research ethics training among faculty members at UNZASoM.
      Mandatory instruction in research ethics among faculty and students is
      recommended.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Chongwe, Gershom
AU  - Chongwe G
AUID- ORCID: https://orcid.org/0000-0003-3303-308X
AD  - Department of Epidemiology and Biostatistics, University of Zambia School of
      Public Health, Lusaka, Zambia.
FAU - Sikateyo, Bornwell
AU  - Sikateyo B
AD  - Department of Health Policy and Management, University of Zambia School of Public
      Health, Lusaka, Zambia.
FAU - Kampata, Linda
AU  - Kampata L
AD  - Department of Health Policy and Management, University of Zambia School of Public
      Health, Lusaka, Zambia.
FAU - Ali, Joseph
AU  - Ali J
AUID- ORCID: https://orcid.org/0000-0002-4767-2512
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
FAU - Hallez, Kristina
AU  - Hallez K
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
FAU - Hyder, Adnan A
AU  - Hyder AA
AUID- ORCID: https://orcid.org/0000-0002-7292-577X
AD  - Milken Institute School of Public Health, George Washington University,
      Washington, DC, USA.
FAU - Kass, Nancy
AU  - Kass N
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
FAU - Michelo, Charles
AU  - Michelo C
AD  - Department of Epidemiology and Biostatistics, University of Zambia School of
      Public Health, Lusaka, Zambia.
LA  - eng
GR  - R25 TW001604/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7734000
OTO - NOTNLM
OT  - Research ethics
OT  - bioethics
OT  - professionalism
OT  - responsible conduct of research
OT  - training
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
CRDT- 2020/12/21 06:03
PHST- 2020/12/21 06:03 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
AID - 10.1080/11287462.2020.1853001 [doi]
AID - 1853001 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Dec 2;31(1):155-163. doi: 10.1080/11287462.2020.1853001.


PMID- 33342794
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20220419
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 16
IP  - 6
DP  - 2020 Oct-Dec
TI  - Comparison of two radiation boost schedules in postlumpectomy patients with
      breast cancer.
PG  - 1344-1349
LID - 10.4103/jcrt.JCRT_549_19 [doi]
AB  - BACKGROUND: We have been practicing hypofractionation, 40 Gy in 16 fractions over
      3 weeks for whole breast irradiation (WBI) for the past five decades with or
      without boost at our center. In this study, we compared two boost schedules of 10
      Gy/5#/1 week with 16 Gy/8#/1.5 weeks in postlumpectomy patients with breast
      cancer after WBI. MATERIALS AND METHODS: From June 2012 to June 2016, the study
      included 87 breast cancer patients postbreast conservation surgery. The
      institutional ethics committee approved the study, which was registered with
      ClinicalTrials.gov (ClinicalTrials.gov identifier no. CT02142907). All patients
      were treated with WBI of 40 Gy/16#/3 weeks. WBI was followed by tumor bed boost
      of 10 Gy/5#/1 week in 44 patients and 16 Gy/8#/1.5 weeks in 43 patients, either
      with electron beam therapy or 3D CRT with photons. The primary endpoint of the
      study was the comparison of local control between two schedules. Secondary
      endpoints were acute and late radiation toxicities, cosmetic score analysis,
      disease-free survival (DFS), and overall survival (OS). The assessment of acute
      and late skin toxicity was made as per RTOG scores and LENT-SOMA scale. The
      cosmetic assessment was made with Harvard/NSABP/RTOG Breast Cosmesis Grading
      Scale. RESULTS: Median follow-up was 55 months (range 18-78 months). Local
      recurrence was seen in 1 (2.3%) patient in the 16 Gy boost only. Acute Grade 2
      skin toxicity was 33% in 16 Gy boost arm compared to 23% in 10 Gy boost arm. Late
      skin toxicities were also high in patients with 16 Gy boost. Grade >/=2
      induration was seen in 4.5% and 14% of patients with 10 Gy and 16 Gy boost,
      respectively. None of the patients with 10 Gy boost had Grade 2 edema as compared
      to 5% with 16 Gy. Pigmentation was observed in 9% and 23% patients with 10 Gy and
      16 Gy boost, respectively. Grade 1 fibrosis was 2% versus 12% in patients with 10
      Gy and 16 Gy boost, respectively. The cosmetic score was good/excellent in 91%
      and 84% of patients with 10 Gy and 16 Gy boost, respectively. Distant metastasis 
      occurred in 2 (4%) and 3 (7%) patients in 10 Gy and 16 Gy boost, respectively.
      DFS and OS at 5 years were comparable between the two boost schedules.
      CONCLUSION: Local control was comparable with 10 Gy and 16 Gy boost. Acute and
      late skin toxicities were higher with 16 Gy boost dose. The cosmetic score was
      better with 10 Gy boost. DFS and OS was comparable with the two boost schedules. 
      Hence, a boost of 10 Gy/5# after WBI may be adequate in patients with breast
      cancer.
FAU - Yadav, Budhi Singh
AU  - Yadav BS
AD  - Department of Radiation Oncology, Regional Cancer Centre, Postgraduate Institute 
      of Medical Education and Research, Chandigarh, India.
FAU - Sharma, Suresh C
AU  - Sharma SC
AD  - Department of Radiation Oncology, MMIMSR, MMU, Mullana, Ambala, Haryana, India.
FAU - Singh, Gurpreet
AU  - Singh G
AD  - Department of General Surgery, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Dahiya, Divya
AU  - Dahiya D
AD  - Department of General Surgery, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
SB  - IM
MH  - Adult
MH  - Breast/radiation effects/surgery
MH  - Breast Neoplasms/mortality/*therapy
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - Electrons/therapeutic use
MH  - Esthetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Mastectomy, Segmental
MH  - Middle Aged
MH  - Photons/therapeutic use
MH  - Prospective Studies
MH  - *Radiation Dose Hypofractionation
MH  - Radiodermatitis/diagnosis/*epidemiology/etiology/prevention & control
MH  - Radiotherapy Planning, Computer-Assisted
MH  - Radiotherapy, Adjuvant/adverse effects/methods
MH  - Radiotherapy, Conformal/*adverse effects/methods
MH  - Severity of Illness Index
MH  - Skin/radiation effects
MH  - Young Adult
OTO - NOTNLM
OT  - Breast cancer
OT  - lumpectomy
OT  - radiation boost
COIS- None
EDAT- 2020/12/22 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/12/21 06:01
PHST- 2020/12/21 06:01 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
AID - JCanResTher_2020_16_6_1344_298076 [pii]
AID - 10.4103/jcrt.JCRT_549_19 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2020 Oct-Dec;16(6):1344-1349. doi: 10.4103/jcrt.JCRT_549_19.


PMID- 33342174
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 26
IP  - 11
DP  - 2020 Nov 15
TI  - The ethical foundation for honesty and the focused use of deception in
      dermatology.
LID - 13030/qt24d872cs [pii]
AB  - Physicians have a fiduciary duty to be honest and to act in the patients' best
      interest. There are times when these two duties conflict. Honesty is paramount in
      supporting the physician-patient relationship and loss of patient trust is
      devastating. Furthermore, even minor deception can suggest a return to the
      physician authoritarianism of the past century that has been decried by modern
      ethicists. Nonetheless, circumstances can arise in which good judgement may
      require less than complete honesty to avoid harm to the patient. If the benefit
      for the patient is large and the risk from deception is small, thoughtful
      application of minor deception could be designed to benefit patients. Of course, 
      research is required to fully assess this strategy.
FAU - Pona, Adrian
AU  - Pona A
AD  - Center for Dermatology Research, Department of Dermatology, Wake Forest School of
      Medicine, Winston-Salem, NC Department of Internal Medicine, Vidant Medical
      Center/East Carolina University, Greenville, NC. pona1318@hotmail.com.
FAU - Huang, William W
AU  - Huang WW
FAU - Burrow, Robert H
AU  - Burrow RH
FAU - Brodell, Robert T
AU  - Brodell RT
FAU - Feldman, Steven R
AU  - Feldman SR
LA  - eng
PT  - Journal Article
DEP - 20201115
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
SB  - IM
MH  - *Deception
MH  - Dermatology/*ethics
MH  - Humans
MH  - Morals
MH  - Physician-Patient Relations
MH  - Physicians/*ethics
MH  - Truth Disclosure/ethics
EDAT- 2020/12/21 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/12/20 22:53
PHST- 2020/05/16 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/12/20 22:53 [entrez]
PHST- 2020/12/21 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PST - epublish
SO  - Dermatol Online J. 2020 Nov 15;26(11).


PMID- 33341760
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 0273-1223 (Print)
IS  - 0273-1223 (Linking)
VI  - 82
IP  - 12
DP  - 2020 Dec
TI  - A comprehensive review of deep learning applications in hydrology and water
      resources.
PG  - 2635-2670
LID - 10.2166/wst.2020.369 [doi]
AB  - The global volume of digital data is expected to reach 175 zettabytes by 2025.
      The volume, variety and velocity of water-related data are increasing due to
      large-scale sensor networks and increased attention to topics such as disaster
      response, water resources management, and climate change. Combined with the
      growing availability of computational resources and popularity of deep learning, 
      these data are transformed into actionable and practical knowledge,
      revolutionizing the water industry. In this article, a systematic review of
      literature is conducted to identify existing research that incorporates deep
      learning methods in the water sector, with regard to monitoring, management,
      governance and communication of water resources. The study provides a
      comprehensive review of state-of-the-art deep learning approaches used in the
      water industry for generation, prediction, enhancement, and classification tasks,
      and serves as a guide for how to utilize available deep learning methods for
      future water resources challenges. Key issues and challenges in the application
      of these techniques in the water domain are discussed, including the ethics of
      these technologies for decision-making in water resources management and
      governance. Finally, we provide recommendations and future directions for the
      application of deep learning models in hydrology and water resources.
FAU - Sit, Muhammed
AU  - Sit M
AD  - Interdisciplinary Graduate Program in Informatics, University of Iowa, Iowa City,
      USA and IIHR - Hydroscience & Engineering, University of Iowa, 100 C. Maxwell
      Stanley Hydraulics Laboratory, Iowa City, Iowa 52242-1585, USA E-mail:
      muhammed-sit@uiowa.edu.
FAU - Demiray, Bekir Z
AU  - Demiray BZ
AD  - Department of Computer Science, University of Iowa, Iowa City, USA.
FAU - Xiang, Zhongrun
AU  - Xiang Z
AD  - Department of Civil and Environmental Engineering, University of Iowa, Iowa City,
      USA.
FAU - Ewing, Gregory J
AU  - Ewing GJ
AD  - Department of Civil and Environmental Engineering, University of Iowa, Iowa City,
      USA.
FAU - Sermet, Yusuf
AU  - Sermet Y
AD  - Department of Electrical and Computer Engineering, University of Iowa, Iowa City,
      USA.
FAU - Demir, Ibrahim
AU  - Demir I
AD  - Department of Civil and Environmental Engineering, University of Iowa, Iowa City,
      USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - England
TA  - Water Sci Technol
JT  - Water science and technology : a journal of the International Association on
      Water Pollution Research
JID - 9879497
SB  - IM
MH  - Climate Change
MH  - *Deep Learning
MH  - Hydrology
MH  - *Water Resources
PMC - wst_2020_369
EDAT- 2020/12/21 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/12/20 20:30
PHST- 2020/12/20 20:30 [entrez]
PHST- 2020/12/21 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.2166/wst.2020.369 [doi]
PST - ppublish
SO  - Water Sci Technol. 2020 Dec;82(12):2635-2670. doi: 10.2166/wst.2020.369.


PMID- 33339814
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201231
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 21
DP  - 2020 Dec 19
TI  - Emergency Cesarean Section at 38 Weeks of Gestation with COVID-19 Pneumonia: A
      Case Report.
PG  - e926591
LID - 10.12659/AJCR.926591 [doi]
AB  - BACKGROUND Up to 47% of pregnant women with COVID-19 have preterm deliveries. A
      severe, symptomatic COVID-19 infection in close-to-term pregnancies can have a
      poor prognosis. Early identification of COVID-19 in pregnant women can prevent
      the progression of the disease. Currently, there is very little guidance on
      treating pregnant close-to-term women with COVID-19; this case report suggests
      changes to current management to maximize positive maternal and fetal outcomes.
      CASE REPORT A pregnant woman (37 weeks of gestation) presented to the Emergency
      Department with a chief complaint of fever with an associated cough for 2 days.
      She was diagnosed with COVID-19 in the Emergency Department, and discharged in a 
      stable condition. She returned 5 days later in preterm labor with severe
      respiratory distress. After an emergency cesarean section, she remained intubated
      in the Surgical Intensive Care Unit; she was persistently hypotensive and hypoxic
      despite maximal ventilator and medical treatment. She died after a cardiac arrest
      and unsuccessful resuscitation, 15 days after the delivery. We discuss the
      possible benefit of a planned C-section for close-to-term pregnancies prior to
      the onset of COVID-19 symptoms. The patient's next of kin gave informed consent
      for this case report. Approval from the Institutional Review Board or Ethics
      Review Board was not required as this is a case report. CONCLUSIONS Currently,
      asymptomatic pregnant women are not tested for COVID-19 infection until
      hospitalization for delivery. It could be beneficial to have a protocol in place 
      to screen asymptomatic pregnant women so they can be identified early and
      monitored, as COVID-19 symptoms can escalate quickly.
FAU - Patel, Priya
AU  - Patel P
AD  - St. George's University School of Medicine, True Blue, Grenada.
FAU - Kulkarni, Sayali
AU  - Kulkarni S
AD  - Department of Surgery, St. Joseph's University Medical Center, Paterson, NJ, USA.
FAU - Guerrero, Manrique
AU  - Guerrero M
AD  - Department of Surgery, St. Joseph's University Medical Center, Paterson, NJ, USA.
FAU - Persaud, Clive
AU  - Persaud C
AD  - Department of Surgery, St. Joseph's University Medical Center, Paterson, NJ, USA.
FAU - Zuberi, Jamshed
AU  - Zuberi J
AD  - Department of Surgery, St. Joseph's University Medical Center, Paterson, NJ, USA.
FAU - Rebein, Benjamin
AU  - Rebein B
AD  - Department of Surgery, St. Joseph's University Medical Center, Paterson, NJ, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201219
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
SB  - IM
MH  - Adult
MH  - COVID-19/*complications
MH  - *Cesarean Section
MH  - *Emergency Treatment
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*virology
PMC - PMC7755590
EDAT- 2020/12/20 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/12/19 05:23
PHST- 2020/12/19 05:23 [entrez]
PHST- 2020/12/20 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 926591 [pii]
AID - 10.12659/AJCR.926591 [doi]
PST - epublish
SO  - Am J Case Rep. 2020 Dec 19;21:e926591. doi: 10.12659/AJCR.926591.


PMID- 33339441
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 24
DP  - 2020 Dec 16
TI  - Various Aspects of a Gene Editing System-CRISPR-Cas9.
LID - E9604 [pii]
LID - 10.3390/ijms21249604 [doi]
AB  - The discovery of clustered, regularly interspaced short palindromic repeats
      (CRISPR) and their cooperation with CRISPR-associated (Cas) genes is one of the
      greatest advances of the century and has marked their application as a powerful
      genome engineering tool. The CRISPR-Cas system was discovered as a part of the
      adaptive immune system in bacteria and archaea to defend from plasmids and
      phages. CRISPR has been found to be an advanced alternative to zinc-finger
      nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) for
      gene editing and regulation, as the CRISPR-Cas9 protein remains the same for
      various gene targets and just a short guide RNA sequence needs to be altered to
      redirect the site-specific cleavage. Due to its high efficiency and precision,
      the Cas9 protein derived from the type II CRISPR system has been found to have
      applications in many fields of science. Although CRISPR-Cas9 allows easy genome
      editing and has a number of benefits, we should not ignore the important ethical 
      and biosafety issues. Moreover, any tool that has great potential and offers
      significant capabilities carries a level of risk of being used for non-legal
      purposes. In this review, we present a brief history and mechanism of the
      CRISPR-Cas9 system. We also describe on the applications of this technology in
      gene regulation and genome editing; the treatment of cancer and other diseases;
      and limitations and concerns of the use of CRISPR-Cas9.
FAU - Janik, Edyta
AU  - Janik E
AUID- ORCID: 0000-0003-0756-002X
AD  - Biohazard Prevention Centre, Faculty of Biology and Environmental Protection,
      University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
FAU - Niemcewicz, Marcin
AU  - Niemcewicz M
AD  - Biohazard Prevention Centre, Faculty of Biology and Environmental Protection,
      University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
FAU - Ceremuga, Michal
AU  - Ceremuga M
AD  - Military Institute of Armament Technology, Prymasa Stefana Wyszynskiego 7, 05-220
      Zielonka, Poland.
FAU - Krzowski, Lukasz
AU  - Krzowski L
AD  - Biodefense Laboratory, Biomedical Engineering Centre, Institute of
      Optoelectronics, Military University of Technology, gen. Sylwestra Kaliskiego 2, 
      00-908 Warsaw, Poland.
FAU - Saluk-Bijak, Joanna
AU  - Saluk-Bijak J
AD  - Department of General Biochemistry, Faculty of Biology and Environmental
      Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
FAU - Bijak, Michal
AU  - Bijak M
AUID- ORCID: 0000-0002-7838-4097
AD  - Biohazard Prevention Centre, Faculty of Biology and Environmental Protection,
      University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201216
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - *CRISPR-Cas Systems
MH  - Epigenesis, Genetic
MH  - Gene Editing/ethics/*methods/standards
MH  - Genetic Therapy/ethics/methods/standards
MH  - Humans
PMC - PMC7767219
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - gene editing
OT  - prime editing
EDAT- 2020/12/20 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/12/19 01:02
PHST- 2020/11/29 00:00 [received]
PHST- 2020/12/12 00:00 [revised]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2020/12/19 01:02 [entrez]
PHST- 2020/12/20 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - ijms21249604 [pii]
AID - 10.3390/ijms21249604 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Dec 16;21(24). pii: ijms21249604. doi: 10.3390/ijms21249604.


PMID- 33338357
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 0869-866X (Print)
IS  - 0869-866X (Linking)
VI  - 28
IP  - 6
DP  - 2020 Nov
TI  - [The section of physician everyday life at the Pirogov Congresses. Report II. The
      problems of revision of the medical sanitary legislation].
PG  - 1386-1390
LID - 10.32687/0869-866X-2020-28-6-1386-1390 [doi]
AB  - The section of physician everyday life of the Pirogov congresses discussed not
      only issues related to economic and legal status of physicians. At its sessions, 
      the need for reforming medical and sanitary legislation and expediency of
      organization of independent Ministry of health care were considered. Also,
      various ethical problems of medical activity were brought up (responsibility for 
      non-attendance of patient, court of honor, medical secrecy). The loaded social
      issues such as abolition of abbacinaire and the death penalty were raised.
FAU - Egorysheva, I V
AU  - Egorysheva IV
AD  - N. A. Semashko National Research Institute of Public Health, 105064, Moscow,
      Russia, egorysheva@rambler.ru.
FAU - Chalova, V V
AU  - Chalova VV
AD  - N. A. Semashko National Research Institute of Public Health, 105064, Moscow,
      Russia.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med
JT  - Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny
JID - 101270373
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - *Physicians
OTO - NOTNLM
OT  - Pirogov congress
OT  - medical community
OT  - section of physician everyday life
EDAT- 2020/12/19 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/12/18 17:12
PHST- 2020/09/08 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/12/18 17:12 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.32687/0869-866X-2020-28-6-1386-1390 [doi]
PST - ppublish
SO  - Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2020 Nov;28(6):1386-1390.
      doi: 10.32687/0869-866X-2020-28-6-1386-1390.


PMID- 33338073
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210111
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - COVID-19 and its impact in the dental setting: A scoping review.
PG  - e0244352
LID - 10.1371/journal.pone.0244352 [doi]
AB  - INTRODUCTION: The scoping review examined the evidence related to infection
      control and transmission measures of the SARS-CoV-2 virus in a dental setting
      during this pandemic. Dental practitioners are normally guided in practice by set
      ethical principles, thus the researchers wanted to determine how these rules are 
      managed during this pandemic. METHODS: A protocol specific for the objectives of 
      this study was developed according to the criteria for a scoping review. Relevant
      databases (Pubmed, Scopus, Elsevier, Science Direct, Wiley), including online
      access to health/ dental organizations (World Health Organization/ American
      Dental Association), were searched to identify evidence which was restricted to
      the English language for the period 2015-2020. Predetermined eligibility criteria
      were applied, evidence was assessed and data extracted for each included article.
      Relevant outcomes assessed were: infection control measures, transmission of the 
      SARS-CoV-2 virus, such as modes and sources of transmission and the ethical
      principles related to the dental setting with a focus on the COVID-19 pandemic.
      RESULTS: Searches yielded a total of 402 articles: 387 from electronic databases 
      and 15 from other sources. Of these, 231 were unrelated to the objectives of the 
      current scoping review. The full text of 69 studies was assessed for eligibility,
      of which 26 were finalized for inclusion following the objectives and inclusion
      criteria set for the scoping review. Most of the included articles were reviews, 
      recommendations and guidelines for dentists. A narrative explanation of the
      pre-specified outcomes is reported for the 3 areas covered for this review. There
      is no clinical evidence available that can support the recommendations by
      individuals, dental organizations or health authorities related to the objectives
      of this review, but these may be considered as the much needed guidelines during 
      the unprecedented COVID-19 pandemic. A different ethical framework is required
      during a pandemic and these must be informed by evidence.
FAU - Kathree, Bashier Ahmed
AU  - Kathree BA
AD  - Department of Restorative Dentistry, Faculty of Dentistry, University of the
      Western Cape, Cape Town, South Africa.
FAU - Khan, Saadika B
AU  - Khan SB
AUID- ORCID: 0000-0001-6017-959X
AD  - Department of Restorative Dentistry, Faculty of Dentistry, University of the
      Western Cape, Cape Town, South Africa.
FAU - Ahmed, Rukshana
AU  - Ahmed R
AD  - Department of Restorative Dentistry, Faculty of Dentistry, University of the
      Western Cape, Cape Town, South Africa.
FAU - Maart, Ronel
AU  - Maart R
AD  - Department of Restorative Dentistry, Faculty of Dentistry, University of the
      Western Cape, Cape Town, South Africa.
FAU - Layloo, Nazreen
AU  - Layloo N
AD  - Department of Restorative Dentistry, Faculty of Dentistry, University of the
      Western Cape, Cape Town, South Africa.
FAU - Asia-Michaels, Winifred
AU  - Asia-Michaels W
AD  - Department of Restorative Dentistry, Faculty of Dentistry, University of the
      Western Cape, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201218
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - COVID-19/*epidemiology/*prevention & control
MH  - Dentistry/*methods/*trends
MH  - Disinfection
MH  - Ethics, Medical
MH  - Humans
MH  - Infection Control/*methods
MH  - Pandemics
MH  - Practice Guidelines as Topic
MH  - United States
PMC - PMC7748282
COIS- No authors have competing interests.
EDAT- 2020/12/19 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/18 17:11
PHST- 2020/07/03 00:00 [received]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2020/12/18 17:11 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1371/journal.pone.0244352 [doi]
AID - PONE-D-20-20576 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 18;15(12):e0244352. doi: 10.1371/journal.pone.0244352.
      eCollection 2020.


PMID- 33337977
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1727-9445 (Electronic)
IS  - 1608-5906 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Dec
TI  - "Growing up and growing old with HIV": HIV+ adolescents' experiences of
      disclosing statuses to romantic partners in Bulawayo, Zimbabwe.
PG  - 312-322
LID - 10.2989/16085906.2020.1841011 [doi]
AB  - This article explores the experiences of HIV-positive adolescents disclosing
      their status to romantic partners in Bulawayo, Zimbabwe. Disclosure of HIV status
      continues to be one of the most pressing issues facing adolescents, especially
      those in relationships, yet health care workers have minimal tailored guidance on
      how to approach this except to encourage full disclosure. Motives for disclosure 
      were: guilty conscience; legal and ethical obligations; preventing partners being
      infected; and supportive people, honesty and trust. Disclosure was done on a
      one-on-one basis in public spaces such as roadsides where the adolescents usually
      met, or in health care facilities through the help of health care workers, and
      through mobile phones using WhatsApp. Results revealed that disclosure was
      associated with negative and positive outcomes ranging from disruption of
      relationships, depression, breaches of confidential information and, in some
      instances, relationship and marriage assurance. However, results clearly showed
      that adolescents living with HIV struggle with disclosure because the process is 
      complex and loaded with emotions and the outcomes can be unpredictable and
      difficult to handle. Optimism towards treatment, social support, rationalisation,
      and social comparison through attributing new meanings to the disease were
      employed to deal with negative outcomes of disclosure. Therefore, the development
      and implementation of evidence-based initiatives to raise awareness and train the
      youth to disclose is recommended. Through their experiences, we can learn what
      works well and what needs to be strengthened.
FAU - Mlilo, Philani
AU  - Mlilo P
AUID- ORCID: https://orcid.org/0000-0002-1545-5564
AD  - Department of Sociology and Social Anthropology, Great Zimbabwe University,
      Masvingo, Zimbabwe.
FAU - Dziva, Cowen
AU  - Dziva C
AUID- ORCID: https://orcid.org/0000-0001-6242-1693
AD  - Nehanda Centre for Gender and Cultural Studies, Great Zimbabwe University,
      Masvingo, Zimbabwe.
FAU - Moyo, Vuyisile Precious
AU  - Moyo VP
AUID- ORCID: https://orcid.org/0000-0003-4305-5178
AD  - Centre for Applied Social Sciences, University of Zimbabwe, Masvingo, Zimbabwe.
FAU - Ndondo, Nonhlanhla Lindelwe
AU  - Ndondo NL
AD  - Alan J Flisher School of Public Mental Health, University of Cape Town, South
      Africa.
FAU - Ndlovu, Zanele
AU  - Ndlovu Z
AD  - Department of Sociology and Social Anthropology, Great Zimbabwe University,
      Masvingo, Zimbabwe.
FAU - Muyambo, Nkosinathi
AU  - Muyambo N
AUID- ORCID: https://orcid.org/0000-0001-7630-1393
AD  - School of Religion, Philosophy and Classics, University of KwaZulu-Natal,
      Pietermaritzburg campus, South Africa.
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - Afr J AIDS Res
JT  - African journal of AIDS research : AJAR
JID - 101146510
SB  - IM
MH  - Adolescent
MH  - *Disclosure/statistics & numerical data
MH  - Female
MH  - HIV Infections/*psychology
MH  - Health Personnel/psychology
MH  - Humans
MH  - Male
MH  - Motivation
MH  - Sexual Partners/*psychology
MH  - Social Support
MH  - Zimbabwe/epidemiology
OTO - NOTNLM
OT  - adolescence
OT  - disclosure
OT  - intimate
OT  - partner
OT  - perspective
OT  - relationship status
OT  - young persons
EDAT- 2020/12/19 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/12/18 17:09
PHST- 2020/12/18 17:09 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 10.2989/16085906.2020.1841011 [doi]
PST - ppublish
SO  - Afr J AIDS Res. 2020 Dec;19(4):312-322. doi: 10.2989/16085906.2020.1841011.


PMID- 33335551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1687-9589 (Print)
IS  - 1687-9597 (Linking)
VI  - 2020
DP  - 2020
TI  - Live Experiences of Adolescent Mothers Attending Mbale Regional Referral
      Hospital: A Phenomenological Study.
PG  - 8897709
LID - 10.1155/2020/8897709 [doi]
AB  - BACKGROUND: Adolescence is a period of transition from childhood to adulthood,
      and is a critical stage in ones' development. It is characterized by immense
      opportunities and risks. By 2016, 16% of the world's population was of
      adolescents, with 82% residing in developing countries. About 12 million births
      were in 15-19 year olds. Sub-Saharan Africa, particularly East Africa, has high
      adolescent pregnancy rates, as high as 35.8% in eastern Uganda. Maternal
      mortality ratio (MMR) attributable to 15-19 years olds is significant with 17.1% 
      of Uganda's MMR 336/100.000 live births being in this age group. Whereas research
      is awash with contributing factors to such pregnancies, little is known about
      lived experiences during early motherhood. This study reports the lived
      experiences of adolescent mothers attending Mbale Hospital. MATERIALS AND
      METHODS: A phenomenological study design was used in which adolescent mothers
      that were attending Young Child Clinic were identified from the register and
      simple random sampling was used to select participants. We called these mothers
      by way of phone numbers and asked them to come for focus group discussions that
      were limited to 9 mothers per group and lasting about 45 minutes-1 hour. Ethical 
      approval was sought and informed written consent obtained from participants. At
      every focus group discussion, the data which had largely been taken in local
      languages was transcribed and translated verbatim into English. RESULTS: The
      research revealed that adolescent mothers go through hard times especially with
      the changes of pregnancy and fear of unknown during intrapartum and immediate
      postpartum period and are largely treated negatively by family and other
      community members in addition to experiencing extreme hardships during parenting.
      However, these early mothers' stress is alleviated by the joy of seeing their own
      babies. CONCLUSION: Adolescent motherhood presents a high risk group and efforts 
      to support them during antenatal care with special adolescent ANC clinics and
      continuous counseling together with their household should be emphasized to
      optimize outcome not only during pregnancy but also thereafter. Involving these
      mothers in technical courses to equip them with skills that can foster
      self-employment and providing support to enable them pursue further education
      should be explored.
CI  - Copyright (c) 2020 Violet Chemutai et al.
FAU - Chemutai, Violet
AU  - Chemutai V
AD  - Department of Obstetrics and Gynaecology, Busitema University Faculty of Health
      Sciences, Box 1460, Mbale, Uganda.
AD  - Department of Community and Public Health, Faculty of Health Sciences Busitema
      University, Mbale Regional Referral and Teaching Hospital, Mbale, Uganda.
FAU - Nteziyaremye, Julius
AU  - Nteziyaremye J
AUID- ORCID: https://orcid.org/0000-0002-6286-2867
AD  - Department of Community and Public Health, Faculty of Health Sciences Busitema
      University, Mbale Regional Referral and Teaching Hospital, Mbale, Uganda.
AD  - Department of Obstetrics and Gynaecology, Faculty of Health Sciences, Busitema
      University, Mbale Town, Uganda.
FAU - Wandabwa, Gabriel Julius
AU  - Wandabwa GJ
AD  - Department of Obstetrics and Gynaecology, Faculty of Health Sciences, Busitema
      University, Mbale Town, Uganda.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - United States
TA  - Obstet Gynecol Int
JT  - Obstetrics and gynecology international
JID - 101517078
PMC - PMC7723483
COIS- The authors declare no conflicts of interest.
EDAT- 2020/12/19 06:00
MHDA- 2020/12/19 06:01
CRDT- 2020/12/18 05:50
PHST- 2020/08/08 00:00 [received]
PHST- 2020/09/24 00:00 [revised]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/12/18 05:50 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2020/12/19 06:01 [medline]
AID - 10.1155/2020/8897709 [doi]
PST - epublish
SO  - Obstet Gynecol Int. 2020 Nov 20;2020:8897709. doi: 10.1155/2020/8897709.
      eCollection 2020.


PMID- 33335071
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 17
TI  - Covert medication and patient identity: placing the ethical analysis in a
      worldwide context.
LID - medethics-2020-106695 [pii]
LID - 10.1136/medethics-2020-106695 [doi]
AB  - In a recent JME article, Guidry-Grimes, Dean and Victor offer some signal and
      challenging insights into the ethical analysis of covert medication (in general) 
      and in particular when administered via food. They warn of impacts on identity
      likely to emerge from using food in this way. In particular, they caution against
      allowing families to be involved in covert medication, in the light of their
      central role in sustaining identity. Their analysis has particular purchase in
      resource rich contexts and those contexts where individual identity is a central 
      concern. But it is less clear that the article's insights are relevant to other
      contexts. This article places the analysis of covert medication and identity in a
      wider context, arguing both that the focus on identity is equally significant
      when analysing potential alternatives to covert medication, such as coercion; and
      that the ethical analysis of covert medication offered by Guidry-Grimes, Dean and
      Victor lacks global applicability. It seems to lack application particularly in
      resource-poor contexts, and in cultures where identity and community are
      interconstituted.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pickering, Neil John
AU  - Pickering NJ
AUID- ORCID: http://orcid.org/0000-0001-8629-1627
AD  - Bioethics Centre, University of Otago Dunedin School of Medicine, Dunedin, New
      Zealand neil.pickering@otago.ac.nz.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639955
OTO - NOTNLM
OT  - clinical ethics
OT  - coercion
OT  - cultural pluralism
OT  - family
COIS- Competing interests: None declared.
EDAT- 2020/12/19 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/12/18 05:41
PHST- 2020/07/13 00:00 [received]
PHST- 2020/10/27 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/12/18 05:41 [entrez]
AID - medethics-2020-106695 [pii]
AID - 10.1136/medethics-2020-106695 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 17. pii: medethics-2020-106695. doi:
      10.1136/medethics-2020-106695.


PMID- 33335070
OWN - NLM
STAT- Publisher
LR  - 20210114
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 17
TI  - Ethical allocation of future COVID-19 vaccines.
LID - medethics-2020-106850 [pii]
LID - 10.1136/medethics-2020-106850 [doi]
AB  - The COVID-19 pandemic will likely recede only through development and
      distribution of an effective vaccine. Although there are many unknowns
      surrounding COVID-19 vaccine development, vaccine demand will likely outstrip
      early supply, making prospective planning for vaccine allocation critical for
      ensuring the ethical distribution of COVID-19 vaccines. Here, we propose three
      central goals for COVID-19 vaccination campaigns: to reduce morbidity and
      mortality, to minimise additional economic and societal burdens related to the
      pandemic and to narrow unjust health inequalities. We evaluate five
      prioritisation approaches, assess their likely impact on advancing the three
      goals of vaccine allocation and identify open scientific questions that may alter
      their outcomes. We argue that no single prioritisation approach will advance all 
      three goals. Instead, we propose a multipronged approach that considers the risk 
      of serious COVID-19 illness, instrumental value and the risk of transmission, and
      is guided by future research on COVID-19-specific clinical and vaccine
      characteristics. While we focus this assessment on the USA, our analysis can
      inform allocation in other contexts.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Gupta, Rohit
AU  - Gupta R
AUID- ORCID: http://orcid.org/0000-0002-7442-1209
AD  - School of Medicine, Baylor College of Medicine, Houston, Texas, USA
      rohit.gupta@bcm.edu.
FAU - Morain, Stephanie R
AU  - Morain SR
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7747493
OTO - NOTNLM
OT  - allocation of health care resources
OT  - clinical ethics
OT  - health care for specific diseases/groups
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/12/19 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/12/18 05:41
PHST- 2020/08/26 00:00 [received]
PHST- 2020/12/07 00:00 [revised]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/12/18 05:41 [entrez]
AID - medethics-2020-106850 [pii]
AID - 10.1136/medethics-2020-106850 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 17. pii: medethics-2020-106850. doi:
      10.1136/medethics-2020-106850.


PMID- 33335058
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 370
IP  - 6523
DP  - 2020 Dec 18
TI  - Transparency is key to ethical vaccine research-Response.
PG  - 1423-1424
LID - 10.1126/science.abf7809 [doi]
FAU - Caplan, Arthur
AU  - Caplan A
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, NY 10016, USA. arthur.caplan@nyumc.org.
FAU - Bateman-House, Alison
AU  - Bateman-House A
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, NY 10016, USA.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Vaccines)
SB  - IM
CON - Science. 2020 Dec 18;370(6523):1422-1423. PMID: 33335056
MH  - *Biomedical Research
MH  - Ethics, Research
MH  - *Vaccines
EDAT- 2020/12/19 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/12/18 05:41
PHST- 2020/12/18 05:41 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 370/6523/1423-b [pii]
AID - 10.1126/science.abf7809 [doi]
PST - ppublish
SO  - Science. 2020 Dec 18;370(6523):1423-1424. doi: 10.1126/science.abf7809.


PMID- 33335057
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210827
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 370
IP  - 6523
DP  - 2020 Dec 18
TI  - Transparency is key to ethical vaccine research-Response.
PG  - 1423
LID - 10.1126/science.abf4883 [doi]
FAU - Guerrini, Christi J
AU  - Guerrini CJ
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX 77030, USA. guerrini@bcm.edu.
FAU - Sherkow, Jacob S
AU  - Sherkow JS
AD  - College of Law, University of Illinois at Urbana-Champaign, Champaign, IL 61820, 
      USA.
AD  - Carl R. Woese Institute for Genomic Biology, University of Illinois at
      Urbana-Champaign, Urbana, IL 61801, USA.
AD  - Center for Advanced Studies in Biomedical Innovation Law, University of
      Copenhagen Faculty of Law, Copenhagen, Denmark.
FAU - Meyer, Michelle N
AU  - Meyer MN
AD  - Center for Translational Bioethics and Health Care Policy and Steele Institute
      for Health Innovation, Geisinger Health System, Danville, PA 17822, USA.
AD  - Geisinger Commonwealth School of Medicine, Scranton, PA 18510, USA.
FAU - Zettler, Patricia J
AU  - Zettler PJ
AD  - Moritz College of Law, The James Comprehensive Cancer Center and Drug Enforcement
      and Policy Center, Ohio State University, Columbus, OH 43210, USA.
LA  - eng
GR  - K01 HG009355/HG/NHGRI NIH HHS/United States
PT  - Letter
PT  - Comment
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Vaccines)
SB  - IM
CON - Science. 2020 Dec 18;370(6523):1422-1423. PMID: 33335056
MH  - *Biomedical Research
MH  - Ethics, Research
MH  - *Vaccines
EDAT- 2020/12/19 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/12/18 05:41
PHST- 2020/12/18 05:41 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 370/6523/1423-a [pii]
AID - 10.1126/science.abf4883 [doi]
PST - ppublish
SO  - Science. 2020 Dec 18;370(6523):1423. doi: 10.1126/science.abf4883.


PMID- 33335056
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 370
IP  - 6523
DP  - 2020 Dec 18
TI  - Transparency is key to ethical vaccine research.
PG  - 1422-1423
LID - 10.1126/science.abf4851 [doi]
FAU - Estep, Preston W
AU  - Estep PW
AD  - Rapid Deployment Vaccine Collaborative (RaDVaC), Lincoln, MA 01773, USA.
      pwestep@radvac.org.
FAU - Church, George M
AU  - Church GM
AD  - Rapid Deployment Vaccine Collaborative (RaDVaC), Lincoln, MA 01773, USA.
AD  - Wyss Institute for Biologically Inspired Engineering, Harvard University,
      Cambridge, MA 02115, USA.
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Vaccines)
SB  - IM
CON - Science. 2020 Sep 25;369(6511):1570-1572. PMID: 32943452
CIN - Science. 2020 Dec 18;370(6523):1423. PMID: 33335057
CIN - Science. 2020 Dec 18;370(6523):1423-1424. PMID: 33335058
MH  - Autoexperimentation
MH  - *Biomedical Research
MH  - Ethics, Research
MH  - *Vaccines
EDAT- 2020/12/19 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/12/18 05:41
PHST- 2020/12/18 05:41 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 370/6523/1422 [pii]
AID - 10.1126/science.abf4851 [doi]
PST - ppublish
SO  - Science. 2020 Dec 18;370(6523):1422-1423. doi: 10.1126/science.abf4851.


PMID- 33334840
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed
      whole-cell/acellular pertussis vaccine schedule.
PG  - e042838
LID - 10.1136/bmjopen-2020-042838 [doi]
AB  - INTRODUCTION: Combination vaccines containing whole-cell pertussis antigens were 
      phased out from the Australian national immunisation programme between 1997 and
      1999 and replaced by the less reactogenic acellular pertussis (aP) antigens. In a
      large case-control study of Australian children born during the transition
      period, those with allergist diagnosed IgE-mediated food allergy were less likely
      to have received whole-cell vaccine in early infancy than matched population
      controls (OR: 0.77 (95% CI, 0.62 to 0.95)). We hypothesise that a single dose of 
      whole-cell vaccine in early infancy is protective against IgE-mediated food
      allergy. METHODS AND ANALYSIS: This adaptive double-blind randomised controlled
      trial is investigating whether a mixed whole-cell/aP vaccine schedule prevents
      allergic disease in the first year of life. The primary outcome is IgE-mediated
      food allergy by 12 months of age. Secondary outcomes include new onset of atopic 
      dermatitis by 6 or 12 months of age; sensitisation to at least one allergen by 12
      months of age; seroconversion in anti-pertussis toxin IgG titres after
      vaccination with aP booster at 18 months of age; and solicited systemic and local
      adverse events following immunisation with pertussis-containing vaccines.
      Analyses will be performed using a Bayesian group sequential design. ETHICS AND
      DISSEMINATION: This study has been approved by the Child and Adolescent Health
      Service Human Research Ethics Committee, Perth, Western Australia (RGS 00019).
      The investigators will ensure that this trial is conducted in accordance with the
      principles of the Declaration of Helsinki and with the International Conference
      on Harmonisation Guidelines for Good Clinical Practice. Individual consent will
      be requested. Parents will be reimbursed reasonable travel and parking costs to
      attend the study visits. The dissemination of these research findings will follow
      the National Health and Medical Research Council of Australia Open Access Policy.
      TRIAL REGISTRATION NUMBER: ACTRN12617000065392p.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Perez Chacon, Gladymar
AU  - Perez Chacon G
AUID- ORCID: 0000-0001-6629-1603
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Nedlands, Western Australia, Australia.
AD  - School of Public Health, Curtin University, Bentley, Western Australia,
      Australia.
FAU - Estcourt, Marie J
AU  - Estcourt MJ
AD  - Health and Clinical Analytics Lab, School of Public Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Totterdell, James
AU  - Totterdell J
AD  - Health and Clinical Analytics Lab, School of Public Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Campbell, Dianne E
AU  - Campbell DE
AD  - Department of Allergy and Immunology, The Children's Hospital at Westmead,
      Sydney, New South Wales, Australia.
AD  - Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New 
      South Wales, Australia.
FAU - Perrett, Kirsten P
AU  - Perrett KP
AD  - Royal Children's Hospital, Murdoch Children's Research Institute, Parkville,
      Victoria, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Marsh, Julie A
AU  - Marsh JA
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Nedlands, Western Australia, Australia.
FAU - Richmond, Peter C
AU  - Richmond PC
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Nedlands, Western Australia, Australia.
AD  - Division of Paediatrics, School of Medicine, Perth Children's Hospital, The
      University of Western Australia, Nedlands, Western Australia, Australia.
FAU - Wood, Nicholas
AU  - Wood N
AD  - Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New 
      South Wales, Australia.
AD  - The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
FAU - Gold, Michael S
AU  - Gold MS
AD  - Discipline of Paediatrics, School of Medicine, University of Adelaide, Adelaide, 
      South Australia, Australia.
FAU - Holt, Patrick G
AU  - Holt PG
AD  - The University of Western Australia, Telethon Kids Institute, Nedlands, Western
      Australia, Australia.
FAU - Waddington, Claire S
AU  - Waddington CS
AD  - Department of Medicine, University of Cambridge, Cambridge, Cambridgeshire, UK.
FAU - Snelling, Thomas L
AU  - Snelling TL
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Nedlands, Western Australia, Australia tom.snelling@sydney.edu.au.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (Pertussis Vaccine)
SB  - IM
EIN - BMJ Open. 2022 May 11;12(5):e042838corr1. PMID: 35545403
MH  - Antibodies, Bacterial
MH  - Australia
MH  - Bayes Theorem
MH  - Case-Control Studies
MH  - *Diphtheria-Tetanus-Pertussis Vaccine
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Pertussis Vaccine
MH  - Randomized Controlled Trials as Topic
MH  - Western Australia
MH  - *Whooping Cough/prevention & control
PMC - PMC7747585
OTO - NOTNLM
OT  - *allergy
OT  - *immunology
OT  - *paediatric infectious disease and immunisation
COIS- Competing interests: GPC has received travel support from Seqirus to attend a
      conference (June 2018; outside the submitted work). DEC is a part-time employee
      of DBV Technologies and reports personal fees from Allergenis, Westmead Fertility
      Centre and Financial Markets Foundation for Children. KPP's institution (Murdoch 
      Children's Research Institute) has received research grants from DBV
      Technologies, GlaxoSmithKline, Medlmmune and Novavax outside the submitted work. 
      PR has served on vaccine scientific advisory boards for GlaxoSmithKline and
      Sanofi (no personal remuneration) outside the submitted work. PR has also
      received institutional funding for investigator-initiated research projects on
      pertussis vaccination from GlaxoSmithKline and Technovalia, outside the submitted
      work. The other authors declare no conflict of interest.
EDAT- 2020/12/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042838 [pii]
AID - 10.1136/bmjopen-2020-042838 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e042838. doi: 10.1136/bmjopen-2020-042838.


PMID- 33334839
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - ED to EPI: protocol for a pragmatic randomised controlled trial of an SMS (text) 
      messaging intervention to improve the transition from the emergency department to
      early psychosis intervention for young people with psychosis.
PG  - e042751
LID - 10.1136/bmjopen-2020-042751 [doi]
AB  - INTRODUCTION: While nearly half of all new psychotic disorders are diagnosed in
      the emergency department (ED), most young people who present to the ED with
      psychosis do not receive timely follow-up with a psychiatrist, and even fewer
      with evidence-based early psychosis intervention (EPI) services. We aim to test
      an intervention delivered using short message service (SMS), a low-cost,
      low-complexity, youth-friendly approach, to improve transitions from the ED to
      EPI services. METHODS AND ANALYSIS: This is a protocol for a pragmatic
      randomised, single blind, controlled trial with accompanying economic and
      qualitative evaluations conducted at the Centre for Addiction and Mental Health
      (CAMH) in Toronto, Canada. A consecutive series of 186 participants aged 16-29
      referred by the ED to CAMH's EPI programme will be recruited for a trial of a
      two-way intervention involving reminders, psychoeducation and check-ins delivered
      via SMS. The primary outcome will be attendance at the first consultation
      appointment within 30 days of study enrolment assessed through chart reviews in
      the electronic health record. We will also extract routine clinical measures,
      including the Brief Psychiatric Rating Scale, Clinical Global Impression and
      Service Engagement Scale, and link with provincial health administrative data to 
      examine system-level outcomes, including ED visits and psychiatric
      hospitalisations, 6 months and up to 2 years after baseline. We will perform a
      cost-effectiveness analysis of the primary study outcome and costs incurred,
      calculating an incremental cost effectiveness ratio. Web-based surveys and
      qualitative interviews will explore intervention user experience. Patients and
      families with lived experience will be engaged in all aspects of the project.
      ETHICS AND DISSEMINATION: Research Ethics Board approval has been obtained.
      Findings will be reported in scientific journal articles and shared with key
      stakeholders including youth, family members, knowledge users and decision
      makers. TRIAL REGISTRATION NUMBER: NCT04298450.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Polillo, Alexia
AU  - Polillo A
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Foussias, George
AU  - Foussias G
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Wong, Albert H C
AU  - Wong AHC
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Ampofo, Augustina
AU  - Ampofo A
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Stergiopoulos, Vicky
AU  - Stergiopoulos V
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Anderson, Kelly K
AU  - Anderson KK
AD  - Epidemiology & Biostatistics, Western University, London, Ontario, Canada.
FAU - Bromley, Sarah
AU  - Bromley S
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - D'Arcey, Jessica
AU  - D'Arcey J
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
FAU - de Oliveira, Claire
AU  - de Oliveira C
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Duda, Lillian
AU  - Duda L
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Henderson, Joanna
AU  - Henderson J
AUID- ORCID: 0000-0002-9387-5193
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Margaret and Wallace McCain Centre for Child, Youth and Family Mental Health,
      Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Kidd, Sean
AU  - Kidd S
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Kurdyak, Paul
AU  - Kurdyak P
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Wang, Wei
AU  - Wang W
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Zaheer, Juveria
AU  - Zaheer J
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Voineskos, Aristotle N
AU  - Voineskos AN
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Kozloff, Nicole
AU  - Kozloff N
AUID- ORCID: 0000-0003-1389-1351
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada n.kozloff@mail.utoronto.ca.
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04298450
GR  - 165726/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Canada
MH  - Emergency Service, Hospital
MH  - Humans
MH  - *Psychotic Disorders/therapy
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - *Text Messaging
MH  - Young Adult
PMC - PMC7747582
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *clinical trials
OT  - *information technology
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/12/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042751 [pii]
AID - 10.1136/bmjopen-2020-042751 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e042751. doi: 10.1136/bmjopen-2020-042751.


PMID- 33334838
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - Study protocol for SPARED trial: randomised non-inferiority phase III trial
      comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with
      neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients 
      receiving cisplatin-based chemotherapy.
PG  - e041737
LID - 10.1136/bmjopen-2020-041737 [doi]
AB  - INTRODUCTION: Dexamethasone (DEX) is administered for multiple days to prevent
      chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic
      chemotherapy (HEC); however, its notorious side effects have been widely
      reported. Although our multicentre randomised double-blind comparative study
      verified non-inferiority of sparing DEX after day 2 of chemotherapy when combined
      with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for
      patients receiving HEC regimen, DEX sparing was not non-inferior in patients
      receiving cisplatin (CDDP)-based HEC regimens in subgroup analysis. Recently, the
      efficacy of the addition of olanzapine (OLZ) to standard triple antiemetic
      therapy on HEC has been demonstrated by several phase III trials. This study aims
      to confirm non-inferiority of DEX sparing when it is combined with NK-1RA, Palo
      and OLZ in patients receiving CDDP-based HEC regimens. METHODS AND ANALYSIS: This
      is a randomised, double-blind, phase III trial. Patients who are scheduled to
      receive CDDP >/=50 mg/m(2) as initial chemotherapy are eligible. Patients are
      randomly assigned to receive either DEX on days 1-4 or DEX on day 1 combined with
      NK1-RA, Palo and OLZ (5 mg). The primary endpoint is complete response (CR) rate,
      defined as no emesis and no rescue medications during the delayed phase (24-120
      hours post-CDDP administration). The non-inferiority margin is set at -15.0%. We 
      assume that CR rates would be 75% in both arms. Two hundred and sixty-two
      patients are required for at least 80% power to confirm non-inferiority at a
      one-sided significance level of 2.5%. After considering the possibility of
      attrition, we set our final required sample size of 280. ETHICS AND
      DISSEMINATION: The institutional review board approved the study protocol at each
      of the participating centres. The trial result will be presented at international
      conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      UMIN000032269.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Minatogawa, Hiroko
AU  - Minatogawa H
AUID- ORCID: 0000-0002-5836-8305
AD  - Department of Pharmacy, St.Marianna University School of Medicine Hospital,
      Kawasaki, Japan.
FAU - Izawa, Naoki
AU  - Izawa N
AD  - Department of Clinical Oncology, St. Marianna University School of Medicine,
      Kawasaki, Japan.
FAU - Kawaguchi, Takashi
AU  - Kawaguchi T
AD  - Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences,
      Tokyo, Japan.
FAU - Miyaji, Tempei
AU  - Miyaji T
AD  - Department of Clinical Trial Data Management, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
FAU - Shimomura, Kazuhiro
AU  - Shimomura K
AD  - Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan.
FAU - Kazunori, Honda
AU  - Kazunori H
AD  - Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
FAU - Iihara, Hirotoshi
AU  - Iihara H
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Ohno, Yasushi
AU  - Ohno Y
AD  - Department of Respirology, Gifu University Graduate School of Medicine, Gifu,
      Japan.
FAU - Inada, Yusuke
AU  - Inada Y
AD  - Department of Pharmacy, Yokohama Rosai Hospital, Yokohama, Japan.
FAU - Arioka, Hitoshi
AU  - Arioka H
AD  - Department of Medical Oncology, Yokohama Rosai Hospital, Yokohama, Japan.
FAU - Morita, Hajime
AU  - Morita H
AD  - Department of Pharmacy, St. Marianna University Yokohama City Seibu Hospital,
      Yokohama, Japan.
FAU - Hida, Naoya
AU  - Hida N
AD  - Department of Internal Medicine, St.Marianna University School of Medicine,
      Kawasaki, Japan.
FAU - Sugawara, Mitsuhiro
AU  - Sugawara M
AD  - Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan.
FAU - Katada, Chikatoshi
AU  - Katada C
AD  - Department of Gastroenterology, Kitasato University School of Medicine,
      Sagamihara, Japan.
FAU - Nawata, Shuichi
AU  - Nawata S
AD  - Department of Hospital Pharmaceutics, Showa University Northern Yokohama
      Hospital, Yokohama, Japan.
FAU - Ishida, Hiroo
AU  - Ishida H
AD  - Department of Internal Medicine, Showa University Northern Yokohama Hospital,
      Yokohama, Japan.
FAU - Tsuboya, Ayako
AU  - Tsuboya A
AD  - Department of Pharmacy, St. Marianna University Kawasakishi Municipal Tama
      Hospital, Kawasaki, Japan.
FAU - Tsuda, Takashi
AU  - Tsuda T
AD  - Department of Clinical Oncology, St. Marianna University School of Medicine,
      Kawasaki, Japan.
AD  - Department of Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai
      Hospital, Fujisawa, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Division of Biostatistics, Tohoku University School of Medicine, Sendai, Japan.
FAU - Nakajima, Takako Eguchi
AU  - Nakajima TE
AD  - Department of Clinical Oncology, St. Marianna University School of Medicine,
      Kawasaki, Japan tnakajima@kuhp.kyoto-u.ac.jp.
AD  - Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS
      Cell Therapy, Kyoto University Hospital, Kyoto, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000032269
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Neurokinin-1 Receptor Antagonists)
RN  - 5D06587D6R (Palonosetron)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - N7U69T4SZR (Olanzapine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiemetics/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Cisplatin/*adverse effects
MH  - Dexamethasone/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neurokinin-1 Receptor Antagonists/*therapeutic use
MH  - Olanzapine/*therapeutic use
MH  - Palonosetron/*therapeutic use
MH  - Pregnancy
MH  - Vomiting/chemically induced/drug therapy/*prevention & control
MH  - Young Adult
PMC - PMC7747608
OTO - NOTNLM
OT  - *adult palliative care
OT  - *adverse events
OT  - *chemotherapy
OT  - *clinical trials
COIS- Competing interests: NI has received honoraria from Takeda Pharma CO., Ltd, Eli
      Lilly, Japan, Ono Pharma CO., Ltd, and Daiichi Sankyo Company. Author HA has
      received grant from Taiho, Chugai and Nippon Kayaku; personal fees from Novartis,
      Sanofi, Ono, Kyowa Kirin and Takeda. TY has received grant and personal fees from
      Ono Pharmaceutical Co., Ltd. TEN has received grant and personal fee from Taiho
      Pharmaceutical Co., Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Sanofi 
      K.K., Daiichi Sankyo Co., Eli Lilly Japan K.K., Nippon Kayaku Co., Ono
      Pharmaceutical Co. and MSD K.K.; personal fees from Mochida Pharmaceutical,
      Celltrion Healthcare Japan, Merck Serono Co., Sawai Pharmaceutical Co., Bayer
      Yakuhin, Bristol-Myers Squibb, Teijin Pharma, Pfizer Japan Inc., Novartis Japan, 
      Yakult Honsha Co. and Nipro Co; grant from Astellas Pharma Inc., Sumitomo
      Dainippon Pharma Co., Eisai Co and Solasia Pharma K.K. The other authors have
      declared no conflicts of interest.
EDAT- 2020/12/19 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-041737 [pii]
AID - 10.1136/bmjopen-2020-041737 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e041737. doi: 10.1136/bmjopen-2020-041737.


PMID- 33334836
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - Reporting of methodological studies in health research: a protocol for the
      development of the MethodologIcal STudy reportIng Checklist (MISTIC).
PG  - e040478
LID - 10.1136/bmjopen-2020-040478 [doi]
AB  - INTRODUCTION: Methodological studies (ie, studies that evaluate the design,
      conduct, analysis or reporting of other studies in health research) address
      various facets of health research including, for instance, data collection
      techniques, differences in approaches to analyses, reporting quality, adherence
      to guidelines or publication bias. As a result, methodological studies can help
      to identify knowledge gaps in the methodology of health research and strategies
      for improvement in research practices. Differences in methodological study names 
      and a lack of reporting guidance contribute to lack of comparability across
      studies and difficulties in identifying relevant previous methodological studies.
      This paper outlines the methods we will use to develop an evidence-based tool-the
      MethodologIcal STudy reportIng Checklist-to harmonise naming conventions and
      improve the reporting of methodological studies. METHODS AND ANALYSIS: We will
      search for methodological studies in the Cumulative Index to Nursing and Allied
      Health Literature, Cochrane Library, Embase, MEDLINE, Web of Science, check
      reference lists and contact experts in the field. We will extract and summarise
      data on the study names, design and reporting features of the included
      methodological studies. Consensus on study terms and recommended reporting items 
      will be achieved via video conference meetings with a panel of experts including 
      researchers who have published methodological studies. ETHICS AND DISSEMINATION: 
      The consensus study has been exempt from ethics review by the Hamilton Integrated
      Research Ethics Board. The results of the review and the reporting guideline will
      be disseminated in stakeholder meetings, conferences, peer-reviewed publications,
      in requests to journal editors (to endorse or make the guideline a requirement
      for authors), and on the Enhancing the QUAlity and Transparency Of health
      Research (EQUATOR) Network and reporting guideline websites. REGISTRATION: We
      have registered the development of the reporting guideline with the EQUATOR
      Network and publicly posted this project on the Open Science Framework
      (www.osf.io/9hgbq).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lawson, Daeria O
AU  - Lawson DO
AUID- ORCID: 0000-0002-6487-3367
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada lawsod3@mcmaster.ca.
FAU - Puljak, Livia
AU  - Puljak L
AUID- ORCID: 0000-0002-8467-6061
AD  - Center for Evidence-Based Medicine and Health Care, Catholic University of
      Croatia, Zagreb, Croatia.
FAU - Pieper, Dawid
AU  - Pieper D
AD  - Institute for Research in Operative Medicine, Witten/Herdecke University,
      Cologne, Germany.
FAU - Schandelmaier, Stefan
AU  - Schandelmaier S
AUID- ORCID: 0000-0002-8429-0337
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Institute for Clinical Epidemiology and Biostatistics, Department of Clinical
      Research, University and University Hospital of Basel, Basel, Switzerland.
FAU - Collins, Gary S
AU  - Collins GS
AD  - Centre for Statistics in Medicine, Nuffield Department of Orthopaedics,
      Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
FAU - Brignardello-Petersen, Romina
AU  - Brignardello-Petersen R
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Moher, David
AU  - Moher D
AUID- ORCID: 0000-0003-2434-4206
AD  - Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research 
      Institute, Ottawa, Ontario, Canada.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Tugwell, Peter
AU  - Tugwell P
AD  - School of Epidemiology and Public Health, Faculty of Medicine and Department of
      Medicine, University of Ottawa, Ottawa, Ontario, Canada.
AD  - Bruyere Research Institute, Ottawa, Ontario, Canada.
FAU - Welch, Vivian A
AU  - Welch VA
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
AD  - Bruyere Research Institute, Ottawa, Ontario, Canada.
FAU - Samaan, Zainab
AU  - Samaan Z
AUID- ORCID: 0000-0002-5974-9361
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Thombs, Brett D
AU  - Thombs BD
AUID- ORCID: 0000-0002-5644-8432
AD  - Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Norskov, Anders K
AU  - Norskov AK
AD  - Copenhagen Trial Unit, Rigshospitalet, Copenhagen University Hospital,
      Copenhagen, Denmark.
FAU - Jakobsen, Janus C
AU  - Jakobsen JC
AUID- ORCID: 0000-0002-3642-2120
AD  - Copenhagen Trial Unit, Rigshospitalet, Copenhagen University Hospital,
      Copenhagen, Denmark.
AD  - Department of Regional Health Research, The Faculty of Heath Sciences, University
      of Southern Denmark, Odense, Denmark.
FAU - Allison, David B
AU  - Allison DB
AD  - Department of Epidemiology and Biostatistics, Indiana University School of Public
      Health-Bloomington, Bloomington, Indiana, USA.
FAU - Mayo-Wilson, Evan
AU  - Mayo-Wilson E
AUID- ORCID: 0000-0001-6126-2459
AD  - Department of Epidemiology and Biostatistics, Indiana University School of Public
      Health-Bloomington, Bloomington, Indiana, USA.
FAU - Young, Taryn
AU  - Young T
AD  - Centre for Evidence-based Health Care, Division of Epidemiology and
      Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, 
      Cape Town, South Africa.
FAU - Chan, An-Wen
AU  - Chan AW
AD  - Department of Medicine, Women's College Research Institute, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Briel, Matthias
AU  - Briel M
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Institute for Clinical Epidemiology and Biostatistics, Department of Clinical
      Research, University and University Hospital of Basel, Basel, Switzerland.
FAU - Guyatt, Gordon H
AU  - Guyatt GH
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence, and Impact, and Departments of
      Paediatrics and Anaesthesia, McMaster University, Hamilton, Ontario, Canada.
AD  - Biostatistics Unit, Father Sean O'Sullivan Research Centre and Centre for
      Evaluation of Medicine, Saint Joseph's Healthcare Hamilton, Hamilton, Ontario,
      Canada.
AD  - Population Health Research Institute, Hamilton Health Sciences, Hamilton,
      Ontario, Canada.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AUID- ORCID: 0000-0001-5855-5461
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Biostatistics Unit, Father Sean O'Sullivan Research Centre, Saint Joseph's
      Healthcare Hamilton, Hamilton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Checklist
MH  - Consensus
MH  - Humans
MH  - Publications
MH  - *Research Design
PMC - PMC7747548
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *epidemiology
OT  - *statistics & research methods
COIS- Competing interests: 'Yes, there are competing interests for one or more authors 
      and I have provided a Competing Interests statement in my manuscript and in the
      box below'.
EDAT- 2020/12/19 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040478 [pii]
AID - 10.1136/bmjopen-2020-040478 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e040478. doi: 10.1136/bmjopen-2020-040478.


PMID- 33334834
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - Rehabilitation for ataxia study: protocol for a randomised controlled trial of an
      outpatient and supported home-based physiotherapy programme for people with
      hereditary cerebellar ataxia.
PG  - e040230
LID - 10.1136/bmjopen-2020-040230 [doi]
AB  - INTRODUCTION: Emerging evidence indicates that rehabilitation can improve ataxia,
      mobility and independence in everyday activities in individuals with hereditary
      cerebellar ataxia. However, with the rarity of the genetic ataxias and known
      recruitment challenges in rehabilitation trials, most studies have been
      underpowered, non-randomised or non-controlled. This study will be the first,
      appropriately powered randomised controlled trial to examine the efficacy of an
      outpatient and home-based rehabilitation programme on improving motor function
      for individuals with hereditary cerebellar ataxia. METHODS AND ANALYSIS: This
      randomised, single-blind, parallel group trial will compare a 30-week
      rehabilitation programme to standard care in individuals with hereditary
      cerebellar ataxia. Eighty individuals with a hereditary cerebellar ataxia, aged
      15 years and above, will be recruited. The rehabilitation programme will include 
      6 weeks of outpatient land and aquatic physiotherapy followed immediately by a
      24- week home exercise programme supported with fortnightly physiotherapy
      sessions. Participants in the standard care group will be asked to continue their
      usual physical activity. The primary outcome will be the motor domain of the
      Functional Independence Measure. Secondary outcomes will measure the motor
      impairment related to ataxia, balance, quality of life and cost-effectiveness.
      Outcomes will be administered at baseline, 7 weeks, 18 weeks and 30 weeks by a
      physiotherapist blinded to group allocation. A repeated measures mixed-effects
      linear regression model will be used to analyse the effect of the treatment group
      for each of the dependent continuous variables. The primary efficacy analysis
      will follow the intention-to-treat principle. ETHICS AND DISSEMINATION: The study
      has been approved by the Monash Health Human Research Ethics Committee
      (HREC/18/MonH/418) and the Human Research Ethics Committee of the Northern
      Territory Department of Health and Menzies School of Health Research (2019/3503).
      Results will be published in peer-reviewed journals, presented at national and/or
      international conferences and disseminated to Australian ataxia support groups.
      TRIAL REGISTRATION NUMBER: ACTRN12618000908235.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Milne, Sarah C
AU  - Milne SC
AUID- ORCID: 0000-0002-9406-8609
AD  - Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research
      Institute, Parkville, Victoria, Australia.
AD  - Physiotherapy Department, Monash Health, Cheltenham, Victoria, Australia.
AD  - School of Primary and Allied Health Care, Monash University, Frankston, Victoria,
      Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
FAU - Corben, Louise A
AU  - Corben LA
AD  - Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research
      Institute, Parkville, Victoria, Australia.
AD  - School of Primary and Allied Health Care, Monash University, Frankston, Victoria,
      Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
FAU - Roberts, Melissa
AU  - Roberts M
AD  - Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research
      Institute, Parkville, Victoria, Australia.
AD  - Physiotherapy Department, Monash Health, Cheltenham, Victoria, Australia.
FAU - Szmulewicz, David
AU  - Szmulewicz D
AD  - Balance Disorders & Ataxia Service, Royal Victorian Eye and Ear Hospital, East
      Melbourne, Victoria, Australia.
AD  - Cerebellar Ataxia Clinic, Alfred Health, Caulfield, Victoria, Australia.
AD  - Monash Medical Centre, Monash Health, Clayton, Victoria, Australia.
AD  - The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria,
      Australia.
FAU - Burns, J
AU  - Burns J
AD  - University of Sydney School of Health Sciences, Faculty of Medicine and Health & 
      Children's Hospital at Westmead, Sydney, New South Wales, Australia.
FAU - Grobler, Anneke C
AU  - Grobler AC
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
AD  - Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research
      Institute, Parkville, Victoria, Australia.
FAU - Williams, Shannon
AU  - Williams S
AD  - Physiotherapy Department, Royal Perth Hospital, Perth, Western Australia,
      Australia.
AD  - Physiotherapy Department, Sir Charles Gairdner Hospital, Nedlands, Western
      Australia, Australia.
FAU - Chua, Jillian
AU  - Chua J
AD  - Physiotherapy Department, Ryde Hospital, Eastwood, New South Wales, Australia.
FAU - Liang, Christina
AU  - Liang C
AD  - Department of Neurology, Royal North Shore Hospital, St Leonards, New South
      Wales, Australia.
AD  - Kolling Institute of Medical Research, University of Sydney, St Leonards, New
      South Wales, Australia.
FAU - Lamont, Phillipa J
AU  - Lamont PJ
AD  - Neurogenetic Unit, Royal Perth Hospital, Perth, Western Australia, Australia.
FAU - Grootendorst, Alison C
AU  - Grootendorst AC
AD  - MJD Foundation, Darwin, Northern Territory, Australia.
FAU - Massey, Libby
AU  - Massey L
AD  - MJD Foundation, Darwin, Northern Territory, Australia.
FAU - Sue, Carolyn
AU  - Sue C
AD  - Department of Neurology, Royal North Shore Hospital, St Leonards, New South
      Wales, Australia.
AD  - Kolling Institute of Medical Research, University of Sydney, St Leonards, New
      South Wales, Australia.
FAU - Dalziel, Kim
AU  - Dalziel K
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Parkville, Victoria, Australia.
FAU - LaGrappe, Desiree
AU  - LaGrappe D
AD  - MJD Foundation, Darwin, Northern Territory, Australia.
FAU - Willis, Liz
AU  - Willis L
AD  - MJD Foundation, Darwin, Northern Territory, Australia.
FAU - Freijah, Aleka
AU  - Freijah A
AD  - Rehabilitation Services, Royal Darwin and Palmerston Hospitals, Darwin, Northern 
      Territory, Australia.
FAU - Gerken, Paul
AU  - Gerken P
AD  - Rehabilitation Services, Royal Darwin and Palmerston Hospitals, Darwin, Northern 
      Territory, Australia.
FAU - Delatycki, Martin B
AU  - Delatycki MB
AD  - Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research
      Institute, Parkville, Victoria, Australia martin.delatycki@vcgs.org.au.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
AD  - Victorian Clinical Genetics Services, Melbourne, Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618000908235
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Ataxia
MH  - Australia
MH  - *Cerebellar Ataxia/rehabilitation
MH  - Exercise Therapy
MH  - Humans
MH  - *Outpatients
MH  - *Physical Therapy Modalities
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
PMC - PMC7747606
OTO - NOTNLM
OT  - *neurology
OT  - *neuromuscular disease
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/19 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040230 [pii]
AID - 10.1136/bmjopen-2020-040230 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e040230. doi: 10.1136/bmjopen-2020-040230.


PMID- 33334832
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - Trauma-focused psychodynamic therapy and STAIR Narrative Therapy of
      post-traumatic stress disorder related to childhood maltreatment: trial protocol 
      of a multicentre randomised controlled trial assessing psychological,
      neurobiological and health economic outcomes (ENHANCE).
PG  - e040123
LID - 10.1136/bmjopen-2020-040123 [doi]
AB  - INTRODUCTION: Success rates of psychotherapy in post-traumatic stress disorder
      related to childhood maltreatment (PTSD-CM) are limited. METHODS AND ANALYSIS:
      Observer-blind multicentre randomised clinical trial (A-1) of 4-year duration
      comparing enhanced methods of STAIR Narrative Therapy (SNT) and of trauma-focused
      psychodynamic therapy (TF-PDT) each of up to 24 sessions with each other and a
      minimal attention waiting list in PTSD-CM. Primary outcome is severity of PTSD
      (Clinician-Administered PTSD Scale for DSM-5 total) assessed by masked raters.
      For SNT and TF-PDT, both superiority and non-inferiority will be tested.
      Intention-to-treat analysis (primary) and per-protocol analysis (secondary).
      Assessments at baseline, after 10 sessions, post-therapy/waiting period and at 6 
      and 12 months of follow-up. Adult patients of all sexes between 18 and 65 years
      with PTSD-CM will be included. Continuing stable medication is permitted. To be
      excluded: psychotic disorders, risk of suicide, ongoing abuse, acute substance
      related disorder, borderline personality disorder, dissociative identity
      disorder, organic mental disorder, severe medical conditions and concurrent
      psychotherapy. To be assessed for eligibility: n=600 patients, to be e randomly
      allocated to the study conditions: n=328. Data management, randomisation and
      monitoring will be performed by an independent European Clinical Research
      Infrastructure Network (ECRIN)-certified data coordinating centre for clinical
      trials (KKS Marburg). Report of AEs to a data monitoring and safety board.
      Complementing study A-1, four inter-related add-on projects, including subsamples
      of the treatment study A-1, will examine (1) treatment integrity (adherence and
      competence) and moderators and mediators of outcome (B-1); (2) biological
      parameters (B-2, eg, DNA damage, reactive oxygen species and telomere
      shortening); (3) structural and functional neural changes by neuroimaging (B-3)
      and (4) cost-effectiveness of the treatments (B-4, costs and utilities). ETHICS
      AND DISSEMINATION: Approval by the institutional review board of the University
      of Giessen (AZ 168/19). Following the Consolidated Standards of Reporting Trials 
      statement for non-pharmacological trials, results will be reported in
      peer-reviewed scientific journals and disseminated to patient organisations and
      media. TRIAL REGISTRATION NUMBER: DRKS 00021142.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Leichsenring, Falk
AU  - Leichsenring F
AUID- ORCID: 0000-0002-3808-0072
AD  - Justus Liebig University Giessen and Philipps University Marburg, Center for
      Mind, Brain and Behavior (CMBB), Giessen and Marburg, Germany
      falk.leichsenring@psycho.med.uni-giessen.de.
AD  - Department of Psychotherapy and Psychosomatics, Justus Liebig University Giessen,
      Giessen, Germany.
FAU - Steinert, Christiane
AU  - Steinert C
AD  - Department of Psychotherapy and Psychosomatics, Justus Liebig University Giessen,
      Giessen, Germany.
AD  - International Psychoanalytic University Berlin gGmbH, Berlin, Germany.
FAU - Beutel, Manfred E
AU  - Beutel ME
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center
      Mainz, Mainz, Germany.
FAU - Feix, Lila
AU  - Feix L
AD  - Department of Psychotherapy and Psychosomatics, Justus Liebig University Giessen,
      Giessen, Germany.
FAU - Gundel, Harald
AU  - Gundel H
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Ulm Medical
      Centre, Ulm, Germany.
FAU - Hermann, Andrea
AU  - Hermann A
AD  - Justus Liebig University Giessen and Philipps University Marburg, Center for
      Mind, Brain and Behavior (CMBB), Giessen and Marburg, Germany.
AD  - Department of Psychotherapy and Systems Neuroscience, Justus Liebig Universitat
      Giessen, Giessen, Germany.
AD  - Justus Liebig University Giessen Bender Institute of Neuroimaging, Giessen,
      Germany.
FAU - Karabatsiakis, Alexander
AU  - Karabatsiakis A
AD  - Clinical Psychology II, University of Innsbruck, Innsbruck, Tirol, Austria.
AD  - Institute for Psychology and Education, Clinical & Biological Psychology, Ulm
      University, Ulm, Germany.
FAU - Knaevelsrud, Christine
AU  - Knaevelsrud C
AD  - Division of Clinical Psychological Intervention, Department of Education and
      Psychology, Freie Universitat Berlin, Berlin, Germany.
FAU - Konig, Hans-Helmut
AU  - Konig HH
AD  - Department for Health Economics and Health Services Research,
      Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany.
FAU - Kolassa, Iris T
AU  - Kolassa IT
AD  - Institute for Psychology and Education, Clinical & Biological Psychology, Ulm
      University, Ulm, Germany.
FAU - Kruse, Johannes
AU  - Kruse J
AD  - Department of Psychotherapy and Psychosomatics, Justus Liebig University Giessen,
      Giessen, Germany.
AD  - Department of Psychotherapy and Psychosomatics, Philipps University Marburg,
      Marburg, Germany.
FAU - Niemeyer, Helen
AU  - Niemeyer H
AD  - Division of Clinical Psychological Intervention, Department of Education and
      Psychology, Freie Universitat Berlin, Berlin, Germany.
FAU - Noske, Fatima
AU  - Noske F
AD  - Department of Psychotherapy and Psychosomatics, Justus Liebig University Giessen,
      Giessen, Germany.
FAU - Palmer, Sebastian
AU  - Palmer S
AD  - Department of Psychotherapy and Systems Neuroscience, Justus Liebig Universitat
      Giessen, Giessen, Germany.
FAU - Peters, Eva
AU  - Peters E
AD  - Psychoneuroimmunology Laboratory, Department of Psychosomatics and Psychotherapy,
      Justus Liebig Universitat Giessen, Giessen, Germany.
AD  - Charite Center 12 Internal Medicine and Dermatology, Division for General
      Internal Medicine, Psychosomatics and Psychotherapy, Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Reese, Jens-Peter
AU  - Reese JP
AD  - Institute for Clinical Epidemiology and Biometry, Julius-Maximilians-Universitat 
      of Wurzburg, Wurzburg, Germany.
AD  - Coordinating Center for Clinical Trials - KKS, Philipps-Universitat Marburg,
      Marburg, Germany.
FAU - Reuss, Alexander
AU  - Reuss A
AD  - Coordinating Center for Clinical Trials - KKS, Philipps-Universitat Marburg,
      Marburg, Germany.
FAU - Salzer, Simone
AU  - Salzer S
AD  - International Psychoanalytic University Berlin gGmbH, Berlin, Germany.
AD  - Clinic of Psychosomatic Medicine and Psychotherapy, Georg-August-University
      Gottingen, Gottingen, Germany.
FAU - Schade-Brittinger, Carmen
AU  - Schade-Brittinger C
AD  - Coordinating Center for Clinical Trials - KKS, Philipps-Universitat Marburg,
      Marburg, Germany.
FAU - Schuster, Patrick
AU  - Schuster P
AD  - Department of Psychotherapy and Psychosomatics, Justus Liebig University Giessen,
      Giessen, Germany.
FAU - Stark, Rudolf
AU  - Stark R
AD  - Justus Liebig University Giessen and Philipps University Marburg, Center for
      Mind, Brain and Behavior (CMBB), Giessen and Marburg, Germany.
AD  - Department of Psychotherapy and Systems Neuroscience, Justus Liebig Universitat
      Giessen, Giessen, Germany.
AD  - Justus Liebig University Giessen Bender Institute of Neuroimaging, Giessen,
      Germany.
FAU - Weidner, Kerstin
AU  - Weidner K
AD  - Department of Psychotherapy and Psychosomatic Medicine, Medizinische Fakultat
      Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany.
FAU - von Wietersheim, Jorn
AU  - von Wietersheim J
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Ulm Medical
      Centre, Ulm, Germany.
FAU - Witthoft, Michael
AU  - Witthoft M
AD  - Department of Clinical Psychology, Psychotherapy and Experimental
      Psychopathology, Johannes Gutenberg University Mainz, Mainz, Germany.
FAU - Woller, Wolfgang
AU  - Woller W
AD  - Independent advisor, Bonn, Germany.
FAU - Hoyer, Jurgen
AU  - Hoyer J
AD  - Institute of Clincal Psychology and Psychotherapy, Technische Universitat
      Dresden, Dresden, Germany.
LA  - eng
SI  - DRKS/DRKS00021142
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Child
MH  - *Child Abuse
MH  - Humans
MH  - *Narrative Therapy
MH  - Psychotherapy
MH  - *Psychotic Disorders
MH  - Randomized Controlled Trials as Topic
MH  - *Stress Disorders, Post-Traumatic/therapy
MH  - Treatment Outcome
PMC - PMC7747578
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *personality disorders
OT  - *suicide & self-harm
COIS- Competing interests: None declared.
EDAT- 2020/12/19 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040123 [pii]
AID - 10.1136/bmjopen-2020-040123 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e040123. doi: 10.1136/bmjopen-2020-040123.


PMID- 33334830
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 17
TI  - Towards biomarkers for outcomes after pancreatic ductal adenocarcinoma and
      ischaemic stroke, with focus on (co)-morbidity and ageing/cellular senescence
      (SASKit): protocol for a prospective cohort study.
PG  - e039560
LID - 10.1136/bmjopen-2020-039560 [doi]
AB  - INTRODUCTION: Ageing-related processes such as cellular senescence are believed
      to underlie the accumulation of diseases in time, causing (co)morbidity,
      including cancer, thromboembolism and stroke. Interfering with these processes
      may delay, stop or reverse morbidity. The aim of this study is to investigate the
      link between (co)morbidity and ageing by exploring biomarkers and molecular
      mechanisms of disease-triggered deterioration in patients with pancreatic ductal 
      adenocarcinoma (PDAC) and (thromboembolic) ischaemic stroke (IS). METHODS AND
      ANALYSIS: We will recruit 50 patients with PDAC, 50 patients with
      (thromboembolic) IS and 50 controls at Rostock University Medical Center,
      Germany. We will gather routine blood data, clinical performance measurements and
      patient-reported outcomes at up to seven points in time, alongside in-depth
      transcriptomics and proteomics at two of the early time points. Aiming for
      clinically relevant biomarkers, the primary outcome is a composite of probable
      sarcopenia, clinical performance (described by ECOG Performance Status for
      patients with PDAC and the Modified Rankin Scale for patients with stroke) and
      quality of life. Further outcomes cover other aspects of morbidity such as
      cognitive decline and of comorbidity such as vascular or cancerous events. The
      data analysis is comprehensive in that it includes biostatistics and machine
      learning, both following standard role models and additional explorative
      approaches. Prognostic and predictive biomarkers for interventions addressing
      senescence may become available if the biomarkers that we find are specifically
      related to ageing/cellular senescence. Similarly, diagnostic biomarkers will be
      explored. Our findings will require validation in independent studies, and our
      dataset shall be useful to validate the findings of other studies. In some of the
      explorative analyses, we shall include insights from systems biology modelling as
      well as insights from preclinical animal models. We anticipate that our detailed 
      study protocol and data analysis plan may also guide other biomarker exploration 
      trials. ETHICS AND DISSEMINATION: The study was approved by the local ethics
      committee (Ethikkommission an der Medizinischen Fakultat der Universitat Rostock,
      A2019-0174), registered at the German Clinical Trials Register (DRKS00021184),
      and results will be published following standard guidelines.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Henze, Larissa
AU  - Henze L
AD  - Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine,
      Rostock University Medical Center and Research Focus Oncology, Rostock, Germany.
FAU - Walter, Uwe
AU  - Walter U
AD  - Department of Neurology, Rostock University Medical Center and Centre for
      Transdisciplinary Neurosciences Rostock, Rostock, Germany.
FAU - Murua Escobar, Hugo
AU  - Murua Escobar H
AD  - Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine,
      Rostock University Medical Center and Research Focus Oncology, Rostock, Germany.
FAU - Junghanss, Christian
AU  - Junghanss C
AD  - Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine,
      Rostock University Medical Center and Research Focus Oncology, Rostock, Germany.
FAU - Jaster, Robert
AU  - Jaster R
AD  - Department of Gastroenterology, Rostock University Medical Center and Research
      Focus Oncology, Rostock, Germany.
FAU - Kohling, Rudiger
AU  - Kohling R
AD  - Oscar Langendorff Institute of Physiology, Rostock University Medical Center and 
      Centre for Transdisciplinary Neurosciences Rostock and Ageing of Individuals and 
      Society, Interdisciplinary Faculty, Rostock University, Rostock, Germany.
FAU - Lange, Falko
AU  - Lange F
AD  - Oscar Langendorff Institute of Physiology, Rostock University Medical Center,
      Rostock, Germany.
FAU - Salehzadeh-Yazdi, Ali
AU  - Salehzadeh-Yazdi A
AD  - Department of Systems Biology and Bioinformatics, University of Rostock, Rostock,
      Germany.
FAU - Wolkenhauer, Olaf
AU  - Wolkenhauer O
AD  - Department of Systems Biology and Bioinformatics, University of Rostock and
      Centre for Transdisciplinary Neurosciences Rostock, Rostock University Medical
      Center, Rostock, Germany.
FAU - Hamed, Mohamed
AU  - Hamed M
AD  - Institute for Biostatistics and Informatics in Medicine and Ageing Research,
      Rostock University Medical Center and Research Focus Oncology, Rostock, Germany.
FAU - Barrantes, Israel
AU  - Barrantes I
AD  - Institute for Biostatistics and Informatics in Medicine and Ageing Research,
      Rostock University Medical Center and Research Focus Oncology, Rostock, Germany.
FAU - Palmer, Daniel
AU  - Palmer D
AD  - Institute for Biostatistics and Informatics in Medicine and Ageing Research,
      Rostock University Medical Center, Rostock, Germany.
FAU - Moller, Steffen
AU  - Moller S
AD  - Institute for Biostatistics and Informatics in Medicine and Ageing Research,
      Rostock University Medical Center, Rostock, Germany.
FAU - Kowald, Axel
AU  - Kowald A
AD  - Institute for Biostatistics and Informatics in Medicine and Ageing Research,
      Rostock University Medical Center, Rostock, Germany.
FAU - Heussen, Nicole
AU  - Heussen N
AD  - Department of Medical Statistics, RWTH Aachen, Aachen, Germany
      fuellen@uni-rostock.de nheussen@ukaachen.de.
FAU - Fuellen, Georg
AU  - Fuellen G
AUID- ORCID: 0000-0002-4994-9829
AD  - Institute for Biostatistics and Informatics in Medicine and Ageing Research,
      Rostock University Medical Center and Centre for Transdisciplinary Neurosciences 
      Rostock and Research Focus Oncology, Rostock and Ageing of Individuals and
      Society, Interdisciplinary Faculty, Rostock University, Rostock, Germany
      fuellen@uni-rostock.de nheussen@ukaachen.de.
LA  - eng
SI  - DRKS/DRKS00021184
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Adenocarcinoma/epidemiology
MH  - Aging
MH  - *Brain Ischemia
MH  - COVID-19
MH  - Cellular Senescence
MH  - Cohort Studies
MH  - Comorbidity
MH  - Female
MH  - Germany/epidemiology
MH  - Humans
MH  - *Ischemic Stroke
MH  - Male
MH  - *Pancreatic Neoplasms/epidemiology
MH  - Prospective Studies
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - *Stroke/epidemiology
PMC - PMC7747584
OTO - NOTNLM
OT  - *health informatics
OT  - *immunology
OT  - *molecular aspects
OT  - *stroke
OT  - *thromboembolism
COIS- Competing interests: UW reports personal fees from Ipsen Pharma, grants and
      personal fees from Merz Pharma, personal fees from Allergan, personal fees from
      Bristol-Myers Squibb, personal fees from Daiichi Sankyo, personal fees from Bayer
      Vital, personal fees from Boehringer Ingelheim, personal fees from Pfizer,
      personal fees from Thieme, and personal fees from Elsevier Press, all outside the
      submitted work. The other authors have nothing to disclose.
EDAT- 2020/12/19 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/12/18 05:40
PHST- 2020/12/18 05:40 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-039560 [pii]
AID - 10.1136/bmjopen-2020-039560 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 17;10(12):e039560. doi: 10.1136/bmjopen-2020-039560.


PMID- 33334463
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1558-4488 (Electronic)
IS  - 0270-9295 (Linking)
VI  - 40
IP  - 5
DP  - 2020 Sep
TI  - RRT Selection for AKI Patients With Critical Illness.
PG  - 498-505
LID - S0270-9295(20)30101-7 [pii]
LID - 10.1016/j.semnephrol.2020.08.006 [doi]
AB  - Acute kidney injury (AKI) is a critical burden on intensive care units in Asia.
      Renal replacement therapy (RRT) acts as strong supportive care for severe AKI.
      However, various RRT modalities are used in Asia because of the diversity in
      ethics, climate, geographic features, and socioeconomic status. Extracorporeal
      blood purification is used commonly in Asian intensive care units; however,
      intermittent RRT is preferred in developing countries because of cost and
      infrastructure issues. Conversely, continuous RRT is preferred in developed
      countries, indicating the predominance of hospital-acquired AKI patients with
      complications of hemodynamic instability. Peritoneal dialysis is delivered less
      frequently, although several studies have suggested promising results for
      peritoneal dialysis in AKI treatment. Of note, not all RRT modalities are
      available as a standard procedure in some Asian regions, and it is absolutely
      necessary to develop a sustainable infrastructure that can deliver optimal care
      for all AKI patients.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Matsuura, Ryo
AU  - Matsuura R
AD  - Department of Nephrology and Endocrinology, The University of Tokyo Hospital,
      Tokyo, Japan.
FAU - Doi, Kent
AU  - Doi K
AD  - Department of Emergency and Critical Care and Medicine, The University of Tokyo
      Hospital, Tokyo, Japan. Electronic address: kdoi-tky@umin.ac.jp.
FAU - Hamasaki, Yoshifumi
AU  - Hamasaki Y
AD  - Department of Hemodialysis and Apheresis, The University of Tokyo, Tokyo, Japan.
FAU - Nangaku, Masaomi
AU  - Nangaku M
AD  - Department of Nephrology and Endocrinology, The University of Tokyo Hospital,
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Nephrol
JT  - Seminars in nephrology
JID - 8110298
SB  - IM
MH  - *Acute Kidney Injury/therapy
MH  - Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - *Peritoneal Dialysis
MH  - Renal Replacement Therapy
OTO - NOTNLM
OT  - Renal replacement therapy
OT  - acute kidney injury
OT  - blood purification
OT  - developed countries
OT  - developing countries
OT  - peritoneal dialysis
EDAT- 2020/12/19 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/12/18 05:30
PHST- 2020/12/18 05:30 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - S0270-9295(20)30101-7 [pii]
AID - 10.1016/j.semnephrol.2020.08.006 [doi]
PST - ppublish
SO  - Semin Nephrol. 2020 Sep;40(5):498-505. doi: 10.1016/j.semnephrol.2020.08.006.


PMID- 33334347
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Dec 18
TI  - Allocation of intensive care resources during an infectious disease outbreak: a
      rapid review to inform practice.
PG  - 404
LID - 10.1186/s12916-020-01871-9 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has placed sustained demand on health systems
      globally, and the capacity to provide critical care has been overwhelmed in some 
      jurisdictions. It is unknown which triage criteria for allocation of resources
      perform best to inform health system decision-making. We sought to summarize and 
      describe existing triage tools and ethical frameworks to aid healthcare
      decision-making during infectious disease outbreaks. METHODS: We conducted a
      rapid review of triage criteria and ethical frameworks for the allocation of
      critical care resources during epidemics and pandemics. We searched Medline,
      EMBASE, and SCOPUS from inception to November 3, 2020. Full-text screening and
      data abstraction were conducted independently and in duplicate by three
      reviewers. Articles were included if they were primary research, an adult
      critical care setting, and the framework described was related to an infectious
      disease outbreak. We summarized each triage tool and ethical guidelines or
      framework including their elements and operating characteristics using
      descriptive statistics. We assessed the quality of each article with applicable
      checklists tailored to each study design. RESULTS: From 11,539 unique citations, 
      697 full-text articles were reviewed and 83 articles were included. Fifty-nine
      described critical care triage protocols and 25 described ethical frameworks. Of 
      these, four articles described both a protocol and ethical framework. Sixty
      articles described 52 unique triage criteria (29 algorithm-based, 23
      point-based). Few algorithmic- or point-based triage protocols were good
      predictors of mortality with AUCs ranging from 0.51 (PMEWS) to 0.85 (admitting
      SOFA > 11). Most published triage protocols included the substantive values of
      duty to provide care, equity, stewardship and trust, and the procedural value of 
      reason. CONCLUSIONS: This review summarizes available triage protocols and
      ethical guidelines to provide decision-makers with data to help select and tailor
      triage tools. Given the uncertainty about how the COVID-19 pandemic will progress
      and any future pandemics, jurisdictions should prepare by selecting and adapting 
      a triage tool that works best for their circumstances.
FAU - Fiest, Kirsten M
AU  - Fiest KM
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
AD  - Department of Community Health Sciences and O'Brien Institute for Public Health, 
      Cumming School of Medicine, University of Calgary, 3134 Hospital Drive NW,
      Calgary, T2N4Z6, Canada.
FAU - Krewulak, Karla D
AU  - Krewulak KD
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
FAU - Plotnikoff, Kara M
AU  - Plotnikoff KM
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
FAU - Kemp, Laryssa G
AU  - Kemp LG
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
FAU - Parhar, Ken Kuljit S
AU  - Parhar KKS
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
FAU - Niven, Daniel J
AU  - Niven DJ
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
AD  - Department of Community Health Sciences and O'Brien Institute for Public Health, 
      Cumming School of Medicine, University of Calgary, 3134 Hospital Drive NW,
      Calgary, T2N4Z6, Canada.
FAU - Kortbeek, John B
AU  - Kortbeek JB
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
AD  - Department of Surgery, Cumming School of Medicine, University of Calgary &
      Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6, Canada.
AD  - Department of Anaesthesia, Cumming School of Medicine, University of Calgary &
      Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6, Canada.
FAU - Stelfox, Henry T
AU  - Stelfox HT
AD  - Department of Critical Care Medicine, Cumming School of Medicine, University of
      Calgary & Alberta Health Services, 3134 Hospital Drive NW, Calgary, T2N4Z6,
      Canada.
AD  - Department of Community Health Sciences and O'Brien Institute for Public Health, 
      Cumming School of Medicine, University of Calgary, 3134 Hospital Drive NW,
      Calgary, T2N4Z6, Canada.
FAU - Parsons Leigh, Jeanna
AU  - Parsons Leigh J
AD  - Faculty of Health, School of Health Administration, Dalhousie University, 5850
      College Street, Halifax, Nova Scotia, B3H4R2, Canada. J.ParsonsLeigh@dal.ca.
AD  - Department of Critical Care Medicine, Faculty of Medicine, Dalhousie University, 
      6299 South St, Halifax, Nova Scotia, B3H4R2, Canada. J.ParsonsLeigh@dal.ca.
LA  - eng
GR  - RN420046-439965/Canadian Institutes of Health Research Canadian 2019 Novel
      Coronavirus (COVID-2019) Rapid Research Funding Opportunity/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201218
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
MH  - *COVID-19
MH  - *Critical Care
MH  - Disease Outbreaks
MH  - Health Care Rationing/*ethics/*methods
MH  - Humans
MH  - SARS-CoV-2
MH  - Triage/ethics/*methods
PMC - PMC7746486
OTO - NOTNLM
OT  - *COVID-19
OT  - *Critical care
OT  - *Intensive care
OT  - *Medical ethics
OT  - *Practice guideline
OT  - *Resource allocation
OT  - *Triage
EDAT- 2020/12/19 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/12/18 05:29
PHST- 2020/09/23 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/18 05:29 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 10.1186/s12916-020-01871-9 [doi]
AID - 10.1186/s12916-020-01871-9 [pii]
PST - epublish
SO  - BMC Med. 2020 Dec 18;18(1):404. doi: 10.1186/s12916-020-01871-9.


PMID- 33331825
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210116
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 17
TI  - Perspectives and Experiences of Policy Makers, Researchers, Health Information
      Technology Professionals, and the Public on Evidence-Based Health Policies:
      Protocol for a Qualitative Study.
PG  - e16268
LID - 10.2196/16268 [doi]
AB  - BACKGROUND: Evidence-based health policy (EBHP) development is critical to the
      judicious use of public funds. EBHPs increase transparency, accountability,
      effectiveness, and efficiency of policies. Encouraging collaboration between
      researchers or knowledge producers and policy makers is important because both
      communities have distinct professional cultures, resulting in them working
      separately without understanding each other. Knowledge sharing is a complex
      process that requires understanding of cultural aspects that may reduce cultural 
      differences and increase the use of common language. Health information
      technology (HIT) is a useful tool to increase knowledge translation, which may
      result in the transparent use of evidence and networking in developing EBHPs. Our
      vision is to leverage HIT tools for a better health system that includes
      digitalized, open source, evidence-based, and transparent ways for collaboration 
      and development of robust mechanisms and for sharing of synthesized evidence with
      knowledge user-friendly forms. OBJECTIVE: The aim of this study is to develop a
      conceptual framework on Knowledge translation and health Information Technology
      for Transparency (KhITT) in policy making and EBHPs (ie, the KhITT framework).
      The framework will be informed by the views of four key stakeholder groups (ie,
      policy makers, knowledge producers, HIT professionals, and the public) toward
      EBHP. The informants may also describe practices that demonstrate the EBHP
      development process and suggest technology platforms to enable this process.
      METHODS: We propose an exploratory, descriptive qualitative study to take place
      in British Columbia, Canada, using in-depth semistructured interviews. To ensure 
      data saturation and trustworthiness, we will use a nonprobability, purposive
      snowball sample of up to 15 eligible participants in each of the four stakeholder
      groups. We will analyze the data using content analysis. RESULTS: The KhITT
      framework focuses on various stakeholders' perspectives to better understand
      their perceived needs and priorities in identifying issues with EBHP, in order to
      make informed recommendations. Ethics approval has been obtained by the
      harmonized Behavioural Research Ethics Board at the University of British
      Columbia. We anticipate that we will complete data collection and analysis by
      December 2020. Preliminary results will be published in summer 2021. CONCLUSIONS:
      Our ultimate goal of this study is to develop a conceptual framework and describe
      the technology platforms that would enable the EBHP process. We anticipate that
      our rigorous content analysis will be able to produce insights and themes that
      are able to address our objectives, contribute to an in-depth understanding of
      the EBHP process within British Columbia, highlight all influential factors,
      explicitly disseminate and communicate the study results, identify issues with
      EBHP and provide informed recommendations to address them, and enhance efforts
      toward transparent EBHPs. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      PRR1-10.2196/16268.
CI  - (c)Anastasia Mallidou, Dzifa Dordunoo, Elizabeth Borycki, Andre Kushniruk,
      Kirsten Sadeghi-Yekta, Julie Fraser, Sirisha Asuri. Originally published in JMIR 
      Research Protocols (http://www.researchprotocols.org), 17.12.2020.
FAU - Mallidou, Anastasia
AU  - Mallidou A
AUID- ORCID: https://orcid.org/0000-0001-6094-567X
AD  - School of Nursing, University of Victoria, Victoria, BC, Canada.
FAU - Dordunoo, Dzifa
AU  - Dordunoo D
AUID- ORCID: https://orcid.org/0000-0002-0290-8261
AD  - School of Nursing, University of Victoria, Victoria, BC, Canada.
FAU - Borycki, Elizabeth
AU  - Borycki E
AUID- ORCID: https://orcid.org/0000-0003-0928-8867
AD  - School of Health Information Science, University of Victoria, Victoria, BC,
      Canada.
FAU - Kushniruk, Andre
AU  - Kushniruk A
AUID- ORCID: https://orcid.org/0000-0002-2557-9288
AD  - School of Health Information Science, University of Victoria, Victoria, BC,
      Canada.
FAU - Sadeghi-Yekta, Kirsten
AU  - Sadeghi-Yekta K
AUID- ORCID: https://orcid.org/0000-0003-1161-465X
AD  - Theatre Department, University of Victoria, Victoria, BC, Canada.
FAU - Fraser, Julie
AU  - Fraser J
AUID- ORCID: https://orcid.org/0000-0003-0492-3067
AD  - Professional Regulatory Practice Department, Fraser Health, Vancouver, BC,
      Canada.
FAU - Asuri, Sirisha
AU  - Asuri S
AUID- ORCID: https://orcid.org/0000-0003-1339-0856
AD  - Primary Care Division, BC Ministry of Health, Victoria, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7775201
OTO - NOTNLM
OT  - evidence-based health policy
OT  - health information technology
OT  - knowledge producers
OT  - knowledge translation
OT  - policy makers
OT  - researchers
OT  - transparency
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:01
CRDT- 2020/12/17 12:07
PHST- 2019/09/16 00:00 [received]
PHST- 2020/02/22 00:00 [accepted]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/12/17 12:07 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:01 [medline]
AID - v9i12e16268 [pii]
AID - 10.2196/16268 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 17;9(12):e16268. doi: 10.2196/16268.


PMID- 33331684
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1541-4337 (Electronic)
IS  - 1541-4337 (Linking)
VI  - 19
IP  - 3
DP  - 2020 May
TI  - Moving from a compliance-based to an integrity-based organizational climate in
      the food supply chain.
PG  - 995-1017
LID - 10.1111/1541-4337.12548 [doi]
AB  - Compliance is the act or status of complying with an imperative regulatory or
      normative requirement, that is, compliance means working within boundaries
      defined by contractual, social, or cultural standards. The aim of this narrative 
      review is to use the food supply chain as a lens of enquiry to distinguish
      between compliance-based and integrity-based organizational climates and frame
      and rationalize why deviant behavior arises and how it can be identified.
      Contemporary theory is explored and critiqued using case studies to contextualize
      the challenge of organizations promoting supply chain compliance and at the same 
      time recognizing the need for deviant behavior to occur in order to drive
      innovation and continuous improvement within food supply chains. Deviant behavior
      can be perceived as either positive in terms of driving continuous improvement or
      destructive where this behavior has a negative impact on the organization.
      Although multiple cultural maturity models seek to characterize positive food
      safety culture and climate, there is minimal research that focuses on the
      characterization of deviant negative behavior or the development of early warning
      systems designed to pinpoint signals, traits, or characteristics of this behavior
      such as low staff morale, theft, property destruction, or absenteeism. The use of
      cultural maturity models and assessment tools is of value in assisting
      organizations to translate from a rule, instrumental, or compliance-based
      organizational climate to an ethically strong organizational climate that focuses
      on integrity, building trust, and values and a new cultural maturity model is
      proposed and explored.
CI  - (c) 2020 Institute of Food Technologists(R).
FAU - Manning, Louise
AU  - Manning L
AUID- ORCID: 0000-0002-9900-7303
AD  - School of Agriculture, Food and Environment, Royal Agricultural University,
      Cirencester, Gloucestershire, GL7 6JS, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200409
PL  - United States
TA  - Compr Rev Food Sci Food Saf
JT  - Comprehensive reviews in food science and food safety
JID - 101305205
SB  - IM
MH  - *Food Safety
MH  - Food Supply/legislation & jurisprudence/*standards
MH  - Humans
MH  - *Organizational Culture
MH  - Safety Management
OTO - NOTNLM
OT  - *behavior
OT  - *climate
OT  - *deviant
OT  - *negative
OT  - *organizational
EDAT- 2020/12/18 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/12/17 08:43
PHST- 2019/09/03 00:00 [received]
PHST- 2019/12/24 00:00 [revised]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/12/17 08:43 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
AID - 10.1111/1541-4337.12548 [doi]
PST - ppublish
SO  - Compr Rev Food Sci Food Saf. 2020 May;19(3):995-1017. doi:
      10.1111/1541-4337.12548. Epub 2020 Apr 9.


PMID- 33331541
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1678-4464 (Electronic)
IS  - 0102-311X (Linking)
VI  - 36
IP  - 12
DP  - 2020
TI  - [Situating atention deficit and hyperactivity in Portugal: social, historical,
      and ethical dimensions of an emerging global health issue].
PG  - e00056420
LID - S0102-311X2020001203002 [pii]
LID - 10.1590/0102-311X00056420 [doi]
AB  - Attention deficit and hyperactivity disorder (ADHD) is considered one of the most
      frequent behavioral and neurodevelopmental problems in school-age children and
      adolescents, both in Portugal and worldwide. The diagnostic categorization of
      ADHD and the prescription of psychostimulants as its first-line treatment have
      been the object not only of scientific research and clinical validation, but also
      of controversy and social critique, especially in light of the concept of
      medicalization. Despite its high profile and salience in such diverse fields as
      education, pharmaceuticals, mental health, and public policy, a significant gap
      remains in the characterization of social-historical, ethical, and institutional 
      dimensions of ADHD outside English-speaking countries. Combining historical and
      ethnographic research with document and media analysis, the article addresses
      that challenge by tracing the social trajectory of ADHD in Portugal, from the
      emergence of "hyperactivity" in the 1970s and 1980s to the current public and
      political debates on psychostimulant treatments and prescribing trends. From this
      interdisciplinary perspective and based on the Portuguese case study, the aim of 
      this article is to contextualize the definition, validation, and expansion of
      ADHD as part of a dynamic and socially situated process in which global
      diagnostic and pharmaceutical systems intersect with institutional and
      socioeconomic contingencies, as well as local specificities and needs. More
      broadly, the article discusses how the case study of ADHD contributes to the
      development of interdisciplinary research that helps rethinking the social scope 
      of mental health across local and global health contexts.
FAU - Filipe, Angela Marques
AU  - Filipe AM
AUID- ORCID: 0000-0002-7899-7336
AD  - McGill University, Montreal, Canada.
LA  - por
PT  - Journal Article
TT  - Situar a hiperatividade e deficit de atencao em Portugal: dimensoes sociais,
      historicas e eticas de um tema emergente na saude global.
DEP - 20201216
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
SB  - IM
MH  - Adolescent
MH  - *Attention Deficit Disorder with Hyperactivity/diagnosis/drug therapy
MH  - Brazil
MH  - Child
MH  - *Global Health
MH  - Humans
MH  - Mental Health
MH  - Portugal
EDAT- 2020/12/18 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/12/17 08:42
PHST- 2020/03/23 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/12/17 08:42 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
AID - S0102-311X2020001203002 [pii]
AID - 10.1590/0102-311X00056420 [doi]
PST - epublish
SO  - Cad Saude Publica. 2020 Dec 16;36(12):e00056420. doi: 10.1590/0102-311X00056420. 
      eCollection 2020.


PMID- 33330613
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2296-875X (Print)
IS  - 2296-875X (Linking)
VI  - 7
DP  - 2020
TI  - 3D Bioprinting and the Future of Surgery.
PG  - 609836
LID - 10.3389/fsurg.2020.609836 [doi]
AB  - Introduction: The disciplines of 3D bioprinting and surgery have witnessed
      incremental transformations over the last century. 3D bioprinting is a
      convergence of biology and engineering technologies, mirroring the clinical need 
      to produce viable biological tissue through advancements in printing,
      regenerative medicine and materials science. To outline the current and future
      challenges of 3D bioprinting technology in surgery. Methods: A comprehensive
      literature search was undertaken using the MEDLINE, EMBASE and Google Scholar
      databases between 2000 and 2019. A narrative synthesis of the resulting
      literature was produced to discuss 3D bioprinting, current and future challenges,
      the role in personalized medicine and transplantation surgery and the global 3D
      bioprinting market. Results: The next 20 years will see the advent of bioprinted 
      implants for surgical use, however the path to clinical incorporation will be
      fraught with an array of ethical, regulatory and technical challenges of which
      each must be surmounted. Previous clinical cases where regulatory processes have 
      been bypassed have led to poor outcomes and controversy. Speculated roles of 3D
      bioprinting in surgery include the production of de novo organs for
      transplantation and use of autologous cellular material for personalized
      medicine. The promise of these technologies has sparked an industrial revolution,
      leading to an exponential growth of the 3D bioprinting market worth billions of
      dollars. Conclusion: Effective translation requires the input of scientists,
      engineers, clinicians, and regulatory bodies: there is a need for a collaborative
      effort to translate this impactful technology into a real-world healthcare
      setting and potentially transform the future of surgery.
CI  - Copyright (c) 2020 Jovic, Combellack, Jessop and Whitaker.
FAU - Jovic, Thomas H
AU  - Jovic TH
AD  - Reconstructive Surgery and Regenerative Medicine Research Group, Swansea
      University, Swansea, United Kingdom.
AD  - Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, United
      Kingdom.
FAU - Combellack, Emman J
AU  - Combellack EJ
AD  - Reconstructive Surgery and Regenerative Medicine Research Group, Swansea
      University, Swansea, United Kingdom.
AD  - Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, United
      Kingdom.
FAU - Jessop, Zita M
AU  - Jessop ZM
AD  - Reconstructive Surgery and Regenerative Medicine Research Group, Swansea
      University, Swansea, United Kingdom.
AD  - Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, United
      Kingdom.
FAU - Whitaker, Iain S
AU  - Whitaker IS
AD  - Reconstructive Surgery and Regenerative Medicine Research Group, Swansea
      University, Swansea, United Kingdom.
AD  - Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, United
      Kingdom.
LA  - eng
GR  - MR/N002431/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20201127
PL  - Switzerland
TA  - Front Surg
JT  - Frontiers in surgery
JID - 101645127
PMC - PMC7728666
OTO - NOTNLM
OT  - 3D printing
OT  - bioprinting
OT  - biotechnology
OT  - reconstruction
OT  - transplantation
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:01
CRDT- 2020/12/17 05:54
PHST- 2020/09/24 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/12/17 05:54 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:01 [medline]
AID - 10.3389/fsurg.2020.609836 [doi]
PST - epublish
SO  - Front Surg. 2020 Nov 27;7:609836. doi: 10.3389/fsurg.2020.609836. eCollection
      2020.


PMID- 33330337
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210101
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Dying Alone Due to COVID-19: Do the Needs of the Many Outweigh the Rights of the 
      Few-or the One?
PG  - 593464
LID - 10.3389/fpubh.2020.593464 [doi]
FAU - Capozzo, Alejandra Victoria
AU  - Capozzo AV
AD  - Institute of Virology and Technical Innovations, IVIT (CONICET-INTA), Consejo
      Nacional de Investigaciones Cientificas y Tecnicas, Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/*mortality/*psychology
MH  - Family Relations/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Patient Isolation/*psychology
MH  - Patients/*psychology
MH  - *Right to Die
MH  - SARS-CoV-2
MH  - Social Isolation/*psychology
PMC - PMC7734051
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - SARS-CoV-2
OT  - ethics
OT  - health policies
OT  - healthcare
COIS- The author declares that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/18 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/12/17 05:53
PHST- 2020/08/12 00:00 [received]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/12/17 05:53 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
AID - 10.3389/fpubh.2020.593464 [doi]
PST - epublish
SO  - Front Public Health. 2020 Nov 30;8:593464. doi: 10.3389/fpubh.2020.593464.
      eCollection 2020.


PMID- 33330320
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Does Patient Access to Clinical Notes Change Documentation?
PG  - 577896
LID - 10.3389/fpubh.2020.577896 [doi]
FAU - Blease, Charlotte
AU  - Blease C
AD  - Division of General Medicine, Beth Israel Deaconess Medical Center and Harvard
      Medical School, Boston, MA, United States.
FAU - Torous, John
AU  - Torous J
AD  - Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard
      Medical School, Boston, MA, United States.
FAU - Hagglund, Maria
AU  - Hagglund M
AD  - Division of General Medicine, Beth Israel Deaconess Medical Center and Harvard
      Medical School, Boston, MA, United States.
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - *Documentation
MH  - *Electronic Health Records
MH  - Humans
PMC - PMC7728689
OTO - NOTNLM
OT  - *clinical documentation and communication
OT  - *electronic medical records
OT  - *medical ethics
OT  - *natural language processing
OT  - *open notes
OT  - *transparency & disclosure
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/17 05:53
PHST- 2020/07/23 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/12/17 05:53 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.3389/fpubh.2020.577896 [doi]
PST - epublish
SO  - Front Public Health. 2020 Nov 27;8:577896. doi: 10.3389/fpubh.2020.577896.
      eCollection 2020.


PMID- 33329274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Executive Functions and Quality of Classroom Interactions in Kindergarten Among
      5-6-Year-Old Children.
PG  - 603776
LID - 10.3389/fpsyg.2020.603776 [doi]
AB  - According to international longitudinal studies, the quality of preschool
      education is of great importance for children's further development. The modern
      research's greatest interest in the field of studying the quality of preschool
      education is precisely the assessment of the relationship between the teacher and
      children as well as the teaching quality in kindergarten groups. In this regard, 
      the Classroom Assessment Scoring System (CLASS) seems to be the one of the most
      relevant for the educational environment quality evaluation. The CLASS
      methodology (which includes emotional support, classroom organization, and
      instrumental support) is based on the cultural-historical approach, which shows
      the interaction between students and adults as the main mechanism for child's
      development. The aim of this study is to investigate the relationships between
      different aspects of the classroom organization quality in kindergarten groups
      and executive functions components (such as cognitive flexibility, inhibitory
      control, and working memory) in 5-6-year-old children. The quality of classroom
      interaction was measured by the CLASS. The study used the Dimensional Change Card
      Sort (DCCS) method to assess cognitive flexibility and the NEPSY-II subtests
      "Inhibition" to assess inhibitory control and "Memory for Designs" and "Sentences
      Repetition" to assess visuo-spatial and verbal working memory, respectively. The 
      study was approved by the Ethics Committee of the Faculty of Psychology at
      Lomonosov Moscow State University. The study involved 26 kindergarten groups in
      Moscow. While conducting the research, extreme groups were identified (5 with low
      quality and 10 with high-quality levels of classroom interaction). Then, three
      kindergarten groups with low level (65 children) and three groups with high level
      (68 children) of interaction within classroom were selected and compared. The
      results revealed that children from groups with low level of classroom
      interaction have higher results in cognitive flexibility tasks when compared with
      children from groups with high level of interaction. Also, children from groups
      with high-quality classroom interaction demonstrated higher results in
      visuo-spatial working memory tasks and inhibitory control tasks as contrasted
      with children from low-quality groups. These findings attest to the importance of
      classroom interaction quality for the executive functions development in the
      preschool age.
CI  - Copyright (c) 2020 Veraksa, Bukhalenkova and Almazova.
FAU - Veraksa, Aleksander
AU  - Veraksa A
AD  - Faculty of Psychology, Lomonosov Moscow State University, Moscow, Russia.
FAU - Bukhalenkova, Daria
AU  - Bukhalenkova D
AD  - Faculty of Psychology, Lomonosov Moscow State University, Moscow, Russia.
FAU - Almazova, Olga
AU  - Almazova O
AD  - Faculty of Psychology, Lomonosov Moscow State University, Moscow, Russia.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7714336
OTO - NOTNLM
OT  - class
OT  - early childhood education
OT  - executive functions
OT  - preschool age
OT  - quality of classroom interaction
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:01
CRDT- 2020/12/17 05:49
PHST- 2020/09/07 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/12/17 05:49 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:01 [medline]
AID - 10.3389/fpsyg.2020.603776 [doi]
PST - epublish
SO  - Front Psychol. 2020 Nov 19;11:603776. doi: 10.3389/fpsyg.2020.603776. eCollection
      2020.


PMID- 33328864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Methadone Suppresses Neuronal Function and Maturation in Human Cortical
      Organoids.
PG  - 593248
LID - 10.3389/fnins.2020.593248 [doi]
AB  - Accumulating evidence has suggested that prenatal exposure to methadone causes
      multiple adverse effects on human brain development. Methadone not only
      suppresses fetal neurobehavior and alters neural maturation, but also leads to
      long-term neurological impairment. Due to logistical and ethical issues of
      accessing human fetal tissue, the effect of methadone on brain development and
      its underlying mechanisms have not been investigated adequately and are therefore
      not fully understood. Here, we use human cortical organoids which resemble fetal 
      brain development to examine the effect of methadone on neuronal function and
      maturation during early development. During development, cortical organoids that 
      are exposed to clinically relevant concentrations of methadone exhibited
      suppressed maturation of neuronal function. For example, organoids developed from
      12th week till 24th week have an about 7-fold increase in AP firing frequency,
      but only half and a third of this increase was found in organoids exposed to 1
      and 10 muM methadone, respectively. We further demonstrated substantial increases
      in I Na (4.5-fold) and I KD (10.8-fold), and continued shifts of Na(+) channel
      activation and inactivation during normal organoid development. Methadone-induced
      suppression of neuronal function was attributed to the attenuated increase in the
      densities of I Na and I KD and the reduced shift of Na(+) channel gating
      properties. Since normal neuronal electrophysiology and ion channel function are 
      critical for regulating brain development, we believe that the effect of
      prolonged methadone exposure contributes to the delayed maturation, development
      fetal brain and potentially for longer term neurologic deficits.
CI  - Copyright (c) 2020 Wu, Yao, Dwivedi, Negraes, Zhao, Wang, Trujillo, Muotri and
      Haddad.
FAU - Wu, Wei
AU  - Wu W
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
FAU - Yao, Hang
AU  - Yao H
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
FAU - Dwivedi, Ila
AU  - Dwivedi I
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
FAU - Negraes, Priscilla D
AU  - Negraes PD
AD  - Department of Cellular and Molecular Medicine, Stem Cell Program, Center for
      Academic Research and Training in Anthropogeny, Kavli Institute for Brain and
      Mind, University of California, San Diego, San Diego, CA, United States.
FAU - Zhao, Helen W
AU  - Zhao HW
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
FAU - Trujillo, Cleber A
AU  - Trujillo CA
AD  - Department of Cellular and Molecular Medicine, Stem Cell Program, Center for
      Academic Research and Training in Anthropogeny, Kavli Institute for Brain and
      Mind, University of California, San Diego, San Diego, CA, United States.
FAU - Muotri, Alysson R
AU  - Muotri AR
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
AD  - Department of Cellular and Molecular Medicine, Stem Cell Program, Center for
      Academic Research and Training in Anthropogeny, Kavli Institute for Brain and
      Mind, University of California, San Diego, San Diego, CA, United States.
FAU - Haddad, Gabriel G
AU  - Haddad GG
AD  - Department of Pediatrics, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
AD  - Department of Neurosciences, School of Medicine, University of California, San
      Diego, San Diego, CA, United States.
AD  - Rady Children's Hospital, San Diego, CA, United States.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7719724
OTO - NOTNLM
OT  - cortical organoid
OT  - iPSCs
OT  - ion channel
OT  - methadone
OT  - neural function
OT  - patch-clamp
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:01
CRDT- 2020/12/17 05:48
PHST- 2020/08/10 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/17 05:48 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:01 [medline]
AID - 10.3389/fnins.2020.593248 [doi]
PST - epublish
SO  - Front Neurosci. 2020 Nov 23;14:593248. doi: 10.3389/fnins.2020.593248.
      eCollection 2020.


PMID- 33328619
OWN - NLM
STAT- Publisher
LR  - 20201217
IS  - 1476-5489 (Electronic)
IS  - 0955-9930 (Linking)
DP  - 2020 Dec 16
TI  - Implant practice building: tenets to growing a successful and rewarding practice.
LID - 10.1038/s41443-020-00384-6 [doi]
AB  - Achieving a thriving sexual medicine practice with a high volume of penile
      implants is both challenging and rewarding for the prosthetic surgeon. It is not 
      an easy feat to accomplish. Techniques of practice building from physician
      referrals and marketing to the patient have changed remarkably in the era of
      social media. Peer-to-peer continues to be a critical source of physician
      referrals, but methods of "getting the word out" to patients have drastically
      altered. Internal marketing to one's own patients and external passing of
      information to prospective clients requires a robust presence on the internet.
      This workshop will focus on the achievement of high-volume implant practices in
      the age of the World Wide Web. Despite accomplishing this triumph through use of 
      digital media, it is important to continue personal attainments to maintain your 
      ethical image amongst your physician peers and the general public.
FAU - Wen, Lexiaochuan
AU  - Wen L
AUID- ORCID: http://orcid.org/0000-0001-8912-3899
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA. Wen.Lexiaochuan@mayo.edu.
FAU - Christine, Brian
AU  - Christine B
AD  - Department of Prosthetic Urology and Men's Sexual Health, Urology Centers of
      Alabama, Birmingham, AL, USA.
FAU - Kohler, Tobias
AU  - Kohler T
AD  - Department of Urology, Mayo Clinic, Rochester, MN, USA.
FAU - Wilson, Steven K
AU  - Wilson SK
AUID- ORCID: http://orcid.org/0000-0002-9342-5475
AD  - Department of Urology, Institutes for Urologic Excellence, La Quinta, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201216
PL  - England
TA  - Int J Impot Res
JT  - International journal of impotence research
JID - 9007383
SB  - IM
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/17 05:45
PHST- 2020/10/12 00:00 [received]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/11/07 00:00 [revised]
PHST- 2020/12/17 05:45 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - 10.1038/s41443-020-00384-6 [doi]
AID - 10.1038/s41443-020-00384-6 [pii]
PST - aheadofprint
SO  - Int J Impot Res. 2020 Dec 16. pii: 10.1038/s41443-020-00384-6. doi:
      10.1038/s41443-020-00384-6.


PMID- 33328261
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 16
TI  - A study protocol for a multicentre, prospective, before-and-after trial
      evaluating the feasibility of implementing targeted SEDation after initiation of 
      mechanical ventilation in the emergency department (The ED-SED Pilot Trial).
PG  - e041987
LID - 10.1136/bmjopen-2020-041987 [doi]
AB  - INTRODUCTION: Sedation is a cornerstone therapy in the management of patients
      receiving mechanical ventilation and is highly influential on outcome. Early
      sedation depth appears especially influential, as early deep sedation is
      associated with worse outcome when compared with light sedation. Our research
      group has shown that patients receiving mechanical ventilation in the emergency
      department (ED) are exposed to deep sedation commonly, and ED sedation depth is
      impactful on intensive care unit (ICU) care and clinical outcomes. While
      extensive investigation has occurred for patients in the ICU, comparatively
      little data exist from the ED. Given the influence that ED sedation seems to
      carry, as well as a lack of ED-based sedation trials, there is significant
      rationale to investigate ED-based sedation as a means to improve outcome. METHODS
      AND ANALYSIS: This is a multicentre (n=3) prospective, before-and-after pilot
      trial examining the feasibility of implementing targeted sedation in the
      immediate postintubation period in the ED. A cohort of 344 patients receiving
      mechanical ventilation in ED will be included. Feasibility outcomes include: (1) 
      participant recruitment; (2) proportion of Richmond Agitation-Sedation Scale
      (RASS) scores in the deep sedation range; (3) reliability (agreement) of RASS
      measurements performed by bedside ED nurses; and (4) adverse events. The
      proportion of deep sedation measurements before and after the intervention will
      be compared using the chi(2) test. Logistic regression will be used to compare
      before-and-after differences, adjusting for potential confounders. The
      inter-rater correlation coefficient will be used to assess paired observations
      between a study team member and bedside ED nurses, and to describe reliability of
      RASS measurements. ETHICS AND DISSEMINATION: The Human Research Protection Office
      at Washington University in St. Louis School of Medicine has approved the study. 
      The publication of peer-reviewed manuscripts and the presentation of abstracts at
      scientific meetings will be used to disseminate the work. REGISTRATION:
      ClinicalTrials.gov identifier NCT04410783; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fuller, Brian M
AU  - Fuller BM
AUID- ORCID: 0000-0003-3757-756X
AD  - Department of Anesthesiology, Division of Critical Care, Department of Emergency 
      Medicine, Washington University in St. Louis School of Medicine, St. Louis,
      Missouri, USA fullerb@wustl.edu.
FAU - Roberts, Brian W
AU  - Roberts BW
AUID- ORCID: 0000-0002-7690-997X
AD  - Department of Emergency Medicine, Cooper University Hospital, One Cooper Plaza,
      Camden, New Jersey, USA.
FAU - Mohr, Nicholas M
AU  - Mohr NM
AD  - Departments of Emergency Medicine and Anesthesiology, Division of Critical Care, 
      Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, 
      Iowa, USA.
FAU - Pappal, Ryan D
AU  - Pappal RD
AD  - Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
FAU - Stephens, Robert J
AU  - Stephens RJ
AUID- ORCID: 0000-0003-4660-251X
AD  - Department of Emergency Medicine, Washington University in St. Louis School of
      Medicine, St. Louis, Missouri, USA.
FAU - Yan, Yan
AU  - Yan Y
AD  - Division of Public Health Sciences, Department of Surgery, Division of
      Biostatistics, Washington University School of Medicine, St. Louis, Missouri,
      USA.
FAU - Carpenter, Chris
AU  - Carpenter C
AD  - Department of Emergency Medicine, Washington University in St. Louis School of
      Medicine, St. Louis, Missouri, USA.
FAU - Kollef, Marin H
AU  - Kollef MH
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine,
      Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
FAU - Avidan, Michael Simon
AU  - Avidan MS
AD  - Department of Anesthesiology, Washington University in St. Louis School of
      Medicine, St. Louis, Missouri, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04410783
GR  - R34 HL150404/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20201216
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Hypnotics and Sedatives)
SB  - IM
MH  - Emergency Service, Hospital
MH  - Feasibility Studies
MH  - Humans
MH  - Hypnotics and Sedatives/therapeutic use
MH  - *Intensive Care Units
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - *Respiration, Artificial
MH  - Washington
PMC - PMC7745689
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *adult intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/12/18 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/17 05:38
PHST- 2020/12/17 05:38 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-041987 [pii]
AID - 10.1136/bmjopen-2020-041987 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 16;10(12):e041987. doi: 10.1136/bmjopen-2020-041987.


PMID- 33328196
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 12
DP  - 2020 Dec
TI  - Search without rescue? Evaluating the international search and rescue response to
      earthquake disasters.
LID - e002398 [pii]
LID - 10.1136/bmjgh-2020-002398 [doi]
AB  - Earthquakes around the world are unnecessarily lethal and destructive, adversely 
      affecting the health and well-being of affected populations. Most immediate
      deaths and injuries are caused by building collapse, making search and rescue
      (SAR) an early priority. In this review, we assess the SAR response to earthquake
      disasters. First, we review the evidence for the majority of individuals being
      rescued locally, often by relatives and neighbours. We then summarise evidence
      for successful live rescues by international SAR (ISAR) teams, along with the
      costs, ethics and other considerations of deployment. Finally, we propose an
      alternative approach to postdisaster ISAR, with the goal of reducing overall
      morbidity and mortality.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rom, Anna
AU  - Rom A
AUID- ORCID: 0000-0002-6014-7069
AD  - UCL Institute for Global Health, London, UK.
FAU - Kelman, Ilan
AU  - Kelman I
AD  - UCL Institute for Global Health and UCL Institute for Risk and Disaster
      Reduction, London, UK ilan_kelman@hotmail.com.
AD  - University of Agder, Kristiansand, Norway.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - *Disasters
MH  - *Earthquakes
MH  - Humans
MH  - *Rescue Work
MH  - Retrospective Studies
PMC - PMC7745699
OTO - NOTNLM
OT  - *environmental health
OT  - *epidemiology
OT  - *health economics
OT  - *health policy
OT  - *prevention strategies
COIS- Competing interests: None declared.
EDAT- 2020/12/18 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/12/17 05:38
PHST- 2020/02/18 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/12/17 05:38 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - bmjgh-2020-002398 [pii]
AID - 10.1136/bmjgh-2020-002398 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Dec;5(12). pii: bmjgh-2020-002398. doi:
      10.1136/bmjgh-2020-002398.


PMID- 33328172
OWN - NLM
STAT- Publisher
LR  - 20220419
IS  - 1475-5785 (Electronic)
IS  - 1353-8047 (Linking)
DP  - 2020 Dec 16
TI  - Testing the efficacy of a hospital-based violence intervention programme:
      protocol and design.
LID - injuryprev-2020-044026 [pii]
LID - 10.1136/injuryprev-2020-044026 [doi]
AB  - INTRODUCTION: Hospital-based violence intervention programmes (HBVIPs) are a
      promising strategy to reduce trauma recidivism and promote safety among victims
      of violent injury. While previous studies have demonstrated cost-effectiveness
      and positive impact on the lives of victims, there are a number of key
      limitations in the study designs of this evidence base. This study seeks to
      address the methodological shortcomings of previous research, determine the
      efficacy of HBVIPs using a randomised control study design, and provide a better 
      understanding of successful service allocation within an HBVIP. METHODS AND
      ANALYSIS: The current study is 1 of 12 demonstration projects being implemented
      around the country with the purpose of bolstering the ability to provide
      effective, culturally appropriate and trauma-informed services for boys and men
      harmed by violence. We propose a randomised control trial in which male victims
      of violence receive one of two interventions: treatment as usual versus enhanced 
      services. The purpose is to determine which intervention leads to reductions in
      trauma recidivism over the period of 1 year from contact with the programme.
      Differences will also be monitored on measures of mental health, quality of life 
      and attitudes towards violence. Analyses employed will include Kaplan-Meier
      analysis and Cox proportional hazards regression with death and recidivism being 
      the outcomes of interest. ETHICS AND DISSEMINATION: Study procedures have been
      approved by the Institutional Review Boards of the University at Buffalo and four
      hospitals. Results will be submitted for publication in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - St Vil, Christopher
AU  - St Vil C
AUID- ORCID: http://orcid.org/0000-0003-3501-2530
AD  - School of Social Work, University at Buffalo - The State University of New York, 
      Buffalo, New York, USA cstvil@buffalo.edu.
AD  - Harborview Injury Prevention & Research Center, Seattle, Washington, USA.
FAU - Hall, Erin C
AU  - Hall EC
AD  - Department of Surgery, Georgetown University Medical Center, Washington, District
      of Columbia, USA.
FAU - Sheppard, Mildred
AU  - Sheppard M
AD  - Community Violence Intervention Program, MedStar Washington Hospital Center,
      Washington, District of Columbia, USA.
FAU - Williams, Mallory
AU  - Williams M
AD  - Department of Surgery, Howard University College of Medicine, Washington,
      District of Columbia, USA.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - England
TA  - Inj Prev
JT  - Injury prevention : journal of the International Society for Child and Adolescent
      Injury Prevention
JID - 9510056
SB  - IM
OTO - NOTNLM
OT  - implementation / translation
OT  - penetrating injury
OT  - public health
OT  - randomised trial
OT  - treatment
OT  - violence
COIS- Competing interests: None declared.
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/17 05:38
PHST- 2020/10/09 00:00 [received]
PHST- 2020/11/22 00:00 [revised]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/17 05:38 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - injuryprev-2020-044026 [pii]
AID - 10.1136/injuryprev-2020-044026 [doi]
PST - aheadofprint
SO  - Inj Prev. 2020 Dec 16. pii: injuryprev-2020-044026. doi:
      10.1136/injuryprev-2020-044026.


PMID- 33328054
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 2589-7500 (Electronic)
IS  - 2589-7500 (Linking)
VI  - 2
IP  - 5
DP  - 2020 May
TI  - Ethical limitations of algorithmic fairness solutions in health care machine
      learning.
PG  - e221-e223
LID - S2589-7500(20)30065-0 [pii]
LID - 10.1016/S2589-7500(20)30065-0 [doi]
FAU - McCradden, Melissa D
AU  - McCradden MD
AD  - Department of Bioethics, The Hospital for Sick Children, Toronto, ON, Canada.
      Electronic address: melissa.mccradden@sickkids.ca.
FAU - Joshi, Shalmali
AU  - Joshi S
AD  - Vector Institute for Artificial Intelligence, Toronto, ON, Canada.
FAU - Mazwi, Mjaye
AU  - Mazwi M
AD  - Department of Critical Care Medicine, The Hospital for Sick Children, Toronto,
      ON, Canada.
FAU - Anderson, James A
AU  - Anderson JA
AD  - Department of Bioethics, The Hospital for Sick Children, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet Digit Health
JT  - The Lancet. Digital health
JID - 101751302
SB  - IM
MH  - *Algorithms
MH  - Delivery of Health Care/*ethics
MH  - Female
MH  - Health Equity/ethics
MH  - Humans
MH  - Machine Learning/*ethics
MH  - Male
MH  - *Models, Biological
MH  - *Social Justice
EDAT- 2020/12/18 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/12/17 05:31
PHST- 2020/01/07 00:00 [received]
PHST- 2020/03/02 00:00 [revised]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/12/17 05:31 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - S2589-7500(20)30065-0 [pii]
AID - 10.1016/S2589-7500(20)30065-0 [doi]
PST - ppublish
SO  - Lancet Digit Health. 2020 May;2(5):e221-e223. doi: 10.1016/S2589-7500(20)30065-0.


PMID- 33327960
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201220
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Dec 16
TI  - Older persons' thoughts about death and dying and their experiences of care in
      end-of-life: a qualitative study.
PG  - 123
LID - 10.1186/s12912-020-00514-x [doi]
AB  - BACKGROUND: Few studies have focused on how older persons living in nursing homes
      perceive their last period of life. Furthermore, previous research on older
      persons' perceptions of death and dying is limited. Hence, there is an urgent
      need to explore their experiences during their final period in life. AIM: To
      explore thoughts about death and dying and experiences of care in end-of-life
      among older persons living in nursing homes. METHODS: This study employed a
      qualitative approach including individual interviews with 36 older persons living
      in Swedish nursing homes. Questions related to quality of life; physical health; 
      thoughts about death, dying, and the future; and experiences related to the
      living condition and environment were asked. The interview transcripts were
      analysed through content analysis. The study was approved by the Regional Ethics 
      Review Board (reference number: 2015/4). RESULTS: The analysis resulted in the
      identification of three main thematic categories: The unavoidable and unknown end
      of life, Thoughts on control and Living your last period of life at a nursing
      home. The older persons did not fear death itself but had some worries about
      dying. Spending the last stage of life at a nursing home contributed to different
      thoughts and feelings among the older persons. With a few exceptions, older
      persons characterized life at the nursing home as boring and felt they were
      surrounded by people who did not belong there. CONCLUSIONS: This study indicates 
      a need for older persons to talk about death, dying and end-life issues.
      Furthermore, this study highlighted that the co-residence of cognitively healthy 
      persons and persons with dementia in the same ward adversely affected cognitively
      healthy persons. This situation resulted in there being not enough time to both
      handle the care needs of persons with dementia and have the conversations that
      cognitively healthy persons desired, such as conversations about thoughts about
      existence, that could have improved their quality of life. TRIAL REGISTRATION:
      NCT02708498 Date of registration 16 February 2016.
FAU - Tjernberg, Johanna
AU  - Tjernberg J
AD  - Department of Health Sciences, Faculty of Medicine, Lund University, P.O. Box
      157, SE-221 00, Lund, Sweden.
FAU - Bokberg, Christina
AU  - Bokberg C
AUID- ORCID: https://orcid.org/0000-0002-0821-1959
AD  - Department of Health Sciences, Faculty of Medicine, Lund University, P.O. Box
      157, SE-221 00, Lund, Sweden. christina.bokberg@med.lu.se.
LA  - eng
SI  - ClinicalTrials.gov/NCT02708498
GR  - 2014-2759/Vetenskapsradet
GR  - 2014-0071/Vardalstiftelsen
PT  - Journal Article
DEP - 20201216
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7739469
OTO - NOTNLM
OT  - Death
OT  - Dying
OT  - End-of-life care
OT  - Nursing homes
OT  - Older persons
OT  - Palliative care
EDAT- 2020/12/18 06:00
MHDA- 2020/12/18 06:01
CRDT- 2020/12/17 05:30
PHST- 2020/05/08 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/12/17 05:30 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2020/12/18 06:01 [medline]
AID - 10.1186/s12912-020-00514-x [doi]
AID - 10.1186/s12912-020-00514-x [pii]
PST - epublish
SO  - BMC Nurs. 2020 Dec 16;19(1):123. doi: 10.1186/s12912-020-00514-x.


PMID- 33327363
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Safety of locating the tip of a medium-long catheter at the axillary front and
      clavicle midline: A protocol for systematic review and meta-analysis.
PG  - e23726
LID - 10.1097/MD.0000000000023726 [doi]
AB  - BACKGROUND: Medium-long catheters are being used more and more widely in clinical
      practice, but we still do not know the impact of different placements, but this
      is an important clinical issue that cannot be ignored. OBJECTIVE: At present, the
      tip positioning of the mid-length catheter mainly includes the anterior part of
      the axilla and the midclavicular line. Different positioning may have different
      effects. Therefore, we did this research to confirm which positioning is more
      safety. METHODS: We systematically searched the Chinese and English databases:
      PubMed, Embase, CENTRAL, CINAHL, Web of Science, China Knowledge Network, China
      Biomedical Literature Database, VIP, Wan Fang. Literature screening, data
      extraction, and quality evaluation were carried out by 2 researchers, and
      finally, use Stata to carry out meta-analysis. RESULTS: This study is ongoing and
      the results will be submitted to a peer-reviewed journal for publication. ETHICS 
      AND DISSEMINATION: Ethical approval is not applicable, since this is an overview 
      based on published articles. PROTOCOL REGISTRATION NUMBER: INPLASY2020110042.
FAU - Zhao, Yali
AU  - Zhao Y
AUID- ORCID: 0000-0003-2619-1012
AD  - Lanzhou University Second Hospital.
FAU - Geng, Jie
AU  - Geng J
AD  - Lanzhou University Second Hospital.
AD  - The School of Nursing, Lanzhou University, Lanzhou, Gansu, People's Republic of
      China.
FAU - Wu, Xing
AU  - Wu X
AD  - Lanzhou University Second Hospital.
FAU - Xiong, Suiting
AU  - Xiong S
AD  - Lanzhou University Second Hospital.
FAU - Wang, Liwei
AU  - Wang L
AD  - Lanzhou University Second Hospital.
FAU - Wang, Juanxia
AU  - Wang J
AD  - Lanzhou University Second Hospital.
FAU - Ma, Haijv
AU  - Ma H
AD  - Lanzhou University Second Hospital.
FAU - Wei, Fengxian
AU  - Wei F
AD  - Lanzhou University Second Hospital.
FAU - Wei, Zhihong
AU  - Wei Z
AD  - Lanzhou University Second Hospital.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Axilla/*blood supply
MH  - Catheterization, Peripheral/*instrumentation/*methods
MH  - Clavicle/*blood supply
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7738149
EDAT- 2020/12/18 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
AID - 10.1097/MD.0000000000023726 [doi]
AID - 00005792-202012110-00144 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23726. doi:
      10.1097/MD.0000000000023726.


PMID- 33327342
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast
      in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC).
PG  - e23633
LID - 10.1097/MD.0000000000023633 [doi]
AB  - BACKGROUND: Transient receptor potential vanilloid 2 (TRPV2) was previously shown
      to play an important role in the maintenance of cancer stem cells, and its
      specific inhibitor, tranilast, also has potential as a targeted therapeutic agent
      for esophageal squamous cell carcinoma (ESCC). The present study is being
      conducted to confirm the safety and efficacy of the additional use of tranilast
      with conventional preoperative adjuvant chemotherapy for patients with advanced
      ESCC. PATIENTS AND METHODS: Between 56 and 59 patients aged between 20 and 74
      years with clinically diagnosed Stage II or Stage III ESCC will be enrolled.
      Eligible patients will receive preoperative adjuvant chemotherapy, 2 cycles of
      combination therapy with cisplatin, 5-fluorouracil, and tranilast. Recruitment
      started in November 2019, with the final follow-up being planned for March 2029. 
      One subject has been enrolled since October 21, 2020. The pathological
      therapeutic effect is the primary endpoint. The objective response rate, safety
      of preoperative adjuvant chemotherapy, recurrence-free survival (RFS), and
      overall survival (OS) are the secondary endpoints. RFS and OS will be calculated 
      as the time from surgery to first recurrence and all-cause death, respectively.
      ETHICS AND DISSEMINATION: This protocol has been approved by the Institutional
      Review Boards of Kyoto Prefectural University of Medicine and all participating
      hospitals in August 30, 2019 (Number: CRB5180001). Written informed consent will 
      be obtained from all patients before their registration, which is in accordance
      with the Declaration of Helsinki. The results of the present study will be
      disseminated via publication in peer-reviewed journals. TRIAL REGISTRATION: Trial
      registration number jRCTs051190076.
FAU - Shiozaki, Atsushi
AU  - Shiozaki A
AUID- ORCID: 0000-0003-3739-160
AD  - Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural
      University of Medicine, Kyoto, Japan.
FAU - Kudou, Michihiro
AU  - Kudou M
FAU - Fujiwara, Hitoshi
AU  - Fujiwara H
FAU - Konishi, Hirotaka
AU  - Konishi H
FAU - Shimizu, Hiroki
AU  - Shimizu H
FAU - Arita, Tomohiro
AU  - Arita T
FAU - Kosuga, Toshiyuki
AU  - Kosuga T
FAU - Yamamoto, Yusuke
AU  - Yamamoto Y
FAU - Morimura, Ryo
AU  - Morimura R
FAU - Ikoma, Hisashi
AU  - Ikoma H
FAU - Kuriu, Yoshiaki
AU  - Kuriu Y
FAU - Kubota, Takeshi
AU  - Kubota T
FAU - Okamoto, Kazuma
AU  - Okamoto K
FAU - Otsuji, Eigo
AU  - Otsuji E
LA  - eng
PT  - Clinical Trial Protocol
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (ortho-Aminobenzoates)
RN  - HVF50SMY6E (tranilast)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Chemotherapy, Adjuvant/adverse effects/*methods
MH  - Cisplatin/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Esophageal Neoplasms/*drug therapy
MH  - Esophageal Squamous Cell Carcinoma/*drug therapy
MH  - Female
MH  - Fluorouracil/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Survival Analysis
MH  - Young Adult
MH  - ortho-Aminobenzoates/administration & dosage/adverse effects/*therapeutic use
PMC - PMC7738016
EDAT- 2020/12/18 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
AID - 10.1097/MD.0000000000023633 [doi]
AID - 00005792-202012110-00123 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23633. doi:
      10.1097/MD.0000000000023633.


PMID- 33327339
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Efficacy of individualized education in patients with type 2 diabetes mellitus: A
      randomized clinical study protocol.
PG  - e23625
LID - 10.1097/MD.0000000000023625 [doi]
AB  - OBJECTIVE: To assess the effect of the program of individualized diabetes
      education on type 2 diabetes mellitus (DM) patients. METHODS: This is a
      single-center randomized controlled trial that will be implemented from December 
      2020 to April 2021. The experiment was granted through the Research Ethics
      Committee of People's Hospital of Chengyang District (03982765). Patients are
      randomly assigned to the study group and control group with 50 cases in each
      group. Patients who meet the following criteria will be included in our study:
      patients diagnosed with type 2 DM based on the World Health Organization
      diagnostic criteria in 1999; patients who can take part in the follow-up
      researches after discharge; patients who can provide the written informed
      consent. And the exclusion criteria include: the known mental or psychological
      disorders, for instance, severe anxiety disorders or depression; severe
      comorbidities, e.g. liver dysfunction, kidney failure, stroke, and cancer;
      Uncontrolled diabetes complications, for instance, infection, acidosis, as well
      as peripheral vascular disease. The clinical examination shall be conducted
      during each follow-up period, and the laboratory examination is implemented as
      necessary in the process of each hospital visit. At the end of the 6-month study,
      each patient's blood pressure, waist circumference, body mass index, blood
      lipids, as well as fasting blood glucose are evaluated. RESULTS: Table 1 reveals 
      the comparison of biochemical results and clinical results between the control
      group and the study group. CONCLUSION: Individualized diabetes education may
      improve the clinical outcomes in patients with type 2 DM. TRIAL REGISTRATION: The
      protocol was registered in Research Registry (researchregistry6232).
FAU - Huang, Li
AU  - Huang L
AD  - Department of Gastroenterology.
FAU - Guo, Hongyan
AU  - Guo H
AD  - Department of Cardiology, People's Hospital of Chengyang District, Qingdao,
      China.
FAU - Xiu, Lihua
AU  - Xiu L
AD  - Department of Gastroenterology.
FAU - Wang, Haowen
AU  - Wang H
AUID- ORCID: 0000-0002-7378-3961
AD  - Department of Gastroenterology.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Diabetes Mellitus, Type 2/*therapy
MH  - Humans
MH  - *Patient Education as Topic
MH  - *Self Care
PMC - PMC7738066
EDAT- 2020/12/18 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1097/MD.0000000000023625 [doi]
AID - 00005792-202012110-00120 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23625. doi:
      10.1097/MD.0000000000023625.


PMID- 33327336
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Self-care education program improves quality of life in patients with chronic
      heart failure: A randomized controlled study protocol.
PG  - e23621
LID - 10.1097/MD.0000000000023621 [doi]
AB  - OBJECTIVE: The objective of our research is to explore the efficiency of
      self-care education on the life quality in chronic heart failure (CHF) patients. 
      METHODS: The experiment will be implemented from July 2021 to July 2022 and was
      granted through the Research Ethics Committee of Shengjing Hospital of China
      Medical University (423507-037). Eighty patients are included in the study. The
      recruitment criteria of patients includes: the patients have been diagnosed with 
      CHF by physician on the basis of echocardiography; being stabilized in the acute 
      disease state; in accordance with medical record, the patients have no
      sensory-cognitive problems. Any reason for not participating in education course 
      (such as not wishing to continue taking part in our experiment or discharge from 
      hospital) is regarded as the exclusion criterion. The primary outcome is the
      patients' life quality, which is evaluated with Iranian heart failure quality of 
      life questionnaire. Other outcomes include the incidence of hospitalization and
      total medical cost. RESULTS: Table 1 suggests the comparison of patients' life
      quality between control group and study group after receiving the education of
      self-care. CONCLUSION: The program of self-care education can be regarded as the 
      proper method to improve the life quality in CHF patients. TRIAL REGISTRATION:
      The protocol was registered in Research Registry (researchregistry6225).
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Critical Care Medicine, Shengjing Hospital of China Medical
      University, Liaoning, China.
FAU - Li, Weiwei
AU  - Li W
AUID- ORCID: 0000-0002-3443-3459
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Female
MH  - Heart Failure/*psychology
MH  - Humans
MH  - Male
MH  - *Patient Education as Topic
MH  - *Quality of Life
MH  - *Self Care
PMC - PMC7738048
EDAT- 2020/12/18 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1097/MD.0000000000023621 [doi]
AID - 00005792-202012110-00117 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23621. doi:
      10.1097/MD.0000000000023621.


PMID- 33327306
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Magnetic resonance imaging for the non-invasive diagnosis in patients with
      ovarian cancer: A protocol for systematic review and meta-analysis.
PG  - e23551
LID - 10.1097/MD.0000000000023551 [doi]
AB  - BACKGROUND: In developed nations, ovarian cancer has resulted in the most
      fatalities from gynecological cancer. Laparoscopy is primarily utilized as the
      test to diagnose ovarian cancer. Besides being costly, there are surgical risks
      associated with laparoscopies. At present, clinical practitioners have access to 
      non-invasive tests for diagnosing ovarian cancer. This study aims to evaluate the
      diagnostic accuracy of magnetic resonance imaging (MRI) for diagnosing ovarian
      cancer. METHODS: In order to obtain eligible studies, cross-sectional studies or 
      randomized controlled trials are searched in electronic databases. The databases 
      include 5 English databases (PubMed, the Cochrane Library, PsycINFO, EMBASE, and 
      Web of Science) and 3 Chinese databases (China Biomedical Literature Database,
      China National Knowledge Infrastructure, and WanFang database). The databases are
      searched from their origin to October 2020. Quality Assessment of Diagnostic
      Accuracy Studies-2 is used to assess the methodological quality of the selected
      studies. RevMan 5.3 and SAS NLMIXED software are used to assess the data
      synthesis, sensitivity analysis, and risk of bias assessment. RESULTS: This study
      evaluates the pooled diagnostic value of MRI for diagnosing ovarian cancer.
      CONCLUSIONS: This study will summarize previously published evidence of MRI in
      relation to diagnosing ovarian cancer. ETHICS AND DISSEMINATION: Since this study
      does not utilize data from patients, this protocol does not require ethical
      approval. PROTOCOL REGISTRATION NUMBER: DOI 10.17605/OSF.IO/A6SPQ
      (https://osf.io/a6spq).
FAU - Su, Yongxue
AU  - Su Y
AD  - Department of Radiology.
FAU - Deng, Lingli
AU  - Deng L
AD  - Department of Radiology.
FAU - Yang, Lijun
AU  - Yang L
AD  - Department of Obstetrics, Maternal and Child Health Hospital of Hubei Province.
FAU - Yuan, Xianhong
AU  - Yuan X
AD  - Department of Radiology.
FAU - Xia, Wei
AU  - Xia W
AD  - Department of Radiology.
AD  - Department of Imaging Center, Wuhan Children's Hospital (Wuhan Maternal and Child
      Healthcare Hospital), Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, Hubei, P. R. China.
FAU - Liu, Ping
AU  - Liu P
AUID- ORCID: 0000-0003-1552-4790
AD  - Department of Radiology.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging/methods
MH  - Ovarian Neoplasms/diagnosis/*diagnostic imaging
MH  - Ovary/diagnostic imaging
PMC - PMC7738010
EDAT- 2020/12/18 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 10.1097/MD.0000000000023551 [doi]
AID - 00005792-202012110-00087 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23551. doi:
      10.1097/MD.0000000000023551.


PMID- 33327300
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Hemiarthroplasty versus total hip arthroplasty for displaced femoral neck
      fracture in patients older than 80 years: A randomized trial protocol.
PG  - e23530
LID - 10.1097/MD.0000000000023530 [doi]
AB  - BACKGROUND: The forms of treatment which are available for these patients include
      internal fixation, hemiarthroplasty (HA), or total hip arthroplasty (THA). Both
      HA and THA are widely used methods of hip replacement after displaced femoral
      neck fracture (DFNF). Our purpose is to analyze the long-term outcomes of these 2
      different forms of treatment, which are suitable for active patients with femoral
      neck intracapsular fractures >/=80 years of age without advanced osteoarthritis
      or rheumatoid arthritis. METHODS: This study is designed as a single-center
      randomized controlled trial. The participants will be randomly assigned to either
      the THA group or the HA group. Information will be collected from all
      participants after obtaining written informed consent in accordance with the
      Declaration of Helsinki and ethical board approval. Inclusion criteria include:
      displaced intracapsular femoral neck fracture, capability to obtain informed
      consent, no known metastatic disease, no contraindications to anesthesia, age
      >/=80 years, and ability to understand written Chinese. Patients will be
      evaluated at 3 months, 6 months, 1 year, and 3 years after surgery. At the time
      of the final follow-up, patients were assessed with use of the Harris hip score
      (HHS) and walking distance. Secondary outcomes of interest include postoperative 
      complications, including 90-day medical complications (acute myocardial
      infarction, deep vein thrombosis, pulmonary embolism, intestinal obstruction,
      renal failure, and pneumonia) and surgical complications within 1 year
      (dislocation, infection, and revision replacement). RESULTS: This trial is
      expected to be the largest randomized trial assessing the efficacy of THA and HA 
      and powered to detect a potential difference in the primary outcome. TRIAL
      REGISTRATION: This study protocol has been registered in Research Registry
      (researchregistry6203).
FAU - Peng, Lin
AU  - Peng L
AD  - Department of Orthopaedics, The Fourth People's Hospital of Jinan, The Third
      Affiliated Hospital of Shandong First Medical University.
FAU - Liu, Hongyu
AU  - Liu H
AD  - Department of Orthopaedics, The Fourth People's Hospital of Jinan, The Third
      Affiliated Hospital of Shandong First Medical University.
FAU - Hu, Xiaoyi
AU  - Hu X
AD  - Department of Disease Control and Prevention, PLA 960th Hospital, Shandong,
      China.
FAU - Liu, Jianqiang
AU  - Liu J
AUID- ORCID: 0000-0003-1019-7305
AD  - Department of Orthopaedics, The Fourth People's Hospital of Jinan, The Third
      Affiliated Hospital of Shandong First Medical University.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged, 80 and over
MH  - *Arthroplasty, Replacement, Hip
MH  - Femoral Neck Fractures/*surgery
MH  - *Hemiarthroplasty
MH  - Hip Joint/surgery
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7738070
EDAT- 2020/12/18 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 10.1097/MD.0000000000023530 [doi]
AID - 00005792-202012110-00081 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23530. doi:
      10.1097/MD.0000000000023530.


PMID- 33327297
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Correlative analysis between cytotoxic T lymphocyte antigen 4 genetic
      polymorphisms and head and neck cancer susceptibility: A protocol for systematic 
      review and meta-analysis.
PG  - e23519
LID - 10.1097/MD.0000000000023519 [doi]
AB  - BACKGROUND: Previous published studies have reported the association of cytotoxic
      T lymphocyte antigen 4 (CTLA-4) genetic polymorphisms with the susceptibility to 
      head and neck cancer, but the results remain controversial. We therefore will
      conduct a meta-analysis to investigate the relationship between CTLA-4 genetic
      polymorphisms and head and neck cancer susceptibility. METHODS: We will
      systematically search case-control studies for potential eligible studies from
      Cochrane Library, EMBASE, Google Scholar, PubMed, China Biomedical Database,
      WanFang database, and China National Knowledge Infrastructure (CNKI).
      Additionally, we will also examine other sources to avoid missing potential
      trials. Two authors will independently collect and perform the study selection,
      data extraction, and study methodological quality. Statistical analyses were
      utilized using STATA 12.0 and RevMan 5.3, and the odds ratios (ORs) with 95%
      confidence intervals (95% CI) were used to estimate the strength of the
      association of CTLA-4 genetic polymorphisms with the susceptibility to head and
      neck cancer. RESULTS: This protocol study will assess the relationship between
      CTLA-4 genetic polymorphisms and head and neck cancer susceptibility. CONCLUSION:
      The findings of this study will provide systematic evidence for future guidance
      developing and clinical decision making in patients with head and neck cancer.
      ETHICS AND DISSEMINATION: Ethical approval will not be required as this study is 
      a systematic review. PROTOCOL REGISTRATION NUMBER: DOI 10.17605/OSF.IO/BFJTZ
      (https://osf.io/bfjtz/).
FAU - Lin, Bo
AU  - Lin B
AD  - Department of Fundamental Nursing, West Anhui Health Vocational College, Lu'an.
FAU - Wang, Ling
AU  - Wang L
AUID- ORCID: 0000-0001-8011-4515
AD  - School of Nursing, Wannan Medical College, Wuhu, Anhui Province, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (CTLA-4 Antigen)
SB  - IM
MH  - Asians
MH  - CTLA-4 Antigen/*genetics
MH  - China
MH  - *Genetic Predisposition to Disease
MH  - Head and Neck Neoplasms/*genetics
MH  - Humans
MH  - Polymorphism, Genetic
PMC - PMC7738009
EDAT- 2020/12/18 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/17 01:02
PHST- 2020/12/17 01:02 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1097/MD.0000000000023519 [doi]
AID - 00005792-202012110-00078 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23519. doi:
      10.1097/MD.0000000000023519.


PMID- 33327269
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Magnetic resonance imaging for evaluating tumor resectability in advanced ovarian
      cancer: A protocol for systematic review and meta-analysis.
PG  - e23419
LID - 10.1097/MD.0000000000023419 [doi]
AB  - BACKGROUND: This study will evaluate the diagnostic accuracy of magnetic
      resonance imaging (MRI) to investigate tumor resectability at primary debulking
      surgery among women experiencing advanced-stage ovarian cancer. METHODS: We will 
      systematically search the randomized controlled trials (RCTs) for potentially
      eligible studies from electronic databases, including 4 English databases
      (PubMed, EMBASE, Web of Science, and Cochrane Library) and 3 Chinese databases
      (China National Knowledge Infrastructure, WanFang, and China Biomedical
      Database). The study language will be restricted to English and Chinese. Also, 2 
      independent authors will collect and carry out data extraction as well as quality
      assessment. Data will be synthesized using appropriate statistical methods.
      RESULTS: We will summarize present study's evidence to assess the diagnostic
      accuracy of MRI for evaluating tumor resectability at primary debulking surgery
      in women experiencing advanced-stage ovarian cancer. CONCLUSION: The present
      study will put forward the latest high-quality evidence for MRI's clinical
      application for evaluating tumor resectability in women experiencing advanced
      ovarian cancer. ETHICS AND DISSEMINATION: Since the present study is a systematic
      review and meta-analysis based on the published literature, ethical approval will
      not be necessary. PROTOCOL REGISTRATION NUMBER: DOI 10.17605/OSF.IO/UWDRF
      (https://osf.io/uwdrf/).
FAU - Liu, Ping
AU  - Liu P
AD  - Department of Radiology.
FAU - Deng, Lingli
AU  - Deng L
AD  - Department of Radiology.
FAU - Yang, Lijun
AU  - Yang L
AD  - Department of Obstetrics, Maternal and Child Health Hospital of Hubei Province.
FAU - Yuan, Xianhong
AU  - Yuan X
AD  - Department of Radiology.
FAU - Xia, Wei
AU  - Xia W
AD  - Department of Radiology.
AD  - Department of Imaging Center, Wuhan Children's Hospital (Wuhan Maternal and Child
      Healthcare Hospital), Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, Hubei, P.R. China.
FAU - Su, Yongxue
AU  - Su Y
AUID- ORCID: 0000-0002-1488-4594
AD  - Department of Radiology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Clinical Decision-Making/*methods
MH  - *Cytoreduction Surgical Procedures
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*diagnostic imaging/surgery
MH  - Ovary/*diagnostic imaging/surgery
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7738068
EDAT- 2020/12/18 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1097/MD.0000000000023419 [doi]
AID - 00005792-202012110-00050 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23419. doi:
      10.1097/MD.0000000000023419.


PMID- 33327264
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Effect of large dosage of Prunella on Hashimoto's thyroiditis: A protocol of
      systematic review and meta-analysis of randomized clinical trials.
PG  - e23391
LID - 10.1097/MD.0000000000023391 [doi]
AB  - INTRODUCTION: Hashimoto's Thyroiditis (HT) is one of the common autoimmune
      diseases, which can lead to thyroid reduction, increase the risk of tumor, and
      seriously affect women's reproductive health. Many other autoimmune diseases are 
      easy to occur, seriously harming people's health.large dose herb Prunella or
      compound prescription contain large dose Prunella for treatment of HT has already
      been confirmed. However, due to the lack of evidence, there is no specific method
      or suggestion, it is necessary to carry out a systematic evaluation on Prunella
      and provide effective evidence for further research. METHODS AND ANALYSIS: The
      following databases will be searched from their inception to October 2020:
      Electronic database includes PubMed, Embase, Cochrane Library, Web of Science,
      Nature, Science online, Chinese Biomedical Database WangFang, VIP medicine
      information, and China National Knowledge Infrastructure. MAIN RESULTS: serum
      thyroid peroxidase antibody (TPOAb), thyroid globulin antibody (TGAb), other
      results: serum thyroid stimulating hormone (TSH), serum free triiodothyronine
      (FT3), serum free thyroid hormone (FT4). Data will be extracted by 2 researchers 
      independently, risk of bias of the meta-analysis will be evaluated based on the
      Cochrane Handbook for Systematic Reviews (SR)of Interventions. All data analysis 
      will be conducted by data statistics software Review Manager V.5.3. and Stata
      V.12.0. RESULTS: The results of this study will systematically evaluate the
      efficacy and safety of large dose prunella salicorrhizae in the intervention of
      people with HT. CONCLUSION: The systematic review of this study will summarize
      the current published evidence of large dose prunella for the treatment of HT,
      which can further guide the promotion and application of it. ETHICS AND
      COMMUNICATION: This study is a systematic review, the outcomes are based on the
      published evidence, so examination and agreement by the ethics committee are not 
      required in this study. We intend to publish the study results in a journal or
      conference presentations.Open Science Fra mework (OSF) registration
      number:October 21, 2020.osf.io/fcyqp. (https://osf.io/fcyqp).
FAU - Chen, Pei
AU  - Chen P
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Li, Chaomin
AU  - Li C
AUID- ORCID: 0000-0002-3425-3976
FAU - Zhao, Siliang
AU  - Zhao S
FAU - Wang, Lizhen
AU  - Wang L
FAU - Liu, Lingyu
AU  - Liu L
FAU - Fan, Qiuhong
AU  - Fan Q
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antithyroid Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Thyroid Hormones)
SB  - IM
MH  - Adult
MH  - Antithyroid Agents/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Hashimoto Disease/blood/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Prunella
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Thyroid Function Tests
MH  - Thyroid Hormones/blood
MH  - Treatment Outcome
PMC - PMC7738013
EDAT- 2020/12/18 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1097/MD.0000000000023391 [doi]
AID - 00005792-202012110-00045 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23391. doi:
      10.1097/MD.0000000000023391.


PMID- 33327263
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Herbal medicines for the prevention and treatment of cerebral vasospasm after
      subarachnoid hemorrhage: A protocol for systematic review and meta-analysis.
PG  - e23388
LID - 10.1097/MD.0000000000023388 [doi]
AB  - BACKGROUND: Despite the rapid advances in medical technology, including
      endovascular interventions and medications, cerebral vasospasm (CVS) after
      subarachnoid hemorrhage (SAH) is still one of the major threats to the lives of
      patients with SAH. In East Asian countries, various types of herbal medicines
      have been used to treat cerebrovascular diseases, including SAH. In this review, 
      we aim to evaluate the efficacy and safety of herbal medicines for the prevention
      and treatment of CVS after SAH. METHODS AND ANALYSIS: Seven databases will be
      searched for relevant studies from inception to the present date "June 2020".
      Only randomized controlled trials (RCTs) that assess the effect and safety of
      herbal medicines for the prevention and treatment of CVS after SAH will be
      included. The methodological quality will be evaluated using the Cochrane risk of
      bias assessment tool. After selecting the appropriate studies, a meta-analysis of
      the RCTs will be performed. RESULTS: This study will provide a high-quality
      synthesis of current evidence of herbal medicines for CVS after SAH. CONCLUSION: 
      Our systematic review will provide evidence to judge whether herbal medicines are
      effective interventions for patients with CVS after SAH. ETHICS AND
      DISSEMINATION: Ethical approval is not required, as this study is based on a
      review of published research. This review will be published in a peer-reviewed
      journal and disseminated electronically and in print. TRIAL REGISTRATION NUMBER: 
      Research registry reviewregistry923.
FAU - Seo, Yuna
AU  - Seo Y
AD  - Department of Korean Medicine Cardiology and Neurology, Graduate School, Kyung
      Hee University, Seoul.
FAU - Lee, Han-Gyul
AU  - Lee HG
AD  - Department of Korean Medicine Cardiology and Neurology, Graduate School, Kyung
      Hee University, Seoul.
FAU - Jin, Chul
AU  - Jin C
AD  - Department of Korean Medicine Cardiology and Neurology, Graduate School, Kyung
      Hee University, Seoul.
FAU - Yang, Seung-Bo
AU  - Yang SB
AD  - Department of Korean Internal Medicine, College of Korean Medicine, Gachon
      University, Gyeonggi-do.
FAU - Cho, Seung-Yeon
AU  - Cho SY
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Park, Seong-Uk
AU  - Park SU
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Jung, Woo-Sang
AU  - Jung WS
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Moon, Sang-Kwan
AU  - Moon SK
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Park, Jung-Mi
AU  - Park JM
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Ko, Chang-Nam
AU  - Ko CN
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Cho, Ki-Ho
AU  - Cho KH
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Kwon, Seungwon
AU  - Kwon S
AUID- ORCID: 0000-0002-1857-3515
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Plants, Medicinal
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Subarachnoid Hemorrhage/complications/*drug therapy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Vasospasm, Intracranial/*drug therapy/etiology
PMC - PMC7738086
EDAT- 2020/12/18 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1097/MD.0000000000023388 [doi]
AID - 00005792-202012110-00044 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23388. doi:
      10.1097/MD.0000000000023388.


PMID- 33327262
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Comparison of the practicability of ultrasound and spiral computed tomography in 
      the diagnosis of colon cancer: A protocol for systematic review and
      meta-analysis.
PG  - e23381
LID - 10.1097/MD.0000000000023381 [doi]
AB  - BACKGROUND: Colon cancer is a common malignant tumor of the gastrointestinal
      tract. Therefore, a clear diagnosis is particularly important for the treatment
      of colon cancer. Ultrasound and spiral computed tomography (CT) can both be used 
      in the diagnosis, but each has its own advantages and disadvantages, which could 
      cause confusion in clinical choice. The purpose of this study was to
      systematically evaluate the practicability of spiral CT and ultrasound in the
      diagnosis of colon cancer. METHODS: A systematic search was performed by
      retrieving on English databases (PubMed, Embase, Web of Science, the Cochrane
      Library) and Chinese databases (CNKI, Wanfang, Weipu [VIP], CBM). Besides,
      manually search for Google and Baidu academic of diagnostic experimental study of
      ultrasound and spiral CT in the diagnosis of Colon Cancer. The retrieval time
      limit was from the establishment of the database to October 2020. Two researchers
      independently extracted and evaluated the quality of the data in the included
      study. A meta-analysis was performed using Meta Disc1.4 and RevMan5.3 software.
      RESULTS: Sensitivity, specificity, positive Likelihood ratio, negative likelihood
      ratio, and diagnostic odds ratio were used to determine the diagnostic efficacy
      of ultrasonography and helical CT in colorectal cancer. CONCLUSIONS: This study
      will compare the practicability of CT and ultrasound in the diagnosis of colon
      cancer and provide reliable evidence-based basis for clinicians to choose the
      appropriate or best evidence-based basis. ETHICS AND DISSEMINATION: The private
      information from individuals will not be published. This systematic review also
      will not involve endangering participant rights. Ethical approval is not
      required. The results may be published in a peer-reviewed journal or disseminated
      in relevant conferences. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/WAJHQ.
FAU - Zhao, Fan
AU  - Zhao F
AD  - Wuwei People's Hospital, Wuwei, Gansu Province, China.
FAU - Yang, Qingya
AU  - Yang Q
FAU - Meng, Cunzhong
AU  - Meng C
FAU - Jiang, Tao
AU  - Jiang T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Colonic Neoplasms/*diagnostic imaging
MH  - Humans
MH  - Likelihood Functions
MH  - Meta-Analysis as Topic
MH  - Odds Ratio
MH  - Research Design
MH  - Sensitivity and Specificity
MH  - Systematic Reviews as Topic
MH  - Tomography, Spiral Computed/methods/*statistics & numerical data
MH  - Ultrasonography/methods/*statistics & numerical data
PMC - PMC7738095
EDAT- 2020/12/18 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1097/MD.0000000000023381 [doi]
AID - 00005792-202012110-00043 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23381. doi:
      10.1097/MD.0000000000023381.


PMID- 33327248
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - External therapy of Chinese medicine for postherpetic neuralgia: A protocol for
      systematic review and meta-analysis.
PG  - e23270
LID - 10.1097/MD.0000000000023270 [doi]
AB  - BACKGROUND: Postherpetic neuralgia (PHN), the most common complication of herpes 
      zoster, brings about a health-care burden at both the individual and societal
      levels. External therapy of Chinese medicine (ETCM) is an effective treatment of 
      PHN generally available in China, yet there is incomplete evidence to evaluate
      the efficacy and safety of it. METHODS: This protocol is based on the previous
      reporting items. We will search 3 English databases (PubMed, EMBASE, and the
      Cochrane Library) and 3 Chinese databases (CNKI, CBM, and Wan Fang Database)
      until January 2020. RCTs to evaluate the efficacy and safety of external therapy 
      of Chinese medicine for postherpetic neuralgia will be included. The primary
      outcome will be assessed by VAS or NRS. We will use the criteria provided by
      Cochrane Handbook 5.3.0 for quality evaluation and risk assessment, and use the
      Revman 5.3 software for meta-analysis. ETHICS AND DISSEMINATION: Ethical approval
      is not required for systematic review and meta- analysis. The results of this
      review will be disseminated in a peer-review journal. PROSPERO REGISTRATION
      NUMBER: CRD42020163511.
FAU - Wang, Zheyi
AU  - Wang Z
AUID- ORCID: 0000-0002-7463-5688
AD  - Beijing University of Chinese Medicine.
AD  - School of Life Science.
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine.
FAU - Sun, Yize
AU  - Sun Y
AD  - Beijing University of Chinese Medicine.
FAU - Liu, Biyuan
AU  - Liu B
AD  - School of Life Science.
FAU - Fan, Zhu
AU  - Fan Z
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Tian, Jinzhou
AU  - Tian J
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine.
FAU - Lu, Tao
AU  - Lu T
AD  - School of Life Science.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Administration, Topical
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Medicine, Chinese Traditional/adverse effects/*methods
MH  - Neuralgia, Postherpetic/*drug therapy
PMC - PMC7738126
EDAT- 2020/12/18 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1097/MD.0000000000023270 [doi]
AID - 00005792-202012110-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23270. doi:
      10.1097/MD.0000000000023270.


PMID- 33327242
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Long-term efficacy and advantages of minimally invasive hepatectomy for
      hepatolithiasis: A protocol for systematic review and meta-analysis.
PG  - e23230
LID - 10.1097/MD.0000000000023230 [doi]
AB  - BACKGROUND: Hepatolithiasis commonly occurs in the bile duct proximal to the
      confluence of the right and left hepatic ducts, regardless of the coexistence of 
      gallstones in gallbladder or the common bile duct. Clinical research proves that 
      minimally invasive surgery is effective in the treatment of hepatolithiasis.
      Although previous meta-analysis also shows that it could reduce intraoperative
      bleeding and blood transfusion, and shorten hospital stay time, there are few
      meta-analyses on its long-term efficacy. We conducted the meta-analysis and
      systematic review to systematically evaluate the long-term efficacy and
      advantages of minimally invasive hepatectomy in the treatment of hepatolithiasis.
      METHODS: Articles of randomized controlled trials will be searched in the PubMed,
      Medline, Embase, Cochrane Library, China National Knowledge Infrastructure,
      Chongqing VIP Chinese Science and Technology Periodical Database, Chinese
      Biological and Medical database, and Wanfang database until September, 2020.
      Literature extraction and risk of bias assessment will be completed by 2
      reviewers independently. Statistical analysis will be conducted in RevMan 5.3.
      RESULTS: This study will summarize the present evidence by exploring the
      long-term efficacy and advantages of minimally invasive hepatectomy in the
      treatment of hepatolithiasis CONCLUSIONS:: The findings of the study will help to
      determine potential long-term efficacy and advantages of minimally invasive
      hepatectomy in the treatment of hepatolithiasis. ETHICS AND DISSEMINATION: The
      private information from individuals will not be published. This systematic
      review also will not involve endangering participant rights. Ethical approval is 
      not required. The results may be published in a peer-reviewed journal or
      disseminated in relevant conferences. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/H6WRV.
FAU - Liu, Jianyang
AU  - Liu J
AUID- ORCID: 0000-0002-9070-0179
AD  - Quzhou People's Hospital.
FAU - Xu, Jinchai
AU  - Xu J
AD  - Quzhou Hospital of Traditional Chinese Medicine, Quzhou.
FAU - Luo, Dengpan
AU  - Luo D
AD  - Quzhou People's Hospital.
FAU - Zhao, Yujun
AU  - Zhao Y
AD  - Quzhou People's Hospital.
FAU - Shen, Hongbo
AU  - Shen H
AD  - Quzhou People's Hospital.
FAU - Rao, Jianzhong
AU  - Rao J
AD  - Jiangshan People's Hospital, Jiangshan, Zhejiang Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Cholelithiasis/*surgery
MH  - *Hepatectomy/adverse effects/methods
MH  - Humans
MH  - *Minimally Invasive Surgical Procedures/adverse effects/methods
MH  - Treatment Outcome
PMC - PMC7738022
EDAT- 2020/12/18 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1097/MD.0000000000023230 [doi]
AID - 00005792-202012110-00023 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23230. doi:
      10.1097/MD.0000000000023230.


PMID- 33327241
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Efficacy and safety of micro-implant anchorage in Angle class II malocclusion
      orthodontic treatment: A protocol for systematic review and meta-analysis.
PG  - e23221
LID - 10.1097/MD.0000000000023221 [doi]
AB  - BACKGROUND: Angle class II malocclusion is clinically complex and common
      malocclusion type, which affects beauty. Conventional treatment has the
      disadvantages of long course of treatment, high cost, easy recurrence and limited
      curative effect. Clinical practice shows that micro-implant anchorage has certain
      advantages in the treatment of Angle II malocclusion, but lacks the evidence of
      evidence-based medicine. This study systematically evaluates the efficacy and
      safety of micro-implant anchorage in the treatment of Angle class II
      malocclusion. METHODS: A systematic search was performed by retrieving on English
      databases (PubMed, Embase, Web of Science, and the Cochrane Library) and Chinese 
      databases (CNKI, Wanfang, Weipu [VIP], CBM). Besides, manually search for Google 
      and Baidu academic of micro-implant anchorage in the treatment of Angle class II 
      malocclusion in randomized controlled clinical research. The retrieval time limit
      was from the establishment of the database to September 2020. Two researchers
      independently extracted and evaluated the quality of the data in the included
      study. A meta-analysis was performed using RevMan5.3 software. RESULTS: In this
      study, the efficacy and safety of micro-implant anchorage against Angle class II 
      malocclusion were evaluated by SNA, BNA, ANB, NLA degrees , Adverse reaction.
      CONCLUSIONS: This study will provide reliable evidence-based evidence for the
      clinical application of micro-implant anchorage in the treatment of Angle class
      II malocclusion. ETHICS AND DISSEMINATION: Private information from individuals
      will not be published. This systematic review also does not involve endangering
      participant rights. Ethical approval was not required. The results may be
      published in a peer-reviewed journal or disseminated at relevant conferences.OSF 
      Registration number: DOI 10.17605/OSF.IO/UPBR8.
FAU - Wang, Kaiting
AU  - Wang K
AUID- ORCID: 0000-0002-4443-2644
AD  - Department of Medicine, Henan Medical College.
FAU - Fan, Hongliang
AU  - Fan H
AD  - Department of Medicine, Henan Medical College.
FAU - Yang, Hongmei
AU  - Yang H
AD  - Department of Medicine, Henan Medical College.
FAU - Li, Jianbin
AU  - Li J
AD  - Henan Borui Dental Clinic.
FAU - Xie, Weihong
AU  - Xie W
AD  - Department of Stomatolagy, The First Affiliated Hospital of Zhengzhou University,
      Zhengzhou, Henan Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Dental Implants)
SB  - IM
MH  - *Dental Implants/adverse effects
MH  - Humans
MH  - Malocclusion, Angle Class II/*therapy
MH  - Orthodontic Anchorage Procedures/adverse effects/*methods
MH  - Orthodontics, Corrective/adverse effects/*methods
PMC - PMC7738121
EDAT- 2020/12/18 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1097/MD.0000000000023221 [doi]
AID - 00005792-202012110-00022 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23221. doi:
      10.1097/MD.0000000000023221.


PMID- 33327236
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Efficacy and safety of Xuefu Zhuyu decoction combined with Western medicine for
      angina pectoris in coronary heart disease: A protocol for systematic review and
      meta-analysis.
PG  - e23195
LID - 10.1097/MD.0000000000023195 [doi]
AB  - BACKGROUND: Angina pectoris in coronary heart disease (CHD) is a common ischemic 
      heart disease clinically. During the onset, patients often have symptoms such as 
      chest discomfort or paroxysmal crushing pain in the posterior sternum, which
      seriously affects the quality of life of patients, and even can lead to
      myocardial infarction and endanger the lives of patients. Clinical studies have
      shown that the compound Chinese prescription Xuefu Zhuyu decoction combined with 
      western medicine has a certain therapeutic effect on angina pectoris in CHD, but 
      lack of evidence of evidence-based medicine. The purpose of this study is to
      evaluate the efficacy and safety of Xuefu Zhuyu decoction combined with western
      medicine in the treatment of angina pectoris in CHD. METHODS: Use computer to
      retrieve English databases (PubMed, Embase, Web of Science, the Cochrane Library)
      and Chinese databases (CNKI, Wan Fang, VIP, Chinese biomedical database), from
      the establishment of database to October 2020, for randomized controlled trials
      (RCTs) of Xuefu Zhuyu decoction combined with Western medicine for angina
      pectoris in CHD. Two investigators independently conducted data extraction and
      assessed the literature quality of the included studies. The Revman5.3 software
      was used for meta-analysis of the included literatures. RESULTS: The efficacy and
      safety of Xuefu Zhuyu decoction combined with western medicine in the treatment
      of angina pectoris in CHD were evaluated by total effective rate, angina pectoris
      pain score, TCM syndrome score, electrocardiogram effect, hemorheology index
      (including whole blood viscosity, plasma viscosity, hematocrit, and fibrinogen), 
      and the incidence of adverse reactions. CONCLUSION: This study will provide
      reliable evidence-based evidence for the clinical application of Xuefu Zhuyu
      decoction combined with western medicine in the treatment of angina pectoris in
      CHD. ETHICS AND DISSEMINATION: Private information from individuals will not be
      published. This systematic review also does not involve endangering participant
      rights. Ethical approval was not required. The results may be published in a
      peer-reviewed journal or disseminated at relevant conferences. OSF REGISTRATION
      NUMBER: DOI 10.17605 / OSF.IO / GFEQ7.
FAU - Wang, Duode
AU  - Wang D
AD  - Wuwei Hospital of Traditional Chinese Medicine, Wuwei, Gansu Province, China.
FAU - Wang, Ping
AU  - Wang P
AUID- ORCID: 0000-0003-1192-2353
FAU - Zhang, Rong
AU  - Zhang R
FAU - Xi, Xiaoping
AU  - Xi X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Prescription Drugs)
RN  - 0 (Xue-Fu-Zhu-Yu decoction)
SB  - IM
MH  - Angina Pectoris/*drug therapy/etiology
MH  - Case-Control Studies
MH  - Coronary Disease/complications/diagnosis/epidemiology
MH  - Drug Therapy, Combination/methods
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Prescription Drugs/*therapeutic use
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7738072
EDAT- 2020/12/18 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1097/MD.0000000000023195 [doi]
AID - 00005792-202012110-00017 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23195. doi:
      10.1097/MD.0000000000023195.


PMID- 33327233
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 50
DP  - 2020 Dec 11
TI  - Barriers and facilitators to exercise in hemodialysis patients: A protocol for
      systematic review.
PG  - e23129
LID - 10.1097/MD.0000000000023129 [doi]
AB  - BACKGROUND: Exercise training has a lot of potential benefits for hemodialysis
      patients. And some guidelines emphasize the importance of exercise for
      maintenance hemodialysis. However, there are many barriers to encourage
      hemodialysis patients to increase their level of physical activity. A broader
      understanding of the specific barriers is needed. METHODS: MEDLINE, EMBASE, Web
      of Science, CINAHL, PsycINFO, PubMed, CBM, CNKI, and WangFang will be searched
      electronically. The Reference lists of included studies will be retrieved
      manually. If the study is designed with qualitative or mixed methods and directly
      explores the factors related to the exercise of dialysis patients, the study will
      be selected. The Critical Appraisal Skills Programme Qualitative Checklist will
      be applied for the study appraisal. The study search, selection and evaluation of
      the study will be conducted by 2 independent reviewers. Thematic synthesis will
      be used for synthesizing the findings of the primary studies. RESULTS: This study
      will provide a high-quality synthesis to examine the barriers and facilitators
      affecting exercise in hemodialysis patients from the perspective of patients,
      caregivers, and health care providers. CONCLUSION: This systematic review will
      contribute to the in-depth understanding of barriers and facilitators affecting
      exercise in hemodialysis patients, and improve the prognosis of this population. 
      ETHIC AND DISSEMINATION: The content of this article does not involve moral
      approval or ethical review because no individual data will be collected. PROSPERO
      REGISTRATION: CRD42020200278.
      (https://www.crd.york.ac.uk/prospero/#recordDetails).
FAU - Li, Tianzi
AU  - Li T
AUID- ORCID: 0000-0002-8643-7240
AD  - Health Science Center, Xi'an Jiaotong University.
FAU - Lv, Aili
AU  - Lv A
AD  - Health Science Center, Xi'an Jiaotong University.
FAU - Xu, Na
AU  - Xu N
AD  - Health Science Center, Xi'an Jiaotong University.
FAU - Huang, Mei
AU  - Huang M
AD  - The Fourth Military Medical University, Xi'an, Shaan Xi, China.
FAU - Su, Yan
AU  - Su Y
AD  - Health Science Center, Xi'an Jiaotong University.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Caregivers/education
MH  - Exercise/*physiology
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Personnel/education
MH  - Humans
MH  - Prognosis
MH  - Qualitative Research
MH  - Renal Dialysis/*adverse effects/*nursing
PMC - PMC7738018
EDAT- 2020/12/18 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/17 01:01
PHST- 2020/12/17 01:01 [entrez]
PHST- 2020/12/18 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1097/MD.0000000000023129 [doi]
AID - 00005792-202012110-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 11;99(50):e23129. doi:
      10.1097/MD.0000000000023129.


PMID- 33326998
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 12
DP  - 2020 Dec 1
TI  - Developing an International Registry for Uterus Transplantation (IRUTx): Promises
      and Challenges.
PG  - 2643-2649
LID - 10.1093/humrep/deaa207 [doi]
AB  - Uterus Transplantation (UTx) is an experimental vascular composite allograft
      designed to provide women with absolute uterine factor infertility with the
      opportunity to gestate and give birth to their future offspring. The number of
      UTx procedures performed worldwide now stands at >/=70 and as the number of cases
      performed increases so too does the volume of potential data that may be gathered
      to inform the development, practice and regulation of UTx. Given the value of
      this data, and the challenges associated with keeping track of cases and outcomes
      where data remains unpublished and/or scattered, scientists and academics
      conducting research into UTx have increasingly called for the swift creation,
      implementation and management of an international registry for Uterus
      Transplantation (IRUTx). This article explores and provides practical guidance
      regarding the potential benefits the IRUTx may provide to stakeholders, as well
      as the legal and ethical challenges that its creation may pose in terms of
      dataset design, consent, privacy, researcher compliance and governance.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Hammond-Browning, Natasha
AU  - Hammond-Browning N
AD  - School of Law and Politics, Cardiff University, Cardiff, UK.
FAU - Williams, Nicola Jane
AU  - Williams NJ
AD  - Department of Politics, Philosophy and Religion, Lancaster University, Lancaster,
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Female
MH  - Humans
MH  - *Infertility, Female
MH  - *Organ Transplantation
MH  - Registries
MH  - Transplantation, Homologous
MH  - Uterus
OTO - NOTNLM
OT  - *Uterus Transplantation
OT  - *data protection and privacy
OT  - *informed consent
OT  - *registry design and governance
OT  - *reproductive transplantation
OT  - *research ethics
EDAT- 2020/12/17 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/12/16 20:09
PHST- 2020/05/13 00:00 [received]
PHST- 2020/07/15 00:00 [revised]
PHST- 2020/12/16 20:09 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - 5906166 [pii]
AID - 10.1093/humrep/deaa207 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Dec 1;35(12):2643-2649. doi: 10.1093/humrep/deaa207.


PMID- 33326430
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Emotions and decisions in the real world: What can we learn from quasi-field
      experiments?
PG  - e0243044
LID - 10.1371/journal.pone.0243044 [doi]
AB  - Researchers in the social sciences have increasingly studied how emotions
      influence decision-making. We argue that research on emotions arising naturally
      in real-world environments is critical for the generalizability of insights in
      this domain, and therefore to the development of this field. Given this, we argue
      for the increased use of the "quasi-field experiment" methodology, in which
      participants make decisions or complete tasks after as-if-random real-world
      events determine their emotional state. We begin by providing the first critical 
      review of this emerging literature, which shows that real-world events provide
      emotional shocks that are at least as strong as what can ethically be induced
      under laboratory conditions. However, we also find that most previous quasi-field
      experiment studies use statistical techniques that may result in biased
      estimates. We propose a more statistically-robust approach, and illustrate it
      using an experiment on negative emotion and risk-taking, in which sports fans
      completed risk-elicitation tasks immediately after watching a series of NFL
      games. Overall, we argue that when appropriate statistical methods are used, the 
      quasi-field experiment methodology represents a powerful approach for studying
      the impact of emotion on decision-making.
FAU - Bhanot, Syon P
AU  - Bhanot SP
AUID- ORCID: 0000-0003-2765-0532
AD  - Department of Economics, Swarthmore College, Swarthmore, PA, United States of
      America.
FAU - Chang, Daphne
AU  - Chang D
AD  - Heinz College of Information Systems and Public Policy, Carnegie Mellon
      University, Pittsburgh, PA, United States of America.
FAU - Lee Cunningham, Julia
AU  - Lee Cunningham J
AD  - Management and Organization Area, Ross School of Business, University of
      Michigan, Ann Arbor, MI, United States of America.
FAU - Ranson, Matthew
AU  - Ranson M
AD  - Athenahealth, Watertown, MA, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201216
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Algorithms
MH  - *Decision Making
MH  - *Emotions
MH  - Football
MH  - Humans
MH  - Models, Statistical
MH  - Social Sciences
PMC - PMC7744061
COIS- Matthew Ranson is an employee of a commercial company, athenahealth (and formerly
      Abt Associates). However, neither athenahealth or Abt Associates provided salary 
      support for Matthew related to this work (the bulk of Matthew's work on the
      project predates his commercial affiliations), nor did the organizations play any
      role in the study design, data collection and analysis, decision to publish, or
      preparation of the manuscript. This commercial affiliation for Matthew Ranson
      also does not alter our adherence to PLOS ONE policies on sharing data and
      materials. None of the additional authors (Syon Bhanot, Daphne Change, or Julia
      Lee) have competing interests that relate to this work, financial or otherwise.
      Similarly, none of the study authors have outside affiliations or interests that 
      influenced any aspect of study design, data collection and analysis, decision to 
      publish, or preparation of the manuscript.
EDAT- 2020/12/17 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/12/16 17:14
PHST- 2019/08/13 00:00 [received]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/12/16 17:14 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1371/journal.pone.0243044 [doi]
AID - PONE-D-19-22858 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 16;15(12):e0243044. doi: 10.1371/journal.pone.0243044.
      eCollection 2020.


PMID- 33326397
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1944-0405 (Electronic)
IS  - 1944-0391 (Linking)
VI  - 46
IP  - Suppl 1
DP  - 2020 Dec 14
TI  - Chilean Medical and Midwifery Faculty's Views on Conscientious Objection for
      Abortion Services.
PG  - 25-34
LID - 10.1363/46e0620 [doi]
AB  - CONTEXT: In 2017, Chile reformed its abortion law to allow the procedure under
      limited circumstances. Exploring the views of Chilean medical and midwifery
      faculty regarding abortion and the use of conscientious objection (CO) at the
      time of reform can inform how these topics are being taught to the country's
      future health care providers. METHODS: Between March and September 2017, 30
      medical and midwifery school faculty from universities in Santiago, Chile were
      interviewed; 20 of the faculty taught at secular universities and 10 taught at
      religiously affiliated universities. Faculty perspectives on CO and abortion, the
      scope of CO, and teaching about CO and abortion were analyzed using a grounded
      theory approach. RESULTS: Most faculty at secular and religiously affiliated
      universities supported the rights of clinicians to refuse to provide abortion
      care. Secular-university faculty generally thought that CO should be limited to
      specific providers and rejected the idea of institutional CO, whereas
      religious-university faculty strongly supported the use of CO by a broad range of
      providers and at the institutional level. Only secular-university faculty
      endorsed the idea that CO should be regulated so that it does not hinder access
      to abortion care. CONCLUSIONS: The broader support for CO in abortion among
      religious-university faculty raises concerns about whether students are being
      taught their ethical responsibility to put the needs of their patients above
      their own. Future research should monitor whether Chile's CO regulations and
      practices are guaranteeing people's access to abortion care.
FAU - Casas, Lidia
AU  - Casas L
AD  - Director, Centro de Derechos Humanos, Facultad de Derecho, Universidad Diego
      Portales, Santiago, Chile.
FAU - Freedman, Lori
AU  - Freedman L
AD  - Associate professor, Advancing New Standards in Reproductive Health (ANSIRH),
      Bixby Center for Global Reproductive Health, University of California, San
      Francisco, Oakland, CA, USA.
FAU - Ramm, Alejandra
AU  - Ramm A
AD  - Associate professor, Escuela de Sociologia, Universidad de Valparaiso,
      Valparaiso, Chile.
FAU - Correa, Sara
AU  - Correa S
AD  - Instructor and secretary of studies, Instituto de Investigacion en Ciencias
      Sociales, Universidad Diego Portales, Santiago, Chile.
FAU - Baba, C Finley
AU  - Baba CF
AD  - Project manager, Advancing New Standards in Reproductive Health (ANSIRH), Bixby
      Center for Global Reproductive Health, University of California, San Francisco,
      Oakland, CA, USA.
FAU - Biggs, M Antonia
AU  - Biggs MA
AD  - Associate professor, Advancing New Standards in Reproductive Health (ANSIRH),
      Bixby Center for Global Reproductive Health, University of California, San
      Francisco, Oakland, CA, USA, antonia.biggs@ucsf.edu.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - United States
TA  - Int Perspect Sex Reprod Health
JT  - International perspectives on sexual and reproductive health
JID - 101504990
SB  - IM
MH  - *Abortion, Induced
MH  - Attitude of Health Personnel
MH  - Chile
MH  - Faculty
MH  - Female
MH  - Humans
MH  - *Midwifery
MH  - Pregnancy
EDAT- 2020/12/17 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/12/16 17:13
PHST- 2020/12/16 17:13 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.1363/46e0620 [doi]
PST - epublish
SO  - Int Perspect Sex Reprod Health. 2020 Dec 14;46(Suppl 1):25-34. doi:
      10.1363/46e0620.


PMID- 33326062
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210914
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - Suppl 1
DP  - 2020 Dec
TI  - Invisible epidemics: ethics and asymptomatic infection.
PG  - 1-16
LID - 10.1007/s40592-020-00123-z [doi]
AB  - Interactions between microbes and human hosts can lead to a wide variety of
      possible outcomes including benefits to the host, asymptomatic infection, disease
      (which can be more or less severe), and/or death. Whether or not they themselves 
      eventually develop disease, asymptomatic carriers can often transmit
      disease-causing pathogens to others. This phenomenon has a range of ethical
      implications for clinical medicine, public health, and infectious disease
      research. The implications of asymptomatic infection are especially significant
      in situations where, and/or to the extent that, the microbe in question is
      transmissible, potentially harmful, and/or untreatable. This article reviews the 
      history and concept of asymptomatic infection, and relevant ethical issues
      associated with this phenomenon. It illustrates the role and ethical significance
      of asymptomatic infection in outbreaks, epidemics, and pandemics-including recent
      crises involving drug resistance, Zika, and Covid19. Serving as the Introduction 
      to this Special Issue of Monash Bioethics Review, it also provides brief
      summaries of the other articles comprising this collection.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AUID- ORCID: http://orcid.org/0000-0001-5940-602X
AD  - The Ethox Centre & Wellcome Centre for Ethics and the Humanities, Nuffield
      Department of Population Health, University of Oxford, Oxford, UK.
      Zeb.Jamrozik@monash.edu.
AD  - Monash Bioethics Centre, Monash University, Clayton, VIC, Australia.
      Zeb.Jamrozik@monash.edu.
AD  - Royal Melbourne Hospital Department of Medicine, University of Melbourne,
      Parkville, VIC, Australia. Zeb.Jamrozik@monash.edu.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AD  - Monash Bioethics Centre, Monash University, Clayton, VIC, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - [216355/Z/19/Z]/WT_/Wellcome Trust/United Kingdom
GR  - [203132/Z/16/Z]/WT_/Wellcome Trust/United Kingdom
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20201216
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - *Asymptomatic Infections
MH  - *Bioethical Issues
MH  - Epidemics/*ethics/history
MH  - Ethics, Clinical
MH  - Ethics, Research
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Public Health/ethics
PMC - PMC7738616
OTO - NOTNLM
OT  - Antimicrobial resistance
OT  - Asymptomatic infection
OT  - Carrier
OT  - Isolation
OT  - Microbial determinism
OT  - Quarantine
EDAT- 2020/12/17 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/12/16 12:13
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/12/16 12:13 [entrez]
AID - 10.1007/s40592-020-00123-z [doi]
AID - 10.1007/s40592-020-00123-z [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(Suppl 1):1-16. doi: 10.1007/s40592-020-00123-z.
      Epub 2020 Dec 16.


PMID- 33325840
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20220413
IS  - 2063-5303 (Electronic)
IS  - 2062-5871 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Dec 16
TI  - Prerequisites for stakeholder framework: Consumer advocacy and health protection 
      in the digital industry. *.
PG  - 898-902
LID - 10.1556/2006.2020.00095 [doi]
AB  - The World Health Organization (WHO) included gaming disorders in International
      Classification of Disease-11th (ICD-11) on May 25, 2019. Since then, some
      academics and the gaming industry have continued to argue over the health
      system's response to online addictive behaviors. Under these circumstances, a
      framework involving groups representing various interests is needed to derive a
      reasonable solution to the dispute over the inclusion of gaming disorders in
      ICD-11. For this framework to work effectively, it is necessary to agree on
      consistent and advanced research findings that harms related to the excessive use
      of digital devices or content continue to occur empirically all over the world
      and that addictive use constitutes a primary addictive disorder. The problematic 
      risk taking involving emerging technologies may include not only health risks
      from addictive use, but also more general harms associated with digital ethics
      and norms such as privacy and transparent money transactions. An understanding of
      a public health model of addiction is required to reduce harms associated with
      online addictive behavior that exist behind risk taking. Such harms are also
      mediated by excessive use, excessive money spending, and exposure to addictive
      content such as violence and pornography. Major stakeholders and their roles can 
      be derived more effectively based on these conceptual models and parameters of
      harms. In conclusion, the context of the proposed stakeholder framework should be
      further optimized on the basis of two principles: (1) advocating consumer rights 
      as a general and standard approach to digital products; and (2) protecting
      consumers' health from harms related to addictive behaviors.
FAU - Lee, Hae Kook
AU  - Lee HK
AUID- ORCID: 0000-0002-4985-001X
AD  - Department of Psychiatry, Uijeongbu St. Mary's Hospital, College of Medicine, The
      Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, South
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - Hungary
TA  - J Behav Addict
JT  - Journal of behavioral addictions
JID - 101602037
SB  - IM
MH  - *Behavior, Addictive/prevention & control
MH  - Consumer Advocacy
MH  - *Disruptive, Impulse Control, and Conduct Disorders
MH  - Humans
MH  - International Classification of Diseases
MH  - *Video Games
PMC - PMC8969714
OTO - NOTNLM
OT  - advocacy
OT  - consumer
OT  - health right
OT  - public health model
EDAT- 2020/12/17 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/12/16 12:10
PHST- 2020/08/23 00:00 [received]
PHST- 2020/10/25 00:00 [revised]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/12/16 12:10 [entrez]
AID - 10.1556/2006.2020.00095 [doi]
PST - epublish
SO  - J Behav Addict. 2020 Dec 16;9(4):898-902. doi: 10.1556/2006.2020.00095.


PMID- 33325829
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Dec 16
TI  - Paradigm Shift Toward Digital Neuropsychology and High-Dimensional
      Neuropsychological Assessments: Review.
PG  - e23777
LID - 10.2196/23777 [doi]
AB  - Neuropsychologists in the digital age have increasing access to emerging
      technologies. The National Institutes of Health (NIH) initiatives for behavioral 
      and social sciences have emphasized these developing scientific and technological
      potentials (eg, novel sensors) for augmented characterization of neurocognitive, 
      behavioral, affective, and social processes. Perhaps these innovative
      technologies will lead to a paradigm shift from disintegrated and data-poor
      behavioral science to cohesive and data-rich science that permits improved
      translation from bench to bedside. The 4 main advances influencing the scientific
      priorities of a recent NIH Office of Behavioral and Social Sciences Research
      strategic plan include the following: integration of neuroscience into behavioral
      and social sciences, transformational advances in measurement science, digital
      intervention platforms, and large-scale population cohorts and data integration. 
      This paper reviews these opportunities for novel brain-behavior
      characterizations. Emphasis is placed on the increasing concern of
      neuropsychology with these topics and the need for development in these areas to 
      maintain relevance as a scientific discipline and advance scientific
      developments. Furthermore, the effects of such advancements necessitate
      discussion and modification of training as well as ethical and legal mandates for
      neuropsychological research and praxes.
CI  - (c)Thomas Parsons, Tyler Duffield. Originally published in the Journal of Medical
      Internet Research (http://www.jmir.org), 16.12.2020.
FAU - Parsons, Thomas
AU  - Parsons T
AUID- ORCID: 0000-0003-0331-5019
AD  - Computational Neuropsychology & Simulation, University of North Texas, Denton,
      TX, United States.
FAU - Duffield, Tyler
AU  - Duffield T
AUID- ORCID: 0000-0003-3101-7027
AD  - Oregon Health & Science University, Portland, OR, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201216
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Big Data
MH  - Humans
MH  - Machine Learning/*standards
MH  - Neuropsychology/*methods
PMC - PMC7773516
OTO - NOTNLM
OT  - *big data
OT  - *informatics
OT  - *machine learning
OT  - *mobile phone
OT  - *neuropsychology
OT  - *smartphone
OT  - *technology
OT  - *virtual reality
EDAT- 2020/12/17 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/12/16 12:10
PHST- 2020/08/22 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/10/26 00:00 [revised]
PHST- 2020/12/16 12:10 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - v22i12e23777 [pii]
AID - 10.2196/23777 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Dec 16;22(12):e23777. doi: 10.2196/23777.


PMID- 33325373
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210310
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 16
TI  - Remote Assessment of Disease and Relapse in Epilepsy: Protocol for a Multicenter 
      Prospective Cohort Study.
PG  - e21840
LID - 10.2196/21840 [doi]
AB  - BACKGROUND: In recent years, a growing body of literature has highlighted the
      role of wearable and mobile remote measurement technology (RMT) applied to
      seizure detection in hospital settings, whereas more limited evidence has been
      produced in the community setting. In clinical practice, seizure assessment
      typically relies on self-report, which is known to be highly unreliable.
      Moreover, most people with epilepsy self-identify factors that lead to increased 
      seizure likelihood, including mood, behavior, sleep pattern, and cognitive
      alterations, all of which are amenable to measurement via multiparametric RMT.
      OBJECTIVE: The primary aim of this multicenter prospective cohort study is to
      assess the usability, feasibility, and acceptability of RMT in the community
      setting. In addition, this study aims to determine whether multiparametric RMT
      collected in populations with epilepsy can prospectively estimate variations in
      seizure occurrence and other outcomes, including seizure frequency, quality of
      life, and comorbidities. METHODS: People with a diagnosis of pharmacoresistant
      epilepsy will be recruited in London, United Kingdom, and Freiburg, Germany.
      Participants will be asked to wear a wrist-worn device and download ad hoc apps
      developed on their smartphones. The apps will be used to collect data related to 
      sleep, physical activity, stress, mood, social interaction, speech patterns, and 
      cognitive function, both passively from existing smartphone sensors (passive
      remote measurement technology [pRMT]) and actively via questionnaires, tasks, and
      assessments (active remote measurement technology [aRMT]). Data will be collected
      continuously for 6 months and streamed to the Remote Assessment of Disease and
      Relapse-base (RADAR-base) server. RESULTS: The RADAR Central Nervous System
      project received funding in 2015 from the Innovative Medicines Initiative 2 Joint
      Undertaking under Grant Agreement No. 115902. This Joint Undertaking receives
      support from the European Union's Horizon 2020 research and innovation program
      and European Federation of Pharmaceutical Industries and Associations. Ethical
      approval was obtained in London from the Bromley Research Ethics Committee
      (research ethics committee reference: 19/LO/1884) in January 2020. The first
      participant was enrolled on September 30, 2020. Data will be collected until
      September 30, 2021. The results are expected to be published at the beginning of 
      2022. CONCLUSIONS: RADAR Epilepsy aims at developing a framework of continuous
      data collection intended to identify ictal and preictal states through the use of
      aRMT and pRMT in the real-life environment. The study was specifically designed
      to evaluate the clinical usefulness of the data collected via new technologies
      and compliance, technology acceptability, and usability for patients. These are
      key aspects to successful adoption and implementation of RMT as a new way to
      measure and manage long-term disorders. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): PRR1-10.2196/21840.
CI  - (c)Elisa Bruno, Andrea Biondi, Sebastian Bottcher, Gergely Vertes, Richard
      Dobson, Amos Folarin, Yatharth Ranjan, Zulqarnain Rashid, Nikolay Manyakov, Aki
      Rintala, Inez Myin-Germeys, Sara Simblett, Til Wykes, Amanda Stoneman, Ann
      Little, Sarah Thorpe, Simon Lees, Andreas Schulze-Bonhage, Mark Richardson.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 16.12.2020.
FAU - Bruno, Elisa
AU  - Bruno E
AUID- ORCID: https://orcid.org/0000-0001-8166-1190
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Biondi, Andrea
AU  - Biondi A
AUID- ORCID: https://orcid.org/0000-0003-1072-665X
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Bottcher, Sebastian
AU  - Bottcher S
AUID- ORCID: https://orcid.org/0000-0002-3407-8290
AD  - Epilepsy Center, Department of Neurosurgery, Medical Center, University of
      Freiburg, Freiburg, Germany.
FAU - Vertes, Gergely
AU  - Vertes G
AUID- ORCID: https://orcid.org/0000-0002-8602-9626
AD  - Epilepsy Seizure Detection - Neurology UCB Pharma, Brussels, Belgium.
FAU - Dobson, Richard
AU  - Dobson R
AUID- ORCID: https://orcid.org/0000-0003-4224-9245
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Folarin, Amos
AU  - Folarin A
AUID- ORCID: https://orcid.org/0000-0002-0333-1927
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Ranjan, Yatharth
AU  - Ranjan Y
AUID- ORCID: https://orcid.org/0000-0003-3079-3120
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Rashid, Zulqarnain
AU  - Rashid Z
AUID- ORCID: https://orcid.org/0000-0002-6843-9920
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Manyakov, Nikolay
AU  - Manyakov N
AUID- ORCID: https://orcid.org/0000-0001-9037-1400
AD  - Feasibility Advanced Analytics, Clinical Insights and Experience, Janssen
      Research and Development, Beerse, Belgium.
FAU - Rintala, Aki
AU  - Rintala A
AUID- ORCID: https://orcid.org/0000-0002-0066-4697
AD  - Department of Neurosciences, Center for Contextual Psychiatry, KU Leuven, Leuven,
      Belgium.
AD  - Faculty of Social Services and Health Care, LAB University of Applied Sciences,
      Lahti, Finland.
FAU - Myin-Germeys, Inez
AU  - Myin-Germeys I
AUID- ORCID: https://orcid.org/0000-0002-3731-4930
AD  - Department of Neurosciences, Center for Contextual Psychiatry, KU Leuven, Leuven,
      Belgium.
FAU - Simblett, Sara
AU  - Simblett S
AUID- ORCID: https://orcid.org/0000-0002-8075-8238
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Wykes, Til
AU  - Wykes T
AUID- ORCID: https://orcid.org/0000-0002-5881-8003
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
FAU - Stoneman, Amanda
AU  - Stoneman A
AUID- ORCID: https://orcid.org/0000-0002-8003-6067
AD  - The RADAR-CNS patient advisory board, King's College London, UK, London, United
      Kingdom.
FAU - Little, Ann
AU  - Little A
AUID- ORCID: https://orcid.org/0000-0002-9587-8507
AD  - The RADAR-CNS patient advisory board, King's College London, UK, London, United
      Kingdom.
FAU - Thorpe, Sarah
AU  - Thorpe S
AUID- ORCID: https://orcid.org/0000-0001-8973-3777
AD  - The RADAR-CNS patient advisory board, King's College London, UK, London, United
      Kingdom.
FAU - Lees, Simon
AU  - Lees S
AUID- ORCID: https://orcid.org/0000-0001-5140-7394
AD  - The RADAR-CNS patient advisory board, King's College London, UK, London, United
      Kingdom.
FAU - Schulze-Bonhage, Andreas
AU  - Schulze-Bonhage A
AUID- ORCID: https://orcid.org/0000-0003-2382-0506
AD  - Epilepsy Center, Department of Neurosurgery, Medical Center, University of
      Freiburg, Freiburg, Germany.
FAU - Richardson, Mark
AU  - Richardson M
AUID- ORCID: https://orcid.org/0000-0001-8925-3140
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College London,
      London, United Kingdom.
LA  - eng
GR  - 171/ALZS_/Alzheimer's Society/United Kingdom
GR  - MC_PC_17214/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20201216
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7773514
OTO - NOTNLM
OT  - epilepsy
OT  - medical device
OT  - mobile phone
OT  - seizures
OT  - telemedicine
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 08:44
PHST- 2020/06/30 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/12/16 08:44 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - v9i12e21840 [pii]
AID - 10.2196/21840 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 16;9(12):e21840. doi: 10.2196/21840.


PMID- 33324933
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2524-3489 (Electronic)
IS  - 2524-3489 (Linking)
VI  - 2
DP  - 2020
TI  - Disease modifying treatment trials in Parkinson's disease: how to balance
      expectations and interests of patients, physicians and industry partners?
PG  - 31
LID - 10.1186/s42466-020-00076-y [doi]
AB  - BACKGROUND: The advent of therapeutic strategies designed to modify the disease
      course in Parkinson's disease has raised great expectations in the currently
      conducted clinical trials. However, we see ethical challenges in the cooperation 
      of industry and clinical partners, specifically evident in the way recruitment is
      performed.We here discuss the different positions and challenges of all involved 
      to set the stage for a study and recruitment culture taking into account the
      expectations of all: (i) patients and their caregivers, ready to take the
      considerable burden of clinical trials in hope for the development of
      disease-modifying treatments; (ii) physicians and study nurses, obligated to the 
      patients' well-being and benefit who accompany and supervise patients closely as 
      basis for the performance of elaborate clinical trials (iii) industrial partners,
      investing years of efforts and finances to develop new treatments. CONCLUSIONS:
      We conclude that the current competitive race for enrollment in clinical studies 
      in PD is challenging the primary goal to ensure patients' benefit and formulate
      requests to the industrial partners to encounter these concerns.
CI  - (c) The Author(s) 2020.
FAU - Berg, D
AU  - Berg D
AD  - Department of Neurology, Christian-Albrecht University of Kiel,
      Arnold-Heller-Strasse 3, 24105 Kiel, Germany.grid.9764.c0000 0001 2153 9986
FAU - Eggert, K
AU  - Eggert K
AD  - Department of Neurology, Philipps-University of Marburg, Marburg,
      Germany.grid.10253.350000 0004 1936 9756
FAU - Haslinger, B
AU  - Haslinger B
AD  - Department of Neurology, TU-Muenchen, Munich, Germany.
FAU - Kassubek, J
AU  - Kassubek J
AD  - Department of Neurology, University of Ulm, RKU, Ulm, Germany.grid.6582.90000
      0004 1936 9748
FAU - Mollenhauer, B
AU  - Mollenhauer B
AD  - Paracelsus Klinik, Kassel, Germany.
FAU - Reetz, K
AU  - Reetz K
AD  - Department of Neurology, RWTH Aachen University, Aachen, Germany.grid.1957.a0000 
      0001 0728 696X
FAU - Rogge, A
AU  - Rogge A
AD  - Institute for Experimental Medicine, Medical Ethics, Christian-Albrecht
      University of Kiel, Kiel, Germany.grid.9764.c0000 0001 2153 9986
FAU - Schaeffer, E
AU  - Schaeffer E
AD  - Department of Neurology, Christian-Albrecht University of Kiel,
      Arnold-Heller-Strasse 3, 24105 Kiel, Germany.grid.9764.c0000 0001 2153 9986
FAU - Tonges, L
AU  - Tonges L
AD  - Department of Neurology, St. Josef-Hospital, Ruhr University, Bochum,
      Germany.grid.5570.70000 0004 0490 981X
FAU - Zeuner, K E
AU  - Zeuner KE
AD  - Department of Neurology, Christian-Albrecht University of Kiel,
      Arnold-Heller-Strasse 3, 24105 Kiel, Germany.grid.9764.c0000 0001 2153 9986
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - England
TA  - Neurol Res Pract
JT  - Neurological research and practice
JID - 101767802
PMC - PMC7650104
OTO - NOTNLM
OT  - Clinical trials
OT  - Disease modifying treatments
OT  - Ethical challenges
OT  - Parkinson's Disease
COIS- Competing interestsD. Berg reports grants from Janssen Pharmaceutica, grants from
      the Damp foundation, grants from the German Parkinson's Disease Association
      (dPV), grants from BMWi, grants from BMBF, grants from the ParkinsonFonds
      Deutschland GmbH, grants and speaker's honoraria from and consultancy honoraria
      of UCB Pharma GmbH, grants and speaker's honoraria from TEVA Pharma GmbH, grants 
      from and consultancies for Novartis Pharma GmbH, grants and speaker's honoraria
      from and consultancy honoraria of Lundbeck, speaker's honoraria from and
      consultancy honoraria for BIAL, speaker's honoraria from and consultancy
      honoraria for Biogen, honoraria from Bayer and Zambon outside the submitted work.
      K. Eggert receives funding from the German Parkinson Society, Abbvie, Acorda,
      Adamas, Addex, Apopharma,Benevolent, Bial, Biogen, Biotie, Impax, Kyowa,
      Mundipharma, Novartis, Orion, Pfizer, Roche. She receives advisory board fees
      from Bial, Grunenthal, Mundipharma and Zambon. She receives speaker fees from
      Bial, Desitin, Grunenthal, Mundipharma, UCB and Zambon. P. Haslinger reports
      grants from the Deutsche Forschungsgemeinschaft, he has served on a scientific
      advisory board for Merz and Bayer, has received speaker honoraria from Allergan
      and Ipsen and has received fees for clinical trials from Addex, Allergan,
      Apopharma, Bial, Biogen, Impax, Intec, Ipsen, Merz, Novartis, Pfizer, Revance and
      Sunovion. J. Kassubek has received personal consulting fees as an advisory board 
      member and honoraria as a speaker from AbbVie, BIAL, Biogen, Boehringer
      Ingelheim, Desitin, Medtronic, NeuroDerm / Mitsubishi Tanabe Pharma, Novartis,
      Sunovion, TEVA Pharmaceuticals, UCB Pharma, and Zambon. He serves as a Section
      Chief Editor of Frontiers in Neurology. B. Mollenhauer has received honoraria for
      consultancy from Roche, Biogen, UCB and Sun Pharma Advanced research Company. She
      is member of the executive steering committee of the Parkinson Progression Marker
      Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox 
      Foundation for Parkinson's Research and has received research funding from the
      Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds
      Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for
      Parkinson's Research. K. Reetz has received grants from the German Federal
      Ministry of Education and Research (BMBF 01GQ1402, 01DN18022), the German
      Research Foundation (IRTG 2150, ZUK32/1), Alzheimer Forschung Initiative e.V.
      (AFI 13812, NL-18002CB) and honoraria for presentations from Lilly and clinical
      trial grants from Pfizer, Merck, Minoryx, Biogen and Roche. A. Rogge has nothing 
      to declare. E. Schaeffer received intramural research funding from the University
      of Kiel and speaker's honoraria from Bayer Vital GmbH and Novartis, outside the
      submitted work. L. Tonges has received travel funding and/or speaker honoraria
      from Abbvie, Bayer, Bial, Desitin, GE, UCB, Zambon and consulted for Abbvie,
      Bayer, Bial, Desitin, UCB, Zambon in the last 3 years. K. E. Zeuner has received 
      research support from an intramural grant from the Christian Albrechts-University
      of Kiel, from the Benign Essential Blepharospasm Foundation and with an
      unrestricted grant from Ipsen. She has received lecture fees from Allergan, Merz,
      AbbVie and Bayer. She has served as a consultant and received fees from Merz and 
      Ipsen.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:39
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/12/16 05:39 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.1186/s42466-020-00076-y [doi]
AID - 76 [pii]
PST - epublish
SO  - Neurol Res Pract. 2020 Nov 2;2:31. doi: 10.1186/s42466-020-00076-y. eCollection
      2020.


PMID- 33324770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201217
IS  - 2433-3298 (Electronic)
IS  - 2433-328X (Linking)
VI  - 3
IP  - 1
DP  - 2020 Jan 15
TI  - Clinical Genetics in Japan: Efforts of Human Genetics Societies and Related
      Organizations.
PG  - 1-8
LID - 10.31662/jmaj.2019-0019 [doi]
AB  - The Japanese government finally started measures to promote the realization of
      genomic medicine that can promote the accumulation of individual genomic
      information for improving medical care in 2015. However, readiness in terms of
      social infrastructure (including legal, administrative, ethical, and educational 
      aspects in Japan) remains inadequate. Associations related to medical genetics
      have been making consistent efforts to realize genomic medicine by establishing
      guidelines, nurturing genetic professionals, providing support for constructing
      cross-disciplinary medical systems, enriching genetic education, etc., and it is 
      important that the Japanese government supports these initiatives.
CI  - Copyright (c) Japan Medical Association.
FAU - Fukushima, Yoshimitsu
AU  - Fukushima Y
AD  - Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto,
      Japan.
FAU - Takada, Fumio
AU  - Takada F
AD  - Department of Medical Genetics and Genomics, Kitasato University Graduate School 
      of Medical Sciences, Sagamihara, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190910
PL  - Japan
TA  - JMA J
JT  - JMA journal
JID - 101769797
PMC - PMC7733759
OTO - NOTNLM
OT  - Clinical Genetics
OT  - Genomic Medicine
OT  - Grassroot movements of academia
COIS- None
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:38
PHST- 2019/03/26 00:00 [received]
PHST- 2019/06/26 00:00 [accepted]
PHST- 2020/12/16 05:38 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.31662/jmaj.2019-0019 [doi]
PST - ppublish
SO  - JMA J. 2020 Jan 15;3(1):1-8. doi: 10.31662/jmaj.2019-0019. Epub 2019 Sep 10.


PMID- 33324767
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Students' preparedness for disasters in schools: a systematic review protocol.
PG  - e000913
LID - 10.1136/bmjpo-2020-000913 [doi]
AB  - INTRODUCTION: Children are one of the most vulnerable groups in disasters.
      Improving students' knowledge and skills to prepare for disasters can play a
      major role in children's health. School as a place to teach children can make a
      significant contribution to provide the necessary skills. This study aims to
      identify the effects, strengths and weaknesses of interventions in schools to
      prepare children for disasters. METHODS AND ANALYSIS: We use Preferred Reporting 
      Items for Systematic Reviews and Meta-Analyses guidelines to develop a protocol
      for this systematic review. The included studies will report on the results of
      interventions targeting 'schoolchildren' defined as individuals between 4 and
      under 18 years old studying in schools. Different electronic databases will be
      used for a comprehensive literature search, including MEDLINE, Web of Science,
      CINAHL, PsycINFO, Cochrane Register of Controlled Trials and EMBASE to identify
      the records that match the mentioned inclusion criteria published till December
      2020. The main search terms are 'disaster', 'preparedness', 'children' and
      'school'. Four types of data will be extracted from the qualified studies
      including study characteristics (study design, year of publication and
      geographical region where the study was conducted), participant characteristics
      (sample size, age and gender), intervention characteristics (aim of intervention,
      intervention facilitators and barriers) and intervention outcomes. The quality
      appraisal of the selected papers will be conducted using Cochrane Collaboration's
      Risk of Bias for quantitative studies and Critical Appraisal Skills Programme
      checklist for qualitative studies. We use a narrative synthesis for this
      systematic review. The narrative synthesis refers to an approach to systematic
      reviews which focuses mostly on applying words and texts to summarise and explain
      findings. ETHICS AND DISSEMINATION: This paper is a part of a Ph.D. thesis of
      Hamed Seddighi at University of Social welfare and Rehabilitation Sciences with
      ethics code IR.USWR.REC.1399.008 approved by the Ethics Committee of the
      above-mentioned university. PROSPERO REGISTRATION NUMBER: CRD42020146536.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Seddighi, Hamed
AU  - Seddighi H
AD  - Student Research Committee, University of Social Welfare and Rehabilitation
      Sciences, Tehran, Iran.
AD  - Department of Social Welfare, University of Social Welfare and Rehabilitation
      Sciences, Tehran, Iran.
FAU - Sajjadi, Homeira
AU  - Sajjadi H
AD  - Social Determinants of Health Research Center, University of Social Welfare and
      Rehabilitation Sciences, Tehran, Iran.
FAU - Yousefzadeh, Sepideh
AU  - Yousefzadeh S
AD  - University Campus Fryslan, University of Groningen, Leeuwarden, Friesland,
      Netherlands.
FAU - Lopez Lopez, Monica
AU  - Lopez Lopez M
AD  - Faculty of Behavioural and Social Sciences, University of Groningen, Groningen,
      Netherlands.
FAU - Vameghi, Meroe
AU  - Vameghi M
AD  - Social Welfare Management Research Center, University of Social Welfare and
      Rehabilitation Sciences, Tehran, Iran.
FAU - Rafiey, Hassan
AU  - Rafiey H
AD  - Department of Social Welfare, University of Social Welfare and Rehabilitation
      Sciences, Tehran, Iran.
AD  - Social Welfare Management Research Center, University of Social Welfare and
      Rehabilitation Sciences, Tehran, Iran.
FAU - Khankeh, Hamid Reza
AU  - Khankeh HR
AD  - Health in Emergency and Disaster Research Center, University of Social Welfare
      and Rehabilitation Sciences, Tehran, Iran.
FAU - Garzon Fonseca, Magdalena
AU  - Garzon Fonseca M
AUID- ORCID: 0000-0002-6984-9577
AD  - Department of Child & Family Welfare, Graduate School of Behavioral Sciences,
      University of Groningen, Groningen, Netherlands.
LA  - eng
PT  - Systematic Review
DEP - 20201204
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7722369
OTO - NOTNLM
OT  - adolescent health
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:38
PHST- 2020/10/13 00:00 [received]
PHST- 2020/11/14 00:00 [revised]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/16 05:38 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.1136/bmjpo-2020-000913 [doi]
AID - bmjpo-2020-000913 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Dec 4;4(1):e000913. doi: 10.1136/bmjpo-2020-000913.
      eCollection 2020.


PMID- 33324766
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Long-term safety of prenatal and neonatal exposure to paracetamol: a protocol for
      a systematic review.
PG  - e000907
LID - 10.1136/bmjpo-2020-000907 [doi]
AB  - INTRODUCTION: A surge in the use of paracetamol in neonates has resulted in
      growing concerns about its potential long-term adverse events. In this study, we 
      conduct a systematic review of the long-term safety of prenatal and neonatal
      exposure to paracetamol in newborn infants. METHODS AND ANALYSIS: We will follow 
      the Joanna Briggs Institute Manual for Evidence Synthesis and the Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses statements to conduct
      and report this review. We will conduct a systematic search of Embase, MEDLINE,
      Web of Science and Google Scholar for studies with data on long-term adverse
      events in neonates that were exposed to paracetamol in the prenatal and/or
      neonatal period. We will not apply language or design limitations. We will use
      standardised risk of bias assessment tools to perform a quality assessment of
      each included article. ETHICS AND DISSEMINATION: This systematic review will only
      involve access to publicly available data, and therefore ethical approval will
      not be required. The results of this study will be communicated to the target
      audience through peer-reviewed publication as well as other knowledge exchange
      platforms, such as conferences, congresses or symposia. TRIAL REGISTRATION: The
      protocol for this systematic review is submitted for registration to
      international database of prospectively registered systematic reviews (PROSPERO, 
      awaiting registration number).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Samiee-Zafarghandy, Samira
AU  - Samiee-Zafarghandy S
AUID- ORCID: 0000-0001-8385-0657
AD  - Department of Pediatrics, McMaster University Faculty of Health Sciences,
      Hamilton, Ontario, Canada.
FAU - Sushko, Katelyn
AU  - Sushko K
AD  - School of Nursing, McMaster University Faculty of Health Sciences, Hamilton,
      Ontario, Canada.
FAU - Van Den Anker, John
AU  - Van Den Anker J
AD  - Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, 
      USA.
AD  - Division of Paediatric Pharmacology and Pharmacometrics, University Children's
      Hospital Basel, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Systematic Review
DEP - 20201207
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7722805
OTO - NOTNLM
OT  - neonatology
OT  - pharmacology
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:38
PHST- 2020/10/07 00:00 [received]
PHST- 2020/11/05 00:00 [revised]
PHST- 2020/11/08 00:00 [accepted]
PHST- 2020/12/16 05:38 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.1136/bmjpo-2020-000907 [doi]
AID - bmjpo-2020-000907 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Dec 7;4(1):e000907. doi: 10.1136/bmjpo-2020-000907.
      eCollection 2020.


PMID- 33324589
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201217
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Promoting Breastfeeding and Interaction of Pediatric Associations With Providers 
      of Nutritional Products.
PG  - 562870
LID - 10.3389/fped.2020.562870 [doi]
AB  - Pediatric associations have been urged not to interact with and not to accept
      support from commercial providers of breast milk substitutes (BMSs), based on the
      assumption that such interaction would lead to diminished promotion and support
      of breastfeeding. The leadership of seven European pediatric learned societies
      reviewed the issue and share their position and policy conclusions here. We
      consider breastfeeding as the best way of infant feeding and strongly encourage
      its active promotion, protection, and support. We support the World Health
      Organization (WHO) Code of Marketing of BMSs. Infant formula and follow-on
      formula for older infants should not be advertised to families or the public, to 
      avoid undermining breastfeeding. With consistently restricted marketing of BMSs, 
      families need counseling on infant feeding choices by well-informed
      pediatricians. Current and trustworthy information is shared through congresses
      and other medical education directed and supervised by independent pediatric
      organizations or public bodies. Financial support from commercial organizations
      for congresses, educational, and scientific activities of pediatric organizations
      is an acceptable option if scientific, ethical, societal, and legal standards are
      followed; any influence of commercial organizations on the program is excluded,
      and transparency is ensured. Public-private research collaborations for improving
      and evaluating pharmaceuticals, vaccines, medical devices, dietetic products, and
      other products and services for children are actively encouraged, provided they
      are guided by the goal of enhancing child health and are performed following
      established high standards. We support increasing investment of public funding
      for research aiming at promoting child health, as well as for medical education.
CI  - Copyright (c) 2020 Bognar, De Luca, Domellof, Hadjipanayis, Haffner, Johnson,
      Kolacek, Koletzko, Saenz de Pipaon, Shingadia, Tissieres, Titomanlio, Topaloglu
      and Truck.
FAU - Bognar, Zsolt
AU  - Bognar Z
AD  - Pediatric Section of the European Society of Emergency Medicine (EUSEM),
      Paediatric Emergency Department, Heim Pal National Paediatric Institute,
      Budapest, Hungary.
FAU - De Luca, Daniele
AU  - De Luca D
AD  - European Society of Paediatric and Neonatal Intensive Care, Paris Saclay
      University Hospitals-APHP, Medical Center A. Beclere, Clamart, France.
FAU - Domellof, Magnus
AU  - Domellof M
AD  - Chair Nutrition Committee, European Society for Paediatric Gastroenterology,
      Hepatology and Nutrition (ESPGHAN), Department of Clinical Sciences, Umea
      University, Umea, Sweden.
FAU - Hadjipanayis, Adamos
AU  - Hadjipanayis A
AD  - European Academy of Paediatrics (EAP), European University Cyprus, Paediatric
      Department, Larnaca General Hospital, Larnaca, Cyprus.
FAU - Haffner, Dieter
AU  - Haffner D
AD  - European Society for Paediatric Nephrology (ESPN), Department of Paediatric
      Kidney, Liver and Metabolic Diseases, Children's Hospital, Hannover Medical
      School, Hanover, Germany.
FAU - Johnson, Mark
AU  - Johnson M
AD  - European Society for Paediatric Research (ESPR), National Institute for Health
      Research, Southampton Biomedical Research Centre, University Hospital Southampton
      NHS Foundation Trust and University of Southampton, Southampton, United Kingdom.
FAU - Kolacek, Sanja
AU  - Kolacek S
AD  - European Society for Paediatric Gastroenterology, Hepatology and Nutrition
      (ESPGHAN), University Department of Paediatrics, Children's Hospital Zagreb,
      Zagreb, Croatia.
FAU - Koletzko, Berthold
AU  - Koletzko B
AD  - European Academy of Paediatrics (EAP), Department of Paediatrics, University
      Hospital LMU Munich, Dr. von Hauner Children's Hospital,
      LMU-Ludwig-MaximiliansUniversitat Munchen, Munich, Germany.
FAU - Saenz de Pipaon, Miguel
AU  - Saenz de Pipaon M
AD  - European Society for Paediatric Research (ESPR), Department of Pediatrics,
      Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Shingadia, Delane
AU  - Shingadia D
AD  - European Society for Paediatric Infectious Diseases (ESPID), Institute of Child
      Health, University College London, Great Ormond Street Hospital, London, United
      Kingdom.
FAU - Tissieres, Pierre
AU  - Tissieres P
AD  - European Society of Paediatric and Neonatal Intensive Care, Paediatric and
      Neonatal Intensive Care Unit, Paris Saclay University Hospitals-APHP, Le
      Kremlin-Bicetre, France.
FAU - Titomanlio, Luigi
AU  - Titomanlio L
AD  - Pediatric Section of the European Society of Emergency Medicine (EUSEM),
      Pediatric Emergency Department and Migraine and Neurovascular Diseases Clinic,
      INSERM U1141-Paris University, Robert Debre Hospital, Paris, France.
FAU - Topaloglu, Rezan
AU  - Topaloglu R
AD  - European Society for Paediatric Nephrology (ESPN), Department Pediatric
      Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
FAU - Truck, Johannes
AU  - Truck J
AD  - European Society for Paediatric Infectious Diseases (ESPID), University
      Children's Hospital Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7723897
OTO - NOTNLM
OT  - continuing medical education
OT  - infant and young child feeding
OT  - infant nutrition
OT  - privately sponsored programs
OT  - public private sector cooperation
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:37
PHST- 2020/05/16 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/12/16 05:37 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.3389/fped.2020.562870 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Nov 25;8:562870. doi: 10.3389/fped.2020.562870. eCollection
      2020.


PMID- 33324506
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 28
DP  - 2020 Dec
TI  - Mercury Exposure in Artisanal and Small-Scale Gold Mining Communities in
      Sukabumi, Indonesia.
PG  - 201209
LID - 10.5696/2156-9614-10.28.201209 [doi]
AB  - BACKGROUND: Artisanal and small-scale gold mining (ASGM) is one of the largest
      sources of mercury (Hg) pollution in Indonesia. In West Java Province, ASGM is
      found in Bogor, Cianjur, and Sukabumi Regencies. OBJECTIVES: The present study
      aimed to evaluate Hg contamination effects and socioeconomic factors in
      communities living around ASGM operations in Sukabumi Regency. METHODS: A
      quantitative method was used to describe socioeconomic ASGM communities. The
      concentrations of total mercury (T-Hg) in hair were measured in 71 respondents.
      This study also assessed perception of the use of Hg in the gold ore processing
      and their impact on the environment. RESULTS: The population of gold miners in
      the studied three villages was 1300 households (25.77% from a total of 5044
      households). Artisanal and small-scale gold mining involves both men and women
      employed as miners and gold amalgam processors, respectively. The average monthly
      income generated as much as Indonesian Rupiah (IDR) 272 000-2 000 000 (about
      19-140 USD). Total Hg analysis was conducted for hair samples of 71 respondents
      (38 men, 33 women). The results showed an average T-Hg in men of 3.27+/-2.89 ppm,
      and women of 5.91+/-4.69 ppm. The level of T-Hg in the respondents was associated
      with distance to the ball mills and not related to distance to the mine site.
      PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: This study was approved by
      Ministry of Environment and Forestry of the Republic of Indonesia. COMPETING
      INTERESTS: The authors declare no competing financial interests.
CI  - (c) Pure Earth 2020.
FAU - Harianja, Alfonsus H
AU  - Harianja AH
AUID- ORCID: https://orcid.org/0000-0002-1585-6755
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
FAU - Saragih, Grace S
AU  - Saragih GS
AUID- ORCID: https://orcid.org/0000-0002-0112-0982
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
FAU - Fauzi, Ridwan
AU  - Fauzi R
AUID- ORCID: https://orcid.org/0000-0003-1089-1639
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
FAU - Hidayat, M Yusup
AU  - Hidayat MY
AUID- ORCID: https://orcid.org/0000-0002-8694-8385
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
FAU - Syofyan, Yunesfi
AU  - Syofyan Y
AUID- ORCID: https://orcid.org/0000-0001-6014-6966
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
FAU - Tapriziah, Ely Rahmy
AU  - Tapriziah ER
AUID- ORCID: https://orcid.org/0000-0003-4585-482X
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
FAU - Kartiningsih, Sri Endah
AU  - Kartiningsih SE
AUID- ORCID: https://orcid.org/0000-0002-0513-1670
AD  - Research and Development Center for Environmental Quality and Laboratory (P3KLL),
      Banten, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7731497
OTO - NOTNLM
OT  - ASGM
OT  - Sukabumi
OT  - mercury
OT  - perception
OT  - socioeconomic characteristics
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:37
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/12/16 05:37 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.5696/2156-9614-10.28.201209 [doi]
PST - epublish
SO  - J Health Pollut. 2020 Dec 2;10(28):201209. doi: 10.5696/2156-9614-10.28.201209.
      eCollection 2020 Dec.


PMID- 33324505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 28
DP  - 2020 Dec
TI  - Work Practices and Health Problems of Spray Painters Exposed to Organic Solvents 
      in Ile-Ife, Nigeria.
PG  - 201208
LID - 10.5696/2156-9614-10.28.201208 [doi]
AB  - BACKGROUND: Automobile spray painters in Nigeria are exposed to organic solvents 
      due to the hazardous nature of their work. Inadequate use of personal protective 
      equipment (PPE) may intensify exposure to high levels of chemical hazards with
      resultant health problems. OBJECTIVES: The present study assessed PPE use and
      work practices and compared work-related health problems of spray painters and
      controls in Ile-Ife, Nigeria. METHODS: A cross-sectional study was conducted
      among 120 spray painters and 120 controls (electronic technicians). Data on
      socio-demographics, work practices, knowledge about organic solvent-related
      hazards and self-reported health symptoms were obtained using a semi-structured
      questionnaire. Clinical examinations were performed for all respondents and the
      composition of organic solvents in paints and paint products were derived from
      material safety data sheets. RESULTS: All respondents were male, and the mean age
      was 32.7+/-13.8 years for painters and 33.9+/-15.5 years for controls. Few (7.5%)
      painters perceived their use of PPE to be adequate. All spray painters worked in 
      enclosed workshops and N-butyl acetate was the most commonly used organic
      solvent. Spray painters reported excessive tear production, recurrent cough, and 
      short-term memory loss more frequently than controls (P<0.05). In addition, 89%
      of painters noticed paint-stained sputum immediately after spray painting. The
      prevalence ratio of respiratory symptoms was higher in spray painters than
      controls (prevalence ratio=21.0, CI=2.9-153.6). On clinical examination, more
      spray painters had corneal opacity and dry skin when compared with controls
      (P<0.05). CONCLUSIONS: Spray painters in the study area worked amidst chemical
      hazards and had poor use of PPE. Exposure to organic solvents may be responsible 
      for the higher prevalence of self-reported health problems among spray painters. 
      Interventions to enforce the use of PPE and improve the knowledge of organic
      solvent-related hazards among spray painters are essential. PARTICIPANT CONSENT: 
      Obtained. ETHICS APPROVAL: Ethical approval to conduct the study was obtained
      from the Health Research and Ethics Committee of the Institute of Public Health, 
      Obafemi Awolowo University, Ile-Ife Nigeria (HREC No: IPHOAU/12/463). COMPETING
      INTERESTS: The authors declare no competing financial interests.
CI  - (c) Pure Earth 2020.
FAU - Ojo, Temitope Olumuyiwa
AU  - Ojo TO
AUID- ORCID: https://orcid.org/0000-0003-1899-5213
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
FAU - Onayade, Adedeji Ayodeji
AU  - Onayade AA
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
AD  - Department of Community Health, Obafemi Awolowo University Teaching Hospitals
      Complex, Ile-Ife, Nigeria.
AD  - Department of Ophthalmology, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
FAU - Afolabi, Olusegun Temitope
AU  - Afolabi OT
AUID- ORCID: 0000-0002-0589-6948
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
FAU - Ijadunola, Macellina Yinyinade
AU  - Ijadunola MY
AUID- ORCID: https://orcid.org/0000-0002-4838-0431
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
FAU - Esan, Oluwaseun Taiwo
AU  - Esan OT
AUID- ORCID: 0000-0002-2908-6034
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
FAU - Akinyemi, Patrick Ayodeji
AU  - Akinyemi PA
AUID- ORCID: https://orcid.org/0000-0001-6253-1059
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
FAU - Awe, Oluwaseun Olaniyi
AU  - Awe OO
AUID- ORCID: https://orcid.org/0000-0002-8701-707X
AD  - Department of Community Health, Faculty of Clinical Sciences, Obafemi Awolowo
      University, Ile-Ife, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7731485
OTO - NOTNLM
OT  - Nigeria
OT  - organic solvents
OT  - spray painters
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:37
PHST- 2020/07/19 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/12/16 05:37 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.5696/2156-9614-10.28.201208 [doi]
PST - epublish
SO  - J Health Pollut. 2020 Dec 2;10(28):201208. doi: 10.5696/2156-9614-10.28.201208.
      eCollection 2020 Dec.


PMID- 33324323
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Hand Focused Upper Extremity Rehabilitation in the Subacute Phase Post-stroke
      Using Interactive Virtual Environments.
PG  - 573642
LID - 10.3389/fneur.2020.573642 [doi]
AB  - Introduction: Innovative motor therapies have attempted to reduce upper extremity
      impairment after stroke but have not made substantial improvement as over 50% of 
      people post-stroke continue to have sensorimotor deficits affecting their
      self-care and participation in daily activities. Intervention studies have
      focused on the role of increased dosing, however recent studies have indicated
      that timing of rehabilitation interventions may be as important as dosing and
      importantly, that dosing and timing interact in mediating effectiveness. This
      study is designed to empirically test dosing and timing. Methods and Analysis: In
      this single-blinded, interventional study, subjects will be stratified on two
      dimensions, impairment level (Fugl-Meyer Upper Extremity Assessment (FM) and
      presence or absence of Motor Evoked Potentials (MEPs) as follows; (1) Severe, FM 
      score 10-19, MEP+, (2) Severe, FM score 10-19, MEP-, (3) Moderate, FM score
      20-49, MEP+, (4) Moderate, FM score 20-49, MEP-. Subjects not eligible for TMS
      will be assigned to either group 2 (if severe) or group 3 (if moderate).
      Stratified block randomization will then be used to achieve a balanced
      assignment. Early Robotic/VR Therapy (EVR) experimental group will receive
      in-patient usual care therapy plus an extra 10 h of intensive upper extremity
      therapy focusing on the hand using robotically facilitated rehabilitation
      interventions presented in virtual environments and initiated 5-30 days
      post-stroke. Delayed Robotic/VR Therapy (DVR) experimental group will receive the
      same intervention but initiated 30-60 days post-stroke. Dose-matched usual care
      group (DMUC) will receive an extra 10 h of usual care initiated 5-30 days
      post-stroke. Usual Care Group (UC) will receive the usual amount of
      physical/occupational therapy. Outcomes: There are clinical, neurophysiological, 
      and kinematic/kinetic measures, plus measures of daily arm use and quality of
      life. Primary outcome is the Action Research Arm Test (ARAT) measured at 4 months
      post-stroke. Discussion: Outcome measures will be assessed to determine whether
      there is an early time period in which rehabilitation will be most effective, and
      whether there is a difference in the recapture of premorbid patterns of movement 
      vs. the development of an efficient, but compensatory movement strategy. Ethical 
      Considerations: The IRBs of New Jersey Institute of Technology, Rutgers
      University, Northeastern University, and Kessler Foundation reviewed and approved
      all study protocols. Study was registered in https://ClinicalTrials.gov
      (NCT03569059) prior to recruitment. Dissemination will include submission to
      peer-reviewed journals and professional presentations.
CI  - Copyright (c) 2020 Merians, Fluet, Qiu, Yarossi, Patel, Mont, Saleh, Nolan,
      Barrett, Tunik and Adamovich.
FAU - Merians, Alma S
AU  - Merians AS
AD  - Department of Rehabilitation and Movement Sciences, School of Health Professions,
      Rutgers Biomedical and Health Sciences, Newark, NJ, United States.
FAU - Fluet, Gerard G
AU  - Fluet GG
AD  - Department of Rehabilitation and Movement Sciences, School of Health Professions,
      Rutgers Biomedical and Health Sciences, Newark, NJ, United States.
FAU - Qiu, Qinyin
AU  - Qiu Q
AD  - Department of Rehabilitation and Movement Sciences, School of Health Professions,
      Rutgers Biomedical and Health Sciences, Newark, NJ, United States.
FAU - Yarossi, Mathew
AU  - Yarossi M
AD  - Movement Neuroscience Laboratory, Department of Physical Therapy, Movement and
      Rehabilitation Science, Bouve College of Health Sciences, Northeastern
      University, Boston, MA, United States.
AD  - SPIRAL Group, Department of Electrical and Computer Engineering, Northeastern
      University, Boston, MA, United States.
FAU - Patel, Jigna
AU  - Patel J
AD  - Department of Rehabilitation and Movement Sciences, School of Health Professions,
      Rutgers Biomedical and Health Sciences, Newark, NJ, United States.
FAU - Mont, Ashley J
AU  - Mont AJ
AD  - Department of Biomedical Engineering, New Jersey Institute of Technology, Newark,
      NJ, United States.
FAU - Saleh, Soha
AU  - Saleh S
AD  - Center for Mobility and Rehabilitation Engineering Research, Kessler Foundation, 
      West Orange, NJ, United States.
AD  - Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical
      School, Newark, NJ, United States.
FAU - Nolan, Karen J
AU  - Nolan KJ
AD  - Center for Mobility and Rehabilitation Engineering Research, Kessler Foundation, 
      West Orange, NJ, United States.
AD  - Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical
      School, Newark, NJ, United States.
FAU - Barrett, A M
AU  - Barrett AM
AD  - Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical
      School, Newark, NJ, United States.
AD  - Center for Stroke Rehabilitation Research, Kessler Foundation, West Orange, NJ,
      United States.
FAU - Tunik, Eugene
AU  - Tunik E
AD  - Movement Neuroscience Laboratory, Department of Physical Therapy, Movement and
      Rehabilitation Science, Bouve College of Health Sciences, Northeastern
      University, Boston, MA, United States.
AD  - Department of Bioengineering, College of Engineering, Northeastern University,
      Boston, MA, United States.
AD  - Department of Electrical and Computer Engineering, College of Engineering,
      Northeastern University, Boston, MA, United States.
FAU - Adamovich, Sergei V
AU  - Adamovich SV
AD  - Department of Rehabilitation and Movement Sciences, School of Health Professions,
      Rutgers Biomedical and Health Sciences, Newark, NJ, United States.
AD  - Department of Biomedical Engineering, New Jersey Institute of Technology, Newark,
      NJ, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT03569059
GR  - R01 HD058301/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20201126
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7726202
OTO - NOTNLM
OT  - EEG
OT  - robotics
OT  - stroke
OT  - subacute
OT  - transcranial magnetic stimulation
OT  - upper limb
OT  - virtual reality
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:36
PHST- 2020/06/17 00:00 [received]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/12/16 05:36 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.3389/fneur.2020.573642 [doi]
PST - epublish
SO  - Front Neurol. 2020 Nov 26;11:573642. doi: 10.3389/fneur.2020.573642. eCollection 
      2020.


PMID- 33324212
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210225
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Linking the Declarations of Helsinki and of Taipei: Critical Challenges of
      Future-Oriented Research Ethics.
PG  - 579714
LID - 10.3389/fphar.2020.579714 [doi]
AB  - Expansion of data-driven research in the 21st century has posed challenges in the
      evolution of the international agreed framework of research ethics. The World
      Medical Association (WMA)'s Declaration of Helsinki (DoH) has provided ethical
      principles for medical research involving humans since 1964, with the last update
      in 2013. To complement the DoH, WMA issued the Declaration of Taipei (DoT) in
      2016 to provide additional principles for health databases and biobanks. However,
      the ethical principles for secondary use of data or material obtained in research
      remain unclear. With such a perspective, the Working Group on Ethics (WGE) of the
      International Federation of Associations of Pharmaceutical Physicians and
      Pharmaceutical Medicine (IFAPP) suggests a closer scientific linkage in the DoH
      to the (Declaration of Taipei) DoT focusing specifically on areas that will
      facilitate data-driven research, and to further strengthen the protection of
      research participants.
CI  - Copyright (c) 2020 Kurihara, Baroutsou, Becker, Brun, Franke-Bray, Carlesi, Chan,
      Collia, Kleist, Laranjeira, Matsuyama, Naseem, Schenk, Silva and Kerpel-Fronius.
FAU - Kurihara, Chieko
AU  - Kurihara C
AD  - National Institutes for Quantum and Radiological Science and Technology, Chiba,
      Japan.
FAU - Baroutsou, Varvara
AU  - Baroutsou V
AD  - Hellenic Society of Independent Medical Consultant, and Consultant,
      Pharmaceutical Medicine, Athens, Greece.
FAU - Becker, Sander
AU  - Becker S
AD  - Consultants in Pharmaceutical Medicine, Dover Heights, Australia.
FAU - Brun, Johan
AU  - Brun J
AD  - LIF, Stockholm, Sweden.
FAU - Franke-Bray, Brigitte
AU  - Franke-Bray B
AD  - Independent Consultant, Basel, Switzerland.
FAU - Carlesi, Roberto
AU  - Carlesi R
AD  - Independent Researcher, Bellagio, Italy.
FAU - Chan, Anthony
AU  - Chan A
AD  - Pfizer Biopharmaceuticals Group, Dublin, Ireland.
FAU - Collia, Luis Francisco
AU  - Collia LF
AD  - Craveri Pharma, Buenos Aires, Argentina.
FAU - Kleist, Peter
AU  - Kleist P
AD  - Cantonal Ethics Committee, Zurich, Switzerland.
FAU - Laranjeira, Luis Filipe
AU  - Laranjeira LF
AD  - Eli Lilly & Co., Lisbon, Portugal.
FAU - Matsuyama, Kotone
AU  - Matsuyama K
AD  - Nippon Medical School, Tokyo, Japan.
FAU - Naseem, Shehla
AU  - Naseem S
AD  - Ferozsons Laboratories Ltd, Karachi, Pakistan.
FAU - Schenk, Johanna
AU  - Schenk J
AD  - PPH plus GmbH & Co. KG, Hochheim am Main, Germany.
FAU - Silva, Honorio
AU  - Silva H
AD  - IFAPP Academy, New York, NY, United States.
FAU - Kerpel-Fronius, Sandor
AU  - Kerpel-Fronius S
AD  - Semmelweis University, Budapest, Hungary.
CN  - Working Group on Ethics of the International Federation of Associations of
      Pharmaceutical Physicians and Pharmaceutical Medicine
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
EIN - Front Pharmacol. 2021 Feb 08;11:637775. PMID: 33628190
PMC - PMC7723451
OTO - NOTNLM
OT  - Declaration of Helsinki
OT  - Declaration of Taipei
OT  - data science
OT  - data sharing
OT  - medicines development
OT  - privacy protection
OT  - research ethics
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:36
PHST- 2020/07/03 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/12/16 05:36 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.3389/fphar.2020.579714 [doi]
AID - 579714 [pii]
PST - epublish
SO  - Front Pharmacol. 2020 Oct 29;11:579714. doi: 10.3389/fphar.2020.579714.
      eCollection 2020.


PMID- 33324149
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210809
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Organ Cultures for Retinal Diseases.
PG  - 583392
LID - 10.3389/fnins.2020.583392 [doi]
AB  - The successful development of novel therapies is closely linked with
      understanding the underlying pathomechanisms of a disease. To do so, model
      systems that reflect human diseases and allow for the evaluation of new
      therapeutic approaches are needed. Yet, preclinical animal studies often have
      limited success in predicting human physiology, pathology, and therapeutic
      responses. Moreover, animal testing is facing increasing ethical and bureaucratic
      hurdles, while human cell cultures are limited in their ability to represent in
      vivo situations due to the lack of the tissue microenvironment, which may alter
      cellular responses. To overcome these struggles, organ cultures, especially those
      of complex organs such as the retina, can be used to study physiological
      reactions to substances or stressors. Human and animal organ cultures are now
      well established and recognized. This mini-review discusses how retinal organ
      cultures can be used to preserve tissue architecture more realistically and
      therefore better represent disease-related changes. It also shows how molecular
      biological, biochemical, and histological techniques can be combined to
      investigate how anatomical localization may alter cellular responses. Examples
      for the use of retinal organ cultures, including models to study age-related
      macular degeneration (AMD), retinitis pigmentosa (RP), central artery occlusion
      (CRAO), and glaucoma are presented, and their advantages and disadvantages are
      discussed. We conclude that organ cultures significantly improve our
      understanding of complex retinal diseases and may advance treatment testing
      without the need for animal testing.
CI  - Copyright (c) 2020 Hurst, Fietz, Tsai, Joachim and Schnichels.
FAU - Hurst, Jose
AU  - Hurst J
AD  - Center for Ophthalmology, University Eye Hospital, University of Tubingen,
      Tubingen, Germany.
FAU - Fietz, Agnes
AU  - Fietz A
AD  - Center for Ophthalmology, University Eye Hospital, University of Tubingen,
      Tubingen, Germany.
FAU - Tsai, Teresa
AU  - Tsai T
AD  - Experimental Eye Research Institute, University Eye Hospital, Ruhr-University
      Bochum, Bochum, Germany.
FAU - Joachim, Stephanie C
AU  - Joachim SC
AD  - Experimental Eye Research Institute, University Eye Hospital, Ruhr-University
      Bochum, Bochum, Germany.
FAU - Schnichels, Sven
AU  - Schnichels S
AD  - Center for Ophthalmology, University Eye Hospital, University of Tubingen,
      Tubingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201125
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
CIN - Front Neurosci. 2021 Jul 23;15:714094. PMID: 34366783
PMC - PMC7724035
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - central artery occlusion
OT  - ex vivo
OT  - glaucoma
OT  - retinal organ culture
OT  - retinitis pigmentosa
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:35
PHST- 2020/07/14 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/12/16 05:35 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.3389/fnins.2020.583392 [doi]
PST - epublish
SO  - Front Neurosci. 2020 Nov 25;14:583392. doi: 10.3389/fnins.2020.583392.
      eCollection 2020.


PMID- 33324132
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 1556-3499 (Print)
IS  - 1556-3499 (Linking)
VI  - 27
DP  - 2020 Dec
TI  - Federal Employees' Compensation Act and Mandating the Use of X-ray for
      Chiropractic Management of Federal Employees: An Exploration of Concerns and a
      Call to Action.
PG  - 11-20
LID - 10.1016/j.echu.2020.10.005 [doi]
AB  - OBJECTIVE: The purpose of this article is to explore concerns regarding sections 
      of the federal workers' compensation law that apply to the treatment and
      management of work-related injuries of federal employees by chiropractors, and to
      offer a call to action for change. DISCUSSION: A 1974 amendment to the Federal
      Employees' Compensation Act (FECA) stipulates that chiropractic services rendered
      to injured federal workers are reimbursable. However, the only reimbursable
      chiropractic treatment is "manual manipulation of the spine to correct a
      subluxation as demonstrated by X-ray to exist." This means the chiropractor must 
      take radiographs in order to be reimbursed. As with other health care
      professions, chiropractors are expected to practice according to best practices
      guided by studies in the scientific literature. Yet in the federal workers'
      compensation arena, this law requires chiropractors to practice in a manner that 
      is fiscally wasteful, contradicts current radiology standards, and may expose
      patients to unnecessary X-ray radiation. Presently, there is discord between what
      the law mandates, chiropractic training and scope, and what professional
      guidelines recommend. In this article we discuss how FECA creates problems in the
      following 7 categories: direct harm, indirect harm, contradiction of best
      practices, ethical dilemma, barriers to conservative treatment, fiscal waste, and
      discrimination. CONCLUSION: The 1974 FECA provision requiring chiropractors to
      take radiographs regardless of presenting medical necessity should be updated to 
      reflect current chiropractic education, training, and best practice. To resolve
      this discrepancy, we suggest that the radiographic requirement and the
      limitations placed on chiropractic physicians should be removed.
CI  - (c) 2020 by National University of Health Sciences.
FAU - Askew, Jeff J
AU  - Askew JJ
AD  - Sanford Health Chiropractic and Occupational Medicine, Bismarck, North Dakota.
FAU - Kranz, Karl C
AU  - Kranz KC
AD  - New York State Chiropractic Association, City, Niskayuna, New York.
FAU - Whalen, Wayne M
AU  - Whalen WM
AD  - Santee, California.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201207
PL  - United States
TA  - J Chiropr Humanit
JT  - Journal of chiropractic humanities
JID - 100890625
PMC - PMC7729097
OTO - NOTNLM
OT  - Chiropractic
OT  - Medicare
OT  - Radiology
OT  - Workers' Compensation
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:35
PHST- 2019/08/06 00:00 [received]
PHST- 2020/08/20 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/12/16 05:35 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - 10.1016/j.echu.2020.10.005 [doi]
AID - S1556-3499(20)30005-X [pii]
PST - epublish
SO  - J Chiropr Humanit. 2020 Dec 7;27:11-20. doi: 10.1016/j.echu.2020.10.005.
      eCollection 2020 Dec.


PMID- 33323959
OWN - NLM
STAT- MEDLINE
DCOM- 20211116
LR  - 20211116
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 588
IP  - 7839
DP  - 2020 Dec
TI  - Nature's 10: the human stories behind an extraordinary year in science.
PG  - 538
LID - 10.1038/d41586-020-03551-3 [doi]
LA  - eng
PT  - Editorial
PT  - Historical Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Group Processes
MH  - History, 21st Century
MH  - Humans
MH  - *Research Personnel/history
MH  - *Science/history
OTO - NOTNLM
OT  - *Ethics
OT  - *Policy
OT  - *Research management
OT  - *Society
EDAT- 2020/12/17 06:00
MHDA- 2021/11/17 06:00
CRDT- 2020/12/16 05:32
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/11/17 06:00 [medline]
PHST- 2020/12/16 05:32 [entrez]
AID - 10.1038/d41586-020-03551-3 [doi]
AID - 10.1038/d41586-020-03551-3 [pii]
PST - ppublish
SO  - Nature. 2020 Dec;588(7839):538. doi: 10.1038/d41586-020-03551-3.


PMID- 33323452
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - Detailing sexual outcomes after treatment of localised prostate cancer with focal
      therapy using various energy sources: protocol for a mixed-methods study.
PG  - e045500
LID - 10.1136/bmjopen-2020-045500 [doi]
AB  - INTRODUCTION: Focal therapy has emerged as a promising treatment option for men
      with localised prostate cancer. However, most of the evaluation of postoperative 
      function has taken place at a relatively high, non-granular level. Most of the
      data we use to provide informed consent for our patients is obtained from
      retrospective series, or derived from prospective studies whose primary outcome
      was oncological. Finally, most studies have focused on erectile function and
      overlooked other, presumably important, elements of male sexual function. The
      present study aims at studying in-depth the sexual consequences of focal therapy 
      with various energy sources. METHODS AND ANALYSIS: This will be a mixed-methods
      research study based on a retrospective and prospective cohort, recruited in
      parallel. The retrospective cohort will consist of patients treated with focal
      irreversible electroporation, and the prospective cohort of patients treated with
      three focal therapy energies. Participants will be recruited from two UK urology 
      centres, one National Health Service and one private. On consent, patients will
      fill in self-administered validated questionnaires (International Index of
      Erectile Function-15 (IIEF-15), Male Sexual Health Questionnaire-Ejaculatory
      Dysfunction-Short Form (MSHQ-EjD-SF)) and semistructured interviews will be
      organised to collect patients' expectations and postoperative changes in domains 
      such as erection, ejaculation, orgasm, libido/sexual desire,
      masculinity/virility, penile morphology, pain or discomfort, regret, shame,
      cancer-related stress, overall impact and partner satisfaction. An exploratory
      thematic analysis will be performed to detail recurring themes that will be
      grouped into clusters of experiences. We will then be able to find clusters of
      agreement and disagreement that will be illustrated using exemplar patient
      quotations. ETHICS AND DISSEMINATION: Ethical approval was obtained (Regional
      Ethics Committee reference 20/NW/0335), as well as Health Research Authority
      approval. Results will be published in open-access peer-reviewed journals.
      Findings will also be translated into patient information resources (leaflets,
      online information sheets). TRIAL REGISTRATION NUMBER: ISRCTN11634296;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fiard, Gaelle
AU  - Fiard G
AUID- ORCID: 0000-0003-3049-5318
AD  - UCL Division of Surgery & Interventional Science, University College London,
      London, UK g.fiard@ucl.ac.uk.
AD  - Department of Urology, University College London Hospital NHS Foundation Trust,
      London, UK.
AD  - Department of Urology, Grenoble Alpes University Hospital, Grenoble, France.
AD  - Universite Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.
FAU - Kelly, Daniel
AU  - Kelly D
AUID- ORCID: 0000-0002-1847-0655
AD  - School of Healthcare Sciences, Cardiff University, Cardiff, UK.
FAU - Yap, Tet
AU  - Yap T
AD  - Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
FAU - Emberton, Mark
AU  - Emberton M
AD  - UCL Division of Surgery & Interventional Science, University College London,
      London, UK.
AD  - Department of Urology, University College London Hospital NHS Foundation Trust,
      London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN11634296
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Erectile Dysfunction
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - *Prostatic Neoplasms/surgery
MH  - Retrospective Studies
MH  - State Medicine
MH  - Surveys and Questionnaires
PMC - PMC7745515
OTO - NOTNLM
OT  - *erectile dysfunction
OT  - *prostate disease
OT  - *qualitative research
OT  - *sexual dysfunction
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/16 05:28
PHST- 2020/12/16 05:28 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-045500 [pii]
AID - 10.1136/bmjopen-2020-045500 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e045500. doi: 10.1136/bmjopen-2020-045500.


PMID- 33323445
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - Effect of a tailored multidimensional intervention on the care burden among
      family caregivers of stroke survivors: study protocol for a randomised controlled
      trial.
PG  - e041637
LID - 10.1136/bmjopen-2020-041637 [doi]
AB  - INTRODUCTION: Caring for stroke survivors creates high levels of care burden
      among family caregivers. Previous initiatives at alleviating the care burden have
      been unsuccessful. The proposed study aims to evaluate the effect of a tailored
      multidimensional intervention on the care burden among family caregivers of
      stroke survivors. Based on the perceived needs of family caregivers, this
      intervention takes into account scientific recommendations to combine three
      different approaches: skill-building, psychoeducation and peer support. METHODS
      AND ANALYSIS: Using a prospective, randomised, open-label, parallel-group design,
      110 family caregivers will be enrolled from Dakahlia Governorate, Egypt between
      December 2019 and May 2020, and randomly assigned to either the intervention
      group or the control group. The tailored multidimensional intervention will be
      administered for 6 months, including three home visits, six home-based telephone 
      calls and one peer support session. The primary outcome is the care burden as
      measured using the Zarit Burden Interview. Secondary outcomes include changes in 
      the family caregivers' perceived needs (Family Needs Questionnaire-Revised),
      coping strategies (Brief-Coping Orientation to Problems Experienced) and quality 
      of life (WHO Quality of Life-BREF). Outcomes evaluation will be conducted at
      baseline (T0), month 3 (T1) and month 6 (T2). Independent t-test will be
      performed to compare the mean values of study variables between the two groups at
      both T1 and T2. After adjusting for confounding variables, analysis of covariance
      will be used to assess the effect of the intervention. In addition, repeated
      measures analysis of variance will be conducted to assess changes in effect over 
      time. ETHICS AND DISSEMINATION: This study was approved by the Research Ethics
      Committee of the Faculty of Nursing, Mansoura University, Mansoura, Egypt
      (P.0195). The results will be published in a scientific peer-reviewed journal,
      and findings will be disseminated at the local and international levels. TRIAL
      REGISTRATION NUMBER: NCT04211662.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Elsheikh, Mahmoud Ahmed
AU  - Elsheikh MA
AUID- ORCID: 0000-0002-4256-9516
AD  - Graduate School of Biomedical and Health Sciences, Hiroshima University,
      Hiroshima, Japan d194332@hiroshima-u.ac.jp.
AD  - Community Health Nursing Department, Faculty of Nursing, Cairo University, Cairo,
      Egypt.
FAU - Moriyama, Michiko
AU  - Moriyama M
AD  - Graduate School of Biomedical and Health Sciences, Hiroshima University,
      Hiroshima, Japan.
FAU - Rahman, Md Moshiur
AU  - Rahman MM
AUID- ORCID: 0000-0002-5475-986X
AD  - Graduate School of Biomedical and Health Sciences, Hiroshima University,
      Hiroshima, Japan.
FAU - Kako, Mayumi
AU  - Kako M
AD  - Graduate School of Biomedical and Health Sciences, Hiroshima University,
      Hiroshima, Japan.
FAU - El-Monshed, Ahmed Hashem
AU  - El-Monshed AH
AUID- ORCID: 0000-0002-0085-4685
AD  - Psychiatric and Mental Health Nursing Department, Faculty of Nursing, Mansoura
      University, Mansoura, Egypt.
FAU - Zoromba, Mohamed
AU  - Zoromba M
AUID- ORCID: 0000-0002-4298-1121
AD  - Psychiatric and Mental Health Nursing Department, Faculty of Nursing, Mansoura
      University, Mansoura, Egypt.
FAU - Zehry, Hamada
AU  - Zehry H
AD  - New Mansoura General Hospital, Neurology, Ministry of Health and Population,
      Mansoura, Egypt.
FAU - Khalil, Maha Hazem
AU  - Khalil MH
AD  - Neurology, Mansoura University Faculty of Medicine, Mansoura, Egypt.
FAU - Amr, Mostafa
AU  - Amr M
AD  - Psychiatry, Mansoura University Faculty of Medicine, Mansoura, Egypt.
LA  - eng
SI  - ClinicalTrials.gov/NCT04211662
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Caregivers
MH  - Egypt
MH  - Humans
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/therapy
MH  - Survivors
PMC - PMC7745514
OTO - NOTNLM
OT  - *public health
OT  - *quality in health care
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/16 05:28
PHST- 2020/12/16 05:28 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041637 [pii]
AID - 10.1136/bmjopen-2020-041637 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e041637. doi: 10.1136/bmjopen-2020-041637.


PMID- 33323442
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - Double-blind RCT of fish oil supplementation in pregnancy and lactation to
      improve the metabolic health in children of mothers with overweight or obesity
      during pregnancy: study protocol.
PG  - e041015
LID - 10.1136/bmjopen-2020-041015 [doi]
AB  - INTRODUCTION: Maternal obesity during pregnancy is associated with adverse
      changes in body composition and metabolism in the offspring. We hypothesise that 
      supplementation during pregnancy of overweight and obese women may help prevent
      the development of greater adiposity and metabolic dysfunction in children.
      Previous clinical trials investigating fish oil supplementation in pregnancy on
      metabolic outcomes and body composition of the children have not focused on the
      pregnancies of overweight or obese women. METHODS AND ANALYSIS: A double-blind
      randomised controlled trial of fish oil (providing 3 g/day of n-3 polyunsaturated
      fatty acids) versus an equal volume of olive oil (control) taken daily from
      recruitment until birth, and in breastfeeding mothers, further continued for 3
      months post partum. Eligible women will have a singleton pregnancy at 12-20
      weeks' gestation and be aged 18-40 years with body mass index >/=25 kg/m(2) at
      baseline. We aim to recruit a minimum of 128 participants to be randomised 1:1.
      Clinical assessments will be performed at baseline and 30 weeks of pregnancy,
      including anthropometric measurements, fasting metabolic markers, measures of
      anxiety, physical activity, quality of life and dietary intake. Subsequent
      assessments will be performed when the infant is 2 weeks, 3 months and 12 months 
      of age for anthropometry, body composition (dual-energy X-ray absorptiometry
      (DXA)) and blood sampling. The primary outcome of the study is a between-group
      difference in infant percentage body fatness, assessed by DXA, at 2 weeks of age.
      Secondary outcomes will include differences in anthropometric measures at each
      time point, percentage body fat at 3 and 12 months and homeostatic model
      assessment of insulin resistance at 3 months. Statistical analysis will be
      carried out on the principle of intention to treat. ETHICS AND DISSEMINATION:
      This trial was approved by the Northern A Health and Disabilities Ethics
      Committee, New Zealand Ministry of Health (17/NTA/154). Results will be published
      in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ACTRN12617001078347p;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Satokar, Vidit V
AU  - Satokar VV
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Cutfield, Wayne S
AU  - Cutfield WS
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - A Better Start - National Science Challenge, University of Auckland, Auckland,
      New Zealand.
FAU - Derraik, Jose G B
AU  - Derraik JGB
AUID- ORCID: 0000-0003-1226-1956
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - A Better Start - National Science Challenge, University of Auckland, Auckland,
      New Zealand.
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
AD  - Department of Endocrinology, Children's Hospital, Zhejiang University School of
      Medicine, Hangzhou, China.
FAU - Harwood, Matire
AU  - Harwood M
AD  - National Hauora Coalition, Auckland, New Zealand.
AD  - Te Kupenga Hauora Maori Teaching, University of Auckland, Auckland, New Zealand.
FAU - Okasene-Gafa, Karaponi
AU  - Okasene-Gafa K
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
FAU - Beck, Kathryn
AU  - Beck K
AD  - School of Sport Exercise and Nutrition, Massey University, Auckland, New Zealand.
FAU - Cameron-Smith, David
AU  - Cameron-Smith D
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - Singapore Institute for Clinical Sciences, Agency for Science, Technology and
      Research, Singapore.
FAU - O'Sullivan, Justin M
AU  - O'Sullivan JM
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Sundborn, Gerhard
AU  - Sundborn G
AD  - Department of Pacific Health, University of Auckland, Auckland, New Zealand.
FAU - Pundir, Shikha
AU  - Pundir S
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Mason, R Preston
AU  - Mason RP
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Albert, Benjamin B
AU  - Albert BB
AUID- ORCID: 0000-0003-0498-3473
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand
      b.albert@auckland.ac.nz.
AD  - A Better Start - National Science Challenge, University of Auckland, Auckland,
      New Zealand.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Fish Oils)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Breast Feeding
MH  - Child
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - *Fish Oils
MH  - Humans
MH  - Infant
MH  - Lactation
MH  - Mothers
MH  - New Zealand
MH  - Obesity/prevention & control
MH  - Overweight
MH  - Pregnancy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Young Adult
PMC - PMC7745511
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *obstetrics
OT  - *paediatrics
OT  - *preventive medicine
COIS- Competing interests: During the conduct of the study, BBA reports an Australasian
      Pediatric Endocrine Care Grant, and MH reports grants from Health Research
      Council of New Zealand, L'Oreal UNESCO FWIS and National Science
      Challenge-Healthier Lives, outside the submitted work. The study sponsor is the
      Liggins Institute, University of Auckland.
EDAT- 2020/12/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/16 05:27
PHST- 2020/12/16 05:27 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041015 [pii]
AID - 10.1136/bmjopen-2020-041015 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e041015. doi: 10.1136/bmjopen-2020-041015.


PMID- 33323438
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - Cardiovascular imaging of women and men visiting the outpatient clinic with chest
      pain or discomfort: design and rationale of the ARGUS Study.
PG  - e040712
LID - 10.1136/bmjopen-2020-040712 [doi]
AB  - INTRODUCTION: Chest pain or discomfort affects 20%-40% of the general population 
      over the course of their life and may be a symptom of myocardial ischaemia. For
      the diagnosis of obstructive macrovascular coronary artery disease (CAD),
      algorithms have been developed; however, these do not exclude microvascular
      angina. This may lead to false reassurance of symptomatic patients, mainly women,
      with functionally significant, yet non-obstructive coronary vascular disease.
      Therefore, this study aims to estimate the prevalence of both macrovascular and
      microvascular coronary vascular disease in women and men presenting with chest
      pain or discomfort, and to subsequently develop a decision-support tool to aid
      cardiologists in referral to cardiovascular imaging for both macrovascular and
      microvascular CAD evaluation. METHODS AND ANALYSIS: Women and men with chest pain
      or discomfort, aged 45 years and older, without a history of cardiovascular
      disease, who are referred to an outpatient cardiology clinic by their general
      practitioner are eligible for inclusion. Coronary CT angiography is used for
      anatomical imaging. Additionally, myocardial perfusion imaging by adenosine
      stress cardiac MRI is performed to detect functionally significant coronary
      vascular disease. Electronic health record data, collected during regular cardiac
      work-up, including medical history, cardiovascular risk factors, physical
      examination, echocardiography, (exercise) ECG and blood samples for standard
      cardiovascular biomarkers and research purposes, are obtained. Participants will 
      be classified as positive or negative for coronary vascular disease based on all 
      available data by expert panel consensus (a cardiovascular radiologist and two
      cardiologists). After completion of the clinical study, all collected data will
      be used to develop a decision support tool using predictive modelling and
      machine-learning techniques. ETHICS AND DISSEMINATION: The study protocol was
      approved by the Institutional Review Board of the University Medical Center
      Utrecht. Results will be disseminated through national and international
      conferences and in peer-reviewed journals in cardiovascular disease. TRIAL
      REGISTRATION NUMBER: Trialregister.nl Registry NL8702.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Groepenhoff, Floor
AU  - Groepenhoff F
AUID- ORCID: 0000-0002-1583-701X
AD  - Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, the
      Netherlands.
AD  - Laboratory of Experimental Cardiology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - Eikendal, Anouk L M
AU  - Eikendal ALM
AD  - Laboratory of Experimental Cardiology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - Bots, Sophie Heleen
AU  - Bots SH
AUID- ORCID: 0000-0002-4483-5582
AD  - Laboratory of Experimental Cardiology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - van Ommen, Anne-Mar
AU  - van Ommen AM
AD  - Laboratory of Experimental Cardiology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - Overmars, L M
AU  - Overmars LM
AD  - Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Kapteijn, Daniek
AU  - Kapteijn D
AD  - Laboratory of Experimental Cardiology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - Pasterkamp, Gerard
AU  - Pasterkamp G
AD  - Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Reiber, Johan H C
AU  - Reiber JHC
AD  - Medical Imaging Systems BV, MEDIS, Leiden, the Netherlands.
FAU - Hautemann, David
AU  - Hautemann D
AD  - Medical Imaging Systems BV, MEDIS, Leiden, the Netherlands.
FAU - Menken, Roxana
AU  - Menken R
AD  - Cardiology, Cardiology Centers Netherlands, Utrecht, the Netherlands.
FAU - Wittekoek, Marianne E
AU  - Wittekoek ME
AD  - Cardiology, HeartLife Clinics, Utrecht, the Netherlands.
FAU - Hofstra, Leonard
AU  - Hofstra L
AD  - Cardiology, Cardiology Centers Netherlands, Utrecht, the Netherlands.
FAU - Onland-Moret, N Charlotte
AU  - Onland-Moret NC
AD  - Department of Epidemiology, Julius Center for Health Sciences and Primary Care,
      Utrecht, the Netherlands.
FAU - Haitjema, Saskia
AU  - Haitjema S
AD  - Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Hoefer, Imo
AU  - Hoefer I
AD  - Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Leiner, Tim
AU  - Leiner T
AD  - Radiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the
      Netherlands.
FAU - den Ruijter, Hester M
AU  - den Ruijter HM
AD  - Laboratory of Experimental Cardiology, University Medical Center Utrecht,
      Utrecht, the Netherlands h.m.denRuijter-2@umcutrecht.nl.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ambulatory Care Facilities
MH  - *Chest Pain/diagnostic imaging/etiology
MH  - Coronary Angiography
MH  - *Coronary Artery Disease/diagnostic imaging
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC7745322
OTO - NOTNLM
OT  - *cardiology
OT  - *cardiovascular imaging
OT  - *coronary heart disease
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/16 05:27
PHST- 2020/12/16 05:27 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040712 [pii]
AID - 10.1136/bmjopen-2020-040712 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e040712. doi: 10.1136/bmjopen-2020-040712.


PMID- 33323435
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - A smartphone app for sedentary behaviour change in cardiac rehabilitation and the
      effect on hospital admissions: the ToDo-CR randomised controlled trial study
      protocol.
PG  - e040479
LID - 10.1136/bmjopen-2020-040479 [doi]
AB  - INTRODUCTION: Cardiac rehabilitation (CR) is recommended for secondary prevention
      of cardiovascular disease and reducing the risk of repeat cardiac events.
      Physical activity is a core component of CR; however, studies show that
      participants remain largely sedentary. Sedentary behaviour is an independent risk
      factor for all-cause mortality. Strategies to encourage sedentary behaviour
      change are needed. This study will explore the effectiveness and costs of a
      smartphone application (Vire) and an individualised online behaviour change
      program (ToDo-CR) in reducing sedentary behaviour, all-cause hospital admissions 
      and emergency department visits over 12 months after commencing CR. METHODS AND
      ANALYSIS: A multicentre, assessor-blind parallel randomised controlled trial will
      be conducted with 144 participants (18+ years). Participants will be recruited
      from three phase-II CR centres. They will be assessed on admission to CR and
      randomly assigned (1:1) to one of two groups: CR plus the ToDo-CR 6-month
      programme or usual care CR. Both groups will be re-assessed at 6 months and 12
      months for the primary outcome of all-cause hospital admissions and presentations
      to the emergency department. Accelerometer-measured changes in sedentary
      behaviour and physical activity will also be assessed. Logistic regression models
      will be used for the primary outcome of hospital admissions and emergency
      department visits. Methods for repeated measures analysis will be used for all
      other outcomes. A cost-effectiveness analysis will be conducted to evaluate the
      effects of the intervention on the rates of hospital admissions and emergency
      department visits within the 12 months post commencing CR. ETHICS AND
      DISSEMINATION: This study received ethical approval from the Australian Capital
      Territory Health (2019.ETH.00162), Calvary Public Hospital Bruce (20-2019) and
      the University of Canberra (HREC-2325) Human Research Ethics Committees (HREC).
      Results will be disseminated through peer-reviewed academic journals. Results
      will be made available to participants on request. TRIAL REGISTRATION NUMBER:
      ACTRN12619001223123.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Patterson, Kacie
AU  - Patterson K
AUID- ORCID: 0000-0001-5965-7101
AD  - Health Research Institute, Faculty of Health, University of Canberra, Canberra,
      Australian Capital Territory, Australia kacie.patterson@canberra.edu.au.
FAU - Davey, Rachel
AU  - Davey R
AD  - Health Research Institute, Faculty of Health, University of Canberra, Canberra,
      Australian Capital Territory, Australia.
FAU - Keegan, Richard
AU  - Keegan R
AD  - Research Institute for Sports and Exercise (UCRISE), Faculty of Health,
      University of Canberra, Bruce, Canberra, Australian Capital Territory, Australia.
FAU - Niyonsenga, Theophile
AU  - Niyonsenga T
AUID- ORCID: 0000-0002-6723-0316
AD  - Health Research Institute, Faculty of Health, University of Canberra, Canberra,
      Australian Capital Territory, Australia.
FAU - Mohanty, Itismita
AU  - Mohanty I
AD  - Health Research Institute, Faculty of Health, University of Canberra, Canberra,
      Australian Capital Territory, Australia.
FAU - van Berlo, Sander
AU  - van Berlo S
AD  - Onmi B.V, Eindhoven, Netherlands.
FAU - Freene, Nicole
AU  - Freene N
AD  - Health Research Institute, Faculty of Health, University of Canberra, Canberra,
      Australian Capital Territory, Australia.
AD  - Physiotherapy, Faculty of Health, University of Canberra, Canberra, Australian
      Capital Territory, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001223123
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Cardiac Rehabilitation
MH  - *Health Behavior
MH  - Hospitalization
MH  - Humans
MH  - *Mobile Applications
MH  - Sedentary Behavior
MH  - Smartphone
PMC - PMC7745513
OTO - NOTNLM
OT  - *complementary medicine
OT  - *coronary heart disease
OT  - *health informatics
OT  - *myocardial infarction
OT  - *preventive medicine
OT  - *rehabilitation medicine
COIS- Competing interests: KP, RD, RK, IM, TN and NF declare they have no competing
      interests. Vire and ToDo-CR was created by a private company, Onmi in
      collaboration with Do Something Different Limited. Onmi will not provide any
      funding for this study. SvB is the Manager and Designer for Onmi
      (https://onmi.design/), the Vire app and ToDo behaviour change program developer.
EDAT- 2020/12/17 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/12/16 05:27
PHST- 2020/12/16 05:27 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
AID - bmjopen-2020-040479 [pii]
AID - 10.1136/bmjopen-2020-040479 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e040479. doi: 10.1136/bmjopen-2020-040479.


PMID- 33323434
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - Effectiveness of routine measurement of health-related quality of life in
      improving the outcomes of patients with musculoskeletal problems-a cluster
      randomised controlled trial: protocol paper.
PG  - e040373
LID - 10.1136/bmjopen-2020-040373 [doi]
AB  - INTRODUCTION: Managing chronic musculoskeletal problems usually focuses on pain
      control using medications, but outcomes are often unsatisfactory and sometimes
      harmful. Information on a patient's health-related quality of life (HRQOL) may
      trigger a doctor to tailor management improving quality of life. The aim of this 
      trial is to find out whether routine measurement and reporting of a patient's
      EuroQoL 5-Dimension 5-Level (EQ-5D-5L) HRQOL data using an electronic platform
      can improve HRQOL and pain in patients with chronic knee or back problems in
      primary care. We will also assess the acceptability of routine electronic
      measurements and reporting of the EQ-5D-5L in primary care settings. METHODS:
      This is a multicentre, prospective, cluster randomised controlled trial set in
      six public primary care clinics in Hong Kong. At the intervention clinics,
      subjects will complete an electronic EQ-5D-5L form at recruitment and at each
      clinic follow-up over 12 months. A report of the patient's longitudinal EQ-5D-5L 
      data will be provided to the doctor. Subjects in the control clinics will receive
      care as usual. All subjects will complete the Western Ontario and McMaster
      Universities Osteoarthritis Index (WOMAC), a 10-point Pain Rating Scale and a
      structured questionnaire to collect sociodemographic information and data on
      morbidity and service utilisation at recruitment at baseline, 3, 6 and 12 months.
      Primary outcome is the change in WOMAC total score. Secondary outcomes are change
      in pain, other patient-reported outcome scores and doctor-rated severity of
      disease. Group differences in the changes in WOMAC and other outcome scores over 
      time will be analysed using generalised estimating equation model with an
      intention-to-treat principle. ETHICS AND DISSEMINATION: Ethics approval has been 
      obtained from The University of Hong Kong/Hospital Authority Hong Kong West
      Cluster (IRB reference number: UW 18-270). The results of the trial will be
      submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: 
      NCT03609762.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lam, Cindy
AU  - Lam C
AD  - Department of Family Medicine and Primary Care, University of Hong Kong Li Ka
      Shing Faculty of Medicine, Hong Kong, China clklam@hku.hk.
FAU - Chin, Weng Yee
AU  - Chin WY
AUID- ORCID: 0000-0003-3171-6792
AD  - Department of Family Medicine and Primary Care, University of Hong Kong Li Ka
      Shing Faculty of Medicine, Hong Kong, China.
FAU - Wong, Carlos King Ho
AU  - Wong CKH
AUID- ORCID: 0000-0002-6895-6071
AD  - Department of Family Medicine and Primary Care, University of Hong Kong Li Ka
      Shing Faculty of Medicine, Hong Kong, China.
FAU - Or, Kalun
AU  - Or K
AD  - Industrial and Manufacturing Systems Engineering, University of Hong Kong Faculty
      of Engineering, Hong Kong, China.
FAU - Fong, Daniel Yee Tak
AU  - Fong DYT
AD  - School of Nursing, University of Hong Kong Li Ka Shing Faculty of Medicine, Hong 
      Kong, China.
FAU - Cheung, Jason Pui Yin
AU  - Cheung JPY
AD  - Department of Orthopaedics and Traumatology, University of Hong Kong Li Ka Shing 
      Faculty of Medicine, Hong Kong, China.
FAU - Chao, David Vai Kiong
AU  - Chao DVK
AD  - Department of Family Medicine and Primary Health Care, United Christian Hospital,
      Hong Kong, China.
FAU - Wong, Eliza L Y
AU  - Wong ELY
AUID- ORCID: 0000-0001-9983-6219
AD  - JC School of Public Health and Primary Care, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Kind, Paul
AU  - Kind P
AD  - Institute of Health Sciences, University of Leeds, Leeds, UK.
AD  - Centre for Health Economics, Management and Policy, National Research University 
      Higher School of Economics, Moskva, Russia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03609762
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Hong Kong
MH  - Humans
MH  - *Musculoskeletal Diseases
MH  - *Pain Measurement
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Self Report
MH  - Surveys and Questionnaires
PMC - PMC7745313
OTO - NOTNLM
OT  - *information technology
OT  - *musculoskeletal disorders
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/12/16 05:27
PHST- 2020/12/16 05:27 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
AID - bmjopen-2020-040373 [pii]
AID - 10.1136/bmjopen-2020-040373 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e040373. doi: 10.1136/bmjopen-2020-040373.


PMID- 33323426
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20220317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 15
TI  - Zika virus infection in pregnancy: a protocol for the joint analysis of the
      prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia.
PG  - e035307
LID - 10.1136/bmjopen-2019-035307 [doi]
AB  - INTRODUCTION: Zika virus (ZIKV) infection in pregnancy has been associated with
      microcephaly and severe neurological damage to the fetus. Our aim is to document 
      the risks of adverse pregnancy and birth outcomes and the prevalence of
      laboratory markers of congenital infection in deliveries to women experiencing
      ZIKV infection during pregnancy, using data from European Commission-funded
      prospective cohort studies in 20 centres in 11 countries across Latin America and
      the Caribbean. METHODS AND ANALYSIS: We will carry out a centre-by-centre
      analysis of the risks of adverse pregnancy and birth outcomes, comparing women
      with confirmed and suspected ZIKV infection in pregnancy to those with no
      evidence of infection in pregnancy. We will document the proportion of deliveries
      in which laboratory markers of congenital infection were present. Finally, we
      will investigate the associations of trimester of maternal infection in
      pregnancy, presence or absence of maternal symptoms of acute ZIKV infection and
      previous flavivirus infections with adverse outcomes and with markers of
      congenital infection. Centre-specific estimates will be pooled using a two-stage 
      approach. ETHICS AND DISSEMINATION: Ethical approval was obtained at each centre.
      Findings will be presented at international conferences and published in
      peer-reviewed open access journals and discussed with local public health
      officials and representatives of the national Ministries of Health, Pan American 
      Health Organization and WHO involved with ZIKV prevention and control activities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ades, A E
AU  - Ades AE
AD  - Department of Population Health Sciences, University of Bristol Medical School,
      Bristol, UK.
FAU - Brickley, Elizabeth B
AU  - Brickley EB
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Alexander, Neal
AU  - Alexander N
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Brown, David
AU  - Brown D
AD  - Flavivirus Reference Laboratory, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
FAU - Jaenisch, Thomas
AU  - Jaenisch T
AD  - Department of Infectious Diseases, Section Clinical Tropical Medicine,
      UniversitatsKlinikum Heidelberg, Heidelberg, Germany.
FAU - Miranda-Filho, Democrito de Barros
AU  - Miranda-Filho DB
AD  - Universidade Federal de Pernambuco, Recife, Brazil.
FAU - Pohl, Moritz
AU  - Pohl M
AD  - Institute of Medical Biometry and Informatics, University of Heidelberg,
      Heidelberg, Germany.
FAU - Rosenberger, Kerstin D
AU  - Rosenberger KD
AD  - Department of Infectious Diseases, Section Clinical Tropical Medicine,
      UniversitatsKlinikum Heidelberg, Heidelberg, Germany.
FAU - Soriano-Arandes, Antoni
AU  - Soriano-Arandes A
AUID- ORCID: 0000-0001-9613-7228
AD  - Paediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari
      Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Spain.
FAU - Thorne, Claire
AU  - Thorne C
AUID- ORCID: 0000-0003-0389-1956
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK claire.thorne@ucl.ac.uk.
FAU - Ximenes, Ricardo Arraes de Alencar
AU  - Ximenes RAA
AD  - Universidade Federal de Pernambuco, Recife, Brazil.
FAU - de Araujo, Thalia Velho Barreto
AU  - de Araujo TVB
AD  - Universidade Federal de Pernambuco, Recife, Brazil.
FAU - Avelino-Silva, Vivian I
AU  - Avelino-Silva VI
AD  - Department of Infectious and Parasitic Diseases, Faculdade de Medicina da
      Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
FAU - Bethencourt Castillo, Sarah Esperanza
AU  - Bethencourt Castillo SE
AD  - Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela.
FAU - Borja Aburto, Victor Hugo
AU  - Borja Aburto VH
AD  - Mexican Institute of Social Security, Mexico City, Mexico.
FAU - Brasil, Patricia
AU  - Brasil P
AD  - Instituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz, Rio de
      Janeiro, RJ, Brazil.
FAU - Christie, Celia D C
AU  - Christie CDC
AD  - Department of Child and Adolescent Health, University of the West Indies at Mona,
      Kingston, Jamaica.
FAU - de Souza, Wayner Vieira
AU  - de Souza WV
AD  - Instituto Aggeu Magalhaes, Fundacao Oswaldo Cruz, Recife, Brazil.
FAU - Gotuzzo H, Jose Eduardo
AU  - Gotuzzo H JE
AD  - Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
FAU - Hoen, Bruno
AU  - Hoen B
AD  - INSERM Centre d'Investigation Clinique 1424, Centre Hospitalier Universitaire de 
      Pointe-a-Pitre, Guadeloupe, France.
AD  - Faculte de Medecine Hyacinthe Bastaraud, Universite des Antilles et de la Guyane,
      Pointe-a-Pitre, Guadeloupe, France.
FAU - Koopmans, Marion
AU  - Koopmans M
AD  - Department of Viroscience, Erasmus Universiteit Rotterdam, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Martelli, Celina Maria Turchi
AU  - Martelli CMT
AD  - Instituto Aggeu Magalhaes, Fundacao Oswaldo Cruz, Recife, Brazil.
FAU - Martins Teixeira, Mauro
AU  - Martins Teixeira M
AD  - Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
FAU - Marques, Ernesto T A
AU  - Marques ETA
AD  - Instituto Aggeu Magalhaes, Fundacao Oswaldo Cruz, Recife, Brazil.
AD  - Department of Infectious Diseases and Microbiology, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
FAU - Miranda, Maria Consuelo
AU  - Miranda MC
AD  - Universidad Industrial de Santander, Bucaramanga, Colombia.
FAU - Montarroyos, Ulisses Ramos
AU  - Montarroyos UR
AD  - Universidade de Pernambuco, Recife, Brazil.
FAU - Moreira, Maria Elisabeth
AU  - Moreira ME
AD  - Figueira National Institute for Women's, Children's and Adolescents Health,
      Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Morris, J Glenn
AU  - Morris JG
AD  - Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
FAU - Rockx, Barry
AU  - Rockx B
AD  - Department of Viroscience, Erasmus Universiteit Rotterdam, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Saba Villarroel, Paola Mariela
AU  - Saba Villarroel PM
AD  - Centro Nacional de Enfermedades Tropicales, Santa Cruz de la Sierra, Santa Cruz
      de la Sierra, Bolivia.
FAU - Soria Segarra, Carmen
AU  - Soria Segarra C
AD  - Universidad Catolica de Santiago de Guayaquil, Guayaquil, Guayas, Ecuador.
AD  - SOSECALI C., Ltda, Guayaquil, Ecuador.
FAU - Tami, Adriana
AU  - Tami A
AUID- ORCID: 0000-0002-1918-9144
AD  - Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela.
AD  - Department of Medical Microbiology and Infection Prevention, University Medical
      Center Groningen, Groningen, The Netherlands.
FAU - Turchi, Marilia Dalva
AU  - Turchi MD
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Brazil.
FAU - Giaquinto, Carlo
AU  - Giaquinto C
AD  - Department of Woman's and Child's Health, Universita degli Studi di Padova,
      Padova, Italy.
FAU - de Lamballerie, Xavier
AU  - de Lamballerie X
AD  - Aix-Marseille Universite Institut Universitaire de Technologie d'Aix-en-Provence,
      Aix-en-Provence, Provence-Alpes-Cote d'Azur, France.
FAU - Wilder-Smith, Annelies
AU  - Wilder-Smith A
AD  - Department of Epidemiology and Global Health, Umea University, Umea, Sweden.
CN  - EC Zika Consortia Vertical Transmission Study Group
LA  - eng
GR  - MC_U145079307/MRC_/Medical Research Council/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
GR  - 205377/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Caribbean Region/epidemiology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Latin America/epidemiology
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/epidemiology
MH  - Prospective Studies
MH  - Risk
MH  - *Zika Virus
MH  - *Zika Virus Infection/epidemiology
PMC - PMC7745317
OTO - NOTNLM
OT  - *epidemiology
OT  - *paediatric infectious disease & immunisation
OT  - *public health
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure
      form. The following authors report grants from the European Commission (AEA, EBB,
      NA, DB, TJ, KDR, CT, CDCC, AS-A, JGM, CG, Xd-L, AW-S); EBB reports funding from
      by Wellcome Trust & the UK's Department for International Development; MT reports
      grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil
      and from Fundacao de Amparo a Pesquisa do EStado de MInas Gerais (FAPEMIG,
      Brazil), during the conduct of the study; MK has a patent on zika diagnostics
      pending.
IR  - Anzinger J
FIR - Anzinger, Joshua
IR  - Bailey H
FIR - Bailey, Heather
IR  - Rochars VB
FIR - Rochars, Valery Beau De
IR  - Damasceno L
FIR - Damasceno, Luana
IR  - Albuquerque MF
FIR - Albuquerque, Maria de Fatima
IR  - Franca RFO
FIR - Franca, Rafael F O
IR  - Ramirez HL
FIR - Ramirez, Hugo Lopez-Gatell
IR  - Gomez A
FIR - Gomez, Adriana
IR  - Gordon F
FIR - Gordon, Fabiana
IR  - Guzman MG
FIR - Guzman, Maria G
IR  - Lang D
FIR - Lang, Daniel
IR  - Louis R
FIR - Louis, Rigan
IR  - Lozano A
FIR - Lozano, Anyela
IR  - Martinez E
FIR - Martinez, Eric
IR  - Mayaud P
FIR - Mayaud, Philippe
IR  - Serrano RO
FIR - Serrano, Ricard Ortiz
IR  - Salgado SP
FIR - Salgado, Silvia P
IR  - Segurado AA
FIR - Segurado, Aluizio Augusto
IR  - Vasconcelos ZFM
FIR - Vasconcelos, Zilton F M
IR  - Tabosa IF
FIR - Tabosa, Isabelle Freire
IR  - Villar LA
FIR - Villar, Luis Angel
EDAT- 2020/12/17 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/12/16 05:27
PHST- 2020/12/16 05:27 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
AID - bmjopen-2019-035307 [pii]
AID - 10.1136/bmjopen-2019-035307 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 15;10(12):e035307. doi: 10.1136/bmjopen-2019-035307.


PMID- 33323364
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Dec
TI  - Democratic and ethical problem of lung cancer screening: exclusion of true
      high-risk populations. Can it be fixed? Yes.
LID - e000811 [pii]
LID - 10.1136/bmjresp-2020-000811 [doi]
AB  - Screening a population for a potentially deadly disease, the ultimate goal must
      be to prevent morbidity and mortality from this disease for the whole population.
      Unlike breast cancer or cervical cancer screening, where all women are screened
      after a certain age, CT screening for lung cancer has been based on selection of 
      putative high-risk individuals based on age and smoking cut-off values. The type 
      of selection used leaves too many high-risk individuals behind. The solution is
      to use only validated risk prediction models for selection.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Roe, Oluf Dimitri
AU  - Roe OD
AUID- ORCID: 0000-0002-4870-5822
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, Trondheim, Norway olufdroe@yahoo.no.
AD  - Cancer Clinic, Levanger Hospital, Nord-Trondelag Health Trust, Levanger, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
SB  - IM
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - *Lung Neoplasms/diagnosis/epidemiology
MH  - Mass Screening
MH  - Risk Factors
MH  - *Uterine Cervical Neoplasms
PMC - PMC7745524
OTO - NOTNLM
OT  - *lung cancer
OT  - *tobacco and the lung
COIS- Competing interests: None declared.
EDAT- 2020/12/17 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/12/16 05:27
PHST- 2020/10/23 00:00 [received]
PHST- 2020/11/29 00:00 [revised]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/16 05:27 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 7/1/e000811 [pii]
AID - 10.1136/bmjresp-2020-000811 [doi]
PST - ppublish
SO  - BMJ Open Respir Res. 2020 Dec;7(1). pii: 7/1/e000811. doi:
      10.1136/bmjresp-2020-000811.


PMID- 33323141
OWN - NLM
STAT- Publisher
LR  - 20201216
IS  - 2051-6967 (Electronic)
IS  - 0790-9667 (Linking)
DP  - 2020 Dec 16
TI  - Vocally disruptive behaviour in nursing home residents in Ireland: a descriptive 
      study.
PG  - 1-11
LID - 10.1017/ipm.2020.124 [doi]
AB  - BACKGROUND: Vocally disruptive behaviour (VDB) is relatively common in nursing
      home residents but difficult to treat. There is limited study on prevalence and
      treatment of VDB. We hypothesise that VDB is a result of complex interaction
      between patient factors and environmental contributors. METHODS: Residents of
      nursing homes in south Dublin were the target population for this study.
      Inclusion criteria were that the residents were 65 years or over and exhibited
      VDB significant enough for consideration in the resident's care plan. Information
      on typology and frequency of VDB, Interventions employed and their efficacy,
      diagnoses, Cohen-Mansfield Agitation Inventory scores, Mini-Mental State
      Examination scores, and Barthel Index scores were obtained. RESULTS: Eight
      percent of nursing home residents were reported to display VDB, most commonly
      screaming (in 39.4% of vocally disruptive residents). VDB was associated with
      physical agitation and dementia; together, these two factors accounted for almost
      two-thirds of the variation in VDB between residents. One-to-one attention,
      engaging in conversation, redirecting behaviour, and use of psychotropic
      medication were reported by nurses as the most useful interventions. Analgesics
      were the medications most commonly used (65.7%) followed by quetiapine (62.9%),
      and these were reportedly effective in 82.6% and 77.2% of residents respectively.
      CONCLUSIONS: VDB is common, challenging, and difficult to manage. The study of
      VDB is limited by a variety of factors that both contribute to this behaviour and
      make its treatment challenging. Issues relating to capacity and ethics make it
      difficult to conduct randomised controlled trials of treatments for VDB in the
      population affected.
FAU - Nwogbunyama, C
AU  - Nwogbunyama C
AD  - West Blanchardstown Mental Health Service, Blanchardstown Primary Care Centre,
      Dublin 15, Ireland.
FAU - Kelly, B D
AU  - Kelly BD
AD  - Department of Psychiatry, Trinity College Dublin, Trinity Centre for Health
      Sciences, Tallaght University Hospital, Dublin 24, Ireland.
FAU - Cooney, C
AU  - Cooney C
AD  - Department of Old Age Psychiatry, Carew House, St Vincent's University Hospital, 
      Dublin 4, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201216
PL  - England
TA  - Ir J Psychol Med
JT  - Irish journal of psychological medicine
JID - 8900208
SB  - IM
OTO - NOTNLM
OT  - Behavioural and psychological symptoms of dementia
OT  - dementia
OT  - mental disorder
OT  - psychiatry
OT  - vocally disruptive behaviour
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/12/16 05:24
PHST- 2020/12/16 05:24 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
AID - S079096672000124X [pii]
AID - 10.1017/ipm.2020.124 [doi]
PST - aheadofprint
SO  - Ir J Psychol Med. 2020 Dec 16:1-11. doi: 10.1017/ipm.2020.124.


PMID- 33322871
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 140
IP  - 18
DP  - 2020 Dec 15
TI  - Ethics experts on the wrong track.
LID - 10.4045/tidsskr.20.0952 [doi]
FAU - Laake, Jon Henrik
AU  - Laake JH
FAU - Hansen, Magna
AU  - Hansen M
FAU - Mo, Skule
AU  - Mo S
FAU - Brathen, Camilla Christin
AU  - Brathen CC
FAU - Adolfsen, Eirik
AU  - Adolfsen E
FAU - Overland, Gunhild
AU  - Overland G
LA  - nor
PT  - Journal Article
TT  - Etikkeksperter pa villspor.
DEP - 20201124
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny
      raekke
JID - 0413423
SB  - IM
CIN - Tidsskr Nor Laegeforen. 2021 Jan 11;141(1):. PMID: 33433095
MH  - *Ethics, Medical
MH  - Humans
EDAT- 2020/12/17 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/12/16 02:45
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/12/16 02:45 [entrez]
AID - 20-0952 [pii]
AID - 10.4045/tidsskr.20.0952 [doi]
PST - epublish
SO  - Tidsskr Nor Laegeforen. 2020 Nov 24;140(18). pii: 20-0952. doi:
      10.4045/tidsskr.20.0952. Print 2020 Dec 15.


PMID- 33322868
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20210304
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 140
IP  - 18
DP  - 2020 Dec 15
TI  - Ethical dilemmas in hospitals during the COVID-19 pandemic.
LID - 10.4045/tidsskr.20.0851 [doi]
FAU - Larsen, Berit Hofset
AU  - Larsen BH
FAU - Magelssen, Morten
AU  - Magelssen M
FAU - Dunlop, Oona
AU  - Dunlop O
FAU - Pedersen, Reidar
AU  - Pedersen R
FAU - Forde, Reidun
AU  - Forde R
LA  - nor
PT  - Journal Article
TT  - Etiske dilemmaer i sykehusene under covid-19-pandemien.
DEP - 20201211
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny
      raekke
JID - 0413423
SB  - IM
MH  - *COVID-19
MH  - Hospitals
MH  - Humans
MH  - *Morals
MH  - *Pandemics
MH  - SARS-CoV-2
EDAT- 2020/12/17 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/16 02:45
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/12/16 02:45 [entrez]
AID - 20-0851 [pii]
AID - 10.4045/tidsskr.20.0851 [doi]
PST - epublish
SO  - Tidsskr Nor Laegeforen. 2020 Dec 11;140(18). pii: 20-0851. doi:
      10.4045/tidsskr.20.0851. Print 2020 Dec 15.


PMID- 33322462
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201229
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Linking)
VI  - 56
IP  - 12
DP  - 2020 Dec 11
TI  - Ethical Challenges in Health Care Policy during COVID-19 Pandemic in Italy.
LID - E691 [pii]
LID - 10.3390/medicina56120691 [doi]
AB  - Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, Italy has
      proven to be one of the countries with the highest coronavirus-linked death rate.
      To reduce the impact of SARS-CoV-2 coronavirus, the Italian Government
      decision-makers issued a series of law decrees that imposed measures limiting
      social contacts, stopped non-essential production activities, and restructured
      public health care in order to privilege assistance to patients infected with
      SARS-CoV-2. Health care services were substantially limited including planned
      hospitalization and elective surgeries. These substantial measures were
      criticized due to their impact on individual rights including freedom and
      autonomy, but were justified by the awareness that hospitals would have been
      unable to cope with the surge of infected people who needed treatment for
      COVID-19. The imbalance between the need to guarantee ordinary care and to deal
      with the pandemic, in a context of limited health resources, raises ethical
      concerns as well as clinical management issues. The emergency scenario caused by 
      the COVID-19 pandemic, especially in the lockdown phase, led the Government and
      health care decision-makers to prioritize community safety above the individuals'
      rights. This new community-centered approach to clinical care has created tension
      among the practitioners and exposed health workers to malpractice claims.
      Reducing the morbidity and mortality rates of the COVID-19 pandemic is the
      priority of every government, but the legitimate question remains whether the
      policy that supports this measure could be less harmful for the health care
      system.
FAU - Ferorelli, Davide
AU  - Ferorelli D
AUID- ORCID: 0000-0001-8150-7476
AD  - Interdisciplinary Department of Medicine, Section of Legal Medicine, University
      of Bari, Piazza Giulio, Cesare 11, 70100 Bari, Italy.
FAU - Mandarelli, Gabriele
AU  - Mandarelli G
AUID- ORCID: 0000-0003-4887-5108
AD  - Interdisciplinary Department of Medicine, Section of Legal Medicine, University
      of Bari, Piazza Giulio, Cesare 11, 70100 Bari, Italy.
FAU - Solarino, Biagio
AU  - Solarino B
AD  - Interdisciplinary Department of Medicine, Section of Legal Medicine, University
      of Bari, Piazza Giulio, Cesare 11, 70100 Bari, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
SB  - IM
MH  - COVID-19/mortality/*prevention & control
MH  - Emergencies
MH  - *Health Policy
MH  - Humans
MH  - Italy/epidemiology
MH  - *Patient Rights
MH  - Public Health Administration/*ethics/legislation & jurisprudence
MH  - Quarantine/*ethics/legislation & jurisprudence
MH  - SARS-CoV-2
PMC - PMC7764230
OTO - NOTNLM
OT  - COVID-19
OT  - balancing rights
OT  - clinical management
OT  - ethical challenges
OT  - legal medicine
OT  - patient-centered care
OT  - public health
EDAT- 2020/12/17 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/16 01:03
PHST- 2020/10/28 00:00 [received]
PHST- 2020/11/28 00:00 [revised]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2020/12/16 01:03 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - medicina56120691 [pii]
AID - 10.3390/medicina56120691 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2020 Dec 11;56(12). pii: medicina56120691. doi:
      10.3390/medicina56120691.


PMID- 33322066
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - In Vitro Differentiation of Human Placenta-Derived Multipotent Cells into
      Schwann-Like Cells.
LID - E1657 [pii]
LID - 10.3390/biom10121657 [doi]
AB  - Human placenta-derived multipotent stem cells (PDMCs) resembling embryonic stem
      cells can differentiate into three germ layer cells, including ectodermal lineage
      cells, such as neurons, astrocytes, and oligodendrocytes. The favorable
      characteristics of noninvasive cell harvesting include fewer ethical, religious, 
      and legal considerations as well as accessible and limitless supply. Thus, PDMCs 
      are attractive for cell-based therapy. The Schwann cell (SC) is the most common
      cell type used for tissue engineering such as nerve regeneration. However, the
      differentiation potential of human PDMCs into SCs has not been demonstrated until
      now. In this study, we evaluated the potential of PDMCs to differentiate into
      SC-like cells in a differentiation medium. After induction, PDMCs not only
      exhibited typical SC spindle-shaped morphology but also expressed SC markers,
      including S100, GFAP, p75, MBP, and Sox 10, as revealed by immunocytochemistry.
      Moreover, a reverse transcription-quantitative polymerase chain reaction analysis
      revealed the elevated gene expression of S100, GFAP, p75, MBP, Sox-10, and
      Krox-20 after SC induction. A neuroblastoma cell line, SH-SY5Y, was cultured in
      the conditioned medium (CM) collected from PDMC-differentiated SCs. The growth
      rate of the SH-SY5Y increased in the CM, indicating the function of PDMC-induced 
      SCs. In conclusion, human PDMCs can be differentiated into SC-like cells and thus
      are an attractive alternative to SCs for cell-based therapy in the future.
FAU - Juan, Chung-Hau
AU  - Juan CH
AUID- ORCID: 0000-0002-3494-2878
AD  - Department of Anesthesiology, Cathay General Hospital, Taipei 106438, Taiwan.
AD  - Department of Biomedical Sciences, National Central University, Taoyuan 32001,
      Taiwan.
FAU - Chen, Mei-Hsiu
AU  - Chen MH
AD  - Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City
      220216, Taiwan.
AD  - Department of Biomedical Engineering, Ming Chuan University, Taoyuan 333321,
      Taiwan.
FAU - Lin, Feng-Hui
AU  - Lin FH
AD  - Department of Biomedical Engineering, National Taiwan University, Taipei 106319, 
      Taiwan.
FAU - Wong, Chih-Shung
AU  - Wong CS
AD  - Department of Anesthesiology, Cathay General Hospital, Taipei 106438, Taiwan.
FAU - Chien, Chih-Cheng
AU  - Chien CC
AD  - Department of Anesthesiology, Cathay General Hospital, Taipei 106438, Taiwan.
FAU - Chen, Ming-Hong
AU  - Chen MH
AD  - Department of Neurosurgery, Taipei Municipal Wangfang Hospital, Taipei 116081,
      Taiwan.
AD  - Department of Biomedical Sciences, Graduate Institute of Nanomedicine and Medical
      Engineering, Taipei Medical University, Taipei 110301, Taiwan.
LA  - eng
GR  - MR9708/Cathay General Hospital/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Biomarkers)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (EGR2 protein, human)
RN  - 0 (Early Growth Response Protein 2)
RN  - 0 (GFAP protein, human)
RN  - 0 (Glial Fibrillary Acidic Protein)
RN  - 0 (Myelin Basic Protein)
RN  - 0 (Neuregulin-1)
RN  - 0 (PSIP1 protein, human)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (S100 Proteins)
RN  - 0 (SOX10 protein, human)
RN  - 0 (SOXE Transcription Factors)
RN  - 0 (Transcription Factors)
RN  - 0 (platelet-derived growth factor A)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 155646-83-6 (heregulin beta1)
RN  - 1F7A44V6OU (Colforsin)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/genetics/metabolism
MH  - Biomarkers/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Colforsin/*pharmacology
MH  - Culture Media, Conditioned/chemistry/pharmacology
MH  - Early Growth Response Protein 2/genetics/metabolism
MH  - Female
MH  - Fibroblast Growth Factor 2/*pharmacology
MH  - Gene Expression
MH  - Glial Fibrillary Acidic Protein/genetics/metabolism
MH  - Humans
MH  - Multipotent Stem Cells/cytology/*drug effects/metabolism
MH  - Myelin Basic Protein/genetics/metabolism
MH  - Neuregulin-1/*pharmacology
MH  - Neurons/cytology/drug effects/metabolism
MH  - Placenta/cytology/metabolism
MH  - Platelet-Derived Growth Factor/*pharmacology
MH  - Pregnancy
MH  - Primary Cell Culture
MH  - S100 Proteins/genetics/metabolism
MH  - SOXE Transcription Factors/genetics/metabolism
MH  - Schwann Cells/cytology/*drug effects/metabolism
MH  - Transcription Factors/genetics/metabolism
PMC - PMC7763858
OTO - NOTNLM
OT  - *Schwann cell
OT  - *differentiation
OT  - *peripheral nerve
OT  - *placenta-derived multipotent stem cell
EDAT- 2020/12/17 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/12/16 01:02
PHST- 2020/09/01 00:00 [received]
PHST- 2020/12/04 00:00 [revised]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2020/12/16 01:02 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - biom10121657 [pii]
AID - 10.3390/biom10121657 [doi]
PST - epublish
SO  - Biomolecules. 2020 Dec 10;10(12). pii: biom10121657. doi: 10.3390/biom10121657.


PMID- 33322055
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2076-2607 (Print)
IS  - 2076-2607 (Linking)
VI  - 8
IP  - 12
DP  - 2020 Dec 10
TI  - Microbiome Research: Open Communication Today, Microbiome Applications in the
      Future.
LID - E1960 [pii]
LID - 10.3390/microorganisms8121960 [doi]
AB  - Microbiome research has recently gained centre-stage in both basic science and
      translational applications, yet researchers often feel that public communication 
      about its potential overpromises. This manuscript aims to share a perspective on 
      how scientists can engage in more open, ethical and transparent communication
      using an ongoing research project on food systems microbiomes as a case study.
      Concrete examples of strategically planned communication efforts are outlined,
      which aim to inspire and empower other researchers. Finally, we conclude with a
      discussion on the benefits of open and transparent communication from early-on in
      innovation pathways, mainly increasing trust in scientific processes and thus
      paving the way to achieving societal milestones such as the UN Sustainable
      Development Goals and the EU Green Deal.
FAU - Schelkle, Bettina
AU  - Schelkle B
AD  - European Food Information Council, Rue des Deux Eglises 14, 1000 Brussels,
      Belgium.
FAU - Galland, Quentin
AU  - Galland Q
AD  - Hague Corporate Affairs, Rue Belliard 40, 1040 Brussels, Belgium.
LA  - eng
GR  - 818290/European Commission Horizon 2020 Funding Programme
PT  - Journal Article
DEP - 20201210
PL  - Switzerland
TA  - Microorganisms
JT  - Microorganisms
JID - 101625893
PMC - PMC7763060
OTO - NOTNLM
OT  - communication
OT  - innovation
OT  - microbiome
OT  - trust
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 01:02
PHST- 2020/10/27 00:00 [received]
PHST- 2020/11/27 00:00 [revised]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2020/12/16 01:02 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - microorganisms8121960 [pii]
AID - 10.3390/microorganisms8121960 [doi]
PST - epublish
SO  - Microorganisms. 2020 Dec 10;8(12). pii: microorganisms8121960. doi:
      10.3390/microorganisms8121960.


PMID- 33320598
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2373-9878 (Electronic)
IS  - 2373-9878 (Linking)
VI  - 6
IP  - 12
DP  - 2020 Dec 14
TI  - Induction of Irritation and Inflammation in a 3D Innervated Tissue Model of the
      Human Cornea.
PG  - 6886-6895
LID - 10.1021/acsbiomaterials.0c01136 [doi]
AB  - Detection of slight changes in the chemical, thermal, and physical environments
      of the ocular surface is necessary to protect eyesight. The cornea, as the most
      densely innervated peripheral tissue in the body, can be damaged as a result of
      caustic chemical exposure. Such damage can be painful and debilitating, thus
      underscoring the need to understand mechanisms of ocular irritation. Both ethical
      and translational limitations regarding the use of animal subjects in part drive 
      the need to develop relevant in vitro cell and tissue models that emulate the
      physiology of the human cornea. In this study, we utilized our 3D in vitro
      cornea-like tissue model to study the effects of irritation mediated by transient
      receptor potential (TRP) channels vanilloid 1 and ankyrin 1 (TRPV1; TRPA1) in
      response to allyl isothiocyanate (AITC) stimulation. Changes in gene expression
      were analyzed to characterize wound healing responses of the epithelial, stromal,
      and neuronal cell populations in the corneal tissue models. Key findings of the
      study include indications of wound healing, such as stromal myofibroblast
      differentiation and epithelial barrier re-establishment, amplification of
      pro-inflammatory cytokines, and downstream ECM protein remodeling due to
      irritation with the addition of sensory innervation. This study further
      establishes this in vitro tissue model as a useful tool for studying corneal
      irritation in vitro in a holistic manner with promise as a novel and sensitive
      tool for studying chemical exposures and subsequent responses.
FAU - Pollard, Rachel E
AU  - Pollard RE
AD  - Department of Biomedical Engineering, Tufts University, 4 Colby St, Medford,
      Massachusetts 02155, United States.
FAU - McKay, Tina B
AU  - McKay TB
AD  - Department of Biomedical Engineering, Tufts University, 4 Colby St, Medford,
      Massachusetts 02155, United States.
FAU - Ford, Andrew
AU  - Ford A
AD  - Department of Biomedical Engineering, Tufts University, 4 Colby St, Medford,
      Massachusetts 02155, United States.
FAU - Cairns, Dana M
AU  - Cairns DM
AD  - Department of Biomedical Engineering, Tufts University, 4 Colby St, Medford,
      Massachusetts 02155, United States.
FAU - Georgakoudi, Irene
AU  - Georgakoudi I
AD  - Department of Biomedical Engineering, Tufts University, 4 Colby St, Medford,
      Massachusetts 02155, United States.
FAU - Kaplan, David L
AU  - Kaplan DL
AUID- ORCID: 0000-0002-9245-7774
AD  - Department of Biomedical Engineering, Tufts University, 4 Colby St, Medford,
      Massachusetts 02155, United States.
LA  - eng
GR  - R01 EY020856/EY/NEI NIH HHS/United States
GR  - P41 EB002520/EB/NIBIB NIH HHS/United States
GR  - S10 OD021624/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201117
PL  - United States
TA  - ACS Biomater Sci Eng
JT  - ACS biomaterials science & engineering
JID - 101654670
SB  - IM
MH  - Animals
MH  - *Cornea
MH  - Humans
MH  - *Inflammation/chemically induced
MH  - Neurons
MH  - Pain
MH  - Wound Healing
OTO - NOTNLM
OT  - *AITC
OT  - *cornea
OT  - *cornea innervation
OT  - *cornea irritation
OT  - *cornea tissue model
EDAT- 2020/12/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/15 17:11
PHST- 2020/12/15 17:11 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1021/acsbiomaterials.0c01136 [doi]
PST - ppublish
SO  - ACS Biomater Sci Eng. 2020 Dec 14;6(12):6886-6895. doi:
      10.1021/acsbiomaterials.0c01136. Epub 2020 Nov 17.


PMID- 33320103
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 15
TI  - An Intervention With Dance and Yoga for Girls With Functional Abdominal Pain
      Disorders (Just in TIME): Protocol for a Randomized Controlled Trial.
PG  - e19748
LID - 10.2196/19748 [doi]
AB  - BACKGROUND: Functional abdominal pain disorders (FAPDs) affect many children
      worldwide, predominantly girls, and cause considerable long-term negative
      consequences for individuals and society. Evidence-based and cost-effective
      treatments are therefore strongly needed. Physical activity has shown promising
      effects in the practical management of FAPDs. Dance and yoga are both popular
      activities that have been shown to provide significant psychological and
      pain-related benefits with minimal risk. The activities complement each other, in
      that dance involves dynamic, rhythmic physical activity, while yoga enhances
      relaxation and focus. OBJECTIVE: This study aims to evaluate the effects of a
      dance and yoga intervention among girls aged 9 to 13 years with FAPDs. METHODS:
      The study is a prospective randomized controlled trial among girls aged 9 to 13
      years with functional abdominal pain, irritable bowel syndrome, or both. The
      target sample size was 150 girls randomized into 2 arms: an intervention arm that
      receives dance and yoga sessions twice weekly for 8 months and a control arm that
      receives standard care. Outcomes will be measured at baseline and after 4, 8, 12,
      and 24 months, and long-term follow-up will be conducted 5 years from baseline.
      Questionnaires, interviews, and biomarker measures, such as cortisol in saliva
      and fecal microbiota, will be used. The primary outcome is the proportion of
      girls in each group with reduced pain, as measured by the faces pain
      scale-revised in a pain diary, immediately after the intervention. Secondary
      outcomes are gastrointestinal symptoms, general health, mental health, stress,
      and physical activity. The study also includes qualitative evaluations and health
      economic analyses. This study was approved by the Regional Ethical Review Board
      in Uppsala (No. 2016/082 1-2). RESULTS: Data collection began in October 2016.
      The intervention has been performed in 3 periods from 2016 through 2019. The
      final 5-year follow-up is anticipated to be completed by fall 2023. CONCLUSIONS: 
      Cost-effective and easily accessible interventions are warranted to reduce the
      negative consequences arising from FAPDs in young girls. Physical activity is an 
      effective strategy, but intervention studies are needed to better understand what
      types of activities facilitate regular participation in this target group. The
      Just in TIME (Try, Identify, Move, and Enjoy) study will provide insights
      regarding the effectiveness of dance and yoga and is anticipated to contribute to
      the challenging work of reducing the burden of FAPDs for young girls. TRIAL
      REGISTRATION: ClinicalTrials.gov (NCT02920268);
      https://clinicaltrials.gov/ct2/show/NCT02920268. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/19748.
CI  - (c)Anna Philipson, Stefan Sarnblad, Lars Ekstav, Mats Eriksson, Ulrika L
      Fagerberg, Margareta Moller, Evalotte Morelius, Anna Duberg. Originally published
      in JMIR Research Protocols (http://www.researchprotocols.org), 15.12.2020.
FAU - Philipson, Anna
AU  - Philipson A
AUID- ORCID: https://orcid.org/0000-0001-8433-6529
AD  - University Health Care Research Center, Faculty of Medicine and Health, Orebro
      University, Orebro, Sweden.
FAU - Sarnblad, Stefan
AU  - Sarnblad S
AUID- ORCID: https://orcid.org/0000-0002-1440-9961
AD  - Department of Paediatrics, Orebro University Hospital, Orebro, Sweden.
AD  - Faculty of Medicine and Health, School of Medical Sciences, Orebro University,
      Orebro, Sweden.
FAU - Ekstav, Lars
AU  - Ekstav L
AUID- ORCID: https://orcid.org/0000-0002-6154-6600
AD  - Department of Paediatrics, Orebro University Hospital, Orebro, Sweden.
FAU - Eriksson, Mats
AU  - Eriksson M
AUID- ORCID: https://orcid.org/0000-0002-5996-2584
AD  - Faculty of Medicine and Health, School of Health Sciences, Orebro University,
      Orebro, Sweden.
FAU - Fagerberg, Ulrika L
AU  - Fagerberg UL
AUID- ORCID: https://orcid.org/0000-0003-2727-7280
AD  - Centre for Clinical Research, Vastmanland Hospital Vasteras, Uppsala University, 
      Uppsala, Sweden.
AD  - Department of Women's and Children's Health, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Moller, Margareta
AU  - Moller M
AUID- ORCID: https://orcid.org/0000-0002-2051-2164
AD  - University Health Care Research Center, Faculty of Medicine and Health, Orebro
      University, Orebro, Sweden.
FAU - Morelius, Evalotte
AU  - Morelius E
AUID- ORCID: https://orcid.org/0000-0002-3256-5407
AD  - Department of Health, Medicine and Caring Sciences, Linkoping University,
      Linkoping, Sweden.
AD  - School of Nursing and Midwifery, Edith Cowan University, Joondalup, Australia.
FAU - Duberg, Anna
AU  - Duberg A
AUID- ORCID: https://orcid.org/0000-0002-5452-1923
AD  - University Health Care Research Center, Faculty of Medicine and Health, Orebro
      University, Orebro, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT02920268
PT  - Journal Article
DEP - 20201215
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7772067
OTO - NOTNLM
OT  - dance
OT  - functional abdominal pain
OT  - functional abdominal pain disorders
OT  - irritable bowel syndrome
OT  - physical activity
OT  - randomized trial
OT  - study protocol
OT  - yoga
EDAT- 2020/12/16 06:00
MHDA- 2020/12/16 06:01
CRDT- 2020/12/15 12:11
PHST- 2020/05/08 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/12/15 12:11 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2020/12/16 06:01 [medline]
AID - v9i12e19748 [pii]
AID - 10.2196/19748 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 15;9(12):e19748. doi: 10.2196/19748.


PMID- 33320097
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Dec 15
TI  - Communicating With Patients About Software for Enhancing Privacy in Secondary
      Database Research Involving Record Linkage: Delphi Study.
PG  - e20783
LID - 10.2196/20783 [doi]
AB  - BACKGROUND: There is substantial prior research on the perspectives of patients
      on the use of health information for research. Numerous communication barriers
      challenge transparency between researchers and data participants in secondary
      database research (eg, waiver of informed consent and knowledge gaps). Individual
      concerns and misconceptions challenge the trust in researchers among patients
      despite efforts to protect data. Technical software used to protect research data
      can further complicate the public's understanding of research. For example,
      MiNDFIRL (Minimum Necessary Disclosure For Interactive Record Linkage) is a
      prototype software that can be used to enhance the confidentiality of data sets
      by restricting disclosures of identifying information during the record linkage
      process. However, software, such as MiNDFIRL, which is used to protect data, must
      overcome the aforementioned communication barriers. One proposed solution is the 
      creation of an interactive web-based frequently asked question (FAQ) template
      that can be adapted and used to communicate research issues to data subjects.
      OBJECTIVE: This study aims to improve communication with patients and
      transparency about how complex software, such as MiNDFIRL, is used to enhance
      privacy in secondary database studies to maintain the public's trust in
      researchers. METHODS: A Delphi technique with 3 rounds of the survey was used to 
      develop the FAQ document to communicate privacy issues related to a generic
      secondary database study using the MiNDFIRL software. The Delphi panel consisted 
      of 38 patients with chronic health conditions. We revised the FAQ between Delphi 
      rounds and provided participants with a summary of the feedback. We adopted a
      conservative consensus threshold of less than 10% negative feedback per FAQ
      section. RESULTS: We developed a consensus language for 21 of the 24 FAQ
      sections. Participant feedback demonstrated preference differences (eg, brevity
      vs comprehensiveness). We adapted the final FAQ into an interactive web-based
      format that 94% (31/33) of the participants found helpful or very helpful. The
      template FAQ and MiNDFIRL source code are available on GitHub. The results
      indicate the following patient communication considerations: patients have
      diverse and varied preferences; the tone is important but challenging; and
      patients want information on security, identifiers, and final disposition of
      information. CONCLUSIONS: The findings of this study provide insights into what
      research-related information is useful to patients and how researchers can
      communicate such information. These findings align with the current understanding
      of health literacy and its challenges. Communication is essential to transparency
      and ethical data use, yet it is exceedingly challenging. Developing FAQ template 
      language to accompany a complex software may enable researchers to provide
      greater transparency when informed consent is not possible.
CI  - (c)Cason Schmit, Kobi V Ajayi, Alva O Ferdinand, Theodoros Giannouchos, Gurudev
      Ilangovan, W Benjamin Nowell, Hye-Chung Kum. Originally published in the Journal 
      of Medical Internet Research (http://www.jmir.org), 15.12.2020.
FAU - Schmit, Cason
AU  - Schmit C
AUID- ORCID: 0000-0002-7929-7198
AD  - Population Informatics Lab, Department of Health Policy & Management, Texas A&M
      University School of Public Health, College Station, TX, United States.
FAU - Ajayi, Kobi V
AU  - Ajayi KV
AUID- ORCID: 0000-0002-9288-5795
AD  - Population Informatics Lab, Department of Health Policy & Management, Texas A&M
      University School of Public Health, College Station, TX, United States.
FAU - Ferdinand, Alva O
AU  - Ferdinand AO
AUID- ORCID: 0000-0002-5941-8335
AD  - Southwest Rural Health Research Center, Department of Health Policy & Management,
      Texas A&M University School of Public Health, College Station, TX, United States.
FAU - Giannouchos, Theodoros
AU  - Giannouchos T
AUID- ORCID: 0000-0002-1574-6767
AD  - Population Informatics Lab, Department of Health Policy & Management, Texas A&M
      University School of Public Health, College Station, TX, United States.
AD  - Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of
      Utah, Salt Lake City, UT, United States.
FAU - Ilangovan, Gurudev
AU  - Ilangovan G
AUID- ORCID: 0000-0003-3973-1620
AD  - Population Informatics Lab, Department of Health Policy & Management, Texas A&M
      University School of Public Health, College Station, TX, United States.
FAU - Nowell, W Benjamin
AU  - Nowell WB
AUID- ORCID: 0000-0002-4951-6476
AD  - Global Healthy Living Foundation, Upper Nyack, NY, United States.
FAU - Kum, Hye-Chung
AU  - Kum HC
AUID- ORCID: 0000-0002-6882-8053
AD  - Population Informatics Lab, Department of Health Policy & Management, Texas A&M
      University School of Public Health, College Station, TX, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201215
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Adult
MH  - Aged
MH  - Communication
MH  - Confidentiality/*standards
MH  - Databases, Factual
MH  - Delphi Technique
MH  - Health Literacy/*standards
MH  - Humans
MH  - Middle Aged
MH  - Software/*standards
MH  - Young Adult
PMC - PMC7772068
OTO - NOTNLM
OT  - *Delphi technique
OT  - *big data
OT  - *communication barriers
OT  - *medical record linkage
OT  - *privacy
OT  - *research subjects
EDAT- 2020/12/16 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/12/15 12:11
PHST- 2020/06/09 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/09/24 00:00 [revised]
PHST- 2020/12/15 12:11 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - v22i12e20783 [pii]
AID - 10.2196/20783 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Dec 15;22(12):e20783. doi: 10.2196/20783.


PMID- 33319943
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210202
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - 31
IP  - 2
DP  - 2020 April August
PG  - 39-55
LID - 10.3917/jibes.312.0039 [doi]
AB  - Understand the deep relations between biology (logic of life, language of life), 
      bioethics (ethos of life) and environment (fruit of the ecosystem-culture
      relationship, Angel Maya, A. 1996), from the South that we embody, implies
      decolonizing, deconstructing these three terms from the Southern Environmental
      Thought. It is about de-anthropizing them and reconfiguring them from
      geo-thought, that is, the thought that arises from our earth.To see ethics in a
      telluric way implies to feel it in the earth, as an understanding of the language
      of nature and of life. Of human life, certainly, but without excluding other
      forms of life. Rather, it is about denouncing the way in which life is exploited,
      put at the service of industrial production.Southern Environmental Thought
      connects bioethics with the environment to show the close aesthetic-complex
      relationship between these two words. The term Abya Yala reflects this reality.
      Originally from Cuna, this word means to live well and refers to the way of
      living of the non-Westernized human. It also means the generous, fertile and
      flowering Earth, words which evoke the way in which the Habitat allows the
      inhabitant to poetically inhabit the Earth.Thus are born new ethico-aesthetic
      epistems: ways of knowing-understanding-recreating, de-westernized, configured
      from other logics, other ways of feeling, and which show the abyssal gulf between
      Western thought and Southern thought.
FAU - Noguera De Echeverri, Ana Patricia
AU  - Noguera De Echeverri AP
LA  - spa
PT  - Journal Article
TT  - Chapitre 3. De-colonizar la Bio-etica y el Ambiente: una tarea prioritaria del
      Pensamiento Ambiental Sur, en tiempos de penuria.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Bioethics
MH  - *Ecosystem
MH  - *Environment
MH  - Humans
EDAT- 2020/12/16 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/15 08:44
PHST- 2020/12/15 08:44 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.3917/jibes.312.0039 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 April August;31(2):39-55. doi:
      10.3917/jibes.312.0039.


PMID- 33319942
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210202
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - 31
IP  - 2
DP  - 2020 April August
PG  - 27-37
LID - 10.3917/jibes.312.0027 [doi]
AB  - In the Post-modern ages, the human being is doubly put into question&#160;:
      naturalisation of humanity (strong naturalism) is challenged by the hypothesis
      that man transcends the natural order; a self-based liberty is challenged by the 
      ethics of responsibility, according which man is requested to be responsible for 
      the Nature he is able to destroy. How can we deal with such a undetermined human 
      nature and on the other hand, with a specific responsibility of mankind over
      Nature? This paper examines several theories of the environment reconsidered as a
      place of humanization that is to be shared. This allows an intercultural ethics
      of the world as vital for all, beyond any ethnocentric normativity. How can we
      justify that the world is not available to appropriation? Nevertheless, how can
      we have a use of the world combining humanization, socialization and personal
      development? How can we &#8216;co-operate&#8217; the world through our vital
      links so that we become more human the ones by the others?
FAU - Jousset, David
AU  - Jousset D
LA  - fre
PT  - Journal Article
TT  - Chapitre 2. De l'environnement au partage de la Terre : le monde vital pour tous.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Environment
MH  - *Ethics
MH  - Humans
EDAT- 2020/12/16 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/15 08:44
PHST- 2020/12/15 08:44 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.3917/jibes.312.0027 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 April August;31(2):27-37. doi:
      10.3917/jibes.312.0027.


PMID- 33319939
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210202
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - 31
IP  - 2
DP  - 2020 April August
PG  - 11-25
LID - 10.3917/jibes.312.0011 [doi]
AB  - We address the ethical causes of the global ecological crisis we are currently
      undergoing, along with the expansion of the instrumental reason that is typical
      of modernity and the critics arisen from ecological ethics and feminism. Helping 
      to solve the ethical crisis found in the base of ecology, with the intention of
      universal rationality, is possible from bioethical approach: utilitarianism and
      radical neoliberalism are useless, and maybe the foundations of our ethical
      duties with the nature and the rest of the living creatures may be found in the
      proposals of the dialogic ethics, neoaristotelian perspective and personalisme.
FAU - Leon Correa, Francisco Javier
AU  - Leon Correa FJ
LA  - spa
PT  - Journal Article
TT  - Chapitre 1. Bioetica y crisis global medioambiental.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Bioethics
MH  - *Ethical Theory
MH  - Humans
MH  - *Morals
EDAT- 2020/12/16 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/15 08:44
PHST- 2020/12/15 08:44 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.3917/jibes.312.0011 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 April August;31(2):11-25. doi:
      10.3917/jibes.312.0011.


PMID- 33319699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 2046-0481 (Electronic)
IS  - 0368-0762 (Linking)
VI  - 73
IP  - 1
DP  - 2020 Nov 17
TI  - Causes of stress and conflict in the veterinary professional workplace - a
      perspective from Poland.
PG  - 23
LID - 10.1186/s13620-020-00177-9 [doi]
AB  - BACKGROUND: The problems of burnout and the moral and ethical distress resulting 
      from various kinds of conflict have been raised in the veterinary profession.
      However, their sources and inter-relationships have not been thoroughly
      recognized mainly due to the multidimensional nature of human interactions
      related to animal breeding, farming, welfare, prophylaxis and therapy. For the
      first time in Poland, an analysis of conflict and conflict-causing factors in
      veterinary practice has been conducted with the participation of veterinarians of
      various specialties and the owners of different animal species. RESULTS: Conflict
      in the course of work is most often experienced by young veterinarians. The
      problems associated with communication between veterinarians and animal owners
      and unforeseen random situations are the general causes of conflict. Approved
      Veterinarians were identified by animal owners as the most common professional
      group associated with the conflict experienced . CONCLUSIONS: There is a lack of 
      professional preparation by veterinary surgeons to cope with unpredicted
      stressful situations at work, resulting from an absence of appropriate
      educational input in this area. The animal owners do not understand the role and 
      duties of Approved Veterinarians.
FAU - Wojtacka, Joanna
AU  - Wojtacka J
AUID- ORCID: http://orcid.org/0000-0002-4216-8368
AD  - Department of Veterinary Public Health, Faculty of Veterinary Medicine,
      University of Warmia and Mazury in Olsztyn, Oczapowskiego St. 14, 10-718,
      Olsztyn, Poland. joanna.wojtacka@uwm.edu.pl.
FAU - Grudzien, Wojciech
AU  - Grudzien W
AD  - Department of Pathophysiology, Forensic Veterinary Medicine and Administration,
      Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn,
      Oczapowskiego St. 13, 10-718, Olsztyn, Poland.
FAU - Wysok, Beata
AU  - Wysok B
AD  - Department of Veterinary Public Health, Faculty of Veterinary Medicine,
      University of Warmia and Mazury in Olsztyn, Oczapowskiego St. 14, 10-718,
      Olsztyn, Poland.
FAU - Szarek, Jozef
AU  - Szarek J
AD  - Department of Pathophysiology, Forensic Veterinary Medicine and Administration,
      Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn,
      Oczapowskiego St. 13, 10-718, Olsztyn, Poland.
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - Ireland
TA  - Ir Vet J
JT  - Irish veterinary journal
JID - 0100762
PMC - PMC7670977
OTO - NOTNLM
OT  - Animal owner
OT  - Conflict
OT  - Conflict-causing factors
OT  - Veterinary profession
EDAT- 2020/12/16 06:00
MHDA- 2020/12/16 06:01
CRDT- 2020/12/15 08:39
PHST- 2019/10/04 00:00 [received]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/12/15 08:39 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2020/12/16 06:01 [medline]
AID - 10.1186/s13620-020-00177-9 [doi]
AID - 10.1186/s13620-020-00177-9 [pii]
PST - epublish
SO  - Ir Vet J. 2020 Nov 17;73(1):23. doi: 10.1186/s13620-020-00177-9.


PMID- 33319032
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 2397-9070 (Electronic)
IS  - 2397-9070 (Linking)
VI  - 4
IP  - 6
DP  - 2020 Dec
TI  - Ethics, gastroenterologists, and pharmaceutical and equipment companies.
PG  - 1025-1026
LID - 10.1002/jgh3.12416 [doi]
FAU - Roberts-Thomson, Ian C
AU  - Roberts-Thomson IC
AUID- ORCID: https://orcid.org/0000-0001-6075-3643
AD  - Faculty of Health and Medical Sciences University of Adelaide Adelaide South
      Australia Australia.
LA  - eng
PT  - Editorial
DEP - 20201211
PL  - Australia
TA  - JGH Open
JT  - JGH open : an open access journal of gastroenterology and hepatology
JID - 101730833
PMC - PMC7731820
EDAT- 2020/12/16 06:00
MHDA- 2020/12/16 06:01
CRDT- 2020/12/15 06:05
PHST- 2020/08/29 00:00 [received]
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/12/15 06:05 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2020/12/16 06:01 [medline]
AID - 10.1002/jgh3.12416 [doi]
AID - JGH312416 [pii]
PST - epublish
SO  - JGH Open. 2020 Dec 11;4(6):1025-1026. doi: 10.1002/jgh3.12416. eCollection 2020
      Dec.


PMID- 33318795
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 60
DP  - 2020 Dec
TI  - Is there adenoma-carcinoma sequence between benign adenoma and papillary cancer
      of thyroid: A genomic linkage study.
PG  - 695-700
LID - 10.1016/j.amsu.2020.11.069 [doi]
AB  - BACKGROUND: The adenoma-carcinoma sequence in thyroid nodules is an enigmatic
      phenomenon. Genomics is the only definitive modality to resolve this hypothesis. 
      Adenomas and papillary carcinomas tend to have mutations in RAS and highly
      specific BRAF gene respectively. In this context, we set out study the prevalence
      and clinical significance of these somatic mutations in surgical tissue samples. 
      MATERIAL AND METHODS: This retrospective study was conducted on surgically
      managed thyroid nodule patients. Institutional ethical committee approval was
      obtained. Diagnosis was based on biochemical confirmation, imaging, fine needle
      aspiration cytology and later confirmed by histopathology. We selected 100 benign
      thyroid adenomas (BTA) and 100 papillary thyroid carcinoma (PTC) cases. Archived 
      tumour tissue samples of selected cases were retrieved. After appropriate
      processing of samples, DNA extraction, cDNA preparation, PCR amplification,
      application of 4 sets of Primers were performed as part of mutational analysis of
      RAS (H-,K-,N-) and BRAF genes. RESULTS: Homozygous mutations in N-RAS were found 
      in 36/100 (36%) of BTA and 7/100 (7%) of PTC cases. No H-RAS or K-RAS mutations
      were found in both groups. Homozygous mutations were found in BRAF gene in 4/100 
      (4%) of BTA cases and 52/100 (52%) of PTC cases. The differences were
      statistically significant. CONCLUSIONS: Similar N-RAS and BRAF mutations were
      prevalent in both benign and malignant thyroid nodules giving some evidence for
      linkage between them. Though not robust, we opine that there is possibility of
      adenoma-carcinoma sequence in thyroid nodules.
CI  - (c) 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group
      Ltd.
FAU - Bangaraiahgari, Ramesh
AU  - Bangaraiahgari R
AD  - Department of Biochemistry, Surabhi Medical College, Hyderabad, Telangana, India.
FAU - Panchangam, Ramakanth Bhargav
AU  - Panchangam RB
AD  - Endocare Hospital, Suryaraopeta, Vijayawada, AP, 520002, India.
FAU - Puthenveetil, Pradeep
AU  - Puthenveetil P
AD  - Department of Endocrine Surgery, Baby Memorial Hospital, Calicut, Kerala, India.
FAU - Mayilvaganan, Sabaretnam
AU  - Mayilvaganan S
AD  - Department of Endocrine Surgery, SGPGIMS, Lucknow, UP, India.
FAU - Bangaraiahgari, Rajesh
AU  - Bangaraiahgari R
AD  - Department of Anatomy, Surabhi Medical College, Hyderabad, Telangana, India.
FAU - Banala, Rajkiran Reddy
AU  - Banala RR
AD  - Department of Genetics and Labaratory, Sunrise Hospitals, Hyderabad, India.
FAU - Karunakaran, Poongkodi
AU  - Karunakaran P
AD  - Department of Endocrine Surgery, Government Mohan Kumaramangalam Medical College,
      Salem, TN, India.
FAU - Md, Rafi
AU  - Md R
AD  - Department of Biochemistry, Surabhi Medical College, Hyderabad, Telangana, India.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7726453
OTO - NOTNLM
OT  - Adenoma
OT  - BRAF gene
OT  - Papillary thyroid cancer
OT  - RAS gene
OT  - Thyroidectomy
EDAT- 2020/12/16 06:00
MHDA- 2020/12/16 06:01
CRDT- 2020/12/15 06:05
PHST- 2020/11/11 00:00 [received]
PHST- 2020/11/24 00:00 [revised]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2020/12/15 06:05 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2020/12/16 06:01 [medline]
AID - 10.1016/j.amsu.2020.11.069 [doi]
AID - S2049-0801(20)30496-9 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Dec 2;60:695-700. doi: 10.1016/j.amsu.2020.11.069.
      eCollection 2020 Dec.


PMID- 33318589
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Dec 14
TI  - Minimum effective volume of ropivacaine for ultrasound-guided supra-inguinal
      fascia iliaca compartment block.
PG  - 21859
LID - 10.1038/s41598-020-79059-7 [doi]
AB  - Supra inguinal fascia iliaca compartment block (FICB) is increasingly used in
      elderly patients with hip fractures. However, the minimum effective volume of
      local anesthetics required for ultrasound-guided supra-inguinal FICB has not been
      determined. With ethical committee approval and written informed consent from
      patients, we studied 21 consecutive patients of ASA physical status I-III
      undergoing surgery for hip fracture who met the inclusion criteria. Blocks were
      performed before going to the operation room. We determined the injection volumes
      of 0.25% ropivacaine for consecutive patients from the preceding patient's
      outcome. The initial volume was 30 ml. The testing interval was set at 10 ml, and
      the lowest volume was 5 ml. An effective block was defined as loss of sensation
      of pinprick in the territory of the femoral nerve and lateral cutaneous nerve of 
      the thigh 30 min after the injection. The aim of this study was to determine the 
      50% effective volume (EV50) and the 95% effective volume (EV95) of 0.25%
      ropivacaine for ultrasound-guided supra-inguinal FICB using Logistic regression
      analysis. EV50 and EV95 of 0.25% ropivacaine for ultrasound-guided supra-inguinal
      FICB calculated with logistic regression analysis were 15.01 ml (95% confidence
      interval, 6.53-22.99 ml) and 26.99 ml (95% confidence interval, 20.54-84.09 ml), 
      respectively. EV50 and EV95 of 0.25% ropivacaine for ultrasound-guided
      supra-inguinal FICB were 15.01 ml and 26.99 ml, respectively.Clinical trial
      number: UMIN000027277 (URL https://www.umin.ac.jp/ctr/index-j.htm ).
FAU - Yamada, Kumiko
AU  - Yamada K
AD  - Department of Anesthesiology, Tsukuba Gakuen Hospital, Tsukuba, Japan.
      kumi5597@yahoo.ac.jp.
FAU - Inomata, Shinichi
AU  - Inomata S
AD  - Division of Clinical Medicine, Department of Anesthesiology, Faculty of Medicine,
      University of Tsukuba, University of Tsukuba Hospital, Tsukuba, Japan.
FAU - Saito, Shigeyuki
AU  - Saito S
AD  - Department of Anesthesiology, Tsukuba Gakuen Hospital, Tsukuba, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000027277
PT  - Clinical Trial
PT  - Journal Article
DEP - 20201214
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anesthetics, Local)
RN  - 7IO5LYA57N (Ropivacaine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anesthetics, Local
MH  - Fascia/diagnostic imaging
MH  - Female
MH  - Femoral Nerve/diagnostic imaging/surgery
MH  - *Hip Fractures/diagnostic imaging/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nerve Block
MH  - Ropivacaine/*administration & dosage
MH  - Ultrasonography, Interventional
PMC - PMC7736848
EDAT- 2020/12/16 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/12/15 06:00
PHST- 2020/09/18 00:00 [received]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/15 06:00 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
AID - 10.1038/s41598-020-79059-7 [doi]
AID - 10.1038/s41598-020-79059-7 [pii]
PST - epublish
SO  - Sci Rep. 2020 Dec 14;10(1):21859. doi: 10.1038/s41598-020-79059-7.


PMID- 33318123
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 13
TI  - Protocol for the Prognosticating Delirium Recovery Outcomes Using Wakefulness and
      Sleep Electroencephalography (P-DROWS-E) study: a prospective observational study
      of delirium in elderly cardiac surgical patients.
PG  - e044295
LID - 10.1136/bmjopen-2020-044295 [doi]
AB  - INTRODUCTION: Delirium is a potentially preventable disorder characterised by
      acute disturbances in attention and cognition with fluctuating severity.
      Postoperative delirium is associated with prolonged intensive care unit and
      hospital stay, cognitive decline and mortality. The development of biomarkers for
      tracking delirium could potentially aid in the early detection, mitigation and
      assessment of response to interventions. Because sleep disruption has been
      posited as a contributor to the development of this syndrome, expression of
      abnormal electroencephalography (EEG) patterns during sleep and wakefulness may
      be informative. Here we hypothesise that abnormal EEG patterns of sleep and
      wakefulness may serve as predictive and diagnostic markers for postoperative
      delirium. Such abnormal EEG patterns would mechanistically link disrupted
      thalamocortical connectivity to this important clinical syndrome. METHODS AND
      ANALYSIS: P-DROWS-E (Prognosticating Delirium Recovery Outcomes Using Wakefulness
      and Sleep Electroencephalography) is a 220-patient prospective observational
      study. Patient eligibility criteria include those who are English-speaking, age
      60 years or older and undergoing elective cardiac surgery requiring
      cardiopulmonary bypass. EEG acquisition will occur 1-2 nights preoperatively,
      intraoperatively, and up to 7 days postoperatively. Concurrent with EEG
      recordings, two times per day postoperative Confusion Assessment Method (CAM)
      evaluations will quantify the presence and severity of delirium. EEG slow wave
      activity, sleep spindle density and peak frequency of the posterior dominant
      rhythm will be quantified. Linear mixed-effects models will be used to evaluate
      the relationships between delirium severity/duration and EEG measures as a
      function of time. ETHICS AND DISSEMINATION: P-DROWS-E is approved by the ethics
      board at Washington University in St. Louis. Recruitment began in October 2018.
      Dissemination plans include presentations at scientific conferences, scientific
      publications and mass media. TRIAL REGISTRATION NUMBER: NCT03291626.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Smith, S Kendall
AU  - Smith SK
AUID- ORCID: 0000-0003-0718-1150
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Nguyen, Thomas
AU  - Nguyen T
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Labonte, Alyssa K
AU  - Labonte AK
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Kafashan, MohammadMehdi
AU  - Kafashan M
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Hyche, Orlandrea
AU  - Hyche O
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Guay, Christian S
AU  - Guay CS
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Wilson, Elizabeth
AU  - Wilson E
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Chan, Courtney W
AU  - Chan CW
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Luong, Anhthi
AU  - Luong A
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Hickman, L Brian
AU  - Hickman LB
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Fritz, Bradley A
AU  - Fritz BA
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Emmert, Daniel
AU  - Emmert D
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Graetz, Thomas J
AU  - Graetz TJ
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Melby, Spencer J
AU  - Melby SJ
AD  - Department of Surgery, Washington University in Saint Louis School of Medicine,
      Saint Louis, Missouri, USA.
FAU - Lucey, Brendan P
AU  - Lucey BP
AD  - Department of Neurology, Washington University in Saint Louis School of Medicine,
      Saint Louis, Missouri, USA.
FAU - Ju, Yo-El S
AU  - Ju YS
AD  - Department of Neurology, Washington University in Saint Louis School of Medicine,
      Saint Louis, Missouri, USA.
FAU - Wildes, Troy S
AU  - Wildes TS
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Avidan, Michael S
AU  - Avidan MS
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA.
FAU - Palanca, Ben J A
AU  - Palanca BJA
AUID- ORCID: 0000-0001-7535-5701
AD  - Department of Anesthesiology, Washington University in Saint Louis School of
      Medicine, Saint Louis, Missouri, USA palancab@wustl.edu.
AD  - Department of Biomedical Engineering, Washington University in St Louis, Saint
      Louis, Missouri, USA.
AD  - Division of Biology and Biomedical Sciences, Washington University in St Louis,
      Saint Louis, Missouri, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03291626
GR  - R01 AG057901/AG/NIA NIH HHS/United States
GR  - T32 GM108539/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201213
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Cardiac Surgical Procedures
MH  - *Delirium/diagnosis
MH  - Electroencephalography
MH  - Humans
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - Sleep
MH  - Wakefulness
MH  - Washington
PMC - PMC7737109
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *cardiothoracic surgery
OT  - *delirium & cognitive disorders
OT  - *neurophysiology
OT  - *old age psychiatry
OT  - *sleep medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/15 05:54
PHST- 2020/12/15 05:54 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-044295 [pii]
AID - 10.1136/bmjopen-2020-044295 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 13;10(12):e044295. doi: 10.1136/bmjopen-2020-044295.


PMID- 33318122
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 13
TI  - Challenges and facilitators of implementation of an information communication and
      technology (ICT)-based human resources management tool in the government health
      sector in Bangladesh: protocol for an exploratory qualitative research study.
PG  - e043939
LID - 10.1136/bmjopen-2020-043939 [doi]
AB  - INTRODUCTION: To improve human resources for health (HRH) management in
      Bangladesh, the directorate general of health services (DGHS) introduced a new
      information and communications technology (ICT) tool, named 'human resources
      information system (HRIS)', to process real-time HRH data of all facilities under
      the DGHS. However, synchronisation is a major concern since multiple authorities 
      are involved in the implementation of the tool at different tiers of the health
      system. Introducing ICT tools in healthcare organisations has always proved
      challenging as evidence from low-income and middle-income countries suggests. The
      knowledge gap in terms of factors that support or constrain the successful
      implementation of the HRIS in Bangladesh will be investigated in this exploratory
      study to identify ways of engaging the key stakeholders in a better way for an
      effective use of the tool. METHODS AND ANALYSIS: Desk review and qualitative data
      collection methods will be used to address the study objectives. Key informant
      interviews and in-depth interviews will be conducted to explore perspectives of
      policy-makers, programme managers, service providers and other stakeholders to
      understand the barriers to implementing HRIS in the context of Bangladesh. We
      plan to organise stakeholder consultation workshops to validate the qualitative
      study findings and to seek suggestions for ensuring a successful implementation
      of the HRIS. Framework analysis will be applied to analyse qualitative data, and 
      an outline with the definitions of a priori codes guided by the policy engagement
      framework will be prepared. Besides, emerging themes will also be identified. A
      data display matrix will be prepared to summarise and interpret the findings for 
      policy review. ETHICS AND DISSEMINATION: The research review committee and the
      ethical review committee of icddr,b have approved the research protocol. Findings
      from the study will be communicated through national and international forums,
      conferences, policy briefs and peer-reviewed journal publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bhattacharyya, Dipika Shankar
AU  - Bhattacharyya DS
AUID- ORCID: 0000-0001-8464-0010
AD  - Health Systems and Population Studies Division (HSPSD), International Centre for 
      Diarrhoeal Disease Research, Dhaka, Bangladesh dipikashankar@gmail.com.
FAU - Shafique, Sohana
AU  - Shafique S
AUID- ORCID: 0000-0002-5234-8522
AD  - Health Systems and Population Studies Division (HSPSD), International Centre for 
      Diarrhoeal Disease Research, Dhaka, Bangladesh.
FAU - Akhter, Sadika
AU  - Akhter S
AD  - Health Systems and Population Studies Division (HSPSD), International Centre for 
      Diarrhoeal Disease Research, Dhaka, Bangladesh.
FAU - Rahman, Aminur
AU  - Rahman A
AUID- ORCID: 0000-0003-1434-3883
AD  - Health Systems and Population Studies Division (HSPSD), International Centre for 
      Diarrhoeal Disease Research, Dhaka, Bangladesh.
FAU - Islam, Md Zahidul
AU  - Islam MZ
AD  - Upazila Health and Family Planning Officer, Directorate General of Health
      Services, Dhaka, Narayanganj, Bangladesh.
FAU - Rahman, Nawsiba
AU  - Rahman N
AD  - Management Information System, Directorate General of Health Services, Dhaka,
      Bangladesh.
FAU - Anwar, Iqbal
AU  - Anwar I
AD  - Health Systems and Population Studies Division (HSPSD), International Centre for 
      Diarrhoeal Disease Research, Dhaka, Bangladesh.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201213
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bangladesh
MH  - *Communication
MH  - *Government
MH  - Humans
MH  - Qualitative Research
MH  - Technology
MH  - Workforce
PMC - PMC7737103
OTO - NOTNLM
OT  - *human resource management
OT  - *information management
OT  - *information technology
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/12/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/15 05:54
PHST- 2020/12/15 05:54 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043939 [pii]
AID - 10.1136/bmjopen-2020-043939 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 13;10(12):e043939. doi: 10.1136/bmjopen-2020-043939.


PMID- 33318121
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 13
TI  - Prevalence of multimorbidity in South Africa: a systematic review protocol.
PG  - e042889
LID - 10.1136/bmjopen-2020-042889 [doi]
AB  - INTRODUCTION: Multimorbidity has increased globally over the past two decades,
      due to ageing populations and increased burden of non-communicable diseases
      (NCDs). In a country like South Africa, with a growing burden of NCDs and a high 
      prevalence of HIV, information on multimorbidity can improve planning for
      healthcare delivery and utilisation, and reduce costs in the context of
      constrained health resources. This review aims to synthesise prevalence studies
      on multimorbidity, and identify dominant clusters and trends of multimorbidity in
      South Africa. METHODS AND ANALYSIS: We will search electronic bibliographic
      databases (PubMed, Scopus, JSTOR, POPLINE, PsycINFO, ScienceDirect, Web of
      Science and CINAHL), and the reference lists of included articles. Two
      researchers will independently screen title and abstracts, and then full text to 
      identify studies published before and in 2020 that report on prevalence of
      multimorbidity in South Africa. Risk of bias assessments will be done for each
      study. Information on the prevalence of multimorbidity and disease clusters will 
      be extracted from each study. Where possible, prevalence of specific clusters of 
      multimorbidity will be pooled using a random effects meta-analysis to account for
      variability between studies. The I(2) statistic will be used to establish the
      extent of heterogeneity due to variation in prevalence estimates rather than due 
      to chance. The systematic review will be reported according to the Preferred
      Reporting Items for Systematic reviews and Meta-Analyses. ETHICS AND
      DISSEMINATION: Only published journal articles will be included in the systematic
      review. This review received ethics approval as part of a larger project by the
      University of the Western Cape Biomedical Science Research Ethics Committee
      (BM20/5/8). The findings from this research will be used to estimate the
      prevalence of multimorbidity in South Africa and will contribute to the design of
      future research projects. The findings will be disseminated in a peer-reviewed
      journal article. PROSPERO REGISTRATION NUMBER: CRD42020196895.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Roomaney, Rifqah A
AU  - Roomaney RA
AUID- ORCID: 0000-0003-3267-8484
AD  - Burden of Disease Research Unit, South African Medical Research Council, Cape
      Town, South Africa rifqah.roomaney@mrc.ac.za.
AD  - School of Public Health, University of the Western Cape, Cape Town, South Africa.
FAU - van Wyk, Brian
AU  - van Wyk B
AUID- ORCID: 0000-0003-1032-1847
AD  - School of Public Health, University of the Western Cape, Cape Town, South Africa.
FAU - Turawa, Eunice Bolanle
AU  - Turawa EB
AUID- ORCID: 0000-0003-3722-1547
AD  - Burden of Disease Research Unit, South African Medical Research Council, Cape
      Town, South Africa.
AD  - Faculty of Medicine and Health Sciences, Community Health, Stellenbosch
      University, Cape Town, South Africa.
FAU - Pillay-van Wyk, Victoria
AU  - Pillay-van Wyk V
AUID- ORCID: 0000-0001-8772-7197
AD  - Burden of Disease Research Unit, South African Medical Research Council, Cape
      Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201213
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Databases, Bibliographic
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Multimorbidity
MH  - Prevalence
MH  - Research Design
MH  - *Research Report
MH  - Review Literature as Topic
MH  - South Africa/epidemiology
PMC - PMC7737082
OTO - NOTNLM
OT  - *epidemiology
OT  - *health policy
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/15 05:54
PHST- 2020/12/15 05:54 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042889 [pii]
AID - 10.1136/bmjopen-2020-042889 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 13;10(12):e042889. doi: 10.1136/bmjopen-2020-042889.


PMID- 33318119
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 13
TI  - Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis
      (PFOX trial): a randomised controlled trial.
PG  - e040798
LID - 10.1136/bmjopen-2020-040798 [doi]
AB  - INTRODUCTION: Interstitial lung diseases are characterised by scarring of lung
      tissue that leads to reduced transfer of oxygen into the blood, decreased
      exercise capacity and premature death. Ambulatory oxygen therapy may be used to
      treat exertional oxyhaemoglobin desaturation, but there is little evidence to
      support its efficacy and there is wide variation in clinical practice. This study
      aims to compare the clinical efficacy and cost-effectiveness of ambulatory oxygen
      versus ambulatory air in people with fibrotic interstitial lung disease and
      exertional desaturation. METHODS AND ANALYSIS: A randomised, controlled trial
      with blinding of participants, clinicians and researchers will be conducted at
      trial sites in Australia and Sweden. Eligible participants will be randomised 1:1
      into two groups. Intervention participants will receive ambulatory oxygen therapy
      using a portable oxygen concentrator (POC) during daily activities and control
      participants will use an identical POC modified to deliver air. Outcomes will be 
      assessed at baseline, 3 months and 6 months. The primary outcome is change in
      physical activity measured by number of steps per day using a physical activity
      monitor (StepWatch). Secondary outcomes are functional capacity (6-minute walk
      distance), health-related quality of life (St George Respiratory Questionnaire,
      EQ-5D-5L and King's Brief Interstitial Lung Disease Questionnaire),
      breathlessness (Dyspnoea-12), fatigue (Fatigue Severity Scale), anxiety and
      depression (Hospital Anxiety and Depression Scale), physical activity level
      (GENEActive), oxygen saturation in daily life, POC usage, and plasma markers of
      skeletal muscle metabolism, systematic inflammation and oxidative stress. A
      cost-effectiveness evaluation will also be undertaken. ETHICS AND DISSEMINATION: 
      Ethical approval has been granted in Australia by Alfred Hospital Human Research 
      Ethics Committee (HREC/18/Alfred/42) with governance approval at all Australian
      sites, and in Sweden (Lund Dnr: 2019-02963). The results will be published in
      peer-reviewed scientific journals, presented at conferences and disseminated to
      consumers in publications for lay audiences. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT03737409).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Holland, Anne E
AU  - Holland AE
AUID- ORCID: 0000-0003-2061-845X
AD  - Department of Physiotherapy, Alfred Health, Melbourne, Victoria, Australia
      a.holland@alfred.org.au.
AD  - Department of Allergy, Immunology and Respiratory Medicine, Monash University,
      Melbourne, Victoria, Australia.
AD  - Institute for Breathing and Sleep, Melbourne, Victoria, Australia.
AD  - NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South 
      Wales, Australia.
FAU - Corte, Tamera
AU  - Corte T
AD  - NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South 
      Wales, Australia.
AD  - Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New
      South Wales, Australia.
AD  - Central Clinical School, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Chambers, Daniel C
AU  - Chambers DC
AD  - NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South 
      Wales, Australia.
AD  - School of Clinical Medicine, The University of Queensland, Brisbane, Queensland, 
      Australia.
AD  - Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane,
      Queensland, Australia.
FAU - Palmer, Andrew J
AU  - Palmer AJ
AD  - NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South 
      Wales, Australia.
AD  - Health Economics Research Group, Menzies Institute for Medical Research, The
      University of Tasmania, Hobart, Tasmania, Australia.
AD  - Centre for Health Policy, School of Population and Global Health, The University 
      of Melbourne, Melbourne, Victoria, Australia.
FAU - Ekstrom, Magnus Per
AU  - Ekstrom MP
AD  - Respiratory Medicine and Allergology, Department of Clinical Sciences, Faculty of
      Medicine, Lund University, Lund, Sweden.
FAU - Glaspole, Ian
AU  - Glaspole I
AD  - Department of Allergy, Immunology and Respiratory Medicine, Monash University,
      Melbourne, Victoria, Australia.
AD  - NHMRC Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South 
      Wales, Australia.
AD  - Department of Respiratory and Sleep Medicine, Alfred Health, Melbourne, Victoria,
      Australia.
FAU - Goh, Nicole S L
AU  - Goh NSL
AD  - Institute for Breathing and Sleep, Melbourne, Victoria, Australia.
AD  - Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Victoria,
      Australia.
FAU - Hepworth, Graham
AU  - Hepworth G
AD  - Statistical Consulting Centre, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Khor, Yet H
AU  - Khor YH
AD  - Institute for Breathing and Sleep, Melbourne, Victoria, Australia.
AD  - Department of Respiratory and Sleep Medicine, Alfred Health, Melbourne, Victoria,
      Australia.
AD  - Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Victoria,
      Australia.
FAU - Hoffman, Mariana
AU  - Hoffman M
AD  - Department of Allergy, Immunology and Respiratory Medicine, Monash University,
      Melbourne, Victoria, Australia.
FAU - Vlahos, Ross
AU  - Vlahos R
AD  - School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne,
      Australia.
FAU - Skold, Magnus
AU  - Skold M
AD  - Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular 
      Medicine, Karolinska Institutet, Stockholm, Sweden.
AD  - Department of Respiratory Medicine and Allergy, Karolinska University Hospital,
      Stockholm, Sweden.
FAU - Dowman, Leona
AU  - Dowman L
AD  - Department of Allergy, Immunology and Respiratory Medicine, Monash University,
      Melbourne, Victoria, Australia.
AD  - Institute for Breathing and Sleep, Melbourne, Victoria, Australia.
AD  - Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Victoria,
      Australia.
AD  - Department of Physiotherapy, Austin Health, Melbourne, Victoria, Australia.
FAU - Troy, Lauren K
AU  - Troy LK
AD  - Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New
      South Wales, Australia.
AD  - Central Clinical School, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Prasad, Jyotika D
AU  - Prasad JD
AD  - Department of Respiratory and Sleep Medicine, Alfred Health, Melbourne, Victoria,
      Australia.
AD  - Department of Respiratory Medicine, Royal Melbourne Hospital, Melbourne,
      Victoria, Australia.
FAU - Walsh, James
AU  - Walsh J
AD  - Physiotherapy Department, The Prince Charles Hospital, Brisbane, Queensland,
      Australia.
FAU - McDonald, Christine F
AU  - McDonald CF
AD  - Institute for Breathing and Sleep, Melbourne, Victoria, Australia.
AD  - Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, Victoria,
      Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03737409
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201213
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Australia
MH  - Humans
MH  - Hypoxia
MH  - Oxygen
MH  - *Pulmonary Fibrosis/complications/therapy
MH  - Quality of Life
MH  - Sweden
PMC - PMC7737108
OTO - NOTNLM
OT  - *clinical trials
OT  - *interstitial lung disease
OT  - *thoracic medicine
COIS- Competing interests: All authors report non-financial support from BOC Australia 
      in the delivery of the trial devices. AEH, YHK, LT, NSLG and CFM report
      non-financial support from Air Liquide Healthcare, outside the submitted work.
      YHK reports grants and personal fees from Boehringer Ingelheim, and personal fees
      from Roche, outside the submitted work. MS received research grants from
      Boehringer Ingelheim and Roche, outside the submitted work.
EDAT- 2020/12/16 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/15 05:54
PHST- 2020/12/15 05:54 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040798 [pii]
AID - 10.1136/bmjopen-2020-040798 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 13;10(12):e040798. doi: 10.1136/bmjopen-2020-040798.


PMID- 33318108
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 13
TI  - Lifestyle InterVention IN Gestational diabetes (LIVING) in India, Bangladesh and 
      Sri Lanka: protocol for process evaluation of a randomised controlled trial.
PG  - e037774
LID - 10.1136/bmjopen-2020-037774 [doi]
AB  - INTRODUCTION: The development of type 2 diabetes mellitus disproportionately
      affects South Asian women with prior gestational diabetes mellitus (GDM). The
      Lifestyle InterVention IN Gestational diabetes (LIVING) Study is a randomised
      controlled trial of a low-intensity lifestyle modification programme tailored to 
      women with previous GDM, in India, Bangladesh and Sri Lanka, aimed at preventing 
      diabetes/pre-diabetes. The aim of this process evaluation is to understand what
      worked, and why, during the LIVING intervention implementation, and to provide
      additional data that will assist in the interpretation of the LIVING Study
      results. The findings will also inform future scale-up efforts if the
      intervention is found to be effective. METHODS AND ANALYSIS: The Reach
      Effectiveness Adoption Implementation Maintenance (RE-AIM) methodological
      approach informed the evaluation framework. Michie's Behaviour Change Theory and 
      Normalisation Process Theory were used to guide the design of our qualitative
      evaluation tools within the overall RE-AIM evaluation framework. Mixed methods
      including qualitative interviews, focus groups and quantitative analyses will be 
      used to evaluate the intervention from the perspectives of the women receiving
      the intervention, facilitators, site investigators and project management staff. 
      The evaluation will use evaluation datasets, administratively collected process
      data accessed during monitoring visits, check lists and logs, quantitative
      participant evaluation surveys, semistructured interviews and focus group
      discussions. Interview participants will be recruited using maximum variation
      purposive sampling. We will undertake thematic analysis of all qualitative data, 
      conducted contemporaneously with data collection until thematic saturation has
      been achieved. To triangulate data, the analysis team will engage in constant
      iterative comparison among data from various stakeholders. ETHICS AND
      DISSEMINATION: Ethics approval has been obtained from the respective human
      research ethics committees of the All India Institute of Medical Sciences, New
      Delhi, India; University of Sydney, New South Wales, Australia; and site-specific
      approval at each local site in the three countries: India, Bangladesh and Sri
      Lanka. This includes approvals from the Institutional Ethics Committee at King
      Edwards Memorial Hospital, Maharaja Agrasen Hospital, Centre for Disease Control 
      New Delhi, Goa Medical College, Jawaharlal Institute of Postgraduate Medical
      Education and Research, Madras Diabetes Research Foundation, Christian Medical
      College Vellore, Fernandez Hospital Foundation, Castle Street Hospital for Women,
      University of Kelaniya, Topiwala National Medical College and BYL Nair Charitable
      Hospital, Birdem General Hospital and the International Centre for Diarrhoeal
      Disease Research. Findings will be documented in academic publications,
      presentations at scientific meetings and stakeholder workshops. TRIAL
      REGISTRATION NUMBERS: Clinical Trials Registry of India (CTRI/2017/06/008744);
      Sri Lanka Clinical Trials Registry (SLCTR/2017/001) and ClinicalTrials.gov
      Registry (NCT03305939); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shanthosh, Janani
AU  - Shanthosh J
AUID- ORCID: 0000-0002-1297-2400
AD  - Faculty of Medicine, The George Institute for Global Health, University of New
      South Wales, Sydney, New South Wales, Australia
      jshanthosh@georgeinstitute.org.au.
FAU - Kapoor, Deksha
AU  - Kapoor D
AD  - Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Josyula, Lakshmi K
AU  - Josyula LK
AD  - Division of Epidemiology, The George Institute for Global Health, Hyderabad,
      India.
AD  - Faculty of Medicine, University of New South Wales, Sydney, New South Wales,
      Australia.
AD  - Prasanna School of Public Health, MAHE, Manipal, India.
FAU - Patel, Anushka
AU  - Patel A
AD  - Faculty of Medicine, The George Institute for Global Health, University of New
      South Wales, Sydney, New South Wales, Australia.
FAU - Gupta, Yashdeep
AU  - Gupta Y
AD  - Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Tandon, Nikhil
AU  - Tandon N
AD  - Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Jan, Stephen
AU  - Jan S
AD  - Faculty of Medicine, The George Institute for Global Health, University of New
      South Wales, Sydney, New South Wales, Australia.
FAU - Teede, Helena J
AU  - Teede HJ
AD  - Monash Centre for Health Research and Implementation, Monash University,
      Melbourne, Victoria, Australia.
FAU - Desai, Ankush
AU  - Desai A
AD  - Endocrine Unit, Department of Medicine, Goa Medical College, Goa, India.
FAU - Joshi, Rohina
AU  - Joshi R
AUID- ORCID: 0000-0002-3374-401X
AD  - Faculty of Medicine, The George Institute for Global Health, University of New
      South Wales, Sydney, New South Wales, Australia.
FAU - Praveen, Devarsetty
AU  - Praveen D
AD  - Division of Epidemiology, The George Institute for Global Health, Hyderabad,
      India.
AD  - Faculty of Medicine, University of New South Wales, Sydney, New South Wales,
      Australia.
AD  - Prasanna School of Public Health, MAHE, Manipal, India.
LA  - eng
SI  - ClinicalTrials.gov/NCT03305939
SI  - CTRI/CTRI/2017/06/008744
SI  - SLCTR/SLCTR/2017/001
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201213
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Bangladesh
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - *Diabetes, Gestational/prevention & control
MH  - Female
MH  - Humans
MH  - India
MH  - Life Style
MH  - New South Wales
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Sri Lanka
PMC - PMC7737084
OTO - NOTNLM
OT  - *diabetes in pregnancy
OT  - *general diabetes
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/15 05:54
PHST- 2020/12/15 05:54 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037774 [pii]
AID - 10.1136/bmjopen-2020-037774 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 13;10(12):e037774. doi: 10.1136/bmjopen-2020-037774.


PMID- 33318032
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 2399-6641 (Electronic)
IS  - 2399-6641 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Dec
TI  - Introducing an innovative model of acute paediatric mental health and addictions 
      care to paediatric emergency departments: a protocol for a multicentre
      prospective cohort study.
LID - e001106 [pii]
LID - 10.1136/bmjoq-2020-001106 [doi]
AB  - INTRODUCTION: Children and youth with mental health and addiction crises are a
      vulnerable patient group that often are brought to the hospital for emergency
      department care. We propose to evaluate the effect of a novel, acute care bundle 
      that standardises a patient-centred approach to care. METHODS AND ANALYSIS: Two
      paediatric emergency departments in Alberta, Canada are involved in this
      prospective, pragmatic, 29-month interventional quasi-experimental study. The
      acute care bundle comprises three components, applied when appropriate: (1)
      assessing self-harm risk at triage using the Ask Suicide-Screening Questionnaire 
      (ASQ) to standardise the questions administered, enabling risk stratification;
      (2) use of the HEADS-ED (Home, Education, Activities/peers, Drug/alcohol,
      Suicidality, Emotions and behaviour, Discharge Resources) to focus mental health 
      evaluations for those who screen high risk on the ASQ; and (3) implementation of 
      a Choice And Partnership Approach to enable shared decision making in care
      following the emergency department visit. The overarching goal is to deliver the 
      right care at the right place and time for the patients. The study design
      involves a longitudinal collection of data 12 months before and after the
      introduction of the bundle and the use of quality improvement strategies such as 
      Plan-Do-Study-Act cycles during a 5-month run-in period to test and implement
      changes. The primary study end-point is child/youth well-being 1 month after the 
      emergency department visit. Secondary outcomes include family functioning,
      child/youth well-being at 3 and 6 months, satisfaction with emergency department 
      care, and health system outcomes (hospital admissions, length of emergency
      department stays, emergency department revisits). ETHICS AND DISSEMINATION: The
      study is registered at www.ClinicalTrials.gov and has received ethics and
      operational approvals from study sites. The results of the study will be reported
      in accordance with the Strengthening the Reporting of Observational Studies in
      Epidemiology statement. Results will be shared broadly with key policy and
      decision makers and disseminated in peer-reviewed academic journals and
      presentations at conferences. TRIAL REGISTRATION NUMBER: NCT04292379.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Freedman, Stephen
AU  - Freedman S
AUID- ORCID: 0000-0003-2319-6192
AD  - Department of Pediatrics, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Departments of Pediatrics and Emergency Medicine, Alberta Children's Hospital,
      Calgary, Alberta, Canada.
FAU - Thull-Freedman, Jennifer
AU  - Thull-Freedman J
AD  - Department of Pediatrics, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Departments of Pediatrics and Emergency Medicine, Alberta Children's Hospital,
      Calgary, Alberta, Canada.
FAU - Lightbody, Teresa
AU  - Lightbody T
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of
      Alberta, Edmonton, Alberta, Canada.
AD  - Children, Youth, and Families, Addiction and Mental Health, Alberta Health
      Services, Edmonton, Alberta, Canada.
FAU - Prisnie, Kassi
AU  - Prisnie K
AD  - Department of Pediatrics, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
FAU - Wright, Bruce
AU  - Wright B
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of
      Alberta, Edmonton, Alberta, Canada.
AD  - Emergency Department, Stollery Children's Hospital, Edmonton, Alberta, Canada.
FAU - Coulombe, Angela
AU  - Coulombe A
AD  - Children, Youth, and Families, Addiction and Mental Health, Alberta Health
      Services, Edmonton, Alberta, Canada.
FAU - Anderson, Linda M
AU  - Anderson LM
AD  - Emergency Department, Alberta Children's Hospital, Calgary, Alberta, Canada.
FAU - Stang, Antonia S
AU  - Stang AS
AD  - Department of Pediatrics, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Departments of Pediatrics and Emergency Medicine, Alberta Children's Hospital,
      Calgary, Alberta, Canada.
FAU - Mikrogianakis, Angelo
AU  - Mikrogianakis A
AD  - Emergency Department, McMaster Children's Hospital, Hamilton, Ontario, Canada.
AD  - Department of Pediatrics, Faculty of Health Sciences, DeGroote School of
      Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - VanRiper, Lindy
AU  - VanRiper L
AD  - Emergency Department, Stollery Children's Hospital, Edmonton, Alberta, Canada.
AD  - Department of Psychiatry, Faculty of Medicine and Dentistry, University of
      Alberta, Edmonton, Alberta, Canada.
FAU - Stubbs, Michael
AU  - Stubbs M
AD  - Department of Psychiatry, Alberta Children's Hospital, Calgary, Alberta, Canada.
FAU - Newton, Amanda
AU  - Newton A
AUID- ORCID: 0000-0003-3020-674X
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of
      Alberta, Edmonton, Alberta, Canada mandi.newton@ualberta.ca.
CN  - Pediatric Emergency Research Canada (PERC)
LA  - eng
SI  - ClinicalTrials.gov/NCT04292379
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Qual
JT  - BMJ open quality
JID - 101710381
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Emergency Service, Hospital
MH  - Humans
MH  - *Mental Health
MH  - *Mental Health Services
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Reproducibility of Results
PMC - PMC7737085
OTO - NOTNLM
OT  - *clinical decision-making
OT  - *emergency department
OT  - *health services research
OT  - *interrupted time series analysis
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/12/16 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/12/15 05:53
PHST- 2020/07/07 00:00 [received]
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/11/28 00:00 [accepted]
PHST- 2020/12/15 05:53 [entrez]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - bmjoq-2020-001106 [pii]
AID - 10.1136/bmjoq-2020-001106 [doi]
PST - ppublish
SO  - BMJ Open Qual. 2020 Dec;9(4). pii: bmjoq-2020-001106. doi:
      10.1136/bmjoq-2020-001106.


PMID- 33315259
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - Human Genome Editing and a Global Socio-bioethics Approach.
PG  - 44-45
LID - 10.1002/hast.1200 [doi]
AB  - A global socio-bioethics is called upon to address the ethical challenges arising
      from the revolutionary gene editing technologies such as CRISPR-Cas9, which
      offers the capability to rewrite the human genome. The ethical inquiry Francoise 
      Baylis has undertaken in the book Altered Inheritance: CRISPR and the Ethics of
      Human Genome Editing (Harvard University Press, 2019) operates at individual,
      societal and global levels. Baylis has not only presented insights on how to
      practice "slow science" and achieve broad societal consensus through empowering
      the public, but she also shown what a global socio-bioethics approach can offer
      for the further development of bioethics.
CI  - (c) 2020 The Hastings Center.
FAU - Nie, Jing-Bao
AU  - Nie JB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Bioethics
MH  - CRISPR-Cas Systems
MH  - Female
MH  - *Gene Editing
MH  - Genome, Human
MH  - Humans
MH  - Morals
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - global bioethics
OT  - harms and wrongs
OT  - human genome editing
OT  - socio-bioethics
EDAT- 2020/12/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1200 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):44-45. doi: 10.1002/hast.1200.


PMID- 33315258
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - Health Research and Social Justice Philosophy.
PG  - 39-40
LID - 10.1002/hast.1197 [doi]
AB  - Situating medical and scientific research within a framework or theory of social 
      justice is long overdue. Attempting to extend principles of research ethics
      beyond the clinic and lab to other affected people or consequences tolerates or
      obfuscates injustice. While it must be done, the timescales, methodologies, and
      commitment to real-world impact are quite different in research ethics versus
      political philosophy.
CI  - (c) 2020 The Hastings Center.
FAU - Venkatapuram, Sridhar
AU  - Venkatapuram S
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
CON - Hastings Cent Rep. 2020 Nov;50(6):27-38. PMID: 33315249
MH  - Ethics, Research
MH  - Humans
MH  - *Philosophy
MH  - *Social Justice
OTO - NOTNLM
OT  - *bioethics
OT  - *health equity
OT  - *health justice
OT  - *research ethics
OT  - *social justice
EDAT- 2020/12/15 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
AID - 10.1002/hast.1197 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):39-40. doi: 10.1002/hast.1197.


PMID- 33315257
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - Living Donors and the Issue of "Informed Consent".
PG  - 8-9
LID - 10.1002/hast.1193 [doi]
AB  - This essay considers the issue of informed consent as it arose in the context of 
      1960s living kidney donors. In one of the earliest empirical inquiries into
      informed consent, psychiatrists Carl H. Fellner and John R. Marshall interviewed 
      donors about their decision-making process and their experience and reflections
      on donorship. In their much-cited 1970 paper, the physicians reported that living
      donors, rather than reaching a reasoned, intellectual, and unemotional decision
      about donating a kidney (as stipulated in the Ethical Guidelines for Organ
      Transplantation issued by the American Medical Association's Judicial Council),
      instead made instantaneous and "irrational" decisions about participation.
      Fellner and Marshall's studies contributed to the public debate and professional 
      discussion about the moral and ethical dimensions of donorship, even as they
      challenged the developing consensus on informed consent.
CI  - (c) 2020 The Hastings Center.
FAU - Lederer, Susan E
AU  - Lederer SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Decision Making
MH  - Empirical Research
MH  - Humans
MH  - Informed Consent
MH  - *Living Donors
MH  - Morals
MH  - *Organ Transplantation
MH  - United States
OTO - NOTNLM
OT  - history of bioethics
OT  - informed consent
OT  - living kidney donors
EDAT- 2020/12/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1193 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):8-9. doi: 10.1002/hast.1193.


PMID- 33315254
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20211102
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - Realizing Present and Future Promise of DIY Biology and Medicine through a Trust 
      Architecture.
PG  - 10-14
LID - 10.1002/hast.1194 [doi]
AB  - The speed and scale of the COVID-19 pandemic has highlighted the limits of
      current health systems and the potential promise of non-establishment research
      such as "DIY" research. We consider one example of how DIY research is responding
      to the pandemic, discuss the challenges faced by DIY research more generally, and
      suggest that a "trust architecture" should be developed now to contribute to
      successful future DIY efforts.
CI  - (c) 2020 The Hastings Center.
FAU - Rasmussen, Lisa M
AU  - Rasmussen LM
FAU - Guerrini, Christi J
AU  - Guerrini CJ
FAU - Kuiken, Todd
AU  - Kuiken T
FAU - Nebeker, Camille
AU  - Nebeker C
FAU - Pearlman, Alex
AU  - Pearlman A
FAU - Ware, Sarah B
AU  - Ware SB
FAU - Wexler, Anna
AU  - Wexler A
FAU - Zettler, Patricia J
AU  - Zettler PJ
LA  - eng
GR  - R34 DA050341/DA/NIDA NIH HHS/United States
GR  - R34DA050341/GF/NIH HHS/United States
GR  - Walton Family Foundation/International
GR  - K01 HG009355/HG/NHGRI NIH HHS/United States
GR  - DP5OD026420/Office of the Director at the National Institutes of
      Health/International
GR  - #1937160/National Science Foundation/International
GR  - DP5 OD026420/OD/NIH HHS/United States
GR  - K01-HG009355/National Human Genome Research Institute of the NIH/International
GR  - 2032598/National Science Foundation/International
GR  - Open Philanthropy Project/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - COVID-19/psychology/*therapy
MH  - *Diffusion of Innovation
MH  - Humans
MH  - *Self Efficacy
MH  - *Social Support
PMC - PMC8114871
MID - NIHMS1673249
OTO - NOTNLM
OT  - *Covid-19
OT  - *DIY bio
OT  - *DIY biology
OT  - *DIY medicine
OT  - *biohacking
OT  - *citizen science
OT  - *community bio
OT  - *pandemic
OT  - *participant-led research
OT  - *personal science
OT  - *research ethics
OT  - *trust architecture
EDAT- 2020/12/15 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1002/hast.1194 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):10-14. doi: 10.1002/hast.1194.


PMID- 33315253
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - Third Parties.
PG  - 2
LID - 10.1002/hast.1190 [doi]
AB  - The lead article in the Hastings Center Report's November-December 2020 issue
      reconsiders the rationale for requiring that patients have a prescription from a 
      physician to obtain a drug. Madison Kilbride, Steve Joffe, and Holly Fernandez
      Lynch conclude that growing respect for patient autonomy should lead to a new
      default for drug access: drugs should be available over the counter unless there 
      are special concerns about harms to third parties or about patients' ability to
      make decisions for themselves. This conclusion would be a substantial
      reorientation of drug policy in the United States. Bioethics at a societal level 
      is a theme in the second article, "The Social Risks of Science," and throughout
      the issue.
CI  - (c) 2020 The Hastings Center.
FAU - Kaebnick, Gregory E
AU  - Kaebnick GE
LA  - eng
PT  - Editorial
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Bioethics
MH  - Humans
MH  - Public Policy
MH  - United States
OTO - NOTNLM
OT  - *FDA policy
OT  - *interpersonal ethics
OT  - *research ethics
OT  - *social ethics
EDAT- 2020/12/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1190 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):2. doi: 10.1002/hast.1190.


PMID- 33315250
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - OK, Boomer, MD: The Rights of Aging Physicians and the Health of Our Communities.
PG  - 3
LID - 10.1002/hast.1191 [doi]
AB  - How do we balance the rights of aging physicians against the right of the public 
      to competent health care? This version of a classic public health ethics dilemma 
      is here now and likely to increase as the population ages. Peer review has long
      been the standard mechanism for assessing physician competence, but it is
      subjective and too easily subverted. New options are needed, both in medicine and
      throughout the professions, but they are challenging to implement. Physicians
      have an ethical obligation to protect the health of the public by acknowledging, 
      assessing, and addressing the cognitive effects of aging on medical competence.
CI  - (c) 2020 The Hastings Center.
FAU - Powell, Tia
AU  - Powell T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Aging
MH  - Delivery of Health Care
MH  - Ethics, Medical
MH  - Humans
MH  - Moral Obligations
MH  - *Physicians
MH  - Public Health
OTO - NOTNLM
OT  - *rights of physicians
EDAT- 2020/12/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1191 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):3. doi: 10.1002/hast.1191.


PMID- 33315249
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - The Social Risks of Science.
PG  - 27-38
LID - 10.1002/hast.1196 [doi]
AB  - Many instances of scientific research impose risks, not just on participants and 
      scientists but also on third parties. This class of social risks unifies a range 
      of problems previously treated as distinct phenomena, including so-called
      bystander risks, biosafety concerns arising from gain-of-function research, the
      misuse of the results of dual-use research, and the harm caused by inductive
      risks. The standard approach to these problems has been to extend two familiar
      principles from human subjects research regulations-a favorable risk-benefit
      ratio and informed consent. We argue, however, that these moral principles will
      be difficult to satisfy in the context of widely distributed social risks about
      which affected parties may reasonably disagree. We propose that framing these
      risks as political rather than moral problems may offer another way. By borrowing
      lessons from political philosophy, we propose a framework that unifies our
      discussion of social risks and the possible solutions to them.
CI  - (c) 2020 The Hastings Center.
FAU - Herington, Jonathan
AU  - Herington J
FAU - Tanona, Scott
AU  - Tanona S
LA  - eng
GR  - 1835366/National Science Foundation
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
CIN - Hastings Cent Rep. 2020 Nov;50(6):39-40. PMID: 33315258
CIN - Hastings Cent Rep. 2021 Mar;51(2):41-42. PMID: 33840106
MH  - Humans
MH  - *Informed Consent
MH  - Moral Obligations
MH  - Philosophy
MH  - Research Design
MH  - *Research Subjects
OTO - NOTNLM
OT  - bystander risks
OT  - dual-use research
OT  - inductive risk
OT  - research ethics
OT  - social risks
EDAT- 2020/12/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1196 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):27-38. doi: 10.1002/hast.1196.


PMID- 33315248
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Nov
TI  - A Small-Town Heart.
PG  - 4-7
LID - 10.1002/hast.1192 [doi]
AB  - Melanie presented at twenty weeks of gestation to an obstetrics clinic in a
      critical access hospital in rural Vermont. She was excited to undergo routine
      fetal ultrasonography, but her obstetrician gave her grave news: the ultrasound
      revealed hypoplastic left heart syndrome, a devastating congenital heart defect. 
      Initially, Melanie agreed in general to pursue surgical care for her fetus-a
      three-stage process that has somewhat uncertain results and could only be done in
      tertiary care facilities far from her home in Vermont. A week later, while the
      maternal fetal medicine and pediatric cardiology units made arrangements with
      colleagues in Boston, Melanie began having second thoughts. An ethics meeting was
      called to discuss conflicting clinician reactions to Melanie's dilemma. Most of
      the clinicians were stunned that the patient would change her mind. What advice
      should the ethics consultant offer the team about caring for Melanie?
CI  - (c) 2020 The Hastings Center.
FAU - Lahey, Tim
AU  - Lahey T
FAU - Herbst, Jennifer L
AU  - Herbst JL
FAU - Gross, Marielle S
AU  - Gross MS
FAU - Scully, Brandi Braud
AU  - Scully BB
LA  - eng
PT  - Case Reports
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Female
MH  - Fetus
MH  - *Heart Defects, Congenital
MH  - Humans
MH  - Pregnancy
OTO - NOTNLM
OT  - *children and health care
OT  - *doctor-patient relationship
OT  - *rural bioethics
EDAT- 2020/12/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/12/14 13:07
PHST- 2020/12/14 13:07 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1002/hast.1192 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Nov;50(6):4-7. doi: 10.1002/hast.1192.


PMID- 33315014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201230
IS  - 2292-9495 (Electronic)
IS  - 2292-9495 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Dec 14
TI  - Health Care Professionals' Experience of a Digital Tool for Patient Exchange,
      Anamnesis, and Triage in Primary Care: Qualitative Study.
PG  - e21698
LID - 10.2196/21698 [doi]
AB  - BACKGROUND: Despite a growing body of knowledge about eHealth innovations, there 
      is still limited understanding of the implementation of such tools in everyday
      primary care. OBJECTIVE: The objective of our study was to describe health care
      staff's experience with a digital communication system intended for patient-staff
      encounters via a digital route in primary care. METHODS: In this qualitative
      study we conducted 21 individual interviews with staff at 5 primary care centers 
      in Sweden that had used a digital communication system for 6 months. The
      interviews were guided by narrative queries, transcribed verbatim, and subjected 
      to content analysis. RESULTS: While the digital communication system was easy to 
      grasp, it was nevertheless complex to use, affecting both staffing and routines
      for communicating with patients, and documenting contacts. Templates strengthened
      equivalent procedures for patients but dictated a certain level of health and
      digital literacy for accuracy. Although patients expected a chat to be
      synchronous, asynchronous communication was extended over time. The system for
      digital communication benefited assessments and enabled more efficient use of
      resources, such as staff. On the other hand, telephone contact was faster and
      better for certain purposes, especially when the patient's voice itself provided 
      data. However, many primary care patients, particularly younger ones, expected
      digital routes for contact. To match preferences for communicating to a place and
      time that suited patients was significant; staff were willing to accept some
      nuisance from a suboptimal service-at least for a while-if it procured patient
      satisfaction. A team effort, including engaged managers, scaffolded the
      implementation process, whereas being subjected to a trial without likely success
      erected barriers. CONCLUSIONS: A digital communication system introduced in
      regular primary care involved complexity beyond merely learning how to manage the
      tool. Rather, it affected routines and required that both the team and the
      context were addressed. Further knowledge is needed about what factors facilitate
      implementation, and how. This study suggested including ethical perspectives on
      eHealth tools, providing an important but novel aspect of implementation.
CI  - (c)Ann Catrine Eldh, Annette Sverker, Preben Bendtsen, Evalill Nilsson.
      Originally published in JMIR Human Factors (http://humanfactors.jmir.org),
      14.12.2020.
FAU - Eldh, Ann Catrine
AU  - Eldh AC
AUID- ORCID: https://orcid.org/0000-0002-7737-169X
AD  - Department of Health, Medicine and Caring Sciences, Linkoping University,
      Linkoping, Sweden.
AD  - Department of Public Health and Caring Sciences, Uppsala University, Uppsala,
      Sweden.
FAU - Sverker, Annette
AU  - Sverker A
AUID- ORCID: https://orcid.org/0000-0002-1188-4273
AD  - Department of Rehabilitation Medicine and Department of Health, Medicine and
      Caring Sciences, Linkoping University, Linkoping, Sweden.
FAU - Bendtsen, Preben
AU  - Bendtsen P
AUID- ORCID: https://orcid.org/0000-0001-5913-2903
AD  - Department of Medical Specialists in Motala and Department of Health, Medicine
      and Caring Sciences, Linkoping University, Linkoping, Sweden.
FAU - Nilsson, Evalill
AU  - Nilsson E
AUID- ORCID: https://orcid.org/0000-0002-4497-8313
AD  - Department of Health, Medicine and Caring Sciences, Linkoping University,
      Linkoping, Sweden.
AD  - e-Health Institute, Department of Medicine and Optometry, Linneaus University,
      Kalmar, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - Canada
TA  - JMIR Hum Factors
JT  - JMIR human factors
JID - 101666561
PMC - PMC7769692
OTO - NOTNLM
OT  - communication
OT  - content analysis
OT  - digital technology
OT  - eHealth
OT  - interviews
OT  - primary health care
OT  - qualitative research
OT  - telemedicine
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 12:08
PHST- 2020/06/22 00:00 [received]
PHST- 2020/11/14 00:00 [accepted]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/12/14 12:08 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - v7i4e21698 [pii]
AID - 10.2196/21698 [doi]
PST - epublish
SO  - JMIR Hum Factors. 2020 Dec 14;7(4):e21698. doi: 10.2196/21698.


PMID- 33314956
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 2219-0635 (Electronic)
IS  - 0030-2465 (Linking)
VI  - 87
IP  - 1
DP  - 2020 Nov 26
TI  - A report on the housing vervet monkeys adjacent to domestic cats as a means of
      environmental enrichment.
PG  - e1-e6
LID - 10.4102/ojvr.v87i1.1870 [doi]
AB  - In current research guidelines, much focus is placed on ethical management of
      animals and the application of principles of reduction, refinement and
      replacement. Of these refinements through environmental enrichment is an
      important aspect when housing primate to prevent behavioural problems. In this
      study, we investigated the co-housing of domestic cats and vervet monkeys as a
      novel method of enrichment based on the cohabitation and stress alleviation
      effect of horses housed with goats and from seeing cats cohabitating with vervet 
      monkeys in an animal sanctuary. The study used a habituation method whereby the
      cats were stepwise introduced to the monkeys by sight and smell but with physical
      separation. Assessment included changes in behaviour, weight and faecal
      glucocorticoid metabolite (fGCM) concentrations over time. On the first day of
      housing, the vervets whilst inquisitive kept their distance. The vervets housed
      in cages that were closest to the cats were the most active and during the first 
      minute of introduction made more alarm calls, which stopped a few days later. The
      fGCMs were non-significantly different. The results of this study provide
      evidence that vervet monkeys and domestic cats could potentially be housed
      together without overt aggression. We thus suggest further observations to
      ascertain if the co-housing could have long-term benefits for vervet monkeys,
      from the companionship that would be offered by the cats.
FAU - Chipangura, John K
AU  - Chipangura JK
AD  - Biomedical Research Centre, Faculty of Veterinary Science, University of
      Pretoria, Pretoria, South Africa; and, Department of Paraclinical Sciences,
      Faculty of Veterinary Science, University of Pretoria, Pretoria.
      john.chipangura@gmail.com.
FAU - Ganswindt, Andre
AU  - Ganswindt A
FAU - Naidoo, Vinny
AU  - Naidoo V
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - South Africa
TA  - Onderstepoort J Vet Res
JT  - The Onderstepoort journal of veterinary research
JID - 0401107
SB  - IM
MH  - Animals
MH  - Cats/*psychology
MH  - Chlorocebus aethiops/*psychology
MH  - Female
MH  - *Housing, Animal/statistics & numerical data
MH  - Male
MH  - Pilot Projects
PMC - PMC7736655
OTO - NOTNLM
OT  - domestic cats
OT  - faecal glucocorticoid metabolites
OT  - stress
OT  - vervet monkeys
EDAT- 2020/12/15 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/12/14 12:08
PHST- 2020/04/01 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/08/29 00:00 [revised]
PHST- 2020/12/14 12:08 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
AID - 10.4102/ojvr.v87i1.1870 [doi]
PST - epublish
SO  - Onderstepoort J Vet Res. 2020 Nov 26;87(1):e1-e6. doi: 10.4102/ojvr.v87i1.1870.


PMID- 33313711
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20211104
IS  - 1559-7776 (Electronic)
IS  - 1559-7768 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Dec 15
TI  - Ethical Issues When Caring for a Pregnant Patient in the Intensive Care Unit.
PG  - 425-430
LID - 10.4037/aacnacc2020953 [doi]
FAU - Tabari, Kayla
AU  - Tabari K
AD  - Kayla Tabari is a PhD student at Oregon Health and Science University, 3555 SW US
      Veterans Hospital Rd, Portland, OR 97239 (tabari@ohsu.edu).
FAU - Uveges, Melissa Kurtz
AU  - Uveges MK
AD  - Melissa Kurtz Uveges is Assistant Professor, Connell School of Nursing, Boston
      College, Boston, Massachusetts.
FAU - Milliken, Aimee
AU  - Milliken A
AD  - Aimee Milliken is Interim Executive Director, Ethics Service, Brigham and Women's
      Hospital, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AACN Adv Crit Care
JT  - AACN advanced critical care
JID - 101269322
MH  - Female
MH  - Humans
MH  - *Intensive Care Units
MH  - Nurse-Patient Relations
MH  - Pregnancy
EDAT- 2020/12/15 06:00
MHDA- 2021/11/05 06:00
CRDT- 2020/12/14 11:02
PHST- 2020/12/14 11:02 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
AID - 31246 [pii]
AID - 10.4037/aacnacc2020953 [doi]
PST - ppublish
SO  - AACN Adv Crit Care. 2020 Dec 15;31(4):425-430. doi: 10.4037/aacnacc2020953.


PMID- 33313590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2667-677X (Print)
IS  - 2149-276X (Linking)
VI  - 48
IP  - 6
DP  - 2020 Dec
TI  - Knowledge and Attitudes about Helsinki Declaration on Patient Safety among
      Anaesthesiologists in Turkey: A Questionnaire Study.
PG  - 497-501
LID - 10.5152/TJAR.2020.477 [doi]
AB  - OBJECTIVE: The Helsinki Declaration on Patient Safety in Anaesthesiology is an
      important document for anaesthesiologists. This study aimed to evaluate the
      knowledge and experiences of anaesthesiologists in Turkey on the "Helsinki
      Declaration on Patient Safety." METHODS: After the ethics committee approval and 
      participants' consent, electronic questionnaires were sent to anesthetists
      working in Turkey. The questionnaire included 48 questions. RESULTS: The mean age
      of the participants was 44.28+/-8.01 years, and 52.1% were women (n=142). The
      mean time spent in the field of anesthesiology was 12.83+/-7.76 years. The
      percentage of participants working in private hospitals was 13.4%. A total of
      58.5% of the participants were educated on patient safety out of whom 57% said
      that their knowledge was sufficient, 37.3% said that it was limited, and 5.6%
      felt that it was insufficient. The knowledge of participants about the Helsinki
      Declaration was sufficient in 31.7%, limited in 39.4%, insufficient in 9.2%, and 
      19.7% had no knowledge. A total of 27% of participants believed that
      implementation of the Helsinki Declaration improved patient safety. It has been
      stated that the minimum patient monitoring standards recommended by the European 
      Board of Anaesthesiology has been complied in operating rooms and recovery units 
      (90.8% and 78.2%, respectively). CONCLUSION: The findings of this survey might
      guide not only the individual anesthetists but also hospital administrators to
      develop strategies to improve patient safety and thus quality of care in the
      light of the recommendations listed in the Helsinki Declaration.
CI  - (c) Copyright 2020 by Turkish Anaesthesiology and Intensive Care Society.
FAU - Corman Dincer, Pelin
AU  - Corman Dincer P
AUID- ORCID: 0000-0001-7085-6232
AD  - Department of Anaesthesiology and Reanimation, Marmara University School of
      Medicine, Istanbul, Turkey.
FAU - Aykac, Zuhal
AU  - Aykac Z
AUID- ORCID: 0000-0002-3803-8501
AD  - Department of Anaesthesiology and Reanimation, Marmara University School of
      Medicine, Istanbul, Turkey.
FAU - Hanci, Volkan
AU  - Hanci V
AUID- ORCID: 0000-0002-2227-194X
AD  - Department of Anaesthesiology and Reanimation, Dokuz Eylul University Faculty of 
      Medicine, Izmir, Turkey.
FAU - Colakoglu, Serhan
AU  - Colakoglu S
AUID- ORCID: 0000-0002-7956-4372
AD  - Lexis Medico-Legal Consulting, Istanbul, Turkey.
FAU - Bakan, Nurten
AU  - Bakan N
AUID- ORCID: 0000-0002-4547-9698
AD  - Department of Anaesthesiology and Reanimation, Ministry of Health Sancaktepe
      Training and Research Hospital, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - Turkey
TA  - Turk J Anaesthesiol Reanim
JT  - Turkish journal of anaesthesiology and reanimation
JID - 101680817
EIN - Turk J Anaesthesiol Reanim. 2021 Feb;49(1):92. PMID: 33718918
PMC - PMC7720833
OTO - NOTNLM
OT  - Anaesthesiology standards
OT  - Helsinki Declaration on Patient Safety
OT  - patient safety
OT  - quality of healthcare standards
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 11:01
PHST- 2020/03/18 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/12/14 11:01 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.5152/TJAR.2020.477 [doi]
AID - tjar-48-6-497 [pii]
PST - ppublish
SO  - Turk J Anaesthesiol Reanim. 2020 Dec;48(6):497-501. doi: 10.5152/TJAR.2020.477.
      Epub 2020 Dec 1.


PMID- 33313588
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2667-677X (Print)
IS  - 2149-276X (Linking)
VI  - 48
IP  - 6
DP  - 2020 Dec
TI  - Evaluation of Preoperative Anxiety in Turkish Paediatric Patients and Validity
      and Reliability of the Turkish Modified Yale Preoperative Anxiety Scale.
PG  - 484-490
LID - 10.5152/TJAR.2020.116 [doi]
AB  - OBJECTIVE: Preoperative anxiety has been related with postoperative behaviour
      changes, and it is characterised by subjective feelings. The modified Yale
      Preoperative Anxiety Scale (mYPAS) is a tool, which indicates preoperative
      anxiety in children older than 2 years. The objective of this study was to
      investigate factors affecting the level of preoperative anxiety after conduct
      validity and reliability of the Turkish version of mYPAS. METHODS: After
      obtaining approval from the ethics committee, 330 children aged 5-16 years were
      included in the study. Relationships between possible anxiety factors and anxiety
      levels were evaluated after validity and interrater reliability of the Turkish
      version. RESULTS: The intraclass correlation coefficient between the three
      observers was 0.9949 (95% confidence interval [CI]: 0.9939-0.9958) for the
      playroom assessments and 0.9952 (95% CI: 0.9942-0.9960) for the operating room
      assessments. The anxiety level was significantly lower in premedicated patients
      (p<0.001). There was a negative correlation between age and anxiety level
      (p<0.001, r=-0.350). CONCLUSION: The Turkish version of mYPAS has high validity
      and reliability and is suitable for use in the paediatric population of our
      country. Premedication significantly decreased preoperative anxiety, and younger 
      patients tended to have higher anxiety level. For the 5-12 years age range, the
      level of anxiety decreased with age. More clinical studies are needed to
      investigate factors that contribute to preoperative anxiety.
CI  - (c) Copyright 2020 by Turkish Anaesthesiology and Intensive Care Society.
FAU - Topalel, Selen
AU  - Topalel S
AUID- ORCID: 0000-0003-2758-220X
AD  - Department of Anaesthesiology and Reanimation, Bingol State Hospital, Bingol,
      Turkey.
FAU - Orekici Temel, Gulhan
AU  - Orekici Temel G
AUID- ORCID: 0000-0002-2835-6979
AD  - Department of Biostatistics and Bioinformatics, Mersin University School of
      Medicine, Mersin, Turkey.
FAU - Azizoglu, Mustafa
AU  - Azizoglu M
AUID- ORCID: 0000-0002-8266-5203
AD  - Department of Anaesthesiology and Reanimation, Mersin University School of
      Medicine, Mersin, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - Turkey
TA  - Turk J Anaesthesiol Reanim
JT  - Turkish journal of anaesthesiology and reanimation
JID - 101680817
PMC - PMC7720823
OTO - NOTNLM
OT  - General anaesthesia
OT  - paediatric anaesthesia
OT  - preoperative anxiety
OT  - the modified Yale Preoperative Anxiety Scale
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 11:01
PHST- 2019/11/20 00:00 [received]
PHST- 2019/11/28 00:00 [accepted]
PHST- 2020/12/14 11:01 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.5152/TJAR.2020.116 [doi]
AID - tjar-48-6-484 [pii]
PST - ppublish
SO  - Turk J Anaesthesiol Reanim. 2020 Dec;48(6):484-490. doi: 10.5152/TJAR.2020.116.
      Epub 2020 May 18.


PMID- 33313151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2305-5839 (Print)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 21
DP  - 2020 Nov
TI  - Hemovac blood after total knee arthroplasty as a source of stem cells.
PG  - 1406
LID - 10.21037/atm-20-2215 [doi]
AB  - BACKGROUND: With increasing life expectancy, stem cell therapy is receiving
      increasing attention. However, its application is restricted by ethical concerns.
      Hence a need exists for design of safe procedures for stem cell procurement.
      Here, we investigated whether hemovac blood (HVB) is an appropriate stem cell
      source. METHODS: HVB concentrates (HVBCs) from 20 total knee arthroplasty (TKA)
      patients and bone marrow aspirate (BMA) concentrates (BMACs) from 15 patients who
      underwent knee cartilage repair were comparatively evaluated. A bone marrow
      aspiration needle was inserted into the anterior superior iliac spine. Aspiration
      was performed using a 50-mL syringe, including 4 mL of anticoagulant, followed by
      centrifugation to obtain BMACs. To obtain HVBCs, blood was aspirated from the
      hemovac immediately after TKA surgery. Different cell types were enumerated.
      Isolation of BMA and HVB mononuclear cells was performed using density gradient
      centrifugation. Non-hematopoietic fibroblast colonies were quantified by colony
      forming unit-fibroblast assay surface marker analysis of HVB, HVBC, BMA, and BMAC
      was performed via flow cytometry. Mesenchymal stem cells (MSCs) isolated from
      HVBCs and BMACs were examined for osteogenic, adipogenic, and chondrogenic
      differentiation potential. Gene expression analysis was performed by quantitative
      real-time polymerase chain reaction (qRT-PCR). RESULTS: The number of cells from 
      HVB and HVBC was significantly lower than from BMA and BMAC; however, the number 
      of colonies in HVBC and BMAC did not differ significantly (P>0.05). Isolated
      cells from both sources had a fibroblast-like appearance, adhered to culture
      flasks, and formed colonies. Under different culture conditions, MSC-specific
      surface markers (CD29, CD44, CD90, CD105), osteogenic markers [RUNX2,
      osteopontin, osteocalcin, and alkaline phosphatase (ALP)] and adipogenic markers 
      (PPARgamma and C/EBPalpha) were expressed. Moreover, SOX9, type II collagen, and 
      aggrecan were significantly upregulated upon chondrogenic differentiation.
      CONCLUSIONS: HVB from TKA patients is a useful source of stem cells for research.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Kim, Seon Ae
AU  - Kim SA
AD  - Department of Orthopedic Surgery, College of Medicine, The Catholic University of
      Korea, Seoul, Republic of Korea.
FAU - Park, Ho Youn
AU  - Park HY
AD  - Department of Orthopedic Surgery, College of Medicine, The Catholic University of
      Korea, Seoul, Republic of Korea.
FAU - Shin, Yong-Woon
AU  - Shin YW
AD  - Department of Orthopaedic Surgery, College of Medicine, The Inje University of
      Korea, Seoul, Republic of Korea.
FAU - Go, Eun Jeong
AU  - Go EJ
AD  - Department of Orthopedic Surgery, College of Medicine, The Catholic University of
      Korea, Seoul, Republic of Korea.
FAU - Kim, Young Ju
AU  - Kim YJ
AD  - Department of Nursing Education & Administration, Uijeongbu St. Mary's Hospital, 
      The Catholic University of Korea, Seoul, Republic of Korea.
FAU - Kim, Yoo Chang
AU  - Kim YC
AD  - Department of Orthopedic Surgery, College of Medicine, The Catholic University of
      Korea, Seoul, Republic of Korea.
FAU - Shetty, Asode Ananthram
AU  - Shetty AA
AD  - Canterbury Christ Church University, Faculty of Health and Wellbeing, Chatham
      Maritime, Kent, UK.
FAU - Kim, Seok Jung
AU  - Kim SJ
AD  - Department of Orthopedic Surgery, College of Medicine, The Catholic University of
      Korea, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7723525
OTO - NOTNLM
OT  - Bone marrow
OT  - bone marrow aspirate concentrate (BMAC)
OT  - hemovac blood (HVB)
OT  - stem cell
OT  - total knee arthroplasty (TKA)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/atm-20-2215). The authors have no
      conflicts of interest to declare.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:59
PHST- 2020/12/14 10:59 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.21037/atm-20-2215 [doi]
AID - atm-08-21-1406 [pii]
PST - ppublish
SO  - Ann Transl Med. 2020 Nov;8(21):1406. doi: 10.21037/atm-20-2215.


PMID- 33312822
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 10
TI  - Body Mass Index and Inguinal Hernia: An Observational Study Focusing on the
      Association of Inguinal Hernia With Body Mass Index.
PG  - e11426
LID - 10.7759/cureus.11426 [doi]
AB  - Objective An inguinal hernia is a common condition associated with advanced age, 
      male gender, smoking, connective tissue disorder, and factors responsible for
      increased intra-abdominal pressure. This study aimed to observe the relationship 
      of body mass index with the development of inguinal hernia in males and females. 
      Methodology This cross-sectional descriptive study using a non-probability
      convenient sampling technique was carried out at Al-Tibri medical college and
      hospital, Karachi, Pakistan. A total of 82 patients were selected: 78 males and
      four females. The ethical approval for the study was taken from Institutional
      Research and Ethical Committee. Inclusion criteria based on the patient age above
      40 of either gender with complaints of pain in the groin region with clinical
      findings like swelling and tenderness. Data were analyzed using Statistical
      Package for the Social Sciences (SPSS) version 20.0 (IBM Inc., Armonk, USA).
      Results The mean age of 82 patients diagnosed with an inguinal hernia on a
      clinical basis was 47.41 +/- 15.49 years. The mean height was 67.09 +/- 3.95
      inches. The mean weight was 63.5 +/- 6.77 kg. The mean BMI was 22.07 +/- 2.17
      kg/m(2). Seventy-eight (96.06%) were males, and four (5.9%) were females.
      Thirty-four (41.5%) patients were diagnosed with right inguinal hernia, 34
      (41.5%) - with a left inguinal hernia, and 14 (17.1%) - with a bilateral inguinal
      hernia. BMI was normal in 68 (86.3%) and low in 14 (20.55%) patients. Our study
      indicated that patients with normal BMI were more likely to suffer from inguinal 
      hernia than patients with low BMI. Conclusion This study concluded that the
      normal body mass index was associated with a high occurrence of inguinal hernia
      among the genders. The normal body mass index in males exhibits more inguinal
      hernia chances than a low body mass index. It was observed that the frequency of 
      unilateral right inguinal hernia is higher than bilateral. Similarly, males are
      more affected than females.
CI  - Copyright (c) 2020, Melwani et al.
FAU - Melwani, Rekha
AU  - Melwani R
AD  - General Surgery, Al-Tibri Medical College and Hospital, Isra University, Karachi,
      PAK.
FAU - Malik, Sadaf Jabeen
AU  - Malik SJ
AD  - General Surgery, Al-Tibri Medical College and Hospital, Isra University, Karachi,
      PAK.
FAU - Arija, Dharmoon
AU  - Arija D
AD  - General Surgery, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
FAU - Sial, Ihsanullah
AU  - Sial I
AD  - General Surgery, Al-Tibri Medical College and Hospital, Isra University, Karachi,
      PAK.
FAU - Bajaj, Ajay Kumar
AU  - Bajaj AK
AD  - General Surgery, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
FAU - Anwar, Adnan
AU  - Anwar A
AD  - Physiology, Al-Tibri Medical College and Hospital, Isra university, Karachi, PAK.
FAU - Hashmi, Atif A
AU  - Hashmi AA
AD  - Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7727769
OTO - NOTNLM
OT  - body mass index
OT  - gender
OT  - inguinal hernia
OT  - intra abdominal pressure
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:58
PHST- 2020/12/14 10:58 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.7759/cureus.11426 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 10;12(11):e11426. doi: 10.7759/cureus.11426.


PMID- 33312819
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 10
TI  - Role of Dedicated Cardiac Emergency Unit in Early Identification and Management
      of Acute Myocardial Infarction in a Developing Country of South Asia.
PG  - e11423
LID - 10.7759/cureus.11423 [doi]
AB  - Background The care of patients presenting with chest pain to multidisciplinary
      services hospital gets compromised due to the busy triage system. A separate and 
      specialized equipped cardiac emergency unit (CAR-ERU) can improve patient's
      outcomes. Objectives To enhance early recognition and treatment of acute
      myocardial infarction (AMI) patients. To sustain key performance quality
      indicators (KPIs) for AMI. Methods In October 2016, a separate CAR-ERU was
      established inside the multidisciplinary emergency department (MED). A dedicated 
      specialized heart-lung and vascular teams were hired under the supervision of
      service line leadership. The KPIs that were identified benchmark with
      international practice guidelines. Data were collected and stored for analysis.
      Exemption from the ethical review committee was obtained. Results A total of 2914
      patients visited CAR-ERU from October 2016 to September 2017 for a period of one 
      year. Out of which 30% were diagnosed with acute coronary syndrome (ACS) and this
      included 8% diagnosis with ST-segment elevation myocardial infarction (STEMI).
      Over 98.8% of the electrocardiogram (ECG) was done within 10 minutes of arrival
      while aspirin was given to 96.5% of patients within one hour. The door to balloon
      time (DBT) of <90 min was achieved in 70% of patients. A significant reduction in
      length of stay in the emergency department and financial burden was noted.
      Sustainability of major KPI was observed over the subsequent years. Conclusion
      The introduction of a dedicated CAR-EU improved clinical outcomes, reduced length
      of stay and financial burden in AMI patients managed in CAR-EU. Our tertiary care
      hospital is the first one of its kind to take this quality initiative in a
      lower-middle-income country (LMIC) Pakistan.
CI  - Copyright (c) 2020, Baloch et al.
FAU - Baloch, Farhala
AU  - Baloch F
AD  - Medicine/Cardiology, The Aga Khan University, Karachi, PAK.
FAU - Khan, Amina
AU  - Khan A
AD  - School of Nursing, The Aga khan University, Karachi, PAK.
FAU - Kabani, Ashmal
AU  - Kabani A
AD  - Medicine, The Aga Khan University, Karachi, PAK.
FAU - Fatimi, Saulat
AU  - Fatimi S
AD  - Cardiothoracic Surgery, The Aga Khan University, Karachi, PAK.
FAU - Tai, Javed
AU  - Tai J
AD  - Cardiology, The Aga Khan Hospital, Karachi, PAK.
FAU - Khan, Aamir H
AU  - Khan AH
AD  - Medicine/Cardiology, The Aga Khan University, Karachi, PAK.
FAU - Hashmi, Shiraz
AU  - Hashmi S
AD  - Cardiothoracic Surgery, The Aga Khan University, Karachi, PAK.
FAU - Aslam, Mazeera
AU  - Aslam M
AD  - School of Nursing, The Aga Khan University, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7727776
OTO - NOTNLM
OT  - acute myocardial infarction
OT  - acute st-elevation myocardial infarction
OT  - cardiac emergency unit
OT  - key performance indicators
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:58
PHST- 2020/12/14 10:58 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.7759/cureus.11423 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 10;12(11):e11423. doi: 10.7759/cureus.11423.


PMID- 33312801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 9
TI  - Publication Non Grata: The Challenge of Publishing Non-COVID-19 Research in the
      COVID Era.
PG  - e11403
LID - 10.7759/cureus.11403 [doi]
AB  - OBJECTIVES: We aimed to determine publication trends in leading clinical research
      journals (impact factor >20) during the rise of the coronavirus disease 2019
      (COVID-19) pandemic and to check for an increase in publication times of
      non-COVID-19 original research articles. METHODS: We collected publication data
      from five print-based medical journals and one online journal--JAMA: The Journal 
      of the American Medical Association, The Lancet (Lancet), The New England Journal
      of Medicine, Annals of Internal Medicine, The BMJ (BMJ), and BMC Medicine (BMC
      Med)--for the December 2019 through May 2020 period. We categorized each article 
      as either "COVID-19-related" or "non-COVID-19-related". When available, we
      further extracted data on submission-to-acceptance dates and
      acceptance-to-publication dates for original research articles for the January
      through July 2019 and January through July 2020 periods. We compared the time
      from submission to publication for non-COVID-19 original research articles during
      the two periods and tested for statistical significance with a one-tailed
      Wilcoxon rank-sum test. RESULTS: We found that non-COVID-19-related articles
      began decreasing in volume as COVID-19-related articles increased. In BMJ and
      Lancet, the COVID-19-related articles began overtaking the non-COVID-19-related
      articles in number during April and May 2020. However, COVID-19-related primary
      research articles only began consistently appearing in journal issues during May 
      2020. Only BMJ and BMC Med publicly recorded complete data regarding their
      publication timelines. After removing outliers, we found that the mean time from 
      submission to publication for articles published in BMJ from January through July
      2019 was 204 days (median: 194 days; IQR: 163-236), and from January through July
      2020 was 223 days (median: 218 days; IQR: 177-261) (p=0.04). In BMC Med, the mean
      time from submission to publication from February through July 2019 was 153 days 
      (median: 150 days; IQR: 123-181), and from February through July 2020 was 163
      days (median: 157 days; IQR: 132-191) (p=0.06). Conclusion: We discovered a
      steadily increasing trend in the percentage of COVID-19-related articles and a
      concomitant decreasing trend in the percentage of non-COVID-19-related articles
      published in high-impact print journals during the period from December 2019
      through May 2020. For non-COVID-19-related articles published in BMJ, we found a 
      statistically significant increase upon comparing the submission-to-publication
      times for the period from January through July 2020 with the
      submission-to-publication times for the period from January through July 2019.
CI  - Copyright (c) 2020, Shan et al.
FAU - Shan, Judy
AU  - Shan J
AD  - Division of Research, Kaiser Permanente, Oakland, USA.
FAU - Ballard, Dustin
AU  - Ballard D
AD  - Emergency Medicine, Kaiser Permanente San Rafael Medical Center, San Rafael, USA.
FAU - Vinson, David R
AU  - Vinson DR
AD  - Emergency Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, USA.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7725412
OTO - NOTNLM
OT  - corona virus disease 2019
OT  - covid 19
OT  - pandemics
OT  - publication bias
OT  - publication ethics
OT  - publication trends
OT  - research and publishing
OT  - research trends
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:58
PHST- 2020/12/14 10:58 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.7759/cureus.11403 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 9;12(11):e11403. doi: 10.7759/cureus.11403.


PMID- 33312674
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220720
IS  - 2054-2577 (Print)
IS  - 2054-2577 (Linking)
VI  - 7
IP  - 6
DP  - 2020 Dec
TI  - Determining medical decision-making capacity in brain tumor patients: why and
      how?
PG  - 599-612
LID - 10.1093/nop/npaa040 [doi]
AB  - BACKGROUND: Brain tumor patients are at high risk of impaired medical
      decision-making capacity (MDC), which can be ethically challenging because it
      limits their ability to give informed consent to medical treatments or
      participation in research. The European Association of Neuro-Oncology Palliative 
      Care Multidisciplinary Task Force performed a systematic review to identify
      relevant evidence with respect to MDC that could be used to give recommendations 
      on how to cope with reduced MDC in brain tumor patients. METHODS: A literature
      search in several electronic databases was conducted up to September 2019,
      including studies with brain tumor and other neurological patients. Information
      related to the following topics was extracted: tools to measure MDC, consent to
      treatment or research, predictive patient- and treatment-related factors,
      surrogate decision making, and interventions to improve MDC. RESULTS: A total of 
      138 articles were deemed eligible. Several structured capacity-assessment
      instruments are available to aid clinical decision making. These instruments
      revealed a high incidence of impaired MDC both in brain tumors and other
      neurological diseases for treatment- and research-related decisions. Incapacity
      appeared to be mostly determined by the level of cognitive impairment. Surrogate 
      decision making should be considered in case a patient lacks capacity, ensuring
      that the patient's "best interests" and wishes are guaranteed. Several methods
      are available that may help to enhance patients' consent capacity. CONCLUSIONS:
      Clinical recommendations on how to detect and manage reduced MDC in brain tumor
      patients were formulated, reflecting among others the timing of MDC assessments, 
      methods to enhance patients' consent capacity, and alternative procedures,
      including surrogate consent.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology and the European Association of Neuro-Oncology. All
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Pace, Andrea
AU  - Pace A
AD  - Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
FAU - Koekkoek, Johan A F
AU  - Koekkoek JAF
AD  - Department of Neurology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands.
FAU - van den Bent, Martin J
AU  - van den Bent MJ
AD  - Department of Neurology, The Brain Tumor Center, Erasmus Medical Center,
      Rotterdam, the Netherlands.
FAU - Bulbeck, Helen J
AU  - Bulbeck HJ
AD  - Brainstrust (The Brain Cancer People), Cowes, Isle of Wight, UK.
FAU - Fleming, Jane
AU  - Fleming J
AD  - Department of Palliative Medicine, University Hospital Waterford, Waterford,
      Ireland.
FAU - Grant, Robin
AU  - Grant R
AD  - Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh,
      Scotland, UK.
FAU - Golla, Heidrun
AU  - Golla H
AD  - Department of Palliative Medicine, University Hospital of Cologne, Cologne,
      Germany.
FAU - Henriksson, Roger
AU  - Henriksson R
AD  - Department of Radiation Sciences and Oncology, Umea University, Umea, Sweden.
FAU - Kerrigan, Simon
AU  - Kerrigan S
AD  - Salford Royal Foundation Trust, Manchester, UK.
FAU - Marosi, Christine
AU  - Marosi C
AD  - Department of Internal Medicine I, Clinical Division of Medical Oncology, Medical
      University of Vienna, Vienna, Austria.
FAU - Oberg, Ingela
AU  - Oberg I
AD  - Department of Neuroscience, Cambridge University Hospitals, Cambridge, UK.
FAU - Oberndorfer, Stefan
AU  - Oberndorfer S
AD  - Department Neurology, University Clinic St Polten, KLPU and KLI-Neurology and
      Neuropsychology, St Polten, Austria.
FAU - Oliver, Kathy
AU  - Oliver K
AD  - International Brain Tumour Alliance, Tadworth, UK.
FAU - Pasman, H Roeline W
AU  - Pasman HRW
AD  - Department of Public and Occupational Health, Amsterdam Public Health Research
      Institute, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
FAU - Le Rhun, Emilie
AU  - Le Rhun E
AD  - Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland.
FAU - Rooney, Alasdair G
AU  - Rooney AG
AD  - Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital,
      Edinburgh, Scotland, UK.
FAU - Ruda, Roberta
AU  - Ruda R
AD  - Department of Neuro-Oncology, University and City of Health and Science Hospital,
      Turin, Italy.
FAU - Veronese, Simone
AU  - Veronese S
AD  - Department of Palliative Care, Fondazione FARO, Turin, Italy.
FAU - Walbert, Tobias
AU  - Walbert T
AD  - Department of Neurology and Neurosurgery, Henry Ford Health System, Detroit,
      Michigan, US.
FAU - Weller, Michael
AU  - Weller M
AUID- ORCID: 0000-0002-1748-174X
AD  - Department of Neurology & Brain Tumor Center, University Hospital and University 
      of Zurich, Zurich, Switzerland.
FAU - Wick, Wolfgang
AU  - Wick W
AUID- ORCID: 0000-0002-6171-634X
AD  - Neurology Clinic and National Centre for Tumour Diseases, University Hospital
      Heidelberg, Heidelberg, Germany.
AD  - German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation
      Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.
FAU - Taphoorn, Martin J B
AU  - Taphoorn MJB
AD  - Department of Neurology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands.
FAU - Dirven, Linda
AU  - Dirven L
AD  - Department of Neurology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands.
LA  - eng
GR  - MR/J000914/1/MRC_/Medical Research Council/United Kingdom
GR  - MRF_C0396/MRF/MRF/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200716
PL  - England
TA  - Neurooncol Pract
JT  - Neuro-oncology practice
JID - 101640528
PMC - PMC7716185
OTO - NOTNLM
OT  - brain metastases
OT  - capacity
OT  - consent
OT  - glioma
OT  - neurodegenerative disease
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:57
PHST- 2020/12/14 10:57 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.1093/nop/npaa040 [doi]
AID - npaa040 [pii]
PST - epublish
SO  - Neurooncol Pract. 2020 Jul 16;7(6):599-612. doi: 10.1093/nop/npaa040. eCollection
      2020 Dec.


PMID- 33312350
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Linking)
VI  - 12
IP  - 11
DP  - 2020
TI  - Spermatogonial stem cells are a promising and pluripotent cell source for
      regenerative medicine.
PG  - 7048-7059
AB  - Regenerative medicine has been shown to hold enormous potential to treat
      traumatic and degenerative diseases, and substantial advancements have been made 
      in the recent decades. In particular, different cell types were evaluated in
      basic research and preclinical studies on cell-based therapy applications.
      Despite the extraordinary achievements made in experimental studies and clinical 
      practice, a considerable number of obstacles, such as the cellular source,
      ethical and safety issues, hinder further clinical applications. Spermatogonial
      stem cells (SSCs) are gradually becoming the research focus of cell-based
      regenerative medicine owing to their unique merits over other types of stem
      cells, particularly the lack of ethical concerns and lower immunogenicity. In
      addition, SSCs have been successfully induced to differentiate into other cell
      types under different appropriate conditions in compelling studies. Based on
      these properties, we systemically reviewed the development of SSCs as an
      attractive cell source for cell-based regenerative medicine.
CI  - AJTR Copyright (c) 2020.
FAU - Chen, Zhe
AU  - Chen Z
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University Xi'an
      710054, China.
FAU - Hong, Fan
AU  - Hong F
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University Xi'an
      710054, China.
FAU - Wang, Zhiyuan
AU  - Wang Z
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University Xi'an
      710054, China.
FAU - Hao, Dingjun
AU  - Hao D
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University Xi'an
      710054, China.
FAU - Yang, Hao
AU  - Yang H
AD  - Translational Medicine Center, Hong Hui Hospital, Xi'an Jiaotong University Xi'an
      710054, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201115
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC7724348
OTO - NOTNLM
OT  - Spermatogonial stem cells
OT  - cell therapy
OT  - degenerative disease
OT  - regenerative medicine
OT  - transdifferentiation
COIS- None.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:57
PHST- 2019/12/17 00:00 [received]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/12/14 10:57 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
PST - epublish
SO  - Am J Transl Res. 2020 Nov 15;12(11):7048-7059. eCollection 2020.


PMID- 33312246
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 1841-9038 (Print)
IS  - 1841-9038 (Linking)
VI  - 15
IP  - 3
DP  - 2020 Sep
TI  - Obesity and pregnancy.
PG  - 318-326
LID - 10.26574/maedica.2020.15.3.318 [doi]
AB  - Introduction: Obesity is the most frequent metabolic disturbance that can target 
      women of reproductive age, among other population groups, and when obese pregnant
      women become patients, it represents a serious risk factor for both mother and
      fetus. Aim: The aim of this study is to offer an overview of the effects exerted 
      by this disturbance on pregnancy. Materials and methods: The study targets 157
      pacients admitted to "Alessandrescu-Rusescu" National Institute for Mother and
      Child Health - Polizu (INSMC), Bucharest, Romania. In order to define the
      criterion for obesity, WHO classification (body mass index > 30 kg/m(2)) was
      used. Data was collected restrospectively after acceptance by the Ethics
      Committee. Also, we gathered anthropometric data (weight, body mass index and
      analysis regarding the metabolic profile, including total cholesterol, HDL
      cholesterol, LDL cholesterol, triglyceride, blood sugar, glycosylated
      haemoglobin) from all subjects. Each analysis was correlated with each patient's 
      body mass index. Another correlation was made between metabolic profile,
      antenatal complications and onset of gestational diabetes and premature birth.
      Statistical analysis was conducted using GraphPad 8 and MedCalc 14.1. Results:
      Patients had an average body weight of 66.75 kg with a standard deviation of
      12.99 kg and a median of 64 kg. Average body mass index was 25.05 kg/m(2), with a
      standard deviation of 5,03 kg/m(2) and a median of 24.2 kg/m(2). There is a
      directly proportional and statistically significative correlation between the
      values of blood sugar, glycosylated haemoglobin, LDL, TG, uric acid and BMI.
      Also, there is a inversely proportional and statistically significative
      correlation between the values of HDL and BMI. The CT/HDL ratio, low HDL level
      and elevated LDL level are the main risk factors for premature birth, while the
      CT/HDL ratio, low HDL level and elevated TG are the main risk factors for the
      onset of gestational diabetes. Conclusions: According to the results of this
      study, the onset of obesity in pregnant woman is rather dependent on each
      patient's metabolic profile than body weight.
FAU - Teodorescu, Cristina Oana Daciana
AU  - Teodorescu COD
AD  - "Alessandrescu-Rusescu" National Institute for Mother and Child Health,
      Department of Obstetrics and Gynecology, Polizu Hospital, Bucharest, Romania.
FAU - Herdea, Alexandru
AU  - Herdea A
AD  - "Carol Davila" University of Medicine and Pharmacy, Department of Pediatric
      Orthopedics, "Grigore Alexandrescu" Children's Emergency Hospital, Bucharest,
      Romania.
FAU - Charkaoui, Adham
AU  - Charkaoui A
AD  - Department of Morphological and Functional Sciences, Faculty of Medicine and
      Pharmacy, "Dunarea de Jos" University of Galati, Romania.
FAU - Teodorescu, Andrei
AU  - Teodorescu A
AD  - University of Oradea, Faculty of Medicine and Pharmacy, Department of
      Morphological Sciences, Oradea, Romania.
FAU - Miron, Andreea-Iuliana
AU  - Miron AI
AD  - "Carol Davila" University of Medicine and Pharmacy; Department of Oncology,
      "Coltea" Clinic Hospital, Bucharest, Romania.
FAU - Popa, Amorin Remus
AU  - Popa AR
AD  - University of Oradea, Faculty of Medicine and Pharmacy, Department of Diabetes,
      Nutrition, Metabolic and Internal Diseaeses, Oradea, Romania.
LA  - eng
PT  - Editorial
PL  - Romania
TA  - Maedica (Bucur)
JT  - Maedica
JID - 101526930
PMC - PMC7726499
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:56
PHST- 2020/12/14 10:56 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.26574/maedica.2020.15.3.318 [doi]
PST - ppublish
SO  - Maedica (Bucur). 2020 Sep;15(3):318-326. doi: 10.26574/maedica.2020.15.3.318.


PMID- 33312136
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Physical Inactivity Is Associated With Increased Levels of Anxiety, Depression,
      and Stress in Brazilians During the COVID-19 Pandemic: A Cross-Sectional Study.
PG  - 565291
LID - 10.3389/fpsyt.2020.565291 [doi]
AB  - Objective: To evaluate the levels of anxiety, depression, and stress associated
      with the practice of physical exercise (PE) during pandemic by COVID-19. Methods:
      This study has a cross-sectional characteristic and was carried out between May
      12 and 14, 2020. An online questionnaire was applied with questions to assess
      sociodemographic characteristics and physical exercise during the CoVID-19
      pandemic, in addition to depression, anxiety, and stress analysis. The study was 
      approved by the local ethics committee (CAAE: 31521720.8.0000.5082). Results: One
      thousand one hundred and fifty four answered the questionnaire (69.84% female).
      During the isolation period, the number of participants who declared not to
      exercise was 54.16%. Women generaly presented higher levels of anxiety,
      depression, and stress when compared to men (p < 0.0001 for all domains). The
      risk of having increased anxiety were 118% higher (OR = 2.183; 95% CI =
      1.717-2.775), the risk of depression was 152% higher (OR = 2.525; 95% CI =
      1.991-3.205), and the risk of stress symptoms increased 75.1% (OR = 1.751; 95% CI
      = 1.386-2.213) in the participants who did not perform PE when compared to those 
      who maintain regular PE. Conclusion: People who was not involved with PE during
      the COVID-19 pandemic had higher anxiety, depression, and stress scores. Based on
      this, it seems important to advise people to continue PE, following all the
      recommendations of preventive measures of the pertinent health organizations.
CI  - Copyright (c) 2020 Silva, Seguro, de Oliveira, Santos, de Oliveira, de Souza
      Filho, de Paula Junior, Gentil and Rebelo.
FAU - Silva, Lucas Raphael Bento
AU  - Silva LRB
AD  - Department of Physical Education, University Center Araguaia, Goiania, Brazil.
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
FAU - Seguro, Camila Simoes
AU  - Seguro CS
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
FAU - de Oliveira, Camila Grasiele Araujo
AU  - de Oliveira CGA
AD  - Department of Physical Education, University Center Araguaia, Goiania, Brazil.
FAU - Santos, Paulo Otavio Silva
AU  - Santos POS
AD  - Department of Physical Education, University Center Araguaia, Goiania, Brazil.
FAU - de Oliveira, Jordana Campos Martins
AU  - de Oliveira JCM
AD  - Department of Physical Education, University Center Araguaia, Goiania, Brazil.
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
FAU - de Souza Filho, Luiz Fernando Martins
AU  - de Souza Filho LFM
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
FAU - de Paula Junior, Celio Antonio
AU  - de Paula Junior CA
AD  - Department of Physical Education, University Center Araguaia, Goiania, Brazil.
FAU - Gentil, Paulo
AU  - Gentil P
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
AD  - Faculty of Physical Education and Dance, Federal University of Goias, Goiania,
      Brazil.
FAU - Rebelo, Ana Cristina Silva
AU  - Rebelo ACS
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
AD  - Faculty of Physical Education and Dance, Federal University of Goias, Goiania,
      Brazil.
AD  - Department of Morphology, Institute of Biological Sciences, Federal University of
      Goias, Goiania, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7704428
OTO - NOTNLM
OT  - COVID-19
OT  - anxiety
OT  - depression
OT  - mental health
OT  - pandemic
OT  - physical exercise
OT  - physical inactivity
OT  - stress
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:55
PHST- 2020/05/24 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/14 10:55 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.3389/fpsyt.2020.565291 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Nov 17;11:565291. doi: 10.3389/fpsyt.2020.565291.
      eCollection 2020.


PMID- 33312027
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1302-7123 (Print)
IS  - 1302-7123 (Linking)
VI  - 54
IP  - 3
DP  - 2020
TI  - Kidney Transplantation: Single-Center Experience.
PG  - 302-305
LID - 10.14744/SEMB.2018.09794 [doi]
AB  - OBJECTIVES: This study aims to present our cadaveric and living related donor
      kidney transplantation experience. METHODS: Between September 2009 to February
      2015, renal transplantations were performed to 417 patients in Medicana
      International Ankara Hospital organ transplantation center. RESULTS: Of the
      patients, 231 were male, and 186 were female. Of the transplantations, 385 came
      from a living donor, and 32 came from a cadaver donor. The degree of kinship; 324
      (77.7%) transplants were received from relatives, 5 (14.1%) with approval by the 
      ethical committee, 32 (7.7%) from cadavers and two (0.5%) with cross-matching.
      Post-Operative Complications in recipients; lymphocele was found within the graft
      in two cases, urinary anastomosis leakage was detected in two cases, wound
      infection was detected in four cases, and hematoma in one case. We had no
      mortality in post operative or early follow up periods. CONCLUSION: The morbidity
      and mortality rates in our organ transplantation center, regarding renal
      transplantations, are consistent with the literature.
CI  - Copyright: (c) 2019 by The Medical Bulletin of Sisli Etfal Hospital.
FAU - Sozener, Ulas
AU  - Sozener U
AD  - Medicana International Ankara Hospital, Organ Transplant Center, Ankara, Turkey.
FAU - Eker, Tevfik
AU  - Eker T
AD  - Department of General Surgery, Gazimagusa State Hospital, Gazimagusa, Kibris.
FAU - Ersoz, Sadik
AU  - Ersoz S
AD  - Department of General Surgery, Ufuk University Faculty of Medicine, Ankara,
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Turkey
TA  - Sisli Etfal Hastan Tip Bul
JT  - Sisli Etfal Hastanesi tip bulteni
JID - 9424130
PMC - PMC7729731
OTO - NOTNLM
OT  - Kidney transplantation
OT  - kidney failure
OT  - transplantation
COIS- Conflict of Interest: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:55
PHST- 2018/05/30 00:00 [received]
PHST- 2018/10/30 00:00 [accepted]
PHST- 2020/12/14 10:55 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.14744/SEMB.2018.09794 [doi]
AID - MBSEH-54-302 [pii]
PST - epublish
SO  - Sisli Etfal Hastan Tip Bul. 2020 Aug 25;54(3):302-305. doi:
      10.14744/SEMB.2018.09794. eCollection 2020.


PMID- 33311983
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 1178-2218 (Print)
IS  - 1178-2218 (Linking)
VI  - 14
DP  - 2020
TI  - The MET(T)A Protocol: Mindfulness and EMDR Treatment Template for Agencies.
PG  - 1178221820977483
LID - 10.1177/1178221820977483 [doi]
AB  - Evidence indicating the relationship between trauma and substance use disorders
      (SUDs), in addition to relapse and treatment retention rates for this population,
      suggests there is a need for a trauma-focused solution to treat SUDs. Eye
      movement desensitization and reprocessing (EMDR) therapy has been studied
      extensively as an effective approach for treating trauma and Posttraumatic Stress
      Disorder (PTSD). The research evaluating its treatment for other mental health
      disorders such as SUDs is promising. Merging mindfulness and ethical mindfulness 
      practices with EMDR therapy lends additional evidence-based elements to make the 
      case for this integrative system of treatment to be studied as a trauma-focused
      primary psychotherapy to treat SUDs. The resulting treatment, the MET(T)A
      Protocol (Mindfulness and EMDR Treatment Template for Agencies), has been created
      to address the need for a trauma-focused solution to treat SUDs. Procedures of
      the MET(T)A Protocol as applied in each of the 8 phases of EMDR therapy are
      described in detail. Clinical examples are provided to explain the application of
      the MET(T)A Protocol.
CI  - (c) The Author(s) 2020.
FAU - Dansiger, Stephen
AU  - Dansiger S
AD  - StartAgain Associates, CA, USA.
FAU - Chabra, Roshni
AU  - Chabra R
AD  - StartAgain Associates, CA, USA.
FAU - Emmel, Lauren
AU  - Emmel L
AD  - StartAgain Associates, CA, USA.
FAU - Kovacs, Justine
AU  - Kovacs J
AUID- ORCID: https://orcid.org/0000-0002-4575-3060
AD  - StartAgain Associates, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - United States
TA  - Subst Abuse
JT  - Substance abuse : research and treatment
JID - 101514834
PMC - PMC7716072
OTO - NOTNLM
OT  - Buddhist psychology
OT  - EMDR therapy
OT  - MET(T)A Protocol
OT  - PTSD
OT  - Substance use disorders
OT  - mindfulness
OT  - trauma
COIS- Declaration of Conflicting Interests:The author(s) declared the following
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Dr. Stephen Dansiger is the creator of the MET(T)A
      Protocol.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:55
PHST- 2020/08/21 00:00 [received]
PHST- 2020/10/31 00:00 [accepted]
PHST- 2020/12/14 10:55 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.1177/1178221820977483 [doi]
AID - 10.1177_1178221820977483 [pii]
PST - epublish
SO  - Subst Abuse. 2020 Dec 1;14:1178221820977483. doi: 10.1177/1178221820977483.
      eCollection 2020.


PMID- 33311913
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 0974-1208 (Print)
IS  - 1998-4766 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Jul-Sep
TI  - A Successful Case for Deselection of Albino Embryo and Live Birth of
      Albinism-Free Healthy Baby Followed by PGT-M.
PG  - 245-248
LID - 10.4103/jhrs.JHRS_38_19 [doi]
AB  - In recent years, Preimplantation genetic testing for monogenic disorders (PGT-M) 
      has gained a lot of focus in the field of assisted reproduction technology,
      various studies have been published in support of it and many are opposing its
      role. It has been criticized due to many ethical as well as scientific reasons,
      but there is no doubt that PGT-M has been one of the most important breakthroughs
      in in vitro fertilization. A critical aspect of this technology is the
      possibility that the biopsy itself can adversely affect the quality of embryo and
      compulsion of embryo freezing. Oculocutaneous albinism (OCA) is a condition which
      is related to skin, hair, eye color (pigments), where affected individuals
      typically have very fair skin and white- or light-colored hair. These patients
      are prone to skin cancers on prolonged sun exposure. It also reduces the
      pigmentation of the colored part of the eyes (the iris) and the light-sensitive
      tissue at the back of the eye (the retina). People with this condition usually
      have problem in vision such as reduced sharpness, involuntary eye movements, and 
      photophobia. Here, we report the successful use of PGT-M and a novel protocol for
      the preimplantation genetic diagnosis of OCA following trophectoderm cell biopsy 
      from blastocysts and the birth of a healthy infant to a couple having previously 
      affected child.
CI  - Copyright: (c) 2020 Journal of Human Reproductive Sciences.
FAU - Patel, Nayana
AU  - Patel N
AD  - Department of IVF, Akanksha Hospital and Research Institute, Anand, India.
FAU - Bhadarka, Harsha K
AU  - Bhadarka HK
AD  - Department of IVF, Akanksha Hospital and Research Institute, Anand, India.
FAU - Vaniawala, Salil
AU  - Vaniawala S
AD  - Department of Genetic, S N Gene Lab, Surat, Gujarat, India.
FAU - Patel, Arpita
AU  - Patel A
AD  - Department of IVF, Akanksha Hospital and Research Institute, Anand, India.
LA  - eng
PT  - Case Reports
DEP - 20201027
PL  - India
TA  - J Hum Reprod Sci
JT  - Journal of human reproductive sciences
JID - 101473512
PMC - PMC7727887
OTO - NOTNLM
OT  - Albinism
OT  - PGT-M
OT  - intracytoplasmic sperm injection
OT  - mutation
OT  - preimplantation genetic diagnosis
COIS- There are no conflicts of interest.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:54
PHST- 2019/05/27 00:00 [received]
PHST- 2019/11/01 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/12/14 10:54 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.4103/jhrs.JHRS_38_19 [doi]
AID - JHRS-13-245 [pii]
PST - ppublish
SO  - J Hum Reprod Sci. 2020 Jul-Sep;13(3):245-248. doi: 10.4103/jhrs.JHRS_38_19. Epub 
      2020 Oct 27.


PMID- 33311872
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0973-1075 (Print)
IS  - 0973-1075 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Jul-Sep
TI  - Effectiveness of High-Fidelity Simulation in Nursing Education for End-of-Life
      Care: A Quasi-experimental Design.
PG  - 312-318
LID - 10.4103/IJPC.IJPC_157_19 [doi]
AB  - BACKGROUND: Providing end of life (EOL) care is a component of palliative care
      but dealing with dying patients and their family members is stressful for the
      healthcare providers. To prepare them for providing EOL care, the high-fidelity
      simulation could be used as a pedagogy in which real-life scenarios are used on
      the computerized manikins mimicking the real patients. AIMS: The aim of this
      study was to measure the effectiveness of high-fidelity simulation to teach EOL
      care in the palliative nursing course in the undergraduate nursing education
      program at the School of Nursing and Midwifery at Aga Khan University which is
      private university in Karachi, Pakistan. METHODS: This study was approved by the 
      ethics review committee of Aga Khan University. It was hypothesized that exposure
      to high-fidelity simulation will lead to an increased positive attitude in
      participants towards the care of dying. A quasi-experimental design was used. In 
      line with the design, there was no control group. The same group of students (n =
      42) were assessed through Frommelt Attitudes Toward Care of the Dying (FATCOD)
      Part B assessment tool. Permission for using this tool was obtained from Dr.
      Katherine Frommelt, the author of this tool. Research participants filled this
      tool before and after the intervention, i.e., providing EOL care to a patient in 
      a high-fidelity simulation lab. RESULTS: Out of 30-FATCOD items, significant
      attitude change was detected on 11-items of which 8 were positively worded
      statements and 3 were negatively worded statements. As per the hypothesis, it was
      expected for the positively worded statements that the mean score for the
      posttest would be significantly greater than the pretest mean score (pretest
      score < posttest score). The hypothesis was proved for items 1, 4, 10, 18, 22,
      25, 27, and 30 as their t-value was significant at 0.05 alpha value (one-tailed).
      For the negatively worded statements, it was expected that the mean score for the
      posttest would be significantly lower than the pretest (pretest score > posttest 
      score). The hypothesis was proved for items 5, 6, and 11 as their t-value was
      significant at 0.05 alpha value (one-tailed). CONCLUSION: In this research
      teaching, EOL care through high-fidelity simulation had improved the attitudes of
      students toward providing care. This pedagogy also provided the participants with
      a learning opportunity to deal with their own emotions. These findings provide a 
      way forward for teaching EOL and other complex skills of clinical practice.
CI  - Copyright: (c) 2020 Indian Journal of Palliative Care.
FAU - Rattani, Salma Amin
AU  - Rattani SA
AD  - School of Nursing and Midwifery, Aga Khan University, Karachi, Pakistan.
FAU - Kurji, Zohra
AU  - Kurji Z
AD  - School of Nursing and Midwifery, Aga Khan University, Karachi, Pakistan.
FAU - Khowaja, Amina Aijaz
AU  - Khowaja AA
AD  - School of Nursing and Midwifery, Aga Khan University, Karachi, Pakistan.
FAU - Dias, Jacqueline Maria
AU  - Dias JM
AD  - College of Health Sciences, University of Sharjah, Sharjah, UAE.
FAU - AliSher, Anila Naz
AU  - AliSher AN
AD  - College of Nursing, King Edward Medical University, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200829
PL  - United States
TA  - Indian J Palliat Care
JT  - Indian journal of palliative care
JID - 101261221
PMC - PMC7725185
OTO - NOTNLM
OT  - Clinical teaching
OT  - Frommelt Attitudes Toward Care of the Dying tool
OT  - end-of-life care
OT  - high-fidelity simulation
OT  - nursing education
OT  - palliative care
COIS- There are no conflicts of interest.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:54
PHST- 2019/09/05 00:00 [received]
PHST- 2019/11/02 00:00 [revised]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2020/12/14 10:54 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.4103/IJPC.IJPC_157_19 [doi]
AID - IJPC-26-312 [pii]
PST - ppublish
SO  - Indian J Palliat Care. 2020 Jul-Sep;26(3):312-318. doi: 10.4103/IJPC.IJPC_157_19.
      Epub 2020 Aug 29.


PMID- 33311779
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 0026-6620 (Print)
IS  - 0026-6620 (Linking)
VI  - 117
IP  - 6
DP  - 2020 Nov-Dec
TI  - Medical Marijuana and Professional Ethics.
PG  - 532
FAU - Cornella, Frank A
AU  - Cornella FA
AD  - MSMA Member since 1998, Oral Surgery of Springfield, Springfield, Missouri.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Mo Med
JT  - Missouri medicine
JID - 0400744
RN  - 0 (Medical Marijuana)
SB  - IM
CON - Mo Med. 2020 Sep-Oct;117(5):400-405. PMID: 33311738
MH  - *Cannabis
MH  - Ethics, Medical
MH  - Ethics, Professional
MH  - Female
MH  - Humans
MH  - Lactation
MH  - *Medical Marijuana
MH  - Pregnancy
PMC - PMC7721417
EDAT- 2020/12/15 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/14 10:54
PHST- 2020/12/14 10:54 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - ms117_p532 [pii]
PST - ppublish
SO  - Mo Med. 2020 Nov-Dec;117(6):532.


PMID- 33311725
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - Suppl 4
DP  - 2020 Sep
TI  - Intravenous norepinephrine and mephentermine for maintenance of blood pressure
      during spinal anaesthesia for caesarean section: An interventional double-blinded
      randomised trial.
PG  - S235-S241
LID - 10.4103/ija.IJA_91_20 [doi]
AB  - BACKGROUND AND AIMS: Spinal anaesthesia induced hypotension (SAIH) and
      bradycardia may prove deleterious to both parturient and baby, hence vasopressors
      play a vital role in their management. Recent studies on norepinephrine as rescue
      vasopressor during subarachnoid block (SAB) enlighten its role for SAIH. This
      randomised double-blind trial was conducted to compare the effect of intermittent
      intravenous boluses of norepinephrine and frequently used mephentermine for
      management of SAIH in caesarean section (CS) to prove whether norepinephrine
      produces comparable effects or superior to mephentermine. METHODS: After approval
      from Institutional Ethics Committee and registration in Clinical Trials Registry 
      India (CTRI/2019/06/019652), 256 parturients posted for elective CS under SAB
      were randomly allocated into Group-N and Group-M (n = 84) using chit system, who 
      received boluses of intravenous norepinephrine 8mug and mephentermine 6mg for
      SAIH, respectively. Systolic blood pressure (SBP), diastolic blood pressure
      (DBP), heart rate (HR), Response%, Apgar score and maternal complications were
      analysed. RESULTS: The changes in SBP and DBP were comparable in both the groups.
      It was significantly low after SAB compared to baseline and significantly high
      compared to 1(st) hypotensive value in both the groups throughout the study
      period (<0.0001). HR was comparable for initial 10 min, thereafter it was
      significantly high in Group-M (<0.0001) till 40 min. Response% after the first
      bolus was significantly high in Group-N (59.30n +/- 29.21 vs 39.78 +/- 25.6; P = 
      <0.0001). CONCLUSION: Intravenous norepinephrine is better than mephentermine
      with respect to high response% and stable maternal HR although both are equally
      effective in maintaining blood pressure following SAIH during elective CS.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Shah, Pratibha Jain
AU  - Shah PJ
AD  - Department of Anaesthesiology and Critical Care, Pt JNM Medical College, Raipur, 
      Chhattisgarh, India.
FAU - Agrawal, Pratiksha
AU  - Agrawal P
AD  - Department of Anaesthesiology and Critical Care, Pt JNM Medical College, Raipur, 
      Chhattisgarh, India.
FAU - Beldar, Rajesh Kumar
AU  - Beldar RK
AD  - Department of Anaesthesiology and Critical Care, Pt JNM Medical College, Raipur, 
      Chhattisgarh, India.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7714008
OTO - NOTNLM
OT  - Caesarean delivery
OT  - mephentermine
OT  - norepinephrine
OT  - spinal anaesthesia induced hypotension
COIS- There are no conflicts of interest.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 10:54
PHST- 2020/03/08 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/12/14 10:54 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.4103/ija.IJA_91_20 [doi]
AID - IJA-64-235 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Sep;64(Suppl 4):S235-S241. doi: 10.4103/ija.IJA_91_20.
      Epub 2020 Sep 22.


PMID- 33311418
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20210331
IS  - 0025-7818 (Print)
IS  - 0025-7818 (Linking)
VI  - 111
IP  - 6
DP  - 2020 Nov 25
TI  - Personalised Medicine: implication and perspectives in the field of occupational 
      health.
PG  - 425-444
LID - 10.23749/mdl.v111i6.10947 [doi]
AB  - "Personalised medicine" relies on identifying and integrating individual
      variability in genomic, biological, and physiological parameters, as well as in
      environmental and lifestyle factors, to define "individually" targeted disease
      prevention and treatment. Although innovative "omic" technologies supported the
      application of personalised medicine in clinical, oncological, and
      pharmacological settings, its role in occupational health practice and research
      is still in a developing phase. Occupational personalised approaches have been
      currently applied in experimental settings and in conditions of unpredictable
      risks, e.g.. war missions and space flights, where it is essential to avoid
      disease manifestations and therapy failure. However, a debate is necessary as to 
      whether personalized medicine may be even more important to support a
      redefinition of the risk assessment processes taking into consideration the
      complex interaction between occupational and individual factors. Indeed, "omic"
      techniques can be helpful to understand the hazardous properties of the
      xenobiotics, dose-response relationships through a deeper elucidation of the
      exposure-disease pathways and internal doses of exposure. Overall, this may guide
      the adoption/implementation of primary preventive measures protective for the
      vast majority of the population, including most susceptible subgroups. However,
      the application of personalised medicine into occupational health requires
      overcoming some practical, ethical, legal, economical, and socio-political
      issues, particularly concerning the protection of privacy, and the risk of
      discrimination that the workers may experience. In this scenario, the concerted
      action of academic, industry, governmental, and stakeholder representatives
      should be encouraged to improve research aimed to guide effective and sustainable
      implementation of personalised medicine in occupational health fields.
FAU - Bollati, Valentina
AU  - Bollati V
AD  - EPIGET LAB, Department of Clinical Sciences and Community Health, Universita
      degli Studi di Milano, Italy. valentina.bollati@unimi.it.
FAU - Ferrari, Luca
AU  - Ferrari L
AD  - EPIGET LAB, Department of Clinical Sciences and Community Health, Universita
      degli Studi di Milano, Italy. luca.ferrari@unimi.it.
FAU - Leso, Veruscka
AU  - Leso V
AD  - Section of Occupational Medicine, Department of Public Health, Universita degli
      Studi di Napoli Federico II, Napoli, Italy. veruscka.leso@unina.it.
FAU - Iavicoli, Ivo
AU  - Iavicoli I
AD  - Section of Occupational Medicine, Department of Public Health, Universita degli
      Studi di Napoli Federico II, Napoli, Italy. ivo.iavicoli@unina.it.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - Italy
TA  - Med Lav
JT  - La Medicina del lavoro
JID - 0401176
SB  - IM
CIN - Med Lav. 2020 Nov 25;111(6):423-424. PMID: 33311417
MH  - Delivery of Health Care
MH  - Humans
MH  - *Occupational Health
MH  - Precision Medicine
PMC - PMC7809984
EDAT- 2020/12/15 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/12/14 10:45
PHST- 2020/11/13 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/14 10:45 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.23749/mdl.v111i6.10947 [doi]
PST - epublish
SO  - Med Lav. 2020 Nov 25;111(6):425-444. doi: 10.23749/mdl.v111i6.10947.


PMID- 33310828
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 13
IP  - 12
DP  - 2020 Dec 12
TI  - Lethal severe congenital tracheal stenosis with tracheal ring complicating
      respiratory distress syndrome in an extremely premature infant: first reported
      case in Qatar with a literature review.
LID - e236107 [pii]
LID - 10.1136/bcr-2020-236107 [doi]
AB  - In the context of prematurity, lethal congenital airways malforamtion can be
      masked by the symptoms of respiratory distress syndrome. A high index of
      suspicion is required. We present the case of a 28-week preterm infant, with
      atypical protracted respiratory insufficiency despite the escalation of
      mechanical ventilation. The possibility of airway obstruction was considered in
      view of severe chest retraction while on the mechanical ventilator. It was also
      difficult to pass suction catheters beyond a certain depth in the trachea;
      however, intubation of the upper trachea was accomplished twice without
      difficulty. Flexible bronchoscopy revealed complete tracheal ring with severe
      tracheal stenosis; there was no evidence of tracheo-oesophageal fistula. Due to
      advanced multi-organ dysfunction at diagnosis, a decision was made with the
      family to re-orientate from intensive care to compassionate care. Ethical
      considerations in similar cases should incorporate the improved outcomes of
      prematurity and recent advances in tracheal reconstruction.
CI  - (c) BMJ Publishing Group Limited 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Nimeri, Nuha
AU  - Nimeri N
AD  - Department of Paediatrics, Hamad Medical Corporation, Doha, Qatar nuha@usa.net.
FAU - Ali, Haytham
AU  - Ali H
AD  - Department of Pediatric, Sidra Medical and Research Center, Doha, Qatar.
FAU - Mahmoud, Nazla
AU  - Mahmoud N
AD  - Department of Paediatrics, Hamad Medical Corporation, Doha, Qatar.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20201212
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - Tracheal agenesis
SB  - IM
MH  - Bronchoscopy
MH  - Constriction, Pathologic/*diagnosis
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Infant, Extremely Premature
MH  - Infant, Newborn
MH  - Intubation, Intratracheal
MH  - Qatar
MH  - Radiography, Thoracic
MH  - Respiratory Distress Syndrome, Newborn/*etiology
MH  - Trachea/*abnormalities
PMC - PMC7735117
OTO - NOTNLM
OT  - ear
OT  - end of life decisions (palliative care)
OT  - neonatal intensive care
OT  - nose and throat/otolaryngology
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/12/14 10:43
PMCR- 2022/12/12 00:00
PHST- 2022/12/12 00:00 [pmc-release]
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - 13/12/e236107 [pii]
AID - 10.1136/bcr-2020-236107 [doi]
PST - epublish
SO  - BMJ Case Rep. 2020 Dec 12;13(12). pii: 13/12/e236107. doi:
      10.1136/bcr-2020-236107.


PMID- 33310808
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Study protocol for the systematic review and meta-analyses of the association
      between schizophrenia and bone fragility.
PG  - e041859
LID - 10.1136/bmjopen-2020-041859 [doi]
AB  - INTRODUCTION: Individuals with schizophrenia are known to be at higher risk of
      comorbid conditions, both physical and psychological. Osteoporosis is possibly
      one of these, leading to public health concerns due to higher rates of associated
      mortality and morbidity. We aim to systematically search all available evidence
      across electronic databases regarding the relationship between schizophrenia and 
      bone fragility. METHODS AND ANALYSIS: A systematic search of the research
      databases CINAHL, MEDLINE Complete, Embase and PsycINFO will be conducted and
      identified papers reviewed for eligibility, with a second reviewer confirming
      inclusions. Searches will be run from database inception to 1 October 2020 and
      supplemented by the hand checking of references of identified articles. A
      previously published scoring system will be used for assessing the methodological
      quality and risk of bias. A meta-analysis is planned. ETHICS AND DISSEMINATION:
      Due to including published literature only, ethical permission will not be
      necessary. Results of this study will be published in a relevant scientific
      journal and presented at a conference in the field of interest. PROSPERO
      REGISTRATION NUMBER: CRD42020171959.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Azimi Manavi, Behnaz
AU  - Azimi Manavi B
AUID- ORCID: 0000-0001-7450-1877
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia
      bazimimanavi@deakin.edu.au.
FAU - Stuart, Amanda L
AU  - Stuart AL
AUID- ORCID: 0000-0001-8770-9511
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
FAU - Pasco, Julie A
AU  - Pasco JA
AUID- ORCID: 0000-0002-8968-4714
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
AD  - Clinical and Biomedical Sciences: Barwon Health, University of Melbourne School
      of BioSciences, Melbourne, Victoria, Australia.
FAU - Hodge, Jason M
AU  - Hodge JM
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
AD  - Geelong Centre for Emerging Infectious Diseases (GCEID), Barwon Health, Geelong, 
      Victoria, Australia.
FAU - Corney, Kayla
AU  - Corney K
AUID- ORCID: 0000-0003-4789-0007
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
FAU - Berk, Michael
AU  - Berk M
AUID- ORCID: 0000-0002-5554-6946
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
AD  - University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital,
      Parkville, Victoria, Australia.
AD  - Florey Institute for Neuroscience and Mental Health, University of Melbourne,
      RoyalMelbourne Hospital, Parkville, Victoria, Australia.
AD  - Centre of Youth Mental Health, University of Melbourne, Parkville, Victoria,
      Australia.
AD  - Orygen, The National Centre of Excellence in Youth Mental Health, Parkville,
      Victoria, Australia.
FAU - Williams, Lana J
AU  - Williams LJ
AUID- ORCID: 0000-0002-1377-1272
AD  - Deakin University, IMPACT - Institute for Mental and Physical Health and Clinical
      Translation, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Bone Diseases, Metabolic
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Osteoporosis/complications
MH  - Public Health
MH  - Research Design
MH  - *Schizophrenia/complications
MH  - Systematic Reviews as Topic
PMC - PMC7735127
OTO - NOTNLM
OT  - *bone density
OT  - *bone fragility
OT  - *bone health
OT  - *bone quality
OT  - *fracture
OT  - *mental disorders
OT  - *neuroscience
OT  - *osteopenia
OT  - *osteoporosis
OT  - *psychiatry
OT  - *schizophrenia
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-041859 [pii]
AID - 10.1136/bmjopen-2020-041859 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e041859. doi: 10.1136/bmjopen-2020-041859.


PMID- 33310806
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Engaging practices and communities in the development of interventions to promote
      HPV vaccine uptake: a protocol for implementing Boot Camp Translation in the
      private practice setting.
PG  - e041685
LID - 10.1136/bmjopen-2020-041685 [doi]
AB  - INTRODUCTION: The Healthy People 2020 report states a goal of 80% uptake of
      recommended vaccines among adolescents, including the human papillomavirus (HPV) 
      vaccine. However, the rate of uptake of the HPV vaccine is estimated at 51% in
      2018, which leaves young people vulnerable to morbidity and mortality from
      preventable, HPV-related cancers. Reasons for this are multifactorial and include
      factors at the level of the provider, primary care practice, patient and family, 
      and community. The development of interventions that are responsive to these
      multifactorial barriers in real-world settings is a priority. Boot Camp
      Translation (BCT) is a community-engaged approach to message development for
      translating evidence-based practices into clinics and communities. This project
      aims to (1) Engage practices and communities in the development of interventions 
      to promote HPV vaccine uptake and (2) Evaluate the impact of the BCT-designed
      intervention on practice-level HPV vaccine initiation rates. We hypothesise that 
      the BCT-designed intervention will increase the rate of HPV vaccine initiation in
      the practices. METHODS AND ANALYSIS: This study will implement HPV-focused BCT in
      three counties in Colorado with a below average county-level vaccination rate.
      Each BCT group will design a multipronged intervention targeted at patients,
      parents, providers and the general community to then be disseminated in the
      participating practices and communities over the subsequent 6-month period. The
      long-term goal is to develop a replicable approach and low-cost method of
      increasing HPV vaccine uptake that is easily adaptable to different settings and 
      sociodemographic contexts. ETHICS AND DISSEMINATION: This study is approved by
      the Colorado Multiple Institutional Review Board. Results will be disseminated
      through peer-reviewed manuscripts and conference presentations, as well as within
      Colorado practice-based research networks. TRIAL REGISTRATION NUMBER:
      NCT04279964.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Brewer, Sarah E
AU  - Brewer SE
AUID- ORCID: 0000-0003-0063-6626
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences
      (ACCORDS), University of Colorado Anschutz Medical Campus, Aurora, CO, USA
      sarah.brewer@cuanschutz.edu.
AD  - Family Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
FAU - Simpson, Matthew J
AU  - Simpson MJ
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences
      (ACCORDS), University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
AD  - Family Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
FAU - Rice, John D
AU  - Rice JD
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences
      (ACCORDS), University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
AD  - Biostatistics and Informatics, Colorado School of Public Health, University of
      Colorado Anschutz Medical Campus, Aurora, CO, USA.
FAU - Skenadore, Amanda
AU  - Skenadore A
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences
      (ACCORDS), University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
FAU - O'Leary, Sean T
AU  - O'Leary ST
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences
      (ACCORDS), University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
AD  - Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04279964
GR  - R21 CA230878/CA/NCI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - Colorado
MH  - *Community Participation
MH  - Humans
MH  - Infant
MH  - *Papillomavirus Infections/prevention & control
MH  - *Papillomavirus Vaccines
MH  - Parents
MH  - *Private Practice
MH  - *Stakeholder Participation
MH  - Vaccination
PMC - PMC7735122
OTO - NOTNLM
OT  - *community child health
OT  - *oncology
OT  - *paediatric infectious disease & immunisation
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-041685 [pii]
AID - 10.1136/bmjopen-2020-041685 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e041685. doi: 10.1136/bmjopen-2020-041685.


PMID- 33310803
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Rotator cuff unloading versus loading exercise program in the conservative
      treatment of patients with rotator cuff tear: protocol of a randomised controlled
      trial.
PG  - e040820
LID - 10.1136/bmjopen-2020-040820 [doi]
AB  - INTRODUCTION: Atraumatic and degenerative rotator cuff tears are common in
      individuals over 55 years of age. This condition can have a high impact on social
      life and is associated with chronic pain, weakness and dysfunction of the upper
      limb. There is evidence that conservative approaches should be the first
      treatment option. Conservative treatment usually addresses a variety of
      therapeutic behaviours without providing scientific arguments for the choice and 
      progression of exercises. OBJECTIVE: To compare the effects of two different
      exercise programmes based on the load of the rotator cuff on a population with
      shoulder pain and rotator cuff tears. METHODS AND ANALYSIS: This is a controlled,
      randomised, blinded clinical trial. Seventy-eight individuals with shoulder pain 
      and presence of atraumatic and degenerative rotator cuff tear will participate
      and will be randomly distributed between two groups. The primary outcome will be 
      quality of life (The Western Ontario Rotator Cuff Index), and secondary outcomes 
      will include pain, function (Disabilities of the Arm, Shoulder and Hand), fear
      avoidance beliefs (Fear Avoidance Beliefs Questionnaire-Brazil), kinesiophobia
      (Tampa Scale), Pain Catastrophizing Scale, muscle strength of abductors, external
      and internal rotators of the shoulder, range of motion of arm elevation and
      patient satisfaction. The treatment will be performed for 12 weeks (2 x/week)
      acording to the selected group (Rotator Cuff Unloading x Rotator Cuff Loading
      Exercise Programme). ETHICS AND DISSEMINATION: The study protocol was approved by
      the Institutional Review Board. The findings of the trial will be disseminated
      through peer-reviewed journals and scientific conferences. TRIAL REGISTRATION
      NUMBER: NCT03962231.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ribeiro, Larissa Pechincha
AU  - Ribeiro LP
AD  - Laboratory of Analysis and Intervention of the Shoulder Complex, Department of
      Physical Therapy, Universidade Federal de Sao Carlos, Sao Carlos, Brazil.
FAU - Cools, Ann
AU  - Cools A
AD  - Department of Rehabilitation Sciences and Physical Therapy, Ghent University,
      Ghent, Belgium.
FAU - Camargo, Paula Rezende
AU  - Camargo PR
AUID- ORCID: 0000-0002-8961-4353
AD  - Laboratory of Analysis and Intervention of the Shoulder Complex, Department of
      Physical Therapy, Universidade Federal de Sao Carlos, Sao Carlos, Brazil
      prcamargo@ufscar.br.
LA  - eng
SI  - ClinicalTrials.gov/NCT03962231
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Animals
MH  - Conservative Treatment
MH  - *Exercise Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Range of Motion, Articular
MH  - *Rotator Cuff
MH  - *Rotator Cuff Injuries/therapy
MH  - Shoulder Pain/therapy
MH  - Treatment Outcome
PMC - PMC7735118
OTO - NOTNLM
OT  - *pain management
OT  - *rehabilitation medicine
OT  - *shoulder
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-040820 [pii]
AID - 10.1136/bmjopen-2020-040820 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e040820. doi: 10.1136/bmjopen-2020-040820.


PMID- 33310802
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Study protocol randomised controlled trial comparison of cost-utility and
      cost-effectiveness of a face-to-face rehabilitation programme versus a
      telemedicine programme in the treatment of patients with chronic low back pain.
PG  - e040633
LID - 10.1136/bmjopen-2020-040633 [doi]
AB  - INTRODUCTION: Chronic lower back pain is a highly prevalent medical condition in 
      Western countries, which that incurs a considerable social and economic burden.
      Although prescription exercise at home for chronic pain has become a widely used 
      alternative to reduce healthcare costs, the evidence regarding patient adherence 
      and decreased in costs in European countries is scarce and inconclusive. The
      objective of this study is to examine the cost-utility and cost-effectiveness in 
      patients with chronic lower back pain treated with the McKenzie Method and
      electroanalgesia via a telemedicine programme versus a face-to-face programme.
      METHODS AND ANALYSIS: This study reports the protocol for a randomised, two-arm, 
      multicentre, parallel controlled trial. A total of 540 patients with chronic
      lower back pain (onset time >/=3 months, Roland Morris Disability Questionnaire
      >/=4) will be recruited in three hospitals in Andalusia. Participants will be
      assigned to one of two groups (n=270, respectively) to receive electroanalgesia
      and Mckenzie method exercises through a telemedicine or a face-to-face programme.
      A total of 24 sessions will be administered three times a week for 8 weeks. Since
      the study design does not allow participant blinding, the outcome assessor and
      the statistician will be blinded. Use of helth care resources and costs due to
      work absenteeism will be captured and analysed. In addition, pain, intensity,
      fear of movement, quality of life and strength of the core muscle and anteflexion
      lumbar will be recorded at 2 and 6 months after the start of treatment. ETHICS
      AND DISSEMINATION: Human Research and Local Ethics Committee of the 'Hospital
      Complex Torrecardenas of Almeria, University Hospital of Granada and Virgen
      Macarena de Sevilla Hospital-Andalusian Health Service'. Study fi ndings will be 
      released to the research, clinical and health service through publication in
      international journals and conferences. TRIAL REGISTRATION NUMBER: NCT04266366.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Castro-Sanchez, Adelaida M
AU  - Castro-Sanchez AM
AD  - Enfermeria, Fisioterapia y Medicina, Universidad de Almeria, Almeria, Spain.
FAU - Mataran-Penarrocha, Guillermo Adolfo
AU  - Mataran-Penarrocha GA
AD  - Andalusian Health Service, Family Medicine and Primary Care, Distrito Sanitario
      Malaga, Malaga, Spain.
FAU - Gomez-Garcia, Silvia
AU  - Gomez-Garcia S
AD  - Clinical Rehabilitation Management Unit, Torrecardenas University Hospital of
      Almeria, Almeria, Spain.
FAU - Garcia-Lopez, Hector
AU  - Garcia-Lopez H
AD  - Department Physical Therapy, Universidad De Almeria Facultad de Ciencias de la
      Educacion Enfermeria y Fisioterapia, Almeria, Spain.
FAU - Andronis, Lazaro
AU  - Andronis L
AD  - Division of Clinical Trials, Warwick Meidical School, University of Warwick,
      Birmingham and Coventry, UK.
FAU - Albornoz-Cabello, Manuel
AU  - Albornoz-Cabello M
AUID- ORCID: 0000-0003-3865-0634
AD  - Department of Physiotherapy, University of Seville, Seville, Spain.
FAU - Lara Palomo, Inmaculada C
AU  - Lara Palomo IC
AUID- ORCID: 0000-0003-1899-2063
AD  - Department Physical Therapy, Universidad De Almeria Facultad de Ciencias de la
      Educacion Enfermeria y Fisioterapia, Almeria, Spain inma.lara.palomo@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04266366
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Chronic Pain/therapy
MH  - Cost-Benefit Analysis
MH  - Europe
MH  - Humans
MH  - *Low Back Pain/therapy
MH  - Multicenter Studies as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Telemedicine
MH  - Treatment Outcome
PMC - PMC7735081
OTO - NOTNLM
OT  - *health economics
OT  - *musculoskeletal disorders
OT  - *pain management
OT  - *protocols & guidelines
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - bmjopen-2020-040633 [pii]
AID - 10.1136/bmjopen-2020-040633 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e040633. doi: 10.1136/bmjopen-2020-040633.


PMID- 33310798
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Protocol on a multicentre statistical and economic modelling study of risk-based 
      stratified and personalised screening for diabetes and its complications in India
      (SMART India).
PG  - e039657
LID - 10.1136/bmjopen-2020-039657 [doi]
AB  - INTRODUCTION: The aim of this study is to develop practical and affordable models
      to (a) diagnose people with diabetes and prediabetes and (b) identify those at
      risk of diabetes complications so that these models can be applied to the
      population in low-income and middle-income countries (LMIC) where laboratory
      tests are unaffordable. METHODS AND ANALYSIS: This statistical and economic
      modelling study will be done on at least 48 000 prospectively recruited
      participants aged 40 years or above through community screening across 20
      predefined regions in India. Each participant will be tested for capillary random
      blood glucose (RBG) and complete a detailed health-related questionnaire. People 
      with known diabetes and all participants with predefined levels of RBG will
      undergo further tests, including point-of-care (POC) glycated haemoglobin
      (HbA1c), POC lipid profile and POC urine test for microalbuminuria, retinal
      photography using non-mydriatic hand-held retinal camera, visual acuity
      assessment in both eyes and complete quality of life questionnaires. The primary 
      aim of the study is to develop a model and assess its diagnostic performance to
      predict HbA1c diagnosed diabetes from simple tests that can be applied in
      resource-limited settings; secondary outcomes include RBG cut-off for definition 
      of prediabetes, diagnostic accuracy of cost-effective risk stratification models 
      for diabetic retinopathy and models for identifying those at risk of
      complications of diabetes. Diagnostic accuracy inter-tests agreement, statistical
      and economic modelling will be performed, accounting for clustering effects.
      ETHICS AND DISSEMINATION: The Indian Council of Medical Research/Health Ministry 
      Screening Committee (HMSC/2018-0494 dated 17 December 2018 and institutional
      ethics committees of all the participating institutions approved the study.
      Results will be published in peer-reviewed journals and will be presented at
      national and international conferences. TRIAL REGISTRATION NUMBER: ISRCTN57962668
      V1.0 24/09/2018.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Sivaprasad, Sobha
AU  - Sivaprasad S
AUID- ORCID: 0000-0001-8952-0659
AD  - NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust,
      London, UK s.sivaprasad@ucl.ac.uk.
AD  - Vision Sciences, UCL Institute of Ophthalmology, London, UK.
FAU - Raman, Rajiv
AU  - Raman R
AUID- ORCID: 0000-0001-5842-0233
AD  - Retina Department, Vision Research Foundation, Sankara Nethralaya, Chennai,
      India.
FAU - Rajalakshmi, Ramachandran
AU  - Rajalakshmi R
AD  - Deaprtment of Diabetes, Madras Diabetes Research Foundation, Dr Mohan's Diabetes 
      Specialities Centre, Chennai, India.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Deaprtment of Diabetes, Madras Diabetes Research Foundation, Dr Mohan's Diabetes 
      Specialities Centre, Chennai, India.
FAU - Deepa, Mohan
AU  - Deepa M
AD  - Deaprtment of Diabetes, Madras Diabetes Research Foundation, Dr Mohan's Diabetes 
      Specialities Centre, Chennai, India.
FAU - Das, Taraprasad
AU  - Das T
AD  - Retina Department, Hyderabad Eye Research Foundation, LV Prasad Eye Institute,
      Hyderabad, India.
FAU - Ramasamy, Kim
AU  - Ramasamy K
AD  - Retina Department, Aravind Medical Research Foundation, Madurai, India.
FAU - Prevost, A Toby
AU  - Prevost AT
AUID- ORCID: 0000-0003-1723-0796
AD  - Nightingale-Saunders Clinical Trials and Epidemiology Unit, King's College
      London, London, UK.
FAU - Wittenberg, Raphael
AU  - Wittenberg R
AD  - Centre for Health Service Economics and Organisation, University of Oxford,
      Oxford, UK.
FAU - Netuveli, Gopalakrishnan
AU  - Netuveli G
AD  - Institute for Connected Communities, University of East London, London, UK.
FAU - Lingam, Gopal
AU  - Lingam G
AD  - Department of Ophthalmology, National University Hospital, Singapore.
FAU - Hanif, Wasim
AU  - Hanif W
AD  - Department of Diabetes, University Hospital, Birmingham, UK.
FAU - Ramakrishnan, Radha
AU  - Ramakrishnan R
AD  - Vision Sciences, UCL Institute of Ophthalmology, London, UK.
FAU - Ramu, Jayashree
AU  - Ramu J
AD  - NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust,
      London, UK.
FAU - Surya, Janani
AU  - Surya J
AD  - Retina Department, Vision Research Foundation, Sankara Nethralaya, Chennai,
      India.
FAU - Conroy, Dolores
AU  - Conroy D
AD  - Vision Sciences, UCL Institute of Ophthalmology, London, UK.
CN  - SMART India Study Collaborators
LA  - eng
SI  - ISRCTN/ISRCTN57962668
GR  - MR/P027881/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Adult
MH  - *Diabetic Retinopathy/diagnosis
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - India
MH  - Multicenter Studies as Topic
MH  - *Prediabetic State/diagnosis
MH  - Quality of Life
PMC - PMC7735124
OTO - NOTNLM
OT  - *diabetic retinopathy
OT  - *epidemiology
OT  - *general diabetes
OT  - *health economics
OT  - *medical retina
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - bmjopen-2020-039657 [pii]
AID - 10.1136/bmjopen-2020-039657 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e039657. doi: 10.1136/bmjopen-2020-039657.


PMID- 33310795
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Effect of surfactant dose on outcomes in preterm infants with respiratory
      distress syndrome: the OPTI-SURF study protocol.
PG  - e038959
LID - 10.1136/bmjopen-2020-038959 [doi]
AB  - INTRODUCTION: Respiratory distress syndrome is a condition seen in preterm
      infants primarily due to surfactant insufficiency. European guidelines recommend 
      the dose and method of surfactant administration. However, in routine practice,
      clinicians often use a 'whole vial' approach to surfactant dosing. The aim of
      this study is to assess whether in preterm infants of gestational age 36(+6)
      weeks(+days) or less, a low first dose of surfactant (100-130 mg/kg) compared
      with a high first dose (170-200 mg/kg) affects survival with no mechanical
      ventilation on either on postnatal days 3 and 4, and other outcomes. METHODS AND 
      ANALYSIS: In this prospective, observational study, we will use the National
      Neonatal Research Database as the main data source. We will obtain additional
      information describing the dose and method of surfactant administration through
      the neonatal EPR system. We will use propensity scores to form matched groups
      with low first dose and high first dose for comparison. ETHICS AND DISSEMINATION:
      This study was approved by the West Midlands-Black Country Research Ethics
      Committee (REC reference: 18/WM/0132; IRAS project ID: 237111). The results of
      the research will be made publicly available through presentations at local,
      national or international conferences and will be submitted for publication in a 
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT03808402; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Goss, Kevin Colin William
AU  - Goss KCW
AUID- ORCID: 0000-0002-6363-6589
AD  - Neonatal Intensive Care Unit, University Hospital Southampton NHS Foundation
      Trust, Southampton, Hampshire, UK kevingoss@nhs.net.
FAU - Gale, Chris
AU  - Gale C
AUID- ORCID: 0000-0003-0707-876X
AD  - Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College
      London, London, UK.
FAU - Malone, Rachel
AU  - Malone R
AD  - Chiesi Ltd, Manchester, UK.
FAU - Longford, Nicholas
AU  - Longford N
AD  - Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College
      London, London, UK.
FAU - Ratcliffe, Kirsty
AU  - Ratcliffe K
AD  - Chiesi Ltd, Manchester, UK.
FAU - Modi, Neena
AU  - Modi N
AD  - Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College
      London, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03808402
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pulmonary Surfactants)
RN  - 0 (Surface-Active Agents)
SB  - IM
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Prospective Studies
MH  - *Pulmonary Surfactants/therapeutic use
MH  - *Respiratory Distress Syndrome, Newborn/drug therapy
MH  - Surface-Active Agents/therapeutic use
PMC - PMC7735095
OTO - NOTNLM
OT  - *neonatal intensive & critical care
OT  - *neonatology
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: KCWG is chief investigator for the OPTI-SURF study. He
      reports receiving personal fees from Chiesi Pharmaceuticals outside of the
      submitted work to support attendance at an educational meeting. CG reports grants
      from Medical Research Council and the National Institute for Health Research,
      Mason Medical Research Foundation, Rosetrees Foundation and Canadian Institute
      for Health Research outside this work. He reports receiving personal fees from
      Chiesi Pharmaceuticals outside of the submitted work to support attendance at
      educational meetings. NM is the director of the Neonatal Data Analysis Unit and
      the chief investigator for the National Neonatal Research Database. She is a
      trustee of the David Harvey Trust, Medical Women's Federation and Action Cerebral
      Palsy and Their World, and is a member of the Nestle Scientific Advisory Board.
      She reports research grants in the last 5 years from the British Heart
      Foundation, Medical Research Council, National Institute of Health Research,
      Westminster Research Fund, Collaboration for Leadership in Applied Health and
      Care Northwest London, Healthcare Quality Improvement Partnership, Bliss, Nestle,
      Prolacta Life Sciences, Chiesi, Shire and HCA International; travel and
      accommodation expenses from Prolacta, Nestle and Chiesi; and a lecture honorarium
      from Chiesi. NL is senior statistician at the Neonatal Data Analysis Unit. He
      reports no competing interests. RM and KR are full-time employees of Chiesi.
EDAT- 2020/12/15 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - bmjopen-2020-038959 [pii]
AID - 10.1136/bmjopen-2020-038959 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e038959. doi: 10.1136/bmjopen-2020-038959.


PMID- 33310790
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 12
TI  - Epidemiology of multimorbidity among people living with HIV in sub-Saharan
      Africa: a systematic review protocol.
PG  - e036988
LID - 10.1136/bmjopen-2020-036988 [doi]
AB  - INTRODUCTION: Sub-Saharan Africa remains the epicentre of the HIV pandemic, yet
      enormous knowledge gaps still exist to elicit a comprehensive portrait of
      multimorbidity and HIV linkage. This study aims to conduct a systematic
      meta-analysis of peer-reviewed literature to investigate the current status of
      multimorbidity epidemiology among people living with HIV (PLHIV) in sub-Saharan
      Africa. METHODS AND ANALYSIS: Our review will assess observational studies (ie,
      cohort, case-control and cross-sectional) on multimorbidity associated with
      HIV/AIDS between 1 January 2005 and 31 October 2020 from sub-Saharan Africa.
      Databases to be searched include PubMed/MEDLINE, Scopus, Web of Science, Cochrane
      library, African Index Medicus and African Journals Online. We will also search
      the WHO clinical trial registry and databases for systematic reviews. The search 
      strategy will involve the use of medical subject headings and key terms to obtain
      studies on the phenomena of HIV and multimorbidity at high precision. Quality
      assessment of eligible studies will be ascertained using a validated quality
      assessment tool for observational studies and risk of bias through sensitivity
      analysis to identify publication bias. Further, data on characteristics of the
      study population, multimorbid conditions, epidemiological rates and spatial
      distribution of multimorbid conditions in PLHIV will be extracted. Heterogeneity 
      of individual studies will be evaluated using the I(2) statistic from combined
      effect size estimates. The statistical analysis will be performed using STATA
      statistical software V.15 and results will be graphically represented on a forest
      plot. ETHICS AND DISSEMINATION: Ethical approval is not applicable in this study 
      as it is a systematic review of published literature. The review findings may
      also be presented at conferences or before other relevant stakeholders. PROSPERO 
      REGISTRATION NUMBER: CRD42020148668.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oladimeji, Kelechi Elizabeth
AU  - Oladimeji KE
AUID- ORCID: 0000-0002-0246-5595
AD  - Faculty of Health Sciences, University of Fort Hare, East London, South Africa
      oladimejikelechi@yahoo.com.
AD  - College of Graduate Studies, University of South Africa, Johannesburg, South
      Africa.
FAU - Dzomba, Armstrong
AU  - Dzomba A
AD  - Medical Research Council/Wits Rural Public Health and Health Transitions Research
      Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University
      of the Witwatersrand, Johannesburg, South Africa.
FAU - Adetokunboh, Olatunji
AU  - Adetokunboh O
AD  - DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), 
      Stellenbosch University, Stellenbosch, South Africa.
AD  - Division of Epidemiology and Biostatistics, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, Western Cape, South Africa.
FAU - Zungu, Lindiwe
AU  - Zungu L
AD  - College of Graduate Studies, University of South Africa, Johannesburg, South
      Africa.
FAU - Yaya, Sanni
AU  - Yaya S
AD  - Faculty of Social Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Goon, Daniel Ter
AU  - Goon DT
AD  - Faculty of Health Sciences, University of Fort Hare, East London, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201212
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - Cross-Sectional Studies
MH  - *HIV Infections/epidemiology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Multimorbidity
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7735099
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - bmjopen-2020-036988 [pii]
AID - 10.1136/bmjopen-2020-036988 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 12;10(12):e036988. doi: 10.1136/bmjopen-2020-036988.


PMID- 33310742
OWN - NLM
STAT- Publisher
LR  - 20211120
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 11
TI  - Love thy neighbour? Allocating vaccines in a world of competing obligations.
LID - medethics-2020-106887 [pii]
LID - 10.1136/medethics-2020-106887 [doi]
AB  - Although a safe, effective, and licensed coronavirus vaccine does not yet exist, 
      there is already controversy over how it ought to be allocated. Justice is
      clearly at stake, but it is unclear what justice requires in the international
      distribution of a scarce vaccine during a pandemic. Many are condemning 'vaccine 
      nationalism' as an obstacle to equitable global distribution. We argue that
      limited national partiality in allocating vaccines will be a component of justice
      rather than an obstacle to it. For there are role-based and community-embedded
      responsibilities to take care of one's own, which constitute legitimate moral
      reasons for some identity-related prioritisation. Furthermore, a good form of
      vaccine nationalism prioritises one's own without denying or ignoring duties
      derived from a principle of equal worth, according to which all persons,
      regardless of citizenship or identity, equally deserve vaccine-induced protection
      from COVID-19. Rather than dismissing nationalism as a tragic obstacle, it is
      necessary to acknowledge that a limited form of it is valuable and expresses
      moral commitments. Only then can one understand our world of competing
      obligations, a world where cosmopolitan duties of benevolence sometimes conflict 
      with special obligations of community membership. Once these competing
      obligations are recognised as such, we can begin the work of designing sound
      ethical frameworks for achieving justice in the global distribution of a
      coronavirus vaccine and developing practical strategies for avoiding, mitigating 
      or resolving conflicts of duty.
CI  - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Ferguson, Kyle
AU  - Ferguson K
AUID- ORCID: http://orcid.org/0000-0001-9285-4975
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, New York, USA kyle.ferguson@nyulangone.org.
FAU - Caplan, Arthur
AU  - Caplan A
AUID- ORCID: http://orcid.org/0000-0002-4061-8011
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2021 Nov;47(11):773-774. PMID: 33589473
PMC - PMC7735068
OTO - NOTNLM
OT  - distributive justice
OT  - ethics
OT  - international affairs
OT  - philosophical ethics
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/09/09 00:00 [received]
PHST- 2020/11/05 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/12/14 10:43 [entrez]
AID - medethics-2020-106887 [pii]
AID - 10.1136/medethics-2020-106887 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 11. pii: medethics-2020-106887. doi:
      10.1136/medethics-2020-106887.


PMID- 33310741
OWN - NLM
STAT- Publisher
LR  - 20201214
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 11
TI  - Prize, not price: reframing rewards for kidney donors.
LID - medethics-2020-106172 [pii]
LID - 10.1136/medethics-2020-106172 [doi]
AB  - Worldwide 1.2 million people are dying from kidney failure each year, and in the 
      USA alone, approximately 100 000 people are currently on the waiting list for a
      kidney transplant. One possible solution to the kidney shortage is for
      governments to pay donors for one of their healthy kidneys and distribute these
      kidneys according to need. There are, however, compelling objections to this
      government-monopsony model. To avoid these objections, I propose a small
      adjustment to the model. I suggest we reward kidney sellers with both money and a
      ceremony that celebrates their noble act. They should, in other words, receive a 
      prize rather than a price.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Sterri, Aksel Braanen
AU  - Sterri AB
AUID- ORCID: http://orcid.org/0000-0002-4804-8033
AD  - Department of Philosophy, Classics, History of Art and Ideas, University of Oslo,
      Oslo, Norway akselbst@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - allocation of organs/tissues
OT  - ethics
OT  - human dignity
OT  - kidneys
OT  - transplantation
COIS- Competing interests: None declared.
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/14 10:43
PHST- 2020/02/28 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2020/12/14 10:43 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - medethics-2020-106172 [pii]
AID - 10.1136/medethics-2020-106172 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 11. pii: medethics-2020-106172. doi:
      10.1136/medethics-2020-106172.


PMID- 33308781
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 266
DP  - 2020 Dec
TI  - [Sustainable and efficient cooperation to protect residents from the COVID-19
      epidemic].
PG  - 37-38
LID - S1293-8505(20)30313-4 [pii]
LID - 10.1016/j.revinf.2020.10.022 [doi]
AB  - The health crisis has had a major impact on residential institutions for
      dependent elderly people. Professionals practising in the Nouvelle-Aquitaine
      region are reviewing the measures adopted to protect residents, their families
      and staff. Resulting from a collective work between four public establishments in
      common direction, the fight against the epidemic of COVID-19 was organized by
      combining management of the immediacy of ministerial directives and anticipation 
      in order to be sustainable.
CI  - Copyright (c) 2020. Publie par Elsevier Masson SAS.
FAU - Bourzeau, Madeleine
AU  - Bourzeau M
AD  - Centre hospitalier Le Genets d'or, Ouches-du-Budelle, 23110 Evaux-les-Bains,
      France; Ehpad Le Chant des rivieres, rue Germeau-Baraillon, 23170
      Chambon-sur-Voueize, France; Ehpad Le Bois Joli, 8, rue du Docteur-Mazeron, 23700
      Auzances, France; Maison de retraite Gaston-Rimareix, 1, rue des Aines, 23700
      Mainsat, France. Electronic address: madeleine.bourzeau@ch-evauxlesbains.fr.
FAU - Desrues, Mireille
AU  - Desrues M
AD  - Maison de retraite Gaston-Rimareix, 1, rue des Aines, 23700 Mainsat, France.
FAU - Gaillard, Emmanuelle
AU  - Gaillard E
AD  - Ehpad Le Bois Joli, 8, rue du Docteur-Mazeron, 23700 Auzances, France.
FAU - Valet, Celine
AU  - Valet C
AD  - Centre hospitalier Le Genets d'or, Ouches-du-Budelle, 23110 Evaux-les-Bains,
      France.
LA  - fre
PT  - Journal Article
TT  - Cooperer pour proteger les residents de la Covid-19.
DEP - 20201110
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - *COVID-19/epidemiology
MH  - Health Facilities
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - Covid-19
OT  - EHPAD
OT  - Ehpad
OT  - care team
OT  - ethics
OT  - management
OT  - prevention
OT  - prevention
OT  - equipe soignante
EDAT- 2020/12/15 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/14 10:03
PHST- 2020/12/14 10:03 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - S1293-8505(20)30313-4 [pii]
AID - 10.1016/j.revinf.2020.10.022 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Dec;69(266):37-38. doi: 10.1016/j.revinf.2020.10.022. Epub 2020 
      Nov 10.


PMID- 33308776
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 266
DP  - 2020 Dec
TI  - [Once a caregiver, always a caregiver].
PG  - 26-28
LID - S1293-8505(20)30301-8 [pii]
LID - 10.1016/j.revinf.2020.10.010 [doi]
AB  - March 2020, COVID-19 pandemic. In France, a state of health emergency is declared
      by the authorities; training managers are called in as reinforcements. This
      return to the field in the context of a health crisis has made it possible to
      re-examine practices and the place of the manager within the health system.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Bourgeois, Alexandra
AU  - Bourgeois A
AD  - Ifsi Theodore-Simon, 19, avenue de Maison-Blanche, 93330 Neuilly-sur-Marne,
      France. Electronic address: a.bourgeois@ifits.fr.
FAU - Carre, Isabelle
AU  - Carre I
AD  - Ifsi Theodore-Simon, 19, avenue de Maison-Blanche, 93330 Neuilly-sur-Marne,
      France.
FAU - Hamel, Christelle
AU  - Hamel C
AD  - Ifsi Theodore-Simon, 19, avenue de Maison-Blanche, 93330 Neuilly-sur-Marne,
      France.
FAU - Lecland, Patricia
AU  - Lecland P
AD  - Ifsi Theodore-Simon, 19, avenue de Maison-Blanche, 93330 Neuilly-sur-Marne,
      France.
LA  - fre
PT  - Journal Article
TT  - Soignant un jour, soignant toujours.
DEP - 20201029
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - *COVID-19
MH  - *Caregivers
MH  - France
MH  - Humans
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - Covid-19
OT  - cadre formateur
OT  - encadrement
OT  - ethics
OT  - reinforcement
OT  - renfort
OT  - supervision
OT  - training manager
OT  - ethique
EDAT- 2020/12/15 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/14 10:03
PHST- 2020/12/14 10:03 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - S1293-8505(20)30301-8 [pii]
AID - 10.1016/j.revinf.2020.10.010 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Dec;69(266):26-28. doi: 10.1016/j.revinf.2020.10.010. Epub 2020 
      Oct 29.


PMID- 33308773
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 266
DP  - 2020 Dec
TI  - [Nurses in multi-disciplinary team to face Sars-CoV-2 in intensive care].
PG  - 18-19
LID - S1293-8505(20)30298-0 [pii]
LID - 10.1016/j.revinf.2020.10.007 [doi]
AB  - At the heart of the epidemic wave of spring 2020, the intensive care units faced 
      the surge of patients with severe forms of the disease. To meet the scale of the 
      needs, the care teams were reorganised, reinforced and adapted, as demonstrated
      by a hospital team specialising in neurology which, beyond the ethical issues,
      shortages and fears, proceeded to the "covidisation" of its resuscitation and the
      total reorganisation of the other units, in order to expertly organise care
      adapted to the needs of the patients. From a distance, and while the epidemic is 
      still active, many questions remain.
CI  - Copyright (c) 2020. Publie par Elsevier Masson SAS.
FAU - Bourmaleau, Julie
AU  - Bourmaleau J
AD  - Service de reanimation, departement de neurologie, hopital Pitie-Salpetriere, 47,
      boulevard de l'Hopital, 75013 Paris, France. Electronic address:
      julie.bourmaleau@aphp.fr.
FAU - Maillard, Sophie
AU  - Maillard S
AD  - Service de reanimation, departement de neurologie, hopital Pitie-Salpetriere, 47,
      boulevard de l'Hopital, 75013 Paris, France.
LA  - fre
PT  - Journal Article
TT  - Les infirmieres en equipe pluridisciplinaire pour affronter le Sars-CoV-2 en
      reanimation.
DEP - 20201029
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - *COVID-19
MH  - Critical Care
MH  - Humans
MH  - Intensive Care Units
MH  - Nurses
MH  - Patient Care Team
MH  - *SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - Covid-19
OT  - competence
OT  - competence
OT  - end of life
OT  - epidemic
OT  - ethics
OT  - fin de vie
OT  - resuscitation
OT  - reanimation
OT  - epidemie
OT  - ethique
EDAT- 2020/12/15 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/14 10:03
PHST- 2020/12/14 10:03 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - S1293-8505(20)30298-0 [pii]
AID - 10.1016/j.revinf.2020.10.007 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Dec;69(266):18-19. doi: 10.1016/j.revinf.2020.10.007. Epub 2020 
      Oct 29.


PMID- 33308290
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210818
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Dec 11
TI  - Death Cafes for prevention of burnout in intensive care unit employees: study
      protocol for a randomized controlled trial (STOPTHEBURN).
PG  - 1019
LID - 10.1186/s13063-020-04929-4 [doi]
AB  - BACKGROUND: Burnout is an occupational syndrome that leads to mental health
      problems, job turnover, and patient safety events. Those caring for critically
      ill patients are especially susceptible due to high patient mortality, long
      hours, and regular encounters with trauma and ethical issues. Interventions to
      prevent burnout in this population are needed. Preliminary studies suggest
      debriefing sessions may reduce burnout. This study aims to assess whether
      participation in regular debriefing can prevent burnout in intensive care unit
      (ICU) clinicians. METHODS: A randomized controlled trial will be conducted in two
      large academic medical centers. Two hundred ICU clinicians will be recruited with
      target enrollment of 100 physicians and 100 non-physicians (nurses, pharmacists, 
      therapists). Participants must have worked in the ICU for the equivalent of at
      least 1 full time work week in the preceding 4 weeks. Enrolled subjects will be
      randomized to virtually attend biweekly debriefing sessions facilitated by a
      psychotherapist for 3 months or to a control arm without sessions. Our debriefs
      are modeled after Death Cafes, which are informal discussions focusing on death, 
      dying, loss, grief, and illness. These sessions allow for reflection on
      distressing events and offer community and collaboration among hospital employees
      outside of work. The primary outcome is clinician burnout as measured by the
      Maslach Burnout Inventory (MBI) Score. Secondary outcomes include depression and 
      anxiety, as measured by the Patient Health Questionnaire 8 (PHQ-8) and
      Generalized Anxiety Disorder 7-item scale (GAD-7), respectively. Questionnaires
      will be administered prior to the intervention, at 1 month, at 3 months, and at 6
      months after enrollment. These values will be compared between groups temporally.
      Qualitative feedback will also be collected and analyzed. DISCUSSION: With ICU
      clinician burnout rates exceeding 50%, Death Cafe debriefing sessions may prove
      to be an effective tool to avert this debilitating syndrome. With COVID-19
      limiting social interactions and overloading ICUs worldwide, the virtual
      administration of the Death Cafe for ICU clinicians provides an innovative
      strategy to potentially mitigate burnout in this vulnerable population. TRIAL
      REGISTRATION: ClinicalTrials.gov NCT04347811 . Registered on 15 April 2020.
FAU - Bateman, Marjorie E
AU  - Bateman ME
AUID- ORCID: http://orcid.org/0000-0003-3323-2337
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA. mbatema@tulane.edu.
FAU - Hammer, Rachel
AU  - Hammer R
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
AD  - Department of Psychiatry, Tulane University School of Medicine, New Orleans, LA, 
      USA.
FAU - Byrne, Abigail
AU  - Byrne A
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
FAU - Ravindran, Nithya
AU  - Ravindran N
AD  - Department of Psychiatry, Tulane University School of Medicine, New Orleans, LA, 
      USA.
FAU - Chiurco, Jennifer
AU  - Chiurco J
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
FAU - Lasky, Sasha
AU  - Lasky S
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
FAU - Denson, Rebecca
AU  - Denson R
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
FAU - Brown, Margo
AU  - Brown M
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
FAU - Myers, Leann
AU  - Myers L
AD  - Department of Biostatistics and Data Science, Tulane University School of Public 
      Health and Tropical Medicine, New Orleans, LA, USA.
FAU - Zu, Yuanhao
AU  - Zu Y
AD  - Department of Biostatistics and Data Science, Tulane University School of Public 
      Health and Tropical Medicine, New Orleans, LA, USA.
FAU - Denson, Joshua L
AU  - Denson JL
AD  - Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue,
      New Orleans, LA, 70112, USA.
AD  - Section of Pulmonary Diseases, Critical Care & Environmental Medicine, Tulane
      University School of Medicine, New Orleans, LA, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04347811
GR  - U54 GM104940/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201211
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Anxiety/diagnosis/epidemiology
MH  - Awareness/physiology
MH  - Burnout, Professional/epidemiology/*prevention & control
MH  - COVID-19/epidemiology/virology
MH  - Case-Control Studies
MH  - Communication
MH  - Critical Illness/mortality/psychology
MH  - Depression/diagnosis/epidemiology
MH  - Humans
MH  - Intensive Care Units/*statistics & numerical data
MH  - Occupational Stress/epidemiology/*psychology
MH  - Patient Health Questionnaire/statistics & numerical data
MH  - Patient Safety/statistics & numerical data
MH  - Personnel Turnover/statistics & numerical data
MH  - SARS-CoV-2/*genetics
MH  - Surveys and Questionnaires
MH  - Terminal Care/*psychology
MH  - User-Computer Interface
PMC - PMC7729694
OTO - NOTNLM
OT  - Anxiety
OT  - Behavioral symptoms
OT  - Burnout
OT  - Critical care
OT  - Death Cafe
OT  - Depression
OT  - Healthcare workers
OT  - Moral distress
OT  - Occupational stress
OT  - Randomized controlled trial
OT  - Teledebriefing
OT  - Virtual debriefing
OT  - Work place retention
EDAT- 2020/12/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/14 09:53
PHST- 2020/05/30 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/14 09:53 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s13063-020-04929-4 [doi]
AID - 10.1186/s13063-020-04929-4 [pii]
PST - epublish
SO  - Trials. 2020 Dec 11;21(1):1019. doi: 10.1186/s13063-020-04929-4.


PMID- 33308277
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201217
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
IP  - 1
DP  - 2020 Dec 14
TI  - Investigation of opposition to diagnostic or therapeutic procedures in older
      people hospitalized in acute geriatric services: the OPTAH pilot study protocol.
PG  - 194
LID - 10.1186/s40814-020-00742-7 [doi]
AB  - BACKGROUND: Shared decision-making is a process that involves collaborative
      discussions between a patient and a care team to ensure informed healthcare
      decisions. This process becomes more complex when the older person's
      decision-making capacities are affected. In these situations, surrogate
      decision-making processes are used to define a person-centered care plan. Despite
      these processes, the implementation of the care plan defined in the best interest
      of the patient may nevertheless be rejected by the patient, particularly in cases
      of neurocognitive disorders or delirium. This concept of opposition and/or
      refusal is frequently used in research. This is not yet well understood in the
      medical literature, and there is a lack of consensus on its definition. We,
      therefore, explored this concept by defining opposition to diagnostic or
      therapeutic proposals. METHOD: Our pilot study protocol is based on a mixed
      methodology (epidemiological and qualitative research) to quantify this
      phenomenon, validate the proposed definition, and explore its core elements.
      Opposition and refusal of care will be quantified, and semi-structured interviews
      will be conducted with patients, their relatives, and referring carers.
      Multidisciplinary meetings that will be associated with these situations will
      also be observed and analyzed. Methodological approaches that can be used to
      explore opposition and refusal of care in a scientific, reproducible framework
      are presented. This methodology considers the specificities of the geriatric,
      polypathological population with neurocognitive disorders. DISCUSSION: Opposition
      and refusal of care are key concepts in clinical research on ethics, particularly
      in the geriatric field. These concepts are frequently mentioned in studies
      involving older patients but have not been specifically defined or studied. This 
      study would undoubtedly lead to greater awareness among professional caregivers
      and relatives of the significance of such opposition, and more respectful
      interactions in these complex hospitalization cases. TRIAL REGISTRATION:
      ClinicalTrial.gov, NCT03373838 . Registered on 14 December 2017.
FAU - Tannou, Thomas
AU  - Tannou T
AUID- ORCID: http://orcid.org/0000-0003-3476-9822
AD  - Geriatrics Department, University Hospital of Besancon, Besancon, France.
      ttannou@chu-besancon.fr.
AD  - Equipe "Ethique et Progres Medical" Inserm, CIC 1431, Centre d'Investigation
      Clinique, University Hospital of Besancon, Besancon, France.
      ttannou@chu-besancon.fr.
AD  - EA 481 Neurosciences, UBFC, Besancon, France. ttannou@chu-besancon.fr.
FAU - Trimaille, Helene
AU  - Trimaille H
AD  - Equipe "Ethique et Progres Medical" Inserm, CIC 1431, Centre d'Investigation
      Clinique, University Hospital of Besancon, Besancon, France.
FAU - Mathieu-Nicot, Florence
AU  - Mathieu-Nicot F
AD  - Equipe "Ethique et Progres Medical" Inserm, CIC 1431, Centre d'Investigation
      Clinique, University Hospital of Besancon, Besancon, France.
AD  - EA 3188 Laboratoire de psychologie, UBFC, Besancon, France.
FAU - Koeberle, Severine
AU  - Koeberle S
AD  - Geriatrics Department, University Hospital of Besancon, Besancon, France.
AD  - Equipe "Ethique et Progres Medical" Inserm, CIC 1431, Centre d'Investigation
      Clinique, University Hospital of Besancon, Besancon, France.
FAU - Aubry, Regis
AU  - Aubry R
AD  - Geriatrics Department, University Hospital of Besancon, Besancon, France.
AD  - Equipe "Ethique et Progres Medical" Inserm, CIC 1431, Centre d'Investigation
      Clinique, University Hospital of Besancon, Besancon, France.
AD  - EA 481 Neurosciences, UBFC, Besancon, France.
FAU - Godard-Marceau, Aurelie
AU  - Godard-Marceau A
AD  - Equipe "Ethique et Progres Medical" Inserm, CIC 1431, Centre d'Investigation
      Clinique, University Hospital of Besancon, Besancon, France.
AD  - EA 481 Neurosciences, UBFC, Besancon, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03373838
GR  - 2017-2019/Fondation Bettencourt Schueller
PT  - Journal Article
DEP - 20201214
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
PMC - PMC7734746
OTO - NOTNLM
OT  - Decision-making
OT  - Epidemiology
OT  - Geriatrics
OT  - Opposition to treatment
OT  - Protocol
OT  - Qualitative study
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
CRDT- 2020/12/14 09:53
PHST- 2020/01/24 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/12/14 09:53 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
AID - 10.1186/s40814-020-00742-7 [doi]
AID - 10.1186/s40814-020-00742-7 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 Dec 14;6(1):194. doi: 10.1186/s40814-020-00742-7.


PMID- 33308274
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Dec 11
TI  - Quantitative response of healthy muscle following the induction of capsaicin: an 
      exploratory randomized controlled trial.
PG  - 1020
LID - 10.1186/s13063-020-04937-4 [doi]
AB  - BACKGROUND: Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder
      primarily characterized by myofascial trigger points (MTrPs). There is limited
      knowledge on the pathophysiology and mechanisms underlying MTrP and its
      development. Research has previously demonstrated the identification of MTrPs
      using ultrasound and vibration sonoelastography, although there is some
      contradictory evidence regarding if MTrPs present as hyper or hypoechoic regions.
      Electromyography (EMG) investigations of MTrP have demonstrated that MTrPs are
      usually located proximal to innervation zones where the peak surface EMG signals 
      are obtained from. Central sensitization has been proposed as the primary
      mechanism underlying MTrP development. Central sensitization is associated with
      hyperexcitability of neuronal responses to normal or noxious stimuli. There is a 
      need for a study that measures ultrasound image textural changes and motor unit
      activity responses in the muscle following sensitization. The purpose of this
      study is to determine whether sensitizing healthy muscle using capsaicin induces 
      a regional change in image texture variables within the specific and surrounding 
      muscles, as well as the motor unit frequency and amplitude changes that accompany
      them. This is an exploratory trial that aims to provide preliminary evidence on
      whether central sensitization is a direct cause of taut band and MTrP
      development. METHODS: Ethical approval was obtained from the University Health
      Network (UHN) Research Ethics Board. This proposed study is a single centered,
      factorial, randomized placebo-controlled trial with two independent variables,
      depth of capsaicin application and dose of capsaicin, for a total of six
      treatment arms and three control treatment groups. DISCUSSION: This will be the
      first study that assesses the B-mode ultrasound image texture of induced
      sensitized muscles and will provide more evidence on muscle motor unit activity
      and regional changes of central sensitization. Findings from this study may
      support one of few hypotheses proposed delineating the involvement of central
      sensitization in the development of trigger points. TRIAL REGISTRATION: National 
      Institutes of Health ClinicalTrials.gov NCT03944889 . Registered on May 07, 2019.
FAU - Evans, Valerie
AU  - Evans V
AD  - Institute of Biomaterials and Biomedical Engineering (IBBME), University of
      Toronto, Toronto, Ontario, Canada.
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Behr, Michael
AU  - Behr M
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Masani, Kei
AU  - Masani K
AD  - Institute of Biomaterials and Biomedical Engineering (IBBME), University of
      Toronto, Toronto, Ontario, Canada.
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Kumbhare, Dinesh
AU  - Kumbhare D
AUID- ORCID: http://orcid.org/0000-0003-3889-7557
AD  - Institute of Biomaterials and Biomedical Engineering (IBBME), University of
      Toronto, Toronto, Ontario, Canada. dinesh.kumbhare@uhn.ca.
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada. dinesh.kumbhare@uhn.ca.
AD  - Department of Medicine, Division of Physical Medicine and Rehabilitation,
      Toronto, Ontario, Canada. dinesh.kumbhare@uhn.ca.
LA  - eng
SI  - ClinicalTrials.gov/NCT03944889
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201211
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - S07O44R1ZM (Capsaicin)
SB  - IM
MH  - Capsaicin/pharmacology
MH  - *Elasticity Imaging Techniques
MH  - Electromyography
MH  - Humans
MH  - Muscle, Skeletal/diagnostic imaging
MH  - *Myofascial Pain Syndromes
MH  - Trigger Points
PMC - PMC7731533
OTO - NOTNLM
OT  - Central sensitization
OT  - Electromyography
OT  - Image texture
OT  - Myofascial pain syndrome
OT  - Trigger points
OT  - Ultrasound
EDAT- 2020/12/15 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/14 09:53
PHST- 2019/07/22 00:00 [received]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/14 09:53 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04937-4 [doi]
AID - 10.1186/s13063-020-04937-4 [pii]
PST - epublish
SO  - Trials. 2020 Dec 11;21(1):1020. doi: 10.1186/s13063-020-04937-4.


PMID- 33308184
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 14
TI  - Discussing personalized prognosis in amyotrophic lateral sclerosis: development
      of a communication guide.
PG  - 446
LID - 10.1186/s12883-020-02004-8 [doi]
AB  - BACKGROUND: Personalized ENCALS survival prediction model reliably estimates the 
      personalized prognosis of patients with amyotrophic lateral sclerosis. Concerns
      were raised on discussing personalized prognosis without causing anxiety and
      destroying hope. Tailoring communication to patient readiness and patient needs
      mediates the impact of prognostic disclosure. We developed a communication guide 
      to support physicians in discussing personalized prognosis tailored to individual
      needs and preferences of people with ALS and their families. METHODS: A
      multidisciplinary working group of neurologists, rehabilitation physicians, and
      healthcare researchers A) identified relevant topics for guidance, B) conducted a
      systematic review on needs of patients regarding prognostic discussion in
      life-limiting disease, C) drafted recommendations based on evidence and expert
      opinion, and refined and finalized these recommendations in consensus rounds,
      based on feedback of an expert advisory panel (patients, family member, ethicist,
      and spiritual counsellor). RESULTS: A) Topics identified for guidance were 1)
      filling in the ENCALS survival model, and interpreting outcomes and uncertainty, 
      and 2) tailoring discussion to individual needs and preferences of patients
      (information needs, role and needs of family, severe cognitive impairment or
      frontotemporal dementia, and non-western patients). B) 17 studies were included
      in the systematic review. C) Consensus procedures on drafted recommendations
      focused on selection of outcomes, uncertainty about estimated survival,
      culturally sensitive communication, and lack of decisional capacity.
      Recommendations for discussing the prognosis include the following: discuss
      prognosis based on the prognostic groups and their median survival, or, if more
      precise information is desired, on the interquartile range of the survival
      probability. Investigate needs and preferences of the patients and their families
      for prognostic disclosure, regardless of cultural background. If the patient does
      not want to know their prognosis, with patient permission discuss the prognosis
      with their family. If the patient is judged to lack decisional capacity, ask the 
      family if they want to discuss the prognosis. Tailor prognostic disclosure step
      by step, discuss it in terms of time range, and emphasize uncertainty of
      individual survival time. CONCLUSION: This communication guide supports
      physicians in tailoring discussion of personalized prognosis to the individual
      needs and preferences of people with ALS and their families.
FAU - van Eenennaam, Remko M
AU  - van Eenennaam RM
AD  - Department of Rehabilitation, Physical Therapy Science & Sports, UMC Utrecht
      Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX,
      Utrecht, the Netherlands.
AD  - Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center,
      University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the
      Netherlands.
AD  - Department of Neurology, UMC Utrecht Brain Center, University Medical Center
      Utrecht, Utrecht, the Netherlands.
FAU - Kruithof, Willeke J
AU  - Kruithof WJ
AD  - Department of Rehabilitation, Physical Therapy Science & Sports, UMC Utrecht
      Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX,
      Utrecht, the Netherlands.
AD  - Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center,
      University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the
      Netherlands.
FAU - van Es, Michael A
AU  - van Es MA
AD  - Department of Neurology, UMC Utrecht Brain Center, University Medical Center
      Utrecht, Utrecht, the Netherlands.
FAU - Kruitwagen-van Reenen, Esther T
AU  - Kruitwagen-van Reenen ET
AD  - Department of Rehabilitation, Physical Therapy Science & Sports, UMC Utrecht
      Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX,
      Utrecht, the Netherlands.
AD  - Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center,
      University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the
      Netherlands.
FAU - Westeneng, Henk-Jan
AU  - Westeneng HJ
AD  - Department of Neurology, UMC Utrecht Brain Center, University Medical Center
      Utrecht, Utrecht, the Netherlands.
FAU - Visser-Meily, Johanna M A
AU  - Visser-Meily JMA
AD  - Department of Rehabilitation, Physical Therapy Science & Sports, UMC Utrecht
      Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX,
      Utrecht, the Netherlands.
AD  - Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center,
      University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the
      Netherlands.
FAU - van den Berg, Leonard H
AU  - van den Berg LH
AD  - Department of Neurology, UMC Utrecht Brain Center, University Medical Center
      Utrecht, Utrecht, the Netherlands.
FAU - Beelen, Anita
AU  - Beelen A
AUID- ORCID: https://orcid.org/0000-0002-1269-0710
AD  - Department of Rehabilitation, Physical Therapy Science & Sports, UMC Utrecht
      Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX,
      Utrecht, the Netherlands. j.a.j.beelen@umcutrecht.nl.
AD  - Center of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Center,
      University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the
      Netherlands. j.a.j.beelen@umcutrecht.nl.
LA  - eng
GR  - 2016-51/ALS stichting Nederland (Netherlands ALS foundation)
PT  - Journal Article
DEP - 20201214
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
SB  - IM
MH  - *Amyotrophic Lateral Sclerosis
MH  - *Communication
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Education as Topic/*methods
MH  - *Physician-Patient Relations
MH  - Prognosis
MH  - *Truth Disclosure
PMC - PMC7734773
OTO - NOTNLM
OT  - Amyotrophic lateral sclerosis
OT  - Communication guide
OT  - Personalized prognosis
OT  - Physician-patient communication
OT  - Prognosis
OT  - Truth disclosure
EDAT- 2020/12/15 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/12/14 09:51
PHST- 2020/08/18 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/14 09:51 [entrez]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 10.1186/s12883-020-02004-8 [doi]
AID - 10.1186/s12883-020-02004-8 [pii]
PST - epublish
SO  - BMC Neurol. 2020 Dec 14;20(1):446. doi: 10.1186/s12883-020-02004-8.


PMID- 33307443
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210110
IS  - 1878-0067 (Electronic)
IS  - 1878-0067 (Linking)
VI  - 33
DP  - 2020 Dec
TI  - Responsible modelling: Unit testing for infectious disease epidemiology.
PG  - 100425
LID - S1755-4365(20)30045-1 [pii]
LID - 10.1016/j.epidem.2020.100425 [doi]
AB  - Infectious disease epidemiology is increasingly reliant on large-scale
      computation and inference. Models have guided health policy for epidemics
      including COVID-19 and Ebola and endemic diseases including malaria and
      tuberculosis. Yet a coding bug may bias results, yielding incorrect conclusions
      and actions causing avoidable harm. We are ethically obliged to make our code as 
      free of error as possible. Unit testing is a coding method to avoid such bugs,
      but it is rarely used in epidemiology. We demonstrate how unit testing can handle
      the particular quirks of infectious disease models and aim to increase the uptake
      of this methodology in our field.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Lucas, Tim C D
AU  - Lucas TCD
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, UK. Centre for Environment and Health, School of Public
      Health, Imperial College, UK. Electronic address: timcdlucas@gmail.com.
FAU - Pollington, Timothy M
AU  - Pollington TM
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, UK. MathSys CDT, University of Warwick, UK.
FAU - Davis, Emma L
AU  - Davis EL
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, UK.
FAU - Hollingsworth, T Deirdre
AU  - Hollingsworth TD
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201126
PL  - Netherlands
TA  - Epidemics
JT  - Epidemics
JID - 101484711
SB  - IM
MH  - COVID-19/epidemiology
MH  - Communicable Diseases/*epidemiology
MH  - Computer Simulation
MH  - Humans
MH  - *Models, Biological
MH  - Pandemics
MH  - Reinfection/epidemiology
MH  - Software
PMC - PMC7690327
OTO - NOTNLM
OT  - *Computational models
OT  - *Reproducible science
OT  - *Software development
OT  - *Unit testing
EDAT- 2020/12/12 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/12/11 20:14
PHST- 2020/07/27 00:00 [received]
PHST- 2020/10/21 00:00 [revised]
PHST- 2020/11/21 00:00 [accepted]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/12/11 20:14 [entrez]
AID - S1755-4365(20)30045-1 [pii]
AID - 10.1016/j.epidem.2020.100425 [doi]
PST - ppublish
SO  - Epidemics. 2020 Dec;33:100425. doi: 10.1016/j.epidem.2020.100425. Epub 2020 Nov
      26.


PMID- 33306902
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 2216-0280 (Electronic)
IS  - 0120-5307 (Linking)
VI  - 38
IP  - 3
DP  - 2020 Oct
TI  - Assessment of the Relationship between Nurses' Perception of Ethical Climate and 
      Job Burnout in Intensive Care Units.
LID - 10.17533/udea.iee.v38n3e12 [doi]
AB  - OBJECTIVES: To determine the relationship between ethical climate and burnout in 
      nurses working in Intensive Care Units (ICUs). METHODS: This cross-sectional and 
      multi-center study was conducted among 212 nurses working in adult ICUs of six
      hospitals affiliated to Shiraz University of Medical Sciences, Iran in 2019. The 
      participants were selected using systematic random sampling technique. Data was
      collected using valid instruments of Olson's Hospital Ethical Climate Survey
      (HECS) and Maslach Burnout Inventory (MBI). RESULTS: Ethical climate was
      favorable (3.5+/-0.6). The intensity (32.2+/-12.4) and frequency (25.5+/-12.4) of
      burnout were high. Ethical climate had significant and inverse relationships with
      frequency of burnout (r =-0.23, p=0.001) and with intensity of burnout (r=-0.186,
      p=0.007). Ethical climate explained 5.9% of burnout. Statistically significant
      relationships were also found between these factors: age with ethical climate
      (p=0.001), work shifts with burnout (p=0.02), and gender and with intensity
      frequency of burnout in ICU nurses (p=0.038). The results of Spearman correlation
      coefficient showed significant and inverse relationships between ethical climate 
      and job burnout (r=-0.243, p < 0.001). CONCLUSIONS: Nurses in ICUs perceived that
      ethical climate was favorable however, burnout was high. Therefore, burnout can
      be affected by many factors and it is necessary to support ICU nurses since they 
      undertake difficult and complicated task. It is recommended to assess factors
      that increase burnout and adopt specific measures and approaches to relieve
      nursing burnout.
CI  - Copyright by the Universidad de Antioquia.
FAU - Rivaz, Mozhgan
AU  - Rivaz M
AD  - School of Nursing and Midwifery, Shiraz University of Medical Sciences, Iran,
      mrivaz@sums.ac.ir.
FAU - Asadi, Fatemeh
AU  - Asadi F
AD  - School of Nursing and Midwifery, Shiraz University of Medical Sciences, Iran,
      asadi.fa@yahoo.com.
FAU - Mansouri, Parisa
AU  - Mansouri P
AD  - School of Nursing and Midwifery, Shiraz University of Medical Sciences, Iran,
      Mansoorip@sums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Colombia
TA  - Invest Educ Enferm
JT  - Investigacion y educacion en enfermeria
JID - 9108180
SB  - IM
MH  - Adult
MH  - Burnout, Professional/diagnosis/epidemiology/*etiology/*psychology
MH  - Critical Care Nursing/*ethics/organization & administration
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Intensive Care Units/*ethics/organization & administration
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Nurses/organization & administration/*psychology
MH  - *Organizational Culture
MH  - Psychological Tests
MH  - Regression Analysis
MH  - Risk Factors
MH  - *Social Perception
PMC - PMC7885543
OTO - NOTNLM
OT  - burnout, professional
OT  - ethics, nursing
OT  - intensive care units
OT  - nurses
COIS- The authors of this article and the planning committee members and staff have no 
      relevant financial relationships with commercial interests to disclose.
EDAT- 2020/12/12 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/12/11 17:10
PHST- 2020/01/25 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/12/11 17:10 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - 10.17533/udea.iee.v38n3e12 [doi]
PST - ppublish
SO  - Invest Educ Enferm. 2020 Oct;38(3). doi: 10.17533/udea.iee.v38n3e12.


PMID- 33306898
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 2216-0280 (Electronic)
IS  - 0120-5307 (Linking)
VI  - 38
IP  - 3
DP  - 2020 Oct
TI  - Changing Home: Experiences of the Indigenous when Receiving Care in Hospital.
LID - 10.17533/udea.iee.v38n3e08 [doi]
AB  - OBJECTIVES: To understand the meaning of the experience of the indigenous when
      receiving care in a low-complexity hospital. METHODS: Qualitative study with
      ethnographic approach conducted in a hospital of Antioquia, Colombia. The study
      had 12 indigenous participants who underwent semi-structured interviews.
      Observation was carried out in hospitalization wards, emergency, and outpatient
      services of the institution during 40 hours. The analysis process was performed
      descriptively. The methodological rigor was maintained by applying criteria of
      confirmability, credibility, transferability, and consistency. The study was
      approved by the Ethics Committee and authorized by the indigenous authorities to 
      enter the field. RESULTS: Five themes emerged: the context of caring for the
      indigenous, the need to consult the hospital, changes experienced by the
      indigenous in the hospital, experiences in relation with treatments, and
      relations established within the hospital. The meaning is constructed from a
      dichotomous perspective based on the favorable or unfavorable aspects of the
      situations and experiences, which for the indigenous is like "changing home".
      CONCLUSIONS: The meaning of the experience of receiving care in hospital for the 
      indigenous is constructed from the context in which they live and receive health 
      services, the changes they live in the dimension of space by virtue of their
      traveling from their vital space to another space that, due to their physical
      characteristics, results strange and different, even not healing. Upon the
      difficulties, the indigenous develop strategies and actions to overcome
      limitations, whether through adaptation and learning.
CI  - Copyright by the Universidad de Antioquia.
FAU - Rojas, Juan Guillermo
AU  - Rojas JG
AD  - Facultad de Enfermeria, Universidad de Antioquia, Colombia,
      guillermo.rojas@udea.edu.co.
FAU - Herrero, Raquel
AU  - Herrero R
AD  - Departamento de Enfermeria, Universidad de Granada, Spain, raquelherrero@ugr.es.
LA  - eng
PT  - Journal Article
PL  - Colombia
TA  - Invest Educ Enferm
JT  - Investigacion y educacion en enfermeria
JID - 9108180
SB  - IM
MH  - Adaptation, Psychological
MH  - Adult
MH  - Anthropology, Cultural
MH  - Attitude to Health/*ethnology
MH  - Colombia
MH  - Cultural Characteristics
MH  - Culturally Competent Care/*ethnology
MH  - Female
MH  - Health Services Accessibility
MH  - *Health Services, Indigenous
MH  - *Hospitalization
MH  - Humans
MH  - Indians, South American/*psychology
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Professional-Patient Relations
MH  - Qualitative Research
MH  - *Transcultural Nursing
MH  - Young Adult
PMC - PMC7885541
OTO - NOTNLM
OT  - anthropology
OT  - cultural
OT  - health of indigenous peoples
OT  - hospitalization
OT  - nursing care
OT  - transcultural nursing
COIS- The authors of this article and the planning committee members and staff have no 
      relevant financial relationships with commercial interests to disclose.
EDAT- 2020/12/12 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/12/11 17:10
PHST- 2020/08/02 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/12/11 17:10 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - 10.17533/udea.iee.v38n3e08 [doi]
PST - ppublish
SO  - Invest Educ Enferm. 2020 Oct;38(3). doi: 10.17533/udea.iee.v38n3e08.


PMID- 33306811
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Nov 30
TI  - An overview of and approach to selecting appropriate patient representations in
      teaching and summative assessment in medical education.
PG  - w20382
LID - 10.4414/smw.2020.20382 [doi]
LID - Swiss Med Wkly. 2020;150:w20382 [pii]
AB  - Medical education has a long tradition of using various patient representations
      in teaching and assessment. With this literature review we aim, first, to provide
      an overview of the most important patient representations used to teach and
      assess clinical skills, considering in particular &ldquo;summative exams&rdquo;
      that have a pass or fail outcome; second, to provide arguments for choosing
      certain patient representations; and third, to show the advantages and
      limitations of different patient representations, especially simulated patients
      (SPs) and real patients (RPs). Typical patient representations include case
      narratives, anatomical models, simulators and mannequins, as well as SPs and RPs.
      The literature indicates that there are multiple ways of using various patient
      representations in teaching and that the intended didactical purpose informs the 
      choice of representation. Early in the educational programme, even low-fidelity
      patient representations can be a good fit for assessment purposes if chosen to
      match the educational level. The use of RPs in summative, high-stakes assessments
      (exams with particularly important consequences for the examinee) is limited for 
      methodological and ethical reasons. The methodological implementation of
      summative exams also entails specific challenges, such as ensuring measurement
      reliability and fairness towards the examinees. Carefully prepared, SPs can
      perform their roles with a sufficient degree of authenticity, making summative
      exams more manageable, and imposing no strain or risk on RPs. The ongoing debate 
      concerning the use of SPs and RPs in summative assessment highlights perceived
      limitations of SPs in relation to RPs that are often not supported by research.
      Evidence shows that SPs, in combination with additional simulation modalities as 
      needed, represent the first choice for summative clinical assessment. We also
      consider the strengths and limitations of this review and reflect on the
      applicability of our findings. We conclude that in order to select the right
      patient representations in clinical teaching and/or assessment, a number of
      perspectives must be considered: (i) the learning goals, aligned with the stage
      of study, (ii) the corresponding requirements of the clinical task itself (e.g., 
      performing a phlebotomy or a communication task), (iii) the level of authenticity
      required and (iv) the resources needed, taking patient safety and feasibility
      into consideration.
FAU - Bauer, Daniel
AU  - Bauer D
AD  - Institute for Medical Education, University of Bern, Switzerland.
FAU - Lahner, Felicitas-Maria
AU  - Lahner FM
AD  - Department of Health Professions, Bern University of Applied Sciences,
      Switzerland.
FAU - Schmitz, Felix Michael
AU  - Schmitz FM
AD  - Institut fur Medizinische Lehre, Medizinische Fakultat Bern.
FAU - Guttormsen, Sissel
AU  - Guttormsen S
AD  - Institute for Medical Education, University of Bern, Switzerland.
FAU - Huwendiek, Soren
AU  - Huwendiek S
AD  - Institute for Medical Education, University of Bern, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201211
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - Clinical Competence
MH  - Communication
MH  - *Education, Medical
MH  - Educational Measurement
MH  - Humans
MH  - Learning
MH  - Reproducibility of Results
EDAT- 2020/12/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/12/11 17:09
PHST- 2020/12/11 17:09 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.4414/smw.2020.20382 [doi]
AID - Swiss Med Wkly. 2020;150:w20382 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Dec 11;150:w20382. doi: 10.4414/smw.2020.20382. eCollection 
      2020 Nov 30.


PMID- 33306728
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Development and validation of a clinical instrument to predict risk of an adverse
      drug reactions in hospitalized patients.
PG  - e0243714
LID - 10.1371/journal.pone.0243714 [doi]
AB  - OBJECTIVE: Development and internal validation of a clinical tool for assessment 
      of the risk of adverse drug reactions (ADR) in hospitalized patients.
      METHODOLOGY: Nested case-control study in an open cohort of all patients admitted
      to a general hospital. Cases of ADR were matched to two controls. Eighty four
      patient variables collected at the time of the ADR were analyzed by conditional
      logistic regression. Multivariate logistic regression with clustering of cases in
      a random sample of 2/3 of the cases and respective controls, with baseline
      odds-ratio corrected with an estimate of ADR incidence, was used to obtain
      regression coefficients for each risk factor and to develop a risk score. The
      clinical tool was validated in the remaining 1/3 observations. The study was
      approved by the institution's research ethics committee. RESULTS: In the 8060
      hospitalized patients, ADR occurred in 343 (5.31%), who were matched to 686
      controls. Fourteen variables were identified as independent risk factors of ADR: 
      female, past history of ADR, heart rate >/=72 bpm, systolic blood pressure>/=148 
      mmHg, diastolic blood pressure <79 mmHg, diabetes mellitus, serum urea >/= 67
      mg/dL, serum sodium >/=141 mmol/L, serum potassium >/=4.9 mmol/L, main diagnosis 
      of neoplasia, prescription of >/=3 ATC class B drugs, prescription of ATC class R
      drugs, prescription of intravenous drugs and >/= 6 oral drugs. In the validation 
      sample, the ADR risk tool based on those variables showed sensitivity 61%,
      specificity 73% and area under the ROC curve 0.73. CONCLUSION: We report a
      clinical tool for ADR risk stratification in patients hospitalized in general
      wards based on 14 variables.
FAU - Lima, Sara Iasmin Vieira Cunha
AU  - Lima SIVC
AUID- ORCID: 0000-0002-4127-7909
AD  - Graduate Program in Pharmaceutical Sciences, Health Sciences Center, Federal
      University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
FAU - Martins, Rand Randall
AU  - Martins RR
AD  - Pharmacy Department, Health Sciences Center, Federal University of Rio Grande do 
      Norte, Natal, Rio Grande do Norte, Brazil.
FAU - Saldanha, Valdjane
AU  - Saldanha V
AD  - Graduate Program in Pharmaceutical Sciences, Health Sciences Center, Federal
      University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
FAU - Silbiger, Vivian Nogueira
AU  - Silbiger VN
AD  - Department of Clinical and Toxicological Analysis, Health Sciences Center,
      Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
FAU - Dos Santos, Isabelle Cristina Clemente
AU  - Dos Santos ICC
AD  - Graduate Program in Pharmaceutical Sciences, Health Sciences Center, Federal
      University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
FAU - Araujo, Ivonete Batista de
AU  - Araujo IB
AD  - Pharmacy Department, Health Sciences Center, Federal University of Rio Grande do 
      Norte, Natal, Rio Grande do Norte, Brazil.
FAU - Oliveira, Antonio Gouveia
AU  - Oliveira AG
AD  - Graduate Program in Pharmaceutical Sciences, Health Sciences Center, Federal
      University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
AD  - Pharmacy Department, Health Sciences Center, Federal University of Rio Grande do 
      Norte, Natal, Rio Grande do Norte, Brazil.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20201211
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Prescription Drugs)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Drug Prescriptions/statistics & numerical data
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Patients' Rooms/statistics & numerical data
MH  - Prescription Drugs/*adverse effects
MH  - ROC Curve
MH  - Risk Assessment/methods
MH  - Risk Factors
PMC - PMC7732084
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/12 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/12/11 17:09
PHST- 2019/10/15 00:00 [received]
PHST- 2020/11/29 00:00 [accepted]
PHST- 2020/12/11 17:09 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1371/journal.pone.0243714 [doi]
AID - PONE-D-19-28832 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 11;15(12):e0243714. doi: 10.1371/journal.pone.0243714.
      eCollection 2020.


PMID- 33306325
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20211007
IS  - 1678-9741 (Electronic)
IS  - 0102-7638 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Dec 1
TI  - Heterotopic Heart Transplantation as a Left Ventricular Biological Assistance: a 
      New Two-Stage Method Proposal.
PG  - 986-989
LID - 10.21470/1678-9741-2020-0506 [doi]
AB  - Since Barnard's first heterotopic heart transplant in 1974, Copeland's method has
      been the greatest contribution to heterotopic transplants but has the drawback of
      donor's right ventricular atrophy. This new method proposes a modification in the
      anastomosis of the superior vena cava aiming to pre-serve donor's right
      ventricular function by decompressing the pulmonary territory and reducing the
      pulmonary arterial pressure, as a biological ventricular assist device. Finally, 
      a second intervention is proposed, where a "twist" is performed to place the
      donor's heart in an orthotopic position after re-moval of the native heart. A
      pioneering research on this method received approval from the ethics committee of
      the Heart Institute of Sao Paulo. We believe that this method has the potential
      to im-prove quality of life in a selected group of patients.
FAU - Gaiotto, Fabio Antonio
AU  - Gaiotto FA
AUID- ORCID: 0000-0002-1615-2557
AD  - Cardiovascular Surgery Division, Instituto do Coracao do Hospital das Clinicas da
      Faculdade de Medicina da Universidade de Sao Paulo (InCor-HCFMUSP), Sao Paulo,
      SP, Brazil.
AD  - Hospital Israelita Albert Einstein - Pavilhao Vick e Joseph Safra, Sao Paulo, SP,
      Brazil.
FAU - Barbosa, Antonio Carlos de Almeida Filho
AU  - Barbosa ACA Filho
AD  - Centro Universitario CESMAC, Maceio, AL, Brazil.
FAU - Tenorio, Davi Freitas
AU  - Tenorio DF
AD  - Cardiovascular Surgery Division, Instituto do Coracao do Hospital das Clinicas da
      Faculdade de Medicina da Universidade de Sao Paulo (InCor-HCFMUSP), Sao Paulo,
      SP, Brazil.
FAU - Steffen, Samuel Padovani
AU  - Steffen SP
AD  - Cardiovascular Surgery Division, Instituto do Coracao do Hospital das Clinicas da
      Faculdade de Medicina da Universidade de Sao Paulo (InCor-HCFMUSP), Sao Paulo,
      SP, Brazil.
FAU - Jatene, Fabio B
AU  - Jatene FB
AD  - Cardiovascular Surgery Division, Instituto do Coracao do Hospital das Clinicas da
      Faculdade de Medicina da Universidade de Sao Paulo (InCor-HCFMUSP), Sao Paulo,
      SP, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20201201
PL  - Brazil
TA  - Braz J Cardiovasc Surg
JT  - Brazilian journal of cardiovascular surgery
JID - 101677045
SB  - IM
CIN - Braz J Cardiovasc Surg. 2021 Jun 01;36(3):436-438. PMID: 34387980
CIN - Braz J Cardiovasc Surg. 2021 Jun 01;36(3):439-440. PMID: 34387981
MH  - *Heart Transplantation
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Quality of Life
MH  - Transplantation, Heterotopic
MH  - Vena Cava, Superior
PMC - PMC7731838
OTO - NOTNLM
OT  - *Atrophy
OT  - *Ethics Committees
OT  - *Heart Transplantation
OT  - *Heart-Assist Devices
OT  - *Quality of Life
OT  - *Vena Cava, Superior
OT  - *Ventricular Functional, Right
EDAT- 2020/12/12 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/12/11 14:22
PHST- 2020/12/11 14:22 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - 10.21470/1678-9741-2020-0506 [doi]
PST - epublish
SO  - Braz J Cardiovasc Surg. 2020 Dec 1;35(6):986-989. doi:
      10.21470/1678-9741-2020-0506.


PMID- 33306065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201215
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - Comparison of cerclage and pessary in prevention of preterm birth in twin
      pregnancies.
PG  - 74
LID - 10.34171/mjiri.34.74 [doi]
AB  - Background: The preterm labor has increased in multiple pregnancies over the past
      2 decades. Preterm labor has led to increase in neonatal mortality rates,
      long-term morbidity, respiratory distress, and neonatal infections. Thus, this
      study aimed at investigating the effect of cerclage versus pessary on the
      prevention of preterm birth in twin pregnancies. Methods: This prospective
      randomized clinical trial was performed on 50 women pregnant with twins who
      visited Taleghani hospital in 2016-2018. Their cervical length, which was
      measured by transvaginal ultrasonography (TVS), was less than 30 millimeters at
      week 14 of pregnancy. The participants were randomly divided into 2 groups
      (n=25). They separately underwent cervical pessary and cerclage. McDonald's
      procedure was performed in cerclage group from 14 to 27 weeks. The suture
      material was Mersilene Ethicon 5-0 double-armed s14 needle. Ring hodge pessary
      was also inserted in the vagina of the participants in the pessary group. All the
      patients were injected 250 mg intramuscular 17 alpha-hydroxyprogesterone caproate
      weekly from week 16 to week 36. All statistical analyses were performed using
      SPSS 18 software. Results: The results of this study showed that the mean +/-
      standard deviation (SD) for pregnancy length of the cerclage and pessary groups
      were 238.6+/-32.4 and 223.6+/-16.6, respectively. Also, significant differences
      were found between the 2 groups (p=0.048). No significant difference was found in
      pregnancy (p=0.565), length of pessary/cerclage use (p=0.491), and BMI before and
      after delivery between the cerclage and pessary groups (p>0.05). Conclusion: The 
      use of cerclage in twin pregnancies is recommended to increase the length of
      pregnancy.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Hajizadeh, Nazanin
AU  - Hajizadeh N
AD  - Preventation Gynecology Research Center, Imam Hossein Hospital, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Saharkhiz, Nasrin
AU  - Saharkhiz N
AUID- ORCID: https://orcid.org/0000-0002-7943-0526
AD  - Preventation Gynecology Research Center, Imam Hossein Hospital, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Hosseini, Sedigheh
AU  - Hosseini S
AD  - Preventation Gynecology Research Center, Imam Hossein Hospital, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Arabzadeh, Behnam
AU  - Arabzadeh B
AD  - Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences,
      Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7711049
OTO - NOTNLM
OT  - Cerclage
OT  - Pessary
OT  - Twin pregnancy
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 12:07
PHST- 2019/03/24 00:00 [received]
PHST- 2020/12/11 12:07 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.34171/mjiri.34.74 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 Jul 6;34:74. doi: 10.34171/mjiri.34.74. eCollection 
      2020.


PMID- 33306057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201215
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - Assessment of psychiatrists' approaches regarding disclosure of psychiatric
      disorders to their patients: a qualitative study.
PG  - 82
LID - 10.34171/mjiri.34.82 [doi]
AB  - Background: Diagnosis disclosure is the result of a shift in medical approaches
      from traditional paternalism to participatory and patient-centered decision
      making. Disclosure of psychiatric diagnosis remained uncommon and controversial. 
      Giving information about psychiatric illnesses is very complicated, and it is
      affected by several factors. While clinical guidelines provide a clear pathway
      for treating patients, in practice, the treatment of patients is influenced by
      cultural and social factors. The aim of the current study was a qualitative
      assessment of psychiatrists' approaches regarding the disclosure of psychiatric
      disorders to their patients. Methods: The current study was conducted with a
      qualitative approach. The participants were purposefully selected psychiatrists
      from three medical universities in Tehran, Iran. The data gathered using the
      semi-structured interview method. Sixteen interviews with 14 psychiatrists were
      conducted. Data were analyzed using thematic analysis. Results: Psychiatrists
      decide to disclose the diagnosis based on several factors. We summarized these
      factors in a central theme, passive situational decision making based on
      paternalism and displacement of responsibility. It has two subthemes, including
      "passive and situational decision making" and "paternalism and displacement of
      responsibility." Each theme presented by detailed quotations. Conclusion: The
      results of this study showed that psychiatrists did not actively disclose the
      diagnosis name to patients. Diagnosis disclosure was influenced by several
      factors, such as the certainty about the diagnosis and the severity of the
      disease. This passive approach does not respect the patient's rights. The
      paternalistic nature of this approach mandates psychiatrists to consider
      themselves as the responsible perosn for their patients' welfare.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Amidi Naeini, Anahita
AU  - Amidi Naeini A
AD  - Medical School, Iran University of Medical Sciences, Tehran, Iran.
FAU - Ranjbar, Hadi
AU  - Ranjbar H
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran.
FAU - Mohammadsadeghi, Homa
AU  - Mohammadsadeghi H
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran.
FAU - Alavi, Kaveh
AU  - Alavi K
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran.
FAU - Ahmadkhaniha, Hamidreza
AU  - Ahmadkhaniha H
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran.
FAU - Rasoulian, Maryam
AU  - Rasoulian M
AUID- ORCID: https://orcid.org/0000-0002-4080-5650
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7711037
OTO - NOTNLM
OT  - Diagnosis
OT  - Disclosure
OT  - Medical ethics
OT  - Mental health
OT  - Psychiatrists
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 12:07
PHST- 2019/01/19 00:00 [received]
PHST- 2020/12/11 12:07 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.34171/mjiri.34.82 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 Jul 20;34:82. doi: 10.34171/mjiri.34.82. eCollection
      2020.


PMID- 33306052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201215
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - Ethical considerations and interdisciplinary approach to research on COVID-19
      pandemic: The response of Iran University of Medical Sciences.
PG  - 87
LID - 10.34171/mjiri.34.87 [doi]
AB  - Background: Research ethics committees are comprised of policymakers,
      supervisors, and decision-makers and aim at increasing adherence to professional 
      ethics standards in conducting health-related research. The existential
      philosophy of these committees is to preserve the patients' health, maintain and 
      promote public trust in health care providers, protect the rights of both
      patients and health care providers, and promote organizational ethics. However,
      this task can be complex and challenging during a public health emergency.
      Research ethics committees set the standard of research in the emergency
      situations through defining which research has the potential to promote the
      quality of response to a public health emergency. Methods: This study aims at
      collecting and classifying the valuable experiences of the research ethics
      committee members and reviewers during the early days of the COVID-19 epidemic in
      Iran University of Medical Sciences, one of the major universities in Tehran. It 
      provides a basic understanding of the key concepts and challenges in reviewing
      and approving research by research ethics committees and the recommendations to
      overcome these challenging issues. Results: To accelerate the review process of
      COVID-19 research proposals, the scientific, methodological and ethical review
      panel was integrated as a large committee called 'IUMS Corona Research Team'. The
      first meeting was held on March 7, two weeks after the official announcement of
      the first case of the disease and is continued once a week. A total of 130
      projects have been discussed and evaluated in this committee, among which 83
      proposals were approved after modification. Conclusion: An interdisciplinary
      approach supports a flexible and effective scientific and ethical review of
      research leading to more protection of research subjects as well as promotion in 
      the treatment and management of the pandemic ahead.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Hashemi, Akram
AU  - Hashemi A
AD  - Department of Medical Ethics, School of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Bahmani, Fatemeh
AU  - Bahmani F
AD  - Department of Medical Ethics, School of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Saeedi Tehrani, Saeedeh
AU  - Saeedi Tehrani S
AD  - Department of Medical Ethics, School of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Forouzandeh, Mina
AU  - Forouzandeh M
AD  - Department of Medical Ethics, School of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Koohpayehzadeh, Jalil
AU  - Koohpayehzadeh J
AD  - Community Medicine Department, Faculty of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Ashrafi, Mortaza
AU  - Ashrafi M
AD  - Department of Medical Ethics, School of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Khalajzadeh, Majid Reza
AU  - Khalajzadeh MR
AD  - Department of Medical Ethics, School of Medicine, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Motevalian, Seyed Abbas
AU  - Motevalian SA
AUID- ORCID: https://orcid.org/0000-0002-0404-4495
AD  - Research Center for Addiction and Risky Behaviors (ReCARB), Psychosocial Health
      Research Institute (PHRI), Iran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7711043
OTO - NOTNLM
OT  - COVID-19
OT  - Pandemic
OT  - Research ethics committee
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 12:07
PHST- 2020/06/04 00:00 [received]
PHST- 2020/12/11 12:07 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.34171/mjiri.34.87 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 Jul 29;34:87. doi: 10.34171/mjiri.34.87. eCollection
      2020.


PMID- 33306031
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201230
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 11
TI  - Feasibility and Effect of the Exergame BOOSTH Introduced to Improve Physical
      Activity and Health in Children: Protocol for a Randomized Controlled Trial.
PG  - e24035
LID - 10.2196/24035 [doi]
AB  - BACKGROUND: Despite the well-known beneficial health effects of physical activity
      (PA), the majority of Dutch primary school children do not meet the recommended
      PA guidelines. Although there is growing evidence on the effectiveness of
      exergames for PA in children, there is limited evidence on their effect on health
      outcomes, such as cardiovascular health and health-related quality of life
      (HRQOL), and on factors influencing their effectiveness and feasibility. The
      exergame BOOSTH uses a wrist-worn activity tracker to measure steps per day. As a
      reward for the performed PA, children can unlock levels in the online BOOSTH
      game. In addition, "BOOSTH battle" enables competition between groups. OBJECTIVE:
      This protocol describes a cluster randomized controlled trial in 16 primary
      schools in the Netherlands investigating the effect of BOOSTH on
      moderate-to-vigorous PA (MVPA) using accelerometry. Secondary aims are to
      investigate the feasibility of BOOSTH (mixed methods: questionnaires and focus
      group interviews) and its effect on cardiovascular risk factors (anthropometrics,
      blood pressure, and retinal microvasculature) and HRQOL. METHODS: Stratification 
      variables and relevant variables related to outcomes (such as BMI [z-score], sex,
      age, and parenting style) and/or missingness will be taken into account.
      Measurements will be performed at baseline and after 3, 6, and 12 months.
      RESULTS: The study has received funding from Province Limburg (SAS-2015-04956)
      and received ethical approval from the Medical Ethics Committee of Maastricht
      University Medical Centre (METC172043/NL64324.068.17). The results of the
      analyses are expected to be published in 2021. CONCLUSIONS: With this study, the 
      ability of the exergame BOOSTH to increase PA and improve health in children of
      primary school age will be investigated. The insights into effectiveness and
      feasibility will result in scientific and societal recommendations, which could
      potentially contribute to widespread implementation of exergames for children.
      TRIAL REGISTRATION: ClinicalTrials.gov NCT03440580;
      https://clinicaltrials.gov/ct2/show/NCT03440580. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/24035.
CI  - (c)Gabrielle ten Velde, Guy Plasqui, Maartje Willeboordse, Bjorn Winkens, Anita
      Vreugdenhil. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 11.12.2020.
FAU - Ten Velde, Gabrielle
AU  - Ten Velde G
AUID- ORCID: https://orcid.org/0000-0001-6389-6762
AD  - Department of Nutrition and Movement Sciences, Maastricht University Medical
      Centre, Maastricht, Netherlands.
FAU - Plasqui, Guy
AU  - Plasqui G
AUID- ORCID: https://orcid.org/0000-0003-4629-6479
AD  - Maastricht University, Maastricht, Netherlands.
FAU - Willeboordse, Maartje
AU  - Willeboordse M
AUID- ORCID: https://orcid.org/0000-0002-9695-9755
AD  - Maastricht University, Maastricht, Netherlands.
FAU - Winkens, Bjorn
AU  - Winkens B
AUID- ORCID: https://orcid.org/0000-0002-6747-6228
AD  - Maastricht University, Maastricht, Netherlands.
FAU - Vreugdenhil, Anita
AU  - Vreugdenhil A
AUID- ORCID: https://orcid.org/0000-0003-1499-5937
AD  - Department of Nutrition and Movement Sciences, Maastricht University Medical
      Centre, Maastricht, Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03440580
PT  - Journal Article
DEP - 20201211
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7762686
OTO - NOTNLM
OT  - exercise
OT  - exergame
OT  - mHealth
OT  - mobile health
OT  - prevention
OT  - pupil
OT  - randomized controlled trial
OT  - sedentary lifestyle
OT  - serious game
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 12:07
PHST- 2020/09/01 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/12/11 12:07 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - v9i12e24035 [pii]
AID - 10.2196/24035 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 11;9(12):e24035. doi: 10.2196/24035.


PMID- 33305066
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 20
DP  - 2020 Dec
TI  - Prescribing laughter to ameliorate mental health, sleep, and wellbeing in
      university students: A protocol for a feasibility study of a randomised
      controlled trial.
PG  - 100676
LID - 10.1016/j.conctc.2020.100676 [doi]
AB  - OBJECTIVES: This research is the first study to investigate the potential effects
      of a laughter prescription on both psychological health and objective sleep
      parameters in university students. The primary objective is to evaluate the
      feasibility of prescribing laughter to inform a larger randomised controlled
      trial. Secondary objectives are to assess if a two-week laughter prescription
      improves subjective and objective sleep outcomes, wellbeing, and/or psychological
      health outcomes. TRIAL DESIGN: To assess the feasibility of a randomised
      controlled trial for laughter prescription in relation to sleep, psychological
      health, and wellbeing. Forty university students will be recruited and randomised
      to one of two conditions (control/experimental). METHODS: Wrist actigraphy and
      sleep diaries will be used to estimate sleep outcomes during a one-week baseline 
      testing phase and across the two-week intervention. The experimental group will
      be shown how to record a Laughie (a 1-min recording of their joyful laughter on
      their smartphone) and prescribed to laugh with it three times daily for 14 days
      (the control group will only track sleep). All participants will complete the WHO
      (Five) Well-being Index, and Hospital Anxiety and Depression Scale pre- and
      post-intervention. The CONSORT checklist, and the Feasibility, Reach-out,
      Acceptability, Maintenance, Efficacy, Implementation, and Tailorabilty (FRAME-IT)
      framework will guide intervention planning and evaluation. Participant interviews
      will be analysed using Differential Qualitative Analysis (DQA). RESULTS: The
      feasibility of a two-week laughter prescription in university students and its
      impact on sleep, wellbeing, and/or psychological health outcomes will be
      assessed. CONCLUSIONS: Zayed University Research Ethics Committee approved the
      study in July 2019. The research will be completed following protocol
      publication. TRIAL REGISTRATION: ClinicalTrials.gov. ID: NCT04171245. Date of
      registration: 18 October 2019.
CI  - (c) 2020 Published by Elsevier Inc.
FAU - Gonot-Schoupinsky, Freda N
AU  - Gonot-Schoupinsky FN
AD  - University of Derby Online Learning, University of Derby, Enterprise Centre,
      Bridge Street, Derby, DE1 3LD, United Kingdom.
FAU - Garip, Gulcan
AU  - Garip G
AD  - University of Derby Online Learning, University of Derby, Enterprise Centre,
      Bridge Street, Derby, DE1 3LD, United Kingdom.
FAU - Sheffield, David
AU  - Sheffield D
AD  - University of Derby Online Learning, University of Derby, Enterprise Centre,
      Bridge Street, Derby, DE1 3LD, United Kingdom.
FAU - Omar, Omar M
AU  - Omar OM
AD  - Birmingham Clinical Trials Unit, College of Medical and Dental Sciences,
      University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
FAU - Arora, Teresa
AU  - Arora T
AD  - Zayed University, College of Natural & Health Sciences, Department of Psychology,
      Abu Dhabi, PO Box 144534, United Arab Emirates.
LA  - eng
SI  - ClinicalTrials.gov/NCT04171245
PT  - Journal Article
DEP - 20201126
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7711131
OTO - NOTNLM
OT  - ANCOVA, Analysis of Covariance
OT  - BPSE-B, Biological
OT  - CBT, Cognitive Behavioural Therapy
OT  - DQA, Differential Qualitative Analysis
OT  - Environmental, and Behavioural
OT  - FRAME-IT, Feasibility
OT  - Feasibility study
OT  - HADS, Hospital Anxiety Depression Scale
OT  - IQR, Interquartile Range
OT  - ITT, Intention To Treat
OT  - Implementation, Tailorability
OT  - Laughter prescription
OT  - Maintenance, Efficacy
OT  - PI, Principal Investigator
OT  - PSG, Polysomnography
OT  - PSQI, Pittsburgh Sleep Quality Index
OT  - Psychological health
OT  - Psychological, Social and socio-economic
OT  - RCT, Randomised Controlled Trial
OT  - Randomised controlled trial
OT  - Reach-out, Acceptability
OT  - SE, Sleep Efficiency
OT  - SOL, Sleep Onset Latency
OT  - Sleep
OT  - TST, Total Sleep Time
OT  - UAE, United Arab Emirates
OT  - University students
OT  - WASO, Wake After Sleep Onset
OT  - WHO, World Health Organization
OT  - Wellbeing
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:05
PHST- 2020/08/03 00:00 [received]
PHST- 2020/11/01 00:00 [revised]
PHST- 2020/11/22 00:00 [accepted]
PHST- 2020/12/11 06:05 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.1016/j.conctc.2020.100676 [doi]
AID - S2451-8654(20)30160-5 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Nov 26;20:100676. doi:
      10.1016/j.conctc.2020.100676. eCollection 2020 Dec.


PMID- 33304841
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 2215-017X (Print)
IS  - 2215-017X (Linking)
VI  - 28
DP  - 2020 Dec
TI  - Safety and bioactive potential of nanoparticles containing Cantaloupe melon
      (Cucumis melo L.) carotenoids in an experimental model of chronic inflammation.
PG  - e00567
LID - 10.1016/j.btre.2020.e00567 [doi]
AB  - The safety and bioactive potential of crude carotenoid extract from Cantaloupe
      melon nanoencapsulated in porcine gelatin (EPG) were evaluated in a chronic
      inflammatory experimental model. Animals were fed a high glycemic index and high 
      glycemic load (HGLI) diet for 17 weeks and treated for ten days with 1) HGLI
      diet, 2) standard diet, 3) HGLI diet+crude carotenoid extract (CE) (12.5mg/kg),
      and 4) HGLI diet+EPG (50mg/kg). General toxicity signals were investigated,
      considering body weight, food intake, hematological, biochemical parameters,
      relative weight, morphology, and histopathology of organs. The biochemical
      parameters indicated the low toxicity of EPG. Acute hepatitis was observed in
      animals' livers, but CE and EPG groups presented improved tissue appearance.
      Chronic enteritis was observed in animals, with villi and intestinal glands
      preservation in the EPG group. The results suggest the safety and the bioactive
      effect of EPG, possibly related to its anti-inflammatory potential.
CI  - (c) 2020 The Authors.
FAU - Medeiros, Isaiane
AU  - Medeiros I
AD  - Postgraduate Program in Nutrition, Health Sciences Center, Federal University of 
      Rio Grande do Norte, Natal, Brazil.
FAU - de Oliveira, Grazielle Louise Ribeiro
AU  - de Oliveira GLR
AD  - Postgraduate Program in Nutrition, Health Sciences Center, Federal University of 
      Rio Grande do Norte, Natal, Brazil.
FAU - de Queiroz, Jaluza Luana Carvalho
AU  - de Queiroz JLC
AD  - Postgraduate Program in Biochemistry, Center for Biosciences, Federal University 
      of Rio Grande do Norte, Natal, Brazil.
FAU - de Carvalho Gomes, Camila
AU  - de Carvalho Gomes C
AD  - Postgraduate Program in Biochemistry, Center for Biosciences, Federal University 
      of Rio Grande do Norte, Natal, Brazil.
FAU - de Carvalho, Fabiana Maria Coimbra
AU  - de Carvalho FMC
AD  - Postgraduate Program in Biochemistry, Center for Biosciences, Federal University 
      of Rio Grande do Norte, Natal, Brazil.
AD  - Nutrition Course, Potiguar University, Natal, Brazil.
FAU - de Souza Lima, Maira Conceicao Jeronimo
AU  - de Souza Lima MCJ
AD  - Veterinary Medicine Course, Potiguar University, Natal, Brazil.
FAU - Serquiz, Alexandre Coelho
AU  - Serquiz AC
AD  - Nutrition Course, University Center of Rio Grande do Norte, Natal, Brazil.
FAU - de Andrade Santos, Pedro Paulo
AU  - de Andrade Santos PP
AD  - Postgraduate Program in Structural and Functional Biology, Center for
      Biosciences, Federal University of Rio Grande do Norte, Natal, Brazil.
AD  - Department of Morphology, Center for Biosciences, Federal University of Rio
      Grande do Norte, Natal, Brazil.
FAU - da Silva Camillo, Christina
AU  - da Silva Camillo C
AD  - Postgraduate Program in Structural and Functional Biology, Center for
      Biosciences, Federal University of Rio Grande do Norte, Natal, Brazil.
AD  - Department of Morphology, Center for Biosciences, Federal University of Rio
      Grande do Norte, Natal, Brazil.
FAU - Maciel, Bruna Leal Lima
AU  - Maciel BLL
AD  - Postgraduate Program in Nutrition, Health Sciences Center, Federal University of 
      Rio Grande do Norte, Natal, Brazil.
AD  - Department of Nutrition, Health Sciences Center, Federal University of Rio Grande
      do Norte, Natal, Brazil.
FAU - de Araujo Morais, Ana Heloneida
AU  - de Araujo Morais AH
AD  - Postgraduate Program in Nutrition, Health Sciences Center, Federal University of 
      Rio Grande do Norte, Natal, Brazil.
FAU - Passos, Thais Souza
AU  - Passos TS
AD  - Department of Nutrition, Health Sciences Center, Federal University of Rio Grande
      do Norte, Natal, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20201121
PL  - Netherlands
TA  - Biotechnol Rep (Amst)
JT  - Biotechnology reports (Amsterdam, Netherlands)
JID - 101637426
PMC - PMC7714681
OTO - NOTNLM
OT  - ALP, alkaline phosphatase
OT  - ALT, alanine aminotransferase
OT  - AST, aspartate transferase
OT  - BSD, Bowman's space dilation
OT  - CE, crude carotenoid extract
OT  - CEUA, Ethics Committee on the Use of Animals
OT  - Curcubitaceae
OT  - EI, efficiency of incorporation
OT  - EPG, crude carotenoid extract from Cantaloupe melon nanoencapsulated in porcine
      gelatin
OT  - FTIR, Fourier Transform Infrared Spectroscopy
OT  - GGT, gamma-glutamyl transferase
OT  - HGLI, high glycemic index and high glycemic load
OT  - IIF, inflammatory infiltrate foci
OT  - Nanotechnology
OT  - OECD, Organization for Economic Co-operation and Development
OT  - Obesity
OT  - PHT, presence of hypertrophic tubules
OT  - PIGI, percentage of intestinal gland integrity
OT  - PUV, percentage of ulcerated villi
OT  - PVA, percentage of villous absence
OT  - PVI, percentage of villus integrity
OT  - PVN, percentage of villous necrosis
OT  - SEM, Scanning Electron Microscope
OT  - THC, tubular hyaline cylinders
OT  - Toxicity
OT  - beta-carotene
COIS- The authors report no declarations of interest.
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:04
PHST- 2020/09/26 00:00 [received]
PHST- 2020/11/19 00:00 [revised]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/11 06:04 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.1016/j.btre.2020.e00567 [doi]
AID - S2215-017X(20)30829-8 [pii]
PST - epublish
SO  - Biotechnol Rep (Amst). 2020 Nov 21;28:e00567. doi: 10.1016/j.btre.2020.e00567.
      eCollection 2020 Dec.


PMID- 33304302
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - No Cutting Corners: The Effect of Parental Involvement on Youth Basketball
      Players in Israel.
PG  - 607000
LID - 10.3389/fpsyg.2020.607000 [doi]
AB  - This paper explores the nature of parental involvement in youth basketball in
      Israel with regard to parenting style and in the context of dilemmas and ethical 
      issues. It is well established that parental involvement in their child's
      sporting activity has vast implications on the child's motivation and enjoyment. 
      With reference to Israeli society, only a few studies have focused on this
      subject. In order to address this lacuna, we used two questionnaires, given to
      173 youth basketball players (child questionnaire) and their parents (parent
      questionnaire). Key findings illustrate three main themes. First, a higher level 
      of satisfaction and contentment among basketball players whose parents
      demonstrated greater involvement; second, that parental emotional involvement is 
      the most important variable for young athletes' satisfaction; and finally,
      differences in gender roles reveal that fathers are more involved with logistics,
      while mothers are more dominant in emotional involvement. Moreover, the findings 
      demonstrate that parents should mainly place emphasis on emotional involvement.
      However, we suggest that parents do not bypass logistical care as this may create
      opportunities for greater emotional support and therefore greater child
      satisfaction.
CI  - Copyright (c) 2020 Lev, Bichman, Moyal, Brenner, Fass and Been.
FAU - Lev, Assaf
AU  - Lev A
AD  - Department of Sports Therapy, Faculty of Health Professions, Ono Academic
      College, Kiryat Ono, Tel Aviv-Yafo, Israel.
FAU - Bichman, Adi
AU  - Bichman A
AD  - School of Education, Ono Academic College, Kiryat Ono, Israel.
FAU - Moyal, Avi
AU  - Moyal A
AD  - School of Education, Ono Academic College, Kiryat Ono, Israel.
FAU - Brenner, Shmulik
AU  - Brenner S
AD  - School of Education, Ono Academic College, Kiryat Ono, Israel.
FAU - Fass, Nir
AU  - Fass N
AD  - School of Education, Ono Academic College, Kiryat Ono, Israel.
FAU - Been, Ella
AU  - Been E
AD  - Department of Sports Therapy, Faculty of Health Professions, Ono Academic
      College, Kiryat Ono, Tel Aviv-Yafo, Israel.
AD  - Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv
      University, Israel.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7701243
OTO - NOTNLM
OT  - basketball
OT  - child's satisfaction
OT  - competitive sports
OT  - parent-child relationship
OT  - questionnaires
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:02
PHST- 2020/09/16 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/12/11 06:02 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.3389/fpsyg.2020.607000 [doi]
PST - epublish
SO  - Front Psychol. 2020 Nov 16;11:607000. doi: 10.3389/fpsyg.2020.607000. eCollection
      2020.


PMID- 33304296
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Corruption, Fast or Slow? Ethical Leadership Interacts With Machiavellianism to
      Influence Intuitive Thinking and Corruption.
PG  - 578419
LID - 10.3389/fpsyg.2020.578419 [doi]
AB  - Ethical leadership has been suggested as an organizational factor that could
      reduce unethical behaviors in an organization. We extend this research by
      examining how and when ethical leadership could reduce followers' corruption. We 
      examined the moderating role of followers' Machiavellianism and the mediating
      role of intuitive thinking style in the negative effect of ethical leadership on 
      corruption. Across two different studies (field study and experiment), we found
      that ethical leadership decreases followers' corruption (Studies 1 and 2) and
      that this negative effect is mediated by followers' intuitive thinking style
      (Study 2). Furthermore, followers' Machiavellianism moderated the direct negative
      effect of ethical leadership on corruption. However, the pattern of this
      moderation was not consistent. In Study 1, we found that ethical leadership has
      the strongest direct negative impact on corruption when followers'
      Machiavellianism is high, whereas in Study 2, we found that ethical leadership
      has the strongest direct negative effect on corruption when followers'
      Machiavellianism is low. The theoretical implications for corruption, ethical
      leadership, and information processing research, as well as practical
      implications for corruption prevention, will be discussed.
CI  - Copyright (c) 2020 Manara, van Gils, Nubold and Zijlstra.
FAU - Manara, Muhammad U
AU  - Manara MU
AD  - Department of Work and Social Psychology, Maastricht University, Maastricht,
      Netherlands.
AD  - Faculty of Psychology, University of Merdeka Malang, Malang, Indonesia.
FAU - van Gils, Suzanne
AU  - van Gils S
AD  - Department of Communication and Culture, BI Norwegian Business School, Oslo,
      Norway.
FAU - Nubold, Annika
AU  - Nubold A
AD  - Department of Work and Social Psychology, Maastricht University, Maastricht,
      Netherlands.
FAU - Zijlstra, Fred R H
AU  - Zijlstra FRH
AD  - Department of Work and Social Psychology, Maastricht University, Maastricht,
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7693446
OTO - NOTNLM
OT  - Machiavellianism
OT  - corruption
OT  - ethical leadership
OT  - experiment
OT  - intuitive thinking style
OT  - survey
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:02
PHST- 2020/06/30 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/11 06:02 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.3389/fpsyg.2020.578419 [doi]
PST - epublish
SO  - Front Psychol. 2020 Nov 13;11:578419. doi: 10.3389/fpsyg.2020.578419. eCollection
      2020.


PMID- 33304245
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1662-5129 (Print)
IS  - 1662-5129 (Linking)
VI  - 14
DP  - 2020
TI  - Brain Waste: The Neglect of Animal Brains.
PG  - 573934
LID - 10.3389/fnana.2020.573934 [doi]
FAU - Cozzi, Bruno
AU  - Cozzi B
AD  - Department of Comparative Biomedicine and Food Science, University of Padova,
      Padova, Italy.
FAU - Bonfanti, Luca
AU  - Bonfanti L
AD  - Department of Veterinary Sciences, University of Torino, Torino, Italy.
AD  - Neuroscience Institute Cavalieri Ottolenghi, Orbassano, Italy.
FAU - Canali, Elisabetta
AU  - Canali E
AD  - Department of Veterinary Medicine, University of Milan, Milan, Italy.
FAU - Minero, Michela
AU  - Minero M
AD  - Department of Veterinary Medicine, University of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - Switzerland
TA  - Front Neuroanat
JT  - Frontiers in neuroanatomy
JID - 101477943
PMC - PMC7693423
OTO - NOTNLM
OT  - animal cognition
OT  - comparative neuroscience
OT  - farm mammals
OT  - neuro-ethics
OT  - translational studies
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:01
PHST- 2020/06/18 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/12/11 06:01 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.3389/fnana.2020.573934 [doi]
PST - epublish
SO  - Front Neuroanat. 2020 Nov 12;14:573934. doi: 10.3389/fnana.2020.573934.
      eCollection 2020.


PMID- 33304069
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0974-2700 (Print)
IS  - 0974-2700 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Jul-Sep
TI  - Local Tranexamic Acid for Local Hemostasis in an Animal Liver Injury Model.
PG  - 196-200
LID - 10.4103/JETS.JETS_17_19 [doi]
AB  - BACKGROUND: Hyperfibrinolysis is a state of increased clot resolution often seen 
      in trauma patients with ongoing hemorrhage. Tranexamic acid (TXA) inhibits
      fibrinolysis preventing clot resolution affecting hemorrhage continuation and is 
      used by intravenous administration. AIMS: The purpose of this study was to
      evaluate the local tranexamic acid application for hemostatic control in an
      experimental animal liver injury model. SETTINGS AND DESIGN: This study was an
      experimental prospective treatment study to check the local TXA effects on liver 
      injury. This study was approved by the Ethics Committee. MATERIALS AND METHODS:
      Twenty adult male Sprague-Dawley white rats were equally randomized to two groups
      after a standardized liver injury was conducted under anesthesia. One group were 
      "liver-packed" with gauze (TXA [-]) and the other group with gauze soaked in TXA 
      (TXA [+]). Bleeding from the injured middle liver lobe was measured at 2 and 15
      min, and at 48h second-look surgery, with euthanasia conducted at 14 days. The
      liver was sent for histopathological and stereological analysis. STATISTICAL
      ANALYSIS AND RESULTS: There was no difference in bleeding at 2 or 15 min after
      packing; however, larger amount of free blood at 48 h in the TXA (-) group was
      noticed. Five animals in the TXA (-) were alive at 14 days compared to eight
      animals in the TXA (+) group. Significantly larger volume density of fibrosis,
      granulation tissue, and amorphous tissue were seen in the TXA (+) group compared 
      to the TXA (-) group at the stereological analysis. CONCLUSION: Local TXA
      application on the injured liver surface might offer better hemostatic control
      than packing alone. Further studies are mandated before the clinical application 
      of our findings.
CI  - Copyright: (c) 2020 Journal of Emergencies, Trauma, and Shock.
FAU - Paydar, Shahram
AU  - Paydar S
AD  - Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University
      of Medical Sciences, Shiraz, Iran.
FAU - Karami, Mohammad Yasin
AU  - Karami MY
AD  - Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University
      of Medical Sciences, Shiraz, Iran.
FAU - Nezhad, Golnoush Sadat Mahmoudi
AU  - Nezhad GSM
AD  - Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University
      of Medical Sciences, Shiraz, Iran.
FAU - Rezaei, Rouhollah
AU  - Rezaei R
AD  - Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University
      of Medical Sciences, Shiraz, Iran.
FAU - Makarem, Alireza
AU  - Makarem A
AD  - Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Noorafshan, Ali
AU  - Noorafshan A
AD  - Department of Anatomy, School of Medicine, Shiraz University of Medical Sciences,
      Shiraz, Iran.
FAU - Mohseni, Shahin
AU  - Mohseni S
AD  - Department of Surgery, Division of Trauma and Emergency Surgery, Orebro
      University Hospital and Orebro University, Orebro, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - India
TA  - J Emerg Trauma Shock
JT  - Journal of emergencies, trauma, and shock
JID - 101493921
PMC - PMC7717464
OTO - NOTNLM
OT  - Liver injury
OT  - local hemostasis
OT  - tranexamic acid
COIS- There are no conflicts of interest.
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:01
PHST- 2019/01/29 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2020/12/11 06:01 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.4103/JETS.JETS_17_19 [doi]
AID - JETS-13-196 [pii]
PST - ppublish
SO  - J Emerg Trauma Shock. 2020 Jul-Sep;13(3):196-200. doi: 10.4103/JETS.JETS_17_19.
      Epub 2020 Sep 18.


PMID- 33304063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 0974-0333 (Print)
IS  - 0974-0333 (Linking)
VI  - 14
IP  - 2
DP  - 2020 May-Aug
TI  - Patient Centricity and the Ethics of Glaucoma Care.
PG  - 68-71
LID - 10.5005/jp-journals-10078-1281 [doi]
AB  - The ultimate goal of glaucoma therapy, as of any other therapeutic intervention, 
      is to achieve superior clinical outcomes, patient satisfaction, and patient
      adherence to treatment. In a chronic asymptomatic disease, such as, glaucoma,
      where diagnostic and therapeutic algorithms may have multiple acceptable
      treatment arms, patient centricity becomes increasingly important. Shared
      decision-making, patient participation, quality of life (QoL) concerns, and
      risk-benefit analyzes further complicate this decision-making. In addition, the
      ethics of research in glaucoma and also that of glaucoma screening may often be
      in conflict with the ethics of patient care. This article aims to highlight the
      ethical dilemmas that confound decision-making in current glaucoma practice, and 
      the doctors' fiduciary duties to the patient. How to cite this article: Bhartiya 
      S. Patient Centricity and the Ethics of Glaucoma Care. J Curr Glaucoma Pract
      2020;14(2):68-71.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Bhartiya, Shibal
AU  - Bhartiya S
AD  - Department of Ophthalmology, Glaucoma Services, Fortis Memorial Research
      Institute, Gurugram, Haryana, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Curr Glaucoma Pract
JT  - Journal of current glaucoma practice
JID - 101492611
PMC - PMC7695931
OTO - NOTNLM
OT  - Ethics
OT  - Glaucoma practice
OT  - Patient centricity
OT  - Quality of life
OT  - Shared decision-making
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 06:01
PHST- 2020/12/11 06:01 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.5005/jp-journals-10078-1281 [doi]
PST - ppublish
SO  - J Curr Glaucoma Pract. 2020 May-Aug;14(2):68-71. doi:
      10.5005/jp-journals-10078-1281.


PMID- 33303646
OWN - NLM
STAT- Publisher
LR  - 20201211
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 10
TI  - To test or not to test: genetic cancer predisposition testing in paediatric
      patients with cancer.
LID - medethics-2020-106656 [pii]
LID - 10.1136/medethics-2020-106656 [doi]
AB  - Genetic cancer predisposition testing in the paediatric population poses unique
      ethical dilemmas. Using the hypothetical example of a teenager with cancer with a
      high probability of having an underlying cancer predisposition syndrome, we
      discuss the ethical considerations that affect the decision-making process.
      Because legally these decisions are made by parents, genetic testing in
      paediatrics can remove a child's autonomy to preserve his or her own 'open
      future'. However, knowledge of results confirming a predisposition syndrome can
      potentially be beneficial in modifying treatment and surveillance plans and
      enabling at-risk family members to obtain cascade testing for themselves.
      Considering virtue ethics to envision the best characters of the patient, parents
      and healthcare providers can guide them to the better choice to test or not to
      test, with the ultimate goal of achieving the best outcome for survival and
      eudaimonia, human flourishing reliably sought out.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Mehta, Sapna
AU  - Mehta S
AD  - Global Health, Biology, University of California San Diego, La Jolla, California,
      USA.
FAU - Kuo, Dennis John
AU  - Kuo DJ
AUID- ORCID: http://orcid.org/0000-0003-4154-0057
AD  - Pediatric Hematology-Oncology, University of California San Diego School of
      Medicine, La Jolla, California, USA dekuo@ucsd.edu.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - genethics
OT  - genetic screening/testing
OT  - paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/07/01 00:00 [received]
PHST- 2020/11/07 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:00 [medline]
AID - medethics-2020-106656 [pii]
AID - 10.1136/medethics-2020-106656 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 10. pii: medethics-2020-106656. doi:
      10.1136/medethics-2020-106656.


PMID- 33303515
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 12
DP  - 2020 Dec
TI  - The empirical evidence underpinning the concept and practice of person-centred
      care for serious illness: a systematic review.
LID - e003330 [pii]
LID - 10.1136/bmjgh-2020-003330 [doi]
AB  - INTRODUCTION: Person-centred care has become internationally recognised as a
      critical attribute of high-quality healthcare. However, the concept has been
      criticised for being poorly theorised and operationalised. Serious illness is
      especially aligned with the need for person-centredness, usually necessitating
      involvement of significant others, management of clinical uncertainty,
      high-quality communication and joint decision-making to deliver care concordant
      with patient preferences. This review aimed to identify and appraise the
      empirical evidence underpinning conceptualisations of 'person-centredness' for
      serious illness. METHODS: Search strategy conducted in May 2020. Databases:
      CINAHL, Embase, PubMed, Ovid Global Health, MEDLINE and PsycINFO. Free text
      search terms related to (1) person-centredness, (2) serious illness and (3)
      concept/practice. Tabulation, textual description and narrative synthesis were
      performed, and quality appraisal conducted using QualSyst tools. Santana et al's 
      person-centred care model (2018) was used to structure analysis. RESULTS: PRISMA 
      (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow data:
      n=12,446 studies screened by title/abstract, n=144 full articles assessed for
      eligibility, n=18 studies retained. All studies (n=18) are from high-income
      countries, and are largely of high quality (median score 0.82). The findings
      suggest that person-centred care encompasses the patient and family being
      respected, given complete information, involved in decision-making and supported 
      in their physical, psychological, social and existential needs. The studies
      highlight the importance of involving and supporting family/friends, promoting
      continuation of normality and self-identity, and structuring service organisation
      to enable care continuity. CONCLUSION: Person-centred healthcare must value the
      social network of patients, promote quality of life and reform structurally to
      improve patients' experience interacting with the healthcare system. Staff must
      be supported to flexibly adapt skills, communication, routines or environments
      for individual patients. There remains a need for primary data investigating the 
      meaning and practice of PCC in a greater diversity of diagnostic groups and
      settings, and a need to ground potential components of PCC within broader
      universal values and ethical theory.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Giusti, Alessandra
AU  - Giusti A
AUID- ORCID: 0000-0003-2667-1665
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's
      College London, London, UK alessandra.giusti@kcl.ac.uk.
AD  - King's Global Health Institute, King's College London, London, UK.
FAU - Nkhoma, Kennedy
AU  - Nkhoma K
AUID- ORCID: 0000-0002-2991-8160
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's
      College London, London, UK.
FAU - Petrus, Ruwayda
AU  - Petrus R
AD  - School of Applied Human Sciences, University of KwaZulu-Natal College of
      Humanities, Durban, South Africa.
FAU - Petersen, Inge
AU  - Petersen I
AD  - School of Applied Human Sciences, University of KwaZulu-Natal College of
      Humanities, Durban, South Africa.
FAU - Gwyther, Liz
AU  - Gwyther L
AD  - School of Public Health and Family Medicine, University of Cape Town Faculty of
      Health Sciences, Cape Town, Western Cape, South Africa.
FAU - Farrant, Lindsay
AU  - Farrant L
AD  - School of Public Health and Family Medicine, University of Cape Town Faculty of
      Health Sciences, Cape Town, Western Cape, South Africa.
FAU - Venkatapuram, Sridhar
AU  - Venkatapuram S
AUID- ORCID: 0000-0003-3076-0783
AD  - King's Global Health Institute, King's College London, London, UK.
FAU - Harding, Richard
AU  - Harding R
AUID- ORCID: 0000-0001-9653-8689
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's
      College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *Clinical Decision-Making
MH  - Communication
MH  - Delivery of Health Care
MH  - Humans
MH  - *Patient-Centered Care
MH  - *Quality of Life
MH  - Uncertainty
PMC - PMC7733074
OTO - NOTNLM
OT  - *health policy
OT  - *health services research
OT  - *health systems
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/07/06 00:00 [received]
PHST- 2020/10/21 00:00 [revised]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - bmjgh-2020-003330 [pii]
AID - 10.1136/bmjgh-2020-003330 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Dec;5(12). pii: bmjgh-2020-003330. doi:
      10.1136/bmjgh-2020-003330.


PMID- 33303471
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Development of a national neonatal intensive care unit-specific antimicrobial
      stewardship programme in Canada: protocol for a cohort study.
PG  - e043403
LID - 10.1136/bmjopen-2020-043403 [doi]
AB  - INTRODUCTION: Early empiric treatment with broad-spectrum antimicrobials is
      common in neonatal intensive care units (NICU) due to the non-specific clinical
      presentation of infection. However, excessive and inappropriate antimicrobial use
      can lead to the emergence of drug-resistant organisms and adverse neonatal
      outcomes. This study aims to develop and implement a nationwide NICU-specific
      antimicrobial stewardship programme (ASP) to promote judicious antimicrobial use 
      and control the emergence of multidrug-resistant organisms (MDROs) in Canada.
      METHODS AND ANALYSIS: Our study population will include all very low-birth-weight
      neonates admitted to participating tertiary NICU in Canada. Based on the existing
      limited literature, we will develop consensus on NICU antimicrobial stewardship
      interventions to enhance best practices. Using an expanded Canadian Neonatal
      Network (CNN) platform, we will collect data on antimicrobial use and the
      susceptibility of organisms identified in clinical samples from blood and
      cerebrospinal fluid over a period of 2 years. These data will be used to provide 
      all NICU stakeholders with benchmarked centre-adjusted antimicrobial use and MDRO
      prevalence reports. An ASP plan will be developed at both individual unit and
      national levels in the subsequent years. Knowledge translation strategies will be
      implemented through the well-established Evidence-based Practice for Improving
      Quality methodology. ETHICS AND DISSEMINATION: Ethics for the study has been
      granted by the University of British Columbia Children's & Women's Research
      Ethics Board (H19-02490) and supported by CNN Executive Committee. The study
      results will be disseminated through national organisations and open access
      peer-reviewed publications. TRIAL REGISTRATION NUMBER: NCT04388293.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ting, Joseph Y
AU  - Ting JY
AUID- ORCID: 0000-0002-5246-8823
AD  - Department of Pediatrics, University of British Columbia, Vancouver, British
      Columbia, Canada jting2@cw.bc.ca.
FAU - Roberts, Ashley
AU  - Roberts A
AD  - Department of Pediatrics, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Tilley, Peter
AU  - Tilley P
AD  - Pathology and Laboratory Medicine, University of British Columbia, Vancouver,
      British Columbia, Canada.
FAU - Robinson, Joan L
AU  - Robinson JL
AUID- ORCID: 0000-0001-9831-5681
AD  - Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
FAU - Dunn, Michael S
AU  - Dunn MS
AD  - Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
FAU - Paquette, Vanessa
AU  - Paquette V
AD  - School of Pharmaceutical Science, University of British Columbia, Vancouver,
      British Columbia, Canada.
FAU - Lee, Kyong-Soon
AU  - Lee KS
AD  - Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
FAU - Shah, Vibhuti
AU  - Shah V
AD  - Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
FAU - Yoon, Eugene
AU  - Yoon E
AD  - Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Richter, Lindsay L
AU  - Richter LL
AD  - Department of Pediatrics, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Lodha, Abhay
AU  - Lodha A
AD  - Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
FAU - Shivananda, Sandesh
AU  - Shivananda S
AD  - Department of Pediatrics, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Thampi, Nisha
AU  - Thampi N
AD  - Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Autmizguine, Julie
AU  - Autmizguine J
AD  - Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada.
FAU - Shah, Prakesh S
AU  - Shah PS
AD  - Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
AD  - Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
CN  - Canadian Neonatal Network Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT04388293
GR  - 201903PJT-420294-CA2-CAAA-245530/CAPMC/ CIHR/Canada
PT  - Clinical Trial
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Antimicrobial Stewardship
MH  - Canada
MH  - Cohort Studies
MH  - Humans
MH  - Infant, Newborn
MH  - *Intensive Care Units, Neonatal
PMC - PMC7733165
OTO - NOTNLM
OT  - *infectious diseases
OT  - *neonatal intensive & critical care
OT  - *neonatology
COIS- Competing interests: JT is supported by the Investigator Grant Award Program
      through the British Columbia Children's Hospital Research Institute. Dr Prakesh S
      Shah reported holding an Applied Research Chair in Reproductive and Child Health 
      Services and Policy Research awarded by the Canadian Institutes of Health
      Research (grant APR-126340).
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043403 [pii]
AID - 10.1136/bmjopen-2020-043403 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e043403. doi: 10.1136/bmjopen-2020-043403.


PMID- 33303470
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20210110
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Birth experience during COVID-19 confinement (CONFINE): protocol for a
      multicentre prospective study.
PG  - e043057
LID - 10.1136/bmjopen-2020-043057 [doi]
AB  - INTRODUCTION: The absence of companionship during childbirth is known to be
      responsible for negative emotional birth experience, which can increase the risk 
      of postpartum depression and post-traumatic stress disorder. The context of
      COVID-19 epidemic and the related confinement could increase the rate of negative
      experience and mental disorders. The main objective is to compare, in immediate
      post partum, the maternal sense of control during childbirth between a group of
      women who gave birth during confinement ('confinement' group) versus a group of
      women who gave birth after confinement but in the context of epidemic ('epidemic'
      group) versus a group of control women ('control' group; excluding confinement
      and epidemic context). METHODS AND ANALYSIS: This is a national multicentre
      prospective cohort study conducted in four French maternity units. We expect to
      include 927 women in a period of 16 months. Women will be recruited immediately
      in post partum during three different periods constituting the three groups:
      'confinement'; 'epidemic' and 'control' group. The maternal sense of control will
      be evaluated by the Labour Agentry Scale questionnaire completed immediately in
      post partum. Postnatal depression (Edinburgh Postnatal Depression Scale),
      post-traumatic stress disorder (Impact of Event Scale-Revised) and breast feeding
      (evaluative statement) will be evaluated at 2 months post partum. ETHICS AND
      DISSEMINATION: The study was approved by the French Ethics Committee, the CPP
      (Comite de Protection des Personnes) SUD OUEST ET OUTRE-MER IV on 16th of April
      2020 with reference number CPP2020-04-040. The results of this study will be
      published in a peer-reviewed journal and will be presented at relevant
      conferences. TRIAL REGISTRATION NUMBER: NCT04348929.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bertholdt, Charline
AU  - Bertholdt C
AUID- ORCID: http://orcid.org/0000-0001-9297-5363
AD  - Gynecology-Obstetric center, University of Lorraine, CHRU-Nancy, Nancy, France
      charline.bertholdt@gmail.com.
AD  - Inserm, Diagnostic and Interventional Adaptive Imaging, University of Lorraine,
      Nancy, France.
FAU - Epstein, Jonathan
AU  - Epstein J
AD  - Inserm, CIC Epidemiologie Clinique, CHRU-Nancy, Nancy, France.
FAU - Banasiak, Claire
AU  - Banasiak C
AD  - Inserm, CIC Innovation Technologique, CHRU-Nancy, Nancy, France.
FAU - Ligier, Fabienne
AU  - Ligier F
AD  - PUPEA, Nancy Psychotherapy Center-EA 4360 APEMAC, MICS team, University of
      Lorraine, Nancy, France.
FAU - Dahlhoff, Sandra
AU  - Dahlhoff S
AD  - Obstetric Gynecology, CHR Metz-Thionville, Metz Mother and Child Hospital,
      Peltre, France.
FAU - Olieric, Marie France
AU  - Olieric MF
AD  - Obstetric Gynecology, CHR Metz-Thionville, Bel-Air Hospital, Thionville, France.
FAU - Mottet, Nicolas
AU  - Mottet N
AD  - Obstetric Gynecology, CHU Besancon Jean-Minjoz Hospital, Besancon, France.
FAU - Beaumont, Marine
AU  - Beaumont M
AD  - Inserm, CIC Innovation Technologique, CHRU-Nancy, Nancy, France.
FAU - Morel, Olivier
AU  - Morel O
AD  - Gynecology-Obstetric center, University of Lorraine, CHRU-Nancy, Nancy, France.
AD  - Inserm, Diagnostic and Interventional Adaptive Imaging, University of Lorraine,
      Nancy, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04348929
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/*psychology
MH  - Depression, Postpartum/etiology
MH  - Female
MH  - France
MH  - Humans
MH  - Parturition/*psychology
MH  - *Physical Distancing
MH  - Postpartum Period/*psychology
MH  - Pregnancy
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Research Design
MH  - Stress Disorders, Post-Traumatic/etiology
MH  - Surveys and Questionnaires
MH  - Time Factors
PMC - PMC7733205
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *depression & mood disorders
OT  - *maternal medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - bmjopen-2020-043057 [pii]
AID - 10.1136/bmjopen-2020-043057 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e043057. doi: 10.1136/bmjopen-2020-043057.


PMID- 33303468
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Single-arm prospective interventional study assessing feasibility of using
      gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients 
      with stage III non-small cell lung cancer.
PG  - e042465
LID - 10.1136/bmjopen-2020-042465 [doi]
AB  - BACKGROUND: In the curative-intent treatment of locally advanced lung cancer,
      significant morbidity and mortality can result from thoracic radiation therapy.
      Symptomatic radiation pneumonitis occurs in one in three patients and can lead to
      radiation-induced fibrosis. Local failure occurs in one in three patients due to 
      the lungs being a dose-limiting organ, conventionally restricting tumour doses to
      around 60 Gy. Functional lung imaging using positron emission tomography (PET)/CT
      provides a geographic map of regional lung function and preclinical studies
      suggest this enables personalised lung radiotherapy. This map of lung function
      can be integrated into Volumetric Modulated Arc Therapy (VMAT) radiotherapy
      planning systems, enabling conformal avoidance of highly functioning regions of
      lung, thereby facilitating increased doses to tumour while reducing normal tissue
      doses. METHODS AND ANALYSIS: This prospective interventional study will
      investigate the use of ventilation and perfusion PET/CT to identify highly
      functioning lung volumes and avoidance of these using VMAT planning. This
      single-arm trial will be conducted across two large public teaching hospitals in 
      Australia. Twenty patients with stage III non-small cell lung cancer will be
      recruited. All patients enrolled will receive dose-escalated (69 Gy) functional
      avoidance radiation therapy. The primary endpoint is feasibility with this
      achieved if >/=15 out of 20 patients meet pre-defined feasibility criteria.
      Patients will be followed for 12 months post-treatment with serial imaging,
      biomarkers, toxicity assessment and quality of life assessment. DISCUSSION: Using
      advanced techniques such as VMAT functionally adapted radiation therapy may
      enable safe moderate dose escalation with an aim of improving local control and
      concurrently decreasing treatment related toxicity. If this technique is proven
      feasible, it will inform the design of a prospective randomised trial to assess
      the clinical benefits of functional lung avoidance radiation therapy. ETHICS AND 
      DISSEMINATION: This study was approved by the Peter MacCallum Human Research
      Ethics Committee. All participants will provide written informed consent. Results
      will be disseminated via publications. TRIALS REGISTRATION NUMBER: NCT03569072;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bucknell, Nicholas
AU  - Bucknell N
AUID- ORCID: 0000-0002-4831-9120
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia nick.bucknell@petermac.org.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Hardcastle, Nicholas
AU  - Hardcastle N
AD  - Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Centre for Medical Radiation Physics, University of Wollongong, Wollongong, New
      South Wales, Australia.
FAU - Jackson, Price
AU  - Jackson P
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - Hofman, Michael
AU  - Hofman M
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter
      MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Callahan, Jason
AU  - Callahan J
AD  - Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter
      MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Eu, Peter
AU  - Eu P
AD  - Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter
      MacCallum Cancer Centre, Melbourne, Victoria, Australia.
AD  - School of Medicine, Deakin University, Geelong, Victoria, Australia.
FAU - Iravani, Amir
AU  - Iravani A
AD  - Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter
      MacCallum Cancer Centre, Melbourne, Victoria, Australia.
AD  - Department of Nuclear Medicine, Washington University School of Medicine, St
      Louis, Missouri, USA.
FAU - Lawrence, Rhonda
AU  - Lawrence R
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - Martin, Olga
AU  - Martin O
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Bressel, Mathias
AU  - Bressel M
AD  - Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre,
      Melbourne, Victoria, Australia.
FAU - Woon, Beverley
AU  - Woon B
AD  - Department of Radiology, Cancer Imaging, Peter MacCallum Cancer Centre,
      Melbourne, Victoria, Australia.
FAU - Blyth, Benjamin
AU  - Blyth B
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - MacManus, Michael
AU  - MacManus M
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Byrne, Keelan
AU  - Byrne K
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - Steinfort, Daniel
AU  - Steinfort D
AD  - Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Respiratory Medicine, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - Kron, Tomas
AU  - Kron T
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - Hanna, Gerard
AU  - Hanna G
AUID- ORCID: 0000-0003-1003-5138
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Ball, David
AU  - Ball D
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Siva, Shankar
AU  - Siva S
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03569072
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Gallium Radioisotopes)
RN  - 98B30EPP5S (Gallium-68)
SB  - IM
MH  - Australia
MH  - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/radiotherapy
MH  - Feasibility Studies
MH  - Gallium Radioisotopes
MH  - Humans
MH  - Lung/diagnostic imaging
MH  - *Lung Neoplasms/diagnostic imaging/radiotherapy
MH  - Perfusion
MH  - Positron Emission Tomography Computed Tomography
MH  - Positron-Emission Tomography
MH  - Prospective Studies
MH  - Quality of Life
MH  - Radiotherapy Planning, Computer-Assisted
MH  - Tomography, X-Ray Computed
PMC - PMC7733178
OTO - NOTNLM
OT  - *nuclear radiology
OT  - *radiation oncology
OT  - *respiratory tract tumours
OT  - *toxicity
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042465 [pii]
AID - 10.1136/bmjopen-2020-042465 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e042465. doi: 10.1136/bmjopen-2020-042465.


PMID- 33303464
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Oncological safety of hysteroscopy in the diagnosis of stage I endometrial
      cancer: protocol for a systematic review and meta-analysis.
PG  - e041981
LID - 10.1136/bmjopen-2020-041981 [doi]
AB  - BACKGROUND: The oncological safety of diagnostic hysteroscopy in patients with
      stage endometrial cancer remains uncertain and conflicting. The aim of the
      proposed systematic review and meta-analysis is to summarise the available
      evidence examining the association between diagnostic hysteroscopy and the
      prognosis of stage endometrial cancer and to statistically synthesise the results
      of relevant studies. METHODS AND ANALYSIS: Systematic searches of PubMed/MEDLINE,
      Embase, Cochrane Library and Web of Science will be undertaken using prespecified
      search strategies. Two authors will independently conduct eligible studies
      selection process, perform data extraction and appraise the quality of included
      studies. Original case-control studies, cohort studies and randomised controlled 
      trails published in English will be considered for inclusion. The outcomes of
      interest will be 5-year recurrence-free survival, disease-specific survival and
      overall survival. Meta-analyses will be performed to calculate pooled estimates. 
      ETHICS AND DISSEMINATION: Our study will be based on published data, and thus
      there is no requirement for ethics approval. The results will be shared through
      publication in a peer-reviewed journal and presentations at academic conferences.
      PROSPERO REGISTRATION NUMBER: CRD42020193696.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Yu
AU  - Xu Y
AUID- ORCID: 0000-0001-9819-1965
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Zhang, Qian Wen
AU  - Zhang QW
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Du, Yi
AU  - Du Y
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Qin, Zhao Juan
AU  - Qin ZJ
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - He, Yue Dong
AU  - He YD
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, China.
FAU - Zheng, Ai
AU  - Zheng A
AUID- ORCID: 0000-0002-3403-9101
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China ZhengAi_WestChina@163.com.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Case-Control Studies
MH  - *Endometrial Neoplasms/diagnosis
MH  - Female
MH  - Humans
MH  - *Hysteroscopy
MH  - Meta-Analysis as Topic
MH  - Pregnancy
PMC - PMC7733216
OTO - NOTNLM
OT  - *gynaecological oncology
OT  - *minimally invasive surgery
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041981 [pii]
AID - 10.1136/bmjopen-2020-041981 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e041981. doi: 10.1136/bmjopen-2020-041981.


PMID- 33303457
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Adaptive randomised controlled non-inferiority multicentre trial (the Ketodex
      Trial) on intranasal dexmedetomidine plus ketamine for procedural sedation in
      children: study protocol.
PG  - e041319
LID - 10.1136/bmjopen-2020-041319 [doi]
AB  - INTRODUCTION: Up to 40% of orthopaedic injuries in children require a closed
      reduction, almost always necessitating procedural sedation. Intravenous ketamine 
      is the most commonly used sedative agent. However, intravenous insertion is
      painful and can be technically difficult in children. We hypothesise that a
      combination of intranasal dexmedetomidine plus intranasal ketamine (Ketodex) will
      be non-inferior to intravenous ketamine for effective sedation in children
      undergoing a closed reduction. METHODS AND ANALYSIS: This is a six-centre,
      four-arm, adaptive, randomised, blinded, controlled, non-inferiority trial. We
      will include children 4-17 years with a simple upper limb fracture or dislocation
      that requires sedation for a closed reduction. Participants will be randomised to
      receive either intranasal Ketodex (one of three dexmedetomidine and ketamine
      combinations) or intravenous ketamine. The primary outcome is adequate sedation
      as measured using the Paediatric Sedation State Scale. Secondary outcomes include
      length of stay, time to wakening and adverse effects. The results of both per
      protocol and intention-to-treat analyses will be reported for the primary
      outcome. All inferential analyses will be undertaken using a response-adaptive
      Bayesian design. Logistic regression will be used to model the dose-response
      relationship for the combinations of intranasal Ketodex. Using the Average Length
      Criterion for Bayesian sample size estimation, a survey-informed non-inferiority 
      margin of 17.8% and priors from historical data, a sample size of 410
      participants will be required. Simulations estimate a type II error rate of 0.08 
      and a type I error rate of 0.047. ETHICS AND DISSEMINATION: Ethics approval was
      obtained from Clinical Trials Ontario for London Health Sciences Centre and
      McMaster Research Ethics Board. Other sites have yet to receive approval from
      their institutions. Informed consent will be obtained from guardians of all
      participants in addition to assent from participants. Study data will be
      submitted for publication regardless of results. TRIAL REGISTRATION NUMBER:
      NCT0419525.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Poonai, Naveen
AU  - Poonai N
AUID- ORCID: 0000-0003-1540-0413
AD  - Departments of Paediatrics and Epidemiology & Biostatistics, Schulich School of
      Medicine and Dentistry, London, Ontario, Canada naveen.poonai@lhsc.on.ca.
AD  - Children's Health Research Institute, London Health Sciences Centre, London,
      Ontario, Canada.
FAU - Coriolano, Kamary
AU  - Coriolano K
AD  - Departments of Paediatrics and Epidemiology & Biostatistics, Schulich School of
      Medicine and Dentistry, London, Ontario, Canada.
FAU - Klassen, Terry
AU  - Klassen T
AD  - Max Rady College of Medicine, Pediatrics and Child Health, Rady Faculty of Health
      Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
AD  - Department of Paediatrics, Children's Hospital Research Institute of Manitoba
      (CHRIM), Winnipeg, Manitoba, Canada.
FAU - Heath, Anna
AU  - Heath A
AD  - Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
AD  - Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Statistical Science, University College London, London, UK.
FAU - Yaskina, Maryna
AU  - Yaskina M
AD  - Women and Children's Health Research Institute (WCHRI), University of Alberta,
      Edmonton, Alberta, Canada.
FAU - Beer, Darcy
AU  - Beer D
AD  - Department of Paediatrics, Children's Hospital of Winnipeg, Winnipeg, Manitoba,
      Canada.
FAU - Sawyer, Scott
AU  - Sawyer S
AD  - Department of Paediatrics, Children's Hospital of Winnipeg, Winnipeg, Manitoba,
      Canada.
FAU - Bhatt, Maala
AU  - Bhatt M
AD  - Department of Paediatrics, University of Ottawa, Children's Hospital of Eastern
      Ontario, Ottawa, Ontario, Canada.
FAU - Kam, April
AU  - Kam A
AD  - Department of Paediatrics, McMaster University, McMaster Children's Hospital,
      Hamilton, Ontario, Canada.
FAU - Doan, Quynh
AU  - Doan Q
AD  - Department of Paediatrics, University of British Columbia, BC Children's
      Hospital, Vancouver, British Columbia, Canada.
FAU - Sabhaney, Vikram
AU  - Sabhaney V
AD  - Department of Paediatrics, University of British Columbia, BC Children's
      Hospital, Vancouver, British Columbia, Canada.
FAU - Offringa, Martin
AU  - Offringa M
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
FAU - Pechlivanoglou, Petros
AU  - Pechlivanoglou P
AD  - Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Hickes, Serena
AU  - Hickes S
AD  - Department of Paediatrics, Children's Hospital Research Institute of Manitoba
      (CHRIM), Winnipeg, Manitoba, Canada.
FAU - Ali, Samina
AU  - Ali S
AUID- ORCID: 0000-0002-0595-364X
AD  - Women and Children's Health Research Institute (WCHRI), University of Alberta,
      Edmonton, Alberta, Canada.
AD  - Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta,
      Edmonton, Alberta, Canada.
CN  - KidsCAN PERC iPCT-SPOR (Innovative Paediatric Clinical Trials - Strategy for
      Patient Oriented Research) Ketodex Study Team
LA  - eng
GR  - MYG-151207, 2017-2020/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Hypnotics and Sedatives)
RN  - 67VB76HONO (Dexmedetomidine)
RN  - 690G0D6V8H (Ketamine)
SB  - IM
MH  - Administration, Intranasal
MH  - Adolescent
MH  - Bayes Theorem
MH  - Child
MH  - Child, Preschool
MH  - *Dexmedetomidine
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - *Ketamine
MH  - London
MH  - Multicenter Studies as Topic
MH  - Ontario
MH  - Randomized Controlled Trials as Topic
PMC - PMC7733175
OTO - NOTNLM
OT  - *paediatric A&E and ambulatory care
OT  - *paediatric anaesthesia
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041319 [pii]
AID - 10.1136/bmjopen-2020-041319 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e041319. doi: 10.1136/bmjopen-2020-041319.


PMID- 33303452
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210920
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Interpersonal factors contributing to tension in the Chinese
      doctor-patient-family relationship: a qualitative study in Hunan Province.
PG  - e040743
LID - 10.1136/bmjopen-2020-040743 [doi]
AB  - OBJECTIVE: To identify actionable barriers to communication that contribute to
      tension in the Chinese doctor-patient-family relationship (DPFR) among surgeons, 
      surgical patients and their family members. DESIGN: We employed qualitative
      research methods using in-depth, semistructured interviews in Mandarin and
      English and conducted preoperatively and postoperatively. Interviews were audio
      recorded, transcribed and translated into English. Data were analysed using
      thematic analysis. SETTING: An urban, tertiary-level teaching hospital in Hunan
      Province, China. PARTICIPANTS: We recruited a purposive sample of 11 inpatients
      undergoing the same minor surgery, 9 of their family members and 9 surgeons
      between June and August 2015. RESULTS: We identified three emergent themes.
      First, trust degradation occurred before and during the healthcare experience.
      Second, the healthcare-seeking experience for patients and family members was
      marked by unmet expectations for achieving a basic understanding of the illness
      as well as powerlessness over their situation. Third, societal pressures on
      doctors contributed to a state of learned helplessness. CONCLUSIONS: Our findings
      suggest that tension in the DPFR is associated with interpersonal and structural 
      challenges, with communication playing an important role. Reforms at all levels
      are needed to promote a more patient-centred experience while ensuring the
      well-being and security of providers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xiao, Siyu
AU  - Xiao S
AUID- ORCID: 0000-0002-4351-6838
AD  - Department of Obstetrics and Gynecology and Women's Health, Albert Einstein
      College of Medicine, Bronx, New York, USA sxiao92@gmail.com.
FAU - Wang, Lixuan
AU  - Wang L
AD  - Division of Disease Control, New York City Department of Health and Hygiene,
      Queens, New York, USA.
FAU - Edelman, E Jennifer
AU  - Edelman EJ
AD  - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut,
      USA.
FAU - Khoshnood, Kaveh
AU  - Khoshnood K
AD  - Department of Epidemiology of Microbial Diseases, Yale School of Public Health,
      New Haven, Connecticut, USA.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - Communication
MH  - *Family Relations
MH  - Humans
MH  - *Physician-Patient Relations
MH  - Qualitative Research
PMC - PMC7733169
OTO - NOTNLM
OT  - *health services administration & management
OT  - *medical ethics
OT  - *public health
OT  - *qualitative research
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040743 [pii]
AID - 10.1136/bmjopen-2020-040743 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e040743. doi: 10.1136/bmjopen-2020-040743.


PMID- 33303450
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Regular running in an air-polluted environment: physiological and anthropometric 
      protocol for a prospective cohort study (Healthy Aging in Industrial Environment 
      Study - Program 4).
PG  - e040529
LID - 10.1136/bmjopen-2020-040529 [doi]
AB  - INTRODUCTION: Ambient air pollution is a global environmental problem, which
      causes adverse health effects and premature deaths worldwide. Although regular
      exercise and physical activity have evident health benefits, the influence of
      long-term air pollution exposure during regular outdoor running has not been
      definitively clarified. METHODS AND ANALYSIS: This study protocol describes the
      physiological and anthropometric perspectives of the 'Healthy Aging in Industrial
      Environment' Study - Programme 4 (4HAIE). The 4HAIE research project is intended 
      to be a single-centre, prospective, longitudinal and multidisciplinary cohort
      study. The presented study protocol describes the cross-sectional measurements
      and analyses. Overall, 1500 adult participants (age 18-65 years), runners and
      inactive individuals, living in a high or low air-polluted area of the Czech
      Republic will be recruited. We will measure and analyse biomarkers of oxidative
      stress and inflammation in the blood, exercise capacity (graded exercise test and
      spiroergometry), blood pressure, lung function (spirometry), cardiac autonomic
      regulation and anthropometry (body composition). ETHICS AND DISSEMINATION: The
      4HAIE study protocol has already been approved by the Ethics Committee of the
      University of Ostrava (3/2018). A detailed participant information sheet will be 
      provided to each individual prior to obtaining their written informed consent.
      The study poses little to no risk to participants. The findings of this study
      will be disseminated at regional and international conferences, in peer-reviewed 
      journals and via social and broadcast media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cipryan, Lukas
AU  - Cipryan L
AUID- ORCID: 0000-0002-2403-8797
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic lukas.cipryan@osu.cz.
FAU - Kutac, Petr
AU  - Kutac P
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic.
FAU - Dostal, Tomas
AU  - Dostal T
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic.
FAU - Zimmermann, Matthew
AU  - Zimmermann M
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic.
FAU - Krajcigr, Miroslav
AU  - Krajcigr M
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic.
FAU - Jandackova, Vera
AU  - Jandackova V
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic.
AD  - Department of Epidemiology and Public Health, University of Ostrava, Ostrava,
      Czech Republic.
FAU - Sram, Radim
AU  - Sram R
AD  - Department of Genetic Toxicology and Epigenetics, Institute of Experimental
      Medicine, Czech Academy of Sciences, Prague, Czech Republic.
AD  - Centre for Epidemiological Research, University of Ostrava, Ostrava, Czech
      Republic.
FAU - Jandacka, Daniel
AU  - Jandacka D
AD  - Department of Human Movement Science, University of Ostrava, Ostrava, Czech
      Republic.
FAU - Hofmann, Peter
AU  - Hofmann P
AD  - Institute of Human Movement Science, Sport & Health, Exercise Physiology,
      Training & Training Therapy Research Group, University of Graz, Graz, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anthropometry
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Czech Republic
MH  - *Healthy Aging
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Running
MH  - Young Adult
PMC - PMC7733192
OTO - NOTNLM
OT  - *physiology
OT  - *public health
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040529 [pii]
AID - 10.1136/bmjopen-2020-040529 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e040529. doi: 10.1136/bmjopen-2020-040529.


PMID- 33303449
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Quality of life following a lower limb reconstructive procedure: a protocol for
      the development of a conceptual framework.
PG  - e040378
LID - 10.1136/bmjopen-2020-040378 [doi]
AB  - INTRODUCTION: Lower limb conditions requiring reconstructive surgery can be
      either congenital or acquired from trauma, infection or other medical conditions.
      Patient-reported outcome measures (PROMs) are often used by healthcare
      professionals to assess the impact of a patient's condition (and treatment) on
      quality of life. However, we are not aware of any measures developed specifically
      for people requiring lower limb reconstructive surgery. Consequently, it is not
      clear the extent to which current PROMs accurately and specifically measure the
      outcomes that are important to these patients. METHODS AND ANALYSIS: The
      'PROLLIT' (Patient-Reported Outcome Measure for Lower Limb Reconstruction)
      involves three phases: to explore what is important to patients with regard to
      quality of life (phase 1), ascertain whether current measures adequately capture 
      these experiences (phase 2) and if not begin, the development of a new PROM
      (phase 3). The population of interest is people requiring, undergoing or after
      undergoing reconstructive surgery for a lower limb condition. In this paper, we
      describe phase 1, which aims to develop a conceptual framework to identify and
      map what is important to this group with regard to social interactions,
      employment, perceived health and quality of life after condition onset/injury and
      throughout recovery. The conceptual framework will be developed through three
      steps: (step A) a qualitative evidence synthesis, (step B) a qualitative study
      with patients and staff to explore patient's views and experiences of lower limb 
      reconstructive surgery and (step C) a round table discussion with key
      stakeholders where findings from step A and step B will be brought together and
      used to finalise the conceptual framework. ETHICS CONSIDERATION AND
      DISSEMINATION: Ethical approval has been granted for the qualitative data
      collection (step B) from South Central Berkshire Research Ethics committee
      (REF:20/SC/0114). Findings from steps A and B will be submitted for peer-reviewed
      publication in academic journals, and presented at academic conferences. PROSPERO
      REGISTRATION NUMBER: CRD42019139587. ISRCTN REGISTRATION NUMBER: ISRCTN75201623.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Leggett, Heather
AU  - Leggett H
AUID- ORCID: 0000-0001-8708-9842
AD  - York Trials Unit, University of York, York, UK heather.leggett@york.ac.uk.
FAU - Scantlebury, Arabella
AU  - Scantlebury A
AUID- ORCID: 0000-0003-3518-2740
AD  - York Trials Unit, University of York, York, UK.
FAU - Sharma, Hemant
AU  - Sharma H
AD  - Trauma and Orthopedics, Hull Royal Infirmary, Hull, UK.
FAU - Hewitt, Catherine
AU  - Hewitt C
AD  - York Trials Unit, University of York, York, UK.
FAU - Harden, Melissa
AU  - Harden M
AD  - Centre for Reviews and Dissemination (CRD), University of York, York, UK.
FAU - McDaid, Catriona
AU  - McDaid C
AUID- ORCID: 0000-0002-3751-7260
AD  - York Trials Unit, University of York, York, UK.
CN  - PROLLIT study collaborators
CN  - PROLLIT study
LA  - eng
SI  - ISRCTN/ISRCTN75201623
PT  - Clinical Trial
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Lower Extremity/surgery
MH  - *Patient Reported Outcome Measures
MH  - Qualitative Research
MH  - *Quality of Life
PMC - PMC7733194
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *protocols & guidelines
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: CM reports grants from Hull University Teaching Hospitals
      NHS Trust, during the conduct of the study; grants from British Orthopaedic
      Association, outside the submitted work. HS reports grants from Health &
      Technology Assessment, during the conduct of the study; grants from B.Braun,
      personal fees from Biocomposites and personal fees from Orthofix, outside the
      submitted work. MH, HL, AS and CH have nothing to disclose.
IR  - Adamson J
FIR - Adamson, Joy
IR  - Jones G
FIR - Jones, Georgina
IR  - Cocks K
FIR - Cocks, Kim
IR  - Gagnier J
FIR - Gagnier, Joel
IR  - Harwood P
FIR - Harwood, Paul
IR  - Ferguson D
FIR - Ferguson, David
IR  - Hamdy R
FIR - Hamdy, Reggie
IR  - Ferriera N
FIR - Ferriera, Nando
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:50
PHST- 2020/12/11 05:50 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040378 [pii]
AID - 10.1136/bmjopen-2020-040378 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e040378. doi: 10.1136/bmjopen-2020-040378.


PMID- 33303447
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Protocol for an implementation and realist evaluation of a new organisational
      model for primary care practices in the canton of Vaud, Switzerland.
PG  - e040154
LID - 10.1136/bmjopen-2020-040154 [doi]
AB  - INTRODUCTION: Continuity of care, especially for patients with complex needs, is 
      a major challenge for healthcare systems in many high-income countries, including
      Switzerland. Since 2015, a collaborative project between Unisante-Department of
      Family Medicine (DMF), some general practitioners (GPs) and canton of Vaud's
      public health authorities has sought to develop a new organisational model for
      the provision of primary care to ensure better care coordination and to provide
      adapted care deliveries to patients' healthcare needs. The model's main component
      is the addition of a primary care nurse to GPs practices. Three additional tools 
      are individualised patient care plans, electronic medical records and patient
      empanelment. To assess this model, a 2-year pilot study has begun in nine GPs'
      practices in the canton. This paper presents the protocol for an evaluation of
      the implementation and effectiveness of the new organisational model. METHOD AND 
      ANALYSIS: We will conduct a before-and-after study using a mixed-methods and a
      realist approach. First, we will use quantitative and qualitative data to assess 
      the new organisational model's implementation (feasibility, fidelity,
      acceptability and costs) and effectiveness (healthcare services use, patient
      experience, staff experience and patient-level costs). Combining this data with
      focus group data will enable a realist evaluation of the pilot project, which
      will help understand the elements of context and mechanism that affect
      implementation. ETHICS AND DISSEMINATION: The evaluation will inform the canton
      of Vaud's health authorities about the limits of and perspectives for this
      organisational model. All results will also be made available to the practices
      and the patients involved. At the end of the project, we will propose
      organisational adaptations and a sustainable financial model for extending the
      model to other practices in the canton and potentially to the national level.The 
      canton of Vaud's Human Research Ethics Committee approved the study, and Data
      Protection and Information Law Authority gave a favourable opinion concerning
      data processing procedures.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Schutz Leuthold, Muriel
AU  - Schutz Leuthold M
AUID- ORCID: 0000-0001-8303-5126
AD  - Departement Medecine de famille, Centre Universitaire de Medecine Generale et
      Sante Publique, Lausanne, Switzerland muriel.schutz@unisante.ch.
FAU - Schwarz, Joelle
AU  - Schwarz J
AD  - Departement Medecine de famille, Centre Universitaire de Medecine Generale et
      Sante Publique, Lausanne, Switzerland.
FAU - Marti, Joachim
AU  - Marti J
AD  - Departement Epidemiologie et Systemes de sante, Centre Universitaire de Medecine 
      Generale et Sante Publique, Lausanne, Switzerland.
FAU - Perraudin, Clemence
AU  - Perraudin C
AD  - Departement des Policliniques, Centre Universitaire de Medecine Generale et Sante
      Publique, Lausanne, Switzerland.
FAU - Hudon, Catherine
AU  - Hudon C
AUID- ORCID: 0000-0001-6140-9916
AD  - Departement de Medecine de Famille et Medecine d'Urgence, Universite de
      Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Peytremann-Bridevaux, Isabelle
AU  - Peytremann-Bridevaux I
AUID- ORCID: 0000-0002-6514-8781
AD  - Departement Epidemiologie et Systemes de sante, Centre Universitaire de Medecine 
      Generale et Sante Publique, Lausanne, Switzerland.
FAU - Senn, Nicolas
AU  - Senn N
AD  - Departement Medecine de famille, Centre Universitaire de Medecine Generale et
      Sante Publique, Lausanne, Switzerland.
FAU - Cohidon, Christine
AU  - Cohidon C
AD  - Departement Medecine de famille, Centre Universitaire de Medecine Generale et
      Sante Publique, Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *General Practitioners
MH  - Humans
MH  - *Models, Organizational
MH  - Pilot Projects
MH  - Primary Health Care
MH  - Switzerland
PMC - PMC7733189
OTO - NOTNLM
OT  - *general medicine (see Internal Medicine)
OT  - *organisation of health services
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040154 [pii]
AID - 10.1136/bmjopen-2020-040154 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e040154. doi: 10.1136/bmjopen-2020-040154.


PMID- 33303446
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Modified minimally invasive surgical technique plus Bio-Oss Collagen for
      regenerative therapy of isolated interdental intrabony defects: study protocol
      for a randomised controlled trial.
PG  - e040046
LID - 10.1136/bmjopen-2020-040046 [doi]
AB  - INTRODUCTION: Periodontal regeneration surgery has been widely used to deal with 
      intrabony defects. Modified minimally invasive surgical technique (M-MIST) is
      designed to deal with isolated interdental intrabony defects, and has achieved
      satisfactory periodontal regenerative effect. Bio-Oss Collagen, as a bioactive
      material, has been applied for periodontal regeneration. It is similar to human
      cancellous bone, with the ability to promote bone formation; furthermore, it has 
      exceptional plasticity and spatial stability. The combination of different
      materials and techniques has become a research hotspot in recent years. By
      combining the superiority of regeneration technology and materials, better
      regenerative effect can be achieved. This study will search for differences
      between M-MIST combined with Bio-Oss Collagen, and M-MIST alone in regeneration
      therapy for intrabony defects. METHODS AND ANALYSIS: The present research is
      designed as a two-group parallel randomised controlled trial. The total number of
      patients is 40. The patients will be randomly assigned to two groups, with 20
      participants in each group, for further periodontal regenerative surgery. Test
      group: M-MIST plus Bio-Oss Collagen. CONTROL GROUP: M-MIST. After 12 months, the 
      measurement indices will be recorded; these will include clinical attachment gain
      and radiographical intrabony defect depth change as the primary results, and
      secondary outcomes of full-mouth plaque scores, probing depth, full-mouth
      bleeding scores, gingival recession, mobility, gingival papilla height and Visual
      Analogue Scale. The paired samples t-test will be applied to detect any
      difference between baseline and 1-year registrations. A general linear model will
      be performed to study the relationship between the secondary and the primary
      outcome. ETHICS AND DISSEMINATION: The present research has received approval
      from the Ethics Committee of Peking University School and Hospital of Stomatology
      (PKUSSIRB-202053002). Data of the present research will be registered with the
      International Clinical Trials Registry Platform. Additionally, we will
      disseminate the results through scientific dental journals. TRIAL REGISTRATION
      NUMBER: ChiCTR-2000030851. PROTOCOL VERSION: Protocol Version 4, 14 July 2020.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Churen
AU  - Zhang C
AUID- ORCID: 0000-0001-9070-7138
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China.
FAU - Zhang, Haidong
AU  - Zhang H
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China.
FAU - Yue, Zhaoguo
AU  - Yue Z
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China.
FAU - Miao, Lili
AU  - Miao L
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China.
FAU - Han, Ye
AU  - Han Y
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China.
FAU - Liu, Kaining
AU  - Liu K
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China liukainingbjmu@163.com jxhou@163.com.
FAU - Hou, Jianxia
AU  - Hou J
AD  - Department of Periodontology, Peking University School and Hospital of
      Stomatology and National Engineering Laboratory for Digital and Material
      Technology of Stomatology and Beijing Key Laboratory of Digital Stomatology,
      Beijing, China liukainingbjmu@163.com jxhou@163.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Bio-Oss)
RN  - 0 (Minerals)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - *Alveolar Bone Loss/surgery
MH  - Collagen
MH  - Follow-Up Studies
MH  - *Guided Tissue Regeneration, Periodontal
MH  - Humans
MH  - Minerals
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7733185
OTO - NOTNLM
OT  - *clinical trials
OT  - *oral & maxillofacial surgery
OT  - *plastic & reconstructive surgery
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040046 [pii]
AID - 10.1136/bmjopen-2020-040046 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e040046. doi: 10.1136/bmjopen-2020-040046.


PMID- 33303445
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Effectiveness of a web-based decision aid for patients with generalised anxiety
      disorder: a protocol for a randomised controlled trial.
PG  - e039956
LID - 10.1136/bmjopen-2020-039956 [doi]
AB  - INTRODUCTION: Patients with generalised anxiety disorder (GAD) have concerns and 
      needs about their health and the healthcare they receive. Patient decision aids
      (PtDAs) are tools that assist patients in making health decisions, when there is 
      uncertainty about treatment choice, incorporating their personal preferences and 
      values about the available treatment options. PtDAs can improve shared
      decision-making and lead to better treatment outcomes. The aim of this study is
      to evaluate the effectiveness of a web-based PtDA for patients with GAD in
      primary care (PC). METHODS AND ANALYSIS: The general study design is comprised of
      two stages: (1) development of a web-based PtDA for patients with GAD, derived
      from an evidence-based Clinical Practice Guideline and (2) assessment of the
      effectiveness of the PtDA in a randomised controlled trial (RCT) design, in PC
      centres in Tenerife (Spain). This RCT will be carried out with 124 patients with 
      GAD, comparing the PtDA to a fact sheet with general information on mental
      health. Patients will review the PtDA in one session accompanied by a researcher.
      Post-intervention measures will be administered immediately after the
      intervention and at 3-month follow-up. The primary outcome will be decisional
      conflict. Secondary outcomes will include knowledge about GAD and its treatment, 
      treatment preference, concordance between treatment preference and choice, and
      decision quality (knowledge >/=60% and concordant decision). ETHICS AND
      DISSEMINATION: The project received ethics approval from the local committee at
      Nuestra Senora de la Candelaria (HUNSC) University Hospital in Santa Cruz de
      Tenerife (code: CHUNSC_2019_58). Informed consent will be obtained from each
      participant before randomisation. Results from the trial will be submitted for
      publication in international peer-reviewed scientific journals and will be
      disseminated through workshops and local and international conferences. TRIAL
      REGISTRATION NUMBER: NCT04364958.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Perestelo-Perez, Lilisbeth
AU  - Perestelo-Perez L
AD  - Evaluation Unit (SESCS), Canary Islands Health Service (SCS), Tenerife, Spain
      lilisbeth.peresteloperez@sescs.es.
AD  - Research Network on Health Services in Chronic Diseases (REDISSEC), Tenerife,
      Spain.
FAU - Rivero-Santana, Amado
AU  - Rivero-Santana A
AD  - Research Network on Health Services in Chronic Diseases (REDISSEC), Tenerife,
      Spain.
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
FAU - Ramos-Garcia, Vanesa
AU  - Ramos-Garcia V
AUID- ORCID: 0000-0002-9106-2420
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
AD  - University of La Laguna, Tenerife, Spain.
FAU - Alvarez-Perez, Yolanda
AU  - Alvarez-Perez Y
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
FAU - Duarte-Diaz, Andrea
AU  - Duarte-Diaz A
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
AD  - University of La Laguna, Tenerife, Spain.
FAU - Torres-Castano, Alezandra
AU  - Torres-Castano A
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
FAU - Trujillo-Martin, Maria Del Mar
AU  - Trujillo-Martin MDM
AD  - Research Network on Health Services in Chronic Diseases (REDISSEC), Tenerife,
      Spain.
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
FAU - Del Pino-Sedeno, Tasmania
AU  - Del Pino-Sedeno T
AD  - Canary Islands Health Research Institute Foundation, Tenerife, Spain.
FAU - Gonzalez-Gonzalez, Ana Isabel
AU  - Gonzalez-Gonzalez AI
AUID- ORCID: 0000-0002-1707-0596
AD  - Research Network on Health Services in Chronic Diseases (REDISSEC), Tenerife,
      Spain.
AD  - Goethe-Universitat Frankfurt am Main Institut fur Allgemeinmedizin, Frankfurt am 
      Main, Germany.
AD  - Centro de Salud Vicente Muzas, Gerencia Asistencial de Atencion Primaria,
      Servicio Madrileno de Salud, Madrid, Spain.
FAU - Serrano-Aguilar, Pedro
AU  - Serrano-Aguilar P
AD  - Evaluation Unit (SESCS), Canary Islands Health Service (SCS), Tenerife, Spain.
AD  - Research Network on Health Services in Chronic Diseases (REDISSEC), Tenerife,
      Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04364958
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anxiety Disorders/therapy
MH  - Decision Making
MH  - *Decision Support Techniques
MH  - Humans
MH  - Internet
MH  - *Patient Participation
MH  - Randomized Controlled Trials as Topic
MH  - Spain
PMC - PMC7733176
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *clinical trials
OT  - *mental health
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039956 [pii]
AID - 10.1136/bmjopen-2020-039956 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e039956. doi: 10.1136/bmjopen-2020-039956.


PMID- 33303444
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Goal-directed perfusion to reduce acute kidney injury after paediatric cardiac
      surgery (GDP-AKIp): study protocol for a prospective randomised controlled trial.
PG  - e039385
LID - 10.1136/bmjopen-2020-039385 [doi]
AB  - INTRODUCTION: Cardiac surgery-associated acute kidney injury (CS-AKI) occurs in
      up to 40%~60% of paediatric patients and increases postoperative morbidity and
      mortality. A goal-directed perfusion (GDP) strategy aimed at maintaining indexed 
      oxygen delivery (DO2i) above the critical threshold (reported to be 260~300
      mL/min/m(2) in adults) during cardiopulmonary bypass (CPB), is effective in
      reducing the incidence of CS-AKI. However, no clear standards of paediatric
      critical DO2i exist. Our prior prospective cohort study exploring the critical
      DO2i threshold during paediatric CPB has found the nadir DO2i <353 mL/min/m(2)
      was an independent risk predictor of CS-AKI. Based on this background, this trial
      is designed to further determine whether the implementation of the GDP initiative
      aimed at maintaining DO2i >/=360 mL/min/m(2) would reduce the rate of CS-AKI in
      paediatrics and improve clinical outcome. METHODS AND ANALYSIS: This is a
      prospective, single-centre, randomised controlled trial. In total, 166 paediatric
      patients undergoing cardiac surgery will be randomly allocated to the GDP group
      or control group. Patients in the GDP arm will be treated with a GDP strategy
      during CPB aimed to maintain DO2i at >/=360 mL/min/m(2) (to ensure safely above
      the risk DO2i threshold we found). The perfusion strategy for patients in the
      control arm will be factored on body surface area and temperature. The primary
      outcome is the rate of postoperative CS-AKI (it is defined according to
      paediatric Risk, Injury, Failure, Loss of renal function and End-stage renal
      disease criteria). The secondary end points include: (1) the other oxygen
      metabolism parameters during CPB; (2) major complication and all-cause mortality 
      (in-hospital or within 30 days postoperatively); (3) short-term clinical outcomes
      (ie, time to extubation, mechanical ventilation time, hospital stay). ETHICS AND 
      DISSEMINATION: The study has been approved by the Biomedical Research Ethics
      committee of West China Hospital of Sichuan University (approval number:
      2019(863)). Results will be disseminated through peer-reviewed publications and
      conferences. TRIAL REGISTRATION NUMBER: ChiCTR2000029232.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Yan
AU  - Zhang Y
AUID- ORCID: 0000-0003-2146-1052
AD  - Anesthesiology, West China Hospital of Sichuan University, Chengdu, China.
FAU - Zhou, Xiujuan
AU  - Zhou X
AD  - Anesthesiology, West China Hospital of Sichuan University, Chengdu, China.
FAU - Wang, Bo
AU  - Wang B
AD  - Anesthesiology, West China Hospital of Sichuan University, Chengdu, China.
FAU - Guo, Lijuan
AU  - Guo L
AD  - Anesthesiology, West China Hospital of Sichuan University, Chengdu, China.
FAU - Zhou, Ronghua
AU  - Zhou R
AD  - Anesthesiology, West China Hospital of Sichuan University, Chengdu, China
      wr.zhou@hotmail.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acute Kidney Injury/etiology/prevention & control
MH  - *Cardiac Surgical Procedures/adverse effects
MH  - Cardiopulmonary Bypass/adverse effects
MH  - Child
MH  - China
MH  - Goals
MH  - Humans
MH  - *Pediatrics
MH  - Perfusion
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7733190
OTO - NOTNLM
OT  - *acute renal failure
OT  - *clinical trials
OT  - *paediatric cardiac surgery
OT  - *paediatric intensive & critical care
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039385 [pii]
AID - 10.1136/bmjopen-2020-039385 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e039385. doi: 10.1136/bmjopen-2020-039385.


PMID- 33303442
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Study protocol for a network meta-analysis of digital-technology-based
      psychotherapies for PTSD in adults.
PG  - e038951
LID - 10.1136/bmjopen-2020-038951 [doi]
AB  - INTRODUCTION: Studies on various types of digital-technology-based
      psychotherapies (DTPs) have indicated that they are effective for post-traumatic 
      stress disorder (PTSD) symptom relief among adults. The intervention efficacy or 
      effectiveness hierarchy, however, is still not clear. Therefore, we propose to
      conduct a network meta-analysis to assess the relative effectiveness of various
      types of DTPs. We aim to establish the differential effectiveness of these
      therapies in terms of symptom reduction and provide high-quality evidence for
      treating PTSD. METHODS AND ANALYSES: We will search Embase, CINAHL, MEDLINE,
      HealthSTAR, the Cochrane Library, PsycINFO, PubMed, the Chinese Biomedical
      Literature Database, clinical trials (eg, ClinicalTrials.gov) and other academic 
      platforms for relevant studies, mainly in English and Chinese (as we plan to
      conduct a trial on PTSD patients in Wuhan, China, based on the results of this
      network meta-analysis), from inception to October 2020. Randomised controlled
      trials (RCTs) and meta-analyses investigating the effectiveness of any DTPs for
      PTSD patients for any controlled condition will be included. The number of
      intervention sessions and the research duration are unlimited; the effects for
      different durations will be tested via sensitivity analysis. For this project,
      the primary measure of outcome will be PTSD symptoms at the end of treatment
      using raw scores for one widely used PTSD scale, PCL-5. Secondary outcome
      measures will include (1) dropout rate; (2) effectiveness at longest follow-up,
      but not more than 12 months and (3) patients' functional recovery ratio (such as 
      the return-to-work ratio or percentage of sick leave). Bayesian network
      meta-analysis will be conducted for all relative outcome measures. We will
      perform subgroup analysis and sensitivity analysis to see whether the results are
      influenced by study characteristics. The Grading of Recommendations, Assessments,
      Development, and Evaluation framework will be adopted to evaluate the quality of 
      evidence contributing to network estimates of the primary outcome. ETHICS AND
      DISSEMINATION: The researchers of the primary trials already have had ethical
      approval for the data used in our study. We will present the results of this
      meta-analysis at academic conferences and publish them in peer-reviewed journals.
      PROSPERO REGISTRATION NUMBER: CRD42020173253.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, Longtao
AU  - He L
AUID- ORCID: 0000-0001-7072-7457
AD  - Research Institute of Social Development, Southwestern University of Finance and 
      Economics, Chengdu, Sichuan, China lzhlt01@hotmail.com.
FAU - Geng, Yanling
AU  - Geng Y
AD  - Department of Social Work, Northwest University, Xi'an, Shanxi, China.
FAU - Pan, Yangu
AU  - Pan Y
AD  - Research Institute of Social Development, Southwestern University of Finance and 
      Economics, Chengdu, Sichuan, China.
FAU - Tian, Jinhui
AU  - Tian J
AD  - Evidence-Based Medicine Centre & School of Basic Science, Lanzhou University,
      Lanzhou, Gansu, China.
FAU - He, Xinyu
AU  - He X
AD  - School of Social Development, Xihua University, Chengdu, Sichuan, China.
FAU - Deng, Xiangshu
AU  - Deng X
AD  - Research Institute of Social Development, Southwestern University of Finance and 
      Economics, Chengdu, Sichuan, China.
FAU - Duan, Wenjie
AU  - Duan W
AD  - Department of Social Work, East China University of Science and Technology,
      Shanghai, China.
FAU - Peng, Huamin
AU  - Peng H
AD  - Department of Social Work and Social Policy, Nanjing University, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - China
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Psychotherapy
MH  - *Stress Disorders, Post-Traumatic/therapy
MH  - Technology
PMC - PMC7733188
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *mental health
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038951 [pii]
AID - 10.1136/bmjopen-2020-038951 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e038951. doi: 10.1136/bmjopen-2020-038951.


PMID- 33303441
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Tuina for spasticity of poststroke: protocol of a systematic review and
      meta-analysis.
PG  - e038705
LID - 10.1136/bmjopen-2020-038705 [doi]
AB  - INTRODUCTION: Spasticity is a common complication of poststroke, tuina is a
      widely used rehabilitation treatment, although there is a lack of supportive
      evidence on efficacy and safety for patients with poststroke spasticity. The aim 
      of this systematic review is to assess and synthesis evidence of efficacy and
      safety of tuina for spasticity of poststroke. METHODS AND ANALYSIS: A
      comprehensive electronic search of EMBASE, MEDLINE, Cochrane Library, Web of
      Science, Wiley, Springer, PEDro, Chinese Science Citation Database, China
      National Knowledge Infrastructure, Chinese Biomedical Literature Database,
      Chinese Scientific and Journal Database (VIP), Wanfang Database (Wanfang),
      Japanese medical database (CiNii), Korean Robotics Institute Summer Scholars and 
      Thailand Thai-Journal Citation Index Centre will be conducted to search
      literatures of randomised controlled trials of tuina for spasticity of poststroke
      survivors range from the establishment to 1 January 2020.There is no time of
      publication limitations. The primary outcome will be measured with the Modified
      Ashworth Scale, and the second outcome will include Fugl-Meyer Assessment Scale, 
      surface electromyogram RMS value, the Modified Barthel Index, Stroke Specific
      Quality of Life Scale, quality of life 36-Item Short-Form Health Survey and
      Visual Analogue Scale. Cochrane Handbook for Systematic Reviews of Interventions 
      will be used to assess the risk of bias, and GRADE will be used to access the
      confidence in cumulative evidence. The protocol will be conducted according to
      approach and Preferred Reporting Items for Systematic Review and Meta-Analysis
      Protocols 2015. ETHICS AND DISSEMINATION: Ethical approval will not be required, 
      for no primary data of individual patients were collected. We will publish the
      findings in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020163384.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Qiongshuai
AU  - Zhang Q
AUID- ORCID: 0000-0003-0594-1654
AD  - Acupuncture and Tuina Department, Changchun University of Chinese Medicine,
      Changchun, China.
FAU - Ji, Guangcheng
AU  - Ji G
AD  - Rehabilitation Medicine Department, Changchun University of Chinese Medicine,
      Changchun, China.
FAU - Cao, Fang
AU  - Cao F
AD  - Acupuncture Department, Henan University of Traditional Chinese Medicine,
      Zhengzhou, China.
FAU - Sun, Yihan
AU  - Sun Y
AD  - TCM Department, Changchun University of Chinese Medicine, Changchun, China.
FAU - Hu, Guanyu
AU  - Hu G
AD  - Acupuncture and Tuina Department, Changchun University of Chinese Medicine,
      Changchun, China.
FAU - Sun, Shaoqian
AU  - Sun S
AD  - Rehabilitation Medicine Department, Jilin University Third Affiliated Hospital,
      Changchun, China.
FAU - Liu, Yanze
AU  - Liu Y
AD  - Acupuncture and Tuina Department, Changchun University of Chinese Medicine,
      Changchun, China.
FAU - Cao, Jiazhen
AU  - Cao J
AD  - Acupuncture and Tuina Department, Changchun University of Chinese Medicine,
      Changchun, China.
FAU - Wang, Yufeng
AU  - Wang Y
AD  - Tuina Department, First Affiliated Hospital to Changchun University of Chinese
      Medicine, Changchun, China.
FAU - Xu, Xiaohong
AU  - Xu X
AD  - Graduate School, Changchun University of Chinese Medicine, Changchun, China.
FAU - Song, Bailin
AU  - Song B
AD  - Acupuncture and Tuina Department, Changchun University of Chinese Medicine,
      Changchun, China jlsongbl@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - *Data Management
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Quality of Life
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Thailand
PMC - PMC7733218
OTO - NOTNLM
OT  - *limb reconstruction
OT  - *rehabilitation medicine
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038705 [pii]
AID - 10.1136/bmjopen-2020-038705 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e038705. doi: 10.1136/bmjopen-2020-038705.


PMID- 33303437
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Randomised controlled trial of paracetamol or ibuprofen, as required for fever
      and pain in the first year of life, for prevention of asthma at age 6 years:
      paracetamol or ibuprofen in the primary prevention of asthma in Tamariki (PIPPA
      Tamariki) protocol.
PG  - e038296
LID - 10.1136/bmjopen-2020-038296 [doi]
AB  - INTRODUCTION: Asthma is one of the most common diseases in the world and is a
      global public health burden. There is an urgent need for research that leads to
      evidenced-based primary prevention strategies to reduce the prevalence of asthma.
      One novel risk factor that might have a role in the pathogenesis of asthma is the
      use of paracetamol in early life. This trial aims to determine if paracetamol,
      compared with ibuprofen use, as required for fever and pain in the first year of 
      life, increases the risk of asthma at age 6 years. METHODS AND ANALYSIS: The
      Paracetamol and Ibuprofen in Primary Prevention of Asthma in Tamariki trial is a 
      multicentre, open-label, two-arm parallel randomised controlled trial. 3922
      infants born at >/=32 weeks' gestation will be randomly allocated to receive only
      paracetamol or only ibuprofen for treatment of fever and pain, if required in the
      first year of life. The primary outcome is asthma at 6 years of age, defined as
      the presence of wheeze in the preceding 12 months. Secondary outcomes include
      hospital admissions for bronchiolitis, wheeze or asthma in the first year of
      life, and within the first 6 years of life; wheeze at 3 years of age; eczema
      within the first year and at 3 and 6 years of age; atopy at 3 and 6 years of age.
      ETHICS AND DISSEMINATION: The trial has been approved by the Northern A Health
      and Disability Ethics Committee of New Zealand (17/NTA/233). Dissemination plans 
      include publication in international peer-reviewed journals, and presentation at 
      national and international scientific meetings, assimilation into national and
      international guidelines, and presentation of findings to lay audiences through
      established media links. TRIAL REGISTRATION NUMBER: ACTRN12618000303246;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tan, Eunicia
AU  - Tan E
AUID- ORCID: 0000-0002-6296-3545
AD  - Department of Surgery, University of Auckland, Auckland, New Zealand.
AD  - Emergency Department, Middlemore Hospital, Auckland, New Zealand.
FAU - Braithwaite, Irene
AU  - Braithwaite I
AUID- ORCID: 0000-0001-5327-3027
AD  - Medical Research Institute of New Zealand, Wellington, New Zealand.
FAU - McKinlay, Christopher
AU  - McKinlay C
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - Kids First Neonatal Care, Middlemore Hospital, Auckland, New Zealand.
FAU - Riley, Judith
AU  - Riley J
AD  - Medical Research Institute of New Zealand, Wellington, New Zealand.
FAU - Hoare, Karen
AU  - Hoare K
AD  - School of Nursing, Massey University, Auckland, New Zealand.
FAU - Okesene-Gafa, Karaponi
AU  - Okesene-Gafa K
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
AD  - Department of Obstetrics and Gynaecology, Middlemore Hospital, Auckland, New
      Zealand.
FAU - Semprini, Alex
AU  - Semprini A
AUID- ORCID: 0000-0003-0949-0555
AD  - Medical Research Institute of New Zealand, Wellington, New Zealand.
FAU - Sheridan, Nicolette
AU  - Sheridan N
AD  - School of Nursing, Massey University, Auckland, New Zealand.
FAU - Grant, Cameron
AU  - Grant C
AD  - Department of Paediatrics: Child and Youth Health, University of Auckland,
      Auckland, New Zealand.
AD  - General Paediatrics, Starship Children's Health, Auckland, Auckland, New Zealand.
FAU - Johnson, David
AU  - Johnson D
AD  - Department of Pediatrics, Physiology and Pharmacology, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Weatherall, Mark
AU  - Weatherall M
AD  - Rehabilitation, Teaching and Research Unit, University of Otago, Wellington, New 
      Zealand.
FAU - Asher, Innes
AU  - Asher I
AD  - Department of Paediatrics: Child and Youth Health, University of Auckland,
      Auckland, New Zealand.
FAU - Beasley, Richard
AU  - Beasley R
AUID- ORCID: 0000-0003-0337-406X
AD  - Medical Research Institute of New Zealand, Wellington, New Zealand.
FAU - Dalziel, Stuart R
AU  - Dalziel SR
AD  - Cure Kids Chair of Child Health Research; Departments of Surgery and Paediatrics:
      Child and Youth Health, University of Auckland, Auckland, New Zealand
      s.dalziel@auckland.ac.nz.
AD  - Children's Emergency Department, Starship Children's Health, Auckland, New
      Zealand.
LA  - eng
SI  - ANZCTR/ACTRN12618000303246
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 362O9ITL9D (Acetaminophen)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - *Acetaminophen/therapeutic use
MH  - *Asthma/drug therapy/prevention & control
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Ibuprofen/therapeutic use
MH  - Infant
MH  - Infant, Newborn
MH  - Multicenter Studies as Topic
MH  - New Zealand
MH  - Pain
MH  - Primary Prevention
MH  - Randomized Controlled Trials as Topic
PMC - PMC7733172
OTO - NOTNLM
OT  - *allergy
OT  - *asthma
OT  - *eczema
OT  - *immunology
OT  - *paediatric thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038296 [pii]
AID - 10.1136/bmjopen-2020-038296 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e038296. doi: 10.1136/bmjopen-2020-038296.


PMID- 33303435
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Safety and feasibility evaluation of planning and execution of surgical
      revascularisation solely based on coronary CTA and FFRCT in patients with complex
      coronary artery disease: study protocol of the FASTTRACK CABG study.
PG  - e038152
LID - 10.1136/bmjopen-2020-038152 [doi]
AB  - INTRODUCTION: The previously published SYNTAX III REVOLUTION trial demonstrated
      that clinical decision-making between coronary artery bypass graft (CABG) and
      percutaneous coronary intervention based on coronary CT angiography (CCTA) had a 
      very high agreement with the treatment decision derived from invasive coronary
      angiography (ICA). The study objective of the FASTTRACK CABG is to assess the
      feasibility of CCTA and fractional flow reserve derived from CTA (FFRCT) to
      replace ICA as a surgical guidance method for planning and execution of CABG in
      patients with three-vessel disease with or without left main disease. METHODS AND
      ANALYSIS: The FASTTRACK CABG is an investigator-initiated single-arm,
      multicentre, prospective, proof-of-concept and first-in-man study with
      feasibility and safety analysis. Surgical revascularisation strategy and
      treatment planning will be solely based on CCTA and FFRCT without knowledge of
      the anatomy defined by ICA. Clinical follow-up visit including CCTA will be
      performed 30 days after CABG in order to assess graft patency and adequacy of the
      revascularisation with respect to the surgical planning based on non-invasive
      imaging (CCTA) with functional assessment (FFRCT) and compared with ICA. Primary 
      feasibility endpoint is CABG planning and execution solely based on CCTA and
      FFRCT in 114 patients. Primary safety endpoint based on 30 day CCTA is graft
      assessment and topographical adequacy of the revascularisation procedure.
      Automatic non-invasive assessment of functional coronary anatomy complexity is
      also evaluated with FFRCT for functional Synergy Between percutaneous coronary
      intervention With Taxus and Cardiac Surgery Score assessment on CCTA. CCTA with
      FFRCT might provide better anatomical and functional analysis of the coronary
      circulation leading to appropriate anatomical and functional revascularisation,
      and thereby contributing to a better outcome. ETHICS AND DISSEMINATION: Each
      patient has to provide written informed consent as approved by the ethical
      committee of the respective clinical site. Results will be submitted for
      publication in peer-reviewed journals and will be disseminated at scientific
      conferences. TRIAL REGISTRATION NUMBER: NCT04142021.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kawashima, Hideyuki
AU  - Kawashima H
AD  - National University of Ireland Galway, Galway, Ireland.
AD  - Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Pompilio, Giulio
AU  - Pompilio G
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
AD  - Department of Biomedical, Surgical and Dental Sciences, University of Milan,
      Milan, Italy.
FAU - Andreini, Daniele
AU  - Andreini D
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
AD  - Department of Biomedical, Surgical and Dental Sciences, University of Milan,
      Milan, Italy.
FAU - Bartorelli, Antonio L
AU  - Bartorelli AL
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
AD  - Department of Biomedical and Clinical Sciences "Luigi Sacco", University of
      Milan, Milan, Italy.
FAU - Mushtaq, Saima
AU  - Mushtaq S
AD  - Centro Cardiologico Monzino, IRCCS, Milan, Italy.
FAU - Ferrari, Enrico
AU  - Ferrari E
AD  - University Hospital and University of Zurich, Zurich, Switzerland.
FAU - Maisano, Francesco
AU  - Maisano F
AD  - University Hospital and University of Zurich, Zurich, Switzerland.
FAU - Buechel, Ronny R
AU  - Buechel RR
AD  - University Hospital and University of Zurich, Zurich, Switzerland.
FAU - Tanaka, Kaoru
AU  - Tanaka K
AD  - Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium.
FAU - La Meir, Mark
AU  - La Meir M
AD  - Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium.
FAU - De Mey, Johan
AU  - De Mey J
AD  - Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium.
FAU - Schneider, Ulrich
AU  - Schneider U
AD  - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.
FAU - Doenst, Torsten
AU  - Doenst T
AD  - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.
FAU - Teichgraber, Ulf
AU  - Teichgraber U
AD  - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.
FAU - Stone, Gregg W
AU  - Stone GW
AD  - Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at 
      Mount Sinai, New York City, NY, USA.
AD  - Cardiovascular Research Foundation, New York City, NY, USA.
FAU - Sharif, Faisal
AU  - Sharif F
AD  - National University of Ireland Galway, Galway, Ireland.
FAU - de Winter, Robbert
AU  - de Winter R
AD  - Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Thomsen, Brian
AU  - Thomsen B
AD  - GE Healthcare, Milwaukee, Wisconsin, USA.
FAU - Taylor, Charles
AU  - Taylor C
AD  - HeartFlow, Inc, Redwood City, California, USA.
FAU - Rogers, Campbell
AU  - Rogers C
AD  - HeartFlow, Inc, Redwood City, California, USA.
FAU - Leipsic, Jonathon
AU  - Leipsic J
AD  - St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia,
      Canada.
FAU - Wijns, William
AU  - Wijns W
AD  - National University of Ireland Galway, Galway, Ireland.
FAU - Onuma, Yoshinobu
AU  - Onuma Y
AD  - National University of Ireland Galway, Galway, Ireland.
FAU - Serruys, Patrick W
AU  - Serruys PW
AUID- ORCID: 0000-0002-9636-1104
AD  - National University of Ireland Galway, Galway, Ireland
      patrick.w.j.c.serruys@gmail.com.
AD  - NHLI, Imperial College London, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04142021
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Coronary Angiography
MH  - Coronary Artery Bypass
MH  - *Coronary Artery Disease/diagnostic imaging/surgery
MH  - Feasibility Studies
MH  - *Fractional Flow Reserve, Myocardial
MH  - Humans
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Tomography, X-Ray Computed
PMC - PMC7733219
OTO - NOTNLM
OT  - *cardiac surgery
OT  - *cardiology
OT  - *cardiothoracic surgery
OT  - *cardiovascular imaging
OT  - *coronary heart disease
OT  - *ischaemic heart disease
COIS- Competing interests: GWS reports personal fees from Terumo, personal fees from
      Amaranth, personal fees from Shockwave, personal fees from Valfix, personal fees 
      from TherOx, personal fees from Reva, personal fees from Vascular Dynamics,
      personal fees from Robocath, personal fees from HeartFlow, personal fees from
      Gore, personal fees from Ablative Solutions, personal fees from Matrizyme,
      personal fees from Miracor, personal fees from Neovasc, personal fees from
      V-wave, personal fees from Abiomed, personal fees from Claret, personal fees from
      Sirtex, personal fees and other from Ancora, personal fees and other from Qool
      Therapeutics, other from Cagent, other from Applied Therapeutics, other from
      Biostar family of funds, other from MedFocus family of funds, personal fees and
      other from SpectraWave, personal fees from MAIA Pharmaceuticals, personal fees
      and other from Orchestra Biomed, other from Aria, outside the submitted work. JL 
      is a consultant to and holds stock options in HeartFlow and Circle CVI and
      receives research grant support from GE Healthcare. BT is an employee of GE
      Healthcare. CT and CR report personal fees from HeartFlow, Inc, during the
      conduct of the study. PWS reports personal fees from Biosensors, Medtronic, Micel
      Technologies, Sinomedical Sciences Technology, St. Jude Medical, Philips/Volcano,
      Xeltis, and HeartFlow, outside the submitted work. All other authors have no
      conflict of interest to declare.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038152 [pii]
AID - 10.1136/bmjopen-2020-038152 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e038152. doi: 10.1136/bmjopen-2020-038152.


PMID- 33303432
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Clinical preventive guidelines for school-aged children and adolescents in
      primary care: a protocol for a systematic review.
PG  - e037396
LID - 10.1136/bmjopen-2020-037396 [doi]
AB  - INTRODUCTION: Guidelines for clinical preventive services targeting school-aged
      children and adolescents in primary care are limited, often inconsistent and
      difficult to apply in clinical contexts. This publication describes the protocol 
      concerning a comprehensive systematic review that primarily aims to collect and
      synthesise available guidelines for prevention in primary care focused on
      school-aged children living in high-income regions. A second objective is to
      assess the quality of identified documents. METHODS AND ANALYSIS: We will search 
      for reports providing clinical practice guidelines or consensus or expert opinion
      on preventive actions in paediatric primary care. We will use the WHO definition 
      of prevention. We will focus on children aged 6-18 years living in the European
      region, the USA, Canada and Australia. We will search PubMed, Embase, Web of
      Science and Cochrane Library and guidelines-specific databases from 1 January
      2010. We will also explore the grey literature using web search engines (Google
      and Google Scholar). We will finally obtain unpublished information through
      personal contact with national paediatric societies. We will summarise all
      identified documents as well as their potential methodological bias. We will
      further use the Appraisal of Guidelines Research and Evaluation Instrument,
      version II tool to critically appraise their quality. ETHICS AND DISSEMINATION:
      Our findings will contribute to the identification of clinical preventive
      guidelines for which implementation in routine paediatric primary care should be 
      considered. We intend to disseminate our results through publication in
      peer-reviewed journals and conference proceedings.PROSPERO registration
      numberCRD42020163184.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Patseadou, Magdalini
AU  - Patseadou M
AUID- ORCID: 0000-0003-3619-4196
AD  - Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva, Switzerland
      magdalini.patseadou@unige.ch.
AD  - Department of Woman, Child and Adolescent Health, Geneva University Hospitals,
      Geneva, Switzerland.
FAU - Pfarrwaller, Eva
AU  - Pfarrwaller E
AD  - Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
FAU - Haller, Dagmar M
AU  - Haller DM
AUID- ORCID: 0000-0003-1781-3318
AD  - Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
AD  - Department of Primary Care Medicine, Geneva University Hospitals, Geneva,
      Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia
MH  - Canada
MH  - Child
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Primary Health Care
MH  - Schools
PMC - PMC7733204
OTO - NOTNLM
OT  - *paediatrics
OT  - *preventive medicine
OT  - *primary care
OT  - *protocols & guidelines
COIS- Competing interests: All authors have completed the icmje uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf and declare that the only support for the
      submitted work was from the funders mentioned in 'funding sources'. The authors
      have no financial relationships with any organisations that might have an
      interest in the submitted work in the previous 3 years and no other relationships
      or activities that could appear to have influenced the submitted work.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037396 [pii]
AID - 10.1136/bmjopen-2020-037396 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e037396. doi: 10.1136/bmjopen-2020-037396.


PMID- 33303428
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 10
TI  - Management of acromioclavicular joint disease by manual therapy versus
      corticosteroid injections: the protocol of a non-inferiority study.
PG  - e034439
LID - 10.1136/bmjopen-2019-034439 [doi]
AB  - INTRODUCTION: Degenerative acromioclavicular joint pain accounts for about 4% of 
      shoulder pain. Various medical and non-medical treatment strategies are available
      for acromioclavicular joint disease but it is difficult to conduct a comparative 
      evaluation of these treatments. The few studies dealing with the medical
      management of the disease have conducted no comparative assessment of drug
      therapies, physiotherapy, joint manipulation and corticosteroid injections. The
      primary goal of this study is to determine whether manual therapy is not inferior
      to ultrasound-guided injection of a corticosteroid preparation to decrease
      acromiocalvicular joint pain at 3 months. METHODS AND ANALYSIS: The
      acromioclavicular arthropathy managed by manual therapy is a monocentric,
      comparative, randomised, controlled, non-inferiority study conducted in the
      Rheumatology Department of Vendee Departmental Hospital, involving two parallel
      groups receiving either corticosteroid injections or manual therapy. The
      inclusion criteria are patients who suffer from pain in the shoulder or the
      proximal part of the arm, with pain located on palpation of the acromioclavicular
      joint associated with a positive cross-arm test and a positive O'Brien test.
      Randomisation will be at a 1:1 ratio. The injection group will receive a single
      ultrasound-guided injection of 1 mL of Diprostene and the manual therapy group
      will receive between one and three sessions at intervals of one per week. The
      primary outcome will be to compare the Visual Analogue Scale for
      pain-activity-related score at 3 months for both groups. ETHICS AND
      DISSEMINATION: The study project has been approved by the appropriate ethics
      committee (Committee for the Protection of Patients Ouest II in Angers, 30 April 
      2019, with the registration number of 2019/22). In agreement with current French 
      regulations, signed informed written consent will be obtained from each patient. 
      Results of the main trial and of the secondary endpoints will be submitted for
      publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT03951480.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Michaut, Alexia
AU  - Michaut A
AD  - Department of Rheumatology, Departmental Hospital Center, La Roche sur Yon,
      Vendee, France alexia.michaut@chd-vendee.fr.
FAU - Planche, Lucie
AU  - Planche L
AD  - Departmental of Rheumatology, Vendee Departmental Hospital Center, La Roche sur
      Yon, France.
FAU - Auzanneau, Lucie
AU  - Auzanneau L
AD  - Departmental of Rheumatology, Vendee Departmental Hospital Center, La Roche sur
      Yon, France.
FAU - Cormier, Gregoire
AU  - Cormier G
AUID- ORCID: 0000-0002-8852-3687
AD  - Departmental of Rheumatology, Vendee Departmental Hospital Center, La Roche sur
      Yon, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03951480
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - *Acromioclavicular Joint/diagnostic imaging
MH  - Adrenal Cortex Hormones
MH  - Humans
MH  - Injections
MH  - *Musculoskeletal Manipulations
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7733203
OTO - NOTNLM
OT  - *acromiocalvicular joint
OT  - *corticosteroid injection
OT  - *degenerative disease
OT  - *manual therapy
OT  - *pain
COIS- Competing interests: None declared.
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:49
PHST- 2020/12/11 05:49 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034439 [pii]
AID - 10.1136/bmjopen-2019-034439 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 10;10(12):e034439. doi: 10.1136/bmjopen-2019-034439.


PMID- 33303024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2052-1847 (Print)
IS  - 2052-1847 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Dec 10
TI  - Effects of whole body vibration exercise on lumbar-abdominal muscles activation
      for patients with chronic low back pain.
PG  - 78
LID - 10.1186/s13102-020-00226-4 [doi]
AB  - BACKGROUND: Whole body vibration (WBV) training as an intervention method can
      cure chronic low back pain (CLBP). Different WBV parameters exert different
      effects on lumbar-abdominal muscle performance. Currently, there is a lack of
      study researched the influence of WBV training on patients with CLBP by
      lumbar-abdominal muscle activity. Therefore, this study aimed to investigate how 
      WBV and exercise and their interactions influence lumbar-abdominal muscle
      activity in patients with CLBP. METHODS: a group of ambulatory patients with
      chronic low back pain. Muscle activities of the multifidus (MF), erector spinae
      (ES), abdominal oblique externus muscle (AOE) and the rectus abdominis muscle
      (RA) were measured by surface electromyography, whereas participants performed 4 
      different exercises (single bridge, plank, side stay and V crunch) during three
      whole body vibration conditions and a no-vibration condition in a single
      experimental session. RESULTS: Compared with the same exercises without whole
      body vibration, muscle activity increased when whole body vibration was added to 
      the exercises. MF; the WBV frequency (P = 0.002,) and exercise (P < 0.001)
      presented significant effects on the root mean square of MF, whereas exercise *
      frequency (P = 0.044) also resulted in significant interaction effects. ES: the
      significant differences were detected at WBV frequency (P < 0.001), exercise (P <
      0.001), the interaction effect of exercise and frequency (P = 0.225) was no
      significant. RA: the significant difference was detected at WBV frequency (P =
      0.018), the effect of exercise (P = 0.590) and the exercise * frequency
      interaction (P = 0.572) were no significant. AOE: the significant difference was 
      detected at WBV frequency (P < 0.001), the effect of exercise (P = 0.152) and the
      exercise * frequency interaction (P = 0.380) were no significant. CONCLUSION:
      Adding whole body vibration to exercise could increase muscle activation of
      lumbar-abdominal muscle in patients with CLBP. The optimum frequency for
      lumbar-abdominal muscles is 15 Hz. The best exercises include plank for
      multifidus and erector spinae, V crunch for rectus abdominis and single bridge
      for abdominal oblique externus. CLINICAL REGISTRATION: Trial registration:
      ChiCTR-TRC-13003708 . Registered 19 October 2013. THE CODE OF ETHICAL APPROVAL:
      2014008.
FAU - Dong, Yulin
AU  - Dong Y
AD  - Department of Treatment, The Second Rehabilitation Hospital of Shanghai, 25
      Changjiang RD, Shanghai, China.
FAU - Wang, Huifang
AU  - Wang H
AD  - Yang Zhi Affiliated Rehabilition Hospital of Tongji, Shanghai, China.
FAU - Zhu, Yan
AU  - Zhu Y
AD  - Department of Treatment, The Second Rehabilitation Hospital of Shanghai, 25
      Changjiang RD, Shanghai, China.
FAU - Chen, Binglin
AU  - Chen B
AD  - The Second School of Clinical Medicine, Xuzhou Medical University, Xuzhou,
      Jiangsu, China.
FAU - Zheng, Yili
AU  - Zheng Y
AD  - Department of Sport Rehabilitation, Shanghai University of Sport, 399 Changhai
      RD, Shanghai, China.
FAU - Liu, Xiaochen
AU  - Liu X
AD  - Department of Sport Rehabilitation, Shanghai University of Sport, 399 Changhai
      RD, Shanghai, China.
FAU - Qiao, Jun
AU  - Qiao J
AUID- ORCID: https://orcid.org/0000-0002-1963-5239
AD  - Department of Treatment, The Second Rehabilitation Hospital of Shanghai, 25
      Changjiang RD, Shanghai, China. qiaojun19791117@126.com.
FAU - Wang, Xueqiang
AU  - Wang X
AUID- ORCID: https://orcid.org/0000-0001-5577-5231
AD  - Department of Sport Rehabilitation, Shanghai University of Sport, 399 Changhai
      RD, Shanghai, China. qiang897@163.com.
LA  - eng
GR  - 20194Y0488/Scientific research project of Shanghai Health Committee
GR  - 81501956, 81871844/National Natural Science Foundation of China
GR  - 161092/Fok Ying Tung Education Foundation (CN)
GR  - 201840346/Shanghai Municipal Commission of Health and Family Planning
GR  - 11DZ2261100/Shanghai Key Lab of Human Performance (Shanghai University of Sport)
GR  - QG2018030/State Physical Culture Administration
GR  - BSZK-2018-A01/Key construction projects of Baoshan health and Family Planning
      Commission
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - BMC Sports Sci Med Rehabil
JT  - BMC sports science, medicine & rehabilitation
JID - 101605016
PMC - PMC7731765
OTO - NOTNLM
OT  - Abdominal muscles
OT  - Low back pain
OT  - Vibration
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 05:36
PHST- 2020/08/05 00:00 [received]
PHST- 2020/12/02 00:00 [accepted]
PHST- 2020/12/11 05:36 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - 10.1186/s13102-020-00226-4 [doi]
AID - 10.1186/s13102-020-00226-4 [pii]
PST - epublish
SO  - BMC Sports Sci Med Rehabil. 2020 Dec 10;12(1):78. doi:
      10.1186/s13102-020-00226-4.


PMID- 33302942
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 10
TI  - Reporting of screening and diagnostic AI rarely acknowledges ethical, legal, and 
      social implications: a mass media frame analysis.
PG  - 325
LID - 10.1186/s12911-020-01353-1 [doi]
AB  - BACKGROUND: Healthcare is a rapidly expanding area of application for Artificial 
      Intelligence (AI). Although there is considerable excitement about its potential,
      there are also substantial concerns about the negative impacts of these
      technologies. Since screening and diagnostic AI tools now have the potential to
      fundamentally change the healthcare landscape, it is important to understand how 
      these tools are being represented to the public via the media. METHODS: Using a
      framing theory approach, we analysed how screening and diagnostic AI was
      represented in the media and the frequency with which media articles addressed
      the benefits and the ethical, legal, and social implications (ELSIs) of screening
      and diagnostic AI. RESULTS: All the media articles coded (n = 136) fit into at
      least one of three frames: social progress (n = 131), economic development (n =
      59), and alternative perspectives (n = 9). Most of the articles were positively
      framed, with 135 of the articles discussing benefits of screening and diagnostic 
      AI, and only 9 articles discussing the ethical, legal, and social implications.
      CONCLUSIONS: We found that media reporting of screening and diagnostic AI
      predominantly framed the technology as a source of social progress and economic
      development. Screening and diagnostic AI may be represented more positively in
      the mass media than AI in general. This represents an opportunity for health
      journalists to provide publics with deeper analysis of the ethical, legal, and
      social implications of screening and diagnostic AI, and to do so now before these
      technologies become firmly embedded in everyday healthcare delivery.
FAU - Frost, Emma K
AU  - Frost EK
AUID- ORCID: 0000-0002-5893-1399
AD  - Australian Centre for Health Engagement, Evidence and Values (ACHEEV), School of 
      Health and Society, Faculty of Arts, Social Sciences, and Humanities, University 
      of Wollongong, Northfields Avenue, Wollongong, NSW, 2522, Australia.
      emmaf@uow.edu.au.
FAU - Carter, Stacy M
AU  - Carter SM
AD  - Australian Centre for Health Engagement, Evidence and Values (ACHEEV), School of 
      Health and Society, Faculty of Arts, Social Sciences, and Humanities, University 
      of Wollongong, Northfields Avenue, Wollongong, NSW, 2522, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - *Artificial Intelligence
MH  - Decision Support Systems, Clinical
MH  - Delivery of Health Care/*ethics/methods/*standards
MH  - Ethics
MH  - Health Facilities
MH  - Humans
MH  - *Mass Media
MH  - Mass Screening/*methods
PMC - PMC7725880
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Diagnosis
OT  - *Ethics
OT  - *Frame analysis
OT  - *Media framing
OT  - *Screening
EDAT- 2020/12/12 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/12/11 05:35
PHST- 2020/07/28 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/11 05:35 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1186/s12911-020-01353-1 [doi]
AID - 10.1186/s12911-020-01353-1 [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Dec 10;20(1):325. doi: 10.1186/s12911-020-01353-1.


PMID- 33302937
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 10
TI  - Doctors in Chinese public hospitals: demonstration of their professional
      identities.
PG  - 501
LID - 10.1186/s12909-020-02339-3 [doi]
AB  - BACKGROUND: An increase in the number of medical disputes and violence against
      doctors indicates a lack of trust in the medical profession by society in Chinese
      public hospitals. Empirical evidence confirms that one cause is the lack of
      professional identity demonstrated by doctors. Medical professionals are required
      to maintain high standards of competence and moral responsibility, and
      demonstrate qualities such as respect, compassion, integrity, responsiveness to
      needs, and commitment to sound ethical practice in order to maintain professional
      privilege. These principles and appropriate professional conduct are the
      foundation of the professional identity of the medical profession. METHODS: A
      quantitative approach was adopted by distributing paper-based questionnaires to
      doctors and patients in two hospitals (Level III and Level II) in Jinan, Shandong
      province, China. FINDINGS: In total, 614 doctors and 1184 inpatients on discharge
      from the surgical and internal medicine units of the two hospitals participated
      in the survey yielding 90% response rates. The study confirmed the variation
      amongst doctors in demonstrating their professionalism in terms of respecting
      patients' views and preferences when determining diagnostic procedures and
      treatment plans, and when making ethical decisions. Although 90% patients
      indicated that they showed respects to doctors, close to 20% of the doctors
      disagreed that they received high respect from patients. About 12% of doctors
      prescribed unnecessary diagnostic procedures to patient for the purpose of
      generating profit and more than 20% of patients indicated that they gave gifts to
      doctors in order to receive better treatment. CONCLUSIONS: Although about 80% of 
      doctors demonstrated certain aspects of professionalism required by
      practitioners, the inconsistency across the medical workforce may exacerbate
      tense doctor-patient relationships. A review of medical curricula and focus of
      the internship program is required in order to assist medical graduates with
      forming required professional identity in order to improve patient satisfaction
      and better clinical outcomes. To be effective, a more systematic approach is
      recommended.
FAU - Liang, Zhanming
AU  - Liang Z
AD  - The Second Affiliated Hospital of Shandong First Medical University, Tai'an,
      Shandong, China.
AD  - La Trobe University, Bundoora, Vic, Australia.
FAU - Xu, Min
AU  - Xu M
AD  - The Second Affiliated Hospital of Shandong First Medical University, Tai'an,
      Shandong, China. x_min_1970@163.com.
AD  - La Trobe University, Bundoora, Vic, Australia. x_min_1970@163.com.
FAU - Liu, Guowei
AU  - Liu G
AD  - Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
FAU - Zhou, Yongli
AU  - Zhou Y
AD  - Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
FAU - Howard, Peter F
AU  - Howard PF
AD  - The Second Affiliated Hospital of Shandong First Medical University, Tai'an,
      Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201210
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - China
MH  - Hospitals, Public
MH  - Humans
MH  - Physician-Patient Relations
MH  - *Physicians
MH  - Professionalism
PMC - PMC7725881
OTO - NOTNLM
OT  - Chinese public hospitals
OT  - Doctor - patient relationships
OT  - Professional identity
EDAT- 2020/12/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/11 05:35
PHST- 2020/04/19 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/12/11 05:35 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02339-3 [doi]
AID - 10.1186/s12909-020-02339-3 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Dec 10;20(1):501. doi: 10.1186/s12909-020-02339-3.


PMID- 33302932
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Dec 10
TI  - Communication patterns in the doctor-patient relationship: evaluating
      determinants associated with low paternalism in Mexico.
PG  - 125
LID - 10.1186/s12910-020-00566-3 [doi]
AB  - BACKGROUND: Paternalism/overprotection limits communication between healthcare
      professionals and patients and does not promote shared therapeutic
      decision-making. In the global north, communication patterns have been regulated 
      to promote autonomy, whereas in the global south, they reflect the physician's
      personal choices. The goal of this study was to contribute to knowledge on the
      communication patterns used in clinical practice in Mexico and to identify the
      determinants that favour a doctor-patient relationship characterized by low
      paternalism/autonomy. METHODS: A self-report study on communication patterns in a
      sample of 761 mental healthcare professionals in Central and Western Mexico was
      conducted. Multiple ordinal logistic regression models were used to analyse
      paternalism and associated factors. RESULTS: A high prevalence (68.7% [95% CI
      60.0-70.5]) of paternalism was observed among mental health professionals in
      Mexico. The main determinants of low paternalism/autonomy were medical specialty 
      (OR 1.67 [95% CI 1.16-2.40]) and gender, with female physicians being more likely
      to explicitly share diagnoses and therapeutic strategies with patients and their 
      families (OR 1.57 [95% CI 1.11-2.22]). A pattern of highly explicit communication
      was strongly associated with low paternalism/autonomy (OR 12.13 [95% CI
      7.71-19.05]). Finally, a modifying effect of age strata on the association
      between communication pattern or specialty and low paternalism/autonomy was
      observed. CONCLUSIONS: Among mental health professionals in Mexico, high
      paternalism prevailed. Gender, specialty, and a pattern of open communication
      were closely associated with low paternalism/autonomy. Strengthening health
      professionals' competencies and promoting explicit communication could contribute
      to the transition towards more autonomist communication in clinical practice in
      Mexico. The ethical implications will need to be resolved in the near future.
FAU - Lazcano-Ponce, Eduardo
AU  - Lazcano-Ponce E
AD  - Population Health Research Centre, National Institute of Public Health,
      Cuernavaca, Morelos, Mexico.
AD  - Centre for Mental Health Research, Australian National University, Canberra,
      Australia.
FAU - Angeles-Llerenas, Angelica
AU  - Angeles-Llerenas A
AD  - Population Health Research Centre, National Institute of Public Health,
      Cuernavaca, Morelos, Mexico. aangelica@insp.mx.
AD  - Research Ethics Committee, National Institute of Public Health, Cuernavaca,
      Morelos, Mexico. aangelica@insp.mx.
FAU - Rodriguez-Valentin, Rocio
AU  - Rodriguez-Valentin R
AD  - Population Health Research Centre, National Institute of Public Health,
      Cuernavaca, Morelos, Mexico.
FAU - Salvador-Carulla, Luis
AU  - Salvador-Carulla L
AD  - Centre for Mental Health Research, Australian National University, Canberra,
      Australia.
FAU - Dominguez-Esponda, Rosalinda
AU  - Dominguez-Esponda R
AD  - Research Ethics Committee, National Institute of Public Health, Cuernavaca,
      Morelos, Mexico.
FAU - Astudillo-Garcia, Claudia Iveth
AU  - Astudillo-Garcia CI
AD  - Psychiatric Care Services, Ministry of Health, Mexico City, Mexico.
FAU - Madrigal-de Leon, Eduardo
AU  - Madrigal-de Leon E
AD  - Hospital Director at the National Institute of Psychiatry Ramon de La Fuente
      Muniz, Mexico City, Mexico.
FAU - Katz, Gregorio
AU  - Katz G
AD  - Department of Mental Health, Faculty of Medicine, National Autonomous University 
      of Mexico, Mexico City, Mexico.
LA  - eng
GR  - 272137/CONACyT/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Communication
MH  - Decision Making
MH  - Female
MH  - Humans
MH  - Mexico
MH  - Paternalism
MH  - *Personal Autonomy
MH  - *Physician-Patient Relations
PMC - PMC7731770
OTO - NOTNLM
OT  - *Autonomy
OT  - *Paternalism
OT  - *Patient-centred medicine
OT  - *Physician-patient communication
OT  - *Self-determination
OT  - *Shared decision-making
EDAT- 2020/12/12 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/11 05:35
PHST- 2020/03/12 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2020/12/11 05:35 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00566-3 [doi]
AID - 10.1186/s12910-020-00566-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Dec 10;21(1):125. doi: 10.1186/s12910-020-00566-3.


PMID- 33302888
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 10
TI  - Decision-making capacity evaluations: the role of neuropsychological assessment
      from a multidisciplinary perspective.
PG  - 535
LID - 10.1186/s12877-020-01932-x [doi]
AB  - Decision-making capacity (DMC) in aging adults has become increasingly salient as
      the number of older adults, life expectancy, and the amount of wealth to be
      transferred from older generations have all increased. The accurate and reliable 
      determination of older adults' DMC is a particularly important topic given its
      implication in legal, financial, and health decisions. Based upon the
      four-ability DMC model promulgated by Appelbaum and Grisso in the 1980's, a
      number of MacArthur Competence Assessment Tools have been developed and widely
      utilized. However, these tools do not include cognitive testing or other sources 
      of objective data and have limited validity in a medico-legal setting,
      necessitating additional options for the evaluation of DMC. This is significant
      from the perspective of the patient because they have a vested interest in
      accurate and objective assessment of their DMC across domains.Given the
      disparities in the assessment of DMC, the authors propose, through this debate
      article, that the evaluation of DMC in the aging adult population utilize a
      combination of traditional interview and domain specific instruments and
      neuropsychological testing. To achieve a consensus on the issue, medical experts 
      in a number of fields related to capacity evaluation, including psychiatry,
      neurology, neuropsychology, and general medicine were consulted and recruited as 
      authors. Experts in Swiss law and ethics were also consulted and provided input.A
      tendency to focus on a single capacity, and in particular, the ability to consent
      to medical treatment, arose in the literature. Similarly, there are many
      instruments purporting to evaluate a single capacity (e.g., consenting to medical
      treatment, managing finances), while other areas important to the evaluation of
      DMC received little attention (e.g., activities of daily living, the ability to
      live independently, to marry, to resist undue influence, and to make a will or
      advanced care directive). Medical and legal experts in the multidisciplinary
      group agreed that there is a clear need for more consistency across evaluation of
      DMC domains and that a combined approach of traditional methods and
      neuropsychological testing provides a more thorough evaluation and better serves 
      the patient.
FAU - Wood, Sarah
AU  - Wood S
AUID- ORCID: 0000-0002-1426-7115
AD  - U.S. Army Behavioral Health Clinic, Wiesbaden, Germany. swood@paloaltou.edu.
FAU - Bally, Klaus
AU  - Bally K
AD  - Center for Primary Health Care, University of Basel, Basel, Switzerland.
FAU - Cabane, Christine
AU  - Cabane C
AD  - Kindes-und Erwachsenenschutzbehorde Baselland, Liestal, Switzerland.
FAU - Fassbind, Patrick
AU  - Fassbind P
AD  - Kindes-und Erwachsenenschutzbehorde Basel-Stadt, Basel, Switzerland.
FAU - Jox, Ralf J
AU  - Jox RJ
AD  - Palliative and Supportive Care Service and Institute of Humanities in Medicine,
      Lausanne University Hospital, and University of Lausanne, Lausanne, Switzerland.
FAU - Leyhe, Thomas
AU  - Leyhe T
AD  - Department of Geriatric Medicine Felix Platter Hospital, University of Basel,
      Basel, Switzerland.
FAU - Monsch, Andreas
AU  - Monsch A
AD  - Department of Geriatric Medicine Felix Platter Hospital, University of Basel,
      Basel, Switzerland.
FAU - Trachsel, Manuel
AU  - Trachsel M
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Zurich, Switzerland.
AD  - Clinical Ethics Unit, University Hospital of Basel, and University Psychiatric
      Clinics Basel, Basel, Switzerland.
LA  - eng
GR  - 000/Stiftung Synapsis - Alzheimer Forschung Schweiz AFS
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - *Activities of Daily Living
MH  - Aged
MH  - Aging
MH  - *Decision Making
MH  - Humans
MH  - Mental Competency
MH  - Neuropsychological Tests
MH  - Referral and Consultation
PMC - PMC7731768
OTO - NOTNLM
OT  - *Autonomy
OT  - *Capacity evaluation
OT  - *Cognition
OT  - *Decision-making
OT  - *Informed consent
EDAT- 2020/12/12 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/12/11 05:34
PHST- 2019/09/12 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/11 05:34 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.1186/s12877-020-01932-x [doi]
AID - 10.1186/s12877-020-01932-x [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Dec 10;20(1):535. doi: 10.1186/s12877-020-01932-x.


PMID- 33302887
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1471-2342 (Electronic)
IS  - 1471-2342 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 10
TI  - Influence of body mass index and weight lifting on bicep brachii muscle and
      distal bicep tendon stiffness evaluated using ultrasound elastography.
PG  - 129
LID - 10.1186/s12880-020-00531-x [doi]
AB  - BACKGROUND: This study aimed to investigate the relationship between stiffness of
      the bicep brachii muscle (BBM) and distal bicep tendon (DBT) and effects of
      weight lifting (pre- to post-workout changes) among groups with different body
      mass indexes (BMI). METHODS: Participants were divided into four groups according
      to BMI: A, underweight (< 18.5 kg/m(2)); B, normal (18.5-24.9 kg/m(2)); C,
      overweight (25.0-29.9 kg/m(2)); and D, obese (> 30.0 kg/m(2)). All participants
      were males who were untrained and had sedentary lifestyle without involvement in 
      sports activities for the past 12 months. Ultrasonographic measurements to
      determine muscle and tendon stiffness was performed on the dominant side (i.e.,
      right side) of the upper extremities in all participants. RESULTS: Twenty-one
      healthy and untrained males volunteered to participate in this study; 14 were
      nonsmokers and 7 were smokers. The mean age and BMI were 22.5 +/- 1.5 years and
      23.8 +/- 6.3 kg/m(2), respectively. Groups A, B, C, and D had four, ten, four,
      and three participants, respectively. The BBM thickness did not increase with
      increase in BMI and was not significantly different (P > .05) between groups. The
      BBM stiffness was significantly different (all P < .05) from pre- to post-workout
      values in all groups, whereas DBT stiffness did not follow the same trend.
      CONCLUSIONS: Our study revealed that the BBM thickness is independent of BMI.
      After weight lifting, BBM stiffness in groups A and B increased for BBM compared 
      to those in groups C and D. A similar trend was also recorded for DBT. Weight
      lifting in concentric and eccentric motions affects the stiffness of the BBM and 
      DBT, thus weight lifting plays a role in adjusting the stiffness of the BBM and
      DBT. Trial registration The study was approved by ethics committee of the College
      of Applied Medical Sciences (CAMS 080-3839; March 14, 2018).
FAU - Al-Qahtani, Mahdi
AU  - Al-Qahtani M
AD  - Biomedical Technology Department, College of Applied Medical Sciences, King Saud 
      University, Riyadh, Kingdom of Saudi Arabia.
FAU - Altuwaijri, Omar
AU  - Altuwaijri O
AD  - Biomedical Technology Department, College of Applied Medical Sciences, King Saud 
      University, Riyadh, Kingdom of Saudi Arabia.
FAU - Altaf, Meteb
AU  - Altaf M
AD  - National Center for Robotics Technology and Intelligent Systems, King Abdulaziz
      City for Science and Technology, Riyadh, Kingdom of Saudi Arabia.
FAU - Al-Enezi, Majed
AU  - Al-Enezi M
AD  - Biomedical Technology Department, College of Applied Medical Sciences, King Saud 
      University, Riyadh, Kingdom of Saudi Arabia.
FAU - Abulmeaty, Mahmoud
AU  - Abulmeaty M
AD  - Community Health Sciences Department, College of Applied Medical Sciences, King
      Saud University, Riyadh, Kingdom of Saudi Arabia.
FAU - Javed, Ravish
AU  - Javed R
AUID- ORCID: 0000-0001-5654-5198
AD  - Biomedical Technology Department, College of Applied Medical Sciences, King Saud 
      University, Riyadh, Kingdom of Saudi Arabia. rkhan1@ksu.edu.sa.
LA  - eng
GR  - RG-1440-117/Deanship of Scientific Research, King Saud University/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201210
PL  - England
TA  - BMC Med Imaging
JT  - BMC medical imaging
JID - 100968553
SB  - IM
MH  - Adult
MH  - *Body Mass Index
MH  - Elasticity
MH  - *Elasticity Imaging Techniques
MH  - Humans
MH  - Male
MH  - Muscle, Skeletal/*diagnostic imaging/*physiology
MH  - Prospective Studies
MH  - Sedentary Behavior
MH  - Tendons/*diagnostic imaging/*physiology
MH  - Weight Lifting/*physiology
MH  - Young Adult
PMC - PMC7731623
OTO - NOTNLM
OT  - *Bicep brachii muscle
OT  - *Body mass index
OT  - *Distal bicep tendon
OT  - *Elastography
OT  - *Strain ratio
OT  - *Ultrasound
EDAT- 2020/12/12 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/12/11 05:34
PHST- 2019/10/24 00:00 [received]
PHST- 2020/11/29 00:00 [accepted]
PHST- 2020/12/11 05:34 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.1186/s12880-020-00531-x [doi]
AID - 10.1186/s12880-020-00531-x [pii]
PST - epublish
SO  - BMC Med Imaging. 2020 Dec 10;20(1):129. doi: 10.1186/s12880-020-00531-x.


PMID- 33302715
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Linking)
VI  - 13
IP  - 12
DP  - 2020 Dec
TI  - Show Me the Money: Patients' Perspectives on a Decision Aid for
      Sacubitril/Valsartan Addressing Out-of-Pocket Cost.
PG  - e007070
LID - 10.1161/CIRCOUTCOMES.120.007070 [doi]
AB  - BACKGROUND: Out-of-pocket medication costs for patients who have heart failure
      with reduced ejection fraction may be an important part of shared
      decision-making, but cost has generally been excluded from clinical discussions. 
      This study reports patients' perspectives on a decision aid for
      sacubitril/valsartan that explicitly addresses out-of-pocket costs. METHODS:
      Structured, in-depth interviews were conducted with 20 patients with heart
      failure with reduced ejection fraction from 2 medical centers to elicit their
      views on a publicly available decision aid for sacubitril/valsartan that
      explicitly incorporates considerations related to out-of-pocket costs.
      Qualitative descriptive analysis was conducted. RESULTS: Key themes identified
      were general enthusiasm for decision aids for medication decisions, openness on
      the part of patients to incorporation of cost into decision-making and the
      decision aid, requests for greater specificity regarding patient-specific cost,
      and challenges communicating evidence of benefit in a way that allows patients to
      make cost-benefit analyses for themselves. Patients also raised questions
      regarding logistical challenges of incorporating a decision aid into the normal
      clinical and decision-making workflow. CONCLUSIONS: Patients were receptive to
      the inclusion of out-of-pocket cost as relevant in a decision aid for
      sacubitril/valsartan. Key challenges to effective integration of cost in these
      decisions include developing mechanisms for acquiring reliable patient-specific
      cost estimates and addressing patients' difficulties (and sometimes skepticism)
      applying trial evidence to their own situation. In addition, implementation
      strategies are important to develop to facilitate decision aid integration for
      routine medical decisions into clinic workflow.
FAU - Dickert, Neal W
AU  - Dickert NW
AD  - Department of Medicine, Division of Cardiology, Emory University School of
      Medicine, ECCRI, Atlanta, GA (N.W.D., A.R.M., A.A.M., C.D.S.).
AD  - Department of Epidemiology, Emory University Rollins School of Public Health,
      Atlanta, GA (N.W.D.).
AD  - Emory Center for Ethics, Atlanta, GA (N.W.D.).
FAU - Mitchell, Andrea R
AU  - Mitchell AR
AD  - Department of Medicine, Division of Cardiology, Emory University School of
      Medicine, ECCRI, Atlanta, GA (N.W.D., A.R.M., A.A.M., C.D.S.).
FAU - Venechuk, Grace E
AU  - Venechuk GE
AD  - Adult and Child Consortium for Outcomes Research and Delivery Science (G.E.V.,
      D.D.M., K.J.P., L.A.A.), University of Colorado School of Medicine, Aurora.
AD  - Center for Demography of Health and Aging, University of Wisconsin-Madison
      (G.E.V.).
FAU - Matlock, Daniel D
AU  - Matlock DD
AD  - Adult and Child Consortium for Outcomes Research and Delivery Science (G.E.V.,
      D.D.M., K.J.P., L.A.A.), University of Colorado School of Medicine, Aurora.
AD  - Division of Geriatric Medicine (D.D.M.), University of Colorado School of
      Medicine, Aurora.
AD  - Veterans Affairs Eastern Colorado Geriatric Research Education and Clinical
      Center, Denver (D.D.M.).
FAU - Moore, Miranda A
AU  - Moore MA
AD  - Department of Family and Preventive Medicine, Emory University School of
      Medicine, Atlanta, GA (M.A.M.).
FAU - Morris, Alanna A
AU  - Morris AA
AD  - Department of Medicine, Division of Cardiology, Emory University School of
      Medicine, ECCRI, Atlanta, GA (N.W.D., A.R.M., A.A.M., C.D.S.).
FAU - Pierce, Kenneth J
AU  - Pierce KJ
AD  - Adult and Child Consortium for Outcomes Research and Delivery Science (G.E.V.,
      D.D.M., K.J.P., L.A.A.), University of Colorado School of Medicine, Aurora.
FAU - Speight, Candace D
AU  - Speight CD
AD  - Department of Medicine, Division of Cardiology, Emory University School of
      Medicine, ECCRI, Atlanta, GA (N.W.D., A.R.M., A.A.M., C.D.S.).
FAU - Allen, Larry A
AU  - Allen LA
AD  - Adult and Child Consortium for Outcomes Research and Delivery Science (G.E.V.,
      D.D.M., K.J.P., L.A.A.), University of Colorado School of Medicine, Aurora.
AD  - Division of Cardiology (L.A.A.), University of Colorado School of Medicine,
      Aurora.
LA  - eng
GR  - R01 HS026081/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20201211
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
CIN - Circ Cardiovasc Qual Outcomes. 2020 Dec;13(12):e007449. PMID: 33302717
MH  - Aged
MH  - Aminobutyrates/economics/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/economics/*therapeutic use
MH  - Biphenyl Compounds/economics/*therapeutic use
MH  - Colorado
MH  - Cost-Benefit Analysis
MH  - *Decision Making, Shared
MH  - *Decision Support Techniques
MH  - Drug Combinations
MH  - *Drug Costs
MH  - Female
MH  - Georgia
MH  - *Health Expenditures
MH  - Heart Failure/diagnosis/*drug therapy/economics/physiopathology
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Neprilysin/antagonists & inhibitors
MH  - Patient Participation
MH  - Patient Satisfaction
MH  - Protease Inhibitors/economics/*therapeutic use
MH  - Treatment Outcome
MH  - Valsartan/economics/*therapeutic use
PMC - PMC7738420
MID - NIHMS1641971
OTO - NOTNLM
OT  - *costs and cost analysis
OT  - *decision support techniques
OT  - *ethics
OT  - *valsartan
OT  - *workflow
EDAT- 2020/12/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/11 05:33
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/12/11 05:33 [entrez]
AID - 10.1161/CIRCOUTCOMES.120.007070 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2020 Dec;13(12):e007070. doi:
      10.1161/CIRCOUTCOMES.120.007070. Epub 2020 Dec 11.


PMID- 33302438
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Dec 8
TI  - Defined Daily Dose and Appropriateness of Clinical Application: The Coxibs and
      Traditional Nonsteroidal Anti-Inflammatory Drugs for Postoperative Orthopaedics
      Pain Control in a Private Hospital in Malaysia.
LID - E235 [pii]
LID - 10.3390/pharmacy8040235 [doi]
AB  - INTRODUCTION: Drug utilization of analgesics in a private healthcare setting is
      useful to examine their prescribing patterns, especially the newer injectable
      cyclooxygenase (COX)-2 inhibitors (coxibs). OBJECTIVES: To evaluate the
      utilization of coxibs and traditional nonsteroidal anti-inflammatory drugs
      (tNSAIDs) indicated for postoperative orthopaedic pain control using defined
      daily dose (DDD) and ratio of use density to use rate (UD/UR). METHOD: A
      retrospective drug utilization review (DUR) of nonsteroidal anti-inflammatory
      drugs (NSAIDs) at an inpatient department of a private teaching hospital in
      Seremban, Malaysia was conducted. Patients' demographic characteristics,
      medications prescribed, clinical lab results, visual analogue scale (VAS) pain
      scores and length of hospital stay were documented. Orthopaedic surgeries, namely
      arthroscopy, reconstructive, and fracture fixation, were included. Stratified
      random sampling was used to select patients. Data were collected through
      patients' medical records. The DDD per 100 admissions and the indicator UD/UR
      were calculated with the World Health Organization's DDD as a benchmark. The
      inclusion criteria were patients undergoing orthopaedic surgery prescribed with
      coxibs (celecoxib capsules, etoricoxib tablets, parecoxib injections) and tNSAIDs
      (dexketoprofen injections, diclofenac sodium tablets). Data were analysed
      descriptively. This research was approved by the academic institution and the
      hospital research ethics committee. RESULT: A total of 195 records of patients
      who received NSAIDs were randomly selected among 1169 cases. In term of the types
      of orthopaedic surgery, the ratio of included records for arthroscopy:fracture
      fixation:reconstructive surgery was 55.4:35.9:8.7. Most of the inpatients had low
      rates of common comorbidities such as cardiovascular disease as supported by
      their baseline parameters. The majority were not prescribed with other
      concomitant prescriptions that could cause drug interaction (74.9%), or
      gastroprotective agents (77.4%). Overall, DDDs per 100 admissions for all NSAIDs 
      were less than 100, except for parecoxib injections (389.23). The UD/UR for all
      NSAIDs were less than 100, except for etoricoxib tablets (105.75) and parecoxib
      injections (108.00). DISCUSSION: As per guidelines, the majority (96.9%) received
      other analgesics to ensure a multimodal approach was carried out to control pain.
      From the UD/UR results, the arthroscopy surgery was probably the most appropriate
      in terms of NSAID utilization. CONCLUSION: The prescribing pattern of NSAIDs
      except parecoxib was appropriate based on adverse effect and concurrent
      medication profile. The findings of this DUR provide insight for a low-risk
      patient population at a private specialized teaching hospital on the recommended 
      use of NSAIDs for postoperative orthopaedic pain control.
FAU - Bakrin, Faizah Safina
AU  - Bakrin FS
AUID- ORCID: 0000-0002-6154-6707
AD  - School of Pharmacy, KPJ Healthcare University College, Nilai 71800, Negeri
      Sembilan, Malaysia.
FAU - Makmor-Bakry, Mohd
AU  - Makmor-Bakry M
AD  - Faculty of Pharmacy, Universiti Kebangsaaan Malaysia, Kuala Lumpur 50300,
      Malaysia.
FAU - Che Hon, Wan Hazmy
AU  - Che Hon WH
AD  - School of Medicine, KPJ Healthcare University College, Nilai 71800, Negeri
      Sembilan, Malaysia.
AD  - KPJ Seremban Specialist Hospital, Seremban 70200, Negeri Sembilan, Malaysia.
FAU - Faizal, Shafeeq Mohd
AU  - Faizal SM
AD  - KPJ Seremban Specialist Hospital, Seremban 70200, Negeri Sembilan, Malaysia.
FAU - Manan, Mohamed Mansor
AU  - Manan MM
AD  - Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam 42300, Selangor,
      Malaysia.
FAU - Ming, Long Chiau
AU  - Ming LC
AUID- ORCID: 0000-0002-6971-1383
AD  - PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410,
      Brunei.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC7768540
OTO - NOTNLM
OT  - coxibs
OT  - drug utilization
OT  - pharmacoepidemiology
OT  - prescribing pattern
OT  - tNSAIDs
EDAT- 2020/12/12 06:00
MHDA- 2020/12/12 06:01
CRDT- 2020/12/11 01:01
PHST- 2020/09/18 00:00 [received]
PHST- 2020/12/02 00:00 [revised]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/12/11 01:01 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2020/12/12 06:01 [medline]
AID - pharmacy8040235 [pii]
AID - 10.3390/pharmacy8040235 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2020 Dec 8;8(4). pii: pharmacy8040235. doi:
      10.3390/pharmacy8040235.


PMID- 33301429
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201224
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 69
IP  - 49
DP  - 2020 Dec 11
TI  - The Advisory Committee on Immunization Practices' Interim Recommendation for
      Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
PG  - 1857-1859
LID - 10.15585/mmwr.mm6949e1 [doi]
AB  - The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019
      (COVID-19), has led to a global pandemic that has disrupted all sectors of
      society. Less than 1 year after the SARS-CoV-2 genome was first sequenced, an
      application* for Emergency Use Authorization for a candidate vaccine has been
      filed with the Food and Drug Administration (FDA). However, even if one or more
      vaccine candidates receive authorization for emergency use, demand for COVID-19
      vaccine is expected to exceed supply during the first months of the national
      vaccination program. The Advisory Committee on Immunization Practices (ACIP)
      advises CDC on population groups and circumstances for vaccine use.(dagger) ACIP 
      convened on December 1, 2020, in advance of the completion of FDA's review of the
      Emergency Use Authorization application, to provide interim guidance to federal, 
      state, and local jurisdictions on allocation of initial doses of COVID-19
      vaccine. ACIP recommended that, when a COVID-19 vaccine is authorized by FDA and 
      recommended by ACIP, both 1) health care personnel( section sign) and 2)
      residents of long-term care facilities (LTCFs)( paragraph sign) be offered
      vaccination in the initial phase of the COVID-19 vaccination program (Phase
      1a**).(daggerdagger) In its deliberations, ACIP considered scientific evidence of
      SARS-CoV-2 epidemiology, vaccination program implementation, and ethical
      principles.( section sign section sign) The interim recommendation might be
      updated over the coming weeks based on additional safety and efficacy data from
      phase III clinical trials and conditions of FDA Emergency Use Authorization.
FAU - Dooling, Kathleen
AU  - Dooling K
FAU - McClung, Nancy
AU  - McClung N
FAU - Chamberland, Mary
AU  - Chamberland M
FAU - Marin, Mona
AU  - Marin M
FAU - Wallace, Megan
AU  - Wallace M
FAU - Bell, Beth P
AU  - Bell BP
FAU - Lee, Grace M
AU  - Lee GM
FAU - Talbot, H Keipp
AU  - Talbot HK
FAU - Romero, Jose R
AU  - Romero JR
FAU - Oliver, Sara E
AU  - Oliver SE
LA  - eng
PT  - Journal Article
DEP - 20201211
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Advisory Committees
MH  - Aged
MH  - *COVID-19 Vaccines/administration & dosage/supply & distribution
MH  - Centers for Disease Control and Prevention, U.S.
MH  - *Health Care Rationing
MH  - Health Personnel
MH  - Humans
MH  - Immunization Programs
MH  - Practice Guidelines as Topic
MH  - Residential Facilities
MH  - United States
PMC - PMC7737687
COIS- All authors have completed and submitted the International Committee of Medical
      Journal Editors form for disclosure of potential conflicts of interest. No
      potential conflicts of interest were disclosed.
EDAT- 2020/12/11 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/10 17:12
PHST- 2020/12/10 17:12 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.15585/mmwr.mm6949e1 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859. doi:
      10.15585/mmwr.mm6949e1.


PMID- 33301132
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2168-4804 (Electronic)
IS  - 2168-4790 (Linking)
VI  - 54
IP  - 3
DP  - 2020 May
TI  - Is There a Difference Between the Readabilities of Informed Consent Forms Used
      for Elective and Emergency Procedures in Turkey?
PG  - 626-630
LID - 10.1007/s43441-019-00096-0 [doi]
AB  - BACKGROUND: Informed consent is an important aspect of ethical medical practice. 
      In legal terms, making an intervention without informed consent may mean
      negligence or malpractice and may lead to legal action, maltreatment, and even
      attack against the doctor. This study aims to evaluate the readability of
      informed consent forms (ICFs) used for elective (urology and general surgery) and
      emergency procedures (emergency medicine and intensive care) by comparing through
      readability formulas. METHOD: Elective and emergency ICFs were accessed through
      the web sites of national health care associations. A total of 387 consent forms 
      were evaluated and the same forms were included only once. A total of 35 consent 
      forms were evaluated for emergency procedures, while a total of 55 consent forms 
      were evaluated for elective procedures. Atesman and Bezirci-Yilmaz formulas
      defined for determining the readability level of Turkish texts and Gunning fog
      and Flesch Kincaid formulas measuring the general readability level were used for
      calculating the readability level of consent forms. RESULTS: Even though elective
      ICFs are more readable compared to those of emergency procedures according to
      Bezirci-Yilmaz formulas, this was statistically insignificant ([Formula: see
      text]). The readability of elective consent forms was found to be at a
      significantly more difficult level to read compared to Atesman, Gunning fog, and 
      Flesch Kincaid formulas ([Formula: see text], [Formula: see text], [Formula: see 
      text], respectively). CONCLUSION: Even though the procedure is emergency or
      elective, a difficult readability level may cause problems for the doctor in
      legal phases. Readable and understandable consent forms should be available to be
      able to explain morbidity and mortality and improve prognosis. Education level of
      our country should also be considered while preparing these consent forms.
FAU - Sonmez, Mehmet Giray
AU  - Sonmez MG
AUID- ORCID: 0000-0003-4615-7348
AD  - Department of Urology, Meram Medical Faculty, Necmettin Erbakan University,
      Konya, 42080, Turkey. drgiraysonmez@gmail.com.
FAU - Sonmez, Leyla Ozturk
AU  - Sonmez LO
AD  - Department of Emergency Medicine, Meram Medical Faculty, Necmettin Erbakan
      University, Konya, Turkey.
AD  - Department of Physiology, Selcuklu Medical School, Selcuk University, Konya,
      Turkey.
FAU - Kozanhan, Betul
AU  - Kozanhan B
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Konya Training and Research Hospital, Konya, Turkey.
FAU - Dundar, Zerrin Defne
AU  - Dundar ZD
AD  - Department of Emergency Medicine, Meram Medical Faculty, Necmettin Erbakan
      University, Konya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200106
PL  - Switzerland
TA  - Ther Innov Regul Sci
JT  - Therapeutic innovation & regulatory science
JID - 101597411
SB  - IM
MH  - *Comprehension
MH  - *Consent Forms
MH  - Informed Consent
MH  - Reading
MH  - Turkey
OTO - NOTNLM
OT  - *emergency
OT  - *informed consent forms
OT  - *intensive care
OT  - *readability
OT  - *understandability
EDAT- 2020/12/11 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/12/10 12:18
PHST- 2019/06/15 00:00 [received]
PHST- 2019/07/11 00:00 [accepted]
PHST- 2020/12/10 12:18 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1007/s43441-019-00096-0 [doi]
AID - 10.1007/s43441-019-00096-0 [pii]
PST - ppublish
SO  - Ther Innov Regul Sci. 2020 May;54(3):626-630. doi: 10.1007/s43441-019-00096-0.
      Epub 2020 Jan 6.


PMID- 33299943
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 2444-8672 (Electronic)
IS  - 2444-8664 (Linking)
VI  - 5
IP  - 2
DP  - 2020 Mar-Apr
TI  - Identifiable relatives in the family history: not without individual consent.
PG  - e62
LID - 10.1097/j.pbj.0000000000000061 [doi]
AB  - The family history is a traditional section of the clinical record. Data on
      family members in the clinical record may be anonymous but yet these may be
      easily identifiable; therefore, exposing the relatives of the patient to the fact
      that a written record is produced, mentioning them, without their consent. This
      is in direct contradiction with European data protection and other regulations
      and in contradiction with a reasonable ethical perspective. For the purpose of
      obtaining an image of the present state of affairs, we used as a convenience
      sample, the series of Case Records published in 2019 in The New England Journal
      of Medicine (January to December). From a total number of 40 reports,
      identifiable relatives were present in 30. The number of identifiable relatives
      varied between none and 6. It is not the right of each individual to disclose
      sensitive clinical information regarding other persons, without consent from
      these latter. Family history should no longer include identifiable relatives,
      unless consent is obtained from each identifiable person. The authors offer the
      following guidelines on this topic: (1) Do not mention any identifiable relative 
      of the patient in the medical history without consent from the said relative; (2)
      Do not mention in the family history clinical conditions seemingly unrelated to
      the present clinical situation; (3) Do not mention in the family history clinical
      conditions that the patient does not (him/) herself have and that may be seen as 
      social stigmata; (4) Consult the institutional Ethics committee in case of
      reasonable doubt.
CI  - Copyright (c) 2020 The Authors. Published by Wolters Kluwer Health, Inc. on
      behalf of PBJ-Associacao Porto Biomedical/Porto Biomedical Society. All rights
      reserved.
FAU - Nunes, Jose Pedro L
AU  - Nunes JPL
AD  - Faculdade de Medicina da Universidade do Porto.
FAU - Faria, Maria do Sameiro
AU  - Faria MDS
AD  - Centro Materno Infantil do Norte, Porto.
FAU - Abreu Amorim, Carlos
AU  - Abreu Amorim C
AD  - Escola de Direito da Universidade do Minho, Braga, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - United States
TA  - Porto Biomed J
JT  - Porto biomedical journal
JID - 101707479
PMC - PMC7722405
OTO - NOTNLM
OT  - consent
OT  - data protection
OT  - family history
COIS- Sponsorships or competing interests that may be relevant to content are disclosed
      at the end of this article.The authors declare no conflicts of interest.
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:01
CRDT- 2020/12/10 05:59
PHST- 2020/01/29 00:00 [received]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/12/10 05:59 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:01 [medline]
AID - 10.1097/j.pbj.0000000000000061 [doi]
AID - PBJ-D-20-00011 [pii]
PST - epublish
SO  - Porto Biomed J. 2020 Mar 26;5(2):e62. doi: 10.1097/j.pbj.0000000000000061.
      eCollection 2020 Mar-Apr.


PMID- 33299471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211105
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jul
TI  - Is There an Ethical Upper Limit on Risks to Study Participants?
PG  - 143-156
LID - 10.1093/phe/phaa028 [doi]
AB  - Are some risks to study participants too much, no matter how valuable the study
      is for society? This article answers in the negative.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. Available online at
      www.phe.oxfordjournals.org.
FAU - Eyal, Nir
AU  - Eyal N
AD  - Center for Population-Level Bioethics, Department of Philosophy, Rutgers
      University and Department of Health Behavior, Society and Policy, Rutgers School 
      of Public Health.
LA  - eng
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
GR  - R56 AI114617/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20201103
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7700797
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:01
CRDT- 2020/12/10 05:57
PHST- 2020/12/10 05:57 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:01 [medline]
AID - 10.1093/phe/phaa028 [doi]
AID - phaa028 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Nov 3;13(2):143-156. doi: 10.1093/phe/phaa028.
      eCollection 2020 Jul.


PMID- 33299361
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1179-1500 (Print)
IS  - 1179-1500 (Linking)
VI  - 12
DP  - 2020
TI  - Analysis of Symptoms of COVID-19 Positive Patients and Potential Effects on
      Initial Assessment.
PG  - 451-457
LID - 10.2147/OAEM.S275983 [doi]
AB  - BACKGROUND: SARS-CoV-2 is a highly contagious virus, significantly impacting
      Germany among other countries since its emergence. Because of heterogeneous
      symptoms and a subset of patients even being asymptomatic at presentation, fast
      identification of infected patients remains challenging. OBJECTIVE: The goal of
      this study is the evaluation of different patient groups with a focus on symptoms
      and pre-existing illness at admission, as this is important for initial
      assessment and adequate emergency care. METHODS: COVID-19 positive patients at
      the University Hospital Heidelberg were retrospectively analyzed for disease
      history and symptoms at the initial presentation as well as mortality. The
      authors obtained institutional review board (IRB) approval by the Ethics
      Committee (Medical Faculty of Heidelberg University) prior to commencing the
      study. RESULTS: Dyspnea was more common in patients admitted to intermediate
      care/intensive care units (48 vs 13%, P<0.001) and showed a significantly higher 
      percentage in the deceased (91 vs 48%, P=0.004). The symptoms of all presenting
      patients were highly variable, and many manifestations commonly associated with
      COVID-19 like cough, fever, and sore throat were only detected in a subset of
      patients, 60%, 43%, and 33%, respectively. CONCLUSION: Dyspnea was present
      significantly more often in patients dying of COVID-19 compared to all patients
      admitted to the IMC/ICU, necessitating adequate observation and monitoring. In
      all presenting patients, initial symptoms showed large variation; therefore,
      COVID should be considered as a main differential diagnosis at every patient
      presentation, and patients with high pre-test probability should, if possible, be
      isolated until testing results are known.
CI  - (c) 2020 Korell et al.
FAU - Korell, Felix
AU  - Korell F
AUID- ORCID: 0000-0001-7699-7212
AD  - Casualty Department, University Hospital Heidelberg, Heidelberg, Germany.
AD  - Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Giannitsis, Evangelos
AU  - Giannitsis E
AUID- ORCID: 0000-0002-1025-2872
AD  - Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Merle, Uta
AU  - Merle U
AUID- ORCID: 0000-0003-1386-3350
AD  - Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Kihm, Lars Philipp
AU  - Kihm LP
AD  - Casualty Department, University Hospital Heidelberg, Heidelberg, Germany.
AD  - Department of Internal Medicine I, University Hospital Heidelberg, Heidelberg,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - New Zealand
TA  - Open Access Emerg Med
JT  - Open access emergency medicine : OAEM
JID - 101570796
PMC - PMC7721290
OTO - NOTNLM
OT  - COVID-19
OT  - dyspnea
OT  - mortality
OT  - triage
COIS- Evangelos Giannitsis reports personal fees from AstraZeneca, grants from Roche
      Diagnostics, Daiichi Sankyo, and Brahms Thermo Fisher. The authors report no
      other potential conflicts of interest for this work.
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:01
CRDT- 2020/12/10 05:56
PHST- 2020/08/11 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/12/10 05:56 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:01 [medline]
AID - 10.2147/OAEM.S275983 [doi]
AID - 275983 [pii]
PST - epublish
SO  - Open Access Emerg Med. 2020 Dec 3;12:451-457. doi: 10.2147/OAEM.S275983.
      eCollection 2020.


PMID- 33299239
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210602
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 12
DP  - 2020 Dec
TI  - Veterinary Medical Ethics.
PG  - 1243-1244
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7659869
EDAT- 2020/12/11 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/12/10 05:56
PHST- 2020/12/10 05:56 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_12_1243 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Dec;61(12):1243-1244.


PMID- 33299026
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Dec 9
TI  - A novel 3D in vitro model of the human gut microbiota.
PG  - 21499
LID - 10.1038/s41598-020-78591-w [doi]
AB  - Clinical trials and animal studies on the gut microbiota are often limited by the
      difficult access to the gut, restricted possibility of in vivo monitoring, and
      ethical issues. An easily accessible and monitorable in vitro model of the gut
      microbiota represents a valid tool for a wider comprehension of the mechanisms by
      which microbes interact with the host and with each other. Herein, we present a
      novel and reliable system for culturing the human gut microbiota in vitro. An
      electrospun gelatin structure was biofabricated as scaffold for microbial growth.
      The efficiency of this structure in supporting microbial proliferation and
      biofilm formation was initially assessed for five microbes commonly inhabiting
      the human gut. The human fecal microbiota was then cultured on the scaffolds and 
      microbial biofilms monitored by confocal laser and scanning electron microscopy
      and quantified over time. Metagenomic analyses and Real-Time qPCRs were performed
      to evaluate the stability of the cultured microbiota in terms of qualitative and 
      quantitative composition. Our results reveal the three-dimensionality of the
      scaffold-adhered microbial consortia that maintain the bacterial biodiversity and
      richness found in the original sample. These findings demonstrate the validity of
      the developed electrospun gelatin-based system for in vitro culturing the human
      gut microbiota.
FAU - Biagini, Francesco
AU  - Biagini F
AD  - Research Center "E. Piaggio", University of Pisa, Largo Lucio Lazzarino 1, 55122,
      Pisa, Italy.
AD  - Department of Information Engineering, University of Pisa, Via G. Caruso 16,
      56122, Pisa, Italy.
FAU - Calvigioni, Marco
AU  - Calvigioni M
AD  - Department of Translational Research and New Technologies in Medicine and
      Surgery, University of Pisa, Via San Zeno 37, 56127, Pisa, Italy.
FAU - Lapomarda, Anna
AU  - Lapomarda A
AD  - Research Center "E. Piaggio", University of Pisa, Largo Lucio Lazzarino 1, 55122,
      Pisa, Italy.
AD  - Department of Information Engineering, University of Pisa, Via G. Caruso 16,
      56122, Pisa, Italy.
FAU - Vecchione, Alessandra
AU  - Vecchione A
AD  - Department of Translational Research and New Technologies in Medicine and
      Surgery, University of Pisa, Via San Zeno 37, 56127, Pisa, Italy.
FAU - Magliaro, Chiara
AU  - Magliaro C
AD  - Research Center "E. Piaggio", University of Pisa, Largo Lucio Lazzarino 1, 55122,
      Pisa, Italy.
AD  - Department of Information Engineering, University of Pisa, Via G. Caruso 16,
      56122, Pisa, Italy.
FAU - De Maria, Carmelo
AU  - De Maria C
AD  - Research Center "E. Piaggio", University of Pisa, Largo Lucio Lazzarino 1, 55122,
      Pisa, Italy.
AD  - Department of Information Engineering, University of Pisa, Via G. Caruso 16,
      56122, Pisa, Italy.
FAU - Montemurro, Francesca
AU  - Montemurro F
AD  - Research Center "E. Piaggio", University of Pisa, Largo Lucio Lazzarino 1, 55122,
      Pisa, Italy.
AD  - Department of Information Engineering, University of Pisa, Via G. Caruso 16,
      56122, Pisa, Italy.
FAU - Celandroni, Francesco
AU  - Celandroni F
AD  - Department of Translational Research and New Technologies in Medicine and
      Surgery, University of Pisa, Via San Zeno 37, 56127, Pisa, Italy.
FAU - Mazzantini, Diletta
AU  - Mazzantini D
AD  - Department of Translational Research and New Technologies in Medicine and
      Surgery, University of Pisa, Via San Zeno 37, 56127, Pisa, Italy.
FAU - Mattioli-Belmonte, Monica
AU  - Mattioli-Belmonte M
AD  - Department of Clinical and Molecular Science-DISCLIMO, Universita Politecnica
      delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.
FAU - Ghelardi, Emilia
AU  - Ghelardi E
AD  - Department of Translational Research and New Technologies in Medicine and
      Surgery, University of Pisa, Via San Zeno 37, 56127, Pisa, Italy.
      emilia.ghelardi@med.unipi.it.
FAU - Vozzi, Giovanni
AU  - Vozzi G
AD  - Research Center "E. Piaggio", University of Pisa, Largo Lucio Lazzarino 1, 55122,
      Pisa, Italy. g.vozzi@ing.unipi.it.
AD  - Department of Information Engineering, University of Pisa, Via G. Caruso 16,
      56122, Pisa, Italy. g.vozzi@ing.unipi.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201209
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 9000-70-8 (Gelatin)
SB  - IM
MH  - Bacteria/growth & development
MH  - Biodiversity
MH  - Biofilms/growth & development
MH  - Feces/microbiology
MH  - Gastrointestinal Microbiome/*physiology
MH  - Gastrointestinal Tract/microbiology
MH  - Gelatin/chemistry
MH  - Humans
MH  - Microbiota/physiology
MH  - Models, Biological
MH  - Tissue Scaffolds/*chemistry
PMC - PMC7725811
EDAT- 2020/12/11 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/12/10 05:49
PHST- 2020/07/17 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/10 05:49 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - 10.1038/s41598-020-78591-w [doi]
AID - 10.1038/s41598-020-78591-w [pii]
PST - epublish
SO  - Sci Rep. 2020 Dec 9;10(1):21499. doi: 10.1038/s41598-020-78591-w.


PMID- 33298940
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210213
IS  - 2057-3995 (Electronic)
IS  - 2057-3995 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Nov 3
TI  - Challenges and translational considerations of mesenchymal stem/stromal cell
      therapy for Parkinson's disease.
PG  - 20
LID - 10.1038/s41536-020-00106-y [doi]
AB  - Parkinson's disease (PD) is the second most common neurodegenerative disease
      characterized by the progressive loss of dopaminergic neurons in the substantia
      nigra pars compacta and the presence of Lewy bodies, which gives rise to motor
      and non-motor symptoms. Unfortunately, current therapeutic strategies for PD
      merely treat the symptoms of the disease, only temporarily improve the patients' 
      quality of life, and are not sufficient for completely alleviating the symptoms. 
      Therefore, cell-based therapies have emerged as a novel promising therapeutic
      approach in PD treatment. Mesenchymal stem/stromal cells (MSCs) have arisen as a 
      leading contender for cell sources due to their regenerative and immunomodulatory
      capabilities, limited ethical concerns, and low risk of tumor formation. Although
      several studies have shown that MSCs have the potential to mitigate the
      neurodegenerative pathology of PD, variabilities in preclinical and clinical
      trials have resulted in inconsistent therapeutic outcomes. In this review, we
      strive to highlight the sources of variability in studies using MSCs in PD
      therapy, including MSC sources, the use of autologous or allogenic MSCs, dose,
      delivery methods, patient factors, and measures of clinical outcome. Available
      evidence indicates that while the use of MSCs in PD has largely been promising,
      conditions need to be standardized so that studies can be effectively compared
      with one another and experimental designs can be improved upon, such that this
      body of science can continue to move forward.
FAU - Fricova, Dominika
AU  - Fricova D
AD  - Department of Laboratory Medicine and Pathology and Center for Regenerative
      Medicine, Mayo Clinic, Jacksonville, FL, USA.
AD  - Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak
      Republic.
FAU - Korchak, Jennifer A
AU  - Korchak JA
AD  - Department of Laboratory Medicine and Pathology and Center for Regenerative
      Medicine, Mayo Clinic, Jacksonville, FL, USA.
FAU - Zubair, Abba C
AU  - Zubair AC
AUID- ORCID: http://orcid.org/0000-0003-4827-4740
AD  - Department of Laboratory Medicine and Pathology and Center for Regenerative
      Medicine, Mayo Clinic, Jacksonville, FL, USA. zubair.abba@mayo.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201103
PL  - United States
TA  - NPJ Regen Med
JT  - NPJ Regenerative medicine
JID - 101699846
PMC - PMC7641157
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:01
CRDT- 2020/12/10 05:45
PHST- 2020/04/20 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/12/10 05:45 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:01 [medline]
AID - 10.1038/s41536-020-00106-y [doi]
AID - 10.1038/s41536-020-00106-y [pii]
PST - epublish
SO  - NPJ Regen Med. 2020 Nov 3;5(1):20. doi: 10.1038/s41536-020-00106-y.


PMID- 33298936
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210213
IS  - 2057-3995 (Electronic)
IS  - 2057-3995 (Linking)
VI  - 5
IP  - 1
DP  - 2020 Dec 1
TI  - Stem cell preservation for regenerative therapies: ethical and governance
      considerations for the health care sector.
PG  - 23
LID - 10.1038/s41536-020-00108-w [doi]
AB  - The stem cell preservation industry has grown substantially with private
      businesses, public hospitals, and academic medical centers considering preserving
      induced pluripotent stem cells, mesenchymal stem cells, and other cell types of
      patients and the public in order to potentially use them for stem cell therapy
      should such an intervention exist in the future. Despite this growth and interest
      among private firms and academic centers, no study has yet considered the
      bioethical issues of such platforms. In this article, we explore several ethical 
      and social issues related to the biopreservation of stem cells for future
      regenerative therapies. We analyze a range of bioethical considerations that
      public and private institutions should bear in mind as they develop stem cell
      preservation platforms. These include medical validation of regenerative
      interventions and their influence on the public understanding of stem cell
      therapies, the impact of public trust of organizations creating a private,
      for-profit venture of stem cell preservation, and logistical issues in the
      governance of the collection including ownership and dispositional authority,
      informed consent and access, and withdrawal and non-payment. These considerations
      should be incorporated into current and future stem cell preservation platforms
      in order to promote the responsible translation of regenerative medicine.
FAU - Master, Zubin
AU  - Master Z
AUID- ORCID: http://orcid.org/0000-0002-3462-4546
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN, 55905, USA.
      Master.Zubin@mayo.edu.
AD  - Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
      Master.Zubin@mayo.edu.
FAU - Crowley, Aidan P
AU  - Crowley AP
AUID- ORCID: http://orcid.org/0000-0002-4606-5622
AD  - College of Science, Department of Biological Sciences, University of Notre Dame, 
      Notre Dame, IN, 46556, USA.
FAU - Smith, Cambray
AU  - Smith C
AUID- ORCID: http://orcid.org/0000-0001-9723-891X
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN, 55905, USA.
AD  - School of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC,
      27599, USA.
FAU - Wigle, Dennis
AU  - Wigle D
AD  - Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
AD  - Department of Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
FAU - Terzic, Andre
AU  - Terzic A
AUID- ORCID: http://orcid.org/0000-0001-9210-009X
AD  - Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
FAU - Sharp, Richard R
AU  - Sharp RR
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN, 55905, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201201
PL  - United States
TA  - NPJ Regen Med
JT  - NPJ Regenerative medicine
JID - 101699846
PMC - PMC7708480
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:01
CRDT- 2020/12/10 05:45
PHST- 2020/04/16 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/12/10 05:45 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:01 [medline]
AID - 10.1038/s41536-020-00108-w [doi]
AID - 10.1038/s41536-020-00108-w [pii]
PST - epublish
SO  - NPJ Regen Med. 2020 Dec 1;5(1):23. doi: 10.1038/s41536-020-00108-w.


PMID- 33298599
OWN - NLM
STAT- Publisher
LR  - 20201215
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 9
TI  - SARS-CoV-2 safer infection sites: moral entitlement, pragmatic harm reduction
      strategy or ethical outrage?
LID - medethics-2020-106567 [pii]
LID - 10.1136/medethics-2020-106567 [doi]
AB  - The pandemic of SARS-CoV-2 has led to unprecedented changes to society, causing
      unique problems that call for extraordinary solutions. We consider one such
      extraordinary proposal: 'safer infection sites' that would offer individuals the 
      opportunity to be intentionally infected with SARS-CoV-2, isolate, and receive
      medical care until they are no longer infectious. Safer infection could have
      value for various groups of workers and students. Health professionals place
      themselves at risk of infection daily and extend this risk to their family
      members and community. Similarly, other essential workers who face workplace
      exposure must continue their work, even if have high-risk household members and
      live in fear of infecting. When schools are kept closed because of the fear that 
      they will be sites of significant transmission, children and their families are
      harmed in multiple ways and college students who are living on campus, whether or
      not they are attending classes in person, are contributing to high rates of
      transmission and experiencing high rates of exposure. We consider whether
      offering safer infection sites to these groups could be ethically defensible and 
      identify the empirical unknowns that would need to resolve before reaching
      definitive conclusions. This article is not an endorsement of intentional
      infection with the coronavirus, but rather is meant to spark conversation on the 
      ethics of out-of-the-box proposals. Perhaps most meaningfully, our paper explores
      the value of control and peace of mind for those among us most impacted by the
      pandemic: those essential workers risking the most to keep us safe.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hunt, Megan F
AU  - Hunt MF
AUID- ORCID: http://orcid.org/0000-0002-6240-9050
AD  - Johns Hopkins School of Medicine, Baltimore, Maryland, USA mhunt25@jhmi.edu.
FAU - Clark, Katharine T
AU  - Clark KT
AD  - Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
FAU - Geller, Gail
AU  - Geller G
AD  - The Johns Hopkins Berman Institute of Bioethics, Baltimore, Maryland, USA.
FAU - Barnhill, Anne
AU  - Barnhill A
AD  - The Johns Hopkins Berman Institute of Bioethics, Baltimore, Maryland, USA.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7733225
OTO - NOTNLM
OT  - children
OT  - education
OT  - ethics
OT  - health workforce
OT  - occupational health
COIS- Competing interests: None declared.
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:00
CRDT- 2020/12/10 05:42
PHST- 2020/06/07 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/10 05:42 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:00 [medline]
AID - medethics-2020-106567 [pii]
AID - 10.1136/medethics-2020-106567 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 9. pii: medethics-2020-106567. doi:
      10.1136/medethics-2020-106567.


PMID- 33298598
OWN - NLM
STAT- Publisher
LR  - 20210127
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 9
TI  - Roles of genetics and blood type in clinical responses to COVID-19: ethical and
      policy concerns.
LID - medethics-2020-106920 [pii]
LID - 10.1136/medethics-2020-106920 [doi]
AB  - Recently, several genetic variants have been associated with increased or
      decreased risks of becoming infected and/or seriously ill with COVID-19-not only 
      offering important potential medical benefits but also posing critical ethical
      questions. These genetic factors, some of which are associated with blood type,
      may account for variations in observed responses to COVID-19. Hence, assessments 
      of these genetic differences and blood type could provide possible benefits in
      gauging patients' risks of disease acquisition and prioritising allocation of
      interventions or vaccines, if supplies are limited. The media has widely reported
      these findings, and people online are now discussing their blood type and its
      possible effects on their COVID-19 risks, but several ethical concerns arise.
      Individuals possessing genetic variants or blood types associated with lower risk
      may engage in 'risk compensation', erroneously assuming that they can protect
      themselves less, and hence less frequently wearing masks or washing hands. Given 
      the ongoing COVID-19 pandemic, many physicians, hospitals, patients,
      policymakers, members of the public, testing companies and others may well
      consider these factors in making critical prevention/treatment decisions.
      Researchers, providers and others should thus begin to address these concerns.
      Increased awareness and education aimed at providers, patients, family members,
      public health officials, political leaders and the public-at-large are critical. 
      Attitudinal research is vital to examine how providers, patients and the public
      understand these findings. Ethical frameworks and guidelines are needed,
      addressing whether such genetic information should be incorporated into decisions
      regarding allocation of scarce resources-including hospital and ICU beds,
      ventilators, medications (eg, remdesivir) and vaccines-and if so, how.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Klitzman, Robert
AU  - Klitzman R
AUID- ORCID: http://orcid.org/0000-0002-6827-8063
AD  - Psychiatry, Columbia University, New York City, New York, USA rlk2@columbia.edu.
LA  - eng
GR  - RM1 HG007257/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7733231
OTO - NOTNLM
OT  - decision-making
OT  - ethics
OT  - genethics
OT  - public health ethics
OT  - public policy
COIS- Competing interests: None declared.
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:00
CRDT- 2020/12/10 05:42
PHST- 2020/09/22 00:00 [received]
PHST- 2020/11/11 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/10 05:42 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:00 [medline]
AID - medethics-2020-106920 [pii]
AID - 10.1136/medethics-2020-106920 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 9. pii: medethics-2020-106920. doi:
      10.1136/medethics-2020-106920.


PMID- 33298088
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1477-7517 (Electronic)
IS  - 1477-7517 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Dec 9
TI  - An ethical analysis of UK drug policy as an example of a criminal justice
      approach to drugs: a commentary on the short film Putting UK Drug Policy into
      Focus.
PG  - 97
LID - 10.1186/s12954-020-00434-8 [doi]
AB  - BACKGROUND: Drug-related deaths in the UK are at the highest level on record-the 
      war on drugs has failed. A short film has been produced intended for public and
      professional audiences featuring academics, representatives of advocacy
      organisations, police and policymakers outlining the problems with, and
      highlighting alternative approaches to, UK drug policy. A range of ethical
      arguments are alluded to, which are distilled here in greater depth for
      interested viewers and a wider professional and academic readership. MAIN BODY:
      The war on drugs is seemingly driven by the idea that the consumption of illegal 
      drugs is immoral. However, the meaning ascribed to 'drug' in the illicit sense
      encompasses a vast range of substances with different properties that have as
      much in common with legal drugs as they do with each other. The only property
      that distinguishes illegal from legal drugs is their legal status, which rather
      than being based on an assessment of how dangerous they are has been defined by
      centuries of socio-political idiosyncrasies. The consequences of criminalising
      people who use drugs often outweigh the risks they face from drug use, and there 
      is not convincing evidence that this prevents wider drug use or drug-related
      harm. Additionally, punishing someone as a means, to the end of deterring others 
      from drug use, is ethically problematic. Although criminalising the production of
      harmful drugs may seem more ethically tenable, it has not reduced the supply of
      drugs and it precludes effective regulation of the market. Other potential policy
      approaches are highlighted, which would be ethically preferable to existing
      punitive policy. CONCLUSION: It is not possible to eliminate all drug use and
      associated harms. The current approach is not only ineffective in preventing
      drug-related harm but itself directly and indirectly causes incalculable harm to 
      those who use drugs and to wider society. For policymakers to gain the mandate to
      rationalise drug policy, or to be held accountable if they do not, wider
      engagement with the electorate is required. It is hoped that this film will
      encourage at least a few to give pause and reflect on how drug policy might be
      improved.
FAU - Holland, Adam
AU  - Holland A
AUID- ORCID: 0000-0002-3617-1966
AD  - School of Population Health Sciences, University of Bristol, Bristol, UK.
      Adam.Holland@Bristol.ac.uk.
LA  - eng
PT  - Letter
DEP - 20201209
PL  - England
TA  - Harm Reduct J
JT  - Harm reduction journal
JID - 101153624
RN  - 0 (Illicit Drugs)
SB  - IM
MH  - *Criminal Law
MH  - Ethical Analysis
MH  - Humans
MH  - *Illicit Drugs
MH  - Public Policy
MH  - United Kingdom
PMC - PMC7724436
OTO - NOTNLM
OT  - *Advocacy
OT  - *Decriminalisation
OT  - *Ethics
OT  - *Film
OT  - *Harm reduction
OT  - *Illicit drugs
OT  - *Policy
OT  - *Regulation
EDAT- 2020/12/11 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/12/10 05:37
PHST- 2020/10/16 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/12/10 05:37 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1186/s12954-020-00434-8 [doi]
AID - 10.1186/s12954-020-00434-8 [pii]
PST - epublish
SO  - Harm Reduct J. 2020 Dec 9;17(1):97. doi: 10.1186/s12954-020-00434-8.


PMID- 33298038
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1471-2482 (Electronic)
IS  - 1471-2482 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 9
TI  - Prognostic value of inflammatory markers for detecting anastomotic leakage after 
      esophageal resection.
PG  - 324
LID - 10.1186/s12893-020-00995-2 [doi]
AB  - BACKGROUND: Early diagnosis of anastomotic leakage (AL) after esophageal
      resection is crucial for the successful management of this complication.
      Inflammatory serological markers are indicators of complications during the
      postoperative course. The aim of the present study was to evaluate the prognostic
      value of routine inflammatory markers to predict anastomotic leakage after
      transthoracic esophageal resection. METHODS: Data from all consecutive patients
      undergoing transthoracic esophageal resection between January 2010 and December
      2016 were analyzed from a prospective database. Besides clinicodemographic
      parameters, C-reactive protein, white blood cell count and albumin were analyzed 
      and the Noble/Underwood (NUn) score was calculated to evaluate their predictive
      value for postoperative anastomotic leakage. Diagnostic accuracy was measured by 
      sensitivity, specificity, and negative and positive predictive values using area 
      under the receiver operator characteristics curve. RESULTS: Overall, 233 patients
      with transthoracic esophageal resection were analyzed, 30-day mortality in this
      group was 3.4%. 57 patients (24.5%) suffered from AL, 176 patients were in the AL
      negative group. We found significant differences in WBCC, CRP and NUn scores
      between patients with and without AL, but the analyzed markers did not show an
      independent relevant prognostic value. For CRP levels below 155 mg/dl from POD3
      to POD 7 the negative predictive value for absence of AI was > 80%. Highest
      diagnostic accuracy was detected for CRP levels on 4(th) POD with a cut-off value
      of 145 mg/l reaching negative predictive value of 87%. CONCLUSIONS: In contrast
      to their prognostic value in other surgical procedures, CRP, WBCC and NUn score
      cannot be recommended as independent markers for the prediction of anastomotic
      leakage after transthoracic esophageal resection. CRP is an accurate negative
      predictive marker and discrimination of AL and no-AL may be helpful for
      postoperative clinical management. Trial registration The study was approved by
      the local ethical committee (S635-2013).
FAU - Liesenfeld, Lukas F
AU  - Liesenfeld LF
AUID- ORCID: http://orcid.org/0000-0002-8124-0756
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany. lukas.liesenfeld@med.uni-heidelberg.de.
FAU - Sauer, Peter
AU  - Sauer P
AD  - Department of Gastroenterology, Heidelberg University Hospital, Im Neuenheimer
      Feld 410, 69120, Heidelberg, Germany.
FAU - Diener, Markus K
AU  - Diener MK
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
FAU - Hinz, Ulf
AU  - Hinz U
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
FAU - Schmidt, Thomas
AU  - Schmidt T
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
FAU - Muller-Stich, Beat P
AU  - Muller-Stich BP
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
FAU - Hackert, Thilo
AU  - Hackert T
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
FAU - Schaible, Anja
AU  - Schaible A
AD  - Department of Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 420,
      69120, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Surg
JT  - BMC surgery
JID - 100968567
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anastomosis, Surgical
MH  - Anastomotic Leak/diagnosis/*etiology
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*metabolism
MH  - Esophageal Neoplasms/*surgery
MH  - Esophagectomy/*adverse effects
MH  - Esophagus/surgery
MH  - Female
MH  - Humans
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
PMC - PMC7726907
OTO - NOTNLM
OT  - Anastomotic leakage
OT  - C-reactive protein
OT  - Esophageal carcinoma
OT  - Esophageal resection
OT  - Nun score
OT  - White blood cell count
EDAT- 2020/12/11 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/12/10 05:36
PHST- 2020/08/17 00:00 [received]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2020/12/10 05:36 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - 10.1186/s12893-020-00995-2 [doi]
AID - 10.1186/s12893-020-00995-2 [pii]
PST - epublish
SO  - BMC Surg. 2020 Dec 9;20(1):324. doi: 10.1186/s12893-020-00995-2.


PMID- 33297457
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Are They Really Trying to Save Their Buddy? The Anthropomorphism of Animal
      Epimeletic Behaviours.
LID - E2323 [pii]
LID - 10.3390/ani10122323 [doi]
AB  - Anthropomorphism is a natural tendency in humans, but it is also influenced by
      many characteristics of the observer (the human) and the observed entity (here,
      the animal species). This study asked participants to complete an online
      questionnaire about three videos showing epimeletic behaviours in three animal
      species. In the videos, an individual (a sparrow, an elephant and a macaque,
      respectively) displayed behaviours towards an inanimate conspecific that suddenly
      regained consciousness at the end of the footage. A fourth video showed a robot
      dog being kicked by an engineer to demonstrate its stability. Each video was
      followed by a series of questions designed to evaluate the degree of
      anthropomorphism of participants, from mentaphobia (no attribution of intentions 
      and beliefs, whatever the animal species) to full anthropomorphism (full
      attribution of intentions and beliefs by animals, to the same extent as in
      humans) and to measure how far the participants had correctly assessed each
      situation in terms of biological reality (current scientific knowledge of each
      species). There is a negative correlation (about 61%) between the mental states
      attributed to animals by humans and the real capability of animals. The
      heterogeneity of responses proved that humans display different forms of
      anthropomorphism, from rejecting all emotional or intentional states in animals
      to considering animals to show the same intentions as humans. However, the scores
      participants attributed to animals differed according to the species shown in the
      video and to human socio-demographic characteristics. Understanding the potential
      usefulness of these factors can lead to better relationships with animals and
      encourage a positive view of human-robot interactions. Indeed, reflective or
      critical anthropomorphism can increase our humanity.
FAU - Sueur, Cedric
AU  - Sueur C
AUID- ORCID: 0000-0001-8206-2739
AD  - Universite de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France.
AD  - Centre Europeen d'Enseignement et de Recherche en Ethique, F-67000 Strasbourg,
      France.
AD  - Institut Universitaire de France, 75006 Paris, France.
FAU - Forin-Wiart, Marie-Amelie
AU  - Forin-Wiart MA
AUID- ORCID: 0000-0002-1996-1907
AD  - Universite de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France.
FAU - Pele, Marie
AU  - Pele M
AUID- ORCID: 0000-0003-2297-5522
AD  - Anthropo-Lab, ETHICS EA7446, Lille Catholic University, 59000 Lille, France.
LA  - eng
PT  - Journal Article
DEP - 20201207
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7762333
OTO - NOTNLM
OT  - animal ethics
OT  - birds
OT  - cognitive biases
OT  - comparative thanatology
OT  - elephants
OT  - empathy
OT  - mentaphobia
OT  - primates
OT  - robot
EDAT- 2020/12/11 06:00
MHDA- 2020/12/11 06:01
CRDT- 2020/12/10 01:03
PHST- 2020/10/26 00:00 [received]
PHST- 2020/11/26 00:00 [revised]
PHST- 2020/12/04 00:00 [accepted]
PHST- 2020/12/10 01:03 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2020/12/11 06:01 [medline]
AID - ani10122323 [pii]
AID - 10.3390/ani10122323 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Dec 7;10(12). pii: ani10122323. doi: 10.3390/ani10122323.


PMID- 33296638
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220418
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 36
IP  - 12
DP  - 2020 Dec
TI  - [Ethical and social consequences of biomarkers that predict impending death in
      humans].
PG  - 1199-1206
LID - 10.1051/medsci/2020228 [doi]
AB  - Fundamental research on ageing has taken an interesting turn in recent years with
      the rapid development of biomarkers predicting mortality in model organisms,
      particularly Drosophila, as well as in humans through improvements in approaches 
      to the identification of circulating molecules in mass. These developments lead
      to a shift in our ability to predict the occurrence of death from the
      historically population level to the individual level. We question here the
      ethical, medical and social implications of this change of scale.
CI  - (c) 2020 medecine/sciences - Inserm.
FAU - Gaille, Marie
AU  - Gaille M
AD  - Universite de Paris, SPHERE, UMR 7219, CNRS-Universite Paris Diderot, batiment
      Condorcet, case 7093, 5 rue Thomas Mann, 75205 Paris, France.
FAU - Araneda, Marco
AU  - Araneda M
AD  - Universite de Paris, Centre de recherche psychanalyse medecine et societe (CRPMS)
      - EA 3522, IUH - EA 3518, batiment Olympe de Gouges, 8 rue Albert-Einstein, 75013
      Paris, France.
FAU - Dubost, Clement
AU  - Dubost C
AD  - Chef de service de reanimation polyvalente, hopital d'instruction des armees
      (HIA) Begin et Groupe de recherche COGNAC-G (Cognition and action group), UMR
      CNRS-Paris Descartes-SSA, Paris, France.
FAU - Guillermain, Clemence
AU  - Guillermain C
AD  - Universite de Paris, SPHERE, UMR 7219, CNRS-Universite Paris Diderot, batiment
      Condorcet, case 7093, 5 rue Thomas Mann, 75205 Paris, France.
FAU - Kaakai, Sarah
AU  - Kaakai S
AD  - Laboratoire Manceau de mathematiques, Institut du risque et de l'assurance, Le
      Mans Universite, 72000 Le Mans, France.
FAU - Ricadat, Elise
AU  - Ricadat E
AD  - Universite de Paris, Centre de recherche psychanalyse medecine et societe (CRPMS)
      - EA 3522, IUH - EA 3518, batiment Olympe de Gouges, 8 rue Albert-Einstein, 75013
      Paris, France.
FAU - Todd, Nicolas
AU  - Todd N
AD  - Max Planck Institute for Demographic Research, Rostock, Allemagne.
FAU - Rera, Michael
AU  - Rera M
AD  - Universite de Paris, Inserm U1284, Center for Research and Interdisciplinarity
      (CRI), F-75006 Paris, France.
LA  - fre
PT  - Journal Article
TT  - Consequences ethiques et sociales de biomarqueurs predictifs de la mort chez
      l'homme - La vieillesse et la mort, problematiques comportementales et
      societales.
DEP - 20201209
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/pathology
MH  - Animals
MH  - *Bioethics
MH  - *Biomarkers
MH  - *Death
MH  - Humans
MH  - Longevity/ethics
MH  - Middle Aged
MH  - Morals
MH  - Prognosis
MH  - Social Change
EDAT- 2020/12/10 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/09 20:06
PHST- 2020/12/09 20:06 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1051/medsci/2020228 [doi]
AID - msc190265 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2020 Dec;36(12):1199-1206. doi: 10.1051/medsci/2020228. Epub
      2020 Dec 9.


PMID- 33296482
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 0189-160X (Print)
IS  - 0189-160X (Linking)
VI  - 37
IP  - 7
DP  - 2020 Dec
TI  - Prospective Cross-Sectional Study of Quality of Life of Vitiligo Patients Using a
      Vitiligo Specific Quality of Life Instrument.
PG  - 745-749
AB  - BACKGROUND: Studies on the QOL of Vitiligo patients are few in Nigeria with
      consequent limited reports of the relationship between QOL and vitiligo. Also,
      the VitiQoL has not been used in Nigerian studies. The objective of this study,
      therefore, was to determine the QOL of Vitiligo patients using the VitiQoL to
      determine the socio-demographic and clinical factors which impair QOL and the QOL
      items affected by vitiligo. METHODS: This was a prospective cross-sectional study
      of 29 newly diagnosed vitiligo patients over a one year period at the skin clinic
      of the Lagos State University Teaching Hospital following ethical approval.
      Patients were clinically evaluated, clinical and socio-demographic
      characteristics were documented using a questionnaire designed for the study.
      Quality of life was assessed using two instruments; the VitiQoL and the DQLI. The
      Statistical Package for Social Sciences (SPSS) IBM version 22 was used for data
      analysis and p<0.05 was considered significant for all statistical tests.
      RESULTS: The mean vitiQoL was 37.4+/-24.4, the lowest and highest vitiQoL were 0 
      and 84. QOL was impaired in 96.6% and the severity of impairment was mild,
      moderate and severe in 27.6%, 24.1% and 44.8% respectively. The items of
      impairment on the vitiQoL were embarrassment (55.5%), bother (55.2%), frustration
      (55.2%), people's perception (40.9%), and worry about spread (75.9%). CONCLUSION:
      The VitiQOL is a reliable instrument for assessing QOL in vitiligo and the main
      item impacted is stigmatization. Social and clinical factors are independent of
      QOL impairment.
FAU - Anaba, E L
AU  - Anaba EL
AD  - Department of Medicine, Lagos State University Teaching Hospital, 1-5 Oba
      Akinjobi Way, Ikeja, Lagos, Nigeria.
FAU - Oaku, R I
AU  - Oaku RI
AD  - Department of Medicine, Lagos State University Teaching Hospital, 1-5 Oba
      Akinjobi Way, Ikeja, Lagos, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - West Afr J Med
JT  - West African journal of medicine
JID - 8301891
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Nigeria
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - *Vitiligo/complications
EDAT- 2020/12/10 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/09 17:09
PHST- 2020/12/09 17:09 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PST - ppublish
SO  - West Afr J Med. 2020 Dec;37(7):745-749.


PMID- 33296329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201219
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 15
TI  - Impact of a Serious Game on the Intention to Change Infection Prevention and
      Control Practices in Nursing Homes During the COVID-19 Pandemic: Protocol for a
      Web-Based Randomized Controlled Trial.
PG  - e25595
LID - 10.2196/25595 [doi]
AB  - BACKGROUND: Nursing home residents are at high risk of complications and death
      due to COVID-19. Lack of resources, both human and material, amplifies the
      likelihood of contamination in these facilities where a single employee can
      contaminate dozens of residents and colleagues. Improving the dissemination of
      and adhesion to infection prevention and control (IPC) guidelines is therefore
      essential. Serious games have been shown to be effective in developing knowledge 
      and in increasing engagement, and could motivate nursing home employees to change
      their IPC practices. OBJECTIVE: Our aim is to assess the impact of "Escape
      COVID-19," a serious game designed to enhance knowledge and application of IPC
      procedures, on the intention of nursing home employees to change their IPC
      practices. METHODS: We will carry out a web-based randomized controlled trial
      following the CONSORT-EHEALTH (Consolidated Standards of Reporting Trials of
      Electronic and Mobile Health Applications and Online Telehealth) guidelines and
      incorporating relevant elements of CHERRIES (Checklist for Reporting Results of
      Internet E-Surveys). Participants will be randomized to either the control or the
      serious game (intervention) group. First, both groups will be asked to answer a
      questionnaire designed to gather demographic data and assess baseline knowledge. 
      The control group will then receive a quick reminder of the current national
      guidelines and links to IPC guidelines for health care professionals, while the
      other group will play the game. Both groups will then have to answer a second
      questionnaire designed to assess their willingness to change their IPC practices 
      after having followed their respective material. After completing this
      questionnaire, they will be granted access to the material presented to the group
      they were not assigned to and receive a course completion certificate. The
      primary outcome will be the proportion of participants willing to change their
      IPC practices according to group. Secondary outcomes will include the analysis of
      specific questions detailing the exact changes considered by the participants.
      Factors associated with participant willingness or reluctance to change behavior 
      will also be assessed. Attrition will also be assessed at each stage of the
      study. RESULTS: The study protocol has been presented to our regional ethics
      committee (Req-2020-01262), which issued a declaration of no objection as such
      projects do not fall within the scope of the Swiss federal law on human research.
      Data collection began on November 5, 2020, and should be completed by December 4,
      2020. CONCLUSIONS: This study should determine whether "Escape COVID-19," a
      serious game designed to improve compliance with COVID-19 safe practices,
      modifies the intention to follow IPC guidelines among nursing home employees.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/25595.
CI  - (c)Laurent Suppan, Mohamed Abbas, Gaud Catho, Loric Stuby, Simon Regard, Stephan 
      Harbarth, Sophia Achab, Melanie Suppan. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 15.12.2020.
FAU - Suppan, Laurent
AU  - Suppan L
AUID- ORCID: https://orcid.org/0000-0001-6989-6421
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Abbas, Mohamed
AU  - Abbas M
AUID- ORCID: https://orcid.org/0000-0002-7265-1887
AD  - Infection Control Programme, WHO Collaborating Centre on Patient Safety,
      University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Catho, Gaud
AU  - Catho G
AUID- ORCID: https://orcid.org/0000-0002-4948-0944
AD  - Infection Control Programme, WHO Collaborating Centre on Patient Safety,
      University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Stuby, Loric
AU  - Stuby L
AUID- ORCID: https://orcid.org/0000-0003-1663-5249
AD  - Geneve TEAM Ambulances, Geneva, Switzerland.
FAU - Regard, Simon
AU  - Regard S
AUID- ORCID: https://orcid.org/0000-0002-3979-7593
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
AD  - Division of General Surgeon, Geneva Directorate of Health, Geneva, Switzerland.
FAU - Harbarth, Stephan
AU  - Harbarth S
AUID- ORCID: https://orcid.org/0000-0002-3551-1025
AD  - Infection Control Programme, WHO Collaborating Centre on Patient Safety,
      University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Achab, Sophia
AU  - Achab S
AUID- ORCID: https://orcid.org/0000-0002-3861-3297
AD  - Specialized Facility in Behavioral Addictions ReConnecte, Geneva University
      Hospitals, Geneva, Switzerland.
AD  - WHO Collaborating Center in Training and Research in Mental Health, University of
      Geneva, Geneva, Switzerland.
FAU - Suppan, Melanie
AU  - Suppan M
AUID- ORCID: https://orcid.org/0000-0002-8807-9619
AD  - Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, 
      Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty
      of Medicine, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201215
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7744143
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-COV-2
OT  - elderly
OT  - health care worker
OT  - infection control
OT  - infection prevention
OT  - infectious disease
OT  - nursing home
OT  - older adult
OT  - randomized controlled trial
OT  - serious game
OT  - transmission
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 17:08
PHST- 2020/11/10 00:00 [received]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2020/12/02 00:00 [revised]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
PHST- 2020/12/09 17:08 [entrez]
AID - v9i12e25595 [pii]
AID - 10.2196/25595 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 15;9(12):e25595. doi: 10.2196/25595.


PMID- 33296036
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 1869-4101 (Print)
IS  - 1869-4101 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec 9
TI  - Lean body weight versus total body weight to calculate the iodinated contrast
      media volume in abdominal CT: a randomised controlled trial.
PG  - 132
LID - 10.1186/s13244-020-00920-4 [doi]
AB  - OBJECTIVES: Iodinated contrast media (ICM) could be more appropriately dosed on
      patient lean body weight (LBW) than on total body weight (TBW). METHODS: After
      Ethics Committee approval, trial registration NCT03384979, patients aged >/= 18
      years scheduled for multiphasic abdominal CT were randomised for ICM dose to LBW 
      group (0.63 gI/kg of LBW) or TBW group (0.44 gI/kg of TBW). Abdominal 64-row CT
      was performed using 120 kVp, 100-200 mAs, rotation time 0.5 s, pitch 1, Iopamidol
      (370 mgI/mL), and flow rate 3 mL/s. Levene, Mann-Whitney U, and chi(2) tests were
      used. The primary endpoint was liver contrast enhancement (LCE). RESULTS: Of 335 
      enrolled patients, 17 were screening failures; 44 dropped out after
      randomisation; 274 patients were analysed (133 LBW group, 141 TBW group). The
      median age of LBW group (66 years) was slightly lower than that of TBW group (70 
      years). Although the median ICM-injected volume was comparable between groups,
      its variability was larger in the former (interquartile range 27 mL versus 21 mL,
      p = 0.01). The same was for unenhanced liver density (IQR 10 versus 7 HU) (p =
      0.02). Median LCE was 40 (35-46) HU in the LBW group and 40 (35-44) HU in the TBW
      group, without significant difference for median (p = 0.41) and variability (p = 
      0.23). Suboptimal LCE (< 40 HU) was found in 64/133 (48%) patients in the LBW
      group and 69/141 (49%) in the TBW group, but no examination needed repeating.
      CONCLUSIONS: The calculation of the ICM volume to be administered for abdominal
      CT based on the LBW does not imply a more consistent LCE.
FAU - Zanardo, Moreno
AU  - Zanardo M
AUID- ORCID: http://orcid.org/0000-0001-9640-8534
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133, Milan, Italy. moreno.zanardo@unimi.it.
FAU - Doniselli, Fabio Martino
AU  - Doniselli FM
AUID- ORCID: https://orcid.org/0000-0002-2272-7855
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133, Milan, Italy.
AD  - Neuroradiology Department, Foundation IRCCS Neurological Institute "C. Besta",
      Via Celoria 11, 20133, Milan, Italy.
FAU - Esseridou, Anastassia
AU  - Esseridou A
AD  - Radiology Unit, IRCCS Policlinico San Donato, Via Morandi 30, 20097, San Donato
      Milanese, Italy.
FAU - Agro, Massimiliano
AU  - Agro M
AD  - Postgraduate School in Radiodiagnostics, Universita degli Studi di Milano, Via
      Festa del Perdono 7, 20122, Milan, Italy.
FAU - Panarisi, Nicol Antonina Rita
AU  - Panarisi NAR
AD  - Postgraduate School in Radiodiagnostics, Universita degli Studi di Milano, Via
      Festa del Perdono 7, 20122, Milan, Italy.
FAU - Monti, Caterina Beatrice
AU  - Monti CB
AUID- ORCID: https://orcid.org/0000-0002-9539-8642
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133, Milan, Italy.
FAU - Di Leo, Giovanni
AU  - Di Leo G
AUID- ORCID: https://orcid.org/0000-0003-0954-2634
AD  - Radiology Unit, IRCCS Policlinico San Donato, Via Morandi 30, 20097, San Donato
      Milanese, Italy.
FAU - Sardanelli, Francesco
AU  - Sardanelli F
AUID- ORCID: https://orcid.org/0000-0001-6545-9427
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133, Milan, Italy.
AD  - Radiology Unit, IRCCS Policlinico San Donato, Via Morandi 30, 20097, San Donato
      Milanese, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - Germany
TA  - Insights Imaging
JT  - Insights into imaging
JID - 101532453
PMC - PMC7726088
OTO - NOTNLM
OT  - *Abdomen
OT  - *Body composition
OT  - *Body weight
OT  - *Contrast media
OT  - *Tomography (x-ray computed)
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 12:15
PHST- 2020/07/08 00:00 [received]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/12/09 12:15 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s13244-020-00920-4 [doi]
AID - 10.1186/s13244-020-00920-4 [pii]
PST - epublish
SO  - Insights Imaging. 2020 Dec 9;11(1):132. doi: 10.1186/s13244-020-00920-4.


PMID- 33296033
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1869-4101 (Print)
IS  - 1869-4101 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec 9
TI  - Radiology artificial intelligence, a systematic evaluation of methods (RAISE): a 
      systematic review protocol.
PG  - 133
LID - 10.1186/s13244-020-00929-9 [doi]
AB  - INTRODUCTION: There has been a recent explosion of research into the field of
      artificial intelligence as applied to clinical radiology with the advent of
      highly accurate computer vision technology. These studies, however, vary
      significantly in design and quality. While recent guidelines have been
      established to advise on ethics, data management and the potential directions of 
      future research, systematic reviews of the entire field are lacking. We aim to
      investigate the use of artificial intelligence as applied to radiology, to
      identify the clinical questions being asked, which methodological approaches are 
      applied to these questions and trends in use over time. METHODS AND ANALYSIS: We 
      will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis
      (PRISMA) guidelines and by the Cochrane Collaboration Handbook. We will perform a
      literature search through MEDLINE (Pubmed), and EMBASE, a detailed data
      extraction of trial characteristics and a narrative synthesis of the data. There 
      will be no language restrictions. We will take a task-centred approach rather
      than focusing on modality or clinical subspecialty. Sub-group analysis will be
      performed by segmentation tasks, identification tasks, classification tasks,
      pegression/prediction tasks as well as a sub-analysis for paediatric patients.
      ETHICS AND DISSEMINATION: Ethical approval will not be required for this study,
      as data will be obtained from publicly available clinical trials. We will
      disseminate our results in a peer-reviewed publication. Registration number
      PROSPERO: CRD42020154790.
FAU - Kelly, Brendan
AU  - Kelly B
AUID- ORCID: http://orcid.org/0000-0002-3449-8017
AD  - St Vincent's University Hospital, Dublin, Ireland. brendanskelly@me.com.
AD  - Insight Centre for Data Analytics, UCD, Dublin, Ireland. brendanskelly@me.com.
AD  - Wellcome Trust - HRB, Irish Clinical Academic Training, Dublin, Ireland.
      brendanskelly@me.com.
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
      brendanskelly@me.com.
FAU - Judge, Conor
AU  - Judge C
AD  - Wellcome Trust - HRB, Irish Clinical Academic Training, Dublin, Ireland.
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
FAU - Bollard, Stephanie M
AU  - Bollard SM
AD  - Wellcome Trust - HRB, Irish Clinical Academic Training, Dublin, Ireland.
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
AD  - HRB-Clinical Research Facility, NUI Galway, Galway, Ireland.
AD  - Plastic and Reconstructive Surgery, Mater Misicordiae University Hospital,
      Dublin, Ireland.
FAU - Clifford, Simon M
AU  - Clifford SM
AD  - St Vincent's University Hospital, Dublin, Ireland.
FAU - Healy, Gerard M
AU  - Healy GM
AD  - St Vincent's University Hospital, Dublin, Ireland.
FAU - Yeom, Kristen W
AU  - Yeom KW
AD  - Lucille Packard Children's Hospital at Stanford, Stanford, CA, USA.
FAU - Lawlor, Aonghus
AU  - Lawlor A
AD  - Insight Centre for Data Analytics, UCD, Dublin, Ireland.
FAU - Killeen, Ronan P
AU  - Killeen RP
AD  - St Vincent's University Hospital, Dublin, Ireland.
LA  - eng
GR  - 203930/B/16/Z/Wellcome Trust (GB)
PT  - Journal Article
PT  - Review
DEP - 20201209
PL  - Germany
TA  - Insights Imaging
JT  - Insights into imaging
JID - 101532453
PMC - PMC7726044
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Methodology
OT  - Radiology
OT  - Systematic review
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 12:15
PHST- 2020/09/02 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/12/09 12:15 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s13244-020-00929-9 [doi]
AID - 10.1186/s13244-020-00929-9 [pii]
PST - epublish
SO  - Insights Imaging. 2020 Dec 9;11(1):133. doi: 10.1186/s13244-020-00929-9.


PMID- 33295289
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 3
DP  - 2020 Jul-Sep
TI  - Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent
      events.
PG  - 202-207
LID - 10.20529/IJME.2020.068 [doi]
AB  - The world is going through an unprecedented medical emergency with no effective
      remedy for the SARS-CoV2 virus causing Covid-19. Two drugs used for other
      indications in the past, hydroxychloroquine (HCQ) and remdesivir (RDV), are
      sought to be repurposed to treat Covid-19. Both these drugs have received
      emergency use authorisation by the US Food and Drug Administration. In this
      review, we critically analyse the identification of and subsequent events
      concerning these two drugs as potential treatment options for Covid-19, and
      conclude by raising some ethical issues that require serious thought from the
      global scientific community concerned with using these two drugs against
      Covid-19.<br><br> Key Words: Covid-19, hydroxychloroquine, remdesivir, USFDA,
      emergency use authorisation<br><br>.
FAU - Dang, Amit
AU  - Dang A
AD  - Founder and CEO, MarksMan Healthcare Communications and KYT Adhere, H No 9-1-67, 
      Plot 67, Behind Q City, Hyderabad, INDIA.
FAU - Vallish, B N
AU  - Vallish BN
AD  - Senior Consultant, Medical Writing and Biostatistics, MarksMan Healthcare
      Communications, H No 9-1-67, Plot 67, Behind Q City, Hyderabad, INDIA.
FAU - Dang, Sumit
AU  - Dang S
AD  - Department of Paediatrics, University of Kentucky, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
RN  - 0 (Antimalarials)
RN  - 0 (Antiviral Agents)
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use
MH  - Alanine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Antimalarials/adverse effects/therapeutic use
MH  - Antiviral Agents/adverse effects/therapeutic use
MH  - COVID-19/*drug therapy/virology
MH  - *Emergencies
MH  - *Ethics
MH  - Humans
MH  - Hydroxychloroquine/adverse effects/*therapeutic use
MH  - Off-Label Use
MH  - Pandemics
MH  - Patient Safety
MH  - SARS-CoV-2
MH  - Treatment Outcome
EDAT- 2020/12/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/09 08:38
PHST- 2020/12/09 08:38 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.20529/IJME.2020.068 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Jul-Sep;V(3):202-207. doi: 10.20529/IJME.2020.068.


PMID- 33295287
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 3
DP  - 2020 Jul-Sep
TI  - To comfort always: Are we ignoring this duty in Covid protocols?
PG  - 189-191
LID - 10.20529/IJME.2020.071 [doi]
AB  - COVID-19 is an amplifier of serious physical suffering and emotional trauma,
      which together could be all-consuming. It is important for health systems to go
      beyond methods of prevention and treatment, and focus on the palliation of
      suffering, and to systematically integrate palliative care into Covid-19
      management.<br><br> Further, in cases where the triage process indicates poor
      chances of survival, it is particularly important to respect autonomy by honest
      and sensitive disclosure of prognosis, and to jointly arrive at goals of care.
      Hooking every dying person to a ventilator would violate the ethical principles
      of beneficence and non-maleficence. It is also important to ensure at least
      electronic communication between the patient and family members.<br><br>
      Keywords: Covid-19, palliative care, end of life care, isolation, quarantine,
      intensive care, ethics of intubation, consent<br><br>.
FAU - Rajagopal, M R
AU  - Rajagopal MR
AD  - Founder Chairman, Pallium India, Thiruvananthapuram, Kerala, 695 009 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - *Beneficence
MH  - COVID-19/psychology/*therapy
MH  - Clinical Protocols
MH  - Communication
MH  - Critical Care/*ethics/psychology
MH  - Family
MH  - Fear
MH  - Humans
MH  - India
MH  - Intubation, Intratracheal
MH  - Medical Futility
MH  - *Moral Obligations
MH  - Pain Management
MH  - Palliative Care/*ethics
MH  - Personal Autonomy
MH  - Prognosis
MH  - SARS-CoV-2
MH  - Social Isolation
MH  - *Stress, Psychological
MH  - Terminal Care/*ethics
EDAT- 2020/12/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/09 08:38
PHST- 2020/12/09 08:38 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.20529/IJME.2020.071 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Jul-Sep;V(3):189-191. doi: 10.20529/IJME.2020.071.


PMID- 33295284
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 3
DP  - 2020 Jul-Sep
TI  - Ethics of clinical research and practice in India during the Covid-19 pandemic.
PG  - 175-180
LID - 10.20529/IJME.2020.080 [doi]
AB  - Covid-19 has been one of the worst public health calamities faced by humankind in
      over a century. As of July 23, 2020, there have been 15,633,159 confirmed cases
      and 635,422 deaths reported, worldwide (1). We are six months into the pandemic, 
      and yet we know little about the disease. The role of medicines is far from
      optimal, and vaccines are still under trials. Therefore, we have little to defend
      ourselves against this novel virus.<br><br>.
FAU - Rathi, Sahaj
AU  - Rathi S
AD  - Visiting Consultant, Department of Medicine, Mahatma Gandhi Institute of Medical 
      Sciences, Sevagram, Maharashtra, 442 102 INDIA.
FAU - Kalantri, S P
AU  - Kalantri SP
AD  - Director-Professor of Medicine and Medical Superintendent, Mahatma Gandhi
      Institute of Medical Sciences, Sevagram, Maharashtra, 442 102 INDIA.
LA  - eng
PT  - Editorial
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
RN  - 0 (Antiviral Agents)
RN  - 0 (Vaccines)
SB  - IM
MH  - Antiviral Agents
MH  - *COVID-19/epidemiology/therapy/virology
MH  - Cost-Benefit Analysis
MH  - *Ethics, Clinical
MH  - *Ethics, Research
MH  - Evidence-Based Medicine
MH  - Humans
MH  - India/epidemiology
MH  - Pandemics/*ethics
MH  - SARS-CoV-2
MH  - Vaccines
EDAT- 2020/12/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/09 08:38
PHST- 2020/12/09 08:38 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.20529/IJME.2020.080 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Jul-Sep;V(3):175-180. doi: 10.20529/IJME.2020.080.


PMID- 33295282
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 3
DP  - 2020 Jul-Sep
TI  - Knowledge and attitudes regarding medical ethics among junior medical graduates
      in a tertiary care hospital, Manipur: A cross-sectional study.
PG  - 254-255
LID - 10.20529/IJME.2020.083 [doi]
AB  - Training in medical ethics has been made mandatory in the undergraduate
      curriculum (1). The Medical Council of India (MCI) in 2002 released its revised
      Code of Ethics, a regulatory document on professional conduct, etiquette, and
      ethics of doctors (2).<br><br> Keywords: Medical ethics, knowledge,
      attitudes,<br><br>.
FAU - Rajkumari, Bishwalata
AU  - Rajkumari B
AD  - Associate Professor, Department of Community Medicine, Jawaharlal Nehru Institute
      of Medical Sciences, Imphal, Manipur-795005.
FAU - Singh, Haobam Danny
AU  - Singh HD
AD  - Tutor; Department of Community Medicine, Jawaharlal Nehru Institute of Medical
      Sciences, Imphal, Manipur-795005.
FAU - Ojit, Khaba
AU  - Ojit K
AD  - Post Graduate Trainee; Department of Community Medicine, Jawaharlal Nehru
      Institute of Medical Sciences, Imphal, Manipur-795005.
FAU - Thounaojam, Tamphasana
AU  - Thounaojam T
AD  - Post Graduate Trainee, Department of Community Medicine, Jawaharlal Nehru
      Institute of Medical Sciences, Imphal, Manipur-795005.
LA  - eng
PT  - Letter
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Education, Medical, Undergraduate
MH  - *Ethics, Medical
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Physicians/*psychology
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
EDAT- 2020/12/10 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/12/09 08:38
PHST- 2020/12/09 08:38 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
AID - 10.20529/IJME.2020.083 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Jul-Sep;V(3):254-255. doi: 10.20529/IJME.2020.083.


PMID- 33295239
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2309-4990 (Electronic)
IS  - 1022-5536 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Sep-Dec
TI  - Management for lumbar spinal stenosis: Protocol for a network meta-analysis and
      systematic review.
PG  - 2309499020975212
LID - 10.1177/2309499020975212 [doi]
AB  - INTRODUCTION: Lumbar spinal stenosis (LSS) is caused by structural changes of the
      spine, which lead to several severe symptoms, including back pain, leg pain,
      numbness and tingling in the legs, as well as reduced physical function. However,
      there is little evidence suggesting whether a patient with LSS should be treated 
      with surgery. If surgery is recommended, which type of surgery benefits the
      patient most? To answer these questions, we will conduct a network meta-analysis 
      and a systematic review to compare surgical and nonsurgical interventions in
      terms of efficacy as well as safety in adult patients with LSS. METHODS AND
      ANALYSIS: We will search the PubMed, Cochrane library, and EMBASE databases for
      articles published prior to October 10, 2019. We will search for randomized
      controlled trials assessing surgical and nonsurgical interventions for adult
      patients with degenerative LSS without any language restrictions. The primary
      outcome measures will be pain and disability. The secondary outcomes will include
      adverse events (number of events or number of people with each type of adverse
      event), reoperations, complications, blood loss and operation time. We will
      obtain the full texts of the potentially relevant studies and independently
      assess them. The quality of evidence will be evaluated according to the Grading
      of Recommendations Assessment, Development and Evaluation framework. A
      random-effects network meta-analysis will be performed to analyze all the
      evidence under the frequentist framework, and the ranking results will be
      presented. We will generate plots depicting the network geometry using Stata. The
      network meta-analysis will be performed according to the Bayesian framework.
      Ethics and dissemination Ethics approval is not required. The research will be
      published in a peer-reviewed journal.
FAU - Wei, Fei-Long
AU  - Wei FL
AUID- ORCID: 0000-0002-9260-5386
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Liu, Ya
AU  - Liu Y
AD  - Department of Outpatient, Xijing Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Zhou, Cheng-Pei
AU  - Zhou CP
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Sun, Si-Guo
AU  - Sun SG
AD  - Department of Orthopaedics, Air Force Medical Center, 56697Fourth Military
      Medical University, Beijing, China.
FAU - Zhu, Kai-Long
AU  - Zhu KL
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Du, Ming-Rui
AU  - Du MR
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Gao, Hao-Ran
AU  - Gao HR
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Yuan, Yi-Fang
AU  - Yuan YF
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Song, Yang
AU  - Song Y
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Qian, Shu
AU  - Qian S
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - An, Bo
AU  - An B
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Wang, Huan
AU  - Wang H
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Li, Xiao-Xiang
AU  - Li XX
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Guo, Shi-Kong
AU  - Guo SK
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Gao, Quan-You
AU  - Gao QY
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Wu, Sheng-Da
AU  - Wu SD
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Yan, Xiao-Dong
AU  - Yan XD
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Sun, Li-Li
AU  - Sun LL
AD  - Department of Neurology, Xijing Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
FAU - Qian, Ji-Xian
AU  - Qian JX
AUID- ORCID: 0000-0002-4023-8828
AD  - Department of Orthopaedics, Tangdu Hospital, 56697Fourth Military Medical
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - England
TA  - J Orthop Surg (Hong Kong)
JT  - Journal of orthopaedic surgery (Hong Kong)
JID - 9440382
SB  - IM
MH  - Adult
MH  - Bayes Theorem
MH  - *Disease Management
MH  - Humans
MH  - *Lumbar Vertebrae
MH  - *Network Meta-Analysis
MH  - Orthopedic Procedures/*methods
MH  - Spinal Stenosis/*therapy
OTO - NOTNLM
OT  - *NMA
OT  - *disability
OT  - *lumbar spinal stenosis
OT  - *non-surgery treatment
OT  - *pain
OT  - *surgery
EDAT- 2020/12/10 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/09 08:37
PHST- 2020/12/09 08:37 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1177/2309499020975212 [doi]
PST - ppublish
SO  - J Orthop Surg (Hong Kong). 2020 Sep-Dec;28(3):2309499020975212. doi:
      10.1177/2309499020975212.


PMID- 33294752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 24
DP  - 2020
TI  - Protocol for a Systematic Review Assessing Surgery versus Primary Endocrine
      Therapy in Operable Breast Cancer. Prep for Pandemic.
PG  - 36-38
LID - 10.1016/j.isjp.2020.10.003 [doi]
AB  - INTRODUCTION: In COVID-19 pandemic epicenters cancer care was severely impacted. 
      All elective and semi-elective procedures, as well as select urgent cases, were
      postponed in order to preserve resources and protect patients and staff from
      SARS-CoV-2 exposure. Structured decision making for breast cancer treatment
      resulted in deferment of surgery with initiation of endocrine therapy. Moreover, 
      the waitlist for elective breast cancer procedures after mitigation is a
      challenge for prioritization. OBJECTIVE AND SIGNIFICANCE: We aim to summarize the
      current body of evidence, comparatively evaluate oncological outcomes of surgery 
      versus primary endocrine therapy (PET), and determine whether PET is a viable
      long-term alternative to surgery in the context of crisis management strategy for
      early, operable hormone receptor positive (HRP) breast cancer. PET could
      potentially be an acceptable bridging or maintenance therapy in select patients
      during pandemic crisis or for those choosing to forgo surgery in the treatment of
      breast cancer. METHODS AND ANALYSIS: The database search includes PubMed, EMBASE,
      and MEDLINE (via Ovid). This systematic review includes women 18 years or older
      undergoing one of two interventions for HRP breast cancer: surgery (with or
      without endocrine therapy post-surgery) or solely PET. Studies comparing one of
      the two interventions of interest to a non-relevant intervention and studies
      reporting only descriptive data will not be included in the quantitative
      synthesis of data. After selection of eligible studies based on title and
      abstract, these studies will be further screened through full text articles by
      two independent reviewers, with a third as an arbitrator. Eligible studies will
      be critically appraised at the study level for methodological quality. Cochrane
      methodology will be utilized for meta-analysis. ETHICS AND DISSEMINATION: This
      study does not require an institutional review board approval given its summary
      design nature. Findings of this systematic review will be published in a
      peer-reviewed journal.
CI  - (c) 2020 The Authors.
FAU - Roberts, Sacha
AU  - Roberts S
AD  - Department of Surgery, Westchester Medical Center, New York Medical College
      School of Medicine, Valhalla, NY, United States.
FAU - Rojas, Aram
AU  - Rojas A
AD  - Department of Surgery, Westchester Medical Center, New York Medical College
      School of Medicine, Valhalla, NY, United States.
FAU - Gachabayov, Mahir
AU  - Gachabayov M
AD  - Department of Surgery, Westchester Medical Center, New York Medical College
      School of Medicine, Valhalla, NY, United States.
FAU - Castaldi, Maria
AU  - Castaldi M
AD  - Department of Surgery, Westchester Medical Center, New York Medical College
      School of Medicine, Valhalla, NY, United States.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7689176
OTO - NOTNLM
OT  - Breast cancer
OT  - COVID-19
OT  - Endocrine therapy
OT  - SARS-Co-V-2
OT  - Surgery
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 06:16
PHST- 2020/09/16 00:00 [received]
PHST- 2020/10/29 00:00 [revised]
PHST- 2020/10/31 00:00 [accepted]
PHST- 2020/12/09 06:16 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1016/j.isjp.2020.10.003 [doi]
AID - S2468-3574(20)30033-4 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Nov 5;24:36-38. doi: 10.1016/j.isjp.2020.10.003.
      eCollection 2020.


PMID- 33294621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2382-1205 (Print)
IS  - 2382-1205 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Pandemics Past and Present: A Guided Inquiry Approach.
PG  - 2382120520976957
LID - 10.1177/2382120520976957 [doi]
AB  - BACKGROUND: COVID-19 exposed undergraduate medical education curricular gaps in
      exploring historical pandemics, how to critically consume scientific literature
      and square it with the lay press, and how to grapple with emerging ethical
      issues. In addition, as medical students were dismissed from clinical
      environments, their capacity to build community and promote professional identity
      formation was compromised. METHODS: A synchronous, online course entitled Life
      Cycle of a Pandemic was developed using a modified guided inquiry approach.
      Students met daily for 2 weeks in groups of 15 to 18 with a process facilitator. 
      During the first week, students reported on lessons learned from past pandemics; 
      in the second week, students discussed ethical concerns surrounding COVID-19
      clinical trials, heard from physicians who provided patient care in the HIV and
      COVID-19 pandemics, and concluded with an opportunity for reflection. Following
      the course, students were asked to complete an anonymous, voluntary survey to
      assess their perceptions of the course. RESULTS: With a response rate of 69%, an 
      overwhelming majority of students agreed or strongly agreed that learning about
      historical pandemics helped them understand COVID-19 (72, 99%). The course
      successfully helped students understand current and potential COVID-19 management
      strategies as 66 (90%) agreed or strongly agreed they developed a better
      understanding of nonpharmacological interventions and new pharmacological
      treatments. Students also gained insight into the experiences of healthcare
      providers who cared for patients with HIV and COVID-19. Qualitative analysis of
      the open-ended comments yielded 5 main themes: critical appraisal of resources,
      responsibility of the physician, humanism, knowledge related to pandemics, and
      learning from history. CONCLUSIONS: The onset of the COVID-19 crisis illustrated 
      curricular gaps that could be remedied by introducing the history and biology of 
      pandemics earlier in the curriculum. It was also apparent that learners need more
      practice in critically reviewing literature and comparing scientific literature
      with lay press. The flexible format of the course promotes the development of
      future iterations that could cover evolving topics related to COVID-19. The
      course could also be repurposed for a graduate or continuing medical education
      audience.
CI  - (c) The Author(s) 2020.
FAU - Willey, Joanne M
AU  - Willey JM
AD  - Department of Science Education, Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Olvet, Doreen M
AU  - Olvet DM
AD  - Department of Science Education, Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Bird, Jeffrey B
AU  - Bird JB
AD  - Department of Science Education, Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Brenner, Judith M
AU  - Brenner JM
AUID- ORCID: https://orcid.org/0000-0002-8697-5401
AD  - Department of Science Education, Donald and Barbara Zucker School of Medicine at 
      Hofstra/Northwell, Hempstead, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - United States
TA  - J Med Educ Curric Dev
JT  - Journal of medical education and curricular development
JID - 101690298
PMC - PMC7705775
OTO - NOTNLM
OT  - COVID-19 curriculum
OT  - Pandemic
OT  - guided inquiry
COIS- Declaration of conflicting interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 06:16
PHST- 2020/08/25 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/12/09 06:16 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1177/2382120520976957 [doi]
AID - 10.1177_2382120520976957 [pii]
PST - epublish
SO  - J Med Educ Curric Dev. 2020 Nov 27;7:2382120520976957. doi:
      10.1177/2382120520976957. eCollection 2020 Jan-Dec.


PMID- 33294030
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201210
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jul
TI  - Vaccinating for Whom? Distinguishing between Self-Protective, Paternalistic,
      Altruistic and Indirect Vaccination.
PG  - 190-200
LID - 10.1093/phe/phaa005 [doi]
AB  - Preventive vaccination can protect not just vaccinated individuals, but also
      others, which is often a central point in discussions about vaccination. To date,
      there has been no systematic study of self- and other-directed motives behind
      vaccination. This article has two major goals: first, to examine and distinguish 
      between self- and other-directed motives behind vaccination, especially with
      regard to vaccinating for the sake of third parties, and second, to explore some 
      ways in which this approach can help to clarify and guide vaccination debates and
      policy. I propose conceiving of vaccination in terms of three basic elements: the
      vaccination decision-maker, the vaccine recipient and the primary beneficiary. I 
      develop a taxonomy based on the relations between these elements to distinguish
      four kinds of vaccination: self-protective, paternalistic, altruistic and
      indirect. I finally discuss the case of human papillomavirus vaccine regulation
      for men and women to show how each kind of vaccination is associated with and
      raises specific ethical questions.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Kraaijeveld, Steven R
AU  - Kraaijeveld SR
AUID- ORCID: 0000-0002-6338-6305
AD  - Wageningen University & Research.
LA  - eng
PT  - Journal Article
DEP - 20200311
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7700798
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 06:13
PHST- 2020/12/09 06:13 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1093/phe/phaa005 [doi]
AID - phaa005 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Mar 11;13(2):190-200. doi: 10.1093/phe/phaa005.
      eCollection 2020 Jul.


PMID- 33294029
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201210
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jul
TI  - Patient Isolation during Infectious Disease Outbreaks: Arguments for Physical
      Family Presence.
PG  - 133-142
LID - 10.1093/phe/phaa024 [doi]
AB  - This article argues that outbreak preparedness and response should implement a
      'family presence' policy for infected patients in isolation that includes the
      option of physical visits and care within the isolation facility under some
      conditions. While such a 'physical family presence' (PFP) policy could increase
      infections during an outbreak and may raise moral dilemmas, we argue that it is
      ethically justified based on the least infringement principle and the need to
      minimize the harms and burdens of isolation as a restrictive measure. Categorical
      prohibition of PFP during the course of an outbreak or epidemic is likely to
      result in unnecessary harms to patients and families, and violate values such as 
      the moral commitments of families to care for each other. Supporting the option
      of PFP under particular circumstances, on the other hand, will least infringe
      these moral considerations. An additional reason for a family presence policy is 
      that it may facilitate voluntary cooperation with isolation and other restrictive
      measures. We provide an analysis of these considerations for supporting modes of 
      family presence during an outbreak emergency, before defending the riskier option
      of PFP in the isolation facility from plausible objections and concerns.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Voo, Teck Chuan
AU  - Voo TC
AD  - Centre for Biomedical Ethics, National University of Singapore, Yong Loo Lin
      School of Medicine.
FAU - Lederman, Zohar
AU  - Lederman Z
AD  - Emergency Department, Assuta Samson Hospital.
FAU - Kaur, Sharon
AU  - Kaur S
AD  - Faculty of Law, University of Malaya.
LA  - eng
PT  - Journal Article
DEP - 20201009
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7700794
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 06:13
PHST- 2020/12/09 06:13 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1093/phe/phaa024 [doi]
AID - phaa024 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Oct 9;13(2):133-142. doi: 10.1093/phe/phaa024.
      eCollection 2020 Jul.


PMID- 33294028
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201210
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jul
TI  - Public Health Ethics in a Pandemic.
PG  - 125-126
LID - 10.1093/phe/phaa032 [doi]
FAU - Verweij, Marcel
AU  - Verweij M
AUID- ORCID: 0000-0001-9169-1852
AD  - Section Communication, Philosophy and Technology, Department of Social Sciences, 
      Wageningen University.
FAU - Dawson, Angus
AU  - Dawson A
AD  - Sydney Health Ethics, School of Public Health, University of Sydney.
LA  - eng
PT  - Editorial
DEP - 20201028
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7700793
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 06:13
PHST- 2020/12/09 06:13 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1093/phe/phaa032 [doi]
AID - phaa032 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Oct 28;13(2):125-126. doi: 10.1093/phe/phaa032.
      eCollection 2020 Jul.


PMID- 33293881
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1179-1608 (Print)
IS  - 1179-1608 (Linking)
VI  - 12
DP  - 2020
TI  - Inspiratory Muscle Training in the Severity of Obstructive Sleep Apnea, Sleep
      Quality and Excessive Daytime Sleepiness: A Placebo-Controlled, Randomized Trial.
PG  - 1105-1113
LID - 10.2147/NSS.S269360 [doi]
AB  - PURPOSE: Exercise programs have been considered as an adjuvant treatment in
      obstructive sleep apnea (OSA). However, few studies have focused on the effects
      of the inspiratory muscle training (IMT) in reducing the severity and the
      symptoms of OSA. PATIENTS AND METHODS: A randomized controlled trial was
      conducted and approved by the local Ethics Committee. All subjects signed the
      informed consent form and were randomized into 2 groups: a) IMT group (n = 8), 8 
      weeks of IMT with 75% of maximal inspiratory pressure (MIP) and b) placebo group 
      (n = 8): subjects performed IMT without load. RESULTS: IMT group showed reduction
      in the apnea-hypopnea index (AHI) (p = 0.01), in the Berlin questionnaire score
      (p = 0.001) and an increase in inspiratory muscle strength (p = 0.018). IMT group
      demonstrated a reduction in the AHI (31.7 +/- 15.9 events/h vs 29.9 +/- 15.8
      events/h; p <0.001), in the Berlin questionnaire scores (2.6 +/- 0.5 vs 1.2 +/-
      0.5; p = 0.016), Pittsburgh Sleep Quality Index (PSQI) score (7.2 +/- 3.6 vs 3.7 
      +/- 1.3; p = 0.008), in the Epworth Sleepiness Scale (ESS) (12.5 +/- 4.0 vs 7.7
      +/- 3.0; p = 0.008) and increase in MIP (83.6 +/- 26.5 cmH2O and 127.9 +/- 32.5
      cmH2O; p = 0.010). CONCLUSION: The IMT promotes discrete changes in the AHI and
      improves sleep quality and excessive daytime sleepiness in OSA. Moreover, IMT is 
      a cheap, useful and simple home-based training program and can be considered as
      an adjunct therapy for OSA patients.
CI  - (c) 2020 Nobrega-Junior et al.
FAU - Nobrega-Junior, Jose Carlos Nogueira
AU  - Nobrega-Junior JCN
AUID- ORCID: 0000-0003-3908-9260
AD  - Department of Physical Therapy, Facottur Faculty, Olinda, Pernambuco, Brazil.
FAU - Dornelas de Andrade, Armele
AU  - Dornelas de Andrade A
AD  - Department of Physical Therapy Federal University of Pernambuco, Recife,
      Pernambuco, Brazil.
FAU - de Andrade, Erika Alves Marinho
AU  - de Andrade EAM
AD  - Department of Physical Therapy Federal University of Pernambuco, Recife,
      Pernambuco, Brazil.
FAU - Andrade, Maria do Amparo
AU  - Andrade MDA
AD  - Department of Physical Therapy Federal University of Pernambuco, Recife,
      Pernambuco, Brazil.
FAU - Ribeiro, Alice Santana Valadares
AU  - Ribeiro ASV
AD  - Department of Rehabilitation, Hospital Otavio de Freitas, Recife, Pernambuco,
      Brazil.
FAU - Pedrosa, Rodrigo Pinto
AU  - Pedrosa RP
AD  - Sleep and Heart Laboratory, Pronto Socorro Cardiologico de Pernambuco (PROCAPE)- 
      University of Pernambuco, Recife, Pernambuco, Brazil.
FAU - Ferreira, Ana Paula de Lima
AU  - Ferreira APL
AUID- ORCID: 0000-0002-0925-0183
AD  - Department of Physical Therapy Federal University of Pernambuco, Recife,
      Pernambuco, Brazil.
FAU - de Lima, Anna Myrna Jaguaribe
AU  - de Lima AMJ
AUID- ORCID: 0000-0002-4224-4009
AD  - Department of Physical Therapy Federal University of Pernambuco, Recife,
      Pernambuco, Brazil.
AD  - Department of Morphology and Animal Physiology, Federal Rural University of
      Pernambuco, Recife, Pernambuco, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - New Zealand
TA  - Nat Sci Sleep
JT  - Nature and science of sleep
JID - 101537767
PMC - PMC7719323
OTO - NOTNLM
OT  - adjuvant therapy
OT  - exercise training
OT  - obstructive sleep apnea symptoms
OT  - respiratory exercises
COIS- All authors certify that they have no affiliations with or involvement in any
      organization or entity with any financial interest (such as honoraria;
      educational grants; participation in speakers' bureaus; membership, employment,
      consultancies, stock ownership, or other equity interest; or expert testimony or 
      patent-licensing arrangements), or non-financial interest (such as personal or
      professional relationships, affiliations, knowledge or beliefs) in the subject
      matter or materials discussed in this manuscript.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 06:13
PHST- 2020/06/27 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/12/09 06:13 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.2147/NSS.S269360 [doi]
AID - 269360 [pii]
PST - epublish
SO  - Nat Sci Sleep. 2020 Dec 2;12:1105-1113. doi: 10.2147/NSS.S269360. eCollection
      2020.


PMID- 33293538
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec 8
TI  - Patient and public perspectives on cell and gene therapies: a systematic review.
PG  - 6265
LID - 10.1038/s41467-020-20096-1 [doi]
AB  - Cell and gene therapies offer opportunities for treating disease with potential
      to restore function, and cure disease. However, they are not without risk and
      pose complex logistical, economic, ethical and social challenges for health
      systems. Here we report our systematic review of the current evidence on patient 
      and public knowledge and perspectives of cell and gene therapies, to inform
      future research, education and awareness raising activities. We screened 10,735
      titles and abstracts, and evaluated the full texts of 151 publications. The final
      selection was 35 publications. Four themes were generated from the narrative
      synthesis of the study findings namely: (1) Knowledge and understanding of cell
      and gene therapies, (2) Acceptance of cell and gene therapies (3) Understanding
      of risk and benefits of therapy, and (4) Information needs and current sources of
      information. As potential funders or future recipients, it is important that the 
      public and patients are aware of these therapies, understand the issues involved,
      and can contribute to the debate. This review highlights the need for appropriate
      patient and public education on the various aspects of cell and gene therapies.
      High quality studies exploring patient and public opinions and experiences of
      cell and gene therapy are required. Patient and public perceptions of these
      therapies, alongside evidence of clinical and cost-effectiveness, will be central
      to their uptake and use.
FAU - Aiyegbusi, Olalekan Lee
AU  - Aiyegbusi OL
AUID- ORCID: 0000-0001-9122-8251
AD  - Centre for Patient Reported Outcomes Research, Institute of Applied Health
      Research, University of Birmingham, Birmingham, UK. O.L.Aiyegbusi@bham.ac.uk.
AD  - National Institute for Health Research Birmingham Biomedical Research Centre,
      University of Birmingham, Birmingham, UK. O.L.Aiyegbusi@bham.ac.uk.
AD  - National Institute for Health Research Applied Research Centre West Midlands, and
      National Institute for Health Research Surgical Reconstruction and Microbiology
      Research Centre, University of Birmingham, Birmingham, UK.
      O.L.Aiyegbusi@bham.ac.uk.
AD  - Birmingham Health Partners Centre for Regulatory Science and Innovation,
      Birmingham, UK. O.L.Aiyegbusi@bham.ac.uk.
FAU - Macpherson, Karen
AU  - Macpherson K
AD  - Healthcare Improvement Scotland, Glasgow, Scotland, UK.
FAU - Elston, Lauren
AU  - Elston L
AD  - Health Technology Wales, Cardiff, UK.
FAU - Myles, Susan
AU  - Myles S
AD  - Health Technology Wales, Cardiff, UK.
FAU - Washington, Jennifer
AU  - Washington J
AD  - Health Technology Wales, Cardiff, UK.
FAU - Sungum, Nisha
AU  - Sungum N
AD  - Birmingham Health Partners Centre for Regulatory Science and Innovation,
      Birmingham, UK.
AD  - Midlands-Wales Advanced Therapy Treatment Centre, University Hospitals Birmingham
      NHS Foundation Trust, Birmingham, UK.
FAU - Briggs, Mark
AU  - Briggs M
AD  - Welsh Blood Service, Velindre University NHS Trust, Cardiff, UK.
FAU - Newsome, Philip N
AU  - Newsome PN
AD  - National Institute for Health Research Birmingham Biomedical Research Centre,
      University of Birmingham, Birmingham, UK.
AD  - National Institute for Health Research Applied Research Centre West Midlands, and
      National Institute for Health Research Surgical Reconstruction and Microbiology
      Research Centre, University of Birmingham, Birmingham, UK.
AD  - Birmingham Health Partners Centre for Regulatory Science and Innovation,
      Birmingham, UK.
AD  - Centre for Liver and Gastrointestinal Research, Institute of Immunology and
      Immunotherapy, University of Birmingham, Birmingham, UK.
AD  - Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
FAU - Calvert, Melanie J
AU  - Calvert MJ
AUID- ORCID: 0000-0002-1856-837X
AD  - Centre for Patient Reported Outcomes Research, Institute of Applied Health
      Research, University of Birmingham, Birmingham, UK.
AD  - National Institute for Health Research Birmingham Biomedical Research Centre,
      University of Birmingham, Birmingham, UK.
AD  - National Institute for Health Research Applied Research Centre West Midlands, and
      National Institute for Health Research Surgical Reconstruction and Microbiology
      Research Centre, University of Birmingham, Birmingham, UK.
AD  - Birmingham Health Partners Centre for Regulatory Science and Innovation,
      Birmingham, UK.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201208
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
SB  - IM
MH  - Cell Transplantation/adverse effects/economics/ethics/*methods
MH  - Cost-Benefit Analysis
MH  - Delivery of Health Care/economics/*ethics
MH  - Genetic Therapy/adverse effects/economics/ethics/*methods
MH  - Health Education
MH  - Humans
MH  - Patient Education as Topic
MH  - *Public Opinion
MH  - Qualitative Research
PMC - PMC7722871
EDAT- 2020/12/10 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/12/09 06:07
PHST- 2020/07/01 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/12/09 06:07 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 10.1038/s41467-020-20096-1 [doi]
AID - 10.1038/s41467-020-20096-1 [pii]
PST - epublish
SO  - Nat Commun. 2020 Dec 8;11(1):6265. doi: 10.1038/s41467-020-20096-1.


PMID- 33293401
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210227
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Which factors should be included in triage? An online survey of the attitudes of 
      the UK general public to pandemic triage dilemmas.
PG  - e045593
LID - 10.1136/bmjopen-2020-045593 [doi]
AB  - OBJECTIVE: As cases of COVID-19 infections surge, concerns have renewed about
      intensive care units (ICUs) being overwhelmed and the need for specific triage
      protocols over winter. This study aimed to help inform triage guidance by
      exploring the views of lay people about factors to include in triage decisions.
      DESIGN, SETTING AND PARTICIPANTS: Online survey between 29th of May and 22nd of
      June 2020 based on hypothetical triage dilemmas. Participants recruited from
      existing market research panels, representative of the UK general population.
      Scenarios were presented in which a single ventilator is available, and two
      patients require ICU admission and ventilation. Patients differed in one of:
      chance of survival, life expectancy, age, expected length of treatment,
      disability and degree of frailty. Respondents were given the option of choosing
      one patient to treat or tossing a coin to decide. RESULTS: Seven hundred and
      sixty-three participated. A majority of respondents prioritised patients who
      would have a higher chance of survival (72%-93%), longer life expectancy
      (78%-83%), required shorter duration of treatment (88%-94%), were younger
      (71%-79%) or had a lesser degree of frailty (60%-69%, all p<0.001). Where there
      was a small difference between two patients, a larger proportion elected to toss 
      a coin to decide which patient to treat. A majority (58%-86%) were prepared to
      withdraw treatment from a patient in intensive care who had a lower chance of
      survival than another patient currently presenting with COVID-19. Respondents
      also indicated a willingness to give higher priority to healthcare workers and to
      patients with young children. CONCLUSION: Members of the UK general public
      potentially support a broadly utilitarian approach to ICU triage in the face of
      overwhelming need. Survey respondents endorsed the relevance of patient factors
      currently included in triage guidance, but also factors not currently included.
      They supported the permissibility of reallocating treatment in a pandemic.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: http://orcid.org/0000-0003-3958-8633
AD  - Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of
      Oxford, Oxford, UK dominic.wilkinson@philosophy.ox.ac.uk.
AD  - Newborn Care Unit, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK.
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
FAU - Zohny, Hazem
AU  - Zohny H
AD  - Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of
      Oxford, Oxford, UK.
FAU - Kappes, Andreas
AU  - Kappes A
AD  - Department of Psychology, School of Arts and Social Sciences, City University of 
      London, London, UK.
FAU - Sinnott-Armstrong, Walter
AU  - Sinnott-Armstrong W
AD  - Kenan Institute for Ethics, Department of Philosophy, Duke University, Durham,
      North Carolina, USA.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of
      Oxford, Oxford, UK.
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK.
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
AD  - Faculty of Law, University of Melbourne, Melbourne, Victoria, Australia.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Attitude to Health
MH  - COVID-19/*psychology/therapy
MH  - Female
MH  - Health Care Rationing/ethics/*organization & administration
MH  - Humans
MH  - Intensive Care Units/organization & administration
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - Triage/ethics/*organization & administration
MH  - United Kingdom
PMC - PMC7725087
OTO - NOTNLM
OT  - *covid-19
OT  - *intensive & critical care
OT  - *medical ethics
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-045593 [pii]
AID - 10.1136/bmjopen-2020-045593 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e045593. doi: 10.1136/bmjopen-2020-045593.


PMID- 33293396
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Vitamin D supplementation prior to in vitro fertilisation in women with
      polycystic ovary syndrome: a protocol of a multicentre randomised, double-blind, 
      placebo-controlled clinical trial.
PG  - e041409
LID - 10.1136/bmjopen-2020-041409 [doi]
AB  - INTRODUCTION: Polycystic ovary syndrome (PCOS) is one of the leading causes of
      female infertility, affecting around 5% of women of childbearing age in China.
      Vitamin D insufficiency is common in women with PCOS and is associated with lower
      live birth rates. However, evidence regarding the effectiveness of vitamin D
      supplementation in women with PCOS is inconclusive. This multicentre randomised, 
      double-blinded, placebo-controlled trial aims to evaluate the effectiveness of
      vitamin D supplementation prior to in vitro fertilisation (IVF) on the live birth
      rate in women with PCOS. METHODS AND ANALYSIS: We plan to enrol women with PCOS
      scheduled for IVF. After informed consent, eligible participants will be
      randomised in a 1:1 ratio to receive oral capsules of 4000 IU vitamin D per day
      or placebo for around 12 weeks until the day of triggering. All IVF procedures
      will be carried out routinely in each centre. The primary outcome is live birth
      after the first embryo transfer. The primary analysis will be by
      intention-to-treat analysis. To demonstrate or refute that treatment with vitamin
      D results in a 10% higher live birth rate than treatment with placebo, we need to
      recruit 860 women (48% vs 38% difference, anticipating 10% loss to follow-up and 
      non-compliance, significance level 0.05 and power 80%). ETHICS AND DISSEMINATION:
      This study has been approved by the Ethics Committee in Women's Hospital of
      Zhejiang University on 2 March 2020 (reference number: IRB-20200035-R). All
      participants will provide written informed consent before randomisation. The
      results of the study will be submitted to scientific conferences and a
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT04082650.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hu, Kai-Lun
AU  - Hu KL
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
FAU - Gan, Kwanghann
AU  - Gan K
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
FAU - Wang, Rui
AU  - Wang R
AUID- ORCID: 0000-0002-6622-8134
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria,
      Australia.
FAU - Li, Wentao
AU  - Li W
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria,
      Australia.
FAU - Wu, Qiongfang
AU  - Wu Q
AD  - Reproductive Medicine Center, Jiangxi Maternal and Child Health Hospital,
      Nanchang, China.
FAU - Zheng, Beihong
AU  - Zheng B
AD  - Reproductive Medicine Center, Fujian Maternity and Child Health Hospital,
      Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Zou, Libo
AU  - Zou L
AD  - Department of Reproductive Medicine, Jinhua People's Hospital, Jinhua, China.
FAU - Zhang, Su
AU  - Zhang S
AD  - Department of Obstetrics and Gynaecology, Huzhou Maternity and Child Health Care 
      Hospital, Huzhou, China.
FAU - Liu, Yifeng
AU  - Liu Y
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
FAU - Wu, Yiqing
AU  - Wu Y
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
FAU - Chen, Ruixue
AU  - Chen R
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
FAU - Cao, Wushuang
AU  - Cao W
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
FAU - Yang, Shuo
AU  - Yang S
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynaecology,
      Peking University Third Hospital, Beijing, China.
FAU - Liu, Fen-Ting
AU  - Liu FT
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynaecology,
      Peking University Third Hospital, Beijing, China.
FAU - Tian, Lifeng
AU  - Tian L
AD  - Reproductive Medicine Center, Jiangxi Maternal and Child Health Hospital,
      Nanchang, China.
FAU - Zeng, Han
AU  - Zeng H
AD  - Reproductive Medicine Center, Jiangxi Maternal and Child Health Hospital,
      Nanchang, China.
FAU - Xu, Huiling
AU  - Xu H
AD  - Reproductive Medicine Center, Fujian Maternity and Child Health Hospital,
      Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Qiu, Shumin
AU  - Qiu S
AD  - Reproductive Medicine Center, Fujian Maternity and Child Health Hospital,
      Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Yang, Lihua
AU  - Yang L
AD  - Department of Reproductive Medicine, Jinhua People's Hospital, Jinhua, China.
FAU - Chen, Xiao
AU  - Chen X
AD  - Department of Reproductive Medicine, Jinhua People's Hospital, Jinhua, China.
FAU - Pan, Xiaoqin
AU  - Pan X
AD  - Department of Obstetrics and Gynaecology, Huzhou Maternity and Child Health Care 
      Hospital, Huzhou, China.
FAU - Wu, Xiaoyun
AU  - Wu X
AD  - Department of Obstetrics and Gynaecology, Huzhou Maternity and Child Health Care 
      Hospital, Huzhou, China.
FAU - Mol, Ben W
AU  - Mol BW
AUID- ORCID: 0000-0001-8337-550X
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria,
      Australia.
FAU - Li, Rong
AU  - Li R
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynaecology,
      Peking University Third Hospital, Beijing, China zhangdan@zju.edu.cn
      roseli001@sina.com.
FAU - Zhang, Dan
AU  - Zhang D
AUID- ORCID: 0000-0003-1295-4795
AD  - Department of Reproductive Endocrinology, Key Laboratory of Reproductive
      Genetics, Ministry of Education, Women's Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China zhangdan@zju.edu.cn roseli001@sina.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04082650
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Adult
MH  - China
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - Pharmaceutical Preparations
MH  - *Polycystic Ovary Syndrome/complications/drug therapy
MH  - Pregnancy
MH  - Vitamin D
MH  - Young Adult
PMC - PMC7725097
OTO - NOTNLM
OT  - *maternal medicine
OT  - *nutritional support
OT  - *reproductive medicine
OT  - *subfertility
COIS- Competing interests: This trial is partly funded by Sinopharm Xingsha
      Pharmaceuticals (Xiamen) Co Ltd, which is the manufacturer of vitamin D. The
      funder has no role in the trial design, trial conduct, data collection, data
      analysis or manuscript preparation. All authors report no conflict of interest.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-041409 [pii]
AID - 10.1136/bmjopen-2020-041409 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e041409. doi: 10.1136/bmjopen-2020-041409.


PMID- 33293395
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Protocol for a systematic review and meta-analysis of respiratory rehabilitation 
      following intensive care unit discharge for COVID-19 survivors.
PG  - e041184
LID - 10.1136/bmjopen-2020-041184 [doi]
AB  - INTRODUCTION: Both physical and mental disorders may be exacerbated in patients
      with COVID-19 due to the experience of receiving intensive care; undergoing
      prolonged mechanical ventilation, sedation, proning and paralysis. Pulmonary
      rehabilitation is aimed to improve dyspnoea, relieve anxiety and depression,
      reduce the incidence of related complications, as well as prevent and improve
      dysfunction. However, the impact of respiratory rehabilitation on discharged
      patients with COVID-19 is currently unclear, especially on patients who have been
      mechanically ventilated over 24 hours. Therefore, we aim to investigate the
      efficacy of respiratory rehabilitation programmes, initiated after discharge from
      the intensive care unit, on the physical and mental health and health-related
      quality of life in critical patients with COVID-19. METHODS AND ANALYSIS: We have
      registered the protocol on PROSPERO and in the process of drafting it, we
      strictly followed the checklist of Preferred Reporting Items for Systematic
      Review and Meta-Analysis Potocols. We will search the PubMed, EMBASE, Web of
      Science, the Cochrane Central Register of Controlled Trials, China National
      Knowledge Infrastructure, WanFang, VIP information databases and Chinese
      Biomedical Literature Database. Additionally, ongoing trials in the WHO
      International Clinical Trials Registry Platform, ClinicalTrials.gov and ISRCTN
      registry will be searched as well. Studies in English or Chinese and from any
      country will be accepted regardless of study design. Two review authors will
      independently extract data and assess the quality of included studies. Continuous
      data are described as standard mean differences (SMDs) with 95% CIs. Dichotomous 
      data from randomised controlled trials are described as risk ratio(RR) with 95%
      CIs; otherwise, it is described as odds ratio(OR) with 95% CIs. I(2) and the
      Cochrane's Q statistic will be used to conduct heterogeneity assessment. The
      quality of evidence of main outcomes will be evaluated according to the Grading
      of Recommendations, Assessment, Development and Evaluation(GRADE) criteria. When 
      included studies are sufficient, we will conduct subgroup analysis and
      sensitivity analysis; the publication bias will be statistically analysed using a
      funnel plot analysis and Egger's test. ETHICS AND DISSEMINATION: Our review,
      planning to include published studies, does not need the request to the ethical
      committee. The final results of this review will be published in a peer-reviewed 
      journal after completion. PATIENT AND PUBLIC INVOLVEMENT: No patient involved.
      PROSPERO REGISTRATION NUMBER: CRD42020186791.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Dan
AU  - Wang D
AUID- ORCID: http://orcid.org/0000-0002-4688-8215
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Li, Jin
AU  - Li J
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, Jiangsu, 
      China.
FAU - Zhu, Feilong
AU  - Zhu F
AUID- ORCID: http://orcid.org/0000-0001-5404-8745
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Hong, Qianqin
AU  - Hong Q
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Zhang, Ming
AU  - Zhang M
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, Jiangsu, 
      China.
FAU - Gao, Min
AU  - Gao M
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, Jiangsu, 
      China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, Jiangsu, 
      China chenwei2339@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/complications/*rehabilitation
MH  - Exercise Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Physical Functional Performance
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Insufficiency/etiology/*rehabilitation
MH  - Respiratory Therapy/*methods
MH  - Systematic Reviews as Topic
PMC - PMC7725092
OTO - NOTNLM
OT  - *COVID-19
OT  - *anxiety disorders
OT  - *protocols & guidelines
OT  - *rehabilitation medicine
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-041184 [pii]
AID - 10.1136/bmjopen-2020-041184 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e041184. doi: 10.1136/bmjopen-2020-041184.


PMID- 33293393
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Informant-based assessment instruments for dementia and their measurement
      properties in persons with intellectual disability: systematic review protocol.
PG  - e040920
LID - 10.1136/bmjopen-2020-040920 [doi]
AB  - INTRODUCTION: Persons with intellectual disability (ID) are at a higher risk of
      developing dementia than persons without ID, with an expected earlier onset.
      Assessment methods for the general population cannot be applied for persons with 
      ID due to their pre-existing intellectual and functional impairments. As there is
      no agreed-upon measure to assess dementia in persons with ID, multiple
      instruments for this purpose have been developed and adapted in the past decades.
      This review aimed to identify all available informant-based instruments for the
      assessment of dementia in persons with ID, to evaluate and compare them according
      to their measurement properties, and to provide a recommendation for the most
      suitable instruments. Additionally, an overview of the amount and quality of
      research on these instruments will be provided. METHODS AND ANALYSIS: This review
      will be conducted and reported according to the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses statement. We will adhere to the
      Consensus-based Standards for the Selection of Health Measurement Instruments
      (COSMIN) guidelines and use a set of characteristics developed for assessment
      instruments for persons with ID, the Characteristics of Assessment Instruments
      for Psychiatric Disorders in Persons with Intellectual Developmental Disorders.
      Two comprehensive, systematic literature searches will be applied in 10
      international databases, including ASSIA, CINAHL, Cochrane Library, ERIC,
      MEDLINE, PsycINFO, Scopus, Web of Science, OpenGrey and ProQuest Dissertations
      and Theses Global. Risk of bias and quality assessment will be done according to 
      COSMIN guidelines. We will apply the modified Grading of Recommendations,
      Assessment, Development and Evaluation approach to rate the overall quality of
      the available evidence. ETHICS AND DISSEMINATION: No ethics statement is needed
      for this study. The results will be submitted to a peer-reviewed journal and will
      be presented at international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zeilinger, Elisabeth L
AU  - Zeilinger EL
AUID- ORCID: 0000-0002-0625-500X
AD  - Faculty of Psychology, University of Vienna, Vienna, Austria
      elisabeth.zeilinger@univie.ac.at.
FAU - Komenda, Sophie
AU  - Komenda S
AD  - Faculty of Psychology, University of Vienna, Vienna, Austria.
FAU - Zrnic, Irina
AU  - Zrnic I
AD  - Faculty of Psychology, University of Vienna, Vienna, Austria.
FAU - Franken, Fabian
AU  - Franken F
AD  - Clinical Psychology and Psychotherapy, Psychologische Hochschule Berlin, Cologne,
      Germany.
FAU - Woditschka, Katharina
AU  - Woditschka K
AD  - Faculty of Psychology, University of Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bias
MH  - *Dementia/diagnosis
MH  - Humans
MH  - *Persons with Mental Disabilities
MH  - Psychometrics
PMC - PMC7725090
OTO - NOTNLM
OT  - *dementia
OT  - *mental health
OT  - *old age psychiatry
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040920 [pii]
AID - 10.1136/bmjopen-2020-040920 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e040920. doi: 10.1136/bmjopen-2020-040920.


PMID- 33293391
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Baccalaureate nursing students' experiences with high-fidelity simulation:
      protocol for a qualitative systematic review.
PG  - e040171
LID - 10.1136/bmjopen-2020-040171 [doi]
AB  - INTRODUCTION: High-fidelity simulation (HFS) can bridge the gap between
      theoretical knowledge and nursing practice and improve safety and quality of
      patient care in baccalaureate nursing education. Although inconsistent assessment
      instruments or lack of high-quality research designs affect the strength of the
      evidence and limit the generalisability of the results, quantitative studies
      generally demonstrate the effectiveness of HFS in baccalaureate nursing
      education. Synthesis of the existing evidence of baccalaureate nursing students' 
      experiences with HFS is crucial for the improvement and revision of simulation
      design and teaching. METHODS AND ANALYSIS: A comprehensive search for qualitative
      studies on baccalaureate nursing students' experiences with HFS will be conducted
      in the following databases: PubMed, Embase, CINAHL, ProQuest, Web of Science,
      PsycINFO, the Cochrane library, China Biology Medicine disc, China National
      Knowledge Infrastructure and VIP Database for Chinese Technical Periodicals. This
      review considered studies reported in English or Chinese, and studies that were
      conducted between January 2000 and December 2019 in view of the launch of
      International Nursing Association for Clinical Simulation and Learning. The
      literature search will be conducted by two independent reviewers, and any
      disagreement will be adjudicated by discussion or with a third reviewer. The two 
      independent reviewers will use the Joanna Briggs Institute (JBI) Critical
      Appraisal Checklist for Qualitative Research to assess the methodological
      validity, following which the JBI standardised data extraction tools will be used
      to extract relevant data. The JBI meta-aggregation method will be subsequently
      used to synthesise the data, eventually forming themes, categories and
      synthesised findings. The final synthesised findings will establish confidence
      levels based on the JBI ConQual approach. ETHICS AND DISSEMINATION: This review
      does not require formal ethical review since it is based on available published
      literature. Findings will be disseminated through publication in a peer-reviewed 
      journal, and, if possible, presented in scientific conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhu, Yuxuan
AU  - Zhu Y
AD  - School of Health Sciences, Wuhan University, Wuhan, Hubei, China.
FAU - Geng, Cong
AU  - Geng C
AUID- ORCID: 0000-0002-9122-248X
AD  - School of Health Sciences, Wuhan University, Wuhan, Hubei, China.
FAU - Pei, Xianbo
AU  - Pei X
AD  - School of Health Sciences, Wuhan University, Wuhan, Hubei, China
      chenxl72@whu.edu.cn peixb@whu.edu.cn.
FAU - Chen, Xiaoli
AU  - Chen X
AD  - School of Health Sciences, Wuhan University, Wuhan, Hubei, China
      chenxl72@whu.edu.cn peixb@whu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - *Education, Nursing, Baccalaureate
MH  - *High Fidelity Simulation Training
MH  - Humans
MH  - Patient Simulation
MH  - *Students, Nursing
PMC - PMC7725085
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *protocols & guidelines
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040171 [pii]
AID - 10.1136/bmjopen-2020-040171 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e040171. doi: 10.1136/bmjopen-2020-040171.


PMID- 33293389
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Effectiveness-implementation hybrid type 2 study evaluating an intervention to
      support 'information work' in dementia care: an implementation study protocol.
PG  - e038397
LID - 10.1136/bmjopen-2020-038397 [doi]
AB  - INTRODUCTION: Patients with long-term conditions consistently report a lack of
      information around services and support available to them. This unmet need for
      information is significant among people with dementia and family carers. A
      quality improvement intervention is being carried out to tackle this issue as
      part of a co-creation initiative in the North East of England (UK). The
      intervention consists of the dissemination (via the local Community Mental Health
      Services for Older People) of a leaflet about services available to people with
      dementia and their family carers in the study site. This protocol is reported in 
      accordance with the Standards for Reporting Implementation Studies. METHODS AND
      ANALYSIS: This effectiveness-implementation hybrid type 2 study aims at
      understanding (1) the unfolding and outcomes of the implementation strategy, (2) 
      the outcomes of the intervention (for people with dementia and family carers,
      staff implementing the intervention and local service providers) and (3) the
      contribution of co-creation to the design and implementation of the intervention 
      and its outcomes. The prospective theory of change of the intervention
      articulated by local stakeholders is used as a reference framework against which 
      to assess the implementation and outcomes of the intervention. Evaluation data
      will be collected through in-depth interviews with people with dementia and
      family carers receiving the intervention, staff implementing the intervention and
      managers from local service providers. Referral data from local service providers
      will be collected to triangulate the interview data. A focus group with key
      stakeholders will support the sense-making of findings. The realist configuration
      of mechanism-context-outcome, operationalised using an information behaviour
      model, will inform data analysis and interpretation. ETHICS AND DISSEMINATION:
      Ethical and research governance approvals have been obtained from the West
      Midlands-South Birmingham Research Ethics Committee. The results of the study
      will be submitted for publication in peer-reviewed journals and disseminated
      through conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - De Poli, Chiara
AU  - De Poli C
AUID- ORCID: 0000-0002-1879-553X
AD  - Department of Social Policy and Department of Management, London School of
      Economics and Political Science, London, UK c.de-poli@lse.ac.uk.
FAU - Oyebode, Jan R
AU  - Oyebode JR
AD  - School of Dementia Studies, University of Bradford, Bradford, West Yorkshire, UK.
FAU - Binns, Christopher
AU  - Binns C
AD  - Tees, Esk and Wear Valleys NHS Foundation Trust, Durham, UK.
FAU - Glover, Richard
AU  - Glover R
AD  - NHS North of England Commissioning Support Unit, Durham, UK.
FAU - Airoldi, Mara
AU  - Airoldi M
AD  - Blavatnik School of Government, University of Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Caregivers
MH  - *Dementia/therapy
MH  - England
MH  - Focus Groups
MH  - Humans
MH  - Prospective Studies
PMC - PMC7725094
OTO - NOTNLM
OT  - *dementia
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038397 [pii]
AID - 10.1136/bmjopen-2020-038397 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e038397. doi: 10.1136/bmjopen-2020-038397.


PMID- 33293388
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 8
TI  - Assessing mental stress on myocardial perfusion and myocardial blood flow in
      women without obstructive coronary disease: protocol for a mechanistic clinical
      trial.
PG  - e038362
LID - 10.1136/bmjopen-2020-038362 [doi]
AB  - INTRODUCTION: Two-thirds of women with symptoms of angina have 'angina with no
      obstructive coronary artery disease' (ANOCA). Growing evidence supports the use
      of coronary artery function testing for the diagnosis of ANOCA. Research into the
      prevalence of mental stress-induced myocardial ischaemia (MSIMI) among women with
      ANOCA is lacking. MSIMI is common in clinically stable patients with coronary
      artery disease. It is not associated coronary stenosis but is a prognostic risk
      factor. Here, we describe the rationale and protocol for a mechanistic clinical
      trial to test the following hypotheses: (1) that MSIMI is more common in women
      with ANOCA women than in age-matched and sex-matched controls, and (2) MSIMI is
      associated with mental stress-induced myocardial blood flow (MBF) change but not 
      with adenosine vasodilator stress-induced MBF change. METHODS AND ANALYSIS: This 
      is a mechanistic clinical trial. 84 women with confirmed ANOCA and 42
      aged-matched healthy women (neither angina symptoms nor coronary stenosis) are to
      be recruited for mental and adenosine vasodilator stress tests. Positron emission
      tomography CT with ammonia N-13 will be used to evaluate the myocardial perfusion
      and MBF changes between stress and rest. MSIMI is defined as a summed difference 
      score (SDS) of >/=3 and adenosine stress-induced myocardial ischaemia is defined 
      as an SDS of >/=4. Other assessments include Reactive Hyperemia Index for
      microvascular endothelial function, peripheral arterial tonometry or digital
      vasomotor response, and a series of blood and psychometric tests. ETHICS AND
      DISSEMINATION: This mechanistic clinical trial was approved by the Ethics
      Committee of Guangdong Provincial People's Hospital. Findings will be
      disseminated through peer-reviewed publications and conference presentations.
      TRIAL REGISTRATION NUMBER: NCT03982901; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ma, Huan
AU  - Ma H
AUID- ORCID: 0000-0003-4150-9201
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Guo, Lan
AU  - Guo L
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Fei, Hongwen
AU  - Fei H
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Yin, Han
AU  - Yin H
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Wang, Haochen
AU  - Wang H
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Bai, Bingqing
AU  - Bai B
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Liu, Yuting
AU  - Liu Y
AD  - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention,
      Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
FAU - Wang, Shuxia
AU  - Wang S
AD  - Department of Nuclear Medicine, Guangdong Provincial People's Hospital, Guangdong
      Academy of Medical Sciences, Guanghzou, Guangdong, China
      wang_shuxia2002@aliyun.com gengqsh@163.net.
FAU - Geng, Qingshan
AU  - Geng Q
AD  - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences,
      Guangzhou, Guangdong, China wang_shuxia2002@aliyun.com gengqsh@163.net.
FAU - Jiang, Wei
AU  - Jiang W
AD  - Department of Psychiatry and Behavioral Sciences, Duke University Medical Center,
      Durham, North Carolina, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03982901
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201208
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Coronary Artery Disease/diagnostic imaging
MH  - Coronary Circulation
MH  - *Coronary Stenosis/diagnostic imaging
MH  - Female
MH  - Humans
MH  - *Myocardial Ischemia
MH  - *Myocardial Perfusion Imaging
MH  - Perfusion
PMC - PMC7725072
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *ischaemic heart disease
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038362 [pii]
AID - 10.1136/bmjopen-2020-038362 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 8;10(12):e038362. doi: 10.1136/bmjopen-2020-038362.


PMID- 33293353
OWN - NLM
STAT- Publisher
LR  - 20201209
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
DP  - 2020 Dec 8
TI  - Ethics in clinical autopsy.
LID - jclinpath-2020-206793 [pii]
LID - 10.1136/jclinpath-2020-206793 [doi]
AB  - This manuscript concerns the ethical aspects of the clinical autopsy procedure.
      Much of the literature on this topic addresses some of the multifaceted issues
      potentially involved: religious beliefs and/or cultural traditions coming to bear
      on the management of autopsies, relations between families and healthcare
      personnel (physicians and technicians) involved in conducting an autopsy, ethical
      implications of regulations to follow and procedures for obtaining biological
      samples for further diagnostics or research. All these issues have ethical
      implications, particularly in today's globalised cultural domain. To preserve for
      future generations the teaching and scientific value of the clinical autopsy,
      scientific societies and academic institutions should endorse educational efforts
      to promote the ethical management of autopsy procedures.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Rugge, Massimo
AU  - Rugge M
AUID- ORCID: http://orcid.org/0000-0002-0679-0563
AD  - Department of Medicine, Pathology and Cytopathology Unit, Universita degli Studi 
      di Padova, Padova, Veneto, Italy massimo.rugge@unipd.it.
AD  - Department of Medicine DIMED, Universita degli Studi di Padova, Padova, Veneto,
      Italy.
FAU - Sacchi, Diana
AU  - Sacchi D
AUID- ORCID: http://orcid.org/0000-0002-2744-4010
AD  - Department of Medicine DIMED, Universita degli Studi di Padova, Padova, Veneto,
      Italy.
FAU - Cesaro, Sonia
AU  - Cesaro S
AD  - Department of Medicine DIMED, Universita degli Studi di Padova, Padova, Veneto,
      Italy.
FAU - Sbaraglia, Marta
AU  - Sbaraglia M
AD  - Department of Medicine DIMED, Universita degli Studi di Padova, Padova, Veneto,
      Italy.
FAU - Locatelli, Franco
AU  - Locatelli F
AD  - Hemato-oncology, Sapienza University of Rome, Roma, Lazio, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201208
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
SB  - IM
OTO - NOTNLM
OT  - autopsy
OT  - ethics
OT  - hospital
OT  - pathology department
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/05/23 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:00 [medline]
AID - jclinpath-2020-206793 [pii]
AID - 10.1136/jclinpath-2020-206793 [doi]
PST - aheadofprint
SO  - J Clin Pathol. 2020 Dec 8. pii: jclinpath-2020-206793. doi:
      10.1136/jclinpath-2020-206793.


PMID- 33293328
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Effectiveness of interventions for improving timely diagnosis of breast and
      cervical cancers in low and middle-income countries: a systematic review
      protocol.
PG  - e042788
LID - 10.1136/bmjopen-2020-042788 [doi]
AB  - INTRODUCTION: Breast and cervical cancers pose a major public health burden
      globally, with disproportionately high incidence, morbidity and mortality in low-
      and middle-income countries (LMICs). The majority of women diagnosed with cancer 
      in LMICs present with late-stage disease, the treatment of which is often
      costlier and less effective. While interventions to improve the timely diagnosis 
      of these cancers are increasingly being implemented in LMICs, there is
      uncertainty about their role and effectiveness. The aim of this review is to
      systematically synthesise available evidence on the nature and effectiveness of
      interventions for improving timely diagnosis of breast and cervical cancers in
      LMICs. METHODS AND ANALYSIS: A comprehensive search of published and relevant
      grey literature will be conducted. The following electronic databases will be
      searched: MEDLINE (via PubMed), Cochrane Library, Scopus, CINAHL, Web of Science 
      and the International Clinical Trials Registry Platform (ICTRP). Evidence will be
      synthesised in accordance with the Preferred Reporting Items for Systematic
      Review and Meta-Analyses (PRISMA). Two reviewers will independently screen the
      search outputs, select studies using predefined inclusion criteria and assess
      each included study for risk of bias. If sufficient data are available and
      studies are comparable in terms of interventions and outcomes, a meta-analysis
      will be conducted. Where studies are not comparable and a meta-analysis is not
      appropriate, a narrative synthesis of findings will be reported. ETHICS AND
      DISSEMINATION: As this will be a systematic review of publicly available data,
      with no primary data collection, it will not require ethical approval. Findings
      will be disseminated widely through a peer-reviewed publication and forums such
      as conferences, workshops and community engagement sessions. This review will
      provide a user-friendly evidence summary for informing further efforts at
      developing and implementing interventions for addressing delays in breast and
      cervical cancer diagnosis in LMICs. PROSPERO REGISTRATION NUMBER: CRD42020177232.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nnaji, Chukwudi Arnest
AU  - Nnaji CA
AUID- ORCID: 0000-0002-4132-1922
AD  - Cancer Research Initiative, Faculty of Health Sciences, University of Cape Town, 
      Cape Town, Western Cape, South Africa nnjchu001@myuct.ac.za.
AD  - School of Public Health and Family Medicine, Faculty of Health Sciences,
      University of Cape Town, Cape Town, Western Cape, South Africa.
FAU - Kuodi, Paul
AU  - Kuodi P
AUID- ORCID: 0000-0003-2483-3499
AD  - Department of Public Health, Faculty of Health Sciences, Lira University, Lira,
      Uganda.
FAU - Walter, Fiona M
AU  - Walter FM
AUID- ORCID: 0000-0002-7191-6476
AD  - The Primary Care Unit, Department of Public Health and Primary Care, University
      of Cambridge, Cambridge, Cambridgeshire, United Kingdom.
FAU - Moodley, Jennifer
AU  - Moodley J
AUID- ORCID: 0000-0002-9398-5202
AD  - Cancer Research Initiative, Faculty of Health Sciences, University of Cape Town, 
      Cape Town, Western Cape, South Africa.
AD  - Women's Health Research Unit, School of Public Health and Family Medicine,
      Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape,
      South Africa.
AD  - SAMRC Gynaecology Cancer Research Centre, University of Cape Town, Cape Town,
      Western Cape, South Africa.
LA  - eng
GR  - MC_PC_16098/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Breast Neoplasms/diagnosis/epidemiology
MH  - Delivery of Health Care
MH  - Developing Countries
MH  - Female
MH  - Humans
MH  - Income
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - *Uterine Cervical Neoplasms/diagnosis
PMC - PMC7722835
OTO - NOTNLM
OT  - *breast imaging
OT  - *health services administration & management
OT  - *oncology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-042788 [pii]
AID - 10.1136/bmjopen-2020-042788 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e042788. doi: 10.1136/bmjopen-2020-042788.


PMID- 33293324
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - What is known about the health service use and follow-up of immediate family
      members bereaved by suicide? Scoping review protocol.
PG  - e041978
LID - 10.1136/bmjopen-2020-041978 [doi]
AB  - INTRODUCTION: Suicide remains a major public health issue around the world.
      People bereaved by suicide are a vulnerable group who are at considerable risk of
      developing mental and physical health problems, such as complicated grief,
      post-traumatic stress disorder or cardiovascular disease. Many unanswered
      questions remain, in particular, in terms of their use of healthcare services.
      This protocol describes how we aim to systematically scope the existing
      literature on the professional follow-up and health service use by families
      bereaved by suicide. The scoping review will help to identify research gaps in
      the literature and aid in the planning and commission of future research. We will
      provide a summary of research findings. METHODS AND ANALYSIS: We will use the
      scoping review framework provided by the Joanna Briggs Institute. The Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping
      Reviews will be used as a guide for reporting our results. We plan to conduct an 
      extensive literature search using relevant health-related databases (MEDLINE,
      Embase, PsycINFO and CINAHL) and Web of Science. Two independent reviewers will
      screen the articles in a two-stage process: (1) titles and abstracts and (2)
      full-text documents. ETHICS AND DISSEMINATION: This scoping review will identify 
      and consider only previously published research. Hence, no ethical approval is
      considered necessary. We will disseminate the results in a scientific journal and
      at conferences, as well as through user organisations for people bereaved by
      suicide and social media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Petersen, Sindre Hoff
AU  - Petersen SH
AUID- ORCID: 0000-0002-9066-3654
AD  - Department of Health Research, SINTEF, Trondheim, Norway.
FAU - Kalseth, Jorid
AU  - Kalseth J
AD  - Department of Health Research, SINTEF, Trondheim, Norway.
FAU - Kaspersen, Silje L
AU  - Kaspersen SL
AD  - Department of Health Research, SINTEF, Trondheim, Norway
      silje.l.kaspersen@sintef.no.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Family
MH  - Family Health
MH  - Follow-Up Studies
MH  - *Health Services
MH  - Humans
MH  - *Patient Acceptance of Health Care
MH  - Review Literature as Topic
MH  - *Social Media
MH  - *Suicide
PMC - PMC7722818
OTO - NOTNLM
OT  - *health policy
OT  - *health services administration & management
OT  - *quality in healthcare
OT  - *suicide & self-harm
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-041978 [pii]
AID - 10.1136/bmjopen-2020-041978 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e041978. doi: 10.1136/bmjopen-2020-041978.


PMID- 33293323
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Factors critical to implementation success of cleaner cooking interventions in
      low-income and middle-income countries: protocol for an umbrella review.
PG  - e041821
LID - 10.1136/bmjopen-2020-041821 [doi]
AB  - INTRODUCTION: Over a third of the world's population relies on solid fuels as
      their primary energy source. These fuels have damaging effects on health, air
      quality and forest resources. Interventions to promote access to cleaner solid
      fuel cookstoves and clean fuels have existed for decades. However, the adoption
      by local communities has largely failed, which led to a waste of resources and
      suboptimal outcomes. Therefore, the objective of this umbrella review is to
      identify factors that determine implementation success for cleaner cooking
      interventions in low-resource settings and weigh their level of confidence in the
      evidence. METHODS AND ANALYSIS: We identified systematic and narrative reviews
      examining factors that influence the acquisition, initial adoption or sustained
      use of cleaner solid fuel cookstoves and clean fuels at any scale by a literature
      search in PubMed, Embase, Global Health Database, Cochrane, PsycINFO, Emcare, Web
      of Science and CINAHL, without date or language restrictions. The search was
      conducted on 23 October 2017 and updated on 10 July 2019. Reviews based on
      qualitative, quantitative or mixed-methods studies were included and will be
      appraised using the Meta Quality Appraisal Tool combined with the Assessment of
      Multiple Systematic Reviews. Data will be extracted and factors affecting
      implementation will be coded using the Consolidated Framework for Implementation 
      Research. The Grading of Recommendations Assessment, Development and
      Evaluation-Confidence in the Evidence from Reviews of Qualitative Research tool
      will be used to determine the level of confidence in the coded factors. Two
      researchers will independently conduct these steps. ETHICS AND DISSEMINATION:
      This umbrella review does not require the approval of an ethical review board.
      Study results will be published in an international peer-reviewed journal. The
      outcomes will be converted into two practical tools: one for cleaner solid fuel
      cookstoves and one for clean fuels. These tools can guide the development of
      evidence-based implementation strategies for cleaner cooking interventions in
      low-income and middle-income countries to improve implementation success. These
      tools should be pilot-tested and promoted among regional and global initiatives. 
      PROSPERO REGISTRATION NUMBER: CRD42018088687.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Boudewijns, Esther A
AU  - Boudewijns EA
AUID- ORCID: 0000-0001-9087-1712
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands
      esther.boudewijns@maastrichtuniversity.nl.
FAU - Vermond, Debbie
AU  - Vermond D
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - van der Kleij, Rianne M J J
AU  - van der Kleij RMJJ
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - Chavannes, Niels H
AU  - Chavannes NH
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - van Schayck, Onno C P
AU  - van Schayck OCP
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands.
FAU - Kirenga, Bruce
AU  - Kirenga B
AD  - Department of Medicine and Makerere Lung Institute, Makerere University, Kampala,
      Uganda.
FAU - Brakema, Evelyn A
AU  - Brakema EA
AUID- ORCID: 0000-0002-7376-4648
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cooking
MH  - *Developing Countries
MH  - Humans
MH  - Income
MH  - Poverty
MH  - Qualitative Research
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7722821
OTO - NOTNLM
OT  - *preventive medicine
OT  - *primary care
OT  - *public health
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-041821 [pii]
AID - 10.1136/bmjopen-2020-041821 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e041821. doi: 10.1136/bmjopen-2020-041821.


PMID- 33293317
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Patient-reported outcome measures (PROMs) following knee arthroplasty: a
      prospective cohort study protocol.
PG  - e040811
LID - 10.1136/bmjopen-2020-040811 [doi]
AB  - INTRODUCTION: To evaluate the quality of clinical practice, patient-reported
      outcome measures (PROMs) are important as certain questions could only be
      answered by the patient himself. PROMs help to get a better understanding what is
      meaningful to a patient and directly affects daily functioning. To move beyond
      traditional measures, we are interested in what matters to patients and developed
      this project. The aim of this article is to provide the protocol for our study
      collecting PROMs in daily medical practice from patients who undergo knee
      arthroplasty. METHODS AND ANALYSIS: This study is a single-site, observational,
      prospective cohort study. We will recruit patients scheduled for a knee
      arthroplasty in our medical office, situated in a private clinic. After signed
      informed consent, patients complete self-reported questionnaires before the
      surgery, after 4 months, 1 year, 2 years, 3 years, 4 years and 5 years. We will
      use the following PROMs: Knee injury and Osteoarthritis Outcome Score, Forgotten 
      Joint Score, EuroQol five dimensions and satisfaction. Additionally, the surgeon 
      will complete the objective Knee Society Score. Administration of the
      questionnaires will be electronically or paper-based. We will assess differences 
      between preoperative and postoperative data with paired t-test for continuous
      variables and Wilcoxon signed-rank test for categorical variables. To assess
      subgroup differences, we will use unpaired t-test for continuous variables and
      Mann-Whitney U test for categorical variables. To assess possible presence of
      bias, we will conduct sensitivity analyses. ETHICS AND DISSEMINATION: The study
      has been reviewed and approved by the local ethics committee in Basel,
      Switzerland. Written informed consent will be obtained from all patients. We will
      disseminate the results of the study through peer-reviewed journals, national and
      international conference presentations and presentations to relevant stakeholders
      through appropriate channels.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vogel, Nicole
AU  - Vogel N
AUID- ORCID: 0000-0002-8322-4514
AD  - Faculty of Medicine, University of Basel, Basel, Switzerland
      nicole.vogel@unibas.ch.
AD  - Practice Leonardo, Hirslanden Klinik Birshof, Munchenstein, Switzerland.
FAU - Rychen, Thomas
AU  - Rychen T
AD  - Practice Leonardo, Hirslanden Klinik Birshof, Munchenstein, Switzerland.
FAU - Kaelin, Raphael
AU  - Kaelin R
AD  - Practice Leonardo, Hirslanden Klinik Birshof, Munchenstein, Switzerland.
FAU - Arnold, Markus P
AU  - Arnold MP
AD  - Faculty of Medicine, University of Basel, Basel, Switzerland.
AD  - Practice Leonardo, Hirslanden Klinik Birshof, Munchenstein, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Arthroplasty, Replacement, Knee
MH  - Humans
MH  - *Osteoarthritis, Knee/surgery
MH  - *Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - Quality of Life
MH  - Switzerland
MH  - Treatment Outcome
PMC - PMC7722830
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *knee
OT  - *orthopaedic & trauma surgery
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2020-040811 [pii]
AID - 10.1136/bmjopen-2020-040811 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e040811. doi: 10.1136/bmjopen-2020-040811.


PMID- 33293316
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Study protocol for a multicentre, prospective cohort study of the association of 
      angiotensin II type 1 receptor blockers on outcomes of coronavirus infection.
PG  - e040768
LID - 10.1136/bmjopen-2020-040768 [doi]
AB  - INTRODUCTION: The COVID-19 epidemic grows and there are clinical trials of
      antivirals. There is an opportunity to complement these trials with investigation
      of angiotensin II type 1 receptor blockers (ARBs) because an ARB (losartan) was
      effective in murine influenza pneumonia. METHODS AND ANALYSIS: Our innovative
      design includes: ARBs; alignment with the WHO Ordinal Scale (primary endpoint) to
      align with other COVID-19 trials; joint longitudinal analysis; and predictive
      biomarkers (angiotensins I, 1-7, II and ACE1 and ACE2). Our hypothesis is: ARBs
      decrease the need for hospitalisation, severity (need for ventilation,
      vasopressors, extracorporeal membrane oxygenation or renal replacement therapy)
      or mortality of hospitalised COVID-19 infected adults. Our two-pronged
      multicentre pragmatic observational cohort study examines safety and
      effectiveness of ARBs in (1) hospitalised adult patients with COVID-19 and (2)
      out-patients already on or not on ARBs. The primary outcome will be evaluated by 
      ordinal logistic regression and main secondary outcomes by both joint
      longitudinal modelling analyses. We will compare rates of hospitalisation of
      ARB-exposed versus not ARB-exposed patients. We will also determine whether
      continuing ARBs or not decreases the primary outcome. Based on published COVID-19
      cohorts, assuming 15% of patients are ARB-exposed, a total sample size of 497
      patients can detect a proportional OR of 0.5 (alpha=0.05, 80% power) comparing
      WHO scale of ARB-exposed versus non-ARB-exposed patients. ETHICS AND
      DISSEMINATION: This study has core institution approval (UBC Providence
      Healthcare Research Ethics Board) and site institution approvals (Health Research
      Ethics Board, University of Alberta; Comite d'etique de la recerche, CHU Sainte
      Justine (for McGill University and University of Sherbrook); Conjoint Health
      Research Ethics Board, University of Calgary; Queen's University Health Sciences 
      & Affiliated Hospitals Research Ethics Board; Research Ethics Board, Sunnybrook
      Health Sciences Centre; Veritas Independent Research Board (for Humber River
      Hospital); Mount Sinai Hospital Research Ethics Board; Unity Health Toronto
      Research Ethics Board, St. Michael's Hospital). Results will be disseminated by
      peer-review publication and social media releases. TRIAL REGISTRATION NUMBER:
      NCT04510623.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Russell, James A
AU  - Russell JA
AUID- ORCID: http://orcid.org/0000-0003-1484-7539
AD  - Medicine, The University of British Columbia Faculty of Medicine, Vancouver,
      British Columbia, Canada jim.russell@hli.ubc.ca.
FAU - Marshall, John C
AU  - Marshall JC
AD  - Surgery, University of Toronto, Toronto, Ontario, Canada.
FAU - Slutsky, Arthur
AU  - Slutsky A
AD  - Medicine, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
FAU - Murthy, Srinivas
AU  - Murthy S
AD  - Paediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Sweet, Dave
AU  - Sweet D
AD  - Emergency Medicine, The University of British Columbia Faculty of Medicine,
      Vancouver, British Columbia, Canada.
FAU - Lee, Terry
AU  - Lee T
AD  - Population and Public Health, University of British Columbia, Vancouver, British 
      Columbia, Canada.
FAU - Singer, Joel
AU  - Singer J
AD  - Population and Public Health, University of British Columbia, Vancouver, British 
      Columbia, Canada.
FAU - Patrick, David M
AU  - Patrick DM
AD  - Population and Public Health, University of British Columbia, Vancouver, British 
      Columbia, Canada.
FAU - Du, Bin
AU  - Du B
AD  - Medical ICU, Peking University, Beijing, China.
FAU - Peng, Zhiyong
AU  - Peng Z
AUID- ORCID: http://orcid.org/0000-0002-0849-5648
AD  - Medicine, Wuhan University Zhongnan Hospital, Wuhan, China.
FAU - Cheng, Matthew
AU  - Cheng M
AD  - Department of Medicine, McGill University, Montreal, Quebec, Canada.
FAU - Burns, Kevin D
AU  - Burns KD
AD  - Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Harhay, Michael O
AU  - Harhay MO
AUID- ORCID: http://orcid.org/0000-0002-0553-674X
AD  - Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman
      School of Medicine, Philadelphia, Pennsylvania, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04510623
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use
MH  - COVID-19/*drug therapy
MH  - Humans
MH  - Logistic Models
MH  - Multicenter Studies as Topic
MH  - Pandemics
MH  - Pragmatic Clinical Trials as Topic
MH  - Prospective Studies
MH  - SARS-CoV-2
MH  - Treatment Outcome
PMC - PMC7722825
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *cardiology
OT  - *hypertension
COIS- Competing interests: JR reports patents owned by the University of British
      Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis, and
      related to the use of vasopressin in septic shock and a patent owned by Ferring
      for use of selepressin in septic shock. JR is an inventor on these patents. JR
      was a founder, Director and shareholder in Cyon Therapeutics Inc. and is a
      shareholder in Molecular You Corp. JR reports receiving consulting fees in the
      last 3 years from: (1) Asahi Kesai Pharmaceuticals of America (AKPA) (was
      developing recombinant thrombomodulin in sepsis). (2) SIB Therapeutics LLC
      (developing a sepsis drug). (3) Ferring Pharmaceuticals (manufactures vasopressin
      and developing selepressin). JR is no longer actively consulting for the
      following: (4) La Jolla Pharmaceuticals (developing angiotensin II; JR chaired
      the DSMB of a trial of angiotensin II from 2015-2017). (5) PAR Pharma (sells
      prepared bags of vasopressin). JR reports having received an
      investigator-initiated grant from Grifols (entitled 'Is HBP a mechanism of
      albumin's efficacy in human septic shock?') that was provided to and administered
      by UBC.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-040768 [pii]
AID - 10.1136/bmjopen-2020-040768 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e040768. doi: 10.1136/bmjopen-2020-040768.


PMID- 33293312
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Enhancing community participation for stroke survivors with cognitive impairment:
      study protocol for a randomised controlled trial in Taiwan.
PG  - e040241
LID - 10.1136/bmjopen-2020-040241 [doi]
AB  - INTRODUCTION: Stroke can lead to life-long disability and constitutes a huge
      financial burden on the family and society. Stroke survivors with cognitive
      impairment often experience considerable challenges in the process of recovery
      and returning to society. Interventions that effectively help individuals resume 
      essential daily activities and return to active participation in their
      communities are lacking. This study examines the efficacy of a newly-developed
      intervention programme, the Optimising Participation after Stroke through
      Strategy-training (OPASS) programme, for improving community participation among 
      stroke survivors with cognitive impairment. METHODS AND ANALYSIS: A single-blind,
      parallel-group randomised controlled trial with allocation concealment and
      assessor blinding will be implemented to assess the efficacy of the OPASS
      programme. An expected 210 adults with cognitive impairment following stroke will
      be randomly assigned to either the experimental intervention (OPASS) group or the
      attention control group. In addition to their usual rehabilitation, both groups
      will receive 45 min sessions, twice weekly for a total of 12-15 sessions. The
      primary outcome is change in participation performance, which will be measured
      using the participation measure-three domains, four dimensions scale. Additional 
      measures include the Activity Measure for Post-Acute Care generic outpatient
      short forms, Montreal Cognitive Assessment, Stroop Test, Trail Making Test and
      General Self-Efficacy Scale. These scales will be administered at baseline,
      post-intervention, 3-month follow-up, 6-month follow-up and 12-month follow-up.
      Their results will be analysed using multiple linear regression models and
      mixed-effects regression models. Further assessment of feasibility and
      acceptability of the intervention will be conducted through structured interviews
      with participants, caregivers and therapists. These interviews will be
      transcribed and thematically analysed. ETHICS AND DISSEMINATION: Ethics approval 
      was obtained from the Ethics Committee of Taipei Medical University (approval
      number: N201804055). The findings will be disseminated through presentations at
      scientific conferences and through publication in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: NCT03792061; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chang, Feng-Hang
AU  - Chang FH
AUID- ORCID: 0000-0002-0711-3644
AD  - Graduate Institute of Injury Prevention and Control, College of Public Health,
      Taipei Medical University, Taipei, Taiwan fhchang@tmu.edu.tw.
AD  - Department of Physical Medicine and Rehabilitation, School of Medicine, College
      of Medicine, Taipei Medical University, Taipei, Taiwan.
FAU - Chiu, Valeria
AU  - Chiu V
AD  - Graduate Institute of Injury Prevention and Control, College of Public Health,
      Taipei Medical University, Taipei, Taiwan.
AD  - Department of Physical Medicine and Rehabilitation, Taipei Tzu Chi Hospital,
      Taipei, Taiwan.
FAU - Ni, Pengsheng
AU  - Ni P
AD  - Health Law, Policy & Management; Biostatistics and Epidemiology Data Analytics
      Center, Boston University School of Public Health, Boston, Massachusetts, USA.
FAU - Lin, Yen-Nung
AU  - Lin YN
AD  - Graduate Institute of Injury Prevention and Control, College of Public Health,
      Taipei Medical University, Taipei, Taiwan.
AD  - Department of Physical Medicine and Rehabilitation, Taipei Municipal Wan-Fang
      Hospital, Taipei, Taiwan.
FAU - Kang, Jiunn-Horng
AU  - Kang JH
AD  - Department of Physical Medicine and Rehabilitation, School of Medicine, College
      of Medicine, Taipei Medical University, Taipei, Taiwan.
AD  - Department of Physical Medicine and Rehabilitation, Taipei Medical University
      Hospital, Taipei, Taiwan.
FAU - Liou, Tsan-Hon
AU  - Liou TH
AD  - Department of Physical Medicine and Rehabilitation, School of Medicine, College
      of Medicine, Taipei Medical University, Taipei, Taiwan.
AD  - Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei,
      Taiwan.
FAU - Lu, Lu
AU  - Lu L
AD  - Department of Physical Medicine and Rehabilitation, National Taiwan University
      Hospital, Taipei, Taiwan.
FAU - Han, Der-Sheng
AU  - Han DS
AD  - Department of Physical Medicine and Rehabilitation, College of Medicine, National
      Taiwan University, Taipei, Taiwan.
AD  - Department of Physical Medicine and Rehabilitation, National Taiwan University
      Hospital Beihu Branch, Taipei, Taiwan.
FAU - Skidmore, Elizabeth R
AU  - Skidmore ER
AD  - Department of Occupational Therapy, School of Health and Rehabilitation Sciences,
      University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
AD  - Department of Physical Medicine & Rehabilitation, School of Medicine, University 
      of Pittsburgh, Pittsburgh, Pennsylvania, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03792061
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cognitive Dysfunction/etiology/therapy
MH  - Community Participation
MH  - Depressive Disorder, Major
MH  - Humans
MH  - Quality of Life
MH  - Reproducibility of Results
MH  - Single-Blind Method
MH  - *Stroke/complications
MH  - *Stroke Rehabilitation
MH  - Survivors
MH  - Taiwan
PMC - PMC7722819
OTO - NOTNLM
OT  - *cognitive dysfunction
OT  - *rehabilitation
OT  - *social participation
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-040241 [pii]
AID - 10.1136/bmjopen-2020-040241 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e040241. doi: 10.1136/bmjopen-2020-040241.


PMID- 33293311
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Study protocol for resolution of organ injury in acute pancreatitis (RESORP): an 
      observational prospective cohort study.
PG  - e040200
LID - 10.1136/bmjopen-2020-040200 [doi]
AB  - INTRODUCTION: Survivors of acute pancreatitis (AP) have shorter overall survival 
      and increased incidence of new-onset cardiovascular, respiratory, liver and renal
      disease, diabetes mellitus and cancer compared with the general population, but
      the mechanisms that explain this are yet to be elucidated. Our aim is to
      characterise the precise nature and extent of organ dysfunction following an
      episode of AP. METHODS AND ANALYSIS: This is an observational prospective cohort 
      study in a single centre comprising a University hospital with an acute and
      emergency receiving unit and clinical research facility. Participants will be
      adult patient admitted with AP. Participants will undergo assessment at
      recruitment, 3 months and 3 years. At each time point, multiple biochemical
      and/or physiological assessments to measure cardiovascular, respiratory, liver,
      renal and cognitive function, diabetes mellitus and quality of life. Recruitment 
      was from 30 November 2017 to 31 May 2020; last follow-up measurements is due on
      31 May 2023. The primary outcome measure is the incidence of new-onset type 3c
      diabetes mellitus during follow-up. Secondary outcome measures include: quality
      of life analyses (SF-36, Gastrointestinal Quality of Life Index); montreal
      cognitive assessment; organ system physiological performance; multiomics
      predictors of AP severity, detection of premature cellular senescence. In a
      nested cohort within the main cohort, individuals may also consent to
      multiparameter MRI scan, echocardiography, pulmonary function testing,
      cardiopulmonary exercise testing and pulse-wave analysis. ETHICS AND
      DISSEMINATION: This study has received the following approvals: UK IRAS Number
      178615; South-east Scotland Research Ethics Committee number 16/SS/0065. Results 
      will be made available to AP survivors, caregivers, funders and other
      researchers. Publications will be open-access. TRIAL REGISTRATION NUMBERS:
      ClinicalTrials.gov Registry (NCT03342716) and ISRCTN50581876; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Sherif, Ahmed E
AU  - Sherif AE
AD  - Clinical Surgery, University of Edinburgh, Edinburgh, UK.
FAU - McFadyen, Rory
AU  - McFadyen R
AD  - Clinical Surgery, University of Edinburgh, Edinburgh, UK.
FAU - Boyd, Julia
AU  - Boyd J
AD  - Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.
FAU - Ventre, Chiara
AU  - Ventre C
AD  - Clinical Surgery, University of Edinburgh, Edinburgh, UK.
FAU - Glenwright, Margaret
AU  - Glenwright M
AD  - Clinical Research Facility, NHS Lothian, Edinburgh, UK.
FAU - Walker, Kim
AU  - Walker K
AD  - Clinical Research Facility, NHS Lothian, Edinburgh, UK.
FAU - Zheng, Xiaozhong
AU  - Zheng X
AD  - Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
FAU - White, Audrey
AU  - White A
AD  - Clinical Research Facility, NHS Lothian, Edinburgh, UK.
FAU - McFadyen, Laura
AU  - McFadyen L
AD  - Clinical Research Facility, NHS Lothian, Edinburgh, UK.
FAU - Connon, Emma
AU  - Connon E
AD  - Clinical Research Facility, NHS Lothian, Edinburgh, UK.
FAU - Damaskos, Dimitrios
AU  - Damaskos D
AD  - Clinical Surgery, University of Edinburgh, Edinburgh, UK.
FAU - Steven, Michelle
AU  - Steven M
AD  - Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.
FAU - Wackett, Anthony
AU  - Wackett A
AD  - Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.
FAU - Thomson, Euan
AU  - Thomson E
AD  - Anaesthesia and Critical Care, NHS Lothian, Edinburgh, UK.
FAU - Cameron, David C
AU  - Cameron DC
AD  - Anaesthesia and Critical Care, NHS Lothian, Edinburgh, UK.
FAU - MacLeod, Jill
AU  - MacLeod J
AD  - Respiratory Physiology, NHS Lothian, Edinburgh, UK.
FAU - Baxter, Shaun
AU  - Baxter S
AD  - Respiratory Physiology, NHS Lothian, Edinburgh, UK.
FAU - Semple, Scott
AU  - Semple S
AD  - Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
FAU - Morris, David
AU  - Morris D
AD  - Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
FAU - Clark-Stewart, Saskia
AU  - Clark-Stewart S
AD  - Clinical Surgery, University of Edinburgh, Edinburgh, UK.
FAU - Graham, Catriona
AU  - Graham C
AD  - Epidemiology and Statistics Core, Edinburgh Clinical Research Facility,
      University of Edinburgh, Edinburgh, UK.
FAU - Mole, Damian J
AU  - Mole DJ
AUID- ORCID: 0000-0001-6884-7302
AD  - Clinical Surgery, University of Edinburgh, Edinburgh, UK damian.mole@ed.ac.uk.
AD  - Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
CN  - RESORP research team
LA  - eng
SI  - ClinicalTrials.gov/NCT03342716
SI  - ISRCTN/ISRCTN50581876
GR  - G0701127/MRC_/Medical Research Council/United Kingdom
GR  - MR/P008887/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acute Disease
MH  - *COVID-19
MH  - Follow-Up Studies
MH  - Humans
MH  - *Pancreatitis
MH  - Prospective Studies
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - Scotland
PMC - PMC7722833
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *general diabetes
OT  - *pancreatic disease
COIS- Competing interests: DJM wishes to declare that he holds a senior position in a
      private company developing medicines for systemic inflammation and cancer, and
      that he has previously received funding for collaborative studies on AP from GSK.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-040200 [pii]
AID - 10.1136/bmjopen-2020-040200 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e040200. doi: 10.1136/bmjopen-2020-040200.


PMID- 33293309
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Protocol for a scoping review of outcomes in clinical studies of interventions
      for venous thromboembolism in adults.
PG  - e040122
LID - 10.1136/bmjopen-2020-040122 [doi]
AB  - INTRODUCTION: Venous thromboembolism (VTE) is a common, potentially fatal yet
      treatable disease. Several advances in treatment of VTE have been made over the
      past decades, but definition and reporting of outcomes across those studies are
      inconsistent. Development of an international core outcome set for clinical
      studies of interventions for VTE addresses this lack of standardisation. The
      first step in the development of a core outcome set is to conduct a scoping
      review which aims to generate an inclusive list of unique outcomes that have been
      reported in previous studies. METHODS AND ANALYSIS: MEDLINE, Embase and the
      Cochrane Central Register of Controlled Trials will be searched with no language 
      restriction for prospective studies reporting on interventions for treatment of
      VTE in patients who are adult and non-pregnant. Records will be sorted in reverse
      chronological order. Study screening and data extraction will be independently
      performed by two authors in blocks based on date of publication, starting with
      2015 to 2020 and subsequent 1-year periods, until no new outcome measures are
      identified from the set of included studies. After homogenising spelling and
      combining outcomes with the same meaning, a list of unique outcomes will be
      determined. Those outcomes will be grouped into outcome domains. Qualitative
      analysis and descriptive statistics will be used to report results. ETHICS AND
      DISSEMINATION: Ethical approval is not required for this study. The results of
      this scoping review will be presented at scientific conferences, published in a
      peer-reviewed journal, and they will provide candidate outcome domains to be
      considered in subsequent steps in the development of a core outcome set for
      clinical studies of interventions for VTE. PROTOCOL REGISTRATION DETAILS:
      http://hdl.handle.net/10393/40459.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tritschler, Tobias
AU  - Tritschler T
AUID- ORCID: 0000-0002-8775-0511
AD  - Department of General Internal Medicine, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland.
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Langlois, Nicole
AU  - Langlois N
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Hutton, Brian
AU  - Hutton B
AUID- ORCID: 0000-0001-5662-8647
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Shea, Beverley J
AU  - Shea BJ
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Shorr, Risa
AU  - Shorr R
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Ng, Sara
AU  - Ng S
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Dubois, Suzanne
AU  - Dubois S
AD  - Canadian Venous Thromboembolism Research Network (CanVECTOR), Patient Partner
      Platform, Ottawa, Ontario, Canada.
FAU - West, Carol
AU  - West C
AD  - Canadian Venous Thromboembolism Research Network (CanVECTOR), Patient Partner
      Platform, Ottawa, Ontario, Canada.
FAU - Iorio, Alfonso
AU  - Iorio A
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Tugwell, Peter
AU  - Tugwell P
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Le Gal, Gregoire
AU  - Le Gal G
AUID- ORCID: 0000-0002-9253-248X
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa, Ontario, Canada glegal@ohri.ca.
LA  - eng
GR  - PJT-165897/CAPMC/ CIHR/Canada
GR  - CDT-142654/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Pregnancy
MH  - Prospective Studies
MH  - Research Report
MH  - *Venous Thromboembolism/drug therapy
PMC - PMC7722803
OTO - NOTNLM
OT  - *bleeding disorders & coagulopathies
OT  - *epidemiology
OT  - *thromboembolism
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-040122 [pii]
AID - 10.1136/bmjopen-2020-040122 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e040122. doi: 10.1136/bmjopen-2020-040122.


PMID- 33293305
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Use of the Safewards Model in healthcare services: a mixed-method scoping review 
      protocol.
PG  - e039109
LID - 10.1136/bmjopen-2020-039109 [doi]
AB  - INTRODUCTION: Safewards is an organisational approach to delivering inpatient
      mental health services. The aim of Safewards is to minimise the number of
      situations in which conflict arises between healthcare workers and patients that 
      lead to the use of coercive interventions (restriction and/or containment).The
      Safewards Model has been developed, implemented and evaluated for its impact on
      all forms of containment. Safewards has been adopted as the recommended approach 
      to preventing patient agitation and clinical aggression in some jurisdictions.
      Notwithstanding these recommendations, the outcomes of Safewards for staff and
      patients have not been comprehensively described.The aim of the scoping review is
      to describe (1) Safewards interventions; (2) how Safewards interventions have
      been implemented in healthcare settings; (3) outcome measures used to evaluate
      the effectiveness of Safewards; (4) barriers and enablers to the uptake and
      sustainability of Safewards. This review will provide a foundation for further
      research and/or systematic review of the effectiveness of Safewards. METHODS AND 
      ANALYSIS: Peer-reviewed manuscripts of quantitative, qualitative and mixed-method
      research in English with be included for the period 01 January 2013- December
      31st 2020. Electronic databases including Cumulative Index to Nursing and Allied 
      Health Literature, Cochrane, Embase, Emcare, Joanna Briggs Institute, Medline,
      Global Health, PsycINFO and Scopus will be searched. Preferred Reporting Items
      for Systematic Reviews and Meta-Analysis extension for Scoping Reviews checklist 
      and explanation and the Preferred Reporting Items for Systematic Reviews and
      Meta-Analysis Protocol will be followed. Publications will be excluded if they do
      not include the required participants, concept or context. Two reviewers will
      independently screen all titles and abstracts and full-text studies for
      inclusion. ETHICS AND DISSEMINATION: Ethical approval for this review is not
      required as the information to be collected is publicly available. There are no
      participants or safety considerations in this review of published literature. Key
      findings for future research and clinical practice will be disseminated though
      peer-reviewed publication, stakeholder reporting and conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gerdtz, Marie
AU  - Gerdtz M
AUID- ORCID: 0000-0002-2100-994X
AD  - Nursing, The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Daniel, Catherine
AU  - Daniel C
AUID- ORCID: 0000-0002-1122-3950
AD  - Nursing, The University of Melbourne, Melbourne, Victoria, Australia
      daniel.c@unimelb.edu.au.
FAU - Jarden, Rebecca
AU  - Jarden R
AUID- ORCID: 0000-0003-4643-7147
AD  - Nursing, The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Kapp, Suzanne
AU  - Kapp S
AUID- ORCID: 0000-0002-5438-8384
AD  - Nursing, The University of Melbourne, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - *Health Services
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Peer Review
MH  - *Research Design
PMC - PMC7722816
OTO - NOTNLM
OT  - *health & safety
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-039109 [pii]
AID - 10.1136/bmjopen-2020-039109 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e039109. doi: 10.1136/bmjopen-2020-039109.


PMID- 33293302
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 7
TI  - Comparison of different mobile health applications for intervention in children
      and adolescent with overweight: a protocol for systematic review with
      meta-analysis and trial sequential analysis.
PG  - e032570
LID - 10.1136/bmjopen-2019-032570 [doi]
AB  - INTRODUCTION: Overweight in children is increasing worldwide. Innovative
      smartphone health applications (mHealth apps) have either sought to deliver
      single or multi-component interventions for the management of overweight in
      children. However, the clinical effects of these apps are poorly explored. The
      objective of the review will be to compare the benefits and harms of different
      categories of mHealth apps for intervention of overweight in children. METHODS
      AND ANALYSIS: We will include randomised clinical trials irrespective of
      publication type, year, status or language. Children and adolescents between 0 to
      18 years will be referred to as children in the remaining part of the paper.
      Children with all degrees of overweight included obesity and morbidly obese in
      the remaining part of the paper will be referred to as overweight. We plan to
      classify different apps according to type of intervention, measurement device,
      coaching and reward system. The following databases will be used: Cochrane
      Library, Excerpta Medica database (Embase), PsycINFO, PubMed, IEEE Explore and
      Web of Science, CINAHL and LILACS. Primary outcomes will be body mass index
      z-score, quality of life and serious adverse event. Secondary outcomes will be
      body weight, self-efficacy, anxiety, depression and adverse event not considered 
      serious. Study inclusion, data extraction and bias risk assessment will be
      conducted independently by at least two authors. We will assess the risk of bias 
      through eight domains and control risks of random errors with Trial Sequential
      Analysis. The quality of the evidence will be assessed using Grading of
      Recommendations Assessment, Development and Evaluation Tool (GRADE). ETHICS AND
      DISSEMINATION: As the protocol is for a systematic reviews, we have not included 
      any patient data and we do not require ethical approval. This review will be
      published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42019120266.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Perego, Paolo
AU  - Perego P
AUID- ORCID: 0000-0003-4960-8888
AD  - Design Department, Politecnico di Milano, Milano, MI, Italy.
FAU - Rashid, Rajeeb
AU  - Rashid R
AD  - Department of Child Life and Health, The University of Edinburgh, Edinburgh, UK.
FAU - Gluud, Christian
AU  - Gluud C
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Jakobsen, Janus C
AU  - Jakobsen JC
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
AD  - Department of Cardiology, Holbaek Sygehus, Holbaek, Sjaelland, Denmark.
FAU - Andreoni, Giuseppe
AU  - Andreoni G
AUID- ORCID: 0000-0002-5537-4128
AD  - Design Department, Politecnico di Milano, Milano, MI, Italy.
FAU - Lissau, Inge
AU  - Lissau I
AUID- ORCID: 0000-0002-2225-9975
AD  - Clinical Research Centre, University Hospital Copenhagen, Copenhagen, Hvidovre,
      Denmark info@ingelissau.dk.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201207
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Mobile Applications
MH  - *Overweight/therapy
MH  - Quality of Life
MH  - Systematic Reviews as Topic
MH  - Telemedicine
PMC - PMC7722812
OTO - NOTNLM
OT  - *information technology
OT  - *paediatric endocrinology
OT  - *paediatrics
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/10 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/09 06:05
PHST- 2020/12/09 06:05 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2019-032570 [pii]
AID - 10.1136/bmjopen-2019-032570 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 7;10(12):e032570. doi: 10.1136/bmjopen-2019-032570.


PMID- 33292881
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
VI  - 36
IP  - 6
DP  - 2020 Dec
TI  - Core competencies for ethics experts in health technology assessment.
PG  - 534-539
LID - 10.1017/S0266462320001968 [doi]
AB  - OBJECTIVES: There is no consensus on who might be qualified to conduct ethical
      analysis in the field of health technology assessment (HTA). Is there a specific 
      expertise or skill set for doing this work? The aim of this article is to (i)
      clarify the concept of ethics expertise and, based on this, (ii) describe and
      specify the characteristics of ethics expertise in HTA. METHODS: Based on the
      current literature and experiences in conducting ethical analysis in HTA, a group
      of members of the Health Technology Assessment International (HTAi) Interest
      Group on Ethical Issues in HTA critically analyzed the collected information
      during two face-to-face workshops. On the basis of the analysis, working
      definitions of "ethics expertise" and "core competencies" of ethics experts in
      HTA were developed. This paper reports the output of the workshop and subsequent 
      revisions and discussions online among the authors. RESULTS: Expertise in a
      domain consists of both explicit and tacit knowledge and is acquired by formal
      training and social learning. There is a ubiquitous ethical expertise shared by
      most people in society; nevertheless, some people acquire specialist ethical
      expertise. To become an ethics expert in the field of HTA, one needs to acquire
      general knowledge about ethical issues as well as specific knowledge of the
      ethical domain in HTA. The core competencies of ethics experts in HTA consist of 
      three fundamental elements: knowledge, skills, and attitudes. CONCLUSIONS: The
      competencies described here can be used by HTA agencies and others involved in
      HTA to call attention to and strengthen ethical analysis in HTA.
FAU - Refolo, Pietro
AU  - Refolo P
AUID- ORCID: https://orcid.org/0000-0003-1055-160X
AD  - Department of Healthcare Surveillance and Bioethics, Universita Cattolica del
      Sacro Cuore, Rome, Italy.
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
FAU - Bond, Kenneth
AU  - Bond K
AUID- ORCID: https://orcid.org/0000-0002-7620-9375
AD  - Institute of Health Economics, Edmonton, Alberta, Canada.
FAU - Bloemen, Bart
AU  - Bloemen B
AUID- ORCID: https://orcid.org/0000-0001-8856-2216
AD  - Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Autti-Ramo, Ilona
AU  - Autti-Ramo I
AD  - Council for Choices in Health Care in Finland and Unit for Steering of Services, 
      Department for Steering of Healthcare and Social Welfare, Ministry of Social
      affairs and Health, Finland.
FAU - Hofmann, Bjorn
AU  - Hofmann B
AD  - Department of Health Science, Norwegian University of Science and Technology,
      Gjovik, Norway.
FAU - Mischke, Claudia
AU  - Mischke C
AD  - Department of Health Care and Health Economics, Institute for Quality and
      Efficiency in Health Care, Cologne, Germany.
FAU - Mueller, Debjani
AU  - Mueller D
AUID- ORCID: https://orcid.org/0000-0001-7796-982X
AD  - Charlotte Maxeke Research Cluster, Johannesburg, South Africa.
FAU - Nabukenya, Sylvia
AU  - Nabukenya S
AUID- ORCID: https://orcid.org/0000-0001-5868-7376
AD  - Infectious Diseases Institute, Makerere University, Kampala, Uganda.
FAU - Oortwijn, Wija
AU  - Oortwijn W
AUID- ORCID: https://orcid.org/0000-0003-4499-8602
AD  - Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Sandman, Lars
AU  - Sandman L
AUID- ORCID: https://orcid.org/0000-0003-0987-7653
AD  - National Centre for Priorities in Health, Department of Health, Medicine and
      Caring Sciences, Linkoping University, Linkoping, Sweden.
FAU - Stanak, Michal
AU  - Stanak M
AUID- ORCID: https://orcid.org/0000-0003-0313-0997
AD  - Austrian Institute for Health Technology Assessment, Vienna, Austria.
FAU - Steele, Duncan
AU  - Steele D
AD  - Alberta Health Services, Calgary, Canada.
FAU - van der Wilt, Gert Jan
AU  - van der Wilt GJ
AUID- ORCID: https://orcid.org/0000-0002-5856-762X
AD  - Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Sacchini, Dario
AU  - Sacchini D
AUID- ORCID: https://orcid.org/0000-0002-1581-3018
AD  - Department of Healthcare Surveillance and Bioethics, Universita Cattolica del
      Sacro Cuore, Rome, Italy.
AD  - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
SB  - IM
MH  - *Ethical Analysis
MH  - Humans
MH  - Knowledge
MH  - Morals
MH  - *Technology Assessment, Biomedical
OTO - NOTNLM
OT  - Competencies
OT  - Ethics
OT  - Expertise
EDAT- 2020/12/10 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/12/09 05:48
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/12/09 05:48 [entrez]
AID - 10.1017/S0266462320001968 [doi]
AID - S0266462320001968 [pii]
PST - ppublish
SO  - Int J Technol Assess Health Care. 2020 Dec;36(6):534-539. doi:
      10.1017/S0266462320001968. Epub 2020 Dec 9.


PMID- 33292788
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 2056-9920 (Print)
IS  - 2056-9920 (Linking)
VI  - 6
IP  - 1
DP  - 2020 Dec 3
TI  - Anatomical and functional outcomes of subthreshold micropulse laser versus
      intravitreal ranibizumab injection in treatment of diabetic macular edema.
PG  - 63
LID - 10.1186/s40942-020-00265-6 [doi]
AB  - BACKGROUND: To compare the therapeutic effects of subthreshold micropulse laser
      (SML) versus intravitreal injection of ranibizumab in treatment of diabetic
      macular edema (DME) both anatomically using optical coherence tomography (OCT)
      and functionally using best corrected visual acuity (BCVA) and multifocal
      electroretinogram (mfERG). METHODS: his study was an interventional prospective
      randomized comparative study. The study included 120 eyes classified into 3
      groups: Group 1 included 40 eyes of 28 patients treated by SML laser, group 2
      included 40 eyes of 32 patients treated by intravitreal injection of ranibizumab,
      and group 3 (control group for mfERG) included 40 eyes of 20 patients with
      diabetes mellitus (DM) of more than 10 year duration with no signs of diabetic
      retinopathy (DR). BCVA measurements, OCT and mfERG were done for the cases before
      and after interference and were followed up for 6 months RESULTS: By the end of
      the follow up period, BCVA significantly improved by 31% in group 1 vs 93% in
      group 2 with a statistically highly significant difference between the two groups
      (p value < 0.001). There was also a significant decrease in central subfield
      thickness in both groups with more reduction in group 2 compared with group 1 (p 
      value < 0.001). There was a significant improvement in P1 amplitude of mf-ERG in 
      group 2 (p value < 0.002) with no significant improvement in group 1. There was a
      significant decrease in P1 implicit time in group 2 (p value < 0.001) while there
      was no significant decrease in group1. CONCLUSIONS: Intravitreal injection of
      ranibizumab is a superior treatment modality for DME compared with SML regarding 
      both anatomical and functional outcomes. TRIAL REGISTRATION: This study has been 
      approved by the local ethical committee of faculty of medicine of Minia
      University and retrospectively registered at the clinical trial gov. with
      Identifier: NCT04332133.
FAU - Abdelrahman, Amr
AU  - Abdelrahman A
AD  - Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Massoud, Wagiha
AU  - Massoud W
AD  - Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Elshafei, Ahmed Mohamed Kamal
AU  - Elshafei AMK
AD  - Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Genidy, Mahmoud
AU  - Genidy M
AD  - Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Abdallah, Raafat Mohyeldeen Abdelrahman
AU  - Abdallah RMA
AUID- ORCID: http://orcid.org/0000-0002-5987-6889
AD  - Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt.
      raafat.abdelrahman@mu.edu.eg.
LA  - eng
SI  - ClinicalTrials.gov/NCT04332133
PT  - Journal Article
DEP - 20201203
PL  - England
TA  - Int J Retina Vitreous
JT  - International journal of retina and vitreous
JID - 101677897
PMC - PMC7712611
OTO - NOTNLM
OT  - Diabetic macular edema
OT  - Multifocal electroretinogram
OT  - Ranibizumab
OT  - Subthreshold micropulse laser
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:47
PHST- 2020/04/06 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/09 05:47 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s40942-020-00265-6 [doi]
AID - 10.1186/s40942-020-00265-6 [pii]
PST - epublish
SO  - Int J Retina Vitreous. 2020 Dec 3;6(1):63. doi: 10.1186/s40942-020-00265-6.


PMID- 33292760
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 0301-0422 (Print)
IS  - 0301-0422 (Linking)
VI  - 41
IP  - 1
DP  - 2020 Nov 27
TI  - Community-based participatory research in rural African contexts: Ethico-cultural
      considerations and lessons from Ghana.
PG  - 27
LID - 10.1186/s40985-020-00145-2 [doi]
AB  - Researchers conducting community-based participatory research (CBPR) with
      vulnerable populations in rural African settings are confronted with distinctive 
      ethical and cultural challenges due to the community context of their research,
      their methods of investigation, and the implications of their findings for
      populations. Ethical considerations such as informed consent, the protection of
      privacy and confidentiality, and relationships between researchers and
      participants take on greater complexity and have implications beyond the
      individual research participant. Drawing on careful reflections of experiences
      from conducting mental health promotion intervention research using the CBPR
      approach and multi-methods in resource-poor rural communities in Ghana, we
      examine a range of ethico-cultural issues associated with community-based group
      intervention research in rural remote settings of Ghana. We offer suggestions to 
      help researchers to envision and manage these complexities in a more appropriate 
      way. Approaches aimed to promote relationships, fairness, respect, and cultural
      harmony between researchers and study participants are outlined. We urge
      prospective researchers to carefully explore and respect the cultural values and 
      practices of community members and observe locally-defined ethical values and
      principles when conducting CBPRs in rural African settings to minimise ethics
      dumping and safeguard the integrity of their research.
FAU - Appiah, Richard
AU  - Appiah R
AUID- ORCID: http://orcid.org/0000-0002-1462-5015
AD  - College of Health Sciences, University of Ghana, Accra, Ghana.
      riappiah@ug.edu.gh.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201127
PL  - Switzerland
TA  - Public Health Rev
JT  - Public health reviews
JID - 0370123
PMC - PMC7694909
OTO - NOTNLM
OT  - Community-based participatory research
OT  - Ethical and cultural considerations
OT  - Ghana
OT  - Intervention research
OT  - Rural Africa
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:47
PHST- 2020/09/03 00:00 [received]
PHST- 2020/11/15 00:00 [accepted]
PHST- 2020/12/09 05:47 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s40985-020-00145-2 [doi]
AID - 10.1186/s40985-020-00145-2 [pii]
PST - epublish
SO  - Public Health Rev. 2020 Nov 27;41(1):27. doi: 10.1186/s40985-020-00145-2.


PMID- 33292629
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220129
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
IP  - 1
DP  - 2020 Nov 19
TI  - A randomised controlled feasibility study of interpersonal art psychotherapy for 
      the treatment of aggression in people with intellectual disabilities in secure
      care.
PG  - 180
LID - 10.1186/s40814-020-00703-0 [doi]
AB  - BACKGROUND: Rates of aggression in inpatient secure care are higher than in other
      psychiatric inpatient settings. People with intellectual disabilities in secure
      care require adapted psychological treatments. Interpersonal art psychotherapy
      incorporates the use of creative art making approaches by participants, thus
      reducing sole reliance upon verbal interactions during psychotherapy for people
      who may have communication difficulties. During interpersonal art psychotherapy, 
      participants are individually supported by their therapist to consider how they
      conduct relationships. This includes the influence and impact of interpersonal
      issues resulting in repeated patterns of conflict. The key feasibility objectives
      were to assess recruitment and retention rates, follow-up rates and trial
      procedures such as randomisation, allocation and identifying any practical or
      ethical problems. In addition, a preliminary 'signal' for the intervention was
      considered and an indicative sample size calculation completed. The acceptability
      of a potential third trial arm attentional control condition, mindful
      colouring-in, was assessed using four single-case design studies and a UK trial
      capacity survey was conducted. METHODS: Adult patients with intellectual
      disabilities in secure care were recruited and randomised to either interpersonal
      art psychotherapy or delayed treatment in this multi-site study. Outcomes were
      assessed using weekly observations via the Modified Overt Aggression Scale and a 
      range of self-report measures. Within study reporting processes, qualitative
      interviews and a survey were completed to inform trial feasibility. RESULTS:
      Recruitment procedures were successful. The target of recruiting 20 participants 
      to the trial from multiple sites was achieved within 8 months of the study
      opening. All participants recruited to the treatment arm completed interpersonal 
      art psychotherapy. Between-group differences of interpersonal art psychotherapy
      versus the delayed treatment control showed a 'signal' effect-size of .65 for
      total scores and .93 in the verbal aggression sub-scale. There were no amendments
      to the published protocol. The assessment of key feasibility objectives were met 
      and the trial procedures were acceptable to all involved in the research.
      CONCLUSION: This study suggested that a randomised controlled trial of
      interpersonal art psychotherapy is acceptable and feasible. TRIAL REGISTRATION:
      ISRCTN14326119 (Retrospectively Registered).
FAU - Hackett, Simon S
AU  - Hackett SS
AUID- ORCID: http://orcid.org/0000-0002-7861-5991
AD  - Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne, UK.
      simon.hackett@newcastle.ac.uk.
AD  - Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle upon Tyne,
      UK. simon.hackett@newcastle.ac.uk.
FAU - Zubala, Ania
AU  - Zubala A
AD  - University of the Highlands and Islands, Inverness, UK.
FAU - Aafjes-van Doorn, Katie
AU  - Aafjes-van Doorn K
AD  - Yeshiva University, New York, USA.
FAU - Chadwick, Thomas
AU  - Chadwick T
AD  - Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne, UK.
FAU - Harrison, Toni Leigh
AU  - Harrison TL
AD  - Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle upon Tyne,
      UK.
FAU - Bourne, Jane
AU  - Bourne J
AD  - Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle upon Tyne,
      UK.
FAU - Freeston, Mark
AU  - Freeston M
AD  - Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne, UK.
FAU - Jahoda, Andrew
AU  - Jahoda A
AD  - Glasgow University, Glasgow, UK.
FAU - Taylor, John L
AU  - Taylor JL
AD  - Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle upon Tyne,
      UK.
AD  - Northumbria University, Newcastle upon Tyne, UK.
FAU - Ariti, Cono
AU  - Ariti C
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - McNamara, Rachel
AU  - McNamara R
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Pennington, Lindsay
AU  - Pennington L
AD  - Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne, UK.
FAU - McColl, Elaine
AU  - McColl E
AD  - Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne, UK.
FAU - Kaner, Eileen
AU  - Kaner E
AD  - Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne, UK.
LA  - eng
GR  - MR/K02325X/1/MRC_/Medical Research Council/United Kingdom
GR  - CL-2014-05-004/Research Trainees Coordinating Centre
PT  - Journal Article
DEP - 20201119
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
EIN - Pilot Feasibility Stud. 2020 Dec 18;6(1):195. PMID: 33339527
PMC - PMC7677838
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:45
PHST- 2020/07/13 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/12/09 05:45 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s40814-020-00703-0 [doi]
AID - 10.1186/s40814-020-00703-0 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 Nov 19;6(1):180. doi: 10.1186/s40814-020-00703-0.


PMID- 33292590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 2050-2974 (Print)
IS  - 2050-2974 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Nov 12
TI  - Likelihood of suffering from an eating disorder in a sample of Spanish cyclists
      and triathletes.
PG  - 70
LID - 10.1186/s40337-020-00350-z [doi]
AB  - BACKGROUND: During recent years, there has been increasing interest in the study 
      of eating disorders within sports practitioners, with prevalence being reported
      to be higher than in the general population. The aim of this study was to
      describe and predict eating disorders according to sex, body mass index, age and 
      sport discipline within a sample of athletes. METHODS: A sample of 4037 cyclists 
      and triathletes from across Spain was selected. Athletes self-reported
      demographic characteristics and completed the revised restraint scale, SCOFF
      questionnaire and Mediterranean diet adherence screener. To be eligible for
      inclusion, participants had to be over eighteen years old. RESULTS: Males were
      significantly less likely than females (p < 0.001; OR = 0.33), and triathletes (p
      < 0.01; OR = 0.76) were less likely than cyclists to suffer from an eating
      disorder. Possibility of suffering from an eating disorder increased with
      increasing body mass index (p < 0.001; OR = 1.38) and decreasing age (p < 0.001; 
      OR = 0.97). CONCLUSION: Findings suggest that the roles of sex, sport discipline,
      age and body mass index predict risk factors for eating disorders in a sample of 
      Spanish athletes. Clinical diagnosis seems necessary to better understand the
      factors and mechanisms at play when Spanish athletes develop an eating disorder. 
      TRIAL REGISTRATION: Ethics Committee of the University of Granada (N degrees 883)
      data: 16/11/2015.
FAU - Muros, Jose J
AU  - Muros JJ
AUID- ORCID: http://orcid.org/0000-0001-7573-0399
AD  - Department of Didactics of Corporal Expression, University of Granada, Campus
      Universitario de la Cartuja s/n, 18071, Granada, Spain. jjmuros@ugr.es.
FAU - Avila-Alche, Angela
AU  - Avila-Alche A
AD  - Department of Physical Education and Sport, University of Granada, Granada,
      Spain.
FAU - Knox, Emily
AU  - Knox E
AD  - Andalusian School of Public Health (EASP), Granada, Spain.
FAU - Zabala, Mikel
AU  - Zabala M
AD  - Department of Physical Education and Sport, University of Granada, Granada,
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - England
TA  - J Eat Disord
JT  - Journal of eating disorders
JID - 101610672
PMC - PMC7664067
OTO - NOTNLM
OT  - BMI
OT  - Diet
OT  - Eating disorders
OT  - Elite athletes
OT  - Risk factors
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:45
PHST- 2020/08/25 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/12/09 05:45 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s40337-020-00350-z [doi]
AID - 10.1186/s40337-020-00350-z [pii]
PST - epublish
SO  - J Eat Disord. 2020 Nov 12;8(1):70. doi: 10.1186/s40337-020-00350-z.


PMID- 33292450
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1710-1484 (Print)
IS  - 1710-1484 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Nov 11
TI  - Prevalence of allergic rhinitis, related comorbidities and risk factors in
      schoolchildren.
PG  - 98
LID - 10.1186/s13223-020-00495-1 [doi]
AB  - BACKGROUND: The study aimed to determine the prevalence and risk factors of
      allergic rhinitis and related comorbidities in school-age children in Budapest,
      capital of Hungary. Data and epidemiological studies on this disease are still
      limited. METHODS: A cross sectional study was conducted in 21 representative and 
      randomly selected primary schools in 2019. International Study of Asthma and
      Allergies in Childhood-based questionnaires (n = 6869) inquiring about prevalence
      and related risk factors of allergic rhinitis were distributed to all parents.
      The data were characterised with standard descriptive statistics: frequencies
      (percentages) and means for categorical and quantitative data, respectively.
      RESULTS: 3836 of the questionnaires (1857 M/1979F) were completed. The prevalence
      of current allergic rhinitis was 29.3% (1043), physician-diagnosed allergic
      rhinitis was 9.7% (373), cumulative allergic rhinitis was 36.2% (1289) and
      current allergic rhinoconjunctivitis was 16.2% (577). The presence of physician
      diagnosed atopic disease-asthma (p < 0.0001, OR = 4.398, 95% CI 3.356-5.807),
      food allergy (p < 0.0001, OR = 2.594, 95% CI 1.995-3.378), and eczema (p <
      0.0001, OR = 1.899, 95% CI 1.568-2.300)-were significantly related to an
      increased risk of cumulative allergic rhinitis. Significant factors associated
      with allergic rhinitis include male gender (p < 0.0001), family history of atopy 
      (p < 0.0001), frequent upper respiratory tract infections (p < 0.0001),
      tonsillectomy (p = 0.0054), antibiotics given in the first year of life (p <
      0.0001), paracetamol given in the first year of life (p = 0.0038), long-lasting
      common infections caused by viruses and/or bacteria before the appearance of the 
      allergy (p < 0.0001), consumption of drinks containing preservatives or
      colourants (p = 0.0023), duration of living in Budapest (p = 0.0386), smoking at 
      home (p = 0.0218), smoking at home in the first year of life (p = 0.0048), birds 
      at home (p = 0.0119), birds at home in the first year of life (p = 0.0052),
      visible mould in the bedroom (p = 0.0139), featherbedding (p = 0.0126), frequent 
      or constant heavy-vehicle traffic (p = 0.0039), living in a weedy area (p <
      0.0001) and living in the vicinity of an air-polluting factory or mine (p =
      0.0128). CONCLUSIONS: The prevalence of allergic rhinoconjunctivitis in
      6-12-year-old children in Budapest is higher than reported for most of the
      surrounding European countries. While asthma (OR = 4.398) is the most significant
      comorbidity, environmental factors such as birds at home in the first year of
      life (OR = 2.394) and living in a weedy area (OR = 1.640) seem to be the most
      important factors associated with AR. Strategies for preventive measures should
      be implemented. TRIAL REGISTRATION NUMBER: KUT-19/2019. The study was approved by
      the Ethics Committee at Heim Pal National Pediatric Institute.
FAU - Sultesz, Monika
AU  - Sultesz M
AD  - Department of Oto-Rhino-Laryngology, Heim Pal National Pediatric Institute, 86.
      Ulloi street, Budapest, 1089, Hungary.
FAU - Horvath, Alpar
AU  - Horvath A
AD  - Pest County Pulmonology Hospital, 70. Munkacsy Mihaly Street, Torokbalint, 2045, 
      Hungary.
AD  - Medical Department of Chiesi Hungary Ltd, 2. Dunavirag street, Budapest, 1138,
      Hungary.
FAU - Molnar, David
AU  - Molnar D
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Medical Centre,
      Hungarian Defence Forces, 109-111. Podmaniczky street, Budapest, 1062, Hungary.
AD  - Department of Anatomy, Histology and Embryology, Semmelweis University, 58
      Tuzolto street, Budapest, 1085, Hungary.
FAU - Katona, Gabor
AU  - Katona G
AD  - Department of Oto-Rhino-Laryngology, Heim Pal National Pediatric Institute, 86.
      Ulloi street, Budapest, 1089, Hungary.
FAU - Mezei, Gyorgyi
AU  - Mezei G
AUID- ORCID: http://orcid.org/0000-0002-6557-8650
AD  - Division of Allergo-Pulmonology, 1st Department of Paediatrics, Semmelweis
      University, 53-54 Bokay Janos street, Budapest, 1083, Hungary.
      mezei.gyorgyi@med.semmelweis-univ.hu.
FAU - Hirschberg, Andor
AU  - Hirschberg A
AD  - Department of Oto-Rhino-Laryngology and Maxillo-Facial Surgery, Saint John's
      Hospital, 1-3. Dios arok, Budapest, 1125, Hungary.
FAU - Galffy, Gabriella
AU  - Galffy G
AD  - Pest County Pulmonology Hospital, 70. Munkacsy Mihaly Street, Torokbalint, 2045, 
      Hungary.
AD  - Department of Thoracic Surgery, Semmelweis University, 7-9 Rath Gyorgy street,
      Budapest, 1122, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20201111
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC7661153
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Budapest
OT  - ISAAC
OT  - Prevalence
OT  - Related atopic diseases
OT  - Risk factors
OT  - Schoolchildren
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:44
PHST- 2020/07/16 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/12/09 05:44 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s13223-020-00495-1 [doi]
AID - 10.1186/s13223-020-00495-1 [pii]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2020 Nov 11;16(1):98. doi:
      10.1186/s13223-020-00495-1.


PMID- 33292441
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Nov 4
TI  - Preparing humanitarians to address ethical problems.
PG  - 72
LID - 10.1186/s13031-020-00319-4 [doi]
AB  - Infectious disease outbreaks represent potentially catastrophic threats to those 
      affected by humanitarian crises. High transmissibility, crowded living
      conditions, widespread co-morbidities, and a lack of intensive care capacity may 
      amplify the effects of the outbreak on already vulnerable populations and present
      humanitarian actors with intense ethical problems. We argue that there are
      significant and troubling gaps in ethical awareness at the level of humanitarian 
      praxis. Though some ethical guidance does exist most of it is directed at public 
      health experts and fails to speak to the day-to-day ethical challenges confronted
      by frontline humanitarians. In responding to infectious disease outbreaks
      humanitarian workers are likely to grapple with complex dilemmas opening the door
      to moral distress and burnout.
FAU - McGowan, Catherine R
AU  - McGowan CR
AUID- ORCID: http://orcid.org/0000-0001-6941-6539
AD  - Humanitarian Public Health Technical Unit, Save the Children UK, 1 St John's
      Lane, London, EC1M 4AR, UK. c.mcgowan@savethechildren.org.uk.
AD  - Department of Public Health, Environments & Society, London School of Hygiene &
      Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK.
      c.mcgowan@savethechildren.org.uk.
FAU - Baxter, Louisa
AU  - Baxter L
AD  - Humanitarian Public Health Technical Unit, Save the Children UK, 1 St John's
      Lane, London, EC1M 4AR, UK.
FAU - DuBois, Marc
AU  - DuBois M
AD  - Department of Development Studies, SOAS University of London, 10 Thornhaugh
      Street, Russell Square, London, WC1H 0XG, UK.
FAU - Sheather, Julian
AU  - Sheather J
AD  - Medecins Sans Frontieres/Doctors Without Borders (MSF), Lower Ground Floor,
      Chancery Exchange, 10 Furnival Street, London, EC4A 1AB, UK.
FAU - Khondaker, Ruma
AU  - Khondaker R
AD  - Mental Health and Psychosocial Support, Save the Children Bangladesh, Rohingya
      Response, Cox's Bazaar, Bangladesh.
FAU - Cummings, Rachael
AU  - Cummings R
AD  - Humanitarian Public Health Technical Unit, Save the Children UK, 1 St John's
      Lane, London, EC1M 4AR, UK.
FAU - Watkins, Kevin
AU  - Watkins K
AD  - Chief Executive Officer, Save the Children UK, 1 St John's Lane, London, EC1M
      4AR, UK.
LA  - eng
PT  - Letter
DEP - 20201104
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7610160
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:44
PHST- 2020/07/31 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/12/09 05:44 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s13031-020-00319-4 [doi]
AID - 10.1186/s13031-020-00319-4 [pii]
PST - epublish
SO  - Confl Health. 2020 Nov 4;14(1):72. doi: 10.1186/s13031-020-00319-4.


PMID- 33292437
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1710-1484 (Print)
IS  - 1710-1484 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Nov 2
TI  - A single centre retrospective study of systemic reactions to subcutaneous
      immunotherapy.
PG  - 93
LID - 10.1186/s13223-020-00491-5 [doi]
AB  - BACKGROUND: Subcutaneous immunotherapy (SCIT) is the standard approach for
      treating patients with sensitizations to aeroallergens. However, immunotherapy
      can trigger severe systemic reactions if delivered inappropriately or to high
      risk patients. We sought to characterize and quantify SCIT systemic reactions
      requiring epinephrine administration during a 6-year period in a Canadian setting
      following the recommendations for components and dosages published in the 2010
      Canadian Society of Allergy and Clinical Immunology (CSACI) Immunotherapy Manual.
      METHODS: A single centre retrospective chart review was performed for all
      patients with systemic reactions to subcutaneous immunotherapy requiring
      intramuscular epinephrine injection between January 2011 and October 2017. Each
      systemic reaction requiring epinephrine was reviewed for baseline patient
      characteristics, details of the reaction, and reaction severity. Research ethics 
      approval was obtained through McMaster University. RESULTS: 28 of 380 patients
      experienced a systemic reaction requiring epinephrine administration, with an
      incidence rate of 1 per 1,047 injection visits (0.095%). 26 of the 28 reactions
      occurred within the mandatory 30-minute observation period post allergen
      immunotherapy. Of the 28 patients that experienced a systemic reaction to SCIT,
      11 patients had asthma and 5 patients had a history of possible food allergy. All
      of the systemic reactions occurred during injections from vial number 4, and five
      patients reacted to their first shot of a re-ordered extract. 10 of the 28
      patients required more than one intramuscular injection of epinephrine, and 20 of
      28 patients were transferred to the hospital by ambulance. CONCLUSIONS: This is
      the first Canadian study to review patients with systemic reactions to
      subcutaneous immunotherapy. Several best practice methods were employed
      throughout the study to optimize subcutaneous delivery of immunotherapy extract, 
      and our recorded per injection incidence rate for systemic reactions was
      comparable or below the rate published in similar studies. The recommendations in
      the CSACI Immunotherapy Manual provide an approach to standardizing prescriptions
      for SCIT to maximize immunotherapy efficacy and reduce the risk of systemic
      reactions, though similar studies in larger multicenter settings are needed to
      confirm these observations. These observations provide important objective
      information to clinicians about the potential risks for systemic reactions in
      patients considering SCIT.
FAU - Robertson, Kara
AU  - Robertson K
AD  - Clinical Immunology and Allergy, Department of Medicine, St. Joseph's Hospital,
      Western University, 268 Grosvenor Street, London, ON, N6A 4V2, Canada.
      kararobertson@dal.ca.
FAU - Montazeri, Nazanin
AU  - Montazeri N
AD  - Clinical Immunology and Allergy, Department of Medicine, St. Joseph's Hospital,
      Western University, 268 Grosvenor Street, London, ON, N6A 4V2, Canada.
FAU - Shelke, Urvashi
AU  - Shelke U
AD  - Department of Sociology and Legal Studies, Faculty of Arts, University of
      Waterloo, 200 University Avenue West, Waterloo, ON, N2L 3G1, Canada.
FAU - Jeimy, Samira
AU  - Jeimy S
AD  - Clinical Immunology and Allergy, Department of Medicine, St. Joseph's Hospital,
      Western University, 268 Grosvenor Street, London, ON, N6A 4V2, Canada.
FAU - Kim, Harold
AU  - Kim H
AD  - Clinical Immunology and Allergy, Department of Medicine, St. Joseph's Hospital,
      Western University, 268 Grosvenor Street, London, ON, N6A 4V2, Canada.
AD  - Division of Clinical Immunology & Allergy, Department of Medicine, McMaster
      University, Belgage Medical Arts Centre Suite 205, 525 Belmont Avenue West,
      Kitchener, ON, N2M 5E2, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC7607692
OTO - NOTNLM
OT  - Aeroallergen
OT  - Allergic rhinitis
OT  - Anaphylaxis
OT  - Epinephrine
OT  - SCIT
OT  - Subcutaneous immunotherapy
OT  - Systemic reaction
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:44
PHST- 2020/06/16 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/12/09 05:44 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s13223-020-00491-5 [doi]
AID - 10.1186/s13223-020-00491-5 [pii]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2020 Nov 2;16(1):93. doi:
      10.1186/s13223-020-00491-5.


PMID- 33292430
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Nov 5
TI  - Health-related articles on Syria before and after the start of armed conflict: a 
      scoping review for The Lancet-American University of Beirut Commission on Syria.
PG  - 73
LID - 10.1186/s13031-020-00316-7 [doi]
AB  - INTRODUCTION: Armed conflict may influence the size and scope of research in Arab
      countries. We aimed to assess the impact of the 2011 Syrian conflict on health
      articles about Syria published in indexed journals. METHODS: We conducted a
      scoping review on Syrian health-related articles using seven electronic
      databases. We included clinical, biomedical, public health, or health system
      topics published between 1991 and 2017. We excluded animal studies and studies
      conducted on Syrian refugees. We used descriptive and social network analyses to 
      assess the differences in rates, types, topics of articles, and authorship before
      and after 2011, the start of the Syrian conflict. RESULTS: Of 1138 articles, 826 
      (72.6%) were published after 2011. Articles published after 2011 were less likely
      to be primary research; had a greater proportion reporting on mental health (4.6%
      vs. 10.0%), accidents and injuries (2.3% vs. 18.8%), and conflict and health
      (1.7% vs. 7.8%) (all p < 0.05); and a lower proportion reporting on child and
      maternal health (8.1 to 3.6%, p = 0.019). The proportion of research articles
      reporting no funding increased from 1.1 to 14.6% (p < 0.01). While international 
      collaborations increased over time, the number of articles with no authors
      affiliated to Syrian institutions overtook those with at least one author
      affiliation to a Syrian institution for the first time in 2015. CONCLUSION: To
      our knowledge, this is the first study to examine the impact of armed conflict on
      health scholarship in Syria. The Syrian conflict was associated with a change in 
      the rates, types, and topics of the health-related articles, and authors'
      affiliations. Our findings have implications for the prioritization of research
      funding, development of inclusive research collaborations, and promoting the
      ethics of conducting research in complex humanitarian settings.
FAU - Abdul-Khalek, Rima A
AU  - Abdul-Khalek RA
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Kayyal, Walaa
AU  - Kayyal W
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Akkawi, Abdul Rahman
AU  - Akkawi AR
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Almalla, Mohamad
AU  - Almalla M
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Arif, Khurram
AU  - Arif K
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Bou-Karroum, Lama
AU  - Bou-Karroum L
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
FAU - El-Harakeh, Amena
AU  - El-Harakeh A
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Elzalabany, Manal K
AU  - Elzalabany MK
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Fadlallah, Racha
AU  - Fadlallah R
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
FAU - Ghaddar, Fatima
AU  - Ghaddar F
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Kashlan, Danna
AU  - Kashlan D
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Kassas, Sara
AU  - Kassas S
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Khater, Tania
AU  - Khater T
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Mobayed, Nisreen
AU  - Mobayed N
AD  - Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Rahme, Dalal
AU  - Rahme D
AD  - AUB Libraries, American University of Beirut, Beirut, Lebanon.
FAU - Saifi, Omran
AU  - Saifi O
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Jabbour, Samer
AU  - Jabbour S
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - El-Jardali, Fadi
AU  - El-Jardali F
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
FAU - Akl, Elie A
AU  - Akl EA
AD  - Clinical Research Institute, American University of Beirut Medical Center,
      Beirut, Lebanon. ea32@aub.edu.lb.
FAU - Jawad, Mohammed
AU  - Jawad M
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
AD  - Public Health Policy Evaluation Unit, Imperial College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201105
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7643257
OTO - NOTNLM
OT  - Conflict
OT  - Health-related articles
OT  - Productivity
OT  - Public health
OT  - Research
OT  - Syria
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:44
PHST- 2020/01/12 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/12/09 05:44 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s13031-020-00316-7 [doi]
AID - 10.1186/s13031-020-00316-7 [pii]
PST - epublish
SO  - Confl Health. 2020 Nov 5;14(1):73. doi: 10.1186/s13031-020-00316-7.


PMID- 33292311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1477-9560 (Print)
IS  - 1477-9560 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Nov 30
TI  - Maternal mortality following thromboembolism; incidences and prophylaxis
      strategies.
PG  - 36
LID - 10.1186/s12959-020-00251-w [doi]
AB  - BACKGROUND: Thromboembolism is one of the main causes of maternal mortality,
      which can be prevented in many cases. The present study was designed to
      investigate the incidence and prophylaxis strategies for maternal mortality
      following thromboembolism in postnatal. METHODS: In this case series study, the
      data of the mortality cases were extracted according to the ethical and security 
      standards of the Ministry of Health of the country and compared with a healthy
      control group. The thromboembolism risk factors measured and scored using a
      questionnaire entitled "the evaluation of risk factors for maternal mortality
      following thromboembolism during pregnancy, labor, or post-partum". RESULTS: The 
      maternal mortality rate was 16 per 100,000 live births. Among 297 mortality
      cases, 27 (9%) death were due to thromboembolism. The mean gestational age was
      32.5 weeks. Dyspnea (88.8%) and tachycardia (18.5%) were found as common clinical
      manifestations in these patients. Sixteen cases (59.3%) did not get heparin, 6
      (22.2%) received single dose and 5 (18.5%) received two doses and more. In these 
      11 cases, 5 (45%) patients received heparin before surgery, 1 after surgery, and 
      5 before and after surgery. Twenty cases deceased in the first hours after
      delivery and the rest after 2 to 12 days. The average score of risk for
      thromboembolism based on Royal College of Obstetricians & Gynecologist (RCOG)
      guideline was 4.6. CONCLUSION: It seems that one of the most important cause of
      maternal mortality in this study was the lack of recognition of high-risk
      patients and the lack of prescription for prophylaxis with heparin and this
      clearly explains the need for accurate screening of high-risk mothers, designing 
      a standard form and the care and treatment of these patients.
FAU - Shirazi, Mahboobeh
AU  - Shirazi M
AD  - Maternal, Fetal and Neonatal Research Center, Tehran University of Medical
      Sciences, Tehran, Iran.
AD  - Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Sahebdel, Behrokh
AU  - Sahebdel B
AD  - Maternal, Fetal and Neonatal Research Center, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Torkzaban, Mahnoosh
AU  - Torkzaban M
AD  - Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
FAU - Feizabad, Elham
AU  - Feizabad E
AD  - Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Ghaemi, Marjan
AU  - Ghaemi M
AUID- ORCID: http://orcid.org/0000-0003-2306-7112
AD  - Valiasr Reproductive Health Research Center, Tehran University of Medical
      Sciences, Tehran, Iran. marjan_ghaemi@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - Thromb J
JT  - Thrombosis journal
JID - 101170542
PMC - PMC7708248
OTO - NOTNLM
OT  - Heparin
OT  - Maternal mortality
OT  - Pregnancy
OT  - Thromboembolism
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:43
PHST- 2020/08/01 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/09 05:43 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s12959-020-00251-w [doi]
AID - 10.1186/s12959-020-00251-w [pii]
PST - epublish
SO  - Thromb J. 2020 Nov 30;18(1):36. doi: 10.1186/s12959-020-00251-w.


PMID- 33292261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1753-6561 (Print)
IS  - 1753-6561 (Linking)
VI  - 14
IP  - Suppl 18
DP  - 2020 Dec 7
TI  - Proceedings from the CIH(LMU) Symposium 2020 on "eHealth: Trends and
      innovations".
PG  - 17
LID - 10.1186/s12919-020-00202-3 [doi]
AB  - Electronic Health (eHealth) is the use of information and communication
      technologies for health and plays a significant role in improving public health. 
      The rapid expansion and development of eHealth initiatives allow researchers and 
      healthcare providers to connect more effectively with patients. The aim of the
      CIH(LMU) Symposium 2020 was to discuss the current challenges facing the field,
      opportunities in eHealth implementation, to share the experiences from different 
      healthcare systems, and to discuss future trends addressing the use of digital
      platforms in health. The symposium on eHealth explored how the health and
      technology sector must increase efforts to reduce the obstacles facing public and
      private investment, the efficacy in preventing diseases and improving patient
      quality of life, and the ethical and legal frameworks that influence the proper
      development of the different platforms and initiatives related to the field. This
      symposium furthered the sharing of knowledge, networking, and patient/user and
      practitioner experiences in low- and middle-income countries (LMIC) in both
      public and private sectors.
FAU - Norena, Ivan
AU  - Norena I
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany. ivan.norena@lrz.uni-muenchen.de.
AD  - Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU
      Munich, Munich, Germany. ivan.norena@lrz.uni-muenchen.de.
FAU - Shah, Nairuti
AU  - Shah N
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
FAU - Ndenkeh, Jackson Jr
AU  - Ndenkeh J Jr
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
FAU - Hernandez, Cecilia
AU  - Hernandez C
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
FAU - Sitoe, Nadia
AU  - Sitoe N
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
AD  - Instituto Nacional de Saude, Maputo, Mozambique.
FAU - Sillah, Abdou
AU  - Sillah A
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
AD  - Medical Research Council Unit the Gambia, London School of Hygiene and Tropical
      Medicine, Fajara, The Gambia.
FAU - Shin, Anna
AU  - Shin A
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
FAU - Han, Wai Wai
AU  - Han WW
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
AD  - Department of Medical Research, Ministry of Health and Sports, Naypyidaw,
      Myanmar.
FAU - Devaera, Yoga
AU  - Devaera Y
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
FAU - Mosoba, Maureen
AU  - Mosoba M
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
FAU - Moonga, Given
AU  - Moonga G
AD  - CIHLMU Center for International Health, University Hospital, LMU Munich, Munich, 
      Germany.
AD  - Department of Epidemiology and Biostatistics, University of Zambia, Lusaka,
      Zambia.
FAU - Hendl, Tereza
AU  - Hendl T
AD  - Institute of Ethics, History, and Theory of Medicine LMU, Munich, Germany.
FAU - Wernick, Alina
AU  - Wernick A
AD  - Alexander von Humboldt Institute for Internet and Society, Berlin, Germany.
FAU - Kiberu, Vincent Micheal
AU  - Kiberu VM
AD  - Makerere University School of Public Health, Kampala, Uganda.
FAU - Menke, Melissa
AU  - Menke M
AD  - Access Afya, Nairobi, Kenya.
FAU - Guggenbuehl Noller, Jessica Michelle
AU  - Guggenbuehl Noller JM
AD  - Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU
      Munich, Munich, Germany.
FAU - Pritsch, Michael
AU  - Pritsch M
AD  - Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU
      Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201207
PL  - England
TA  - BMC Proc
JT  - BMC proceedings
JID - 101316936
PMC - PMC7720516
OTO - NOTNLM
OT  - Implementation science
OT  - Public health
OT  - Technology transfer
OT  - Universal health care
OT  - eHealth
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s12919-020-00202-3 [doi]
AID - 10.1186/s12919-020-00202-3 [pii]
PST - epublish
SO  - BMC Proc. 2020 Dec 7;14(Suppl 18):17. doi: 10.1186/s12919-020-00202-3.


PMID- 33292217
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220418
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - In defence of a single body of clinical and public health, medical ethics.
PG  - 1070
LID - 10.1186/s12913-020-05887-y [doi]
AB  - BACKGROUND: Since some form of dual clinical/public health practice is desirable,
      this paper explains why their ethics should be combined to influence medical
      practice and explores a way to achieve that. MAIN TEXT: In our attempt to merge
      clinical and public health ethics, we empirically compared the individual and
      collective health consequences of two illustrative lists of medical and public
      health ethical tenets and discussed their reciprocal relevance to praxis. The
      studied codes share four principles, namely, 1. respect for individual/collective
      rights and the patient's autonomy; 2. cultural respect and treatment that upholds
      the patient's dignity; 3. honestly informed consent; and 4. confidentiality of
      information. However, they also shed light on the strengths and deficiencies of
      each other's tenets. Designing a combined clinical and public health code
      requires fleshing out three similar principles, namely, beneficence, medical and 
      public health engagement in favour of health equality, and community and
      individual participation; and adopting three stand-alone principles, namely,
      professional excellence, non-maleficence, and scientific excellence. Finally, we 
      suggest that eco-biopsychosocial and patient-centred care delivery and dual
      clinical/public health practice should become a doctor's moral obligation. We
      propose to call ethics based on non-maleficence, beneficence, autonomy, and
      justice - the values upon which, according to Pellegrino and Thomasma, the others
      are grounded and that physicians and ethicists use to resolve ethical dilemmas - 
      "neo-Hippocratic". The neo- prefix is justified by the adjunct of a distributive 
      dimension (justice) to traditional Hippocratic ethics. CONCLUSION: Ethical codes 
      ought to be constantly updated. The above values do not escape the rule. We have 
      formulated them to feed discussions in health services and medical associations. 
      Not only are these values fragmentary and in progress, but they have no universal
      ambition: they are applicable to the dilemmas of modern Western medicine only,
      not Ayurvedic or Shamanic medicine, because each professional culture has its own
      philosophical rationale. Efforts to combine clinical and public health ethics
      whilst resolving medical dilemmas can reasonably be expected to call upon the
      physician's professional identity because they are intellectual challenges to be 
      associated with case management.
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Office de la Naissance et de l'Enfance, French Community of Belgium, Chaussee de 
      Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
FAU - Roland, Michel
AU  - Roland M
AD  - Departement de Medecine Generale, Universite Libre de Bruxelles, Route de Lennik,
      808, BP 612/1, B-1070, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Beneficence
MH  - *Ethics, Medical
MH  - Humans
MH  - Moral Obligations
MH  - *Public Health
MH  - Social Justice
PMC - PMC7723753
OTO - NOTNLM
OT  - Clinical integration
OT  - Disease control
OT  - Doctor-patient relationship
OT  - Medical ethics
OT  - Public health ethics
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05887-y [doi]
AID - 10.1186/s12913-020-05887-y [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1070. doi:
      10.1186/s12913-020-05887-y.


PMID- 33292215
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220418
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - A plea to merge clinical and public health practices: reasons and consequences.
PG  - 1068
LID - 10.1186/s12913-020-05885-0 [doi]
AB  - BACKGROUND: Revisiting professionalism, both as a medical ideal and educational
      topic, this paper asks whether, in the rise of artificial intelligence,
      healthcare commoditisation and environmental challenges, a rationale exists for
      merging clinical and public health practices. To optimize doctors' impact on
      community health, clinicians should introduce public health thinking and action
      into clinical practice, above and beyond controlling nosocomial infections and
      iatrogenesis. However, in the interest of effectiveness they should do everything
      possible to personalise care delivery. To solve this paradox, we explore why it
      is necessary for the boundaries between medicine and public health to be blurred.
      MAIN BODY: Proceeding sequentially, we derive standards for medical
      professionalism from care quality criteria, neo-Hippocratic ethics, public health
      concepts, and policy outcomes. Thereby, we formulate benchmarks for health care
      management and apply them to policy evaluation. During this process we justify
      the social, professional - and by implication, non-commercial, non-industrial -
      mission of healthcare financing and policies. The complexity of ethical,
      person-centred, biopsychosocial practice requires a human interface between
      suffering, health risks and their therapeutic solution - and thus legitimises the
      medical profession's existence. Consequently, the universal human right to
      healthcare is a right to access professionally delivered care. Its enforcement
      requires significant updating of the existing medical culture, and not just in
      respect of the man/machine interface. This will allow physicians to focus on what
      artificial intelligence cannot do, or not do well. These duties should become the
      touchstone of their practice, knowledge and ethics. Artificial intelligence must 
      support medical professionalism, not determine it. Because physicians need
      sufficient autonomy to exercise professional judgement, medical ethics will
      conflict with attempts to introduce clinical standardisation as a managerial
      paradigm, which is what happens when industrial-style management is applied to
      healthcare. CONCLUSION: Public healthcare financing and policy ought to support
      medical professionalism, alongside integrated clinical and public health
      practice, and its management. Publicly-financed health management should actively
      promote ethics in publicly- oriented services. Commercialised healthcare is
      antithetical to ethical medical, and to clinical / public health practice
      integration. To lobby governments effectively, physicians need to appreciate the 
      political economy of care.
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Office de la Naissance et de l'Enfance, French Community of Belgium, Chaussee de 
      Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
FAU - Roland, Michel
AU  - Roland M
AD  - Departement de Medecine Generale, Universite Libre de Bruxelles, Route de Lennik,
      808, BP 612/1, B-1070, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - *Artificial Intelligence
MH  - Delivery of Health Care
MH  - Ethics, Medical
MH  - *Health Services Administration
MH  - Humans
MH  - Public Health Practice
PMC - PMC7725113
OTO - NOTNLM
OT  - Health management
OT  - Health policy
OT  - Medical education
OT  - Medical professionalism
OT  - Public health
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05885-0 [doi]
AID - 10.1186/s12913-020-05885-0 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1068. doi:
      10.1186/s12913-020-05885-0.


PMID- 33292212
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220418
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - Objectives, methods, and results in critical health systems and policy research: 
      evaluating the healthcare market.
PG  - 1072
LID - 10.1186/s12913-020-05889-w [doi]
AB  - BACKGROUND: Since the 1980s, markets have turned increasingly to intangible goods
      - healthcare, education, the arts, and justice. Over 40 years, the authors
      investigated healthcare commoditisation to produce policy knowledge relevant to
      patients, physicians, health professionals, and taxpayers. This paper revisits
      their objectives, methods, and results to enlighten healthcare policy design and 
      research. MAIN TEXT: This paper meta-analyses the authors' research that
      evaluated the markets impact on healthcare and professional culture and
      investigated how they influenced patients' timely access to quality care and
      physicians' working conditions. Based on these findings, they explored the
      political economic of healthcare. In low-income countries the analysed research
      showed that, through loans and cooperation, multilateral agencies restricted the 
      function of public services to disease control, with subsequent catastrophic
      reductions in access to care, health de-medicalisation, increased avoidable
      mortality, and failure to attain the narrow MDGs in Africa. The pro-market
      reforms enacted in middle-income countries entailed the purchaser-provider split,
      privatisation of healthcare pre-financing, and government contracting of health
      finance management to private insurance companies. To establish the materiality
      of a cause-and-effect relationship, the authors compared the efficiency of Latin 
      American national health systems according to whether or not they were pro-market
      and complied with international policy standards. While pro-market health
      economists acknowledge that no market can offer equitable access to healthcare
      without effective regulation and control, the authors showed that both regulation
      and control were severely constrained in Asia by governance and medical secrecy
      issues. In high-income countries they questioned the interest for population
      health of healthcare insurance companies, whilst comparing access to care and
      health expenditures in the European Union vs. the U.S., the Netherlands, and
      Switzerland. They demonstrated that commoditising healthcare increases mortality 
      and suffering amenable to care considerably and carries professional, cultural,
      and ethical risks for doctors and health professionals. Pro-market policies
      systems cause health systems inefficiency, inequity in access to care and strain 
      professionals' ethics. CONCLUSION: Policy research methodologies benefit from
      being inductive, as health services and systems evaluations, and population
      health studies are prerequisites to challenge official discourse and to explore
      the historical, economic, sociocultural, and political determinants of public
      policies.
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Medical Director, Office de la Naissance et de l'Enfance, French Community of
      Belgium, Chaussee de Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Africa
MH  - Asia
MH  - *Health Care Sector
MH  - *Health Policy
MH  - Humans
MH  - Netherlands
MH  - Switzerland
PMC - PMC7724781
OTO - NOTNLM
OT  - Health policy
OT  - Health systems research
OT  - Research methodology
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05889-w [doi]
AID - 10.1186/s12913-020-05889-w [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1072. doi:
      10.1186/s12913-020-05889-w.


PMID- 33292211
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220418
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - Integrating clinical and public health knowledge in support of joint medical
      practice.
PG  - 1073
LID - 10.1186/s12913-020-05886-z [doi]
AB  - BACKGROUND: Strong relations between medicine and public health have long been
      advocated. Today, professional medical practice assumes joint clinical/public
      health objectives: GPs are expected to practice community medicine; Hospital
      specialists can be involved in disease control and health service organisation;
      Doctors can teach, coach, evaluate, and coordinate care; Clinicians should
      interpret protocols with reference to clinical epidemiology. Public health
      physicians should tailor preventive medicine to individual health risks. This
      paper is targeted at those practitioners and academics responsible for their
      teams' professionalism and the accessibility of care, where the authors argue in 
      favour of the epistemological integration of clinical medicine and public health.
      MAIN TEXT: Based on empirical evidence the authors revisit the epistemological
      border of clinical and public health knowledge to support joint practice. From
      action-research and cognitive psychology, we derive clinical/public health
      knowledge categories that require different transmission and discovery
      techniques. The knowledge needed to support the universal human right to access
      professional care bridges both clinical and public health concepts, and summons
      professional ethics to validate medical decisions. To provide a rational
      framework for teaching and research, we propose the following categories:
      'Know-how/practice techniques', corresponding a.o. to behavioural, communication,
      and manual skills; 'Procedural knowledge' to choose and apply procedures that
      meet explicit quality criteria; 'Practical knowledge' to design new procedures
      and inform the design of established procedures in new contexts; and Theoretical 
      knowledge teaches the reasoning and theory of knowledge and the laws of existence
      and functioning of reality to validate clinical and public health procedures.
      Even though medical interventions benefit from science, they are, in essence,
      professional: science cannot standardise eco-biopsychosocial decisions;
      doctor-patient negotiations; emotional intelligence; manual and behavioural
      skills; and resolution of ethical conflicts. CONCLUSION: Because the quality of
      care utilises the professionals' skill-base but is also affected by their
      intangible motivations, health systems should individually tailor continuing
      medical education and treat collective knowledge management as a priority.
      Teamwork and coaching by those with more experience provide such opportunities.
      In the future, physicians and health professionals could jointly develop
      clinical/public health integrated knowledge. To this end, governments should make
      provision to finance non-clinical activities.
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Office de la Naissance et de l'Enfance, French Community of Belgium, Chaussee de 
      Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
FAU - Roland, Michel
AU  - Roland M
AD  - Departement de Medecine Generale, Universite Libre de Bruxelles, Route de Lennik,
      808, BP 612/1, B-1070, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Health Personnel
MH  - Humans
MH  - *Knowledge
MH  - Physician-Patient Relations
MH  - Professional Practice
MH  - *Public Health
PMC - PMC7724788
OTO - NOTNLM
OT  - Health epistemology
OT  - Health management
OT  - Health policy
OT  - Medical and public health practice
OT  - Medical education
OT  - Medical research
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05886-z [doi]
AID - 10.1186/s12913-020-05886-z [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1073. doi:
      10.1186/s12913-020-05886-z.


PMID- 33292206
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - Medical heuristics and action-research: professionalism versus science.
PG  - 1071
LID - 10.1186/s12913-020-05888-x [doi]
AB  - BACKGROUND: Professional knowledge aims at improving practice. It reduces
      uncertainty in decision-making, improves effectiveness in action and relevance in
      evaluation, stimulates reflexivity, and subjects practice to ethical standards.
      Heuristics is an approach to problem-solving, learning, and discovery employing a
      practical methodology that, although not optimal, is sufficient for achieving
      immediate goals. This article identifies the desirable, heuristic particularities
      of research in professional, medical practice; and it identifies what
      distinguishes this research from scientific research. MAIN TEXT: We examine the
      limits of biomedical and sociological research to produce professional knowledge.
      Then, we derive the heuristic characteristics of professional research from a
      meta-analysis of two action-research projects aimed at securing access to
      essential generic drugs in Senegal and improving physicians' self-assessment and 
      healthcare coordination in Belgium. To study healthcare, biomedical sciences
      ignore how clinical decisions are implemented. Decisions are built into an
      articulated knowledge system, such as (clinical) epidemiology, where those
      studied are standardisable - while taking care of patients is an idiosyncratic,
      value-based, person-to-person process that largely eludes probabilistic
      methodologies. Social sciences also reach their limits here because descriptive, 
      interpretative methods cannot help with gesture and speech quality, while the
      management of the patient's suffering and risks makes each of them unique.
      Research into medical professionalism is normative as it is intended to formulate
      recommendations. Scientific data and descriptions are useful to the practitioner 
      randomly, only from the similarities in the environment of the authors and their 
      readers. Such recommendations can be conceived of as strategies, i.e.,
      multi-resource and multi-stage action models to improve clinical and public
      health practice. Action learning and action-research are needed to design and
      implement these strategies, because their complexity implies trial and error. To 
      validate a strategy, repeated experiences are needed. Its reproducibility assumes
      the description of the context. To participate in medical action-research, the
      investigator needs professional proficiency - a frequent difficulty in academic
      settings. CONCLUSION: Some criteria to assess the relevance of publicly funded
      clinical and public health research can be derived from the difference between
      scientific and professional knowledge, i.e. the knowledge gained with real-life
      experience in the field.
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Office de la Naissance et de l'Enfance, French Community of Belgium, Chaussee de 
      Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Belgium
MH  - *Heuristics
MH  - Humans
MH  - *Professionalism
MH  - Reproducibility of Results
MH  - Senegal
PMC - PMC7724783
OTO - NOTNLM
OT  - Action-research
OT  - Health management science
OT  - Health systems
OT  - Medical knowledge
OT  - Operation research
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05888-x [doi]
AID - 10.1186/s12913-020-05888-x [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1071. doi:
      10.1186/s12913-020-05888-x.


PMID- 33292200
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Dec 8
TI  - The use of induced pluripotent stem cells in domestic animals: a narrative
      review.
PG  - 477
LID - 10.1186/s12917-020-02696-7 [doi]
AB  - Induced pluripotent stem cells (iPSCs) are undifferentiated stem cells
      characterized by the ability to differentiate into any cell type in the body.
      iPSCs are a relatively new and rapidly developing technology in many fields of
      biology, including developmental anatomy and physiology, pathology, and
      toxicology. These cells have great potential in research as they are
      self-renewing and pluripotent with minimal ethical concerns. Protocols for their 
      production have been developed for many domestic animal species, which have since
      been used to further our knowledge in the progression and treatment of diseases. 
      This research is valuable both for veterinary medicine as well as for the
      prospect of translation to human medicine. Safety, cost, and feasibility are
      potential barriers for this technology that must be considered before widespread 
      clinical adoption. This review will analyze the literature pertaining to iPSCs
      derived from various domestic species with a focus on iPSC production and
      characterization, applications for tissue and disease research, and applications 
      for disease treatment.
FAU - Scarfone, Rachel A
AU  - Scarfone RA
AUID- ORCID: http://orcid.org/0000-0002-5985-4874
AD  - Department of Biomedical Sciences, Ontario Veterinary College, University of
      Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada.
FAU - Pena, Samantha M
AU  - Pena SM
AD  - Department of Biomedical Sciences, Ontario Veterinary College, University of
      Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada.
FAU - Russell, Keith A
AU  - Russell KA
AD  - Department of Biomedical Sciences, Ontario Veterinary College, University of
      Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada.
FAU - Betts, Dean H
AU  - Betts DH
AD  - Department of Physiology and Pharmacology, The University of Western Ontario,
      London, Ontario, N6A 5C1, Canada.
FAU - Koch, Thomas G
AU  - Koch TG
AD  - Department of Biomedical Sciences, Ontario Veterinary College, University of
      Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada. tkoch@uoguelph.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201208
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
SB  - IM
MH  - Animals
MH  - Animals, Domestic
MH  - Cell Culture Techniques/methods/veterinary
MH  - *Cell Differentiation
MH  - Induced Pluripotent Stem Cells/*cytology/physiology
MH  - Regenerative Medicine/methods
MH  - Veterinary Medicine/methods
PMC - PMC7722595
OTO - NOTNLM
OT  - Characterization
OT  - Disease modelling
OT  - Disease treatment
OT  - Domestic species
OT  - Induced pluripotent stem cells
OT  - Production
OT  - Veterinary medicine
EDAT- 2020/12/10 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/07/02 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
AID - 10.1186/s12917-020-02696-7 [doi]
AID - 10.1186/s12917-020-02696-7 [pii]
PST - epublish
SO  - BMC Vet Res. 2020 Dec 8;16(1):477. doi: 10.1186/s12917-020-02696-7.


PMID- 33292193
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220418
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - Neo-Hippocratic healthcare policies: professional or industrial healthcare
      delivery? A choice for doctors, patients, and their organisations.
PG  - 1067
LID - 10.1186/s12913-020-05890-3 [doi]
AB  - BACKGROUND: Ethical medical practice requires managing health services to promote
      professionalism and secure accessibility to care. Commercially financed and
      industrially managed services strain the physicians' clinical autonomy and ethics
      because the industry's profitability depends on commercial, clinical
      standardisation. Private insurance companies also reduce access to care whilst
      fragmenting and segmenting health systems. Against this background, given the
      powerful, symbolic significance of their common voice, physicians' and patients' 
      organisations could effectively leverage together political parties and
      employers' organisations to promote policies favouring access to professional
      care. MAIN TEXT: To provide a foundation for negotiations between physicians' and
      patients' organisations, we propose policy principles derived from an analysis of
      rights-holders and duty-bearers' stakes, i.e., patients, physicians and health
      professionals, and taxpayers. Their concerns are scrutinised from the standpoints
      of public health and right to health. Illustrated with post-WWII European
      policies, these principles are formulated as inputs for tentative
      action-research. The paper also identifies potential stumbling blocks for
      collective doctor/patient negotiations based on the authors' personal experience.
      The patients' concerns are care accessibility, quality, and price. Those of
      physicians and other professionals are problem-solving capacity, autonomy,
      intellectual progress, ethics, work environment, and revenue. The majority of
      taxpayers have an interest in taxes being progressive and public spending on
      health regressive. Mutual aid associations tend to under-estimate the physician's
      role in delivering care. Physicians' organisations often disregard the mission of
      financing care and its impact on healthcare quality. CONCLUSION: The proposed
      physicians-patients' alliance could promote policies in tune with professional
      ethics, prevent European policies' putting industrial concerns above suffering
      and death, bar care financing from the ambit of international trade treaties, and
      foster international cooperation policies consistent with the principles that
      inspire the design of healthcare policies at home and so reduce international
      migration. To be credible partners in this alliance, physicians' associations
      should promote a public health culture amongst their members and a team culture
      in healthcare services. To promote a universal health system, patients'
      organisations should strive to represent universal health interests rather than
      those of patients with specific diseases, ethnic groups, or social classes.
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Office de la Naissance et de l'Enfance, French Community of Belgium, Chaussee de 
      Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
FAU - Roland, Michel
AU  - Roland M
AD  - Departement de Medecine Generale, Universite Libre de Bruxelles, Route de Lennik,
      808, BP 612/1, B-1070, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - *Commerce
MH  - Health Policy
MH  - Humans
MH  - Internationality
MH  - Physician-Patient Relations
MH  - *Physicians
PMC - PMC7724692
OTO - NOTNLM
OT  - Health policy
OT  - Health systems
OT  - Healthcare accessibility
OT  - Medical professionalism
OT  - Non-profit health organisations
OT  - Public services
OT  - Quality of health care
EDAT- 2020/12/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05890-3 [doi]
AID - 10.1186/s12913-020-05890-3 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1067. doi:
      10.1186/s12913-020-05890-3.


PMID- 33292181
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Nov 30
TI  - The effect of ethical leadership on subjective wellbeing, given the moderator job
      satisfaction (a case study of private hospitals in Mashhad).
PG  - 111
LID - 10.1186/s12912-020-00496-w [doi]
AB  - BACKGROUND: The emerging ethical leadership, a unique approach in leadership
      viewpoint, has provided the ground for constructing and advancing individual and 
      managerial efficiency by highlighting ethics in organizations. The present study 
      aims to investigate the influence of Ethical Leadership on Subjective Wellbeing, 
      Given the Moderator Job Satisfaction in Private Hospitals in Mashhad. METHODS:
      This descriptive-correlational research design stud was conducted in 2015-2016 to
      inspect the possible effect of ethical leadership on subjective wellbeing and job
      satisfaction, as dependent and mediator variables, among the Iranian private
      hospitals' nurses in Mashhad. Simple random sampling method was used to select
      the sample of 166 nurses out of the population of 730 nurses, in total. The valid
      and reliable adapted version of the questionnaire designed by Yang (2014) was
      used to collect the data, and structural equation modeling (SEM) was used to
      analyze the data set. RESULTS: The results showed that there is a positive
      significant correlation between ethical leadership and job satisfaction. More
      specifically, the findings indicated that Ethical leadership affected the
      subjective wellbeing of nurses through job satisfaction both directly and
      indirectly. CONCLUSIONS: The findings illustrated that focus on ethics and
      ethically-oriented leaders in hospitals, enriched by job satisfaction can lead to
      the nurses' subjective wellbeing by providing them a positive climate.
FAU - Kaffashpoor, Azar
AU  - Kaffashpoor A
AUID- ORCID: http://orcid.org/0000-0003-3539-855X
AD  - Management Department, Faculty of Economics and Administrative Sciences, Ferdowsi
      University of Mashhad, Mashhad, Iran. kafashpor@um.ac.ir.
FAU - Sadeghian, Samaneh
AU  - Sadeghian S
AD  - Department of Management, Tabaran Institute of Higher Education, Mashhad, Iran.
LA  - eng
GR  - 52087/Ferdowsi University of Mashhad (IR)
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7708090
OTO - NOTNLM
OT  - Ethical leadership
OT  - Job satisfaction
OT  - Organizational performance
OT  - Subjective wellbeing (SWB)
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:42
PHST- 2020/03/03 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s12912-020-00496-w [doi]
AID - 10.1186/s12912-020-00496-w [pii]
PST - epublish
SO  - BMC Nurs. 2020 Nov 30;19(1):111. doi: 10.1186/s12912-020-00496-w.


PMID- 33292178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210219
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - Suppl 2
DP  - 2020 Dec 9
TI  - The physician and professionalism today: challenges to and strategies for ethical
      professional medical practice.
PG  - 1069
LID - 10.1186/s12913-020-05884-1 [doi]
FAU - Unger, Jean-Pierre
AU  - Unger JP
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium. jeanpierre.unger@gmail.com.
FAU - Morales, Ingrid
AU  - Morales I
AD  - Office de la Naissance et de l'Enfance, French Community of Belgium, Chaussee de 
      Charleroi 95, B-1060, Brussels, Belgium.
FAU - De Paepe, Pierre
AU  - De Paepe P
AD  - Department of Public Health, Institute of Tropical Medicine, Nationalestraat 155,
      B-2000, Antwerp, Belgium.
FAU - Roland, Michel
AU  - Roland M
AD  - Departement de Medecine Generale, Universite Libre de Bruxelles, Route de Lennik,
      808, BP 612/1, B-1070, Brussels, Belgium.
LA  - eng
PT  - Editorial
DEP - 20201209
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
PMC - PMC7723462
OTO - NOTNLM
OT  - *Health management
OT  - *Health policy
OT  - *Medical education
OT  - *Medical professionalism
OT  - *Medical research
OT  - *Public health
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 05:42
PHST- 2020/12/09 05:42 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - 10.1186/s12913-020-05884-1 [doi]
AID - 10.1186/s12913-020-05884-1 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 9;20(Suppl 2):1069. doi:
      10.1186/s12913-020-05884-1.


PMID- 33291805
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201226
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - The Role of Genetic Selection on Agonistic Behavior and Welfare of Gestating Sows
      Housed in Large Semi-Static Groups.
LID - E2299 [pii]
LID - 10.3390/ani10122299 [doi]
AB  - Confinement of gestating sows is becoming banished in favor of group-housing in
      countries worldwide, forcing breeding companies to develop genetic lines adapted 
      for social living. This study aimed at assessing the influence of two genetic
      lines selected for high performance (HP1, HP2, derived from Landrace x Yorkshire)
      on welfare and reproductive performance of sows housed in large semi-static
      groups (20 groups of 46-91 animals) across several parities. To address this,
      agonistic behaviors were recorded on d0, d2, d27, and d29 post-mixing while body 
      lesions were scored on d1, d26, and d84. Sows' individual and reproductive
      performances were also recorded. HP2 sows were more aggressive than HP1 sows
      since they fought (p = 0.028) and bullied (p = 0.0009) pen-mates more frequently 
      on d0-d2. HP2 sows had more total body lesions throughout gestation than HP1 sows
      at higher parities (p < 0.0001). Regarding reproductive performance, HP2 sows
      lost less piglets (p < 0.0001) and tended to wean more piglets (p = 0.067) than
      HP1 sows. In conclusion, while HP2 sows were the most aggressive, HP1 sows had
      piglets with lower survivability, which raises ethical issues in both cases and
      points to the need of considering social aspects when developing genetic lines
      for group-housing.
FAU - Brajon, Sophie
AU  - Brajon S
AD  - Department of Animal Science, Faculty of Agriculture and Food Sciences, Laval
      University, 2425 Rue de l'Agriculture Bureau 1122, Quebec, QC G1V 0A6, Canada.
FAU - Ahloy-Dallaire, Jamie
AU  - Ahloy-Dallaire J
AUID- ORCID: 0000-0001-6515-4009
AD  - Department of Animal Science, Faculty of Agriculture and Food Sciences, Laval
      University, 2425 Rue de l'Agriculture Bureau 1122, Quebec, QC G1V 0A6, Canada.
FAU - Devillers, Nicolas
AU  - Devillers N
AUID- ORCID: 0000-0002-5866-9394
AD  - Sherbrooke Research and Development Centre, Agriculture and Agri-Food Canada,
      2000 College Street, Sherbrooke, QC J1M 0C8, Canada.
FAU - Guay, Frederic
AU  - Guay F
AD  - Department of Animal Science, Faculty of Agriculture and Food Sciences, Laval
      University, 2425 Rue de l'Agriculture Bureau 1122, Quebec, QC G1V 0A6, Canada.
LA  - eng
GR  - IT12933/Mitacs
GR  - IT12933/Agri-Marche
PT  - Journal Article
DEP - 20201204
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7762012
OTO - NOTNLM
OT  - Sus scrofa
OT  - aggression
OT  - body lesion
OT  - genetic line
OT  - group-housing
OT  - pig industry
OT  - productivity
OT  - social relationships
OT  - swine
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
CRDT- 2020/12/09 01:02
PHST- 2020/10/19 00:00 [received]
PHST- 2020/11/26 00:00 [revised]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/09 01:02 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
AID - ani10122299 [pii]
AID - 10.3390/ani10122299 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Dec 4;10(12). pii: ani10122299. doi: 10.3390/ani10122299.


PMID- 33290245
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 18
TI  - Using the Online Psychotherapy Tool to Address Mental Health Problems in the
      Context of the COVID-19 Pandemic: Protocol for an Electronically Delivered
      Cognitive Behavioral Therapy Program.
PG  - e24913
LID - 10.2196/24913 [doi]
AB  - BACKGROUND: The considerable rise of mental health challenges during the COVID-19
      pandemic has had detrimental effects on the public health sector and economy. To 
      meet the overwhelming and growing demand for mental health care, innovative
      approaches must be employed to significantly expand mental health care delivery
      capacity. Although it is not feasible to increase the number of mental health
      care providers or hours they work in the short term, improving their time
      efficiency may be a viable solution. Virtually and digitally delivering
      psychotherapy, which has been shown to be efficient and clinically effective,
      might be a good method for addressing this growing demand. OBJECTIVE: This
      research protocol aims to evaluate the feasibility and efficacy of using an
      online, digital, asynchronous care model to treat mental health issues that are
      started or aggravated by stressors associated with the COVID-19 pandemic.
      METHODS: This nonrandomized controlled trial intervention will be delivered
      through the Online Psychotherapy Tool, a secure, cloud-based, digital mental
      health platform. Participants will be offered a 9-week electronically delivered
      cognitive behavioral therapy program that is tailored to address mental health
      problems in the context of the COVID-19 pandemic. This program will involve
      weekly self-guided educational material that provides an overview of behavioral
      skills and weekly homework. Participants (N=80) will receive personalized
      feedback from and weekly interaction with a therapist throughout the course of
      the program. The efficacy of the program will be evaluated using clinically
      validated symptomology questionnaires, which are to be completed by participants 
      at baseline, week 5, and posttreatment. Inclusion criteria includes the capacity 
      to consent; a primary diagnosis of generalized anxiety disorder or major
      depressive disorder, with symptoms that started or worsened during the COVID-19
      pandemic; the ability to speak and read English; and consistent and reliable
      access to the internet. Exclusion criteria includes active psychosis, acute
      mania, severe alcohol or substance use disorder, and active suicidal or homicidal
      ideation. RESULTS: This study received funding in May 2020. Ethics approval was
      received in June 2020. The recruitment of participants began in June 2020.
      Participant recruitment is being conducted via social media, web-based
      communities, and physician referrals. To date, 58 participants have been
      recruited (intervention group: n=35; control group: n=23). Data collection is
      expected to conclude by the end of 2020. Analyses (ie, linear regression analysis
      for continuous outcomes and binomial regression analysis for categorical
      outcomes) are expected to be completed by February 2021. CONCLUSIONS: If proven
      feasible, this care delivery method could increase care capacity by up to
      fourfold. The findings from this study can potentially influence clinical
      practices and policies and increase accessibility to care during the COVID-19
      pandemic, without sacrificing the quality of care. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT04476667; https://clinicaltrials.gov/ct2/show/NCT04476667. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/24913.
CI  - (c)Nazanin Alavi, Megan Yang, Callum Stephenson, Niloofar Nikjoo, Niloufar
      Malakouti, Gina Layzell, Jasleen Jagayat, Amirhossein Shirazi, Dianne Groll,
      Mohsen Omrani, Anne O'Riordan, Sarosh Khalid-Khan, Rafael Freire, Elisa Brietzke,
      Fabiano Alves Gomes, Roumen Milev, Claudio N Soares. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 18.12.2020.
FAU - Alavi, Nazanin
AU  - Alavi N
AUID- ORCID: https://orcid.org/0000-0003-2784-1283
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
FAU - Yang, Megan
AU  - Yang M
AUID- ORCID: https://orcid.org/0000-0001-6365-2039
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
FAU - Stephenson, Callum
AU  - Stephenson C
AUID- ORCID: https://orcid.org/0000-0002-7929-1546
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
FAU - Nikjoo, Niloofar
AU  - Nikjoo N
AUID- ORCID: https://orcid.org/0000-0002-2137-5878
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
FAU - Malakouti, Niloufar
AU  - Malakouti N
AUID- ORCID: https://orcid.org/0000-0001-9752-8597
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - School of Rehabilitation Therapy, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
FAU - Layzell, Gina
AU  - Layzell G
AUID- ORCID: https://orcid.org/0000-0001-8102-5442
AD  - Centre for Behavioural Studies, St. Lawrence College, Kingston, ON, Canada.
FAU - Jagayat, Jasleen
AU  - Jagayat J
AUID- ORCID: https://orcid.org/0000-0002-1709-0773
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
FAU - Shirazi, Amirhossein
AU  - Shirazi A
AUID- ORCID: https://orcid.org/0000-0002-8586-3707
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
AD  - OPTT Inc, Digital Media Zone, Ryerson University, Toronto, ON, Canada.
FAU - Groll, Dianne
AU  - Groll D
AUID- ORCID: https://orcid.org/0000-0001-6913-5710
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
FAU - Omrani, Mohsen
AU  - Omrani M
AUID- ORCID: https://orcid.org/0000-0002-0461-1947
AD  - OPTT Inc, Digital Media Zone, Ryerson University, Toronto, ON, Canada.
FAU - O'Riordan, Anne
AU  - O'Riordan A
AUID- ORCID: https://orcid.org/0000-0002-1095-9683
AD  - Kingston Health Sciences Centre, Kingston, ON, Canada.
FAU - Khalid-Khan, Sarosh
AU  - Khalid-Khan S
AUID- ORCID: https://orcid.org/0000-0002-5729-9643
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
FAU - Freire, Rafael
AU  - Freire R
AUID- ORCID: https://orcid.org/0000-0003-3875-4601
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
FAU - Brietzke, Elisa
AU  - Brietzke E
AUID- ORCID: https://orcid.org/0000-0003-2697-1342
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
AD  - Inpatient Psychiatry Unit, Kingston General Hospital, Kingston Health Science
      Centre, Kingston, ON, Canada.
FAU - Gomes, Fabiano Alves
AU  - Gomes FA
AUID- ORCID: https://orcid.org/0000-0002-0244-5228
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
FAU - Milev, Roumen
AU  - Milev R
AUID- ORCID: https://orcid.org/0000-0001-6884-171X
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
FAU - Soares, Claudio N
AU  - Soares CN
AUID- ORCID: https://orcid.org/0000-0001-7056-7174
AD  - Department of Psychiatry, Faculty of Health Sciences, Queen's University,
      Kingston, ON, Canada.
AD  - Centre for Neuroscience Studies, Faculty of Health Sciences, Queen's University, 
      Kingston, ON, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04476667
PT  - Journal Article
DEP - 20201218
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7752186
OTO - NOTNLM
OT  - COVID-19
OT  - anxiety
OT  - cognitive behavioural therapy
OT  - depression
OT  - electronic
OT  - internet
OT  - mental health
OT  - mental health care
OT  - online
OT  - psychotherapy
EDAT- 2020/12/09 06:00
MHDA- 2020/12/09 06:01
CRDT- 2020/12/08 17:16
PHST- 2020/10/22 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2020/11/30 00:00 [revised]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/09 06:01 [medline]
PHST- 2020/12/08 17:16 [entrez]
AID - v9i12e24913 [pii]
AID - 10.2196/24913 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 18;9(12):e24913. doi: 10.2196/24913.


PMID- 33289623
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1778-3585 (Electronic)
IS  - 0924-9338 (Linking)
VI  - 63
IP  - 1
DP  - 2020 Apr 1
TI  - European Psychiatric Association policy paper on ethical aspects in communication
      with patients and their families.
PG  - e36
LID - 10.1192/j.eurpsy.2020.33 [doi]
AB  - BACKGROUND: Establishing a valid communication is not only a basic clinical need 
      to be met but also a relevant ethical commitment. METHODS: On the basis of the
      relevant literature, ethical issues arising from specific, important situations
      in clinical practice were identified. RESULTS: The main ethical problems
      regarding communication about the disorder, both in general and in relation to
      prodromal stages, were described and discussed together with those regarding
      communication about voluntary and involuntary treatments, "dual roles" enacted in
      clinical practice, genetic counseling, and end-of-life conditions; on the basis
      of what emerged, ethically driven indications and suggestions were provided.
      CONCLUSIONS: Several situations put the psychiatrist in front of relevant
      dilemmas and doubts which are no easy to face with; an ethically driven approach 
      based upon the principle of the best interest of patients may support clinicians 
      in their decisions.
FAU - Carpiniello, Bernardo
AU  - Carpiniello B
AUID- ORCID: 0000-0002-5385-7871
AD  - Department of Medical Science and Public Health, Psychiatric Unit, University
      Hospital Cagliari, Cagliari, Italy.
FAU - Wasserman, Danuta
AU  - Wasserman D
AUID- ORCID: 0000-0002-8436-3989
AD  - National Centre for Suicide Research and Prevention of Mental Ill-Health (NASP)
      LIME, Karolinska Institutet-CHIS, Stockholm, Sweden.
CN  - EPA Council of National Psychiatric Associations Working Group on Communication
      with Patients and Families*
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - England
TA  - Eur Psychiatry
JT  - European psychiatry : the journal of the Association of European Psychiatrists
JID - 9111820
SB  - IM
MH  - *Communication
MH  - *Family
MH  - Humans
MH  - Physician-Patient Relations/*ethics
MH  - Policy
MH  - Psychiatry/*ethics
PMC - PMC7355125
OTO - NOTNLM
OT  - *Communication
OT  - *diagnosis
OT  - *ethical issues
OT  - *mental disorders
OT  - *treatments
EDAT- 2020/12/09 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/12/08 12:17
PHST- 2020/12/08 12:17 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
AID - 10.1192/j.eurpsy.2020.33 [doi]
AID - S0924933820000334 [pii]
PST - epublish
SO  - Eur Psychiatry. 2020 Apr 1;63(1):e36. doi: 10.1192/j.eurpsy.2020.33.


PMID- 33288984
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201209
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jul
TI  - Ethical Advice for an Intensive Care Triage Protocol in the COVID-19 Pandemic:
      Lessons Learned from The Netherlands.
PG  - 157-165
LID - 10.1093/phe/phaa027 [doi]
AB  - At the height of the COVID-19 crisis in the Netherlands a shortness of intensive 
      care beds was looming. Dutch professional medical organizations asked a group of 
      ethicists for assistance in drafting guidelines and criteria for selection of
      patients for intensive care (IC) treatment in case of absolute scarcity, when
      medical selection criteria would no longer suffice. This article describes the
      Dutch context, the process of drafting the advice and reflects on the role of
      ethicists and lessons learned. We argue that timely interaction between clinical 
      and ethical expertise is necessary since the distinction between medical and
      non-medical considerations is not as clearcut as sometimes assumed. Furthermore, 
      pragmatic considerations related to the specifics of an epidemic are of
      importance, for example, in relation to prioritizing health care workers. As a
      consequence, any protocol already present before the pandemic would need
      alterations to fit the current situation. The 'fair innings' criterion we
      proposed, rephrased as an argument of intergenerational solidarity, was
      considered reasonable by professionals as well as patient organizations. While it
      is desirable to draft ethical guidelines in 'peacetime' as a matter of pandemic
      preparedness, the pressure of an actual crisis facilitates decision-making,
      although it will also complicate a more democratic approach.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Verweij, Marcel
AU  - Verweij M
AUID- ORCID: 0000-0001-9169-1852
AD  - Philosophy Group, Wageningen University.
FAU - van de Vathorst, Suzanne
AU  - van de Vathorst S
AD  - Medical Ethics, Philosophy and History of Medicine, Erasmus MC.
FAU - Schermer, Maartje
AU  - Schermer M
AD  - Medical Ethics, Philosophy and History of Medicine, Erasmus MC.
FAU - Willems, Dick
AU  - Willems D
AD  - Amsterdam UMC.
FAU - de Vries, Martine
AU  - de Vries M
AD  - Leiden University Medical Centre.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7499738
EDAT- 2020/12/09 06:00
MHDA- 2020/12/09 06:01
CRDT- 2020/12/08 05:45
PHST- 2020/12/08 05:45 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/09 06:01 [medline]
AID - 10.1093/phe/phaa027 [doi]
AID - phaa027 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Sep 3;13(2):157-165. doi: 10.1093/phe/phaa027.
      eCollection 2020 Jul.


PMID- 33288647
OWN - NLM
STAT- Publisher
LR  - 20201208
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 7
TI  - Ethically incentivising healthy behaviours: views of parents and adolescents with
      type 1 diabetes.
LID - medethics-2020-106428 [pii]
LID - 10.1136/medethics-2020-106428 [doi]
AB  - BACKGROUND: To assess ethical concerns associated with participation in a
      financial incentive (FI) programme to help adolescents with type 1 diabetes
      improve diabetes self-management. METHODS: Focus groups with 46 adolescents with 
      type 1 diabetes ages 12-17 and 38 of their parents were conducted in the Seattle,
      Washington metropolitan area. Semistructured focus group guides addressed ethical
      concerns related to the use of FI to promote change in diabetes self-management. 
      Qualitative data were analysed and emergent themes identified. RESULTS: We
      identified three themes related to the ethical issues adolescents and parents
      anticipated with FI programme participation. First, FI programmes may variably
      change pressure and conflict in different families in ways that are not
      necessarily problematic. Second, the pressure to share FIs in some families and
      how FI payments are structured may lead to unfairness in some cases. Third, some 
      adolescents may be likely to fabricate information in any circumstances, not
      simply because of FIs, but this could compromise the integrity of FI programmes
      relying on measures that cannot be externally verified. CONCLUSIONS: Many
      adolescents with type 1 diabetes and their parents see positive potential of FIs 
      to help adolescents improve their self-management. However, ethical concerns
      about unfairness, potentially harmful increases in conflict/pressure and
      dishonesty should be addressed in the design and evaluation of FI programmes.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Shah, Seema
AU  - Shah S
AD  - Advanced General Pediatrics, Ann and Robert H Lurie Children's Hospital of
      Chicago, Chicago, Illinois, USA Seema.Shah@northwestern.edu.
AD  - Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, United 
      States.
FAU - Malik, Faisal
AU  - Malik F
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
AD  - Pediatrics, University of Washington, Seattle, Washington, USA.
FAU - Senturia, Kristen D
AU  - Senturia KD
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
FAU - Lind, Cara
AU  - Lind C
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
FAU - Chalmers, Kristen
AU  - Chalmers K
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
FAU - Yi-Frazier, Joyce
AU  - Yi-Frazier J
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
AD  - Pediatrics, University of Washington, Seattle, Washington, USA.
FAU - Pihoker, Catherine
AU  - Pihoker C
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
AD  - Pediatrics, University of Washington, Seattle, Washington, USA.
FAU - Wright, Davene
AU  - Wright D
AD  - Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care
      Institute, Boston, MA, United States.
LA  - eng
PT  - Journal Article
DEP - 20201207
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - behaviour modification
OT  - clinical ethics
OT  - health economics
OT  - minors/parental consent
COIS- Competing interests: None declared.
EDAT- 2020/12/09 06:00
MHDA- 2020/12/09 06:00
CRDT- 2020/12/08 05:39
PHST- 2020/05/11 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/12/08 05:39 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/09 06:00 [medline]
AID - medethics-2020-106428 [pii]
AID - 10.1136/medethics-2020-106428 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 7. pii: medethics-2020-106428. doi:
      10.1136/medethics-2020-106428.


PMID- 33287895
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 2054-9369 (Electronic)
IS  - 2054-9369 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Dec 8
TI  - CRISPR/Cas9 from bench to bedside: what clinicians need to know before
      application?
PG  - 61
LID - 10.1186/s40779-020-00292-2 [doi]
AB  - In October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel
      Prize in Chemistry for their pioneering work in precise genome editing using the 
      CRISPR technology. Although CRISPR technology has developed rapidly in the last
      decade, there are still many uncertainties before eventual use in clinical
      settings. In this mini review, we summarize the current efforts in addressing the
      limitations of CRISPR technology and future directions.
FAU - Li, Zi-Qing
AU  - Li ZQ
AUID- ORCID: 0000-0003-3596-3520
AD  - Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong 
      First Medical University, Jinan, 250021, China. ziqingli@upenn.edu.
AD  - Department of Basic and Translational Sciences, School of Dental Medicine,
      University of Pennsylvania, Philadelphia, PA, 19104, USA. ziqingli@upenn.edu.
FAU - Li, Chao-Hong
AU  - Li CH
AD  - Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen
      University, Guangzhou, 510080, China.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20201208
PL  - England
TA  - Mil Med Res
JT  - Military Medical Research
JID - 101643181
SB  - IM
MH  - *CRISPR-Cas Systems
MH  - Humans
MH  - Point-of-Care Systems/*trends
PMC - PMC7722470
OTO - NOTNLM
OT  - *CRISPR/Cas9
OT  - *Ethical concerns
OT  - *Genome editing
OT  - *Nobel prize
OT  - *Off-target effect
EDAT- 2020/12/09 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/12/08 05:32
PHST- 2020/11/26 00:00 [received]
PHST- 2020/12/02 00:00 [accepted]
PHST- 2020/12/08 05:32 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
AID - 10.1186/s40779-020-00292-2 [doi]
AID - 10.1186/s40779-020-00292-2 [pii]
PST - epublish
SO  - Mil Med Res. 2020 Dec 8;7(1):61. doi: 10.1186/s40779-020-00292-2.


PMID- 33287790
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210727
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 7
TI  - A multicenter randomized trial to assess the efficacy of CONvalescent plasma
      therapy in patients with Invasive COVID-19 and acute respiratory failure treated 
      with mechanical ventilation: the CONFIDENT trial protocol.
PG  - 317
LID - 10.1186/s12890-020-01361-x [doi]
AB  - BACKGROUND: The COVID-19 pandemic reached Europe in early 2020. Convalescent
      plasma is used without a consistent evidence of efficacy. Our hypothesis is that 
      passive immunization with plasma collected from patients having contracted
      COVID-19 and developed specific neutralizing antibodies may alleviate symptoms
      and reduce mortality in patients treated with mechanical ventilation for severe
      respiratory failure during the evolution of SARS-CoV-2 pneumonia. METHODS: We
      plan to include 500 adult patients, hospitalized in 16 Belgian intensive care
      units between September 2020 and 2022, diagnosed with SARS-CoV-2 pneumonia, under
      mechanical ventilation for less than 5 days and a clinical frailty scale less
      than 6. The study treatment will be compared to standard of care and allocated by
      randomization in a 1 to 1 ratio without blinding. The main endpoint will be
      mortality at day 28. We will perform an intention to treat analysis. The number
      of patients to include is based on an expected mortality rate at day 28 of 40
      percent and an expected relative reduction with study intervention of 30 percent 
      with alpha risk of 5 percent and beta risk of 20 percent. DISCUSSION: This study 
      will assess the efficacy of plasma in the population of mechanically ventilated
      patients. A stratification on the delay from mechanical ventilation and inclusion
      will allow to approach the optimal time use. Selecting convalescent plasmas with 
      a high titer of neutralizing antibodies against SARS-CoV-2 will allow a
      homogeneous study treatment. The inclusion in the study is based on the consent
      of the patient or his/her legal representative, and the approval of the
      Investigational Review Board of the University hospital of Liege, Belgium. A data
      safety monitoring board (DSMB) has been implemented. Interim analyses have been
      planned at 100, 2002, 300 and 400 inclusions in order to decide whether the trail
      should be discontinued prematurely for ethical issues. We plan to publish our
      results in a peer-reviewed journal and to present them at national and
      international conferences. FUNDING AND REGISTRATION: The trial is funded by the
      Belgian Health Care Knowledge Center KCE # COV201004 TRIAL REGISTRATION:
      Clinicaltrials.gov registration number NCT04558476. Registered 14 September
      2020-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04558476.
FAU - Misset, Benoit
AU  - Misset B
AUID- ORCID: http://orcid.org/0000-0001-6466-0065
AD  - Department of Intensive Care Medicine, Liege University Hospital, Domaine
      Universitaire du Sart Tilman, 4020, Liege, Belgium. benoit.misset@chuliege.be.
FAU - Hoste, Eric
AU  - Hoste E
AD  - Department of Intensive Care Medicine, Gent University Hospital, Gent, Belgium.
FAU - Donneau, Anne-Francoise
AU  - Donneau AF
AD  - Biostatistic Unit, Public Health Department, Liege University, Liege, Belgium.
FAU - Grimaldi, David
AU  - Grimaldi D
AD  - Department of Intensive Care Medicine, Cliniques Universitaires de Bruxelles -
      Erasme, Universite Libre de Bruxelles, Brussels, Belgium.
FAU - Meyfroidt, Geert
AU  - Meyfroidt G
AD  - Department of Intensive Care Medicine, University Hospitals Leuven, Leuven,
      Belgium.
FAU - Moutschen, Michel
AU  - Moutschen M
AD  - Department of Infectious Diseases, Liege University Hospital, Liege, Belgium.
FAU - Compernolle, Veerle
AU  - Compernolle V
AD  - Blood Services from the Red Cross, Mechelen, Belgium.
FAU - Gothot, Andre
AU  - Gothot A
AD  - Department of Immunohematology, Liege University Hospital, Liege, Belgium.
FAU - Desmecht, Daniel
AU  - Desmecht D
AD  - Department of Animal Pathology, Liege University, Liege, Belgium.
FAU - Garigliany, Mutien
AU  - Garigliany M
AD  - Department of Animal Pathology, Liege University, Liege, Belgium.
FAU - Najdovski, Tome
AU  - Najdovski T
AD  - Blood Services From the Red Cross, Suarlee, Belgium.
FAU - Laterre, Pierre-Francois
AU  - Laterre PF
AD  - Department of Intensive Care Medicine, Saint-Luc University Hospital, Brussels,
      Belgium.
LA  - eng
SI  - ClinicalTrials.gov/NCT04558476
GR  - COV201004/KCE
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201207
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (Antibodies, Viral)
RN  - COVID-19 serotherapy
SB  - IM
EIN - BMC Pulm Med. 2021 Jul 26;21(1):248. PMID: 34311718
MH  - Adult
MH  - Antibodies, Viral/blood/immunology
MH  - Belgium
MH  - COVID-19/mortality/*therapy
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - Immunization, Passive
MH  - Intensive Care Units
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Respiration, Artificial
MH  - Severe Acute Respiratory Syndrome/mortality/*therapy
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7719725
OTO - NOTNLM
OT  - COVID-19
OT  - Convalescent plasma
OT  - Mechanical ventilation
OT  - Randomized
OT  - Respiratory failure
EDAT- 2020/12/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/08 05:31
PHST- 2020/11/17 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/08 05:31 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12890-020-01361-x [doi]
AID - 10.1186/s12890-020-01361-x [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Dec 7;20(1):317. doi: 10.1186/s12890-020-01361-x.


PMID- 33287439
OWN - NLM
STAT- MEDLINE
DCOM- 20210907
LR  - 20210907
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 18
IP  - 12
DP  - 2020 Dec 3
TI  - Application of Six Detection Methods for Analysis of Paralytic Shellfish Toxins
      in Shellfish from Four Regions within Latin America.
LID - E616 [pii]
LID - 10.3390/md18120616 [doi]
AB  - With the move away from use of mouse bioassay (MBA) to test bivalve mollusc
      shellfish for paralytic shellfish poisoning (PSP) toxins, countries around the
      world are having to adopt non-animal-based alternatives that fulfil ethical and
      legal requirements. Various assays have been developed which have been subjected 
      to single-laboratory and multi-laboratory validation studies, gaining acceptance 
      as official methods of analysis and approval for use in some countries as
      official control testing methods. The majority of validation studies conducted to
      date do not, however, incorporate shellfish species sourced from Latin America.
      Consequently, this study sought to investigate the performance of five
      alternative PSP testing methods together with the MBA, comparing the PSP toxin
      data generated both qualitatively and quantitatively. The methods included a
      receptor binding assay (RBA), two liquid chromatography with fluorescence
      detection (LC-FLD) methods including both pre-column and post-column oxidation,
      liquid chromatography with tandem mass spectrometry (LC-MS/MS) and a commercial
      lateral flow assay (LFA) from Scotia. A total of three hundred and forty-nine
      shellfish samples from Argentina, Mexico, Chile and Uruguay were assessed. For
      the majority of samples, qualitative results compared well between methods. Good 
      statistical correlations were demonstrated between the majority of quantitative
      results, with a notably excellent correlation between the current EU reference
      method using pre-column oxidation LC-FLD and LC-MS/MS. The LFA showed great
      potential for qualitative determination of PSP toxins, although the findings of
      high numbers of false-positive results and two false negatives highlighted that
      some caution is still needed when interpreting results. This study demonstrated
      that effective replacement methods are available for countries that no longer
      wish to use the MBA, but highlighted the importance of comparing toxin data from 
      the replacement method using local shellfish species of concern before
      implementing new methods in official control testing programs.
FAU - Turner, Andrew D
AU  - Turner AD
AUID- ORCID: 0000-0003-1390-0924
AD  - Centre for Environment, Fisheries and Aquaculture Science (Cefas), Barrack Road, 
      The Nothe, Weymouth, Dorset DT4 8UB, UK.
FAU - Tarnovius, Sophie
AU  - Tarnovius S
AD  - Centre for Environment, Fisheries and Aquaculture Science (Cefas), Barrack Road, 
      The Nothe, Weymouth, Dorset DT4 8UB, UK.
AD  - Technische Universitat Munchen, Walther-Meissner-Strasse 3, 85748 Garching,
      Germany.
FAU - Hatfield, Robert G
AU  - Hatfield RG
AD  - Centre for Environment, Fisheries and Aquaculture Science (Cefas), Barrack Road, 
      The Nothe, Weymouth, Dorset DT4 8UB, UK.
FAU - Teixeira-Alves, Mickael
AU  - Teixeira-Alves M
AD  - Centre for Environment, Fisheries and Aquaculture Science (Cefas), Barrack Road, 
      The Nothe, Weymouth, Dorset DT4 8UB, UK.
FAU - Broadwater, Maggie
AU  - Broadwater M
AD  - National Oceanic and Atmospheric Administration, National Centers for Coastal
      Ocean Science Stressor Detection and Impacts Division, Charleston, SC 29412, USA.
FAU - Dolah, Frances Van
AU  - Dolah FV
AD  - National Oceanic and Atmospheric Administration, National Centers for Coastal
      Ocean Science Stressor Detection and Impacts Division, Charleston, SC 29412, USA.
FAU - Garcia-Mendoza, Ernesto
AU  - Garcia-Mendoza E
AUID- ORCID: 0000-0003-1738-7419
AD  - Departamento de Oceanografia Biologica, Centro de Investigacion Cientifica y de
      Educacion Superior de Ensenada. Carr. Ens-Tij 3608, Ensenada, Baja California
      22860, Mexico.
FAU - Medina, Dinorah
AU  - Medina D
AD  - Direccion Nacional de Recursos Acuaticos, PO Box 1612, Constituyente 1497,
      Montevideo 11200, Uruguay.
FAU - Salhi, Maria
AU  - Salhi M
AD  - Direccion Nacional de Recursos Acuaticos, PO Box 1612, Constituyente 1497,
      Montevideo 11200, Uruguay.
FAU - Goya, Alejandra B
AU  - Goya AB
AD  - Marine Biotoxin Department, Mar del Plata Regional Laboratory, Agri-food Health
      and Quality National Service (Senasa), Mar del Plata 7600, Argentina.
FAU - Barrera, Fernanda
AU  - Barrera F
AD  - Laboratory of Marine Toxins, Institute of Biomedical Sciences, Faculty of
      Medicine, University of Chile, Santiago 8320000, Chile.
FAU - Carrasco, Daniel
AU  - Carrasco D
AD  - Laboratory of Marine Toxins, Institute of Biomedical Sciences, Faculty of
      Medicine, University of Chile, Santiago 8320000, Chile.
FAU - Rubilar, Ignacio
AU  - Rubilar I
AD  - Laboratory of Marine Toxins, Institute of Biomedical Sciences, Faculty of
      Medicine, University of Chile, Santiago 8320000, Chile.
FAU - Suarez-Isla, Benjamin A
AU  - Suarez-Isla BA
AD  - Laboratory of Marine Toxins, Institute of Biomedical Sciences, Faculty of
      Medicine, University of Chile, Santiago 8320000, Chile.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (Marine Toxins)
SB  - IM
MH  - Animals
MH  - Biological Assay
MH  - Bivalvia
MH  - Chromatography, High Pressure Liquid
MH  - False Positive Reactions
MH  - Latin America
MH  - Marine Toxins/*chemistry/*toxicity
MH  - Mice
MH  - Paralysis/*chemically induced
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Shellfish/*analysis
MH  - Shellfish Poisoning/*diagnosis
MH  - Tandem Mass Spectrometry
MH  - Toxicity Tests/*standards
PMC - PMC7761785
OTO - NOTNLM
OT  - LC-FLD
OT  - LC-MS/MS
OT  - MBA
OT  - RBA
OT  - paralytic shellfish poisoning (PSP)
OT  - toxin profiles
EDAT- 2020/12/09 06:00
MHDA- 2021/09/08 06:00
CRDT- 2020/12/08 01:08
PHST- 2020/11/13 00:00 [received]
PHST- 2020/11/27 00:00 [revised]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/08 01:08 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/09/08 06:00 [medline]
AID - md18120616 [pii]
AID - 10.3390/md18120616 [doi]
PST - epublish
SO  - Mar Drugs. 2020 Dec 3;18(12). pii: md18120616. doi: 10.3390/md18120616.


PMID- 33287348
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 11
IP  - 12
DP  - 2020 Dec 3
TI  - Prenatal Detection of Uniparental Disomies (UPD): Intended and Incidental Finding
      in the Era of Next Generation Genomics.
LID - E1454 [pii]
LID - 10.3390/genes11121454 [doi]
AB  - Prenatal detection of uniparental disomy (UPD) is a methodological challenge, and
      a positive testing result requires comprehensive considerations on the clinical
      consequences as well as ethical issues. Whereas prenatal testing for UPD in
      families which are prone to UPD formation (e.g., in case of chromosomal variants,
      imprinting disorders) is often embedded in genetic counselling, the incidental
      identification of UPD is often more difficult to manage. With the increasing
      application of high-resolution test systems enabling the identification of UPD,
      an increase in pregnancies with incidental detection of UPD can be expected. This
      paper will cover the current knowledge on uniparental disomies, their clinical
      consequences with focus on prenatal testing, genetic aspects and predispositions,
      genetic counselling, as well as methods (conventional tests and high-throughput
      assays).
FAU - Eggermann, Thomas
AU  - Eggermann T
AUID- ORCID: 0000-0002-8419-0264
AD  - Institute of Human Genetics, University Hospital, RWTH Aachen, Pauwelsstr 30,
      D-52074 Aachen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201203
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
SB  - IM
MH  - Female
MH  - Genetic Counseling/methods
MH  - Genomics/methods
MH  - Humans
MH  - Incidental Findings
MH  - Pregnancy
MH  - Prenatal Diagnosis/methods
MH  - Uniparental Disomy/*diagnosis/*genetics
PMC - PMC7761756
OTO - NOTNLM
OT  - *next generation genomics
OT  - *non-invasive prenatal testing
OT  - *prenatal testing
OT  - *uniparental disomy
EDAT- 2020/12/09 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/12/08 01:07
PHST- 2020/11/14 00:00 [received]
PHST- 2020/11/30 00:00 [revised]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2020/12/08 01:07 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
AID - genes11121454 [pii]
AID - 10.3390/genes11121454 [doi]
PST - epublish
SO  - Genes (Basel). 2020 Dec 3;11(12). pii: genes11121454. doi: 10.3390/genes11121454.


PMID- 33287301
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 3
TI  - Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic
      Agents.
LID - E2589 [pii]
LID - 10.3390/cells9122589 [doi]
AB  - CD5 and CD6 are closely related signal-transducing class I scavenger receptors
      mainly expressed on lymphocytes. Both receptors are involved in the modulation of
      the activation and differentiation cell processes triggered by clonotypic
      antigen-specific receptors present on T and B cells (TCR and BCR, respectively). 
      To serve such a relevant immunomodulatory function, the extracellular region of
      CD5 and CD6 interacts with soluble and/or cell-bound endogenous counterreceptors 
      but also microbial-associated molecular patterns (MAMPs). Evidence from
      genetically-modified mouse models indicates that the absence or blockade of CD5- 
      and CD6-mediated signals results in dysregulated immune responses, which may be
      deleterious or advantageous in some pathological conditions, such as infection,
      cancer or autoimmunity. Bench to bedside translation from transgenic data is
      constrained by ethical concerns which can be overcome by exogenous administration
      of soluble proteins acting as decoy receptors and leading to transient
      "functional knockdown". This review gathers information currently available on
      the therapeutic efficacy of soluble CD5 and CD6 receptor infusion in different
      experimental models of disease. The existing proof-of-concept warrants the
      interest of soluble CD5 and CD6 as safe and efficient immunotherapeutic agents in
      diverse and relevant pathological conditions.
FAU - Velasco-de Andres, Maria
AU  - Velasco-de Andres M
AD  - Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions
      Biomediques August Pi i Sunyer, 08036 Barcelona, Spain.
FAU - Casado-Llombart, Sergi
AU  - Casado-Llombart S
AUID- ORCID: 0000-0003-0137-4701
AD  - Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions
      Biomediques August Pi i Sunyer, 08036 Barcelona, Spain.
FAU - Catala, Cristina
AU  - Catala C
AD  - Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions
      Biomediques August Pi i Sunyer, 08036 Barcelona, Spain.
FAU - Leyton-Pereira, Alejandra
AU  - Leyton-Pereira A
AD  - Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions
      Biomediques August Pi i Sunyer, 08036 Barcelona, Spain.
FAU - Lozano, Francisco
AU  - Lozano F
AUID- ORCID: 0000-0003-1119-4368
AD  - Immunoreceptors del Sistema Innat i Adaptatiu, Institut d'Investigacions
      Biomediques August Pi i Sunyer, 08036 Barcelona, Spain.
AD  - Servei d'Immunologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
AD  - Immunoregulacio de la Resposta Innata i Adaptativa, Department de Biomedicina,
      Universitat de Barcelona, 08036 Barcelona, Spain.
FAU - Aranda, Fernando
AU  - Aranda F
AUID- ORCID: 0000-0002-9364-474X
AD  - Program of Immunology and Immunotherapy, Center for Applied Medical Research
      (CIMA), University of Navarra, 31008 Pamplona, Spain.
AD  - Instituto de Investigacion de Navarra (IDISNA), 31008 Pamplona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201203
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD5 Antigens)
RN  - 0 (CD6 antigen)
RN  - 0 (Receptors, Scavenger)
SB  - IM
MH  - Animals
MH  - Antigens, CD/*immunology
MH  - Antigens, Differentiation, T-Lymphocyte/*immunology
MH  - B-Lymphocytes/*immunology
MH  - CD5 Antigens/*immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Receptors, Scavenger/*immunology
MH  - T-Lymphocytes/*immunology
PMC - PMC7761703
OTO - NOTNLM
OT  - *autoimmunity
OT  - *cancer
OT  - *immunomodulation
OT  - *immunotherapy
OT  - *infection
OT  - *soluble CD5
OT  - *soluble CD6
EDAT- 2020/12/09 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/12/08 01:07
PHST- 2020/11/05 00:00 [received]
PHST- 2020/11/30 00:00 [revised]
PHST- 2020/12/01 00:00 [accepted]
PHST- 2020/12/08 01:07 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - cells9122589 [pii]
AID - 10.3390/cells9122589 [doi]
PST - epublish
SO  - Cells. 2020 Dec 3;9(12). pii: cells9122589. doi: 10.3390/cells9122589.


PMID- 33287188
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 23
DP  - 2020 Dec 3
TI  - Urban Emotion Sensing Beyond 'Affective Capture': Advancing Critical
      Interdisciplinary Methods.
LID - E9003 [pii]
LID - 10.3390/ijerph17239003 [doi]
AB  - The use of mobile sensor methodologies in urban analytics to study 'urban
      emotions' is currently outpacing the science required to rigorously interpret the
      data generated. Interdisciplinary research on 'urban stress' could help inform
      urban wellbeing policies relating to healthier commuting and alleviation of work 
      stress. The purpose of this paper is to address-through methodological
      experimentation-ethical, political and conceptual issues identified by critical
      social scientists with regards to emotion tracking, wearables and data analytics.
      We aim to encourage more dialogue between the critical approach and applied
      environmental health research. The definition of stress is not unambiguous or
      neutral and is mediated by the very technologies we use for research. We outline 
      an integrative methodology in which we combine pilot field research using
      biosensing technologies, a novel method for identifying 'moments of stress' in a 
      laboratory setting, psychometric surveys and narrative interviews on workplace
      and commuter stress in urban environments.
FAU - Pykett, Jessica
AU  - Pykett J
AUID- ORCID: 0000-0002-0036-9639
AD  - School of Geography, Earth and Environmental Sciences, University of Birmingham, 
      Edgbaston B15 2TT, UK.
FAU - Chrisinger, Benjamin W
AU  - Chrisinger BW
AUID- ORCID: 0000-0002-1480-6481
AD  - Department of Social Policy and Intervention, University of Oxford, Oxford OX1
      2ER, UK.
FAU - Kyriakou, Kalliopi
AU  - Kyriakou K
AUID- ORCID: 0000-0002-9387-852X
AD  - Department of Public Health Sciences, Institute for Risk Assessment Sciences,
      Utrecht University, 3584 CM Utrecht, The Netherlands.
AD  - Department of Geoinformatics, University of Salzburg, 5020 Salzburg, Austria.
FAU - Osborne, Tess
AU  - Osborne T
AUID- ORCID: 0000-0003-3323-8237
AD  - Population Research Centre, Faculty of Spatial Sciences, University of Groningen,
      9700 Groningen, The Netherlands.
FAU - Resch, Bernd
AU  - Resch B
AUID- ORCID: 0000-0002-2233-6926
AD  - Department of Geoinformatics, University of Salzburg, 5020 Salzburg, Austria.
AD  - Center for Geographic Analysis, Harvard University, Cambridge, MA 02138, USA.
FAU - Stathi, Afroditi
AU  - Stathi A
AUID- ORCID: 0000-0003-2162-777X
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Edgbaston B15 2TT, UK.
FAU - Whittaker, Anna C
AU  - Whittaker AC
AUID- ORCID: 0000-0002-5461-0598
AD  - Faculty of Health Sciences and Sport, University of Stirling, Stirling FK9 4LA,
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Emotions
MH  - *Environmental Health/statistics & numerical data
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
MH  - *Social Sciences/methods
MH  - Surveys and Questionnaires
MH  - Transportation
MH  - *Urban Population/statistics & numerical data
PMC - PMC7731212
OTO - NOTNLM
OT  - *biosensing
OT  - *interdisciplinarity
OT  - *mobile methods
OT  - *urban wellbeing
EDAT- 2020/12/09 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/12/08 01:07
PHST- 2020/10/15 00:00 [received]
PHST- 2020/11/23 00:00 [revised]
PHST- 2020/11/30 00:00 [accepted]
PHST- 2020/12/08 01:07 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - ijerph17239003 [pii]
AID - 10.3390/ijerph17239003 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 3;17(23). pii: ijerph17239003. doi:
      10.3390/ijerph17239003.


PMID- 33285767
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Infrared thermography in the diagnosis of musculoskeletal injuries: A protocol
      for a systematic review and meta-analysis.
PG  - e23529
LID - 10.1097/MD.0000000000023529 [doi]
AB  - BACKGROUND: Musculoskeletal injuries (MSDs) have become a major public health
      problem worldwide. Current diagnosis techniques for MSDs are often associated
      with radiation exposure, expensive cost, or contraindication. Infrared
      thermography (IRT) is becoming a proposed tool to assist in diagnosing MSDs, but 
      current evidence is inconclusive. Thus, herein we aimed to evaluate the
      diagnostic accuracy of IRT for MSDs. METHODS: We will search EMBASE, MEDLINE,
      EBSCO, Cochrane Library, SCOPUS, Web of Science, CNKI, SinoMed, and Wangfang. Two
      researchers will independently screen eligible studies. Study quality will be
      evaluated based on the Quality Assessment of Diagnostic Accuracy Studies
      (QUADAS-2) tool. Data synthesis will be completed using STATA 14.0 software. A
      bivariate random-effects analysis will be utilized to estimate the pooled
      estimation of the diagnostic odds ratio (DOR) and the summary receiver operating 
      characteristics (SROC) curve. Subgroup analyses will be performed to determine
      heterogeneity sources. RESULTS: This systematic review and meta-analysis will
      provide reliable evidence about the diagnostic accuracy of IRT for MSDs.
      CONCLUSION: The conclusion of this study will be published in a peer-reviewed
      journal. ETHICS AND COMMUNICATION: Given that this is a systematic review of
      published research, patient consent and ethical approval are not relevant. The
      findings of this study will be disseminated through conference presentations and 
      publication in peer-reviewed journals. PROSPERO REGISTRATION NUMBER:
      CRD42020184867.
FAU - Li, Xiaoyu
AU  - Li X
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou
      City, Zhejiang Province.
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Zhang, Yajun
AU  - Zhang Y
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Sun, Haiju
AU  - Sun H
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Jiang, Yongliang
AU  - Jiang Y
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Lou, Jiali
AU  - Lou J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - He, Xiaofen
AU  - He X
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Diagnosis, Differential
MH  - Humans
MH  - *Infrared Rays
MH  - Meta-Analysis as Topic
MH  - Musculoskeletal System/*injuries
MH  - Odds Ratio
MH  - ROC Curve
MH  - Research Design
MH  - Sensitivity and Specificity
MH  - Systematic Reviews as Topic
MH  - Thermography/*methods
MH  - Wounds and Injuries/*diagnosis
PMC - PMC7717754
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023529 [doi]
AID - 00005792-202012040-00104 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23529. doi: 10.1097/MD.0000000000023529.


PMID- 33285764
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Aerobic, resistance and combined training for adults with chronic kidney disease:
      A protocol for a systematic review and network meta-analysis.
PG  - e23518
LID - 10.1097/MD.0000000000023518 [doi]
AB  - BACKGROUND: Chronic kidney disease (CKD) as a disease that poses a great threat
      to human health, which has become a public health issue of great concern. Studies
      have found that exercise training has a positive effect on improving the
      condition of chronic kidney disease. We will conduct a network meta-analysis to
      assess the effects of aerobic training, resistance training and combined aerobic 
      and resistance training in treating CKD patients. METHODS: We will search PubMed,
      EMBASE, Medline, Cochrane Central Register of Controlled Trials (CENTRAL), and
      Web of science to identify randomized control trails (RCTs) that assessed the
      effect of different exercise training for CKD patients. Cochrane Handbook will be
      used to evaluate the risk of bias of included articles. We will use Stata or R
      software to perform data analysis. RESULTS AND CONCLUSION: Our systematic review 
      and network meta-analysis will be the first study that investigates the effect of
      different exercise training for CKD patients, and will provide evidence for
      management of chronic kidney disease. ETHICS AND DISSEMINATION: The data involved
      in this study are from published articles. For this reason, there is no need for 
      ethical approval or patient consent. TRIAL REGISTRATION: the registration number 
      was: CRD42020157280.
FAU - Zeng, Rong
AU  - Zeng R
AUID- ORCID: 0000-0001-5241-8765
AD  - Department of Nephrology, the Second Hospital.
FAU - Lai, Honghao
AU  - Lai H
AD  - School of Public Health, Lanzhou University.
FAU - Li, Zhuoyan
AU  - Li Z
AD  - Department of Nephrology, the Second Hospital.
FAU - Chen, Beibei
AU  - Chen B
AD  - The First Clinical Medical College of Lanzhou University, Lanzhou, China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Nephrology, the Second Hospital.
FAU - Zhang, Yali
AU  - Zhang Y
AD  - Department of Nephrology, the Second Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Renal Insufficiency, Chronic/physiopathology/*therapy
MH  - Research Design
MH  - Resistance Training/*methods
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7717791
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023518 [doi]
AID - 00005792-202012040-00101 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23518. doi: 10.1097/MD.0000000000023518.


PMID- 33285761
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - The effect of Tai Chi on the quality of life in the elderly patients recovering
      from coronavirus disease 2019: A protocol for systematic review and
      meta-analysis.
PG  - e23509
LID - 10.1097/MD.0000000000023509 [doi]
AB  - BACKGROUND: coronavirus disease 2019 (COVID-19) is spreading fast starting late
      2019. As their cardiopulmonary and immune functions gradually decline, elderly
      people are prone to COVID-19. Tai Chi has a positive impact on heart function,
      blood pressure, lung function, blood circulation, and so on, and it's suitable
      for the elderly. Quality of life (QoL)can reflect of individuals' physical and
      mental health, it can also reflects their ability to participate in society. This
      systematic review and meta-analysis will summarize the current evidence that Tai 
      Chi improve the QoL in the elderly patients recovering from COVID-19. METHODS: We
      will search PubMed, EMBASE, MEDLINE, the Cochrane Library, Chinese National
      Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Science
      and Technology Periodical Database, Wanfang Database, Clinical Trials and Chinese
      Clinical Trial Registry. The complete process will include study selection, data 
      extraction, risk of bias assessment and meta-analyses. Endnote X9.3 will be used 
      to manage data screening. The statistical analysis will be completed by Stata/SE 
      15.1 software. RESULTS: This proposed study will evaluate the effectiveness and
      safety of Tai Chi for the improvement of QoL in elderly COVID-19 patients during 
      the recovery period. CONCLUSION: The conclusion of this study will provide
      evidence to prove the safety and effectiveness of Tai Chi on elderly COVID-19
      patients during the recovery period. ETHICS AND DISSEMINATION: This protocol will
      not evaluate individual patient information or infringe patient rights and
      therefore does not require ethical approval. REGISTRATION: PEROSPERO
      CRD42020206875.
FAU - Luo, Ziyu
AU  - Luo Z
AUID- ORCID: 0000-0003-0975-9948
AD  - School of Acupuncture and Moxibustion and Tuina.
FAU - Chen, Ying
AU  - Chen Y
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine.
FAU - Wang, Lina
AU  - Wang L
AD  - Laboratory of Statistics and Measurement, Beijing Sport University, Beijing
      University of Chinese Medicine, Beijing, China.
FAU - Chi, Wenxin
AU  - Chi W
AD  - School of Acupuncture and Moxibustion and Tuina.
FAU - Cheng, Xiaoxuan
AU  - Cheng X
AD  - School of Acupuncture and Moxibustion and Tuina.
FAU - Zhu, Xiangyu
AU  - Zhu X
AUID- ORCID: 0000-0003-4132-9470
AD  - School of Acupuncture and Moxibustion and Tuina.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - COVID-19/*therapy
MH  - Health Status
MH  - Humans
MH  - Mental Health
MH  - Pandemics
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
MH  - Social Participation
MH  - Tai Ji/adverse effects/*methods
PMC - PMC7717820
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023509 [doi]
AID - 00005792-202012040-00098 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23509. doi: 10.1097/MD.0000000000023509.


PMID- 33285753
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Effects and safety of massage therapy for patients with metatarsal pain: A
      protocol for systematic review and meta-analysis.
PG  - e23484
LID - 10.1097/MD.0000000000023484 [doi]
AB  - BACKGROUND: Metatarsalgia refers to localized or generalized forefoot pain in the
      region of the metatarsal heads. Often this pain is plantar, beneath the
      metatarsal heads, and arises from either mechanical or iatrogenic causes. The
      treatment of metatarsalgia remains controversial. A thorough understanding of the
      biomechanics of the forefoot and the underlying pathology of the particular type 
      of metatarsalgia affecting the patient is a prerequisite to selecting the proper 
      treatment. In recent years, massage therapy has been increasingly accepted by
      patients due to its lower costs, fewer unwanted side effects, and safety for
      clinical use. In this systematic review, we aim to evaluate the effectiveness and
      safety of massage therapy for patients with metatarsal pain. METHODS: We will
      search the following electronic databases for randomized controlled trials to
      evaluate the effectiveness and safety of massage therapy in treating metatarsal
      pain: Wanfang and PubMed Database, CNKI, CENTRAL, CINAHL, and EMBASE. Each
      database will be searched from inception to October 2020. The entire process will
      include study selection, data extraction, risk of bias assessment, and
      meta-analyses. RESULTS: This proposed study will evaluate the effectiveness and
      safety of massage therapy for patients with metatarsal pain. The outcomes will
      include changes in metatarsal pain relief and adverse effect. CONCLUSIONS: This
      proposed systematic review will evaluate the existing evidence on the
      effectiveness and safety of massage therapy for patients with metatarsalgia.
      DISSEMINATION AND ETHICS: The results of this review will be disseminated through
      peer-reviewed publication. Because all of the data used in this systematic review
      and meta-analysis has been published, this review does not require ethical
      approval. Furthermore, all data will be analyzed anonymously during the review
      process. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/C6KFJ.
FAU - Zhou, Ke-Lin
AU  - Zhou KL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dong, Shuo
AU  - Dong S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Bai, Xiao
AU  - Bai X
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dai, Xiao-Hui
AU  - Dai XH
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Guo, Sheng
AU  - Guo S
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Guan, Qing
AU  - Guan Q
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Wei, Pei-Dong
AU  - Wei PD
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Mi, Bao-Lai
AU  - Mi BL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Ren, Mei-Ling
AU  - Ren ML
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Yang, Yong
AU  - Yang Y
AUID- ORCID: 0000-0003-3086-0071
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Massage/*methods
MH  - Meta-Analysis as Topic
MH  - Metatarsalgia/*therapy
MH  - Pain Measurement
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7717819
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023484 [doi]
AID - 00005792-202012040-00090 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23484. doi: 10.1097/MD.0000000000023484.


PMID- 33285749
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Effects of massage therapy for patients with thoracic facet joint disorders: A
      protocol for systematic review and meta-analysis.
PG  - e23480
LID - 10.1097/MD.0000000000023480 [doi]
AB  - BACKGROUND: Thoracic facet joint disorder is a common thoracic disorder in
      clinic, inducing pain and discomfort at the dislocated thoracic vertebrae,
      radiating to pain of the neck and back. The incidence of thoracic facet joint
      disorder is higher than the facet disorder of the cervical and lumbar vertebrae. 
      Therefore, an ideal strategy to relieve thoracic facet joint disorder is urgently
      needed. In recent years, massage therapy has been increasingly accepted by
      thoracic facet joint disorder patients due to its lower costs, fewer unwanted
      side effects and safety for clinical use. In this systematic review, we aim to
      evaluate the effectiveness and safety of massage therapy for patients with
      thoracic facet joint disorder. METHODS: We will search the following electronic
      databases for randomized controlled trials to evaluate the effectiveness of
      massage therapy in treating thoracic facet joint disorder: Wanfang and PubMed
      Database, CNKI, CENTRAL, CINAHL and EMBASE. Each database will be searched from
      inception to October 2020. The entire process will include study selection, data 
      extraction, risk of bias assessment and meta-analyses. RESULTS: This proposed
      study will evaluate the effectiveness of massage therapy for patients with
      thoracic facet joint disorder. CONCLUSIONS: This proposed systematic review will 
      evaluate the existing evidence on the effectiveness and safety of massage therapy
      for patients with thoracic facet joint disorder. DISSEMINATION AND ETHICS: The
      results of this review will be disseminated through peer-reviewed publication.
      Because all of the data used in this systematic review and meta-analysis has been
      published, this review does not require ethical approval. Furthermore, all data
      will be analyzed anonymously during the review process. OSF REGISTRATION NUMBER: 
      DOI 10.17605/OSF.IO/XMEJD.
FAU - Zhou, Ke-Lin
AU  - Zhou KL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dong, Shuo
AU  - Dong S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Ji, Wei
AU  - Ji W
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Yang, Jing-Yi
AU  - Yang JY
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Ren, Mei-Ling
AU  - Ren ML
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Mi, Bao-Lai
AU  - Mi BL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Guo, Sheng
AU  - Guo S
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Cai, Ming-Heng
AU  - Cai MH
AUID- ORCID: 0000-0002-9172-181
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Disability Evaluation
MH  - Female
MH  - Humans
MH  - Joint Diseases/physiopathology/*therapy
MH  - Male
MH  - Massage/*methods
MH  - Meta-Analysis as Topic
MH  - Pain Measurement
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Thoracic Vertebrae/*physiopathology
MH  - Treatment Outcome
MH  - Zygapophyseal Joint/*physiopathology
PMC - PMC7717749
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023480 [doi]
AID - 00005792-202012040-00086 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23480. doi: 10.1097/MD.0000000000023480.


PMID- 33285746
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Music intervention improves the physical and mental status for patients with
      breast cancer: A protocol of randomized controlled trial.
PG  - e23461
LID - 10.1097/MD.0000000000023461 [doi]
AB  - BACKGROUND: Breast cancer is the most familiar cancer and the major cause of the 
      cancer death in women worldwide. The breast cancer patients may suffer from
      severe mental and physical trauma. At present, there are few studies on the music
      therapy for patients with breast cancer. The objective of our paper is to assess 
      the effect of music intervention on mental and physical state of breast cancer
      patients. METHODS: The experiment will be implemented from June 2021 to June 2022
      at Jinan Central Hospital. The experiment was granted through the Research Ethics
      Committee of Jinan Central Hospital (no.08847765). The inclusion criteria
      requires that the age of female patients ranges from 25 to 65 years old, and the 
      pathological diagnosis of breast cancer requires radical mastectomy (containing
      extensive radical mastectomy and modified radical mastectomy). Patients who do
      not like to listen to music or have severe debilitating diseases or are allergic 
      to the sound will be excluded. Patients in the intervention group are given music
      intervention, and in control group, patients do not receive any information about
      the music therapy in the period of this study. The primary outcome is quality of 
      life, psychological distress. The secondary outcomes are the heart rate, blood
      pressure, as well as Visual Analog Scale (VAS). RESULTS: Table 1 will illustrate 
      the postoperative outcomes after music interventions between groups. CONCLUSION: 
      Music intervention can improve the mental and physical health of the breast
      cancer patients. TRIAL REGISTRATION: This study protocol was registered in
      Research Registry (researchregistry6168).
FAU - Li, Xiuting
AU  - Li X
AD  - Department of Radiology.
FAU - Du, Guangpeng
AU  - Du G
AD  - Department of General Medicine.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Neurology.
FAU - Wang, Fangfei
AU  - Wang F
AUID- ORCID: 0000-0003-4853-6421
AD  - Department of Urology, Jinan Central Hospital, Shandong, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*psychology/surgery
MH  - Female
MH  - Humans
MH  - Mastectomy/*psychology
MH  - Middle Aged
MH  - Music/psychology
MH  - Music Therapy/*methods
MH  - Postoperative Complications/psychology/*therapy
MH  - Postoperative Period
MH  - Psychiatric Status Rating Scales
MH  - Quality of Life/psychology
MH  - Randomized Controlled Trials as Topic
MH  - Stress, Psychological/etiology/*therapy
MH  - Treatment Outcome
MH  - Visual Analog Scale
PMC - PMC7717794
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023461 [doi]
AID - 00005792-202012040-00083 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23461. doi: 10.1097/MD.0000000000023461.


PMID- 33285735
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Auricular therapy improves gastrointestinal function in patients with
      gynecological laparoscopic surgery: A protocol for systematic review and meta
      analysis.
PG  - e23421
LID - 10.1097/MD.0000000000023421 [doi]
AB  - BACKGROUND: Gynecological laparoscopic surgery is the main method to treat
      gynecological diseases, but postoperative gastrointestinal reactions are more
      common in patients. Auricular therapy, as a characteristic therapy of Traditional
      Chinese Medicine, can improve gastrointestinal symptoms such as nausea and
      vomiting by stimulating the conduction of acupoints through the nervous system on
      internal organs, but there are studies questioning the efficacy of auricular
      therapy. Therefore, the purpose of this study is to prove the efficacy and safety
      of auricular therapy in promoting gastrointestinal function recovery after
      gynecological laparoscopic surgery, and to provide reference value for future
      clinical practice. METHODS: To search English databases (PubMed, Excerpta Medical
      Database [Embase], Web of Science, the Cochrane Library) and Chinese databases
      (Chinese National Knowledge Internet [CNKI], WanFang, Viper, Chinese Biomedical
      Literature Database) by computer, and conduct a randomized controlled trial on
      the effect of aural point therapy on gastrointestinal function recovery of
      patients after gynecological laparoscopic surgery from the establishment of the
      database to October 2020. Two researchers independently evaluate the quality of
      the included studies and extract the data, and meta-analysis of the included
      literature is carried out using RevMan5.3 software. RESULTS: In this study, the
      efficacy and safety of auricular therapy in the recovery of gastrointestinal
      function after gynecological laparoscopic surgery are evaluated from the aspects 
      of first anal exhaust time, bowel sound recovery time, and incidence of
      gastrointestinal complications. CONCLUSION: This study will provide reliable
      evidence-based evidence for auricular therapy in the treatment of
      gastrointestinal function after gynecologic laparoscopic surgery. ETHICS AND
      DISSEMINATION: Private information from individuals will not be published. This
      systematic review also does not involve endangering participant rights. Ethical
      approval was not required. The results may be published in a peer-reviewed
      journal or disseminated at relevant conferences. OSF REGISTRATION NUMBER: DOI
      10.17605 / OSF.IO / ZSPGA.
FAU - Hu, Ying
AU  - Hu Y
AUID- ORCID: 0000-0002-3116-752
AD  - Zhejiang Hospital.
FAU - Cheng, Xianying
AU  - Cheng X
AD  - Zhejiang Hospital.
FAU - Su, Xinglin
AU  - Su X
AD  - Sandun District Zhejiang Hospital, Hangzhou, Zhejiang Province, China.
FAU - Fu, Yun
AU  - Fu Y
AD  - Sandun District Zhejiang Hospital, Hangzhou, Zhejiang Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture, Ear/adverse effects/*methods
MH  - Gastrointestinal Diseases/*etiology/*therapy
MH  - Gastrointestinal Transit
MH  - Gynecologic Surgical Procedures/*adverse effects
MH  - Humans
MH  - Laparoscopy/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7717805
EDAT- 2020/12/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1097/MD.0000000000023421 [doi]
AID - 00005792-202012040-00072 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23421. doi: 10.1097/MD.0000000000023421.


PMID- 33285734
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Wrist ankle acupuncture in the treatment of acute lumbar sprain: A protocol for
      systematic review and meta-analysis.
PG  - e23420
LID - 10.1097/MD.0000000000023420 [doi]
AB  - BACKGROUND: Acute lumbar sprain (ALS) frequently occurs in the young and
      middle-aged people, causing great harm to people's quality of life. The
      systematic review program was designed to describe a meta-analysis to evaluate
      the efficacy and safety of wrist-ankle acupuncture (WAA) in treating patients
      with ALS. METHODS AND ANALYSIS: Our systematic review will search electronically 
      and manually for WAA treatments for ALS by August, 2020, regardless of
      publication status and language. Databases include: MEDLINE, PubMed, EMBASE,
      Springer, Web of Science, Cochrane Library, WHO International Clinical Trial
      Registration Platform (ICTRP), Chinese Medicine Database (TCMD), China National
      Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM),
      China Science Journal Database (VIP), and Wanfang Database. Other sources of
      information, including bibliographies and meeting minutes for identified
      publications, will also be searched. Manually search for grey literature,
      including unpublished conference articles. Any clinical randomized controlled
      trials related to WAA treatments for ALS, regardless of publication status and
      language limitations, will be included in the study. Study selection, data
      extraction, and research quality assessment will be done independently by 2
      researchers. The primary outcome included the effective rate and visual analogue 
      scale (VAS) or other validated scales used to relieve pain after the treatment.
      If possible, meta-analysis will be performed using RevMan V.5.3 statistical
      software. If it is not suitable for meta-analysis, a descriptive analysis or
      subgroup analysis is performed. RESULTS: This study will provide a comprehensive 
      review and evaluation of the available evidence for the treatment of ALS using
      WAA. CONCLUSION: This study will provide new evidence to evaluate the
      effectiveness and side effects of WAA on ALS. Because the data is not
      personalized, no formal ethical approval is required. REGISTRATION NUMBER:
      PROSPERO CRD42020162945.
FAU - Liang, Shumin
AU  - Liang S
AUID- ORCID: 0000-0002-3050-2787
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Guilong
AU  - Zhang G
AD  - Affifiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Li, Jianhong
AU  - Li J
AD  - The TCM Hospital of Longquanyi District,Chengdu, Chengdu, Sichuan, China.
FAU - Zhong, Lei
AU  - Zhong L
AD  - Affifiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Chi
AU  - Zhang C
AD  - Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - *Ankle
MH  - Humans
MH  - Lumbosacral Region/*injuries
MH  - Pain Measurement
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Sprains and Strains/*therapy
MH  - *Wrist
PMC - PMC7717768
EDAT- 2020/12/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1097/MD.0000000000023420 [doi]
AID - 00005792-202012040-00071 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23420. doi: 10.1097/MD.0000000000023420.


PMID- 33285733
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Effects of Danlou tablet for the treatment of stable angina pectoris: A study
      protocol of a randomized, double-blind, and placebo-controlled clinical trial.
PG  - e23416
LID - 10.1097/MD.0000000000023416 [doi]
AB  - INTRODUCTION: Stable angina pectoris has a high prevalence and causes serious
      harm. Revascularization therapy can relieve angina pectoris to some extent, but
      it is not widely accepted in China due to the cost and secondary events. The
      Chinese proprietary medicine Danlou tablet has been widely used to treat angina
      pectoris, but previous trials had inadequate methodologies. In this study, we aim
      to conduct a randomized controlled trial to evaluate its efficacy and safety on
      stable angina. METHODS AND ANALYSIS: This study is a WeChat-based randomized,
      double-blind, and placebo-controlled clinical trial in China. Eligible
      participants are adults (aged 30-75 years) with CT-confirmed stable angina and
      traditional Chinese medicine-diagnosed intermingled phlegm and blood stasis
      syndrome. A total of 76 participants will be randomly allocated in a 1:1 ratio to
      the oral Danlou tablet group (1.5 mg a time, 3 times daily for 28 days) or the
      placebo group. Patients are permitted concomitant use of routine medications
      during these 28 days. The primary outcome is angina frequency per week. The
      secondary outcomes include angina severity, angina duration, traditional Chinese 
      medicine efficacy, the withdrawal rate of emergency medications, blood lipids,
      and electrocardiograph efficacy. The WeChat app will be used to remind patients
      to take their medicines and fill out the forms. All data will be recorded in case
      report forms and analyzed by Statistical Analysis System software. ETHICS AND
      DISSEMINATION: This study has been approved by the Ethics Committee of
      Guang'anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China
      (No. 2019-225-KY). TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, ID:
      ChiCTR1900028068.
FAU - Yang, Guang
AU  - Yang G
AUID- ORCID: 0000-0002-9906-7023
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - He, Haoqiang
AU  - He H
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Li, Hongzheng
AU  - Li H
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Shen, Zinuo
AU  - Shen Z
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhou, Siyuan
AU  - Zhou S
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Lu, Bingxu
AU  - Lu B
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - He, Qingyong
AU  - He Q
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Zhang, Zhenpeng
AU  - Zhang Z
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Liu, Yongmei
AU  - Liu Y
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Chen, Hengwen
AU  - Chen H
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Lipids)
RN  - 0 (danlou tablet)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina, Stable/*drug therapy
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Electrocardiography
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
PMC - PMC7717752
EDAT- 2020/12/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1097/MD.0000000000023416 [doi]
AID - 00005792-202012040-00070 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23416. doi: 10.1097/MD.0000000000023416.


PMID- 33285724
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Efficacy and safety of antimicrobial de-escalation of treatment for sepsis: A
      protocol for systematic review and meta-analysis.
PG  - e23385
LID - 10.1097/MD.0000000000023385 [doi]
AB  - BACKGROUND: Sepsis has become a global healthcare problem and continues to be one
      of the leading causes of death due to infection. In essence, early recognition
      and diagnosis of sepsis is needed to inhibit the transition into septic shock,
      which is correlated with higher mortality. Many studies have suggested
      antimicrobial de-escalation as one of the strategies to replace the empirical
      broad-spectrum antimicrobial treatment using a narrower antimicrobial therapy,
      especially among patients with sepsis. However, antimicrobial de-escalation
      therapeutic effects in sepsis remains unclear. We therefore performed the present
      study in an attempt to assess efficacy and safety of antimicrobial de-escalation 
      therapy in patients with sepsis. METHODS: We will carry out a systematic
      literature search to establish the potentially eligible trials from electronic
      databases, including EMBASE (1980 to October 16, 2020), MEDLINE via PubMed (1966 
      to October 16, 2020), Web of Science (1965 to October 16, 2020), Cochrane Library
      (CENTRAL; 2020, Issue 10), WanFang databases (last searched October 16, 2020),
      and China National Knowledge Infrastructure (CNKI; last searched October 16,
      2020). For this study, the language restrictions are English or Chinese. Two
      authors independently examined quality based on the Cochrane Risk of Bias Tool
      V.2.0 and extracted data. Data obtained from the study will be synthesised using 
      applicable statistical methods. RESULTS: The results of the present study will
      systematically assess efficacy and safety of antimicrobial de-escalation therapy 
      among patients with sepsis. CONCLUSION: The results of the present study will
      help to establish the efficacy and safety of antimicrobial de-escalation to treat
      patients with sepsis. It can also help to identify the most efficient and safe
      therapeutically-relevant method. ETHICS AND DISSEMINATION: The present study is a
      meta-analysis and the pooled results are based on published evidence. Therefore, 
      ethics approval is not necessary. OSF REGISTRATION NUMBER: October 22,
      2020.osf.io/93wym. (https://osf.io/93wym/).
FAU - Zhu, Hong
AU  - Zhu H
AUID- ORCID: 0000-0003-3184-1913
AD  - Medical Intensive Care Unit.
FAU - Peng, Pai
AU  - Peng P
AD  - Ultrasound Imaging Department, Dalian Municipal Central Hospital, DaLian,
      Liaoning, China.
FAU - Zhao, Rui
AU  - Zhao R
AD  - Medical Intensive Care Unit.
FAU - Fang, Kai-Yu
AU  - Fang KY
AD  - Medical Intensive Care Unit.
FAU - Han, Shi-Quan
AU  - Han SQ
AD  - Medical Intensive Care Unit.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Resistance, Microbial
MH  - Humans
MH  - Intensive Care Units/statistics & numerical data
MH  - Length of Stay
MH  - Randomized Controlled Trials as Topic
MH  - Reinfection/epidemiology
MH  - Research Design
MH  - Sepsis/*drug therapy/mortality
PMC - PMC7717729
EDAT- 2020/12/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1097/MD.0000000000023385 [doi]
AID - 00005792-202012040-00061 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23385. doi: 10.1097/MD.0000000000023385.


PMID- 33285722
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - The efficacy of a nursing care and follow-up program for patients with heart
      failure: Study protocol for a randomized controlled trial.
PG  - e23380
LID - 10.1097/MD.0000000000023380 [doi]
AB  - BACKGROUND: Heart failure (HF) is one of the primary causes of the increasing
      public health costs, incidence rate and mortality of heart disease. As treatment 
      options for the HF have evolved, people have a better understanding of overall
      burden of HF, resulting a more centralized method for the treatment of these
      patients with chronic diseases. At present, with the rapid progress of medical
      technology, the nursing mode must be updated accordingly. The objective of this
      trial is to investigate the effects of the program of nursing care and follow-up 
      on life quality, self-care, and the rehospitalization of patients with HF.
      METHOD: This is a randomized controlled study to be carried out from November
      2020 to March 2021 and was granted through the Ethics Committee of Changshan
      County People's Hospital (CCPH002376). The patients meet the following criteria
      will be included: the age of the patients is 18 years and above, and the
      functional classification is NYHA II or NYHA III. The patients with the following
      criteria will be excluded: patients who have received the by-pass surgery in the 
      last 6 months; cancer patients are given radiotherapy or chemotherapy; patients
      with severe renal failure requiring dialysis; patients with chronic obstructive
      pulmonary disease who need ventilation; and patients with hearing or visual
      impairment. In our experiment, patient information scale, the life quality scale 
      (The Left Ventricular Dysfunction Scale) and Self-Care of HF Index are utilized
      for the assessment. All the analyses are implemented with SPSS for Windows
      Version 20.0. RESULTS: Impact of experimental programs on outcomes will be
      illustrated in the Table. CONCLUSION: We hypothesize that the nursing care
      conducted for the HF patients may improve the life quality and self-care. TRIAL
      REGISTRATION NUMBER: researchregistry 6129.
FAU - Zhang, Zhimin
AU  - Zhang Z
AUID- ORCID: 0000-0002-1832-3081
AD  - Department of Cardiovascular Medicine.
FAU - Bai, Jincheng
AU  - Bai J
AD  - Department of Cardiovascular Medicine.
FAU - Huang, Yongmei
AU  - Huang Y
AD  - Department of Nursing, Changshan County People's Hospital, Zhejiang, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Female
MH  - Heart Failure/*nursing/*therapy
MH  - Humans
MH  - Male
MH  - Quality of Life
MH  - Self Care
PMC - PMC7717929
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023380 [doi]
AID - 00005792-202012040-00059 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23380. doi: 10.1097/MD.0000000000023380.


PMID- 33285721
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Efficacy and safety of different doses of tenecteplase for the treatment of acute
      ischemic stroke: A protocol for a systematic review and network meta-analysis.
PG  - e23379
LID - 10.1097/MD.0000000000023379 [doi]
AB  - BACKGROUND: Acute ischemic stroke (AIS) has become the major reason of causing
      death around the world. As a newer generation fibrinolytic agent, the potential
      of tenecteplase in treating AIS has been determined in clinical studies and
      meta-analysis. However, various doses have been prescribed for tenecteplase in
      clinical practice, and the optimal dose is not yet clear. METHODS: We will
      perform a systematic search to capture all potential randomized controlled trials
      (RCTs) of persons with confirmed AIS who were instructed to administer
      tenecteplase that report at least one outcome in PubMed, Embase, and the Cochrane
      Library. Two reviewers will independently check the titles, abstracts, and
      full-texts, extracting data, assessing the risk of bias and evaluating the
      certainty of evidence. We will use a random-effect model based on the Bayesian
      framework to completely direct and network meta-analyses. We will also test the
      robustness of all pooled results through conducting subgroup analyses according
      to the following criteria: DISCUSSION:: Our systematic review and network
      meta-analysis will generate several valuable findings and have several strengths 
      including:We therefore believe that findings from this network meta-analysis will
      benefit future study design and improve evidence-based treatment of AIS. ETHICS
      AND DISSEMINATION: We will disseminate the results from the present study through
      submitting it to conferences or peer-reviewed journal. PROTOCOL REGISTRY: The
      protocol of our systematic review and network meta-analysis was registered in
      International Plateform of Registered Systematic Review and Meta-Analysis
      Protocols (INPLASY) platform with an approval number of INPLASY2020100086
      (https://inplasy.com/inplasy-2020-10-0086/). Moreover, this protocol was funded
      through a protocol registry.
FAU - Shen, Ting
AU  - Shen T
AD  - Department of Neurology, Zhuji Hospital Affiliated to Shaoxing University of Arts
      and Science, Zhuji, Shaoxing.
FAU - Zhou, Jinjian
AU  - Zhou J
AD  - Department of Neurology, Zhuji Hospital Affiliated to Shaoxing University of Arts
      and Science, Zhuji, Shaoxing.
FAU - Zhao, Yan
AU  - Zhao Y
AUID- ORCID: 0000-0003-4898-4208
AD  - Department of Neurology, People's Hospital of Banan District of Chongqing,
      Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Fibrinolytic Agents)
RN  - WGD229O42W (Tenecteplase)
SB  - IM
MH  - Acute Disease
MH  - Bayes Theorem
MH  - Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Ischemic Stroke/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Tenecteplase/administration & dosage/adverse effects/*therapeutic use
PMC - PMC7717732
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023379 [doi]
AID - 00005792-202012040-00058 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23379. doi: 10.1097/MD.0000000000023379.


PMID- 33285707
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Comparison of dexmedetomidine-propofol and ketamine-propofol administration
      during sedation-guided upper gastrointestinal system endoscopy.
PG  - e23317
LID - 10.1097/MD.0000000000023317 [doi]
AB  - BACKGROUND: Dexmedetomidine and ketamine popular sedative agents that result in
      minimal respiratory depression and the presence of analgesic activity. We aimed
      to compare the effectiveness and safety of a dexmedetomidine-propofol combination
      and a ketamine-propofol combination during upper gastrointestinal system
      endoscopy. METHODS: The study commenced after receiving approval from the local
      ethics committee. Patients between 18 and 60 years in the American Society of
      Anesthesiologists (ASA) I and II groups were included. Patients who had severe
      organ disease, who had allergies to the study drugs, and who refused to
      participate were excluded. Cases were randomized into a dexmedetomidine-propofol 
      group (Group D, n = 30) and a ketamine-propofol group (Group K, n = 30). Cardiac 
      monitoring, peripheral oxygen saturation, and bispectral index (BIS) monitoring
      were performed. Group D received 1 mg/kg dexmedetomidine + 0.5 mg/kg propofol
      intravenous (IV) bolus, 0.5 mug/kg/h dexmedetomidine + 0.5 mg/kg/h propfol
      infusion. Group K received 1 mg/kg ketamine + 0.125 mL/kg propofol iv bolus, 0.25
      mg/kg/h ketamine + 0.125 mL/kg/h propfol infusion. Patients were followed up with
      a Ramsay Sedation Scale (RSS) of >/=4. Means, standard deviations, lowest and
      highest frequency values, and ratio values were used for descriptive statistics, 
      and the SPSS 22.0 program was used for statistical analyses. RESULTS: In Group K,
      recovery time and mean blood pressure (MBP) values were significantly shorter.
      Furthermore, coughing rate, pulse, and BIS values were higher than in Group D (P 
      < .05). Although there were no significant differences between the groups in
      terms of endoscopic tolerance and endoscopist satisfaction, we observed that the 
      dexmedetomidine group experienced more comfortable levels of sedation.
      CONCLUSION: Dexmedetomidine-propofol and ketamine-propofol combinations may be
      suitable and safe for endoscopy sedation due to their different properties. It
      was observed that the dexmedetomidine-propfol combination was superior in terms
      of sedation depth and that the ketamine-propofol combination was superior in
      terms of early recovery. As a result, we suggest the dexmedetomidine-propofol
      combination for upper gastrointestinal system endoscopy sedation due to
      hemodynamic stability and minimal adverse effects.
FAU - Tekeli, Arzu Esen
AU  - Tekeli AE
AUID- ORCID: 0000-0001-6468-8850
AD  - Department of Anesthesiology and Reanimation, Van Yuzuncu Yil University School
      of Medicine.
FAU - Oguz, Ali Kendal
AU  - Oguz AK
AUID- ORCID: 0000-0001-5489-989
AD  - Department of Anesthesiology and Reanimation, Van Yuzuncu Yil University School
      of Medicine.
FAU - Tuncdemir, Yunus Emre
AU  - Tuncdemir YE
AUID- ORCID: 0000-0003-0382-1122
AD  - Department of Anesthesiology and Reanimation, Van Yuzuncu Yil University School
      of Medicine.
FAU - Almali, Necat
AU  - Almali N
AUID- ORCID: 0000-0003-3534-1078
AD  - Department of General Surgery, Van Yuzuncu Yil University School of Medicine,
      Van, Turkey.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0 (Hypnotics and Sedatives)
RN  - 67VB76HONO (Dexmedetomidine)
RN  - 690G0D6V8H (Ketamine)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Pressure
MH  - Dexmedetomidine/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - Endoscopy, Digestive System/*methods
MH  - Female
MH  - Humans
MH  - Hypnotics and Sedatives/administration & dosage/adverse effects/*therapeutic use
MH  - Ketamine/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Propofol/administration & dosage/adverse effects/*therapeutic use
MH  - Young Adult
PMC - PMC7717792
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023317 [doi]
AID - 00005792-202012040-00044 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23317. doi: 10.1097/MD.0000000000023317.


PMID- 33285705
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Effect and safety of Chinese patent medicine capsules for recurrent angina
      pectoris after percutaneous coronary intervention: A protocol for systematic
      review and meta-analysis.
PG  - e23287
LID - 10.1097/MD.0000000000023287 [doi]
AB  - INTRODUCTION: Recurrent angina pectoris after percutaneous coronary intervention 
      (PCI) is a common clinical syndrome, which seriously reduces the quality of life 
      and health of patients, increases medical costs, and causes the risk of
      cardiogenic death. The efficacy of various western medicine improving angina
      symptoms has not been fully confirmed at the moment, whereas Chinese patent
      medicine capsules (CPMC) have been generally used in clinical practice due to the
      therapeutic efficacy and safety. This study evaluates the efficacy and safety of 
      CPMC for stable angina after PCI, designed to provide more evidence for clinical 
      treatment. METHODS: This protocol was based on the previous reporting items. We
      will search 3 English databases (PubMed, Excerpta Medica Database, and the
      Cochrane Library) and 3 Chinese databases (China Network Knowledge
      Infrastructure, Wan Fang Database, and Chinese Biomedicine) until January 2020.
      RCTs to evaluate the efficacy and safety of CPMC for recurrent stable angina
      pectoris after PCI will be included. The primary outcome will be assessed by
      major adverse cardiovascular events and angina attack frequency. We will use the 
      criteria provided by Cochrane risk of bias tool for quality evaluation and risk
      assessment, and use the Revman 5.3 for meta-analysis. ETHICS AND DISSEMINATION:
      Ethical approval is not required for systematic review and meta-analysis. The
      results of this review will be disseminated in a peer-review journal. PROSPERO
      REGISTRATION NUMBER: CRD42020164005.
FAU - Sun, Yize
AU  - Sun Y
AUID- ORCID: 0000-0002-9110-300
AD  - Beijing University of Chinese Medicine.
FAU - Wang, Zheyi
AU  - Wang Z
AD  - Beijing University of Chinese Medicine.
FAU - Wang, Chao
AU  - Wang C
AD  - Oriental Hospital, Beijing University of Chinese Medicine, Beijing, China.
FAU - Tang, Zhuoran
AU  - Tang Z
AD  - Beijing University of Chinese Medicine.
FAU - Shi, Jinyu
AU  - Shi J
AD  - Beijing University of Chinese Medicine.
FAU - Zhao, Haibin
AU  - Zhao H
AD  - Oriental Hospital, Beijing University of Chinese Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Nonprescription Drugs)
SB  - IM
MH  - Angina Pectoris/*drug therapy
MH  - Cardiovascular Diseases/epidemiology
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Humans
MH  - Nonprescription Drugs/adverse effects/*therapeutic use
MH  - Percutaneous Coronary Intervention
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Research Design
PMC - PMC7717720
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023287 [doi]
AID - 00005792-202012040-00042 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23287. doi: 10.1097/MD.0000000000023287.


PMID- 33285704
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Efficacy and safety of Maxing Shigan Decoction in the treatment of chronic
      obstructive pulmonary disease: A protocol for a systematic review and
      meta-analysis.
PG  - e23284
LID - 10.1097/MD.0000000000023284 [doi]
AB  - BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth 
      leading cause of death in the world but is projected to be the 3rd leading cause 
      of death by 2030. Chronic obstructive pulmonary disease is an important public
      health challenge, which can be prevented and treated. COPD is an important public
      health challenge, both preventable and treatable. In China, Maxing Shigan
      Decoction (MSD) has been used as a traditional Chinese medicine compound for the 
      treatment of respiratory diseases for thousands of years. In order to evaluate
      the efficacy and safety of MSD in the treatment of COPD, we need to conduct
      meta-analysis and systematic reviews. METHODS: The data comes from 7 publicly
      published databases, including: PubMed, The Cochrane Central Register of
      Controlled Trials (CENTRAL), EMbase, China National Knowledge Infrastructure
      (CNKI), Chinese Biomedical Database(CBM), VIP Database, and Wanfang database. We 
      will include randomized controlled trials (RCTs) to evaluate the effectiveness
      and safety of MSD in the treatment of COPD. Result measurement indicators
      include: TCM syndrome scores, lung function indicators, serum inflammatory
      factors, blood gas indicators, adverse reactions. RevMan 5.0 will be used for
      meta-analysis. RESULTS: This study will provide high-quality evidence for the
      effectiveness and safety of traditional Chinese medicine therapy for COPD.
      CONCLUSION: The results of this study will help us determine whether MSD can
      effectively treat COPD. ETHICS AND DISSEMINATION: All analyses in this study are 
      based on previously published research, so this study does not require ethical
      approval or patient consent. We will disseminate our findings electronically or
      in print by publishing results in peer-reviewed journals. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/H5UNB.
FAU - Chen, Jinyun
AU  - Chen J
AUID- ORCID: 0000-0003-3861-8255
AD  - College of basic medicine, Chengdu university of Traditional Chinese Medicine,
      Chengdu.
FAU - Wang, Chunrong
AU  - Wang C
AD  - College of basic medicine, Chengdu university of Traditional Chinese Medicine,
      Chengdu.
FAU - Xiong, Min
AU  - Xiong M
AD  - College of basic medicine, Chengdu university of Traditional Chinese Medicine,
      Chengdu.
FAU - Shen, Qilin
AU  - Shen Q
AUID- ORCID: 0000-0002-2096-1445
AD  - College of basic medicine, Mianyang traditional Chinese medicine hospital,
      Mianyang, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Inflammation Mediators)
RN  - 0 (maxingshigan)
SB  - IM
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Respiratory Function Tests
PMC - PMC7717823
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023284 [doi]
AID - 00005792-202012040-00041 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23284. doi: 10.1097/MD.0000000000023284.


PMID- 33285703
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Evaluation of the association between vitamin D and lung cancer skin metastasis: 
      A protocol for systematic review.
PG  - e23281
LID - 10.1097/MD.0000000000023281 [doi]
AB  - BACKGROUND: This study aims to investigate the association between vitamin D (VD)
      and lung cancer skin metastasis (LCSM). METHODS: The following databases will be 
      retrieved from the beginning to the present of each database without language
      limitation: PUBMED, EMBASE, Cochrane Library, Web of Science, CBM, and CNKI. The 
      reference lists of included trials and other sources will also be checked. Two
      researchers will independently undertake literature selection, data collection,
      and study quality evaluation. We will utilize a fixed or random-effect model to
      pool the data according to the heterogeneity test. The RevMan 5.3 software will
      be used to analyze the data and perform meta-analysis. RESULTS: This study will
      summarize high quality study to explore the association between VD and LCSM.
      CONCLUSION: The findings of this study will help to judge whether there is
      association between VD and LCSM. ETHICS AND DISSEMINATION: No research ethical
      approval is required in this study, because it will only analyze published data. 
      It is expected to disseminate through a peer-reviewed journal. STUDY
      REGISTRATION: osf.io/ph2au.
FAU - Zhao, Dan
AU  - Zhao D
AD  - Department of Dermatology, Second Affiliated Hospital of Mudanjiang Medical
      University.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Chest Surgery, The Affiliated Hongqi Hospital of Mudanjiang Medical
      University, Mudanjiang, China.
FAU - Li, Yu-Feng
AU  - Li YF
AD  - Department of Chest Surgery, The Affiliated Hongqi Hospital of Mudanjiang Medical
      University, Mudanjiang, China.
FAU - Huang, Jian-Wei
AU  - Huang JW
AUID- ORCID: 0000-0003-2834-158
AD  - Department of Chest Surgery, The Affiliated Hongqi Hospital of Mudanjiang Medical
      University, Mudanjiang, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Humans
MH  - Lung Neoplasms/*blood/pathology
MH  - Neoplasm Metastasis
MH  - Skin/pathology
MH  - Skin Neoplasms/*blood/*secondary
MH  - Systematic Reviews as Topic
MH  - Vitamin D/*blood
PMC - PMC7717721
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023281 [doi]
AID - 00005792-202012040-00040 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23281. doi: 10.1097/MD.0000000000023281.


PMID- 33285695
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Standardized nursing and clinical efficacy of OxyContin in reducing oral mucosal 
      pain in patients with nasopharyngeal carcinoma: A randomized, double-blind,
      placebo-controlled study protocol.
PG  - e23205
LID - 10.1097/MD.0000000000023205 [doi]
AB  - BACKGROUND: Pain caused by oral mucositis (OM) is the main problem in the process
      of concurrent chemoradiotherapy for the nasopharyngeal carcinoma (NPC). This
      protocol aims to explore the standardized nursing and therapeutic effect of
      OxyContin on OM pain in the patients with NPC undergoing the concurrent
      chemoradiotherapy. METHODS: The experiment is a randomized clinical research,
      which was granted through the Research Ethics Committee of Shandong Provincial
      Third Hospital (No.20200802097). In this research, 90 NPC patients with OM
      induced by chemotherapy are enrolled, and the score of visual analogue >5 and the
      grade of OM >1 are evaluated. Patients with known allergy to OxyContin, the
      opioid abuse history, or major organ dysfunction, for instance, hepatic
      insufficiency, renal failure, and respiratory and heart failure, as well as a
      series of severe mental illness are excluded from our research. Patients in study
      groups receive standardized nursing and oral OxyContin. Patients in control
      groups only receive oral OxyContin. The analgesic effect could be assessed with
      the comparison of the visual analogue scale after and before the treatment.
      Safety evaluations contain the assessment of the vital signs, laboratory tests,
      as well as adverse events. The Karnofsky performance status standards of the
      International Cancer Control Union is utilized to evaluate the quality of life.
      RESULTS: The comparison of outcomes after taking OxyContin in both groups will be
      shown in .(Table is included in full-text article.) CONCLUSION:: The combination 
      of OxyContin and standardized nursing care appears to improve the analgesic
      efficacy and life quality in NPC patients. TRIAL REGISTRATION: We registered this
      protocol in Research Registry (researchregistry6098).
FAU - Sun, Nina
AU  - Sun N
AD  - Department of otolaryngology.
FAU - Li, Yunxia
AU  - Li Y
AD  - Cancer Centre, Shandong Provincial Third Hospital, Shandong, China.
FAU - Nie, Peihua
AU  - Nie P
AUID- ORCID: 0000-0002-8716-5814
AD  - Department of otolaryngology.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Analgesics, Opioid)
RN  - CD35PMG570 (Oxycodone)
SB  - IM
MH  - Analgesics, Opioid/*therapeutic use
MH  - Chemoradiotherapy/*adverse effects
MH  - Double-Blind Method
MH  - Humans
MH  - Mucositis/*drug therapy/etiology/nursing
MH  - Nasopharyngeal Carcinoma/therapy
MH  - Nasopharyngeal Neoplasms/therapy
MH  - Oxycodone/*therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC7717733
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000023205 [doi]
AID - 00005792-202012040-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23205. doi: 10.1097/MD.0000000000023205.


PMID- 33285679
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Chinese herbal medicine on treating obese women with polycystic ovary syndrome: A
      systematic review and meta-analysis protocol.
PG  - e22982
LID - 10.1097/MD.0000000000022982 [doi]
AB  - INTRODUCTION: Known as an endocrine disorder, Polycystic ovary syndrome (PCOS)
      has posed an influence on 6% to 20% reproductive females worldwide. The commonly 
      used pharmaceutical agents currently are Oral Contraceptives (OCs) and
      insulin-sensitizing agents. However, OCs is not appropriate for females pursuing 
      pregnancy. Furthermore, some of insulin-sensitizing agents are found to be
      related to a high incidence of gastrointestinal adverse effects. In this regard, 
      the effectiveness of Chinese herbal medicine in handling reproductive and
      metabolic defects simultaneously has been proved by extensive evidence. In this
      research, the effectiveness and safety of Chinese herbal medicine for obese
      females with PCOS were examined. METHODS AND ANALYSIS: In the systematic review, 
      we searched databases of AMED, Science Online, EMbase, WorldSciNet, the Cochrane 
      Library, PubMed, Nature, MEDLINE, China National Knowledge Infrastructure, the
      Wanfang Databse and China Biology Medicine Disc and the Chongqing VIP Chinese
      Science and Technology Periodical Database, to find out the papers published in
      Chinese or English by September 25, 2020 in this field. In addition, potential
      reference lists, relevant conference proceedings, qualified studies, related
      system reviews and other resources were also considered. Two researchers were
      responsible for independently selecting the research papers, collecting data, and
      evaluating research quality. Moreover, the data were synthesized with the
      combination of a fixed-effects or random-effects model with the heterogeneity
      test. According to the objective and self-reported assessment, the primary
      outcomes will be Nausea and vomiting were primary outcomes. RevMan 5 software was
      used to analyze the collected data, the evidence level of which was evaluated by 
      GRADE. The selection between the fixed-effects and random-effects models was
      determined by the heterogeneity level. In addition to the 95% Confidence Interval
      (CI), odds ratio (OR), or risk ratio (RR) was applied to the 2 categories.
      Moreover, 95% CI and standardized mean difference (SMD) or the weighted mean
      difference (WMD) were taken as the continuous variables. When existing meaningful
      heterogeneity could not be explained by any assessment such as subgroup analysis,
      we would not conduct a meta-analysis. During the subgroup analysis, each subgroup
      in specific cases should be comprehensively considered. ETHICS AND DISSEMINATION:
      The evaluation of rights or personal information of patients was not involved in 
      the systematic review. Hence, we need not gain approval from ethical
      institutions. This paper will be present at related conferences for communication
      and published in journals. REGISTRATION: Open Science Framework (OSF)
      Preregistration: osf.io/yp86h.
FAU - Ding, Ning
AU  - Ding N
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Yue, Rensong
AU  - Yue R
AUID- ORCID: 0000-0002-4417-3312
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Yang, Hongjing
AU  - Yang H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Gonadal Hormones)
SB  - IM
MH  - Acne Vulgaris/drug therapy/epidemiology
MH  - Adolescent
MH  - Adult
MH  - Body Weights and Measures
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Gonadal Hormones/blood
MH  - Humans
MH  - Obesity/*drug therapy/*epidemiology
MH  - Polycystic Ovary Syndrome/*drug therapy/*epidemiology
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Young Adult
PMC - PMC7717816
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1097/MD.0000000000022982 [doi]
AID - 00005792-202012040-00016 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e22982. doi: 10.1097/MD.0000000000022982.


PMID- 33284869
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0300-1652 (Print)
IS  - 0300-1652 (Linking)
VI  - 61
IP  - 4
DP  - 2020 Jul-Aug
TI  - Assessment of Health-care Research and Its Challenges among Medical Doctors in
      Nigeria.
PG  - 218-222
LID - 10.4103/nmj.NMJ_46_20 [doi]
AB  - INTRODUCTION: Health-care research in Nigeria has been growing over the years but
      is constrained by many difficulties. This study aimed to identify the challenges 
      encountered in health-care research and suggest policies to address these
      problems. MATERIALS AND METHODS: It was a cross-sectional study of medical
      doctors who have been involved in health-related researches. All participants
      filled a self-administered online questionnaire comprising 31 questions in five
      sections. The responses were analyzed using the Google forms and the Statistical 
      Package for the Social Sciences software version 23. RESULTS: The mean age of the
      study participants was 41.0 +/- 8.4 years. Three-quarters of the respondents
      (75.5%) worked in teaching hospitals. Nearly all (96.6%) carried out their
      studies using personal funds and only one in 10 had been involved in high-budget 
      projects (>/=1,000,000). The generation of quality researches was impeded by the 
      restriction of literature review to free online journals (93.2%), incomplete
      health records (88.0%), limited access to research kits (65.7%), limited use of
      advanced statistical analysis (29.8%), and challenges with obtaining ethical
      approval (21.2%). Despite the average online visibility of these researches
      (52.2%), only 28.5% stated that it has been locally adopted to influence medical 
      practice in their center. CONCLUSION: There is a wide disparity in research
      capacity among hospital tiers. It is important to leverage on and expand existing
      partnerships to provide institutional access to premium literature, offer robust,
      and assessable financial support for the conduct of high-quality researches and
      provide a framework to bridge the gap in the use of these works to influence
      practice change in Nigeria.
CI  - Copyright: (c) 2020 Nigerian Medical Journal.
FAU - Tolani, Musliu Adetola
AU  - Tolani MA
AD  - Department of Surgery, Ahmadu Bello University/Ahmadu Bello University Teaching
      Hospital, Zaria, Kaduna State, Nigeria.
FAU - Ahmed, Muhammed
AU  - Ahmed M
AD  - Department of Surgery, Ahmadu Bello University/Ahmadu Bello University Teaching
      Hospital, Zaria, Kaduna State, Nigeria.
FAU - Ojewola, Rufus Wale
AU  - Ojewola RW
AD  - Department of Surgery, College of Medicine, University of Lagos and Lagos
      University Teaching Hospital, Idi-Araba, Lagos, Nigeria.
FAU - Abdulwahab-Ahmed, Abdullahi
AU  - Abdulwahab-Ahmed A
AD  - Department of Surgery, Usman Danfodio University/Usman Danfodio University
      Teaching Hospital, Sokoto, Nigeria.
FAU - Abdulkadir, Abubakar
AU  - Abdulkadir A
AD  - Department of Surgery, Bayero University/Aminu Kano Teaching Hospital, Kano,
      Nigeria.
FAU - Mbaeri, Timothy Uzoma
AU  - Mbaeri TU
AD  - Department of Surgery, Nnamdi Azikiwe University Teaching Hospital, Nnewi,
      Anambra State, Nigeria.
FAU - Raphael, John
AU  - Raphael J
AD  - Department of Surgery, University of Port Harcourt/University of Port Harcourt
      Teaching Hospital, Port Harcourt, Rivers State, Nigeria.
FAU - Atim, Terkaa
AU  - Atim T
AD  - Department of Surgery, College of Health Sciences, University of Abuja and
      University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria.
FAU - Ajape, Akanbi Abdulwahab
AU  - Ajape AA
AD  - Department of Surgery, University of Ilorin and University of Ilorin Teaching
      Hospital, Ilorin, Kwara State, Nigeria.
FAU - Shuaibu, Samaila Ibrahim
AU  - Shuaibu SI
AD  - Department of Surgery, University of Jos/Jos University Teaching Hospital, Jos,
      Plateau State, Nigeria.
FAU - Tela, Usman Mohammed
AU  - Tela UM
AD  - Department of Surgery, University of Maiduguri Teaching Hospital, Maiduguri,
      Borno State, Nigeria.
FAU - Lawal, Ahmad Tijjani
AU  - Lawal AT
AD  - Department of Surgery, Ahmadu Bello University/Ahmadu Bello University Teaching
      Hospital, Zaria, Kaduna State, Nigeria.
FAU - Nasir, Oyelowo
AU  - Nasir O
AD  - Department of Surgery, Ahmadu Bello University/Ahmadu Bello University Teaching
      Hospital, Zaria, Kaduna State, Nigeria.
FAU - Maitama, Hussaini Yusuf
AU  - Maitama HY
AD  - Department of Surgery, Ahmadu Bello University/Ahmadu Bello University Teaching
      Hospital, Zaria, Kaduna State, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - Nigeria
TA  - Niger Med J
JT  - Nigerian medical journal : journal of the Nigeria Medical Association
JID - 0315137
PMC - PMC7688027
OTO - NOTNLM
OT  - Challenges
OT  - Nigeria
OT  - healthcare
OT  - research
COIS- There are no conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 17:11
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/12/07 17:11 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.4103/nmj.NMJ_46_20 [doi]
AID - NMJ-61-218 [pii]
PST - ppublish
SO  - Niger Med J. 2020 Jul-Aug;61(4):218-222. doi: 10.4103/nmj.NMJ_46_20. Epub 2020
      Aug 4.


PMID- 33284691
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1544-5208 (Electronic)
IS  - 0278-2715 (Linking)
VI  - 39
IP  - 12
DP  - 2020 Dec
TI  - Valuing Health Impacts In Climate Policy: Ethical Issues And Economic Challenges.
PG  - 2105-2112
AB  - Deciding which climate policies to enact, and where and when to enact them,
      requires weighing their costs against the expected benefits. A key challenge in
      climate policy is how to value health impacts, which are likely to be large and
      varied, considering that they will accrue over long time horizons (centuries),
      will occur throughout the world, and will be distributed unevenly within
      countries depending in part on socioeconomic status. These features raise a
      number of important economic and ethical issues including how to value human life
      in different countries at different levels of development, how to value future
      people, and how much priority to give the poor and disadvantaged. In this article
      we review each of these issues, describe different approaches for addressing them
      in quantitative climate policy analysis, and show how their treatment can
      dramatically change what should be done about climate change. Finally, we use the
      social cost of carbon, which reflects the cost of adding carbon emissions to the 
      atmosphere, as an example of how analysis of climate impacts is sensitive to
      ethical assumptions. We consider $20 a reasonable lower bound for the social cost
      of carbon, but we show that a much higher value is warranted given a strong
      concern for equity within and across generations.
FAU - Scovronick, Noah
AU  - Scovronick N
AD  - Noah Scovronick (scovronick@emory.edu) is an assistant professor in the Gangarosa
      Department of Environmental Health at the Rollins School of Public Health, Emory 
      University, in Atlanta, Georgia.
FAU - Ferranna, Maddalena
AU  - Ferranna M
AD  - Maddalena Ferranna is a research associate in the Department of Global Health and
      Population at Harvard University, in Boston, Massachusetts.
FAU - Dennig, Francis
AU  - Dennig F
AD  - Francis Dennig is an assistant professor of social sciences at Yale-NUS College, 
      in Singapore.
FAU - Budolfson, Mark
AU  - Budolfson M
AD  - Mark Budolfson is an assistant professor in the Department of Environmental and
      Occupational Health and Justice, the Center for Population-Level Bioethics, and
      the Department of Philosophy at Rutgers University, in New Brunswick, New Jersey.
LA  - eng
GR  - P30 ES019776/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Health Aff (Millwood)
JT  - Health affairs (Project Hope)
JID - 8303128
SB  - IM
MH  - *Climate Change
MH  - Humans
MH  - *Policy
MH  - Policy Making
PMC - PMC7891186
MID - NIHMS1666626
EDAT- 2020/12/08 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/12/07 17:10
PHST- 2020/12/07 17:10 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.1377/hlthaff.2020.01117 [pii]
PST - ppublish
SO  - Health Aff (Millwood). 2020 Dec;39(12):2105-2112.


PMID- 33284391
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20220218
IS  - 1573-0980 (Electronic)
IS  - 1386-7415 (Linking)
VI  - 41
IP  - 4
DP  - 2020 Aug
TI  - Relational suffering and the moral authority of love and care.
PG  - 165-178
LID - 10.1007/s11017-020-09530-z [doi]
AB  - Suffering is a ubiquitous yet elusive concept in health care. In a field devoted 
      to the pursuit of objective data, suffering is a phenomenon with deep ties to
      subjective experience, moral values, and cultural norms. Suffering's tie to
      subjective experience makes it challenging to discern and respond to the
      suffering of others. In particular, the question of whether a child with profound
      neurocognitive disabilities can suffer has generated a robust discourse, rooted
      in philosophical conceptualizations of personhood as well as the academic and
      experiential expertise of practiced health-care professionals. The issue remains 
      unresolved because it is difficult, perhaps impossible, to ever truly know an
      infant's lived experience. But what if this is not the best question? What if
      instead of asking "can this infant suffer?" the discourse is broadened to ask "is
      there suffering here?" This latter question demands attention to patients'
      subjective experiences of suffering, but also to the web of relationships that
      envelop them. Without losing sight of the importance of patients' experiences,
      consideration of their relationships may elucidate the presence of suffering when
      the patients themselves are unable to provide the same clarity. In this essay,
      care ethics frames an examination of how suffering manifests in the loving and
      caring relationships that surround an infant with profound neurocognitive
      disabilities, changing those relationships and affecting the individuals within
      them. Exploring suffering through these relationships may offer clarity on the
      presence and content of suffering for infants with profound cognitive
      disabilities, in turn offering moral guidance for responding to suffering and
      supporting flourishing in this context.
FAU - Campelia, Georgina D
AU  - Campelia GD
AD  - Department of Bioethics and Humanities, University of Washington School of
      Medicine, Seattle, WA, USA. gdcamp@uw.edu.
AD  - Clinical Ethics Consultation Service, University of Washington School of
      Medicine, Seattle, WA, USA. gdcamp@uw.edu.
FAU - Kett, Jennifer C
AU  - Kett JC
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, WA, USA.
AD  - Division of Bioethics and Palliative Care, Department of Pediatrics, University
      of Washington School of Medicine, Seattle, WA, USA.
FAU - Wightman, Aaron
AU  - Wightman A
AD  - Department of Bioethics and Humanities, University of Washington School of
      Medicine, Seattle, WA, USA.
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, WA, USA.
AD  - Division of Bioethics and Palliative Care, Department of Pediatrics, University
      of Washington School of Medicine, Seattle, WA, USA.
AD  - Division of Pediatric Nephrology, Department of Pediatrics, University of
      Washington School of Medicine, Seattle, WA, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Theor Med Bioeth
JT  - Theoretical medicine and bioethics
JID - 9805378
SB  - IM
MH  - Family/*psychology
MH  - Humans
MH  - *Love
MH  - *Moral Obligations
MH  - Personhood
PMC - PMC7720443
OTO - NOTNLM
OT  - *Care
OT  - *Love
OT  - *Pediatrics
OT  - *Relationality
OT  - *Suffering
EDAT- 2020/12/08 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/12/07 12:10
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2020/12/07 12:10 [entrez]
AID - 10.1007/s11017-020-09530-z [doi]
AID - 10.1007/s11017-020-09530-z [pii]
PST - ppublish
SO  - Theor Med Bioeth. 2020 Aug;41(4):165-178. doi: 10.1007/s11017-020-09530-z.


PMID- 33283150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2514-8281 (Print)
IS  - 2514-8281 (Linking)
VI  - 104
IP  - 1
DP  - 2020 Nov 25
TI  - Differentiation between Cerebral Hemorrhage and Contrast Extravasation Using Dual
      Energy Computed Tomography after Intra-Arterial Neuro Interventional Procedures.
PG  - 70
LID - 10.5334/jbsr.2083 [doi]
AB  - PURPOSE: To evaluate the value of dual-energy computed tomography (DECT) in
      differentiating cerebral hemorrhage from blood brain barrier (BBB) disruption
      after neuro-interventional procedures with intra-arterial injection of iodinated 
      contrast material. MATERIAL AND METHODS: This prospective study was approved by
      the local ethics committee, and informed consent was obtained for all patients.
      Thirty five patients with acute ischemic stroke or un-ruptured brain aneurysm who
      had received intra-arterial administration of iodinated contrast material were
      evaluated using DECT at 80 and 150 kV immediately after the procedure.A
      three-material decomposition algorithm was used to obtain virtual non-contrast
      (VNC) images and iodine overlay maps (IOM). A follow-up examination (brain
      magnetic resonance imaging MRI or conventional CT) was used as the standard of
      reference for hemorrhage, defined as a persistant hyperdensity on a conventional 
      CT or T2* hypo-intensity on brain MRI. The diagnostic values of DECT in
      differentiating hemorrhage and iodinated contrast material were obtained.
      RESULTS: Mixed images obtained with DECT showed intra-parenchymal or subarachnoid
      hyperattenuation in 18/35 patients. Among these, 16 were classified (according to
      VNC images and IOM) as contrast extravasations and two with a mixture of
      hemorrhage and contrast material. On follow-up imaging, there were two patients
      with hemorrhage. The sensitivity, specificity, and accuracy of DECT in the
      identifying hemorrhage was calculated as 67% (2/3), 100% (32/32) and 97% (32/33) 
      respectively. CONCLUSION: DECT allows an early and accurate differentiation
      between cerebral hemorrhage and BBB disruption after intra-arterial
      neuro-interventional procedures.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Zaouak, Yasmine
AU  - Zaouak Y
AD  - Erasme Hospital, BE.
FAU - Sadeghi, Niloufar
AU  - Sadeghi N
AD  - Erasme Hospital, BE.
FAU - Sarbu, Nicolae
AU  - Sarbu N
AD  - Erasme Hospital, BE.
FAU - Ligot, Noemie
AU  - Ligot N
AD  - Erasme Hospital, BE.
FAU - Lubicz, Boris
AU  - Lubicz B
AD  - Erasme Hospital, BE.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - J Belg Soc Radiol
JT  - Journal of the Belgian Society of Radiology
JID - 101698198
PMC - PMC7693760
OTO - NOTNLM
OT  - blood brain barrier
OT  - cerebral haemorrhage
OT  - contrast extravasation
OT  - dual energy ct
OT  - neuro interventional
COIS- The authors have no competing interests to declare.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:37
PHST- 2020/12/07 05:37 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.5334/jbsr.2083 [doi]
PST - epublish
SO  - J Belg Soc Radiol. 2020 Nov 25;104(1):70. doi: 10.5334/jbsr.2083.


PMID- 33282974
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201208
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Nursing education in the path of globalization: Promotion or challenge?
PG  - 269
LID - 10.4103/jehp.jehp_775_19 [doi]
AB  - Globalization has been attracted by great literature and papers of many
      disciplines in recent years. Although globalization has considerable social,
      political, and economic effects, it has turned to an important challenge in
      health-care systems. Nursing, as the largest part of the health system in the
      world, has also been affected by globalization. The purpose of the present paper 
      is to critique globalization and its impacts on the nursing profession. This
      review article was conducted by searching for reliable internet resources in the 
      English language on the impact of globalization on nursing. Published articles
      were searched until 2018, and related articles were extracted in three stages:
      1-selection of articles by reading abstract, 2-selection with an overview of the 
      text, and 3-selection with a full review of the article's text. According to the 
      literature of globalization, we categorize and discuss the nursing areas that are
      affected by globalization in nine areas: global nursing development, nurses
      emigration,information interchange and interactions in nursing, higher education 
      in nursing, professional territory, nursing specialization, professional ethics, 
      management and supervision, and professional independence. The intensity of
      globalization effects on the nursing profession has not been the same in all
      societies, and factors such as compliance of society, culture, and technology are
      among the most important factors that affect it. Globalization is an inevitable
      process and brings with itself many prominent promotions such as global nursing
      development and important challenges such as nursing emigration and ethical
      issues.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Dorri, Safoura
AU  - Dorri S
AD  - School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan,
      Iran.
FAU - Abedi, Azar
AU  - Abedi A
AD  - Department of Medical-Surgical Nursing, Isfahan University of Medical Sciences,
      Isfahan, Iran.
FAU - Mohammadi, Nooredin
AU  - Mohammadi N
AD  - Department of Critical Care Nursing, Nursing Care Research Center, Iran
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201030
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7709778
OTO - NOTNLM
OT  - Education
OT  - globalization
OT  - internationalization
OT  - nursing
OT  - nursing challenges
COIS- There are no conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:36
PHST- 2019/12/31 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/12/07 05:36 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.4103/jehp.jehp_775_19 [doi]
AID - JEHP-9-269 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Oct 30;9:269. doi: 10.4103/jehp.jehp_775_19.
      eCollection 2020.


PMID- 33282765
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2231-0762 (Print)
IS  - 2231-0762 (Linking)
VI  - 10
IP  - 5
DP  - 2020 Sep-Oct
TI  - Implementation of a Medical Ethics Course in Undergraduate Dental Education and
      Assessment of Knowledge and Attitudes.
PG  - 569-578
LID - 10.4103/jispcd.JISPCD_364_19 [doi]
AB  - OBJECTIVES: A medical ethics course was launched in 2012 in a French University
      Dental School. We compared knowledge and attitudes, before and after
      implementation of that course. The aim of this study was to compare students who 
      received an ethics course (third year) to those who did not have such training,
      however, most of them did have some clinical traineeship. MATERIALS AND METHODS: 
      An anonymous questionnaire was sent to the second-, third-, and sixth-year
      students. It comprised questions with Likert item format answers and clinical
      vignettes with open responses. The results were analyzed by two approaches: a
      statistical analysis (chi-square or Fischer exact tests) and a content analysis
      using a predefined grid. RESULTS: A total of 299 respondents replied (75%
      students) the questionnaire. The analysis showed a statistically significant
      association between knowledge of the law and information procedures (P < 0.0001),
      access to medical files (P = 0.004), and recording consent (P = 0.049). It was
      also significant between knowledge of the law and the principles of biomedical
      ethics (P < 0.0001 for autonomy and beneficence). The third-year students could
      state the principles of medical ethics with their percentage always greater than 
      the sixth-year students. After the third year, the students' attitudes switched
      from a social to a medical emphasis, and their point of view regarding patient's 
      autonomy evolved. Patient's refusal of care raised potential conflicts between
      autonomy, professional judgment, information, and consent. CONCLUSION: Ethics
      teaching could offer a way to turn positive attitudes into real competencies and 
      should be considered at an early stage.
CI  - Copyright: (c) 2020 Journal of International Society of Preventive and Community 
      Dentistry.
FAU - Tenenbaum, Annabelle
AU  - Tenenbaum A
AD  - Department of Dental Public Health, Faculty of Dentistry, University Paris
      Diderot, Paris, France.
AD  - Education and Health Practices Laboratory (LEPS) (EA 3412), UFR SMBH, Paris 13
      University, Sorbonne Paris Cite, Bobigny, France.
FAU - Moutel, Gregoire
AU  - Moutel G
AD  - Department of Forensic Medicine, Health Law and Medical Ethics CHU Caen; Anticipe
      (Inserm 1086), University Caen Normandie, Paris, France.
FAU - Wolikow, Maryse
AU  - Wolikow M
AD  - Faculty of Dentistry, Montrouge, University Paris Descartes, Paris, France.
FAU - Vial-Dupuy, Amandine
AU  - Vial-Dupuy A
AD  - Clinical Research Unit, Bichat Hospital, Paris, France.
FAU - Azogui-Levy, Sylvie
AU  - Azogui-Levy S
AD  - Department of Dental Public Health, Faculty of Dentistry, University Paris
      Diderot, Paris, France.
AD  - Education and Health Practices Laboratory (LEPS) (EA 3412), UFR SMBH, Paris 13
      University, Sorbonne Paris Cite, Bobigny, France.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - India
TA  - J Int Soc Prev Community Dent
JT  - Journal of International Society of Preventive & Community Dentistry
JID - 101618802
PMC - PMC7685267
OTO - NOTNLM
OT  - Attitude of health personnel
OT  - education dental professional
OT  - ethics
OT  - informed consent
OT  - personal autonomy
COIS- There are no conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:35
PHST- 2019/09/07 00:00 [received]
PHST- 2019/10/14 00:00 [accepted]
PHST- 2020/12/07 05:35 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.4103/jispcd.JISPCD_364_19 [doi]
AID - JISPCD-10-569 [pii]
PST - epublish
SO  - J Int Soc Prev Community Dent. 2020 Aug 31;10(5):569-578. doi:
      10.4103/jispcd.JISPCD_364_19. eCollection 2020 Sep-Oct.


PMID- 33282641
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2211-4122 (Print)
IS  - 2211-4122 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Apr-Jun
TI  - Discordant Echocardiographic Grading in Low Gradient Aortic Stenosis (DEGAS
      Study) From the Italian Society of Echocardiography and Cardiovascular Imaging
      Research Network: Rationale and Study Design.
PG  - 52-61
LID - 10.4103/jcecho.jcecho_68_20 [doi]
AB  - BACKGROUND: Low-gradient aortic stenosis (LG-AS) is characterized by the
      combination of an aortic valve area compatible with severe stenosis and a low
      transvalvular mean gradient with low-flow state (i.e., indexed stroke volume <35 
      mL/m(2)) in the presence of reduced (classical low-flow AS) or preserved
      (paradoxical low-flow AS) ejection fraction. Furthermore, the occurrence of a
      normal-flow LG-AS is still advocated by many authors. Within this diagnostic
      complexity, the diagnosis of severe AS remains challenging. OBJECTIVE: The
      general objective of the Discordant Echocardiographic Grading in Low-gradient AS 
      (DEGAS Study) study will be to assess the prevalence of true severe AS in this
      population and validate new parameters to improve the assessment and the clinical
      decision-making in patients with LG-AS. METHODS AND ANALYSES: The DEGAS Study of 
      the Italian Society of Echocardiography and Cardiovascular Imaging is a
      prospective, multicenter, observational diagnostic study that will enroll
      consecutively adult patients with LG-AS over 2 years. AS severity will be ideally
      confirmed by a multimodality approach, but only the quantification of calcium
      score by multidetector computed tomography will be mandatory. The primary
      clinical outcome variable will be 12-month all-cause mortality. The secondary
      outcome variables will be (i) 30-day mortality (for patients treated by Surgical 
      aortic valve replacement or TAVR); (ii) 12-month cardiovascular mortality; (iii) 
      12-month new major cardiovascular events such as myocardial infarction, stroke,
      vascular complications, and rehospitalization for heart failure; and (iv)
      composite endpoint of cardiovascular mortality and hospitalization for heart
      failure. Data collection will take place through a web platform (REDCap),
      absolutely secure based on current standards concerning the ethical requirements 
      and data integrity.
CI  - Copyright: (c) 2020 Journal of Cardiovascular Echography.
FAU - Barbieri, Andrea
AU  - Barbieri A
AD  - Division of Cardiology, Department of Diagnostics, Clinical and Public Health
      Medicine, Policlinico University Hospital of Modena, Milano, Italy.
FAU - Antonini-Canterin, Francesco
AU  - Antonini-Canterin F
AD  - Rehabilitative Cardiology, Ospedale Riabilitativo di Alta Specializzazione di
      Motta di Livenza (TV), Milano, Italy.
FAU - Pepi, Mauro
AU  - Pepi M
AD  - Monzino Cardiology Center, IRCCS, Milano, Italy.
FAU - Monte, Ines Paola
AU  - Monte IP
AD  - Cardiology, AOU Policlinic, University of Catania, Italy.
FAU - Trocino, Giuseppe
AU  - Trocino G
AD  - Cardiology, Hospital of Desio, S. Antonio Hospital, AO Padova, Italy.
FAU - Barchitta, Agata
AU  - Barchitta A
AD  - Emergency Medicine, S. Antonio Hospital, AO Padova, Italy.
FAU - Ciampi, Quirino
AU  - Ciampi Q
AD  - Cardiology, Fatebenefratelli Hospital, Benevento, Italy.
FAU - Cresti, Alberto
AU  - Cresti A
AD  - Cardiology, Dip. Cardio Neuro Vascolare Asl sudest Toscana, Hospital of Grosseto,
      Italy.
FAU - Miceli, Sofia
AU  - Miceli S
AD  - Geriatrics, AOU Mater-Domini, Catanzaro, Italy.
FAU - Petrella, Licia
AU  - Petrella L
AD  - Cardiology, "Mazzini" Hospital, Teramo, Italy.
FAU - Benedetto, Frank
AU  - Benedetto F
AD  - Cardiology, G.O.M. "Bianchi Melacrino Morelli", Reggio Calabria, Italy.
FAU - Zito, Concetta
AU  - Zito C
AD  - Department of Clinical and Experimental Medicine - Section of Cardiology, G.
      Martino General Hospital, University of Messina, Italy.
FAU - Benfari, Giovanni
AU  - Benfari G
AD  - Section of Cardiology, Department of Medicine, University of Verona, Italy.
FAU - Bursi, Francesca
AU  - Bursi F
AD  - Division of Cardiology, Heart and Lung Department, San Paolo Hospital, ASST Santi
      Paolo and Carlo, University of Milan, Italy.
FAU - Malagoli, Alessandro
AU  - Malagoli A
AD  - AOU Modena Baggiovara, Italy.
FAU - Bartolacelli, Ylenia
AU  - Bartolacelli Y
AD  - Pediatric and Adult Congenital Heart Cardiac Surgery, S.Orsola Malpighi Hospital,
      University of Bologna, Italy.
FAU - Mantovani, Francesca
AU  - Mantovani F
AD  - Azienda USL- IRCCS di Reggio Emilia, Italy.
FAU - Clavel, Marie-Annick
AU  - Clavel MA
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec, Universite
      Laval, Quebec City, Quebec, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - India
TA  - J Cardiovasc Echogr
JT  - Journal of cardiovascular echography
JID - 101562228
PMC - PMC7706377
OTO - NOTNLM
OT  - Aortic valve calcium score
OT  - aortic valve stenosis
OT  - diagnosis
OT  - dobutamine stress echocardiography
OT  - echocardiography
COIS- There are no conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:34
PHST- 2020/06/26 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/12/07 05:34 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.4103/jcecho.jcecho_68_20 [doi]
AID - JCE-30-52 [pii]
PST - ppublish
SO  - J Cardiovasc Echogr. 2020 Apr-Jun;30(2):52-61. doi: 10.4103/jcecho.jcecho_68_20. 
      Epub 2020 Aug 17.


PMID- 33282609
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201208
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec 3
TI  - Assessment of Vitamin D Levels in Patients Presenting With Chronic Low Back Pain 
      at a Tertiary Care Hospital.
PG  - e11867
LID - 10.7759/cureus.11867 [doi]
AB  - Objective To evaluate the association of chronic low back pain with levels of
      vitamin D in the affected population. Methodology This observational study was
      carried out from August 2016 to August 2019 at Khairpur Medical College and
      Shaheed Mohatarma Benazir Bhutto Medical College, Karachi, Pakistan. Patients
      aged 18 years and above suffering from chronic low back pain with pain persisting
      for more than 12 weeks were the study participants after written consent and
      prior approval from the ethical review committee was obtained for conducting the 
      study. Data was recorded on predesigned performa and analyzed on SPSS Version 20 
      (IBM Corp.). Results There were 1,152 cases with chronic lower back pain, of whom
      632 (54.9%) were females and 520 (45.1%) were males. The mean age of the patients
      was 41.76 +/- 11.18 years. The mean visual analog scale (VAS) level was 5.36 +/- 
      1.65; 707 cases (61.4%) had moderate pain according to VAS, 292 (25.3%) had
      severe pain, and 153 (13.3%) had mild pain. Concerning vitamin D levels, the mean
      levels were 22.74 +/- 13.80, with 599 (52%) of the patients having deficient
      levels of vitamin D, 347 (30.1%) having insufficient levels, and only 204 (17.7%)
      of the cases having normal vitamin D levels. Conclusions Lower back pain is one
      of the common presenting problems in orthopedic clinics. We found no relationship
      between chronic lower back pain and vitamin D levels in our study.
CI  - Copyright (c) 2020, Kumar et al.
FAU - Kumar, Mukesh
AU  - Kumar M
AD  - Orthopedic Surgery, Begum Haji Yousuf (BHY) Jamiyiat Hospital Karachi, Karachi,
      PAK.
FAU - Ahmed, Masroor
AU  - Ahmed M
AD  - Orthopedic Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi,
      PAK.
FAU - Hussain, Ghulam
AU  - Hussain G
AD  - Orthopedic Surgery, Sheikh Zayed Taluka Headquarter Hospital, Karachi, PAK.
FAU - Bux, Muhammad
AU  - Bux M
AD  - Orthopedic Surgery, Shaheed Mohtarma Benazir Bhutto Medical College, Karachi,
      PAK.
FAU - Ahmed, Naveed
AU  - Ahmed N
AD  - Orthopedic Surgery, Khairpur Medical College, Sindh, PAK.
FAU - Kumar, Sunil
AU  - Kumar S
AD  - Trauma and Orthopedic Surgery, Dow University of Health Sciences, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201203
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7714737
OTO - NOTNLM
OT  - chronic low back pain (clbp)
OT  - vas for pain
OT  - vitamin d
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:34
PHST- 2020/12/07 05:34 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.7759/cureus.11867 [doi]
PST - epublish
SO  - Cureus. 2020 Dec 3;12(12):e11867. doi: 10.7759/cureus.11867.


PMID- 33282219
OWN - NLM
STAT- MEDLINE
DCOM- 20201228
LR  - 20201228
IS  - 2047-2986 (Electronic)
IS  - 2047-2978 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Dec
TI  - The ethical dilemma of ventilator sharing during the COVID-19 pandemic.
PG  - 020392
LID - 10.7189/jogh.10.020392 [doi]
FAU - Bhatt, Harshil
AU  - Bhatt H
AD  - Goshen Hospital, Goshen, Indiana, USA.
AD  - Indiana University School of Medicine, South Bend, Indiana, USA.
FAU - Singh, Sandeep
AU  - Singh S
AD  - Indiana University School of Medicine, South Bend, Indiana, USA.
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - J Glob Health
JT  - Journal of global health
JID - 101578780
SB  - IM
MH  - COVID-19/*therapy
MH  - *Ethics, Medical
MH  - Global Health
MH  - Humans
MH  - Informed Consent
MH  - *Resource Allocation
MH  - Respiratory Insufficiency/therapy
MH  - SARS-CoV-2
MH  - Standard of Care/ethics
MH  - Ventilators, Mechanical/*supply & distribution
PMC - PMC7688199
COIS- Competing interests: The authors completed the ICMJE Unified Competing Interest
      form (available upon request from the corresponding author) and declare no
      conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/07 05:33
PHST- 2020/12/07 05:33 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.7189/jogh.10.020392 [doi]
AID - jogh-10-020392 [pii]
PST - ppublish
SO  - J Glob Health. 2020 Dec;10(2):020392. doi: 10.7189/jogh.10.020392.


PMID- 33281581
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201208
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Linking)
VI  - 14
DP  - 2020
TI  - Researcher Perspectives on Ethical Considerations in Adaptive Deep Brain
      Stimulation Trials.
PG  - 578695
LID - 10.3389/fnhum.2020.578695 [doi]
AB  - Interest and investment in closed-loop or adaptive deep brain stimulation (aDBS) 
      systems have quickly expanded due to this neurotechnology's potential to more
      safely and effectively treat refractory movement and psychiatric disorders
      compared to conventional DBS. A large neuroethics literature outlines potential
      ethical concerns about conventional DBS and aDBS systems. Few studies, however,
      have examined stakeholder perspectives about ethical issues in aDBS research and 
      other next-generation DBS devices. To help fill this gap, we conducted
      semi-structured interviews with researchers involved in aDBS trials (n = 23) to
      gain insight into the most pressing ethical questions in aDBS research and any
      concerns about specific features of aDBS devices, including devices' ability to
      measure brain activity, automatically adjust stimulation, and store neural data. 
      Using thematic content analysis, we identified 8 central themes in researcher
      responses. The need to measure and store neural data for aDBS raised concerns
      among researchers about data privacy and security issues (noted by 91% of
      researchers), including the avoidance of unintended or unwanted third-party
      access to data. Researchers reflected on the risks and safety (83%) of aDBS due
      to the experimental nature of automatically modulating then observing stimulation
      effects outside a controlled clinical setting and in relation to need for
      surgical battery changes. Researchers also stressed the importance of ensuring
      informed consent and adequate patient understanding (74%). Concerns related to
      automaticity and device programming (65%) were discussed, including current
      uncertainties about biomarker validity. Additionally, researchers discussed the
      potential impacts of automatic stimulation on patients' autonomy and control over
      stimulation (57%). Lastly, researchers discussed concerns related to patient
      selection (defining criteria for candidacy) (39%), challenges of ensuring
      post-trial access to care and device maintenance (39%), and potential effects on 
      personality and identity (30%). To help address researcher concerns, we discuss
      the need to minimize cybersecurity vulnerabilities, advance biomarker validity,
      promote the balance of device control between patients and clinicians, and
      enhance ongoing informed consent. The findings from this study will help inform
      policies that will maximize the benefits and minimize potential harms of aDBS and
      other next-generation DBS devices.
CI  - Copyright (c) 2020 Munoz, Kostick, Sanchez, Kalwani, Torgerson, Hsu,
      Sierra-Mercado, Robinson, Outram, Koenig, Pereira, McGuire, Zuk and Lazaro-Munoz.
FAU - Munoz, Katrina A
AU  - Munoz KA
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Kostick, Kristin
AU  - Kostick K
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Sanchez, Clarissa
AU  - Sanchez C
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Kalwani, Lavina
AU  - Kalwani L
AD  - Department of Neuroscience, Rice University, Houston, TX, United States.
FAU - Torgerson, Laura
AU  - Torgerson L
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Hsu, Rebecca
AU  - Hsu R
AD  - Evans School of Public Policy & Governance, University of Washington, Seattle,
      WA, United States.
FAU - Sierra-Mercado, Demetrio
AU  - Sierra-Mercado D
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
AD  - Department of Anatomy & Neurobiology, University of Puerto Rico School of
      Medicine, San Juan, Puerto Rico.
FAU - Robinson, Jill O
AU  - Robinson JO
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Outram, Simon
AU  - Outram S
AD  - Program in Bioethics, University of California, San Francisco, San Francisco, CA,
      United States.
FAU - Koenig, Barbara A
AU  - Koenig BA
AD  - Program in Bioethics, University of California, San Francisco, San Francisco, CA,
      United States.
FAU - Pereira, Stacey
AU  - Pereira S
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - McGuire, Amy
AU  - McGuire A
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Zuk, Peter
AU  - Zuk P
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
FAU - Lazaro-Munoz, Gabriel
AU  - Lazaro-Munoz G
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, United States.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC7689343
OTO - NOTNLM
OT  - ELSI
OT  - bioethics
OT  - closed-loop
OT  - deep brain stimulation
OT  - ethics
OT  - interviews
OT  - neuroethics
OT  - neuromodulation
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:30
PHST- 2020/07/01 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/12/07 05:30 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.3389/fnhum.2020.578695 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2020 Nov 12;14:578695. doi: 10.3389/fnhum.2020.578695.
      eCollection 2020.


PMID- 33281315
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 10
DP  - 2020 Oct
TI  - A Multicenter Questionnaire-based Study to Know the Awareness and Medical
      Treatment Plan of Physicians Involved in the Management of COVID-19 Patients.
PG  - 919-925
LID - 10.5005/jp-journals-10071-23567 [doi]
AB  - INTRODUCTION: The pandemic coronavirus disease 2019 (COVID-19) is on the rise in 
      our country and there is no specific treatment modality available presently. The 
      treatment of the disease largely remains symptomatic but repurposed drugs used to
      treat other disease conditions are being used to treat moderate to severe form of
      the disease. As the clinical trials for these drugs are ongoing, we conducted
      this survey to know the physicians' medical treatment plan for COVID-19 patients.
      MATERIALS AND METHODS: It was a web-based questionnaire study. Institutional
      ethical committee clearance was taken before the commencement of the study. There
      were a total of 17 questions, the first 6 being about the demographics, place of 
      work, and whether the clinician was involved in the care of COVID-19 patients.
      Subsequent 11 questions were to assess physician's awareness and plan of the
      medical management of the COVID-19 patients. RESULTS: The majority of the
      clinicians were aware of the various treatment modalities available for the
      treatment of COVID-19. Regarding the plan for use of hydroxychloroquine (HCQ),
      55% of the total respondents intended to use the drug in combination with
      azithromycin, even as 62% agreed that there was no clear evidence yet. About 90% 
      of all clinicians, from junior residents to consultants, were monitoring
      electrocardiogram (ECG) during HCQ therapy; however, there were 10% of physicians
      who were not practicing ECG monitoring. About 68% of clinicians were aware of the
      various therapeutic options being tested, like convalescent plasma,
      lopinavir-ritonavir, and 64% knew about remdesivir. There was divergence
      regarding the use of steroids in a cytokine storm among the physicians, with only
      39% of consultants planning to use steroids whereas about 50% of junior residents
      and 79% of junior consultants were planning to use the drug. CONCLUSION: The
      majority of the clinicians involved in the management of COVID-19 were aware of
      the various drug modalities available for treatment. However, more emphasis on
      the adverse effects and possible drug interactions is required. There is
      disaccord regarding the use of steroids in cytokine storm in COVID-19 and further
      guidelines and educational programs should address these issues. CLINICAL
      SIGNIFICANCE: Clinicians have to be made more aware of the possible adverse
      effects and drug interactions of the medications used for the treatment of
      COVID-19. The treatment of the serious, cytokine storm syndrome and the role of
      steroids must be elucidated as soon as it is feasible. HOW TO CITE THIS ARTICLE: 
      Maddani SS, Chaudhuri S, Deepa HC, Amara V. A Multicenter Questionnaire-based
      Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in 
      the Management of COVID-19 Patients. Indian J Crit Care Med 2020;24(10):919-925.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Maddani, Sagar S
AU  - Maddani SS
AD  - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy
      of Higher Education, Manipal, Karnataka, India.
FAU - Chaudhuri, Souvik
AU  - Chaudhuri S
AD  - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy
      of Higher Education, Manipal, Karnataka, India.
FAU - Deepa, Hunasaghatta Chandrappa
AU  - Deepa HC
AD  - Department of Pathology, Kasturba Medical College, Manipal Academy of Higher
      Education, Manipal, Karnataka, India.
FAU - Amara, Vedaghosh
AU  - Amara V
AD  - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy
      of Higher Education, Manipal, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7689132
OTO - NOTNLM
OT  - Coronavirus disease 2019
OT  - Cytokine storm
OT  - Hydroxychloroquine
OT  - Medical management
OT  - Remdesivir
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
CRDT- 2020/12/07 05:29
PHST- 2020/12/07 05:29 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
AID - 10.5005/jp-journals-10071-23567 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Oct;24(10):919-925. doi:
      10.5005/jp-journals-10071-23567.


PMID- 33281274
OWN - NLM
STAT- Publisher
LR  - 20201208
IS  - 0343-2521 (Print)
IS  - 0343-2521 (Linking)
DP  - 2020 Nov 28
TI  - Refugee research in the shadow of fear.
PG  - 1-13
LID - 10.1007/s10708-020-10342-w [doi]
AB  - What does it mean to conduct community-based and praxis-oriented research at a
      time when those whose lives you study and with whom you work are the subjects of 
      increasing levels of xenophobia, marginalization, and demonization? How does one 
      conceive of research ethics, of the relationship between the roles of scholars,
      teachers, and citizens in light of such dynamics? In what ways can scholarship
      help to intervene in the world around us, in particular to improve the perception
      and amplify the voices of marginalized groups and individuals? This paper
      considers these issues in the context of research ethics and the growing field of
      community geography. I draw in particular on an example from a multi-year study
      of refugee resettlement in non-traditional destinations across the US. When the
      study began, refugee policies and settlement patterns were little known to the
      general public in the US. Since then, refugees and migration more broadly have
      become increasingly prominent and controversial worldwide. In this paper I
      explore some of the challenges regarding collaborations between university
      researchers and community partners, highlighting the tensions exposed through the
      use of the visualization technique known as Photovoice, meant to provide
      alternative perspectives on ideas for urban change amongst participants. I also
      consider some ideas for steps to address these challenges, including the building
      of networks and training for researchers and formalized partnership processes for
      community groups.
CI  - (c) Springer Nature B.V. 2020.
FAU - Bose, Pablo S
AU  - Bose PS
AUID- ORCID: 0000-0002-8727-8667
AD  - Department of Geography, University of Vermont, 200 Old Mill Building, 94
      University Place, Burlington, VT 05405 USA.grid.59062.380000 0004 1936 7689
LA  - eng
PT  - Journal Article
DEP - 20201128
PL  - Germany
TA  - GeoJournal
JT  - GeoJournal
JID - 101084445
PMC - PMC7699016
OTO - NOTNLM
OT  - Community geography
OT  - Photovoice
OT  - Refugees
OT  - Research ethics
OT  - Xenophobia
COIS- Conflict of interestThe authors declare they have no conflicts of interest.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:00
CRDT- 2020/12/07 05:29
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/07 05:29 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:00 [medline]
AID - 10.1007/s10708-020-10342-w [doi]
AID - 10342 [pii]
PST - aheadofprint
SO  - GeoJournal. 2020 Nov 28:1-13. doi: 10.1007/s10708-020-10342-w.


PMID- 33278822
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1460-2156 (Electronic)
IS  - 0006-8950 (Linking)
VI  - 143
IP  - 11
DP  - 2020 Dec 5
TI  - Brain science in Nazi Germany: ethics and euthanasia.
PG  - 3506-3509
LID - 10.1093/brain/awaa322 [doi]
FAU - MacDonogh, Giles
AU  - MacDonogh G
AD  - London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Brain
JT  - Brain : a journal of neurology
JID - 0372537
SB  - IM
EDAT- 2020/12/06 06:00
MHDA- 2020/12/06 06:01
CRDT- 2020/12/05 20:14
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/02 00:00 [received]
PHST- 2020/12/05 20:14 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2020/12/06 06:01 [medline]
AID - 5959869 [pii]
AID - 10.1093/brain/awaa322 [doi]
PST - ppublish
SO  - Brain. 2020 Dec 5;143(11):3506-3509. doi: 10.1093/brain/awaa322.


PMID- 33278005
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210601
IS  - 0301-5556 (Print)
IS  - 0301-5556 (Linking)
VI  - 232
DP  - 2020
TI  - Identifying Mechanisms of Endometriosis-Associated Reduced Fecundity in a Rat
      Model: Novel Insights toward Understanding Human Infertility.
PG  - 9-24
LID - 10.1007/978-3-030-51856-1_2 [doi]
AB  - The existence of endometriosis has been known since at least the nineteenth
      century, yet the lack of understanding of causes of infertility and therefore
      inadequate treatment approaches in endometriosis creates a significant challenge 
      in reproductive medicine. Women worldwide suffer not only pain and infertility
      but also economical, societal, and physiological burdens. Studies of reproductive
      events in women are difficult to conduct due to a host of confounding personal
      and environmental factors and ethically limited due to the very nature of working
      with reproductive tissues and cells, especially embryos. Animal models are a
      viable adjunct to study mechanisms causing human reproductive anomalies and
      infertility in endometriosis. This chapter discusses reproductive anomalies
      causing infertility in endometriosis and well-established animal models which
      help decipher the problems and lead to heretofore unknown nonsurgical,
      nonhormonal methods to manage endometriosis in women. In addition, studies of
      effects of developmental exposure to endometriosis are revealing for the first
      time, in both female and male offspring, transgenerational subfertility in a rat 
      model providing insights into the familial nature of endometriosis and possible
      epigenetic involvement.
FAU - Sharpe-Timms, Kathy L
AU  - Sharpe-Timms KL
AD  - Division of Reproductive & Perinatal Research, The University of Missouri School 
      of Medicine, Columbia, MO, USA. Timmsk@missouri.edu.
FAU - Nabli, Henda
AU  - Nabli H
AD  - Department of Obstetrics, Gynecology and Women's Health, University of Missouri
      School of Medicine, Columbia, MO, USA.
FAU - Stilley, Julie A W
AU  - Stilley JAW
AD  - Department of Obstetrics, Gynecology and Women's Health, University of Missouri
      School of Medicine, Columbia, MO, USA.
AD  - Division of Animal Science, College of Agriculture, Food, and Natural Resources, 
      The University of Missouri, Columbia, MO, USA.
AD  - Department of Emergency Medicine, University of Missouri School of Medicine,
      Columbia, MO, USA.
LA  - eng
GR  - R21 HD080763/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - Germany
TA  - Adv Anat Embryol Cell Biol
JT  - Advances in anatomy, embryology, and cell biology
JID - 0407712
SB  - IM
MH  - Animals
MH  - Endometriosis/*complications/physiopathology
MH  - Female
MH  - Fertility/*physiology
MH  - Humans
MH  - Infertility, Female/*etiology/physiopathology
MH  - Rats
OTO - NOTNLM
OT  - *Developmental biology
OT  - *Developmental origins of health and disease
OT  - *Endometriosis
OT  - *Fecundity
OT  - *Female infertility
OT  - *Male infertility
EDAT- 2020/12/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/05 12:04
PHST- 2020/12/05 12:04 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1007/978-3-030-51856-1_2 [doi]
PST - ppublish
SO  - Adv Anat Embryol Cell Biol. 2020;232:9-24. doi: 10.1007/978-3-030-51856-1_2.


PMID- 33278004
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 0301-5556 (Print)
IS  - 0301-5556 (Linking)
VI  - 232
DP  - 2020
TI  - Introduction to Preclinical Evidence from Animal Models of Endometriosis.
PG  - 1-8
LID - 10.1007/978-3-030-51856-1_1 [doi]
AB  - Endometriosis, the presence and growth of uterine endometrial glandular
      epithelial and stroma cells outside the uterine cavity, causes pain and
      infertility in women and girls of reproductive age. As randomized,
      double-blinded, controlled studies of endometriosis in women are impractical and 
      at times ethically prohibitive, animal models for endometriosis arose as an
      important adjunct to gain mechanistic insights into the etiology and
      pathophysiological mechanisms of this perplexing disorder. A more thorough
      understanding of endometriosis in women may help develop novel noninvasive
      diagnostics, classification systems, therapeutic regimes, and even preventative
      methods for the management of endometriosis. This chapter is intended to
      introduce a brief historical background, biological and epidemiological aspects, 
      the major symptoms, the effects of endocrine-disrupting chemicals, and an example
      of an epigenetic factor of endometriosis in women.
FAU - Sharpe-Timms, Kathy L
AU  - Sharpe-Timms KL
AD  - Division of Reproductive & Perinatal Research, The University of Missouri School 
      of Medicine, Columbia, MO, USA. Timmsk@missouri.edu.
FAU - Stilley, Julie A W
AU  - Stilley JAW
AD  - Department of Obstetrics, Gynecology and Women's Health, University of Missouri
      School of Medicine, Columbia, MO, USA.
AD  - Division of Animal Science, College of Agriculture, Food, and Natural Resources, 
      The University of Missouri, Columbia, MO, USA.
AD  - Department of Emergency Medicine, University of Missouri School of Medicine,
      Columbia, MO, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Adv Anat Embryol Cell Biol
JT  - Advances in anatomy, embryology, and cell biology
JID - 0407712
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Endometriosis/*etiology/pathology
MH  - Endometrium/*pathology
MH  - Female
MH  - Humans
MH  - Infertility, Female/*etiology/pathology
OTO - NOTNLM
OT  - *Animal models
OT  - *Endocrine-disrupting chemicals
OT  - *Endometriosis
OT  - *Infertility
OT  - *Management of endometriosis
OT  - *Pain
OT  - *microRNAs
EDAT- 2020/12/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/05 12:04
PHST- 2020/12/05 12:04 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1007/978-3-030-51856-1_1 [doi]
PST - ppublish
SO  - Adv Anat Embryol Cell Biol. 2020;232:1-8. doi: 10.1007/978-3-030-51856-1_1.


PMID- 33277407
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1473-4265 (Electronic)
IS  - 1468-215X (Linking)
VI  - 46
IP  - 4
DP  - 2020 Dec
TI  - The heart in medicine, history and culture.
PG  - 350-351
LID - 10.1136/medhum-2020-012090 [doi]
FAU - Feiler, Therese
AU  - Feiler T
AD  - Evangelisch-Theologische Fakultat, Ludwig-Maximilians-Universitat Munchen,
      Munich, Germany therese.feiler@evtheol.uni-muenchen.de.
FAU - Hordern, Joshua
AU  - Hordern J
AUID- ORCID: http://orcid.org/0000-0002-0709-683X
AD  - Faculty of Theology and Religion, University of Oxford, Oxford, UK.
LA  - eng
PT  - Editorial
PT  - Historical Article
PL  - United States
TA  - Med Humanit
JT  - Medical humanities
JID - 100959585
SB  - IM
MH  - *Bioethics
MH  - Christianity
MH  - Cultural Diversity
MH  - *Heart
MH  - *History of Medicine
MH  - Humans
MH  - Interdisciplinary Communication
MH  - Morals
MH  - Philosophy
MH  - Social Values
MH  - Theology
OTO - NOTNLM
OT  - cultural history
OT  - history
OT  - medical ethics/bioethics
OT  - philosophy
OT  - theology
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/05 05:27
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/05 05:27 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
AID - medhum-2020-012090 [pii]
AID - 10.1136/medhum-2020-012090 [doi]
PST - ppublish
SO  - Med Humanit. 2020 Dec;46(4):350-351. doi: 10.1136/medhum-2020-012090.


PMID- 33277349
OWN - NLM
STAT- Publisher
LR  - 20201205
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Dec 4
TI  - Recognising our 'invisible infants': there is no internationally agreed
      definition of live birth-is this ethically acceptable?
LID - medethics-2020-106653 [pii]
LID - 10.1136/medethics-2020-106653 [doi]
AB  - Globally, there is a lack of adherence to the WHO definition of live birth. This 
      is leading to untenable ethical inconsistencies due to significant variation in
      which infants are being acknowledged and registered as alive. If an infant is not
      registered as alive, there can be no acknowledgement of their rights as a child, 
      and there are subsequent implications for worldwide child health resources and
      funding. Being alive should not be a quality that is geographically determined.
      This paper explores the differing definitions that are used regarding live birth 
      and the ethical and practical implications for infants, their families and child 
      health worldwide.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Peterson, Jennifer
AU  - Peterson J
AUID- ORCID: http://orcid.org/0000-0002-7248-2016
AD  - Neonatal Intensive Care Unit, St Mary's Maternity Hospital, Manchester University
      NHS Foundation Trust, Manchester, Greater Manchester, UK
      jennifer.peterson@hotmail.co.uk.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - clinical ethics
OT  - neonatology
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2020/12/06 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/07/20 00:00 [received]
PHST- 2020/10/17 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2020/12/06 06:00 [medline]
AID - medethics-2020-106653 [pii]
AID - 10.1136/medethics-2020-106653 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Dec 4. pii: medethics-2020-106653. doi:
      10.1136/medethics-2020-106653.


PMID- 33277290
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Multicentre, prospective registry study of amyotrophic lateral sclerosis in
      mainland China (CHALSR): study protocol.
PG  - e042603
LID - 10.1136/bmjopen-2020-042603 [doi]
AB  - INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a representative rare
      disease characterised by progressive, fatal motor neuron degeneration. Due to the
      unknown aetiology and variability of the phenotypes, there are no accurate
      reports concerning the epidemiology or clinical characteristics of the disease.
      The low prevalence, as previously reported, makes it difficult to carry out
      studies with large samples. The aim of this study was to explore the natural
      history and clinical features of ALS in mainland China through a multicentre,
      prospective cohort study. The findings will both offer a better understanding of 
      ALS and also support the development of a model to study other rare diseases.
      METHODS AND ANALYSIS: Patients from 88 representative hospitals in different
      parts of mainland China will be recruited through a specially designed online
      data system (http://www.chalsr.net/). We aim to recruit 4752 ALS patients over a 
      3-year period. Baseline data will be recorded, and follow-up data will be
      collected every 3 months. The primary outcome is effective survival. Overall
      survival and indices of disease progression will be measured as the secondary
      outcomes. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the
      ethics committee of Peking University Third Hospital (M2019388). Informed written
      consent will be obtained from each participant. Dissemination of the study
      protocol and data will take place primarily through a specially designed online
      data system (http://www.chalsr.net/). The collective results of the study will be
      published in peer-reviewed journals and shared in scientific presentations. TRIAL
      REGISTRATION NUMBER: NCT04328675.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, Ji
AU  - He J
AD  - Neurology, Peking University Third Hospital, Beijing, China.
FAU - Fu, Jia Yu
AU  - Fu JY
AD  - Neurology, Peking University Third Hospital, Beijing, China.
FAU - Chen, Lu
AU  - Chen L
AD  - Neurology, Peking University Third Hospital, Beijing, China.
FAU - He, Jing
AU  - He J
AD  - Neurology, Beijing Hospital, Beijing, Beijing, China.
FAU - Dang, Jingxia
AU  - Dang J
AD  - Neurology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,
      Shaanxi, China.
FAU - Zou, Zhangyu
AU  - Zou Z
AD  - Neurology, Fujian Medical University Union Hospital, Xiamen, Fujian, China.
FAU - Ma, Sha
AU  - Ma S
AD  - Neurology, The First People's Hospital of Yunnan Province, Kunming, Yunnan,
      China.
FAU - Li, Nan
AU  - Li N
AD  - Research Center of Clinical Epidemiology, Peking University Third Hospital,
      Beijing, China.
FAU - Fan, Dongsheng
AU  - Fan D
AUID- ORCID: 0000-0002-6679-0864
AD  - Neurology, Peking University Third Hospital, Beijing, China dsfan2010@sohu.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04328675
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Amyotrophic Lateral Sclerosis/epidemiology
MH  - China/epidemiology
MH  - Disease Progression
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Registries
PMC - PMC7722390
OTO - NOTNLM
OT  - *adult neurology
OT  - *motor neurone disease
OT  - *neuromuscular disease
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042603 [pii]
AID - 10.1136/bmjopen-2020-042603 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e042603. doi: 10.1136/bmjopen-2020-042603.


PMID- 33277289
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Impact of a compression garment, on top of the usual care, in patients with
      breast cancer with early disturbance of the lymphatic transport: protocol of a
      randomised controlled trial.
PG  - e042018
LID - 10.1136/bmjopen-2020-042018 [doi]
AB  - INTRODUCTION: Breast cancer-related lymphoedema (BCRL) is a common phenomenon.
      When lymphoedema is diagnosed late, options for treatment are diminished.
      Therefore, early diagnosis and treatment are very important to alter the
      potential deleterious evolution. Lymphofluoroscopy visualises the superficial
      lymphatic architecture in detail, giving the opportunity to detect a disturbance 
      in the lymphatic transport (ie, dermal backflow) before the lymphoedema is
      clinically visible.The main objective is to investigate if there is an additional
      effect of a compression garment on top of the usual care (ie, information and
      exercises) in patients with early disturbance of the lymphatic transport after
      breast cancer treatment. Development of clinical lymphoedema and/or deterioration
      of the dermal backflow visualised by lymphofluoroscopy is investigated.
      METHODOLOGY: All patients scheduled for breast cancer surgery with unilateral
      axillary lymph node dissection or sentinel node biopsy in the Multidisciplinary
      Breast Clinic of the University Hospitals Leuven are being considered. Patients
      are assessed before surgery and at 1, 3, 6, 9, 12, 18, 24 and 36 months
      postoperatively. At each visit, a clinical assessment is performed determining
      the volume difference between both arms and hands (through circumference
      measurements and water displacement), the water content, the extracellular fluid,
      the pitting status and the skinfold thickness. Quality of life questionnaires are
      filled in. At each visit, a lymphofluoroscopy is performed as well. When a
      disturbance of the lymphatic transport is seen on lymphofluoroscopy, without the 
      presence of clinical lymphoedema, the patient is randomised in either a control
      group receiving usual care or a preventive treatment group receiving usual care
      and a compression garment (whether or not combined with a glove). ETHICS AND
      DISSEMINATION: The trial is conducted in compliance with the principles of the
      Declaration of Helsinki (2008), the principles of Good Clinical Practice and in
      accordance with all applicable regulatory requirements. This protocol has been
      approved by the Ethical Committee of the University Hospitals Leuven. Results
      will be disseminated by peer-reviewed scientific journals and presentation at
      international congresses. TRIAL REGISTRATION NUMBER: NCT03210311 CONCLUSION: The 
      investigators hypothesise that development of clinical BCRL can be prevented
      and/or the dermal backflow can be stabilised or improved, if a preventive
      treatment with compression garment is started in the early phase of disturbance.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Thomis, Sarah
AU  - Thomis S
AUID- ORCID: 0000-0002-8491-6264
AD  - Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium
      sarah.thomis@uzleuven.be.
AD  - Department Cardiovascular sciences, Research unit Vascular Surgery, KU Leuven -
      University of Leuven, Leuven, Belgium.
FAU - Devoogdt, Nele
AU  - Devoogdt N
AD  - Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.
AD  - Department of Rehabilitation Sciences, KU Leuven - University Hospitals of
      Leuven, Leuven, Belgium.
FAU - Bechter-Hugl, Beate
AU  - Bechter-Hugl B
AD  - Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.
FAU - Nevelsteen, Ines
AU  - Nevelsteen I
AD  - Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium.
FAU - Neven, Patrick
AU  - Neven P
AD  - Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium.
FAU - Fourneau, Inge
AU  - Fourneau I
AD  - Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.
AD  - Department Cardiovascular sciences, Research unit Vascular Surgery, KU Leuven -
      University of Leuven, Leuven, Belgium.
LA  - eng
SI  - ClinicalTrials.gov/NCT03210311
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Breast Cancer Lymphedema/diagnostic imaging/therapy
MH  - *Breast Neoplasms/complications
MH  - Clothing
MH  - Humans
MH  - Quality of Life
PMC - PMC7722384
OTO - NOTNLM
OT  - *breast tumours
OT  - *cardiovascular imaging
OT  - *vascular surgery
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - bmjopen-2020-042018 [pii]
AID - 10.1136/bmjopen-2020-042018 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e042018. doi: 10.1136/bmjopen-2020-042018.


PMID- 33277287
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Protocol for an implementation study of an evidence-based home cardiac
      rehabilitation programme for people with heart failure and their caregivers in
      Scotland (SCOT:REACH-HF).
PG  - e040771
LID - 10.1136/bmjopen-2020-040771 [doi]
AB  - INTRODUCTION: Despite evidence that cardiac rehabilitation (CR) is an essential
      component of care for people with heart failure, uptake is low. A centre-based
      format is a known barrier, suggesting that home-based programmes might improve
      accessibility. The aim of SCOT: Rehabilitation EnAblement in CHronic Heart
      Failure (REACH-HF) is to assess the implementation of the REACH-HF home-based CR 
      intervention in the context of the National Health Service (NHS) in Scotland.This
      paper presents the design and protocol for this observational implementation
      study. Specific objectives of SCOT:REACH-HF are to: (1) assess service-level
      facilitators and barriers to the implementation of REACH-HF; (2) compare
      real-world patient and caregiver outcomes to those seen in a prior clinical
      trial; and (3) estimate the economic (health and social) impact of implementing
      REACH-HF in Scotland. METHODS AND ANALYSIS: The REACH-HF intervention will be
      delivered in partnership with four 'Beacon sites' across six NHS Scotland Health 
      Boards, covering rural and urban areas. Health professionals from each site will 
      be trained to facilitate delivery of the 12-week programme to 140 people with
      heart failure and their caregivers. Patient and caregiver outcomes will be
      assessed at baseline and 4-month follow-up. Assessments include the Minnesota
      Living with Heart Failure Questionnaire (MLHFQ), five-dimension EuroQol 5L,
      Hospital Anxiety and Depression Scale, and the Caregiver Burden Questionnaire.
      Qualitative interviews will be conducted with up to 20 health professionals
      involved in programme delivery (eg, cardiac nurses, physiotherapists). 65
      facilitator-patient consultations will be audio recorded and assessed for
      fidelity. Integrative analysis will address key research questions on fidelity,
      context and CR participant-related outcomes. The SCOT:REACH-HF findings will
      inform the future potential roll-out of REACH-HF in Scotland. ETHICS AND
      DISSEMINATION: The study has been given ethical approval by the West of Scotland 
      Research Ethics Service (reference 20/WS/0038, approved 25 March 2020). Written
      informed consent will be obtained from all participants. The study is listed on
      the ISRCTN registry with study ID ISRCTN53784122. The research team will ensure
      that the study is conducted in accordance with both General Data Protection
      Regulations and the University of Glasgow's Research Governance Framework.
      Findings will be reported to the funder and shared with Beacon Sites, to
      facilitate service evaluation, planning and good practice. To broaden interest
      in, and understanding of REACH-HF, we will seek to publish in peer-reviewed
      scientific journals and present at stakeholder events, national and international
      conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Purcell, Carrie
AU  - Purcell C
AUID- ORCID: 0000-0002-2651-9201
AD  - MRC/CSO SPHSU, University of Glasgow, Glasgow, UK Carrie.Purcell@glasgow.ac.uk.
FAU - Daw, Paulina
AU  - Daw P
AUID- ORCID: 0000-0002-0942-3953
AD  - School of Sport, Exercise & Rehabilitation Sciences, University of Birmingham,
      Birmingham, UK.
FAU - Kerr, Claire
AU  - Kerr C
AD  - Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
FAU - Cleland, J
AU  - Cleland J
AD  - Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
FAU - Cowie, Aynsley
AU  - Cowie A
AD  - Cardiac Rehabilitation, University Hospital Crosshouse, NHS Ayrshire and Arran,
      Kilmarnock, UK.
FAU - Dalal, Hasnain M
AU  - Dalal HM
AUID- ORCID: 0000-0002-7316-7544
AD  - Royal Cornwall Hospitals NHS Trust, Truro, UK.
AD  - College of Medicine and Health, University of Exeter Medical School, Exeter, UK.
FAU - Ibbotson, Tracy
AU  - Ibbotson T
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Murphy, Clare
AU  - Murphy C
AD  - Royal Alexandra Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
FAU - Taylor, Rod
AU  - Taylor R
AD  - MRC/CSO Social and Public Health Sciences Unit and Robertson Centre for
      Biostatistics, University of Glasgow, Glasgow, UK.
LA  - eng
GR  - SPHSU14/CSO_/Chief Scientist Office/United Kingdom
GR  - MC_PC_13027/MRC_/Medical Research Council/United Kingdom
GR  - SPHSU16/CSO_/Chief Scientist Office/United Kingdom
GR  - MC_UU_12017/14/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00022/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19
MH  - *Cardiac Rehabilitation
MH  - Caregivers
MH  - Heart Failure
MH  - Humans
MH  - Prospective Studies
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - Scotland
MH  - State Medicine
PMC - PMC7722379
OTO - NOTNLM
OT  - *cardiology
OT  - *heart failure
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-040771 [pii]
AID - 10.1136/bmjopen-2020-040771 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e040771. doi: 10.1136/bmjopen-2020-040771.


PMID- 33277286
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Scoping review protocol: the use of telemedicine in providing opioid agonist
      treatment and related psychosocial supports.
PG  - e040556
LID - 10.1136/bmjopen-2020-040556 [doi]
AB  - INTRODUCTION: The global opioid-related disease burden is significant. Opioid
      agonist treatment (OAT) can be effective in reducing illicit opioid use and fatal
      overdose, and improving multiple health and social outcomes. Despite evidence for
      its effectiveness, there are significant deficits in OAT globally. COVID-19 has
      required rapid adaptation of remote models of healthcare. Telemedicine is not
      used routinely in OAT, and little is known about the current levels of use and
      effectiveness. The objective of this review is to describe models of telemedicine
      and their efficacy. METHODS AND ANALYSIS: This scoping review uses the review
      methodology described by Arksey and O'Malley and adapted by Levac et al. The
      search strategy developed by the medical librarian at the Irish College of
      General Practitioners in conjunction with the research team will involve five
      databases (PubMed, EMBASE, the Cochrane Library, PsycInfo and OpenGrey) and the
      hand searching of reference lists. A limited initial search of two databases will
      be completed to refine search terms, followed by a second comprehensive search
      using newly refined search terms of all databases and finally hand searching
      references of included studies. To be included, studies must report on remote
      ways of providing OAT (including assessment, induction and monitoring) or related
      psychosocial support; be published in English after 2010. Two researchers will
      independently screen titles, abstracts and full-text articles considered for
      inclusion. Data will be extracted onto an agreed template and will undergo a
      descriptive analysis of the contextual or process-oriented data and simple
      quantitative analysis using descriptive statistics. ETHICS AND DISSEMINATION:
      Research ethics approval is not required for this scoping review. The results of 
      this scoping review will inform the development of a national remote model of
      OAT. The results will be published in peer-reviewed journals and presented at
      relevant conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Crowley, Des
AU  - Crowley D
AUID- ORCID: http://orcid.org/0000-0002-8491-9596
AD  - School of Medicine, University College Dublin, Dublin, Ireland
      doctordes@hotmail.com.
FAU - Homeniuk, Robyn
AU  - Homeniuk R
AUID- ORCID: http://orcid.org/0000-0002-5526-4113
AD  - Management of Addiction in Primary Care, Irish College of General Practitioners, 
      Dublin, Ireland.
FAU - Delargy, Ide
AU  - Delargy I
AD  - Substance Misuse, Irish College of General Practitioners, Dublin, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/*therapeutic use
MH  - Humans
MH  - Opioid Epidemic
MH  - Opioid-Related Disorders/*therapy
MH  - *Psychosocial Support Systems
MH  - Review Literature as Topic
MH  - Telemedicine/*methods
PMC - PMC7722370
OTO - NOTNLM
OT  - *public health
OT  - *substance misuse
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-040556 [pii]
AID - 10.1136/bmjopen-2020-040556 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e040556. doi: 10.1136/bmjopen-2020-040556.


PMID- 33277285
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Randomised controlled trial of conditioning regimen for cord blood
      transplantation for adult myeloid malignancies comparing high-dose
      cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF
      priming: G-CONCORD study protocol.
PG  - e040467
LID - 10.1136/bmjopen-2020-040467 [doi]
AB  - INTRODUCTION: A better long-term quality of life after umbilical cord blood
      transplantation (CBT) is observed compared with transplants from other
      alternative donors, whereas graft failure and relapses after CBT are still major 
      issues. To minimise graft failure and relapse after CBT, intensification of
      conditioning by the addition of high-dose cytosine arabinoside (CA) and
      concomitant continuous use of granulocyte-colony stimulating factor (G-CSF) are
      reported to convey a significantly better survival after CBT in some
      retrospective studies. To confirm the effect of G-CSF plus CA combination, in
      addition to the standard conditioning regimen, cyclophosphamide (CY)/total body
      irradiation (TBI), we design a randomised controlled study comparing CA/CY/TBI
      with versus without G-CSF priming (G-CSF combined conditioned cord blood
      transplantation [G-CONCORD] study). METHODS AND ANALYSIS: This is a multicentre, 
      open-label, randomised phase III study that aimed to compare G-CSF+CA/CY/TBI as a
      conditioning regimen for CBT with CA/CY/TBI. Patients with acute myeloid
      leukaemia or myelodysplastic syndrome, aged 16-55 years, are eligible. The target
      sample size is 160 and the registration period is 4 years. The primary endpoint
      is the 2-year disease-free survival rate after CBT. The secondary endpoints are
      overall survival, relapse, non-relapse mortality, acute and chronic
      graft-versus-host disease, engraftment rate, time to neutrophil recovery,
      short-term adverse events, incidence of infections and causes of death.This study
      employs a single one-to-one web-based randomisation between the with-G-CSF versus
      without-G-CSF groups after patient registration. Combination of high-dose CA and 
      CY/TBI in both groups is used for conditioning. ETHICS AND DISSEMINATION: The
      study protocol was approved by the central review board, Nagoya University
      Certified Review Board, after the enforcement of the Clinical Trials Act in
      Japan. The manuscripts presenting data from this study will be submitted for
      publication in quality peer-reviewed medical journals. Study findings will be
      disseminated via presentations at national/international conferences and
      peer-reviewed journals. TRIAL REGISTRATION NUMBERS: UMIN000029947 and
      jRCTs041180059.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Terakura, Seitaro
AU  - Terakura S
AUID- ORCID: 0000-0002-1194-8046
AD  - Department of Hematology and Oncology, Nagoya University Graduate School of
      Medicine, Nagoya, Japan tseit@med.nagoya-u.ac.jp.
FAU - Konuma, Takaaki
AU  - Konuma T
AD  - Department of Hematology/Oncology, The Institute of Medical Science The
      University of Tokyo, Tokyo, Japan.
FAU - Tanaka, Masatsugu
AU  - Tanaka M
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Ozawa, Yukiyasu
AU  - Ozawa Y
AD  - Department of Hematology and Oncology, Japanese Red Cross Nagoya First Hospital, 
      Nagoya, Japan.
FAU - Onizuka, Makoto
AU  - Onizuka M
AD  - Department of Hematology and Oncology, Tokai University School of Medicine
      Graduate School of Medicine, Isehara, Japan.
FAU - Nanno, Satoshi
AU  - Nanno S
AD  - Department of Hematology, Osaka City University Graduate School of Medicine
      School of Medicine, Osaka, Japan.
FAU - Onishi, Yasushi
AU  - Onishi Y
AD  - Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai,
      Japan.
FAU - Aotsuka, Nobuyuki
AU  - Aotsuka N
AD  - Division of Hematology-Oncology, Japanese Red Cross Society Narita Hospital,
      Narita, Japan.
FAU - Kondo, Tadakazu
AU  - Kondo T
AD  - Department of Hematology and Oncology, Kyoto University Graduate School of
      Medicine, Kyoto, Japan.
FAU - Kawakita, Toshiro
AU  - Kawakita T
AD  - Department of Hematology, National Hospital Organisation Kumamoto Medical Center,
      Kumamoto, Japan.
FAU - Kato, Jun
AU  - Kato J
AD  - Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
FAU - Kobayashi, Takeshi
AU  - Kobayashi T
AD  - Division of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Nishida, Tetsuya
AU  - Nishida T
AD  - Department of Hematology and Oncology, Nagoya University Graduate School of
      Medicine, Nagoya, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Department of Biostatistics, Graduate School of Medicine, Tohoku University,
      Sendai, Japan.
FAU - Kuwatsuka, Yachiyo
AU  - Kuwatsuka Y
AD  - Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
FAU - Takahashi, Satoshi
AU  - Takahashi S
AD  - Department of Hematology/Oncology, The Institute of Medical Science The
      University of Tokyo, Tokyo, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000029947
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 04079A1RDZ (Cytarabine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Cord Blood Stem Cell Transplantation
MH  - Cyclophosphamide
MH  - Cytarabine
MH  - Granulocyte Colony-Stimulating Factor
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Japan
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - Whole-Body Irradiation
MH  - Young Adult
PMC - PMC7722372
OTO - NOTNLM
OT  - *bone marrow transplantation
OT  - *leukaemia
OT  - *transplant medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - bmjopen-2020-040467 [pii]
AID - 10.1136/bmjopen-2020-040467 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e040467. doi: 10.1136/bmjopen-2020-040467.


PMID- 33277284
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Study protocol: treatment with caffeine of the very preterm infant in the
      delivery room: a feasibility study.
PG  - e040105
LID - 10.1136/bmjopen-2020-040105 [doi]
AB  - INTRODUCTION: Early treatment with caffeine in the delivery room has been
      proposed to decrease the need for mechanical ventilation (MV) by limiting
      episodes of apnoea and improving respiratory mechanics in preterm infants. Thus, 
      the purpose of this feasibility study is to verify the hypothesis that
      intravenous or enteral administration of caffeine can be performed in the preterm
      infant in the delivery room. METHODS AND ANALYSIS: In this multicentre
      prospective study, infants with 25(+0)-29(+6) weeks of gestational age will be
      enrolled and randomised to receive 20 mg/kg of caffeine citrate intravenously,
      via the umbilical vein, or enterally, through an orogastric tube, within 10 min
      of birth. Caffeine plasma level will be measured at 60+/-15 min after
      administration and 60+/-15 min before the next dose (5 mg/kg). The primary
      endpoint will be evaluation of the success rate of intravenous and enteral
      administration of caffeine in the delivery room. Secondary endpoints will be the 
      comparison of success rate of intravenous versus oral administration and the
      evaluation of the need for MV in treated infants. In the absence of previous
      references, we arbitrarily decided to study 20 infants treated with intravenous
      caffeine and 20 infants treated with enteral caffeine. Primary endpoint will be
      evaluated measuring the success rate of intravenous and enteral caffeine
      administration which will be considered a success when it is followed by the
      achievement of the caffeine therapeutic level (8-25 microg/mL) 60+/-15 min before
      administration of the second dose. ETHICS AND DISSEMINATION: The study has been
      approved by the Italian Medicines Agency (AIFA: AIFA/RSC/P/32755) and by Comitato
      Etico Pediatrico Regione Toscana. The results will be published in peer-reviewed 
      academic journals. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier
      NCT04044976; EudraCT number 2018-003626-91.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dani, Carlo
AU  - Dani C
AUID- ORCID: 0000-0002-1639-621X
AD  - Department of Neurosciences, Psychology, Drug Research and Child Health,
      University of Florence, Firenze, Italy cdani@unifi.it.
FAU - Cecchi, Alessandra
AU  - Cecchi A
AD  - Division of Neonatology, Careggi University Hospital of Florence, Florence,
      Italy.
FAU - Remaschi, Giulia
AU  - Remaschi G
AD  - Division of Neonatology, Careggi University Hospital of Florence, Florence,
      Italy.
FAU - Mercadante, Domenica
AU  - Mercadante D
AD  - Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico of Milan, University of 
      Milan, Florence, Italy.
AD  - Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca Granda 
      Ospedale Maggiore Policlinico, Milan, Italy.
FAU - la Marca, Giancarlo
AU  - la Marca G
AD  - Laboratory of Clinical Chemistry and Pharmacology of the A Meyer Pediatric
      Hospital of Florence, University of Florence, Florence, Italy.
FAU - Boni, Luca
AU  - Boni L
AD  - Department of Human Pathology and Oncology, University of Florence, Florence,
      Italy.
FAU - Mosca, Fabio
AU  - Mosca F
AD  - Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca Granda 
      Ospedale Maggiore Policlinico, Milan, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT04044976
SI  - EudraCT/2018-003626-91
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 3G6A5W338E (Caffeine)
SB  - IM
MH  - Caffeine/*pharmacology
MH  - *Delivery Rooms
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Italy
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7722383
OTO - NOTNLM
OT  - *neonatology
OT  - *perinatology
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - bmjopen-2020-040105 [pii]
AID - 10.1136/bmjopen-2020-040105 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e040105. doi: 10.1136/bmjopen-2020-040105.


PMID- 33277281
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Effects of novel flash glucose monitoring system on glycaemic control in adult
      patients with type 1 diabetes mellitus: protocol of a multicentre randomised
      controlled trial.
PG  - e039400
LID - 10.1136/bmjopen-2020-039400 [doi]
AB  - INTRODUCTION: Optimal glycaemic control is beneficial to prevent and delay
      microvascular complications in patients with type 1 diabetes mellitus (T1DM). The
      benefits of flash glucose monitoring (FGM) have been proved among well-controlled
      adults with T1DM, but evidence for FGM in adults with T1DM who have suboptimal
      glycaemic control is limited. This study aims to evaluate the effect of FGM in
      suboptimally controlled adult patients with T1DM . METHODS AND ANALYSIS: This
      open-label, multicentre, randomised trial will be conducted at eight tertiary
      hospitals and recruit 104 adult participants (>/=18 years old) with T1DM
      diagnosed for at least 1 year and with suboptimal glycaemic control (glycated
      haemoglobin (HbA1c) ranging from 7.0% to 10.0%). After a run-in period (baseline,
      0-2 weeks), eligible participants will be randomised 1:1 to either use FGM or
      self-monitoring of blood glucose alone consequently for the next 24 weeks. At
      baseline, 12-14 weeks and 24-26 weeks, retrospective continuous glucose
      monitoring (CGM) systems will be used in both groups for device-related data
      collection. Biological metrics, including HbA1c, blood routine, lipid profiles,
      liver enzymes, questionnaires and adverse events, will be assessed at baseline,
      week 14 and week 26. All analyses will be conducted on the intent-to-treat
      population. Efficacy endpoint analyses will also be repeated on the per-protocol 
      population. The primary outcome is the change of HbA1c from baseline to week 26. 
      The secondary outcomes are the changes of CGM metrics, including time spent in
      range, time spent in target, time spent below range, time spent above range, SD, 
      coefficient of variation, mean amplitude of glucose excursions, high or low blood
      glucose index, mean of daily differences, percentage of HbA1c in target (<7%),
      frequency of FGM use, total daily insulin dose and the scores of questionnaires
      including Diabetes Distress Scale, Hypoglycemia Fear Scale and European Quality
      of Life Scale. ETHICS AND DISSEMINATION: This study was approved by the Ethics
      Committee of the Third Affiliated Hospital of Sun Yat-sen University in January
      2017. Ethical approval has been obtained at all centres. All participants will be
      provided with oral and written information about the trial. The study will be
      disseminated by peer-review publications and conference presentations. TRIAL
      REGISTRATION NUMBER: NCT03522870.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhou, Yongwen
AU  - Zhou Y
AUID- ORCID: 0000-0002-0558-6712
AD  - Department of Endocrinology, the First Affiliated Hospital of USTC, Division of
      Life Science and Medicine, University of Science and Technology of China, Hefei, 
      China.
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China.
FAU - Deng, Hongrong
AU  - Deng H
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China.
FAU - Liu, Hongxia
AU  - Liu H
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China.
FAU - Yang, Daizhi
AU  - Yang D
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China.
FAU - Xu, Wen
AU  - Xu W
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China.
FAU - Yao, Bin
AU  - Yao B
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China.
FAU - Yan, Jinhua
AU  - Yan J
AD  - Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun
      Yat-sen University;Guangdong Provincial Key Laboratory of Diabetology, Guangzhou,
      China yanjh79@163.com wengjp@ustc.edu.cn.
FAU - Weng, Jianping
AU  - Weng J
AD  - Department of Endocrinology, the First Affiliated Hospital of USTC, Division of
      Life Science and Medicine, University of Science and Technology of China, Hefei, 
      China yanjh79@163.com wengjp@ustc.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03522870
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 1/drug therapy
MH  - Glycated Hemoglobin A/analysis
MH  - Glycemic Control
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Quality of Life
MH  - Retrospective Studies
PMC - PMC7722373
OTO - NOTNLM
OT  - *clinical trials
OT  - *diabetes & endocrinology
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - bmjopen-2020-039400 [pii]
AID - 10.1136/bmjopen-2020-039400 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e039400. doi: 10.1136/bmjopen-2020-039400.


PMID- 33277279
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Multilevel influences on resilient healthcare in six countries: an international 
      comparative study protocol.
PG  - e039158
LID - 10.1136/bmjopen-2020-039158 [doi]
AB  - INTRODUCTION: Resilient healthcare (RHC) is an emerging area of theory and
      applied research to understand how healthcare organisations cope with the
      dynamic, variable and demanding environments in which they operate, based on
      insights from complexity and systems theory. Understanding adaptive capacity has 
      been a focus of RHC studies. Previous studies clearly show why adaptations are
      necessary and document the successful adaptive actions taken by clinicians. To
      our knowledge, however, no studies have thus far compared RHC across different
      teams and countries. There are gaps in the research knowledge related to the
      multilevel nature of resilience across healthcare systems and the team-based
      nature of adaptive capacity.This cross-country comparative study therefore aims
      to add knowledge of how resilience is enabled in diverse healthcare systems by
      examining adaptive capacity in hospital teams in six countries. The study will
      identify how team, organisational and national healthcare system factors support 
      or hinder the ability of teams to adapt to variability and change. Findings from 
      this study are anticipated to provide insights to inform the design of RHC
      systems by considering how macro-level and meso-level structures support adaptive
      capacity at the micro-level, and to develop guidance for organisations and
      policymakers. METHODS AND ANALYSIS: The study will employ a multiple comparative 
      case study design of teams nested within hospitals, in turn embedded within six
      countries: Australia, Japan, the Netherlands, Norway, Switzerland and the UK. The
      design will be based on the Adaptive Teams Framework placing adaptive teams at
      the centre of the healthcare system with layers of environmental, organisational 
      and system level factors shaping adaptive capacity. In each of the six countries,
      a focused mapping of the macro-level features of the healthcare system will be
      undertaken by using documentary sources and interviews with key informants
      operating at the macro-level.A sampling framework will be developed to select two
      hospitals in each country to ensure variability based on size, location and
      teaching status. Four teams will be selected in each hospital-one each of a
      structural, hybrid, responsive and coordinating team. A total of eight teams will
      be studied in each country, creating a total sample of 48 teams. Data collection 
      methods will be observations, interviews and document analysis. Within-case
      analysis will be conducted according to a standardised template using a
      combination of deductive and inductive qualitative coding, and cross-case
      analysis will be conducted drawing on the Qualitative Comparative Analysis
      framework. ETHICS AND DISSEMINATION: The overall Resilience in Healthcare
      research programme of which this study is a part has been granted ethical
      approval by the Norwegian Centre for Research Data (Ref. No. 8643334 and Ref. No.
      478838). Ethical approval will also be sought in each country involved in the
      study according to their respective regulatory procedures. Country-specific
      reports of study outcomes will be produced for dissemination online. A collection
      of case study summaries will be made freely available, translated into multiple
      languages. Brief policy communications will be produced to inform policymakers
      and regulators about the study results and to facilitate translation into
      practice. Academic dissemination will occur through publication in journals
      specialising in health services research. Findings will be presented at academic,
      policy and practitioner conferences, including the annual RHC Network meeting and
      other healthcare quality and safety conferences. Presentations at practitioner
      and academic conferences will include workshops to translate the findings into
      practice and influence quality and safety programmes internationally.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Anderson, Janet E
AU  - Anderson JE
AD  - School of Health Sciences, City, University of London, London, UK.
AD  - SHARE-Centre for Resilience in Healthcare, Faculty of Health Sciences, University
      of Stavanger, Stavanger, Norway.
FAU - Aase, Karina
AU  - Aase K
AUID- ORCID: 0000-0002-5363-5152
AD  - SHARE-Centre for Resilience in Healthcare, Faculty of Health Sciences, University
      of Stavanger, Stavanger, Norway.
FAU - Bal, Roland
AU  - Bal R
AD  - School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam,
      South Holland, The Netherlands.
FAU - Bourrier, Mathilde
AU  - Bourrier M
AD  - Department of Sociology, University of Geneva, Geneva, Switzerland.
FAU - Braithwaite, Jeffrey
AU  - Braithwaite J
AUID- ORCID: 0000-0003-0296-4957
AD  - Centre for Healthcare Resilience and Implementation Science, Australian Institute
      of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
FAU - Nakajima, Kazue
AU  - Nakajima K
AD  - Department of Clinical Quality Management, Osaka University Hospital, Osaka,
      Japan.
FAU - Wiig, Siri
AU  - Wiig S
AD  - SHARE-Centre for Resilience in Healthcare, Faculty of Health Sciences, University
      of Stavanger, Stavanger, Norway.
FAU - Guise, Veslemoy
AU  - Guise V
AUID- ORCID: 0000-0002-9124-1664
AD  - SHARE-Centre for Resilience in Healthcare, Faculty of Health Sciences, University
      of Stavanger, Stavanger, Norway veslemoy.guise@uis.no.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - *Medicare
MH  - *State Medicine
MH  - United States
PMC - PMC7722365
OTO - NOTNLM
OT  - *health policy
OT  - *organisation of health services
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - bmjopen-2020-039158 [pii]
AID - 10.1136/bmjopen-2020-039158 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e039158. doi: 10.1136/bmjopen-2020-039158.


PMID- 33277275
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 4
TI  - Comprehensive database and individual patient data meta-analysis of randomised
      controlled trials on psychotherapies reducing suicidal thoughts and behaviour:
      study protocol.
PG  - e037566
LID - 10.1136/bmjopen-2020-037566 [doi]
AB  - INTRODUCTION: Psychotherapy may reduce suicidal thoughts and behaviour, but its
      effectiveness is not well examined. Furthermore, conventional meta-analyses are
      unable to test possible effects of moderators affecting this relationship. This
      protocol outlines the building of a comprehensive database of the literature in
      this research field. In addition, we will conduct an individual patient data
      meta-analysis (IPD-MA) to establish the effectiveness of psychotherapy in
      reducing suicidality, and to examine which factors moderate the efficacy of these
      interventions. METHODS AND ANALYSIS: To build a comprehensive database,
      randomised controlled trials examining the effect of any psychotherapy targeting 
      any psychiatric disorder on suicidal thoughts or behaviour will be identified by 
      running a systematic search in PubMed, Embase, PsycINFO, Web of Science, Scopus
      and The Cochrane Central Register of Controlled Trials from data inception to 12 
      August 2019. For the IPD-MA, we will focus on adult outpatients with suicidal
      ideation or behaviour. In addition, as a comparison group we will focus on a
      control group (waiting-list, care as usual or placebo). A 1-stage IPD-MA will be 
      used to determine the effectiveness of psychotherapy on suicidal ideation,
      suicide attempts and/or suicide deaths, and to investigate potential
      patient-related and intervention-related moderators. Subgroup and sensitivity
      analyses will be conducted to test the robustness of the findings. Additionally, 
      a conventional MA will be conducted to determine the differences between studies 
      that provided IPD and those that did not. IPD-MA may determine the effectiveness 
      of psychotherapy in reducing suicidality and provide insights into the moderating
      factors influencing the efficacy of psychotherapy. Answering these questions will
      inform mental healthcare practitioners about optimal treatments for different
      groups of individuals with suicidal ideation and/or behaviour and consequently
      help to reduce suicide risk. ETHICS AND DISSEMINATION: An ethical approval is not
      required for this study. The results will be published in a peer-review journal. 
      PROSPERO REGISTRATION NUMBER: CRD42020140573.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hu, Mandy Xian
AU  - Hu MX
AUID- ORCID: 0000-0002-4496-8772
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands
      x.hu@113.nl.
AD  - 113 Zelfmoordpreventie, Amsterdam, The Netherlands.
AD  - Department of Psychiatry, Amsterdam Public Health Research Institute, VU
      University Medical Center and GGZinGeest, Amsterdam, The Netherlands.
FAU - Palantza, Christina
AU  - Palantza C
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
AD  - Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Setkowski, Kim
AU  - Setkowski K
AD  - 113 Zelfmoordpreventie, Amsterdam, The Netherlands.
FAU - Gilissen, Renske
AU  - Gilissen R
AD  - 113 Zelfmoordpreventie, Amsterdam, The Netherlands.
FAU - Karyotaki, Eirini
AU  - Karyotaki E
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
FAU - Cuijpers, Pim
AU  - Cuijpers P
AUID- ORCID: 0000-0001-5497-2743
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
FAU - Riper, Heleen
AU  - Riper H
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
FAU - de Beurs, Derek
AU  - de Beurs D
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
FAU - Nuij, Chani
AU  - Nuij C
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
FAU - Christensen, Helen
AU  - Christensen H
AD  - Black Dog Institute, University of New South Wales, Sydneyali, New South Wales,
      Australia.
FAU - Calear, Alison
AU  - Calear A
AD  - Centre for Mental Health Research, The Australian National University, Canberra, 
      Australian Capital Territory, Australia.
FAU - Werner-Seidler, Aliza
AU  - Werner-Seidler A
AUID- ORCID: 0000-0002-9046-6159
AD  - Black Dog Institute, University of New South Wales, Sydneyali, New South Wales,
      Australia.
FAU - Hoogendoorn, Adriaan
AU  - Hoogendoorn A
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
FAU - van Balkom, Anton
AU  - van Balkom A
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
AD  - Department of Psychiatry, Amsterdam Public Health Research Institute, VU
      University Medical Center and GGZinGeest, Amsterdam, The Netherlands.
FAU - Eikelenboom, Merijn
AU  - Eikelenboom M
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
AD  - Department of Psychiatry, Amsterdam Public Health Research Institute, VU
      University Medical Center and GGZinGeest, Amsterdam, The Netherlands.
FAU - Smit, Jan
AU  - Smit J
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
AD  - 113 Zelfmoordpreventie, Amsterdam, The Netherlands.
AD  - Department of Psychiatry, Amsterdam Public Health Research Institute, VU
      University Medical Center and GGZinGeest, Amsterdam, The Netherlands.
FAU - van Ballegooijen, Wouter
AU  - van Ballegooijen W
AD  - GGZ InGeest Specialized Mental Health Care, Amsterdam, The Netherlands.
AD  - Department of Psychiatry, Amsterdam Public Health Research Institute, VU
      University Medical Center and GGZinGeest, Amsterdam, The Netherlands.
AD  - Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Databases, Factual
MH  - Humans
MH  - *Psychotherapy
MH  - Randomized Controlled Trials as Topic
MH  - *Suicidal Ideation
PMC - PMC7722389
OTO - NOTNLM
OT  - *Suicide prevention
OT  - *individual patient data
OT  - *meta-analysis
OT  - *protocol
OT  - *psychotherapy
OT  - *randomized controlled trial
COIS- Competing interests: None declared.
EDAT- 2020/12/06 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/12/05 05:26
PHST- 2020/12/05 05:26 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - bmjopen-2020-037566 [pii]
AID - 10.1136/bmjopen-2020-037566 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 4;10(12):e037566. doi: 10.1136/bmjopen-2020-037566.


PMID- 33276900
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1268-6034 (Print)
IS  - 1268-6034 (Linking)
VI  - 25
IP  - 146
DP  - 2020 Nov - Dec
TI  - [Ethics and Covid-19 in nursing homes, a return of experience].
PG  - 21-22
LID - S1268-6034(20)30167-5 [pii]
LID - 10.1016/j.sger.2020.09.007 [doi]
AB  - Covid epidemic and containment have generated numerous ethical dilemmas. Autonomy
      is the most frequently jeopardized ethical principle. Continued commitment has
      run into specific funerary rules of deceased residents. Professional proficiency 
      has been eroded by omnipresent feelings of fear and powerlessness, and by
      medicalized daily activity. Decontainment and after-crisis raise specific ethical
      questionnings.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Zawieja, Philippe
AU  - Zawieja P
AD  - Groupe Orpea, 12 rue Jean-Jaures, 92806 Puteaux cedex, France; Equipe
      organisations en sante, ecole de gestion, universite de Sherbrooke, 2500
      boulevard de l'universite, Sherbrooke J1K2R1, Quebec, Canada; UMR 7367,
      dynamiques europeennes, Centre national de la recherche scientifique/universite
      de Strasbourg, 5 allee du General Rouvillois CS 50008, 67083 Strasbourg cedex,
      France; Centre de recherches Psychanalyse, medecine et societe, UER Etudes
      psychanalytiques, universite de Paris, 8 rue Albert Einstein, 75013 Paris,
      France. Electronic address: p.zawieja-ext@orpea.net.
FAU - Benattar, Linda
AU  - Benattar L
AD  - Groupe Orpea, 12 rue Jean-Jaures, 92806 Puteaux cedex, France.
LA  - fre
PT  - Journal Article
TT  - Ethique et Covid-19 en Ehpad, retour d'experience.
DEP - 20200929
PL  - France
TA  - Soins Gerontol
JT  - Soins. Gerontologie
JID - 9616322
MH  - COVID-19
MH  - *Decision Making
MH  - *Ethics, Nursing
MH  - Ethics, Professional
MH  - Humans
MH  - Nursing Homes/*ethics/organization & administration
MH  - Pandemics
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19
OT  - autonomie
OT  - autonomy
OT  - competence
OT  - continued commitment
OT  - ehpad
OT  - engagement
OT  - ethics
OT  - proficiency
OT  - ethique
EDAT- 2020/12/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/05 05:22
PHST- 2020/12/05 05:22 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S1268-6034(20)30167-5 [pii]
AID - 10.1016/j.sger.2020.09.007 [doi]
PST - ppublish
SO  - Soins Gerontol. 2020 Nov - Dec;25(146):21-22. doi: 10.1016/j.sger.2020.09.007.
      Epub 2020 Sep 29.


PMID- 33276891
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1526-3231 (Electronic)
IS  - 0749-8063 (Linking)
VI  - 36
IP  - 12
DP  - 2020 Dec
TI  - Editorial Commentary: YouTube Videos Provide Poor-Quality Medical Information:
      Don't Believe What You Watch!
PG  - 3048-3049
LID - S0749-8063(20)30656-3 [pii]
LID - 10.1016/j.arthro.2020.07.042 [doi]
AB  - Providing accurate information to patients regarding health conditions, treatment
      options, and prognosis is a crucial aspect of medical management and an ethical
      obligation. Office visits may be limited due to time constraints imposed by
      scheduling, which may result in missed opportunities to provide extensive
      information when history, physical examination, review of diagnostic testing, and
      planning is required. As the Internet is now an established platform and easily
      accessible, patients are increasingly seeking information from websites out of
      curiosity and for additional questions pertaining to their health condition.
      However, the reliability and accuracy of anterior cruciate ligament videos on
      YouTube are of evidence-based very low quality and reliability.
CI  - Copyright (c) 2020 Arthroscopy Association of North America. Published by
      Elsevier Inc. All rights reserved.
FAU - Kunze, Kyle N
AU  - Kunze KN
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - Arthroscopy
JT  - Arthroscopy : the journal of arthroscopic & related surgery : official
      publication of the Arthroscopy Association of North America and the International
      Arthroscopy Association
JID - 8506498
SB  - IM
CON - Arthroscopy. 2020 Dec;36(12):3037-3047. PMID: 32679296
MH  - *Anterior Cruciate Ligament Reconstruction
MH  - Humans
MH  - Reproducibility of Results
MH  - Return to Sport
MH  - *Social Media
MH  - Video Recording
EDAT- 2020/12/06 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/12/05 05:21
PHST- 2020/07/27 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/12/05 05:21 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - S0749-8063(20)30656-3 [pii]
AID - 10.1016/j.arthro.2020.07.042 [doi]
PST - ppublish
SO  - Arthroscopy. 2020 Dec;36(12):3048-3049. doi: 10.1016/j.arthro.2020.07.042.


PMID- 33276815
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec 4
TI  - Single-cell RNA sequencing of equine mesenchymal stromal cells from primary
      donor-matched tissue sources reveals functional heterogeneity in immune
      modulation and cell motility.
PG  - 524
LID - 10.1186/s13287-020-02043-5 [doi]
AB  - BACKGROUND: The efficacy of mesenchymal stromal cell (MSC) therapy is thought to 
      depend on the intrinsic heterogeneity of MSC cultures isolated from different
      tissue sources as well as individual MSCs isolated from the same tissue source,
      neither of which is well understood. To study this, we used MSC cultures isolated
      from horses. The horse is recognized as a physiologically relevant large animal
      model appropriate for translational MSC studies. Moreover, due to its large size 
      the horse allows for the simultaneous collection of adequate samples from
      multiple tissues of the same animal, and thus, for the unique collection of donor
      matched MSC cultures from different sources. The latter is much more challenging 
      in mice and humans due to body size and ethical constraints, respectively.
      METHODS: In the present study, we performed single-cell RNA sequencing
      (scRNA-seq) on primary equine MSCs that were collected from three donor-matched
      tissue sources; adipose tissue (AT), bone marrow (BM), and peripheral blood (PB).
      Based on transcriptional differences detected with scRNA-seq, we performed
      functional experiments to examine motility and immune regulatory function in
      distinct MSC populations. RESULTS: We observed both inter- and intra-source
      heterogeneity across the three sources of equine MSCs. Functional experiments
      demonstrated that transcriptional differences correspond with phenotypic variance
      in cellular motility and immune regulatory function. Specifically, we found that 
      (i) differential expression of junctional adhesion molecule 2 (JAM2) between MSC 
      cultures from the three donor-matched tissue sources translated into altered cell
      motility of BM-derived MSCs when RNA interference was used to knock down this
      gene, and (ii) differences in C-X-C motif chemokine ligand 6 (CXCL6) expression
      in clonal MSC lines derived from the same tissue source correlated with the
      chemoattractive capacity of PB-derived MSCs. CONCLUSIONS: Ultimately, these
      findings will enhance our understanding of MSC heterogeneity and will lead to
      improvements in the therapeutic potential of MSCs, accelerating the transition
      from bench to bedside.
FAU - Harman, Rebecca M
AU  - Harman RM
AD  - Baker Institute for Animal Health, College of Veterinary Medicine, Cornell
      University, Ithaca, NY, 14853, USA.
FAU - Patel, Roosheel S
AU  - Patel RS
AD  - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York,
      NY, 10029, USA.
FAU - Fan, Jennifer C
AU  - Fan JC
AD  - Baker Institute for Animal Health, College of Veterinary Medicine, Cornell
      University, Ithaca, NY, 14853, USA.
FAU - Park, Jee E
AU  - Park JE
AD  - Baker Institute for Animal Health, College of Veterinary Medicine, Cornell
      University, Ithaca, NY, 14853, USA.
FAU - Rosenberg, Brad R
AU  - Rosenberg BR
AD  - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York,
      NY, 10029, USA.
FAU - Van de Walle, Gerlinde R
AU  - Van de Walle GR
AUID- ORCID: 0000-0002-2064-8029
AD  - Baker Institute for Animal Health, College of Veterinary Medicine, Cornell
      University, Ithaca, NY, 14853, USA. grv23@cornell.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201204
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells
MH  - Cell Differentiation
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Horses
MH  - *Mesenchymal Stem Cells
MH  - Mice
MH  - Sequence Analysis, RNA
PMC - PMC7716481
OTO - NOTNLM
OT  - *Cell motility
OT  - *Heterogeneity
OT  - *Immune modulation
OT  - *Mesenchymal stromal cells
OT  - *Single-cell RNA sequencing
EDAT- 2020/12/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/05 05:20
PHST- 2020/08/28 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/05 05:20 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-02043-5 [doi]
AID - 10.1186/s13287-020-02043-5 [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Dec 4;11(1):524. doi: 10.1186/s13287-020-02043-5.


PMID- 33276810
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Dec 4
TI  - A systematic review of the "promising zone" design.
PG  - 1000
LID - 10.1186/s13063-020-04931-w [doi]
AB  - INTRODUCTION: Sample size calculations require assumptions regarding treatment
      response and variability. Incorrect assumptions can result in under- or
      overpowered trials, posing ethical concerns. Sample size re-estimation (SSR)
      methods investigate the validity of these assumptions and increase the sample
      size if necessary. The "promising zone" (Mehta and Pocock, Stat Med 30:3267-3284,
      2011) concept is appealing to researchers for its design simplicity. However, it 
      is still relatively new in the application and has been a source of controversy. 
      OBJECTIVES: This research aims to synthesise current approaches and practical
      implementation of the promising zone design. METHODS: This systematic review
      comprehensively identifies the reporting of methodological research and of
      clinical trials using promising zone. Databases were searched according to a
      pre-specified search strategy, and pearl growing techniques implemented. RESULTS:
      The combined search methods resulted in 270 unique records identified; 171 were
      included in the review, of which 30 were trials. The median time to the interim
      analysis was 60% of the original target sample size (IQR 41-73%). Of the 15
      completed trials, 7 increased their sample size. Only 21 studies reported the
      maximum sample size that would be considered, for which the median increase was
      50% (IQR 35-100%). CONCLUSIONS: Promising zone is being implemented in a range of
      trials worldwide, albeit in low numbers. Identifying trials using promising zone 
      was difficult due to the lack of reporting of SSR methodology. Even when SSR
      methodology was reported, some had key interim analysis details missing, and only
      eight papers provided promising zone ranges.
FAU - Edwards, Julia M
AU  - Edwards JM
AUID- ORCID: http://orcid.org/0000-0001-8337-8962
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK. jmedwards@sheffield.ac.uk.
FAU - Walters, Stephen J
AU  - Walters SJ
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
FAU - Kunz, Cornelia
AU  - Kunz C
AD  - Boehringer Ingelheim, Biberach an der Riss, Biberach, Germany.
FAU - Julious, Steven A
AU  - Julious SA
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201204
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Humans
MH  - *Research Design
MH  - Sample Size
PMC - PMC7718653
OTO - NOTNLM
OT  - Promising zone
OT  - Sample size calculations
OT  - Systematic review
OT  - Unblinded sample size re-estimation
EDAT- 2020/12/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/05 05:20
PHST- 2020/06/08 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/05 05:20 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04931-w [doi]
AID - 10.1186/s13063-020-04931-w [pii]
PST - epublish
SO  - Trials. 2020 Dec 4;21(1):1000. doi: 10.1186/s13063-020-04931-w.


PMID- 33276789
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 4
TI  - Interprofessional versus monoprofessional case-based learning in childhood cancer
      and the effect on healthcare professionals' knowledge and attitudes: study
      protocol for a randomised trial.
PG  - 1124
LID - 10.1186/s12913-020-05980-2 [doi]
AB  - BACKGROUND: Interprofessional education in childhood cancer is a multifaceted
      field involving multiple healthcare professionals with general and specialised
      knowledge and skills. Complex treatment, care and rehabilitation require
      continuous professional development and maintenance of healthcare professionals' 
      competencies in their field of expertise. However, limited knowledge exists in
      comparing interprofessional and monoprofessional education. Only a few randomised
      studies have evaluated the effectiveness and efficiency of interprofessional
      education. The objective of this single-centre, investigator-initiated cluster
      randomised trial is to study the effect of interprofessional versus
      monoprofessional case-based learning on healthcare professionals' knowledge of
      gastrointestinal side effects and attitudes towards team collaboration. METHODS: 
      This study will randomise healthcare professionals to participate in either the
      experimental interprofessional group or the control monoprofessional group of
      case-based learning. The topic of the case-based intervention will be
      gastrointestinal side effects, one of six categories identified in a three-round 
      Scandinavian Delphi study as relevant for interprofessional education in
      childhood cancer. The primary outcome is the self-reported questionnaire
      Assessment of Interprofessional Team Collaboration Scale. Secondary outcomes are 
      measured by the self-reported questionnaires Readiness for Interprofessional
      Learning Scale Questionnaire, Safety Attitudes Questionnaire, and knowledge will 
      be evaluated using a multiple-choice quiz. Participants will receive the
      self-reported questionnaires about 2 weeks before and 1 month after the
      intervention. On the day of the intervention, participants will answer a
      multiple-choice quiz before and after the case-based learning. Linear mixed
      models will be used to compare differences between the two groups in mean scores 
      postintervention, adjusting for preintervention scores. DISCUSSION: This study
      will provide insight into the differences between interprofessional and
      monoprofessional case-based learning and how it affects healthcare professionals'
      knowledge of gastrointestinal side effects and attitudes towards team
      collaboration. TRIAL REGISTRATION: The intervention was registered at Clinical
      Trials.gov : NCT04204109 on December 102,019 and with the National Committee on
      Health Research Ethics: H-19087506 December 112,019 and the Danish Data
      Protection Agency: P-2019-637 October 152,019.
FAU - Topperzer, Martha Krogh
AU  - Topperzer MK
AUID- ORCID: http://orcid.org/0000-0002-6628-5067
AD  - Paediatric Oncology Research Laboratory, Department of Paediatrics and Adolescent
      Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100,
      Copenhagen, Denmark. martha.krogh.topperzer@regionh.dk.
FAU - Hoffmann, Marianne
AU  - Hoffmann M
AD  - Department of Paediatrics and Adolescent Medicine, Rigshospitalet, University of 
      Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Larsen, Hanne Baekgaard
AU  - Larsen HB
AD  - Paediatric Oncology Research Laboratory, Department of Paediatrics and Adolescent
      Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100,
      Copenhagen, Denmark.
FAU - Rosthoj, Susanne
AU  - Rosthoj S
AD  - Section of Biostatistics, Faculty of Health Sciences, University of Copenhagen,
      Oster Farimagsgade 5, 1014, Copenhagen, Denmark.
FAU - Nersting, Jacob
AU  - Nersting J
AD  - Paediatric Oncology Research Laboratory, Department of Paediatrics and Adolescent
      Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100,
      Copenhagen, Denmark.
FAU - Roug, Louise Ingerslev
AU  - Roug LI
AD  - Paediatric Oncology Research Laboratory, Department of Paediatrics and Adolescent
      Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100,
      Copenhagen, Denmark.
FAU - Pontoppidan, Peter
AU  - Pontoppidan P
AD  - Department of Paediatrics and Adolescent Medicine, Rigshospitalet, University of 
      Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Andres-Jensen, Liv
AU  - Andres-Jensen L
AD  - Paediatric Oncology Research Laboratory, Department of Paediatrics and Adolescent
      Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100,
      Copenhagen, Denmark.
FAU - Lausen, Birgitte
AU  - Lausen B
AD  - Department of Paediatrics and Adolescent Medicine, Rigshospitalet, University of 
      Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Schmiegelow, Kjeld
AU  - Schmiegelow K
AD  - Paediatric Oncology Research Laboratory, Department of Paediatrics and Adolescent
      Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100,
      Copenhagen, Denmark.
AD  - Department of Paediatrics and Adolescent Medicine, Rigshospitalet, University of 
      Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Sorensen, Jette Led
AU  - Sorensen JL
AD  - Juliane Marie Centre, Rigshospitalet and Department of Clinical Medicine,
      University of Copenhagen, Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04204109
GR  - 2015-73/Bornecancerfonden
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201204
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Attitude of Health Personnel
MH  - Child
MH  - Health Personnel
MH  - Humans
MH  - Interprofessional Relations
MH  - *Neoplasms/therapy
MH  - *Patient Care Team
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
PMC - PMC7718682
OTO - NOTNLM
OT  - Childhood cancer
OT  - Continuing professional education
OT  - Interprofessional education
OT  - Team collaboration
EDAT- 2020/12/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/05 05:20
PHST- 2020/04/13 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/05 05:20 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05980-2 [doi]
AID - 10.1186/s12913-020-05980-2 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Dec 4;20(1):1124. doi: 10.1186/s12913-020-05980-2.


PMID- 33276783
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1743-0003 (Electronic)
IS  - 1743-0003 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Dec 4
TI  - A comprehensive scheme for the objective upper body assessments of subjects with 
      cerebellar ataxia.
PG  - 162
LID - 10.1186/s12984-020-00790-3 [doi]
AB  - BACKGROUND: Cerebellar ataxia refers to the disturbance in movement resulting
      from cerebellar dysfunction. It manifests as inaccurate movements with delayed
      onset and overshoot, especially when movements are repetitive or rhythmic.
      Identification of ataxia is integral to the diagnosis and assessment of severity,
      and is important in monitoring progression and improvement. Ataxia is identified 
      and assessed by clinicians observing subjects perform standardised movement tasks
      that emphasise ataxic movements. Our aim in this paper was to use data recorded
      from motion sensors worn while subjects performed these tasks, in order to make
      an objective assessment of ataxia that accurately modelled the clinical
      assessment. METHODS: Inertial measurement units and a Kinect(c) system were used 
      to record motion data while control and ataxic subjects performed four
      instrumented version of upper extremities tests, i.e. finger chase test (FCT),
      finger tapping test (FTT), finger to nose test (FNT) and dysdiadochokinesia test 
      (DDKT). Kinematic features were extracted from this data and correlated with
      clinical ratings of severity of ataxia using the Scale for the Assessment and
      Rating of Ataxia (SARA). These features were refined using Feed Backward feature 
      Elimination (the best performing method of four). Using several different
      learning models, including Linear Discrimination, Quadratic Discrimination
      Analysis, Support Vector Machine and K-Nearest Neighbour these extracted features
      were used to accurately discriminate between ataxics and control subjects.
      Leave-One-Out cross validation estimated the generalised performance of the
      diagnostic model as well as the severity predicting regression model. RESULTS:
      The selected model accurately ([Formula: see text]) predicted the clinical scores
      for ataxia and correlated well with clinical scores of the severity of ataxia
      ([Formula: see text], [Formula: see text]). The severity estimation was also
      considered in a 4-level scale to provide a rating that is familiar to the current
      clinically-used rating of upper limb impairments. The combination of FCT and FTT 
      performed as well as all four test combined in predicting the presence and
      severity of ataxia. CONCLUSION: Individual bedside tests can be emulated using
      features derived from sensors worn while bedside tests of cerebellar ataxia were 
      being performed. Each test emphasises different aspects of stability, timing,
      accuracy and rhythmicity of movements. Using the current models it is possible to
      model the clinician in identifying ataxia and assessing severity but also to
      identify those test which provide the optimum set of data. Trial registration
      Human Research and Ethics Committee, Royal Victorian Eye and Ear Hospital, East
      Melbourne, Australia (HREC Reference Number: 11/994H/16).
FAU - Tran, Ha
AU  - Tran H
AUID- ORCID: 0000-0001-5832-7872
AD  - School of Engineering, Deakin University, Pigdons Road, Waurn Ponds, VIC, 3220,
      Australia. thuha@deakin.edu.au.
FAU - Nguyen, Khoa D
AU  - Nguyen KD
AD  - School of Engineering, Deakin University, Pigdons Road, Waurn Ponds, VIC, 3220,
      Australia.
FAU - Pathirana, Pubudu N
AU  - Pathirana PN
AD  - School of Engineering, Deakin University, Pigdons Road, Waurn Ponds, VIC, 3220,
      Australia.
FAU - Horne, Malcolm K
AU  - Horne MK
AD  - Florey Institute of Neuroscience and Mental Health, Royal Parade, Parkville, VIC,
      3052, Australia.
FAU - Power, Laura
AU  - Power L
AD  - Balance Disorders & Ataxia Service, Royal Victorian Eye and Ear Hospital (RVEEH),
      Gisborne St, East Melbourne, VIC, 3002, Australia.
FAU - Szmulewicz, David J
AU  - Szmulewicz DJ
AD  - Florey Institute of Neuroscience and Mental Health, Royal Parade, Parkville, VIC,
      3052, Australia.
AD  - Balance Disorders & Ataxia Service, Royal Victorian Eye and Ear Hospital (RVEEH),
      Gisborne St, East Melbourne, VIC, 3002, Australia.
AD  - Cerebellar Ataxia Clinic, Alfred Hospital, Commercial Road, Prahran, VIC, 3004,
      Australia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201204
PL  - England
TA  - J Neuroeng Rehabil
JT  - Journal of neuroengineering and rehabilitation
JID - 101232233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia
MH  - Biomechanical Phenomena
MH  - Cerebellar Ataxia/*diagnosis/physiopathology
MH  - Discriminant Analysis
MH  - Female
MH  - Fingers/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Movement/physiology
MH  - *Signal Processing, Computer-Assisted
MH  - Upper Extremity/physiopathology
MH  - *Wearable Electronic Devices
PMC - PMC7718681
OTO - NOTNLM
OT  - *Cerebellar ataxia
OT  - *Dysdiadochokinesia
OT  - *Feed backward feature elimination
OT  - *Finger chase
OT  - *Finger tapping
OT  - *Finger to nose
OT  - *Objective assessment
EDAT- 2020/12/06 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/12/05 05:20
PHST- 2020/08/16 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/05 05:20 [entrez]
PHST- 2020/12/06 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
AID - 10.1186/s12984-020-00790-3 [doi]
AID - 10.1186/s12984-020-00790-3 [pii]
PST - epublish
SO  - J Neuroeng Rehabil. 2020 Dec 4;17(1):162. doi: 10.1186/s12984-020-00790-3.


PMID- 33275917
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20220716
IS  - 2352-3018 (Electronic)
IS  - 2352-3018 (Linking)
VI  - 7
IP  - 12
DP  - 2020 Dec
TI  - Adolescent participation in HIV research: consortium experience in low and
      middle-income countries and scoping review.
PG  - e844-e852
LID - S2352-3018(20)30269-1 [pii]
LID - 10.1016/S2352-3018(20)30269-1 [doi]
AB  - Adolescents in low and middle-income countries (LMICs) have a high prevalence of 
      HIV, therefore, it is important that they are included in HIV research. However, 
      ethical challenges regarding consent can hinder adolescent research
      participation. We examined examples from the Prevention and Treatment Through a
      Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained
      Settings (PATC3H) research consortium, which investigates adolescent HIV
      prevention and treatment in seven LMICs: Brazil, Kenya, Mozambique, Nigeria,
      South Africa, Uganda, and Zambia. PATC3H researchers were asked to identify
      ethical and practical challenges of adolescent consent to research participation 
      in these countries. We also did a scoping review of strategies that could improve
      adolescent participation in LMIC HIV studies. Examples from PATC3H research
      highlighted many ethical challenges that affect adolescent participation,
      including inconsistent or absent consent guidance, guidelines that fail to
      account for the full array of adolescents' lives, and variation in how ethical
      review committees assess adolescent studies. Our scoping review identified three 
      consent-related strategies to expand adolescent inclusion: waiving parental
      consent requirements, allowing adolescents to independently consent, and
      implementing surrogate decision making. Our analyses suggest that these
      strategies should be further explored and incorporated into ethical and legal
      research guidance to increase adolescent inclusion in LMIC HIV research.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Day, Suzanne
AU  - Day S
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill, Chapel Hill, NC, USA. Electronic address:
      suzanne.day@med.unc.edu.
FAU - Kapogiannis, Bill G
AU  - Kapogiannis BG
AD  - Maternal and Pediatric Infectious Diseases Branch, Eunice Kennedy Shriver
      National Institute of Child Health and Human Development, Bethesda, MD, USA.
FAU - Shah, Seema K
AU  - Shah SK
AD  - Department of Pediatrics, Northwestern University Feinberg School of Medicine,
      Chicago, IL, USA; Mary Ann and J Milburn Smith Child Health Research, Outreach,
      and Advocacy Center, Stanley Manne Children's Research Institute, Ann and Robert 
      H Lurie Children's Hospital of Chicago, Chicago, IL, USA.
FAU - Wilson, Erin C
AU  - Wilson EC
AD  - San Francisco Department of Public Health, San Francisco, CA, USA.
FAU - Ruel, Theodore D
AU  - Ruel TD
AD  - Department of Pediatrics, University of California, San Francisco, CA, USA.
FAU - Conserve, Donaldson F
AU  - Conserve DF
AD  - Department of Prevention and Community Health, The George Washington University, 
      Washington, DC, USA.
FAU - Strode, Ann
AU  - Strode A
AD  - School of Law, University of KwaZulu-Natal, University Road, Durban, South
      Africa.
FAU - Donenberg, Geri R
AU  - Donenberg GR
AD  - Center for Dissemination and Implementation Science, Department of Medicine,
      University of Illinois at Chicago, Chicago, IL, USA.
FAU - Kohler, Pamela
AU  - Kohler P
AD  - Department of Global Health, University of Washington, Seattle, WA, USA;
      Department of Child, Family, and Population Health Nursing, University of
      Washington, Seattle, WA, USA.
FAU - Slack, Catherine
AU  - Slack C
AD  - HIV AIDS Vaccines Ethics Group, School of Applied Human Sciences, University of
      KwaZulu-Natal, Scottsville, Pietermaritzburg, South Africa.
FAU - Ezechi, Oliver
AU  - Ezechi O
AD  - Nigerian Institute of Medical Research, Medical Compound, Yaba, Lagos, Nigeria.
FAU - Tucker, Joseph D
AU  - Tucker JD
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill, Chapel Hill, NC, USA; School of Medicine, University of North
      Carolina at Chapel Hill, Chapel Hill, NC, USA; Faculty of Infectious Diseases,
      London School of Hygiene & Tropical Medicine.
CN  - PATC3H Consortium Adolescent Bioethics Working Group
LA  - eng
GR  - UG3 HD096908/HD/NICHD NIH HHS/United States
GR  - K99 R00MH110343/MH/NIMH NIH HHS/United States
GR  - UG3 HD096926/HD/NICHD NIH HHS/United States
GR  - R00 MH110343/MH/NIMH NIH HHS/United States
GR  - UH3 HD096929/HD/NICHD NIH HHS/United States
GR  - UG3 HD096929/HD/NICHD NIH HHS/United States
GR  - UG3 HD096906/HD/NICHD NIH HHS/United States
GR  - UM1 AI069476/AI/NIAID NIH HHS/United States
GR  - UG3 HD096914/HD/NICHD NIH HHS/United States
GR  - UG3 HD096875/HD/NICHD NIH HHS/United States
GR  - UG3 HD096920/HD/NICHD NIH HHS/United States
GR  - K24 AI143471/AI/NIAID NIH HHS/United States
GR  - UG3 HD096915/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - Netherlands
TA  - Lancet HIV
JT  - The lancet. HIV
JID - 101645355
SB  - IM
CIN - Lancet HIV. 2021 Apr;8(4):e181. PMID: 33794178
MH  - Age Factors
MH  - Developing Countries
MH  - Ethics, Research
MH  - HIV Infections/*epidemiology
MH  - Humans
MH  - Research
MH  - Socioeconomic Factors
PMC - PMC8491773
MID - NIHMS1712472
EDAT- 2020/12/05 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/12/04 20:08
PHST- 2020/05/07 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/12/04 20:08 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - S2352-3018(20)30269-1 [pii]
AID - 10.1016/S2352-3018(20)30269-1 [doi]
PST - ppublish
SO  - Lancet HIV. 2020 Dec;7(12):e844-e852. doi: 10.1016/S2352-3018(20)30269-1.


PMID- 33275700
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1520-4383 (Electronic)
IS  - 1520-4383 (Linking)
VI  - 2020
IP  - 1
DP  - 2020 Dec 4
TI  - Informed consent for genetic testing in hematology.
PG  - 213-218
LID - 10.1182/hematology.2020000107 [doi]
AB  - Informed consent is a fundamental component of modern health care. All competent 
      adult patients have the legal and ethical authority to accept (consent) or refuse
      (dissent) recommended health-related interventions. Various models of informed
      consent have been described, and herein I introduce a model that divides informed
      consent into 7 distinct elements: competence, voluntariness, disclosure,
      recommendation, understanding, decision, and authorization. Genetic testing,
      which is rapidly becoming a common feature of both clinical care and research in 
      hematology, adds additional layers of complexity to each of these consent
      elements. Using the example case of Mr. Smith, a man with newly diagnosed acute
      myeloid leukemia whose clinicians offer him genetic testing of the leukemia
      through a clinical trial, I highlight the challenges and controversies of
      informed consent for genetic testing, focusing on each consent element as it
      pertains to genetic testing in such a setting. Ultimately, given the growing
      importance of genetic testing for hematologic disorders, clinicians, and
      researchers in hematology should be facile at participating in all aspects of
      informed consent for genetic testing.
CI  - (c) 2020 by The American Society of Hematology.
FAU - Marron, Jonathan M
AU  - Marron JM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
SB  - IM
MH  - *Genetic Testing
MH  - Hematology
MH  - Humans
MH  - *Informed Consent
MH  - Leukemia, Myeloid, Acute/diagnosis/*genetics
MH  - Male
MH  - Middle Aged
PMC - PMC7727563
COIS- Conflict of interest disclosure: J.M.M. receives salary support from the Harvard 
      Medical School Center for Bioethics.
EDAT- 2020/12/05 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/12/04 17:10
PHST- 2020/12/04 17:10 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - 474311 [pii]
AID - 10.1182/hematology.2020000107 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):213-218. doi:
      10.1182/hematology.2020000107.


PMID- 33275570
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20220418
IS  - 0272-9490 (Print)
IS  - 0272-9490 (Linking)
VI  - 74
IP  - 6
DP  - 2020 Nov/Dec
TI  - Current Landscape of Teaching Diversity in Occupational Therapy Education: A
      Scoping Review.
PG  - 7406205100p1-7406205100p15
LID - 10.5014/ajot.2020.044214 [doi]
AB  - IMPORTANCE: Critical research in health professions education makes clear the
      role of educational institutions in perpetuating problematic discourses related
      to diversity, as well as their potential role in dismantling and rebuilding those
      discourses to reflect the realities of power relations that create systemic
      injustice. OBJECTIVE: To provide a comprehensive overview of current pedagogical 
      practices and educational paradigms used by occupational therapy educators to
      teach concepts of, and skills for, equity and diversity. DATA SOURCES: Seven
      education and health care databases were searched for articles published between 
      2007 and 2018. STUDY SELECTION AND DATA COLLECTION: Consensually developed
      criteria were refined until an agreement rate of >80% was achieved among the
      authors. Inclusion criteria focused on entry-level occupational therapy education
      across the world and explicitly examined approaches to teaching diversity. All
      articles meeting the criteria were kept for full-text review (N = 87). FINDINGS: 
      Diversity in professional occupational therapy education programs is taught
      within five main underlying educational paradigms and theories: competency-based 
      (44%), social justice (29%), critical (11%), social accountability (10%), and
      constructivism (6%). Within these paradigms, 14 key pedagogical practices were
      applied, with community service learning (37%), international service learning
      (25%), and didactic or course-based practices (23%) making up the majority of
      pedagogical practices. CONCLUSIONS AND RELEVANCE: Although current occupational
      therapy research demonstrates a trend toward critical paradigms and practices,
      problematic cultural competency theories and uncritical international service
      learning practices continue to dominate occupational therapy education for
      diversity. Educators should implement pedagogies and approaches within critical
      educational paradigms. WHAT THIS ARTICLE ADDS: This article highlights the
      importance to occupational therapy education of attending to coherence across
      educational ethics, paradigms, and learning outcomes in teaching for diversity
      and health equity.
CI  - Copyright (c) 2020 by the American Occupational Therapy Association, Inc.
FAU - Grenier, Marie-Lyne
AU  - Grenier ML
AD  - Marie-Lyne Grenier, MScOT, DOT, is PhD Student, Department of Integrated Studies 
      in Education, Faculty of Education, and Faculty Lecturer, School of Physical and 
      Occupational Therapy, McGill University, Quebec City, Quebec, Canada.
FAU - Zafran, Hiba
AU  - Zafran H
AD  - Hiba Zafran, PhD, OT-Psychotherapist, is Assistant Professor (Professional),
      School of Physical and Occupational Therapy, and Curriculum Developer, Indigenous
      Health Professions Program, McGill University, Quebec City, Quebec, Canada;
      hiba.zafran@mcgill.ca.
FAU - Roy, Laurence
AU  - Roy L
AD  - Laurence Roy, PhD, OT, is Associate Professor, School of Physical and
      Occupational Therapy, McGill University, and Researcher, Douglas Mental Health
      University Institute, Quebec City, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Occup Ther
JT  - The American journal of occupational therapy : official publication of the
      American Occupational Therapy Association
JID - 7705978
SB  - IM
MH  - Humans
MH  - Learning
MH  - *Occupational Therapy/education
MH  - Occupations
MH  - Teaching
EDAT- 2020/12/05 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/04 17:09
PHST- 2020/12/04 17:09 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.5014/ajot.2020.044214 [doi]
PST - ppublish
SO  - Am J Occup Ther. 2020 Nov/Dec;74(6):7406205100p1-7406205100p15. doi:
      10.5014/ajot.2020.044214.


PMID- 33275539
OWN - NLM
STAT- Publisher
LR  - 20220423
IS  - 1543-6136 (Electronic)
IS  - 1381-1118 (Linking)
DP  - 2020 Dec 4
TI  - The Association Between Suicide-Related Media Coverage and Suicide: A
      Cross-Sectional Observational Study.
PG  - 1-14
LID - 10.1080/13811118.2020.1851833 [doi]
AB  - OBJECTIVE: To examine the association between the publication and content of
      suicide-related media reports and actual suicide in Noord Brabant, a province of 
      the Netherlands. METHOD: Between April 2017 and March 2018, a retrospective
      cross-sectional observational study was conducted on suicide-related media
      reports and incident data regarding suicides. Linear regression, Mann-Whitney U
      and negative binomial regression analyses were conducted. RESULTS: In
      Noord-Brabant, a total of 352 people died from suicide during the observation
      period and 440 reports were identified by using the search terms "suicide",
      "self-killing", and "self-murder". No associations between media reports and
      actual suicides were found for any of the analyses performed. CONCLUSIONS: No
      indications were found for an association between media coverage of suicide and
      increases or decreases in actual suicides in Noord-Brabant. The descriptive
      statistics of this study reveal that the regional and national Dutch media are
      doing well with respect to not including elements in their reports that could
      encourage copycat behavior, such as simplifying, romanticizing or dramatizing.
      They could improve on including protective content, for example, providing
      supportive background information. A recommendation for further research is to
      evaluate causal relationships between media and actual suicide. A stepped wedge
      trial might be needed, as this provides an ethical research design to investigate
      this issue in a controlled setting. Also, in such a study, other variables
      influencing the decision to attempt suicide should be taken into account as much 
      as possible.
FAU - Hofstra, Emma
AU  - Hofstra E
AUID- ORCID: https://orcid.org/0000-0003-4871-8997
FAU - Bakker, Marjan
AU  - Bakker M
FAU - Diepstraten, Chiara A M
AU  - Diepstraten CAM
FAU - Elfeddali, Iman
AU  - Elfeddali I
FAU - Lucas, Mathilde S
AU  - Lucas MS
FAU - van Nieuwenhuizen, Chijs
AU  - van Nieuwenhuizen C
FAU - van der Feltz-Cornelis, Christina M
AU  - van der Feltz-Cornelis CM
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - England
TA  - Arch Suicide Res
JT  - Archives of suicide research : official journal of the International Academy for 
      Suicide Research
JID - 9504451
SB  - IM
OTO - NOTNLM
OT  - Guidelines
OT  - Netherlands
OT  - media
OT  - prevention
OT  - suicide
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:00
CRDT- 2020/12/04 17:09
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:00 [medline]
PHST- 2020/12/04 17:09 [entrez]
AID - 10.1080/13811118.2020.1851833 [doi]
PST - aheadofprint
SO  - Arch Suicide Res. 2020 Dec 4:1-14. doi: 10.1080/13811118.2020.1851833.


PMID- 33275387
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1538-1145 (Electronic)
IS  - 1527-4160 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Nov
TI  - Therapeutic Risk Management for Violence: Stratifying Risk and Characterizing
      Violence.
PG  - 503-509
LID - 10.1097/PRA.0000000000000510 [doi]
AB  - Violence risk assessment is a requisite component of mental health treatment.
      Adhering to standards of care and ethical and legal requirements necessitates a
      cogent process for conducting, and then documenting, other-directed violence risk
      screening, assessment, and management. In this 5-part series, we describe a model
      for achieving therapeutic risk management of the potentially violent patient,
      with essential elements involving: clinical interview augmented by structured
      screening or assessment tools; risk stratification in terms of temporality and
      severity; chain analysis to intervene on the functions of violent ideation and
      behavior; and personalized safety plans to mitigate/manage risk. This third
      column in the series describes other-directed violence risk stratification in
      terms of both severity and temporality, as well an approach for characterizing
      (ie, predatory/planned or impulsive/reactive) the violence risk posed by an
      individual.
FAU - Wortzel, Hal S
AU  - Wortzel HS
FAU - Barnes, Sean M
AU  - Barnes SM
FAU - Gerard, Georgia
AU  - Gerard G
FAU - Clark, Kaily
AU  - Clark K
FAU - Borges, Lauren M
AU  - Borges LM
FAU - McGarity, Suzanne
AU  - McGarity S
FAU - Nazem, Sarra
AU  - Nazem S
FAU - Bahraini, Nazanin H
AU  - Bahraini NH
FAU - Matarazzo, Bridget B
AU  - Matarazzo BB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Psychiatr Pract
JT  - Journal of psychiatric practice
JID - 100901141
SB  - IM
MH  - Adult
MH  - Humans
MH  - Impulsive Behavior
MH  - Male
MH  - Risk Assessment
MH  - *Risk Management
MH  - Safety
MH  - Violence/*prevention & control/*psychology
EDAT- 2020/12/05 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/12/04 13:39
PHST- 2020/12/04 13:39 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.1097/PRA.0000000000000510 [doi]
AID - 00131746-202011000-00008 [pii]
PST - ppublish
SO  - J Psychiatr Pract. 2020 Nov;26(6):503-509. doi: 10.1097/PRA.0000000000000510.


PMID- 33275190
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Dec
TI  - Emerging moral status issues.
PG  - 95-104
LID - 10.1007/s40592-020-00124-y [doi]
AB  - Many controversies in bioethics turn on questions of moral status. Some moral
      status issues have received extensive bioethical attention, including those
      raised by abortion, embryo experimentation, and animal research. Beyond these
      established debates lie a less familiar set of moral status issues, many of which
      are tied to recent scientific breakthroughs. This review article surveys some key
      developments that raise moral status issues, including the development of in
      vitro brains, part-human animals, "synthetic" embryos, and artificial womb
      technologies. It introduces the papers in this Special Issue, contextualises
      their contributions to the moral status literature, and highlights some enduring 
      challenges of determining the moral status of novel types of beings.
FAU - Koplin, Julian J
AU  - Koplin JJ
AUID- ORCID: http://orcid.org/0000-0002-2752-7334
AD  - Melbourne Law School, University of Melbourne, 185 Pelham St, Carlton, VIC, 3053,
      Australia. koplinj@unimelb.edu.au.
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute, Carlton,
      VIC, Australia. koplinj@unimelb.edu.au.
FAU - Gyngell, Christopher
AU  - Gyngell C
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute, Carlton,
      VIC, Australia.
AD  - Department of Paediatrics, University of Melbourne, Carlton, VIC, Australia.
LA  - eng
GR  - JK and CG, through their involvement with the Murdoch Children's Research
      Institute, received funding through from the Victorian State Government through
      the Operational Infrastructure Support (OIS) Program./Victoria State Government
PT  - Journal Article
PT  - Review
DEP - 20201204
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - Abortion, Induced/*ethics
MH  - Animal Experimentation/*ethics
MH  - Artificial Organs/ethics
MH  - *Bioethical Issues
MH  - Bioethics
MH  - Biotechnology/*ethics
MH  - Brain
MH  - Dissent and Disputes
MH  - Embryo Research/*ethics
MH  - Female
MH  - Humans
MH  - *Moral Status
MH  - Pregnancy
MH  - Uterus
OTO - NOTNLM
OT  - Animal ethics
OT  - Cerebral organoids
OT  - Ectogenesis
OT  - Embryo research
OT  - Moral status
EDAT- 2020/12/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/12/04 12:08
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/12/04 12:08 [entrez]
AID - 10.1007/s40592-020-00124-y [doi]
AID - 10.1007/s40592-020-00124-y [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(2):95-104. doi: 10.1007/s40592-020-00124-y. Epub
      2020 Dec 4.


PMID- 33275115
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 4
TI  - The Web-Based Uprise Program for Mental Health in Australian University Students:
      Protocol for a Pilot Randomized Controlled Trial.
PG  - e21307
LID - 10.2196/21307 [doi]
AB  - BACKGROUND: University students are vulnerable to poor mental health,
      psychological distress, and loneliness relative to nonuniversity student peers.
      However, the rate of seeking mental health treatment among university students is
      low. Web-based psychological interventions may provide an opportunity for
      supporting vulnerable university students who are unlikely to otherwise seek
      support. OBJECTIVE: The aim of this study is to examine the feasibility,
      acceptability, safety, and efficacy of an existing web-based transdiagnostic
      cognitive behavioral therapy (CBT) mental health program for use among Australian
      university students. METHODS: This is a pilot randomized controlled trial
      comparing a self-directed web-based CBT mental health program with a waitlist
      control. The self-directed modules will be augmented with optional webchat or
      telephone coaching with a therapist. The recruitment target is 70 university
      students who do not present with a clinical mental health disorder. Allocation
      will be made in a 1:1 ratio and will occur after the initial baseline assessment.
      Assessments will be completed at baseline, upon completion of a 4-week waitlist
      (waitlist group only), upon completion of the program, and at 3 months after
      completion of the program. RESULTS: The trial was funded in June 2018, and the
      protocol was approved by the Swinburne University Human Research Ethics Committee
      in September 2018. Recruitment commenced in October 2018, with the first
      participant allocated in November 2018. A total of 70 participants were recruited
      to the trial. The trial recruitment ceased in June 2019, and data collection was 
      finalized in December 2019. We expect the final data analysis to be completed by 
      November 2020 and results to be published early in 2021. The primary outcomes are
      feasibility, acceptability, safety, and symptoms of depression, anxiety, and
      stress. The secondary outcomes are psychological wellbeing, quality of life,
      loneliness, self-reported physical health status, emotion regulation, and
      cognitive and mindfulness processes. CONCLUSIONS: The acceptability, feasibility,
      safety, and efficacy of a web-based mental health program in university students 
      will be evaluated. Web-based mental health programs offer the opportunity to
      engage university students who may be reluctant to seek support through
      traditional face-to-face mental health services, and the transdiagnostic approach
      of the program has the potential to address the breadth of mental health concerns
      of university students. TRIAL REGISTRATION: Australian New Zealand Clinical Trial
      Registry ACTRN12618001604291;
      https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=1261800160429
      1. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/21307.
CI  - (c)Karra D Harrington, Robert Eres, Michelle H Lim. Originally published in JMIR 
      Research Protocols (http://www.researchprotocols.org), 04.12.2020.
FAU - Harrington, Karra D
AU  - Harrington KD
AUID- ORCID: https://orcid.org/0000-0001-9230-2978
AD  - Iverson Health Innovation Research Institute, Swinburne University of Technology,
      Hawthorn, Australia.
AD  - Center for Healthy Aging, The Pennsylvania State University, University Park, PA,
      United States.
FAU - Eres, Robert
AU  - Eres R
AUID- ORCID: https://orcid.org/0000-0002-0444-5918
AD  - Iverson Health Innovation Research Institute, Swinburne University of Technology,
      Hawthorn, Australia.
AD  - Centre for Mental Health, Swinburne University of Technology, Hawthorn,
      Australia.
FAU - Lim, Michelle H
AU  - Lim MH
AUID- ORCID: https://orcid.org/0000-0002-4136-5909
AD  - Iverson Health Innovation Research Institute, Swinburne University of Technology,
      Hawthorn, Australia.
AD  - Centre for Mental Health, Swinburne University of Technology, Hawthorn,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7748961
OTO - NOTNLM
OT  - digital technology
OT  - e-mental health
OT  - mental health
OT  - randomized controlled trial
OT  - university students
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:01
CRDT- 2020/12/04 12:07
PHST- 2020/06/10 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/04 00:00 [revised]
PHST- 2020/12/04 12:07 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:01 [medline]
AID - v9i12e21307 [pii]
AID - 10.2196/21307 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 4;9(12):e21307. doi: 10.2196/21307.


PMID- 33275034
OWN - NLM
STAT- Publisher
LR  - 20220418
IS  - 1942-7522 (Electronic)
IS  - 0145-5613 (Linking)
DP  - 2020 Dec 4
TI  - Institution-Specific Strategies for Head and Neck Oncology Triage During the
      COVID-19 Pandemic.
PG  - 145561320975509
LID - 10.1177/0145561320975509 [doi]
AB  - BACKGROUND: This work seeks to better understand the triage strategies employed
      by head and neck oncologic surgical divisions during the initial phases of the
      coronavirus 2019 (COVID-19) outbreak. METHODS: Thirty-six American head and neck 
      surgical oncology practices responded to questions regarding the triage
      strategies employed from March to May 2020. RESULTS: Of the programs surveyed, 11
      (31%) had official department or hospital-specific guidelines for mitigating care
      delays and determining which surgical cases could proceed. Seventeen (47%)
      programs left the decision to proceed with surgery to individual surgeon
      discretion. Five (14%) programs employed committee review, and 7 (19%) used
      chairman review systems to grant permission for surgery. Every program surveyed, 
      including multiple in COVID-19 outbreak epicenters, continued to perform complex 
      head and neck cancer resections with free flap reconstruction. CONCLUSIONS:
      During the initial phases of the COVID-19 pandemic experience in the United
      States, head and neck surgical oncology divisions largely eschewed formal triage 
      policies and favored practices that allowed individual surgeons discretion in the
      decision whether or not to operate. Better understanding the shortcomings of such
      an approach could help mitigate care delays and improve oncologic outcomes during
      future outbreaks of COVID-19 and other resource-limiting events. LEVEL OF
      EVIDENCE: 4.
FAU - Freeman, Michael H
AU  - Freeman MH
AUID- ORCID: https://orcid.org/0000-0002-5232-8695
AD  - Department of Otolaryngology, Head and Neck Surgery, Vanderbilt University
      Medical Center, Nashville, TN, USA.
FAU - Shinn, Justin R
AU  - Shinn JR
AUID- ORCID: https://orcid.org/0000-0002-1271-1657
AD  - Department of Otolaryngology, Head and Neck Surgery, Vanderbilt University
      Medical Center, Nashville, TN, USA.
FAU - Langerman, Alexander
AU  - Langerman A
AD  - Department of Otolaryngology, Head and Neck Surgery, Vanderbilt University
      Medical Center, Nashville, TN, USA.
AD  - Department of Radiology and Radiological Sciences, Vanderbilt University Medical 
      Center, Nashville, TN, USA.
AD  - International Center for Surgical Safety, Li Ka Shing Knowledge Institute, St.
      Michael's Hospital, Toronto, ON, USA.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - United States
TA  - Ear Nose Throat J
JT  - Ear, nose, & throat journal
JID - 7701817
SB  - IM
PMC - PMC7720027
OTO - NOTNLM
OT  - head and neck oncology
OT  - organizational response
OT  - pandemic response
OT  - qualitative research
OT  - surgical ethics
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:00
CRDT- 2020/12/04 12:06
PHST- 2020/12/04 12:06 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:00 [medline]
AID - 10.1177/0145561320975509 [doi]
PST - aheadofprint
SO  - Ear Nose Throat J. 2020 Dec 4:145561320975509. doi: 10.1177/0145561320975509.


PMID- 33274710
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - What Is Ethically Informed Risk Management?
PG  - E965-975
LID - amajethics.2020.965 [pii]
LID - 10.1001/amajethics.2020.965 [doi]
AB  - Ethically informed risk management includes both the management of ethical risks 
      and the ethical management of risks (professional ethics). This article aims to
      rekindle dormant discussion of professional ethics in health care risk
      management. It frames ethically informed risk management as a patient-centered
      and evidence-based practice, aligns its scope with that of biomedical ethics, and
      proposes specific ethical duties to guide risk management practice. It provides a
      starting point for more robust debate and the development of ethical standards
      for health care risk managers.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Card, Alan J
AU  - Card AJ
AD  - Assistant professor in the Department of Pediatrics at the University of
      California, San Diego School of Medicine.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Bioethics
MH  - Humans
MH  - *Moral Obligations
MH  - Risk Management
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.965 [pii]
AID - 10.1001/amajethics.2020.965 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E965-975. doi: 10.1001/amajethics.2020.965.


PMID- 33274709
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - A Call for Behavioral Emergency Response Teams in Inpatient Hospital Settings.
PG  - E956-964
LID - amajethics.2020.956 [pii]
LID - 10.1001/amajethics.2020.956 [doi]
AB  - Medical rapid response teams, now ubiquitous throughout hospitals, were designed 
      to identify and proactively treat early warning signs of acute medical
      decompensation. Behavioral emergencies-including clinical psychiatric
      emergencies, coping/stress reactions, and iatrogenic injuries-are not responded
      to with the same vigor. At worst, behavioral crises are treated as unarmed
      security threats. Limited or inappropriate responses to such crises can lead to
      suboptimal outcomes on numerous levels, especially avoidable harm to patients and
      frontline clinicians. Widespread implementation of behavioral emergency response 
      teams for patient-centered behavioral interventions has been impeded by a
      pervasive perception that these endeavors are medically unnecessary and optional.
      This article calls for a paradigm shift in responding to behavioral emergencies
      by arguing that security-driven risk management practices during behavioral
      emergencies are incompatible with fundamental medical and ethics principles.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Parker, Carmen Black
AU  - Parker CB
AD  - Assistant professor of psychiatry at the Yale University School of Medicine with 
      a primary clinical appointment at the Connecticut Mental Health Center in New
      Haven, Connecticut.
FAU - Calhoun, Amanda
AU  - Calhoun A
AD  - Clinical fellow in the Albert J. Solnit Integrated Adult/Child Psychiatry Program
      at the Yale University School of Medicine in New Haven, Connecticut.
FAU - Wong, Ambrose H
AU  - Wong AH
AD  - Assistant professor of emergency medicine at the Yale University School of
      Medicine in New Haven, Connecticut.
FAU - Davidson, Larry
AU  - Davidson L
AD  - Professor of psychiatry at the Yale University School of Medicine in New Haven,
      Connecticut.
FAU - Dike, Charles
AU  - Dike C
AD  - Associate professor of psychiatry at the Yale University School of Medicine in
      New Haven, Connecticut.
LA  - eng
GR  - KL2 TR001862/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Emergencies
MH  - Emergency Service, Hospital
MH  - Hospitals
MH  - Humans
MH  - *Inpatients
MH  - Risk Management
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.956 [pii]
AID - 10.1001/amajethics.2020.956 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E956-964. doi: 10.1001/amajethics.2020.956.


PMID- 33274708
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - How Should Risks Posed by Decision Support Be Managed?
PG  - E952-955
LID - amajethics.2020.952 [pii]
LID - 10.1001/amajethics.2020.952 [doi]
AB  - Managing risk in cases that involve the use of clinical decision support tools is
      ethically complex. This article highlights some of these complexities and offers 
      3 considerations for risk managers to draw upon when assessing risk in cases
      using clinical decision support: (1) the type of decision support offered, (2)
      how well a decision support tool helps accomplish work that needs to be done, and
      (3) how well values embedded in a tool align with patients' and caregivers'
      professed values.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Nystrom, Daniel
AU  - Nystrom D
AD  - Clinical risk manager at Intermountain Healthcare's Primary Children's Hospital
      in Salt Lake City, Utah.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Caregivers
MH  - Humans
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.952 [pii]
AID - 10.1001/amajethics.2020.952 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E952-955. doi: 10.1001/amajethics.2020.952.


PMID- 33274707
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - How Might Artificial Intelligence Applications Impact Risk Management?
PG  - E945-951
LID - amajethics.2020.945 [pii]
LID - 10.1001/amajethics.2020.945 [doi]
AB  - Artificial intelligence (AI) applications have attracted considerable ethical
      attention for good reasons. Although AI models might advance human welfare in
      unprecedented ways, progress will not occur without substantial risks. This
      article considers 3 such risks: system malfunctions, privacy protections, and
      consent to data repurposing. To meet these challenges, traditional risk managers 
      will likely need to collaborate intensively with computer scientists,
      bioinformaticists, information technologists, and data privacy and security
      experts. This essay will speculate on the degree to which these AI risks might be
      embraced or dismissed by risk management. In any event, it seems that integration
      of AI models into health care operations will almost certainly introduce, if not 
      new forms of risk, then a dramatically heightened magnitude of risk that will
      have to be managed.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Banja, John
AU  - Banja J
AD  - Professor and medical ethicist at Emory University in Atlanta, Georgia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - *Physicians
MH  - Privacy
MH  - Risk Management
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.945 [pii]
AID - 10.1001/amajethics.2020.945 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E945-951. doi: 10.1001/amajethics.2020.945.


PMID- 33274706
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - AMA Code of Medical Ethics' Opinions Related to Risk Management Ethics.
PG  - E940-944
LID - amajethics.2020.940 [pii]
LID - 10.1001/amajethics.2020.940 [doi]
AB  - The AMA Code of Medical Ethics offers guidance on ethical issues pertaining to
      risks involving patient discharge, which provides an example of how the Code
      might pertain to issues in risk management. This article presents one example
      case regarding patient discharge and how the Code might be applied in such a
      scenario to help guide physicians in ethically discharging a patient while also
      managing associated risks.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Schweikart, Scott J
AU  - Schweikart SJ
AD  - Senior research associate for the American Medical Association Council on Ethical
      and Judicial Affairs in Chicago, Illinois.
FAU - Eng, Deborah M
AU  - Eng DM
AD  - Consultant medical writer and editor.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *American Medical Association
MH  - Codes of Ethics
MH  - Ethics, Medical
MH  - Humans
MH  - *Physicians
MH  - Risk Management
MH  - United States
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.940 [pii]
AID - 10.1001/amajethics.2020.940 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E940-944. doi: 10.1001/amajethics.2020.940.


PMID- 33274705
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering.
PG  - E933-939
LID - amajethics.2020.933 [pii]
LID - 10.1001/amajethics.2020.933 [doi]
AB  - How hospital lawyers assess legal risk in clinically and ethically complex cases 
      can shape risk management operations, influence clinicians' morale, and affect
      the care patients receive. This article suggests that many disagreements,
      particularly those involving key ethical and legal questions arising from a
      patient's care, should launch a process that might include family meetings, early
      palliative care integration, and ethics consultation or committee review of
      clinical teams' and surrogates' reasons and perspectives. This article also
      explains why exploration of these perspectives can motivate fuller understanding 
      of the sources of clinical and ethical disagreements and inform the approach to
      legal advice that hospital executives and risk managers should foster.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - McGrath, Norine A
AU  - McGrath NA
AD  - Director of the John J. Lynch, MD Center for Ethics at MedStar Washington
      Hospital Center and an assistant professor at Georgetown University School of
      Medicine in Washington, DC.
FAU - DeRenzo, Evan G
AU  - DeRenzo EG
AD  - Assistant director of the John J. Lynch, MD Center for Ethics at MedStar
      Washington Hospital Center in Washington, DC.
FAU - Kilcullen, John K
AU  - Kilcullen JK
AD  - Critical care physician at a tertiary hospital in the Washington, DC area.
FAU - Schwartz, Jack
AU  - Schwartz J
AD  - Adjunct law professor at the University of Maryland Francis King Carey School of 
      Law in Baltimore.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Ethics Consultation
MH  - Hospitals
MH  - Humans
MH  - Morals
MH  - Palliative Care
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.933 [pii]
AID - 10.1001/amajethics.2020.933 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E933-939. doi: 10.1001/amajethics.2020.933.


PMID- 33274703
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - What Is an Ethically Informed Approach to Managing Patient Safety Risk During
      Discharge Planning?
PG  - E919-923
LID - amajethics.2020.919 [pii]
LID - 10.1001/amajethics.2020.919 [doi]
AB  - Hospital discharge planning for patients who might not be safe at
      home-particularly those leaving against medical advice-can require risk managers 
      to navigate the complex intersection of tort law, federal and state regulations, 
      and clinical ethics. An overarching duty is to ensure that a patient is as safe
      as possible in the environment to which the patient is being discharged, although
      it's not always possible to formulate a safe discharge plan. When patients have
      decision-making capacity, they can make a decision to be in an environment that's
      not safe. When patients do not have decision-making capacity, it is not always
      legally permissible to hold them against their wishes to keep them in a safe
      environment, so some kind of discharge plan must be made. This article considers 
      the role of a risk manager in navigating this set of circumstances.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - West, John C
AU  - West JC
AD  - Principal of West Consulting Services, LLC.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Humans
MH  - *Patient Discharge
MH  - *Patient Safety
MH  - Risk Management
EDAT- 2020/12/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/12/04 08:36
PHST- 2020/12/04 08:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.919 [pii]
AID - 10.1001/amajethics.2020.919 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Nov 1;22(11):E919-923. doi: 10.1001/amajethics.2020.919.


PMID- 33274617
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201217
IS  - 1309-0399 (Print)
IS  - 1309-0380 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Dec 4
TI  - Gynecological cancers and the global COVID-19 pandemic
PG  - 272-278
LID - 10.4274/jtgga.galenos.2020.2020.0119 [doi]
AB  - Coronavirus disease-2019 (COVID-19) has reduced the availability of health
      resources which will affect treatment of gynecological cancers. The present study
      aimed to provide a treatment protocol for patients with gynecological cancers
      during the global COVID-19 pandemic. International databases with keywords of
      COVID-19; Severe Acute Respiratory Syndrome; Middle East Respiratory Syndrome;
      gynecologic cancer; cervical cancer; and vaginal cancer, vulvar cancer, ovarian
      cancer, endometrial cancer, tumor, elective surgery, chemotherapy, radiotherapy, 
      cancer, guideline, guidance, women, management, outpatient clinic visits, and
      triage were comprehensively searched. All the obtained guidelines were studied
      and the contents were summarized. During the COVID-19 pandemic, early stage
      endometrial cancer was preferably treated with hormone therapy while radiotherapy
      was given in preference in later stages. Cervical intraepithelial neoplasia 3 and
      high-grade squamous intraepithelial lesions should be treated immediately after
      diagnosis using at least a loop electrosurgical excision procedure while any
      major surgery should be postponed by 10-12 weeks. In the early stage of cervical 
      cancer, surgery may be delayed by 2-4 weeks, and radiotherapy prescribed for the 
      intervening period. In cases of an ovarian mass with negative tumor markers, no
      sign of cancer on imaging investigations, no ascites, a low serum CA-125 level,
      and no papillary projection or vegetation in the base of the cyst, the patient
      may be given hormone therapy for 2-3 months. In cases of newly diagnosed
      confirmed ovarian cancers, surgery should be performed as early as possible
      (maximum: 2-3 weeks). Vulvar and vaginal cancers can be treated within 10-12
      weeks of diagnosis, but radiotherapy should be given in preference in this
      situation. A molar pregnancy is an oncological emergency for which a suction
      curettage is mandatory; the patient must be monitored for metastases. Information
      concerning the choice between open or laparoscopic surgery is limited. Given that
      any patient may be an asymptomatic carrier of the coronavirus, major surgery
      should be preceded by chest computerized tomography, with and without contrast
      medium, in order to detect lung lesions. Evidence concerning these
      recommendations is limited because of the novel and unknown nature of the
      COVID-19 pandemic. Furthermore, data pertaining to ethical debates about delayed 
      treatment and treatment approaches deviating from current guidelines are also
      limited.
FAU - Alkatout, Ibrahim
AU  - Alkatout I
AUID- ORCID: 0000-0002-7194-6034
AD  - Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein,
      Kiel School of Gynaecological Endoscopy, Kiel, Germany
FAU - Karimi-Zarchi, Mojgan
AU  - Karimi-Zarchi M
AUID- ORCID: 0000-0002-8734-9971
AD  - Department of Gynecology Oncology, Firoozgar Hospital, Iran University of Medical
      Sciences, Tehran, Iran
FAU - Allahqoli, Leila
AU  - Allahqoli L
AUID- ORCID: 0000-0002-9851-6771
AD  - Iran University of Medical Sciences, Tehran, Iran
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - J Turk Ger Gynecol Assoc
JT  - Journal of the Turkish German Gynecological Association
JID - 101272522
PMC - PMC7726457
OTO - NOTNLM
OT  - *COVID-19
OT  - *chemotherapy
OT  - *elective surgery
OT  - *gynecological cancer
OT  - *oncology
OT  - *radiotherapy
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:01
CRDT- 2020/12/04 06:12
PHST- 2020/12/04 06:12 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:01 [medline]
AID - 10.4274/jtgga.galenos.2020.2020.0119 [doi]
PST - ppublish
SO  - J Turk Ger Gynecol Assoc. 2020 Dec 4;21(4):272-278. doi:
      10.4274/jtgga.galenos.2020.2020.0119.


PMID- 33274529
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 0745-5194 (Print)
IS  - 0745-5194 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Dec
TI  - The Culling: Pandemic, Gerocide, Generational Affect.
PG  - 542-560
LID - 10.1111/maq.12627 [doi]
AB  - Old age has been central to public health rationalities and contestations of the 
      2019-2020 coronavirus pandemic. This article thinks through what age is and does 
      in pandemic times by juxtaposing four domains of ethical publicity in which age
      comes to matter: (1) mass fatality of old persons under conditions of variable
      unpreparedness; (2) circulation of social-Darwinist argument for herd immunity
      through culling of the weak; (3) everyday challenges of late life care as these
      are amplified under quarantine; and (4) long-term conditions of economic and
      political impasse and environmental collapse, experienced as failure of older
      generations and abandonment of younger ones, a situation here termed generational
      affect. It asks to what extent the figure of the cullable old renders racialized 
      disparities natural and makes sense through a generational affect in which the
      world feels as if the survival of the young is in question.
CI  - (c) 2020 by the American Anthropological Association.
FAU - Cohen, Lawrence
AU  - Cohen L
AUID- ORCID: 0000-0002-0112-8642
AD  - Departments of Anthropology and of South and Southeast Asian Studies, University 
      of California, Berkeley.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - United States
TA  - Med Anthropol Q
JT  - Medical anthropology quarterly
JID - 8405037
SB  - IM
MH  - Aged
MH  - *Aging
MH  - Anthropology, Medical
MH  - COVID-19/*epidemiology/mortality
MH  - Humans
MH  - Immunity, Herd
MH  - *Patient Selection
MH  - Public Health/*ethics/methods
MH  - *SARS-CoV-2
MH  - Social Responsibility
OTO - NOTNLM
OT  - *coronavirus
OT  - *old age
OT  - *pandemic
OT  - *social Darwinism
OT  - *triage
EDAT- 2020/12/05 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/12/04 05:51
PHST- 2020/06/23 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/12/04 05:51 [entrez]
AID - 10.1111/maq.12627 [doi]
PST - ppublish
SO  - Med Anthropol Q. 2020 Dec;34(4):542-560. doi: 10.1111/maq.12627. Epub 2020 Dec 4.


PMID- 33274170
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 29
TI  - Survival After Hip Fracture: A Comparative Analysis Between a Private and a
      Public Health Center in Chile.
PG  - e11773
LID - 10.7759/cureus.11773 [doi]
AB  - Purpose The purpose of the study is to compare the survival after hip fracture in
      patients older than 50 years after hip fracture between a private and a public
      health center in Chile. We hypothesize that treatment at a private health center 
      (PRH) may be associated with lower one-year mortality and longer median survival 
      time after hip fracture (adjusted by gender and age) compared to a public health 
      center (PLH). Methods PRH and PLH patients who were coded with a diagnosis of hip
      fracture were included in this study. PRH patients were included between 2002 to 
      2018, and PLH patients were included from 2012 to 2018. One-year mortality was
      estimated by logistic regression; meanwhile, median survival time was estimated
      by exponential regression. A survival analysis study was designed and approved by
      our institutional ethics review board. Results A total of 2130 patients were
      included in the PLH cohort, and a total of 1110 patients were included in the
      PRH. The one-year mean mortality, adjusted by age and gender, was 0.23 (range:
      0.21 to 0.25) in the PLH and 0.16 (range: 0.13 to 0.18) in the PRH cohort. The
      median survival time, adjusted by age and gender, was 4.2 years (range: 4.1 to
      4.4) in the PLH and 6.8 years (range: 6.3 to 7.29) in the PRH cohort. Conclusion 
      Patients older than 50 years treated in a private health center have a higher
      median survival time and a lower probability of dying one year after a hip
      fracture.
CI  - Copyright (c) 2020, Barahona et al.
FAU - Barahona, Maximiliano
AU  - Barahona M
AD  - Orthopaedic Department, Hospital Clinico Universidad De Chile, Santiago, CHL.
FAU - Martinez, Alvaro Sr
AU  - Martinez A Sr
AD  - Orthopaedic Department, Hospital San Jose, Santiago, CHL.
FAU - Barrientos, Cristian
AU  - Barrientos C
AD  - Orthopaedic Department, Hospital Clinico Universidad de Chile, Santiago, CHL.
AD  - Orthopaedic Department, Hospital San Jose, Santiago, CHL.
AD  - Orthopaedic Department, Clinica Santa Maria, Santiago, CHL.
FAU - Barahona, Macarena A
AU  - Barahona MA
AD  - Orthopaedic Department, Hospital Clinico Universidad de Chile, Santiago, CHL.
FAU - Cavada, Gabriel
AU  - Cavada G
AD  - Epidemiology Department, Universidad de Chile, Santiago, CHL.
FAU - Branes, Julian
AU  - Branes J
AD  - Orthopaedic Department, Hospital San Jose, Santiago, CHL.
AD  - Orthopaedic Department, Hospital Clinico Universidad de Chile, Santiago, CHL.
LA  - eng
PT  - Journal Article
DEP - 20201129
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7707142
OTO - NOTNLM
OT  - epidemiology
OT  - health inequity
OT  - hip fractures
OT  - mortality rate
OT  - survival
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:01
CRDT- 2020/12/04 05:48
PHST- 2020/12/04 05:48 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:01 [medline]
AID - 10.7759/cureus.11773 [doi]
PST - epublish
SO  - Cureus. 2020 Nov 29;12(11):e11773. doi: 10.7759/cureus.11773.


PMID- 33273986
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20220418
IS  - 1875-8584 (Electronic)
IS  - 0953-4180 (Linking)
VI  - 2020
DP  - 2020
TI  - Collective Housing of Mice of Different Age Groups before Maturity Affects Mouse 
      Behavior.
PG  - 6856935
LID - 10.1155/2020/6856935 [doi]
AB  - BACKGROUND: Although population housing is recommended by many animal management 
      and ethical guidelines, the effect of collective housing of mice of different age
      groups on mouse behavior has not been clarified. Since the development of the
      central nervous system continues to occur before sexual maturation, the stress of
      social ranking formation among male individuals in mixed housing conditions can
      affect postmaturation behavior. To assess these effects, sexually immature mice
      of different ages were housed in the same cage and a series of behavioral tests
      were performed after maturation. RESULTS: The findings for three groups of
      mice-junior mice housed with older mice, senior mice housed with younger mice,
      and mice housed with other mice of the same age-were compared. Junior mice showed
      higher body weight and activity as well as lower grip strength and anxiety-like
      behaviors than other mice. In contrast, senior mice showed lower body temperature
      and increased aggression, antinociceptive effect, and home-cage activity in the
      dark period in comparison with other mice. CONCLUSIONS: Thus, combined housing of
      immature mice of different age groups affects mouse behavior after maturation.
      Appropriate prematuration housing conditions are crucial to eliminate the
      uncontrollable bias caused by age-related social stratification.
CI  - Copyright (c) 2020 Hiroshi Ueno et al.
FAU - Ueno, Hiroshi
AU  - Ueno H
AUID- ORCID: https://orcid.org/0000-0003-0360-5761
AD  - Department of Medical Technology, Kawasaki University of Medical Welfare, Okayama
      701-0193, Japan.
FAU - Suemitsu, Shunsuke
AU  - Suemitsu S
AD  - Department of Psychiatry, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Murakami, Shinji
AU  - Murakami S
AD  - Department of Psychiatry, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Kitamura, Naoya
AU  - Kitamura N
AD  - Department of Psychiatry, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Wani, Kenta
AU  - Wani K
AD  - Department of Psychiatry, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Takahashi, Yu
AU  - Takahashi Y
AD  - Department of Psychiatry, Kawasaki Medical School, Kurashiki 701-0192, Japan.
FAU - Matsumoto, Yosuke
AU  - Matsumoto Y
AD  - Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and
      Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
FAU - Okamoto, Motoi
AU  - Okamoto M
AD  - Department of Medical Technology, Graduate School of Health Sciences, Okayama
      University, Okayama 700-8558, Japan.
FAU - Ishihara, Takeshi
AU  - Ishihara T
AD  - Department of Psychiatry, Kawasaki Medical School, Kurashiki 701-0192, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - Netherlands
TA  - Behav Neurol
JT  - Behavioural neurology
JID - 8914585
SB  - IM
MH  - *Aggression
MH  - Animals
MH  - Anxiety
MH  - Behavior, Animal
MH  - *Housing
MH  - Male
MH  - Mice
PMC - PMC7676975
COIS- The authors declare no competing interests.
EDAT- 2020/12/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/12/04 05:47
PHST- 2020/02/10 00:00 [received]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/12/04 05:47 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.1155/2020/6856935 [doi]
PST - epublish
SO  - Behav Neurol. 2020 Nov 12;2020:6856935. doi: 10.1155/2020/6856935. eCollection
      2020.


PMID- 33273128
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1078-4535 (Print)
IS  - 1078-4535 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Nov 1
TI  - Arts and Humanities to Teach Civility in Health Professions.
PG  - 241-245
LID - 10.1891/CRNR-D-18-00053 [doi]
AB  - Incivility is defined as rude or disruptive behavior which may result in
      psychological or physiological distress for the people involved. These behaviors,
      which appear to be more pervasive than ever in today's society, both in academia 
      and in the health-care system, negatively affect professionals' well-being and
      the workplace environment. Nurses have an obligation to practice with compassion 
      and respect, and to develop creative solutions for addressing incivility.
      Education about incivility should begin in prelicensure programs for all health
      professions, so that students understand the behavior expected of them as
      professionals. When health-care professionals embody the ideals of respect and
      civility, they set an example for others to follow. The arts and humanities can
      be used as a pedagogical tool to provide innovative learning opportunities to
      teach these values through the affective domain of learning. This article
      discusses one of the creative avenues for facilitating such opportunity, the use 
      of the arts and humanities to teach civility in health professions education.
CI  - (c) Copyright 2020 Creative Health Care Management.
FAU - Hall, Katherine
AU  - Hall K
AUID- ORCID: https://orcid.org/0000-0002-1986-3047
FAU - De Gagne, Jennie C
AU  - De Gagne JC
AUID- ORCID: https://orcid.org/0000-0001-9814-5942
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Creat Nurs
JT  - Creative nursing
JID - 9505022
MH  - Adult
MH  - *Art
MH  - Attitude of Health Personnel
MH  - Female
MH  - Health Personnel/*education/*psychology
MH  - Humanities/*education
MH  - Humans
MH  - Incivility/*prevention & control
MH  - Interprofessional Relations
MH  - Male
MH  - Middle Aged
MH  - Optimism/*psychology
MH  - Professionalism
MH  - Surveys and Questionnaires
MH  - Workplace/*psychology
OTO - NOTNLM
OT  - affective domain
OT  - arts and humanities
OT  - civility
OT  - ethics
OT  - professionalism
EDAT- 2020/12/05 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/12/04 05:38
PHST- 2020/12/04 05:38 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
AID - 26/4/241 [pii]
AID - 10.1891/CRNR-D-18-00053 [doi]
PST - ppublish
SO  - Creat Nurs. 2020 Nov 1;26(4):241-245. doi: 10.1891/CRNR-D-18-00053.


PMID- 33273060
OWN - NLM
STAT- MEDLINE
DCOM- 20201228
LR  - 20201228
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 370
IP  - 6522
DP  - 2020 Dec 11
TI  - COVID-19 vaccine trial ethics once we have efficacious vaccines.
PG  - 1277-1279
LID - 10.1126/science.abf5084 [doi]
FAU - Wendler, David
AU  - Wendler D
AD  - Department of Bioethics, National Institutes of Health (NIH) Clinical Center,
      Bethesda, MD, USA. dwendler@nih.gov.
FAU - Ochoa, Jorge
AU  - Ochoa J
AD  - Department of Bioethics, National Institutes of Health (NIH) Clinical Center,
      Bethesda, MD, USA.
FAU - Millum, Joseph
AU  - Millum J
AD  - Department of Bioethics, National Institutes of Health (NIH) Clinical Center,
      Bethesda, MD, USA.
AD  - Fogarty International Center, NIH, Bethesda, MD, USA.
FAU - Grady, Christine
AU  - Grady C
AD  - Department of Bioethics, National Institutes of Health (NIH) Clinical Center,
      Bethesda, MD, USA.
FAU - Taylor, Holly A
AU  - Taylor HA
AD  - Department of Bioethics, National Institutes of Health (NIH) Clinical Center,
      Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20201203
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Placebos)
SB  - IM
MH  - COVID-19 Vaccines/*adverse effects/*therapeutic use
MH  - Controlled Clinical Trials as Topic/*ethics
MH  - Drug Approval
MH  - Healthy Volunteers
MH  - Humans
MH  - Placebos
MH  - Risk Assessment
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2020/12/05 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/12/04 05:38
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/12/04 05:38 [entrez]
AID - science.abf5084 [pii]
AID - 10.1126/science.abf5084 [doi]
PST - ppublish
SO  - Science. 2020 Dec 11;370(6522):1277-1279. doi: 10.1126/science.abf5084. Epub 2020
      Dec 3.


PMID- 33273049
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 3
TI  - Protocol for a multicentre longitudinal mixed-methods study: feeding and
      survivorship outcomes in previously healthy young paediatric Intensive care
      survivors (the PIES Study).
PG  - e041234
LID - 10.1136/bmjopen-2020-041234 [doi]
AB  - INTRODUCTION: An admission to paediatric intensive care unit (PICU) is associated
      with multiple physical and environmental stressors, often involving many negative
      and painful oral experiences. Evidence from children with complex medical
      conditions suggests that feeding difficulties post-PICU stay are common, causing 
      significant parental anxiety. Adult intensive care unit (ICU) survivor studies
      suggest feeding issues lasting up to 3 months post-discharge from ICU. There is, 
      however, a paucity of evidence regarding feeding outcomes for previously healthy 
      children following a PICU admission and whether painful oral experiences during
      an admission contribute to feeding difficulties post-discharge, negatively
      impacting on parental/caregiver anxiety. METHODS AND ANALYSIS: This longitudinal 
      mixed-methods study will explore the impact of feeding difficulties, identifying 
      any clinical risk factors during the first 6 months of PICU discharge in
      previously healthy young children (</=4 years). Parents/caregivers of children
      will be asked to complete questionnaires relating to: feeding difficulties,
      parental/caregiver stress, and child and parental/caregivers' feeding behaviours 
      at the point of PICU discharge, 1, 3 and 6 months post-discharge.
      Parents/caregivers will be invited to participate in qualitative semistructured
      interviews at 3 and 6 months post-PICU discharge exploring parental/caregiver
      experiences of feeding their child after PICU. Statistical analysis of the survey
      data will consist of descriptive and inferential statistics, plus qualitative
      analysis of any free text comments using thematic analysis. ETHICS AND
      DISSEMINATION: This study will provide an insight and increase our understanding 
      of the prevalence of feeding difficulties in previously healthy children admitted
      to PICU and parental/caregiver experiences. Multiple methods will be used to
      ensure that the findings are effectively disseminated to service users,
      clinicians, policy and academic audiences. The study has full ethical approval
      from the National Health Service Research Ethics Committee (Ref: 20/YH/0160) and 
      full governance clearance.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Morton, Kathryn
AU  - Morton K
AUID- ORCID: 0000-0003-0970-0081
AD  - Paediatric Intensive Care Unit, Southampton Children's Hospital, Southampton, UK 
      kathryn.morton@uhs.nhs.uk.
AD  - School of Health Sciences, University of Southampton, Southampton, UK.
FAU - Darlington, Anne-Sophie Emma
AU  - Darlington AE
AD  - School of Health Sciences, University of Southampton, Southampton, UK.
FAU - Marino, L V
AU  - Marino LV
AD  - NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation
      Trust, Southampton, UK.
AD  - Department of Dietetics and Speech and Language Therapy, University Hospital
      Southampton NHS Foundation Trust, Southampton, UK.
LA  - eng
GR  - ICA-CL-2016-02-001/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aftercare
MH  - Child
MH  - Child, Preschool
MH  - Critical Care
MH  - Humans
MH  - Intensive Care Units, Pediatric
MH  - Patient Discharge
MH  - State Medicine
MH  - Survivors
MH  - *Survivorship
PMC - PMC7716671
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *paediatric intensive & critical care
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/12/05 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/12/04 05:38
PHST- 2020/12/04 05:38 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-041234 [pii]
AID - 10.1136/bmjopen-2020-041234 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 3;10(12):e041234. doi: 10.1136/bmjopen-2020-041234.


PMID- 33273048
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 3
TI  - Research protocol for the validation of a new portable technology for real-time
      continuous monitoring of Early Warning Score (EWS) in hospital practice and for
      an early-stage multistakeholder assessment.
PG  - e040738
LID - 10.1136/bmjopen-2020-040738 [doi]
AB  - INTRODUCTION: The real-time continuous monitoring of vital parameters in patients
      affected by multiple chronic conditions and/or COVID-19 can lead to several
      benefits to the Italian National Healthcare System (IT-NHS). The UBiquitous
      Integrated CARE (UBICARE) technology is a novel health digital platform at the
      validation stage in hospital setting. UBICARE might support the urgent need for
      digitalisation and early intervention, as well as minimise the face-to-face
      delivery of care in both hospital and community-based care settings. This
      research protocol aims to design an early-stage assessment of the
      multidimensional impact induced by UBICARE within the IT-NHS alongside technology
      validation in a hospital ward. METHODS AND ANALYSIS: The targeted patients will
      be medium/high-risk hypertensive individuals as an illustrative first example of 
      how UBICARE might bring benefits to susceptible patients. A mixed-method study
      will be applied to incorporate to the validation study a multistakeholder
      perspective, including perceived patient experiences and preferences, and
      facilitate technology adoption. First, semistructured interviews will be
      undertaken with a variety of stakeholders including clinicians, health managers
      and policy-makers to capture views on the likely technology utility, economic
      sustainability, impact of adoption in hospital practice and alternative adoption 
      scenarios. Second, a monocentric, non-randomised and non-comparative clinical
      study, supplemented by the administration of standardised usability
      questionnaires to patients and health professionals, will validate the use of
      UBICARE in hospital practice. Finally, the results of the previous stages will be
      discussed in a multidisciplinary-facilitated workshop with IT-NHS relevant
      stakeholders to reconcile stakeholders' perspectives. Limitations include a
      non-random recruitment strategy in the clinical study, small sample size of the
      key stakeholders and potential stakeholder recruitment bias introduced by the
      research technique. ETHICS AND DISSEMINATION: The Ethics Committee for Clinical
      Experimentation of Tuscany Region approved the protocol. Participation in this
      study is voluntary. Study results will be disseminated through peer-reviewed
      publications and academic conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Manetti, Stefania
AU  - Manetti S
AUID- ORCID: http://orcid.org/0000-0002-9652-8293
AD  - Management and Health Laboratory, Institute of Management and EMbeDS Department, 
      Scuola Superiore Sant'Anna, Pisa, Italy stefania.manetti@santannapisa.it.
FAU - Vainieri, Milena
AU  - Vainieri M
AD  - Management and Health Laboratory, Institute of Management and EMbeDS Department, 
      Scuola Superiore Sant'Anna, Pisa, Italy.
FAU - Guidotti, Elisa
AU  - Guidotti E
AD  - Management and Health Laboratory, Institute of Management and EMbeDS Department, 
      Scuola Superiore Sant'Anna, Pisa, Italy.
FAU - Zuccarino, Sara
AU  - Zuccarino S
AD  - Management and Health Laboratory, Institute of Management and EMbeDS Department, 
      Scuola Superiore Sant'Anna, Pisa, Italy.
FAU - Ferre, Francesca
AU  - Ferre F
AUID- ORCID: http://orcid.org/0000-0001-5781-517X
AD  - Management and Health Laboratory, Institute of Management and EMbeDS Department, 
      Scuola Superiore Sant'Anna, Pisa, Italy.
FAU - Morelli, Maria Sole
AU  - Morelli MS
AD  - Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
FAU - Emdin, Michele
AU  - Emdin M
AD  - Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
AD  - C.O.U of Cardiology and Cardiovascular Medicine, Gabriele Monasterio Foundation, 
      Pisa, Italy.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19
MH  - *Early Warning Score
MH  - Monitoring, Ambulatory/*methods
MH  - Pandemics
MH  - Qualitative Research
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - Validation Studies as Topic
PMC - PMC7716668
OTO - NOTNLM
OT  - *health economics
OT  - *hypertension
OT  - *organisation of health services
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/12/05 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/04 05:38
PHST- 2020/12/04 05:38 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-040738 [pii]
AID - 10.1136/bmjopen-2020-040738 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 3;10(12):e040738. doi: 10.1136/bmjopen-2020-040738.


PMID- 33272937
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 12
DP  - 2020 Dec
TI  - Global health education in UK medical schools: a review of undergraduate
      university curricula.
LID - e002801 [pii]
LID - 10.1136/bmjgh-2020-002801 [doi]
AB  - INTRODUCTION: In recognition of our increasingly globalised world, global health 
      is now a required component of the medical school curriculum in the UK. We review
      the current provision of global health education (GHE) in UK medical schools to
      identify gaps in compulsory teaching. METHODS: We conducted a review of the
      literature to inform a two-part electronic survey of global health compulsory
      teaching, optional teaching and pre-elective training. Surveys were sent to all
      33 UK medical schools for completion by the faculty lead on global health and the
      nominated final year student representative. RESULTS: Surveys were returned by 29
      (88%) medical school faculty and 15 (45%) medical student representatives; 24
      (83%) faculty and 10 (67%) students reported including GHE in the core
      curriculum; however, there was wide variation in the learning outcomes covered.
      On average 75% of faculty and 82% of students reported covering recommended
      global health themes 'global burden of disease', 'socioeconomic and environmental
      determinants of health', 'human rights and ethics', and 'cultural diversity and
      health', while only 48% of faculty and 33% of students reported teaching on
      'health systems' and 'global health governance'. Almost all institutions offered 
      optional global health programmes and most offered some form of pre-elective
      training, although content and delivery were variable. CONCLUSION: Over the last 
      decade, the inclusion of global health in the core curriculum of UK medical
      schools has increased dramatically. Yet, despite interest among students,
      significant gaps are apparent in current GHE. Governing bodies in medical
      education should establish a comprehensive national strategy to help improve
      access to fundamental GHE for all medical students.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Matthews, Natasha Roya
AU  - Matthews NR
AUID- ORCID: 0000-0003-2170-9011
AD  - Faculty of Medicine, School of Public Health, Imperial College London, London,
      UK.
FAU - Davies, Bethan
AU  - Davies B
AD  - Faculty of Medicine, School of Public Health, Imperial College London, London,
      UK.
FAU - Ward, Helen
AU  - Ward H
AD  - Faculty of Medicine, School of Public Health, Imperial College London, London, UK
      h.ward@imperial.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Global Health
MH  - *Health Education
MH  - Humans
MH  - *Schools, Medical
MH  - Students
MH  - United Kingdom
MH  - Universities
PMC - PMC7716673
OTO - NOTNLM
OT  - *health education and promotion
OT  - *health policy
OT  - *review
COIS- Competing interests: NRM is an alumnus of Students for Global Health (formerly
      Medsin) and the International Federation of Medical Students' Associations
      (IFMSA). HW is Director of Education for the School of Public Health and
      founder/director of the BSc in Global Health, the Global Master of Public Health 
      and a short course in Global Health at Imperial College London.
EDAT- 2020/12/05 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/12/04 05:37
PHST- 2020/05/01 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/12/04 05:37 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - bmjgh-2020-002801 [pii]
AID - 10.1136/bmjgh-2020-002801 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Dec;5(12). pii: bmjgh-2020-002801. doi:
      10.1136/bmjgh-2020-002801.


PMID- 33272846
OWN - NLM
STAT- Publisher
LR  - 20210519
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
DP  - 2020 Nov 30
TI  - [The informed consent in the mature minor: Understanding and decision-making
      capacity].
LID - S1695-4033(20)30453-7 [pii]
LID - 10.1016/j.anpedi.2020.10.011 [doi]
AB  - INTRODUCTION: The informed consent of the minor is a fundamental requirement of
      paediatric research. There is a lack of harmonisation as regards the age of the
      mature minor to consent, and there are no systematic tools available to assess
      competence in decision-making capacity. The objective of this work is to analyse 
      the ethical and legal situation of consent by minors, as well as studies that use
      an objective assessment tool in the mature minor. MATERIAL AND METHODS:
      Systematic review of scientific articles in PubMed, Embase and the Grey
      Literature, published with keywords "informed consent minors", without date
      restriction until March 2019. Abstracts and a selection of complete articles were
      reviewed following a protocol including identification, screening, eligibility,
      and inclusion. RESULTS: Of the 260 records identified, 139 were excluded. After
      categorising the resulting 121 publications, 13 were finally selected following
      the eligibility criteria, including 7 articles on international ethical and legal
      regulations and 6 on understanding and decision- making capacity assessment. The 
      MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR)
      semi-structured interview was used in 4 studies, including different age ranges
      (6-21 years) in healthy and sick children. CONCLUSIONS: The semi-structured
      MacArthur interview adapted to adolescents could be an appropriate tool with
      robust psychometric measures for assessing competence for the informed consent of
      minors between 9 and 12 years of age. The regulation of informed consent in
      paediatric research should consider this evidence.
CI  - Copyright (c) 2020. Publicado por Elsevier Espana, S.L.U.
FAU - Boceta, Reyes
AU  - Boceta R
AD  - Departamento de Epidemiologia y Salud Publica, Universidad Rey Juan Carlos,
      Mostoles, Madrid, Espana. Electronic address: reyesboceta@gmail.com.
FAU - Martinez-Casares, Olga
AU  - Martinez-Casares O
AD  - Departamento de Epidemiologia y Salud Publica, Universidad Rey Juan Carlos,
      Mostoles, Madrid, Espana.
FAU - Albert, Marta
AU  - Albert M
AD  - Departamento de Epidemiologia y Salud Publica, Universidad Rey Juan Carlos,
      Mostoles, Madrid, Espana.
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - El consentimiento informado en el menor maduro: comprension y capacidad de
      decision.
DEP - 20201130
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
SB  - IM
OTO - NOTNLM
OT  - Capacidad de decision
OT  - Competence assessment
OT  - Consentimiento informado
OT  - Decision-making capacity
OT  - Evaluacion de competencias
OT  - Informed consent
OT  - Menor
OT  - Minor
EDAT- 2020/12/05 06:00
MHDA- 2020/12/05 06:00
CRDT- 2020/12/04 05:36
PHST- 2020/07/07 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/12/04 05:36 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2020/12/05 06:00 [medline]
AID - S1695-4033(20)30453-7 [pii]
AID - 10.1016/j.anpedi.2020.10.011 [doi]
PST - aheadofprint
SO  - An Pediatr (Engl Ed). 2020 Nov 30. pii: S1695-4033(20)30453-7. doi:
      10.1016/j.anpedi.2020.10.011.


PMID- 33272456
OWN - NLM
STAT- MEDLINE
DCOM- 20210910
LR  - 20210910
IS  - 1879-193X (Electronic)
IS  - 0890-4065 (Linking)
VI  - 55
DP  - 2020 Dec
TI  - Advanced old age as a developmental dilemma: An in-depth comparison of
      established fourth age conceptualizations.
PG  - 100896
LID - S0890-4065(20)30066-9 [pii]
LID - 10.1016/j.jaging.2020.100896 [doi]
AB  - Distinguishing the Fourth Age (FoA) from the Third Age (ThA) has become a common 
      practice in aging research. In this theoretical paper, we focus on four
      established conceptualizations of the ThA-FoA distinction, i.e., (1) Neugarten's 
      work on the young-old vs. the old-old; (2) Laslett's concept of the innovative
      life period of the ThA; (3) Erikson's 9th life stage approach; and (4) Baltes'
      approach considering the FoA as the most radical incompleteness of the human
      condition. After a comparative descriptive analysis, we extract evaluative
      elements inherent in the four approaches according to six categories: (1)
      fundamental values; (2) positive evaluative elements; (3) negative evaluative
      elements; (4) the decline vs. growth view; (5) the continuity vs. discontinuity
      view; and (6) values related to practical issues. As an overarching result of our
      analysis, we conclude that all conceptions face - in different ways - dilemmas
      that seem difficult to solve. One option may be to give up all ambitions toward
      agency for the FoA and indeed qualify this phase as the "aging without agency"
      phase of life. Doing so, however, seems ethically questionable, because it would 
      give up acknowledged values connected with a good human life such as human
      goal-directed autonomy and freedom. In conclusion, the ThA-FoA distinction,
      although arguably a needed and helpful roadmap for the recent decades of aging
      science, comes with enduring disadvantages and eventually even risks. Therefore, 
      in future aging science, we recommend avoiding the ThA-FoA distinction or at
      least using it only in combination with a critical attitude.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Wahl, Hans-Werner
AU  - Wahl HW
AD  - Heidelberg University, Network Aging Research, Heidelberg, Germany. Electronic
      address: wahl@nar.uni-heidelberg.de.
FAU - Ehni, Hans-Jorg
AU  - Ehni HJ
AD  - University of Tubingen, Institute for the Ethics and History of Medicine,
      Tubingen, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - J Aging Stud
JT  - Journal of aging studies
JID - 8916517
SB  - IM
MH  - *Aging
MH  - *Concept Formation
MH  - Forecasting
MH  - Humans
OTO - NOTNLM
OT  - Agency and aging
OT  - Ethics of aging
OT  - Fourth age
OT  - Third age
OT  - Young-old vs. old-old
EDAT- 2020/12/05 06:00
MHDA- 2021/09/11 06:00
CRDT- 2020/12/04 05:33
PHST- 2020/07/29 00:00 [received]
PHST- 2020/10/02 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/12/04 05:33 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/09/11 06:00 [medline]
AID - S0890-4065(20)30066-9 [pii]
AID - 10.1016/j.jaging.2020.100896 [doi]
PST - ppublish
SO  - J Aging Stud. 2020 Dec;55:100896. doi: 10.1016/j.jaging.2020.100896. Epub 2020
      Oct 20.


PMID- 33272452
OWN - NLM
STAT- MEDLINE
DCOM- 20210910
LR  - 20210910
IS  - 1879-193X (Electronic)
IS  - 0890-4065 (Linking)
VI  - 55
DP  - 2020 Dec
TI  - Family care across diverse cultures: Re-envisioning using a transnational lens.
PG  - 100892
LID - S0890-4065(20)30062-1 [pii]
LID - 10.1016/j.jaging.2020.100892 [doi]
AB  - In an increasingly globalized world, the importance of developing a more
      culturally complex understanding of family care has been clearly identified. This
      study explored family care across three different cultural groups - Chinese,
      South Asian, and Latin American - living in a metropolitan, Pacific-West,
      Canadian city. In-depth qualitative interviews were conducted with 29 family
      members from one of the three family groups exploring how they practiced 'care'
      for their aging, often frail, relatives. The importance of conceptualizing family
      care as a transnational, collective undertaking emerged from the outset as
      critical for understanding care practices in all three cultural communities.
      Three themes identified contributed to this conceptualization: the need to
      broaden the understanding of family care; the centrality of geographic mobility, 
      and the need to rethink the location of aging and consider its relationship to
      mobility; and the use of technology by extended family networks to facilitate
      continuity and connection. An over-riding notion of 'flow' or fluid movement,
      rather than a fixed, static arrangement, emerged as critical for understanding
      family care. This perspective challenges the dominant approach to studying family
      care in gerontology that generally conceptualizes family care practice as one
      local primary caregiver, often female, with some support from other family
      members. Understanding family care from a transnational lens builds support for
      the importance of a feminist Ethics of Care lens and has important implications
      for policy and service delivery practices.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Andruske, Cynthia Lee
AU  - Andruske CL
AD  - Centro de Investigacion en Educacion, Salud y Deporte - Arequipa, Peru; Red
      Iberoamericana de Investigacion en Desarrollo Biologico Humano, Talca, Chile;
      University of British Columbia, Vancouver, BC, Canada. Electronic address:
      candruske@gmail.com.
FAU - O'Connor, Deborah
AU  - O'Connor D
AD  - School of Social Work, University of British Columbia, Centre for Research on
      Personhood in Dementia (CRPD), Vancouver, BC, Canada; Centre for Research on
      Personhood in Dementia (CRPD), University of British Columbia, Vancouver, BC,
      Canada. Electronic address: deborah.oconnor@ubc.ca.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - J Aging Stud
JT  - Journal of aging studies
JID - 8916517
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Canada
MH  - *Caregivers
MH  - *Family
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC7573693
OTO - NOTNLM
OT  - Culture
OT  - Ethics of care
OT  - Family care
OT  - Flow of care
OT  - Technology
OT  - Transnational aging
EDAT- 2020/12/05 06:00
MHDA- 2021/09/11 06:00
CRDT- 2020/12/04 05:33
PHST- 2019/11/25 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/12/04 05:33 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/09/11 06:00 [medline]
AID - S0890-4065(20)30062-1 [pii]
AID - 10.1016/j.jaging.2020.100892 [doi]
PST - ppublish
SO  - J Aging Stud. 2020 Dec;55:100892. doi: 10.1016/j.jaging.2020.100892. Epub 2020
      Oct 20.


PMID- 33272336
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
VI  - 36
IP  - 6
DP  - 2020 Dec
TI  - Ethics analysis of light and vitamin D therapies for seasonal affective disorder.
PG  - 549-559
LID - 10.1017/S0266462320000884 [doi]
AB  - OBJECTIVE: The aim of this ethics analysis was to highlight the overt and covert 
      value issues with regard to two health technologies (light therapy and vitamin D 
      therapy), the health technology assessment (HTA) and the disease of seasonal
      affective disorder (SAD). The present ethics analysis served as a chapter of a
      full HTA report that aimed to assist decision makers concerning the two
      technologies. METHOD: First, we used the revised Socratic approach of Hofmann et 
      al. to build overarching topics of ethical issues, and then, we conducted a hand 
      search and a comprehensive systematic literature search on between 12 and 14
      February 2019 in seven databases. RESULTS: The concrete ethical issues found
      concerned vulnerability of the target population and the imperative to treat
      depressive symptoms for the sake of preventing future harm. Further
      disease-related ethical issues concerned the questionable nature of SAD as a
      disease, autonomy, authenticity, and capacity for decision making of SAD
      patients, and the potential stigma related to the underdiagnosis of SAD, which is
      contrasted with the concern over unnecessary medicalization. Regarding the
      interventions and comparators, the ethical issues found concerned their
      benefit-harm ratios and the question of social inequality. The ethical issues
      related to the assessment process relate to the choice of comparators and the
      input data for the selected health economic studies. CONCLUSIONS: The concrete
      ethical issues related to the interventions, the disease, and the assessment
      process itself were made overt in this ethics analysis. The ethics analysis
      provided an (additional) value context for making future decisions regarding
      light and vitamin D therapies.
FAU - Stanak, Michal
AU  - Stanak M
AUID- ORCID: https://orcid.org/0000-0003-0313-0997
AD  - Austrian Institute for Health Technology Assessment (former Ludwig Boltzmann
      Institute for Health Technology Assessment), Vienna, Austria.
AD  - Department of Philosophy, University of Vienna, Vienna, Austria.
FAU - Strohmaier, Christoph
AU  - Strohmaier C
AD  - Austrian Institute for Health Technology Assessment (former Ludwig Boltzmann
      Institute for Health Technology Assessment), Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20201204
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Biomedical Technology
MH  - Humans
MH  - *Seasonal Affective Disorder/therapy
MH  - Technology Assessment, Biomedical
MH  - Vitamin D
OTO - NOTNLM
OT  - Depression
OT  - Ethics
OT  - Morals
OT  - Phototherapy
OT  - Seasonal affective disorder
OT  - Vitamin D
EDAT- 2020/12/05 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/12/04 05:31
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/12/04 05:31 [entrez]
AID - 10.1017/S0266462320000884 [doi]
AID - S0266462320000884 [pii]
PST - ppublish
SO  - Int J Technol Assess Health Care. 2020 Dec;36(6):549-559. doi:
      10.1017/S0266462320000884. Epub 2020 Dec 4.


PMID- 33272207
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 3
TI  - Emphasise capability, not disability: exploring public perceptions, facilitators 
      and barriers to living well with dementia in Northern Ireland.
PG  - 525
LID - 10.1186/s12877-020-01933-w [doi]
AB  - BACKGROUND: Improving public knowledge and understanding about dementia has been 
      identified as a priority area by people living with the condition, researchers,
      educators, and policymakers for several years. Societies that have a better
      understanding of the condition are more likely to enable people living with
      dementia to enjoy a better quality of life. The aim of this study was to explore 
      current public perceptions of dementia along with the facilitators and barriers
      to living well from the perspective of people living with the condition in
      Northern Ireland. METHODS: Four focus group interviews were conducted with a
      total of 20 people living with dementia across three Northern Irish Counties in
      June 2019. These interviews were audio-recorded, transcribed verbatim and
      analysed using thematic analysis. Ethical approval was obtained for this study
      prior to data collection. FINDINGS: Following thematic analysis, three themes
      emerged in relation to barriers and facilitators to living well with dementia.
      These were: 'Emphasis on Disability NOT Capability', which highlighted societal
      misconceptions about the activities and modes of life which people with dementia 
      could or could not do; 'Normalise Dementia - We Don't Want a Fool's Pardon',
      which focused on how the public could encourage people living with the condition 
      to enjoy greater independence, and 'Dementia isn't a Death Sentence', which
      considered how professionals, family members and friends treated the person after
      diagnosis. CONCLUSIONS: Public perceptions about dementia have the potential to
      act as both facilitators and barriers to living well with dementia. People with
      dementia stated that they are more likely sustain wellbeing when they are valued 
      and can maintain independence. On the contrary, poor public and professional
      attitudes to dementia had the potential to disempower people living with
      dementia.
FAU - Mitchell, Gary
AU  - Mitchell G
AUID- ORCID: 0000-0003-2133-2998
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, 97 Lisburn Road, County Antrim, Northern Ireland, BT9 7BL.
      Gary.Mitchell@qub.ac.uk.
FAU - McTurk, Victoria
AU  - McTurk V
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, 97 Lisburn Road, County Antrim, Northern Ireland, BT9 7BL.
FAU - Carter, Gillian
AU  - Carter G
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, 97 Lisburn Road, County Antrim, Northern Ireland, BT9 7BL.
FAU - Brown-Wilson, Christine
AU  - Brown-Wilson C
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, 97 Lisburn Road, County Antrim, Northern Ireland, BT9 7BL.
LA  - eng
GR  - DSDTQUB2019/Dementia Services Development Trust
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - *Dementia/diagnosis/epidemiology
MH  - Focus Groups
MH  - Humans
MH  - Northern Ireland/epidemiology
MH  - Public Opinion
MH  - Qualitative Research
MH  - *Quality of Life
PMC - PMC7713159
OTO - NOTNLM
OT  - *Dementia
OT  - *Dementia perception
OT  - *Dementia-friendly
OT  - *Person-Centred
OT  - *Public health
OT  - *Qualitative research
EDAT- 2020/12/05 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/12/04 05:30
PHST- 2020/05/06 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/04 05:30 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.1186/s12877-020-01933-w [doi]
AID - 10.1186/s12877-020-01933-w [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Dec 3;20(1):525. doi: 10.1186/s12877-020-01933-w.


PMID- 33270724
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 12
DP  - 2020
TI  - Endothelial function is preserved in light to moderate alcohol drinkers but is
      impaired in heavy drinkers in women: Flow-mediated Dilation Japan (FMD-J) study.
PG  - e0243216
LID - 10.1371/journal.pone.0243216 [doi]
AB  - Light to moderate alcohol consumption has protective effects on all-cause death
      and coronary artery disease in women. It is thought that light to moderate
      alcohol consumption has a beneficial effect on vascular function in women. We
      measured flow-mediated vasodilation (FMD) in 702 women aged 17-86 years who
      provided information on alcohol consumption. We divided the subjects into four
      groups: non-drinkers (0 g/week), light drinkers (>0 to 140 g/week), moderate
      drinkers (>140 to 280 g/week) and heavy drinkers (>280 g/week). There was no
      significant difference in FMD among the four groups. Multivariate regression
      analysis revealed that alcohol consumption in non-drinkers and light drinkers was
      not an independent predictor of FMD (beta = -0.001, P = 0.98). We compared 50
      moderate drinkers and 50 non-drinkers matched for age and medical histories and
      22 heavy drinkers and 22 non-drinkers in matched pair analysis. There was no
      significant difference in FMD between moderate drinkers and non-drinkers
      (8.2+/-4.3% vs. 8.1+/-3.5, P = 0.91), while FMD in heavy drinkers was
      significantly lower than that in non-drinkers (5.9+/-2.5% vs. 8.9+/-3.5%, P =
      0.002). These findings suggest that heavy alcohol consumption is associated with 
      endothelial dysfunction but that light to moderate alcohol consumption is not
      associated with endothelial dysfunction in women. Clinical trial registration
      information This study was approved by principal authorities and ethical issues
      in Japan (University Hospital Medical Information Network UMIN000012952,
      01/12/2009). www.umin.ac.jp/.
FAU - Oda, Nozomu
AU  - Oda N
AD  - Department of Cardiology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
FAU - Kajikawa, Masato
AU  - Kajikawa M
AD  - Division of Regeneration and Medicine, Medical Center for Translational and
      Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
FAU - Maruhashi, Tatsuya
AU  - Maruhashi T
AD  - Department of Cardiovascular Regeneration and Medicine, Research Institute for
      Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
FAU - Kishimoto, Shinji
AU  - Kishimoto S
AD  - Department of Cardiovascular Regeneration and Medicine, Research Institute for
      Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
FAU - Yusoff, Farina Mohamad
AU  - Yusoff FM
AD  - Department of Cardiovascular Regeneration and Medicine, Research Institute for
      Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
FAU - Goto, Chikara
AU  - Goto C
AD  - Department of Physical Therapy, Hiroshima International University, Hiroshima,
      Japan.
FAU - Nakashima, Ayumu
AU  - Nakashima A
AD  - Department of Stem Cell Biology and Medicine, Hiroshima University Graduate
      School of Biomedical Sciences, Hiroshima, Japan.
FAU - Tomiyama, Hirofumi
AU  - Tomiyama H
AD  - Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
FAU - Takase, Bonpei
AU  - Takase B
AD  - Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
AD  - Division of Biomedical Engineering, National Defense Medical College Research
      Institute, Tokorozawa, Japan.
FAU - Yamashina, Akira
AU  - Yamashina A
AD  - Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
FAU - Higashi, Yukihito
AU  - Higashi Y
AUID- ORCID: 0000-0001-5813-3672
AD  - Division of Regeneration and Medicine, Medical Center for Translational and
      Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
AD  - Department of Cardiovascular Regeneration and Medicine, Research Institute for
      Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000012952
PT  - Journal Article
DEP - 20201203
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alcohol Drinking/blood/epidemiology/*physiopathology
MH  - Blood Pressure
MH  - Endothelium, Vascular/*physiopathology
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Vasodilation
MH  - Young Adult
PMC - PMC7714190
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/04 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/03 17:15
PHST- 2020/05/05 00:00 [received]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2020/12/03 17:15 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1371/journal.pone.0243216 [doi]
AID - PONE-D-20-13210 [pii]
PST - epublish
SO  - PLoS One. 2020 Dec 3;15(12):e0243216. doi: 10.1371/journal.pone.0243216.
      eCollection 2020.


PMID- 33269693
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 67
IP  - 12
DP  - 2020 Nov 20
TI  - Health status of refugees newly resettled in Denmark.
LID - A08200567 [pii]
AB  - INTRODUCTION: The municipality of Copenhagen offers general health assessment
      (GHA) to all newly resettled refugees, conducted at the Section of Immigrant
      Medicine, Hvidovre Hospital. This study described their disease burden and
      sociodemographic characteristics. METHODS: In this cross-sectional study, all
      adult individuals assessed from 1 January 2017 to 30 January 2019 were included. 
      Doctors performed the GHA, including a structured questionnaire, clinical
      examination and blood testing. RESULTS: In total, 160 refugees were included. Few
      suffered from communicable diseases (e.g., 1% hepatitis B virus) or other somatic
      diseases (4% diabetes Type 2). However, deficiencies such as vitamin D deficiency
      (76%), vitamin B12 deficiency (31%) and anaemia (12%) were frequent. The majority
      reported headache (54%) or other pain (53%). Furthermore, signs of post-traumatic
      stress disorder were frequent (33%) and significantly associated with experience 
      of torture, prison and persecution. CONCLUSIONS: The population presented with
      pertinent health issues such as vitamin deficiencies, mental health issues and
      symptoms of pain. Few suffered from non-communicable or communicable diseases.
      Our results suggest that an offer of specialised services at municipality level
      for all newly resettled refugees may be beneficial. Furthermore, the study
      underlines the need for more research within the field of refugee health.
      FUNDING: None. TRIAL REGISTRATION: Ethical approval was obtained from the Capital
      Region of Denmark and the Danish Patient Safety Authority.
CI  - Articles published in the DMJ are "open access". This means that the articles are
      distributed under the terms of the Creative Commons Attribution Non-commercial
      License, which permits any non-commercial use, distribution, and reproduction in 
      any medium, provided the original author(s) and source are credited.
FAU - Andersen, Mathilde Horn
AU  - Andersen MH
AD  - mathilde.horn.andersen@regionh.dk.
FAU - Kruse, Alexandra
AU  - Kruse A
FAU - Frederiksen, Hanne Winther
AU  - Frederiksen HW
FAU - Ahmadi, Afsaneh
AU  - Ahmadi A
FAU - Norredam, Marie
AU  - Norredam M
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
CIN - Ugeskr Laeger. 2021 Mar 8;183(10):. PMID: 33734068
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Denmark/epidemiology
MH  - Health Status
MH  - Humans
MH  - *Refugees
MH  - *Stress Disorders, Post-Traumatic
MH  - *Torture
EDAT- 2020/12/04 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/12/03 08:34
PHST- 2020/12/03 08:34 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - A08200567 [pii]
PST - epublish
SO  - Dan Med J. 2020 Nov 20;67(12). pii: A08200567.


PMID- 33269357
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
DP  - 2020 Nov 25
TI  - Vitamin D supplementation to prevent acute respiratory infections: systematic
      review and meta-analysis of aggregate data from randomised controlled trials.
LID - 2020.07.14.20152728 [pii]
LID - 10.1101/2020.07.14.20152728 [doi]
AB  - BACKGROUND: A 2017 meta-analysis of data from 25 randomised controlled trials of 
      vitamin D supplementation for the prevention of acute respiratory infections
      revealed a protective effect of the intervention. Since then, 20 new RCTs have
      been completed. METHODS: Systematic review and meta-analysis of data from
      randomised controlled trials (RCTs) of vitamin D for ARI prevention using a
      random effects model. Pre-specified sub-group analyses were done to determine
      whether effects of vitamin D on risk of ARI varied according to baseline
      25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. We searched
      MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL),
      Web of Science and the ClinicalTrials.gov registry from inception to 1st May
      2020. Double-blind RCTs of supplementation with vitamin D or calcidiol, of any
      duration, were eligible if they were approved by a Research Ethics Committee and 
      if ARI incidence was collected prospectively and pre-specified as an efficacy
      outcome. Aggregate data, stratified by baseline 25(OH)D concentration, were
      obtained from study authors. The study was registered with PROSPERO (no.
      CRD42020190633). FINDINGS: We identified 45 eligible RCTs (total 73,384
      participants). Data were obtained for 46,331 (98.0%) of 47,262 participants in 42
      studies, aged 0 to 95 years. For the primary comparison of vitamin D
      supplementation vs. placebo, the intervention reduced risk of ARI overall (Odds
      Ratio [OR] 0.91, 95% CI 0.84 to 0.99; P for heterogeneity 0.01). No statistically
      significant effect of vitamin D was seen for any of the sub-groups defined by
      baseline 25(OH)D concentration. However, protective effects were seen for trials 
      in which vitamin D was given using a daily dosing regimen (OR 0.75, 95% CI 0.61
      to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 95% CI 0.55 to
      0.89); and for a duration of </=12 months (OR 0.82, 95% CI 0.72 to 0.93). No
      significant interaction was seen between allocation to vitamin D vs. placebo and 
      dose frequency, dose size, or study duration. Vitamin D did not influence the
      proportion of participants experiencing at least one serious adverse event (OR
      0.97, 95% CI 0.86 to 1.09). Risk of bias within individual studies was assessed
      as being low for all but three trials. A funnel plot showed left-sided asymmetry 
      (P=0.008, Egger's test). INTERPRETATION: Vitamin D supplementation was safe and
      reduced risk of ARI, despite evidence of significant heterogeneity across trials.
      Protection was associated with administration of daily doses of 400-1000 IU
      vitamin D for up to 12 months. The relevance of these findings to COVID-19 is not
      known and requires investigation. FUNDING: None.
FAU - Jolliffe, David A
AU  - Jolliffe DA
AD  - Institute for Population Health Sciences, Barts and The London School of Medicine
      and Dentistry, Queen Mary University of London, London, UK.
AD  - Asthma UK Centre for Applied Research, Queen Mary University of London, London,
      UK.
FAU - Camargo, Carlos A Jr
AU  - Camargo CA Jr
AD  - Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical
      School, Boston, MA, USA.
FAU - Sluyter, John D
AU  - Sluyter JD
AD  - School of Population Health, University of Auckland, Auckland, New Zealand.
FAU - Aglipay, Mary
AU  - Aglipay M
AD  - Department of Pediatrics, St Michael's Hospital, Toronto, Ontario, Canada.
FAU - Aloia, John F
AU  - Aloia JF
AD  - Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY, USA.
FAU - Ganmaa, Davaasambuu
AU  - Ganmaa D
AD  - Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.
FAU - Bergman, Peter
AU  - Bergman P
AD  - Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Borzutzky, Arturo
AU  - Borzutzky A
AD  - Department of Pediatric Infectious Diseases and Immunology, School of Medicine,
      Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Damsgaard, Camilla T
AU  - Damsgaard CT
AD  - Department of Nutrition, Exercise and Sports, University of Copenhagen,
      Frederiksberg, Denmark.
FAU - Dubnov-Raz, Gal
AU  - Dubnov-Raz G
AD  - Exercise, Lifestyle and Nutrition Clinic, Edmond and Lily Safra Children's
      Hospital, Tel Hashomer, Israel.
FAU - Esposito, Susanna
AU  - Esposito S
AD  - Pediatric Clinic, Pietro Barilla Children's Hospital, Department of Medicine and 
      Surgery, University of Parma, Parma, Italy.
FAU - Gilham, Clare
AU  - Gilham C
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Ginde, Adit A
AU  - Ginde AA
AD  - Department of Emergency Medicine, University of Colorado School of Medicine,
      Aurora, CO, USA.
FAU - Golan-Tripto, Inbal
AU  - Golan-Tripto I
AD  - Saban Pediatric Medical Center, Soroka University Medical Center, Faculty of
      Health Sciences, Ben-Gurion University, Beer Sheva, Israel.
FAU - Goodall, Emma C
AU  - Goodall EC
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, ON, Canada.
FAU - Grant, Cameron C
AU  - Grant CC
AD  - Department of Paediatrics: Child & Youth Health, Faculty of Medical and Health
      Sciences, University of Auckland, Auckland, New Zealand.
FAU - Griffiths, Christopher J
AU  - Griffiths CJ
AD  - Institute for Population Health Sciences, Barts and The London School of Medicine
      and Dentistry, Queen Mary University of London, London, UK.
AD  - Asthma UK Centre for Applied Research, Queen Mary University of London, London,
      UK.
FAU - Hibbs, Anna Maria
AU  - Hibbs AM
AD  - Department of Pediatrics, Case Western Reserve University School of Medicine,
      Cleveland, OH, USA.
AD  - University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
FAU - Janssens, Wim
AU  - Janssens W
AD  - Universitair ziekenhuis Leuven, Leuven, Belgium.
FAU - Khadilkar, Anuradha Vaman
AU  - Khadilkar AV
AD  - Hirabai Cowasji Jehangir Medical Research Institute, Maharashtra, India.
FAU - Laaksi, Ilkka
AU  - Laaksi I
AD  - Faculty of Medicine and Health Technology, University of Tampere, Tampere,
      Finland.
FAU - Lee, Margaret T
AU  - Lee MT
AD  - Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia
      University Medical Center, New York, NY USA.
FAU - Loeb, Mark
AU  - Loeb M
AD  - Department of Pathology and Molecular Medicine, McMaster University, Hamilton,
      ON, Canada.
FAU - Maguire, Jonathon L
AU  - Maguire JL
AD  - Department of Pediatrics, St Michael's Hospital, Toronto, Ontario, Canada.
FAU - Majak, Pawel
AU  - Majak P
AD  - Department of Pediatric Pulmonology, Medical University of Lodz, Lodz, Poland.
FAU - Mauger, David T
AU  - Mauger DT
AD  - Department of Statistics, The Pennsylvania State University, Hershey, PA, USA.
FAU - Manaseki-Holland, Semira
AU  - Manaseki-Holland S
AD  - Department of Public Health, Epidemiology and Biostatistics, Institute of Applied
      Health Sciences, College of Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Murdoch, David R
AU  - Murdoch DR
AD  - Department of Pathology, University of Otago, Christchurch, New Zealand.
FAU - Nakashima, Akio
AU  - Nakashima A
AD  - Jikei University School of Medicine, Tokyo, Japan.
FAU - Neale, Rachel E
AU  - Neale RE
AD  - Population Health Department, QIMR Berghofer Medical Research Institute,
      Queensland, Australia.
FAU - Pham, Hai
AU  - Pham H
AD  - Population Health Department, QIMR Berghofer Medical Research Institute,
      Queensland, Australia.
FAU - Rake, Christine
AU  - Rake C
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Rees, Judy R
AU  - Rees JR
AD  - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, 
      USA.
FAU - Rosendahl, Jenni
AU  - Rosendahl J
AD  - Children's Hospital, Pediatric Research Centre, University of Helsinki and
      Helsinki University Hospital, Helsinki, Finland.
FAU - Scragg, Robert
AU  - Scragg R
AD  - School of Population Health, University of Auckland, Auckland, New Zealand.
FAU - Shah, Dheeraj
AU  - Shah D
AD  - Department of Paediatrics, University College of Medical Sciences, Delhi, India.
FAU - Shimizu, Yoshiki
AU  - Shimizu Y
AD  - FANCL Research Institute, FANCL Corporation, Yokohama, Japan.
FAU - Simpson-Yap, Steve
AU  - Simpson-Yap S
AD  - Neuroepidemiology Unit, Melbourne School of Population & Global Health, The
      University of Melbourne, Melbourne, VIC, Australia.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS,
      Australia.
FAU - Kumar, Geeta Trilok
AU  - Kumar GT
AD  - Institute of Home Economics, University of Delhi, New Delhi, India.
FAU - Urashima, Mitsuyoshi
AU  - Urashima M
AD  - Jikei University School of Medicine, Tokyo, Japan.
FAU - Martineau, Adrian R
AU  - Martineau AR
AD  - Institute for Population Health Sciences, Barts and The London School of Medicine
      and Dentistry, Queen Mary University of London, London, UK.
AD  - Asthma UK Centre for Applied Research, Queen Mary University of London, London,
      UK.
LA  - eng
GR  - 08/116/48/DH_/Department of Health/United Kingdom
GR  - 13/03/25/DH_/Department of Health/United Kingdom
GR  - RP-PG-0407-10398/DH_/Department of Health/United Kingdom
PT  - Preprint
DEP - 20201125
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Lancet Diabetes Endocrinol. 2021 Mar 30;:. PMID: 33798465
PMC - PMC7709175
EDAT- 2020/12/04 06:00
MHDA- 2020/12/04 06:01
CRDT- 2020/12/03 05:47
PHST- 2020/12/03 05:47 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/04 06:01 [medline]
AID - 10.1101/2020.07.14.20152728 [doi]
PST - epublish
SO  - medRxiv. 2020 Nov 25. doi: 10.1101/2020.07.14.20152728.


PMID- 33269209
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210721
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Dec
TI  - Toward the Development of a Functional Analysis Risk Assessment Decision Tool.
PG  - 978-990
LID - 10.1007/s40617-020-00433-y [doi]
AB  - Risk-benefit analyses are essential in the decision-making process when selecting
      the most effective and least restrictive assessment and treatment options for our
      clients. Clinical expertise, informed by the client's preferences and the
      research literature, is needed in order to weigh the potential detrimental
      effects of a procedure against its expected benefits. Unfortunately, safety
      recommendations pertaining to functional analyses (FAs) are scattered or not
      consistently reported in the literature, which could lead some practitioners to
      misjudge the risks of FA. We surveyed behavior analysts to determine their
      perceived need for a risk assessment tool to evaluate risks prior to conducting
      an FA. In a sample of 664 Board Certified Behavior Analysts (BCBAs) and
      doctoral-level Board Certified Behavior Analysts (BCBA-Ds), 96.2% reported that a
      tool that evaluated the risks of proceeding with an FA would be useful for the
      professional practice of applied behavior analysis. We then developed an
      interactive tool to assess risk, which provides suggestions to mitigate the risks
      of an FA and validity recommendations. Subsequently, an expert panel of 10
      BCBA-Ds reviewed the tool. Experts suggested that it was best suited as an
      instructional resource for those learning about the FA process and as a
      supporting resource for early practitioners' clinical decision making.
CI  - (c) Association for Behavior Analysis International 2020, corrected publication
      2020.
FAU - Deochand, Neil
AU  - Deochand N
AD  - Behavior Analysis Program, School of Human Services, University of Cincinnati,
      450H Teachers-Dyer Complex, 2610 McMicken Cir., Cincinnati, OH 45221
      USA.grid.24827.3b0000 0001 2179 9593
FAU - Eldridge, Rebecca R
AU  - Eldridge RR
AD  - Department of Psychology, Western Michigan University, Kalamazoo, MI
      USA.grid.268187.20000 0001 0672 1122
FAU - Peterson, Stephanie M
AU  - Peterson SM
AD  - Department of Psychology, Western Michigan University, Kalamazoo, MI
      USA.grid.268187.20000 0001 0672 1122
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200720
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
EIN - Behav Anal Pract. 2020 Aug 24;13(4):991. PMID: 33270813
PMC - PMC7666254
OTO - NOTNLM
OT  - Clinical decision making
OT  - Ethical practice
OT  - Functional analysis
OT  - Risk assessment
OT  - Safety precautions
COIS- Conflict of InterestThe authors know of no conflicts of interest that would
      present any financial or nonfinancial gain as a result of the potential
      publication of this manuscript.
EDAT- 2020/12/04 06:00
MHDA- 2020/12/04 06:01
CRDT- 2020/12/03 05:47
PHST- 2020/12/03 05:47 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/04 06:01 [medline]
AID - 10.1007/s40617-020-00433-y [doi]
AID - 433 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Jul 20;13(4):978-990. doi: 10.1007/s40617-020-00433-y.
      eCollection 2020 Dec.


PMID- 33269203
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210818
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Dec
TI  - A Guide to Establishing Ethics Committees in Behavioral Health Settings.
PG  - 939-949
LID - 10.1007/s40617-020-00455-6 [doi]
AB  - Ethical statements typically involve rules. All rules can vary in accuracy and
      specificity depending on the context to which they are applied. Codes of ethics
      often involve ethical rules that are written generally to cover the wide-ranging 
      set of possible situations that any one member of the profession may encounter.
      But, despite being written generally, codes of ethics are applied to specific
      situations that professional members encounter. The application of general rules 
      to specific contexts can sometimes be challenging and complex. Health care
      organizations have several options to help their employees behave ethically. One 
      approach is to appoint a single ethics coordinator. In contrast, the dominant
      approach in most health care organizations is to develop an organizational ethics
      committee (Moon Pediatrics, 143(5), e20190659, 2019). Despite the popularity of
      the ethics committee in other professions, the extent to which organizations that
      provide applied behavior analysis services have established and operate ethics
      committees is unknown. Ethics coordinator roles and ethics committees both have
      benefits and drawbacks. This article reviews the benefits and drawbacks of
      appointing an ethics coordinator and establishing an ethics committee. And, for
      interested organizations, this article outlines the steps and considerations that
      organizations can use to guide the creation of an ethics committee.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - Cox, David J
AU  - Cox DJ
AUID- ORCID: 0000-0003-4376-2104
AD  - Behavioral Pharmacology Research Unit, Department of Psychiatry & Behavioral
      Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr.,
      Baltimore, MD 21224 USA.grid.21107.350000 0001 2171 9311
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7666231
OTO - NOTNLM
OT  - Behavioral systems
OT  - Ethical behavior
OT  - Ethical decision making
OT  - Ethics
OT  - Ethics committee
EDAT- 2020/12/04 06:00
MHDA- 2020/12/04 06:01
CRDT- 2020/12/03 05:47
PHST- 2020/12/03 05:47 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/04 06:01 [medline]
AID - 10.1007/s40617-020-00455-6 [doi]
AID - 455 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Aug 17;13(4):939-949. doi: 10.1007/s40617-020-00455-6.
      eCollection 2020 Dec.


PMID- 33269200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210729
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Dec
TI  - Promoting Ethical Discussions and Decision Making in a Human Service Agency.
PG  - 905-913
LID - 10.1007/s40617-020-00454-7 [doi]
AB  - This article describes the development of a system, the Ethics Network, designed 
      to promote discussion of ethical issues in a human services organization. The
      system includes several core components, including people (e.g., leaders,
      ambassadors), tools (e.g., hotline, training modules), and resources (e.g.,
      monthly talking points). Data from 6 years of hotline submissions were analyzed
      to identify the most common concerns, and the data were compared to the pattern
      of violation notices submitted to the Behavior Analyst Certification Board.
      Recommendations are provided for creating similar systems in other organizations.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - LeBlanc, Linda A
AU  - LeBlanc LA
AUID- ORCID: 0000-0001-7711-0978
AD  - LeBlanc Behavioral Consulting, Golden, CO USA.
FAU - Onofrio, Olivia M
AU  - Onofrio OM
AD  - Trumpet Behavioral Health, 390 Union Blvd., Suite #300, Lakewood, CO 80228 USA.
FAU - Valentino, Amber L
AU  - Valentino AL
AD  - Trumpet Behavioral Health, 390 Union Blvd., Suite #300, Lakewood, CO 80228 USA.
FAU - Sleeper, Joshua D
AU  - Sleeper JD
AD  - Trumpet Behavioral Health, 390 Union Blvd., Suite #300, Lakewood, CO 80228 USA.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7666260
OTO - NOTNLM
OT  - Behavior Analyst Certification Board
OT  - Clinical standards
OT  - Compliance code
OT  - Ethics
OT  - Organizational system
OT  - Reporting
COIS- Conflict of InterestThe authors of this manuscript declare no conflict of
      interest regarding this manuscript.
EDAT- 2020/12/04 06:00
MHDA- 2020/12/04 06:01
CRDT- 2020/12/03 05:47
PHST- 2020/12/03 05:47 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/04 06:01 [medline]
AID - 10.1007/s40617-020-00454-7 [doi]
AID - 454 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Jul 28;13(4):905-913. doi: 10.1007/s40617-020-00454-7.
      eCollection 2020 Dec.


PMID- 33268934
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 0974-2727 (Print)
IS  - 0974-2727 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Dec
TI  - Experience with Orbital Tumors from a Tertiary Cancer Centre of North East India:
      A Pathology Perspective.
PG  - 171-177
LID - 10.1055/s-0040-1721148 [doi]
AB  - Background The orbit is an anatomically complex structure comprising the globe,
      extraocular muscles, fat, vascular, nervous, glandular, and connective tissues. A
      wide variety of neoplasms can arise from different orbital structures, which can 
      create a diagnostic challenge to the pathologists. No formal study has been
      conducted in this regard in North East India. Aim and Objectives This article
      aims to document the pattern and prevalence of orbital tumors in our institute
      and assess the utility of histopathological examination (HPE) and
      immunohistochemistry (IHC) in the precise diagnosis of these neoplasms. Materials
      and Methods A retrospective analysis of orbital tumors was performed over a
      period of 5 years from 2013 to 2018 in the department of pathology at a tertiary 
      cancer center of North East India following all the guidelines of the
      institutional ethics committee. Results A total of 35 cases of orbital neoplasms,
      evaluated by HPE and IHC, were found, all of them being malignant tumors. The age
      range was 4 months to 85 years. Male to female ratio was 1.5:1. The most common
      tumor found was lymphoma, accounting for 10 cases (28.6%), all of which were
      non-Hodgkin lymphoma (NHL). All these cases except one occurred in adults, thus
      making it the most common tumor in adults in this study. Diffuse large B cell
      lymphoma, not otherwise specified, was the most common NHL, followed by
      follicular lymphoma, mature T cell NHL, extranodal marginal zone lymphoma, and B 
      cell lymphoblastic lymphoma. Rhabdomyosarcoma and poorly
      differentiated/undifferentiated carcinoma jointly were the second most common
      tumors, totaling seven cases (21.21%) each. This was followed by melanoma (three 
      cases), myeloid sarcoma (three cases), Ewing sarcoma/peripheral neuroectodermal
      tumor (PNET) (three cases), neuroblastoma (one case), and angiosarcoma (one
      case). Among these, rhabdomyosarcoma, granulocytic sarcoma, Ewing sarcoma/PNET,
      and neuroblastoma exclusively troubled the children. IHC markers including the
      lymphoma panel, and soft tissue ones were crucial in the precise diagnosis of the
      neoplasms encountered. Conclusion A variety of malignant orbital tumors may be
      seen in clinical practice. Management of these tumors requires a
      multidisciplinary approach. HPE in conjunction with IHC evaluation is of utmost
      importance in the veracious recognition of orbital tumors for their proper
      management.
CI  - The Indian Association of Laboratory Physicians. This is an open access article
      published by Thieme under the terms of the Creative Commons
      Attribution-NonDerivative-NonCommercial-License, permitting copying and
      reproduction so long as the original work is given appropriate credit. Contents
      may not be used for commercial purposes, or adapted, remixed, transformed or
      built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.).
FAU - Chowdhury, Zachariah
AU  - Chowdhury Z
AD  - Department of Pathology, Homi Bhabha Cancer Hospital/MPMMCC (Tata Memorial
      Hospital), Varanasi, Uttar Pradesh, India.
FAU - Sharma, Jagannath Dev
AU  - Sharma JD
AD  - Department of Pathology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India.
FAU - Kakoti, Lopa Mudra
AU  - Kakoti LM
AD  - Department of Pathology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India.
FAU - Sarma, Anupam
AU  - Sarma A
AD  - Department of Pathology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India.
FAU - Ahmed, Shiraj
AU  - Ahmed S
AD  - Department of Pathology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India.
FAU - Hazarika, Munlima
AU  - Hazarika M
AD  - Department of Medical Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam,
      India.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - Germany
TA  - J Lab Physicians
JT  - Journal of laboratory physicians
JID - 101551511
PMC - PMC7684989
OTO - NOTNLM
OT  - histopathology
OT  - immunohistochemistry
OT  - lymphoma
OT  - orbit
OT  - rhabdomyosarcoma
COIS- Presentation at a MeetingStatement of EthicsConflict of Interest None. The study 
      followed all the guidelines of the institutional ethics committee and adhered to 
      the principles of the Declaration of Helsinki. None.
EDAT- 2020/12/04 06:00
MHDA- 2020/12/04 06:01
CRDT- 2020/12/03 05:46
PHST- 2020/12/03 05:46 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/04 06:01 [medline]
AID - 10.1055/s-0040-1721148 [doi]
AID - JLP2040127 [pii]
PST - ppublish
SO  - J Lab Physicians. 2020 Dec;12(3):171-177. doi: 10.1055/s-0040-1721148. Epub 2020 
      Nov 23.


PMID- 33268726
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 47
IP  - 11
DP  - 2020 Nov
TI  - [Nutritional Management in Cancer Chemotherapy Based on Pathophysiology of
      Sarcopenia].
PG  - 1552-1556
AB  - There are 4 purposes in the nutritional management for cancer patient. At first, 
      we had better perform the early metabolic recovery from several invasive damages 
      by some cancer treatments. At second, we give some special nutritional management
      for improvement from cancer cachexia. At third, we consider palliative
      nutritional management to terminal cancer patients based on pathophysiology of
      cachexia, their life styles and ethics. Finally, we give the social nutritional
      management for keeping high quality of life through well eating until the end of 
      life. The basic nutritional management for cancer patients is administration of
      adequate amount of energy, protein/amino acids and micronutrients with suitable
      rehabilitation in order to prevent sarcopenia and malnutrition. In this paper, we
      explained about the metabolic influences to normal tissues, especially skeletal
      muscle, during chemotherapy. Also we mentioned importance to prevent sarcopenia
      and malnutrition during cancer treatment especially chemotherapy. Additionally,
      we showed the new topic about assessment for malnutrition, such as GLIM criteria,
      which is the global nutritional assessment formula for malnutrition including
      weight loss, low BMI and reduce of muscle mass. Now, we can recommend to use the 
      global nutritional assessment and nutritional therapies even for cancer patients.
FAU - Higashiguchi, Takashi
AU  - Higashiguchi T
AD  - Yonaha General Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
SB  - IM
MH  - Cachexia/etiology/therapy
MH  - Humans
MH  - *Malnutrition/etiology/therapy
MH  - *Neoplasms/complications/drug therapy
MH  - Nutrition Assessment
MH  - Nutritional Status
MH  - Quality of Life
MH  - *Sarcopenia/etiology/therapy
EDAT- 2020/12/04 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/03 05:41
PHST- 2020/12/03 05:41 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2020 Nov;47(11):1552-1556.


PMID- 33268434
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Endoscopic polypectomy performed in clinic for chronic rhinosinusitis with nasal 
      polyps: study protocol for the EPIC multicentre randomised controlled trial.
PG  - e042413
LID - 10.1136/bmjopen-2020-042413 [doi]
AB  - INTRODUCTION: Chronic rhinosinusitis (CRS) is common, with a Canadian prevalence 
      of 5%, and associated with significant morbidity. Understandably, CRS impairs
      workplace productivity but that productivity substantially increases following
      surgical treatment. CRS with nasal polyps (CRSwNP), the most common type of CRS, 
      is usually treated with a combination of medications and endoscopic sinus surgery
      (ESS). Historically, surgical treatment has only been performed in the operating 
      room at a cost of about $C3500. However, recent studies have shown that a
      de-escalated procedure, endoscopic polypectomy performed in clinic (EPIC), can
      provide an improvement in patient symptoms to levels equal to those for ESS.
      Moreover, EPIC has additional proposed advantages including shorter recovery
      time, significantly lower cost to the healthcare system and shorter wait time for
      the patient. There is currently insufficient evidence to draw conclusions about
      the superiority of polypectomy or ESS for the management of CRSwNP. METHODS AND
      ANALYSIS: We designed a multicentre, open-label, randomised controlled trial to
      evaluate whether EPIC was non-inferior to the current clinical standard, ESS for 
      the treatment of CRSwNP. The primary outcome is the Sinonasal Outcome Test-22
      score measured at baseline and at 3 months after surgery. Other outcomes include 
      peak nasal inspiratory flow, quality of life measured by the EuroQoL 5 Dimensions
      5 Levels questionnaire and work impairment using the Work Productivity and
      Activity Impairment Questionnaire.We aim to recruit 140 patients from sites
      across Canada. Participants will be randomly assigned to EPIC or ESS and followed
      up for 3 months in clinic after the procedure. Additionally, participants will
      enter a 5-year long-term follow-up period. ETHICS AND DISSEMINATION: This study
      was approved by the Ottawa Health Sciences Network Research Ethics Board for all 
      sites in Ontario, Canada (study number CTO0801). Sites located outside of Ontario
      obtained approval from their local/institutional research ethics board. TRIAL
      REGISTRATION NUMBER: NCT02975310.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kilty, Shaun
AU  - Kilty S
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada skilty@toh.ca.
AD  - Department of Otolaryngology- Head & Neck Surgery, University of Ottawa, Ottawa, 
      Ontario, Canada.
FAU - Thavorn, Kednapa
AU  - Thavorn K
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - ICES uOttawa, Institute for Clinical Evaluative Sciences, Ottawa, Ontario,
      Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, 
      Canada.
FAU - Janjua, Arif
AU  - Janjua A
AD  - Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, The
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Lee, John
AU  - Lee J
AD  - Department of Otolaryngology-Head and Neck Surgery, Saint Michael's Hospital,
      Toronto, Ontario, Canada.
FAU - MacDonald, Kristian
AU  - MacDonald K
AD  - Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Meen, Eric
AU  - Meen E
AD  - Department of Otolaryngology, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Micomonaco, Damian
AU  - Micomonaco D
AD  - Department of Clinical Sciences, Northern Ontario School of Medicine, Thunder
      Bay, Ontario, Canada.
FAU - Rotenberg, Brian
AU  - Rotenberg B
AD  - Department of Otolaryngology - Head and Neck Surgery, Western University, London,
      Ontario, Canada.
FAU - Sowerby, Leigh J
AU  - Sowerby LJ
AD  - Department of Otolaryngology - Head and Neck Surgery, Western University, London,
      Ontario, Canada.
FAU - Tewfik, Marc
AU  - Tewfik M
AD  - Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, 
      Quebec, Canada.
FAU - Adams, Susan
AU  - Adams S
AD  - Patient Representative, Ottawa, Ontario, Canada.
FAU - Frenette, Hubert
AU  - Frenette H
AD  - Patient Representative, Ottawa, Ontario, Canada.
FAU - Lasso, Andrea
AU  - Lasso A
AUID- ORCID: 0000-0002-9552-264X
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, 
      Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa,
      Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT02975310
GR  - PJT148734/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - Endoscopy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Nasal Polyps/complications/surgery
MH  - Ontario
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Rhinitis/surgery
MH  - *Sinusitis/surgery
MH  - Treatment Outcome
PMC - PMC7713191
OTO - NOTNLM
OT  - *adult otolaryngology
OT  - *endoscopic surgery
OT  - *health economics
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:40
PHST- 2020/12/03 05:40 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042413 [pii]
AID - 10.1136/bmjopen-2020-042413 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e042413. doi: 10.1136/bmjopen-2020-042413.


PMID- 33268431
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - The DemWG study: reducing the risk of hospitalisation through a complex
      intervention for people with dementia and mild cognitive impairment (MCI) in
      German shared-housing arrangements: study protocol of a prospective,
      mixed-methods, multicentre, cluster-randomised controlled trial.
PG  - e041891
LID - 10.1136/bmjopen-2020-041891 [doi]
AB  - INTRODUCTION: Shared-housing arrangements (SHAs) are small, home-like care
      environments in Germany. Residents are predominantly people with dementia. The
      risk for all-cause hospitalisation is consistently higher for people with
      dementia compared with people without dementia and there is currently no
      evidence-based intervention to reduce the risk of hospitalisation. Thus, the
      DemWG study investigates whether a complex intervention is effective in reducing 
      hospitalisation (primary outcome), behavioural and psychological symptoms of
      dementia and falls and for stabilising cognitive functioning and quality of life 
      in people with dementia and mild cognitive impairment (MCI) in German SHAs.
      METHODS AND ANALYSIS: Based on the UK Medical Research Council framework
      'Developing and evaluating complex interventions', a prospective, mixed-methods, 
      multicentre, cluster-randomised controlled trial combining primary and secondary 
      data analyses as well as quantitative and qualitative research methods is being
      conducted. The intervention consists of three parts: (A) education of nursing
      staff in SHAs; (B) awareness raising and continuing medical education (CME) of
      general practitioners; (C) multicomponent non-pharmacological group intervention 
      MAKS-mk+ ('m'=motor training; 'k'=cognitive training; '+'=fall prevention) for
      people with dementia and MCI. Randomisation is stratified by the German federal
      states and type of setting (rural vs urban). Neither the trained professionals
      nor the participants are blinded. Data are collected at baseline and after 6, 12 
      and 18 months with standardised instruments. Quantitative data will be analysed
      by multivariate analyses according to the general linear model, qualitative data 
      using qualitative content analysis. Recruitment is still ongoing until 31
      December 2020. ETHICS AND DISSEMINATION: All procedures were approved by the
      Ethics Committee of the University of Bremen (Ref. 2019-18-06-3). Informed
      consent will be obtained before enrolment of participants. Due to findings of
      previous randomised controlled trials, serious adverse events are not expected.
      Results will be disseminated in peer-reviewed journal publications and conference
      presentations. TRIAL REGISTRATION NUMBER: ISRCTN89825211.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kratzer, Andre
AU  - Kratzer A
AUID- ORCID: 0000-0001-7906-3079
AD  - Centre for Health Services Research in Medicine, Department of Psychiatry and
      Psychotherapy, University Hospital Erlangen, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany andre.kratzer@uk-erlangen.de.
FAU - Scheel, Jennifer
AU  - Scheel J
AD  - Centre for Health Services Research in Medicine, Department of Psychiatry and
      Psychotherapy, University Hospital Erlangen, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany.
FAU - Wolf-Ostermann, Karin
AU  - Wolf-Ostermann K
AD  - Department of Health Care Research, Institute of Public Health and Nursing
      Research (IPP), University of Bremen, Bremen, Germany.
FAU - Schmidt, Annika
AU  - Schmidt A
AD  - Department of Health Care Research, Institute of Public Health and Nursing
      Research (IPP), University of Bremen, Bremen, Germany.
FAU - Ratz, Katrin
AU  - Ratz K
AD  - Department of Health Care Research, Institute of Public Health and Nursing
      Research (IPP), University of Bremen, Bremen, Germany.
FAU - Donath, Carolin
AU  - Donath C
AD  - Centre for Health Services Research in Medicine, Department of Psychiatry and
      Psychotherapy, University Hospital Erlangen, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany.
FAU - Graessel, Elmar
AU  - Graessel E
AD  - Centre for Health Services Research in Medicine, Department of Psychiatry and
      Psychotherapy, University Hospital Erlangen, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany.
LA  - eng
SI  - ISRCTN/ISRCTN89825211
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cognitive Dysfunction/prevention & control
MH  - *Dementia
MH  - Germany
MH  - Hospitalization
MH  - Housing
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7713202
OTO - NOTNLM
OT  - *delirium & cognitive disorders
OT  - *dementia
OT  - *geriatric medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:40
PHST- 2020/12/03 05:40 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041891 [pii]
AID - 10.1136/bmjopen-2020-041891 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e041891. doi: 10.1136/bmjopen-2020-041891.


PMID- 33268430
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210121
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Clinical manifestations, prevalence, risk factors, outcomes, transmission,
      diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living
      systematic review protocol.
PG  - e041868
LID - 10.1136/bmjopen-2020-041868 [doi]
AB  - INTRODUCTION: Rapid, robust and continually updated evidence synthesis is
      required to inform management of COVID-19 in pregnant and postpartum women and to
      keep pace with the emerging evidence during the pandemic. METHODS AND ANALYSIS:
      We plan to undertake a living systematic review to assess the prevalence,
      clinical manifestations, risk factors, rates of maternal and perinatal
      complications, potential for mother-to-child transmission, accuracy of diagnostic
      tests and effectiveness of treatment for COVID-19 in pregnant and postpartum
      women (including after miscarriage or abortion). We will search Medline, Embase, 
      WHO COVID-19 database, preprint servers, the China National Knowledge
      Infrastructure system and Wanfang databases from 1 December 2019. We will
      supplement our search with studies mapped by Cochrane Fertility and Gynaecology
      group, Evidence for Policy and Practice Information and Co-ordinating Centre
      (EPPI-Centre), COVID-19 study repositories, reference lists and social media
      blogs. The search will be updated every week and not be restricted by language.
      We will include observational cohort (>/=10 participants) and randomised studies 
      reporting on prevalence of COVID-19 in pregnant and postpartum women, the rates
      of clinical manifestations and outcomes, risk factors in pregnant and postpartum 
      women alone or in comparison with non-pregnant women with COVID-19 or pregnant
      women without COVID-19 and studies on tests and treatments for COVID-19. We will 
      additionally include case reports and series with evidence on mother-to-child
      transmission of SARS-CoV-2 in utero, intrapartum or postpartum. We will appraise 
      the quality of the included studies using appropriate tools to assess the risk of
      bias. At least two independent reviewers will undertake study selection, quality 
      assessment and data extraction every 2 weeks. We will synthesise the findings
      using quantitative random effects meta-analysis and report OR or proportions with
      95% CIs and prediction intervals. Case reports and series will be reported as
      qualitative narrative synthesis. Heterogeneity will be reported as I(2) and
      tau(2) statistics. ETHICS AND DISSEMINATION: Ethical approval is not required as 
      this is a synthesis of primary data. Regular updates of the results will be
      published on a dedicated website
      (https://www.birmingham.ac.uk/research/who-collaborating-centre/pregcov/index.asp
      x) and disseminated through publications, social media and webinars. PROSPERO
      REGISTRATION NUMBER: CRD42020178076.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Yap, Magnus
AU  - Yap M
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Debenham, Luke
AU  - Debenham L
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Kew, Tania
AU  - Kew T
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Chatterjee, Shaunak Rhiju
AU  - Chatterjee SR
AUID- ORCID: http://orcid.org/0000-0002-3444-3948
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Allotey, John
AU  - Allotey J
AD  - WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and
      Systems Research, University of Birmingham, Birmingham, UK
      j.allotey.1@bham.ac.uk.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Stallings, Elena
AU  - Stallings E
AD  - Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal (IRYCIS),
      Madrid, Spain.
AD  - CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
FAU - Coomar, Dyuti
AU  - Coomar D
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Lee, Siang Ing
AU  - Lee SI
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Qiu, Xiu
AU  - Qiu X
AD  - Department of Woman and Child Health Care, Guangzhou Women and Children's Medical
      Center, Guangzhou Medical University, Guangzhou, China.
AD  - Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
AD  - Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical
      Center, Guangzhou Medical University, Guangzhou, China.
FAU - Yuan, Mingyang
AU  - Yuan M
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
AD  - Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Clave Llavall, Anna
AU  - Clave Llavall A
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Dixit, Anushka
AU  - Dixit A
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Zhou, Dengyi
AU  - Zhou D
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - Balaji, Rishab
AU  - Balaji R
AD  - Birmingham Medical School, College Medical and Dental Sciences, University of
      Birmingham, Birmingham, UK.
FAU - van Wely, Madelon
AU  - van Wely M
AD  - Netherlands Satellite of the Cochrane Gynaecology and Fertility Group, Amsterdam 
      University Medical Center, Amsterdam, The Netherlands.
FAU - Kostova, Elena
AU  - Kostova E
AD  - Netherlands Satellite of the Cochrane Gynaecology and Fertility Group, Amsterdam 
      University Medical Center, Amsterdam, The Netherlands.
FAU - van Leeuwen, Elisabeth
AU  - van Leeuwen E
AD  - Department of Obstetrics and Gynaecology, Amsterdam University Medical Center,
      Amsterdam, The Netherlands.
FAU - Mofenson, Lynne
AU  - Mofenson L
AD  - Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, Maryland, USA.
FAU - Kunst, Heinke
AU  - Kunst H
AD  - Blizard Institute, Queen Mary University of London, London, UK.
FAU - Khalil, Asma
AU  - Khalil A
AD  - Department of Obstetrics and Gynaecology, St George's University London, London, 
      UK.
FAU - Tiberi, Simon
AU  - Tiberi S
AD  - Blizard Institute, Queen Mary University of London, London, UK.
AD  - Department of Infectious Diseases, Barts Health NHS Trust, London, UK.
FAU - Thomas, James
AU  - Thomas J
AD  - UCL Institute of Education, University College London, London, UK.
FAU - Brizuela, Vanessa
AU  - Brizuela V
AUID- ORCID: http://orcid.org/0000-0002-4860-0828
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Broutet, Nathalie
AU  - Broutet N
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Kara, Edna
AU  - Kara E
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Kim, Caron
AU  - Kim C
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Thorson, Anna
AU  - Thorson A
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Rayco-Solon, Pura
AU  - Rayco-Solon P
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Pardo-Hernandez, Hector
AU  - Pardo-Hernandez H
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Oladapo, Olufemi Taiwo
AU  - Oladapo OT
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Zamora, Javier
AU  - Zamora J
AUID- ORCID: http://orcid.org/0000-0003-4901-588X
AD  - Women's Health Research Unit, Queen Mary University of London, London, UK.
FAU - Bonet, Mercedes
AU  - Bonet M
AD  - Department of Sexual and Reproductive Health and Research,
      UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
      Research Training in Human Reproduction (HRP), World Health Organization, Geneva,
      Switzerland.
FAU - Thangaratinam, Shakila
AU  - Thangaratinam S
AD  - WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and
      Systems Research, University of Birmingham, Birmingham, UK.
AD  - Department of Obstetrics and Gynaecology, Birmingham Women's and Children's NHS
      Foundation Trust, Birmingham, UK.
CN  - PregCOV-19 Consortium
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *COVID-19/diagnosis/physiopathology/therapy/transmission
MH  - Female
MH  - Humans
MH  - Infectious Disease Transmission, Vertical
MH  - Meta-Analysis as Topic
MH  - Postpartum Period
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/diagnosis/physiopathology/therapy
MH  - Pregnancy Outcome
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7712931
OTO - NOTNLM
OT  - *maternal medicine
OT  - *neonatology
OT  - *perinatology
OT  - *protocols & guidelines
OT  - *virology
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/03 05:40
PHST- 2020/12/03 05:40 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-041868 [pii]
AID - 10.1136/bmjopen-2020-041868 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e041868. doi: 10.1136/bmjopen-2020-041868.


PMID- 33268429
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Study protocol for evaluation of aid to diagnosis for developmental dysplasia of 
      the hip in general practice: controlled trial randomised by practice.
PG  - e041837
LID - 10.1136/bmjopen-2020-041837 [doi]
AB  - INTRODUCTION: In the UK, a compulsory '6-week hip check' is performed in primary 
      care for the detection of developmental dysplasia of the hip (DDH). However,
      missed diagnoses and infants incorrectly labelled with DDH remain a problem,
      potentially leading to adverse consequences for infants, their families and the
      National Health Service. National policy states that infants should be referred
      to hospital if the 6-week check suggests DDH, though there is no available tool
      to aid examination or offer guidelines for referral. We developed standardised
      diagnostic criteria for DDH, based on international Delphi consensus, and a
      9-item checklist that has the potential to enable non-experts to diagnose DDH in 
      a manner approaching that of experts. METHODS AND ANALYSIS: We will conduct a
      controlled trial randomised by practice that will compare a diagnostic aid
      against standard care for the hip check. The primary objective is to determine
      whether an aid to the diagnosis of DDH reduces the number of clinically
      insignificant referrals from primary care to hospital and the number of late
      diagnosed DDH. The trial will include a qualitative process evaluation, an
      assessment of professional behavioural change and a full health economic
      evaluation. We will recruit 152 general practitioner practices in England. These 
      will be randomised to conduct the hip checks with use of the study diagnostic aid
      and/or as per usual practice. The total number of infants seen during a 15-month 
      recruitment period will be 110 per practice. Two years after the 6-week hip
      check, we will measure the number of referred infants that are (1) clinically
      insignificant for DDH and (2) those that constitute appropriate referrals. ETHICS
      AND DISSEMINATION: This study has approval from the Health Research Authority
      (16/1/2020) and the Confidentiality Advisory Group (18/2/2020). Results will be
      published in peer-reviewed academic journals, disseminated to patient
      organisations and the media. TRIAL REGISTRATION NUMBER: NCT04101903; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Roposch, Andreas
AU  - Roposch A
AUID- ORCID: 0000-0002-0143-7840
AD  - Great Ormond Street Institute of Child Health, UCL, London, UK
      a.roposch@ucl.ac.uk.
AD  - Department of Orthopaedic Surgery, Great Ormond Street Hospital for Children,
      London, UK.
FAU - Warsame, Kaltuun
AU  - Warsame K
AD  - Great Ormond Street Institute of Child Health, UCL, London, UK.
FAU - Chater, Angel
AU  - Chater A
AD  - Department of Sport Science and Physical, University of Bedfordshire, Luton, UK.
FAU - Green, Judith
AU  - Green J
AD  - Department of Population Health Sciences, Kings College London, London, UK.
FAU - Hunter, Rachael
AU  - Hunter R
AUID- ORCID: 0000-0002-7447-8934
AD  - Research Department of Primary Care and Population Health, UCL, London, UK.
FAU - Wood, John
AU  - Wood J
AD  - PRIMENT Clinical Trials Unit, UCL, London, UK.
FAU - Freemantle, Nick
AU  - Freemantle N
AD  - Comprehensive Clinical Trials Unit, UCL, London, UK.
FAU - Nazareth, Irwin
AU  - Nazareth I
AD  - Research Department of Primary Care and Population Health, UCL, London, UK.
AD  - PRIMENT Clinical Trials Unit, UCL, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04101903
GR  - RP-PG-0616-20006/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Developmental Dysplasia of the Hip
MH  - England
MH  - *General Practice
MH  - *Hip Dislocation, Congenital/diagnosis
MH  - Humans
MH  - Infant
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
PMC - PMC7713187
OTO - NOTNLM
OT  - *paediatric orthopaedics
OT  - *paediatrics
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:40
PHST- 2020/12/03 05:40 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041837 [pii]
AID - 10.1136/bmjopen-2020-041837 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e041837. doi: 10.1136/bmjopen-2020-041837.


PMID- 33268426
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Design and rationale of the COVID-19 Critical Care Consortium international,
      multicentre, observational study.
PG  - e041417
LID - 10.1136/bmjopen-2020-041417 [doi]
AB  - INTRODUCTION: There is a paucity of data that can be used to guide the management
      of critically ill patients with COVID-19. In response, a research and
      data-sharing collaborative-The COVID-19 Critical Care Consortium-has been
      assembled to harness the cumulative experience of intensive care units (ICUs)
      worldwide. The resulting observational study provides a platform to rapidly
      disseminate detailed data and insights crucial to improving outcomes. METHODS AND
      ANALYSIS: This is an international, multicentre, observational study of patients 
      with confirmed or suspected SARS-CoV-2 infection admitted to ICUs. This is an
      evolving, open-ended study that commenced on 1 January 2020 and currently
      includes >350 sites in over 48 countries. The study enrols patients at the time
      of ICU admission and follows them to the time of death, hospital discharge or 28 
      days post-ICU admission, whichever occurs last. Key data, collected via an
      electronic case report form devised in collaboration with the International
      Severe Acute Respiratory and Emerging Infection Consortium/Short Period Incidence
      Study of Severe Acute Respiratory Illness networks, include: patient demographic 
      data and risk factors, clinical features, severity of illness and respiratory
      failure, need for non-invasive and/or mechanical ventilation and/or
      extracorporeal membrane oxygenation and associated complications, as well as data
      on adjunctive therapies. ETHICS AND DISSEMINATION: Local principal investigators 
      will ensure that the study adheres to all relevant national regulations, and that
      the necessary approvals are in place before a site may contribute data. In
      jurisdictions where a waiver of consent is deemed insufficient, prospective,
      representative or retrospective consent will be obtained, as appropriate. A
      web-based dashboard has been developed to provide relevant data and descriptive
      statistics to international collaborators in real-time. It is anticipated that,
      following study completion, all de-identified data will be made open access.
      TRIAL REGISTRATION NUMBER: ACTRN12620000421932
      (http://anzctr.org.au/ACTRN12620000421932.aspx).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li Bassi, Gianluigi
AU  - Li Bassi G
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia g.libassi@uq.edu.au.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
AD  - Queensland University of Technology, Brisbane, Queensland, Australia.
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
FAU - Suen, Jacky
AU  - Suen J
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Barnett, Adrian Gerard
AU  - Barnett AG
AUID- ORCID: http://orcid.org/0000-0001-6339-0374
AD  - Institute of Health and Biomedical Innovation, Queensland University of
      Technology, Brisbane, Queensland, Australia.
FAU - Corley, Amanda
AU  - Corley A
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Millar, Jonathan
AU  - Millar J
AD  - Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom.
FAU - Fanning, Jonathon
AU  - Fanning J
AUID- ORCID: http://orcid.org/0000-0002-1675-0522
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
AD  - Critical Care Medicine, UnitingCare Health, Brisbane, Queensland, Australia.
FAU - Lye, India
AU  - Lye I
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Colombo, Sebastiano
AU  - Colombo S
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan,
      Italy.
FAU - Wildi, Karin
AU  - Wildi K
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Livingstone, Samantha
AU  - Livingstone S
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Abbate, Gabriella
AU  - Abbate G
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
FAU - Hinton, Samuel
AU  - Hinton S
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Liquet, Benoit
AU  - Liquet B
AD  - University of Queensland, Brisbane, Queensland, Australia.
AD  - University of Pau et Pays De L'Adour, Pau, France.
FAU - Shrapnel, Sally
AU  - Shrapnel S
AD  - University of Queensland, Brisbane, Queensland, Australia.
FAU - Dalton, Heidi
AU  - Dalton H
AD  - Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
FAU - Fraser, John F
AU  - Fraser JF
AD  - Critical Care Research Group, Prince Charles Hospital, Chermside, Queensland,
      Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
AD  - Queensland University of Technology, Brisbane, Queensland, Australia.
AD  - Critical Care Medicine, UnitingCare Health, Brisbane, Queensland, Australia.
CN  - COVID-19 Critical Care Consortium Investigators
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/mortality/*therapy
MH  - Evidence-Based Medicine
MH  - Global Health
MH  - Humans
MH  - Intensive Care Units/*statistics & numerical data
MH  - Observational Studies as Topic
MH  - Outcome Assessment, Health Care
MH  - Pandemics
MH  - Pragmatic Clinical Trials as Topic
MH  - *Registries
MH  - SARS-CoV-2
PMC - PMC7714653
OTO - NOTNLM
OT  - *epidemiology
OT  - *intensive & critical care
OT  - *public health
OT  - *respiratory infections
COIS- Competing interests: GLB and JFF received research funds, through their
      affiliated institution, from Fisher & Paykel for studies related to high-flow
      oxygen therapy.
EDAT- 2020/12/04 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/03 05:40
PHST- 2020/12/03 05:40 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-041417 [pii]
AID - 10.1136/bmjopen-2020-041417 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e041417. doi: 10.1136/bmjopen-2020-041417.


PMID- 33268424
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Simplifying and optimising management of acute malnutrition in children aged 6 to
      59 months: study protocol for a community-based individually randomised
      controlled trial in Kasai, Democratic Republic of Congo.
PG  - e041213
LID - 10.1136/bmjopen-2020-041213 [doi]
AB  - INTRODUCTION: Acute malnutrition (AM) is a continuum condition, arbitrarily
      divided into moderate and severe AM (SAM) categories, funded and managed in
      separate programmes under different protocols. Optimising acute MAlnutrition
      (OptiMA) treatment aims to simplify and optimise AM management by treating
      children with mid-upper arm circumference (MUAC) <125 mm or oedema with one
      product-ready-to-use therapeutic food-at a gradually tapered dose. Our main
      objective was to compare the OptiMA strategy with the standard nutritional
      protocol in children 6-59 months presenting with MUAC <125 mm or oedema without
      additional complications, as well as in children classified as uncomplicated SAM 
      (ie, MUAC <115 mm or weight-for-height Z-score (WHZ) <-3 or with oedema). METHODS
      AND ANALYSIS: This study was a non-inferiority, individually randomised
      controlled clinical trial conducted at community level in the Democratic Republic
      of Congo. Children 6-59 months presenting with MUAC <125 mm or WHZ <-3 or with
      bipedal oedema and without medical complication were included after signed
      informed consent in outpatient health facilities. All participants were followed 
      for 6 months. Success in both arms was defined at 6 months post inclusion as
      being alive, not acutely malnourished per the definition applied at inclusion and
      without an additional episode of AM throughout the 6-month observation period.
      Recovery among children with uncomplicated SAM was the main secondary outcome.
      For the primary objective, 890 participants were needed, and 480 children with
      SAM were needed for the main secondary objective. We will perform non-inferiority
      analyses in per-protocol and intention-to-treat basis for both outcomes. ETHICS
      AND DISSEMINATION: Ethics approvals were obtained from the National Health Ethics
      Committee of the Democratic Republic of Congo and from the Ethics Evaluation
      Committee of Inserm, the French National Institute for Health and Medical
      Research (Paris, France). We will submit results for publication to a
      peer-reviewed journal and disseminate findings in international and national
      conferences and meetings. TRIAL REGISTRATION NUMBER: NCT03751475. Registered 19
      September 2018, https://clinicaltrials.gov/ct2/show/NCT03751475.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Cazes, Cecile
AU  - Cazes C
AUID- ORCID: 0000-0002-5501-6224
AD  - University of Bordeaux, Inserm, French National Research Institute for
      Sustainable Development (IRD), Bordeaux Population Health Research Center, Team
      IDLIC, UMR 1219, Bordeaux, France cecile.cazes@u-bordeaux.fr.
FAU - Phelan, Kevin
AU  - Phelan K
AUID- ORCID: 0000-0002-7017-7464
AD  - The Alliance for International Medical Action (ALIMA), Paris, France.
FAU - Hubert, Victoire
AU  - Hubert V
AD  - The Alliance for International Medical Action (ALIMA), Kamuesha, Democratic
      Republic of Congo.
FAU - Alitanou, Rodrigue
AU  - Alitanou R
AD  - The Alliance for International Medical Action (ALIMA), Kamuesha, Democratic
      Republic of Congo.
FAU - Boubacar, Harouna
AU  - Boubacar H
AD  - The Alliance for International Medical Action (ALIMA), Kamuesha, Democratic
      Republic of Congo.
FAU - Izie Bozama, Lievin
AU  - Izie Bozama L
AD  - National Nutrition Programme (PRONANUT), Ministry of Health, Kinshasa, Democratic
      Republic of Congo.
FAU - Tshibangu Sakubu, Gilbert
AU  - Tshibangu Sakubu G
AD  - Kamuesha Health Zone in the Kasai Province, Ministry of Health, Kamuesha,
      Democratic Republic of Congo.
FAU - Beuscart, Aurelie
AU  - Beuscart A
AD  - University of Bordeaux, Inserm, French National Research Institute for
      Sustainable Development (IRD), Bordeaux Population Health Research Center, Team
      IDLIC, UMR 1219, Bordeaux, France.
FAU - Yao, Cyrille
AU  - Yao C
AD  - PACCI Research Programme, University Hospital of Treichville, Abidjan, Cote
      d'Ivoire.
FAU - Gabillard, Delphine
AU  - Gabillard D
AUID- ORCID: 0000-0002-9122-2674
AD  - University of Bordeaux, Inserm, French National Research Institute for
      Sustainable Development (IRD), Bordeaux Population Health Research Center, Team
      IDLIC, UMR 1219, Bordeaux, France.
FAU - Kinda, Moumouni
AU  - Kinda M
AD  - The Alliance for International Medical Action (ALIMA), Dakar, Senegal.
FAU - Augier, Augustin
AU  - Augier A
AD  - The Alliance for International Medical Action (ALIMA), Paris, France.
FAU - Anglaret, Xavier
AU  - Anglaret X
AUID- ORCID: 0000-0003-3319-8423
AD  - University of Bordeaux, Inserm, French National Research Institute for
      Sustainable Development (IRD), Bordeaux Population Health Research Center, Team
      IDLIC, UMR 1219, Bordeaux, France.
FAU - Shepherd, Susan
AU  - Shepherd S
AUID- ORCID: 0000-0001-9515-4333
AD  - The Alliance for International Medical Action (ALIMA), Dakar, Senegal.
FAU - Becquet, Renaud
AU  - Becquet R
AUID- ORCID: 0000-0003-3277-0985
AD  - University of Bordeaux, Inserm, French National Research Institute for
      Sustainable Development (IRD), Bordeaux Population Health Research Center, Team
      IDLIC, UMR 1219, Bordeaux, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03751475
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Child Nutrition Disorders/diagnosis/therapy
MH  - Child, Preschool
MH  - Democratic Republic of the Congo
MH  - Humans
MH  - Infant
MH  - *Malnutrition
MH  - Randomized Controlled Trials as Topic
PMC - PMC7713214
OTO - NOTNLM
OT  - *clinical trials
OT  - *community child health
OT  - *nutrition
OT  - *paediatric pathology
OT  - *protocols and guidelines
OT  - *public health
COIS- Competing interests: KP serves on the Social Purposes Advisory Commission of
      Nutriset, a main producer of lipid-based nutrient supplement products.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:40
PHST- 2020/12/03 05:40 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041213 [pii]
AID - 10.1136/bmjopen-2020-041213 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e041213. doi: 10.1136/bmjopen-2020-041213.


PMID- 33268423
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Predicting severe pneumonia in the emergency department: a global study of the
      Pediatric Emergency Research Networks (PERN)-study protocol.
PG  - e041093
LID - 10.1136/bmjopen-2020-041093 [doi]
AB  - INTRODUCTION: Pneumonia is a frequent and costly cause of emergency department
      (ED) visits and hospitalisations in children. There are no evidence-based,
      validated tools to assist physicians in management and disposition decisions for 
      children presenting to the ED with community-acquired pneumonia (CAP). The
      objective of this study is to develop a clinical prediction model to accurately
      stratify children with CAP who are at risk for low, moderate and severe disease
      across a global network of EDs. METHODS AND ANALYSIS: This study is a prospective
      cohort study enrolling up to 4700 children with CAP at EDs at ~80 member sites of
      the Pediatric Emergency Research Networks (PERN; https://pern-global.com/). We
      will include children aged 3 months to <14 years with a clinical diagnosis of
      CAP. We will exclude children with hospital admissions within 7 days prior to the
      study visit, hospital-acquired pneumonias or chronic complex conditions.
      Clinical, laboratory and imaging data from the ED visit and hospitalisations
      within 7 days will be collected. A follow-up telephone or text survey will be
      completed 7-14 days after the visit. The primary outcome is a three-tier
      composite of disease severity. Ordinal logistic regression, assuming a partial
      proportional odds specification, and recursive partitioning will be used to
      develop the risk stratification models. ETHICS AND DISSEMINATION: This study will
      result in a clinical prediction model to accurately identify risk of severe
      disease on presentation to the ED. Ethics approval was obtained for all sites
      included in the study. Cincinnati Children's Hospital Institutional Review Board 
      (IRB) serves as the central IRB for most US sites. Informed consent will be
      obtained from all participants. Results will be disseminated through
      international conferences and peer-reviewed publications. This study overcomes
      limitations of prior pneumonia severity scores by allowing for broad
      generalisability of findings, which can be actively implemented after model
      development and validation.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Florin, Todd Adam
AU  - Florin TA
AUID- ORCID: 0000-0002-4387-2605
AD  - Department of Pediatrics, Division of Pediatric Emergency Medicine, Northwestern 
      University Feinberg School of Medicine, Ann and Robert H. Lurie Children's
      Hospital of Chicago, Chicago, Illinois, USA taflorin@luriechildrens.org.
FAU - Tancredi, Daniel Joseph
AU  - Tancredi DJ
AUID- ORCID: 0000-0002-3884-7907
AD  - Department of Pediatrics, UC Davis School of Medicine, Sacramento, California,
      USA.
FAU - Ambroggio, Lilliam
AU  - Ambroggio L
AD  - Department of Pediatrics, University of Colorado and Sections of Emergency
      Medicine and Hospital Medicine, Children's Hospital Colorado, Aurora, Colorado,
      USA.
FAU - Babl, Franz E
AU  - Babl FE
AUID- ORCID: 0000-0002-1107-2187
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
AD  - Emergency Department, Royal Children's Hospital, Melbourne, Victoria, Australia.
FAU - Dalziel, Stuart R
AU  - Dalziel SR
AD  - Departments of Surgery and Paediatrics: Child and Youth Health, University of
      Auckland, Auckland, New Zealand.
AD  - Children's Emergency Department, Starship Children's Hospital, Newmarket, New
      Zealand.
FAU - Eckerle, Michelle
AU  - Eckerle M
AD  - Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center,
      Cincinnati, Ohio, USA.
AD  - Department of Pediatrics, University of Cincinnati College of Medicine,
      Cincinnati, Ohio, USA.
FAU - Mintegi, Santiago
AU  - Mintegi S
AD  - Pediatric Emergency Department, Biocruces Bizkaia Health Research Institute,
      Hospital Universitario Cruces, Barakaldo, Spain.
AD  - University of the Basque Country, UPV/EHU, Bilbao, Spain.
FAU - Neuman, Mark
AU  - Neuman M
AD  - Division of Emergency Medicine, Department of Pediatrics, Boston Children's
      Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Plint, Amy C
AU  - Plint AC
AD  - Departments of Pediatrics and Emergency Medicine, University of Ottawa and
      Division of Pediatric Emergency Medicine, Children's Hospital of Eastern Ontario,
      Ottawa, Ontario, Canada.
FAU - Kuppermann, Nathan
AU  - Kuppermann N
AD  - Departments of Emergency Medicine and Pediatrics, UC Davis School of Medicine and
      UC Davis Health, Sacramento, California, USA.
CN  - Pediatric Emergency Research Networks (PERN) Pneumonia Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Infant
MH  - *Models, Statistical
MH  - *Pneumonia/diagnosis/epidemiology
MH  - Prognosis
MH  - Prospective Studies
PMC - PMC7713188
OTO - NOTNLM
OT  - *paediatric A&E and ambulatory care
OT  - *paediatric infectious disease & immunisation
OT  - *paediatrics
COIS- Competing interests: None declared.
IR  - Ahmad FA
FIR - Ahmad, Fahd A
IR  - Alvarez-Alvarez A
FIR - Alvarez-Alvarez, Andrea
IR  - Arrighini A
FIR - Arrighini, Alberto
IR  - Avva U
FIR - Avva, Usha
IR  - Olivia EA
FIR - Olivia, Elena Aquino
IR  - Azubuine U
FIR - Azubuine, Uchechi
IR  - Babl FE
FIR - Babl, Franz E
IR  - Gonzalez de Suso LB
FIR - Gonzalez de Suso, Luisa Baron
IR  - Bergmann KR
FIR - Bergmann, Kelly R
IR  - A Bradin S
FIR - A Bradin, Stuart
IR  - Breslin K
FIR - Breslin, Kristen
IR  - Borland ML
FIR - Borland, Meredith L
IR  - Maria Calderon Checa R
FIR - Maria Calderon Checa, Rosa
IR  - Campo Fernandez MN
FIR - Campo Fernandez, Maria Natali
IR  - Campos-Calleja C
FIR - Campos-Calleja, Carmen
IR  - Caperell K
FIR - Caperell, Kerry
IR  - Chamberlain J
FIR - Chamberlain, James
IR  - Chaudhari PP
FIR - Chaudhari, Pradip P
IR  - Cherry J
FIR - Cherry, Jonathan
IR  - Chong SL
FIR - Chong, Shu-Ling
IR  - Chua WJ
FIR - Chua, Wee-Jhong
IR  - Murray IC
FIR - Murray, Ida Concha
IR  - Craig S
FIR - Craig, Simon
IR  - Deepali T
FIR - Deepali, Thosar
IR  - Eckerle M
FIR - Eckerle, Michelle
IR  - Espina PR
FIR - Espina, Pinky-Rose
IR  - Fairbrother S
FIR - Fairbrother, Susan
IR  - Farish A
FIR - Farish, Alexandria
IR  - Fein DM
FIR - Fein, Daniel M
IR  - Alvarez RF
FIR - Alvarez, Ramon Fernandez
IR  - Florin TA
FIR - Florin, Todd A
IR  - Freedman S
FIR - Freedman, Stephen
IR  - Forward K
FIR - Forward, Karen
IR  - Gafencu M
FIR - Gafencu, Mihai
IR  - Tristan JG
FIR - Tristan, Jara Gaitero
IR  - Galetto-Lacour A
FIR - Galetto-Lacour, Annick
IR  - Gangoiti I
FIR - Gangoiti, Iker
IR  - Gardiner MA
FIR - Gardiner, Michael A
IR  - George S
FIR - George, Shane
IR  - Greber-Platzer S
FIR - Greber-Platzer, Susanne
IR  - Gomez-Barrena V
FIR - Gomez-Barrena, Virginia
IR  - Birn TH
FIR - Birn, Tamara Hirsch
IR  - Isacoff A
FIR - Isacoff, Adam
IR  - Jani S
FIR - Jani, Shefali
IR  - Kam AJ
FIR - Kam, April J
IR  - Kannikeswaran N
FIR - Kannikeswaran, Nirupama
IR  - Kochar A
FIR - Kochar, Amit
IR  - Kuppermann N
FIR - Kuppermann, Nathan
IR  - Kwok MY
FIR - Kwok, Maria Y
IR  - M Lunoe M
FIR - M Lunoe, Maren
IR  - McKee R
FIR - McKee, Ryan
IR  - McLaren SH
FIR - McLaren, Son H
IR  - McLean L
FIR - McLean, Lianne
IR  - Meckler GD
FIR - Meckler, Garth D
IR  - Midulla F
FIR - Midulla, Fabio
IR  - Mills E
FIR - Mills, Erin
IR  - Moldovan DA
FIR - Moldovan, Diana Aniela
IR  - Mora-Capin A
FIR - Mora-Capin, Andrea
IR  - Morales V
FIR - Morales, Viera
IR  - Morris CR
FIR - Morris, Claudia R
IR  - Morrison AK
FIR - Morrison, Andrea K
IR  - Navanandan N
FIR - Navanandan, Nidhya
IR  - Neuman MI
FIR - Neuman, Mark I
IR  - Oglesby R
FIR - Oglesby, Rebecca
IR  - Orfanos I
FIR - Orfanos, Ioannis
IR  - Pavlicich SV
FIR - Pavlicich, Sonia Viviana
IR  - Fuenzalida AP
FIR - Fuenzalida, Astrid Pezoa
IR  - Plint AC
FIR - Plint, Amy C
IR  - Poonai N
FIR - Poonai, Naveen
IR  - Fosch MP
FIR - Fosch, Merce Puigdomenech
IR  - Rao A
FIR - Rao, Arjun
IR  - Carlos Romero MA
FIR - Carlos Romero, Miguel Angelats
IR  - Sabhaney V
FIR - Sabhaney, Vikram
IR  - Sahyoun C
FIR - Sahyoun, Cyril
IR  - Samson F
FIR - Samson, Frederic
IR  - Shah NP
FIR - Shah, Nipam P
IR  - Calvo PS
FIR - Calvo, Pilar Storch-de-Gracia
IR  - Tucker J
FIR - Tucker, Jennifer
IR  - Turner T
FIR - Turner, Tristan
IR  - Waseem M
FIR - Waseem, Muhammad
IR  - Watkins N
FIR - Watkins, Nicholas
IR  - Wright B
FIR - Wright, Bruce
IR  - Zorc J
FIR - Zorc, Joseph
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041093 [pii]
AID - 10.1136/bmjopen-2020-041093 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e041093. doi: 10.1136/bmjopen-2020-041093.


PMID- 33268422
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Effects of low-dose hydrocortisone and hydrocortisone plus fludrocortisone in
      adults with septic shock: a protocol for a systematic review and meta-analysis of
      individual participant data.
PG  - e040931
LID - 10.1136/bmjopen-2020-040931 [doi]
AB  - INTRODUCTION: The benefits and risks of low-dose hydrocortisone in patients with 
      septic shock have been investigated in numerous randomised controlled trials and 
      trial-level meta-analyses. Yet, the routine use of this treatment remains
      controversial. To overcome the limitations of previous meta-analyses inherent to 
      the use of aggregate data, we will perform an individual patient data
      meta-analysis (IPDMA) on the effect of hydrocortisone with or without
      fludrocortisone compared with placebo or usual care on 90-day mortality and other
      outcomes in patients with septic shock. METHODS AND ANALYSIS: To assess the
      benefits and risks of hydrocortisone, with or without fludrocortisone for adults 
      with septic shock, we will search major electronic databases from inception to
      September 2020 (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE
      and Latin American Caribbean Health Sciences Literature), complimented by a
      search for unpublished trials. The primary analysis will compare hydrocortisone
      with or without fludrocortisone to placebo or no treatment in adult patients with
      septic shock. Secondary analyses will compare hydrocortisone to placebo (or usual
      care), hydrocortisone plus fludrocortisone to placebo (or usual care), and
      hydrocortisone versus hydrocortisone plus fludrocortisone. The primary outcome
      will be all cause mortality at 90 days. We will conduct both one-stage IPDMA
      using mixed-effect models and machine learning with targeted maximum likelihood
      analyses. We will assess the risk of bias related to unshared data and related to
      the quality of individual trial. ETHICS AND DISSEMINATION: This IPDMA will use
      existing data from completed randomised clinical trials and will comply with the 
      ethical and regulatory requirements regarding data sharing for each of the
      component trials. The findings of this study will be submitted for publication in
      a peer-review journal with straightforward policy for open access. PROSPERO
      REGISTRATION NUMBER: CRD42017062198.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Annane, Djillali
AU  - Annane D
AUID- ORCID: 0000-0001-6805-8944
AD  - School of Medicine, Versailles Saint-Quentin-en-Yvelines University, Versailles, 
      Ile-de-France, France djillali.annane@aphp.fr.
AD  - Universite Paris-Saclay, Saint-Aubin, Ile-de-France, France.
FAU - Pirracchio, Romain
AU  - Pirracchio R
AD  - Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco,
      California, USA.
FAU - Billot, Laurent
AU  - Billot L
AUID- ORCID: 0000-0002-4975-9793
AD  - Statistics Division, The George Institute for Global Health, Newtown, New South
      Wales, Australia.
FAU - Waschka, Andre
AU  - Waschka A
AD  - University of California Berkeley, Berkeley, California, USA.
FAU - Chevret, Sylvie
AU  - Chevret S
AD  - University of Paris, Paris, Ile-de-France, France.
FAU - Cohen, Jeremy
AU  - Cohen J
AD  - University of Queensland, Brisbane, Queensland, Australia.
FAU - Finfer, Simon
AU  - Finfer S
AD  - The George Institute for Global Health, Newtown, New South Wales, Australia.
FAU - Gordon, Anthony
AU  - Gordon A
AD  - Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College
      London, London, UK.
FAU - Hammond, Naomi
AU  - Hammond N
AD  - George Institute for Global Health, Camperdown, New South Wales, Australia.
FAU - Myburgh, John
AU  - Myburgh J
AD  - St George Clinical School, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - Venkatesh, Balasubramanian
AU  - Venkatesh B
AD  - Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
FAU - Delaney, Anthony
AU  - Delaney A
AD  - The George Institute for Global Health, Newtown, New South Wales, Australia.
CN  - ULYSSES IPDMA Collaborators
LA  - eng
GR  - NIHR/CS/009/007/DH_/Department of Health/United Kingdom
GR  - PB-PG-0610-22350/DH_/Department of Health/United Kingdom
GR  - RP-2015-06-018/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - U0476M545B (Fludrocortisone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Caribbean Region
MH  - *Fludrocortisone/therapeutic use
MH  - Humans
MH  - Hydrocortisone
MH  - Meta-Analysis as Topic
MH  - *Shock, Septic/drug therapy
PMC - PMC7713227
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *clinical pharmacology
OT  - *clinical trials
COIS- Competing interests: DA: has received funding from French government to conduct
      trials that will be included in this systematic review (trials acronym:
      Ger-Inf-05; COIITSS, APROCCHS)-he received funding for FHU SEPSIS and RHU RECORDS
      research programs. The current IPDMA he was responsible for the Cochrane
      systematic review on corticosteroids for sepsis in children and adults, and this 
      work will use part of data obtained in the Cochrane review. AG: has received
      funding from an NIHR Research Professorship (RP-2015-06-18), consulting fees paid
      to his institution from GlaxoSmithKline and Bristol Myers Squibb, and personal
      consulting fees from Baxter Healthcare. RP, LB, AW, SC, JC, SF, NH, JM, BV and
      AD: no conflict of interest.
IR  - Arabi Y
FIR - Arabi, Yaseen
IR  - Bollaert PE
FIR - Bollaert, Pierre Edouard
IR  - Briegel J
FIR - Briegel, Josef
IR  - Keh D
FIR - Keh, Didier
IR  - Liu L
FIR - Liu, Ling
IR  - Umberto G
FIR - Umberto, G
IR  - Mirea L
FIR - Mirea, Liliana
IR  - Charles L
FIR - Charles, L
IR  - Tilouche N
FIR - Tilouche, Nejla
IR  - Tongyoo S
FIR - Tongyoo, Surat
IR  - Zheng R
FIR - Zheng, Ruiqiang
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040931 [pii]
AID - 10.1136/bmjopen-2020-040931 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e040931. doi: 10.1136/bmjopen-2020-040931.


PMID- 33268421
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Impact of a Pharmacist-included Mobile Geriatrics team intervention on
      potentially inappropriate drug prescribing: protocol for a prospective
      feasibility study (PharMoG study).
PG  - e040917
LID - 10.1136/bmjopen-2020-040917 [doi]
AB  - INTRODUCTION: Research has shown that potentially inappropriate drug prescription
      (PIDP) is highly prevalent in older people. The presence of PIDPs is associated
      with adverse health outcomes. This study aims to evaluate the impact of a
      PHARmacist-included MObile Geriatrics (PharMoG) team intervention on PIDPs in
      older patients hospitalised in the medical, surgical and emergency departments of
      a university hospital. METHODS AND ANALYSIS: The PharMoG study is a prospective, 
      interventional, single-centre feasibility study describing the impact of a
      PharMoG team on PIDPs in older hospitalised patients. Pharmacist intervention
      will be a treatment optimisation (clinical medication review) based on a
      combination of explicit and implicit criteria to detect PIDPs. The primary
      outcome is the acceptance rate of the mobile team's proposed treatment
      optimisations related to PIDPs, measured at the patient's discharge from the
      department. This pharmacist will work in cooperation with the physician of the
      mobile geriatric team. After the intervention of the mobile geriatric team, the
      proposals for improving therapy will be sent to the hospital medical team caring 
      for the patient and to the patient's attending physician. The patient will be
      followed for 3 months after discharge from the hospital. ETHICS AND
      DISSEMINATION: This study was approved by the South-West and Overseas Territories
      II Ethics Committee. Oral consent must be obtained prior to participation, either
      from the patient or from the patient's representative (trusted person and/or a
      family member). The results will be presented at national and international
      conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT04151797.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pages, Arnaud
AU  - Pages A
AUID- ORCID: 0000-0002-2337-8693
AD  - Department of Pharmacy, Toulouse University Hospital, Toulouse, France
      pages.ar@chu-toulouse.fr.
AD  - Institute of Aging, Gerontopole, INSPIRE project, Toulouse University Hospital,
      Toulouse, France.
AD  - Centre for Epidemiology and Population Health Research (CERPOP), UMR 1027,
      Inserm, University of Toulouse (UPS), Toulouse, France.
FAU - Roland, Christel
AU  - Roland C
AD  - Department of Pharmacy, Toulouse University Hospital, Toulouse, France.
FAU - Qassemi, Soraya
AU  - Qassemi S
AD  - Department of Pharmacy, Toulouse University Hospital, Toulouse, France.
FAU - Abdeljalil, Anne-Bahia
AU  - Abdeljalil AB
AD  - Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
FAU - Houles, Mathieu
AU  - Houles M
AD  - Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
FAU - Romain, Marjolaine
AU  - Romain M
AD  - Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
FAU - Toulza, Olivier
AU  - Toulza O
AD  - Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
FAU - Belloc, Audrey
AU  - Belloc A
AD  - Department of Research and Innovation, Toulouse University Hospital, Toulouse,
      France.
FAU - McCambridge, Cecile
AU  - McCambridge C
AD  - Department of Pharmacy, Toulouse University Hospital, Toulouse, France.
FAU - Voisin, Thierry
AU  - Voisin T
AD  - Centre for Epidemiology and Population Health Research (CERPOP), UMR 1027,
      Inserm, University of Toulouse (UPS), Toulouse, France.
AD  - Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
FAU - Cestac, Philippe
AU  - Cestac P
AD  - Department of Pharmacy, Toulouse University Hospital, Toulouse, France.
AD  - Centre for Epidemiology and Population Health Research (CERPOP), UMR 1027,
      Inserm, University of Toulouse (UPS), Toulouse, France.
FAU - Juillard-Condat, Blandine
AU  - Juillard-Condat B
AD  - Department of Pharmacy, Toulouse University Hospital, Toulouse, France.
AD  - Centre for Epidemiology and Population Health Research (CERPOP), UMR 1027,
      Inserm, University of Toulouse (UPS), Toulouse, France.
CN  - PharMoG study group
LA  - eng
SI  - ClinicalTrials.gov/NCT04151797
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Drug Prescriptions
MH  - Feasibility Studies
MH  - *Geriatrics
MH  - Humans
MH  - Inappropriate Prescribing
MH  - Pharmacists
MH  - Prospective Studies
PMC - PMC7713213
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *geriatric medicine
OT  - *organisation of health services
COIS- Competing interests: None declared.
IR  - Cestac P
FIR - Cestac, Philippe
IR  - Voisin T
FIR - Voisin, Thierry
IR  - McCambridge C
FIR - McCambridge, Cecile
IR  - Belloc A
FIR - Belloc, Audrey
IR  - Dunet C
FIR - Dunet, Charlotte
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040917 [pii]
AID - 10.1136/bmjopen-2020-040917 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e040917. doi: 10.1136/bmjopen-2020-040917.


PMID- 33268419
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20220418
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy 
      in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol.
PG  - e040580
LID - 10.1136/bmjopen-2020-040580 [doi]
AB  - INTRODUCTION: SARS-CoV-2 (COVID-19) has caused an international pandemic of
      respiratory illness, resulting in significant healthcare and economic turmoil. To
      date, no robust vaccine or treatment has been identified. Elemental zinc has
      previously been demonstrated to have beneficial effects on coronaviruses and
      other viral respiratory infections due to its effect on RNA polymerase.
      Additionally, zinc has well-demonstrated protective effects against hypoxic
      injury-a clear mechanism of end-organ injury in respiratory distress syndrome. We
      aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2
      infection. The end of study analyses will evaluate the reduction of impact of
      oxygen saturations or requirement of oxygen supplementation. METHODS AND
      ANALYSIS: We designed a double-blind randomised controlled trial of daily HDIVZn 
      (0.5 mg/kg) versus placebo. Primary outcome measures are lowest oxygen saturation
      (or greatest level of supplemental oxygenation) for non-ventilated patients and
      worst PaO2/FiO2 for ventilated patients. Following power calculations, 60
      hospitalised patients and 100 ventilated patients will be recruited to
      demonstrate a 20% difference. The duration of follow-up is up to the point of
      discharge. ETHICS AND DISSEMINATION: Ethical approval was obtained through the
      independent Human Research Ethics Committee. Participant recruitment will
      commence in May 2020. Results will be published in peer-reviewed medical
      journals. TRIAL REGISTRATION NUMBER: ACTRN126200000454976.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Perera, Marlon
AU  - Perera M
AUID- ORCID: http://orcid.org/0000-0002-1138-6389
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia
      marlonlperera@gmail.com.
FAU - El Khoury, John
AU  - El Khoury J
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
FAU - Chinni, Vidyasagar
AU  - Chinni V
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
FAU - Bolton, Damien
AU  - Bolton D
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
FAU - Qu, Liang
AU  - Qu L
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
FAU - Johnson, Paul
AU  - Johnson P
AD  - Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
FAU - Trubiano, Jason
AU  - Trubiano J
AUID- ORCID: http://orcid.org/0000-0002-5111-6367
AD  - Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
FAU - McDonald, Christine F
AU  - McDonald CF
AD  - Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia.
FAU - Jones, Daryl
AU  - Jones D
AD  - Intensive Care Unit Austin Hospital, Austin Health, Heidelberg, Victoria,
      Australia.
AD  - Department of Medicine, Austin Health, Heidelberg, Victoria, Australia.
FAU - Bellomo, Rinaldo
AU  - Bellomo R
AD  - Intensive Care Unit Austin Hospital, Austin Health, Heidelberg, Victoria,
      Australia.
AD  - Department of Medicine, Austin Health, Heidelberg, Victoria, Australia.
FAU - Patel, Oneel
AU  - Patel O
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
FAU - Ischia, Joseph
AU  - Ischia J
AD  - Department of Surgery, Austin Health, Heidelberg, Victoria, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - J41CSQ7QDS (Zinc)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Administration, Intravenous
MH  - Adult
MH  - COVID-19/*drug therapy
MH  - Clinical Trials, Phase II as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hypoxia/prevention & control
MH  - Male
MH  - Oxygen/blood
MH  - Pandemics
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Zinc/*administration & dosage/adverse effects
PMC - PMC7712927
OTO - NOTNLM
OT  - infectious diseases
OT  - public health
OT  - respiratory infections
OT  - virology
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - bmjopen-2020-040580 [pii]
AID - 10.1136/bmjopen-2020-040580 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e040580. doi: 10.1136/bmjopen-2020-040580.


PMID- 33268417
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Adolescent transition to adult care for HIV-infected adolescents in Kenya
      (ATTACH): study protocol for a hybrid effectiveness-implementation cluster
      randomised trial.
PG  - e039972
LID - 10.1136/bmjopen-2020-039972 [doi]
AB  - INTRODUCTION: Successfully transitioning adolescents to adult HIV care is
      critical for optimising outcomes. Disclosure of HIV status, a prerequisite to
      transition, remains suboptimal in sub-Saharan Africa. Few interventions have
      addressed both disclosure and transition. An adolescent transition package (ATP) 
      that combines disclosure and transition tools could support transition and
      improve outcomes. METHODS AND ANALYSIS: In this hybrid type 1
      effectiveness-implementation cluster randomised controlled trial, 10 HIV clinics 
      with an estimated >/=100 adolescents and young adults age 10-24 living with HIV
      (ALWHIV) in Kenya will be randomised to implement the ATP and compared with 10
      clinics receiving standard of care. The ATP includes provider tools to assist
      disclosure and transition. Healthcare providers at intervention clinics will
      receive training on ATP use and support to adapt it through continuous quality
      improvement cycles over the initial 6 months of the study, with continued
      implementation for 1 year. The primary outcome is transition readiness among
      ALWHIV ages 15-24 years, assessed 6 monthly using a 22-item readiness score.
      Secondary outcomes including retention and viral suppression among ALWHIV at the 
      end of the intervention period (month 18), implementation outcomes
      (acceptability, feasibility, fidelity, coverage and penetration) and programme
      costs complement effectiveness outcomes. The primary analysis will be intent to
      treat, using mixed-effects linear regression models to compare transition
      readiness scores (overall and by domain (HIV literacy, self-management,
      communication, support)) over time in control and intervention sites with
      adjustment for multiple testing, accounting for clustering by clinic and repeated
      assessments. We will estimate the coefficients and 95% CIs with a two- sided
      alpha=0.05. ETHICS AND DISSEMINATION: The study was approved by the University of
      Washington Institutional Review Board and the Kenyatta National Hospital Ethics
      and Research Committee. Study results will be shared with participating
      facilities, county and national policy-makers. TRIALS REGISTRATION NUMBER:
      NCT03574129; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Njuguna, Irene N
AU  - Njuguna IN
AUID- ORCID: 0000-0003-4250-3231
AD  - Research and Programs, Kenyatta National Hospital, Nairobi, Kenya
      njugunairene06@yahoo.com.
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Beima-Sofie, Kristin
AU  - Beima-Sofie K
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Mburu, Caren W
AU  - Mburu CW
AD  - Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
FAU - Mugo, Cyrus
AU  - Mugo C
AD  - Research and Programs, Kenyatta National Hospital, Nairobi, Kenya.
AD  - Epidemiology, University of Washington, Seattle, Washington, United States.
FAU - Neary, Jillian
AU  - Neary J
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Itindi, Janet
AU  - Itindi J
AD  - Kenya Medical Research Institute, Nairobi, Kenya.
FAU - Onyango, Alvin
AU  - Onyango A
AD  - University of Nairobi, Nairobi, Nairobi, Kenya.
FAU - Richardson, Barbra A
AU  - Richardson BA
AD  - Global Health, University of Washington, Seattle, Washington, USA.
AD  - Biostatistics, University of Washington, Seattle, Washington, United States.
FAU - Rubin Means, Arianna
AU  - Rubin Means A
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Sharma, Monisha
AU  - Sharma M
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Weiner, Bryan J
AU  - Weiner BJ
AD  - Global Health, University of Washington, Seattle, Washington, USA.
AD  - Department of Health Services, University of Washington, Seattle, Washington,
      USA.
FAU - Wagner, Anjuli D
AU  - Wagner AD
AUID- ORCID: 0000-0002-5851-1220
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Oyiengo, Laura
AU  - Oyiengo L
AD  - Neonatal and Child Health Services, Ministry of Health, Nairobi, Kenya.
FAU - Wamalwa, Dalton
AU  - Wamalwa D
AD  - Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
FAU - John-Stewart, Grace
AU  - John-Stewart G
AD  - Global Health, University of Washington, Seattle, Washington, USA.
AD  - Epidemiology, University of Washington, Seattle, Washington, United States.
AD  - Pediatrics, University of Washington, Seattle, Washington, United States.
AD  - Medicine, University of Washington, Seattle, Washington, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT03574129
GR  - D43 TW009783/TW/FIC NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Communication
MH  - *HIV Infections/drug therapy
MH  - Health Personnel
MH  - Humans
MH  - Kenya
MH  - Randomized Controlled Trials as Topic
MH  - *Transition to Adult Care
MH  - Young Adult
PMC - PMC7713196
OTO - NOTNLM
OT  - *HIV
OT  - *adolescents
OT  - *sub-Saharan Africa
OT  - *transition to adult care
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039972 [pii]
AID - 10.1136/bmjopen-2020-039972 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e039972. doi: 10.1136/bmjopen-2020-039972.


PMID- 33268416
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210727
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Effects of a peer co-facilitated educational programme for parents of children
      with ADHD: a feasibility randomised controlled trial protocol.
PG  - e039852
LID - 10.1136/bmjopen-2020-039852 [doi]
AB  - INTRODUCTION: Significant numbers of children with attention deficit
      hyperactivity disorder (ADHD) display problems that cause multiple disabilities, 
      deficits and handicaps that interfere with social relationships, development and 
      school achievement. They may have multiple problems, which strain family dynamics
      and influence the child's treatment. Parent activation, described as parents'
      knowledge, skills and confidence in dealing with their child's health and
      healthcare, has been shown to be an important factor in improving health
      outcomes. Research suggests that parents need edification to learn skills crucial
      to the treatment and management of their children's healthcare. Promoting
      positive parenting techniques may reduce negative parenting factors in families. 
      This study aims to assess the acceptability, feasibility and estimated sample
      size of a randomised controlled trial (RCT) comparing an ADHD peer co-led
      educational programme added to treatment as usual (TAU). METHODS AND ANALYSIS:
      Using a randomised waitlist controlled trial, parents of children aged 6-12 years
      newly diagnosed with ADHD, and referred to a child mental health outpatient
      clinic in Mid-Norway, will receive TAU concomitant with a peer co-facilitated
      parental engagement educational programme (n=25). Parents in the control group
      will receive TAU, and the educational programme treatment within a waitlist
      period of 3-6 months (n=25). Parent activation, satisfaction, well-being, quality
      of life and treatment adherence, will be assessed at baseline (T0), 2 weeks (T1) 
      pre-post intervention (T2, T3) and at 3 months follow-up (T4). Shared decision
      making, parents preferred role in health-related decisions and involvement,
      parent-reported symptoms of ADHD and child's overall level of functioning will be
      assessed at T0 and T4. Such data will be used to calculate the required sample
      size for a full-scale RCT. ETHICS AND DISSEMINATION: Approval was obtained from
      the Regional Committee for Medicine and Health Research Ethics in Mid-Norway
      (ref: 2018/1196). The findings of this study are expected to provide valuable
      knowledge about how to optimise family education and management of ADHD and will 
      be disseminated through presentations at conferences and publication in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04010851.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mundal, Ingunn
AU  - Mundal I
AUID- ORCID: 0000-0001-7716-7122
AD  - Department of Mental Health, Faculty of medicine and health sciences, Norwegian
      University of Science and Technology (NTNU), Trondheim, Norway
      ingunn.p.mundal@ntnu.no.
AD  - Faculty of Health and Social Sciences, Molde University College, Molde, Norway.
AD  - Division of Psychiatry, Kristiansund Community Mental Health Centre, More og
      Romsdal Hospital Trust, Kristiansund, Norway.
FAU - Grawe, Rolf W
AU  - Grawe RW
AD  - Department of Mental Health, Faculty of medicine and health sciences, Norwegian
      University of Science and Technology (NTNU), Trondheim, Norway.
AD  - Division of Psychiatry, Nidaros Community Mental Health Centre, St Olav's
      University Hospital, Trondheim, Norway.
FAU - Hafstad, Hege
AU  - Hafstad H
AD  - Division of Mid-Norway, Varres Regional User Involvement Centre, Trondheim,
      Norway.
FAU - De Las Cuevas, Carlos
AU  - De Las Cuevas C
AD  - Department of Internal Medicine, Dermatology and Psychiatry, Universidad de La
      Laguna, San Cristobal de La Laguna, Tenerife, Spain.
AD  - Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, San
      Cristobal deLa Laguna, Tenerife, Spain.
FAU - Lara-Cabrera, Mariela Loreto
AU  - Lara-Cabrera ML
AD  - Department of Mental Health, Faculty of medicine and health sciences, Norwegian
      University of Science and Technology (NTNU), Trondheim, Norway.
AD  - Division of Psychiatry, Tiller Community Mental Health Centre, St Olav's
      University Hospital, Trondheim, Norway.
AD  - Department of Research and Development, Division of Mental Health, St Olav's
      University Hospital, Trondheim, Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT04010851
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Attention Deficit Disorder with Hyperactivity/therapy
MH  - Child
MH  - Feasibility Studies
MH  - Humans
MH  - Norway
MH  - Parenting
MH  - Parents
MH  - Randomized Controlled Trials as Topic
PMC - PMC7713204
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *developmental neurology & neurodisability
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039852 [pii]
AID - 10.1136/bmjopen-2020-039852 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e039852. doi: 10.1136/bmjopen-2020-039852.


PMID- 33268415
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Mapping the evidence regarding school-to-work/university transition and health
      inequalities among young adults: a scoping review protocol.
PG  - e039831
LID - 10.1136/bmjopen-2020-039831 [doi]
AB  - INTRODUCTION: School-to-work/university transition is a sensitive period that can
      have a substantial impact on health and health behaviour over the life course.
      There is some indication that health and health behaviour is socially patterned
      in the age span of individuals in this transition (16-24 years) and that there
      are differences by socioeconomic position (SEP). However, evidence regarding this
      phenomenon has not been systematically mapped. In addition, little is known about
      the role of institutional characteristics (eg, of universities, workplaces) in
      the development of health and possible inequalities in health during this
      transition. Hence, the first objective of this scoping review is to
      systematically map the existing evidence regarding health and health behaviours
      (and possible health inequalities, for example, differences by SEP) in the age
      group of 16-24 years and during school-to-work transition noted in Germany and
      abroad. The second objective is to summarise the evidence on the potential
      effects of contextual and compositional characteristics of specific institutions 
      entered during this life stage on health and health behaviours. Third, indicators
      and measures of these characteristics will be summarised. METHODS AND ANALYSIS:
      We will systematically map the evidence on health inequalities during
      school-to-work-transitions among young adults (aged 16-24 years), following the
      methodological framework proposed by Arksey and O'Malley. The literature search
      is performed in Ovid MEDLINE, Web of Science, International Labour Organization
      and National Institute for Occupational Safety and Health, using a predetermined 
      search strategy. Articles published between January 2000 and February 2020 in
      English or German are considered for the review. The selection process follows a 
      two-step approach: (1) screening of titles and abstracts, and (2) screening of
      full texts, both steps by two independent reviewers. Any discrepancies in the
      selection process are resolved by a third researcher. Data extraction will be
      performed using a customised data extraction sheet. The results will be presented
      in tabular and narrative form. ETHICS AND DISSEMINATION: Ethical approval is not 
      required for this scoping review. The results will be published in a
      peer-reviewed scientific journal and presented at international conferences and
      project workshops.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Matos Fialho, Paula Mayara
AU  - Matos Fialho PM
AUID- ORCID: 0000-0003-3988-7350
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      University of Duesseldorf, Duesseldorf, Germany paulamayara2@gmail.com.
FAU - Dragano, Nico
AU  - Dragano N
AUID- ORCID: 0000-0002-0378-0757
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      University of Duesseldorf, Duesseldorf, Germany.
FAU - Reuter, Marvin
AU  - Reuter M
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      University of Duesseldorf, Duesseldorf, Germany.
FAU - Metzendorf, Maria-Inti
AU  - Metzendorf MI
AUID- ORCID: 0000-0002-4154-5782
AD  - Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice
      (ifam), Centre for Health and Society, Medical Faculty, University of
      Duesseldorf, Duesseldorf, Duesseldorf, Germany.
FAU - Richter, Bernd
AU  - Richter B
AUID- ORCID: 0000-0002-7117-3983
AD  - Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice
      (ifam), Centre for Health and Society, Medical Faculty, University of
      Duesseldorf, Duesseldorf, Duesseldorf, Germany.
FAU - Hoffmann, Stephanie
AU  - Hoffmann S
AD  - Department of Public Health, Faculty for Social Work, Health, and Music,
      Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
FAU - Diehl, Katharina
AU  - Diehl K
AUID- ORCID: 0000-0002-5408-652X
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Wachtler, Benjamin
AU  - Wachtler B
AUID- ORCID: 0000-0002-3959-5676
AD  - Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, 
      Germany.
FAU - Sundmacher, L
AU  - Sundmacher L
AD  - Department of Health Services Management, Ludwig Maximilians University Munich,
      Munich, Germany.
FAU - Herke, Max
AU  - Herke M
AUID- ORCID: 0000-0001-6425-4366
AD  - Institute of Medical Sociology, Medical Faculty, Martin-Luther-Universitat
      Halle-Wittenberg, Halle (Saale), Germany.
FAU - Pischke, Claudia
AU  - Pischke C
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      University of Duesseldorf, Duesseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Germany
MH  - *Health Status Disparities
MH  - Humans
MH  - Review Literature as Topic
MH  - United States
MH  - *Universities
MH  - Young Adult
PMC - PMC7713198
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *public health
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039831 [pii]
AID - 10.1136/bmjopen-2020-039831 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e039831. doi: 10.1136/bmjopen-2020-039831.


PMID- 33268408
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Resilience support to enhance positive health outcomes for police officers in
      five Anglosphere nations: a scoping review protocol.
PG  - e038895
LID - 10.1136/bmjopen-2020-038895 [doi]
AB  - INTRODUCTION: Law enforcement involves exposure to threatening situations and
      traumatic events that place police officers at risk for negative physical and
      mental health outcomes. Resilience support, among other elements of training, may
      help mitigate these risks, yet little is known about which aspects of resilience 
      support help officers achieve better health and quality of life outcomes. METHODS
      AND ANALYSIS: This review will consider all literature that examines the links
      between resilience support, physical/mental health and quality of life outcomes
      for police officers in five Anglosphere nations: Canada, the USA, Australia, New 
      Zealand and the UK. This review will include all literature (including those that
      show null or negative links) involving any public policing agency that has a
      formal rank structure and includes a localized, uniformed emergency response
      function. Resilience support may include, but is not limited to: tools, policies,
      models, frameworks, programmes and organizational features that seek to promote
      positive, physical/mental health and quality of life outcomes at three levels of 
      resilience: (1) readiness and preparedness, (2) response and adaptation, (3)
      recovery and adjustment. Peer reviewed and grey literature examining resilience
      support since 2000 that focuses on police officers are eligible for inclusion.
      Databases/sources to be searched will include: PsycINFO, Academic Search Premier,
      CINAHL, Public Affair Index, Campbell Collaboration, ProQuest Dissertations and
      Theses Global, Business Source Complete, Scopus and Google. Retrieval of
      full-text, English-language studies (and other literature), data extraction, data
      synthesis and data mapping will be performed independently by two reviewers,
      following Joanna Briggs Institute methodology. ETHICS AND DISSEMINATION: Ethics
      approval is not required for this scoping review, and the literature search will 
      start in November 2020 or upon acceptance of this protocol. The findings of the
      scoping review will be available [April 2021] and will be published in a peer
      reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Steenbeek, Audrey
AU  - Steenbeek A
AUID- ORCID: 0000-0003-0409-158X
AD  - Nursing, Dalhousie University, Halifax, Nova Scotia, Canada a.steenbeek@dal.ca.
AD  - Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A Joanna
      Briggs Institute Centre of Excellence, School of Nursing, Dalhousie University,
      Halifax, Nova Scotia, Canada.
FAU - Giacomantonio, Chris
AU  - Giacomantonio C
AD  - Halifax Regional Police, Halifax, Nova Scotia, Canada.
FAU - Brooks, Arlene
AU  - Brooks A
AD  - Halifax Regional Police, Halifax, Nova Scotia, Canada.
FAU - Holmvall, Camilla
AU  - Holmvall C
AD  - Psychology & Management, Saint Mary's University, Halifax, Nova Scotia, Canada.
FAU - Yu, Ziwa
AU  - Yu Z
AD  - Nursing, Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A Joanna
      Briggs Institute Centre of Excellence, School of Nursing, Dalhousie University,
      Halifax, Nova Scotia, Canada.
FAU - Rothfus, Melissa
AU  - Rothfus M
AD  - W.K. Kellogg Health Sciences Library, Dalhousie University, Halifax, Nova Scotia,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Canada
MH  - Humans
MH  - New Zealand
MH  - Outcome Assessment, Health Care
MH  - *Police
MH  - *Quality of Life
MH  - Review Literature as Topic
PMC - PMC7713211
OTO - NOTNLM
OT  - *Health & safety
OT  - *MENTAL HEALTH
OT  - *Organisational development
OT  - *Risk management
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038895 [pii]
AID - 10.1136/bmjopen-2020-038895 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e038895. doi: 10.1136/bmjopen-2020-038895.


PMID- 33268406
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Restaurant interventions for salt reduction in China: protocol for a randomised
      controlled trial.
PG  - e038744
LID - 10.1136/bmjopen-2020-038744 [doi]
AB  - INTRODUCTION: Salt intake in China is high, and most of it comes from that added 
      by consumers. Nevertheless, recent years have seen a rapid increase in the
      frequency at which people eat out. The aim of this study is to evaluate the
      effectiveness of interventions designed for salt reduction in restaurants through
      a randomised controlled trial in China. METHODS AND ANALYSIS: As a randomised
      controlled trial with restaurants as study subjects, we recruited 192 restaurants
      from 12 counties of 6 provinces in China. After the baseline survey, restaurants 
      were randomly assigned to intervention or control group. Using social cognitive
      theory, comprehensive intervention activities were designed to encourage salt
      reduction in all restaurant foods, and at the same time, to encourage consumers
      to choose lower salt options when eating out. The interventions will be conducted
      only in restaurants of the intervention group during the first year. The
      follow-up assessment will be conducted at the end of the trial. The primary
      outcome is the change in the average salt content of the five best-selling dishes
      of the restaurant, as measured by laboratory tests. Secondary outcomes include
      differences in the monthly use of salt and salty condiments between intervention 
      and control restaurants, and the knowledge, attitude and practice on salt among
      restaurant consumers. ETHICS AND DISSEMINATION: The study was reviewed and
      approved by the Review Board of the National Institute for Nutrition and Health, 
      Chinese Center for Disease Control and Prevention and Queen Mary Research Ethics 
      Committee. Results will be disseminated through presentations, publications and
      social media. TRIAL REGISTRATION NUMBER: ChiCTR1800019694; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Du, Wenwen
AU  - Du W
AUID- ORCID: 0000-0002-4476-2985
AD  - National Institute for Nutrition and Health, Chinese Center for Disease Control
      and Prevention, Beijing, China.
FAU - Zhang, Jiguo
AU  - Zhang J
AD  - National Institute for Nutrition and Health, Chinese Center for Disease Control
      and Prevention, Beijing, China.
FAU - Li, Yuan
AU  - Li Y
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
FAU - He, Feng J
AU  - He FJ
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London,
      London, UK.
FAU - Zhou, Xue
AU  - Zhou X
AD  - Heilongjiang Provincial Center for Disease Control and Prevention, Harbin, China.
FAU - Xu, Zhihua
AU  - Xu Z
AUID- ORCID: 0000-0002-0547-3355
AD  - Qinghai Provincial Center for Disease Control and Prevention, Xining, China.
FAU - Gao, Yifu
AU  - Gao Y
AD  - Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.
FAU - Yin, Lei
AU  - Yin L
AD  - Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
FAU - Chang, Xiaoyu
AU  - Chang X
AD  - Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China.
FAU - Yan, Wei
AU  - Yan W
AD  - Jiangxi Provincial Center for Disease Control and Prevention, Nanchang, China.
FAU - Tan, Monique
AU  - Tan M
AUID- ORCID: 0000-0003-4287-5553
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London,
      London, UK.
FAU - MacGregor, Graham A
AU  - MacGregor GA
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London,
      London, UK.
FAU - Luo, Rong
AU  - Luo R
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
FAU - Zhang, Puhong
AU  - Zhang P
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China wanghj@ninh.chinacdc.cn zpuhong@georgeinstitute.org.cn.
FAU - Wang, Huijun
AU  - Wang H
AD  - National Institute for Nutrition and Health, Chinese Center for Disease Control
      and Prevention, Beijing, China wanghj@ninh.chinacdc.cn
      zpuhong@georgeinstitute.org.cn.
LA  - eng
GR  - 16/136/77/DH_/Department of Health/United Kingdom
GR  - MR/J015903/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Sodium Chloride, Dietary)
SB  - IM
MH  - China
MH  - Feeding Behavior
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Restaurants
MH  - *Sodium Chloride, Dietary
MH  - Surveys and Questionnaires
PMC - PMC7713225
OTO - NOTNLM
OT  - *epidemiology
OT  - *health policy
OT  - *nutrition & dietetics
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: FJH is a member of the Consensus Action on Salt & Health
      (CASH), a non-profit charitable organisation, and its international branch World 
      Action on Salt & Health (WASH). FJH does not receive any financial support from
      CASH or WASH. GAM is the chairman of Blood Pressure UK (BPUK), chairman of CASH
      and chairman of WASH and does not receive any financial support from any of these
      organisations. BPUK, CASH and WASH are non-profit charitable organisations. All
      other authors have no competing interests to declare.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038744 [pii]
AID - 10.1136/bmjopen-2020-038744 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e038744. doi: 10.1136/bmjopen-2020-038744.


PMID- 33268405
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Functional MRI in the effect of transcranial magnetic stimulation therapy for
      patients with schizophrenia: a meta-analysis protocol.
PG  - e038557
LID - 10.1136/bmjopen-2020-038557 [doi]
AB  - INTRODUCTION: Schizophrenia is a psychiatric illness associated with brain
      function alterations and varying degree of treatment resistance, often leading to
      severe social malfunctioning. In recent decades, numerous studies have been
      investigating the therapeutic potential of transcranial magnetic stimulation
      (TMS) as a non-invasive therapy for schizophrenia. However, its clinical efficacy
      remains controversial, as a number of clinical trials indicated moderate
      therapeutic effect while others failed to reproduce the positive result.
      Moreover, the neurobiological mechanism of action remains unclear, possibly
      constricting the application of TMS in clinical practice. The present protocol of
      meta-analysis aims to investigate the TMS-related functional neuroimaging (ie,
      functional MRI) features and alterations in subjects with schizophrenia, and to
      discuss the potential of functional MRI in TMS researches. METHODS AND ANALYSIS: 
      The study selection process will follow the Preferred Reporting Items for
      Meta-Analyses guideline and quality assessment will be conducted with a
      customised checklist. We plan to search in the following databases: PubMed,
      Embase, OVID, China National Knowledge Infrastructure and Wanfang Data, from
      their respective dates of inception to 1 May 2020, with language restricted to
      English and Chinese. Studies focusing on the brain functional alterations in
      patients with schizophrenia treated by TMS will be retrieved. ETHICS AND
      DISSEMINATION: This work does not require ethics approval as it will be based on 
      published studies. This systematic review will be publicly disseminated in
      peer-reviewed journals. PROSPERO REGISTRATION NUMBER: CRD42020166288.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhong, Siqian
AU  - Zhong S
AD  - PsyNI Lab, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 
      China.
FAU - Hu, Yiru
AU  - Hu Y
AD  - PsyNI Lab, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 
      China.
FAU - Fu, Yu
AU  - Fu Y
AD  - PsyNI Lab, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 
      China.
FAU - Cao, Liping
AU  - Cao L
AD  - PsyNI Lab, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 
      China.
FAU - Zhang, Bin
AU  - Zhang B
AUID- ORCID: 0000-0002-9280-8247
AD  - PsyNI Lab, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 
      China zhang.bin845@foxmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brain/diagnostic imaging
MH  - China
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - *Schizophrenia/therapy
MH  - Systematic Reviews as Topic
MH  - *Transcranial Magnetic Stimulation
PMC - PMC7713205
OTO - NOTNLM
OT  - *magnetic resonance imaging
OT  - *neuroradiology
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038557 [pii]
AID - 10.1136/bmjopen-2020-038557 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e038557. doi: 10.1136/bmjopen-2020-038557.


PMID- 33268401
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Comparison of a progestin-primed ovarian stimulation protocol with a flexible
      GnRH antagonist protocol in patients with polycystic ovary syndrome who are
      participating in an IVF programme: study protocol for a randomised controlled
      trial.
PG  - e038153
LID - 10.1136/bmjopen-2020-038153 [doi]
AB  - INTRODUCTION: Women with polycystic ovary syndrome (PCOS) undergoing in vitro
      fertilization (IVF) protocols are typically characterised by an increased number 
      of oocytes retrieved. The oocytes are often of poor quality, leading to lower
      pregnancy rates, higher miscarriage rates and an increased risk of developing
      ovarian hyperstimulation syndrome (OHSS). Since our previous preliminary study
      showed that a novel progestin-primed ovarian stimulation (PPOS) protocol blocked 
      the luteinising hormone (LH) surge during IVF and achieved a higher pregnancy
      rate with a lower incidence of OHSS, we designed a prospective randomised
      controlled trial to compare the efficacy and safety of this PPOS protocol with
      the flexible gonadotropin-releasing hormone (GnRH) antagonist protocol in
      patients with PCOS who are undergoing IVF procedures. METHODS AND ANALYSIS:
      Patients with PCOS will be randomised to one of two controlled ovarian
      stimulation regimens-GnRH antagonist or PPOS-using a computer-generated random
      number. A freeze-all strategy using embryo vitrification techniques and frozen
      embryo transfer will be performed in both groups. The primary outcome is the
      live-birth rate per transfer. Secondary outcomes include the incidence of
      premature LH surges, the duration and total dose of human menopausal gonadotropin
      stimulation, the number of oocytes retrieved, the incidence of moderate or severe
      OHSS, the number of embryos available for transfer, implantation rates, clinical 
      pregnancy rates, pregnancy loss rates, ectopic pregnancy rates, pregnancy and
      neonatal complications, and congenital anomalies. The necessary sample size for
      this trial was estimated as 392 participants, with 196 participants in each
      group. Intention-to-treat analysis was used in processing our experimental data. 
      ETHICS AND DISSEMINATION: This study was approved by the Institutional Review
      Board of the hospital (2016-133-T82). The trial will be conducted according to
      the principles of the World Medical Association's Declaration of Helsinki and in 
      accordance with Good Clinical Practice standards. The findings of this trial will
      be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      ChiCTRIPR16009580.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Ningling
AU  - Wang N
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China.
FAU - Zhu, Qianqian
AU  - Zhu Q
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China.
FAU - Ma, Meng
AU  - Ma M
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China.
FAU - Liang, Zhou
AU  - Liang Z
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China.
FAU - Tao, Yu
AU  - Tao Y
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China.
FAU - Wang, Yun
AU  - Wang Y
AUID- ORCID: 0000-0002-5640-5010
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China sammy20080228@icloud.com.
FAU - Kuang, Yanping
AU  - Kuang Y
AD  - Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Progestins)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
MH  - Female
MH  - Fertilization in Vitro
MH  - Gonadotropin-Releasing Hormone
MH  - Humans
MH  - Infant, Newborn
MH  - *Ovarian Hyperstimulation Syndrome/epidemiology/prevention & control
MH  - Ovulation Induction
MH  - *Polycystic Ovary Syndrome/complications
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Progestins
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7713223
OTO - NOTNLM
OT  - *embryology
OT  - *epidemiology
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038153 [pii]
AID - 10.1136/bmjopen-2020-038153 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e038153. doi: 10.1136/bmjopen-2020-038153.


PMID- 33268397
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 2
TI  - Making information and communications technologies (ICTs) work for health:
      protocol for a mixed-methods study exploring processes for institutionalising
      geo-referenced health information systems to strengthen maternal neonatal and
      child health (MNCH) service planning, referral and oversight in urban Bangladesh.
PG  - e032820
LID - 10.1136/bmjopen-2019-032820 [doi]
AB  - INTRODUCTION: Disparities in health outcomes and access to maternal neonatal and 
      child health (MNCH) are apparent among urban poor compared with national, rural
      or urban averages. A fundamental first step in addressing inequities in MNCH
      services is knowing what services exist in urban areas, where these are located, 
      who provides them and who uses them. This study aims to institutionalise the
      Urban Health Atlas (UHA)-a novel information and communications technology (ICT) 
      tool-to strengthen health service delivery and oversight and generate critical
      evidence to inform health policy and planning in urban Bangladesh. METHODS AND
      ANALYSIS: This mixed-method implementation research will be conducted in four
      purposively selected urban sites representing larger and smaller cities. Research
      activities will include an assessment of information needs and task review
      analysis of information users, stakeholder mapping and cost estimation. To
      document stakeholder perceptions and experiences, key informant interviews and
      in-depth interviews will be conducted along with desk reviews to understand MNCH 
      planning and referral decisions. The UHA will be refined to increase
      responsiveness to user needs and capacities, and hands-on training will be
      provided to health managers. Cost estimation will be conducted to assess the
      financial implications of UHA uptake and scale-up. Systematic documentation of
      the implementation process will be undertaken. Policy decision-making and ICT
      health policy process flowcharts will be prepared using desk reviews and
      qualitative interviews. Thematic analysis of qualitative data will involve both
      emergent and a priori coding guided by WHO PATH toolkit and Policy Engagement
      Framework. Stakeholder analysis will apply standard techniques and measurement
      scales. Descriptive analysis of quantitative data and cost estimation analysis
      will also be performed. ETHICS AND DISSEMINATION: The study has been approved by 
      the Institutional Review Board of icddr,b (# PR-16057). Study findings will be
      disseminated through national and international workshops, conferences, policy
      briefs and peer-reviewed publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Islam, Rubana
AU  - Islam R
AUID- ORCID: 0000-0002-9538-5390
AD  - School of Population Health, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - Adams, Alayne Mary
AU  - Adams AM
AUID- ORCID: 0000-0002-0961-9825
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill
      University, Montreal, Quebec, Canada.
FAU - Hasan, Shaikh Mehdi
AU  - Hasan SM
AUID- ORCID: 0000-0002-3455-7072
AD  - Universal Health Coverage Programme, Health Systems and Population Studies
      Division, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka,
      Dhaka District, Bangladesh.
FAU - Ahmed, Rushdia
AU  - Ahmed R
AUID- ORCID: 0000-0001-6917-3266
AD  - Universal Health Coverage Programme, Health Systems and Population Studies
      Division, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka,
      Dhaka District, Bangladesh.
FAU - Bhattacharyya, Dipika Shankar
AU  - Bhattacharyya DS
AUID- ORCID: 0000-0003-0887-8937
AD  - Universal Health Coverage Programme, Health Systems and Population Studies
      Division, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka,
      Dhaka District, Bangladesh.
FAU - Shafique, Sohana
AU  - Shafique S
AUID- ORCID: 0000-0002-5234-8522
AD  - Universal Health Coverage Programme, Health Systems and Population Studies
      Division, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka,
      Dhaka District, Bangladesh sohana.shafique@icddrb.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bangladesh
MH  - Child
MH  - *Child Health
MH  - *Health Information Systems
MH  - Humans
MH  - Infant, Newborn
MH  - Referral and Consultation
MH  - Rural Population
PMC - PMC7712401
OTO - NOTNLM
OT  - *Bangladesh
OT  - *Urban health
OT  - *geographic information systems
OT  - *health management information systems
OT  - *information communication and technology
OT  - *maternal
OT  - *neonatal and child health
COIS- Competing interests: None declared.
EDAT- 2020/12/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-032820 [pii]
AID - 10.1136/bmjopen-2019-032820 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 2;10(12):e032820. doi: 10.1136/bmjopen-2019-032820.


PMID- 33268336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 371
DP  - 2020 Dec 2
TI  - Covid-19: Concerns persist about purpose, ethics, and effect of rapid testing in 
      Liverpool.
PG  - m4690
LID - 10.1136/bmj.m4690 [doi]
FAU - Wise, Jacqui
AU  - Wise J
AD  - London.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
EDAT- 2020/12/04 06:00
MHDA- 2020/12/04 06:01
CRDT- 2020/12/03 05:39
PHST- 2020/12/03 05:39 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2020/12/04 06:01 [medline]
AID - 10.1136/bmj.m4690 [doi]
PST - epublish
SO  - BMJ. 2020 Dec 2;371:m4690. doi: 10.1136/bmj.m4690.


PMID- 33266138
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 11
IP  - 12
DP  - 2020 Nov 30
TI  - Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to
      Pharmacogenomics.
LID - E1443 [pii]
LID - 10.3390/genes11121443 [doi]
AB  - One application of personalized medicine is the tailoring of medication to the
      individual, so that the medication will have the highest chance of success. In
      order to individualize medication, one must have a complete inventory of all
      current pharmaceutical compounds (a detailed formulary) combined with
      pharmacogenetic datasets, the genetic makeup of the patient, their (medical)
      family history and other health-related data. For healthcare professionals to
      make the best use of this information, it must be visualized in a way that makes 
      the most medically relevant data accessible for their decision-making. Similarly,
      to enable bioinformatics analysis of these data, it must be prepared and provided
      through an interface for controlled computational analysis. Due to the high
      degree of personal information gathered for such initiatives, privacy-sensitive
      implementation choices and ethical standards are paramount. The Personal Genetic 
      Locker project provides an approach to enable the use of personal genomic data in
      primary care. In this paper, we provide a description of the Personal Genetic
      Locker project and show its utility through a use case based on open standards,
      which is illustrated by the 4MedBox system.
FAU - Overkleeft, Rick
AU  - Overkleeft R
AD  - Cooperatie 4LifeSupport Europa u.a., 2321 JW Leiden, The Netherlands.
AD  - 4MedBox, 2321 JW Leiden, The Netherlands.
FAU - Tommel, Judith
AU  - Tommel J
AD  - Health, Medical and Neuropsychology Unit, Institute of Psychology, Faculty of
      Social and Behavioural Sciences, Leiden University, 2333 AK Leiden, The
      Netherlands.
FAU - Evers, Andrea W M
AU  - Evers AWM
AD  - Health, Medical and Neuropsychology Unit, Institute of Psychology, Faculty of
      Social and Behavioural Sciences, Leiden University, 2333 AK Leiden, The
      Netherlands.
FAU - den Dunnen, Johan T
AU  - den Dunnen JT
AD  - Departments of Human Genetics and Clinical Genetics, Leiden University Medical
      Center, 2333 ZA Leiden, The Netherlands.
FAU - Roos, Marco
AU  - Roos M
AUID- ORCID: 0000-0002-8691-772X
AD  - Human Genetics Department, Leiden University Medical Center, 2333 ZA Leiden, The 
      Netherlands.
FAU - Hoefmans, Marie-Jose
AU  - Hoefmans MJ
AD  - Schluss, 1013 KS Amsterdam, The Netherlands.
FAU - Schrader, Walter E
AU  - Schrader WE
AD  - General Practitioner, 2313 AX Leiden, The Netherlands.
FAU - Swen, Jesse J
AU  - Swen JJ
AUID- ORCID: 0000-0002-3965-5552
AD  - Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center,
      2333 ZA Leiden, The Netherlands.
FAU - Numans, Mattijs E
AU  - Numans ME
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Centre, 2333 ZA Leiden, The Netherlands.
FAU - Houwink, Elisa J F
AU  - Houwink EJF
AUID- ORCID: 0000-0002-9927-7266
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Centre, 2333 ZA Leiden, The Netherlands.
AD  - National eHealth Living Lab (NELL), 2333 ZD Leiden, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
SB  - IM
MH  - Computational Biology/*methods
MH  - Electronic Health Records
MH  - Genetic Testing/methods
MH  - Genomics/*methods
MH  - Humans
MH  - Pharmacogenetics/*methods
MH  - Precision Medicine/methods
MH  - Primary Health Care/*methods
PMC - PMC7761137
OTO - NOTNLM
OT  - *Personal Genetic Locker
OT  - *ethics
OT  - *genomics
OT  - *personalized medicine
OT  - *pharmacogenomics
OT  - *primary care
OT  - *research
EDAT- 2020/12/04 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/12/03 01:05
PHST- 2020/10/31 00:00 [received]
PHST- 2020/11/25 00:00 [revised]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/03 01:05 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
AID - genes11121443 [pii]
AID - 10.3390/genes11121443 [doi]
PST - epublish
SO  - Genes (Basel). 2020 Nov 30;11(12). pii: genes11121443. doi:
      10.3390/genes11121443.


PMID- 33266120
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Nov 30
TI  - Plant Proteins: Assessing Their Nutritional Quality and Effects on Health and
      Physical Function.
LID - E3704 [pii]
LID - 10.3390/nu12123704 [doi]
AB  - Consumer demand for plant protein-based products is high and expected to grow
      considerably in the next decade. Factors contributing to the rise in popularity
      of plant proteins include: (1) potential health benefits associated with
      increased intake of plant-based diets; (2) consumer concerns regarding adverse
      health effects of consuming diets high in animal protein (e.g., increased
      saturated fat); (3) increased consumer recognition of the need to improve the
      environmental sustainability of food production; (4) ethical issues regarding the
      treatment of animals; and (5) general consumer view of protein as a "positive"
      nutrient (more is better). While there are health and physical function benefits 
      of diets higher in plant-based protein, the nutritional quality of plant proteins
      may be inferior in some respects relative to animal proteins. This review
      highlights the nutritional quality of plant proteins and strategies for wisely
      using them to meet amino acid requirements. In addition, a summary of studies
      evaluating the potential benefits of plant proteins for both health and physical 
      function is provided. Finally, potential safety issues associated with increased 
      intake of plant proteins are addressed.
FAU - Hertzler, Steven R
AU  - Hertzler SR
AD  - Scientific and Medical Affairs, Abbott Nutrition, 2900 Easton Square Place,
      Columbus, OH 43219, USA.
FAU - Lieblein-Boff, Jacqueline C
AU  - Lieblein-Boff JC
AD  - Scientific and Medical Affairs, Abbott Nutrition, 2900 Easton Square Place,
      Columbus, OH 43219, USA.
FAU - Weiler, Mary
AU  - Weiler M
AUID- ORCID: 0000-0003-2865-667X
AD  - Scientific and Medical Affairs, Abbott Nutrition, 2900 Easton Square Place,
      Columbus, OH 43219, USA.
FAU - Allgeier, Courtney
AU  - Allgeier C
AD  - Scientific and Medical Affairs, Abbott Nutrition, 2900 Easton Square Place,
      Columbus, OH 43219, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201130
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Amino Acids, Essential)
RN  - 0 (Animal Proteins, Dietary)
RN  - 0 (Fatty Acids)
RN  - 0 (Plant Proteins)
RN  - 0 (Whey Proteins)
RN  - 0RH81L854J (Glutamine)
SB  - IM
MH  - Amino Acids, Essential/analysis
MH  - Animal Proteins, Dietary
MH  - Body Mass Index
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus/prevention & control
MH  - Diet, Vegetarian
MH  - Fatty Acids/analysis
MH  - Functional Food
MH  - Glutamine/analysis
MH  - Humans
MH  - Metabolic Diseases/prevention & control
MH  - Neoplasms/prevention & control
MH  - *Nutritive Value
MH  - *Plant Proteins
MH  - Risk Factors
MH  - Whey Proteins/analysis
PMC - PMC7760812
OTO - NOTNLM
OT  - DIAAS
OT  - PDCAAS
OT  - amino acids
OT  - plant protein
OT  - protein quality
OT  - protein requirements
OT  - vegetable protein
EDAT- 2020/12/04 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/12/03 01:05
PHST- 2020/11/02 00:00 [received]
PHST- 2020/11/21 00:00 [revised]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/03 01:05 [entrez]
PHST- 2020/12/04 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - nu12123704 [pii]
AID - 10.3390/nu12123704 [doi]
PST - epublish
SO  - Nutrients. 2020 Nov 30;12(12). pii: nu12123704. doi: 10.3390/nu12123704.


PMID- 33264530
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 0038-3317 (Print)
IS  - 0038-3317 (Linking)
VI  - 73
IP  - 10
DP  - 2020 Oct
TI  - Ethics and Professionalism on the Frontline: Controlled Human Infection Trials in
      COVID-19 Vaccine Development: Ethical Considerations.
PG  - 490-492
FAU - Lucido, Christopher
AU  - Lucido C
AD  - University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - S D Med
JT  - South Dakota medicine : the journal of the South Dakota State Medical Association
JID - 101265265
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - COVID-19/*prevention & control
MH  - COVID-19 Vaccines/*administration & dosage
MH  - Clinical Trials as Topic/*ethics
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - Pandemics
MH  - *Professionalism
EDAT- 2020/12/03 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/02 17:13
PHST- 2020/12/02 17:13 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PST - ppublish
SO  - S D Med. 2020 Oct;73(10):490-492.


PMID- 33263624
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20220629
IS  - 1980-5322 (Electronic)
IS  - 1807-5932 (Linking)
VI  - 75
DP  - 2020
TI  - The need to standardize use of the newly deceased in medical trainings.
PG  - e2391
LID - S1807-59322020000100308 [pii]
LID - 10.6061/clinics/2020/e2391 [doi]
AB  - OBJECTIVES: The present study aimed to identify the characteristics of use of the
      deceased in invasive training and the bioethical principles that govern this
      practice. In this context, it has become imperative to deduce which professional 
      skills are critical to develop. METHODS: A prospective study investigated a
      cadaver's use in medical (and related) schools through a questionnaire, which was
      made available for 48 hours on social networks (Facebook and LinkedIn) to groups 
      of doctors and medical students using a communication app (WhatsApp). The
      inclusion criteria were being a medical student or a doctor. Cases in which the
      answers to the questionnaire were inadequate, or when the student had reason to
      withdraw, were excluded. Each participant could only answer the questionnaire
      once, and could not modify the responses after submitting it. RESULTS: A
      disproportionate relationship was found regarding the replacement of the newly
      deceased by other means (such as dummies and simulators). This outcome suggests
      that there is no substitution, concomitant with the importance of a prior request
      for consent from the patient and/or subsequent consent from family members.
      CONCLUSION: According to the findings, the significance of-and need for-training 
      is undeniable. Hence, it is urgent to normalize the practice and definition of
      the ethical limitations of medical conduct.
FAU - Cabar, Fabio Roberto
AU  - Cabar FR
AUID- ORCID: 0000-0001-8178-2136
AD  - Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo, SP, BR.
FAU - Lacerda, Daniele Costa Rachid
AU  - Lacerda DCR
AUID- ORCID: 0000-0002-4813-2630
AD  - Faculdade de Medicina, Universidade Federal de Juiz de Fora, Juiz de Fora, MG,
      BR.
FAU - de Freitas, Gabriela Thome Souza
AU  - de Freitas GTS
AUID- ORCID: 0000-0003-4416-4085
AD  - Faculdade das Americas, Sao Paulo, SP, BR.
FAU - Gorga, Maria Luiza
AU  - Gorga ML
AUID- ORCID: 0000-0003-0961-7907
AD  - Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao
      Paulo, Sao Paulo, SP, BR.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - United States
TA  - Clinics (Sao Paulo)
JT  - Clinics (Sao Paulo, Brazil)
JID - 101244734
SB  - IM
CIN - Clinics (Sao Paulo). 2021 Jun 14;76:e2991. PMID: 34133485
MH  - Humans
MH  - *Physicians
MH  - Prospective Studies
MH  - *Students, Medical
MH  - Surveys and Questionnaires
PMC - PMC7654940
EDAT- 2020/12/03 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/12/02 12:08
PHST- 2020/09/02 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/12/02 12:08 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - S1807-5932(22)00452-5 [pii]
AID - 10.6061/clinics/2020/e2391 [doi]
PST - epublish
SO  - Clinics (Sao Paulo). 2020 Nov 27;75:e2391. doi: 10.6061/clinics/2020/e2391.
      eCollection 2020.


PMID- 33263555
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20211221
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Dec 2
TI  - How Internet Contracts Impact Research: Content Analysis of Terms of Service on
      Consumer Product Websites.
PG  - e23579
LID - 10.2196/23579 [doi]
AB  - BACKGROUND: Companies use brand websites as a promotional tool to engage
      consumers on the web, which can increase product use. Given that some products
      are harmful to the health of consumers, it is important for marketing associated 
      with these products to be subject to public health surveillance. However, terms
      of service (TOS) governing the use of brand website content may impede such
      important research. OBJECTIVE: The aim of this study is to explore the TOS for
      brand websites with public health significance to assess possible legal and
      ethical challenges for conducting research on consumer product websites. METHODS:
      Using Statista, we purposefully constructed a sample of 15 leading American
      tobacco, alcohol, psychiatric pharmaceutical, fast-food, and gun brands that have
      associated websites. We developed and implemented a structured coding system for 
      the TOS on these websites and coded for the presence versus absence of different 
      types of restriction that might impact the ability to conduct research. RESULTS: 
      All TOS stated that by accessing the website, users agreed to abide by the TOS
      (15/15, 100%). A total of 11 out of 15 (73%) websites had age restrictions in
      their TOS. All alcohol brand websites (5/15, 33%) required users to enter their
      age or date of birth before viewing website content. Both websites for tobacco
      brands (2/15, 13%) further required that users register and verify their age and 
      identity to access any website content and agree that they use tobacco products. 
      Only one website (1/15, 7%) allowed users to display, download, copy, distribute,
      and translate the website content as long as it was for personal and not
      commercial use. A total of 33% (5/15) of TOS unconditionally prohibited or put
      substantial restrictions on all of these activities and/or failed to specify if
      they were allowed or prohibited. Moreover, 87% (13/15) of TOS indicated that
      website access could be restricted at any time. A total of 73% (11/15) of
      websites specified that violating TOS could result in deleting user content from 
      the website, revoking access by having the user's Internet Protocol address
      blocked, terminating log-in credentials, or enforcing legal action resulting in
      civil or criminal penalties. CONCLUSIONS: TOS create complications for public
      health surveillance related to e-marketing on brand websites. Recent court
      opinions have reduced the risk of federal criminal charges for violating TOS on
      public websites, but this risk remains unclear for private websites. The public
      health community needs to establish standards to guide and protect researchers
      from the possibility of legal repercussions related to such efforts.
CI  - (c)Caitlin Weiger, Katherine C Smith, Joanna E Cohen, Mark Dredze, Meghan Bridgid
      Moran. Originally published in JMIR Public Health and Surveillance
      (http://publichealth.jmir.org), 02.12.2020.
FAU - Weiger, Caitlin
AU  - Weiger C
AUID- ORCID: 0000-0002-6029-0033
AD  - Department of Health, Behavior & Society, Johns Hopkins Bloomberg School of
      Public Health, Baltimore, MD, United States.
FAU - Smith, Katherine C
AU  - Smith KC
AUID- ORCID: 0000-0003-2140-1690
AD  - Institute for Global Tobacco Control, Department of Health, Behavior & Society,
      Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
FAU - Cohen, Joanna E
AU  - Cohen JE
AUID- ORCID: 0000-0002-3869-3637
AD  - Institute for Global Tobacco Control, Department of Health, Behavior & Society,
      Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
FAU - Dredze, Mark
AU  - Dredze M
AUID- ORCID: 0000-0002-0422-2474
AD  - Department of Computer Science, Johns Hopkins University, Baltimore, MD, United
      States.
FAU - Moran, Meghan Bridgid
AU  - Moran MB
AUID- ORCID: 0000-0001-6745-6668
AD  - Department of Health, Behavior & Society, Johns Hopkins Bloomberg School of
      Public Health, Baltimore, MD, United States.
LA  - eng
GR  - T32 CA009314/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201202
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - Access to Information/legislation & jurisprudence
MH  - Contracts/legislation & jurisprudence/*standards
MH  - Humans
MH  - Internet/*instrumentation/legislation & jurisprudence
MH  - Marketing/methods/statistics & numerical data
PMC - PMC7744264
OTO - NOTNLM
OT  - *contracts
OT  - *ethics
OT  - *internet
OT  - *jurisprudence
OT  - *marketing
EDAT- 2020/12/03 06:00
MHDA- 2021/07/28 06:00
CRDT- 2020/12/02 12:07
PHST- 2020/08/19 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/10/13 00:00 [revised]
PHST- 2020/12/02 12:07 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
AID - v6i4e23579 [pii]
AID - 10.2196/23579 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 Dec 2;6(4):e23579. doi: 10.2196/23579.


PMID- 33262602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Biomedical Data Sharing Among Researchers: A Study from Jordan.
PG  - 1669-1676
LID - 10.2147/JMDH.S284294 [doi]
AB  - BACKGROUND: Data sharing is an encouraged practice to support research in all
      fields. For that purpose, it is important to examine perceptions and concerns of 
      researchers about biomedical data sharing, which was investigated in the current 
      study. METHODS: This is a cross-sectional survey study that was distributed among
      biomedical researchers in Jordan, as an example of developing countries. The
      study survey consisted of questions about demographics and about respondent's
      attitudes toward sharing of biomedical data. RESULTS: Among study participants,
      46.9% (n=82) were positive regarding making their research data available to the 
      public, whereas 53.1% refused the idea. The reasons for refusing to publicly
      share their data included "lack of regulations" (33.5%), "access to research data
      should be limited to the research team" (29.5%), "no place to deposit the data"
      (6.5%), and "lack of funding for data deposition" (6.0%). Agreement with the idea
      of making data available was associated with academic rank (P=0.003). Moreover,
      gender (P-value=0.043) and number of publications (P-value=0.005) were associated
      with a time frame for data sharing (ie, agreeing to share data before vs after
      publication). CONCLUSION: About half of the respondents reported a positive
      attitude toward biomedical data sharing. Proper regulations and facilitation data
      deposition can enhance data sharing in Jordan.
CI  - (c) 2020 Al-Ebbini et al.
FAU - Al-Ebbini, Lina
AU  - Al-Ebbini L
AUID- ORCID: 0000-0002-0893-2959
AD  - Department of Biomedical Systems and Informatics Engineering, Hijjawi for
      Engineering Technology, Yarmouk University, Irbid 21163, Jordan.
FAU - Khabour, Omar F
AU  - Khabour OF
AUID- ORCID: 0000-0002-3006-3104
AD  - Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences,
      Jordan University of Science and Technology, Irbid 22110, Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AUID- ORCID: 0000-0002-2808-5099
AD  - Department of Clinical Pharmacy, Jordan University of Science and Technology,
      Irbid 22110, Jordan.
FAU - Alkaraki, Almuthanna K
AU  - Alkaraki AK
AUID- ORCID: 0000-0003-0983-1348
AD  - Department of Biological Sciences, Faculty of Science, Yarmouk University, Irbid 
      21163, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7695599
OTO - NOTNLM
OT  - Jordan
OT  - data sharing
OT  - ethical issues
OT  - responsible conduct of research
COIS- The authors report no conflicts of interest for this work.
EDAT- 2020/12/03 06:00
MHDA- 2020/12/03 06:01
CRDT- 2020/12/02 05:32
PHST- 2020/09/28 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/12/02 05:32 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/03 06:01 [medline]
AID - 10.2147/JMDH.S284294 [doi]
AID - 284294 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Nov 23;13:1669-1676. doi: 10.2147/JMDH.S284294.
      eCollection 2020.


PMID- 33262194
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220621
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 1
TI  - Randomised controlled trial of tailored support to increase physical activity and
      reduce smoking in smokers not immediately ready to quit: protocol for the Trial
      of physical Activity-assisted Reduction of Smoking (TARS) Study.
PG  - e043331
LID - 10.1136/bmjopen-2020-043331 [doi]
AB  - INTRODUCTION: Smoking reduction can lead to increased success in quitting. This
      study aims to determine if a client-focused motivational support package for
      smoking reduction (and quitting) and increasing (or otherwise using) physical
      activity (PA) can help smokers who do not wish to quit immediately to reduce the 
      amount they smoke, and ultimately quit. This paper reports the study design and
      methods. METHODS AND ANALYSIS: A pragmatic, multicentred, parallel, two group,
      randomised controlled superiority clinical trial, with embedded process
      evaluation and economics evaluation. Participants who wished to reduce smoking
      with no immediate plans to quit were randomised 1:1 to receive either (1)
      tailored individual health trainer face-to-face and/or telephone support to
      reduce smoking and increase PA as an aid to smoking reduction (intervention) or
      (2) brief written/electronic advice to reduce or quit smoking (control).
      Participants in both arms of the trial were also signposted to usual local
      support for smoking reduction and quitting. The primary outcome measure is
      6-month carbon monoxide-confirmed floating prolonged abstinence following
      participant self-reported quitting on a mailed questionnaire at 3 and 9 months
      post-baseline. Participants confirmed as abstinent at 9 months will be followed
      up at 15 months. ETHICS AND DISSEMINATION: Approved by SW Bristol National Health
      Service Research Committee (17/SW/0223). Dissemination will include publication
      of findings for the stated outcomes, parallel process evaluation and economic
      evaluation in peer-reviewed journals. Results will be disseminated to trial
      participants and healthcare providers. TRIAL REGISTRATION NUMBER: ISRCTN47776579;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Taylor, Adrian
AU  - Taylor A
AUID- ORCID: 0000-0003-2701-9468
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK
      adrian.taylor@plymouth.ac.uk.
FAU - Thompson, Tom P
AU  - Thompson TP
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Ussher, Michael
AU  - Ussher M
AD  - Division of Population Health Sciences and Education, University of London, St
      George's, London, UK.
AD  - Institute for Social Marketing, University of Stirling, Stirling, UK.
FAU - Aveyard, Paul
AU  - Aveyard P
AUID- ORCID: 0000-0002-1802-4217
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Division of Public Health and Primary Health Care, Oxford, UK.
FAU - Murray, Rachael L
AU  - Murray RL
AUID- ORCID: 0000-0001-5477-2557
AD  - School of Medicine, University of Nottingham, Nottingham, UK.
FAU - Harris, Tess
AU  - Harris T
AUID- ORCID: 0000-0002-8671-1553
AD  - Division of Population Health Sciences and Education, University of London, St
      George's, London, UK.
FAU - Creanor, Siobhan
AU  - Creanor S
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Green, Colin
AU  - Green C
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
FAU - Streeter, Adam Justin
AU  - Streeter AJ
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Chynoweth, Jade
AU  - Chynoweth J
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Ingram, Wendy
AU  - Ingram W
AUID- ORCID: 0000-0003-0182-9462
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Greaves, Colin J
AU  - Greaves CJ
AD  - School of Sport, Exercise and Rehabilitation Science, University of Birmingham,
      Birmingham, UK.
FAU - Hancocks, Helen
AU  - Hancocks H
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Snowsill, Tristan
AU  - Snowsill T
AUID- ORCID: 0000-0001-7406-2819
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
FAU - Callaghan, Lynne
AU  - Callaghan L
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Price, Lisa
AU  - Price L
AD  - Sport and Health Sciences, University of Exeter, Exeter, UK.
FAU - Horrell, Jane
AU  - Horrell J
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - King, Jennie
AU  - King J
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Gude, Alex
AU  - Gude A
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - George, Mary
AU  - George M
AD  - Division of Population Health Sciences and Education, University of London, St
      George's, London, UK.
FAU - Wahlich, Charlotte
AU  - Wahlich C
AD  - Division of Population Health Sciences and Education, University of London, St
      George's, London, UK.
FAU - Hamilton, Louisa
AU  - Hamilton L
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Division of Public Health and Primary Health Care, Oxford, UK.
FAU - Cheema, Kelisha
AU  - Cheema K
AD  - School of Medicine, University of Nottingham, Nottingham, UK.
FAU - Campbell, Sarah
AU  - Campbell S
AD  - School of Medicine, Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Preece, Dan
AU  - Preece D
AD  - Public Health, Plymouth City Council, Windsor House, Plymouth, Devon, UK.
LA  - eng
SI  - ISRCTN/ISRCTN47776579
GR  - 07/78/02/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201201
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Exercise
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Smokers
MH  - Smoking
MH  - *Smoking Cessation
MH  - State Medicine
PMC - PMC7709511
OTO - NOTNLM
OT  - *clinical trials
OT  - *primary care
OT  - *public health
COIS- Competing interests: AG, AJS, AT, CJG, CG, CW, DP, HH, JC, JK, LC, LH, MG, MU,
      PA, RLM, SCr, SCa, TH, TS, TPT and WI report a grant from NIHR (NIHR HTA award
      ref 15/111/01) during the conduct of the study. PA is an NIHR Senior Investigator
      and is part funded by NIHR Oxford Biomedical Research Centre and Applied Research
      Centre. SCr reports grants from NIHR HTA during the conduct of the study, and
      various other grants from NIHR and UK charities outside the submitted work. She
      is also Interim Codirector (and previously Director) of the UKCRC-registered
      Peninsula Clinical Trials Unit, which is in receipt of NIHR Clinical Trials Unit 
      Support Funding (current award ends 31 August 2021). LP reports consultancy fees 
      from NIHR during the conduct of the study; grants from Living Streets Charity,
      personal fees from NIHR, personal fees from NIHR PHR, personal fees from NIHR PHR
      rapid response, grants from Wellcome Trust seed corn (internal funding) outside
      the submitted work; and discloses that the physical activity group in Sport and
      Health Sciences at the University of Exeter has a collaboration with
      Activinsights (the manufacturer of the physical activity monitor), to provide
      study design advice and data analysis, but that analysis of the physical activity
      data in the present study was not undertaken as part of that service.
EDAT- 2020/12/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/02 05:25
PHST- 2020/12/02 05:25 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043331 [pii]
AID - 10.1136/bmjopen-2020-043331 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 1;10(12):e043331. doi: 10.1136/bmjopen-2020-043331.


PMID- 33262189
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Dec 1
TI  - Simvastatin add-on to escitalopram in patients with comorbid obesity and major
      depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, 
      placebo-controlled trial.
PG  - e040119
LID - 10.1136/bmjopen-2020-040119 [doi]
AB  - INTRODUCTION: Major depressive disorder (MDD) and obesity are both common
      disorders associated with significant burden of disease worldwide. Importantly,
      MDD and obesity often co-occur, with each disorder increasing the risk for
      developing the other by about 50%-60%. Statins are among the most prescribed
      medications with well-established safety and efficacy. Statins are recommended in
      primary prevention of cardiovascular disease, which has been linked to both MDD
      and obesity. Moreover, statins are promising candidates to treat MDD because a
      meta-analysis of pilot randomised controlled trials has found antidepressive
      effects of statins as adjunct therapy to antidepressants. However, no study so
      far has tested the antidepressive potential of statins in patients with MDD and
      comorbid obesity. Importantly, this is a difficult-to-treat population that often
      exhibits a chronic course of MDD and is more likely to be treatment resistant.
      Thus, in this confirmatory randomised controlled trial, we will determine whether
      add-on simvastatin to standard antidepressant medication with escitalopram is
      more efficacious than add-on placebo over 12 weeks in 160 patients with MDD and
      comorbid obesity. METHODS AND ANALYSIS: This is a protocol for a randomised,
      placebo-controlled, double-blind multicentre trial with parallel-group design
      (phase II). One hundred and sixty patients with MDD and comorbid obesity will be 
      randomised 1:1 to simvastatin or placebo as add-on to standard antidepressant
      medication with escitalopram. The primary outcome is change in the
      Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to week 12.
      Secondary outcomes include MADRS response (defined as 50% MADRS score reduction
      from baseline), MADRS remission (defined as MADRS score <10), mean change in
      patients' self-reported Beck Depression Inventory (BDI-II) and mean change in
      high-density lipoprotein, low-density lipoprotein and total cholesterol from
      baseline to week 12. ETHICS AND DISSEMINATION: This protocol has been approved by
      the ethics committee of the federal state of Berlin (Ethik-Kommission des Landes 
      Berlin, reference: 19/0226-EK 11) and by the relevant federal authority
      (Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM), reference:
      4043387). Study findings will be published in peer-reviewed journals and will be 
      presented at (inter)national conferences. TRIAL REGISTRATION NUMBERS:
      NCT04301271, DRKS00021119, EudraCT 2018-002947-27.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Otte, Christian
AU  - Otte C
AUID- ORCID: 0000-0002-4051-997X
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany christian.otte@charite.de.
FAU - Chae, Woo Ri
AU  - Chae WR
AUID- ORCID: 0000-0002-6326-8333
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Nowacki, Jan
AU  - Nowacki J
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Kaczmarczyk, Michael
AU  - Kaczmarczyk M
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Piber, Dominique
AU  - Piber D
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Roepke, Stefan
AU  - Roepke S
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Marschenz, Stefanie
AU  - Marschenz S
AUID- ORCID: 0000-0003-3303-5819
AD  - NeuroCure Clinical Research Center, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Lischewski, Sandra
AU  - Lischewski S
AD  - NeuroCure Clinical Research Center, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
FAU - Schmidt, Sein
AU  - Schmidt S
AD  - Clinical Research Unit, Charite - Universitatsmedizin Berlin, corporate member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Ettrich, Barbara
AU  - Ettrich B
AD  - Department of Psychiatry and Psychotherapy, University Hospital of Leipzig,
      Leipzig, Germany.
FAU - Grabe, Hans Joergen
AU  - Grabe HJ
AD  - Department of Psychiatry and Psychotherapy, University Medicine Greifswald,
      Greifswald, Germany.
FAU - Hegerl, Ulrich
AU  - Hegerl U
AD  - Department of Psychiatry, Psychosomatics and Psychotherapy, Hospital of the
      Goethe University Frankfurt, Frankfurt am Main, Hessen, Germany.
FAU - Hinkelmann, Kim
AU  - Hinkelmann K
AD  - Department of Psychosomatic Medicine, Center for Internal Medicine and
      Dermatology, Charite - Universitatsmedizin Berlin, corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Hofmann, Tobias
AU  - Hofmann T
AD  - Department of Psychosomatic Medicine, Center for Internal Medicine and
      Dermatology, Charite - Universitatsmedizin Berlin, corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Janowitz, Deborah
AU  - Janowitz D
AD  - Department of Psychiatry and Psychotherapy, University Medicine Greifswald,
      Greifswald, Germany.
FAU - Junghanns, Klaus
AU  - Junghanns K
AD  - Department of Psychiatry and Psychotherapy, Medical University of Luebeck,
      Luebeck, Germany.
FAU - Kahl, Kai G
AU  - Kahl KG
AD  - Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical
      School, Hannover, Germany.
FAU - Klein, Jan Philipp
AU  - Klein JP
AUID- ORCID: 0000-0001-9882-2261
AD  - Department of Psychiatry and Psychotherapy, Medical University of Luebeck,
      Luebeck, Germany.
FAU - Krueger, Tillmann H C
AU  - Krueger THC
AD  - Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical
      School, Hannover, Germany.
FAU - Leicht, Gregor
AU  - Leicht G
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Prvulovic, David
AU  - Prvulovic D
AD  - Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Hospital of
      the Goethe University Frankfurt, Frankfurt am Main, Germany.
FAU - Reif, Andreas
AU  - Reif A
AD  - Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Hospital of
      the Goethe University Frankfurt, Frankfurt am Main, Germany.
FAU - Schoettle, Daniel
AU  - Schoettle D
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Strauss, Maria
AU  - Strauss M
AD  - Department of Psychiatry and Psychotherapy, University Hospital of Leipzig,
      Leipzig, Germany.
FAU - Westermair, Anna
AU  - Westermair A
AD  - Department of Psychiatry and Psychotherapy, Medical University of Luebeck,
      Luebeck, Germany.
FAU - Friede, Tim
AU  - Friede T
AUID- ORCID: 0000-0001-5347-7441
AD  - Department of Medical Statistics, University Medical Center Gottingen, Gottingen,
      Germany.
FAU - Gold, Stefan M
AU  - Gold SM
AUID- ORCID: 0000-0001-5188-4799
AD  - Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin,
      corporate member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and
      Berlin Institute of Health, Berlin, Germany.
AD  - Department of Psychosomatic Medicine, Center for Internal Medicine and
      Dermatology, Charite - Universitatsmedizin Berlin, corporate member of Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
AD  - Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular
      Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT04301271
SI  - DRKS/DRKS00021119
SI  - EudraCT/2018-002947-27
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201201
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0DHU5B8D6V (Citalopram)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Berlin
MH  - Citalopram/therapeutic use
MH  - Depression
MH  - *Depressive Disorder, Major/complications/drug therapy/epidemiology
MH  - Double-Blind Method
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Obesity/complications/epidemiology
MH  - Randomized Controlled Trials as Topic
MH  - Simvastatin/therapeutic use
MH  - Treatment Outcome
PMC - PMC7709515
OTO - NOTNLM
OT  - *clinical trials
OT  - *depression & mood disorders
OT  - *mental health
COIS- Competing interests: CO reports personal fees from Allergan, Ferring,
      Fortbildungskolleg, Limes Klinikgruppe, Lundbeck, MedOnline, Medical Tribune,
      Neuraxpharm, SAGE Therapeutics and Stillachhaus outside the submitted work and
      reports grants from the German Research Foundation (DFG), German Ministry of
      Education and Research (BMBF), the European Union (Innovative Medicines
      Initiative) and the Brain & Behavior Foundation (NARSAD). MK participates in the 
      Berlin Institute of Health - Charite Clinician Scientist Program funded by the
      Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. SM reports
      grants from Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
      during the conduct of the study. HJG reports grants and personal fees from
      Fresenius Medical Care, personal fees from Neuraxpharm, Servier, Janssen Cilag
      and grants from German Research Foundation (DFG), German Ministry of Education
      and Research (BMBF), Damp Foundation, European Union Joint Programme
      Neurodegenerative Disorders (JPND) and European Social Fund (ESF) outside the
      submitted work. UH reports personal fees from Janssen and Servier outside the
      submitted work. TF reports grants and non-financial support from German Ministry 
      of Education and Research (BMBF) during the conduct of the study. KGK reports
      personal fees and other from Eli Lilly, Servier and Neuraxpharm, and grants,
      personal fees and other from Ferrer outside the submitted work. JPK reports
      grants and personal fees from Servier, personal fees from Springer, Hogrefe,
      Elsevier and Beltz outside the submitted work. THCK reports grants from German
      Ministry of Education and Research (BMBF) during the conduct of the study and
      personal fees from Allergan, Lundbeck, Otsuka, Trommsdorf, Novartis and Schwabe
      outside the submitted work. AR reports grants and personal fees from Medice,
      personal fees from Shire/Takeda, Janssen, Neuraxpharm, Servier and SAGE outside
      the submitted work. DS reports honoraria for lectures from or has been an advisor
      to Janssen, Lundbeck, Otsuka Pharma, Medice and Takeda. TF reports personal fees 
      from Novartis, Bayer, Janssen, SGS, Roche, Boehringer Ingelheim, Daiichi-Sankyo, 
      Galapagos, Penumbra, Parexel, Vifor, BiosenseWebster, CSL Behring, Fresenius
      Kabi, Coherex Medical and LivaNova outside the submitted work. SMG reports grants
      from German Ministry of Education and Research (BMBF), German Research Foundation
      (DFG), Federal Ministry of Health (BMG), Biogen and National Multiple Sclerosis
      Society (NMSS) during the conduct of the study and personal fees from Almirall
      S.A., Mylan, Celgene and FomF outside the submitted work. WRC, JN, DoP, SR,
      SL,SS, BE, KH, DJ, KJ, GL, DaP, MS and AW have nothing to disclose.
EDAT- 2020/12/03 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/12/02 05:25
PHST- 2020/12/02 05:25 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - bmjopen-2020-040119 [pii]
AID - 10.1136/bmjopen-2020-040119 [doi]
PST - epublish
SO  - BMJ Open. 2020 Dec 1;10(12):e040119. doi: 10.1136/bmjopen-2020-040119.


PMID- 33262068
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20220323
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
VI  - 50
DP  - 2020 Aug
TI  - Human challenge trials in vaccine development.
PG  - 101429
LID - S1044-5323(20)30045-2 [pii]
LID - 10.1016/j.smim.2020.101429 [doi]
AB  - The increasing recent interest in human challenge studies or controlled human
      infection model studies for accelerating vaccine development has been driven by
      the recognition of the unique ability of these studies to contribute to the
      understanding of response to infection and the performance of vaccines. With
      streamlining of ethical processes, conduct and supervision and the availability
      of new investigative tools from immunophenotyping to glycobiology, the potential 
      to derive valuable data to inform vaccine testing and development has never been 
      greater. However, issues of availability and standardization of challenge
      strains, conduct of studies in disease endemic locations and the iteration
      between clinical and laboratory studies still need to be addressed to gain
      maximal value for vaccine development.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Sekhar, Amrita
AU  - Sekhar A
AD  - Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.
FAU - Kang, Gagandeep
AU  - Kang G
AD  - Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.
      Electronic address: gkang@cmcvellore.ac.in.
LA  - eng
GR  - MR/R005982/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20201129
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
RN  - 0 (Vaccines)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Infections/*immunology
MH  - Research
MH  - Vaccination
MH  - Vaccines/*immunology
PMC - PMC7700100
OTO - NOTNLM
OT  - *Controlled human infection models
OT  - *Human challenge studies
OT  - *Human infection studies
OT  - *Vaccines
EDAT- 2020/12/03 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/12/02 05:24
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/25 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/12/02 05:24 [entrez]
AID - S1044-5323(20)30045-2 [pii]
AID - 10.1016/j.smim.2020.101429 [doi]
PST - ppublish
SO  - Semin Immunol. 2020 Aug;50:101429. doi: 10.1016/j.smim.2020.101429. Epub 2020 Nov
      29.


PMID- 33261713
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201222
IS  - 2045-7979 (Electronic)
IS  - 2045-7960 (Linking)
VI  - 29
DP  - 2020 Dec 2
TI  - The use of mechanical restraint in Pacific Rim countries: an international
      epidemiological study.
PG  - e190
LID - 10.1017/S2045796020001031 [doi]
AB  - AIMS: The use of mechanical restraint is a challenging area for psychiatry.
      Although mechanical restraint remains accepted as standard practice in some
      regions, there are ethical, legal and medical reasons to minimise or abolish its 
      use. These concerns have intensified following the Convention on the Rights of
      Persons with Disabilities. Despite national policies to reduce use, the reporting
      of mechanical restraint has been poor, hampering a reasonable understanding of
      the epidemiology of restraint. This paper aims to develop a consistent measure of
      mechanical restraint and compare the measure within and across countries in the
      Pacific Rim. METHODS: We used the publicly available data from four Pacific Rim
      countries (Australia, New Zealand, Japan and the United States) to compare and
      contrast the reported rates of mechanical restraint. Summary measures were
      computed so as to enable international comparisons. Variation within each
      jurisdiction was also analysed. RESULTS: International rates of mechanical
      restraint in 2017 varied from 0.03 (New Zealand) to 98.9 (Japan) restraint events
      per million population per day, a variation greater than 3000-fold. Restraint in 
      Australia (0.17 events per million) and the United States (0.37 events per
      million) fell between these two extremes. Variation as measured by restraint
      events per 1000 bed-days was less extreme but still substantial. Within all four 
      countries there was also significant variation in restraint across districts.
      Variation across time did not show a steady reduction in restraint in any country
      during the period for which data were available (starting from 2003 at the
      earliest). CONCLUSIONS: Policies to reduce or abolish mechanical restraint do not
      appear to be effecting change. It is improbable that the variation in restraint
      within the four examined Pacific Rim countries is accountable for by
      psychopathology. Greater efforts at reporting, monitoring and carrying out
      interventions to achieve the stated aim of reducing restraint are urgently
      needed.
FAU - Newton-Howes, G
AU  - Newton-Howes G
AUID- ORCID: https://orcid.org/0000-0002-5167-1213
AD  - University of Otago, 32 Mein Street, Wellington, New Zealand.
FAU - Savage, M K
AU  - Savage MK
AUID- ORCID: https://orcid.org/0000-0002-2080-0676
AD  - Victoria University of Wellington, Wellington, New Zealand.
FAU - Arnold, R
AU  - Arnold R
AD  - Victoria University of Wellington, Wellington, New Zealand.
FAU - Hasegawa, T
AU  - Hasegawa T
AD  - Kyorin University, Mitaka, Tokyo, Japan.
FAU - Staggs, V
AU  - Staggs V
AD  - University of Missouri-Kansas City and Children's Mercy Kansas City, Kansas City,
      MO, USA.
FAU - Kisely, S
AU  - Kisely S
AUID- ORCID: https://orcid.org/0000-0003-4021-2924
AD  - The University of Queensland, St Lucia, QLD, Australia.
AD  - Dalhousie University, Halifax, NS, Canada.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201202
PL  - England
TA  - Epidemiol Psychiatr Sci
JT  - Epidemiology and psychiatric sciences
JID - 101561091
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Australia
MH  - Coercion
MH  - Cross-Cultural Comparison
MH  - Epidemiologic Studies
MH  - Hospitals, Psychiatric/*statistics & numerical data
MH  - Humans
MH  - Japan
MH  - Mental Disorders/epidemiology/therapy
MH  - Middle Aged
MH  - New Zealand
MH  - Patient Isolation/*statistics & numerical data
MH  - Restraint, Physical/*statistics & numerical data
MH  - United States
PMC - PMC7737169
OTO - NOTNLM
OT  - Coercion
OT  - Pacific Rim
OT  - prevalence
OT  - restraint
EDAT- 2020/12/03 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/12/02 05:21
PHST- 2020/12/02 05:21 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.1017/S2045796020001031 [doi]
AID - S2045796020001031 [pii]
PST - epublish
SO  - Epidemiol Psychiatr Sci. 2020 Dec 2;29:e190. doi: 10.1017/S2045796020001031.


PMID- 33261579
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Dec 1
TI  - Design and protocol of the multimorbidity and mental health cohort study in
      frailty and aging (MiMiCS-FRAIL): unraveling the clinical and molecular
      associations between frailty, somatic disease burden and late life depression.
PG  - 573
LID - 10.1186/s12888-020-02963-9 [doi]
AB  - BACKGROUND: To explore the mutual relationship between multimorbidity, mental
      illness and frailty, we have set-up the Multimorbidity and Mental health Cohort
      Study in FRAILty and Aging (MiMiCS-FRAIL) cohort. At the population level,
      multimorbidity, frailty and late-life depression are associated with similar
      adverse outcomes (i.e. falls, disability, hospitalization, death), share the same
      risk factors, and partly overlap in their clinical presentation. Moreover, these 
      three variables may share a common underlying pathophysiological mechanism like
      immune-metabolic dysregulation. The overall objectives of MiMiCS-FRAIL are 1) to 
      explore (determinants of) the cross-sectional and longitudinal relationship
      between multimorbidity, depression, and frailty among non-demented geriatric
      outpatients; 2) to evaluate molecular levels of senoinflammation as a broad
      pathophysiological process underlying these conditions; and 3) to examine adverse
      outcomes of multimorbidity, frailty and depression and their interconnectedness. 
      METHODS: MiMiCS-FRAIL is an ongoing observational cohort study of geriatric
      outpatients in Brazil, with an extensive baseline assessment and yearly follow-up
      assessments. Each assessment includes a comprehensive geriatric assessment to
      identify multimorbidity and geriatric syndromes, a structured psychiatric
      diagnostic interview and administration of the PHQ-9 to measure depression, and
      several frailty measures (FRAIL, Physical Phenotype criteria, 36-item Frailty
      Index). Fasten blood samples are collected at baseline to assess circulating
      inflammatory and anti-inflammatory cytokines, leukocytes' subpopulations, and to 
      perform immune-metabolic-paired miRome analyses. The primary outcome is death and
      secondary outcomes are the number of falls, hospital admissions, functional
      ability, well-being, and dementia. Assuming a 5-year mortality rate between 25
      and 40% and a hazard rate varying between 1.6 and 2.3 for the primary
      determinants require a sample size between 136 and 711 patients to detect a
      statistically significant effect with a power of 80% (beta = 0.2), an alpha of 5%
      (0.05), and an R(2) between the predictor (death) and all covariates of 0.20.
      Local ethical board approved this study. DISCUSSION: Frailty might be
      hypothesized as a final common pathway by which many clinical conditions like
      depression and chronic diseases (multimorbidity) culminate in many adverse
      effects. The MiMiCS-FRAIL cohort will help us to understand the interrelationship
      between these variables, from a clinical perspective as well as their underlying 
      molecular signature.
FAU - Aprahamian, Ivan
AU  - Aprahamian I
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Mamoni, Ronei Luciano
AU  - Mamoni RL
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Cervigne, Nilva Karla
AU  - Cervigne NK
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Augusto, Taize Machado
AU  - Augusto TM
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Romanini, Carla Vasconcelos
AU  - Romanini CV
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Petrella, Marina
AU  - Petrella M
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - da Costa, Daniele Lima
AU  - da Costa DL
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Lima, Natalia Almeida
AU  - Lima NA
AD  - Geriatrics Division, Department of Internal Medicine, Faculty of Medicine of
      Jundiai, Jundiai, Brazil.
FAU - Borges, Marcus K
AU  - Borges MK
AD  - Institute and Department of Psychiatry, University of Sao Paulo, Sao Paulo,
      Brazil.
FAU - Oude Voshaar, Richard C
AU  - Oude Voshaar RC
AUID- ORCID: 0000-0003-1501-4774
AD  - Institute and Department of Psychiatry, University of Sao Paulo, Sao Paulo,
      Brazil. r.c.oude.voshaar@umcg.nl.
AD  - University Medical Center Groningen, University Center for Psychiatry and
      Interdisciplinary Center for Psychopathology of Emotion Regulation, Groningen,
      Netherlands. r.c.oude.voshaar@umcg.nl.
LA  - eng
GR  - National Public grant level 2/National Council for Scientific and Technological
      Development (Ministry of Science, Technology, Innovation and Communications,
      Brazil)
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201201
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
MH  - Aged
MH  - Aging
MH  - Brazil
MH  - Cohort Studies
MH  - Cost of Illness
MH  - Cross-Sectional Studies
MH  - Depression/epidemiology
MH  - Frail Elderly
MH  - *Frailty/epidemiology
MH  - Geriatric Assessment
MH  - Humans
MH  - Mental Health
MH  - Multimorbidity
PMC - PMC7706060
OTO - NOTNLM
OT  - *Cohort study
OT  - *Depression
OT  - *Elderly
OT  - *Frailty
OT  - *Inflammation
OT  - *Multimorbidity
EDAT- 2020/12/03 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/12/02 05:20
PHST- 2020/07/19 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/12/02 05:20 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - 10.1186/s12888-020-02963-9 [doi]
AID - 10.1186/s12888-020-02963-9 [pii]
PST - epublish
SO  - BMC Psychiatry. 2020 Dec 1;20(1):573. doi: 10.1186/s12888-020-02963-9.


PMID- 33261139
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 23
DP  - 2020 Nov 27
TI  - Telemedicine as a Medical Examination Tool During the Covid-19 Emergency: The
      Experience of the Onco-Haematology Center of Tor Vergata Hospital in Rome.
LID - E8834 [pii]
LID - 10.3390/ijerph17238834 [doi]
AB  - BACKGROUND: Our study analysed the outpatient activity of the onco-hematology
      Complex Operative Unit (UOC) of Tor Vergata Hospital, Rome coronavirus disease
      2019 (Covid-19) center, where, as a result of the sudden and unexpected
      emergency, healthcare services were provided through telemedicine procedures that
      can be considered very close to Telehealth. AIM OF THE STUDY: our retrospective
      study aimed to assess the widespread use of telemedicine in terms of feasibility 
      and safety related to adverse events, a crucial experience which will make it
      possible to predict any effective use of such a method in patients with
      hematological disorders even after the end of the Covid-19 emergency. MATERIALS
      AND METHODS: At the Day Hospital clinic, from 8 March to 31 May 2020, an
      outpatient group received 3828 medical teleconsultations and 11,484 additional
      contacts following the first examination; each patient examined through the
      telematic method required an average of three supplementary contacts via e-mail
      or telephone. RESULTS: The follow-up lasted 145 days, and all the events that
      occurred were monitored. In total, we recorded 16 clinical adverse events, 5 of
      which classified as major events, and 11 as minor events. CONCLUSION: The 3828
      telematic clinical examinations and the 11,484 additional contacts following the 
      first examination carried out by the onco-haematology UOC of Tor Vergata
      Hospital, proved how telemedicine, albeit in its basic form, was a key tool in
      facing the sanitary emergency caused by the sudden spread of Covid-19. An
      experience that can be considered reliable enough to be replicated in possible
      post-Covid-19 emergencies. From a medical forensic point of view, the main issues
      to consider are informed consent, personal data management and professional
      responsibility profiles.
FAU - Postorino, Massimiliano
AU  - Postorino M
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Treglia, Michele
AU  - Treglia M
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Giammatteo, Jacopo
AU  - Giammatteo J
AUID- ORCID: 0000-0002-0076-4583
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Pallocci, Margherita
AU  - Pallocci M
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Petroni, Giulia
AU  - Petroni G
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Quintavalle, Giuseppe
AU  - Quintavalle G
AD  - Local Public Health Unit ASL Roma 4, Civitavecchia, 00053 Rome, Italy.
FAU - Picchioni, Ombretta
AU  - Picchioni O
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Cantonetti, Maria
AU  - Cantonetti M
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
FAU - Marsella, Luigi Tonino
AU  - Marsella LT
AD  - Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *COVID-19
MH  - Hematology/*trends
MH  - Hospitals
MH  - Humans
MH  - Pandemics
MH  - Retrospective Studies
MH  - Rome
MH  - *Telemedicine
PMC - PMC7729865
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *legal medicine
OT  - *onco-haematology
OT  - *telemedicine
EDAT- 2020/12/03 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/02 01:03
PHST- 2020/11/05 00:00 [received]
PHST- 2020/11/23 00:00 [revised]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/02 01:03 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - ijerph17238834 [pii]
AID - 10.3390/ijerph17238834 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 27;17(23). pii: ijerph17238834. doi:
      10.3390/ijerph17238834.


PMID- 33259344
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Remembering Al Jonsen.
PG  - 383
LID - 2020314383 [pii]
AB  - The author, editor-in-chief of The Journal of Clinical Ethics, recalls the
      contributions of Albert R. Jonsen, PhD, one of the founding members of the
      editorial board of the journal.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Howe, Edmund G
AU  - Howe EG
AD  - Programs in Medical Ethics, Uniformed Services University of the Health Sciences,
      4301 Jones Bridge Road, Bethesda, Maryland 20814 USA. edmund.howe@uhuhs.edu.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Advisory Committees
MH  - Bioethical Issues
MH  - Editorial Policies
MH  - Ethicists/*history
MH  - Ethics, Clinical
MH  - History, 20th Century
MH  - Humans
MH  - Male
MH  - Periodicals as Topic/*history
MH  - Publishing/*history
PS  - Jonsen A
FPS - Jonsen, Al
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314383 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):383.


PMID- 33259343
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - The Making of a Clinical Ethicist: A Personal Tribute to Al Jonsen.
PG  - 381-382
LID - 2020314381 [pii]
AB  - In this account, the author shares her long-standing personal and professional
      relationship with her mentor, Albert R. Jonsen, PhD, a prominent figure in the
      history of bioethics.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Mishra, Ruchika
AU  - Mishra R
AD  - Sutter Health's Program in Medicine and Human Values in San Francisco, CA USA.
      MishraRM@sutterhealth.org.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Bioethics/*history
MH  - Ethicists/*history
MH  - Ethics, Clinical/*history
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
PS  - Jonsen A
FPS - Jonsen, Al
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314381 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):381-382.


PMID- 33259342
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Do Clinical Ethics Fellowships Prepare Trainees for their First Jobs? A National 
      Survey of Former Clinical Ethics Fellows.
PG  - 372-380
LID - 2020314372 [pii]
AB  - Clinical ethics consultants provide a range of services in hospital settings and 
      in teaching environments. Training to achieve the skills needed to meet the
      expectations of employers comes in various forms, ranging from on-the-job
      training to formal fellowship training programs. We surveyed graduates of
      clinical ethics fellowships to evaluate their self-reported preparedness for
      their first job after fellowship training. The results indicated several areas of
      need, including greater exposure to program-building skills, quality improvement 
      skills, and approaches to working with members of higher administration. These
      data will be of use to educators as well as to fellows who advocate for elements 
      of training in preparation for their first position.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Guerin, Robert M
AU  - Guerin RM
AD  - University Hospitals Cleveland Medical Center; and Case Western Reserve
      University Department of Bioethics, Cleveland, OH USA.
      Robert.Guerin@UHhospitals.org.
FAU - Diekema, Douglas S
AU  - Diekema DS
AD  - Treuman Katz Center for Pediatric Bioethics; and Institutional Review Board
      Committee, Center for Pediatric Bioethics, Seattle Children's Research Institute,
      Seattle, WA USA. diek@uw.edu.
FAU - Hizlan, Sahabat
AU  - Hizlan S
AD  - Cleveland Clinic, Cleveland, OH USA. hizlans@ccf.org.
FAU - Weise, Kathryn L
AU  - Weise KL
AD  - Retired, Department of Pediatrics, School of Medicine, and Department of
      Bioethics, Case Western Reserve University, Cleveland, OH USA.
      k.weise@sbcglobal.net.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Adult
MH  - Ethics, Clinical/*education
MH  - Evaluation Studies as Topic
MH  - *Fellowships and Scholarships
MH  - Female
MH  - Humans
MH  - Male
MH  - Self Report
MH  - Surveys and Questionnaires
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314372 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):372-380.


PMID- 33259341
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Moral Distress: A Framework for Offering Relief through Debrief.
PG  - 364-371
LID - 2020314364 [pii]
AB  - Moral distress, if left unaddressed, leads to a number of harmful emotions and
      behaviors that take a toll on the personal and professional well-being of
      healthcare workers. In this article, a clinical case is used to illustrate a
      moral distress debriefing framework that can be utilized by clinical ethicists
      and healthcare professionals with the appropriate skill set. The first part of
      the framework is preparatory; it includes guidance on how to identify the needs
      of healthcare providers, set goals for a debriefing session, gather relevant
      information, and plan the logistics of the meeting. The second part of the
      framework is implemental; it outlines an eight-step method to conduct the session
      from beginning to end. It describes how to constructively reflect on the
      experience, explore emotional responses, share coping strategies, and identify
      take-aways for future positive outcomes. This framework can be used to empower
      healthcare team members to deal with moral distress and be better equipped to
      handle challenging situations.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Shashidhara, Shilpa
AU  - Shashidhara S
AD  - Sutter Health Program in Medicine and Human Values, San Francisco, CA USA.
      shashis@sutterhealth.org.
FAU - Kirk, Shaylona
AU  - Kirk S
AD  - Sutter Health Program in Medicine and Human Values, San Francisco, CA USA.
      Shaylona.Kirk@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Adaptation, Psychological
MH  - Burnout, Professional/prevention & control/psychology
MH  - *Ethicists
MH  - Health Personnel/*psychology
MH  - Humans
MH  - *Morals
MH  - Occupational Health
MH  - Patient Care Team
MH  - *Practice Guidelines as Topic
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314364 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):364-371.


PMID- 33259340
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Psychiatric Advance Directives as an Ethical Communication Tool: An Analysis of
      Definitions.
PG  - 353-363
LID - 2020314351 [pii]
AB  - A psychiatric advance directive (PAD) is a communication tool that promotes
      patients' autonomy and gives capacitated adults who live with serious mental
      illnesses the ability to record their preferences for care and designate a proxy 
      decision maker before a healthcare crisis. Despite a high degree of interest by
      patients and previous studies that recommend that clinicians facilitate the
      completion of PADs, the rate of implementation of PAD remains low. Research
      indicates that many clinicians lack the necessary experience to facilitate the
      completion of PADs and to use them, and, as a consequence, do not effectively
      engage patients about PADs. This study developed practical recommendations for
      clinicians to improve their ability to communicate and facilitate PADs. We (1)
      thematically analyzed definitions of PADs published in 118 articles across
      disciplines, and (2) presented our recommendations for enhanced communication in 
      clinical practice that emphasizes patient-centeredness, usefulness, and clarity, 
      aligned with evidence-based practices that put patients' autonomy and
      understanding first. While there is no one-size-fits-all script to engage
      patients in complex conversations, our recommended strategies include an emphasis
      on patients' autonomy, the adaptation of word choices, the use of metaphor not
      simile, and checking for patients' understanding as effective methods of clinical
      communication.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Table, Billy
AU  - Table B
AD  - Department of Population Health, Dell Medical School, University of Texas at
      Austin, Austin, TX USA. billy.table@austin.utexas.edu.
FAU - Thomas, Jaime
AU  - Thomas J
AD  - Department of Population Health, Dell Medical School, University of Texas at
      Austin, Austin, TX USA. james.thomas@austin.utexas.edu.
FAU - Brown, Virginia A
AU  - Brown VA
AD  - Department of Population Health, Dell Medical School, University of Texas at
      Austin, Austin, TX USA. Virginia.brown@austin.utexas.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Adult
MH  - Advance Directives/*ethics
MH  - *Communication
MH  - Humans
MH  - Mental Disorders/psychology/*therapy
MH  - Mental Health Services/*ethics
MH  - Morals
MH  - Patient Rights
MH  - Patient-Centered Care
MH  - Personal Autonomy
MH  - *Practice Guidelines as Topic
MH  - Proxy
MH  - Terminal Care/psychology
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314353 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):353-363.


PMID- 33259339
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Living in the Hospital: The Vulnerability of Children with Chronic Critical
      Illness.
PG  - 340-352
LID - 2020314340 [pii]
AB  - The number of children with chronic critical illness (CCI) is a growing
      population in the United States. A defining characteristic of this population is 
      a prolonged hospital stay. Our study assessed the proportion of pediatric
      patients with chronic critical illness in U.S. hospitals at a specific point in
      time, and identified a subset of children whose hospital stay lasted for months
      to years. The potential harms of a prolonged hospitalization for children with
      CCI, which include over treatment, infection, disruption of family life, and the 
      intensive utilization of resources-combined with the moral distress experienced
      by the clinicians who care for the children, suggest the need for ethical
      analysis of this growing issue to identify actions that could be taken at the
      clinical and health systems levels to reduce the harms associated with prolonged 
      hospital stay. In this article we present three real cases from our study that
      involved a very long hospital stay. We applied a framework developed by
      Mackenzie, Rogers, and Dodds to analyze inherent, situational, and pathogenic
      vulnerabilities to examine the ways that interventions intended to remedy one
      source of harm for the children in our cohort inadvertently created other harms. 
      We examined the complex ways that children with protracted hospitalization are
      vulnerable to the choices made by their family and clinicians, as well as by
      healthcare systems and communities. Finally, we used this analysis to summarize
      actions and ethical responses to this growing patient population. Such an
      understanding is essential to make clinical and ethical decisions that arise for 
      children who are at risk for a very long stay in the hospital.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Ruth, Alexandra R
AU  - Ruth AR
AD  - Johns Hopkins Bloomberg School of Public Health in Baltimore, MD USA.
      aruth3@jhu.edu.
FAU - Boss, Renee D
AU  - Boss RD
AD  - Johns Hopkins Berman Institute of Bioethics and Division of Neonatal-Perinatal
      Medicine, Division of Neonatology, Johns Hopkins School of Medicine, Baltimore,
      MD USA. rboss1@jhu.edu.
FAU - Donohue, Pamela K
AU  - Donohue PK
AD  - Johns Hopkins Bloomberg School of Public Health, Department of Population,
      Family, and Reproductive Health; Pediatrics, Johns Hopkins University School of
      Medicine, Baltimore, MD USA. pdonohue@jhmi.edu.
FAU - Shapiro, Miriam C
AU  - Shapiro MC
AD  - University of Minnesota School of Medicine, Department of Pediatrics; University 
      of Minnesota Masonic Children's Hospital, Minneapolis, MN USA. mshapiro @umn.edu.
FAU - Raisanen, Jessica C
AU  - Raisanen JC
AD  - Johns Hopkins Berman Institute of Bioethics, Baltimore, MD USA. jraisan1
      @jhu.edu.
FAU - Henderson, Carrie M
AU  - Henderson CM
AD  - University of Mississippi Medical Center, Center for Bioethics and Medical
      Humanities, and Division of Pediatric Critical Care, Jackson, MS USA.
      Cmhenderson2@umd.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease/*epidemiology
MH  - Critical Illness/*epidemiology
MH  - Female
MH  - Hospitalization
MH  - Hospitals
MH  - Humans
MH  - Intensive Care Units, Pediatric/*statistics & numerical data
MH  - Length of Stay/*statistics & numerical data
MH  - Male
MH  - Quality of Life
MH  - United States/epidemiology
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314340 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):340-352.


PMID- 33259337
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - The Pediatrician's Moral Obligation to Counsel Directively Against Youth Tackle
      Football.
PG  - 331-337
LID - 2020314331 [pii]
AB  - In this issue of The Journal of Clinical Ethics, Professor Ruth Tallman argues
      that pediatricians ought to support adolescent football players in their athletic
      goals. She does not deny that doing so means "helping children hurt themselves"; 
      rather she argues that this would be consistent with a shared decision-making
      model in which both the physician and the patient seek to promote the patient's
      well-being in light of the patient's own goals. I argue that this ignores the
      role of the parents, meaning that Tallman is suggesting "helping parents allow
      their children to hurt themselves." As a general pediatrician, I would classify
      this as child neglect, if not downright child abuse. I argue that pediatricians
      should counsel directively against youth tackle football, employ a deliberative
      approach to shared decision making within the triadic doctor-patient-parent
      relationship, and support youth sport policies that seek to reduce traumatic
      brain injury by advocating for flag football, by prohibiting checking in boys'
      ice hockey, and by minimizing heading the ball in soccer below a certain age.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Ross, Lainie Friedman
AU  - Ross LF
AD  - University of Chicago Departments of Pediatrics, Medicine, Surgery and the
      College; MacLean Center for Clinical Medical Ethics, Chicago, IL USA.
      Lross@uchicago.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Athletic Injuries/*prevention & control
MH  - Brain Concussion/prevention & control
MH  - Child
MH  - Directive Counseling/*ethics
MH  - Female
MH  - Football
MH  - Humans
MH  - Male
MH  - *Moral Obligations
MH  - Pediatricians/*ethics
MH  - *Pediatrics
MH  - Soccer
MH  - *Youth Sports
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314331 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):331-337.


PMID- 33259335
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Beyond Shared Decision Making.
PG  - 293-302
LID - 2020314293 [pii]
AB  - Shared decision making (SDM) is the state of the art for clinicians'
      communication with patients and surrogate decision makers. SDM involves give and 
      take, in which all parties interact to maximize the autonomy of patients. In this
      article I summarize the core steps of SDM and explore ways to use it to benefit
      patients to the greatest extent. I review three articles included in this issue
      of The Journal of Clinical Ethics that highlight additional approaches we can use
      to help patients and parents to see what may be in their own or their child's
      best interest. I describe how these approaches can be used in most other medical 
      fields. I explore ways to share information with patients that are outside the
      usual scope of SDM. Finally, I discuss how we might look, together with patients,
      at what all parties are feeling before we begin the process of SDM.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Hower, Edmund G
AU  - Hower EG
AD  - Programs in Medical Ethics, Uniformed Services University of the Health Sciences,
      4301 Jones Bridge Road, Bethesda, Maryland 20814 USA. edmund.howe@uhuhs.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Child, Preschool
MH  - *Communication
MH  - Decision Making/*ethics
MH  - *Decision Making, Shared
MH  - Humans
MH  - Parents
MH  - *Patient Participation
MH  - Patient-Centered Care/*ethics
MH  - Physician-Patient Relations
EDAT- 2020/12/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/12/01 17:09
PHST- 2020/12/01 17:09 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 2020314293 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):293-302.


PMID- 33259326
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201231
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 18
TI  - Online and Recovery-Oriented Support Groups Facilitated by Peer Support Workers
      in Times of COVID-19: Protocol for a Feasibility Pre-Post Study.
PG  - e22500
LID - 10.2196/22500 [doi]
AB  - BACKGROUND: In times of pandemics, social distancing, isolation, and quarantine
      have precipitated depression, anxiety, and substance misuse. Scientific
      literature suggests that patients living with mental health problems or illnesses
      (MHPIs) who interact with peer support workers (PSWs) experience not only the
      empathy and connectedness that comes from similar life experiences but also feel 
      hope in the possibility of recovery. So far, it is the effect of mental health
      teams or programs with PSWs that has been evaluated. OBJECTIVE: This paper
      presents the protocol for a web-based intervention facilitated by PSWs. The five 
      principal research questions are whether this intervention will have an impact in
      terms of (Q1) personal-civic recovery and (Q2) clinical recovery, (Q3) how these 
      recovery potentials can be impacted by the COVID-19 pandemic, (Q4) how the lived 
      experience of persons in recovery can be mobilized to cope with such a situation,
      and (Q5) how sex and gender considerations can be taken into account for the
      pairing of PSWs with service users beyond considerations based solely on
      psychiatric diagnoses or specific MHPIs. This will help us assess the impact of
      PSWs in this setting. METHODS: PSWs will lead a typical informal peer support
      group within the larger context of online peer support groups, focusing on
      personal-civic recovery. They will be scripted with a fixed, predetermined
      duration (a series of 10 weekly 90-minute online workshops). There will be 2
      experimental subgroups-patients diagnosed with (1) psychotic disorders (n=10) and
      (2) anxiety or mood disorders (n=10)-compared to a control group (n=10). Random
      assignment to the intervention and control arms will be conducted using a 2:1
      ratio. Several instruments will be used to assess clinical recovery (eg, the
      Recovery Assessment Scale, the Citizenship Measure questionnaire). The COVID-19
      Stress Scales will be used to assess effects in terms of clinical recovery and
      stress- or anxiety-related responses to COVID-19. Changes will be compared
      between groups from baseline to endpoint in the intervention and control groups
      using the Student paired sample t test. RESULTS: This pilot study was funded in
      March 2020. The protocol was approved on June 16, 2020, by the Research Ethics
      Committees of the Montreal Mental Health University Institute. Recruitment took
      place during the months of July and August, and results are expected in December 
      2020. CONCLUSIONS: Study results will provide reliable evidence on the
      effectiveness of a web-based intervention provided by PSWs. The investigators,
      alongside key decision makers and patient partners, will ensure knowledge
      translation throughout, and our massive open online course (MOOC), The
      Fundamentals of Recovery, will be updated with the evidence and new knowledge
      generated by this feasibility study. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT04445324; https://clinicaltrials.gov/ct2/show/NCT04445324. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/22500.
CI  - (c)Jean-Francois Pelletier, Janie Houle, Marie-Helene Goulet, Robert-Paul Juster,
      Charles-Edouard Giguere, Jonathan Bordet, Isabelle Henault, Alain Lesage, Luigi
      De Benedictis, Frederic Denis, Roger Ng. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 18.12.2020.
FAU - Pelletier, Jean-Francois
AU  - Pelletier JF
AUID- ORCID: https://orcid.org/0000-0003-4701-1826
AD  - Department of Psychiatry and Addictology, Montreal Mental Health University
      Institute - Research Centre, University of Montreal, Montreal, QC, Canada.
AD  - Department of Psychiatry, Yale University, New Haven, CT, United States.
FAU - Houle, Janie
AU  - Houle J
AUID- ORCID: https://orcid.org/0000-0003-0370-5076
AD  - Department of Psychology, Universite du Quebec a Montreal, Montreal, QC, Canada.
FAU - Goulet, Marie-Helene
AU  - Goulet MH
AUID- ORCID: https://orcid.org/0000-0002-7764-6286
AD  - School of Nursing, University of Montreal, Montreal, QC, Canada.
FAU - Juster, Robert-Paul
AU  - Juster RP
AUID- ORCID: https://orcid.org/0000-0003-4133-4042
AD  - Department of Psychiatry and Addictology, Montreal Mental Health University
      Institute - Research Centre, University of Montreal, Montreal, QC, Canada.
FAU - Giguere, Charles-Edouard
AU  - Giguere CE
AUID- ORCID: https://orcid.org/0000-0002-8507-6412
AD  - Montreal Mental Health University Institute - Research Centre, Montreal, QC,
      Canada.
FAU - Bordet, Jonathan
AU  - Bordet J
AUID- ORCID: https://orcid.org/0000-0003-4812-3125
AD  - Montreal Mental Health University Institute - Research Centre, Montreal, QC,
      Canada.
FAU - Henault, Isabelle
AU  - Henault I
AUID- ORCID: https://orcid.org/0000-0001-8400-0005
AD  - Quebec Association of Peer Support Workers, Montreal, QC, Canada.
FAU - Lesage, Alain
AU  - Lesage A
AUID- ORCID: https://orcid.org/0000-0002-4226-4683
AD  - Department of Psychiatry and Addictology, Montreal Mental Health University
      Institute - Research Centre, University of Montreal, Montreal, QC, Canada.
FAU - De Benedictis, Luigi
AU  - De Benedictis L
AUID- ORCID: https://orcid.org/0000-0002-6747-074X
AD  - Montreal Mental Health University Institute - Research Centre, Montreal, QC,
      Canada.
FAU - Denis, Frederic
AU  - Denis F
AUID- ORCID: https://orcid.org/0000-0002-5439-8689
AD  - Universite de Tours, Tours, France.
FAU - Ng, Roger
AU  - Ng R
AUID- ORCID: https://orcid.org/0000-0002-2808-992X
AD  - Kowloon Hospital, Hong Kong, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04445324
PT  - Journal Article
DEP - 20201218
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7752185
OTO - NOTNLM
OT  - COVID-19
OT  - COVID-19 Stress Scales
OT  - clinical recovery
OT  - feasibility
OT  - internet-based peer support groups
OT  - intervention
OT  - mental health
OT  - peer support
OT  - peer support workers
OT  - personal-civic recovery
OT  - recovery
EDAT- 2020/12/02 06:00
MHDA- 2020/12/02 06:01
CRDT- 2020/12/01 17:09
PHST- 2020/07/14 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/02 06:01 [medline]
PHST- 2020/12/01 17:09 [entrez]
AID - v9i12e22500 [pii]
AID - 10.2196/22500 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 18;9(12):e22500. doi: 10.2196/22500.


PMID- 33257495
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Randomised controlled trial of integrated trauma-focused psychotherapy for
      traumatic stress and substance use among adolescents: trial protocol.
PG  - e043742
LID - 10.1136/bmjopen-2020-043742 [doi]
AB  - INTRODUCTION: Post-traumatic stress disorder (PTSD) and substance use disorder
      frequently co-occur and tend to have their onset during adolescence. Although
      research has highlighted the importance of treating these disorders in an
      integrated fashion, there is a dearth of empirically validated integrated
      treatment options for adolescents with this comorbidity. This paper describes the
      study protocol for a randomised controlled trial (RCT) examining the efficacy of 
      an integrated trauma-focused cognitive-behavioural treatment for traumatic stress
      and substance use among adolescents (Concurrent Treatment of PTSD and Substance
      Use Using Prolonged Exposure - Adolescent (COPE-A)), relative to a supportive
      counselling control condition (Person-Centred Therapy (PCT)). METHODS AND
      ANALYSIS: A two-arm, parallel, single-blind RCT with blinded follow-up at 4 and
      12 months poststudy entry will be conducted in Sydney, Australia. Participants
      (n~100 adolescents aged 12-18 years) and their caregivers (caregiver
      participation is optional) will be allocated to undergo either COPE-A or PCT
      (allocation ratio 1:1) using minimisation. Both therapies will be delivered
      individually by project psychologists over a maximum of 16 sessions of 60-90 min 
      duration and will include provision of up to four 30 min optional caregiver
      sessions. The primary outcome will be between-group differences in change in the 
      severity of PTSD symptoms from baseline to 4-month follow-up, as measured by the 
      Clinician-Administered PTSD Scale for Children and Adolescents for DSM-5. ETHICS 
      AND DISSEMINATION: Ethical approval has been obtained from the human research
      ethics committees of the Sydney Children's Hospital Network (HREC/17/SCHN/306)
      and the University of Sydney (HREC 2018/863). Findings will be published in
      peer-reviewed journals and presented at scientific conferences. TRIAL
      REGISTRATION NUMBER: ACTRN12618000785202; Pre-reults. PROTOCOL VERSION: Version
      1, 31 July 2017.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mills, Katherine L
AU  - Mills KL
AUID- ORCID: 0000-0002-9714-1832
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia
      katherine.mills@sydney.edu.au.
FAU - Barrett, Emma
AU  - Barrett E
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Back, Sudie E
AU  - Back SE
AD  - Department of Psychiatry and Behavioral Sciences, Medical University of South
      Carolina, Charleston, South Carolina, USA.
FAU - Cobham, Vanessa E
AU  - Cobham VE
AD  - School of Psychology, The University of Queensland, Saint Lucia, Queensland,
      Australia.
AD  - Children's Health Queensland, Child and Youth Mental Health Service, Brisbane,
      Queensland, Australia.
FAU - Bendall, Sarah
AU  - Bendall S
AD  - Orygen, Parkville, Victoria, Australia.
AD  - Centre for Youth Mental Health, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Perrin, Sean
AU  - Perrin S
AD  - Department of Psychology, Lund University, Lund, Sweden.
FAU - Brady, Kathleen T
AU  - Brady KT
AD  - Department of Psychiatry and Behavioral Sciences, Medical University of South
      Carolina, Charleston, South Carolina, USA.
FAU - Ross, Joanne
AU  - Ross J
AD  - National Drug and Alcohol Research Centre, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Peach, Natalie
AU  - Peach N
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Kihas, Ivana
AU  - Kihas I
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Cassar, Joanne
AU  - Cassar J
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Schollar-Root, Olivia
AU  - Schollar-Root O
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Teesson, Maree
AU  - Teesson M
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618000785202
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Psychotherapy
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - Stress Disorders, Post-Traumatic/therapy
MH  - *Substance-Related Disorders/therapy
MH  - Treatment Outcome
PMC - PMC7705546
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *child & adolescent psychiatry
OT  - *substance misuse
COIS- Competing interests: KM is a recipient of grant funding and commissions from the 
      National Health and Medical Research Council (NHMRC), Australian Government, NSW 
      Health, Australian Rotary Health, Central Eastern Sydney Primary Health Network, 
      the Sax Institute, Paul Ramsay Foundation, icare; receives royalties from Oxford 
      University Press for the sale of the adult COPE manual; receives honorarium and
      payment for lectures, seminars and webinars; and is a member of the NSW Health
      Mental Health Review Tribunal. MT is a recipient of grant funding and commissions
      from the NHMRC, NSW Health, Sax Institute, Australian Government, Australian
      Rotary Health, Paul Ramsay Foundation and icare. She receives royalties from
      Oxford University Press for the sale of the adult COPE manual; receives
      honorarium and payment for lectures, seminars and webinars. She is a director of 
      Climate Schools Pty Ltd, a company established to distribute evidence-based
      prevention resources to schools. SEB is a recipient of grant funding from the
      National Institutes of Health (NIH), Department of Defense and Veterans Affairs; 
      receives royalties from Oxford University Press for the sale of the adult COPE
      manual; and receives honorarium and payment for lectures and grant reviews. EB is
      a recipient of grant funding from NSW Health, NHMRC, Australian Rotary Health,
      Sax Institute and icare, and receives payment for lectures, seminars and
      webinars. VC is a recipient of grant funding from the NHMRC, Australian Rotary
      Health and Children's Hospital Foundation. She receives royalties from New
      Harbinger Press for the sale of a self-help book for parents of anxious children;
      and receives honorarium and payment for lectures, seminars and marking of theses.
      She is the first author of Fear-less Triple P and may in the future receive
      royalties from the dissemination of this resource. SB is a recipient of grant
      funding from the NHMRC, Movember Foundation, The Mental Illness Research Fund,
      Australian Rotary Health and the Telstra Foundation. She receives honorarium and 
      payment for lectures, seminars and workshops. SP is a recipient of grant funding 
      from National Institutes for Health Research and charitable organisations in the 
      UK and Sweden and receives income from books/book chapters and workshops on
      cognitive-behavioural therapy for paediatric post-traumatic stress disorder and
      anxiety disorders. JR is a recipient of grant funding from the NHMRC. KTB is a
      recipient of grant funding and commissions from the NIH, the Department of
      Defense and the Veterans Administration Medical System; receives royalties from
      American Psychiatric Press; receives honorarium and payment for lectures,
      seminars and webinars. NP is a recipient of grant funding from Australian Rotary 
      Health. IK is a recipient of grant funding from Australian Rotary Health.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-043742 [pii]
AID - 10.1136/bmjopen-2020-043742 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e043742. doi: 10.1136/bmjopen-2020-043742.


PMID- 33257491
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Protocol for PD SENSORS: Parkinson's Disease Symptom Evaluation in a Naturalistic
      Setting producing Outcome measuRes using SPHERE technology. An observational
      feasibility study of multi-modal multi-sensor technology to measure symptoms and 
      activities of daily living in Parkinson's disease.
PG  - e041303
LID - 10.1136/bmjopen-2020-041303 [doi]
AB  - INTRODUCTION: The impact of disease-modifying agents on disease progression in
      Parkinson's disease is largely assessed in clinical trials using clinical rating 
      scales. These scales have drawbacks in terms of their ability to capture the
      fluctuating nature of symptoms while living in a naturalistic environment. The
      SPHERE (Sensor Platform for HEalthcare in a Residential Environment) project has 
      designed a multi-sensor platform with multimodal devices designed to allow
      continuous, relatively inexpensive, unobtrusive sensing of motor, non-motor and
      activities of daily living metrics in a home or a home-like environment. The aim 
      of this study is to evaluate how the SPHERE technology can measure aspects of
      Parkinson's disease. METHODS AND ANALYSIS: This is a small-scale feasibility and 
      acceptability study during which 12 pairs of participants (comprising a person
      with Parkinson's and a healthy control participant) will stay and live freely for
      5 days in a home-like environment embedded with SPHERE technology including
      environmental, appliance monitoring, wrist-worn accelerometry and camera sensors.
      These data will be collected alongside clinical rating scales, participant diary 
      entries and expert clinician annotations of colour video images. Machine learning
      will be used to look for a signal to discriminate between Parkinson's disease and
      control, and between Parkinson's disease symptoms 'on' and 'off' medications.
      Additional outcome measures including bradykinesia, activity level, sleep
      parameters and some activities of daily living will be explored. Acceptability of
      the technology will be evaluated qualitatively using semi-structured interviews. 
      ETHICS AND DISSEMINATION: Ethical approval has been given to commence this study;
      the results will be disseminated as widely as appropriate.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Morgan, Catherine
AU  - Morgan C
AUID- ORCID: 0000-0003-0333-2417
AD  - Translational Health Sciences, University of Bristol Medical School, Bristol, UK 
      catherine.morgan@bristol.ac.uk.
AD  - Movement Disorders Group, North Bristol NHS Trust, Avon, UK.
FAU - Craddock, Ian
AU  - Craddock I
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Tonkin, Emma L
AU  - Tonkin EL
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Kinnunen, Kirsi M
AU  - Kinnunen KM
AD  - Research and Development, IXICO, London, UK.
FAU - McNaney, Roisin
AU  - McNaney R
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Whitehouse, Sam
AU  - Whitehouse S
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Mirmehdi, Majid
AU  - Mirmehdi M
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Heidarivincheh, Farnoosh
AU  - Heidarivincheh F
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - McConville, Ryan
AU  - McConville R
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Carey, Julia
AU  - Carey J
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Horne, Alison
AU  - Horne A
AD  - Population Health Sciences, University of Bristol Medical School, Bristol, UK.
FAU - Rolinski, Michal
AU  - Rolinski M
AUID- ORCID: 0000-0003-1191-7060
AD  - Translational Health Sciences, University of Bristol Medical School, Bristol, UK.
AD  - Movement Disorders Group, North Bristol NHS Trust, Avon, UK.
FAU - Rochester, Lynn
AU  - Rochester L
AD  - Institute of Neuroscience, Newcastle University, Newcastle, UK.
AD  - NHS Foundation Trust, Newcastle Upon Tyne Hospitals, Newcastle Upon Tyne, UK.
FAU - Maetzler, Walter
AU  - Maetzler W
AD  - Department of Neurology, University Medical Center Schleswig-Holstein Campus
      Kiel, Kiel, Germany.
FAU - Matthews, Helen
AU  - Matthews H
AD  - Research Department, Cure Parkinson's Trust, London, UK.
FAU - Watson, Oliver
AU  - Watson O
AD  - Project Management, Bristol Health Partners, Bristol, UK.
FAU - Eardley, Rachel
AU  - Eardley R
AD  - School of Computer Science, Electrical and Electronic Engineering and Engineering
      Mathematics, Faculty of Engineering, University of Bristol, Bristol, UK.
FAU - Whone, Alan L
AU  - Whone AL
AD  - Translational Health Sciences, University of Bristol Medical School, Bristol, UK.
AD  - Movement Disorders Group, North Bristol NHS Trust, Avon, UK.
LA  - eng
GR  - 204813/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - Feasibility Studies
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - *Parkinson Disease/diagnosis
MH  - Symptom Assessment
MH  - Technology
PMC - PMC7705501
OTO - NOTNLM
OT  - *information technology
OT  - *parkinson's disease
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Conflicts of interests: KK is employed by IXICO, that have provided some
      financial support for the study. Their search may lead to the development of
      products which may be licensed to IXICO.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-041303 [pii]
AID - 10.1136/bmjopen-2020-041303 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e041303. doi: 10.1136/bmjopen-2020-041303.


PMID- 33257489
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Multicentre randomised phase II study of the perioperative administration of
      flurbiprofen axetil in patients with non-small cell lung cancer: study protocol
      of the FLAX Study.
PG  - e040969
LID - 10.1136/bmjopen-2020-040969 [doi]
AB  - INTRODUCTION: In patients with non-small cell lung cancer, surgical treatment
      with postoperative adjuvant chemotherapy is performed. However, the improvement
      of overall survival achieved by postoperative adjuvant chemotherapy may be
      insufficient in consideration of the deterioration of quality of life (QOL).
      Considering the relationships among surgical treatments, inflammation and
      carcinogenesis, non-steroidal anti-inflammatory drugs (NSAIDs) are a candidate
      postoperative treatment for preventing recurrence and maintaining QOL. In this
      study, we investigate the effects of the perioperative administration of
      flurbiprofen axetil on postoperative recurrence in patients with non-small cell
      lung cancer. METHODS AND ANALYSIS: This study is a multicentre, parallel group,
      open label, randomised controlled trial. Patients clinically suspected of
      non-small cell lung cancer are randomly assigned to the flurbiprofen axetil group
      or the no-NSAIDs group. A total of 420 patients (210 per group) will be
      registered. The primary analysis will evaluate the treatment effect of
      flurbiprofen axetil on postoperative recurrence. ETHICS AND DISSEMINATION: The
      study protocol was approved by the Clinical Research Review Board of Saitama
      Medical University in September 2019 (No. 192002) and will be approved by each
      institutional review board of all participating institutions before patient
      enrolment. This study complies with the latest version of the Declaration of
      Helsinki, Clinical Trial Act and related notifications. Results will be published
      in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical
      Trials (jRCTs031190167; Pre-results) (https://jrct.niph.go.jp/).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sakamaki, Kentaro
AU  - Sakamaki K
AD  - Center for Data Science, Yokohama City University, Yokohama, Japan.
FAU - Watanabe, Katsuya
AU  - Watanabe K
AUID- ORCID: 0000-0001-8898-0370
AD  - General Thoracic Surgery, National Hospital Organisation Yokohama Medical Center,
      Yokohama, Japan watanabe.katsuya.gt@mail.hosp.go.jp.
FAU - Woo, Tetsukan
AU  - Woo T
AD  - Respiratory Center, Yokohama City University Medical Center, Yokohama, Japan.
FAU - Masuda, Munetaka
AU  - Masuda M
AD  - Surgery, Yokohama City University, Yokohama, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 5GRO578KLP (Flurbiprofen)
RN  - I0OU31PUI5 (flurbiprofen axetil)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/surgery
MH  - Clinical Trials, Phase II as Topic
MH  - Flurbiprofen/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Japan
MH  - *Lung Neoplasms/drug therapy
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local/prevention & control
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7705564
OTO - NOTNLM
OT  - *anaesthesia in oncology
OT  - *respiratory tract tumours
OT  - *thoracic surgery
COIS- Competing interests: None declared.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040969 [pii]
AID - 10.1136/bmjopen-2020-040969 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040969. doi: 10.1136/bmjopen-2020-040969.


PMID- 33257488
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - The Philippine COVID-19 Outcomes: a Retrospective study Of Neurological
      manifestations and Associated symptoms (The Philippine CORONA study): a protocol 
      study.
PG  - e040944
LID - 10.1136/bmjopen-2020-040944 [doi]
AB  - INTRODUCTION: The SARS-CoV-2, virus that caused the COVID-19 global pandemic,
      possesses a neuroinvasive potential. Patients with COVID-19 infection present
      with neurological signs and symptoms aside from the usual respiratory
      affectation. Moreover, COVID-19 is associated with several neurological diseases 
      and complications, which may eventually affect clinical outcomes. OBJECTIVES: The
      Philippine COVID-19 Outcomes: a Retrospective study Of Neurological
      manifestations and Associated symptoms (The Philippine CORONA) study
      investigators will conduct a nationwide, multicentre study involving 37
      institutions that aims to determine the neurological manifestations and factors
      associated with clinical outcomes in COVID-19 infection. METHODOLOGY AND
      ANALYSIS: This is a retrospective cohort study (comparative between patients with
      and without neurological manifestations) via medical chart review involving adult
      patients with COVID-19 infection. Sample size was determined at 1342 patients.
      Demographic, clinical and neurological profiles will be obtained and summarised
      using descriptive statistics. Student's t-test for two independent samples and
      chi(2) test will be used to determine differences between distributions. HRs and 
      95% CI will be used as an outcome measure. Kaplan-Meier curves will be
      constructed to plot the time to onset of mortality (survival), respiratory
      failure, intensive care unit (ICU) admission, duration of ventilator dependence, 
      length of ICU stay and length of hospital stay. The log-rank test will be
      employed to compare the Kaplan-Meier curves. Stratified analysis will be
      performed to identify confounders and effects modifiers. To compute for adjusted 
      HR with 95% CI, crude HR of outcomes will be adjusted according to the
      prespecified possible confounders. Cox proportional regression models will be
      used to determine significant factors of outcomes. Testing for goodness of fit
      will also be done using Hosmer-Lemeshow test. Subgroup analysis will be performed
      for proven prespecified effect modifiers. The effects of missing data and
      outliers will also be evaluated in this study. ETHICS AND DISSEMINATION: This
      protocol was approved by the Single Joint Research Ethics Board of the Philippine
      Department of Health (SJREB-2020-24) and the institutional review board of the
      different study sites. The dissemination of results will be conducted through
      scientific/medical conferences and through journal publication. The lay versions 
      of the results may be provided on request. TRIAL REGISTRATION NUMBER:
      NCT04386083.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Espiritu, Adrian I
AU  - Espiritu AI
AUID- ORCID: 0000-0001-5621-1833
AD  - Department of Neurosciences, College of Medicine and Philippine General Hospital,
      University of the Philippines Manila, Manila, Philippines aiespiritu@up.edu.ph.
AD  - Department of Clinical Epidemiology, College of Medicine, University of the
      Philippines Manila, Manila, Philippines.
FAU - Sy, Marie Charmaine C
AU  - Sy MCC
AUID- ORCID: 0000-0003-1135-6400
AD  - Department of Neurosciences, College of Medicine and Philippine General Hospital,
      University of the Philippines Manila, Manila, Philippines.
FAU - Anlacan, Veeda Michelle M
AU  - Anlacan VMM
AUID- ORCID: 0000-0002-1241-8805
AD  - Department of Neurosciences, College of Medicine and Philippine General Hospital,
      University of the Philippines Manila, Manila, Philippines.
FAU - Jamora, Roland Dominic G
AU  - Jamora RDG
AUID- ORCID: 0000-0001-5317-7369
AD  - Department of Neurosciences, College of Medicine and Philippine General Hospital,
      University of the Philippines Manila, Manila, Philippines.
LA  - eng
SI  - ClinicalTrials.gov/NCT04386083
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - *COVID-19/epidemiology/mortality/virology
MH  - Case-Control Studies
MH  - Critical Care
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nervous System
MH  - Nervous System Diseases/*etiology/virology
MH  - Pandemics
MH  - Philippines
MH  - Research Design
MH  - Respiratory Insufficiency
MH  - Retrospective Studies
MH  - *SARS-CoV-2
MH  - Severity of Illness Index
MH  - Young Adult
PMC - PMC7705427
OTO - NOTNLM
OT  - *COVID-19
OT  - *adult neurology
OT  - *epidemiology
OT  - *neurology
COIS- Competing interests: None declared.
EDAT- 2020/12/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-040944 [pii]
AID - 10.1136/bmjopen-2020-040944 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040944. doi: 10.1136/bmjopen-2020-040944.


PMID- 33257487
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Evaluating the impact of a champion on implementation of the Back Skills Training
      (BeST) programme in Canada: a mixed methods feasibility study protocol.
PG  - e040834
LID - 10.1136/bmjopen-2020-040834 [doi]
AB  - INTRODUCTION: There is global recognition that low back pain (LBP) should be
      managed with a biopsychosocial approach. Previous implementation of this approach
      resulted in low uptake and highlighted the need for ongoing support. This study
      aims to explore the feasibility of (i) training and using a champion to support
      implementation, (ii) using a cluster randomised controlled trial (RCT), (iii)
      collecting patient reported outcome measures in a Canadian public healthcare
      setting and to identify contextual barriers to implementation. METHODS: A
      pragmatic cluster RCT with embedded qualitative study with physiotherapists
      treating LBP in publicly funded physiotherapy departments in Newfoundland and
      Labrador, Canada. Participants will complete a previously developed online
      training course to equip them to deliver a biopsychosocial intervention for LBP. 
      Clusters randomised to the intervention arm will receive additional support from 
      a champion. A minimum champion training package has been developed based on known
      barriers in the literature. This includes strategies to target barriers relating 
      to group-based scheduling issues, lack of managerial support, perceived patient
      factors such as addressing patient expectations for other types of treatments or 
      selecting which patients might be best suited for this intervention, and anxiety 
      about delivering something new. This package will be further codeveloped with
      study champions based on identified implementation barriers using the Behaviour
      Change Wheel. Clusters will be monitored for 6 months to assess champion and
      physiotherapist recruitment and retention, acceptability and implementation of
      the champion training, and the viability of conducting a cluster RCT in this
      setting. A purposive sample of physiotherapists will be interviewed from both
      arms. ETHICS AND DISSEMINATION: This study was approved by Newfoundland and
      Labrador Health Research Ethics Authority in December 2018. Results will be
      disseminated to academic audiences through conferences and peer reviewed
      publications; to all study participants, their clinical leads, and patients with 
      LBP. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04377529;
      Memorial University of Newfoundland Protocol Record 20190025; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hall, Amanda
AU  - Hall A
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland Faculty of 
      Medicine, St. John's, Newfoundland and Labrador, Canada amanda.hall@med.mun.ca.
FAU - Richmond, Helen
AU  - Richmond H
AUID- ORCID: 0000-0002-2149-6637
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland Faculty of 
      Medicine, St. John's, Newfoundland and Labrador, Canada.
FAU - Bursey, Krystal
AU  - Bursey K
AUID- ORCID: 0000-0002-6501-0002
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland Faculty of 
      Medicine, St. John's, Newfoundland and Labrador, Canada.
FAU - Hansen, Zara
AU  - Hansen Z
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      Oxford University, Oxford, UK.
FAU - Williamson, Esther
AU  - Williamson E
AUID- ORCID: 0000-0003-0638-0406
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      Oxford University, Oxford, UK.
FAU - Copsey, Bethan
AU  - Copsey B
AUID- ORCID: 0000-0001-9783-6549
AD  - Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Albury, Charlotte
AU  - Albury C
AD  - Primary Care Health Sciences, Oxford University, Oxford, UK.
FAU - Asghari, Shabnam
AU  - Asghari S
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland Faculty of 
      Medicine, St. John's, Newfoundland and Labrador, Canada.
FAU - Curran, Vernon
AU  - Curran V
AD  - Faculty of Medicine, Memorial University of Newfoundland, St. John's,
      Newfoundland and Labrador, Canada.
FAU - Pike, Andrea
AU  - Pike A
AUID- ORCID: 0000-0003-4020-2291
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland Faculty of 
      Medicine, St. John's, Newfoundland and Labrador, Canada.
FAU - Etchegary, Holly
AU  - Etchegary H
AD  - Faculty of Medicine, Memorial University of Newfoundland, St. John's,
      Newfoundland and Labrador, Canada.
FAU - Lamb, Sarah
AU  - Lamb S
AD  - Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04377529
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Feasibility Studies
MH  - Humans
MH  - *Low Back Pain/therapy
MH  - Newfoundland and Labrador
MH  - *Physical Therapists
MH  - Randomized Controlled Trials as Topic
PMC - PMC7705520
OTO - NOTNLM
OT  - *back pain
OT  - *change management
OT  - *education & training (see medical education & training)
OT  - *organisational development
OT  - *pain management
OT  - *primary care
COIS- Competing interests: ZH provides private training to healthcare professionals in 
      cognitive behavioural therapy.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040834 [pii]
AID - 10.1136/bmjopen-2020-040834 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040834. doi: 10.1136/bmjopen-2020-040834.


PMID- 33257486
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Effectiveness of real-time continuous glucose monitoring to improve glycaemic
      control and pregnancy outcome in patients with gestational diabetes mellitus: a
      study protocol for a randomised controlled trial.
PG  - e040498
LID - 10.1136/bmjopen-2020-040498 [doi]
AB  - INTRODUCTION: Real-time continuous glucose monitoring (rt-CGM) informs users
      about current interstitial glucose levels and allows early detection of glycaemic
      excursions and timely adaptation by behavioural change or pharmacological
      intervention. Randomised controlled studies adequately powered to evaluate the
      impact of long-term application of rt-CGM systems on the reduction of adverse
      obstetric outcomes in women with gestational diabetes (GDM) are missing. We aim
      to assess differences in the proportion of large for gestational age newborns in 
      women using rt-CGM as compared with women with self-monitored blood glucose
      (primary outcome). Rates of neonatal hypoglycaemia, caesarean section and
      shoulder dystocia are secondary outcomes. A comparison of glucose metabolism and 
      quality of life during and after pregnancy completes the scope of this study.
      METHODS AND ANALYSIS: Open-label multicentre randomised controlled trial with two
      parallel groups including 372 female patients with a recent diagnosis of GDM
      (between 24+0 until 31+6 weeks of gestation): 186 with rt-CGM (Dexcom G6) and 186
      with self-monitored blood glucose (SMBG). Women with GDM will be consecutively
      recruited and randomised to rt-CGM or control (SMBG) group after a run-in period 
      of 6-8 days. The third visit will be scheduled 8-10 days later and then every 2
      weeks. At every visit, glucose measurements will be evaluated and all patients
      will be treated according to the standard care. The control group will receive a 
      blinded CGM for 10 days between the second and third visit and between week 36+0 
      and 38+6. Cord blood will be sampled immediately after delivery. 48 hours after
      delivery neonatal biometry and maternal glycosylated haemoglobin A1c (HbA1c) will
      be assessed, and between weeks 8 and 16 after delivery all patients receive a
      re-examination of glucose metabolism including blinded CGM for 8-10 days. ETHICS 
      AND DISSEMINATION: This study received ethical approval from the main ethic
      committee in Vienna. Data will be presented at international conferences and
      published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT03981328;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huhn, Evelyn Annegret
AU  - Huhn EA
AUID- ORCID: 0000-0001-5382-1353
AD  - Department of Obstetrics and Gynaecology, University Hospital Basel, Basel,
      Switzerland.
FAU - Linder, Tina
AU  - Linder T
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Eppel, Daniel
AU  - Eppel D
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Weisshaupt, Karen
AU  - Weisshaupt K
AD  - Clinic of Obstetrics, Charite-Universitatsmedizin Berlin, Corporate Member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Klapp, Christine
AU  - Klapp C
AD  - Clinic of Obstetrics, Charite-Universitatsmedizin Berlin, Corporate Member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Schellong, Karen
AU  - Schellong K
AD  - Clinic of Obstetrics, Charite-Universitatsmedizin Berlin, Corporate Member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Henrich, Wolfgang
AU  - Henrich W
AD  - Clinic of Obstetrics, Charite-Universitatsmedizin Berlin, Corporate Member of
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of
      Health, Berlin, Germany.
FAU - Yerlikaya-Schatten, Gulen
AU  - Yerlikaya-Schatten G
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Rosicky, Ingo
AU  - Rosicky I
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Husslein, Peter
AU  - Husslein P
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Chalubinski, Kinga
AU  - Chalubinski K
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Mittlbock, Martina
AU  - Mittlbock M
AD  - Center of Medical Statistics, Informatics, and Intelligent Systems, Section for
      Clinical Biometrics, Medical University of Vienna, Vienna, Austria.
FAU - Rust, Petra
AU  - Rust P
AD  - Department of Nutritional Sciences, University of Vienna, Vienna, Austria.
FAU - Hoesli, Irene
AU  - Hoesli I
AD  - Department of Obstetrics and Gynaecology, University Hospital Basel, Basel,
      Switzerland.
FAU - Winzeler, Bettina
AU  - Winzeler B
AD  - Department of Endocrinology, Diabetology and Metabolism, University Hospital
      Basel, Basel, Switzerland.
FAU - Jendle, Johan
AU  - Jendle J
AD  - Institution of Medical Sciences, Orebro University, Orebro, Sweden.
FAU - Fehm, T
AU  - Fehm T
AD  - Department of Obstetrics and Gynaecology, Medical Faculty, Heinrich-Heine
      University Dusseldorf, Dusseldorf, Germany.
FAU - Icks, Andrea
AU  - Icks A
AD  - Institute of Health Services Research and Health Economics, Centre for Health and
      Society, Faculty of Medicine, Heinrich Heine University, Dusseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center at Heinrich-Heine University Dusseldorf, Leibniz Institute for Diabetes
      Research, Dusseldorf, Germany.
AD  - German Center for Diabetes Research, Munchen-Neuherberg, Oberschleissheim,
      Germany.
FAU - Vomhof, Markus
AU  - Vomhof M
AD  - Institute of Health Services Research and Health Economics, Centre for Health and
      Society, Faculty of Medicine, Heinrich Heine University, Dusseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center at Heinrich-Heine University Dusseldorf, Leibniz Institute for Diabetes
      Research, Dusseldorf, Germany.
AD  - German Center for Diabetes Research, Munchen-Neuherberg, Oberschleissheim,
      Germany.
FAU - Greiner, Gregory Gordon
AU  - Greiner GG
AUID- ORCID: 0000-0001-7341-0818
AD  - Institute of Health Services Research and Health Economics, Centre for Health and
      Society, Faculty of Medicine, Heinrich Heine University, Dusseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center at Heinrich-Heine University Dusseldorf, Leibniz Institute for Diabetes
      Research, Dusseldorf, Germany.
AD  - German Center for Diabetes Research, Munchen-Neuherberg, Oberschleissheim,
      Germany.
FAU - Szendrodi, Julia
AU  - Szendrodi J
AD  - German Center for Diabetes Research, Munchen-Neuherberg, Oberschleissheim,
      Germany.
AD  - Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine
      University Dusseldorf, Dusseldorf, Germany.
AD  - Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Institute for
      Diabetes Research at Heinrich-Heine University, Dusseldorf, Germany.
FAU - Roden, Michael
AU  - Roden M
AD  - German Center for Diabetes Research, Munchen-Neuherberg, Oberschleissheim,
      Germany.
AD  - Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine
      University Dusseldorf, Dusseldorf, Germany.
AD  - Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Institute for
      Diabetes Research at Heinrich-Heine University, Dusseldorf, Germany.
FAU - Tura, Andrea
AU  - Tura A
AD  - Metabolic Unit, Institute of Neuroscience, National Research Council, Padova,
      Italy.
FAU - Gobl, Christian S
AU  - Gobl CS
AD  - Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-maternal
      Medicine, Medical University of Vienna, Vienna, Austria
      christian.goebl@meduniwien.ac.at.
LA  - eng
SI  - ClinicalTrials.gov/NCT03981328
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - Cesarean Section
MH  - Diabetes Mellitus, Type 1
MH  - Diabetes Mellitus, Type 2
MH  - *Diabetes, Gestational/drug therapy
MH  - Female
MH  - Glycemic Control
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7705524
OTO - NOTNLM
OT  - *clinical trials
OT  - *diabetes in pregnancy
OT  - *fetal medicine
OT  - *maternal medicine
COIS- Competing interests: The authors declare that there are no further financial or
      personal relationships with other people or organisations that could
      inappropriately influence the work reported or the conclusions, implications or
      opinions stated.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040498 [pii]
AID - 10.1136/bmjopen-2020-040498 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040498. doi: 10.1136/bmjopen-2020-040498.


PMID- 33257485
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Feasibility of reporting results of large randomised controlled trials to
      participants: experience from the Fluoxetine Or Control Under Supervision (FOCUS)
      trial.
PG  - e040492
LID - 10.1136/bmjopen-2020-040492 [doi]
AB  - OBJECTIVES: Informing research participants of the results of studies in which
      they took part is viewed as an ethical imperative. However, there is little
      guidance in the literature about how to do this. The Fluoxetine Or Control Under 
      Supervision trial randomised 3127 patients with a recent acute stroke to 6 months
      of fluoxetine or placebo and was published in the Lancet on 5 December 2018. The 
      trial team decided to inform the participants of the results at exactly the same 
      time as the Lancet publication, and also whether they had been allocated
      fluoxetine or placebo. In this report, we describe how we informed participants
      of the results. DESIGN: In the 6-month and 12-month follow-up questionnaires, we 
      invited participants to provide an email address if they wished to be informed of
      the results of the trial. We re-opened our trial telephone helpline between 5
      December 2018 and 31 March 2019. SETTING: UK stroke services. PARTICIPANTS: 3127 
      participants were randomised. 2847 returned 6-month follow-up forms and 2703
      returned 12-month follow-up forms; the remaining participants had died (380),
      withdrawn consent or did not respond. RESULTS: Of those returning follow-up
      questionnaires, a total of 1845 email addresses were provided and a further 50
      people requested results to be sent by post. Results were sent to all email and
      postal addresses provided; 309 emails were returned unrecognised. Seventeen
      people replied, of whom three called the helpline and the rest responded by
      email. CONCLUSION: It is feasible to disseminate results of large trials to
      research participants, though only around 60% of those randomised wanted to
      receive the results. The system we developed was efficient and required very
      little resource, and could be replicated by trialists in the future. TRIAL
      REGISTRATION NUMBER: ISRCTN83290762; Post-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Mead, Gillian
AU  - Mead G
AUID- ORCID: 0000-0001-7494-2023
AD  - Geriatric Medicine, University of Edinburgh, Edinburgh, UK
      gillian.e.mead@ed.ac.uk.
FAU - Dennis, Martin
AU  - Dennis M
AD  - Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
CN  - FOCUS trial Collaboration
LA  - eng
SI  - ISRCTN/ISRCTN83290762
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 01K63SUP8D (Fluoxetine)
SB  - IM
MH  - Double-Blind Method
MH  - Electronic Mail
MH  - Feasibility Studies
MH  - Fluoxetine/*therapeutic use
MH  - Humans
MH  - *Stroke/drug therapy
PMC - PMC7705542
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *statistics & research methods
OT  - *stroke medicine
COIS- Competing interests: None declared.
IR  - Anderson R
FIR - Anderson, R
IR  - Buchanan D
FIR - Buchanan, D
IR  - Deary A
FIR - Deary, A
IR  - Drever J
FIR - Drever, J
IR  - Fraser R
FIR - Fraser, R
IR  - Graham C
FIR - Graham, C
IR  - Innes K
FIR - Innes, K
IR  - McGill C
FIR - McGill, C
IR  - Perry D
FIR - Perry, D
IR  - Walker P
FIR - Walker, P
IR  - Williams C
FIR - Williams, C
IR  - Dennis M
FIR - Dennis, Martin
IR  - Barugh A
FIR - Barugh, A
IR  - Blair G
FIR - Blair, G
IR  - Chun Y
FIR - Chun, Y
IR  - Maschauer E
FIR - Maschauer, E
IR  - Mead G
FIR - Mead, Gillian
IR  - Scott M
FIR - Scott, M
IR  - Forbes J
FIR - Forbes, J
IR  - Hackett M
FIR - Hackett, M
IR  - Hankey G
FIR - Hankey, G
IR  - House A
FIR - House, A
IR  - Lewis S
FIR - Lewis, S
IR  - Lundstrom E
FIR - Lundstrom, E
IR  - Sandercock P
FIR - Sandercock, Peter
IR  - Lewis S
FIR - Lewis, Steff
IR  - Williamson J
FIR - Williamson, Judith
IR  - Forbes J
FIR - Forbes, John
IR  - Hankey G
FIR - Hankey, Graeme
IR  - Hackett M
FIR - Hackett, Maree
IR  - Murray V
FIR - Murray, Veronica
IR  - Innes K
FIR - Innes, Karen
IR  - French R
FIR - French, Ray
IR  - Stott D
FIR - Stott, David
IR  - Burgess D
FIR - Burgess, David
IR  - Emberson J
FIR - Emberson, Jonathan
IR  - Ellis G
FIR - Ellis, Graham
IR  - Tyrrell P
FIR - Tyrrell, Pippa
IR  - Sandercock P
FIR - Sandercock, P
IR  - MacLeod M
FIR - MacLeod, M
IR  - Sullivan F
FIR - Sullivan, F
IR  - Anderson C
FIR - Anderson, C
IR  - Morales D
FIR - Morales, D
IR  - Langhorne P
FIR - Langhorne, P
IR  - Reid F
FIR - Reid, F
IR  - Rodgers H
FIR - Rodgers, H
IR  - Hunter N
FIR - Hunter, N
IR  - Parakramawansha R
FIR - Parakramawansha, R
IR  - Fazal A
FIR - Fazal, A
IR  - Taylor P
FIR - Taylor, P
IR  - Rutherford W
FIR - Rutherford, W
IR  - McCormick K
FIR - McCormick, K
IR  - Buchan R
FIR - Buchan, R
IR  - MacRaild A
FIR - MacRaild, A
IR  - Paulton R
FIR - Paulton, R
IR  - Burgess S
FIR - Burgess, S
IR  - McGowan D
FIR - McGowan, D
IR  - Skwarski J
FIR - Skwarski, J
IR  - Proudfoot F
FIR - Proudfoot, F
IR  - Murphy R
FIR - Murphy, R
IR  - Perry J
FIR - Perry, J
IR  - Bamford J
FIR - Bamford, J
IR  - Bedford C
FIR - Bedford, C
IR  - Waugh D
FIR - Waugh, D
IR  - Veraque E
FIR - Veraque, E
IR  - Kambafwile M
FIR - Kambafwile, M
IR  - Makawa L
FIR - Makawa, L
IR  - Smalley P
FIR - Smalley, P
IR  - Randall M
FIR - Randall, M
IR  - Idrovo L
FIR - Idrovo, L
IR  - Hassan A
FIR - Hassan, A
IR  - Thirugnana-Chandran T
FIR - Thirugnana-Chandran, T
IR  - Vowden R
FIR - Vowden, R
IR  - Jackson J
FIR - Jackson, J
IR  - Bhalla A
FIR - Bhalla, A
IR  - Tam C
FIR - Tam, C
IR  - Rudd A
FIR - Rudd, A
IR  - Gibbs C
FIR - Gibbs, C
IR  - Birns J
FIR - Birns, J
IR  - Lee Carbon L
FIR - Lee Carbon, L
IR  - Cattermole E
FIR - Cattermole, E
IR  - Cape A
FIR - Cape, A
IR  - Hurley L
FIR - Hurley, L
IR  - Marks K
FIR - Marks, K
IR  - Kullane S
FIR - Kullane, S
IR  - Smyth N
FIR - Smyth, N
IR  - Giallombardo E
FIR - Giallombardo, E
IR  - Eglinton C
FIR - Eglinton, C
IR  - Wilson J
FIR - Wilson, J
IR  - Dellafera D
FIR - Dellafera, D
IR  - Reidy P
FIR - Reidy, P
IR  - Pitt M
FIR - Pitt, M
IR  - Sykes L
FIR - Sykes, L
IR  - Frith A
FIR - Frith, A
IR  - Croome V
FIR - Croome, V
IR  - Duffy J
FIR - Duffy, J
IR  - Cooke D
FIR - Cooke, D
IR  - Hancevic M
FIR - Hancevic, M
IR  - Kerwood L
FIR - Kerwood, L
IR  - Narh C
FIR - Narh, C
IR  - Merritt C
FIR - Merritt, C
IR  - Willson J
FIR - Willson, J
IR  - Ali A
FIR - Ali, A
IR  - Bell S
FIR - Bell, S
IR  - Jackson T
FIR - Jackson, T
IR  - Bowler H
FIR - Bowler, H
IR  - Kamara C
FIR - Kamara, C
IR  - Naqvi A
FIR - Naqvi, A
IR  - Howe J
FIR - Howe, J
IR  - Stocks K
FIR - Stocks, K
IR  - Dunn G
FIR - Dunn, G
IR  - Endean K
FIR - Endean, K
IR  - Claydon F
FIR - Claydon, F
IR  - Duty S
FIR - Duty, S
IR  - Doyle C
FIR - Doyle, C
IR  - Harkness K
FIR - Harkness, K
IR  - Richards E
FIR - Richards, E
IR  - Meegada M
FIR - Meegada, M
IR  - Maatouk A
FIR - Maatouk, A
IR  - Barron L
FIR - Barron, L
IR  - Dakin K
FIR - Dakin, K
IR  - Lindert R
FIR - Lindert, R
IR  - Majid A
FIR - Majid, A
IR  - Rana P
FIR - Rana, P
IR  - Nair A
FIR - Nair, A
IR  - Brighouse-Johnson C
FIR - Brighouse-Johnson, C
IR  - Greig J
FIR - Greig, J
IR  - Kyu M
FIR - Kyu, M
IR  - Prasad S
FIR - Prasad, S
IR  - Robinson M
FIR - Robinson, M
IR  - Mclean B
FIR - Mclean, B
IR  - Alam I
FIR - Alam, I
IR  - Greenhalgh L
FIR - Greenhalgh, L
IR  - Ahmed Z
FIR - Ahmed, Z
IR  - Roffe C
FIR - Roffe, C
IR  - Brammer S
FIR - Brammer, S
IR  - Barry A
FIR - Barry, A
IR  - Beardmore C
FIR - Beardmore, C
IR  - Finney K
FIR - Finney, K
IR  - Maguire H
FIR - Maguire, H
IR  - Hollinshead P
FIR - Hollinshead, P
IR  - Grocott J
FIR - Grocott, J
IR  - Natarajan I
FIR - Natarajan, I
IR  - Chembala J
FIR - Chembala, J
IR  - Sanyal R
FIR - Sanyal, R
IR  - Lijko S
FIR - Lijko, S
IR  - Abano N
FIR - Abano, N
IR  - Remegoso A
FIR - Remegoso, A
IR  - Ferdinand P
FIR - Ferdinand, P
IR  - Stevens S
FIR - Stevens, S
IR  - Stephen C
FIR - Stephen, C
IR  - Whitmore P
FIR - Whitmore, P
IR  - Butler A
FIR - Butler, A
IR  - Causley C
FIR - Causley, C
IR  - Varquez R
FIR - Varquez, R
IR  - Muddegowda G
FIR - Muddegowda, G
IR  - Carpio R
FIR - Carpio, R
IR  - Hiden J
FIR - Hiden, J
IR  - Denic H
FIR - Denic, H
IR  - Sword J
FIR - Sword, J
IR  - Hall F
FIR - Hall, F
IR  - Cageao J
FIR - Cageao, J
IR  - Keenan S
FIR - Keenan, S
IR  - Curwen R
FIR - Curwen, R
IR  - James M
FIR - James, M
IR  - Mudd P
FIR - Mudd, P
IR  - Roughan C
FIR - Roughan, C
IR  - Kingwell H
FIR - Kingwell, H
IR  - Hemsley A
FIR - Hemsley, A
IR  - Lohan C
FIR - Lohan, C
IR  - Davenport S
FIR - Davenport, S
IR  - Chapter T
FIR - Chapter, T
IR  - Bowring A
FIR - Bowring, A
IR  - Hough M
FIR - Hough, M
IR  - Strain D
FIR - Strain, D
IR  - Gupwell K
FIR - Gupwell, K
IR  - Miller K
FIR - Miller, K
IR  - Goff A
FIR - Goff, A
IR  - Cusack E
FIR - Cusack, E
IR  - Todd S
FIR - Todd, S
IR  - Partridge R
FIR - Partridge, R
IR  - Jennings G
FIR - Jennings, G
IR  - Thorpe K
FIR - Thorpe, K
IR  - Stephenson J
FIR - Stephenson, J
IR  - Littlewood K
FIR - Littlewood, K
IR  - Barber M
FIR - Barber, M
IR  - Brodie F
FIR - Brodie, F
IR  - Marshall S
FIR - Marshall, S
IR  - Esson D
FIR - Esson, D
IR  - McInnes C
FIR - McInnes, C
IR  - Coburn I
FIR - Coburn, I
IR  - Ross F
FIR - Ross, F
IR  - Withers V
FIR - Withers, V
IR  - Bowie E
FIR - Bowie, E
IR  - Barcroft H
FIR - Barcroft, H
IR  - Miller L
FIR - Miller, L
IR  - Willcoxson P
FIR - Willcoxson, P
IR  - Keeling M
FIR - Keeling, M
IR  - Donninson M
FIR - Donninson, M
IR  - Evans R
FIR - Evans, R
IR  - Daniel D
FIR - Daniel, D
IR  - Coyle J
FIR - Coyle, J
IR  - Elliott M
FIR - Elliott, M
IR  - Wanklyn P
FIR - Wanklyn, P
IR  - Wightman J
FIR - Wightman, J
IR  - Iveson E
FIR - Iveson, E
IR  - Porteous A
FIR - Porteous, A
IR  - Dyer N
FIR - Dyer, N
IR  - Haritakis M
FIR - Haritakis, M
IR  - Ward M
FIR - Ward, M
IR  - Wright L
FIR - Wright, L
IR  - Bell J
FIR - Bell, J
IR  - Emms C
FIR - Emms, C
IR  - Wood P
FIR - Wood, P
IR  - Cottrell P
FIR - Cottrell, P
IR  - Doughty L
FIR - Doughty, L
IR  - Carr L
FIR - Carr, L
IR  - Anazodo C
FIR - Anazodo, C
IR  - Neill MO
FIR - Neill, M O
IR  - Westmoreland J
FIR - Westmoreland, J
IR  - Rodriguez R
FIR - Rodriguez, R
IR  - Mir R
FIR - Mir, R
IR  - Donne C
FIR - Donne, C
IR  - Bamford E
FIR - Bamford, E
IR  - Clark Brown P
FIR - Clark Brown, P
IR  - Stanners A
FIR - Stanners, A
IR  - Ghouri I
FIR - Ghouri, I
IR  - Needle A
FIR - Needle, A
IR  - Eastwood M
FIR - Eastwood, M
IR  - Carpenter M
FIR - Carpenter, M
IR  - Datta P
FIR - Datta, P
IR  - Davey R
FIR - Davey, R
IR  - Razik F
FIR - Razik, F
IR  - Bateman G
FIR - Bateman, G
IR  - Archer J
FIR - Archer, J
IR  - Balasubramanian V
FIR - Balasubramanian, V
IR  - Jackson L
FIR - Jackson, L
IR  - Benton L
FIR - Benton, L
IR  - Ball J
FIR - Ball, J
IR  - Bowers R
FIR - Bowers, R
IR  - Ellam J
FIR - Ellam, J
IR  - Norton K
FIR - Norton, K
IR  - Guyler P
FIR - Guyler, P
IR  - Tysoe S
FIR - Tysoe, S
IR  - Harman P
FIR - Harman, P
IR  - Kundu A
FIR - Kundu, A
IR  - Dowling T
FIR - Dowling, T
IR  - Chandler S
FIR - Chandler, S
IR  - Omodunbi O
FIR - Omodunbi, O
IR  - Loganathan T
FIR - Loganathan, T
IR  - Noor S
FIR - Noor, S
IR  - Kunhunny S
FIR - Kunhunny, S
IR  - Sinha D
FIR - Sinha, D
IR  - Siddiqui A
FIR - Siddiqui, A
IR  - Sheppard M
FIR - Sheppard, M
IR  - Shah S
FIR - Shah, S
IR  - Kelavkar S
FIR - Kelavkar, S
IR  - Ng K
FIR - Ng, K
IR  - Wilson L
FIR - Wilson, L
IR  - Ropun A
FIR - Ropun, A
IR  - Kamuriwo L
FIR - Kamuriwo, L
IR  - Orath Prabakaran R
FIR - Orath Prabakaran, R
IR  - France E
FIR - France, E
IR  - Rashmi S
FIR - Rashmi, S
IR  - Mangion D
FIR - Mangion, D
IR  - Constantin C
FIR - Constantin, C
IR  - Markova S
FIR - Markova, S
IR  - Hardwick A
FIR - Hardwick, A
IR  - Borley J
FIR - Borley, J
IR  - De Michele Hock L
FIR - De Michele Hock, L
IR  - Lawrence T
FIR - Lawrence, T
IR  - Fletcher J
FIR - Fletcher, J
IR  - Netherton K
FIR - Netherton, K
IR  - Spencer R
FIR - Spencer, R
IR  - Palmer H
FIR - Palmer, H
IR  - Soliman M
FIR - Soliman, M
IR  - Leach S
FIR - Leach, S
IR  - Sharma J
FIR - Sharma, J
IR  - Brown R
FIR - Brown, R
IR  - Taylor C
FIR - Taylor, C
IR  - Wahishi I
FIR - Wahishi, I
IR  - Arif S
FIR - Arif, S
IR  - Fields A
FIR - Fields, A
IR  - Butler S
FIR - Butler, S
IR  - Hindle J
FIR - Hindle, J
IR  - Watson E
FIR - Watson, E
IR  - Hewitt C
FIR - Hewitt, C
IR  - Cullen C
FIR - Cullen, C
IR  - Hamill D
FIR - Hamill, D
IR  - Mellor Z
FIR - Mellor, Z
IR  - Fluskey T
FIR - Fluskey, T
IR  - Hankin V
FIR - Hankin, V
IR  - Keeling A
FIR - Keeling, A
IR  - Durairaj R
FIR - Durairaj, R
IR  - Wood D
FIR - Wood, D
IR  - Peters J
FIR - Peters, J
IR  - Shackcloth D
FIR - Shackcloth, D
IR  - Tangney R
FIR - Tangney, R
IR  - Hlaing T
FIR - Hlaing, T
IR  - Sutton V
FIR - Sutton, V
IR  - Harrison M
FIR - Harrison, M
IR  - Stevenson S
FIR - Stevenson, S
IR  - Ewing J
FIR - Ewing, J
IR  - Patterson C
FIR - Patterson, C
IR  - Price J
FIR - Price, J
IR  - Wilson H
FIR - Wilson, H
IR  - Ramadan H
FIR - Ramadan, H
IR  - Maguire S
FIR - Maguire, S
IR  - Khan S
FIR - Khan, S
IR  - Bellfield R
FIR - Bellfield, R
IR  - Hamid U
FIR - Hamid, U
IR  - Hooley M
FIR - Hooley, M
IR  - Ghulam R
FIR - Ghulam, R
IR  - Masters L
FIR - Masters, L
IR  - Gaba W
FIR - Gaba, W
IR  - Quinn O
FIR - Quinn, O
IR  - Sekaran L
FIR - Sekaran, L
IR  - Tate M
FIR - Tate, M
IR  - Mohammed N
FIR - Mohammed, N
IR  - Sethuraman S
FIR - Sethuraman, S
IR  - Alwis L
FIR - Alwis, L
IR  - Robinson R
FIR - Robinson, R
IR  - Bharaj K
FIR - Bharaj, K
IR  - Pattni R
FIR - Pattni, R
IR  - Justin F
FIR - Justin, F
IR  - Tam C
FIR - Tam, C
IR  - Chauhan M
FIR - Chauhan, M
IR  - Eldridge L
FIR - Eldridge, L
IR  - Mintias S
FIR - Mintias, S
IR  - Palmones J
FIR - Palmones, J
IR  - Holmes C
FIR - Holmes, C
IR  - Guthrie L
FIR - Guthrie, L
IR  - Murphy P
FIR - Murphy, P
IR  - Devitt N
FIR - Devitt, N
IR  - Leonard J
FIR - Leonard, J
IR  - Osborn M
FIR - Osborn, M
IR  - Ball L
FIR - Ball, L
IR  - Steele A
FIR - Steele, A
IR  - Dodd E
FIR - Dodd, E
IR  - Holloway A
FIR - Holloway, A
IR  - Baker P
FIR - Baker, P
IR  - Patel R
FIR - Patel, R
IR  - Penwarden I
FIR - Penwarden, I
IR  - Caine S
FIR - Caine, S
IR  - Clarke S
FIR - Clarke, S
IR  - Dow L
FIR - Dow, L
IR  - Williams S
FIR - Williams, S
IR  - Wynn-Williams R
FIR - Wynn-Williams, R
IR  - Kennedy J
FIR - Kennedy, J
IR  - DeVeciana A
FIR - DeVeciana, A
IR  - Mathieson P
FIR - Mathieson, P
IR  - Reckless I
FIR - Reckless, I
IR  - Teal R
FIR - Teal, R
IR  - Schulz U
FIR - Schulz, U
IR  - Ford G
FIR - Ford, G
IR  - Mccann P
FIR - Mccann, P
IR  - Cluckie G
FIR - Cluckie, G
IR  - Howell G
FIR - Howell, G
IR  - Ayer J
FIR - Ayer, J
IR  - Moynihan B
FIR - Moynihan, B
IR  - Ghatala R
FIR - Ghatala, R
IR  - Clarke B
FIR - Clarke, B
IR  - Cloud G
FIR - Cloud, G
IR  - Patel B
FIR - Patel, B
IR  - Khan U
FIR - Khan, U
IR  - Al-Samarrai N
FIR - Al-Samarrai, N
IR  - Watson F
FIR - Watson, F
IR  - Adedoyin T
FIR - Adedoyin, T
IR  - Trippier S
FIR - Trippier, S
IR  - Chopra N
FIR - Chopra, N
IR  - Zhang L
FIR - Zhang, L
IR  - Choy L
FIR - Choy, L
IR  - Kennedy K
FIR - Kennedy, K
IR  - Williams R
FIR - Williams, R
IR  - Jones V
FIR - Jones, V
IR  - Clarke N
FIR - Clarke, N
IR  - Dainty A
FIR - Dainty, A
IR  - Blight A
FIR - Blight, A
IR  - Selvarajah J
FIR - Selvarajah, J
IR  - Smith W
FIR - Smith, W
IR  - Moreton F
FIR - Moreton, F
IR  - Welch A
FIR - Welch, A
IR  - Kalladka D
FIR - Kalladka, D
IR  - Cheripelli B
FIR - Cheripelli, B
IR  - Douglas E
FIR - Douglas, E
IR  - Lush A
FIR - Lush, A
IR  - Huang X
FIR - Huang, X
IR  - El Tawil S
FIR - El Tawil, S
IR  - Day N
FIR - Day, N
IR  - Montgomery K
FIR - Montgomery, K
IR  - Hamilton H
FIR - Hamilton, H
IR  - Ritchie D
FIR - Ritchie, D
IR  - Ramachandra S
FIR - Ramachandra, S
IR  - McLeish K
FIR - McLeish, K
IR  - Cohen D
FIR - Cohen, D
IR  - Badiani B
FIR - Badiani, B
IR  - Abdul-Saheb M
FIR - Abdul-Saheb, M
IR  - Chamberlain A
FIR - Chamberlain, A
IR  - Mpelembue M
FIR - Mpelembue, M
IR  - Bathula R
FIR - Bathula, R
IR  - Lang M
FIR - Lang, M
IR  - Devine J
FIR - Devine, J
IR  - Southworth L
FIR - Southworth, L
IR  - Burgess L
FIR - Burgess, L
IR  - Epie N
FIR - Epie, N
IR  - David A
FIR - David, A
IR  - Owoyele E
FIR - Owoyele, E
IR  - Guo F
FIR - Guo, F
IR  - Oshodi A
FIR - Oshodi, A
IR  - Sudkeo V
FIR - Sudkeo, V
IR  - Thavanesan K
FIR - Thavanesan, K
IR  - Tiwari D
FIR - Tiwari, D
IR  - Ovington C
FIR - Ovington, C
IR  - Rogers E
FIR - Rogers, E
IR  - Bower R
FIR - Bower, R
IR  - Hann G
FIR - Hann, G
IR  - Longland B
FIR - Longland, B
IR  - David O
FIR - David, O
IR  - Hogan A
FIR - Hogan, A
IR  - Loganathan S
FIR - Loganathan, S
IR  - Roberts J
FIR - Roberts, J
IR  - Cox C
FIR - Cox, C
IR  - Orr S
FIR - Orr, S
IR  - Keltos M
FIR - Keltos, M
IR  - Rashed K
FIR - Rashed, K
IR  - Williams-Yesson B
FIR - Williams-Yesson, B
IR  - Board J
FIR - Board, J
IR  - De Bruijn S
FIR - De Bruijn, S
IR  - Buckley C
FIR - Buckley, C
IR  - Vickers C
FIR - Vickers, C
IR  - Board S
FIR - Board, S
IR  - Allison J
FIR - Allison, J
IR  - Keeling E
FIR - Keeling, E
IR  - Duckett T
FIR - Duckett, T
IR  - Donaldson D
FIR - Donaldson, D
IR  - Barron C
FIR - Barron, C
IR  - Balian L
FIR - Balian, L
IR  - Edwards A
FIR - Edwards, A
IR  - England T
FIR - England, T
IR  - Hedstrom A
FIR - Hedstrom, A
IR  - Bedford E
FIR - Bedford, E
IR  - Harper M
FIR - Harper, M
IR  - Melikyan E
FIR - Melikyan, E
IR  - Abbott W
FIR - Abbott, W
IR  - Subramanian K
FIR - Subramanian, K
IR  - Goldsworthy M
FIR - Goldsworthy, M
IR  - Srinivasan M
FIR - Srinivasan, M
IR  - Mukherjee I
FIR - Mukherjee, I
IR  - Ghani U
FIR - Ghani, U
IR  - Yeomans A
FIR - Yeomans, A
IR  - Hurford F
FIR - Hurford, F
IR  - Chapman R
FIR - Chapman, R
IR  - Shahzad S
FIR - Shahzad, S
IR  - Motherwell N
FIR - Motherwell, N
IR  - Tonks L
FIR - Tonks, L
IR  - Young R
FIR - Young, R
IR  - Dutta D
FIR - Dutta, D
IR  - Brown P
FIR - Brown, P
IR  - Davis F
FIR - Davis, F
IR  - Ward D
FIR - Ward, D
IR  - Turfrey J
FIR - Turfrey, J
IR  - Obaid M
FIR - Obaid, M
IR  - Cartwright B
FIR - Cartwright, B
IR  - Topia B
FIR - Topia, B
IR  - Spurway J
FIR - Spurway, J
IR  - Hughes C
FIR - Hughes, C
IR  - Hill L
FIR - Hill, L
IR  - OConnell S
FIR - OConnell, S
IR  - Collins K
FIR - Collins, K
IR  - Bakawala R
FIR - Bakawala, R
IR  - Chatterjee K
FIR - Chatterjee, K
IR  - Webster T
FIR - Webster, T
IR  - Haider S
FIR - Haider, S
IR  - Rushworth P
FIR - Rushworth, P
IR  - Macleod F
FIR - Macleod, F
IR  - Perkins C
FIR - Perkins, C
IR  - Nallasivan A
FIR - Nallasivan, A
IR  - Burns E
FIR - Burns, E
IR  - Leason S
FIR - Leason, S
IR  - Carter T
FIR - Carter, T
IR  - Seagrave S
FIR - Seagrave, S
IR  - Sami E
FIR - Sami, E
IR  - Parkinson S
FIR - Parkinson, S
IR  - Hassan M
FIR - Hassan, M
IR  - Naqvi S
FIR - Naqvi, S
IR  - Armstrong L
FIR - Armstrong, L
IR  - Mawer S
FIR - Mawer, S
IR  - Darnbrook G
FIR - Darnbrook, G
IR  - Booth C
FIR - Booth, C
IR  - Hairsine B
FIR - Hairsine, B
IR  - Smith M
FIR - Smith, M
IR  - Williamson S
FIR - Williamson, S
IR  - Farquhar F
FIR - Farquhar, F
IR  - Esisi B
FIR - Esisi, B
IR  - Cassidy T
FIR - Cassidy, T
IR  - McClelland B
FIR - McClelland, B
IR  - Mankin G
FIR - Mankin, G
IR  - Bokhari M
FIR - Bokhari, M
IR  - Sproates D
FIR - Sproates, D
IR  - Epstein E
FIR - Epstein, E
IR  - Blackburn R
FIR - Blackburn, R
IR  - Hurdowar S
FIR - Hurdowar, S
IR  - Sukhdeep N
FIR - Sukhdeep, N
IR  - Razak S
FIR - Razak, S
IR  - Upton N
FIR - Upton, N
IR  - Hashmi A
FIR - Hashmi, A
IR  - Osman K
FIR - Osman, K
IR  - Fotherby K
FIR - Fotherby, K
IR  - Willberry A
FIR - Willberry, A
IR  - Morgan D
FIR - Morgan, D
IR  - Sahota G
FIR - Sahota, G
IR  - Jennings-Preece K
FIR - Jennings-Preece, K
IR  - Butler D
FIR - Butler, D
IR  - Das S
FIR - Das, S
IR  - Stevens A
FIR - Stevens, A
IR  - Ahmad N
FIR - Ahmad, N
IR  - Kauldhar K
FIR - Kauldhar, K
IR  - Harrington F
FIR - Harrington, F
IR  - Mate A
FIR - Mate, A
IR  - Skewes J
FIR - Skewes, J
IR  - Adie K
FIR - Adie, K
IR  - Bond K
FIR - Bond, K
IR  - Courtauld G
FIR - Courtauld, G
IR  - Schofield C
FIR - Schofield, C
IR  - Lucas L
FIR - Lucas, L
IR  - James A
FIR - James, A
IR  - Ellis S
FIR - Ellis, S
IR  - Maund B
FIR - Maund, B
IR  - Allsop L
FIR - Allsop, L
IR  - Brodie C
FIR - Brodie, C
IR  - Johnson M
FIR - Johnson, M
IR  - Driver E
FIR - Driver, E
IR  - Harris K
FIR - Harris, K
IR  - Drake M
FIR - Drake, M
IR  - Moore K
FIR - Moore, K
IR  - Thomas E
FIR - Thomas, E
IR  - Burn M
FIR - Burn, M
IR  - Hamilton A
FIR - Hamilton, A
IR  - Mahalingam S
FIR - Mahalingam, S
IR  - Benford A
FIR - Benford, A
IR  - Hilton D
FIR - Hilton, D
IR  - Misra A
FIR - Misra, A
IR  - Hazell L
FIR - Hazell, L
IR  - Ofori K
FIR - Ofori, K
IR  - Mathew M
FIR - Mathew, M
IR  - Thomas A
FIR - Thomas, A
IR  - Dayal S
FIR - Dayal, S
IR  - Burn I
FIR - Burn, I
IR  - Bruce D
FIR - Bruce, D
IR  - Naeem M
FIR - Naeem, M
IR  - Burnip R
FIR - Burnip, R
IR  - Hayman R
FIR - Hayman, R
IR  - Earnshaw P
FIR - Earnshaw, P
IR  - Brown E
FIR - Brown, E
IR  - Clayton S
FIR - Clayton, S
IR  - Gamble P
FIR - Gamble, P
IR  - Dima S
FIR - Dima, S
IR  - Dhakal M
FIR - Dhakal, M
IR  - Rogers G
FIR - Rogers, G
IR  - Stephenson L
FIR - Stephenson, L
IR  - Nendick R
FIR - Nendick, R
IR  - Pai Y
FIR - Pai, Y
IR  - Nyo K
FIR - Nyo, K
IR  - Cvoro V
FIR - Cvoro, V
IR  - Couser M
FIR - Couser, M
IR  - Simpson M
FIR - Simpson, M
IR  - Tachtatzis A
FIR - Tachtatzis, A
IR  - Ullah K
FIR - Ullah, K
IR  - Cain R
FIR - Cain, R
IR  - Chapman N
FIR - Chapman, N
IR  - Pound S
FIR - Pound, S
IR  - McAuley S
FIR - McAuley, S
IR  - Hargroves D
FIR - Hargroves, D
IR  - Ransom B
FIR - Ransom, B
IR  - Mears K
FIR - Mears, K
IR  - Griffiths K
FIR - Griffiths, K
IR  - Cowie L
FIR - Cowie, L
IR  - Hammond T
FIR - Hammond, T
IR  - Webb T
FIR - Webb, T
IR  - Balogun I
FIR - Balogun, I
IR  - Rudenko H
FIR - Rudenko, H
IR  - Thomson A
FIR - Thomson, A
IR  - Ceccarelli D
FIR - Ceccarelli, D
IR  - Gillian A
FIR - Gillian, A
IR  - Beranova E
FIR - Beranova, E
IR  - Verrion A
FIR - Verrion, A
IR  - Chattha N
FIR - Chattha, N
IR  - Schumacher N
FIR - Schumacher, N
IR  - Bahk A
FIR - Bahk, A
IR  - Walker S
FIR - Walker, S
IR  - Sims D
FIR - Sims, D
IR  - Jones R
FIR - Jones, R
IR  - Smith J
FIR - Smith, J
IR  - Tongue R
FIR - Tongue, R
IR  - Willmot M
FIR - Willmot, M
IR  - Sutton C
FIR - Sutton, C
IR  - Littleton E
FIR - Littleton, E
IR  - Khaira J
FIR - Khaira, J
IR  - Maiden S
FIR - Maiden, S
IR  - Cunningham J
FIR - Cunningham, J
IR  - Chin Y
FIR - Chin, Y
IR  - Green C
FIR - Green, C
IR  - Bates M
FIR - Bates, M
IR  - Ahlquist K
FIR - Ahlquist, K
IR  - Kane I
FIR - Kane, I
IR  - Breeds J
FIR - Breeds, J
IR  - Sargent T
FIR - Sargent, T
IR  - Latter L
FIR - Latter, L
IR  - Pitt Ford A
FIR - Pitt Ford, A
IR  - Levett T
FIR - Levett, T
IR  - Gainsborough N
FIR - Gainsborough, N
IR  - Thompson P
FIR - Thompson, P
IR  - Dunne A
FIR - Dunne, A
IR  - Barbon E
FIR - Barbon, E
IR  - Hervey S
FIR - Hervey, S
IR  - Ragab S
FIR - Ragab, S
IR  - Sandell T
FIR - Sandell, T
IR  - Dickson C
FIR - Dickson, C
IR  - Power S
FIR - Power, S
IR  - Dube J
FIR - Dube, J
IR  - Evans N
FIR - Evans, N
IR  - Wadams B
FIR - Wadams, B
IR  - Elitova S
FIR - Elitova, S
IR  - Aubrey B
FIR - Aubrey, B
IR  - Garcia T
FIR - Garcia, T
IR  - Mcilmoyle J
FIR - Mcilmoyle, J
IR  - Ahmed A
FIR - Ahmed, A
IR  - Dickinson C
FIR - Dickinson, C
IR  - Jeffs C
FIR - Jeffs, C
IR  - Dhar S
FIR - Dhar, S
IR  - Jones K
FIR - Jones, K
IR  - Howard J
FIR - Howard, J
IR  - Armer C
FIR - Armer, C
IR  - Frudd J
FIR - Frudd, J
IR  - Kumar S
FIR - Kumar, S
IR  - Potter A
FIR - Potter, A
IR  - Donaldson S
FIR - Donaldson, S
IR  - Collas D
FIR - Collas, D
IR  - Sundayi S
FIR - Sundayi, S
IR  - Denham L
FIR - Denham, L
IR  - Oza D
FIR - Oza, D
IR  - Walker E
FIR - Walker, E
IR  - Bhandari M
FIR - Bhandari, M
IR  - Ispoglou S
FIR - Ispoglou, S
IR  - Sharobeem K
FIR - Sharobeem, K
IR  - Hayes A
FIR - Hayes, A
IR  - Howard-Brown J
FIR - Howard-Brown, J
IR  - Walton E
FIR - Walton, E
IR  - Shanu S
FIR - Shanu, S
IR  - Billingham S
FIR - Billingham, S
IR  - Weir N
FIR - Weir, N
IR  - Howard G
FIR - Howard, G
IR  - Wood E
FIR - Wood, E
IR  - Pressly V
FIR - Pressly, V
IR  - Crawford P
FIR - Crawford, P
IR  - Burton H
FIR - Burton, H
IR  - Walters A
FIR - Walters, A
IR  - Marigold J
FIR - Marigold, J
IR  - Said R
FIR - Said, R
IR  - Allen C
FIR - Allen, C
IR  - Evans S
FIR - Evans, S
IR  - Egerton S
FIR - Egerton, S
IR  - Hakkak J
FIR - Hakkak, J
IR  - Andrews J
FIR - Andrews, J
IR  - Lampard R
FIR - Lampard, R
IR  - Smith S
FIR - Smith, S
IR  - Tsang S
FIR - Tsang, S
IR  - Creeden R
FIR - Creeden, R
IR  - Gartrell I
FIR - Gartrell, I
IR  - Smith F
FIR - Smith, F
IR  - Jenkins C
FIR - Jenkins, C
IR  - Price F
FIR - Price, F
IR  - Pryor J
FIR - Pryor, J
IR  - Hedges A
FIR - Hedges, A
IR  - Moseley L
FIR - Moseley, L
IR  - Mercer L
FIR - Mercer, L
IR  - Warburton E
FIR - Warburton, E
IR  - Handley D
FIR - Handley, D
IR  - Finlay S
FIR - Finlay, S
IR  - Hannon N
FIR - Hannon, N
IR  - Espanol A
FIR - Espanol, A
IR  - Kelly S
FIR - Kelly, S
IR  - Mcgee J
FIR - Mcgee, J
IR  - Markus H
FIR - Markus, H
IR  - Chandrasena D
FIR - Chandrasena, D
IR  - Sesay J
FIR - Sesay, J
IR  - Hayden D
FIR - Hayden, D
IR  - Hayhoe H
FIR - Hayhoe, H
IR  - Macdonald J
FIR - Macdonald, J
IR  - Bolton M
FIR - Bolton, M
IR  - Mitchell J
FIR - Mitchell, J
IR  - Farron C
FIR - Farron, C
IR  - Amis E
FIR - Amis, E
IR  - Day D
FIR - Day, D
IR  - Culbert A
FIR - Culbert, A
IR  - Whitehead L
FIR - Whitehead, L
IR  - Crisp S
FIR - Crisp, S
IR  - Francis J
FIR - Francis, J
IR  - OConnell J
FIR - OConnell, J
IR  - Osborne E
FIR - Osborne, E
IR  - Beard R
FIR - Beard, R
IR  - Corrigan P
FIR - Corrigan, P
IR  - Smith A
FIR - Smith, A
IR  - Edwards M
FIR - Edwards, M
IR  - Mokoena L
FIR - Mokoena, L
IR  - Sattar N
FIR - Sattar, N
IR  - Myint M
FIR - Myint, M
IR  - Krishnamurthy R
FIR - Krishnamurthy, R
IR  - Azim A
FIR - Azim, A
IR  - Whitworth S
FIR - Whitworth, S
IR  - Nicolson A
FIR - Nicolson, A
IR  - Alam S
FIR - Alam, S
IR  - White J
FIR - White, J
IR  - Krasinska-Chavez M
FIR - Krasinska-Chavez, M
IR  - Imam J
FIR - Imam, J
IR  - Chaplin S
FIR - Chaplin, S
IR  - Singh D
FIR - Singh, D
IR  - Curtis J
FIR - Curtis, J
IR  - Wood L
FIR - Wood, L
IR  - McGowan D
FIR - McGowan, D
IR  - Byrne A
FIR - Byrne, A
IR  - McGhee C
FIR - McGhee, C
IR  - Smart A
FIR - Smart, A
IR  - Donaldson F
FIR - Donaldson, F
IR  - Blackburn J
FIR - Blackburn, J
IR  - Copeland C
FIR - Copeland, C
IR  - Scott R
FIR - Scott, R
IR  - Fitzsimmons P
FIR - Fitzsimmons, P
IR  - Fletcher G
FIR - Fletcher, G
IR  - Manoj A
FIR - Manoj, A
IR  - Cox P
FIR - Cox, P
IR  - Trainor L
FIR - Trainor, L
IR  - Lopez P
FIR - Lopez, P
IR  - Wilkinson M
FIR - Wilkinson, M
IR  - Denny L
FIR - Denny, L
IR  - Kavanagh K
FIR - Kavanagh, K
IR  - Allsop H
FIR - Allsop, H
IR  - Sukys U
FIR - Sukys, U
IR  - Valentine S
FIR - Valentine, S
IR  - Jarrett D
FIR - Jarrett, D
IR  - Dodsworth K
FIR - Dodsworth, K
IR  - Wands M
FIR - Wands, M
IR  - Watkinson C
FIR - Watkinson, C
IR  - Golding W
FIR - Golding, W
IR  - Khan N
FIR - Khan, N
IR  - Tandy J
FIR - Tandy, J
IR  - Butler R
FIR - Butler, R
IR  - Yip K
FIR - Yip, K
IR  - James C
FIR - James, C
IR  - Davies Y
FIR - Davies, Y
IR  - Williams M
FIR - Williams, M
IR  - Suttling A
FIR - Suttling, A
IR  - Nagaratnam K
FIR - Nagaratnam, K
IR  - Mannava N
FIR - Mannava, N
IR  - Haque N
FIR - Haque, N
IR  - Shields N
FIR - Shields, N
IR  - Preston K
FIR - Preston, K
IR  - Mason G
FIR - Mason, G
IR  - Short K
FIR - Short, K
IR  - Uitenbosch G
FIR - Uitenbosch, G
IR  - Lumsdale G
FIR - Lumsdale, G
IR  - Emsley H
FIR - Emsley, H
IR  - Sultan S
FIR - Sultan, S
IR  - Walmsley B
FIR - Walmsley, B
IR  - Ahmed S
FIR - Ahmed, S
IR  - Doyle D
FIR - Doyle, D
IR  - McLoughlin A
FIR - McLoughlin, A
IR  - Hough L
FIR - Hough, L
IR  - Gregary B
FIR - Gregary, B
IR  - Raj S
FIR - Raj, S
IR  - Maney A
FIR - Maney, A
IR  - Blane S
FIR - Blane, S
IR  - Gamble G
FIR - Gamble, G
IR  - Hague A
FIR - Hague, A
IR  - Charles B
FIR - Charles, B
IR  - Duran B
FIR - Duran, B
IR  - Lambert C
FIR - Lambert, C
IR  - Stagg K
FIR - Stagg, K
IR  - Whiting R
FIR - Whiting, R
IR  - Brown S
FIR - Brown, S
IR  - Hussain M
FIR - Hussain, M
IR  - Harvey M
FIR - Harvey, M
IR  - Homan J
FIR - Homan, J
IR  - Foote L
FIR - Foote, L
IR  - Graham L
FIR - Graham, L
IR  - Lane C
FIR - Lane, C
IR  - Kemp L
FIR - Kemp, L
IR  - Rowe J
FIR - Rowe, J
IR  - Durman H
FIR - Durman, H
IR  - Brotherton L
FIR - Brotherton, L
IR  - Hunt N
FIR - Hunt, N
IR  - Foot J
FIR - Foot, J
IR  - Whitcher A
FIR - Whitcher, A
IR  - Pawley C
FIR - Pawley, C
IR  - Sutton P
FIR - Sutton, P
IR  - Mcdonald S
FIR - Mcdonald, S
IR  - Pak D
FIR - Pak, D
IR  - Wiltshire A
FIR - Wiltshire, A
IR  - Balami J
FIR - Balami, J
IR  - Self C
FIR - Self, C
IR  - Jagger J
FIR - Jagger, J
IR  - Metcalf A
FIR - Metcalf, A
IR  - Healey G
FIR - Healey, G
IR  - Crofts M
FIR - Crofts, M
IR  - Chakrabarti A
FIR - Chakrabarti, A
IR  - Hmu C
FIR - Hmu, C
IR  - Keshet-Price J
FIR - Keshet-Price, J
IR  - Ravenhill G
FIR - Ravenhill, G
IR  - Grimmer C
FIR - Grimmer, C
IR  - Soe T
FIR - Soe, T
IR  - Potter I
FIR - Potter, I
IR  - Tam P
FIR - Tam, P
IR  - Langley M
FIR - Langley, M
IR  - Cooper P
FIR - Cooper, P
IR  - Christie M
FIR - Christie, M
IR  - Irvine J
FIR - Irvine, J
IR  - Joyson A
FIR - Joyson, A
IR  - Annison F
FIR - Annison, F
IR  - Christie D
FIR - Christie, D
IR  - Meneses C
FIR - Meneses, C
IR  - Johnson A
FIR - Johnson, A
IR  - Nelson S
FIR - Nelson, S
IR  - Taylor V
FIR - Taylor, V
IR  - Furnace J
FIR - Furnace, J
IR  - Gow H
FIR - Gow, H
IR  - Reid J
FIR - Reid, J
IR  - Clarke R
FIR - Clarke, R
IR  - Abousleiman Y
FIR - Abousleiman, Y
IR  - Bloom S
FIR - Bloom, S
IR  - Goshawk S
FIR - Goshawk, S
IR  - Purcell J
FIR - Purcell, J
IR  - Beadling T
FIR - Beadling, T
IR  - Collins S
FIR - Collins, S
IR  - Jones S
FIR - Jones, S
IR  - Sangaralingham S
FIR - Sangaralingham, S
IR  - Munuswamy Vaiyapuri E
FIR - Munuswamy Vaiyapuri, E
IR  - Landicho M
FIR - Landicho, M
IR  - Begum Y
FIR - Begum, Y
IR  - Mutton S
FIR - Mutton, S
IR  - Allen J
FIR - Allen, J
IR  - Lowe J
FIR - Lowe, J
IR  - Hughes M
FIR - Hughes, M
IR  - Wiggam I
FIR - Wiggam, I
IR  - Tauro S
FIR - Tauro, S
IR  - Cuddy S
FIR - Cuddy, S
IR  - Wells B
FIR - Wells, B
IR  - Mohd Nor A
FIR - Mohd Nor, A
IR  - Persad N
FIR - Persad, N
IR  - Kalita M
FIR - Kalita, M
IR  - Weinling M
FIR - Weinling, M
IR  - Weatherby S
FIR - Weatherby, S
IR  - Lashley D
FIR - Lashley, D
IR  - Pace A
FIR - Pace, A
IR  - Brown C
FIR - Brown, C
IR  - Mucha A
FIR - Mucha, A
IR  - Shah A
FIR - Shah, A
IR  - Baker J
FIR - Baker, J
IR  - Marner M
FIR - Marner, M
IR  - Westcott J
FIR - Westcott, J
IR  - Wilmshurst N
FIR - Wilmshurst, N
IR  - Cowan R
FIR - Cowan, R
IR  - Chadha D
FIR - Chadha, D
IR  - Fairweather M
FIR - Fairweather, M
IR  - Walstow D
FIR - Walstow, D
IR  - Fong R
FIR - Fong, R
IR  - Krishnan M
FIR - Krishnan, M
IR  - Thompson Jones H
FIR - Thompson Jones, H
IR  - Lynda C
FIR - Lynda, C
IR  - Clements C
FIR - Clements, C
IR  - Anjum T
FIR - Anjum, T
IR  - Sharon S
FIR - Sharon, S
IR  - Lynne D
FIR - Lynne, D
IR  - Thomas L
FIR - Thomas, L
IR  - Tucker S
FIR - Tucker, S
IR  - Colwill D
FIR - Colwill, D
IR  - Jones P
FIR - Jones, P
IR  - Vasileiadis E
FIR - Vasileiadis, E
IR  - Parry A
FIR - Parry, A
IR  - Mason C
FIR - Mason, C
IR  - Holden M
FIR - Holden, M
IR  - Petrides K
FIR - Petrides, K
IR  - Nishiyama T
FIR - Nishiyama, T
IR  - Mehta H
FIR - Mehta, H
IR  - Mumani S
FIR - Mumani, S
IR  - Johnston S
FIR - Johnston, S
IR  - Almadenboyle C
FIR - Almadenboyle, C
IR  - Carson S
FIR - Carson, S
IR  - Ross S
FIR - Ross, S
IR  - Nair P
FIR - Nair, P
IR  - Stirling M
FIR - Stirling, M
IR  - Tenbruck E
FIR - Tenbruck, E
IR  - Broughton D
FIR - Broughton, D
IR  - Annamalai A
FIR - Annamalai, A
IR  - Wong J
FIR - Wong, J
IR  - Tryambake D
FIR - Tryambake, D
IR  - Dixon L
FIR - Dixon, L
IR  - Skotnicka A
FIR - Skotnicka, A
IR  - Thompson J
FIR - Thompson, J
IR  - Sigsworth A
FIR - Sigsworth, A
IR  - Whitehouse S
FIR - Whitehouse, S
IR  - Pagan J
FIR - Pagan, J
IR  - Pusalkar A
FIR - Pusalkar, A
IR  - Beadle H
FIR - Beadle, H
IR  - Chan K
FIR - Chan, K
IR  - Dangri P
FIR - Dangri, P
IR  - Asokanathan A
FIR - Asokanathan, A
IR  - Rana A
FIR - Rana, A
IR  - Gohil S
FIR - Gohil, S
IR  - Crabtree K
FIR - Crabtree, K
IR  - Cook A
FIR - Cook, A
IR  - Massyn M
FIR - Massyn, M
IR  - Aruldoss P
FIR - Aruldoss, P
IR  - Dabbagh S
FIR - Dabbagh, S
IR  - Black T
FIR - Black, T
IR  - Clarke C
FIR - Clarke, C
IR  - Fennelly R
FIR - Fennelly, R
IR  - Nardone L
FIR - Nardone, L
IR  - DiMartino V
FIR - DiMartino, V
IR  - Anthony A
FIR - Anthony, A
IR  - Mead D
FIR - Mead, D
IR  - Tribbeck M
FIR - Tribbeck, M
IR  - Affley B
FIR - Affley, B
IR  - Sunderland C
FIR - Sunderland, C
IR  - Young E
FIR - Young, E
IR  - Goldenberg L
FIR - Goldenberg, L
IR  - Khan A
FIR - Khan, A
IR  - Wilkinson P
FIR - Wilkinson, P
IR  - Abbott L
FIR - Abbott, L
IR  - Nari R
FIR - Nari, R
IR  - Lock S
FIR - Lock, S
IR  - Stewart J
FIR - Stewart, J
IR  - Shakhon A
FIR - Shakhon, A
IR  - Pereira R
FIR - Pereira, R
IR  - DSouza M
FIR - DSouza, M
IR  - Dunn S
FIR - Dunn, S
IR  - Cron N
FIR - Cron, N
IR  - Mckenna A
FIR - Mckenna, A
IR  - Sivakumar R
FIR - Sivakumar, R
IR  - Cook S
FIR - Cook, S
IR  - Wright A
FIR - Wright, A
IR  - Ngeh J
FIR - Ngeh, J
IR  - Saksena R
FIR - Saksena, R
IR  - Ketley-O'Donel J
FIR - Ketley-O'Donel, J
IR  - Needle R
FIR - Needle, R
IR  - Chinery E
FIR - Chinery, E
IR  - Greenwood R
FIR - Greenwood, R
IR  - Howaniec L
FIR - Howaniec, L
IR  - Watchurst C
FIR - Watchurst, C
IR  - Patel K
FIR - Patel, K
IR  - Erande R
FIR - Erande, R
IR  - Brezitski M
FIR - Brezitski, M
IR  - Passeron N
FIR - Passeron, N
IR  - Elliott E
FIR - Elliott, E
IR  - Oji N
FIR - Oji, N
IR  - Austin D
FIR - Austin, D
IR  - Banaras A
FIR - Banaras, A
IR  - Hogan C
FIR - Hogan, C
IR  - Corbett T
FIR - Corbett, T
IR  - Shah R
FIR - Shah, R
IR  - Kidd M
FIR - Kidd, M
IR  - Hull G
FIR - Hull, G
IR  - Simpson J
FIR - Simpson, J
IR  - Punekar S
FIR - Punekar, S
IR  - Nevinson J
FIR - Nevinson, J
IR  - Penney H
FIR - Penney, H
IR  - Ward J
FIR - Ward, J
IR  - Wareing W
FIR - Wareing, W
IR  - Hayes N
FIR - Hayes, N
IR  - Bunworth K
FIR - Bunworth, K
IR  - Connell L
FIR - Connell, L
IR  - Mahawish K
FIR - Mahawish, K
IR  - Drummond G
FIR - Drummond, G
IR  - Sengupta N
FIR - Sengupta, N
IR  - Metiu M
FIR - Metiu, M
IR  - Gonzalez C
FIR - Gonzalez, C
IR  - Margalef J
FIR - Margalef, J
IR  - Funnell S
FIR - Funnell, S
IR  - Peters G
FIR - Peters, G
IR  - Chadbourn I
FIR - Chadbourn, I
IR  - Proeschel H
FIR - Proeschel, H
IR  - Ashcroft P
FIR - Ashcroft, P
IR  - Sharpe S
FIR - Sharpe, S
IR  - Cook P
FIR - Cook, P
IR  - Jenkinson D
FIR - Jenkinson, D
IR  - Kelly D
FIR - Kelly, D
IR  - Bray H
FIR - Bray, H
IR  - Gunathilagan G
FIR - Gunathilagan, G
IR  - Tilbey S
FIR - Tilbey, S
IR  - Abubakar S
FIR - Abubakar, S
IR  - Cooper M
FIR - Cooper, M
IR  - Rajapakse A
FIR - Rajapakse, A
IR  - Nasar A
FIR - Nasar, A
IR  - Janbieh J
FIR - Janbieh, J
IR  - Wade L
FIR - Wade, L
IR  - Otter L
FIR - Otter, L
IR  - Wynter I
FIR - Wynter, I
IR  - Haigh S
FIR - Haigh, S
IR  - Boulton R
FIR - Boulton, R
IR  - Burgoyne J
FIR - Burgoyne, J
IR  - Boulton A
FIR - Boulton, A
IR  - Vassallo J
FIR - Vassallo, J
IR  - Hasan A
FIR - Hasan, A
IR  - Orrell L
FIR - Orrell, L
IR  - Qamar S
FIR - Qamar, S
IR  - Graham S
FIR - Graham, S
IR  - Leonard D
FIR - Leonard, D
IR  - Hewitt E
FIR - Hewitt, E
IR  - Haque M
FIR - Haque, M
IR  - Awolesi J
FIR - Awolesi, J
IR  - Bradshaw E
FIR - Bradshaw, E
IR  - Kent A
FIR - Kent, A
IR  - Duggan C
FIR - Duggan, C
IR  - Hynes A
FIR - Hynes, A
IR  - Nurse E
FIR - Nurse, E
IR  - Raza S
FIR - Raza, S
IR  - Pallikona U
FIR - Pallikona, U
IR  - Edwards B
FIR - Edwards, B
IR  - Morgan G
FIR - Morgan, G
IR  - Tench H
FIR - Tench, H
IR  - Loosley R
FIR - Loosley, R
IR  - Dennett K
FIR - Dennett, K
IR  - Trugeon-Smith T
FIR - Trugeon-Smith, T
IR  - Robson D
FIR - Robson, D
IR  - Rayessa R
FIR - Rayessa, R
IR  - Abdul-Hamid A
FIR - Abdul-Hamid, A
IR  - Lowthorpe V
FIR - Lowthorpe, V
IR  - Mitchelson K
FIR - Mitchelson, K
IR  - Clarkson E
FIR - Clarkson, E
IR  - Rhian H
FIR - Rhian, H
IR  - Fleming A
FIR - Fleming, A
IR  - Kirthivasan R
FIR - Kirthivasan, R
IR  - Topliffe J
FIR - Topliffe, J
IR  - Keskeys R
FIR - Keskeys, R
IR  - McNeela F
FIR - McNeela, F
IR  - Bohannan E
FIR - Bohannan, E
IR  - Cooper L
FIR - Cooper, L
IR  - Zachariah G
FIR - Zachariah, G
IR  - Cairns F
FIR - Cairns, F
IR  - James T
FIR - James, T
IR  - Fergey L
FIR - Fergey, L
IR  - Smolen S
FIR - Smolen, S
IR  - Lyle A
FIR - Lyle, A
IR  - Cannon E
FIR - Cannon, E
IR  - Omer S
FIR - Omer, S
IR  - Mavinamane S
FIR - Mavinamane, S
IR  - Meenakshisundaram S
FIR - Meenakshisundaram, S
IR  - Ranga L
FIR - Ranga, L
IR  - Bate J
FIR - Bate, J
IR  - Hill A
FIR - Hill, A
IR  - Hargreaves M
FIR - Hargreaves, M
IR  - Smith T
FIR - Smith, T
IR  - Dealing S
FIR - Dealing, S
IR  - Harrison L
FIR - Harrison, L
IR  - Amlani S
FIR - Amlani, S
IR  - Gulli G
FIR - Gulli, G
IR  - Hawkes-Blackburn M
FIR - Hawkes-Blackburn, M
IR  - Levy S
FIR - Levy, S
IR  - Francis L
FIR - Francis, L
IR  - Holland S
FIR - Holland, S
IR  - Peacocke A
FIR - Peacocke, A
IR  - Amero J
FIR - Amero, J
IR  - Burova M
FIR - Burova, M
IR  - Speirs O
FIR - Speirs, O
IR  - Brotheridge S
FIR - Brotheridge, S
IR  - Al Hussayni S
FIR - Al Hussayni, S
IR  - Lyon H
FIR - Lyon, H
IR  - Hare C
FIR - Hare, C
IR  - Jackson S
FIR - Jackson, S
IR  - Featherstone J
FIR - Featherstone, J
IR  - Bwalya A
FIR - Bwalya, A
IR  - Singh A
FIR - Singh, A
IR  - Goorah M
FIR - Goorah, M
IR  - Walford J
FIR - Walford, J
IR  - Bell A
FIR - Bell, A
IR  - Kelly C
FIR - Kelly, C
IR  - Rusk D
FIR - Rusk, D
IR  - Sutton D
FIR - Sutton, D
IR  - Patel F
FIR - Patel, F
IR  - Duberley S
FIR - Duberley, S
IR  - Hayes K
FIR - Hayes, K
IR  - Hunt L
FIR - Hunt, L
IR  - Ahmed El Nour E
FIR - Ahmed El Nour, E
IR  - Dyer S
FIR - Dyer, S
IR  - Brown L
FIR - Brown, L
IR  - Elliott K
FIR - Elliott, K
IR  - Temlett E
FIR - Temlett, E
IR  - Paterson J
FIR - Paterson, J
IR  - Honour S
FIR - Honour, S
IR  - Box C
FIR - Box, C
IR  - Young S
FIR - Young, S
IR  - Furness R
FIR - Furness, R
IR  - Orugun E
FIR - Orugun, E
IR  - Crowther H
FIR - Crowther, H
IR  - Glover R
FIR - Glover, R
IR  - Brewer C
FIR - Brewer, C
IR  - Thornthwaite S
FIR - Thornthwaite, S
IR  - Sein M
FIR - Sein, M
IR  - Haque K
FIR - Haque, K
IR  - Bailey L
FIR - Bailey, L
IR  - Wong S
FIR - Wong, S
IR  - Gibson E
FIR - Gibson, E
IR  - Burton K
FIR - Burton, K
IR  - Brookes L
FIR - Brookes, L
IR  - Rotchell K
FIR - Rotchell, K
IR  - Waltho K
FIR - Waltho, K
IR  - Lindley C
FIR - Lindley, C
IR  - Holland M
FIR - Holland, M
IR  - Kumar P
FIR - Kumar, P
IR  - Khan M
FIR - Khan, M
IR  - Harlekar P
FIR - Harlekar, P
IR  - Culmsee C
FIR - Culmsee, C
IR  - Booth L
FIR - Booth, L
IR  - Drew J
FIR - Drew, J
IR  - Ritchie J
FIR - Ritchie, J
IR  - Mackenzie N
FIR - Mackenzie, N
IR  - Thomas C
FIR - Thomas, C
IR  - Barker J
FIR - Barker, J
IR  - Haley M
FIR - Haley, M
IR  - Cotterill D
FIR - Cotterill, D
IR  - Lane L
FIR - Lane, L
IR  - Simmons D
FIR - Simmons, D
IR  - Warinton R
FIR - Warinton, R
IR  - Saunders G
FIR - Saunders, G
IR  - Dymond H
FIR - Dymond, H
IR  - Kidd S
FIR - Kidd, S
IR  - Little C
FIR - Little, C
IR  - Neves-Silva Y
FIR - Neves-Silva, Y
IR  - Nevajda B
FIR - Nevajda, B
IR  - Villaruel M
FIR - Villaruel, M
IR  - Patel S
FIR - Patel, S
IR  - Umasankar U
FIR - Umasankar, U
IR  - Man A
FIR - Man, A
IR  - Gadi N
FIR - Gadi, N
IR  - Christmas N
FIR - Christmas, N
IR  - Ladner R
FIR - Ladner, R
IR  - Rangasamy R
FIR - Rangasamy, R
IR  - Butt G
FIR - Butt, G
IR  - Alvares W
FIR - Alvares, W
IR  - Power M
FIR - Power, M
IR  - Hagan S
FIR - Hagan, S
IR  - Dynan K
FIR - Dynan, K
IR  - Wilson D
FIR - Wilson, D
IR  - Crothers S
FIR - Crothers, S
IR  - Leonard C
FIR - Leonard, C
IR  - Wroath B
FIR - Wroath, B
IR  - Douris G
FIR - Douris, G
IR  - Vahidassr D
FIR - Vahidassr, D
IR  - Gallen B
FIR - Gallen, B
IR  - McKenna S
FIR - McKenna, S
IR  - Thompson A
FIR - Thompson, A
IR  - Edwards C
FIR - Edwards, C
IR  - McGoldrick C
FIR - McGoldrick, C
IR  - Bhattad M
FIR - Bhattad, M
IR  - Putteril J
FIR - Putteril, J
IR  - Gallifent R
FIR - Gallifent, R
IR  - Makanju E
FIR - Makanju, E
IR  - Lepore M
FIR - Lepore, M
IR  - McRedmond C
FIR - McRedmond, C
IR  - Arundell L
FIR - Arundell, L
IR  - Goulding A
FIR - Goulding, A
IR  - Kawafi K
FIR - Kawafi, K
IR  - Jacob P
FIR - Jacob, P
IR  - Turner L
FIR - Turner, L
IR  - Saravanan N
FIR - Saravanan, N
IR  - Johnson L
FIR - Johnson, L
IR  - Morse D
FIR - Morse, D
IR  - Namushi R
FIR - Namushi, R
IR  - Humphrey S
FIR - Humphrey, S
IR  - McLaughlin J
FIR - McLaughlin, J
IR  - Salehin M
FIR - Salehin, M
IR  - Tinsley S
FIR - Tinsley, S
IR  - Jones T
FIR - Jones, T
IR  - Bailey D
FIR - Bailey, D
IR  - Garcia-Alen L
FIR - Garcia-Alen, L
IR  - Kalathil L
FIR - Kalathil, L
IR  - Miller R
FIR - Miller, R
IR  - Gautam N
FIR - Gautam, N
IR  - Horton J
FIR - Horton, J
IR  - Meir J
FIR - Meir, J
IR  - Margerum E
FIR - Margerum, E
IR  - Ritchings A
FIR - Ritchings, A
IR  - Jones A
FIR - Jones, A
IR  - Amor K
FIR - Amor, K
IR  - Nadarajan V
FIR - Nadarajan, V
IR  - Laurence J
FIR - Laurence, J
IR  - Fung Lo S
FIR - Fung Lo, S
IR  - Melander S
FIR - Melander, S
IR  - Nicholas P
FIR - Nicholas, P
IR  - Woodford E
FIR - Woodford, E
IR  - McKenzie G
FIR - McKenzie, G
IR  - Le V
FIR - Le, V
IR  - Crause J
FIR - Crause, J
IR  - OMahony P
FIR - OMahony, P
IR  - Orefo C
FIR - Orefo, C
IR  - McDonald C
FIR - McDonald, C
IR  - Osikominu E
FIR - Osikominu, E
IR  - Khan T
FIR - Khan, T
IR  - Appiatse G
FIR - Appiatse, G
IR  - Wardale A
FIR - Wardale, A
IR  - Augustin M
FIR - Augustin, M
IR  - Stone H
FIR - Stone, H
IR  - Luder R
FIR - Luder, R
IR  - Bhargava M
FIR - Bhargava, M
IR  - Bhome G
FIR - Bhome, G
IR  - Johnson V
FIR - Johnson, V
IR  - Chesser D
FIR - Chesser, D
IR  - Bridger H
FIR - Bridger, H
IR  - Murali E
FIR - Murali, E
IR  - Scott J
FIR - Scott, J
IR  - Morrison S
FIR - Morrison, S
IR  - Burns A
FIR - Burns, A
IR  - Graham J
FIR - Graham, J
IR  - Duffy M
FIR - Duffy, M
IR  - Ali K
FIR - Ali, K
IR  - Pitcher E
FIR - Pitcher, E
IR  - Gaylard J
FIR - Gaylard, J
IR  - Newman J
FIR - Newman, J
IR  - Punnoose S
FIR - Punnoose, S
IR  - Oakley S
FIR - Oakley, S
IR  - Murray V
FIR - Murray, V
IR  - Bent C
FIR - Bent, C
IR  - Walker R
FIR - Walker, R
IR  - Purohit K
FIR - Purohit, K
IR  - Rees A
FIR - Rees, A
IR  - Davy M
FIR - Davy, M
IR  - Besley S
FIR - Besley, S
IR  - Chohan O
FIR - Chohan, O
IR  - Argandona L
FIR - Argandona, L
IR  - Cuenoud L
FIR - Cuenoud, L
IR  - Hassan H
FIR - Hassan, H
IR  - Erumere E
FIR - Erumere, E
IR  - OCallaghan A
FIR - OCallaghan, A
IR  - Howaniec L
FIR - Howaniec, L
IR  - Redjep O
FIR - Redjep, O
IR  - Auld G
FIR - Auld, G
IR  - Gompertz P
FIR - Gompertz, P
IR  - Song A
FIR - Song, A
IR  - Hungwe R
FIR - Hungwe, R
IR  - Kabash H
FIR - Kabash, H
IR  - Tarkas T
FIR - Tarkas, T
IR  - Livingstone G
FIR - Livingstone, G
IR  - Butler F
FIR - Butler, F
IR  - Bradfield S
FIR - Bradfield, S
IR  - Gordon L
FIR - Gordon, L
IR  - Schmit J
FIR - Schmit, J
IR  - Wijewardane A
FIR - Wijewardane, A
IR  - Medcalf C
FIR - Medcalf, C
IR  - Edmunds T
FIR - Edmunds, T
IR  - Wills R
FIR - Wills, R
IR  - Peixoto C
FIR - Peixoto, C
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040492 [pii]
AID - 10.1136/bmjopen-2020-040492 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040492. doi: 10.1136/bmjopen-2020-040492.


PMID- 33257484
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Interface management concepts in healthcare for rare diseases in Germany: a study
      protocol for a mixed-methods study to develop best practice recommendations.
PG  - e040470
LID - 10.1136/bmjopen-2020-040470 [doi]
AB  - INTRODUCTION: Patients and families affected by a rare disease are burdened in
      multiple ways. Functional interface management can unburden patients or relatives
      from the need to be solely accountable for the navigation through the healthcare 
      system. This study aims at (1) providing an assessment of approaches and
      interface management concepts in the care of rare diseases, (2) evaluating
      selected existing approaches and concepts and (3) developing best practice
      recommendations for interface management. METHODS AND ANALYSIS: We will conduct a
      mixed-methods study with three phases. In phase 1, we will develop a tool to
      assess existing concepts of interface management for rare diseases based on a
      literature search and an expert workshop. The tool will be applied in a telephone
      survey with representatives of centres or clinics of expertise for rare diseases 
      (target: n=100) and cooperating practitioners (target: n=60). Based on the
      results of phase 1, we will select four to six centres of expertise with
      interface management concepts, which will be evaluated extensively in phase 2.
      For the evaluation, we will conduct semistructured interviews with practitioners 
      cooperating with centres or clinics for rare diseases (target: n=50), a
      paper-based survey including patients or parents/legal guardians (target: n=300) 
      from the selected centres or clinics, and semistructured interviews with patients
      or parents/legal guardians (target: n=50). The final phase of the study will be
      an integration of results from phases 1 and 2 to develop best practice
      recommendations for interface management in healthcare of rare diseases. In a
      concluding expert workshop, recommendations will be presented and finalised.
      ETHICS AND DISSEMINATION: This study was approved by the Local Psychological
      Ethics Committee of the Center for Psychosocial Medicine of the University
      Medical Center Hamburg-Eppendorf (LPEK-0062). The findings of our study will be
      presented on national and international conferences and published in scientific, 
      peer-reviewed journals. To assure that centres for rare diseases get access to
      the study results, centres are invited to send a representative to a final expert
      workshop in phase 3. Moreover, an executive summary will be provided and sent to 
      relevant stakeholders. TRIAL REGISTRATION NUMBER: German Clinical Trials Registry
      (DRKS00020488).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Inhestern, Laura
AU  - Inhestern L
AUID- ORCID: 0000-0003-2513-7954
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany l.inhestern@uke.de.
FAU - Zybarth, David
AU  - Zybarth D
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Otto, Ramona
AU  - Otto R
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Brandt, Maja
AU  - Brandt M
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Harter, Martin
AU  - Harter M
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Bergelt, Corinna
AU  - Bergelt C
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
LA  - eng
SI  - DRKS/DRKS00020488
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Trials as Topic
MH  - *Delivery of Health Care
MH  - Germany
MH  - Health Facilities
MH  - Health Personnel
MH  - Humans
MH  - *Rare Diseases/therapy
PMC - PMC7705519
OTO - NOTNLM
OT  - *genetics
OT  - *organisation of health services
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040470 [pii]
AID - 10.1136/bmjopen-2020-040470 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040470. doi: 10.1136/bmjopen-2020-040470.


PMID- 33257483
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica
      spectrum disorders: a protocol for systematic review and meta-analysis.
PG  - e040371
LID - 10.1136/bmjopen-2020-040371 [doi]
AB  - INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory 
      and heterogeneous astrocyte disorder of the central nervous system with the
      characteristic of higher incidence in women and Asian people. Most patients with 
      NMOSD have a course of recurrence and remission that is prone to cause paralysis 
      and blindness. Several studies have confirmed the efficacy and promising prospect
      of mycophenolate mofetil (MMF) in the treatment of NMOSD. Yet its therapeutic
      effect and safety are controversial. Although there has been two published
      literature that is relevant to the topic of this study, both of them have certain
      defects, and they can only provide answers about the efficacy or safety of MMF in
      the treatment of NMOSD from partial perspectives or conclusions. This research
      aims to perform a direct and comprehensive systematic review and meta-analysis to
      evaluate MMF's effectiveness and safety in treating NMOSD. METHODS AND ANALYSIS: 
      This systematic review will cover all comparative researches, from randomised
      controlled trials to cohort studies, and case-control study. A relevant
      literature search will be conducted in PubMed, Web of Science, EMBASE, the
      Cochrane Library, China National Knowledge Infrastructure, Wanfang Database,
      China Science and Technology Journal Database and Chinese Biomedical Literature
      Database from their inception to 31 June 2020. We will also search registers of
      clinical trials, potential grey literature and abstracts from conferences. There 
      are no limits on language and publication status. The reporting quality and risk 
      of bias will be assessed by two researchers independently. Expanded Disability
      Status Scales and annualised relapse rate will be evaluated as the primary
      outcome. The secondary outcomes will consist of the frequency and severity of
      adverse events, best-corrected visual acuity, relapse-free rate and time to the
      next attack. A meta-analysis will be performed using RevMan V.5.3 software
      provided by the Cochrane Collaboration and Stata V.12.0. ETHICS AND
      DISSEMINATION: Because the data used for this systematic review will be
      exclusively extracted from published studies, ethical approval and informed
      consent of patients will not be required. The systematic review will be published
      in a peer-reviewed journal, presented at conferences and will be shared on social
      media platforms. PROSPERO REGISTRATION NUMBER: CRD42020164179.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Han, Mengyu
AU  - Han M
AUID- ORCID: 0000-0003-2342-268X
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Nong, Luqi
AU  - Nong L
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Liu, Ziqiang
AU  - Liu Z
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Chen, You
AU  - Chen Y
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Chen, Yang
AU  - Chen Y
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Meng, Huan
AU  - Meng H
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Qin, Yali
AU  - Qin Y
AD  - Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.
FAU - Wang, Zhijun
AU  - Wang Z
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Jin, Ming
AU  - Jin M
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China
      jinmingyk@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Case-Control Studies
MH  - China
MH  - Female
MH  - Humans
MH  - Mycophenolic Acid/adverse effects/*therapeutic use
MH  - *Neuromyelitis Optica/drug therapy
MH  - Recurrence
PMC - PMC7705552
OTO - NOTNLM
OT  - *immunology
OT  - *neuro-ophthalmology
OT  - *neurology
OT  - *ophthalmology
COIS- Competing interests: None declared.
EDAT- 2020/12/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040371 [pii]
AID - 10.1136/bmjopen-2020-040371 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e040371. doi: 10.1136/bmjopen-2020-040371.


PMID- 33257482
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Methods for the health technology assessment of complex interventions: a protocol
      for a scoping review.
PG  - e039263
LID - 10.1136/bmjopen-2020-039263 [doi]
AB  - INTRODUCTION: In healthcare policy and economic literature, research on the
      health technology assessment (HTA) of complex interventions (CIs) is becoming
      increasingly important. In many developed countries, HTA guides decision-making
      to help achieve greater value for money when funding health care. However,
      research has yet to identify the forms of evidence and evaluation criteria that
      should be used in the HTA of CIs. Previous research has established that the HTA 
      of CIs requires multiple factors to be evaluated but there is no agreement on
      which factors ought always to be considered. There is equally little agreement on
      which forms of evidence ought to be collected or synthesised and how. We plan to 
      perform a systematic scoping review in order to identify the range of evaluation 
      criteria and types of evidence currently used in the HTA of CIs. METHOD AND
      ANALYSIS: This protocol was developed to guide the methodological framework for
      the conduct of a scoping review on health technology assessment (HTA) of complex 
      interventions (CIs), using the Joanna Briggs Institute guidelines and the
      six-stage framework proposed by Arksey and O'Malley, in addition to more recent
      innovations in scoping review methodology. A grey literature search will
      supplement the primary searches of seven electronic databases for studies
      available in English between January 2000 and August 2020. Two reviewers will
      independently screen all search results for inclusion and data will be extracted 
      using a customised data extraction or charting form. Any dispute will be resolved
      by consensus or through arbitration by a third author. The mnemonic Population,
      Concept and Context will be adopted to establish criteria for selecting relevant 
      literature, and the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses: Extension for Scoping Review will be used for reporting the
      results. Several explanatory-descriptive methods will be used for analysing the
      extracted data including frequency and trend analyses as well as reflexive
      thematic coding and analysis.Mapping evidence on the HTA of CIs will allow us to 
      gain a better understanding of both established and emerging practices, including
      the information types, requirements, values and parameters that are incorporated 
      in the HTA of CIs. We also expect the findings of the scoping review to help
      identify research gaps that will guide future studies. As healthcare becomes more
      complex in its delivery, it is timely to determine how these complex
      interventions should be assessed so that policy decisions can be made about
      whether implementation and public funding is warranted. ETHICS AND DISSEMINATION:
      This scoping review will involve secondary analysis of already collected data,
      and thus, does not require ethics approval. The research findings will be
      submitted to peer-reviewed journals for publication and will also be disseminated
      at conferences and seminars.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Baghbanian, Abdolvahab
AU  - Baghbanian A
AUID- ORCID: 0000-0003-3651-337X
AD  - Adelaide Health Technology Assessment (AHTA), School of Public Health, The
      University of Adelaide, Adelaide, South Australia, Australia
      abdolvahab.baghbanian@adelaide.edu.au.
FAU - Merlin, Tracy
AU  - Merlin T
AD  - Adelaide Health Technology Assessment (AHTA), School of Public Health, The
      University of Adelaide, Adelaide, South Australia, Australia.
FAU - Carter, Drew
AU  - Carter D
AD  - Adelaide Health Technology Assessment (AHTA), School of Public Health, The
      University of Adelaide, Adelaide, South Australia, Australia.
FAU - Wang, Shuhong
AU  - Wang S
AD  - Adelaide Health Technology Assessment (AHTA), School of Public Health, The
      University of Adelaide, Adelaide, South Australia, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Health Policy
MH  - Peer Review
MH  - *Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
MH  - *Technology Assessment, Biomedical
PMC - PMC7705549
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *health services administration & management
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/12/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039263 [pii]
AID - 10.1136/bmjopen-2020-039263 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e039263. doi: 10.1136/bmjopen-2020-039263.


PMID- 33257481
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - Mothers' experiences of perinatal care in Belgian public hospitals: exploring the
      social inequalities. Protocol for a cross-sectional survey.
PG  - e038400
LID - 10.1136/bmjopen-2020-038400 [doi]
AB  - INTRODUCTION: In Europe, the social inequalities in perinatal health are usually 
      found to be to the disadvantage of non-European immigrants and women with lower
      levels of education and income. Among the possible underlying mechanisms are
      inadequate access to healthcare services and suboptimal care. To explore this
      hypothesis in the Belgian context, our research will describe detailed maternal
      socioeconomic and migration characteristics, explore how these factors relate to 
      each other, and how they relate to women's perinatal care trajectories and
      experiences of care. METHODS: Using a modified version of the Migrant-Friendly
      Maternity Care Questionnaire, we will survey 900 mothers of Belgian nationality
      or a nationality from a North or Sub-Saharan African country, and having given
      birth in four maternity wards in Brussels. The questionnaire has been adapted to 
      the study objectives and the Belgian context. Interviewers will administer the
      116-item questionnaire to all women agreeing to participate and meeting inclusion
      criteria, within 14 days of having given birth. Clinical information will be
      extracted from hospital records. ANALYSIS: We will estimate the associations of
      women's socioeconomic and migration characteristics with:Women's antenatal care
      trajectories (timing of first antenatal consultation, minimum recommended number 
      of consultations, and problems accessing care).Obstetric practices such as
      episiotomies, emergency caesarean sections, and inductions.Patient experience
      such as feelings of discrimination, respect, and understanding of information.We 
      will use descriptive statistics, multiple correspondence analysis, and simple and
      multiple logistic regressions. ETHICS AND DISSEMINATION: Ethical approval has
      been obtained from the hospital Ethics Committees and from the Universite libre
      de Bruxelles (No: P2017/055/B406201730877). Written informed consent will be
      sought from all participants.In addition to disseminating findings and
      recommendations to the scientific community through open-source journal articles 
      and conferences, we will also address local organisations and healthcare
      professionals via a written report and seminars.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Schonborn, Claudia
AU  - Schonborn C
AUID- ORCID: 0000-0002-4524-7192
AD  - Research Centre in Social Approaches to Health, School of Public Health,
      Universite libre de Bruxelles, Brussels, Belgium claudia.schoenborn@ulb.be.
FAU - Castetbon, Katia
AU  - Castetbon K
AD  - Research Centre in Epidemiology, Biostatistics and Clinical Research, School of
      Public Health, Universite libre de Bruxelles, Brussels, Belgium.
FAU - Sow, Mouctar
AU  - Sow M
AUID- ORCID: 0000-0001-8038-6326
AD  - Research Centre in Social Approaches to Health, School of Public Health,
      Universite libre de Bruxelles, Brussels, Belgium.
FAU - Racape, Judith
AU  - Racape J
AD  - Research Centre in Epidemiology, Biostatistics and Clinical Research, School of
      Public Health, Universite libre de Bruxelles, Brussels, Belgium.
FAU - De Spiegelaere, Myriam
AU  - De Spiegelaere M
AD  - Research Centre in Social Approaches to Health, School of Public Health,
      Universite libre de Bruxelles, Brussels, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Belgium
MH  - Child
MH  - Cross-Sectional Studies
MH  - Europe
MH  - Female
MH  - Hospitals, Public
MH  - Humans
MH  - Infant, Newborn
MH  - *Maternal Health Services
MH  - *Mothers
MH  - Perinatal Care
MH  - Pregnancy
MH  - Socioeconomic Factors
PMC - PMC7705495
OTO - NOTNLM
OT  - *perinatology
OT  - *public health
OT  - *quality in health care
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/12/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038400 [pii]
AID - 10.1136/bmjopen-2020-038400 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e038400. doi: 10.1136/bmjopen-2020-038400.


PMID- 33257480
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 30
TI  - 'Where have all the doctors gone?' A protocol for an ethnographic study of the
      retention problem in emergency medicine in the UK.
PG  - e038229
LID - 10.1136/bmjopen-2020-038229 [doi]
AB  - INTRODUCTION: 'Emergency medicine (EM) in the UK has a medical staffing crisis.' 
      Inadequate staffing, in EM and across healthcare, is a problem that affects the
      quality of patient care globally. Retention of doctors in EM is a particularly
      acute problem in the UK's National Health Service. Sustainable careers in
      healthcare are gaining increasing attention at a national and international
      policy level, but research to understand the factors that facilitate retention is
      lacking.This study aims to develop understanding of what drives retention of
      doctors in EM by focusing on those who remain in these careers, where previous
      research has targeted those who have left. By addressing the problem of retention
      in a different way, using innovative methods in this context, we aim to develop a
      deeper and more nuanced understanding of sustainable careers in EM. METHODS AND
      ANALYSIS: This is an ethnographic study combining participant observation in two 
      emergency departments, interviews with doctors from these departments, from
      organisations with influence or interest at a policy level and with doctors who
      have left EM. The analyses will integrate detailed workplace observation
      alongside key academic and policy documents using reflexive thematic analysis.
      ETHICS AND DISSEMINATION: Approvals have been obtained from Lancaster University 
      via the Faculty of Health and Medicine Research Ethics Committee (FHMREC18058)
      and the Health Research Authority (IRAS number 256306). The findings will inform 
      understanding of sustainable careers in EM that may be transferable to other
      settings, professions, and locations that share key characteristics with EM such 
      as paediatrics, emergency nursing and general practice. Findings will be
      disseminated through a series of academic publications and presentations, through
      local and specialty research engagement, and through targeted policy statements.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Darbyshire, Daniel
AU  - Darbyshire D
AUID- ORCID: 0000-0001-5619-0331
AD  - Emergency Department, Salford Royal NHS Foundation Trust, Salford, UK
      d.darbyshire@lancaster.ac.uk.
AD  - Lancaster Medical School, Lancaster University, Lancaster, UK.
FAU - Brewster, Liz
AU  - Brewster L
AUID- ORCID: 0000-0003-3604-2897
AD  - Lancaster Medical School, Lancaster University, Lancaster, UK.
FAU - Isba, Rachel
AU  - Isba R
AUID- ORCID: 0000-0002-2896-4309
AD  - Lancaster Medical School, Lancaster University, Lancaster, UK.
AD  - Children's Accident and Emergency Department, North Manchester General Hospital, 
      Manchester, UK.
FAU - Body, Richard
AU  - Body R
AUID- ORCID: 0000-0001-9089-8130
AD  - Division of Cardiovascular Sciences, The University of Manchester, Manchester,
      UK.
AD  - Emergency Department, Manchester University NHS Foundation Trust, Manchester,
      Greater Manchester, UK.
FAU - Goodwin, Dawn
AU  - Goodwin D
AUID- ORCID: 0000-0002-9435-9107
AD  - Lancaster Medical School, Lancaster University, Lancaster, UK.
LA  - eng
GR  - NIHR300168/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anthropology, Cultural
MH  - Child
MH  - *Emergency Medicine
MH  - Humans
MH  - *Physicians
MH  - State Medicine
MH  - United Kingdom
PMC - PMC7705583
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health policy
OT  - *medical education & training
OT  - *qualitative research
COIS- Competing interests: This publication presents independent research funded by the
      National Institute for Health Research (NIHR). All authors have completed the
      ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: DD
      had financial support from the NIHR, BMA Foundation and the Royal College of
      Emergency Medicine for the submitted work.
EDAT- 2020/12/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/01 05:55
PHST- 2020/12/01 05:55 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038229 [pii]
AID - 10.1136/bmjopen-2020-038229 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 30;10(11):e038229. doi: 10.1136/bmjopen-2020-038229.


PMID- 33257407
OWN - NLM
STAT- Publisher
LR  - 20201201
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 Nov 30
TI  - Antimicrobial use at the end of life: a scoping review.
LID - bmjspcare-2020-002558 [pii]
LID - 10.1136/bmjspcare-2020-002558 [doi]
AB  - OBJECTIVE: To examine antibiotic use in patients approaching end of life, in
      terms of frequency of prescription, aim of treatment, beneficial and adverse
      effects and contribution to the development of antimicrobial resistance. DESIGN: 
      Scoping review DATA SOURCES: An information scientist searched Ovid MEDLINE, Ovid
      EMBASE, The Cochrane library, PubMed Clinical Queries, NHS Evidence,
      Epistemonikos, SIGN, NICE, Google Scholar from inception to February 2019 for any
      study design including, but not limited to, randomised clinical trials,
      prospective interventional or observational studies, retrospective studies and
      qualitative studies. The search of Ovid MEDLINE was updated on the 10 June 2020. 
      STUDY SELECTION: Studies reporting antibiotic use in patients approaching end of 
      life in any setting and clinicians' attitudes and behaviour in relation to
      antibiotic prescribing in this population DATA EXTRACTION: Two reviewers screened
      studies for eligibility; two reviewers extracted data from included studies. Data
      were analysed to describe antibiotic prescribing patterns across different
      patient populations, the benefits and adverse effects (for individual patients
      and wider society), the rationale for decision making and clinicians behaviours
      and attitudes to treatment with antibiotics in this patient group. RESULTS:
      Eighty-eight studies were included. Definition of the end of life is highly
      variable as is use of antibiotics in patients approaching end of life.
      Prescribing decisions are influenced by patient age, primary diagnosis, care
      setting and therapy goals, although patients' preferences are not always
      documented or adhered to. Urinary and lower respiratory tract infections are the 
      most commonly reported indications with outcomes in terms of symptom control and 
      survival variably reported. Small numbers of studies reported on adverse events
      and antimicrobial resistance. Clinicians sometimes feel uncomfortable discussing 
      antibiotic treatment at end of life and would benefit from guidelines to direct
      care. CONCLUSIONS: Use of antibiotics in patients approaching the end of life is 
      common although there is significant variation in practice. There are a myriad of
      intertwined biological, ethical, social, medicolegal and clinical issues
      associated with the topic.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Fairweather, Jack
AU  - Fairweather J
AD  - University Hospital Monklands, Airdrie, Scotland.
FAU - Cooper, Lesley
AU  - Cooper L
AUID- ORCID: http://orcid.org/0000-0002-7755-5667
AD  - Scottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland
      Glasgow, Glasgow, UK lesley.cooper17@nhs.net.
FAU - Sneddon, Jacqueline
AU  - Sneddon J
AD  - Scottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland
      Glasgow, Glasgow, UK.
FAU - Seaton, R Andrew
AU  - Seaton RA
AD  - Queen Elizabeth University Hospital, Glasgow, UK.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - drug administration
OT  - end of life care
OT  - home care
OT  - hospice care
OT  - hospital care
OT  - nursing home care
COIS- Competing interests: LC, JS and RAS contributions to this work were undertaken as
      part of their roles in the Scottish Antimicrobial Prescribing Group. (SAPG is
      funded by the Scottish Government).
EDAT- 2020/12/02 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/12/01 05:54
PHST- 2020/07/07 00:00 [received]
PHST- 2020/10/27 00:00 [revised]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/12/01 05:54 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
AID - bmjspcare-2020-002558 [pii]
AID - 10.1136/bmjspcare-2020-002558 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 Nov 30. pii: bmjspcare-2020-002558. doi:
      10.1136/bmjspcare-2020-002558.


PMID- 33256961
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1538-9375 (Electronic)
IS  - 1525-8610 (Linking)
VI  - 21
IP  - 12
DP  - 2020 Dec
TI  - Ethical Considerations During COVID-19: Informed Consent Cannot Be Made in
      Advance.
PG  - 1815-1817
LID - S1525-8610(20)30889-6 [pii]
LID - 10.1016/j.jamda.2020.10.013 [doi]
FAU - Oliver, Jill
AU  - Oliver J
AD  - William Osler Health System, Brampton, Ontario, Canada.
FAU - Chidwick, Paula
AU  - Chidwick P
AD  - William Osler Health System, Brampton, Ontario, Canada.
FAU - Forsyth, Pamela
AU  - Forsyth P
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Chauhan, Nipa
AU  - Chauhan N
AD  - William Osler Health System, Brampton, Ontario, Canada.
FAU - Nitti, Theresa
AU  - Nitti T
AD  - William Osler Health System, Brampton, Ontario, Canada.
FAU - Siu, Henry Yu-Hin
AU  - Siu HY
AD  - McMaster University, Hamilton, Ontario, Canada.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20201016
PL  - United States
TA  - J Am Med Dir Assoc
JT  - Journal of the American Medical Directors Association
JID - 100893243
SB  - IM
CON - J Am Med Dir Assoc. 2020 Jul;21(7):943-947. PMID: 32674824
MH  - *COVID-19
MH  - Communication
MH  - Humans
MH  - Informed Consent
MH  - *Pandemics
MH  - SARS-CoV-2
PMC - PMC7566825
EDAT- 2020/12/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/01 05:42
PHST- 2020/09/03 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/12/01 05:42 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S1525-8610(20)30889-6 [pii]
AID - 10.1016/j.jamda.2020.10.013 [doi]
PST - ppublish
SO  - J Am Med Dir Assoc. 2020 Dec;21(12):1815-1817. doi: 10.1016/j.jamda.2020.10.013. 
      Epub 2020 Oct 16.


PMID- 33256826
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 30
TI  - Test evaluation trials present different challenges for trial managers compared
      to intervention trials.
PG  - 987
LID - 10.1186/s13063-020-04861-7 [doi]
AB  - INTRODUCTION: Test evaluation trials present different challenges for trial
      managers compared to intervention trials. There has been very little research on 
      the management of test evaluation trials and how this impacts on trial success,
      in comparison with intervention trials. Evaluations of medical tests present
      specific challenges, because they are a pivot point bridging the complexities of 
      pathways prompting testing with treatment decision-making. We systematically
      explored key differences in the trial design and management of test evaluation
      trials compared to intervention trials at the different stages of study design
      and delivery. We identified challenges in test evaluation trials that were more
      pronounced than in intervention trials, based on experience from 10 test
      evaluation trials. METHODS: We formed a focus group of 7 trial managers and a
      statistician who had been involved in the day-to-day management of both test
      evaluation trials and intervention trials. We used discussion and content
      analysis to group challenges from 10 trials into a structured thematic format.
      The trials covered a range of medical conditions, diagnostic tests, clinical
      pathways and conditions including chronic kidney disease, chronic pelvic pain,
      colitis, detrusor over-activity, group B streptococcal colonisation, tuberculosis
      and colorectal, lung, ovarian and thyroid cancers. RESULTS: We identified 10
      common themes underlying challenges that are more pronounced in test evaluation
      compared to intervention trials. We illustrate these themes with examples from 10
      trials, including with 31 specific challenges we experienced. The themes were
      ethics/governance; accessing patient populations; recruitment; patient
      preference; test processes, clinical pathways and samples storage; uncertainty of
      diagnostic results; verifying diagnosis (reference standard); follow-up; adverse 
      effects; and diagnostic impact. CONCLUSION: We present 10 common themes,
      including 31 challenges, in test evaluation trials that will be helpful to others
      designing and managing future test evaluation trials. Proactive identification of
      potential challenges at the design and planning stages of test evaluation trials 
      will enable strategies to improve trial design and management that may be
      different from standard strategies used for intervention trials. Future work
      could extend this topic to include challenges for other trial stakeholders
      including participants, clinicians, statisticians and funders. TRIAL
      REGISTRATION: All trials reviewed in this project were registered and are
      provided in Table 1.
FAU - Rick, Caroline
AU  - Rick C
AUID- ORCID: http://orcid.org/0000-0001-7713-9834
AD  - Nottingham Clinical Trials Unit Building 42, University of Nottingham,
      Nottingham, NG7 2RD, UK. caroline.rick@nottingham.ac.uk.
FAU - Mallett, Sue
AU  - Mallett S
AD  - UCL Centre for Medical Imaging, University College London, London, UK.
FAU - Brown, James
AU  - Brown J
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
FAU - Ottridge, Ryan
AU  - Ottridge R
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
FAU - Palmer, Andrew
AU  - Palmer A
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
FAU - Parker, Victoria
AU  - Parker V
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
FAU - Priest, Lee
AU  - Priest L
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
FAU - Deeks, Jonathan J
AU  - Deeks JJ
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
AD  - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS
      Foundation Trust and University of Birmingham, Birmingham, UK.
AD  - Test Evaluation Research Group, Institute of Applied Health Research, University 
      of Birmingham, Birmingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Chronic Pain
MH  - Humans
MH  - *Research Design
MH  - Research Personnel
PMC - PMC7706229
OTO - NOTNLM
OT  - Clinical trial
OT  - Diagnostic test accuracy
OT  - Randomised controlled trials
OT  - Recruitment
OT  - Sensitivity and specificity
OT  - Test evaluation
EDAT- 2020/12/02 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/12/01 05:37
PHST- 2020/02/11 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/12/01 05:37 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04861-7 [doi]
AID - 10.1186/s13063-020-04861-7 [pii]
PST - epublish
SO  - Trials. 2020 Nov 30;21(1):987. doi: 10.1186/s13063-020-04861-7.


PMID- 33256715
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 30
TI  - Explainability for artificial intelligence in healthcare: a multidisciplinary
      perspective.
PG  - 310
LID - 10.1186/s12911-020-01332-6 [doi]
AB  - BACKGROUND: Explainability is one of the most heavily debated topics when it
      comes to the application of artificial intelligence (AI) in healthcare. Even
      though AI-driven systems have been shown to outperform humans in certain
      analytical tasks, the lack of explainability continues to spark criticism. Yet,
      explainability is not a purely technological issue, instead it invokes a host of 
      medical, legal, ethical, and societal questions that require thorough
      exploration. This paper provides a comprehensive assessment of the role of
      explainability in medical AI and makes an ethical evaluation of what
      explainability means for the adoption of AI-driven tools into clinical practice. 
      METHODS: Taking AI-based clinical decision support systems as a case in point, we
      adopted a multidisciplinary approach to analyze the relevance of explainability
      for medical AI from the technological, legal, medical, and patient perspectives. 
      Drawing on the findings of this conceptual analysis, we then conducted an ethical
      assessment using the "Principles of Biomedical Ethics" by Beauchamp and Childress
      (autonomy, beneficence, nonmaleficence, and justice) as an analytical framework
      to determine the need for explainability in medical AI. RESULTS: Each of the
      domains highlights a different set of core considerations and values that are
      relevant for understanding the role of explainability in clinical practice. From 
      the technological point of view, explainability has to be considered both in
      terms how it can be achieved and what is beneficial from a development
      perspective. When looking at the legal perspective we identified informed
      consent, certification and approval as medical devices, and liability as core
      touchpoints for explainability. Both the medical and patient perspectives
      emphasize the importance of considering the interplay between human actors and
      medical AI. We conclude that omitting explainability in clinical decision support
      systems poses a threat to core ethical values in medicine and may have
      detrimental consequences for individual and public health. CONCLUSIONS: To ensure
      that medical AI lives up to its promises, there is a need to sensitize
      developers, healthcare professionals, and legislators to the challenges and
      limitations of opaque algorithms in medical AI and to foster multidisciplinary
      collaboration moving forward.
FAU - Amann, Julia
AU  - Amann J
AUID- ORCID: 0000-0003-2155-5286
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Hottingerstrasse 10, 8092, Zurich, Switzerland. julia.amann@hest.ethz.ch.
FAU - Blasimme, Alessandro
AU  - Blasimme A
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Hottingerstrasse 10, 8092, Zurich, Switzerland.
FAU - Vayena, Effy
AU  - Vayena E
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Hottingerstrasse 10, 8092, Zurich, Switzerland.
FAU - Frey, Dietmar
AU  - Frey D
AD  - Charite Lab for Artificial Intelligence in Medicine-CLAIM, Charite -
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Madai, Vince I
AU  - Madai VI
AD  - Charite Lab for Artificial Intelligence in Medicine-CLAIM, Charite -
      Universitatsmedizin Berlin, Berlin, Germany.
AD  - School of Computing and Digital Technology, Faculty of Computing, Engineering and
      the Built Environment, Birmingham City University, Birmingham, UK.
CN  - Precise4Q consortium
LA  - eng
GR  - 777107/Horizon 2020 Research and Innovation Programme/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - *Artificial Intelligence
MH  - *Decision Support Systems, Clinical
MH  - *Delivery of Health Care
MH  - Health Facilities
MH  - Humans
MH  - Informed Consent
PMC - PMC7706019
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Clinical decision support
OT  - *Explainability
OT  - *Interpretability
OT  - *Machine learning
EDAT- 2020/12/02 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/01 05:36
PHST- 2020/07/22 00:00 [received]
PHST- 2020/11/15 00:00 [accepted]
PHST- 2020/12/01 05:36 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1186/s12911-020-01332-6 [doi]
AID - 10.1186/s12911-020-01332-6 [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Nov 30;20(1):310. doi: 10.1186/s12911-020-01332-6.


PMID- 33256650
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 30
TI  - A mixed-methods community-based participatory research to explore stakeholder's
      perspectives and to quantify the effect of crop residue burning on air and human 
      health in Central India: study protocol.
PG  - 1824
LID - 10.1186/s12889-020-09844-6 [doi]
AB  - BACKGROUND: Crop residue burning adversely affects air quality and consequently
      human health. India, being one of the largest agro-economies of the world,
      produces around 500 Million tonnes of crop residue annually most of which is
      burnt on-farm. However, integrated studies that simultaneously quantify the
      effects of crop residue burning while exploring the subjective determinants of
      the practice are lacking in India. This paper describes the protocol for a
      longitudinal mixed methods research study employing a community-based
      participatory approach to fill this gap. METHODS: Both quantitative and
      qualitative data will be collected in a rural setting of the central Indian
      province of Madhya Pradesh, over 1 year. A steering committee comprising of the
      research team and community representatives will be formed. The proportion of
      cultivable land burnt in one crop burning season will be estimated. The
      association between crop residue burning, level of ambient air pollutants, and
      pulmonary function of village residents will be determined. Focus groups,
      interviews, and participatory rural appraisal methods will be used to explore
      stakeholder perspectives about crop residue burning. Potential barriers and
      opportunities for substituting burning with an alternative crop residue
      management technique will be ascertained as the basis for future interventions.
      Ethics approval has been obtained from the Institutional Ethics Committee of the 
      National Institute for Research in Environmental Health (No:
      NIREH/BPL/IEC/2019-20/1494, dt 06/01/2020). DISCUSSION: This manuscript describes
      the protocol for a novel community-based participatory study to investigate
      thoroughly the phenomenon of crop residue burning from the perspective of the
      agricultural community through their active collaboration. The lack of
      comprehensive evidence regarding the factors responsible for crop residue burning
      in India underlines the importance of implementing this study protocol to fill in
      this critical gap in knowledge. While acknowledging that findings of this study
      will be not generalizable to agricultural communities other than the one studied,
      it is expected that the study will generate baseline evidence that might be
      beneficial in developing and implementing an appropriate intervention strategy.
FAU - Trushna, Tanwi
AU  - Trushna T
AD  - Department of Environmental Health and Epidemiology, ICMR-National Institute for 
      Research in Environmental Health, Bhopal, Madhya Pradesh, India.
FAU - Diwan, Vishal
AU  - Diwan V
AUID- ORCID: http://orcid.org/0000-0001-7948-8579
AD  - Department of Environmental Monitoring And Exposure Assessment (Water and Soil), 
      ICMR-National Institute for Research in Environmental Health, Bhopal, Madhya
      Pradesh, India. vishaldiwan@hotmail.com.
AD  - Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
      vishaldiwan@hotmail.com.
FAU - Nandi, Subroto Shambhu
AU  - Nandi SS
AD  - Department of Environmental Monitoring And Exposure Assessment (Air),
      ICMR-National Institute for Research in Environmental Health, Bhopal, Madhya
      Pradesh, India.
FAU - Aher, Satish Bhagwatrao
AU  - Aher SB
AD  - Department of Environmental Monitoring And Exposure Assessment (Air),
      ICMR-National Institute for Research in Environmental Health, Bhopal, Madhya
      Pradesh, India.
FAU - Tiwari, Rajnarayan R
AU  - Tiwari RR
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, Madhya
      Pradesh, India.
FAU - Sabde, Yogesh Damodar
AU  - Sabde YD
AD  - Department of Environmental Health and Epidemiology, ICMR-National Institute for 
      Research in Environmental Health, Bhopal, Madhya Pradesh, India.
LA  - eng
GR  - 66/12/SAC/NIREH/2018-NCD-II, dt. 04/11/2019/Indian Council of Medical Research
PT  - Journal Article
DEP - 20201130
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adult
MH  - Air Pollution/*adverse effects/*analysis
MH  - Community-Based Participatory Research/methods
MH  - *Crops, Agricultural
MH  - Female
MH  - *Fires
MH  - Focus Groups
MH  - Humans
MH  - India
MH  - Male
MH  - Qualitative Research
MH  - Research Design
MH  - Stakeholder Participation/psychology
PMC - PMC7706198
OTO - NOTNLM
OT  - Air pollution
OT  - Community-based participatory research
OT  - Crop residue burning
OT  - Focus groups
OT  - India
OT  - Key informant interview
EDAT- 2020/12/02 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/12/01 05:35
PHST- 2020/10/17 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/12/01 05:35 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - 10.1186/s12889-020-09844-6 [doi]
AID - 10.1186/s12889-020-09844-6 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Nov 30;20(1):1824. doi: 10.1186/s12889-020-09844-6.


PMID- 33256605
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 30
TI  - Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in 
      new onset acute coronary syndrome: a retrospective cohort study.
PG  - 500
LID - 10.1186/s12872-020-01773-x [doi]
AB  - BACKGROUND: Inflammation is involved in the pathogenesis and progression of
      coronary artery diseases (CADs), including acute coronary syndrome. The
      neutrophil-to-lymphocyte ratio (NLR) has been identified as a novel marker of the
      pro-inflammatory state. We aimed to evaluate the predictive efficacy of the NLR
      for the prognosis of patients with new-onset ACS. METHODS: We retrospectively
      included consecutive patients with new-onset ACS treated with emergency coronary 
      angiography. NLR was measured at baseline and analyzed by tertiles. The severity 
      of coronary lesions was evaluated by the Gensini score. Correlations of NLR with 
      the severity of CAD and the incidence of major adverse cardiovascular diseases
      (MACEs) during follow-up were determined. RESULTS: Overall, 737 patients were
      included. The NLR was positively correlated with the severity of coronary lesions
      as assessed by Gensini score (P < 0.05). During the follow-up period (mean, 43.49
      +/- 23.97 months), 65 MACEs occurred. No significant association was detected
      between baseline NLR and the risk of MACEs during follow-up by either
      Kaplan-Meier or Cox regression analysis. Multivariable logistic regression
      analysis showed that a higher NLR was independently associated with coronary
      lesion severity as measured by the Gensini score (1st tertile vs. 3rd tertile
      hazard ratio [HR]: 0.527, P < 0.001, and 2nd tertile vs. 3rd tertile HR: 0.474, P
      = 0.025). CONCLUSIONS: The NLR may be associated with coronary disease severity
      at baseline but is not associated with adverse outcomes in patients with
      new-onset ACS. ETHICS APPROVAL NUMBER: 2019XE0208.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Cardiology Fourth Ward, The Xinjiang Medical University Affiliated 
      Hospital of Traditional Chinese Medicine, Urumqi, 830011, China.
FAU - Xu, Yanan
AU  - Xu Y
AD  - The People's Hospital of Xuancheng City, Anhui, 242000, China.
FAU - Wang, Jun
AU  - Wang J
AD  - The People's Hospital of Xuancheng City, Anhui, 242000, China.
FAU - Zhai, Xueqin
AU  - Zhai X
AD  - Department of Cardiology Fourth Ward, The Xinjiang Medical University Affiliated 
      Hospital of Traditional Chinese Medicine, Urumqi, 830011, China.
FAU - Jiang, Haibing
AU  - Jiang H
AD  - Department of Cardiology Fourth Ward, The Xinjiang Medical University Affiliated 
      Hospital of Traditional Chinese Medicine, Urumqi, 830011, China. 15545959@qq.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201130
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
SB  - IM
MH  - Acute Coronary Syndrome/blood/*diagnosis/therapy
MH  - Aged
MH  - Coronary Angiography
MH  - Female
MH  - Humans
MH  - Lymphocyte Count
MH  - *Lymphocytes
MH  - Male
MH  - Middle Aged
MH  - *Neutrophils
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Time Factors
PMC - PMC7706201
OTO - NOTNLM
OT  - *Acute coronary syndrome
OT  - *Gensini score
OT  - *Major adverse cardiovascular events
OT  - *Neutrophil and lymphocyte ratio
EDAT- 2020/12/02 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/12/01 05:35
PHST- 2020/01/03 00:00 [received]
PHST- 2020/11/08 00:00 [accepted]
PHST- 2020/12/01 05:35 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1186/s12872-020-01773-x [doi]
AID - 10.1186/s12872-020-01773-x [pii]
PST - epublish
SO  - BMC Cardiovasc Disord. 2020 Nov 30;20(1):500. doi: 10.1186/s12872-020-01773-x.


PMID- 33256438
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1535-7228 (Electronic)
IS  - 0002-953X (Linking)
VI  - 177
IP  - 12
DP  - 2020 Dec 1
TI  - Involuntary Commitments: Billing Patients for Forced Psychiatric Care.
PG  - 1115-1116
LID - 10.1176/appi.ajp.2020.20030319 [doi]
FAU - Morris, Nathaniel P
AU  - Morris NP
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University School of
      Medicine, Palo Alto, Calif.
FAU - Kleinman, Robert A
AU  - Kleinman RA
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University School of
      Medicine, Palo Alto, Calif.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Psychiatry
JT  - The American journal of psychiatry
JID - 0370512
SB  - IM
MH  - Commitment of Mentally Ill/*economics/*ethics
MH  - Health Care Costs/*ethics
MH  - Humans
MH  - Involuntary Commitment/*ethics
OTO - NOTNLM
OT  - *Administration and Management
OT  - *Emergency Psychiatry
OT  - *Ethics
OT  - *Inpatient Psychiatry
OT  - *Mental Health Care/Service Delivery Systems
OT  - *Sociopolitical Issues
EDAT- 2020/12/02 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/12/01 05:34
PHST- 2020/12/01 05:34 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1176/appi.ajp.2020.20030319 [doi]
PST - ppublish
SO  - Am J Psychiatry. 2020 Dec 1;177(12):1115-1116. doi:
      10.1176/appi.ajp.2020.20030319.


PMID- 33256202
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2305-6320 (Print)
IS  - 2305-6320 (Linking)
VI  - 7
IP  - 12
DP  - 2020 Nov 26
TI  - Auricular Acupuncture for Preoperative Anxiety-Protocol of Systematic Review and 
      Meta-Analysis of Randomized Controlled Trials.
LID - E73 [pii]
LID - 10.3390/medicines7120073 [doi]
AB  - Background: Preoperative anxiety causes profound psychological and physiological 
      reactions that may lead to a worse postoperative recovery, higher intensity of
      acute and persistent postsurgical pain and impaired quality of life in the
      postoperative period. Previous randomized controlled trials (RCTs) suggest that
      auricular acupuncture (AA) is safe and effective in the treatment of preoperative
      anxiety; however there is a lack of systematic evidence on this topic. Therefore,
      this protocol was developed following the PRISMA guidelines to adequately
      evaluate the existing literature regarding the value of AA for the reduction in
      anxiety in patients in a preoperative setting, compared to other forms of
      acupuncture, pharmacological, or no control interventions and measured with
      questionnaires regarding anxiety and fear. Methods: The following databases will 
      be searched: MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled
      Trials (CENTRAL), ISI Web of Science, and Scopus Database. RCTs will be included 
      if an abstract is available in English. Data collection and analysis will be
      conducted by two reviewers independently. Quality and risk assessment of included
      studies will be done using the Cochrane 5.1.0 handbook criteria and meta-analysis
      of effectiveness and symptom scores will be conducted using the statistical
      software RevMan V.5.3. Conclusions: This systematic review will evaluate the
      efficacy and safety of AA for preoperative anxiety. Since all data used in this
      systematic review and meta-analysis have been published, this review does not
      require ethical approval. The results may be published in a peer-reviewed journal
      or be presented in relevant conferences. Registration number: PROSPERO ID
      CRD42020.
FAU - Dietzel, Joanna
AU  - Dietzel J
AD  - Institute of Social Medicine, Epidemiology and Health Economics, Charite
      University Medicine, 10117 Berlin, Germany.
FAU - Cummings, Mike
AU  - Cummings M
AUID- ORCID: 0000-0003-2224-8835
AD  - British Medical Acupuncture Society, London WC1N 3HR, UK.
FAU - Hua, Kevin
AU  - Hua K
AD  - Institute of Social Medicine, Epidemiology and Health Economics, Charite
      University Medicine, 10117 Berlin, Germany.
FAU - Hahnenkamp, Klaus
AU  - Hahnenkamp K
AD  - Department of Anesthesiology, University Medicine of Greifswald, 17475
      Greifswald, Germany.
FAU - Brinkhaus, Benno
AU  - Brinkhaus B
AD  - Institute of Social Medicine, Epidemiology and Health Economics, Charite
      University Medicine, 10117 Berlin, Germany.
FAU - Usichenko, Taras I
AU  - Usichenko TI
AD  - Department of Anesthesiology, University Medicine of Greifswald, 17475
      Greifswald, Germany.
AD  - Department of Anesthesia, McMaster University, Hamilton, ON L8S 4K1, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - Switzerland
TA  - Medicines (Basel)
JT  - Medicines (Basel, Switzerland)
JID - 101671069
PMC - PMC7768405
OTO - NOTNLM
OT  - auricular acupuncture
OT  - meta-analysis
OT  - preoperative anxiety
OT  - protocol
OT  - randomized controlled trials
OT  - systematic review
EDAT- 2020/12/02 06:00
MHDA- 2020/12/02 06:01
CRDT- 2020/12/01 01:11
PHST- 2020/10/31 00:00 [received]
PHST- 2020/11/20 00:00 [revised]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2020/12/01 01:11 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/02 06:01 [medline]
AID - medicines7120073 [pii]
AID - 10.3390/medicines7120073 [doi]
PST - epublish
SO  - Medicines (Basel). 2020 Nov 26;7(12). pii: medicines7120073. doi:
      10.3390/medicines7120073.


PMID- 33255970
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 23
DP  - 2020 Nov 26
TI  - Recovery-Oriented Intersectoral Care in Mental Health: As Perceived by Healthcare
      Professionals and Users.
LID - E8777 [pii]
LID - 10.3390/ijerph17238777 [doi]
AB  - This study aimed to explore how mental health professionals and users perceive
      recovery-oriented intersectoral care when comparing mental health hospitals and
      community mental healthcare. Methodological design: Five audio-recorded focus
      group interviews of nurses, other health professionals and users were explored
      using manifest and latent content analysis. ETHICAL ISSUES AND APPROVAL: The
      study was designed in accordance with the ethical principles of the Helsinki
      Declaration and Danish law. Each study participant in the two intersectoral
      sectors gave their informed consent after verbal and written information was
      provided. FINDINGS: From the health professionals' perspective, the main theme
      informed by subthemes and categories was formulated: 'Recovery-oriented
      intersectoral care requires more coordination and desire for collaboration'. Two 
      subthemes were subsequently formulated: 'The users perspective of the centre' and
      'Need for a common agenda and understanding of recovery-oriented intersectoral
      care'. From the users perspective, the main theme was formulated as:
      'Recovery-oriented intersectoral care in tension between medical- and
      holistically oriented care'. This theme was informed by two subthemes: 'The users
      perspective is not in focus' and 'A trusting relationship and a holistic approach
      brings coherence'. CONCLUSIONS: This study reveals that health professionals want
      to work in a recovery-oriented manner in intersectoral care, but several
      challenges appear which make achieving this aim difficult. A common understanding
      of recovery and how it should be carried out in intersectoral care does not
      exist. Care decisions are primarily made paternalistically, where the users' and 
      relatives' voices are ignored. In an attempt to create coherence across sectors, 
      intersectoral network meetings have been established with health professionals
      from both sectors. However, the meetings are characterised by a lack of a clear
      purpose regarding the meeting structure and content, and users are only minimally
      involved. Our results can contribute to dealing with the challenges of
      incorporating recovery-oriented intersectoral care as an ideology in all
      psychiatric and municipal contexts and is, therefore, important for health
      professionals and users.
FAU - Jorgensen, Kim
AU  - Jorgensen K
AUID- ORCID: 0000-0001-9362-7600
AD  - The Research Collaboration, Psychiatric Centre North Zealand, Dyrehavevej 48,
      DK-3400 Hilleroed, Denmark.
FAU - Rasmussen, Tonie
AU  - Rasmussen T
AD  - Center for Quality and Development, Department of Social Health, Rudersdal
      Kommune, Stationsvej 36, 3460 Birkerod, Denmark.
FAU - Hansen, Morten
AU  - Hansen M
AD  - Psychiatric Outpatient Clinic Norrebro Griffenfeldsgade 46, 2200 Copenhagen,
      Denmark.
FAU - Andreasson, Kate
AU  - Andreasson K
AD  - The Research Collaboration, Psychiatric Centre North Zealand, Dyrehavevej 48,
      DK-3400 Hilleroed, Denmark.
FAU - Karlsson, Bengt
AU  - Karlsson B
AD  - Center for Mental Health and Substance Abuse, Department of Health, Social and
      Welfare Studies, Faculty of Health and Social Sciences, University of
      South-Eastern Norway, Postbox 7053, 3007 Drammen, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Delivery of Health Care
MH  - Focus Groups
MH  - Health Personnel
MH  - Humans
MH  - *Mental Health
MH  - *Mental Health Services
PMC - PMC7734578
OTO - NOTNLM
OT  - *collaboration
OT  - *community mental healthcare
OT  - *healthcare professionals
OT  - *intersectoral care
OT  - *mental health hospitals
OT  - *nursing care
OT  - *patient participation
OT  - *recovery-oriented
OT  - *users
EDAT- 2020/12/02 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/12/01 01:10
PHST- 2020/09/08 00:00 [received]
PHST- 2020/10/15 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/12/01 01:10 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - ijerph17238777 [pii]
AID - 10.3390/ijerph17238777 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 26;17(23). pii: ijerph17238777. doi:
      10.3390/ijerph17238777.


PMID- 33255482
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 23
DP  - 2020 Nov 24
TI  - Self-Perceptions and Behavior of Older People Living Alone.
LID - E8739 [pii]
LID - 10.3390/ijerph17238739 [doi]
AB  - It is currently acknowledged that older people prefer to live in their own home, 
      even if they are lonely or disabled in some way. The factors that condition aging
      among older people members of the population living alone include the following: 
      the existence or absence of a social network, gender, the home or place where
      they live, their capacity to function, and welfare and health resources. The main
      goal of this study was to explore the perceptions of older peoples over 75 years 
      old about adaptation strategies and the social, gender, physical autonomy, and
      socio-health resource factors that determine their permanence at home. The
      authors used a qualitative methodology, within a critical social framework, based
      on the theories of Pierre Bourdieu. When the interviewees' discourse was
      analyzed, four main categories were evident: (a) "A desire to stay at home", (b) 
      "Changes and every-day aspects of domestic life", (c) "Reliance on social and
      family assistance", and (d) "The use of social services and resources". In
      synthesis, the participants questioned the benefits of the type of home life
      offered by members of the family. They believed that, in some cases, this option 
      did not overcome the problem of loneliness or the need to hire assistance. The
      findings of the study revealed that one needs to dispel the notion of geriatric
      care as a form of charity, and to distinguish between the activities of caring,
      providing support, and offering companionship to someone. It is important to
      identify products designed for older people who might live for a long time.
FAU - Molina-Mula, Jesus
AU  - Molina-Mula J
AUID- ORCID: 0000-0002-5789-1313
AD  - Nursing and Physiotherapy Department, Universitat de les Illes Balears, 07122
      Palma (Illes Balears), Spain.
FAU - Gallo-Estrada, Julia
AU  - Gallo-Estrada J
AD  - Nursing and Physiotherapy Department, Universitat de les Illes Balears, 07122
      Palma (Illes Balears), Spain.
FAU - Gonzalez-Trujillo, Antonio
AU  - Gonzalez-Trujillo A
AD  - Center for Innovation and Development in Nursing and Physiotherapy of the
      Balearic Islands of the Nursing Union (SATSE-CIDEFIB), 07003 Palma (Illes
      Balears), Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging
MH  - *Disabled Persons
MH  - Humans
MH  - *Loneliness
MH  - *Self Concept
PMC - PMC7727835
OTO - NOTNLM
OT  - *Bourdieu
OT  - *elderly people
OT  - *ethical issues
OT  - *public policy
OT  - *self-perceptions
EDAT- 2020/12/02 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/12/01 01:08
PHST- 2020/10/21 00:00 [received]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/01 01:08 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - ijerph17238739 [pii]
AID - 10.3390/ijerph17238739 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 24;17(23). pii: ijerph17238739. doi:
      10.3390/ijerph17238739.


PMID- 33255445
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201226
IS  - 2079-4991 (Print)
IS  - 2079-4991 (Linking)
VI  - 10
IP  - 12
DP  - 2020 Nov 24
TI  - The Chorioallantoic Membrane Assay in Nanotoxicological Research-An Alternative
      for In Vivo Experimentation.
LID - E2328 [pii]
LID - 10.3390/nano10122328 [doi]
AB  - Nanomaterials unveil many applicational possibilities for technical and medical
      purposes, which range from imaging techniques to the use as drug carriers. Prior 
      to any human application, analysis of undesired effects and characterization of
      their toxicological profile is mandatory. To address this topic, animal models,
      and rodent models in particular, are most frequently used. However, as the
      reproducibility and transferability to the human organism of animal experimental 
      data is increasingly questioned and the awareness of animal welfare in society
      increases at the same time, methodological alternatives are urgently required.
      The chorioallantoic membrane (CAM) assay is an increasingly popular in ovo
      experimental organism suitable for replacement of rodent experimentation. In this
      review, we outline several application fields for the CAM assay in the field of
      nanotoxicology. Furthermore, analytical methods applicable with this model were
      evaluated in detail. We further discuss ethical, financial, and bureaucratic
      aspects and benchmark the assay with other established in vivo models such as
      rodents.
FAU - Buhr, Christoph R
AU  - Buhr CR
AD  - Department of Otorhinolaryngology, University Medical Center of the Johannes
      Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz,
      Rhineland-Palatinate, Germany.
FAU - Wiesmann, Nadine
AU  - Wiesmann N
AUID- ORCID: 0000-0001-5661-6953
AD  - Department of Otorhinolaryngology, University Medical Center of the Johannes
      Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz,
      Rhineland-Palatinate, Germany.
AD  - Department of Oral and Maxillofacial Surgery, -Plastic Surgery, University
      Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1,
      55131 Mainz, Rhineland-Palatinate, Germany.
FAU - Tanner, Rachel C
AU  - Tanner RC
AUID- ORCID: 0000-0002-8317-4916
AD  - Department of Otorhinolaryngology, University Medical Center of the Johannes
      Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz,
      Rhineland-Palatinate, Germany.
FAU - Brieger, Jurgen
AU  - Brieger J
AD  - Department of Otorhinolaryngology, University Medical Center of the Johannes
      Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz,
      Rhineland-Palatinate, Germany.
FAU - Eckrich, Jonas
AU  - Eckrich J
AD  - Department of Otorhinolaryngology, University Medical Center of the Johannes
      Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz,
      Rhineland-Palatinate, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201124
PL  - Switzerland
TA  - Nanomaterials (Basel)
JT  - Nanomaterials (Basel, Switzerland)
JID - 101610216
PMC - PMC7760845
OTO - NOTNLM
OT  - CAM assay
OT  - CAM model
OT  - animal models
OT  - chorioallantoic membrane assay
OT  - in vivo models
OT  - nanoparticles
OT  - nanotoxicology
OT  - rodent models
OT  - toxicology
EDAT- 2020/12/02 06:00
MHDA- 2020/12/02 06:01
CRDT- 2020/12/01 01:08
PHST- 2020/10/25 00:00 [received]
PHST- 2020/11/18 00:00 [revised]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2020/12/01 01:08 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/02 06:01 [medline]
AID - nano10122328 [pii]
AID - 10.3390/nano10122328 [doi]
PST - epublish
SO  - Nanomaterials (Basel). 2020 Nov 24;10(12). pii: nano10122328. doi:
      10.3390/nano10122328.


PMID- 33254574
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 144
DP  - 2020 Nov
TI  - Is there an under-representation of skin of colour images during the COVID-19
      outbreak?
PG  - 110270
LID - S0306-9877(20)32725-0 [pii]
LID - 10.1016/j.mehy.2020.110270 [doi]
FAU - Kluger, Nicolas
AU  - Kluger N
AD  - Departments of Dermatology, Allergology and Venereology, Helsinki University
      Hospital, Meilahdentie 2, P.O. Box 160, 00029 HUS Helsinki, Finland. Electronic
      address: nicolas.kluger@hus.fi.
FAU - Samimi, Mahtab
AU  - Samimi M
AD  - Department of Dermatology, University Hospital of Tours, University of Tours,
      Tours, France; ISP 1282 INRA University of Tours, Tours, France.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200913
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
SB  - IM
CON - Br J Dermatol. 2020 Sep;183(3):593-595. PMID: 32471009
MH  - *COVID-19
MH  - Disease Outbreaks
MH  - Humans
MH  - Pandemics
MH  - Publications
MH  - SARS-CoV-2
MH  - Skin
MH  - Skin Pigmentation
PMC - PMC7487202
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Ethnic skin
OT  - *Minorities
OT  - *SARS-CoV-2
OT  - *Skin of colour
EDAT- 2020/12/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/12/01 01:02
PHST- 2020/08/26 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/12/01 01:02 [entrez]
PHST- 2020/12/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S0306-9877(20)32725-0 [pii]
AID - 10.1016/j.mehy.2020.110270 [doi]
PST - ppublish
SO  - Med Hypotheses. 2020 Nov;144:110270. doi: 10.1016/j.mehy.2020.110270. Epub 2020
      Sep 13.


PMID- 33254206
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 2208-7958 (Electronic)
VI  - 49
IP  - 12
DP  - 2020 Dec
TI  - Making a good mental health diagnosis: Science, art and ethics.
PG  - 797-802
LID - 10.31128/AJGP-08-20-5606 [doi]
AB  - BACKGROUND: There are limitations to psychiatric classification, which affects
      the utility of diagnosis in general practice. OBJECTIVE: The aim of this article 
      is to explore the principles of science, art and ethics to create clinically
      useful psychiatric diagnoses in general practice. DISCUSSION: Psychiatric
      classification systems provide useful constructs for clinical practice and
      research. Evidence-based treatments are based on the classification of mental
      illnesses. However, while classification is necessary, it is not sufficient to
      provide a full understanding of 'what is going on'. A good psychiatric diagnosis 
      will also include a formulation, which provides an understanding of the
      psychosocial factors that provide a context for illness. Experiences such as
      trauma and marginalisation will change the illness experience but also provide
      other forms of evidence that shape therapy. Diagnoses also carry ethical
      implications, including stigma and changes in selfconcept. The science, art and
      ethics of diagnosis need to be integrated to provide a complete assessment.
FAU - Stone, Louise
AU  - Stone L
AD  - MBBS, BA, DipRACOG, GDFamMed, MPH, MQHR, PhD,@FRACGP, FACRRM, Clinical Associate 
      Professor, Academic Unit@of General Practice, ANU Medical School, Australian
      National University, ACT.
FAU - Waldron, Elizabeth
AU  - Waldron E
AD  - Flinders University, SA.
FAU - Nowak, Heather
AU  - Nowak H
AD  - DipCSMH, Consumer representative, National Mental Health Consumer and Carer
      Forum,@ACT.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust J Gen Pract
JT  - Australian journal of general practice
JID - 101718099
SB  - IM
MH  - Child
MH  - Diagnosis, Differential
MH  - Humans
MH  - Male
MH  - Mental Disorders/*diagnosis/psychology
MH  - Psychology, Child/instrumentation/methods
EDAT- 2020/12/01 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/11/30 20:16
PHST- 2020/11/30 20:16 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
AID - 10.31128/AJGP-08-20-5606 [doi]
PST - ppublish
SO  - Aust J Gen Pract. 2020 Dec;49(12):797-802. doi: 10.31128/AJGP-08-20-5606.


PMID- 33253513
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210713
IS  - 1488-2310 (Electronic)
IS  - 0008-428X (Linking)
VI  - 63
IP  - 6
DP  - 2020 Nov 30
TI  - North-South surgical training partnerships: a systematic review.
PG  - E551-E561
LID - 10.1503/cjs.008219 [doi]
AB  - Background: Fostering the success of surgical trainees from low- and
      middle-income countries (LMICs) plausibly addresses the existing workforce
      deficit in a sustainable manner, but it is unclear whether and how these trainees
      are targeted as strategic learners for educational exchanges. The purpose of this
      review was to assess the quality and outcomes of existing literature on exchanges
      of surgical trainees between high-income countries (HICs) and LMICs. Methods: We 
      conducted a systematic review of reported instances of surgical training
      exchanges between HICs and LMICs. After database searching, 2 independent
      reviewers evaluated titles, abstracts and manuscripts. Selected studies were
      critically appraised with the use the Critical Assessment Skills Programme
      Qualitative Checklist and analyzed for trainee level, institutions, countries and
      subspecialties, as well as reported outcomes of the exchange. Results:
      Twenty-eight reports met the inclusion criteria and were analyzed. Most
      publications (18 [64%]) detailed North-to-South exchanges; 1 exchange was
      bidirectional. General surgery was the most common discipline identified, with 9 
      other subspecialties described involving learners at all phases of training.
      Reports were generally of good quality, although outcomes were reported variably,
      and most authors failed to acknowledge the ethical implications of their study.
      Conclusion: The articles identified described a variety of surgical exchanges
      across disciplines, learner types and host/home countries. Few of the exchanges
      prioritized the learning of surgical trainees from LMICs. There is an increasing 
      need to formalize these exchanges via clear goals and objectives, as well as to
      prioritize the proper matching of educational goals with local clinical needs.
      Level of evidence: V - Evidence from systematic reviews of descriptive and
      qualitative studies.
CI  - (c) 2020 Joule Inc. or its licensors.
FAU - Greive-Price, Tim
AU  - Greive-Price T
AD  - From the Division of Pediatric Surgery, University of British Colombia,
      Vancouver, BC.
FAU - Mistry, Hardee
AU  - Mistry H
AD  - From the Division of Pediatric Surgery, University of British Colombia,
      Vancouver, BC.
FAU - Baird, Robert
AU  - Baird R
AD  - From the Division of Pediatric Surgery, University of British Colombia,
      Vancouver, BC.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201130
PL  - Canada
TA  - Can J Surg
JT  - Canadian journal of surgery. Journal canadien de chirurgie
JID - 0372715
SB  - IM
CIN - Can J Surg. 2021 Apr 08;64(2):E240. PMID: 33829733
CIN - Can J Surg. 2021 Apr 08;64(2):E240. PMID: 33829734
MH  - Clinical Competence
MH  - *Developed Countries
MH  - *Developing Countries
MH  - Education, Medical, Continuing/*methods
MH  - Humans
MH  - *International Educational Exchange
MH  - Qualitative Research
MH  - Surgeons/*education
PMC - PMC7747846
COIS- None declared
EDAT- 2020/12/01 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/11/30 18:11
PHST- 2020/11/30 18:11 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - 10.1503/cjs.008219 [doi]
PST - epublish
SO  - Can J Surg. 2020 Nov 30;63(6):E551-E561. doi: 10.1503/cjs.008219.


PMID- 33253269
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Publication rates of research projects of an internal funding program of a
      university medical center in Germany: A retrospective study (2004-2013).
PG  - e0243092
LID - 10.1371/journal.pone.0243092 [doi]
AB  - OBJECTIVES: Non-publication and publication bias are topics of considerable
      importance to the scientific community. These issues may limit progress toward
      the 3R principle for animal research, promote waste of public resources, and
      generate biased interpretations of clinical outcomes. To investigate current
      publishing practices and to gain some understanding of the extent to which
      research results are reported, we examined publication rates of research projects
      that were approved within an internal funding program of the Faculty of Medicine 
      at a university medical center in Germany, which is exemplary for comparable
      research funding programs for the promotion of young researchers in Germany and
      Europe. METHODS: We analyzed the complete set (n = 363) of research projects that
      were supported by an internal funding program between 2004 and 2013. We divided
      the projects into four different proposal types that included those that required
      an ethics vote, those that included an animal proposal, those that included both 
      requirements, and those that included neither requirement. RESULTS: We found that
      65% of the internally funded research projects resulted in at least one
      peer-reviewed publication; this increased to 73% if other research contributions 
      were considered, including abstracts, book and congress contributions, scientific
      posters, and presentations. There were no significant differences with respect to
      publication rates based on (a) the clinic/institute of the applicant, (b) project
      duration, (c) scope of funding or (d) proposal type. CONCLUSION: To the best of
      our knowledge, this is the first study to explore publication rates associated
      with early-career medical research funding. As >70% of the projects ultimately
      generated some form of publication, the program was overall effective toward this
      goal; however, non-publication of research results is still prevalent. Further
      research will explore the reasons underlying non-publication. We hope to use
      these findings to develop strategies that encourage publication of research
      results.
FAU - Deutsch, Susanne
AU  - Deutsch S
AUID- ORCID: 0000-0001-8264-697X
AD  - Faculty of Medicine, Institute for Laboratory Animal Science & Experimental
      Surgery, RWTH Aachen University, Aachen, Germany.
FAU - Reuter, Silke
AU  - Reuter S
AD  - Faculty of Medicine, Dean's Office, RWTH Aachen University, Aachen, Germany.
FAU - Rose, Astrid
AU  - Rose A
AD  - Faculty of Medicine, Dean's Office, RWTH Aachen University, Aachen, Germany.
FAU - Tolba, Rene
AU  - Tolba R
AD  - Faculty of Medicine, Institute for Laboratory Animal Science & Experimental
      Surgery, RWTH Aachen University, Aachen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201130
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Academic Medical Centers/*economics/standards
MH  - Biomedical Research/economics/standards
MH  - *Capital Financing
MH  - Germany/epidemiology
MH  - Humans
MH  - Peer Review, Research
MH  - Publication Bias
MH  - Publications/economics/*standards
MH  - Research/economics/*standards
MH  - Retrospective Studies
PMC - PMC7703943
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/01 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/11/30 17:13
PHST- 2020/06/19 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/11/30 17:13 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1371/journal.pone.0243092 [doi]
AID - PONE-D-20-14186 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 30;15(11):e0243092. doi: 10.1371/journal.pone.0243092.
      eCollection 2020.


PMID- 33252677
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20220531
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 12
DP  - 2020 Dec 1
TI  - Top 10 priorities for future infertility research: an international consensus
      development studydagger double dagger.
PG  - 2715-2724
LID - 10.1093/humrep/deaa242 [doi]
AB  - STUDY QUESTION: Can the priorities for future research in infertility be
      identified? SUMMARY ANSWER: The top 10 research priorities for the four areas of 
      male infertility, female and unexplained infertility, medically assisted
      reproduction and ethics, access and organization of care for people with
      fertility problems were identified. WHAT IS KNOWN ALREADY: Many fundamental
      questions regarding the prevention, management and consequences of infertility
      remain unanswered. This is a barrier to improving the care received by those
      people with fertility problems. STUDY DESIGN, SIZE, DURATION: Potential research 
      questions were collated from an initial international survey, a systematic review
      of clinical practice guidelines and Cochrane systematic reviews. A rationalized
      list of confirmed research uncertainties was prioritized in an interim
      international survey. Prioritized research uncertainties were discussed during a 
      consensus development meeting. Using a formal consensus development method, the
      modified nominal group technique, diverse stakeholders identified the top 10
      research priorities for each of the categories male infertility, female and
      unexplained infertility, medically assisted reproduction and ethics, access and
      organization of care. PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare
      professionals, people with fertility problems and others (healthcare funders,
      healthcare providers, healthcare regulators, research funding bodies and
      researchers) were brought together in an open and transparent process using
      formal consensus methods advocated by the James Lind Alliance. MAIN RESULTS AND
      THE ROLE OF CHANCE: The initial survey was completed by 388 participants from 40 
      countries, and 423 potential research questions were submitted. Fourteen clinical
      practice guidelines and 162 Cochrane systematic reviews identified a further 236 
      potential research questions. A rationalized list of 231 confirmed research
      uncertainties was entered into an interim prioritization survey completed by 317 
      respondents from 43 countries. The top 10 research priorities for each of the
      four categories male infertility, female and unexplained infertility (including
      age-related infertility, ovarian cysts, uterine cavity abnormalities and tubal
      factor infertility), medically assisted reproduction (including ovarian
      stimulation, IUI and IVF) and ethics, access and organization of care were
      identified during a consensus development meeting involving 41 participants from 
      11 countries. These research priorities were diverse and seek answers to
      questions regarding prevention, treatment and the longer-term impact of
      infertility. They highlight the importance of pursuing research which has often
      been overlooked, including addressing the emotional and psychological impact of
      infertility, improving access to fertility treatment, particularly in lower
      resource settings and securing appropriate regulation. Addressing these
      priorities will require diverse research methodologies, including
      laboratory-based science, qualitative and quantitative research and population
      science. LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods,
      which have inherent limitations, including the representativeness of the
      participant sample, methodological decisions informed by professional judgment
      and arbitrary consensus definitions. WIDER IMPLICATIONS OF THE FINDINGS: We
      anticipate that identified research priorities, developed to specifically
      highlight the most pressing clinical needs as perceived by healthcare
      professionals, people with fertility problems and others, will help research
      funding organizations and researchers to develop their future research agenda.
      STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the Auckland Medical
      Research Foundation, Catalyst Fund, Royal Society of New Zealand and Maurice and 
      Phyllis Paykel Trust. G.D.A. reports research sponsorship from Abbott, personal
      fees from Abbott and LabCorp, a financial interest in Advanced Reproductive Care,
      committee membership of the FIGO Committee on Reproductive Medicine,
      International Committee for Monitoring Assisted Reproductive Technologies,
      International Federation of Fertility Societies and World Endometriosis Research 
      Foundation, and research sponsorship of the International Committee for
      Monitoring Assisted Reproductive Technologies from Abbott and Ferring. Siladitya 
      Bhattacharya reports being the Editor-in-Chief of Human Reproduction Open and
      editor for the Cochrane Gynaecology and Fertility Group. J.L.H.E. reports being
      the Editor Emeritus of Human Reproduction. A.W.H. reports research sponsorship
      from the Chief Scientist's Office, Ferring, Medical Research Council, National
      Institute for Health Research and Wellbeing of Women and consultancy fees from
      AbbVie, Ferring, Nordic Pharma and Roche Diagnostics. M.L.H. reports grants from 
      Merck, grants from Myovant, grants from Bayer, outside the submitted work and
      ownership in Embrace Fertility, a private fertility company. N.P.J. reports
      research sponsorship from AbbVie and Myovant Sciences and consultancy fees from
      Guerbet, Myovant Sciences, Roche Diagnostics and Vifor Pharma. J.M.L.K. reports
      research sponsorship from Ferring and Theramex. R.S.L. reports consultancy fees
      from AbbVie, Bayer, Ferring, Fractyl, Insud Pharma and Kindex and research
      sponsorship from Guerbet and Hass Avocado Board. B.W.M. reports consultancy fees 
      from Guerbet, iGenomix, Merck, Merck KGaA and ObsEva. E.H.Y.N. reports research
      sponsorship from Merck. C.N. reports being the Co Editor-in-Chief of Fertility
      and Sterility and Section Editor of the Journal of Urology, research sponsorship 
      from Ferring and retains a financial interest in NexHand. J.S. reports being
      employed by a National Health Service fertility clinic, consultancy fees from
      Merck for educational events, sponsorship to attend a fertility conference from
      Ferring and being a clinical subeditor of Human Fertility. A.S. reports
      consultancy fees from Guerbet. J.W. reports being a statistical editor for the
      Cochrane Gynaecology and Fertility Group. A.V. reports that he is a Statistical
      Editor of the Cochrane Gynaecology & Fertility Review Group and the journal
      Reproduction. His employing institution has received payment from Human
      Fertilisation and Embryology Authority for his advice on review of research
      evidence to inform their 'traffic light' system for infertility treatment
      'add-ons'. N.L.V. reports consultancy and conference fees from Ferring, Merck and
      Merck Sharp and Dohme. The remaining authors declare no competing interests in
      relation to the present work. All authors have completed the disclosure form.
      TRIAL REGISTRATION NUMBER: N/A.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology.
FAU - Duffy, J M N
AU  - Duffy JMN
AD  - King's Fertility, Fetal Medicine Research Institute, London, UK.
AD  - Institute for Women's Health, University College London, London, UK.
FAU - Adamson, G D
AU  - Adamson GD
AD  - ARC Fertility, Cupertino, CA, USA.
FAU - Benson, E
AU  - Benson E
AD  - Patient and Public Participation Group, Priority Setting Partnership for
      Infertility, University of Auckland, Auckland, New Zealand.
FAU - Bhattacharya, S
AU  - Bhattacharya S
AD  - Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
FAU - Bhattacharya, S
AU  - Bhattacharya S
AD  - Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
FAU - Bofill, M
AU  - Bofill M
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
FAU - Brian, K
AU  - Brian K
AD  - Women's Network, Royal College of Obstetricians and Gynecologists, London, UK.
FAU - Collura, B
AU  - Collura B
AD  - Resolve: The National Infertility Association, VA, USA.
FAU - Curtis, C
AU  - Curtis C
AD  - School of Psychology, University of Waikato, Hamilton, New Zealand.
FAU - Evers, J L H
AU  - Evers JLH
AD  - Centre for Reproductive Medicine and Biology, University Medical Centre
      Maastricht, Maastricht, The Netherlands.
FAU - Farquharson, R G
AU  - Farquharson RG
AD  - Department of Obstetrics and Gynaecology, Liverpool Women's NHS Foundation Trust,
      Liverpool, UK.
FAU - Fincham, A
AU  - Fincham A
AD  - Fertility Europe, Belgium.
FAU - Franik, S
AU  - Franik S
AD  - Department of Obstetrics and Gynaecology, Munster University Hospital, Munster,
      Germany.
FAU - Giudice, L C
AU  - Giudice LC
AD  - Center for Research, Innovation and Training in Reproduction and Infertility,
      Center for Reproductive Sciences, University of California, San Francisco, CA,
      USA.
AD  - International Federation of Fertility Societies, Mount Royal, NJ, USA.
FAU - Glanville, E
AU  - Glanville E
AD  - Auckland District Health Board, Auckland, New Zealand.
FAU - Hickey, M
AU  - Hickey M
AD  - Department of Obstetrics and Gynaecology, University of Melbourne, Victoria,
      Australia.
FAU - Horne, A W
AU  - Horne AW
AD  - MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.
FAU - Hull, M L
AU  - Hull ML
AD  - Robinson Research Institute and Adelaide Medical School, University of Adelaide, 
      Adelaide, Australia.
FAU - Johnson, N P
AU  - Johnson NP
AD  - Robinson Research Institute and Adelaide Medical School, University of Adelaide, 
      Adelaide, Australia.
FAU - Jordan, V
AU  - Jordan V
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
FAU - Khalaf, Y
AU  - Khalaf Y
AD  - Department of Women and Children's Health, Kings College London, London, UK.
FAU - Knijnenburg, J M L
AU  - Knijnenburg JML
AD  - Freya, Gorinchem, The Netherlands.
FAU - Legro, R S
AU  - Legro RS
AD  - Department of Obstetrics and Gynaecology, Penn State College of Medicine, PA,
      USA.
FAU - Lensen, S
AU  - Lensen S
AD  - Department of Obstetrics and Gynaecology, University of Melbourne, Victoria,
      Australia.
FAU - MacKenzie, J
AU  - MacKenzie J
AD  - Fertility Plus, Auckland, New Zealand.
FAU - Mavrelos, D
AU  - Mavrelos D
AD  - Reproductive Medicine Unit, University College Hospital, London, UK.
FAU - Mol, B W
AU  - Mol BW
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne,
      Australia.
FAU - Morbeck, D E
AU  - Morbeck DE
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
AD  - Fertility Associates, Auckland, New Zealand.
FAU - Nagels, H
AU  - Nagels H
AD  - Cochrane Gynaecology and Fertility, University of Auckland, Auckland, New
      Zealand.
FAU - Ng, E H Y
AU  - Ng EHY
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong.
AD  - Shenzhen Key Laboratory of Fertility Regulation, The University of Hong
      Kong-Shenzhen Hospital, China.
FAU - Niederberger, C
AU  - Niederberger C
AD  - Department of Urology, University of Illinois at Chicago College of Medicine,
      Chicago, IL, USA.
FAU - Otter, A S
AU  - Otter AS
AD  - Osakidetza OSI, Bilbao, Spain.
FAU - Puscasiu, L
AU  - Puscasiu L
AD  - Institute for Women's Health, University College London, London, UK.
AD  - ARC Fertility, Cupertino, CA, USA.
AD  - Center for Reproductive Medicine, Amsterdam Reproduction and Development
      Institute, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
FAU - Rautakallio-Hokkanen, S
AU  - Rautakallio-Hokkanen S
AD  - Fertility Europe, Belgium.
FAU - Sadler, L
AU  - Sadler L
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
AD  - Auckland District Health Board, Auckland, New Zealand.
FAU - Sarris, I
AU  - Sarris I
AD  - King's Fertility, Fetal Medicine Research Institute, London, UK.
FAU - Showell, M
AU  - Showell M
AD  - Cochrane Gynaecology and Fertility, University of Auckland, Auckland, New
      Zealand.
FAU - Stewart, J
AU  - Stewart J
AD  - British Fertility Society, Middlesex, UK.
FAU - Strandell, A
AU  - Strandell A
AD  - Sahlgrenska Academy, Department of Obstetrics and Gynecology, University of
      Gothenburg, Sahlgrenska University Hospital, Goteborg, Sweden.
FAU - Strawbridge, C
AU  - Strawbridge C
AD  - Fertility Network UK, London, UK.
FAU - Vail, A
AU  - Vail A
AD  - Centre for Biostatistics, University of Manchester, Manchester Academic Health
      Science Centre, Manchester, UK.
FAU - van Wely, M
AU  - van Wely M
AD  - Center for Reproductive Medicine, Amsterdam Reproduction and Development
      Institute, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
FAU - Vercoe, M
AU  - Vercoe M
AD  - Cochrane Gynaecology and Fertility, University of Auckland, Auckland, New
      Zealand.
FAU - Vuong, N L
AU  - Vuong NL
AD  - Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy at 
      Ho Chi Minh City, Ho Chi Minh City, Vietnam.
FAU - Wang, A Y
AU  - Wang AY
AD  - Australian Centre for Public and Population Health Research, Faculty of Health,
      University of Technology, Sydney, Australia.
FAU - Wang, R
AU  - Wang R
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne,
      Australia.
FAU - Wilkinson, J
AU  - Wilkinson J
AD  - Centre for Biostatistics, University of Manchester, Manchester Academic Health
      Science Centre, Manchester, UK.
FAU - Wong, K
AU  - Wong K
AD  - School of Psychology, University of Waikato, Hamilton, New Zealand.
FAU - Wong, T Y
AU  - Wong TY
AD  - Auckland District Health Board, Auckland, New Zealand.
FAU - Farquhar, C M
AU  - Farquhar CM
AD  - Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New
      Zealand.
AD  - Cochrane Gynaecology and Fertility, University of Auckland, Auckland, New
      Zealand.
CN  - Priority Setting Partnership for Infertility
FAU - AlAhwany, Hisham
AU  - AlAhwany H
AD  - Priority Setting Partnership for Infertility
FAU - Balaban, Ofra
AU  - Balaban O
AD  - Priority Setting Partnership for Infertility
FAU - Barton, Faith
AU  - Barton F
AD  - Priority Setting Partnership for Infertility
FAU - Beebeejaun, Yusuf
AU  - Beebeejaun Y
AD  - Priority Setting Partnership for Infertility
FAU - Boivin, Jacky
AU  - Boivin J
AD  - Priority Setting Partnership for Infertility
FAU - Bosteels, Jan J. A.
AU  - Bosteels JJA
AD  - Priority Setting Partnership for Infertility
FAU - Calhaz-Jorge, Carlos
AU  - Calhaz-Jorge C
AD  - Priority Setting Partnership for Infertility
FAU - D'Angelo, Arianna
AU  - D'Angelo A
AD  - Priority Setting Partnership for Infertility
FAU - F. Dann, Leona
AU  - F. Dann L
AD  - Priority Setting Partnership for Infertility
FAU - J. De Jonge, Christopher
AU  - J. De Jonge C
AD  - Priority Setting Partnership for Infertility
FAU - du Mez, Elyce
AU  - du Mez E
AD  - Priority Setting Partnership for Infertility
FAU - A. Ferriani, Rui
AU  - A. Ferriani R
AD  - Priority Setting Partnership for Infertility
FAU - Gerval, Marie-Odile
AU  - Gerval MO
AD  - Priority Setting Partnership for Infertility
FAU - J. Gingel, Lynda
AU  - J. Gingel L
AD  - Priority Setting Partnership for Infertility
FAU - Greenblatt, Ellen M.
AU  - Greenblatt EM
AD  - Priority Setting Partnership for Infertility
FAU - Hartshorne, Geraldine
AU  - Hartshorne G
AD  - Priority Setting Partnership for Infertility
FAU - Helliwell, Charlie
AU  - Helliwell C
AD  - Priority Setting Partnership for Infertility
FAU - Hughes, Lynda J.
AU  - Hughes LJ
AD  - Priority Setting Partnership for Infertility
FAU - Jo, Junyoung
AU  - Jo J
AD  - Priority Setting Partnership for Infertility
FAU - Jovanovic, Jelena
AU  - Jovanovic J
AD  - Priority Setting Partnership for Infertility
FAU - Kiesel, Ludwig
AU  - Kiesel L
AD  - Priority Setting Partnership for Infertility
FAU - Kietpeerakool, Chumnan
AU  - Kietpeerakool C
AD  - Priority Setting Partnership for Infertility
FAU - Kostova, Elena
AU  - Kostova E
AD  - Priority Setting Partnership for Infertility
FAU - Kucuk, Tansu
AU  - Kucuk T
AD  - Priority Setting Partnership for Infertility
FAU - Kumar, Rajesh
AU  - Kumar R
AD  - Priority Setting Partnership for Infertility
FAU - Lawrence, Robyn L.
AU  - Lawrence RL
AD  - Priority Setting Partnership for Infertility
FAU - Lee, Nicole
AU  - Lee N
AD  - Priority Setting Partnership for Infertility
FAU - Lindemann, Katy E.
AU  - Lindemann KE
AD  - Priority Setting Partnership for Infertility
FAU - Loto, Olabisi M.
AU  - Loto OM
AD  - Priority Setting Partnership for Infertility
FAU - Lutjen, Peter J.
AU  - Lutjen PJ
AD  - Priority Setting Partnership for Infertility
FAU - MacKinven, Michelle
AU  - MacKinven M
AD  - Priority Setting Partnership for Infertility
FAU - Mascarenhas, Mariano
AU  - Mascarenhas M
AD  - Priority Setting Partnership for Infertility
FAU - McLaughlin, Helen
AU  - McLaughlin H
AD  - Priority Setting Partnership for Infertility
FAU - Mourad, Selma M.
AU  - Mourad SM
AD  - Priority Setting Partnership for Infertility
FAU - Nguyen, Linh K.
AU  - Nguyen LK
AD  - Priority Setting Partnership for Infertility
FAU - Norman, Robert J.
AU  - Norman RJ
AD  - Priority Setting Partnership for Infertility
FAU - Olic, Maja
AU  - Olic M
AD  - Priority Setting Partnership for Infertility
FAU - Overfield, Kristine L.
AU  - Overfield KL
AD  - Priority Setting Partnership for Infertility
FAU - Parker-Harris, Maria
AU  - Parker-Harris M
AD  - Priority Setting Partnership for Infertility
FAU - Repping, Sjoerd
AU  - Repping S
AD  - Priority Setting Partnership for Infertility
FAU - Rizzo, Roberta
AU  - Rizzo R
AD  - Priority Setting Partnership for Infertility
FAU - Salacone, Pietro
AU  - Salacone P
AD  - Priority Setting Partnership for Infertility
FAU - Saunders, Catherine H.
AU  - Saunders CH
AD  - Priority Setting Partnership for Infertility
FAU - Sengupta, Rinku
AU  - Sengupta R
AD  - Priority Setting Partnership for Infertility
FAU - Sfontouris, Ioannis A.
AU  - Sfontouris IA
AD  - Priority Setting Partnership for Infertility
FAU - Silverman, Natalie R.
AU  - Silverman NR
AD  - Priority Setting Partnership for Infertility
FAU - Torrance, Helen L.
AU  - Torrance HL
AD  - Priority Setting Partnership for Infertility
FAU - Uphoff, Eleonora P.
AU  - Uphoff EP
AD  - Priority Setting Partnership for Infertility
FAU - Wakeman, Sarah A.
AU  - Wakeman SA
AD  - Priority Setting Partnership for Infertility
FAU - Wischmann, Tewes
AU  - Wischmann T
AD  - Priority Setting Partnership for Infertility
FAU - Woodward, Bryan J.
AU  - Woodward BJ
AD  - Priority Setting Partnership for Infertility
FAU - Youssef, Mohamed A.
AU  - Youssef MA
AD  - Priority Setting Partnership for Infertility
LA  - eng
GR  - DRF-2014-07-050/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Consensus
MH  - Female
MH  - Humans
MH  - *Infertility/therapy
MH  - Male
MH  - New Zealand
MH  - Ovulation Induction
MH  - *State Medicine
PMC - PMC7744161
OTO - NOTNLM
OT  - *Consensus science methods
OT  - *infertility
OT  - *modified Delphi method
OT  - *modified Nominal Group Technique
OT  - *reproductive medicine
OT  - *research priorities
EDAT- 2020/12/01 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/11/30 12:11
PHST- 2020/05/11 00:00 [received]
PHST- 2020/07/05 00:00 [revised]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
PHST- 2020/11/30 12:11 [entrez]
AID - 6010639 [pii]
AID - 10.1093/humrep/deaa242 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Dec 1;35(12):2715-2724. doi: 10.1093/humrep/deaa242.


PMID- 33252352
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 30
TI  - The Precision Health and Everyday Democracy (PHED) Project: Protocol for a
      Transdisciplinary Collaboration on Health Equity and the Role of Health in
      Society.
PG  - e17324
LID - 10.2196/17324 [doi]
AB  - BACKGROUND: The project "Precision Health and Everyday Democracy" (PHED) is a
      transdisciplinary partnership that combines a diverse range of perspectives
      necessary for understanding the increasingly complex societal role played by
      modern health care and medical research. The term "precision health" is being
      increasingly used to express the need for greater awareness of environmental and 
      genomic characteristics that may lead to divergent health outcomes between
      different groups within a population. Enhancing awareness of diversity has
      parallels with calls for "health democracy" and greater patient-public
      participation within health care and medical research. Approaching health care in
      this way goes beyond a narrow focus on the societal determinants of health, since
      it requires considering health as a deliberative space, which occurs often at the
      banal or everyday level. As an initial empirical focus, PHED is directed toward
      the health needs of marginalized migrants (including refugees and asylum seekers,
      as well as migrants with temporary residency, often involving a legally or
      economically precarious situation) as vulnerable groups that are often overlooked
      by health care. Developing new transdisciplinary knowledge on these groups
      provides the potential to enhance their wellbeing and benefit the wider society
      through challenging the exclusions of these groups that create pockets of extreme
      ill-health, which, as we see with COVID-19, should be better understood as "acts 
      of self-harm" for the wider negative impact on humanity. OBJECTIVE: We aim to
      establish and identify precision health strategies, as well as promote equal
      access to quality health care, drawing upon knowledge gained from studying the
      health care of marginalized migrants. METHODS: The project is based in Sweden at 
      Malmo and Lund Universities. At the outset, the network activities do not require
      ethical approval where they will not involve data collection, since the purpose
      of PHED is to strengthen international research contacts, establish new research 
      within precision strategies, and construct educational research activities for
      junior colleagues within academia. However, whenever new research is funded and
      started, ethical approval for that specific data collection will be sought.
      RESULTS: The PHED project has been funded from January 1, 2019. Results of the
      transdisciplinary collaboration will be disseminated via a series of
      international conferences, workshops, and web-based materials. To ensure the
      network project advances toward applied research, a major goal of dissemination
      is to produce tools for applied research, including information to enhance health
      accessibility for vulnerable communities, such as marginalized migrant
      populations in Sweden. CONCLUSIONS: There is a need to identify tools to enable
      the prevention and treatment of a wide spectrum of health-related outcomes and
      their link to social as well as environmental issues. There is also a need to
      identify and investigate barriers to precision health based on democratic
      principles. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/17324.
CI  - (c)Michael Strange, Carol Nilsson, Slobodan Zdravkovic, Elisabeth Mangrio.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 30.11.2020.
FAU - Strange, Michael
AU  - Strange M
AUID- ORCID: https://orcid.org/0000-0002-2903-7267
AD  - Department of Global Political Studies, Malmo University, Malmo, Sweden.
AD  - Malmo Institute for Studies of Migration, Diversity & Welfare, Malmo University, 
      Malmo, Sweden.
FAU - Nilsson, Carol
AU  - Nilsson C
AUID- ORCID: https://orcid.org/0000-0002-2838-8751
AD  - Department of Experimental Medical Science, Lund University, Lund, Sweden.
FAU - Zdravkovic, Slobodan
AU  - Zdravkovic S
AUID- ORCID: https://orcid.org/0000-0002-8491-4349
AD  - Malmo Institute for Studies of Migration, Diversity & Welfare, Malmo University, 
      Malmo, Sweden.
AD  - Department of Care Sciences, Malmo University, Malmo, Sweden.
FAU - Mangrio, Elisabeth
AU  - Mangrio E
AUID- ORCID: https://orcid.org/0000-0002-9493-6808
AD  - Malmo Institute for Studies of Migration, Diversity & Welfare, Malmo University, 
      Malmo, Sweden.
AD  - Department of Care Sciences, Malmo University, Malmo, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7735904
OTO - NOTNLM
OT  - everyday democracy
OT  - health care access
OT  - health literacy
OT  - precision health
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 12:10
PHST- 2019/12/19 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/10/15 00:00 [revised]
PHST- 2020/11/30 12:10 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
AID - v9i11e17324 [pii]
AID - 10.2196/17324 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 30;9(11):e17324. doi: 10.2196/17324.


PMID- 33252344
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201219
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 30
TI  - Long-Term Follow-Up of a Randomized Controlled Trial to Reduce Excessive Weight
      Gain in Infancy: Protocol for the Prevention of Overweight in Infancy (POI)
      Follow-Up Study at 11 Years.
PG  - e24968
LID - 10.2196/24968 [doi]
AB  - BACKGROUND: The Prevention of Overweight in Infancy (POI) randomized controlled
      trial assessed the effect of a more conventional food, physical activity, and
      breastfeeding intervention, with a more novel sleep intervention on weight
      outcomes at 2 years of age. The trial had 58% uptake at recruitment, and
      retention was 86% at age 2 years, 77% at age 3.5 years, and 69% at age 5 years.
      Children who received the brief sleep intervention in infancy had just half the
      risk of obesity at 2 years of age compared to those who did not receive the sleep
      intervention. Importantly, this substantially reduced risk was still apparent at 
      our follow-up at 5 years of age. OBJECTIVE: The primary aim of this follow-up at 
      age 11 years is to determine whether differences in BMI z-score and obesity risk 
      remain apparent now that it is at least 9 years since cessation of the sleep
      intervention. Several secondary outcomes of interest will also be examined
      including 24-hour movement patterns, mental health and wellbeing, and use of
      electronic media, particularly prior to sleep. METHODS: We will seek renewed
      consent from all 734 of the original 802 POI families who expressed interest in
      further involvement. Children and parent(s) will attend 2 clinics and 1 home
      appointment to obtain measures of anthropometry and body composition (dual-energy
      x-ray absorptiometry scan), 24-hour movement patterns (sleep, sedentary time, and
      physical activity measured using an AX3 accelerometer), mental health and
      wellbeing (validated questionnaires), family functioning (validated
      questionnaires), use of electronic media (wearable and stationary cameras,
      questionnaires), and diet and eating behaviors (24-hour recall, questionnaires). 
      RESULTS: This follow-up study has full ethical approval from the University of
      Otago Human Ethics Committee (H19/109) and was funded in May 2019 by the Health
      Research Council of New Zealand (grant 19/346). Data collection commenced in June
      2020, and first results are expected to be submitted for publication in 2022.
      CONCLUSIONS: Long-term outcomes of early obesity intervention are rare. Despite
      the growing body of evidence linking insufficient sleep with an increased risk of
      obesity in children, interventions targeting improvements in sleep have been
      insufficiently explored. Our initial follow-up at 5 years of age suggested that
      an early sleep intervention may have long-term benefits for effective weight
      management in children. Further analysis in our now preteen population will
      provide much-needed evidence regarding the long-term effectiveness of sleep
      interventions in infancy as an obesity prevention approach. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT00892983; https://tinyurl.com/y3xepvxf. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/24968.
CI  - (c)Taiwo O Adebowale, Barry J Taylor, Andrew R Gray, Barbara C Galland,
      Anne-Louise M Heath, Sarah Fortune, Kim A Meredith-Jones, Trudy Sullivan, Deborah
      McIntosh, Bradley Brosnan, Rachael W Taylor. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 30.11.2020.
FAU - Adebowale, Taiwo O
AU  - Adebowale TO
AUID- ORCID: https://orcid.org/0000-0001-8002-9871
AD  - Department of Medicine, University of Otago, Dunedin, New Zealand.
FAU - Taylor, Barry J
AU  - Taylor BJ
AUID- ORCID: https://orcid.org/0000-0002-6450-8677
AD  - Department of Women's and Children's Health, Children's Pavilion Dunedin Public
      Hospital, University of Otago, Dunedin, New Zealand.
FAU - Gray, Andrew R
AU  - Gray AR
AUID- ORCID: https://orcid.org/0000-0003-4299-2194
AD  - Biostatistics Centre, University of Otago, Dunedin, New Zealand.
FAU - Galland, Barbara C
AU  - Galland BC
AUID- ORCID: https://orcid.org/0000-0002-2376-3575
AD  - Department of Women's and Children's Health, University of Otago, Dunedin, New
      Zealand.
FAU - Heath, Anne-Louise M
AU  - Heath AM
AUID- ORCID: https://orcid.org/0000-0003-2856-0782
AD  - Department of Human Nutrition, University of Otago, Dunedin, New Zealand.
FAU - Fortune, Sarah
AU  - Fortune S
AUID- ORCID: https://orcid.org/0000-0002-8864-8295
AD  - Department of Psychological Medicine, University of Otago, Dunedin, New Zealand.
FAU - Meredith-Jones, Kim A
AU  - Meredith-Jones KA
AUID- ORCID: https://orcid.org/0000-0002-5445-4871
AD  - Department of Medicine, University of Otago, Dunedin, New Zealand.
FAU - Sullivan, Trudy
AU  - Sullivan T
AUID- ORCID: https://orcid.org/0000-0001-8452-2591
AD  - Department of Preventive and Social Medicine, University of Otago, Dunedin, New
      Zealand.
FAU - McIntosh, Deborah
AU  - McIntosh D
AUID- ORCID: https://orcid.org/0000-0003-1251-8563
AD  - Department of Medicine, University of Otago, Dunedin, New Zealand.
FAU - Brosnan, Bradley
AU  - Brosnan B
AUID- ORCID: https://orcid.org/0000-0001-5367-2634
AD  - Department of Medicine, University of Otago, Dunedin, New Zealand.
FAU - Taylor, Rachael W
AU  - Taylor RW
AUID- ORCID: https://orcid.org/0000-0003-0810-0033
AD  - Department of Medicine, University of Otago, Dunedin, New Zealand.
LA  - eng
SI  - ClinicalTrials.gov/NCT00892983
PT  - Journal Article
DEP - 20201130
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7735907
OTO - NOTNLM
OT  - child
OT  - diet
OT  - infant
OT  - mental wellbeing
OT  - obesity
OT  - physical activity
OT  - prevention
OT  - screen time
OT  - sleep
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 12:09
PHST- 2020/10/14 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/30 12:09 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
AID - v9i11e24968 [pii]
AID - 10.2196/24968 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 30;9(11):e24968. doi: 10.2196/24968.


PMID- 33252340
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201219
IS  - 2561-326X (Electronic)
IS  - 2561-326X (Linking)
VI  - 4
IP  - 11
DP  - 2020 Nov 30
TI  - Smartphone and App Usage in Orthopedics and Trauma Surgery: Survey Study of
      Physicians Regarding Acceptance, Risks, and Future Prospects in Germany.
PG  - e14787
LID - 10.2196/14787 [doi]
AB  - BACKGROUND: In the course of digitization, smartphones are affecting an
      increasing number of areas of users' lives, giving them almost ubiquitous access 
      to the internet and other web applications. Mobile health (mHealth) has become an
      integral part of some areas of patient care. In contrast to other disciplines,
      routine integration of mobile devices in orthopedics and trauma surgery in
      Germany is still in its infancy. OBJECTIVE: This study aimed to investigate
      physicians' current state of opinion regarding acceptance, future prospects, and 
      risks of medical apps in the field of orthopedics and trauma surgery in Germany. 
      METHODS: A web-based survey among orthopedics and trauma surgeons in German
      university hospitals on the use of medical apps in everyday clinical practice was
      conducted between September 2018 and February 2019. The survey consisted of 13
      open- and closed-ended or multiple-choice questions. A logistic regression
      analysis was performed to ascertain the effects of interindividual
      characteristics on the likelihood of participants' app and smartphone usage
      behavior. RESULTS: A total of 206 physicians participated in the survey. All of
      the participants (206/206, 100%) owned a smartphone, and 79.1% (159/201) used the
      device, while 64.7% (130/201) used apps regularly in everyday clinical practice. 
      Medical apps were perceived as beneficial, given their substantial future
      promise, by 90.1% (181/201) of the participants. However, 62.5% (120/192) of the 
      participants were not satisfied with the current supply of medical apps in app
      stores. Desired specifications for future apps were "intuitive usability"
      (167/201, 83.1%), "no advertising" (145/201, 72.1%), and "free apps" (92/201,
      45.8%). The attributes "transparent app development and app sponsoring" (75/201, 
      37.3%) and the existence of an "easy-to-understand privacy statement" (50/201,
      24.9%) were of minor relevance. The majority of the participants (162/194, 83.5%)
      considered that future apps in the field of "medical research" would provide the 
      greatest benefit. The greatest predicted risks were "data misuse" (147/189,
      77.8%), "usage of untrustworthy apps" (135/189, 71.4%), and "alienation from
      patients" (51/189, 27.0%). Increasing age was significantly associated with a
      reduction in the likelihood of regular smartphone (odds ratio [OR] 0.91, 95% CI
      0.86-0.97; P=.002) and app (OR 0.90, 95% CI 0.85-0.96; P=.001) usage, while the
      medical profession grade had no significant impact on the usage behavior.
      CONCLUSIONS: The study demonstrates that young German doctors in orthopedics and 
      trauma surgery already use smartphones and apps in everyday clinical practice.
      Medical apps are considered to play an important role in the future. However, a
      significant discrepancy exists between the supply and demand of mHealth
      applications, which creates a legal and ethical vacuum with regard to data
      protection.
CI  - (c)Florian Dittrich, David Alexander Back, Anna Katharina Harren, Stefan
      Landgraeber, Felix Reinecke, Sebastian Serong, Sascha Beck. Originally published 
      in JMIR Formative Research (http://formative.jmir.org), 30.11.2020.
FAU - Dittrich, Florian
AU  - Dittrich F
AUID- ORCID: https://orcid.org/0000-0002-5135-4736
AD  - Department for Orthopaedics and Orthopaedic Surgery, Saarland University Medical 
      Center and Saarland University Faculty of Medicine, Homburg, Germany.
AD  - Joint Centre Bergisch Land, Department for Orthopaedics, Sana Fabricius Clinic
      Remscheid, Remscheid, Germany.
FAU - Back, David Alexander
AU  - Back DA
AUID- ORCID: https://orcid.org/0000-0001-7552-7753
AD  - Clinic of Traumatology and Orthopedics, Bundeswehr Hospital, Berlin, Germany.
FAU - Harren, Anna Katharina
AU  - Harren AK
AUID- ORCID: https://orcid.org/0000-0002-0750-2420
AD  - Department of Plastic, Reconstructive & Aesthetic Surgery, Specialized Clinic
      Hornheide, Munster, Germany.
FAU - Landgraeber, Stefan
AU  - Landgraeber S
AUID- ORCID: https://orcid.org/0000-0002-6472-4038
AD  - Department for Orthopaedics and Orthopaedic Surgery, Saarland University Medical 
      Center and Saarland University Faculty of Medicine, Homburg, Germany.
FAU - Reinecke, Felix
AU  - Reinecke F
AUID- ORCID: https://orcid.org/0000-0001-8762-9394
AD  - Clinic of Trauma, Hand and Reconstructive Surgery, Essen University Hospital,
      Essen, Germany.
FAU - Serong, Sebastian
AU  - Serong S
AUID- ORCID: https://orcid.org/0000-0001-5163-2241
AD  - Department for Orthopaedics and Orthopaedic Surgery, Saarland University Medical 
      Center and Saarland University Faculty of Medicine, Homburg, Germany.
FAU - Beck, Sascha
AU  - Beck S
AUID- ORCID: https://orcid.org/0000-0003-1012-4296
AD  - Clinic for Orthopaedics and Trauma Surgery, Sportsclinic Hellersen, Ludenscheid, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20201130
PL  - Canada
TA  - JMIR Form Res
JT  - JMIR formative research
JID - 101726394
PMC - PMC7735902
OTO - NOTNLM
OT  - communication
OT  - mHealth
OT  - medicine
OT  - orthopedics
OT  - smartphone
OT  - surveys and questionnaires
OT  - technology
OT  - trauma surgery
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 12:09
PHST- 2019/05/24 00:00 [received]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/08/02 00:00 [revised]
PHST- 2020/11/30 12:09 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
AID - v4i11e14787 [pii]
AID - 10.2196/14787 [doi]
PST - epublish
SO  - JMIR Form Res. 2020 Nov 30;4(11):e14787. doi: 10.2196/14787.


PMID- 33251993
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20211204
IS  - 2376-1032 (Electronic)
VI  - 26
IP  - 12
DP  - 2020 Dec
TI  - A regional analysis of payer and provider views on cholesterol management: PCSK9 
      inhibitors as an illustrative alignment model.
PG  - 1517-1528
LID - 10.18553/jmcp.2020.26.12.1517 [doi]
AB  - BACKGROUND: Multiple barriers exist for appropriate use of the proprotein
      convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9i) in patients with
      atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia
      (FH) with inadequately controlled hypercholesterolemia despite standard
      therapies. Among these barriers, high payer rejection rates and inadequate prior 
      authorization (PA) documentation by providers hinder optimal use of PCSK9i.
      OBJECTIVES: To (a) identify and discuss provider and payer discordances on
      barriers to authorization and use of PCSK9i based on clinical and real-world
      evidence and (b) align understanding and application of clinical, cost, safety,
      and efficacy data of PCSK9i. METHODS: Local groups of 3 payers and 3 providers
      met in 6 separate locations across the United States through a collaborative
      project of AMCP and PRIME Education. Responses to selected pre- and postmeeting
      survey questions measured changes in attitudes and beliefs regarding treatment
      barriers, lipid thresholds for considering PCSK9i therapy, and tactics for
      improving PA processes. Statistical analysis of inter- and intragroup changes in 
      attitudes were performed by Cox proportional hazards test and Fisher's exact test
      for < 5 variables. RESULTS: The majority of providers and payers (67%-78%) agreed
      that high patient copayments and inadequate PA documentation were significant
      barriers to PCSK9i usage. However, payers and providers differed on beliefs that 
      current evidence does not support PCSK9i cost-effectiveness (6% providers, 56%
      payers; P = 0.003) and that PA presents excessive administrative burden (72%
      providers, 44% payers; P = 0.09) Average increases pre- to postmeeting were noted
      in provider beliefs that properly documented PA forms expedite access to PCSK9i
      (22%-50% increase) and current authorization criteria accurately distinguish
      patients who benefit most from PCSK9i (6%-22%). Payers decreased in their belief 
      that current authorization criteria accurately distinguish benefiting patients
      (72%-50%). Providers and payers increased in their belief that PCSK9i are
      cost-effective (44%-61% and 28%-50%, respectively) and were more willing to
      consider PCSK9i at the low-density lipoprotein cholesterol threshold of > 70
      mg/dL for patients with ASCVD (78%-83% and 44%-67%, respectively) or FH (22%-39% 
      and 22%-33%). Payers were more agreeable to less stringent PA requirements for
      patients with FH (33%-72%, P = 0.019) and need for standardized PA requirements
      (50%-83%, P = 0.034); these considerations remained high (89%) among providers
      after the meeting. Most participants supported educational programs for patient
      treatment adherence (83%) and physician/staff PA processes (83%-94%).
      CONCLUSIONS: Provider and payer representatives in 6 distinct geographic
      locations provided recommendations to improve quality of care in patients
      eligible for PCSK9i. Participants also provided tactical recommendations for
      streamlining PA documentation processes and improving awareness of PCSK9i
      cost-effectiveness and clinical efficacy. The majority of participants supported 
      development of universal, standardized patient eligibility criteria and PA forms.
      DISCLOSURES: The study reported in this article was part of a continuing
      education program funded by an independent educational grant awarded by Sanofi US
      and Regeneron Pharmaceuticals to PRIME Education. The grantor had no role in the 
      study design, execution, analysis, or reporting. AMCP received grant funding from
      PRIME to assist in the study, as well as in writing the manuscript. McCormick,
      Bhatt, Bays, Taub, Caldwell, Guerin, Steinhoff, and Ahmad received an honorarium 
      from PRIME for serving as faculty for the continuing education program.
      McCormick, Bhatt, Bays, Taub, Caldwell, Guerin, Steinhoff, and Ahmad were
      involved as participants in the study. Bhatt discloses the following
      relationships: Advisory board: Cardax, CellProthera, Cereno Scientific, Elsevier 
      Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, 
      Regado Biosciences; Board of directors: Boston VA Research Institute, Society of 
      Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality 
      Oversight Committee; Data monitoring committees: Baim Institute for Clinical
      Research (formerly Harvard Clinical Research Institute, for the PORTICO trial,
      funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the
      ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke
      Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the
      ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; 
      Honoraria: American College of Cardiology (Senior Associate Editor, Clinical
      Trials and News, ACC.org; Vice chair, ACC Accreditation Committee), Baim
      Institute for Clinical Research (formerly Harvard Clinical Research Institute;
      RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim;
      AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor
      in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial
      steering committees, including for the PRONOUNCE trial, funded by Ferring
      Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology),
      Journal of the American College of Cardiology (Guest Editor; Associate Editor),
      K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD
      (CME steering committees), MJH Life Sciences, Population Health Research
      Institute (for the COMPASS operations committee, publications committee, steering
      committee, and USA national co-leader, funded by Bayer), Slack Publications
      (Chief Medical Editor, Cardiology Today's Intervention), Society of
      Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering
      committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry
      Steering Committee (Chair), VA CART Research and Publications Committee (Chair); 
      Research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer
      Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon,
      Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood,
      Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron,
      Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier
      (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); 
      Site co-investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now
      Abbott), Svelte; Trustee: American College of Cardiology; Unfunded research:
      FlowCo, Merck, Novo Nordisk, Takeda. Bays' research site has received research
      grants from 89Bio, Acasti, Akcea, Allergan, Alon Medtech/Epitomee, Amarin, Amgen,
      AstraZeneca, Axsome, Boehringer Ingelheim, Civi, Eli Lilly, Esperion, Evidera,
      Gan and Lee, Home Access, Janssen, Johnson and Johnson, Lexicon, Matinas, Merck, 
      Metavant, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Selecta, TIMI, and
      Urovant. Bays has served as a consultant/advisor for 89Bio, Amarin, Esperion,
      Matinas, and Gelesis, and speaker for Esperion. McCormick, Caldwell, Guerin,
      Ahmad, Singh, Moreo, Carter, Heggen, and Sapir have nothing to disclose.
FAU - McCormick, Dana
AU  - McCormick D
AD  - Blue Cross Blue Shield of Texas, Richardson, TX.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical
      School, Boston, MA.
FAU - Bays, Harold E
AU  - Bays HE
AD  - Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY.
FAU - Taub, Pam R
AU  - Taub PR
AD  - Division of Cardiovascular Medicine, University of California San Diego School of
      Medicine.
FAU - Caldwell, Kim A
AU  - Caldwell KA
AD  - Texas Star Healthcare Consulting, McKinney.
FAU - Guerin, Chris K
AU  - Guerin CK
AD  - Tri-City Medical Center and University of California San Diego School of
      Medicine.
FAU - Steinhoff, Jeff
AU  - Steinhoff J
AD  - Largo Medical Center, Largo, FL; HCA Healthcare/USF Morsani College of Medicine, 
      Tampa, FL; and Nova Southeastern University, Davie, FL.
FAU - Ahmad, Zahid
AU  - Ahmad Z
AD  - Division of Nutrition and Metabolic Disease, UT Southwestern Medical Center,
      Dallas, TX.
FAU - Singh, Rubina
AU  - Singh R
AD  - AMCP, Alexandria, VA.
FAU - Moreo, Kathleen
AU  - Moreo K
AD  - PRIME Education, Fort Lauderdale, FL.
FAU - Carter, Jeffrey
AU  - Carter J
AD  - PRIME Education, Fort Lauderdale, FL.
FAU - Heggen, Cherilyn L
AU  - Heggen CL
AD  - PRIME Education, Fort Lauderdale, FL.
FAU - Sapir, Tamar
AU  - Sapir T
AD  - PRIME Education, Fort Lauderdale, FL.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Manag Care Spec Pharm
JT  - Journal of managed care & specialty pharmacy
JID - 101644425
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (PCSK9 Inhibitors)
RN  - EC 3.4.21.- (PCSK9 protein, human)
SB  - IM
MH  - Anticholesteremic Agents/*administration & dosage/adverse effects/economics
MH  - Atherosclerosis/drug therapy/economics
MH  - Cardiovascular Diseases/*drug therapy/economics
MH  - Cost-Benefit Analysis
MH  - Documentation
MH  - Drug Costs
MH  - Focus Groups
MH  - Humans
MH  - Hyperlipoproteinemia Type II/*drug therapy/economics
MH  - Medication Adherence
MH  - *PCSK9 Inhibitors
MH  - Quality of Health Care
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - United States
EDAT- 2020/12/01 06:00
MHDA- 2021/08/14 06:00
CRDT- 2020/11/30 08:41
PHST- 2020/11/30 08:41 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
AID - 10.18553/jmcp.2020.26.12.1517 [doi]
PST - ppublish
SO  - J Manag Care Spec Pharm. 2020 Dec;26(12):1517-1528. doi:
      10.18553/jmcp.2020.26.12.1517.


PMID- 33251349
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 11
DP  - 2020 Nov
TI  - Leishmaniasis in Dhaka Medical College-experience of three years.
PG  - e05414
LID - 10.1016/j.heliyon.2020.e05414 [doi]
AB  - The People's Republic of Bangladesh has been working to eliminate visceral
      leishmaniasis or Kala-azar cases since there was a memorandum of understanding
      signed between neighboring countries in 2005. As a part of the elimination
      activity, 44 cases of Kala-azar were diagnosed and treated in the regional
      referral center Dhaka Medical College Hospital (DMCH) during the last three
      years, which is reported here. Confirmed leishmaniasis cases were included.
      Patients attending this specialized center with different demographic
      characteristics and varied presentations with laboratory findings were reviewed
      and recorded in a structured case record form. Ethical clearance was obtained
      prior to starting the study. A total of 44 patients with leishmaniasis were
      reviewed. Approximately 89% (n = 39) were New Kala-azar (NKA), 7% (n = 3) were
      Relapse Kala-azar (Relapse KA), only one case (2%) was Kala-azar Treatment
      Failure (KATF) and Post Kala-azar Dermal Leishmaniasis (PKDL) for both. The mean 
      age of presentation was 32 years. Forty percent of patients had houses made by
      mud, 26% by tin shed, and the rest lived in buildings and semi-buildings. The
      predominant clinical features were fever (90.9%), pallor (88.6%), splenomegaly
      (81.8%) and hepatomegaly (68.2%). rK39 was positive in 90.7% of cases, and 94.4% 
      of cases were positive for LD bodies on splenic aspirate. Of all, 90.90% were
      treated with Inj. Liposomal amphotericin B and 9.10% with the combination of Inj.
      Liposomal Amphotericin B and Inj. Miltefosine. Moving forward to the elimination 
      of leishmaniasis from Bangladesh, the study highlights the status,
      characteristics and treatment of the disease in the country.
CI  - (c) 2020 The Author(s).
FAU - Amin, Mohammad Robed
AU  - Amin MR
AD  - Dhaka Medical College, Dhaka, Bangladesh.
FAU - Fardin, Jubayer
AU  - Fardin J
AD  - Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh.
FAU - Noor, Nawsabah
AU  - Noor N
AD  - Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh.
FAU - Mallik, Pranab Kumar
AU  - Mallik PK
AD  - Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh.
FAU - Tabassum, Tamanna
AU  - Tabassum T
AD  - Pi Research Consultancy Center, Bangladesh.
FAU - Khan, Md Abdullah Saeed
AU  - Khan MAS
AD  - Pi Research Consultancy Center, Bangladesh.
FAU - Hasan, Mohammad Jahid
AU  - Hasan MJ
AD  - Pi Research Consultancy Center, Bangladesh.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7679253
OTO - NOTNLM
OT  - Bangladesh
OT  - Clinical research
OT  - Epidemiology
OT  - Infectious disease
OT  - Internal medicine
OT  - Kala-azar
OT  - Leishmania donovani
OT  - Leishmaniasis
OT  - Public health
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 05:55
PHST- 2020/07/24 00:00 [received]
PHST- 2020/09/26 00:00 [revised]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/30 05:55 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e05414 [doi]
AID - S2405-8440(20)32257-X [pii]
PST - epublish
SO  - Heliyon. 2020 Nov 16;6(11):e05414. doi: 10.1016/j.heliyon.2020.e05414.
      eCollection 2020 Nov.


PMID- 33251050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2167-4876 (Print)
IS  - 2167-4876 (Linking)
VI  - 8
IP  - 4
DP  - 2020
TI  - From Beyond the Grave: Use of Medical Information from the Deceased to Guide Care
      of Living Relatives.
PG  - 147-153
LID - 10.1007/s40142-020-00196-6 [doi]
AB  - PURPOSE OF REVIEW: In order to inform patients of their genetic risks, access to 
      the medical records and/or stored samples of their relatives is often helpful. We
      consider some of the obstacles to such access when these relatives are deceased
      and suggest how they might be navigated. RECENT FINDINGS: We explore an issue
      first highlighted in 2004 by Lucassen et al. (Br Med J 328:952-953, 2004) and
      re-evaluate it in the wake of novel technologies and mainstreaming of genomic
      medicine. We find that it is still an issue in practice despite professional
      guidelines advocating access to familial information (Joint Committee on Genomics
      in Medicine 2019) and that the Human Tissue Act 2004 is often wrongly constructed
      as a reason to block access. Access is often obstructed by failing to adopt the
      necessary relational concept of autonomy that applies in genetic medicine as
      reported by Horton and Lucassen (Curr Genet Med Rep 7:85-91, 2019) and by
      considering confidentiality to be absolute, even after death. In response to a
      recent legal case about the confidentiality of genetic test results, and their
      disclosure to family members (ABC v St George's Healthcare NHS Trust 2020), Dove 
      et al. (J Med Ethics 45:504-507, 2019) suggested that a duty to consider the
      interests of genetic relatives could co-exist alongside a duty of confidentiality
      to a patient. In this way, healthcare professionals can use professional
      judgement about the relative value of genetic information to family members. This
      is equally relevant in accessing deceased relatives' information. A recent
      systematic review found a high level of acceptability of postmortem use of
      genetic data for medical research amongst participants and their relatives, and
      it is reasonable to assume that this acceptability would extend to clinical
      practice as reported by Bak et al. (Eur J Hum Genet 28:403-416, 2020). SUMMARY:
      Within clinical practice, access to medical records/samples of deceased relatives
      is often obstructed unnecessarily, potentially resulting in harm to the living
      relatives seeking advice. Consent to such access is important but need not be the
      bureaucratic hurdle that is often imposed.
CI  - (c) The Author(s) 2020.
FAU - Tadros, Shereen
AU  - Tadros S
AD  - North East Thames Regional Genetics Service, Great Ormond Street Hospital,
      London, UK.grid.420468.c
AD  - St. George's University of London, Cranmer Terrace, Tooting, London, SW17 0RE
      UK.grid.264200.20000 0000 8546 682X
FAU - Carley, Helena
AU  - Carley H
AD  - St. George's University of London, Cranmer Terrace, Tooting, London, SW17 0RE
      UK.grid.264200.20000 0000 8546 682X
AD  - South East Thames Regional Genetics Service, Guy's Hospital, London,
      UK.grid.239826.40000 0004 0391 895X
AD  - South West Thames Regional Genetics Service, St George's Hospital, London,
      UK.grid.264200.20000 0000 8546 682X
FAU - Lucassen, Anneke
AU  - Lucassen A
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.grid.5491.90000
      0004 1936 9297
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201124
PL  - United States
TA  - Curr Genet Med Rep
JT  - Current genetic medicine reports
JID - 101601192
PMC - PMC7683580
OTO - NOTNLM
OT  - Access to records
OT  - Confidentiality
OT  - Consent
OT  - Genetics
OT  - Next of kin
COIS- Conflict of InterestShereen Tadros and Helena Carley declare no conflict of
      interest. Anneke Lucassen declares her relationships as Vice Chair of the British
      Society for Genetic Medicine, Member of the Ethics Advisory Committee for
      Genomics England, and Chair of the Ethics Advisory Committee for UK Biobank. She 
      holds a Wellcome Trust Collaborative Award 208053/Z/17/Z.
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 05:54
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
PHST- 2020/11/30 05:54 [entrez]
AID - 10.1007/s40142-020-00196-6 [doi]
AID - 196 [pii]
PST - ppublish
SO  - Curr Genet Med Rep. 2020;8(4):147-153. doi: 10.1007/s40142-020-00196-6. Epub 2020
      Nov 24.


PMID- 33251036
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210702
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Ethical implications of BRAIN 2.0: Beyond bioethics, beyond borders.
PG  - 196-198
LID - 10.1080/21507740.2020.1778124 [doi]
FAU - Felsen, Gidon
AU  - Felsen G
AD  - Department of Physiology and Biophysics, University of Colorado School of
      Medicine.
AD  - Center for Bioethics and Humanities, University of Colorado School of Medicine.
LA  - eng
GR  - R01 NS079518/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200727
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - *Bioethics
MH  - *Brain
MH  - Morals
PMC - PMC7694739
MID - NIHMS1618321
EDAT- 2020/12/01 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/11/30 05:54
PHST- 2020/11/30 05:54 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1080/21507740.2020.1778124 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):196-198. doi: 10.1080/21507740.2020.1778124.
      Epub 2020 Jul 27.


PMID- 33251026
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2055-6640 (Print)
IS  - 2055-6640 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Nov
TI  - Time for revolution? Enhancing meaningful involvement of people living with HIV
      and affected communities in HIV cure-focused science.
PG  - 100018
LID - 10.1016/j.jve.2020.100018 [doi]
AB  - INTRODUCTION: Involving affected communities and people living with HIV (PLHIV)
      in HIV cure-focused clinical trials has ethical and practical benefits. However, 
      there can be barriers to meaningful involvement of 'lay people' in scientific
      research meaning community consultation is often limited or tokenistic. This
      paper reports on an Australian project, the INSPIRE project (Improve, Nurture and
      Strengthen education, collaboration, and communication between PLHIV and
      Researchers), which aimed to explore barriers and enablers to enactment of the
      principles of meaningful involvement of PLHIV (MIPA) and affected communities in 
      HIV cure-focused research. METHODS: The project involved a workshop attended by
      40 stakeholders involved in HIV care, research or advocacy including PLHIV,
      community organizations, basic scientists, and clinicians. The workshop involved 
      a facilitated discussion about community involvement in a hypothetical HIV
      cure-focused clinical trial. Data were collected through notetaking and video
      recordings. Qualitative, thematic analysis was undertaken to organize the data
      and identify core themes related to MIPA. RESULTS: Workshop discussions revealed 
      community stakeholders often feel their involvement in HIV clinical research is
      undervalued, evidenced by limited financial remuneration and minimal capacity to 
      influence the research design or processes. Building long-term, formal and
      informal relationships between community organizations, PLHIV, researchers and
      research teams or laboratories was identified as a strategy to support MIPA at
      all stages of a clinical trial, from design to dissemination of findings.
      CONCLUSIONS: Enacting MIPA principles in HIV cure-focused research requires a
      better understanding of the potential to improve research outcomes and ensure
      quality in the research process.
CI  - (c) 2020 The Author(s).
FAU - Lau, Jillian S Y
AU  - Lau JSY
AD  - Alfred Health and Monash University, Melbourne, Australia.
FAU - Smith, Miranda Z
AU  - Smith MZ
AD  - Peter Doherty Institute for Infection and Immunity, University of Melbourne,
      Melbourne, Australia.
FAU - Allan, Brent
AU  - Allan B
AD  - International Council of AIDS Service Organizations, Toronto, Canada.
FAU - Dube, Karine
AU  - Dube K
AD  - Gillings School of Global Public Health, University of North Carolina, Chapel
      Hill, USA.
FAU - Young, A Toni
AU  - Young AT
AD  - District of Columbia Centre for AIDS Research, Community Education Group,
      Washington D.C., USA.
FAU - Power, Jennifer
AU  - Power J
AD  - Australian Research Centre in Sex, Health and Society, La Trobe University,
      Melbourne, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - J Virus Erad
JT  - Journal of virus eradication
JID - 101654142
PMC - PMC7646668
OTO - NOTNLM
OT  - Clinical trial
OT  - Community
OT  - HIV
OT  - HIV cure
OT  - People living with HIV
OT  - Social sciences
OT  - Workshop
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 05:54
PHST- 2020/04/23 00:00 [received]
PHST- 2020/10/11 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/30 05:54 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
AID - 10.1016/j.jve.2020.100018 [doi]
AID - S2055-6640(20)31467-9 [pii]
PST - epublish
SO  - J Virus Erad. 2020 Oct 15;6(4):100018. doi: 10.1016/j.jve.2020.100018.
      eCollection 2020 Nov.


PMID- 33250954
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 1938-971X (Print)
IS  - 1938-971X (Linking)
VI  - 13
IP  - 4
DP  - 2020
TI  - Civil Forensic Evaluation in Psychological Injury and Law: Legal, Professional,
      and Ethical Considerations.
PG  - 327-353
LID - 10.1007/s12207-020-09398-3 [doi]
AB  - Psychologists who work as therapists or administrators, or who engage in forensic
      practice in criminal justice settings, find it daunting to transition into
      practice in civil cases involving personal injury, namely psychological injury
      from the psychological perspective. In civil cases, psychological injury arises
      from allegedly deliberate or negligent acts of the defendant(s) that the
      plaintiff contends caused psychological conditions to appear. These alleged acts 
      are disputed in courts and other tribunals. Conditions considered in
      psychological injury cases include posttraumatic stress disorder, depression,
      chronic pain conditions, and sequelae of traumatic brain injury. This article
      outlines a detailed case sequence from referral through the end of expert
      testimony to guide the practitioner to work effectively in this field of
      practice. It addresses the rules and regulations that govern admissibility of
      expert evidence in court. The article provides ethical and professional guidance 
      throughout, including best practices in assessment and testing, and emphasizes
      evidence-based forensic practice.
CI  - (c) Springer Science+Business Media, LLC, part of Springer Nature 2020.
FAU - Foote, William E
AU  - Foote WE
AUID- ORCID: 0000-0001-5875-4444
AD  - University of New Mexico, Albuquerque, USA.grid.266832.b0000 0001 2188 8502
FAU - Goodman-Delahunty, Jane
AU  - Goodman-Delahunty J
AD  - Charles Sturt University, Manly, Australia.grid.1037.50000 0004 0368 0777
FAU - Young, Gerald
AU  - Young G
AD  - Glendon College, York University, Toronto, Canada.grid.21100.320000 0004 1936
      9430
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201124
PL  - United States
TA  - Psychol Inj Law
JT  - Psychological injury and law
JID - 101535954
PMC - PMC7683260
OTO - NOTNLM
OT  - Civil rights
OT  - Ethics
OT  - Forensic assessment
OT  - Litigation
OT  - Professional issues
OT  - Tort cases
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 05:53
PHST- 2020/10/25 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
PHST- 2020/11/30 05:53 [entrez]
AID - 10.1007/s12207-020-09398-3 [doi]
AID - 9398 [pii]
PST - ppublish
SO  - Psychol Inj Law. 2020;13(4):327-353. doi: 10.1007/s12207-020-09398-3. Epub 2020
      Nov 24.


PMID- 33250625
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20211204
IS  - 1945-0826 (Electronic)
IS  - 1049-510X (Linking)
VI  - 30
IP  - Suppl 2
DP  - 2020
TI  - Lessons from my Elders on Recruitment and Retention into Health Research.
PG  - 781-784
LID - 10.18865/ed.30.S2.781 [doi]
AB  - In this brief report, the author shares lessons from Loretta Jones, MA and
      William Jenkins, PhD, two elders who shaped her research with communities that
      occupy intersecting marginalized categories. These lessons were echoed and
      amplified by the community panelists at the RCMAR workshop on recruitment and
      retention of diverse elders. They include centering the priorities of communities
      themselves, helping community members envision the types of positive
      transformations that research can help bring about, engaging and valuing the
      contributions of diverse sectors of the community, and recognizing the desire of 
      aging individuals and communities to leave a legacy. Because heath care,
      research, and governmental institutions have engendered so much mistrust in
      racial/ethnic minority communities, researchers must learn first the particular
      histories and experience of the populations they intend to study. Equipped with
      this knowledge, cultural humility, and a willingness to listen, researchers can
      then use these strategies to earn the trust necessary for successful recruitment 
      and retention in research.
CI  - Copyright (c) 2020, Ethnicity & Disease, Inc.
FAU - Harawa, Nina T
AU  - Harawa NT
AD  - Department of Medicine, David Geffen School of Medicine at University of
      California Los Angeles (UCLA); Department of Psychiatry and Human Behavior,
      Charles R. Drew University of Medicine and Science (CDU); Department of
      Epidemiology, Fielding School of Public Health at UCLA, CA.
LA  - eng
GR  - R13 AG023033/AG/NIA NIH HHS/United States
GR  - R24 AG059308/AG/NIA NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
GR  - UL1 TR001881/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201119
PL  - United States
TA  - Ethn Dis
JT  - Ethnicity & disease
JID - 9109034
SB  - IM
MH  - Aged
MH  - Ethnicity/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Income
MH  - Minority Groups/*statistics & numerical data
MH  - Patient Participation/*statistics & numerical data
MH  - *Patient Selection
MH  - *Trust
PMC - PMC7683032
OTO - NOTNLM
OT  - *Black/African Americans
OT  - *Ethics
OT  - *Older Adults
OT  - *Racial Disparity
COIS- Competing Interests: None declared.
EDAT- 2020/12/01 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/30 05:52
PHST- 2020/11/30 05:52 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.18865/ed.30.S2.781 [doi]
AID - ed.30.S2.781 [pii]
PST - epublish
SO  - Ethn Dis. 2020 Nov 19;30(Suppl 2):781-784. doi: 10.18865/ed.30.S2.781.
      eCollection 2020.


PMID- 33250590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 0966-3622 (Print)
IS  - 0966-3622 (Linking)
VI  - 28
IP  - 3
DP  - 2020
TI  - Households, bubbles and hugging grandparents: Caring and lockdown rules during
      COVID-19.
PG  - 329-339
LID - 10.1007/s10691-020-09445-z [doi]
AB  - Efforts to combat the COVID-19 crisis brought mountains of legislation and
      guidance to coerce or encourage people to stay at home and reduce the spread of
      the virus. During peak lockdown in the United Kingdom (UK) regulations defined
      when people could or could not leave their homes. Meanwhile guidance on social
      distancing advised people to stay within 'households'. This paper explores the
      legislation under lockdowns in the UK from March to October 2020 and the
      implications for women's gendered caring roles. The regulations and guidance
      assumed that households were separate units and ignored the interdependencies
      which exist between households and between individuals and wider society. The
      continuing focus in the lockdown regulations has been on households as
      autonomous, safe, adequate and secure. This overlooks the interdependency of
      human life, gendered aspects of caring and the inequalities of housing and living
      conditions, highlighted by feminist scholarship.
CI  - (c) The Author(s) 2020.
FAU - Gulland, Jackie
AU  - Gulland J
AUID- ORCID: 0000-0002-8236-3635
AD  - School of Social and Political Science, University of Edinburgh, Chrystal
      Macmillan Building, 15a George Square, Edinburgh, EH8 9LD UK.grid.4305.20000 0004
      1936 7988
LA  - eng
PT  - Editorial
DEP - 20201123
PL  - Netherlands
TA  - Fem Leg Stud
JT  - Feminist legal studies
JID - 101270453
PMC - PMC7680985
OTO - NOTNLM
OT  - COVID-19
OT  - Care
OT  - Ethics of care
OT  - Gender
OT  - Households
OT  - Interdependency
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
CRDT- 2020/11/30 05:51
PHST- 2020/11/07 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
PHST- 2020/11/30 05:51 [entrez]
AID - 10.1007/s10691-020-09445-z [doi]
AID - 9445 [pii]
PST - ppublish
SO  - Fem Leg Stud. 2020;28(3):329-339. doi: 10.1007/s10691-020-09445-z. Epub 2020 Nov 
      23.


PMID- 33249985
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20220418
IS  - 0969-0700 (Print)
IS  - 0969-0700 (Linking)
VI  - 29
IP  - LatAm sup 1
DP  - 2020 Jan 1
TI  - Topical cream containing nanoparticles with vitamin E to prevent radiodermatitis 
      in women with breast cancer: a clinical trial protocol.
PG  - 18-26
LID - 10.12968/jowc.2020.29.LatAm_sup_1.18.eng [doi]
AB  - OBJECTIVE: Little is known about the efficacy of products aiming to prevent
      radiodermatitis, which affects between 90-95% of women with breast cancer. The
      use of antioxidants is promising, however, there is a lack of evidenceon their
      effectiveness. Here, the authors present a clinical trial protocol to evaluate
      the effects of applying a cream containing nanoparticles with vitamin E to
      prevent radiodermatitis in patients with breast cancer. METHOD: The protocol
      recommends that 108 women with breast cancer, receiving radiotherapy, are
      included in this triple-blinded, randomized, controlled study at an oncology
      hospital. Patients will be divided in three groups of 36 individuals each: group 
      A will receive a cream with lipid nanoparticles and vitamin E, group B will
      receive a cream without nanoparticles nor vitamin E, and group C will receive a
      cream with nanoparticles without vitamin E. The primary endpoints will evaluate
      the incidence, degree, and time of onset of radiodermatitis. The secondary
      endpoints will focus on the quality of life, symptoms, and local temperature.
      Patients will be assessed three times a week, from the start of their
      radiotherapy treatment to two weeks after the last session. This protocol was
      approved by the research ethics committee of the institutions involved and
      registered on an international trials database.
FAU - Schmidt, Fernanda Mateus Queiroz
AU  - Schmidt FMQ
AD  - Instituto Federal de Educacao, Ciencia e Tecnologia do Sul de Minas Gerais
      (IFSULDEMINAS), Passos, Minas Gerais, Brazil.
FAU - Gonzalez, Carol V Serna
AU  - Gonzalez CVS
AD  - Graduate Program in Adult Health Nursing, Universidade de Sao Paulo, Escola de
      Enfermagem (EEUSP), Sao Paulo, Brazil.
FAU - Mattar, Rodrigo Calixto
AU  - Mattar RC
AD  - Cancer Regional Hospital, Santa Casa de Misericordia de Passos, Minas Gerais,
      Brazil.
FAU - Lopes, Luciana Biagini
AU  - Lopes LB
AD  - Pharmacology Department, Universidade de Sao Paulo, Instituto de Ciencias
      Biomedicas (ICB-USP), Sao Pablo, Brazil.
FAU - Santos, Marinilce Fagundes Dos
AU  - Santos MFD
AD  - Cell Biology and Development Department, Universidade de Sao Paulo, Instituto de 
      Ciencias Biomedicas (ICB-USP), Sao Pablo, Brazil.
FAU - de Gouveia Santos, Vera L C
AU  - de Gouveia Santos VLC
AD  - Department of Medial-Surgical Nursing, Universidade de Sao Paulo, Escola de
      Enfermagem (EEUSP), Sao Paulo, Brazil.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - England
TA  - J Wound Care
JT  - Journal of wound care
JID - 9417080
RN  - 1406-18-4 (Vitamin E)
MH  - *Breast Neoplasms/drug therapy/radiotherapy
MH  - Female
MH  - Humans
MH  - *Nanoparticles
MH  - Quality of Life
MH  - Radiodermatitis/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Vitamin E/*therapeutic use
OTO - NOTNLM
OT  - breast cancer
OT  - nanoparticles
OT  - protocol
OT  - radiodermatitis
OT  - vitamin E
EDAT- 2020/12/01 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/11/30 05:25
PHST- 2020/11/30 05:25 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
AID - 10.12968/jowc.2020.29.LatAm_sup_1.18.eng [doi]
PST - ppublish
SO  - J Wound Care. 2020 Jan 1;29(LatAm sup 1):18-26. doi:
      10.12968/jowc.2020.29.LatAm_sup_1.18.eng.


PMID- 33249851
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 0310-057X (Print)
IS  - 0310-057X (Linking)
VI  - 48
IP  - 3_suppl
DP  - 2020 Nov
TI  - Anarcha, Betsey, Lucy, and the women whose names were not recorded: The legacy of
      J Marion Sims.
PG  - 6-13
LID - 10.1177/0310057X20966606 [doi]
AB  - In April 2018, a statue commemorating J Marion Sims was removed from Central
      Park, New York, and relocated to Green-Wood Cemetery in Brooklyn, where he is
      buried. In 1849, Sims developed a repeatable surgical solution for obstetric
      fistula, a debilitating condition caused by prolonged, obstructed labour, which
      damages the vaginal wall, resulting in permanent leakage via the vagina from
      either the bowel or bladder and sometimes both. Initially, Sims appears worthy of
      widespread adulation. There are several commemorative statues of him, he has been
      afforded the title of the 'father of modern gynaecology', and for 37 years, the
      American Urogynecological Society held an annual eponymous lecture, among other
      honours. Obstetric fistula rendered women social pariahs, unable to engage fully 
      in either domestic or public life. Sims was able to create a reliably repeatable 
      surgical solution but did so through ongoing experimentation on enslaved women.
      One of these women, Anarcha, was operated on at least 30 times without the use of
      anaesthesia over a four-year period, despite the availability of anaesthesia for 
      the majority of the experimentation period. Over 170 years later, Sims' story
      retains its relevance because it represents a clear point at which race, gender
      and class intersect with medicine. This paper will use Sims' own account to drive
      the narrative, then examine matters of agency, ethics and consent that come from 
      it, to show that his work, and subsequent renown, were only possible because of
      the inherent violence of chattel slavery and other systemic forms of oppression.
FAU - Cronin, Monica
AU  - Cronin M
AUID- ORCID: https://orcid.org/0000-0002-9622-0440
AD  - Geoffrey Kaye Museum of Anaesthetic History, Australian and New Zealand College
      of Anaesthetists, Melbourne, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201129
PL  - United States
TA  - Anaesth Intensive Care
JT  - Anaesthesia and intensive care
JID - 0342017
SB  - IM
MH  - *Anesthesia
MH  - Female
MH  - *Gynecology
MH  - Humans
MH  - Pregnancy
MH  - United States
MH  - *Vesicovaginal Fistula
OTO - NOTNLM
OT  - History
OT  - anaesthesia
OT  - ethics
OT  - gender
OT  - race
EDAT- 2020/12/01 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/11/30 05:24
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/11/30 05:24 [entrez]
AID - 10.1177/0310057X20966606 [doi]
PST - ppublish
SO  - Anaesth Intensive Care. 2020 Nov;48(3_suppl):6-13. doi: 10.1177/0310057X20966606.
      Epub 2020 Nov 29.


PMID- 35088005
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220128
IS  - 2500-0462 (Print)
IS  - 2500-3259 (Linking)
VI  - 24
IP  - 8
DP  - 2020 Dec
TI  - Generation of donor organs in chimeric animals via blastocyst complementation.
PG  - 913-921
LID - 10.18699/VJ20.690 [doi]
AB  - The lack of organs for transplantation is an important problem in medicine today.
      The growth of organs in chimeric animals may be the solution of this. The
      proposed technology is the interspecific blastocyst complementation method in
      combination with genomic editing for obtaining "free niches" and pluripotent stem
      cell production methods. The CRISPR/Cas9 method allows the so-called "free
      niches" to be obtained for blastocyst complementation. The technologies of
      producing induced pluripotent stem cells give us the opportunity to obtain human 
      donor cells capable of populating a "free niche". Taken together, these
      technologies allow interspecific blastocyst complementation between humans and
      other animals, which makes it possible in the future to grow human organs for
      transplantations inside chimeric animals. However, in practice, in order to
      achieve successful interspecific blastocyst complementation, it is necessary to
      solve a number of problems: to improve methods for producing "chimeric competent"
      cells, to overcome specific interspecific barriers, to select compatible cell
      developmental stages for injection and the corresponding developmental stage of
      the host embryo, to prevent apoptosis of donor cells and to achieve effective
      proliferation of the human donor cells in the host animal. Also, it is very
      important to analyze the ethical aspects related to developing technologies of
      chimeric organisms with the participation of human cells. Today, many researchers
      are trying to solve these problems and also to establish new approaches in the
      creation of interspecific chimeric organisms in order to grow human organs for
      transplantation. In the present review we described the historical stages of the 
      development of the blastocyst complementation method, examined in detail the
      technologies that underlie modern blastocyst complementation, and analyzed
      current progress that gives us the possibility to grow human organs in chimeric
      animals. We also considered the barriers and issues preventing the successful
      implementation of interspecific blastocyst complementation in practice, and
      discussed the further development of this method.
CI  - Copyright (c) AUTHORS.
FAU - Babochkina, T I
AU  - Babochkina TI
AD  - Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of
      Sciences, Novosibirsk, Russia.
FAU - Gerlinskaya, L A
AU  - Gerlinskaya LA
AD  - Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of
      Sciences, Novosibirsk, Russia.
FAU - Moshkin, M P
AU  - Moshkin MP
AD  - Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of
      Sciences, Novosibirsk, Russia.
LA  - eng
PT  - Journal Article
PL  - Russia (Federation)
TA  - Vavilovskii Zhurnal Genet Selektsii
JT  - Vavilovskii zhurnal genetiki i selektsii
JID - 101583566
PMC - PMC8763716
OTO - NOTNLM
OT  - CRISPR/Cas9
OT  - chimerism
OT  - embryo SC
OT  - iPSC
OT  - interspecies chimera
OT  - organ generation
EDAT- 2020/12/01 00:00
MHDA- 2020/12/01 00:01
CRDT- 2022/01/28 05:55
PHST- 2020/04/10 00:00 [received]
PHST- 2020/10/21 00:00 [revised]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2022/01/28 05:55 [entrez]
PHST- 2020/12/01 00:00 [pubmed]
PHST- 2020/12/01 00:01 [medline]
AID - 10.18699/VJ20.690 [doi]
PST - ppublish
SO  - Vavilovskii Zhurnal Genet Selektsii. 2020 Dec;24(8):913-921. doi:
      10.18699/VJ20.690.


PMID- 33248867
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20210216
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 265
DP  - 2020 Nov
TI  - Caring through distancing: Spatial boundaries and proximities in the cystic
      fibrosis clinic.
PG  - 113531
LID - S0277-9536(20)30750-4 [pii]
LID - 10.1016/j.socscimed.2020.113531 [doi]
AB  - This paper re-examines relations between proximity, distance and care, focusing
      on practices of 'distancing' in the cystic fibrosis (CF) clinic. While care is
      often thought of in terms of proximity, literature on 'landscapes of care'
      highlights the potential for 'care at a distance'. We extend this literature to
      examine practices of social distancing, specifically the act of maintaining a
      'space between' bodies in communal areas - a practice currently brought to the
      fore by the COVID-19 pandemic. Using the CF clinic as a case study, we examine
      how distancing can be understood as an emplaced practice of care, shaped by - and
      shaping - architectures and materialities in particular contexts. We explore
      these issues drawing on data from Pathways, practices and architectures:
      containing antimicrobial resistance in the cystic fibrosis clinic, a UK AHRC
      funded study (AH/R002037/1) examining practices in three cystic fibrosis clinics 
      using visual and ethnographic methods. Clinical staff practices of maintaining
      distancing were often regarded by patients as 'care-ful', part of personalised
      'care in place', embroiling a wider care assemblage including ancillary staff,
      materialities and architectures. Patients also actively participate in distancing
      as an 'ethic of care', using strategies of 'holding back' and 'looking out' in
      confined spaces. Yet our findings also highlight tensions between care, proximity
      and distance in circulation spaces and communal areas, including transient spaces
      where the assemblage of care breaks down. The article concludes by considering
      wider implications for healthcare design and for the COVID-19 pandemic.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Buse, Christina
AU  - Buse C
AD  - Department of Sociology, University of York, UK. Electronic address:
      christina.buse@york.ac.uk.
FAU - Brown, Nik
AU  - Brown N
AD  - Department of Sociology, University of York, UK.
FAU - Nettleton, Sarah
AU  - Nettleton S
AD  - Department of Sociology, University of York, UK.
FAU - Martin, Daryl
AU  - Martin D
AD  - Department of Sociology, University of York, UK.
FAU - Lewis, Alan
AU  - Lewis A
AD  - School of Environment, Education and Development, University of Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20201117
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
CON - Health (London). 2019 Aug 7;:1363459319866894. PMID: 31387378
MH  - Anti-Bacterial Agents
MH  - *COVID-19
MH  - *Cystic Fibrosis
MH  - Drug Resistance, Bacterial
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Architectures
OT  - *Boundary work
OT  - *Care
OT  - *Cystic fibrosis
OT  - *Distancing
OT  - *Infection prevention
OT  - *Materialities
OT  - *Place
EDAT- 2020/11/30 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/11/29 20:27
PHST- 2020/11/03 00:00 [revised]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/30 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/11/29 20:27 [entrez]
AID - S0277-9536(20)30750-4 [pii]
AID - 10.1016/j.socscimed.2020.113531 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Nov;265:113531. doi: 10.1016/j.socscimed.2020.113531. Epub 2020
      Nov 17.


PMID- 33247528
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - Ethical Considerations for Short-Term Global Health Projects.
PG  - 767-776
LID - 10.1111/jmwh.13162 [doi]
AB  - Various types of health professional volunteers from high-income nations are
      increasingly engaged in short-term global health projects in low- and
      middle-income countries. The goal of global health projects is to improve health 
      for all people and address health inequities. Short-term projects lasting days to
      months can create challenges for volunteers and hosts. Despite attempting to do
      good, volunteer efforts may unwittingly cause harm to host organizations by
      planning projects without consideration for the local infrastructure, the
      community, and the health care staff. Although well-intentioned and often
      beneficial, volunteer efforts can fail to provide adequate follow-up or may
      disrupt or override local health efforts. In some low-resource settings, dire
      health needs and lack of supervision may result in volunteers practicing beyond
      their professional scope. Recently published guidelines, competencies, and
      position statements have addressed ethical behaviors for short-term global health
      experiences. Partnerships that are founded on principles of justice and autonomy 
      provide an avenue for mutual collaboration. Short-term global health projects
      that focus on host needs are likely to strengthen local capacity to improve
      health outcomes. This article reviews guidelines for short-term global health
      experiences and addresses the ethical principles for planning effective projects.
CI  - (c) 2020 by the American College of Nurse-Midwives.
FAU - Penney, Debra
AU  - Penney D
AUID- ORCID: 0000-0002-3998-4639
AD  - University of Utah College of Nursing, Salt Lake City, Utah.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201128
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - Delivery of Health Care
MH  - Ethics, Research
MH  - *Global Health/ethics
MH  - Health Personnel
MH  - Humans
MH  - *Volunteers
OTO - NOTNLM
OT  - *ethics
OT  - *global health
OT  - *midwifery
OT  - *short-term experiences
OT  - *short-term experiences in global health
OT  - *short-term medical missions
EDAT- 2020/11/29 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/11/28 05:38
PHST- 2020/01/15 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/11/28 05:38 [entrez]
AID - 10.1111/jmwh.13162 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):767-776. doi: 10.1111/jmwh.13162. Epub 
      2020 Nov 28.


PMID- 33247516
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - Relational Decision-Making in the Context of Life-Limiting Fetal Anomalies: Two
      Cases of Anencephaly Diagnosis.
PG  - 813-817
LID - 10.1111/jmwh.13161 [doi]
AB  - Life-limiting fetal diagnoses such as anencephaly require families to make
      decisions in which no options offered will lead to the desired outcome of a
      healthy newborn. Although informed choice and shared decision-making are
      important aspects of ethics regarding care choices, they have limitations. In
      this article, 2 cases of anencephaly diagnosis are presented, and a relational
      decision-making model of care is proposed as an alternative for aiding pregnant
      people and their families in making challenging choices in the context of
      perinatal care.
CI  - (c) 2020 by the American College of Nurse-Midwives.
FAU - Zielinski, Ruth E
AU  - Zielinski RE
AUID- ORCID: 0000-0002-5119-9123
AD  - School of Nursing, University of Michigan, Ann Arbor, Michigan.
FAU - Roosevelt, Lee
AU  - Roosevelt L
AD  - School of Nursing, University of Michigan, Ann Arbor, Michigan.
FAU - Nelson, Kathryn
AU  - Nelson K
AD  - School of Nursing, University of Michigan, Ann Arbor, Michigan.
FAU - Vargas, Brittaney
AU  - Vargas B
AD  - Mercy Women's Health, Toledo, Ohio.
FAU - Thomas, Jonalea W
AU  - Thomas JW
AD  - Mercy Women's Health, Toledo, Ohio.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201128
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - *Anencephaly
MH  - Child
MH  - *Decision Making
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Perinatal Care
MH  - Pregnancy
MH  - *Prenatal Diagnosis
OTO - NOTNLM
OT  - *anencephaly
OT  - *decision-making
OT  - *ethics
OT  - *informed choice
OT  - *life-limiting fetal diagnoses
OT  - *prenatal care
OT  - *relational decision-making
OT  - *shared decision-making
EDAT- 2020/11/29 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/11/28 05:38
PHST- 2020/01/29 00:00 [received]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/11/28 05:38 [entrez]
AID - 10.1111/jmwh.13161 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):813-817. doi: 10.1111/jmwh.13161. Epub 
      2020 Nov 28.


PMID- 33247504
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - The Ethical Justification for Conscience Clauses in Nurse-Midwifery Practice:
      Context, Power, and a Changing Landscape.
PG  - 759-766
LID - 10.1111/jmwh.13170 [doi]
AB  - In the last century, conscientious objection has moved from objection to
      conscripted military service to include health care providers who have moral
      concerns about participation in specific aspects of health care. Although
      guidance for the use of conscientious objection has developed in both nursing and
      midwifery, changes in the political landscape may be creating a source of
      conflict between providers and the use of conscientious objection. Particularly
      in aspects of sexual and reproductive care like abortion, contraception, and
      lesbian, gay, bisexual, transgender, or queer health care, the ethical
      requirement for prompt referral is becoming increasingly difficult to meet in
      many contexts. Changes to federal regulations protecting conscience clauses have 
      tilted strongly in favor of the rights of providers in recent years; this
      challenges the delicate balance of patient and provider rights that has developed
      over the years. These may now represent an unavoidable conflict between different
      aspects of the ethical obligations of providers, in particular the obligation to 
      seek justice, and bring into question whether the current status of conscientious
      objection is sustainable. In this article, we examine these conflicts in the
      context of the current political climate.
CI  - (c) 2020 by the American College of Nurse-Midwives.
FAU - Eagen-Torkko, Meghan
AU  - Eagen-Torkko M
AUID- ORCID: 0000-0001-9064-6494
AD  - School of Nursing and Health Studies, University of Washington Bothell, Bothell, 
      Washington.
FAU - Levi, Amy J
AU  - Levi AJ
AD  - College of Nursing, University of New Mexico, Albuquerque, New Mexico.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201128
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - *Abortion, Induced
MH  - *Conscience
MH  - Female
MH  - Humans
MH  - *Midwifery
MH  - Morals
MH  - Pregnancy
MH  - Refusal to Treat
OTO - NOTNLM
OT  - *abortion
OT  - *conscience
OT  - *ethics
OT  - *midwifery professional issues
OT  - *refusal to treat
EDAT- 2020/11/29 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/11/28 05:38
PHST- 2020/01/31 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/11/28 05:38 [entrez]
AID - 10.1111/jmwh.13170 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):759-766. doi: 10.1111/jmwh.13170. Epub 
      2020 Nov 28.


PMID- 33247025
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Enhancing Prehospital Outcomes for Cardiac Arrest (EPOC) study: sequential
      mixed-methods study protocol in Michigan, USA.
PG  - e041277
LID - 10.1136/bmjopen-2020-041277 [doi]
AB  - INTRODUCTION: Out-of-hospital cardiac arrest (OHCA) is a common, life-threatening
      event encountered routinely by first responders, including police, fire and
      emergency medical services (EMS). Current literature suggests that there is
      significant regional variation in outcomes, some of which may be related to
      modifiable factors. Yet, there is a persistent knowledge gap regarding strategies
      to guide quality improvement efforts in OHCA care and, by extension, survival.
      The Enhancing Prehospital Outcomes for Cardiac Arrest (EPOC) study aims to fill
      these gaps and to improve outcomes. METHODS AND ANALYSIS: This mixed-methods
      study includes three aims. In aim I, we will define variation in OHCA survival to
      the emergency department (ED) among EMS agencies that participate in the Michigan
      Cardiac Arrest Registry to Enhance Survival (CARES) in order to sample EMS
      agencies with high-survival and low-survival outcomes. In aim II, we will conduct
      site visits to emergency medical systems-including 911/dispatch, police,
      non-transport fire, and EMS agencies-in approximately eight high-survival and
      low-survival communities identified in aim I. At each site, key informant
      interviews and a multidisciplinary focus group will identify themes associated
      with high OHCA survival. Transcripts will be coded using a structured codebook
      and analysed through thematic analysis. Results from aims I and II will inform
      the development of a survey instrument in aim III that will be administered to
      all EMS agencies in Michigan. This survey will test the generalisability of
      factors associated with increased OHCA survival in the qualitative work to
      ultimately build an EPOC Toolkit which will be distributed to a broad range of
      stakeholders as a practical 'how-to' guide to improve outcomes. ETHICS AND
      DISSEMINATION: The EPOC study was deemed exempt by the University of Michigan
      Institutional Review Board. Findings will be compiled in an 'EPOC Toolkit' and
      disseminated in the USA through partnerships including, but not limited to,
      policymakers, EMS leadership and health departments.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Salhi, Rama A
AU  - Salhi RA
AUID- ORCID: 0000-0002-6533-5878
AD  - Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan,
      USA.
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Fouche, Sydney
AU  - Fouche S
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Mendel, Peter
AU  - Mendel P
AD  - RAND Corporation, Santa Monica, California, USA.
FAU - Nelson, Christopher
AU  - Nelson C
AD  - RAND Corporation, Santa Monica, California, USA.
FAU - Fetters, Michael D
AU  - Fetters MD
AD  - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Guetterman, Timothy
AU  - Guetterman T
AD  - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Forman, Jane
AU  - Forman J
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
AD  - Center for Clinical Management Research, Veterans Affairs Health System, Ann
      Arbor, Michigan, USA.
FAU - Nham, Wilson
AU  - Nham W
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Goldstick, Jason E
AU  - Goldstick JE
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Lehrich, Jessica
AU  - Lehrich J
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Forbush, Bill
AU  - Forbush B
AD  - City of Alpena Fire Department, Alpena County EMS, City of Alpena, Alpena,
      Michigan, USA.
FAU - Iovan, Samantha
AU  - Iovan S
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Hsu, Antony
AU  - Hsu A
AD  - Department of Emergency Medicine, Saint Joseph Mercy Health System, Ann Arbor,
      Michigan, USA.
FAU - Shields, Theresa A
AU  - Shields TA
AD  - Department of Emergency Medicine, University of Michigan Health System, Ann
      Arbor, Michigan, USA.
FAU - Domeier, Robert
AU  - Domeier R
AD  - Department of Emergency Medicine, Saint Joseph Mercy Health System, Ann Arbor,
      Michigan, USA.
FAU - Setodji, Claude M
AU  - Setodji CM
AD  - RAND Corporation, Santa Monica, California, USA.
FAU - Neumar, Robert W
AU  - Neumar RW
AD  - Department of Emergency Medicine, University of Michigan Health System, Ann
      Arbor, Michigan, USA.
CN  - CARES Surveillance Group
FAU - Nallamothu, Brahmajee K
AU  - Nallamothu BK
AD  - Division of Cardiovascular Diseases and the Department of Internal Medicine,
      University of Michigan Health System, Ann Arbor, Michigan, USA.
FAU - Abir, Mahshid
AU  - Abir M
AD  - Acute Care Research Unit, Institute for Healthcare Policy and Innovation,
      University of Michigan, Ann Arbor, Michigan, USA mahshida@med.umich.edu.
AD  - Department of Emergency Medicine, University of Michigan Health System, Ann
      Arbor, Michigan, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cardiopulmonary Resuscitation
MH  - *Emergency Medical Dispatch
MH  - *Emergency Medical Services
MH  - Humans
MH  - Michigan/epidemiology
MH  - *Out-of-Hospital Cardiac Arrest/therapy
MH  - Treatment Outcome
PMC - PMC7703417
OTO - NOTNLM
OT  - *ACCIDENT & EMERGENCY MEDICINE
OT  - *CARDIOLOGY
OT  - *Organisation of health services
OT  - *Protocols & guidelines
COIS- Competing interests: During the study period, MA received funding from the
      American Heart Association for the Michigan-Resuscitation Innovation and Science 
      Enterprise, a collaboration focused on improvement of neurological outcomes after
      cardiac arrest.
EDAT- 2020/11/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-041277 [pii]
AID - 10.1136/bmjopen-2020-041277 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e041277. doi: 10.1136/bmjopen-2020-041277.


PMID- 33247024
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Mapping the current knowledge in syndemic research applied to men who have sex
      with men: a scoping review protocol.
PG  - e041238
LID - 10.1136/bmjopen-2020-041238 [doi]
AB  - INTRODUCTION: Men who have sex with men (MSM) are disproportionally affected by a
      number of health conditions that are associated with violence, stigma,
      discrimination, poverty, unemployment or poor healthcare access. In recent years,
      syndemic theory provided a framework to explore the interactions of these health 
      disparities on the biological and social levels. Research in this field has been 
      increasing for the past 10 years, but methodologies have evolved and sometimes
      differed from the original concept. The aim of this paper is to provide an
      overview of the existing literature on syndemic theory applied to MSM in order to
      identify knowledge gaps, inform future investigations and expand our
      understanding of the complex interactions between avoidable health conditions in 
      a vulnerable population. METHODS AND ANALYSIS: The proposed scoping review will
      follow the methodological framework developed by Arksey and O'Malley with
      subsequent enhancements by Levac et al, Colquhoun et al and Peters et al as well 
      as the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      extension for scoping review. A systematic search of MEDLINE, PsycInfo, Scopus,
      Cochrane Central Register of Controlled Trials and ProQuest Sociological
      Abstracts will be conducted. Reference lists of the included studies will be
      hand-searched for additional studies. Screening and data charting will be
      achieved using DistillerSR. Data collating, summarising and reporting will be
      performed using R and RStudio. Tabular and graphical summaries will be presented,
      alongside an evidence map and a descriptive overview of the main results. ETHICS 
      AND DISSEMINATION: This scoping review does not require ethical approval. Data
      and code will be made accessible after manuscript submission. Final results will 
      be disseminated through publication in a peer-reviewed journal and collaboration 
      with grassroots Lesbian, Gay, Bisexual, Transgender, Queer, Intersex and Asexual 
      (LGBTQIA+) organisations. REGISTRATION: This protocol was registered on
      manuscript submission on the Open Science Framework at the following address:
      https://osf.io/jwxtd; DOI: 10.17605/OSF.IO/JWXTD.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ouafik, Maxence
AU  - Ouafik M
AUID- ORCID: 0000-0002-9795-5721
AD  - General Practice Department - Primary Care and Health Research Unit, Liege
      University, Liege, Belgium maxence.ouafik@student.uliege.be.
FAU - Buret, Laetitia
AU  - Buret L
AD  - General Practice Department - Primary Care and Health Research Unit, Liege
      University, Liege, Belgium.
FAU - Belche, Jean-Luc
AU  - Belche JL
AD  - General Practice Department - Primary Care and Health Research Unit, Liege
      University, Liege, Belgium.
FAU - Scholtes, Beatrice
AU  - Scholtes B
AD  - General Practice Department - Primary Care and Health Research Unit, Liege
      University, Liege, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Female
MH  - *Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Peer Review
MH  - *Sexual and Gender Minorities
MH  - Syndemic
MH  - Vulnerable Populations
PMC - PMC7703413
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *mental health
OT  - *public health
OT  - *sexual medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-041238 [pii]
AID - 10.1136/bmjopen-2020-041238 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e041238. doi: 10.1136/bmjopen-2020-041238.


PMID- 33247023
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20210410
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Mental health of Urban Mothers (MUM) study: a multicentre randomised controlled
      trial, study protocol.
PG  - e041133
LID - 10.1136/bmjopen-2020-041133 [doi]
AB  - INTRODUCTION: Mental health disorders are common during pregnancy and the
      postnatal period and can have serious adverse effects on women and their
      children. The consequences for global mental health due to COVID-19 are likely to
      be significant and may have a long-term impact on the global burden of disease.
      Besides physical vulnerability, pregnant women are at increased risk of mental
      health problems such as anxiety, depression and post-traumatic stress disorder
      due to the consequences of social distancing. It can result in altered healthcare
      routines, less support from the family and friends, and in some cases, partners
      not being allowed to be present during prenatal visits, labour and delivery.
      Higher than expected, rates of perinatal anxiety and depression have been already
      reported during the pandemic. Pregnant women may also feel insecure and worried
      about the effects of COVID-19 on their unborn child if they get infected during
      pregnancy. Today, young urban women are used to using internet services
      frequently and efficiently. Therefore, providing mental health support to
      pregnant women via internet may be effective in ameliorating their
      anxiety/depression, reducing the risk of serious mental health disorders, and
      lead to improved maternal and perinatal outcomes. OVERARCHING AIM: Our aim is to 
      explore the effectiveness of a web-based psychosocial peer-to-peer support
      intervention in reducing the risk and severity of perinatal mental health
      disorders and preventing adverse pregnancy outcomes among pregnant women living
      in metropolitan urban settings. METHODS AND ANALYSIS: We plan to conduct a
      multicentre prospective randomised controlled trial, Mental health of Urban
      Mothers trial. Pregnant women living in large metropolitan cities will be
      recruited using internet-based application through non-profit organisations'
      websites. The women who consent will be randomised to receive a web-based
      peer-to-peer support intervention or usual care. Data will be analysed to
      identify the effects of intervention on Edinburgh Postnatal Depression Score and 
      Generalised Anxiety Disorder 7 scores as well as pregnancy outcomes. The impact
      of COVID-19 pandemic on maternal stress will be assesed using Impact Event
      Scale-R. Any differences in outcomes between cities will be addressed in subgroup
      analyses. ETHICS AND DISSEMINATION: The study will be conducted according to the 
      principles of Good Clinical Practice and will follow the ethical principles of
      the Declaration of Helsinki. The study protocol has been approved by the ethical 
      review board of Chinese University of Hong Kong (IRB number 2019-8170) and
      Shanghai Center for Women's and Children's Health (international review board
      (IRB) number 2020-F001-12). The results will be disseminated at national and
      international scientific conferences, published in peer-reviewed medical journals
      and spread to the public through social media, news outlets and podcasts. TRIAL
      REGISTRATION NUMBER: NCT04363177; Trial sponsor Karolinska Institute, CLINTEC,
      Stockholm, Sweden.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Schwank, Simone Eliane
AU  - Schwank SE
AUID- ORCID: 0000-0002-1955-1123
AD  - CLINTEC, Karolinska Institute, Stockholm, Sweden simone.schwank@ki.se.
AD  - Women's Health and Perinatology Research Group, Department of Clinical Medicine, 
      UiT-The Arctic University of Norway, Tromso, Norway.
FAU - Chung, Ho-Fung
AU  - Chung HF
AD  - Psychiatry, The University of Hong Kong, Hong Kong, Hong Kong.
FAU - Hsu, Mandy
AU  - Hsu M
AD  - Psychological and Brain Sciences, Johns Hopkins University, Baltimore, Maryland, 
      USA.
FAU - Fu, Shih-Chien
AU  - Fu SC
AD  - Counseling Psychology, National Taipei University of Education, Taipei, Taiwan.
FAU - Du, Li
AU  - Du L
AD  - Department of Research and Education, Tongji University, Shanghai, Shanghai,
      China.
FAU - Zhu, Liping
AU  - Zhu L
AD  - Department of Research and Education, Tongji University, Shanghai, Shanghai,
      China.
FAU - Huang, Hsuan-Ying
AU  - Huang HY
AD  - Anthropology, The Chinese University Hong Kong, Hong Kong, Hong Kong.
FAU - Andersson, Ewa
AU  - Andersson E
AD  - Department of Women's and Children's Health, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Acharya, Ganesh
AU  - Acharya G
AD  - Women's Health and Perinatology Research Group, Department of Clinical Medicine, 
      UiT-The Arctic University of Norway, Tromso, Norway.
AD  - CLINTEC Department of Clinical Technology, Karolinska Institutet, Stockholm,
      Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT04363177
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anxiety/etiology/prevention & control
MH  - COVID-19/*psychology
MH  - Child
MH  - Depression/etiology/prevention & control
MH  - Depression, Postpartum/prevention & control
MH  - Female
MH  - Humans
MH  - Internet
MH  - Mental Disorders/etiology/*prevention & control
MH  - *Mental Health
MH  - Mothers/psychology
MH  - Pandemics
MH  - Peer Group
MH  - Physical Distancing
MH  - Pregnancy
MH  - Pregnancy Complications/*psychology
MH  - Pregnancy Outcome
MH  - Pregnant Women/psychology
MH  - Psychotherapy/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Stress, Psychological/etiology/*prevention & control
MH  - *Urban Population
PMC - PMC7703424
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *infectious diseases
OT  - *perinatology
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-041133 [pii]
AID - 10.1136/bmjopen-2020-041133 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e041133. doi: 10.1136/bmjopen-2020-041133.


PMID- 33247021
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Dementias Platform UK Clinical Studies and Great Minds Register: protocol of a
      targeted brain health studies recontact database.
PG  - e040766
LID - 10.1136/bmjopen-2020-040766 [doi]
AB  - INTRODUCTION: The case for de-risking neurodegenerative research and development 
      through highly informative experimental medicine studies early in the disease
      process is strong. Such studies depend on the availability of genetic as well as 
      high-granularity, longitudinal, phenotypic data in healthy ageing individuals who
      can be recruited into early phase trials on the basis of their perceived dementia
      risk. Until now the creation of such research infrastructure has been hampered by
      the lack of expense and time required to gather the rich longitudinal data needed
      for adequate risk stratification. Dementias Platform UK (DPUK) is a
      public-private partnership that brings together data from over 40 cohorts in a
      standardised framework, which represent an until now unavailable opportunity to
      create such a resource through a streamlined brain health recontact platform
      based on existing cohorts, as well as prospectively collected data. METHODS AND
      ANALYSIS: The DPUK recontact platform consists of an opt-in (Great Minds, GM) and
      an opt-out component (Clinical Studies Register, CSR). GM requires invited DPUK
      cohort participants to consent to targeted recontact at the GM website and then
      to provide self-reported demographic and medical history information relevant to 
      recruitment into clinical studies. Participants complete prospective
      browser-based and smartphone-based cognitive tests and are given the option for
      remote genetic and actigraphy testing. The GM data are linked to the
      retrospective DPUK cohort dataset, including genotypic and longitudinal
      phenotypic data. The CSR is a solution for cohorts explicitly allowing targeted
      recontact. Approved studies provide prescreening criteria on the basis of the
      CSR/GM dataset, and individuals meeting these criteria are offered participation 
      directly (GM) or through the parent DPUK cohort (CSR). Descriptive statistics
      will be used to summarise the outcomes relevant to the number of participants
      engaged with the register. Its sample size is not defined but is limited by the
      size of the DPUK parent cohorts. ETHICS AND DISSEMINATION: The database was
      approved by the South Central-Oxford C Research Ethics Committee, reference
      18/SC/0268 on the 27th of June 2018 and amended on the 1st of November 2019. The 
      availability of the register to researchers will be disseminated through DPUK's
      official communication channels as well as national and international scientific 
      meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Koychev, Ivan
AU  - Koychev I
AUID- ORCID: 0000-0001-6813-8493
AD  - Psychiatry, University of Oxford, Oxford, UK ivan.koychev@psych.ox.ac.uk.
FAU - Young, Simon
AU  - Young S
AD  - Psychiatry, University of Oxford, Oxford, UK.
FAU - Holve, Heather
AU  - Holve H
AD  - Psychiatry, University of Oxford, Oxford, UK.
FAU - Ben Yehuda, Michael
AU  - Ben Yehuda M
AUID- ORCID: 0000-0002-6405-5022
AD  - Psychiatry, University of Oxford, Oxford, UK.
FAU - Gallacher, John
AU  - Gallacher J
AD  - Psychiatry, University of Oxford, Oxford, UK.
LA  - eng
GR  - MR/L023784/2/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Dec 23;10(12):e040766corr1. PMID: 33361172
MH  - Brain
MH  - *Dementia
MH  - *Duty to Recontact
MH  - Humans
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - United Kingdom
PMC - PMC7703421
OTO - NOTNLM
OT  - *dementia
OT  - *preventive medicine
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040766 [pii]
AID - 10.1136/bmjopen-2020-040766 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e040766. doi: 10.1136/bmjopen-2020-040766.


PMID- 33247018
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Promotion or education: a content analysis of industry-authored oral health
      educational materials targeted at acute care nurses.
PG  - e040541
LID - 10.1136/bmjopen-2020-040541 [doi]
AB  - OBJECTIVES: To assess the nature, quality and independence of scientific evidence
      provided in support of claims in industry-authored educational materials in oral 
      health. DESIGN: A content analysis of educational materials authored by the four 
      major multinational oral health product manufacturers. SETTING: Acute care
      settings. PARTICIPANTS: 68 documents focused on oral health or oral care,
      targeted at acute care clinicians and identified as 'educational' on companies'
      international websites. MAIN OUTCOME MEASURES: Data were extracted in duplicate
      for three areas of focus: (a) products referenced in the documents, (b)
      product-related claims and (c) citations substantiating claims. We assessed
      claim-citation pairs to determine if information in the citation supported the
      claim. We analysed the inter-relationships among cited authors and companies
      using social network analysis. RESULTS: Documents ranged from training videos to 
      posters to brochures to continuing education courses. The majority of educational
      materials explicitly mentioned a product (59/68, 87%), a branded product (35/68, 
      51%), and made a product-related claim (55/68, 81%). Among claims accompanied by 
      a citation, citations did not support the majority (91/147, 62%) of claims,
      largely because citations were unrelated. References used to support claims most 
      often represented lower levels of evidence: only 9% were systematic reviews
      (7/76) and 13% were randomised controlled trials (10/76). We found a network of
      20 authors to account for 37% (n=77/206) of all references in claim-citation
      pairs; 60% (12/20) of the top 20 cited authors received financial support from
      one of the four sampled manufacturers. CONCLUSIONS: Resources to support
      clinicians' ongoing education are scarce. However, caution should be exercised
      when relying on industry-authored materials to support continuing education for
      oral health. Evidence of sponsorship bias and reliance on key opinion leaders
      suggests that industry-authored educational materials have promotional intent and
      should be regulated as such.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Grundy, Quinn
AU  - Grundy Q
AUID- ORCID: 0000-0002-7640-8614
AD  - Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario,
      Canada quinn.grundy@utoronto.ca.
FAU - Millington, Anna
AU  - Millington A
AUID- ORCID: 0000-0002-8250-3546
AD  - Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Cussen, Cliodna
AU  - Cussen C
AUID- ORCID: 0000-0002-5588-7943
AD  - Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Held, Fabian
AU  - Held F
AUID- ORCID: 0000-0002-5260-5576
AD  - Office of the Deputy Vice-Chancellor (Education-Enterprise and Engagement), The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Dale, Craig M
AU  - Dale CM
AUID- ORCID: 0000-0002-5042-0332
AD  - Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Health Education, Dental
MH  - Humans
MH  - *Oral Health
PMC - PMC7703418
OTO - NOTNLM
OT  - *health policy
OT  - *health services administration & management
OT  - *medical ethics
OT  - *oral medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040541 [pii]
AID - 10.1136/bmjopen-2020-040541 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e040541. doi: 10.1136/bmjopen-2020-040541.


PMID- 33247016
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Endovascular treatment versus standard medical treatment for acute basilar artery
      occlusion: protocol for a systematic review and meta-analysis.
PG  - e040415
LID - 10.1136/bmjopen-2020-040415 [doi]
AB  - INTRODUCTION: Acute basilar artery occlusion (BAO) can cause posterior
      circulation stroke. There are two predominant therapies for BAO: standard medical
      treatment (SMT) and SMT plus endovascular thrombectomy (EVT). However, a
      conclusive systematic comparison of the safety and efficacy of SMT and those of
      SMT plus EVT for the treatment of BAO is lacking. Thus, a systematic review and
      meta-analysis is needed to evaluate the safety and efficacy of SMT and SMT plus
      EVT for the treatment of BAO. METHODS AND ANALYSIS: This protocol is drafted
      referring to the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses for Protocols guidelines. We will search eligible studies from four
      main databases including MEDLINE, Web of Science, Cochrane Library and Embase.
      Randomised controlled trials (RCTs) and observational studies published before 1 
      October 2020 will be included. Two reviewers in our team will conduct the study
      selection and data extraction independently. Risk of bias will be assessed by
      Cochrane Collaboration criteria and the Newcastle-Ottawa scale for RCTs and
      observational studies, respectively. We will assess the good functional outcomes 
      defining the modified Rankin scale score </=2 at 90 days after treatment,
      short-term stroke severity as National Institutes of Health Stroke Scale score at
      24 hours after intervention, and successful recanalisation as a modified
      Thrombolysis in Cerebral Infarction scale score of >/=2b after intervention.
      Also, safety outcomes will be assessed. The performance of this meta-analysis
      will depend on the quantity of included studies. The assessment of study
      heterogeneity will be performed by the I(2) statistic. If there is mild
      heterogeneity (I(2)<20%) of intervention outcomes in included studies, the
      fixed-effect model will be applied; otherwise, the random-effect model will be
      performed. Subgroup analyses and an assessment of publication bias will also be
      conducted with sufficient data. ETHICS AND DISSEMINATION: No collection of
      primary data from patients is needed. Therefore, the ethical approval is
      unnecessary. The results may be presented in a peer-reviewed journal and related 
      conferences. PROSPERO REGISTRATION NUMBER: CRD42020176764.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bai, Xuesong
AU  - Bai X
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
FAU - Zhang, Xiao
AU  - Zhang X
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
FAU - Li, Long
AU  - Li L
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
FAU - Wang, Tao
AU  - Wang T
AUID- ORCID: 0000-0003-1225-0173
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
FAU - Dmytriw, Adam Andrew
AU  - Dmytriw AA
AUID- ORCID: 0000-0003-0131-5699
AD  - Department of Medical Imaging, University of Toronto Faculty of Medicine,
      Toronto, Ontario, Canada.
AD  - Neuroradiology & Neurointervention Service, Brigham and Women's Hospital, Harvard
      Medical School, Boston, Massachusetts, USA.
FAU - Feng, Yao
AU  - Feng Y
AUID- ORCID: 0000-0001-7923-8158
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
FAU - Yang, Kun
AU  - Yang K
AD  - Department of Evidence-based Medicine, Xuanwu Hospital, Capital Medical
      University, Beijing, China.
FAU - Wang, Xue
AU  - Wang X
AD  - Medical Library, Xuanwu Hospital, Capital Medical University, Beijing, China.
FAU - Ma, Yan
AU  - Ma Y
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
FAU - Jiao, Liqun
AU  - Jiao L
AUID- ORCID: 0000-0003-4982-6295
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China liqunjiao@sina.cn.
AD  - China International Neuroscience Institute (China-INI), Beijing, China.
AD  - Department of Interventional Neuroradiology, Xuanwu Hospital, Capital Medical
      University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Adolescent
MH  - Basilar Artery
MH  - *Brain Ischemia
MH  - *Endovascular Procedures
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Reference Standards
MH  - *Stroke/therapy
MH  - Systematic Reviews as Topic
MH  - Tissue Plasminogen Activator
PMC - PMC7703427
OTO - NOTNLM
OT  - *neuroradiology
OT  - *neurosurgery
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-040415 [pii]
AID - 10.1136/bmjopen-2020-040415 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e040415. doi: 10.1136/bmjopen-2020-040415.


PMID- 33247014
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - International observational atopic dermatitis cohort to follow natural history
      and treatment course: TARGET-DERM AD study design and rationale.
PG  - e039928
LID - 10.1136/bmjopen-2020-039928 [doi]
AB  - INTRODUCTION: As new topical and systemic treatments become available for atopic 
      dermatitis (AD), there is a need to understand how treatments are being used in
      routine clinical practice, their comparative effectiveness and their long-term
      safety in diverse clinical settings. METHODS AND ANALYSIS: The TARGET-DERM AD
      cohort is a longitudinal, observational study of patients with AD of all ages,
      designed to provide practical information on long-term effectiveness and safety
      unobtainable in traditional registration trials. Patients with
      physician-diagnosed AD receiving prescription treatment (topical or systemic)
      will be enrolled at academic and community clinical centres. Up to 3 years of
      retrospective medical records, 5 years of prospective medical records, and
      optional biological samples and patient-reported outcomes will be collected. The 
      primary aims include characterisation of AD treatment regimens, evaluation of
      response to therapy, and description of adverse events. ETHICS AND DISSEMINATION:
      TARGET-DERM has been approved by a central IRB (Copernicus Group IRB, 5000
      Centregreen Way Suite 200, Cary, North Carolina 27513) as well as local and
      institutional IRBs. No additional Ethics Committee reviews. Results will be
      reviewed by a publications committee and submitted to peer-reviewed journals.
      TRIAL REGISTRATION NUMBER: NCT03661866, pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Abuabara, Katrina
AU  - Abuabara K
AUID- ORCID: 0000-0002-7736-6946
AD  - Department of Dermatology, University of California, San Francisco, San
      Francisco, CA, USA katrina.abuabara@ucsf.edu.
FAU - Silverberg, Jonathan I
AU  - Silverberg JI
AUID- ORCID: 0000-0003-3686-7805
AD  - Department of Dermatology, George Washington University, Washington, DC, USA.
FAU - Simpson, Eric L
AU  - Simpson EL
AUID- ORCID: 0000-0002-8793-7087
AD  - Department of Dermatology, Oregon Health & Science University, Portland, Oregon, 
      USA.
FAU - Paller, Amy S
AU  - Paller AS
AUID- ORCID: 0000-0001-6187-6549
AD  - Department of Dermatology, Northwestern University, Chicago, Illinois, USA.
FAU - Eichenfield, Lawrence F
AU  - Eichenfield LF
AUID- ORCID: 0000-0002-2760-0474
AD  - Department of Dermatology, University of California, San Diego School, La Jolla, 
      California, USA.
FAU - Bissonnette, Robert
AU  - Bissonnette R
AUID- ORCID: 0000-0001-5927-6587
AD  - Innovaderm Research, Montreal, Quebec, Canada.
FAU - Krueger, James
AU  - Krueger J
AUID- ORCID: 0000-0002-3775-1778
AD  - Department of Immunology, Virology and Microbiology, Rockefeller Institute for
      Medical Research, New York, New York, USA.
FAU - Harris, John E
AU  - Harris JE
AUID- ORCID: 0000-0002-7815-6430
AD  - Department of Dermatology, University of Massachusetts Medical School, Worcester,
      MA, USA.
FAU - Dalfonso, Laura
AU  - Dalfonso L
AUID- ORCID: 0000-0001-5442-9433
AD  - Clinical Operations, TARGET PharmaSolutions, Durham, North Carolina, USA.
FAU - Watkins, Stephanie E
AU  - Watkins SE
AD  - Scientific and Medical Affairs, TARGET PharmaSolutions, Durham, North Carolina,
      USA.
FAU - Crawford, Julie M
AU  - Crawford JM
AUID- ORCID: 0000-0001-8976-8558
AD  - Scientific and Medical Affairs, TARGET PharmaSolutions, Durham, North Carolina,
      USA.
FAU - Thaci, D
AU  - Thaci D
AUID- ORCID: 0000-0001-8513-550X
AD  - Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck,
      Schleswig-Holstein, Germany.
FAU - Guttman-Yassky, Emma
AU  - Guttman-Yassky E
AUID- ORCID: 0000-0002-9363-324X
AD  - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New
      York, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03661866
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Dermatitis, Atopic/drug therapy
MH  - Humans
MH  - North Carolina
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC7703415
OTO - NOTNLM
OT  - *eczema
OT  - *medical history
OT  - *statistics & research methods
OT  - *therapeutics
COIS- Competing interests: KA: receives compensation for consulting services from
      TARGET PharmaSolutions; no other competing interests. JIS: AbbVie, Anaptysbio,
      Arena, Asana, Boehringer-Ingelheim, Dermira, Dermavant, DS Biopharma, Eli Lilly, 
      Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa, LEO Pharma, Luna, Menlo,
      Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi - consultant or advisory
      board member; Regeneron Pharmaceuticals, Sanofi - speaker. ELS: grants and
      personal fees from AbbVie, grants and personal fees from Eli Lilly, grants from
      Galderma, grants from Kyowa Hakko Kirin, grants and personal fees from Leo
      Pharmaceutical, grants from Merck, grants and personal fees from Pfizer, grants
      and personal fees from Regeneron, personal fees from Sanofi, personal fees from
      Dermira, grants from Galderma, grants and personal fees from MedImmune, grants
      from Novartis, grants from Tioga, grants from Celgene, personal fees from
      Boehringer-Ingelheim, personal fees from Dermavant, personal fees from Forte Bio,
      personal fees from Incyte, personal fees from Menlo Therapeutics, personal fees
      from Ortho Dermatologics, personal fees from Pierre Fabre Dermo Cosmetique,
      personal fees from Valeant. ASP: investigator for AbbVie, Anaptysbio, Celgene,
      Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis, and Regeneron; consultant
      with honorarium for Almirall, Amgen, Asana, Boehringer-Ingelheim, Castle Creek,
      Celgene, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Galderma, Lenus, Leo,
      MEDA Corp, Meiji Seika, Novan, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and
      Sol Gel. LE: Consultant/Speaker/Advisory Board: Almirall, Dermavant, Dermira, DS 
      Biopharma, Forte, Galderma, Incyte, LEO, Lilly, L'Oreal, Matrisys, Otsuka,
      Novartis, Ortho Dermatologics/Valeant, Pfizer/Anacor, Regeneron, Sanofi-Genzyme. 
      Investigator: Abvie, LEO, Regeneron, Sanofi-Genzyme. DSM: Asana, Ichnos/Glenmark.
      RB: Advisory Board Member, Consultant, Speaker, Investigator for and/or receives 
      honoraria or grant from AbbVie, AntibioTx, Arcutis, Arena Pharma, Asana
      BioSciences, Bellus Health, Boehringer-Ingelheim, Dermavant, Eli Lilly, EMD
      Serono, Galderma, Incyte, Kiniksa, Kyowa Kirin, Neokera, LEO Pharma, Novan,
      Pfizer, Ralexar, RAPT, Regeneron, Sanofi Genzyme and Sienna. Employee and
      shareholder of Innovaderm Research. JK: Personal fees from Novartis, Pfizer,
      Amgen, Lilly, Boehringer, BMS, Biogenldec, Janssen, AbbVie, Leo Pharma, ESCALIER,
      Valeant, Allergan, Aurigene, Sienna, UCB, Allergan, Asana, Celgene, Nimbus,
      Menlo, Aristea, Sanofi, Sun Pharma, Almirall, Arena, Ventyx, Aclaris, Galapagos. 
      Grants paid to Institution from Novartis, Pfizer, Amgen, Lilly, Boehringer,
      Innovaderm, BMS, Janssen, AbbVie, Parexel, Leo Pharma, Vitae, Akros, Regeneron,
      Allergan, Novan, Biogen MA, Sienna, UCB, Celgene, Botanix, Incyte, Avillion,
      Exicure. JH: consultant for Pfizer, Genzyme/Sanofi, Aclaris Therapeutics, Incyte,
      Theos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics,
      Dermavant, Temprian, AbbVie, Inc., Janssen, TeVido BioDevices, EMD Serono,
      Almirall, Boston Pharma, Sonoma Biotherapeutics, Inc., Methuselah Health, Twi
      Biotech, Pandion, Cogen Therapeutics, Inc., Admirx and BridgeBio. Investigator
      for Pfizer, Genzyme/Sanofi, Aclaris Therapeutics, Incyte, Theos Medicines, Sun
      Pharmaceuticals, LEO Pharma, Villaris Therapeutics, Dermavant, AbbVie, Inc.,
      TeVido BioDevices, EMD Serono and Pandion. Equity in TeVido Biodevices, Rheos,
      Villaris Therapeutics, Inc. Scientific Founder of Villaris Therapeutics, Inc. LD:
      employee at TARGET PharmaSolutions. SEW: employee at TARGET PharmaSolutions. JMC:
      employee at TARGET PharmaSolutions. DT: is a lecturer and/or consultant for
      AbbVie, Almirall, Amgen, Asana Biosciences, Biogen Idec, BIOCAD, Boehringer
      Ingelheim, Bristol-Myers Squibb, Celgene, DS-Biopharma, GlaxoSmithKline,
      Janssen-Cilag, Kyowa Kirin, Leo Pharma, Eli Lilly, Novartis, Regeneron, Sandoz,
      Sanofi-Aventis and UCB, and received grants from AbbVie and Novartis (paid to
      institution). EGY: employee of Mount Sinai and has received research funds
      (grants paid to the institution) from Abbvie, Almirall, Amgen, AnaptysBio, Asana 
      Biosciences, Boerhinger-Ingelhiem, Celgene, Dermavant, DS Biopharma, Eli Lilly,
      Galderma, Ichnos Sciences, Innovaderm, Janssen, Kiniska, Kyowa Kirin, Leo Pharma,
      Novan, Pfizer, Ralexar, Regeneron, Sienna Biopharma, UCB, and Union Therapeutics.
      EGY is also a consultant for Abbvie, Almirall, Amgen, Arena Pharmaceuticals,
      Asana Biosciences, AstraZeneca Biopharmaceuticals, Boerhinger-Ingelhiem, Cara
      Therapeutics, Celgene, Concert, DBV, Dermira, DS Biopharma, Eli Lilly, EMD
      Serono, Escalier, Galderma, Ichnos Sciences, Kyowa Kirin, Leo Pharma, Mitsubishi 
      Tanabe, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron, Sanofi,
      Sienna Biopharma, and Union Therapeutics.
EDAT- 2020/11/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-039928 [pii]
AID - 10.1136/bmjopen-2020-039928 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e039928. doi: 10.1136/bmjopen-2020-039928.


PMID- 33247012
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Study protocol and implementation details for a pragmatic, stepped-wedge cluster 
      randomised trial of a digital adherence technology to facilitate tuberculosis
      treatment completion.
PG  - e039895
LID - 10.1136/bmjopen-2020-039895 [doi]
AB  - INTRODUCTION: Low-cost digital adherence technologies (DATs) such as 99DOTS have 
      emerged as an alternative to directly observed therapy (DOT), the current
      standard for tuberculosis (TB) treatment supervision. However, there are limited 
      data to support DAT scale-up. The 'DOT to DAT' trial aims to evaluate the
      effectiveness and implementation of a 99DOTS-based TB treatment supervision
      strategy. METHODS AND ANALYSIS: This is a pragmatic, stepped-wedge cluster
      randomised trial, with hybrid type 2 effectiveness-implementation design. The
      trial will include all adults (estimated N=1890) treated for drug-susceptible
      pulmonary TB over an 8-month period at 18 TB treatment units in Uganda. Three
      sites per month will switch from routine care (DOT) to the intervention
      (99DOTS-based treatment supervision) beginning in month 2, with the order
      determined randomly. 99DOTS enables patients to be monitored while
      self-administering TB medicines. Patients receive daily automated short message
      service (SMS) dosing reminders and confirm dosing by calling toll-free numbers.
      The primary effectiveness outcome is the proportion of patients completing TB
      treatment. With 18 clusters randomised into six steps and an average cluster size
      of 15 patients per month, the study will have 89% power to detect a 10% or
      greater increase in treatment completion between the routine care and
      intervention periods. Secondary outcomes include more proximal effectiveness
      measures as well as quantitative and qualitative assessments of the reach,
      adoption and implementation of the intervention. ETHICS AND DISSEMINATION: Ethics
      approval was granted by institutional review boards at Makerere University School
      of Public Health and the University of California San Francisco. Findings will be
      disseminated through peer-reviewed publications, presentations at scientific
      conferences and presentations to key stakeholders. TRIAL REGISTRATION NUMBER:
      PACTR201808609844917.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Crowder, Rebecca
AU  - Crowder R
AD  - Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San
      Francisco General Hospital, University of California San Francisco, San
      Francisco, California, USA.
FAU - Kityamuwesi, Alex
AU  - Kityamuwesi A
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Kiwanuka, Noah
AU  - Kiwanuka N
AD  - School of Public Heatlh, Makerere University College of Health Sciences, Kampala,
      Uganda.
FAU - Lamunu, Maureen
AU  - Lamunu M
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Namale, Catherine
AU  - Namale C
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Tinka, Lynn Kunihira
AU  - Tinka LK
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Nakate, Agnes Sanyu
AU  - Nakate AS
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Ggita, Joseph
AU  - Ggita J
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Turimumahoro, Patricia
AU  - Turimumahoro P
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Babirye, Diana
AU  - Babirye D
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Oyuku, Denis
AU  - Oyuku D
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Berger, Christopher Allen
AU  - Berger CA
AUID- ORCID: 0000-0002-0034-7544
AD  - Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San
      Francisco General Hospital, University of California San Francisco, San
      Francisco, California, USA.
FAU - Tucker, Austin
AU  - Tucker A
AD  - Department of Epidemiology, Johns Hopkins University Bloomberg School of Public
      Health, Baltimore, Maryland, USA.
FAU - Patel, Devika
AU  - Patel D
AD  - The Better Lab, Department of Surgery, Zuckerberg San Francisco General Hospital,
      University of California San Francisco, San Francisco, California, USA.
FAU - Sammann, Amanda
AU  - Sammann A
AD  - The Better Lab, Department of Surgery, Zuckerberg San Francisco General Hospital,
      University of California San Francisco, San Francisco, California, USA.
FAU - Dowdy, David
AU  - Dowdy D
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
AD  - Department of Epidemiology, Johns Hopkins University Bloomberg School of Public
      Health, Baltimore, Maryland, USA.
FAU - Stavia, Turyahabwe
AU  - Stavia T
AD  - National Tuberculosis and Leprosy Program, Republic of Uganda Ministry of Health,
      Kampala, Uganda.
FAU - Cattamanchi, Adithya
AU  - Cattamanchi A
AD  - Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San
      Francisco General Hospital, University of California San Francisco, San
      Francisco, California, USA.
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
FAU - Katamba, Achilles
AU  - Katamba A
AUID- ORCID: 0000-0002-2347-4183
AD  - Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda
      axk95@case.edu.
AD  - School of Medicine, Makerere University College of Health Sciences, Kampala,
      Uganda.
LA  - eng
SI  - PACTR/PACTR201808609844917
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - San Francisco
MH  - Technology
MH  - *Text Messaging
MH  - *Tuberculosis/drug therapy
MH  - Uganda
PMC - PMC7703448
OTO - NOTNLM
OT  - *international health services
OT  - *public health
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039895 [pii]
AID - 10.1136/bmjopen-2020-039895 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e039895. doi: 10.1136/bmjopen-2020-039895.


PMID- 33247008
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - 3D-printed brace in the treatment of adolescent idiopathic scoliosis: a study
      protocol of a prospective randomised controlled trial.
PG  - e038373
LID - 10.1136/bmjopen-2020-038373 [doi]
AB  - INTRODUCTION: Adolescent idiopathic scoliosis (AIS) is a three-dimensional
      deformity of the spine. Brace treatment is effective for eligible patients with
      AIS and the effectiveness is significantly correlated with the average brace-wear
      time per day. Three-dimensional (3D) printing technology is a recent advancement 
      that offers unique opportunities for biomedical applications, and customisation
      of scoliosis braces might lead to greater patient satisfaction and improved
      compliance. We present here the design of a randomised controlled trial on the
      clinical effectiveness of 3D-printed braces versus thoracolumbosacral orthoses
      (TLSO) for patients with AIS. METHODS AND ANALYSIS: Patients with AIS (age 10-16 
      years) with Risser sign 0-II, Cobb angle of main curve of 20 degrees -40 degrees 
      , premenarchal or no more than 1-year postmenarchal (for women), and no history
      of treatment are eligible, unless they are unable to tolerate the treatment or
      refuse participation. A total of 88 patients will be randomised into either the
      3D group or TLSO group on a 1:1 basis. Participants in the 3D group will choose
      between a 3D-printed brace and TLSO, according to the Zelen's design of the
      trial. Primary outcome measures will include the average brace-wear time per day,
      health-related quality of life and Cobb angle progression of the primary curve.
      Secondary outcome measures will include immediate in-brace correction of Cobb
      angle of the primary curve, rate of conversion to surgery and incidence of any
      adverse events. This study is designed as a single-centre, two-arm, superiority
      and open-label randomised controlled trial. The sample size is calculated with
      reference to the preliminary study and based on the sample size calculation
      formula. ETHICS AND DISSEMINATION: This study was approved by the Peking
      University Third Hospital Medicine Science Research Ethics Committee (No:
      2019-017-02). Results of the trial will be submitted for publication in a
      peer-reviewed journal and as conference presentations. TRIAL REGISTRATION NUMBER:
      ChiCTR1900027379, pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Youyu
AU  - Zhang Y
AUID- ORCID: 0000-0001-5606-620X
AD  - Department of Orthopedics, Peking University Third Hospital, Beijing, China.
FAU - Liang, Junyang
AU  - Liang J
AD  - Department of Spinal Surgery, Weihai Wei People's Hospital, Weihai, China.
FAU - Xu, Nanfang
AU  - Xu N
AUID- ORCID: 0000-0001-5888-293X
AD  - Department of Orthopedics, Peking University Third Hospital, Beijing, China
      xunanfang@foxmail.com.
FAU - Zeng, Lin
AU  - Zeng L
AUID- ORCID: 0000-0001-8707-5854
AD  - Research Center of Clinical Epidemiology, Peking University Third Hospital,
      Beijing, China.
FAU - Du, Chaojun
AU  - Du C
AD  - Department of Orthotics and Prosthetics, Peking University Third Hospital,
      Beijing, China.
FAU - Du, Yaoxu
AU  - Du Y
AD  - Department of Orthotics and Prosthetics, Peking University Third Hospital,
      Beijing, China.
FAU - Zeng, Yan
AU  - Zeng Y
AD  - Department of Orthopedics, Peking University Third Hospital, Beijing, China.
FAU - Yu, Miao
AU  - Yu M
AD  - Department of Orthopedics, Peking University Third Hospital, Beijing, China.
FAU - Liu, Zhongjun
AU  - Liu Z
AD  - Department of Orthopedics, Peking University Third Hospital, Beijing, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Braces
MH  - Child
MH  - Female
MH  - Humans
MH  - Printing, Three-Dimensional
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Scoliosis/diagnostic imaging/therapy
MH  - Treatment Outcome
PMC - PMC7703428
OTO - NOTNLM
OT  - *clinical trials
OT  - *paediatric orthopaedics
OT  - *scoliosis
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038373 [pii]
AID - 10.1136/bmjopen-2020-038373 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e038373. doi: 10.1136/bmjopen-2020-038373.


PMID- 33247007
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Effects of behavioural parent training for children with
      attention-deficit/hyperactivity disorder on parenting behaviour: a protocol for
      an individual participant data meta-analysis.
PG  - e037749
LID - 10.1136/bmjopen-2020-037749 [doi]
AB  - INTRODUCTION: Behavioural parent training (BPT) is a well-established treatment
      for children with attention-deficit/hyperactivity disorder (ADHD). BPT is based
      on the hypothesis that improvements in parenting are mediators of improvements in
      children's behaviours. However, meta-analyses show considerate heterogeneity in
      effects of BPT on child outcomes, and meta-analyses on parenting outcomes are
      scarce. Also, few studies have investigated parenting factors as mediators of
      child outcomes. This study aims to examine the effects and moderators of BPT on
      parenting outcomes and whether improvements in parenting mediate amelioration of 
      behaviour and impairment in children with ADHD. METHODS AND ANALYSES: We will
      conduct an individual participant data meta-analysis (IPDMA), making use of
      individual data of existing trials, and giving the opportunity for highly powered
      moderator analyses. This IPDMA will be performed by the Psychosocial ADHD
      INTervention (PAINT) collaboration. We will include randomised controlled trials 
      of BPT, for individuals with ADHD below 18 years old. Systematic searches have
      been performed to locate relevant papers. Authors are currently contacted to
      share their data with the PAINT-IPDMA project. We will examine effects of BPT on 
      parenting outcomes (eg, positive and negative parenting, management of affect,
      perceived parenting competence, parenting stress), moderators of these effects
      (eg, parental depression, parenting stress, severity of the child's ADHD
      symptoms) and subsequently perform mediation analyses where parenting outcomes
      are modelled as mediators of child outcomes (eg, symptoms and severity of ADHD,
      comorbid psychopathology and impairment). ETHICS AND DISSEMINATION: We will
      include data from randomised control trials for which ethical approval has been
      received and consent forms have been signed. Deidentified data will be provided
      by the original investigators. We aim to disseminate our findings through
      peer-reviewed scientific journals, presentations at (inter)national scientific
      meetings, newsletters, the website of our project and the Dutch academic
      workspace ADHD. PROSPERO REGISTRATION NUMBER: CRD42017069877.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Steenhuis, Laura
AU  - Steenhuis L
AUID- ORCID: 0000-0002-1256-3754
AD  - Department of Child and Adolescent Psychiatry, University of Groningen,
      University Medical Center Groningen, Groningen, the Netherlands.
FAU - Groenman, Annabeth P
AU  - Groenman AP
AUID- ORCID: 0000-0002-8394-6605
AD  - Department of Child and Adolescent Psychiatry, University of Groningen,
      University Medical Center Groningen, Groningen, the Netherlands
      a.groenman@accare.nl.
FAU - Hoekstra, Pieter J
AU  - Hoekstra PJ
AD  - Department of Child and Adolescent Psychiatry, University of Groningen,
      University Medical Center Groningen, Groningen, the Netherlands.
FAU - Hornstra, Rianne
AU  - Hornstra R
AD  - Department of Child and Adolescent Psychiatry, University of Groningen,
      University Medical Center Groningen, Groningen, the Netherlands.
FAU - Luman, Marjolein
AU  - Luman M
AD  - Dept. Clinical Neuropsychology, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
AD  - Bascule, academic centre for child and adolescent psychiatry, Amsterdam, the
      Netherlands.
FAU - van der Oord, Saskia
AU  - van der Oord S
AD  - Clinical Psychology, KU Leuven, Leuven, Flanders, Belgium.
FAU - van den Hoofdakker, Barbara J
AU  - van den Hoofdakker BJ
AD  - Department of Child and Adolescent Psychiatry, University of Groningen,
      University Medical Center Groningen, Groningen, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Attention Deficit Disorder with Hyperactivity/therapy
MH  - Behavior Therapy
MH  - Child
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Parenting
MH  - Parents
PMC - PMC7703408
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *mental health
OT  - *paediatrics
OT  - *psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037749 [pii]
AID - 10.1136/bmjopen-2020-037749 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e037749. doi: 10.1136/bmjopen-2020-037749.


PMID- 33247005
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 27
TI  - Study to evaluate the effectiveness and cost-effectiveness of different screening
      strategies for identifying undiagnosed COPD among residents (>/=40 years) in four
      cities in China: protocol for a multicentre cross-sectional study on behalf of
      the Breathe Well group.
PG  - e035738
LID - 10.1136/bmjopen-2019-035738 [doi]
AB  - INTRODUCTION: The latest chronic obstructive pulmonary disease (COPD)
      epidemiology survey in China estimated that there were 99 million potential COPD 
      patients in the country, the majority of whom are undiagnosed. Screening for COPD
      in primary care settings is of vital importance for China, but it is not known
      which strategy would be the most suitable for adoption in primary care. Studies
      have been conducted to test the accuracy of questionnaires, expiratory peak flow 
      meters and microspirometers to screen for COPD, but no study has directly
      evaluated and compared the effectiveness and cost-effectiveness of these methods 
      in the Chinese setting. METHODS AND ANALYSIS: We present the protocol for a
      multicentre cross-sectional study, to be conducted in eight community hospitals
      from four cities among Chinese adults aged 40 years or older to investigate the
      effectiveness and cost-effectiveness of different case-finding methods for COPD, 
      and determine the test performance of individual and combinations of screening
      tests and strategies in comparison with quality diagnostic spirometry. Index
      tests are screening questionnaires (COPD Diagnostic Questionnaire (CDQ), COPD
      Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and
      Exacerbation Risk Questionnaire (CAPTURE), symptom-based questionnaire, COPD
      Screening Questionnaire (COPD-SQ)), microspirometer and peak flow. Each
      participant will complete all of these tests in one assessment. The primary
      analysis will compare the performance of a screening questionnaire with a
      handheld device. Secondary analyses will include the comparative performance of
      each index test, as well as a comparison of strategies where we use a screening
      questionnaire and a handheld device. Approximately 2000 participants will be
      recruited over 9 to 12 months. ETHICS AND DISSEMINATION: The study has been
      approved by Peking University Hospital and University of Birmingham. All study
      participants will provide written informed consent. Study results will be
      published in appropriate journal and presented at national and international
      conferences, as well as relevant social media and various community/stakeholder
      engagement activities. TRIAL REGISTRATION NUMBER: ISRCTN13357135.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Pan, Zihan
AU  - Pan Z
AUID- ORCID: 0000-0003-4502-1107
AD  - Department of General Practice, Peking University First Hospital, Beijing, China.
AD  - Department of Pulmonary and Critical Care Medicine, Peking University Third
      Hospital, Beijing, China.
FAU - Dickens, Andrew P
AU  - Dickens AP
AUID- ORCID: 0000-0002-7591-8129
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK
      chichunhua2012@qq.com A.P.Dickens@bham.ac.uk.
FAU - Chi, Chunhua
AU  - Chi C
AD  - Department of General Practice, Peking University First Hospital, Beijing, China 
      chichunhua2012@qq.com A.P.Dickens@bham.ac.uk.
FAU - Kong, Xia
AU  - Kong X
AD  - Department of General Practice, Peking University First Hospital, Beijing, China.
FAU - Enocson, Alexandra
AU  - Enocson A
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Adab, Peymane
AU  - Adab P
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Cheng, Kar Keung
AU  - Cheng KK
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
AD  - General Practice Development and Research Centre, Peking University Health
      Science Centre, Beijing, China.
FAU - Sitch, Alice J
AU  - Sitch AJ
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Jowett, Sue
AU  - Jowett S
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Jordan, Rachel
AU  - Jordan R
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
CN  - Breathe Well Group
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201127
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - China/epidemiology
MH  - Cities
MH  - Cost-Benefit Analysis
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis/epidemiology
MH  - Surveys and Questionnaires
PMC - PMC7703419
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *health economics
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035738 [pii]
AID - 10.1136/bmjopen-2019-035738 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 27;10(11):e035738. doi: 10.1136/bmjopen-2019-035738.


PMID- 33246999
OWN - NLM
STAT- Publisher
LR  - 20201128
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 27
TI  - Need for patient-developed concepts of empowerment to rectify epistemic injustice
      and advance person-centred care.
LID - medethics-2020-106558 [pii]
LID - 10.1136/medethics-2020-106558 [doi]
AB  - The dominant discourse in chronic disease management centres on the ideal of
      person-centred healthcare, with an empowered patient taking an active role in
      decision-making with their healthcare provider. Despite these encouraging
      developments toward healthcare democracy, many person-centred conceptions of
      healthcare and programming continue to focus on the healthcare institution's
      perspective and priorities. In these debates, the patient's voice has largely
      been absent. This article takes the example of patient empowerment to show how
      the concept has been influenced by a variety of competing and shifting influences
      that have led to conceptualisations and programming designed for the patient, but
      developed without the patient. The framework of epistemic injustice is proposed
      to unravel the complexity of these omissions. The concept can be defined as a
      wrong done to someone specifically in their capacity as a knower. It occurs when 
      a person is ignored or not believed due to a prejudice of some kind. It has been 
      applied to healthcare in order to better understand barriers for patient
      participation and will be used to better understand the problems with current
      empowerment definitions and implementation strategies. The article will end by
      proposing some methodologies to facilitate patient-developed concepts of
      empowerment.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Bogaert, Brenda
AU  - Bogaert B
AUID- ORCID: http://orcid.org/0000-0001-7557-3709
AD  - Healthcare Values Chair, Institut de Recherches Philosophiques de Lyon, Jean
      Moulin University Lyon 3, Lyon 69007, Auvergne-Rhone-Alpes, France
      brenda.bogaert@univ-lyon3.fr.
AD  - Humanities and Social Sciences Department, Laboratory of Sciences, Societe,
      Historicite, Education et Pratiques (S2HEP), Universite Lyon 1 Faculte de
      Medecine Lyon-Est, Lyon 69008, Auvergne-Rhone-Alpes, France.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - clinical ethics
OT  - decision-making
OT  - health promotion
OT  - paternalism
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2020/11/29 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/06/04 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/11/29 06:00 [medline]
AID - medethics-2020-106558 [pii]
AID - 10.1136/medethics-2020-106558 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 27. pii: medethics-2020-106558. doi:
      10.1136/medethics-2020-106558.


PMID- 33246998
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 27
TI  - Healthcare professionals' responsibility for informing relatives at risk of
      hereditary disease.
LID - medethics-2020-106236 [pii]
LID - 10.1136/medethics-2020-106236 [doi]
AB  - Advances in genetic diagnostics lead to more patients being diagnosed with
      hereditary conditions. These findings are often relevant to patients' relatives. 
      For example, the success of targeted cancer prevention is dependent on effective 
      disclosure to relatives at risk. Without clear information, individuals cannot
      take advantage of predictive testing and preventive measures. Against this
      background, we argue that healthcare professionals have a duty to make actionable
      genetic information available to their patients' at-risk relatives. We do not try
      to settle the difficult question of how this duty should be balanced against
      other duties, such as the duty of confidentiality and a possible duty not to know
      one's genetic predisposition. Instead, we argue for the importance of recognising
      a general responsibility towards at-risk relatives, to be discharged as well as
      possible within the limits set by conflicting duties and practical
      considerations. According to a traditional and still dominant perspective, it is 
      the patient's duty to inform his or her relatives, while healthcare professionals
      are only obliged to support their patients in discharging this duty. We argue
      that this perspective is a mistake and an anomaly. Healthcare professionals do
      not have a duty to ensure that their patients promote the health of third
      parties. It is often effective and desirable to engage patients in disseminating 
      information to their relatives. However, healthcare professionals should not
      thereby deflect their own moral responsibility.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Grill, Kalle
AU  - Grill K
AD  - Radiation Sciences, Umea university, Umea, Sweden kalle.grill@umu.se.
FAU - Rosen, Anna
AU  - Rosen A
AD  - Radiation Sciences, Umea university, Umea, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639958
OTO - NOTNLM
OT  - applied and professional ethics
OT  - genetic information
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2020/11/29 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/03/29 00:00 [received]
PHST- 2020/10/07 00:00 [revised]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/11/29 06:00 [medline]
AID - medethics-2020-106236 [pii]
AID - 10.1136/medethics-2020-106236 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 27. pii: medethics-2020-106236. doi:
      10.1136/medethics-2020-106236.


PMID- 33246997
OWN - NLM
STAT- Publisher
LR  - 20210507
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 27
TI  - Sleep softly: Schubert, ethics and the value of dying well.
LID - medethics-2020-106937 [pii]
LID - 10.1136/medethics-2020-106937 [doi]
AB  - Ethical discussions about medical treatment for seriously ill babies or children 
      often focus on the 'value of life' or on 'quality of life' and what that might
      mean. In this paper, I look at the other side of the coin-on the value of death, 
      and on the quality of dying. In particular, I examine whether there is such a
      thing as a good way to die, for an infant or an adult, and what that means for
      medical care. To do that, I call on philosophy and on personal experience.
      However, I will also make reference to art, poetry and music. That is partly
      because the topic of mortality has long been reflected on by artists as well as
      philosophers and ethicists. It is also because, as we will see, there may be some
      useful parallels to draw.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: http://orcid.org/0000-0003-3958-8633
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
      dominic.wilkinson@philosophy.ox.ac.uk.
AD  - Newborn Care, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
AD  - Murdoch Children's Research Institute, Melbourne, Vic, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8053338
OTO - NOTNLM
OT  - death
OT  - palliative care
OT  - quality/value of life/personhood
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2020/11/29 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/09/22 00:00 [received]
PHST- 2020/10/15 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/11/29 06:00 [medline]
AID - medethics-2020-106937 [pii]
AID - 10.1136/medethics-2020-106937 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 27. pii: medethics-2020-106937. doi:
      10.1136/medethics-2020-106937.


PMID- 33246996
OWN - NLM
STAT- Publisher
LR  - 20201128
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 27
TI  - Reconsidering scarce drug rationing: implications for clinical research.
LID - medethics-2020-106739 [pii]
LID - 10.1136/medethics-2020-106739 [doi]
AB  - Hospital systems commonly face the challenge of determining just ways to allocate
      scarce drugs during national shortages. There is no standardised approach of how 
      this should be instituted, but principles of distributive justice are commonly
      used so that patients who are most likely to benefit from the drug receive it. As
      a result, clinical indications, in which the evidence for the drug is assumed to 
      be established, are often prioritised over research use. In this manuscript, we
      present a case of a phase II investigational trial of intravenous thiamine for
      delirium prevention in patients undergoing haematopoietic stem cell
      transplantation to emphasise several shortcomings in the overarching
      prioritisation of clinical over research uses of scarce drugs. Specifically, we
      present the following considerations: (1) clinical use may not have stronger
      evidence than research use; (2) a strong scientific rationale for research use
      may outweigh the claim for clinical indications in which there is weak evidence; 
      (3) treatment within the context of a clinical trial may be the standard of care;
      and (4) research use may not only benefit patients receiving the treatment but
      also offers the prospect of improving future clinical care. In summary, we argue 
      against allocation schemes that prohibit all research uses of scarce drugs and
      instead recommend that allocation schemes include a balanced approach that weighs
      risks and benefits of access to scarce drugs irrespective of the research versus 
      clinical use designation.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Nakamura, Zev M
AU  - Nakamura ZM
AD  - Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA zev_nakamura@med.unc.edu.
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, North Carolina, USA.
FAU - MacKay, Douglas P
AU  - MacKay DP
AD  - Public Policy, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA.
AD  - Center of Bioethics, University of North Carolina at Chapel Hill, Chapel Hill,
      North Carolina, USA.
FAU - Davis, Arlene M
AU  - Davis AM
AD  - Center of Bioethics, University of North Carolina at Chapel Hill, Chapel Hill,
      North Carolina, USA.
AD  - Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North 
      Carolina, USA.
FAU - Brassfield, Elizabeth R
AU  - Brassfield ER
AD  - Philosophy, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA.
AD  - University of North Carolina at Chapel Hill School of Medicine, Chapel Hill,
      North Carolina, USA.
FAU - Joyner, Benny L Jr
AU  - Joyner BL Jr
AD  - Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North 
      Carolina, USA.
AD  - Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA.
AD  - Anesthesiology, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA.
FAU - Rosenstein, Donald L
AU  - Rosenstein DL
AD  - Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA.
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel
      Hill, Chapel Hill, North Carolina, USA.
AD  - Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North
      Carolina, USA.
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical trials
OT  - distributive Justice
OT  - ethics
OT  - ethics committees/consultation
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/29 06:00
MHDA- 2020/11/29 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/07/24 00:00 [received]
PHST- 2020/10/15 00:00 [revised]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/28 05:30 [entrez]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/11/29 06:00 [medline]
AID - medethics-2020-106739 [pii]
AID - 10.1136/medethics-2020-106739 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 27. pii: medethics-2020-106739. doi:
      10.1136/medethics-2020-106739.


PMID- 33246909
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 82
IP  - Pt B
DP  - 2020 Dec
TI  - Revascularisation surgery for paediatric moyamoya disease: The Singapore
      experience.
PG  - 207-213
LID - S0967-5868(20)31624-6 [pii]
LID - 10.1016/j.jocn.2020.11.008 [doi]
AB  - Moyamoya disease (MMD) is characterized by the spontaneous occlusion of the
      distal internal carotid arteries and resultant neo-angiogenesis of fragile
      collateral blood vessels. Direct and indirect revascularization surgeries have
      shown to effectively reduce stroke risks in paediatric MMD, whereby the latter is
      a more utilised technique in children. This study was undertaken to determine the
      outcomes of revascularization in Singapore's multi-ethnic, Southeast Asian
      paediatric population. This is an ethics-approved study conducted in Singapore's 
      2 tertiary children hospital units: KK Women's and Children's Hospital and
      National University Hospital. Sixteen patients with a diagnosis of ischaemic-type
      MMD are recruited between 01 January 2002 to 31 January 2019; and a total of 24
      surgeries are undertaken (24 cerebral hemispheres). There are 2 cases of stroke
      within 30 days post-surgery. However, no stroke recurrence is observed beyond 30 
      days after surgery in all patients. Four patients reported recurrent transient
      ischaemic attack symptoms in the follow-up period ranging from 3 months to 12
      years. Data analyses show a statistically significant improvement in modified
      Rankin's Scale (mMRS) in post-operative patients from baseline to discharge, and 
      at 3 months after surgery. Our study also observes that predictors of recurrent
      ischaemic events include higher pre-operative MRS, Suzuki stage and perioperative
      infarction. To the authors' knowledge, this is the first study to date reporting 
      the outcomes of revascularisation in a paediatric Southeast Asian cohort.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Ong, Jamie Ah
AU  - Ong JA
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road Level 11, 119228, Singapore.
FAU - Low, Sharon Yy
AU  - Low SY
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      229899, Singapore; Department of Neurosurgery, National Neuroscience Institute,
      Singapore; SingHealth Duke-NUS Neuroscience Academic Clinical Program, Singapore,
      11 Jalan Tan Tock Seng, 308433, Singapore. Electronic address:
      sharon.low.y.y@singhealth.com.sg.
FAU - Seow, Wan Tew
AU  - Seow WT
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      229899, Singapore; Department of Neurosurgery, National Neuroscience Institute,
      Singapore; SingHealth Duke-NUS Neuroscience Academic Clinical Program, Singapore,
      11 Jalan Tan Tock Seng, 308433, Singapore.
FAU - Goh, Chun Peng
AU  - Goh CP
AD  - Division of Neurosurgery, Department of Surgery, National University Hospital, 5 
      Lower Kent Ridge Rd, 119074, Singapore.
FAU - Yeo, Tseng Tsai
AU  - Yeo TT
AD  - Division of Neurosurgery, Department of Surgery, National University Hospital, 5 
      Lower Kent Ridge Rd, 119074, Singapore.
FAU - Chou, Ning
AU  - Chou N
AD  - Division of Neurosurgery, Department of Surgery, National University Hospital, 5 
      Lower Kent Ridge Rd, 119074, Singapore.
FAU - Low, David Cy
AU  - Low DC
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      229899, Singapore; Department of Neurosurgery, National Neuroscience Institute,
      Singapore; SingHealth Duke-NUS Neuroscience Academic Clinical Program, Singapore,
      11 Jalan Tan Tock Seng, 308433, Singapore.
FAU - Nga, Vincent
AU  - Nga V
AD  - Division of Neurosurgery, Department of Surgery, National University Hospital, 5 
      Lower Kent Ridge Rd, 119074, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
SB  - IM
MH  - Adult
MH  - Cerebral Infarction
MH  - *Cerebral Revascularization
MH  - Child
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Ischemic Attack, Transient
MH  - Male
MH  - Moyamoya Disease/*surgery
MH  - Singapore
MH  - Stroke/epidemiology
MH  - Treatment Outcome
MH  - *Vascular Surgical Procedures
MH  - Young Adult
OTO - NOTNLM
OT  - Paediatric moyamoya disease
OT  - Revascularisation
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/11/29 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/11/28 05:30
PHST- 2020/05/08 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/11/28 05:30 [entrez]
AID - S0967-5868(20)31624-6 [pii]
AID - 10.1016/j.jocn.2020.11.008 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Dec;82(Pt B):207-213. doi: 10.1016/j.jocn.2020.11.008. Epub
      2020 Nov 25.


PMID- 33246221
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 73
DP  - 2020 Nov - Dec
TI  - Experiences of involuntary psychiatric admission decision-making: a systematic
      review and meta-synthesis of the perspectives of service users, informal carers, 
      and professionals.
PG  - 101645
LID - S0160-2527(20)30104-7 [pii]
LID - 10.1016/j.ijlp.2020.101645 [doi]
AB  - BACKGROUND: In involuntary psychiatric admission, used globally, professionals or
      caretakers decide upon hospitalization regardless of what the person with
      psychosocial disabilities decides. This raises clinical, ethical, legal, and
      human rights concerns, and it goes against Convention on the Rights of Persons
      with Disabilities (CRPD). CRPD mandates that member states respect the autonomy
      of people with disabilities. Through Article 12, it recognizes full enjoyment of 
      legal capacity for persons with disabilities. Implementation of Article 12 is
      challenging in every country, and exploring all the stakeholders' experiences at 
      admission decision-making will help us to understand the challenges that the
      current psychiatry system poses for service users to exercise their autonomy and 
      identify the areas where service users need support to have their rights, will,
      and preferences respected. AIM: To describe the experiences of service users,
      informal carers, and professionals in involuntary psychiatric admission
      decision-making and throughout the subsequent involuntary admission. We explored 
      the support that the service users need to have their rights, will, and
      preferences respected. METHOD: A search of twelve databases in medicine,
      sociology, and law in Danish, English, Japanese, Norwegian, Portuguese, Spanish, 
      and Swedish was conducted in 2017 and 2018, limited to the past 10 years, using
      terms such as "involuntary," "admission," "mental illness," and "experience". The
      search identified 682 articles. Four researchers independently reviewed the
      articles to find those that completed original qualitative or mixed method
      studies exploring experiences of involuntary psychiatric admission among adults. 
      We added seven publications from the articles' references, contacted experts in
      the field (no publications were added), and excluded two articles that were in
      German. Three researchers analyzed the articles' results using Thematic Analysis 
      (PROSPERO registration number CRD42019072874). RESULTS: Overall, 37 articles were
      included from 11 countries; they involved 731 service users, 100 informal carers,
      and 291 mental health professionals. We identified a lack of communication and a 
      power imbalance among the stakeholders, which was exacerbated by the
      professionals' attitudes. At admission decision-making, the service users wanted 
      to be heard and wanted to understand the situation. The families felt
      responsibility for the service users, they were careful not to ruin
      relationships, and they struggled to obtain support from the mental health
      system. Professionals believed that threats or harming others should lead to
      admission regardless of what the service users or their families felt.
      Professionals sometimes felt that it was not necessary to explain the information
      to the service users because they would not understand. Professionals were
      concerned and frustrated with difficulties in coordinating among themselves.
      During admission, service users struggled with the ward environment and
      relationship with staff; they most objected to coercion, such as forced
      medication. Families were frustrated that they were not involved in the treatment
      planning, especially as the service users moved toward discharge. The
      professionals often rationalized that coercion was necessary, and they believed
      that they knew what was best for the service users. CONCLUSIONS: A lack of
      communication and a power imbalance among the stakeholders hindered respect for
      the service users' rights, will, and preferences. This was exacerbated by
      professionals rationalizing coercion and assuming that service users were
      incapable of understanding information. Services that encourage communication and
      overcome power imbalances (e.g. Crisis Plans, Family Group Conferencing) combined
      with stronger community mental health support will respect service users' rights,
      will, and preferences and avoid substituted decision-making on issues such as
      involuntary admission and forced medication.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Sugiura, Kanna
AU  - Sugiura K
AD  - Department of Mental Health, The University of Tokyo, Tokyo, Japan. Electronic
      address: kannasugiura@googlemail.com.
FAU - Pertega, Elvira
AU  - Pertega E
AD  - Faculty of Law, University of Technology Sydney, Sydney, Australia.
FAU - Holmberg, Christopher
AU  - Holmberg C
AD  - Department of Psychotic Disorders, Sahlgrenska University Hospital, Gothenburg,
      Sweden; Institute of Health and Care Science, University of Gothenburg,
      Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201124
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Caregivers/*psychology
MH  - Coercion
MH  - Communication
MH  - *Decision Making
MH  - Disabled Persons/legislation & jurisprudence/psychology
MH  - Humans
MH  - *Involuntary Treatment, Psychiatric
MH  - Mentally Ill Persons/*psychology
MH  - Patient Preference/psychology
MH  - Patient Rights/legislation & jurisprudence
OTO - NOTNLM
OT  - *CRPD
OT  - *Informal carers
OT  - *Involuntary admission
OT  - *Professionals
OT  - *Service users
OT  - *Supported decision-making
EDAT- 2020/11/28 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/11/27 20:11
PHST- 2020/08/11 00:00 [received]
PHST- 2020/10/26 00:00 [revised]
PHST- 2020/10/31 00:00 [accepted]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2020/11/27 20:11 [entrez]
AID - S0160-2527(20)30104-7 [pii]
AID - 10.1016/j.ijlp.2020.101645 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Nov - Dec;73:101645. doi: 10.1016/j.ijlp.2020.101645. 
      Epub 2020 Nov 24.


PMID- 33245782
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Nov 16
TI  - Going first: the ethics of vaccine self-experimentation in coronavirus times.
PG  - w20415
LID - 10.4414/smw.2020.20415 [doi]
LID - Swiss Med Wkly. 2020;150:w20415 [pii]
FAU - Manriquez Roa, Tania
AU  - Manriquez Roa T
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich.
FAU - Biller-Andorno, Nikola
AU  - Biller-Andorno N
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20201126
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
RN  - 0 (Vaccines)
SB  - IM
CON - Rejuvenation Res. 2019 Feb;22(1):31-42. PMID: 29926769
MH  - Autoexperimentation
MH  - *Coronavirus
MH  - Ethics Committees
MH  - Humans
MH  - *Vaccines
EDAT- 2020/11/28 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/27 17:05
PHST- 2020/11/27 17:05 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.4414/smw.2020.20415 [doi]
AID - Swiss Med Wkly. 2020;150:w20415 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Nov 26;150:w20415. doi: 10.4414/smw.2020.20415. eCollection 
      2020 Nov 16.


PMID- 33245645
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 0869-2084 (Print)
IS  - 0869-2084 (Linking)
VI  - 65
IP  - 9
DP  - 2020 Sep 16
TI  - Conceptual principles and patterns of legal regulation of the processes of
      storage, access and data protection of genome sequencing in foreign countries as 
      the basis for the modernization of Russian legislation.
PG  - 580-586
LID - 10.18821/0869-2084-2020-65-9-580-586 [doi]
AB  - The relevance of the study of the general principles and patterns of legal
      regulation of access storage processes and data protection of genome sequencing
      in foreign countries is determined by the need to develop a general concept of
      legal regulation of this type of activity in Russia. The purpose of this study is
      to develop the system-forming principles and patterns of access storage and data 
      protection of genome sequencing in Russia. To achieve this goal, tasks were set
      and solved to identify and study the general principles and patterns of legal
      regulation of access storage processes and data protection of genome sequencing
      in foreign countries. The international documents regulating the features of
      regulation of access storage processes and data protection of genome-wide
      sequencing, the doctrinal sources of Great Britain, the USA, France, Israel, and 
      Japan are studied. Methods used: general philosophical, general scientific,
      private scientific, special (structural-legal, comparative-legal, formal-legal). 
      The general principles for the formation of the concept of legal regulation of
      genome sequencing in Russia are proposed. It was revealed that the creation of a 
      universal regulatory regulator aimed at protecting the subject of personal data
      in view of the prevalence of public interests over private ones and the constant 
      expansion of the scope of application of genetic data obtained as a result of
      genome-wide sequencing is the main problem in developing a legal regulation
      mechanism in the studied area. For the first time, the authors determine the
      basic principles for developing the concept of genome-wide sequencing in Russia, 
      including: recognition of human rights and human dignity as the highest value,
      the necessity of researchers' responsibility for the well-being of participants
      in view of the obtained research results, the mandatory informed consent of which
      should be voluntary, permanent, their right to get acquainted with the results
      obtained if it concerns their health, access to such information, ensuring the
      right to non-knowledge of research results and others.
FAU - Suranova, T G
AU  - Suranova TG
AUID- ORCID: 0000-0003-0768-8365
AD  - Federal Research and Clinical Center of the Federal Medical-Biological Agency.
FAU - Suvorov, G N
AU  - Suvorov GN
AUID- ORCID: 0000-0001-8452-5522
AD  - Federal Research and Clinical Center of the Federal Medical-Biological Agency.
FAU - Zenin, S S
AU  - Zenin SS
AUID- ORCID: 0000-0002-4520-757X
AD  - Kutafin Moscow State Law University (MSAL).
LA  - eng
PT  - Journal Article
TT  - capital KA, Cyrillicsmall o, Cyrillicsmall en, Cyrillicsmall tse, Cyrillicsmall
      ie, Cyrillicsmall pe, Cyrillicsmall te, Cyrillicsmall u, Cyrillicsmall a,
      Cyrillicsmall el, Cyrillicsmall soft sign, Cyrillicsmall en, Cyrillicsmall yeru, 
      Cyrillicsmall ie, Cyrillic small pe, Cyrillicsmall er, Cyrillicsmall i,
      Cyrillicsmall en, Cyrillicsmall tse, Cyrillicsmall i, Cyrillicsmall pe,
      Cyrillicsmall yeru, Cyrillic small i, Cyrillic small ze, Cyrillicsmall a,
      Cyrillicsmall ka, Cyrillicsmall o, Cyrillicsmall en, Cyrillicsmall o,
      Cyrillicsmall em, Cyrillicsmall ie, Cyrillicsmall er, Cyrillicsmall en,
      Cyrillicsmall o, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall i, Cyrillic
      small pe, Cyrillicsmall er, Cyrillicsmall a, Cyrillicsmall ve, Cyrillicsmall o,
      Cyrillicsmall ve, Cyrillicsmall o, Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic
      small er, Cyrillicsmall ie, Cyrillicsmall ghe, Cyrillicsmall u, Cyrillicsmall el,
      Cyrillicsmall i, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ve,
      Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic
      small pe, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall tse, Cyrillicsmall ie,
      Cyrillicsmall es, Cyrillicsmall es, Cyrillicsmall o, Cyrillicsmall ve, Cyrillic
      small ha, Cyrillicsmall er, Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall ie, 
      Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic, small de,
      Cyrillicsmall o, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall u,
      Cyrillicsmall pe, Cyrillicsmall a, Cyrillic small i, Cyrillic small ze,
      Cyrillicsmall a, Cyrillicsmall shcha, Cyrillicsmall i, Cyrillicsmall te,
      Cyrillicsmall yeru, Cyrillic small de, Cyrillicsmall a, Cyrillicsmall en,
      Cyrillicsmall en, Cyrillicsmall yeru, Cyrillicsmall ha, Cyrillic small pe,
      Cyrillicsmall o, Cyrillicsmall el, Cyrillicsmall en, Cyrillicsmall o,
      Cyrillicsmall ghe, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall o,
      Cyrillicsmall em, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall ghe,
      Cyrillicsmall o, Cyrillic small es, Cyrillicsmall ie, Cyrillicsmall ka,
      Cyrillicsmall ve, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i,
      Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall a,
      Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic small ve, Cyrillic 
      small ze, Cyrillicsmall a, Cyrillicsmall er, Cyrillicsmall u, Cyrillicsmall be,
      Cyrillicsmall ie, Cyrillicsmall zhe, Cyrillicsmall en, Cyrillicsmall yeru,
      Cyrillicsmall ha, Cyrillic small es, Cyrillicsmall te, Cyrillicsmall er,
      Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall a, Cyrillicsmall ha, Cyrillic
      small ka, Cyrillicsmall a, Cyrillicsmall ka, Cyrillic small o, Cyrillicsmall es, 
      Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall a, Cyrillic
      small de, Cyrillicsmall el, Cyrillicsmall ya, Cyrillic small em, Cyrillicsmall o,
      Cyrillicsmall de, Cyrillicsmall ie, Cyrillicsmall er, Cyrillicsmall en,
      Cyrillicsmall i, Cyrillicsmall ze, Cyrillicsmall a, Cyrillicsmall tse,
      Cyrillicsmall i, Cyrillicsmall i, Cyrillic small er, Cyrillicsmall o,
      Cyrillicsmall es, Cyrillicsmall es, Cyrillicsmall i, Cyrillicsmall short i,
      Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall o, Cyrillicsmall ghe,
      Cyrillicsmall o, Cyrillic small ze, Cyrillicsmall a, Cyrillicsmall ka,
      Cyrillicsmall o, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall de,
      Cyrillicsmall a, Cyrillicsmall te, Cyrillicsmall ie, Cyrillicsmall el,
      Cyrillicsmall soft sign, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall ve,
      Cyrillicsmall a, Cyrillic.
PL  - Russia (Federation)
TA  - Klin Lab Diagn
JT  - Klinicheskaia laboratornaia diagnostika
JID - 9432021
SB  - IM
MH  - *Computer Security
MH  - *Human Rights
MH  - Humans
MH  - Internationality
MH  - Japan
MH  - Russia
OTO - NOTNLM
OT  - concept
OT  - ethical and legal problems
OT  - human rights
OT  - storage access and data protection of genome-wide sequencing
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/28 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/11/27 12:10
PHST- 2020/11/27 12:10 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.18821/0869-2084-2020-65-9-580-586 [doi]
PST - ppublish
SO  - Klin Lab Diagn. 2020 Sep 16;65(9):580-586. doi:
      10.18821/0869-2084-2020-65-9-580-586.


PMID- 33245347
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - Suppl 9
DP  - 2020 Nov 27
TI  - Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't
      Do?
PG  - S794-S801
LID - 10.1093/infdis/jiaa420 [doi]
AB  - The opioid epidemic has resulted in an increase in organ donors with hepatitis C 
      virus (HCV) infection in the United States. With the development of direct-acting
      antiviral regimens that offer high sustained virologic response rates even in the
      setting of immunosuppression after transplantation, these HCV-viremic organs are 
      now being offered to transplant candidates with or without preexisting HCV
      infection. Strategies for HCV treatment with HCV-viremic organs have included
      delayed and preemptive approaches. This review will discuss key studies in the
      different solid organ transplants, recent reports of adverse events, and ethical 
      and regulatory considerations. The efficacy of current HCV therapies has created 
      this important opportunity to improve survival for patients with end-organ
      failure through greater access to organ transplantation and decreased waitlist
      mortality rate.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Kappus, Matthew R
AU  - Kappus MR
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of
      Medicine, Durham, North Carolina, USA.
AD  - Division of Infectious Diseases, Department of Medicine, Duke University School
      of Medicine, Durham, North Carolina, USA.
FAU - Wolfe, Cameron R
AU  - Wolfe CR
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of
      Medicine, Durham, North Carolina, USA.
AD  - Division of Infectious Diseases, Department of Medicine, Duke University School
      of Medicine, Durham, North Carolina, USA.
FAU - Muir, Andrew J
AU  - Muir AJ
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of
      Medicine, Durham, North Carolina, USA.
AD  - Division of Infectious Diseases, Department of Medicine, Duke University School
      of Medicine, Durham, North Carolina, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Donor Selection
MH  - Hepatitis C/complications/*drug therapy
MH  - Humans
MH  - Immunocompromised Host
MH  - Organ Transplantation/*adverse effects
MH  - Tissue Donors/*statistics & numerical data
MH  - United States
OTO - NOTNLM
OT  - *antiviral agents
OT  - *donor selection
OT  - *hepatitis C
OT  - *organ transplantation
EDAT- 2020/11/28 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/11/27 12:07
PHST- 2020/11/27 12:07 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - 6007496 [pii]
AID - 10.1093/infdis/jiaa420 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Nov 27;222(Suppl 9):S794-S801. doi: 10.1093/infdis/jiaa420.


PMID- 33244420
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2059-8661 (Electronic)
IS  - 2059-8661 (Linking)
VI  - 4
IP  - 4
DP  - 2020 Jan 10
TI  - How are US institutions implementing the new key information requirement?
PG  - 365-369
LID - 10.1017/cts.2020.1 [doi]
AB  - Recent revisions to the Federal Policy for the Protections of Human Subjects
      require that informed consent documents begin with a "concise and focused
      presentation" of the key information a participant requires. Key information
      "must be organized and presented in a way that facilitates comprehension." The
      regulations do not specify what information be included, nor how it must be
      presented to facilitate comprehension. It is unknown how institutions and
      Institutional Review Boards (IRBs) are interpreting the current regulations. We
      conducted a review of randomly sampled available key information templates at 46 
      US medical institutions to determine how they are implementing the new
      regulations.
CI  - (c) The Association for Clinical and Translational Science 2020.
FAU - Mozersky, Jessica
AU  - Mozersky J
AUID- ORCID: https://orcid.org/0000-0002-4942-4571
AD  - Bioethics Research Center, Washington University School of Medicine, Box 8005,
      St. Louis, MO, USA.
FAU - Wroblewski, Matthew P
AU  - Wroblewski MP
AD  - Bioethics Research Center, Washington University School of Medicine, Box 8005,
      St. Louis, MO, USA.
FAU - Solomon, Erin D
AU  - Solomon ED
AD  - Bioethics Research Center, Washington University School of Medicine, Box 8005,
      St. Louis, MO, USA.
FAU - DuBois, James M
AU  - DuBois JM
AD  - Bioethics Research Center, Washington University School of Medicine, Box 8005,
      St. Louis, MO, USA.
LA  - eng
GR  - R01 AG058254/AG/NIA NIH HHS/United States
GR  - UL1 TR002345/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200110
PL  - England
TA  - J Clin Transl Sci
JT  - Journal of clinical and translational science
JID - 101689953
PMC - PMC7681124
OTO - NOTNLM
OT  - Revised Common Rule
OT  - implementation
OT  - informed consent
OT  - key information
OT  - regulatory guidance
OT  - research ethics
OT  - review
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/11/28 06:00
MHDA- 2020/11/28 06:01
CRDT- 2020/11/27 05:45
PHST- 2020/11/27 05:45 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2020/11/28 06:01 [medline]
AID - 10.1017/cts.2020.1 [doi]
AID - S2059866120000011 [pii]
PST - epublish
SO  - J Clin Transl Sci. 2020 Jan 10;4(4):365-369. doi: 10.1017/cts.2020.1.


PMID- 33244336
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20220418
IS  - 1937-8688 (Electronic)
VI  - 37
DP  - 2020
TI  - Health providers knowledge on maternal and newborn care: implications on health
      systems strengthening in Vihiga County, Kenya.
PG  - 73
LID - 10.11604/pamj.2020.37.73.24597 [doi]
AB  - INTRODUCTION: pregnant women need access to skilled attendance at birth and
      emergency obstetric care (EmOC) to avert maternal deaths. While poor EmOC
      services may explain the high maternal mortality, inadequate knowledge of
      providers is also part of the problem. This forms the basis of this paper, in a
      setting where 50.2% of women deliver in a health facility but maternal mortality 
      remains high at 531/100,000 live births, compared to the national average of
      362/100,000 in Kenya. METHODS: a facility based cross-sectional survey was
      conducted in 2018 with a set of knowledge questions extracted from the averting
      maternal death and disability toolkit. Providers knowledge for maternal and
      newborn health (MNH) was assessed by interviewing nurses on duty in the maternity
      units. Data were entered in Ms Access and exported to R version 3.6.2 for
      descriptive and logistic regression analysis. Ethical clearance was obtained from
      Kenya Medical Research Unit. RESULTS: a total of 55 nurses were interviewed.
      Majority (71%) of the respondents were diploma nurses. The overall knowledge
      score for MNH among the providers was adequate with a score of (64%). Generally, 
      the midwives and higher diploma nurses consistently scored higher than diploma
      nurses in all the topic areas of MNH. In the mixed linear regression,
      determinants of knowledge score were seen in provider-level variables.
      CONCLUSION: overall, the providers scores were higher on intrapartum and newborn 
      care compared to scores on care for complications. We conclude that in-service
      training on EmOC to providers is critical to reduction of maternal mortality.
CI  - Copyright: Imelda Namayi et al.
FAU - Namayi, Imelda
AU  - Namayi I
AD  - School of Public Health, Jomo Kenyatta University of Agriculture and Technology
      (JKUAT), Nairobi, Kenya.
FAU - Makokha, Anselimo
AU  - Makokha A
AD  - Department of Food Science, Jomo Kenyatta University of Agriculture and
      Technology (JKUAT), Nairobi, Kenya.
FAU - Echoka, Elizabeth
AU  - Echoka E
AD  - Centre of Public Health Research (CPHR), Kenya Medical Research Institute
      (KEMRI), Nairobi, Kenya.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adult
MH  - Child Health Services/*standards
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*statistics & numerical data
MH  - Humans
MH  - Infant Health
MH  - Infant, Newborn
MH  - Kenya
MH  - Maternal Death/prevention & control
MH  - Maternal Health
MH  - Maternal Health Services/*standards
MH  - Maternal Mortality
MH  - Middle Aged
MH  - Midwifery/statistics & numerical data
MH  - Pregnancy
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7680226
OTO - NOTNLM
OT  - Kenya
OT  - Maternal
OT  - health
OT  - health provider
OT  - intrapartum
OT  - knowledge
OT  - newborn
COIS- The authors declare no competing interests.
EDAT- 2020/11/28 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/11/27 05:45
PHST- 2020/06/26 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/11/27 05:45 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.11604/pamj.2020.37.73.24597 [doi]
AID - PAMJ-37-73 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Sep 18;37:73. doi: 10.11604/pamj.2020.37.73.24597.
      eCollection 2020.


PMID- 33243821
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Standardised protocol for a prospective cross-sectional multicentre clinic-based 
      evaluation of two dual point-of-care tests for the screening of HIV and syphilis 
      in men who have sex with men, sex workers and pregnant women.
PG  - e044479
LID - 10.1136/bmjopen-2020-044479 [doi]
AB  - INTRODUCTION: Dual point-of-care tests (POCTs) for detecting antibodies to HIV
      and syphilis have been developed for use with venous whole blood, serum/plasma or
      finger-prick capillary whole blood. Several tests are commercially available
      showing encouraging performance compared with 'gold-standard' reference tests in 
      laboratory-based studies. However, data on their performance in the field are
      limited. This prospective cross-sectional study will conduct a clinic-based
      evaluation to assess the performance characteristics and acceptability to
      end-users of two dual HIV/syphilis POCTs for the screening of HIV and syphilis
      among men who have sex with men (MSM), sex workers (SWs) and pregnant women (PW).
      This master protocol outlines the overall research approach that will be used in 
      seven countries. METHOD AND ANALYSIS: MSM, SWs and PW presenting at clinic
      evaluation sites in high, low and middle-income countries will be enrolled. The
      (WHO preapproved) POCTs to be evaluated are SD Bioline HIV/Syphilis Duo (Abbott) 
      and Dual Path Platform HIV-Syphilis Assay (Chembio). Finger-prick blood will be
      collected to perform POCTs and compared with laboratory results (venepuncture
      blood). Procedures will be carried out by trained healthcare staff and tests
      performed according to the manufacturers' directions. Sample size was calculated 
      based on local prevalence of HIV and syphilis. The sensitivity, specificity,
      positive and negative predictive values for each POCT will be calculated. The
      study is ongoing with recruitment expected to be completed in all countries by
      mid to late 2021. ETHICS AND DISSEMINATION: This core protocol was independently 
      peer reviewed and approved by the Research Project Review Panel (RP2) of the WHO 
      Department of Sexual and Reproductive Health and Research and by the WHO Ethics
      Review Committee (ERC). The protocol has been adapted to individual countries and
      approved by RP2, ERC and institutional review boards at each site. Results will
      be disseminated through peer-reviewed journals and relevant conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
CN  - ProSPeRo Network
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Female
MH  - *HIV Infections/diagnosis/epidemiology
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Point-of-Care Testing
MH  - Pregnancy
MH  - Pregnant Women
MH  - Prospective Studies
MH  - *Sex Workers
MH  - *Sexual and Gender Minorities
MH  - *Syphilis/diagnosis/epidemiology
PMC - PMC7692839
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: The POCT manufacturers disclose and furnish free of charge
      to WHO the information and sufficient quantities of the product(s) in order to
      enable this evaluation as part of the WHO/RHR STI POC initiative. WHO is entitled
      to evaluate and publish the trial results, and to exclusively control this
      evaluation and the content of the aforesaid publication. WHO shall submit any
      proposed publication to the manufacturers for review, comments received will be
      considered in good faith, but the decision to publish rests with WHO.
IR  - Cordioli M
FIR - Cordioli, Maddalena
IR  - Gios L
FIR - Gios, Lorenzo
IR  - Mirandola M
FIR - Mirandola, Massimo
IR  - Zorzi A
FIR - Zorzi, Antonella
IR  - Barbara C
FIR - Barbara, Christopher
IR  - Padovese V
FIR - Padovese, Valeska
IR  - Hancali A
FIR - Hancali, Amina
IR  - Oumzi H
FIR - Oumzi, Hicham
IR  - Caceres C
FIR - Caceres, Carlos
IR  - Vargas S
FIR - Vargas, Silver
IR  - Kularatne R
FIR - Kularatne, Ranmini
IR  - Mwima S
FIR - Mwima, Simon
IR  - Kyambadde P
FIR - Kyambadde, Peter
IR  - Huber J
FIR - Huber, Jorg
IR  - Peeling R
FIR - Peeling, Rosanna
IR  - Sawyer A
FIR - Sawyer, Alexandra
IR  - Sherriff N
FIR - Sherriff, Nigel
IR  - Vera J
FIR - Vera, Jaime
IR  - Ballard R
FIR - Ballard, Ronald
IR  - Blondeel K
FIR - Blondeel, Karel
IR  - Kiarie J
FIR - Kiarie, James
IR  - Thwin SS
FIR - Thwin, Soe Soe
IR  - Toskin I
FIR - Toskin, Igor
EDAT- 2020/11/28 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - bmjopen-2020-044479 [pii]
AID - 10.1136/bmjopen-2020-044479 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e044479. doi: 10.1136/bmjopen-2020-044479.


PMID- 33243817
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20220405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study
      using linked Scottish national data.
PG  - e042813
LID - 10.1136/bmjopen-2020-042813 [doi]
AB  - INTRODUCTION: The effects of SARS-CoV-2 in pregnancy are not fully delineated. We
      will describe the incidence of COVID-19 in pregnancy at population level in
      Scotland, in a prospective cohort study using linked data. We will determine
      associations between COVID-19 and adverse pregnancy, neonatal and maternal
      outcomes and the proportion of confirmed cases of SARS-CoV-2 infection in
      neonates associated with maternal COVID-19. METHODS AND ANALYSIS: Prospective
      cohort study using national linked data sets. We will include all women in
      Scotland, UK, who were pregnant on or became pregnant after, 1 March 2020 (the
      date of the first confirmed case of SARS-CoV-2 infection in Scotland) and all
      births in Scotland from 1 March 2020 onwards. Individual-level data will be
      extracted from data sets containing details of all livebirths, stillbirth,
      terminations of pregnancy and miscarriages and ectopic pregnancies treated in
      hospital or attending general practice. Records will be linked within the Early
      Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform,
      which includes primary care records, virology and serology results and details of
      COVID-19 Community Hubs and Assessment Centre contacts and deaths. We will
      perform analyses using definitions for confirmed, probable and possible COVID-19 
      and report serology results (where available). Outcomes will include congenital
      anomaly, miscarriage, stillbirth, termination of pregnancy, preterm birth,
      neonatal infection, severe maternal disease and maternal deaths. We will perform 
      descriptive analyses and appropriate modelling, adjusting for demographic and
      pregnancy characteristics and the presence of comorbidities. The cohort will
      provide a platform for future studies of the effectiveness and safety of
      therapeutic interventions and immunisations for COVID-19 and their effects on
      childhood and developmental outcomes. ETHICS AND DISSEMINATION: COVID-19 in
      Pregnancy in Scotland is a substudy of EAVE II(, which has approval from the
      National Research Ethics Service Committee. Findings will be reported to Scottish
      Government, Public Health Scotland and published in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Stock, Sarah Jane
AU  - Stock SJ
AUID- ORCID: 0000-0003-4308-856X
AD  - Tommy's Centre for Maternal and Fetal Health, The University of Edinburgh MRC
      Centre for Reproductive Health, Edinburgh, UK sarah.stock@ed.ac.uk.
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - McAllister, David
AU  - McAllister D
AUID- ORCID: 0000-0003-3550-1764
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
AD  - Public Health Scotland, Glasgow, UK.
FAU - Vasileiou, Eleftheria
AU  - Vasileiou E
AUID- ORCID: 0000-0001-6850-7578
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Simpson, Colin R
AU  - Simpson CR
AUID- ORCID: 0000-0002-5194-8083
AD  - School of Health, Victoria University of Wellington, Wellington, New Zealand.
FAU - Stagg, Helen R
AU  - Stagg HR
AUID- ORCID: 0000-0003-4022-3447
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Agrawal, Utkarsh
AU  - Agrawal U
AUID- ORCID: 0000-0001-5181-6120
AD  - School of Medicine, University of St Andrews, St Andrews, Fife, UK.
FAU - McCowan, Colin
AU  - McCowan C
AUID- ORCID: 0000-0002-9466-833X
AD  - School of Medicine, University of St Andrews, St Andrews, Fife, UK.
FAU - Hopkins, Leanne
AU  - Hopkins L
AUID- ORCID: 0000-0002-7487-4363
AD  - Public Health Scotland, Edinburgh, UK.
FAU - Donaghy, Jack
AU  - Donaghy J
AUID- ORCID: 0000-0002-6137-1601
AD  - Public Health Scotland, Edinburgh, UK.
FAU - Ritchie, Lewis
AU  - Ritchie L
AUID- ORCID: 0000-0002-9380-7641
AD  - General Practice and Primary Care, Aberdeen University, Aberdeen, UK.
FAU - Robertson, Chris
AU  - Robertson C
AUID- ORCID: 0000-0001-6848-5241
AD  - Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
FAU - Sheikh, Aziz
AU  - Sheikh A
AUID- ORCID: 0000-0001-7022-3056
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Wood, Rachael
AU  - Wood R
AUID- ORCID: 0000-0003-4453-623X
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
AD  - Public Health Scotland, Edinburgh, UK.
AD  - Child Life and Health, University of Edinburgh, Edinburgh, UK.
LA  - eng
GR  - MC_PC_19004/MRC_/Medical Research Council/United Kingdom
GR  - MR/R008345/1/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_19075/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_20029/MRC_/Medical Research Council/United Kingdom
GR  - 209560/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - COVID-19/*epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Infant, Newborn
MH  - Pandemics
MH  - *Population Surveillance
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*epidemiology
MH  - Premature Birth/*epidemiology
MH  - Prospective Studies
MH  - *SARS-CoV-2
MH  - Scotland/epidemiology
PMC - PMC7691999
OTO - NOTNLM
OT  - *COVID-19
OT  - *epidemiology
OT  - *neonatology
OT  - *obstetrics
OT  - *perinatology
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-042813 [pii]
AID - 10.1136/bmjopen-2020-042813 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e042813. doi: 10.1136/bmjopen-2020-042813.


PMID- 33243816
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Experiences of Venous Leg Ulcer persons following an individualised nurse-led
      education: protocol for a qualitative study using a constructivist grounded
      theory approach.
PG  - e042605
LID - 10.1136/bmjopen-2020-042605 [doi]
AB  - INTRODUCTION: Venous leg ulcers are slow-healing wounds with a high risk of
      recurrences. To prevent recurrences and promote healing, different nurse-led
      educational interventions have been developed. The impact of these interventions 
      on self-management is ambiguous. Also, how persons with a venous leg ulcer
      experiences these educational sessions are poorly described. AIM: This study
      protocol presents the methodology to provide a comprehensive explanation of
      participants' journeys-of how they experience their individualised education
      sessions concerning self-management. METHODS AND ANALYSIS: A constructivist
      grounded theory approach according to Charmaz involving 30 participants will be
      used. Data will be collected through semistructured face-to-face interviews.
      Interviews will be transcribed verbatim and analysed with initial and focus
      coding using MAXQDA. Data collection and data analysis will occur iteratively,
      focusing on constant comparison to obtain well-developed categories. Categories
      will be reinforced using existent literature. ETHICS AND DISSEMINATION: This
      pre-results study is embedded in a clinical trial (NCT04019340) and approved by
      ethical committee of the canton of Geneva (CCER: 2019-01964). A theory will
      emerge from participants' journeys informing future education sessions for
      patients with venous leg ulcers. The findings will be disseminated through
      peer-reviewed publications and communications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bobbink, Paul
AU  - Bobbink P
AUID- ORCID: 0000-0001-6407-455X
AD  - HES-SO, University of Applied Sciences and Arts Western Switzerland, Geneva
      School of Health Sciences, Geneva, Switzerland paul.bobbink@hesge.ch.
AD  - University Institute of Higher Education and Research in Healthcare, Faculty of
      Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
FAU - Larkin, Philip J
AU  - Larkin PJ
AD  - University of Lausanne and University Hospital Lausanne, Lausanne, Switzerland.
FAU - Probst, Sebastian
AU  - Probst S
AUID- ORCID: 0000-0001-9603-1570
AD  - HES-SO, University of Applied Sciences and Arts Western Switzerland, Geneva
      School of Health Sciences, Geneva, Switzerland.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - Grounded Theory
MH  - Humans
MH  - Recurrence
MH  - *Varicose Ulcer/therapy
MH  - Wound Healing
PMC - PMC7692966
OTO - NOTNLM
OT  - *dermatology
OT  - *qualitative research
OT  - *wound management
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - bmjopen-2020-042605 [pii]
AID - 10.1136/bmjopen-2020-042605 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e042605. doi: 10.1136/bmjopen-2020-042605.


PMID- 33243815
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody
      CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African 
      women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
PG  - e042247
LID - 10.1136/bmjopen-2020-042247 [doi]
AB  - INTRODUCTION: New HIV prevention strategies are urgently required. The discovery 
      of broadly neutralising antibodies (bNAbs) has provided the opportunity to
      evaluate passive immunisation as a potential prevention strategy and facilitate
      vaccine development. Since 2014, several bNAbs have been isolated from a clade
      C-infected South African donor, CAPRISA 256. One particular bNAb,
      CAP256-VRC26.25, was found to be extremely potent, with good coverage against
      clade C viruses, the dominant HIV clade in sub-Saharan Africa. Challenge studies 
      in non-human primates demonstrated that this antibody was fully protective even
      at extremely low doses. This bNAb was subsequently structurally engineered and
      the clinical variant is now referred to as CAP256V2LS. METHODS AND ANALYSIS:
      CAPRISA 012B is the second of three trials in the CAPRISA 012 bNAb trial
      programme. It is a first-in-human, phase I study to assess the safety and
      pharmacokinetics of CAP256V2LS. The study is divided into four groups. Group 1 is
      a dose escalation of CAP256V2LS administered intravenously to HIV-negative and
      HIV-positive women. Group 2 is a dose escalation of CAP256V2LS administered
      subcutaneously (SC), with and without the dispersing agent recombinant human
      hyaluronidase (rHuPH20) as single or repeat doses in HIV-negative women. Groups 3
      and 4 are randomised placebo controlled to assess two (CAP256V2LS+VRC07-523LS;
      CAP256V2LS+PGT121) and three (CAP256V2LS+VRC07-523LS+PGT121) bNAb combinations
      administered SC to HIV-negative women. Safety will be assessed by the frequency
      of reactogenicity and adverse events related to the study product.
      Pharmacokinetic disposition of CAP256V2LS alone and in combination with
      VRC07-523LS and PGT121 will be assessed via dose subgroups and route of
      administration. ETHICS AND DISSEMINATION: The University of KwaZulu-Natal
      Biomedical Research Ethics Committee (BREC) and the South African Health Products
      Regulatory Authority (SAHPRA) have granted regulatory approval (trial reference
      numbers: BREC00000857/2019 and SAHPRA 20200123). Trial results will be
      disseminated through conference presentations, peer-reviewed publications and the
      clinical trial registry. TRIAL REGISTRATION NUMBER: PACTR202003767867253;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mahomed, Sharana
AU  - Mahomed S
AUID- ORCID: 0000-0002-4530-234X
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa Sharana.Mahomed@caprisa.org.
FAU - Garrett, Nigel
AU  - Garrett N
AUID- ORCID: 0000-0002-4530-234X
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
AD  - Department of Public Health Medicine, School of Nursing and Public Health,
      University of KwaZulu-Natal, Durban, South Africa.
FAU - Karim, Quarraisha A
AU  - Karim QA
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
AD  - Department of Epidemiology, Mailman School of Public Health, Columba University, 
      New York, New York, USA.
FAU - Zuma, Nonhlanhla Y
AU  - Zuma NY
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
FAU - Capparelli, Edmund
AU  - Capparelli E
AD  - University of California San Diego, San Diego, California, USA.
FAU - Baxter, Cheryl
AU  - Baxter C
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
FAU - Gengiah, Tanuja
AU  - Gengiah T
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
FAU - Archary, Derseree
AU  - Archary D
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
FAU - Samsunder, Natasha
AU  - Samsunder N
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
FAU - Rose, Nicole D
AU  - Rose ND
AD  - Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Moore, Penny
AU  - Moore P
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
AD  - National Institute for Communicable Diseases of the National Health Laboratory
      Services, Johannesburg, South Africa.
FAU - Williamson, Carolyn
AU  - Williamson C
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
AD  - National Health Laboratory Services of South Africa, Johannesburg, South Africa.
AD  - Division of Medical Virology, Institute of Infectious Disease and Molecular
      Medicine, University of Cape Town, Cape Town, South Africa.
FAU - Barouch, Dan H
AU  - Barouch DH
AD  - Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center,
      Boston, Massachusetts, USA.
FAU - Fast, Patricia E
AU  - Fast PE
AD  - International Aids Vaccine Initiative, New York, New York, USA.
FAU - Pozzetto, Bruno
AU  - Pozzetto B
AD  - GIMAP (EA3064), University of Saint-Etienne/University of Lyon, Saint-Etienne,
      France.
FAU - Hankins, Catherine
AU  - Hankins C
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, The
      Netherlands.
FAU - Carlton, Kevin
AU  - Carlton K
AD  - Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Ledgerwood, Julie
AU  - Ledgerwood J
AD  - Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Morris, Lynn
AU  - Morris L
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
AD  - National Institute for Communicable Diseases of the National Health Laboratory
      Services, Johannesburg, South Africa.
FAU - Mascola, John
AU  - Mascola J
AD  - Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Abdool Karim, Salim
AU  - Abdool Karim S
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban,
      South Africa.
AD  - Department of Epidemiology, Mailman School of Public Health, Columba University, 
      New York, New York, USA.
LA  - eng
SI  - PACTR/PACTR202003767867253
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (HIV Antibodies)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antibodies, Neutralizing
MH  - HIV Antibodies
MH  - *HIV Infections/prevention & control
MH  - *HIV-1
MH  - Humans
PMC - PMC7692975
OTO - NOTNLM
OT  - *epidemiology
OT  - *hiv & aids
OT  - *infectious diseases
OT  - *microbiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - bmjopen-2020-042247 [pii]
AID - 10.1136/bmjopen-2020-042247 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e042247. doi: 10.1136/bmjopen-2020-042247.


PMID- 33243812
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Protocol for the cultural adaptation of pulmonary rehabilitation and subsequent
      testing in a randomised controlled feasibility trial for adults with chronic
      obstructive pulmonary disease in Sri Lanka.
PG  - e041677
LID - 10.1136/bmjopen-2020-041677 [doi]
AB  - INTRODUCTION: International guidelines recommend pulmonary rehabilitation (PR)
      should be offered to adults living with chronic obstructive pulmonary disease
      (COPD), but PR availability is limited in Sri Lanka. Culturally appropriate PR
      needs to be designed and implemented in Sri Lanka. The study aims to adapt PR to 
      the Sri Lankan context and determine the feasibility of conducting a future trial
      of the adapted PR in Sri Lanka. METHODS AND ANALYSIS: Eligible participants will 
      be identified and will be invited to take part in the randomised controlled
      feasibility trial, which will be conducted in Central Chest Clinic, Colombo, Sri 
      Lanka. A total of 50 participants will be recruited (anticipated from April 2021)
      to the trial and randomised (1:1) into one of two groups; control group receiving
      usual care or the intervention group receiving adapted PR. The trial intervention
      is a Sri Lankan-specific PR programme, which will consist of 12 sessions of
      exercise and health education, delivered over 6 weeks. Focus groups with adults
      living with COPD, caregivers and nurses and in-depth interviews with doctors and 
      physiotherapist will be conducted to inform the Sri Lankan specific PR
      adaptations. After completion of PR, routine measures in both groups will be
      assessed by a blinded assessor. The primary outcome measure is feasibility,
      including assessing eligibility, uptake and completion. Qualitative evaluation of
      the trial using focus groups with participants and in-depth interviews with PR
      deliverers will be conducted to further determine feasibility and acceptability
      of PR, as well as the ability to run a larger future trial. ETHICS AND
      DISSEMINATION: Ethical approval was obtained from the ethics review committee of 
      Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka and
      University of Leicester, UK. The results of the trial will be disseminated
      through patient and public involvement events, local and international conference
      proceedings, and peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      ISRCTN13367735.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Jayamaha, Akila R
AU  - Jayamaha AR
AUID- ORCID: 0000-0002-3372-4537
AD  - Health Sciences, KIU, Colombo, Sri Lanka 1226arj@gmail.com.
FAU - Perera, Chamilya H
AU  - Perera CH
AD  - Health Sciences, KIU, Colombo, Sri Lanka.
FAU - Orme, Mark W
AU  - Orme MW
AUID- ORCID: 0000-0003-4678-6574
AD  - Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical
      Research Centre-Respiratory, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Jones, Amy V
AU  - Jones AV
AD  - Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical
      Research Centre-Respiratory, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Wijayasiri, Upendra K D C
AU  - Wijayasiri UKDC
AD  - Sports Medicine Unit, Colombo South Teaching Hospital, Kalubowila-Dehiwela, Sri
      Lanka.
FAU - Amarasekara, Thamara D
AU  - Amarasekara TD
AD  - Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Nugegoda,
      Sri Lanka.
FAU - Karunatillake, Ravini S
AU  - Karunatillake RS
AD  - Central Chest Clinic, National Hospital of Sri Lanka, Colombo, Sri Lanka.
FAU - Fernando, Amitha
AU  - Fernando A
AD  - Central Chest Clinic, National Hospital of Sri Lanka, Colombo, Sri Lanka.
FAU - Seneviratne, Anthony L P
AU  - Seneviratne ALP
AD  - Primary Care Respiratory Group, Colombo, Sri Lanka.
FAU - Barton, Andy
AU  - Barton A
AD  - Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Jones, Rupert
AU  - Jones R
AD  - Faculty of Health, University of Plymouth, Plymouth, UK.
FAU - Yusuf, Zainab K
AU  - Yusuf ZK
AD  - Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical
      Research Centre-Respiratory, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Miah, Ruhme B
AU  - Miah RB
AD  - Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical
      Research Centre-Respiratory, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Malcolm, Dominic
AU  - Malcolm D
AD  - School of Sport, Exercise and Health Sciences, Loughborough University,
      Loughborough, UK.
FAU - Matheson, Jesse A
AU  - Matheson JA
AD  - Department of Economics, University of Sheffield, Sheffield, UK.
FAU - Free, Robert C
AU  - Free RC
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Manise, Adrian
AU  - Manise A
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Steiner, Michael C
AU  - Steiner MC
AD  - Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical
      Research Centre-Respiratory, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
FAU - Wimalasekera, Savithri W
AU  - Wimalasekera SW
AD  - Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri
      Lanka.
FAU - Singh, Sally J
AU  - Singh SJ
AD  - Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical
      Research Centre-Respiratory, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Exercise
MH  - Feasibility Studies
MH  - Focus Groups
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive
MH  - Sri Lanka
PMC - PMC7692826
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *emphysema
OT  - *protocols & guidelines
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - bmjopen-2020-041677 [pii]
AID - 10.1136/bmjopen-2020-041677 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e041677. doi: 10.1136/bmjopen-2020-041677.


PMID- 33243811
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Individualised physical exercise training and enhanced protein intake in older
      citizens during municipality-based rehabilitation: protocol for a randomised
      controlled trial.
PG  - e041605
LID - 10.1136/bmjopen-2020-041605 [doi]
AB  - INTRODUCTION: Successful rehabilitation of the growing number of older citizens
      receiving healthcare services can lead to preservation of functional independence
      and improvement in quality of life. Adequate intake of dietary protein and
      physical training are key factors in counteracting the age-related decline in
      strength performance and physical function. However, during rehabilitation, many 
      older people/persons have insufficient protein intake, and difficulties in
      performing exercise training with sufficient intensity and volume. The primary
      aim of this trial is to investigate if individualised physical exercise training 
      programmes combined with increased protein intake (IPET+P) can improve measures
      on all International Classification of Functioning, Disability and Health levels,
      such as strength, gait speed and health-related quality of life, when compared
      with care as usual in municipality-based rehabilitation alone (usual care, UC) or
      care as usual in combination with increased protein intake (UC+P). Further, the
      trial investigates whether UC+P will potentiate more significant improvements in 
      outcome measures than UC. METHODS AND ANALYSIS: The trial is a three-armed
      multicentre, block-randomised controlled trial consisting of a 12-week
      intervention period with a 1-year follow-up. Citizens above 65 years referred to 
      rehabilitation in the municipality without restricting comorbidities are
      eligible. Participants are randomised to either a UC group, a UC group with
      protein supplementation receiving 27.5 g protein/day (UC+P), or an IPET+P
      supplementation of 27.5 g protein/day. The Short Musculoskeletal Function
      Assessment questionnaire is the primary outcome. ETHICS AND DISSEMINATION:
      Approvals from The Ethics Committee in Region Zealand, Denmark (SJ-758), and the 
      General Data Protection Regulation at the University of Southern Denmark, Odense 
      (10.330) have been obtained. TRIAL REGISTRATION NUMBER: NCT04091308.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Teljigovic, Sanel
AU  - Teljigovic S
AUID- ORCID: 0000-0001-7784-7451
AD  - Department of Physiotherapy, University College Absalon, Naestved, Denmark
      sate@pha.dk.
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Sogaard, Karen
AU  - Sogaard K
AUID- ORCID: 0000-0003-3968-6364
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Sandal, Louise Fleng
AU  - Sandal LF
AUID- ORCID: 0000-0001-8436-1046
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Dalager, Tina
AU  - Dalager T
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Nielsen, Nina Odgaard
AU  - Nielsen NO
AD  - Department of Physiotherapy, University College Absalon, Naestved, Denmark.
FAU - Sjogaard, Gisela
AU  - Sjogaard G
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Holm, Lars
AU  - Holm L
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04091308
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Proteins)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Exercise
MH  - Exercise Therapy
MH  - Health Status
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Outcome Assessment, Health Care
MH  - Proteins/*therapeutic use
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
PMC - PMC7692977
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *nutrition & dietetics
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - bmjopen-2020-041605 [pii]
AID - 10.1136/bmjopen-2020-041605 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e041605. doi: 10.1136/bmjopen-2020-041605.


PMID- 33243800
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Phase I feasibility study of Magnetic Resonance guided High Intensity Focused
      Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and
      cyclophosphamide in de novo stage IV breast cancer patients: study protocol of
      the i-GO study.
PG  - e040162
LID - 10.1136/bmjopen-2020-040162 [doi]
AB  - INTRODUCTION: In breast cancer, local tumour control is thought to be optimised
      by administering higher local levels of cytotoxic chemotherapy, in particular
      doxorubicin. However, systemic administration of higher dosages of doxorubicin is
      hampered by its toxic side effects. In this study, we aim to increase doxorubicin
      deposition in the primary breast tumour without changing systemic doxorubicin
      concentration and thus without interfering with systemic efficacy and toxicity.
      This is to be achieved by combining Lyso-Thermosensitive Liposomal Doxorubicin
      (LTLD, ThermoDox, Celsion Corporation, Lawrenceville, NJ, USA) with mild local
      hyperthermia, induced by Magnetic Resonance guided High Intensity Focused
      Ultrasound (MR-HIFU). When heated above 39.5 degrees C, LTLD releases a high
      concentration of doxorubicin intravascularly within seconds. In the absence of
      hyperthermia, LTLD leads to a similar biodistribution and antitumour efficacy
      compared with conventional doxorubicin. METHODS AND ANALYSIS: This is a
      single-arm phase I study in 12 chemotherapy-naive patients with de novo stage IV 
      HER2-negative breast cancer. Previous endocrine treatment is allowed. Study
      treatment consists of up to six cycles of LTLD at 21-day intervals, administered 
      during MR-HIFU-induced hyperthermia to the primary tumour. We will aim for 60 min
      of hyperthermia at 40 degrees C-42 degrees C using a dedicated MR-HIFU breast
      system (Profound Medical, Mississauga, Canada). Afterwards, intravenous
      cyclophosphamide will be administered. Primary endpoints are safety, tolerability
      and feasibility. The secondary endpoint is efficacy, assessed by radiological
      response.This approach could lead to optimal loco-regional control with less
      extensive or even no surgery, in de novo stage IV patients and in stage II/III
      patients allocated to receive neoadjuvant chemotherapy. ETHICS AND DISSEMINATION:
      This study has obtained ethical approval by the Medical Research Ethics Committee
      Utrecht (Protocol NL67422.041.18, METC number 18-702). Informed consent will be
      obtained from all patients before study participation. Results will be published 
      in an academic peer-reviewed journal. TRIAL REGISTRATION NUMBERS: NCT03749850,
      EudraCT 2015-005582-23.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Maar, Josanne S
AU  - de Maar JS
AUID- ORCID: 0000-0002-7493-4215
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands j.s.demaar@umcutrecht.nl.
FAU - Suelmann, Britt B M
AU  - Suelmann BBM
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - Braat, Manon N G J A
AU  - Braat MNGJA
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - van Diest, P J
AU  - van Diest PJ
AD  - Department of Pathology, University Medical Center Utrecht, Utrecht, The
      Netherlands.
FAU - Vaessen, H H B
AU  - Vaessen HHB
AD  - Department of Anesthesiology, University Medical Center Utrecht, Utrecht, The
      Netherlands.
FAU - Witkamp, Arjen J
AU  - Witkamp AJ
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
AD  - Department of Surgical Oncology, University Medical Center Utrecht, Utrecht, The 
      Netherlands.
FAU - Linn, S C
AU  - Linn SC
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - Moonen, Chrit T W
AU  - Moonen CTW
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - van der Wall, Elsken
AU  - van der Wall E
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - Deckers, Roel
AU  - Deckers R
AD  - Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03749850
SI  - EudraCT/2015-005582-23
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (liposomal doxorubicin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - *Breast Neoplasms/drug therapy
MH  - COVID-19
MH  - Canada
MH  - Cyclophosphamide
MH  - Doxorubicin/analogs & derivatives
MH  - Feasibility Studies
MH  - Humans
MH  - Hyperthermia
MH  - Magnetic Resonance Spectroscopy
MH  - Polyethylene Glycols
MH  - SARS-CoV-2
MH  - Tissue Distribution
PMC - PMC7692846
OTO - NOTNLM
OT  - *breast tumours
OT  - *chemotherapy
OT  - *interventional radiology
OT  - *magnetic resonance imaging
OT  - *oncology
OT  - *ultrasound
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - bmjopen-2020-040162 [pii]
AID - 10.1136/bmjopen-2020-040162 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e040162. doi: 10.1136/bmjopen-2020-040162.


PMID- 33243799
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Open-label, single-centre, cluster-randomised controlled trial to Evaluate the
      Potential Impact of Computerisedantimicrobial stewardship (EPIC) on the
      antimicrobial use after cardiovascular surgeries: EPIC trial study original
      protocol.
PG  - e039717
LID - 10.1136/bmjopen-2020-039717 [doi]
AB  - INTRODUCTION: Inappropriate antimicrobial use increases the prevalence of
      antimicrobial-resistant bacteria. Surgeons are reluctant to implement
      recommendations of guidelines in clinical practice. Antimicrobial stewardship
      (AMS) is effective in antimicrobial management, but it remains labour intensive. 
      The computerised decision support system (CDSS) has been identified as an
      effective way to enable key elements of AMS in clinical settings. However,
      insufficient evidence is available to evaluate the efficacy of computerised AMS
      in surgical settings. METHODS AND ANALYSIS: The Evaluate of the Potential Impact 
      of Computerised AMS trial is an open-label, single-centre, two-arm,
      cluster-randomised, controlled trial, which aims to determine whether a
      multicomponent CDSS intervention reduces overall antimicrobial use after
      cardiovascular surgeries compared with usual clinical care in a specialty
      hospital with a big volume of cardiovascular surgeries. Eighteen cardiovascular
      surgical teams will be randomised 1:1 to either the intervention or the control
      arm. The intervention will consist of (1) re-evaluation alerts and decision
      support for the duration of antimicrobial treatment decision, (2) re-evaluation
      alerts and decision support for the choice of antimicrobial, (3) quality control 
      audit and feedback. The primary outcome will be the overall systemic
      antimicrobial use measured in days of therapy (DOT) per admission and DOT per
      1000 patient-days over the whole intervention period (6 months). Secondary
      outcomes include a series of indices to evaluate antimicrobial use, microbial
      resistance, perioperative infection outcomes, patient safety, resource
      consumption, and user compliance and satisfaction. ETHICS AND DISSEMINATION: The 
      Ethics Committee in Fuwai Hospital approved this study (2020-1329). The results
      of the trial will be submitted for publication in a peer-reviewed journal. TRIAL 
      REGISTRATION NUMBER: NCT04328090.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yuan, Xin
AU  - Yuan X
AD  - State Key Laboratory of Cardiovascular Disease, National Centre for
      Cardiovascular Diseases, Beijing, China.
AD  - Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, Beijing, China.
FAU - Chen, Kai
AU  - Chen K
AUID- ORCID: 0000-0002-3045-7955
AD  - State Key Laboratory of Cardiovascular Disease, National Centre for
      Cardiovascular Diseases, Beijing, China.
AD  - Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, Beijing, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Information Centre, Fuwai Hospital, Chinese Academy of Medical Science and Peking
      Union Medical College, Beijing, China.
FAU - Hu, Shuang
AU  - Hu S
AD  - National Clinical Research Centre of Cardiovascular Diseases, State Key
      Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for
      Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union
      Medical College, Beijing, China.
FAU - Yu, Fei
AU  - Yu F
AD  - Information Centre, Fuwai Hospital, Chinese Academy of Medical Science and Peking
      Union Medical College, Beijing, China.
FAU - Diao, Xiaolin
AU  - Diao X
AD  - Information Centre, Fuwai Hospital, Chinese Academy of Medical Science and Peking
      Union Medical College, Beijing, China.
FAU - Chen, Xingwei
AU  - Chen X
AD  - Department of Pharmacy, Fuwai Hospital, Chinese Academy of Medical Science and
      Peking Union Medical College, Beijing, China.
FAU - Hu, Shengshou
AU  - Hu S
AD  - State Key Laboratory of Cardiovascular Disease, National Centre for
      Cardiovascular Diseases, Beijing, China huss@fuwaihospital.org.
AD  - Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, Beijing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04328090
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Infective Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Anti-Infective Agents/therapeutic use
MH  - *Antimicrobial Stewardship
MH  - Feedback
MH  - Hospitals
MH  - Humans
MH  - Randomized Controlled Trials as Topic
PMC - PMC7692825
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiac surgery
OT  - *clinical trials
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039717 [pii]
AID - 10.1136/bmjopen-2020-039717 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e039717. doi: 10.1136/bmjopen-2020-039717.


PMID- 33243796
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - How much do we know about the effectiveness of warm-up intervention on work
      related musculoskeletal disorders, physical and psychosocial functions: protocol 
      for a systematic review.
PG  - e039063
LID - 10.1136/bmjopen-2020-039063 [doi]
AB  - INTRODUCTION: Work-related musculoskeletal disorders (WMSDs) are a growing
      worldwide burden and effective interventions to prevent them are needed. Physical
      activity at the workplace is now recognised as a relevant component of WMSDs
      prevention. Along these lines, warm-up interventions are now offered in a large
      number of companies to manage WMSDs. Although benefits of warm-up have been
      previously documented in sports context, to the best of our knowledge, the
      effectiveness of such intervention in workplaces still remains to be established.
      Within this context, the aim of the present review is to identify from published 
      literature the available evidence regarding the effects of warm-up on WMSDs and
      physical and psychosocial functions. METHODS: The following electronic databases 
      will be searched (from inception onwards to June 2020): Cochrane Central Register
      of Controlled Trials, PubMed (Medline), Web of Science and Physiotherapy Evidence
      Database. Randomised and non-randomised controlled studies will be included in
      this review. Participants should be adult employees without specific
      comorbidities. Interventions should include a warm-up physical intervention in
      real-workplaces. The primary outcomes will be pain, discomfort or fatigue. The
      secondary outcomes will be job control or motivation at work. This review will
      follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      guidelines and two team members will independently screen all citations,
      full-text articles and abstract data. A systematic narrative synthesis will be
      provided with information presented in the text and tables to summarise the
      characteristics and findings of the included studies. ETHICS AND DISSEMINATION:
      The approval of an ethical committee is not required. All the included studies
      will comply with the current ethical standards. The results of this review will
      summarise the effects of warm-up intervention on WMSDs, physical or psychosocial 
      functions. This information could help professionals in decision making related
      to the use of these interventions to prevent WMSDs. Findings will be disseminated
      to academic audiences through peer-reviewed publications, as well as to
      policy-makers. PROSPERO REGISTRATION NUMBER: CRD42019137211.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Larinier, Nicolas
AU  - Larinier N
AD  - AGEIS, University Grenoble Alpes, Grenoble, France.
AD  - Opti'Mouv, St Paul, France.
FAU - Balaguier, Romain
AU  - Balaguier R
AUID- ORCID: 0000-0001-6393-1556
AD  - AGEIS, University Grenoble Alpes, Grenoble, France romain.balaguier@hotmail.fr.
AD  - Opti'Mouv, St Paul, France.
FAU - Vuillerme, Nicolas
AU  - Vuillerme N
AD  - AGEIS, University Grenoble Alpes, Grenoble, France.
AD  - Opti'Mouv, St Paul, France.
AD  - Institut Universitaire de France, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Exercise
MH  - Humans
MH  - *Musculoskeletal Diseases/prevention & control
MH  - Research Design
MH  - Review Literature as Topic
MH  - Workplace
PMC - PMC7692815
OTO - NOTNLM
OT  - *musculoskeletal disorders
OT  - *public health
OT  - *sports medicine
COIS- Competing interests: Opti'Mouv is a company that provides workplace health
      promotion services as workplace physical activity programmes.
EDAT- 2020/11/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039063 [pii]
AID - 10.1136/bmjopen-2020-039063 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e039063. doi: 10.1136/bmjopen-2020-039063.


PMID- 33243791
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 26
TI  - Nurse-led, screening-triggered, early specialised palliative care intervention
      programme for patients with advanced lung cancer: study protocol for a
      multicentre randomised controlled trial.
PG  - e037759
LID - 10.1136/bmjopen-2020-037759 [doi]
AB  - INTRODUCTION: It has been suggested that palliative care integrated into standard
      cancer treatment from the early phase of the disease can improve the quality of
      life of patients with cancer. In this paper, we present the protocol for a
      multicentre randomised controlled trial to examine the effectiveness of a
      nurse-led, screening-triggered, early specialised palliative care intervention
      programme for patients with advanced lung cancer. METHODS AND ANALYSIS: A total
      of 206 patients will be randomised (1:1) to the intervention group or the control
      group (usual care). The intervention, triggered with a brief self-administered
      screening tool, comprises comprehensive need assessments, counselling and service
      coordination by advanced-level nurses. The primary outcome is the Trial Outcome
      Index of the Functional Assessment of Cancer Therapy (FACT) at 12 weeks. The
      secondary outcomes include participants' quality of life (FACT-Lung), depression 
      (Patient Health Questionnaire-9), anxiety (Generalized Anxiety Disorder-7),
      illness perception (Prognosis and Treatment Perceptions Questionnaire), medical
      service use and survival. A mixed-method approach is expected to provide an
      insight about how this intervention works. ETHICS AND DISSEMINATION: This study
      has been approved by the Institutional Review Board of the National Cancer Center
      Japan (approval number: 2016-235). The findings will be disseminated through
      peer-reviewed publications and conference presentations and will be reflected on 
      to the national healthcare policy. TRIAL REGISTRATION NUMBER: UMIN000025491.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fujisawa, Daisuke
AU  - Fujisawa D
AUID- ORCID: 0000-0003-1913-6955
AD  - Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku,
      Tokyo, Japan.
AD  - Psycho-Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba,
      Japan.
FAU - Umemura, Shigeki
AU  - Umemura S
AD  - Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa,
      Chiba, Japan.
FAU - Okizaki, Ayumi
AU  - Okizaki A
AUID- ORCID: 0000-0001-6685-965X
AD  - Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa,
      Chiba, Japan.
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
AD  - Behavioral and Survivorship Research Group, Center for Public Health Sciences,
      National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Satomi, Eriko
AU  - Satomi E
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Chuo-ku,
      Tokyo, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Division of Biostatistics, Tohoku University School of Medicine, Sendai, Miyagi, 
      Japan.
FAU - Miyaji, Tempei
AU  - Miyaji T
AUID- ORCID: 0000-0001-8370-1352
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
AD  - Department of Clinical Trial Data Management, Graduate School of Medicine, The
      University of Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - Mashiko, Tomoe
AU  - Mashiko T
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Kobayashi, Naoko
AU  - Kobayashi N
AD  - Department of Nursing, National Cancer Center Hospital East, Kashiwa, Chiba,
      Japan.
FAU - Kinoshita, Hiroya
AU  - Kinoshita H
AD  - Department of Palliative Care, Tokatsu Hospital, Nagareyama, Chiba, Japan.
FAU - Mori, Masanori
AU  - Mori M
AD  - Palliative and Supportive Care, Seirei Mikatahara Hospital, Hamamatsu, Shizuoka, 
      Japan.
FAU - Morita, Tatsuya
AU  - Morita T
AD  - Palliative and Supportive Care, Seirei Mikatahara Hospital, Hamamatsu, Shizuoka, 
      Japan.
FAU - Uchitomi, Yosuke
AU  - Uchitomi Y
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
AD  - Behavioral and Survivorship Research Group, Center for Public Health Sciences,
      National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Goto, Koichi
AU  - Goto K
AD  - Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa,
      Chiba, Japan.
FAU - Ohe, Yuichiro
AU  - Ohe Y
AD  - Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo,
      Japan.
FAU - Matsumoto, Yoshihisa
AU  - Matsumoto Y
AUID- ORCID: 0000-0003-3112-4818
AD  - Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa,
      Chiba, Japan yosmatsu@east.ncc.go.jp.
LA  - eng
SI  - UMIN-CTR/UMIN000025491
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201126
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Early Detection of Cancer
MH  - Humans
MH  - Japan
MH  - *Lung Neoplasms/diagnosis/therapy
MH  - Multicenter Studies as Topic
MH  - Nurse's Role
MH  - *Palliative Care
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7692832
OTO - NOTNLM
OT  - *oncology
OT  - *palliative care
OT  - *respiratory tract tumours
COIS- Competing interests: None declared.
EDAT- 2020/11/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/27 05:38
PHST- 2020/11/27 05:38 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037759 [pii]
AID - 10.1136/bmjopen-2020-037759 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 26;10(11):e037759. doi: 10.1136/bmjopen-2020-037759.


PMID- 33243215
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 26
TI  - The differences of clinical characteristics and outcomes between imported and
      local patients of COVID-19 in Hunan: a two-center retrospective study.
PG  - 313
LID - 10.1186/s12931-020-01551-5 [doi]
AB  - BACKGROUND: The clinical characteristics and outcomes of the 2019 novel
      coronavirus (COVID-19) pneumonia are different in Hubei compared to other regions
      in China. But there are few comparative studies on the differences between
      imported and local patients which may provide information of the different
      courses of the virus after transmission. METHODS: We investigated 169 cases of
      COVID-19 pneumonia in two centers in Hunan Province, and divided them into two
      groups according to epidemiological history, "imported patients" refers to
      patient with a clear history of travel in Wuhan within 14 days before onset, and 
      " local patients" refers to local resident without a recent history of travel in 
      Wuhan, aiming to analyze the difference in clinical characteristics and outcomes 
      between the two groups. All the epidemiological, clinical, imaging, and
      laboratory data were analyzed and contrasted. RESULTS: The incidence of fever on 
      admission in imported patients was significantly higher than local patients.
      There was a significantly higher proportion of abnormal pulmonary signs,
      hypokalemia, hyponatremia, prolonged PT, elevated D-dimer and elevated blood
      glucose in imported patients. Compared with local patients, the proportion using 
      antibiotics, glucocorticoids and gamma globulin were significantly higher in
      imported patients. The moderate type was more common in local patients, and the
      severe type were more frequent in imported patients. In addition, the median
      duration of viral clearance was longer in imported patients. CONCLUSIONS: In
      summary, we found that imported cases were more likely to develop into severe
      cases, compared with local patients and required more powerful treatments. Trial 
      registration Registered 21st March 2020, and this study has been approved by the 
      Medical Ethics Committee (Approved Number. 2020017).
FAU - Wang, Chang
AU  - Wang C
AD  - Department of Nephrology, The Second Xiangya Hospital, Central South University, 
      Changsha, 410011, Hunan, China.
FAU - Zhou, Lizhi
AU  - Zhou L
AD  - Department of Urology, The Second Xiangya Hospital, Central South University,
      Changsha, 410011, Hunan, China.
FAU - Chen, Juan
AU  - Chen J
AD  - Department of Radiology, The Central Hospital of Xiangtan, Xiangtan, 410011,
      Hunan, China.
FAU - Yang, Yong
AU  - Yang Y
AD  - Department of Intensive Care Unit, The Central Hospital of Changsha, Nanhua
      University, Hengyang, 410011, Hunan, China.
FAU - Huang, Tianlong
AU  - Huang T
AD  - Department of Orthopaedics, The Second Xiangya Hospital, Central South
      University, Changsha, 410011, Hunan, China.
FAU - Fu, Min
AU  - Fu M
AD  - Department of Neurology, the Fourth Hospital of Changsha, Changsha, 410011,
      Hunan, China.
FAU - Li, Ya
AU  - Li Y
AD  - Department of Radiology, The Second Xiangya Hospital, Central South University,
      Changsha, 410011, Hunan, China.
FAU - George, Daniel M
AU  - George DM
AD  - Royal Adelaide Hospital Adelaide, Adelaide, SA, Australia.
FAU - Chen, Xiangyu
AU  - Chen X
AD  - Department of Radiology, The Second Xiangya Hospital, Central South University,
      Changsha, 410011, Hunan, China. chenxiangyu@csu.edu.cn.
LA  - eng
GR  - 81900661/The National Natural Science Foundation of China
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201126
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
SB  - IM
MH  - Adult
MH  - Aged
MH  - COVID-19/*diagnosis/mortality/*therapy
MH  - China/epidemiology
MH  - Female
MH  - Fever/virology
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Respiration, Artificial/statistics & numerical data
MH  - Retrospective Studies
MH  - *Travel
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7689384
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical characteristics
OT  - Outcomes
OT  - SARS-CoV-2
OT  - Virulence
EDAT- 2020/11/28 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/11/27 05:29
PHST- 2020/04/15 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/27 05:29 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1186/s12931-020-01551-5 [doi]
AID - 10.1186/s12931-020-01551-5 [pii]
PST - epublish
SO  - Respir Res. 2020 Nov 26;21(1):313. doi: 10.1186/s12931-020-01551-5.


PMID- 33243206
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Nov 26
TI  - Quality of interventional animal experiments in Chinese journals: compliance with
      ARRIVE guidelines.
PG  - 460
LID - 10.1186/s12917-020-02664-1 [doi]
AB  - BACKGROUND: In view of the inadequacy and incompleteness of currently-reported
      animal experiments and their overall poor quality, we retrospectively evaluated
      the reporting quality of animal experiments published in Chinese journals
      adhering to the Animal Research: Reporting of In Vivo Experiments (ARRIVE)
      guidelines. RESULTS: The databases CNKI, WanFang, VIP, and CBM were searched from
      inception until July 2018. Two appropriately-trained reviewers screened and
      extracted articles independently. The ARRIVE guidelines were used to assess the
      quality of the published reports of animal experiments. The compliance rate of
      every item was analyzed relative to their date of publication. A total of 4342
      studies were included, of which 73.0% had been cited </=5 times. Only 29.0%
      (1261/4342) were published in journals listed in the Chinese Science Citation
      Database. The results indicate that the compliance rate of approximately half of 
      the sub-items (51.3%, 20/39) was less than 50%, of which 65.0% (13/20) was even
      less than 10%. CONCLUSIONS: The reporting quality of animal experiments in
      Chinese journals is not at a high level. Following publication of the ARRIVE
      guidelines in 2010, the compliance rate of the majority of its requirements has
      improved to some extent. However, less attention has been paid to the ethics and 
      welfare of experimental animals, and a number of specific items in the Methods,
      Results, and Discussion sections continue to not be reported in sufficient
      detail. Therefore, it is necessary to popularize the ARRIVE guidelines, advocate 
      researchers to adhere to them in the future, and in particular promote the use of
      the guidelines in specialized journals in order that the design, implementation, 
      and reporting of animal experiments is promoted, to ultimately improve their
      quality.
FAU - Zhao, Bing
AU  - Zhao B
AD  - Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, No.199, Donggang West Road, Lanzhou City, 730000, Gansu Province,
      China.
FAU - Jiang, Yanbiao
AU  - Jiang Y
AD  - Second clinical medical college, Lanzhou University, Lanzhou, 730000, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, No.199, Donggang West Road, Lanzhou City, 730000, Gansu Province,
      China.
FAU - Shang, Zhizhong
AU  - Shang Z
AD  - Second clinical medical college, Lanzhou University, Lanzhou, 730000, China.
FAU - Zhang, Weiyi
AU  - Zhang W
AD  - School of Public Health, Lanzhou University, Lanzhou, 730000, China.
FAU - Hu, Kaiyan
AU  - Hu K
AD  - School of Nursing, Lanzhou University, Lanzhou, 730000, China.
FAU - Chen, Fei
AU  - Chen F
AD  - School of Nursing, Lanzhou University, Lanzhou, 730000, China.
FAU - Mei, Fan
AU  - Mei F
AD  - School of Nursing, Lanzhou University, Lanzhou, 730000, China.
FAU - Gao, Qianqian
AU  - Gao Q
AD  - School of Nursing, Lanzhou University, Lanzhou, 730000, China.
FAU - Zhao, Li
AU  - Zhao L
AD  - School of Nursing, Lanzhou University, Lanzhou, 730000, China.
FAU - Kwong, Joey S W
AU  - Kwong JSW
AD  - School of Public Health and Primary Medical Care, Jockey Club, Chinese University
      of Hong Kong, Hong Kong, 999077, China. jswkwong@hotmail.com.
FAU - Ma, Bin
AU  - Ma B
AUID- ORCID: http://orcid.org/0000-0001-7247-8714
AD  - Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, No.199, Donggang West Road, Lanzhou City, 730000, Gansu Province,
      China. kittymb2017@163.com.
LA  - eng
GR  - 81873184/National Natural Science Foundation of China
GR  - lzujbky-2018-96/Basic Scientific Research Projects of Central Colleges and
      Universities of Lanzhou University
PT  - Journal Article
DEP - 20201126
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
SB  - IM
MH  - Animal Experimentation/*standards/statistics & numerical data
MH  - Animal Welfare/standards
MH  - Animals
MH  - China
MH  - Guideline Adherence/*statistics & numerical data
MH  - Publications/standards
MH  - Research Design/*standards
MH  - Retrospective Studies
PMC - PMC7690085
OTO - NOTNLM
OT  - ARRIVE
OT  - Animal experiments
OT  - Reporting quality
EDAT- 2020/11/28 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/11/27 05:29
PHST- 2020/02/12 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/27 05:29 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - 10.1186/s12917-020-02664-1 [doi]
AID - 10.1186/s12917-020-02664-1 [pii]
PST - epublish
SO  - BMC Vet Res. 2020 Nov 26;16(1):460. doi: 10.1186/s12917-020-02664-1.


PMID- 33243050
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 37
IP  - 1
DP  - 2020 Nov 15
TI  - Feasibility and efficacy study of microwave ablation of recurrent small HCC
      guided by enhanced liver-specific magnetic resonance imaging contrast agent.
PG  - 1330-1335
LID - 10.1080/02656736.2020.1850886 [doi]
AB  - OBJECTIVES: To investigate the feasibility and efficacy of liver-specific
      magnetic resonance imaging (MRI) with gadolinium-containing contrast agent
      guidance for microwave ablation (MWA) of recurrent small hepatocellular carcinoma
      (HCC). MATERIALS AND METHODS: The Ethics Committee of the First Affiliated
      Hospital of Fujian Medical University approved this study. Eighteen patients
      presented with 30 recurrent small HCCs, at least one lesion per patient was
      undetectable on unenhanced MRI, but this was clearly demonstrated in the
      hepatobiliary phase after liver-specific MRI contrast agent administration.
      Gd-BOPTA (16 cases) or Gd-EOB-DTPA (2 cases) were injected half an hour before
      the procedure, and MWA was performed by percutaneous puncture of the target
      lesion with a magnetic resonance-compatible microwave antenna under 1.5 T MRI
      guidance. RESULTS: The technical success rate was 100%. The mean maximum diameter
      of the lesions was 9.7 +/- 2.8 mm (5.0-15.4 mm). The mean follow-up time was 11.6
      +/- 4.7 months (range, 4-19 months), and no local recurrence was observed.
      CONCLUSIONS: MWA of small HCCs guided by enhanced liver-specific MRI contrast
      agent is a safe and effective technique.
FAU - Lin, Zheng-Yu
AU  - Lin ZY
AD  - The Department of Interventional Radiology, Molecular Oncology Research
      Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Fang, Yan
AU  - Fang Y
AD  - Nursing Department, First Affiliated Hospital of Fujian Medical University,
      Fuzhou, China.
FAU - Chen, Jin
AU  - Chen J
AD  - The Department of Interventional Radiology, Molecular Oncology Research
      Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Lin, Qing-Feng
AU  - Lin QF
AD  - The Department of Interventional Radiology, Molecular Oncology Research
      Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Yan, Yuan
AU  - Yan Y
AD  - The Department of Interventional Radiology, Molecular Oncology Research
      Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Chen, Jian
AU  - Chen J
AD  - The Department of Interventional Radiology, Molecular Oncology Research
      Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
FAU - Li, Yu-Liang
AU  - Li YL
AD  - The Department of Interventional Radiology, Molecular Oncology Research
      Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
RN  - 0 (Contrast Media)
SB  - IM
MH  - *Carcinoma, Hepatocellular/diagnostic imaging/surgery
MH  - Contrast Media
MH  - Feasibility Studies
MH  - Humans
MH  - *Liver Neoplasms/diagnostic imaging/surgery
MH  - Magnetic Resonance Imaging
MH  - Microwaves/therapeutic use
MH  - Neoplasm Recurrence, Local/diagnostic imaging/surgery
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *Magnetic resonance imaging
OT  - *ablation techniques
OT  - *gadolinium ethoxybenzyl DTPA
OT  - *hepatocellular carcinoma
OT  - *microwave
EDAT- 2020/11/28 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/27 05:28
PHST- 2020/11/27 05:28 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1080/02656736.2020.1850886 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2020 Nov 15;37(1):1330-1335. doi:
      10.1080/02656736.2020.1850886.


PMID- 33243018
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - Quxie Capsule Modulating Gut Microbiome and Its Association With T cell
      Regulation in Patients With Metastatic Colorectal Cancer: Result From a
      Randomized Controlled Clinical Trial.
PG  - 1534735420969820
LID - 10.1177/1534735420969820 [doi]
AB  - AIM: Quxie capsule(QX), a TCM compound, had shown benefit on survival outcomes
      for metastatic colorectal cancer(mCRC) patients and could inhibit tumor growth
      through immune regulation. This study aimed to evaluate whether such effect is
      associated with gut microbiome modulation. METHOD: We conducted a randomized
      double-blinded placebo controlled clinical trial in Xiyuan Hospital, China
      Academy of Chinese Medical Sciences. All patients were randomly assigned into QX 
      or placebo control group. Before and after 1-month interventions, we collected
      patients' stool samples for microbiome analysis by 16s rRNA sequencing
      approaches, as well as blood samples to analyze T lymphocyte subsets by flow
      cytometry methods. Microbiome analysis among groups was done through
      bioinformation analysis platform. The study had been proved by the ethics
      committee of Xiyuan Hospital (2016XLA122-1) had been registered on Chinese
      Clinical Trial Registry (registration number: ChiCTR2000029599). All patients
      consented before enrollment. RESULTS: We randomly assigned 40 patients and 34
      were finally analyzed. Among them, 29% were female, with an average age of 63
      years old, and 74% had liver or lung metastasis. Both CD4 T(TH) cell and CD8
      T(TC) cell counts increased after QX treatment, while TH cells were significantly
      more in QX than in control group (737 vs 449, P = .024). Microbiome community
      analysis on Class level showed that the proportion of Actinobacteria declined in 
      the control group, but significantly increased after QX treatments (0.83% vs
      4.7%, P = .017). LEfSe analysis showed that after treatments, samples from QX
      group were highly related with Oscillibacter, Eubacterium, and Lachnospiraceae.
      RDA analysis showed that after QX interventions, stool samples and microbiome
      species had relevance with TC/TH cells counts but were not statistically
      significant. Heatmap analysis on Genus level revealed that after QX treatments,
      higher amounts of TH cells were significantly associated with less abundance of
      g_Bifidobacterium (coef. -0.76, P = .002), Collinsella (coef.-0.61, P = .02),
      Ruminiclostridium_9 (coef. -0.64, P = .01). CONCLUSION: QX capsule could enhance 
      TH cells level among mCRC patients and increase the abundance of gut anticancer
      bacteria such as Actinobacteria as well as butyrate-producing bacteria such as
      Lachnospiraceae. These results indicated that QX capsule might have the property 
      of dual effects of antitumor and immunity enhancement, both mediated by the
      microbiome.
FAU - Sun, Lingyun
AU  - Sun L
AUID- ORCID: 0000-0002-7191-6177
AD  - China Academy of Chinese Medical Sciences, Beijing, P.R. China.
FAU - Yan, Yunzi
AU  - Yan Y
AD  - Beijing University of Chinese Medicine, Beijing, P.R. China.
FAU - Chen, Dongmei
AU  - Chen D
AD  - China-Japan Friendship Hospital, Beijing, P.R. China.
FAU - Yang, Yufei
AU  - Yang Y
AD  - China Academy of Chinese Medical Sciences, Beijing, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 0 (quxie)
SB  - IM
MH  - *Colonic Neoplasms
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal
MH  - Female
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - RNA, Ribosomal, 16S/genetics
PMC - PMC7876934
OTO - NOTNLM
OT  - *T cell immunity
OT  - *Traditional Chinese Medicine
OT  - *gut microbiome
OT  - *metastatic colorectal cancer
OT  - *randomized clinical trial
EDAT- 2020/11/28 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/27 05:28
PHST- 2020/11/27 05:28 [entrez]
PHST- 2020/11/28 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.1177/1534735420969820 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2020 Jan-Dec;19:1534735420969820. doi:
      10.1177/1534735420969820.


PMID- 33242812
OWN - NLM
STAT- Publisher
LR  - 20201126
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 289
DP  - 2020 May 6
TI  - COVID-19 Pandemic: Impact on psychiatric care in the United States.
PG  - 113069
LID - S0165-1781(20)31226-9 [pii]
LID - 10.1016/j.psychres.2020.113069 [doi]
AB  - The World Health Organization declared the coronavirus outbreak a pandemic on
      March 11, 2020. Infection by the SARS-CoV2 virus leads to the COVID-19 disease
      which can be fatal, especially in older patients with medical co-morbidities. The
      impact to the US healthcare system has been disruptive, and the way healthcare
      services are provided has changed drastically. Here, we present a compilation of 
      the impact of the COVID-19 pandemic on psychiatric care in the US, in the various
      settings: outpatient, emergency room, inpatient units, consultation services, and
      the community. We further present effects seen on psychiatric physicians in the
      setting of new and constantly evolving protocols where adjustment and flexibility
      have become the norm, training of residents, leading a team of professionals with
      different expertise, conducting clinical research, and ethical considerations.
      The purpose of this paper is to provide examples of "how to" processes based on
      our current front-line experiences and research to practicing psychiatrists and
      mental health clinicians, inform practitioners about national guidelines
      affecting psychiatric care during the pandemic, and inform health care policy
      makers and health care systems about the challenges and continued needs of
      financial and administrative support for psychiatric physicians and mental health
      systems.
CI  - Published by Elsevier B.V.
FAU - Bojdani, Ermal
AU  - Bojdani E
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States. Electronic
      address: ebojdani@mclean.harvard.edu.
FAU - Rajagopalan, Aishwarya
AU  - Rajagopalan A
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States.
FAU - Chen, Anderson
AU  - Chen A
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States.
FAU - Gearin, Priya
AU  - Gearin P
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States.
FAU - Olcott, William
AU  - Olcott W
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States.
FAU - Shankar, Vikram
AU  - Shankar V
AD  - Emergency Medicine Residency Program, Kern Medical, Bakersfield, CA, United
      States.
FAU - Cloutier, Alesia
AU  - Cloutier A
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States.
FAU - Solomon, Haley
AU  - Solomon H
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States; Department of Psychiatry, Harvard Medical School, Boston, MA, United
      States; VA Boston Healthcare System, Brockton, MA, United States.
FAU - Naqvi, Nida Z
AU  - Naqvi NZ
AD  - Department of Internal Medicine, University of Maryland Upper Chesapeake Medical 
      Center, Bel Air, MD, United States.
FAU - Batty, Nicolas
AU  - Batty N
AD  - Indiana University School of Business, Bloomington, IN, United States.
FAU - Festin, Fe Erlita D
AU  - Festin FED
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States; VA
      Boston Healthcare System, Brockton, MA, United States.
FAU - Tahera, Dil
AU  - Tahera D
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States; VA
      Boston Healthcare System, Brockton, MA, United States.
FAU - Chang, Grace
AU  - Chang G
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States; VA
      Boston Healthcare System, Brockton, MA, United States.
FAU - DeLisi, Lynn E
AU  - DeLisi LE
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States;
      Cambridge Health Alliance, Cambridge Hospital, Cambridge, MA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200506
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
SB  - IM
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/26 20:13
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/11/26 20:13 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
AID - S0165-1781(20)31226-9 [pii]
AID - 10.1016/j.psychres.2020.113069 [doi]
PST - aheadofprint
SO  - Psychiatry Res. 2020 May 6;289:113069. doi: 10.1016/j.psychres.2020.113069.


PMID- 33241908
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - Missing Ethical Discussions in Gender Care for Transgender and Non-binary People:
      Secondary Sex Characteristics.
PG  - 741-744
LID - 10.1111/jmwh.13166 [doi]
FAU - Rabelais, Em
AU  - Rabelais E
AUID- ORCID: 0000-0002-1646-4139
AD  - Department of Women, Children, and Family Health Science, College of Nursing,
      University of Illinois at Chicago, Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - Gender Identity
MH  - Humans
MH  - Sex Characteristics
MH  - *Transgender Persons
MH  - *Transsexualism
EDAT- 2020/11/27 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/11/26 08:46
PHST- 2019/11/30 00:00 [received]
PHST- 2020/08/01 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/11/26 08:46 [entrez]
AID - 10.1111/jmwh.13166 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):741-744. doi: 10.1111/jmwh.13166. Epub 
      2020 Nov 26.


PMID- 33241090
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2352-0477 (Print)
IS  - 2352-0477 (Linking)
VI  - 7
DP  - 2020
TI  - Novel multi-linear quantitative brain volume formula for manual radiological
      evaluation of brain atrophy.
PG  - 100281
LID - 10.1016/j.ejro.2020.100281 [doi]
AB  - OBJECTIVES: The brain atrophy commonly occurs in elderly and in some childhood
      conditions making the techniques for quantifying brain volume needful. Since the 
      automated quantitative methods of brain volume assessment have limited
      availability in developing countries, it was the purpose of this study to design 
      and test an alternative formula that is applicable to all healthcare levels.
      METHODS: The multi-linear diagonal brain fraction formula (DBF) was designed from
      dimensions of brain relative to skull and ventricles. To test a developed
      formula, a total of 347 subjects aged between 0 and 18 years who had brain CT
      scans performed recruited and subjected to a systematic measurement of their
      brains in a diagonal brain fashion. RESULTS: Out of 347 patients evaluated, 62
      subjects (17.8 %) were found to be cases of brain atrophy. The three radiological
      measurements which included sulcal width (SW), ventricular width (VW) and Evans
      Index (EI) were concurrently performed. SW and VW showed good age correlation.
      Similar tests were extended to diagonal brain fraction (DBF) and skull vertical
      horizontal ratio (VHR) in which DBF showed significant age correlation.
      CONCLUSIONS: The DBF formula shows significant ability of differentiating changes
      of brain volume suggesting that it can be utilized as an alternative brain
      fraction quantification method bearing technical simplicity in assessing gross
      brain volume. ADVANCES IN KNOWLEDGE: The designed formula is unique in that it
      captures even the possible asymmetrical volume loss of brain through diagonal
      lines. The proposed scores being in term of ratios give four grades of brain
      atrophy.
CI  - (c) 2020 The Authors.
FAU - Sungura, R
AU  - Sungura R
AD  - Department of Health and Biomedical Sciences, School of Life Science and
      Bioengineering, Nelson Mandela-African Institution of Science and Technology,
      Arusha, Tanzania.
FAU - Mpolya, E
AU  - Mpolya E
AD  - Department of Health and Biomedical Sciences, School of Life Science and
      Bioengineering, Nelson Mandela-African Institution of Science and Technology,
      Arusha, Tanzania.
FAU - Spitsbergen, J M
AU  - Spitsbergen JM
AD  - Department of Biological Sciences, Western Michigan University, USA.
FAU - Onyambu, C
AU  - Onyambu C
AD  - Department of Diagnostic and Radiation Medicine, School of Health Sciences,
      University of Nairobi, Kenya.
FAU - Sauli, E
AU  - Sauli E
AD  - Department of Health and Biomedical Sciences, School of Life Science and
      Bioengineering, Nelson Mandela-African Institution of Science and Technology,
      Arusha, Tanzania.
FAU - Vianney, J-M
AU  - Vianney JM
AD  - Department of Health and Biomedical Sciences, School of Life Science and
      Bioengineering, Nelson Mandela-African Institution of Science and Technology,
      Arusha, Tanzania.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - England
TA  - Eur J Radiol Open
JT  - European journal of radiology open
JID - 101650225
PMC - PMC7674282
OTO - NOTNLM
OT  - BIANCA, Brain Intensity Abnormality Classification Algorithm
OT  - BPF, Brain parenchymal fraction
OT  - Brain atrophy
OT  - Brain volume
OT  - CD, Compact disc
OT  - CSF, Cerebral spina fluid
OT  - CT, Computerized tomography
OT  - DBF, Diagonal brain fraction
OT  - DVD, Digital versatile disc
OT  - EI, Evans index
OT  - KNCHREC, Kibong'oto, Nelson Mandela and Cedha Research and Ethical Committee
OT  - MRI, Magnetic resonance imaging
OT  - MTA, medial temporal atrophy
OT  - Neuroimaging
OT  - Quantification
OT  - SW, Sulcal width
OT  - VBM, Volume based morphometry
OT  - VHR, Vertical-horizontal ratio
OT  - VW, Ventricular width
COIS- The authors report no declarations of interest.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:48
PHST- 2020/09/22 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/26 05:48 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.1016/j.ejro.2020.100281 [doi]
AID - S2352-0477(20)30070-8 [pii]
PST - epublish
SO  - Eur J Radiol Open. 2020 Nov 13;7:100281. doi: 10.1016/j.ejro.2020.100281.
      eCollection 2020.


PMID- 33240920
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 2296-861X (Print)
IS  - 2296-861X (Linking)
VI  - 7
DP  - 2020
TI  - Randomized Controlled Lifestyle Intervention (LION) Study for Weight Loss and
      Maintenance in Adults With Obesity-Design and Methods.
PG  - 586985
LID - 10.3389/fnut.2020.586985 [doi]
AB  - Introduction: Due to the increasing prevalence of obesity, approaches for a more 
      effective treatment especially in the long-term perspective are needed. However, 
      studies on weight loss and maintenance show heterogeneous results with large
      inter-individual variations. Therefore, it is of interest to identify factors
      that contribute to inter-individual differences and predict the success of
      long-term weight management. Methods and Analysis: The primary outcome of the
      Lifestyle Intervention (LION) Study is to evaluate the effect of two diets (low
      carb vs. low fat) and two digital counseling tools (newsletter vs. mobile
      application) on weight maintenance 12 months after weight loss. The
      identification of predictive factors (e.g., genetic, epigenetic, physiological,
      psychological) for the success of weight loss and maintenance is a secondary
      outcome. Men and women with a body mass index (BMI) between 30.0 and 39.9
      kg/m(2), aged 18-65 years, and without severe diseases are considered eligible.
      After phenotyping (e.g., anthropometry, resting metabolic rate, meal challenges, 
      blood parameters) participants will follow a formula-based, low-calorie diet
      (LCD) for 8 weeks. In addition, the intake of 200 g raw or cooked non-starchy
      vegetables are allowed per day. Subsequently, 252 participants will be randomized
      into one of the four intervention groups (low carb/app, low carb/newsletter, low 
      fat/app, low fat/newsletter) for the 12-month weight maintenance step. The study 
      will be concluded after another 12 months of follow-up. Results should provide
      indications for successful weight management and give insights into the
      personalized treatment of obesity. Ethics and Dissemination: This study has been 
      granted ethical approval by the local Ethics Review Committee of the School of
      Medicine, Technical University of Munich (vote: 69/19 S). Trial Registration
      Number: This study has been registered within ClinicalTrials.gov (NCT04023942)
      and the German Clinical Trials Register (DRKS00017819).
CI  - Copyright (c) 2020 Reik and Holzapfel.
FAU - Reik, Anna
AU  - Reik A
AD  - Institute for Nutritional Medicine, School of Medicine, University Hospital
      "Klinikum Rechts der Isar", Technical University of Munich, Munich, Germany.
FAU - Holzapfel, Christina
AU  - Holzapfel C
AD  - Institute for Nutritional Medicine, School of Medicine, University Hospital
      "Klinikum Rechts der Isar", Technical University of Munich, Munich, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT04023942
PT  - Journal Article
DEP - 20201110
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC7683381
OTO - NOTNLM
OT  - formula diet
OT  - lifestyle
OT  - low carb
OT  - low fat
OT  - mobile application (app)
OT  - obesity
OT  - personalized nutrition
OT  - weight maintenance
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:48
PHST- 2020/07/24 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/26 05:48 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.3389/fnut.2020.586985 [doi]
PST - epublish
SO  - Front Nutr. 2020 Nov 10;7:586985. doi: 10.3389/fnut.2020.586985. eCollection
      2020.


PMID- 33240763
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210604
IS  - 2198-3844 (Print)
IS  - 2198-3844 (Linking)
VI  - 7
IP  - 22
DP  - 2020 Nov
TI  - Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of
      Animal Validation Studies?
PG  - 2002030
LID - 10.1002/advs.202002030 [doi]
AB  - For the past century, experimental data obtained from animal studies have been
      required by reviewers of scientific articles and grant applications to validate
      the physiological relevance of in vitro results. At the same time, pharmaceutical
      researchers and regulatory agencies recognize that results from preclinical
      animal models frequently fail to predict drug responses in humans. This Progress 
      Report reviews recent advances in human organ-on-a-chip (Organ Chip) microfluidic
      culture technology, both with single Organ Chips and fluidically coupled human
      "Body-on-Chips" platforms, which demonstrate their ability to recapitulate human 
      physiology and disease states, as well as human patient responses to clinically
      relevant drug pharmacokinetic exposures, with higher fidelity than other in vitro
      models or animal studies. These findings raise the question of whether continuing
      to require results of animal testing for publication or grant funding still makes
      scientific or ethical sense, and if more physiologically relevant human Organ
      Chip models might better serve this purpose. This issue is addressed in this
      article in context of the history of the field, and advantages and disadvantages 
      of Organ Chip approaches versus animal models are discussed that should be
      considered by the wider research community.
CI  - (c) 2020 The Authors. Published by Wiley-VCH GmbH.
FAU - Ingber, Donald E
AU  - Ingber DE
AUID- ORCID: https://orcid.org/0000-0002-4319-6520
AD  - Wyss Institute for Biologically Inspired Engineering at Harvard University Boston
      MA 02115 USA.
AD  - Vascular Biology Program, Department of Surgery Boston Children's Hospital and
      Harvard Medical School Boston MA 02115 USA.
AD  - Harvard John A. Paulson School of Engineering and Applied Sciences Cambridge MA
      02138 USA.
LA  - eng
GR  - UH3 HL141797/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201012
PL  - Germany
TA  - Adv Sci (Weinh)
JT  - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
JID - 101664569
PMC - PMC7675190
OTO - NOTNLM
OT  - microfluidics
OT  - microphysiological systems
OT  - organoids
OT  - organ-on-a-chip
OT  - preclinical studies
COIS- The author has the following potential conflicts: Emulate Inc., equity,
      consulting, chair of SAB; BOA Biomedical Inc., equity, consulting, chair of SAB, 
      board member; Free Flow Medical Device, equity; SynDevRx, equity; Consortia Rx,
      equity, board member; Roche, consulting; Astrazeneca, sponsored research; Fulcrum
      Therapeutics, sponsored research; Kraft Heinz, sponsored research; and inventor
      of multiple patent applications.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:47
PHST- 2020/05/29 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/11/26 05:47 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.1002/advs.202002030 [doi]
AID - ADVS2029 [pii]
PST - epublish
SO  - Adv Sci (Weinh). 2020 Oct 12;7(22):2002030. doi: 10.1002/advs.202002030.
      eCollection 2020 Nov.


PMID- 33240726
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 24
TI  - Is Artificial Intelligence the New Friend for Radiologists? A Review Article.
PG  - e11137
LID - 10.7759/cureus.11137 [doi]
AB  - Artificial intelligence (AI) is a path-breaking advancement for many industries, 
      including the health care sector. The expeditious development of information
      technology and data processing has led to the formation of recent tools known as 
      artificial intelligence. Radiology has been a portal for medical technological
      advancements, and AI will likely be no dissimilar. Radiology is the platform for 
      many technological advances in the medical field; AI can undoubtedly impact every
      step of a radiologist's workflow. AI can simplify every activity like ordering
      and scheduling, protocoling and acquisition, image interpretation, reporting,
      communication, and billing. AI has eminent potential to augment efficiency and
      accuracy throughout radiology, but it also possesses inherent drawbacks and
      biases. We collected studies that were published in the past five years using
      PubMed as our database. We chose studies that were relevant to artificial
      intelligence in radiology. We mainly focused on the overview of AI in radiology, 
      components included in the functioning of AI, AI assisting in the radiologists'
      workflow, ethical aspects of AI, challenges, and biases that AI experiencing
      together with some clinical applications of AI. Of all 33 studies, we found 15
      articles discussed the overview and components of AI, five articles about AI
      affecting radiologist's workflow, five articles related to challenges and biases 
      in AI, two articles discussed ethical aspects of AI, and six articles about
      practical implications of AI. We found out that the application of AI could make 
      time-dependent tasks that can be performed effortlessly, permitting radiologists 
      more time and opportunities to engage in patient care via increased time for
      consultation and development in imaging and extracting useful data from those
      images. AI could only be an aid to radiologists but will not replace a
      radiologist. Radiologists who use AI to their benefit, rather than to avoid it
      out of fear, might supersede those radiologists who do not. Substantial research 
      should be done regarding the practical implications of AI algorithms for
      residents curriculum and the benefits of AI in radiology.
CI  - Copyright (c) 2020, Gampala et al.
FAU - Gampala, Sravani
AU  - Gampala S
AD  - Radiology, GSL Medical College, Rajahmundry, IND.
FAU - Vankeshwaram, Varun
AU  - Vankeshwaram V
AD  - Medicine, Zaporozhye State Medical University, Zaporozhye, UKR.
FAU - Gadula, Satya Siva P
AU  - Gadula SSP
AD  - Internal Medicine, GSL Medical College, Rajahmundry, IND.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201024
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7682942
OTO - NOTNLM
OT  - artificial intelligence in radiology
OT  - deep learning
OT  - machine learning
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:47
PHST- 2020/11/26 05:47 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.7759/cureus.11137 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 24;12(10):e11137. doi: 10.7759/cureus.11137.


PMID- 33240556
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2151-4585 (Print)
IS  - 2151-4585 (Linking)
VI  - 11
DP  - 2020
TI  - Using a Wearable Activity Monitor to Accurately Measure Mobility After Surgery
      for Hip Fractures (MASH)-A Feasibility Study Protocol.
PG  - 2151459320964086
LID - 10.1177/2151459320964086 [doi]
AB  - INTRODUCTION: Hip fractures are the most common reason for acute orthopaedic
      admission in the United Kingdom (UK) and pose a substantial cost to the National 
      Health Service (NHS). A significant proportion of this expenditure is accounted
      for by hospital bed days, with additional contributions from health and social
      aftercare. Early ambulation following hip fracture surgery improves outcomes by
      accelerating functional recovery and reducing the need for ongoing care. The
      ability to track a patient's rehabilitation is important in assessing their care 
      needs. While this is challenging to assess accurately, doing so may help to
      further improve outcomes. The aim of this feasibility study is to determine
      whether it is possible to accurately measure Mobility After Surgery for Hip
      fractures (MASH) in the immediate post-operative period by tracking the frequency
      of mobilization, distance walked and overall activity in the first week following
      surgery using a wearable activity monitor, the activPAL device. METHODS AND
      MATERIALS: A total of 50 patients will be recruited to participate in the study. 
      Ethical approval was given to recruit patients with and without capacity to
      consent. Immediately after undergoing hip fracture surgery, a activPAL monitor
      weighing 9 grams and measuring 23.5 mm x 43 x 5 mm in size will be applied to the
      anterior aspect of the participants thigh with a standard adhesive dressing. We
      will be assessing the feasibility of using the activPALto measure mobility in
      this patient group. DISCUSSION: The MASH study will contribute to the design and 
      execution of the MASH trial, which will seek to assess the accuracy by which
      mobility can be measured following hip fracture surgery and how this information 
      can best be used to improve rehabilitation and care.
CI  - (c) The Author(s) 2020.
FAU - Berwin, James T
AU  - Berwin JT
AUID- ORCID: https://orcid.org/0000-0001-9893-5434
AD  - Gloucestershire Royal Hospital, Gloucester, United Kingdom.156721
FAU - Macdonald, Hamish
AU  - Macdonald H
AD  - Gloucestershire Royal Hospital, Gloucester, United Kingdom.156721
FAU - Fleming, Tom
AU  - Fleming T
AD  - Gloucestershire Royal Hospital, Gloucester, United Kingdom.156721
FAU - Kempshall, Peter
AU  - Kempshall P
AD  - Gloucestershire Royal Hospital, Gloucester, United Kingdom.156721
FAU - Engelke, Daniel
AU  - Engelke D
AD  - Gloucestershire Royal Hospital, Gloucester, United Kingdom.156721
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - United States
TA  - Geriatr Orthop Surg Rehabil
JT  - Geriatric orthopaedic surgery & rehabilitation
JID - 101558150
PMC - PMC7672772
OTO - NOTNLM
OT  - fracture
OT  - hip
OT  - outcomes
OT  - rehabilitation
COIS- Declaration of Conflicting Interests: The author(s) declared the following
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Smith & Nephew loaned the use of the activPAL
      devices, but have not influenced study design, data collection, analysis and
      interpretation of data in the writing of this report.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:46
PHST- 2020/01/27 00:00 [received]
PHST- 2020/08/12 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/26 05:46 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.1177/2151459320964086 [doi]
AID - 10.1177_2151459320964086 [pii]
PST - epublish
SO  - Geriatr Orthop Surg Rehabil. 2020 Nov 12;11:2151459320964086. doi:
      10.1177/2151459320964086. eCollection 2020.


PMID- 33240516
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: 
      Guidance From the Canadian Society of Transplantation Pediatric Group.
PG  - 2054358120967845
LID - 10.1177/2054358120967845 [doi]
AB  - PURPOSE OF THE PROGRAM: To provide guidance on the management of pediatric kidney
      transplant patients during the COVID-19 pandemic. SOURCES OF INFORMATION:
      Program-specific documents, preexisting, and related to COVID-19; documents from 
      provincial, national, and international kidney transplant societies/agencies and 
      organ procurement agencies; national and international webinars, including
      webinars that we hosted for input and feedback; with additional information from 
      formal and informal review of published academic literature. METHODS: Challenges 
      in the care of pediatric kidney transplant patients during the COVID-19 pandemic 
      were highlighted within the Canadian Society of Transplantation (CST) Pediatric
      Group. It identified pediatric kidney transplant nephrologists (including a
      pediatric nephrologist ethicist) across the country and formed a workgroup. The
      initial guidance document was drafted and members of the workgroup reviewed and
      discussed all suggestions in detail via e-mail and virtual meetings.
      Disagreements were resolved by consensus. The document was reviewed by the CST
      Kidney Transplant Working Group, by the Canadian Society of Nephrology (CSN)
      COVID-19 Rapid Response Team (RRT), and an infectious disease expert. The
      suggestions were presented at an interactive webinar sponsored by CSN in
      collaboration with the CST and Canadian Association of Pediatric Nephrologists
      (CAPN), and attended by pediatric kidney health care professionals for further
      peer input. Final revisions were made based on feedback received. CJKHD editors
      reviewed the parallel process peer review and edited the manuscript for clarity. 
      KEY FINDINGS: We identified 8 key areas of pediatric kidney transplant care that 
      may be affected by the COVID-19 pandemic: (1) transplant activity, (2) outpatient
      clinic activity, (3) monitoring, (4) multidisciplinary care, (5) medications
      (immunosuppression and others), (6) patient/family education/support, (7) school 
      and employment, and (8) management of pediatric kidney transplant patients who
      are COVID-19 positive. We make specific suggestions for each of these areas.
      LIMITATIONS: A full systematic review of available literature was not undertaken 
      for the sake of expediency in development of this guideline. There is a paucity
      of literature to support evidence-based recommendations at this time. Instead,
      these guidelines were formulated based on expert opinion derived from available
      knowledge/experience and are subject to the biases associated with this level of 
      evidence. The parallel review process that was created to expedite the
      publication of this work may not be as robust as standard arms' length peer
      review processes. IMPLICATIONS: These recommendations are meant to serve as a
      guide to pediatric kidney transplant directors, clinicians, and administrators
      for providing the best patient care in the context of limited resources while
      protecting patients and health care providers wherever possible by limiting
      exposure to COVID-19. We recognize that recommendations may not be applicable to 
      all provincial/local health authority practices and that they may not be
      delivered to all patients given the time and resource constraints affecting the
      individual provincial/local health jurisdiction.
CI  - (c) The Author(s) 2020.
FAU - Teoh, Chia Wei
AU  - Teoh CW
AUID- ORCID: https://orcid.org/0000-0002-5994-0799
AD  - Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.
AD  - Transplant & Regenerative Medicine Centre, The Hospital for Sick Children,
      Toronto, ON, Canada.
AD  - Department of Paediatrics, University of Toronto, ON, Canada.
FAU - Gaudreault-Tremblay, Marie-Michele
AU  - Gaudreault-Tremblay MM
AD  - Division of Nephrology, Montreal Children's Hospital, QC, Canada.
AD  - Department of Paediatrics, McGill University, Montreal, QC, Canada.
FAU - Blydt-Hansen, Tom D
AU  - Blydt-Hansen TD
AD  - Division of Nephrology, BC Children's Hospital, Vancouver, Canada.
AD  - Department of Paediatrics, The University of British Columbia, Vancouver, Canada.
FAU - Goldberg, Aviva
AU  - Goldberg A
AD  - Division of Nephrology, The Children's Hospital of Winnipeg, MB, Canada.
AD  - Department of Paediatrics and Child Health, University of Manitoba, Winnipeg,
      Canada.
FAU - Arora, Steven
AU  - Arora S
AD  - Division of Nephrology, McMaster Children's Hospital, Hamilton, ON, Canada.
AD  - Department of Paediatrics, McMaster University, Hamilton, ON, Canada.
FAU - Feber, Janusz
AU  - Feber J
AUID- ORCID: https://orcid.org/0000-0002-3687-6691
AD  - Division of Nephrology, Children's Hospital of Eastern Ontario, Ottawa, Canada.
AD  - Department of Paediatrics, University of Ottawa, ON, Canada.
FAU - Langlois, Valerie
AU  - Langlois V
AD  - Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.
AD  - Transplant & Regenerative Medicine Centre, The Hospital for Sick Children,
      Toronto, ON, Canada.
AD  - Department of Paediatrics, University of Toronto, ON, Canada.
FAU - Ruhl, Michelle
AU  - Ruhl M
AD  - Division of Nephrology, Jim Pattison Children's Hospital, Saskatoon, SK, Canada.
AD  - Department of Paediatrics, University of Saskatchewan, Saskatoon, Canada.
FAU - Phan, Veronique
AU  - Phan V
AD  - Division of Nephrology, CHU Sainte-Justine, Montreal, QC, Canada.
AD  - Department of Paediatrics, University de Montreal, QC, Canada.
FAU - Morgan, Catherine
AU  - Morgan C
AD  - Division of Nephrology, Stollery Children's Hospital, Edmonton, AB, Canada.
AD  - Department of Paediatrics, University of Alberta, Edmonton, Canada.
FAU - Acott, Philip
AU  - Acott P
AD  - Division of Nephrology, IWK Health Centre, Halifax, NS, Canada.
AD  - Department of Paediatrics, Dalhousie University, Halifax, NS, Canada.
FAU - Hamiwka, Lorraine
AU  - Hamiwka L
AD  - Division of Nephrology, Alberta Children's Hospital, Calgary, Canada.
AD  - Department of Paediatrics, University of Calgary, AB, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
CIN - Transplantation. 2021 Jul 1;105(7):e74-e75. PMID: 33795595
PMC - PMC7672730
OTO - NOTNLM
OT  - kidney transplantation
OT  - pediatric
OT  - pediatric kidney transplant
OT  - pediatric nephrology
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:46
PHST- 2020/09/24 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/11/26 05:46 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.1177/2054358120967845 [doi]
AID - 10.1177_2054358120967845 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Nov 13;7:2054358120967845. doi:
      10.1177/2054358120967845. eCollection 2020.


PMID- 33240510
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 2050-3369 (Print)
IS  - 2050-3369 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Nov
TI  - Big Data and Artificial Intelligence: Opportunities and Threats in
      Electrophysiology.
PG  - 146-154
LID - 10.15420/aer.2020.26 [doi]
AB  - The combination of big data and artificial intelligence (AI) is having an
      increasing impact on the field of electrophysiology. Algorithms are created to
      improve the automated diagnosis of clinical ECGs or ambulatory rhythm devices.
      Furthermore, the use of AI during invasive electrophysiological studies or
      combining several diagnostic modalities into AI algorithms to aid diagnostics are
      being investigated. However, the clinical performance and applicability of
      created algorithms are yet unknown. In this narrative review, opportunities and
      threats of AI in the field of electrophysiology are described, mainly focusing on
      ECGs. Current opportunities are discussed with their potential clinical benefits 
      as well as the challenges. Challenges in data acquisition, model performance,
      (external) validity, clinical implementation, algorithm interpretation as well as
      the ethical aspects of AI research are discussed. This article aims to guide
      clinicians in the evaluation of new AI applications for electrophysiology before 
      their clinical implementation.
CI  - Copyright (c) 2020, Radcliffe Cardiology.
FAU - van de Leur, Rutger R
AU  - van de Leur RR
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Boonstra, Machteld J
AU  - Boonstra MJ
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Bagheri, Ayoub
AU  - Bagheri A
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
AD  - Department of Methodology and Statistics, Utrecht University, Utrecht, the
      Netherlands.
FAU - Roudijk, Rob W
AU  - Roudijk RW
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
AD  - Netherlands Heart Institute, Utrecht, the Netherlands.
FAU - Sammani, Arjan
AU  - Sammani A
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Taha, Karim
AU  - Taha K
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
AD  - Netherlands Heart Institute, Utrecht, the Netherlands.
FAU - Doevendans, Pieter Afm
AU  - Doevendans PA
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
AD  - Netherlands Heart Institute, Utrecht, the Netherlands.
AD  - Central Military Hospital Utrecht, Ministerie van Defensie, Utrecht, the
      Netherlands.
FAU - van der Harst, Pim
AU  - van der Harst P
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - van Dam, Peter M
AU  - van Dam PM
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Hassink, Rutger J
AU  - Hassink RJ
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - van Es, Rene
AU  - van Es R
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Asselbergs, Folkert W
AU  - Asselbergs FW
AD  - Department of Cardiology, Division of Heart and Lungs, University Medical Center 
      Utrecht, Utrecht University, Utrecht, the Netherlands.
AD  - Institute of Cardiovascular Science, Faculty of Population Health Sciences,
      University College London, London, UK.
AD  - Health Data Research UK and Institute of Health Informatics, University College
      London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Arrhythm Electrophysiol Rev
JT  - Arrhythmia & electrophysiology review
JID - 101637930
PMC - PMC7675143
OTO - NOTNLM
OT  - Artificial intelligence
OT  - ECG
OT  - big data
OT  - cardiology
OT  - deep learning
OT  - electrophysiology
OT  - neural networks
COIS- Disclosure: The authors have no conflicts of interest to declare. Funding: This
      study was partly supported by The Netherlands Organisation for Health Research
      and Development (ZonMw, grant number 104021004) and partly supported by the
      Netherlands Cardiovascular Research Initiative, an initiative with support of the
      Dutch Heart Foundation (grant numbers CVON2015-12 eDETECT and QRS-VISION
      2018B007). FWA is supported by UCL Hospitals NIHR Biomedical Research Center. AS 
      is supported by the UMC Utrecht Alexandre Suerman MD/PhD programme.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:46
PHST- 2020/11/26 05:46 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.15420/aer.2020.26 [doi]
PST - ppublish
SO  - Arrhythm Electrophysiol Rev. 2020 Nov;9(3):146-154. doi: 10.15420/aer.2020.26.


PMID- 33240180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Effectiveness of Expressive Writing in the Reduction of Psychological Distress
      During the COVID-19 Pandemic: A Randomized Controlled Trial.
PG  - 587282
LID - 10.3389/fpsyg.2020.587282 [doi]
AB  - OBJECTIVE: Due to the wide impact of the COVID-19 pandemic on mental health, the 
      need for scalable interventions that can effectively reduce psychological
      distress has been recognized. Expressive writing (EW) can be beneficial for
      different conditions, including depression, suicidal ideation, and coping with
      trauma. Therefore, we aim to assess the applicability and effectiveness of an
      online format of EW in the reduction of psychological distress in context of the 
      COVID-19 pandemic. METHODS: In this parallel-group, randomized controlled trial, 
      participants (n = 120) were randomly allocated to (1) the intervention group-who 
      completed five EW sessions over the 2 week period-or (2) the control group-who
      received treatment as usual (TAU). Participants were assessed for primary and
      secondary outcome measures at baseline, post-treatment, and follow-up-1-month
      after the treatment. The primary outcome was severity of psychological distress
      assessed at post-treatment, operationalized as Depression Anxiety Stress Scale
      (DASS) summary score. Secondary outcomes were severity of depression, anxiety,
      and stress (DASS subscale scores), well-being (WHO-5), subjective perception of
      quality of life (SQOL), and subjective evaluation of difficulties coping with
      pandemic, which were also assessed at post-treatment. Per protocol, analysis was 
      conducted with available cases only. RESULTS: A less favorable outcome was found 
      in the intervention group on psychological distress, and symptoms of stress,
      after controlling for baseline scores. Increased stress was recorded in the
      treatment group, with no effect in the control group. There was no significant
      difference between the groups on depression, anxiety, well-being, and subjective 
      quality of life. No group effect for any of the outcomes measures was recorded at
      follow-up. Additional analysis revealed moderation effects of age and gender with
      older and male participants scoring higher on distress measures. CONCLUSION:
      Engaging in EW during the pandemic was found to elevate stress; thus, when
      applied in the context of the COVID-19 pandemic, it may be harmful. Hence, EW or 
      similar self-guided interventions should not be applied without prior evidence on
      their effects in the context of a pandemic and similar stressful and
      unpredictable circumstances. CLINICAL TRIAL REGISTRATION: This study is approved 
      by the Institutional Ethics Committee (Protocol number #2020-20), and a trial has
      been registered at ISRCTN registry https://www.isrctn.com/ISRCTN17898730.
CI  - Copyright (c) 2020 Vukcevic Markovic, Bjekic and Priebe.
FAU - Vukcevic Markovic, Masa
AU  - Vukcevic Markovic M
AD  - Department of Psychology, Faculty of Philosophy, University of Belgrade,
      Belgrade, Serbia.
AD  - Psychosocial Innovation Network (PIN), Belgrade, Serbia.
FAU - Bjekic, Jovana
AU  - Bjekic J
AD  - Psychosocial Innovation Network (PIN), Belgrade, Serbia.
AD  - Institute for Medical Research, University of Belgrade, Belgrade, Serbia.
FAU - Priebe, Stefan
AU  - Priebe S
AD  - Unit for Social and Community Psychiatry (World Health Organization Collaborating
      Centre for Mental Health Services Development), Queen Mary University of London, 
      London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7683413
OTO - NOTNLM
OT  - anxiety
OT  - depression
OT  - expressive writing
OT  - mental health intervention (MeSH)
OT  - online intervention
OT  - psychological distress
OT  - stress
OT  - well-being
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:45
PHST- 2020/07/25 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/26 05:45 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.3389/fpsyg.2020.587282 [doi]
PST - epublish
SO  - Front Psychol. 2020 Nov 10;11:587282. doi: 10.3389/fpsyg.2020.587282. eCollection
      2020.


PMID- 33240171
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Ethical Leadership and Knowledge Sharing: The Impacts of Prosocial Motivation and
      Two Facets of Conscientiousness.
PG  - 581236
LID - 10.3389/fpsyg.2020.581236 [doi]
AB  - This study adopts the social learning theory to explain how and when ethical
      leadership can predict knowledge sharing in the context of Chinese higher
      education. We collected two-wave data from 302 postgraduate students from 38
      scientific research teams in Chinese universities. The results of this study show
      that ethical leadership has a direct and positive effect on knowledge sharing,
      and prosocial motivation fully mediates this relationship. Moreover, the boundary
      conditions for such effects have affirmed the positive effects of dutifulness and
      the adverse effects of achievement-striving on the relationship between prosocial
      motivation and knowledge sharing. The indirect effects of ethical leadership on
      knowledge sharing are stronger when dutifulness is high and achievement-striving 
      is low. Several theoretical and practical implications are provided by this
      study. It suggests that the role of prosocial motivation, in tandem with the two 
      facets of conscientiousness, deserves to be highlighted when studying knowledge
      sharing behavior in correlation with ethical leadership.
CI  - Copyright (c) 2020 Xia and Yang.
FAU - Xia, Zhichen
AU  - Xia Z
AD  - Normal College, Changshu Institute of Technology, Changshu, China.
FAU - Yang, Fan
AU  - Yang F
AD  - School of Education, Soochow University, Suzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7680888
OTO - NOTNLM
OT  - achievement-striving
OT  - dutifulness
OT  - ethical leadership
OT  - knowledge sharing
OT  - prosocial motivation
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:45
PHST- 2020/07/08 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/11/26 05:45 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.3389/fpsyg.2020.581236 [doi]
PST - epublish
SO  - Front Psychol. 2020 Nov 9;11:581236. doi: 10.3389/fpsyg.2020.581236. eCollection 
      2020.


PMID- 33240143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Going Beyond the Catch-22 of Autism Diagnosis and Research. The Moral
      Implications of (Not) Asking "What Is Autism?"
PG  - 529193
LID - 10.3389/fpsyg.2020.529193 [doi]
AB  - Psychiatric diagnoses such as Autism Spectrum Disorder (ASD) are primarily
      attributed on the basis of behavioral criteria. The aim of most of the biomedical
      research on ASD is to uncover the underlying mechanisms that lead to or even
      cause pathological behavior. However, in the philosophical and sociological
      literature, it has been suggested that autism is also to some extent a 'social
      construct' that cannot merely be reduced to its biological explanation. We show
      that a one-sided adherence to either a biological or a social explanation leads
      to a moral dilemma, a Catch-22, for autistics and for those living with them.
      Such explanations close the space for self-identifying as autistic and at the
      same time being considered to be in good mental health. They foreclose the
      possibility of making sense of the lived experience of (and with) autistics. In
      this paper we argue that such lack of space for moral imagination inherently
      leads to scientific stalemate. We propose that one can only go beyond this
      stalemate by taking an ethical stance in theorizing, one that enables better
      intersubjective understanding. Only on such a view can behavior and biology be
      linked without either disconnecting them or reducing the one to the other.
CI  - Copyright (c) 2020 Bervoets and Hens.
FAU - Bervoets, Jo
AU  - Bervoets J
AD  - NeuroEpigenEthics, Department of Philosophy, University of Antwerp, Antwerp,
      Belgium.
AD  - Brain and Cognition Unit, Department of Psychology, Katholieke Universiteit
      Leuven, Leuven, Belgium.
AD  - Leuven Autism Research Unit, Department of Health Sciences, Katholieke
      Universiteit Leuven, Leuven, Belgium.
FAU - Hens, Kristien
AU  - Hens K
AD  - NeuroEpigenEthics, Department of Philosophy, University of Antwerp, Antwerp,
      Belgium.
AD  - Leuven Autism Research Unit, Department of Health Sciences, Katholieke
      Universiteit Leuven, Leuven, Belgium.
AD  - Centre for Logic and Philosophy of Science, Higher Institute of Philosophy,
      Katholieke Universiteit Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7683513
OTO - NOTNLM
OT  - ASC
OT  - ASD
OT  - anomalous monism
OT  - autism
OT  - ethics
OT  - interdisciplinarity
OT  - neurodiversity
OT  - psychiatry
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 05:44
PHST- 2020/01/23 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/26 05:44 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - 10.3389/fpsyg.2020.529193 [doi]
PST - epublish
SO  - Front Psychol. 2020 Nov 10;11:529193. doi: 10.3389/fpsyg.2020.529193. eCollection
      2020.


PMID- 33239471
OWN - NLM
STAT- Publisher
LR  - 20210615
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 25
TI  - Trust does not need to be human: it is possible to trust medical AI.
LID - medethics-2020-106922 [pii]
LID - 10.1136/medethics-2020-106922 [doi]
AB  - In his recent article 'Limits of trust in medical AI,' Hatherley argues that, if 
      we believe that the motivations that are usually recognised as relevant for
      interpersonal trust have to be applied to interactions between humans and medical
      artificial intelligence, then these systems do not appear to be the appropriate
      objects of trust. In this response, we argue that it is possible to discuss trust
      in medical artificial intelligence (AI), if one refrains from simply assuming
      that trust describes human-human interactions. To do so, we consider an account
      of trust that distinguishes trust from reliance in a way that is compatible with 
      trusting non-human agents. In this account, to trust a medical AI is to rely on
      it with little monitoring and control of the elements that make it trustworthy.
      This attitude does not imply specific properties in the AI system that in fact
      only humans can have. This account of trust is applicable, in particular, to all 
      cases where a physician relies on the medical AI predictions to support his or
      her decision making.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ferrario, Andrea
AU  - Ferrario A
AUID- ORCID: http://orcid.org/0000-0001-9968-9474
AD  - Department of Management, Technology and Economics, ETH Zurich, Zurich,
      Switzerland aferrario@ethz.ch.
FAU - Loi, Michele
AU  - Loi M
AUID- ORCID: http://orcid.org/0000-0002-7053-4724
AD  - Digital Society Initiative (DSI) and Institute of Biomedical Ethics and History
      of Medicine (IBME), University of Zurich, Zurich, Switzerland.
FAU - Vigano, Eleonora
AU  - Vigano E
AUID- ORCID: http://orcid.org/0000-0002-1640-2763
AD  - Digital Society Initiative (DSI) and Institute of Biomedical Ethics and History
      of Medicine (IBME), University of Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8165138
OTO - NOTNLM
OT  - clinical ethics
OT  - information technology
OT  - philosophical ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/26 05:37
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/26 05:37 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
AID - medethics-2020-106922 [pii]
AID - 10.1136/medethics-2020-106922 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 25. pii: medethics-2020-106922. doi:
      10.1136/medethics-2020-106922.


PMID- 33239470
OWN - NLM
STAT- Publisher
LR  - 20201126
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 25
TI  - Cancer Research UK'S obesity campaign in 2018 and 2019: effective health
      promotion or perpetuating the stigmatisation of obesity?
LID - medethics-2020-106192 [pii]
LID - 10.1136/medethics-2020-106192 [doi]
AB  - In 2018 and 2019 Cancer Research UK (CRUK) launched a controversial advertising
      campaign to inform the British public of obesity being a preventable cause of
      cancer. On each occasion the advertisements used were emotive and provoked
      frustration among the British public which was widely vocalised on social media. 
      As well serving to educate the public of this association, the advertisements
      also had the secondary effect of acting as health promotion through social
      marketing, a form of advertising designed to influence behavioural changes. As
      CRUK delivered a public health message through its campaign, the advertisements
      should be held according to the ethical principles which underpin healthcare in
      the UK. This article evaluates whether the advertisements used by CRUK in 2018
      and 2019 fulfilled the ethical principles of beneficence, autonomy,
      non-maleficence and justice. It is found that while providing an important
      message, the oversimplification of obesity as being the result of personal
      decisions ignored the complex aetiology and served to stigmatise the target
      demographic, potentially disengaging them from the message. Additionally, posting
      cancer as the consequence of obesity invokes feelings of fear due to its
      connotations of suffering and premature death. Based on available evidence, the
      use of fear in social marketing does not create sustained behavioural change.
      This essay recommends that CRUK discontinue its use of such strategies in its
      future social marketing endeavours.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Varshney, Natasha
AU  - Varshney N
AD  - Liverpool School of Medicine, University of Liverpool, Liverpool, UK
      hlnvarsh@liv.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - autonomy
OT  - health promotion
OT  - political philosophy
OT  - psychology
COIS- Competing interests: None declared.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/26 05:37
PHST- 2020/03/10 00:00 [received]
PHST- 2020/10/17 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/26 05:37 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
AID - medethics-2020-106192 [pii]
AID - 10.1136/medethics-2020-106192 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 25. pii: medethics-2020-106192. doi:
      10.1136/medethics-2020-106192.


PMID- 33239469
OWN - NLM
STAT- Publisher
LR  - 20201126
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 25
TI  - Problems and development strategies for research ethics committees in China's
      higher education institutions.
LID - medethics-2020-106768 [pii]
LID - 10.1136/medethics-2020-106768 [doi]
AB  - The establishment of research ethics committees (REC) in China's higher education
      institutions (HEI) is lagging far behind western developed countries. This has at
      least partly directly led to anomie in scientific research ethics, as seen in the
      recent controversies involving a proposed human head transplant and gene-edited
      babies. At present, the problems for REC in China's HEI include lack of
      regulation, informal ethics reviews, lack of supervision and insufficient ethics 
      review capacity. To counteract these problems, suggested measures include
      mandatory formation of formal ethics committee, administrative support from HEI, 
      ethics approval letter prior to funding application, formulation of regulations
      and standard operating procedures, selecting and training for members and
      independent consultants, training for secretaries and staff, ethics training for 
      investigators, and learning from the experience of HEI outside of China, such as 
      the USA and Canada. The establishment of REC in China's HEI will greatly enhance 
      the overall quality of ethics reviews in China. In addition to better protecting 
      the rights and welfare of human participants, it is also conducive to maintaining
      the reputation of China's HEI.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Zhou, Jiyin
AU  - Zhou J
AUID- ORCID: http://orcid.org/0000-0003-4313-4191
AD  - Second Affiliated Hospital, Army Medical University, Chongqing, China
      zhoujiyin@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - ethics committees/consultation
OT  - policy guidelines/inst. review boards/review cttes
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/26 05:37
PHST- 2020/08/04 00:00 [received]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/26 05:37 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
AID - medethics-2020-106768 [pii]
AID - 10.1136/medethics-2020-106768 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 25. pii: medethics-2020-106768. doi:
      10.1136/medethics-2020-106768.


PMID- 33239106
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 25
TI  - Impact of a package of diagnostic tools, clinical algorithm, and training and
      communication on outpatient acute fever case management in low- and middle-income
      countries: protocol for a randomized controlled trial.
PG  - 974
LID - 10.1186/s13063-020-04897-9 [doi]
AB  - BACKGROUND: The management of acute febrile illnesses places a heavy burden on
      clinical services in many low- and middle-income countries (LMICs). Bacterial and
      viral aetiologies of acute fevers are often clinically indistinguishable and, in 
      the absence of diagnostic tests, the 'just-in-case' use of antibiotics by many
      health workers has become common practice, which has an impact on drug-resistant 
      infections. Our study aims to answer the following question: in patients with
      undifferentiated febrile illness presenting to outpatient clinics/peripheral
      health centres in LMICs, can we demonstrate an improvement in clinical outcomes
      and reduce unnecessary antibiotic prescription over current practice by using a
      combination of simple, accurate diagnostic tests, clinical algorithms, and
      training and communication (intervention package)? METHODS: We designed a
      randomized, controlled clinical trial to evaluate the impact of our intervention 
      package on clinical outcomes and antibiotic prescription rates in acute febrile
      illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific 
      (host markers), rapid diagnostic tests (RDTs) included in the intervention
      package were selected based on pre-defined criteria. Nine clinical study sites in
      six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which
      represent heterogeneous outpatient care settings, were selected. We considered
      the expected seasonal variations in the incidence of acute febrile illnesses
      across all the sites by ensuring a recruitment period of 12 months. A master
      protocol was developed and adapted for country-specific ethical submissions.
      Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies
      of acute febrile illnesses in each country. We included a qualitative evaluation 
      of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for 
      acute febrile illnesses. Sample size estimations were based on historical site
      data of antibiotic prescription practices for malarial and non-malarial acute
      fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876
      patients and an aggregate data meta-analysis will be conducted on completion.
      DISCUSSION: This study is expected to generate vital evidence needed to inform
      policy decisions on the role of rapid diagnostic tests in the clinical management
      of acute febrile illnesses, with a view to controlling the rise of antimicrobial 
      resistance in LMICs. TRIAL REGISTRATION: Clinicaltrials.gov NCT04081051 .
      Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019.
FAU - Salami, Olawale
AU  - Salami O
AUID- ORCID: http://orcid.org/0000-0001-9186-8160
AD  - Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines
      9, 1202, Geneva, Switzerland.
FAU - Horgan, Philip
AU  - Horgan P
AD  - Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
FAU - Moore, Catrin E
AU  - Moore CE
AD  - Big Data Institute, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
FAU - Giri, Abhishek
AU  - Giri A
AD  - Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur,
      Nepal.
FAU - Sserwanga, Asadu
AU  - Sserwanga A
AD  - Infectious Diseases Research Collaboration (IDRC), Nakasero Hill Rd, Kampala,
      Uganda.
FAU - Pathak, Ashish
AU  - Pathak A
AD  - RD Gardi Medical College, Ujjain, Madhya Pradesh, 456001, India.
FAU - Basnyat, Buddha
AU  - Basnyat B
AD  - Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur,
      Nepal.
FAU - Kiemde, Francois
AU  - Kiemde F
AD  - Institut de Recherche en Sciences de la Sante Clinical Research Unit of Nanoro
      (IRSS-URCN), Nanoro, Burkina Faso.
FAU - Smithuis, Frank
AU  - Smithuis F
AD  - Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar.
FAU - Kitutu, Freddy
AU  - Kitutu F
AD  - Department of Pharmacy, School of Health Sciences, Makerere University, Kampala, 
      Uganda.
FAU - Phutke, Gajanan
AU  - Phutke G
AD  - Jan Swasthya Sahyog, Ganiyari, India.
FAU - Tinto, Halidou
AU  - Tinto H
AD  - Institut de Recherche en Sciences de la Sante Clinical Research Unit of Nanoro
      (IRSS-URCN), Nanoro, Burkina Faso.
FAU - Hopkins, Heidi
AU  - Hopkins H
AD  - London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London,
      WC1E 7HT, UK.
FAU - Kapisi, James
AU  - Kapisi J
AD  - Infectious Diseases Research Collaboration (IDRC), Nakasero Hill Rd, Kampala,
      Uganda.
FAU - Swe, Myo Maung Maung
AU  - Swe MMM
AD  - Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar.
FAU - Taneja, Neelam
AU  - Taneja N
AD  - Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh,
      India.
FAU - Baiden, Rita
AU  - Baiden R
AD  - Dodowa Health Research Centre, P.O. Box DD1, Dodowa, Ghana.
FAU - Dutta, Shanta
AU  - Dutta S
AD  - National Institute of Cholera and Enteric Diseases (NICED), Kolkata, India.
FAU - Compaore, Adelaide
AU  - Compaore A
AD  - London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London,
      WC1E 7HT, UK.
FAU - Kaawa-Mafigiri, David
AU  - Kaawa-Mafigiri D
AD  - School of Social Sciences, Makerere University, Kampala, Uganda.
FAU - Hussein, Rashida
AU  - Hussein R
AD  - Myanmar Oxford Clinical Research Unit (MOCRU), Yangon, Myanmar.
FAU - Shakya, Summita Udas
AU  - Shakya SU
AD  - Oxford University Clinical Research Unit (OUCRU-Nepal), Patan Hospital, Lalitpur,
      Nepal.
FAU - Kukula, Vida
AU  - Kukula V
AD  - Dodowa Health Research Centre, P.O.Box DD1, Dodowa, Ghana.
FAU - Ongarello, Stefano
AU  - Ongarello S
AD  - Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines
      9, 1202, Geneva, Switzerland.
FAU - Tomar, Anjana
AU  - Tomar A
AD  - FIND India, 9th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi, 110001,
      India.
FAU - Chadha, Sarabjit S
AU  - Chadha SS
AD  - FIND India, 9th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi, 110001,
      India.
FAU - Walia, Kamini
AU  - Walia K
AD  - Indian Council of Medical Research, Division of Epidemiology and Communicable
      Diseases, Indian Council of Medical Research, Ansari Nagar, New Delhi, 110029,
      India.
FAU - Kelly-Cirino, Cassandra
AU  - Kelly-Cirino C
AD  - Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines
      9, 1202, Geneva, Switzerland.
FAU - Olliaro, Piero
AU  - Olliaro P
AD  - Foundation for Innovative New Diagnostics (FIND) Campus Biotech, Chemin des Mines
      9, 1202, Geneva, Switzerland. piero.olliaro@finddx.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT04081051
GR  - 810571721/Swiss Agency for Development and Cooperation, Global Health Division
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Algorithms
MH  - Burkina Faso
MH  - *Case Management
MH  - Communication
MH  - Delivery of Health Care/*methods
MH  - *Developing Countries
MH  - Fever/diagnosis/*therapy
MH  - Ghana
MH  - Humans
MH  - India
MH  - Meta-Analysis as Topic
MH  - Myanmar
MH  - Nepal
MH  - Outpatients
MH  - Randomized Controlled Trials as Topic
MH  - Uganda
PMC - PMC7687811
OTO - NOTNLM
OT  - Antibiotic prescription
OT  - Antimicrobial resistance
OT  - Febrile illness
OT  - Outpatient fever management
OT  - Randomized controlled trial
EDAT- 2020/11/27 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/11/26 05:31
PHST- 2020/08/04 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/26 05:31 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
AID - 10.1186/s13063-020-04897-9 [doi]
AID - 10.1186/s13063-020-04897-9 [pii]
PST - epublish
SO  - Trials. 2020 Nov 25;21(1):974. doi: 10.1186/s13063-020-04897-9.


PMID- 33239089
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Nov 25
TI  - From strict moral standards to ethical neutrality: a policy-guided shift in the
      patentability of human embryonic stem cells in China.
PG  - 499
LID - 10.1186/s13287-020-02013-x [doi]
AB  - Attitudes towards human embryonic stem cells (hESCs) in China have witnessed a
      significant shift in 2020 that can be attributed to China's policy guidance. For 
      ethical reasons, stricter standards are adopted to curb related regulations and
      patent licensing. Through the introduction of policies, some research on hESCs
      has been recognized as legitimate and feasible to a certain standard and scope.
      In the subsequent practice of patent examination, the dual influence of policy
      support and public interest has led to a shift in the examination standards of
      China's intellectual property authority from "strict morality" to "ethical
      neutrality", implying limited recognition of hESCs' patentability. In view of the
      promotion of policy incentives for the transformation and application of
      corresponding research, there is considerable social demand to provide patent
      protection for research results. In this context, an adjustment of related
      regulations is illustrated in this revision, manifesting a partial shift in
      regulations towards a supportive stance consistent with policy.
FAU - Xie, Xuekai
AU  - Xie X
AD  - School of Law, East China University of Science and Technology, 130 Meilong Road,
      Xuhui District, Shanghai, China.
FAU - Chen, Jiajv
AU  - Chen J
AUID- ORCID: 0000-0003-4990-4302
AD  - School of Law, Zhejiang University of Finance & Economics, Hangzhou, 18 Xueyuan
      Street, Jianggan District, Hangzhou, Zhejiang, China. yzchenjiajv@163.com.
FAU - Shu, Zhengyang
AU  - Shu Z
AD  - School of Law, Zhejiang University of Finance & Economics, Hangzhou, 18 Xueyuan
      Street, Jianggan District, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - China
MH  - *Ethics, Medical
MH  - *Human Embryonic Stem Cells
MH  - Humans
MH  - *Morals
MH  - Policy
MH  - Reference Standards
PMC - PMC7687789
OTO - NOTNLM
OT  - *Ethics
OT  - *Human embryonic stem cells (hESCs)
OT  - *Patentability
OT  - *Policy
EDAT- 2020/11/27 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/11/26 05:31
PHST- 2020/07/20 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/26 05:31 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - 10.1186/s13287-020-02013-x [doi]
AID - 10.1186/s13287-020-02013-x [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Nov 25;11(1):499. doi: 10.1186/s13287-020-02013-x.


PMID- 33239071
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Nov 25
TI  - Age over 65 years and high levels of C-reactive protein are associated with the
      risk of preoperative deep vein thrombosis following closed distal femur
      fractures: a prospective cohort study.
PG  - 559
LID - 10.1186/s13018-020-02089-4 [doi]
AB  - BACKGROUND: In this study, we investigated the epidemiological characteristics
      and predictors of preoperative new-onset deep vein thrombosis (DVT) in adult
      patients with closed distal femur fractures (DFFs). METHODS: The study was
      designed as a prospective cohort trial at the Third Hospital of Hebei Medical
      University. From October 2018 to June 2020, a total of 160 patients with closed
      DFFs were enrolled to assess the location and prognosis of preoperative DVT. The 
      patients were followed up for 2 months. Duplex ultrasonography (DUS) was used to 
      diagnose patients with DVT. The patients were divided into two groups (DVT group 
      and non-DVT group). The DVT was then classified into proximal, distal, and mixed 
      thromboses. The Mann-Whitney U test or t test, receiver operating characteristic 
      (ROC) analyses, univariate Chi-square analyses, and multiple logistic regression 
      analyses were used to analyze the adjusted predictors of DVT. RESULTS: The
      overall incidence of preoperative DVTs was 52.5% (n = 84), which was diagnosed at
      a mean period of 3.1 days after injury. Among patients diagnosed with DVTs, 50.0%
      (n = 42) had distal thrombosis while 47.6% (n = 40) had mixed thrombosis. The
      calf muscle veins were the most common sites of DVTs (90.5%, n = 76). Of note,
      45.2% (n = 38) of diagnosed DVTs were completely recanalized at a mean period of 
      12.0 days after the initial (first) diagnosis. Multivariate analysis revealed
      that age of >/= 65 years of age (odds ratio [OR], 4.390; 95% confidence interval 
      [CI] 1.727-11.155; p = 0.002), C-reactive protein (CRP) levels exceeding 11 mg/L 
      (OR 4.158; 95% CI 1.808-11.289; p = 0.001), platelet (PLT) levels over 217 x
      109/L (OR, 2.55; 95% CI 1.07-6.07; p = 0.035), D-dimer levels over 1.0 mg/L (OR
      3.496; 95% CI 1.483-8.237; p = 0.004), and an American Society of
      Anesthesiologists (ASA) score of III-V (OR 2.753; 95% CI 1.216-6.729; p = 0.026) 
      were the independent risk factors of preoperative DVT. CONCLUSIONS: High levels
      of CRP, PLT, D-dimer, ASA, and >/= 65 years of age increase the risk of
      preoperative DVTs in adult patients with closed DFFs. Thus, the prediction of
      preoperative DVTs can significantly be improved by identifying older patients
      over the age of 65, and establishing the biochemical cut-off values of CRP, PLT, 
      ASA, and D-dimer. TRIAL REGISTRATION: No. 2018-026-1, 24 October 2018,
      prospectively registered. This trial was registered prospectively on 24 October
      2018 before the first participant was enrolled. This study protocol conformed to 
      the Declaration of Helsinki and approved by the Institutional Review Board. The
      ethics committee approved the study on the factors of prognosis for patients with
      fractures. Data used in this study were obtained from the patients who underwent 
      orthopedic surgery between October 2018 and June 2020.
FAU - Zhang, Junzhe
AU  - Zhang J
AD  - Department of Orthopaedic Surgery, the Third Hospital of Hebei Medical
      University, No. 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, People's 
      Republic of China.
AD  - Key Laboratory of Biomechanics of Hebei Province, Orthopaedic Research
      Institution of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of
      China.
FAU - Zhao, Kuo
AU  - Zhao K
AD  - Department of Orthopaedic Surgery, the Third Hospital of Hebei Medical
      University, No. 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, People's 
      Republic of China.
AD  - Key Laboratory of Biomechanics of Hebei Province, Orthopaedic Research
      Institution of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of
      China.
FAU - Li, Junyong
AU  - Li J
AD  - Department of Orthopaedic Surgery, the Third Hospital of Hebei Medical
      University, No. 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, People's 
      Republic of China.
AD  - Key Laboratory of Biomechanics of Hebei Province, Orthopaedic Research
      Institution of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of
      China.
AD  - Department of Orthopedic Surgery, the Second Hospital of Shijiazhuang City,
      Shijiazhuang, Hebei Province, People's Republic of China.
FAU - Meng, Hongyu
AU  - Meng H
AD  - Department of Orthopaedic Surgery, the Third Hospital of Hebei Medical
      University, No. 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, People's 
      Republic of China.
AD  - Key Laboratory of Biomechanics of Hebei Province, Orthopaedic Research
      Institution of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of
      China.
FAU - Zhu, Yanbin
AU  - Zhu Y
AD  - Department of Orthopaedic Surgery, the Third Hospital of Hebei Medical
      University, No. 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, People's 
      Republic of China.
AD  - Key Laboratory of Biomechanics of Hebei Province, Orthopaedic Research
      Institution of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of
      China.
FAU - Zhang, Yingze
AU  - Zhang Y
AUID- ORCID: http://orcid.org/0000-0003-2874-897X
AD  - Department of Orthopaedic Surgery, the Third Hospital of Hebei Medical
      University, No. 139 Ziqiang Road, Shijiazhuang, 050051, Hebei Province, People's 
      Republic of China. dr_yzzhang@126.com.
AD  - Key Laboratory of Biomechanics of Hebei Province, Orthopaedic Research
      Institution of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of
      China. dr_yzzhang@126.com.
LA  - eng
GR  - NSFC 81401789/the National Natural Science Foundation of China
GR  - CXZZBS2020123/the Innovation Project for Postgraduates of Hebei Province
      Education Department
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - *C-Reactive Protein
MH  - Closed Fracture Reduction/*methods
MH  - Female
MH  - Femoral Fractures/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/diagnosis/*etiology
MH  - Predictive Value of Tests
MH  - Preoperative Period
MH  - Prospective Studies
MH  - Risk
MH  - Venous Thrombosis/diagnosis/*etiology
PMC - PMC7687830
OTO - NOTNLM
OT  - C-reactive protein
OT  - Deep vein thrombosis
OT  - Distal femoral fracture
OT  - Old age
OT  - Predictor
EDAT- 2020/11/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/26 05:30
PHST- 2020/10/13 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/11/26 05:30 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13018-020-02089-4 [doi]
AID - 10.1186/s13018-020-02089-4 [pii]
PST - epublish
SO  - J Orthop Surg Res. 2020 Nov 25;15(1):559. doi: 10.1186/s13018-020-02089-4.


PMID- 33239025
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 25
TI  - An effective frequency-domain feature of atrial fibrillation based on
      time-frequency analysis.
PG  - 308
LID - 10.1186/s12911-020-01337-1 [doi]
AB  - BACKGROUND: Atrial fibrillation is a type of persistent arrhythmia that can lead 
      to serious complications. Therefore, accurate and quick detection of atrial
      fibrillation by surface electrocardiogram has great importance on further
      treatment. The practical electrocardiogram signals contain various interferences 
      in different frequencies, such as myoelectricity interference, power interference
      and so on. Detection speed and accuracy largely depend on the atrial fibrillation
      signal features extracted by the algorithm. But some of the discovered atrial
      fibrillation features are not well distinguishable, resulting in poor
      classification effect. METHODS: This paper proposed a high distinguishable
      frequency feature-the frequency corresponding to the maximum amplitude in the
      frequency spectrum. We used the R-R interval detection method optimized with the 
      mathematical morphology method and combined with the wavelet transform method for
      analysis. According to the two features-the maximum amplitude in the frequency
      spectrum and R-R interval irregular, we could recognize atrial fibrillation
      signals in electrocardiogram signals by decision tree classification algorithm.
      RESULTS: The data used in the experiment come from the MIT-BIH database, which is
      publicly accessible via the web and with ethical approval and consent. Based on
      the input of time-domain and frequency-domain features, we classified sinus
      rhythm signals and AF signals using the decision tree generated by classification
      and regression tree (CART) algorithm. From the confusion matrix, we got the
      accuracy was 98.9%, sensitivity was 97.93% and specificity was 99.63%.
      CONCLUSIONS: The experimental results can prove the validity of the maximum
      amplitude in the frequency spectrum and the practicability and accuracy of the
      detection method, which applied this frequency-domain feature. Through the
      detection method, we obtained good accuracy of classifying sinus rhythm signals
      and atrial fibrillation signals. And the sensitivity and specificity of our
      method were pretty good by comparison with other studies.
FAU - Hu, Yusong
AU  - Hu Y
AD  - College of Information Science and Engineering, Northeastern University,
      Shenyang, Liaoning, China.
FAU - Zhao, Yantao
AU  - Zhao Y
AD  - College of Information Science and Engineering, Northeastern University,
      Shenyang, Liaoning, China.
FAU - Liu, Jihong
AU  - Liu J
AUID- ORCID: 0000-0002-0733-4746
AD  - College of Information Science and Engineering, Northeastern University,
      Shenyang, Liaoning, China. liujihong@ise.neu.edu.cn.
FAU - Pang, Jin
AU  - Pang J
AD  - College of Information Science and Engineering, Northeastern University,
      Shenyang, Liaoning, China.
FAU - Zhang, Chen
AU  - Zhang C
AD  - College of Information Science and Engineering, Northeastern University,
      Shenyang, Liaoning, China.
FAU - Li, Peizhe
AU  - Li P
AD  - College of Information Science and Engineering, Northeastern University,
      Shenyang, Liaoning, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201125
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - Algorithms
MH  - Atrial Fibrillation/*diagnostic imaging
MH  - Databases, Factual
MH  - *Decision Trees
MH  - *Electrocardiography
MH  - Humans
MH  - Sensitivity and Specificity
PMC - PMC7690088
OTO - NOTNLM
OT  - *Atrial fibrillation
OT  - *Decision tree algorithm
OT  - *ECG
OT  - *Frequency-domain feature
OT  - *Time-frequency analysis
EDAT- 2020/11/27 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/11/26 05:30
PHST- 2020/01/16 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/11/26 05:30 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1186/s12911-020-01337-1 [doi]
AID - 10.1186/s12911-020-01337-1 [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Nov 25;20(1):308. doi: 10.1186/s12911-020-01337-1.


PMID- 33238991
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 25
TI  - A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety 
      and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for 
      the treatment of patients with community-acquired bacterial pneumonia admitted to
      the intensive care unit.
PG  - 309
LID - 10.1186/s12890-020-01324-2 [doi]
AB  - BACKGROUND: Community-acquired bacterial pneumonia (CABP) can lead to sepsis and 
      is associated with high mortality rates in patients presenting with shock and/or 
      respiratory failure and who require mechanical ventilation and admission to
      intensive care units, thus reflecting the limited effectiveness of current
      therapy. Preclinical studies support the efficacy of expanded allogeneic
      adipose-derived mesenchymal stem cells (eASCs) in the treatment of sepsis. In
      this study, we aim to test the safety, tolerability and efficacy of eASCs as
      adjunctive therapy in patients with severe CABP (sCABP). METHODS: In addition to 
      standard of care according to local guidelines, we will administer eASCs (Cx611) 
      or placebo intravenously as adjunctive therapy to patients with sCABP. Enrolment 
      is planned for approximately 180 patients who will be randomised to treatment
      groups in a 1:1 ratio according to a pre-defined randomization list. An equal
      number of patients is planned for allocation to each group. Cx611 will be
      administered on Day 1 and on Day 3 at a dose of 160 million cells (2 million
      cells / mL, total volume 80 mL) through a 20-30 min (240 mL/hr) intravenous (IV) 
      central line infusion after dilution with Ringer Lactate solution. Placebo
      (Ringer Lactate) will also be administered through a 20-30 min (240 mL/hr) IV
      central line infusion at the same quantity (total volume of 80 mL) and following 
      the same schedule as the active treatment. The study was initiated in January
      2017 and approved by competent authorities and ethics committees in Belgium,
      Spain, Lithuania, Italy, Norway and France; monitoring will be performed at
      regular intervals. Funding is from the European Union's Horizon 2020 Research and
      Innovation Program. DISCUSSION: SEPCELL is the first trial to assess the effects 
      of eASCs in sCABP. The data generated will advance understanding of the mode of
      action of Cx611 and will provide evidence on the safety, tolerability and
      efficacy of Cx611 in patients with sCABP. These data will be critical for the
      design of future confirmatory clinical investigations and will assist in defining
      endpoints, key biomarkers of interest and sample size determination. TRIAL
      REGISTRATION: NCT03158727 , retrospectively registered on 9 May 2017.
FAU - Laterre, Pierre-Francois
AU  - Laterre PF
AUID- ORCID: https://orcid.org/0000-0001-5712-7449
AD  - Intensive Care Unit, St Luc University Hospital, Universite Catholique de
      Louvain, 10 avenue, 1200, Brussels, Belgium.
      pierre-francois.laterre@uclouvain.be.
FAU - Sanchez-Garcia, Miguel
AU  - Sanchez-Garcia M
AD  - Intensive Care Department, Hospital Clinico San Carlos, Madrid, Spain.
FAU - van der Poll, Tom
AU  - van der Poll T
AUID- ORCID: https://orcid.org/0000-0002-9199-5079
AD  - The Center of Experimental and Molecular Medicine, Amsterdam University Medical
      Center, University of Amsterdam, Amsterdam, the Netherlands.
FAU - de la Rosa, Olga
AU  - de la Rosa O
AD  - Takeda Madrid, Cell Therapy Technology Center, Tres Cantos, Spain.
FAU - Cadogan, Kathy-Ann
AU  - Cadogan KA
AD  - Takeda Pharmaceuticals, Cambridge, MA, USA.
FAU - Lombardo, Eleuterio
AU  - Lombardo E
AD  - Takeda Madrid, Cell Therapy Technology Center, Tres Cantos, Spain.
FAU - Francois, Bruno
AU  - Francois B
AUID- ORCID: https://orcid.org/0000-0002-2531-1652
AD  - Intensive Care Unit, and Inserm CIC1435 & UMR1092, Dupuytren University Hospital,
      Limoges, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03158727
GR  - 681031/Horizon 2020
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
SB  - IM
MH  - Adipose Tissue/*cytology
MH  - Administration, Intravenous
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Community-Acquired Infections/*therapy
MH  - Double-Blind Method
MH  - France
MH  - Humans
MH  - Intensive Care Units
MH  - Mesenchymal Stem Cell Transplantation/adverse effects/*methods
MH  - Multicenter Studies as Topic
MH  - Pneumonia, Bacterial/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Respiration, Artificial
MH  - Severity of Illness Index
MH  - Treatment Outcome
PMC - PMC7686829
OTO - NOTNLM
OT  - Adjunctive therapy
OT  - Clinical trial
OT  - Community acquired bacterial pneumonia
OT  - Mesenchymal stem cells
OT  - Study protocol
EDAT- 2020/11/27 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/11/26 05:29
PHST- 2020/10/06 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/11/26 05:29 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
AID - 10.1186/s12890-020-01324-2 [doi]
AID - 10.1186/s12890-020-01324-2 [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Nov 25;20(1):309. doi: 10.1186/s12890-020-01324-2.


PMID- 33238953
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 25
TI  - The role of antibody expression and their association with bladder cancer
      recurrence: a single-centre prospective clinical-pilot study in 35 patients.
PG  - 187
LID - 10.1186/s12894-020-00759-3 [doi]
AB  - BACKGROUND: Bladder cancer (BC) is the 10th most common cancer in the UK, with
      about 10,000 new cases annually. About 75-85% of BC are non-muscle invasive
      (NMIBC), which is associated with high recurrence and progression rates (50-60%
      within 7-10 years). There are no routine biomarkers currently available for
      identifying BC patients at increased risk of developing recurrence. The focus of 
      this research study was to evaluate antibody expression in BC patients and their 
      association with cancer recurrence. METHODS: 35 patients scheduled for TURBT were
      recruited after written informed consent. Ethical approval for the project was
      granted via IRAS (REC4: 14/WA/0033). Following surgical procedure, tissues were
      preserved in 10% buffered formalin and processed within 24 h in FFPE blocks. 7
      sections (4 microm each) were cut from each block and stained for CD31, Human
      epidermal growth factor receptor-2 (HER-2), S100P, Cyclooxygenase-2 (COX-2),
      VEGFR-3 thrombomodulin and CEACAM-1 using immunohistochemistry. Clinical outcome 
      measures (obtained via cystoscopy) were monitored for up to 6 months following
      surgical procedure. RESULTS: There was significantly increased expression of CD31
      (p < 0.001), HER-2 (p = 0.032), S100P (p < 0.001), COX-2 (p < 0.001), VEGFR-3 (p 
      < 0.001) and decreased expression of thrombomodulin (p = 0.010) and CEACAM-1 (p <
      0.001) in bladder tumours compared to normal bladder tissues. HER-2 expression
      was also significantly associated with cancer grade (p = 0.003), especially
      between grade 1 and grade 2 (p = 0.002) and between grade 1 and grade 3 (p =
      0.004). There was also a significant association between cancer stage and HER-2
      expression (p < 0.001). Although recurrence was significantly associated with
      cancer grade, there was no association with antibody expression. CONCLUSION:
      Findings from the present study may indicate an alternative approach in the
      monitoring and management of patients with BC. It is proposed that by allowing
      urological surgeons access to laboratory markers such as HER-2, Thrombomodulin
      and CD31 (biomarker profile), potentially, in the future, these biomarkers may be
      used in addition to, or in combination with, currently used scoring systems to
      predict cancer recurrence. However, verification and validation of these
      biomarkers are needed using larger cohorts.
FAU - Ella-Tongwiis, Peter
AU  - Ella-Tongwiis P
AD  - North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board
      (BCUHB), Wrexham Maelor Hospital, Wrexham, Wales, UK.
AD  - Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK.
FAU - Lamb, Rebecca May
AU  - Lamb RM
AD  - Department of Biological Sciences, University of Chester, Chester, UK.
FAU - Makanga, Alexander
AU  - Makanga A
AD  - Department of Histopathology, Ysbyty Glan Clwd, Betsi Cadwaladr University Health
      Board (BCUHB), Wrexham, UK.
FAU - Shergill, Iqbal
AU  - Shergill I
AD  - North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board
      (BCUHB), Wrexham Maelor Hospital, Wrexham, Wales, UK.
AD  - Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK.
AD  - Department of Urology, BCUHB Wrexham Maelor Hospital, Wrexham, Wales, UK.
FAU - Hughes, Stephen Fon
AU  - Hughes SF
AUID- ORCID: http://orcid.org/0000-0001-6558-9037
AD  - North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board
      (BCUHB), Wrexham Maelor Hospital, Wrexham, Wales, UK.
      Stephen.hughes6@wales.nhs.uk.
AD  - Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK.
      Stephen.hughes6@wales.nhs.uk.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20201125
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Antibody Formation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*immunology
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Urinary Bladder Neoplasms/*immunology
PMC - PMC7690172
OTO - NOTNLM
OT  - Biomarkers
OT  - Bladder
OT  - Immunohistochemistry
OT  - Recurrence
EDAT- 2020/11/27 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/11/26 05:29
PHST- 2020/08/19 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/11/26 05:29 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
AID - 10.1186/s12894-020-00759-3 [doi]
AID - 10.1186/s12894-020-00759-3 [pii]
PST - epublish
SO  - BMC Urol. 2020 Nov 25;20(1):187. doi: 10.1186/s12894-020-00759-3.


PMID- 33238376
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Dog Welfare, Well-Being and Behavior: Considerations for Selection, Evaluation
      and Suitability for Animal-Assisted Therapy.
LID - E2188 [pii]
LID - 10.3390/ani10112188 [doi]
AB  - Health care and human service providers may include dogs in formal intervention
      settings to positively impact human physical, cognitive and psychosocial domains.
      Dogs working within this context are asked to cope with a multitude of variables 
      including settings, populations, activities, and schedules. In this article, the 
      authors highlight how both the preparation and operation of dogs within
      animal-assisted therapy (AAT) differs from less structured animal-assisted
      activities (AAA) and more exclusive assistance animal work; the authors highlight
      the gaps in our knowledge in this regard, and propose an ethically sound
      framework for pragmatic solutions. This framework also emphasizes the need for
      good dog welfare to safeguard all participants. If dogs are not properly matched 
      to a job or handler, they may be subjected to unnecessary stress, anxiety, and
      miscommunication that can lead to disinterest in the work, overt problematic
      behavioral or health outcomes, or general unsuitability. Such issues can have
      catastrophic outcomes for the AAT. The authors propose standards for best
      practices for selection, humane-based preparation and training, and ongoing
      evaluation to ensure the health, welfare and well-being of dogs working in AAT,
      which will have concomitant benefits for clients and the professionalism of the
      field.
FAU - Winkle, Melissa
AU  - Winkle M
AD  - Center for Human Animal Interventions, Oakland University, Rochester, MI 48309,
      USA.
FAU - Johnson, Amy
AU  - Johnson A
AD  - Center for Human Animal Interventions, Oakland University, Rochester, MI 48309,
      USA.
FAU - Mills, Daniel
AU  - Mills D
AUID- ORCID: 0000-0002-4765-9625
AD  - School of Life Sciences, University of Lincoln, Lincoln, Lincs LN6 7DL, UK.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7700550
OTO - NOTNLM
OT  - behavior
OT  - companion animals
OT  - dogs
OT  - evaluation
OT  - shelter
OT  - training/positive reinforcement training
OT  - welfare
OT  - well-being
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
CRDT- 2020/11/26 01:00
PHST- 2020/10/07 00:00 [received]
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2020/11/26 01:00 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
AID - ani10112188 [pii]
AID - 10.3390/ani10112188 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Nov 23;10(11). pii: ani10112188. doi: 10.3390/ani10112188.


PMID- 33238331
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1975-5937 (Electronic)
IS  - 1975-5937 (Linking)
VI  - 17
DP  - 2020
TI  - Key competencies for Korean nurses in prenatal genetic nursing: experiential
      genetic nursing knowledge, and ethics and law
PG  - 36
LID - 10.3352/jeehp.2020.17.36 [doi]
AB  - PURPOSE: This study aims at determining the competencies of Korean nurses in
      prenatal genetic nursing. METHODS: First, a 3-round Delphi survey was conducted
      to establish prenatal genetic nursing competencies. Second, a prenatal genetic
      nursing education program (PGNEP), incorporating the findings from the Delphi
      survey, was designed. Third, a single group pre- and post-quasi-experimental
      study at a PGNEP workshop was conducted to assess the effectiveness of the
      integration of the competencies into the PGNEP with the measurements of knowledge
      about prenatal genetic testing and nursing (K-PGTN) and information needs about
      prenatal genetic testing and nursing (I-PGTN). Finally, the identified
      competencies were reexamined for their clarity RESULTS: Based on the Delphi
      survey 78 competency components were identified. The components were then
      classified under 10 categories, which were organized under 4 domains. The domain 
      of "experiential genetic nursing knowledge" and the domain of "ethics and law"
      were ranked as the first and the second in significance. The quasi experimental
      study showed that the mean scores in K-PGTN were significantly increased from
      8.19+/-2.67 to 11.25+/-2.51 (P<0.001). The mean scores of "ethics and law" in
      I-PGTN decreased significantly (P=0.023). The headings of 4 categories and 2
      domains were revised. CONCLUSION: This study identified competencies for prenatal
      genetic nursing and nursing education in Korea. There is a need for nursing
      instructors and researchers to improve the competencies of nurses in the
      identified areas. Particular emphasis should be placed on experiential nursing
      knowledge and on ethics and law related to prenatal genetic nursing.
FAU - Shin, Gyeyoung
AU  - Shin G
AD  - College of Nursing, Shinhan University, Dongducheon, Korea
FAU - Jun, Myunghee
AU  - Jun M
AD  - Department of Nursing and Health Studies, University of Wisconsin-Green Bay,
      Green Bay, WI, USA.
FAU - Kim, Hye-Kyung
AU  - Kim HK
AD  - Department of Philosophy, University of Wisconsin-Green Bay, Green Bay, WI, USA.
FAU - Wreen, Michael
AU  - Wreen M
AD  - Department of Philosophy, Marquette University, Milwaukee, WI, USA.
FAU - Kubsch, Sylvia Mimi
AU  - Kubsch SM
AD  - Department of Nursing and Health Studies, University of Wisconsin-Green Bay,
      Green Bay, WI, USA.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - Korea (South)
TA  - J Educ Eval Health Prof
JT  - Journal of educational evaluation for health professions
JID - 101490061
SB  - IM
MH  - Clinical Competence
MH  - Delphi Technique
MH  - *Education, Nursing, Baccalaureate
MH  - Faculty, Nursing
MH  - Humans
MH  - *Nurses
MH  - Republic of Korea
PMC - PMC7847985
OTO - NOTNLM
OT  - *Korea
OT  - *prenatal care
OT  - *Genetics
OT  - *Nursing education
OT  - *Nursing ethics
EDAT- 2020/11/26 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/11/25 20:15
PHST- 2020/10/17 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/11/25 20:15 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - jeehp.2020.17.36 [pii]
AID - 10.3352/jeehp.2020.17.36 [doi]
PST - ppublish
SO  - J Educ Eval Health Prof. 2020;17:36. doi: 10.3352/jeehp.2020.17.36. Epub 2020 Nov
      26.


PMID- 33238029
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 1090-3941 (Print)
IS  - 1090-3941 (Linking)
VI  - 37
DP  - 2020 Nov 28
TI  - A Multicenter Prospective Non-Randomized Study Comparing Ferguson
      Hemorrhoidectomy and Transanal Hemorrhoidal Dearterialization for Prolapsed,
      Nonincarcerated, Reducible Hemorrhoids: A Study Protocol.
PG  - 109-112
AB  - INTRODUCTION: Current evidence suggests that transanal hemorrhoidal
      dearterialization (THD) is associated with less postoperative pain and faster
      recovery than Ferguson hemorrhoidectomy. However, there is some uncertainty
      regarding the durability of the therapeutic effect in terms of recurrent disease.
      Objective and significance: The aim of this study will be to evaluate the outcome
      of THD compared to Ferguson hemorrhoidectomy in terms of recurrence rate at
      1-year follow-up. METHODS: This is a multicenter, parallel-arm, non-randomized
      prospective study comparing Ferguson hemorrhoidectomy and THD in terms of
      recurrence rate at one year. The primary endpoint is recurrence rate at one year 
      defined as prolapsing internal hemorrhoids at physical examination. Secondary
      endpoints include the following postoperative complications: urinary retention,
      constipation (requiring laxative or emergency room visit), dysuria, pruritis ani,
      anal pain, anal stenosis, unhealed wound, fissure, fecal urgency, and flatus or
      stool incontinence. Adults older than 18 years with prolapsed, non-incarcerated, 
      reducible hemorrhoids in at least 3 columns at physical examination will be
      included in one of the study arms: Ferguson hemorrhoidectomy and THD. Surgeons
      with proven expertise in hemorrhoids surgery will enroll patients undergoing
      Ferguson hemorrhoidectomy and THD (not both). Each participating surgeon will
      enroll a maximum of 10 patients. Ethics and Dissemination: This study was
      approved by the Institutional Review Boards of Stony Brook University
      (previously) and New York Medical College (currently), and registered in
      ClinicalTrials.gov (NCT03245086). The findings of the study will be published in 
      a peer-reviewed journal.
FAU - Gachabayov, Mahir
AU  - Gachabayov M
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY.
FAU - Angelos, George
AU  - Angelos G
AD  - Division of Colon and Rectal Surgery, Stony Brook University.
FAU - George, Geena
AU  - George G
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY.
FAU - Kajmolli, Agon
AU  - Kajmolli A
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY.
FAU - McGuirk, Matthew
AU  - McGuirk M
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY.
FAU - Bergamaschi, Roberto
AU  - Bergamaschi R
AD  - Section of Colorectal Surgery, Department of Surgery, Westchester Medical Center,
      New York Medical College, Valhalla, NY.
LA  - eng
SI  - ClinicalTrials.gov/NCT03245086
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Surg Technol Int
JT  - Surgical technology international
JID - 9604509
SB  - IM
MH  - Adult
MH  - *Hemorrhoidectomy
MH  - *Hemorrhoids/surgery
MH  - Humans
MH  - Prospective Studies
MH  - Rectum
MH  - Treatment Outcome
EDAT- 2020/11/26 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/11/25 17:25
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2020/11/25 17:25 [entrez]
AID - sti37/1381 [pii]
PST - ppublish
SO  - Surg Technol Int. 2020 Nov 28;37:109-112.


PMID- 33237927
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Computational simulation to assess patient safety of uncompensated COVID-19
      two-patient ventilator sharing using the Pulse Physiology Engine.
PG  - e0242532
LID - 10.1371/journal.pone.0242532 [doi]
AB  - BACKGROUND: The COVID-19 pandemic is stretching medical resources
      internationally, sometimes creating ventilator shortages that complicate clinical
      and ethical situations. The possibility of needing to ventilate multiple patients
      with a single ventilator raises patient health and safety concerns in addition to
      clinical conditions needing treatment. Wherever ventilators are employed,
      additional tubing and splitting adaptors may be available. Adjustable
      flow-compensating resistance for differences in lung compliance on individual
      limbs may not be readily implementable. By exploring a number and range of
      possible contributing factors using computational simulation without risk of
      patient harm, this paper attempts to define useful bounds for ventilation
      parameters when compensatory resistance in limbs of a shared breathing circuit is
      not possible. This desperate approach to shared ventilation support would be a
      last resort when alternatives have been exhausted. METHODS: A whole-body
      computational physiology model (using lumped parameters) was used to simulate
      each patient being ventilated. The primary model of a single patient with a
      dedicated ventilator was augmented to model two patients sharing a single
      ventilator. In addition to lung mechanics or estimation of CO2 and pH expected
      for set ventilation parameters (considerations of lung physiology alone), full
      physiological simulation provides estimates of additional values for
      oxyhemoglobin saturation, arterial oxygen tension, and other patient parameters. 
      A range of ventilator settings and patient characteristics were simulated for
      paired patients. FINDINGS: To be useful for clinicians, attention has been
      directed to clinically available parameters. These simulations show patient
      outcome during multi-patient ventilation is most closely correlated to lung
      compliance, oxygenation index, oxygen saturation index, and end-tidal carbon
      dioxide of individual patients. The simulated patient outcome metrics were
      satisfactory when the lung compliance difference between two patients was less
      than 12 mL/cmH2O, and the oxygen saturation index difference was less than 2
      mmHg. INTERPRETATION: In resource-limited regions of the world, the COVID-19
      pandemic will result in equipment shortages. While single-patient ventilation is 
      preferable, if that option is unavailable and ventilator sharing using limbs
      without flow resistance compensation is the only available alternative, these
      simulations provide a conceptual framework and guidelines for clinical patient
      selection.
FAU - Webb, Jeffrey B
AU  - Webb JB
AUID- ORCID: 0000-0001-8113-0365
AD  - Kitware, Inc., Carrboro, North Carolina, United States of America.
FAU - Bray, Aaron
AU  - Bray A
AUID- ORCID: 0000-0002-2188-7646
AD  - Kitware, Inc., Carrboro, North Carolina, United States of America.
FAU - Asare, Philip K
AU  - Asare PK
AD  - Electrical and Computer Engineering, Bucknell University, Lewisburg,
      Pennsylvania, United States of America.
FAU - Clipp, Rachel B
AU  - Clipp RB
AUID- ORCID: 0000-0001-6077-978X
AD  - Kitware, Inc., Carrboro, North Carolina, United States of America.
FAU - Mehta, Yatin B
AU  - Mehta YB
AD  - Critical Care Medicine, Geisinger, Danville, Pennsylvania, United States of
      America.
FAU - Penupolu, Sudheer
AU  - Penupolu S
AD  - Critical Care Medicine, Geisinger, Danville, Pennsylvania, United States of
      America.
FAU - Patel, Aalpen A
AU  - Patel AA
AUID- ORCID: 0000-0001-7554-3286
AD  - Department of Radiology and Steele Institute for Health Innovation, Geisinger,
      Danville, Pennsylvania, United States of America.
FAU - Poler, S Mark
AU  - Poler SM
AUID- ORCID: 0000-0002-5130-4739
AD  - Anesthesiology, Geisinger, Danville, Pennsylvania, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 142M471B3J (Carbon Dioxide)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - COVID-19/epidemiology/*prevention & control/virology
MH  - Carbon Dioxide
MH  - *Computer Simulation
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Lung/physiology
MH  - Lung Compliance
MH  - Oxygen
MH  - Pandemics
MH  - *Patient Safety
MH  - Respiration, Artificial/*instrumentation
MH  - Respiratory Mechanics/*physiology
MH  - *SARS-CoV-2
MH  - Tidal Volume/physiology
MH  - Ventilators, Mechanical/*supply & distribution
PMC - PMC7688119
COIS- Kitware Inc provided support in the form of salaries for authors JBW, AB and RBC.
      There are no patents, products in development or marketed products associated
      with this research to declare. This does not alter our adherence to PLOS ONE
      policies on sharing data and materials.
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 17:25
PHST- 2020/06/03 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/25 17:25 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1371/journal.pone.0242532 [doi]
AID - PONE-D-20-16650 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 25;15(11):e0242532. doi: 10.1371/journal.pone.0242532.
      eCollection 2020.


PMID- 33237895
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201218
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 69
IP  - 47
DP  - 2020 Nov 27
TI  - The Advisory Committee on Immunization Practices' Ethical Principles for
      Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
PG  - 1782-1786
LID - 10.15585/mmwr.mm6947e3 [doi]
AB  - To reduce the spread of SARS-CoV-2, the virus that causes coronavirus disease
      2019 (COVID-19) and its associated impacts on health and society, COVID-19
      vaccines are essential. The U.S. government is working to produce and deliver
      safe and effective COVID-19 vaccines for the entire U.S. population. The Advisory
      Committee on Immunization Practices (ACIP)* has broadly outlined its approach for
      developing recommendations for the use of each COVID-19 vaccine authorized or
      approved by the Food and Drug Administration (FDA) for Emergency Use
      Authorization or licensure (1). ACIP's recommendation process includes an
      explicit and transparent evidence-based method for assessing a vaccine's safety
      and efficacy as well as consideration of other factors, including implementation 
      (2). Because the initial supply of vaccine will likely be limited, ACIP will also
      recommend which groups should receive the earliest allocations of vaccine. The
      ACIP COVID-19 Vaccines Work Group and consultants with expertise in ethics and
      health equity considered external expert committee reports and published
      literature and deliberated the ethical issues associated with COVID-19 vaccine
      allocation decisions. The purpose of this report is to describe the four ethical 
      principles that will assist ACIP in formulating recommendations for the
      allocation of COVID-19 vaccine while supply is limited, in addition to scientific
      data and implementation feasibility: 1) maximize benefits and minimize harms; 2) 
      promote justice; 3) mitigate health inequities; and 4) promote transparency.
      These principles can also aid state, tribal, local, and territorial public health
      authorities as they develop vaccine implementation strategies within their own
      communities based on ACIP recommendations.
FAU - McClung, Nancy
AU  - McClung N
FAU - Chamberland, Mary
AU  - Chamberland M
FAU - Kinlaw, Kathy
AU  - Kinlaw K
FAU - Bowen Matthew, Dayna
AU  - Bowen Matthew D
FAU - Wallace, Megan
AU  - Wallace M
FAU - Bell, Beth P
AU  - Bell BP
FAU - Lee, Grace M
AU  - Lee GM
FAU - Talbot, H Keipp
AU  - Talbot HK
FAU - Romero, Jose R
AU  - Romero JR
FAU - Oliver, Sara E
AU  - Oliver SE
FAU - Dooling, Kathleen
AU  - Dooling K
LA  - eng
PT  - Journal Article
DEP - 20201127
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Advisory Committees
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Drug Approval/legislation & jurisprudence
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Immunization/standards
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - United States/epidemiology
MH  - United States Food and Drug Administration
MH  - Viral Vaccines/*administration & dosage
PMC - PMC7727606
COIS- All authors have completed and submitted the International Committee of Medical
      Journal Editors form for disclosure of potential conflicts of interest. No
      potential conflicts of interest were disclosed.
EDAT- 2020/11/26 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/25 17:25
PHST- 2020/11/25 17:25 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.15585/mmwr.mm6947e3 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1782-1786. doi:
      10.15585/mmwr.mm6947e3.


PMID- 33237185
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1809-4546 (Electronic)
IS  - 0100-6991 (Linking)
VI  - 47
DP  - 2020
TI  - Laparoscopy & robotics: a historical parallel.
PG  - e20202811
LID - S0100-69912020000100104 [pii]
LID - 10.1590/0100-6991e-20202811 [doi]
AB  - The evolution of robotic platforms has brought up ethical, economic, educational,
      and clinical applicability issues that refer to the early 1990s, when laparoscopy
      began its dissemination as a technology that would revolutionize surgery.
      Introduced in Brazil since 1990, laparoscopy has received a lot of resistance
      from different sectors, including the medical academy itself. The technique was
      considered expensive, complex, poorly available and with limited clinical
      applications. However, in a short time, it was established as the gold standard
      for the treatment of most diseases in different organ systems and surgical
      specialties. At this time, similarly to laparoscopy, robotic surgery is expressed
      as a disruptive technology, determining an important breakdown of paradigms, and 
      moving the wheel of history forward. The author draws a parallel in relation to
      the use of both technologies in the surgeon's armamentarium. The fear of the "new
      technology", seen when laparoscopy appeared, is repeated with the advent of
      robotic surgery. Laparoscopy and robotic surgery, at the same time, imposed new
      knowledge challenges for surgeons, anesthetists, nurses, engineers - the need to 
      learn again, to develop new skills. The previous experience of implementing
      laparoscopy should always be remembered and considered, optimizing the current
      scenario of the robotic platform, in its introduction and dissemination with the 
      surgical community. The advent of the "robotic era" and its evolutionary
      potential will continue to assist surgeons in their mission to serve their
      patients with quality and safety.
FAU - Nacul, Miguel Prestes
AU  - Nacul MP
AUID- ORCID: http://orcid.org/0000-0002-0153-1941
AD  - - Colegio Brasileiro de Cirurgioes, Comissao de Cirurgia Minimamente Invasiva e
      Robotica - Porto Alegre - RS - Brasil.
LA  - eng
LA  - por
PT  - Editorial
PT  - Historical Article
DEP - 20201123
PL  - Brazil
TA  - Rev Col Bras Cir
JT  - Revista do Colegio Brasileiro de Cirurgioes
JID - 7809515
SB  - IM
MH  - Brazil
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Laparoscopy/*history
MH  - Robotic Surgical Procedures/*history
MH  - Robotics/*history
MH  - *Surgeons
EDAT- 2020/11/26 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/25 12:16
PHST- 2020/08/26 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/25 12:16 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - S0100-69912020000100104 [pii]
AID - 10.1590/0100-6991e-20202811 [doi]
PST - epublish
SO  - Rev Col Bras Cir. 2020 Nov 23;47:e20202811. doi: 10.1590/0100-6991e-20202811.
      eCollection 2020.


PMID- 33236972
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1547-6898 (Electronic)
IS  - 1040-8444 (Linking)
VI  - 50
IP  - 9
DP  - 2020 Oct
TI  - Towards a mechanism-based approach for the prediction of nongenotoxic
      carcinogenic potential of agrochemicals.
PG  - 725-739
LID - 10.1080/10408444.2020.1841732 [doi]
AB  - Chemical substances are subjected to assessment of genotoxic and carcinogenic
      effects before being marketed to protect man and the environment from health
      risks. For agrochemicals, the long-term rodent carcinogenicity study is currently
      required from a regulatory perspective. Although it is the current mainstay for
      the detection of nongenotoxic carcinogens, carcinogenicity studies are shown to
      have prominent weaknesses and are subject to ethical and scientific debate. A
      transition toward a mechanism-based weight-of-evidence approach is considered a
      requirement to enhance the prediction of carcinogenic potential for environmental
      (agro)chemicals. The resulting approach should make optimal use of innovative
      (computational) tools and be less animal demanding. To identify the various mode 
      of actions (MOAs) underlying the nongenotoxic carcinogenic potential of
      agrochemicals, we conducted an extensive analysis of 411 unique agrochemicals
      that have been evaluated for carcinogenicity by the United States Environmental
      Protection Agency (US EPA) and the European Chemicals Agency (ECHA). About
      one-third of these substances could be categorized as nongenotoxic carcinogens
      with an average of approximately two tumor types per substance, observed in a
      variety of organs. For two-third of the tumor cases, an underlying MOA (network) 
      could be identified. This analysis demonstrates that a limited set of MOA
      (networks) is underlying nongenotoxic carcinogenicity of agrochemicals,
      illustrating that the transition toward a MOA-driven approach appears manageable.
      Ultimately the approach should cover relevant MOAs and its associated key events;
      this will also facilitate the evaluation of the human relevance. This manuscript 
      describes the results of the analysis while identifying knowledge gaps and
      necessities to achieve a mechanism-based weight-of-evidence approach.
FAU - Heusinkveld, Harm
AU  - Heusinkveld H
AUID- ORCID: 0000-0002-3269-5586
AD  - Centre for Health Protection, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, the Netherlands.
FAU - Braakhuis, Hedwig
AU  - Braakhuis H
AD  - Centre for Health Protection, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, the Netherlands.
FAU - Gommans, Robin
AU  - Gommans R
AD  - Centre for Health Protection, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, the Netherlands.
FAU - Botham, Phil
AU  - Botham P
AD  - Syngenta Crop Protection, Bracknell, UK.
FAU - Corvaro, Marco
AU  - Corvaro M
AUID- ORCID: 0000-0002-3215-9820
AD  - Corteva Agriscience, Rome, Italy.
FAU - van der Laan, Jan Willem
AU  - van der Laan JW
AUID- ORCID: 0000-0003-2963-6136
AD  - Medicines Evaluation Board, Utrecht, the Netherlands.
FAU - Lewis, Dick
AU  - Lewis D
AD  - Syngenta Crop Protection, Bracknell, UK.
FAU - Madia, Federica
AU  - Madia F
AUID- ORCID: 0000-0002-8438-0957
AD  - European Commission, Joint Research Centre (JRC), Ispra, Italy.
FAU - Manou, Irene
AU  - Manou I
AD  - European Partnership for Alternative Approaches to Animal Testing (EPAA),
      Brussels, Belgium.
FAU - Schorsch, Frederic
AU  - Schorsch F
AD  - Bayer SAS, Lyon, France.
FAU - Wolterink, Gerrit
AU  - Wolterink G
AUID- ORCID: 0000-0001-8825-984X
AD  - Centre for Nutrition, Prevention and Health Services, National Institute for
      Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
FAU - Woutersen, Ruud
AU  - Woutersen R
AD  - TNO Quality of Life, Zeist, and Wageningen University & Research, Wageningen, the
      Netherlands.
FAU - Corvi, Raffaella
AU  - Corvi R
AD  - European Commission, Joint Research Centre (JRC), Ispra, Italy.
FAU - Mehta, Jyotigna
AU  - Mehta J
AUID- ORCID: 0000-0002-4705-0158
AD  - ADAMA Agricultural Solutions Ltd, Reading, UK.
FAU - Luijten, Mirjam
AU  - Luijten M
AUID- ORCID: 0000-0002-5277-1443
AD  - Centre for Health Protection, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201125
PL  - England
TA  - Crit Rev Toxicol
JT  - Critical reviews in toxicology
JID - 8914275
RN  - 0 (Agrochemicals)
RN  - 0 (Carcinogens)
SB  - IM
MH  - Agrochemicals/*toxicity
MH  - Animals
MH  - Carcinogenesis
MH  - Carcinogenicity Tests
MH  - Carcinogens/*toxicity
MH  - DNA Damage
MH  - Humans
MH  - Neoplasms
MH  - Risk Assessment
MH  - United States
MH  - United States Environmental Protection Agency
OTO - NOTNLM
OT  - *Pesticides
OT  - *carcinogenicity
OT  - *hazard assessment
OT  - *mode of action
OT  - *risk assessment
OT  - *rodent cancer bioassay
OT  - *weight-of-evidence
EDAT- 2020/11/26 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/11/25 12:13
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/11/25 12:13 [entrez]
AID - 10.1080/10408444.2020.1841732 [doi]
PST - ppublish
SO  - Crit Rev Toxicol. 2020 Oct;50(9):725-739. doi: 10.1080/10408444.2020.1841732.
      Epub 2020 Nov 25.


PMID- 33235845
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 11
IP  - 5
DP  - 2020 Sep-Oct
TI  - Dermoscopy of Onycholysis Due to Nail Psoriasis, Onychomycosis and Trauma: A
      Cross Sectional Study in Skin of Color.
PG  - 777-783
LID - 10.4103/idoj.IDOJ_475_19 [doi]
AB  - BACKGROUND: Clinical differentiation of onycholysis due to various etiologies is 
      difficult task that compels to do invasive investigations to arrive at accurate
      diagnosis. Wrong diagnosis often leads to treatment failure and physicians and
      patient's anxiety. Dermoscopic patterns in nail psoriasis, onychomycosis are well
      established. Here, authors attempted to describe dermoscopic patterns in
      onycholysis due to psoriasis, onychomycosis and trauma in skin of color.
      METHODOLOGY: Study was conducted in a tertiary hospital in Southern India.
      Ethical clearance and informed consent from patients was obtained. Sixty
      consecutive patients who attended dermatology outpatient department with
      onycholysis were included in the study. Nail potassium hydroxide (KOH) study was 
      done in all the cases. Onychoscopy was done with DermLite 3 with ultrasound gel
      as interface medium. RESULTS: Totally 60 patients (42 males; 18 females) with
      onycholysis were included. Mean age was 37 years (range; 6-68 years). KOH was
      positive in 22 (36.6%) cases. Onychoscopy showed proximal erythematous rim, red
      dots, splinter hemorrhages in 23(65.71), 26 (74.28) and 21(60) in nail psoriasis 
      respectively. Spiked and jagged-edges, aurora borealis and ruins pattern (65%)
      suggestive of onychomycosis were seen in 18(90%), 17 (85%) and 13 (65%) patients 
      respectively. Plain edges without erythema or spikes were noted in 5 (8.33%) in
      traumatic onycholysis group. CONCLUSION: Onychoscopy is a non- invasive modality 
      to diagnose psoriasis, onychomycosis and traumatic involvement of nail apparatus 
      by demonstrating characteristic patterns. Hence, it also plays an important role 
      in effective management of such cases.
CI  - Copyright: (c) 2020 Indian Dermatology Online Journal.
FAU - Ankad, Balachandra S
AU  - Ankad BS
AD  - Department of Dermatology, S.Nijalingappa Medical College, Bagalkot, Karnataka,
      India.
FAU - Gupta, Aakash
AU  - Gupta A
AD  - Department of Dermatology, S.Nijalingappa Medical College, Bagalkot, Karnataka,
      India.
FAU - Alekhya, Rallapalli
AU  - Alekhya R
AD  - La Belle Skin Clinic, West Maredpally, Secunderbad, Telangana, India.
FAU - Saipriya, Morlawar
AU  - Saipriya M
AD  - Layers Skin and Hair Clinic, Hyderabad, Telangana, India.
LA  - eng
PT  - Journal Article
DEP - 20200919
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC7678536
OTO - NOTNLM
OT  - Nail psoriasis
OT  - onychomycosis
OT  - onychoscopy
COIS- There are no conflicts of interest.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:47
PHST- 2019/09/19 00:00 [received]
PHST- 2020/01/01 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/11/25 05:47 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.4103/idoj.IDOJ_475_19 [doi]
AID - IDOJ-11-777 [pii]
PST - epublish
SO  - Indian Dermatol Online J. 2020 Sep 19;11(5):777-783. doi:
      10.4103/idoj.IDOJ_475_19. eCollection 2020 Sep-Oct.


PMID- 33235837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 11
IP  - 5
DP  - 2020 Sep-Oct
TI  - Use of Topical Steroids in Dermatology: A Questionnaire Based Study.
PG  - 725-730
LID - 10.4103/idoj.IDOJ_566_19 [doi]
AB  - CONTEXT: Topical steroids, the most widely prescribed drugs in dermatology are
      being increasingly misused. AIMS: This study was conducted to assess knowledge
      and practices regarding the use of topical steroids and to analyze prescriptions 
      containing topical steroids. SUBJECTS AND METHODS: Following approval from the
      institutional ethics committee, participants were recruited as per the selection 
      criteria and divided into those treated in the institution and those having
      outside prescription. They were administered a pre-validated questionnaire to
      assess knowledge and practices regarding the use of topical steroids. STATISTICAL
      ANALYSIS USED: Comparison of awareness between two patient categories was done
      using Chi-square test. Prescription variables were analyzed using descriptive
      statistics. Significance of P value was set at 0.05. RESULTS: Out of 400
      patients, 167 had external prescriptions whereas 233 were institutional patients.
      Only 5.5% of all patients knew about the type of drug prescribed whereas 31.25%
      were aware of the indication. A total of 33.75% of the patients knew topical
      steroids required a prescription and 5.6% said they were aware that topical
      steroid use was associated with side effects. Side effects were reported by 96
      patients. Awareness regarding knowledge, indication, and need for prescription
      were significantly better in institutional patients whereas knowledge about side 
      effects was lacking in both groups. Psoriasis was the most common indication
      overall whereas tinea was the most common indication (51.5%) among externally
      prescribed. CONCLUSIONS: Although this study showed that institutional patients
      had comparatively better knowledge than community-treated patients, there is a
      need to create more awareness among patients overall and implement measures to
      stop irrational prescribing practices in the community.
CI  - Copyright: (c) 2020 Indian Dermatology Online Journal.
FAU - Karekar, Sonali R
AU  - Karekar SR
AD  - Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM
      Hospital, Mumbai, Maharashtra, India.
FAU - Marathe, Padmaja A
AU  - Marathe PA
AD  - Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM
      Hospital, Mumbai, Maharashtra, India.
FAU - Nagarajan, Vetrivel Babu
AU  - Nagarajan VB
AD  - Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM
      Hospital, Mumbai, Maharashtra, India.
FAU - Khopkar, Uday S
AU  - Khopkar US
AD  - Department of Dermatology, Seth GS Medical College and KEM Hospital, Mumbai,
      Maharashtra, India.
FAU - Chikhalkar, Siddhi B
AU  - Chikhalkar SB
AD  - Department of Dermatology, Seth GS Medical College and KEM Hospital, Mumbai,
      Maharashtra, India.
FAU - Desai, Priyashree K
AU  - Desai PK
AD  - Department of Third Year MBBS Student, Seth GS Medical College and KEM Hospital, 
      Mumbai, Maharashtra, India.
FAU - Dongre, Minakshi S
AU  - Dongre MS
AD  - Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM
      Hospital, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200919
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC7678551
OTO - NOTNLM
OT  - Awareness
OT  - fixed-dose combination
OT  - steroid abuse
OT  - topical steroids
COIS- There are no conflicts of interest.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:47
PHST- 2019/11/19 00:00 [received]
PHST- 2019/01/27 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/11/25 05:47 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.4103/idoj.IDOJ_566_19 [doi]
AID - IDOJ-11-725 [pii]
PST - epublish
SO  - Indian Dermatol Online J. 2020 Sep 19;11(5):725-730. doi:
      10.4103/idoj.IDOJ_566_19. eCollection 2020 Sep-Oct.


PMID- 33235802
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201125
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Going solo: the law and ethics of childbirth during the COVID-19 pandemic.
PG  - lsaa079
LID - 10.1093/jlb/lsaa079 [doi]
FAU - Yakovi Gan-Or, Nofar
AU  - Yakovi Gan-Or N
AD  - Columbia Law School, New York, NY 10027, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7665682
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/05/08 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.1093/jlb/lsaa079 [doi]
AID - lsaa079 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Oct 6;7(1):lsaa079. doi: 10.1093/jlb/lsaa079. eCollection 2020
      Jan-Jun.


PMID- 33235632
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220217
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - Reciprocity in Quarantine: Observations from Wuhan's COVID-19 Digital Landscapes.
PG  - 435-457
LID - 10.1007/s41649-020-00150-2 [doi]
AB  - The 2003 SARS pandemic heralded the return of quarantine as a vital part of
      twenty-first century public health practice. Over the last two decades, MERS,
      Ebola, and other emerging infectious diseases each posed unique challenges for
      applying quarantine ethics lessons learned from the 2003 SARS-CoV-1 outbreak. In 
      an increasingly interdependent and connected global world, the use of quarantine 
      to contain the spread of SARS-CoV-2, or COVID-19, similarly poses new and
      unexpected ethical challenges. In this essay, we look beyond standard debates
      about the ethics of quarantine and state power to explore a key quarantine
      principle, Reciprocity, and how it is being negotiated by healthcare workers,
      volunteers, and citizens in the context of the Wuhan, China, quarantine. We
      analyze Reciprocity through the lens of two Wuhan case studies: (1) healthcare
      workers, particularly nurses, who are simultaneously essential workers and
      quarantined citizens, asked by their hospital administration to shave their heads
      because adequate PPE was not available, and (2) citizen-to-citizen mutual aid
      societies attempting to fill gaps in essential supplies left unfilled by the
      state. We analyze social media and video-blogs from Wuhan, on the platforms of
      Douyin and Sina Weibo, to understand how people define and respond to ethical and
      legal obligations in the wake of COVID-19. It is no surprise that quarantine
      principles from the 2003 SARS outbreak are inadequate for COVID-19 and that both 
      infectious disease outbreak responses and ethics must adapt to the virtual age.
      We offer ideas to strengthen and clarify Reciprocal obligations for the state,
      hospital administrators, and citizens as the globe prepares for the next wave of 
      COVID-19 circulating now.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Ni, Yanping
AU  - Ni Y
AUID- ORCID: https://orcid.org/0000-0001-9110-0047
AD  - Asian/Pacific Studies Institute, Duke University, Durham, NC
      USA.grid.26009.3d0000 0004 1936 7961
FAU - Fabbri, Morris
AU  - Fabbri M
AUID- ORCID: https://orcid.org/0000-0001-7390-4631
AD  - Science & Society, Duke University, Durham, NC USA.grid.26009.3d0000 0004 1936
      7961
FAU - Zhang, Chi
AU  - Zhang C
AUID- ORCID: https://orcid.org/0000-0002-5950-5754
AD  - Duke Global Health Institute, Duke University, Durham, NC USA.grid.26009.3d0000
      0004 1936 7961
FAU - Stewart, Kearsley A
AU  - Stewart KA
AUID- ORCID: https://orcid.org/0000-0002-9624-9956
AD  - Global Health and Cultural Anthropology, Duke Global Health Institute, Duke
      University, Durham, NC USA.grid.26009.3d0000 0004 1936 7961
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7677737
OTO - NOTNLM
OT  - COVID-19
OT  - China
OT  - Douyin
OT  - Mutual aid
OT  - Quarantine
OT  - Reciprocity
OT  - SARS-CoV-2
OT  - Social media
OT  - TikTok
OT  - Wuhan
COIS- Conflict of InterestAll authors declare that they have no conflicts of interest.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/07/10 00:00 [received]
PHST- 2020/09/26 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
PHST- 2020/11/25 05:46 [entrez]
AID - 10.1007/s41649-020-00150-2 [doi]
AID - 150 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Nov 20;12(4):435-457. doi: 10.1007/s41649-020-00150-2.
      eCollection 2020 Dec.


PMID- 33235580
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 7
DP  - 2020 Nov-Dec
TI  - Effect of energy drink consumption on baroreceptor sensitivity in young normal
      weight and overweight/obese males.
PG  - 1590-1595
LID - 10.12669/pjms.36.7.2419 [doi]
AB  - OBJECTIVES: There is lack of evidence exploring sympathetic effect by
      baroreceptor sensitivity in obese consuming energy drink. The purpose of this
      study was to investigate the acute effect of energy drink on individuals
      baroreceptor sensitivity in young healthy normal weight and overweight/obese
      males. METHODS: This cross-sectional study was performed in the Department of
      Physiology, Imam Abdulrahman Bin Faisal University, Kingdom of Saudi Arabia.
      After getting ethical approval, 25 male participants were recruited by convenient
      sampling and informed consent was obtained. Participants were grouped into normal
      weight and overweight/obese on basis of body mass index. Finger arterial blood
      pressure was recorded with Finometer(R) at baseline, 30min and 60 minutes in the 
      post-energy drink period and baroreceptor sensitivity was calculated. As data was
      not normally distributed it was log transformed. RESULTS: The baseline
      baroreceptor sensitivity was lower (P<0.05) in overweight/obese compared to
      normal weight participants. Baroreceptor sensitivity reduced significantly
      (P<0.05) at 60 minutes after energy drink consumption in the whole cohort of both
      normal weight and overweight/obese. Baroreceptor sensitivity remained lower in
      overweight/obese compared to normal weight at 60min but the difference was not
      significant. CONCLUSION: Consumption of energy drink acutely reduced baroreceptor
      sensitivity in both normal weight and obese young healthy males with an earlier
      onset of effect in overweight/obese indicating enhanced sympathetic activity.
      Energy drinks consumption could place the obese in a more vulnerable state to
      hypertension and arrhythmia.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Majeed, Farrukh
AU  - Majeed F
AD  - Dr. Farrukh Majeed, FCPS. Department of Physiology, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
FAU - Yar, Talay
AU  - Yar T
AD  - Dr. Talay Yar, PhD. Department of Physiology, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
FAU - Alsunni, Ahmed A
AU  - Alsunni AA
AD  - Dr. Ahmed A Alsunni, PhD. Department of Physiology, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
FAU - AlHawaj, Ali F
AU  - AlHawaj AF
AD  - Dr. Ali F Alhawaj, MBBS. Department of Physiology, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
FAU - AlRahim, Ahmed A
AU  - AlRahim AA
AD  - Dr. Ahmed A AlRahim, MBBS. Department of Physiology, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7674872
OTO - NOTNLM
OT  - Baroreceptor sensitivity
OT  - Caffeine
OT  - Energy drink
OT  - Obesity
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.12669/pjms.36.7.2419 [doi]
AID - PJMS-36-1590 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Nov-Dec;36(7):1590-1595. doi: 10.12669/pjms.36.7.2419.


PMID- 33235578
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 7
DP  - 2020 Nov-Dec
TI  - Attitude of athletes towards doping: A dilemma in Pakistan.
PG  - 1579-1584
LID - 10.12669/pjms.36.7.1922 [doi]
AB  - OBJECTIVES: To evaluate the attitude and of athletes towards performance
      enhancement through doping and leading reason of their decision for the use of
      doping in a country. METHODS: This Cross-Sectional descriptive study was
      conducted with non-probability convenience sampling over a period of six months
      from November 2018 to May 2019. This study included n=377 National and
      international athletes/players, of both genders aged 17-35 years, camping for
      preparation of 13(th) South Asian Games 2019 at Pakistan Sports Board, Jinnah
      Complex Islamabad, Pakistan. The athletes/ players with any disease, trauma or
      working as coaches or officials were excluded. Basic demographic sheet and
      Athletes Attitude to Doping Questionnaire were used for data collection which was
      analyzed using SPSS 21. RESULTS: Study revealed significant difference in the
      Mean and Median scores of the six anti-doping factors with very low scores for
      "Long Term Health Implications" (Mean= 2.14, Md=2) and "Psychosocial Influences" 
      (Mean=3, Md=3) compared to a high score for the remaining factors, indicating
      that the participants did not agree these two factors influenced their decision
      for not doping. Also, there was significant difference in the scores as revealed 
      by Wilcoxon signed test, between Personal Ethical Standards and the remaining
      factors except Illegality of Substances (z=-1.705, p=0.088). Gender association
      was noted for anti-doping education and testing, with higher scores in males
      (p=0.031). Also Type of Main Sport had association with most factors except Long 
      Term Health Implications while Level of Sport did not show any association except
      for Influence of Significant Others. CONCLUSION: Study concludes that Illegality 
      of Substances and Personal ethical standards are the most significant factor for 
      athletes' decision for not doping.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Anjum, Ghulam Shabbir
AU  - Anjum GS
AD  - Ghulam Shabbir Anjum, M Phil (Sports Sciences & Health Physical Education),
      National Athletics Coach, Pakistan Sports Board, Islamabad, Pakistan.
FAU - Mumtaz, Nazia
AU  - Mumtaz N
AD  - Dr. Nazia Mumtaz, PhD (Rehabilitation Sciences), Head of Department, Department
      of Speech Language pathology, Faculty of Rehab and Allied Health Sciences, Riphah
      International University, Lahore, Pakistan.
FAU - Saqulain, Ghulam
AU  - Saqulain G
AD  - Dr. Ghulam Saqulain, F.C.P.S (Otorhinolaryngology) Head, Department of
      Otorhinolaryngology, Capital Hospital PGMI, Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7674904
OTO - NOTNLM
OT  - Anti-doping
OT  - Attitudes
OT  - Performance enhancing drugs
OT  - Sports
COIS- Conflict of interest: None.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.12669/pjms.36.7.1922 [doi]
AID - PJMS-36-1579 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Nov-Dec;36(7):1579-1584. doi: 10.12669/pjms.36.7.1922.


PMID- 33235577
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 7
DP  - 2020 Nov-Dec
TI  - Common Cancers in Karachi, Pakistan: 2010-2019 Cancer Data from the Dow Cancer
      Registry.
PG  - 1572-1578
LID - 10.12669/pjms.36.7.3056 [doi]
AB  - OBJECTIVES: To present 2010-2019 cancer data from the Dow Cancer Registry
      representing all districts of Karachi (~17.4 million). METHODS: The study was
      conducted at the Dow University of Health Sciences. After ethical approval, the
      Dow Cancer Registry was established at the largest government-run diagnostic and 
      reference center of Karachi (Dow Labs). All cancers registered during 2010-2019
      were analyzed. Patients >18years of age were labeled as adults while those with
      ages </=18years were classified as children/young adults. RESULTS: During
      2010-2019, a total of 22,858 cancers were registered. Of these, 9,112(39.9%)
      cancers were diagnosed in males while 13,746(60.1%) in females. Incidence rates
      for all cancers (all ages) were 108/1,00,000 for males and 188.6/1,00,000 for
      females. In adult males, cancer of lip and oral cavity was the most frequently
      diagnosed cancer (33.6%), followed by non-melanoma -skin-cancer (NMSC) (7.2%),
      oesophagus (6.8%), colorectum (6.7%) and stomach (4.9%). In adult females, breast
      cancer was the most frequently recorded malignancy (53.2%), followed by cancers
      of lip and oral cavity (10.4%), oesophagus (5.3%), colorectum (3.3%) and NMSC
      (3%). In children, most common malignancy was that of brain and nervous system
      (15.3%), followed by Hodgkin's lymphoma (14.2%), colorectum (8.1%),
      endocrine-&-related organs (8%) and non-Hodgkin's lymphoma (7.8%). CONCLUSION:
      Cancers of lip and oral cavity and breast cancer were the most common
      malignancies in males and females respectively. In paediatric group, cancers of
      brain and nervous system were most common. Alarmingly, Karachi males have highest
      ASR of cancers of lip and oral cavity compared to any other city of Pakistan.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Qureshi, Muhammad Asif
AU  - Qureshi MA
AD  - Prof. Dr. Muhammad Asif Qureshi, MBBS, PhD (Glasgow-UK), MA (IR), Postdoc
      (Germany), CHPE. Department of Pathology, Dow International Medical College, Dow 
      University of Health Sciences Karachi, Karachi - Pakistan.
FAU - Khan, Saeed
AU  - Khan S
AD  - Prof. Dr. Saeed Khan, MSc, PhD, Postdoc (USA). Department of Pathology, Dow
      International Medical College, Dow University of Health Sciences Karachi, Karachi
      - Pakistan.
FAU - Sharafat, Shaheen
AU  - Sharafat S
AD  - Prof. Dr. Shaheen Sharafat, MBBS, M.Phil., PhD. Department of Pathology, Dow
      International Medical College, Dow University of Health Sciences Karachi, Karachi
      - Pakistan.
FAU - Quraishy, Mohammed Saeed
AU  - Quraishy MS
AD  - Prof. Dr. Mohammed Saeed Quraishy, FCPS, FRCS. Department of Surgery & Vice
      Chancellor, Dow International Medical College, Dow University of Health Sciences 
      Karachi, Karachi - Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7674861
OTO - NOTNLM
OT  - Cancer patterns
OT  - Cancer registry
OT  - Karachi
OT  - Pakistan
COIS- Conflict of Interest: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.12669/pjms.36.7.3056 [doi]
AID - PJMS-36-1572 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Nov-Dec;36(7):1572-1578. doi: 10.12669/pjms.36.7.3056.


PMID- 33235560
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 7
DP  - 2020 Nov-Dec
TI  - Outbreak of Coronavirus Disease 2019 (COVID19) in Pakistan: Psychological impact 
      and coping strategies of Health Care Professionals.
PG  - 1478-1483
LID - 10.12669/pjms.36.7.2988 [doi]
AB  - OBJECTIVE: This study was conducted to explore factors that can impact
      psychological health and coping strategies to help health care professionals
      (HCPs) to perform their duties. METHODS: A cross sectional survey was conducted
      using structured questionnaire electronically shared with the participants after 
      ethical approval. Descriptive statistics were calculated for socio demographic
      variables. Chi squared chi(2) test was used to compare the responses between
      different groups of HCPs. RESULTS: Survey was completed by 250 participants. They
      performed their duties diligently during outbreak but were concerned about their 
      safety, had fear of infecting themselves and their family members. Lack of
      evidence-based guidelines for patient management, news about pandemic situation
      through media and to deal with uncooperative patients not willing for quarantine 
      added to their stress. receiving honour and respect from general public in
      recognition of services, monetary benefit, adequate training to treat COVID-19,
      provision of personal protective equipment from government were reported as
      coping strategies for psychological impact. CONCLUSIONS: COVID-19 outbreak had
      psychological impact on HCPs, yet they continued to perform their duties
      carefully as moral obligation. Continued moral with financial support and
      acknowledgement of their services by government, organization and general public 
      was reported to have psychological benefit.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Noreen, Khola
AU  - Noreen K
AD  - Dr. Khola Noreen Assistant Professor Community Medicine Rawalpindi Medical
      University, Rawalpindi, Pakistan.
FAU - Umar, Muhammad
AU  - Umar M
AD  - Prof Dr. Muhammad Umar Vice Chancellor Rawalpindi Medical University, Rawalpindi,
      Pakistan.
FAU - Sabir, Syed Arshad
AU  - Sabir SA
AD  - Prof. Dr. Syed Arshad Sabir Dean Public Health & Community Medicine Rawalpindi
      Medical University, Rawalpindi, Pakistan.
FAU - Rehman, Rehana
AU  - Rehman R
AD  - Dr. Rehana Rehman Department of Biological & Biomedical Sciences, Aga Khan
      University, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7674889
OTO - NOTNLM
OT  - COVID-19
OT  - Coping Strategies
OT  - Front liners
OT  - Health care Professionals
OT  - Outbreak of Corona Virus
OT  - Psychological health
COIS- Conflict of interests: None.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.12669/pjms.36.7.2988 [doi]
AID - PJMS-36-1478 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Nov-Dec;36(7):1478-1483. doi: 10.12669/pjms.36.7.2988.


PMID- 33235554
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 7
DP  - 2020 Nov-Dec
TI  - Comprehensive Survey of Plagiarism in Iran.
PG  - 1441-1448
LID - 10.12669/pjms.36.7.3456 [doi]
AB  - BACKGROUND AND OBJECTIVE: We conducted this study to assess the prevalence of
      plagiarism and to shed light on some dark aspects of this issue. The main
      objectives included to find out the etiology, prevalence, and detection of
      various forms plagiarism. METHODS: In this Cross-sectional study we used a
      questionnaire, face-to-face interview, analyzing the present notifications and
      codes, websites, and literature review. The current study was conducted
      throughout Iran from 2017-2018. Those associated with scientific journalism,
      academic staffs, and authors were interviewed or asked to fill out a prepared
      questionnaire. RESULTS: Nine hundred seventy nine questionnaires were circulated.
      Out of this 706 (72.1%) were completed and returned. Those with a master degree
      were most cooperative in filling out the questionnaires (36.4%); followed by
      Assistant Professors (29.6%). About 74.1% of respondents, had not participated in
      any educational workshops on plagiarism (P<0.001) while 10.8% had not heard
      anything about plagiarism (P<0.001). As regards correct reply as for definition
      and detecting plagiarism; 91.1%, 40.8%, 48.4% and 57.9% could reply correctly
      (P<0.001). Forty-one-point one percent of the participants believed that
      reprimand would be the best punishment. The percentage of plagiarism as per
      people associated in journal administration, was 22.9%; based on experts'
      opinions, it was 30.0%; and based on analysis of some journals published in Iran,
      it was 25.5%. CONCLUSION: We found a noticeable prevalence of plagiarism in Iran.
      Many factors are involved in this misconduct; most important being the need for
      academic staff and students to publish e more papers regardless of their quality 
      to meet some of the academic requirements. Considering the high rank of Iran in
      terms of scientific growth worldwide, it is expected from the regulatory
      authorities to monitor all aspects of scientific misconducts in medical
      journalism.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Rokni, Mohammad Bagher
AU  - Rokni MB
AD  - Mohammad Bagher Rokni, PhD, Department of Basic Sciences, Iranian Academy of
      Medical Sciences, Tehran, Iran Department of Medical Parasitology and Mycology,
      School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Bizhani, Negar
AU  - Bizhani N
AD  - Negar BIZHANI, PhD Candidate, Department of Medical Parasitology and Mycology,
      School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Habibzadeh, Farrokh
AU  - Habibzadeh F
AD  - Farrokh Habibzadeh, MD, R&D Headquarters, Petroleum Industry Health Organization,
      Shiraz, Iran.
FAU - Farhud, Dariush Daneshvar
AU  - Farhud DD
AD  - Dariush Daneshvar Farhud, MD, PhD, Department of Basic Sciences, Iranian Academy 
      of Medical Sciences, Tehran, Iran.
FAU - Mohammadi, Neda
AU  - Mohammadi N
AD  - Neda Mohammadi, Department of Epidemiology and Biostatistics, School of Public
      Health, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Alizadeh, Ahad
AU  - Alizadeh A
AD  - Ahad Alizadeh, PhD, Department of Epidemiology and Biostatistics, School of
      Public Health, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Rokni, Ladan
AU  - Rokni L
AD  - Ladan Rokni, PhD, Asia Contents Institute, Konkuk University, Seoul, South Korea.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7674871
OTO - NOTNLM
OT  - Iran
OT  - Plagiarism
OT  - Publication ethics
OT  - Scientific Misconduct
COIS- Conflict of interest: None.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.12669/pjms.36.7.3456 [doi]
AID - PJMS-36-1441 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Nov-Dec;36(7):1441-1448. doi: 10.12669/pjms.36.7.3456.


PMID- 33235533
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201126
IS  - 1179-1594 (Print)
IS  - 1179-1594 (Linking)
VI  - 13
DP  - 2020
TI  - Challenges for Nurses in Disaster Management: A Scoping Review.
PG  - 2627-2634
LID - 10.2147/RMHP.S279513 [doi]
AB  - To reduce the impact of disasters, healthcare providers, especially nurses, need 
      to be prepared to respond immediately. However, nurses face several challenges in
      all phases of disaster management. The findings of a literature review based on
      scoping approaches, which utilized the Joanna Briggs Institute methodology,
      indicated that the major barriers facing nurses include the following: (1)
      disaster nursing is a new specialty; (2) inadequate level of preparedness; (3)
      poor formal education; (4) lack of research; (5) ethical and legal issues; and
      (6) issues related to nurses' roles in disasters. Educators, researchers, and
      stakeholders need to make efforts to tackle these issues and improve disaster
      nursing.
CI  - (c) 2020 Al Harthi et al.
FAU - Al Harthi, Manal
AU  - Al Harthi M
AD  - Nursing Department, College of Applied Medical Sciences, Taif University, Ta'if, 
      Saudi Arabia.
AD  - King Faisal Medical Complex, Ministry of Health, Taif, Saudi Arabia.
FAU - Al Thobaity, Abdulellah
AU  - Al Thobaity A
AUID- ORCID: 0000-0002-2313-7355
AD  - Nursing Department, College of Applied Medical Sciences, Taif University, Ta'if, 
      Saudi Arabia.
FAU - Al Ahmari, Waleed
AU  - Al Ahmari W
AD  - Nursing Department, College of Applied Medical Sciences, Taif University, Ta'if, 
      Saudi Arabia.
FAU - Almalki, Mohammed
AU  - Almalki M
AD  - Nursing Department, College of Applied Medical Sciences, Taif University, Ta'if, 
      Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201116
PL  - England
TA  - Risk Manag Healthc Policy
JT  - Risk management and healthcare policy
JID - 101566264
PMC - PMC7678497
OTO - NOTNLM
OT  - challenges
OT  - disaster nursing
OT  - disaster preparedness
OT  - disaster response
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:46
PHST- 2020/09/04 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/25 05:46 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.2147/RMHP.S279513 [doi]
AID - 279513 [pii]
PST - epublish
SO  - Risk Manag Healthc Policy. 2020 Nov 16;13:2627-2634. doi: 10.2147/RMHP.S279513.
      eCollection 2020.


PMID- 33235488
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Linking)
VI  - 13
DP  - 2020
TI  - Compliance with COVID-19 Preventive and Control Measures among Food and Drink
      Establishments in Bench-Sheko and West-Omo Zones, Ethiopia, 2020.
PG  - 1147-1155
LID - 10.2147/IJGM.S280532 [doi]
AB  - INTRODUCTION: Despite the implementation of many preventive and control systems
      developed by governments, the spread of COVID-19 and its resulting infection rate
      are alarmingly increasing from time to time all over the world. In Ethiopia,
      public places visited by large numbers of people where preventive and control
      measures are poorly practiced are considered to be potentially contributing to
      the spread of the disease. Food and drink establishments are among the highly
      susceptible public establishments visited by large numbers of people who interact
      among themselves and with employees. Hence, this study aimed to measure the
      compliance with COVID-19 preventive and control measures among food and drink
      establishments in the selected towns of Bench-Sheko and West-Omo Zones in
      Ethiopia. METHODS: A cross-sectional study was conducted among food and drink
      establishments in selected towns of Bench-Sheko and West-Omo zones from May 15,
      2020 to June 15, 2020. A census of all 324 food and drink establishments found in
      the study area was conducted, and data were obtained from managers of the
      establishments through face-to-face interviews. Data were entered in to Epidata
      manager and exported to SPSS version 24.0 for analysis. Percentage compliance
      score was computed to describe the level of compliance. Ethical approval was
      obtained from Mizan-Tepi University Institutional Review Board, and written
      informed consent was obtained from every participant. RESULTS: The overall
      compliance level with COVID-19 preventive and control measures was 55.5%. The
      majority (89%) of the food and drink establishments had functional hand washing
      facilities at the main entrance gate. Less than half of the food and drink
      establishments had posted written materials promoting hand washing, arranged
      tables and chairs in a manner that they accommodate not more than four people at 
      once and at least 2 meters apart, carry out daily cleaning and disinfection of
      frequented touched surfaces, and provided education or training for their workers
      about COVID-19. CONCLUSION: The overall compliance level with COVID-19 preventive
      and control measures among food and drink establishments was very poor. Thus, it 
      is highly recommended that the federal government of Ethiopia, the federal
      ministry of health, and local health authorities consider a move towards more
      solid, strict, and comprehensive compulsory measures, including fines that can
      lead up to the closure of non-compliant establishments.
CI  - (c) 2020 Kayrite et al.
FAU - Kayrite, Qaro Qanche
AU  - Kayrite QQ
AUID- ORCID: 0000-0002-8051-2529
AD  - Department of Public Health, College of Health Science, Mizan-Tepi University,
      Mizan Aman, Ethiopia.
FAU - Hailu, Adane Asefa
AU  - Hailu AA
AUID- ORCID: 0000-0001-9374-978X
AD  - Department of Public Health, College of Health Science, Mizan-Tepi University,
      Mizan Aman, Ethiopia.
FAU - Tola, Tadesse Nigussie
AU  - Tola TN
AUID- ORCID: 0000-0003-3123-5809
AD  - Department of Public Health, College of Health Science, Mizan-Tepi University,
      Mizan Aman, Ethiopia.
FAU - Adula, Tadesse Duguma
AU  - Adula TD
AD  - Department of Medical Laboratory, College of Health Science, Mizan-Tepi
      University, Mizan Aman, Ethiopia.
FAU - Lambyo, Shewangizaw Hailemariam
AU  - Lambyo SH
AD  - Department of Midwifery, College of Health Science, Mizan-Tepi University, Mizan 
      Aman, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC7680164
OTO - NOTNLM
OT  - COVID-19
OT  - compliance
OT  - food and drink establishments
OT  - preventive and control measures
COIS- The authors declare that they have no competing interests.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 05:45
PHST- 2020/09/05 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/25 05:45 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - 10.2147/IJGM.S280532 [doi]
AID - 280532 [pii]
PST - epublish
SO  - Int J Gen Med. 2020 Nov 17;13:1147-1155. doi: 10.2147/IJGM.S280532. eCollection
      2020.


PMID- 33235136
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Efficacy of massage therapy for postprandial distress syndrome: A protocol for
      systematic review and meta-analysis.
PG  - e23473
LID - 10.1097/MD.0000000000023473 [doi]
AB  - BACKGROUND: Postprandial distress syndrome (PDS), characterized by the presence
      of prevalently meal-related early satiation and fullness, is a highly prevalent
      condition with major socioeconomic and healthcare impact. To date, there is a
      lack of pharmacological treatment proven value for PDS. Therefore, an ideal
      strategy to relieve PDS is urgently needed. In recent years, massage therapy has 
      been increasingly accepted by PDS patients due to its lower costs, fewer unwanted
      side effects and safety for clinical use. In this systematic review, we aim to
      evaluate the effectiveness and safety of massage therapy for patients with
      postprandial distress syndrome. METHODS: We will search the following electronic 
      databases for randomized controlled trials to evaluate the effectiveness and
      safety of massage therapy in treating postprandial distress syndrome: Wanfang and
      Pubmed Database, CNKI, CENTRAL, CINAHL, and EMBASE. Each database will be
      searched from inception to October 2020. The entire process will include study
      selection, data extraction, risk of bias assessment, and meta-analyses. RESULTS: 
      This proposed study will evaluate the effectiveness and safety of massage therapy
      for patients with postprandial distress syndrome. The outcomes will include
      changes in PDS relief and adverse effect. CONCLUSIONS: This proposed systematic
      review will evaluate the existing evidence on the effectiveness and safety of
      massage therapy for patients with postprandial distress syndrome. DISSEMINATION
      AND ETHICS: The results of this review will be disseminated through peer-reviewed
      publication. Because all of the data used in this systematic review and
      meta-analysis has been published, this review does not require ethical approval. 
      Furthermore, all data will be analyzed anonymously during the review process. OSF
      REGISTRATION NUMBER: DOI 10.17605/OSF.IO/9WRX8.
FAU - Zhou, Ke-Lin
AU  - Zhou KL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dong, Shuo
AU  - Dong S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Shen, Qian
AU  - Shen Q
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Wang, Kang
AU  - Wang K
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Wei, Pei-Dong
AU  - Wei PD
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Bai, Xiao
AU  - Bai X
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Cai, Ming-Heng
AU  - Cai MH
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Guo, Sheng
AU  - Guo S
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Liu, Yang
AU  - Liu Y
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Dyspepsia/*therapy
MH  - Humans
MH  - *Massage
MH  - Meta-Analysis as Topic
MH  - *Postprandial Period
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7710185
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023473 [doi]
AID - 00005792-202011250-00084 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23473. doi:
      10.1097/MD.0000000000023473.


PMID- 33235122
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Efficacy of autologous platelet-rich plasma use for arthroscopic meniscal repair:
      A randomized trial protocol.
PG  - e23422
LID - 10.1097/MD.0000000000023422 [doi]
AB  - BACKGROUND: Meniscus tear is one of the most familiar orthopedic injury, and it
      is also the leading cause of the dysfunction of knee joint. Recent efforts to
      improve the success rate of the meniscus repair surgery involve the addition of
      platelet-rich plasma (PRP). The aim of our experiment is to assess the clinical
      effects of arthroscopic repair of meniscal tears without or with PRP. METHODS:
      This is a randomized and parallel-group superiority study. The study protocol is 
      approved through the review committee of the corresponding institutions in PLA
      Army 80th Group Military Hospital. All patients will provide written informed
      consent to participate in the study. We implement our investigation on the basis 
      of the ethical standards outlined in the Helsinki Declaration of 1964 and then
      report our outcomes according to the CONSORT statement of 2010. All the patients 
      follow a same rehabilitation program. Patients are assessed at baseline (day
      before operation), 12 months and 24 months after the last time of injection;
      outcome assessments involve Ikeuchi score, Lysholm score, and the visual analogue
      scales for failure and pain rate. P value less than .05 indicates that there is
      statistical significance. RESULTS: We suppose that arthroscopic PRP repair of
      meniscus tears results in improved pain and functional results owing to the
      release of bioactive molecules that may affect the healing of meniscus. TRIAL
      REGISTRATION: This study protocol was registered in Research Registry
      (researchregistry6175).
FAU - Yu, Hongchang
AU  - Yu H
AD  - Department of Orthopaedics.
FAU - Tan, Rongrong
AU  - Tan R
AD  - Department of Orthopaedics.
FAU - Lou, Baozhen
AU  - Lou B
AD  - Department of Anesthesiology, PLA Army 80th Group Military Hospital, Shandong,
      China.
FAU - Xue, Dingshan
AU  - Xue D
AD  - Department of Orthopaedics.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Arthroscopy
MH  - Equivalence Trials as Topic
MH  - Humans
MH  - Lysholm Knee Score
MH  - *Platelet-Rich Plasma
MH  - Tibial Meniscus Injuries/*therapy
MH  - Visual Analog Scale
PMC - PMC7710189
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023422 [doi]
AID - 00005792-202011250-00070 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23422. doi:
      10.1097/MD.0000000000023422.


PMID- 33235112
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - The efficacy of enteral nutrition combined with accelerated rehabilitation in
      non-small cell lung cancer surgery: A randomized controlled trial protocol.
PG  - e23382
LID - 10.1097/MD.0000000000023382 [doi]
AB  - OBJECTIVE: To investigate the effect of enteral nutrition combined with
      accelerated rehabilitation in treating the non-small cell lung cancer (NSCLC).
      METHODS: It is a randomized controlled experiment to be carried out from June
      2021 to December 2021. It was permitted through the Ethics Committee of Cancer
      Hospital Affiliated to Shandong First Medical University (00923876). 100 patients
      are included in the study. The inclusion criteria contain: (1) patients with
      NSCLCs receiving surgery as the primary treatment; (2) over 18 years of age. The 
      exclusion criteria are as follows: (1) age >/=65 years; (2) severe metabolic and 
      systemic diseases, such as diabetes, hypertension, or severe liver and kidney
      dysfunction; (3) the body mass index <18.5 kg/m; (4) patients who have received
      preoperational radiotherapy or chemotherapy. Patients in the control group are
      provided routine nutrition, including preoperative nutritional risk screening and
      assessment and preoperative nutrition education and dietary guidance, while
      patients in the nutrition group are provided additional enteral nutrition
      preparations combined with accelerated rehabilitation as in the control group.
      The primary outcomes include the perioperative change of serum albumin, serum
      prealbumin, hemoglobin, and total lymphocyte counts. The second outcomes include 
      length of hospitalization, quality of life, and risk of postoperative
      complications. RESULTS: shows the comparison of indicators after surgery between 
      the 2 groups. CONCLUSION: Enteral nutrition combined with accelerated
      rehabilitation appears to be beneficial in decreasing the complications and
      improving postoperative recovery after NSCLC surgery.
FAU - Ji, Xiaona
AU  - Ji X
AD  - Department of Thoracic Surgery, Cancer Hospital Affiliated to Shandong First
      Medical University.
FAU - Ding, Haiyan
AU  - Ding H
AD  - Department of Intensive-Care Unit, Jinan Children's Hospital, Shandong, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Carcinoma, Non-Small-Cell Lung/*rehabilitation/*surgery
MH  - Enteral Nutrition/*methods
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*rehabilitation/*surgery
MH  - Male
MH  - Middle Aged
MH  - Young Adult
PMC - PMC7710191
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023382 [doi]
AID - 00005792-202011250-00060 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23382. doi:
      10.1097/MD.0000000000023382.


PMID- 33235111
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Effect of pharmaceutical care on the treatment of COVID-19: A protocol for
      systematic review and meta analysis.
PG  - e23377
LID - 10.1097/MD.0000000000023377 [doi]
AB  - BACKGROUND: We aimed to conduct a meta-analysis to assess the effect of
      pharmaceutical care on the treatment of coronavirus disease 2019 (COVID-19).
      METHODS: All case-controlled studies related to pharmaceutical care on the
      treatment of COVID-19 will be included in this review. We will use index words
      related to pharmaceutical care and COVID-19 to perform literature searches in
      PubMed, Embase, MEDLINE, CNKI, and Wanfang databases, to include articles indexed
      as of October 20, 2020 in English and Chinese language. Two reviewers will select
      trials independently for inclusion and assess trial quality. Two pairs of review 
      authors will independently extract information for each included trials. Primary 
      outcomes are clinical outcomes, average hospital stays, costs, patient
      satisfaction, and incidence of adverse drug reactions. We will evaluate the risk 
      of bias of the included studies based on Cochrane assessment tool. Revman 5.3
      (the Cochrane collaboration, Oxford, UK) will be used for heterogeneity
      assessment, generating funnel-plots, data synthesis, subgroup analysis, and
      sensitivity analysis. RESULTS: We will provide targeted and practical results
      assessing the effect of pharmaceutical care on the treatment of COVID-19.
      CONCLUSION: The stronger evidence about the effect of pharmaceutical care on the 
      treatment of COVID-19 will be provided for clinicians. SYSTEMATIC REVIEW
      REGISTRATION NUMBER: PROSPERO CRD42020214223 ETHICS AND DISSEMINATION:: There is 
      no need for ethical approval, and the review will be reported in a peer-reviewed 
      journal.
FAU - Niu, Jiali
AU  - Niu J
AD  - Department of Clinical Pharmacy.
FAU - Chen, Hongjun
AU  - Chen H
AD  - Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated
      Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
FAU - Chen, Kaixia
AU  - Chen K
AD  - Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated
      Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
FAU - Liu, Yin
AU  - Liu Y
AD  - Department of Clinical Pharmacy.
FAU - Ju, Feng
AU  - Ju F
AD  - Department of Clinical Pharmacy.
FAU - Xue, Ting
AU  - Xue T
AD  - Department of Clinical Pharmacy.
FAU - Yin, Dengyang
AU  - Yin D
AD  - Department of Clinical Pharmacy.
FAU - Li, Chaoqun
AU  - Li C
AD  - Department of Clinical Pharmacy.
FAU - Yin, Chunxia
AU  - Yin C
AD  - Department of Clinical Pharmacy.
FAU - Jiao, Lingyun
AU  - Jiao L
AD  - Department of Clinical Pharmacy.
FAU - Zhao, Guangyu
AU  - Zhao G
AD  - Department of Clinical Pharmacy.
FAU - Huang, Jixun
AU  - Huang J
AD  - Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated
      Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - COVID-19 drug treatment
SB  - IM
MH  - COVID-19/*drug therapy
MH  - Case-Control Studies
MH  - Health Expenditures
MH  - Humans
MH  - Length of Stay
MH  - Patient Satisfaction
MH  - Research Design
MH  - SARS-CoV-2
PMC - PMC7710203
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023377 [doi]
AID - 00005792-202011250-00059 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23377. doi:
      10.1097/MD.0000000000023377.


PMID- 33235110
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Efficacy and safety of traditional Chinese medicine for erosive oral lichen
      planus: A protocol for systematic review and meta analysis.
PG  - e23375
LID - 10.1097/MD.0000000000023375 [doi]
AB  - BACKGROUND: Oral lichen planus (OLP) is a common disease among oral mucous
      membrane diseases. Erosive oral lichen planus (EOLP) is a type of OLP, it has a
      potential tendency of cancerization. There have been some randomized controlled
      trials (RCTs) using Traditional Chinese Medicine (TCM) to treat EOLP. No
      systematic review on the RCTs of TCM for EOLP has been reported, so we would
      propose a study protocol that aims to evaluate the evidence the efficacy and
      safety of TCM for treating patients with EOLP. METHODS: The following databases
      from the inception to June 30, 2020 electronically, including PubMed, EMBASE,
      Cochrane Library, Chinese National Knowledge Infrastructure, VIP, Wanfang
      database, China Biomedical Literature Database will be searched. RCTs that meet
      the pre-specified eligibility criteria will be included. RevMan software (V5.3)
      will be performed data synthesis following data extraction and publication risk
      assessment. Subgroup and sensitivity analysis will be performed according to the 
      condition of included RCTs. The primary outcomes include visual analogy scale,
      laboratory immune indicators, and scores of oral lesions and signs. Additional
      outcomes are clinical effective rate, adverse event rate, and recurrence rate.
      The Grading of Recommendations Assessment, Development and Evaluation system will
      be used to assess the strength of the evidence. RESULTS: This study will provide 
      a well-reported synthesis of RCTs on the efficacy and safety of TCM in the
      treatment of EOLP. CONCLUSION: This systematic review protocol will be helpful
      for providing evidence of whether TCM is an effective and safe therapeutic
      approach for patients with EOLP. ETHICS AND DISSEMINATION: Ethical approval is
      not necessary as this protocol is only for systematic review and it does not
      involve privacy data or conduct an animal experiment. This protocol will be
      disseminated by a peer-review journal or conference presentation. SYSTEMATIC
      REVIEW REGISTRATION: PROSPERO CRD42020172366.
FAU - You, Yanyan
AU  - You Y
AD  - West China Hospital of stomatology, Sichuan University, South Renmin Road, Wu Hou
      District.
FAU - Huang, Xiaojin
AU  - Huang X
AD  - West China Hospital of stomatology, Sichuan University, South Renmin Road, Wu Hou
      District.
FAU - Chen, Yunhui
AU  - Chen Y
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - You, Yu
AU  - You Y
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Lichen Planus, Oral/*drug therapy
MH  - Pain Measurement
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7710173
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023375 [doi]
AID - 00005792-202011250-00058 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23375. doi:
      10.1097/MD.0000000000023375.


PMID- 33235084
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by
      COVID-19: A protocol for a systematic review and meta-analysis.
PG  - e23261
LID - 10.1097/MD.0000000000023261 [doi]
AB  - BACKGROUND: Assessing the effectiveness and safety of Traditional Chinese
      medicine formula Xiaoqinglong decoction for cough caused by COVID-19 is the main 
      purpose of this systematic review protocol. METHODS: The following electronic
      databases will be searched from their respective inception dates to October 1,
      2020: PubMed, MEDLINE, the Cochrane Library, Embase, WorldSciNet, Ovid, the
      Allied and Complementary Medicine Database, the Web of Science, Chinese
      Biomedical Literature Database, China National Knowledge Infrastructure, the
      Chongqing VIP Chinese Science and Technology Periodical Database (VIP), the
      Wanfang Database, and the China Biology Medicine Disc. All published randomized
      controlled trials in English or Chinese related to Traditional Chinese medicine
      formula Xiaoqinglong decoction for cough caused by COVID-19 will be included. The
      primary outcome is the time and rate of appearance of coughing. The secondary
      outcomes are the length of hospital stay. Two reviewers will conduct the study
      selection, data extraction, and assessment independently. The assessment of risk 
      of bias and data synthesis will be conducted with RevMan V.5.2. RESULTS: The
      results will provide a high-quality synthesis of current evidence for researchers
      in this subject area. CONCLUSION: The conclusion of our study will provide an
      evidence to judge whether traditional Chinese medicine formula Xiaoqinglong
      decoction is an effective intervention for patients with cough caused by
      COVID-19. ETHICS AND DISSEMINATION: Formal ethical approval is not necessary as
      the data cannot be individualized. The results of this protocol will be
      disseminated in a peer-reviewed journal or presented at relevant conferences.
      PROSPERO REGISTRATION NUMBER: CRD42020202079.
FAU - Ren, Xiaodan
AU  - Ren X
AD  - The Second Affiliated Hospital of Army Medical University.
FAU - Shi, Yu
AU  - Shi Y
AD  - Beibei Traditional Chinese Medical Hospital, Chongqing, China.
FAU - Li, Guizhong
AU  - Li G
AD  - Beibei Traditional Chinese Medical Hospital, Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - COVID-19 drug treatment
SB  - IM
MH  - COVID-19/*drug therapy
MH  - Cough/*drug therapy
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Pandemics
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
PMC - PMC7710204
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023261 [doi]
AID - 00005792-202011250-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23261. doi:
      10.1097/MD.0000000000023261.


PMID- 33235072
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Psychological nursing intervention on anxiety and depression in patients with
      urinary incontinence after radical prostatectomy: A randomized controlled study
      protocol.
PG  - e23127
LID - 10.1097/MD.0000000000023127 [doi]
AB  - BACKGROUND: Prostate cancer (PC) is one of the most familiar disease of the male 
      reproductive system globally. In treating the clinically localized PC, the
      radical prostatectomy is regarded as a gold standard, but it is associated with
      syndromes as urinary incontinence (UI), which can have a significant impact on
      patients' quality of life. Nurse takes responsibility in the management of the UI
      for their convenience compared with doctors to contact with patients and build
      better trust relationships with survivals. However, most of the studies focus on 
      the physiological level, the psychological nursing intervention research is less.
      The purpose of the trial is to introduce a psychological intervention program and
      to study its effects on anxiety and depression after prostatectomy in IU
      patients. METHODS: This is a single-center randomized controlled trial that was
      authorized by Ethics Committee of the First People's Hospital of Chenzhou City
      (2020054). One hundred participants who undergo radical prostatectomy are
      analyzed. Inclusion criteria are the following: PC is diagnosed based on
      histological results; Participants in the study voluntarily sign the informed
      consent table; Severe UI after extubation; Patients with postoperative UI do not 
      receive any drug treatment. Exclusion criteria are the followings: patients with 
      the history of prostate operation; patients with the history of severe renal and 
      liver malignancy; UI caused by reasons other than prostatectomy. The main
      outcomes are the degree of anxiety and depression 2 months after urinary catheter
      is removed. The secondary outcomes are the quality of life 2 months after urinary
      catheter is removed. All data are collected and analyzed by the Social Science
      software version 21.0 (SPSS, Inc., Chicago, IL) program. RESULTS: The relevant
      indexes of severe UI patients are compared in the table. CONCLUSION:
      Psychological nursing intervention may have a positive effect on depression and
      anxiety in the UI patients after receiving the radical prostatectomy.
FAU - Yang, Liying
AU  - Yang L
AD  - Department of Urology, Taizhou Hospital.
FAU - Ling, Danjuan
AU  - Ling D
AD  - Outpatient Injection Room, Linhai Hospital of Traditional Chinese Medicine,
      Zhejiang Province.
FAU - Ye, Lanfen
AU  - Ye L
AD  - Department of Urology, Taizhou Hospital.
FAU - Zeng, Manping
AU  - Zeng M
AD  - Department of Traditional Chinese Medicine, First People's Hospital of Chenzhou
      City, Hunan Province, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Anxiety Disorders/*nursing/prevention & control/psychology
MH  - Humans
MH  - Male
MH  - *Nursing Process
MH  - Postoperative Complications/nursing/prevention & control
MH  - *Prostatectomy
MH  - Treatment Outcome
MH  - Urinary Incontinence/*nursing/prevention & control/psychology
PMC - PMC7710194
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023127 [doi]
AID - 00005792-202011250-00020 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23127. doi:
      10.1097/MD.0000000000023127.


PMID- 33235065
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Effects of Shenqi compound on intestinal microbial metabolites in patients with
      type 2 diabetes: A protocol for systematic review and meta analysis.
PG  - e23017
LID - 10.1097/MD.0000000000023017 [doi]
AB  - INTRODUCTION: According to the data from the 2017 Chinese Guidelines for the
      Prevention and Treatment of Type 2 Diabetes [Chin J Diabetes. 2017;20:81-117], in
      2013, the incidence of T2DM in China was 10.4%, while nearly 63% of the patients 
      did not receive standard diagnosis. T2DM has become a serious public health
      problem in China and even in the world. Intestinal flora, as a research hotspot
      related to T2DM and other diseases in recent years, is a kind of microorganism
      with a large number in the human intestinal tract, which is considered as one of 
      the important factors affecting the metabolism of the endocrine system and the
      human internal environment. In fact, many concepts of traditional Chinese
      medicine (TCM) coincide with modern research results of intestinal flora. In
      fact, TCM is also widely used to regulate intestinal flora disorders, and plays a
      very important role in restoring the dysfunctional intestinal flora [Hu et al.
      Drug Eval. 2013:8-10]. T2DM is a chronic systemic progressive disease. Studies
      [Wang et al. Tianjin Chin Med. 2007;24:507-508] have shown that even ideal blood 
      glucose control cannot prevent the failure of islet cells [Wang et al. Tianjin
      Chin Med. 2007;24:507-508], and how to restore the function and number of islet
      cells has naturally become the focus and difficulty of our current research.
      Studies have shown that the changes in the contents of intestinal microflora and 
      their metabolites are closely related to the performance of T2DM such as
      hyperglycemia, insulin resistance, and restoration of islet function, and play an
      important role in pathophysiological mechanisms such as chronic inflammation of
      T2DM [Sun et al. Shi Zhen Chin Med. 2012;23:1434-1436]. It has been confirmed
      that Shenqi compound, a TCM, regulates intestinal flora of T2DM. However, due to 
      the lack of evidence, there is no specific method or suggestion, it is necessary 
      to make a systematic evaluation of Shenqi compound to provide effective evidence 
      for further research. METHODS AND ANALYSIS: Electronic databases included PubMed,
      Embase, Cochrane Library, Web of Science, Nature, Science Online, WanFang China
      Biomedical Database, VIP Medical Information, China national Knowledge
      Infrastructure (CNKI). MAIN RESULTS: Endotoxin, short-chain fatty acid, bile
      acid, indole.Other results: low density lipoprotein (LDL), high density
      lipoprotein (HDL), triglyceride (TG), total serum cholesterol (TC). The data will
      be extracted independently by 2 researchers, and the risk of bias in the
      meta-analysis will be systematically evaluated according to the Cochrane
      handbook. All data analysis will be performed using the Data statistics software 
      Review Manager V.5.3. And occupy V.12.0. RESULTS: The results of this study will 
      systematically evaluate the effectiveness and safety of Shenqi compound on the
      effects of intestinal flora metabolites in patients with type 2 diabetes.
      CONCLUSION: Through the systematic review of this study, the published evidence
      of the effect of Shenqi compound on intestinal flora metabolites in patients with
      type 2 diabetes was summarized to further guide its promotion and application.
      ETHICS AND COMMUNICATION: This study is a systematic review with findings based
      on published evidence and does not require erB review or consent. We plan to
      publish the results in a journal or conference report. OPEN SCIENCE FRAMEWORK
      (OSF) REGISTRATION NUMBER: September 29, 2020.
      osf.io/gb3m2.(https://osf.io/gb3m2).
FAU - Xiong, Ran
AU  - Xiong R
AD  - Hospital of Traditional Chinese Medicine Affiliated to Southwest Medical
      University.
AD  - Southwest Medical University, Luzhou.
FAU - Zhao, Changying
AU  - Zhao C
AD  - Hospital of Traditional Chinese Medicine Affiliated to Southwest Medical
      University.
AD  - Southwest Medical University, Luzhou.
FAU - Zhong, Min
AU  - Zhong M
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Zhang, Xinxia
AU  - Zhang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Liu, Wanfu
AU  - Liu W
AD  - Yibin Hospital of Traditional Chinese Medicine, Yibin, Sichuan, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (shenqi)
SB  - IM
MH  - *Diabetes Mellitus, Type 2
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
PMC - PMC7710176
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023017 [doi]
AID - 00005792-202011250-00013 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e23017. doi:
      10.1097/MD.0000000000023017.


PMID- 33235056
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - The prevalence and incidence of community-acquired pressure injury: A protocol
      for systematic review and meta-analysis.
PG  - e22348
LID - 10.1097/MD.0000000000022348 [doi]
AB  - BACKGROUND: Pressure injury (PI) is a serious problem in health care settings
      globally. It leads to tremendous burden both individuals and healthcare systems. 
      Since 2008, hospital-acquired pressure injuries have been a major focus of
      nursing quality improvement programs within hospitals and are considered never
      events. However, insufficiency attention has been paid to community-acquired
      pressure injuries (CAPI) or pressure ulcers that occur at home or in nursing
      homes. The prevalence or incidence of community-acquired pressure injury has been
      reported but never been synthesized in a meta-analysis manner. To fill the gaps
      in the evidence matrix, the aims of this study are to estimate the prevalence of 
      CAPI in the general population and to pool the overall incidence of CAPI in the
      general population. METHODS: PubMed, Web of Science, EMBASE, CINHAL, the Cochrane
      Library, Chongqing VIP, and China National Knowledge Infrastructure were
      electronically searched to identify eligible studies updated to May 2020 to
      collect studies on the prevalence or incidence of community-acquired pressure
      injuries. Two reviewers independently will screen the literature, extracted data,
      and assess the risk of bias of included studies using the Strengthening the
      Reporting of Observational Studies in Epidemiology (STROBE) guideline.
      Meta-analyses of pooled weighted estimates will be calculated using random effect
      models with 95% CIs reported due to high heterogeneity. RESULTS: Of the 5242
      studies initially identified, of the 22 studies (total 479,761 participants) 17
      reporting prevalence of community-acquired pressure injury and 5 reporting
      incidence were included. Other results of this study will be published in a
      peer-reviewed journal. CONCLUSION: This study will summarize the pooled estimate 
      prevalence and incidence of community-acquired pressure injuries and the pooled
      estimate of frequencies of different anatomic sites. ETHICS AND DISSEMINATION:
      Ethics approval and patient consent are not required, because this study is a
      meta-analysis based on published studies. INPLASY REGISTRATION NUMBER:
      INPLASY202080044.
FAU - Chen, Geng
AU  - Chen G
AD  - Evidence-based Nursing Center, School of Nursing, Lanzhou University.
FAU - Lin, Lv
AU  - Lin L
AD  - Wound Ostomy Care Center.
FAU - Yan-Lin, Yang
AU  - Yan-Lin Y
AD  - Evidence-based Nursing Center, School of Nursing, Lanzhou University.
FAU - Loretta, Chung Yuet-Foon
AU  - Loretta CY
AD  - Evidence-based Nursing Center, School of Nursing, Lanzhou University.
FAU - Han, Lin
AU  - Han L
AD  - Evidence-based Nursing Center, School of Nursing, Lanzhou University.
AD  - Department of Nursing, Gansu Provincial Hospital, Lanzhou, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Incidence
MH  - *Nursing Homes
MH  - Pressure Ulcer/*epidemiology/etiology
MH  - Prevalence
MH  - Research Design
PMC - PMC7710219
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000022348 [doi]
AID - 00005792-202011250-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e22348. doi:
      10.1097/MD.0000000000022348.


PMID- 33235055
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 48
DP  - 2020 Nov 25
TI  - Comparison of perioperative hidden blood loss for intertrochanteric fractures in 
      the elderly by different intramedullary fixations: A randomized controlled study 
      protocol.
PG  - e21666
LID - 10.1097/MD.0000000000021666 [doi]
AB  - BACKGROUND: Till date only a few studies have reported the clinical outcomes of
      intraoperative hidden blood loss of intertrochanteric fracture in the old people 
      treated with various intramedullary immobilizations. The aim of the trial is to
      investigate the best choice for treating intertrochanteric fractures, as well as 
      the hidden blood loss among different intramedullary fixations. METHODS: This
      randomized, single-blind, superiority clinical trial was admitted by the Ethics
      Committee in our hospital (The 7th Medical Center of PLA, 20200602DM). The
      eligibility criteria were:Patients who met any of the following conditions would 
      not be able to participate in the test: composite femoral fracture, under 65
      years of ages, experience of femoral fractures, surgical contraindications,
      nonambulatory before the presenting injury, or presence of any other traumatic
      fractures. 120 participants with unstable intertrochanteric fractures, treated by
      Gammar nail, (n = 40), Proximal Femoral Nail Antirotation (n = 40) and
      Intertrochanteric Antegrade Nail (n = 40) instruments were enrolled in this
      research. The main outcome measures were total blood loss and hidden blood loss, 
      which were evaluated based on the haematocrit change after the operation. The
      experimental data was analyzed and sorted out with SPSS program (ver.19; SPSS
      Inc., Chicago, IL). RESULTS: This experiment had strict inclusive criteria and
      exclusive criteria and a well- regulated intervention. CONCLUSIONS: The results
      of this trial will provide more evidence on which technique can better treat
      unstable intertrochanteric fracture. TRIAL REGISTRATION: This study protocol was 
      registered in Research Registry (researchregistry5788).
FAU - Zheng, Huayong
AU  - Zheng H
AD  - Department of Orthopedics, Department of orthopedics, The 7th Medical Center of
      PLA, Beijing.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Department of Orthopedics, Department of orthopedics, The 7th Medical Center of
      PLA, Beijing.
FAU - Wang, Hao
AU  - Wang H
AD  - Department of Orthopedics, Department of orthopedics, The 7th Medical Center of
      PLA, Beijing.
FAU - Sun, Tiansheng
AU  - Sun T
AD  - Department of Orthopedics, Department of orthopedics, The 7th Medical Center of
      PLA, Beijing.
FAU - Sun, Qicai
AU  - Sun Q
AD  - Department of Orthopedics, Sandun Branch, Zhejiang Hospital, Zhejiang, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Blood Loss, Surgical
MH  - *Bone Nails
MH  - Female
MH  - Femoral Fractures/*surgery
MH  - Fracture Fixation, Intramedullary
MH  - Health Services for the Aged
MH  - Humans
MH  - Intraoperative Complications
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
PMC - PMC7710182
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000021666 [doi]
AID - 00005792-202011250-00003 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 25;99(48):e21666. doi:
      10.1097/MD.0000000000021666.


PMID- 33235008
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1529-4242 (Electronic)
IS  - 0032-1052 (Linking)
VI  - 146
IP  - 6
DP  - 2020 Dec
TI  - Time for a Consensus? Considerations of Ethical Social Media Use by Pediatric
      Plastic Surgeons.
PG  - 841e-842e
LID - 10.1097/PRS.0000000000007389 [doi]
FAU - Hetzler, Peter T
AU  - Hetzler PT
AD  - Department of Plastic Surgery, MedStar Georgetown University Hospital,
      Washington, D.C.
FAU - Makar, Katelyn G
AU  - Makar KG
AD  - Department of Plastic Surgery, University of Michigan Hospital and Health
      Systems, University of Michigan, Ann Arbor, Mich.
FAU - Baker, Stephen B
AU  - Baker SB
AD  - Department of Plastic Surgery, MedStar Georgetown University Hospital,
      Washington, D.C.
FAU - Fan, Kenneth L
AU  - Fan KL
AD  - Department of Plastic Surgery, MedStar Georgetown University Hospital,
      Washington, D.C.
FAU - Vercler, Christian J
AU  - Vercler CJ
AD  - Department of Plastic Surgery, University of Michigan Hospital and Health
      Systems, University of Michigan, Ann Arbor, Mich.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
SB  - IM
MH  - Age Factors
MH  - Child
MH  - *Consensus
MH  - Craniofacial Abnormalities/*surgery
MH  - *Ethics, Medical
MH  - Humans
MH  - Informed Consent/standards
MH  - Marketing of Health Services/ethics
MH  - Patient Education as Topic/ethics
MH  - Practice Guidelines as Topic
MH  - Privacy
MH  - Social Media/economics/*ethics/standards
MH  - Societies, Medical/ethics/standards
MH  - Surgery, Plastic/economics/*ethics/standards
MH  - United States
EDAT- 2020/11/26 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/11/25 05:39
PHST- 2020/11/25 05:39 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 10.1097/PRS.0000000000007389 [doi]
AID - 00006534-202012000-00064 [pii]
PST - ppublish
SO  - Plast Reconstr Surg. 2020 Dec;146(6):841e-842e. doi:
      10.1097/PRS.0000000000007389.


PMID- 33234786
OWN - NLM
STAT- Publisher
LR  - 20201125
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
DP  - 2020 Nov 23
TI  - A Deep Learning Pipeline to Automate High-Resolution Arterial Segmentation with
      or without Intravenous Contrast.
LID - 10.1097/SLA.0000000000004595 [doi]
AB  - BACKGROUND: Existing methods to reconstruct vascular structures from a
      computerized tomography (CT) angiogram rely on contrast injection to enhance the 
      radio-density within the vessel lumen. However, pathological changes in the
      vasculature may be present that prevent accurate reconstruction. In aortic
      aneurysmal disease, a thrombus adherent to the aortic wall within the expanding
      aneurysmal sac is present in > 90% of cases. These deformations prevent the
      automatic extraction of vital clinical information by existing image
      reconstruction methods. AIM: In this study, a deep learning architecture
      consisting of a modified U-Net with attention-gating was implemented to establish
      a high-throughput and automated segmentation pipeline of pathological blood
      vessels in CT images acquired with or without the use of a contrast agent.
      METHODS AND RESULTS: Seventy-Five patients with paired non-contrast and
      contrast-enhanced CT images were randomly selected from an ongoing study (Ethics 
      Ref 13/SC/0250), manually annotated and used for model training and evaluation.
      Data augmentation was implemented to diversify the training data set in a ratio
      of 10:1. The performance of our Attention-based U-Net in extracting both the
      inner (blood flow) lumen and the wall structure of the aortic aneurysm from CT
      angiograms (CTA) was compared against a generic 3-D U-Net and displayed superior 
      results. Implementation of this network within the aortic segmentation pipeline
      for both contrast and non-contrast CT images has allowed for accurate and
      efficient extraction of the morphological and pathological features of the entire
      aortic volume. CONCLUSION: This extraction method can be used to standardize
      aneurysmal disease management and sets the foundation for complex geometric and
      morphological analysis. Furthermore, this pipeline can be extended to other
      vascular pathologies.
FAU - Chandrashekar, Anirudh
AU  - Chandrashekar A
AD  - Nuffield Department of Surgical Sciences, University of Oxford.
FAU - Handa, Ashok
AU  - Handa A
AD  - Nuffield Department of Surgical Sciences, University of Oxford.
FAU - Shivakumar, Natesh
AU  - Shivakumar N
AD  - Nuffield Department of Surgical Sciences, University of Oxford.
FAU - Lapolla, Pierfrancesco
AU  - Lapolla P
AD  - Nuffield Department of Surgical Sciences, University of Oxford.
FAU - Uberoi, Raman
AU  - Uberoi R
AD  - Nuffield Department of Surgical Sciences, University of Oxford.
FAU - Grau, Vicente
AU  - Grau V
AD  - Department of Engineering Science, University of Oxford.
FAU - Lee, Regent
AU  - Lee R
AD  - Nuffield Department of Surgical Sciences, University of Oxford.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/25 05:38
PHST- 2020/11/25 05:38 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1097/SLA.0000000000004595 [doi]
PST - aheadofprint
SO  - Ann Surg. 2020 Nov 23. doi: 10.1097/SLA.0000000000004595.


PMID- 33234663
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Household medication safety practices during the COVID-19 pandemic: a descriptive
      qualitative study protocol.
PG  - e044441
LID - 10.1136/bmjopen-2020-044441 [doi]
AB  - INTRODUCTION: Those who are staying at home and reducing contact with other
      people during the COVID-19 pandemic are likely to be at greater risk of
      medication-related problems than the general population. This study aims to
      explore household medication practices by and for this population, identify
      practices that benefit or jeopardise medication safety and develop best practice 
      guidance about household medication safety practices during a pandemic, grounded 
      in individual experiences. METHODS AND ANALYSIS: This is a descriptive
      qualitative study using semistructured interviews, by telephone or video call.
      People who have been advised to 'cocoon'/'shield' and/or are aged 70 years or
      over and using at least one long-term medication, or their caregivers, will be
      eligible for inclusion. We will recruit 100 patient/carer participants: 50 from
      the UK and 50 from Ireland. Recruitment will be supported by our patient and
      public involvement (PPI) partners, personal networks and social media. Individual
      participant consent will be sought, and interviews audio/video recorded and/or
      detailed notes made. A constructivist interpretivist approach to data analysis
      will involve use of the constant comparative method to organise the data, along
      with inductive analysis. From this, we will iteratively develop best practice
      guidance about household medication safety practices during a pandemic from the
      patient's/carer's perspective. ETHICS AND DISSEMINATION: This study has Trinity
      College Dublin, University of Limerick and University College London ethics
      approvals. We plan to disseminate our findings via presentations at relevant
      patient/public, professional, academic and scientific meetings, and for
      publication in peer-reviewed journals. We will create a list of helpful
      strategies that participants have reported and share this with participants, PPI 
      partners and on social media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Grimes, Tamasine C
AU  - Grimes TC
AUID- ORCID: 0000-0002-7154-3243
AD  - School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin,
      Ireland.
FAU - Garfield, Sara
AU  - Garfield S
AD  - UCL School of Pharmacy, University College London, London, UK.
AD  - Centre for Medication Safety and Service Quality, Imperial College Healthcare NHS
      Trust, London, UK.
FAU - Kelly, Dervla
AU  - Kelly D
AUID- ORCID: 0000-0001-9836-5400
AD  - School of Medicine, University of Limerick, Limerick, Ireland.
FAU - Cahill, Joan
AU  - Cahill J
AD  - Centre for Innovative Human Systems (CIHS), School of Psychology, Trinity College
      Dublin, Dublin, Ireland.
FAU - Cromie, Sam
AU  - Cromie S
AD  - Centre for Innovative Human Systems (CIHS), School of Psychology, Trinity College
      Dublin, Dublin, Ireland.
FAU - Wheeler, Carly
AU  - Wheeler C
AD  - Centre for Medication Safety and Service Quality, Imperial College Healthcare NHS
      Trust, London, UK.
FAU - Franklin, Bryony Dean
AU  - Franklin BD
AD  - UCL School of Pharmacy, University College London, London, UK
      bryony.deanfranklin@ucl.ac.uk.
AD  - Centre for Medication Safety and Service Quality, Imperial College Healthcare NHS
      Trust, London, UK.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Aged
MH  - Antiviral Agents/*pharmacology
MH  - COVID-19/*drug therapy/epidemiology
MH  - Family Characteristics
MH  - Humans
MH  - Ireland/epidemiology
MH  - London/epidemiology
MH  - *Pandemics
MH  - *Qualitative Research
MH  - *SARS-CoV-2
MH  - Safety
PMC - PMC7688439
OTO - NOTNLM
OT  - *COVID-19
OT  - *primary care
OT  - *public health
OT  - *qualitative research
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-044441 [pii]
AID - 10.1136/bmjopen-2020-044441 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e044441. doi: 10.1136/bmjopen-2020-044441.


PMID- 33234662
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy 
      with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with
      metastatic melanoma refractory to standard of care treatments: the ACTME trial.
PG  - e044036
LID - 10.1136/bmjopen-2020-044036 [doi]
AB  - INTRODUCTION: Treatment with anti-PD-1 immunotherapy does not lead to
      long-lasting clinical responses in approximately 60% of patients with metastatic 
      melanoma. These refractory patients, however, can still respond to treatment with
      tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa). A combination 
      of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1 is expected to
      provide a safe, feasible and effective therapy for patients with metastatic
      melanoma, who are refractory to standard of care treatment options. METHODS AND
      ANALYSIS: Patients are treated in two phases. In phase I, the safety of the
      combination TIL and anti-PD-1 is assessed (cohort 1) according to CTCAE 4.03
      criteria. Subsequently, the safety of cotreatment with PEG-IFNa is tested in
      cohort 2. The efficacy will be evaluated in the second phase of the trial.
      Efficacy is evaluated according to RECIST 1.1 and immune-related response
      criteria. Clinical and immunological parameters will be evaluated for their
      relation with clinical responsiveness. ETHICS AND DISSEMINATION: Ethical approval
      of the trial was obtained from the Central Committee on Research Involving Human 
      Subjects in the Netherlands. The trial results will be shared with the scientific
      community at (inter)national conferences and by publication in a peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: NCT03638375; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - van der Kooij, Monique K
AU  - van der Kooij MK
AUID- ORCID: 0000-0002-9764-5467
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - Verdegaal, Els M E
AU  - Verdegaal EME
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - Visser, Marten
AU  - Visser M
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - de Bruin, Linda
AU  - de Bruin L
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - van der Minne, Caroline E
AU  - van der Minne CE
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - Meij, Pauline M
AU  - Meij PM
AD  - Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Roozen, Inge C F M
AU  - Roozen ICFM
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
FAU - Jonker, Mare A
AU  - Jonker MA
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
FAU - van den Bosch, Shelley
AU  - van den Bosch S
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
FAU - Liefers, Gerrit-Jan
AU  - Liefers GJ
AD  - Surgery, Leids Universitair Medisch Centrum, Leiden, The Netherlands.
FAU - Speetjens, Frank M
AU  - Speetjens FM
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
FAU - van der Burg, Sjoerd H
AU  - van der Burg SH
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - Kapiteijn, Ellen
AU  - Kapiteijn E
AD  - Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
      H.W.kapiteijn@lumc.nl.
LA  - eng
SI  - ClinicalTrials.gov/NCT03638375
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Interferon-alpha)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Cell- and Tissue-Based Therapy
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Interferon-alpha
MH  - *Melanoma/drug therapy
MH  - Netherlands
MH  - Polyethylene Glycols
MH  - *Standard of Care
PMC - PMC7689077
OTO - NOTNLM
OT  - *dermatological tumours
OT  - *immunology
OT  - *oncology
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-044036 [pii]
AID - 10.1136/bmjopen-2020-044036 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036.


PMID- 33234658
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - T-piece versus pressure-support ventilation for spontaneous breathing trials
      before extubation in patients at high risk of reintubation: protocol for a
      multicentre, randomised controlled trial (TIP-EX).
PG  - e042619
LID - 10.1136/bmjopen-2020-042619 [doi]
AB  - INTRODUCTION: In intensive care unit (ICU), the decision of extubation is a
      critical time because mortality is particularly high in case of reintubation. To 
      reduce that risk, guidelines recommend to systematically perform a spontaneous
      breathing trial (SBT) before extubation in order to mimic the postextubation
      physiological conditions. SBT is usually performed with a T-piece disconnecting
      the patient from the ventilator or with low levels of pressure-support
      ventilation (PSV). However, work of breathing is lower during PSV than during
      T-piece. Consequently, while PSV trial may hasten extubation, it may also
      increase the risk of reintubation. We hypothesise that, compared with T-piece,
      SBT performed using PSV may hasten extubation without increasing the risk of
      reintubation. METHODS AND ANALYSIS: This study is an investigator-initiated,
      multicentre randomised controlled trial comparing T-piece vs PSV for SBTs in
      patients at high risk of reintubation in ICUs. Nine hundred patients will be
      randomised with a 1:1 ratio in two groups according to the type of SBT. The
      primary outcome is the number of ventilator-free days at day 28, defined as the
      number of days alive and without invasive mechanical ventilation between the
      initial SBT (day 1) and day 28. Secondary outcomes include the number of days
      between the initial SBT and the first extubation attempt, weaning difficulty, the
      number of patients extubated after the initial SBT and not reintubated within the
      following 72 hours, the number of patients extubated within the 7 days following 
      the initial SBT, the number of patients reintubated within the 7 days following
      extubation, in-ICU length of stay and mortality in ICU, at day 28 and at day 90. 
      ETHICS AND DISSEMINATION: The study has been approved by the central ethics
      committee 'Ile de France V' (2019-A02151-56) and patients will be included after 
      informed consent. The results will be submitted for publication in peer-reviewed 
      journals. TRIAL REGISTRATION NUMBER: NCT04227639.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Thille, Arnaud W
AU  - Thille AW
AUID- ORCID: 0000-0002-7798-6715
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire de Poitiers,
      Poitiers, France aw.thille@gmail.com.
AD  - ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers,
      Poitou-Charentes, France.
FAU - Coudroy, Remi
AU  - Coudroy R
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire de Poitiers,
      Poitiers, France.
AD  - ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers,
      Poitou-Charentes, France.
FAU - Gacouin, Arnaud
AU  - Gacouin A
AD  - Service des Maladies Infectieuses et Reanimation Medicale, Hopital Ponchaillou,
      Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.
FAU - Ehrmann, Stephan
AU  - Ehrmann S
AD  - Medecin Intensive Reanimation, CIC 1415, CRICS-TriggerSEP, Centre d'etude des
      pathologies respiratoires, INSERM U1100, Universite de Tours, Centre Hospitalier 
      Regional Universitaire de Tours, Tours, Centre, France.
FAU - Contou, Damien
AU  - Contou D
AD  - Service de Reanimation Polyvalente, Centre Hospitalier Victor Dupouy
      d'Argenteuil, Argenteuil, Ile-de-France, France.
FAU - Dangers, Laurence
AU  - Dangers L
AD  - Service de Reanimation Polyvalente, Centre Hospitalier Universitaire Felix Guyon,
      Saint-Denis, La Reunion, Reunion.
FAU - Romen, Antoine
AU  - Romen A
AD  - Service de Reanimation, Centre Hospitalier de Pau, Pau,
      Aquitaine-Limousin-Poitou, France.
FAU - Guitton, Christophe
AU  - Guitton C
AD  - Medecine intensive reanimation, Centre Hospitalier du Mans, Le Mans, Pays de la
      Loire, France.
FAU - Lacave, Guillaume
AU  - Lacave G
AD  - Service de Reanimation Medico-Chirurgicale, Centre Hospitalier de Versailles, Le 
      Chesnay, Ile-de-France, France.
FAU - Quenot, Jean-Pierre
AU  - Quenot JP
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire de Dijon, Dijon,
      Bourgogne, France.
FAU - Lacombe, Beatrice
AU  - Lacombe B
AD  - Reanimation Polyvalente, Centre Hospitalier de Bretagne Sud, Lorient, Bretagne,
      France.
FAU - Pradel, Gael
AU  - Pradel G
AD  - Service de Reanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac,
      Auvergne-Rhone-Alpes, France.
FAU - Terzi, Nicolas
AU  - Terzi N
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire Grenoble Alpes, 
      Grenoble, Rhone-Alpes, France.
AD  - INSERM, U1042, HP2, Universite Grenoble Alpes, Saint-Martin-d'Heres, Rhone-Alpes,
      France.
FAU - Prat, Gwenael
AU  - Prat G
AD  - Medecine Intensive et Reanimation, Centre Hospitalier Universitaire de Brest,
      Brest, Bretagne, France.
FAU - Labro, Guylaine
AU  - Labro G
AD  - Service de Reanimation Medicale, Site Emile Muller, Groupe Hospitalier de la
      Region de Mulhouse et Sud Alsace, Mulhouse, Grand Est, France.
FAU - Reignier, Jean
AU  - Reignier J
AUID- ORCID: 0000-0002-3768-3496
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire de Nantes,
      Nantes, Pays de la Loire, France.
FAU - Beduneau, Gaetan
AU  - Beduneau G
AD  - Departement de Reanimation Medicale, Hopital Charles Nicolle, Normandie
      Universite, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.
FAU - Dellamonica, Jean
AU  - Dellamonica J
AD  - Reanimation Medicale Archet 1, UR2CA-Unite de Recherche Clinique Cote d'Azur,
      Universite Cote d'Azur, Centre Hospitalier Universitaire de Nice, Nice,
      Provence-Alpes-Cote d'Azur, France.
FAU - Nay, Mai-Anh
AU  - Nay MA
AUID- ORCID: 0000-0002-6116-4987
AD  - Medecine Intensive Reanimation, Centre Hospitalier Regional d'Orleans Hopital de 
      La Source, Orleans, France.
FAU - Rouze, Anahita
AU  - Rouze A
AD  - Centre de Reanimation, Universite de Lille, Centre Hospitalier Universitaire de
      Lille, Lille, Hauts-de-France, France.
FAU - Delbove, Agathe
AU  - Delbove A
AD  - Reanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes,
      Bretagne, France.
FAU - Sedillot, Nicholas
AU  - Sedillot N
AD  - Hopital Fleyriat, Reanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse,
      Bourg-en-Bresse, Rhone-Alpes, France.
FAU - Mira, Jean-Paul
AU  - Mira JP
AD  - Groupe Hospitalier Paris Centre - Cochin University Hospital - Medical Intensive 
      Care Unit, Assistance Publique - Hopitaux de Paris, Paris, Ile-de-France, France.
FAU - Bourenne, Jeremy
AU  - Bourenne J
AD  - Medecine Intensive Reanimation, Reanimation des Urgences, CHU La Timone 2,
      Aix-Marseille Universite, Assistance Publique - Hopitaux de Marseille, Marseille,
      Provence-Alpes-Cote d'Azu, France.
FAU - Lautrette, Alexandre
AU  - Lautrette A
AD  - Service de Reanimation, Unicancer, Centre Jean Perrin, Clermont-Ferrand,
      Auvergne-Rhone-Alpes, France.
FAU - Argaud, Laurent
AU  - Argaud L
AD  - Medecine Intensive Reanimation, Hopital Edouard Herriot, Hospices Civils de Lyon,
      Lyon, Auvergne-Rhone-Alpes, France.
FAU - Levrat, Quentin
AU  - Levrat Q
AD  - Service de Reanimation, Centre hospitalier de la Rochelle, La Rochelle,
      Nouvelle-Aquitaine, France.
FAU - Devaquet, Jerome
AU  - Devaquet J
AD  - Service de Reanimation Polyvalente, Hopital Foch, Suresnes, Ile-de-France,
      France.
FAU - Vivier, Emmanuel
AU  - Vivier E
AD  - Reanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon,
      Rhone-Alpes, France.
FAU - Azais, Marie-Ange
AU  - Azais MA
AD  - Service de Medecine Intensive et Reanimation, Centre Hospitalier Departmental La 
      Roche-sur-Yon, La Roche-sur-Yon, Pays de la Loire, France.
FAU - Leroy, Christophe
AU  - Leroy C
AD  - Service de Reanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, Auvergne,
      France.
FAU - Dres, Martin
AU  - Dres M
AD  - Service de Pneumologie, Medecine Intensive et Reanimation, Hopital
      Pitie-Salpetriere, Sorbonne Universite, Assistance Publique - Hopitaux de Paris, 
      Paris, Ile-de-France, France.
FAU - Robert, Rene
AU  - Robert R
AUID- ORCID: 0000-0001-5989-5409
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire de Poitiers,
      Poitiers, France.
AD  - ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers,
      Poitou-Charentes, France.
FAU - Ragot, Stephanie
AU  - Ragot S
AD  - ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers,
      Poitou-Charentes, France.
FAU - Frat, Jean-Pierre
AU  - Frat JP
AD  - Medecine Intensive Reanimation, Centre Hospitalier Universitaire de Poitiers,
      Poitiers, France.
AD  - ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers,
      Poitou-Charentes, France.
CN  - REVA research network
LA  - eng
SI  - ClinicalTrials.gov/NCT04227639
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Airway Extubation
MH  - France
MH  - Humans
MH  - Positive-Pressure Respiration
MH  - Respiration, Artificial
MH  - *Ventilator Weaning
PMC - PMC7689072
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *respiratory medicine (see thoracic medicine)
OT  - *respiratory physiology
COIS- Competing interests: AWT reports financial support (payment for lectures and
      travel expenses coverage to attend scientific meetings) by Fisher & Paykel,
      Covidien, Maquet-Getinge, GE Healthcare. J-PF reports consulting fees from Fisher
      & Paykel and SOS oxygene.
EDAT- 2020/11/26 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-042619 [pii]
AID - 10.1136/bmjopen-2020-042619 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e042619. doi: 10.1136/bmjopen-2020-042619.


PMID- 33234656
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Protocol for a prospective, longitudinal cohort of people with COVID-19 and their
      household members to study factors associated with disease severity: the
      Predi-COVID study.
PG  - e041834
LID - 10.1136/bmjopen-2020-041834 [doi]
AB  - INTRODUCTION: A few major clinical factors such as sex, obesity or comorbidities 
      have already been associated with COVID-19 severity, but there is a need to
      identify new epidemiological, clinical, digital and biological characteristics
      associated with severity and perform deep phenotyping of patients according to
      severity. The objectives of the Predi-COVID study are (1) to identify new
      determinants of COVID-19 severity and (2) to conduct deep phenotyping of patients
      by stratifying them according to risk of complications, as well as risk factors
      for infection among household members of Predi-COVID participants (the
      Predi-COVID-H ancillary study). METHODS AND ANALYSIS: Predi-COVID is a
      prospective, hybrid cohort study composed of laboratory-confirmed COVID-19 cases 
      in Luxembourg who will be followed up remotely for 1 year to monitor their health
      status and symptoms. Predi-COVID-H is an ancillary cohort study on household
      members of index cases included in Predi-COVID to monitor symptoms and household 
      clusters in this high-risk population. A subcohort of up to 200 Predi-COVID and
      300 Predi-COVID-H participants with biological samples will be included. Severity
      of infection will be evaluated by occurrence and duration of hospitalisation,
      admission and duration of stay in intensive care units or equivalent structures, 
      provision of and duration of supplemental oxygen and ventilation therapy,
      transfer to another hospital, as well as the impact of infection on daily
      activities following hospital discharge. ETHICS AND DISSEMINATION: The study has 
      been approved by the National Research Ethics Committee of Luxembourg (study
      number 202003/07) in April 2020. An informed consent is signed by study
      participants. Scientific articles will be submitted to international
      peer-reviewed journals, along with press releases for lay audience for major
      results. TRIAL REGISTRATION NUMBER: NCT04380987.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fagherazzi, Guy
AU  - Fagherazzi G
AUID- ORCID: 0000-0001-5033-5966
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Fischer, Aurelie
AU  - Fischer A
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Betsou, Fay
AU  - Betsou F
AD  - IBBL, Luxembourg, Luxembourg.
FAU - Vaillant, Michel
AU  - Vaillant M
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Ernens, Isabelle
AU  - Ernens I
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Masi, Silvana
AU  - Masi S
AD  - Direction de la Sante, Luxembourg Ministere de la Sante, Luxembourg, Luxembourg.
FAU - Mossong, Joel
AU  - Mossong J
AUID- ORCID: 0000-0003-0717-9835
AD  - Laboratoire National de Sante, Luxembourg, Luxembourg.
FAU - Staub, Therese
AU  - Staub T
AD  - Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
FAU - Brault, Dominique
AU  - Brault D
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Bahlawane, Christelle
AU  - Bahlawane C
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Rashid, Mohammed Ally
AU  - Rashid MA
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
AD  - Ifakara Health Institute, Bagamoyo, Tanzania.
FAU - Ollert, Markus
AU  - Ollert M
AD  - Department of Infection and Immunity, Luxembourg Institute of Health, Strassen,
      Luxembourg.
AD  - Department of Dermatology and Allergy Center, Odense Research Center for
      Anaphylaxis, Odense University Hospital, University of Southern Denmark, Odense, 
      Denmark.
FAU - Gantenbein, Manon
AU  - Gantenbein M
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
FAU - Huiart, Laetitia
AU  - Huiart L
AUID- ORCID: 0000-0002-5401-1958
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg laetitia.huiart@lih.lu.
LA  - eng
SI  - ClinicalTrials.gov/NCT04380987
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - COVID-19/*diagnosis/epidemiology
MH  - COVID-19 Testing/*methods
MH  - *Family Characteristics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - *Intensive Care Units
MH  - Luxembourg/epidemiology
MH  - Male
MH  - Pandemics
MH  - Prospective Studies
MH  - Risk Factors
MH  - *SARS-CoV-2
MH  - Severity of Illness Index
MH  - Time Factors
PMC - PMC7684799
OTO - NOTNLM
OT  - *epidemiology
OT  - *molecular diagnostics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-041834 [pii]
AID - 10.1136/bmjopen-2020-041834 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e041834. doi: 10.1136/bmjopen-2020-041834.


PMID- 33234655
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Comparing efficacy and safety in catheter ablation strategies for atrial
      fibrillation: protocol of a network meta-analysis of randomised controlled
      trials.
PG  - e041819
LID - 10.1136/bmjopen-2020-041819 [doi]
AB  - INTRODUCTION: Atrial fibrillation (AF) is the most common sustained arrhythmia.
      Catheter ablation (CA) of AF is an increasingly offered therapeutic approach,
      primary to relieve AF-related symptoms. Despite the development of new ablation
      approaches, there is no consensus regarding the most efficient ablation strategy.
      The objective of this network meta-analysis (NMA) is to compare the efficacy and 
      safety of all different CA approaches for the treatment of patients with
      paroxysmal (PAF) and non-PAF (non-PAF). METHODS AND ANALYSIS: We will perform a
      systematic search to identify randomised controlled trials of different CA
      approaches for the treatment of PAF and non-PAF, through the final search date of
      1 March 2020. Information sources will include major bibliographic databases
      (MEDLINE, Web of Science and CENTRAL) and clinical trial registries. Our primary 
      outcomes will be the efficacy (recurrence-free survival) and safety of different 
      CA approaches for the treatment of AF. Secondary outcomes will be all-cause
      mortality and procedural time. An NMA will be performed to determine the relative
      effects of different catheter ablation approaches (such as pulmonary vein
      isolation alone or in combination with ablation lines, ablation of complex
      fractionated atrial electrograms, etc). In PAF, a separate analysis will be
      performed including different energy sources (such as radiofrequency, cryogenic
      and laser energy). Risk of bias assessment and sensitivity analyses will be
      conducted to assess the robustness of the findings to potential bias. ETHICS AND 
      DISSEMINATION: No ethical approval will be needed because data are collected from
      previous studies. The results will be presented through peer-review journals and 
      conference presentation. PROSPERO REGISTRATION NUMBER: CRD42020169494.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Charitakis, Emmanouil
AU  - Charitakis E
AUID- ORCID: 0000-0002-2514-5324
AD  - Department of Cardiology and Department of Health, Medicine and Caring Sciences, 
      Linkoping University Hospital, Linkoping, Sweden emmanouil.charitakis@liu.se.
FAU - Karlsson, Lars O
AU  - Karlsson LO
AD  - Department of Cardiology and Department of Health, Medicine and Caring Sciences, 
      Linkoping University Hospital, Linkoping, Sweden.
FAU - Rizas, Kostantinos
AU  - Rizas K
AD  - Department of Cardiology, LMU Munchen, Munchen, Germany.
FAU - Almroth, Henrik
AU  - Almroth H
AD  - Department of Cardiology and Department of Health, Medicine and Caring Sciences, 
      Linkoping University Hospital, Linkoping, Sweden.
FAU - Hassel Jonsson, Anders
AU  - Hassel Jonsson A
AD  - Department of Cardiology and Department of Health, Medicine and Caring Sciences, 
      Linkoping University Hospital, Linkoping, Sweden.
FAU - Schweiler, Jonas
AU  - Schweiler J
AD  - Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
FAU - Sideris, Skevos
AU  - Sideris S
AD  - Department of Cardiology, Hippokration Hospital, National and Kapodistrian
      University of Athens, Athens, Attica, Greece.
FAU - Tsartsalis, Dimitrios
AU  - Tsartsalis D
AD  - Department of Clinical Physiology, Linkoping University Hospital, Linkoping,
      Sweden.
FAU - Dragioti, Elena
AU  - Dragioti E
AUID- ORCID: 0000-0001-9019-4125
AD  - Pain and Rehabilitation Center and Department of Health and Caring Sciences,
      Linkoping University, Linkoping, Sweden.
FAU - Chaimani, Anna
AU  - Chaimani A
AD  - Research Center of Epidemiology and Statistics (CRESS-U1153), Univeriste de
      Paris, Paris, Ile-de-France, France.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Atrial Fibrillation/surgery
MH  - *Catheter Ablation
MH  - Humans
MH  - Network Meta-Analysis
MH  - *Pulmonary Veins/surgery
MH  - Recurrence
MH  - Treatment Outcome
PMC - PMC7684831
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiac epidemiology
OT  - *pacing & electrophysiology
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-041819 [pii]
AID - 10.1136/bmjopen-2020-041819 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e041819. doi: 10.1136/bmjopen-2020-041819.


PMID- 33234653
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Brief mindfulness-based intervention of 'STOP (Stop, Take a Breath, Observe,
      Proceed) touching your face': a study protocol of a randomised controlled trial.
PG  - e041364
LID - 10.1136/bmjopen-2020-041364 [doi]
AB  - INTRODUCTION: Face-touching behaviour often happens frequently and automatically,
      and poses potential risk for spreading infectious disease. Mindfulness-based
      interventions (MBIs) have shown its efficacy in the treatment of behaviour
      disorders. This study aims to evaluate an online mindfulness-based brief
      intervention skill named 'STOP (Stop, Take a Breath, Observe, Proceed) touching
      your face' in reducing face-touching behaviour. METHODS AND ANALYSIS: This will
      be an online-based, randomised, controlled, trial. We will recruit 1000
      participants, and will randomise and allocate participants 1:1 to the 'STOP
      touching your face' (both 750-word text and 5 min audio description by online)
      intervention group (n=500) and the wait-list control group (n=500). All
      participants will be asked to monitor and record their face-touching behaviour
      during a 60 min period before and after the intervention. Primary outcome will be
      the efficacy of short-term mindfulness-based 'STOP touching your face'
      intervention for reducing the frequency of face-touching. The secondary outcomes 
      will be percentage of participants touching their faces; the correlation between 
      the psychological traits of mindfulness and face-touching behaviour; and the
      differences of face-touching behaviour between left-handers and right-handers.
      Analysis of covariance, regression analysis, chi(2) test, t-test, Pearson's
      correlations will be applied in data analysis. We will recruit 1000 participants 
      from April to July 2020 or until the recruitment process is complete. The
      follow-up will be completed in July 2020. We expect all trial results to be
      available by the end of July 2020. ETHICS AND DISSEMINATION: The study protocol
      has been approved by the Ethics Committee of Sir Run Run Shaw Hospital, an
      affiliate of Zhejiang University, Medical College (No. 20200401-32). Study
      results will be disseminated via social media and peer-reviewed publications.
      TRIAL REGISTRATION NUMBER: NCT04330352.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liao, Yanhui
AU  - Liao Y
AUID- ORCID: 0000-0003-4735-3252
AD  - Department of Psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China liaoyanhui@zju.edu.cn.
AD  - Key Laboratory of Medical Neurobiology of Zhejiang Province, Hangzhou, China.
AD  - Addictions Department, Institute of Psychiatry, Psychology and Neuroscience,
      King's College London, London, UK.
FAU - Wang, Ling
AU  - Wang L
AD  - Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's
      College London, London, UK.
FAU - Luo, Tao
AU  - Luo T
AD  - Department of Social Medicine and Health Management, Xiangya School of Public
      Health, Central South University, Changsha, China.
AD  - The Treatment Center for Addiction, Jiangxi Mental Hospital, Nanchang, China.
FAU - Wu, Shiyou
AU  - Wu S
AD  - Department of Psychiatry, The Third Affiliated Hospital of Guizhou Medical
      University, Qiannan, China.
FAU - Wu, Zhenzhen
AU  - Wu Z
AD  - Department of Psychiatry, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center on Mental Disorders, Changsha, China.
FAU - Chen, Jianhua
AU  - Chen J
AD  - Shanghai Clinical Research Center for Mental Health, Shanghai Key Laboratory of
      Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University
      School of Medicine, Shanghai, China.
FAU - Pan, Chen
AU  - Pan C
AD  - Department of Clinical Psychology, The Third Xiangya Hospital, Central South
      University, Changsha, China.
FAU - Wang, Yunfei
AU  - Wang Y
AD  - Department of Psychiatry, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center on Mental Disorders, Changsha, China.
FAU - Liu, Yueheng
AU  - Liu Y
AD  - Department of Psychiatry, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - National Clinical Research Center on Mental Disorders, Changsha, China.
FAU - Luo, Qinghua
AU  - Luo Q
AD  - Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Guo, Xin
AU  - Guo X
AD  - Psychiatry Department, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Xie, Liqin
AU  - Xie L
AD  - Department of Educational Affairs, Changsha Social Work College, Changsha, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Nursing Department, School of Medicine, Changsha Social Work College, Changsha,
      China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
AD  - Key Laboratory of Medical Neurobiology of Zhejiang Province, Hangzhou, China.
FAU - Tang, Jinsong
AU  - Tang J
AUID- ORCID: 0000-0003-3796-1377
AD  - Department of Psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang
      University, Hangzhou, China.
AD  - Key Laboratory of Medical Neurobiology of Zhejiang Province, Hangzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04330352
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Crisis Intervention
MH  - Humans
MH  - *Mindfulness
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
MH  - Touch
PMC - PMC7689065
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *health & safety
OT  - *mental health
OT  - *public health
COIS- Competing interests: YLiao developed the 'STOP touching your face' training
      programme.
EDAT- 2020/11/26 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-041364 [pii]
AID - 10.1136/bmjopen-2020-041364 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e041364. doi: 10.1136/bmjopen-2020-041364.


PMID- 33234651
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Assessment of serological techniques for screening patients for COVID-19
      (COVID-SER): a prospective, multicentric study.
PG  - e041268
LID - 10.1136/bmjopen-2020-041268 [doi]
AB  - INTRODUCTION: The COVID-19 pandemic caused by SARS-CoV-2 threatens global public 
      health, and there is an urgent public health need to assess acquired immunity to 
      SARS-CoV-2. Serological tests might provide results that can be complementary to 
      or confirm suspected COVID-19 cases and reveal previous infection. The
      performance of serological assays (sensitivity and specificity) has to be
      evaluated before their use in the general population. The neutralisation capacity
      of the produced antibodies also has to be evaluated. METHODS AND ANALYSIS: We set
      up a prospective, multicentric clinical study to evaluate the performance of
      serological kits among a population of healthcare workers presenting mild
      symptoms suggestive of SARS-CoV-2 infection. Four hundred symptomatic healthcare 
      workers will be included in the COVID-SER study. The values obtained from a
      control cohort included during the prepandemic time will be used as reference. A 
      workflow was set up to study serological response to SARS-CoV-2 infection and to 
      evaluate antibody neutralisation capacity in patients with a confirmed SARS-CoV-2
      infection. The sensitivity and specificity of the tests will be assessed using
      molecular detection of the virus as a reference. The measurement of IgM and IgG
      antibodies will be performed once per week for 6 consecutive weeks and then at 6,
      12, 18, 24 and 36 months after the diagnosis. The kinetics of IgM and IgG will
      determine the optimal period to perform serological testing. The proportion of
      false negative PCR tests in symptomatic subjects will be determined on the basis 
      of subsequent seroconversions. ETHICS AND DISSEMINATION: Ethical approval has
      been obtained from the national review board for biomedical research in April
      2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France)
      (ID RCB 2020-A00932-37). Results will be disseminated through presentations at
      scientific meetings and publications in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: NCT04341142.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Trouillet-Assant, Sophie
AU  - Trouillet-Assant S
AD  - Virpath - Universite Lyon, CIRI, INSERM U1111, CNRS 5308, ENS, UCBL, Faculte de
      Medecine Lyon Est, Lyon, France.
AD  - Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Albert Vega, Chloe
AU  - Albert Vega C
AUID- ORCID: 0000-0002-5914-3554
AD  - Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Bal, Antonin
AU  - Bal A
AD  - Virpath - Universite Lyon, CIRI, INSERM U1111, CNRS 5308, ENS, UCBL, Faculte de
      Medecine Lyon Est, Lyon, France.
AD  - Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils
      de Lyon, Groupement Hospitalier Nord, Lyon, France.
FAU - Nazare, Julie Anne
AU  - Nazare JA
AD  - CRNH Rhone-Alpes, University Lyon 1, Laboratoire CarMeN, Inserm U1060, INRA
      U1397, Pierre Benite, France.
FAU - Fascia, Pascal
AU  - Fascia P
AD  - Centre d'appui a la Prevention des Infections Associees aux Soins Auvergne -
      Rhone-Alpes, Hospices Civils de Lyon - Hopital H Gabrielle, 20 route de Vourles, 
      Saint Genis Laval, France.
FAU - Paul, Adele
AU  - Paul A
AD  - UMR T 9405, Univ Lyon, Univ Eiffel, Univ Lyon 1, IFSTTAR, UMRESTTE, Lyon, France.
AD  - Service de medecine du travail et des pathologies professionnelles, Hospices
      Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Massardier-Pilonchery, Amelie
AU  - Massardier-Pilonchery A
AD  - UMR T 9405, Univ Lyon, Univ Eiffel, Univ Lyon 1, IFSTTAR, UMRESTTE, Lyon, France.
AD  - Service de medecine du travail et des pathologies professionnelles, Hospices
      Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - D Aubarede, Constance
AU  - D Aubarede C
AD  - Service de medecine du travail et des pathologies professionnelles, Hospices
      Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Guibert, Nicolas
AU  - Guibert N
AD  - UMR T 9405, Univ Lyon, Univ Eiffel, Univ Lyon 1, IFSTTAR, UMRESTTE, Lyon, France.
AD  - Service de medecine du travail et des pathologies professionnelles, Hospices
      Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Pitiot, Virginie
AU  - Pitiot V
AD  - Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Lahousse, Matthieu
AU  - Lahousse M
AD  - Infectious and Tropical Diseases Unit, Hospices Civils de Lyon, Edouard Herriot
      Hospital, Lyon, France.
FAU - Boibieux, Andre
AU  - Boibieux A
AD  - Infectious and Tropical Diseases Unit, Hospices Civils de Lyon, Edouard Herriot
      Hospital, Lyon, France.
FAU - Makhloufi, Djamila
AU  - Makhloufi D
AD  - Infectious and Tropical Diseases Unit, Hospices Civils de Lyon, Edouard Herriot
      Hospital, Lyon, France.
FAU - Simon, Chantal
AU  - Simon C
AD  - CRNH Rhone-Alpes, University Lyon 1, Laboratoire CarMeN, Inserm U1060, INRA
      U1397, Pierre Benite, France.
AD  - Service d'Endocrinologie, diabete, nutrition, Hospices Civils de Lyon, Centre
      Hospitalier Lyon Sud, Pierre Benite, France.
FAU - Rabilloud, Muriel
AU  - Rabilloud M
AD  - Universite de Lyon; Universite Lyon 1; Hospices Civils de Lyon, Pole Sante
      Publique, Service de Biostatistique et Bioinformatique ; CNRS, UMR 5558,
      Laboratoire de Biometrie et Biologie Evolutive, Equipe Biostatistique-Sante,
      Lyon, France.
FAU - Trabaud, Mary Anne
AU  - Trabaud MA
AD  - Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils
      de Lyon, Groupement Hospitalier Nord, Lyon, France.
FAU - Gueyffier, Francois
AU  - Gueyffier F
AD  - UMR5558, Service des Donnees de Sante, Pole de Sante Publique, Hospices Civils de
      Lyon, & Universite de Lyon, Universite Lyon 1, CNRS, Laboratoire de Biometrie et 
      Biologie Evolutive, Villeurbanne, France.
FAU - Fassier, Jean-Baptiste
AU  - Fassier JB
AD  - UMR T 9405, Univ Lyon, Univ Eiffel, Univ Lyon 1, IFSTTAR, UMRESTTE, Lyon, France 
      jean-baptiste.fassier@chu-lyon.fr.
AD  - Service de medecine du travail et des pathologies professionnelles, Hospices
      Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite, France.
CN  - COVID-SER study group
LA  - eng
SI  - ClinicalTrials.gov/NCT04341142
PT  - Clinical Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Antibodies, Viral/*analysis
MH  - COVID-19/*diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Screening/*methods
MH  - *Pandemics
MH  - Prospective Studies
MH  - SARS-CoV-2/*immunology
MH  - Serologic Tests
PMC - PMC7688438
OTO - NOTNLM
OT  - *diagnostic microbiology
OT  - *molecular diagnostics
OT  - *public health
COIS- Competing interests: AB has received grant from bioMerieux and has served as
      consultant for bioMerieux for work and research not related to this manuscript.
IR  - Adnot J
FIR - Adnot, Jerome
IR  - Alfaiate D
FIR - Alfaiate, Dulce
IR  - Bal A
FIR - Bal, Antonin
IR  - Bergeret A
FIR - Bergeret, Alain
IR  - Boibieux A
FIR - Boibieux, Andre
IR  - Bonnet F
FIR - Bonnet, Florent
IR  - Bourgeois G
FIR - Bourgeois, Gaelle
IR  - Brunel-Dalmas F
FIR - Brunel-Dalmas, Florence
IR  - Caire E
FIR - Caire, Eurydice
IR  - Charbotel B
FIR - Charbotel, Barbara
IR  - Chiarello P
FIR - Chiarello, Pierre
IR  - Cotte L
FIR - Cotte, Laurent
IR  - d'Aubarede C
FIR - d'Aubarede, Constance
IR  - Durupt F
FIR - Durupt, Francois
IR  - Vanessa E
FIR - Vanessa, Escuret
IR  - Pascal F
FIR - Pascal, Fascia
IR  - Jean-Baptiste F
FIR - Jean-Baptiste, Fassier
IR  - Juliette F
FIR - Juliette, Fontaine
IR  - Lucie GD
FIR - Lucie, Gaillot-Durand
IR  - Alexandre G
FIR - Alexandre, Gaymard
IR  - Myriam G
FIR - Myriam, Gillet
IR  - Matthieu G
FIR - Matthieu, Godinot
IR  - Francois G
FIR - Francois, Gueyffier
IR  - Nicolas G
FIR - Nicolas, Guibert
IR  - Laurence J
FIR - Laurence, Josset
IR  - Matthieu L
FIR - Matthieu, Lahousse
IR  - Bruno L
FIR - Bruno, Lina
IR  - Helene L
FIR - Helene, Lozano
IR  - Djamila M
FIR - Djamila, Makhloufi
IR  - Amelie MP
FIR - Amelie, Massardier-Pilonchery
IR  - Marie-Paule M
FIR - Marie-Paule, Milon
IR  - Frederic M
FIR - Frederic, Moll
IR  - Florence M
FIR - Florence, Morfin
IR  - David N
FIR - David, Narbey
IR  - Julie-Anne N
FIR - Julie-Anne, Nazare
IR  - Fatima O
FIR - Fatima, Oria
IR  - Adele P
FIR - Adele, Paul
IR  - Marielle P
FIR - Marielle, Perry
IR  - Virginie P
FIR - Virginie, Pitiot
IR  - Melanie P
FIR - Melanie, Prudent
IR  - Muriel R
FIR - Muriel, Rabilloud
IR  - Audrey S
FIR - Audrey, Samperiz
IR  - Isabelle S
FIR - Isabelle, Schlienger
IR  - Chantal S
FIR - Chantal, Simon
IR  - Mary-Anne T
FIR - Mary-Anne, Trabaud
IR  - Sophie TA
FIR - Sophie, Trouillet-Assant
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-041268 [pii]
AID - 10.1136/bmjopen-2020-041268 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e041268. doi: 10.1136/bmjopen-2020-041268.


PMID- 33234650
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Exploring the effectiveness of technology-based learning on the educational
      outcomes of undergraduate healthcare students: an overview of systematic reviews 
      protocol.
PG  - e041153
LID - 10.1136/bmjopen-2020-041153 [doi]
AB  - INTRODUCTION: Rapid technology development due to the introduction of Industrial 
      Revolution 4.0 and Internet of Things has created a demand and gradual transition
      from traditional teaching and learning to technology-based learning in higher
      education, including healthcare education. The COVID-19 pandemic has accelerated 
      this process, with educators now required to quickly adapt to and adopt such
      changes. The abundance of available systematic reviews has made the effectiveness
      of such approaches ambiguous especially in healthcare education. Therefore, a
      protocol of the overview of systematic reviews (OoSR) is planned to extrapolate
      the effectiveness of technology-based learning in undergraduate healthcare
      education. METHODS AND ANALYSIS: Scopus, CINAHL, Academic Search Complete,
      Cochrane Library, MEDLINE and Psychology and Behavioral Sciences Collection
      databases were selected. Screening was conducted independently by at least two
      authors and the decision for inclusion was done through discussion or involvement
      of an arbiter against a predetermined criteria. Included articles will be
      evaluated for quality using A MeaSurement Tool to Assess systematic Reviews and
      Risk of Bias in Systematic Review tools, while primary systematic review articles
      will be cross-checked and reported for any overlapping using the 'corrected
      covered area' method. Only narrative synthesis will be employed according to the 
      predefined themes into two major dimensions-theory and knowledge generation
      (focusing on cognitive taxonomy due to its ability to be generalised across
      disciplines), and clinical-based competence (focusing on psychomotor and
      affective taxonomies due to discipline-specific influence). The type of
      technology used will be identified and extracted. ETHICS AND DISSEMINATION: The
      OoSR involves analysis of secondary data from published literature, thus ethical 
      approval is not required. The findings will provide a valuable insight for
      policymakers, stakeholders, and researchers in terms of technology-based learning
      implementation and gaps identification. The findings will be published in several
      reports due to the extensiveness of the topic and will be disseminated through
      peer-reviewed publications and conferences. PROSPERO REGISTRATION NUMBER:
      CRD4202017974.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Romli, Muhammad Hibatullah
AU  - Romli MH
AUID- ORCID: 0000-0003-4361-8102
AD  - Department of Rehabilitation Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
AD  - Malaysian Research Institute on Ageing (MyAgeing), Universiti Putra Malaysia,
      43400 UPM Serdang, Selangor, Malaysia.
FAU - Cheema, Manraj Singh
AU  - Cheema MS
AUID- ORCID: 0000-0002-3763-3456
AD  - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
FAU - Mehat, Muhammad Zulfadli
AU  - Mehat MZ
AUID- ORCID: 0000-0002-9740-6458
AD  - Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti 
      Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
FAU - Md Hashim, Nur Fariesha
AU  - Md Hashim NF
AUID- ORCID: 0000-0002-4361-2061
AD  - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.
FAU - Abdul Hamid, Hafizah
AU  - Abdul Hamid H
AUID- ORCID: 0000-0001-5333-4694
AD  - Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti 
      Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia a_hafizah@upm.edu.my.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - COVID-19/*epidemiology
MH  - *Curriculum
MH  - Education, Medical/*methods
MH  - Educational Status
MH  - Health Personnel/*education
MH  - Humans
MH  - *Learning
MH  - *SARS-CoV-2
MH  - *Students
PMC - PMC7684815
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *general medicine (see internal medicine)
OT  - *medical education & training
OT  - *natural science disciplines
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-041153 [pii]
AID - 10.1136/bmjopen-2020-041153 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e041153. doi: 10.1136/bmjopen-2020-041153.


PMID- 33234648
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Dexmedetomidine for the prevention of postoperative delirium in patients after
      intracranial operation for brain tumours (DEPOD study): a study protocol and
      statistical plan for a multicentre randomised controlled trial.
PG  - e040939
LID - 10.1136/bmjopen-2020-040939 [doi]
AB  - INTRODUCTION: Postoperative delirium (POD) is prevalent in patients after major
      surgery and is associated with adverse outcomes. Several studies have reported
      that dexmedetomidine, a highly selective alpha2-adrenergic receptor agonist, can 
      decrease the incidence of POD. However, neurosurgical patients are usually
      excluded from previous studies. The present study was designed to investigate the
      impact of prophylactic use of low-dose dexmedetomidine on the incidence of POD in
      patients after intracranial operation. METHODS AND ANALYSIS: This is a
      multicentre, randomised, double-blinded and placebo-controlled trial. Seven
      hundred intensive care unit admitted patients after elective intracranial
      operation for brain tumours under general anaesthesia are randomly assigned to
      the dexmedetomidine group or the placebo group with a 1:1 ratio. For patients in 
      the dexmedetomidine group, a continuous infusion of dexmedetomidine will be
      started at a rate of 0.1 mug/kg/hour immediately after enrolment on the day of
      operation and continued until 08:00 on postoperative day 1. For patients in the
      placebo group, normal saline will be administered at the same rate as in the
      dexmedetomidine group. The patients will be followed up for 28 days after
      enrolment. The primary endpoint is the incidence of POD, which is assessed two
      times per day using the Confusion Assessment Method for the intensive care unit
      (ICU), during the first 5 postoperative days. The secondary endpoints include the
      incidence of dexmedetomidine-related adverse events and non-delirium
      complications, the length of stay in the ICU and hospital and all-cause 28-day
      mortality after the operation. ETHICS AND DISSEMINATION: The study protocol was
      approved by the Institutional Review Board of Beijing Tiantan Hospital Affiliated
      to Capital Medical University (No KY2019-091-02) and registered at
      ClinicalTrials.gov. The results of the trial will be presented at national and
      international conferences relevant to subject fields and submitted to
      international peer-reviewed journals. TRIAL REGISTRATION NUMBER: Trial
      registration number: NCT04399343; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, Xuan
AU  - He X
AD  - Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Cheng, Kun-Ming
AU  - Cheng KM
AD  - Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Zhang, Linlin
AU  - Zhang L
AD  - Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Gu, Hongqiu
AU  - Gu H
AUID- ORCID: 0000-0003-1608-1856
AD  - China National Clinical Research Center for Neurological Diseases, Beijing
      Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Qu, Xin
AU  - Qu X
AD  - Department of Neurosurgical Critical Care, Xuanwu Hospital, Capital Medical
      University, Beijing, China.
FAU - Xu, Yuan
AU  - Xu Y
AD  - Department of Critical Care Medicine, Tsinghua University Affiliated Beijing
      Tsinghua Changgung Hospital, Beijing, China.
FAU - Ma, Penglin
AU  - Ma P
AUID- ORCID: 0000-0002-8265-2947
AD  - Department of Critical Care Medicine, Peking University Third Hospital, Beijing, 
      China.
FAU - Zhou, Jian-Xin
AU  - Zhou JX
AUID- ORCID: 0000-0002-1559-7554
AD  - Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China zhoujx.cn@icloud.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04399343
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Adrenergic alpha-2 Receptor Agonists)
RN  - 0 (Hypnotics and Sedatives)
RN  - 67VB76HONO (Dexmedetomidine)
SB  - IM
MH  - *Adrenergic alpha-2 Receptor Agonists/therapeutic use
MH  - *Brain Neoplasms/surgery
MH  - *Delirium/epidemiology/etiology/prevention & control
MH  - *Dexmedetomidine/therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Hypnotics and Sedatives/adverse effects
MH  - Randomized Controlled Trials as Topic
PMC - PMC7684814
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *delirium & cognitive disorders
OT  - *neurosurgery
COIS- Competing interests: The experimental agents (dexmedetomidine hydrochloride and
      normal saline) are manufactured, packed and provided by the Jiangsu Nhwa
      Pharmaceutical Co., (Jiangsu, China). Agents provider has no role in the study
      design and conduct; the data collection, management, analysis and interpretation;
      or the preparation and approval of the manuscript.
EDAT- 2020/11/26 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040939 [pii]
AID - 10.1136/bmjopen-2020-040939 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e040939. doi: 10.1136/bmjopen-2020-040939.


PMID- 33234647
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Computerised cognitive training in Parkinson's disease: a protocol for a
      systematic review and updated meta-analysis.
PG  - e040656
LID - 10.1136/bmjopen-2020-040656 [doi]
AB  - INTRODUCTION: Cognitive impairment is recognised as an important non-motor
      symptom in Parkinson's disease (PD) and there is a need for evidence-based
      non-pharmacological interventions that may prevent or slow cognitive decline in
      this patient group. One such intervention is computerised cognitive training
      (CCT), which has shown efficacious for cognition across older adult populations. 
      This systematic review aims to investigate the efficacy of CCT across cognitive, 
      psychosocial and functional domains for people with PD and examine study and
      intervention design factors that could moderate CCT effects on cognition. METHODS
      AND ANALYSIS: Randomised controlled trials investigating the effects of CCT in
      patients with PD without dementia, on cognitive, psychosocial or functional
      outcomes, will be included. The primary outcome is overall cognitive function.
      Secondary outcomes are domain-specific cognitive function, psychosocial
      functioning and functional abilities. We systematically searched MEDLINE, Embase 
      and PsycINFO through 14 May 2020 to identify relevant literature. Risk of bias
      will be assessed using the revised Cochrane Risk of Bias tool. Effect sizes will 
      be calculated as standardised mean difference of baseline to postintervention
      change (Hedges' g) with 95% CI for each eligible outcome measure. Pooling of
      outcomes across studies will be conducted using random-effects models, accounting
      for dependency structure of effect sizes within studies. Heterogeneity will be
      assessed using tau(2) and I(2) statistic. Potential moderators, based on key
      study and intervention design factors, will be investigated using mixed-effects
      meta-regression models. ETHICS AND DISSEMINATION: No ethical approval is
      required. The findings will be disseminated in a peer-reviewed scientific
      journal. PROSPERO REGISTRATION NUMBER: CRD42020185386.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Gavelin, Hanna Malmberg
AU  - Gavelin HM
AUID- ORCID: 0000-0003-3256-9018
AD  - Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University
      of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Psychology, Umea University, Umea, Sweden.
FAU - Domellof, Magdalena
AU  - Domellof M
AUID- ORCID: 0000-0002-2348-1164
AD  - Department of Psychology, Umea University, Umea, Sweden.
FAU - Leung, Isabella
AU  - Leung I
AD  - Healthy Brain Ageing Program, Brain and Mind Centre, The University of Sydney,
      Camperdown, New South Wales, Australia.
AD  - Central Clinical School, Faculty of Medicine and Health, Charles Perkins Centre, 
      The University of Sydney, Camperdown, New South Wales, Australia.
FAU - Neely, Anna Stigsdotter
AU  - Neely AS
AUID- ORCID: 0000-0003-3450-8067
AD  - Department of Social and Psychological Studies, Karlstad University, Karlstad,
      Sweden.
FAU - Finke, Carsten
AU  - Finke C
AUID- ORCID: 0000-0002-7665-1171
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, Berlin, Germany.
AD  - Berlin School of Mind and Brain, Humboldt-Universitat zu Berlin, Berlin, Germany.
FAU - Lampit, Amit
AU  - Lampit A
AUID- ORCID: 0000-0001-6522-8397
AD  - Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University
      of Melbourne, Melbourne, Victoria, Australia amit.lampit@unimelb.edu.au.
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, Berlin, Germany.
AD  - Berlin School of Mind and Brain, Humboldt-Universitat zu Berlin, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Cognition
MH  - *Cognition Disorders
MH  - *Cognitive Dysfunction/etiology/therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Outcome Assessment, Health Care
MH  - *Parkinson Disease/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7689075
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *geriatric medicine
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040656 [pii]
AID - 10.1136/bmjopen-2020-040656 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e040656. doi: 10.1136/bmjopen-2020-040656.


PMID- 33234646
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - MyCare study: protocol for a controlled trial evaluating the effect of a
      community-based intervention on psychosocial, clinical outcomes and hospital
      admission rates for adults with severe mental illness.
PG  - e040610
LID - 10.1136/bmjopen-2020-040610 [doi]
AB  - INTRODUCTION: People with serious mental illness (SMI) often fail to receive
      adequate treatment. To provide a higher level of support, mental health systems
      have been reformed substantially to integrate mental healthcare into the
      community. MyCare is one such community-based mental health model of care. This
      paper describes the study protocol of a controlled trial examining the effect of 
      MyCare on psychosocial and clinical outcomes and hospital admission and duration 
      rates for adults with SMI. METHODS AND ANALYSIS: This is a multisite
      non-randomised controlled trial with a 3, 6 and 12-month follow-up period. The
      study participants will be adults (18-64 years of age) with SMI recruited from
      Hobart, Launceston and the North-West of Tasmania. The treatment group will
      include adults who receive both the MyCare intervention and standard mental
      health support; the control group will include adults who receive only standard
      mental health support. The primary outcome includes psychosocial and clinical
      functioning and the secondary outcome will examine hospital admission rates and
      duration of stay. Mixed-effects models will be used to examine outcome
      improvements between intake and follow-up. This trial will generate the evidence 
      needed to evaluate the effect of a community mental health support programme
      delivered in Tasmania, Australia. If MyCare results in sustained positive
      outcomes for adults with SMI, it could potentially be scaled up more broadly
      across Australia, addressing the inequity and lack of comprehensive treatment
      that many individuals with SMI experience. ETHICS AND DISSEMINATION: This study
      has been approved by the Tasmanian Health and Medical Human Research Ethics
      Committee. The findings will be disseminated to participants and staff who
      delivered the intervention, submitted for publication in a peer-reviewed journal 
      and shared at academic conferences. TRIAL REGISTRATION NUMBER:
      ACTRN12620000673943.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - O'Donnell, Renee
AU  - O'Donnell R
AUID- ORCID: 0000-0003-2563-2867
AD  - Monash Centre for Health Research and Implementation, Monash University, Clayton,
      Victoria, Australia.
FAU - Savaglio, Melissa
AU  - Savaglio M
AD  - Monash Centre for Health Research and Implementation, Monash University, Clayton,
      Victoria, Australia.
FAU - Fast, Debra
AU  - Fast D
AD  - Baptcare, Tasmania, Victoria, Australia.
FAU - Vincent, Ash
AU  - Vincent A
AD  - Baptcare, Tasmania, Victoria, Australia.
FAU - Vicary, Dave
AU  - Vicary D
AD  - Baptcare, Footscray, Victoria, Australia.
FAU - Skouteris, Helen
AU  - Skouteris H
AD  - Monash Centre for Health Research and Implementation, Monash University, Clayton,
      Victoria, Australia helen.skouteris@monash.edu.
AD  - Warwick Business School, University of Warwick, Coventry, West Midlands, UK.
LA  - eng
SI  - ANZCTR/ACTRN12620000673943
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - *Community Health Services
MH  - Hospitals
MH  - Humans
MH  - *Mental Health
MH  - Middle Aged
MH  - Patient Admission
MH  - Tasmania
MH  - Young Adult
PMC - PMC7684817
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *psychiatry
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040610 [pii]
AID - 10.1136/bmjopen-2020-040610 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e040610. doi: 10.1136/bmjopen-2020-040610.


PMID- 33234645
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Azathioprine immunosuppression and disease modification in Parkinson's disease
      (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.
PG  - e040527
LID - 10.1136/bmjopen-2020-040527 [doi]
AB  - INTRODUCTION: The immune system is implicated in the aetiology and progression of
      Parkinson's disease (PD). Inflammation and immune activation occur both in the
      brain and in the periphery, and a proinflammatory cytokine profile is associated 
      with more rapid clinical progression. Furthermore, the risk of developing PD is
      related to genetic variation in immune-related genes and reduced by the use of
      immunosuppressant medication. We are therefore conducting a 'proof of concept'
      trial of azathioprine, an immunosuppressant medication, to investigate whether
      suppressing the peripheral immune system has a disease-modifying effect in PD.
      METHODS AND ANALYSIS: AZA-PD is a phase II randomised placebo-controlled
      double-blind trial in early PD. Sixty participants, with clinical markers
      indicating an elevated risk of disease progression and no inflammatory or immune 
      comorbidity, will be treated (azathioprine:placebo, 1:1) for 12 months, with a
      further 6-month follow-up. The primary outcome is the change in the Movement
      Disorder Society-Unified Parkinson's Disease Rating Scale gait/axial score in the
      OFF state over the 12-month treatment period. Exploratory outcomes include
      additional measures of motor and cognitive function, non-motor symptoms and
      quality of life. In addition, peripheral and central immune markers will be
      investigated through analysis of blood, cerebrospinal fluid and PK-11195 positron
      emission tomography imaging. ETHICS AND DISSEMINATION: The study was approved by 
      the London-Westminster research ethics committee (reference 19/LO/1705) and has
      been accepted by the Medicines and Healthcare products Regulatory Agency (MHRA)
      for a clinical trials authorisation (reference CTA 12854/0248/001-0001). In
      addition, approval has been granted from the Administration of Radioactive
      Substances Advisory Committee. The results of this trial will be disseminated
      through publication in scientific journals and presentation at national and
      international conferences, and a lay summary will be available on our website.
      TRIAL REGISTRATION NUMBERS: ISRCTN14616801 and EudraCT- 2018-003089-14.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Greenland, Julia C
AU  - Greenland JC
AUID- ORCID: 0000-0001-9267-0586
AD  - Department of Clinical Neurosciences, University of Cambridge, Cambridge,
      Cambridgeshire, UK jcg69@cam.ac.uk.
FAU - Cutting, Emma
AU  - Cutting E
AD  - Department of Clinical Neurosciences, University of Cambridge, Cambridge,
      Cambridgeshire, UK.
AD  - Cambridge Clinical Trials Unit, Cambridge, Cambridgeshire, UK.
FAU - Kadyan, Sonakshi
AU  - Kadyan S
AD  - Cambridge Clinical Trials Unit, Cambridge, Cambridgeshire, UK.
FAU - Bond, Simon
AU  - Bond S
AD  - Cambridge Clinical Trials Unit, Cambridge, Cambridgeshire, UK.
FAU - Chhabra, Anita
AU  - Chhabra A
AD  - Department of Pharmacy, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge, Cambridgeshire, UK.
FAU - Williams-Gray, Caroline H
AU  - Williams-Gray CH
AD  - Department of Clinical Neurosciences, University of Cambridge, Cambridge,
      Cambridgeshire, UK.
LA  - eng
SI  - ISRCTN/ISRCTN14616801
SI  - EudraCT/2018-003089-14
GR  - MR/R007446/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Immunosuppressive Agents)
RN  - MRK240IY2L (Azathioprine)
SB  - IM
MH  - *Azathioprine/therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Immunosuppression Therapy
MH  - *Immunosuppressive Agents/therapeutic use
MH  - *Parkinson Disease/drug therapy
MH  - Quality of Life
MH  - Treatment Outcome
PMC - PMC7684836
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *immunology
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040527 [pii]
AID - 10.1136/bmjopen-2020-040527 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e040527. doi: 10.1136/bmjopen-2020-040527.


PMID- 33234644
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Improving the Safety and Continuity Of Medicines management at Transitions of
      care (ISCOMAT): protocol for a process evaluation of a cluster randomised control
      trial.
PG  - e040493
LID - 10.1136/bmjopen-2020-040493 [doi]
AB  - INTRODUCTION: A key priority for the UK National Health Service and patients is
      to ensure that medicines are used safely and effectively. However, medication
      changes are not always optimally communicated and implemented when patients
      transfer from hospital into community settings. Heart failure is a common reason 
      for admission to hospital. Patients with heart failure have a high burden of
      morbidity, mortality and complex pharmacotherapeutic regimens. The Improving the 
      Safety and Continuity Of Medicines management at Transitions of care programme
      comprises a cluster randomised controlled trial which will test the effectiveness
      of a complex behavioural intervention aimed at improving medications management
      at the interface between hospitals discharge and community care. We will conduct 
      a rigorous process evaluation to inform interpretation of the trial findings,
      inform implementation of the intervention on a wider scale and aid dissemination 
      of the intervention. METHODS AND ANALYSIS: The process evaluation will be
      conducted in six purposively selected intervention sites (ie, hospital trusts and
      associated community pharmacies) using a mixed-methods design. Fidelity and
      barriers/enablers of implementation of the Medicines at Transitions Intervention 
      (MaTI) will be explored using observation, interviews (20 patients, 40 healthcare
      professionals), surveys and routine trial data collection on adherence to MaTI. A
      parallel mixed analysis will be applied. Qualitative data will be thematically
      analysed using Framework analysis and survey data will be analysed descriptively.
      Data will be synthesised, triangulated and mapped to the Consolidated Framework
      for Implementation Research where appropriate. The process evaluation commenced
      on June 2018 and is due to end on February 2021. ETHICS AND DISSEMINATION:
      Approved by Research Ethics Committee and the UK Health Research Authority REC:
      18/YH/0017/IRAS: 231 431. Findings will be disseminated via academic and policy
      conferences, peer-reviewed publications and social media. TRIAL REGISTRATION
      NUMBER: ISRCTN66212970.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Powell, Catherine
AU  - Powell C
AUID- ORCID: 0000-0001-7590-0247
AD  - School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of 
      Bradford, Bradford, UK C.Powell2@bradford.ac.uk.
AD  - Wolfson Centre for Applied Health Research, Bradford, UK.
FAU - Breen, Liz
AU  - Breen L
AUID- ORCID: 0000-0001-5204-1187
AD  - School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of 
      Bradford, Bradford, UK.
AD  - Wolfson Centre for Applied Health Research, Bradford, UK.
AD  - Bradford Institute for Health Research, NIHR Yorkshire and Humber Patient Safety 
      Translational Research Centre, Bradford, UK.
FAU - Fylan, Beth
AU  - Fylan B
AUID- ORCID: 0000-0003-0599-4537
AD  - School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of 
      Bradford, Bradford, UK.
AD  - Wolfson Centre for Applied Health Research, Bradford, UK.
AD  - Bradford Institute for Health Research, NIHR Yorkshire and Humber Patient Safety 
      Translational Research Centre, Bradford, UK.
FAU - Ismail, Hanif
AU  - Ismail H
AUID- ORCID: 0000-0002-7885-6648
AD  - School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of 
      Bradford, Bradford, UK.
AD  - Wolfson Centre for Applied Health Research, Bradford, UK.
FAU - Alderson, Sarah L
AU  - Alderson SL
AUID- ORCID: 0000-0002-5418-0495
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Gale, Chris P
AU  - Gale CP
AUID- ORCID: 0000-0003-4732-382X
AD  - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds,
      Leeds, UK.
AD  - Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
AD  - Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Gardner, Peter
AU  - Gardner P
AUID- ORCID: 0000-0002-8799-0443
AD  - School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of 
      Bradford, Bradford, UK.
AD  - Wolfson Centre for Applied Health Research, Bradford, UK.
FAU - Farrin, Amanda J
AU  - Farrin AJ
AUID- ORCID: 0000-0002-2876-0584
AD  - Clinical Trials Research Unit, University of Leeds, Leeds, UK.
FAU - Alldred, David P
AU  - Alldred DP
AUID- ORCID: 0000-0002-2525-4854
AD  - Wolfson Centre for Applied Health Research, Bradford, UK.
AD  - Bradford Institute for Health Research, NIHR Yorkshire and Humber Patient Safety 
      Translational Research Centre, Bradford, UK.
AD  - School of Healthcare, University of Leeds, Leeds, UK.
CN  - ISCOMAT Programme Management Team
LA  - eng
SI  - ISRCTN/ISRCTN66212970
GR  - RP-PG-0514-20009/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Heart Failure
MH  - Hospitalization
MH  - Humans
MH  - Patient Discharge
MH  - Randomized Controlled Trials as Topic
MH  - *State Medicine
MH  - Surveys and Questionnaires
PMC - PMC7689064
OTO - NOTNLM
OT  - *cardiology
OT  - *clinical trials
OT  - *heart failure
OT  - *statistics & research methods
COIS- Competing interests: None declared.
IR  - Silcock J
FIR - Silcock, Jon
IR  - Raynor DK
FIR - Raynor, David K
IR  - Turner R
FIR - Turner, Robert
IR  - Wright J
FIR - Wright, John
IR  - Kellar I
FIR - Kellar, Ian
IR  - Longo R
FIR - Longo, Roberta
IR  - Holloway I
FIR - Holloway, Ivana
IR  - Bojke C
FIR - Bojke, Chris
EDAT- 2020/11/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040493 [pii]
AID - 10.1136/bmjopen-2020-040493 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e040493. doi: 10.1136/bmjopen-2020-040493.


PMID- 33234643
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Associations between gestational diabetes mellitus and the neurodevelopment of
      offspring from 1 month to 72 months: study protocol for a cohort study.
PG  - e040305
LID - 10.1136/bmjopen-2020-040305 [doi]
AB  - INTRODUCTION: Gestational diabetes mellitus (GDM) is a common gestational disease
      and an important global public health problem. GDM may affect the short-term and 
      long-term health of offspring, but the associations between GDM and the
      neurodevelopment of offspring of mothers with GDM (OGDM) are still unclear, and
      studies based on the Chinese population are lacking. We aim to determine the
      associations between GDM and the neurodevelopment of OGDM by studying a cohort of
      OGDM and offspring of non-GDM mothers. METHODS AND ANALYSIS: The single-centre
      prospective cohort study is being conducted in China over 7 years. A total of 490
      OGDM (GDM group) and 490 fromof healthy mothers (control group) will be enrolled 
      during the same period. Baseline characteristics, neuropsychological development 
      scores and clinical data at specific time points (at 0, 1, 3, 6, 12, 24, 36, 48, 
      60 and 72 months old) will be collected from the children in both groups until
      the age of 6 years. The associations between GDM and the neurodevelopment of OGDM
      from infancy to preschool age will be analysed using a multiple linear regression
      model adjusted for confounders. In addition, we will compare longitudinal data to
      further assess the effects of GDM on neurodevelopmental trajectories. ETHICS AND 
      DISSEMINATION: The study has been approved by the Ethics Committee of the
      Children's Hospital of Chongqing Medical University (Approval Number: (2019)
      Institutional Review Board (IRB) (STUDY) No. 85). The findings of this study will
      be disseminated through open access journals, peer-reviewed journals and
      scientific meetings. TRIAL REGISTRATION NUMBER: NCT03997396.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Chao
AU  - Li C
AUID- ORCID: 0000-0003-2596-3754
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China.
AD  - Department of Child Care, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Zhou, Ping
AU  - Zhou P
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China.
FAU - Cai, Yixi
AU  - Cai Y
AD  - Department of Child Care, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Peng, Bin
AU  - Peng B
AD  - Department of Health Statistics, Chongqing Medical University, Chongqing, China.
FAU - Liu, Yongfang
AU  - Liu Y
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China.
FAU - Yang, Ting
AU  - Yang T
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China.
FAU - Li, Yinying
AU  - Li Y
AD  - Department of Child Care, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Hu, Yirong
AU  - Hu Y
AD  - Department of Outpatient, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Fu, Yajun
AU  - Fu Y
AD  - Department of Obstetrics, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Wang, Zhenming
AU  - Wang Z
AD  - Department of Obstetrics, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Peng, Hong
AU  - Peng H
AD  - Department of Child Care, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Department of Child Care, The First People's Hospital of Chongqing Liangjiang New
      Area, Chongqing, China.
FAU - Chen, Jie
AU  - Chen J
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China.
FAU - Li, Tingyu
AU  - Li T
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China.
FAU - Chen, Li
AU  - Chen L
AUID- ORCID: 0000-0002-2614-1528
AD  - Growth, Development and Mental Health Center of Children and Adolescents,
      Children's Hospital of Chongqing Medical University; National Clinical Research
      Center for Child Health and Disorders; Ministry of Education Key Laboratory of
      Child Development and Disorders; Chongqing Key Laboratory of Child Health and
      Nutrition, Chongqing, China chenli@cqmu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03997396
PT  - Clinical Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - China/epidemiology
MH  - Cohort Studies
MH  - *Diabetes, Gestational/epidemiology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Mothers
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7689080
OTO - NOTNLM
OT  - *community child health
OT  - *developmental neurology & neurodisability
OT  - *diabetes in pregnancy
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040305 [pii]
AID - 10.1136/bmjopen-2020-040305 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e040305. doi: 10.1136/bmjopen-2020-040305.


PMID- 33234638
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Theory-based digital intervention to promote weight loss and weight loss
      maintenance (Choosing Health): protocol for a randomised controlled trial.
PG  - e040183
LID - 10.1136/bmjopen-2020-040183 [doi]
AB  - INTRODUCTION: Digital behavioural weight loss interventions have the potential to
      improve public health; however, these interventions are often not adequately
      tailored to the needs of the participants. This is the protocol for a trial that 
      aims to determine the effectiveness and cost-effectiveness of the Choosing Health
      programme as a means to promote weight loss and weight loss maintenance among
      overweight/obese adults. METHODS AND ANALYSIS: The proposed study is a two-group 
      randomised controlled trial with a nested interrupted time series (ITS)
      within-person design. Participants (n=285) will be randomly assigned to either
      the Choosing Health digital intervention or a control group. For intervention
      participants, ecological momentary assessment will be used to identify
      behavioural determinants for each individual in order to tailor evidence-based
      behaviour change techniques and intervention content.Control group participants
      will receive non-tailored weight loss advice via e-book and generic emails. The
      primary outcome is the mean difference in weight loss between groups at 6 months 
      controlled for baseline. Secondary outcomes include blood pressure and percentage
      of body fat; self-reported measures of physical activity, sitting time, quality
      of life, cost and theory-derived correlates of weight loss. Secondary outcomes
      will be measured at baseline, 3, 6 and 12 months. The primary outcome for ITS
      will be daily weight loss plan adherence. Data will be analysed using regression 
      and time series analyses. ETHICS AND DISSEMINATION: Ethics approval was granted
      by Faculty of Psychology, SWPS University of Social Sciences and Humanities,
      Wroclaw, Poland, approval number 03/P/12/2019. The project results will be
      disseminated through structured strategy implemented in collaboration with the
      Ministry of Health. TRIAL REGISTRATION DETAILS: This trial was registered with
      www.clinicaltrials.gov; registration number NCT04291482.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kwasnicka, Dominika
AU  - Kwasnicka D
AUID- ORCID: 0000-0002-5961-837X
AD  - Faculty of Psychology, SWPS University of Social Sciences and Humanities,
      Wroclaw, Poland dkwasnicka@swps.edu.pl.
FAU - Luszczynska, Aleksandra
AU  - Luszczynska A
AD  - Faculty of Psychology, SWPS University of Social Sciences and Humanities,
      Wroclaw, Poland.
FAU - Hagger, Martin S
AU  - Hagger MS
AD  - Psychological Sciences, University of California, Merced, Merced, California,
      United States.
AD  - Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla,
      Finland.
FAU - Quested, Eleanor
AU  - Quested E
AD  - Physical Activity and Well-being Research Group, School of Psychology, Curtin
      University, Perth, Western Australia, Australia.
FAU - Pagoto, Sherry L
AU  - Pagoto SL
AD  - Department of Allied Health Sciences, The UConn Center for mHealth and Social
      Media, University of Connecticut, Connecticut, New England, United States.
FAU - Verboon, Peter
AU  - Verboon P
AD  - Department of Psychology and Educational Sciences, Open Universiteit Nederland
      Faculteit Managementwetenschappen, Heerlen, Limburg, The Netherlands.
FAU - Robinson, Suzanne
AU  - Robinson S
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Januszewicz, Anna
AU  - Januszewicz A
AD  - Faculty of Psychology, SWPS University of Social Sciences and Humanities,
      Wroclaw, Poland.
FAU - Idziak, Paulina
AU  - Idziak P
AD  - Faculty of Psychology, SWPS University of Social Sciences and Humanities,
      Wroclaw, Poland.
FAU - Palacz, Iga
AU  - Palacz I
AD  - Faculty of Psychology, SWPS University of Social Sciences and Humanities,
      Wroclaw, Poland.
FAU - Naughton, Felix
AU  - Naughton F
AUID- ORCID: 0000-0001-9790-2796
AD  - School of Health Sciences, University of East Anglia Faculty of Medicine and
      Health Sciences, Norwich, Norfolk, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04291482
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Electronic Mail
MH  - Humans
MH  - Overweight/therapy
MH  - Poland
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Weight Loss
PMC - PMC7684829
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040183 [pii]
AID - 10.1136/bmjopen-2020-040183 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e040183. doi: 10.1136/bmjopen-2020-040183.


PMID- 33234637
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Women's health-related vulnerabilities in natural disaster-affected areas of
      Bangladesh: a mixed-methods study protocol.
PG  - e039772
LID - 10.1136/bmjopen-2020-039772 [doi]
AB  - INTRODUCTION: Global climate change has produced growing natural disasters across
      the world especially in Global South. Different countries experience varied
      vulnerabilities depending on their geographical location, economic status and
      ability of management. In a highly disaster susceptible developing country like
      Bangladesh, many individuals experience a greater rate of natural disasters with 
      devastating health effects. Compare with men, women have a higher incidence of
      mortality and health effects following natural disasters. The study aims to
      explore women's experience of physical and psychological health vulnerabilities
      with primary causes in natural disaster-affected areas of Bangladesh. METHODS AND
      ANALYSIS: This is an exploratory mixed-method study comprising survey and
      in-depth interviews with equal priority to identify physical and psychological
      health vulnerabilities of women living in natural disaster-affected areas of
      Bangladesh. Quantitative data will be collected using self-administered
      sociodemographic and perceived severity instrument, 12-item Short-Form, Impact of
      Event Scale-Revised and Brief Coping Scale, while specific open-ended guidelines 
      will be used for the qualitative part. The instruments will be translated into
      Bangla following the Brislin (1970) model of translation. The survey will be
      administered in paper copies, with at least 384 respondents, whereas 30
      participants will be in-depth interviewed using an audio recorder. Survey data
      will be analysed using SPSS V.25 following descriptive and inferential statistics
      as required. The recorded open-ended responses will be transcribed and analysed
      using thematic analysis. Finally, both data sets will be integrated and
      synthesised according to the sequential mixed-method approach. ETHICS AND
      DISSEMINATION: The study has been reviewed and approved by the Human Research
      Ethics Committee of the University of New England. The results will be actively
      disseminated through peer-reviewed journals, conference presentations, social
      media, the internet and various community engagement activities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Riyad Fatema, Syadani
AU  - Riyad Fatema S
AUID- ORCID: 0000-0002-1096-1230
AD  - School of Health, University of New England, Armidale, New South Wales, Australia
      sriyadfa@myune.edu.au.
AD  - Department of Sociology, Noakhali Science and Technology University, Noakhali,
      Noakhali, Bangladesh.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - Bangladesh
MH  - England
MH  - Female
MH  - Humans
MH  - Male
MH  - *Natural Disasters
MH  - Pilot Projects
MH  - *Women's Health
PMC - PMC7689102
OTO - NOTNLM
OT  - *mental health
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-039772 [pii]
AID - 10.1136/bmjopen-2020-039772 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e039772. doi: 10.1136/bmjopen-2020-039772.


PMID- 33234634
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Randomised, double-blind, multicentre, phase / dose escalation and expansion
      trial of GR1501 in patients with plaque psoriasis: study protocol.
PG  - e039067
LID - 10.1136/bmjopen-2020-039067 [doi]
AB  - INTRODUCTION: Psoriasis is a life-long, immune-mediated disease that greatly
      reduces the quality of life of patients. Plaque psoriasis is the most common form
      of psoriasis. Treatment options for plaque psoriasis with good tolerance and
      sufficient response remain profoundly limited. Based on mechanistic findings that
      suggest the key pathogenic role of interleukin (IL)-17 in plaque psoriasis, we
      hypothesise that GR1501, a new monoclonal antibody (IL-17A targeted), will be an 
      efficacious treatment for plaque psoriasis. This phase I/II trial aims to
      evaluate the safety, tolerability, pharmacokinetics, immunogenicity and
      preliminary efficacy of GR1501. METHODS AND ANALYSIS: A multicentre, randomised, 
      double-blind, phase I/II dose escalation and expansion trial will be conducted at
      four hospitals in China. In total, 226 patients with plaque psoriasis will be
      enrolled in the study, with 46 cases in the dose-escalation stage and 180 cases
      randomised to GR1501 or the placebo in a 3:1 ratio in the expansion cohort. The
      primary outcomes are safety and tolerability; the secondary outcomes include
      pharmacokinetics, immunogenicity and efficacy. ETHICS AND DISSEMINATION: The
      study is in accordance with the Declaration of Helsinki, and the ethics approvals
      of the protocol have been obtained from the ethics committees of all
      participating centres, including Peking University People's Hospital, Chinese PLA
      General Hospital, The First Affiliated Hospital, College of Medicine, Zhejiang
      University and the Second Xiangya Hospital of Central South University. The
      findings of the study will be presented in published journals or at scientific
      conferences or meetings. TRIAL REGISTRATION NUMBER: ChiCTR1800017956.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dong, Wenliang
AU  - Dong W
AUID- ORCID: 0000-0003-4316-1608
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, China.
AD  - Department of Pharmacy Administration & Clinical Pharmacy, School of
      Pharmaceutical Sciences, Peking University, Beijing, Beijing, China.
FAU - Nie, Xiaoyan
AU  - Nie X
AD  - Department of Pharmacy Administration & Clinical Pharmacy, School of
      Pharmaceutical Sciences, Peking University, Beijing, Beijing, China.
FAU - Wang, Jiaxue
AU  - Wang J
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, China.
AD  - Department of Pharmacy Administration & Clinical Pharmacy, School of
      Pharmaceutical Sciences, Peking University, Beijing, Beijing, China.
FAU - Xia, Lin
AU  - Xia L
AD  - Department of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Cai, Lin
AU  - Cai L
AD  - Department of Dermatology, Peking University People's Hospital, Beijing, China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Genrix (Shanghai) Biopharmaceutical Co., Shanghai, China, Shanghai, China.
FAU - Fu, Weixing
AU  - Fu W
AD  - Genrix (Shanghai) Biopharmaceutical Co., Shanghai, China, Shanghai, China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, China.
AD  - Department of Pharmacy Administration & Clinical Pharmacy, School of
      Pharmaceutical Sciences, Peking University, Beijing, Beijing, China.
FAU - Shen, Tiantian
AU  - Shen T
AD  - Department of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Fan, Huaying
AU  - Fan H
AD  - Department of Science and Research, Peking University People's Hospital, Beijing,
      China.
FAU - Niu, Suping
AU  - Niu S
AD  - Department of Science and Research, Peking University People's Hospital, Beijing,
      China.
FAU - Cui, Yimin
AU  - Cui Y
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, China.
FAU - Zheng, Qingshan
AU  - Zheng Q
AD  - Center for Drug Clinical Research, Shanghai University of Traditional Chinese
      Medicine, Shanghai, Shanghai, China.
FAU - Zhang, Jianzhong
AU  - Zhang J
AD  - Department of Dermatology, Peking University People's Hospital, Beijing, China.
FAU - Fang, Yi
AU  - Fang Y
AD  - Department of Pharmacy, Peking University People's Hospital, Beijing, China
      phaseistudy@163.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/therapeutic use
MH  - China
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Psoriasis/drug therapy
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7689088
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *clinical trials
OT  - *psoriasis
COIS- Competing interests: WW and WF are employees of Genrix (Shanghai)
      Biopharmaceutical Co.
EDAT- 2020/11/26 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-039067 [pii]
AID - 10.1136/bmjopen-2020-039067 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e039067. doi: 10.1136/bmjopen-2020-039067.


PMID- 33234633
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Design and development of the Pediatric Urology Recovery After Surgery Endeavor
      (PURSUE) multicentre pilot and exploratory study.
PG  - e039035
LID - 10.1136/bmjopen-2020-039035 [doi]
AB  - INTRODUCTION: Lower urinary tract reconstruction in paediatric urology represents
      a physiologically stressful event that is associated with high complication
      rates, including readmissions and emergency room visits. Enhanced recovery after 
      surgery (ERAS) protocol is a set of multidisciplinary, perioperative strategies
      designed to expedite surgical recovery without adversely impacting readmission or
      reoperation rates. Early paediatric urology data demonstrated ERAS reduced
      complications in this population. METHODS AND ANALYSIS: In 2016, a working group 
      of paediatric urologists and anaesthesiologists convened to develop an ERAS
      protocol suitable for patients undergoing lower urinary tract reconstruction and 
      define study process measures, patient-reported outcomes and clinically relevant 
      outcomes in paediatric and adolescent/young adult patients. A multicentre,
      prospective, propensity-matched, case-control study design was chosen. Each
      centre will enrol five pilot patients to verify implementation. Subsequent
      enrolled patients will be propensity matched to historical controls. Eligible
      patients must be aged 4-25 years and undergoing planned operations (bladder
      augmentation, continent ileovesicostomy or appendicovesicostomy, or urinary
      diversion). 64 ERAS patients and 128 controls will be needed to detect a decrease
      in mean length of stay by 2 days. Pilot phase outcomes include attainment of
      >/=70% mean protocol adherence per patient and reasons for protocol deviations.
      Exploratory phase primary outcome is ERAS protocol adherence, with secondary
      outcomes including length of stay, readmissions, reoperations, emergency room
      visits, 90-day complications, pain scores, opioid usage and differences in
      Quality of Recovery 9 scores. ETHICS AND DISSEMINATION: This study has been
      registered with authors' respective institution review boards and will be
      published in peer-reviewed journals. It will provide robust insight into the
      feasibility of ERAS in paediatric urology, determine patient outcomes and allow
      for iteration of ERAS implementations as new best practices and evidence for
      paediatric surgical care arise. We anticipate this study will take 4 years to
      fully accrue with completed follow-up. TRIAL REGISTRATION NUMBER: NCT03245242;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rove, Kyle O
AU  - Rove KO
AUID- ORCID: 0000-0002-2323-4139
AD  - Department of Pediatric Urology, Children's Hospital Colorado, Aurora, Colorado, 
      USA kyle.rove@childrenscolorado.org.
AD  - Division of Urology, Department of Surgery, University of Colorado, Aurora,
      Colorado, USA.
FAU - Strine, Andrew C
AU  - Strine AC
AD  - Division of Pediatric Urology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, Ohio, USA.
FAU - Wilcox, Duncan T
AU  - Wilcox DT
AD  - Department of Pediatric Urology, Children's Hospital Colorado, Aurora, Colorado, 
      USA.
AD  - Division of Urology, Department of Surgery, University of Colorado, Aurora,
      Colorado, USA.
FAU - Vricella, Gino J
AU  - Vricella GJ
AD  - Division of Pediatric Urology, St Louis Children's Hospital, St Louis, Missouri, 
      USA.
AD  - Division of Urology, Department of Surgery, Washington University in Saint Louis 
      School of Medicine, Saint Louis, Missouri, USA.
FAU - Welch, Timothy P
AU  - Welch TP
AD  - Division of Urology, Department of Surgery, Washington University in Saint Louis 
      School of Medicine, Saint Louis, Missouri, USA.
AD  - Department of Anesthesiology, St Louis Children's Hospital, St Louis, Missouri,
      USA.
FAU - VanderBrink, Brian
AU  - VanderBrink B
AD  - Division of Pediatric Urology, Cincinnati Children's Hospital Medical Center,
      Cincinnati, Ohio, USA.
FAU - Chu, David I
AU  - Chu DI
AD  - Division of Urology, Ann and Robert H Lurie Children's Hospital of Chicago,
      Chicago, Illinois, USA.
FAU - Chaudhry, Rajeev
AU  - Chaudhry R
AD  - Division of Pediatric Urology, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Zee, Rebecca S
AU  - Zee RS
AD  - Division of Urology, Children's Hospital of Richmond at VCU, Richmond, Virginia, 
      USA.
FAU - Brockel, Megan A
AU  - Brockel MA
AD  - Department of Anesthesiology, Children's Hospital Colorado, Aurora, Colorado,
      USA.
AD  - Department of Anesthesiology, University of Colorado, Aurora, Colorado, USA.
CN  - PURSUE Study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03245242
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - *Enhanced Recovery After Surgery
MH  - Humans
MH  - Length of Stay
MH  - Postoperative Complications/epidemiology
MH  - Prospective Studies
MH  - *Urology
MH  - Young Adult
PMC - PMC7684811
OTO - NOTNLM
OT  - *Mitrofanoff
OT  - *bladder augmentation
OT  - *enhanced recovery after surgery
OT  - *protocol
OT  - *urinary diversion
COIS- Competing interests: None declared.
IR  - Coplen DE
FIR - Coplen, Douglas E
IR  - Austin PF
FIR - Austin, Paul F
IR  - Traxel EJ
FIR - Traxel, Erica J
IR  - AuBuchon J
FIR - AuBuchon, Jacob
IR  - Moore RP
FIR - Moore, Robert P
IR  - Vemulakonda VM
FIR - Vemulakonda, Vijaya M
IR  - Caldwell BT
FIR - Caldwell, Brian T
IR  - Sevick CJ
FIR - Sevick, Carter J
IR  - Burjek N
FIR - Burjek, Nicholas
IR  - Yerkes EB
FIR - Yerkes, Elizabeth B
IR  - Chan YY
FIR - Chan, Yvonne Y
IR  - Anthony Herndon CD
FIR - Anthony Herndon, C D
EDAT- 2020/11/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039035 [pii]
AID - 10.1136/bmjopen-2020-039035 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e039035. doi: 10.1136/bmjopen-2020-039035.


PMID- 33234632
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Protocol for measuring indoor exposure to coal fly ash and heavy metals, and
      neurobehavioural symptoms in children aged 6 to 14 years old.
PG  - e038960
LID - 10.1136/bmjopen-2020-038960 [doi]
AB  - INTRODUCTION: Fly ash is a waste product generated from burning coal for
      electricity. It is comprised of spherical particles ranging in size from 0.1
      microm to over 100 microm in diameter that contain trace levels of heavy metals. 
      Large countries such as China and India generate over 100 million tons per year
      while smaller countries like Italy and France generate 2 to 3 million tons per
      year. The USA generates over 36 million tons of ash, making it one of the largest
      industrial waste streams in the nation. Fly ash is stored in landfills and
      surface impoundments exposing communities to fugitive dust and heavy metals that 
      leach into the groundwater. Limited information exists on the health impact of
      exposure to fly ash. This protocol represents the first research to assess
      children's exposure to coal fly ash and neurobehavioural outcomes. METHODS: We
      measure indoor exposure to fly ash and heavy metals, and neurobehavioural
      symptoms in children aged 6 to 14 years old. Using air pollution samplers and
      lift tape samples, we collect particulate matter </=10 microm that is analysed
      for fly ash and heavy metals. Toenails and fingernails are collected to assess
      body burden for 72 chemical elements. Using the Behavioural Assessment and
      Research System and the Child Behaviour Checklist, we collect information on
      neurobehavioural outcomes. Data collection began in September 2015 and will
      continue until February 2021. ETHICS AND DISSEMINATION: This study was approved
      by the Institutional Review Boards of the University of Louisville (#14.1069) and
      the University of Alabama at Birmingham (#300003807). We have collected data from
      267 children who live within 10 miles of two power plants. Children are at a
      greater risk for environmental exposure which justifies the rationale for this
      study. Results of this study will be distributed at conferences, in peer-reviewed
      journals and to the participants of the study.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zierold, Kristina M
AU  - Zierold KM
AUID- ORCID: 0000-0002-9246-0404
AD  - Environmental Health Sciences, School of Public Health, The University of Alabama
      at Birmingham, Birmingham, Alabama, USA kzierold@uab.edu.
FAU - Sears, Clara G
AU  - Sears CG
AD  - Epidemiology, Brown University, Providence, Rhode Island, USA.
FAU - Hagemeyer, Abby N
AU  - Hagemeyer AN
AD  - Epidemiology and Population Health, University of Louisville, Louisville,
      Kentucky, USA.
FAU - Brock, Guy N
AU  - Brock GN
AD  - Bioinformatics and the Center for Biostatistics, The Ohio State University,
      Columbus, Ohio, USA.
FAU - Polivka, Barbara J
AU  - Polivka BJ
AD  - School of Nursing, University of Kansas Medical Center, Kansas City, Kansas, USA.
FAU - Zhang, Charlie H
AU  - Zhang CH
AUID- ORCID: 0000-0003-1633-2440
AD  - Department of Geography and Geosciences, College of Arts and Sciences, University
      of Louisville, Louisville, Kentucky, USA.
FAU - Sears, Lonnie
AU  - Sears L
AD  - Department of Pediatrics, Health Sciences Center, University of Louisville,
      Louisville, Kentucky, USA.
LA  - eng
GR  - R01 ES024757/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Coal)
RN  - 0 (Coal Ash)
RN  - 0 (Metals, Heavy)
RN  - 0 (Particulate Matter)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - China
MH  - Coal
MH  - *Coal Ash/analysis
MH  - France
MH  - Humans
MH  - India
MH  - Italy
MH  - *Metals, Heavy/analysis
MH  - Particulate Matter/adverse effects/analysis
PMC - PMC7684807
OTO - NOTNLM
OT  - *community child health
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038960 [pii]
AID - 10.1136/bmjopen-2020-038960 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e038960. doi: 10.1136/bmjopen-2020-038960.


PMID- 33234625
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 24
TI  - Experiences and perceived health benefits of individuals with a disability
      participating in sport: A systematic review protocol.
PG  - e038214
LID - 10.1136/bmjopen-2020-038214 [doi]
AB  - INTRODUCTION: Sports participation has many physical and mental health benefits
      for individuals with a disability, including improved functionality and reduced
      anxiety. Despite this, a large proportion of individuals with a disability are
      inactive. This review will be the first to synthesise the literature on the
      experiences and perceived health benefits of sport participation for children,
      adolescents, adults, elite athletes and veterans with a disability. Investigation
      of these phenomena will enable an understanding of the positive aspects and
      benefits of sport participation specific to each population, which may help to
      improve participation rates and ultimately improve health through promotion of
      these benefits. METHODS: A protocol for systematic review is reported in line
      with Preferred Reporting Items for Systematic Reviews and Meta-Analysis-P. The
      phenomena of interest are the experiences and perceived health benefits of
      individuals with a disability participating in sport. There will be no age limit 
      on participants and all study designs, besides reviews, will be included. Studies
      in languages other than English will be excluded. Two independent reviewers will 
      conduct the searches, study selection, data collection and quality assessment
      independently. The online databases MEDLINE, EMBASE, PsychINFO, CINAHL Plus, Web 
      of Science and SportDiscus will be electronically searched from database
      inception to February 2020. Grey literature will be searched and several
      sport-related journals will be hand-searched. The Quality Assessment Tool for
      Studies with Diverse Designs will be used for quality assessment of included
      studies. Thematic synthesis will be used to analyse the qualitative studies,
      narrative synthesis will be used to analyse the quantitative studies and the
      perceived health benefits will be analysed using content analysis. The strength
      of the overall body of evidence will be assessed and reported using GRADE-CERQual
      (Grading of Recommendations, Assessment, Development and Evaluation-Confidence in
      the Evidence from Reviews of Qualitative research) for qualitative studies and
      GRADE for quantitative studies. These approaches will be applied to mixed-methods
      studies, respectively, where necessary. ETHICS AND DISSEMINATION: This systematic
      review raises no ethical issues. Results will be published in a peer reviewed
      journal and disseminated to key stakeholders to inform practice. PROSPERO
      REGISTRATION NUMBER: CRD42020169224.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aitchison, Beth
AU  - Aitchison B
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences,
      University of Birmingham, Birmingham, UK.
FAU - Rushton, Alison
AU  - Rushton A
AUID- ORCID: 0000-0001-8114-7669
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences,
      University of Birmingham, Birmingham, UK.
AD  - School of Physical Therapy, Western University, London, Ontario, Canada.
FAU - Martin, Paul
AU  - Martin P
AD  - English Institute of Sport, The Manchester Institute of Health and Performance,
      Manchester, UK.
FAU - Soundy, Andrew
AU  - Soundy A
AUID- ORCID: 0000-0002-5118-5872
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences,
      University of Birmingham, Birmingham, UK.
FAU - Heneghan, Nicola R
AU  - Heneghan NR
AUID- ORCID: 0000-0001-7599-3674
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences,
      University of Birmingham, Birmingham, UK n.heneghan@bham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201124
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Health Status
MH  - Humans
MH  - Mental Health
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Qualitative Research
MH  - *Research Design
MH  - *Sports
MH  - Systematic Reviews as Topic
PMC - PMC7689099
OTO - NOTNLM
OT  - *public health
OT  - *rehabilitation medicine
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-038214 [pii]
AID - 10.1136/bmjopen-2020-038214 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 24;10(11):e038214. doi: 10.1136/bmjopen-2020-038214.


PMID- 33234615
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 23
TI  - Needs assessment for a decision support tool in oral cancer requiring major
      resection and reconstruction: a mixed-methods study protocol.
PG  - e036969
LID - 10.1136/bmjopen-2020-036969 [doi]
AB  - INTRODUCTION: Advanced oral cancer and its ensuing treatment engenders
      significant morbidity and mortality. Patients are often elderly with significant 
      comorbidities. Toxicities associated with surgical resection can be devastating
      and they are often highlighted by patients as impactful. Given the potential for 
      suboptimal oncological and functional outcomes in this vulnerable patient
      population, promotion and performance of shared decision making (SDM) is
      crucial.Decision aids (DAs) are useful instruments for facilitating the SDM
      process by presenting patients with up-to-date evidence regarding risks, benefits
      and the possible postoperative course. Importantly, DAs also help elicit and
      clarify patient values and preferences. The use of DAs in cancer treatment has
      been shown to reduce decisional conflict and increase SDM. No DAs for oral cavity
      cancer have yet been developed.This study endeavours to answer the question: Is
      there a patient or surgeon driven need for development and implementation of a DA
      for adult patients considering major surgery for oral cancer? METHODS AND
      ANALYSIS: This study is the first step in a multiphase investigation of SDM
      during major head and neck surgery. It is a multi-institutional convergent
      parallel mixed-methods needs assessment study. Patients and surgeon dyads will be
      recruited to complete questionnaires related to their perception of the SDM
      process (nine-item Shared Decision-Making Questionnaire, SDM-Q-9 and SDM-Q-Doc)
      and to take part in semistructured interviews. Patients will also complete
      questionnaires examining decisional self-efficacy (Ottawa Decision Self-Efficacy 
      Scale) and decisional conflict (Decisional Conflict Scale). Questionnaires will
      be completed at time of recruitment and will be used to assess the current level 
      of SDM, self-efficacy and conflict in this setting. Thematic analysis will be
      used to analyse transcripts of interviews. Quantitative and qualitative
      components of the study will be integrated through triangulation, with matrix
      developed to promote visualisation of the data. ETHICS AND DISSEMINATION: This
      study has been approved by the research ethics boards of the Nova Scotia Health
      Authority (Halifax, Nova Scotia) and the University Health Network (Toronto,
      Ontario). Dissemination to clinicians will be through traditional approaches and 
      creation of a head and neck cancer SDM website. Dissemination to patients will
      include a section within the website, patient advocacy groups and postings within
      clinical environments.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Forner, David
AU  - Forner D
AUID- ORCID: 0000-0002-1014-3545
AD  - Otolaryngology -- Head & Neck Surgery, Queen Elizabeth II Health Sciences Centre 
      and Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Hong, Paul
AU  - Hong P
AD  - Otolaryngology -- Head & Neck Surgery, Queen Elizabeth II Health Sciences Centre 
      and Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - Otolaryngology -- Head & Neck Surgery, IWK Health Centre, Halifax, Nova Scotia,
      Canada.
FAU - Corsten, Martin
AU  - Corsten M
AD  - Otolaryngology -- Head & Neck Surgery, Queen Elizabeth II Health Sciences Centre 
      and Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Rac, Valeria E
AU  - Rac VE
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Toronto Health Economics and Technology Assessment (THETA) Collaborative and
      Toronto General Hospital Research Institute (TGHRI), University Health Network,
      Toronto, Ontario, Canada.
FAU - Martino, Rosemary
AU  - Martino R
AD  - Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.
FAU - Shuman, Andrew G
AU  - Shuman AG
AD  - Otolaryngology -- Head & Neck Surgery, University of Michigan, Ann Arbor,
      Michigan, USA.
FAU - Chepeha, Douglas B
AU  - Chepeha DB
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada.
FAU - Sawka, Anna M
AU  - Sawka AM
AD  - Endocrinology, University Health Network, Toronto, Ontario, Canada.
FAU - de Almeida, John R
AU  - de Almeida JR
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada.
FAU - Irish, Jonathan C
AU  - Irish JC
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada.
FAU - Brown, Dale H
AU  - Brown DH
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada.
FAU - Taylor, S Mark
AU  - Taylor SM
AD  - Otolaryngology -- Head & Neck Surgery, Queen Elizabeth II Health Sciences Centre 
      and Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Gullane, Patrick J
AU  - Gullane PJ
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada.
FAU - Trites, Jonathan R
AU  - Trites JR
AD  - Otolaryngology -- Head & Neck Surgery, Queen Elizabeth II Health Sciences Centre 
      and Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Gilbert, Ralph
AU  - Gilbert R
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada.
FAU - Rigby, Matthew H
AU  - Rigby MH
AD  - Otolaryngology -- Head & Neck Surgery, Queen Elizabeth II Health Sciences Centre 
      and Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Ringash, Jolie
AU  - Ringash J
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Radiation Oncology, University Health Network, Toronto, Ontario, Canada.
FAU - Goldstein, David
AU  - Goldstein D
AD  - Otolaryngology -- Head & Neck Surgery, University Health Network, Toronto,
      Ontario, Canada David.Goldstein@uhn.ca.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Decision Making
MH  - Humans
MH  - *Mouth Neoplasms/surgery
MH  - Needs Assessment
MH  - Nova Scotia
MH  - Ontario
MH  - Patient Participation
PMC - PMC7684801
OTO - NOTNLM
OT  - *decision aid
OT  - *needs assessment
OT  - *oral cancer
OT  - *shared decision-making
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036969 [pii]
AID - 10.1136/bmjopen-2020-036969 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 23;10(11):e036969. doi: 10.1136/bmjopen-2020-036969.


PMID- 33234548
OWN - NLM
STAT- Publisher
LR  - 20201125
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 24
TI  - Ethical considerations for universal newborn hearing screening in the Pacific
      Islands: a Samoan case study.
LID - medethics-2020-106718 [pii]
LID - 10.1136/medethics-2020-106718 [doi]
AB  - Permanent congenital and early-onset hearing impairment (PCEOHI) is the most
      common sensory disorder among newborns. The WHO recommends newborn and infant
      hearing screening for all member states to facilitate early identification and
      intervention for children with PCEOHI. Ethical implications of newborn/infant
      hearing screening in low-income and middle-income countries should be considered.
      Although the Pacific Island region is estimated to have among the highest global 
      burden of hearing loss, hearing health services are limited and virtually
      non-existent in Pacific Island countries. The aim of this brief report is to
      consider the ethical implications of implementing hospital-based universal
      newborn hearing screening (UNHS) in Samoa. Based on well-acknowledged screening
      principles, this report found that the Samoan context does not satisfy the
      screening principles for such a programme, and that the implementation of UNHS
      would, therefore, be unethical. This conclusion was reached even after
      considering the hypothetical provision of necessary screening and diagnostic
      audiology equipment from external donors. We recommend that current efforts
      should be directed towards the wider professional community involved in the daily
      care of children with a permanent hearing loss. Given the high prevalence of
      paediatric ear disease in the Pacific Islander population, an interim ear and
      hearing programme could be considered at the community level. These strategies
      should provide the infrastructure and referral pathways required in the advent of
      UNHS in Samoa.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kaspar, Annette
AU  - Kaspar A
AUID- ORCID: http://orcid.org/0000-0002-4035-3236
AD  - ENT Department, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa
      annette.kaspar@gmail.com.
AD  - Audiology Division, School of Health and Rehabilitation Sciences, University of
      Queensland, Brisbane, QLD, Australia.
FAU - Driscoll, Carlie
AU  - Driscoll C
AD  - Audiology Division, School of Health and Rehabilitation Sciences, University of
      Queensland, Brisbane, QLD, Australia.
FAU - Pifeleti, Sione
AU  - Pifeleti S
AD  - ENT Department, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa.
FAU - Faumuina, Penaia A
AU  - Faumuina PA
AD  - ENT Department, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa.
AD  - ORL Consultant, Wanganui Hospital, Wanganui, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20201124
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - capacity
OT  - children
OT  - ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/07/19 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - medethics-2020-106718 [pii]
AID - 10.1136/medethics-2020-106718 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 24. pii: medethics-2020-106718. doi:
      10.1136/medethics-2020-106718.


PMID- 33234546
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Fair go: pay research participants properly or not at all.
PG  - 837-839
LID - 10.1136/medethics-2020-107060 [doi]
FAU - Grimwade, Olivia
AU  - Grimwade O
AUID- ORCID: 0000-0002-3278-778X
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton,
      Victoria, Australia.
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
FAU - Savulescu, Julian
AU  - Savulescu J
AUID- ORCID: 0000-0003-1691-6403
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
      julian.savulescu@philosophy.ox.ac.uk.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
AD  - Melbourne Law School, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Giubilini, Alberto
AU  - Giubilini A
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, United
      Kingdom.
FAU - Oakley, Justin
AU  - Oakley J
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia.
FAU - Nussberger, Anne-Marie
AU  - Nussberger AM
AD  - Department of Experimental Psychology, University of Oxford, Oxford, UK.
LA  - eng
GR  - 203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20201124
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Dec;46(12):815-826. PMID: 32978306
CON - J Med Ethics. 2020 Dec;46(12):827-828. PMID: 33051381
CON - J Med Ethics. 2020 Dec;46(12):831-832. PMID: 33115857
CON - J Med Ethics. 2020 Dec;46(12):835-836. PMID: 33154089
CON - J Med Ethics. 2020 Dec;46(12):829-830. PMID: 33154091
CON - J Med Ethics. 2020 Dec;46(12):833-834. PMID: 33234545
MH  - *Attitude
MH  - Humans
MH  - *Resource Allocation
OTO - NOTNLM
OT  - *research ethics
OT  - *research on special populations
OT  - *resource allocation
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/12 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/11/25 05:37 [entrez]
AID - medethics-2020-107060 [pii]
AID - 10.1136/medethics-2020-107060 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):837-839. doi: 10.1136/medethics-2020-107060. Epub
      2020 Nov 24.


PMID- 33234545
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - On measuring attitudes about payment for research.
PG  - 833-834
LID - 10.1136/medethics-2020-106996 [doi]
FAU - Gelinas, Luke
AU  - Gelinas L
AD  - Advarra Inc, Columbia, Maryland, USA Luke.Gelinas@advarra.com.
AD  - Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and
      Harvard, Cambridge, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20201124
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Dec;46(12):815-826. PMID: 32978306
CIN - J Med Ethics. 2020 Dec;46(12):837-839. PMID: 33234546
MH  - Attitude
MH  - *Ethics Committees, Research
MH  - *Ethics, Research
MH  - Humans
OTO - NOTNLM
OT  - *ethics
OT  - *informed consent
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/10/13 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/11/25 05:37 [entrez]
AID - medethics-2020-106996 [pii]
AID - 10.1136/medethics-2020-106996 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):833-834. doi: 10.1136/medethics-2020-106996. Epub
      2020 Nov 24.


PMID- 33234503
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 371
DP  - 2020 Nov 24
TI  - Need for ethical framework to guide mass testing for asymptomatic covid-19.
PG  - m4567
LID - 10.1136/bmj.m4567 [doi]
FAU - Cox, Caitriona
AU  - Cox C
AD  - The Healthcare Improvement Studies Institute, Clifford Allbutt Building Cambridge
      Biomedical Campus, Cambridge CB2 0AH, UK.
FAU - Dixon-Woods, Mary
AU  - Dixon-Woods M
AD  - The Healthcare Improvement Studies Institute, Clifford Allbutt Building Cambridge
      Biomedical Campus, Cambridge CB2 0AH, UK.
LA  - eng
PT  - Letter
DEP - 20201124
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
MH  - *Asymptomatic Infections
MH  - COVID-19/*diagnosis
MH  - COVID-19 Testing/*ethics
MH  - Humans
MH  - Mass Screening/*ethics/methods
MH  - Pandemics
COIS- Competing interests: None declared.
EDAT- 2020/11/26 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/11/25 05:37
PHST- 2020/11/25 05:37 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.1136/bmj.m4567 [doi]
PST - epublish
SO  - BMJ. 2020 Nov 24;371:m4567. doi: 10.1136/bmj.m4567.


PMID- 33233745
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 1424-8220 (Electronic)
IS  - 1424-8220 (Linking)
VI  - 20
IP  - 22
DP  - 2020 Nov 20
TI  - Advances in Wearable Sensors: Signalling the Provenance of Garments Using Radio
      Frequency Watermarks.
LID - E6661 [pii]
LID - 10.3390/s20226661 [doi]
AB  - There is a significant nascent market for ethically produced products with
      enormous commercial potential around the world. A reliable method to signal the
      provenance of products is therefore critical for industry, given that competition
      based on price is not a viable strategy. The ability to trace and signal ethical 
      treatment of animals is also of significant value to textiles manufactures. The
      efficacy of such a method can be measured with respect to the cost of
      implementation, scalability, and the difficulty of counterfeiting. The key to
      traceability is to win the trust of the consumer about the veracity of this
      information. Wearable sensors make it possible to monitor and improve the
      management of traceability and/or provenance. In this paper, we introduce a
      method for signalling the provenance of garments using radio frequency
      watermarks. The proposed model consists of two levels of authentication that are 
      easy to use by legitimate vendors, but extremely difficult to imitate or hack,
      because the watermark is built-in and based on the radiation signature of
      electroactive materials.
FAU - Foroughi, Javad
AU  - Foroughi J
AUID- ORCID: 0000-0003-1979-5213
AD  - School of Electrical, Computer and Telecommunications Engineering, Faculty of
      Engineering and Information Sciences, University of Wollongong, Wollongong, NSW
      2522, Australia.
AD  - Westgerman Heart and Vascular Center, University of Duisburg-Essen, 45122 Essen, 
      Germany.
FAU - Safaei, Farzad
AU  - Safaei F
AUID- ORCID: 0000-0002-4322-4448
AD  - School of Electrical, Computer and Telecommunications Engineering, Faculty of
      Engineering and Information Sciences, University of Wollongong, Wollongong, NSW
      2522, Australia.
FAU - Raad, Raad
AU  - Raad R
AUID- ORCID: 0000-0002-2347-4837
AD  - School of Electrical, Computer and Telecommunications Engineering, Faculty of
      Engineering and Information Sciences, University of Wollongong, Wollongong, NSW
      2522, Australia.
FAU - Mitew, Teodor
AU  - Mitew T
AUID- ORCID: 0000-0002-0830-0863
AD  - School of the Arts, English and Media, University of Wollongong, Wollongong, NSW 
      2522, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Switzerland
TA  - Sensors (Basel)
JT  - Sensors (Basel, Switzerland)
JID - 101204366
SB  - IM
PMC - PMC7699914
OTO - NOTNLM
OT  - chipless RFID
OT  - garment
OT  - provenance
OT  - radio frequency
OT  - smart textiles
OT  - traceability
OT  - watermarks
OT  - wearable sensors
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 01:04
PHST- 2020/10/23 00:00 [received]
PHST- 2020/11/11 00:00 [revised]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/11/25 01:04 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - s20226661 [pii]
AID - 10.3390/s20226661 [doi]
PST - epublish
SO  - Sensors (Basel). 2020 Nov 20;20(22). pii: s20226661. doi: 10.3390/s20226661.


PMID- 33233556
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201226
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Nov 20
TI  - Breaking Bad News, a Pertinent Yet Still an Overlooked Skill: An International
      Survey Study.
LID - E501 [pii]
LID - 10.3390/healthcare8040501 [doi]
AB  - Delivering bad news to patients is a challenging yet impactful everyday task in
      clinical practice. Ideally, healthcare practitioners should receive formal
      training in implementing these protocols, practice in simulation environments,
      and real-time supervision with feedback. We aimed to investigate whether
      healthcare providers involved in delivering bad news have indeed received formal 
      training to do so. We conducted a cross-sectional survey study that targeted all 
      healthcare providers in the intensive care units of 174 institutions in 40
      different countries. Participants included physicians, nurses, medical students, 
      nursing students, pharmacists, respiratory technicians, and others. The survey
      tool was created, validated, and translated to the primary languages of these
      countries to overcome language barriers. A total of 10,106 surveys were
      collected. Only one third of participants indicated that they had received a
      formal training. Providers who had received formal training were more likely to
      deliver bad news than those who had not. Younger and less experienced providers
      tend to deliver bad news more than older, more experienced providers. The
      percentage of medical students who claimed they deliver bad news was comparable
      to that of physicians. Medical schools and post-graduate training programs are
      strongly encouraged to tackle this gap in medical education.
FAU - Alshami, Abbas
AU  - Alshami A
AD  - Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ
      07753, USA.
AD  - Research Department, Dorrington Medical Associates, Houston, TX 77030, USA.
FAU - Douedi, Steven
AU  - Douedi S
AUID- ORCID: 0000-0001-5006-828X
AD  - Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ
      07753, USA.
FAU - Avila-Ariyoshi, America
AU  - Avila-Ariyoshi A
AD  - Research Department, Dorrington Medical Associates, Houston, TX 77030, USA.
FAU - Alazzawi, Mohammed
AU  - Alazzawi M
AD  - Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ
      07753, USA.
FAU - Patel, Swapnil
AU  - Patel S
AD  - Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ
      07753, USA.
FAU - Einav, Sharon
AU  - Einav S
AD  - Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
FAU - Surani, Salim
AU  - Surani S
AUID- ORCID: 0000-0001-7105-4266
AD  - Department of Medicine, Texas A&M University, Corpus Christi, TX 77843, USA.
FAU - Varon, Joseph
AU  - Varon J
AD  - Department of Pulmonary and Critical Care, The University of Texas Health Science
      Center at Houston, Houston, TX 77030, USA.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7711660
OTO - NOTNLM
OT  - communication
OT  - ethical issues
OT  - intensive care units
OT  - life change events
OT  - physician-patient relations
OT  - truth disclosure
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
CRDT- 2020/11/25 01:04
PHST- 2020/09/24 00:00 [received]
PHST- 2020/10/29 00:00 [revised]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/11/25 01:04 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
AID - healthcare8040501 [pii]
AID - 10.3390/healthcare8040501 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Nov 20;8(4). pii: healthcare8040501. doi:
      10.3390/healthcare8040501.


PMID- 33233111
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1873-7145 (Electronic)
IS  - 0963-9969 (Linking)
VI  - 137
DP  - 2020 Nov
TI  - Comments on "A comparison of different physical stomach models and an analysis of
      shear stresses and strains in these system" by Zhong and Langrish (2020).
PG  - 109429
LID - S0963-9969(20)30454-3 [pii]
LID - 10.1016/j.foodres.2020.109429 [doi]
AB  - Understanding of the fate of foods or specific nutrient(s) during digestion
      within the different compartments of the gastrointestinal (GI) tract is important
      for making healthier food products and formulate appropriate dietary advice. In
      vitro GI models have been extensively employed for digestion-related studies in
      recent years because they can overcome many of the difficulties associated with
      human or animal studies as the latter are not always technically, financially and
      ethically feasible. The origins, mechanisms, advantages/disadvantages and
      applications of typical in vitro physical stomach models have been summarized and
      compared in many review papers. These will contribute to the design and
      construction of more advanced and physiologically-relevant in vitro GI models.
      The letter to the editor comments on a recently published review paper aiming to 
      clarify some inaccurate descriptions of the rat and human stomach systems in
      terms of the mechanisms of gastric peristalsis and the materials of construction 
      for the stomach models.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Wu, Peng
AU  - Wu P
AD  - School of Chemical and Environmental Engineering, College of Chemistry, Chemical 
      Engineering and Material Science, Soochow University, Suzhou 215123, Jiangsu
      Province, China.
FAU - Chen, Xiao Dong
AU  - Chen XD
AD  - School of Chemical and Environmental Engineering, College of Chemistry, Chemical 
      Engineering and Material Science, Soochow University, Suzhou 215123, Jiangsu
      Province, China. Electronic address: xdchen@mail.suda.edu.cn.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200609
PL  - Canada
TA  - Food Res Int
JT  - Food research international (Ottawa, Ont.)
JID - 9210143
SB  - IM
CON - Food Res Int. 2020 Sep;135:109296. PMID: 32527487
CIN - Food Res Int. 2020 Oct;136:109542. PMID: 32846597
CIN - Food Res Int. 2020 Nov;137:109442. PMID: 33233122
MH  - Animals
MH  - *Digestion
MH  - Gastrointestinal Tract
MH  - Peristalsis
MH  - Rats
MH  - *Stomach
MH  - Stress, Mechanical
OTO - NOTNLM
OT  - *Digestion
OT  - *Gastric peristalsis
OT  - *Physical stomach models
OT  - *Silicone rubber
EDAT- 2020/11/26 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/11/25 01:01
PHST- 2020/05/28 00:00 [received]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/11/25 01:01 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - S0963-9969(20)30454-3 [pii]
AID - 10.1016/j.foodres.2020.109429 [doi]
PST - ppublish
SO  - Food Res Int. 2020 Nov;137:109429. doi: 10.1016/j.foodres.2020.109429. Epub 2020 
      Jun 9.


PMID- 33232496
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 0098-9134 (Print)
IS  - 0098-9134 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec 1
TI  - Lucidity in the Context of Advanced Neurodegenerative Disorders: A Concept
      Analysis.
PG  - 42-50
LID - 10.3928/00989134-20201106-06 [doi]
AB  - Individuals with advanced dementias resulting from neurodegenerative disorders
      (NDs) occasionally surprise caregivers with episodes of clarity and cognitive
      function that are not usually present. Lucid episodes-aptly named paradoxical
      lucidity in the literature-seem to involve a return of the "old self" during
      advanced neurodegenerative changes. Lucid episodes pose a problem for theories of
      neurological degeneration, which position dementias as progressive, incurable,
      and irreversible. In addition, lucid episodes raise ethical questions about
      whether information gleaned during lucid episodes is appropriate to direct future
      patient-centered care. The concept requires analysis and clarification if it is
      to guide future theorizing and research. The underlying goals of the current
      concept analysis are twofold: (a) to clarify the meaning of lucidity in the
      context of advanced NDs; and (b) to develop a theoretical definition that can
      guide future practice, research, and policy development. Walker and Avant's
      method is used to identify uses of the concept, defining attributes, antecedents,
      consequences, and empirical referents. [Journal of Gerontological Nursing,
      46(12), 42-50.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Morris, Patricia
AU  - Morris P
FAU - Bulman, Donna
AU  - Bulman D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Gerontol Nurs
JT  - Journal of gerontological nursing
JID - 7510258
MH  - *Caregivers
MH  - Cognition
MH  - *Concept Formation
MH  - Humans
EDAT- 2020/11/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/24 17:14
PHST- 2020/02/11 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/11/24 17:14 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.3928/00989134-20201106-06 [doi]
PST - ppublish
SO  - J Gerontol Nurs. 2020 Dec 1;46(12):42-50. doi: 10.3928/00989134-20201106-06.


PMID- 33231594
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 2047-4849 (Electronic)
IS  - 2047-4830 (Linking)
VI  - 8
IP  - 23
DP  - 2020 Dec 7
TI  - NIR-II FL/PA dual-modal imaging long-term tracking of human umbilical
      cord-derived mesenchymal stem cells labeled with melanin nanoparticles and
      visible HUMSC-based liver regeneration for acute liver failure.
PG  - 6592-6602
LID - 10.1039/d0bm01221a [doi]
AB  - Acetaminophen (APAP) has been widely used for relieving pain and fever, whilst
      overdose would lead to the occurrence of acute liver failure (ALF). Currently,
      few effective treatments are available for ALF in clinic, especially for severe, 
      advanced- or end-stage patients who need liver transplantation. Human umbilical
      cord-derived mesenchymal stem cells (hUMSCs), as one of the mesenchymal stem
      cells, not only contribute to relieving hepatotoxicity and promoting hepatocyte
      regeneration due to their self-renewing, multi-differentiation potential,
      anti-inflammatory, immunomodulatory and paracrine properties, but possess lower
      immunomodulatory effects, faster self-renewal properties and noncontroversial
      ethical concerns, which may play a better role in the treatment of ALF. In this
      work, hUMSCs were rapidly labeled with near-infrared II fluorescent dye-modified 
      melanin nanoparticles (MNP-PEG-H2), which could realize long-term tracking of
      hUMSCs by NIR-II fluorescent (FL)/photoacoustic (PA) dual-modal imaging and could
      visualize hUMSC-based liver regeneration in ALF. The nanoparticles exhibited good
      dispersibility and biocompatibility, high labeling efficiency for hUMSCs and
      excellent NIR-II FL/PA imaging performance. Moreover, the MNP-PEG-H2 labeled
      hUMSCs could be continuously traced in vivo for up to 21 days. After intravenous 
      delivery, the NIR-II FL and PA images revealed that labeled hUMSCs were able to
      engraft in the injured liver and repair damaged tissue in ALF mice. Therefore,
      the hUMSCs labeled with endogenous melanin nanoparticles solve the key tracing
      problem of MSC-based regenerative medicine and realize the visualization of the
      treatment process, which may provide an efficient, safe and potential choice for 
      ALF.
FAU - Cai, Wenwen
AU  - Cai W
AD  - Imaging Department, The Third Hospital of Shanxi Medical University, Shanxi
      Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan 030032, China.
      zrp_7142@sxmu.edu.cn.
FAU - Sun, Jinghua
AU  - Sun J
FAU - Sun, Yao
AU  - Sun Y
FAU - Zhao, Xuhui
AU  - Zhao X
FAU - Guo, Chunyan
AU  - Guo C
FAU - Dong, Jie
AU  - Dong J
FAU - Peng, Xiaoyang
AU  - Peng X
FAU - Zhang, Ruiping
AU  - Zhang R
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - England
TA  - Biomater Sci
JT  - Biomaterials science
JID - 101593571
RN  - 0 (Melanins)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Humans
MH  - *Liver Failure, Acute/therapy
MH  - Liver Regeneration
MH  - Melanins
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - Mice
MH  - *Nanoparticles
MH  - Umbilical Cord
EDAT- 2020/11/25 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/11/24 12:11
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/11/24 12:11 [entrez]
AID - 10.1039/d0bm01221a [doi]
PST - ppublish
SO  - Biomater Sci. 2020 Dec 7;8(23):6592-6602. doi: 10.1039/d0bm01221a. Epub 2020 Oct 
      14.


PMID- 33231553
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201212
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 24
TI  - Family Members' Perspectives on Family and Social Support Available to Suicidal
      Patients, and Health Systems' Interactions and Responses to Suicide Cases in
      Alberta: Protocol for a Quantitative Research Study.
PG  - e19112
LID - 10.2196/19112 [doi]
AB  - BACKGROUND: Suicide is a major cause of preventable death globally and a leading 
      cause of death by injury in Canada. To support people who experience suicidal
      thoughts and behaviors and to ultimately prevent people from dying by suicide, it
      is important to understand individual and familial experiences with the health
      care system. OBJECTIVE: We present the protocol for a study, the objective of
      which is to explore how people who died by suicide, and their family members,
      interacted with the health care system. METHODS: This is a quantitative research 
      study. Data will be collected through a self-administered paper-based or online
      survey of the family member of patients who died by suicide. The sample size was 
      calculated to be 385 (margin of error +/-3%). RESULTS: Data collection will start
      in October 2020 and results will be available by March 2021. We expect the
      results to shed light on the experiences of individuals who died by suicide and
      their family members with the health care system. The study has received ethical 
      clearance from the Health Ethics Research Board of the University of Alberta
      (Pro00096342). CONCLUSIONS: Our study may inform practice, policy, and future
      research. The findings may shape how members of the health care system respond to
      people who are at risk of suicide and their families. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): PRR1-10.2196/19112.
CI  - (c)Rabab M Abou El-Magd, Liana Urichuk, Shireen Surood, Daniel Li, Andrew
      Greenshaw, Mara Grunau, Laureen MacNeil, Ione Challborn, David Grauwiler, Robert 
      Olson, Vincent Israel Opoku Agyapong. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 24.11.2020.
FAU - Abou El-Magd, Rabab M
AU  - Abou El-Magd RM
AUID- ORCID: https://orcid.org/0000-0002-6931-9277
AD  - Department of Psychiatry, Faculty of Medicine, University of Alberta, Edmonton,
      AB, Canada.
FAU - Urichuk, Liana
AU  - Urichuk L
AUID- ORCID: https://orcid.org/0000-0003-1013-5921
AD  - Addiction & Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Surood, Shireen
AU  - Surood S
AUID- ORCID: https://orcid.org/0000-0002-9776-2348
AD  - Addiction & Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Li, Daniel
AU  - Li D
AUID- ORCID: https://orcid.org/0000-0003-2644-5342
AD  - Addiction & Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Greenshaw, Andrew
AU  - Greenshaw A
AUID- ORCID: https://orcid.org/0000-0002-9097-900X
AD  - Department of Psychiatry, Faculty of Medicine, University of Alberta, Edmonton,
      AB, Canada.
FAU - Grunau, Mara
AU  - Grunau M
AUID- ORCID: https://orcid.org/0000-0002-6145-0801
AD  - Centre for Suicide Prevention, Calgary, AB, Canada.
FAU - MacNeil, Laureen
AU  - MacNeil L
AUID- ORCID: https://orcid.org/0000-0003-2607-9063
AD  - Canadian Mental Health Association, Calgary, AB, Canada.
FAU - Challborn, Ione
AU  - Challborn I
AUID- ORCID: https://orcid.org/0000-0003-4812-2202
AD  - Canadian Mental Health Association, Edmonton, AB, Canada.
FAU - Grauwiler, David
AU  - Grauwiler D
AUID- ORCID: https://orcid.org/0000-0003-0524-3127
AD  - Canadian Mental Health Association, Edmonton, AB, Canada.
FAU - Olson, Robert
AU  - Olson R
AUID- ORCID: https://orcid.org/0000-0002-7903-8911
AD  - Centre for Suicide Prevention, Calgary, AB, Canada.
FAU - Agyapong, Vincent Israel Opoku
AU  - Agyapong VIO
AUID- ORCID: https://orcid.org/0000-0002-2743-0372
AD  - Department of Psychiatry, Faculty of Medicine, University of Alberta, Edmonton,
      AB, Canada.
AD  - Addiction & Mental Health, Alberta Health Services, Edmonton, AB, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201124
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7723743
OTO - NOTNLM
OT  - family members' perspectives
OT  - health systems interactions
OT  - social support
OT  - suicide
OT  - suicide in Alberta
EDAT- 2020/11/25 06:00
MHDA- 2020/11/25 06:01
CRDT- 2020/11/24 12:11
PHST- 2020/04/04 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/08/02 00:00 [revised]
PHST- 2020/11/24 12:11 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2020/11/25 06:01 [medline]
AID - v9i11e19112 [pii]
AID - 10.2196/19112 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 24;9(11):e19112. doi: 10.2196/19112.


PMID- 33231407
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20220531
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 140
IP  - 17
DP  - 2020 Nov 24
TI  - Failure to report results of registered trials of treatments for shoulder
      complaints.
LID - 10.4045/tidsskr.20.0254 [doi]
AB  - BACKGROUND: It is well documented that the results of clinical trials are often
      not made publicly available. It is not known whether this also applies to trials 
      of treatment for shoulder complaints. METHOD: Searches were conducted in the
      registries ClinicalTrials.gov, EUCTR and ISRCTN for registered and completed
      randomised and non-randomised trials of conservative and surgical interventions
      for shoulder complaints. The percentage that had published results in a
      peer-reviewed journal and/or reported results to a registry was determined.
      RESULTS: A total of 278 randomised and 70 non-randomised trials were completed in
      the period 1 January 2000-31 December 2018. Of these, 177 (51 %) had published
      their results in a peer-reviewed journal as of 31 May 2020 and/or described their
      results in a registry. More than 15 000 patients had taken part in trials for
      which results were not available. Results reporting had little connection with
      trial size or design, funding source, or type of intervention or shoulder
      complaint. Nor was there evidence that the reporting improved during the period
      in which the trials were conducted. INTERPRETATION: The high percentage of
      completed trials without information about results weakens the evidence basis for
      treatment of shoulder complaints. Moreover, such a practice is ethically
      unacceptable.
FAU - Holtedahl, Robin
AU  - Holtedahl R
LA  - eng
LA  - nor
PT  - Journal Article
TT  - Mangelfull rapportering av resultater fra registrerte studier om skulderplager.
DEP - 20201123
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny
      raekke
JID - 0413423
SB  - IM
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Registries
MH  - *Shoulder
MH  - Shoulder Injuries
EDAT- 2020/11/25 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/11/24 08:46
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/11/24 08:46 [entrez]
AID - 20-0254 [pii]
AID - 10.4045/tidsskr.20.0254 [doi]
PST - epublish
SO  - Tidsskr Nor Laegeforen. 2020 Nov 23;140(17). pii: 20-0254. doi:
      10.4045/tidsskr.20.0254. Print 2020 Nov 24.


PMID- 33231040
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1668-3501 (Electronic)
IS  - 0325-0075 (Linking)
VI  - 118
IP  - 6
DP  - 2020 Dec
TI  - The placebo effect and ethics in medical practice.
PG  - 370-371
LID - 10.5546/aap.2020.eng.370 [doi]
FAU - Ceriani Cernadas, Jose Maria
AU  - Ceriani Cernadas JM
LA  - eng
LA  - spa
PT  - Editorial
TT  - El efecto placebo y la etica en la practica medica.
PL  - Argentina
TA  - Arch Argent Pediatr
JT  - Archivos argentinos de pediatria
JID - 0372460
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - *Placebo Effect
COIS- None
EDAT- 2020/11/25 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/11/24 08:16
PHST- 2020/11/24 08:16 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.5546/aap.2020.eng.370 [doi]
PST - ppublish
SO  - Arch Argent Pediatr. 2020 Dec;118(6):370-371. doi: 10.5546/aap.2020.eng.370.


PMID- 33231039
OWN - NLM
STAT- MEDLINE
DCOM- 20210923
LR  - 20210923
IS  - 1471-5457 (Electronic)
IS  - 0730-9384 (Linking)
VI  - 39
IP  - 2
DP  - 2020 Nov 18
TI  - PsychTable.org: A tool for biopolitical researchers, policymakers, and citizens.
PG  - 228-233
LID - 10.1017/pls.2020.10 [doi]
AB  - PsychTable.org is a new online, mass-collaborative tool for the social sciences
      that aggregates evidence for and classifies the evolved psychological adaptations
      (EPAs) that have been proposed to comprise the human mind. This article provides 
      an overview of the need for this reference tool and how it can benefit
      researchers who incorporate the behavioral sciences into their work. The article 
      walks the reader through a hypothetical use case for PsychTable.org and describes
      the features of the website. PsychTable.org is intended to help key stakeholders 
      better understand the linkages between EPAs and political behavior, public
      policy, and ethics.
FAU - Glass, Daniel J
AU  - Glass DJ
AD  - PsychTable.org, Project Co-leader, Project Co-leader, Cambridge, Massachusetts,
      djglass@suffolk.edu.
FAU - Balachandran, Niruban
AU  - Balachandran N
AD  - PsychTable.org, Project Co-leader, Project Co-leader, Cambridge, Massachusetts.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Politics Life Sci
JT  - Politics and the life sciences : the journal of the Association for Politics and 
      the Life Sciences
JID - 8800535
SB  - IM
MH  - Humans
MH  - Information Seeking Behavior
MH  - *Internet
MH  - *Policy Making
MH  - *Politics
MH  - *Public Policy
MH  - Research Personnel
MH  - Social Sciences
OTO - NOTNLM
OT  - *Evolutionary behavioral science
OT  - *evolved psychological adaptations
OT  - *openscience
OT  - *taxonomy; classification
EDAT- 2020/11/25 06:00
MHDA- 2021/09/24 06:00
CRDT- 2020/11/24 07:47
PHST- 2020/11/24 07:47 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/09/24 06:00 [medline]
AID - 10.1017/pls.2020.10 [doi]
PST - ppublish
SO  - Politics Life Sci. 2020 Nov 18;39(2):228-233. doi: 10.1017/pls.2020.10.


PMID- 33230988
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 35
IP  - 45
DP  - 2020 Nov 23
TI  - Reporting Survey Based Studies - a Primer for Authors.
PG  - e398
LID - 10.3346/jkms.2020.35.e398 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has led to a massive rise in
      survey-based research. The paucity of perspicuous guidelines for conducting
      surveys may pose a challenge to the conduct of ethical, valid and meticulous
      research. The aim of this paper is to guide authors aiming to publish in
      scholarly journals regarding the methods and means to carry out surveys for valid
      outcomes. The paper outlines the various aspects, from planning, execution and
      dissemination of surveys followed by the data analysis and choosing target
      journals. While providing a comprehensive understanding of the scenarios most
      conducive to carrying out a survey, the role of ethical approval, survey
      validation and pilot testing, this brief delves deeper into the survey designs,
      methods of dissemination, the ways to secure and maintain data anonymity, the
      various analytical approaches, the reporting techniques and the process of
      choosing the appropriate journal. Further, the authors analyze retracted
      survey-based studies and the reasons for the same. This review article intends to
      guide authors to improve the quality of survey-based research by describing the
      essential tools and means to do the same with the hope to improve the utility of 
      such studies.
CI  - (c) 2020 The Korean Academy of Medical Sciences.
FAU - Gaur, Prithvi Sanjeevkumar
AU  - Gaur PS
AUID- ORCID: https://orcid.org/0000-0002-2341-1932
AD  - Smt. Kashibai Navale Medical College and General Hospital, Pune, India.
FAU - Zimba, Olena
AU  - Zimba O
AUID- ORCID: https://orcid.org/0000-0002-4188-8486
AD  - Department of Internal Medicine No. 2, Danylo Halytsky Lviv National Medical
      University, Lviv, Ukraine.
FAU - Agarwal, Vikas
AU  - Agarwal V
AUID- ORCID: https://orcid.org/0000-0002-4508-1233
AD  - Department Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate
      Institute of Medical Sciences, Lucknow, India.
FAU - Gupta, Latika
AU  - Gupta L
AUID- ORCID: https://orcid.org/0000-0003-2753-2990
AD  - Department Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate
      Institute of Medical Sciences, Lucknow, India. drlatikagupta@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201123
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
SB  - IM
MH  - Authorship
MH  - COVID-19/pathology/virology
MH  - Humans
MH  - Periodicals as Topic
MH  - *Publishing/standards
MH  - *Research
MH  - SARS-CoV-2/isolation & purification
MH  - Surveys and Questionnaires
PMC - PMC7683244
OTO - NOTNLM
OT  - Data Analysis
OT  - Pandemics
OT  - Periodicals as Topic
OT  - Publishing
OT  - Surveys and Questionnaires
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2020/11/25 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/24 06:12
PHST- 2020/10/09 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/11/24 06:12 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 35.e398 [pii]
AID - 10.3346/jkms.2020.35.e398 [doi]
PST - epublish
SO  - J Korean Med Sci. 2020 Nov 23;35(45):e398. doi: 10.3346/jkms.2020.35.e398.


PMID- 33230986
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 35
IP  - 45
DP  - 2020 Nov 23
TI  - Fundamental Shifts in Research, Ethics and Peer Review in the Era of the COVID-19
      Pandemic.
PG  - e395
LID - 10.3346/jkms.2020.35.e395 [doi]
AB  - The era of the coronavirus disease 2019 (COVID-19) pandemic has led to
      fundamental shifts in research, ethics, and peer review including reframing of
      the research design, adapting methodologies to the study type, transitioning of
      research mechanics, changing research methodologies, overcoming data collection
      and standardization constraints, upholding research standards and ethics,
      maintaining informativeness and social value, and providing guarded peer review
      flexibility. Indeed, the COVID-19 crisis, despite disrupting research worldwide
      to an unprecedented degree, has also become a catalyst to develop strategies of
      adaptation to this disruption. As the COVID-19 pandemic continuous to evolve,
      new, cost-effective, and highly flexible research models need to be developed.
      Planning is crucial for ensuring short-term and long-term contingency funds to
      support research logistics and personnel. A mental shift must accompany changes
      in methodologies to mentor and support researchers who are vital to the
      continuity of high-caliber research in the long term. A global research
      perspective through interinstitutional and interprofessional collaboration will
      sustain adherence to the highest standards of data collection and research
      reporting.
CI  - (c) 2020 The Korean Academy of Medical Sciences.
FAU - Barroga, Edward
AU  - Barroga E
AUID- ORCID: https://orcid.org/0000-0002-8920-2607
AD  - Department of General Education, Graduate School of Nursing Science, St. Luke's
      International University, Tokyo, Japan. edward-barroga@slcn.ac.jp.
FAU - Matanguihan, Glafera Janet
AU  - Matanguihan GJ
AUID- ORCID: https://orcid.org/0000-0003-2624-1219
AD  - Department of Biological Sciences, Messiah University, Mechanicsburg, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201123
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
SB  - IM
MH  - COVID-19/*pathology/virology
MH  - *Ethics, Research
MH  - Humans
MH  - Pandemics
MH  - *Peer Review
MH  - *Research
MH  - Research Design
MH  - SARS-CoV-2/isolation & purification
PMC - PMC7683245
OTO - NOTNLM
OT  - COVID-19
OT  - Data Collection
OT  - Ethics
OT  - Peer Review
OT  - Research Design
OT  - Research Methodology
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2020/11/25 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/24 06:12
PHST- 2020/10/23 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/24 06:12 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 35.e395 [pii]
AID - 10.3346/jkms.2020.35.e395 [doi]
PST - epublish
SO  - J Korean Med Sci. 2020 Nov 23;35(45):e395. doi: 10.3346/jkms.2020.35.e395.


PMID- 33230809
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 11
DP  - 2020 Dec
TI  - Hippocrates would be on Twitter.
PG  - 506-507.e1
LID - 10.5694/mja2.50873 [doi]
FAU - Szabo, Rebecca A
AU  - Szabo RA
AUID- ORCID: 0000-0002-7426-0978
AD  - Royal Women's Hospital, Melbourne, VIC.
AD  - University of Melbourne, Melbourne, VIC.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
DEP - 20201123
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Education, Medical
MH  - History, Ancient
MH  - Humans
MH  - Information Dissemination
MH  - *Social Media
PS  - Hippocrates
FPS - Hippocrates
OTO - NOTNLM
OT  - *Ethics
OT  - *Social media
OT  - *professional
EDAT- 2020/11/25 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/11/24 06:07
PHST- 2019/12/12 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/11/24 06:07 [entrez]
AID - 10.5694/mja2.50873 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Dec;213(11):506-507.e1. doi: 10.5694/mja2.50873. Epub 2020 Nov
      23.


PMID- 33229767
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 31
IP  - 5
DP  - 2020 Sep-Oct
TI  - Ethical and Cultural Issues in Transplantation: The Views and Attitudes of
      Nurses.
PG  - 1042-1050
LID - 10.4103/1319-2442.301169 [doi]
AB  - Organ transplantation is lifesaving for individuals with end-stage organ failure.
      However, many people are still waiting for organ transplantation due to religious
      beliefs and the perspectives of society. Many studies on organ donation have
      shown that the knowledge levels and attitudes of nurses have an important effect 
      on organ donation rates. The aim of this study was to evaluate the views and
      attitudes of nurses about ethical and cultural issues related to transplantation.
      This descriptive study was conducted on 220 nurses who worked in a university
      hospital in Istanbul, Turkey. Data were collected using a questionnaire form
      included sociodemographic characteristics, ethical-cultural values, and knowledge
      levels about transplantation of the participants. Descriptive statistics and
      Chi-square test were used for the analysis of data. The mean age of the
      participants was 24.8 +/- 6.04 years. Sixty percent of the participants reported 
      that a person with brain-death was the most ideal candidate for organ donation.
      Seventy-seven percent of them suggested that organ sale was the most common
      ethical problem in organ transplantation. Sixty-three percent reported that the
      patient awaiting transplantation for a long time had priority order for organ
      transplantation. Most of the nurses (91.0%) believed that organ transplantation
      was religiously and culturally appropriate; however, 67.7% of them reported that 
      it was not considered appropriate by the society due to religious and cultural
      beliefs. Sixty-two percent of them suggested that the society believed that organ
      transplantation was unlawful (haram) religiously. Nurses generally had positive
      views and attitudes about organ transplantation.
FAU - Gezginci, Elif
AU  - Gezginci E
AD  - Department of Surgical Nursing, Hamidiye Faculty of Nursing, University of Health
      Sciences Turkey, Istanbul, Turkey.
FAU - Goktas, Sonay
AU  - Goktas S
AD  - Department of Surgical Nursing, Hamidiye Faculty of Nursing, University of Health
      Sciences Turkey, Istanbul, Turkey.
FAU - Caglayan, Sabiha
AU  - Caglayan S
AD  - Department of Nursing Training and Development, Medipol Mega University Hospital,
      Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Attitude of Health Personnel/*ethnology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Nurses/psychology/statistics & numerical data
MH  - *Organ Transplantation/ethics/nursing/psychology
MH  - Surveys and Questionnaires
MH  - *Tissue and Organ Procurement
MH  - Turkey
MH  - Young Adult
EDAT- 2020/11/25 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/11/24 05:57
PHST- 2020/11/24 05:57 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
AID - SaudiJKidneyDisTranspl_2020_31_5_1042_301169 [pii]
AID - 10.4103/1319-2442.301169 [doi]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2020 Sep-Oct;31(5):1042-1050. doi:
      10.4103/1319-2442.301169.


PMID- 33229586
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210524
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 48
DP  - 2020 Dec 1
TI  - Ethics in field experimentation: A call to establish new standards to protect the
      public from unwanted manipulation and real harms.
PG  - 30014-30021
LID - 10.1073/pnas.2012021117 [doi]
AB  - In 1966, Henry Beecher published his foundational paper "Ethics and Clinical
      Research," bringing to light unethical experiments that were routinely being
      conducted by leading universities and government agencies. A common theme was the
      lack of voluntary consent. Research regulations surrounding laboratory
      experiments flourished after his work. More than half a century later, we seek to
      follow in his footsteps and identify a new domain of risk to the public: certain 
      types of field experiments. The nature of experimental research has changed
      greatly since the Belmont Report. Due in part to technological advances including
      social media, experimenters now target and affect whole societies, releasing
      interventions into a living public, often without sufficient review or controls. 
      A large number of social science field experiments do not reflect compliance with
      current ethical and legal requirements that govern research with human
      participants. Real-world interventions are being conducted without consent or
      notice to the public they affect. Follow-ups and debriefing are routinely not
      being undertaken with the populations that experimenters injure. Importantly,
      even when ethical research guidelines are followed, researchers are following
      principles developed for experiments in controlled settings, with little
      assessment or protection for the wider societies within which individuals are
      embedded. We strive to improve the ethics of future work by advocating the
      creation of new norms, illustrating classes of field experiments where scholars
      do not appear to have recognized the ways such research circumvents ethical
      standards by putting people, including those outside the manipulated group, into 
      harm's way.
FAU - McDermott, Rose
AU  - McDermott R
AUID- ORCID: 0000-0002-0920-1541
AD  - Political Science, Brown University, Providence, RI 02912.
FAU - Hatemi, Peter K
AU  - Hatemi PK
AUID- ORCID: 0000-0001-6514-2614
AD  - Political Science, Pennsylvania State University, University Park, PA 16802;
      Phatemi@gmail.com.
AD  - Microbiology and Biochemistry, Pennsylvania State University, University Park, PA
      16802.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - *Ethics, Research
MH  - Human Experimentation/*ethics/*standards
MH  - Humans
MH  - Reference Standards
MH  - Risk
MH  - Social Media
MH  - Social Sciences
PMC - PMC7720186
OTO - NOTNLM
OT  - *ethics
OT  - *field experiments
OT  - *research
COIS- The authors declare no competing interest.
EDAT- 2020/11/25 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/11/24 05:57
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/11/24 05:57 [entrez]
AID - 2012021117 [pii]
AID - 10.1073/pnas.2012021117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30014-30021. doi:
      10.1073/pnas.2012021117. Epub 2020 Nov 23.


PMID- 33229377
OWN - NLM
STAT- Publisher
LR  - 20201124
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 23
TI  - A new kind of paternalism in surrogate decision-making? The case of Barnsley
      Hospitals NHS Foundation Trust v MSP.
LID - medethics-2020-106797 [pii]
LID - 10.1136/medethics-2020-106797 [doi]
AB  - The modern legal and ethical movement against traditional welfare paternalism in 
      medical decision-making extends to how decisions are made for patients lacking
      decisional capacity, prioritising surrogates' judgment about what patients would 
      have decided over even their best interests. In England and Wales, the Mental
      Capacity Act 2005 follows this trend of prioritising the patient's prior wishes, 
      values and beliefs but the dominant interpretation in life-sustaining treatment
      cases does so by in effect calling those values the 'best interests' of the
      patient and focusing nearly exclusively on the 'subjective' viewpoint of the
      patient. In this article, we examine the recent Court of Protection judgment in
      Barnsley Hospitals NHS Foundation Trust v MSP [2020] EWCOP 26, which adhered
      closely to this approach, to suggest that it could have unexpected negative
      consequences. These include insufficient information gathering about and
      attention to patients' objective medical interests, inadequacy of the evidentiary
      standard used for the substituted decision-making and, in some cases, even
      prioritising a surrogate's current substituted judgment over the potential for an
      actual judgment by the patient.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kim, Scott Y H
AU  - Kim SYH
AUID- ORCID: http://orcid.org/0000-0002-9444-4627
AD  - Department of Bioethics, National Institutes of Health, Bethesda, Maryland, USA
      scott.kim@nih.gov.
FAU - Ruck Keene, Alexander
AU  - Ruck Keene A
AD  - 39 Essex Chambers, London, UK.
AD  - Dickson Poon School of Law, King's College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - competence/incompetence
OT  - decision-making
OT  - end of life care
OT  - legal aspects
COIS- Competing interests: None declared.
EDAT- 2020/11/25 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/24 05:55
PHST- 2020/08/17 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/24 05:55 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - medethics-2020-106797 [pii]
AID - 10.1136/medethics-2020-106797 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 23. pii: medethics-2020-106797. doi:
      10.1136/medethics-2020-106797.


PMID- 33228796
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 2050-7283 (Electronic)
IS  - 2050-7283 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Nov 23
TI  - Assessment of the psychosocial and economic impact according to sex in non-small 
      cell lung cancer patients: an exploratory longitudinal study.
PG  - 123
LID - 10.1186/s40359-020-00489-z [doi]
AB  - BACKGROUND: Little is known about the impact of sex on lung cancer patients from 
      the psychological, economic and social perspectives. This study was designed to
      explore the psychosocial and economic impact according to sex of metastatic
      non-small cell lung cancer (mNSCLC) in patients and caregivers. METHODS:
      Exploratory study of two cohorts of patients starting first-line treatment for
      mNSCLC. The following questionnaires were administered at baseline, 4 months
      later and following the first and second disease progression: APGAR, relationship
      impact scale, DUKE-UNC scale, economic impact in patients and caregiver, and
      Zarit scale. It was planned to include 1250 patients to get an 80% possibility of
      detecting as significant (p < 0.05) effect sizes less than 0.19 between men and
      women. Univariate comparisons were made between the tests applied to men and
      women. Overall survival was estimated with Kaplan-Meier method. Cox analyses were
      done to estimate hazard ratios (HRs) with 95% CI. RESULTS: 333 patients were
      included. Most families reported to continue being functional despite the lung
      cancer diagnosis. Regardless of sex, they did not perceive changes in their
      partner relationship. Most patients felt their social support was normal. Roughly
      25% of people reported a worsening in their economic situation, without
      remarkable differences by sex. Statistically significant differences were found
      between both groups regarding the caregiver's relationship to the patient (more
      parents were the caregiver in females than in males, p < 0.0001) and the
      caregiver's employment situation (more employed caregivers in females) (p <
      0.0001). Most caregivers of both sexes considered that taking care of their
      relative did not pose a significant burden. CONCLUSIONS: This study provides a
      preliminary insight into sex-related characteristics in the management of
      advanced NSCLC and its impact on the emotional, social and economic burden of
      patients and their caregivers, and recall the high priority of researching in
      cancer from a sex perspective. Nevertheless, due to the low recruitment rate and 
      the relevant loss of patients during the follow-up, it was difficult to find
      differences by sex. TRIAL REGISTRATION: ClinicalTrials.gov identifier:
      NCT02336061. ETHICS COMMITTEE: Comite Etico de Investigacion Clinica del Hospital
      Clinic de Barcelona, Spain. Reference number: HCB/2014/0705.
FAU - Vinolas, N Nuria
AU  - Vinolas NN
AUID- ORCID: http://orcid.org/0000-0001-5354-8553
AD  - Medical Oncology Department, Hospital Clinic i Provincial de Barcelona, Carrer
      Villarroel, 170, 08036, Barcelona, Spain. nvinolas@clinic.cat.
AD  - Translational Genomics and Targeted Therapeutics in Solid Tumors, Agusti Pi i
      Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
      nvinolas@clinic.cat.
FAU - Garcia-Campelo, Rosario
AU  - Garcia-Campelo R
AD  - Medical Oncology Department, Complexo Hospitalario Universitario A Coruna
      (CHUAC), A Coruna, Spain.
FAU - Majem, Margarita
AU  - Majem M
AD  - Medical Oncology Department, Instituto H. Santa Creu i Sant Pau, Barcelona,
      Spain.
FAU - Carcereny, Enric
AU  - Carcereny E
AD  - Medical Oncology Department, Hospital Universitari Germans Trias I Pujol,
      Badalona, Barcelona, Spain.
FAU - Isla, Dolores
AU  - Isla D
AD  - Medical Oncology Department, Hospital Lozano Blesa, Zaragoza, Spain.
FAU - Gonzalez-Larriba, Jose Luis
AU  - Gonzalez-Larriba JL
AD  - Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain.
FAU - Coves, Juan
AU  - Coves J
AD  - Medical Oncology Department, Hospital Son Llatzer, Palma de Mallorca, Spain.
FAU - De-Castro, Javier
AU  - De-Castro J
AD  - Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
FAU - Domine, Manuel
AU  - Domine M
AD  - Medical Oncology Department, Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Lianes, Piar
AU  - Lianes P
AD  - Medical Oncology Department, Hospital de Mataro, Barcelona, Spain.
FAU - Artal, Angel
AU  - Artal A
AD  - Medical Oncology Department, Hospital Miguel Servet, Zaragoza, Spain.
FAU - Remon, Jordi
AU  - Remon J
AD  - Medical Oncology Department, CIOCC Barcelona - HM Delfos, Barcelona, Spain.
FAU - Felip, Enriqueta
AU  - Felip E
AD  - Medical Oncology Department, Hospital Universitario Vall d'Hebron, Barcelona,
      Spain.
FAU - Garrido, Pilar
AU  - Garrido P
AD  - Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT02336061
PT  - Journal Article
PT  - Observational Study
DEP - 20201123
PL  - England
TA  - BMC Psychol
JT  - BMC psychology
JID - 101627676
SB  - IM
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/pathology/*psychology
MH  - Caregivers/*psychology
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Lung Neoplasms/pathology/*psychology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Sex Factors
MH  - Social Support
MH  - Socioeconomic Factors
PMC - PMC7685640
OTO - NOTNLM
OT  - Carcinoma
OT  - Caregivers
OT  - Non-small-cell lung
OT  - Sex characteristics
EDAT- 2020/11/25 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/24 05:39
PHST- 2020/03/02 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/24 05:39 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1186/s40359-020-00489-z [doi]
AID - 10.1186/s40359-020-00489-z [pii]
PST - epublish
SO  - BMC Psychol. 2020 Nov 23;8(1):123. doi: 10.1186/s40359-020-00489-z.


PMID- 33228755
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 23
TI  - An investigation into the factors affecting investigator-initiated trial start-up
      in Ireland.
PG  - 962
LID - 10.1186/s13063-020-04893-z [doi]
AB  - BACKGROUND: In common with many countries, Ireland has seen an increasing trend
      in the number of clinical trials conducted over the past few years. Yet, as
      elsewhere, trialists in Ireland face several problems and barriers in the
      starting-up of clinical trials. These barriers impede trial activity
      significantly, with consequent impacts on patient care. It is critical to
      understand these issues, to develop approaches to facilitate trial start up. This
      study identifies the challenges in conducting clinical trials in Ireland and
      specifically the contractual, ethical, logistical, and regulatory barriers that
      hinder the start-up of investigator-led trials in Ireland. METHODS: Data for this
      study were collected in two stages. In the first stage, a survey was conducted
      among trialists in Ireland. A total of 44 trialists responded to the survey, and 
      information was collected about their experience in conducting clinical trials,
      the scale and nature of their most recently completed trial, and the details of
      specific barriers they encountered during the starting-up of the trial. In the
      second stage, nine semi-structured interviews were conducted with the awardees of
      2018 Irish Health Research Board's Definitive Intervention Feasibility Award.
      These interviews facilitated a deeper exploration of issues and problems in
      conducting clinical trials in Ireland. RESULTS: This study identified several
      issues and bottlenecks in starting-up clinical trials in Ireland with contracts
      and ethical approval cited as the major issues. The data shows that site
      identification and activation was also problematic in some cases. Several
      respondents reported difficulties in accessing dedicated time for protocol
      development and believe that support in this area can be greatly beneficial. It
      was reported that availability of skilled staff members like statisticians and
      data managers was as an issue, especially for small trials. CONCLUSION: This
      study found that several factors impact trial initiation and progression in
      Ireland. Delays associated with obtaining contract and ethics approval are
      perceived as major barriers. Specialist supports in areas such as ethics and
      regulatory affairs and availability of specialised staff members in areas such as
      statistics and data management are key actions to enable enhanced clinical trial 
      activity in Ireland.
FAU - Leddy, Lauren
AU  - Leddy L
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
FAU - Sukumar, Prasanth
AU  - Sukumar P
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
FAU - O'Sullivan, Lydia
AU  - O'Sullivan L
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
AD  - HRB Trials Methodology Research Network, NUI Galway, Galway, Ireland.
FAU - Keane, Fionnuala
AU  - Keane F
AD  - HRB Clinical Research Coordination Ireland, Upper Mount Street, Dublin 2,
      Ireland.
FAU - Devane, Declan
AU  - Devane D
AD  - HRB Trials Methodology Research Network, NUI Galway, Galway, Ireland.
AD  - National University of Ireland, Galway, Ireland.
FAU - Doran, Peter
AU  - Doran P
AUID- ORCID: http://orcid.org/0000-0003-2064-5335
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
      peter.doran@ucd.ie.
LA  - eng
GR  - 00000/HRBI_/Health Research Board/Ireland
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Contracts
MH  - Humans
MH  - Ireland
MH  - *Research Design
MH  - *Research Personnel
MH  - Surveys and Questionnaires
PMC - PMC7684941
EDAT- 2020/11/25 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/24 05:39
PHST- 2019/12/27 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/24 05:39 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04893-z [doi]
AID - 10.1186/s13063-020-04893-z [pii]
PST - epublish
SO  - Trials. 2020 Nov 23;21(1):962. doi: 10.1186/s13063-020-04893-z.


PMID- 33228608
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20220418
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 23
TI  - Variations in processes for guideline adaptation: a qualitative study of World
      Health Organization staff experiences in implementing guidelines.
PG  - 1758
LID - 10.1186/s12889-020-09812-0 [doi]
AB  - BACKGROUND: The World Health Organisation (WHO) publishes a large number of
      clinical practice and public health guidelines to promote evidence-based practice
      across the world. Due to the variety of health system capacities and contextual
      issues in different regions and countries, adapting the recommendations in the
      guidelines to the local situation is vital for the success of their
      implementation. We aim to understand the range of experiences with guideline
      adaptation from the perspectives of those working in WHO regional and country
      offices. Our findings will inform development of guidance on how to improve
      adaptability of WHO guidelines. METHODS: A grounded theory-informed, qualitative 
      study was carried out between March 2018 and December 2018. Seventeen
      semi-structured interviews were conducted with participants who included WHO
      guideline developers and staff in the headquarters, regional and country offices 
      recruited from a sample of published WHO guidelines. Participants were eligible
      for recruitment if they had recent experience in clinical practice or public
      health guideline implementation. Deidentified transcripts of these interview were
      analysed through three cycles of coding. RESULTS: We categorised the adaptation
      processes described by the participants into two dominant models along a spectrum
      of guideline adaptation processes. First, the Copy or Customise Model is a
      pragmatic approach of either copying or customising WHO guidelines to suit local 
      needs. This is done by local health authorities and/or clinicians directly
      through consultations with WHO staff. Selections and adjustments of guideline
      recommendations are made according to what the implementers deemed important,
      feasible and applicable through the consensus discussions. Second, the Capacity
      Building Model focuses on WHO building local capacity in evidence synthesis
      methods and adaptation frameworks to support local development of a national
      guideline informed by international guidelines. CONCLUSIONS: In comparing and
      contrasting these two models of guideline adaptation, we outline the different
      kinds of support from WHO that may be necessary to improve the effectiveness and 
      efficiency of the respective models. We also suggest clarifications in the
      descriptions of the process of guideline adaptation in WHO and academic
      literature, to help guideline adaptors and implementers decide on the appropriate
      course of action according to their specific circumstances. ETHICS: This project 
      was conducted with ethics approval from The University of Sydney (Project number:
      2017/723) and WHO (Protocol ID: 00001).
FAU - Wang, Zhicheng
AU  - Wang Z
AUID- ORCID: http://orcid.org/0000-0003-0559-4736
AD  - Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney 
      School of Pharmacy, Sydney, Australia. zwan7718@uni.sydney.edu.au.
FAU - Grundy, Quinn
AU  - Grundy Q
AD  - Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney 
      School of Pharmacy, Sydney, Australia.
AD  - Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada.
FAU - Parker, Lisa
AU  - Parker L
AD  - Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney 
      School of Pharmacy, Sydney, Australia.
FAU - Bero, Lisa
AU  - Bero L
AD  - Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney 
      School of Pharmacy, Sydney, Australia.
AD  - Colorado School of Public Health and Center for Bioethics and Humanities,
      University of Colorado School of Medicine, Aurora, USA.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Evidence-Based Practice/*organization & administration
MH  - Global Health
MH  - *Guidelines as Topic
MH  - Health Policy
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Qualitative Research
MH  - World Health Organization/*organization & administration
PMC - PMC7686668
OTO - NOTNLM
OT  - Adaptation
OT  - Global health
OT  - Guidelines
OT  - Implementation
OT  - Research utilisation
OT  - WHO
EDAT- 2020/11/25 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/24 05:37
PHST- 2020/02/06 00:00 [received]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/24 05:37 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - 10.1186/s12889-020-09812-0 [doi]
AID - 10.1186/s12889-020-09812-0 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Nov 23;20(1):1758. doi: 10.1186/s12889-020-09812-0.


PMID- 33228599
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 23
TI  - Challenges in public health and epidemiology research in humanitarian settings:
      experiences from the field.
PG  - 1761
LID - 10.1186/s12889-020-09851-7 [doi]
AB  - BACKGROUND: Humanitarian settings often present unique scientific challenges and 
      conditions that distinguish them from standard research settings. While a number 
      of these challenges are faced in both standard settings and humanitarian
      settings, factors unique to humanitarian settings such as inaccessibility and
      time sensitivities further exacerbate the effects of these challenges. This
      analysis focuses on experiences in post-disaster contexts such as Indonesia and
      India following the 2004 Indian Ocean Tsunami, the Philippines following Typhoon 
      Haiyan in 2013, and Nepal following the 2015 earthquake. DISCUSSION: Particular
      issues that we faced in undertaking research in post-disaster settings include
      challenges with uncharted ethical and cultural considerations, non-standardised
      administrative methods for record keeping, data sharing and dissemination. While 
      these issues are not unique to post-disaster humanitarian settings, the
      time-sensitive nature of our work exacerbated the effects of these concerns.
      Relying on local partners and making quick decisions to tackle issues is
      imperative for navigating both foreseen and unforeseen challenges. While
      pre-emptive action to address these concerns is the most efficient means to
      expedite research protocols, adaptability and contingency planning are key
      components of practical research implementation in dynamic situations.
      CONCLUSIONS: Research is not always a priority in humanitarian settings, so
      innovative methods are necessary to conduct meaningful and situationally
      appropriate research in these venues. By understanding available resources, local
      culture, and political considerations and working efficiently and decisively, we 
      can begin to jump hurdles associated with epidemiologic research in humanitarian 
      settings.
FAU - Guha-Sapir, Debarati
AU  - Guha-Sapir D
AD  - Centre for Research on the Epidemiology of Disasters (CRED), Institute for Health
      and Society, Clos Chapelle-aux-Champs, University Louvain, Bte B1.30, 15 1200,
      Brussels, Belgium.
FAU - Scales, Sarah Elizabeth
AU  - Scales SE
AUID- ORCID: http://orcid.org/0000-0001-9983-5304
AD  - Mailman School of Public Health, Columbia University, 722 W 168th St, New York,
      NY, 10032, USA. ses2248@caa.columbia.edu.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - *Altruism
MH  - Cyclonic Storms
MH  - *Disasters
MH  - Earthquakes
MH  - *Epidemiologic Studies
MH  - Humans
MH  - India/epidemiology
MH  - Indonesia/epidemiology
MH  - Nepal/epidemiology
MH  - Philippines/epidemiology
MH  - *Public Health
MH  - Tsunamis
PMC - PMC7684900
OTO - NOTNLM
OT  - Disasters
OT  - Epidemiology
OT  - Humanitarian settings
OT  - Natural hazards
EDAT- 2020/11/25 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/24 05:37
PHST- 2020/05/22 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/24 05:37 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - 10.1186/s12889-020-09851-7 [doi]
AID - 10.1186/s12889-020-09851-7 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Nov 23;20(1):1761. doi: 10.1186/s12889-020-09851-7.


PMID- 33227756
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201125
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 275
DP  - 2020 Nov 23
TI  - A Decentralized Framework for Biostatistics and Privacy Concerns.
PG  - 137-141
LID - 10.3233/SHTI200710 [doi]
AB  - Biostatistics and machine learning have been the cornerstone of a variety of
      recent developments in medicine. In order to gather large enough datasets, it is 
      often necessary to set up multi-centric studies; yet, centralization of
      measurements can be difficult, either for practical, legal or ethical reasons. As
      an alternative, federated learning enables leveraging multiple centers' data
      without actually collating them. While existing works generally require a center 
      to act as a leader and coordinate computations, we propose a fully decentralized 
      framework where each center plays the same role. In this paper, we apply this
      framework to logistic regression, including confidence intervals computation. We 
      test our algorithm on two distinct clinical datasets split among different
      centers, and show that it matches results from the centralized framework. In
      addition, we discuss possible privacy leaks and potential protection mechanisms, 
      paving the way towards further research.
FAU - Mangold, Paul
AU  - Mangold P
AD  - CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data 
      Exploration, 59000, Lille, France.
AD  - INRIA Lille Nord Europe, Magnet Team, 59650, Villeneuve d'Ascq, France.
AD  - ENS de Lyon, 69007, Lyon, France.
FAU - Filiot, Alexandre
AU  - Filiot A
AD  - CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data 
      Exploration, 59000, Lille, France.
FAU - Moussa, Mouhamed
AU  - Moussa M
AD  - CHU Lille, Pole d'Anesthesie-Reanimation, 59000, Lille, France.
FAU - Sobanski, Vincent
AU  - Sobanski V
AD  - CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data 
      Exploration, 59000, Lille, France.
FAU - Ficheur, Gregoire
AU  - Ficheur G
AD  - CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data 
      Exploration, 59000, Lille, France.
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de sante 
      et des Pratiques medicales, 59000, Lille, France.
FAU - Andrey, Paul
AU  - Andrey P
AD  - CHU Lille, INCLUDE: Integration Center of the Lille University Hospital for Data 
      Exploration, 59000, Lille, France.
FAU - Lamer, Antoine
AU  - Lamer A
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de sante 
      et des Pratiques medicales, 59000, Lille, France.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - Algorithms
MH  - Biometry
MH  - *Biostatistics
MH  - Machine Learning
MH  - *Privacy
OTO - NOTNLM
OT  - biostatistics
OT  - data privacy
OT  - federated learning
EDAT- 2020/11/24 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/23 20:16
PHST- 2020/11/23 20:16 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - SHTI200710 [pii]
AID - 10.3233/SHTI200710 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Nov 23;275:137-141. doi: 10.3233/SHTI200710.


PMID- 33227072
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0019-5545 (Print)
IS  - 0019-5545 (Linking)
VI  - 62
IP  - Suppl 3
DP  - 2020 Sep
TI  - Psychological impact and psychosocial consequences of the COVID 19 pandemic
      Resilience, mental well-being, and the coronavirus pandemic.
PG  - S395-S403
LID - 10.4103/psychiatry.IndianJPsychiatry_1031_20 [doi]
AB  - Since December 2019, the coronavirus (COVID19) outbreak has impacted everyone's
      daily lives globally, especially those experiencing mental health issues. The
      well-being and mental healthcare of patients, families, and health-care
      professionals who have been directly or indirectly affected by this pandemic has 
      not been well addressed. Governments have asked their citizens to take actions,
      some of which include making sacrifices that may result in dignity violations and
      moral injury, a term originating in the military to describe the psychological
      distress that results from actions, or the lack of them, which violate a person's
      moral or ethical code. Health professionals, individuals, and communities have
      changed their way of life and working to decrease coronavirus infectivity,
      causing additional stress and increasing potential for moral injury. It is
      important to hear the first-hand experience of people affected to understand the 
      new psychosocial stressors that they face in their day to day lives and what they
      found helpful in managing these. This global survey carried out by the World
      Dignity Project in collaboration with the Global Mental Health Peer Network is to
      ensure that the voices of people with lived experience of mental health, their
      families, and professionals that work with them are heard. AIMS: To understand
      the impact of the coronavirus pandemic on mental health, well-being, and dignity,
      what has helped and what lessons can be learned to support coping in future.
      MATERIALS AND METHODS: Online qualitative and quantitative survey (April 15-June 
      15, 2020)Participants gave narrative responses to several questions, posting
      photos or images. ANALYSIS: Narrative responses were analyzed using the Gioia
      approach, a systematic inductive approach to develop concepts that help make
      sense of socially constructed worlds. Visual ethnographic data was used to give
      insight into the participant's socio-cultural context.
CI  - Copyright: (c) 2020 Indian Journal of Psychiatry.
FAU - Ivbijaro, Gabriel
AU  - Ivbijaro G
AD  - NOVA Medical School, NOVA University, Lisbon, Portugal, London, UK.
AD  - Faculty of Management, Law and Social Sciences, University of Bradford, Bradford,
      UK.
AD  - The World Dignity Project, London, UK.
AD  - The Wood Street Health Centre, London, UK.
FAU - Brooks, Claire
AU  - Brooks C
AD  - ModelPeople Inc., Global Brand Insights and Strategy, USA.
AD  - The World Dignity Project, London, UK.
FAU - Kolkiewicz, Lucja
AU  - Kolkiewicz L
AD  - NOVA Medical School, NOVA University, Lisbon, Portugal, London, UK.
AD  - The World Dignity Project, London, UK.
FAU - Sunkel, Charlene
AU  - Sunkel C
AD  - Global Mental Health Peer Network, Global Office, Johannesburg, South Africa.
FAU - Long, Andrew
AU  - Long A
AD  - ModelPeople Inc., Global Brand Insights and Strategy, USA.
AD  - The World Dignity Project, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200928
PL  - India
TA  - Indian J Psychiatry
JT  - Indian journal of psychiatry
JID - 0013255
PMC - PMC7659783
OTO - NOTNLM
OT  - Coronavirus
OT  - resilience
OT  - wellbeing
COIS- There are no conflicts of interest.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 17:10
PHST- 2020/08/27 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/11/23 17:10 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.4103/psychiatry.IndianJPsychiatry_1031_20 [doi]
AID - IJPsy-62-395 [pii]
PST - ppublish
SO  - Indian J Psychiatry. 2020 Sep;62(Suppl 3):S395-S403. doi:
      10.4103/psychiatry.IndianJPsychiatry_1031_20. Epub 2020 Sep 28.


PMID- 33227030
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Becoming and being a biobank donor: The role of relationships and ethics.
PG  - e0242828
LID - 10.1371/journal.pone.0242828 [doi]
AB  - Relational aspects, such as involvement of donor's relatives or friends in the
      decision-making on participation in a research biobank, providing relatives'
      health data to researchers, or sharing research findings with relatives should be
      considered when reflecting on ethical aspects of research biobanks. The aim of
      this paper is to explore what the role of donor's relatives and friends is in the
      process of becoming and being a biobank donor and which ethical issues arise in
      this context. We performed qualitative analysis of 40 qualitative semi-structured
      interviews with biobank donors and researchers. The results show that relatedness
      to relatives or other types of close relationships played a significant role in
      the donors' motivation to be involved in a biobank, risk-benefit assessment, and 
      decisions on sharing information on research and its results. Interviewees
      mentioned ethical issues in the context of sharing relatives' health-related data
      for research purposes and returning research findings that may affect their
      relatives. We conclude that the question of what information on family members
      may be shared with a biobank by research participants without informed consent of
      those relatives, and when family members become research subjects, lacks a clear 
      answer and detailed guidelines, especially in the context of the introduction of 
      the European Union's (EU) General Data Protection Regulation. Researchers in
      Latvia and EU face ethical questions and dilemmas about returning research
      results and incidental findings to donors' relatives, and donors need more
      information on sharing research results with relatives in the informed consent
      process.
FAU - Mezinska, Signe
AU  - Mezinska S
AUID- ORCID: 0000-0002-3190-100X
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Riga,
      Latvia.
FAU - Kaleja, Jekaterina
AU  - Kaleja J
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Riga,
      Latvia.
FAU - Mileiko, Ilze
AU  - Mileiko I
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Riga,
      Latvia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Biological Specimen Banks
MH  - Biomedical Research/*ethics
MH  - *Clinical Decision-Making
MH  - Family/psychology
MH  - Female
MH  - Friends
MH  - Humans
MH  - Latvia/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Motivation/ethics
MH  - Research Personnel/ethics
MH  - Tissue Donors/*ethics
PMC - PMC7682884
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/24 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/11/23 17:10
PHST- 2020/08/28 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/11/23 17:10 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 10.1371/journal.pone.0242828 [doi]
AID - PONE-D-20-27082 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 23;15(11):e0242828. doi: 10.1371/journal.pone.0242828.
      eCollection 2020.


PMID- 33226986
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Becoming more of an insider: A grounded theory study on patients' experience of a
      person-centred e-health intervention.
PG  - e0241801
LID - 10.1371/journal.pone.0241801 [doi]
AB  - OBJECTIVE: The aim was to explore the experiences of a person-centred e-health
      intervention, in patients diagnosed with chronic obstructive pulmonary disease
      (COPD) or chronic heart failure (CHF). DESIGN: Grounded theory was applied to
      gather and analyse data. SETTING: The study is part of a research project
      evaluating the effects of person-centred care (PCC) using a digital platform and 
      structured telephone support for people with COPD or CHF recruited from nine
      primary care units in Sweden. PARTICIPANTS: Twelve patients from the intervention
      group were purposefully selected in accordance with the initial sampling
      criteria. INTERVENTION: The intervention was delivered through a digital platform
      and telephone support system for 6 months. The intervention relied on
      person-centred ethics operationalised through three core PCC components: patient 
      narratives, partnership and shared documentation. RESULTS: A core category was
      formulated: Being welcomed through the side door when lacking the front door
      keys. The core category reflects how a PCC intervention delivered remotely
      provides access to mutual and informal meetings at times when professional
      contacts were desired to support patient self-management goals. According to
      patients' wishes, family and friends were seldom invited as care partners in the 
      e-health context. CONCLUSIONS: A PCC intervention delivered remotely as a
      complement to standard care in a primary care setting for patients diagnosed with
      COPD or CHF is a viable approach to increase patients' access and involvement in 
      preventive care. The e-health intervention seemed to facilitate PCC, strengthen
      patients' position in the health service system and support their
      self-management.
FAU - Barenfeld, Emmelie
AU  - Barenfeld E
AUID- ORCID: 0000-0002-4945-4623
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - University of Gothenburg Centre for Person-Centred Care (GPCC), Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Ali, Lilas
AU  - Ali L
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - University of Gothenburg Centre for Person-Centred Care (GPCC), Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Wallstrom, Sara
AU  - Wallstrom S
AUID- ORCID: 0000-0001-7579-4974
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - University of Gothenburg Centre for Person-Centred Care (GPCC), Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Fors, Andreas
AU  - Fors A
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - University of Gothenburg Centre for Person-Centred Care (GPCC), Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Narhalsan Research and Development Primary Health Care, Region Vastra Gotaland,
      Sweden.
FAU - Ekman, Inger
AU  - Ekman I
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - University of Gothenburg Centre for Person-Centred Care (GPCC), Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Chronic Disease
MH  - Female
MH  - *Grounded Theory
MH  - Heart Failure
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient-Centered Care/*methods
MH  - Primary Health Care/methods
MH  - Pulmonary Disease, Chronic Obstructive
MH  - Sweden
MH  - Telephone
PMC - PMC7682879
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/24 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/11/23 17:09
PHST- 2020/05/29 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/23 17:09 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
AID - 10.1371/journal.pone.0241801 [doi]
AID - PONE-D-20-16256 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 23;15(11):e0241801. doi: 10.1371/journal.pone.0241801.
      eCollection 2020.


PMID- 33226336
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210514
IS  - 2050-084X (Electronic)
IS  - 2050-084X (Linking)
VI  - 9
DP  - 2020 Nov 23
TI  - Neuronal timescales are functionally dynamic and shaped by cortical
      microarchitecture.
LID - 10.7554/eLife.61277 [doi]
LID - e61277 [pii]
AB  - Complex cognitive functions such as working memory and decision-making require
      information maintenance over seconds to years, from transient sensory stimuli to 
      long-term contextual cues. While theoretical accounts predict the emergence of a 
      corresponding hierarchy of neuronal timescales, direct electrophysiological
      evidence across the human cortex is lacking. Here, we infer neuronal timescales
      from invasive intracranial recordings. Timescales increase along the principal
      sensorimotor-to-association axis across the entire human cortex, and scale with
      single-unit timescales within macaques. Cortex-wide transcriptomic analysis shows
      direct alignment between timescales and expression of excitation- and
      inhibition-related genes, as well as genes specific to voltage-gated
      transmembrane ion transporters. Finally, neuronal timescales are functionally
      dynamic: prefrontal cortex timescales expand during working memory maintenance
      and predict individual performance, while cortex-wide timescales compress with
      aging. Thus, neuronal timescales follow cytoarchitectonic gradients across the
      human cortex and are relevant for cognition in both short and long terms,
      bridging microcircuit physiology with macroscale dynamics and behavior.
CI  - (c) 2020, Gao et al.
FAU - Gao, Richard
AU  - Gao R
AUID- ORCID: 0000-0001-5916-6433
AD  - Department of Cognitive Science, University of California, San Diego, La Jolla,
      United States.
FAU - van den Brink, Ruud L
AU  - van den Brink RL
AUID- ORCID: 0000-0002-3142-7248
AD  - Section Computational Cognitive Neuroscience, Department of Neurophysiology and
      Pathophysiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Pfeffer, Thomas
AU  - Pfeffer T
AUID- ORCID: 0000-0001-9561-3085
AD  - Center for Brain and Cognition, Computational Neuroscience Group, Universitat
      Pompeu Fabra, Barcelona, Spain.
FAU - Voytek, Bradley
AU  - Voytek B
AUID- ORCID: 0000-0003-1640-2525
AD  - Department of Cognitive Science, University of California, San Diego, La Jolla,
      United States.
AD  - Halicioglu Data Science Institute, University of California, San Diego, La Jolla,
      United States.
AD  - Neurosciences Graduate Program, University of California, San Diego, La Jolla,
      United States.
AD  - Kavli Institute for Brain and Mind, University of California, San Diego, La
      Jolla, United States.
LA  - eng
GR  - FG-2015-66057/Alfred P. Sloan Foundation/International
GR  - 2017-12-73/Whitehall Foundation/International
GR  - R01 GM134363/GM/NIGMS NIH HHS/United States
GR  - CGSD3-488052-2016/Natural Sciences and Engineering Research Council of
      Canada/International
GR  - BCS-1736028/National Science Foundation/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201123
PL  - England
TA  - Elife
JT  - eLife
JID - 101579614
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aging/physiology
MH  - Animals
MH  - Cerebral Cortex/*physiology
MH  - Electrocorticography
MH  - Female
MH  - Humans
MH  - Macaca
MH  - Male
MH  - Memory, Short-Term/*physiology
MH  - Middle Aged
MH  - *Models, Neurological
MH  - Neurons/*physiology
MH  - Transcriptome
MH  - Young Adult
PMC - PMC7755395
OAB - The human brain can both quickly react to a fleeting sight, like a changing
      traffic light, and slowly integrate complex information to form a long-term plan.
      To mirror these requirements, how long a neuron can be activated for - its
      'timescale' - varies greatly between cells. A range of timescales has been
      identified in animal brains, by measuring single neurons at a few different
      locations. However, a comprehensive study of this property in humans has been
      hindered by technical and ethical concerns. Without this knowledge, it is
      difficult to understand the factors that may shape different timescales, and how 
      these can change in response to environmental demands. To investigate this
      question, Gao et al. used a new computational method to analyse publicly
      available datasets and calculate neuronal timescales across the human brain. The 
      data were produced using a technique called invasive electrocorticography, where 
      electrodes placed directly on the brain record the total activity of many
      neurons. This allowed Gao et al. to examine the relationship between timescales
      and brain anatomy, gene expression, and cognition. The analysis revealed a
      continuous gradient of neuronal timescales between areas that require neurons to 
      react quickly and those relying on long-term activity. 'Under the hood', these
      timescales were associated with a number of biological processes, such as the
      activity of genes that shape the nature of the connections between neurons and
      the amount of proteins that let different charged particles in and out of cells. 
      In addition, the timescales could be flexible: they could lengthen when areas
      specialised in working memory were actively maintaining information, or shorten
      with age across many areas of the brain. Ultimately, the technique and findings
      reported by Gao et al. could have useful applications in the clinic, using
      neuronal timescale to better understand brain disorders and pinpoint their
      underlying causes.
OABL- eng
OTO - NOTNLM
OT  - *computational biology
OT  - *cortical gradients
OT  - *functional specialization
OT  - *human
OT  - *neuronal timescales
OT  - *neuroscience
OT  - *rhesus macaque
OT  - *spectral analysis
OT  - *systems biology
OT  - *transcriptomics
COIS- RG, Rv, TP, BV No competing interests declared
EDAT- 2020/11/24 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/11/23 12:10
PHST- 2020/07/21 00:00 [received]
PHST- 2020/11/22 00:00 [accepted]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2020/11/23 12:10 [entrez]
AID - 10.7554/eLife.61277 [doi]
AID - 61277 [pii]
PST - epublish
SO  - Elife. 2020 Nov 23;9. pii: 61277. doi: 10.7554/eLife.61277.


PMID- 33225943
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 23
TI  - Physicians' attitudes in relation to end-of-life decisions in Neonatal Intensive 
      Care Units: a national multicenter survey.
PG  - 121
LID - 10.1186/s12910-020-00555-6 [doi]
AB  - BACKGROUND: End-of-life decisions for neonates with adverse prognosis are
      controversial and raise ethical and legal issues. In Greece, data on physicians' 
      profiles, motivation, values and attitudes underlying such decisions and the
      correlation with their background are scarce. The aim was to investigate
      neonatologists' attitudes in Neonatal Intensive Care Units and correlate them
      with self-reported practices of end-of-life decisions and with their background
      data. METHODS: A structured questionnaire was distributed to all 28 Neonatal
      Intensive Care Units in Greece. One hundred and sixty two out of 260 eligible
      physicians answered anonymously the questionnaire (response rate 66%).
      Demographic and professional characteristics, self-reported practices and
      opinions were included in the questionnaire, along with a questionnaire of 12
      items measuring physicians' attitude and views ranging from value of life to
      quality of life approach (scale 1-5). RESULTS: Continuation of treatment in
      neonates with adverse prognosis without adding further therapeutic interventions 
      was the most commonly reported EoL practice, when compared to withdrawal of
      mechanical ventilation. Physicians with a high attitude score (indicative of
      value of quality-of-life) were more likely to limit, while those with a low score
      (indicative of value of sanctity-of-life) were more likely for continuation of
      intensive care. Physicians' educational level (p:0.097), involvement in research 
      (p:0.093), religion (p:0.024) and position on the existing legal framework (p <
      0.001) were factors that affected the attitude score. CONCLUSIONS: Physicians
      presented with varying end-of-life practices. Limiting interventions in neonates 
      with poor prognosis was strongly related to their attitudes. The most important
      predictors for physicians' attitudes were religiousness and belief for Greek
      legal system reform.
FAU - Chatziioannidis, Ilias
AU  - Chatziioannidis I
AUID- ORCID: 0000-0002-5570-9514
AD  - 2nd Neonatal Department and Neonatal Intensive Care Unit, Papageorgiou Hospital, 
      Aristotle University of Thessaloniki, Thessaloniki, Greece.
      drilias@windowslive.com.
FAU - Iliodromiti, Zoi
AU  - Iliodromiti Z
AD  - Neonatal Department, School of Medicine, Aretaieio Hospital, National and
      Kapodistrian University of Athens, Athens, Greece.
FAU - Boutsikou, Theodora
AU  - Boutsikou T
AD  - Neonatal Department, School of Medicine, Aretaieio Hospital, National and
      Kapodistrian University of Athens, Athens, Greece.
FAU - Pouliakis, Abraham
AU  - Pouliakis A
AD  - 2nd Department of Pathology, School of Medicine, "Attikon" University Hospital,
      National and Kapodistrian University of Athens, Athens, Greece.
FAU - Giougi, Evangelia
AU  - Giougi E
AD  - Conseillere Direction Medicale CHR, Liege, Belgium.
FAU - Sokou, Rozeta
AU  - Sokou R
AD  - Neonatal Department, School of Medicine, Aretaieio Hospital, National and
      Kapodistrian University of Athens, Athens, Greece.
FAU - Vidalis, Takis
AU  - Vidalis T
AD  - Hellenic National Bioethics Commission, Athens, Greece.
FAU - Xanthos, Theodoros
AU  - Xanthos T
AD  - European University of Cyprus, Nicosia, Cyprus.
FAU - Marina, Cuttini
AU  - Marina C
AD  - Clinical Care and Management Innovation Research Area, Bambino Gesu Children's
      Hospital, IRCCS, Rome, Italy.
FAU - Iacovidou, Nicoletta
AU  - Iacovidou N
AD  - Neonatal Department, School of Medicine, Aretaieio Hospital, National and
      Kapodistrian University of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201123
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Attitude of Health Personnel
MH  - Death
MH  - Decision Making
MH  - Humans
MH  - Infant, Newborn
MH  - Intensive Care Units
MH  - Intensive Care Units, Neonatal
MH  - *Physicians
MH  - Quality of Life
MH  - Surveys and Questionnaires
MH  - *Terminal Care
MH  - Withholding Treatment
PMC - PMC7681959
OTO - NOTNLM
OT  - *Attitude
OT  - *End-of-life care
OT  - *Neonatal Intensive Care Units
OT  - *Neonates
OT  - *Withdrawing treatment
OT  - *Withholding treatment
EDAT- 2020/11/24 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/23 08:42
PHST- 2020/04/21 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/23 08:42 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00555-6 [doi]
AID - 10.1186/s12910-020-00555-6 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 23;21(1):121. doi: 10.1186/s12910-020-00555-6.


PMID- 33225910
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210110
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 23
TI  - Knowledge of novel coronavirus disease (COVID-19) among dental surgeons of Nepal:
      a nationwide study.
PG  - 871
LID - 10.1186/s12879-020-05620-4 [doi]
AB  - BACKGROUND: COVID-19 is an emerging respiratory disease caused by a novel
      coronavirus. There is not much evidence assessing the knowledge of dental
      surgeons regarding COVID-19. This study was conducted to assess the knowledge of 
      COVID-19 among dental surgeons of Nepal. METHODS: A web-based cross-sectional
      study was conducted among registered dental surgeons of Nepal. Ethical approval
      was obtained. Consent was taken, and knowledge on COVID-19 was assessed via a
      pre-tested structured questionnaire using Google form. The form was emailed to
      the participants. Descriptive analysis was performed using frequency, percentage,
      median and inter-quartile range. Man-Whitney test and Kruskal-Wallis tests were
      carried out to see the difference in knowledge score. P-value < 0.05 was
      considered statistically significant. RESULTS: Total 227 dental surgeons
      responded to the questionnaire (male: 46.4%; female: 53.7%). Almost two-third (
      65.2% ) of the respondents were B.D.S. (Bachelor of Dental Surgery) graduates.
      Only 29.1% worked in the government hospitals. 17.6% were currently involved in
      COVID-19 management. Of the participants, 87.7% knew about the condition of the
      requirement of Personal Protective Equipment (PPE) but only 29.1% could correctly
      answer the framed question for PPE. The median knowledge score calculated was
      14.0 (8.0-18.0). The bivariate analysis showed a statistically significant
      difference in knowledge score among the age group >/=30 years and < 30 years (p =
      0.013); M.D.S. (Master of Dental Surgery) graduate and B.D.S. graduate (0.041);
      dental surgeons of government healthcare facilities and other healthcare
      facilities (p < 0.001); dental surgeons of COVID-19 centers and non-COVID-19
      centers (0.002). CONCLUSION: The dental surgeons of Nepal have a good knowledge
      of COVID-19, and they can be utilized for assisting in the management of COVID-19
      cases in Nepal.
FAU - Sah, Mukesh Kumar
AU  - Sah MK
AUID- ORCID: https://orcid.org/0000-0002-4363-9678
AD  - Department of Emergency Medicine and General Practice, Patan Academy of Health
      Sciences, Lalitpur, Bagmati Province, Nepal. sahmukeshkumar88@gmail.com.
FAU - Singh, Abanish
AU  - Singh A
AUID- ORCID: https://orcid.org/0000-0001-5659-9807
AD  - Narayani Hospital, Birgunj, Province 2, Nepal.
FAU - Sangroula, Raj Kumar
AU  - Sangroula RK
AUID- ORCID: https://orcid.org/0000-0002-3841-7819
AD  - Nepal Public Health Research and Development Center, Shankhamul, New Baneshor,
      Kathmandu, Bagmati Province, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
SB  - IM
MH  - Adult
MH  - COVID-19/epidemiology/*prevention & control/*psychology/virology
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Hospitals, Public
MH  - Humans
MH  - Infection Control/methods
MH  - Male
MH  - Nepal/epidemiology
MH  - Oral and Maxillofacial Surgeons/*psychology
MH  - Personal Protective Equipment
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - SARS-CoV-2/*genetics
MH  - Surveys and Questionnaires
PMC - PMC7681182
OTO - NOTNLM
OT  - COVID-19
OT  - Case management
OT  - Dental surgeons
OT  - Knowledge
EDAT- 2020/11/24 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/23 08:42
PHST- 2020/07/02 00:00 [received]
PHST- 2020/11/15 00:00 [accepted]
PHST- 2020/11/23 08:42 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12879-020-05620-4 [doi]
AID - 10.1186/s12879-020-05620-4 [pii]
PST - epublish
SO  - BMC Infect Dis. 2020 Nov 23;20(1):871. doi: 10.1186/s12879-020-05620-4.


PMID- 33225783
OWN - NLM
STAT- Publisher
LR  - 20201123
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2020 Nov 23
TI  - Retrospective Matched Case-Control Study on the Use of CO2 Laser for the
      Treatment of Nonhealing Diabetic Foot Ulcers: The DULCIS-2 (Diabetic ULcer, CO2
      Laser, and Infections) Study.
PG  - 1534734620960298
LID - 10.1177/1534734620960298 [doi]
AB  - PURPOSE: Infection, which is one of the possible complications of diabetic foot
      ulcers (DFUs), makes the treatment of ulcers challenging because of its negative 
      impact on healing processes and the high prevalence of multiresistant germs. This
      study is aimed at verifying the effect of a surgical CO2 laser (which reduces the
      bacterial load and allows a more accurate debridement), as compared with the
      traditional lancets, on the healing rate of DFU. METHODS: The present
      case-control retrospective analysis was performed on patients with chronic (>6
      months) DFU with Texas grade >1, treated with 80 W surgical CO2 laser (DEKA
      SmartXide2 C80, El.En. Group) and compared with a matched sample of patients with
      similar characteristics, who were treated with a traditional surgical approach.
      The debridement was performed trying to achieve the complete removal of nonviable
      tissues. The principal endpoint was the proportion of patients healed at 6
      months. All analyses were carried out with SPSS 25.0. The study protocol was
      approved by the local ethical committee. RESULTS: This study included 118
      patients (59 cases and 59 controls). At 6 months, the proportion of healing
      patients was 35% and 18% in cases and controls, respectively (P = .034). The
      corresponding figure at 1 year was 62% and 38% (P = .009), whereas no difference 
      was observed at 1, 2, and 3 months. No serious adverse event was observed.
      CONCLUSIONS: In this article, we show for the first time that CO2 laser
      treatment, in comparison with traditional surgical approaches, can be associated 
      with an increased healing rate in patients with DFU.
FAU - Monami, Matteo
AU  - Monami M
AUID- ORCID: https://orcid.org/0000-0001-9349-828X
AD  - Careggi Hospital and University of Florence, Florence, Italy.
FAU - Ragghianti, Benedetta
AU  - Ragghianti B
AD  - Careggi Hospital and University of Florence, Florence, Italy.
FAU - Silverii, Antonio
AU  - Silverii A
AD  - Careggi Hospital and University of Florence, Florence, Italy.
FAU - Scatena, Alessia
AU  - Scatena A
AD  - San Donato Hospital, Arezzo, Italy.
FAU - Landi, Letizia
AU  - Landi L
AD  - Careggi Hospital and University of Florence, Florence, Italy.
FAU - Cosentino, Claudia
AU  - Cosentino C
AD  - Careggi Hospital and University of Florence, Florence, Italy.
FAU - Vitale, Valentina
AU  - Vitale V
AD  - Careggi Hospital and University of Florence, Florence, Italy.
FAU - Mannucci, Edoardo
AU  - Mannucci E
AD  - Careggi Hospital and University of Florence, Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - United States
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
SB  - IM
OTO - NOTNLM
OT  - CO2 laser
OT  - debridement
OT  - diabetic foot ulcer
OT  - ulcer healing
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/23 08:41
PHST- 2020/11/23 08:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1177/1534734620960298 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2020 Nov 23:1534734620960298. doi:
      10.1177/1534734620960298.


PMID- 33225655
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1819-2718 (Electronic)
IS  - 1025-9589 (Linking)
VI  - 32
IP  - 4
DP  - 2020 Oct-Dec
TI  - Determinants Of Eating Habits And Physical Activity Among Female Students Of
      Government Schools Of Urban City Of Pakistan.
PG  - 517-522
AB  - BACKGROUND: Obesity is constantly increasing among adolescents since the last few
      decades becoming an alarming situation worldwide. The objective of this study was
      to know the determinants of eating habits and physical activities among
      school-going female adolescents of public sectors schools of Rawalpindi Pakistan.
      METHODS: A cross sectional study with mixed method with both quantitative and
      qualitative approach was conducted on three public sector schools of Rawalpindi
      Pakistan. Sample size of 384 female students of grade 5-10 were interviewed on
      reliable and validated tool after taking their consent and ethically approval.
      Moreover, four focus group discussion (FGD) with 30-45 minutes spent on each were
      conducted by inviting 6-8 participants in each group. Qualitative findings were
      triangulated with quantitative results. Study was ethically approved from the
      institutional review board of Health Services Academy Islamabad Pakistan.
      RESULTS: Females schools' students were included in this study were 384 with mean
      (SD) age 11.9+/-1 year. Majority (38%) were of class 7th and their mothers (42%) 
      were educated. Mostly (42%) students were obese (53%) eat the vegetables rarely
      in their diet. Above half (59%) were those students who eat deep fried potato
      chips daily. There was a significance difference were seen among normal and obese
      female students regarding the dietary habits in different class of enrolment
      (<0.001), mother's education (0.04), intake of sweat confectionary (0.01), intake
      of meat (0.00), junk food (0.00), use of energy drink (0.03), use of milk (0.02),
      physical activity (0.00) and play games (0.00). However, intake of vegetables
      (0.23) and mother's education (0.081) were found insignificant in this study.
      Majority (88.5%) of students were also playing games in their daily activity.
      Below half (44%) respondents used to involve in physical activity. Qualitative
      findings triangulate with quantitative findings and themes were generated like;
      awareness on healthy diet, eating junk food, dislikes vegetables in diet and
      physical activity. CONCLUSIONS: Study concluded the factors including student's
      age, mother's education, intake of junk food, physical activity and play games
      are associated with obesity among the female students of government school in
      urban area of the country.
FAU - Javaid, Fasiha
AU  - Javaid F
AD  - Health Services Academy, Ministry of National Health Services Regulation and
      Coordination Islamabad, Pakistan.
FAU - Sheerani, Nand Lal
AU  - Sheerani NL
AD  - Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan.
FAU - Haider, Shagufta
AU  - Haider S
AD  - Health Services Academy, Ministry of National Health Services Regulation and
      Coordination Islamabad, Pakistan.
FAU - Anwar, Fozia
AU  - Anwar F
AD  - COMSATS Institute of information Technology Islamabad, Pakistan.
FAU - Azad, Maria
AU  - Azad M
AD  - Federal Government Polyclinic Hospital, Islamabad, Pakistan.
FAU - Kumari, Priyanka
AU  - Kumari P
AD  - Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan.
FAU - Kanwal, Saira
AU  - Kanwal S
AD  - Health Services Academy, Ministry of National Health Services Regulation and
      Coordination Islamabad, Pakistan.
FAU - Kumar, Ramesh
AU  - Kumar R
AD  - Health Services Academy, Ministry of National Health Services Regulation and
      Coordination Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Ayub Med Coll Abbottabad
JT  - Journal of Ayub Medical College, Abbottabad : JAMC
JID - 8910750
SB  - IM
MH  - Child
MH  - Cross-Sectional Studies
MH  - Diet/*statistics & numerical data
MH  - Exercise/*physiology
MH  - Feeding Behavior/*physiology
MH  - Female
MH  - Humans
MH  - Pakistan
MH  - Pediatric Obesity
MH  - Students/statistics & numerical data
OTO - NOTNLM
OT  - Adolescent; Active games and exercise
OT  - Eating habits; Determinants; Physical activity; Female students
EDAT- 2020/11/24 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/11/23 05:47
PHST- 2020/11/23 05:47 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 8205/2972 [pii]
PST - ppublish
SO  - J Ayub Med Coll Abbottabad. 2020 Oct-Dec;32(4):517-522.


PMID- 33225404
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Nov 23
TI  - Ethics and Privacy in Social Media Research for Mental Health.
PG  - 84
LID - 10.1007/s11920-020-01205-9 [doi]
AB  - PURPOSE OF REVIEW: This review provides an overview of recent research which uses
      social media data in the context of mental health. It also provides an overview
      of challenges in relation to consent, privacy, and usage of such data. RECENT
      FINDINGS: A broad range of research has been conducted in recent years, using
      text-based and visual data from social media platforms, for purposes such as risk
      detection at the individual level, providing crisis outreach, and developing a
      better understanding of the lived experience of mental ill-health. Challenges
      remain in relation to obtaining truly informed consent for research using social 
      media data-however platforms allowing data donation may address these concerns.
      There is an imperative need to ensure that privacy is preserved at all stages of 
      the research process, from data collection, to analysis, and the responsible use 
      of raw data in publications.
FAU - Nicholas, Jennifer
AU  - Nicholas J
AD  - Orygen, Parkville, Victoria, Australia.
AD  - Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria,
      Australia.
FAU - Onie, Sandersan
AU  - Onie S
AD  - Black Dog Institute, University of New South Wales, Hospital Road, Randwick, NSW,
      2031, Australia.
FAU - Larsen, Mark E
AU  - Larsen ME
AD  - Black Dog Institute, University of New South Wales, Hospital Road, Randwick, NSW,
      2031, Australia. mark.larsen@blackdog.org.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201123
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
SB  - IM
MH  - Data Collection
MH  - Humans
MH  - Mental Health
MH  - *Privacy
MH  - *Social Media
OTO - NOTNLM
OT  - *Data protection
OT  - *Ethics
OT  - *Mental health
OT  - *Privacy
OT  - *Social media
EDAT- 2020/11/24 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/11/23 05:43
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/23 05:43 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
AID - 10.1007/s11920-020-01205-9 [doi]
AID - 10.1007/s11920-020-01205-9 [pii]
PST - epublish
SO  - Curr Psychiatry Rep. 2020 Nov 23;22(12):84. doi: 10.1007/s11920-020-01205-9.


PMID- 33225097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 11
DP  - 2020 Nov
TI  - Making impressions count: An evaluation of the quality of information provided by
      orthodontic practices in London in response to the COVID-19 pandemic.
PG  - e05516
LID - 10.1016/j.heliyon.2020.e05516 [doi]
AB  - INTRODUCTION/OBJECTIVES: As a result of the coronavirus disease 2019 (COVID-19)
      pandemic, primary care specialist orthodontic practices have been limited to
      providing emergency treatment only. This has resulted in a cessation of normal
      face-to-face services and patient advice can only be offered by remote means. A
      service evaluation was carried out to assess the quality of information published
      on websites and social media pages of specialist orthodontic practices in London,
      against General Dental Council guidance on communication and advertising and the 
      British Orthodontic Society (BOS) COVID-19 specific guidance for orthodontics in 
      primary care in relation to Coronavirus Disease 2019 (COVID-19) pandemic. This
      study also aimed to provide a gold standard template for orthodontic practices to
      aid in the delivery of information on a digital platform during the current
      (COVID-19) pandemic and future possible spikes. MATERIALS AND METHODS: All
      orthodontic practices providing care in the London region were identified from a 
      CQC Database and subsequently checked against predetermined criteria based on the
      BOS guidance and the GDC Guidance on Ethical Advertising. RESULTS: Of the 83
      orthodontic practices sampled; 78 had a website of which 18 (23.1%) were
      non-compliant with GDC guidance. Facebook pages were identified for 62
      orthodontic practices. 17 practices did not provide any update in relation to the
      COVID-19 pandemic. This was more frequently carried out on practice websites
      (78.2%) compared to Facebook pages (33.9%). A number of practices were identified
      as having novel strategies to manage communication during the COVID-19 pandemic. 
      CONCLUSION: Variation was observed in information published by practices despite 
      the regularly updated, blanket information provided by the BOS. Communication may
      have been delivered by a different means during the pandemic which this study did
      not account for. In addition, the sampling method may not have identified all
      practices within the London region, however the sample size seems appropriate to 
      draw meaningful conclusions. The checklist created should help improve the
      delivery of future information.
CI  - (c) 2020 Published by Elsevier Ltd.
FAU - Woolley, Julian
AU  - Woolley J
AD  - Dental Core Trainee, King's College London, King's College Hospital NHS
      Foundation Trust, United Kingdom.
FAU - Donnell, Christopher
AU  - Donnell C
AD  - Dental Core Trainee, Newcastle Dental Hospital, Newcastle Upon Tyne NHS Hospitals
      Foundation Trust, United Kingdom.
FAU - Worthington, Stuart
AU  - Worthington S
AD  - Specialty Regsitrar, Dental Public Health, Public Health England, Newcastle upon 
      Tyne, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7667436
OTO - NOTNLM
OT  - COVID-19
OT  - Digital marketing
OT  - Ethical advertising
OT  - Orthodontic practice
OT  - Pandemic
OT  - SARS-Cov-2
OT  - Social science
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:42
PHST- 2020/09/03 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/23 05:42 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e05516 [doi]
AID - S2405-8440(20)32359-8 [pii]
PST - ppublish
SO  - Heliyon. 2020 Nov;6(11):e05516. doi: 10.1016/j.heliyon.2020.e05516. Epub 2020 Nov
      16.


PMID- 33225074
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - The ethics of data sharing and biobanking in health research.
PG  - 270
LID - 10.12688/wellcomeopenres.16351.1 [doi]
AB  - The importance of data sharing and biobanking are increasingly being recognised
      in global health research. Such practices are perceived to have the potential to 
      promote science by maximising the utility of data and samples. However, they also
      raise ethical challenges which can be exacerbated by existing disparities in
      power, infrastructure and capacity. The Global Forum on Bioethics in Research
      (GFBR) convened in Stellenbosch, South Africa in November 2018, to explore the
      ethics of data sharing and biobanking in health research. Ninety-five
      participants from 35 countries drew on case studies and their experiences with
      sharing in their discussion of issues relating to respecting research
      participants and communities, promoting equitable sharing, and international and 
      national approaches to governing data sharing and biobanking. In this editorial
      we will briefly review insights relating to each of these three themes.
CI  - Copyright: (c) 2020 Bull S and Bhagwandin N.
FAU - Bull, Susan
AU  - Bull S
AUID- ORCID: https://orcid.org/0000-0002-9730-091X
AD  - The Ethox Centre and Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
FAU - Bhagwandin, Niresh
AU  - Bhagwandin N
AD  - South African Medical Research Council, Cape Town, South Africa.
LA  - eng
PT  - Editorial
DEP - 20201116
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7670475
OTO - NOTNLM
OT  - Data sharing
OT  - LMIC
OT  - biobanking
OT  - ethics
OT  - global health
OT  - governance
COIS- No competing interests were disclosed.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:41
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/11/23 05:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.12688/wellcomeopenres.16351.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Nov 16;5:270. doi: 10.12688/wellcomeopenres.16351.1.
      eCollection 2020.


PMID- 33225033
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201123
IS  - 2352-3409 (Electronic)
IS  - 2352-3409 (Linking)
VI  - 33
DP  - 2020 Dec
TI  - Dataset knowledge, attitude, and trust of Indonesian selected public group toward
      agribiotechnology application.
PG  - 106496
LID - 10.1016/j.dib.2020.106496 [doi]
AB  - The focus of this research is to present an analysis of the knowledge, attitude, 
      and trust of selected Indonesian public groups regarding the application of
      Agribiotechnology. This study employs a descriptive research design. The data
      consists of 266 respondents in two different localities in east Java, Indonesia: 
      Jember and Bondowoso. Eight different categories of respondents were defined:
      students, scientists, non-government organizations, media, policymakers,
      consumers, producers and religious scholars. Participants responded to items
      assessing their knowledge, attitudes and trust toward the use of
      agribiotechnology, specifically in food production and how their cultural ethics,
      norms, or religious beliefs influence their engagement with the technology. The
      findings highlighted varying perspectives on the knowledge, attitude, and trust
      among the eight groups towards agribiotechnology application concerning responses
      that emphasized several content areas such as the genetic modification of crops
      and plants and implications of the technology on the daily lives of the
      Indonesian.
CI  - (c) 2020 The Author(s).
FAU - Hidayat, Rachmat
AU  - Hidayat R
AD  - Faculty of Social and Political Science, University of Jember, East Java,
      Indonesia.
FAU - Pamungkas, Tree Setiawan
AU  - Pamungkas TS
AD  - Faculty of Social and Political Science, University of Jember, East Java,
      Indonesia.
FAU - Baratha, Lukman Wijaya
AU  - Baratha LW
AD  - Faculty of Social and Political Science, University of Jember, East Java,
      Indonesia.
FAU - Mubarok, Ahmad Munif
AU  - Mubarok AM
AD  - Faculty of Social and Political Science, University of Jember, East Java,
      Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - Netherlands
TA  - Data Brief
JT  - Data in brief
JID - 101654995
PMC - PMC7666304
OTO - NOTNLM
OT  - Agribiotechnology
OT  - Attitude
OT  - Knowledge
OT  - Trust
COIS- The researcher does not have a conflict of interest with various parties in
      presenting the research data, and no party intervenes in the research results.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:41
PHST- 2020/06/20 00:00 [received]
PHST- 2020/10/28 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/23 05:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.1016/j.dib.2020.106496 [doi]
AID - S2352-3409(20)31378-0 [pii]
PST - epublish
SO  - Data Brief. 2020 Nov 4;33:106496. doi: 10.1016/j.dib.2020.106496. eCollection
      2020 Dec.


PMID- 33225019
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 2333-7214 (Print)
IS  - 2333-7214 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Tough Decisions During the COVID 19 Pandemic: A Frail Latino Patient.
PG  - 2333721420970336
LID - 10.1177/2333721420970336 [doi]
AB  - The pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
      had overwhelmed the healthcare system worldwide with multiple ethical dilemmas.
      Several tools have been used to assess risk factors in these patients. One of
      them, the Clinical Frailty scale, has shown good correlation between the patient 
      functional status and hospital stay with overall mortality. We present a case
      were the Clinical Frailty Scale was used to assess patient management and goals
      of care.
CI  - (c) The Author(s) 2020.
FAU - Huayanay, Irma
AU  - Huayanay I
AUID- ORCID: https://orcid.org/0000-0002-1910-1501
AD  - The University of Texas Rio Grande Valley, Edinburg, TX, USA.
AD  - University of Texas Rio Grande Valley, Edinburg, TX, USA.
AD  - Doctors Hospital at Renaissance, Edinburg, TX, USA.
FAU - Luu, Stephanie
AU  - Luu S
AD  - The University of Texas Rio Grande Valley, Edinburg, TX, USA.
AD  - University of Texas Rio Grande Valley, Edinburg, TX, USA.
AD  - Doctors Hospital at Renaissance, Edinburg, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - United States
TA  - Gerontol Geriatr Med
JT  - Gerontology & geriatric medicine
JID - 101662571
PMC - PMC7649914
OTO - NOTNLM
OT  - COVID-19
OT  - clinical frailty scale
OT  - code status
OT  - frail
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:41
PHST- 2020/09/16 00:00 [received]
PHST- 2020/10/11 00:00 [accepted]
PHST- 2020/11/23 05:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.1177/2333721420970336 [doi]
AID - 10.1177_2333721420970336 [pii]
PST - epublish
SO  - Gerontol Geriatr Med. 2020 Nov 4;6:2333721420970336. doi:
      10.1177/2333721420970336. eCollection 2020 Jan-Dec.


PMID- 33224977
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20220418
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Prediction of Fluid Responsiveness by Stroke Volume Variation in Children
      Undergoing Fontan Operation.
PG  - 2595960
LID - 10.1155/2020/2595960 [doi]
AB  - BACKGROUND: Fontan operation is a palliative medical procedure performed on
      children with single-ventricle defects. As postoperative success of the procedure
      largely depends on the preload volume, it is necessary to maintain an appropriate
      pressure gradient between the systemic vein and the left atrium to ensure the
      effective volume of systemic circulation. However, there is a lack of effective
      indexes to evaluate fluid responsiveness in Fontan patients. Stroke volume
      variation (SVV) is a dynamic hemodynamic parameter based on cardiopulmonary
      interaction in mechanical ventilation. This study is aimed at validating the
      sensitivity and specificity of SVV and central venous pressure (CVP) in assessing
      the fluid responsiveness of Fontan patients. METHOD: Sixty-four children with
      single ventricle who underwent modified Fontan operation between May 2018 and
      January 2020 were included in this study. Patients were administered 10 ml.kg(-1)
      albumin for fluid challenge within 10 min after cardiopulmonary bypass. Before
      and after fluid challenge, the invasive arterial pressure module was connected to
      MostCare equipment to collect the cardiac index (CI) and SVV dynamically in a
      time window of 30 s at a frequency of 1000 Hz. According to the range of CI
      change, patients with DeltaCI >/= 15% were classified into the responder (R)
      group and those with DeltaCI < 15% into the nonresponder (NR) group. Using SVV
      and CVP as indicators, the receiver operating characteristic (ROC) curve of the
      patients was established, and the area under curve (AUC), diagnostic threshold,
      sensitivity, and specificity were calculated. RESULTS: The SVV values were 16.28%
      (25th and 75th percentiles 14.17%-19.24%) and 13.68% (25th and 75th percentiles
      12.90%-15.89%) before and after fluid challenge treatment in responders,
      respectively, and the values were 18.60 +/- 1.83 mmHg before and 20.20 +/- 2.39
      mmHg for CVP after treatment. The AUC of SVV was 0.74 (95% confidence interval
      (CI) 0.54-0.94, P < 0.05), and the cutoff value was 16%, offering a sensitivity
      of 50% and a specificity of 91.7%. Meanwhile, the AUC of CVP was 0.70 (95% CI
      0.50-0.92, P > 0.05), and the cutoff value was 19.5 mmHg, offering a sensitivity 
      of 58% and a specificity of 76%. CONCLUSION: SVV exhibited a good predictive
      value for fluid responsiveness in pediatric Fontan patients. Appropriate fluid
      therapy according to SVV could improve the cardiac function of such patients.
      Trial registration. This study was registered in Chinese Clinical Trail Registry 
      on Jan 26, 2018. Registration number is ChiCTR1800014654. Registry URL is
      http://www.chictr.org.cn/showproj.aspx?proj=25019. This observational prospective
      study was approved by the Local Ethics Committee of Shanghai Children's Medical
      Center affiliated to Shanghai Jiao Tong University (SCMCIRB-K2017035).
CI  - Copyright (c) 2020 Yun'an Song et al.
FAU - Song, Yun'an
AU  - Song Y
AUID- ORCID: https://orcid.org/0000-0003-3611-2576
AD  - Department of Anesthesiology, Shanghai Children's Medical Center, Shanghai Jiao
      Tong University School of Medicine & National Children's Medical Center
      (Shanghai), 1678 Dongfang Road, Shanghai 200127, China.
AD  - Pediatric Clinical Pharmacology Laboratory, Shanghai Children's Medical Center,
      Shanghai Jiao Tong University School of Medicine & National Children's Medical
      Center (Shanghai), Shanghai, China.
FAU - Hou, Huiyan
AU  - Hou H
AUID- ORCID: https://orcid.org/0000-0003-1267-9244
AD  - Department of Anesthesiology, Shanghai Children's Medical Center, Shanghai Jiao
      Tong University School of Medicine & National Children's Medical Center
      (Shanghai), 1678 Dongfang Road, Shanghai 200127, China.
AD  - Pediatric Clinical Pharmacology Laboratory, Shanghai Children's Medical Center,
      Shanghai Jiao Tong University School of Medicine & National Children's Medical
      Center (Shanghai), Shanghai, China.
FAU - Bai, Jie
AU  - Bai J
AUID- ORCID: https://orcid.org/0000-0001-8424-7702
AD  - Department of Anesthesiology, Shanghai Children's Medical Center, Shanghai Jiao
      Tong University School of Medicine & National Children's Medical Center
      (Shanghai), 1678 Dongfang Road, Shanghai 200127, China.
AD  - Pediatric Clinical Pharmacology Laboratory, Shanghai Children's Medical Center,
      Shanghai Jiao Tong University School of Medicine & National Children's Medical
      Center (Shanghai), Shanghai, China.
FAU - Gu, Hongbin
AU  - Gu H
AUID- ORCID: https://orcid.org/0000-0002-8993-5608
AD  - Department of Anesthesiology, Shanghai Children's Medical Center, Shanghai Jiao
      Tong University School of Medicine & National Children's Medical Center
      (Shanghai), 1678 Dongfang Road, Shanghai 200127, China.
AD  - Pediatric Clinical Pharmacology Laboratory, Shanghai Children's Medical Center,
      Shanghai Jiao Tong University School of Medicine & National Children's Medical
      Center (Shanghai), Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Albumins)
SB  - IM
MH  - Albumins/therapeutic use
MH  - Arterial Pressure
MH  - Central Venous Pressure
MH  - Child, Preschool
MH  - Female
MH  - Fluid Therapy/*methods
MH  - Fontan Procedure/*methods
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - ROC Curve
MH  - *Stroke Volume
MH  - Treatment Outcome
PMC - PMC7669329
COIS- The authors declare no conflict of interest regarding the publication of this
      paper.
EDAT- 2020/11/24 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/11/23 05:41
PHST- 2020/06/14 00:00 [received]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/23 05:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - 10.1155/2020/2595960 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Nov 7;2020:2595960. doi: 10.1155/2020/2595960. eCollection
      2020.


PMID- 33224947
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 2296-634X (Print)
IS  - 2296-634X (Linking)
VI  - 8
DP  - 2020
TI  - Global Gene Expression Profiling Reveals Isorhamnetin Induces Hepatic-Lineage
      Specific Differentiation in Human Amniotic Epithelial Cells.
PG  - 578036
LID - 10.3389/fcell.2020.578036 [doi]
AB  - Human amnion epithelial cells (hAECs), derived from discarded term placenta, is
      anticipated as a new stem cell resource because of their advantages over
      embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), such as
      no risk of tumorigenicity and minimal ethical issue. hAECs have been reported to 
      differentiate into hepatic-like cells (HLCs) with variable functionalities
      suitable for cell-based therapy of end-stage liver diseases, drug screening, and 
      drug toxicity tests. On the other hand, a new research stream has been evolving
      to use natural compounds as stimulants of stem cell differentiation because of
      their high availability and minimum side effects. Isorhamnetin is a naturally
      occurring flavonoid commonly found in fruits and vegetables and has been reported
      to improve hepatic fibrosis and steatosis. In this present study, we have
      screened the differentiation potential of isorhamnetin in hAECs. The cells were
      grown on 3D cell culture and were treated with 20 muM of synthesized isorhamnetin
      for 10 days without adding any additional growth factors. DNA microarray global
      gene expression analysis was conducted for differentially expressed genes between
      isorhamnetin-treated and untreated control cells, gene expression validation was 
      carried out using RT-qPCR method, and finally, several hepatic functions were
      assessed. Microarray analysis showed that isorhamnetin could activate essential
      biological processes, molecular functions, and signaling pathways for hepatic
      differentiation. Hepatic progenitor markers, EPCAM and DLK1, were upregulated in 
      the isorhamnetin-treated hAECs. AFP was downregulated, while ALB was upregulated 
      on Day 10. Furthermore, isorhamnetin-treated cells could show increased CYP
      enzyme mRNA levels, ICG uptake and release, glycogen storage activity, and urea
      secretion. Additionally, isorhamnetin-treated cells did not show any trace of
      transdifferentiation evident by significant downregulation of several colon- and 
      cholangiocyte-specific markers. However, longer treatment with isorhamnetin did
      not promote hepatic maturation. Altogether, our findings indicate that
      isorhamnetin has a promising effect on directing the hepatic-lineage specific
      differentiation in hAECs.
CI  - Copyright (c) 2020 Uchida, Ferdousi, Zheng, Oda and Isoda.
FAU - Uchida, Yoshiaki
AU  - Uchida Y
AD  - School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tsukuba, 
      Japan.
FAU - Ferdousi, Farhana
AU  - Ferdousi F
AD  - Alliance for Research on the Mediterranean and North Africa (ARENA), University
      of Tsukuba, Tsukuba, Japan.
AD  - AIST-University of Tsukuba Open Innovation Laboratory for Food and Medicinal
      Resource Engineering (FoodMed-OIL), AIST, University of Tsukuba, Tsukuba, Japan.
FAU - Zheng, Yun-Wen
AU  - Zheng YW
AD  - Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of 
      Medicine, University of Tsukuba, Tsukuba, Japan.
FAU - Oda, Tatsuya
AU  - Oda T
AD  - AIST-University of Tsukuba Open Innovation Laboratory for Food and Medicinal
      Resource Engineering (FoodMed-OIL), AIST, University of Tsukuba, Tsukuba, Japan.
AD  - Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of 
      Medicine, University of Tsukuba, Tsukuba, Japan.
FAU - Isoda, Hiroko
AU  - Isoda H
AD  - School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tsukuba, 
      Japan.
AD  - Alliance for Research on the Mediterranean and North Africa (ARENA), University
      of Tsukuba, Tsukuba, Japan.
AD  - AIST-University of Tsukuba Open Innovation Laboratory for Food and Medicinal
      Resource Engineering (FoodMed-OIL), AIST, University of Tsukuba, Tsukuba, Japan.
AD  - Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba,
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC7674172
OTO - NOTNLM
OT  - hepatic-lineage-specific differentiation
OT  - human amnion epithelial cell
OT  - isorhamnetin
OT  - microarray and bioinformatics
OT  - natural compound
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:41
PHST- 2020/06/30 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/23 05:41 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.3389/fcell.2020.578036 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2020 Nov 5;8:578036. doi: 10.3389/fcell.2020.578036.
      eCollection 2020.


PMID- 33224669
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 21
TI  - The Effect of Ureteric Stenting on Female Sexual Function: A Prospective Cohort
      Study.
PG  - e11075
LID - 10.7759/cureus.11075 [doi]
AB  - Background and objective Urolithiasis is a highly prevalent disease worldwide,
      with Pakistan belonging to the stone belt of Asia. The usage of the double J (DJ)
      stent is highly effective when it comes to the management of urolithiasis.
      However, studies investigating the side effects of DJ stent placement on sexual
      function in individuals are scarce. In this study, we aimed to assess the impact 
      of DJ stent placement on sexual function in women. Methods After obtaining
      ethical approval, a prospective study was conducted at a university hospital from
      June 2018 to September 2019. All sexually active women requiring semi-rigid
      ureteroscopy (URS) or flexible URS [retrograde intrarenal surgery (RIRS)] were
      enrolled. Women with DJ stent placement (Group A) were compared to women who did 
      not require DJ stent (Group B). The outcome variable was to assess temporary
      sexual dysfunction after DJ stent placement using the standardized Female Sexual 
      Functionality Index (FSFI) in English or its validated vernacular version. The
      FSFI was completed at four weeks, and again at three months, following URS/RIRS. 
      Results Of the 106 sexually active women initially included in the study, 69 were
      found to be eligible for final analysis. In Group A, the mean FSFI score at the
      initial presentation was 31.54 +/-4.37. The mean FSFI score at four weeks was
      lower compared to the baseline score (0 time): 13.96 +/-5.5 (p<0.05). At three
      months, the mean FSFI score returned to near baseline at 32.053 +/-5.35 with no
      significant difference (p=0.65). In comparison to women in Group B, the mean FSFI
      score at four weeks was significantly lower in Group A (28.87 +/-6.59 vs. 13.96
      +/-5.49; p<0.05). However, there was no significant difference between the mean
      FSFI scores at any of the three time points within Group B. Conclusion DJ stent
      insertion results in transient postoperative sexual dysfunction in women, which
      resolves spontaneously within a span of three months after stent removal.
CI  - Copyright (c) 2020, Kazmi et al.
FAU - Kazmi, Zehra
AU  - Kazmi Z
AD  - Urology, The Aga Khan University, Karachi, PAK.
FAU - Umer, Daniya
AU  - Umer D
AD  - Surgery, The Aga Khan University, Karachi, PAK.
FAU - Ather, M Hammad
AU  - Ather MH
AD  - Urology, The Aga Khan University, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7678765
OTO - NOTNLM
OT  - dj stent
OT  - fsd
OT  - fsfi
OT  - jj stent
OT  - sexual dysfunction
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:40
PHST- 2020/11/23 05:40 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.7759/cureus.11075 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 21;12(10):e11075. doi: 10.7759/cureus.11075.


PMID- 33224586
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 2160-200X (Print)
IS  - 2160-200X (Linking)
VI  - 10
IP  - 4
DP  - 2020
TI  - Percutaneous repair of post-myocardial infarction ventricular septal rupture
      presenting with cardiogenic shock.
PG  - 376-381
AB  - Ventricular septal rupture (VSR) is an uncommon and devastating complication with
      a high mortality rate due to limited available interventions required by expert
      hands in a small window of opportunity. Most commonly seen following delayed
      myocardial infarctions (MI), the rate of VSR has decreased partly from protocol
      driven reperfusion therapy; however, cases are still present, particularly when
      diagnosis is delayed. We present a case of a critically ill patient in
      cardiogenic shock following a large anterolateral wall ST-elevation MI
      complicated by a large VSR whom was transferred to our academic institution for
      percutaneous repair. Of note, such intervention was initially performed by Lock
      in 1988 and a comprehensive review published in 2016 noted only 273 such cases.
      This review noted patient cases since that initial percutaneous closure by Lock
      with a majority of cases utilizing an Amplatzer system; others being Clamshell
      and CardioSEAL. Our patient underwent the percutaneous VSR closure utilizing an
      Amplatzer Occluder delivery system with successful insertion of an 18 mm muscular
      VSD Amplatzer closure device. Although the rarely performed procedure was
      successful and provided invaluable insights into the treatment and management of 
      VSR, the patient succumbed to multiple critical disease processes in the
      following days post intervention. Patient consent and ethics committee approval
      for publication, as per Saint Louis University case publication guidelines, were 
      confirmed and approved.
CI  - AJCD Copyright (c) 2020.
FAU - Oman, Zach
AU  - Oman Z
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
FAU - Kumar, Sundeep
AU  - Kumar S
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
FAU - Ghani, Ali
AU  - Ghani A
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
FAU - Sayed-Ahmad, Ziad
AU  - Sayed-Ahmad Z
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
FAU - Horbal, Piotr
AU  - Horbal P
AD  - Department of Internal Medicine, Saint Louis University Saint Louis, Missouri,
      USA.
FAU - Nasir, Ammar
AU  - Nasir A
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
FAU - Forsberg, Michael
AU  - Forsberg M
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
FAU - Helmy, Tarek
AU  - Helmy T
AD  - Center for Comprehensive Cardiovascular Care, Saint Louis University Saint Louis,
      Missouri, USA.
LA  - eng
PT  - Case Reports
DEP - 20201015
PL  - United States
TA  - Am J Cardiovasc Dis
JT  - American journal of cardiovascular disease
JID - 101569582
PMC - PMC7675175
OTO - NOTNLM
OT  - ST-elevation myocardial infarction
OT  - Ventricular septal rupture
OT  - cardiogenic shock
OT  - critical care
OT  - interventional cardiology
OT  - intracardiac shunt
OT  - occluder device
OT  - percutaneous repair
OT  - septal surgery
OT  - ventricular assist device
COIS- None.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:39
PHST- 2020/05/23 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/11/23 05:39 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
PST - epublish
SO  - Am J Cardiovasc Dis. 2020 Oct 15;10(4):376-381. eCollection 2020.


PMID- 33224550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2471-1411 (Electronic)
IS  - 2471-1411 (Linking)
VI  - 5
IP  - 3
DP  - 2020 May 26
TI  - Disaster victim identification operations with fragmented, burnt, or commingled
      remains: experience-based recommendations.
PG  - 191-201
LID - 10.1080/20961790.2020.1751385 [doi]
AB  - Human-made and natural disasters can result in severely fragmented, compromised, 
      and commingled human remains. The related disaster victim identification (DVI)
      operations are invariably challenging, with the state of the remains potentially 
      precluding some identifications. Practitioners involved in these DVI operations
      will routinely face logistical, practical, and ethical challenges. This review
      provides information and guidance derived from first-hand experiences to
      individuals tasked with managing DVI operations with fragmented human remains. We
      outline several key issues that should be addressed during disaster preparedness 
      planning and at the outset of an operation, when incident-specific strategies are
      developed. Specific challenges during recovery and examination of fragmented
      remains are addressed, highlighting the importance of experienced specialists at 
      the scene and in the mortuary. DNA sample selection and sampling techniques are
      reviewed, as well as downstream effects of commingling and contamination, which
      can complicate reconciliation and emphasise the need for rigorous quality
      control. We also touch on issues that may arise during communication with
      families. While recommendations are provided, they are not intended as
      proscriptive policy but rather as an addition to the general recommendations
      given in the International Criminal Police Organization (INTERPOL) DVI Guide, to 
      inform preparative discussions between government officials, judiciary, police,
      and forensic specialists.Key pointsA DVI operation for an incident characterised 
      by many fragmented and otherwise compromised human remains poses specific
      challenges that may prolong and complicate identifications.Specialists should be 
      consulted at the outset to address key issues related to the aim and extent of
      the operation.Specialist expertise in handling compromised human remains is
      indispensable at the scene, in the mortuary, during reconciliation, and for
      quality control.Continuous consultation between representatives from government, 
      the judiciary, law enforcement, the media, and various forensic specialists will 
      prevent unnecessary delay and facilitate accurate and timely communication.
CI  - (c) 2020 The Author(s). Published by Taylor & Francis Group on behalf of the
      Academy of Forensic Science.
FAU - de Boer, Hans H
AU  - de Boer HH
AUID- ORCID: https://orcid.org/0000-0001-8590-0945
AD  - Department of Forensic Medicine, Netherlands Forensic Institute, The Hague, The
      Netherlands.
AD  - Department of Pathology, Amsterdam UMC, University of Amsterdam, The Netherlands.
FAU - Roberts, Julie
AU  - Roberts J
AUID- ORCID: https://orcid.org/0000-0002-6838-216X
AD  - Faculty of Science, School of Biological and Environmental Sciences, Liverpool
      John Moores University, Liverpool, UK.
AD  - Principal Forensic Services Ltd, Bromley, UK.
FAU - Delabarde, Tania
AU  - Delabarde T
AUID- ORCID: https://orcid.org/0000-0001-6331-5526
AD  - Institut Medico-Legal de Paris, Paris, France.
AD  - Universite de Paris, BABEL, CNRS, Paris, France.
FAU - Mundorff, Amy Z
AU  - Mundorff AZ
AD  - Department of Anthropology, University of Tennessee, Knoxville, TN, USA.
FAU - Blau, Soren
AU  - Blau S
AUID- ORCID: https://orcid.org/0000-0001-6499-7741
AD  - Department of Forensic Services, Victorian Institute of Forensic Medicine,
      Melbourne, Australia.
AD  - Department of Forensic Medicine, Monash University, Melbourne, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200526
PL  - England
TA  - Forensic Sci Res
JT  - Forensic sciences research
JID - 101724928
PMC - PMC7654639
OTO - NOTNLM
OT  - DNA
OT  - DVI
OT  - Forensic sciences
OT  - burnt
OT  - commingled
OT  - forensic anthropology
OT  - fragmented human remains
COIS- The authors declare that they have no conflict of interest and that this work has
      not received any funding.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:39
PHST- 2020/11/23 05:39 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.1080/20961790.2020.1751385 [doi]
AID - 1751385 [pii]
PST - epublish
SO  - Forensic Sci Res. 2020 May 26;5(3):191-201. doi: 10.1080/20961790.2020.1751385.


PMID- 33223864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1187-7863 (Print)
IS  - 1187-7863 (Linking)
VI  - 33
IP  - 3-6
DP  - 2020
TI  - Behavioral Ethics and the Incidence of Foodborne Illness Outbreaks.
PG  - 531-548
LID - 10.1007/s10806-020-09837-w [doi]
AB  - Cognitive biases play an important role in creating and perpetuating problems
      that lead to foodborne illness outbreaks. By using insights from behavioral
      ethics, we argue that sometimes people engage in unethical behavior that
      increases the likelihood of foodborne illness outbreaks without necessarily
      intending to or being consciously aware of it. We demonstrate these insights in
      an analysis of the 2011 Listeriosis outbreak in the U.S. from the consumption of 
      contaminated cantaloupes. We then provide policy implications that can improve
      our understanding of other kinds of disease outbreaks and epidemics.
CI  - (c) Springer Nature B.V. 2020.
FAU - James, Harvey S Jr
AU  - James HS Jr
AUID- ORCID: 0000-0003-0189-271X
AD  - Division of Applied Social Sciences, University of Missouri, Columbia, MO 65211
      USA.grid.134936.a0000 0001 2162 3504
FAU - Segovia, Michelle S
AU  - Segovia MS
AUID- ORCID: 0000-0001-5298-5612
AD  - Division of Applied Social Sciences, University of Missouri, Columbia, MO 65211
      USA.grid.134936.a0000 0001 2162 3504
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - Canada
TA  - J Agric Environ Ethics
JT  - Journal of agricultural & environmental ethics
JID - 101083580
PMC - PMC7668284
OTO - NOTNLM
OT  - Behavioral ethics
OT  - Cognitive biases
OT  - Food safety
OT  - Foodborne illness outbreaks
COIS- Conflict of interestThe authors declare they have no conflict of interests.
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:36
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
PHST- 2020/11/23 05:36 [entrez]
AID - 10.1007/s10806-020-09837-w [doi]
AID - 9837 [pii]
PST - ppublish
SO  - J Agric Environ Ethics. 2020;33(3-6):531-548. doi: 10.1007/s10806-020-09837-w.
      Epub 2020 Nov 16.


PMID- 33223608
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1465-3303 (Electronic)
IS  - 0816-4649 (Linking)
VI  - 35
IP  - 104
DP  - 2020 Jul 23
TI  - Queering the Social Imaginaries of the Dead.
PG  - 170-185
LID - 10.1080/08164649.2020.1791690 [doi]
AB  - I offer a philosophical examination and feminist queering of the social
      imaginaries of the dead - with specific reference to recent public disclosures
      about death in Ireland's Mother and Baby Homes - by looking at the issue of
      spectrality through the work of Jacques Derrida and others. What does it mean to 
      respond to the dead, who, though temporarily forgotten, return to haunt us not as
      remembered human beings but as remnants or remainders? The normative distinctions
      between past and present; past, present and future; between living and
      non-living; absence and presence; and self and other are all made indistinct when
      displaced by a non-linear temporality. What differential is in play with respect 
      to those who are grievable (in Judith Butler's terms) and the others who
      constitute what Giorgio Agamben calls bare life? The strategy of memorialising
      the re/discovered dead seems inadequate, and I outline an alternative
      hauntological ethics, as suggested by Derrida, and ask if there are queer social 
      imaginaries that allow us to live well with the dead not because we give respect,
      but because death itself has been rethought. I close with some speculations
      arising from Deleuzian vitalism and Rosi Braidotti's optimistic claim that 'death
      frees us into life'.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Shildrick, Margrit
AU  - Shildrick M
AD  - Department of Ethnology, History of Religions and Gender Studies, Stockholm
      University, Stockholm, Sweden.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200723
PL  - England
TA  - Aust Fem Stud
JT  - Australian feminist studies
JID - 101772848
PMC - PMC7610213
OTO - NOTNLM
OT  - Death
OT  - Ireland
OT  - hauntology
OT  - social imaginaries
OT  - temporality
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2020/11/24 06:00
MHDA- 2020/11/24 06:01
CRDT- 2020/11/23 05:35
PHST- 2020/11/23 05:35 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2020/11/24 06:01 [medline]
AID - 10.1080/08164649.2020.1791690 [doi]
AID - 1791690 [pii]
PST - epublish
SO  - Aust Fem Stud. 2020 Jul 23;35(104):170-185. doi: 10.1080/08164649.2020.1791690.


PMID- 33223502
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - Suppl 1
DP  - 2020 Nov
TI  - The availability of global guidance for the promotion of women's, newborns',
      children's and adolescents' health and nutrition in conflicts.
LID - e002060 [pii]
LID - 10.1136/bmjgh-2019-002060 [doi]
AB  - BACKGROUND: Significant global gains in sexual, reproductive, maternal, newborn, 
      child and adolescent health and nutrition (SRMNCAH&N) will be difficult unless
      conflict settings are adequately addressed. We aimed to determine the amount,
      scope and quality of publically available guidance documents, to characterise the
      process by which agencies develop their guidance and to identify gaps in guidance
      on SRMNCAH&N promotion in conflicts. METHODS: We identified guidance documents
      published between 2008 and 2018 through English-language Internet sites of
      humanitarian response organisations, reviewed them for their scope and assessed
      their quality with the AGREE II (Appraisal of Guidelines for REsearch and
      Evaluation II) tool. Additionally, we interviewed 22 key informants on guidance
      development, dissemination processes, perceived guidance gaps and applicability. 
      FINDINGS: We identified 105 conflict-relevant guidance documents from 75
      organisations. Of these, nine were specific to conflicts, others were applicable 
      also to other humanitarian settings. Fifteen documents were technical normative
      guidelines, others were operational guides (67), descriptive documents (21) or
      advice on legal, human rights or ethics questions (2). Nutrition was the most
      addressed health topic, followed by communicable diseases and violence. The
      documents rated high quality in their 'scope and purpose' and 'clarity of
      presentation' and low for 'rigour of development' and 'editorial independence'.
      Key informants reported end user need as the primary driver for guideline
      development and WHO technical guidelines as their main evidence base.
      Insufficient local contextualisation, lack of inter-agency coordination and lack 
      of systematic implementation were considered problems in guideline development.
      Several guidance gaps were noted, including abortion care, newborn care, early
      child development, mental health, adolescent health beyond sexual and
      reproductive health and non-communicable diseases. INTERPRETATION: Organisations 
      are motivated and actively producing guidance for SRMNCAH&N promotion in
      humanitarian settings, but few documents address conflicts specifically and there
      are important guidance gaps. Improved inter-organisation collaboration for
      guidance on SRMNCAH&N promotion in conflicts and other humanitarian settings is
      needed.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aboubaker, Samira
AU  - Aboubaker S
AD  - Independent Consultant, Geneva, Switzerland.
FAU - Evers, Egmond Samir
AU  - Evers ES
AD  - Department of Maternal, Newborn, Child and Adolescent Health, WHO, Geneva,
      Switzerland.
FAU - Kobeissi, Loulou
AU  - Kobeissi L
AD  - Department of Reproductive Health and Research, WHO, Geneva, Switzerland.
FAU - Francis, Lauren
AU  - Francis L
AD  - Department of Maternal, Newborn, Child and Adolescent Health, WHO, Geneva,
      Switzerland.
FAU - Najjemba, Robinah
AU  - Najjemba R
AD  - Independent Consultant, Geneva, Switzerland.
FAU - Miller, Nathan P
AU  - Miller NP
AD  - Health Section, UNICEF, New York, New York, USA.
FAU - Wall, Steve
AU  - Wall S
AD  - Saving Newborn Lives, Save the Children, Washington, DC, USA.
FAU - Martinez, Daniel
AU  - Martinez D
AD  - Medical Department, MSF, Geneva, Switzerland.
FAU - Vargas, Joseph
AU  - Vargas J
AD  - UNHCR, Geneva, Switzerland.
FAU - Ashorn, Per
AU  - Ashorn P
AUID- ORCID: 0000-0003-2311-2593
AD  - Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
      per.ashorn@tuni.fi.
CN  - members of the BRANCH steering committee
CN  - BRANCH steering committee
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health
MH  - Adult
MH  - *Armed Conflicts
MH  - Child
MH  - Female
MH  - *Food Security
MH  - *Guidelines as Topic
MH  - *Human Rights
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - *Reproductive Health
MH  - *Women's Health
PMC - PMC7684670
OTO - NOTNLM
OT  - *child health
OT  - *health policy
OT  - *maternal health
OT  - *nutrition
OT  - *public health
COIS- Competing interests: None declared.
IR  - Bhutta ZA
FIR - Bhutta, Zulfiqar A
IR  - Black RE
FIR - Black, Robert E
IR  - Blanchet K
FIR - Blanchet, Karl
IR  - Boerma T
FIR - Boerma, Ties
IR  - Gaffey MF
FIR - Gaffey, Michelle F
IR  - Langer A
FIR - Langer, Ana
IR  - Spiegel P
FIR - Spiegel, Paul
IR  - Waldman R
FIR - Waldman, Ronald
IR  - Wise PH
FIR - Wise, Paul H
EDAT- 2020/11/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/23 05:34
PHST- 2019/10/07 00:00 [received]
PHST- 2020/10/24 00:00 [revised]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/23 05:34 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - bmjgh-2019-002060 [pii]
AID - 10.1136/bmjgh-2019-002060 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Nov;5(Suppl 1). pii: bmjgh-2019-002060. doi:
      10.1136/bmjgh-2019-002060.


PMID- 33222737
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 30
IP  - 11
DP  - 2020 Nov
TI  - Peer-assisted Learning (PAL) as an Instructional Tool in Undergraduate Dental
      Education.
PG  - 1184-1187
LID - 10.29271/jcpsp.2020.11.1184 [doi]
AB  - OBJECTIVE: To evaluate the difference in peer-assisted learning (PAL) and
      expert-assisted learning (EAL) sessions for selected topics of orthodontics,
      conducted by either a peer or faculty member, respectively as measured by their
      test scores. STUDY DESIGN: Experimental study. Place and Duration of Study:
      Department of Orthodontics, Altamash Institute of Dental Medicine (AIDM) Karachi,
      Pakistan, from October 2019 to March 2020. Methodology: The study was carried out
      with the final year undergraduate dental students in the subject of orthodontics,
      selected by using non-probability sampling method. Selected students were given
      an introductory lecture on PAL approach at the start of the study. Two PAL
      sessions were conducted in smaller groups with all students utilised as an
      adjunct to traditional large group lectures; and at the end assessment was
      conducted comprising of multiple choice questions (MCQ). For the consecutive four
      weeks, same students went through traditional EAL, followed by similar type of
      assessment. Their test scores were compared for significance, set at p <0.05.
      RESULTS: A total of six sessions were conducted, two faculty members (professors 
      of orthodontics) conducted two sessions each, and subsequent two sessions were
      conducted by employing PAL approach by students (earlier trained by the faculty).
      The mean differences in the scores of students was compared between faculty
      teaching and PAL-related teaching. It was observed that the EAL group
      significantly performed better than PAL group (p<0.05). CONCLUSION: In terms of
      test scores, academic performance and overall learning in PAL sessions was not
      higher than EAL group. Nonetheless, PAL can be utilised as an important
      supplement to synchronous teaching tele-presence by faculty as being practised
      during current pandemic situation in many medical and dental institutes. Key
      Words: Peer-assisted learning, Educational strategies, Professional development, 
      Expert-assisted learning, Ethical review committee, Team-based learning.
FAU - Ehsan, Ambreen Afzal
AU  - Ehsan AA
AD  - Department of Orthodontics, Altamash Institute of Dental Medicine, Karachi,
      Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
SB  - IM
MH  - Education, Dental
MH  - *Education, Medical, Undergraduate
MH  - Humans
MH  - Pakistan
MH  - Peer Group
MH  - *Students, Medical
MH  - Teaching
EDAT- 2020/11/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/23 05:24
PHST- 2020/06/16 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/23 05:24 [entrez]
PHST- 2020/11/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 040579197 [pii]
AID - 10.29271/jcpsp.2020.11.1184 [doi]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2020 Nov;30(11):1184-1187. doi:
      10.29271/jcpsp.2020.11.1184.


PMID- 35114660
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 2057-1976 (Electronic)
IS  - 2057-1976 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Nov 24
TI  - Assessing the cost-effectiveness of DNA origami nanostructures for targeted
      delivery of anti-cancer drugs to tumours.
LID - 10.1088/2057-1976/abbe73 [doi]
AB  - Chemotherapy drugs are generally cytotoxic and can cause major side effects,
      including vomiting/nausea, fatigue, hair loss and pain. The use of targeted
      nanostructures to deliver drugs directly to tumours has the potential to reduce
      the side effects by decreasing the exposure of healthy cells and reducing the
      amount of drug needed. DNA can be used as a structural material to build
      drug-delivering nanorobots, but questions remain over the practicality of this
      approach. Here we show that it is potentially feasible for DNA nanostructure drug
      delivery to be more cost-effective than the drug-only approach. Our result
      suggests that the barriers to the development of DNA nanostructure-based drug
      delivery are likely to be primarily technical, regulatory and ethical rather than
      financial, as the potential exists for this to be a profitable therapeutic
      approach.
CI  - Creative Commons Attribution license.
FAU - Coleridge, Edward L
AU  - Coleridge EL
AD  - School of Engineering, Institute for Bioengineering, University of Edinburgh, The
      King's Buildings, Edinburgh, EH9 3DW, Scotland, United Kingdom.
FAU - Dunn, Katherine E
AU  - Dunn KE
AUID- ORCID: 0000-0002-5068-4354
AD  - School of Engineering, Institute for Bioengineering, University of Edinburgh, The
      King's Buildings, Edinburgh, EH9 3DW, Scotland, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201124
PL  - England
TA  - Biomed Phys Eng Express
JT  - Biomedical physics & engineering express
JID - 101675002
RN  - 0 (Antineoplastic Agents)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - *Antineoplastic Agents
MH  - Cost-Benefit Analysis
MH  - DNA/chemistry
MH  - Humans
MH  - *Nanostructures/chemistry
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - *DNA nanotechnology
OT  - *chemotherapy
OT  - *cost-effectiveness
OT  - *health economics
OT  - *targeted drug delivery
EDAT- 2020/11/24 00:00
MHDA- 2022/03/15 06:00
CRDT- 2022/02/03 20:19
PHST- 2020/05/18 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2022/02/03 20:19 [entrez]
PHST- 2020/11/24 00:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
AID - 10.1088/2057-1976/abbe73 [doi]
PST - epublish
SO  - Biomed Phys Eng Express. 2020 Nov 24;6(6). doi: 10.1088/2057-1976/abbe73.


PMID- 35047692
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 2398-8703 (Electronic)
IS  - 2398-8703 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Multicentre translational Trial of Remote Ischaemic Conditioning in Acute
      Ischaemic Stroke (TRICS): protocol of multicentre, parallel group, randomised,
      preclinical trial in female and male rat and mouse from the Italian Stroke
      Organization (ISO) Basic Science network.
PG  - e100063
LID - 10.1136/bmjos-2020-100063 [doi]
AB  - INTRODUCTION: Multicentre preclinical randomised controlled trials (pRCT) are
      emerging as a necessary step to confirm efficacy and improve translation into the
      clinic. The aim of this project is to perform two multicentre pRCTs (one in rats 
      and one in mice) to investigate the efficacy of remote ischaemic conditioning
      (RIC) in an experimental model of severe ischaemic stroke. METHODS AND ANALYSIS: 
      Seven research laboratories within the Italian Stroke Organization (ISO) Basic
      Science network will participate in the study. Transient endovascular occlusion
      of the proximal right middle cerebral artery will be performed in two species
      (rats and mice) and in both sexes. Animals will be randomised to receive RIC by
      transient surgical occlusion of the right femoral artery, or sham surgery, after 
      reperfusion. Blinded outcome assessment will be performed for dichotomised
      functional neuroscore (primary endpoint) and infarct volume (secondary endpoint) 
      at 48 hours. A sample size of 80 animals per species will yield 82% power to
      detect a significant difference of 30% in the primary outcome in both pRCTs.
      Analyses will be performed in a blind status and according to an
      intention-to-treat paradigm. The results of this study will provide robust,
      translationally oriented, high-quality evidence on the efficacy of RIC in
      multiple species of rodents with large ischaemic stroke. ETHICS AND
      DISSEMINATION: This is approved by the Animal Welfare Regulatory Body of the
      University of Milano Bicocca, under project license from the Italian Ministry of 
      Health. Trial results will be subject to publication according to the definition 
      of the outcome presented in this protocol. TRIAL REGISTRATION NUMBER:
      PCTE0000177.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Tettamanti, Mauro
AU  - Tettamanti M
AD  - Department of Neuroscience Research, Istituto di Ricerche Farmacologiche Mario
      Negri Sede di Milano, Milano, Lombardia, Italy.
FAU - Beretta, Simone
AU  - Beretta S
AUID- ORCID: 0000-0002-9417-2748
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Pignataro, Giuseppe
AU  - Pignataro G
AD  - Department of Pharmacology, University of Naples Federico II, Napoli, Campania,
      Italy.
FAU - Fumagalli, Stefano
AU  - Fumagalli S
AD  - Department of Neuroscience Research, Istituto di Ricerche Farmacologiche Mario
      Negri Sede di Milano, Milano, Lombardia, Italy.
FAU - Perego, Carlo
AU  - Perego C
AD  - Department of Neuroscience Research, Istituto di Ricerche Farmacologiche Mario
      Negri Sede di Milano, Milano, Lombardia, Italy.
FAU - Sironi, Luigi
AU  - Sironi L
AD  - Department of Pharmacology, University of Milan, Milano, Lombardia, Italy.
FAU - Pedata, Felicita
AU  - Pedata F
AD  - Department of Pharmacology, University of Florence, Firenze, Toscana, Italy.
FAU - Amantea, Diana
AU  - Amantea D
AUID- ORCID: 0000-0002-7513-3495
AD  - Department of Pharmacology, Universita della Calabria, Arcavacata di Rende,
      Calabria, Italy.
FAU - Bacigaluppi, Marco
AU  - Bacigaluppi M
AD  - Department of Neurology, San Raffaele Hospital, Milano, Lombardia, Italy.
FAU - Vinciguerra, Antonio
AU  - Vinciguerra A
AD  - Department of Pharmacology, University of Naples Federico II, Napoli, Campania,
      Italy.
FAU - Valente, Alessia
AU  - Valente A
AD  - Department of Neuroscience Research, Istituto di Ricerche Farmacologiche Mario
      Negri Sede di Milano, Milano, Lombardia, Italy.
FAU - Diamanti, Susanna
AU  - Diamanti S
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Mariani, Jacopo
AU  - Mariani J
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Vigano, Martina
AU  - Vigano M
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Santangelo, Francesco
AU  - Santangelo F
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Zoia, Chiara Paola
AU  - Zoia CP
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Rogriguez-Menendez, Virginia
AU  - Rogriguez-Menendez V
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - Castiglioni, Laura
AU  - Castiglioni L
AD  - Department of Pharmacology, University of Milan, Milano, Lombardia, Italy.
FAU - Rzemieniec, Joanna
AU  - Rzemieniec J
AD  - Department of Pharmacology, University of Milan, Milano, Lombardia, Italy.
FAU - Dettori, Ilaria
AU  - Dettori I
AD  - Department of Pharmacology, University of Florence, Firenze, Toscana, Italy.
FAU - Bulli, Irene
AU  - Bulli I
AD  - Department of Pharmacology, University of Florence, Firenze, Toscana, Italy.
FAU - Coppi, Elisabetta
AU  - Coppi E
AD  - Department of Pharmacology, University of Florence, Firenze, Toscana, Italy.
FAU - Gullotta, Giorgia Serena
AU  - Gullotta GS
AD  - Department of Neurology, San Raffaele Hospital, Milano, Lombardia, Italy.
FAU - Bagetta, Giacinto
AU  - Bagetta G
AD  - Department of Pharmacology, Universita della Calabria, Arcavacata di Rende,
      Calabria, Italy.
FAU - Martino, Gianvito
AU  - Martino G
AD  - Department of Neurology, San Raffaele Hospital, Milano, Lombardia, Italy.
FAU - Ferrarese, Carlo
AU  - Ferrarese C
AD  - Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
FAU - De Simoni, Maria Grazia
AU  - De Simoni MG
AD  - Department of Neuroscience Research, Istituto di Ricerche Farmacologiche Mario
      Negri Sede di Milano, Milano, Lombardia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201124
PL  - England
TA  - BMJ Open Sci
JT  - BMJ open science
JID - 101778290
PMC - PMC8647600
COIS- Competing interests: None declared.
EDAT- 2020/11/24 00:00
MHDA- 2020/11/24 00:01
CRDT- 2022/01/20 06:08
PHST- 2020/02/22 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2022/01/20 06:08 [entrez]
PHST- 2020/11/24 00:00 [pubmed]
PHST- 2020/11/24 00:01 [medline]
AID - 10.1136/bmjos-2020-100063 [doi]
AID - bmjos-2020-100063 [pii]
PST - epublish
SO  - BMJ Open Sci. 2020 Nov 24;4(1):e100063. doi: 10.1136/bmjos-2020-100063.
      eCollection 2020.


PMID- 33222352
OWN - NLM
STAT- Publisher
LR  - 20201122
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
DP  - 2020 Nov 22
TI  - Ethical considerations and challenges in herbal drug trials with the focus on
      scientific validity and risk assessment.
LID - 10.1002/ptr.6962 [doi]
AB  - Scientific validity and risk assessment are two main ethical issues which raise
      specific challenges and are unique to clinical trials investigating crude
      extracts/fractions from herbal materials. There are considerable challenges for
      both clinical investigators and ethics committee members in dealing with such
      issues, many of them remain unresolved, resulting in a large variation in ethical
      requirements, justification, and decisions. Despite a remarkable surge in herbal 
      medicine research globally, a number of clinical investigators or even ethics
      committee members have limited confidence in dealing with related ethical issues.
      In this article, we extensively review and discuss the two main ethical issues
      (i.e., scientific validity and risk assessment) and highlight key considerations 
      that are important for ethical review and justification for the conduct of herbal
      drug trials.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Koonrungsesomboon, Nut
AU  - Koonrungsesomboon N
AUID- ORCID: https://orcid.org/0000-0003-4649-597X
AD  - Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang
      Mai, Thailand.
AD  - Musculoskeletal Science and Translational Research Center, Chiang Mai University,
      Chiang Mai, Thailand.
FAU - Morakote, Nimit
AU  - Morakote N
AD  - Department of Parasitology, Faculty of Medicine, Chiang Mai University, Chiang
      Mai, Thailand.
FAU - Karbwang, Juntra
AU  - Karbwang J
AD  - Department of Clinical Product Development, Institute of Tropical Medicine,
      Nagasaki University, Nagasaki, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201122
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
SB  - IM
OTO - NOTNLM
OT  - clinical trials
OT  - drug development
OT  - herbal medicine
OT  - research ethics
EDAT- 2020/11/23 06:00
MHDA- 2020/11/23 06:00
CRDT- 2020/11/22 20:48
PHST- 2020/06/03 00:00 [received]
PHST- 2020/10/21 00:00 [revised]
PHST- 2020/11/07 00:00 [accepted]
PHST- 2020/11/22 20:48 [entrez]
PHST- 2020/11/23 06:00 [pubmed]
PHST- 2020/11/23 06:00 [medline]
AID - 10.1002/ptr.6962 [doi]
PST - aheadofprint
SO  - Phytother Res. 2020 Nov 22. doi: 10.1002/ptr.6962.


PMID- 33222258
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Bystanders, risks, and consent.
PG  - 906-911
LID - 10.1111/bioe.12673 [doi]
AB  - This paper considers the moral status of bystanders affected by medical research 
      trials. Recent proposals advocate a very low threshold of permissible risk
      imposition upon bystanders that is insensitive to the prospective benefits of the
      trial, in part because we typically lack bystanders' consent. I argue that the
      correct threshold of permissible risk will be sensitive to the prospective gains 
      of the trial. I further argue that one does not always need a person's consent to
      expose her to significant risks of even serious harm for the sake of others. That
      we typically need the consent of participants is explained by the fact that
      trials risk harmfully using participants, which is very hard to justify without
      consent. Bystanders, in contrast, are harmed as a side-effect, which is easier to
      justify. I then consider whether the degree of risk that a trial may impose on a 
      bystander is sensitive to whether she is a prospective beneficiary of that trial.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Frowe, Helen
AU  - Frowe H
AUID- ORCID: 0000-0003-4754-6847
AD  - Department of Philosophy, Stockholm University, Stockholm, Sweden.
LA  - eng
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
GR  - 1521101/Knut och Alice Wallenbergs Stiftelse/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191025
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Female
MH  - Humans
MH  - *Informed Consent
MH  - Prospective Studies
PMC - PMC7684685
MID - NIHMS1047086
OTO - NOTNLM
OT  - *bystanders
OT  - *human subjects research
OT  - *informed consent
OT  - *research ethics
OT  - *research subjects
OT  - *risk
EDAT- 2020/11/23 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/11/22 20:46
PHST- 2019/01/09 00:00 [received]
PHST- 2019/08/06 00:00 [revised]
PHST- 2019/08/16 00:00 [accepted]
PHST- 2020/11/22 20:46 [entrez]
PHST- 2020/11/23 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 10.1111/bioe.12673 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):906-911. doi: 10.1111/bioe.12673. Epub 2019 Oct 25.


PMID- 35822826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2673-6284 (Electronic)
IS  - 2673-6284 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Nov 23
TI  - The Future of Biobanking: What Is Next?
LID - 23 [pii]
LID - 10.3390/biotech9040023 [doi]
AB  - Biobanks are an extraordinary tool for research and scientific progress. Since
      their origin, the debate on the main technical, regulatory and ethical aspects
      has not stopped. The future of biobanks should take into account many factors:
      the need to improve the technical standards of collection, conservation and use
      of the sample, the usefulness of achieving forms of harmonization and common
      governance, the improvement of biobank networks, including through public-private
      partnerships and improving the sustainability of these infrastructures.
FAU - Caenazzo, Luciana
AU  - Caenazzo L
AUID- ORCID: 0000-0003-3142-2874
AD  - Laboratory of Forensic Genetics, Department of Molecular Medicine, University of 
      Padova, 35121 Padova, Italy.
FAU - Tozzo, Pamela
AU  - Tozzo P
AUID- ORCID: 0000-0003-3736-1144
AD  - Laboratory of Forensic Genetics, Department of Molecular Medicine, University of 
      Padova, 35121 Padova, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - Switzerland
TA  - BioTech (Basel)
JT  - Biotech (Basel (Switzerland))
JID - 9918383086206676
PMC - PMC9258311
OTO - NOTNLM
OT  - biobank
OT  - biospecimen
OT  - harmonization
OT  - regulation
EDAT- 2020/11/23 00:00
MHDA- 2020/11/23 00:01
CRDT- 2022/07/13 08:13
PHST- 2020/10/27 00:00 [received]
PHST- 2020/11/19 00:00 [revised]
PHST- 2020/11/20 00:00 [accepted]
PHST- 2022/07/13 08:13 [entrez]
PHST- 2020/11/23 00:00 [pubmed]
PHST- 2020/11/23 00:01 [medline]
AID - biotech9040023 [pii]
AID - 10.3390/biotech9040023 [doi]
PST - epublish
SO  - BioTech (Basel). 2020 Nov 23;9(4). pii: biotech9040023. doi:
      10.3390/biotech9040023.


PMID- 33219013
OWN - NLM
STAT- Publisher
LR  - 20201124
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 20
TI  - Development of a structured process for fair allocation of critical care
      resources in the setting of insufficient capacity: a discussion paper.
LID - medethics-2020-106771 [pii]
LID - 10.1136/medethics-2020-106771 [doi]
AB  - Early in the COVID-19 pandemic there was widespread concern that healthcare
      systems would be overwhelmed, and specifically, that there would be insufficient 
      critical care capacity in terms of beds, ventilators or staff to care for
      patients. In the UK, this was avoided by a threefold approach involving
      widespread, rapid expansion of critical care capacity, reduction of healthcare
      demand from non-COVID-19 sources by temporarily pausing much of normal healthcare
      delivery, and by governmental and societal responses that reduced demand through 
      national lockdown. Despite high-level documents designed to help manage limited
      critical care capacity, none provided sufficient operational direction to enable 
      use at the bedside in situations requiring triage. We present and describe the
      development of a structured process for fair allocation of critical care
      resources in the setting of insufficient capacity. The document combines a wide
      variety of factors known to impact on outcome from critical illness, integrated
      with broad-based clinical judgement to enable structured, explicit, transparent
      decision-making founded on robust ethical principles. It aims to improve
      communication and allocate resources fairly, while avoiding triage decisions
      based on a single disease, comorbidity, patient age or degree of frailty. It is
      designed to support and document decision-making. The document has not been
      needed to date, nor adopted as hospital policy. However, as the pandemic evolves,
      the resumption of necessary non-COVID-19 healthcare and economic activity mean
      capacity issues and the potential need for triage may yet return. The document is
      presented as a starting point for stakeholder feedback and discussion.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Cook, Tim
AU  - Cook T
AUID- ORCID: http://orcid.org/0000-0002-3654-497X
AD  - Anaesthesia and Intensive Care Medicine, Royal United Hospital Bath NHS Trust,
      Bath, UK timcook007@gmail.com.
FAU - Gupta, Kim
AU  - Gupta K
AD  - Anaesthesia and Intensive Care Medicine, Royal United Hospital Bath NHS Trust,
      Bath, UK.
FAU - Dyer, Chris
AU  - Dyer C
AD  - Older Persons Unit, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Fackrell, Robin
AU  - Fackrell R
AD  - Older Persons Unit, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Wexler, Sarah
AU  - Wexler S
AD  - Haematology, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Boyes, Heather
AU  - Boyes H
AD  - Legal Department, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Colleypriest, Ben
AU  - Colleypriest B
AD  - Gastroenterology, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Graham, Richard
AU  - Graham R
AD  - Radiology, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Meehan, Helen
AU  - Meehan H
AD  - Palliative Care, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Merritt, Sarah
AU  - Merritt S
AD  - Women and Childrens Services, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Robinson, Derek
AU  - Robinson D
AD  - Orthopaedics, Royal United Hospital Bath NHS Trust, Bath, UK.
FAU - Marden, Bernie
AU  - Marden B
AD  - Paediatrics, Royal United Hospital Bath NHS Trust, Bath, UK.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7681792
OTO - NOTNLM
OT  - allocation of healthcare resources
OT  - clinical ethics
OT  - decision-making
COIS- Competing interests: None declared.
EDAT- 2020/11/22 06:00
MHDA- 2020/11/22 06:00
CRDT- 2020/11/21 05:30
PHST- 2020/08/05 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/21 05:30 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/11/22 06:00 [medline]
AID - medethics-2020-106771 [pii]
AID - 10.1136/medethics-2020-106771 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 20. pii: medethics-2020-106771. doi:
      10.1136/medethics-2020-106771.


PMID- 33218461
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 0039-3681 (Print)
IS  - 0039-3681 (Linking)
VI  - 84
DP  - 2020 Dec
TI  - Severe weather event attribution: Why values won't go away.
PG  - 142-149
LID - S0039-3681(20)30173-4 [pii]
LID - 10.1016/j.shpsa.2020.09.003 [doi]
AB  - We start by reviewing the complicated situation in methods of scientific
      attribution of climate change to extreme weather events. We emphasize the social 
      values involved in using both so-called ''storyline'' and ordinary probabilistic 
      or ''risk-based'' methods, noting that one important virtue claimed by the
      storyline approach is that it features a reduction in false negative results,
      which has much social and ethical merit, according to its advocates. This merit
      is critiqued by the probabilistic, risk-based, opponents, who claim the high
      ground; the usual probabilistic approach is claimed to be more objective and more
      ''scientific'', under the grounds that it reduces false positive error. We
      examine this mostly-implicit debate about error, which apparently mirrors the old
      Jeffrey-Rudner debate. We also argue that there is an overlooked component to the
      role of values in science: that of second-order inductive risk, and that it makes
      the relative role of values in the two methods different from what it first
      appears to be. In fact, neither method helps us to escape social values, and be
      more scientifically ''objective'' in the sense of being removed or detached from 
      human values and interests. The probabilistic approach does not succeed in doing 
      so, contrary to the claims of its proponents. This is important to understand,
      because neither method is, fundamentally, a successful strategy for climate
      scientists to avoid making value judgments.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Winsberg, Eric
AU  - Winsberg E
AD  - University of South Florida, Department of Philosophy, USA. Electronic address:
      winsberg@usf.edu.
FAU - Oreskes, Naomi
AU  - Oreskes N
AD  - Harvard University, Department of History of Science, USA.
FAU - Lloyd, Elisabeth
AU  - Lloyd E
AD  - Indiana University Bloomington, Department of History and Philosophy of Science, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - Stud Hist Philos Sci
JT  - Studies in history and philosophy of science
JID - 1250602
MH  - *Climate Change
MH  - Humans
MH  - *Social Values
MH  - Weather
OTO - NOTNLM
OT  - *Climate
OT  - *Models
OT  - *Risk
OT  - *Severe weather
OT  - *Values
EDAT- 2020/11/22 06:00
MHDA- 2022/04/05 06:00
CRDT- 2020/11/21 05:24
PHST- 2020/02/13 00:00 [received]
PHST- 2020/09/10 00:00 [revised]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/11/21 05:24 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - S0039-3681(20)30173-4 [pii]
AID - 10.1016/j.shpsa.2020.09.003 [doi]
PST - ppublish
SO  - Stud Hist Philos Sci. 2020 Dec;84:142-149. doi: 10.1016/j.shpsa.2020.09.003. Epub
      2020 Sep 25.


PMID- 33218363
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1756-994X (Electronic)
IS  - 1756-994X (Linking)
VI  - 12
IP  - 1
DP  - 2020 Nov 20
TI  - Transparency, trust, and community welfare: towards a precision public health
      ethics framework for the genomics era.
PG  - 98
LID - 10.1186/s13073-020-00800-y [doi]
AB  - Infectious disease control is experiencing a paradigm shift, as pathogen
      sequencing technologies and digital applications are increasingly implemented for
      control of diseases such as tuberculosis, Ebola, and COVID-19. A new ethical
      framework should be a critical part of this emerging paradigm to ensure that the 
      benefit of precision public health interventions based on advances in genomics
      research is not outweighed by the risks they pose to individuals, families, and
      vulnerable segments of the population. We suggest that the ethical framework
      guiding practice in this domain combines standard precepts from public health
      ethics with emerging ethics principles from precision medicine.
FAU - Juengst, Eric T
AU  - Juengst ET
AD  - Center for Bioethics, School of Medicine, University of North Carolina at Chapel 
      Hill, 333 MacNider Hall, Chapel Hill, NC, 27599-7240, USA. ejuengst@med.unc.edu.
FAU - Van Rie, Annelies
AU  - Van Rie A
AD  - Family Medicine and Population Health, Faculty of Medicine, University of
      Antwerp, Campus Drie Eiken R232, Universiteitsplein 1, 2610, Wilrijk, Belgium.
LA  - eng
GR  - G0F8316N and T001018N./Fonds voor Wetenschappelijk onderzoek (BE)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - Genome Med
JT  - Genome medicine
JID - 101475844
SB  - IM
MH  - Bioethical Issues
MH  - COVID-19/*epidemiology
MH  - Genomics/*ethics
MH  - Humans
MH  - *Pandemics
MH  - Precision Medicine/*ethics
MH  - Public Health/*ethics
MH  - *SARS-CoV-2
PMC - PMC7677909
OTO - NOTNLM
OT  - *Ethics
OT  - *Genomic epidemiology
OT  - *Pathogen sequencing
OT  - *Precision public health
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 05:22
PHST- 2020/07/15 00:00 [received]
PHST- 2020/11/06 00:00 [accepted]
PHST- 2020/11/21 05:22 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s13073-020-00800-y [doi]
AID - 10.1186/s13073-020-00800-y [pii]
PST - epublish
SO  - Genome Med. 2020 Nov 20;12(1):98. doi: 10.1186/s13073-020-00800-y.


PMID- 33218359
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Nov 20
TI  - Economic arguments in migrant health policymaking: proposing a research agenda.
PG  - 113
LID - 10.1186/s12992-020-00642-8 [doi]
AB  - Welfare states around the world restrict access to public healthcare for some
      migrant groups. Formal restrictions on migrants' healthcare access are often
      justified with economic arguments; for example, as a means to prevent excess
      costs and safeguard scarce resources. However, existing studies on the economics 
      of migrant health policies suggest that restrictive policies increase rather than
      decrease costs. This evidence has largely been ignored in migration debates.
      Amplifying the relationship between welfare state transformations and the
      production of inequalities, the Covid-19 pandemic may fuel exclusionary rhetoric 
      and politics; or it may serve as an impetus to reconsider the costs that one
      group's exclusion from health can entail for all members of society.The public
      health community has a responsibility to promote evidence-informed health
      policies that are ethically and economically sound, and to counter anti-migrant
      and racial discrimination (whether overt or masked with economic reasoning).
      Toward this end, we propose a research agenda which includes 1) the generation of
      a comprehensive body of evidence on economic aspects of migrant health policies, 
      2) the clarification of the role of economic arguments in migration debates, 3)
      (self-)critical reflection on the ethics and politics of the production of
      economic evidence, 4) the introduction of evidence into migrant health
      policymaking processes, and 5) the endorsement of inter- and transdisciplinary
      approaches. With the Covid-19 pandemic and surrounding events rendering the
      suggested research agenda more topical than ever, we invite individuals and
      groups to join forces toward a (self-)critical examination of economic arguments 
      in migration and health, and in public health generally.
FAU - Gottlieb, Nora
AU  - Gottlieb N
AUID- ORCID: 0000-0001-9199-2321
AD  - Department of Health Care Management, Berlin Technical University, Berlin,
      Germany. nora.gottlieb@uni-bielefeld.de.
AD  - Department of Population Medicine and Health Services Research, School of Public 
      Health, Bielefeld University, Bielefeld, Germany. nora.gottlieb@uni-bielefeld.de.
FAU - Trummer, Ursula
AU  - Trummer U
AD  - Center for Health and Migration, Vienna, Austria.
FAU - Davidovitch, Nadav
AU  - Davidovitch N
AD  - Department of Health Systems Management, School of Public Health, Ben-Gurion
      University of the Negev, Beer Sheva, Israel.
FAU - Krasnik, Allan
AU  - Krasnik A
AD  - Department of Public Health, Center for Migration, Ethnicity and Health,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Juarez, Sol P
AU  - Juarez SP
AD  - Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
AD  - Centre for Health Equity Studies (CHESS), Stockholm University/Karolinska
      Institute, Stockholm, Sweden.
FAU - Rostila, Mikael
AU  - Rostila M
AD  - Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
AD  - Centre for Health Equity Studies (CHESS), Stockholm University/Karolinska
      Institute, Stockholm, Sweden.
FAU - Biddle, Louise
AU  - Biddle L
AD  - Section for Health Equity Studies and Migration, Department of General Practice
      and Health Services Research, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Bozorgmehr, Kayvan
AU  - Bozorgmehr K
AD  - Department of Population Medicine and Health Services Research, School of Public 
      Health, Bielefeld University, Bielefeld, Germany.
AD  - Section for Health Equity Studies and Migration, Department of General Practice
      and Health Services Research, University Hospital Heidelberg, Heidelberg,
      Germany.
LA  - eng
GR  - 600209/H2020 Marie Sklodowska-Curie Actions/International
GR  - 2016-07128/Svenska Forskningsradet Formas/International
GR  - 2016-07128/Svenska Forskningsradet Formas/International
GR  - 01GY1611/Bundesministerium fur Bildung und Forschung/International
GR  - 01GY1611/Bundesministerium fur Bildung und Forschung/International
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20201120
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
SB  - IM
MH  - COVID-19/*economics
MH  - Developed Countries
MH  - *Dissent and Disputes
MH  - *Emigrants and Immigrants
MH  - Emigration and Immigration
MH  - Europe/epidemiology
MH  - Health Policy/*economics
MH  - Health Services Accessibility/*economics/ethics
MH  - Humans
MH  - Pandemics
MH  - *Policy Making
MH  - Politics
MH  - Population Health
MH  - Research
MH  - Resource Allocation
MH  - Social Welfare
MH  - Socioeconomic Factors
MH  - *Transients and Migrants
PMC - PMC7677743
OTO - NOTNLM
OT  - *Discourse analysis
OT  - *Economics
OT  - *Equity
OT  - *Health economics
OT  - *Health policy
OT  - *Health political science
OT  - *Migrant health
OT  - *Political decision-making
OT  - *Political economy
OT  - *Translational research
EDAT- 2020/11/22 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/11/21 05:22
PHST- 2020/06/12 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/11/21 05:22 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12992-020-00642-8 [doi]
AID - 10.1186/s12992-020-00642-8 [pii]
PST - epublish
SO  - Global Health. 2020 Nov 20;16(1):113. doi: 10.1186/s12992-020-00642-8.


PMID- 33218152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Nov 18
TI  - Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction
      (ADR) Reporting in Dammam, Saudi Arabia.
LID - E222 [pii]
LID - 10.3390/pharmacy8040222 [doi]
AB  - This study aimed to assess public knowledge about medicine information, safety,
      and adverse drug reaction reporting (ADR) in Dammam, Saudi Arabia. A cross
      sectional study was conducted using purposive stratified sampling in different
      settings of Dammam city for three months (January-March 2020). The target
      population was identified as consumers who had used the medicines in the last 3
      months. The questionnaire was adopted from the literature and was validated.
      Content and face validities were established, and reliability was assessed. The
      study was approved by the concerned ethics committee. A total of 915 participants
      returned completed questionnaires. A total of 54.4% participants aged between 18 
      and 30 years, 65.8% were females and 53.1% had obtained bachelor level education.
      The mean score for knowledge of medicines (K1) was 5.46 +/- 1.07. The mean score 
      for knowledge regarding medication safety (K2) was 5.94 +/- 1.73. The mean score 
      for tendency to report a suspected ADR (T1) was 3.43 +/- 1.57. Gender was a
      determinant of knowledge regarding medication safety (K2) (p < 0.01) and ADR
      reporting tendency (T1) (p < 0.01). The marital status of patients was a
      determinant for both knowledge of medicines (K1) (p < 0.01) and, knowledge
      regarding medication safety (K2) (p < 0.01). The results of this study
      highlighted that although the scores for knowledge of medicines, and tendency to 
      report ADR were better, the score for knowledge regarding medication safety was
      unsatisfactory.
FAU - Islam, Md Ashraful
AU  - Islam MA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam 31441, Saudi Arabia.
FAU - Al-Karasneh, Aseel Fuad
AU  - Al-Karasneh AF
AUID- ORCID: 0000-0003-2856-664X
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam 31441, Saudi Arabia.
FAU - Naqvi, Atta Abbas
AU  - Naqvi AA
AUID- ORCID: 0000-0003-4848-6807
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam 31441, Saudi Arabia.
FAU - AlShayban, Dhfer Mahdi
AU  - AlShayban DM
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam 31441, Saudi Arabia.
FAU - Al-Hayek, Fatimah
AU  - Al-Hayek F
AD  - College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam
      31441, Saudi Arabia.
FAU - Al-Badrani, Sarah
AU  - Al-Badrani S
AD  - College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam
      31441, Saudi Arabia.
FAU - Al-Salem, Raghad
AU  - Al-Salem R
AD  - College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam
      31441, Saudi Arabia.
FAU - Ghori, Syed Azizullah
AU  - Ghori SA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam 31441, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC7712078
OTO - NOTNLM
OT  - Saudi Arabia
OT  - adverse drug reporting
OT  - medicine information
OT  - pharmacovigilance
EDAT- 2020/11/22 06:00
MHDA- 2020/11/22 06:01
CRDT- 2020/11/21 01:01
PHST- 2020/09/13 00:00 [received]
PHST- 2020/10/29 00:00 [revised]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/21 01:01 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/11/22 06:01 [medline]
AID - pharmacy8040222 [pii]
AID - 10.3390/pharmacy8040222 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2020 Nov 18;8(4). pii: pharmacy8040222. doi:
      10.3390/pharmacy8040222.


PMID- 33217883
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Association of glycosylated hemoglobin and outcomes in patients with COVID-19 and
      pre-existing type 2 diabetes: A protocol for systematic review and meta-analysis.
PG  - e23392
LID - 10.1097/MD.0000000000023392 [doi]
AB  - BACKGROUND: The impact of glycosylated hemoglobin on mortality in patients with
      coronavirus disease 2019 (COVID-19) and type 2 diabetes (T2D) remains uncertain. 
      In this study, we aim to assess the effect of pre-hospital blood glucose
      regulation on patients with COVID-19 and pre-existing T2D. METHODS: All
      randomized controlled trials (RCTs) and cohort studies of association of
      glycosylated hemoglobin and outcomes in patients with COVID-19 and T2D will be
      included in this review. PubMed, Embase, and CNKI will be searched for relevant
      literature, up to August 20, 2020 in English and Chinese language. Two reviewers 
      will select trials independently for inclusion and assess trial quality. Two
      pairs of authors will independently extract information for each included trials.
      Primary outcomes are death and composite adverse outcomes: the number of
      participants who died or remained severely disabled. Revman 5.3 will be used for 
      heterogeneity assessment, data synthesis, subgroup analysis, sensitivity
      analysisa and generating funnel-plots. RESULTS: We will provide practical results
      about the association of glycosylated hemoglobin and outcomes in patients with
      COVID-19 and T2D. CONCLUSION: The stronger evidence about the association of
      glycosylated hemoglobin and outcomes in patients with COVID-19 and T2D will be
      provided for clinical practice. SYSTEMATIC REVIEW REGISTRATION: PROSPERO
      CRD42020200574. ETHICS AND DISSEMINATION: There is no need for ethical approval, 
      and the review will be reported in a peer-reviewed journal.
FAU - Zhang, Nie
AU  - Zhang N
AD  - Department of Endocrinology, Jingjiang People's Hospital, the Seventh Affiliated 
      Hospital of Yangzhou University, Jiangsu, China.
FAU - Yun, Ruiyuan
AU  - Yun R
FAU - Liu, Lin
AU  - Liu L
FAU - Yang, Liu
AU  - Yang L
AUID- ORCID: 0000-0003-3843-4587
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cohort Studies
MH  - Coronavirus Infections/*blood/mortality
MH  - Diabetes Mellitus, Type 2/*blood/mortality/virology
MH  - Female
MH  - Glycated Hemoglobin A/*analysis
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*blood/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
MH  - *Severity of Illness Index
MH  - Systematic Reviews as Topic
PMC - PMC7676522
EDAT- 2020/11/22 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1097/MD.0000000000023392 [doi]
AID - 00005792-202011200-00098 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23392. doi:
      10.1097/MD.0000000000023392.


PMID- 33217876
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Efficacy and safety of massage therapy for chronic atrophic gastritis: A protocol
      for systematic review and meta-analysis.
PG  - e23347
LID - 10.1097/MD.0000000000023347 [doi]
AB  - BACKGROUND: Chronic atrophic gastritis (CAG) is an established precursor of
      gastric carcinoma with high prevalence worldwide. It is a typical complex
      gastro-intestinal disease with multiple influence factors, of which exact
      mechanisms remain unelucidated. Therefore, an ideal strategy to relieve CAG is
      urgently needed. In recent years, massage therapy has been increasingly accepted 
      by CAG patients due to its lower costs, fewer unwanted side effects and safety
      for clinical use. In this systematic review, we aim to evaluate the effectiveness
      and safety of massage therapy for patients with chronic atrophic gastritis.
      METHODS: We will search the following electronic databases for randomized
      controlled trials to evaluate the effectiveness and safety of massage therapy in 
      treating chronic atrophic gastritis: Wanfang and Pubmed Database, China National 
      Knowledge Infrastructure Database, Cochrane Central register of controlled
      trials, Cumulative Index of Nursing and Allied Health Literature, and Excerpta
      Medica database. Each database will be searched from inception to September 2020.
      The entire process will include study selection, data extraction, risk of bias
      assessment, and meta-analyses. RESULT: This proposed study will evaluate the
      effectiveness and safety of massage therapy for patients with chronic atrophic
      gastritis. The outcomes will include changes in CAG relief and adverse effect.
      CONCLUSION: This proposed systematic review will evaluate the existing evidence
      on the effectiveness and safety of massage therapy for patients with chronic
      atrophic gastritis. DISSEMINATION AND ETHICS: The results of this review will be 
      disseminated through peer-reviewed publication. Because all of the data used in
      this systematic review and meta-analysis has been published, this review does not
      require ethical approval. Furthermore, all data will be analyzed anonymously
      during the review process.
FAU - Zhou, Ke-Lin
AU  - Zhou KL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dong, Shuo
AU  - Dong S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Guo, Sheng
AU  - Guo S
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dai, Xiao-Hui
AU  - Dai XH
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Yang, Jing-Yi
AU  - Yang JY
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Liu, Yang
AU  - Liu Y
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Mi, Bao-Lai
AU  - Mi BL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Wang, Shao-Wei
AU  - Wang SW
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Fu, Guo-Bing
AU  - Fu GB
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Wei, Pei-Dong
AU  - Wei PD
AUID- ORCID: 0000-0001-9828-7684
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Chronic Disease
MH  - Gastritis, Atrophic/*therapy
MH  - Humans
MH  - *Massage
MH  - Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7676512
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023347 [doi]
AID - 00005792-202011200-00091 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23347. doi:
      10.1097/MD.0000000000023347.


PMID- 33217858
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Effect of acupuncture of sphenopalatine ganglion for the treatment of allergic
      rhinitis: A protocol for a systematic review and meta-analysis.
PG  - e23286
LID - 10.1097/MD.0000000000023286 [doi]
AB  - BACKGROUND: Allergic rhinitis is an allergic disease of the nasal mucosa mediated
      by IgE after the body is exposed to allergens. Acupuncture of sphenoid ganglion
      is a new technique developed by Professor Li Xinwu in the 1860 s to treat
      allergic rhinitis the efficacy of acupuncture on the sphenopalatine ganglion in
      the treatment of AR has been clinically verified, but a systematic review and
      meta-analysis of them is lacking. Our purpose is to evaluate the efficacy and
      safety of acupuncture on the sphenopalatine ganglion in the treatment of AR.
      METHODS: We will search 8 electronic databases, including: Web of Science,
      PubMed, Cochrane Library, Embase, CNKI, CBM, Wanfang, VIP, WHO ICTRP, ChiCTR,
      Clinical Trials, Grey Literature Database. The literature search, screening and
      extraction will be carried out independently by 2 researchers. When the opinions 
      are not uniform, it depends on the opinion of the third researcher. We will use
      RevmanV.5.3 to perform a fixed-effect meta-analysis on the date of clinical
      homogeneity studies, and the level of evidence will pass GRADE method. RESULTS:
      This systematic review and meta-analysis will put a high-quality synthesis of the
      efficacy and safety of acupuncture of sphenoid ganglion treatment in AR.
      CONCLUSION: The review will provide a comprehensive basis for the treatment of AR
      patients with acupuncture on the sphenopalatine ganglion. ETHICS AND
      DISSEMINATION: Since this article does not involve patient privacy, ethical
      approval is not required. TRIAL REGISTRATION NUMBER: INPLASY2020100067.
FAU - Xiong, PeiYu
AU  - Xiong P
AD  - College of Basic medicine, Chengdu University of Traditional Chinese Medicine,
      Chengdu, PR China.
FAU - Yuan, Tao
AU  - Yuan T
FAU - Xu, Lu
AU  - Xu L
FAU - Jia, Bo
AU  - Jia B
AUID- ORCID: 0000-0002-8161-843
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - China
MH  - Ganglia, Autonomic
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - Rhinitis, Allergic/*therapy
MH  - Systematic Reviews as Topic/*methods
PMC - PMC7676590
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023286 [doi]
AID - 00005792-202011200-00073 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23286. doi:
      10.1097/MD.0000000000023286.


PMID- 33217857
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Acupuncture therapy for treating postherpetic neuralgia: A protocol for an
      overview of systematic reviews and meta-analysis.
PG  - e23283
LID - 10.1097/MD.0000000000023283 [doi]
AB  - BACKGROUND: Postherpetic neuralgia (PHN) is the most common complication and
      sequela of herpes zoster (HZ) that greatly affects the life and emotional
      experience of patients. Acupuncture therapy has been confirmed as an effective
      and safe treatment for PHN. Several systematic reviews (SRs) and meta-analysis
      (MAs) have reported the evidence of acupuncture therapy for treating PHN.
      However, the evidence has not been systematically synthesized. This overview aims
      to synthesize and assess the reliability of evidence generated from these SRs and
      MAs of acupuncture therapy for PHN. METHODS: We will conduct a systematic search 
      of the China Biology Medicine (CBM), VIP database, Wangfang database, China
      National Knowledge Infrastructure (CNKI), Pubmed, Cochrane Library, Excerpt
      Medical Database (Embase), and Web of Science to identify eligible SRs and MAs,
      from their inception to October 31, 2020. We will use Assessment of Multiple
      Systematic Reviews-2 (AMSTAR2) for methodological quality assessment, Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for report
      quality assessment, Grading of Recommendations, Assessment, Development, and
      Evaluation (GRADE) for the quality of evidence assessment, and ROBIS for the bias
      assessment. Our reviewers will conduct systematic reviews, qualification
      evaluation, data extraction, methodological quality, and evidence quality
      screening in pairs. The outcomes include pain intensity, Quality of life (QoL),
      Hamilton Anxiety Scale (HAMA), Global impression, and adverse events. All the
      extracted data will be provided in tabular form to summarize characteristics of
      each review. The evidence will be a narrative synthesis of the type and content
      of the intervention and the results reported. RESULTS: The results of this study 
      will be published in a peer-reviewed journal. CONCLUSIONS: This overview will
      provide comprehensive evidence of acupuncture therapy for patients with PHN.
      ETHICS AND DISSEMINATION: This review will not involve private information of
      participants, so the ethical approval will not be required. The results will be
      disseminated in a peer-reviewed journal or conference presentation. Important
      protocol modifications will be updated on PROSPERO. PROSPERO REGISTRATION NUMBER:
      CRD42020178738.
FAU - Yu, Jie
AU  - Yu J
AD  - Department of Acupuncture and Massage, Affiliated Hangzhou First People's
      Hospital, Zhejiang University School of Medicine.
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Tu, Mingqi
AU  - Tu M
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Shi, Yan
AU  - Shi Y
AD  - Department of Acupuncture and Massage, Affiliated Hangzhou First People's
      Hospital, Zhejiang University School of Medicine.
FAU - Liu, Yingjun
AU  - Liu Y
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - He, Xiaofen
AU  - He X
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Qiu, Fanghui
AU  - Qiu F
AD  - Department of Acupuncture and Massage, Affiliated Hangzhou First People's
      Hospital, Zhejiang University School of Medicine.
FAU - Xu, Yunyun
AU  - Xu Y
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Sun, Ruohan
AU  - Sun R
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Jiang, Yongliang
AU  - Jiang Y
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - China
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Neuralgia, Postherpetic/*therapy
MH  - *Research Design
MH  - Systematic Reviews as Topic/*methods
PMC - PMC7676539
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023283 [doi]
AID - 00005792-202011200-00072 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23283. doi:
      10.1097/MD.0000000000023283.


PMID- 33217854
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Nursing intervention reduces depression for patients with rheumatoid arthritis: A
      randomized controlled trial protocol.
PG  - e23268
LID - 10.1097/MD.0000000000023268 [doi]
AB  - BACKGROUND: Rheumatoid arthritis (RA) is a kind of chronic disease of
      inflammatory joint, which can lead to the damage and disability of bone and
      cartilage. Psychiatric comorbidity is related to the adverse results of RA.
      Symptoms of depression is associated with the increased disease activity and
      decreased response to the treatments. Therefore, the depression may be an
      effective intervention target to improve the life quality and subjective health
      of the patients with RA. The objective of this experiment is to evaluate the
      effectiveness of nursing intervention for reducing depression for patients with
      RA. METHOD: It is a single-center randomized controlled study to be conducted
      from January 2021 to December 2021. It was admitted via the Ethics Committee of
      Tianjin Medical University (202018384). One hundred patients are included in the 
      study. The inclusion criteria contains:The exclusion criteria contains:All the
      patients participating in this study are randomly divided into control group and 
      study group, with 50 patients in each group. The primary result is the severity
      of depression in the patients with RA, based on the generally utilized
      questionnaires (Hospital Anxiety and Depression Scale). The secondary outcome is 
      the patients life quality, which is evaluated with the short form 36
      questionnaire. The analysis of all the data are conducted with the software of
      IBM SPSS Statistics for Windows, version 20. RESULTS: Table will show the
      clinical outcomes after various interventions. CONCLUSION: This paper instructs
      the nurses to develop protocol based on evidence to improve the clinical efficacy
      for the RA patients. TRIAL REGISTRATION NUMBER: researchregistry6114.
FAU - Liu, Moying
AU  - Liu M
AD  - School of Nursing, Tianjin Medical University, Tianjin, China.
FAU - Shi, Baoxin
AU  - Shi B
AUID- ORCID: 0000-0001-9261-0874
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Arthritis, Rheumatoid/*complications/*psychology
MH  - Depression/*etiology/*nursing
MH  - Humans
MH  - Randomized Controlled Trials as Topic/*methods
PMC - PMC7676538
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023268 [doi]
AID - 00005792-202011200-00069 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23268. doi:
      10.1097/MD.0000000000023268.


PMID- 33217842
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Postauricular injection glucocorticoid in the treatment of sudden hearing loss: A
      protocol for systematic review and meta-analysis.
PG  - e23241
LID - 10.1097/MD.0000000000023241 [doi]
AB  - BACKGROUND: Sudden hearing loss is an emergency health problem in the Department 
      of Otolaryngology that must be treated in a timely manner, or may cause lifelong 
      regrets. The application of postauricular injection of glucocorticoid is a
      popular treatment to recover patients hearing level in recent years. However, the
      effectiveness and safety of postauricular injection of glucocorticoid needs to be
      assessed systematically. METHODS AND ANALYSIS: The purpose of the study is to
      undertake a systematic review and meta-analysis on the effectiveness and safety
      of postauricular injection of glucocorticoid to treat patient diagnosed with
      sudden hearing loss. We will search the following databases from the date of
      publication to July 1, 2020: PubMed, EMBASE, Web of Science, the Cochrane
      Library, CNKI, Wanfang databases, the Chinese Biomedical Literature Database
      (CBM), the Chinese Science and Technology Periodical Database (VIP) and the
      Chinese Cochrane Centre's Clinical Trial Registry Platform. Observational studies
      regarding the association between postauricular injection of glucocorticoid and
      sudden hearing loss were written in English and Chinese were included.
      RevManV.5.3 software will be used for meta-analysis. According to the
      heterogeneity of the research results, fixed effects model, random effects model,
      subgroup analysis, sensitivity analysis, and others will be used. Ethics approval
      was not required for this protocol. The findings will be disseminated through
      journal articles and conference presentations. RESULTS: Objectively, evaluate the
      efficacy and safety of postauricular injection of glucocorticoid for sudden
      hearing loss. CONCLUSION: To provide evidence-based medicine for glucocorticoid
      treatment methods in patients with sudden hearing loss. OSF REGISTRATION NUMBER: 
      DOI 10.17605/OSF.IO/N5RV3.
FAU - Liang, Jiao
AU  - Liang J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, No. 39
      Shi-er-qiao Road, Chengdu, Sichuan Province, PR China.
FAU - Xie, Hui
AU  - Xie H
AUID- ORCID: 0000-0001-6381-3613
FAU - Chiang, Han-Jen
AU  - Chiang HJ
FAU - Li, Sha
AU  - Li S
FAU - Liu, Zhiqing
AU  - Liu Z
FAU - Li, Jiongke
AU  - Li J
FAU - Zeng, Chenyi
AU  - Zeng C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Glucocorticoids/administration & dosage/adverse effects/*therapeutic use
MH  - Hearing Loss, Sudden/*drug therapy
MH  - Humans
MH  - Injections
MH  - Meta-Analysis as Topic
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7676517
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023241 [doi]
AID - 00005792-202011200-00057 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23241. doi:
      10.1097/MD.0000000000023241.


PMID- 33217841
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Efficacy and safety of warm needle treatment for scapulohumeral periarthritis: A 
      protocol for systematic review and meta-analysis.
PG  - e23237
LID - 10.1097/MD.0000000000023237 [doi]
AB  - BACKGROUND: To evaluate the effectiveness and safety of warm needle acupuncture
      (WNA) treatment for Scapulohumeral periarthritis. METHODS: Relevant randomized
      controlled trials will be searched from the databases of Pubmed, the Cochrane
      Library, Embase, CNKI, Wanfang Database, CBM and VIP Database from their
      inception to September 2021. The primary outcomes are effective rate, visual
      analog scale score. The secondary outcomes are Constant-Murley score, Japanese
      Orthopaedic Association scores, adverse events. Two reviewers will independently 
      select studies, collect data, and assess the methodology quality by the Cochrane 
      risk of bias tool. The Stata 14.0 will be used for meta-analysis. RESULTS: This
      study is ongoing and will be submitted to a peer-reviewed journal for
      publication. CONCLUSION: This study will provide an assessment of the current
      state of WNA for the scapulohumeral periarthritis, aiming to show the efficacy
      and safety of WNA treatment. ETHICS AND DISSEMINATION: There is no requirement of
      ethical approval and informed consent, and it will be in print or published by
      electronic copies. REGISTRATION: INPLASY2020100049.
FAU - Wang, Xiaoyu
AU  - Wang X
AUID- ORCID: 0000-0002-0084-7258
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin.
FAU - Hai, Xinghua
AU  - Hai X
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin.
FAU - Jiang, Dongli
AU  - Jiang D
AD  - Acupuncture and Rehabilitation Clinical College, Guangzhou University of Chinese 
      Medicine.
FAU - Yin, Lianjun
AU  - Yin L
AD  - Recovery Unit, The Third Affiliated Hospital of Southern Medical University,
      Guangzhou.
FAU - Li, Huanan
AU  - Li H
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Public Health and Preventive Medicine, Baotou Medical College,
      Baotou.
FAU - Liu, Fang
AU  - Liu F
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin.
FAU - Xu, Guoqiang
AU  - Xu G
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin.
FAU - Sun, Qing
AU  - Sun Q
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Humans
MH  - Humerus
MH  - Meta-Analysis as Topic
MH  - Periarthritis/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Scapula
MH  - *Shoulder Joint
MH  - Systematic Reviews as Topic
PMC - PMC7676557
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023237 [doi]
AID - 00005792-202011200-00056 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23237. doi:
      10.1097/MD.0000000000023237.


PMID- 33217840
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Efficacy and safety of endovascular coiling vs surgical clipping for patients
      with ruptured carotid-ophthalmic aneurysm: A protocol for systematic review and
      meta-analysis.
PG  - e23235
LID - 10.1097/MD.0000000000023235 [doi]
AB  - BACKGROUND: Carotid-ophthalmic aneurysms are relatively rare, and represent 1% of
      all intracranial aneurysms. Generally, endovascular coiling and surgical clipping
      are the 2 most commonly used methods to treat ruptured carotid-ophthalmic
      aneurysms, it provides the most favorable outcome for a patient. This study aims 
      to assess the efficiency and safety of endovascular coiling vs surgical clipping 
      for patients with a ruptured carotid-ophthalmic aneurysm. METHODS: A
      comprehensive systematic literature review was done in PubMed, EMBASE, Cochrane
      Library, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), 
      and WanFang databases. Only randomized trials that compared endovascular coiling 
      with surgical clipping in patients with ruptured carotid-ophthalmic aneurysm was 
      included. Data was extracted independently by 2 review authors. Moreover, the
      quality of study and bias risk was evaluated by utilizing an appropriate method. 
      Triallists will be contacted to acquire missing information. The data is
      presented as risk ratio and mean difference, or standardized mean difference with
      95% confidence intervals. RESULTS: The results from the present research shall be
      published in a peer-reviewed journal. CONCLUSION: The present study summarizes
      the direct and in-direct evidence to judge the efficiency and safety of these 2
      methodologies to treat ruptured carotid-ophthalmic aneurysms and attempt to find 
      the most efficiency and safety therapeutical method. ETHICS AND DISSEMINATION:
      The present study is a meta-analysis based on published evidence. As a result,
      ethics approval and patient consent are not needed.
FAU - Feng, Guan-Jun
AU  - Feng GJ
AD  - Department of Neurosurgery, People's Hospital of Xinjiang Uygur Autonomous
      Region, Urumqi, China.
FAU - Gao, Feng
AU  - Gao F
FAU - Huang, Xiao-Yuan
AU  - Huang XY
FAU - Hati, Paer
AU  - Hati P
FAU - Yang, Xiao-Peng
AU  - Yang XP
FAU - Wu, Hong-Xing
AU  - Wu HX
AUID- ORCID: 0000-0002-1695-0110
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aneurysm, Ruptured/*therapy
MH  - *Carotid Artery, Internal
MH  - Embolization, Therapeutic/instrumentation/*methods
MH  - Endovascular Procedures/instrumentation/methods
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Ophthalmic Artery
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7676553
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023235 [doi]
AID - 00005792-202011200-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23235. doi:
      10.1097/MD.0000000000023235.


PMID- 33217834
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Thyroid dysfunction and cardiovascular events in patients with chronic kidney
      disease: A protocol of systematic review and meta-analysis.
PG  - e23218
LID - 10.1097/MD.0000000000023218 [doi]
AB  - BACKGROUND: Cardiovascular disease is the main cause of death in patients with
      chronic kidney disease (CKD). Studies have found that hypothyroidism can
      significantly increase cardiovascular risk. Meanwhile, hypothyroidism is a common
      complication of CKD, but the correlation between hypothyroidism and
      cardiovascular risk in CKD patients has not been verified and paid enough
      attention. We therefore plan to conduct a systematic review and meta-analysis to 
      explore whether hypothyroidism was independently predictive for the
      cardiovascular risk in patients with CKD. METHODS: We will search in PubMed,
      Embase Database, Web of Science, China National Knowledge Infrastructure (CNKI), 
      China Biology Medicine Database (CBM), and Wanfang Database, and include the
      cross-sectional studies, case--control studies, and cohort studies that explore
      the association between hypothyroidism and cardiovascular risk in CKD patients.
      According to the eligibility criteria, two researchers will independently screen 
      the retrieved literature, evaluate the methodological quality, and extract data. 
      We will combine the extracted data based on STATA and TSA software. RESULTS: This
      systematic review will assess the association between hypothyroidism and
      cardiovascular risk in CKD patients based on the incidence of cardiovascular
      events in CKD people with hypothyroidism. CONCLUSIONS: This study will provide
      more evidence for the correlation between hypothyroidism and cardiovascular risk 
      in CKD patients, which will contribute to the management and clinical practice of
      CKD population. ETHICS AND DISSEMINATION: This protocol is based on available
      literatures so that the ethical approval and informed consent are not applicable.
      The results of this study will be published in a peer-reviewed journals or
      relevant conferences. PROTOCOL REGISTRATION NUMBER: INPLASY2020100022.
FAU - Liu, Tongtong
AU  - Liu T
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
FAU - Guan, Yingjie
AU  - Guan Y
AD  - Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese
      Medicine, Beijing, China.
FAU - Li, Juan
AU  - Li J
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
FAU - Mao, Huimin
AU  - Mao H
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
FAU - Zhan, Yongli
AU  - Zhan Y
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Cardiovascular Diseases/*epidemiology
MH  - Humans
MH  - Hypothyroidism/*complications/*epidemiology
MH  - Incidence
MH  - Meta-Analysis as Topic
MH  - Renal Insufficiency, Chronic/*complications
MH  - Research Design
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7676516
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000023218 [doi]
AID - 00005792-202011200-00049 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23218. doi:
      10.1097/MD.0000000000023218.


PMID- 33217794
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Evaluation of walking exercise on glycemic control in patients with type 2
      diabetes mellitus: A protocol for systematic review and meta-analysis of
      randomized cross-over controlled trials.
PG  - e22735
LID - 10.1097/MD.0000000000022735 [doi]
AB  - INTRODUCTION: Hyperglycemia is closely associated with the occurrence of diabetic
      complications, especially for patients with type 2 diabetes mellitus. Clinical
      trials indicated that walking exercise could improve glycemic control in patients
      with type 2 diabetes mellitus, but it is difficult to draw definitive and
      reliable conclusions due to the small sample size and possible exaggerated
      efficacy of various individual clinical trials. Therefore, we will conduct
      systematic review and meta-analysis to assess the current evidence for the
      efficacy of walking on glycemic control. METHODS AND ANALYSIS: The databases of
      PubMed, EMBASE, Web of Science and Cochrane Library will be searched for this
      review. Cochrane risk-of-bias assessment tool will be applied to assess the risk 
      of bias of included studies. A meta-analysis will be performed according to the
      Cochrane Handbook for Systematic Reviews of Interventions by using RevMan 5.3 and
      STATA/SE 14.0 software. Subgroup analysis will be conducted to investigate the
      sources of heterogeneity. Sensitivity analysis will be performed to assess the
      reliability and stability of the meta-analysis. Publication bias and small-study 
      effects will be evaluated by a funnel plot and Eggers test if there are at least 
      10 studies. Additionally, the quality of evidence for this review will be
      assessed by Grades of Recommendations Assessment, Development and Evaluation
      (GRADE). RESULTS: This systematic review and meta-analysis will be to assess the 
      efficacy of walking exercise on glycemic control. CONCLUSION: We will provide
      strong evidence to determine whether walking can improve glycemic control in
      patients with type 2 diabetes mellitus. This study is supposed to provide
      references for clinical trials and patients with type 2 diabetes mellitus. ETHICS
      AND DISSEMINATION: This study does not require ethical approval. The results of
      this review will be published in a peer reviewed journal. INPLASY REGISTRATION
      NUMBER: INPLASY202090046.
FAU - Hu, Hengchang
AU  - Hu H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Lei, Yuanhong
AU  - Lei Y
AD  - Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
FAU - Yin, Liping
AU  - Yin L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Luo, Xiaoqiong
AU  - Luo X
AD  - Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Blood Glucose/*analysis
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic
MH  - Walking/*physiology
PMC - PMC7676596
EDAT- 2020/11/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/MD.0000000000022735 [doi]
AID - 00005792-202011200-00009 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e22735. doi:
      10.1097/MD.0000000000022735.


PMID- 33216831
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1524-6205 (Print)
IS  - 1524-6205 (Linking)
VI  - 2020
DP  - 2020 Sep-Oct
TI  - Neuroscience for Global Mental Health.
LID - cer-08-20 [pii]
AB  - Our author-Professor of Neuroscience & Society at the University of Oxford and
      co-director of the Wellcome Trust Center for Ethics and Humanities-reflects on
      efforts to grow recognition of neuroscience in low- and middle-income countries.
CI  - Copyright 2020 The Dana Foundation All Rights Reserved.
FAU - Singh, Ilina
AU  - Singh I
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - Cerebrum
JT  - Cerebrum : the Dana forum on brain science
JID - 100888555
PMC - PMC7664820
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 17:15
PHST- 2020/11/20 17:15 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - cer-08-20 [pii]
PST - epublish
SO  - Cerebrum. 2020 Oct 1;2020. pii: cer-08-20. eCollection 2020 Sep-Oct.


PMID- 33216781
OWN - NLM
STAT- MEDLINE
DCOM- 20201228
LR  - 20201228
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Professionals' attitudes towards the use of cognitive enhancers in academic
      settings.
PG  - e0241968
LID - 10.1371/journal.pone.0241968 [doi]
AB  - INTRODUCTION AND AIMS: The non-medical use of prescription stimulants such as
      methylphenidate, dexamphetamine and modafinil is increasing in popularity within 
      tertiary academic settings. There is a paucity of information on awareness,
      attitudes, and acceptability by professionals of use in this context. This study 
      aimed to investigate professionals' knowledge of and attitudes towards the use of
      cognitive enhancers (CEs) in academic settings, and their willingness to use a
      hypothetical CE. DESIGN AND METHODS: A mail survey was sent to doctors,
      pharmacists, nurses, accountants and lawyers in New Zealand. These disciplines
      were chosen as they require professional registration to practice. The
      questionnaire comprised four sections: (1) demographics, (2) knowledge of CEs,
      (3) attitudes towards the use of CEs, and (4) willingness to use hypothetical
      CEs. RESULTS: The response rate was 34.5% (414/1200). Overall, participants
      strongly disagreed that it was fair to allow university students to use CEs for
      cognitive enhancement (Mdn = 1, IQR: 1,3), or that it is ethical for students
      without a prescription to use cognitive enhancers for any reason (Mdn = 1, IQR:
      1,2). Professions differed in their attitudes towards whether it is ethical for
      students without a prescription to use CEs for any reason (p = 0.001, H 31.527). 
      DISCUSSION AND CONCLUSION: Divergent views and lack of clear consensus within
      professions and between professionals on the use of CEs have the potential to
      influence both professionals and students as future professionals. These
      divergent views may stem from differences in the core values of self-identity as 
      well as extrinsic factors of acceptability within the profession in balancing the
      elements of opportunity, fairness and authenticity in cognitive enhancement.
      Further research is required to inform the development of policy and guidelines
      that are congruent with all professions.
FAU - Ram, Sanyogita Sanya
AU  - Ram SS
AUID- ORCID: 0000-0002-5774-1972
AD  - Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical
      Science, Monash University (Parkville Campus), Parkville, Australia.
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, University of
      Auckland, Auckland, New Zealand.
FAU - Russell, Bruce
AU  - Russell B
AD  - Clinical Pharmacy, School of Pharmacy, University of Otago, Dunedin, New Zealand.
FAU - Kirkpatrick, Carl
AU  - Kirkpatrick C
AD  - Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical
      Science, Monash University (Parkville Campus), Parkville, Australia.
FAU - Stewart, Kay
AU  - Stewart K
AD  - Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical
      Science, Monash University (Parkville Campus), Parkville, Australia.
FAU - Scahill, Shane
AU  - Scahill S
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, University of
      Auckland, Auckland, New Zealand.
FAU - Henning, Marcus
AU  - Henning M
AD  - Centre for Medical and Health Sciences Education, Faculty of Medical and Health
      Sciences, University of Auckland, Auckland, New Zealand.
FAU - Curley, Louise
AU  - Curley L
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, University of
      Auckland, Auckland, New Zealand.
FAU - Hussainy, Safeera
AU  - Hussainy S
AD  - Department of General Practice, School of Primary and Allied Health Care, Faculty
      of Medicine, Nursing and Health Sciences Monash University, Notting Hill,
      Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Prescription Drugs)
RN  - 207ZZ9QZ49 (Methylphenidate)
RN  - R3UK8X3U3D (Modafinil)
RN  - TZ47U051FI (Dextroamphetamine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Attitude of Health Personnel
MH  - Central Nervous System Stimulants/therapeutic use
MH  - Cognition/*drug effects
MH  - Dextroamphetamine/therapeutic use
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Male
MH  - Methylphenidate/therapeutic use
MH  - Middle Aged
MH  - Modafinil/therapeutic use
MH  - New Zealand
MH  - Prescription Drugs/*therapeutic use
MH  - Students/psychology
MH  - Surveys and Questionnaires
MH  - Universities
MH  - Young Adult
PMC - PMC7679021
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/21 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/11/20 17:14
PHST- 2020/07/21 00:00 [received]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/20 17:14 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1371/journal.pone.0241968 [doi]
AID - PONE-D-20-22579 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 20;15(11):e0241968. doi: 10.1371/journal.pone.0241968.
      eCollection 2020.


PMID- 33216010
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210317
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 20
TI  - The Active Brains Digital Intervention to Reduce Cognitive Decline in Older
      Adults: Protocol for a Feasibility Randomized Controlled Trial.
PG  - e18929
LID - 10.2196/18929 [doi]
AB  - BACKGROUND: Increasing physical activity, improving diet, and performing brain
      training exercises are associated with reduced cognitive decline in older adults.
      OBJECTIVE: In this paper, we describe a feasibility trial of the Active Brains
      intervention, a web-based digital intervention developed to support older adults 
      to make these 3 healthy behavior changes associated with improved cognitive
      health. The Active Brains trial is a randomized feasibility trial that will test 
      how accessible, acceptable, and feasible the Active Brains intervention is and
      the effectiveness of the study procedures that we intend to use in the larger,
      main trial. METHODS: In the randomized controlled trial (RCT), we use a parallel 
      design. We will be conducting the intervention with 2 populations recruited
      through GP practices (family practices) in England from 2018 to 2019: older
      adults with signs of cognitive decline and older adults without any cognitive
      decline. Trial participants were randomly allocated to 1 of 3 study groups: usual
      care, the Active Brains intervention, or the Active Brains website plus brief
      support from a trained coach (over the phone or by email). The main outcomes are 
      performance on cognitive tasks, quality of life (using EuroQol-5D 5 level),
      Instrumental Activities of Daily Living, and diagnoses of dementia. Secondary
      outcomes (including depression, enablement, and health care costs) and process
      measures (including qualitative interviews with participants and supporters) will
      also be collected. The trial has been approved by the National Health Service
      Research Ethics Committee (reference 17/SC/0463). RESULTS: Results will be
      published in peer-reviewed journals, presented at conferences, and shared at
      public engagement events. Data collection was completed in May 2020, and the
      results will be reported in 2021. CONCLUSIONS: The findings of this study will
      help us to identify and make important changes to the website, the support
      received, or the study procedures before we progress to our main randomized phase
      III trial. TRIAL REGISTRATION: International Standard Randomized Controlled Trial
      Number 23758980; http://www.isrctn.com/ISRCTN23758980. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/18929.
CI  - (c)Kirsten Ailsa Smith, Katherine Bradbury, Rosie Essery, Sebastien Pollet, Fiona
      Mowbray, Joanna Slodkowska-Barabasz, James Denison-Day, Victoria Hayter, Jo
      Kelly, Jane Somerville, Jin Zhang, Elisabeth Grey, Max Western, Anne E Ferrey,
      Adele Krusche, Beth Stuart, Nanette Mutrie, Sian Robinson, Guiqing Lily Yao,
      Gareth Griffiths, Louise Robinson, Martin Rossor, John Gallacher, Simon Griffin, 
      Tony Kendrick, Shanaya Rathod, Bernard Gudgin, Rosemary Phillips, Tom Stokes,
      John Niven, Paul Little, Lucy Yardley. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 20.11.2020.
FAU - Smith, Kirsten Ailsa
AU  - Smith KA
AUID- ORCID: https://orcid.org/0000-0001-9073-2130
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Bradbury, Katherine
AU  - Bradbury K
AUID- ORCID: https://orcid.org/0000-0001-5513-7571
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Essery, Rosie
AU  - Essery R
AUID- ORCID: https://orcid.org/0000-0002-2702-6951
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Pollet, Sebastien
AU  - Pollet S
AUID- ORCID: https://orcid.org/0000-0001-9924-9225
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Mowbray, Fiona
AU  - Mowbray F
AUID- ORCID: https://orcid.org/0000-0002-3297-4163
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Slodkowska-Barabasz, Joanna
AU  - Slodkowska-Barabasz J
AUID- ORCID: https://orcid.org/0000-0003-0878-9504
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Denison-Day, James
AU  - Denison-Day J
AUID- ORCID: https://orcid.org/0000-0003-0223-0005
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Hayter, Victoria
AU  - Hayter V
AUID- ORCID: https://orcid.org/0000-0002-2157-2855
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Kelly, Jo
AU  - Kelly J
AUID- ORCID: https://orcid.org/0000-0001-7690-6763
AD  - Primary Care and Population Sciences, University of Southampton, Southampton,
      United Kingdom.
FAU - Somerville, Jane
AU  - Somerville J
AUID- ORCID: https://orcid.org/0000-0002-8474-9013
AD  - Primary Care and Population Sciences, University of Southampton, Southampton,
      United Kingdom.
FAU - Zhang, Jin
AU  - Zhang J
AUID- ORCID: https://orcid.org/0000-0001-9583-6000
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Grey, Elisabeth
AU  - Grey E
AUID- ORCID: https://orcid.org/0000-0001-9719-9690
AD  - Department for Health, University of Bath, Bath, United Kingdom.
FAU - Western, Max
AU  - Western M
AUID- ORCID: https://orcid.org/0000-0003-1107-8498
AD  - Department for Health, University of Bath, Bath, United Kingdom.
FAU - Ferrey, Anne E
AU  - Ferrey AE
AUID- ORCID: https://orcid.org/0000-0002-5644-2735
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
AD  - NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
      Foundation Trust, Oxford, United Kingdom.
FAU - Krusche, Adele
AU  - Krusche A
AUID- ORCID: https://orcid.org/0000-0002-6876-3755
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
FAU - Stuart, Beth
AU  - Stuart B
AUID- ORCID: https://orcid.org/0000-0001-5432-7437
AD  - Primary Care and Population Sciences, University of Southampton, Southampton,
      United Kingdom.
FAU - Mutrie, Nanette
AU  - Mutrie N
AUID- ORCID: https://orcid.org/0000-0002-5018-6398
AD  - Physical Activity for Health Research Centre, University of Edinburgh, Edinburgh,
      United Kingdom.
FAU - Robinson, Sian
AU  - Robinson S
AUID- ORCID: https://orcid.org/0000-0003-1766-7269
AD  - NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle
      upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
FAU - Yao, Guiqing Lily
AU  - Yao GL
AUID- ORCID: https://orcid.org/0000-0002-9095-6676
AD  - Primary Care and Population Sciences, University of Southampton, Southampton,
      United Kingdom.
FAU - Griffiths, Gareth
AU  - Griffiths G
AUID- ORCID: https://orcid.org/0000-0002-9579-8021
AD  - Southampton Clinical Trials Unit, University of Southampton and University
      Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
FAU - Robinson, Louise
AU  - Robinson L
AUID- ORCID: https://orcid.org/0000-0003-0209-2503
AD  - Institute of Population Health Sciences, University of Newcastle, Newcastle upon 
      Tyne, United Kingdom.
FAU - Rossor, Martin
AU  - Rossor M
AUID- ORCID: https://orcid.org/0000-0001-8215-3120
AD  - Dementia Research Centre, University College London, London, United Kingdom.
FAU - Gallacher, John
AU  - Gallacher J
AUID- ORCID: https://orcid.org/0000-0002-2394-5299
AD  - Department of Psychiatry, University of Oxford, Oxford, United Kingdom.
FAU - Griffin, Simon
AU  - Griffin S
AUID- ORCID: https://orcid.org/0000-0002-2157-4797
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      United Kingdom.
FAU - Kendrick, Tony
AU  - Kendrick T
AUID- ORCID: https://orcid.org/0000-0003-1618-9381
AD  - Primary Care and Population Sciences, University of Southampton, Southampton,
      United Kingdom.
FAU - Rathod, Shanaya
AU  - Rathod S
AUID- ORCID: https://orcid.org/0000-0001-5126-3503
AD  - Southern Health NHS Foundation Trust, Southampton, United Kingdom.
FAU - Gudgin, Bernard
AU  - Gudgin B
AUID- ORCID: https://orcid.org/0000-0001-9606-5121
AD  - Public and Patient Involvement (PPI) representative, University of Southampton,
      Southampton, United Kingdom.
FAU - Phillips, Rosemary
AU  - Phillips R
AUID- ORCID: https://orcid.org/0000-0002-7885-8205
AD  - Public and Patient Involvement (PPI) representative, University of Southampton,
      Southampton, United Kingdom.
FAU - Stokes, Tom
AU  - Stokes T
AUID- ORCID: https://orcid.org/0000-0002-4358-227X
AD  - Public and Patient Involvement (PPI) representative, University of Southampton,
      Southampton, United Kingdom.
FAU - Niven, John
AU  - Niven J
AUID- ORCID: https://orcid.org/0000-0001-9538-2942
AD  - Public and Patient Involvement (PPI) representative, University of Southampton,
      Southampton, United Kingdom.
FAU - Little, Paul
AU  - Little P
AUID- ORCID: https://orcid.org/0000-0003-3664-1873
AD  - Primary Care and Population Sciences, University of Southampton, Southampton,
      United Kingdom.
FAU - Yardley, Lucy
AU  - Yardley L
AUID- ORCID: https://orcid.org/0000-0002-3853-883X
AD  - Centre for Community and Clinical Applications of Health Psychology, University
      of Southampton, Southampton, United Kingdom.
AD  - School of Psychological Science, University of Bristol, Bristol, United Kingdom.
LA  - eng
GR  - MC_UU_00006/6/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12015/4/MRC_/Medical Research Council/United Kingdom
GR  - MR/L023784/2/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20201120
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7718093
OTO - NOTNLM
OT  - dementia
OT  - feasibility studies
OT  - geriatrics
OT  - internet-based intervention
OT  - randomized controlled trial
OT  - telemedicine
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 12:13
PHST- 2020/03/27 00:00 [received]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/11/20 12:13 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - v9i11e18929 [pii]
AID - 10.2196/18929 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 20;9(11):e18929. doi: 10.2196/18929.


PMID- 33215835
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 11
DP  - 2020 Nov
TI  - Promoting ethics across the healthcare sector: what can codes achieve?
PG  - 1333-1338
LID - 10.1111/imj.15051 [doi]
AB  - Over the course of the twentieth century, numerous national and international
      ethics 'codes' have been developed. While such codes serve important substantive 
      and symbolic functions, they can also pose challenges. In this article, we
      discuss these challenges, noting that they fall into four main categories
      relating to conceptual tensions, power imbalances, organisational barriers, and
      threats of exploitation. We illustrate these challenges using examples provided
      from the United Nations Educational Scientific and Cultural Organization (UNESCO)
      Universal Declaration on Bioethics and Human Rights. We emphasise the importance 
      of accountability in the development and maintenance of national and
      international codes and argue that, despite all their challenges, codes provide
      an important common language among otherwise disparate and sometimes adversarial 
      groups, and provide visible and explicit sets of standards that may be invoked by
      community members to criticise and hold powerful bodies to account. This is
      particularly important for practitioners and researchers who belong to
      organisations that are signatories to codes, who can use these codes to both
      guide and justify ethical behaviour in the face of competing organisational,
      professional and political imperatives.
CI  - (c) 2020 Royal Australasian College of Physicians.
FAU - Lipworth, Wendy
AU  - Lipworth W
AUID- ORCID: 0000-0002-0234-657X
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Department of Haematology, Royal North Shore Hospital and Sydney Health Ethics,
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Montgomery, Kathleen
AU  - Montgomery K
AD  - Graduate Division, University of California, Riverside, California, USA.
FAU - Komesaroff, Paul A
AU  - Komesaroff PA
AUID- ORCID: 0000-0002-1360-3375
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne,
      Victoria, Australia.
LA  - eng
GR  - National Health and Medical Research Council (NHMRC) Career Development
      Fellowship [no colon here please]
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
MH  - *Bioethics
MH  - *Health Care Sector
MH  - Human Rights
MH  - Humans
MH  - International Cooperation
MH  - United Nations
OTO - NOTNLM
OT  - *Asia Pacific Economic Cooperative
OT  - *United Nations
OT  - *ethics code
OT  - *organisational ethics
EDAT- 2020/11/21 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/11/20 08:41
PHST- 2020/07/01 00:00 [received]
PHST- 2020/07/19 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/11/20 08:41 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1111/imj.15051 [doi]
PST - ppublish
SO  - Intern Med J. 2020 Nov;50(11):1333-1338. doi: 10.1111/imj.15051.


PMID- 33215602
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 67
IP  - 11
DP  - 2020 Oct 20
TI  - Comparison between temporal and rectal temperature measurement.
LID - A04200270 [pii]
AB  - INTRODUCTION: Various digital thermometers for non-invasive use have been used
      increasingly in Danish hospitals, including the temporal artery thermometer
      (TAT). However, previous studies have concluded that the accuracy of the TAT is
      unsatisfying for paediatric, surgical, cancer and intensive care patients. The
      purpose of this study was to compare the accuracy of the TAT with that of a
      conventional rectal thermometer (REC) within acutely admitted medical patients at
      an emergency department. METHODS: This was a prospective, comparative study. For 
      two months, 381 patients were included. At a maximum interval of seven minutes,
      the temperature was measured first with a temporal artery thermometer and then
      with an REC. The measurements were analysed in a Bland-Altman plot, and the
      sensitivity and specificity of the TAT were calculated. RESULTS: The differences 
      between the TAT and the REC ranged from -1.7 degrees C to 1.7 degrees C. The mean
      of the difference was drawn in the Bland-Altman plot through 0.17 with a standard
      deviation of +/- 0.47. The sensitivity and specificity were calculated to 67% and
      96%, respectively. CONCLUSIONS: Based on this study, we do not recommend the use 
      of the TAT as an alternative to an REC for non-invasive measuring of the body
      temperature in acutely admitted medical patients. FUNDING: All authors received
      honoraria from The Capital Region of Denmark. TRIAL REGISTRATION: Study
      procedures were approved by the local ethical committee and submitted to
      www.clinicaltrials.org (NCT01817881).
CI  - Articles published in the DMJ are "open access". This means that the articles are
      distributed under the terms of the Creative Commons Attribution Non-commercial
      License, which permits any non-commercial use, distribution, and reproduction in 
      any medium, provided the original author(s) and source are credited.
FAU - Nygaard, Hanne
AU  - Nygaard H
AD  - hanne.nygaard@regionh.dk.
FAU - Maschmann, Christian
AU  - Maschmann C
FAU - Ekmann, Anette
AU  - Ekmann A
LA  - eng
SI  - ClinicalTrials.gov/NCT01817881
PT  - Journal Article
DEP - 20201020
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
MH  - *Body Temperature
MH  - Child
MH  - Humans
MH  - Prospective Studies
MH  - Rectum
MH  - Sensitivity and Specificity
MH  - Temperature
MH  - Temporal Arteries
MH  - *Thermometers
EDAT- 2020/11/21 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/20 08:39
PHST- 2020/11/20 08:39 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - A04200270 [pii]
PST - epublish
SO  - Dan Med J. 2020 Oct 20;67(11). pii: A04200270.


PMID- 33215600
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 67
IP  - 11
DP  - 2020 Oct 20
TI  - Osteoporosis after adjuvant treatment for early-stage breast cancer.
LID - A04200223 [pii]
AB  - INTRODUCTION: Adjuvant treatment of early-stage breast cancer has been associated
      with bone loss in randomised trials, but evidence from unselected populations is 
      needed. In a single-center study, we assessed the annual percentage change in
      bone mineral density (BMDt) and risk of osteoporosis from two to five years after
      adjuvant chemotherapy in patients with oestrogen-receptor-positive and
      oestrogen-receptor-negative tumours. METHODS: Dual energy X-ray absorptiometry
      (DXA) was performed in 241 recurrence-free Danish breast cancer patients, among
      whom 157 had a prior DXA scan within two years of chemotherapy ("early"). Linear 
      regression was used to assess BMDt in spine and hip according to age, different
      health-related variables and time since early DXA. RESULTS: Based on 157
      patients, we observed annual decreases in spine BMD of 1.73% (95% confidence
      interval (CI): -2.01--1.44, p less than 0.001) and hip BMD of 1.30% (95% CI:
      -1.51--1.09, p less than 0.001). Patients aged less than 50 years at diagnosis
      had a significant decrease in mean spine BMD of 2.23% (95% CI: -2.78--1.68),
      whereas the decline was more limited in patients aged 50-59 years and patients
      aged 60 years or older with a mean spine BMD of 1.70% (95% CI: -2.07--1.34) and
      0.81% (95% CI: -1.42--0.20), respectively. The results persisted in multivariable
      analyses. Osteoporosis was diagnosed in 9% of patients, all postmenopausal.
      CONCLUSIONS: Adjuvant anthracycline-taxane-based chemotherapy followed by
      endocrine therapy caused bone loss, especially in younger compared with older
      patients with early-stage breast cancer, confirming the results from randomised
      trials. FUNDING: This work was supported by the Region of Southern Denmark (grant
      number 13/7078); the University of Southern Denmark (grant number 00-101-000);
      the Danish Cancer Society (grant number R90-A6210-14-52); the Department of
      Oncology and Department of Endocrinology, Odense University Hospital; and the
      Consultant Council Scholarship, Odense University Hospital. TRIAL REGISTRATION:
      The study was approved by the Ethics Committee in Region of Southern Denmark
      (Project ID S-20140142) and the Danish Data Protection Board (ID 2008-58-0035).
CI  - Articles published in the DMJ are "open access". This means that the articles are
      distributed under the terms of the Creative Commons Attribution Non-commercial
      License, which permits any non-commercial use, distribution, and reproduction in 
      any medium, provided the original author(s) and source are credited.
FAU - Christensen, Carina Orts
AU  - Christensen CO
AD  - Carina.Oerts.Christensen@rsyd.dk.
FAU - Jensen, Maj-Britt
AU  - Jensen MB
FAU - Hermann, Anne Pernille
AU  - Hermann AP
FAU - Ewertz, Marianne
AU  - Ewertz M
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
MH  - Absorptiometry, Photon
MH  - Bone Density
MH  - *Breast Neoplasms/drug therapy
MH  - Chemotherapy, Adjuvant/adverse effects
MH  - Female
MH  - Humans
MH  - Neoplasm Recurrence, Local
MH  - *Osteoporosis/chemically induced/diagnostic imaging
EDAT- 2020/11/21 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/20 08:39
PHST- 2020/11/20 08:39 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - A04200223 [pii]
PST - epublish
SO  - Dan Med J. 2020 Oct 20;67(11). pii: A04200223.


PMID- 33215298
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 2524-4442 (Electronic)
IS  - 2524-4442 (Linking)
VI  - 3
IP  - 1
DP  - 2020 Nov 20
TI  - Modeling of moral decisions with deep learning.
PG  - 27
LID - 10.1186/s42492-020-00063-9 [doi]
AB  - One example of an artificial intelligence ethical dilemma is the autonomous
      vehicle situation presented by Massachusetts Institute of Technology researchers 
      in the Moral Machine Experiment. To solve such dilemmas, the MIT researchers used
      a classic statistical method known as the hierarchical Bayesian (HB) model. This 
      paper builds upon previous work for modeling moral decision making, applies a
      deep learning method to learn human ethics in this context, and compares it to
      the HB approach. These methods were tested to predict moral decisions of
      simulated populations of Moral Machine participants. Overall, test results
      indicate that deep neural networks can be effective in learning the group
      morality of a population through observation, and outperform the Bayesian model
      in the cases of model mismatches.
FAU - Wiedeman, Christopher
AU  - Wiedeman C
AD  - Department of Electrical and Computer Systems Engineering, Rensselaer Polytechnic
      Institute, Troy, NY, USA.
FAU - Wang, Ge
AU  - Wang G
AD  - Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY,
      USA. wangg6@rpi.edu.
FAU - Kruger, Uwe
AU  - Kruger U
AD  - Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Germany
TA  - Vis Comput Ind Biomed Art
JT  - Visual computing for industry, biomedicine, and art
JID - 101759975
PMC - PMC7677418
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Bayesian method
OT  - Deep learning
OT  - Moral machine experiment
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 05:51
PHST- 2020/06/18 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/20 05:51 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - 10.1186/s42492-020-00063-9 [doi]
AID - 10.1186/s42492-020-00063-9 [pii]
PST - epublish
SO  - Vis Comput Ind Biomed Art. 2020 Nov 20;3(1):27. doi: 10.1186/s42492-020-00063-9.


PMID- 33215109
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2633-1462 (Electronic)
IS  - 2633-1462 (Linking)
VI  - 1
IP  - 4
DP  - 2020 Apr
TI  - Arthroplasty information on the internet: quality or quantity?
PG  - 64-73
LID - 10.1302/2633-1462.14.BJO-2020-0006 [doi]
AB  - AIMS: Total joint replacement (TJR) is a high-cost, high-volume procedure that
      impacts patients' quality of life. Informed decisions are important for patients 
      facing TJR. The quality of information provided by websites regarding TJR is
      highly variable. We aimed to measure the quality of TJR information online.
      METHODS: We identified 10,800 websites using 18 TJR-related keywords (conditions 
      and procedures) across the Australian, French, German and Spanish Google search
      engines. We used the Health on the Net (HON) toolbar to evaluate the first 150
      websites downloaded for every keyword in each language. The quality of
      information on websites was inspected, accounting for differences by language and
      tertiles. We also undertook an analysis of English websites to explore types of
      website providers. RESULTS: 'Total joint replacement' had the most results
      returned (150 million websites), and 9% of websites are HON-accredited.
      Differences in information quality were seen across search terms (p < 0.001) and 
      tertiles (p < 0.001), but not between languages (p = 0.226). A larger proportion 
      of HON-accredited websites were seen from keywords in the condition and
      arthroplasty categories. The first tertile contained the highest number of
      HON-accredited websites for the majority of search terms. Government/educational 
      bodies sponsored the majority of websites. CONCLUSION: Clinicians must consider
      the shortage of websites providing validated information, with disparities in
      both number and quality of websites for TJR conditions and procedures. As such,
      the challenge for clinicians is to lead the design of reliable, accurate and
      ethical orthopaedic websites online and direct patients to them. This stands to
      reward both parties greatly.
CI  - (c) 2020 Author(s) et al.
FAU - Davaris, Myles T
AU  - Davaris MT
AD  - Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne,
      Australia.
FAU - Dowsey, Michelle M
AU  - Dowsey MM
AD  - Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne,
      Australia.
FAU - Bunzli, Samantha
AU  - Bunzli S
AD  - Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne,
      Australia.
FAU - Choong, Peter F
AU  - Choong PF
AD  - Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Bone Jt Open
JT  - Bone & joint open
JID - 101770336
PMC - PMC7659687
OTO - NOTNLM
OT  - Arthroplasty
OT  - Internet
OT  - Orthopaedic
OT  - Patient education
OT  - Surgery
OT  - Websites
COIS- ICMJE COI statement: P. Choong declares personal fees paid by Stryker
      Orthopaedics. Depuy Johnson & Johnson, Ziimer, and Kluwer, and grants paid by
      Medacta and Depuy. M. Dowsey declares grants paid by Medacta, National Health &
      Medical Research Council, Australian Research Council, and Pfizer.
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 05:50
PHST- 2020/11/20 05:50 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - 10.1302/2633-1462.14.BJO-2020-0006 [doi]
AID - BJO-1-64 [pii]
PST - epublish
SO  - Bone Jt Open. 2020 Apr 20;1(4):64-73. doi: 10.1302/2633-1462.14.BJO-2020-0006.
      eCollection 2020 Apr.


PMID- 33214762
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201121
IS  - 1364-5021 (Print)
IS  - 1364-5021 (Linking)
VI  - 476
IP  - 2242
DP  - 2020 Oct
TI  - Editorial: citation malpractice.
PG  - 20200746
LID - 10.1098/rspa.2020.0746 [doi]
AB  - At Proceedings of the Royal Society A, something we are always concerned and
      vigilant about is publication malpractice. This editorial examines the background
      to some small changes to our reviewer forms that will help us in identifying
      patterns of worrying behaviour. The importance of this in the context of the
      relationship of science to policy-making and the public perception of science is 
      stressed.
CI  - (c) 2020 The Author(s).
FAU - Lockwood, M
AU  - Lockwood M
AUID- ORCID: 0000-0002-7397-2172
AD  - Department of Meteorology, University of Reading, Reading, UK.
LA  - eng
PT  - Editorial
DEP - 20201021
PL  - England
TA  - Proc Math Phys Eng Sci
JT  - Proceedings. Mathematical, physical, and engineering sciences
JID - 9891746
PMC - PMC7655756
OTO - NOTNLM
OT  - bibliometrics
OT  - citations
OT  - ethics
COIS- I declare I have no competing interest.
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 05:49
PHST- 2020/09/16 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/11/20 05:49 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - 10.1098/rspa.2020.0746 [doi]
AID - rspa20200746 [pii]
PST - ppublish
SO  - Proc Math Phys Eng Sci. 2020 Oct;476(2242):20200746. doi: 10.1098/rspa.2020.0746.
      Epub 2020 Oct 21.


PMID- 33214648
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Nov 19
TI  - Analysis of vitamin D level among asymptomatic and critically ill COVID-19
      patients and its correlation with inflammatory markers.
PG  - 20191
LID - 10.1038/s41598-020-77093-z [doi]
AB  - COVID-19 is characterized by marked variability in clinical severity. Vitamin D
      had recently been reviewed as one of the factors that may affect the severity in 
      COVID-19. The objective of current study is to analyze the vitamin D level in
      COVID-19 patients and its impact on the disease severity. After approval from
      Ethics Committee, M.L.B Medical College the current study was undertaken as
      continuous prospective observational study of 6 weeks. Participants were COVID-19
      patients of age group 30-60 years admitted during the study period of 6 weeks.
      Study included either asymptomatic COVID-19 patients (Group A) or severely ill
      patients requiring ICU admission (Group B). Serum concentration of 25 (OH)D, were
      measured along with serum IL-6; TNFalpha and serum ferritin. Standard statistical
      analysis was performed to analyze the differences. Current Study enrolled 154
      patients, 91 in Group A and 63 patients in Group B. The mean level of vitamin D
      (in ng/mL) was 27.89 +/- 6.21 in Group A and 14.35 +/- 5.79 in Group B, the
      difference was highly significant. The prevalence of vitamin D deficiency was
      32.96% and 96.82% respectively in Group A and Group B. Out of total 154 patients,
      90 patients were found to be deficient in vitamin D (Group A: 29; Group B: 61).
      Serum level of inflammatory markers was found to be higher in vitamin D deficient
      COVID-19 patients viz. IL-6 level (in pg/mL) 19.34 +/- 6.17 vs 12.18 +/- 4.29;
      Serum ferritin 319.17 +/- 38.21 ng/mL vs 186.83 +/- 20.18 ng/mL; TNFalpha level
      (in pg/mL) 13.26 +/- 5.64 vs 11.87 +/- 3.15. The fatality rate was high in
      vitamin D deficient (21% vs 3.1%). Vitamin D level is markedly low in severe
      COVID-19 patients. Inflammatory response is high in vitamin D deficient COVID-19 
      patients. This all translates into increased mortality in vitamin D deficient
      COVID-19 patients. As per the flexible approach in the current COVID-19 pandemic 
      authors recommend mass administration of vitamin D supplements to population at
      risk for COVID-19.
FAU - Jain, Anshul
AU  - Jain A
AD  - Department of Anaesthesiology, M.L.B Medical College, Jhansi, India.
FAU - Chaurasia, Rachna
AU  - Chaurasia R
AD  - Department of Radiodiagnosis, M.L.B Medical College, Jhansi, India.
FAU - Sengar, Narendra Singh
AU  - Sengar NS
AD  - Department of Nephrology, M.L.B Medical College, Jhansi, India.
FAU - Singh, Mayank
AU  - Singh M
AD  - Department of Pathology, M.L.B Medical College, Jhansi, India.
      drmayanksinghkgmu@gmail.com.
FAU - Mahor, Sachin
AU  - Mahor S
AD  - Department of Radiotherapy, COVID-19 Block M.L.B Medical College, Jhansi, India.
FAU - Narain, Sumit
AU  - Narain S
AD  - Department of Pathology, M.L.B Medical College, Jhansi, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201119
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 1406-16-2 (Vitamin D)
RN  - 9007-73-2 (Ferritins)
SB  - IM
MH  - Adult
MH  - Asymptomatic Diseases/epidemiology
MH  - Biomarkers/blood
MH  - COVID-19/*blood/epidemiology/pathology
MH  - Critical Illness/epidemiology
MH  - Female
MH  - Ferritins/blood
MH  - Humans
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Vitamin D/*blood
MH  - Vitamin D Deficiency/blood/*epidemiology
PMC - PMC7677378
EDAT- 2020/11/21 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/20 05:47
PHST- 2020/08/21 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/11/20 05:47 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-77093-z [doi]
AID - 10.1038/s41598-020-77093-z [pii]
PST - epublish
SO  - Sci Rep. 2020 Nov 19;10(1):20191. doi: 10.1038/s41598-020-77093-z.


PMID- 33213591
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 1469-7629 (Electronic)
IS  - 0022-0299 (Linking)
VI  - 87
IP  - S1
DP  - 2020 Aug
TI  - Refining consumer attitudes to milk and dairy product purchase and use to reduce 
      food waste and improve animal welfare on-farm.
PG  - 9-12
LID - 10.1017/S0022029920000631 [doi]
AB  - This Research Reflection raises awareness of the need to broaden perspectives and
      levels of multidisciplinary and interdisciplinary approaches when considering
      on-farm dairy cattle welfare. It starts with a brief overview of current animal
      welfare issues on dairy farms and how they are perceived by different
      stakeholders. Some divergences in points of view are discussed in more detail and
      the first steps in networking are mentioned. Particular emphasis is given to both
      milk and dairy product waste in industrialized countries and the potential
      effects of its reduction on changes in the production system. The needs for a
      quantification of such quota and retailer involvement are also analyzed from the 
      perspective that on-farm animal welfare is directly linked to the amount of milk 
      that might be removed from the food chain by adoption of welfare-friendly
      management, such as cow-calf systems.
FAU - Brscic, Marta
AU  - Brscic M
AD  - Department of Animal Medicine, Production and Health (MAPS), University of
      Padova, Viale dell'Universita 16, 35020 Legnaro (PD), Italy.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - England
TA  - J Dairy Res
JT  - The Journal of dairy research
JID - 2985125R
SB  - IM
MH  - Animal Welfare
MH  - Animals
MH  - *Attitude
MH  - Awareness
MH  - Cattle
MH  - *Consumer Behavior
MH  - Dairy Products/*economics
MH  - Dairying/economics/ethics/*methods
MH  - Female
MH  - Milk/*economics
MH  - Sustainable Development
OTO - NOTNLM
OT  - Animal welfare
OT  - calf at foot
OT  - conscious food purchase
OT  - dairy product waste
OT  - ethical milk
EDAT- 2020/11/21 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/20 05:30
PHST- 2020/11/20 05:30 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1017/S0022029920000631 [doi]
AID - S0022029920000631 [pii]
PST - ppublish
SO  - J Dairy Res. 2020 Aug;87(S1):9-12. doi: 10.1017/S0022029920000631. Epub 2020 Jul 
      30.


PMID- 33213562
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2056-4694 (Print)
IS  - 2056-4694 (Linking)
VI  - 44
IP  - 6
DP  - 2020 Dec
TI  - Disclosing mental illness: a doctor's dilemma.
PG  - 227-230
LID - 10.1192/bjb.2020.25 [doi]
AB  - SUMMARY: There is increasing evidence that doctors have high levels of mental
      illness, and there are concerns that, for some, this may be exacerbated by their 
      working environment. It can be difficult for doctors to disclose mental illness, 
      either to senior or junior colleagues, and perhaps even harder to know what, if
      anything, to say to patients. Many doctors may be unsure of their position as
      regards disclosing to governing bodies; others may disclose widely on social
      media. I am a psychiatrist who also has a significant mental illness, and refer
      both to my personal experience and the literature to explore some of these
      issues.
FAU - Lawrence, Rebecca
AU  - Lawrence R
AUID- ORCID: https://orcid.org/0000-0002-6433-7249
AD  - Ritson Clinic, Royal Edinburgh Hospital, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJPsych Bull
JT  - BJPsych bulletin
JID - 101650950
PMC - PMC7684779
OTO - NOTNLM
OT  - Stigma and discrimination
OT  - education and training
OT  - ethics
OT  - physician health
OT  - supervision
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 05:30
PHST- 2020/11/20 05:30 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - 10.1192/bjb.2020.25 [doi]
AID - S205646942000025X [pii]
PST - ppublish
SO  - BJPsych Bull. 2020 Dec;44(6):227-230. doi: 10.1192/bjb.2020.25.


PMID- 33213560
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220803
IS  - 2056-4694 (Print)
IS  - 2056-4694 (Linking)
VI  - 44
IP  - 6
DP  - 2020 Dec
TI  - A visual step-by-step guide for clinicians to use video consultations in mental
      health services: NHS examples of real-time practice in times of normal and
      pandemic healthcare delivery.
PG  - 277-284
LID - 10.1192/bjb.2020.71 [doi]
AB  - Despite the increasingly widespread use of video consultations, there are very
      few documented descriptions of how to set up and implement video consultations in
      real-time practice. This step-by-step guide will describe the set-up process
      based on the authors' experience of two real-time National Health Service (NHS)
      examples: a single health board use (delivered in normal time), and an All-Wales 
      National Video Consultation Service roll-out (delivered during an emergency
      pandemic as part of the COVID-19 response). This paper provides a simple visual
      step-by-step guide for using telepsychiatry via the remote use of video
      consultations in mental health services, and outlines the mandatory steps to
      achieving a safe, successful and sustainable use of video consultations in the
      NHS by ensuring that video consultations fit into existing and new NHS workflow
      systems and adhere to legal and ethical guidelines.
FAU - Johns, Gemma
AU  - Johns G
AUID- ORCID: 0000-0002-3983-362X
AD  - Aneurin Bevan University Health Board, UK.
FAU - Tan, Jacinta
AU  - Tan J
AD  - Aneurin Bevan University Health Board, UK.
FAU - Burhouse, Anna
AU  - Burhouse A
AD  - Northumbria Healthcare NHS Foundation Trust, UK.
FAU - Ogonovsky, Mike
AU  - Ogonovsky M
AD  - Aneurin Bevan University Health Board, UK.
FAU - Rees, Catrin
AU  - Rees C
AD  - Life Sciences Hub, Welsh Government, UK.
FAU - Ahuja, Alka
AU  - Ahuja A
AD  - Aneurin Bevan University Health Board, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJPsych Bull
JT  - BJPsych bulletin
JID - 101650950
EIN - BJPsych Bull. 2022 Jun;46(3):192-193. PMID: 33323148
PMC - PMC7360952
OTO - NOTNLM
OT  - *COVID-19
OT  - *Video consultations
OT  - *digital health
OT  - *mental health
OT  - *telepsychiatry
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
CRDT- 2020/11/20 05:30
PHST- 2020/11/20 05:30 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
AID - 10.1192/bjb.2020.71 [doi]
AID - S2056469420000716 [pii]
PST - ppublish
SO  - BJPsych Bull. 2020 Dec;44(6):277-284. doi: 10.1192/bjb.2020.71.


PMID- 33213454
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 19
TI  - Oxygen desaturation during flexible bronchoscopy with propofol sedation is
      associated with sleep apnea: the PROSA-Study.
PG  - 306
LID - 10.1186/s12931-020-01573-z [doi]
AB  - BACKGROUND: Obstructive sleep apnea (OSA) is characterized by repetitive episodes
      of complete or partial obstruction of the upper airways during sleep. Conscious
      sedation for flexible bronchoscopy (FB) places patients in a sleep-like
      condition. We hypothesize that oxygen desaturation during flexible bronchoscopy
      may help to detect undiagnosed sleep apnea. METHODS: Single-centre,
      investigator-initiated and driven study including consecutive patients undergoing
      FB for clinical indication. Patients completed the Epworth Sleepiness Scale
      (ESS), Lausanne NoSAS score, STOP-BANG questionnaire and the Berlin questionnaire
      and underwent polygraphy within 7 days of FB. FB was performed under conscious
      sedation with propofol. Oxygen desaturation during bronchoscopy was measured with
      continuous monitoring of peripheral oxygen saturation with ixTrend (ixellence
      GmbH, Germany). RESULTS: 145 patients were included in the study, 62% were male, 
      and the average age was 65.8 +/- 1.1 years. The vast majority of patients (n =
      131, 90%) proved to fulfill OSA criteria based on polygraphy results: 52/131
      patients (40%) had mild sleep apnea, 49/131 patients (37%) moderate sleep apnea
      and 30/131 patients (23%) severe sleep apnea. Patients with no oxygen
      desaturation had a significantly lower apnea-hypopnea index than patients with
      oxygen desaturation during bronchoscopy (AHI 11.94/h vs 21.02/h, p = 0.011). This
      association remained significant when adjusting for the duration of bronchoscopy 
      and propofol dose (p = 0.023; 95% CI 1.382; 18.243) but did not hold when also
      adjusting for age and BMI. CONCLUSION: The severity of sleep apnea was associated
      to oxygen desaturation during flexible bronchoscopy under conscious sedation.
      Patients with oxygen desaturation during bronchoscopy might be considered for
      sleep apnea screening. TRIAL REGISTRATION: The Study was approved by the Ethics
      Committee northwest/central Switzerland, EKNZ (EK 16/13) and was carried out
      according to the Declaration of Helsinki and Good Clinical Practice guidelines.
      Due to its observational character, the study did not require registration at a
      clinical trial registry.
FAU - Darie, Andrei M
AU  - Darie AM
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Schumann, Desiree M
AU  - Schumann DM
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Laures, Marco
AU  - Laures M
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Strobel, Werner
AU  - Strobel W
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Jahn, Kathleen
AU  - Jahn K
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Pflimlin, Eric
AU  - Pflimlin E
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Tamm, Michael
AU  - Tamm M
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland.
FAU - Stolz, Daiana
AU  - Stolz D
AD  - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital
      of Basel, Petersgraben 4, 4031, Basel, Switzerland. daiana.stolz@usb.ch.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201119
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - 0 (Hypnotics and Sedatives)
RN  - S88TT14065 (Oxygen)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Aged
MH  - Blood Gas Monitoring, Transcutaneous/methods
MH  - Bronchoscopy/adverse effects/*methods
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Hypnotics and Sedatives/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Oxygen/*blood
MH  - Propofol/*administration & dosage/adverse effects
MH  - Prospective Studies
MH  - Sleep Apnea, Obstructive/*blood/*diagnosis/epidemiology
MH  - Switzerland/epidemiology
PMC - PMC7678046
OTO - NOTNLM
OT  - Bronchoscopy
OT  - Hypoxia
OT  - Sleep apnea
OT  - Tonometry
EDAT- 2020/11/21 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/11/20 05:29
PHST- 2020/08/17 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/20 05:29 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - 10.1186/s12931-020-01573-z [doi]
AID - 10.1186/s12931-020-01573-z [pii]
PST - epublish
SO  - Respir Res. 2020 Nov 19;21(1):306. doi: 10.1186/s12931-020-01573-z.


PMID- 33213452
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1743-0003 (Electronic)
IS  - 1743-0003 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Nov 19
TI  - A novel use of inertial sensors to measure the craniocervical flexion range of
      motion associated to the craniocervical flexion test: an observational study.
PG  - 152
LID - 10.1186/s12984-020-00784-1 [doi]
AB  - BACKGROUND: The craniocervical flexion test (CCFT) is recommended when examining 
      patients with neck pain related conditions and as a deep cervical retraining
      exercise option. During the execution of the CCFT the examiner should visually
      assess that the amount of craniocervical flexion range of motion (ROM)
      progressively increases. However, this task is very subjective. The use of
      inertial wearable sensors may be a user-friendly option to measure and
      objectively monitor the ROM. The objectives of our study were (1) to measure
      craniocervical flexion range of motion (ROM) associated with each stage of the
      CCFT using a wearable inertial sensor and to determine the reliability of the
      measurements and (2) to determine craniocervical flexion ROM targets associated
      with each stage of the CCFT to standardize their use for assessment and training 
      of the deep cervical flexor (DCF) muscles. METHODS: Adults from a university
      community able to successfully perform the CCFT participated in this study. Two
      independent examiners evaluated the CCFT in two separate sessions. During the
      CCFT, a small wireless inertial sensor was adhered to the centre of the forehead 
      to provide real-time monitoring and to record craniocervical flexion ROM. The
      intra- and inter-rater reliability of the assessment of craniocervical ROM was
      calculated. This study was approved by the Research Ethics Committee of CEU San
      Pablo University (236/17/08). RESULTS: Fifty-six participants (18 males, 23
      females; mean [SD] age, 21.8 [3.45] years) were included in the study and
      successfully completed the study protocol. All interclass correlation coefficient
      (ICC) values indicated good or excellent reliability of the assessment of
      craniocervical ROM using a wearable inertial sensor. There was high variability
      between subjects on the amount of craniocervical ROM necessary to achieve each
      stage of the CCFT. CONCLUSIONS: The use of inertial sensors is a reliable method 
      to measure the craniocervical flexion ROM associated with the CCFT. The great
      variability in the ROM limits the possibility to standardize a set of targets of 
      craniocervical flexion ROM equivalent to each of the pressure targets of the
      pressure biofeedback unit.
FAU - Perez-Fernandez, Tomas
AU  - Perez-Fernandez T
AD  - Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU,
      CEU Universities, Madrid, Spain.
FAU - Armijo-Olivo, Susan
AU  - Armijo-Olivo S
AD  - Faculty of Business and Social Sciences, University of Applied Sciences,
      Caprivistr, 30A, 49076, Osnabruck, Germany.
AD  - Department of Physical Therapy, Faculty of Rehabilitation Medicine, University of
      Alberta, 3-48 Corbett Hall, Edmonton, AB, Canada.
FAU - Liebana, Sonia
AU  - Liebana S
AD  - Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU,
      CEU Universities, Madrid, Spain.
FAU - de la Torre Ortiz, Pablo Jose
AU  - de la Torre Ortiz PJ
AD  - Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU,
      CEU Universities, Madrid, Spain.
FAU - Fernandez-Carnero, Josue
AU  - Fernandez-Carnero J
AD  - Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical
      Medicine, Rey Juan Carlos University, Madrid, Spain.
AD  - La Paz Hospital Institute for Health Research, IdiPAZ, Madrid, Spain.
AD  - Grupo Multidisciplinar de Investigacion y Tratamiento del Dolor, Grupo de
      Excelencia Investigadora URJC-Banco de Santander, Madrid, Spain.
FAU - Raya, Rafael
AU  - Raya R
AD  - Departmento de Ingenieria de Sistemas de Informacion, Universidad San Pablo-CEU, 
      CEU Universities, Madrid, Spain.
AD  - Werium Solutions, Arganda del Rey, 28500, Madrid, Spain.
FAU - Martin-Pintado-Zugasti, Aitor
AU  - Martin-Pintado-Zugasti A
AUID- ORCID: 0000-0003-3945-8222
AD  - Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU,
      CEU Universities, Madrid, Spain. martinpintado.a@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - J Neuroeng Rehabil
JT  - Journal of neuroengineering and rehabilitation
JID - 101232233
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Neck Muscles/*physiology
MH  - Neck Pain/*diagnosis/*rehabilitation
MH  - Physical Examination/*instrumentation/methods
MH  - Range of Motion, Articular
MH  - Reproducibility of Results
MH  - *Wearable Electronic Devices
MH  - Young Adult
PMC - PMC7678052
OTO - NOTNLM
OT  - *Exercise
OT  - *Headache
OT  - *Movement disorders
OT  - *Neck muscles
OT  - *Neck pain
OT  - *Reproducibility
OT  - *Temporomandibular joint disorders
EDAT- 2020/11/21 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/11/20 05:29
PHST- 2020/07/23 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/20 05:29 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
AID - 10.1186/s12984-020-00784-1 [doi]
AID - 10.1186/s12984-020-00784-1 [pii]
PST - epublish
SO  - J Neuroeng Rehabil. 2020 Nov 19;17(1):152. doi: 10.1186/s12984-020-00784-1.


PMID- 33213445
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 19
TI  - Intensive and pharmacological care in times of COVID-19: A "special ethics" for
      emergency?
PG  - 117
LID - 10.1186/s12910-020-00562-7 [doi]
AB  - BACKGROUND: The Authors have laid out an analysis of Italian COVID-19 confirmed
      data and fatality rates, pointing out how a dearth of health care resources in
      northern regions has resulted in hard, ethically challenging decisions in terms
      of granting patient access to intensive care units (ICU). MAIN TEXT: Having to
      make such decisions certainly entails substantial difficulties, and that has led 
      many health care professional to seek ethical guidance. The Italian Society of
      Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted
      to meet that growing need by a set of recommendations, applying "clinical
      soundness" as a beacon standard; that approach tends to prioritize patients with 
      higher life expectancy, which could be characterized as a "moderately
      utilitarian" approach. Yet, such a selection has engendered daunting ethical
      quandaries. The authors believe it can only be warranted and acceptable if rooted
      in a transparent decision-making process and verifiable, reviewed criteria.
      Moreover, the authors have stressed how clinical experimentation in a pandemic
      setting is a subtext of great interest from an ethical perspective. In Italy, no 
      drug therapy and trials were undertaken for COVID-19 patients for a rather long
      period of time. When the epidemic was already circulating, an intervention proved
      necessary on the system of administrative procedures, aimed at expediting the
      authorization and validation of protocols, then bogged down by bureaucracy. A new
      system has since been instituted by a government decree that was signed about one
      month after the first Covid-19 case was officially recorded in the country. Such 
      a swift implementation, which took just a few weeks, is noteworthy and proves
      that clinical trials can be initiated in a timely fashion, even with a pandemic
      unfolding. The concerted, action of supportive care and RCTs is the only way to
      attain effective forms of treatments for COVID-19 and any other future outbreak. 
      CONCLUSIONS: The authors have arrived at the conclusion that the most effective
      and ethically sound response on the part of any national health care system would
      be to adequately reconfigure its organizational mechanisms, by making clinical
      trials and all related administrative procedures consistent with the current
      state of emergency.
FAU - Marinelli, Enrico
AU  - Marinelli E
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome, Italy.
FAU - Busardo, Francesco Paolo
AU  - Busardo FP
AD  - Department of Excellence of Biomedical Sciences and Public Health, University
      Politecnica delle Marche, Ancona, Italy. fra.busardo@libero.it.
FAU - Zaami, Simona
AU  - Zaami S
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Attitude of Health Personnel
MH  - COVID-19/*epidemiology
MH  - Critical Illness/epidemiology
MH  - Emergency Service, Hospital/*ethics
MH  - *Ethics, Medical
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Italy
PMC - PMC7675378
OTO - NOTNLM
OT  - *COVID-19
OT  - *Emergency
OT  - *Ethics
EDAT- 2020/11/21 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/20 05:29
PHST- 2020/05/31 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/20 05:29 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12910-020-00562-7 [doi]
AID - 10.1186/s12910-020-00562-7 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 19;21(1):117. doi: 10.1186/s12910-020-00562-7.


PMID- 33213433
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 19
TI  - "Who is watching the watchdog?": ethical perspectives of sharing health-related
      data for precision medicine in Singapore.
PG  - 118
LID - 10.1186/s12910-020-00561-8 [doi]
AB  - BACKGROUND: We aimed to examine the ethical concerns Singaporeans have about
      sharing health-data for precision medicine (PM) and identify suggestions for
      governance strategies. Just as Asian genomes are under-represented in PM, the
      views of Asian populations about the risks and benefits of data sharing are
      under-represented in prior attitudinal research. METHODS: We conducted seven
      focus groups with 62 participants in Singapore from May to July 2019. They were
      conducted in three languages (English, Mandarin and Malay) and analysed with
      qualitative content and thematic analysis. RESULTS: Four key themes emerged:
      nuanced understandings of data security and data sensitivity; trade-offs between 
      data protection and research benefits; trust (and distrust) in the public and
      private sectors; and governance and control options. Participants were aware of
      the inherent risks associated with data sharing for research. Participants
      expressed conditional support for data sharing, including genomic sequence data
      and information contained within electronic medical records. This support
      included sharing data with researchers from universities and healthcare
      institutions, both in Singapore and overseas. Support was conditional on the
      perceived social value of the research and appropriate de-identification and data
      security processes. Participants suggested that a data sharing oversight body
      would help strengthen public trust and comfort in data research for PM in
      Singapore. CONCLUSION: Maintenance of public trust in data security systems and
      governance regimes can enhance participation in PM and data sharing for research.
      Contrary to themes in much prior research, participants demonstrated a
      sophisticated understanding of the inherent risks of data sharing, analysed
      trade-offs between risks and potential benefits of PM, and often adopted an
      international perspective.
FAU - Lysaght, Tamra
AU  - Lysaght T
AUID- ORCID: 0000-0002-7125-4206
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore. tlysaght@nus.edu.sg.
FAU - Ballantyne, Angela
AU  - Ballantyne A
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
AD  - Department of Primary Health Care and General Practice, University of Otago,
      Dunedin, New Zealand.
FAU - Xafis, Vicki
AU  - Xafis V
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
FAU - Ong, Serene
AU  - Ong S
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
FAU - Schaefer, Gerald Owen
AU  - Schaefer GO
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore, Singapore.
FAU - Ling, Jeffrey Min Than
AU  - Ling JMT
AD  - Faculty of Science, National University of Singapore, Singapore, Singapore.
FAU - Newson, Ainsley J
AU  - Newson AJ
AD  - Sydney Health Ethics, Faculty of Medicine and Health, Sydney School of Public
      Health, University of Sydney, Camperdown, Australia.
FAU - Khor, Ing Wei
AU  - Khor IW
AD  - Department of Medicine,Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore, Singapore.
FAU - Tai, E Shyong
AU  - Tai ES
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore, Singapore.
AD  - Duke-National University of Singapore Graduate Medical School, Singapore,
      Singapore.
LA  - eng
GR  - MOE2017-SSRTG-028/Ministry of Education - Singapore/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Humans
MH  - *Information Dissemination
MH  - *Precision Medicine
MH  - Qualitative Research
MH  - Singapore
MH  - Trust
PMC - PMC7678103
OTO - NOTNLM
OT  - *Bioethics
OT  - *Data sharing
OT  - *Governance
OT  - *Precision medicine
OT  - *Public attitudes
OT  - *Public trust
OT  - *Qualitative research
OT  - *Singapore
EDAT- 2020/11/21 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/20 05:29
PHST- 2020/04/29 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/20 05:29 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00561-8 [doi]
AID - 10.1186/s12910-020-00561-8 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 19;21(1):118. doi: 10.1186/s12910-020-00561-8.


PMID- 33213202
OWN - NLM
STAT- Publisher
LR  - 20220418
IS  - 1942-7522 (Electronic)
IS  - 0145-5613 (Linking)
DP  - 2020 Nov 20
TI  - Vestibular Function in Psoriasis Patients.
PG  - 145561320970683
LID - 10.1177/0145561320970683 [doi]
AB  - INTRODUCTION: Psoriasis is an inflammatory skin disease that is characterized by 
      T-cell-mediated hyperproliferation of the keratinocytes. It develops through
      immune-mediated mechanisms and is defined as an immune-mediated inflammatory
      disease. The inner ear is susceptible to inflammatory attacks, and vertigo and
      dizziness can occur as a complication. There is little information about
      psoriasis and the vestibular system. OBJECTIVE: This study aimed to investigate
      the cervical vestibular-evoked myogenic potential (cVEMP) results of psoriasis
      patients and the effect of psoriasis on the vestibular system. MATERIALS AND
      METHODS: Randomly selected and included in the study were patients who had been
      admitted to the Dermatology Outpatient Clinic of the Afyon Kocatepe University
      Medical Faculty, between November 15, 2017, and March 15, 2018, with the
      diagnosis of psoriasis, in addition to a healthy control group. This research was
      designed as cross-sectional study. Ethics committee permission was received. Both
      cVEMP and distortion product otoacoustic emission (DPOAE) tests were administered
      to all of the participants. Values were compared between the control group and
      psoriasis patients. RESULTS: The study included 43 psoriasis patients and 40
      controls. The duration of treatment of the patients and the drugs that they were 
      using were noted. The psoriasis patients had lower p13-n23 amplitude differences 
      in their cVEMP tests (P < .05). These patients also had lower signal to noise
      ratio values, at 4 and 6 kHz, on their DPOAE tests (P < .05). CONCLUSION:
      Psoriasis is an immune-mediated inflammatory disease that can be associated with 
      vestibulocochlear dysfunction.
FAU - Kinar, Abdullah
AU  - Kinar A
AUID- ORCID: https://orcid.org/0000-0002-2968-4165
AD  - Department of Ear, Nose, and Throat Head and Neck Diseases, 53002Afyonkarahisar
      State Hospital, Afyonkarahisar, Turkey.
FAU - Bucak, Abdulkadir
AU  - Bucak A
AD  - Department of Ear, Nose, and Throat Head and Neck Diseases, 53002Afyonkarahisar
      Health Sciences University School of Medicine, Afyonkarahisar, Turkey.
FAU - Ulu, Sahin
AU  - Ulu S
AUID- ORCID: https://orcid.org/0000-0003-0193-1942
AD  - Department of Ear, Nose, and Throat Head and Neck Diseases, 53002Afyonkarahisar
      Health Sciences University School of Medicine, Afyonkarahisar, Turkey.
FAU - Duman, Nilay
AU  - Duman N
AD  - Department of Dermatology, 53002Afyonkarahisar Health Sciences University School 
      of Medicine, Afyonkarahisar, Turkey.
FAU - Bastug, Nur Betul
AU  - Bastug NB
AD  - Department of Dermatology, 53002Afyonkarahisar Health Sciences University School 
      of Medicine, Afyonkarahisar, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - United States
TA  - Ear Nose Throat J
JT  - Ear, nose, & throat journal
JID - 7701817
SB  - IM
OTO - NOTNLM
OT  - cVEMP
OT  - inflammation
OT  - psoriasis
OT  - vestibular
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/20 05:27
PHST- 2020/11/20 05:27 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - 10.1177/0145561320970683 [doi]
PST - aheadofprint
SO  - Ear Nose Throat J. 2020 Nov 20:145561320970683. doi: 10.1177/0145561320970683.


PMID- 33145010
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Stage 2 Registered Report: How subtle linguistic cues prevent unethical
      behaviors.
PG  - 996
LID - 10.12688/f1000research.25573.2 [doi]
AB  - Background: Differences in descriptions can influence people's evaluations and
      behaviors. A previous study by Bryan and colleagues suggested that subtle
      linguistic differences in ethical reminders can differentially prevent readers'
      unethical behavior. The present study tried to replicate the previous finding in 
      the Japanese context (Experiment 1); additionally, we explored the influence of
      unfamiliar Japanese instruction words that captured participants' attention
      (Experiment 2). Methods: In two online experiments, participants were asked to
      make 10 coin-tosses and report the number of "heads" results, which would
      indicate the amount of money that they could earn. In Experiment 1, we analyzed
      the difference in the number of "heads" results as reported by 768 participants
      under three conditions with different instructions ("Don't cheat" vs. "Don't be a
      cheater" vs. baseline as a control). In Experiment 2, we conducted an extended
      experiment with an additional task in which more attention was directed toward
      the text. Results: In Experiment 1, we successfully replicated the results of the
      original experiment. The results of Experiment 2 showed no evidence that the
      results in Experiment 1 were influenced by attentional factors. Conclusions: In
      conclusion, the results of the present study supported the hypothesis that
      self-identity-related words of moral reminder curb unethical behaviors more
      effectively. Stage 1 report: https://doi.org/10.12688/f1000research.20183.4.
CI  - Copyright: (c) 2020 Guo W et al.
FAU - Guo, Wen
AU  - Guo W
AUID- ORCID: 0000-0002-5544-0033
AD  - Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan.
FAU - Liu, Huanxu
AU  - Liu H
AUID- ORCID: 0000-0001-7078-5956
AD  - Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan.
FAU - Yang, Jingwen
AU  - Yang J
AUID- ORCID: 0000-0002-6050-656X
AD  - Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan.
FAU - Mo, Yuqi
AU  - Mo Y
AD  - Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan.
FAU - Zhong, Can
AU  - Zhong C
AD  - Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan.
FAU - Yamada, Yuki
AU  - Yamada Y
AUID- ORCID: 0000-0003-1431-568X
AD  - Faculty of Arts and Science, Kyushu University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200818
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - *Cues
MH  - Deception
MH  - Linguistics
MH  - *Morals
PMC - PMC7590892
OTO - NOTNLM
OT  - *attention
OT  - *cheating
OT  - *labeling
OT  - *moral
OT  - *persuasion
OT  - *self construal
COIS- No competing interests were disclosed.
EDAT- 2020/11/21 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/11/20 05:49
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/20 05:49 [entrez]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.12688/f1000research.25573.2 [doi]
PST - epublish
SO  - F1000Res. 2020 Aug 18;9:996. doi: 10.12688/f1000research.25573.2. eCollection
      2020.


PMID- 33212557
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1671-0274 (Print)
IS  - 1671-0274 (Linking)
VI  - 23
IP  - 11
DP  - 2020 Nov 25
TI  - [Effect of open-lung ventilation strategy on oxygenation-impairment during
      laparoscopic colorectal cancer resection].
PG  - 1081-1087
LID - 10.3760/cma.j.issn.441530-20191209-00507 [doi]
AB  - Objective: After general anesthesia and mechanical ventilation for laparoscopic
      colorectal cancer resection, about 90% of patients would have different degrees
      of atelectasis. Authors speculated that an open-lung strategy (OLS) comprising
      moderate positive end-expiratory pressure (PEEP) and intermittent recruitment
      maneuvers (RM) can reduce atelectrauma and thus reduce the incidence of
      oxygenation-impairment during low-tidal-volume ventilation for laparoscopic
      colorectal cancer resection. The purpose of this study was to verify this
      hypothesis and provide a better intraoperative ventilation scheme for
      laparoscopic colorectal cancer resection. Methods: This was a prospectively
      randomized controlled clinical trial which was approved by the Ethics Committee
      of the Sixth Affiliated Hospital, Sun Yat-sen University (2017ZSLYEC-002), and
      registered at the ClinicalTrials.gov (NCT03160144). From January to July 2017,
      patients who underwent laparoscopic colorectal cancer resection, with age > 40
      years, estimated pneumoperitoneum time >/= 1.5 h, pulse oxygen saturation >/=
      92%, and risk grade for postoperative pulmonary complications >/= 2 were
      prospectively enrolled. The patients with American Society of Anesthesiologists
      physical status >/= IV, body mass index >/= 30 kg/m(2), pneumonia, acute
      respiratory failure or sepsis within 1 month, severe chronic obstructive
      pulmonary disease, pulmonary bullae and progressive neuromuscular diseases, and
      those participating in other interventional clinical trials were excluded. The
      enrolled patients were randomly assigned (1:1) to the OLS group (with a PEEP of
      6-8 cm H(2)O and intermittent RM), and the NOLS group (without using PEEP and
      RM). Partial pressure of arterial oxygen (PaO(2)) /fraction of inspired oxygen
      (FiO(2)) and shunt fraction (Q(S)/Q(T)) were calculated via arterial and central 
      venous blood gas analysis performed at 0.5 h (T(1)), 1.5 h (T(2)) after
      pneumoperitoneum induction and at 20 min after admission to the recovery room.
      Driving pressure immediately before pneumoperitoneum induction (T(0)) and at T(2)
      were calculated via monitoring data. The primary outcome was
      oxygenation-impairment (PaO(2)/FiO(2) </= 300 mmHg) during mechanical
      ventilation. Results: In each group, 48 patients under general anesthesia and
      low-tidal-volume ventilation were included in the final analysis. During
      ventilation, the oxygenation-impairment occurred in 7 patients (14.6%) of OLS
      group and in 17 patients (35.4%) of NOLS group, whose difference was
      statistically significant between two groups (chi(2)=5.556, RR=0.31, 95%CI: 0.12 
      to 0.84, P=0.033). During ventilation, the patients in the OLS group had higher
      PaO(2)/FiO(2) [T(1): (427+/-103) mmHg vs. (366+/-109) mmHg, t=-2.826, P=0.006;
      T(2): (453+/-103) mmHg vs. (388+/-122) mmHg, t=-2.739, P=0.007], lower Q(S)/Q(T) 
      [ T(1): (9.2+/-6.5) % vs. (12.6+/-7.7) %, t=2.322, P=0.022; T(2): (7.0+/-5.8)%
      vs.(10.9+/-9.2)%, t=2.408, P=0.019], and lower driving pressure [T(0): (6+/-3) cm
      H(2)O vs. (10+/-2) cm H(2)O, t=7.421, P<0.001; T(2): (13+/-3) cm H(2)O vs.
      (17+/-4) cm H(2)O, t=5.417, P<0.001] than those in the NOLS group, with
      stratistical differences in all comparisons. In recovery room, though
      PaO(2)/FiO(2) [(70.3+/-9.4) mmHg vs. (66.8+/-9.4) mmHg, P=0.082] was still higher
      and Q(S)/Q(T) [(18.6+/-8.3)% vs. (21.8+/-8.4)%, P=0.070] was still lower in the
      OLS group as compared to the NOLS group, the differences were not statistically
      significant (both P>0.05). Conclusion: The application of such an OLS during
      low-tidal-volume ventilation can greatly reduce the incidence of
      oxygenation-impairment in laparoscopic colorectal cancer resection, and such
      effect may last to the period of emergence from anesthesia.
FAU - Li, H
AU  - Li H
AD  - Department of Anesthesiology, the Sixth Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, Guangdong 510655, China.
FAU - Guo, J
AU  - Guo J
AD  - Department of Anesthesiology, the Sixth Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, Guangdong 510655, China.
FAU - Wang, K
AU  - Wang K
AD  - Department of Anesthesiology, the Sixth Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, Guangdong 510655, China.
FAU - Zhang, N R
AU  - Zhang NR
AD  - Department of Anesthesiology, the Sixth Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, Guangdong 510655, China.
FAU - Zheng, Z N
AU  - Zheng ZN
AD  - Department of Anesthesiology, the Sixth Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, Guangdong 510655, China.
FAU - Jin, S Q
AU  - Jin SQ
AD  - Department of Anesthesiology, the Sixth Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, Guangdong 510655, China.
LA  - chi
SI  - ClinicalTrials.gov/NCT03160144
GR  - A2017045/Medical Scientific Research Foundation of Guangdong Province
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Wei Chang Wai Ke Za Zhi
JT  - Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
JID - 101177990
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Colectomy/adverse effects/methods
MH  - *Colorectal Neoplasms/surgery
MH  - Humans
MH  - *Laparoscopy/adverse effects
MH  - Oxygen/analysis
MH  - Positive-Pressure Respiration/methods
MH  - Prospective Studies
MH  - Pulmonary Atelectasis/etiology/*prevention & control
MH  - Respiration, Artificial/*methods
OTO - NOTNLM
OT  - Colorectal neoplasms
OT  - Laparoscopic surgery
OT  - Low-tidal-volume ventilation
OT  - Open-lung strategy
OT  - Oxygenation-impairment
EDAT- 2020/11/20 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/11/19 22:26
PHST- 2020/11/19 22:26 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.3760/cma.j.issn.441530-20191209-00507 [doi]
PST - ppublish
SO  - Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Nov 25;23(11):1081-1087. doi:
      10.3760/cma.j.issn.441530-20191209-00507.


PMID- 33212456
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 0353-5053 (Print)
IS  - 0353-5053 (Linking)
VI  - 32
IP  - Suppl 4
DP  - 2020 Nov
TI  - Quality of Life and Mental Health in Multiple Sclerorsis Patients in Bosnia and
      Herzegovina Measured by Generc and Disease-Specific Questionaire.
PG  - 505-510
AB  - BACKGROUND: Multiple sclerosis (MS) as chronic neurodegenerative disease
      significantly impact patients' quality of life (QoL). QoL instruments can be
      generic (EQ-5D, SF-36) and disease-specific like MSQoL-54. Use of
      disease-specific instruments is preferred since it captures broader symptoms
      related to MS than generic instruments. Mental health is impacted by MS and
      different psychiatric conditions significantly impact QoL. We have conducted
      prospective non-interventional study among MS patients. Aim was to measure and
      compare MS patients QoL by generic and disease-specific instrument at baseline
      and after one year and to identify potential correlation between these two types 
      of measurements and to assess mental health scores among MS patients in Bosnia
      and Herzegovina (B&H) and other countries. SUBJECTS AND METHODS: Study included
      62 patients diagnosed with MS and treated at Neurology clinic in Sarajevo from
      April 2016 to May 2017. Study was approved by Ethical Committee. QoL has been
      measured by EQ-5D and MSQoL-54. Measurement has been performed at baseline and
      after 12 months. RESULTS: Average utility score measured by EQ-5D at the baseline
      and end of the study were 0.688 and 0.639 respectively with no significant
      difference (p=0.850). EQ-5D utility and MSQoL-54 score showed high correlation at
      baseline; rho=0.873 p=0.0001 for physical health and rho=0.711 p=0.0001 for
      mental health. At the end of the study no significant correlations have been
      found (p>0.05). High negative correlation found between EDSS and scores measured 
      by EQ-5D and MSQoL-54; at baseline (rho=-0.744 p=0.0001) and at the end of the
      study (rho=-0.832 p=0.0001). Similar MS impact and loss of QoL found in B&H and
      other countries. CONCLUSIONS: Both instruments can be used in measuring QoL but
      disease-specific are preferred since they capture broader symptoms impacting MS
      patient QoL. Using QoL instruments could drive clinician decision and
      patient-centric care as well as reimbursement and policy decision by recording
      treatment outcomes.
FAU - Catic, Tarik
AU  - Catic T
AD  - Society for Pharmacoeconomics and Outcomes Research in Bosnia and Herzegovina,
      Muhameda Hadzijahica 53, 71000 Sarajevo, Bosnia and Herzegovina,
      tarikcatic@bih.net.ba.
FAU - Culig, Josip
AU  - Culig J
FAU - Suljic, Enra
AU  - Suljic E
FAU - Masic, Admir
AU  - Masic A
FAU - Gojak, Refet
AU  - Gojak R
LA  - eng
PT  - Journal Article
PL  - Croatia
TA  - Psychiatr Danub
JT  - Psychiatria Danubina
JID - 9424753
SB  - IM
MH  - Adult
MH  - Bosnia and Herzegovina
MH  - Female
MH  - *Health Surveys
MH  - Humans
MH  - Male
MH  - Mental Disorders/complications/*diagnosis/*psychology
MH  - *Mental Health
MH  - Middle Aged
MH  - Multiple Sclerosis/complications/*psychology
MH  - Prospective Studies
MH  - *Quality of Life
EDAT- 2020/11/20 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/11/19 20:16
PHST- 2020/11/19 20:16 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PST - ppublish
SO  - Psychiatr Danub. 2020 Nov;32(Suppl 4):505-510.


PMID- 33211309
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210123
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1260
DP  - 2020
TI  - Digital and Social Media in Anatomy Education.
PG  - 109-122
LID - 10.1007/978-3-030-47483-6_6 [doi]
AB  - The use of images in various forms (drawing, photography, digital applications)
      has always been intrinsically associated with anatomy; however, the way in which 
      anatomy educators and students create, access, view and interact with images has 
      changed dramatically over the last 20 years. The method that anatomy educators
      use to engage with students and the wider public and how students engage with
      each other and faculty has also changed since the turn of the century, largely
      due to the emergence of social media. These two facets, the move towards digital 
      images and the use of social media, are now intricately interlinked because
      social media enable anatomy educators to share digital learning resources easily 
      and instantly to a global audience. This new trend of using social media to share
      digital images has created some ethical dilemmas that anatomy educators are
      researching and seeking guidance on to ensure that they are representing the
      potential conflicting needs and/or requirements of different stakeholders,
      including donors, donor families, students, the public, regulators and anatomy
      educators themselves. Meeting the various needs of stakeholders is complex;
      however, this chapter suggests an ethical approach for how digital images and
      social media can continue to be part of anatomy education.
FAU - Hennessy, Catherine M
AU  - Hennessy CM
AD  - Department of Anatomy, Brighton and Sussex Medical School, University of Sussex, 
      Brighton, UK. c.hennessy@bsms.ac.uk.
FAU - Smith, Claire F
AU  - Smith CF
AD  - Department of Anatomy, Brighton and Sussex Medical School, University of Sussex, 
      Brighton, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - Anatomy/*education
MH  - *Educational Technology
MH  - Humans
MH  - *Social Media
OTO - NOTNLM
OT  - Anatomy education
OT  - Cadaveric images
OT  - Consent
OT  - Digital images
OT  - Social media
EDAT- 2020/11/20 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/19 12:16
PHST- 2020/11/19 12:16 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1007/978-3-030-47483-6_6 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2020;1260:109-122. doi: 10.1007/978-3-030-47483-6_6.


PMID- 33211017
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201210
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 19
TI  - Quality Assessment of an Integrated Care Pathway Using Telemonitoring in Patients
      with Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: Protocol
      for a Quasi-Experimental Study.
PG  - e20571
LID - 10.2196/20571 [doi]
AB  - BACKGROUND: Chronic heart failure (CHF) and chronic obstructive pulmonary disease
      (COPD) often coexist and are associated with a high morbidity and reduced quality
      of life (QoL). Although these diseases share similarities in symptoms and
      clinical course, and exacerbations of both diseases often overlap, care pathways 
      for both conditions are usually not integrated. This results in frequent
      outpatient consultations and suboptimal treatment during exacerbations, leading
      to frequent hospital admissions. Therefore, we propose an integrated care pathway
      for both diseases, using telemonitoring to detect deterioration at an early stage
      and a single case manager for both diseases. OBJECTIVE: This study aims to
      investigate whether an integrated care pathway using telemonitoring in patients
      with combined CHF and COPD results in a higher general health-related QoL (HRQoL)
      as compared with the traditional care pathways. Secondary end points include
      disease-specific HRQoL, level of self-management, patient satisfaction,
      compliance to the program, and cost-effectiveness. METHODS: This is a monocenter,
      prospective study using a quasi-experimental interrupted time series design.
      Thirty patients with combined CHF and COPD are included. The study period of 2.5 
      years per patient is divided into a preintervention phase (6 months) and a
      postintervention phase (2 years) in which end points are assessed. The
      intervention consists of an on-demand treatment strategy based on monitoring
      symptoms related to CHF/COPD and vital parameters (weight, blood pressure, heart 
      rate, oxygen saturation, temperature), which are uploaded on a digital platform. 
      The monitoring frequency and the limit values of the measurements to detect
      abnormalities are determined individually. Monitoring is performed by a case
      manager, who has the opportunity for a daily multidisciplinary meeting with both 
      the cardiologist and the pulmonologist. Routine appointments at the outpatient
      clinic are cancelled and replaced by telemonitoring-guided treatment. RESULTS:
      Following ethical approval of the study protocol, the first patient was included 
      in May 2018. Inclusion is expected to be complete in May 2021. CONCLUSIONS: This 
      study is the first to evaluate the effects of a novel integrated care pathway
      using telemonitoring for patients with combined CHF and COPD. Unique to this
      study is the concept of remote on-demand disease management by a single case
      manager for both diseases, combined with multidisciplinary meetings. Moreover,
      modern telemonitoring technology is used instead of, rather than as an addition
      to, regular care. TRIAL REGISTRATION: Netherlands Trial Register NL6741;
      https://www.trialregister.nl/trial/6741. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): DERR1-10.2196/20571.
CI  - (c)Cyrille Herkert, Jos Johannes Kraal, Rudolph Ferdinand Spee, Anouk Serier,
      Lidwien Graat-Verboom, Hareld Marijn Clemens Kemps. Originally published in JMIR 
      Research Protocols (http://www.researchprotocols.org), 19.11.2020.
FAU - Herkert, Cyrille
AU  - Herkert C
AUID- ORCID: https://orcid.org/0000-0002-1191-8322
AD  - Flow, Center for Prevention, Telemedicine and Rehabilitation in Chronic Disease, 
      Maxima Medical Center, Eindhoven, Netherlands.
FAU - Kraal, Jos Johannes
AU  - Kraal JJ
AUID- ORCID: https://orcid.org/0000-0001-9667-6926
AD  - Faculty of Industrial Design Engineering, Delft University of Technology, Delft, 
      Netherlands.
FAU - Spee, Rudolph Ferdinand
AU  - Spee RF
AUID- ORCID: https://orcid.org/0000-0003-2885-8538
AD  - Flow, Center for Prevention, Telemedicine and Rehabilitation in Chronic Disease, 
      Maxima Medical Center, Eindhoven, Netherlands.
AD  - Department of Cardiology, Maxima Medical Center, Eindhoven, Netherlands.
FAU - Serier, Anouk
AU  - Serier A
AUID- ORCID: https://orcid.org/0000-0002-2798-5941
AD  - Flow, Center for Prevention, Telemedicine and Rehabilitation in Chronic Disease, 
      Maxima Medical Center, Eindhoven, Netherlands.
FAU - Graat-Verboom, Lidwien
AU  - Graat-Verboom L
AUID- ORCID: https://orcid.org/0000-0002-7209-040X
AD  - Flow, Center for Prevention, Telemedicine and Rehabilitation in Chronic Disease, 
      Maxima Medical Center, Eindhoven, Netherlands.
AD  - Department of Pulmonology, Maxima Medical Center, Eindhoven, Netherlands.
FAU - Kemps, Hareld Marijn Clemens
AU  - Kemps HMC
AUID- ORCID: https://orcid.org/0000-0003-0272-4355
AD  - Flow, Center for Prevention, Telemedicine and Rehabilitation in Chronic Disease, 
      Maxima Medical Center, Eindhoven, Netherlands.
AD  - Department of Cardiology, Maxima Medical Center, Eindhoven, Netherlands.
AD  - Department of Industrial Design, Eindhoven University of Technology, Eindhoven,
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7714643
OTO - NOTNLM
OT  - chronic heart failure
OT  - chronic obstructive pulmonary disease
OT  - integrated care pathway
OT  - telemonitoring
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 12:13
PHST- 2020/05/22 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/11/19 12:13 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - v9i11e20571 [pii]
AID - 10.2196/20571 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 19;9(11):e20571. doi: 10.2196/20571.


PMID- 33211009
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 2050-084X (Electronic)
IS  - 2050-084X (Linking)
VI  - 9
DP  - 2020 Nov 19
TI  - Journal policies and editors' opinions on peer review.
LID - 10.7554/eLife.62529 [doi]
LID - e62529 [pii]
AB  - Peer review practices differ substantially between journals and disciplines. This
      study presents the results of a survey of 322 editors of journals in ecology,
      economics, medicine, physics and psychology. We found that 49% of the journals
      surveyed checked all manuscripts for plagiarism, that 61% allowed authors to
      recommend both for and against specific reviewers, and that less than 6% used a
      form of open peer review. Most journals did not have an official policy on
      altering reports from reviewers, but 91% of editors identified at least one
      situation in which it was appropriate for an editor to alter a report. Editors
      were also asked for their views on five issues related to publication ethics. A
      majority expressed support for co-reviewing, reviewers requesting access to data,
      reviewers recommending citations to their work, editors publishing in their own
      journals, and replication studies. Our results provide a window into what is
      largely an opaque aspect of the scientific process. We hope the findings will
      inform the debate about the role and transparency of peer review in scholarly
      publishing.
CI  - (c) 2020, Hamilton et al.
FAU - Hamilton, Daniel G
AU  - Hamilton DG
AUID- ORCID: 0000-0001-8104-474X
AD  - Interdisciplinary Metaresearch Group, School of BioSciences, University of
      Melbourne, Melbourne, Australia.
FAU - Fraser, Hannah
AU  - Fraser H
AUID- ORCID: 0000-0003-2443-4463
AD  - Interdisciplinary Metaresearch Group, School of BioSciences, University of
      Melbourne, Melbourne, Australia.
FAU - Hoekstra, Rink
AU  - Hoekstra R
AUID- ORCID: 0000-0002-1588-7527
AD  - Department of Educational Sciences, University of Groningen, Groningen,
      Netherlands.
FAU - Fidler, Fiona
AU  - Fidler F
AD  - Interdisciplinary Metaresearch Group, School of BioSciences, University of
      Melbourne, Melbourne, Australia.
AD  - School of Historical and Philosophical Studies, University of Melbourne,
      Melbourne, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - Elife
JT  - eLife
JID - 101579614
SB  - IM
MH  - *Editorial Policies
MH  - Humans
MH  - *Peer Review
MH  - *Periodicals as Topic
MH  - Surveys and Questionnaires
PMC - PMC7717900
OTO - NOTNLM
OT  - *academic publishing
OT  - *data sharing
OT  - *editorial policies
OT  - *human
OT  - *meta-research
OT  - *peer review
OT  - *publication ethics
COIS- DH, HF, RH, FF No competing interests declared
EDAT- 2020/11/20 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/11/19 12:13
PHST- 2020/08/27 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/11/19 12:13 [entrez]
AID - 10.7554/eLife.62529 [doi]
AID - 62529 [pii]
PST - epublish
SO  - Elife. 2020 Nov 19;9. pii: 62529. doi: 10.7554/eLife.62529.


PMID- 33210719
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1873-5843 (Electronic)
IS  - 0887-6177 (Linking)
VI  - 35
IP  - 8
DP  - 2020 Nov 19
TI  - Home-Based Pediatric Teleneuropsychology: A validation study.
PG  - 1266-1275
LID - 10.1093/arclin/acaa070 [doi]
AB  - OBJECTIVE: To evaluate home-based teleneuropsychology in a pediatric cohort to
      determine if assessment via in-person and home-based videoconference yield
      similar results. The second objective was to determine the level of satisfaction 
      with videoconference-based assessment among participants and caregivers. METHOD: 
      Fifty-eight participants, aged 6-20 years, were recruited through specialty
      programs for pediatric demyelinating disorders. Each participant was administered
      the same brief neuropsychological battery of common measures twice, once during
      an in-person session and once during a remote home-based videoconference session.
      Order of sessions was counterbalanced and time between assessments ranged from 1 
      to 50 days. It was hypothesized that results obtained through in-person vs.
      remote videoconference sessions would not be significantly different and that
      most participants and caregivers would rate the experience with
      teleneuropsychology as satisfactory. RESULTS: Mann-Whitney U tests showed no
      significant differences in results obtained in the in-person first vs. remote
      videoconference first sessions or the change in performance across sessions.
      Satisfaction ratings by participants and caregivers were largely favorable for
      the use of the videoconference testing format. CONCLUSIONS: The current study is 
      the first to validate home-based teleneuropsychology and is the first to validate
      teleneuropsychological assessment in a pediatric sample. Future studies should
      replicate these findings as well as expand on sample size, diversity of
      populations evaluated, and the assessment tools administered. Careful
      consideration of ethical and practical factors should be given before providing
      pediatric teleneuropsychology services.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights
      reserved. For permissions, please e-mail: journals.permission@oup.com.
FAU - Harder, Lana
AU  - Harder L
AD  - Children's Health, Children's Medical Center, Dallas, TX, USA.
AD  - Department of Psychiatry, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
AD  - Department of Neurology and Neurotherapeutics, University of Texas Southwestern
      Medical Center, Dallas, TX, USA.
FAU - Hernandez, Ana
AU  - Hernandez A
AD  - Children's Health, Children's Medical Center, Dallas, TX, USA.
FAU - Hague, Cole
AU  - Hague C
AD  - Department of Psychiatry, Boston Children's Hospital, Boston, MA, USA.
FAU - Neumann, Joy
AU  - Neumann J
AD  - Children's Health, Children's Medical Center, Dallas, TX, USA.
AD  - Department of Psychiatry, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
FAU - McCreary, Morgan
AU  - McCreary M
AD  - Department of Neurology and Neurotherapeutics, University of Texas Southwestern
      Medical Center, Dallas, TX, USA.
FAU - Cullum, C Munro
AU  - Cullum CM
AD  - Department of Psychiatry, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
AD  - Department of Neurology and Neurotherapeutics, University of Texas Southwestern
      Medical Center, Dallas, TX, USA.
AD  - Department of Neurological Surgery, University of Texas Southwestern Medical
      Center, Dallas, TX, USA.
FAU - Greenberg, Benjamin
AU  - Greenberg B
AD  - Department of Neurology and Neurotherapeutics, University of Texas Southwestern
      Medical Center, Dallas, TX, USA.
AD  - Department of Pediatrics, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Clin Neuropsychol
JT  - Archives of clinical neuropsychology : the official journal of the National
      Academy of Neuropsychologists
JID - 9004255
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Humans
MH  - Neuropsychological Tests
MH  - *Personal Satisfaction
MH  - *Videoconferencing
MH  - Young Adult
OTO - NOTNLM
OT  - Assessment
OT  - Home-based teleneuropsychology
OT  - Pediatric teleneuropsychology
OT  - Teleneuropsychology
EDAT- 2020/11/20 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/11/19 08:47
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/11/19 08:47 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 5906143 [pii]
AID - 10.1093/arclin/acaa070 [doi]
PST - ppublish
SO  - Arch Clin Neuropsychol. 2020 Nov 19;35(8):1266-1275. doi: 10.1093/arclin/acaa070.


PMID- 33210655
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Nov 14
TI  - Oral Cancer Awareness Among Undergraduate Dental Students of Kantipur Dental
      College and Hospital.
PG  - 541-543
LID - 10.33314/jnhrc.v18i3.2873 [doi]
AB  - BACKGROUND: Oral Cancer is one of the most common form of cancer in the world.
      The early diagnosis and identification of cancerous lesions are necessary to
      reduce the morbidity and mortality of oral cancer. Today's dental students are
      tomorrow's dental surgeons and specialists who identify and manage the oral
      cancer patients. The aim of the study is to assess the knowledge and attitude
      regarding etiology and clinical features of oral cancer. METHODS: The study was a
      descriptive cross-sectional study conducted at Kantipur Dental College,
      Kathmandu, Nepal after the ethical approval by Kantipur Dental College
      Institutional Ethical Review Committee. The study population were clinical
      students from third, fourth and fifth year of Bachelor of Dental Surgery.
      RESULTS: Out of 101 participants, 67.3% students always examined their patient's 
      oral mucosa. Only 3.0% students felt very well-informed about clinical appearance
      of oral cancer. Of of total, 54.5% students identified floor of mouth as most
      common site of oral cancer and 60.4% identified border of tongue as most common
      site of oral cancer. Of total participants, only 22.8% students had examined oral
      cancer lesion before the study. Almost all (99%) students reported they wanted
      lacked knowledge and wanted more information on oral cancer. CONCLUSIONS: The
      undergraduate students lacked knowledge on the identification and detection of
      oral cancer. They were also not examining patient's oral mucosa routinely. Many
      students did not have sufficient information on risk factors and associated oral 
      cancer lesions.
FAU - Pokhrel, Prenit
AU  - Pokhrel P
AD  - Kantipur Dental College and Hospital , Kathmandu, Nepal.
FAU - Khadka, Bandana
AU  - Khadka B
AD  - Kantipur Dental College and Hospital , Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201114
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - Cross-Sectional Studies
MH  - Health Knowledge, Attitudes, Practice
MH  - Hospitals
MH  - Humans
MH  - *Mouth Neoplasms/diagnosis/epidemiology
MH  - Nepal
MH  - *Students, Dental
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Cancerous lesions; dental students; oral cancer; oral mucosa.
EDAT- 2020/11/20 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/19 08:47
PHST- 2020/07/11 00:00 [received]
PHST- 2020/11/14 00:00 [accepted]
PHST- 2020/11/19 08:47 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.33314/jnhrc.v18i3.2873 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Nov 14;18(3):541-543. doi:
      10.33314/jnhrc.v18i3.2873.


PMID- 33210085
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2632-1297 (Electronic)
IS  - 2632-1297 (Linking)
VI  - 2
IP  - 2
DP  - 2020
TI  - Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a 
      controversy 'gone viral'.
PG  - fcaa149
LID - 10.1093/braincomms/fcaa149 [doi]
AB  - Severe acute respiratory syndrome coronavirus 2 first appeared in December 2019
      in Wuhan, China, and developed into a worldwide pandemic within the following 3
      months causing severe bilateral pneumonia (coronavirus disease 2019) with in part
      fatal outcomes. After first experiences and tentative strategies to face this new
      disease, several cases were published describing severe acute respiratory
      syndrome coronavirus 2 infection related to the onset of neurological complaints 
      and diseases such as, for instance, anosmia, stroke or meningoencephalitis. Of
      note, there is still a controversy about whether or not there is a causative
      relation between severe acute respiratory syndrome coronavirus 2 and these
      neurological conditions. Other concerns, however, seem to be relevant as well.
      This includes not only the reluctance of patients with acute neurological
      complaints to report to the emergency department for fear of contracting severe
      acute respiratory syndrome coronavirus 2 but also the ethical and practical
      implications for neurology patients in everyday clinical routine. This paper aims
      to provide an overview of the currently available evidence for the occurrence of 
      severe acute respiratory syndrome coronavirus 2 in the central and peripheral
      nervous system and the neurological diseases potentially involving this virus.
CI  - (c) The Author(s) (2020). Published by Oxford University Press on behalf of the
      Guarantors of Brain.
FAU - Forster, Moritz
AU  - Forster M
AUID- ORCID: 0000-0003-0682-9859
AD  - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225
      Dusseldorf, Germany.
FAU - Weyers, Vivien
AU  - Weyers V
AD  - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225
      Dusseldorf, Germany.
FAU - Kury, Patrick
AU  - Kury P
AD  - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225
      Dusseldorf, Germany.
FAU - Barnett, Michael
AU  - Barnett M
AUID- ORCID: 0000-0002-2156-8864
AD  - Department of Neurology, Royal Prince Alfred Hospital, University of Sydney,
      Sydney, NSW, Australia.
FAU - Hartung, Hans-Peter
AU  - Hartung HP
AD  - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225
      Dusseldorf, Germany.
FAU - Kremer, David
AU  - Kremer D
AD  - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225
      Dusseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200917
PL  - England
TA  - Brain Commun
JT  - Brain communications
JID - 101755125
PMC - PMC7543269
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - neurological manifestations
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 05:51
PHST- 2020/08/18 00:00 [received]
PHST- 2020/08/18 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/11/19 05:51 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - 10.1093/braincomms/fcaa149 [doi]
AID - fcaa149 [pii]
PST - epublish
SO  - Brain Commun. 2020 Sep 17;2(2):fcaa149. doi: 10.1093/braincomms/fcaa149.
      eCollection 2020.


PMID- 33209861
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201120
IS  - 2279-9028 (Print)
IS  - 2279-9028 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Oct 14
TI  - Assessing healthcare workers' knowledge, emotions and perceived institutional
      preparedness about COVID-19 pandemic at Saudi hospitals in the early phase of the
      pandemic.
PG  - 1936
LID - 10.4081/jphr.2020.1936 [doi]
AB  - Background: Coronavirus disease 2019 (COVID-19) pandemic extended to reach most
      countries in the globe during few months. Preparedness of healthcare institutions
      and healthcare workers (HCWs) are crucial for applying effective prevention and
      control measures. This study aimed to assess HCWs knowledge, emotions and
      perception of preparedness of their institutions towards COVID-19 pandemic.
      Design: A cross-sectional, web-based survey was conducted among hospital HCWs in 
      Saudi Arabia during April 27, 2020 to May 03, 2020. Results: Overall, 1004
      completed responses were received. The majority were females (78.8), nurses
      (84.9%) at middle age 25-39 years (71.8%). Among participants, 95.5% reported
      receiving training on safely use of personal protective equipment (PPE) and 94.9%
      did fit the test for N95 respirator. The participants possessed a fair knowledge 
      about COVID-19 disease with a mean knowledge score 6. 61+/-1.35 points on a scale
      of 10 points. Most participants (88.7%) were committed to continue work as a
      professional and ethical duty, however, 27.1% of them scored high on a negative
      emotional impact scale. Participants appreciated most aspects of institutional
      preparedness for COVID-19 pandemic; however, they were concerned with the
      continuous PPE supply. Factors that independently associated with good knowledge 
      and negative emotional response were determined using multivariate logistic
      regression analysis. Conclusions: Findings revealed fair knowledge about COVID-19
      pandemic among HCWs in Saudi hospitals. Concerns and worries were expressed
      regard working with the highly infectious COVID-19 patients. Participants,
      appreciated most aspects of institutional preparedness, however they were
      concerned about the continuous availability and supply of PPE.
CI  - (c)Copyright: the Author(s).
FAU - Alreshidi, Nashi Masnad
AU  - Alreshidi NM
AD  - Nusing Administration, Ministry of Health, Hail Region, Hail.
FAU - Haridi, Hassan Kasim
AU  - Haridi HK
AD  - Research Department, Ministry of Heath, Hail Region, Hail, Saudi Arabia.
FAU - Alaseeri, Rana
AU  - Alaseeri R
AD  - Nusing Administration, Ministry of Health, Hail Region, Hail.
FAU - Garcia, Michelle
AU  - Garcia M
AD  - Nusing Administration, Ministry of Health, Hail Region, Hail.
FAU - Gaspar, Fe
AU  - Gaspar F
AD  - Nusing Administration, Ministry of Health, Hail Region, Hail.
FAU - Alrashidi, Laila
AU  - Alrashidi L
AD  - Nusing Administration, Ministry of Health, Hail Region, Hail.
LA  - eng
PT  - Journal Article
DEP - 20201103
PL  - United States
TA  - J Public Health Res
JT  - Journal of public health research
JID - 101580775
PMC - PMC7656182
OTO - NOTNLM
OT  - COVID-19
OT  - Saudi Arabia
OT  - emotions
OT  - healthcare workers
OT  - institutional preparedness
OT  - knowledge
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 05:48
PHST- 2020/09/10 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/11/19 05:48 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - 10.4081/jphr.2020.1936 [doi]
PST - epublish
SO  - J Public Health Res. 2020 Nov 3;9(4):1936. doi: 10.4081/jphr.2020.1936.
      eCollection 2020 Oct 14.


PMID- 33209801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - Prevalence and awareness of varicose veins among teachers in Abha, Saudi Arabia.
PG  - 4784-4787
LID - 10.4103/jfmpc.jfmpc_490_20 [doi]
AB  - BACKGROUND: Teachers, compelled by the nature of their profession, are required
      to stand for a significant amount of time. This prolonged standing, being one of 
      the risk factors for venous insufficiency, puts them at risk to develop varicose 
      veins. Hence, as there is a need to educate and sensitize the teachers. This
      study was carried out to investigate the prevalence and awareness regarding
      varicose veins in school teachers. METHODS: A cross sectional, questionnaire
      based study was carried out on 391 school teachers of the Aseer region, KSA,
      after obtaining ethical committee clearance and informed consent. Questions
      included personal, occupational, and varicose vein based questions. Responses
      were collected and analyzed using SPSS version 25.0 software. Frequencies and
      percentages were calculated. RESULTS: Forty two percent of the teachers were
      found to have varicose veins most of which were females. Around 62% of the
      teachers suffering from varicose veins were between 36 and 45 years of age.
      Participants who did regular exercises were less prone to varicose than
      irregularly exercising participants (P = 0.0001). No association was observed
      between smoking and varicose veins (odds ratio 0.15, 95% confidence interval
      0.05-0.44). CONCLUSION: Due to high prevalence of varicose veins among teachers, 
      it is necessary to spread awareness regarding varicose veins among them and
      sensitize them with the methods to prevent its formation.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Dalboh, Abdullah
AU  - Dalboh A
AD  - Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi
      Arabia.
FAU - Alshehri, Nawaf Amer
AU  - Alshehri NA
AD  - Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi
      Arabia.
FAU - Alrafie, Abdulmajeed Abdullah
AU  - Alrafie AA
AD  - Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi
      Arabia.
FAU - Bakri, Khalid Ali
AU  - Bakri KA
AD  - Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi
      Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7652175
OTO - NOTNLM
OT  - Occupation
OT  - venous insufficiency
OT  - venous ulcers
COIS- There are no conflicts of interest.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 05:48
PHST- 2020/03/28 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/11/19 05:48 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_490_20 [doi]
AID - JFMPC-9-4784 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Sep 30;9(9):4784-4787. doi:
      10.4103/jfmpc.jfmpc_490_20. eCollection 2020 Sep.


PMID- 33209771
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - Factors affecting nutritional status of Anganwadi children: A cross-sectional
      study.
PG  - 4613-4617
LID - 10.4103/jfmpc.jfmpc_410_20 [doi]
AB  - INTRODUCTION: As per the National Family Health Survey (NFHS) 2015-16, 35.7%
      children below 5 years of age are underweight. In light of Malnutrition rates
      still remaining alarming in children, it becomes pertinent to elicit the factors 
      that affect nutritional status of children. So, this study was undertaken.
      MATERIALS AND METHODS: After obtaining ethical approval from institutional ethics
      committee, data were collected on a pretested questionnaire. Information from
      mothers of 1085 children attending Anganwadi center in an urban block of Patiala 
      was collected and analyzed. RESULTS: Among females, 35.85% were underweight,
      whereas the proportion for males was 28.68%. The proportion among immunized
      children who were underweight was 31.34%, whereas the proportion among
      unimmunized children was 38.91%. Those who received supplementary nutrition were 
      also in more in numbers in normal weight range than those who did not.
      CONCLUSION: Gender, birth order, and immunization status of child are
      significantly associated with nutritional status. This study showed that
      prevalence of malnutrition was less among those who received supplementary
      nutrition as compared to ones who did not.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Jain, Ira
AU  - Jain I
AD  - Department of Community Medicine, Government Medical College, Patiala, Punjab,
      India.
FAU - Oberoi, Simmi
AU  - Oberoi S
AD  - Department of Community Medicine, Government Medical College, Patiala, Punjab,
      India.
FAU - Jain, Ankur
AU  - Jain A
AD  - Department of Community Medicine, Government Medical College, Patiala, Punjab,
      India.
FAU - Balgir, Rajinder S
AU  - Balgir RS
AD  - Department of Community Medicine, Government Medical College, Patiala, Punjab,
      India.
FAU - Sandhu, Manhardeep K
AU  - Sandhu MK
AD  - Department of Community Medicine, Government Medical College, Patiala, Punjab,
      India.
FAU - Lugani, Yogita
AU  - Lugani Y
AD  - Department of Biotechnology, Punjabi University, Patiala, Punjab, India.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7652108
OTO - NOTNLM
OT  - Anganwadi
OT  - nutritional status
OT  - socio-demographic factors
OT  - underweight children
COIS- There are no conflicts of interest.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 05:47
PHST- 2020/03/19 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/11/19 05:47 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_410_20 [doi]
AID - JFMPC-9-4613 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Sep 30;9(9):4613-4617. doi:
      10.4103/jfmpc.jfmpc_410_20. eCollection 2020 Sep.


PMID- 33209655
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2223-4691 (Print)
IS  - 2223-4683 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Oct
TI  - Single perineal incision for artificial urinary sphincter: analysis of technique,
      outcomes, and experience.
PG  - 1912-1919
LID - 10.21037/tau-20-508 [doi]
AB  - BACKGROUND: To describe a large series of male patients who underwent a minimally
      invasive single perineal incision artificial urinary sphincter (AUS) placement in
      patients with stress urinary incontinence. METHODS: A retrospective cohort study 
      was performed with data collected from men undergoing AUS placement by a single
      high-volume surgeon over a 12-year period (2005 to 2017). Demographic and
      outcomes data related to AUS placement were recorded from electronic medical
      records, which included subjective histories and questionnaires. Institutional
      ethics approval was received. RESULTS: A total of 145 AUS were placed over the
      study period. Of these, 84 were performed through a single perineal incision for 
      both device and reservoir placement. Almost all (n=81, 96%) reported
      pre-operative incontinence of more than 3 pads per day. Postoperatively, 75% were
      satisfied with their continence, with 21 (25%) complaining of recurrent
      incontinence. A total of 5 (6%) patients developed a post-operative infection, 10
      (12%) had device erosion and 11 (13%) had device malfunction, but only 3 (4%) had
      reservoir dysfunction. A total of 24 (29%) patients required revision of their
      device at median of 20 months (IQR, 6-32.5 months). CONCLUSIONS: Single perineal 
      incision is a feasible, safe, and potentially superior approach for AUS placement
      and warrants consideration as an accepted approach due to its more rapid surgical
      times, lower morbidity related to a single incision with minimal fascial defect, 
      and favorable complication rates.
CI  - 2020 Translational Andrology and Urology. All rights reserved.
FAU - Punjani, Nahid
AU  - Punjani N
AD  - Center for Reproductive Medicine and Surgery, Weill Cornell Medicine, New York,
      NY, USA.
AD  - Division of Urology, Department of Surgery, Schulich School of Medicine &
      Dentistry, Western University, London, ON, USA.
FAU - Chan, Ernest
AU  - Chan E
AD  - Division of Urology, Department of Surgery, Schulich School of Medicine &
      Dentistry, Western University, London, ON, USA.
FAU - Chan, Garson
AU  - Chan G
AD  - Division of Urology, Department of Surgery, Schulich School of Medicine &
      Dentistry, Western University, London, ON, USA.
FAU - Abed, Haider
AU  - Abed H
AD  - Division of Urology, Department of Surgery, Schulich School of Medicine &
      Dentistry, Western University, London, ON, USA.
FAU - Campbell, Jeffrey
AU  - Campbell J
AD  - Division of Urology, Department of Surgery, Schulich School of Medicine &
      Dentistry, Western University, London, ON, USA.
FAU - Brock, Gerald
AU  - Brock G
AD  - Division of Urology, Department of Surgery, Schulich School of Medicine &
      Dentistry, Western University, London, ON, USA.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
CIN - J Urol. 2021 Jul;206(1):151-152. PMID: 33874727
PMC - PMC7658167
OTO - NOTNLM
OT  - Artificial urinary sphincter (AUS)
OT  - post-prostatectomy incontinence (PPI)
OT  - single incision
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/tau-20-508). GB serves as an unpaid
      editorial board member of Translational Lung Cancer Research from Mar 2018 to Feb
      2020. GB reports other from Boston Scientific, Eli Lilly, Acerus Pharma, Pfizer, 
      Paladin, Merck, Upjohn, outside the submitted work. The authors have no other
      conflicts of interest to declare.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 05:46
PHST- 2020/11/19 05:46 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - 10.21037/tau-20-508 [doi]
AID - tau-09-05-1912 [pii]
PST - ppublish
SO  - Transl Androl Urol. 2020 Oct;9(5):1912-1919. doi: 10.21037/tau-20-508.


PMID- 33208976
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 587
IP  - 7834
DP  - 2020 Nov
TI  - Is facial recognition too biased to be let loose?
PG  - 347-349
LID - 10.1038/d41586-020-03186-4 [doi]
FAU - Castelvecchi, Davide
AU  - Castelvecchi D
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Nature. 2019 Aug;572(7771):565. PMID: 31455918
MH  - *Facial Recognition
MH  - Machine Learning
MH  - Pattern Recognition, Automated
MH  - Technology
OTO - NOTNLM
OT  - *Computer science
OT  - *Ethics
OT  - *Machine learning
EDAT- 2020/11/20 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/11/19 05:40
PHST- 2020/11/19 05:40 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
AID - 10.1038/d41586-020-03186-4 [doi]
AID - 10.1038/d41586-020-03186-4 [pii]
PST - ppublish
SO  - Nature. 2020 Nov;587(7834):347-349. doi: 10.1038/d41586-020-03186-4.


PMID- 33208967
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20211204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 587
IP  - 7834
DP  - 2020 Nov
TI  - The ethical questions that haunt facial-recognition research.
PG  - 354-358
LID - 10.1038/d41586-020-03187-3 [doi]
FAU - Van Noorden, Richard
AU  - Van Noorden R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Age Factors
MH  - Algorithms
MH  - Automated Facial Recognition/*ethics
MH  - Censorship, Research
MH  - China
MH  - Datasets as Topic/*ethics
MH  - *Ethics, Research
MH  - *Ethnicity
MH  - Female
MH  - Human Rights/*ethics
MH  - Humans
MH  - Informed Consent/*ethics
MH  - *Islam
MH  - Korea/ethnology
MH  - Male
MH  - Military Science/ethics
MH  - Photography/ethics
MH  - Politics
MH  - Privacy
MH  - Sex Factors
MH  - Tibet/ethnology
OTO - NOTNLM
OT  - *Computer science
OT  - *Ethics
OT  - *Machine learning
OT  - *Politics
EDAT- 2020/11/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/19 05:40
PHST- 2020/11/19 05:40 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/d41586-020-03187-3 [doi]
AID - 10.1038/d41586-020-03187-3 [pii]
PST - ppublish
SO  - Nature. 2020 Nov;587(7834):354-358. doi: 10.1038/d41586-020-03187-3.


PMID- 33208966
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 587
IP  - 7834
DP  - 2020 Nov
TI  - Resisting the rise of facial recognition.
PG  - 350-353
LID - 10.1038/d41586-020-03188-2 [doi]
FAU - Roussi, Antoaneta
AU  - Roussi A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Automated Facial Recognition/*ethics/*trends
MH  - Bias
MH  - COVID-19/epidemiology/prevention & control
MH  - China
MH  - Crime/legislation & jurisprudence/prevention & control/statistics & numerical
      data
MH  - Europe
MH  - Female
MH  - Humans
MH  - Information Storage and Retrieval/ethics/standards
MH  - Informed Consent/ethics/legislation & jurisprudence
MH  - Law Enforcement/*ethics/*methods
MH  - Male
MH  - Pandemics
MH  - Police/*ethics/*legislation & jurisprudence
MH  - Politics
MH  - Population Surveillance/methods
MH  - Prejudice/ethics
MH  - *Public Opinion
MH  - Quarantine/legislation & jurisprudence
MH  - United States
OTO - NOTNLM
OT  - *Ethics
OT  - *Information technology
OT  - *Politics
OT  - *Technology
EDAT- 2020/11/20 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/11/19 05:40
PHST- 2020/11/19 05:40 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - 10.1038/d41586-020-03188-2 [doi]
AID - 10.1038/d41586-020-03188-2 [pii]
PST - ppublish
SO  - Nature. 2020 Nov;587(7834):350-353. doi: 10.1038/d41586-020-03188-2.


PMID- 33208964
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 587
IP  - 7834
DP  - 2020 Nov
TI  - Facial-recognition research needs an ethical reckoning.
PG  - 330
LID - 10.1038/d41586-020-03256-7 [doi]
LA  - eng
PT  - Editorial
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Algorithms
MH  - Automated Facial Recognition/economics/*ethics
MH  - Datasets as Topic/ethics
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Photography
OTO - NOTNLM
OT  - *Computer science
OT  - *Ethics
OT  - *Government
OT  - *Industry
EDAT- 2020/11/20 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/11/19 05:40
PHST- 2020/11/19 05:40 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - 10.1038/d41586-020-03256-7 [doi]
AID - 10.1038/d41586-020-03256-7 [pii]
PST - ppublish
SO  - Nature. 2020 Nov;587(7834):330. doi: 10.1038/d41586-020-03256-7.


PMID- 33208908
OWN - NLM
STAT- Publisher
LR  - 20201120
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Nov 19
TI  - What scientists really think about the ethics of facial recognition research.
LID - 10.1038/d41586-020-03257-6 [doi]
FAU - Van Noorden, Richard
AU  - Van Noorden R
LA  - eng
PT  - News
DEP - 20201119
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Ethics
OT  - Government
OT  - Technology
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/19 05:38
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/11/19 05:38 [entrez]
AID - 10.1038/d41586-020-03257-6 [doi]
AID - 10.1038/d41586-020-03257-6 [pii]
PST - aheadofprint
SO  - Nature. 2020 Nov 19. pii: 10.1038/d41586-020-03257-6. doi:
      10.1038/d41586-020-03257-6.


PMID- 33208481
OWN - NLM
STAT- Publisher
LR  - 20201119
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 18
TI  - Is there room for privacy in medical crowdfunding?
LID - medethics-2020-106676 [pii]
LID - 10.1136/medethics-2020-106676 [doi]
AB  - When people use online platforms to solicit funds from others for health-related 
      needs, they are engaging in medical crowdfunding. This form of crowdfunding is
      growing in popularity, and its visibility is increasing as campaigns are commonly
      shared via social networking. A number of ethical issues have been raised about
      medical crowdfunding, one of which is that it introduces a number of privacy
      concerns. While campaigners are encouraged to share very personal details to
      encourage donations, the sharing of such details may result in privacy losses for
      the beneficiary. Here, we explore the ways in which privacy can be threatened
      through the practice of medical crowdfunding by exploring campaigns (n=100) for
      children with defined health needs scraped from the GoFundMe platform. We found
      specific privacy concerns related to the disclosure of private details about the 
      beneficiary, the inclusion of images and the nature of the relationship between
      campaigner, funding recipient and beneficiary. For example, it was found that
      identifying personal and medical details about the beneficiary, including
      symptoms (n=52) and treatment history (n=43), were often mentioned by
      campaigners. While the privacy concerns identified are problematic, they are also
      difficult to remedy given the strong financial incentive to crowdfund. However,
      crowdfunding platforms can enhance privacy protections by, for example, requiring
      those campaigning on behalf of child beneficiaries to ensure consent has been
      obtained from their guardians and providing additional guidelines for the
      inclusion of personal information in campaigns made on behalf of those not able
      to give their consent to the campaign.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Snyder, Jeremy
AU  - Snyder J
AUID- ORCID: http://orcid.org/0000-0002-8236-2923
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia,
      Canada jcs12@sfu.ca.
FAU - Crooks, Valorie A
AU  - Crooks VA
AD  - Department of Geography, Simon Fraser University, Burnaby, British Columbia,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - Children
OT  - Confidentiality/Privacy
OT  - Ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/19 05:33
PHST- 2020/07/06 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/11/19 05:33 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - medethics-2020-106676 [pii]
AID - 10.1136/medethics-2020-106676 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 18. pii: medethics-2020-106676. doi:
      10.1136/medethics-2020-106676.


PMID- 33208479
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 18
TI  - Prevention in the age of personal responsibility: epigenetic risk-predictive
      screening for female cancers as a case study.
LID - medethics-2020-106146 [pii]
LID - 10.1136/medethics-2020-106146 [doi]
AB  - Epigenetic markers could potentially be used for risk assessment in
      risk-stratified population-based cancer screening programmes. Whereas current
      screening programmes generally aim to detect existing cancer, epigenetic markers 
      could be used to provide risk estimates for not-yet-existing cancers. Epigenetic 
      risk-predictive tests may thus allow for new opportunities for risk assessment
      for developing cancer in the future. Since epigenetic changes are presumed to be 
      modifiable, preventive measures, such as lifestyle modification, could be used to
      reduce the risk of cancer. Moreover, epigenetic markers might be used to monitor 
      the response to risk-reducing interventions. In this article, we address ethical 
      concerns related to personal responsibility raised by epigenetic risk-predictive 
      tests in cancer population screening. Will individuals increasingly be held
      responsible for their health, that is, will they be held accountable for bad
      health outcomes? Will they be blamed or subject to moral sanctions? We will
      illustrate these ethical concerns by means of a Europe-wide research programme
      that develops an epigenetic risk-predictive test for female cancers.
      Subsequently, we investigate when we can hold someone responsible for her
      actions. We argue that the standard conception of personal responsibility does
      not provide an appropriate framework to address these concerns. A different,
      prospective account of responsibility meets part of our concerns, that is,
      concerns about inequality of opportunities, but does not meet all our concerns
      about personal responsibility. We argue that even if someone is responsible on
      grounds of a negative and/or prospective account of responsibility, there may be 
      moral and practical reasons to abstain from moral sanctions.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bolt, Ineke
AU  - Bolt I
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands L.Bolt@erasmusmc.nl.
FAU - Bunnik, Eline M
AU  - Bunnik EM
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands.
FAU - Tromp, Krista
AU  - Tromp K
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands.
FAU - Pashayan, Nora
AU  - Pashayan N
AD  - UCL Department of Applied Health Research, University College London, London, UK.
FAU - Widschwendter, Martin
AU  - Widschwendter M
AD  - Department of Women's Cancer, University College London, London, UK.
FAU - de Beaufort, Inez
AU  - de Beaufort I
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639925
OTO - NOTNLM
OT  - genetic screening/testing
OT  - technology/risk assessment
COIS- Competing interests: UCLB (UCL's commercialisation company) has filed patents on 
      DNA methylation and risk prediction on which Martin Widschwendter is named as an 
      inventor.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/19 05:33
PHST- 2020/02/14 00:00 [received]
PHST- 2020/08/18 00:00 [revised]
PHST- 2020/08/23 00:00 [accepted]
PHST- 2020/11/19 05:33 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - medethics-2020-106146 [pii]
AID - 10.1136/medethics-2020-106146 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 18. pii: medethics-2020-106146. doi:
      10.1136/medethics-2020-106146.


PMID- 33208478
OWN - NLM
STAT- Publisher
LR  - 20201119
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 18
TI  - Conventional revolution: the ethical implications of the natural progress of
      neonatal intensive care to artificial wombs.
LID - medethics-2020-106754 [pii]
LID - 10.1136/medethics-2020-106754 [doi]
AB  - Research teams have used extra-uterine systems (Biobags) to support premature
      fetal lambs and to bring them to maturation in a way not previously possible. The
      researchers have called attention to possible implications of these systems for
      sustaining premature human fetuses in a similar way. Some commentators have
      pointed out that perfecting these systems for human fetuses might alter a
      standard expectation in abortion practices: that the termination of a pregnancy
      also (inevitably) entails the death of the fetus. With Biobags, it might be
      possible, some argue, that no woman has the right to expect that outcome if the
      technology is able to sustain fetal life after an abortion. In order to protect
      the expectation that the termination of a pregnancy always entails the death of
      the fetus, Elizabeth Romanis has argued that fetuses sustained in Biobags have a 
      status different than otherwise 'born' children. In support of that view, she
      argues that these 'gestatelings' are incapable of independent life. This argument
      involves a misunderstanding of the gestational support involved, as well as a
      misapprehension of neonatology practice. Here, we argue that any human fetus
      sustained in a Biobag would be as 'independent' as any other premature infant,
      and just as 'born'. Neonatologists would seem to have certain presumptive moral
      responsibilities toward any human fetus gestating in a Biobag. It remains a
      separate question whether the perfection and widespread application of Biobags
      for premature human beings would or should alter the expectation that ending a
      pregnancy also entails fetal death.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Wozniak, Phillip Stefan
AU  - Wozniak PS
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA
      phillip.wozniak@osumc.edu.
FAU - Fernandes, Ashley Keith
AU  - Fernandes AK
AD  - College of Medicine, The Ohio State University, Columbus, Ohio, USA.
AD  - Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - abortion
OT  - ethics
OT  - neonatology
COIS- Competing interests: None declared.
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/19 05:33
PHST- 2020/07/29 00:00 [received]
PHST- 2020/10/08 00:00 [revised]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/19 05:33 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - medethics-2020-106754 [pii]
AID - 10.1136/medethics-2020-106754 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 18. pii: medethics-2020-106754. doi:
      10.1136/medethics-2020-106754.


PMID- 33208339
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 18
TI  - Adjusting working conditions and evaluating the risk of infection during the
      COVID-19 pandemic in different workplace settings in Germany: a study protocol
      for an explorative modular mixed methods approach.
PG  - e043908
LID - 10.1136/bmjopen-2020-043908 [doi]
AB  - INTRODUCTION: Currently, many countries, affected by the COVID-19 pandemic,
      discuss how the 'lockdown-restrictions' could be lifted to restart the economy
      and public life after the first wave of the COVID-19 disease has subsided. This
      study protocol describes an approach designed to provide an in-depth
      understanding of how companies and their employees in Germany deal with their
      working conditions during the COVID-19 pandemic. We are also interested in how
      and why the risk of infection with SARS-CoV-2 could vary across different
      professional activities, company sites and regions with different epidemiological
      activity or infection control measures in Germany. We expect the results of this 
      study to contribute to the development of working conditions protecting the
      health of employees during and beyond the COVID-19 pandemic. METHODS AND
      ANALYSIS: An explorative multimodal mixed methods approach will be applied.
      Module 1 comprises a document analysis of prevailing federal and regional laws
      and regulations at the respective location of the participating company. Module 2
      includes qualitative interviews with key actors at different companies. Module 3 
      is a repeated standardised employee survey designed to capture potential changes 
      in the participants' experiences and attitudes towards working conditions,
      occupational safety regulations/measures, and infection control measures during
      the COVID-19 pandemic. Module 4 comprises SARS-CoV-2 seroprevalence testing. This
      is carried out by the medical service of the participating company sites as a
      voluntary offer for employees. Qualitative data will be analysed through document
      and content analysis. The complexity of the quantitative analysis depends on the 
      response rates of modules 3 and 4. ETHICS AND DISSEMINATION: The approval of the 
      study design was received in June 2020 from the responsible local ethical
      committee of the Medical Faculty, University of Tubingen and University Hospital 
      Tubingen (No. 423/2020BO). The results will be presented at national and
      international conferences and published in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rind, Esther
AU  - Rind E
AUID- ORCID: 0000-0001-8200-4862
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital Tubingen, University of Tubingen, Tubingen, Germany
      esther.rind@med.uni-tuebingen.de.
FAU - Kimpel, Klaus
AU  - Kimpel K
AD  - Medical Services, Robert Bosch GmbH, Stuttgart, Germany.
FAU - Preiser, Christine
AU  - Preiser C
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital Tubingen, University of Tubingen, Tubingen, Germany.
AD  - Coordination Centre, Core Facility for Health Services Research, University of
      Tubingen, Faculty of Medicine, Tubingen, Germany.
FAU - Papenfuss, Falko
AU  - Papenfuss F
AD  - Medical Services, Robert Bosch GmbH, Stuttgart, Germany.
FAU - Wagner, Anke
AU  - Wagner A
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital Tubingen, University of Tubingen, Tubingen, Germany.
FAU - Alsyte, Karina
AU  - Alsyte K
AD  - Medical Services, Robert Bosch GmbH, Stuttgart, Germany.
FAU - Siegel, Achim
AU  - Siegel A
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital Tubingen, University of Tubingen, Tubingen, Germany.
FAU - Klink, Antje
AU  - Klink A
AD  - Medical Services, Robert Bosch GmbH, Stuttgart, Germany.
FAU - Steinhilber, Benjamin
AU  - Steinhilber B
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital Tubingen, University of Tubingen, Tubingen, Germany.
FAU - Kauderer, Johanna
AU  - Kauderer J
AD  - Medical Services, Robert Bosch GmbH, Stuttgart, Germany.
FAU - Rieger, Monika A
AU  - Rieger MA
AD  - Institute of Occupational and Social Medicine and Health Services Research,
      University Hospital Tubingen, University of Tubingen, Tubingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201118
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - COVID-19/*epidemiology
MH  - Female
MH  - Germany/epidemiology
MH  - Humans
MH  - Male
MH  - *Occupational Health
MH  - *Pandemics
MH  - Risk Assessment/*methods
MH  - *SARS-CoV-2
MH  - Seroepidemiologic Studies
MH  - Surveys and Questionnaires
MH  - Workplace/*organization & administration
PMC - PMC7677339
OTO - NOTNLM
OT  - *COVID-19
OT  - *infection control
OT  - *occupational & industrial medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/19 05:33
PHST- 2020/11/19 05:33 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-043908 [pii]
AID - 10.1136/bmjopen-2020-043908 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 18;10(11):e043908. doi: 10.1136/bmjopen-2020-043908.


PMID- 33208333
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 18
TI  - Smoking cessation interventions for people living in rural and remote areas: a
      systematic review protocol.
PG  - e041011
LID - 10.1136/bmjopen-2020-041011 [doi]
AB  - INTRODUCTION: Smoking rates among people living in rural and remote areas are
      higher and quit rates are lower over the past 10 years compared with people
      living in suburban and urban areas. Higher smoking rates contribute to greater
      tobacco-related disease and morbidity in rural and remote areas. Physical and
      social isolation, greater exposure to pro-tobacco marketing, pro-tobacco social
      norms, and lower socioeconomic and educational levels are contributing to these
      higher smoking rates and lower quit rates. Smoking cessation interventions for
      people in rural and remote areas have been conducted, however little is known
      about their effectiveness or their mechanisms of action as well as the quality of
      such research. Behaviour change techniques (BCTs) are mechanisms of action
      derived from behaviour change theory, such as goal setting and reward. Improved
      understanding of the contribution of BCTs for smoking cessation in the rural and 
      remote population will support future intervention development. We aim to review 
      the literature on smoking cessation interventions for people living in rural and 
      remote areas to inform evidence about intervention effectiveness and mechanisms
      of action. METHODS AND ANALYSIS: We will conduct a systematic review using seven 
      scientific databases (EMBASE, MedLine, PsycINFO, CINAHL, Cochrane, Informit
      Health and Scopus). We will include peer-reviewed journal articles published in
      English that examine a smoking cessation intervention delivered to people living 
      in rural and remote areas in the USA, Canada and Australia. We will examine
      outcome data relating to intervention effectiveness (eg, point prevalence
      abstinence or continuous abstinence), as well as the BCTs used in included
      interventions and their relationship with intervention outcomes. We will also
      assess the feasibility, acceptability and quality of research interventions of
      included articles, and provide graded recommendations based on the review
      outcomes. Data will be synthesised using narrative approaches and interpreted
      using content analysis. ETHICS AND DISSEMINATION: Ethics was not required for
      this systematic review. The results will be disseminated through peer-reviewed
      publication and at conferences by presentations. PROSPERO REGISTRATION NUMBER:
      177398.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lum, Alistair
AU  - Lum A
AD  - School of Medicine & Public Health, University of Newcastle, Callaghan, NSW,
      Australia alistair.lum@newcastle.edu.au.
FAU - Skelton, Eliza
AU  - Skelton E
AD  - School of Medicine & Public Health, University of Newcastle, Callaghan, NSW,
      Australia.
FAU - McCarter, Kristen Louise
AU  - McCarter KL
AUID- ORCID: 0000-0002-2638-6381
AD  - School of Medicine & Public Health, University of Newcastle, Callaghan, NSW,
      Australia.
FAU - Handley, Tonelle
AU  - Handley T
AD  - School of Medicine & Public Health, University of Newcastle, Callaghan, NSW,
      Australia.
FAU - Judd, Lucy
AU  - Judd L
AD  - School of Medicine & Public Health, University of Newcastle, Callaghan, NSW,
      Australia.
FAU - Bonevski, Billie
AU  - Bonevski B
AD  - School of Medicine & Public Health, University of Newcastle, Callaghan, NSW,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201118
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Behavior Therapy
MH  - Canada
MH  - Humans
MH  - Smoking
MH  - *Smoking Cessation
MH  - Systematic Reviews as Topic
PMC - PMC7677358
OTO - NOTNLM
OT  - *adult cardiology
OT  - *adult oncology
OT  - *psychiatry
OT  - *quality in health care
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/19 05:32
PHST- 2020/11/19 05:32 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041011 [pii]
AID - 10.1136/bmjopen-2020-041011 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 18;10(11):e041011. doi: 10.1136/bmjopen-2020-041011.


PMID- 33208330
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 18
TI  - Predicting treatment outcomes for bilinguals with aphasia using computational
      modeling: Study protocol for the PROCoM randomised controlled trial.
PG  - e040495
LID - 10.1136/bmjopen-2020-040495 [doi]
AB  - INTRODUCTION: Bilinguals with aphasia (BWA) present varying degrees of lexical
      access impairment and recovery across their two languages. Because both languages
      may benefit from therapy, identifying the optimal target language for treatment
      is a current challenge for research and clinical practice. Prior research has
      demonstrated that the BiLex computational model can accurately simulate lexical
      access in healthy bilinguals, and language impairment and treatment response in
      bilingual aphasia. Here, we aim to determine whether BiLex can predict treatment 
      outcomes in BWA in the treated and the untreated language and compare these
      outcome predictions to determine the optimal language for rehabilitation. METHODS
      AND ANALYSIS: The study involves a prospective parallel-group, double-blind,
      randomised controlled trial. Forty-eight Spanish-English BWA will receive 20
      sessions of semantic treatment for lexical retrieval deficits in one of their
      languages and will complete assessments in both languages prior and after
      treatment. Participants will be randomly assigned to an experimental group
      receiving treatment in the optimal language determined by the model or a control 
      group receiving treatment in the language opposite to the model's recommendation.
      Primary treatment outcomes include naming probes while secondary treatment
      outcomes include tests tapping additional language domains. Treatment outcomes
      will be compared across the two groups using 2x2 mixed effect models for repeated
      measures Analysis of variance (ANOVA) on metrics of treatment effects commonly
      employed in rehabilitation studies (ie, effect size and percentage change).
      ETHICS AND DISSEMINATION: All procedures included in this protocol (protocol
      number 29, issue date: 19 March 2019) were approved by the Boston University
      Charles River Campus Institutional Review Board at Boston, Massachusetts
      (reference number: 4492E). The results of this study will be published in
      peer-reviewed scientific journals and will be presented at national and
      international conferences. TRIAL REGISTRATION NUMBER: NCT02916524.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Penaloza, Claudia
AU  - Penaloza C
AUID- ORCID: 0000-0003-1200-5936
AD  - Aphasia Research Laboratory, Department of Speech, Language and Hearing Sciences,
      Boston University, Boston, Massachusetts, USA penaloza@bu.edu.
FAU - Dekhtyar, Maria
AU  - Dekhtyar M
AUID- ORCID: 0000-0002-7365-6508
AD  - Aphasia Research Laboratory, Department of Speech, Language and Hearing Sciences,
      Boston University, Boston, Massachusetts, USA.
FAU - Scimeca, Michael
AU  - Scimeca M
AUID- ORCID: 0000-0002-1683-7767
AD  - Aphasia Research Laboratory, Department of Speech, Language and Hearing Sciences,
      Boston University, Boston, Massachusetts, USA.
FAU - Carpenter, Erin
AU  - Carpenter E
AUID- ORCID: 0000-0002-7958-6803
AD  - Aphasia Research Laboratory, Department of Speech, Language and Hearing Sciences,
      Boston University, Boston, Massachusetts, USA.
FAU - Mukadam, Nishaat
AU  - Mukadam N
AUID- ORCID: 0000-0001-9674-3519
AD  - Aphasia Research Laboratory, Department of Speech, Language and Hearing Sciences,
      Boston University, Boston, Massachusetts, USA.
FAU - Kiran, Swathi
AU  - Kiran S
AUID- ORCID: 0000-0003-1586-8913
AD  - Aphasia Research Laboratory, Department of Speech, Language and Hearing Sciences,
      Boston University, Boston, Massachusetts, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02916524
GR  - U01 DC014922/DC/NIDCD NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201118
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Aphasia/therapy
MH  - Boston
MH  - Humans
MH  - Massachusetts
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7677370
OTO - NOTNLM
OT  - *adult neurology
OT  - *anomia therapy
OT  - *bilingual aphasia
OT  - *clinical trials
OT  - *computational modeling
OT  - *internal medicine
OT  - *neurology
OT  - *randomized controlled trial
OT  - *rehabilitation
OT  - *rehabilitation medicine
OT  - *semantic treatment
OT  - *stroke
OT  - *therapeutics
COIS- Competing interests: SK serves as a consultant for The Learning Corporation with 
      no scientific overlap with the present study. Claudia Penaloza, Michael Scimeca
      and Erin Carpenter are currently employed by Boston University under NIH/NIDCD
      grant number U01DC014922 awarded to SK.
EDAT- 2020/11/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/19 05:32
PHST- 2020/11/19 05:32 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040495 [pii]
AID - 10.1136/bmjopen-2020-040495 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 18;10(11):e040495. doi: 10.1136/bmjopen-2020-040495.


PMID- 33208326
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211203
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 18
TI  - Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam:
      study protocol for an effectiveness-implementation trial evaluating an integrated
      model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
PG  - e039234
LID - 10.1136/bmjopen-2020-039234 [doi]
AB  - INTRODUCTION: In Vietnam, people who inject drugs (PWID), who are the major
      population infected by hepatitis C virus (HCV), remain largely undiagnosed and
      unlinked to HCV prevention and care despite recommended universal hepatitis C
      treatment. The data on the outcomes of HCV treatment among PWID also remain
      limited in resource-limited settings. The DRug use & Infections in
      ViEtnam-hepatitis C (DRIVE-C) study examines the effectiveness of a model of
      hepatitis C screening and integrated care targeting PWID that largely uses
      community-based organisations (CBO) in Hai Phong, Vietnam. In a wider
      perspective, this model may have the potential to eliminate HCV among PWID in
      this city. METHODS AND ANALYSIS: The model of care comprises large
      community-based mass screening, simplified treatment with direct-acting
      antivirals (DAAs) and major involvement of CBO for PWID reaching out, linkage to 
      care, treatment adherence and prevention of reinfection. The effectiveness of DAA
      care strategy among PWID, the potential obstacles to widespread implementation
      and its impact at population level will be assessed. A cost-effectiveness
      analysis is planned to further inform policy-makers. The enrolment target is 1050
      PWID, recruited from the DRIVE study in Hai Phong. After initiation of
      pan-genotypic treatment consisting of sofosbuvir and daclatasvir administrated
      for 12 weeks, with ribavirin added in cases of cirrhosis, participants are
      followed-up for 48 weeks. The primary outcome is the proportion of patients with 
      sustained virological response at week 48, that will be compared with a
      theoretical expected rate of 70%. ETHICS AND DISSEMINATION: The study was
      approved by Haiphong University of Medicine and Pharmacy's Ethics Review Board
      and the Vietnamese Ministry of Health. The sponsor and the investigators are
      committed to conducting this study in accordance with ethics principles contained
      in the World Medical Association's Declaration of Helsinki (Ethical Principles
      for Medical Research Involving Human Subjects). Informed consent is obtained
      before study enrolment. The data are anonymised and stored in a secure database. 
      The study is ongoing. Results will be presented at international conferences and 
      submitted to international peer-review journals. TRIAL REGISTRATION NUMBER:
      NCT03537196.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rapoud, Delphine
AU  - Rapoud D
AUID- ORCID: 0000-0001-6677-2714
AD  - Pathogenesis and Control of Chronic Infections, Inserm, Etablissement Francais du
      Sang, University of Montpellier, Montpellier, France delphine.rapoud@inserm.fr.
FAU - Quillet, Catherine
AU  - Quillet C
AD  - Pathogenesis and Control of Chronic Infections, Inserm, Etablissement Francais du
      Sang, University of Montpellier, Montpellier, France.
FAU - Pham Minh, Khue
AU  - Pham Minh K
AD  - Faculty of Public Health, Haiphong University of Medicine and Pharmacy, Hai
      Phong, Vietnam.
FAU - Vu Hai, Vinh
AU  - Vu Hai V
AD  - Department of Infectious and Tropical Diseases, Viet Tiep Hospital, Hai Phong,
      Vietnam.
FAU - Nguyen Thanh, Binh
AU  - Nguyen Thanh B
AD  - Faculty of Public Health, Haiphong University of Medicine and Pharmacy, Hai
      Phong, Vietnam.
FAU - Nham Thi Tuyet, Thanh
AU  - Nham Thi Tuyet T
AD  - Center for Supporting Community Development Initiatives, Hanoi, Vietnam.
FAU - Tran Thi, Hong
AU  - Tran Thi H
AD  - Faculty of Public Health, Haiphong University of Medicine and Pharmacy, Hai
      Phong, Vietnam.
FAU - Moles, Jean-Pierre
AU  - Moles JP
AD  - Pathogenesis and Control of Chronic Infections, Inserm, Etablissement Francais du
      Sang, University of Montpellier, Montpellier, France.
FAU - Vallo, Roselyne
AU  - Vallo R
AD  - Pathogenesis and Control of Chronic Infections, Inserm, Etablissement Francais du
      Sang, University of Montpellier, Montpellier, France.
FAU - Michel, Laurent
AU  - Michel L
AD  - CESP Inserm UMRS 1018, Paris Saclay University, Pierre Nicole Center, French Red 
      Cross, Paris, France.
FAU - Feelemyer, Jonathan
AU  - Feelemyer J
AD  - College of Global Public Health, New York University, New York, New York, USA.
FAU - Weiss, Laurence
AU  - Weiss L
AD  - Department of Clinical Immunology, Hotel Dieu Hospital, Paris, France.
FAU - Lemoine, Maud
AU  - Lemoine M
AD  - Department of Surgery and Cancer, Liver Unit, Imperial College London, London,
      UK.
FAU - Vickerman, Peter
AU  - Vickerman P
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Fraser, Hannah
AU  - Fraser H
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Duong Thi, Huong
AU  - Duong Thi H
AD  - Faculty of Public Health, Haiphong University of Medicine and Pharmacy, Hai
      Phong, Vietnam.
FAU - Khuat Thi Hai, Oanh
AU  - Khuat Thi Hai O
AD  - Center for Supporting Community Development Initiatives, Hanoi, Vietnam.
FAU - Des Jarlais, Don
AU  - Des Jarlais D
AD  - College of Global Public Health, New York University, New York, New York, USA.
FAU - Nagot, Nicolas
AU  - Nagot N
AD  - Pathogenesis and Control of Chronic Infections, Inserm, Etablissement Francais du
      Sang, University of Montpellier, Montpellier, France.
FAU - Laureillard, Didier
AU  - Laureillard D
AD  - Department of Infectious and Tropical Diseases, Nimes University Hospital, Nimes,
      France.
CN  - DRIVE-C Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03537196
GR  - R01 DA041978/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201118
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Hepacivirus
MH  - *Hepatitis C/drug therapy/prevention & control
MH  - *Hepatitis C, Chronic/drug therapy/prevention & control
MH  - Humans
MH  - *Pharmaceutical Preparations
MH  - *Substance Abuse, Intravenous/drug therapy
MH  - Vietnam
PMC - PMC7677340
OTO - NOTNLM
OT  - *Clinical trials
OT  - *Hepatology
OT  - *Infection control
OT  - *Public health
OT  - *THERAPEUTICS
COIS- Competing interests: None declared.
EDAT- 2020/11/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/19 05:32
PHST- 2020/11/19 05:32 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039234 [pii]
AID - 10.1136/bmjopen-2020-039234 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 18;10(11):e039234. doi: 10.1136/bmjopen-2020-039234.


PMID- 33208325
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 18
TI  - Biofortification of wheat with zinc for eliminating deficiency in Pakistan: study
      protocol for a cluster-randomised, double-blind, controlled effectiveness study
      (BIZIFED2).
PG  - e039231
LID - 10.1136/bmjopen-2020-039231 [doi]
AB  - INTRODUCTION: Micronutrient deficiencies, commonly referred to as 'hidden
      hunger', affect more than two billion people worldwide, with zinc and
      iron-deficiency frequently reported. The aim of this study is to examine the
      impact of consuming zinc biofortified flour (Zincol-2016) on biochemical and
      functional measures of status in adolescent girls and children living in a
      low-resource setting in Pakistan. METHODS AND ANALYSIS: We are conducting a
      pragmatic, cluster-randomised, double-blind, controlled trial. A total of 482
      households have been recruited from two catchment areas approximately 30-40 km
      distance from Peshawar. Household inclusion criteria are the presence of both an 
      adolescent girl, aged 10-16 years, and a child aged 1-5 years. The study duration
      is 12 months, divided into two 6-month phases. During phase 1, all households
      will be provided with locally procured flour from standard varieties of wheat.
      During phase 2, clusters will be paired, and randomised to either the control or 
      intervention arm of the study. The intervention arm will be provided with zinc
      biofortified wheat flour, with a target zinc concentration of 40 mg/kg. The
      control arm will be provided with locally procured wheat flour from standard
      varieties with an expected zinc concentration of 20 mg/kg. The primary outcome
      measure is plasma zinc concentration. Secondary outcomes include anthropometric
      measurements, biomarkers of iron and zinc status, and the presence and duration
      of respiratory tract infections and diarrhoea. ETHICS AND DISSEMINATION: Ethical 
      approval was granted from the University of Central Lancashire STEMH Ethics
      Committee (reference number: STEMH 1014) and Khyber Medical University Ethics
      Committee (DIR/KMU-EB/BZ/000683). The final study methods will be published in
      peer-reviewed journals, alongside the study outcomes. In addition, findings will 
      be disseminated to the scientific community via conference presentations and
      abstracts and communicated to the study participants through the village elders
      at an appropriate community forum. TRIAL REGISTRATION NUMBER: ISRCTN17107812;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lowe, Nicola M
AU  - Lowe NM
AUID- ORCID: 0000-0002-6934-2768
AD  - UCLan Research Centre for Global Development, University of Central Lancashire,
      Preston, UK NMLowe@uclan.ac.uk.
FAU - Zaman, Mukhtiar
AU  - Zaman M
AD  - Department of Pulmonology, Rehman Medical Institute, Peshawar, Khyber
      Pakhtunkhwa, Pakistan.
FAU - Moran, Victoria Hall
AU  - Moran VH
AUID- ORCID: 0000-0003-3165-4448
AD  - UCLan Research Centre for Global Development, University of Central Lancashire,
      Preston, UK.
FAU - Ohly, Heather
AU  - Ohly H
AD  - UCLan Research Centre for Global Development, University of Central Lancashire,
      Preston, UK.
FAU - Sinclair, Jonathan
AU  - Sinclair J
AD  - UCLan Research Centre for Global Development, University of Central Lancashire,
      Preston, UK.
FAU - Fatima, Sadia
AU  - Fatima S
AD  - Institute of Basic Medical sciences, Khyber Medical University, Peshawar,
      Pakistan.
FAU - Broadley, Martin R
AU  - Broadley MR
AD  - School of Biosciences, University of Nottingham, Sutton Bonington Campus,
      Nottingham, UK.
FAU - Joy, Edward J M
AU  - Joy EJM
AD  - Department of Population Health, London School of Hygiene and Tropical Medicine, 
      London, London, UK.
FAU - Mahboob, Usman
AU  - Mahboob U
AD  - Institute of Health Professions Education and Research, Khyber Medical
      University, Peshawar, Pakistan.
FAU - Lark, R Murray
AU  - Lark RM
AD  - School of Biosciences, University of Nottingham, Sutton Bonington Campus,
      Nottingham, UK.
FAU - Zia, Munir H
AU  - Zia MH
AD  - Research and Development, Fauji Fertilizer Co Ltd, Rawalpindi, Punjab, Pakistan.
FAU - Ander, E Louise
AU  - Ander EL
AD  - Inorganic Chemistry, Centre for Environmental Geochemistry, British Geological
      Survey, Nottingham, UK.
FAU - Sharp, Paul A
AU  - Sharp PA
AD  - Nutritional Sciences, Kings College London, London, UK.
FAU - Bailey, Elizabeth H
AU  - Bailey EH
AD  - School of Biosciences, University of Nottingham, Sutton Bonington Campus,
      Nottingham, UK.
FAU - Young, Scott D
AU  - Young SD
AD  - School of Biosciences, University of Nottingham, Sutton Bonington Campus,
      Nottingham, UK.
FAU - Khan, Muhammad Jaffar
AU  - Khan MJ
AD  - Institute of Basic Medical sciences, Khyber Medical University, Peshawar,
      Pakistan.
LA  - eng
SI  - ISRCTN/ISRCTN17107812
GR  - BB/SO13989/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201118
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - J41CSQ7QDS (Zinc)
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - *Biofortification
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Flour
MH  - Humans
MH  - Infant
MH  - Pakistan
MH  - Randomized Controlled Trials as Topic
MH  - *Triticum
MH  - Zinc
PMC - PMC7677336
OTO - NOTNLM
OT  - *Pakistan
OT  - *agronomic biofortification
OT  - *iron
OT  - *wheat
OT  - *zinc
OT  - *zinc status
COIS- Competing interests: None declared.
EDAT- 2020/11/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/19 05:32
PHST- 2020/11/19 05:32 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039231 [pii]
AID - 10.1136/bmjopen-2020-039231 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 18;10(11):e039231. doi: 10.1136/bmjopen-2020-039231.


PMID- 33208223
OWN - NLM
STAT- Publisher
LR  - 20210312
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
DP  - 2020 Nov 19
TI  - Health Care Workers' Legal Liability and Immunity During the COVID-19 Pandemic.
PG  - 1-2
LID - 10.1017/dmp.2020.449 [doi]
AB  - The coronavirus disease (COVID-19) pandemic is the most unprecedented crisis
      facing modern health care governance in a century. Many health care activities
      are attracting scrutiny from ethical and legal perspectives. Therefore, health
      care professionals are concerned about legal ambiguity regarding legal liability 
      and immunity in their areas of practice. Law is a key response activity that
      promotes a sense of safety and security among health care workers. This article
      describes why it is important formally to address issues of altered operations in
      health care practice during emergencies. Furthermore, this article provides
      suggestions regarding solutions to the issue of legal liability during disasters.
      Implementing ethical and legal clarity during a disaster response is necessary
      for a strong health care system at international and local levels to achieve a
      stable health care workforce operating for the public good within a safe and
      secure working environment.
FAU - Al-Azri, Nasser Hammad
AU  - Al-Azri NH
AD  - Emergency Department, Ibri Hospital, Ministry of Health, Muscat, Oman.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
PMC - PMC7943943
OTO - NOTNLM
OT  - healthcare provider
OT  - legal liability
OT  - pandemic
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/19 05:31
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/11/19 05:31 [entrez]
AID - S1935789320004498 [pii]
AID - 10.1017/dmp.2020.449 [doi]
PST - aheadofprint
SO  - Disaster Med Public Health Prep. 2020 Nov 19:1-2. doi: 10.1017/dmp.2020.449.


PMID- 33208155
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20211006
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Nov 19
TI  - Adding flexibility to clinical trial designs: an example-based guide to the
      practical use of adaptive designs.
PG  - 352
LID - 10.1186/s12916-020-01808-2 [doi]
AB  - Adaptive designs for clinical trials permit alterations to a study in response to
      accumulating data in order to make trials more flexible, ethical, and efficient. 
      These benefits are achieved while preserving the integrity and validity of the
      trial, through the pre-specification and proper adjustment for the possible
      alterations during the course of the trial. Despite much research in the
      statistical literature highlighting the potential advantages of adaptive designs 
      over traditional fixed designs, the uptake of such methods in clinical research
      has been slow. One major reason for this is that different adaptations to trial
      designs, as well as their advantages and limitations, remain unfamiliar to large 
      parts of the clinical community. The aim of this paper is to clarify where
      adaptive designs can be used to address specific questions of scientific
      interest; we introduce the main features of adaptive designs and commonly used
      terminology, highlighting their utility and pitfalls, and illustrate their use
      through case studies of adaptive trials ranging from early-phase dose escalation 
      to confirmatory phase III studies.
FAU - Burnett, Thomas
AU  - Burnett T
AD  - Department of Mathematics and Statistics, Lancaster University, Fylde College,
      Lancaster, LA1 4YF, UK. t.burnett1@lancaster.ac.uk.
FAU - Mozgunov, Pavel
AU  - Mozgunov P
AD  - Department of Mathematics and Statistics, Lancaster University, Fylde College,
      Lancaster, LA1 4YF, UK.
FAU - Pallmann, Philip
AU  - Pallmann P
AD  - Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Villar, Sofia S
AU  - Villar SS
AD  - MRC Biostatistics Unit, University of Cambridge School of Clinical Medicine,
      Cambridge Institute of Public Health, Forvie Site, Robinson Way, Cambridge
      Biomedical Campus, Cambridge, CB2 0SR, UK.
FAU - Wheeler, Graham M
AU  - Wheeler GM
AD  - Cancer Research UK & UCL Cancer Trials Centre, University College London, 90
      Tottenham Court Road, London, W1T 4TJ, UK.
FAU - Jaki, Thomas
AU  - Jaki T
AD  - Department of Mathematics and Statistics, Lancaster University, Fylde College,
      Lancaster, LA1 4YF, UK.
AD  - MRC Biostatistics Unit, University of Cambridge School of Clinical Medicine,
      Cambridge Institute of Public Health, Forvie Site, Robinson Way, Cambridge
      Biomedical Campus, Cambridge, CB2 0SR, UK.
LA  - eng
GR  - MC UU 0002/14/MRC_/Medical Research Council/United Kingdom
GR  - NIHR300576/National Institute for Health Research/International
GR  - MR/L004933/1/MRC_/Medical Research Council/United Kingdom
GR  - NIHR300576/DH_/Department of Health/United Kingdom
GR  - MC UU 00002/3/MRC_/Medical Research Council/United Kingdom
GR  - NIHR-SRF-2015-08-001/National Institute for Health Research/International
GR  - MC_UU_00002/14/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00002/15/MRC_/Medical Research Council/United Kingdom
GR  - SRF-2015-08-001/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201119
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Prospective Studies
MH  - *Research Design
MH  - Sample Size
PMC - PMC7677786
OTO - NOTNLM
OT  - *Efficient methods
OT  - *Enrichment designs
OT  - *Innovative trials
OT  - *Multi-arm multi-stage platform trials
OT  - *Novel designs
EDAT- 2020/11/20 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/11/19 05:30
PHST- 2020/06/29 00:00 [received]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/11/19 05:30 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - 10.1186/s12916-020-01808-2 [doi]
AID - 10.1186/s12916-020-01808-2 [pii]
PST - epublish
SO  - BMC Med. 2020 Nov 19;18(1):352. doi: 10.1186/s12916-020-01808-2.


PMID- 33208150
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 18
TI  - Clinical Ethics Committees in Africa: lost in the shadow of RECs/IRBs?
PG  - 115
LID - 10.1186/s12910-020-00559-2 [doi]
AB  - BACKGROUND: Clinical Ethics Committees (CECs) are well established at healthcare 
      institutions in resource-rich countries. However, there is limited information on
      established CECs in resource poor countries, especially in Africa. This study
      aimed to establish baseline data regarding existing formal CECs in Africa to
      raise awareness of and to encourage the establishment of CECs or Clinical Ethics 
      Consultation Services (CESs) on the continent. METHODS: A descriptive study was
      undertaken using an online questionnaire via SunSurveys to survey healthcare
      professionals and bioethicists in Africa. Data were subjected to descriptive
      analysis and Fischer's exact test was applied to determine associations. Texts
      from the open-ended questions were thematically analysed. RESULTS: In total 109
      participants from 37 African countries completed the survey in December 2019. A
      significant association was found between participants' bioethics qualification
      or training and involvement in clinical ethics (p = 0.005). All participants were
      familiar with Research Ethics Committees (RECs), and initially conflated RECs
      with CECs. When CECs were explained in detail, approximately 85.3% reported that 
      they had no formal CECs in their institutions. The constraints to developing CECs
      included lack of training, limited resources, and lack of awareness of CECs.
      However, the majority of participants (81.7%) were interested in establishing
      CECs. Participants listed assistance required in establishing CECs including
      funding, resources, capacity building and collaboration with other known CECs.
      The results do not reflect CECs established since the onset of COVID-19 in
      Africa. CONCLUSIONS: This study provides a first look into CECs in Africa and
      found very few formal CECs on the continent indicating an urgent need for the
      establishment of CECs or CESs in Africa. While the majority of healthcare
      professionals and bioethicists are aware of ethical dilemmas in healthcare, the
      concept of formal CECs is foreign. This study served to raise awareness of CECs. 
      Research ethics and RECs overshadow CECs in Africa because international funders 
      from the global north support capacity development in research ethics and
      establish RECs to approve the research they fund in Africa. Raising awareness via
      educational opportunities, research and conferences about CECs and their role in 
      improving the quality of health care in Africa is sorely needed.
FAU - Moodley, Keymanthri
AU  - Moodley K
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
      km@sun.ac.za.
FAU - Kabanda, Siti Mukaumbya
AU  - Kabanda SM
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
FAU - Soldaat, Leza
AU  - Soldaat L
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
FAU - Kleinsmidt, Anita
AU  - Kleinsmidt A
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
FAU - Obasa, Adetayo Emmanuel
AU  - Obasa AE
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
FAU - Kling, Sharon
AU  - Kling S
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
AD  - Department of Paediatrics and Child Health, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Tygerberg, South Africa.
LA  - eng
GR  - IN-1160267/Universiteit Stellenbosch/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201118
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Africa
MH  - COVID-19/*epidemiology
MH  - Cooperative Behavior
MH  - Developing Countries
MH  - Ethics Committees, Clinical/*organization & administration
MH  - Ethics Committees, Research/*organization & administration
MH  - Ethics, Clinical
MH  - Humans
PMC - PMC7672173
OTO - NOTNLM
OT  - *Africa
OT  - *Clinical ethics
OT  - *Clinical ethics committees
OT  - *Clinical ethics consultation service
OT  - *Developing countries
OT  - *Dilemma
OT  - *Ethics
EDAT- 2020/11/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/19 05:30
PHST- 2020/07/24 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/19 05:30 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12910-020-00559-2 [doi]
AID - 10.1186/s12910-020-00559-2 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 18;21(1):115. doi: 10.1186/s12910-020-00559-2.


PMID- 33208140
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 18
TI  - Ethics framework for treatment use of investigational drugs.
PG  - 116
LID - 10.1186/s12910-020-00560-9 [doi]
AB  - BACKGROUND: Expanded access is the use of investigational drugs (IDs) outside of 
      clinical trials. Generally it is performed in patients with serious and
      life-threatening diseases who cannot be treated satisfactorily with authorized
      drugs. Legal regulations of expanded access to IDs have been introduced among
      others in the USA, the European Union (EU), Canada and Australia. In addition, in
      the USA an alternative to expanded access is treatment under the Right-to-Try
      law. However, the treatment use of IDs is inherently associated with a number of 
      ethically relevant problems. MAIN TEXT: The objective of this article is to
      present a coherent framework made up of eight requirements which have to be met
      for any treatment use of an ID to be ethical. These include a justified need for 
      the use of an ID, no threat to clinical development of the ID, adequate
      scientific evidence to support the treatment, patient's benefit as the primary
      goal of the use of an ID, informed decision of a patient, fair access of patients
      to IDs, independent review, as well as the dissemination of treatment results.
      CONCLUSIONS: While this framework is essentially consistent with the legal
      regulations of expanded access of the USA, the EU, Canada and Australia, it is
      substantially wider in scope because it addresses some important issues that are 
      not covered by the regulations. Overall, the framework that we developed
      minimizes the risks and threats, and maximizes potential benefits to each of the 
      four key stakeholders involved in the treatment use of IDs including patients,
      doctors, drug manufacturers, and society at large.
FAU - Borysowski, Jan
AU  - Borysowski J
AUID- ORCID: 0000-0001-5256-1959
AD  - Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka Str.
      59, 02-006, Warsaw, Poland. jborysowski@interia.pl.
AD  - Centre for Studies on Research Integrity, Institute of Law Studies, Polish
      Academy of Sciences, Nowy Swiat 72, 00-330, Warsaw, Poland.
      jborysowski@interia.pl.
FAU - Gorski, Andrzej
AU  - Gorski A
AD  - Laboratory of Bacteriophages, Ludwik Hirszfeld Institute of Immunology and
      Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla Str. 12, 53-114,
      Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201118
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - Australia
MH  - Canada
MH  - *Compassionate Use Trials
MH  - *Drugs, Investigational
MH  - European Union
MH  - Humans
PMC - PMC7672838
OTO - NOTNLM
OT  - *Compassionate use
OT  - *Declaration of Helsinki
OT  - *Expanded access
OT  - *Investigational drug
OT  - *Right-to-try law
EDAT- 2020/11/20 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/19 05:30
PHST- 2020/03/12 00:00 [received]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2020/11/19 05:30 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00560-9 [doi]
AID - 10.1186/s12910-020-00560-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 18;21(1):116. doi: 10.1186/s12910-020-00560-9.


PMID- 33207842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2076-2607 (Print)
IS  - 2076-2607 (Linking)
VI  - 8
IP  - 11
DP  - 2020 Nov 16
TI  - Monitoring Gene Expression during a Galleria mellonella Bacterial Infection.
LID - E1798 [pii]
LID - 10.3390/microorganisms8111798 [doi]
AB  - Galleria mellonella larvae are an alternative in vivo model that has been
      extensively used to study the virulence and pathogenicity of different bacteria
      due to its practicality and lack of ethical constraints. However, the larvae
      possess intrinsic autofluorescence that obstructs the use of fluorescent proteins
      to study bacterial infections, hence better methodologies are needed. Here, we
      report the construction of a promoter probe vector with bioluminescence
      expression as well as the optimization of a total bacterial RNA extraction
      protocol to enhance the monitoring of in vivo infections. By employing the vector
      to construct different gene promoter fusions, variable gene expression levels
      were efficiently measured in G. mellonella larvae at various time points during
      the course of infection and without much manipulation of the larvae.
      Additionally, our optimized RNA extraction protocol facilitates the study of
      transcriptional gene levels during an in vivo infection. The proposed
      methodologies will greatly benefit bacterial infection studies as they can
      contribute to a better understanding of the in vivo infection processes and
      pathogen-mammalian host interactions.
FAU - Moya-Anderico, Laura
AU  - Moya-Anderico L
AUID- ORCID: 0000-0001-8471-9853
AD  - Bacterial Infections and Antimicrobial Therapies Group, Institute for
      Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and
      Technology (BIST), 08028 Barcelona, Spain.
FAU - Admella, Joana
AU  - Admella J
AUID- ORCID: 0000-0002-0063-6768
AD  - Bacterial Infections and Antimicrobial Therapies Group, Institute for
      Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and
      Technology (BIST), 08028 Barcelona, Spain.
FAU - Fernandes, Rodrigo
AU  - Fernandes R
AD  - Bacterial Infections and Antimicrobial Therapies Group, Institute for
      Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and
      Technology (BIST), 08028 Barcelona, Spain.
FAU - Torrents, Eduard
AU  - Torrents E
AUID- ORCID: 0000-0002-3010-1609
AD  - Bacterial Infections and Antimicrobial Therapies Group, Institute for
      Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and
      Technology (BIST), 08028 Barcelona, Spain.
AD  - Microbiology Section, Department of Genetics, Microbiology, and Statistics,
      Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain.
LA  - eng
GR  - RTI2018-098573-B-100/Ministerio e Economia, Industria, y Competividad, SPAIN
GR  - L16-FQLC/La Caixa
GR  - 2017SGR-1079/AGAUR-Generalitat de Catalunya
PT  - Journal Article
DEP - 20201116
PL  - Switzerland
TA  - Microorganisms
JT  - Microorganisms
JID - 101625893
PMC - PMC7697238
OTO - NOTNLM
OT  - Galleria mellonella
OT  - P. aeruginosa
OT  - bioluminescence
OT  - hemocytes
OT  - hemolymph
OT  - optimized RNA extraction
OT  - promoter probe vector
OT  - ribonucleotide reductases
EDAT- 2020/11/20 06:00
MHDA- 2020/11/20 06:01
CRDT- 2020/11/19 01:02
PHST- 2020/10/27 00:00 [received]
PHST- 2020/11/12 00:00 [revised]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/11/19 01:02 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/20 06:01 [medline]
AID - microorganisms8111798 [pii]
AID - 10.3390/microorganisms8111798 [doi]
PST - epublish
SO  - Microorganisms. 2020 Nov 16;8(11). pii: microorganisms8111798. doi:
      10.3390/microorganisms8111798.


PMID- 33207598
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201218
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 22
DP  - 2020 Nov 16
TI  - Facing a Second Wave from a Regional View: Spatial Patterns of COVID-19 as a Key 
      Determinant for Public Health and Geoprevention Plans.
LID - E8468 [pii]
LID - 10.3390/ijerph17228468 [doi]
AB  - Several studies on spatial patterns of COVID-19 show huge differences depending
      on the country or region under study, although there is some agreement that
      socioeconomic factors affect these phenomena. The aim of this paper is to
      increase the knowledge of the socio-spatial behavior of coronavirus and
      implementing a geospatial methodology and digital system called SITAR (Fast
      Action Territorial Information System, by its Spanish acronym). We analyze as a
      study case a region of Spain called Cantabria, geocoding a daily series of
      microdata coronavirus records provided by the health authorities (Government of
      Cantabria-Spain) with the permission of Medicines Ethics Committee from Cantabria
      (CEIm, June 2020). Geocoding allows us to provide a new point layer based on the 
      microdata table that includes cases with a positive result in a COVID-19 test.
      Regarding general methodology, our research is based on Geographical Information 
      Technologies using Environmental Systems Research Institute (ESRI) Technologies. 
      This tool is a global reference for spatial COVID-19 research, probably due to
      the world-renowned COVID-19 dashboard implemented by the Johns Hopkins University
      team. In our analysis, we found that the spatial distribution of COVID-19 in
      urban locations presents a not random distribution with clustered patterns and
      density matters in the spread of the COVID-19 pandemic. As a result, large
      metropolitan areas or districts with a higher number of persons tightly linked
      together through economic, social, and commuting relationships are the most
      vulnerable to pandemic outbreaks, particularly in our case study. Furthermore,
      public health and geoprevention plans should avoid the idea of economic or
      territorial stigmatizations. We hold the idea that SITAR in particular and
      Geographic Information Technologies in general contribute to strategic spatial
      information and relevant results with a necessary multi-scalar perspective to
      control the pandemic.
FAU - Cos, Olga De
AU  - Cos O
AUID- ORCID: 0000-0002-2245-5378
AD  - Department of Geography, Urbanism and Land Planning, University of Cantabria,
      39005 Santander, Spain.
AD  - Research Group of Health Economics and Health Services Management-Research
      Institute Marques de Valdecilla (IDIVAL), 39011 Santander, Spain.
FAU - Castillo, Valentin
AU  - Castillo V
AD  - Department of Geography, Urbanism and Land Planning, University of Cantabria,
      39005 Santander, Spain.
AD  - Research Group of Health Economics and Health Services Management-Research
      Institute Marques de Valdecilla (IDIVAL), 39011 Santander, Spain.
FAU - Cantarero, David
AU  - Cantarero D
AD  - Research Group of Health Economics and Health Services Management-Research
      Institute Marques de Valdecilla (IDIVAL), 39011 Santander, Spain.
AD  - Department of Economics, University of Cantabria, 39005 Santander, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*prevention & control
MH  - Geographic Mapping
MH  - *Geography, Medical
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*epidemiology/*prevention & control
MH  - Public Health
MH  - SARS-CoV-2
MH  - Spain
PMC - PMC7697593
OTO - NOTNLM
OT  - *ArcGIS
OT  - *COVID-19
OT  - *geographic information technologies
OT  - *geoprevention
OT  - *microdata
OT  - *public health
OT  - *spatial patterns
EDAT- 2020/11/20 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/19 01:01
PHST- 2020/10/10 00:00 [received]
PHST- 2020/11/12 00:00 [revised]
PHST- 2020/11/13 00:00 [accepted]
PHST- 2020/11/19 01:01 [entrez]
PHST- 2020/11/20 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - ijerph17228468 [pii]
AID - 10.3390/ijerph17228468 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 16;17(22). pii: ijerph17228468. doi:
      10.3390/ijerph17228468.


PMID- 35141605
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2666-5484 (Electronic)
IS  - 2666-5484 (Linking)
VI  - 4
DP  - 2020 Dec
TI  - The preliminary opinion of Canadian spine surgeons on Medical Assistance in Dying
      (MAID); a cross-sectional survey of Canadian Spine Society (CSS) members.
PG  - 100037
LID - 10.1016/j.xnsj.2020.100037 [doi]
AB  - BACKGROUND: On June 17, 2016, providing medical assistance in dying became legal 
      in Canada. This controversial change has had reverberating implications for the
      entire medical community. This is especially true for physicians that regularly
      deal with end-of-life decisions, among them neurosurgical and orthopedic spine
      surgeons, whose patients suffer from a variety of debilitating conditions. With
      this study we sought to document the opinions of Canadian spine surgeons in hopes
      of better understanding the sentiment within the speciality towards this change
      and assess how it evolves over time. METHODS: A cross-sectional survey was sent
      out to members of the Canadian Spine Society (CSS). The survey encompassed 21
      questions pertaining to opinions and attitudes regarding MAID and different
      facets of the legislation. RESULTS: A total of 51 surgeons responded to the
      survey, comprised of a mix of orthopedic surgeons (68.6%), pediatric orthopedic
      surgeons (5.9%), and neurosurgeons (21.6%), practicing all across Canada. The
      majority support the patients' right to obtain MAID (62.8%) and the right of
      physicians to participate (82.4%). Most also support the right to conscientious
      objection (90.1%). The results were split on duty to refer patients for MAID
      (49.0%). Respondents were also divided on whether they could foresee themselves
      referring to a MAID service, with 37.2% responding yes. A small minority of
      respondents (3.9%) felt they could see themselves actively involved in MAID.
      CONCLUSIONS: At the advent of legal MAID, the majority of members of the CSS
      supported both the right of patients to participate in MAID and the right of
      physicians to provide this service if they so choose, while still respecting the 
      principle of conscientious objection. Of note, only a small minority were willing
      to be actively involved. This survey provides a useful baseline of opinions in
      this practice area and will be used to analyze changes over the next 10 years.
CI  - (c) 2020 Published by Elsevier Ltd on behalf of North American Spine Society.
FAU - Leck, Erika
AU  - Leck E
AD  - Dalhousie University, Faculty of Medicine, Halifax, Nova Scotia B3H 4R2, Canada.
AD  - Nova Scotia Health Authority Department of Surgery, Division of Neurosurgery,
      1796 Summer Street, Halifax Infirmary, Halifax, Nova scotia B3H 3A6, Canada.
FAU - Christie, Sean
AU  - Christie S
AD  - Dalhousie University, Faculty of Medicine, Halifax, Nova Scotia B3H 4R2, Canada.
AD  - Nova Scotia Health Authority Department of Surgery, Division of Neurosurgery,
      1796 Summer Street, Halifax Infirmary, Halifax, Nova scotia B3H 3A6, Canada.
FAU - Barry, Tricia
AU  - Barry T
AD  - Nova Scotia Health Authority Department of Surgery, Division of Neurosurgery,
      1796 Summer Street, Halifax Infirmary, Halifax, Nova scotia B3H 3A6, Canada.
FAU - Barry, Sean
AU  - Barry S
AD  - Dalhousie University, Faculty of Medicine, Halifax, Nova Scotia B3H 4R2, Canada.
AD  - Nova Scotia Health Authority Department of Surgery, Division of Neurosurgery,
      1796 Summer Street, Halifax Infirmary, Halifax, Nova scotia B3H 3A6, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - United States
TA  - N Am Spine Soc J
JT  - North American Spine Society journal
JID - 9918335076906676
PMC - PMC8820034
OTO - NOTNLM
OT  - Canada
OT  - Ethics
OT  - Medical assistance in dying
OT  - Policy
OT  - Spine surgery
EDAT- 2020/11/20 00:00
MHDA- 2020/11/20 00:01
CRDT- 2022/02/10 05:40
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2022/02/10 05:40 [entrez]
PHST- 2020/11/20 00:00 [pubmed]
PHST- 2020/11/20 00:01 [medline]
AID - 10.1016/j.xnsj.2020.100037 [doi]
AID - S2666-5484(20)30037-8 [pii]
PST - epublish
SO  - N Am Spine Soc J. 2020 Nov 20;4:100037. doi: 10.1016/j.xnsj.2020.100037.
      eCollection 2020 Dec.


PMID- 33207142
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20201218
IS  - 2328-5273 (Electronic)
IS  - 2328-4633 (Linking)
VI  - 78
IP  - 4
DP  - 2020 Dec
TI  - Ethical Implications of Resuming Elective Orthopedic Surgery During the COVID-19 
      Pandemic.
PG  - 221-226
AB  - The COVID-19 pandemic has had unprecedented impact on the United States health
      care system. One of the consider-ations was the decision to halt elective
      orthopedic surgery to preserve consumption of scarce resources. However, as the
      number of COVID-19 cases decrease, there will be discus-sions regarding the
      modality of resuming elective orthopedic surgery. Ethical considerations will
      come to the forefront in terms of determining the best course of action, patient 
      selection, resource rationing, and financial implications. These factors will be 
      examined through the lens of the four tenets of bioethics, beneficence,
      maleficence, autonomy, and justice, to elucidate the best approach in ethically
      manag-ing elective orthopedic surgery during a global pandemic.
FAU - Moses, Michael J.
AU  - Moses MJ
FAU - Bosco, Joseph A. III
AU  - Bosco JA III
FAU - Schwarzkopf, Ran
AU  - Schwarzkopf R
FAU - Zuckerman, Joseph D.
AU  - Zuckerman JD
FAU - Long, William J.
AU  - Long WJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bull Hosp Jt Dis (2013)
JT  - Bulletin of the Hospital for Joint Disease (2013)
JID - 101614130
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control/transmission
MH  - Elective Surgical Procedures/*ethics
MH  - Humans
MH  - Infection Control/*organization & administration
MH  - Orthopedic Procedures/*ethics
MH  - Pandemics/*prevention & control
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/epidemiology/*prevention & control/transmission
MH  - SARS-CoV-2
MH  - United States
EDAT- 2020/11/19 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/18 20:04
PHST- 2020/11/18 20:04 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PST - ppublish
SO  - Bull Hosp Jt Dis (2013). 2020 Dec;78(4):221-226.


PMID- 33206898
OWN - NLM
STAT- MEDLINE
DCOM- 20211014
LR  - 20220418
IS  - 0124-0064 (Print)
IS  - 0124-0064 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Nov 16
TI  - [Repercussions of the prevalence of metabolic syndrome on adults and elderly
      people in the context of primary health care].
PG  - 735-740
LID - 10.15446/rsap.V20n6.65564 [doi]
AB  - OBJECTIVE: To identify the prevalence of metabolic syndrome in users of the
      hypertension and diabetes mellitus program at a Health Center in Jequie City,
      Bahia, Brazil. MATERIALS AND METHODS: This is a descriptive cross-sectional
      study. The sample consisted of 100 patients enrolled in HIPERDIA. This study was 
      approved by the Research Ethics Committee of the State University of Southwest of
      Bahia (Minutes no. 013/2011). RESULTS: The prevalence of metabolic syndrome in
      these users was 43%. Regarding sex, the prevalence was 35% among men and 47%
      among women, considering that in 23% of the medical records there were
      insufficient data for classification. CONCLUSIONS: It was evidenced that the
      metabolic syndrome reaches proportionately more women than men, whereas, in
      relation to age, a higher prevalence of the disease was verified in individuals
      older than 60 years.
FAU - Carmo Silva-Junior, Antonio do
AU  - Carmo Silva-Junior AD
AD  - AS: Enfermeiro. (UESB), Jequie/BA, Brasil. jr_enf@hotmail.com.
FAU - Cruz, Diego Pires
AU  - Cruz DP
AD  - DC: Enfermeiro. Ph.D. Ciencias da Saude pelo Programa de Pos-Graduacao em
      Enfermagem e Saude (PPGES) da Universidade Estadual do Sudoeste da Bahia (UESB), 
      Jequie/BA, Brasil. diego_pcruz@hotmail.com.
FAU - Vitorio De Souza Junior, Edison
AU  - Vitorio De Souza Junior E
AD  - EDS: Academico de Enfermagem pela Universidade Estadual do Sudoeste da Bahia
      (UESB), Jequie/BA, Brasil. edison.vitorio@gmail.com.
FAU - Souza Rosa, Randson
AU  - Souza Rosa R
AD  - RR: Enfermeiro. M. Sc. Ciencias da Saude pelo Programa de Pos-Graduacao em
      Enfermagem e Saude (PPGES) da Universidade Estadual do Sudoeste da Bahia (UESB), 
      Jequie/BA, Brasil. enfrandson@gmail.com.
FAU - Missias Moreira, Ramon
AU  - Missias Moreira R
AD  - RM: Educador Fisico. Ph.D. Educacao pelo Programa de Pos-Graduacao em Educacao da
      Universidade Federal da Bahia (UFBA). Professor permanente do Programa de
      Pos-Graduacao em Psicologia da Universidade Federal do Vale do Sao Francisco
      (UNIVASF). Petrolina-PE, Brasil. ramon.missias@univasf.edu.br.
FAU - Santana Cardoso Santos, Isleide
AU  - Santana Cardoso Santos I
AD  - IC: Enfermeira. Ph.D. Ciencias da Saude Programa de Pos-Graduacao em Enfermagem e
      Saude (PPGES) da Universidade Estadual do Sudoeste da Bahia (UESB). Docente da
      Universidade do Estadual do Sudoeste da Bahia (UESB), Jequie/BA, Brasil.
      isleide71@yahoo.com.br.
LA  - por
PT  - Journal Article
TT  - Repercussoes da prevalencia da sindrome metabolica em adultos e idosos no
      contexto da atencao primaria.
PL  - Colombia
TA  - Rev Salud Publica (Bogota)
JT  - Revista de salud publica (Bogota, Colombia)
JID - 100936348
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Body Mass Index
MH  - Brazil/epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/*epidemiology
MH  - Middle Aged
MH  - Prevalence
MH  - Primary Health Care/*statistics & numerical data
MH  - Risk Factors
MH  - Sex Distribution
MH  - Urban Population/statistics & numerical data
EDAT- 2020/11/19 06:00
MHDA- 2021/10/15 06:00
CRDT- 2020/11/18 17:10
PHST- 2017/06/08 00:00 [received]
PHST- 2018/06/10 00:00 [accepted]
PHST- 2020/11/18 17:10 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/10/15 06:00 [medline]
AID - 10.15446/rsap.V20n6.65564 [doi]
PST - ppublish
SO  - Rev Salud Publica (Bogota). 2020 Nov 16;20(6):735-740. doi:
      10.15446/rsap.V20n6.65564.


PMID- 33206823
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201124
IS  - 2177-6709 (Electronic)
IS  - 2176-9451 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Sep-Oct
TI  - A contraindication to orthodontic and endodontic treatment: periapical
      cemento-osseous dysplasia.
PG  - 17-22
LID - S2176-94512020000500017 [pii]
LID - 10.1590/2177-6709.25.5.017-022.oin [doi]
AB  - INTRODUCTION: The dental pulp is completely normal in teeth with periapical
      cemento-osseous dysplasia. However, orthodontic and endodontic treatments are
      contraindicated in cases with this injury. OBJECTIVE: Present some biological,
      clinical and imaging reasons opposing these contraindications and questioning
      which are the real ones impediments and the reasons for the lack of research on
      the disease, analyzing cases submitted to orthopedic treatment under controlled
      and ethically approved conditions. CONCLUSION: The clinician can act safely based
      in available knowledge and aware of the possible consequences of orthodontic
      movement in teeth with periapical cemento-osseous dysplasia, as well as in the
      proper way of making a safe and definitive diagnosis.
FAU - Consolaro, Alberto
AU  - Consolaro A
AUID- ORCID: http://orcid.org/0000-0002-5902-5646
AD  - Universidade de Sao Paulo, Faculdade de Odontologia de Bauru Bauru/SP, Brazil.
AD  - Universidade de Sao Paulo, Faculdade de Odontologia de Ribeirao Preto Ribeirao
      Preto/SP, Brazil.
FAU - Hadaya, Omar
AU  - Hadaya O
AUID- ORCID: http://orcid.org/0000-0002-5973-2543
AD  - Digital Center Radiologia Maringa/PR, Brazil.
FAU - Consolaro, Renata Bianco
AU  - Consolaro RB
AUID- ORCID: http://orcid.org/0000-0001-8841-6913
AD  - Faculdades Adamantinenses Integradas Adamantina/SP, Brazil.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Dental Press J Orthod
JT  - Dental press journal of orthodontics
JID - 101532240
SB  - IM
MH  - *Cementoma/diagnosis
MH  - Contraindications
MH  - Diagnosis, Differential
MH  - Humans
PMC - PMC7668062
EDAT- 2020/11/19 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/18 17:10
PHST- 2020/08/19 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/11/18 17:10 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - S2176-94512020000500017 [pii]
AID - 10.1590/2177-6709.25.5.017-022.oin [doi]
PST - ppublish
SO  - Dental Press J Orthod. 2020 Sep-Oct;25(5):17-22. doi:
      10.1590/2177-6709.25.5.017-022.oin.


PMID- 33206812
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201122
IS  - 2317-6385 (Electronic)
IS  - 1679-4508 (Linking)
VI  - 18
DP  - 2020
TI  - Initial survey on the use of animals in scientific research and teaching reveals 
      divided opinion of the Brazilian population.
PG  - eAO5451
LID - S1679-45082020000100279 [pii]
LID - 10.31744/einstein_journal/2020AO5451 [doi]
AB  - OBJECTIVE: Specific legislation regulating the use of animals in research in
      Brazil was introduced in 2008. However, the viewpoint of the Brazilian population
      regarding the use of animals in research and teaching activities remains largely 
      unknown. Investigation of the public viewpoint on and understanding of the topic 
      is required given the current shifts in the animal ethics scenario in Brazil. The
      objective of this study was to provide the first insight into the Brazilian
      population viewpoint on the use of animals in scientific research and teaching
      activities. METHODS: Data collected in a survey involving 2,115 individuals aged 
      16 years or older and residing in 130 municipalities distributed across the five 
      Brazilian macroregions (North, Northeast, South, Southeast, and Midwest) were
      analyzed. The margin of error for entire sample was set at 2%, with a 95%
      confidence interval. RESULTS: This survey revealed that most Brazilian citizens
      are in favor of the use animals in research, particularly for medical purposes.
      Different views depending on the nature of research were identified.
      Approximately 80% of respondents were also in favor of frequent oversight of
      laboratories and animal facilities. CONCLUSION: Survey findings indicate that the
      opinion of the Brazilian population is divided when it comes to the use of
      animals in scientific research and teaching. Divided opinions expose a limited
      understanding of the importance of basic sciences and emphasizes the need for
      improved communication between the scientific community and the general
      population. Further strategies aimed to promote animal welfare are discussed.
FAU - Andersen, Monica Levy
AU  - Andersen ML
AUID- ORCID: http://orcid.org/0000-0002-1894-6748
AD  - Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Floeter-Winter, Lucile Maria
AU  - Floeter-Winter LM
AUID- ORCID: http://orcid.org/0000-0002-8954-8704
AD  - Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Tufik, Sergio
AU  - Tufik S
AUID- ORCID: http://orcid.org/0000-0002-3804-8865
AD  - Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20201113
PL  - Brazil
TA  - Einstein (Sao Paulo)
JT  - Einstein (Sao Paulo, Brazil)
JID - 101281800
SB  - IM
MH  - *Animal Experimentation
MH  - Animals
MH  - Brazil
MH  - Cities
MH  - Humans
MH  - *Public Opinion
MH  - Surveys and Questionnaires
PMC - PMC7647387
EDAT- 2020/11/19 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/18 17:10
PHST- 2019/01/23 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/11/18 17:10 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - S1679-45082020000100279 [pii]
AID - 10.31744/einstein_journal/2020AO5451 [doi]
PST - epublish
SO  - Einstein (Sao Paulo). 2020 Nov 13;18:eAO5451. doi:
      10.31744/einstein_journal/2020AO5451. eCollection 2020.


PMID- 33206771
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20220418
IS  - 2317-1782 (Electronic)
IS  - 2317-1782 (Linking)
VI  - 32
IP  - 6
DP  - 2020
TI  - Interaction betwenn family and child/adolescent with hearing deficiency.
PG  - e20190147
LID - S2317-17822020000600302 [pii]
LID - 10.1590/2317-1782/20202019147 [doi]
AB  - PURPOSE: to know the family interaction with the hearing impaired
      child/adolescent. METHODS: descriptive and exploratory qualitative research
      developed at a Special School in Southern Brazil. Participants were 10 primary
      caregivers of deaf children/adolescents between 10 and 19 years old. The
      collection took place in November 2017, through semi-structured interviews
      containing questions about the communication process of deaf children/adolescents
      with their families. The information was analyzed through thematic analysis. The 
      study was submitted and approved by the Ethics Committee under opinion number
      2.333.560. RESULTS: as the main theme of the study "Interaction between the
      family and the child/adolescent with hearing impairment", it addresses two
      sub-themes: potentialities and weaknesses in the communication of the family with
      the child/adolescent with hearing impairment and learning in the care of the
      child/adolescent with hearing impairment. CONCLUSION: it was identified that the 
      interaction of the deaf with the family and society is impaired by people's lack 
      of knowledge about the deaf community and the Brazilian Sign Language, which
      raises concern in caregivers who often overprotect the child/adolescent which may
      limit the full development of their skills and autonomy.
FAU - Thomaz, Manuela Maschendorf
AU  - Thomaz MM
AUID- ORCID: http://orcid.org/0000-0002-5016-1705
AD  - Faculdade de Enfermagem, Universidade Federal de Pelotas, Pelotas (RS), Brasil.
FAU - Milbrath, Viviane Marten
AU  - Milbrath VM
AUID- ORCID: http://orcid.org/0000-0001-5523-3803
AD  - Faculdade de Enfermagem, Universidade Federal de Pelotas, Pelotas (RS), Brasil.
FAU - Gabatz, Ruth Irmgard Bartschi
AU  - Gabatz RIB
AUID- ORCID: http://orcid.org/0000-0001-6075-8516
AD  - Faculdade de Enfermagem, Universidade Federal de Pelotas, Pelotas (RS), Brasil.
FAU - Freitag, Vera Lucia
AU  - Freitag VL
AUID- ORCID: http://orcid.org/0000-0002-5897-7012
AD  - Centro de Ciencias da Saude e Agrarias, Universidade de Cruz Alta, Cruz Alta
      (RS), Brasil.
FAU - Vaz, Jessica Cardoso
AU  - Vaz JC
AUID- ORCID: http://orcid.org/0000-0002-2581-1091
AD  - Faculdade de Enfermagem, Universidade Federal de Pelotas, Pelotas (RS), Brasil.
LA  - por
LA  - eng
PT  - Journal Article
TT  - Interacao entre a familia e a crianca/adolescente com deficiencia auditiva.
DEP - 20201113
PL  - Brazil
TA  - Codas
JT  - CoDAS
JID - 101623246
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brazil
MH  - Child
MH  - *Deafness
MH  - Family
MH  - Hearing
MH  - Humans
MH  - Sign Language
MH  - Young Adult
EDAT- 2020/11/19 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/18 17:10
PHST- 2019/06/15 00:00 [received]
PHST- 2019/12/04 00:00 [accepted]
PHST- 2020/11/18 17:10 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - S2317-17822020000600302 [pii]
AID - 10.1590/2317-1782/20202019147 [doi]
PST - epublish
SO  - Codas. 2020 Nov 13;32(6):e20190147. doi: 10.1590/2317-1782/20202019147.
      eCollection 2020.


PMID- 33206710
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20211118
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - "[It] is now my responsibility to fulfill that wish:" Clinical and rapid autopsy 
      staff members' experiences and perceptions of HIV reservoir research at the end
      of life.
PG  - e0242420
LID - 10.1371/journal.pone.0242420 [doi]
AB  - INTRODUCTION: Little is known about the effects of HIV reservoir research at the 
      end of life on staff members involved. Staff members' perceptions and experiences
      were assessed related to their involvement in the Last Gift, a rapid autopsy
      study at the University of California San Diego enrolling people living with HIV 
      who are terminally ill and have a desire to contribute to HIV cure-related
      research. METHODS: Two focus group discussions consisting of clinical (n = 7) and
      rapid research autopsy (n = 8) staff members were conducted to understand the
      perspectives of staff members and the impact the Last Gift rapid autopsy study
      had on them. The total sample consisted of 66.7% females and 33.3% males and was 
      ethnically diverse (66.7% Caucasian, 6.7% African American, 20.0% Asian descent, 
      6.7% Hispanic descent and American Indian) with a range of experience in the HIV 
      field from 1 year to 30 years. RESULTS: Qualitative focus group data revealed
      five major themes underlying study staff members' multilayered mental and
      practical involvement: 1) positive perceptions of the Last Gift study, with
      sub-themes including Last Gift study participants' altruism, fulfillment, and
      control at the end of life, 2) perceptions of staff members' close involvement in
      the Last Gift study, with sub-themes related to staff members' cognitive
      processing, self-actualization and fulfillment, stress management and resilience,
      coping mechanisms, and gratitude toward Last Gift participants and toward the
      study itself, 3) considerations for successful and sustainable study
      implementation, such as ethical awareness and sustained community and patient
      engagement, 4) collaborative learning and organizational processes and the value 
      of interdependence between staff members, and 5) considerations for potential
      study scale-up at other clinical research sites. DISCUSSION: Understanding staff 
      members' nuanced emotional and procedural experiences is crucial to the Last Gift
      study's sustainability and will inform similar cure research studies conducted
      with people living with HIV at the end of life. The study's potential
      reproducibility depends on a robust research infrastructure with established,
      interdependent clinical and rapid autopsy teams, continuous community engagement,
      and an ethical and well-informed engagement process with people living with HIV.
FAU - Perry, Kelly E
AU  - Perry KE
AUID- ORCID: 0000-0002-8637-4729
AD  - UNC Gillings School of Global Public Health, Chapel Hill, NC, United States of
      America.
FAU - Taylor, Jeff
AU  - Taylor J
AD  - AntiViral Research Center Community Advisory Board, San Diego, CA, United States 
      of America.
AD  - HIV + Aging Research Project-Palm Springs (HARP-PS), Palm Springs, CA, United
      States of America.
FAU - Patel, Hursch
AU  - Patel H
AUID- ORCID: 0000-0002-0725-4922
AD  - UNC Gillings School of Global Public Health, Chapel Hill, NC, United States of
      America.
FAU - Javadi, Sogol Stephanie
AU  - Javadi SS
AD  - AntiViral Research Center (AVRC), University of California San Diego, San Diego, 
      CA, United States of America.
FAU - Mathur, Kushagra
AU  - Mathur K
AD  - AntiViral Research Center (AVRC), University of California San Diego, San Diego, 
      CA, United States of America.
FAU - Kaytes, Andy
AU  - Kaytes A
AD  - AntiViral Research Center Community Advisory Board, San Diego, CA, United States 
      of America.
FAU - Concha-Garcia, Susanna
AU  - Concha-Garcia S
AD  - AntiViral Research Center (AVRC), University of California San Diego, San Diego, 
      CA, United States of America.
AD  - HIV Neurobehavioral Research Center, University of California San Diego, San
      Diego, CA, United States of America.
FAU - Little, Susan
AU  - Little S
AUID- ORCID: 0000-0002-7645-9737
AD  - AntiViral Research Center (AVRC), University of California San Diego, San Diego, 
      CA, United States of America.
AD  - Division of Infectious Diseases and Global Public Health, University of
      California San Diego, San Diego, CA, United States of America.
FAU - Smith, Davey
AU  - Smith D
AD  - AntiViral Research Center (AVRC), University of California San Diego, San Diego, 
      CA, United States of America.
AD  - Division of Infectious Diseases and Global Public Health, University of
      California San Diego, San Diego, CA, United States of America.
FAU - Gianella, Sara
AU  - Gianella S
AD  - AntiViral Research Center (AVRC), University of California San Diego, San Diego, 
      CA, United States of America.
AD  - Division of Infectious Diseases and Global Public Health, University of
      California San Diego, San Diego, CA, United States of America.
FAU - Dube, Karine
AU  - Dube K
AUID- ORCID: 0000-0003-3458-1539
AD  - UNC Gillings School of Global Public Health, Chapel Hill, NC, United States of
      America.
LA  - eng
GR  - P30 MH062512/MH/NIMH NIH HHS/United States
GR  - R25 MH067127/MH/NIMH NIH HHS/United States
GR  - R21 MH118120/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201118
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Altruism
MH  - Autopsy
MH  - Death
MH  - Female
MH  - Focus Groups/methods
MH  - HIV/pathogenicity
MH  - HIV Infections/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Participation/psychology
MH  - Qualitative Research
MH  - Research Personnel/*psychology
MH  - Social Behavior
MH  - Terminal Care/*psychology
PMC - PMC7673534
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/19 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/18 17:09
PHST- 2020/03/13 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/18 17:09 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1371/journal.pone.0242420 [doi]
AID - PONE-D-20-07324 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 18;15(11):e0242420. doi: 10.1371/journal.pone.0242420.
      eCollection 2020.


PMID- 33206283
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Capability Sensitive Design for Health and Wellbeing Technologies.
PG  - 3363-3391
LID - 10.1007/s11948-020-00275-5 [doi]
AB  - This article presents the framework Capability Sensitive Design (CSD), which
      consists of merging the design methodology Value Sensitive Design (VSD) with
      Martha Nussbaum's capability theory. CSD aims to normatively assess technology
      design in general, and technology design for health and wellbeing in particular. 
      Unique to CSD is its ability to account for human diversity and to counter
      (structural) injustices that manifest in technology design. The basic framework
      of CSD is demonstrated by applying it to the hypothetical design case of a
      therapy chatbot for mental health. By applying CSD to a design case, the merits
      of this new framework over the standard VSD approach become apparent. Also, the
      application demonstrates what a technology design would look like when attention 
      is paid to capabilities right from the start of the design process.
FAU - Jacobs, Naomi
AU  - Jacobs N
AUID- ORCID: http://orcid.org/0000-0002-7088-4628
AD  - Department of Philosophy and Ethics, and Human-Technology Interaction, Eindhoven 
      University of Technology, Eindhoven, The Netherlands. n.jacobs@tue.nl.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humans
MH  - *Mental Health
MH  - *Technology
PMC - PMC7755618
OTO - NOTNLM
OT  - Capability approach
OT  - Capability sensitive design
OT  - Design framework
OT  - Ethics
OT  - Ethics by design
OT  - Value sensitive design
EDAT- 2020/11/19 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/18 12:13
PHST- 2019/12/18 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/11/18 12:13 [entrez]
AID - 10.1007/s11948-020-00275-5 [doi]
AID - 10.1007/s11948-020-00275-5 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3363-3391. doi: 10.1007/s11948-020-00275-5. Epub
      2020 Nov 18.


PMID- 33205768
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220419
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 11
DP  - 2020 Nov
TI  - [Citizens' engagement in healthcare.]
PG  - 673-674
LID - 10.1701/3474.34571 [doi]
AB  - The engagement of citizens and patients in health care was one of the ethical
      principles that led to the Healthcare Reform of 1978 in Italy. Since then, this
      principle has been constantly reaffirmed. Yet, the patient is not at the center
      of the system: rather, he suffers the bureaucratic and administrative burden of
      complex, irrational, inefficient paths in the labyrinth between primary care and 
      specialist assistance. The working group of the MaCroScopio project aims to
      propose concrete and operational suggestions to the central and regional
      authorities, to enhance the role of the citizen and the patient.
FAU - Martini, Nello
AU  - Martini N
AD  - Fondazione Ricerca e Salute.
LA  - ita
PT  - Journal Article
TT  - L'engagement dei cittadini nella sanita.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
MH  - Italy
MH  - Male
EDAT- 2020/11/19 06:00
MHDA- 2022/04/20 06:00
CRDT- 2020/11/18 08:37
PHST- 2020/11/18 08:37 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
AID - 10.1701/3474.34571 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Nov;111(11):673-674. doi: 10.1701/3474.34571.


PMID- 33205767
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220419
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 11
DP  - 2020 Nov
TI  - [Freedom to choose treatments in incurable disease.Summary. The lack of knowledge
      and application of legal and ethical norms have often justified behaviors of many
      health workers not adequate to the care needs of people with ALS or other
      incurable diseases, highlighting their cultural unpreparedness. The narration of 
      the experience and reflections of a palliativist doctor with an ALS patient can
      be reason for mainly ethical considerations.]
PG  - 670-672
LID - 10.1701/3474.34570 [doi]
FAU - Rigotti, Laura
AU  - Rigotti L
AD  - SC Cure Palliative ASST Mantova; Dipartimento Interaziendale Cure Palliative ATS 
      Valpadana.
LA  - ita
PT  - Journal Article
TT  - Liberta di scegliere i trattamenti nella malattia inguaribile.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - *Amyotrophic Lateral Sclerosis/therapy
MH  - Freedom
MH  - Health Personnel
MH  - Humans
MH  - Narration
MH  - *Physicians
EDAT- 2020/11/19 06:00
MHDA- 2022/04/20 06:00
CRDT- 2020/11/18 08:37
PHST- 2020/11/18 08:37 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
AID - 10.1701/3474.34570 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Nov;111(11):670-672. doi: 10.1701/3474.34570.


PMID- 33205761
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220419
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 11
DP  - 2020 Nov
TI  - [Artificial intelligence and palliative care: opportunities and limitations.]
PG  - 639-645
LID - 10.1701/3474.34564 [doi]
AB  - The so-called artificial intelligence tools applied to palliative care (machine
      learning, natural language processing) have great potential to support clinicians
      in improving decision-making processes and in identifying those who are at high
      risk of mortality or at greater risk of inappropriate treatment and/or
      non-positive outcomes. The improvement of prognostic abilities may help to avoid 
      that some choices of patients with serious diseases are taken only in the last
      days of life, in the face of treatment options not previously discussed in an
      adequate and shared way. These tools can facilitate some essential aspects in the
      practice of palliative care, for example the activation of interviews that have
      as their objective the advance care planning and the definition of treatments
      consistent with the needs and desires of patients, especially in final stages of 
      life. The development, also in our country, of projects for the application of
      artificial intelligence in palliative care requires particular attention to the
      possible organizational repercussions and to some ethical and relational aspects.
      It will be necessary to reflect on the most appropriate organizational models and
      on the specialized resources necessary in relation to the foreseeable increase in
      the number and variability of patients with early identified palliative care
      needs. These tools must not interfere in fundamental elements of the relationship
      between patient and doctor, that is the ability to communicate a poor prognosis
      in an individualized and ethically appropriate way.
FAU - Peruselli, Carlo
AU  - Peruselli C
AD  - Past President Societa Italiana Cure Palliative (SICP).
FAU - De Panfilis, Ludovica
AU  - De Panfilis L
AD  - Unitadi Bioetica, Azienda USL-IRCCS di Reggio Emilia.
FAU - Gobber, Gino
AU  - Gobber G
AD  - UOM Cure Palliative, Azienda Provinciale per i Servizi Sanitari, Trento.
FAU - Melo, Massimo
AU  - Melo M
AD  - UOM Cure Palliative, Azienda Provinciale per i Servizi Sanitari, Trento.
FAU - Tanzi, Silvia
AU  - Tanzi S
AD  - Unita di Cure Palliative, Azienda USL-IRCCS di Reggio Emilia, Clinical and
      Experimental Medicine PhD Program, Universita di Modena e Reggio Emilia.
LA  - ita
PT  - Journal Article
TT  - Intelligenza artificiale e cure palliative: opportunita e limiti.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - *Palliative Care
EDAT- 2020/11/19 06:00
MHDA- 2022/04/20 06:00
CRDT- 2020/11/18 08:37
PHST- 2020/11/18 08:37 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
AID - 10.1701/3474.34564 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Nov;111(11):639-645. doi: 10.1701/3474.34564.


PMID- 33205727
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 10
DP  - 2020 Sep 30
TI  - Cannabis legalisation and testing for cannabis use in safety- and risk-sensitive 
      environments.
PG  - 995-998
LID - 10.7196/SAMJ.2020.v110i10.14615 [doi]
AB  - The legalisation of cannabis by the High Court of South Africa, which was
      confirmed by the Constitutional Court, imposes challenges to occupational medical
      practitioners acting as medical review officers in compliance testing and
      fit-for-service medical examinations. The lipophilic character of the
      psychoactive component of cannabis, delta-9-tetrahydrocannabinol (Delta9-THC),
      and its prolonged elimination half-life, create challenges for the ethically and 
      scientifically correct management of the legal use of cannabis in risk-sensitive 
      environments. Important issues to consider in testing for cannabis use are: the
      stance of 'zero tolerance'; screening and confirmation cut-off concentrations;
      and the bio-matrices used for testing. Constitutional rights relate to privacy,
      freedom, autonomy, freedom of religion and the equal enjoyment of rights and
      privileges, which must be balanced against the health and safety of others.
FAU - Laurens, J B
AU  - Laurens JB
AD  - Forensic Toxicology Laboratory, Department of Chemistry, Faculty of Agriculture
      and Natural Sciences, University of Pretoria, South Africa. tim.laurens@up.ac.za.
FAU - Carstens, P A
AU  - Carstens PA
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Body Fluids/chemistry
MH  - Dronabinol/blood/*pharmacokinetics/urine
MH  - Employment
MH  - Half-Life
MH  - Humans
MH  - Marijuana Smoking/blood/*legislation & jurisprudence/*metabolism/urine
MH  - *Occupational Health
MH  - Physical Examination/methods
MH  - Risk Assessment/*methods
MH  - South Africa
MH  - Time Factors
EDAT- 2020/11/19 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/11/18 08:36
PHST- 2020/09/30 00:00 [received]
PHST- 2020/11/18 08:36 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i10.14615 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Sep 30;110(10):995-998. doi: 10.7196/SAMJ.2020.v110i10.14615.


PMID- 33205726
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 10
DP  - 2020 Aug 21
TI  - May a sample be legally removed or an autopsy undertaken without an advance
      directive or proxy consent to determine whether a critical care patient at risk
      of COVID-19 infection has died as a result of the virus?
PG  - 993-994
LID - 10.7196/SAMJ.2020.v110i10.15190 [doi]
AB  - It has recently been suggested that ethically and legally the obtaining of
      biological samples for research after death during the COVID-19 pandemic in South
      Africa justifies a waiver of consent followed by a deferred proxy consent.
      However, it is submitted that because deceased persons are not protected by the
      Constitution, and only partially protected by common law and statute law, such
      consent and the need for consent to autopsies may be dispensed with altogether
      under the common law doctrine of 'necessity'. It is pointed out that such
      information is in the public interest because it will inform critical care
      facilities on how to save lives of future patients and assist government in
      responding to the COVID-19 pandemic by adequate planning. It is also reasonably
      justifiable in the public interest to ascertain the COVID-19 status of deceased
      persons who may have been exposed to the virus, in order to protect their family,
      friends, healthcare practitioners, undertakers and staff members, and members of 
      the public with whom they have been in contact. Finally, it is suggested that the
      law can be clarified by amending the Disaster Management COVID-19 regulations to 
      do away with consent for such autopsies or tissue sample collections from
      deceased persons exposed to the risk of contracting the virus, subject to certain
      conditions.
FAU - McQuoid-Mason, D J
AU  - McQuoid-Mason DJ
AD  - Centre for Socio-Legal Studies, University of KwaZulu-Natal, Durban, South
      Africa. mcquoidm@ukzn.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20200821
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Advance Directives/*legislation & jurisprudence
MH  - *Autopsy
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*mortality
MH  - Humans
MH  - Informed Consent/*legislation & jurisprudence
MH  - Pandemics/*legislation & jurisprudence
MH  - Pneumonia, Viral/*mortality
MH  - SARS-CoV-2
MH  - South Africa
EDAT- 2020/11/19 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/18 08:36
PHST- 2020/08/21 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/11/18 08:36 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i10.15190 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Aug 21;110(10):993-994. doi: 10.7196/SAMJ.2020.v110i10.15190.


PMID- 33205431
OWN - NLM
STAT- MEDLINE
DCOM- 20210907
LR  - 20210907
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 60 Suppl 1
DP  - 2020 Oct
TI  - The Current Landscape of Novel Formulations and the Role of Mathematical Modeling
      in Their Development.
PG  - S77-S97
LID - 10.1002/jcph.1715 [doi]
AB  - Drug delivery is an integral part of the drug development process, influencing
      safety and efficacy of active pharmaceutical ingredients. The application of
      nanotechnology has enabled the discovery of novel formulations for numerous
      therapeutic purposes across multiple disease areas. However, evaluation of novel 
      formulations in clinical scenarios is slow and hampered due to various ethical
      and logistical barriers. Computational models have the ability to integrate
      existing domain knowledge and mathematical correlations, to rationalize the
      feasibility of using novel formulations for safely enhancing drug delivery,
      identifying suitable candidates, and reducing the burden on preclinical and
      clinical studies. In this review, types of novel formulations and their
      application through several routes of administration and the use of modeling
      approaches that can find application in different stages of the novel formulation
      development process are discussed.
CI  - (c) 2020 The Authors. The Journal of Clinical Pharmacology published by Wiley
      Periodicals LLC on behalf of American College of Clinical Pharmacology.
FAU - Cottura, Nicolas
AU  - Cottura N
AD  - Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and 
      Integrative Biology, University of Liverpool, Liverpool, UK.
FAU - Howarth, Alice
AU  - Howarth A
AD  - Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and 
      Integrative Biology, University of Liverpool, Liverpool, UK.
FAU - Rajoli, Rajith K R
AU  - Rajoli RKR
AD  - Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and 
      Integrative Biology, University of Liverpool, Liverpool, UK.
FAU - Siccardi, Marco
AU  - Siccardi M
AD  - Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and 
      Integrative Biology, University of Liverpool, Liverpool, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
SB  - IM
MH  - Drug Administration Routes
MH  - *Drug Compounding
MH  - *Drug Delivery Systems
MH  - *Drug Development
MH  - Humans
MH  - Models, Theoretical
OTO - NOTNLM
OT  - *Drug development
OT  - *Long-acting
OT  - *Nanomedicine
OT  - *PBPK
OT  - *Pharmacokinetics and drug metabolism
OT  - *Pharmacometrics
EDAT- 2020/11/19 06:00
MHDA- 2021/09/08 06:00
CRDT- 2020/11/18 06:03
PHST- 2020/03/16 00:00 [received]
PHST- 2020/07/25 00:00 [accepted]
PHST- 2020/11/18 06:03 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/09/08 06:00 [medline]
AID - 10.1002/jcph.1715 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2020 Oct;60 Suppl 1:S77-S97. doi: 10.1002/jcph.1715.


PMID- 33205089
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 2666-3899 (Electronic)
IS  - 2666-3899 (Linking)
VI  - 1
IP  - 1
DP  - 2020 Apr 10
TI  - Who Should Do Data Ethics?
PG  - 100015
LID - 10.1016/j.patter.2020.100015 [doi]
AB  - Who decides what good data science looks like? And who gets to decide what "data 
      ethics" means? The answer is all of us. Good data science should incorporate the 
      perspectives of people who create and work with data, people who study the
      interactions between science and society, and people whose lives are affected by 
      data science.
CI  - (c) 2020 The Author(s).
FAU - Wylie, Caitlin D
AU  - Wylie CD
AD  - School of Engineering and Applied Science, University of Virginia,
      Charlottesville, VA, USA.
LA  - eng
PT  - News
DEP - 20200410
PL  - United States
TA  - Patterns (N Y)
JT  - Patterns (New York, N.Y.)
JID - 101767765
PMC - PMC7660418
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 06:01
PHST- 2020/11/18 06:01 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1016/j.patter.2020.100015 [doi]
AID - S2666-3899(20)30015-5 [pii]
PST - epublish
SO  - Patterns (N Y). 2020 Apr 10;1(1):100015. doi: 10.1016/j.patter.2020.100015.
      eCollection 2020 Apr 10.


PMID- 33204878
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 11
DP  - 2020 Nov
TI  - Top business schools legitimacy quest through the Sustainable Development Goals.
PG  - e05395
LID - 10.1016/j.heliyon.2020.e05395 [doi]
AB  - An organization acquires legitimacy when it operates in an appropriate and
      desirable manner, satisfying the stakeholders' needs and expectations.
      Stakeholders claim to business schools sustainable and responsible management,
      knowledge transfer and research. In the last years, business schools adopted
      Corporate Social Responsibility as guideline of an integrated and holistic
      approach for their legitimation process. The aim of this research is to
      understand how business schools are reacting to the criticism that affects them
      and how they are reshaping their strategies in order to fulfill stakeholders'
      expectations, and to confirm which UN Sustainable Development Goals are the most 
      cited in the sustainability reports of the best business schools in the world. We
      perform a content analysis of the latest sustainability reports published by the 
      top 50 business schools, analyzing the 17 UN Sustainable Development Goals. We
      highlight that business schools focus social responsibility strategies mainly to 
      define the professional standards to train future leaders qualified to manage
      organizations with a social, economic and environmental positive impact for all
      the stakeholders and capable to shape a better world.
CI  - (c) 2020 The Author(s).
FAU - Miotto, Giorgia
AU  - Miotto G
AD  - Ramon Llull University, Blanquerna - Communication and International Relations
      School, Placa Joan Coromines, s/n, 08001, Barcelona, Spain.
FAU - Blanco-Gonzalez, Alicia
AU  - Blanco-Gonzalez A
AD  - Rey Juan Carlos University, Social Sciences and Law School, Paseo de los
      Artilleros s/n, 28032, Madrid, Spain.
FAU - Diez-Martin, Francisco
AU  - Diez-Martin F
AD  - Rey Juan Carlos University, Social Sciences and Law School, Paseo de los
      Artilleros s/n, 28032, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7649273
OTO - NOTNLM
OT  - Business school
OT  - Corporate social responsibility
OT  - Educational development
OT  - Ethic
OT  - High education
OT  - Legitimacy
OT  - Management
OT  - Marketing
OT  - Sustainable business
OT  - Sustainable development goals
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/18 06:00 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e05395 [doi]
AID - S2405-8440(20)32238-6 [pii]
PST - epublish
SO  - Heliyon. 2020 Nov 4;6(11):e05395. doi: 10.1016/j.heliyon.2020.e05395. eCollection
      2020 Nov.


PMID- 33204864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 2405-6618 (Electronic)
IS  - 2405-6618 (Linking)
VI  - 11
DP  - 2020 Nov
TI  - Cross-border reproductive care in the USA: Who comes, why do they come, what do
      they purchase?
PG  - 42-47
LID - 10.1016/j.rbms.2020.09.003 [doi]
AB  - This article explores the participation of non-US-resident patients/clients in
      the US reproductive market, garnering a picture of cross-border reproductive care
      (CBRC) into the USA by drawing on the existing literature, identifying the
      frequency of and motivations for such arrangements, the primary sending
      countries, and the reproductive services sought. I find that although the expense
      of US CBRC necessarily limits the patient/client pool, it is largely non-economic
      factors that drive CBRC into the USA. The US CBRC patient/client base, which is
      diverse in terms of national origin, race and sexual orientation, is recruited by
      the US fertility industry and drawn to the full range of assisted reproductive
      technology (ART) services, such as in-vitro fertilization, surrogacy, oocyte
      donation and preimplantation genetic screening/preimplantation genetic diagnosis,
      available in the US market which are often restricted or limited in their
      countries of origin. CBRC patients/clients enjoy the legal clarity for
      establishing parentage and citizenship for their children available in the USA,
      as well as what some view as a medically and ethically superior ART market.
CI  - (c) 2020 The Author(s).
FAU - Jacobson, Heather
AU  - Jacobson H
AD  - Department of Sociology and Anthropology, The University of Texas at Arlington,
      Arlington, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - England
TA  - Reprod Biomed Soc Online
JT  - Reproductive biomedicine & society online
JID - 101700286
PMC - PMC7653003
OTO - NOTNLM
OT  - CBRC
OT  - assisted reproduction
OT  - cross-border reproductive care
OT  - reproductive travel
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/11/18 06:00 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1016/j.rbms.2020.09.003 [doi]
AID - S2405-6618(20)30019-8 [pii]
PST - epublish
SO  - Reprod Biomed Soc Online. 2020 Oct 14;11:42-47. doi: 10.1016/j.rbms.2020.09.003. 
      eCollection 2020 Nov.


PMID- 33204840
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Nov 12
TI  - The Zombie Virus Pandemic: An Innovative Simulation Integrating Virology,
      Population Health, and Bioethics for Preclinical Medical Students.
PG  - 11016
LID - 10.15766/mep_2374-8265.11016 [doi]
AB  - Introduction: Understanding population health in the context of infectious
      disease outbreaks is an important physician competency. However, identifying
      effective ways to engage early medical students in this content remains a
      challenge. We designed an innovative pandemic simulation for first-year medical
      students utilizing the pop culture theme of zombies. Methods: This 2.5-hour
      simulation was conducted in 2018 and 2020 during students' virology course.
      Student teams collected and analyzed data to formulate hypotheses for the source 
      pathogen. The teams completed reports explaining their diagnostic hypotheses,
      infection containment recommendations, and resource allocation recommendations.
      Learners completed an evaluation of the simulation through an online survey.
      Responses were analyzed using descriptive statistics; narrative responses were
      analyzed qualitatively for themes. A content analysis was performed on students' 
      reports. Results: Two hundred eighty-four medical students participated in this
      activity. Nearly all respondents agreed that the small-group format (98%, 2018
      and 2020) and pace and duration (92%, 2018; 94%, 2020) were appropriate and that 
      the activity was intellectually stimulating (97%, 2018; 96%, 2020). Learner
      engagement measures were high (90%-97%, 2018; 83%-96%, 2020). Analysis of
      students' reports revealed evidence of cognitive integration of virology,
      population health, and bioethics concepts, including integration of new learning 
      content. Discussion: Collaborative problem-solving during a simulated
      zombie-themed pandemic provided preclinical medical students with an engaging
      opportunity to integrate virology, population health, and bioethics concepts.
      Implementing this event required advanced planning, use of multiple spaces,
      learning materials preparation, and recruitment of several faculty, staff, and
      actors.
CI  - (c) 2020 Jackson et al.
FAU - Jackson, Jennifer M
AU  - Jackson JM
AD  - Associate Professor, Department of Pediatrics, Wake Forest School of Medicine;
      Co-Course Director, Clinical Skills Curriculum, Wake Forest School of Medicine;
      Co-Course Director, Virology Course, Wake Forest School of Medicine; Assistant
      Dean for Curricular Innovation, Wake Forest School of Medicine.
FAU - Shen, E
AU  - Shen E
AD  - Assistant Professor, Department of General Internal Medicine, Wake Forest School 
      of Medicine; Director of Healthcare Teaching and Learning, Wake Forest School of 
      Medicine.
FAU - Peters, Timothy R
AU  - Peters TR
AD  - Professor, Department of Pediatrics, Wake Forest School of Medicine; Associate
      Dean for Educational Strategy & Innovation, Wake Forest School of Medicine;
      Co-Course Director, Virology Course, Wake Forest School of Medicine.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - *Bioethics
MH  - Humans
MH  - Learning
MH  - Pandemics
MH  - *Population Health
MH  - *Students, Medical
PMC - PMC7666840
OTO - NOTNLM
OT  - *Bioethics
OT  - *Biostatistics & Epidemiology
OT  - *Clinical Reasoning/Diagnostic Reasoning
OT  - *Editor's Choice
OT  - *Epidemiology
OT  - *Ethics/Bioethics
OT  - *Health Systems
OT  - *Infectious Disease
OT  - *Population Health
OT  - *Simulation
OT  - *Virology
EDAT- 2020/11/19 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/18 06:00
PHST- 2020/11/18 06:00 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.11016 [doi]
AID - 11016 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Nov 12;16:11016. doi: 10.15766/mep_2374-8265.11016.


PMID- 33204831
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Nov 3
TI  - Pediatric Refugee Health Care Delivery in the Community Setting: An Educational
      Workshop for Multidisciplinary Family-Centered Care During Resettlement.
PG  - 10988
LID - 10.15766/mep_2374-8265.10988 [doi]
AB  - Introduction: With 70.8 million people displaced worldwide, there is an
      increasing need for medical professionals to provide medical care to refugees.
      Insufficient training on refugee health poses a barrier to effective care
      delivery. Methods: This workshop addressed common challenges in providing
      family-centered pediatric refugee care in community settings as well as barriers 
      related to policy changes. Presentations covered prearrival experiences, medical 
      screening, and trauma-based care. In small groups, participants discussed cases
      that featured medical, behavioral health, social, and cultural factors impacting 
      the provision of family-centered pediatric care that was culturally respectful
      and included shared decision-making. After the breakout session, each small group
      informed the larger group of topics discussed. Facilitators identified themes and
      reinforced key learning points. At the workshop's conclusion, participants were
      guided to create their own personalized action plan. Results: This workshop was
      presented at two international conferences to more than 47 participants,
      including clinicians, nurse practitioners, pediatric residents, and medical
      students. Evaluations were completed by 34 individuals. Participants' overall
      comfort level with taking care of refugee patients increased from 3.3 to 4.0 (on 
      a 5-point scale, p = .24) during the 3-hour version of the workshop and from 3.8 
      to 4.0 (p = .43) in the 1-hour version of the workshop. Mean overall ratings of
      the 3- and 1-hour workshop versions on conference-administered evaluations were
      4.8 and 4.2, respectively, on a 5-point scale. Discussions: This workshop was
      well received and equipped participants with knowledge, tools, and strategies
      regarding pediatric refugee health in a community setting.
CI  - (c) 2020 Nehal et al.
FAU - Nehal, Umbereen S
AU  - Nehal US
AD  - Chief Medical Officer and Vice President of Medical Affairs, Community Healthcare
      Network; Assistant Professor, Department of Pediatrics, University of
      Massachusetts Medical School.
FAU - Kanahara, Satoko
AU  - Kanahara S
AD  - Medical Director of South Bronx Center, Community Healthcare Network.
FAU - Tanabe, Mihoko
AU  - Tanabe M
AD  - Medical Student, Philadelphia College of Osteopathic Medicine.
FAU - Hayner, Grace
AU  - Hayner G
AD  - Advanced Practice Nurse, Community Healthcare Network.
FAU - Nelson, Brett D
AU  - Nelson BD
AD  - Associate Professor, Department of Pediatrics, Harvard Medical School.
LA  - eng
PT  - Journal Article
DEP - 20201103
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - Child
MH  - Delivery of Health Care
MH  - Humans
MH  - Patient-Centered Care
MH  - *Refugees
MH  - *Students, Medical
PMC - PMC7666829
OTO - NOTNLM
OT  - *Community
OT  - *Community-Based Medicine
OT  - *Cultural Competence
OT  - *Cultural Respect
OT  - *Diversity
OT  - *Ethics
OT  - *Family-Centered Care
OT  - *Global Health
OT  - *Health Equity
OT  - *Inclusion
OT  - *Pediatrics
OT  - *Refugees
OT  - *Shared Decision Making
OT  - *Trauma-Informed Care
EDAT- 2020/11/19 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/18 06:00
PHST- 2020/11/18 06:00 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10988 [doi]
AID - 10988 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Nov 3;16:10988. doi: 10.15766/mep_2374-8265.10988.


PMID- 33204568
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 2090-6900 (Print)
VI  - 2020
DP  - 2020
TI  - Management Challenges of Metastatic Spinal Cord Compression in Pregnancy.
PG  - 8891021
LID - 10.1155/2020/8891021 [doi]
AB  - Primary and secondary spinal tumours with cord compression often represent a
      challenging condition for the patient and clinicians alike, even more so during
      pregnancy. The balance between safe delivery of a healthy baby and management of 
      the mother's disease bears many clinical, psychological, and ethical dilemmas.
      Pregnancy sets a conflict between the optimal surgical and oncological
      managements of the mother's tumour and the well-being of her foetus. We followed 
      the CARE guidelines from the EQUATOR Network to report an exemplificative case of
      a 39-year-old woman with a 10-year history of breast cancer, presenting in the
      second trimester of her first pregnancy with acute onset severe thoracic spinal
      instability, causing mechanical pain and weakness in lower limbs.
      Neuroradiological investigations revealed multilevel spinal deposits with a
      pathological T10 fracture responsible for spinal cord compression. The patient
      was adamant that she wanted a continuation of the pregnancy and her baby
      delivered. After discussion with her oncologist and obstetrician, we agreed to
      perform emergency spinal surgery-decompression and instrumented fixation. The
      literature search did not reveal a similar case of spinal metastatic breast
      cancer undergoing spinal instrumentation and delivery of a healthy baby a few
      months later. Following the delivery, the patient had further oncological
      treatment, including chemotherapy and radiotherapy. The paucity of such reports
      prompted us to present this case and highlight the relevance of a
      multidisciplinary approach involving obstetrician, oncologist, spinal surgeon,
      and radiologist to guide the optimal decision-making process.
CI  - Copyright (c) 2020 Davor Dasic et al.
FAU - Dasic, Davor
AU  - Dasic D
AUID- ORCID: https://orcid.org/0000-0002-0247-9639
AD  - Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool,
      UK.
FAU - Rath, Narendra K
AU  - Rath NK
AD  - Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool,
      UK.
FAU - Ganau, Mario
AU  - Ganau M
AUID- ORCID: https://orcid.org/0000-0002-8676-1147
AD  - Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust,
      Oxford, UK.
FAU - Sarsam, Zaid
AU  - Sarsam Z
AD  - Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool,
      UK.
LA  - eng
PT  - Case Reports
DEP - 20201101
PL  - United States
TA  - Case Rep Surg
JT  - Case reports in surgery
JID - 101580191
PMC - PMC7652620
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:59
PHST- 2020/07/25 00:00 [received]
PHST- 2020/10/13 00:00 [revised]
PHST- 2020/10/24 00:00 [accepted]
PHST- 2020/11/18 05:59 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1155/2020/8891021 [doi]
PST - epublish
SO  - Case Rep Surg. 2020 Nov 1;2020:8891021. doi: 10.1155/2020/8891021. eCollection
      2020.


PMID- 33204523
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 2090-0023 (Print)
IS  - 2090-0023 (Linking)
VI  - 2020
DP  - 2020
TI  - Prevalence and Intensity of Intestinal Helminth Infections in Preschool Pupils in
      Lugari Subcounty, Kakamega County, Kenya.
PG  - 8871042
LID - 10.1155/2020/8871042 [doi]
AB  - Intestinal helminths cause anaemia, malnutrition, indigestion disorders, retarded
      growth, and low mental abilities in pupils. About 1.5 billion are infected
      globally. Intestinal helminth infections are caused by Ascaris lumbricoides,
      Trichuris trichiura, Strongyloides stercoralis, Enterobius vermicularis,
      Ancylostoma duodenale, and Necator americanus. Lugari Subcounty has poor
      sanitation and inadequate clean water. This study determined the prevalence of
      intestinal helminth infections in preschool pupils in Lugari Subcounty. A
      stratified multistage cluster experimental design was used. Sampling was carried 
      out in four wards: Lumakanda, Lugari, Luandeti, and Chekalini. Preschool pupils
      of either gender were selected randomly. Written consents and verbal assent were 
      obtained from parents or guardians and preschool pupils, respectively.
      Questionnaires were administered in order to collect sociodemographic data. Stool
      samples were collected and tested for the presence of eggs using the standard
      Kato-Katz technique. Prevalence rate and prevalence ratio were calculated as the 
      percentage of infected preschool pupils among the total number of preschool
      pupils examined. Preschool pupils positive with helminths were treated freely,
      and a follow-up screening was conducted three months after treatment. Approval of
      the study was sought from the Masinde Muliro University of Science and Technology
      Institutional Ethical Review Board (MMUST IRB). The overall prevalence of
      intestinal helminths was 12.3%. Only one species, Ascaris lumbricoides, was
      identified. Statistical tests were carried out at a 5% significance level (p <
      0.05, confidence interval (CI) 95%). There was a statistically significant
      association for prevalence and intensity of intestinal helminths versus factors
      like school location, knowledge of washing hands before eating, and awareness of 
      washing hands after visiting a toilet. Although this study revealed a low
      prevalence and light intensity, some factors had significant effects on
      intestinal helminth infections among the preschool children. Therefore, there is 
      a need to intensify efforts for their intestinal helminth control.
CI  - Copyright (c) 2020 Daniel Kevin Werunga et al.
FAU - Werunga, Daniel Kevin
AU  - Werunga DK
AUID- ORCID: https://orcid.org/0000-0001-9900-4519
AD  - Department of Biological Sciences, Masinde Muliro University of Science and
      Technology, P.O. Box 190, Kakamega, Kenya.
FAU - Omukunda, Elizabeth Nanjala
AU  - Omukunda EN
AUID- ORCID: https://orcid.org/0000-0001-7516-7962
AD  - Department of Biological Sciences, Masinde Muliro University of Science and
      Technology, P.O. Box 190, Kakamega, Kenya.
FAU - Korir, Jackson Cheruiyot
AU  - Korir JC
AUID- ORCID: https://orcid.org/0000-0003-3264-3054
AD  - Department of Biological Sciences, Masinde Muliro University of Science and
      Technology, P.O. Box 190, Kakamega, Kenya.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - United States
TA  - J Parasitol Res
JT  - Journal of parasitology research
JID - 101526294
PMC - PMC7666631
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:59
PHST- 2020/07/06 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/11/18 05:59 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1155/2020/8871042 [doi]
PST - epublish
SO  - J Parasitol Res. 2020 Nov 7;2020:8871042. doi: 10.1155/2020/8871042. eCollection 
      2020.


PMID- 33204499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 2058-5241 (Print)
IS  - 2058-5241 (Linking)
VI  - 5
IP  - 10
DP  - 2020 Oct
TI  - Frontiers in non-union research.
PG  - 574-583
LID - 10.1302/2058-5241.5.190062 [doi]
AB  - Multifactorial aetiology defines non-unions, with a biological and a mechanical
      distortion of the timeline of bone healing.Research on new advances to increase
      osteogenesis and promote non-union healing is strongly directed towards new forms
      of cell products.Basic science and research on non-union treatments is needed to 
      compile preclinical data on new treatments.Bone marrow concentration and expanded
      mesenchymal stromal cells still require extensive clinical research to confirm
      efficacy in non-union treatment.Solid preclinical studies, precise cell product
      definition and preparation, and appropriate ethical and regulatory approvals are 
      needed to assess new advanced therapy medicinal products. Cite this article:
      EFORT Open Rev 2020;5:574-583. DOI: 10.1302/2058-5241.5.190062.
CI  - (c) 2020 The author(s).
FAU - Gomez-Barrena, Enrique
AU  - Gomez-Barrena E
AD  - Servicio de Cirugia Ortopedica y Traumatologia, Hospital La Paz-IdiPAZ,
      Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Padilla-Eguiluz, Norma G
AU  - Padilla-Eguiluz NG
AD  - Servicio de Cirugia Ortopedica y Traumatologia, Hospital La Paz-IdiPAZ,
      Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Rosset, Philippe
AU  - Rosset P
AD  - Service de Chirurgie Orthopedique et Traumatologie, CHU Tours, Universite de
      Tours, Tours, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201026
PL  - England
TA  - EFORT Open Rev
JT  - EFORT open reviews
JID - 101695674
PMC - PMC7608578
OTO - NOTNLM
OT  - ATMPs (advanced therapy medicinal products)
OT  - MSCs (mesenchymal stromal cells) and biomaterials
OT  - bone healing
OT  - cell therapy
OT  - non-union
COIS- ICMJE Conflict of interest statement: EG-B reports DSMB membership on HipGenCT,
      research funding from Exactech, speaker for Link; travel partial funding for
      ESSKA, all unrelated to this paper. The other authors declare no conflict of
      interest relevant to this work.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:59
PHST- 2020/11/18 05:59 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1302/2058-5241.5.190062 [doi]
AID - 10.1302_2058-5241.5.190062 [pii]
PST - epublish
SO  - EFORT Open Rev. 2020 Oct 26;5(10):574-583. doi: 10.1302/2058-5241.5.190062.
      eCollection 2020 Oct.


PMID- 33204420
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 60
DP  - 2020 Dec
TI  - Risk factors, clinical outcomes and predictors of stroke mortality in Sierra
      Leoneans: A retrospective hospital cohort study.
PG  - 293-300
LID - 10.1016/j.amsu.2020.10.060 [doi]
AB  - BACKGROUND: Stroke data from Sierra Leone is limited, despite the increase in
      global burden of the disease. The aim of this study was to assess the risk
      factors, clinical outcomes and predictors of stroke mortality at a tertiary
      hospital in Freetown, Sierra Leone. METHODS: This retrospective cohort study was 
      conducted on stroke patients admitted at the Connaught Teaching Hospital between 
      1st January to December 31, 2018. Clinical data related to stroke, with variables
      including patients' demographics, stroke subtype, vascular risk factors, modified
      Rankin Scale (mRS), and outcomes were documented. In-hospital mortality,
      associated risk factors and predictors of stroke were determined. The study was
      approved by the Sierra Leone Ethics and Scientific Review Committee. It was
      registered under Research Registry
      https://www.researchregistry.com/browse-the-registry#home/with the unique
      identifying number researchregistry6009. RESULT: We studied 178 (95 male and 83
      female) patients. The mean age was 59.8 +/- 14.0 years, median was 58.1years
      (ranging: 29-88 years). The commonest risk factors were hypertension (84.3%),
      tobacco smoking (35.9%) and alcohol (31.4%). Ischemic stroke confirmed by CT scan
      was 76.3%. In-hospital mortality was 34.8% and at discharge, mean modified Rankin
      Score (mRS) was 3.89 +/- 1.62. The independent predictors for stroke mortality
      were: hypertension [AOR = 2.2; C.I 95%: (1.32-3.80), p = 0.001], previous stroke 
      [AOR = 2.31; C.I 95%: (1.43-5.74), p = 0.001], GCS < 8 [AOR = 6.06; C.I 95%:
      (3.17-12.79), p < 0.001], clinical diagnosis in the absence of imaging [AOR =
      3.11; C.I 95%: (2.1-9.87), p = 0.001], hemorrhagic stroke [AOR = 2.96; C.I 95%:
      (1.96-9.54), p < 0.001], and aspiration pneumonia [(AOR = 3.03; C.I
      95%:(1.44-6.36), p = 0.001]. Women had poorer outcome than men. CONCLUSION: This 
      study highlights a high stroke mortality in a resource limited hospital, with
      some stroke patients having difficulties in accessing Computer Tomogram (CT) scan
      services. It illustrates the need to establish a stroke care setting to improve
      the quality of stroke care.
CI  - (c) 2020 The Authors.
FAU - Russell, James B W
AU  - Russell JBW
AD  - Department of Internal Medicine, Connaught Teaching Hospital, Ministry of Health 
      and Sanitation, Sierra Leone.
AD  - Department of Internal Medicine, Faculty of Clinical Sciences, College of
      Medicine and Allied Health Sciences, University of Sierra Leone, Sierra Leone.
FAU - Charles, Elijah
AU  - Charles E
AD  - Department of Internal Medicine, Connaught Teaching Hospital, Ministry of Health 
      and Sanitation, Sierra Leone.
FAU - Conteh, Victor
AU  - Conteh V
AD  - Department of Internal Medicine, Connaught Teaching Hospital, Ministry of Health 
      and Sanitation, Sierra Leone.
AD  - Department of Internal Medicine, Faculty of Clinical Sciences, College of
      Medicine and Allied Health Sciences, University of Sierra Leone, Sierra Leone.
FAU - Lisk, Durodami R
AU  - Lisk DR
AD  - Department of Internal Medicine, Connaught Teaching Hospital, Ministry of Health 
      and Sanitation, Sierra Leone.
AD  - Department of Internal Medicine, Faculty of Clinical Sciences, College of
      Medicine and Allied Health Sciences, University of Sierra Leone, Sierra Leone.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7649580
OTO - NOTNLM
OT  - Mortality
OT  - Outcomes
OT  - Risk factors
OT  - Sierra Leone
OT  - Stroke
COIS- The authors declare that they have no competing interests.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:58
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/25 00:00 [revised]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/18 05:58 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.1016/j.amsu.2020.10.060 [doi]
AID - S2049-0801(20)30415-5 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Nov 4;60:293-300. doi: 10.1016/j.amsu.2020.10.060.
      eCollection 2020 Dec.


PMID- 33204112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-6957 (Print)
IS  - 1178-6957 (Linking)
VI  - 13
DP  - 2020
TI  - The Potentiality of Human Umbilical Cord Isolated Mesenchymal Stem/Stromal Cells 
      for Cardiomyocyte Generation.
PG  - 91-101
LID - 10.2147/SCCAA.S253108 [doi]
AB  - BACKGROUND: The new therapeutic strategy of managing cardiac diseases is based on
      cell therapy; it highly suggests the use of multipotent mesenchymal stem/stromal 
      cells (MSCs). MSCs widely used in researches are known to be isolated from bone
      marrow. However, this research seeks to use a human umbilical cord (HUC) as an
      alternative source of MSCs. Since HUC Wharton's jelly (WJ)-isolated MSCs
      originate as fetal tissue they are highly preferable for their potential
      advantages over other adult tissues. METHODS: The researchers used enzymatic
      digestion to establish a primary HUC-WJ-isolated MSC line. Then, flow cytometry
      was used to characterize MSCs and hematopoietic stem cells (HSCs) markers'
      expression. In addition, the cardiac differentiation capacity of HUC-WJ-isolated 
      MSCs in vitro was investigated by two protocols. Protocol-1 necessitates the
      dependence on merely 5-azacytidine (5-Aza), whereas in protocol-2, 5-Aza was
      supported by basic fibroblast growth factor (BFGF). The comparative study between
      the two protocols was applied by inspecting the ultrastructure of differentiated 
      cells, measuring RT-PCR mRNA cardiac markers and the quantitative detection of
      cardiac proteins. RESULTS: HUC-WJ isolated MSCs were expressed by CD90(+ve),
      CD105(+ve), CD106(+ve), CD45(-ve), and CD146(-ve). Remarkable TNNT1, NKX2.5, and 
      Desmin mRNA expression and higher quantitative LDH and cTnI were detected by
      applying protocol-2. This same protocol-2 induced cardiac morphological features 
      that were revealed by identifying cardiomyocyte-like cells and typical
      sarcomeres. CONCLUSION: HUC-WJ is proved to be an ethical and effective source of
      MSCs induced cardiac differentiation, whereas BFGF supports 5-Aza in
      MSCs-cardiomyocytes differentiation.
CI  - (c) 2020 Abou-ElNaga et al.
FAU - Abou-ElNaga, Amoura
AU  - Abou-ElNaga A
AD  - Zoology Department, Faculty of Sciences, Mansoura University, Mansoura 35516,
      Egypt.
FAU - El-Chennawi, Farha
AU  - El-Chennawi F
AD  - Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura
      35516, Egypt.
FAU - Ibrahim Kamel, Samar
AU  - Ibrahim Kamel S
AD  - Zoology Department, Faculty of Sciences, Mansoura University, Mansoura 35516,
      Egypt.
FAU - Mutawa, Ghada
AU  - Mutawa G
AUID- ORCID: 0000-0003-0831-5392
AD  - Department of Basic Science, Faculty of Dentistry, Horus University in Egypt
      (HUE), New Damietta 34518, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - New Zealand
TA  - Stem Cells Cloning
JT  - Stem cells and cloning : advances and applications
JID - 101535817
EIN - Stem Cells Cloning. 2021 Jan 26;14:1. PMID: 33531818
PMC - PMC7667202
OTO - NOTNLM
OT  - 5-azacytidine
OT  - Wharton's jelly
OT  - cardiomyocytes
OT  - fibroblast growth factor
OT  - human umbilical cord
OT  - mesenchymal stem/stromal cells
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:57
PHST- 2020/07/16 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/11/18 05:57 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.2147/SCCAA.S253108 [doi]
AID - 253108 [pii]
PST - epublish
SO  - Stem Cells Cloning. 2020 Nov 9;13:91-101. doi: 10.2147/SCCAA.S253108. eCollection
      2020.


PMID- 33204098
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Instruments for Patient Education: Psychometric Evaluation of the Expected
      Knowledge (EKhp) and the Received Knowledge of Hospital Patients (RKhp).
PG  - 1481-1505
LID - 10.2147/JMDH.S271043 [doi]
AB  - PURPOSE: In patient education, there is a need for valid and reliable instruments
      to assess and tailor empowering educational activities. In this study, we
      summarize the process of producing two parallel instruments for analyzing
      hospital patients' expectations (Expected Knowledge of Hospital Patients, EKhp)
      and received knowledge (Received Knowledge of Hospital Patients, RKhp) and
      evaluate the psychometrics of the instruments based on international data. In the
      instruments, six elements of empowering knowledge are included
      (bio-physiological, functional, experiential, ethical, social, and financial).
      PATIENTS AND METHODS: The original Finnish versions of EKhp and RKhp were tested 
      for the first time in 2003, after which they have been used in several national
      studies. For international purposes, the instruments were first translated into
      English, then to languages of the seven participating European countries, using
      double-checking procedure in each one, and subsequently evaluated and confirmed
      by local researchers and language experts. International data collection was
      performed in 2009-2012 with a total sample of 1,595 orthopedic patients.
      Orthopedic patients were selected due to the increase in their numbers, and need 
      for educational activities. Here we report the psychometrics of the instruments
      for potential international use and future development. RESULTS: Content
      validities were confirmed by each participating country. Confirmatory factor
      analyses supported the original theoretical, six-dimensional structure of the
      instruments. For some subscales, however, there is a need for further
      clarification. The summative factors, based on the dimensions, have a
      satisfactory internal consistency. The results support the use of the instruments
      in patient education in orthopedic nursing, and preferably also in other fields
      of surgical nursing care. CONCLUSION: EKhp and RKhp have potential for
      international use in the evaluation of empowering patient education. In the
      future, testing of the structure is needed, and validation in other fields of
      clinical care besides surgical nursing is especially warranted.
CI  - (c) 2020 Leino-Kilpi et al.
FAU - Leino-Kilpi, Helena
AU  - Leino-Kilpi H
AUID- ORCID: 0000-0003-2477-971X
AD  - Department of Nursing Science, University of Turku, Turku, Finland.
AD  - Turku University Hospital, Turku, Finland.
FAU - Inkeroinen, Saija
AU  - Inkeroinen S
AUID- ORCID: 0000-0001-5989-9442
AD  - Department of Nursing Science, University of Turku, Turku, Finland.
FAU - Cabrera, Esther
AU  - Cabrera E
AUID- ORCID: 0000-0002-7353-0542
AD  - School of Health Sciences, TecnoCampus, University Pompeu Fabra, Barcelona,
      Spain.
AD  - Department of Care Management and Social Work, Sechenov University, Moscow,
      Russia.
FAU - Charalambous, Andreas
AU  - Charalambous A
AUID- ORCID: 0000-0003-4050-031X
AD  - Department of Nursing Science, University of Turku, Turku, Finland.
AD  - Nursing Department, Cyprus University of Technology, Limassol, Cyprus.
FAU - Fatkulina, Natalja
AU  - Fatkulina N
AUID- ORCID: 0000-0002-6562-053X
AD  - Department of Nursing, Klaipeda University, Klaipeda, Lithuania.
AD  - Institute of Health Sciences, Faculty of Medicine, Vilnius University, Vilnius,
      Lithuania.
FAU - Katajisto, Jouko
AU  - Katajisto J
AUID- ORCID: 0000-0003-0189-4176
AD  - Department of Mathematics and Statistics, University of Turku, Turku, Finland.
FAU - Sigurethardottir, Arun K
AU  - Sigurethardottir AK
AUID- ORCID: 0000-0002-4287-5409
AD  - School of Health Sciences, University of Akureyri, Akureyri, Iceland.
AD  - Akureyri Hospital, Akureyri, Iceland.
FAU - Sourtzi, Panayota
AU  - Sourtzi P
AUID- ORCID: 0000-0002-2335-5272
AD  - Faculty of Nursing, National and Kapodistrian University of Athens, Athens,
      Greece.
FAU - Suhonen, Riitta
AU  - Suhonen R
AUID- ORCID: 0000-0002-4315-5550
AD  - Department of Nursing Science, University of Turku, Turku, Finland.
AD  - Turku University Hospital, Turku, Finland.
AD  - Welfare Division, City of Turku, Turku, Finland.
FAU - Zabalegui, Adelaida
AU  - Zabalegui A
AUID- ORCID: 0000-0003-1205-3997
AD  - Hospital Clinic of Barcelona, Barcelona, Spain.
AD  - Department of Nursing, Universitat de Barcelona, Barcelona, Spain.
FAU - Valkeapaa, Kirsi
AU  - Valkeapaa K
AUID- ORCID: 0000-0003-4375-4825
AD  - Department of Nursing Science, University of Turku, Turku, Finland.
AD  - Human Performance Division, Finnish Defense Research Agency, Jarvenpaa, Finland.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7667700
OTO - NOTNLM
OT  - empowerment
OT  - nursing
OT  - patient education as topic
OT  - patient participation
OT  - patient-centered care
OT  - surveys and questionnaires
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:57
PHST- 2020/07/10 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/11/18 05:57 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - 10.2147/JMDH.S271043 [doi]
AID - 271043 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Nov 10;13:1481-1505. doi: 10.2147/JMDH.S271043.
      eCollection 2020.


PMID- 33203780
OWN - NLM
STAT- MEDLINE
DCOM- 20211118
LR  - 20211118
IS  - 1943-5657 (Electronic)
IS  - 0033-8397 (Linking)
VI  - 92
IP  - 2
DP  - 2020 Nov
TI  - Computed Tomography Image Reconstruction.
PG  - 155CT-169CT
AB  - Filtered back projection was used in computed tomography (CT) but produced
      low-dose CT images that were noisy and included artifacts. Iterative
      reconstruction was introduced, which reduced noise and demonstrated dose
      reduction; however, reconstruction times were lengthy and noise texture appeared 
      unnatural. Now, artificial intelligence (AI), is being applied to CT image
      reconstruction. These algorithms are fast and produce images comparable to those 
      produced by iterative reconstruction. This article outlines image reconstruction 
      techniques, including a generalized framework for deep learning. Ethics of AI in 
      radiology also is discussed.
CI  - (c) 2020 American Society of Radiologic Technologists.
FAU - Seeram, Euclid
AU  - Seeram E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Radiol Technol
JT  - Radiologic technology
JID - 0401256
SB  - IM
MH  - Algorithms
MH  - *Artificial Intelligence
MH  - Radiation Dosage
MH  - *Radiographic Image Interpretation, Computer-Assisted
MH  - Tomography, X-Ray Computed
EDAT- 2020/11/19 06:00
MHDA- 2021/11/19 06:00
CRDT- 2020/11/18 05:51
PHST- 2020/11/18 05:51 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/11/19 06:00 [medline]
AID - 92/2/155CT [pii]
PST - ppublish
SO  - Radiol Technol. 2020 Nov;92(2):155CT-169CT.


PMID- 33203635
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 17
TI  - Motivational Interviewing for Maternal Immunisation (MI4MI) study: a protocol for
      an implementation study of a clinician vaccine communication intervention for
      prenatal care settings.
PG  - e040226
LID - 10.1136/bmjopen-2020-040226 [doi]
AB  - INTRODUCTION: Vaccination against influenza and pertussis in pregnancy offers a
      'two-for-one' opportunity to protect mother and child. Pregnant patients have
      increased risk of severe disease from influenza and newborns have increased risk 
      of severe disease from both influenza and pertussis. Obstetricians need
      communication tools to support their self-efficacy and effectiveness in
      communicating the importance of immunisation during pregnancy and ultimately
      improving maternal vaccination rates. METHODS AND ANALYSIS: We describe the
      protocol for a pragmatic study testing the feasibility and potential impact of a 
      clinician communication strategy on maternal vaccination uptake. This study will 
      be conducted in five prenatal care settings in Colorado, USA. The Motivational
      Interviewing for Maternal Immunisation strategy involves training prenatal care
      providers to use motivational interviewing in the vaccine conversation with
      pregnant patients. Our primary outcomes will be the adoption and implementation
      of the intervention measured using the Enhanced RE-AIM/Practical Robust
      Implementation and Sustainability Model for dissemination and implementation.
      Secondary outcomes will include provider time spent, fidelity to Motivational
      Interviewing and self-efficacy measured through audio recorded visits and
      provider surveys, patients' visit experience based on audio recorded visits and
      follow-up interviews, and maternal vaccine uptake as measured through chart
      reviews. ETHICS AND DISSEMINATION: This study is approved by the following
      institutional review boards: Colorado Multiple Institutional Review Board.
      Results will be disseminated through peer-reviewed manuscripts and conference
      presentations. TRIAL REGISTRATION NUMBER: NCT04302675.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Brewer, Sarah E
AU  - Brewer SE
AUID- ORCID: 0000-0003-0063-6626
AD  - Family Medicine, University of Colorado Anschutz Medical Campus, Aurora,
      Colorado, USA sarah.brewer@cuanschutz.edu.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences,
      University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
FAU - Cataldi, Jessica R
AU  - Cataldi JR
AD  - Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado,
      USA.
FAU - Fisher, Mary
AU  - Fisher M
AD  - Family Medicine, University of Colorado Anschutz Medical Campus, Aurora,
      Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences,
      University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
FAU - Glasgow, Russell E
AU  - Glasgow RE
AD  - Family Medicine, University of Colorado Anschutz Medical Campus, Aurora,
      Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences,
      University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
FAU - Garrett, Kathleen
AU  - Garrett K
AD  - Colorado School of Public Health, University of Colorado Anschutz Medical Campus,
      Aurora, CO, United States.
FAU - O'Leary, Sean T
AU  - O'Leary ST
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Sciences,
      University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
AD  - Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado,
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04302675
GR  - P50 CA244688/CA/NCI NIH HHS/United States
GR  - R21 AI141822/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201117
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Colorado
MH  - Communication
MH  - Female
MH  - Humans
MH  - Immunization
MH  - Infant, Newborn
MH  - *Motivational Interviewing
MH  - Pregnancy
MH  - *Prenatal Care
MH  - Vaccination
PMC - PMC7674098
OTO - NOTNLM
OT  - *epidemiology
OT  - *infectious diseases
OT  - *maternal medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/18 05:50
PHST- 2020/11/18 05:50 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040226 [pii]
AID - 10.1136/bmjopen-2020-040226 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 17;10(11):e040226. doi: 10.1136/bmjopen-2020-040226.


PMID- 33203631
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 17
TI  - Diet and exercise interventions for individuals at risk for type 2 diabetes: a
      scoping review protocol.
PG  - e039532
LID - 10.1136/bmjopen-2020-039532 [doi]
AB  - INTRODUCTION: Global rates of type 2 diabetes (T2D) are on the rise and there is 
      a need for both effective and replicable interventions to decrease this
      incidence. Systematic reviews highlight the efficacy of diet and exercise
      interventions in decreasing T2D risk; however, no review to date provides clear
      information regarding intervention details (eg, what is delivered, by whom, to
      whom, when, and mode of delivery). This paper outlines the protocol for a scoping
      review summarising intervention characteristics of diet and exercise programmes
      for individuals at risk for T2D. From the included studies and through the use of
      the Template for Intervention Description and Replication (TIDieR), the scoping
      review that results from this protocol paper will provide a narrative analysis of
      how diabetes prevention programmes are being reported and implemented. METHODS: A
      comprehensive search strategy is outlined to identify studies within Medline,
      CINAHL, PsycINFO, EMBASE and SPORTDiscus. The search strategy will include terms 
      relating to diet and exercise interventions and diabetes risk. To determine
      eligible studies, predefined inclusion and exclusion criteria will be used
      independently by two review authors. To be included, studies must be delivering a
      diet and/or exercise intervention among adults who have been identified as at
      risk for developing T2D with an outcome related to diabetes prevention. Data
      extraction of those studies that meet inclusion criteria will be guided by the
      TIDieR). ETHICS AND DISSEMINATION: Ethical approval is not required as this
      review will be using previously collected data. Review findings will be presented
      at scientific conferences and published in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - MacPherson, Megan
AU  - MacPherson M
AD  - School of Health and Exercise Sciences, The University of British Columbia,
      Kelowna, British Columbia, Canada.
FAU - Cranston, Kaela
AU  - Cranston K
AD  - School of Health and Exercise Sciences, The University of British Columbia,
      Kelowna, British Columbia, Canada.
FAU - Locke, Sean
AU  - Locke S
AD  - Faculty of Applied Health Sciences, Brock University, St. Catharines, Ontario,
      Canada.
FAU - Vis-Dunbar, Mathew
AU  - Vis-Dunbar M
AD  - Library, The University of British Columbia, Kelowna, British Columbia, Canada.
FAU - Jung, Mary E
AU  - Jung ME
AUID- ORCID: 0000-0002-2360-0952
AD  - School of Health and Exercise Sciences, The University of British Columbia,
      Kelowna, British Columbia, Canada mary.jung@ubc.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201117
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - Diet
MH  - Exercise
MH  - Exercise Therapy
MH  - Health Services
MH  - Humans
MH  - Review Literature as Topic
PMC - PMC7674078
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *nutrition & dietetics
OT  - *preventive medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/11/19 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/18 05:50
PHST- 2020/11/18 05:50 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-039532 [pii]
AID - 10.1136/bmjopen-2020-039532 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 17;10(11):e039532. doi: 10.1136/bmjopen-2020-039532.


PMID- 33203627
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 17
TI  - Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL)
      protocol: a double-blind randomised clinical trial.
PG  - e037700
LID - 10.1136/bmjopen-2020-037700 [doi]
AB  - INTRODUCTION: Erythema nodosum leprosum (ENL) is an immunological complication of
      leprosy. ENL results in morbidity and disability and if it is not treated can
      lead to death. The current treatment consists of thalidomide or high doses of
      oral corticosteroids for prolonged periods. Thalidomide is not available in many 
      leprosy endemic countries. The use of corticosteroids is associated with
      morbidity and mortality. Identifying treatment regimens that reduce the use of
      corticosteroids in ENL is essential. Methotrexate (MTX) is used to treat many
      inflammatory diseases and has been used successfully to treat patients with ENL
      not controlled by other drugs, including prednisolone and thalidomide. We present
      the protocol of the 'MTX and prednisolone study in ENL' (MaPs in ENL) a
      randomised controlled trial (RCT) designed to test the efficacy of MTX in the
      management of ENL. METHODS AND ANALYSIS: MaPs in ENL is an international
      multicentre RCT, which will be conducted in leprosy referral centres in
      Bangladesh, Brazil, Ethiopia, India, Indonesia and Nepal. Patients diagnosed with
      ENL who consent to participate will be randomly allocated to receive 48 weeks of 
      weekly oral MTX plus 20 weeks of prednisolone or 48 weeks of placebo plus 20
      weeks of prednisolone. Participants will be stratified by type of ENL into those 
      with acute ENL and those with chronic and recurrent ENL. The primary objective is
      to determine whether MTX reduces the requirement for additional prednisolone.
      Patients' reported outcome measures will be used to assess the efficacy of MTX.
      Participants will be closely monitored for adverse events. ETHICS AND
      DISSEMINATION: Results will be submitted for publication in peer-reviewed
      journals. Ethical approval was obtained from the Observational/Interventions
      Research Ethics Committee of the London School of Hygiene & Tropical Medicine
      (15762); The Leprosy Mission International Bangladesh Institutional Research
      Board (in process); AHRI-ALERT Ethical Review Committee, Ethiopia; Ethics
      Committee of the Managing Committee of the Bombay Leprosy Project; and The
      Leprosy Mission Trust India Ethics Committee; the Nepal Health and Research
      Council and Health Research Ethics Committee Dr. Soetomo, Indonesia. This study
      is registered at www.clinicaltrials.gov. This is the first RCT of MTX for ENL and
      will contribute to the evidence for the management of ENL.Trial registration
      numberNCT 03775460.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Barros, Barbara
AU  - de Barros B
AUID- ORCID: 0000-0002-5382-8165
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK barbara.de-barros@lshtm.ac.uk.
FAU - Lambert, Saba M
AU  - Lambert SM
AUID- ORCID: 0000-0003-4376-5495
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
AD  - Clinical Research Department, ALERT Center, Addis Ababa, London, Ethiopia.
FAU - Shah, Mahesh
AU  - Shah M
AD  - Department of Dermatology and Mycobacterial Research Laboratories, The Leprosy
      Mission Nepal, Anandaban Hospital, Kathmandu, Nepal.
FAU - Pai, Vivek V
AU  - Pai VV
AD  - Bombay Leprosy Project, Mumbai, India.
FAU - Darlong, Joydeepa
AU  - Darlong J
AD  - The Leprosy Mission Trust India, New Delhi, Indonesia.
FAU - Rozario, Benjamin Jewel
AU  - Rozario BJ
AD  - DBLM Hospital, The Leprosy Mission International Bangladesh, Nilphamari,
      Bangladesh.
FAU - Alinda, Medhi Denisa
AU  - Alinda MD
AD  - Department of Dermatology and Venereology, Faculty of Medicine Universitas
      Airlangga, Dr Soetomo General Hospital, Surabaya, Jawa Timur, Indonesia.
FAU - Sales, Anna M
AU  - Sales AM
AD  - Leprosy Laboratory, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
FAU - Doni, Shimelis
AU  - Doni S
AD  - Clinical Research Department, ALERT Center, Addis Ababa, London, Ethiopia.
FAU - Hagge, Deanna A
AU  - Hagge DA
AD  - Department of Dermatology and Mycobacterial Research Laboratories, The Leprosy
      Mission Nepal, Anandaban Hospital, Kathmandu, Nepal.
FAU - Shrestha, Dilip
AU  - Shrestha D
AD  - Department of Dermatology and Mycobacterial Research Laboratories, The Leprosy
      Mission Nepal, Anandaban Hospital, Kathmandu, Nepal.
FAU - Listiawan, M Yulianto
AU  - Listiawan MY
AD  - Department of Dermatology and Venereology, Faculty of Medicine Universitas
      Airlangga, Dr Soetomo General Hospital, Surabaya, Jawa Timur, Indonesia.
FAU - Yitaye, Abeba M
AU  - Yitaye AM
AD  - Clinical Research Department, ALERT Center, Addis Ababa, London, Ethiopia.
FAU - Nery, Jose A C
AU  - Nery JAC
AD  - Leprosy Laboratory, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
FAU - Neupane, Kapil D
AU  - Neupane KD
AD  - Department of Dermatology and Mycobacterial Research Laboratories, The Leprosy
      Mission Nepal, Anandaban Hospital, Kathmandu, Nepal.
FAU - Dias, Vivianne L A
AU  - Dias VLA
AD  - Leprosy Laboratory, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
FAU - Butlin, C Ruth
AU  - Butlin CR
AD  - DBLM Hospital, The Leprosy Mission International Bangladesh, Nilphamari,
      Bangladesh.
FAU - Nicholls, Peter G
AU  - Nicholls PG
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Lockwood, Diana
AU  - Lockwood D
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Walker, Stephen L
AU  - Walker SL
AUID- ORCID: 0000-0002-2034-8376
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201117
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Leprostatic Agents)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Bangladesh
MH  - Brazil
MH  - *Erythema Nodosum/drug therapy
MH  - Ethiopia
MH  - Humans
MH  - India
MH  - Indonesia
MH  - Leprostatic Agents/therapeutic use
MH  - *Leprosy, Lepromatous/drug therapy
MH  - London
MH  - Methotrexate/*therapeutic use
MH  - Nepal
MH  - Prednisolone/*therapeutic use
PMC - PMC7674097
OTO - NOTNLM
OT  - *bacteriology
OT  - *dermatology
OT  - *tropical medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/19 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/18 05:50
PHST- 2020/11/18 05:50 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-037700 [pii]
AID - 10.1136/bmjopen-2020-037700 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 17;10(11):e037700. doi: 10.1136/bmjopen-2020-037700.


PMID- 33203626
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 17
TI  - Effectiveness and cost-effectiveness of the Assessment of Burden of Chronic
      Conditions (ABCC) tool in patients with COPD, asthma, diabetes mellitus type 2
      and heart failure: protocol for a pragmatic clustered quasi-experimental study.
PG  - e037693
LID - 10.1136/bmjopen-2020-037693 [doi]
AB  - INTRODUCTION: The number of people that have one or multiple condition(s) with a 
      chronic course is rising, which consequently challenges healthcare systems.
      Healthcare geared to long-term care should focus on patient-centredness, shared
      decision making and self-management. The Assessment of Burden of Chronic
      Conditions (ABCC) tool was developed to integrate these elements in daily
      healthcare practice. The ABCC tool assesses and visualises burden of disease(s), 
      helps to make shared decisions and stimulates self-management. The present paper 
      documents a protocol for a quasi-experimental study investigating the
      effectiveness and cost-effectiveness of the ABCC tool for people with chronic
      obstructive pulmonary disease, asthma, type 2 diabetes mellitus and/or heart
      failure. METHODS AND ANALYSIS: The study has a pragmatic clustered
      quasi-experimental design and will be conducted in the Netherlands. The
      intervention will be allocated at the level of general practice. The intervention
      group (18 general practices, 180 patients) will use the ABCC tool during regular 
      consultations; the control group (18 general practices, 180 patients) will
      maintain usual care. Outcomes include change in quality of care (Patient
      Assessment of Chronic Illness Care), quality of life (EuroQol-5D-5L), capability 
      well-being (ICEpop CAPability measure for Adults), patients' activation (Patient 
      Activation Measure) and costs. Follow-up time will be 18 months. Outcomes will be
      analysed using linear mixed models. ETHICS AND DISSEMINATION: Ethical approval
      was obtained from the Medical Ethics Committee Zuyderland-Zuyd Heerlen, the
      Netherlands (METCZ20180131). Results will be published in peer-reviewed journals 
      and will be presented at national and international conferences. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04127383).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Boudewijns, Esther A
AU  - Boudewijns EA
AUID- ORCID: 0000-0001-9087-1712
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands
      esther.boudewijns@maastrichtuniversity.nl.
FAU - Claessens, Danny
AU  - Claessens D
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands.
FAU - Joore, Manuela
AU  - Joore M
AD  - Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA),
      Maastricht University Medical Centre, Maastricht, The Netherlands.
FAU - Keijsers, Lotte C E M
AU  - Keijsers LCEM
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands.
FAU - van Schayck, Onno C P
AU  - van Schayck OCP
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands.
FAU - Winkens, Bjorn
AU  - Winkens B
AD  - Department of Methodology and Statistics, Care and Public Health Research
      Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
FAU - Gidding-Slok, Annerika H M
AU  - Gidding-Slok AHM
AD  - Department of Family Medicine, Care and Public Health Research Institute
      (CAPHRI), Maastricht University, Maastricht, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT04127383
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201117
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Asthma/therapy
MH  - *Chronic Disease
MH  - Cost-Benefit Analysis
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - *Heart Failure
MH  - Humans
MH  - Netherlands
MH  - *Pulmonary Disease, Chronic Obstructive/therapy
MH  - Quality of Life
PMC - PMC7674093
OTO - NOTNLM
OT  - *asthma
OT  - *chronic airways disease
OT  - *diabetes & endocrinology
OT  - *heart failure
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/11/19 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/18 05:50
PHST- 2020/11/18 05:50 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-037693 [pii]
AID - 10.1136/bmjopen-2020-037693 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 17;10(11):e037693. doi: 10.1136/bmjopen-2020-037693.


PMID- 33203625
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 17
TI  - Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori
      infection eradication: protocol for a single-centre, single-blind,
      non-inferiority, randomised clinical trial.
PG  - e037182
LID - 10.1136/bmjopen-2020-037182 [doi]
AB  - INTRODUCTION: Helicobacter pylori (H. pylori) is the most well-known risk factor 
      for gastric cancer. At present, H. pylori shows varying levels of resistance to
      different treatments, leading to a lower rate of H. pylori eradication. The aim
      of this study is to evaluate the efficacy of polaprezinc-containing quadruple
      therapy (PQT) for the eradication of H. pylori infection and, thus, to provide
      more evidence to inform the clinical treatment of H. pylori infection in China.
      METHODS AND ANALYSIS: This is a single-centre, single-blind, non-inferiority,
      randomised controlled trial, enrolling 158 patients with H. pylori infection.
      Patients are randomised (1:1) to the two groups for a 14-day therapy. Treatment
      group: PQT (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg,
      polaprezinc 75 mg) two times per day; control group: bismuth-containing quadruple
      therapy (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, bismuth
      potassium citrate 220 mg) two times per day. The primary outcome is the rate of
      H. pylori eradication. Secondary outcomes are the incidence of adverse events and
      the gastrointestinal microbiota distribution. The 16S ribosomal RNA (16S rRNA)
      next-generation sequencing (NGS) is used to evaluate the effect of two different 
      therapies on the distribution of the gastrointestinal microbiota. ETHICS AND
      DISSEMINATION: This study was approved by the Ethics Committee of Sichuan Cancer 
      Center & Hospital (No. SCCHEC-02-2019-015). Any amendment to the research
      protocol will be submitted for ethical approval. All participants must provide
      informed consent. On completion, the results of the study will be published in
      the appropriate peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      ChiCTR1900025800; preresults.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wu, Dingkun
AU  - Wu D
AUID- ORCID: 0000-0003-1600-9571
AD  - School of Medicine, University of Electronic Science and Technology of China,
      Chengdu, China.
AD  - Center for Cancer Prevention Research, Sichuan Cancer Hospital & Institute,
      Sichuan Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, China.
FAU - Sun, Zhen
AU  - Sun Z
AD  - Department of Gastroenterology, Jilin People's Hospital, Jilin, China.
FAU - Li, Tingyuan
AU  - Li T
AD  - Center for Cancer Prevention Research, Sichuan Cancer Hospital & Institute,
      Sichuan Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, China.
FAU - Tan, Qinwen
AU  - Tan Q
AD  - Center for Cancer Prevention Research, Sichuan Cancer Hospital & Institute,
      Sichuan Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, China.
AD  - Chongqing Medical University, Chongqing, China.
FAU - Sun, Yue
AU  - Sun Y
AD  - Center for Cancer Prevention Research, Sichuan Cancer Hospital & Institute,
      Sichuan Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, China.
FAU - Chen, Tingting
AU  - Chen T
AD  - West China School of Public Health/West China Fourth Hospital, Sichuan
      University, Chengdu, China.
FAU - Liu, Yujing
AU  - Liu Y
AD  - Department of Cancer Epidemiology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
FAU - Li, Jun
AU  - Li J
AD  - Cancer Prevention and Treatment Office, Yanting Cancer Hospital, Mianyang, China.
FAU - Jiang, Haidong
AU  - Jiang H
AD  - Cancer Prevention and Treatment Office, Yanting Cancer Hospital, Mianyang, China.
FAU - Yuan, Zhiqiang
AU  - Yuan Z
AD  - Cancer Prevention and Treatment Office, Yanting Cancer Hospital, Mianyang, China.
FAU - Zhao, Yuqian
AU  - Zhao Y
AUID- ORCID: 0000-0002-2736-4766
AD  - Center for Cancer Prevention Research, Sichuan Cancer Hospital & Institute,
      Sichuan Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, China gw_zhaoyuqian@126.com chenwen@cicams.ac.cn.
FAU - Chen, Wen
AU  - Chen W
AD  - Center for Cancer Prevention Research, Sichuan Cancer Hospital & Institute,
      Sichuan Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, China gw_zhaoyuqian@126.com chenwen@cicams.ac.cn.
AD  - Department of Cancer Epidemiology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201117
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Organometallic Compounds)
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 0 (Zinc Compounds)
RN  - 0WA1B15A1Z (polaprezinc)
RN  - 804826J2HU (Amoxicillin)
RN  - 8HO6PVN24W (Carnosine)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Carnosine/*analogs & derivatives/therapeutic use
MH  - China
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Helicobacter Infections/drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Organometallic Compounds/*therapeutic use
MH  - RNA, Ribosomal, 16S
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - Treatment Outcome
MH  - Zinc Compounds/therapeutic use
PMC - PMC7674085
OTO - NOTNLM
OT  - *gastroenterology
OT  - *gastrointestinal infections
OT  - *microbiology
COIS- Competing interests: None declared.
EDAT- 2020/11/19 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/18 05:50
PHST- 2020/11/18 05:50 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-037182 [pii]
AID - 10.1136/bmjopen-2020-037182 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 17;10(11):e037182. doi: 10.1136/bmjopen-2020-037182.


PMID- 33203623
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 17
TI  - Optimisation, validation and field applicability of a 13C-sucrose breath test to 
      assess intestinal function in environmental enteropathy among children in
      resource poor settings: study protocol for a prospective study in Bangladesh,
      India, Kenya, Jamaica, Peru and Zambia.
PG  - e035841
LID - 10.1136/bmjopen-2019-035841 [doi]
AB  - INTRODUCTION: Environmental enteropathy (EE) is suspected to be a cause of growth
      faltering in children with sustained exposure to enteric pathogens, typically in 
      resource-limited settings. A major hindrance to EE research is the lack of
      sensitive, non-invasive biomarkers. Current biomarkers measure intestinal
      permeability and inflammation, but not the functional capacity of the gut.
      Australian researchers have demonstrated proof of concept for an EE breath test
      based on using naturally (13)C-enriched sucrose, derived from maize, to assay
      intestinal sucrase activity, a digestive enzyme that is impaired in villus
      blunting. Here, we describe a coordinated research project to optimise, validate 
      and evaluate the usability of a breath test protocol based on highly enriched
      (13)C-sucrose to quantify physiological dysfunction in EE in relevant target
      populations. METHODS AND ANALYSIS: We use the (13)C-sucrose breath test
      ((13)C-SBT) to evaluate intestinal sucrase activity in two phases. First, an
      optimisation and validation phase will (1) confirm that a (13)C-SBT using highly 
      enriched sucrose tracers reports similar information to the naturally enriched
      (13)C-SBT; (2) examine the dose-response relationship of the test to an
      intestinal sucrase inhibitor; (3) validate the (13)C-SBT in paediatric coeliac
      disease (4) validate the highly enriched (13)C-SBT against EE defined by biopsy
      in adults and (5) validate the (13)C-SBT against EE defined by the urinary
      lactulose:rhamnose ratio (LR) among children in Peru. Second, a cross-sectional
      study will be conducted in six resource-limited countries (Bangladesh, India,
      Jamaica, Kenya, Peru and Zambia) to test the usability of the optimised (13)C-SBT
      to assess EE among 600 children aged 12-15 months old. ETHICS AND DISSEMINATION: 
      Ethical approval will be obtained from each participating study site. By working 
      as a consortium, the test, if shown to be informative of EE, will demonstrate
      strong evidence for utility across diverse, low-income and middle-income country 
      paediatric populations. TRIAL REGISTRATION NUMBER: NCT04109352; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lee, Gwenyth O
AU  - Lee GO
AUID- ORCID: 0000-0002-7889-3852
AD  - Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA
      golee@umich.edu.
FAU - Schillinger, Robert
AU  - Schillinger R
AD  - Scottish Universities Environmental Research Centre, University of Glasgow,
      Glasgow, UK.
FAU - Shivakumar, Nirupama
AU  - Shivakumar N
AD  - Division of Nutrition, Saint John's Research Institute, Bangalore, Karnataka,
      India.
FAU - Whyte, Sherine
AU  - Whyte S
AD  - Caribbean Institute for Health Research (formerly, Tropical Medicine Research
      Institute), University of the West Indies at Mona, Mona, Saint Andrew, Jamaica.
FAU - Huq, Sayeeda
AU  - Huq S
AD  - Nutrition and Clinical Services Division, International Centre for Diarrhoeal
      Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
FAU - Ochieng Konyole, Silvenus
AU  - Ochieng Konyole S
AD  - Biomedical Sciences Department, Tropical Diseases Research Centre, Ndola,
      Copperbelt, Zambia.
FAU - Chileshe, Justin
AU  - Chileshe J
AD  - Department of Nutritional Sciences, Masinde Muliro University of Science and
      Technology, Kakamega, Kenya.
FAU - Paredes-Olortegui, Maribel
AU  - Paredes-Olortegui M
AD  - Research and Development Area, Asociaciomicronn Benefica Proyectos de
      Informatica, Salud, Medicina, y Agricultura (A.B. PRISMA), Iquitos, Loreto, Peru.
FAU - Owino, Victor
AU  - Owino V
AD  - Nutritional and Health Related Environmental Studies Section, Division of Human
      Health, International Atomic Energy Agency, Vienna, Austria.
FAU - Yazbeck, Roger
AU  - Yazbeck R
AD  - Department of Surgery, College of Medicine and Public Health, Flinders
      University, Adelaide, South Australia, Australia.
AD  - Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South
      Australia, Australia.
FAU - Kosek, Margaret N
AU  - Kosek MN
AD  - Research and Development Area, Asociaciomicronn Benefica Proyectos de
      Informatica, Salud, Medicina, y Agricultura (A.B. PRISMA), Iquitos, Loreto, Peru.
AD  - Division of Infectious Diseases & International Health, University of Virginia,
      Charlottesville, Virginia, USA.
FAU - Kelly, Paul
AU  - Kelly P
AUID- ORCID: 0000-0003-0844-6448
AD  - Blizard Institute, Barts and The London School of Medicine, London, UK.
AD  - Tropical Gastroenterology and Nutrition group, University of Zambia School of
      Medicine, Lusaka, Lusaka, Zambia.
FAU - Morrison, Douglas
AU  - Morrison D
AD  - Scottish Universities Environmental Research Centre, University of Glasgow,
      Glasgow, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04109352
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201117
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Carbon Isotopes)
RN  - 57-50-1 (Sucrose)
RN  - FDJ0A8596D (Carbon-13)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - Bangladesh
MH  - *Breath Tests
MH  - Carbon Isotopes/analysis
MH  - Child
MH  - Cross-Sectional Studies
MH  - Humans
MH  - India
MH  - Jamaica
MH  - Kenya
MH  - Peru
MH  - Prospective Studies
MH  - *Sucrose
MH  - Zambia
PMC - PMC7674092
OTO - NOTNLM
OT  - *coeliac disease
OT  - *community child health
OT  - *endoscopy
OT  - *gastrointestinal infections
OT  - *paediatric gastroenterology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/19 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/11/18 05:50
PHST- 2020/11/18 05:50 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035841 [pii]
AID - 10.1136/bmjopen-2019-035841 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 17;10(11):e035841. doi: 10.1136/bmjopen-2019-035841.


PMID- 33203621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210111
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 18
TI  - Feasibility, Acceptability, and Effectiveness of Enhanced Cognitive Behavioral
      Therapy (eCBT) for Children and Adolescents With Obsessive-Compulsive Disorder:
      Protocol for an Open Trial and Therapeutic Intervention.
PG  - e24057
LID - 10.2196/24057 [doi]
AB  - BACKGROUND: Although the evidence base of cognitive behavioral therapy (CBT) for 
      pediatric obsessive-compulsive disorder (OCD) has been broadly established, the
      treatment is hampered by limited access, poor compliance, and nonresponse. New
      technologies offer the opportunity to improve the accessibility, user
      friendliness, and effectiveness of traditional office-based CBT. By employing an 
      integrated and age-appropriate technologically enhanced treatment package, we aim
      to execute a more focused and attractive application of CBT principles to
      increase the treatment effect for pediatric OCD. OBJECTIVE: The aim of this open 
      study is to explore the acceptability, feasibility, and effectiveness of a newly 
      developed enhanced CBT (eCBT) package for pediatric OCD. METHODS: This study is
      an open trial using a historical control design conducted at the outpatient
      clinic of the Department of Child and Adolescent Psychiatry at St. Olavs
      University Hospital (Trondheim) or at BUP Klinikk (Aalesund). Participants are 30
      children (age 7-17 years) with a primary Diagnostic and Statistical Manual of
      Mental Disorders (DSM)-5 diagnosis of OCD, and their parents. All participants
      receive eCBT. eCBT consists of the usual evidence-based CBT for pediatric OCD in 
      an "enhanced" format. Enhancements include videoconferencing sessions
      (supervision and guided exposure exercises at home) in addition to face-to-face
      sessions; an app system of interconnected apps for the child, the parents, and
      the therapist; psychoeducative videos; and frequent online self-assessments with 
      direct feedback to patients and the therapist. Primary outcome measures are the
      Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) (effectiveness), the
      Client Satisfaction Questionnaire-8 (acceptability), and treatment drop out
      (feasibility). Assessments are conducted pretreatment, posttreatment, and at 3-
      and 6-month follow-ups. A 12-month follow-up assessment is envisioned. The
      treatment outcome (CY-BOCS) will be compared to traditional face-to-face CBT
      (data collected in the Nordic Long-term OCD Treatment Study). RESULTS: Ethical
      approval has been obtained (2016/716/REK nord). Inclusion started on September
      04, 2017. Data collection is ongoing. CONCLUSIONS: This study is the first step
      in testing the acceptability, feasibility, and preliminary effectiveness of eCBT.
      In case of positive results, future steps include improving the eCBT treatment
      package based on feedback from service users, examining cost-effectiveness in a
      randomized controlled trial, and making the package available to clinicians and
      other service providers treating OCD in children and adolescents. TRIAL
      REGISTRATION: ISRCTN, ISRCTN37530113; registered on January 31, 2020
      (retrospectively registered); https://www.isrctn.com/ISRCTN37530113.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/24057.
CI  - (c)Lidewij H Wolters, Bernhard Weidle, Lucia Babiano-Espinosa, Norbert
      Skokauskas. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 18.12.2020.
FAU - Wolters, Lidewij H
AU  - Wolters LH
AUID- ORCID: https://orcid.org/0000-0002-6348-268X
AD  - Department of Mental Health, Regional Centre for Child and Youth Mental Health
      and Child Welfare (RKBU Central Norway), Norwegian University of Science and
      Technology (NTNU), Trondheim, Norway.
AD  - de Bascule/Levvel, Academic Center for Child and Adolescent Psychiatry,
      Amsterdam, Netherlands.
FAU - Weidle, Bernhard
AU  - Weidle B
AUID- ORCID: https://orcid.org/0000-0002-1822-7671
AD  - Department of Mental Health, Regional Centre for Child and Youth Mental Health
      and Child Welfare (RKBU Central Norway), Norwegian University of Science and
      Technology (NTNU), Trondheim, Norway.
AD  - Department of Child and Adolescent Psychiatry, St Olavs University Hospital,
      Trondheim, Norway.
FAU - Babiano-Espinosa, Lucia
AU  - Babiano-Espinosa L
AUID- ORCID: https://orcid.org/0000-0002-1529-3075
AD  - Department of Mental Health, Regional Centre for Child and Youth Mental Health
      and Child Welfare (RKBU Central Norway), Norwegian University of Science and
      Technology (NTNU), Trondheim, Norway.
AD  - Department of Child and Adolescent Psychiatry, St Olavs University Hospital,
      Trondheim, Norway.
FAU - Skokauskas, Norbert
AU  - Skokauskas N
AUID- ORCID: https://orcid.org/0000-0002-9195-4621
AD  - Department of Mental Health, Regional Centre for Child and Youth Mental Health
      and Child Welfare (RKBU Central Norway), Norwegian University of Science and
      Technology (NTNU), Trondheim, Norway.
AD  - Department of Child and Adolescent Psychiatry, St Olavs University Hospital,
      Trondheim, Norway.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7775822
OTO - NOTNLM
OT  - adolescents
OT  - behavioral
OT  - children
OT  - cognitive
OT  - cognitive behavioral therapy
OT  - e-mental health
OT  - obsessive-compulsive disorder
OT  - pediatric
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 05:50
PHST- 2020/09/02 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
PHST- 2020/11/18 05:50 [entrez]
AID - v9i12e24057 [pii]
AID - 10.2196/24057 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 18;9(12):e24057. doi: 10.2196/24057.


PMID- 33203469
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 17
TI  - Clinical trials with cannabis medicines-guidance for ethics committees,
      governance officers and researchers to streamline ethics applications and
      ensuring patient safety: considerations from the Australian experience.
PG  - 932
LID - 10.1186/s13063-020-04862-6 [doi]
AB  - With cannabis medicines now obtaining legal status in many international
      jurisdictions (generally on the authorisation of a medical professional), a rapid
      increase in consumer demand for access to cannabis as a therapeutic option in the
      treatment and management of a range of indications is being noted. Despite this
      accessibility, knowledge on optimal use is lacking. Further drug development and 
      clinical trials at regulatory standards are necessary both if a better
      understanding of the efficacy of cannabis medicines, optimal product formulation 
      and indication-specific dosing is needed and to ensure the broader quality and
      safety of cannabis medicines in the clinical setting.To enable this, clinical,
      academic and public calls for the undertaking of rigorous clinical trials to
      establish an evidence base for the therapeutic use of cannabis medicines have
      been made internationally. While this commitment to undertake human studies with 
      cannabis medicines is welcomed, it has highlighted unique challenges, notably in 
      the review stages of ethics and governance. This often results in lengthy delays 
      to approval by Human Research Ethics Committees (herein 'HREC', Australia's
      nomenclature for Institutional Review Boards) and trial commencement. A principal
      concern in these cases is that in contrast to clinical trials using other more
      conventional pharmaceutical products, trials of cannabis medicines in humans
      often involve the use of an investigational product prior to some (or any) of the
      preclinical and pharmaceutical safety issues being established. This paucity of
      data around product safety, potential drug interactions, continuity of supply,
      shelf life and product storage results in apprehension by HRECs and governance
      bodies to endorse trials using cannabis medicines.This manuscript draws from the 
      experiences of Australian researchers and staff involved in clinical trials of
      cannabis medicines to describe some of the common difficulties that may be faced 
      in the HREC approval process. It also presents practical advice aimed to assist
      researchers, HRECs and governance officers navigate this complex terrain. While
      the authors' experiences are situated within the Australian setting, many of the 
      barriers described are applicable within the international context and thus, the 
      solutions that have been proposed are typically adaptive for use within other
      jurisdictions.
FAU - Martin, Jennifer H
AU  - Martin JH
AUID- ORCID: http://orcid.org/0000-0002-8614-0199
AD  - Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE),
      Division of Clinical Pharmacology, School of Medicine and Public Health,
      University of Newcastle, Newcastle, New South Wales, Australia.
      jen.martin@newcastle.edu.au.
FAU - Hill, Courtney
AU  - Hill C
AD  - Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE),
      Division of Clinical Pharmacology, School of Medicine and Public Health,
      University of Newcastle, Newcastle, New South Wales, Australia.
FAU - Walsh, Anna
AU  - Walsh A
AD  - NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Efron, Daryl
AU  - Efron D
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
AD  - The Royal Children's Hospital, Parkville, Victoria, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
FAU - Taylor, Kaitlyn
AU  - Taylor K
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
FAU - Kennedy, Michael
AU  - Kennedy M
AD  - St Vincent's Clinical School, UNSW Medicine, UNSW Sydney and Department of
      Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney, Sydney, New
      South Wales, Australia.
FAU - Galettis, Rachel
AU  - Galettis R
AD  - Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE),
      Division of Clinical Pharmacology, School of Medicine and Public Health,
      University of Newcastle, Newcastle, New South Wales, Australia.
FAU - Lightfoot, Paul
AU  - Lightfoot P
AD  - Department of Neurology, Austin Health, Heidelberg, Victoria, Australia.
FAU - Hanson, Julie
AU  - Hanson J
AD  - School of Nursing, Midwifery and Paramedicine, University of the Sunshine Coast, 
      Maroochydore, Queensland, Australia.
FAU - Irving, Helen
AU  - Irving H
AD  - Children's Health Queensland, Hospital and Health Service, University of
      Queensland, Brisbane, Queensland, Australia.
FAU - Agar, Meera
AU  - Agar M
AD  - IMPACCT, University of Technology Sydney, Sydney, New South Wales, Australia.
FAU - Lacey, Judith
AU  - Lacey J
AD  - Chris O'Brien Lifehouse Comprehensive Cancer Hospital, Camperdown, New South
      Wales, Australia.
AD  - School of Medicine, University of Sydney, Sydney, New South Wales, Australia.
AD  - NICM Health and Research Institute, Western Sydney University, Penrith, New South
      Wales, Australia.
LA  - eng
GR  - Centre of Research Excellence 2017-22/National Health and Medical Research
      Council
PT  - Letter
DEP - 20201117
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Australia
MH  - *Cannabis/adverse effects
MH  - Ethics Committees, Research
MH  - Humans
MH  - Research Design
PMC - PMC7673085
OTO - NOTNLM
OT  - Cannabinoids
OT  - Cannabis medicines
OT  - Cannabis medicines research
OT  - Clinical trials
OT  - Governance
OT  - Human research ethics
OT  - Investigational medicinal product
EDAT- 2020/11/19 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/18 05:35
PHST- 2020/05/13 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/18 05:35 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04862-6 [doi]
AID - 10.1186/s13063-020-04862-6 [pii]
PST - epublish
SO  - Trials. 2020 Nov 17;21(1):932. doi: 10.1186/s13063-020-04862-6.


PMID- 33203434
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1747-5341 (Electronic)
IS  - 1747-5341 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Nov 18
TI  - The impact of twenty-first century personalized medicine versus twenty-first
      century medicine's impact on personalization.
PG  - 11
LID - 10.1186/s13010-020-00095-2 [doi]
AB  - BACKGROUND: Over the past decade, the exponential growth of the literature
      devoted to personalized medicine has been paralleled by an ever louder chorus of 
      epistemic and ethical criticisms. Their differences notwithstanding, both
      advocates and critics share an outdated philosophical understanding of the
      concept of personhood and hence tend to assume too simplistic an understanding of
      personalization in health care. METHODS: In this article, we question this
      philosophical understanding of personhood and personalization, as these concepts 
      shape the field of personalized medicine. We establish a dialogue with
      phenomenology and hermeneutics (especially with E. Husserl, M. Merleau-Ponty and 
      P. Ricoeur) in order to achieve a more sophisticated understanding of the meaning
      of these concepts We particularly focus on the relationship between personal
      subjectivity and objective data. RESULTS: We first explore the gap between the
      ideal of personalized healthcare and the reality of today's personalized
      medicine. We show that the nearly exclusive focus of personalized medicine on the
      objective part of personhood leads to a flawed ethical debate that needs to be
      reframed. Second, we seek to contribute to this reframing by drawing on the
      phenomenological-hermeneutical movement in philosophy. Third, we show that these 
      admittedly theoretical analyses open up new conceptual possibilities to tackle
      the very practical ethical challenges that personalized medicine faces.
      CONCLUSION: Finally, we propose a reversal: if personalization is a continuous
      process by which the person reappropriates all manner of objective data, giving
      them meaning and thereby shaping his or her own way of being human, then
      personalized medicine, rather than being personalized itself, can facilitate
      personalization of those it serves through the data it provides.
FAU - Abettan, Camille
AU  - Abettan C
AD  - Center of Interdisciplinary Researches in Human and Social Sciences (CRISES, EA
      4424), Paul Valery University, Rue du Professeur Henri Serre, 34090, Montpellier,
      France. camille.abettan@gmail.com.
FAU - Welie, Jos V M
AU  - Welie JVM
AD  - University College Maastricht, Zwingelput 4, 6211KH, Maastricht, Netherlands.
AD  - Department of Interdisciplinary Studies, Graduate School, Creighton University,
      2500 California Plaza, Omaha, NE, 68178, USA.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - England
TA  - Philos Ethics Humanit Med
JT  - Philosophy, ethics, and humanities in medicine : PEHM
JID - 101258058
SB  - IM
MH  - Hermeneutics
MH  - Morals
MH  - *Personhood
MH  - *Philosophy, Medical
MH  - *Precision Medicine
PMC - PMC7672902
OTO - NOTNLM
OT  - *Husserl
OT  - *Merleau-Ponty
OT  - *Personalized medicine
OT  - *Ricoeur
OT  - *Subjectivity
EDAT- 2020/11/19 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/11/18 05:34
PHST- 2019/11/18 00:00 [received]
PHST- 2020/10/11 00:00 [accepted]
PHST- 2020/11/18 05:34 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.1186/s13010-020-00095-2 [doi]
AID - 10.1186/s13010-020-00095-2 [pii]
PST - epublish
SO  - Philos Ethics Humanit Med. 2020 Nov 18;15(1):11. doi: 10.1186/s13010-020-00095-2.


PMID- 33203421
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1746-4358 (Electronic)
IS  - 1746-4358 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Nov 17
TI  - Factors that influence mothers' prenatal decision to breastfeed in Spain.
PG  - 97
LID - 10.1186/s13006-020-00341-5 [doi]
AB  - BACKGROUND: Parents' decisions about how to feed their newborns are influenced by
      multiple factors. Our objective was to identify the factors that can influence
      the decision to breastfeed. METHODS: Cross-sectional observational online study
      was conducted in Spain on women who gave birth between 2013 and 2018. The total
      number of participants was 5671. Data collection was after approval by the ethics
      committee in 2019. The data were collected retrospectively because the
      information was obtained from women who were mothers during the years 2013-2018. 
      An online survey was distributed to breastfeeding associations and postpartum
      groups. Multivariate analysis with binary logistic regression was done to
      calculate the Adjusted Odds Ratios (aOR). The main result variable was "intention
      to breastfeed". RESULTS: Ninety-seven percent (n = 5531) of women made the
      decision to breastfeed prior to giving birth. The internet played a role in
      deciding to breastfeed in 33.7% (n = 2047) of women, while 20.1% (n = 1110) said 
      the same thing about their midwife. We identified five significant factors
      associated with the mother's prenatal decision to breastfeed: attending maternal 
      education (aOR 2.10; 95% CI 1.32, 3.34), having two (aOR 0.52; 95% CI 0.28, 0.99)
      and three children (aOR 0.24; 95% CI 0.10, 0.59), previous breastfeeding
      experience (aOR 6.99; 95% CI 3.46, 14.10), support from partner (aOR 1.58; 95% CI
      1.09,2.28) and having a condition during pregnancy (aOR 0.62; 95% CI 0.43, 0.91).
      CONCLUSIONS: Factors related with previous breastfeeding experience and education
      for mothers are decisive when it comes to making the decision to breastfeed.
      Given the proven influence that partners have in decision-making, it is important
      for them to be fully involved in the process.
FAU - Ballesta-Castillejos, Ana
AU  - Ballesta-Castillejos A
AD  - Department of Obstetrics & Gynaecology, Centro de Salud San Clemente, Cuenca,
      Spain.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AD  - Department of Sociology, Social Work and Public Health, University of Huelva,
      21071, Huelva, Spain.
AD  - Safety and Health Postgrade Program, Universidad Espiritu Santo, 091650,
      Guayaquil, Ecuador.
FAU - Rodriguez-Almagro, Julian
AU  - Rodriguez-Almagro J
AUID- ORCID: 0000-0002-6239-2842
AD  - Department of Nursing, Faculty of Nursing of Ciudad Real, University of
      Castilla-La Mancha, Ciudad Real, Spain. julianj.rodriguez@uclm.es.
FAU - Ortiz-Esquinas, Inmaculada
AU  - Ortiz-Esquinas I
AD  - Department of Obstetrics & Gynaecology, Complejo Hospitalario Jaen, Jaen, Spain.
FAU - Hernandez-Martinez, Antonio
AU  - Hernandez-Martinez A
AD  - Department of Nursing, Faculty of Nursing of Ciudad Real, University of
      Castilla-La Mancha, Ciudad Real, Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201117
PL  - England
TA  - Int Breastfeed J
JT  - International breastfeeding journal
JID - 101251562
SB  - IM
MH  - Adult
MH  - Breast Feeding/economics/*psychology/statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Decision Making
MH  - Female
MH  - Humans
MH  - Income
MH  - Middle Aged
MH  - Mothers/*psychology/statistics & numerical data
MH  - Spain
MH  - Young Adult
PMC - PMC7672988
OTO - NOTNLM
OT  - *Breastfeeding
OT  - *Decision to breastfeed
OT  - *Internet
OT  - *Midwife
OT  - *Partner support
EDAT- 2020/11/19 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/11/18 05:34
PHST- 2020/04/13 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/18 05:34 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
AID - 10.1186/s13006-020-00341-5 [doi]
AID - 10.1186/s13006-020-00341-5 [pii]
PST - epublish
SO  - Int Breastfeed J. 2020 Nov 17;15(1):97. doi: 10.1186/s13006-020-00341-5.


PMID- 33203415
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 17
TI  - Moral neutralization: Nurses' evolution in unethical climate workplaces.
PG  - 114
LID - 10.1186/s12910-020-00558-3 [doi]
AB  - INTRODUCTION: Good quality of care is dependent on nurses' strong clinical skills
      and moral competencies, as well. While most nurses work with high moral
      standards, the moral performance of some nurses in some organizations shows a
      deterioration in their moral sensitivity and actions. The study reported in this 
      paper aimed to explore the experiences of nurses regarding negative changes in
      their moral practice. MATERIALS AND METHODS: This was a qualitative study
      utilizing an inductive thematic analysis approach, which was conducted from
      February 2017 to September 2019. Twenty-five nurses participated in
      semi-structured interviews. RESULTS: The main theme that emerged from our
      analysis was one of moral neutralization in the context of an unethical moral
      climate. We found five sub-themes, including: (1) feeling discouraged; (2)
      normalization; (3) giving up; (4) becoming a justifier; and (5) moral
      indifference. CONCLUSIONS: Unethical moral climates in health organizations can
      result in deterioration of morality in nurses which can harm both patients and
      health systems. Some unethical behaviors in nurses can be explained by this
      process.
FAU - Hakimi, Hamideh
AU  - Hakimi H
AD  - Nursing Care Research Center (NCRC), School of Nursing and Midwifery, Iran
      University of Medical Sciences, Tehran, Iran.
FAU - Joolaee, Soodabeh
AU  - Joolaee S
AD  - UBC Centre for Health Evaluation and Outcome Sciences (CHEOS), Vancouver, BC,
      Canada.
FAU - Ashghali Farahani, Mansoureh
AU  - Ashghali Farahani M
AD  - Nursing Care Research Center (NCRC), School of Nursing and Midwifery, Iran
      University of Medical Sciences, Tehran, Iran.
FAU - Rodney, Patricia
AU  - Rodney P
AD  - School of Nursing, University of British Columbia, Vancouver, Canada.
FAU - Ranjbar, Hadi
AU  - Ranjbar H
AUID- ORCID: 0000-0002-3672-7266
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran. ranjbar.h@iums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Attitude of Health Personnel
MH  - Clinical Competence
MH  - Humans
MH  - Morals
MH  - *Nurses
MH  - Qualitative Research
MH  - *Workplace
PMC - PMC7672869
OTO - NOTNLM
OT  - *Ethical practice
OT  - *Health care system
OT  - *Moral climate
OT  - *Morality
OT  - *Nurses
EDAT- 2020/11/19 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/18 05:34
PHST- 2020/03/24 00:00 [received]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/18 05:34 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00558-3 [doi]
AID - 10.1186/s12910-020-00558-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 17;21(1):114. doi: 10.1186/s12910-020-00558-3.


PMID- 33203381
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 17
TI  - Cultivation of humanistic values in medical education through anatomy pedagogy
      and gratitude ceremony for body donors.
PG  - 440
LID - 10.1186/s12909-020-02292-1 [doi]
AB  - BACKGROUND: One of the most important objectives of modern medical education is
      to empower medical students to become humanistic clinicians. Human anatomy plays 
      a crucial role in this mission by using cadavers to cause reflections on death,
      dying, illness, and the role of medical practitioners in humanistic care. The
      objective of this study was to introduce, describe, and evaluate the impact of a 
      ceremony in honor of the body donors on ethical and humanistic attitudes of
      medical students. METHODS: We used a phenomenological research approach to
      explore and understand the lived experiences of the anatomy teachers as they
      teach anatomy in the context of humanism and ethics. A separate survey of
      third-year medical students was carried out to understand their perceptions of
      changes in themselves, respect for donors and donor families, and their
      relationship with patients. Data were collected in two phases: a desktop review
      of teaching materials followed by in-depth interviews of the main anatomy
      teachers followed by a self-administered, 5-item Likert scaled questionnaire
      given to students. RESULTS: In the present article, we describe the rituals
      conducted in honor of body donors at our School of Medicine. We also describe the
      lived experiences of anatomy teachers as they work on improving humanistic
      education quality through the introduction of the concept of "silent mentor"
      which refers to a cadaver that quietly allows medical students to learn from it. 
      In turn, a ceremony in honor of body donors who have altruistically donated their
      bodies so that learning anatomy through dissection would be possible is also
      introduced. A survey of the impact of the ceremony in honor of body donors on
      medical students revealed positive responses in terms of promoting studying
      anatomy (3.96 Vs 3.95) as well as reflections on own death (4.44 Vs 4.35), the
      life of body donors (4.07 Vs 4.04), and how to humanely view future patients and 
      their significant others (4.32 Vs 4.24) relative to those that did not attend the
      ceremony (5-item Likert scale). The majority of the students that attended the
      ceremony also indicated that it had a positive impact on their future
      doctor-patient relationship, thinking about the possibility of donating their
      body for teaching as well as about medical ethics. Most of them also think that
      attending the ceremony helped reduce their anxiety, fear, and disgust of seeing
      corpses or dissecting and 90% insisted that memorial ceremonies should continue
      being conducted at Zhongshan Medical School. CONCLUSION: The combination of the
      anatomy component of the basic medical curriculum and gratitude ceremonies as
      well as activities to promote body bequeathal programs might help to accomplish
      the goal of cultivating high-quality medical students and professionals for the
      future. The long-term benefits would be a medical graduate who exudes empathy,
      relates well with patients and their significant others, leading to a productive 
      doctor-patient relationship.
FAU - Guo, Kaihua
AU  - Guo K
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China.
FAU - Luo, Tao
AU  - Luo T
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China.
FAU - Zhou, Li-Hua
AU  - Zhou LH
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China. zhoulih@mail.sysu.edu.cn.
AD  - Department of Anatomy, Sun Yat-sen University School of Medicine, Sun Yat-Sen
      University, Guangzhou, 510089, People's Republic of China.
      zhoulih@mail.sysu.edu.cn.
FAU - Xu, Dazheng
AU  - Xu D
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China.
FAU - Zhong, Guangming
AU  - Zhong G
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China.
FAU - Wang, Huaqiao
AU  - Wang H
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China.
FAU - Xu, Jie
AU  - Xu J
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China.
FAU - Chu, Guoliang
AU  - Chu G
AD  - Department of Anatomy, Zhongshan School of Medicine, Sun Yat-Sen University,
      Guangzhou, 510080, People's Republic of China. chugl@mail.sysu.edu.cn.
LA  - eng
GR  - Grant number: 2016/236#/Higher Education Reform Programme of Guangdong Province
      in China,
GR  - Grant numbers 2019/285#, 2018/151#, and 2017/79#./Undergraduate Teaching Reform
      and Quality Programme of Sun Yat-Sen University
PT  - Journal Article
DEP - 20201117
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - *Anatomy/education
MH  - Cadaver
MH  - *Education, Medical
MH  - *Education, Medical, Undergraduate
MH  - Humanism
MH  - Humans
MH  - Physician-Patient Relations
MH  - *Students, Medical
PMC - PMC7672936
OTO - NOTNLM
OT  - Ethics
OT  - Human anatomy
OT  - Humanistic qualities
OT  - Medical education
OT  - Silent mentor
EDAT- 2020/11/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/18 05:34
PHST- 2020/07/21 00:00 [received]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/11/18 05:34 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02292-1 [doi]
AID - 10.1186/s12909-020-02292-1 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Nov 17;20(1):440. doi: 10.1186/s12909-020-02292-1.


PMID- 33202958
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2073-4360 (Electronic)
IS  - 2073-4360 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 13
TI  - 3D Printing for Hip Implant Applications: A Review.
LID - E2682 [pii]
LID - 10.3390/polym12112682 [doi]
AB  - There is a rising demand for replacement, regeneration of tissues and organ
      repairs for patients who suffer from diseased/damaged bones or tissues such as
      hip pains. The hip replacement treatment relies on the implant, which may not
      always meet the requirements due to mechanical and biocompatibility issues which 
      in turn may aggravate the pain. To surpass these limitations, researchers are
      investigating the use of scaffolds as another approach for implants.
      Three-dimensional (3D) printing offers significant potential as an efficient
      fabrication technique on personalized organs as it is capable of biomimicking the
      intricate designs found in nature. In this review, the determining factors for
      hip replacement and the different fabrication techniques such as direct 3D
      printing, Fused Deposition Modelling (FDM), Selective Laser Sintering (SLS) and
      stereolithography (SLA) for hip replacement. The study also covers surface
      modifications of 3D printed implants and provides an overview on 3D tissue
      regeneration. To appreciate the current conventional hip replacement practices,
      the conventional metallic and ceramic materials are covered, highlighting their
      rationale as the material of choice. Next, the challenges, ethics and trends in
      the implants' 3D printing are covered and conclusions drawn. The outlook and
      challenges are also presented here. The knowledge from this review indicates that
      3D printing has enormous potential for providing a pathway for a sustainable hip 
      replacement.
FAU - Okolie, Obinna
AU  - Okolie O
AUID- ORCID: 0000-0001-9221-4441
AD  - Centre of Advanced Engineering Materials, School of Engineering, Robert Gordon
      University, Riverside East, Garthdee Road, Aberdeen AB10 7AQ, UK.
FAU - Stachurek, Iwona
AU  - Stachurek I
AUID- ORCID: 0000-0002-4788-9455
AD  - Lukasiewicz Research Network-Krakow Institute of Technology, 73 Zakopianska
      Street, 30-418 Krakow, Poland.
FAU - Kandasubramanian, Balasubramanian
AU  - Kandasubramanian B
AUID- ORCID: 0000-0003-4257-8807
AD  - Rapid Prototyping Lab, Department of Metallurgical and Materials Engineering,
      Defence Institute of Advanced Technology (DU), Ministry of Defence, Girinagar,
      Pune, Maharashtra 411025, India.
FAU - Njuguna, James
AU  - Njuguna J
AUID- ORCID: 0000-0001-8055-4457
AD  - Centre of Advanced Engineering Materials, School of Engineering, Robert Gordon
      University, Riverside East, Garthdee Road, Aberdeen AB10 7AQ, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201113
PL  - Switzerland
TA  - Polymers (Basel)
JT  - Polymers
JID - 101545357
PMC - PMC7697992
OTO - NOTNLM
OT  - 3D printing
OT  - biocompatibility
OT  - biomaterials
OT  - cell adhesion
OT  - hip replacement
OT  - tissue regeneration
EDAT- 2020/11/19 06:00
MHDA- 2020/11/19 06:01
CRDT- 2020/11/18 01:02
PHST- 2020/10/28 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/18 01:02 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2020/11/19 06:01 [medline]
AID - polym12112682 [pii]
AID - 10.3390/polym12112682 [doi]
PST - epublish
SO  - Polymers (Basel). 2020 Nov 13;12(11). pii: polym12112682. doi:
      10.3390/polym12112682.


PMID- 33202103
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1934-8258 (Electronic)
IS  - 1934-8258 (Linking)
VI  - 108
IP  - 1
DP  - 2020 Dec
TI  - Informed Consent for Genetic and Genomic Research.
PG  - e104
LID - 10.1002/cphg.104 [doi]
AB  - Genetic research often utilizes or generates information that is potentially
      sensitive to individuals, families, or communities. For these reasons, genetic
      research may warrant additional scrutiny from investigators and governmental
      regulators, compared to other types of biomedical research. The informed consent 
      process should address the range of social and psychological issues that may
      arise in genetic research. This article addresses a number of these issues,
      including recruitment of participants, disclosure of results, psychological
      impact of results, insurance and employment discrimination, community engagement,
      consent for tissue banking, and intellectual property issues. Points of
      consideration are offered to assist in the development of protocols and consent
      processes in light of contemporary debates on a number of these issues. (c) 2020 
      Wiley Periodicals LLC.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Botkin, Jeffrey R
AU  - Botkin JR
AD  - University of Utah, Salt Lake City, Utah.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Protoc Hum Genet
JT  - Current protocols in human genetics
JID - 101287858
SB  - IM
MH  - Disclosure/legislation & jurisprudence
MH  - Genetic Research/*legislation & jurisprudence
MH  - Genome, Human/*genetics
MH  - Genomics/*legislation & jurisprudence/methods
MH  - Humans
MH  - *Informed Consent
MH  - Intellectual Property
MH  - Risk Factors
MH  - Whole Exome Sequencing/methods/statistics & numerical data
MH  - Whole Genome Sequencing/methods/statistics & numerical data
OTO - NOTNLM
OT  - *consent
OT  - *disclosure
OT  - *ethics
OT  - *genetic testing
OT  - *regulatory
EDAT- 2020/11/18 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/11/17 17:14
PHST- 2020/11/17 17:14 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.1002/cphg.104 [doi]
PST - ppublish
SO  - Curr Protoc Hum Genet. 2020 Dec;108(1):e104. doi: 10.1002/cphg.104.


PMID- 33202020
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210918
IS  - 1527-974X (Electronic)
IS  - 1067-5027 (Linking)
VI  - 27
IP  - 11
DP  - 2020 Nov 1
TI  - A call for social informatics.
PG  - 1798-1801
LID - 10.1093/jamia/ocaa175 [doi]
AB  - As evidence of the associations between social factors and health outcomes
      continues to mount, capturing and acting on social determinants of health (SDOH) 
      in clinical settings has never been more relevant. Many professional medical
      organizations have endorsed screening for SDOH, and the U.S. Office of the
      National Coordinator for Health Information Technology has recommended increased 
      capacity of health information technology to integrate and support use of SDOH
      data in clinical settings. As these efforts begin their translation to practice, 
      a new subfield of health informatics is emerging, focused on the application of
      information technologies to capture and apply social data in conjunction with
      health data to advance individual and population health. Developing this
      dedicated subfield of informatics-which we term social informatics-is important
      to drive research that informs how to approach the unique data, interoperability,
      execution, and ethical challenges involved in integrating social and medical
      care.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association. All rights reserved. For permissions,
      please email: journals.permissions@oup.com.
FAU - Pantell, Matthew S
AU  - Pantell MS
AD  - Department of Pediatrics, University of California, San Francisco, California,
      USA.
AD  - Center for Health and Community, University of California, San Francisco,
      California, USA.
FAU - Adler-Milstein, Julia
AU  - Adler-Milstein J
AD  - Department of Medicine, University of California, San Francisco, California, USA.
AD  - Center for Clinical Informatics and Improvement Research, University of
      California, San Francisco, California, USA.
FAU - Wang, Michael D
AU  - Wang MD
AD  - Department of Medicine, University of California, San Francisco, California, USA.
AD  - Center for Clinical Informatics and Improvement Research, University of
      California, San Francisco, California, USA.
FAU - Prather, Aric A
AU  - Prather AA
AD  - Center for Health and Community, University of California, San Francisco,
      California, USA.
AD  - Department of Psychiatry, University of California, San Francisco, California,
      USA.
FAU - Adler, Nancy E
AU  - Adler NE
AD  - Department of Pediatrics, University of California, San Francisco, California,
      USA.
AD  - Center for Health and Community, University of California, San Francisco,
      California, USA.
AD  - Department of Psychiatry, University of California, San Francisco, California,
      USA.
AD  - Social Interventions Research and Evaluation Network, University of California,
      San Francisco, California, USA.
FAU - Gottlieb, Laura M
AU  - Gottlieb LM
AD  - Center for Health and Community, University of California, San Francisco,
      California, USA.
AD  - Social Interventions Research and Evaluation Network, University of California,
      San Francisco, California, USA.
AD  - Department of Family and Community Medicine, University of California, San
      Francisco, California, USA.
LA  - eng
GR  - K12 HS026383/HS/AHRQ HHS/United States
GR  - KL2 TR001870/TR/NCATS NIH HHS/United States
GR  - L60 MD013257/MD/NIMHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Am Med Inform Assoc
JT  - Journal of the American Medical Informatics Association : JAMIA
JID - 9430800
SB  - IM
MH  - Humans
MH  - *Informatics/ethics
MH  - *Social Determinants of Health
PMC - PMC7671633
OTO - NOTNLM
OT  - *health informatics
OT  - *health information technology
OT  - *social determinants of health
OT  - *social needs
EDAT- 2020/11/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/11/17 17:13
PHST- 2020/06/22 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/11/17 17:13 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 5907049 [pii]
AID - 10.1093/jamia/ocaa175 [doi]
PST - ppublish
SO  - J Am Med Inform Assoc. 2020 Nov 1;27(11):1798-1801. doi: 10.1093/jamia/ocaa175.


PMID- 33200958
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Dec
TI  - Surrogacy: New Challenges to Law and Ethics.
PG  - 293-297
LID - 10.1080/20502877.2020.1835205 [doi]
FAU - Dickenson, Donna
AU  - Dickenson D
AUID- ORCID: 0000-0002-0312-3204
AD  - Medical Ethics and Humanities, University of London, London, UK.
FAU - van Beers, Britta
AU  - van Beers B
AUID- ORCID: 0000-0002-4766-1709
AD  - Biolaw and Bioethics, Department of Legal Philosophy, Faculty of Law, Vrije
      Universiteit Amsterdam, Amsterdam, the Netherlands.
LA  - eng
PT  - Editorial
DEP - 20201117
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Reproductive Techniques, Assisted
MH  - *Surrogate Mothers
EDAT- 2020/11/18 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/11/17 12:13
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/11/17 12:13 [entrez]
AID - 10.1080/20502877.2020.1835205 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Dec;26(4):293-297. doi: 10.1080/20502877.2020.1835205. Epub 2020
      Nov 17.


PMID- 33199483
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 1945-7049 (Electronic)
IS  - 1061-3749 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Dec 1
TI  - Development and Validation of a Moral Distress Scale for Nursing Students.
PG  - 583-597
LID - 10.1891/JNM-D-19-00001 [doi]
AB  - BACKGROUND AND PURPOSE: This study aimed to develop and validate a scale to
      measure the frequency and the intensity of the moral distress experienced by
      nursing students. METHOD: Methodological study in which a guideline with eight
      steps: (a) to determine what to measure, (b) to produce items, (c) format to
      measure, (d) review by experts, (e) validation of items, (f) sample, (g)
      assessment (h) scale length was used to develop and validate a scale. The sample 
      was composed of 499 undergraduate nursing students from three Brazilian
      universities. RESULTS: Six constructs were identified in the factor analysis. The
      instrument and dimensions presented satisfactory internal consistency, with
      Cronbach's alpha coefficients equal to .97 and between .60 and .97, respectively.
      CONCLUSION: The developed scale is able to analyze the intensity and the
      frequency of Moral Distress in nursing students, in a valid and reliable way.
CI  - (c) Copyright 2020 Springer Publishing Company, LLC.
FAU - Bordignon, Simoni Saraiva
AU  - Bordignon SS
AUID- ORCID: 0000-0003-2039-1961
AD  - Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brasil
      simonibordignon@gmail.com.
FAU - Lunardi, Valeria Lerch
AU  - Lunardi VL
AD  - Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brasil.
FAU - Barlem, Edison Luiz
AU  - Barlem EL
AUID- ORCID: 0000-0001-6239-8657
AD  - Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brasil.
FAU - Dalmolin, Graziele de Lima
AU  - Dalmolin GL
AD  - Universidade Federal de Santa Maria, Santa Maria, Rio Grande do Sul, Brasil.
FAU - Silveira, Rosemary Silva da
AU  - Silveira RSD
AD  - Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brasil.
FAU - Souza Ramos, Flavia Regina
AU  - Souza Ramos FR
AD  - Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, Brasil.
FAU - Barlem, Jamila Tomaschewski
AU  - Barlem JT
AD  - Universidade Federal do Rio Grande, Rio Grande, Rio Grande do Sul, Brasil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - United States
TA  - J Nurs Meas
JT  - Journal of nursing measurement
JID - 9318902
SB  - IM
MH  - Adult
MH  - Brazil
MH  - *Ethics, Nursing
MH  - Factor Analysis, Statistical
MH  - Female
MH  - Humans
MH  - Male
MH  - *Morals
MH  - Psychometrics/standards
MH  - Reproducibility of Results
MH  - *Stress, Psychological
MH  - Students, Nursing/*psychology
MH  - Surveys and Questionnaires/standards
MH  - Young Adult
OTO - NOTNLM
OT  - *education
OT  - *ethics
OT  - *morals
OT  - *nursing
OT  - *students
OT  - *validation study
EDAT- 2020/11/18 06:00
MHDA- 2021/10/27 06:00
CRDT- 2020/11/17 06:13
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2020/11/17 06:13 [entrez]
AID - JNM-D-19-00001 [pii]
AID - 10.1891/JNM-D-19-00001 [doi]
PST - ppublish
SO  - J Nurs Meas. 2020 Dec 1;28(3):583-597. doi: 10.1891/JNM-D-19-00001. Epub 2020 Nov
      16.


PMID- 33199427
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - A novel ACT-based video game to support mental health through embedded learning: 
      a mixed-methods feasibility study protocol.
PG  - e041667
LID - 10.1136/bmjopen-2020-041667 [doi]
AB  - INTRODUCTION: In recent years, serious video games have been used to promote
      emotional regulation in individuals with mental health issues. Although these
      therapeutic strategies are innovative, they are limited with respect to scope of 
      treatment, often focusing on specific cognitive skills, to help remediate a
      specific mental health disorder. OBJECTIVE: Here, we propose a protocol for
      assessing the feasibility of a novel acceptance and commitment therapy
      (ACT)-based video game for young adults. METHODS AND ANALYSIS: The Medical
      Research Council (MRC) framework will be used for developing a complex
      intervention to design and test the feasibility of an ACT-based video game
      intervention using a mixed-methods approach involving qualitative and
      quantitative data. The primary outcomes will include feasibility testing of
      recruitment processes and the acceptability of the intervention through
      qualitative interviews, attendance and rates of attrition. Secondary outcomes
      will involve a series of quantitative questionnaires to obtain effect sizes for
      power analysis, allowing for the ideal sample size for an appropriately powered, 
      randomised controlled trial to be determined. ETHICS AND DISSEMINATION: This
      study has been approved by the Psychology Department Research Ethics Committee
      (2020-4929-3923) at Swansea University in the UK. Dissemination activities will
      involve publications in peer-reviewed journals, presentations at local and
      national conferences and promotion through social media. TRIAL REGISTRATION
      NUMBER: NCT04566042.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Edwards, Darren J
AU  - Edwards DJ
AUID- ORCID: 0000-0002-2143-1198
AD  - Department of Public Health, Policy, and Social Sciences, Swansea University,
      Swansea, UK D.J.Edwards@swansea.ac.uk.
FAU - Kemp, Andrew H
AU  - Kemp AH
AD  - Department of Psychology, Swansea University, Swansea, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04566042
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acceptance and Commitment Therapy
MH  - Feasibility Studies
MH  - Humans
MH  - *Mental Disorders/therapy
MH  - Mental Health
MH  - *Video Games
PMC - PMC7670940
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *impulse control disorders
COIS- Competing interests: At the time of writing this, DJE is discussing with Agor IP 
      at Swansea University the potential to commercialise the described video game as 
      a mobile application; however, at this time no agreements have been made or
      signed. AHK has no competing interests.
EDAT- 2020/11/18 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-041667 [pii]
AID - 10.1136/bmjopen-2020-041667 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e041667. doi: 10.1136/bmjopen-2020-041667.


PMID- 33199425
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - Interventions to facilitate return to work in adults with chronic non-malignant
      pain: a protocol for a systematic review and network meta-analysis.
PG  - e040962
LID - 10.1136/bmjopen-2020-040962 [doi]
AB  - INTRODUCTION: Work absenteeism due to chronic non-malignant pain (CNMP) is a
      major societal and individual cause of concern that requires effective
      treatments. OBJECTIVE: We present a protocol for a systematic review and network 
      meta-analysis (NMA) aiming to compare available interventions for return to work 
      (RTW) in adults with CNMP. METHODS AND ANALYSIS: PubMed, Embase, PsycINFO, Web of
      Knowledge and Cochrane Central Register of Controlled Trials databases will be
      searched till 31 August 2020 for randomised controlled trials (RCTs) examining
      interventions for RTW outcomes among patients with CNMP. Two independent
      investigators will search the databases, perform data extraction and assess the
      methodological quality of the selected RCTs. The primary outcome will be RTW, if 
      possible, full-time or part-time after work absence due to chronic pain from
      baseline to the last available follow-up. Secondary outcomes will include
      self-reported workability or work capacity, or self-reported physical functioning
      and quality of life as measured by any validated scale. Pairwise meta-analysis
      and NMA will be conducted for each outcome using a random-effects model. For the 
      primary outcomes, we will also obtain the ranking of all competing interventions 
      within each NMA using surface under the cumulative ranking curve. The assumption 
      of coherence (ie, that direct and indirect evidence are in statistical agreement)
      will be examined using both a local and a global approach. We will also conduct
      subgroup and meta-regression analyses, whenever feasible, to investigate the
      unexplained variation in effect size. The comparison-adjusted funnel plot will be
      used to evaluate small-study effects. The overall quality of evidence will be
      rated with the Confidence in Network Meta-Analysis tool. Data analysis will be
      conducted using Stata V.16.0. ETHICS AND DISSEMINATION: This systematic review
      does not require ethical approval since it will not disseminate any private
      patient data. The results of this study will be disseminated through
      peer-reviewed publication. PROSPERO REGISTRATION NUMBER: CRD42020171429.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bjork, Mathilda
AU  - Bjork M
AD  - Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring
      Sciences, Linkoping University, Linkoping, Sweden.
FAU - Gerdle, Bjorn
AU  - Gerdle B
AD  - Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring
      Sciences, Linkoping University, Linkoping, Sweden.
FAU - Liedberg, Gunilla
AU  - Liedberg G
AD  - Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring
      Sciences, Linkoping University, Linkoping, Sweden.
FAU - Svanholm, Frida
AU  - Svanholm F
AD  - Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring
      Sciences, Linkoping University, Linkoping, Sweden.
FAU - Solmi, Marco
AU  - Solmi M
AD  - Neurosciences Department, University of Padua, Padua, Italy.
FAU - Thompson, Trevor
AU  - Thompson T
AD  - School of Human Sciences, University of Greenwich, London, UK.
FAU - Chaimani, Anna
AU  - Chaimani A
AD  - Research Center of Epidemiology and Statistics Sorbonne Paris Cite (CRESS
      UMR1153), INSERM, INRA, Universite de Paris, Paris, France.
FAU - Dragioti, Elena
AU  - Dragioti E
AUID- ORCID: 0000-0001-9019-4125
AD  - Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring
      Sciences, Linkoping University, Linkoping, Sweden elena.dragioti@liu.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Chronic Pain/therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Return to Work
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7670949
OTO - NOTNLM
OT  - *occupational & industrial medicine
OT  - *pain management
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040962 [pii]
AID - 10.1136/bmjopen-2020-040962 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e040962. doi: 10.1136/bmjopen-2020-040962.


PMID- 33199424
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - Influence of the month of birth on persistence of ADHD in prospective studies:
      protocol for an individual patient data meta-analysis.
PG  - e040952
LID - 10.1136/bmjopen-2020-040952 [doi]
AB  - INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a
      neurodevelopmental disorder with symptoms, especially the hyperactive ones, that 
      tend to decrease in severity with age. Interestingly, children born just before
      the school-entry cut-off date (ie, the youngest pupils of a classroom) are at
      higher risk of being diagnosed with ADHD compared with children born just after
      the cut-off date. Noteworthy, this month-of-birth effect tends to disappear with 
      increasing absolute age. Therefore, it is possible that young children
      erroneously diagnosed with ADHD due to their month of birth present a lower
      chance to have their diagnosis confirmed at a later age, artificially reinforcing
      the low persistence of ADHD across the lifespan. This protocol outlines an
      individual patient data (IPD) meta-analysis of prospective observational studies 
      to explore the role of the month of birth in the low persistence of ADHD across
      the lifespan. METHODS AND ANALYSIS: Five databases will be systematically
      searched in order to find prospective observational studies where the presence of
      ADHD is assessed both at baseline and at a follow-up of at least 4 years. We will
      use a two-stage IPD meta-analytic approach to estimate the role of the month of
      birth in the persistence of ADHD. Various sensitivity analyses will be performed 
      to assess the robustness of the results. ETHICS AND DISSEMINATION: No additional 
      data will be collected and no de-identified raw data will be used. Ethics
      approval is thus not required for the present study. Results of this IPD
      meta-analysis will be submitted for publication in a peer-reviewed journal.
      PROSPERO REGISTRATION NUMBER: CRD42020212650.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gosling, Corentin J
AU  - Gosling CJ
AUID- ORCID: 0000-0003-1133-9344
AD  - Department of Psychology, DysCo Lab, Paris-Nanterre University, Nanterre, France 
      corentin.gosling@parisnanterre.fr.
AD  - Department of Psychology, EA 4057, Universite de Paris, Paris, France.
FAU - Pinabiaux, Charlotte
AU  - Pinabiaux C
AD  - Department of Psychology, DysCo Lab, Paris-Nanterre University, Nanterre, France.
FAU - Caparos, Serge
AU  - Caparos S
AD  - Department of Psychology, DysCo Lab, Paris 8 University, Saint-Denis, France.
AD  - Institut Universitaire de France, Paris, France.
FAU - Delorme, Richard
AU  - Delorme R
AD  - Department of Child and Adolescent Psychiatry, Assistance Publique - Hopitaux de 
      Paris, Paris, France.
AD  - Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France.
FAU - Cortese, Samuele
AU  - Cortese S
AD  - Center for Innovation in Mental Health, School of Psychology, Faculty of
      Environmental and Life Sciences, University of Southampton, Southampton, UK.
AD  - Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine,
      University of Southampton, Southampton, UK.
AD  - Solent NHS Trust, Southampton, UK.
AD  - Hassenfeld Children's Hospital at NYU Langone, New York University Child Study
      Center, New York City, New York, USA.
AD  - Division of Psychiatry and Applied Psychology, School of Medicine, University of 
      Nottingham, Nottingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Attention Deficit Disorder with Hyperactivity/epidemiology
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Schools
PMC - PMC7670948
OTO - NOTNLM
OT  - *ADHD
OT  - *meta-analysis
OT  - *month of birth
OT  - *persistence
COIS- Competing interests: SCo declares honoraria and reimbursement for travel and
      accommodation expenses for lectures from the following non-profit associations:
      Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD
      Alliance Resource (CADDRA), British Association of Pharmacology (BAP), and from
      Healthcare Convention for educational activity on ADHD. All other authors have no
      conflict of interest to declare.
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040952 [pii]
AID - 10.1136/bmjopen-2020-040952 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e040952. doi: 10.1136/bmjopen-2020-040952.


PMID- 33199423
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - Study protocol for a randomised controlled trial evaluating the effect of folic
      acid supplementation beyond the first trimester on maternal plasma unmetabolised 
      folic acid in late gestation.
PG  - e040416
LID - 10.1136/bmjopen-2020-040416 [doi]
AB  - INTRODUCTION: Taking folic acid containing supplements prior to and during early 
      pregnancy reduces the risk of neural tube defects. Neural tube defects occur
      prior to 28 days postconception, after which, there is no proven benefit of
      continuing to take folic acid. However, many women continue to take folic acid
      containing supplements throughout the pregnancy. At higher intakes, folic acid is
      not converted to its active form and accumulates in circulation as unmetabolised 
      folic acid (UMFA). Recently, concerns have been raised about possible links
      between late gestation folic acid supplementation and childhood allergy,
      metabolic disease and autism spectrum disorders. We aim to determine if removing 
      folic acid from prenatal micronutrient supplements after 12 weeks gestation
      reduces circulating levels of maternal UMFA at 36 weeks gestation. METHODS AND
      ANALYSIS: This is a parallel-design, double-blinded randomised controlled trial. 
      Women >/=12 and <16 weeks' gestation with a singleton pregnancy and able to give 
      informed consent are eligible to participate. Women (n=100; 50 per group) will be
      randomised to receive either a micronutrient supplement containing 0.8 mg of
      folic acid or a micronutrient supplement without folic acid daily from enrolment 
      until delivery. The primary outcome is plasma UMFA concentration at 36 weeks
      gestation. Secondary outcomes include red blood cell folate and total plasma
      folate concentration. We will assess whether there is a difference in mean UMFA
      levels at 36 weeks gestation between groups using linear regression with
      adjustment for baseline UMFA levels and gestational age at trial entry. The
      treatment effect will be described as a mean difference with 95% CI. ETHICS AND
      DISSEMINATION: Ethical approval has been granted from the Women's and Children's 
      Health Network Research Ethics Committee (HREC/19/WCHN/018). The results of this 
      trial will be presented at scientific conferences and published in peer-reviewed 
      journals. TRIAL REGISTRATION NUMBER: ACTRN12619001511123.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sulistyoningrum, Dian
AU  - Sulistyoningrum D
AUID- ORCID: 0000-0001-9654-2151
AD  - SAHMRI Women and Kids Theme, South Australia Health and Medical Research
      Institute, Adelaide, South Australia, Australia.
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Green, Tim
AU  - Green T
AD  - SAHMRI Women and Kids Theme, South Australia Health and Medical Research
      Institute, Adelaide, South Australia, Australia.
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Palmer, Debbie
AU  - Palmer D
AD  - Telethon Kids Institute, University of Western Australia, Nedlands, Western
      Australia, Australia.
FAU - Sullivan, Thomas
AU  - Sullivan T
AD  - SAHMRI Women and Kids Theme, South Australia Health and Medical Research
      Institute, Adelaide, South Australia, Australia.
AD  - Faculty of Health and Medical Sciences, School of Public Health, The University
      of Adelaide, Adelaide, South Australia, Australia.
FAU - Wood, Simon
AU  - Wood S
AD  - Faculty of Science and Engineering, Curtin University, Perth, West Australia,
      Australia.
AD  - Faculty of Land and Food Systems, University of British Columbia, Vancouver,
      British Columbia, Canada.
FAU - Makrides, Maria
AU  - Makrides M
AD  - SAHMRI Women and Kids Theme, South Australia Health and Medical Research
      Institute, Adelaide, South Australia, Australia.
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Skubisz, Monika
AU  - Skubisz M
AD  - SAHMRI Women and Kids Theme, South Australia Health and Medical Research
      Institute, Adelaide, South Australia, Australia.
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Best, Karen P
AU  - Best KP
AD  - SAHMRI Women and Kids Theme, South Australia Health and Medical Research
      Institute, Adelaide, South Australia, Australia karen.best@sahmri.com.
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001511123
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vitamins)
RN  - 935E97BOY8 (Folic Acid)
SB  - IM
MH  - Child
MH  - Dietary Supplements
MH  - Female
MH  - *Folic Acid
MH  - Humans
MH  - *Neural Tube Defects
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Randomized Controlled Trials as Topic
MH  - Vitamins
PMC - PMC7670954
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *obstetrics
OT  - *public health
COIS- Competing interests: MM reports that she has a financial relationship outside the
      submitted work with Trajan Nutrition as a member of the board. SW is a consultant
      for the Factors Group of Companies. DS, TG, DP, TS MS and KPB have nothing to
      disclose.
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040416 [pii]
AID - 10.1136/bmjopen-2020-040416 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e040416. doi: 10.1136/bmjopen-2020-040416.


PMID- 33199422
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - A study protocol for a phase II randomised, double-blind, placebo-controlled
      trial of sodium selenate as a disease-modifying treatment for behavioural variant
      frontotemporal dementia.
PG  - e040100
LID - 10.1136/bmjopen-2020-040100 [doi]
AB  - INTRODUCTION: Behavioural variant frontotemporal dementia (bvFTD) is a
      neurodegenerative disorder often neuropathologically associated with the
      accumulation of abnormally hyperphosphorylated tau, for which there is currently 
      no disease-modifying treatment. Previous work by our group has shown sodium
      selenate upregulates the activity of protein phosphatase 2 in the brain,
      increasing the rate of tau dephosphorylation. The objective of this study is to
      evaluate the efficacy and safety of sodium selenate as a disease-modifying
      treatment for bvFTD. METHODS AND ANALYSIS: This will be a multisite, phase IIb,
      double-blind placebo-controlled trial of sodium selenate. One hundred and twenty 
      participants will be enrolled across 4 Australian academic hospitals. Following
      screening eligible participants will be randomised (1:1) to sodium selenate (15
      mg three times a day) or placebo for 52 weeks. Participants will have regular
      safety and efficacy visits throughout the study period. The primary study outcome
      will be percentage brain volume change (PBVC) as measured on MRI over 52 weeks of
      treatment. This will be analysed with a general linear model (analysis of
      covariance (ANCOVA)) with the PBVC as an output, the treatment as an input and
      the baseline brain volume as covariate for adjustment purposes. Secondary
      outcomes include safety and tolerability measures, and efficacy measures; change 
      in cerebrospinal fluid total-tau, Addenbrooke's Cognitive Examination-III and
      Cambridge Behavioural Inventory-Revised scores over the 52 weeks of treatment.
      These will also be analysed with ANCOVA where the corresponding baseline measure 
      will be incorporated in the model. Additional exploratory outcomes will include
      other imaging, cognitive and biospecimen analyses. ETHICS AND DISSEMINATION: The 
      study was approved by the Human Research and Ethics Committee of the lead site as
      part of the Australian Multisite Ethics approval system. The results of the study
      will be presented at national and international conferences and published in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: ACTRN12620000236998 .
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vivash, Lucy
AU  - Vivash L
AUID- ORCID: 0000-0002-1182-0907
AD  - Department of Neuroscience, Monash University, Melbourne, Victoria, Australia
      lucy.vivash@monash.edu.
AD  - Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - Departments of Medicine and Radiology, University of Melbourne, Parkville,
      Victoria, Australia.
FAU - Malpas, Charles B
AU  - Malpas CB
AD  - Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - CORe, Department of Medicine, University of Melbourne, Parkville, VIC, Australia.
FAU - Churilov, Leonid
AU  - Churilov L
AD  - Departments of Medicine and Radiology, University of Melbourne, Parkville,
      Victoria, Australia.
FAU - Walterfang, Mark
AU  - Walterfang M
AD  - Department of Neuropsychiatry, Royal Melbourne Hospital, Melbourne, Victoria,
      Australia.
AD  - Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria,
      Australia.
FAU - Brodtmann, Amy
AU  - Brodtmann A
AD  - Department of Neurology, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - Florey Institute for Neuroscience and Mental Health, Melbourne, Victoria,
      Australia.
AD  - Eastern Cognitive Disorders Clinic, Monash University, Box Hill, Victoria,
      Australia.
AD  - Melbourne Dementia Research Centre, University of Melbourne, Parkville, VIC,
      Australia.
FAU - Piguet, Olivier
AU  - Piguet O
AD  - School of Psychology, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Brain and Mind Centre, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Ahmed, Rebekah M
AU  - Ahmed RM
AD  - Brain and Mind Centre, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Memory and Cognition Clinic, Royal Prince Alfred Hospital, Sydney, New South
      Wales, Australia.
FAU - Bush, Ashley I
AU  - Bush AI
AD  - Florey Institute for Neuroscience and Mental Health, Melbourne, Victoria,
      Australia.
AD  - Melbourne Dementia Research Centre, University of Melbourne, Parkville, VIC,
      Australia.
FAU - Hovens, Christopher M
AU  - Hovens CM
AD  - Department of Surgery, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
FAU - Kalincik, T
AU  - Kalincik T
AD  - Department of Neurology, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - CORe, Department of Medicine, University of Melbourne, Parkville, VIC, Australia.
FAU - Darby, David
AU  - Darby D
AD  - Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - Departments of Medicine and Radiology, University of Melbourne, Parkville,
      Victoria, Australia.
AD  - Eastern Cognitive Disorders Clinic, Monash University, Box Hill, Victoria,
      Australia.
FAU - Velakoulis, Dennis
AU  - Velakoulis D
AD  - Department of Neuropsychiatry, Royal Melbourne Hospital, Melbourne, Victoria,
      Australia.
AD  - Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Victoria,
      Australia.
FAU - O'Brien, Terence J
AU  - O'Brien TJ
AD  - Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
AD  - Department of Neurology, Royal Melbourne Hospital, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - Departments of Medicine and Radiology, University of Melbourne, Parkville,
      Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12620000236998
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - HV0Y51NC4J (Selenic Acid)
SB  - IM
MH  - Australia
MH  - Clinical Trials, Phase II as Topic
MH  - Double-Blind Method
MH  - *Frontotemporal Dementia/diagnostic imaging/drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Selenic Acid
MH  - Treatment Outcome
PMC - PMC7670941
OTO - NOTNLM
OT  - *clinical trials
OT  - *dementia
OT  - *psychiatry
COIS- Competing interests: All authors report a grant from the NHMRC to support this
      study. The authors report the following disclosures outside of this study: LV
      reports personal fees from Biogen Australia. AIB reports personal fees from
      Collaborative Medicinal Development, and shares in Alterity, Cogstate,
      Grunbiotics and Mesoblast. CH reports issued patents US 9415063 and US 8920951.
      TK reports grants from the University of Melbourne and Biogen Australia; personal
      fees from Biogen, Roche, Genzyme-Sanofi, Merck, Novartis, WebMD Global, Teva and 
      BioCSL; and non-financial support from Biogen, Genzyme-Sanofi and Merck. TOB
      reports research funding from Biogen, Eisai, UCB, Anavex and Praxis. CM, LC MW,
      AB, OP, RA, DD and DV have nothing to disclose.
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040100 [pii]
AID - 10.1136/bmjopen-2020-040100 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e040100. doi: 10.1136/bmjopen-2020-040100.


PMID- 33199421
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus
      infliximab for terminal ileitis in Crohn's disease: a randomised, controlled,
      open-label trial.
PG  - e038429
LID - 10.1136/bmjopen-2020-038429 [doi]
AB  - INTRODUCTION: Crohn's disease is a chronic inflammatory disease of the
      gastrointestinal tract with an increasing incidence and prevalence worldwide. The
      early use of anti--tumour necrosis factor agents, such as infliximab, in patients
      with an aggressive form of Crohn's disease has become part of routine practice.
      However, infliximab has limitations, and early surgery might benefit patients
      more. The objective of this study was to compare laparoscopic bowel resection
      with infliximab treatment in patients with moderately or severely active Crohn's 
      disease with respect to endoscopic remission. The laparoscopic bowel resection
      combined with infliximab treatment trial is the first randomised controlled trial
      to demonstrate if early surgery can improve the outcome of patients with Crohn's 
      disease with limited non-stricturing disease treated with infliximab. METHODS AND
      ANALYSIS: This is a randomised, open-label, controlled trial at Renji Hospital.
      In this study, a total of 106 adult patients aged 18-80 years with moderately or 
      severely active and steroid-dependent or steroid-resistant Crohn's disease of the
      distal ileum will be randomly assigned in a 1:1 ratio to the control and surgery 
      groups. The primary outcome is 12-month endoscopic remission measured by the
      Simple Endoscopic Score for Crohn's Disease in the control group and the
      Rutgeerts score in the surgery group. The secondary outcomes are clinical
      remission, surgery rate, quality of life, Crohn's disease-related medical costs
      and Crohn's disease-related morbidity. The patients will be followed up every 6
      months after randomisation through intestinal magnetic resonance enterography and
      colonoscopy for either 3 years or until clinical remission. ETHICS AND
      DISSEMINATION: All participants will provide informed consent. The protocol has
      been approved by the Medical Ethical Committee of the Academic Medical Center in 
      Shanghai (No KY2019-180). Results will be disseminated through peer-reviewed
      journals and scientific conference presentations. TRIAL REGISTRATION NUMBER:
      ChiCTR2000029323.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hao, Xiuxiu
AU  - Hao X
AUID- ORCID: 0000-0002-1011-2829
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China.
FAU - Feng, Tienan
AU  - Feng T
AUID- ORCID: 0000-0001-7770-3714
AD  - Clinical Research Institute, Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Yang, Yang
AU  - Yang Y
AUID- ORCID: 0000-0002-1684-7105
AD  - Department of Gastroenterology, Daping Hospital, Army Medical University,
      Chongqing, China.
FAU - Shi, Yuan
AU  - Shi Y
AUID- ORCID: 0000-0002-4745-8532
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China.
FAU - Jing, Ran
AU  - Jing R
AUID- ORCID: 0000-0003-0406-897X
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China.
FAU - Liu, Sailiang
AU  - Liu S
AUID- ORCID: 0000-0002-6091-2541
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China.
FAU - Luo, Yang
AU  - Luo Y
AUID- ORCID: 0000-0001-7477-4728
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China.
FAU - Qiao, Yuqi
AU  - Qiao Y
AUID- ORCID: 0000-0002-0374-5089
AD  - Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology
      and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center,
      Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University School of 
      Medicine Affiliated to Renji Hospital, Shanghai, China fishmeangood@163.com
      zhongming011271@renji.com qiaoyuqi@renji.com.
FAU - Zhong, Ming
AU  - Zhong M
AUID- ORCID: 0000-0002-1869-3648
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China fishmeangood@163.com
      zhongming011271@renji.com qiaoyuqi@renji.com.
FAU - Yu, Minhao
AU  - Yu M
AUID- ORCID: 0000-0001-6058-0586
AD  - Department of Gastrointestinal Surgery, Shanghai Jiao Tong University School of
      Medicine Affiliated to Renji Hospital, Shanghai, China fishmeangood@163.com
      zhongming011271@renji.com qiaoyuqi@renji.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - China
MH  - *Crohn Disease/drug therapy/surgery
MH  - Humans
MH  - Infliximab/therapeutic use
MH  - *Laparoscopy
MH  - Middle Aged
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7670938
OTO - NOTNLM
OT  - *clinical trials
OT  - *inflammatory bowel disease
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038429 [pii]
AID - 10.1136/bmjopen-2020-038429 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e038429. doi: 10.1136/bmjopen-2020-038429.


PMID- 33199419
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - Randomised sham-controlled double-blind trial evaluating remote ischaemic
      preconditioning in solid organ transplantation: a study protocol for the RIPTRANS
      trial.
PG  - e038340
LID - 10.1136/bmjopen-2020-038340 [doi]
AB  - INTRODUCTION: Remote ischaemic preconditioning (RIPC) using a non-invasive
      pneumatic tourniquet is a potential method for reducing ischaemia-reperfusion
      injury. RIPC has been extensively studied in animal models and cardiac surgery,
      but scarcely in solid organ transplantation. RIPC could be an inexpensive and
      simple method to improve function of transplanted organs. Accordingly, we aim to 
      study whether RIPC performed in brain-dead organ donors improves function and
      longevity of transplanted organs. METHODS AND ANALYSES: RIPTRANS is a
      multicentre, sham-controlled, parallel group, randomised superiority trial
      comparing RIPC intervention versus sham-intervention in brain-dead organ donors
      scheduled to donate at least one kidney. Recipients of the organs (kidney, liver,
      pancreas, heart, lungs) from a randomised donor will be included provided that
      they give written informed consent. The RIPC intervention is performed by
      inflating a thigh tourniquet to 300 mm Hg 4 times for 5 min. The intervention is 
      done two times: first right after the declaration of brain death and second
      immediately before transferring the donor to the operating theatre. The sham
      group receives the tourniquet, but it is not inflated. The primary endpoint is
      delayed graft function (DGF) in kidney allografts. Secondary endpoints include
      short-term functional outcomes of transplanted organs, rejections and graft
      survival in various time points up to 20 years. We aim to show that RIPC reduces 
      the incidence of DGF from 25% to 15%. According to this, the sample size is set
      to 500 kidney transplant recipients. ETHICS AND DISSEMINATION: This study has
      been approved by Helsinki University Hospital Ethics Committee and Helsinki
      University Hospital's Institutional Review Board. The study protocol was be
      presented at the European Society of Organ Transplantation congress in Copenhagen
      14-15 September 2019. The study results will be submitted to an international
      peer-reviewed scientific journal for publication. TRIAL REGISTRATION NUMBER:
      NCT03855722.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Uutela, Aki
AU  - Uutela A
AUID- ORCID: 0000-0003-1324-5894
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland.
FAU - Helantera, Ilkka
AU  - Helantera I
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland.
FAU - Lemstrom, Karl
AU  - Lemstrom K
AD  - Department of Cardiothoracic Surgery, Helsinki University Hospital and University
      of Helsinki, Helsinki, Finland.
FAU - Passov, Arie
AU  - Passov A
AD  - Department of Perioperative, Intensive Care and Pain Medicine, Helsinki
      University Hospital and University of Helsinki, Helsinki, Finland.
FAU - Syrjala, Simo
AU  - Syrjala S
AD  - Department of Cardiothoracic Surgery, Helsinki University Hospital and University
      of Helsinki, Helsinki, Finland.
FAU - Aberg, Fredrik
AU  - Aberg F
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland.
FAU - Makisalo, Heikki
AU  - Makisalo H
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland.
FAU - Nordin, Arno
AU  - Nordin A
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland.
FAU - Lempinen, Marko
AU  - Lempinen M
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland.
FAU - Sallinen, Ville
AU  - Sallinen V
AD  - Department of Transplantation and Liver Surgery, Helsinki University Hospital and
      University of Helsinki, Helsinki, Finland ville.sallinen@helsinki.fi.
CN  - RIPTRANS Study Group collaborators
LA  - eng
SI  - ClinicalTrials.gov/NCT03855722
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Double-Blind Method
MH  - Humans
MH  - *Ischemic Preconditioning
MH  - Multicenter Studies as Topic
MH  - *Organ Transplantation
MH  - Randomized Controlled Trials as Topic
MH  - *Reperfusion Injury/prevention & control
MH  - Treatment Outcome
PMC - PMC7670950
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *cardiac surgery
OT  - *hepatology
OT  - *renal transplantation
OT  - *transplant medicine
OT  - *transplant surgery
COIS- Competing interests: None declared.
IR  - Backlund M
FIR - Backlund, Minna
IR  - Skrifvars M
FIR - Skrifvars, Markus
IR  - Luostarinen T
FIR - Luostarinen, Teemu
IR  - Reitala J
FIR - Reitala, Janne
IR  - Lang M
FIR - Lang, Maarit
IR  - Leppanen I
FIR - Leppanen, Ilona
IR  - Langsjo J
FIR - Langsjo, Jaakko
IR  - Gronlund J
FIR - Gronlund, Juha
IR  - Loisa P
FIR - Loisa, Pekka
IR  - Pulkkinen A
FIR - Pulkkinen, Anni
IR  - Jaschke B
FIR - Jaschke, Bjorn
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038340 [pii]
AID - 10.1136/bmjopen-2020-038340 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e038340. doi: 10.1136/bmjopen-2020-038340.


PMID- 33199418
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 16
TI  - Randomised controlled trial to assess the effectiveness of apnoeic oxygenation in
      adults using low-flow or high-flow nasal cannula with head side elevation versus 
      usual care to prevent desaturation during endotracheal intubation in the
      emergency department (ApOxED): study protocol.
PG  - e037964
LID - 10.1136/bmjopen-2020-037964 [doi]
AB  - INTRODUCTION: Apnoeic oxygenation is a process of delivering continuous oxygen
      through nasal cannula during direct laryngoscopy. The oxygen that is delivered
      through these nasal cannulas is either low flow or high flow. Although the
      effectiveness of apnoeic oxygenation has been shown through systematic reviews
      and randomised controlled trials, a comparison of high-flow versus low-flow
      oxygen delivery has not been tested through a superiority study design. In this
      study we propose to assess the effectiveness of giving low-flow oxygen with head 
      side elevation versus high-flow oxygen with head side elevation against the usual
      practice of care in which no oxygen is provided during direct laryngoscopy.
      METHODS AND ANALYSIS: This will be a three-arm study instituting a block
      randomisation technique with a sample size of 46 in each arm (see table 1). Due
      to the nature of the intervention, no blinding will be introduced. The primary
      outcomes will be lowest non-invasive oxygen saturation measurement during direct 
      laryngoscopy and during the 2 min after the placement of the tube and the first
      pass success rate. The intervention constitutes head side elevation up to 30
      degrees for improving glottis visualisation together with low-flow or high-flow
      oxygen delivery through nasal cannula to increase safe apnoea time for
      participants undergoing endotracheal intubation. Primary analysis will be
      intention to treat. ETHICS AND DISSEMINATION: The study is approved by the
      Ethical Review Committee of Aga Khan University Hospital (2019-0726-2463). The
      project is an institution University Research Committee grant recipient 192
      002ER-PK. The results of the study will be disseminated among participants,
      patient communities and healthcare professionals in the institution through
      seminars, presentations and emails. Further, the findings will be published in a 
      highly accessed peer-reviewed medical journal and will be presented at both
      national and international conferences. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT04242537).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Waheed, Shahan
AU  - Waheed S
AUID- ORCID: 0000-0002-0954-1642
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan
      docshahan83@hotmail.com.
FAU - Kapadia, Nazir Najeeb
AU  - Kapadia NN
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
FAU - Khan, Muhammad Faisal
AU  - Khan MF
AD  - Department of Anaesthesiology, Aga Khan University Hospital, Karachi, Pakistan.
FAU - Kerai, Salima Mansoor
AU  - Kerai SM
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
FAU - Raheem, Ahmed
AU  - Raheem A
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
FAU - Naeem, Rubaba
AU  - Naeem R
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
LA  - eng
SI  - ClinicalTrials.gov/NCT04242537
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201116
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Cannula
MH  - Emergency Service, Hospital
MH  - Humans
MH  - *Intubation, Intratracheal
MH  - Oxygen Inhalation Therapy
MH  - Randomized Controlled Trials as Topic
MH  - Respiration, Artificial
PMC - PMC7670939
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *adult intensive & critical care
OT  - *intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 06:12
PHST- 2020/11/17 06:12 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037964 [pii]
AID - 10.1136/bmjopen-2020-037964 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 16;10(11):e037964. doi: 10.1136/bmjopen-2020-037964.


PMID- 33198819
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20211204
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Nov 16
TI  - Differentiation of human induced pluripotent stem cells into erythroid cells.
PG  - 483
LID - 10.1186/s13287-020-01998-9 [doi]
AB  - During the last years, several strategies have been made to obtain mature
      erythrocytes or red blood cells (RBC) from the bone marrow or umbilical cord
      blood (UCB). However, UCB-derived hematopoietic stem cells (HSC) are a limited
      source and in vitro large-scale expansion of RBC from HSC remains problematic.
      One promising alternative can be human pluripotent stem cells (PSCs) that provide
      an unlimited source of cells. Human PSCs, including embryonic stem cells (ESCs)
      and induced pluripotent stem cells (iPSCs), are self-renewing progenitors that
      can be differentiated to lineages of ectoderm, mesoderm, and endoderm. Several
      previous studies have revealed that human ESCs can differentiate into functional 
      oxygen-carrying erythrocytes; however, the ex vivo expansion of human ESC-derived
      RBC is subjected to ethical concerns. Human iPSCs can be a suitable therapeutic
      choice for the in vitro/ex vivo manufacture of RBCs. Reprogramming of human
      somatic cells through the ectopic expression of the transcription factors (OCT4, 
      SOX2, KLF4, c-MYC, LIN28, and NANOG) has provided a new avenue for disease
      modeling and regenerative medicine. Various techniques have been developed to
      generate enucleated RBCs from human iPSCs. The in vitro production of human
      iPSC-derived RBCs can be an alternative treatment option for patients with blood 
      disorders. In this review, we focused on the generation of human iPSC-derived
      erythrocytes to present an overview of the current status and applications of
      this field.
FAU - Ebrahimi, Mohsen
AU  - Ebrahimi M
AD  - Neonatal and Children's Health Research Center, Golestan University of Medical
      Sciences, Gorgan, Iran.
FAU - Forouzesh, Mehdi
AU  - Forouzesh M
AD  - Legal Medicine Organization of Iran, Legal Medicine Research Center, Legal
      Medicine organization, Tehran, Iran.
FAU - Raoufi, Setareh
AU  - Raoufi S
AD  - Faculty of Medical Sciences and Technologies, Science and Research Branch,
      Islamic Azad University, Tehran, Iran.
FAU - Ramazii, Mohammad
AU  - Ramazii M
AD  - Kerman University of Medical Sciences, University of Kerman, Kerman, Iran.
FAU - Ghaedrahmati, Farhoodeh
AU  - Ghaedrahmati F
AD  - Department of Immunology, School of Medicine, Isfahan University of Medical
      Sciences, Isfahan, Iran.
FAU - Farzaneh, Maryam
AU  - Farzaneh M
AUID- ORCID: 0000-0001-6239-8745
AD  - Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences,
      Ahvaz, Iran. Maryamfarzaneh2013@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201116
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Cell Differentiation
MH  - Embryonic Stem Cells
MH  - Erythroid Cells
MH  - *Human Embryonic Stem Cells
MH  - Humans
MH  - *Induced Pluripotent Stem Cells
MH  - Kruppel-Like Factor 4
PMC - PMC7667818
OTO - NOTNLM
OT  - *Blood disorders
OT  - *Differentiation
OT  - *Erythrocytes
OT  - *Induced pluripotent stem cells
OT  - *Large-scale
OT  - *Reprogramming
EDAT- 2020/11/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/17 05:45
PHST- 2020/09/22 00:00 [received]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/11/17 05:45 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-01998-9 [doi]
AID - 10.1186/s13287-020-01998-9 [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Nov 16;11(1):483. doi: 10.1186/s13287-020-01998-9.


PMID- 33198714
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 16
TI  - Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable
      COPD.
PG  - 302
LID - 10.1186/s12890-020-01323-3 [doi]
AB  - BACKGROUND: The increasing trend of Chronic Obstructive Pulmonary Disease (COPD) 
      in becoming the third leading cause of deaths by 2020 is of great concern,
      globally as well as in India. Dysregulation of protease/anti-protease balance in 
      COPD has been reported to cause tissue destruction, inflammation and airway
      remodelling; which are peculiar characteristics of COPD. Therefore, it is
      imperative to explore various serum proteases involved in COPD pathogenesis, as
      candidate biomarkers. COPD and Asthma often have overlapping symptoms and
      therefore involvement of certain proteases in their pathogenesis would render
      accurate diagnosis of COPD to be difficult. METHODS: Serum samples from controls,
      COPD and Asthma patients were collected after requisite institutional ethics
      committee approvals. The preliminary analysis qualitatively and quantitatively
      analyzed various serum proteases by ELISA and mass spectrometry techniques. In
      order to identify a distinct biomarker of COPD, serum neutrophil elastase (NE)
      and matrix metalloprotease-2 (MMP-2) from COPD and Asthma patients were compared;
      as these proteases tend to have overlapping activities in both the diseases. A
      quantitative analysis of the reactive oxygen species (ROS) in the serum of
      controls and COPD patients was also performed. Statistical analysis for
      estimation of p-values was performed using unpaired t-test with 95% confidence
      interval. RESULTS: Amongst the significantly elevated proteases in COPD patients 
      vs the controls- neutrophil elastase (NE) [P < 0.0241], caspase-7 [P < 0.0001]
      and matrix metalloprotease-2 (MMP-2) [P < 0.0001] were observed, along with
      increased levels of reactive oxygen species (ROS) [P < 0.0001]. The serum
      dipeptidyl peptidase-IV (DPP-IV) [P < 0.0010) concentration was found to be
      decreased in COPD patients as compared to controls. Interestingly, a distinct
      elevation of MMP-2 was observed only in COPD patients, but not in Asthma, as
      compared to controls. Mass spectrometry analysis further identified significant
      alterations (fold-change) in various proteases (carboxy peptidase, MMP-2 and
      human leukocyte elastase), anti-proteases (Preg. zone protein, alpha-2
      macroglobulin, peptidase inhibitor) and signalling mediators (cytokine
      suppressor- SOCS-3). CONCLUSION: The preliminary study of various serum proteases
      in stable COPD patients distinctly identified elevated MMP-2 as a candidate
      biomarker for COPD, subject to its validation in large cohort studies.
FAU - Mahor, Durga
AU  - Mahor D
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, India.
FAU - Kumari, Vandana
AU  - Kumari V
AD  - ICMR-National Institute of Malaria Research, New Delhi, India.
FAU - Vashisht, Kapil
AU  - Vashisht K
AD  - ICMR-National Institute of Malaria Research, New Delhi, India.
FAU - Galgalekar, Ruma
AU  - Galgalekar R
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, India.
FAU - Samarth, Ravindra M
AU  - Samarth RM
AD  - Bhopal Memorial Hospital & Research Centre, Bhopal, India.
FAU - Mishra, Pradyumna K
AU  - Mishra PK
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, India.
FAU - Banerjee, Nalok
AU  - Banerjee N
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, India.
FAU - Dixit, Rajnikant
AU  - Dixit R
AD  - ICMR-National Institute of Malaria Research, New Delhi, India.
FAU - Saluja, Rohit
AU  - Saluja R
AD  - All India Institute of Medical Sciences, Bibinagar, Hyderabad, India.
AD  - All India Institute of Medical Sciences, Bhopal, India.
FAU - De, Sajal
AU  - De S
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, India.
FAU - Pandey, Kailash C
AU  - Pandey KC
AUID- ORCID: http://orcid.org/0000-0003-3936-4357
AD  - ICMR-National Institute for Research in Environmental Health, Bhopal, India.
      kailash.pandey@icmr.gov.in.
AD  - ICMR-National Institute of Malaria Research, New Delhi, India.
      kailash.pandey@icmr.gov.in.
LA  - eng
GR  - 65/2/KP/NIREH/2016-NCD-II/Indian Council of Medical Research
PT  - Journal Article
DEP - 20201116
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (Biomarkers)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 3.4.21.37 (ELANE protein, human)
RN  - EC 3.4.21.37 (Leukocyte Elastase)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
SB  - IM
MH  - Biomarkers/blood
MH  - Humans
MH  - India
MH  - Leukocyte Elastase/*blood
MH  - Matrix Metalloproteinase 2/*blood
MH  - Pulmonary Disease, Chronic Obstructive/*blood/pathology
MH  - Reactive Oxygen Species/*blood
MH  - Severity of Illness Index
PMC - PMC7670729
OTO - NOTNLM
OT  - Biomarker
OT  - COPD
OT  - Caspases
OT  - Cysteine proteases
OT  - Metallo proteases
OT  - Protease inhibitors
OT  - Serine proteases
EDAT- 2020/11/18 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/17 05:43
PHST- 2020/06/08 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/17 05:43 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1186/s12890-020-01323-3 [doi]
AID - 10.1186/s12890-020-01323-3 [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Nov 16;20(1):302. doi: 10.1186/s12890-020-01323-3.


PMID- 33198710
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 16
TI  - Crossed versus conventional pseudophakic monovision for high myopic eyes: a
      prospective, randomized pilot study.
PG  - 447
LID - 10.1186/s12886-020-01694-5 [doi]
AB  - BACKGROUND: Aiming at spectacle independence, conventional pseudophakic
      monovision has been widely used in myopia patients with bilateral monofocal
      intraocular lens implantation. However, the crossed monovision, which is to
      correct the dominant eye for near vision and the non-dominant eye for distant
      vision, has been mentioned preferable for high myopic cataract patients by some
      studies. We have conducted this study to compare clinical results to assess the
      feasibility of conventional and crossed monovision for high myopic pseudophakic
      patients by comparing patient satisfaction, visual function and spectacle
      independence. METHOD: Forty-sixth high myopia patients were divided into two
      groups: 22 in crossed monovision group with patients whose refraction targeted to
      - 2.00 diopters (D) in the dominant eye and - 0.50D in the non-dominant eye; 24
      in conventional monovision group with patients whose refraction targeted to -
      0.50D in the dominant eye and - 2.00D in the non-dominant eye. Binocular
      uncorrected distance visual acuity (BUDVA), binocular uncorrected near visual
      acuity (BUNVA), binocular corrected distant visual acuity (BCDVA), binocular
      corrected near visual acuity (BCNVA), contrast visual acuity and stereoacuity
      were examined at postoperative 2 weeks, 1 month and 3 months. Questionnaires were
      completed by patients 3 months after binocular surgery to evaluate patients'
      satisfaction and spectacle independence. RESULTS: The conventional monovision and
      the crossed monovision group showed no significant differences of mean BUDVA,
      BUNVA, BCDVA, BCNVA 2 weeks, 1 month or 3 months postoperatively (P > 0.05).
      There was no difference in the bilateral contrast sensitivity or stereoscopic
      function between the convention conventional and crossed monovision groups (P >
      0.05). Patient satisfaction with near and distant vision, as well as spectacle
      dependence did not differ significantly between the two groups (P > 0.05).
      CONCLUSION: Crossed pseudophakic monovision exhibited similar visual function
      when compared with conventional monovision technique, which indicates that it is 
      an effective option to improve the visual functionality and quality of life for
      high myopic patients who considering bilateral cataract surgery. TRIAL
      REGISTRATION: The Institutional Review Board and Ethics committee of the First
      Affiliated Hospital of Chongqing Medical University, Chongqing, China. The trial 
      registration was submitted in September 2018 and passed on March 18, 2020, and
      the registration number is: ChiCTR2000030935 .
FAU - Xun, Yan
AU  - Xun Y
AD  - Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical
      University, No.1 Youyi Road, Yuzhong District, Chongqing, 400000, P.R. China.
FAU - Wan, Wenjuan
AU  - Wan W
AD  - Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical
      University, No.1 Youyi Road, Yuzhong District, Chongqing, 400000, P.R. China.
FAU - Jiang, Lu
AU  - Jiang L
AD  - Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical
      University, No.1 Youyi Road, Yuzhong District, Chongqing, 400000, P.R. China.
FAU - Hu, Ke
AU  - Hu K
AUID- ORCID: http://orcid.org/0000-0002-8055-389X
AD  - Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical
      University, No.1 Youyi Road, Yuzhong District, Chongqing, 400000, P.R. China.
      42222@qq.com.
LA  - eng
GR  - 81100657/The National Natural Science Foundation of China
GR  - 81570832/Major Research Plan
GR  - 81870650/Major Research Plan
GR  - cstc2018jcyjA0429/Chongqing Science and Technology Development Foundation
GR  - CQGJ17062B/Chongqing Education Commission Project Fund of China
GR  - 2018GDRC008/Project of Chongqing Health Commission combined with Science and
      Technology Commission of China
GR  - 2018MSXM003/the Project of Chongqing Health Commission combined with Science and 
      Technology Commission of China
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201116
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
SB  - IM
MH  - China
MH  - Humans
MH  - Lens Implantation, Intraocular
MH  - *Lenses, Intraocular
MH  - *Myopia
MH  - Patient Satisfaction
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Pseudophakia
MH  - Quality of Life
MH  - Vision, Monocular
PMC - PMC7667742
OTO - NOTNLM
OT  - Cataract
OT  - High myopia
OT  - Monovision
OT  - Spectacle independence
OT  - Vision quality
EDAT- 2020/11/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/17 05:43
PHST- 2020/03/05 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/17 05:43 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12886-020-01694-5 [doi]
AID - 10.1186/s12886-020-01694-5 [pii]
PST - epublish
SO  - BMC Ophthalmol. 2020 Nov 16;20(1):447. doi: 10.1186/s12886-020-01694-5.


PMID- 33198286
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 22
DP  - 2020 Nov 12
TI  - The Paradox of Group Citizenship and Constructive Deviance: A Resolution of
      Environmental Dynamism and Moral Justification.
LID - E8371 [pii]
LID - 10.3390/ijerph17228371 [doi]
AB  - Previous research on antecedents to constructive deviance remains scattered and
      inclusive. Our study conceptualizes constructive deviance from the perspective of
      ethical decision making and explores its antecedents, mechanism, and conditions. 
      Drawing on moral licensing theory and social information processing theory, we
      propose that group citizenship behavior facilitates moral justification and
      constructive deviance when environmental dynamism is high and inhibits them when 
      it is low; and moral justification fully mediates the relationship between the
      interaction of group citizenship behavior and environmental dynamism and
      constructive deviance. With two-wave panel data collected from 339 employees in
      54 groups of five service companies in retailing, finance, and tourism randomly
      selected from three provinces in southern China, these hypotheses are all
      supported empirically. Our findings broaden the antecedents and occurrence
      mechanism of constructive deviance through an ethical decision-making lens. Our
      study contributes to the moral licensing literature by enriching the sources of
      moral licensing in the workplace and empirically demonstrating that moral
      justification may function as an underlying mechanism of moral licensing.
FAU - Liu, Tingting
AU  - Liu T
AD  - College of Business Administration, Hunan University of Technology and Business, 
      Changsha 410205, China.
FAU - Chen, Yahui
AU  - Chen Y
AD  - School of Business and Tourism Management, Yunnan University, Kunming 650106,
      China.
FAU - Hu, Chenhong
AU  - Hu C
AD  - College of Business Administration, Hunan University of Technology and Business, 
      Changsha 410205, China.
FAU - Yuan, Xiao
AU  - Yuan X
AD  - College of Business Administration, Hunan University of Technology and Business, 
      Changsha 410205, China.
FAU - Liu, Chang-E
AU  - Liu CE
AD  - Mobile E-Business Collaborative Innovation Center of Hunan Province, Key
      Laboratory of Hunan Province for Mobile Business Intelligence, College of
      Business Administration, Hunan University of Technology and Business, Changsha
      410205, China.
FAU - He, Wei
AU  - He W
AD  - Scott College of Business, Indiana State University, Terre Haute, IN 47802, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - China
MH  - *Decision Making/ethics
MH  - Female
MH  - Group Processes
MH  - Humans
MH  - Male
MH  - *Morals
MH  - *Workplace/psychology/statistics & numerical data
PMC - PMC7698231
OTO - NOTNLM
OT  - *constructive deviance
OT  - *environmental dynamism
OT  - *group citizenship behavior
OT  - *moral justification
OT  - *moral licensing theory
EDAT- 2020/11/18 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/11/17 01:05
PHST- 2020/08/24 00:00 [received]
PHST- 2020/10/28 00:00 [revised]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/11/17 01:05 [entrez]
PHST- 2020/11/18 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
AID - ijerph17228371 [pii]
AID - 10.3390/ijerph17228371 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 12;17(22). pii: ijerph17228371. doi:
      10.3390/ijerph17228371.


PMID- 35047694
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 2398-8703 (Electronic)
IS  - 2398-8703 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Effects of dietary fat manipulation on cognition in mice and rats: protocol for a
      systematic review and meta-analysis.
PG  - e100108
LID - 10.1136/bmjos-2020-100108 [doi]
AB  - INTRODUCTION AND OBJECTIVE: The Western diet that comprises high levels of
      long-chain saturated fats and sugar is associated not only with metabolic
      disorders such as obesity and type 2 diabetes but also has been recently linked
      to brain changes and cognitive dysfunction. However, in animal studies, reported 
      effects are variable, and the mechanisms underlying these effects are unclear. In
      the proposed review, we aim to summarise the diverse evidence of the effects of
      so-called 'high-fat' and ketogenic diets on behavioural measures of cognition in 
      postweaning mice and rats, relative to animals on standard diets and to determine
      potential underlying mechanisms of high-fat diet-induced effects. SEARCH
      STRATEGY: A comprehensive search strategy was designed to retrieve studies
      reporting use of a high-fat or ketogenic diet in postweaning mice and rats that
      included cognitive assessments. Three databases (Medline, SCOPUS and Web of
      Science) were searched and 4487 unique references were retrieved. SCREENING AND
      ANNOTATION: Studies were screened for inclusion by two independent reviewers,
      with 330 studies retained for analysis. Characteristics of disease model choice, 
      experimental design, intervention use and outcome assessment are to be extracted 
      using the Systematic Review Facility (http://syrf.org.uk/) tool. Studies will be 
      assessed for study quality and risk of bias and confidence of mechanistic
      involvement. DATA MANAGEMENT AND REPORTING: For cognitive outcomes, effect sizes 
      will be calculated using normalised mean difference and summarised using a random
      effects model. The contribution of potential sources of heterogeneity to the
      observed effects of diet on cognition will be assessed using multivariable
      meta-regression, with partitioning of heterogeneity as a sensitivity analysis. A 
      preliminary version of this protocol was published on 9 April 2019 on the
      Collaborative Approach to Meta-Analysis and Review of Animal Data from
      Experimental Studies website
      (http://www.dcn.ed.ac.uk/camarades/research.html%23protocols). ETHICS AND
      DISSEMINATION: No ethical approval is required as there are no subjects in the
      proposed study.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ramage, Fiona J
AU  - Ramage FJ
AUID- ORCID: 0000-0002-4855-7911
AD  - Department of Systems Medicine, University of Dundee, School of Medicine, Dundee,
      UK.
FAU - Clewlow, Alexander S
AU  - Clewlow AS
AUID- ORCID: 0000-0002-5841-2476
AD  - Department of Systems Medicine, University of Dundee, School of Medicine, Dundee,
      UK.
AD  - GKT School of Medical Education, King's College London, Faculty of Life Sciences 
      and Medicine, London, UK.
FAU - Williams, Lynda M
AU  - Williams LM
AUID- ORCID: 0000-0002-8921-4173
AD  - The Rowett Institute, University of Aberdeen Rowett Institute of Nutrition and
      Health, Aberdeen, UK.
FAU - Macleod, Malcolm R
AU  - Macleod MR
AUID- ORCID: 0000-0001-9187-9839
AD  - Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh
      Medical School, Edinburgh, Scotland, UK.
FAU - Langston, Rosamund F
AU  - Langston RF
AUID- ORCID: 0000-0002-4668-3105
AD  - Department of Systems Medicine, University of Dundee, School of Medicine, Dundee,
      UK.
LA  - eng
PT  - Systematic Review
DEP - 20201118
PL  - England
TA  - BMJ Open Sci
JT  - BMJ open science
JID - 101778290
PMC - PMC8647606
COIS- Competing interests: The authors do not declare any conflicts of interest.
EDAT- 2020/11/18 00:00
MHDA- 2020/11/18 00:01
CRDT- 2022/01/20 06:08
PHST- 2020/06/18 00:00 [received]
PHST- 2020/09/25 00:00 [revised]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2022/01/20 06:08 [entrez]
PHST- 2020/11/18 00:00 [pubmed]
PHST- 2020/11/18 00:01 [medline]
AID - 10.1136/bmjos-2020-100108 [doi]
AID - bmjos-2020-100108 [pii]
PST - epublish
SO  - BMJ Open Sci. 2020 Nov 18;4(1):e100108. doi: 10.1136/bmjos-2020-100108.
      eCollection 2020.


PMID- 33197991
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1975-5937 (Electronic)
IS  - 1975-5937 (Linking)
VI  - 17
DP  - 2020
TI  - Level of professional ethics awareness and medical ethics competency of dental
      hygienists and dental hygiene students: the need to add ethics items to the
      Korean Dental Hygienist Licensing Examination
PG  - 34
LID - 10.3352/jeehp.2020.17.34 [doi]
AB  - PURPOSE: This study aimed to evaluate the level of professional ethics awareness 
      and medical ethics competency in order to assess the potential need for ethics
      items to be included on the Korean Dental Hygienist Licensing Examination.
      METHODS: In total, 358 clinical dental hygienists and dental hygiene students
      completed a structured questionnaire to evaluate their level of ethical awareness
      and medical ethics competency. The sub-factors of medical ethics were classified 
      into relationships with patients, medical and social relations, and individual
      specialized fields. RESULTS: Only 32.1% of participants indicated that they had
      taken a course on professional ethics in the university curriculum, but 95.2% of 
      respondents considered professional ethics to be important. The overall score for
      medical ethics competency was average (3.37 out of 5). The score for
      relationships with patients was 3.75 points, followed by medical and social
      relations (3.19 points) and individual specialized fields (3.16 points). The
      level of professional ethics awareness was higher among participants who had
      taken a course on professional ethics than among those who had not done so or who
      did not remember whether they had done so. CONCLUSION: Dental hygienists were
      aware of the importance of professional ethics, but their medical ethics
      competency was moderate. Therefore, medical ethics should be treated as a
      required subject in the university curriculum, and medical ethics competency
      evaluations should be strengthened by adding ethics items to the Korean Dental
      Hygienist Licensing Examination.
FAU - Hwang, Yoon-Sook
AU  - Hwang YS
AD  - Department of Dental Hygiene, Hanyang Women's University, Seoul, Korea.
FAU - Jang, Jong-Hwa
AU  - Jang JH
AD  - Department of Dental Hygiene, College of Health Science, Dankook University,
      Cheonan, Korea.
FAU - Kang, Kyung-Hee
AU  - Kang KH
AD  - Department of Dental Hygiene, Konyang University, Daejeon, Korea.
FAU - Kim, Minji
AU  - Kim M
AD  - Dongjak-gu Community Health Center, Seoul, Korea.
FAU - Park, Jeong-Ran
AU  - Park JR
AD  - Department of Dental Hygiene, Baekseok University, Cheonan, Korea.
FAU - Son, Sohyun
AU  - Son S
AD  - Department of Dental Hygiene, Hanyang Women's University, Seoul, Korea.
FAU - Lee, Sun-Mi
AU  - Lee SM
AD  - Department of Dental Hygiene, Dongnam Health University, Suwon, Korea.
FAU - Jeung, Da-Yee
AU  - Jeung DY
AD  - Department of Dental Hygiene, Hanyang Women's University, Seoul, Korea.
FAU - Ha, Jung-Eun
AU  - Ha JE
AD  - Department of Dental Hygiene, Baekseok University, Cheonan, Korea.
FAU - Hong, Su-Min
AU  - Hong SM
AD  - Department of Dental Hygiene, Baekseok University, Cheonan, Korea.
FAU - Jang, Young-Eun
AU  - Jang YE
AD  - Department of Dental Hygiene, Baekseok University, Cheonan, Korea.
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - Korea (South)
TA  - J Educ Eval Health Prof
JT  - Journal of educational evaluation for health professions
JID - 101490061
SB  - IM
MH  - *Dental Hygienists
MH  - Ethics, Medical
MH  - Ethics, Professional
MH  - Humans
MH  - *Oral Hygiene
MH  - Republic of Korea
MH  - Students
PMC - PMC7758182
OTO - NOTNLM
OT  - *Dental hygienists
OT  - *Licensure
OT  - *Professional ethics
OT  - *Republic of Korea
OT  - *Medical ethics
EDAT- 2020/11/17 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/11/16 23:38
PHST- 2020/10/05 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/11/16 23:38 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - jeehp.2020.17.34 [pii]
AID - 10.3352/jeehp.2020.17.34 [doi]
PST - ppublish
SO  - J Educ Eval Health Prof. 2020;17:34. doi: 10.3352/jeehp.2020.17.34. Epub 2020 Nov
      17.


PMID- 33197958
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 11
DP  - 2020 Dec
TI  - Meningitis and the military: the remarkable story of the first use of penicillin 
      in Australia (1943).
PG  - 508-510.e1
LID - 10.5694/mja2.50846 [doi]
FAU - Khatami, Ameneh
AU  - Khatami A
AUID- ORCID: 0000-0001-9114-6694
AD  - The University of Sydney, Sydney, NSW.
AD  - Sydney Children's Hospital Network, Sydney, NSW.
FAU - Britton, Philip N
AU  - Britton PN
AD  - The University of Sydney, Sydney, NSW.
AD  - Sydney Children's Hospital Network, Sydney, NSW.
FAU - Farrow, Glendon
AU  - Farrow G
AD  - Sydney Children's Hospital Network, Sydney, NSW.
FAU - Phelps, Megan
AU  - Phelps M
AD  - The University of Sydney, Sydney, NSW.
FAU - Kakakios, Alyson
AU  - Kakakios A
AD  - The University of Sydney, Sydney, NSW.
AD  - Sydney Children's Hospital Network, Sydney, NSW.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20201116
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Penicillins)
SB  - IM
MH  - Australia
MH  - Child
MH  - History, 20th Century
MH  - Humans
MH  - Male
MH  - Meningitis, Pneumococcal/drug therapy/*history
MH  - Military Medicine/*history
MH  - Penicillins/*history
OTO - NOTNLM
OT  - *Anti-infective agents
OT  - *Ethics, research
OT  - *Meningitis
EDAT- 2020/11/17 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/11/16 20:17
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/11/16 20:17 [entrez]
AID - 10.5694/mja2.50846 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Dec;213(11):508-510.e1. doi: 10.5694/mja2.50846. Epub 2020 Nov
      16.


PMID- 33196975
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Towards Transparency by Design for Artificial Intelligence.
PG  - 3333-3361
LID - 10.1007/s11948-020-00276-4 [doi]
AB  - In this article, we develop the concept of Transparency by Design that serves as 
      practical guidance in helping promote the beneficial functions of transparency
      while mitigating its challenges in automated-decision making (ADM) environments. 
      With the rise of artificial intelligence (AI) and the ability of AI systems to
      make automated and self-learned decisions, a call for transparency of how such
      systems reach decisions has echoed within academic and policy circles. The term
      transparency, however, relates to multiple concepts, fulfills many functions, and
      holds different promises that struggle to be realized in concrete applications.
      Indeed, the complexity of transparency for ADM shows tension between transparency
      as a normative ideal and its translation to practical application. To address
      this tension, we first conduct a review of transparency, analyzing its challenges
      and limitations concerning automated decision-making practices. We then look at
      the lessons learned from the development of Privacy by Design, as a basis for
      developing the Transparency by Design principles. Finally, we propose a set of
      nine principles to cover relevant contextual, technical, informational, and
      stakeholder-sensitive considerations. Transparency by Design is a model that
      helps organizations design transparent AI systems, by integrating these
      principles in a step-by-step manner and as an ex-ante value, not as an
      afterthought.
FAU - Felzmann, Heike
AU  - Felzmann H
AD  - Centre of Bioethical Research and Analysis (COBRA), NUI Galway, Galway, Ireland.
FAU - Fosch-Villaronga, Eduard
AU  - Fosch-Villaronga E
AUID- ORCID: 0000-0002-8325-5871
AD  - eLaw Center for Law and Digital Technologies, Leiden University, Leiden, The
      Netherlands. e.fosch.villaronga@law.leidenuniv.nl.
FAU - Lutz, Christoph
AU  - Lutz C
AUID- ORCID: 0000-0003-4389-6006
AD  - Nordic Centre for Internet and Society (NCIS), BI Norwegian Business School,
      Oslo, Norway.
FAU - Tamo-Larrieux, Aurelia
AU  - Tamo-Larrieux A
AUID- ORCID: 0000-0003-3404-7643
AD  - Forschungsinstitut fur Arbeit und Arbeitswelten (FAA-HSG), University of St.
      Gallen, St. Gallen, Switzerland.
LA  - eng
GR  - 707404/H2020 Marie Sklodowska-Curie Actions ()/International
GR  - 275347/Research Council of Norway/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201116
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
PMC - PMC7755865
OTO - NOTNLM
OT  - *Accountability
OT  - *Artificial intelligence
OT  - *Automated decision-making
OT  - *Design
OT  - *Ethics
OT  - *Framework
OT  - *Interdisciplinary
OT  - *Transparency
EDAT- 2020/11/17 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/16 14:50
PHST- 2020/01/11 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/11/16 14:50 [entrez]
AID - 10.1007/s11948-020-00276-4 [doi]
AID - 10.1007/s11948-020-00276-4 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3333-3361. doi: 10.1007/s11948-020-00276-4. Epub
      2020 Nov 16.


PMID- 33196449
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 16
TI  - A Self-Administered Multicomponent Web-Based Mental Health Intervention for the
      Mexican Population During the COVID-19 Pandemic: Protocol for a Randomized
      Controlled Trial.
PG  - e23117
LID - 10.2196/23117 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has become a public health emergency of
      international concern; it has not only threatened people's physical health but
      has also affected their mental health and psychological well-being. It is
      necessary to develop and offer strategies to reduce the psychological impact of
      the outbreak and promote adaptive coping. OBJECTIVE: This study protocol aims to 
      describe a self-administered web-based intervention (Mental Health COVID-19)
      based on the principles of positive psychology supported by elements of cognitive
      behavioral therapy and behavioral activation therapy to reduce the symptoms of
      anxiety and depression and increase positive emotions and sleep quality during
      and after the COVID-19 outbreak through a telepsychology system. METHODS: A
      randomized controlled clinical superiority trial with two independent groups will
      be performed, with intrasubject measures at four evaluation periods: pretest,
      posttest, 3-month follow-up, and 6-month follow-up. Participants will be randomly
      assigned to one of two groups: self-administered intervention with assistance via
      chat or self-administered intervention without assistance via chat. The total
      required sample size will be 166 participants (83 per group). RESULTS: The
      clinical trial is ongoing. This protocol was approved by the Research Ethics
      Board of the Free School of Psychology-University of Behavioral Sciences (Escuela
      libre de Psicologia-Universidad de Ciencias del Comportamiento). The aim is to
      publish the preliminary results in December 2020. A conservative approach will be
      adopted, and the size effect will be estimated using the Cohen d index with a
      significance level (alpha) of .05 (95% reliability) and a conventional 80% power 
      statistic. CONCLUSIONS: The central mechanism of action will be to investigate
      the effectiveness of an intervention based on positive psychology through a web
      platform that can be delivered through computers and tablets, with content that
      has been rigorously contextualized to the Mexican culture to provide functional
      strategies to help the target users cope with the COVID-19 pandemic. TRIAL
      REGISTRATION: ClinicalTrials.gov NCT04468893;
      https://clinicaltrials.gov/ct2/show/NCT04468893. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/23117.
CI  - (c)Alejandro Dominguez-Rodriguez, Anabel De La Rosa-Gomez, M Jesus Hernandez
      Jimenez, Paulina Arenas-Landgrave, Sofia Cristina Martinez-Luna, Joabian Alvarez 
      Silva, Jose Ernesto Garcia Hernandez, Carlos Arzola-Sanchez, Victoria Acosta
      Guzman. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 16.11.2020.
FAU - Dominguez-Rodriguez, Alejandro
AU  - Dominguez-Rodriguez A
AUID- ORCID: https://orcid.org/0000-0003-3547-8824
AD  - Valencian International University, Valencia, Spain.
FAU - De La Rosa-Gomez, Anabel
AU  - De La Rosa-Gomez A
AUID- ORCID: https://orcid.org/0000-0002-3527-1500
AD  - Coordinacion de Educacion a Distancia, Facultad de Estudios Superiores Iztacala, 
      Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Hernandez Jimenez, M Jesus
AU  - Hernandez Jimenez MJ
AUID- ORCID: https://orcid.org/0000-0001-7933-8968
AD  - Valencian International University, Valencia, Spain.
FAU - Arenas-Landgrave, Paulina
AU  - Arenas-Landgrave P
AUID- ORCID: https://orcid.org/0000-0002-0578-5367
AD  - Facultad de Psicologia, Universidad Nacional Autonoma de Mexico, Mexico City,
      Mexico.
FAU - Martinez-Luna, Sofia Cristina
AU  - Martinez-Luna SC
AUID- ORCID: https://orcid.org/0000-0002-4782-9065
AD  - Facultad de Psicologia, Universidad Nacional Autonoma de Mexico, Mexico City,
      Mexico.
FAU - Alvarez Silva, Joabian
AU  - Alvarez Silva J
AUID- ORCID: https://orcid.org/0000-0003-2737-4574
AD  - ITLAB Mexico, Juarez, Mexico.
FAU - Garcia Hernandez, Jose Ernesto
AU  - Garcia Hernandez JE
AUID- ORCID: https://orcid.org/0000-0003-1765-8776
AD  - Plan Estrategico de Juarez A C, Juarez, Mexico.
FAU - Arzola-Sanchez, Carlos
AU  - Arzola-Sanchez C
AUID- ORCID: https://orcid.org/0000-0002-6774-2813
AD  - Institute of Social Sciences, Autonomous University of Ciudad Juarez, Juarez,
      Mexico.
FAU - Acosta Guzman, Victoria
AU  - Acosta Guzman V
AUID- ORCID: https://orcid.org/0000-0002-5545-4902
AD  - Institute of Social Sciences, Autonomous University of Ciudad Juarez, Juarez,
      Mexico.
LA  - eng
SI  - ClinicalTrials.gov/NCT04468893
PT  - Journal Article
DEP - 20201116
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7704282
OTO - NOTNLM
OT  - cognitive behavioral therapy, behavioral activation therapy, COVID-19
OT  - e-health
OT  - internet
OT  - intervention
OT  - positive psychology
OT  - telepsychology, Mexican sample
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 14:48
PHST- 2020/08/01 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/10/24 00:00 [revised]
PHST- 2020/11/16 14:48 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - v9i11e23117 [pii]
AID - 10.2196/23117 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 16;9(11):e23117. doi: 10.2196/23117.


PMID- 33196403
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20201218
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Dec
TI  - New York State Creates New Governance of Commercial Gestational Surrogacy.
PG  - 328-350
LID - 10.1080/20502877.2020.1835204 [doi]
AB  - United States law recognizes adult reproductive liberty and many states view
      surrogacy services through that lens. During the COVID-19 pandemic in March,
      2020, New York State enacted the Child-Parent Surrogacy Act (CPSA) into law,
      after feminists and their allies had caused its defeat in 2019. Just before
      approval of the CPSA, a group of legislators introduced the Alternative Surrogacy
      Bill (ASB). This article is a case study that examines how the CPSA and not the
      ASB became law, examining surrogate rights, the best interests of the child, and 
      the ethical issues related to adult donor-conceived and surrogacy born children's
      rights to information about their ancestry.
FAU - Darling, Marsha J Tyson
AU  - Darling MJT
AD  - History and Interdisciplinary Studies, Adelphi University, Garden City, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - Access to Information
MH  - Adult
MH  - COVID-19
MH  - Child
MH  - Child Welfare
MH  - Commerce/ethics/*legislation & jurisprudence
MH  - Coronavirus Infections/epidemiology
MH  - Dissent and Disputes
MH  - Family
MH  - Female
MH  - *Human Rights
MH  - Humans
MH  - Industry/ethics/legislation & jurisprudence
MH  - Legislation, Medical/*ethics
MH  - Mothers
MH  - New York/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology
MH  - Pregnancy
MH  - Reproductive Techniques/economics/ethics/*legislation & jurisprudence
MH  - *Social Control, Formal
MH  - Surrogate Mothers/*legislation & jurisprudence
MH  - Women's Rights
OTO - NOTNLM
OT  - New York state gestational surrogacy legislation
OT  - adult donor-conceived and surrogacy-born children
OT  - gestational surrogacy
OT  - the best interests of the child
EDAT- 2020/11/17 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/11/16 14:47 [entrez]
AID - 10.1080/20502877.2020.1835204 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Dec;26(4):328-350. doi: 10.1080/20502877.2020.1835204. Epub 2020
      Nov 16.


PMID- 33196397
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20201118
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - Ethical Analysis and Beyond! How Christian Anthropology and the Concept of
      Dignity Can Also Address Moral Distress in End-of-Life Care.
PG  - 23-25
LID - 10.1080/15265161.2020.1832616 [doi]
FAU - Horner, Claire
AU  - Horner C
AUID- ORCID: 0000-0002-8351-2380
AD  - Baylor College of Medicine, Center for Medical Ethics & Health Policy.
FAU - Garvis, David
AU  - Garvis D
AD  - Baylor St. Luke's Medical Center.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Dec;20(12):5-13. PMID: 33196380
MH  - Anthropology
MH  - Christianity
MH  - Ethical Analysis
MH  - Humans
MH  - *Respect
MH  - *Terminal Care
EDAT- 2020/11/17 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1080/15265161.2020.1832616 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Dec;20(12):23-25. doi: 10.1080/15265161.2020.1832616.


PMID- 33196396
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20201229
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - Vulnerable Life: Reflections on the Relationship Between Theological and
      Philosophical Ethics.
PG  - 21-23
LID - 10.1080/15265161.2020.1832615 [doi]
FAU - Braun, Matthias
AU  - Braun M
AUID- ORCID: 0000-0002-6687-6027
AD  - Friedrich-Alexander-Universitat Erlangen-Nurnberg.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Dec;20(12):5-13. PMID: 33196380
CIN - Am J Bioeth. 2021 Jan;21(1):W1-W3. PMID: 33373579
MH  - *Bioethics
MH  - Humans
MH  - *Theology
EDAT- 2020/11/17 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1080/15265161.2020.1832615 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Dec;20(12):21-23. doi: 10.1080/15265161.2020.1832615.


PMID- 33196388
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20201229
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - Pluralism in the Jewish Ethical Tradition.
PG  - 16-18
LID - 10.1080/15265161.2020.1832613 [doi]
FAU - Davis, Keenan
AU  - Davis K
AUID- ORCID: 0000-0002-3311-1503
AD  - Emory University.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Dec;20(12):5-13. PMID: 33196380
CIN - Am J Bioeth. 2020 Dec;20(12):1-4. PMID: 33215978
CIN - Am J Bioeth. 2021 Jan;21(1):W1-W3. PMID: 33373579
MH  - *Cultural Diversity
MH  - Humans
MH  - *Jews
MH  - Judaism
MH  - Morals
EDAT- 2020/11/17 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1080/15265161.2020.1832613 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Dec;20(12):16-18. doi: 10.1080/15265161.2020.1832613.


PMID- 33196380
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - There's No Harm in Talking: Re-Establishing the Relationship Between Theological 
      and Secular Bioethics.
PG  - 5-13
LID - 10.1080/15265161.2020.1832611 [doi]
AB  - Theological and secular voices in bioethics have drifted into separate silos.
      Such a separation results in part from (1) theologians focusing less on conveying
      ideas in ways that contribute to a pluralistic and public bioethical discourse
      and (2) the dwindling receptivity of religious arguments within secular
      bioethics. This essay works against these drifts by putting forward an argument
      that does not bounce around a religious echo-chamber, but instead demonstrates
      how insights of Christian anthropology can be meaningfully responsive to secular 
      bioethics' rightful concerns with inequality and injustice. We offer core
      concepts from Christian bioethics that encourage dialogue with secular and
      theological bioethicists. The theologically-grounded concepts, human dignity,
      sin, and the common good, provide intellectual resources to address major areas
      of bioethical concern that remain unresolved.
FAU - McCarthy, Michael
AU  - McCarthy M
AUID- ORCID: 0000-0003-3484-8360
AD  - Loyola University Chicago Stritch School of Medicine.
FAU - Homan, Mary
AU  - Homan M
AUID- ORCID: 0000-0002-8582-8792
AD  - Medical College of Wisconsin.
FAU - Rozier, Michael
AU  - Rozier M
AUID- ORCID: 0000-0002-1477-0570
AD  - Saint Louis University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Dec;20(12):42-44. PMID: 33196383
CIN - Am J Bioeth. 2020 Dec;20(12):45-47. PMID: 33196384
CIN - Am J Bioeth. 2020 Dec;20(12):40-42. PMID: 33196385
CIN - Am J Bioeth. 2020 Dec;20(12):34-37. PMID: 33196386
CIN - Am J Bioeth. 2020 Dec;20(12):37-39. PMID: 33196387
CIN - Am J Bioeth. 2020 Dec;20(12):16-18. PMID: 33196388
CIN - Am J Bioeth. 2020 Dec;20(12):18-20. PMID: 33196389
CIN - Am J Bioeth. 2020 Dec;20(12):14-16. PMID: 33196390
CIN - Am J Bioeth. 2020 Dec;20(12):49-51. PMID: 33196392
CIN - Am J Bioeth. 2020 Dec;20(12):32-34. PMID: 33196393
CIN - Am J Bioeth. 2020 Dec;20(12):25-28. PMID: 33196394
CIN - Am J Bioeth. 2020 Dec;20(12):29-31. PMID: 33196395
CIN - Am J Bioeth. 2020 Dec;20(12):21-23. PMID: 33196396
CIN - Am J Bioeth. 2020 Dec;20(12):23-25. PMID: 33196397
CIN - Am J Bioeth. 2020 Dec;20(12):1-4. PMID: 33215978
CIN - Am J Bioeth. 2021 Jan;21(1):W1-W3. PMID: 33373579
MH  - *Bioethics
MH  - Christianity
MH  - Cultural Diversity
MH  - Ethicists
MH  - Humans
MH  - *Religion
MH  - Theology
OTO - NOTNLM
OT  - *Anthropology
OT  - *clinical ethics
OT  - *public health
OT  - *religion
OT  - *research ethics
OT  - *theological bioethics
EDAT- 2020/11/17 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1832611 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Dec;20(12):5-13. doi: 10.1080/15265161.2020.1832611.


PMID- 33196359
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Service and Status Competition May Help Explain Perceived Ethical Acceptability.
PG  - 258-260
LID - 10.1080/21507740.2020.1830874 [doi]
FAU - Desmond, Hugh
AU  - Desmond H
AUID- ORCID: 0000-0002-4822-923X
AD  - KU Leuven.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CON - AJOB Neurosci. 2020 Oct-Dec;11(4):224-237. PMID: 33196348
MH  - Cognition
MH  - *Morals
MH  - *Public Opinion
EDAT- 2020/11/17 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1080/21507740.2020.1830874 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Oct-Dec;11(4):258-260. doi: 10.1080/21507740.2020.1830874.


PMID- 33196357
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20211201
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - The Ethics of Getting Ahead When All Heads Are Enhanced.
PG  - 256-258
LID - 10.1080/21507740.2020.1830875 [doi]
FAU - Kostick, Kristin Marie
AU  - Kostick KM
AUID- ORCID: 0000-0003-2510-0174
AD  - Baylor College of Medicine.
FAU - Blumenthal-Barby, J S
AU  - Blumenthal-Barby JS
AD  - Baylor College of Medicine.
FAU - Storch, Eric A
AU  - Storch EA
AUID- ORCID: 0000-0002-7631-3703
AD  - Baylor College of Medicine.
FAU - Lazaro-Munoz, Gabriel
AU  - Lazaro-Munoz G
AUID- ORCID: 0000-0003-1933-9453
AD  - Baylor College of Medicine.
LA  - eng
GR  - R01 MH114854/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CON - AJOB Neurosci. 2020 Oct-Dec;11(4):224-237. PMID: 33196348
MH  - Cognition
MH  - *Ethics, Medical
MH  - *Public Opinion
EDAT- 2020/11/17 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1080/21507740.2020.1830875 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Oct-Dec;11(4):256-258. doi: 10.1080/21507740.2020.1830875.


PMID- 33196351
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Empirical Data Is Failing to Break the Ethics Stalemate in the Cognitive
      Enhancement Debate.
PG  - 240-242
LID - 10.1080/21507740.2020.1830883 [doi]
FAU - Forlini, Cynthia
AU  - Forlini C
AUID- ORCID: 0000-0003-3809-8229
AD  - Deakin University.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CON - AJOB Neurosci. 2020 Oct-Dec;11(4):224-237. PMID: 33196348
MH  - Cognition
MH  - Empirical Research
MH  - *Ethics, Medical
MH  - *Public Opinion
EDAT- 2020/11/17 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1080/21507740.2020.1830883 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Oct-Dec;11(4):240-242. doi: 10.1080/21507740.2020.1830883.


PMID- 33196330
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201218
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Linking)
VI  - 29
IP  - 11
DP  - 2020 Nov
TI  - Application of the Principles of Biomedical Ethics to the Labor and Delivery Unit
      During the COVID-19 Pandemic.
PG  - 1361-1371
LID - 10.1089/jwh.2020.8812 [doi]
AB  - After its identification as a human pathogen in 2019, the novel coronavirus,
      SARS-CoV-2, has spread rapidly around the world. Health care workers worldwide
      have had the task of preparing and responding to the pandemic with little
      evolving data or guidelines. Regarding the protocols for our labor and delivery
      unit, we focused on applying the four pillars of biomedical ethics-beneficence,
      nonmaleficence, autonomy, and justice-while considering the women, their fetuses,
      their significant others and support persons, health care professionals and
      auxiliary staff, and society as a whole. We also considered the downstream effect
      of our decisions in labor and delivery on other disciplines of medicine,
      including pediatrics, anesthesiology, and critical care. This article focuses on 
      how these prima facie principles helped guide our recommendations in this
      unprecedented time.
FAU - Boyle, Annelee
AU  - Boyle A
AD  - Department of Obstetrics and Gynecology, West Virginia University School of
      Medicine, Morgantown, West Virginia, USA.
FAU - Dotson, Sarah
AU  - Dotson S
AD  - Department of Obstetrics and Gynecology, West Virginia University School of
      Medicine, Morgantown, West Virginia, USA.
FAU - Ellison, Pavithra
AU  - Ellison P
AD  - Department of Anesthesiology, West Virginia University School of Medicine,
      Morgantown, West Virginia, USA.
FAU - Hayanga, Heather
AU  - Hayanga H
AD  - Department of Anesthesiology, West Virginia University School of Medicine,
      Morgantown, West Virginia, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - Coronavirus
MH  - Coronavirus Infections/epidemiology/*prevention & control/transmission
MH  - Female
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Labor, Obstetric
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*prevention & control/transmission
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*prevention & control/*virology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *labor and delivery
EDAT- 2020/11/17 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/16 14:47
PHST- 2020/11/16 14:47 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1089/jwh.2020.8812 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2020 Nov;29(11):1361-1371. doi: 10.1089/jwh.2020.8812.


PMID- 33195885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 24
DP  - 2020
TI  - Precave: Immediate neoadjuvant instillation of chemotherapy for the prevention of
      non-muscle invasive bladder carcinoma recurrence: A prospective randomized
      clinical trial protocol.
PG  - 21-26
LID - 10.1016/j.isjp.2020.10.001 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Recurrence rates for patients presenting with
      non-muscle invasive bladder carcinoma (NMIBC) can be as high as 60% during the
      first year after a transurethral resection of bladder tumor (TURBT). Currently,
      an immediate postoperative instillation of chemotherapy (IPOIC) is recommended
      for the prevention of recurrences in patients with low to intermediate risk
      disease. Although in real clinical practice this specific instillation of
      chemotherapy has many difficulties to be standardized, including its
      contraindications (suspected or confirmed bladder perforation, wide or extensive 
      resection and, continuous bladder irrigation requirement), which will only make
      it feasible for around 30% of patients.We propose in this controlled study, to
      administer an immediate neoadjuvant instillation of chemotherapy (INAIC), which
      can be applied technically to all patients, no matter the surgical outcomes and
      compare it with a control group. We expect to find a reduction in the recurrence 
      rate in the experimental group of at least 15%. METHODS: We designed a phase IV, 
      randomized, controlled, open label clinical trial. Main inclusion criteria are:
      patients with a clinical diagnosis of localized, papillary-type bladder cancer
      (suspected low to intermediate risk) with a disease-free interval of at least 6
      months. Eligible patients will be allocated into group A (INAIC plus TURBT) or
      group B (TURBT) using a computer-generated block randomization sequence/ratio
      1:1. Time to recurrence of both groups will be analyzed and compared using
      Kaplan-Meier estimates, log-rank tests and, Cox-regression. Univariate and
      multivariate analyzes will be performed to determine factors which influence
      recurrence. The study has received the approval of the Ethics Committee for Drug 
      Research (CEIm) of La Paz University Hospital and the Spanish Agency for
      Medicines and Health Products.
CI  - (c) 2020 The Author(s).
FAU - Carrion, Diego M
AU  - Carrion DM
AD  - Department of Urology, La Paz University Hospital, Madrid, Spain.
AD  - Autonomous University of Madrid, Madrid, Spain.
AD  - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain.
FAU - Gomez Rivas, Juan
AU  - Gomez Rivas J
AD  - Department of Urology, La Paz University Hospital, Madrid, Spain.
AD  - Autonomous University of Madrid, Madrid, Spain.
AD  - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain.
FAU - Ballesteros Ruiz, Cristina
AU  - Ballesteros Ruiz C
AD  - Department of Urology, La Paz University Hospital, Madrid, Spain.
AD  - Autonomous University of Madrid, Madrid, Spain.
AD  - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain.
FAU - Alvarez-Maestro, Mario
AU  - Alvarez-Maestro M
AD  - Department of Urology, La Paz University Hospital, Madrid, Spain.
AD  - Autonomous University of Madrid, Madrid, Spain.
AD  - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain.
FAU - Aguilera Bazan, Alfredo
AU  - Aguilera Bazan A
AD  - Department of Urology, La Paz University Hospital, Madrid, Spain.
AD  - Autonomous University of Madrid, Madrid, Spain.
AD  - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain.
FAU - Martinez-Pineiro, Luis
AU  - Martinez-Pineiro L
AD  - Department of Urology, La Paz University Hospital, Madrid, Spain.
AD  - Autonomous University of Madrid, Madrid, Spain.
AD  - La Paz University Hospital Institute of Health Research (IdiPAZ), Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201017
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7644741
OTO - NOTNLM
OT  - Bladder carcinoma
OT  - Intravesical chemotherapy
OT  - Mitomycin c
OT  - Recurrence
OT  - Urothelial carcinoma
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:56
PHST- 2020/09/28 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/16 08:56 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.1016/j.isjp.2020.10.001 [doi]
AID - S2468-3574(20)30030-9 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Oct 17;24:21-26. doi: 10.1016/j.isjp.2020.10.001.
      eCollection 2020.


PMID- 33195753
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2352-0132 (Electronic)
IS  - 2352-0132 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Oct 10
TI  - Understanding autism spectrum disorder and coping mechanism by parents: An
      explorative study.
PG  - 413-418
LID - 10.1016/j.ijnss.2020.08.003 [doi]
AB  - OBJECTIVE: This study aimed to explore the perceptions of parents of children
      with autism spectrum disorder (ASD) and their coping strategies. METHODS: The
      data of the study was collected using face-to-face semi-structured interviews.
      The participants were purposefully selected from the three schools in Mpumalanga 
      Province because they had children diagnosed with ASD and data was analyzed using
      thematic content analysis. In this study, primary caregivers were selected. In
      the end, 12 women were interviewed, and the data saturation was reached. Ethical 
      considerations and measures to ensure trustworthiness were carried out throughout
      the study. RESULTS: The findings revealed two themes: caregivers' understanding
      and misconceptions of ASD and coping mechanisms used in dealing challenges of
      caring for a child with ASD; and five subthemes: lack of knowledge, cultural
      beliefs, prayer, strong support system, and acceptance. CONCLUSION: Based on the 
      findings, more awareness campaigns should be done on ASD to increase parents'
      understanding of the condition. Understanding the cultural beliefs of parents
      regarding ASD may assist health care professionals in developing care practices
      that are accepted in their culture, and may enhance parents' coping skills.
CI  - (c) 2020 The authors. Published by Elsevier B.V. on behalf of the Chinese Nursing
      Association.
FAU - Shilubane, Hilda
AU  - Shilubane H
AD  - Department of Advanced Nursing Science, University of Venda, Thohoyandou, South
      Africa.
FAU - Mazibuko, Nomfundo
AU  - Mazibuko N
AD  - Department of Public Health, University of Venda, Thohoyandou, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - China
TA  - Int J Nurs Sci
JT  - International journal of nursing sciences
JID - 101660887
PMC - PMC7644554
OTO - NOTNLM
OT  - Autism spectrum disorder
OT  - Child
OT  - Cognition
OT  - Coping
OT  - Parents
OT  - Qualitative research
COIS- The authors have no conflict of interest to declare.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:55
PHST- 2020/04/16 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/11/16 08:55 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.1016/j.ijnss.2020.08.003 [doi]
AID - S2352-0132(20)30124-1 [pii]
PST - epublish
SO  - Int J Nurs Sci. 2020 Aug 24;7(4):413-418. doi: 10.1016/j.ijnss.2020.08.003.
      eCollection 2020 Oct 10.


PMID- 33195463
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2297-055X (Print)
IS  - 2297-055X (Linking)
VI  - 7
DP  - 2020
TI  - Primary Prevention Implantable Cardiac Defibrillators: A Townsville District
      Perspective.
PG  - 577248
LID - 10.3389/fcvm.2020.577248 [doi]
AB  - Background: Despite major advances in treating patients with severe heart
      failure, deciding who should receive an implantable cardiac defibrillator (ICD)
      remains challenging. Objective: To study the risk factors and mortality in
      patients after receiving an ICD (January 2008-December 2015) in a regional
      hospital in Australia. Methods: Eighty-two primary prevention patients received
      an ICD for ischemic cardiomyopathy (ICM, n = 41) and non-ischemic cardiomyopathy 
      (NICM, n = 40) with 4.8-yrs follow-up. One patient had mixed ICM/NICM
      indications. Ventricular arrhythmias were assessed using intracardiac
      electrograms. Statistical analysis compared the total population and ICM and NICM
      groups using Kaplan-Meier for survival, Cox regression for mortality predictors, 
      and binary logistic regression for predictors of ventricular arrhythmias (p <
      0.05). Results: Major risk factors were hypercholesterolemia (70.7%),
      hypertension (47.6%), and obesity (41.5%). Severe obstructive sleep apnea (OSA)
      was found exclusively in NICM patients (23.7%, p = 0.001). Mortality was 30.5%
      after 4.8-yrs. The majority of patients (n=67) had no sustained ventricular
      arrhythmias yet 28% received therapy (n = 23), 18.51% were appropriate (n = 15), 
      and 13.9% inappropriate (n = 11). Patients receiving >/=2 incidences of
      inappropriate shocks were 18-times more likely to die (p = 0.013). Three sudden
      cardiac deaths (SCD) (3.7%) were prevented by the ICD. Conclusion: Patients
      implanted with an ICD in Townsville had 30.5% all-cause mortality after 4.8-yrs. 
      Only 28% of patients received ICD therapy and 13.9% were inappropriate. OSA may
      have contributed to the fourfold increase in inappropriate therapy in NICM
      patients. Our study raises important efficacy, ethical and healthcare cost
      questions about who should receive an ICD, and possible regional and urban center
      disparities.
CI  - Copyright (c) 2020 Engstrom, Dobson, Ng and Letson.
FAU - Engstrom, Nathan
AU  - Engstrom N
AD  - College of Medicine & Dentistry, Heart, Trauma and Sepsis Research Laboratory,
      James Cook University, Townsville, QLD, Australia.
AD  - Cardiac Investigations, The Townsville University Hospital, Douglas, QLD,
      Australia.
FAU - Dobson, Geoffrey P
AU  - Dobson GP
AD  - College of Medicine & Dentistry, Heart, Trauma and Sepsis Research Laboratory,
      James Cook University, Townsville, QLD, Australia.
FAU - Ng, Kevin
AU  - Ng K
AD  - Cardiology Clinic, Cairns Hospital, Cairns, QLD, Australia.
FAU - Letson, Hayley L
AU  - Letson HL
AD  - College of Medicine & Dentistry, Heart, Trauma and Sepsis Research Laboratory,
      James Cook University, Townsville, QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC7652736
OTO - NOTNLM
OT  - arrhythmia
OT  - heart failure
OT  - implantable cardiac defibrillator
OT  - primary prevention
OT  - shocks
OT  - sudden cardiac death
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:54
PHST- 2020/06/29 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/11/16 08:54 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fcvm.2020.577248 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2020 Oct 27;7:577248. doi: 10.3389/fcvm.2020.577248.
      eCollection 2020.


PMID- 33195343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and 
      Reality.
PG  - 585722
LID - 10.3389/fmed.2020.585722 [doi]
AB  - Objectives: To analyze the current situation of cross-border access to clinical
      trials in the EU with an overview of stakeholders' real-life experience, and to
      identify the needs, challenges, and potential for facilitation of cross-border
      access. Methods: We employed a mixed methods design. Semi-structured interviews
      and an online survey were conducted with a wide range of stakeholders: patient
      representatives, investigators/physicians, policy and regulatory experts,
      academic and commercial sponsor representatives, ethics committee members.
      Interviews underwent a framework analysis. The survey was analyzed descriptively.
      Results: Three hundred ninety six individuals responded to the survey. The
      majority were investigators/physicians (46%) and patient representatives (33%).
      Thirty eight individuals were interviewed. The majority were
      investigators/physicians (29%) and patient representatives (29%). All European
      regions were represented in the study. The highest response rate was received
      from residents of Western European countries (38% of survey respondents, 45% of
      interviewees), the lowest from Eastern Europe (9% of survey respondents, 5% of
      interviewees). The study suggested that cross-border participation in clinical
      trials occurs in practice, however very rarely. Ninety two percentage of survey
      respondents and the majority of interviewees perceived as needed the possibility 
      to access clinical trials abroad. However, most interviewees also opined that
      patients ideally should not have to travel in order to access experimental
      treatment. The lack of access to treatment in the home country of the patient was
      described as the main motivation to participate in a clinical trial in another
      country. The logistical and financial burden for patients was perceived as the
      biggest challenge. Different stakeholders expressed diverging opinions regarding 
      the allocation of financial and organizational responsibility for enabling
      cross-border access to clinical trials. Participants provided a number of
      proposals for improving the current system, which were carefully evaluated by the
      research team and informed future recommendations. Conclusions: Participation in 
      clinical trials abroad is happening rarely but should be facilitated. There was a
      consensus on the need for reliable and accessible information regarding practical
      aspects, as well as multi-stakeholder, multi-national recommendations on existing
      options and best practice on cross-border access to clinical trials. Broader
      interdisciplinary research is recommended before discussing options in the EU
      legislative framework to enable clearly defined conditions for cross-border
      access to clinical trials.
CI  - Copyright (c) 2020 Lalova, Padeanu, Negrouk, Lacombe, Geissler, Klingmann and
      Huys.
FAU - Lalova, Teodora
AU  - Lalova T
AD  - Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology 
      and Pharmacotherapy, KU Leuven, Leuven, Belgium.
AD  - Center for IT & IP law (CiTiP), KU Leuven, Leuven, Belgium.
FAU - Padeanu, Cristina
AU  - Padeanu C
AD  - European Forum for Good Clinical Practice, Brussels, Belgium.
FAU - Negrouk, Anastassia
AU  - Negrouk A
AD  - European Organization for Research and Treatment of Cancer, Brussels, Belgium.
FAU - Lacombe, Denis
AU  - Lacombe D
AD  - European Organization for Research and Treatment of Cancer, Brussels, Belgium.
FAU - Geissler, Jan
AU  - Geissler J
AD  - Patvocates, Munich, Germany.
FAU - Klingmann, Ingrid
AU  - Klingmann I
AD  - European Forum for Good Clinical Practice, Brussels, Belgium.
FAU - Huys, Isabelle
AU  - Huys I
AD  - Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology 
      and Pharmacotherapy, KU Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7642582
OTO - NOTNLM
OT  - clinical trials
OT  - clinical trials sponsors
OT  - cross-border access
OT  - cross-border healthcare
OT  - exploratory study
OT  - patient rights
OT  - pharmaceutical industry
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:54
PHST- 2020/07/21 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/11/16 08:54 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fmed.2020.585722 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Oct 22;7:585722. doi: 10.3389/fmed.2020.585722.
      eCollection 2020.


PMID- 33195309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - The Care for Non-COVID-19 Patients: A Matter of Choice or Moral Obligation?
PG  - 564038
LID - 10.3389/fmed.2020.564038 [doi]
FAU - Hassan, Bashar
AU  - Hassan B
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Arawi, Thalia
AU  - Arawi T
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7662890
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - coronavirus
OT  - elective surgeries
OT  - ethics
OT  - mental health
OT  - non-COVID-19 patients
OT  - psychological interventions
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:54
PHST- 2020/05/20 00:00 [received]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/11/16 08:54 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fmed.2020.564038 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Oct 29;7:564038. doi: 10.3389/fmed.2020.564038.
      eCollection 2020.


PMID- 33195124
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and
      Sustainable Substrates for Regenerative Medicine and Biotechnology.
PG  - 557758
LID - 10.3389/fbioe.2020.557758 [doi]
AB  - Safety, quality, and regulatory-driven iterative optimization of therapeutic cell
      source selection has constituted the core developmental bedrock for primary fetal
      progenitor cell (FPC) therapy in Switzerland throughout three decades. Customized
      Fetal Transplantation Programs were pragmatically devised as straightforward
      workflows for tissue procurement, traceability maximization, safety, consistency,
      and robustness of cultured progeny cellular materials. Whole-cell bioprocessing
      standardization has provided plethoric insights into the adequate conjugation of 
      modern biotechnological advances with current restraining legislative, ethical,
      and regulatory frameworks. Pioneer translational advances in cutaneous and
      musculoskeletal regenerative medicine continuously demonstrate the therapeutic
      potential of FPCs. Extensive technical and clinical hindsight was gathered by
      managing pediatric burns and geriatric ulcers in Switzerland. Concomitant
      industrial transposition of dermal FPC banking, following good manufacturing
      practices, demonstrated the extensive potential of their therapeutic value.
      Furthermore, in extenso, exponential revalorization of Swiss FPC technology may
      be achieved via the renewal of integrative model frameworks. Consideration of
      both longitudinal and transversal aspects of simultaneous fetal tissue
      differential processing allows for a better understanding of the quasi-infinite
      expansion potential within multi-tiered primary FPC banking. Multiple fetal
      tissues (e.g., skin, cartilage, tendon, muscle, bone, lung) may be simultaneously
      harvested and processed for adherent cell cultures, establishing a unique model
      for sustainable therapeutic cellular material supply chains. Here, we integrated 
      fundamental, preclinical, clinical, and industrial developments embodying the
      scientific advances supported by Swiss FPC banking and we focused on advances
      made to date for FPCs that may be derived from a single organ donation. A renewed
      model of single organ donation bioprocessing is proposed, achieving sustained
      standards and potential production of billions of affordable and efficient
      therapeutic doses. Thereby, the aim is to validate the core therapeutic value
      proposition, to increase awareness and use of standardized protocols for
      translational regenerative medicine, potentially impacting millions of patients
      suffering from cutaneous and musculoskeletal diseases. Alternative applications
      of FPC banking include biopharmaceutical therapeutic product manufacturing,
      thereby indirectly and synergistically enhancing the power of modern therapeutic 
      armamentariums. It is hypothesized that a single qualifying fetal organ donation 
      is sufficient to sustain decades of scientific, medical, and industrial
      developments, as technological optimization and standardization enable high
      efficiency.
CI  - Copyright (c) 2020 Laurent, Hirt-Burri, Scaletta, Michetti, de Buys Roessingh,
      Raffoul and Applegate.
FAU - Laurent, Alexis
AU  - Laurent A
AD  - Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, 
      Epalinges, Switzerland.
AD  - Tec-Pharma SA, Bercher, Switzerland.
AD  - LAM Biotechnologies SA, Epalinges, Switzerland.
FAU - Hirt-Burri, Nathalie
AU  - Hirt-Burri N
AD  - Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, 
      Epalinges, Switzerland.
FAU - Scaletta, Corinne
AU  - Scaletta C
AD  - Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, 
      Epalinges, Switzerland.
FAU - Michetti, Murielle
AU  - Michetti M
AD  - Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, 
      Epalinges, Switzerland.
FAU - de Buys Roessingh, Anthony S
AU  - de Buys Roessingh AS
AD  - Children and Adolescent Surgery Service, Lausanne University Hospital, University
      of Lausanne, Lausanne, Switzerland.
FAU - Raffoul, Wassim
AU  - Raffoul W
AD  - Plastic, Reconstructive and Hand Surgery Service, Lausanne University Hospital,
      University of Lausanne, Lausanne, Switzerland.
FAU - Applegate, Lee Ann
AU  - Applegate LA
AD  - Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, 
      Epalinges, Switzerland.
AD  - Oxford Suzhou Center for Advanced Research, Science and Technology Co., Ltd.,
      Oxford University, Suzhou, China.
AD  - Competence Center for Applied Biotechnology and Molecular Medicine, University of
      Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7644790
OTO - NOTNLM
OT  - biotechnology
OT  - cell therapy
OT  - clinical cell banking
OT  - fetal cell transplantation
OT  - primary fetal progenitor cells
OT  - regenerative medicine
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:53
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/11/16 08:53 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fbioe.2020.557758 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 Oct 23;8:557758. doi: 10.3389/fbioe.2020.557758.
      eCollection 2020.


PMID- 33194986
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Study Protocol: Social Capital as a Resource for the Planning and Design of
      Socially Sustainable and Health Promoting Neighborhoods- A Mixed Method Study.
PG  - 581078
LID - 10.3389/fpubh.2020.581078 [doi]
AB  - Introduction: Promoting inclusive, safe, resilient, and sustainable communities
      is one of the 17 Sustainable Development Goals ratified in 2015 by 193 UN member 
      states, not least in Sweden. Social sustainability involves preserving particular
      societal values (e.g., local identity) as well as developing values (e.g., social
      cohesion) that are perceived as needed. Socially sustainable development also
      implies promoting integration and preventing segregation. Social capital is one
      important indicator to measure how socially sustainable an area is. This project 
      aims to explore how social capital can be used as a conceptual tool in developing
      housing policy for social sustainability in Umea Municipality. Methods: The three
      sub-studies in this project combine quantitative and qualitative methods. We will
      conduct a review of the municipality's documents to understand how the ideas of
      social sustainability have influenced political declarations and implemented
      social and housing policies and interventions during the period 2006-2020. The
      quantitative study includes a longitudinal follow-up to the 2006 survey's
      respondents to assess the longitudinal impacts of neighborhood social capital on 
      health and well-being; as well as a new repeated cross-sectional survey to
      investigate how social capital has changed in local neighborhoods from 2006 to
      2020. The qualitative study includes case studies in neighborhoods with different
      social capital dynamics to understand how different resident sub-groups perceive 
      their neighborhoods and how implemented social and housing policies have
      influenced the social capital dynamics and responded to the needs of different
      sub-groups. The project is run in close collaboration with the Commission for a
      Socially Sustainable Umea. Discussions: This project will create new and unique
      perspectives on long-term structural changes of relevance for a socially
      sustainable housing policy; knowledge that is highly valuable for continuous
      municipal planning; and will outline recommendations to guide local housing
      policies for social sustainable neighborhoods in Umea Municipality. Ethics: This 
      study has been assessed and approved by the Swedish Ethics Review Authority (Dnr:
      2019-04395; Dnr: 2020-00160; Dnr 2020-02757). Dissemination: The dissemination
      goals of this project are (1) sustained engagement of key stakeholders throughout
      the project and (2) dissemination of the research findings through popular
      science, conferences, and scientific papers.
CI  - Copyright (c) 2020 Santosa, Ng, Zetterberg and Eriksson.
FAU - Santosa, Ailiana
AU  - Santosa A
AD  - School of Public Health and Community Medicine, Institution of Medicine,
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Ng, Nawi
AU  - Ng N
AD  - School of Public Health and Community Medicine, Institution of Medicine,
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Epidemiology and Global Health, Faculty of Medicine, Umea
      University, Umea, Sweden.
FAU - Zetterberg, Liv
AU  - Zetterberg L
AD  - Department of Social Work, Umea University, Umea, Sweden.
FAU - Eriksson, Malin
AU  - Eriksson M
AD  - Department of Social Work, Umea University, Umea, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Cross-Sectional Studies
MH  - Housing
MH  - Residence Characteristics
MH  - Review Literature as Topic
MH  - *Social Capital
MH  - Sweden
PMC - PMC7604308
OTO - NOTNLM
OT  - *health promotion
OT  - *mixed method approach
OT  - *neighborhood
OT  - *social capital
OT  - *sustainability
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:53
PHST- 2020/07/07 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/11/16 08:53 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpubh.2020.581078 [doi]
PST - epublish
SO  - Front Public Health. 2020 Oct 19;8:581078. doi: 10.3389/fpubh.2020.581078.
      eCollection 2020.


PMID- 33194944
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Mixture of Organophosphates Chronic Exposure and Pancreatic Dysregulations in Two
      Different Population Samples.
PG  - 534902
LID - 10.3389/fpubh.2020.534902 [doi]
AB  - Organophosphates (OP) are a major agrochemical. The application of OP pesticides 
      is expected to increase multifold in the coming decades. The etiology of diabetic
      diseases is attributed to multiple factors including OP pesticide exposure. The
      present study investigates pancreatic dysregulation with respect to exocrine
      enzymes and diabesity in groups of Pakistani and Cameroonian people exposed to a 
      mixture of OP pesticides. Nine hundred and four OP exposed individuals were
      enrolled for this cross-sectional study after due consent and approval from an
      ethical review committee. Pesticides' residues were measured by GC-MS
      spectrometry. Cholinergic enzymes were measured by Elman's method. Serum glucose,
      insulin, serum amylase, lipase, and triglyceride were measured by
      spectrophotometry and ELISA; HOMA-IR was determined in OP exposed and non-exposed
      participants. Stata 15 and R 3.2.0 software were used for statistical analysis of
      the data. Malathion, chlorpyrifos, and parathion residues were evident in plasma 
      samples. RBC-acetylcholinesterase was significantly depressed in OP exposed
      groups. In both population samples, investigated pancreatic functions were found 
      to be statistically significantly more dysregulated than non-exposed. OP exposure
      indicated risk of diabetes and insulin, glycaemia, adiponectin, triglycerides,
      and TNF-alpha dysregulations. The study concludes that both OP exposed population
      groups exhibited a mixture of OP residues and pancreatic dysregulation, although 
      the effect was more pronounced in the Cameroonian population. In addition, serum 
      lipase has a positive correlation with OP exposure and diabetes and may be
      suggested as an alternate/additional diagnostic marker for diabesity under OP
      exposure. However, screening of other environmental co-factors with OP for
      pancreatic dysregulation is suggested.
CI  - Copyright (c) 2020 Leonel Javeres, Raza, Judith, Anwar, Habib, Batool and
      Nurulain.
FAU - Leonel Javeres, Mbah Ntepe
AU  - Leonel Javeres MN
AD  - Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
FAU - Raza, Saqlain
AU  - Raza S
AD  - Department of Mathematics, COMSATS University Islamabad, Islamabad, Pakistan.
FAU - Judith, Ngondi
AU  - Judith N
AD  - Department of Biochemistry, Yaounde I University, Yaounde, Cameroon.
FAU - Anwar, Fozia
AU  - Anwar F
AD  - Department of Health Informatic, COMSATS University Islamabad, Islamabad,
      Pakistan.
FAU - Habib, Rabia
AU  - Habib R
AD  - Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
FAU - Batool, Sajida
AU  - Batool S
AD  - Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
FAU - Nurulain, Syed Muhammed
AU  - Nurulain SM
AD  - Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201028
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 0 (Insecticides)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Pesticides)
RN  - JCS58I644W (Chlorpyrifos)
MH  - *Chlorpyrifos
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Insecticides
MH  - Organophosphorus Compounds
MH  - *Pesticides/toxicity
PMC - PMC7655777
OTO - NOTNLM
OT  - *diabetes
OT  - *exocrine pancreas
OT  - *organophosphates
OT  - *pesticides
OT  - *serum lipase
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:53
PHST- 2020/02/14 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/11/16 08:53 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpubh.2020.534902 [doi]
PST - epublish
SO  - Front Public Health. 2020 Oct 28;8:534902. doi: 10.3389/fpubh.2020.534902.
      eCollection 2020.


PMID- 33194886
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Non-invasive Ventilation and CPAP Failure in Children and Indications for
      Invasive Ventilation.
PG  - 544921
LID - 10.3389/fped.2020.544921 [doi]
AB  - Non-invasive ventilation (NIV) and continuous positive airway pressure (CPAP) are
      effective treatments for children with severe sleep disordered breathing (SBD).
      However, some patients may present too severe SDB that do not respond to NIV/CPAP
      or insufficient compliance to treatment. A careful revaluation of the interface
      and of ventilator settings should be performed before considering alternative
      treatments. In patients with obstructive sleep apnea (OSA), alternatives to
      CPAP/NIV rely on the underlying disease. Ear-nose-throat (ENT) surgery such as
      adeno-tonsillectomy (AT), turbinectomy or supraglottoplasty represent an
      effective treatment in selected patients before starting CPAP/NIV and should be
      reconsidered in case of CPAP failure. Rapid maxillary expansion (RME) is
      restricted to children with OSA and a narrow palate who have little
      adenotonsillar tissue, or for those with residual OSA after AT. Weight loss is
      the first line therapy for obese children with OSA before starting CPAP and
      should remain a priority in the long-term. Selected patients may benefit from
      maxillo-facial surgery such as mandibular distraction osteogenesis (MDO) or from 
      neurosurgery procedures like fronto-facial monobloc advancement. Nasopharyngeal
      airway (NPA) or high flow nasal cannula (HFNC) may constitute efficient
      alternatives to CPAP in selected patients. Hypoglossal nerve stimulation has been
      proposed in children with Down syndrome not tolerant to CPAP. Ultimately,
      tracheostomy represents the unique alternative in case of failure of all the
      above-mentioned treatments. All these treatments require a multidisciplinary
      approach with a personalized treatment tailored on the different diseases and
      sites of obstruction. In patients with neuromuscular, neurological or lung
      disorders, non-invasive management in case of NIV failure is more challenging.
      Diaphragmatic pacing has been proposed for some patients with central congenital 
      hypoventilation syndrome (CCHS) or neurological disorders, however its experience
      in children is limited. Finally, invasive ventilation via tracheotomy represents 
      again the ultimate alternative for children with severe disease and little or no 
      ventilatory autonomy. However, ethical considerations weighting the efficacy
      against the burden of this treatment should be discussed before choosing this
      last option.
CI  - Copyright (c) 2020 Amaddeo, Khirani, Griffon, Teng, Lanzeray and Fauroux.
FAU - Amaddeo, Alessandro
AU  - Amaddeo A
AD  - Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hopital Necker-Enfants
      malades, Paris, France.
AD  - Universite de Paris, VIFASOM, Paris, France.
FAU - Khirani, Sonia
AU  - Khirani S
AD  - Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hopital Necker-Enfants
      malades, Paris, France.
AD  - Universite de Paris, VIFASOM, Paris, France.
AD  - ASV Sante, Gennevilliers, France.
FAU - Griffon, Lucie
AU  - Griffon L
AD  - Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hopital Necker-Enfants
      malades, Paris, France.
AD  - Universite de Paris, VIFASOM, Paris, France.
FAU - Teng, Theo
AU  - Teng T
AD  - Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hopital Necker-Enfants
      malades, Paris, France.
FAU - Lanzeray, Agathe
AU  - Lanzeray A
AD  - Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hopital Necker-Enfants
      malades, Paris, France.
FAU - Fauroux, Brigitte
AU  - Fauroux B
AD  - Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hopital Necker-Enfants
      malades, Paris, France.
AD  - Universite de Paris, VIFASOM, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201026
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7649204
OTO - NOTNLM
OT  - CPAP (continuous positive air pressure)
OT  - ENT surgeries
OT  - NIV failure
OT  - educational therapeutic assistance
OT  - sleep disordered breathing (obstructive/central sleep apnea)
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:53
PHST- 2020/04/01 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/11/16 08:53 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fped.2020.544921 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Oct 26;8:544921. doi: 10.3389/fped.2020.544921. eCollection
      2020.


PMID- 33194500
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 14
TI  - Educational and Personal Opportunity Costs of Medical Student Preparation for the
      United States Medical Licensing Examination Step 1 Exam: A Single-Center Study.
PG  - e10938
LID - 10.7759/cureus.10938 [doi]
AB  - Purpose To assess the degree to which medical students choose to disengage from
      their regular preclinical curriculum and extracurricular activities in order to
      focus on United States Medical Licensing Examination (USMLE) Step 1 exam
      preparation, as well as learner-perceived effects of Step 1 preparation on their 
      physical, social, and mental health. Method Online survey of medical students who
      have taken the USMLE Step 1 exam at a single large Midwestern academic medical
      center. Results The response rate was 54%. Students often reported absenteeism
      from a variety of preclinical curricular activities, including lectures (44%) and
      didactics focusing on medical ethics (37%), clinical skills (28%), and encounters
      with actual and standardized patients (9%) in order to study for USMLE Step 1.
      Many students also forewent extracurricular opportunities including research
      (53%), elective patient care opportunities (45%), community service (39%), and
      healthcare advocacy experiences (38%) in order to study for USMLE Step 1.
      Majorities of students identified Step 1 preparation as a cause of burnout (79%) 
      or significant anxiety or depression (61%), for which nearly a third sought
      mental healthcare; students also reported Step 1 preparation as a cause of
      engaging in dangerous behaviors such as illicit prescription stimulant use as
      well as driving or providing patient care while impaired by fatigue. In narrative
      comments, students frequently described Step 1 to be a barrier to their
      development into effective clinicians, the traditional medical school curriculum 
      to be a barrier to performance on Step 1, or both. Conclusions Medical students
      often prioritize Step 1 exam preparation over engaging with the standard
      preclinical curriculum, extracurricular opportunities, and activities to promote 
      wellbeing. These findings have implications for the emphasis residency program
      directors place on single high-stakes standardized exams in the resident
      recruitment process.
CI  - Copyright (c) 2020, Cortes-Penfield et al.
FAU - Cortes-Penfield, Nicolas W
AU  - Cortes-Penfield NW
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha,
      USA.
FAU - Khazanchi, Rohan
AU  - Khazanchi R
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha,
      USA.
AD  - School of Public Health, University of Minnesota, Minneapolis, USA.
FAU - Talmon, Geoffery
AU  - Talmon G
AD  - Department of Pathology and Microbiology, University of Nebraska Medical Center, 
      Omaha, USA.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7660126
OTO - NOTNLM
OT  - medical education
OT  - medical student education
OT  - nmbe
OT  - residency application process
OT  - residency preparation
OT  - score
OT  - step 1
OT  - step 1 score
OT  - usmle
OT  - usmle step 1
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:51
PHST- 2020/11/16 08:51 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.7759/cureus.10938 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 14;12(10):e10938. doi: 10.7759/cureus.10938.


PMID- 33194477
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 12
TI  - General Anesthesia Practices During the COVID-19 Pandemic in Turkey: A Cohort
      Study With a National Survey.
PG  - e10910
LID - 10.7759/cureus.10910 [doi]
AB  - Introduction This study aimed to examine the anesthesia practices applied to the 
      cases during the pandemic, to analyze the rate of the precautions taken in
      emergency/elective operations in non-COVID patients, what precautions were taken,
      what resources the clinics had, and the patient management in the perioperative
      period by organizing a survey among anesthesiologist in Turkey. Methods After
      obtaining approval from the Turkish Ministry of Health (2020-05-04T09_30_03) and 
      the local ethics committee (GOKAEK-2020/10.09), a survey consisting of 21
      questions was formed over the online survey inquiry (surveymonkey.com). The
      survey was conducted in Turkish. Results The survey aimed at reaching the
      anesthesiologists, who were Turkish Anesthesiology and Reanimation Society (TARD)
      members, by e-mail, and it was seen that 120 people out of approximately 2700
      members who had received our e-mail participated in the survey. After the first
      case was reported in our country, it was understood that 62.1% of the
      participants stopped accepting elective cases in their institutions. The
      anesthesia method preferred in this period was general anesthesia by 47.6%,
      regional anesthesia by 52.1%, and sedation by 0.3%. The arrival time of
      coronavirus disease COVID-19 tests (PCR and/or rapid diagnostic kits showing
      antibodies) to the hospital was questioned; seven people (5.83%) stated that
      tests were not performed at their hospitals. It was observed that tests arrived
      and were applied at the hospitals of the remaining participants in an average of 
      2.7 +/- 1.6 weeks. It was determined that 59.32% of the participants avoided
      positive pressure ventilation after induction, 5.98% of the intubation on the
      patients were performed by anesthesia technicians, 66.67% by anesthesiologists,
      25.64% by senior resident doctors with at least two years of experience, and
      1.71% by junior anesthesia assistants with less than two years of experience. The
      use of personal protective equipment (PPE) is applied by 95% of the participants.
      22.69% of the participants stated that they preferred to use supraglottic airway 
      (SGA) devices during this period. While 45.06% of the participants stated that
      they provided oxygen support to the patient with the mask belonging to the
      circuit after extubation, 14.8% preferred the nasal cannula, and 33.1% used an
      oxygen mask. Our results showed that 90% of additional precautions were taken in 
      our country's clinics, and 95% of PPE was used. Also, the use of video
      laryngoscope (VL) was 75% in this period. Finally, it was found that 50.85% of
      the patients were taken to the recovery unit after being extubated, and 49.15%
      were sent directly to the service. Conclusion We can reveal that each clinic made
      arrangements according to its own conditions. We think that plans should be made 
      to standardize clinical facilities and algorithms throughout the country. Apart
      from technological and financial facilities, we believe that the continuity of
      the training organized by national and international associations should be
      ensured so that anesthesiologists' knowledge, skills, and experience who manage
      this process can remain at the highest level.
CI  - Copyright (c) 2020, Aksu et al.
FAU - Aksu, Can
AU  - Aksu C
AD  - Anesthesiology, Kocaeli University, Kocaeli, TUR.
FAU - Cesur, Sevim
AU  - Cesur S
AD  - Anesthesiology, Kocaeli University School of Medicine, Kocaeli, TUR.
FAU - Kus, Alparslan
AU  - Kus A
AD  - Anesthesiology and Reanimation, Kocaeli University, Kocaeli, TUR.
FAU - Toker, Kamil
AU  - Toker K
AD  - Anesthesiology and Reanimation, Istinye University, Istanbul, TUR.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7657308
OTO - NOTNLM
OT  - covid-19
OT  - general anesthesia practice
OT  - personal protective equipment (ppe)
OT  - positive pressure ventilation
OT  - video laryngoscope
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:51
PHST- 2020/11/16 08:51 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.7759/cureus.10910 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 12;12(10):e10910. doi: 10.7759/cureus.10910.


PMID- 33194450
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Linking)
VI  - 8
DP  - 2020
TI  - The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality:
      a systematic review.
PG  - e10322
LID - 10.7717/peerj.10322 [doi]
AB  - BACKGROUND: In the absence of highly effective antiviral therapies against
      SARS-CoV-2, it is crucial to counter the known pathophysiological causes of
      severe COVID-19. Evaluating the efficacy existing drugs may expedite the
      development of such therapeutics. Severe COVID-19 is largely the result of a
      dysregulated immune response characterized by lymphocytopenia, neutrophilia and
      critical hypercytokinemia, or "cytokine storm," which is largely mediated by the 
      cytokine interleukin-6 (IL-6). The IL-6 inhibitor tocilizumab (TCZ) could
      potentially suppress the effects of the pro-inflammatory cytokine and thereby
      lower mortality from the disease. This systematic analysis aimed to investigate
      and synthesize existing evidence for the efficacy of TCZ in reducing COVID-19
      mortality. METHODOLOGY: PubMed and SearchWorks searches were performed to locate 
      clinical studies with primary data on TCZ treatment for severe COVID-19. Sixteen 
      case-control studies comparing mortality between TCZ and standard of care (SOC)
      were identified for quantitative synthesis. The systematic analysis was
      pre-approved through PROSPERO (CRD42020193479). RESULTS: Combined mortality for
      the TCZ-treated and SOC groups were 26.0% and 43.4% respectively. In all but one 
      of the studies, the odds ratio of mortality from COVID-19 pointed towards lower
      fatality with TCZ vs the SOC. A combined random effects odds ratio calculation
      yielded an odds ratio of 0.453 (95% CI [0.376-0.547], p < 0.001). Additionally,
      18 uncontrolled trials were identified for qualitative analysis producing a raw
      combined mortality rate of 16.0%. CONCLUSIONS: Important caveats to this research
      include the lack of prospective randomized control trials and the absence of data
      from the large COVATA study from the published literature. However, results from 
      this systematic analysis of published research provide positive evidence for the 
      potential efficacy of TCZ to treat severe COVID-19, validating the ethical basis 
      and merit of ongoing randomized controlled clinical trials.
CI  - (c) 2020 Kaye and Siegel.
FAU - Kaye, Avi Gurion
AU  - Kaye AG
AD  - Human Biology, Stanford University, Stanford, CA, USA.
FAU - Siegel, Robert
AU  - Siegel R
AD  - Human Biology, Stanford University, Stanford, CA, USA.
AD  - Microbiology & Immunology, Stanford University, Stanford, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC7643559
OTO - NOTNLM
OT  - COVID-19
OT  - IL-6
OT  - SARS-COV-2
OT  - Tocilizumab
COIS- The authors declare that they have no competing interests.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:51
PHST- 2020/09/04 00:00 [received]
PHST- 2020/10/18 00:00 [accepted]
PHST- 2020/11/16 08:51 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.7717/peerj.10322 [doi]
AID - 10322 [pii]
PST - epublish
SO  - PeerJ. 2020 Nov 2;8:e10322. doi: 10.7717/peerj.10322. eCollection 2020.


PMID- 33194219
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2055-2076 (Print)
IS  - 2055-2076 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Artificial intelligence and the future of psychiatry: Qualitative findings from a
      global physician survey.
PG  - 2055207620968355
LID - 10.1177/2055207620968355 [doi]
AB  - BACKGROUND: The potential for machine learning to disrupt the medical profession 
      is the subject of ongoing debate within biomedical informatics. OBJECTIVE: This
      study aimed to explore psychiatrists' opinions about the potential impact
      innovations in artificial intelligence and machine learning on psychiatric
      practice. METHODS: In Spring 2019, we conducted a web-based survey of 791
      psychiatrists from 22 countries worldwide. The survey measured opinions about the
      likelihood future technology would fully replace physicians in performing ten key
      psychiatric tasks. This study involved qualitative descriptive analysis of
      written responses ("comments") to three open-ended questions in the survey.
      RESULTS: Comments were classified into four major categories in relation to the
      impact of future technology on: (1) patient-psychiatrist interactions; (2) the
      quality of patient medical care; (3) the profession of psychiatry; and (4) health
      systems. Overwhelmingly, psychiatrists were skeptical that technology could
      replace human empathy. Many predicted that 'man and machine' would increasingly
      collaborate in undertaking clinical decisions, with mixed opinions about the
      benefits and harms of such an arrangement. Participants were optimistic that
      technology might improve efficiencies and access to care, and reduce costs.
      Ethical and regulatory considerations received limited attention. CONCLUSIONS:
      This study presents timely information on psychiatrists' views about the scope of
      artificial intelligence and machine learning on psychiatric practice.
      Psychiatrists expressed divergent views about the value and impact of future
      technology with worrying omissions about practice guidelines, and ethical and
      regulatory issues.
CI  - (c) The Author(s) 2020.
FAU - Blease, C
AU  - Blease C
AUID- ORCID: https://orcid.org/0000-0002-0205-1165
AD  - General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard 
      Medical School, Boston, MA, USA.
AD  - School of Psychology, University College Dublin, Ireland.
FAU - Locher, C
AU  - Locher C
AD  - Division of Clinical Psychology and Psychotherapy, University of Basel, Basel,
      Switzerland.
AD  - Department of Psychology, University of Plymouth, UK.
FAU - Leon-Carlyle, M
AU  - Leon-Carlyle M
AD  - Faculty of Medicine, University of Toronto, Canada.
FAU - Doraiswamy, M
AU  - Doraiswamy M
AD  - Departments of Psychiatry and Behavioral Science, and Medicine, Duke University
      Medical School, Durham, NC, USA.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - United States
TA  - Digit Health
JT  - Digital health
JID - 101690863
PMC - PMC7597571
OTO - NOTNLM
OT  - Artificial intelligence
OT  - attitudes
OT  - future
OT  - machine learning
OT  - mental health
OT  - opinions
OT  - psychiatry
OT  - qualitative research
OT  - technology
COIS- Declaration of Conflicting Interests: The author(s) declared the following
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Doraiswamy has received research grants from and/or 
      served as an advisor or board member to government agencies, technology and
      healthcare businesses, and advocacy groups for other projects in this field.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:50
PHST- 2019/10/02 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/11/16 08:50 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.1177/2055207620968355 [doi]
AID - 10.1177_2055207620968355 [pii]
PST - epublish
SO  - Digit Health. 2020 Oct 27;6:2055207620968355. doi: 10.1177/2055207620968355.
      eCollection 2020 Jan-Dec.


PMID- 33194212
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Ethical Issues in the Design and Conduct of Pragmatic Cluster Randomized Trials
      in Hemodialysis Care: An Interview Study With Key Stakeholders.
PG  - 2054358120964119
LID - 10.1177/2054358120964119 [doi]
AB  - BACKGROUND: Pragmatic cluster randomized trials (CRTs) offer an opportunity to
      improve health care by answering important questions about the comparative
      effectiveness of treatments using a trial design that can be embedded in routine 
      care. There is a lack of empirical research that addresses ethical issues
      generated by pragmatic CRTs in hemodialysis. OBJECTIVE: To identify stakeholder
      perceptions of ethical issues in pragmatic CRTs conducted in hemodialysis.
      DESIGN: Qualitative study using semi-structured interviews. SETTING: In-person or
      telephone interviews with an international group of stakeholders. PARTICIPANTS:
      Stakeholders (clinical investigators, methodologists, ethicists and research
      ethics committee members, and other knowledge users) who had been involved in the
      design or conduct of a pragmatic individual patient or cluster randomized trial
      in hemodialysis, or their role would require them to review and evaluate
      pragmatic CRTs in hemodialysis. METHODS: Interviews were conducted in-person or
      over the telephone and were audio-recorded with consent. Recorded interviews were
      transcribed verbatim prior to analysis. Transcripts and field notes were analyzed
      using a thematic analysis approach. RESULTS: Sixteen interviews were conducted
      with 19 individuals. Interviewees were largely drawn from North America (84%) and
      were predominantly clinical investigators (42%). Six themes were identified in
      which pragmatic CRTs in hemodialysis raise ethical issues: (1) patients treated
      with hemodialysis as a vulnerable population, (2) appropriate approaches to
      informed consent, (3) research burdens, (4) roles and responsibilities of
      gatekeepers, (5) inequities in access to research, and (6) advocacy for
      patient-centered research and outcomes. LIMITATIONS: Participants were largely
      from North America and did not include research staff, who may have differing
      perspectives. CONCLUSIONS: The six themes reflect concerns relating to individual
      rights, but also the need to consider population-level issues. To date, concerns 
      regarding inequity of access to research and the need for patient-centered
      research have received less coverage than other, well-known, issues such as
      consent. Pragmatic CRTs offer a potential approach to address equity concerns and
      we suggest future ethical analyses and guidance for pragmatic CRTs in
      hemodialysis embed equity considerations within them. We further note the
      potential for the co-creation of health data infrastructure with patients which
      would aid care but also facilitate patient-centered research. These present
      results will inform planned future guidance in relation to the ethical design and
      conduct of pragmatic CRTs in hemodialysis. TRIAL REGISTRATION: Registration is
      not applicable as this is a qualitative study.
CI  - (c) The Author(s) 2020.
FAU - Nicholls, Stuart G
AU  - Nicholls SG
AUID- ORCID: https://orcid.org/0000-0003-0485-9069
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Canada.
FAU - Carroll, Kelly
AU  - Carroll K
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Canada.
FAU - Weijer, Charles
AU  - Weijer C
AD  - Department of Philosophy, Western University, London, Canada.
AD  - Department of Medicine, Western University, London, Canada.
AD  - Department of Epidemiology and Biostatistics, Western University, London, Canada.
FAU - Goldstein, Cory E
AU  - Goldstein CE
AD  - Department of Philosophy, Western University, London, Canada.
FAU - Brehaut, Jamie
AU  - Brehaut J
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
FAU - Sood, Manish M
AU  - Sood MM
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Canada.
AD  - Jindal Research Chair for the Prevention of Kidney Disease, The Ottawa Hospital, 
      Ottawa, Canada.
AD  - Institute for Clinical Evaluative Sciences, Ontario, Canada.
FAU - Al-Jaishi, Ahmed
AU  - Al-Jaishi A
AUID- ORCID: https://orcid.org/0000-0003-0376-2214
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
FAU - Basile, Erika
AU  - Basile E
AD  - Research Ethics and Compliance, Western University, London, Canada.
FAU - Grimshaw, Jeremy M
AU  - Grimshaw JM
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
AD  - Department of Medicine, University of Ottawa, Ottawa, Canada.
FAU - Garg, Amit X
AU  - Garg AX
AUID- ORCID: https://orcid.org/0000-0003-3398-3114
AD  - Department of Epidemiology and Biostatistics, Western University, London, Canada.
AD  - Institute for Clinical Evaluative Sciences, Ontario, Canada.
AD  - Division of Nephrology- Department of Medicine, Western University, London,
      Canada.
AD  - Nephrology, London Health Sciences Centre, London, Canada.
FAU - Taljaard, Monica
AU  - Taljaard M
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7597560
OTO - NOTNLM
OT  - cluster randomized trials
OT  - equity
OT  - informed consent
OT  - patient-oriented research
OT  - research ethics
COIS- Declaration of Conflicting Interests: The author(s) declared the following
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: C.W. receives consulting income from Cardialen, Eli 
      Lilly & Company, and Research Triangle Institute (RTI) International.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:50
PHST- 2020/03/25 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/11/16 08:50 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.1177/2054358120964119 [doi]
AID - 10.1177_2054358120964119 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Oct 26;7:2054358120964119. doi:
      10.1177/2054358120964119. eCollection 2020.


PMID- 33194144
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Investigation of moral intelligence's predictive components in students of Shahid
      Beheshti university of medical sciences (SBMU).
PG  - 13
LID - 10.18502/jmehm.v13i13.4389 [doi]
AB  - This study aimed to investigate dominant predictor components of moral
      intelligence (MI) based on the Lennick and Kiel's model in students of Shahid
      Beheshti University of Medical Sciences (SBMU). In this descriptive-analytical
      study, 322 students of SBMU were chosen through cluster sampling. To collect
      data, a 40-item questionnaire, whose validity and reliability was confirmed in
      previous studies, based on the Lennick and Kiel's model was used. The collected
      data were analyzed by SPSS 21 software using appropriate descriptive and
      analytical statistics. Of 322 participants, 180 and 142 were female and male,
      respectively. The mean age of the participants was 22.30+/-2.69 years. The
      study's regression analysis revealed that the most and the least direct effects
      were related to the forgiveness (R2=0.320) and compassion (R2=0.284) components, 
      respectively. Among the inspected components, the responsibility component with
      an overall effect of R2=0.655 was shown to be the strongest predictor component
      of MI. Universities play a significant role in students' moral development and
      enhancement. The present study's findings suggest that developing strategic plans
      and interventions can enhance MI level (e.g., incentive systems for individuals
      maintaining high moral responsibility). Since today's students will be tomorrow's
      medical and healthcare professionals, upgrading of MI level in students studying 
      in various divisions of medical sciences enhances their moral responsibility
      through setting out strong ethics principles to follow and the quality of care
      that they will provide to patients, thereby improving health.
CI  - (c) 2020 Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences. All rights reserved.
FAU - Mohammadi, Maryam
AU  - Mohammadi M
AD  - Assistant Professor, Health Education and Health Promotion, Department of Public 
      Health, School of Public Health, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Mohammadi, Shabnam
AU  - Mohammadi S
AD  - Assistant Professor, Neurogenic Inflammation Research Center, Mashhad University 
      of Medical Sciences, Mashhad, Iran.
FAU - Mehri, Ali
AU  - Mehri A
AD  - Assistant Professor, Department of Health Education, School of Health, Sabzevar
      University of Medical Sciences, Sabzevar, Iran.
FAU - Bagheri Mazraeh, Fatemeh
AU  - Bagheri Mazraeh F
AD  - Researcher, Student of Public Health, School of Public Health, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200920
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7602045
OTO - NOTNLM
OT  - Lennick and Kiel's model.
OT  - Medical sciences
OT  - Moral intelligence
OT  - Students
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:50
PHST- 2019/09/23 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/11/16 08:50 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.18502/jmehm.v13i13.4389 [doi]
AID - JMEHM-13-13 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Sep 20;13:13. doi: 10.18502/jmehm.v13i13.4389.
      eCollection 2020.


PMID- 33193618
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Next Generation Sequencing and Bioinformatics Analysis of Family Genetic
      Inheritance.
PG  - 544162
LID - 10.3389/fgene.2020.544162 [doi]
AB  - Mendelian and complex genetic trait diseases continue to burden and affect
      society both socially and economically. The lack of effective tests has hampered 
      diagnosis thus, the affected lack proper prognosis. Mendelian diseases are caused
      by genetic mutations in a singular gene while complex trait diseases are caused
      by the accumulation of mutations in either linked or unlinked genomic regions.
      Significant advances have been made in identifying novel diseases associated
      mutations especially with the introduction of next generation and third
      generation sequencing. Regardless, some diseases are still without diagnosis as
      most tests rely on SNP genotyping panels developed from population based genetic 
      analyses. Analysis of family genetic inheritance using whole genomes, whole
      exomes or a panel of genes has been shown to be effective in identifying
      disease-causing mutations. In this review, we discuss next generation and third
      generation sequencing platforms, bioinformatic tools and genetic resources
      commonly used to analyze family based genomic data with a focus on identifying
      inherited or novel disease-causing mutations. Additionally, we also highlight the
      analytical, ethical and regulatory challenges associated with analyzing personal 
      genomes which constitute the data used for family genetic inheritance.
CI  - Copyright (c) 2020 Kanzi, San, Chimukangara, Wilkinson, Fish, Ramsuran and de
      Oliveira.
FAU - Kanzi, Aquillah M
AU  - Kanzi AM
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
FAU - San, James Emmanuel
AU  - San JE
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
FAU - Chimukangara, Benjamin
AU  - Chimukangara B
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
FAU - Wilkinson, Eduan
AU  - Wilkinson E
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
FAU - Fish, Maryam
AU  - Fish M
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
FAU - Ramsuran, Veron
AU  - Ramsuran V
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
FAU - de Oliveira, Tulio
AU  - de Oliveira T
AD  - Kwazulu-Natal Research and Innovation Sequencing Platform (KRISP), School of
      Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
      of KwaZulu-Natal, Durban, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201023
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7649788
OTO - NOTNLM
OT  - family genetic inheritance
OT  - genetic variants
OT  - next generation sequencing
OT  - phenotypic traits
OT  - third generation sequencing
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:48
PHST- 2020/03/20 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/16 08:48 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fgene.2020.544162 [doi]
PST - epublish
SO  - Front Genet. 2020 Oct 23;11:544162. doi: 10.3389/fgene.2020.544162. eCollection
      2020.


PMID- 33193608
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Queensland Consumers' Awareness and Understanding of Clinical Genetics Services.
PG  - 537743
LID - 10.3389/fgene.2020.537743 [doi]
AB  - As genetic testing becomes increasingly utilized in health care, consumer
      awareness and understanding is critical. Both are reported to be low in
      Australia, though there are limited studies to date. A consumer survey assessed
      perceived knowledge, awareness and attitudes toward genetic medicine, prior to
      consumers' genomics forums in Queensland in 2018 and 2019. Data was analyzed
      using t-test and Mann-Whitney U tests analysis to detect any associations between
      sociodemographic factors and familiarity or attitudes. This highly educated and
      experienced health consumer cohort reported they were significantly more familiar
      with the healthcare system generally than genetic medicine specifically (p <
      0.0001). Consumers perceived that genetic testing would be significantly more
      important in the future than it is currently (p < 0.00001). Consumers agreed that
      genetic testing should be promoted (91.4%), made available (100%), better funded 
      (94.2%), and offered to all pregnant women (81.6%). The preferred learning
      modality about genetics was internet sites (62.7%) followed by
      talks/presentations (30.8%). Benefits of genetic testing, reported in qualitative
      responses, included the potential for additional information to promote personal 
      control and improve healthcare. Perceived concerns included ethical implications 
      (including privacy and discrimination), and current limitations of science,
      knowledge and/or practice. This study demonstrates that even knowledgeable
      consumers have little familiarity with genetic medicine but are optimistic about 
      its potential benefits. Ethical concerns, particularly concerns regarding genetic
      discrimination should inform legislation and policy. Consumers are supportive of 
      online resources in increasing genomic literacy.
CI  - Copyright (c) 2020 Wallingford, Cutler, Istiko, Fowles, Lamb, Bean, Healy,
      Hondow, Pratt, Vidgen, Waddell, Evans, Bunker and McInerney-Leo.
FAU - Wallingford, Courtney K
AU  - Wallingford CK
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      University of Queensland, Brisbane, QLD, Australia.
AD  - Graduate School of Health, University of Technology Sydney, Sydney, NSW,
      Australia.
FAU - Cutler, Katrina
AU  - Cutler K
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Istiko, Satrio Nindyo
AU  - Istiko SN
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Fowles, Lindsay F
AU  - Fowles LF
AD  - Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD,
      Australia.
FAU - Lamb, Rachel
AU  - Lamb R
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Bean, Jessica
AU  - Bean J
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Healy, Louise
AU  - Healy L
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Hondow, Gary
AU  - Hondow G
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Pratt, Gregory
AU  - Pratt G
AD  - QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
FAU - Vidgen, Miranda E
AU  - Vidgen ME
AD  - QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
FAU - Waddell, Nicola
AU  - Waddell N
AD  - QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
FAU - Evans, Erin
AU  - Evans E
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - Bunker, David
AU  - Bunker D
AD  - Queensland Genomics, Brisbane, QLD, Australia.
FAU - McInerney-Leo, Aideen M
AU  - McInerney-Leo AM
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      University of Queensland, Brisbane, QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7593610
OTO - NOTNLM
OT  - attitudes
OT  - awareness
OT  - genetics
OT  - genomics
OT  - health consumers
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:48
PHST- 2020/02/25 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/16 08:48 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fgene.2020.537743 [doi]
PST - epublish
SO  - Front Genet. 2020 Oct 15;11:537743. doi: 10.3389/fgene.2020.537743. eCollection
      2020.


PMID- 33193602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - GenomeChronicler: The Personal Genome Project UK Genomic Report Generator
      Pipeline.
PG  - 518644
LID - 10.3389/fgene.2020.518644 [doi]
AB  - In recent years, there has been a significant increase in whole genome sequencing
      data of individual genomes produced by research projects as well as direct to
      consumer service providers. While many of these sources provide their users with 
      an interpretation of the data, there is a lack of free, open tools for generating
      reports exploring the data in an easy to understand manner. GenomeChronicler was 
      developed as part of the Personal Genome Project UK (PGP-UK) to address this
      need. PGP-UK provides genomic, transcriptomic, epigenomic and self-reported
      phenotypic data under an open-access model with full ethical approval. As a
      result, the reports generated by GenomeChronicler are intended for research
      purposes only and include information relating to potentially beneficial and
      potentially harmful variants, but without clinical curation. GenomeChronicler can
      be used with data from whole genome or whole exome sequencing, producing a genome
      report containing information on variant statistics, ancestry and known
      associated phenotypic traits. Example reports are available from the PGP-UK data 
      page (personalgenomes.org.uk/data). The objective of this method is to leverage
      existing resources to find known phenotypes associated with the genotypes
      detected in each sample. The provided trait data is based primarily upon
      information available in SNPedia, but also collates data from ClinVar,
      GETevidence, and gnomAD to provide additional details on potential health
      implications, presence of genotype in other PGP participants and population
      frequency of each genotype. The analysis can be run in a self-contained
      environment without requiring internet access, making it a good choice for cases 
      where privacy is essential or desired: any third party project can embed
      GenomeChronicler within their off-line safe-haven environments. GenomeChronicler 
      can be run for one sample at a time, or in parallel making use of the Nextflow
      workflow manager. The source code is available from GitHub
      (https://github.com/PGP-UK/GenomeChronicler), container recipes are available for
      Docker and Singularity, as well as a pre-built container from SingularityHub
      (https://singularity-hub.org/collections/3664) enabling easy deployment in a
      variety of settings. Users without access to computational resources to run
      GenomeChronicler can access the software from the Lifebit CloudOS platform
      (https://lifebit.ai/cloudos) enabling the production of reports and variant calls
      from raw sequencing data in a scalable fashion.
CI  - Copyright (c) 2020 Guerra-Assuncao, Conde, Moghul, Webster, Ecker, Chervova,
      Chatzipantsiou, Prieto, Beck and Herrero.
FAU - Guerra-Assuncao, Jose Afonso
AU  - Guerra-Assuncao JA
AD  - Infection and Immunity, University College London, London, United Kingdom.
AD  - Bill Lyons Informatics Centre, UCL Cancer Institute, University College London,
      London, United Kingdom.
FAU - Conde, Lucia
AU  - Conde L
AD  - Bill Lyons Informatics Centre, UCL Cancer Institute, University College London,
      London, United Kingdom.
FAU - Moghul, Ismail
AU  - Moghul I
AD  - Medical Genomics, UCL Cancer Institute, University College London, London, United
      Kingdom.
FAU - Webster, Amy P
AU  - Webster AP
AD  - Medical Genomics, UCL Cancer Institute, University College London, London, United
      Kingdom.
FAU - Ecker, Simone
AU  - Ecker S
AD  - Medical Genomics, UCL Cancer Institute, University College London, London, United
      Kingdom.
FAU - Chervova, Olga
AU  - Chervova O
AD  - Medical Genomics, UCL Cancer Institute, University College London, London, United
      Kingdom.
FAU - Chatzipantsiou, Christina
AU  - Chatzipantsiou C
AD  - Lifebit, London, United Kingdom.
FAU - Prieto, Pablo P
AU  - Prieto PP
AD  - Lifebit, London, United Kingdom.
FAU - Beck, Stephan
AU  - Beck S
AD  - Medical Genomics, UCL Cancer Institute, University College London, London, United
      Kingdom.
FAU - Herrero, Javier
AU  - Herrero J
AD  - Bill Lyons Informatics Centre, UCL Cancer Institute, University College London,
      London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7541957
OTO - NOTNLM
OT  - PGP-UK
OT  - cloud computing
OT  - genomic report
OT  - open consent
OT  - open source
OT  - participant engagement
OT  - personal genomics
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:48
PHST- 2019/12/09 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/11/16 08:48 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fgene.2020.518644 [doi]
PST - epublish
SO  - Front Genet. 2020 Sep 24;11:518644. doi: 10.3389/fgene.2020.518644. eCollection
      2020.


PMID- 33192907
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220714
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Problems With Police Reports as Data Sources: A Researchers' Perspective.
PG  - 582428
LID - 10.3389/fpsyg.2020.582428 [doi]
FAU - Guss, C Dominik
AU  - Guss CD
AD  - Department of Psychology, University of North Florida, Jacksonville, FL, United
      States.
FAU - Tuason, Ma Teresa
AU  - Tuason MT
AD  - Department of Public Health, Clinical Mental Health Counseling, University of
      North Florida, Jacksonville, FL, United States.
FAU - Devine, Alicia
AU  - Devine A
AD  - Department of Psychology, University of North Florida, Jacksonville, FL, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
CIN - Front Psychol. 2022 Jun 27;13:873235. PMID: 35832926
PMC - PMC7642213
OTO - NOTNLM
OT  - biases
OT  - data
OT  - ethics
OT  - police reports
OT  - quality
OT  - validity
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:46
PHST- 2020/07/11 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/16 08:46 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpsyg.2020.582428 [doi]
PST - epublish
SO  - Front Psychol. 2020 Oct 22;11:582428. doi: 10.3389/fpsyg.2020.582428. eCollection
      2020.


PMID- 33192777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Identifiability, Risk, and Information Credibility in Discussions on
      Moral/Ethical Violation Topics on Chinese Social Networking Sites.
PG  - 535605
LID - 10.3389/fpsyg.2020.535605 [doi]
AB  - One heated argument in recent years concerns whether requiring real name
      supervision on social media will inhibit users' participation in discoursing
      online speech. The current study explores the impact of identification, perceived
      anonymity, perceived risk, and information credibility on participating in
      discussions on moral/ethical violation events on social network sites (SNS) in
      China. In this study, we constructed a model based on the literature and tested
      it on a sample of 218 frequent SNS users. The results demonstrate the influence
      of identification and perception of anonymity: although the relationship between 
      the two factors is negative, both are conducive to participation in discussion on
      moral/ethical violation topics, and information credibility also has a positive
      impact. The results confirmed the significance of risk perception on comments
      posted about moral/ethical violation. Our results have reference value for
      identity management and internet governance. Policies regarding users' real names
      on the internet need to take into account the reliability of the identity
      authentication mechanism, as well as netizens' perceptions of privacy about their
      identity and the necessity of guaranteeing content and information reliability
      online. We also offer some suggestions for future research, with a special
      emphasis on applicability to different cultures, contexts, and social networking 
      sites.
CI  - Copyright (c) 2020 Chen, Huang and Cheng.
FAU - Chen, Xi
AU  - Chen X
AD  - School of Business Administration and Tourism Management, Yunnan University,
      Kunming, China.
FAU - Huang, Chenli
AU  - Huang C
AD  - School of Business Administration and Tourism Management, Yunnan University,
      Kunming, China.
FAU - Cheng, Yi
AU  - Cheng Y
AD  - School of Business Administration and Tourism Management, Yunnan University,
      Kunming, China.
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7644537
OTO - NOTNLM
OT  - anonymity perception
OT  - content moderation
OT  - information credibility
OT  - real names on social media
OT  - risk perception
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:45
PHST- 2020/04/01 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/11/16 08:45 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpsyg.2020.535605 [doi]
PST - epublish
SO  - Front Psychol. 2020 Oct 23;11:535605. doi: 10.3389/fpsyg.2020.535605. eCollection
      2020.


PMID- 33192704
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Moral Dilemmas in Contact-Based Care: The Relevance of Moral Case Deliberation
      for Forensic Psychiatry.
PG  - 574336
LID - 10.3389/fpsyt.2020.574336 [doi]
AB  - Currently, forensic psychiatry shows a shift from a control-based to a
      contact-based approach. Working from contact may, however, entail new moral
      questions and dilemmas. How to secure safety when focusing on contact? Does
      contact imply being physically close to the patient, or should one refrain from
      intimate relations? In order to help care professionals to deal with these moral 
      issues, clinical ethics support can be useful. A specific approach in clinical
      ethics support is moral case deliberation (MCD). An MCD is a structured dialogue 
      between professionals on a moral issue they experience in practice, structured by
      a conversation method and guided by a facilitator. In this article, we describe
      the background and procedures of MCD. Furthermore, we present a case example in
      which care professionals reflect on the moral question of whether provision of
      care in forensic psychiatry may entail physical closeness. The MCD shows that an 
      open conversation results in a better understanding of different perspectives and
      creates the basis for finding a joint way to proceed in the case. We conclude
      that MCD can enable professionals to reflect on moral issues and develop shared
      values in forensic psychiatry.
CI  - Copyright (c) 2020 Gerritsen, Widdershoven, Bossenbroek and Voskes.
FAU - Gerritsen, Sylvia
AU  - Gerritsen S
AD  - Department of Ethics, Law, and Humanities, Amsterdam University Medical Center,
      Amsterdam, Netherlands.
FAU - Widdershoven, Guy A M
AU  - Widdershoven GAM
AD  - Department of Ethics, Law, and Humanities, Amsterdam University Medical Center,
      Amsterdam, Netherlands.
FAU - Bossenbroek, Bernard J
AU  - Bossenbroek BJ
AD  - Fivoor, Forensische Psychiatrische Afdeling/Forensische Psychiatrische Kliniek,
      Rotterdam, Netherlands.
FAU - Voskes, Yolande
AU  - Voskes Y
AD  - Department of Ethics, Law, and Humanities, Amsterdam University Medical Center,
      Amsterdam, Netherlands.
AD  - GGz Breburg, Tilburg, Netherlands.
AD  - Tranzo, Tilburg University, Tilburg, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7655130
OTO - NOTNLM
OT  - clinical ethics support (CES)
OT  - contact-based approach
OT  - forensic psychiatry
OT  - moral case deliberation
OT  - moral dilemma
OT  - physical intimacy
OT  - safety
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:45
PHST- 2020/06/19 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/11/16 08:45 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpsyt.2020.574336 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Oct 27;11:574336. doi: 10.3389/fpsyt.2020.574336.
      eCollection 2020.


PMID- 33192677
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Removing Compliance: Interpersonal and Social Factors Affecting Insight
      Assessments.
PG  - 560039
LID - 10.3389/fpsyt.2020.560039 [doi]
AB  - This paper probes the format and underlying assumptions of insight
      conceptualizations and assessment procedures in psychiatry. It does so with
      reference to the often-neglected perspective of the assessed person. It
      delineates what the mental steps involved in an insight assessment are for the
      assessed person, and how they become affected by the context and dynamics of the 
      clinical setting. The paper examines how expectations of compliance in insight
      assessment tools and procedures extend far beyond treatment adherence, to
      compliance with diagnostic language and the assessment relationship. Such
      compliance can be ethically problematic and not in line with human rights
      standards, notably the Convention on the Rights of Persons with Disabilities.
      Most importantly, it can be counterproductive in supporting an individual to gain
      better insight in the sense of self-knowledge. The paper concludes with
      guidelines for a new approach to insight. This new approach requires taking into 
      account currently neglected components of insight, in particular its relational
      and social dimensions, through which a person's insight operates and develops,
      and through which it could be supported. Concretely, this would mean removing the
      condition of compliance and reflecting on the influence of the clinician-patient 
      relationship and assessment situation on insight.
CI  - Copyright (c) 2020 Curk, Gurbai and Freyenhagen.
FAU - Curk, Polona
AU  - Curk P
AD  - Independent Researcher, London, United Kingdom.
FAU - Gurbai, Sandor
AU  - Gurbai S
AD  - Human Rights Centre, School of Law, University of Essex, Colchester, United
      Kingdom.
AD  - Essex Autonomy Project, School of Philosophy and Art History, University of
      Essex, Colchester, United Kingdom.
AD  - Faculty of Special Needs Education, Institute for Disability and Social
      Participation, ELTE Eotvos Lorand University, Budapest, Hungary.
FAU - Freyenhagen, Fabian
AU  - Freyenhagen F
AD  - Human Rights Centre, School of Law, University of Essex, Colchester, United
      Kingdom.
AD  - School of Philosophy and Art History, University of Essex, Colchester, United
      Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7533568
OTO - NOTNLM
OT  - clinical insight
OT  - human rights
OT  - insight assessment
OT  - supporting insight
OT  - therapeutic relationship
OT  - treatment compliance
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:45
PHST- 2020/05/07 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/11/16 08:45 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpsyt.2020.560039 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Sep 17;11:560039. doi: 10.3389/fpsyt.2020.560039.
      eCollection 2020.


PMID- 33192675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - The Role of Parental Capacity for Medical Decision-Making in Medical Ethics and
      the Care of Psychiatrically Ill Youth: Case Report.
PG  - 559263
LID - 10.3389/fpsyt.2020.559263 [doi]
AB  - Introduction: Parents/legal guardians are medical decision-makers for their minor
      children. Lack of parental capacity to appreciate the implications of the
      diagnosis and consequences of refusing recommended treatment may impede pediatric
      patients from receiving adequate medical care. Child and adolescent psychiatrists
      (CAPs) need to appreciate the ethical considerations relevant to overriding
      parental medical decision-making when faced with concerns for medical neglect.
      Methods: Two de-identified cases illustrate the challenges inherent in clinical
      and ethical decision-making reflected in concerns for parental capacity for
      medical decision-making. Key ethical principles are reviewed. Case 1: Treatment
      of an adolescent with an eating disorder ethically complex due to the legal
      guardian's inability to adhere with treatment recommendations leading to the
      patient's recurrent abrupt weight loss. Case 2: Questions of parental decisional 
      capacity amid treatment of an adolescent with schizoaffective disorder raised due
      to parental mistrust of diagnosis, disagreement with treatment recommendations,
      and lack of appreciation of the medical severity of the situation with repeated
      discharges against medical advice and medication nonadherence. Discussion:
      Decisions to question parental capacity for medical decision-making when risk of 
      imminent harm is low but concern for medical neglect exists are controversial.
      Systematic review of cases concerning for medical neglect benefits from the
      assessment of parental decisional capacity, review of ethical standards and
      principles. Conclusion: Recognition of the importance of parental decision-making
      capacity as relates to parental autonomy and medical neglect and understanding
      key ethical principles will enhance the CAP's capacity in medical decision-making
      when stakes are high and absolute recommendations are lacking.
CI  - Copyright (c) 2020 Bieber, Edelsohn, McGee, Shekunov, Romanowicz, Vande Voort and
      McKean.
FAU - Bieber, Ewa D
AU  - Bieber ED
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United
      States.
FAU - Edelsohn, Gail A
AU  - Edelsohn GA
AD  - Community Care Behavioral Health Organization, UPMC Insurance Division,
      Pittsburgh, PA, United States.
FAU - McGee, Maria E
AU  - McGee ME
AD  - Department of Psychiatry, Creighton University School of Medicine, Omaha, NE,
      United States.
FAU - Shekunov, Julia
AU  - Shekunov J
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United
      States.
FAU - Romanowicz, Magdalena
AU  - Romanowicz M
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United
      States.
FAU - Vande Voort, Jennifer L
AU  - Vande Voort JL
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United
      States.
FAU - McKean, Alastair J S
AU  - McKean AJS
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7644854
OTO - NOTNLM
OT  - child and adolescent psychiatry
OT  - decisional capacity
OT  - ethical dilemma
OT  - harm principle
OT  - medical neglect
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:45
PHST- 2020/05/05 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/11/16 08:45 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpsyt.2020.559263 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Oct 23;11:559263. doi: 10.3389/fpsyt.2020.559263.
      eCollection 2020.


PMID- 33192647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210204
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Sharing Clinical Notes in Psychotherapy: A New Tool to Strengthen Patient
      Autonomy.
PG  - 527872
LID - 10.3389/fpsyt.2020.527872 [doi]
FAU - Blease, Charlotte R
AU  - Blease CR
AD  - OpenNotes, General Medicine and Primary Care Research, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, MA, United States.
FAU - Walker, Jan
AU  - Walker J
AD  - OpenNotes, General Medicine and Primary Care Research, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, MA, United States.
FAU - Torous, John
AU  - Torous J
AD  - Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard
      Medical School, Boston, MA, United States.
FAU - O'Neill, Stephen
AU  - O'Neill S
AD  - OpenNotes, General Medicine and Primary Care Research, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, MA, United States.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
EIN - Front Psychiatry. 2021 Jan 18;11:636411. PMID: 33536954
PMC - PMC7655789
OTO - NOTNLM
OT  - electronic health records
OT  - evidence- based practice
OT  - informed consent
OT  - open notes
OT  - patient autonomy
OT  - psychotherapy
OT  - psychotherapy ethics
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:45
PHST- 2020/01/17 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/11/16 08:45 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fpsyt.2020.527872 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Oct 28;11:527872. doi: 10.3389/fpsyt.2020.527872.
      eCollection 2020.


PMID- 33192414
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201118
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Linking)
VI  - 14
DP  - 2020
TI  - Publication of Study Exit Procedures in Clinical Trials of Deep Brain
      Stimulation: A Focused Literature Review.
PG  - 581090
LID - 10.3389/fnhum.2020.581090 [doi]
AB  - Considerable variability exists in the publication of clinical research study
      procedures related to study enrollment and participant exit from clinical trials.
      Despite recent efforts to encourage research data sharing and greater
      transparency regarding research outcomes, reporting of research procedures
      remains inconsistent. Transparency about study procedures has important
      implications for the interpretation of study outcomes and the consistent
      implementation of best practices in clinical trial design and conduct. This
      review of publications from clinical trials of deep brain stimulation (DBS) using
      the MEDLINE database examines the frequency and consistency of publication of
      research procedures and data related to exit from DBS research. Related
      considerations, such as device explant or continued use, battery and other device
      hardware replacements, and post-trial follow-up care are also reviewed. This
      review finds significant variability in the publication and reporting of study
      exit procedures. Of the 47 clinical trials included in this review, 19% (9)
      disclosed procedures related to exit from research. Reporting of other
      exit-related data and study procedures examined in this review was identified in 
      fewer than half of the included clinical trials. The rate of participant
      retention and duration of follow-up was reported more than any other category of 
      data included in this review. Results inform efforts to improve consistency in
      research design, conduct, and publication of results from clinical trials in DBS 
      and related areas of clinical research.
CI  - Copyright (c) 2020 Sankary, Nallapan, Hogue, Machado and Ford.
FAU - Sankary, Lauren R
AU  - Sankary LR
AD  - Neuroethics Program, Cleveland Clinic, Cleveland, OH, United States.
AD  - Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
FAU - Nallapan, Akila M
AU  - Nallapan AM
AD  - School of Graduate Studies, Case Western Reserve University, Cleveland, OH,
      United States.
FAU - Hogue, Olivia
AU  - Hogue O
AD  - Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland 
      Clinic, Cleveland, OH, United States.
FAU - Machado, Andre G
AU  - Machado AG
AD  - Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland 
      Clinic, Cleveland, OH, United States.
FAU - Ford, Paul J
AU  - Ford PJ
AD  - Neuroethics Program, Cleveland Clinic, Cleveland, OH, United States.
LA  - eng
GR  - F32 MH115419/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201021
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC7609884
OTO - NOTNLM
OT  - deep brain stimulation
OT  - neuro-psychiatric disorders
OT  - neuroethics
OT  - neuromodulation
OT  - research ethics
OT  - review
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 08:44
PHST- 2020/07/07 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/11/16 08:44 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
AID - 10.3389/fnhum.2020.581090 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2020 Oct 21;14:581090. doi: 10.3389/fnhum.2020.581090.
      eCollection 2020.


PMID- 33191803
OWN - NLM
STAT- Publisher
LR  - 20220422
IS  - 1360-046X (Electronic)
IS  - 0268-8697 (Linking)
DP  - 2020 Nov 16
TI  - Introduction of a newly created AW stereotactic frame: a phantom-based accuracy
      evaluation and an initial experience in clinical usage.
PG  - 1-8
LID - 10.1080/02688697.2020.1837728 [doi]
AB  - BACKGROUND: A new stereotactic frame was created in 2015, based on a linear
      algorithm. It is called Albert Wong (AW) frame. A simple AW stereo-calculator was
      also designed based on Excel((R)) (Microscoft Corporation, Redmond, WA) programme
      for the frame. OBJECTIVE: The aim of this study is to test the accuracy of the AW
      frame by a direct head to head comparison with CRW((R)) frame (Integra Life
      Sciences, Plainsboro, NJ) on a phantom. METHODS: This is a prospective pilot
      cross-sectional phantom study with a total of 42 (21 for AW and 21 for CRW((R))) 
      laboratory testings performed in 2017 at our institute to compare the accuracies 
      of both frames in a consecutive manner. A phantom (BL phantom) was newly created,
      where targets can be placed at different heights and positions on a platform
      attached under the frame for accuracy testing comparing between the AW and
      CRW((R)) frames. RESULTS: A comparable accuracy testing results were observed
      between the AW and CRW((R)) frames of 0.64 mm versus 1.07 mm respectively.
      Approval from the local ethics committee for a clinical trial was obtained. We
      report on three case illustrations who had the AW frame-based biopsies with
      definitive diagnoses and without any post-biopsy related complication.
      CONCLUSION: AW frame successfully demonstrated a good accuracy of 0.64 mm in
      phantom testing using the BL phantom by a linear algorithmic calculation. The
      clinical trial with three patients demonstrated definitive diagnoses and safety
      with its use.
FAU - Lau, Bik Liang
AU  - Lau BL
AD  - Department of Neurosciences, School of Medical Sciences, Universiti Sains
      Malaysia, Kubang Kerian, Kelantan, Malaysia.
AD  - Department of Neurosurgery, Sarawak General Hospital, Ministry of Health, Jalan
      Hospital, Kuching, Sarawak, Malaysia.
FAU - Idris, Zamzuri
AU  - Idris Z
AD  - Department of Neurosciences, School of Medical Sciences, Universiti Sains
      Malaysia, Kubang Kerian, Kelantan, Malaysia.
AD  - Brain Behaviour Cluster, Universiti Sains Malaysia, Kubang Kerian, Kelantan,
      Malaysia.
FAU - Abdullah, Jafri Malin
AU  - Abdullah JM
AD  - Department of Neurosciences, School of Medical Sciences, Universiti Sains
      Malaysia, Kubang Kerian, Kelantan, Malaysia.
AD  - Brain Behaviour Cluster, Universiti Sains Malaysia, Kubang Kerian, Kelantan,
      Malaysia.
FAU - Bujang, Mohamad Adam
AU  - Bujang MA
AD  - Clinical Research Centre, Sarawak General Hospital, Ministry of Health, Jalan
      Hospital, Kuching, Sarawak, Malaysia.
FAU - Wong, Albert Sii Hieng
AU  - Wong ASH
AD  - Department of Neurosurgery, Sarawak General Hospital, Ministry of Health, Jalan
      Hospital, Kuching, Sarawak, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - England
TA  - Br J Neurosurg
JT  - British journal of neurosurgery
JID - 8800054
SB  - IM
OTO - NOTNLM
OT  - AW frame
OT  - CRW(R) frame
OT  - Stereotactic
OT  - accuracy
OT  - biopsy
OT  - phantom
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:00
CRDT- 2020/11/16 08:41
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:00 [medline]
PHST- 2020/11/16 08:41 [entrez]
AID - 10.1080/02688697.2020.1837728 [doi]
PST - aheadofprint
SO  - Br J Neurosurg. 2020 Nov 16:1-8. doi: 10.1080/02688697.2020.1837728.


PMID- 33191266
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - Uptake and use of a minimum data set (MDS) for older people living and dying in
      care homes in England: a realist review protocol.
PG  - e040397
LID - 10.1136/bmjopen-2020-040397 [doi]
AB  - INTRODUCTION: Care homes provide nursing and social care for older people who can
      no longer live independently at home. In the UK, there is no consistent approach 
      to how information about residents' medical history, care needs and preferences
      are collected and shared. This limits opportunities to understand the care home
      population, have a systematic approach to assessment and documentation of care,
      identifiy care home residents at risk of deterioration and review care. Countries
      with standardised approaches to residents' assessment, care planning and review
      (eg, minimum data sets (MDS)) use the data to understand the care home
      population, guide resource allocation, monitor services delivery and for
      research. The aim of this realist review is to develop a theory-driven
      understanding of how care home staff implement and use MDS to plan and deliver
      care of individual residents. METHODS AND ANALYSIS: A realist review will be
      conducted in three research stages.Stage 1 will scope the literature and develop 
      candidate programme theories of what ensures effective uptake and sustained
      implementation of an MDS.Stage2 will test and refine these theories through
      further iterative searches of the evidence from the literature to establish how
      effective uptake of an MDS can be achieved.Stage 3 will consult with relevant
      stakeholders to test or refine the programme theory (theories) of how an MDS
      works at the resident level of care for different stakeholders and in what
      circumstances. Data synthesis will use realist logic to align data from each
      eligible article with possible context-mechanism-outcome configurations or
      specific elements that answer the research questions. ETHICS AND DISSEMINATION:
      The University of Hertfordshire Ethics Committee has approved this study
      (HSK/SF/UH/04169). Findings will be disseminated through briefings with
      stakeholders, conference presentations, a national consultation on the use of an 
      MDS in UK long-term care settings, publications in peer-reviewed journals and in 
      print and social media publications accessible to residents, relatives and care
      home staff. PROSPERO REGISTRATION NUMBER: CRD42020171323; this review protocol is
      registered on the International Prospective Register of Systematic Reviews.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Musa, Massirfufulay Kpehe
AU  - Musa MK
AUID- ORCID: 0000-0001-5506-4720
AD  - Faculty of Nursing, Midwifery and Palliative Care, King's College London, London,
      UK.
AD  - Centre for Research in Public health and Community Care (CRIPACC), School of
      Health and Social Work, University of Hertfordshire, Hatfield, United Kingdom.
FAU - Akdur, Gizdem
AU  - Akdur G
AUID- ORCID: 0000-0001-7326-4750
AD  - Centre for Research in Public health and Community Care (CRIPACC), School of
      Health and Social Work, University of Hertfordshire, Hatfield, United Kingdom.
FAU - Hanratty, Barbara
AU  - Hanratty B
AUID- ORCID: 0000-0002-3122-7190
AD  - Population Health Sciences Institute, Campus for Ageing and Vitality, Newcastle
      University, Newcastle upon Tyne, United Kingdom.
AD  - NIHR Applied Research Collaboration, North East and North Cumbra, UK.
FAU - Kelly, Sarah
AU  - Kelly S
AUID- ORCID: 0000-0002-1114-2456
AD  - Institute of Public Health, University of Cambridge, Cambridge, UK.
FAU - Gordon, Adam
AU  - Gordon A
AUID- ORCID: 0000-0003-1676-9853
AD  - Division of Rehabilitation, Ageing and Wellbeing, School of Medicine, University 
      of Nottingham, Nottingham, United Kingdom.
AD  - NIHR Applied Research Collaboration, East Midlands, UK.
FAU - Peryer, Guy
AU  - Peryer G
AUID- ORCID: 0000-0003-0425-6911
AD  - Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
FAU - Spilsbury, Karen
AU  - Spilsbury K
AUID- ORCID: 0000-0002-6908-0032
AD  - School of Healthcare, University of Leeds, Leeds, UK.
AD  - NIHR Applied Research Collaboration, Yorkshire and Humber, UK.
FAU - Killett, Anne
AU  - Killett A
AD  - Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
FAU - Burton, Jennifer
AU  - Burton J
AUID- ORCID: 0000-0002-4752-6988
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      UK.
FAU - Meyer, Julienne
AU  - Meyer J
AD  - National Care Forum/Care for Older People, School of Health Sciences, Division of
      Nursing, City, University of London, London, United Kingdom.
FAU - Fortescue, Sue
AU  - Fortescue S
AD  - Alzheimer Society Research Network, London, UK.
FAU - Towers, Ann-Marie
AU  - Towers AM
AUID- ORCID: 0000-0003-3597-1061
AD  - Centre for Health Services Studies, University of Kent, Canterbury, UK.
AD  - NIHR Applied Research Collaboration, Kent Surrey and Sussex, UK.
FAU - Irvine, Lisa
AU  - Irvine L
AUID- ORCID: 0000-0003-1936-3584
AD  - Centre for Research in Public health and Community Care (CRIPACC), School of
      Health and Social Work, University of Hertfordshire, Hatfield, United Kingdom.
FAU - Goodman, Claire
AU  - Goodman C
AUID- ORCID: 0000-0002-8938-4893
AD  - Centre for Research in Public health and Community Care (CRIPACC), School of
      Health and Social Work, University of Hertfordshire, Hatfield, United Kingdom
      c.goodman@herts.ac.uk.
AD  - NIHR Applied Research Collaboration, East of England, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - England
MH  - *Homes for the Aged
MH  - Humans
MH  - *Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7668360
OTO - NOTNLM
OT  - *epidemiology
OT  - *geriatric medicine
OT  - *health services administration & management
OT  - *palliative care
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/11/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/16 05:57 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040397 [pii]
AID - 10.1136/bmjopen-2020-040397 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e040397. doi: 10.1136/bmjopen-2020-040397.


PMID- 33191263
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201210
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - Efficacy and safety of early treatment with sarilumab in hospitalised adults with
      COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a
      phase II, open-label, randomised, multicentre, controlled clinical trial.
PG  - e039951
LID - 10.1136/bmjopen-2020-039951 [doi]
AB  - INTRODUCTION: About 25% of patients with COVID-19 develop acute respiratory
      distress syndrome (ARDS) associated with a high release of pro-inflammatory
      cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to
      demonstrate that early administration of sarilumab (an IL-6 receptor inhibitor)
      in hospitalised patients with COVID-19, pulmonary infiltrates and a high IL-6 or 
      D-dimer serum level could reduce the progression of ARDS requiring high-flow
      nasal oxygen or mechanical ventilation (non-invasive or invasive). METHODS AND
      ANALYSIS: Phase II, open-label, randomised, multicentre, controlled clinical
      trial to study the efficacy and safety of the administration of two doses of
      sarilumab (200 and 400 mg) plus best available therapy (BAT) in hospitalised
      adults with COVID-19 presenting cytokine release syndrome. This strategy will be 
      compared with a BAT control group. The efficacy and safety will be monitored up
      to 28 days postadministration. A total of 120 patients will be recruited (40
      patients in each arm). ETHICS AND DISSEMINATION: The clinical trial has been
      approved by the Research Ethics Committee of the coordinating centre and
      authorised by the Spanish Agency of Medicines and Medical Products. If the
      hypothesis is verified, the dissemination of the results could change clinical
      practice by increasing early administration of sarilumab in adult patients with
      COVID-19 presenting cytokine release syndrome, thus reducing intensive care unit 
      admissions. TRIAL REGISTRATION NUMBER: NCT04357860.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Leon Lopez, Rafael
AU  - Leon Lopez R
AD  - Intensive Care Unit, Hospital Universitario Reina Sofia, Cordoba, Andalucia,
      Spain.
AD  - IMIBIC, Cordoba, Andalucia, Spain.
FAU - Fernandez, Sheila Carcel
AU  - Fernandez SC
AUID- ORCID: 0000-0002-8102-9520
AD  - Intensive Care Unit, Hospital Universitario Reina Sofia, Cordoba, Andalucia,
      Spain.
AD  - IMIBIC, Cordoba, Andalucia, Spain.
FAU - Limia Perez, Laura
AU  - Limia Perez L
AD  - IMIBIC, Cordoba, Andalucia, Spain.
AD  - Internal Medicine Unit, Hospital Universitario Reina Sofia, Cordoba, Andalucia,
      Spain.
FAU - Romero Palacios, Alberto
AU  - Romero Palacios A
AD  - Infectious Diseases Unit, Hospital Universitario de Puerto Real, Puerto Real,
      Andalucia, Spain.
FAU - Fernandez-Roldan, Maria Concepcion
AU  - Fernandez-Roldan MC
AD  - Infectious Diseases Unit, Hospital Universitario Virgen de las Nieves, Granada,
      Andalucia, Spain.
FAU - Aguilar Alonso, Eduardo
AU  - Aguilar Alonso E
AD  - Intensive Care Unit, Hospital Infanta Margarita, Cabra, Andalucia, Spain.
FAU - Perez Camacho, Ines
AU  - Perez Camacho I
AD  - Infectious Diseases Unit, Hospital Regional Universitario de Malaga, Malaga,
      Andalucia, Spain.
FAU - Rodriguez-Bano, Jesus
AU  - Rodriguez-Bano J
AD  - Infectious Diseases Unit, Hospital Universitario Virgen Macarena, Sevilla,
      Andalucia, Spain.
AD  - Spanish Network for Research in Infectious Diseases, Carlos III Health Institute,
      Madrid, Comunidad de Madrid, Spain.
FAU - Merchante, Nicolas
AU  - Merchante N
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de
      Valme, Sevilla, Andalucia, Spain.
FAU - Olalla, Julian
AU  - Olalla J
AD  - Internal Medicine Service, Hospital Costa del Sol, Marbella, Andalucia, Spain.
FAU - Esteban-Moreno, M Angeles
AU  - Esteban-Moreno MA
AD  - Infectious Diseases Unit, Complejo Hospitalario Torrecardenas, Almeria,
      Andalucia, Spain.
FAU - Santos, Marta
AU  - Santos M
AD  - Infectious Diseases Unit, Hospital Universitario de Jerez de la Frontera, Jerez
      de la Frontera, Andalucia, Spain.
FAU - Luque-Pineda, Antonio
AU  - Luque-Pineda A
AUID- ORCID: 0000-0002-4353-3662
AD  - Clinical Trials Unit, IMIBIC, Cordoba, Spain antonio.luque@imibic.org.
AD  - Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain.
FAU - Torre-Cisneros, Julian
AU  - Torre-Cisneros J
AD  - IMIBIC, Cordoba, Andalucia, Spain.
AD  - Internal Medicine Unit, Hospital Universitario Reina Sofia, Cordoba, Andalucia,
      Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04357860
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Interleukin-6)
RN  - 0 (fibrin fragment D)
RN  - NU90V55F8I (sarilumab)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials, Phase II as Topic
MH  - Coronavirus Infections/*drug therapy/immunology
MH  - Cytokine Release Syndrome/*drug therapy/immunology
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/metabolism
MH  - Humans
MH  - Interleukin-6/immunology
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/immunology
MH  - Randomized Controlled Trials as Topic
MH  - Respiration, Artificial
MH  - Respiratory Distress Syndrome/*drug therapy/immunology
MH  - SARS-CoV-2
MH  - Young Adult
PMC - PMC7668373
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *infectious diseases
OT  - *internal medicine
OT  - *virology
COIS- Competing interests: None declared.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/16 05:57 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjopen-2020-039951 [pii]
AID - 10.1136/bmjopen-2020-039951 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e039951. doi: 10.1136/bmjopen-2020-039951.


PMID- 33191260
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - ASPIRE trial: study protocol for a double-blind randomised controlled trial of
      aspirin for overheating during exercise in multiple sclerosis.
PG  - e039691
LID - 10.1136/bmjopen-2020-039691 [doi]
AB  - INTRODUCTION: The many benefits of exercise for persons with multiple sclerosis
      (MS) are well established, yet patients often refrain from exercise due to
      overheating and exhaustion. The present randomised controlled trial tests aspirin
      (acetylsalicylic acid (ASA)) as a convenient method to prevent overheating and
      improve exercise performance in persons with MS. The effects of ASA are compared 
      with those of acetaminophen (APAP) and placebo. METHODS AND ANALYSIS:
      Participants are seen for a laboratory maximal exercise test on 3 separate days
      separated by at least 1 week. At each session, body temperature is measured
      before oral administration of a standard adult dose (650 mg) of ASA, APAP or
      placebo. One hour after drug administration, participants perform a maximal ramp 
      test on a cycle ergometer. Primary outcomes are (a) time to exhaustion (that is, 
      time spent cycling to peak exertion) and (b) body temperature change. Crossover
      analyses will include tests for effects of treatment, period, treatment-period
      interaction (carryover effect) and sequence. ETHICS AND DISSEMINATION: Ethical
      approval was granted by the institutional review board at Columbia University
      Irving Medical Center (reference: AAAS2529). Results of the trial will be
      published in peer-reviewed scientific journals and presented at national and
      international conferences. Neurologists, physiatrists, primary care physicians
      and physiotherapists are important stakeholders and will be targeted during
      dissemination. Positive trial results have the potential to promote aspirin
      therapy, an inexpensive and readily available treatment, to reduce overheating
      and allow more persons with MS to benefit from exercise. TRIAL REGISTRATION
      NUMBER: NCT03824938.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kever, Anne
AU  - Kever A
AUID- ORCID: 0000-0002-3860-6839
AD  - Translational Cognitive Neuroscience Laboratory, Department of Neurology,
      Columbia University Irving Medical Center, New York, NY, USA.
FAU - Nelson, Katherine E
AU  - Nelson KE
AD  - Translational Cognitive Neuroscience Laboratory, Department of Neurology,
      Columbia University Irving Medical Center, New York, NY, USA.
AD  - Center for Translational & Computational Neuroimmunology, Department of
      Neurology, Columbia University Irving Medical Center, New York, NY, USA.
AD  - Multiple Sclerosis Center, Department of Neurology, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Aguerre, Ines M
AU  - Aguerre IM
AD  - Translational Cognitive Neuroscience Laboratory, Department of Neurology,
      Columbia University Irving Medical Center, New York, NY, USA.
AD  - Center for Translational & Computational Neuroimmunology, Department of
      Neurology, Columbia University Irving Medical Center, New York, NY, USA.
AD  - Multiple Sclerosis Center, Department of Neurology, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Riley, Claire S
AU  - Riley CS
AD  - Multiple Sclerosis Center, Department of Neurology, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Boehme, Amelia
AU  - Boehme A
AD  - Department of Neurology and Epidemiology, Columbia University Irving Medical
      Center, New York, NY, USA.
FAU - Lee, Nancy W
AU  - Lee NW
AD  - Department of Rehabilitation and Regenerative Medicine, Columbia University
      Vangelos College of Physicians and Surgeons, New York, NY, USA.
FAU - Strauss Farber, Rebecca
AU  - Strauss Farber R
AD  - Multiple Sclerosis Center, Department of Neurology, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Levin, Seth N
AU  - Levin SN
AD  - Multiple Sclerosis Center, Department of Neurology, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Stein, Joel
AU  - Stein J
AD  - Department of Rehabilitation and Regenerative Medicine, Columbia University
      Vangelos College of Physicians and Surgeons, New York, NY, USA.
FAU - Leavitt, Victoria M
AU  - Leavitt VM
AD  - Translational Cognitive Neuroscience Laboratory, Department of Neurology,
      Columbia University Irving Medical Center, New York, NY, USA
      VL2337@cumc.columbia.edu.
AD  - Multiple Sclerosis Center, Department of Neurology, Columbia University Irving
      Medical Center, New York, NY, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03824938
GR  - R21 HD091836/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - *Multiple Sclerosis/drug therapy
PMC - PMC7668379
OTO - NOTNLM
OT  - *clinical trials
OT  - *multiple sclerosis
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/17 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/16 05:57 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - bmjopen-2020-039691 [pii]
AID - 10.1136/bmjopen-2020-039691 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e039691. doi: 10.1136/bmjopen-2020-039691.


PMID- 33191258
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - Inequalities in the uptake of, adherence to and effectiveness of behavioural
      weight management interventions: systematic review protocol.
PG  - e039518
LID - 10.1136/bmjopen-2020-039518 [doi]
AB  - INTRODUCTION: It has been suggested that interventions focusing on individual
      behaviour change, such as behavioural weight management interventions, may
      exacerbate health inequalities. These intervention-generated inequalities may
      occur at different stages, including intervention uptake, adherence and
      effectiveness. We will synthesise evidence on how different measures of
      inequality moderate the uptake, adherence and effectiveness of behavioural weight
      management interventions in adults. METHODS AND ANALYSIS: We will update a
      previous systematic literature review from the United States Preventive Services 
      Taskforce to identify trials of behavioural weight management interventions in
      adults aged 18 years and over that were, or could feasibly be, conducted in or
      recruited from primary care. Medline, Cochrane database (CENTRAL) and PsycINFO
      will be searched. Only randomised controlled trials (RCTs) and cluster-RCTs will 
      be included. Two investigators will independently screen articles for eligibility
      and conduct risk of bias assessment. We will curate publication families for
      eligible trials. The PROGRESS-Plus acronym (place of residence, race/ethnicity,
      occupation, gender, religion, education, socioeconomic status, social capital,
      plus other discriminating factors) will be used to consider a comprehensive range
      of health inequalities. Data on trial uptake, intervention adherence, weight
      change and PROGRESS-Plus-related data will be extracted. Data will be synthesised
      narratively. We will present a Harvest plot for each PROGRESS-Plus criterion and 
      whether each trial found a negative, positive or no health inequality gradient.
      We will also identify potential sources of unpublished original research data on 
      these factors which can be synthesised through a future individual participant
      data meta-analysis. ETHICS AND DISSEMINATION: Ethical approval is not required as
      no primary data are being collected. The completed systematic review will be
      disseminated in a peer-reviewed journal, at conferences, and contribute to the
      lead author's PhD thesis. Authors of trials included in the completed systematic 
      review may be invited to collaborate on a future individual participant data
      meta-analysis. PROSPERO REGISTRATION NUMBER: CRD42020173242.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Birch, Jack Michael
AU  - Birch JM
AUID- ORCID: 0000-0001-6292-1647
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK jack.birch@mrc-epid.cam.ac.uk.
FAU - Griffin, Simon J
AU  - Griffin SJ
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
AD  - Primary Care Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Kelly, Michael P
AU  - Kelly MP
AD  - Primary Care Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Ahern, Amy L
AU  - Ahern AL
AUID- ORCID: 0000-0001-5069-4758
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
LA  - eng
GR  - MC_UU_00006/6/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12015/4/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - *Nutrition Therapy
MH  - Obesity
MH  - Overweight
MH  - Pregnancy
MH  - *Quality of Life
MH  - Systematic Reviews as Topic
MH  - Weight Loss
PMC - PMC7668382
OTO - NOTNLM
OT  - *preventive medicine
OT  - *primary care
OT  - *public health
COIS- Competing interests: ALA is principal investigator on two publicly funded (NIHR, 
      MRC) trials where the intervention is provided by WW (formerly Weight Watchers)
      at no cost. MPK has undertaken consultancy for Slimming World, and led the
      clinical and public health guidelines development for NICE from 2005 until 2014.
EDAT- 2020/11/17 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/16 05:57 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - bmjopen-2020-039518 [pii]
AID - 10.1136/bmjopen-2020-039518 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e039518. doi: 10.1136/bmjopen-2020-039518.


PMID- 33191256
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 
      diabetes: a systematic review and network meta-analysis protocol.
PG  - e038970
LID - 10.1136/bmjopen-2020-038970 [doi]
AB  - INTRODUCTION: Obesity increases the risk of comorbidities and diabetes-related
      complications and, consequently, efforts to prevent and reduce excess weight in
      people with type 1 diabetes are essential. The aim of this systematic review and 
      network meta-analysis is to assess the effect of adjunctive glucose-lowering
      drugs on body weight and other important health outcomes in people with type 1
      diabetes. METHODS AND ANALYSIS: This systematic review and network meta-analysis 
      will include randomised controlled trials (RCTs) evaluating the use of adjunctive
      glucose-lowering drugs for treatment of people with type 1 diabetes. MEDLINE,
      EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of
      Systematic Reviews, ClinicalTrials.gov and WHO International Clinical Trials
      Registry Platform will be searched from inception to present. Key eligibility
      criteria include: RCT study design; adult participants with type 1 diabetes;
      treatment with a glucose-lowering drug for >/=24 weeks; and comparison of the
      intervention to placebo, usual care or another glucose-lowering drug. The primary
      outcome is change in body weight. Other major outcomes include change in HbA1c
      and total daily insulin dose and risk of hypoglycaemia and other adverse events. 
      Dual study selection, data extraction and risk of bias assessment will be
      performed. Results from the meta-analysis will be presented as weighted mean
      differences for continuous outcomes and risk ratios for dichotomous outcomes.
      Sources of heterogeneity will be explored by subgroup and sensitivity analysis. A
      network meta-analysis for the primary outcome will be performed using an
      arm-based random-effects model based on the Bayesian framework while assessing
      for transitivity across studies and consistency between direct and indirect
      estimates. The overall quality of the evidence will be assessed using the Grading
      of Recommendations, Assessment, Development and Evaluation approach for each
      outcome. ETHICS AND DISSEMINATION: No ethical assessment is required. The results
      of this review will be disseminated through peer-reviewed publication and
      conference presentation. PROSPERO REGISTRATION NUMBER: CRD42020158676.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Laugesen, Christian
AU  - Laugesen C
AUID- ORCID: 0000-0001-9253-9457
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark
      christian.laugesen@regionh.dk.
FAU - Ranjan, Ajenthen G
AU  - Ranjan AG
AUID- ORCID: 0000-0002-2253-6071
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Schmidt, Signe
AU  - Schmidt S
AUID- ORCID: 0000-0002-6968-6675
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Rasmussen, Lauge Neimann
AU  - Rasmussen LN
AUID- ORCID: 0000-0001-9584-2443
AD  - Education, Diabetes Knowledge Center, Steno Diabetes Center Copenhagen, Gentofte,
      Denmark.
FAU - Norgaard, Ole
AU  - Norgaard O
AUID- ORCID: 0000-0002-1681-4338
AD  - Education, Diabetes Knowledge Center, Steno Diabetes Center Copenhagen, Gentofte,
      Denmark.
FAU - Christensen, Robin
AU  - Christensen R
AUID- ORCID: 0000-0002-6600-0631
AD  - Musculoskeletal Statistics Unit, the Parker Institute, Frederiksberg and
      Bispebjerg Hospital, Copenhagen, Denmark.
AD  - Research Unit of Rheumatology, Department of Clinical Research, University of
      Southern Denmark, Odense University Hospital, Odense, Denmark.
FAU - Norgaard, Kirsten
AU  - Norgaard K
AUID- ORCID: 0000-0003-1620-8271
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Bayes Theorem
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 1/drug therapy
MH  - Diabetes Mellitus, Type 2
MH  - Glucose
MH  - Humans
MH  - Network Meta-Analysis
MH  - Pharmaceutical Preparations
PMC - PMC7668353
OTO - NOTNLM
OT  - *clinical trials
OT  - *diabetes & endocrinology
OT  - *statistics & research methods
OT  - *therapeutics
COIS- Competing interests: CL, AGR, SS, LNR, ON and RC have nothing to disclose. KN
      owns shares in Novo Nordisk and has received research grants and fees for
      lecturing from Novo Nordisk and Zealand Pharma. No other potential conflicts of
      interest relevant to this article were reported.
EDAT- 2020/11/17 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/11/16 05:57
PHST- 2020/11/16 05:57 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - bmjopen-2020-038970 [pii]
AID - 10.1136/bmjopen-2020-038970 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e038970. doi: 10.1136/bmjopen-2020-038970.


PMID- 33191252
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - Embryo incubation by time-lapse systems versus conventional incubators in Chinese
      women with diminished ovarian reserve undergoing IVF/ICSI: a study protocol for a
      randomised controlled trial.
PG  - e038657
LID - 10.1136/bmjopen-2020-038657 [doi]
AB  - INTRODUCTION: The time-lapse imaging system (TLS) is a newly developed
      non-invasive embryo assessment system. Compared with conventional incubators, a
      TLS provides stable culture conditions and consistent observations of embryo
      development, thereby potentially improving embryo quality and selection of the
      best quality embryo. Although TLSs have been routinely used in many in vitro
      fertilisation (IVF) centres globally, there is insufficient evidence to indicate 
      that TLSs result in higher cumulative live birth rates over conventional
      incubators. The purpose of this study is to compare the cumulative live birth
      rates and safety including miscarriage in infertile patients with diminished
      ovarian reserve (DOR) from both TLSs and conventional incubators. METHODS AND
      ANALYSIS: This study is a double-blind randomised controlled clinical trial (1:1 
      treatment ratio of TLSs vs conventional incubator). A total of 730 patients with 
      DOR undergoing the first or second cycle of IVF or intracytoplasmic sperm
      injection (ICSI) will be enrolled and randomised into two parallel groups.
      Participants will undergo embryo culture in the TLSs (group A) or the
      conventional incubators (group B), respectively. Embryos are selected for
      transfer in both groups by the morphological characteristics. The embryo
      selection algorithm software is not used in the TLSs. The primary outcome is the 
      cumulative live birth rate of the trial IVF/ICSI cycle within 12 months after
      randomisation. This study is powered to detect an absolute difference of 10% (35%
      vs 25%) at the significance level of 0.05% and 80% statistical power based on a
      two-sided test. ETHICS AND DISSEMINATION: This trial has been approved by the
      Institutional Ethical Committee of Shanghai First Maternity and Infant Hospital
      (KS1958). All participants in the trial will provide written informed consent.
      The study will be conducted according to the principles outlined in the
      Declaration of Helsinki and its amendments. Results of this study will be
      disseminated in peer-reviewed scientific journals. TRIAL REGISTRATION NUMBER:
      Chinese Clinical Trial Registry (ChiCTR1900027746).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Miaoxin
AU  - Chen M
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Wu, Yuanyuan
AU  - Wu Y
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Huang, Xin
AU  - Huang X
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Li, Wentao
AU  - Li W
AD  - Department of Obstetrics and Gynaecology, Monash Medical Centre, Monash
      University, Melbourne, Victoria, Australia.
FAU - Sun, Chunyan
AU  - Sun C
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Meng, Zhenzhen
AU  - Meng Z
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Ai, Ai
AU  - Ai A
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Hong, Ling
AU  - Hong L
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Tang, Chuanling
AU  - Tang C
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Li, Kunming
AU  - Li K
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Fu, Yonglun
AU  - Fu Y
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Chen, Zhiqin
AU  - Chen Z
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Kong, Pengcheng
AU  - Kong P
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Guo, Yi
AU  - Guo Y
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Liu, Wenqiang
AU  - Liu W
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China.
FAU - Mol, Ben W
AU  - Mol BW
AUID- ORCID: 0000-0001-8337-550X
AD  - Department of Obstetrics and Gynaecology, Monash Medical Centre, Monash
      University, Melbourne, Victoria, Australia.
FAU - Teng, Xiaoming
AU  - Teng X
AUID- ORCID: 0000-0003-3810-4027
AD  - Centre for Reproductive Medicine, Shanghai First Maternity and Infant Hospital,
      Tongji University School of Medicine, Shanghai, China tengxiaoming@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - Double-Blind Method
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - Incubators
MH  - Infant, Newborn
MH  - *Ovarian Reserve
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - *Premature Birth
MH  - Sperm Injections, Intracytoplasmic
MH  - Time-Lapse Imaging
PMC - PMC7668367
OTO - NOTNLM
OT  - *embryology
OT  - *fetal medicine
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/17 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/11/16 05:56
PHST- 2020/11/16 05:56 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - bmjopen-2020-038657 [pii]
AID - 10.1136/bmjopen-2020-038657 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e038657. doi: 10.1136/bmjopen-2020-038657.


PMID- 33191251
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 14
TI  - Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65):
      protocol and statistical analysis plan for a randomised clinical trial.
PG  - e037947
LID - 10.1136/bmjopen-2020-037947 [doi]
AB  - INTRODUCTION: Vasodilatory hypotension is common among intensive care unit (ICU) 
      patients; vasopressors are considered standard of care. However, optimal mean
      arterial pressure (MAP) targets for vasopressor titration are unknown. The
      objective of the Optimal VAsopressor TitraTION in patients 65 years and older
      (OVATION-65) trial is to ascertain the effect of permissive hypotension
      (vasopressor titration to achieve MAP 60-65 mm Hg) versus usual care on
      biomarkers of organ injury in hypotensive patients aged >/=65 years. METHODS AND 
      ANALYSIS: OVATION-65 is an allocation-concealed randomised trial in 7 Canadian
      hospitals. Eligible patients are >/=65 years of age, in an ICU with vasodilatory 
      hypotension, receiving vasopressors for </=12 hours to maintain MAP >/=65 mm Hg
      during or after adequate fluid resuscitation, and expected to receive
      vasopressors for >/=6 additional hours. Patients are excluded for any of the
      following: active treatment for spinal cord or acute brain injury; vasopressors
      given solely for bleeding, ventricular failure or postcardiopulmonary bypass
      vasoplegia; withdrawal of life-sustaining treatments expected within 48 hours;
      death perceived as imminent; previous enrolment in OVATION-65; organ transplant
      within the last year; receiving extracorporeal life support or lack of physician 
      equipoise. Patients are randomised to permissive hypotension versus usual care
      for up to 28 days. The primary outcome is high-sensitivity troponin T, a
      biomarker of cardiac injury, on day 3. Secondary outcomes include biomarkers of
      injury to other organs (brain, liver, intestine, skeletal muscle); lactate (a
      biomarker of global tissue dysoxia); resource utilisation; adverse events;
      mortality (90 days and 6 months) and cognitive function (6 months). Assessors of 
      biomarkers, mortality and cognitive function are blinded to allocation. ETHICS
      AND DISSEMINATION: This protocol has been approved at all sites. Consent is
      obtained from the eligible patient, the substitute decision-maker if the patient 
      is incapable, or in a deferred fashion where permitted. End-of-grant
      dissemination plans include presentations, publications and social media
      platforms and discussion forums. TRIAL REGISTRATION NUMBER: NCT03431181.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Masse, Marie-Helene
AU  - Masse MH
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
FAU - Battista, Marie-Claude
AU  - Battista MC
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Wilcox, Mary Elizabeth
AU  - Wilcox ME
AD  - Interdepartmental Division of Critical Care Medicine, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Department of Medicine, University Health Network, Toronto, Ontario, Canada.
FAU - Pinto, Ruxandra
AU  - Pinto R
AD  - Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada.
FAU - Marinoff, Nicole
AU  - Marinoff N
AD  - Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada.
FAU - D'Aragon, Frederick
AU  - D'Aragon F
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
AD  - Department of Anesthesiology, Universite de Sherbrooke, Sherbrooke, Quebec,
      Canada.
FAU - St-Arnaud, Charles
AU  - St-Arnaud C
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Mayette, Michael
AU  - Mayette M
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Leclair, Marc-Andre
AU  - Leclair MA
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Quiroz Martinez, Hector
AU  - Quiroz Martinez H
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Grondin-Beaudoin, Brian
AU  - Grondin-Beaudoin B
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Poulin, Yannick
AU  - Poulin Y
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Carbonneau, Elaine
AU  - Carbonneau E
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
FAU - Seely, Andrew J E
AU  - Seely AJE
AD  - Departments of Surgery and Critical Care Medicine, University of Ottawa, Ottawa, 
      Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Watpool, Irene
AU  - Watpool I
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Porteous, Rebecca
AU  - Porteous R
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Chasse, Michael
AU  - Chasse M
AD  - Department of Medicine, Universite de Montreal, Montreal, Quebec, Canada.
AD  - Centre de recherche, Centre Hospitalier de l'Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Lebrasseur, Martine
AU  - Lebrasseur M
AD  - Centre de recherche, Centre Hospitalier de l'Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Lauzier, Francois
AU  - Lauzier F
AD  - Population Health and Optimal Health Practices Research Unit, Centre de recherche
      du CHU de Quebec-Universite Laval, Quebec, Quebec, Canada.
FAU - Turgeon, Alexis F
AU  - Turgeon AF
AUID- ORCID: 0000-0001-5675-8791
AD  - Population Health and Optimal Health Practices Research Unit, Centre de recherche
      du CHU de Quebec-Universite Laval, Quebec, Quebec, Canada.
FAU - Bellemare, David
AU  - Bellemare D
AD  - Population Health and Optimal Health Practices Research Unit, Centre de recherche
      du CHU de Quebec-Universite Laval, Quebec, Quebec, Canada.
FAU - Mehta, Sangeeta
AU  - Mehta S
AD  - Interdepartmental Division of Critical Care Medicine, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.
FAU - Charbonney, Emmanuel
AU  - Charbonney E
AD  - Department of Medicine, Universite de Montreal, Montreal, Quebec, Canada.
AD  - Centre de recherche, Centre Hospitalier de l'Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Belley-Cote, Emilie
AU  - Belley-Cote E
AD  - Department of Medicine, Division of Cardiology, McMaster University, Hamilton,
      Ontario, Canada.
AD  - Population Health Research Institute, Hamilton, Ontario, Canada.
FAU - Botton, Edouard
AU  - Botton E
AD  - Patient partners, Sherbrooke, Quebec, Canada.
FAU - Cohen, Dian
AU  - Cohen D
AD  - Patient partners, Sherbrooke, Quebec, Canada.
FAU - Lamontagne, Francois
AU  - Lamontagne F
AD  - Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, 
      Quebec, Canada.
AD  - Department of Medicine, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Adhikari, Neill K J
AU  - Adhikari NKJ
AUID- ORCID: 0000-0003-4038-5382
AD  - Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada neill.adhikari@utoronto.ca.
AD  - Interdepartmental Division of Critical Care Medicine and Institute of Health
      Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario,
      Canada.
CN  - OVATION-65 team members
CN  - Canadian Critical Care Trials Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03431181
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vasoconstrictor Agents)
SB  - IM
MH  - Aged
MH  - Canada
MH  - Critical Care
MH  - Fluid Therapy
MH  - Humans
MH  - *Hypotension/chemically induced/drug therapy
MH  - Pandemics
MH  - Vasoconstrictor Agents/*therapeutic use
PMC - PMC7668371
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *clinical chemistry
OT  - *clinical trials
COIS- Competing interests: None declared.
IR  - Adhikari NK
FIR - Adhikari, Neill Kj
IR  - Lamontagne F
FIR - Lamontagne, Francois
IR  - Wilcox ME
FIR - Wilcox, Mary Elizabeth
IR  - Battista MC
FIR - Battista, Marie-Claude
IR  - Masse MH
FIR - Masse, Marie-Helene
IR  - Laupacis A
FIR - Laupacis, Andreas
IR  - Griffith L
FIR - Griffith, Lauren
IR  - Halpern S
FIR - Halpern, Scott
IR  - Robert-Petit L
FIR - Robert-Petit, Louise
IR  - Thibault ME
FIR - Thibault, Marie-Eve
IR  - Boisvert FM
FIR - Boisvert, Francois-Michel
IR  - Tai LH
FIR - Tai, Lee Hwa
IR  - Parent JL
FIR - Parent, Jean-Luc
IR  - Roucou X
FIR - Roucou, Xavier
IR  - D'Aragon F
FIR - D'Aragon, Frederick
IR  - Leclair MA
FIR - Leclair, Marc-Andre
IR  - Mayette M
FIR - Mayette, Michael
IR  - Poulin Y
FIR - Poulin, Yannick
IR  - Quiroz-Martinez H
FIR - Quiroz-Martinez, Hector
IR  - St-Arnaud C
FIR - St-Arnaud, Charles
IR  - Carbonneau E
FIR - Carbonneau, Elaine
IR  - Cote L
FIR - Cote, Line
IR  - Ladouceur M
FIR - Ladouceur, Marilene
IR  - Marchand J
FIR - Marchand, Joannie
IR  - Turcotte N
FIR - Turcotte, Noemie
IR  - Chasse M
FIR - Chasse, Michael
IR  - Lebrasseur M
FIR - Lebrasseur, Martine
IR  - Benettaib F
FIR - Benettaib, Fatna
IR  - Boumahni D
FIR - Boumahni, Dounia
IR  - Cantin ME
FIR - Cantin, Marie-Eve
IR  - Ghamraoui A
FIR - Ghamraoui, Ali
IR  - Salame M
FIR - Salame, Maya
IR  - Seely A
FIR - Seely, Andrew
IR  - Watpool I
FIR - Watpool, Irene
IR  - Porteous R
FIR - Porteous, Rebecca
IR  - Miezitis S
FIR - Miezitis, Sydney
IR  - Amaral AC
FIR - Amaral, Andre Carlos
IR  - Cuthbertson BH
FIR - Cuthbertson, Brian H
IR  - Fowler RA
FIR - Fowler, Robert A
IR  - Scales DC
FIR - Scales, Damon C
IR  - Marinoff N
FIR - Marinoff, Nicole
IR  - Kaur N
FIR - Kaur, Navjot
IR  - Mohammed W
FIR - Mohammed, Wael
IR  - Lauzier F
FIR - Lauzier, Francois
IR  - Turgeon A
FIR - Turgeon, Alexis
IR  - Francoeur C
FIR - Francoeur, Charles
IR  - Leblanc G
FIR - Leblanc, Guillaume
IR  - Bellemare D
FIR - Bellemare, David
IR  - Costerousse O
FIR - Costerousse, Olivier
IR  - Grenier S
FIR - Grenier, Stephanie
IR  - Guilbault G
FIR - Guilbault, Gabrielle
IR  - Daigle M
FIR - Daigle, Marjorie
IR  - Cloutier E
FIR - Cloutier, Eve
IR  - St-Hilaire I
FIR - St-Hilaire, Isabelle
IR  - Mehta S
FIR - Mehta, Sangeeta
IR  - Munshi L
FIR - Munshi, Laveena
IR  - Shah S
FIR - Shah, Sumesh
IR  - Singh J
FIR - Singh, Jeffrey
IR  - Walczak K
FIR - Walczak, Karolina
IR  - Rochwerg B
FIR - Rochwerg, Bram
IR  - Millen T
FIR - Millen, Tina
EDAT- 2020/11/17 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/11/16 05:56
PHST- 2020/11/16 05:56 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - bmjopen-2020-037947 [pii]
AID - 10.1136/bmjopen-2020-037947 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 14;10(11):e037947. doi: 10.1136/bmjopen-2020-037947.


PMID- 33191136
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2212-1692 (Electronic)
IS  - 1875-9572 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Dec
TI  - Don't leave me alone! Ethics of quarantine and isolation in young children.
PG  - 573-576
LID - S1875-9572(20)30167-4 [pii]
LID - 10.1016/j.pedneo.2020.10.004 [doi]
FAU - Zain, Amanda
AU  - Zain A
AD  - Khoo Teck Puat-National University Children's Medical Institute, National
      University Health System, Singapore.
FAU - Sinnathamby, Annushkha S
AU  - Sinnathamby AS
AD  - Khoo Teck Puat-National University Children's Medical Institute, National
      University Health System, Singapore.
FAU - Aishworiya, Ramkumar
AU  - Aishworiya R
AD  - Khoo Teck Puat-National University Children's Medical Institute, National
      University Health System, Singapore; Paediatric Ethics and Advocacy Centre, Khoo 
      Teck Puat- National University Children's Medical Institute, National University 
      Health System, Singapore.
FAU - Chan, Si Min
AU  - Chan SM
AD  - Khoo Teck Puat-National University Children's Medical Institute, National
      University Health System, Singapore. Electronic address: si_min_chan@nuhs.edu.sg.
FAU - Biswas, Agnihotri
AU  - Biswas A
AD  - Paediatric Ethics and Advocacy Centre, Khoo Teck Puat- National University
      Children's Medical Institute, National University Health System, Singapore;
      Department of Neonatology, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Health System, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Singapore
TA  - Pediatr Neonatol
JT  - Pediatrics and neonatology
JID - 101484755
SB  - IM
PMC - PMC7581354
COIS- Declaration of competing interest The authors have indicated they have no
      potential conflicts of interest to disclose.
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
CRDT- 2020/11/16 05:31
PHST- 2020/08/07 00:00 [received]
PHST- 2020/09/10 00:00 [revised]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
PHST- 2020/11/16 05:31 [entrez]
AID - S1875-9572(20)30167-4 [pii]
AID - 10.1016/j.pedneo.2020.10.004 [doi]
PST - ppublish
SO  - Pediatr Neonatol. 2020 Dec;61(6):573-576. doi: 10.1016/j.pedneo.2020.10.004. Epub
      2020 Oct 22.


PMID- 33189370
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20220816
IS  - 2352-2291 (Electronic)
IS  - 0104-0014 (Linking)
VI  - 70
IP  - 6
DP  - 2020 Nov-Dec
TI  - [Perineural dexamethasone in ultrasound-guided interscalene brachial plexus block
      with levobupivacaine for shoulder arthroscopic surgery in the outpatient setting:
      randomized controlled trial].
PG  - 588-594
LID - S0034-7094(20)30432-3 [pii]
LID - 10.1016/j.bjan.2020.07.003 [doi]
AB  - BACKGROUND AND OBJECTIVES: In shoulder arthroscopy, on an outpatient basis, the
      patient needs a good control of the postoperative pain that can be achieved
      through regional blocks. Perineural dexamethasone may prolong the effect of these
      blocks. The aim of this study was to evaluate the effect of perineural
      dexamethasone on the prolongation of the sensory block in the postoperative
      period for arthroscopic shoulder surgery in outpatient setting. METHODS: After
      approval by the Research Ethics Committee and informed consent, patients
      undergoing arthroscopic shoulder surgery under general anesthesia and
      ultrasound-guided interscalene brachial plexus block were randomized into Group D
      - blockade performed with 30 mL of 0.5% levobupivacaine with vasoconstrictor and 
      6 mg (1.5 mL) of dexamethasone and Group C - 30 mL of 0.5% levobupivacaine with
      vasoconstrictor and 1.5 mL of 0.9% saline. The duration of the sensory block was 
      evaluated in 4 postoperative moments (0, 4, 12 and 24 hours) as well as the need 
      for rescue analgesia, nausea and vomiting incidence, and Visual Analog Pain Scale
      (VAS). RESULTS: Seventy-four patients were recruited and 71 completed the study
      (Group C, n=37; Group D, n=34). Our findings showed a prolongation of the mean
      time of the sensitive blockade in Group D (1440+/-0 min vs. 1267+/-164 min,
      p<0.001). It was observed that Group C had a higher mean pain score according to 
      VAS (2.08+/-1.72 vs. 0.02+/-0.17, p <0.001) and a greater number of patients
      (68.4% vs. 0%, p <0.001) required rescue analgesia in the first 24 hours. The
      incidence of postoperative nausea and vomiting was not statistically significant.
      CONCLUSION: Perineural dexamethasone significantly prolonged the sensory blockade
      promoted by levobupivacaine in interscalene brachial plexus block, reduced pain
      intensity and rescue analgesia needs in the postoperative period.
CI  - Copyright (c) 2020 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier
      Editora Ltda. All rights reserved.
FAU - Vasconcelos, Mateus Meira
AU  - Vasconcelos MM
AD  - Hospital Santa Genoveva, Uberlandia, MG, Brasil.
FAU - Pontes, Joao Paulo Jordao
AU  - Pontes JPJ
AD  - Hospital Santa Genoveva, Uberlandia, MG, Brasil; Sociedade Brasileira de
      Anestesiologia (TSA-SBA), Rio de Janeiro, RJ, Brasil; European Diploma in
      Anaesthesiology and Intensive Care (EDAIC), European Society of Anaesthesiology, 
      Brussels, Belgium. Electronic address: pontes_ufu@yahoo.com.br.
FAU - Rodrigues, Alexandre de Menezes
AU  - Rodrigues AM
AD  - Hospital Santa Genoveva, Uberlandia, MG, Brasil.
FAU - Neto, Democrito Ribeiro de Brito
AU  - Neto DRB
AD  - Hospital Santa Genoveva, Uberlandia, MG, Brasil; Sociedade Brasileira de
      Anestesiologia (TSA-SBA), Rio de Janeiro, RJ, Brasil.
FAU - Alves, Rodrigo Rodrigues
AU  - Alves RR
AD  - Hospital Santa Genoveva, Uberlandia, MG, Brasil; Sociedade Brasileira de
      Anestesiologia (TSA-SBA), Rio de Janeiro, RJ, Brasil.
FAU - Silva, Fernando Cassio do Prado
AU  - Silva FCDP
AD  - Hospital Santa Genoveva, Uberlandia, MG, Brasil; Sociedade Brasileira de
      Anestesiologia (TSA-SBA), Rio de Janeiro, RJ, Brasil; Hospital Santa Genoveva,
      CET, Uberlandia, MG, Brasil.
FAU - Souza, Denis Fabiano de
AU  - Souza DF
AD  - Instituto do Coracao do Triangulo (ICT), Uberlandia, MG, Brasil; Universidade
      Federal de Uberlandia (UFU), Ciencias da Saude, MG, Brasil.
LA  - por
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Dexametasona perineural em bloqueio de plexo braquial interescalenico com
      levobupivacaina guiado por ultrassonografia para artroscopia de ombro em regime
      ambulatorial: ensaio clinico controlado e randomizado.
DEP - 20201022
PL  - Brazil
TA  - Braz J Anesthesiol
JT  - Brazilian journal of anesthesiology (Elsevier)
JID - 101624623
RN  - 0 (Anesthetics, Local)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Saline Solution)
RN  - 0 (Vasoconstrictor Agents)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - A5H73K9U3W (Levobupivacaine)
SB  - IM
MH  - Analgesia
MH  - Analysis of Variance
MH  - Anesthetics, Local
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Arthroscopy/adverse effects/*methods
MH  - Brachial Plexus Block/*methods
MH  - Dexamethasone/*administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Levobupivacaine
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Postoperative/diagnosis/drug therapy
MH  - Postoperative Nausea and Vomiting/epidemiology
MH  - Prospective Studies
MH  - Saline Solution/administration & dosage
MH  - Shoulder Joint/*surgery
MH  - Time Factors
MH  - Ultrasonography, Interventional/*methods
MH  - Vasoconstrictor Agents/administration & dosage
PMC - PMC9373568
OTO - NOTNLM
OT  - Anestesia por conducao
OT  - Anesthesia, conduction
OT  - Arthroscopy
OT  - Artroscopia
OT  - Bloqueio de plexo braquial
OT  - Brachial plexus block
OT  - Dexametasona
OT  - Dexamethasone
OT  - Ultrasonography
OT  - Ultrassonografia
EDAT- 2020/11/16 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/11/15 20:22
PHST- 2018/12/03 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/11/16 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/11/15 20:22 [entrez]
AID - S0034-7094(20)30432-3 [pii]
AID - 10.1016/j.bjan.2020.07.003 [doi]
PST - ppublish
SO  - Braz J Anesthesiol. 2020 Nov-Dec;70(6):588-594. doi: 10.1016/j.bjan.2020.07.003. 
      Epub 2020 Oct 22.


PMID- 33189147
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Nov 14
TI  - Preoperative prognostic factors associated with postoperative delirium in older
      people undergoing surgery: protocol for a systematic review and individual
      patient data meta-analysis.
PG  - 261
LID - 10.1186/s13643-020-01518-z [doi]
AB  - BACKGROUND: Early identification of patients at risk for postoperative delirium
      is essential because adequate well-timed interventions could reduce the
      occurrence of delirium and the related detrimental outcomes. METHODS: We will
      conduct a systematic review and individual patient data (IPD) meta-analysis of
      prognostic studies evaluating the predictive value of risk factors associated
      with an increased risk of postoperative delirium in elderly patients undergoing
      elective surgery. We will identify eligible studies through systematic search of 
      MEDLINE, EMBASE, and CINAHL from their inception to May 2020. Eligible studies
      will enroll older adults (>/= 50 years) undergoing elective surgery and assess
      pre-operative prognostic risk factors for delirium and incidence of delirium
      measured by a trained individual using a validated delirium assessment tool.
      Pairs of reviewers will, independently and in duplicate, screen titles and
      abstracts of identified citations, review the full texts of potentially eligible 
      studies. We will contact chief investigators of eligible studies requesting to
      share the IPD to a secured repository. We will use one-stage approach for IPD
      meta-analysis and will assess certainty of evidence using the GRADE approach.
      DISCUSSION: Since we are using existing anonymized data, ethical approval is not 
      required for this study. Our results can be used to guide clinical decisions
      about the most efficient way to prevent postoperative delirium in elderly
      patients. SYSTEMATIC REVIEW REGISTRATION: CRD42020171366 .
FAU - Buchan, Tayler A
AU  - Buchan TA
AD  - Ted Rogers Center for Heart Research, University Health Network, 200 Elizabeth
      Street, Toronto, ON, M5G 2C4, Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
FAU - Sadeghirad, Behnam
AU  - Sadeghirad B
AUID- ORCID: 0000-0001-9422-5232
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      1280 Main Street West, Hamilton, ON, L8S 4K1, Canada. sadeghb@mcmaster.ca.
AD  - Department of Anesthesia, McMaster University, 1280 Main Street West, Hamilton,
      ON, L8S 4K1, Canada. sadeghb@mcmaster.ca.
FAU - Schmutz, Nayeli
AU  - Schmutz N
AD  - PIPRA AG, Josefstrasse 219, 8005, Zurich, Switzerland.
AD  - St. Claraspital, Kleinriehenstrasse 30, 4058, Basel, Switzerland.
FAU - Goettel, Nicolai
AU  - Goettel N
AD  - Department of Anesthesia, Prehospital Emergency Medicine and Pain Therapy,
      University Hospital Basel, Spitalstrasse 21, CH-4031, Basel, Switzerland.
AD  - Department of Clinical Research, University of Basel, Schanzenstrasse 55,
      CH-4031, Basel, Switzerland.
FAU - Foroutan, Farid
AU  - Foroutan F
AD  - Ted Rogers Center for Heart Research, University Health Network, 200 Elizabeth
      Street, Toronto, ON, M5G 2C4, Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
FAU - Couban, Rachel
AU  - Couban R
AD  - Department of Anesthesia, McMaster University, 1280 Main Street West, Hamilton,
      ON, L8S 4K1, Canada.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
AD  - Biostatistics Unit/The Research Institute, St. Joseph's Healthcare, McMaster
      University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
FAU - Dodsworth, Benjamin T
AU  - Dodsworth BT
AD  - PIPRA AG, Josefstrasse 219, 8005, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201114
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - Aged
MH  - *Delirium/diagnosis/prevention & control
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Incidence
MH  - Meta-Analysis as Topic
MH  - Prognosis
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7666505
OTO - NOTNLM
OT  - *Elderly
OT  - *Individual patient data meta-analysis
OT  - *Postoperative
OT  - *Prognostic factors
EDAT- 2020/11/16 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/15 20:18
PHST- 2020/07/12 00:00 [received]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2020/11/15 20:18 [entrez]
PHST- 2020/11/16 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01518-z [doi]
AID - 10.1186/s13643-020-01518-z [pii]
PST - epublish
SO  - Syst Rev. 2020 Nov 14;9(1):261. doi: 10.1186/s13643-020-01518-z.


PMID- 33188345
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20220310
IS  - 1476-5373 (Electronic)
IS  - 0007-0610 (Linking)
VI  - 229
IP  - 9
DP  - 2020 Nov
TI  - An evaluation of civilian and military dental foundation training.
PG  - 615-619
LID - 10.1038/s41415-020-2275-2 [doi]
AB  - Background and aim There is little available material relating to the quality of 
      continuing professional development for dental professionals and no studies to
      investigate whether dental foundation training (DFT) is meeting its aims and
      objectives. This study aimed to evaluate the components of DFT within the
      military and Oxford deaneries from the perspective of the educational supervisors
      (ESs) and foundation trainees (FTs).Method Questionnaires were sent to all 124
      FTs and ESs involved in DFT in the Oxfordshire and military deaneries between
      2012 to 2015. Following thematic analysis of the free text from the
      questionnaires, an interview guide was produced which mapped the main themes for 
      a series of semi-structured interviews.Results Sixty-six questionnaires were
      returned (53% response rate) from 18 military and 3 Oxford ESs (21), and 30
      military and 15 Oxford FTs (45). Eighteen interviews were carried out (6 ES/12
      FT). The questionnaires highlighted the educational benefit of workplace-based
      assessments, joint clinical sessions and the importance of an ES as a positive
      role model, while the interviews highlighted the facilitative benefit of
      effective supervision, timely feedback, practice-wide teamwork, appropriate
      assessments and formal/informal peer review.Conclusions This study demonstrates
      the benefit of creating an optimal learning environment for DFT within the
      context of professional and ethical organisational support and appropriate
      clinical resources. ESs have a critical part to play as professional and clinical
      role models, and in ensuring an accountable and formal educational delivery,
      targeted learning goals, flexible delivery and timely feedback.
FAU - Richardson, Mark
AU  - Richardson M
AD  - Group Captain, Chief Dental Officer (Defence), Defence Primary Healthcare
      (Dental), DMS Whittington, Lichfield, Staffordshire, WS14 9PY, UK.
      mark.richardson275@mod.gov.uk.
FAU - Dermont, Mark
AU  - Dermont M
AD  - Wing Commander, Consultant in Dental Public Health, Defence Public Health Unit,
      DMS Whittington, Lichfield, Staffordshire, WS14 9PY, UK.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - England
TA  - Br Dent J
JT  - British dental journal
JID - 7513219
SB  - IM
MH  - Clinical Competence
MH  - Education, Medical, Graduate
MH  - Educational Measurement
MH  - Feedback
MH  - Humans
MH  - *Military Personnel
EDAT- 2020/11/15 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/11/14 05:28
PHST- 2020/04/26 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/11/14 05:28 [entrez]
PHST- 2020/11/15 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - 10.1038/s41415-020-2275-2 [doi]
AID - 10.1038/s41415-020-2275-2 [pii]
PST - ppublish
SO  - Br Dent J. 2020 Nov;229(9):615-619. doi: 10.1038/s41415-020-2275-2. Epub 2020 Nov
      13.


PMID- 33187204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - A Comparative Neuro-Histological Assessment of Gluteal Skin Thickness and
      Cutaneous Nociceptor Distribution in Horses and Humans.
LID - E2094 [pii]
LID - 10.3390/ani10112094 [doi]
AB  - The current project aims to build on knowledge of the nociceptive capability of
      equine skin to detect superficial acute pain, particularly in comparison to human
      skin. Post-mortem samples of gluteal skin were taken from men (n = 5) and women
      (n = 5), thoroughbreds and thoroughbred types (mares, n = 11; geldings, n = 9).
      Only sections that contained epidermis and dermis through to the hypodermis were 
      analysed. Epidermal depth, dermal depth and epidermal nerve counts were conducted
      by a veterinary pathologist. The results revealed no significant difference
      between the epidermal nerve counts of humans and horses (t = 0.051, p = 0.960).
      There were no significant differences between epidermal thickness of humans (26.8
      microm) and horses (31.6 microm) for reference (left side) samples (t = 0.117, p 
      = 0.908). The human dermis was significantly thinner than the horse dermis (t =
      -2.946, p = 0.007). Epidermal samples were thicker on the right than on the left,
      but only significantly so for horses (t = 2.291, p = 0.023), not for humans (t = 
      0.694, p = 0.489). The thicker collagenous dermis of horse skin may afford some
      resilience versus external mechanical trauma, though as this is below the
      pain-detecting nerve endings, it is not considered protective from external
      cutaneous pain. The superficial pain-sensitive epidermal layer of horse skin is
      as richly innervated and is of equivalent thickness as human skin, demonstrating 
      that humans and horses have the equivalent basic anatomic structures to detect
      cutaneous pain. This finding challenges assumptions about the physical capacity
      of horses to feel pain particularly in comparison to humans, and presents
      physical evidence to inform the discussion and debate regarding the ethics of
      whipping horses.
FAU - Tong, Lydia
AU  - Tong L
AUID- ORCID: 0000-0002-8526-662X
AD  - Taronga Conservation Society Australia, Mosman, Sydney, NSW 2088, Australia.
FAU - Stewart, Melinda
AU  - Stewart M
AD  - Starling Scientific, Pearl Beach, NSW 2256, Australia.
FAU - Johnson, Ian
AU  - Johnson I
AUID- ORCID: 0000-0001-5951-6990
AD  - Faculty of Medicine, Health and Human Sciences, Macquarie University, Sidney, NSW
      2109, Australia.
FAU - Appleyard, Richard
AU  - Appleyard R
AD  - Faculty of Medicine, Health and Human Sciences, Macquarie University, Sidney, NSW
      2109, Australia.
FAU - Wilson, Bethany
AU  - Wilson B
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
FAU - James, Olivia
AU  - James O
AD  - Australian Veterinary Equine Dentistry, 27 Bellevue Terrace, Clayfield, QLD 4011,
      Australia.
FAU - Johnson, Craig
AU  - Johnson C
AD  - School of Veterinary Science, Tawharau Ora, Massey University, Private Bag 11
      222, Palmerston North 4442, New Zealand.
FAU - McGreevy, Paul
AU  - McGreevy P
AUID- ORCID: 0000-0001-7220-8378
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
LA  - eng
GR  - ./RSPCA Australia
PT  - Journal Article
DEP - 20201111
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7696388
OTO - NOTNLM
OT  - dermis
OT  - epidermis
OT  - innervation
OT  - nerve cell counts
OT  - pain
OT  - whipping
EDAT- 2020/11/15 06:00
MHDA- 2020/11/15 06:01
CRDT- 2020/11/14 01:03
PHST- 2020/09/25 00:00 [received]
PHST- 2020/11/07 00:00 [revised]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/11/14 01:03 [entrez]
PHST- 2020/11/15 06:00 [pubmed]
PHST- 2020/11/15 06:01 [medline]
AID - ani10112094 [pii]
AID - 10.3390/ani10112094 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Nov 11;10(11). pii: ani10112094. doi: 10.3390/ani10112094.


PMID- 33187152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Metabolomics of Interstitial Fluid, Plasma and Urine in Patients with Arterial
      Hypertension: New Insights into the Underlying Mechanisms.
LID - E936 [pii]
LID - 10.3390/diagnostics10110936 [doi]
AB  - There is growing evidence that lymphatic system plays a pivotal role in the
      pathogenesis of hypertension. Here, for the first time, the metabolome of
      interstitial fluid is analyzed in patients with arterial hypertension. Due to
      ethical issues to obtain human interstitial fluid samples, this study included
      only oncological patients after axillary lymph node dissection (ALND). These
      patients were matched into hypertensive (n = 29) and normotensive (n = 35) groups
      with similar oncological status. Simultaneous evaluation of interstitial fluid,
      plasma, and urine was obtained by combining high-resolution proton nuclear
      magnetic resonance ((1)H NMR) spectroscopy with chemometric analysis. Orthogonal 
      partial least squares discriminant analysis (OPLS-DA) provided a clear
      differentiation between the hypertension and normotensive group, with the
      discrimination visible in each biofluid. In interstitial fluid nine potential
      metabolomic biomarkers for hypertension could be identified (creatinine, proline,
      pyroglutamine, glycine, alanine, 1-methylhistidine, the lysyl group of albumin,
      threonine, lipids), seven distinct markers in plasma (creatinine, mannose,
      isobutyrate, glycine, alanine, lactate, acetate, ornithine), and seven
      respectively in urine (methylmalonate, citrulline, phenylacetylglycine, fumarate,
      citrate, 1-methylnicotinamide, trans-aconitate). Biomarkers in plasma and urine
      allowed for the identification of specific biochemical pathways involved in
      hypertension, as previously suggested. Analysis of the interstitial fluid
      metabolome provided additional biomarkers compared to plasma or urine. Those
      biomarkers reflected primarily alterations in the metabolism of lipids and amino 
      acids, and indicated increased levels of oxidative stress/inflammation in
      patients with hypertension.
FAU - Chachaj, Angelika
AU  - Chachaj A
AUID- ORCID: 0000-0001-8087-8005
AD  - Department of Angiology, Hypertension and Diabetology, Wroclaw Medical
      University, Borowska 213 Street, 50-556 Wroclaw, Poland.
FAU - Matkowski, Rafal
AU  - Matkowski R
AUID- ORCID: 0000-0002-1705-5097
AD  - Department of Oncology, Wroclaw Medical University, 12 Hirszfeld Square, 53-413
      Wroclaw, Poland.
AD  - Wroclaw Comprehensive Cancer Center, 12 Hirszfeld Square, 53-413 Wroclaw, Poland.
FAU - Grobner, Gerhard
AU  - Grobner G
AD  - Department of Chemistry, Umea University, Linnaeus vag 6, 901 87 Umea, Sweden.
FAU - Szuba, Andrzej
AU  - Szuba A
AUID- ORCID: 0000-0002-7555-6201
AD  - Department of Angiology, Hypertension and Diabetology, Wroclaw Medical
      University, Borowska 213 Street, 50-556 Wroclaw, Poland.
FAU - Dudka, Ilona
AU  - Dudka I
AUID- ORCID: 0000-0002-0153-7278
AD  - Department of Chemistry, Umea University, Linnaeus vag 6, 901 87 Umea, Sweden.
LA  - eng
GR  - ST.E220.17.047/Wroclaw Medical University Grant
GR  - ("NMR for Life" Programme)/the Knut and Alice Wallenberg foundation
GR  - (Swedish NMR Centre)/the Kempe Foundation, the SciLifeLab
GR  - and the Swedish Cancer Foundation/the Swedish Research Council
PT  - Journal Article
DEP - 20201111
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7698256
OTO - NOTNLM
OT  - 1H NMR spectroscopy
OT  - biomarkers
OT  - interstitial fluid
OT  - lymphatic system
OT  - metabolic phenotyping
OT  - prenodal lymph
OT  - primary hypertension
EDAT- 2020/11/15 06:00
MHDA- 2020/11/15 06:01
CRDT- 2020/11/14 01:03
PHST- 2020/09/17 00:00 [received]
PHST- 2020/11/07 00:00 [revised]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/11/14 01:03 [entrez]
PHST- 2020/11/15 06:00 [pubmed]
PHST- 2020/11/15 06:01 [medline]
AID - diagnostics10110936 [pii]
AID - 10.3390/diagnostics10110936 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2020 Nov 11;10(11). pii: diagnostics10110936. doi:
      10.3390/diagnostics10110936.


PMID- 33185616
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1875-8894 (Electronic)
IS  - 1874-5393 (Linking)
VI  - 13
IP  - 3
DP  - 2020
TI  - Children with disabilities in the United States and the COVID-19 pandemic.
PG  - 415-424
LID - 10.3233/PRM-200769 [doi]
AB  - Children with disabilities are disproportionately impacted by COVID-19 and the
      containment response. Their caregivers must now adapt to increased stressors such
      as lack of access to needed therapies, medical supplies, and nursing care. Prior 
      to COVID-19 these families were already marginalized, and this has only worsened 
      during the pandemic. As a vulnerable population, children with disabilities have 
      not been the focus of much discussion during the pandemic, likely because the
      disease disproportionately impacts older individuals. Nonetheless, children with 
      disabilities should be a focus of evaluation and intervention to mitigate the
      negative consequences of COVID-19 and the resulting containment strategies. Their
      needs should be included in future crisis planning, as well. In order to raise
      awareness of pediatric rehabilitation professionals, health care administrators, 
      policy makers, and advocates, this manuscript provides a discussion of the
      following topics: the immediate and ongoing impacts on children with disabilities
      and their families, the ethical concerns and implications of triage protocols for
      scarce resources that consider disability in their scoring systems, and
      optimizing medical care and educational needs in the time of COVID.
FAU - Houtrow, Amy
AU  - Houtrow A
AD  - Departments of Physical Medicine and Rehabilitation and Pediatrics, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, USA.
FAU - Harris, Debbi
AU  - Harris D
AD  - Family Voices of Minnesota, Minneapolis, MN, USA.
FAU - Molinero, Ashli
AU  - Molinero A
AD  - Disability Resource Center, UPMC, Pittsburgh, PA, USA.
FAU - Levin-Decanini, Tal
AU  - Levin-Decanini T
AD  - Complex Care Center, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
FAU - Robichaud, Christopher
AU  - Robichaud C
AD  - Kennedy School of Government, Harvard University, Cambridge, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Pediatr Rehabil Med
JT  - Journal of pediatric rehabilitation medicine
JID - 101490944
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Child
MH  - Comorbidity
MH  - Disabled Children/*statistics & numerical data
MH  - Humans
MH  - *Pandemics
MH  - SARS-CoV-2
MH  - United States/epidemiology
OTO - NOTNLM
OT  - COVID-19
OT  - Children with disabilities
OT  - Individualized Education Program
OT  - discrimination
OT  - health care inequities
EDAT- 2020/11/14 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/11/13 12:09
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/11/13 12:09 [entrez]
AID - PRM200769 [pii]
AID - 10.3233/PRM-200769 [doi]
PST - ppublish
SO  - J Pediatr Rehabil Med. 2020;13(3):415-424. doi: 10.3233/PRM-200769.


PMID- 33185566
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2561-326X (Electronic)
IS  - 2561-326X (Linking)
VI  - 4
IP  - 11
DP  - 2020 Nov 13
TI  - Evaluation of Treatment Descriptions and Alignment With Clinical Guidance of Apps
      for Depression on App Stores: Systematic Search and Content Analysis.
PG  - e14988
LID - 10.2196/14988 [doi]
AB  - BACKGROUND: The use of apps for the treatment of depression shows great promise. 
      However, there is uncertainty regarding the alignment of publicly available apps 
      for depression with clinical guidance, their treatment fidelity and evidence
      base, and their overall safety. OBJECTIVE: Built on previous analyses and
      reviews, this study aims to explore the treatment and safety issues of publicly
      available apps for depression. METHODS: We conducted a content analysis of apps
      for depression in the 2 main UK app stores (Google Play and Apple App Store). App
      store listings were analyzed for intervention content, treatment fidelity, and
      fit with the National Institute for Health and Care Excellence (NICE) guidelines 
      for the treatment of depression in adults. RESULTS: A total of 353 apps for
      depression were included in the review. App descriptions reported the use of 20
      treatment approaches and 37 treatment strategies. Many apps used transdiagnostic 
      (155/353, 43.9%) and multitheoretical interventions to treat multiple disorders
      including depression. Although many interventions appeared to be
      evidence-informed, there were issues with treatment fidelity, research evidence, 
      and fit with clinical guidelines. None of the apps fully aligned with the NICE
      guidelines for depression. CONCLUSIONS: App developers have adopted many
      evidence-informed treatments in their interventions; however, more work is needed
      to improve clinical validity, treatment fidelity, and the safety of apps. We urge
      developers to consult relevant guidelines and standards, and to engage in
      reflective questioning on treatment and safety to address these issues and to
      improve treatment content and intervention design.
CI  - (c)Dionne Bowie-DaBreo, Sandra I Sunram-Lea, Corina Sas, Heather Iles-Smith.
      Originally published in JMIR Formative Research (http://formative.jmir.org),
      13.11.2020.
FAU - Bowie-DaBreo, Dionne
AU  - Bowie-DaBreo D
AUID- ORCID: https://orcid.org/0000-0002-0050-0115
AD  - Research and Innovation Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United
      Kingdom.
AD  - Department of Psychology, Lancaster University, Lancaster, United Kingdom.
FAU - Sunram-Lea, Sandra I
AU  - Sunram-Lea SI
AUID- ORCID: https://orcid.org/0000-0001-9889-9867
AD  - Department of Psychology, Lancaster University, Lancaster, United Kingdom.
FAU - Sas, Corina
AU  - Sas C
AUID- ORCID: https://orcid.org/0000-0001-9297-9612
AD  - School of Computing and Communications, Lancaster University, Lancaster, United
      Kingdom.
FAU - Iles-Smith, Heather
AU  - Iles-Smith H
AUID- ORCID: https://orcid.org/0000-0002-0520-2694
AD  - Research and Innovation, Northern Care Alliance NHS Group, Salford, United
      Kingdom.
AD  - University of Salford, Salford, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - Canada
TA  - JMIR Form Res
JT  - JMIR formative research
JID - 101726394
PMC - PMC7695532
OTO - NOTNLM
OT  - NHS
OT  - NICE guidelines
OT  - clinical guidance
OT  - content analysis
OT  - depression
OT  - ethics
OT  - mHealth
OT  - mobile apps
OT  - mobile mental health
OT  - safety
EDAT- 2020/11/14 06:00
MHDA- 2020/11/14 06:01
CRDT- 2020/11/13 12:09
PHST- 2019/06/10 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/05/19 00:00 [revised]
PHST- 2020/11/13 12:09 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/11/14 06:01 [medline]
AID - v4i11e14988 [pii]
AID - 10.2196/14988 [doi]
PST - epublish
SO  - JMIR Form Res. 2020 Nov 13;4(11):e14988. doi: 10.2196/14988.


PMID- 33185501
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1547-6898 (Electronic)
IS  - 1040-8444 (Linking)
VI  - 50
IP  - 9
DP  - 2020 Oct
TI  - Treating organophosphates poisoning: management challenges and potential
      solutions.
PG  - 764-779
LID - 10.1080/10408444.2020.1837069 [doi]
AB  - Organophosphorus agents (OP) are widely used as pesticides due to their cost
      effectiveness, yet they present a significant public health risk owing to their
      high toxicity, especially in cases of occupational exposure in agriculture,
      during suicide attempts using pesticides, and as nerve agents in warfare. Their
      vigorous permeability through inhalation, ingestion, and dermal exposure results 
      in a high number of reported OP poisoning cases and alarming mortality rates.
      Initial first-aid management involves decontamination, ventilation, and
      hemodialysis. Additionally, current treatment guidelines recommend prompt
      administration of atropine as a first-line antidote, oximes as a follow-up,
      benzodiazepines for seizure control, and pyridostigmine for prophylaxis.
      Nevertheless, current treatment options are associated with several challenges.
      Thus, recent research has focused on investigating novel approaches for their
      potential in improving current management strategies. This article intends to
      review recent advances in OP poisoning treatment, including agents investigated
      for their use as an alternative or adjunctive therapy, novel formulations such as
      nasal drops or sublingual tablets for emergency administration of atropine, as
      well as innovative strategies for enhanced oximes delivery and overall efficacy. 
      However, two major barriers may limit these innovations, ethical issues
      associated with their clinical assessment in emergencies, and limited
      profitability in countries where most cases occur.
FAU - Alozi, Maria
AU  - Alozi M
AD  - College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
FAU - Rawas-Qalaji, Mutasem
AU  - Rawas-Qalaji M
AUID- ORCID: 0000-0001-8890-3818
AD  - College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
AD  - Research Institute for Medical and Health Sciences, University of Sharjah,
      Sharjah, United Arab Emirates.
AD  - Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 
      Fort Lauderdale, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201113
PL  - England
TA  - Crit Rev Toxicol
JT  - Critical reviews in toxicology
JID - 8914275
RN  - 0 (Antidotes)
RN  - 0 (Chemical Warfare Agents)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Organophosphates)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Oximes)
RN  - 0 (Pesticides)
RN  - 7C0697DR9I (Atropine)
SB  - IM
MH  - Animals
MH  - Antidotes/therapeutic use
MH  - Atropine/therapeutic use
MH  - Chemical Warfare Agents
MH  - Cholinesterase Inhibitors
MH  - Humans
MH  - Organophosphate Poisoning/*drug therapy
MH  - Organophosphates
MH  - Organophosphorus Compounds
MH  - Oximes
MH  - Pesticides/toxicity
MH  - Seizures
OTO - NOTNLM
OT  - *Atropine sulfate
OT  - *nerve agent
OT  - *organophosphates
OT  - *pesticides
OT  - *poisoning
OT  - *sarin
OT  - *soman
OT  - *tabun
EDAT- 2020/11/14 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/11/13 12:09
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/11/13 12:09 [entrez]
AID - 10.1080/10408444.2020.1837069 [doi]
PST - ppublish
SO  - Crit Rev Toxicol. 2020 Oct;50(9):764-779. doi: 10.1080/10408444.2020.1837069.
      Epub 2020 Nov 13.


PMID- 33185405
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20210310
IS  - 2575-3126 (Electronic)
IS  - 2575-3126 (Linking)
VI  - 14
IP  - 13
DP  - 2020 Nov
TI  - Autologous Epidural Blood Patch in a Coronavirus Disease 2019-Positive Patient:
      Ethical Issues.
PG  - e01344
LID - 10.1213/XAA.0000000000001344 [doi]
FAU - Nair, Abhijit
AU  - Nair A
AD  - Department of Anesthesiology, Basavatarakam Indo-American Cancer Hospital and
      Research Institute, Hyderabad, India, abhijitnair95@gmail.com.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - A A Pract
JT  - A&A practice
JID - 101714112
SB  - IM
CON - A A Pract. 2020 Aug;14(10):e01303. PMID: 32845101
MH  - Betacoronavirus
MH  - Blood Patch, Epidural
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Post-Dural Puncture Headache/therapy
MH  - SARS-CoV-2
EDAT- 2020/11/14 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/11/13 10:50
PHST- 2020/11/13 10:50 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1213/XAA.0000000000001344 [doi]
AID - 02054229-202011000-00007 [pii]
PST - ppublish
SO  - A A Pract. 2020 Nov;14(13):e01344. doi: 10.1213/XAA.0000000000001344.


PMID- 33184529
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210924
IS  - 0889-048X (Print)
IS  - 0889-048X (Linking)
VI  - 37
IP  - 4
DP  - 2020
TI  - Palatable disruption: the politics of plant milk.
PG  - 945-962
LID - 10.1007/s10460-020-10022-y [doi]
AB  - Plant-based milk alternatives-or mylks-have surged in popularity over the past
      ten years. We consider the politics and consumer subjectivities fostered by mylks
      as part of the broader trend towards 'plant-based' food. We demonstrate how mylk 
      companies inherit and strategically deploy positive framings of milk as wholesome
      and convenient, as well as negative framings of dairy as environmentally damaging
      and cruel, to position plant-based as the 'better' alternative. By navigating
      this affective landscape, brands attempt to (re)make mylk as simultaneously
      palatable and disruptive to the status quo. We examine the politics of mylks
      through the concept of palatable disruption, where people are encouraged to care 
      about the environment, health, and animal welfare enough to adopt mylks but to
      ultimately remain consumers of a commodity food. By encouraging consumers to
      reach for "plant-based" as a way to cope with environmental catastrophe and a
      life out of balance, mylks promote a neoliberal ethic: they individualize
      systemic problems and further entrench market mechanisms as solutions, thereby
      reinforcing the political economy of industrial agriculture. In conclusion, we
      reflect on the limits of the current plant-based trend for transitioning to more 
      just and sustainable food production and consumption.
CI  - (c) The Author(s) 2020.
FAU - Clay, Nathan
AU  - Clay N
AD  - School of Geography and the Environment, University of Oxford, South Parks Road, 
      Oxford, OX1 3QY UK.grid.4991.50000 0004 1936 8948
FAU - Sexton, Alexandra E
AU  - Sexton AE
AD  - School of Geography and the Environment, University of Oxford, South Parks Road, 
      Oxford, OX1 3QY UK.grid.4991.50000 0004 1936 8948
FAU - Garnett, Tara
AU  - Garnett T
AD  - Food Climate Research Network, Oxford, UK.
AD  - Environmental Change Institute, University of Oxford, South Parks Road, Oxford,
      OX1 3QY UK.grid.4991.50000 0004 1936 8948
FAU - Lorimer, Jamie
AU  - Lorimer J
AD  - School of Geography and the Environment, University of Oxford, South Parks Road, 
      Oxford, OX1 3QY UK.grid.4991.50000 0004 1936 8948
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 205212/WT_/Wellcome Trust/United Kingdom
GR  - 205212/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200130
PL  - United States
TA  - Agric Human Values
JT  - Agriculture and human values
JID - 100973331
PMC - PMC7644520
MID - EMS103413
OTO - NOTNLM
OT  - Alternative food network
OT  - Dairy
OT  - Food industry
OT  - Neoliberal
OT  - Protein
OT  - Vegan
EDAT- 2020/11/14 06:00
MHDA- 2020/11/14 06:01
CRDT- 2020/11/13 05:52
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/11/13 05:52 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/11/14 06:01 [medline]
AID - 10.1007/s10460-020-10022-y [doi]
AID - 10022 [pii]
PST - ppublish
SO  - Agric Human Values. 2020;37(4):945-962. doi: 10.1007/s10460-020-10022-y. Epub
      2020 Jan 30.


PMID- 33184125
OWN - NLM
STAT- Publisher
LR  - 20201113
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 12
TI  - Conscientious participants and the ethical dimensions of physician support for
      legalised voluntary assisted dying.
LID - medethics-2020-106702 [pii]
LID - 10.1136/medethics-2020-106702 [doi]
AB  - The Australian state of Victoria legalised voluntary assisted dying (VAD) in June
      2019. Like most jurisdictions with legalised VAD, the Victorian law constructs
      physicians as the only legal providers of VAD. Physicians with conscientious
      objection to VAD are not compelled to participate in the practice, requiring
      colleagues who are willing to participate to transact the process for eligible
      applicants. Physicians who provide VAD because of their active, moral and
      purposeful support for the law are known as conscientious participants.
      Conscientious participation has received scant attention in the bioethics
      literature. Patient access to VAD is contingent on the development of a
      sufficient corpus of conscientious participants in permissive jurisdictions. This
      article reports the findings of a small empirical study into how some Victorian
      physicians with no in-principle opposition towards the legalisation of VAD, are
      ethically orientating themselves towards the law, in the first 8 months of the
      law's operation. It finds that in-principle-supportive physicians employ
      bioethical principles to justify their position but struggle to reconcile that
      approach with the broader medical profession's opposition. This study is part of 
      the first tranche of empirical research emerging from Australia since the
      legalisation of VAD in that country for the first time in over 20 years.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Rutherford, Jodhi
AU  - Rutherford J
AUID- ORCID: http://orcid.org/0000-0003-3396-0158
AD  - Australian Cente for Health Law Research, Queensland University of Technology
      Faculty of Law, Brisbane, Queensland, Australia jodhi.rutherford@qut.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - end-of-life
OT  - euthanasia
OT  - law
OT  - suicide/assisted suicide
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2020/11/14 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/07/15 00:00 [received]
PHST- 2020/10/05 00:00 [revised]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/11/14 06:00 [medline]
AID - medethics-2020-106702 [pii]
AID - 10.1136/medethics-2020-106702 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 12. pii: medethics-2020-106702. doi:
      10.1136/medethics-2020-106702.


PMID- 33184090
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - Mapping mental health recovery tools developed by mental health service users and
      ex-users: protocol for a scoping review.
PG  - e043957
LID - 10.1136/bmjopen-2020-043957 [doi]
AB  - INTRODUCTION: Since the emergence in 1997 of the Wellness Recovery Action Plan, a
      number of other tools developed by users and/or ex-users of mental health
      services have been published and implemented. All these tools aim to promote
      self-determination in mental health recovery processes. A scoping review will be 
      carried out in order to (1) identify existing tools, (2) describe their
      distinctive characteristics and (3) examine how they have been implemented and
      evaluated. METHODS AND ANALYSIS: The scoping review will be guided by the
      methodological framework proposed by Arksey and O'Malley and expanded by Levac et
      al. It will involve, primarily, a literature search of the following electronic
      databases: Cochrane database, Cumulative Index to Nursing and Allied Health
      Literature, PsycInfo, PsycArticles, Scopus, PubMed and Web of Science. In
      addition, the search process will consider grey literature databases. Users,
      ex-users and survivors organisations and networks will be contacted in order to
      identify any relevant material. The reference lists of the articles identified
      through the literature search will be inspected. Finally, hand searches of
      journals will be conducted in order to increase the confidence in the search. Two
      main approaches will be used to present the charted data: a descriptive analysis 
      and a thematic analysis. The study will be performed between April and December
      2020. The results will be reported in accordance with the Preferred Reporting
      Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews.
      ETHICS AND DISSEMINATION: This study does not require ethical approval because
      the data used are from publicly available materials. The study results will be
      disseminated through an article submitted for publication to a scientific journal
      and presented at relevant conferences. The results will also be shared in future 
      workshops and seminars as part of continuing education programmes for mental
      health professionals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sampietro, Hernan Maria
AU  - Sampietro HM
AD  - Activament Catalunya Associacio, Barcelona, Spain.
AD  - Department of Social Psychology and Quantitative Psychology, University of
      Barcelona, Barcelona, Spain.
FAU - Carmona, Viviana R
AU  - Carmona VR
AUID- ORCID: 0000-0002-0525-0987
AD  - Activament Catalunya Associacio, Barcelona, Spain recerca@activament.org.
FAU - Rojo, J Emilio
AU  - Rojo JE
AD  - Hospital Benito Menni CASM, Sant Boi de Llobregat, Spain.
AD  - Department of Psychiatry, International University of Catalunya, Barcelona,
      Spain.
FAU - Gomez-Benito, Juana
AU  - Gomez-Benito J
AD  - Department of Social Psychology and Quantitative Psychology, University of
      Barcelona, Barcelona, Spain.
AD  - Institute of Neurosciences, University of Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Health Personnel
MH  - Humans
MH  - *Mental Health Recovery
MH  - *Mental Health Services
MH  - Research Design
PMC - PMC7662537
OTO - NOTNLM
OT  - *mental health
OT  - *psychiatry
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-043957 [pii]
AID - 10.1136/bmjopen-2020-043957 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e043957. doi: 10.1136/bmjopen-2020-043957.


PMID- 33184089
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - Thromboelastography-guided blood transfusion during cytoreductive surgery
      combined with hyperthermic intraperitoneal chemotherapy: study protocol for a
      prospective randomised controlled trial.
PG  - e042741
LID - 10.1136/bmjopen-2020-042741 [doi]
AB  - INTRODUCTION: Cytoreductive surgery combined with hyperthermic intraperitoneal
      chemotherapy (CRS/HIPEC) is a well-established treatment for peritoneal cancer
      (PC). However, this kind of combination therapy is associated with a high
      incidence of complications. Moreover, relative studies have indicated that
      traditional laboratory testing is insufficient to demonstrate the overall
      haemostatic physiology of CRS/HIPEC. Thromboelastography (TEG), administered by
      monitoring dynamic changes in haemostasis, has been shown to contribute to
      reducing transfusion requirements and improving survival. However, there is no
      evidence to verify whether TEG can be applied to guide transfusion strategies
      during CRS/HIPEC. Therefore, we aim to investigate whether TEG-guided blood
      product transfusion (TEG-BT) therapy is superior to traditional blood product
      transfusion (T-BT) therapy for guiding perioperative blood transfusion treatment 
      and improving the prognosis of patients undergoing CRS/HIPEC. METHODS AND
      ANALYSIS: The TEG-BT versus T-BT study is a single-centre, randomised, blinded
      outcome assessment clinical trial of 162 patients with PC, aged 18-64 years and
      undergoing CRS/HIPEC. Participants will be randomly allocated to receive TEG-BT
      or T-BT. The primary outcome will be the evaluation of perioperative blood
      transfusion, which refers to the total amount of blood transfusion given from the
      time patients enter the operating room up to 72 hours postoperatively. The
      secondary outcomes will include the transfusion volume during surgery, total
      amount of intraoperative infusion, amount of blood lost during the operation,
      total blood transfusion between 0 and 72 hours after surgery, lowest haemoglobin 
      level within 72 hours after surgery, intensive care unit duration, overall length
      of stay, total cost of hospitalisation and adverse events. Data will be analysed 
      according to the intention-to-treat principle. ETHICS AND DISSEMINATION: The
      study protocol has been approved by the Scientific Research Ethics Committee of
      Beijing Shijitan Hospital Affiliated with Capital Medical University (Approval
      Number: sjtkyll-lx-2020-3). The results will be published in peer-reviewed
      journals. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry
      (ChiCTR2000028835).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Shaoheng
AU  - Wang S
AUID- ORCID: 0000-0002-7060-1122
AD  - Department of Anesthesiology, Beijing Shijitan Hospital, Capital Medical
      University, Beijing, China.
FAU - Zhang, Qing
AU  - Zhang Q
AUID- ORCID: 0000-0002-8567-0067
AD  - Department of Anesthesiology, Beijing Shijitan Hospital, Capital Medical
      University, Beijing, China.
FAU - Chen, Linfeng
AU  - Chen L
AD  - Department of Blood Transfusion, Beijing Shijitan Hospital, Capital Medical
      University, Beijing, China.
FAU - Liu, Gang
AU  - Liu G
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital
      Medical University, Beijing, China.
FAU - Liu, Peng Fei
AU  - Liu PF
AUID- ORCID: 0000-0001-8098-8925
AD  - Department of Anesthesiology, Beijing Shijitan Hospital, Capital Medical
      University, Beijing, China sfflpf@126.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Blood Transfusion
MH  - Combined Modality Therapy
MH  - *Cytoreduction Surgical Procedures
MH  - Humans
MH  - *Hyperthermia, Induced
MH  - Middle Aged
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Thrombelastography
MH  - Young Adult
PMC - PMC7662436
OTO - NOTNLM
OT  - *anaesthesia in oncology
OT  - *bleeding disorders & coagulopathies
OT  - *gastrointestinal tumours
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-042741 [pii]
AID - 10.1136/bmjopen-2020-042741 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e042741. doi: 10.1136/bmjopen-2020-042741.


PMID- 33184084
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind,
      double-dummy, non-inferiority randomised controlled trial comparing intranasal
      1.4 mg to intramuscular 0.8 mg naloxone for prehospital use.
PG  - e041556
LID - 10.1136/bmjopen-2020-041556 [doi]
AB  - INTRODUCTION: Intranasal (IN) naloxone is widely used to treat opioid overdoses. 
      The advantage of nasal administration compared with injection lies in its
      suitability for administration by lay people as it is needless. Approved
      formulations of nasal naloxone with bioavailability of approximately 50% have
      only undergone trials in healthy volunteers, while off-label nasal sprays with
      low bioavailability have been studied in patients. Randomised clinical trials are
      needed to investigate efficacy and safety of approved IN naloxone in patients
      suffering overdose. This study investigates whether the administration of 1.4 mg 
      naloxone in 0.1 mL per dose is non-inferior to 0.8 mg intramuscular injection in 
      patients treated for opioid overdose. METHODS AND ANALYSIS: Sponsor is the
      Norwegian University of Science and Technology. The study has been developed in
      collaboration with user representatives. The primary endpoint is the restoration 
      of spontaneous respiration>/=10 breaths/min based on a sample of 200 opioid
      overdose cases. Double-dummy design ensures blinding, which will be maintained
      until the database is locked. ETHICS AND DISSEMINATION: The study was approved by
      the Norwegian Medicines Agency and Regional Ethics Committees (REC: 2016/2000).
      It adheres to the Good Clinical Practice guidelines as set out by the
      International Council for Harmonisation of Technical Requirements for
      Pharmaceuticals for Human Use.Informed consent will be sought through a
      differentiated model. This allows for deferred consent after inclusion for
      patients who have regained the ability to consent. Patients who are unable to
      consent prior to discharge by emergency services are given written information
      and can withdraw at a later date in line with user recommendations. Metadata will
      be published in the Norwegian University of Science and Technology Open
      repository. Deidentified individual participant data will be made available to
      recipients conditional of data processor agreement being entered. TRIAL
      REGISTRATION NUMBERS: EudraCT Registry (2016-004072-22) and Clinicaltrials.gov
      Registry (NCT03518021).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Skulberg, Arne Kristian
AU  - Skulberg AK
AUID- ORCID: 0000-0002-1735-4820
AD  - Department of Circulation and Medical Imaging, Norwegian University of Science
      and Technology, Trondheim, Norway arne.skulberg@ntnu.no.
AD  - Division of Prehospital Services, Oslo University Hospital, Oslo, Norway.
FAU - Tylleskar, Ida
AU  - Tylleskar I
AD  - Department of Circulation and Medical Imaging, Norwegian University of Science
      and Technology, Trondheim, Norway.
AD  - Clinic of Emergency Medicine and Prehospital Care, St Olavs Hospital, Trondheim
      University Hospital, Trondheim, Norway.
FAU - Braarud, Anne-Cathrine
AU  - Braarud AC
AD  - Division of Prehospital Services, Oslo University Hospital, Oslo, Norway.
FAU - Dale, Jostein
AU  - Dale J
AD  - Clinic of Emergency Medicine and Prehospital Care, St Olavs Hospital, Trondheim
      University Hospital, Trondheim, Norway.
AD  - Department of Research and Development, Norwegian Air Ambulance Foundation, Oslo,
      Norway.
FAU - Heyerdahl, Fridtjof
AU  - Heyerdahl F
AD  - Division of Prehospital Services, Oslo University Hospital, Oslo, Norway.
AD  - Department of Research and Development, Norwegian Air Ambulance Foundation, Oslo,
      Norway.
FAU - Mellesmo, Sindre
AU  - Mellesmo S
AD  - Division of Prehospital Services, Oslo University Hospital, Oslo, Norway.
FAU - Valberg, Morten
AU  - Valberg M
AD  - Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway.
FAU - Dale, Ola
AU  - Dale O
AD  - Department of Circulation and Medical Imaging, Norwegian University of Science
      and Technology, Trondheim, Norway.
AD  - Department of Research and Development, St Olavs University Hospital, Oslo,
      Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT03518021
SI  - EudraCT/2016-004072-22
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Narcotic Antagonists)
RN  - 36B82AMQ7N (Naloxone)
SB  - IM
MH  - Administration, Intranasal
MH  - Adolescent
MH  - Aged
MH  - Double-Blind Method
MH  - Drug Overdose/drug therapy
MH  - *Emergency Medical Services
MH  - Humans
MH  - Naloxone/*therapeutic use
MH  - Narcotic Antagonists/therapeutic use
MH  - Norway
MH  - Randomized Controlled Trials as Topic
PMC - PMC7662429
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *clinical pharmacology
OT  - *medical ethics
OT  - *statistics & research methods
OT  - *toxicology
COIS- Competing interests: The contents and production of study kits are funded by dne 
      pharma as, Oslo, Norway. Norwegian University of Science and Technology (NTNU)
      and its subsidiary Technical Transfer Office have signed cooperative and
      licensing contracts with dne pharma as to seek commercialisation of this nasal
      naloxone formulation. This regulates potential royalties for OD through NTNU. dne
      pharma as has compensated OD for business travel from Trondheim to Oslo and to
      Lisbon. AKS spoke at a seminar arranged by dne pharma as in Lisbon in October
      2019 without an honorarium or other compensation. The other authors declare no
      conflicts of interest. The funding sources have no role in the study design, data
      collection, data analysis, data interpretation or writing of the clinical study
      report.
EDAT- 2020/11/14 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-041556 [pii]
AID - 10.1136/bmjopen-2020-041556 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e041556. doi: 10.1136/bmjopen-2020-041556.


PMID- 33184083
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to 
      SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised
      trial.
PG  - e040110
LID - 10.1136/bmjopen-2020-040110 [doi]
AB  - INTRODUCTION: Lopinavir/ritonavir (LPV/r) has been proposed as repurposed drugs
      for pre-exposure and postexposure prophylaxis as well as therapy of COVID-19.
      Coronavirus postexposure prophylaxis (COPEP) trial aims at assessing their
      efficacy as postexposure ring-prophylaxis among adults exposed to SARS-CoV-2.
      METHODS AND ANALYSIS: COPEP is a two-arm open-label cluster-randomised trial
      conducted in three cantons of Switzerland. Asymptomatic contacts (>/=16 years) of
      individuals diagnosed with COVID-19 will be randomised (2:1) to either LPV/r (400
      mg/100 mg two times per day) for 5 days, or a standard of care arm (no
      treatment). Asymptomatic individuals may be either SARS-CoV-2 positive or
      negative. Contacts living in the single household will form a cluster and will be
      randomised into the same arm. All participants will be followed-up for 21 days
      and undergo daily monitoring for COVID-19 symptoms. The primary endpoint is
      21-day incidence of laboratory-confirmed COVID-19 with >/=1 compatible symptom,
      analysed in an intention-to-treat (ITT) analysis. The secondary endpoints include
      the 21-day incidence of COVID-19 as well as SARS-CoV-2 infection in a modified
      ITT analysis, excluding participants who had a positive SARS-CoV-2 RT-PCR from
      oropharyngeal swab and/or a positive SARS-CoV-2 IgG serology at baseline.
      Assuming a 21-day incidence for COVID-19 of 20% among contacts without
      postexposure chemoprophylaxis, to detect a relative risk reduction of 60% (ie,
      translating in an absolute reduction from 20% to 8%), with a power of 80%, an
      alpha of 5%. Accounting for design effect of cluster design of circa 1.1, we plan
      to enrol 200 participants to the LPV/r arm and 100 to the standard of care arm,
      300 participants in total. ETHICS AND DISSEMINATION: Ethics approval has been
      granted by the Commission Cantonale d'Ethique de la Recherche, Ethikkommission
      Nordwest- und Zentralschweiz and Comitato Etico Cantonale (ref 2020-00864) and
      Swissmedic (2020DR3056). Results from this trial will be disseminated via journal
      articles and presentations at national and international conferences. TRIAL
      REGISTRATION NUMBER: Clinicaltrials.gov Registry (NCT04364022); Swiss National
      Clinical Trial Portal Registry (SNCTP 000003732). REGISTERED REPORT IDENTIFIER:
      CCER 2020-0864.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Smit, Mikaela
AU  - Smit M
AUID- ORCID: 0000-0001-8530-748X
AD  - HIV Unit, Geneva University Hospitals, Geneva, Switzerland mikaela.smit@hcuge.ch.
AD  - Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Marinosci, Annalisa
AU  - Marinosci A
AD  - HIV Unit, Geneva University Hospitals, Geneva, Switzerland.
FAU - Nicoletti, Giovanni Jacopo
AU  - Nicoletti GJ
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
FAU - Perneger, Thomas
AU  - Perneger T
AUID- ORCID: 0000-0001-5667-0968
AD  - Faculty of Medicine, University of Geneva, Geneva, Switzerland.
AD  - Division of Clinical Epidemiology, Geneva University Hospitals, Geneva,
      Switzerland.
FAU - Ragozzino, Silvio
AU  - Ragozzino S
AD  - Department of Infectious Diseases and Hospital Epidemiology, University of Basel,
      Basel, Switzerland.
FAU - Andrey, Diego O
AU  - Andrey DO
AD  - HIV Unit, Geneva University Hospitals, Geneva, Switzerland.
AD  - Faculty of Medicine, University of Geneva, Geneva, Switzerland.
AD  - Division of Laboratory Medicine, Diagnostic Department, Geneva University
      Hospitals, Geneva, Switzerland.
FAU - Stoeckle, Marcel
AU  - Stoeckle M
AD  - Department of Infectious Diseases and Hospital Epidemiology, University of Basel,
      Basel, Switzerland.
FAU - Jacquerioz, Frederique
AU  - Jacquerioz F
AUID- ORCID: 0000-0002-6957-0920
AD  - Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.
FAU - Lebowitz, Dan
AU  - Lebowitz D
AD  - Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.
AD  - Direction Generale de la Sante, Republique et Canton de Geneve, Geneva,
      Switzerland.
FAU - Agoritsas, Thomas
AU  - Agoritsas T
AD  - Faculty of Medicine, University of Geneva, Geneva, Switzerland.
AD  - Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Meyer, Benjamin
AU  - Meyer B
AD  - Centre for Vaccinology, Department of Pathology and Immunology, University of
      Geneva, Geneva, Switzerland.
FAU - Spechbach, Herve
AU  - Spechbach H
AD  - Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.
FAU - Salamun, Julien
AU  - Salamun J
AD  - Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.
FAU - Back, Moritz
AU  - Back M
AD  - Gesundheitsdepartement, Canton of Basel City, Basel, Switzerland.
FAU - Schaubhut, Carla
AU  - Schaubhut C
AD  - Gesundheitsdepartement, Canton of Basel City, Basel, Switzerland.
FAU - Fuchs, Simon
AU  - Fuchs S
AD  - Gesundheitsdepartement, Canton of Basel City, Basel, Switzerland.
FAU - Decosterd, Laurent
AU  - Decosterd L
AD  - Laboratory of Clinical Pharmacology, University of Lausanne, Lausanne,
      Switzerland.
FAU - Battegay, Manuel
AU  - Battegay M
AD  - Department of Infectious Diseases and Hospital Epidemiology, University of Basel,
      Basel, Switzerland.
FAU - Guessous, Idris
AU  - Guessous I
AD  - Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.
FAU - Chappuis, Francois
AU  - Chappuis F
AD  - Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland.
FAU - Kaiser, Laurent
AU  - Kaiser L
AD  - Division of Infectious Diseases, Geneva University Hospitals, Geneva,
      Switzerland.
AD  - Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,
      Switzerland.
FAU - Labhardt, Niklaus D
AU  - Labhardt ND
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
AD  - Department of Infectious Diseases and Hospital Epidemiology, University of Basel,
      Basel, Switzerland.
FAU - Calmy, Alexandra
AU  - Calmy A
AD  - HIV Unit, Geneva University Hospitals, Geneva, Switzerland.
AD  - Faculty of Medicine, University of Geneva, Geneva, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04364022
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (lopinavir-ritonavir drug combination)
RN  - 2494G1JF75 (Lopinavir)
RN  - O3J8G9O825 (Ritonavir)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Drug Combinations
MH  - Humans
MH  - Lopinavir/*therapeutic use
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Post-Exposure Prophylaxis/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Ritonavir/*therapeutic use
MH  - SARS-CoV-2
MH  - Switzerland
PMC - PMC7662450
OTO - NOTNLM
OT  - *COVID-19
OT  - *clinical trials
OT  - *epidemiology
OT  - *infectious diseases
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjopen-2020-040110 [pii]
AID - 10.1136/bmjopen-2020-040110 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e040110. doi: 10.1136/bmjopen-2020-040110.


PMID- 33184081
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - Protocol for a case-control study of vitamin D status, adult multidrug-resistant 
      tuberculosis disease and tuberculosis infection in Mumbai, India.
PG  - e039935
LID - 10.1136/bmjopen-2020-039935 [doi]
AB  - INTRODUCTION: Vitamin D status may be an important determinant of
      multidrug-resistant tuberculosis (MDR-TB) infection, progression to disease and
      treatment outcomes. Novel and potentially cost-effective therapies such as
      vitamin D supplementation are needed to stem the tide of TB and MDR-TB globally, 
      particularly in India, a country that accounts for the largest fraction of the
      world's TB incidence and MDR-TB incidence, and where vitamin D deficiency is
      endemic. While vitamin D has shown some promise in the treatment of MDR-TB, its
      role in the context of MDR-TB infection and progression to disease is largely
      unknown. METHODS AND ANALYSIS: Through a case-control study in Mumbai, India, we 
      aim to examine associations between vitamin D status and active MDR-TB and to
      investigate vitamin D status and TB infection among controls. Cases are adult
      outpatient pulmonary patients with MDR-TB recruited from two public TB clinics.
      Controls are recruited from the cases' household contacts and from
      non-respiratory departments of the facilities where cases were recruited. Cases
      and controls are assessed for serum 25-hydroxyvitamin D concentration, nutrient
      intake, diet quality, anthropometry and other relevant clinical and
      sociodemographic parameters. Controls undergo additional clinical assessments to 
      rule out active TB and laboratory assessments to determine presence of TB
      infection. Statistical analysis investigates associations between vitamin D
      status and active MDR-TB and between vitamin D status and TB infection among
      controls, accounting for potential confounding effects of diet, anthropometry and
      other covariates. ETHICS AND DISSEMINATION: This study has been approved by
      Harvard T.H. Chan School of Public Health Institutional Review Board; Foundation 
      for Medical Research Institutional Research Ethics Committee and Health
      Ministry's Screening Committee of the Indian Council for Medical Research.
      Permission was granted by the Municipal Corporation of Greater Mumbai, India, a
      collaborating partner on this research. Outcomes will be disseminated through
      publication and scientific presentation. TRIAL REGISTRATION NUMBER: NCT04342598.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mistry, Nerges
AU  - Mistry N
AD  - Department of Tuberculosis Research, Foundation for Medical Research, Mumbai,
      India.
FAU - Hemler, Elena C
AU  - Hemler EC
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, Massachusetts, USA.
FAU - Dholakia, Yatin
AU  - Dholakia Y
AD  - Department of Tuberculosis Research, Foundation for Medical Research, Mumbai,
      India.
FAU - Bromage, Sabri
AU  - Bromage S
AUID- ORCID: 0000-0002-6552-4871
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Shukla, Anupam
AU  - Shukla A
AD  - Department of Tuberculosis Research, Foundation for Medical Research, Mumbai,
      India.
FAU - Dev, Prachi
AU  - Dev P
AD  - Department of Tuberculosis Research, Foundation for Medical Research, Mumbai,
      India.
FAU - Govekar, Laxmi
AU  - Govekar L
AD  - Department of Tuberculosis Research, Foundation for Medical Research, Mumbai,
      India.
FAU - Tipre, Pranita
AU  - Tipre P
AD  - Municipal Corporation of Greater Mumbai, Mumbai, India.
FAU - Shah, Daksha
AU  - Shah D
AD  - Municipal Corporation of Greater Mumbai, Mumbai, India.
FAU - Keshavjee, Salmaan A
AU  - Keshavjee SA
AD  - Department of Global Health and Social Medicine, Harvard Medical School, Boston, 
      Massachusetts, USA.
FAU - Fawzi, Wafaie W
AU  - Fawzi WW
AUID- ORCID: 0000-0002-2908-600X
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, Massachusetts, USA mina@hsph.harvard.edu.
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04342598
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antitubercular Agents)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Adult
MH  - Antitubercular Agents/therapeutic use
MH  - Case-Control Studies
MH  - Humans
MH  - India/epidemiology
MH  - *Tuberculosis/drug therapy
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy/epidemiology
MH  - Vitamin D
PMC - PMC7662534
OTO - NOTNLM
OT  - *epidemiology
OT  - *nutrition & dietetics
OT  - *public health
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039935 [pii]
AID - 10.1136/bmjopen-2020-039935 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e039935. doi: 10.1136/bmjopen-2020-039935.


PMID- 33184079
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - Which moral barriers and facilitators do physicians encounter in advance care
      planning conversations about the end of life of persons with dementia? A
      meta-review of systematic reviews and primary studies.
PG  - e038528
LID - 10.1136/bmjopen-2020-038528 [doi]
AB  - IMPORTANCE AND OBJECTIVE: Conducting advance care planning (ACP) conversations
      with people with dementia and their relatives contributes to providing care
      according to their preferences. In this review, we identify moral considerations 
      which may hinder or facilitate physicians in conducting ACP in dementia. DESIGN: 
      For this meta-review of systematic reviews and primary studies, we searched the
      PubMed, Web of Science and PsycINFO databases between 2005 and 30 August 2019. We
      included empirical studies concerning physicians' moral barriers and facilitators
      of conversations about end-of-life preferences in dementia care. The protocol was
      registered at Prospero (CRD42019123308). SETTING AND PARTICIPANTS: Physicians and
      nurse practitioners providing medical care to people with dementia in long-term
      and primary care settings. We also include observations from patients or family
      caregivers witnessing physicians' moral considerations. MAIN OUTCOMES:
      Physicians' moral considerations involving ethical dilemmas for ACP. We define
      moral considerations as the weighing by the professional caregiver of values and 
      norms aimed at providing good care that promotes the fundamental interests of the
      people involved and which possibly ensues dilemmas. RESULTS: Of 1347 studies, we 
      assessed 22 systematic reviews and 51 primary studies as full texts. We included 
      11 systematic reviews and 13 primary studies. Themes included: (1) beneficence
      and non-maleficence; (2) respecting dignity; (3) responsibility and ownership;
      (4) relationship and (5) courage. Moral dilemmas related to the physician as a
      professional and as a person. For most themes, there were considerations that
      either facilitated or hindered ACP, depending on physician's interpretation or
      the context. CONCLUSIONS: Physicians feel a responsibility to provide
      high-quality end-of-life care to patients with dementia. However, the moral
      dilemmas this may involve, can lead to avoidant behaviour concerning ACP. If
      these dilemmas are not recognised, discussed and taken into account,
      implementation of ACP as a process between physicians, persons with dementia and 
      their family caregivers may fail.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Keijzer-van Laarhoven, Angela Jjm
AU  - Keijzer-van Laarhoven AJ
AUID- ORCID: 0000-0002-3362-1407
AD  - Department of Expertise and Treatment, Argos Zorggroep, Schiedam, The Netherlands
      A.J.J.M.Keijzer@lumc.nl jtvandersteen@lumc.nl.
AD  - Department of Medical Ethics and Health Law (E&R), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands.
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands.
AD  - Department of Expertise and Treatment, Laurens, Rotterdam, The Netherlands.
FAU - Touwen, Dorothea P
AU  - Touwen DP
AD  - Department of Medical Ethics and Health Law (E&R), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands.
FAU - Tilburgs, Bram
AU  - Tilburgs B
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands.
FAU - van Tilborg-den Boeft, Madelon
AU  - van Tilborg-den Boeft M
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands.
AD  - Quin, Amsterdam, The Netherlands.
FAU - Pees, Claudia
AU  - Pees C
AD  - Walaeus Library, Leiden University Medical Center (LUMC), Leiden, The
      Netherlands.
FAU - Achterberg, Wilco P
AU  - Achterberg WP
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands.
FAU - van der Steen, Jenny T
AU  - van der Steen JT
AUID- ORCID: 0000-0002-9063-7501
AD  - Department of Public Health and Primary Care (PHEG), Leiden University Medical
      Center (LUMC), Leiden, The Netherlands A.J.J.M.Keijzer@lumc.nl
      jtvandersteen@lumc.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Advance Care Planning
MH  - Death
MH  - *Dementia
MH  - Humans
MH  - *Physicians
MH  - Systematic Reviews as Topic
PMC - PMC7662455
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *medical ethics
OT  - *palliative care
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038528 [pii]
AID - 10.1136/bmjopen-2020-038528 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e038528. doi: 10.1136/bmjopen-2020-038528.


PMID- 33184076
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 12
TI  - Treatment with the anti-IgE monoclonal antibody omalizumab in women with asthma
      undergoing fertility treatment: a proof-of-concept study-The PRO-ART study
      protocol.
PG  - e037041
LID - 10.1136/bmjopen-2020-037041 [doi]
AB  - INTRODUCTION: Asthma is associated with prolonged time to pregnancy and a higher 
      need for fertility treatment. However, the mechanism underlying this association 
      remains incompletely understood. Previous research points to asthma-driven
      systemic inflammation also affecting the reproductive organs and thereby
      fertility. The aim of this study was to determine if treatment with omalizumab
      prior to fertility treatment will increase pregnancy rate among women with asthma
      by decreasing the systemic asthma-related inflammation and, by that, to provide
      insight into the underlying mechanisms. METHODS AND ANALYSIS: This is an ongoing 
      prospective multicentre randomised controlled trial planned to enrol 180 women
      with asthma recruited from fertility clinics in Denmark. The patients are
      randomised 1:1 to either omalizumab or placebo. The primary endpoint is the
      difference in pregnancy rate confirmed with ultrasound at gestational week 7 of
      pregnancy. The secondary endpoints are change in sputum and blood eosinophil cell
      count, change in biomarkers, change in microbiota, together with rate of
      pregnancy loss, frequency of malformations, pre-eclampsia, preterm birth, birth
      weight, small for gestational age and perinatal death between groups. ETHICS AND 
      DISSEMINATION: The methods used in this study are of low risk, but if successful,
      our findings will have a large impact on a large group of patients as infertility
      and asthma are the most common chronic diseases among the young population. The
      study has been approved by the Ethics Committee-Danish national research ethics
      committee (H-18016605) and the Danish Medicines Agency (EudraCT no:
      2018-001137-41) and the Danish Data Protection Agency (journal number: VD-2018486
      and I-Suite number 6745). The test results will be published regardless of
      whether they are positive, negative or inconclusive. Publication in international
      peer-reviewed scientific journals is planned. TRIAL REGISTRATION NUMBER:
      NCT03727971.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tidemandsen, Casper
AU  - Tidemandsen C
AUID- ORCID: 0000-0001-6032-6414
AD  - Department of Respiratory Diseases, Hvidovre Hospital, University of Copenhagen, 
      Copenhagen, Denmark casper.tidemandsen.02@regionh.dk.
FAU - Juul Gade, Elisabeth
AU  - Juul Gade E
AD  - Department of Obstetrics and Gynecology, Roskilde Hospital, Copenhagen, Denmark.
FAU - Ulrik, Charlotte Suppli
AU  - Ulrik CS
AD  - Department of Respiratory Diseases, Hvidovre Hospital, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Nielsen, Henriette Svarre
AU  - Nielsen HS
AD  - Department of Obstetrics and Gynaecology, The Fertility Clinic, Copenhagen
      University Hospital, Hvidovre Hospital, Copenhagen, Denmark.
FAU - Oxlund-Mariegaard, Birgitte Sophie
AU  - Oxlund-Mariegaard BS
AD  - Fertility Clinic, Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Kristiansen, Karsten
AU  - Kristiansen K
AD  - Laboratory of Genomics and Molecular Biomedicine, Department of Biology,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Freiesleben, Nina La Cour
AU  - Freiesleben NC
AD  - Department of Obstetrics and Gynaecology, The Fertility Clinic, Copenhagen
      University Hospital, Hvidovre Hospital, Copenhagen, Denmark.
FAU - Nohr, Bugge
AU  - Nohr B
AD  - Fertility Clinic, Herlev Hospital, Herlev, Denmark.
FAU - Udengaard, Hanne
AU  - Udengaard H
AD  - Fertility Clinic, Herlev Hospital, Herlev, Denmark.
FAU - Backer, Vibeke
AU  - Backer V
AD  - Centre for Physical Activity Research, Rigshospitalet, Kobenhavn, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03727971
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201112
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Antibodies, Anti-Idiotypic
MH  - *Asthma/drug therapy
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Multicenter Studies as Topic
MH  - Omalizumab/therapeutic use
MH  - Pregnancy
MH  - *Premature Birth
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7662444
OTO - NOTNLM
OT  - *asthma
OT  - *reproductive medicine
OT  - *respiratory medicine (see thoracic medicine)
OT  - *subfertility
COIS- Competing interests: None declared.
EDAT- 2020/11/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/13 05:45
PHST- 2020/11/13 05:45 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037041 [pii]
AID - 10.1136/bmjopen-2020-037041 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 12;10(11):e037041. doi: 10.1136/bmjopen-2020-037041.


PMID- 33183551
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 2405-4577 (Electronic)
IS  - 2405-4577 (Linking)
VI  - 40
DP  - 2020 Dec
TI  - Reducing 30-day post gastrostomy insertion mortality with a feeding issues
      multidisciplinary team meeting.
PG  - 282-287
LID - S2405-4577(20)30192-3 [pii]
LID - 10.1016/j.clnesp.2020.09.005 [doi]
AB  - INTRODUCTION: Decision-making regarding percutaneous endoscopic gastrostomy (PEG)
      insertion can be complex both medically and ethically. Thirty-day mortality
      following (PEG) insertion is an important quality indicator for endoscopy
      accreditation and for service evaluation. It also forms part of the measures
      assessed within the 'Getting It Right First Time' programme (GIRFT). We aimed to 
      assess the impact of a newly adopted Feeding Issues MDT (FIMDT) and the clinical 
      application of the Royal Free Gastrostomy Score (RFGS). METHOD: We adopted a
      retrospective observational methodology to assess the impact of a feeding issues 
      MDT within our trust. The included study period ran from January 2016 to December
      2019 (4 years). This formed part of a quality improvement (QI) project initiated 
      upon receipt of the GIRFT report for our NHS trust. Statistical analysis and QI
      methodology was used to interpret and present the data. RESULTS: Two hundred and 
      sixty eight PEG insertions occurred during the study period. 188 PEGs were
      inserted prior to the start of FIMDT and 45 following its inception. On average
      there were 66 PEGs performed per year. There was no significant difference in age
      for those undergoing PEG insertion pre (68 years) and post (69 years) FIMDT
      adoption. Prior to FIMDT those that died within 30 days post PEG were
      significantly older than those who did not (p < 0.001), whilst following FIMDT
      adoption there was no such difference. Prior to FIMDT the 30-day post PEG
      mortality was 10.64%, whilst following adoption of the FIMDT the mortality rate
      fell to 6.6% (p = 0.04). The mean number of procedures performed between a 30-day
      mortality occurring rose from 7.5 to 13.6. Furthermore, the mean number of days
      between a 30-day post insertion mortality occurring also rose from a mean of
      53.0-111.8, pre and post FIMDT adoption. The Royal Free Gastrostomy Score (RFGS) 
      for those discussed at FIMDT and declined for PEG insertion was significantly
      higher than those accepted for PEG insertion (p = 0.01). Over the entire study
      period those who died within 30 days following PEG insertion had a significantly 
      greater RFGS (p < 0.0001). CONCLUSION: In our trust the adoption of a FIMDT has
      significantly reduced the 30-day mortality for PEG insertion. We have also
      demonstrated the clinical utility to assess mortality risk of the RFGS when
      making decisions around patient suitability for PEG insertion.
CI  - Copyright (c) 2020 European Society for Clinical Nutrition and Metabolism.
      Published by Elsevier Ltd. All rights reserved.
FAU - Bond, A
AU  - Bond A
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK. Electronic address:
      ashleybond@doctors.org.uk.
FAU - Conley, T
AU  - Conley T
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
FAU - Fiske, J
AU  - Fiske J
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
FAU - Raymond, V
AU  - Raymond V
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
FAU - Young, A
AU  - Young A
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
FAU - Collins, P
AU  - Collins P
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
FAU - Dibb, M
AU  - Dibb M
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
FAU - Smith, P J
AU  - Smith PJ
AD  - Dept of Gastroenterology, Royal Liverpool University Hospital, Liverpool
      University Foundation Trust, Prescot Street, Liverpool, UK.
LA  - eng
GR  - G0902022/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20201001
PL  - England
TA  - Clin Nutr ESPEN
JT  - Clinical nutrition ESPEN
JID - 101654592
SB  - IM
MH  - Aged
MH  - *Endoscopy
MH  - *Gastrostomy
MH  - Humans
MH  - Patient Care Team
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *Mortality
OT  - *Multidisciplinary team meeting
OT  - *Percutaneous endoscopic gastrostomy
EDAT- 2020/11/14 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/11/13 05:34
PHST- 2020/06/26 00:00 [received]
PHST- 2020/09/03 00:00 [revised]
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/11/13 05:34 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
AID - S2405-4577(20)30192-3 [pii]
AID - 10.1016/j.clnesp.2020.09.005 [doi]
PST - ppublish
SO  - Clin Nutr ESPEN. 2020 Dec;40:282-287. doi: 10.1016/j.clnesp.2020.09.005. Epub
      2020 Oct 1.


PMID- 33183358
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201218
IS  - 2045-4015 (Electronic)
IS  - 2045-4015 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Nov 12
TI  - Age, ageing, ageism and "age-itation" in the Age of COVID-19: rights and
      obligations relating to older persons in Israel as observed through the lens of
      medical ethics.
PG  - 64
LID - 10.1186/s13584-020-00416-y [doi]
AB  - COVID-19, the illness caused by the SARS-CoV-2 virus, has reached pandemic
      proportions. Although the virus can cause disease in anyone, it is particularly
      dangerous for those with various "co-morbidities" such as heart disease,
      hypertension, diabetes, obesity and others. Furthermore, advancing age (from
      about 60 on), even in those older persons without any accompanying illnesses, is 
      a strong and independent risk factor for pneumonia, need for an ICU bed and death
      from the virus. It is therefore essential to find ways to protect all at-risk
      persons (old or young) from the virus but at the same time not harming, more than
      absolutely necessary their essential freedoms as well as taking into account
      their social/psychological needs. Compared with other OECD countries, Israel's
      population is still relatively young, with only 11.5% being over 65+ with a
      smaller proportion of older persons in long-term institutions than that found in 
      most other comparable jurisdictions. These factors might explain a part of the
      country's (so far) relatively low rates of serious disease and mortality compared
      to those seen in other developed countries. However there are still over a
      million older citizens at risk and the numbers of infected, hospitalized and
      seriously ill persons are rising once again. This is no time for complacency.An
      analysis of the effect of age on the disease as seen through the principles of
      medical ethics is followed by a proposal as to how best to balance these
      sometimes conflicting goals. This paper relates mainly to older persons in the
      community since the Ministry of Health early on in the pandemic initiated an
      effective program (Magen Avot) meant to protect those older persons in long-term 
      care institutions. Recommendations include the Ministry of Health publishing
      clear guidelines as to risk factors and offering sensible advice on how to
      practice physical (not "social") distancing without exacerbating an older
      person's sense of social isolation. In order to reduce the incidence of influenza
      (which can clinically be confused with COVID-19) and the potentially disastrous
      consequences of a "double pandemic" this coming winter, a robust flu vaccination 
      program needs immediate implementation. Persons at all ages (but especially those
      60+) should be encouraged and assisted to sign advance directives, especially
      those who do not wish to undergo invasive therapy. An individual older person's
      wish to "make way" for younger people should be respected as an expression of
      his/her autonomy. As we enter the second wave, triage mechanisms and protocols
      need to be circulated in readiness for and well before a situation in which an
      acute imbalance develops between the availability for acute resources and the
      population's need for them. The Ministry of Health, in cooperation with other
      relevant ministries and NGOs, should take the lead in developing plans, ensuring 
      that they are carried out in an orderly, timely and transparent manner. The
      blanket is indeed not large enough but we must place it as judiciously as
      possible in order as much as possible to protect, cover and keep warm the body
      politic.
FAU - Clarfield, A Mark
AU  - Clarfield AM
AUID- ORCID: 0000-0002-0388-5663
AD  - Geriatric Medicine, Centre for Global Health and the Medical School for
      International Health, Faculty of Health Sciences, Ben-Gurion University of the
      Negev, MSIH-Bet Caroline, PO Box 653, 8410501, Beer-sheva, Israel.
      markclar@bgu.ac.il.
AD  - McGill University, Montreal, Canada. markclar@bgu.ac.il.
FAU - Jotkowitz, Alan
AU  - Jotkowitz A
AD  - Medical School for International Health and The Jakobovits Center for Jewish
      Medical Ethics, Faculty of Health Sciences, Ben-Gurion University of the Negev,
      Beer-sheva, Israel.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - England
TA  - Isr J Health Policy Res
JT  - Israel journal of health policy research
JID - 101584158
SB  - IM
MH  - Aged
MH  - *Ageism
MH  - *Aging
MH  - COVID-19
MH  - Comorbidity
MH  - *Coronavirus Infections
MH  - *Ethics, Medical
MH  - Humans
MH  - Israel
MH  - *Pandemics
MH  - *Pneumonia, Viral
PMC - PMC7658431
EDAT- 2020/11/14 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/13 05:33
PHST- 2020/07/02 00:00 [received]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/11/13 05:33 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1186/s13584-020-00416-y [doi]
AID - 10.1186/s13584-020-00416-y [pii]
PST - epublish
SO  - Isr J Health Policy Res. 2020 Nov 12;9(1):64. doi: 10.1186/s13584-020-00416-y.


PMID- 33183059
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Nov
TI  - Comparison of comfort and complications in breast cancer patients of implantable 
      venous access port (IVAP) with ultrasound guided internal jugular vein (IJV) and 
      axillary vein/subclavian vein (AxV/SCV) puncture: a randomized controlled study
      protocol.
PG  - 4323-4331
LID - 10.21037/apm-20-1752 [doi]
AB  - BACKGROUND: Internal jugular vein (IJV) and axillary vein/subclavian vein
      (AxV/SCV) are commonly used for implantable venous access port (IVAP)
      implantation in breast cancer (BC) patients with chemotherapy. Previous studies
      focused on complications between these different approaches and ignored patient
      comfort. In this study, we aim to compare patient comfort between IJV and AxV/SCV
      approaches, as well as surgery duration and complications. METHODS: This is a
      single-center prospective randomized controlled clinical trial. A total of 200
      patients diagnosed with invasive BC will be enrolled in this study. After signing
      written informed consent, patients schedule to undergo IVAP implantation will be 
      randomized at a 1:1 ratio to receive central venous catheters (CVC) with either
      IJV or AxV/SCV approaches. Baseline as well as demographic data and procedure
      time of port implantation will be recorded. All patients will receive assessment 
      of comfort with a comfort scale table at days 1, 2 and 7 after implantation
      surgery. Patients will be followed up and complications will be recorded until
      devices are removed at the end of the treatment period, or in case of
      complications. Patient comfort, procedure time of implantation and complications 
      will be compared and analyzed between these two arms. DISCUSSION: To the best of 
      our knowledge, this is the first study to compare patient comfort as primary
      outcome measure between IJV and AxV/SCV puncture. This study will further confirm
      the benefits of ultrasound guidance and may provide a better choice of IVAP
      implantation for BC patients. TRIAL REGISTRATION: This study has been registered 
      at Chinese Clinical Trial Registry (ChiCTR, www. chictr.org.cn) and Chinese
      Ethics Committee of Registering Clinical Trials (No. ChiCTR2000034986).
FAU - Chen, Yan-Bo
AU  - Chen YB
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Bao, Hao-Shi
AU  - Bao HS
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Deng, He-Ran
AU  - Deng HR
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Hu, Ting-Ting
AU  - Hu TT
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Wen, Biao-Lin
AU  - Wen BL
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Yi, Chun-Yan
AU  - Yi CY
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Chen, Xiu-Wan
AU  - Chen XW
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Yan, Li
AU  - Yan L
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China. hfxyl@163.net.
FAU - Wu, Jian-Nan
AU  - Wu JN
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor, Epigenetics and Gene
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
      China; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen
      University, Guangzhou, China. king8702@163.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201110
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
SB  - IM
MH  - Axillary Vein/diagnostic imaging
MH  - *Breast Neoplasms
MH  - *Catheterization, Central Venous/adverse effects
MH  - *Central Venous Catheters
MH  - Humans
MH  - Jugular Veins/diagnostic imaging
MH  - Prospective Studies
MH  - Punctures
MH  - Randomized Controlled Trials as Topic
MH  - Subclavian Vein
MH  - Ultrasonography, Interventional
OTO - NOTNLM
OT  - Breast cancer (BC)
OT  - axillary vein/ subclavian vein (AxV/SCV)
OT  - comfort
OT  - complications
OT  - implantable venous access port (IVAP)
OT  - internal jugular vein (IJV)
EDAT- 2020/11/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/13 05:31
PHST- 2020/08/31 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/11/13 05:31 [entrez]
AID - 10.21037/apm-20-1752 [doi]
AID - apm-20-1752 [pii]
PST - ppublish
SO  - Ann Palliat Med. 2020 Nov;9(6):4323-4331. doi: 10.21037/apm-20-1752. Epub 2020
      Nov 10.


PMID- 33181940
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1879-3363 (Electronic)
IS  - 0025-326X (Linking)
VI  - 160
DP  - 2020 Nov
TI  - Effects of single and combined exposures of gold (nano versus ionic form) and
      gemfibrozil in a liver organ culture of Sparus aurata.
PG  - 111665
LID - S0025-326X(20)30783-9 [pii]
LID - 10.1016/j.marpolbul.2020.111665 [doi]
AB  - In vitro methods have gained rising importance in ecotoxicology due to ethical
      concerns. The aim of this study was to assess the single and combined in vitro
      effects of gold, as nanoparticle (AuNPs) and ionic (Au(+)) form, and the
      pharmaceutical gemfibrozil (GEM). Sparus aurata liver organ culture was exposed
      to gold (4 to 7200 mug.L(-1)), GEM (1.5 to 15,000 mug.L(-1)) and combination 80
      mug.L(-1) gold +150 mug.L(-1) GEM for 24 h. Endpoints related with antioxidant
      status, peroxidative/genetic damage were assessed. AuNPs caused more effects than
      Au(+), increasing catalase and glutathione reductase activities and damaging DNA 
      and cellular membranes. Effects were dependent on AuNPs size, coating and
      concentration. GEM damaged DNA at an environmentally relevant concentration, 1.5 
      mug.L(-1). Overall, the effects of the combined exposures were higher than the
      predicted, based on single exposures. This study showed that liver culture can be
      a useful model to study contaminants effects.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Barreto, A
AU  - Barreto A
AD  - Departamento de Biologia & CESAM, Universidade de Aveiro, 3810-193 Aveiro,
      Portugal. Electronic address: abarreto@ua.pt.
FAU - Carvalho, A
AU  - Carvalho A
AD  - Departamento de Biologia & CESAM, Universidade de Aveiro, 3810-193 Aveiro,
      Portugal.
FAU - Silva, D
AU  - Silva D
AD  - Departamento de Biologia & CESAM, Universidade de Aveiro, 3810-193 Aveiro,
      Portugal.
FAU - Pinto, E
AU  - Pinto E
AD  - Departamento de Saude Ambiental, Escola Superior de Saude, P. Porto. CISA/Centro 
      de Investigacao em saude e Ambiente, Rua Dr. Antonio Bernardino de Almeida, 400, 
      4200-072 Porto, Portugal; LAQV/REQUIMTE, Departamento de Ciencias Quimicas,
      Faculdade de Farmacia, Universidade do Porto, Rua Jorge Viterbo Ferreira, 228,
      4050-313 Porto, Portugal.
FAU - Almeida, A
AU  - Almeida A
AD  - LAQV/REQUIMTE, Departamento de Ciencias Quimicas, Faculdade de Farmacia,
      Universidade do Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Paiga, P
AU  - Paiga P
AD  - REQUIMTE/LAQV, Instituto Superior de Engenharia do Porto, Instituto Politecnico
      do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, 4200-072 Porto, Portugal.
FAU - Correira-Sa, L
AU  - Correira-Sa L
AD  - REQUIMTE/LAQV, Instituto Superior de Engenharia do Porto, Instituto Politecnico
      do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, 4200-072 Porto, Portugal.
FAU - Delerue-Matos, C
AU  - Delerue-Matos C
AD  - REQUIMTE/LAQV, Instituto Superior de Engenharia do Porto, Instituto Politecnico
      do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, 4200-072 Porto, Portugal.
FAU - Trindade, T
AU  - Trindade T
AD  - Departamento de Quimica & CICECO - Aveiro Instituto de Materiais, Universidade de
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Soares, A M V M
AU  - Soares AMVM
AD  - Departamento de Biologia & CESAM, Universidade de Aveiro, 3810-193 Aveiro,
      Portugal.
FAU - Hylland, K
AU  - Hylland K
AD  - Department of Biosciences, University of Oslo, PO Box 1066, N-0316 Oslo, Norway.
FAU - Loureiro, S
AU  - Loureiro S
AD  - Departamento de Biologia & CESAM, Universidade de Aveiro, 3810-193 Aveiro,
      Portugal.
FAU - Oliveira, M
AU  - Oliveira M
AD  - Departamento de Biologia & CESAM, Universidade de Aveiro, 3810-193 Aveiro,
      Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - England
TA  - Mar Pollut Bull
JT  - Marine pollution bulletin
JID - 0260231
RN  - 7440-57-5 (Gold)
RN  - Q8X02027X3 (Gemfibrozil)
SB  - IM
MH  - Animals
MH  - Gemfibrozil/toxicity
MH  - Gold
MH  - Liver
MH  - *Metal Nanoparticles/toxicity
MH  - Organ Culture Techniques
MH  - *Sea Bream
OTO - NOTNLM
OT  - DNA integrity
OT  - Fish liver culture
OT  - Gilthead seabream
OT  - Ionic gold
OT  - Nanotoxicology
OT  - Oxidative stress
EDAT- 2020/11/14 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/11/13 01:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/08/15 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/11/13 01:00 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - S0025-326X(20)30783-9 [pii]
AID - 10.1016/j.marpolbul.2020.111665 [doi]
PST - ppublish
SO  - Mar Pollut Bull. 2020 Nov;160:111665. doi: 10.1016/j.marpolbul.2020.111665. Epub 
      2020 Sep 14.


PMID- 33181708
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Qualitative study on the key elements of obesity counseling in Korean Medicine.
PG  - e23228
LID - 10.1097/MD.0000000000023228 [doi]
AB  - INTRODUCTION: The increasing prevalence of obesity worldwide necessitates the
      provision of support for many patients. Patients with obesity appreciate
      receiving advice from doctors. Previous studies have qualitatively explored
      clinicians' counseling for weight loss; however, this is limited to primary
      physicians or general practitioners working in community health centers. In
      contrast, Korean Medicine Doctors (KMDs) have treated patients with obesity using
      a holistic approach with a multicomponent approach on counseling. However, there 
      is currently no data regarding KMDs' consulting practices for weight loss.
      Therefore, the present study will explore KMDs' experience in counseling for
      weight loss and describe the constituents of counseling for weight loss in Korean
      medicine practice. METHODS: This qualitative study utilizes a phenomenological
      framework. The KMDs who have worked >1 year as practitioners in treating patients
      with obesity will be invited to describe their lived experiences of counseling
      patients for weight loss. Purposive and snowball sampling will be undertaken to
      ensure that the sample provides information-rich cases that are representative of
      KMDs' experiences of counseling for weight loss. Face-to-face, individual, and
      semi-structured interviews will be conducted with the participants, which will be
      analyzed using a phenomenological method. ETHICS AND DISSEMINATION: Ethical
      approval was granted by the Human Research Ethics Committee of the Korea
      Institute of Oriental Medicine (I-1908/006-001). The results will be disseminated
      via journal articles and conference presentations. TRIAL REGISTRATION NUMBER:
      Korean Clinical Trial Registry, KCT0004985.
FAU - Kim, Sungha
AU  - Kim S
AUID- ORCID: 0000-0001-5542-3850
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine.
FAU - Han, Kyungsun
AU  - Han K
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine.
FAU - Lee, Jun-Hwan
AU  - Lee JH
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine.
AD  - Korean Medicine Life Science, University of Science & Technology, Campus of the
      Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Counseling/*methods
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Obesity/*complications/psychology
MH  - Practice Patterns, Physicians'/standards
MH  - Qualitative Research
MH  - Republic of Korea
MH  - Weight Reduction Programs/standards
PMC - PMC7668521
EDAT- 2020/11/13 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1097/MD.0000000000023228 [doi]
AID - 00005792-202011130-00076 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e23228. doi:
      10.1097/MD.0000000000023228.


PMID- 33181705
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Sacroiliac joint fusion VS conservative management for chronic low back pain
      attributed to the sacroiliac joint: A protocol for systematic review and meta
      analysis.
PG  - e23223
LID - 10.1097/MD.0000000000023223 [doi]
AB  - INTRODUCTION: Low back pain (LBP) is high prevalent and it is the leading cause
      of years lived with disability in both developed and developing countries. The
      sacroiliac joint (SIJ) is a common reason that caused LBP. At present, the
      treatment of chronic LBP attributed to SIJ is mainly conservative treatment and
      surgical treatment. However, there are still controversies between the 2 treating
      methods, and there is no recognized standard of treatment or surgical
      indications. Recent publications indicated that minimally invasive sacroiliac
      joint arthrodesis was safe and more effective improving pain, disability, and
      quality of life compared with conservative management in 2 years follow-up, which
      re-raise the focus of sacroiliac joints fusion. This paper will systematically
      review the available evidence, comparing the effectiveness of sacroiliac joint
      fusion and conservative therapy for the treatment of gait retraining for patients
      suffered from LBP attributed to the sacroiliac joint. METHOD AND ANALYSIS: A
      systematic review and meta-analysis of relevant studies in Pubmed, Embase,
      SCOPUS, and Cochrane Library will be synthesized. Inclusion criteria will be
      studies evaluating clinical outcomes (i.e., changes to pain and/or function)
      comparing sacroiliac joint fusion and conservative therapy in populations
      sacroiliac join related LBP; studies with less than 10 participants in total will
      be excluded. The primary outcomes measured will be pain score, Oswestry
      Disability Index (ODI), and adverse events during treatment. Review Manager
      (Revman; Version 5.3) software will be used for data synthesis, sensitivity
      analysis, meta-regression, subgroup analysis, and risk of bias assessment. A
      funnel plot will be developed to evaluate reporting bias and Begg and Egger tests
      will be used to assess funnel plot symmetries. We will use the Grading of
      Recommendations Assessment, Development and Evaluation system to assess the
      quality of evidence. ETHICS AND DISSEMINATION: Our aim is to publish this
      systematic review and meta-analysis in a peer-reviewed journal. Our findings will
      provide information comparing the efficacy and safety comparing sacroiliac joint 
      fusion and non-surgical treatment for patients with LBP attributed to the
      sacroiliac joint. This review will not require ethical approval as there are no
      issues about participant privacy.
FAU - Chen, Li-Ye
AU  - Chen LY
AD  - Department of Orthopaedics, The Affiliated TCM Hospital of Guangzhou Medical
      University, Guangzhou 510130, People's Republic of China.
FAU - Liang, Hao-Dong
AU  - Liang HD
FAU - Qin, Qi-Ning
AU  - Qin QN
FAU - Tian, Tian-Zhao
AU  - Tian TZ
FAU - Liu, Bao-Xin
AU  - Liu BX
FAU - Shi, Min
AU  - Shi M
FAU - Cai, Ying-Feng
AU  - Cai YF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Clinical Protocols
MH  - Conservative Treatment/*standards
MH  - Humans
MH  - Low Back Pain/physiopathology/*therapy
MH  - Meta-Analysis as Topic
MH  - Sacroiliac Joint/*abnormalities/diagnostic imaging
MH  - Spinal Fusion/methods/*standards
MH  - Systematic Reviews as Topic
PMC - PMC7668445
EDAT- 2020/11/13 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1097/MD.0000000000023223 [doi]
AID - 00005792-202011130-00073 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e23223. doi:
      10.1097/MD.0000000000023223.


PMID- 33181701
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - The impact of substance use disorder on the mental health among COVID-19
      patients: A protocol for systematic review and meta-analysis.
PG  - e23203
LID - 10.1097/MD.0000000000023203 [doi]
AB  - Substance use disorder (SUD) is associated with a high risk of physical and
      mental illness such as anxiety, depression, personality disorders, eating
      disorders, and abnormal mood changes. During the pandemic, SUD, a significant
      problem related to Coronavirus disease 2019 (COVID-19), is affecting adolescents.
      The recent available literature also emphasizes understanding the relationship
      between mental illness and SUD. Hence, it is essential to evaluate the scientific
      approach and examine the presented findings of articles published on SUD during
      the COVID-19 pandemic. A systematic review will be conducted using PubMed, PubMed
      Central, and Scopus bibliographic databases. The grey literature on the impact of
      SUD on mental health during the COVID-19 pandemic among adolescents will be
      identified using scholar google. The dependability and credibility of the
      findings will be examined using the ConQual approach. The methodologies of the
      included studies will be compared using ROBIS (risk of bias in systematic reviews
      tool), a measurement tool to assess systematic reviews (AMSTAR), and the JBI
      critical appraisal tool. The systematic review will be carried out on published
      articles, so it is exempt from ethics approval. The Center for Open Science (OSF)
      will be used as a data repository during the preparation of the protocol and
      completion of the systematic review. The research findings will be published in a
      related peer-reviewed journal.
FAU - Kim, Yun Jin
AU  - Kim YJ
AD  - School of Traditional Chinese Medicine, Xiamen University Malaysia, Jalan
      Sunsuria, Bandar Sunsuria, Sepang, Selangor, Malaysia.
FAU - Qian, Linchao
AU  - Qian L
FAU - Aslam, Muhammad Shahzad
AU  - Aslam MS
AUID- ORCID: 0000-0003-2728-6726
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*psychology
MH  - Humans
MH  - Mental Health/*statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*psychology
MH  - Research Design
MH  - SARS-CoV-2
MH  - Substance-Related Disorders/*epidemiology
PMC - PMC7668455
EDAT- 2020/11/13 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1097/MD.0000000000023203 [doi]
AID - 00005792-202011130-00069 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e23203. doi:
      10.1097/MD.0000000000023203.


PMID- 33181673
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Effectiveness of Kinesio taping on peripheral facial paralysis: A protocol for
      systematic review and meta-analysis.
PG  - e23090
LID - 10.1097/MD.0000000000023090 [doi]
AB  - BACKGROUND: Peripheral facial paralysis is a rapid unilateral facial paralysis or
      paralysis of unknown etiology. Nearly 30% of patients leave sequela that have a
      negative impact on the patient's quality of life, both physically and
      psychologically. As its safety, convenience and effectiveness, Kinesio taping has
      been gradually used in the rehabilitation of peripheral facial paralysis.
      However, whether Kinesio taping is effective for peripheral facial paralysis is
      still unknown. The purpose of this systematic review (SR) and meta-analysis will 
      summarize the current evidence of Kinesio taping used as an intervention for
      peripheral facial paralysis. METHODS AND ANALYSIS: We will search the following
      electronic databases for randomized controlled trials (RCTs) and controlled
      clinical trials (CCTs) to evaluate the effectiveness of Kinesio taping in
      treating peripheral facial paralysis: China National Knowledge Infrastructure
      (CNKI), Wanfang Date, SinoMed, Technology Periodical Database (VIP), PubMed,
      Embase, Web of Science, and The Cochrane Library. Each database will be searched 
      from inception to April 2020. Studies that present clear descriptions of Kinesio 
      taping in treating peripheral facial paralysis administration are published in
      peer-reviewed journals in any languages and are published in full will be taken
      into consideration. The entire process will include study selection, data
      extraction, risk of bias assessment and meta-analyses. Assessment of risk of bias
      and data synthesis will be conducted using Review Manager 5.3 software. RESULTS: 
      The current evidence on the Kinesio taping for managing peripheral facial
      paralysis will be illustrated using subjective reports and objective measures of 
      performance. The primary outcome is the effective rate. Secondary outcomes
      include House-Brackmann scale, Portmann score, facial nerve conduction velocity, 
      Facial Disability Index, Facial Disability Index include Facial Function score
      and social Function score. CONCLUSION: This protocol will present evidence on the
      efficacy of Kinesio taping in relieving peripheral facial paralysis. ETHICS AND
      DISSEMINATION: Since all the data used in this SR and meta-analysis have been
      published, ethical approval is not required for this review. The results of this 
      SR will be published in a peer-reviewed journal or presented at conferences.
      INPLASY ID:: (INPLASY2020100008).
FAU - Sun, Zai-Hui
AU  - Sun ZH
AUID- ORCID: 0000-0001-9971-6559
AD  - School of Health Preservation and Rehabilitation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Tian, Yan-Ping
AU  - Tian YP
AD  - School of Health Preservation and Rehabilitation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Tan, Yan-Fu
AU  - Tan YF
AD  - School of Health Preservation and Rehabilitation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Tao, Dan
AU  - Tao D
AD  - School of Health Preservation and Rehabilitation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Li, Wen-Bo
AU  - Li WB
AD  - Eye College of Chengdu University of Traditional Chinese Medicine.
FAU - Ding, Ji-Lin
AU  - Ding JL
AD  - Mianyang Hospital affiliated to Chengdu University of Traditional Chinese
      Medicine, Sichuan, China.
FAU - Ai, Shuang-Chun
AU  - Ai SC
AD  - Mianyang Hospital affiliated to Chengdu University of Traditional Chinese
      Medicine, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Athletic Tape
MH  - Facial Paralysis/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Patient Care/instrumentation/methods
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7668467
EDAT- 2020/11/13 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1097/MD.0000000000023090 [doi]
AID - 00005792-202011130-00041 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e23090. doi:
      10.1097/MD.0000000000023090.


PMID- 33181664
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Acupoint injection versus sacral canal injection in lumbar disc herniation: A
      protocol of randomized controlled trial.
PG  - e23000
LID - 10.1097/MD.0000000000023000 [doi]
AB  - BACKGROUND: Both acupoint injection and sacral canal injection are widely adopted
      in the treatment of lumbar disc herniation (LDH), but there are still doubts
      about the effectiveness and safety of the 2 methods. Therefore, the objective of 
      the randomized controlled trial is to evaluate the effectiveness and safety of
      acupoint injection and sacral canal injection in the treatment of LDH. METHOD:
      This is a prospective randomized controlled trial to study the effectiveness and 
      safety of acupoint injection and sacral canal injection in the treatment of LDH. 
      With the approval by the clinical research ethics committee of our hospital,
      patients were randomly included into 1 of 2 treatment protocols:Patients,
      doctors, nurses, and research assistants responsible for collecting data were
      blinded to group allocation. Main outcome observation indicator: visual analogue 
      scale; secondary outcome observation indicator: Oswestry disability index scores;
      paresthesia score; adverse reactions. Data were analyzed using the statistical
      software package SPSS version 25.0 (Chicago, IL). DISCUSSION: The effectiveness
      and safety of acupoint injection and sacral canal injection in the treatment of
      LDH were evaluated in this study, and the results of this trial would establish
      clinical evidence for the adoption of acupoint injection or sacral canal
      injection to treat LDH. TRIAL REGISTRATION NUMBER: DOI 10.17605 / OSF.IO / VTFUD.
FAU - Li, Wei
AU  - Li W
AUID- ORCID: 0000-0001-5659-5267
AD  - The People's Hospital of Dazu District, Dazu, Chongqing, China.
FAU - Wang, Huaying
AU  - Wang H
FAU - Wang, Lijun
AU  - Wang L
FAU - Tang, Peng
AU  - Tang P
FAU - Huang, Yaokai
AU  - Huang Y
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Points
MH  - Acupuncture Therapy/*methods
MH  - Adult
MH  - Aged
MH  - Clinical Protocols
MH  - Disability Evaluation
MH  - Female
MH  - Humans
MH  - Injections, Spinal/*methods
MH  - Intervertebral Disc Displacement/*therapy
MH  - *Lumbar Vertebrae
MH  - Lumbosacral Plexus
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - Treatment Outcome
MH  - Visual Analog Scale
MH  - Young Adult
PMC - PMC7668483
EDAT- 2020/11/13 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1097/MD.0000000000023000 [doi]
AID - 00005792-202011130-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e23000. doi:
      10.1097/MD.0000000000023000.


PMID- 33181663
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Effectiveness and safety of Baduanjin exercise (BDJE) on heart failure with
      preserved left ventricular ejection fraction (HFpEF): A protocol for systematic
      review and meta-analysis.
PG  - e22994
LID - 10.1097/MD.0000000000022994 [doi]
AB  - BACKGROUND: Nearly half of the heart failure (HF) patients have been classified
      as HF with preserved left ventricular ejection fraction (HFpEF) and the
      prevalence has been increasing over time. The subject of this study is to assess 
      the clinical effectiveness and safety of Baduanjin exercise (BDJE), as a kind of 
      traditional Chinese exercises, for HFpEF patients. METHODS: A systematic
      literature search for articles up to September 2020 will be performed in
      following electronic databases: PubMed, Embase, the Cochrane Library, China
      National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database
      (VIP) Database, Chinese Biomedical Database (CBM), Chinese Biomedical Literature 
      Service System (SinoMed) and Wanfang Database. Inclusion criteria are randomized 
      controlled trials of BDJE applied on HFpEF patients. The primary outcome measures
      will be exercise capacity (cardiopulmonary exercise test or 6-minute walking
      test) and quality of life. The secondary outcomes will be as the following: blood
      pressure, heart rate, echocardiography, endothelial function, arterial stiffness 
      and hypersensitive C-reactive protein and N-Terminal pro-B-type natriuretic
      peptide. The safety outcome measures will be adverse events, liver and kidney
      function. RevMan 5.3 software will be used for data synthesis, sensitivity
      analysis, subgroup analysis and risk of bias assessment. A funnel plot will be
      developed to evaluate reporting bias. Stata 12.0 will be used for meta-regression
      and Egger tests. We will use the Grading of Recommendations Assessment,
      Development and Evaluation (GRADE) system to assess the quality of evidence.
      CONCLUSION: The study will give an explicit evidence to evaluate the
      effectiveness and safety of BDJE for HFpEF patients. ETHICS AND DISSEMINATION:
      This systematic review does not require ethics approval and will be submitted to 
      a peer-reviewed journal. TRIAL REGISTRATION NUMBER: PROSPERO CRD42020200324.
FAU - Chen, Mingtai
AU  - Chen M
AD  - Department of Cardiovascular Disease.
FAU - Ou, Lijun
AU  - Ou L
AD  - Department of Cardiovascular Disease.
FAU - Chen, Yingnan
AU  - Chen Y
AD  - Department of Cardiovascular Disease.
FAU - Men, Ling
AU  - Men L
AD  - Nephrology Department.
FAU - Zhong, Xiaoling
AU  - Zhong X
AD  - Reproductive Health Department, Shenzhen Traditional Chinese Medicine Hospital,
      Shenzhen, China.
FAU - Yang, Shudong
AU  - Yang S
AD  - Nephrology Department.
FAU - Luan, Jienan
AU  - Luan J
AD  - Department of Cardiovascular Disease.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Heart Failure/physiopathology/*therapy
MH  - Humans
MH  - Male
MH  - Medicine, Chinese Traditional/*methods
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Research Design
MH  - Stroke Volume
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Ventricular Function, Left
MH  - Young Adult
PMC - PMC7668503
EDAT- 2020/11/13 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1097/MD.0000000000022994 [doi]
AID - 00005792-202011130-00031 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e22994. doi:
      10.1097/MD.0000000000022994.


PMID- 33181644
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in
      chronic kidney disease on hemodialysis patients: A protocol for a systematic
      review and meta-analysis.
PG  - e22566
LID - 10.1097/MD.0000000000022566 [doi]
AB  - BACKGROUND: Secondary hyperparathyroidism (SHPT) have been associated with poor
      health outcomes in hemodialysis patients. The cinacalcet has popularized in
      clinic which has efficacy but more adverse events; the novel oral calcimimetic
      agents evocalcet has appeared in recent years. However, it is currently unknown
      whether evocalcet produces more beneficial effects and fewer adverse events in
      patients with SHPT. The aim of this systematic review is to estimate the safety
      and efficacy of evocacelt. METHODS: Only randomized controlled trials (RCT) will 
      be included in MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and
      PUBMED from July 2010 to July 2020. Two reviewers will screen, select studies,
      extract data, and assess quality independently. The methodological quality
      including the risk of bias of the included studies will be evaluated using a
      modified assessment form, which is based on Cochrane assessment tool. Review
      Manager 5.3 software will be used for heterogeneity assessment, generating
      funnel-plots, data synthesis, subgroup analysis, and sensitivity analysis. We
      will use GRADE system to evaluate the quality of our evidence. RESULTS: We will
      provide some more practical and targeted results investigating the effect and
      safety of evocalcet for SHPT on hemodialysis in the current meta-analysis.
      CONCLUSION: The stronger evidence about evocalcet effect and safety will be
      provided for clinicians and policymakers. ETHICS AND DISSEMINATION: Ethical
      approval will be unnecessary because the data being included in this systematic
      review come from published literature and there will be no concerns regarding
      privacy. Findings of this research will be disseminated in a peer-reviewed
      journal or conference presentations. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/N59RB.
FAU - Xie, Jing
AU  - Xie J
AUID- ORCID: 0000-0003-2345-9626
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Li, Xueying
AU  - Li X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Chen, Yang
AU  - Chen Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Chen, Ming
AU  - Chen M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Mao, Nan
AU  - Mao N
AD  - Department of Nephrology, The First Clinical Medical College.
FAU - Fan, Junming
AU  - Fan J
AUID- ORCID: 0000-0003-2213-4782
AD  - Department of Nephrology, The First Clinical Medical College.
AD  - Chengdu Medical College, Chengdu, PR China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Calcimimetic Agents)
RN  - 0 (Naphthalenes)
RN  - 0 (Pyrrolidines)
RN  - E58MLH082P (evocalcet)
SB  - IM
MH  - Calcimimetic Agents/standards/therapeutic use
MH  - Clinical Protocols
MH  - Humans
MH  - Hyperparathyroidism, Secondary/*drug therapy
MH  - Meta-Analysis as Topic
MH  - Naphthalenes/*standards/therapeutic use
MH  - Pyrrolidines/*standards/therapeutic use
MH  - Renal Dialysis/*methods/trends
MH  - Renal Insufficiency, Chronic
MH  - Systematic Reviews as Topic
PMC - PMC7668479
EDAT- 2020/11/13 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1097/MD.0000000000022566 [doi]
AID - 00005792-202011130-00012 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e22566. doi:
      10.1097/MD.0000000000022566.


PMID- 33181637
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 46
DP  - 2020 Nov 13
TI  - Moxibustion therapy on myofascial pain syndrome: An evidence-based clinical
      practice guideline.
PG  - e22342
LID - 10.1097/MD.0000000000022342 [doi]
AB  - BACKGROUND: Myofascial pain syndrome (MPS) is a chronic systemic pain disorder.
      Among the common treatments, moxibustion has an irreplaceable therapeutic effect 
      and is an effective Traditional Chinese Medicine therapy for MPS. However, the
      lack of clinical practice guidelines (CPGs) has prompted the publication of
      guidelines on the use of moxibustion in the treatment of MPS. METHODS: The
      clinical practice guideline will base on the Institute of Medicine, the World
      Health Organization guideline handbook, the Grade of Recommendations Assessment, 
      Development, and Evaluation the Appraisal of Guidelines for Research & Evaluation
      II, Reporting Items for practice, Guideline in Healthcare and recommendations
      thereof will be made on the basis of systematic reviews. We will establish a
      guidelines development team that will draft clinical questions in the form of
      population, intervention, comparison, results and conduct a literature search and
      quality of evidence assessment. The experts will make recommendations after 2 or 
      3 rounds of Delphi investigations. We will carefully consider the patient's
      values and preferences and conduct a peer review. ETHICS AND DISSEMINATION: The
      guidelines will not contain any personal data and will not prejudice individual
      rights, so no ethical approval will be required. The guidelines will be subject
      to rigorous peer review and may be published in a journal or circulated at
      relevant conferences. RESULTS: The guidelines will be published in relevant
      peer-reviewed journals. CONCLUSION: This guideline will make it easier for
      clinicians to treat MPs in the clinical setting and improve the effectiveness of 
      treatment for MPS. STUDY REGISTRATION: The study is registered with the
      International Practice Guideline Registry Platform (IPGRP): IPGRP-2020CN030.
FAU - Wu, Zenan
AU  - Wu Z
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang.
FAU - Xu, Guixing
AU  - Xu G
AD  - Chengdu University of Traditional Chinese Medicine, Nanchang, Chengdu.
FAU - Xiong, Jun
AU  - Xiong J
AD  - The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang, China.
FAU - Zuo, Zhengyun
AU  - Zuo Z
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang.
FAU - Yu, Xinyu
AU  - Yu X
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang.
FAU - Xie, Qiongshan
AU  - Xie Q
AD  - Jiangxi University of Traditional Chinese Medicine, Nanchang.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - China
MH  - Guidelines as Topic
MH  - Humans
MH  - Moxibustion/instrumentation/*methods
MH  - Myofascial Pain Syndromes/*drug therapy
PMC - PMC7668527
EDAT- 2020/11/13 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/12 20:17
PHST- 2020/11/12 20:17 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1097/MD.0000000000022342 [doi]
AID - 00005792-202011130-00005 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 13;99(46):e22342. doi:
      10.1097/MD.0000000000022342.


PMID- 33181473
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20220716
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 73
DP  - 2020 Nov - Dec
TI  - Under which conditions are changes in the treatment of people under involuntary
      commitment justified during the COVID-19 pandemic? An ethical evaluation of
      current developments in Germany.
PG  - 101615
LID - S0160-2527(20)30074-1 [pii]
LID - 10.1016/j.ijlp.2020.101615 [doi]
AB  - The COVID-19 pandemic poses significant challenges in psychiatric hospitals,
      particularly in the context of the treatment of people under involuntary
      commitment. The question arises at various points in the procedure for and
      process of involuntary commitment whether procedural modifications or further
      restrictive measures are necessary to minimise the spread of COVID-19 and protect
      all people involved from infection. In the light of current developments in
      Germany, this article examines under which conditions changes in the treatment of
      people under involuntary commitment are ethically justified in view of the
      COVID-19 pandemic. Among others, we discuss ethical arguments for and against
      involuntary commitments with reference to COVID-19, the use of different coercive
      interventions, the introduction of video hearings, an increased use of video
      surveillance and interventions based on the German Infection Protection Act. We
      argue that strict hygiene concepts, the provision of sufficient personal
      protective equipment and frequent testing for COVID-19 should be the central
      strategies to ensure the best possible protection against infection. Any further 
      restrictions of the liberty of people under involuntary commitment require a
      sound ethical justification based on the criteria of suitability, necessity and
      proportionality. A strict compliance with these criteria and the continued
      oversight by external and independent control mechanisms are important to prevent
      ethically unjustified restrictions and discrimination against people with the
      diagnosis of a mental disorder during the COVID-19 pandemic.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Gather, J
AU  - Gather J
AD  - Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University
      Hospital, Ruhr University Bochum, Germany; Institute for Medical Ethics and
      History of Medicine, Ruhr University Bochum, Germany. Electronic address:
      jakov.gather@rub.de.
FAU - Juckel, G
AU  - Juckel G
AD  - Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University
      Hospital, Ruhr University Bochum, Germany.
FAU - Henking, T
AU  - Henking T
AD  - University of Applied Sciences Wurzburg-Schweinfurt, Germany.
FAU - Efkemann, S A
AU  - Efkemann SA
AD  - Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University
      Hospital, Ruhr University Bochum, Germany.
FAU - Vollmann, J
AU  - Vollmann J
AD  - Institute for Medical Ethics and History of Medicine, Ruhr University Bochum,
      Germany.
FAU - Scholten, M
AU  - Scholten M
AD  - Institute for Medical Ethics and History of Medicine, Ruhr University Bochum,
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Commitment of Mentally Ill/*ethics/*legislation & jurisprudence
MH  - Communicable Disease Control/*legislation & jurisprudence
MH  - Germany/epidemiology
MH  - Hospitals, Psychiatric
MH  - Humans
MH  - Involuntary Commitment/*ethics/*legislation & jurisprudence
MH  - Pandemics
MH  - SARS-CoV-2
PMC - PMC9190307
OTO - NOTNLM
OT  - *Basic rights
OT  - *Coercion
OT  - *Coronavirus
OT  - *Involuntary admission
OT  - *Medical ethics
OT  - *Psychiatry
EDAT- 2020/11/13 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/11/12 20:16
PHST- 2020/05/31 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/11/12 20:16 [entrez]
AID - S0160-2527(20)30074-1 [pii]
AID - 10.1016/j.ijlp.2020.101615 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Nov - Dec;73:101615. doi: 10.1016/j.ijlp.2020.101615. 
      Epub 2020 Nov 10.


PMID- 33180739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210920
IS  - 2368-7959 (Print)
IS  - 2368-7959 (Linking)
VI  - 7
IP  - 12
DP  - 2020 Dec 8
TI  - Videoconferencing-Based Telemental Health: Important Questions for the COVID-19
      Era From Clinical and Patient-Centered Perspectives.
PG  - e24021
LID - 10.2196/24021 [doi]
AB  - The COVID-19 pandemic has intensified the search for digital approaches in mental
      health treatment, particularly due to patients and clinicians practicing social
      distancing. This has resulted in the dramatic growth of videoconferencing-based
      telemental health (V-TMH) services. It is critical for behavioral health
      providers and those in the mental health field to understand the implications of 
      V-TMH expansion on the stakeholders who use such services, such as patients and
      clinicians, to provide the service that addresses both patient and clinical
      needs. Several key questions arise as a result, such as the following: (1) in
      what ways does V-TMH affect the practice of psychotherapy (ie, clinical needs),
      (2) to what extent are ethical and patient-centered concerns warranted in terms
      of V-TMH services (ie, patient needs), and (3) how do factors related to user
      experience affect treatment dynamics for both the patient and therapist (ie,
      patient and clinical needs)? We discuss how behavioral health providers can
      consider the future delivery of mental health care services based on these
      questions, which pose strong implications for technological innovation, the
      adaptation of treatments to new technologies, and training professionals in the
      delivery of V-TMH services and other digital health interventions.
CI  - (c)Emil Chiauzzi, Ashley Clayton, Jina Huh-Yoo. Originally published in JMIR
      Mental Health (http://mental.jmir.org), 08.12.2020.
FAU - Chiauzzi, Emil
AU  - Chiauzzi E
AUID- ORCID: https://orcid.org/0000-0003-4995-7308
AD  - Tridiuum Inc, Philadelphia, PA, United States.
FAU - Clayton, Ashley
AU  - Clayton A
AUID- ORCID: https://orcid.org/0000-0001-6475-5857
AD  - Yale School of Medicine, Yale University, New Haven, CT, United States.
FAU - Huh-Yoo, Jina
AU  - Huh-Yoo J
AUID- ORCID: https://orcid.org/0000-0001-5811-9256
AD  - Department of Information Science, College of Computing and Informatics, Drexel
      University, Philadelphia, PA, United States.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20201208
PL  - Canada
TA  - JMIR Ment Health
JT  - JMIR mental health
JID - 101658926
PMC - PMC7725495
OTO - NOTNLM
OT  - COVID-19
OT  - ethics
OT  - lived experience
OT  - mental health
OT  - patient-centered
OT  - privacy
OT  - psychotherapy
OT  - telehealth
OT  - telemental health
OT  - videoconferencing
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 17:11
PHST- 2020/09/07 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
PHST- 2020/11/12 17:11 [entrez]
AID - v7i12e24021 [pii]
AID - 10.2196/24021 [doi]
PST - epublish
SO  - JMIR Ment Health. 2020 Dec 8;7(12):e24021. doi: 10.2196/24021.


PMID- 33180160
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20210110
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 12
DP  - 2020 Dec
TI  - [Moral distress in medical students and young professionals: research desiderata 
      in the context of the COVID-19 pandemic].
PG  - 1483-1490
LID - 10.1007/s00103-020-03244-2 [doi]
AB  - BACKGROUND: The COVID-19 pandemic poses particular challenges for people working 
      in the medical sector. Some of the medical students and young medical
      professionals who are starting their work in healthcare facilities during this
      time are confronted with extraordinary moral challenges. A portion of them does
      not yet have sufficient coping skills to adequately deal with these challenges.
      This can lead to so-called moral distress (MoD). Permanent or intensive exposure 
      to MoD can have serious consequences. Appropriate support services have the
      potential to improve the handling of MoD. OBJECTIVE: This article aims to provide
      an overview of the current state of research on MoD among medical students and
      young medical professionals in order to sensitize lecturers with responsibility
      for education and training and doctors in leading positions to the problem. MAIN 
      PART: This article presents the scientific concept of MoD, known triggers, and
      options for prevention and intervention. The topic is presented with reference to
      the changes in patient care in the context of the COVID-19 pandemic and research 
      needs are presented. CONCLUSION: The article illustrates the necessity of a
      German-language, interdisciplinary discourse on MoD among medical students and
      young professionals.
FAU - Kuhlmeyer, Katja
AU  - Kuhlmeyer K
AD  - Institut fur Ethik, Geschichte und Theorie der Medizin,
      Ludwig-Maximilians-Universitat (LMU), Lessingstr. 2, 80336, Munchen, Deutschland.
      katja.kuehlmeyer@med.lmu.de.
FAU - Kuhn, Eva
AU  - Kuhn E
AD  - Philosophisches Seminar, Lehrstuhl fur Praktische Philosophie,
      Christian-Albrechts-Universitat zu Kiel (CAU), Kiel, Deutschland.
FAU - Knochel, Kathrin
AU  - Knochel K
AD  - Institut fur Geschichte und Ethik der Medizin, Klinikum rechts der Isar der
      Technischen Universitat Munchen (TUM), Munchen, Deutschland.
AD  - Kinderpalliativzentrum, Klinikum der Ludwig-Maximilians-Universitat Munchen (LMU 
      Klinikum), Munchen, Deutschland.
FAU - Hildesheim, Hanna
AU  - Hildesheim H
AD  - Institut fur Experimentelle Medizin, Medizinethik.,
      Christian-Albrechts-Universitat zu Kiel (CAU), Kiel, Deutschland.
FAU - Witt, Victoria Dorothea
AU  - Witt VD
AD  - Segeberger Kliniken, Neurologisches Zentrum, Bad Segeberg, Deutschland.
FAU - Friedrich, Orsolya
AU  - Friedrich O
AD  - Fakultat fur Kultur- und Sozialwissenschaften, Institut fur Philosophie,
      Juniorprofessur fur Medizinethik, FernUniversitat in Hagen, Hagen, Deutschland.
FAU - Rogge, Annette
AU  - Rogge A
AD  - Institut fur Experimentelle Medizin, Medizinethik.,
      Christian-Albrechts-Universitat zu Kiel (CAU), Kiel, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Moralischer Stress bei Medizinstudierenden und arztlichen Berufseinsteigenden:
      Forschungsdesiderate im Rahmen der COVID-19-Pandemie.
DEP - 20201112
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Germany
MH  - Humans
MH  - Morals
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Students, Medical
PMC - PMC7659897
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical ethics
OT  - Ethics
OT  - Medical school
OT  - Mental health
OT  - Moral distress
EDAT- 2020/11/13 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/12 12:11
PHST- 2020/06/06 00:00 [received]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/11/12 12:11 [entrez]
AID - 10.1007/s00103-020-03244-2 [doi]
AID - 10.1007/s00103-020-03244-2 [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Dec;63(12):1483-1490. doi: 10.1007/s00103-020-03244-2. Epub 2020 Nov 12.


PMID- 33180023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 12
TI  - Using Wearable Devices to Monitor Physical Activity in Patients Undergoing Aortic
      Valve Replacement: Protocol for a Prospective Observational Study.
PG  - e20072
LID - 10.2196/20072 [doi]
AB  - BACKGROUND: In last few decades, several tools have been developed to measure
      physical function objectively; however, their use has not been well established
      in clinical practice. OBJECTIVE: This study aims to describe the preoperative
      physical function and to assess and compare 6-month postoperative changes in the 
      physical function of patients undergoing treatment for aortic stenosis with
      either surgical aortic valve replacement (SAVR) or transcatheter aortic valve
      replacement (TAVR). The study also aims to evaluate the feasibility of wearable
      devices in assessing physical function in such patients. METHODS: This is a
      prospective observational study. The enrollment will be conducted 1 month before 
      patients' SAVR/TAVR. Patients will be provided with the wearable device at
      baseline (activity tracker device, Garmin vivoactive 3). They will be trained in 
      the use of the device, and they will be requested to wear it on the wrist of
      their preferred hand until 12 months after SAVR/TAVR. After baseline assessment, 
      they will undergo 4 follow-up assessments at 1, 3, 6, and 12 months after
      SAVR/TAVR. At baseline and each follow-up, they will undergo a set of standard
      and validated tests to assess physical function, health-related quality of life, 
      and sleep quality. RESULTS: The ethics committee of Vicenza in Veneto Region in
      Italy approved the study (Protocol No. 943; January 4, 2019). As of October 2020,
      the enrollment of participants is ongoing. CONCLUSIONS: The use of the wearable
      devices for real-time monitoring of physical activity of patients undergoing
      aortic valve replacement is a promising opportunity for improving the clinical
      management and consequently, the health outcomes of such patients. TRIAL
      REGISTRATION: Clinicaltrials.gov NCT03843320; https://tinyurl.com/yyareu5y.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/20072.
CI  - (c)Giulia Lorenzoni, Danila Azzolina, Chiara Fraccaro, Alessandro Di Liberti,
      Augusto D'Onofrio, Chiara Cavalli, Tommaso Fabris, Gianpiero D'Amico, Giorgia
      Cibin, Luca Nai Fovino, Honoria Ocagli, Gino Gerosa, Giuseppe Tarantini, Dario
      Gregori. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 12.11.2020.
FAU - Lorenzoni, Giulia
AU  - Lorenzoni G
AUID- ORCID: https://orcid.org/0000-0003-1771-4686
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac,
      Thoracic, Vascular Sciences and Public Health, University of Padova, Padova,
      Italy.
FAU - Azzolina, Danila
AU  - Azzolina D
AUID- ORCID: https://orcid.org/0000-0002-8185-5742
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac,
      Thoracic, Vascular Sciences and Public Health, University of Padova, Padova,
      Italy.
FAU - Fraccaro, Chiara
AU  - Fraccaro C
AUID- ORCID: https://orcid.org/0000-0002-3972-4642
AD  - Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular
      Sciences and Public Health, University of Padova, Padova, Italy.
FAU - Di Liberti, Alessandro
AU  - Di Liberti A
AUID- ORCID: https://orcid.org/0000-0002-1357-6143
AD  - Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular
      Sciences and Public Health, University of Padova, Padova, Italy.
FAU - D'Onofrio, Augusto
AU  - D'Onofrio A
AUID- ORCID: https://orcid.org/0000-0002-9835-9091
AD  - Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and
      Public Health, University of Padova, Padova, Italy.
FAU - Cavalli, Chiara
AU  - Cavalli C
AUID- ORCID: https://orcid.org/0000-0001-5568-8365
AD  - Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and
      Public Health, University of Padova, Padova, Italy.
FAU - Fabris, Tommaso
AU  - Fabris T
AUID- ORCID: https://orcid.org/0000-0003-0818-3094
AD  - Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular
      Sciences and Public Health, University of Padova, Padova, Italy.
FAU - D'Amico, Gianpiero
AU  - D'Amico G
AUID- ORCID: https://orcid.org/0000-0003-1259-5163
AD  - Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular
      Sciences and Public Health, University of Padova, Padova, Italy.
FAU - Cibin, Giorgia
AU  - Cibin G
AUID- ORCID: https://orcid.org/0000-0002-2584-2613
AD  - Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and
      Public Health, University of Padova, Padova, Italy.
FAU - Nai Fovino, Luca
AU  - Nai Fovino L
AUID- ORCID: https://orcid.org/0000-0002-5823-2088
AD  - Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular
      Sciences and Public Health, University of Padova, Padova, Italy.
FAU - Ocagli, Honoria
AU  - Ocagli H
AUID- ORCID: https://orcid.org/0000-0002-5823-1659
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac,
      Thoracic, Vascular Sciences and Public Health, University of Padova, Padova,
      Italy.
FAU - Gerosa, Gino
AU  - Gerosa G
AUID- ORCID: https://orcid.org/0000-0002-6261-699X
AD  - Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and
      Public Health, University of Padova, Padova, Italy.
FAU - Tarantini, Giuseppe
AU  - Tarantini G
AUID- ORCID: https://orcid.org/0000-0002-5055-2917
AD  - Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular
      Sciences and Public Health, University of Padova, Padova, Italy.
FAU - Gregori, Dario
AU  - Gregori D
AUID- ORCID: https://orcid.org/0000-0001-7906-0580
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac,
      Thoracic, Vascular Sciences and Public Health, University of Padova, Padova,
      Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT03843320
PT  - Journal Article
DEP - 20201112
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7691084
OTO - NOTNLM
OT  - physical function
OT  - surgical aortic valve replacement
OT  - transcatheter aortic valve replacement
OT  - wearable devices
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 12:10
PHST- 2020/05/11 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/11/12 12:10 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - v9i11e20072 [pii]
AID - 10.2196/20072 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 12;9(11):e20072. doi: 10.2196/20072.


PMID- 33179131
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20201201
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 12
DP  - 2020 Dec
TI  - [The publication of clinical trial results by German universities is
      insufficient-this should change].
PG  - 1531-1537
LID - 10.1007/s00103-020-03246-0 [doi]
AB  - The results of all clinical drug trials should be published promptly and
      nonselectively after trial completion. The publication of results appears as a
      central ethical rule in the Declaration of Helsinki of the World Medical
      Association. German university hospitals are increasingly being criticized for
      not meeting these requirements sufficiently.In this article, different forms of
      publication of clinical drug trial results are discussed (summary results on
      registries and journal articles) and the current performance of German university
      hospitals is analyzed. Three registries and databases for clinical studies were
      examined for publication of summary results: the European Union Clinical Trials
      Register (EUCTR), the US registry ClinicalTrials.gov and the exclusively German
      language portal PharmNet.Bund. Positions of different stakeholders are outlined
      and possible steps for improvement are proposed.German university hospitals do
      not sufficiently fulfil their regulatory and ethical obligations regarding the
      publication of clinical drug trial results. Two years after the study completion 
      date, two thirds of the studies listed on ClinicalTrials.gov that were completed 
      from 2010-2014 had not yet published results in scientific journals and only 4.7%
      had posted summary results in the registry. In the European trial registry, the
      publication rate in the form of summary results has been found to be less than
      7%. Less than 15% of relevant entries in the PharmNet.Bund database have results 
      available.In order to improve the reporting performance of German university
      hospitals, political will and commitment of the hospitals themselves are needed. 
      The benefits of access to all clinical drug trial results for public health and
      science far outweigh the (marginal) additional investments that university
      hospitals have to make to ensure that all their trial results are made public in 
      line with regulatory and ethical requirements.
FAU - Grabitz, Peter
AU  - Grabitz P
AD  - QUEST - Center, Berlin Institute of Health (BIH), Charite - Universitatsmedizin
      Berlin, Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Deutschland.
      peter.grabitz@charite.de.
FAU - Bruckner, Till
AU  - Bruckner T
AD  - QUEST - Center, Berlin Institute of Health (BIH), Charite - Universitatsmedizin
      Berlin, Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Deutschland.
AD  - TranspariMED, Bristol, Grossbritannien.
FAU - Strech, Daniel
AU  - Strech D
AD  - QUEST - Center, Berlin Institute of Health (BIH), Charite - Universitatsmedizin
      Berlin, Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Deutsche Universitaten machen Ergebnisse klinischer Arzneimittelstudien
      unzureichend offentlich - Das sollte sich andern.
DEP - 20201111
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - Databases, Factual
MH  - Germany
MH  - *Language
MH  - Registries
MH  - *Universities
PMC - PMC7686199
OTO - NOTNLM
OT  - Clinical trials
OT  - Guideline adherence
OT  - Publication bias
OT  - Registries
OT  - Research ethics
OT  - Retrospective study
OT  - University medical centers
EDAT- 2020/11/13 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/11/12 05:46
PHST- 2020/05/04 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/11/12 05:46 [entrez]
AID - 10.1007/s00103-020-03246-0 [doi]
AID - 10.1007/s00103-020-03246-0 [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Dec;63(12):1531-1537. doi: 10.1007/s00103-020-03246-0. Epub 2020 Nov 11.


PMID- 33178959
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 2513-9878 (Electronic)
IS  - 2513-9878 (Linking)
VI  - 2
IP  - 1
DP  - 2020
TI  - The ethical adoption of artificial intelligence in radiology.
PG  - 20190020
LID - 10.1259/bjro.20190020 [doi]
AB  - Artificial intelligence (AI) is rapidly transforming healthcare-with radiology at
      the pioneering forefront. To be trustfully adopted, AI needs to be lawful,
      ethical and robust. This article covers the different aspects of a safe and
      sustainable deployment of AI in radiology during: training, integration and
      regulation. For training, data must be appropriately valued, and deals with AI
      companies must be centralized. Companies must clearly define anonymization and
      consent, and patients must be well-informed about their data usage. Data fed into
      algorithms must be made AI-ready by refining, purification, digitization and
      centralization. Finally, data must represent various demographics. AI needs to be
      safely integrated with radiologists-in-the-loop: guiding forming concepts of AI
      solutions and supervising training and feedback. To be well-regulated, AI systems
      must be approved by a health authority and agreements must be made upon liability
      for errors, roles of supervised and unsupervised AI and fair workforce
      distribution (between AI and radiologists), with a renewal of policy at regular
      intervals. Any errors made must have a root-cause analysis, with outcomes fedback
      to companies to close the loop-thus enabling a dynamic best prediction system. In
      the distant future, AI may act autonomously with little human supervision.
      Ethical training and integration can ensure a "transparent" technology that will 
      allow insight: helping us reflect on our current understanding of imaging
      interpretation and fill knowledge gaps, eventually moulding radiological
      practice. This article proposes recommendations for ethical practise that can
      guide a nationalized framework to build a sustainable and transparent system.
CI  - (c) 2020 The Authors. Published by the British Institute of Radiology.
FAU - Mudgal, Keshav Shree
AU  - Mudgal KS
AD  - King's College Hospital Foundation Trust, London, UK.
FAU - Das, Neelanjan
AU  - Das N
AD  - East Kent Hospitals Foundation Trust, Canterbury, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200101
PL  - England
TA  - BJR Open
JT  - BJR open
JID - 101749810
PMC - PMC7605209
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:46
PHST- 2019/03/22 00:00 [received]
PHST- 2019/09/11 00:00 [revised]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2020/11/12 05:46 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.1259/bjro.20190020 [doi]
PST - epublish
SO  - BJR Open. 2020 Jan 1;2(1):20190020. doi: 10.1259/bjro.20190020. eCollection 2020.


PMID- 33178903
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
IS  - 2475-644X (Electronic)
IS  - 2475-6431 (Linking)
VI  - 11
DP  - 2020 Spring
TI  - Agency and Accountability: Ethical Considerations for Brain-Computer Interfaces.
PG  - 9-20
AB  - Brain-computer interfaces (BCIs) are systems in which a user's real-time brain
      activity is used to control an external device, such as a prosthetic limb. BCIs
      have great potential for restoring lost motor functions in a wide range of
      patients. However, this futuristic technology raises several ethical questions,
      especially concerning the degree of agency a BCI affords its user and the extent 
      to which a BCI user ought to be accountable for actions undertaken via the
      device. This paper examines these and other ethical concerns found at each of the
      three major parts of the BCI system: the sensor that records neural activity, the
      decoder that converts raw data into usable signals, and the translator that uses 
      these signals to control the movement of an external device.
FAU - Davidoff, Erika J
AU  - Davidoff EJ
AD  - Rutgers University, Department of Biomedical Engineering.
LA  - eng
GR  - T32 GM135141/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Rutgers J Bioeth
JT  - The Rutgers journal of bioethics
JID - 101772691
PMC - PMC7654969
MID - NIHMS1640382
OTO - NOTNLM
OT  - agency
OT  - brain-computer interfaces
OT  - neural implants
OT  - neuroprosthetics
OT  - responsibility
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:45
PHST- 2020/11/12 05:45 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
PST - ppublish
SO  - Rutgers J Bioeth. 2020 Spring;11:9-20.


PMID- 33178849
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 2322-2220 (Print)
IS  - 2322-2220 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Oct
TI  - Professionalism in practice: Exploring the ethical perplexity of involving
      students in Medical Education Research.
PG  - 200-203
LID - 10.30476/jamp.2020.74921.0 [doi]
AB  - With the worldwide increase in the number of medical education researches, few
      ethical quagmires have emerged regarding the recruitment and inclusion of
      students in research projects. The ethicists often tend to raise questions
      regarding the possibilities of students getting coerced to participate, such as
      whether they receive extra course credits in exchange for their participation, or
      whether their privacy is getting violated in the course of data collection. It is
      the need of the hour to address the perplexity behind these ethical dilemmas.
      Some answers to the ethical questions might call for implication of change in the
      organization of research, thereby affecting the output. This commentary tries to 
      address these issues in a genuine manner and affords a way forward in the context
      of ethics related to educational research. By treading the delicate path between 
      framing the research question which never encompass any ethical breaches and
      compromising the rigour of the study design to suffice certain baseless
      hindrances, we could appreciate the importance of practical ethics in educational
      researches.
CI  - Copyright: (c) Journal of Advances in Medical Education & Professionalism.
FAU - Kumar V, Dinesh
AU  - Kumar V D
AD  - Department of Anatomy, Jawaharlal Institute of Postgraduate Medical Education and
      Research, Puducherry, India.
FAU - Murugan, Magi
AU  - Murugan M
AD  - Department of Anatomy, Pondicherry Institute of Medical Sciences, Puducherry,
      India.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - J Adv Med Educ Prof
JT  - Journal of advances in medical education & professionalism
JID - 101617859
PMC - PMC7642472
OTO - NOTNLM
OT  - Ethics
OT  - Medical education
OT  - Professionalism
OT  - Recruitment
OT  - Research
COIS- Conflict of Interest: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:45
PHST- 2020/11/12 05:45 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.30476/jamp.2020.74921.0 [doi]
AID - JAMP-8-4 [pii]
PST - ppublish
SO  - J Adv Med Educ Prof. 2020 Oct;8(4):200-203. doi: 10.30476/jamp.2020.74921.0.


PMID- 33178844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2322-2220 (Print)
IS  - 2322-2220 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Oct
TI  - Evaluation of one-month foundation course for the first year undergraduate
      students at a Medical College in Puducherry, India.
PG  - 165-171
LID - 10.30476/jamp.2020.86857.1272 [doi]
AB  - INTRODUCTION: Medical Council of India has revised the undergraduate medical
      curriculum by introducing "Competency-based Medical Education" which emphasizes
      the foundation course of one-month duration. This period is said to be essential 
      for students to get acclimatized to the new college environment. The present
      study evaluated the first one-month foundation course from students and faculty
      members' point of view. METHODS: The present study was program evaluation. The
      study participants were all 150 first year medical students joining the college
      and preclinical department faculty in the academic year, 2019-20. The foundation 
      program was pre-planned and implemented as per the Medical Council of India
      guidelines. The program was evaluated using a pre-designed questionnaire where
      the items were aligned with the research question and inputs were obtained from
      all faculty members. Kirkpatrick framework level 1 was used for evaluation.
      Feedback was received from the faculty members by force field analysis and from
      student's using a five-point Likert scale. A summative approach to the
      qualitative content analysis was done to identify certain themes from the text
      data and infer meaning for the force field analysis obtained from the faculty.
      Considering the high rating for most of the sessions, we arbitrarily considered
      values above 75% to reflect good consensus and below 75% to reflect poor
      consensus. Consensus measure expressed in percentage was obtained for each item. 
      The quantitative data were analyzed using open Epi info version 7.0. RESULTS: The
      consensus scores ranged from 73.7 to 83.3 percent. The sessions on learning
      styles, student support system, self-directed learning, communication skills,
      medical ethics, soft skills, and orientation to health systems in India reflected
      good consensus, indicating that these sessions were well received by the
      students. Other sessions like stress management, interpersonal skills,
      presentation skills, email writing and ethics for mobile usage reflected poor
      consensus, implying the need for further improvement. As per the faculty
      perception, good coordination, teamwork, and proper planning at interdepartmental
      and intradepartmental levels were the key features for the successful
      implementation of the course. CONCLUSION: Overall, the sessions in the foundation
      course were well received by the students. As felt by both students and faculty, 
      more interactive sessions need to be incorporated. The major strength of the
      course was the skill module, visit to special school, and field visit to the
      community and primary health center. The findings will help us to improve our
      next year foundation program to meet the purpose of the Foundation course.
CI  - Copyright: (c) Journal of Advances in Medical Education & Professionalism.
FAU - Velusami, Deepika
AU  - Velusami D
AD  - Department of Physiology, Sri Manakula Vinayagar Medical College and Hospital,
      Kallitherthalkuppam, Madagadipet, Puducherry- 605 107, India.
FAU - R Dongre, Amol
AU  - R Dongre A
AD  - Department of Community Medicine, Sri Manakula Vinayagar Medical College and
      Hospital, Kallitherthalkuppam, Madagadipet, Puducherry-605 107, India.
FAU - N Kagne, Rajendra
AU  - N Kagne R
AD  - Department of Forensic Medicine, Sri Manakula Vinayagar Medical College and
      Hospital, Kallitherthalkuppam, Madagadipet, Puducherry-605 107, India.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - J Adv Med Educ Prof
JT  - Journal of advances in medical education & professionalism
JID - 101617859
PMC - PMC7642479
OTO - NOTNLM
OT  - Medical college
OT  - Medical students
OT  - Medical teaching
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:45
PHST- 2020/11/12 05:45 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.30476/jamp.2020.86857.1272 [doi]
AID - JAMP-8-4 [pii]
PST - ppublish
SO  - J Adv Med Educ Prof. 2020 Oct;8(4):165-171. doi: 10.30476/jamp.2020.86857.1272.


PMID- 33178843
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2322-2220 (Print)
IS  - 2322-2220 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Oct
TI  - Seven Factors Affecting Medical Undergraduate Students' Performance in Academics:
      A Study Using Ron Fry Questionnaire in Eastern India.
PG  - 158-164
LID - 10.30476/jamp.2020.86444.1239 [doi]
AB  - INTRODUCTION: Undergraduate medical students are adult learners facing various
      assessments through examination during academic course, but the result is
      unsatisfactory. This study aimed at identifying the gaps in academics and finding
      out areas for improvement among the identified factors affecting the students'
      performance. METHODS: A questionnaire survey prospective, cross-sectional,
      observational, questionnaire- based study was conducted among the 3rd semester
      undergraduate students (N=215) in a Government Medical College of Eastern India
      by census method using predesigned, pretested, validated tool designed by Ron
      Fry. A total of 200 students participated in this study. A closed questionnaire
      containing 28 questions with dichotomous options was distributed. Data collected 
      were tabulated in MS Excel spreadsheet and evaluated according to the proposed
      guidelines on seven factors: concentration, comprehension, test anxiety,
      organization, research aptitude, computer skill, and taking notes. Statistical
      significance of the data distribution among different groups was estimated using 
      Chi-square tests in MS Excel 2010 software, and p<0.05 was considered as
      significant. RESULTS: Among 200 participants (response rate=93%), 196 were
      (Male=142, Female= 54) accepted; the respondats' age range was 18-22 years. Of
      them, 48 students obtained honours marks (>/=75% in any subject). 137 (69.9%)
      students had lacunae in any of the above-mentioned domains, comprehension (97.9%)
      being the highest. The major determining factors were test anxiety along with
      note taking and concentration. The differences between the males and females
      regarding concentration (p=0.008) and note taking (p=0.009) were statistically
      significant. Test anxiety was the differentiating factor (p=0.013) between
      honours and non-honours candidates. CONCLUSION: Researches worldwide have
      identified extrinsic, intrinsic, personal, and miscellaneous factors affecting
      the students' performances. This is a multifaceted issue which can be managed
      individually. Few of the most important determinants were dealt with in this
      study. To perform well, every student should understand what to learn, what to
      remember, and how to represent in examinations. This study will help the
      education authorities to guide the students and implement Competency Based
      Medical Education (CBME) based on Attitude, Ethics, and Communication (AETCOM)
      module in India.
CI  - Copyright: (c) Journal of Advances in Medical Education & Professionalism.
FAU - DAS, Abhishek
AU  - DAS A
AD  - Upgraded Department of Forensic and State Medicine, Medical College Kolkata, 88
      College Street, Pin-700073, West Bengal, India.
FAU - Bhattacharya, Shuvro
AU  - Bhattacharya S
AD  - Medical College Kolkata, 88 College Street, Pin-700073, West Bengal, India.
FAU - Chakraborty, Arani
AU  - Chakraborty A
AD  - Medical College Kolkata, 88 College Street, Pin-700073, West Bengal, India.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - J Adv Med Educ Prof
JT  - Journal of advances in medical education & professionalism
JID - 101617859
PMC - PMC7642478
OTO - NOTNLM
OT  - Anxiety
OT  - Attention
OT  - Education
OT  - Medical
OT  - Surveys and questionnaires
OT  - Undergraduate
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:45
PHST- 2020/11/12 05:45 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.30476/jamp.2020.86444.1239 [doi]
AID - JAMP-8-4 [pii]
PST - ppublish
SO  - J Adv Med Educ Prof. 2020 Oct;8(4):158-164. doi: 10.30476/jamp.2020.86444.1239.


PMID- 33178558
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2214-9996 (Electronic)
IS  - 2214-9996 (Linking)
VI  - 86
IP  - 1
DP  - 2020 Oct 26
TI  - Developing Ethical and Sustainable Global Health Educational Exchanges for
      Clinical Trainees: Implementation and Lessons Learned from the 30-Year Academic
      Model Providing Access to Healthcare (AMPATH) Partnership.
PG  - 137
LID - 10.5334/aogh.2782 [doi]
AB  - Background: There is strong interest among healthcare trainees and academic
      institutions in global health rotations. There are a number of guidelines
      detailing the ethical principles for equitable and ethical global health
      rotations and bilateral exchanges, but it is often challenging to know to
      implement those principles and develop longstanding partnerships. Objectives: The
      Academic Model Providing Access to Healthcare (AMPATH) is a 30-year continuous
      partnership between a consortium of 12 universities in North America and Moi
      University in Kenya. The AMPATH bilateral educational exchange has had 1,871
      North American and over 400 Kenyan clinical trainees participate to date. The
      article describes the bilateral exchange of trainees including curriculum,
      housing, and costs and discusses how each is an application of the principles of 
      ethical global engagement. Findings: The article takes the experiences of the
      AMPATH partnership and offers practical strategies for implementing similar
      partnerships based on previously published ethical principles. Conclusions:
      AMPATH provides a model for developing an institutional partnership for a
      bilateral educational exchange grounded in cultural humility, bidirectional
      relationships, and longitudinal, sustainable engagement.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Turissini, Matthew
AU  - Turissini M
AD  - Department of Medicine, Indiana University School of Medicine, Indianapolis,
      Indiana, US.
AD  - Department of Medicine, Moi University School of Medicine, Eldoret, KE.
FAU - Mercer, Tim
AU  - Mercer T
AD  - Department of Population Health, The University of Texas at Austin Dell Medical
      School, Austin, Texas, US.
FAU - Baenziger, Jenny
AU  - Baenziger J
AD  - Department of Medicine, Indiana University School of Medicine and the Indiana
      University Center for Global Health, Indianapolis, Indiana, US.
FAU - Atwoli, Lukoye
AU  - Atwoli L
AD  - Moi University College of Health Sciences Department of Mental Health, Aga Khan
      University Medical College East Africa, KE.
FAU - Einterz, Robert
AU  - Einterz R
AD  - Department of Medicine, Indiana University School of Medicine and the Indiana
      University Center for Global Health, Indianapolis, Indiana, US.
FAU - Gardner, Adrian
AU  - Gardner A
AD  - Department of Medicine, Indiana University School of Medicine and the Indiana
      University Center for Global Health, Indianapolis, Indiana, US.
FAU - Litzelman, Debra
AU  - Litzelman D
AD  - Department of Medicine, Indiana University School of Medicine and the Indiana
      University Center for Global Health, Indianapolis, Indiana, US.
FAU - Ayuo, Paul
AU  - Ayuo P
AD  - College of Health Sciences, Moi University, Eldoret, KE.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - United States
TA  - Ann Glob Health
JT  - Annals of global health
JID - 101620864
SB  - IM
MH  - Curriculum
MH  - *Delivery of Health Care
MH  - *Global Health
MH  - Humans
MH  - Kenya
MH  - Organizations
PMC - PMC7597575
COIS- The authors have no competing interests to declare.
EDAT- 2020/11/13 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/11/12 05:44
PHST- 2020/11/12 05:44 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.5334/aogh.2782 [doi]
PST - epublish
SO  - Ann Glob Health. 2020 Oct 26;86(1):137. doi: 10.5334/aogh.2782.


PMID- 33178536
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 10
TI  - A Case of False-Positive HIV Test in a Patient With Newly Diagnosed Hodgkin
      Lymphoma and Literature Review.
PG  - e10884
LID - 10.7759/cureus.10884 [doi]
AB  - Hodgkin lymphoma (HL) is one of the non-acquired immunodeficiency syndrome
      (AIDS)-defining cancers (NADCs). HIV testing has become a part of routine testing
      in HL because of commonly anticipated association. Here we report an unusual case
      where the need for HIV screening in a newly diagnosed case of HL raised an
      ethical dilemma and a medical challenge due to false-positive HIV test results.
      In literature, pregnancy, autoimmune disorders, some viral infections, and the
      presence of hypergammopathy of hematologic malignancy have all been linked with
      false-positive HIV screening. The reactive results require additional testing
      with an HIV-1/HIV-2 antibody differentiation assay. The specimens show reactivity
      on the initial screening immunoassay, but negative or indeterminate antibody
      differentiation assay should undergo nucleic acid testing. Nevertheless, several 
      instances of discordance between screening and confirmatory techniques have been 
      described. It is speculated that this might be due to coincidental cross-reaction
      of subtypes of polyclonal gamma globulin with the HIV p24 antigen. In conclusion,
      this case signifies the understanding of the HIV testing algorithm and the use of
      reflex testing in the context of a positive HIV test before disclosing such
      preliminary results to patients and/or physicians.
CI  - Copyright (c) 2020, Bukhari et al.
FAU - Bukhari, Sumera
AU  - Bukhari S
AD  - Internal Medicine/Hospital Medicine/Palliative Medicine, Cambridge Health
      Alliance/Harvard Medical School, Cambridge, USA.
FAU - Dirweesh, Ahmed
AU  - Dirweesh A
AD  - Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, 
      Minneapolis, USA.
FAU - Amodu, Afolarin
AU  - Amodu A
AD  - Internal Medicine: Nephrology, Boston University Medical Center, Boston, USA.
FAU - Nadeem, Muhammad
AU  - Nadeem M
AD  - Internal Medicine, Seton Hall University, Saint Francis Medical Center, Trenton, 
      USA.
FAU - Wallach, Sara L
AU  - Wallach SL
AD  - Internal Medicine, Seton Hall University, Saint Francis Medical Center, Trenton, 
      USA.
LA  - eng
PT  - Case Reports
DEP - 20201010
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7652365
OTO - NOTNLM
OT  - false hiv test
OT  - hiv testing
OT  - hodgkin lymphoma
OT  - mediastinal mass
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:44
PHST- 2020/11/12 05:44 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.7759/cureus.10884 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 10;12(10):e10884. doi: 10.7759/cureus.10884.


PMID- 33178501
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 8
TI  - Assessment of Quality of Life in Bronchial Asthma Patients.
PG  - e10845
LID - 10.7759/cureus.10845 [doi]
AB  - Introduction Asthma, a well-known chronic respiratory disease, is common
      worldwide. This study aimed to assess the quality of life in bronchial asthma
      patients and to determine the factors leading to poor quality of life among these
      patients. Materials and methods A cross-sectional study was conducted at a public
      sector hospital. The sample size was calculated as 134, with a nonprobability
      consecutive sampling technique. The Ethical Review Committee approved the study
      protocol. Demographic and asthma quality of life data were collected via a
      questionnaire. Data were analyzed IBM SPSS Statistics for Windows, Version 19.0
      (Armonk, NY: IBM Corp.). Multivariate logistic regression was performed to
      observed the effect of these variables on the poor quality of life. A regression 
      coefficient and odds ratio with a confidence interval of 95% and P-value </= .05 
      were taken as significant. Results The average age of patients was 40.6 +/- 9.5
      years. In this study, 96 of 134 patients (71.4%) with bronchial asthma reported a
      poor quality of life. In the univariate analysis, advanced age (>/= 40 years),
      obesity, being female, family history of asthma, pets at home, and moderate
      severity of asthma significantly contributed to poor quality of life.
      Multivariate logistic regression was performed, and it was observed that advanced
      age (>/= 40 years), being female, a pet at home, and moderate severity of asthma 
      were four to 13 times more likely to predict a poor quality of life for patients 
      with bronchial asthma. Conclusions The severity of asthma significantly
      contributed to poor quality of life. Health facilitators should look into the
      causes of such risk to increase the perception of health-related quality of life 
      (HRQoL) among asthma patients.
CI  - Copyright (c) 2020, Ali et al.
FAU - Ali, Rashid
AU  - Ali R
AD  - Chest Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Ahmed, Naseem
AU  - Ahmed N
AD  - Chest Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Salman, Muhammad
AU  - Salman M
AD  - Paediatrics and Child Health, The Aga Khan University, Karachi, PAK.
FAU - Daudpota, Sofia
AU  - Daudpota S
AD  - Pulmonary Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Masroor, Madiha
AU  - Masroor M
AD  - Internal Medicine, Critical Care Unit, South City Hospital, Karachi, PAK.
FAU - Nasir, Muhammad
AU  - Nasir M
AD  - Critical Care Medicine, Anesthesiology, South City Hospital, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7651774
OTO - NOTNLM
OT  - asthma
OT  - bronchial asthma
OT  - copd
OT  - hrqol
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:44
PHST- 2020/11/12 05:44 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.7759/cureus.10845 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 8;12(10):e10845. doi: 10.7759/cureus.10845.


PMID- 33178447
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2055-7647 (Print)
IS  - 2055-7647 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - Evaluation of a novel strategy to implement exercise evidence into clinical
      practice in breast cancer care: protocol for the NEXT-BRCA randomised controlled 
      trial.
PG  - e000922
LID - 10.1136/bmjsem-2020-000922 [doi]
AB  - INTRODUCTION: The burden of breast cancer in Canada is steadily growing. More
      women are surviving breast cancer, yet, survivors live with side effects for
      years after treatments have ended. The benefits of exercise for women with breast
      cancer are well established and include improvement in treatment-related physical
      and emotional side effects. Despite these benefits, few survivors meet exercise
      guidelines. Exercise programmes are needed within the cancer institution in
      Canada to bridge the current knowledge to practice gap. The purpose of this study
      is to test the effects of a novel implementation strategy that includes
      institution-based exercise plus self-management (SM) or SM alone versus usual
      care in improving exercise level, quality of life, aerobic capacity, muscle
      strength and use of healthcare services over 12 months for women with breast
      cancer receiving chemotherapy. METHODS AND ANALYSIS: Participants: Women with
      stages I-III breast cancer undergoing chemotherapy. Intervention: Group 1:
      institution-based exercise and SM (8 exercise sessions plus 8 SM modules); Group 
      2: SM alone; Group 3: usual care. Outcomes: The primary effectiveness outcome is 
      minutes per week of moderate to vigorous physical activity. Secondary outcomes
      include quality of life, aerobic capacity, muscle strength, and use of healthcare
      services. Randomisation: Participants will be randomised (1:1:1) to one of the
      three groups by a blinded statistician and will be stratified based on age of
      participant (<40, 40-60, and >60 years). Statistical analysis: Outcomes will be
      measured at baseline, post-intervention, 6-month and 12-month follow-up using an 
      analysis of covariance to test changes between groups over time adjusted for age.
      ETHICS AND DISSEMINATION: This study addresses a long-standing need to help women
      with breast cancer undergoing chemotherapy become and stay more active by
      implementing novel rehabilitation strategies into real-world practice. This is
      vital in order for this population to minimise the lingering side effects of
      treatment, improve function and quality of life and prevent cancer recurrence.
      TRIAL REGISTRATION NUMBER: The study protocol (v1: July 2020) has been registered
      on ClinicalTrials.gov (NCT04109274).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Smith-Turchyn, Jenna
AU  - Smith-Turchyn J
AUID- ORCID: 0000-0002-5309-2856
AD  - School of Rehabilitation Science, McMaster University, Hamilton, Canada.
FAU - Mukherjee, Som
AU  - Mukherjee S
AD  - Department of Oncology, McMaster University, Hamilton, Canada.
AD  - Juravinski Cancer Centre, Hamilton, Canada.
FAU - Richardson, Julie
AU  - Richardson J
AD  - School of Rehabilitation Science, McMaster University, Hamilton, Canada.
FAU - Ball, Elizabeth
AU  - Ball E
AD  - Medical Sciences, McMaster University, Hamilton, Canada.
FAU - Bordeleau, Louise
AU  - Bordeleau L
AD  - Department of Oncology, McMaster University, Hamilton, Canada.
AD  - Juravinski Cancer Centre, Hamilton, Canada.
AD  - Health Research Methods, Evidence and Impact, McMaster University, Hamilton,
      Canada.
FAU - Neil-Sztramko, Sarah
AU  - Neil-Sztramko S
AD  - School of Nursing, McMaster University, Hamilton, Canada.
FAU - Levine, Oren
AU  - Levine O
AD  - Department of Oncology, McMaster University, Hamilton, Canada.
AD  - Juravinski Cancer Centre, Hamilton, Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Health Research Methods, Evidence and Impact, McMaster University, Hamilton,
      Canada.
FAU - Sathiyapalan, Arani
AU  - Sathiyapalan A
AD  - Department of Oncology, McMaster University, Hamilton, Canada.
AD  - Juravinski Cancer Centre, Hamilton, Canada.
FAU - Sabiston, Catherine
AU  - Sabiston C
AD  - Kinesiology and Physical Education, University of Toronto, Toronto, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04109274
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - BMJ Open Sport Exerc Med
JT  - BMJ open sport & exercise medicine
JID - 101681007
PMC - PMC7642584
OTO - NOTNLM
OT  - Exercise
OT  - Oncology
OT  - Physical activity
OT  - Physiotherapy
OT  - Rehabilitation
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:43
PHST- 2020/07/30 00:00 [received]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/11/12 05:43 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.1136/bmjsem-2020-000922 [doi]
AID - bmjsem-2020-000922 [pii]
PST - epublish
SO  - BMJ Open Sport Exerc Med. 2020 Oct 7;6(1):e000922. doi:
      10.1136/bmjsem-2020-000922. eCollection 2020.


PMID- 33178395
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 1948-0210 (Print)
IS  - 1948-0210 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 26
TI  - Medical, ethical, and legal aspects of hematopoietic stem cell transplantation
      for Crohn's disease in Brazil.
PG  - 1113-1123
LID - 10.4252/wjsc.v12.i10.1113 [doi]
AB  - Crohn's disease (CD) is a chronic inflammatory bowel disease that can affect any 
      part of the gastrointestinal tract. The etiology of CD is unknown; however,
      genetic, epigenetic, environmental, and lifestyle factors could play an essential
      role in the onset and establishment of the disease. CD results from immune
      dysregulation due to loss of the healthy symbiotic relationship between host and 
      intestinal flora and or its antigens. It affects both sexes equally with a male
      to female ratio of 1.0, and its onset can occur at any age, but the diagnosis is 
      most commonly observed in the range of 20 to 40 years of age. CD diminishes
      quality of life, interferes with social activities, traumatizes due to the stigma
      of incontinence, fistulae, strictures, and colostomies, and in severe cases,
      affects survival when compared to the general population. Symptoms fluctuate
      between periods of remission and activity in which complications such as
      fistulas, strictures, and the need for bowel resection, surgery, and colostomy
      implantation make up the most severe aspects of the disease. CD can be
      progressive and the complications recurrent despite treatment with
      anti-inflammatory drugs, corticosteroids, immunosuppressants, and biological
      agents. However, over time many patients become refractory without treatment
      alternatives, and in this scenario, hematopoietic stem cell transplantation
      (HSCT) has emerged as a potential treatment option. The rationale for the use of 
      HSCT for CD is anchored in animal studies and human clinical trials where HSCT
      could reset a patient's immune system by eliminating disease-causing effector
      cells and upon immune recovery increase regulatory and suppressive immune cells. 
      Autologous HSCT using a non-myeloablative regimen of cyclophosphamide and
      anti-thymocyte globulin without CD34+ selection has been to date the most common 
      transplant conditioning regimen adopted. In this review we will address the
      current situation regarding CD treatment with HSCT and emphasize the medical,
      ethical, and legal aspects that permeate the procedure in Brazil.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Ruiz, Milton Artur
AU  - Ruiz MA
AD  - Department of Bone Marrow Transplant, Beneficencia Portuguesa Hospital, Sao Jose 
      do Rio Preto 15090 470, Brazil, milruiz@yahoo.com.br.
FAU - Junior, Roberto Luiz Kaiser
AU  - Junior RLK
AD  - Department of Proctology, Beneficencia Portuguesa Hospital, Sao Jose do Rio Preto
      15090 470, Brazil.
FAU - Piron-Ruiz, Lilian
AU  - Piron-Ruiz L
AD  - Department of Bone Marrow Transplantation, Beneficencia Portuguesa Hospital, Sao 
      Jose do Rio Preto 15090 470, Brazil.
FAU - Saran, Priscila Samara
AU  - Saran PS
AD  - Department of Bone Marrow Transplantation, Beneficencia Portuguesa Hospital, Sao 
      Jose do Rio Preto 15090 470, Brazil.
FAU - Castiglioni, Lilian
AU  - Castiglioni L
AD  - Genetics and Molecular Biology, FAMERP- Faculdade de Medicina de Sao Jose do Rio 
      Preto, Sao Jose do Rio Preto 15090 470 Brazil.
FAU - de Quadros, Luiz Gustavo
AU  - de Quadros LG
AD  - Department of Endoscopy, Beneficencia Portuguesa Hospital, ABC Medical School,
      Sao Bernardo 15015 110, Brazil.
FAU - Pinho, Tainara Souza
AU  - Pinho TS
AD  - Department of Bone Marrow Transplantation, Beneficencia Portuguesa Hospital, Sao 
      Jose do Rio Preto 15090 470, Brazil.
FAU - Burt, Richard K
AU  - Burt RK
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine,
      Chicago, IL 60611, United States.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Stem Cells
JT  - World journal of stem cells
JID - 101535826
PMC - PMC7596442
OTO - NOTNLM
OT  - Autologous transplant
OT  - Crohn disease
OT  - Ethics
OT  - Hematopoietic stem cell transplant
OT  - Stem cell therapy
OT  - Treatment
COIS- Conflict-of-interest statement: Authors declare no conflict of interests for this
      article.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:43
PHST- 2020/05/02 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/11/12 05:43 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.4252/wjsc.v12.i10.1113 [doi]
PST - ppublish
SO  - World J Stem Cells. 2020 Oct 26;12(10):1113-1123. doi: 10.4252/wjsc.v12.i10.1113.


PMID- 33178365
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201219
IS  - 1205-7088 (Print)
IS  - 1205-7088 (Linking)
VI  - 25
IP  - 7
DP  - 2020 Nov
TI  - A call for a streamlined ethics review process for multijurisdictional, child
      health research studies.
PG  - 406-408
LID - 10.1093/pch/pxz160 [doi]
AB  - To be time and resource efficient in neonatal research and to answer clinically
      relevant questions with validity and generalizability, large numbers of infants
      from multiple hospitals need to be included. Multijurisdictional research in
      Canada is currently fraught with research ethics review process hurdles that lead
      to delays, administrative costs, and possibly termination of projects. We
      describe our experience applying for ethics review to 13 sites in 7 provinces for
      a project comparing two standard of care therapies for preterm born infants with 
      respiratory distress syndrome. We welcome the current opportunity created by the 
      Institute of Human Development Child and Youth Health and the Institute for
      Genetics, to collaboratively identify practical solutions that would benefit
      Canadian researchers, Research Ethics Boards, and children and families.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the
      Canadian Paediatric Society. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Lemyre, Brigitte
AU  - Lemyre B
AUID- ORCID: 0000-0003-2743-0417
AD  - Division of Neonatology, Children's Hospital of Eastern Ontario, Ottawa.
AD  - Department of Pediatrics, University of Ottawa, Ottawa.
FAU - Bodani, Jaya P
AU  - Bodani JP
AD  - Department of Pediatrics Regina General Hospital, Saskatchewan Health Authority, 
      Regina.
AD  - Department of Pediatrics, College of Medicine, University of Saskatchewan,
      Regina.
FAU - Doucette, Stefani
AU  - Doucette S
AD  - Department of Paediatrics, Cumming School of Medicine, University of Calgary,
      Calgary.
FAU - Dunn, Michael S
AU  - Dunn MS
AD  - Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences
      Center, Toronto.
FAU - Louis, Deepak
AU  - Louis D
AD  - Department of Paediatrics and Child Health, Max Rady Faculty of Medicine,
      University of Manitoba, Winnipeg.
FAU - Monterrosa, Luis
AU  - Monterrosa L
AD  - Department of Pediatrics, Division of Neonatology, Dalhousie University,
      Saint-John.
FAU - Mukerji, Amit
AU  - Mukerji A
AD  - Division of Neonatology, McMaster University, Hamilton.
FAU - Schmolzer, Georg M
AU  - Schmolzer GM
AD  - Centre for the Studies of Asphyxia and Resuscitation, Neonatal Research Unit,
      Royal Alexandra Hospital, Edmonton, Alberta.
AD  - Department of Pediatrics, Faculty of Medicine and Dentistry, University of
      Alberta, Edmonton, Alberta.
FAU - Shah, Prakeshkumar
AU  - Shah P
AD  - Department of Pediatrics, Mount Sinai Hospital and University of Toronto,
      Toronto.
FAU - Singh, Balpreet
AU  - Singh B
AD  - Division of Neonatal-Perinatal Medicine, IWK Health Center, Halifax.
AD  - Department of Pediatrics, Dalhousie University, Halifax.
FAU - Wong, Jonathan
AU  - Wong J
AUID- ORCID: 0000-0001-6489-358X
AD  - Department of Pediatrics, BC University of British Columbia, Vancouver.
FAU - Lacaze-Masmonteil, Thierry
AU  - Lacaze-Masmonteil T
AD  - Department of Paediatrics, Cumming School of Medicine, University of Calgary,
      Calgary.
FAU - Offringa, Martin
AU  - Offringa M
AD  - Division of Neonatology, The Hospital for Sick Children, Toronto.
LA  - eng
PT  - Journal Article
DEP - 20191219
PL  - England
TA  - Paediatr Child Health
JT  - Paediatrics & child health
JID - 9815960
PMC - PMC7606166
OTO - NOTNLM
OT  - Multicenter research
OT  - neonatology
OT  - research ethics review
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:43
PHST- 2019/08/13 00:00 [received]
PHST- 2019/10/23 00:00 [accepted]
PHST- 2020/11/12 05:43 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.1093/pch/pxz160 [doi]
AID - pxz160 [pii]
PST - epublish
SO  - Paediatr Child Health. 2019 Dec 19;25(7):406-408. doi: 10.1093/pch/pxz160.
      eCollection 2020 Nov.


PMID- 33177884
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1179-1373 (Print)
IS  - 1179-1373 (Linking)
VI  - 12
DP  - 2020
TI  - Voluntary HIV Counseling and Testing Among Commercial Motorcyclist Youths: An
      Exploration of Ethical Challenges and Coping Mechanisms in Dar es Salaam.
PG  - 675-685
LID - 10.2147/HIV.S259997 [doi]
AB  - BACKGROUND: Regardless, the known benefits of voluntary testing and counseling
      (VCT) in the fight against HIV/AIDS, its uptake is still low among youth. This
      study explored ethical challenges facing voluntary counseling and testing for
      HIV/AIDS among youth engaged in commercial motorcycling in Kinondoni
      municipality, Dar es Salaam city. METHODS: Qualitative exploratory study was
      carried out to 35 people using key informants' interviews (KIIs), in-depth
      interviews (IDIs), and focus group discussions (FGDs). Key informants were
      purposefully selected based on their roles in VCT services, while the FGD
      participants and in-depth interview respondents were purposefully selected among 
      youth commercial motorcyclists. Qualitative content data analysis was used to
      analyze the gathered information. FINDINGS: Results of this study show that lack 
      of privacy during counseling and treatment, fear of HIV status disclosure to
      others by counselors and difficulties in counseling are the main ethical
      challenges facing VCT services among youth in Kinondoni municipality. Shortage of
      counselors to match the number of VCT services' clients and lack of on-job
      training on HIV/AIDS testing and counseling among counselors partly contributed
      to the revealed ethical challenges. In an attempt to address the ethical
      challenges, youth peer educators and routine supervision were the available
      initiatives on improving VCT services among youth. CONCLUSION: VCT services face 
      ethical challenges which are either health facility-based, community-based or are
      at the national level. Addressing the ethical challenges is necessary in order to
      improve the uptake of VCT services and thus strengthen the fight against
      HIV/AIDS. Deployment of enough counselors, refresher training to counselors, and 
      raising community awareness on HIV/AIDS and the negative impacts of stigma are
      among the initial strategies for remedying the situation.
CI  - (c) 2020 Mlughu et al.
FAU - Mlughu, Thadei S
AU  - Mlughu TS
AD  - Department of Bioethics and Health Professionalism, Muhimbili University of
      Health and Allied Sciences, Dar es Salaam, Tanzania.
FAU - Anaeli, Amani
AU  - Anaeli A
AD  - Department of Development Studies, Muhimbili University of Health and Allied
      Sciences, Dar es Salaam, Tanzania.
FAU - Joseph, Renatha
AU  - Joseph R
AD  - Department of Bioethics and Health Professionalism, Muhimbili University of
      Health and Allied Sciences, Dar es Salaam, Tanzania.
FAU - Sirili, Nathanael
AU  - Sirili N
AUID- ORCID: 0000-0001-5205-624X
AD  - Department of Development Studies, Muhimbili University of Health and Allied
      Sciences, Dar es Salaam, Tanzania.
LA  - eng
PT  - Journal Article
DEP - 20201103
PL  - New Zealand
TA  - HIV AIDS (Auckl)
JT  - HIV/AIDS (Auckland, N.Z.)
JID - 101515943
PMC - PMC7650004
OTO - NOTNLM
OT  - HIV/AIDS
OT  - Tanzania
OT  - commercial motorcyclists
OT  - counseling
OT  - ethical challenges
OT  - shortage of counselors
OT  - testing
OT  - voluntary
OT  - youth and HIV
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:01
CRDT- 2020/11/12 05:41
PHST- 2020/04/26 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/11/12 05:41 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:01 [medline]
AID - 10.2147/HIV.S259997 [doi]
AID - 259997 [pii]
PST - epublish
SO  - HIV AIDS (Auckl). 2020 Nov 3;12:675-685. doi: 10.2147/HIV.S259997. eCollection
      2020.


PMID- 33177147
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 11
TI  - Creating an ethical culture to support recovery from substance use disorders.
LID - medethics-2020-106661 [pii]
LID - 10.1136/medethics-2020-106661 [doi]
AB  - There is a long-standing failure to create an ethical culture around substance
      use disorders (SUDs) or dependence that actively supports people's recovery
      efforts. Issues which impede the development of prorecovery environments are
      complex, but include the far-reaching effects of the social stigma that surrounds
      SUDs; and the failure to harness relational and social support that allows
      debates to transcend blaming individual substance users. As part of efforts to
      create prorecovery environments, it is important to acknowledge that bioethics
      debate on SUDs is narrow in scope, prioritising topics related to its traditional
      interests in individual autonomy and novel technologies. As a result, it has not 
      played a significant role in helping to transform the ethical cultures in which
      substance use recovery takes place. For example, it largely neglects the ethical 
      challenges of developing an empathic, person-centred approach to substance use
      problems that listens and responds to the voices of clients. It has also
      participated little in efforts to develop a positive response to reducing the
      toxic effects of stigma. Indeed, some contributions from the field fan stigma,
      rather than alleviate it. The aim of this paper is to seed broader ethical
      debate, in academic literature and lay/professional communities, on how societies
      should respond to SUDs: steering a course between the critical, but narrow
      approach of bioethics and the empowerment discourse of evidence-based treatments.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Williamson, Laura
AU  - Williamson L
AUID- ORCID: http://orcid.org/0000-0001-6461-2346
AD  - Center for Bioethics and Health Policy, Institute of Public & Preventive Health, 
      Augusta University, Augusta, Georgia, USA LAURAWILLIAMSON07@GMAIL.COM.
LA  - eng
PT  - Journal Article
DEP - 20201111
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639939
OTO - NOTNLM
OT  - applied and professional ethics
OT  - autonomy
OT  - clinical ethics
OT  - substance abusers/users of controlled substances
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/07/02 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - medethics-2020-106661 [pii]
AID - 10.1136/medethics-2020-106661 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 11. pii: medethics-2020-106661. doi:
      10.1136/medethics-2020-106661.


PMID- 33177145
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a
      randomised controlled open-label superiority meta-trial.
PG  - e041520
LID - 10.1136/bmjopen-2020-041520 [doi]
AB  - INTRODUCTION: Prone positioning (PP) is an effective first-line intervention to
      treat patients with moderate to severe acute respiratory distress syndrome (ARDS)
      receiving invasive mechanical ventilation, as it improves gas exchanges and
      reduces mortality. The use of PP in awake spontaneous breathing patients with
      ARDS secondary to COVID-19 was reported to improve oxygenation in few
      retrospective trials with small sample size. High-level evidence of awake PP for 
      hypoxaemic patients with COVID-19 patients is still lacking. METHODS AND
      ANALYSIS: The protocol of this meta-trial is a prospective collaborative
      individual participant data meta-analysis of randomised controlled open label
      superiority trials. This design is particularly adapted to a rapid scientific
      response in the pandemic setting. It will take place in multiple sites, among
      others in USA, Canada, Ireland, France and Spain. Patients will be followed up
      for 28 days. Patients will be randomised to receive whether awake PP and nasal
      high flow therapy or standard medical treatment and nasal high flow therapy.
      Primary outcome is defined as the occurrence rate of tracheal intubation or death
      up to day 28. An interim analysis plan has been set up on aggregated data from
      the participating research groups. ETHICS AND DISSEMINATION: Ethics approvals
      were obtained in all participating countries. Results of the meta-trial will be
      submitted for publication in a peer-reviewed journal. Each randomised controlled 
      trial was registered individually, as follows: NCT04325906, NCT04347941,
      NCT04358939, NCT04395144 and NCT04391140.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tavernier, Elsa
AU  - Tavernier E
AUID- ORCID: 0000-0003-0798-1182
AD  - Clinical Investigation Center, INSERM 1415, CHRU Tours, Tours, Centre, France
      elsa.tavernier@univ-tours.fr.
AD  - Methods in Patients-Centered Outcomes and Health Research, INSERM UMR 1246,
      Nantes, Loire-Atlantique, France.
FAU - McNicholas, Bairbre
AU  - McNicholas B
AD  - Department of Anaesthesia and Intensive Care Medicine, School of Medicine,
      National University of Ireland Galway, Galway, Ireland.
AD  - Department of Anaesthesia, University Hospital Galway, Saolta University Hospital
      Group, Galway, Ireland.
FAU - Pavlov, Ivan
AU  - Pavlov I
AD  - Department of Emergency Medicine, Hopital de Verdun, Montreal, Quebec, Canada.
FAU - Roca, Oriol
AU  - Roca O
AD  - Critical Care Department, Vall d'Hebron University Hospital, Vall d'Hebron
      Research Institute, Barcelona, Catalunya, Spain.
AD  - Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Catalunya,
      Spain.
FAU - Perez, Yonatan
AU  - Perez Y
AD  - Medecin Intensive Reanimation, CIC 1415, CRICS-TriggerSEP, Centre d'etude des
      pathologies respiratoires, INSERM U1100, Universite de Tours, CHU Tours, Tours,
      Centre, France.
FAU - Laffey, John
AU  - Laffey J
AD  - Department of Anaesthesia and Intensive Care Medicine, School of Medicine,
      National University of Ireland Galway, Galway, Ireland.
AD  - Department of Anaesthesia, University Hospital Galway, Saolta University Hospital
      Group, Galway, Ireland.
FAU - Mirza, Sara
AU  - Mirza S
AD  - Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush
      University, Chicago, Illinois, USA.
FAU - Cosgrave, David
AU  - Cosgrave D
AD  - Department of Anaesthesia and Intensive Care Medicine, School of Medicine,
      National University of Ireland Galway, Galway, Ireland.
AD  - Department of Anaesthesia, University Hospital Galway, Saolta University Hospital
      Group, Galway, Ireland.
FAU - Vines, David
AU  - Vines D
AD  - Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush
      University, Chicago, Illinois, USA.
FAU - Frat, Jean-Pierre
AU  - Frat JP
AD  - Reanimation Medicale, CHU Poitiers, Poitiers, France.
FAU - Ehrmann, Stephan
AU  - Ehrmann S
AD  - Medecin Intensive Reanimation, CIC 1415, CRICS-TriggerSEP, Centre d'etude des
      pathologies respiratoires, INSERM U1100, Universite de Tours, CHU Tours, Tours,
      Centre, France.
FAU - Li, Jie
AU  - Li J
AUID- ORCID: 0000-0003-0121-1291
AD  - Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush
      University, Chicago, Illinois, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04358939
SI  - ClinicalTrials.gov/NCT04347941
SI  - ClinicalTrials.gov/NCT04395144
SI  - ClinicalTrials.gov/NCT04391140
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cannula
MH  - Coronavirus Infections/*therapy
MH  - Equivalence Trials as Topic
MH  - Humans
MH  - Hypoxia/*therapy
MH  - Meta-Analysis as Topic
MH  - Oxygen Inhalation Therapy/*methods
MH  - Pandemics
MH  - Patient Positioning/*methods
MH  - Pneumonia, Viral/*therapy
MH  - *Prone Position
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Wakefulness
PMC - PMC7661350
OTO - NOTNLM
OT  - *COVID-19
OT  - *adult intensive & critical care
OT  - *international health services
OT  - *respiratory infections
OT  - *statistics & research methods
COIS- Competing interests: IP has been a speaker for Fisher & Pakyel Healthcare within 
      the last 3 years. All compensation was paid to the charitable foundation at the
      hospital where he works, and he did not personally receive any compensation. JL
      discloses research support from Fisher & Paykel Healthcare for another research
      project. SE received unrestricted research grants, travel fee reimbursements and 
      speaker fees from Fisher & Paykel Healthcare, consulting fees from La Diffusion
      Technique Francaise, consulting fees and unrestricted research grants from
      Aerogen Ltd and an unrestricted research grant from Hamiton medical. OR provides 
      consultancy to Hamilton Medical but he did not receive any personal fee. All
      compensation were received by the Institute of Research of his Institution. He
      received speaker fees by Air Liquide. J-PF reports grants from the French
      Ministry of Health; grants, personal fees and non-financial support from Fisher &
      Paykel Heathcare; personal fees and non-financial support from SOS oxygene,
      outside the submitted work.
EDAT- 2020/11/13 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjopen-2020-041520 [pii]
AID - 10.1136/bmjopen-2020-041520 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e041520. doi: 10.1136/bmjopen-2020-041520.


PMID- 33177144
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Understanding the underlying drivers of obesity in Africa: a scoping review
      protocol.
PG  - e040940
LID - 10.1136/bmjopen-2020-040940 [doi]
AB  - INTRODUCTION: The worldwide prevalence of obesity and overweight has doubled
      since 1980, such that approximately a third of the world's population is reported
      as obese or overweight. Obesity rates have increased in all ages and both sexes
      irrespective of geographical area, ethnicity or socioeconomic status. Due to the 
      high prevalence, related health consequences and costs of childhood and adult
      obesity, there is a need to comprehensively identify and assess the major
      underlying drivers of obesity and overweight in the African context. METHODS AND 
      ANALYSIS: This scoping review will be carried out as per the methodological
      outline by Arksey and O'Malley. The search strategy will be developed and search 
      performed in the Scopus and PubMed electronic databases. In the first search, we 
      will identify concepts that are used as an equivalent to obesity and overweight. 
      Subsequently, we will search for studies comprising of search terms on the
      underlying factors that drive the development of obesity and overweight. Lastly, 
      we will check reference lists for additional publications. Abstracts and
      full-text studies will independently be screened by two authors. ETHICS AND
      DISSEMINATION: The proposed study will generate evidence from published data and 
      hence does not require ethics approval. Evidence generated from this review will 
      be disseminated through journal publications and conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Jaca, Anelisa
AU  - Jaca A
AUID- ORCID: 0000-0002-9814-8374
AD  - Cochrane South Africa, South African Medical Research Council, Tygerberg, South
      Africa anelisaj@gmail.com.
FAU - Iwu, Chinwe
AU  - Iwu C
AUID- ORCID: 0000-0003-0765-7497
AD  - Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences,
      Stellenbosch University, Cape Town, South Africa.
FAU - Durao, Solange
AU  - Durao S
AD  - Cochrane South Africa, South African Medical Research Council, Tygerberg, South
      Africa.
FAU - Onyango, Adelheid W
AU  - Onyango AW
AD  - Department of Nutrition for Health and Development, World Health Organization,
      Brazzaville, Congo.
FAU - Wiysonge, Charles Shey
AU  - Wiysonge CS
AUID- ORCID: 0000-0002-1273-4779
AD  - Cochrane South Africa, South African Medical Research Council, Tygerberg, South
      Africa.
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
AD  - Department of Global Health, Stellenbosch University, Cape Town, South Africa.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Africa/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Obesity/epidemiology
MH  - *Overweight/epidemiology
MH  - Review Literature as Topic
PMC - PMC7661354
OTO - NOTNLM
OT  - *gastroenterology
OT  - *health policy
OT  - *health services administration & management
OT  - *nutrition & dietetics
OT  - *nutritional support
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040940 [pii]
AID - 10.1136/bmjopen-2020-040940 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e040940. doi: 10.1136/bmjopen-2020-040940.


PMID- 33177142
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Development of a risk prediction model of potentially avoidable readmission for
      patients hospitalised with community-acquired pneumonia: study protocol and
      population.
PG  - e040573
LID - 10.1136/bmjopen-2020-040573 [doi]
AB  - INTRODUCTION: 30-day readmission rate is considered an adverse outcome reflecting
      suboptimal quality of care during index hospitalisation for community-acquired
      pneumonia (CAP). However, potentially avoidable readmission would be a more
      relevant metric than all-cause readmission for tracking quality of hospital care 
      for CAP. The objectives of this study are (1) to estimate potentially avoidable
      30-day readmission rate and (2) to develop a risk prediction model intended to
      identify potentially avoidable readmissions for CAP. METHODS AND ANALYSIS: The
      study population consists of consecutive patients admitted in two hospitals from 
      the community or nursing home setting with pneumonia. To qualify for inclusion,
      patients must have a primary or secondary discharge diagnosis code of pneumonia. 
      Data sources include routinely collected administrative claims data as part of
      diagnosis-related group prospective payment system and structured chart reviews. 
      The main outcome measure is potentially avoidable readmission within 30 days of
      discharge from index hospitalisation. The likelihood that a readmission is
      potentially avoidable will be quantified using latent class analysis based on
      independent structured reviews performed by four panellists. We will use a
      two-stage approach to develop a claims data-based model intended to identify
      potentially avoidable readmissions. The first stage implies deriving a clinical
      model based on data collected through retrospective chart review only. In the
      second stage, the predictors comprising the medical record model will be
      translated into International Classification of Diseases, 10th revision discharge
      diagnosis codes in order to obtain a claim data-based risk model.The study sample
      consists of 1150 hospital stays with a diagnosis of CAP. 30-day index hospital
      readmission rate is 17.5%. ETHICS AND DISSEMINATION: The protocol was reviewed by
      the Comite de Protection des Personnes Sud Est V (IRB#6705). Efforts will be made
      to release the primary study results within 6 months of data collection
      completion. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT02833259).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mounayar, Anne-Laure
AU  - Mounayar AL
AUID- ORCID: 0000-0003-3172-1612
AD  - Infectious Diseases, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Francois, Patrice
AU  - Francois P
AD  - Medical Assessment, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France
      pfrancois@chu-grenoble.fr.
FAU - Pavese, Patricia
AU  - Pavese P
AD  - Infectious Diseases, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Sellier, Elodie
AU  - Sellier E
AD  - Medical Information, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Gaillat, Jacques
AU  - Gaillat J
AD  - Medical Information and Assessment, Annecy Genevois Hospital Centre, Epagny
      Metz-Tessy, Rhone-Alpes, France.
FAU - Camara, Boubou
AU  - Camara B
AD  - Pneumology Department, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Degano, Bruno
AU  - Degano B
AD  - Pneumology Department, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Maillet, Mylene
AU  - Maillet M
AD  - Infectious Diseases, Annecy Genevois Hospital Centre, Epagny Metz-Tessy,
      Rhone-Alpes, France.
FAU - Bouisse, Magali
AU  - Bouisse M
AD  - Medical Assessment, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
FAU - Courtois, Xavier
AU  - Courtois X
AD  - Medical Information and Assessment, Annecy Genevois Hospital Centre, Epagny
      Metz-Tessy, Rhone-Alpes, France.
FAU - Labarere, Jose
AU  - Labarere J
AUID- ORCID: 0000-0001-7621-6586
AD  - Medical Assessment, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
AD  - BCM, Laboratoire TIMC-IMAG, La Tronche, Rhone-Alpes, France.
FAU - Seigneurin, Arnaud
AU  - Seigneurin A
AD  - Medical Assessment, CHU Grenoble Alpes, Grenoble, Rhone-Alpes, France.
AD  - BCM, Laboratoire TIMC-IMAG, La Tronche, Rhone-Alpes, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT02833259
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Length of Stay
MH  - Patient Discharge
MH  - *Patient Readmission
MH  - *Pneumonia/epidemiology/therapy
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC7661353
OTO - NOTNLM
OT  - *hospital readmission
OT  - *pneumonia
OT  - *prediction model
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040573 [pii]
AID - 10.1136/bmjopen-2020-040573 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e040573. doi: 10.1136/bmjopen-2020-040573.


PMID- 33177140
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Development and validity testing of the Adolescent Health Literacy Questionnaire 
      (AHLQ): Protocol for a mixed methods study within the Irish school setting.
PG  - e039920
LID - 10.1136/bmjopen-2020-039920 [doi]
AB  - INTRODUCTION: Health literacy research has focused predominantly on the adult
      population, and much less is understood about this concept from an adolescent
      perspective. The tools currently available to measure adolescent health literacy 
      have been adapted from adult versions. This limits their applicability to young
      people because of the developmental characteristics that impact on adolescents'
      behaviour, including impulse control and judgement skills. This protocol
      describes the intended development and validity testing of a questionnaire to
      measure health literacy in adolescents. METHODS AND ANALYSIS: This protocol
      describes this mixed methods study that has three phases: the first phase will
      involve grounded research with adolescents using qualitative group interviews,
      co-design and concept mapping workshops to understand what health and healthy
      behaviours mean to adolescents and to explore their health literacy needs and the
      potential domains for the questionnaire. The draft health literacy domains
      identified will be presented to the youth advisory panel, and the questionnaire
      will be altered based on their feedback. Cognitive pretesting of the
      questionnaire items will also be conducted. Phase 2 will involve piloting the
      questionnaire to a two-stage random sample of young people in five urban and
      rural schools in Ireland. Test-retest reliability will be conducted using Pearson
      correlation coefficient. Confirmatory factor analysis will also be conducted to
      analyse the psychometric properties of the questionnaire. Phase 3 will involve
      the questionnaire being rolled out to a nationally representative sample of
      adolescents (n=6052) in Ireland to assess their levels of health literacy. ETHICS
      AND DISSEMINATION: Ethical approval to conduct this study has been granted from
      the University College Dublin Human Research Ethics Committee - Sciences
      (LS-20-08). Informed assent from adolescents and informed consent from
      parents/guardians will be sought. The findings of this research will be
      disseminated at national and international conferences, as well as through
      publication in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Spillane, Ailbhe
AU  - Spillane A
AUID- ORCID: 0000-0002-1172-2151
AD  - School of Public Health, Physiotherapy and Sports Science, University College
      Dublin, Dublin, Ireland ailbhespillane@gmail.com.
FAU - Belton, Sarahjane
AU  - Belton S
AD  - School of Health and Human Performance, Dublin City University, Dublin, Ireland.
FAU - McDermott, Clare
AU  - McDermott C
AD  - School of Health and Human Performance, Dublin City University, Dublin, Ireland.
FAU - Issartel, Johann
AU  - Issartel J
AD  - School of Health and Human Performance, Dublin City University, Dublin, Ireland.
FAU - Osborne, Richard H
AU  - Osborne RH
AD  - Centre for Global Health and Equity, Swinburne University of Technology,
      Hawthorn, Victoria, Australia.
FAU - Elmer, Shandell
AU  - Elmer S
AD  - Centre for Global Health and Equity, Swinburne University of Technology,
      Hawthorn, Victoria, Australia.
FAU - Murrin, Celine
AU  - Murrin C
AD  - School of Public Health, Physiotherapy and Sports Science, University College
      Dublin, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adolescent Health
MH  - Adult
MH  - *Health Literacy
MH  - Humans
MH  - Ireland
MH  - Reproducibility of Results
MH  - Schools
MH  - Surveys and Questionnaires
PMC - PMC7661365
OTO - NOTNLM
OT  - *health policy
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039920 [pii]
AID - 10.1136/bmjopen-2020-039920 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e039920. doi: 10.1136/bmjopen-2020-039920.


PMID- 33177139
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Assessing the benefits on quality of life of a multicomponent intervention for
      fibromyalgia syndrome in primary care: patients' and health professionals'
      appraisals: a qualitative study protocol.
PG  - e039873
LID - 10.1136/bmjopen-2020-039873 [doi]
AB  - INTRODUCTION: Fibromyalgia syndrome (FMS) is a complex condition still scarcely
      understood and with ambiguity when prescribing treatment. Both patients and
      healthcare providers can supply valuable information for the development of new
      treatment strategies. The qualitative narrative analysis of participant's
      accounts is potentially helpful to reveal new insights about their opinions,
      needs, and experiences and, consequently, to model healthcare interventions
      accurately. International treatment guidelines suggest a promising future for
      multicomponent intervention (MI) approaches for FMS. This study aims to assess
      the benefits of a MI for patients with FMS in the context of primary care (PC) in
      Terres de L'Ebre, Catalonia (Spain). Furthermore, it is intended to detect the
      overall perception of effectiveness and to understand patients' lived experience 
      and its impact on the quality of life. METHOD AND ANALYSIS: Qualitative research 
      from a socioconstructivism paradigm perspective and a Hermeneutic
      Phenomenological method. For data collection, four focus group discussions (FGDs)
      of 8-12 people (2 FGDs of patients and 2 of professionals) and 10-12 key
      informant interviews with the participants in the MI group will be carried out.
      All the information will be recorded and verbatim transcribed to perform an
      interpretive thematic analysis. ETHICS AND DISSEMINATION: This study protocol has
      been approved by the Clinical Research Ethics Committee from the IDIAPJGol
      Institute, on 25 April 2018 (code P18/068), according to the Declaration of
      Helsinki/Tokyo. All participants will receive oral/written information about the 
      study, and they will be required to sign an informed consent sheet. Data
      anonymity will be guaranteed. Dissemination will be carried out through
      publications in scientific journals, presentations in academic meetings,
      workshops and through the local and national media. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov: NCT04049006; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arfuch, Victoria Mailen
AU  - Arfuch VM
AUID- ORCID: 0000-0001-5935-6907
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, IDIAP Jordi Gol, Barcelona,
      Catalunya, Spain.
AD  - Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine,
      Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain.
FAU - Caballol Angelats, Rosa
AU  - Caballol Angelats R
AD  - Equip d'Atencio Primaria Tortosa Est, Institut Catala de la Salut, Tortosa,
      Catalunya, Spain.
AD  - Unitat d'Expertesa en Sindromes de Sensibilitzacio Central Terres de l'Ebre,
      Institut Catala de la Salut, Tortosa, Catalunya, Spain.
FAU - Aguilar Martin, Carina
AU  - Aguilar Martin C
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, IDIAP Jordi Gol, Barcelona,
      Catalunya, Spain.
AD  - Unitat d'Avaluacio, Direccio d'Atencio Primaria Terres de l'Ebre, Institut Catala
      de la Salut, Tortosa, Catalunya, Spain.
FAU - Carrasco-Querol, Noelia
AU  - Carrasco-Querol N
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, IDIAP Jordi Gol, Barcelona,
      Catalunya, Spain.
FAU - Sancho Sol, Maria Cinta
AU  - Sancho Sol MC
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, IDIAP Jordi Gol, Barcelona,
      Catalunya, Spain.
AD  - Unitat d'Expertesa en Sindromes de Sensibilitzacio Central Terres de l'Ebre,
      Institut Catala de la Salut, Tortosa, Catalunya, Spain.
FAU - Gonzalez Serra, Gemma
AU  - Gonzalez Serra G
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, IDIAP Jordi Gol, Barcelona,
      Catalunya, Spain.
AD  - Unitat d'Expertesa en Sindromes de Sensibilitzacio Central Terres de l'Ebre,
      Institut Catala de la Salut, Tortosa, Catalunya, Spain.
FAU - Fuste Anguera, Immaculada
AU  - Fuste Anguera I
AD  - Equip d'Atencio Primaria Tortosa Est, Institut Catala de la Salut, Tortosa,
      Catalunya, Spain.
AD  - Unitat d'Expertesa en Sindromes de Sensibilitzacio Central Terres de l'Ebre,
      Institut Catala de la Salut, Tortosa, Catalunya, Spain.
FAU - Goncalves, Alessandra Queiroga
AU  - Goncalves AQ
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, IDIAP Jordi Gol, Barcelona,
      Catalunya, Spain.
AD  - Unitat Docent de Medicina de Familia i Comunitaria Tortosa-Terres de L'Ebre,
      Institut Catala de la Salut, Tortosa, Catalunya, Spain.
FAU - Berenguera, Anna
AU  - Berenguera A
AUID- ORCID: 0000-0002-0889-2002
AD  - Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine,
      Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain
      aberenguera@idiapjgol.org.
AD  - Central Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04049006
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Fibromyalgia/therapy
MH  - Health Personnel
MH  - Humans
MH  - Primary Health Care
MH  - Qualitative Research
MH  - *Quality of Life
MH  - Spain
MH  - Tokyo
PMC - PMC7661363
OTO - NOTNLM
OT  - *primary care
OT  - *public health
OT  - *qualitative research
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-039873 [pii]
AID - 10.1136/bmjopen-2020-039873 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e039873. doi: 10.1136/bmjopen-2020-039873.


PMID- 33177137
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Protocol for a systematic review on the methodological and reporting quality of
      prediction model studies using machine learning techniques.
PG  - e038832
LID - 10.1136/bmjopen-2020-038832 [doi]
AB  - INTRODUCTION: Studies addressing the development and/or validation of diagnostic 
      and prognostic prediction models are abundant in most clinical domains.
      Systematic reviews have shown that the methodological and reporting quality of
      prediction model studies is suboptimal. Due to the increasing availability of
      larger, routinely collected and complex medical data, and the rising application 
      of Artificial Intelligence (AI) or machine learning (ML) techniques, the number
      of prediction model studies is expected to increase even further. Prediction
      models developed using AI or ML techniques are often labelled as a 'black box'
      and little is known about their methodological and reporting quality. Therefore, 
      this comprehensive systematic review aims to evaluate the reporting quality, the 
      methodological conduct, and the risk of bias of prediction model studies that
      applied ML techniques for model development and/or validation. METHODS AND
      ANALYSIS: A search will be performed in PubMed to identify studies developing
      and/or validating prediction models using any ML methodology and across all
      medical fields. Studies will be included if they were published between January
      2018 and December 2019, predict patient-related outcomes, use any study design or
      data source, and available in English. Screening of search results and data
      extraction from included articles will be performed by two independent reviewers.
      The primary outcomes of this systematic review are: (1) the adherence of ML-based
      prediction model studies to the Transparent Reporting of a multivariable
      prediction model for Individual Prognosis Or Diagnosis (TRIPOD), and (2) the risk
      of bias in such studies as assessed using the Prediction model Risk Of Bias
      ASsessment Tool (PROBAST). A narrative synthesis will be conducted for all
      included studies. Findings will be stratified by study type, medical field and
      prevalent ML methods, and will inform necessary extensions or updates of TRIPOD
      and PROBAST to better address prediction model studies that used AI or ML
      techniques. ETHICS AND DISSEMINATION: Ethical approval is not required for this
      study because only available published data will be analysed. Findings will be
      disseminated through peer-reviewed publications and scientific conferences.
      SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42019161764.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Andaur Navarro, Constanza L
AU  - Andaur Navarro CL
AUID- ORCID: 0000-0002-7745-2887
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands
      c.l.andaurnavarro@umcutrecht.nl.
AD  - Cochrane Netherlands, University Medical Center Utrecht, Utrecht University,
      Utrecht, The Netherlands.
FAU - Damen, Johanna A A G
AU  - Damen JAAG
AUID- ORCID: 0000-0001-7401-4593
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
AD  - Cochrane Netherlands, University Medical Center Utrecht, Utrecht University,
      Utrecht, The Netherlands.
FAU - Takada, Toshihiko
AU  - Takada T
AUID- ORCID: 0000-0002-8032-6224
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
FAU - Nijman, Steven W J
AU  - Nijman SWJ
AUID- ORCID: 0000-0001-6798-2078
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
FAU - Dhiman, Paula
AU  - Dhiman P
AUID- ORCID: 0000-0002-0989-0623
AD  - Center for Statistics in Medicine, University of Oxford, Oxford, UK.
FAU - Ma, Jie
AU  - Ma J
AUID- ORCID: 0000-0002-3900-1903
AD  - Center for Statistics in Medicine, University of Oxford, Oxford, UK.
FAU - Collins, Gary S
AU  - Collins GS
AUID- ORCID: 0000-0002-2772-2316
AD  - Center for Statistics in Medicine, University of Oxford, Oxford, UK.
FAU - Bajpai, Ram
AU  - Bajpai R
AUID- ORCID: 0000-0002-1227-2703
AD  - School of Primary, Community and Social Care, Keele University, Keele, UK.
FAU - Riley, Richard D
AU  - Riley RD
AD  - School of Primary, Community and Social Care, Keele University, Keele, UK.
FAU - Moons, Karel Gm
AU  - Moons KG
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
AD  - Cochrane Netherlands, University Medical Center Utrecht, Utrecht University,
      Utrecht, The Netherlands.
FAU - Hooft, Lotty
AU  - Hooft L
AUID- ORCID: 0000-0002-7950-2980
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
AD  - Cochrane Netherlands, University Medical Center Utrecht, Utrecht University,
      Utrecht, The Netherlands.
LA  - eng
GR  - C49297/A27294/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bias
MH  - Humans
MH  - *Machine Learning
MH  - Prognosis
MH  - *Research Design
PMC - PMC7661369
OTO - NOTNLM
OT  - *epidemiology
OT  - *preventive medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-038832 [pii]
AID - 10.1136/bmjopen-2020-038832 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e038832. doi: 10.1136/bmjopen-2020-038832.


PMID- 33177136
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Use of implementation science in tobacco control intervention studies in the USA 
      between 2000 and 2020: a scoping review protocol.
PG  - e038617
LID - 10.1136/bmjopen-2020-038617 [doi]
AB  - INTRODUCTION: Despite continuing efforts to reduce tobacco use in the USA,
      decline in smoking rates have stalled and smoking remains a major contributor to 
      preventable death. Implementation science could potentially improve uptake and
      impact of evidence-based tobacco control interventions; however, no previous
      studies have systematically examined how implementation science has been used in 
      this field. Our scoping review will describe the use of implementation science in
      tobacco control in the USA, identify relevant gaps in research and suggest future
      directions for implementation science application to tobacco control. METHODS AND
      ANALYSIS: Our team, including a medical research librarian, will conduct a
      scoping review guided primarily by Arksey and O'Malley's methodology. We will
      search English language peer-reviewed literature published from 2000 to 31
      December 2020 for terms synonymous with 'tobacco use', 'prevention', 'cessation' 
      and 'implementation science'. The databases included in this search are MEDLINE
      (PubMed), Embase (Ovid), CINAHL (EBSCOhost), PsycINFO (ProQuest), ERIC (ProQuest)
      and the Cochrane Library (Wiley). We will include cohort and quasi-experimental
      studies, single-group experiments and randomised trials that report qualitative
      and/or quantitative data related to applying implementation science to the
      planning and/or delivery of interventions to prevent or decrease the use of
      tobacco products. Studies must target potential or active tobacco users,
      intervention providers such as educators or healthcare professionals, or US
      policy-makers. A minimum of two reviewers will independently examine each title
      and abstract for relevance, and each eligible full text for inclusion and
      analysis. Use of implementation science, demonstrated by explicit reference to
      implementation frameworks, strategies or outcomes, will be extracted from
      included studies and summarised. ETHICS AND DISSEMINATION: This study is exempt
      from ethics board approval. We will document the equity-orientation of included
      studies with the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses-Equity Extension checklist. Results will be submitted for
      conferences and peer-reviewed journals. TRIAL REGISTRATION NUMBER: Open Science
      Framework Registry (6YRK8).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Selove, Rebecca
AU  - Selove R
AUID- ORCID: 0000-0003-2929-8763
AD  - Center for Prevention Research, Tennessee State University, Nashville, Tennessee,
      USA rselove@tnstate.edu.
FAU - Neil-Sztramko, Sarah
AU  - Neil-Sztramko S
AUID- ORCID: 0000-0002-9600-3403
AD  - Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Leng, Jennifer
AU  - Leng J
AUID- ORCID: 0000-0003-4925-2842
AD  - Immigrant Health and Cancer Disparities Center, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Walker, Philip D
AU  - Walker PD
AUID- ORCID: 0000-0002-1712-2886
AD  - Eskind Biomedical Library, Vanderbilt University, Nashville, Tennessee, USA.
FAU - Salloum, Ramzi George
AU  - Salloum RG
AUID- ORCID: 0000-0002-8139-2418
AD  - Health Outcomes & Biomedical Informatics, University of Florida College of
      Medicine, Gainesville, Florida, USA.
FAU - Ginossar, Tamar
AU  - Ginossar T
AUID- ORCID: 0000-0002-0136-6675
AD  - Communications & Journalism, University of New Mexico, Albuquerque, New Mexico,
      USA.
FAU - Heckman, Carolyn
AU  - Heckman C
AUID- ORCID: 0000-0003-1016-3965
AD  - Division of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, New 
      Jersey, USA.
FAU - Scheuermann, Taneisha S
AU  - Scheuermann TS
AUID- ORCID: 0000-0001-9543-903X
AD  - Population Health, University of Kansas School of Medicine, Lawrence, Kansas,
      USA.
FAU - Combs, Todd
AU  - Combs T
AUID- ORCID: 0000-0003-1015-6589
AD  - Center for Public Health Systems Science, Washington University in Saint Louis,
      Saint Louis, Missouri, USA.
FAU - Qualls-Hampton, Raquel
AU  - Qualls-Hampton R
AUID- ORCID: 0000-0003-2401-4231
AD  - Meharry Medical College, Nashville, Tennessee, USA.
FAU - Armstrong, Rebecca
AU  - Armstrong R
AUID- ORCID: 0000-0003-4146-7427
AD  - Australian Institute of Family Studies, Melbourne, Victoria, Australia.
FAU - Ellis, Shellie
AU  - Ellis S
AUID- ORCID: 0000-0002-3599-0804
AD  - Population Health, University of Kansas School of Medicine, Lawrence, Kansas,
      USA.
LA  - eng
GR  - K01 DA040745/DA/NIDA NIH HHS/United States
GR  - U54 CA163066/CA/NCI NIH HHS/United States
GR  - P20 GM130423/GM/NIGMS NIH HHS/United States
GR  - R25 CA171994/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Child
MH  - Female
MH  - Humans
MH  - *Implementation Science
MH  - Pregnancy
MH  - Prospective Studies
MH  - Tobacco
MH  - *Tobacco Products
MH  - Tobacco Use/prevention & control
MH  - United States
PMC - PMC7661380
OTO - NOTNLM
OT  - *health services administration & management
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-038617 [pii]
AID - 10.1136/bmjopen-2020-038617 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e038617. doi: 10.1136/bmjopen-2020-038617.


PMID- 33177134
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Investigating a new tablet-based telerehabilitation app in patients with aphasia:
      a randomised, controlled, evaluator-blinded, multicentre trial protocol.
PG  - e037702
LID - 10.1136/bmjopen-2020-037702 [doi]
AB  - INTRODUCTION: Aphasia is a common language disorder acquired after stroke that
      reduces the quality of life of affected patients. The impairment is frequently
      accompanied by a deficit in cognitive functions. The state-of-the-art therapy is 
      speech and language therapy but recent findings highlight positive effects of
      high-frequency therapy. Telerehabilitation has the potential to enable
      high-frequency therapy for patients at home. This study investigates the effects 
      of high-frequency telerehabilitation speech and language therapy (teleSLT) on
      language functions in outpatients with aphasia compared with telerehabilitative
      cognitive training. We hypothesise that patients training with high-frequency
      teleSLT will show higher improvement in language functions and quality of life
      compared with patients with high-frequency tele-rehabilitative cognitive training
      (teleCT). METHODS AND ANALYSIS: This study is a randomised controlled,
      evaluator-blinded multicentre superiority trial comparing the outcomes following 
      either high-frequency teleSLT or teleCT. A total of 100 outpatients with aphasia 
      will be recruited and assigned in a 1:1 ratio stratified by trial site and
      severity of impairment to one of two parallel groups. Both groups will train over
      a period of 4 weeks for 2 hours per day. Patients in the experimental condition
      will devote 80% of their training time to teleSLT and the remaining 20% (24
      min/day) to teleCT, vice versa for patients in the control condition. The primary
      outcome measure is the understandability of verbal communication on the Amsterdam
      Nijmegen Everyday Language Test and secondary outcome measures are
      intelligibility of the verbal communication, impairment of receptive and
      expressive language functions, confrontation naming. Other outcomes measures are 
      quality of life and acceptance (usability and subjective experience) of the
      teleSLT system. ETHICS AND DISSEMINATION: This study is approved by the Ethics
      Committee Bern (ID 2016-01577). Results will be submitted to a peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: NCT03228264.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Uslu, Arif Sinan
AU  - Uslu AS
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland.
FAU - Gerber, Stephan M
AU  - Gerber SM
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland.
FAU - Schmidt, Nadine
AU  - Schmidt N
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland.
FAU - Rothlisberger, Carina
AU  - Rothlisberger C
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland.
FAU - Wyss, Patric
AU  - Wyss P
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland.
FAU - Vanbellingen, Tim
AU  - Vanbellingen T
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland.
AD  - Neurocenter, Luzerner Kantonsspital, Luzern, Switzerland.
FAU - Schaller, Sandra
AU  - Schaller S
AD  - Department of Neurology, Inselspital, Bern University Hospital, University of
      Bern, Bern, Switzerland.
FAU - Wyss, Corina
AU  - Wyss C
AD  - Department of Neurology, Inselspital, Bern University Hospital, University of
      Bern, Bern, Switzerland.
FAU - Koenig-Bruhin, Monica
AU  - Koenig-Bruhin M
AD  - Neurocenter, Luzerner Kantonsspital, Luzern, Switzerland.
FAU - Berger, Thomas
AU  - Berger T
AD  - Department of Clinical Psychology and Psychotherapy, University of Bern, Bern,
      Switzerland.
FAU - Nyffeler, Thomas
AU  - Nyffeler T
AD  - Neurocenter, Luzerner Kantonsspital, Luzern, Switzerland.
FAU - Muri, Rene
AU  - Muri R
AD  - Department of Neurology, Inselspital, Bern University Hospital, University of
      Bern, Bern, Switzerland.
FAU - Nef, Tobias
AU  - Nef T
AD  - ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland.
FAU - Urwyler, Prabitha
AU  - Urwyler P
AUID- ORCID: 0000-0002-7641-8898
AD  - Gerontechnology and Rehabilitation Group, University of Bern, Bern, Switzerland
      prabitha.urwyler@artorg.unibe.ch.
AD  - Department of Neurology, Inselspital, Bern University Hospital, University of
      Bern, Bern, Switzerland.
AD  - ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03228264
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Aphasia/etiology
MH  - Humans
MH  - *Mobile Applications
MH  - Quality of Life
MH  - Speech Therapy
MH  - *Telerehabilitation
PMC - PMC7661375
OTO - NOTNLM
OT  - *neurological injury
OT  - *neurology
OT  - *rehabilitation medicine
OT  - *stroke
OT  - *telemedicine
COIS- Competing interests: SMG was involved in the development of the Bern Aphasia App.
      NS, CR and ASU were involved in populating (exercises) the Bern Aphasia App.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-037702 [pii]
AID - 10.1136/bmjopen-2020-037702 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e037702. doi: 10.1136/bmjopen-2020-037702.


PMID- 33177133
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Effects of Creative Expressive Arts-based Storytelling (CrEAS) programme on older
      adults with mild cognitive impairment: protocol for a randomised, controlled
      three-arm trial.
PG  - e036915
LID - 10.1136/bmjopen-2020-036915 [doi]
AB  - INTRODUCTION: Early non-pharmacological interventions can prevent cognitive
      decline in older adults with mild cognitive impairment (MCI). Creative expression
      (CrExp) can potentially mitigate cognitive decline and enhance the physical and
      mental health of older people. However, it is unclear whether activities
      involving CrExp can improve cognitive function and other health-related outcomes 
      in older adults with MCI. The aim of the present study is to develop a Creative
      Expressive Arts-based Storytelling (CrEAS) programme that integrates verbal and
      non-verbal expressive activities and evaluate its effectiveness in improving
      cognitive function and other outcome indicators so as to explore its possible
      mechanism from the perspective of neuroimaging. METHODS AND ANALYSIS: This
      parallel randomised controlled trial with three arms (one intervention and two
      control arms) will be conducted over a 24-week period. A total of 111
      participants will be enrolled and randomised to the CrEAS, recreation and usual
      activity groups. The CrEAS programme combines visual arts therapy and
      storytelling (TimeSlips) under the Expressive Therapy Continuum theoretical
      framework and provides an opportunity for people with MCI to actively engage in
      activities to improve cognitive function through verbal and nonverbal CrExp.
      Global cognitive function, specific domains of cognition (memory, executive
      function, language and attention) and other health-related outcomes (anxiety,
      depression and quality of life) will be measured at baseline, at the end of the
      intervention, and at the 24-week follow-up. Structural/functional brain MRI data 
      will be collected at baseline and immediately after the intervention. ETHICS AND 
      DISSEMINATION: Ethics approval was obtained from the Ethics Committee of Fujian
      Provincial Hospital (K2018-03-061). The study results will be disseminated
      through peer-reviewed journals and at academic conferences. TRIAL REGISTRATION
      NUMBER: ChiCTR1900021526.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lin, Rong
AU  - Lin R
AUID- ORCID: 0000-0003-3147-2716
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Yan, Yuan-Jiao
AU  - Yan YJ
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Zhou, Yi
AU  - Zhou Y
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Luo, Yu-Ting
AU  - Luo YT
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Cai, Zhen-Zhen
AU  - Cai ZZ
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Zhu, Kai-Yan
AU  - Zhu KY
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Li, Hong
AU  - Li H
AD  - The School of Nursing, Fujian Medical University, Fuzhou, Fujian, China
      leehong99@126.com.
AD  - Department of Nursing, Fujian Provincial Hospital, Fuzhou, Fujian, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cognition
MH  - *Cognitive Dysfunction/therapy
MH  - Executive Function
MH  - Humans
MH  - Memory
MH  - *Quality of Life
PMC - PMC7661382
OTO - NOTNLM
OT  - *clinical trials
OT  - *dementia
OT  - *magnetic resonance imaging
OT  - *neurology
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-036915 [pii]
AID - 10.1136/bmjopen-2020-036915 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e036915. doi: 10.1136/bmjopen-2020-036915.


PMID- 33177132
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a
      prospective, multicentre registry study.
PG  - e036809
LID - 10.1136/bmjopen-2020-036809 [doi]
AB  - INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal
      lung disease characterised by a fibrotic histological pattern found in usual
      interstitial pneumonia. Its causes, pathogenesis, clinical phenotype and
      molecular mechanisms are poorly defined. Large-scale, multicentre studies are
      warranted to better understand IPF as a disease in China, its associated risk
      factors, clinical characteristics, diagnosis, disease progression and treatment. 
      METHODS AND ANALYSIS: The Idiopathic Pulmonary Fibrosis Registry China Study
      (PORTRAY) is a prospective, multicentre registry study of patients with IPF in
      China. Eight hundred patients will be enrolled over a 36-month period and
      followed for at least 3 years to generate a comprehensive database on baseline
      characteristics and various follow-up parameters including patient-reported
      outcomes. Biological specimens will also be collected from patients to develop a 
      library of blood, bronchoalveolar lavage fluid and lung biopsy samples, to
      support future research. As of 15 December 2019, 204 patients from 19 large
      medical centres with relatively high IPF diagnosis and treatment rates had been
      enrolled. Patient characteristics will be presented using descriptive statistics.
      The Kaplan-Meier method will be used for survival analyses. Repeated measures
      will be used to compare longitudinal changes in lung function, imaging and
      laboratory tests. Results following analysis have been projected to be available 
      by July 2025. ETHICS AND DISSEMINATION: The study protocol was reviewed and
      approved by the Institutional Review Board from all the study sites currently
      recruiting patients. Study results will be published in peer-reviewed journals.
      TRIAL REGISTRATION NUMBER: NCT03666234.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xie, Bingbing
AU  - Xie B
AUID- ORCID: 0000-0003-0781-435X
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
AD  - Graduate School of Peking Union Medical College, Chinese Academy of Medical
      Science and Peking Union Medical College, Beijing, China.
FAU - Ren, Yanhong
AU  - Ren Y
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
FAU - Geng, Jing
AU  - Geng J
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
FAU - He, Xuan
AU  - He X
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
FAU - Ban, Chengjun
AU  - Ban C
AD  - Department of Respiration of Dongzhimen Hospital, Beijing University of Chinese
      Medicine, Beijing, China.
FAU - Wang, Shiyao
AU  - Wang S
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
FAU - Jiang, Dingyuan
AU  - Jiang D
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
FAU - Luo, Sa
AU  - Luo S
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
FAU - Chen, Qihang
AU  - Chen Q
AD  - Department of Radiology, Beijing Hospital, Beijing, China.
FAU - Liu, Min
AU  - Liu M
AD  - Department of Radiology, China-Japan Friendship Hospital, Beijing, China.
FAU - Feng, Ruie
AU  - Feng R
AD  - Department of Pathology, Peking Union Hospital, Beijing, China.
FAU - Zhao, Ling
AU  - Zhao L
AD  - Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
FAU - Dai, Huaping
AU  - Dai H
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China daihuaping@ccmu.edu.cn.
AD  - Graduate School of Peking Union Medical College, Chinese Academy of Medical
      Science and Peking Union Medical College, Beijing, China.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Capital Medical University, National
      Center for Respiratory Medicine, National Clinical Research Center for
      Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of
      Medical Science, Beijing, China.
AD  - Graduate School of Peking Union Medical College, Chinese Academy of Medical
      Science and Peking Union Medical College, Beijing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03666234
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bronchoalveolar Lavage Fluid
MH  - China/epidemiology
MH  - Humans
MH  - *Idiopathic Pulmonary Fibrosis/diagnosis/epidemiology
MH  - Prospective Studies
MH  - Registries
PMC - PMC7661367
OTO - NOTNLM
OT  - *epidemiology
OT  - *interstitial lung disease
OT  - *thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-036809 [pii]
AID - 10.1136/bmjopen-2020-036809 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e036809. doi: 10.1136/bmjopen-2020-036809.


PMID- 33177131
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Effectiveness of deep electroacupuncture with strong deqi and shallow
      electroacupuncture with no deqi for lumbar disk herniation: study protocol for a 
      randomised controlled trial.
PG  - e036528
LID - 10.1136/bmjopen-2019-036528 [doi]
AB  - INTRODUCTION: Lumbar disk herniation (LDH) is a common cause of low back pain and
      dysfunction. Studies have shown that electroacupuncture (EA) can achieve pain
      relief in patients with LDH. However, there is a lack of evidence regarding the
      effectiveness of deep EA with strong deqi and shallow EA with no deqi in patients
      with LDH. This study aims to evaluate the effectiveness of deep EA with strong
      deqi and shallow EA with no deqi in the treatment of LDH. METHODS AND ANALYSIS:
      In this randomised controlled trial, patients with LDH who have low back pain
      with or without radiculopathy for at least 12 weeks will be enrolled. In total,
      44 patients will be recruited from the Third Affiliated Hospital of Beijing
      University of Chinese Medicine, Beijing, China. Patients will be randomised into 
      the deep EA group and the shallow EA group in a ratio of 1:1 and will be
      administered 12 sessions of EA treatment (three times a week for 4 weeks, 20 min 
      for each session). The follow-up duration will be 4 weeks. Low back pain
      intensity and leg pain intensity (in patients with radicular pain) measured using
      the Visual Analogue Scale (VAS) will be assessed as the primary outcomes.
      Function (measured using the Roland-Morris Disability Questionnaire), quality of 
      life (measured using the EuroQol Five-Dimensional Five-Level Questionnaire) and
      patient-evaluated therapeutic effect will be assessed as the secondary outcomes. 
      Patients' expectations of EA, the success of the blinding method and safety will 
      also be evaluated. Statistical analyses will be followed by the
      intention-to-treat analysis. ETHICS AND DISSEMINATION: This study was approved by
      the Ethics Committee of the Third Affiliated Hospital of Beijing University of
      Chinese Medicine (approval number: 2019-XS-ZB06). Study results will be
      disseminated through publication in an open access journal. TRIAL REGISTRATION
      NUMBER: ChiCTR-1900026518.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huang, Ziling
AU  - Huang Z
AUID- ORCID: 0000-0002-3461-9595
AD  - Department of Acupuncture, The Third Affiliated Hospital, Beijing University of
      Chinese Medicine, Beijing, China.
AD  - Department of Acupuncture, Beijing University of Chinese Medicine, Beijing,
      China.
FAU - Zhao, Jianxin
AU  - Zhao J
AD  - Department of Acupuncture, The Third Affiliated Hospital, Beijing University of
      Chinese Medicine, Beijing, China beijingzhaojianxin@163.com.
FAU - Pei, Xinghong
AU  - Pei X
AD  - Department of Acupuncture, The Third Affiliated Hospital, Beijing University of
      Chinese Medicine, Beijing, China.
AD  - Department of Acupuncture, Beijing University of Chinese Medicine, Beijing,
      China.
FAU - Wang, Bobo
AU  - Wang B
AD  - Department of Acupuncture, The Third Affiliated Hospital, Beijing University of
      Chinese Medicine, Beijing, China.
AD  - Department of Acupuncture, Beijing University of Chinese Medicine, Beijing,
      China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - China
MH  - *Electroacupuncture
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7661371
OTO - NOTNLM
OT  - *clinical trials
OT  - *complementary medicine
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2019-036528 [pii]
AID - 10.1136/bmjopen-2019-036528 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e036528. doi: 10.1136/bmjopen-2019-036528.


PMID- 33177130
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Implementation, mechanisms of impact and key contextual factors involved in
      outcomes of the Modification of Diet, Exercise and Lifestyle (MODEL) randomised
      controlled trial in Australian adults: protocol for a mixed-method process
      evaluation.
PG  - e036395
LID - 10.1136/bmjopen-2019-036395 [doi]
AB  - INTRODUCTION: The Modification of Diet, Exercise and Lifestyle (MODEL) study aims
      to examine the impact of providing visualisation and pictorial representation of 
      advanced structural vascular disease (abdominal aortic calcification), on
      'healthful' improvements to diet and lifestyle. This paper reports the protocol
      for the process evaluation for the MODEL study. METHODS AND ANALYSIS: The overall
      aim of the process evaluation is to understand the processes that took place
      during participation in the MODEL study trial and which elements were effective
      or ineffective for influencing 'healthful' behavioural change, and possible ways 
      of improvement to inform wider implementation strategies. A mixed-method approach
      will be employed with the use of structured questionnaires and semistructured
      in-depth interviews. All 200 participants enrolled in the trial will undertake
      the quantitative component of the study and maximum variation sampling will be
      used to select a subsample for the qualitative component. The sample size for the
      qualitative component will be determined based on analytical saturation.
      Interviews will be digitally recorded and transcribed verbatim. Qualitative data 
      will be analysed thematically and reported according to the Consolidated Criteria
      for Reporting Qualitative Research (COREQ) guidelines. ETHICS AND DISSEMINATION: 
      The MODEL study process evaluation has received approval from Edith Cowan
      University Human Research Ethics Committee (Project Number: 20513 HODGSON).
      Written informed consent will be obtained from all participants before they are
      included in the study. The study results will be shared with the individuals and 
      institutions associated with this study as well as academic audiences through
      peer-reviewed publication and probable presentation at conferences. TRIAL
      REGISTRATION NUMBER: ACTRN12618001087246.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Anokye, Reindolf
AU  - Anokye R
AUID- ORCID: 0000-0002-7669-7057
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia ranokye@our.ecu.edu.au.
FAU - Radavelli-Bagatini, Simone
AU  - Radavelli-Bagatini S
AUID- ORCID: 0000-0001-6821-5217
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Bondonno, Catherine P
AU  - Bondonno CP
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Sim, Marc
AU  - Sim M
AUID- ORCID: 0000-0001-5166-0605
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Blekkenhorst, Lauren C
AU  - Blekkenhorst LC
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Connolly, Emma
AU  - Connolly E
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Bondonno, Nicola P
AU  - Bondonno NP
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Schousboe, John T
AU  - Schousboe JT
AD  - Park Nicollet Osteoporosis Center and Health Partners Institute and Division of
      Health Policy and Management, University of Minnesota, Minneapolis, Minnesota,
      USA.
FAU - Woodman, Richard
AU  - Woodman R
AD  - Flinders Centre for Epidemiology and Biostatistics, Flinders University,
      Adelaide, South Australia, Australia.
FAU - Zhu, Kun
AU  - Zhu K
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
AD  - Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital,
      Nedlands, Western Australia, Australia.
FAU - Szulc, Pawel
AU  - Szulc P
AD  - INSERM UMR1033, University of Lyon, Lyon, France.
FAU - Jackson, Ben
AU  - Jackson B
AD  - School of Human Sciences (Exercise and Sport Science), University of Western
      Australia, Perth, Western Australia, Australia.
FAU - Dimmock, James
AU  - Dimmock J
AD  - Department of Psychology, College of Healthcare Sciences, James Cook University, 
      Townsville, Queensland, Australia.
FAU - Schlaich, Markus P
AU  - Schlaich MP
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Cox, Kay L
AU  - Cox KL
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Kiel, Douglas P
AU  - Kiel DP
AD  - Hinda and Arthur Marcus Institute for Aging Research, Hebrew Senior Life, Beth
      Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts,
      USA.
FAU - Lim, Wai H
AU  - Lim WH
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
AD  - Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western
      Australia, Australia.
FAU - Devine, Amanda
AU  - Devine A
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Thompson, Peter L
AU  - Thompson PL
AD  - Department of Cardiology, University of Western Australia, Perth, Western
      Australia, Australia.
FAU - Gianoudis, Jenny
AU  - Gianoudis J
AD  - Institute for Physical Activity and Nutrition, School of Exercise and Nutrition
      Science, Deakin University, Geelong, Victoria, Australia.
FAU - De Ross, Belinda
AU  - De Ross B
AD  - Institute for Physical Activity and Nutrition, School of Exercise and Nutrition
      Science, Deakin University, Geelong, Victoria, Australia.
FAU - Daly, Robin M
AU  - Daly RM
AD  - Institute for Physical Activity and Nutrition, School of Exercise and Nutrition
      Science, Deakin University, Geelong, Victoria, Australia.
FAU - Hodgson, Jonathan M
AU  - Hodgson JM
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Lewis, Joshua R
AU  - Lewis JR
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
AD  - Centre for Kidney Research, Children's Hospital at Westmead, School of Public
      Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Stanley, Mandy
AU  - Stanley M
AUID- ORCID: 0000-0002-7958-5181
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618001087246
GR  - R01 AR041398/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Australia
MH  - Diet
MH  - Humans
MH  - *Life Style
MH  - Qualitative Research
MH  - *Research Design
PMC - PMC7661373
OTO - NOTNLM
OT  - *medical ethics
OT  - *public health
OT  - *qualitative research
OT  - *social medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2019-036395 [pii]
AID - 10.1136/bmjopen-2019-036395 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e036395. doi: 10.1136/bmjopen-2019-036395.


PMID- 33177129
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 11
TI  - Modification of diet, exercise and lifestyle (MODEL) study: a randomised
      controlled trial protocol.
PG  - e036366
LID - 10.1136/bmjopen-2019-036366 [doi]
AB  - INTRODUCTION: Most cardiovascular disease (CVD)-related events could be prevented
      or substantially delayed with improved diet and lifestyle. Providing information 
      on structural vascular disease may improve CVD risk factor management, but its
      impact on lifestyle change remains unclear. This study aims to determine whether 
      providing visualisation and pictorial representation of structural vascular
      disease (abdominal aortic calcification (AAC)) can result in healthful diet and
      lifestyle change. METHODS AND ANALYSIS: This study, including men and women aged 
      60-80 years, is a 12-week, two-arm, multisite randomised controlled trial. At
      baseline, all participants will have AAC assessed from a lateral spine image
      captured using a bone densitometer. Participants will then be randomised to
      receive their AAC results at baseline (intervention group) or a usual care
      control group that will receive their results at 12 weeks. All participants will 
      receive information about routinely assessed CVD risk factors and standardised
      (video) diet and lifestyle advice with three simple goals: (1) increase fruit and
      vegetable (FV) intake by at least one serve per day, (2) improve other aspects of
      the diet and (3) reduce sitting time and increase physical activity. Clinical
      assessments will be performed at baseline and 12 weeks. OUTCOMES: The primary
      outcome is a change in serum carotenoid concentrations as an objective measure of
      FV intake. The study design, procedures and treatment of data will adhere to
      Standard Protocol Items for Randomized Trials guidelines. ETHICS AND
      DISSEMINATION: Ethics approval for this study has been granted by the Edith Cowan
      University and the Deakin University Human Research Ethics Committees (Project
      Numbers: 20513 HODGSON and 2019-220, respectively). Results of this study will be
      published in peer-reviewed academic journals and presented in scientific meetings
      and conferences. Information regarding consent, confidentiality, access to data, 
      ancillary and post-trial care and dissemination policy has been disclosed in the 
      participant information form. TRIAL REGISTRATION NUMBER: Australian New Zealand
      Clinical Trial Registry (ACTRN12618001087246).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Radavelli-Bagatini, Simone
AU  - Radavelli-Bagatini S
AUID- ORCID: 0000-0001-6821-5217
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia simoneradavelli@hotmail.com.
FAU - Bondonno, Catherine P
AU  - Bondonno CP
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Sim, Marc
AU  - Sim M
AUID- ORCID: 0000-0001-5166-0605
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Blekkenhorst, Lauren C
AU  - Blekkenhorst LC
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Anokye, Reindolf
AU  - Anokye R
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Connolly, Emma
AU  - Connolly E
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Bondonno, Nicola P
AU  - Bondonno NP
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Schousboe, John T
AU  - Schousboe JT
AD  - Park Nicollet Osteoporosis Center and Health Partners Institute, and Division of 
      Health Policy and Management, University of Minnesota, Minneapolis, Minnesota,
      USA.
FAU - Woodman, Richard J
AU  - Woodman RJ
AD  - Flinders Centre for Epidemiology and Biostatistics, Flinders University,
      Adelaide, South Australia, Australia.
FAU - Zhu, Kun
AU  - Zhu K
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
AD  - Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital,
      Nedlands, Western Australia, Australia.
FAU - Szulc, Pawel
AU  - Szulc P
AD  - INSERM UMR 1033, University of Lyon, Hospices Civils de Lyon, Lyon, France.
FAU - Jackson, Ben
AU  - Jackson B
AD  - Faculty of Science, School of Human Sciences, University of Western Australia,
      Perth, Western Australia, Australia.
FAU - Dimmock, James
AU  - Dimmock J
AD  - Department of Psychology, College of Healthcare Sciences, James Cook University, 
      Townsville, Queensland, Australia.
FAU - Schlaich, Markus P
AU  - Schlaich MP
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Cox, Kay L
AU  - Cox KL
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Kiel, Douglas P
AU  - Kiel DP
AD  - Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Beth
      Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts,
      USA.
FAU - Lim, Wai H
AU  - Lim WH
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
AD  - Department of Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western
      Australia, Australia.
FAU - Stanley, Mandy
AU  - Stanley M
AUID- ORCID: 0000-0002-7958-5181
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Devine, Amanda
AU  - Devine A
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Thompson, Peter L
AU  - Thompson PL
AD  - Department of Cardiology, Sir Charles Gairdner Hospital, Perth, Western
      Australia, Australia.
FAU - Gianoudis, Jenny
AU  - Gianoudis J
AD  - Institute for Physical Activity and Nutrition, School of Exercise and Nutrition
      Science, Deakin University, Melbourne, VIC, Australia.
FAU - De Ross, Belinda
AU  - De Ross B
AD  - Institute for Physical Activity and Nutrition, School of Exercise and Nutrition
      Science, Deakin University, Melbourne, VIC, Australia.
FAU - Daly, Robin M
AU  - Daly RM
AD  - Institute for Physical Activity and Nutrition, School of Exercise and Nutrition
      Science, Deakin University, Melbourne, VIC, Australia.
FAU - Lewis, Joshua R
AU  - Lewis JR
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
AD  - Centre for Kidney Research, Children's Hospital at Westmead, School of Public
      Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
FAU - Hodgson, Jonathan M
AU  - Hodgson JM
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618001087246
GR  - R01 AR041398/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201111
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia
MH  - Diet
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - *Life Style
MH  - Male
MH  - Middle Aged
PMC - PMC7661361
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *public health
OT  - *vascular medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/12 05:33
PHST- 2020/11/12 05:33 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2019-036366 [pii]
AID - 10.1136/bmjopen-2019-036366 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 11;10(11):e036366. doi: 10.1136/bmjopen-2019-036366.


PMID- 33176537
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Linking)
VI  - 11
DP  - 2020 Jan-Dec
TI  - Development of Best Practice Guidelines for Primary Care to Support Patients Who 
      Use Substances.
PG  - 2150132720963656
LID - 10.1177/2150132720963656 [doi]
AB  - INTRODUCTION: People who use substances often mistrust the primary care system,
      impeding access. OBJECTIVES: To build on research clarifying how to improve
      patients' feelings of safety, through co-creating best practice guidelines with
      physicians and patient representatives. METHODS: After obtaining Research Ethics 
      Board approval, this qualitative study engaged 22 participants including
      patients, physicians, and health system partners. We held a series of workshops, 
      co-facilitated by patients and researchers, corresponding to 3 phases of the
      research: (1) establishment of cultural safety processes for participants during 
      the workshops; (2) a facilitated, collaborative world cafe to develop guideline
      content; (3) validation of best practice guidelines. An implementation plan was
      developed and implemented. Finally, an external peer review was conducted by
      McGill University. RESULTS: Best practices guidelines were developed giving the
      patient perspective on how to enhance primary care, as follows: (1) become trauma
      informed; (2) consider your clinical environment; (3) build a network; (4) supply
      an array of resources; (5) co-create a long-term treatment plan; (6) help me to
      stay healthy; (7) ensure timely access to specialized medical and surgical care; 
      (8) be an advocate; (9) ask for feedback; (10) follow up. Resources were
      developed and disseminated. CONCLUSION: The best practice guidelines reflect the 
      patients' perspectives on common challenges patients have encountered, which
      impede their access to primary care. They support primary care physicians in
      providing more effective services to this challenging population of patients.
FAU - Hartney, Elizabeth
AU  - Hartney E
AUID- ORCID: 0000-0002-3617-9685
AD  - Royal Roads University, Victoria, BC, Canada.
FAU - Barnard, D Kelly
AU  - Barnard DK
AD  - Independent Medical Consultant, Canada.
FAU - Richman, Jillian
AU  - Richman J
AD  - Royal Roads University, Victoria, BC, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
SB  - IM
MH  - Humans
MH  - *Physicians
MH  - *Primary Health Care
MH  - Qualitative Research
PMC - PMC7675907
OTO - NOTNLM
OT  - *behavioral health
OT  - *hazardous drinking
OT  - *patient-centeredness
OT  - *practice management
OT  - *primary care
EDAT- 2020/11/13 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/12 05:28
PHST- 2020/11/12 05:28 [entrez]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1177/2150132720963656 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2020 Jan-Dec;11:2150132720963656. doi:
      10.1177/2150132720963656.


PMID- 33175482
STAT- Publisher
DA  - 20201112
PB  - Institute for Quality and Efficiency in Health Care (IQWiG)
CTI - Institute for Quality and Efficiency in Health Care: Extracts
DP  - 2020 Oct 8
BTI - Suicidal crises in unipolar depression: How do non-drug interventions impact
      their management? IQWiG Reports - Commission No. HT17-03
AB  - RESEARCH QUESTIONS OF THE HTA REPORT: The aims of this investigation are to -
      assess the benefit of (1) crisis intervention programmes/services or (2)
      psychosocial interventions (technology based or not) in outpatient care in
      comparison with a different non-drug therapy, drug therapy, inpatient treatment, 
      or no therapy / waiting list in adult suicidal patients with unipolar depression 
      with regard to patient-relevant outcomes, - determine the costs incurred by (1)
      crisis intervention programmes/services or (2) psychosocial interventions
      (technology based or not) in outpatient care in comparison with a different
      non-drug therapy, drug therapy, inpatient treatment, or no therapy / waiting list
      in adult suicidal patients with unipolar depression (intervention costs), -
      assess the cost effectiveness of (1) crisis intervention programmes/services or
      (2) psychosocial interventions in outpatient care (technology based or not) in
      comparison with another non-drug therapy, drug therapy, inpatient treatment, or
      no therapy / waiting list in adult suicidal patients with unipolar depression was
      well as - review ethical, social, legal, and organizational aspects associated
      with the medical interventions. CONCLUSION OF THE HTA REPORT (SEE CHAPTER 9): To 
      answer the question submitted to ThemenCheck, "Suicidal crises in unipolar
      depression: How do non-drug measures impact their management?", the following
      interventions were investigated: (1) crisis intervention programmes/services in
      outpatient care and (2) psychosocial interventions in outpatient care, namely (i)
      psychotherapeutic strategies for preventing suicide and (ii) suicide preventive
      follow-up services and contact offers. Despite this initially broad definition of
      interventions to be investigated in the outpatient care of adult suicidal
      patients with unipolar depression, only studies on cognitive behavioural therapy 
      (CBT) were found, all of which focused on suicidality. These studies examined
      CBTs from the second and third "waves" of behavioural therapy (BT). The second
      wave of BT originated in the developments of the 1960s and 1970s, where classic
      BT was for the first time expanded to include cognitive aspects such as thoughts 
      and convictions. In the 1980s, these considerations led to the approach of CBT.
      In the third wave of BT, the classic cognitive-behavioural concept, which largely
      focuses on restructuring processes, is expanded by the additional aspects of
      mindfulness and acceptance of difficult-to-control internal experiences.
      Additional conceptual differences concern the fundamental attitude and the
      patient-therapist relationship. CBT is a service already covered by the statutory
      health insurance. Four randomized controlled trials (RCTs) of moderate
      qualitative certainty of results were included. They primarily investigated the
      patient-relevant outcomes of anxiety, depressive symptoms, hopelessness,
      posttraumatic stress, suicidal ideation, and (follow-up) suicide attempts, each
      at the survey time points of 1, 3, 6, 18, and >/= 18 months. With regard to the
      patient-relevant outcomes of suicidal ideation (6 months), suicide attempts (>/= 
      18 months), depressive symptoms (3, 6, and 18 months), and hopelessness (6 and 18
      months), the results revealed an indication of (added) benefit of second-wave CBT
      in comparison with treatment as usual (TAU). With regard to the patient-relevant 
      outcome of depressive symptoms, the results revealed a hint of (added) benefit at
      the survey time point of 1 month for third-wave CBT in comparison with TAU. These
      results are based on the data from one study. The currently still outstanding
      results from another study might supplement the results of this health technology
      assessment (HTA). For the outcomes of anxiety and posttraumatic stress (each at
      3, 6, and 18 months), suicidal ideation (1, 3, and 18 months), depressive
      symptoms (1 month), and hopelessness (1 month and 3 months), no hint of (added)
      benefit of second-wave CBT versus TAU was found. With regard to third-wave CBT,
      for the outcome of depressive symptoms at the survey time point of 3 months, no
      hint of (added) benefit of third-wave CBT versus TAU was found. For the outcome
      of suicidal ideation at the time point of 1 month, no hint of (added) benefit of 
      third-wave CBT versus TAU was found. For the following outcomes, data on second
      or third-wave CBT were either unavailable or unusable: all-cause mortality /
      overall survival, suicide mortality, physical functioning including activities of
      daily living / everyday functioning, inpatient admission, serious adverse events,
      discontinuation due to adverse events, health-related quality of life, and
      health-related social functioning, including occupational and social
      participation. Concerning second-wave CBT, data were also reported on social
      problem-solving ability, but they were disregarded due to reporting bias.
      However, patients in the initially conducted discussions highlighted the
      patient-relevant outcomes listed above as being particularly relevant. Therefore,
      there is clearly a need for further research, particularly high-quality RCTs, in 
      this area. No studies were found with regard to cost effectiveness, and no
      conclusion can be drawn on this topic. To generate more evidence in this area as 
      well, future investigations might concurrently collect data on both effectiveness
      as well as resource use and the costs of the intervention and comparator
      treatment. The costs listed in the present report are stated as ranges for
      patients with mild and severe disease courses. They range from EUR188.67 per
      treatment case for solely drug-based treatment to EUR2684.14 for one-on-one
      short-term outpatient therapy, and up to EUR15,314.23 for long-term outpatient
      therapy. However, comparability between the costs of the individual interventions
      per patient or per patient and treatment case is limited since their separate
      analyses do not fully reflect the realities of care. Depressive disorders differ 
      widely between individuals in terms of their severity and course; therefore,
      actual costs might be lower or higher than those presented herein. Interventions 
      other than CBT, including some low-threshold interventions such as telephone
      counselling or internet-based services, were also mentioned both in the focus
      groups and in the literature. Due to a lack of studies, however, it was not
      possible to compare these interventions to TAU. As already concluded by authors
      of other reviews, future studies should include such interventions as well and
      determine their effectiveness at early survey time points in order to ensure
      rapid treatment in crisis situations. The analysis of the ethical, social, legal,
      and organizational aspects has shown that they are highly relevant to the topic
      and, in particular, have a major impact on access to measures. Due to the
      complexity and multidimensional nature of the topic, the individual domains
      cannot and should not be analysed in isolation. Rather, their mutual interactions
      should be contemplated and discussed, as illustrated in the logical model.
CI  - (c) IQWiG (Institute for Quality and Efficiency in Health Care).
LA  - eng
PT  - Review
PT  - Book
PL  - Cologne (Germany)
OTO - NLM
OT  - Depressive Disorder
OT  - Suicide
OT  - Benefit Assessment
OT  - Systematic Review
OT  - Technology Assessment - Biomedical
EDAT- 2020/11/12 06:01
MHDA- 2020/11/12 06:01
CDAT- 2020/11/12 06:01
AID - NBK563860 [bookaccession]


PMID- 33176390
OWN - NLM
STAT- MEDLINE
DCOM- 20211105
LR  - 20211112
IS  - 1869-0327 (Electronic)
IS  - 1869-0327 (Linking)
VI  - 11
IP  - 5
DP  - 2020 Oct
TI  - Ethical Considerations on Pediatric Genetic Testing Results in Electronic Health 
      Records.
PG  - 755-763
LID - 10.1055/s-0040-1718753 [doi]
AB  - BACKGROUND: Advances in technology and access to expanded genetic testing have
      resulted in more children and adolescents receiving genetic testing for
      diagnostic and prognostic purposes. With increased adoption of the electronic
      health record (EHR), genetic testing is increasingly resulted in the EHR.
      However, this leads to challenges in both storage and disclosure of genetic
      results, particularly when parental results are combined with child genetic
      results. PRIVACY AND ETHICAL CONSIDERATIONS: Accidental disclosure and erroneous 
      documentation of genetic results can occur due to the nature of their
      presentation in the EHR and documentation processes by clinicians. Genetic
      information is both sensitive and identifying, and requires a considered approach
      to both timing and extent of disclosure to families and access to clinicians.
      METHODS: This article uses an interdisciplinary approach to explore ethical
      issues surrounding privacy, confidentiality of genetic data, and access to
      genetic results by health care providers and family members, and provides
      suggestions in a stakeholder format for best practices on this topic for
      clinicians and informaticians. Suggestions are made for clinicians on documenting
      and accessing genetic information in the EHR, and on collaborating with genetics 
      specialists and disclosure of genetic results to families. Additional
      considerations for families including ethics around results of adolescents and
      special scenarios for blended families and foster minors are also provided.
      Finally, administrators and informaticians are provided best practices on both
      institutional processes and EHR architecture, including security and access
      control, with emphasis on the minimum necessary paradigm and parent/patient
      engagement and control of the use and disclosure of data. CONCLUSION: The authors
      hope that these best practices energize specialty societies to craft practice
      guidelines on genetic information management in the EHR with interdisciplinary
      input that addresses all stakeholder needs.
CI  - Thieme. All rights reserved.
FAU - Kanungo, Shibani
AU  - Kanungo S
AD  - Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker M.D.
      School of Medicine, Kalamazoo, Michigan, United States.
FAU - Barr, Jayne
AU  - Barr J
AD  - Internal Medicine-Pediatrics, MetroHealth, Cleveland, Ohio, United States.
FAU - Crutchfield, Parker
AU  - Crutchfield P
AD  - Medical Ethics, Humanities, and Law, Western Michigan University Homer Stryker
      M.D. School of Medicine, Kalamazoo, Michigan, United States.
FAU - Fealko, Casey
AU  - Fealko C
AD  - Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker M.D.
      School of Medicine, Kalamazoo, Michigan, United States.
FAU - Soares, Neelkamal
AU  - Soares N
AD  - Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker M.D.
      School of Medicine, Kalamazoo, Michigan, United States.
LA  - eng
PT  - Journal Article
DEP - 20201111
PL  - Germany
TA  - Appl Clin Inform
JT  - Applied clinical informatics
JID - 101537732
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Confidentiality
MH  - Disclosure
MH  - *Electronic Health Records
MH  - Genetic Testing
MH  - Humans
MH  - Privacy
PMC - PMC7657708
COIS- None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/11/06 06:00
CRDT- 2020/11/11 20:11
PHST- 2020/11/11 20:11 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/11/06 06:00 [medline]
AID - 10.1055/s-0040-1718753 [doi]
PST - ppublish
SO  - Appl Clin Inform. 2020 Oct;11(5):755-763. doi: 10.1055/s-0040-1718753. Epub 2020 
      Nov 11.


PMID- 33176048
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1445-2197 (Electronic)
IS  - 1445-1433 (Linking)
VI  - 90
IP  - 12
DP  - 2020 Dec
TI  - Patterns of arterial involvement and feasibility of revascularization in
      thromboangiitis obliterans: a tertiary care centre experience.
PG  - 2506-2509
LID - 10.1111/ans.16417 [doi]
AB  - BACKGROUND: Arterial revascularization is seldom considered as a treatment option
      in thromboangiitis obliterans (TAO) due to diffuse segmental involvement of
      medium- and small-sized extremity vessels. Although typical angiographic features
      include bilaterally symmetrical involvement of infrapopliteal vessels, larger
      vessels too can be affected. Similarly, there could be distal target vessels
      feasible for revascularization. This study was conducted to describe the patterns
      of arterial involvement in TAO and assess the feasibility of revascularization.
      METHODS: The study was approved by the Institutional Review Board and research
      ethics committee of Christian Medical College, Vellore (IRB no: 12034). A
      retrospective study was conducted in the Department of Vascular Surgery,
      Christian Medical College, Vellore, India, between January 2009 and December
      2018. There were 329 patients who fulfilled the clinical criteria for TAO of whom
      83 had an angiogram done. These 83 patients formed the study cohort. RESULTS:
      Large vessel involvement was seen in 56.6% of patients and 79.5% of patients had 
      at least one or more distal target artery feasible for revascularization. The
      anterior tibial artery and peroneal artery were the most common target vessels
      that were patent for revascularization. Of the 22 patients who underwent
      revascularization (16 bypasses and six angioplasties), the patency rate was 64.8%
      and the limb salvage rate was 80.9% at the end of 6 months. CONCLUSION: The study
      shows that one-third of our patients with TAO have a distal target artery
      feasible for revascularization. As most of the affected patients are in the
      economically productive age group, every attempt should be made to salvage the
      limb with revascularization for which the use of angiography should be more
      liberal.
CI  - (c) 2020 Royal Australasian College of Surgeons.
FAU - Dsouza, Royson J
AU  - Dsouza RJ
AUID- ORCID: 0000-0002-0905-5740
AD  - Department of Vascular Surgery, Christian Medical College Hospital, Vellore,
      India.
FAU - Premkumar, Prabhu
AU  - Premkumar P
AD  - Department of Vascular Surgery, Christian Medical College Hospital, Vellore,
      India.
FAU - Samuel, Vimalin
AU  - Samuel V
AD  - Department of Vascular Surgery, Christian Medical College Hospital, Vellore,
      India.
FAU - Kota, Albert
AU  - Kota A
AD  - Department of Vascular Surgery, Christian Medical College Hospital, Vellore,
      India.
FAU - Agarwal, Sunil
AU  - Agarwal S
AD  - Department of Vascular Surgery, Christian Medical College Hospital, Vellore,
      India.
LA  - eng
PT  - Journal Article
DEP - 20201111
PL  - Australia
TA  - ANZ J Surg
JT  - ANZ journal of surgery
JID - 101086634
SB  - IM
MH  - Arteries/diagnostic imaging/surgery
MH  - Feasibility Studies
MH  - Humans
MH  - India
MH  - Ischemia/surgery
MH  - Limb Salvage
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - *Thromboangiitis Obliterans/surgery
MH  - Treatment Outcome
MH  - Vascular Patency
OTO - NOTNLM
OT  - *endovascular therapy
OT  - *patterns of vessel involvement
OT  - *revascularization
OT  - *thromboangiitis obliterans
EDAT- 2020/11/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/11 17:15
PHST- 2020/07/09 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/11/11 17:15 [entrez]
AID - 10.1111/ans.16417 [doi]
PST - ppublish
SO  - ANZ J Surg. 2020 Dec;90(12):2506-2509. doi: 10.1111/ans.16417. Epub 2020 Nov 11.


PMID- 33175992
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Dec
TI  - Pregnant people, inseminators and tissues of human origin: how ectogenesis
      challenges the concept of abortion.
PG  - 197-204
LID - 10.1007/s40592-020-00122-0 [doi]
AB  - The potential benefits of an alternative to physical gestation are numerous.
      These include providing reproductive options for prospective parents who are
      unable to establish or maintain a physiological pregnancy, and saving the lives
      of some infants born prematurely. Ectogenesis could also promote sexual equality 
      in reproduction, and represents a necessary option for women experiencing an
      unwanted pregnancy who are morally opposed to abortion. Despite these broad, and 
      in some cases unique benefits, one major ethical concern is the potential impact 
      of this emerging technology on abortion rights. This article will argue that
      ectogenesis poses a challenge to many common arguments in favour of a pregnant
      woman's right to choose, but only insomuch as it highlights that their underlying
      justifications for abortion are based on flawed conceptions of what the foetus
      and pregnancy actually are. By interrogating the various interests and
      relationships involved in a pregnancy, this article will demonstrate that the
      emergence of artificial gestation need not impact existing abortion rights or
      legislation, nor definitions of independent viability or moral status.
FAU - Kendal, Evie
AU  - Kendal E
AUID- ORCID: http://orcid.org/0000-0002-8414-0427
AD  - Faculty of Health, Arts and Design, Swinburne University of Technology, Hawthorn,
      VIC, Australia. ekendal@swin.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201111
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - Abortion, Induced/*ethics
MH  - Biotechnology/ethics
MH  - Dissent and Disputes
MH  - Ectogenesis/*ethics
MH  - Female
MH  - Fetus
MH  - Humans
MH  - Insemination
MH  - Male
MH  - *Moral Status
MH  - Pregnancy
MH  - Reproduction/*ethics
MH  - *Reproductive Rights
MH  - *Women's Rights
OTO - NOTNLM
OT  - Abortion
OT  - Artificial reproductive technologies
OT  - Artificial womb
OT  - Arts
OT  - Ectogenesis
OT  - Legal parenthood
OT  - Moral status
OT  - Termination of pregnancy
EDAT- 2020/11/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/11 17:14
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/11/11 17:14 [entrez]
AID - 10.1007/s40592-020-00122-0 [doi]
AID - 10.1007/s40592-020-00122-0 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(2):197-204. doi: 10.1007/s40592-020-00122-0. Epub 
      2020 Nov 11.


PMID- 33175045
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 25
IP  - 11
DP  - 2020 Nov
TI  - Body care and health obligation: hexis and power in modernity.
PG  - 4361-4368
LID - S1413-81232020001104361 [pii]
LID - 10.1590/1413-812320202511.06062019 [doi]
AB  - The aim of this essay is to provide a brief reflection on the contemporary ethics
      imposed on the body, which points to a growing responsibility and obligation of
      the individual regarding healthy and correct ways of living. The central object
      of analysis is the body constitution in modernity, in a space of technical
      intervention, problematizing contemporary forms of body care, such as diets and
      physical exercises, which express taxonomies that come from the matrix of
      meanings in modernity.
FAU - Giordani, Rubia Carla Formighieri
AU  - Giordani RCF
AUID- ORCID: http://orcid.org/0000-0001-5698-7981
AD  - Departamento de Nutricao, Universidade Federal do Parana (UFPR). R. Pref.
      Lothario Meissner 632, Jardim Botanico. 80210-170 Curitiba PR Brasil.
      rubiagiordani@gmail.com.
FAU - Hoffmann-Horochovski, Marisete Teresinha
AU  - Hoffmann-Horochovski MT
AUID- ORCID: http://orcid.org/0000-0002-5220-3614
AD  - Departamento de Sociologia, UFPR. Curitiba PR Brasil.
LA  - por
LA  - eng
PT  - Journal Article
TT  - O cuidado com o corpo e a obrigatoriedade da saude: sobre hexis e poder na
      modernidade.
DEP - 20190410
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
SB  - IM
MH  - *Diet
MH  - *Exercise
MH  - Health Status
MH  - Humans
EDAT- 2020/11/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/11 12:12
PHST- 2018/08/27 00:00 [received]
PHST- 2019/04/08 00:00 [accepted]
PHST- 2020/11/11 12:12 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - S1413-81232020001104361 [pii]
AID - 10.1590/1413-812320202511.06062019 [doi]
PST - ppublish
SO  - Cien Saude Colet. 2020 Nov;25(11):4361-4368. doi:
      10.1590/1413-812320202511.06062019. Epub 2019 Apr 10.


PMID- 33174997
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20201218
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Linking)
VI  - 28
DP  - 2020
TI  - Hospital care for elderly COVID-19 patients.
PG  - e3396
LID - S0104-11692020000100428 [pii]
LID - 10.1590/1518-8345.4649.3396 [doi]
AB  - OBJECTIVE: to analyze the newspaper articles on hospital care for elderly
      COVID-19 patients in online newspapers. METHOD: documentary, retrospective,
      descriptive and exploratory research. The data were collected from articles
      published on open-access websites of 12 newspapers from the following countries: 
      Brazil, Spain, United States, France, Italy and Portugal. RESULTS: out of 4,220
      newspaper articles identified in this regard, 101 were selected after applying
      the inclusion criteria, the majority coming from Italy. The data analysis
      revealed three thematic categories: the care for patients with COVID-19 in the
      health system; the work process of the health team and its concern with
      contagion; and ethical dilemma in care for the elderly during hospitalization.
      CONCLUSION: the COVID-19 pandemic presented itself quickly and was widely
      reported in all countries. The health systems need to reorganize for care to the 
      global population, especially the elderly, considering their weaknesses and also 
      the lack of prior professional training to offer care to this population.
FAU - Fhon, Jack Roberto Silva
AU  - Fhon JRS
AUID- ORCID: http://orcid.org/0000-0002-1880-4379
AD  - Universidade de Sao Paulo, Escola de Enfermagem, Sao Paulo, SP, Brazil.
FAU - Silva, Luipa Michele
AU  - Silva LM
AUID- ORCID: http://orcid.org/0000-0001-6147-9164
AD  - Universidade Federal de Goias Regional Catalao, Escola de Enfermagem, Catalao,
      GO, Brazil.
FAU - Leiton-Espinoza, Zoila Esperanza
AU  - Leiton-Espinoza ZE
AUID- ORCID: http://orcid.org/0000-0001-5040-7042
AD  - Universidad Nacional de Trujillo, Escuela de Enfermeria, Trujillo, La Libertad,
      Peru.
FAU - Matiello, Fernanda de Brito
AU  - Matiello FB
AUID- ORCID: http://orcid.org/0000-0002-8617-5922
AD  - Universidade de Sao Paulo, Escola de Enfermagem de Ribeirao Preto, PAHO/WHO
      Collaborating Centre for Nursing Research Development, Ribeirao Preto, SP,
      Brazil.
FAU - Araujo, Jessica Silva de
AU  - Araujo JS
AUID- ORCID: http://orcid.org/0000-0002-9332-8042
AD  - Universidade de Sao Paulo, Escola de Enfermagem de Ribeirao Preto, PAHO/WHO
      Collaborating Centre for Nursing Research Development, Ribeirao Preto, SP,
      Brazil.
FAU - Rodrigues, Rosalina Aparecida Partezani
AU  - Rodrigues RAP
AUID- ORCID: http://orcid.org/0000-0001-8916-1078
AD  - Universidade de Sao Paulo, Escola de Enfermagem de Ribeirao Preto, PAHO/WHO
      Collaborating Centre for Nursing Research Development, Ribeirao Preto, SP,
      Brazil.
LA  - eng
LA  - por
LA  - spa
PT  - Journal Article
DEP - 20201106
PL  - Brazil
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Aged
MH  - Betacoronavirus
MH  - Brazil
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Portugal
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Spain
MH  - United States
PMC - PMC7647414
EDAT- 2020/11/12 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/11/11 12:12
PHST- 2020/06/24 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/11/11 12:12 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - S0104-11692020000100428 [pii]
AID - 10.1590/1518-8345.4649.3396 [doi]
PST - epublish
SO  - Rev Lat Am Enfermagem. 2020 Nov 6;28:e3396. doi: 10.1590/1518-8345.4649.3396.
      eCollection 2020.


PMID- 33174849
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 11
TI  - Effects of a Collective Family-Based Mobile Health Intervention Called
      "SMARTFAMILY" on Promoting Physical Activity and Healthy Eating: Protocol for a
      Randomized Controlled Trial.
PG  - e20534
LID - 10.2196/20534 [doi]
AB  - BACKGROUND: Numerous smartphone apps are targeting physical activity and healthy 
      eating, but empirical evidence on their effectiveness for initialization and
      maintenance of behavior change, especially in children and adolescents, is still 
      limited. OBJECTIVE: The aim of this study was to conceptualize a theory-based and
      evidence-based mHealth intervention called SMARTFAMILY (SF) that targets physical
      activity and healthy eating in a collective family-based setting. Subsequently,
      the app will be refined and re-evaluated to analyze additional effects of
      just-in-time adaptive interventions (JITAIs) and gamification features. METHODS: 
      A smartphone app based on behavior change theories and behavior change techniques
      was developed and implemented and will be evaluated with family members
      individually and cooperatively (SF trial). Existing evidence and gained results
      were used to refine and will be used to re-evaluate the app (SF2.0 trial). Both
      trials are cluster randomized controlled trials with 3 measurement occasions. The
      intervention group uses the app for 3 consecutive weeks, whereas the control
      group receives no treatment. Baseline measurements (T0) and postintervention
      measurements (T1) include physical activity (ie, self-reported and accelerometry)
      and healthy eating measurements (ie, self-reported fruit and vegetable intake) as
      the primary outcomes. The secondary outcomes (ie, self-reported) are intrinsic
      motivation, behavior-specific self-efficacy, and the family health climate,
      complemented by an intentional measure in SF2.0. Four weeks following T1, a
      follow-up assessment (T2) is completed by the participants, consisting of all
      questionnaire items to assess the stability of the intervention effects.
      Mixed-method analysis of covariance will be used to calculate the primary
      intervention effects (ie, physical activity, fruit and vegetable intake) while
      controlling for covariates, including family health climate, behavior-specific
      self-efficacy, and intrinsic motivation. RESULTS: This study is funded by the
      German Federal Ministry of Education and Research and ethically approved by the
      Karlsruhe Institute of Technology. For both trials, it is hypothesized that the
      apps will positively influence physical activity and healthy eating in the whole 
      family. Furthermore, SF2.0 is expected to produce stronger effects (ie, higher
      effect sizes) compared to SF. SF app development and piloting are completed. Data
      acquisition for the SF trial is terminated and discontinued due to the COVID-19
      pandemic. SF2.0 app development and piloting are completed, while data
      acquisition is ongoing. Participant recruitment for the SF 2.0 trial started in
      February 2020. The results for SF are expected to be published in mid-2021, and
      the results of SF2.0 are expected to be published in mid-2022. CONCLUSIONS: In
      this study, it is hypothesized that targeting the whole family will facilitate
      behavior change at the individual level and the family level, as the implemented 
      strategies address changes in daily family life. Furthermore, subsequent app
      development (SF2.0) with supplementary addition of motivation-enhancing features 
      and a JITAI approach is expected to enhance positive intervention effects. TRIAL 
      REGISTRATION: German Clinical Trials Register DRKS00010415;
      https://tinyurl.com/yyo87yyu. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/20534.
CI  - (c)Kathrin Wunsch, Tobias Eckert, Janis Fiedler, Laura Cleven, Christina
      Niermann, Harald Reiterer, Britta Renner, Alexander Woll. Originally published in
      JMIR Research Protocols (http://www.researchprotocols.org), 11.11.2020.
FAU - Wunsch, Kathrin
AU  - Wunsch K
AUID- ORCID: https://orcid.org/0000-0001-9400-4130
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
FAU - Eckert, Tobias
AU  - Eckert T
AUID- ORCID: https://orcid.org/0000-0002-0565-7998
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
FAU - Fiedler, Janis
AU  - Fiedler J
AUID- ORCID: https://orcid.org/0000-0002-9291-2191
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
FAU - Cleven, Laura
AU  - Cleven L
AUID- ORCID: https://orcid.org/0000-0001-8213-9417
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
FAU - Niermann, Christina
AU  - Niermann C
AUID- ORCID: https://orcid.org/0000-0002-2087-5328
AD  - Department of Sports Science, University of Konstanz, Konstanz, Germany.
FAU - Reiterer, Harald
AU  - Reiterer H
AUID- ORCID: https://orcid.org/0000-0001-8528-8928
AD  - Department of Computer and Information Science, University of Konstanz, Konstanz,
      Germany.
FAU - Renner, Britta
AU  - Renner B
AUID- ORCID: https://orcid.org/0000-0001-8385-2839
AD  - Department of Psychology, University of Konstanz, Konstanz, Germany.
FAU - Woll, Alexander
AU  - Woll A
AUID- ORCID: https://orcid.org/0000-0002-5736-2980
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201111
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7688389
OTO - NOTNLM
OT  - accelerometer
OT  - behavior change
OT  - digital intervention
OT  - exercise
OT  - family
OT  - food and nutrition
OT  - health behavior
OT  - just-in-time adaptive intervention
OT  - mobile app
OT  - mobile phone
OT  - primary prevention
OT  - randomized controlled trial
OT  - social cognitive determinants
OT  - telemedicine
OT  - wearable electronic devices
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:01
CRDT- 2020/11/11 12:12
PHST- 2020/05/21 00:00 [received]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/11/11 12:12 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:01 [medline]
AID - v9i11e20534 [pii]
AID - 10.2196/20534 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 11;9(11):e20534. doi: 10.2196/20534.


PMID- 33174697
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20201124
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 16
IP  - 714
DP  - 2020 Nov 11
TI  - [Too old or too frail for intensive care?]
PG  - 2160-2164
AB  - What are the criteria for admitting an elderly polymorbid patient to intensive
      care ? The multidimensional geriatric evaluation is a tool to screen for
      geriatric syndromes, with the division of elderly patients into 3 categories:
      robust, vulnerable and dependent. Targeting certain co-morbidities such as
      cognitive disorders, delirium, frailty, polymedication and malnutrition, allows
      clinicians to estimate the risks of mortality and functional and cognitive
      handicaps during a stay in intensive care. Based on a review of the literature,
      this article offers some guidelines for triage of older patients for admission to
      intensive care, using an ethical, multidisciplinary approach that takes into
      account the patient's fears and preferences.
FAU - Coutaz, Martial
AU  - Coutaz M
AD  - Service de geriatrie du Valais romand, Hopital du Valais, 1920 Martigny.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Trop age ou trop fragile pour beneficier des soins intensifs ?
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
SB  - IM
MH  - Aged
MH  - Cognition Disorders/diagnosis
MH  - Critical Care/*statistics & numerical data
MH  - Delirium/diagnosis
MH  - *Frail Elderly/psychology
MH  - Frailty/*diagnosis
MH  - *Geriatric Assessment
MH  - Humans
MH  - Malnutrition/diagnosis
COIS- L'auteur n'a declare aucun conflit d'interets en relation avec cet article.
EDAT- 2020/11/12 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/11 08:40
PHST- 2020/11/11 08:40 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - RMS0714-004 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2020 Nov 11;16(714):2160-2164.


PMID- 33173702
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2169-7574 (Print)
IS  - 2169-7574 (Linking)
VI  - 8
IP  - 10
DP  - 2020 Oct
TI  - Artificial Intelligence in Plastic Surgery: Current Applications, Future
      Directions, and Ethical Implications.
PG  - e3200
LID - 10.1097/GOX.0000000000003200 [doi]
AB  - BACKGROUND: Artificial intelligence (AI) in healthcare delivery has become an
      important area of research due to the rapid progression of technology, which has 
      allowed the growth of many processes historically reliant upon human input. AI
      has become particularly important in plastic surgery in a variety of settings.
      This article highlights current applications of AI in plastic surgery and
      discusses future implications. We further detail ethical issues that may arise in
      the implementation of AI in plastic surgery. METHODS: We conducted a systematic
      literature review of all electronically available publications in the PubMed,
      Scopus, and Web of Science databases as of February 5, 2020. All returned
      publications regarding the application of AI in plastic surgery were considered
      for inclusion. RESULTS: Of the 89 novel articles returned, 14 satisfied inclusion
      and exclusion criteria. Articles procured from the references of those of the
      database search and those pertaining to historical and ethical implications were 
      summarized when relevant. CONCLUSIONS: Numerous applications of AI exist in
      plastic surgery. Big data, machine learning, deep learning, natural language
      processing, and facial recognition are examples of AI-based technology that
      plastic surgeons may utilize to advance their surgical practice. Like any
      evolving technology, however, the use of AI in healthcare raises important
      ethical issues, including patient autonomy and informed consent, confidentiality,
      and appropriate data use. Such considerations are significant, as high ethical
      standards are key to appropriate and longstanding implementation of AI.
CI  - Copyright (c) 2020 The Authors. Published by Wolters Kluwer Health, Inc. on
      behalf of The American Society of Plastic Surgeons.
FAU - Jarvis, Tyler
AU  - Jarvis T
AD  - Mayo Clinic Alix School of Medicine, Scottsdale, Ariz.
FAU - Thornburg, Danielle
AU  - Thornburg D
AD  - Division of Plastic and Reconstructive Surgery, Department of Surgery, Mayo
      Clinic, Phoenix, Ariz.
FAU - Rebecca, Alanna M
AU  - Rebecca AM
AD  - Division of Plastic and Reconstructive Surgery, Department of Surgery, Mayo
      Clinic, Phoenix, Ariz.
FAU - Teven, Chad M
AU  - Teven CM
AD  - Division of Plastic and Reconstructive Surgery, Department of Surgery, Mayo
      Clinic, Phoenix, Ariz.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - United States
TA  - Plast Reconstr Surg Glob Open
JT  - Plastic and reconstructive surgery. Global open
JID - 101622231
PMC - PMC7647513
COIS- Disclosure: The authors have no financial or commercial conflicts of interest to 
      disclose.
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:01
CRDT- 2020/11/11 05:59
PHST- 2020/07/19 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/11/11 05:59 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:01 [medline]
AID - 10.1097/GOX.0000000000003200 [doi]
PST - epublish
SO  - Plast Reconstr Surg Glob Open. 2020 Oct 29;8(10):e3200. doi:
      10.1097/GOX.0000000000003200. eCollection 2020 Oct.


PMID- 33173540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - The Value of Mouse Models of Rare Diseases: A Spanish Experience.
PG  - 583932
LID - 10.3389/fgene.2020.583932 [doi]
AB  - Animal models are invaluable for biomedical research, especially in the context
      of rare diseases, which have a very low prevalence and are often complex.
      Concretely mouse models provide key information on rare disease mechanisms and
      therapeutic strategies that cannot be obtained by using only alternative methods,
      and greatly contribute to accelerate the development of new therapeutic options
      for rare diseases. Despite this, the use of experimental animals remains
      controversial. The combination of respectful management, ethical laws and
      transparency regarding animal experimentation contributes to improve society's
      opinion about biomedical research and positively impacts on research quality,
      which eventually also benefits patients. Here we present examples of current
      advances in preclinical research in rare diseases using mouse models, together
      with our perspective on future directions and challenges.
CI  - Copyright (c) 2020 Murillo-Cuesta, Artuch, Asensio, de la Villa, Dierssen,
      Enriquez, Fillat, Fourcade, Ibanez, Montoliu, Oliver, Pujol, Salido, Vallejo and 
      Varela-Nieto.
FAU - Murillo-Cuesta, Silvia
AU  - Murillo-Cuesta S
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM), Consejo Superior de 
      Investigaciones Cientificas/Universidad Autonoma de Madrid, Madrid, Spain.
AD  - Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
FAU - Artuch, Rafael
AU  - Artuch R
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, Spain.
FAU - Asensio, Fernando
AU  - Asensio F
AD  - Gregorio Maranon Institute for Health Research (IISGM), Madrid, Spain.
FAU - de la Villa, Pedro
AU  - de la Villa P
AD  - Faculty of Medicine, University of Alcala (UAH), Alcala de Henares, Spain.
FAU - Dierssen, Mara
AU  - Dierssen M
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Centre for Genomic Regulation (CRG), Barcelona Institute of Science and
      Technology (BIST), Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
FAU - Enriquez, Jose Antonio
AU  - Enriquez JA
AD  - Spanish National Center for Cardiovascular Research (CNIC), Institute of Health
      Carlos III, Madrid, Spain.
AD  - Biomedical Research Networking Center on Frailty and Healthy Ageing (CIBERFES),
      Institute of Health Carlos III, Madrid, Spain.
FAU - Fillat, Cristina
AU  - Fillat C
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona,
      Spain.
FAU - Fourcade, Stephane
AU  - Fourcade S
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat,
      Barcelona, Spain.
FAU - Ibanez, Borja
AU  - Ibanez B
AD  - Spanish National Center for Cardiovascular Research (CNIC), Institute of Health
      Carlos III, Madrid, Spain.
AD  - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV),
      Institute of Health Carlos III, Madrid, Spain.
AD  - Cardiology Department, Fundacion Jimenez Diaz University Hospital Health Research
      Institute (IIS-FJD), Madrid, Spain.
FAU - Montoliu, Lluis
AU  - Montoliu L
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - National Center for Biotechnology (CNB), Spanish National Research Council,
      Madrid, Spain.
FAU - Oliver, Eduardo
AU  - Oliver E
AD  - Spanish National Center for Cardiovascular Research (CNIC), Institute of Health
      Carlos III, Madrid, Spain.
AD  - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV),
      Institute of Health Carlos III, Madrid, Spain.
FAU - Pujol, Aurora
AU  - Pujol A
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat,
      Barcelona, Spain.
AD  - Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain.
FAU - Salido, Eduardo
AU  - Salido E
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Unidad de Investigacion, Hospital Universitario de Canarias, Instituto de
      Tecnologias Biomedicas (ITB), La Laguna, Spain.
FAU - Vallejo, Mario
AU  - Vallejo M
AD  - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM), Consejo Superior de 
      Investigaciones Cientificas/Universidad Autonoma de Madrid, Madrid, Spain.
AD  - Biomedical Research Networking Center on Diabetes and Metabolic Diseases
      (CIBERDEM), Institute of Health Carlos III, Madrid, Spain.
FAU - Varela-Nieto, Isabel
AU  - Varela-Nieto I
AD  - Biomedical Research Networking Center on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM), Consejo Superior de 
      Investigaciones Cientificas/Universidad Autonoma de Madrid, Madrid, Spain.
AD  - Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7591746
OTO - NOTNLM
OT  - animal models
OT  - ethics
OT  - novel therapies
OT  - orphan diseases
OT  - preclinical research
OT  - transparency
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:01
CRDT- 2020/11/11 05:58
PHST- 2020/07/15 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/11/11 05:58 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:01 [medline]
AID - 10.3389/fgene.2020.583932 [doi]
PST - epublish
SO  - Front Genet. 2020 Oct 14;11:583932. doi: 10.3389/fgene.2020.583932. eCollection
      2020.


PMID- 33173511
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the
      Psychological Burden of Coronavirus.
PG  - 563319
LID - 10.3389/fpsyt.2020.563319 [doi]
AB  - BACKGROUND: Living in the time of the COVID-19 means experiencing not only a
      global health emergency but also extreme psychological stress with potential
      emotional side effects such as sadness, grief, irritability, and mood swings.
      Crucially, lockdown and confinement measures isolate people who become the first 
      and the only ones in charge of their own mental health: people are left alone
      facing a novel and potentially lethal situation, and, at the same time, they need
      to develop adaptive strategies to face it, at home. In this view, easy-to-use,
      inexpensive, and scientifically validated self-help solutions aiming to reduce
      the psychological burden of coronavirus are extremely necessary. AIMS: This
      pragmatic trial aims to provide the evidence that a weekly self-help virtual
      reality (VR) protocol can help overcome the psychological burden of the
      Coronavirus by relieving anxiety, improving well-being, and reinforcing social
      connectedness. The protocol will be based on the "Secret Garden" 360 VR video
      online (www.covidfeelgood.com) which simulates a natural environment aiming to
      promote relaxation and self-reflection. Three hundred sixty-degree or spherical
      videos allow the user to control the viewing direction. In this way, the user can
      explore the content from any angle like a panorama and experience presence and
      immersion. The "Secret Garden" video is combined with daily exercises that are
      designed to be experienced with another person (not necessarily physically
      together), to facilitate a process of critical examination and eventual revision 
      of core assumptions and beliefs related to personal identity, relationships, and 
      goals. METHODS: This is a multicentric, pragmatic pilot randomized controlled
      trial involving individuals who experienced the COVID-19 pandemic and underwent a
      lockdown and quarantine procedures. The trial is approved by the Ethics Committee
      of the Istituto Auxologico Italiano. Each research group in all the countries
      joining the pragmatic trial, aims at enrolling at least 30 individuals in the
      experimental group experiencing the self-help protocol, and 30 in the control
      group, over a period of 3 months to verify the feasibility of the intervention.
      CONCLUSION: The goal of this protocol is for VR to become the "surgical mask" of 
      mental health treatment. Although surgical masks do not provide the wearer with a
      reliable level of protection against the coronavirus compared with FFP2 or FFP3
      masks, surgical masks are very effective in protecting others from the wearer's
      respiratory emissions. The goal of the VR protocol is the same: not necessarily
      to solve complex mental health problems but rather to improve well-being and
      preserve social connectedness through the beneficial social effects generated by 
      positive emotions.
CI  - Copyright (c) 2020 Riva, Bernardelli, Browning, Castelnuovo, Cavedoni, Chirico,
      Cipresso, de Paula, Di Lernia, Fernandez-Alvarez, Figueras-Puigderrajols, Fuji,
      Gaggioli, Gutierrez-Maldonado, Hong, Mancuso, Mazzeo, Molinari, Moretti, Ortiz de
      Gortari, Pagnini, Pedroli, Repetto, Sforza, Stramba-Badiale, Tuena, Malighetti,
      Villani and Wiederhold.
FAU - Riva, Giuseppe
AU  - Riva G
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Bernardelli, Luca
AU  - Bernardelli L
AD  - Become-Hub, Milan, Italy.
FAU - Browning, Matthew H E M
AU  - Browning MHEM
AD  - Virtual Reality and Nature Lab, Clemson University, Clemson, SC, United States.
FAU - Castelnuovo, Gianluca
AU  - Castelnuovo G
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Cavedoni, Silvia
AU  - Cavedoni S
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
FAU - Chirico, Alice
AU  - Chirico A
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Cipresso, Pietro
AU  - Cipresso P
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - de Paula, Dirce Maria Bengel
AU  - de Paula DMB
AD  - Sociedad Espanola de Realidad Virtual y Psicologia, Las Rozas - Madrid, Spain.
FAU - Di Lernia, Daniele
AU  - Di Lernia D
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Fernandez-Alvarez, Javier
AU  - Fernandez-Alvarez J
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Figueras-Puigderrajols, Natalia
AU  - Figueras-Puigderrajols N
AD  - Department of Clinical Psychology and Psychobiology, University of Barcelona,
      Barcelona, Spain.
FAU - Fuji, Kei
AU  - Fuji K
AD  - Division of Psychology, University of Tsukuba, Tokyo, Japan.
FAU - Gaggioli, Andrea
AU  - Gaggioli A
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Gutierrez-Maldonado, Jose
AU  - Gutierrez-Maldonado J
AD  - Department of Clinical Psychology and Psychobiology, University of Barcelona,
      Barcelona, Spain.
FAU - Hong, Upyong
AU  - Hong U
AD  - Department of Media and Communication, Konkuk University, Seoul, South Korea.
FAU - Mancuso, Valentina
AU  - Mancuso V
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
FAU - Mazzeo, Milena
AU  - Mazzeo M
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Molinari, Enrico
AU  - Molinari E
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Moretti, Luciana F
AU  - Moretti LF
AD  - Sociedad Espanola de Realidad Virtual y Psicologia, Las Rozas - Madrid, Spain.
FAU - Ortiz de Gortari, Angelica B
AU  - Ortiz de Gortari AB
AD  - The Centre for the Science of Learning & Technology (SLATE), University of
      Bergen, Bergen, Norway.
AD  - Psychology and Neuroscience of Cognition Research Unit, University of Liege,
      Liege, Belgium.
FAU - Pagnini, Francesco
AU  - Pagnini F
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Pedroli, Elisa
AU  - Pedroli E
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Faculty of Psychology, University of eCampus, Novedrate, Italy.
FAU - Repetto, Claudia
AU  - Repetto C
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Sforza, Francesca
AU  - Sforza F
AD  - Become-Hub, Milan, Italy.
FAU - Stramba-Badiale, Chiara
AU  - Stramba-Badiale C
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
FAU - Tuena, Cosimo
AU  - Tuena C
AD  - IRCCS Istituto Auxologico Italiano, Milan, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Malighetti, Clelia
AU  - Malighetti C
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Villani, Daniela
AU  - Villani D
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Wiederhold, Brenda K
AU  - Wiederhold BK
AD  - Virtual Reality Medical Center, La Jolla, CA, United States.
AD  - Virtual Reality Medical Institute, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7538634
OTO - NOTNLM
OT  - COVID
OT  - emotion regulation
OT  - mental health
OT  - self-help
OT  - stress
OT  - virtual reality
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:01
CRDT- 2020/11/11 05:58
PHST- 2020/05/20 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/11/11 05:58 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:01 [medline]
AID - 10.3389/fpsyt.2020.563319 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Sep 23;11:563319. doi: 10.3389/fpsyt.2020.563319.
      eCollection 2020.


PMID- 33172958
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2059-7029 (Electronic)
IS  - 2059-7029 (Linking)
VI  - 5
IP  - 6
DP  - 2020 Nov
TI  - Discussing motherhood when the oncological prognosis is dire: ethical
      considerations for physicians.
PG  - e000956
LID - S2059-7029(20)32746-0 [pii]
LID - 10.1136/esmoopen-2020-000956 [doi]
AB  - Physicians are increasingly open to discussing and supporting pregnancy after
      cancer treatment. However, counselling patients who are seeking pregnancy despite
      advanced oncological disease and/or uncertain prognosis is still challenging. Two
      paradigmatic cases are presented and analysed to illustrate the ethical
      uneasiness faced by treating physicians when seriously ill patients seek
      fertility preservation and/or pregnancy. Review of ethical issues is built around
      the four principles of biomedical ethics. Respect for patients autonomy in
      relation to managing realistic expectations and avoiding giving patients false
      hopes opens the analysis. It is followed by considering fair allocation of
      resources and meaningful distinction between protecting patients from harm and
      contributing to their welfare. Responsibilities towards the unborn child are
      discussed in a light of maternal and fetal interdependency. Respecting personal
      autonomy requires abstaining from controlling inferences to the individual
      patient's choices, but it does not mean that patients should be left on their own
      to pick and choose their disease management approaches without advice and
      guidance from healthcare professionals. Physicians should reason evaluating the
      potential harms and checking if benefits will outweigh the risks and if costs
      will produce the best overall results. Responsibilities towards the unborn child 
      can be managed by balancing the respect for maternal autonomy and beneficence for
      pregnant woman and her fetus. The oncologist cannot determine how patients should
      view their disease but with empathy and compassion can help them understand the
      logical rationale behind clinical advice.
CI  - (c) Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. Published by BMJ on behalf of the European Society for Medical
      Oncology.
FAU - Linkeviciute, Alma
AU  - Linkeviciute A
AD  - Department of Gynaecologic Oncology, European Institute of Oncology IRCCS,
      Milano, Italy.
FAU - Buonomo, Barbara
AU  - Buonomo B
AD  - Department of Gynaecologic Oncology, European Institute of Oncology IRCCS,
      Milano, Italy.
FAU - Fazio, Nicola
AU  - Fazio N
AD  - Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European
      Institute of Oncology IRCCS, Milano, Italy.
FAU - Spada, Francesca
AU  - Spada F
AD  - Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European
      Institute of Oncology IRCCS, Milano, Italy.
FAU - Peccatori, Fedro A
AU  - Peccatori FA
AD  - Department of Gynaecologic Oncology, European Institute of Oncology IRCCS,
      Milano, Italy. Electronic address: fedro.peccatori@ieo.it.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
SB  - IM
MH  - Beneficence
MH  - Child
MH  - Female
MH  - Humans
MH  - *Personal Autonomy
MH  - *Physicians
MH  - Pregnancy
MH  - Pregnant Women
MH  - Prognosis
PMC - PMC7656910
OTO - NOTNLM
OT  - *advanced cancer
OT  - *counselling
OT  - *ethics
OT  - *fertility preservation
OT  - *metastatic cancer
OT  - *motherhood
OT  - *pregnancy
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/08/01 00:00 [received]
PHST- 2020/09/10 00:00 [revised]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - S2059-7029(20)32746-0 [pii]
AID - 10.1136/esmoopen-2020-000956 [doi]
PST - ppublish
SO  - ESMO Open. 2020 Nov;5(6):e000956. doi: 10.1136/esmoopen-2020-000956.


PMID- 33172953
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Treating sleep problems in young people at ultra-high-risk of psychosis: study
      protocol for a single-blind parallel group randomised controlled feasibility
      trial (SleepWell).
PG  - e045235
LID - 10.1136/bmjopen-2020-045235 [doi]
AB  - BACKGROUND: Effective interventions, targeting key contributory causal factors,
      are needed to prevent the emergence of severe mental health problems in young
      people. Insomnia is a common clinical issue that is problematic in its own right 
      but that also leads to the development and persistence of psychotic experiences. 
      The implication is that treating sleep problems may prevent the onset of
      psychosis. We collected initial case series data with 12 young people at
      ultra-high-risk of psychosis. Post-intervention, there were improvements in
      sleep, depression and psychotic experiences. Now we test the feasibility of a
      randomised controlled trial, with a clinical aim to treat sleep problems and
      hence reduce depression, psychotic experiences, and prevent transition to
      psychosis. METHODS AND ANALYSIS: A randomised controlled feasibility trial will
      be conducted. Forty patients aged 14 to 25 years who are at ultra-high-risk of
      psychosis and have sleep disturbance will be recruited from National Health
      Service (NHS) mental health services. Participants will be randomised to receive 
      either a novel, targeted, youth-focussed sleep intervention in addition to usual 
      care or usual care alone. Assessor-blinded assessments will be conducted at
      baseline, 3 months (post-intervention) and 9 months (follow-up). The
      eight-session psychological intervention will target the key mechanisms which
      disrupt sleep: circadian rhythm irregularities, low sleep pressure, and
      hyperarousal. To gain an in-depth understanding of participants' views on the
      acceptability of the intervention and study procedures, 16 participants (n=10
      intervention, n=6 control) will take part in qualitative interviews. Analyses
      will focus on feasibility outcomes (recruitment, retention, and treatment uptake 
      rates) and provide initial CI estimates of intervention effects. Thematic
      analysis of the qualitative interviews will assess the acceptability of the
      intervention and trial procedures. ETHICS AND DISSEMINATION: The trial has
      received ethical approval from the NHS Health Research Authority. Findings will
      be disseminated through peer-reviewed publications, conference presentations, and
      lay networks. TRIAL REGISTRATION NUMBER: ISRCTN85601537.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Waite, Felicity
AU  - Waite F
AUID- ORCID: 0000-0002-2749-1386
AD  - Department of Psychiatry, University of Oxford, Oxford, UK
      felicity.waite@psych.ox.ac.uk.
AD  - Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, UK.
FAU - Kabir, Thomas
AU  - Kabir T
AD  - The McPin Foundation, London, UK.
FAU - Johns, Louise
AU  - Johns L
AD  - Department of Psychiatry, University of Oxford, Oxford, UK.
AD  - Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, UK.
FAU - Mollison, Jill
AU  - Mollison J
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Tsiachristas, Apostolos
AU  - Tsiachristas A
AD  - Health Economics Research Centre, Nuffield Department of Population Health,
      University of Oxford, Oxford, Oxfordshire, UK.
FAU - Petit, Ariane
AU  - Petit A
AD  - Department of Psychiatry, University of Oxford, Oxford, UK.
FAU - Cernis, Emma
AU  - Cernis E
AD  - Department of Psychiatry, University of Oxford, Oxford, UK.
AD  - Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, UK.
FAU - Maughan, Daniel
AU  - Maughan D
AD  - Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, UK.
FAU - Freeman, Daniel
AU  - Freeman D
AUID- ORCID: 0000-0002-2541-2197
AD  - Department of Psychiatry, University of Oxford, Oxford, UK.
AD  - Oxford Health NHS Foundation Trust, Oxford, Oxfordshire, UK.
LA  - eng
SI  - ISRCTN/ISRCTN85601537
GR  - NIHR200481/DH_/Department of Health/United Kingdom
GR  - RP-2014-05-003/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Feasibility Studies
MH  - Humans
MH  - Prospective Studies
MH  - Psychotic Disorders/therapy
MH  - Quality of Life
MH  - Single-Blind Method
MH  - *Sleep Wake Disorders/prevention & control
MH  - State Medicine
MH  - Young Adult
PMC - PMC7656948
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *child & adolescent psychiatry
OT  - *clinical trials
OT  - *mental health
OT  - *schizophrenia & psychotic disorders
OT  - *sleep medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-045235 [pii]
AID - 10.1136/bmjopen-2020-045235 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e045235. doi: 10.1136/bmjopen-2020-045235.


PMID- 33172952
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Neuromonitoring with near-infrared spectroscopy (NIRS) in aneurysmal subarachnoid
      haemorrhage: a systematic review protocol.
PG  - e043300
LID - 10.1136/bmjopen-2020-043300 [doi]
AB  - INTRODUCTION: Aneurysmal subarachnoid haemorrhage (aSAH) is a devastating disease
      associated with high mortality and morbidity. The main threat to patients is
      delayed cerebral ischaemia (DCI). Near-infrared spectroscopy (NIRS) is a recent
      technology allowing continuous, non-invasive cerebral oximetry that could permit 
      timely detection of impending DCI and appropriate intervention to improve
      outcomes. However, the ability of regional oxygen saturation to detect DCI, its
      association to the outcome, or benefits of any interventions based on NIRS data, 
      are lacking. Our aims are to evaluate NIRS technology both as a therapeutic tool 
      to improve outcomes in aSAH patients and as a diagnostic tool for DCI. METHODS
      AND ANALYSIS: MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of
      Controlled Trials and the Cochrane Database of Systematic Reviews will be
      searched from their inception and without language restriction. Our search
      strategy will cover the themes of subarachnoid haemorrhage and cerebral oximetry,
      without limitations regarding studied outcomes. We will identify all
      observational and interventional human studies of adult patients hospitalised
      after aSAH that were monitored using NIRS. Functional outcome measures, including
      the modified Rankin Scale, the Glasgow Outcome Scale and the Barthel Index, will 
      constitute the primary outcome. The Cochrane Risk of Bias tool will be used for
      randomised controlled trials, the ROBINS-I tool to assess non-randomised studies 
      of interventions and the Newcastle-Ottawa Scale for cohort or case-control
      studies. The Quality Assessment of Diagnostic Accuracy Studies-2 will be applied 
      to studies evaluating NIRS diagnostic accuracy for DCI. We will evaluate the
      quality of the evidence of the effect based on the Grading of Recommendations
      Assessment, Development and Evaluation methodology. ETHICS AND DISSEMINATION:
      Dissemination will proceed through submission for journal publication, trial
      registry completion and abstract presentation. Ethics approval is not required.
      PROSPERO REGISTRATION NUMBER: CRD42020077522.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bensaidane, Mohamed Reda
AU  - Bensaidane MR
AD  - CHU de Quebec - Universite Laval Research Center, Population Health and Optimal
      Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine),
      Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Medicine, Universite Laval, Quebec City, Quebec, Canada.
FAU - Turgeon, Alexis F
AU  - Turgeon AF
AUID- ORCID: 0000-0001-5675-8791
AD  - CHU de Quebec - Universite Laval Research Center, Population Health and Optimal
      Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine),
      Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Division of Critical
      Care Medicine, Universite Laval, Quebec City, Quebec, Canada.
FAU - Lauzier, Francois
AU  - Lauzier F
AD  - CHU de Quebec - Universite Laval Research Center, Population Health and Optimal
      Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine),
      Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Medicine, Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Division of Critical
      Care Medicine, Universite Laval, Quebec City, Quebec, Canada.
FAU - English, Shane W
AU  - English SW
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, 
      Ontario, Canada.
FAU - Leblanc, Guillaume
AU  - Leblanc G
AD  - CHU de Quebec - Universite Laval Research Center, Population Health and Optimal
      Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine),
      Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Division of Critical
      Care Medicine, Universite Laval, Quebec City, Quebec, Canada.
FAU - Francoeur, Charles L
AU  - Francoeur CL
AUID- ORCID: 0000-0002-8147-8852
AD  - CHU de Quebec - Universite Laval Research Center, Population Health and Optimal
      Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine),
      Universite Laval, Quebec City, Quebec, Canada
      charles-langis.francoeur.2@ulaval.ca.
AD  - Department of Medicine, Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Division of Critical
      Care Medicine, Universite Laval, Quebec City, Quebec, Canada.
LA  - eng
GR  - 148449/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cerebrovascular Circulation
MH  - Humans
MH  - Oximetry
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Spectroscopy, Near-Infrared
MH  - *Subarachnoid Hemorrhage/diagnostic imaging
MH  - Systematic Reviews as Topic
PMC - PMC7656947
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *adult neurology
OT  - *neurosurgery
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-043300 [pii]
AID - 10.1136/bmjopen-2020-043300 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e043300. doi: 10.1136/bmjopen-2020-043300.


PMID- 33172951
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Economic costs of infertility care for patients in low-income and middle-income
      countries: a systematic review protocol.
PG  - e042951
LID - 10.1136/bmjopen-2020-042951 [doi]
AB  - INTRODUCTION: Infertility, a condition of the reproductive system, affects
      millions of individuals and couples worldwide. Despite infertility treatment's
      existence, it is largely unavailable and inaccessible in low/middle-income
      countries (LMICs) due to the prohibitive costs compounded by an absence of
      financing. Previous systematic reviews have shown that there is scanty
      information in LMICs on out-of-pocket (OOP) payments for infertility treatment.
      This protocol outlines the methodological approach and analytical process to
      appraise the extent of economic burden due to payments for infertility care
      services in LMICs. METHOD AND ANALYSIS: Using the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses approach, we will primarily search for
      articles indexed in PubMed, Web of Science, Cumulative Index of Nursing and
      Allied Health Literature, EconLit and PsycINFO databases. Grey literature from
      relevant organisations' virtual libraries shall also be searched. Backward and
      forward searches on the articles selected will also be done. Quantitative studies
      on infertility treatment costs from LMICs across the world regions within the
      last 20 years will be considered. The primary outcome of interest shall include
      OOP payments, catastrophic health expenditure and direct costs for infertility
      services. Conversely, informal payments and indirect costs related to infertility
      treatments shall be considered as secondary outcomes. Integrated quality Criteria
      for Review Of Multiple Study designs will be used to assess the quality of the
      studies included in the review. Meta-analysis shall be considered if sufficient
      studies identified are homogenous in characteristics. Also, the review shall
      analyse the average cost of infertility treatment against the respective
      countries' economic indicators like gross domestic product per capita if data
      permit. ETHICS AND DISSEMINATION: Research and ethics approval will not be
      required given this will be a review of published articles on the subject. The
      findings shall be disseminated through publication in a peer-reviewed journal and
      presentation to the WHO and its partners. PROSPERO REGISTRATION NUMBER:
      CRD42020199312.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Njagi, Purity
AU  - Njagi P
AUID- ORCID: 0000-0003-3157-4413
AD  - Maastricht Graduate School of Governance, United Nations
      University-MERIT/Maastricht University, Maastricht, Netherlands
      p.njagi@student.maastrichtuniversity.nl.
FAU - Groot, Wim
AU  - Groot W
AD  - Maastricht Graduate School of Governance, United Nations
      University-MERIT/Maastricht University, Maastricht, Netherlands.
AD  - Department of Health Services Research, Faculty of Health, Medicine and Life
      Sciences, Maastricht University, Maastricht, Netherlands.
FAU - Arsenijevic, Jelena
AU  - Arsenijevic J
AD  - School of Governance, Faculty of Law, Economics and Governance, Utrecht
      University, Utrecht, Netherlands.
FAU - Dyer, Silke
AU  - Dyer S
AD  - Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town,
      South Africa.
FAU - Mburu, Gitau
AU  - Mburu G
AD  - Department of Sexual and Reproductive Health and Research (SHR), World Health
      Organization, Geneve, Switzerland.
FAU - Kiarie, James
AU  - Kiarie J
AD  - Department of Sexual and Reproductive Health and Research (SHR), World Health
      Organization, Geneve, Switzerland.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Developing Countries
MH  - Humans
MH  - Income
MH  - *Infertility/therapy
MH  - Poverty
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7656943
OTO - NOTNLM
OT  - *health economics
OT  - *reproductive medicine
OT  - *subfertility
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-042951 [pii]
AID - 10.1136/bmjopen-2020-042951 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e042951. doi: 10.1136/bmjopen-2020-042951.


PMID- 33172948
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Multicentre longitudinal study of fluid and neuroimaging BIOmarkers of AXonal
      injury after traumatic brain injury: the BIO-AX-TBI study protocol.
PG  - e042093
LID - 10.1136/bmjopen-2020-042093 [doi]
AB  - INTRODUCTION AND AIMS: Traumatic brain injury (TBI) often results in persistent
      disability, due particularly to cognitive impairments. Outcomes remain difficult 
      to predict but appear to relate to axonal injury. Several new approaches
      involving fluid and neuroimaging biomarkers show promise to sensitively quantify 
      axonal injury. By assessing these longitudinally in a large cohort, we aim both
      to improve our understanding of the pathophysiology of TBI, and provide better
      tools to predict clinical outcome. METHODS AND ANALYSIS: BIOmarkers of AXonal
      injury after TBI is a prospective longitudinal study of fluid and neuroimaging
      biomarkers of axonal injury after moderate-to-severe TBI, currently being
      conducted across multiple European centres. We will provide a detailed
      characterisation of axonal injury after TBI, using fluid (such as
      plasma/microdialysate neurofilament light) and neuroimaging biomarkers (including
      diffusion tensor MRI), which will then be related to detailed clinical, cognitive
      and functional outcome measures. We aim to recruit at least 250 patients,
      including 40 with cerebral microdialysis performed, with serial assessments
      performed twice in the first 10 days after injury, subacutely at 10 days to 6
      weeks, at 6 and 12 months after injury. ETHICS AND DISSEMINATION: The relevant
      ethical approvals have been granted by the following ethics committees: in
      London, by the Camberwell St Giles Research Ethics Committee; in Policlinico
      (Milan), by the Comitato Etico Milano Area 2; in Niguarda (Milan), by the
      Comitato Etico Milano Area 3; in Careggi (Florence), by the Comitato Etico
      Regionale per la Sperimentazione Clinica della Regione Toscana, Sezione area
      vasta centro; in Trento, by the Trento Comitato Etico per le Sperimentazioni
      Cliniche, Azienda Provinciale per i Servizi Sanitari della Provincia autonoma di 
      Trento; in Lausanne, by the Commission cantonale d'ethique de la recherche sur
      l'etre humain; in Ljubljana, by the National Medical Ethics Committee at the
      Ministry of Health of the Republic of Slovenia. The study findings will be
      disseminated to patients, healthcare professionals, academics and policy-makers
      including through presentation at conferences and peer-reviewed publications.
      Data will be shared with approved researchers to provide further insights for
      patient benefit. TRIAL REGISTRATION NUMBER: NCT03534154.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Graham, Neil Samuel Nyholm
AU  - Graham NSN
AUID- ORCID: 0000-0002-0183-3368
AD  - Department of Brain Sciences, Imperial College London, London, UK.
AD  - UK DRI Centre for Care Research and Technology, London, UK.
FAU - Zimmerman, Karl A
AU  - Zimmerman KA
AD  - Department of Brain Sciences, Imperial College London, London, UK.
AD  - UK DRI Centre for Care Research and Technology, London, UK.
FAU - Bertolini, Guido
AU  - Bertolini G
AD  - Public Health, IRCCS-'Mario Negri' Institute for Pharmacological Research,
      Ranica, Italy.
FAU - Magnoni, Sandra
AU  - Magnoni S
AD  - Department of Anesthesia and Intensive Care, Santa Chiara Hospital, Trento,
      Italy.
FAU - Oddo, Mauro
AU  - Oddo M
AD  - Department of Intensive Care Medicine, CHUV Lausanne University Hospital,
      Lausanne, Switzerland.
FAU - Zetterberg, Henrik
AU  - Zetterberg H
AD  - Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology,
      London, UK.
AD  - Department of Psychiatry and Neurochemistry, Institute of Neuroscience and
      Physiology, University of Gothenburg Sahlgrenska Academy, Molndal, Sweden.
FAU - Moro, Federico
AU  - Moro F
AD  - Public Health, IRCCS-'Mario Negri' Institute for Pharmacological Research,
      Ranica, Italy.
FAU - Novelli, Deborah
AU  - Novelli D
AD  - Public Health, IRCCS-'Mario Negri' Institute for Pharmacological Research,
      Ranica, Italy.
FAU - Heslegrave, Amanda
AU  - Heslegrave A
AD  - UCL Queen Square Institute of Neurology, London, UK.
FAU - Chieregato, Arturo
AU  - Chieregato A
AUID- ORCID: 0000-0001-6690-8597
AD  - Neurorianimazione, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
FAU - Fainardi, Enrico
AU  - Fainardi E
AD  - Department of Experimental and Clinical Sciences, Careggi University Hospital,
      University of Firenze, Florence, Italy.
FAU - Fleming, Joanne M
AU  - Fleming JM
AD  - Public Health, IRCCS-'Mario Negri' Institute for Pharmacological Research,
      Ranica, Italy.
FAU - Garbero, Elena
AU  - Garbero E
AUID- ORCID: 0000-0003-4902-0144
AD  - Public Health, IRCCS-'Mario Negri' Institute for Pharmacological Research,
      Ranica, Italy.
FAU - Abed-Maillard, Samia
AU  - Abed-Maillard S
AD  - Department of Intensive Care Medicine, CHUV Lausanne University Hospital,
      Lausanne, Switzerland.
FAU - Gradisek, Primoz
AU  - Gradisek P
AD  - Clinical Department of Anaesthesiology and Intensive Therapy, University Medical 
      Center, Ljubljana, Slovenia.
FAU - Bernini, Adriano
AU  - Bernini A
AD  - Department of Intensive Care Medicine, CHUV Lausanne University Hospital,
      Lausanne, Switzerland.
FAU - Sharp, David J
AU  - Sharp DJ
AD  - Department of Brain Sciences, Imperial College London, London, UK
      david.sharp@imperial.ac.uk.
AD  - UK DRI Centre for Care Research and Technology, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03534154
GR  - MR/R004528/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers
MH  - *Brain Injuries, Traumatic/diagnostic imaging
MH  - Humans
MH  - London
MH  - Longitudinal Studies
MH  - *Neuroimaging
MH  - Prospective Studies
PMC - PMC7656955
OTO - NOTNLM
OT  - *biochemistry
OT  - *magnetic resonance imaging
OT  - *neurological injury
OT  - *trauma management
COIS- Competing interests: HZ has served at advisory boards for Eli Lilly, Roche
      Diagnostics and Pharmasum Therapeutics, and is a cofounder of Brain Biomarker
      Solutions in Gothenburg AB, a GU Ventures-based platform company at the
      University of Gothenburg. The other authors have no potential conflicts to
      declare.
EDAT- 2020/11/12 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - bmjopen-2020-042093 [pii]
AID - 10.1136/bmjopen-2020-042093 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e042093. doi: 10.1136/bmjopen-2020-042093.


PMID- 33172947
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Differences in terms of presentation and outcomes between patients with lung
      cancer as opposed to other solid organ cancer after infection with SARS-CoV-2:
      protocol for a systematic review.
PG  - e041790
LID - 10.1136/bmjopen-2020-041790 [doi]
AB  - INTRODUCTION: Scholars believe that COVID-19 can be particularly lethal for
      patients with cancer. Some studies found that COVID-19 appears to be more lethal 
      in patients with lung cancer than in other cancer patients. In order to take
      appropriate measures to balance a delay in lung cancer treatment against the risk
      for a potential COVID-19 exposure, we first need to know whether patients with
      lung cancer have special risks. We aim to conduct a systematic review and
      meta-analysis to examine differences in terms of presentation and outcomes
      between patients with lung cancer as opposed to other solid organ cancer after
      infection with SARS-CoV-2. METHODS AND ANALYSIS: A comprehensive search of
      published original research studies will be performed in Embase, MEDLINE, Web of 
      Science, WangFangData, CQVIP, COMPENDEX and CNKI. The medRxiv preprint server
      will also be searched for applicable studies (grey literature). Original research
      studies will be included if they include patients with: (A) laboratory-confirmed 
      SARS-CoV-2 infection and (B) confirmed solid cancer, and (C) measurable clinical 
      presentation or outcome, such as mortality rate, intensive care unit admission
      rate, incidence of pneumonia. One author will conduct the electronic database
      searches, two authors will independently screen studies, two will extract data
      and two will assess study quality. If I(2) exceeds 60% for the pooled analysis,
      we will explore sources of heterogeneity in subgroups of studies. We will use
      fixed-effect, random-effects or mixed-effects models to estimate the relative
      risk or OR. If the data reporting allows, a subgroup analysis between non-small
      cell lung cancer and small cell lung cancer patients will be performed. ETHICS
      AND DISSEMINATION: The proposed study will not collect individual-level data and,
      therefore, does not require ethical approval. We will submit our findings to a
      peer-reviewed scientific journal and will disseminate results through
      presentations at international scientific conferences. PROSPERO REGISTRATION
      NUMBER: CRD42020190118.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Haisheng
AU  - Chen H
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Shi, Jing
AU  - Shi J
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Shi, Wenna
AU  - Shi W
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Xu, Hengwei
AU  - Xu H
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Duan, Cunxian
AU  - Duan C
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Fan, Qing
AU  - Fan Q
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Wang, Yanhong
AU  - Wang Y
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China.
FAU - Li, Hui
AU  - Li H
AUID- ORCID: 0000-0001-5583-5329
AD  - Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First
      Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong,
      China 874223972@qq.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Case-Control Studies
MH  - Comorbidity
MH  - Coronavirus Infections/mortality/*physiopathology
MH  - Humans
MH  - Intensive Care Units/statistics & numerical data
MH  - Lung Neoplasms/*epidemiology
MH  - Meta-Analysis as Topic
MH  - Neoplasms/*epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/mortality/*physiopathology
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
PMC - PMC7656885
OTO - NOTNLM
OT  - *COVID-19
OT  - *microbiology
OT  - *oncology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjopen-2020-041790 [pii]
AID - 10.1136/bmjopen-2020-041790 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e041790. doi: 10.1136/bmjopen-2020-041790.


PMID- 33172943
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Association between birth interval and wasting in children under 5 years of age
      in Ethiopia: a systematic review and meta-analysis protocol.
PG  - e037976
LID - 10.1136/bmjopen-2020-037976 [doi]
AB  - INTRODUCTION: According to the UNICEF, WHO and World Bank joint estimation, 1 in 
      every 13 children suffered from wasting globally. The highest burden of
      undernutrition recorded in Asia and Africa. Wasting remains a considerable public
      health problem in Ethiopia despite the introduction of exhaustive nutritional
      programmes. As reported in the literature, the prevalence of wasting in Ethiopia 
      has remained high over the last four decades. In Ethiopia, more than one-third of
      child deaths are associated with malnutrition. The current nutritional
      interventions implemented in Ethiopia need to be evidence based. For this
      purpose, systematic review is preferable as it can present a more reliable and
      precise estimate than individual studies. The aim of this review is to assess the
      pooled prevalence of wasting and its association with birth interval in Ethiopia.
      METHODOLOGY: Studies published after 20 January 2012 will be retrieved from
      databases, mainly PubMed/Medline, Scopus, Embase, CINAHL and HINARI. The articles
      retrieved from databases will be selected after reading the title, abstract and
      full text. Three reviewers will independently assess the quality of each study
      using both the Joanna Briggs Institute and Ottawa Scale critical appraisal
      checklists. The Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses checklist will be used to maintain scientific strength. Funnel
      plots, Egger's test and Begg's test will be used to deal with publication bias,
      and I(2), forest plots and Cochrane's Q square statistics will be used for
      heterogeneity. Potential causes of heterogeneity will be explored through
      sensitivity and subgroup analyses. Because heterogeneity among studies is
      inevitable, given the wide geographical area and variety of study designs, the
      Der-Simonian and Laird random-effects model will be used. The presence of a
      statistical association between birth interval and wasting will be declared if
      the p value is <0.05 with the 95% CI. ETHICS AND DISSEMINATION: Ethical issues
      will not be applicable to this review and meta-analysis. This review and
      meta-analysis will report the pooled prevalence of wasting and its association
      with birth interval in Ethiopia. Effort will be made to publish the findings in a
      peer-reviewed journal such as the Ethiopian Journal of Health and Development,
      and the findings will be presented at national conferences. A hard copy will also
      be sent to Woldia University and Debre Berhan University.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kassaw, Mesfin Wudu
AU  - Kassaw MW
AUID- ORCID: 0000-0002-6327-7723
AD  - Nursing, Woldia University, Woldia, Amhara, Ethiopia mesfine12a@gmail.com.
FAU - Abebe, Ayele Mamo
AU  - Abebe AM
AD  - Nursing, Debre Berhan University, Debre Berhan, Amhara, Ethiopia.
FAU - Abate, Biruk Beletew
AU  - Abate BB
AUID- ORCID: 0000-0003-0833-2504
AD  - Nursing, Woldia University, Woldia, Amhara, Ethiopia.
FAU - Kassie, Ayelign Mengesha
AU  - Kassie AM
AUID- ORCID: 0000-0003-1505-9390
AD  - Nursing, Woldia University, Woldia, Amhara, Ethiopia.
FAU - Acik, Murat
AU  - Acik M
AD  - Nutrition and Dietetics, Ankara University, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Asia
MH  - *Birth Intervals
MH  - Child
MH  - Child, Preschool
MH  - Ethiopia/epidemiology
MH  - Humans
MH  - *Malnutrition
MH  - Meta-Analysis as Topic
MH  - Prevalence
MH  - Systematic Reviews as Topic
PMC - PMC7656953
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *child protection
OT  - *community child health
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037976 [pii]
AID - 10.1136/bmjopen-2020-037976 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e037976. doi: 10.1136/bmjopen-2020-037976.


PMID- 33172941
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 10
TI  - Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage
      (DASH): protocol for a phase II double-blind randomised controlled feasibility
      trial.
PG  - e037555
LID - 10.1136/bmjopen-2020-037555 [doi]
AB  - INTRODUCTION: Intracerebral haemorrhage (ICH) can be devastating and is a common 
      cause of death and disability worldwide. Pre-ICH antiplatelet drug use is
      associated with a 27% relative increase in 1 month case fatality compared with
      patients not using antithrombotic drugs. We aim to assess the feasibility of
      conducting a randomised controlled testing the safety and efficacy of
      desmopressin for patients with antiplatelet-associated ICH. METHODS AND ANALYSIS:
      We aim to include 50 patients within 24 hours of spontaneous ICH onset,
      associated with oral antiplatelet drug(s) use in at least the preceding 7 days.
      Patients will be randomised (1:1) to receive intravenous desmopressin 20 microg
      in 50 mL sodium chloride 0.9% infused over 20 min or matching placebo. We will
      mask participants, relatives and outcome assessors to treatment allocation.
      Feasibility outcomes include proportion of patients approached being randomised, 
      number of patients receiving allocated treatment, rate of recruitment and
      adherence to treatment and follow-up. Secondary outcomes include change in ICH
      volume at 24 hours; hyponatraemia at 24 hours, length of hospital stay, discharge
      destination, early death less than 28 days, death or dependency at day 90, death 
      up to day 90, serious adverse events (including thromboembolic events) up to day 
      90; disability (Barthel index, day 90), quality of life (EuroQol 5D (EQ-5D), day 
      90), cognition (telephone mini-mental state examination day 90) and health
      economic assessment (EQ-5D). ETHICS AND DISSEMINATION: The Desmopressin for
      reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH) trial received
      ethical approval from the East Midlands-Nottingham 2 research ethics committee
      (18/EM/0184). The DASH trial is funded by National Institute for Health and Care 
      Research RfPB grant: PB-PG-0816-20011. Trial results will be published in a peer 
      reviewed academic journal and disseminated through academic conferences and
      through patient stroke support groups. Reporting will be in compliance with
      Consolidated Standards of Reporting Trials recommendations. TRIAL REGISTRATION
      NUMBERS: NCT03696121; ISRCTN67038373; EudraCT 2018-001904-12.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Desborough, Michael J R
AU  - Desborough MJR
AUID- ORCID: 0000-0002-1951-5616
AD  - Haemostasis and Thrombosis Centre, St Thomas' Hospital, London, UK.
FAU - Al-Shahi Salman, Rustam
AU  - Al-Shahi Salman R
AD  - Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
FAU - Stanworth, Simon J
AU  - Stanworth SJ
AD  - Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
AD  - Department of Haematology, Oxford University Hospitals NHS Foundation Trust,
      Oxford, UK.
AD  - Radcliffe Department of Medicine, University of Oxford and NIHR Oxford Biomedical
      Research Centre, Oxford, UK.
FAU - Havard, Diane
AU  - Havard D
AD  - Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
AD  - Nottignham University Hospitals NHS Trust, Nottingham, UK.
FAU - Brennan, Paul M
AU  - Brennan PM
AD  - Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
FAU - Dineen, Robert A
AU  - Dineen RA
AD  - Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
AD  - Nottignham University Hospitals NHS Trust, Nottingham, UK.
FAU - Coats, Timothy J
AU  - Coats TJ
AD  - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
FAU - Hepburn, Trish
AU  - Hepburn T
AD  - Clinical Trials Unit, University of Nottingham, Nottingham, UK.
FAU - Bath, Philip M
AU  - Bath PM
AD  - Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
AD  - Nottignham University Hospitals NHS Trust, Nottingham, UK.
FAU - Sprigg, Nikola
AU  - Sprigg N
AD  - Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
      nikola.sprigg@nottingham.ac.uk.
AD  - Nottignham University Hospitals NHS Trust, Nottingham, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03696121
SI  - ISRCTN/ISRCTN67038373
SI  - EudraCT/2018-001904-12
GR  - PB-PG-0816-20011/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - ENR1LLB0FP (Deamino Arginine Vasopressin)
SB  - IM
MH  - Clinical Trials, Phase II as Topic
MH  - Deamino Arginine Vasopressin/therapeutic use
MH  - Double-Blind Method
MH  - Feasibility Studies
MH  - Humans
MH  - *Platelet Aggregation Inhibitors/adverse effects
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/complications/drug therapy
MH  - Treatment Outcome
PMC - PMC7656949
OTO - NOTNLM
OT  - *anticoagulation
OT  - *bleeding disorders & coagulopathies
OT  - *clinical trials
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037555 [pii]
AID - 10.1136/bmjopen-2020-037555 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 10;10(11):e037555. doi: 10.1136/bmjopen-2020-037555.


PMID- 33172937
OWN - NLM
STAT- Publisher
LR  - 20220418
IS  - 2515-4478 (Electronic)
IS  - 2515-446X (Linking)
DP  - 2020 Nov 10
TI  - An evidence map of randomised controlled trials evaluating genetic therapies.
LID - bmjebm-2020-111448 [pii]
LID - 10.1136/bmjebm-2020-111448 [doi]
AB  - OBJECTIVES: Genetic therapies replace or inactivate disease-causing genes or
      introduce new or modified genes. These therapies have the potential to cure in a 
      single application rather than treating symptoms through repeated
      administrations. This evidence map provides a broad overview of the genetic
      therapies that have been evaluated in randomised controlled trials (RCTs) for
      efficacy and safety. ELIGIBILITY CRITERIA: Two independent reviewers screened
      publications using predetermined eligibility criteria. Study details and data on 
      safety and efficacy were abstracted from included trials. Results were visualised
      in an evidence map. INFORMATION SOURCES: We searched PubMed, EMBASE, Web of
      Science, ClinicalTrials.gov and grey literature to November 2018. RISK OF BIAS:
      Only RCTs were included in this review to reduce the risk of selection bias in
      the evaluation of genetic therapy safety and efficacy. INCLUDED STUDIES: We
      identified 119 RCTs evaluating genetic therapies for a variety of clinical
      conditions. SYNTHESIS OF RESULTS: On average, samples included 107 participants
      (range: 1-1022), and were followed for 15 months (range: 0-124). Interventions
      using adenoviruses (40%) to treat cardiovascular diseases (29%) were the most
      common. DESCRIPTION OF THE EFFECT: In RCTs reporting safety and efficacy
      outcomes, in the majority (60%) genetic therapies were associated with improved
      symptoms but in nearly half (45%) serious adverse event (SAEs) were also
      reported. Improvement was reported in trials treating cancer, cardiovascular,
      ocular and muscular diseases. However, only 19 trials reported symptom
      improvement for at least 1 year. STRENGTHS AND LIMITATIONS OF EVIDENCE: This is
      the first comprehensive evidence map of RCTs evaluating the safety and efficacy
      of genetic therapies. Evidence for long-term effectiveness and safety is still
      sparse. This lack of evidence has implications for the use, ethics, pricing and
      logistics of genetic therapies. INTERPRETATION: This evidence map provides a
      broad overview of research studies that allow strong evidence statements
      regarding the safety and efficacy of genetic therapies. Most interventions
      improve symptoms, but SAE are also common. More research is needed to evaluate
      genetic therapies with regard to the potential to cure diseases.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Apaydin, Eric A
AU  - Apaydin EA
AUID- ORCID: http://orcid.org/0000-0002-3044-9090
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA eapaydin@rand.org.
AD  - Center for the Study of Healthcare Innovation, Implementation and Policy, VA
      Greater Los Angeles Healthcare System, Los Angeles, California, USA.
FAU - Richardson, Andrea S
AU  - Richardson AS
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Pittsburgh, Pennsylvania, USA.
FAU - Baxi, Sangita
AU  - Baxi S
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA.
FAU - Vockley, Jerry
AU  - Vockley J
AD  - Division of Medical Genetics, Children's Hospital of Pittsburgh, University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Akinniranye, Olamigoke
AU  - Akinniranye O
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA.
FAU - Ross, Rachel
AU  - Ross R
AD  - West Los Angeles Medical Center, Kaiser Foundation Hospitals, Los Angeles,
      California, USA.
FAU - Larkin, Jody
AU  - Larkin J
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA.
FAU - Motala, Aneesa
AU  - Motala A
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA.
FAU - Azhar, Gulrez
AU  - Azhar G
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA.
FAU - Hempel, Susanne
AU  - Hempel S
AD  - Southern California Evidence-based Practice Center, Health Care, RAND
      Corporation, Santa Monica, California, USA.
AD  - Southern California Evidence Review Center, Keck School of Medicine, University
      of Southern California, Los Angeles, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201110
PL  - England
TA  - BMJ Evid Based Med
JT  - BMJ evidence-based medicine
JID - 101719009
SB  - IM
OTO - NOTNLM
OT  - evidence map
OT  - genetics
OT  - therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - bmjebm-2020-111448 [pii]
AID - 10.1136/bmjebm-2020-111448 [doi]
PST - aheadofprint
SO  - BMJ Evid Based Med. 2020 Nov 10. pii: bmjebm-2020-111448. doi:
      10.1136/bmjebm-2020-111448.


PMID- 33172909
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 10
TI  - Disclosure of non-recent (historic) childhood sexual abuse: What should
      researchers do?
LID - medethics-2020-106343 [pii]
LID - 10.1136/medethics-2020-106343 [doi]
AB  - Non-recent (historic) childhood sexual abuse is an important issue to research,
      though often regarded as taboo and frequently met with caution, avoidance or even
      opposition from research ethics committees. Sensitive research, such as that
      which asks victim-survivors to recount experiences of abuse or harm, has the
      propensity to be emotionally challenging for both the participant and the
      researcher. However, most research suggests that any distress experienced is
      usually momentary and not of any clinical significance. Moreover, this type of
      research offers a platform for voices which have often been silenced, and many
      participants report the cathartic effect of recounting their experiences in a
      safe, non-judgemental space. With regard to the course of such research, lines of
      inquiry which ask adult participants to discuss their experiences of childhood
      sexual abuse may result in a first-time disclosure of that abuse by the
      victim-survivor to the researcher. Guidance about how researchers should respond 
      to first-time disclosure is lacking. In this article, we discuss our response to 
      one research ethics committee which had suggested that for a qualitative study
      for which we were seeking ethical approval (investigating experiences of
      pregnancy and childbirth having previously survived childhood sexual abuse), any 
      disclosure of non-recent (historic) childhood sexual abuse which had not been
      previously reported would result in the researcher being obliged to report it to 
      relevant authorities. We assess this to be inconsistent with both law and
      professional guidance in the United Kingdom; and provide information and
      recommendations for researchers and research ethics committees to consider.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Silverio, Sergio A
AU  - Silverio SA
AUID- ORCID: http://orcid.org/0000-0001-7177-3471
AD  - Department of Women & Children's Health, King's College London, Westminster,
      London, UK Sergio.Silverio@kcl.ac.uk.
AD  - Elizabeth Garrett Anderson Institute for Women's Health, University College
      London, Bloomsbury, London, UK.
FAU - Bewley, Susan
AU  - Bewley S
AUID- ORCID: http://orcid.org/0000-0001-8064-652X
AD  - Department of Women & Children's Health, King's College London, Westminster,
      London, UK.
FAU - Montgomery, Elsa
AU  - Montgomery E
AUID- ORCID: http://orcid.org/0000-0002-4193-1261
AD  - Department of Midwifery, King's College London, Waterloo, London, UK.
FAU - Roberts, Chelsey
AU  - Roberts C
AUID- ORCID: http://orcid.org/0000-0002-1960-1514
AD  - Elizabeth Garrett Anderson Institute for Women's Health, University College
      London, Bloomsbury, London, UK.
FAU - Richens, Yana
AU  - Richens Y
AUID- ORCID: http://orcid.org/0000-0002-8280-4912
AD  - Elizabeth Garrett Anderson Institute for Women's Health, University College
      London, Bloomsbury, London, UK.
AD  - Maternity Services, University College London Hospitals NHS Foundation Trust,
      Fitzrovia, London, UK.
FAU - Maxted, Fay
AU  - Maxted F
AD  - The Survivors Trust, Rugby, Warwickshire, UK.
FAU - Sandall, Jane
AU  - Sandall J
AUID- ORCID: http://orcid.org/0000-0003-2000-743X
AD  - Department of Women & Children's Health, King's College London, Westminster,
      London, UK.
AD  - Centre for Midwifery, Child and Family Health, University of Technology Sydney,
      Sydney, New South Wales, Australia.
FAU - Montgomery, Jonathan
AU  - Montgomery J
AUID- ORCID: http://orcid.org/0000-0002-4592-0930
AD  - Faculty of Laws, University College London, Bloomsbury, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639901
OTO - NOTNLM
OT  - ethics
OT  - public health ethics
OT  - research ethics
OT  - research on special populations
OT  - women
COIS- Competing interests: JM was Chair of the Health Research Authority from 2012-19
      and Chair of the Task and Finish Group that supported the development of the
      GMC's guidance on Confidentiality: Good practice in handling patient information 
      (2017).
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/11/11 05:50
PHST- 2020/04/24 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/11 05:50 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - medethics-2020-106343 [pii]
AID - 10.1136/medethics-2020-106343 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 10. pii: medethics-2020-106343. doi:
      10.1136/medethics-2020-106343.


PMID- 33172467
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Nov 10
TI  - Validation of a Spanish version of the health-related quality of life (HRQoL)
      measure for Chronic Otitis Media (COMQ-12).
PG  - 362
LID - 10.1186/s12955-020-01616-5 [doi]
AB  - BACKGROUND: Evaluation of health-related quality of life (HRQoL) is considered an
      important aspect of clinical assessment and health research. Chronic Otitis Media
      (COM) is related to the quality of life deterioration subsequent to COM symptoms,
      social communication impairments, and lower work performance. However, there is
      no reliable information regarding the impact of this disease on health and
      quality of life in many resource-poor countries. Therefore, we translated into
      Spanish the Chronic Otitis Media Questionnaire-12 (COMQ-12) for the evaluation of
      HRQoL of Chronic Otitis Media (COM) in adult patients. Also, we assessed the
      psychometric properties of the Spanish version of the questionnaire. METHODS: Two
      otology referral centers in Bogota, Colombia were included. The Spanish version
      of COMQ-12 was applied twice to 200 adult patients with confirmed COM diagnosis
      and 31 healthy controls to perform the validation process and assess the internal
      consistency of this questionnaire. Psychometric characteristics (internal
      consistency, test-retest reliability, and construct validity) of the COMQ-12 were
      assessed. Exploratory Factor Analysis and Confirmatory Factor Analysis were
      conducted via structural equation modeling to test the questionnaire's structure.
      RESULTS: The Spanish version of the COMQ-12 showed good internal consistency
      (Cronbach's Alpha: 0.86, McDonald's Omega: 0.89). Coefficients corresponding to
      Lin's Concordance test and test-retest reliability were 0.95 and 0.83
      respectively. Correlation between the Visual Analogue Scale (VAS) and the COMQ-12
      was 0.68 (95% CI 0.59-0.75, p value < 0.001). Factor analysis of the Spanish
      version of the COMQ-12 indicated a questionnaire structure with three domains:
      smelly discharge related symptoms; hearing loss related symptoms; and impact on
      work, lifestyle, and health services. CONCLUSION: This Spanish version of the
      COMQ-12 showed high reliability and high internal consistency. This questionnaire
      can be used as an objective clinical tool to assess the HRQoL of patients who
      have a COM diagnosis. TRIAL REGISTRATION: Hospital Universitario Fundacion Santa 
      Fe, Ethical Committee Registration ID: CCEI-8807-2018. Hospital de San Jose,
      Ethical Committee: Record number 500, DI-I-0632-18.
FAU - Otoya-Tono, Ana M
AU  - Otoya-Tono AM
AD  - Fundacion Universitaria de Ciencias de la Salud - Hospital de San Jose, Bogota,
      Colombia.
FAU - Perez-Herrera, Lucia C
AU  - Perez-Herrera LC
AD  - Universidad de Los Andes, Cra 1 N masculine 18A - 12, Bogota, Colombia.
AD  - Otolaryngology and Allergology Research Groups, Unimeq-Orl, Bogota, Colombia.
FAU - Penaranda, Daniel
AU  - Penaranda D
AD  - Fundacion Universitaria de Ciencias de la Salud - Hospital de San Jose, Bogota,
      Colombia.
FAU - Moreno-Lopez, Sergio
AU  - Moreno-Lopez S
AD  - Universidad de Los Andes, Cra 1 N masculine 18A - 12, Bogota, Colombia.
AD  - Otolaryngology and Allergology Research Groups, Unimeq-Orl, Bogota, Colombia.
FAU - Sanchez-Pedraza, Ricardo
AU  - Sanchez-Pedraza R
AD  - Clinical Research Institute, Universidad Nacional de Colombia, Bogota, Colombia.
FAU - Garcia, Juan Manuel
AU  - Garcia JM
AD  - Fundacion Universitaria de Ciencias de la Salud - Hospital de San Jose, Bogota,
      Colombia.
AD  - Universidad de Los Andes, Cra 1 N masculine 18A - 12, Bogota, Colombia.
AD  - Hospital Universitario Fundacion Santa Fe de Bogota, Cra. 7 #117 - 15, Bogota,
      Colombia.
FAU - Phillips, John S
AU  - Phillips JS
AD  - Ear, Nose and Throat Department, Norfolk and Norwich University Hospital
      Foundation Trust, Norwich, Norfolk, UK.
FAU - Penaranda, Augusto
AU  - Penaranda A
AUID- ORCID: http://orcid.org/0000-0003-1598-8472
AD  - Universidad de Los Andes, Cra 1 N masculine 18A - 12, Bogota, Colombia.
      augpenar@gmail.com.
AD  - Hospital Universitario Fundacion Santa Fe de Bogota, Cra. 7 #117 - 15, Bogota,
      Colombia. augpenar@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Validation Study
DEP - 20201110
PL  - England
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Chronic Disease/psychology
MH  - Colombia
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Otitis Media/*psychology
MH  - Psychometrics/instrumentation
MH  - *Quality of Life
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires/*standards
PMC - PMC7654037
OTO - NOTNLM
OT  - COMQ-12
OT  - Chronic Suppurative Otitis Media
OT  - Health-related quality of life
OT  - Validity
EDAT- 2020/11/12 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/11/11 05:36
PHST- 2020/02/14 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/11 05:36 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - 10.1186/s12955-020-01616-5 [doi]
AID - 10.1186/s12955-020-01616-5 [pii]
PST - epublish
SO  - Health Qual Life Outcomes. 2020 Nov 10;18(1):362. doi:
      10.1186/s12955-020-01616-5.


PMID- 33172466
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201218
IS  - 1472-6874 (Electronic)
IS  - 1472-6874 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 10
TI  - COVID-19 and violence: a research call to action.
PG  - 249
LID - 10.1186/s12905-020-01115-1 [doi]
AB  - COVID-19 related guidelines and movement restrictions are designed to protect the
      public's health and reduce disease transmission; yet, COVID-19 related
      restrictions on movement including social distancing, isolation, quarantine, and 
      shelter-in-place orders have an unknown effect on violence and abuse within
      relationships. As the pandemic has progressed, many have justifiably speculated
      that such restrictions may pose a danger to the safety and well-being of people
      experiencing such violence. Early in the pandemic, countries hard hit by COVID-19
      began raising the alarm bell about the impacts of the disease on IPV occurrence. 
      Police in China report that 90% of the causes of recent IPV cases could be
      attributed to the COVID-19 epidemic. Rising fears and anxiety about prolonged
      movement restrictions, increased economic strain and diminished health care
      capacity to support survivors are among the potential reasons for such dramatic
      effects. Under normal circumstances: low income, unemployment, economic stress,
      depression, emotional insecurity and social isolation are all risk factors for
      using violence against partners. Many of these factors may worsen in the context 
      of COVID-19. Despite the urgency in addressing COVID-19, existing health concerns
      like Intimate Partner Violence (IPV) persist-and may well be worsened by the
      virus. We simply do not yet know the effects of COVID-19 on violence, nor do we
      know which interventions work best to prevent and respond to it within the
      context of the pandemic. The vast majority of information available about IPV and
      violence during the pandemic has been based on anecdotal reports. The call to
      action for the research community is clear. We must systematically measure the
      effects of COVID-19 and movement related restrictions on violence. As always when
      researching violence, serious consideration must be given to ethics and safety.
      Violence researchers must mobilize to investigate the impacts of COVID-19 on
      violence and human health.
FAU - Evans, Dabney P
AU  - Evans DP
AUID- ORCID: 0000-0002-2201-5655
AD  - Hubert Department of Global Health, Emory University, 1518 Clifton Rd, NE,
      Atlanta, GA, 30322, USA. Dabney.evans@emory.edu.
LA  - eng
PT  - Letter
DEP - 20201110
PL  - England
TA  - BMC Womens Health
JT  - BMC women's health
JID - 101088690
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - China
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Intimate Partner Violence
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Research/trends
MH  - SARS-CoV-2
PMC - PMC7653443
OTO - NOTNLM
OT  - *COVID-19
OT  - *Emergencies
OT  - *Intimate partner violence
OT  - *Pandemic
OT  - *Research
OT  - *Violence against women
EDAT- 2020/11/12 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/11/11 05:36
PHST- 2020/06/11 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/11 05:36 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1186/s12905-020-01115-1 [doi]
AID - 10.1186/s12905-020-01115-1 [pii]
PST - epublish
SO  - BMC Womens Health. 2020 Nov 10;20(1):249. doi: 10.1186/s12905-020-01115-1.


PMID- 33172395
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 10
TI  - Adding ursodeoxycholic acid to the endoscopic treatment and common bile duct
      stenting for large and multiple biliary stones: Will it improve the outcomes?
PG  - 374
LID - 10.1186/s12876-020-01523-5 [doi]
AB  - BACKGROUND: The role of common bile duct (CBD) stenting in the establishment of
      bile stream in the elderly patients and the ones who are not good candidates for 
      surgery due to not responding to treatments was well documented in previous
      studies. The current study aimed at investigating the effect of adding
      Ursodeoxycholic acid (UDCA) to CBD stenting alone in order to reduce the size of 
      large and multiple CBD stones. METHODS: Clinical outcomes including success rates
      in CBD stones clearance, incidence of pancreatitis, perforation, bleeding, as
      well as, decrease in size of stones and liver enzymes after a two-month period
      were assessed in the UDCA + CBD stenting group. RESULTS: A total of 64 patients
      referring to Shahid Beheshti Hospital in Qom, Iran with multiple or large CBD
      stones (above three or larger than 15 mm) received standard endoscopic therapies 
      and UDCA + CBD stenting (group B) and controls only received standard endoscopic 
      therapies with only CBD stenting (group A). The mean reduction in the size of
      stones in group B was significantly higher than that of group A (3.22 +/- 1.31 vs
      4.09 +/- 1.87 mm) (p = 0.034). There was no difference in the incidence rate of
      complications including pancreatitis, cholangitis, bleeding, and perforation
      between the two groups (P > 0.05). CONCLUSION: Adding UDCA to CBD stenting, due
      to decrease in the stone size and subsequently facilitation of the stones outlet,
      can be considered as the first-line treatment for patients with large and
      multiple CBD stones. Also, in the cases with large or multi stones may be
      effective in reducing size and subsequently stone retrieval. Trial registry The
      study protocol was approved by the Ethics Committee of Qom University of Medical 
      Sciences (ethical code: IR.MUQ.REC.1397.075); the study was also registered in
      the Iranian Registry of Clinical Trials (No. IRCT20161205031252N8). This study
      adheres to CONSORT guidelines.
FAU - Hormati, Ahmad
AU  - Hormati A
AUID- ORCID: http://orcid.org/0000-0002-1322-1318
AD  - Gastroenterology and Hepatology Diseases Research Center, Qom University of
      Medical Sciences, Qom, Iran.
AD  - Gastrointestinal and Liver Diseases Research Center, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Ghadir, Mohammad Reza
AU  - Ghadir MR
AUID- ORCID: http://orcid.org/0000-0001-5674-3477
AD  - Gastroenterology and Hepatology Diseases Research Center, Qom University of
      Medical Sciences, Qom, Iran.
FAU - Sarkeshikian, Seyed Saeed
AU  - Sarkeshikian SS
AD  - Gastroenterology and Hepatology Diseases Research Center, Qom University of
      Medical Sciences, Qom, Iran.
FAU - Alemi, Faezeh
AU  - Alemi F
AUID- ORCID: http://orcid.org/0000-0002-5702-7410
AD  - Gastroenterology and Hepatology Diseases Research Center, Qom University of
      Medical Sciences, Qom, Iran. faezeh.alemi@gmail.com.
FAU - Moghaddam, Majid
AU  - Moghaddam M
AUID- ORCID: http://orcid.org/0000-0003-0789-4871
AD  - Gastroenterology and Hepatology Diseases Research Center, Qom University of
      Medical Sciences, Qom, Iran.
FAU - Ahmadpour, Sajjad
AU  - Ahmadpour S
AUID- ORCID: http://orcid.org/0000-0003-4321-874X
AD  - Gastroenterology and Hepatology Diseases Research Center, Qom University of
      Medical Sciences, Qom, Iran.
FAU - Mohammadbeigi, Abolfazl
AU  - Mohammadbeigi A
AUID- ORCID: http://orcid.org/0000-0002-3142-6413
AD  - Research Center for Environmental Pollutants, Qom University of Medical Sciences,
      Qom, Iran.
FAU - Sivandzadeh, Gholam Reza
AU  - Sivandzadeh GR
AUID- ORCID: http://orcid.org/0000-0001-5461-5754
AD  - Department of Internal Medicine, Gatroenterohepatology Research Center, Shiraz
      University of Medical Sciences, Shiraz, Iran.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20201110
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 724L30Y2QR (Ursodeoxycholic Acid)
SB  - IM
MH  - Aged
MH  - *Cholangiopancreatography, Endoscopic Retrograde/adverse effects
MH  - Common Bile Duct
MH  - Humans
MH  - Iran
MH  - *Sphincterotomy, Endoscopic/adverse effects
MH  - Treatment Outcome
MH  - *Ursodeoxycholic Acid/therapeutic use
PMC - PMC7653844
OTO - NOTNLM
OT  - Cholangiopancreatography
OT  - Cholelithiasis
OT  - Common bile duct
OT  - Endoscopic
OT  - Endoscopic retrograde
OT  - Gallstones
OT  - Sphincterotomy
OT  - Ursodiol
EDAT- 2020/11/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/11/11 05:35
PHST- 2020/09/01 00:00 [received]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/11 05:35 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - 10.1186/s12876-020-01523-5 [doi]
AID - 10.1186/s12876-020-01523-5 [pii]
PST - epublish
SO  - BMC Gastroenterol. 2020 Nov 10;20(1):374. doi: 10.1186/s12876-020-01523-5.


PMID- 33172338
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1813-4424 (Electronic)
IS  - 1729-0376 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Dec
TI  - Attitudes and beliefs of immigrants regarding HIV and AIDS in Mopani district,
      South Africa.
PG  - 16-21
LID - 10.1080/17290376.2020.1831582 [doi]
AB  - Sub-Saharan Africa faces and is severely affected by many conflicts. Human
      Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS)
      threaten both the physical and financial well-being of individuals in these
      struggling countries. This research aims to investigate the immigrants' attitudes
      and beliefs regarding HIV/AIDS in the Mopani district, Limpopo Province.
      Qualitative and quantitative designs were used, and 200 immigrants were sampled. 
      Data was collected using a questionnaire with closed and open-ended questions.
      Ethical standards were maintained. The study revealed that many respondents
      expressed discriminatory practices towards individuals infected by HIV. Many
      viewed promiscuity and the disease called Makhume (meaning illness caused by the 
      omission of purification rites following the death of a family member) as causes 
      of HIV/AIDS. These attitudes could hinder the achievement of healthy lives and
      the promotion of well-being at all ages if not addressed appropriately. The
      collaboration of various departments in the Mopani district is required to change
      these negative attitudes and beliefs that influence immigrants' behaviours. Also,
      the use of audio-visuals and peer teaching is most successful in changing
      attitudes and beliefs.
FAU - Khoza, Lunic B
AU  - Khoza LB
AUID- ORCID: 0000-0003-1368-8759
AD  - Department of Advanced Nursing Science, University of Venda, Thohoyandou, South
      Africa.
FAU - Shilubane, Hilda N
AU  - Shilubane HN
AUID- ORCID: 0000-0002-6121-0488
AD  - Department of Advanced Nursing Science, University of Venda, Thohoyandou, South
      Africa.
FAU - Lowane, Mygirl P
AU  - Lowane MP
AUID- ORCID: 0000-0002-1705-5919
AD  - Department of Public Health, Sefako Makgato Health Sciences University, Pretoria,
      South Africa.
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - SAHARA J
JT  - SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance
JID - 101226212
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*epidemiology/*psychology
MH  - Adult
MH  - Emigrants and Immigrants/*psychology/*statistics & numerical data
MH  - Female
MH  - HIV Infections/*epidemiology/*psychology
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Social Stigma
MH  - South Africa/epidemiology
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7671655
OTO - NOTNLM
OT  - *Attitudes
OT  - *HIV/AIDS
OT  - *beliefs
OT  - *immigrants
EDAT- 2020/11/12 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/11/11 05:35
PHST- 2020/11/11 05:35 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.1080/17290376.2020.1831582 [doi]
PST - ppublish
SO  - SAHARA J. 2020 Dec;17(1):16-21. doi: 10.1080/17290376.2020.1831582.


PMID- 33171862
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 7
TI  - An Evaluation of Portuguese Societal Opinion towards the Practice of
      Bullfighting.
LID - E2065 [pii]
LID - 10.3390/ani10112065 [doi]
AB  - Bullfighting is a controversial sport that continues to be legally permitted in a
      number of countries around the world, including Portugal. The spectacle has
      attracted significant attention from animal protectionist groups for many years
      because of concerns for animal distress, pain, and suffering during the fights.
      While there has been strong support for the sport in Portugal in the past, there 
      is a need to study social profiles regarding the acceptability of this sport
      before a case can be made for changes in regional and national legislation. In
      this study, Portuguese attendance patterns at bullfights were assessed in
      addition to public opinions on welfare and ethical aspects of bullfighting, based
      on demographic variables. Study participants (n = 8248) were largely recruited
      through Portuguese social media channels (respondents may not be representative
      of the Portuguese population). Questionnaire data were evaluated by means of
      frequency tables, multiple correspondence analyses, and a two-step cluster
      analysis. Most respondents had a negative opinion about bullfighting and
      perceived that bullfighting had no positive impact on the country. However, while
      most respondents thought that the bull suffered during bullfighting, the opinion 
      regarding banning bullfighting was far from unanimous. Based on the demographic
      analysis, the profile of individuals with more favorable responses towards
      bullfighting were men > 65 years old, of Roman Catholic faith, of low- or
      high-income levels, from more rural areas of Portugal. Somewhat surprisingly,
      there was a tendency to favor bullfighting amongst veterinary professionals. We
      conclude that there were still large pockets of individuals who desire to
      maintain the practice of traditional bullfighting within Portuguese society,
      despite recognition of animal suffering during the event.
FAU - Dieguez, Francisco Javier
AU  - Dieguez FJ
AUID- ORCID: 0000-0003-3642-481X
AD  - Departamento de Anatomia, Produccion Animal y Ciencias Clinicas Veterinarias,
      Facultad de Veterinaria, Universidad de Santiago de Compostela, Campus
      Universitario s/n, 27002 Lugo, Spain.
FAU - Zau, Yara
AU  - Zau Y
AD  - MYPZ-Farma&Vet, Av. Joaquim Agostinho 8; Loja B, Santa Cruz, 2560-065
      A-Dos-Cunhados-Torres Vedras, Portugal.
FAU - Viegas, Ines
AU  - Viegas I
AD  - ICAAM-Mediterranean Institute of Agronomical and Environmental Sciences,
      Institute for Advanced Research and Formation, Evora University, Polo da Mitra,
      Ap. 94, 7006-554 Evora, Portugal.
FAU - Fragoso, Sara
AU  - Fragoso S
AD  - Centro Para o Conhecimento Animal. Av. Bombeiros Voluntarios de Alges 40A,
      1495-143 Alges, Portugal.
AD  - LabCAP-Instituto Superior de Estudos Interculturais e Transdisciplinares (ISEIT),
      Instituto Piaget de Almada, Avenida Jorge Peixinho, 30 Quinta da Arreinela,
      2805-059 Almada, Portugal.
FAU - Turner, Patricia V
AU  - Turner PV
AUID- ORCID: 0000-0003-1547-0139
AD  - Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
AD  - Charles River Laboratories, Wilmington, MA 01887, USA.
FAU - da Graca-Pereira, Goncalo
AU  - da Graca-Pereira G
AD  - Centro Para o Conhecimento Animal. Av. Bombeiros Voluntarios de Alges 40A,
      1495-143 Alges, Portugal.
AD  - Escola Superior Agraria de Elvas, Instituto Politecnico de Portalegre, Av. 14 de 
      Janeiro 13, 7350-092 Elvas, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7695134
OTO - NOTNLM
OT  - Portugal
OT  - animal ethics
OT  - animal welfare
OT  - demography
OT  - multiple correspondence analysis
OT  - tauromachy
EDAT- 2020/11/12 06:00
MHDA- 2020/11/12 06:01
CRDT- 2020/11/11 01:02
PHST- 2020/07/29 00:00 [received]
PHST- 2020/10/29 00:00 [revised]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/11 01:02 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2020/11/12 06:01 [medline]
AID - ani10112065 [pii]
AID - 10.3390/ani10112065 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Nov 7;10(11). pii: ani10112065. doi: 10.3390/ani10112065.


PMID- 33171478
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20210930
IS  - 1423-0305 (Electronic)
IS  - 1016-2291 (Linking)
VI  - 55
IP  - 5
DP  - 2020
TI  - The Glasgow Outcome Scale-Extended Pediatric Scores of Intracranial Bleeding
      Patients with Acquired Prothrombin Complex Deficiency Post Craniotomy and
      Duraplasty.
PG  - 254-258
LID - 10.1159/000511020 [doi]
AB  - INTRODUCTION: Surgical evacuation of intracranial bleeding in pediatric patients 
      due to acquired prothrombin complex deficiency (APCD) is a life-saving surgery
      when conservative treatment insufficient and impending brain herniation. This
      study aimed to evaluate the Glasgow outcome scale-extended pediatric (GOS-ePed)
      score of the pediatric intracranial bleeding patients with APCD after craniotomy 
      and duraplasty. METHOD: This was a retrospective study in the last 5 years of our
      experience. All of the pediatric patients with intracranial bleeding due to APCD 
      who needed surgery were investigated. The data were collected from medical
      records after their parents have given their written informed concern and
      approved by the Ethics Review Committee, Faculty of Medicine, Universitas Kristen
      Indonesia. The inclusion criteria were patients who operated on by craniotomy and
      duraplasty. The patient with a second disease was excluded. Blood tests include
      hemoglobin, prothrombin time, activated prothrombin time, and platelets were
      investigated before and after intravenous vitamin K injection, transfusion packed
      red cells (PRCs), and fresh frozen plasma (FFP) administration. The Glasgow coma 
      scale (GCS) pre- and postoperatively was evaluated using a modified GCS for
      infants and children. The outcome was evaluated by the GOS-ePed score. All data
      were analyzed with the normality test and paired t test. RESULTS: There were 5
      patients age between 37 and 60 days, and all patients did not get vitamin K
      prophylaxis after birth. The blood tests of all patients revealed anemia,
      prothrombin, and activated prothrombin time increased, but platelets were normal.
      All these values returned to normal after vitamin K injection, transfusion of
      PRCs, and FFP. The paired t tests were p < 0.05. The GCS of all patients before
      surgery was 8 or below. After surgery, the GCS of 4 patients was increased become
      12 and 15. One patient did not change significantly. The GOS-ePed score showed 4 
      patients (80%) had upper or lower good recovery, and 1 patient (20%) was in a
      vegetative state. CONCLUSIONS: The GOS-ePed score of the pediatric intracranial
      bleeding with APCD after craniotomy and duraplasty was mostly in upper or lower
      good recovery.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Sinurat, Robert
AU  - Sinurat R
AD  - Surgery Department, Medical Faculty of Universitas Kristen Indonesia, Jakarta,
      Indonesia, robertsinurat@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - Switzerland
TA  - Pediatr Neurosurg
JT  - Pediatric neurosurgery
JID - 9114967
RN  - Acquired hypoprothrombinemia
SB  - IM
MH  - Craniotomy/*standards/trends
MH  - Glasgow Outcome Scale/*standards/trends
MH  - Humans
MH  - Hypoprothrombinemias/blood/*diagnostic imaging/*surgery
MH  - Infant
MH  - Intracranial Hemorrhages/blood/*diagnostic imaging/*surgery
MH  - Male
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acquired prothrombin complex deficiency
OT  - Craniotomy
OT  - Duraplasty
OT  - GOS-ePed score
OT  - Intracranial bleeding
EDAT- 2020/11/11 06:00
MHDA- 2021/10/01 06:00
CRDT- 2020/11/10 20:15
PHST- 2020/01/21 00:00 [received]
PHST- 2020/08/15 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2020/11/10 20:15 [entrez]
AID - 000511020 [pii]
AID - 10.1159/000511020 [doi]
PST - ppublish
SO  - Pediatr Neurosurg. 2020;55(5):254-258. doi: 10.1159/000511020. Epub 2020 Nov 10.


PMID- 33170165
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 13-S
DP  - 2020 Nov 9
TI  - Ethics committees for clinical experimentation at international level with a
      focus on Italy.
PG  - e2020016
LID - 10.23750/abm.v91i13-S.10643 [doi]
AB  - Guiding legislation and associated bureaucracy for the ethical review of clinical
      trials observational studies and food related research play an important role in 
      the competitiveness of a nation in the face of tough global competition to
      attract sponsors and investigators. This is of particular relevance in the case
      of multicentre trials and multidisciplinary research. Accordingly, in this report
      we tried to gather in-depth knowledge of the current role and practices of ethics
      committees nationwide in both clinical and research settings. This mini-review
      aims to describe the formulation and organization of ethical committees in Italy 
      in order to provide a focus for deliberations on ethical issues in medical and
      scientific research in line with human rights, as set out in the European Union
      charter. Furthermore, we evaluated the impact of an institution's ethical
      committee intervention on reducing the time required to obtain an opinion from
      Research Ethics Committees by guiding investigators in addressing ethical issues 
      in their proposed studies.
FAU - Naureen, Zakira
AU  - Naureen Z
AD  - Department of Biological Sciences and Chemistry, College of Arts and Sciences,
      University of Nizwa, Nizwa, Oman. zakiranaureen@gmail.com.
FAU - Beccari, Tommaso
AU  - Beccari T
AD  - Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
      tommaso.beccari@unipg.it.
FAU - Marks, Robert S
AU  - Marks RS
AD  - Avram and Stella Goldstein-Goren Department of Biotechnology Engineering,
      Ben-Gurion University of the Negev, Beer-Sheva, Israel. rsmarks@bgu.ac.il.
FAU - Brown, Richard
AU  - Brown R
AD  - Department of Psychology and Neuroscience, Dalhousie University, Halifax, Nova
      Scotia, Canada. Richard.Brown@Dal.Ca.
FAU - Lorusso, Lorenzo
AU  - Lorusso L
AD  - Neurology Unit, ASST-Lecco, Merate (LC), Italy. lorusso.lorenzo@gmail.com.
FAU - Pheby, Derek
AU  - Pheby D
AD  - Visiting Professor of Epidemiology (retired), Buckinghamshire New University,
      High Wycombe, UK. derekpheby@btinternet.com.
FAU - Miertus, Stanislav
AU  - Miertus S
AD  - Department of Biotechnology, University of SS. Cyril and Methodius, Trnava,
      Slovakia. stanislav.miertus@ucm.sk.
FAU - Herbst, Karen L
AU  - Herbst KL
AD  - College of Medicine, University of Arizona, Tucson, Arizona, United States.
      kaherbst@gmail.com.
FAU - Stuppia, Liborio
AU  - Stuppia L
AD  - Department of Psychological, Health and Territorial Sciences, School of Medicine 
      and Health Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
      stuppia@unich.it.
FAU - Henehan, Gary
AU  - Henehan G
AD  - School of Food Science and Environmental Health, Technological University Dublin,
      Dublin 1, Ireland. gary.henehan@TUDublin.ie.
FAU - Falsini, Benedetto
AU  - Falsini B
AD  - Institute of Ophthalmology, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
      Benedetto.Falsini@unicatt.it.
FAU - Lumer, Ludovica
AU  - Lumer L
AD  - Department of Anatomy and Developmental Biology, Univerity College London,
      London, UK. ludovicalumer@yahoo.com.
FAU - Dundar, Munis
AU  - Dundar M
AD  - Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri,
      Turkey. dundar@erciyes.edu.tr.
FAU - Bertelli, Matteo
AU  - Bertelli M
AD  - EBTNA-LAB, Rovereto (TN), Italy; MAGI EUREGIO, Bolzano, Italy; MAGI'S LAB,
      Rovereto (TN), Italy. matteo.bertelli@assomagi.org.
FAU - Study Group, International Bioethical
AU  - Study Group IB
AD  - International Bioethical Study Group. matteo.bertelli@assomagi.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201109
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - *Ethical Review
MH  - *Ethics Committees, Research
MH  - European Union
MH  - Humans
MH  - Italy
MH  - Research Design
PMC - PMC8023139
EDAT- 2020/11/11 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/11/10 12:12
PHST- 2020/09/15 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/10 12:12 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.23750/abm.v91i13-S.10643 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Nov 9;91(13-S):e2020016. doi: 10.23750/abm.v91i13-S.10643.


PMID- 33170161
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 13-S
DP  - 2020 Nov 9
TI  - Genetic test for the prescription of diets in support of physical activity.
PG  - e2020011
LID - 10.23750/abm.v91i13-S.10584 [doi]
AB  - Owing to the fields of nutrigenetics and nutrigenomics today we can think of
      devising approaches to optimize health, delay onset of diseases and reduce its
      severity according to our genetic blue print. However this requires a deep
      understanding of nutritional impact on expression of genes that may result in a
      specific phenotype. The extensive research and observational studies during last 
      two decades reporting interactions between genes, diet and physical activity
      suggest a cross talk between various genetic and environmental factors and
      lifestyle interventions. Although considerable efforts have been made in
      unraveling the mechanisms of gene-diet interactions the scientific evidences
      behind developing commercial genetic tests for providing personalized nutrition
      recommendations are still scarce. In this scenario the current mini-review aims
      to provide useful insights into salient feature of nutrition based genetic
      research and its commercial application and the ethical issue and concerns
      related to its outcome.
FAU - Naureen, Zakira
AU  - Naureen Z
AD  - Department of Biological Sciences and Chemistry, College of Arts and Sciences,
      University of Nizwa, Nizwa, Oman. zakiranaureen@gmail.com.
FAU - Miggiano, Giacinto Abele Donato
AU  - Miggiano GAD
AD  - Human Nutrition Research Center, Sacro Cuore Catholic University, Rome, Italy.
      GiacintoAbele.Miggiano@unicatt.it.
FAU - Aquilanti, Barbara
AU  - Aquilanti B
AD  - UOC Nutrizione Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS,
      Rome, Italy. barbara.aquilanti@policlinicogemelli.it.
FAU - Velluti, Valeria
AU  - Velluti V
AD  - UOC Nutrizione Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS,
      Rome, Italy. valeriavelluti@gmail.com.
FAU - Matera, Giuseppina
AU  - Matera G
AD  - UOC Nutrizione Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS,
      Rome, Italy. giusmatera@yahoo.it.
FAU - Gagliardi, Lucilla
AU  - Gagliardi L
AD  - UOC Nutrizione Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS,
      Rome, Italy. lucilla.gagliardi@gmail.com.
FAU - Zulian, Alessandra
AU  - Zulian A
AD  - MAGI'S LAB, Rovereto (TN), Italy. alessandra.zulian@assomagi.org.
FAU - Romanelli, Roberta
AU  - Romanelli R
AD  - MAGI'S LAB, Rovereto (TN), Italy. roberta.romanelli@assomagi.org.
FAU - Bertelli, Matteo
AU  - Bertelli M
AD  - MAGI'S LAB, Rovereto (TN), Italy; MAGI EUREGIO, Bolzano, Italy; EBTNA-LAB,
      Rovereto (TN), Italy. matteo.bertelli@assomagi.org.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - *Diet
MH  - Exercise
MH  - Genetic Testing
MH  - *Nutrigenomics
MH  - Prescriptions
PMC - PMC8023120
EDAT- 2020/11/11 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/11/10 12:12
PHST- 2020/09/03 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/11/10 12:12 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.23750/abm.v91i13-S.10584 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Nov 9;91(13-S):e2020011. doi: 10.23750/abm.v91i13-S.10584.


PMID- 33169563
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201218
IS  - 1872-2075 (Electronic)
IS  - 1000-3061 (Linking)
VI  - 36
IP  - 10
DP  - 2020 Oct 25
TI  - [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].
PG  - 1970-1978
LID - 10.13345/j.cjb.200216 [doi]
AB  - At present, SARS-CoV-2 is raging, and novel coronavirus pneumonia (COVID-19) has 
      caused more than 35 million confirmed patients and more than 500 000 cases death,
      which seriously endanger human health, socioeconomic development, as well as
      global medical and public health systems. COVID-19 is highly contagious, has a
      long incubation period, and causes many death cases due to lack of effective
      specific treatment. Mesenchymal stem cells have powerful anti-inflammatory and
      immunoregulatory functions, and can effectively reduce the cytokine storm caused 
      by coronavirus in patients, and improve the pulmonary fibrosis of patients,
      promote the repair of damaged lung tissue, and reduce the mortality. Currently, a
      number of related clinical trials of mesenchymal stem cell treatment of COVID-19 
      have been conducted, and have confirmed the safety and efficacy, suggesting a
      good clinical application prospect. While progress has been made in mesenchymal
      stem cell therapy for COVID-19, we should also catch sight of the problems and
      challenges faced by mesenchymal stem cell clinical trials under severe epidemic
      situation, including clinical trials design, stem cell quality management, and
      ethics in treatment. Only by paying attention to these can we guarantee the safe 
      and effective development of mesenchymal stem cell clinical trials in the
      treatment of COVID-19.
FAU - Wang, Jiayi
AU  - Wang J
AD  - Stem Cell Clinical Research Institute, the First Affiliated Hospital of Dalian
      Medical University, Dalian 116000, Liaoning, China.
AD  - Dalian Stem Cell and Precision Medicine Innovation Institute, Dalian 116000,
      Liaoning, China.
FAU - Zou, Wei
AU  - Zou W
AD  - Dalian Stem Cell and Precision Medicine Innovation Institute, Dalian 116000,
      Liaoning, China.
AD  - College of Life Sciences, Liaoning Normal University, Dalian 116029, Liaoning,
      China.
FAU - Liu, Jing
AU  - Liu J
AD  - Stem Cell Clinical Research Institute, the First Affiliated Hospital of Dalian
      Medical University, Dalian 116000, Liaoning, China.
AD  - Dalian Stem Cell and Precision Medicine Innovation Institute, Dalian 116000,
      Liaoning, China.
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Sheng Wu Gong Cheng Xue Bao
JT  - Sheng wu gong cheng xue bao = Chinese journal of biotechnology
JID - 9426463
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic
MH  - Coronavirus Infections/*therapy
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*cytology
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - clinical trail
OT  - immune regulation
OT  - mesenchymal stem cells
OT  - regeneration and repair
EDAT- 2020/11/11 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/11/10 05:50
PHST- 2020/11/10 05:50 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.13345/j.cjb.200216 [doi]
PST - ppublish
SO  - Sheng Wu Gong Cheng Xue Bao. 2020 Oct 25;36(10):1970-1978. doi:
      10.13345/j.cjb.200216.


PMID- 33169295
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2509-9280 (Electronic)
IS  - 2509-9280 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Nov 10
TI  - Impact of inter-reader contouring variability on textural radiomics of colorectal
      liver metastases.
PG  - 62
LID - 10.1186/s41747-020-00189-8 [doi]
AB  - BACKGROUND: Radiomics is expected to improve the management of metastatic
      colorectal cancer (CRC). We aimed at evaluating the impact of liver lesion
      contouring as a source of variability on radiomic features (RFs). METHODS: After 
      Ethics Committee approval, 70 liver metastases in 17 CRC patients were segmented 
      on contrast-enhanced computed tomography scans by two residents and checked by
      experienced radiologists. RFs from grey level co-occurrence and run length
      matrices were extracted from three-dimensional (3D) regions of interest (ROIs)
      and the largest two-dimensional (2D) ROIs. Inter-reader variability was evaluated
      with Dice coefficient and Hausdorff distance, whilst its impact on RFs was
      assessed using mean relative change (MRC) and intraclass correlation coefficient 
      (ICC). For the main lesion of each patient, one reader also segmented a circular 
      ROI on the same image used for the 2D ROI. RESULTS: The best inter-reader
      contouring agreement was observed for 2D ROIs according to both Dice coefficient 
      (median 0.85, interquartile range 0.78-0.89) and Hausdorff distance (0.21 mm,
      0.14-0.31 mm). Comparing RF values, MRC ranged 0-752% for 2D and 0-1567% for 3D. 
      For 24/32 RFs (75%), MRC was lower for 2D than for 3D. An ICC > 0.90 was observed
      for more RFs for 2D (53%) than for 3D (34%). Only 2/32 RFs (6%) showed a
      variability between 2D and circular ROIs higher than inter-reader variability.
      CONCLUSIONS: A 2D contouring approach may help mitigate overall inter-reader
      variability, albeit stable RFs can be extracted from both 3D and 2D segmentations
      of CRC liver metastases.
FAU - Rizzetto, Francesco
AU  - Rizzetto F
AD  - Department of Radiology, ASST Grande Ospedale Metropolitano Niguarda, Piazza
      Ospedale Maggiore 3, 20162, Milan, Italy.
FAU - Calderoni, Francesca
AU  - Calderoni F
AD  - Department of Medical Physics, ASST Grande Ospedale Metropolitano Niguarda,
      Piazza Ospedale Maggiore 3, 20162, Milan, Italy.
FAU - De Mattia, Cristina
AU  - De Mattia C
AD  - Department of Medical Physics, ASST Grande Ospedale Metropolitano Niguarda,
      Piazza Ospedale Maggiore 3, 20162, Milan, Italy.
FAU - Defeudis, Arianna
AU  - Defeudis A
AD  - Department of Surgical Sciences, University of Turin, via Verdi 8, 10124, Turin, 
      Italy.
AD  - Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 km
      3.95, 10060, Candiolo, Turin, Italy.
FAU - Giannini, Valentina
AU  - Giannini V
AD  - Department of Surgical Sciences, University of Turin, via Verdi 8, 10124, Turin, 
      Italy.
AD  - Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 km
      3.95, 10060, Candiolo, Turin, Italy.
FAU - Mazzetti, Simone
AU  - Mazzetti S
AD  - Department of Surgical Sciences, University of Turin, via Verdi 8, 10124, Turin, 
      Italy.
AD  - Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 km
      3.95, 10060, Candiolo, Turin, Italy.
FAU - Vassallo, Lorenzo
AU  - Vassallo L
AD  - Radiology Unit, SS Annunziata Hospital ASLCN1 Cuneo, via Ospedali 14, 12038,
      Cuneo, Savigliano, Italy.
FAU - Ghezzi, Silvia
AU  - Ghezzi S
AD  - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Piazza Ospedale
      Maggiore 3, 20162, Milan, Italy.
FAU - Sartore-Bianchi, Andrea
AU  - Sartore-Bianchi A
AD  - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Piazza Ospedale
      Maggiore 3, 20162, Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, via
      Festa del Perdono 7, 20122, Milan, Italy.
FAU - Marsoni, Silvia
AU  - Marsoni S
AD  - Precision Oncology, IFOM - The FIRC Institute of Molecular Oncology, via Adamello
      16, 20139, Milan, Italy.
FAU - Siena, Salvatore
AU  - Siena S
AD  - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Piazza Ospedale
      Maggiore 3, 20162, Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, via
      Festa del Perdono 7, 20122, Milan, Italy.
FAU - Regge, Daniele
AU  - Regge D
AD  - Department of Surgical Sciences, University of Turin, via Verdi 8, 10124, Turin, 
      Italy.
AD  - Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 km
      3.95, 10060, Candiolo, Turin, Italy.
FAU - Torresin, Alberto
AU  - Torresin A
AD  - Department of Medical Physics, ASST Grande Ospedale Metropolitano Niguarda,
      Piazza Ospedale Maggiore 3, 20162, Milan, Italy.
AD  - Department of Physics, Universita degli Studi di Milano, via Giovanni Celoria 16,
      20133, Milan, Italy.
FAU - Vanzulli, Angelo
AU  - Vanzulli A
AUID- ORCID: 0000-0002-2452-3370
AD  - Department of Radiology, ASST Grande Ospedale Metropolitano Niguarda, Piazza
      Ospedale Maggiore 3, 20162, Milan, Italy. angelo.vanzulli@unimi.it.
AD  - Department of Oncology and Hemato-Oncology, Universita degli Studi di Milano, via
      Festa del Perdono 7, 20122, Milan, Italy. angelo.vanzulli@unimi.it.
LA  - eng
GR  - 21091/Associazione Italiana per la Ricerca sul Cancro/International
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201110
PL  - England
TA  - Eur Radiol Exp
JT  - European radiology experimental
JID - 101721752
RN  - 0 (Contrast Media)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Colorectal Neoplasms/drug therapy/*pathology
MH  - Contrast Media
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*diagnostic imaging/drug therapy/*secondary
MH  - Male
MH  - Middle Aged
MH  - *Observer Variation
MH  - Radiographic Image Interpretation, Computer-Assisted
MH  - Reproducibility of Results
MH  - Tomography, X-Ray Computed/*methods
PMC - PMC7652946
OTO - NOTNLM
OT  - *Colorectal neoplasms
OT  - *Image processing (computer-assisted)
OT  - *Liver neoplasms
OT  - *Radiomics
OT  - *Tomography (x-ray
OT  - *computed)
EDAT- 2020/11/11 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/06/22 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/10 05:46 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1186/s41747-020-00189-8 [doi]
AID - 10.1186/s41747-020-00189-8 [pii]
PST - epublish
SO  - Eur Radiol Exp. 2020 Nov 10;4(1):62. doi: 10.1186/s41747-020-00189-8.


PMID- 33169269
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Engaged Ethics in the Time of COVID: Caring for All or Excluding Some from the
      Lifeboat?
PG  - 489-493
LID - 10.1007/s11673-020-10063-2 [doi]
AB  - If good ethics is the process of ongoing dialogical deliberation on basic
      normative questions for the purpose of instituting principles for action, then
      the COVID crisis, or any crisis, is not a good time for developing ethical
      precepts on the run. Given dominant ethical trends, such reactive ethics tends to
      lead to either individualized struggles over the right way to act or hasty sets
      of guidelines that leave out contextualizing questions concerning regimes of
      care. Good people will find themselves suggesting strange things, from setting up
      lifeboat scenarios to supporting structural racism. This essay argues against
      both these paths-crisis-ridden agonism or algorithmic resource-allocation-and
      turns instead to a form of ethics of care which takes its departure from older
      forms of ethics, while recognizing that modern and postmodern challenges no
      longer allow their grounding in animated relations, natural rights, or
      cosmological truths.
FAU - James, Paul
AU  - James P
AUID- ORCID: http://orcid.org/0000-0002-8591-4594
AD  - Institute for Culture and Society, Western Sydney University, Locked Bag 1797,
      Penrith, NSW, 2751, Australia. paul.james@westernsydney.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - *Ethics, Medical
MH  - Humans
MH  - Morals
MH  - *Racism
MH  - SARS-CoV-2
PMC - PMC7651790
OTO - NOTNLM
OT  - Crisis
OT  - Ethics of care
OT  - Modern ethics
OT  - Postmodern ethics
EDAT- 2020/11/11 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/06/17 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10063-2 [doi]
AID - 10.1007/s11673-020-10063-2 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):489-493. doi: 10.1007/s11673-020-10063-2. Epub 2020 
      Nov 9.


PMID- 33169266
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - It Didn't Have to be This Way: Reflections on the Ethical Justification of the
      Running Ban in Northern Italy in Response to the 2020 COVID-19 Outbreak.
PG  - 643-648
LID - 10.1007/s11673-020-10056-1 [doi]
AB  - In this paper I discuss the ethical justifiability of the limitation of freedom
      of movement, in particular of the ban on running outdoors, enforced in Italy as a
      response to the COVID-19 outbreak in the spring of 2020. I argue that through the
      lens of public health ethics literature, the ban on running falls short of the
      criterion of proportionality that public health ethics scholars and international
      guidelines for the ethical management of infectious disease outbreak recommend
      for any measure that restricts essential individual freedoms, such as the freedom
      of movement. The public health ethics framework, however, falls short of
      explaining the widespread public support that the running ban has had in Italy. I
      discuss possible factors which could explain the public support for the ban in
      Italy. Finally, I raise the question of what societal implications the
      abandonment of the public health ethics framework based on proportionality might 
      have. I conclude that if it is the case, as the history of pandemics teaches us, 
      we will experience further waves of COVID-19 outbreaks, it becomes very important
      to raise these questions now, with an eye towards informing public health
      policies for the management of future COVID-19 outbreaks. This discussion should 
      not become politicized along the lines of liberal pro-lockdown/conservative
      anti-lockdown. Instead, we should reflect on the trade-offs of lockdown policies 
      according to a pluralist framework, in which COVID-19 related deaths are not the 
      only possible value to pursue.
FAU - Camporesi, Silvia
AU  - Camporesi S
AUID- ORCID: http://orcid.org/0000-0003-4135-1723
AD  - Department of Global Health & Social Medicine, School of Global Affairs, King's
      College London, Room 3.10 Bush House NE Wing, 30 Aldwych, London, WC2B 4BG, UK.
      silvia.camporesi@kcl.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/*epidemiology/*prevention & control
MH  - Communicable Disease Control/*methods
MH  - Humans
MH  - Italy/epidemiology
MH  - Pandemics/*ethics
MH  - Running/*ethics
MH  - SARS-CoV-2
MH  - *Social Control, Formal
PMC - PMC7651802
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Italy
OT  - Pandemic
OT  - Public health ethics
OT  - Running ban
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/04/21 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10056-1 [doi]
AID - 10.1007/s11673-020-10056-1 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):643-648. doi: 10.1007/s11673-020-10056-1. Epub 2020 
      Nov 9.


PMID- 33169265
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Facing the Ethical Challenges: Consumer Involvement in COVID-19 Pandemic
      Research.
PG  - 743-748
LID - 10.1007/s11673-020-10060-5 [doi]
AB  - Consumer involvement in clinical research is an essential component of a
      comprehensive response during emergent health challenges. During the COVID-19
      pandemic, the moderation of research policies and regulation to facilitate
      research may raise ethical issues. Meaningful, diverse consumer involvement can
      help to identify practical approaches to prioritize, design, and conduct rapidly 
      developed clinical research amid current events. Consumer involvement might also 
      elucidate the acceptability of flexible ethics review approaches that aim to
      protect participants whilst being sensitive to the challenging context in which
      research is taking place. This article describes the main ethical challenges
      arising from pandemic research and how involving consumers and the community
      could enable resolution of such issues.
FAU - Straiton, N
AU  - Straiton N
AUID- ORCID: http://orcid.org/0000-0002-5013-0159
AD  - Australian Clinical Trials Alliance, Suite 1, Level 2, 24 Albert Road, Melbourne,
      VIC, 3205, Australia. nicola_straiton@hotmail.com.
FAU - McKenzie, A
AU  - McKenzie A
AD  - Telethon Kids Institute, Consumer Engagement, Perth, Australia.
FAU - Bowden, J
AU  - Bowden J
AD  - AccessCR, Sydney, Australia.
FAU - Nichol, A
AU  - Nichol A
AD  - Monash University, Melbourne, Australia.
AD  - St. Vincent's University Hospital, Dublin, Ireland.
FAU - Murphy, R
AU  - Murphy R
AD  - University of Auckland, Auckland, New Zealand.
FAU - Snelling, T
AU  - Snelling T
AD  - University of Sydney, Faculty of Medicine and Health, Sydney, Australia.
FAU - Zalcberg, J
AU  - Zalcberg J
AD  - Monash University, Cancer Research, Melbourne, Australia.
FAU - Clements, J
AU  - Clements J
AD  - Australian Clinical Trials Alliance, Consumer Engagement, Melbourne, Australia.
FAU - Stubbs, J
AU  - Stubbs J
AD  - Australian Clinical Trials Alliance, Consumer Engagement, Melbourne, Australia.
FAU - Economides, A
AU  - Economides A
AD  - Brain and Mind Centre, University of Sydney, Sydney, Australia.
FAU - Kent, D
AU  - Kent D
AD  - Australian Clinical Trials Alliance, Consumer Engagement, Melbourne, Australia.
FAU - Ansell, J
AU  - Ansell J
AD  - Consumers Health Forum, Canberra, Australia.
FAU - Symons, T
AU  - Symons T
AD  - Australian Clinical Trials Alliance, Consumer Engagement, Melbourne, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - *Community Participation
MH  - *Ethics, Research
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
PMC - PMC7651817
OTO - NOTNLM
OT  - *Community
OT  - *Consumer
OT  - *Ethics
OT  - *Involvement
OT  - *Pandemic
OT  - *Research
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/08 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10060-5 [doi]
AID - 10.1007/s11673-020-10060-5 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):743-748. doi: 10.1007/s11673-020-10060-5. Epub 2020 
      Nov 9.


PMID- 33169261
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Justice, Well-Being, and Civic Duty in the Age of a Pandemic: Why we all Need to 
      Do our bit.
PG  - 737-742
LID - 10.1007/s11673-020-10053-4 [doi]
AB  - This article presents an argument related to justice obligations during a
      pandemic and explores implications of the argument. A just society responds to a 
      serious threat to the well-being of its people such as a viral pandemic to
      mitigate the impact of the pandemic on the well-being of its members. This
      creates identifiable societal obligations which are discharged by the
      institutions and individuals within society that are situated to do so. There are
      therefore identifiable obligations resting on various societal institutions, such
      as government, churches, schools, and corporate institutions, as well as
      obligations resting on individuals. Should an institution or individual fail to
      act in ways consistent with these social obligations, they perpetrate an
      injustice on society and its members.
FAU - Bester, Johan C
AU  - Bester JC
AUID- ORCID: http://orcid.org/0000-0002-8038-6454
AD  - UNLV School of Medicine, University of Nevada, Las Vegas, 2040 W Charleston Blvd,
      4th Floor, Las Vegas, Nevada, USA. johan.bester@unlv.edu.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19
MH  - Delivery of Health Care/ethics
MH  - Humans
MH  - *Pandemics
MH  - Personal Satisfaction
MH  - *Social Justice
MH  - *Social Responsibility
PMC - PMC7651792
OTO - NOTNLM
OT  - COVID-19
OT  - Justice
OT  - Public health ethics
OT  - Social justice
OT  - Well-being
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/22 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10053-4 [doi]
AID - 10.1007/s11673-020-10053-4 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):737-742. doi: 10.1007/s11673-020-10053-4. Epub 2020 
      Nov 9.


PMID- 33169260
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220716
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - What Triage Issues Reveal: Ethics in the COVID-19 Pandemic in Italy and France.
PG  - 675-679
LID - 10.1007/s11673-020-10059-y [doi]
AB  - In today's pandemic, many countries have experienced shortages of medical
      resources and many healthcare providers have often been faced with dramatic
      decisions about how to allocate beds, intensive care, or ventilators. Despite
      recognizing the need for triage, responses are not the same everywhere, and
      opinions and practices differ around what guidelines should be used, how they
      should be implemented, and who should ultimately decide. To some extent, triage
      issues reflect community values, revealing a given society's moral standards and 
      ideals. Our goal is to study two countries which share many common features-Italy
      and France-as they deal with the pandemic, revealing the moral organization of
      medicine and healthcare, the power structures, and the nature of the disruptions 
      in each context.
FAU - Orfali, Kristina
AU  - Orfali K
AD  - Department of Pediatrics, Division of Neonatology, Columbia University Medical
      Center, 622 W 168th street PH17-, New York, NY, 10032, USA.
      ko2145@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/*epidemiology/*therapy
MH  - Delivery of Health Care/*ethics
MH  - France/epidemiology
MH  - Humans
MH  - Italy/epidemiology
MH  - Pandemics/*ethics
MH  - SARS-CoV-2
MH  - *Social Values
MH  - Triage/*ethics
PMC - PMC7651791
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - Community values
OT  - France
OT  - Guidelines
OT  - Intensive care
OT  - Italy
OT  - Triage
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/29 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10059-y [doi]
AID - 10.1007/s11673-020-10059-y [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):675-679. doi: 10.1007/s11673-020-10059-y. Epub 2020 
      Nov 9.


PMID- 33169259
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Social Justice for Public Health: The COVID-19 Response in Portugal.
PG  - 669-674
LID - 10.1007/s11673-020-10058-z [doi]
AB  - The COVID-19 pandemic requires emergency policies to be put in place in order to 
      avoid a global health catastrophe. At the same time, there has been an increasing
      preoccupation that argues urgent policies for public health neglect social
      justice. By looking at Portugal's successful confinement case during the early
      stages of the pandemic, I argue that ethically driven social justice policies are
      not just compatible but also an instrumentally important element in addressing
      this pandemic in an effective way. The Portuguese case study suggests that
      enhancing social justice towards socio-economically vulnerable groups correlates 
      with the prevention of the spread of COVID-19; these benefits to public health
      can be explained by the fact that those policies create social distancing and
      less exposure to the COVID-19 virus and other contagious diseases and also remove
      disincentives to the use of healthcare services.
FAU - Cordeiro-Rodrigues, Luis
AU  - Cordeiro-Rodrigues L
AUID- ORCID: http://orcid.org/0000-0001-9571-2120
AD  - Department of Philosophy, Yuelu Academy, Hunan University, Changsha, People's
      Republic of China. lccmr1984@gmail.com.
LA  - eng
GR  - add later/Fundamental Research Funds for the Central Universities
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Communicable Disease Control/*methods
MH  - Humans
MH  - Pandemics
MH  - Portugal/epidemiology
MH  - Public Health/*ethics
MH  - *Public Policy
MH  - *Social Justice
PMC - PMC7651827
OTO - NOTNLM
OT  - COVID-19
OT  - Domestic violence
OT  - Economic austerity
OT  - Immigrants
OT  - Portugal
OT  - Prisons
OT  - Public health
OT  - Social justice
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/06/19 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10058-z [doi]
AID - 10.1007/s11673-020-10058-z [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):669-674. doi: 10.1007/s11673-020-10058-z. Epub 2020 
      Nov 9.


PMID- 33169257
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Telling the Truth to Child Cancer Patients in COVID-19 Times.
PG  - 797-801
LID - 10.1007/s11673-020-10052-5 [doi]
AB  - A notable feature of the COVID-19 pandemic is that children are less at risk of
      becoming infected or, if infected, less likely to become seriously unwell, so
      ethical discussions have consequently focused on the adult healthcare setting.
      However, despite a lower risk of children becoming acutely ill with COVID-19,
      there nevertheless may be significant and potentially sustained effects of
      COVID-19 on the physical, psychological, and emotional health and well-being of
      children. Focusing on the context of children's cancer care, and specifically
      bone marrow transplant (BMT), we describe some of these effects and then address 
      one specific ethical challenge that arises. That is the question of what and how 
      much to tell children whose cancer treatment has been changed because of
      COVID-19. Drawing on our previous work on the ethical reasons for telling the
      truth to younger children (aged 5-12) we link different ethical reasons to the
      different types of information that could be given to children in this context.
      We argue that children should be given an explanation of the changes that they
      will directly experience, including some changes to the process of their actual
      medical treatment; but not about increased risk associated with these changes,
      unless they specifically ask for this information.
FAU - Gillam, Lynn
AU  - Gillam L
AUID- ORCID: http://orcid.org/0000-0001-6481-5004
AD  - Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Australia.
      Lynn.gillam@rch.org.au.
AD  - Melbourne School of Population and Global Health, The University of Melbourne, 50
      Flemington Road, Parkville, Victoria, 3052, Australia. Lynn.gillam@rch.org.au.
FAU - Spriggs, Merle
AU  - Spriggs M
AD  - Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Australia.
AD  - Melbourne School of Population and Global Health, The University of Melbourne, 50
      Flemington Road, Parkville, Victoria, 3052, Australia.
AD  - Honorary Research Fellow, Murdoch Children's Research Institute, Melbourne,
      Australia.
FAU - Delany, Clare
AU  - Delany C
AD  - Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Australia.
AD  - Department of Medical Education, Melbourne Medical School, The University of
      Melbourne, 50 Flemington Road, Parkville, Victoria, 3052, Australia.
AD  - Peter MacCallum, Cancer Centre, Melbourne, Australia.
FAU - Conyers, Rachael
AU  - Conyers R
AD  - Children's Cancer Centre, The Royal Children's Hospital, Melbourne, Australia.
AD  - Department of Paediatrics, University of Melbourne, 50 Flemington Road,
      Parkville, Victoria, 3052, Australia.
AD  - Cardiac Regeneration, Cell Biology, Murdoch Children's Research Institute,
      Melbourne, Australia.
FAU - McCarthy, Maria
AU  - McCarthy M
AD  - Department of Paediatrics, University of Melbourne, 50 Flemington Road,
      Parkville, Victoria, 3052, Australia.
AD  - Psycho-oncology Program, The Royal Children's Hospital, Melbourne, Australia.
AD  - Brain and Mind, Murdoch Children's Research Institute, Melbourne, Australia.
LA  - eng
GR  - DP170102906/Australian Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Bioethics
MH  - *COVID-19
MH  - Child
MH  - Child, Preschool
MH  - *Communication
MH  - Humans
MH  - *Neoplasms
MH  - Truth Disclosure/*ethics
PMC - PMC7651796
OTO - NOTNLM
OT  - *Bioethics
OT  - *COVID-19
OT  - *Cancer care
OT  - *Communication
OT  - *Disclosure
OT  - *Pre-adolescent child
OT  - *Truth-telling
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/12 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10052-5 [doi]
AID - 10.1007/s11673-020-10052-5 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):797-801. doi: 10.1007/s11673-020-10052-5. Epub 2020 
      Nov 9.


PMID- 33169255
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Synergistic Disparities and Public Health Mitigation of COVID-19 in the Rural
      United States.
PG  - 649-656
LID - 10.1007/s11673-020-10049-0 [doi]
AB  - Public health emergencies expose social injustice and health disparities,
      resulting in calls to address their structural causes once the acute crisis has
      passed. The COVID-19 pandemic is highlighting and exacerbating global, national, 
      and regional disparities in relation to the benefits and burdens of undertaking
      critical basic public health mitigation measures such as physical distancing. In 
      the United States, attempts to address the COVID-19 pandemic are complicated by
      striking racial, economic, and geographic inequities. These synergistic
      inequities exist in both urban and rural areas but take on a particular character
      and impact in areas of rural poverty. Rural areas face a diverse set of
      structural challenges, including inadequate public health, clinical, and other
      infrastructure and economic precarity, hampering the ability of communities and
      individuals to implement mitigation measures. Public health ethics demands that
      personnel address both the tactical, real-time adjustment of typical mitigation
      tools to improve their effectiveness among the rural poor as well as the
      strategic, longer-term structural causes of health and social injustice that
      continue to disadvantage this population.
FAU - Chillag, Kata L
AU  - Chillag KL
AD  - Davidson College, Box 7135, 405 N Main Street, Davidson, NC, 28035, USA.
      kachillag@davidson.edu.
FAU - Lee, Lisa M
AU  - Lee LM
AD  - Virginia Tech, Scholarly Integrity and Research Compliance and Department of
      Population Health Sciences, North End Center, Suite 4120 (0497), 300 Turner St
      NW, Blacksburg, VA, 24061, USA.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/epidemiology/*prevention & control
MH  - *Healthcare Disparities
MH  - Humans
MH  - Pandemics/*ethics
MH  - *Poverty Areas
MH  - Public Health Practice/*ethics
MH  - Rural Health/*ethics
MH  - SARS-CoV-2
MH  - Social Problems/*ethics
MH  - United States/epidemiology
PMC - PMC7651816
OTO - NOTNLM
OT  - Equity
OT  - Health disparities
OT  - Justice
OT  - Public health ethics
OT  - Rural health
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/15 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10049-0 [doi]
AID - 10.1007/s11673-020-10049-0 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):649-656. doi: 10.1007/s11673-020-10049-0. Epub 2020 
      Nov 9.


PMID- 33169254
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220716
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - We Need to Talk About Rationing: The Need to Normalize Discussion About
      Healthcare Rationing in a Post COVID-19 Era.
PG  - 731-735
LID - 10.1007/s11673-020-10051-6 [doi]
AB  - The global COVID-19 pandemic has brought the issue of rationing finite healthcare
      resources to the fore. There has been much academic debate, media attention, and 
      conversation in the homes of everyday individuals about the allocation of medical
      resources, diagnostic testing kits, ventilators, and personal protective
      equipment. Yet decisions to prioritize treatment for some individuals over others
      occur implicitly and explicitly in everyday practices. The pandemic has propelled
      the socially taboo and unavoidably prickly issue of healthcare rationing into the
      public spotlight-and as such, healthcare rationing demands ongoing public
      attention and transparent discussion. This article concludes that in the
      aftermath of COVID-19, policymakers should work towards normalizing rationing
      discussions by engaging in transparent and honest debate in the wider community
      and public domain. Further, injecting greater openness and objectivity into
      rationing decisions might go some way towards dismantling the societal taboo
      surrounding rationing in healthcare.
FAU - Bhatia, Neera
AU  - Bhatia N
AD  - Deakin University, School of Law, Melbourne, VIC, 3125, Australia.
      neera.bhatia@deakin.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - Decision Making
MH  - *Health Care Rationing/ethics/legislation & jurisprudence
MH  - Humans
MH  - *Pandemics
MH  - SARS-CoV-2
PMC - PMC7651801
OTO - NOTNLM
OT  - Allocation
OT  - COVID-19
OT  - Ethics
OT  - Healthcare rationing
OT  - Law
OT  - Pandemic
OT  - Public health
OT  - Resources
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/05 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10051-6 [doi]
AID - 10.1007/s11673-020-10051-6 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):731-735. doi: 10.1007/s11673-020-10051-6. Epub 2020 
      Nov 9.


PMID- 33169252
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - What Matters? Palliative Care, Ethics, and the COVID-19 Pandemic.
PG  - 793-796
LID - 10.1007/s11673-020-10046-3 [doi]
AB  - As is often the case in clinical ethics, the discourse in COVID-19 has focused
      primarily on difficult and controversial decision-making junctures such as how to
      decide who gets access to intensive care resources if demand outstrips supply.
      However, the lived experience of COVID-19 raises less controversial but arguably 
      more profound moral questions around what it means to look after each other
      through the course of the pandemic and how this translates in care for the dying.
      This piece explores the interface between the pandemic, ethics, and the role of
      palliative care. We argue that the ethical discourse should be broader, and that 
      the principles that underly the discipline of palliative care provide a solid
      ethical foundation for the care of all patients through the coronavirus pandemic.
FAU - Sheahan, Linda
AU  - Sheahan L
AUID- ORCID: http://orcid.org/0000-0003-4718-9659
AD  - Sount East Sydney Local Health District and St George Hospital, Gray St, Kogarah,
      NSW, 2217, Australia. linda.sheahan@health.nsw.gov.au.
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
      linda.sheahan@health.nsw.gov.au.
FAU - Brennan, Frank
AU  - Brennan F
AD  - St George Hospital, Kogarah, NSW, 2217, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - Decision Making
MH  - Empathy
MH  - *Ethics, Clinical
MH  - Humans
MH  - *Palliative Care
MH  - *Pandemics
MH  - SARS-CoV-2
PMC - PMC7651800
OTO - NOTNLM
OT  - COVID 19
OT  - Ethic(s)
OT  - Palliative care
OT  - Pandemic
OT  - Virtue ethics
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/04/29 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10046-3 [doi]
AID - 10.1007/s11673-020-10046-3 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):793-796. doi: 10.1007/s11673-020-10046-3. Epub 2020 
      Nov 9.


PMID- 33169251
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Ethical Challenges in Clinical Research During the COVID-19 Pandemic.
PG  - 717-722
LID - 10.1007/s11673-020-10045-4 [doi]
AB  - The sudden emergence of the COVID-19 pandemic brought global disruption to every 
      aspect of society including healthcare, supply chain, the economy, and social
      interaction. Among the many emergent considerations were the safety and public
      health of the public, patients, essential workers, and healthcare professionals. 
      In certain locations, clinical research was halted-or terminated-in deference to 
      the immediate needs of patient care, and clinical trials focusing on the
      treatment and prevention of coronavirus infection were prioritized over studies
      focusing on other diseases. Difficult decisions were made rapidly; flexibility
      and reconsideration were necessary not only because the intensity and severity of
      infection varied over time and by locale but also because knowledge of the
      disease and understanding of its treatment (and prevention) grew. Here we discuss
      the ethical challenges in decision-making and competing ethical tensions during
      the pandemic in an effort to advance future preparedness.
FAU - Bierer, B E
AU  - Bierer BE
AUID- ORCID: http://orcid.org/0000-0001-6448-8170
AD  - Multi-Regional Clinical Trials Center of the Brigham and Women's Hospital and
      Harvard, 14 Story Street, Cambridge, MA, 02138, USA. bbierer@bwh.harvard.edu.
AD  - Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street,
      Boston, MA, 02115, USA. bbierer@bwh.harvard.edu.
FAU - White, S A
AU  - White SA
AD  - Multi-Regional Clinical Trials Center of the Brigham and Women's Hospital and
      Harvard, 14 Story Street, Cambridge, MA, 02138, USA.
AD  - Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
FAU - Barnes, J M
AU  - Barnes JM
AD  - Multi-Regional Clinical Trials Center of the Brigham and Women's Hospital and
      Harvard, 14 Story Street, Cambridge, MA, 02138, USA.
AD  - Ropes & Gray, LLP, 800 Boylston Street, Boston, MA, 02199, USA.
FAU - Gelinas, L
AU  - Gelinas L
AD  - Multi-Regional Clinical Trials Center of the Brigham and Women's Hospital and
      Harvard, 14 Story Street, Cambridge, MA, 02138, USA.
AD  - Advarra, 6940 Columbia Gateway Drive, Suite 110, Columbia, MD, 21046, USA.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - Clinical Studies as Topic/*ethics
MH  - Humans
MH  - Pandemics
MH  - *Patient Safety
MH  - SARS-CoV-2
PMC - PMC7651825
OTO - NOTNLM
OT  - Bioethics
OT  - COVID-19
OT  - Clinical Research
OT  - Clinical Trials
OT  - Pandemic
OT  - Prioritization
OT  - Safety
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/08/16 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10045-4 [doi]
AID - 10.1007/s11673-020-10045-4 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):717-722. doi: 10.1007/s11673-020-10045-4. Epub 2020 
      Nov 9.


PMID- 33169249
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220716
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Ethical Considerations for Restrictive and Physical Distancing Measures in Brazil
      During COVID-19: Facilitators and Barriers.
PG  - 627-631
LID - 10.1007/s11673-020-10023-w [doi]
AB  - COVID-19 was recognized as a pandemic on March 11, 2020. Nine days later in
      Brazil, community transmission was deemed ongoing, and following what was already
      being put in place in various affected countries, restrictive and physical
      distancing measures that varied in severity across the different states were
      adopted. Adherence to restrictive and physical distancing measures depends on the
      general acceptance of public health measures as well as communities' financial
      leverage. This article aims to explore and discuss ethical facilitators and
      barriers to the implementation of physical distancing measures within three
      dimensions: political, socio-economic, and scientific. Furthermore, we would like
      to discuss ways to ethically promote restrictive and physical distancing measures
      in a large and unequal country like Brazil. There is an urgent need for
      transparent, consistent, and inclusive communication with the public, respecting 
      the most vulnerable populations and attempting to minimize the disproportionate
      burden on them.
FAU - Thome, Beatriz C
AU  - Thome BC
AUID- ORCID: http://orcid.org/0000-0002-3941-3756
AD  - Departamento de Medicina Preventiva, Universidade Federal de Sao Paulo, Rua
      Botucatu, 740, 4th floor, room 457, Sao Paulo, SP, 04023-062, Brazil.
      beatriz.thome@unifesp.br.
FAU - Matta, Gustavo C
AU  - Matta GC
AD  - Oswaldo Cruz Foundation - FIOCRUZ, Rua Leopoldo Bulhoes, 1480 Room 716, Rio de
      Janeiro, RJ, 21041210, Brazil.
FAU - Rego, Sergio T A
AU  - Rego STA
AD  - National School of Public Health Sergio Arouca, Oswaldo Cruz Foundation-FIOCRUZ, 
      Rua Leopoldo Bulhoes, 1480 Room 919, Rio de Janeiro, RJ, 21041210, Brazil.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 218750/Z/19/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *Bioethical Issues
MH  - Brazil/epidemiology
MH  - COVID-19/*epidemiology/*prevention & control
MH  - Communicable Disease Control/*organization & administration
MH  - Humans
MH  - Pandemics
MH  - Physical Distancing
MH  - Public Health/ethics
MH  - Quarantine/ethics
MH  - SARS-CoV-2
PMC - PMC7651820
OTO - NOTNLM
OT  - *Bioethics
OT  - *COVID-19
OT  - *Prevention and control
OT  - *Socioeconomic factors
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/01 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10023-w [doi]
AID - 10.1007/s11673-020-10023-w [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):627-631. doi: 10.1007/s11673-020-10023-w. Epub 2020 
      Nov 9.


PMID- 33169247
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - A Global Ecological Ethic for Human Health Resources.
PG  - 575-580
LID - 10.1007/s11673-020-10039-2 [doi]
AB  - COVID 19 has highlighted with lethal force the need to re-imagine and re-design
      the provisioning of human resources for health, starting from the reality of our 
      radical interdependence and concern for global health and justice. Starting from 
      the structured health injustice suffered by migrant workers during the pandemic
      and its impact on the health of others in both destination and source countries, 
      I argue here for re-structuring the system for educating and distributing care
      workers around what I call a global ecological ethic. Rather than rely on a
      system that privileges nationalism, that is unjust, and that sustains and even
      worsens injustice, including health injustice, and that has profound consequences
      for global health, a global ecological ethic would have us see health as
      interdependent and aim at "ethical place-making" across health ecosystems to
      enable people everywhere to have the capability to be healthy.
FAU - Eckenwiler, Lisa A
AU  - Eckenwiler LA
AD  - George Mason University Department of Philosophy, Fairfax, VA, USA.
      leckenwi@gmu.edu.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19/therapy
MH  - Delivery of Health Care/*ethics
MH  - Ecosystem
MH  - *Foreign Professional Personnel
MH  - *Global Health
MH  - Health Equity
MH  - *Health Personnel
MH  - Health Resources
MH  - *Health Workforce
MH  - Humans
MH  - Internationality
MH  - Pandemics
MH  - SARS-CoV-2
MH  - *Social Justice
PMC - PMC7651803
OTO - NOTNLM
OT  - Care workers
OT  - Global justice
OT  - Globalization
OT  - Health equity
OT  - Health justice
OT  - Health workers
OT  - Human health resources
OT  - Migrant care workers
OT  - Structural injustice
OT  - Vulnerability
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/11 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10039-2 [doi]
AID - 10.1007/s11673-020-10039-2 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):575-580. doi: 10.1007/s11673-020-10039-2. Epub 2020 
      Nov 9.


PMID- 33169246
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Imagining and Preparing for the Aftermath of the COVID-19 Pandemic: A
      Justification for Taking Caring Responsibilities into Consideration when
      Allocating Scarce Resources.
PG  - 773-776
LID - 10.1007/s11673-020-10041-8 [doi]
AB  - Various models have been used to "emplot" our collective experience of the
      COVID-19 pandemic, including the epidemiological curve, threshold models, and
      narrative. Drawing on a threshold model that was designed to frame
      resource-allocation decisions in clinical care, I offer an ethical justification 
      for taking caring responsibilities into consideration in such decisions during
      pandemics. My basic argument is that we should prioritize the survival of
      patients with caring responsibilities for similar reasons we should prioritize
      the survival of healthcare professionals. More generally, the pandemic reveals
      the fundamental importance of informal care and affords an opportunity to raise
      questions of justice relating to it.
FAU - Jordens, Christopher F C
AU  - Jordens CFC
AUID- ORCID: http://orcid.org/0000-0001-9454-1059
AD  - Sydney Health Ethics, Medical Foundation Building K25, The University of Sydney, 
      Sydney, NSW, 2206, Australia. chris.jordens@sydney.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - Health Resources/*supply & distribution
MH  - Humans
MH  - *Pandemics
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - *Social Responsibility
MH  - Triage
PMC - PMC7651793
OTO - NOTNLM
OT  - COVID-19
OT  - Informal care
OT  - Justice
OT  - Narrative
OT  - Pandemic
OT  - Resource allocation
OT  - Triage
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10041-8 [doi]
AID - 10.1007/s11673-020-10041-8 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):773-776. doi: 10.1007/s11673-020-10041-8. Epub 2020 
      Nov 9.


PMID- 33169245
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Ought Conscientious Refusals to Implement Reverse Triage Decisions be
      Accommodated?
PG  - 783-787
LID - 10.1007/s11673-020-10042-7 [doi]
AB  - Although one can argue that they do not represent a radical departure from
      existing practices, protocols for reverse triage certainly step beyond what is
      ordinarily done in medicine and healthcare. Nevertheless, there seems to be some 
      degree of moral concern regarding the ethical legitimacy of practicing reverse
      triage in the context of a pandemic. Such concern can be taken as a reflection of
      the moral antipathy some exhibit towards current practices of withdrawing
      treatment-that is, when withdrawal of treatment is arguably in the best interests
      of patients-and a rejection of the purported normative insignificance of
      withholding and withdrawing. Given that the relevance of the psychological
      attitudes of some healthcare professionals to the moral assessment of withdrawing
      and withholding treatment continues to be debated, it would seem that some
      thought should be given to the introduction and implementation of reverse triage 
      decisions in response to a pandemic. This brief paper will consider if provision 
      should be made for healthcare professionals to conscientiously refuse to
      participate in reverse triage.
FAU - Emmerich, Nathan
AU  - Emmerich N
AUID- ORCID: https://orcid.org/0000-0001-8199-4673
AD  - The Medical School, Australian National University, Canberra, Australia.
      nathan.emmerich@anu.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/therapy
MH  - *Decision Making
MH  - Humans
MH  - Pandemics
MH  - *Triage
MH  - Withholding Treatment/*ethics
PMC - PMC7651830
OTO - NOTNLM
OT  - COVID-19
OT  - Conscientious objection
OT  - Conscientious refusal
OT  - Pandemic
OT  - Reverse triage
OT  - Triage
OT  - Withdrawing
EDAT- 2020/11/11 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10042-7 [doi]
AID - 10.1007/s11673-020-10042-7 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):783-787. doi: 10.1007/s11673-020-10042-7. Epub 2020 
      Nov 9.


PMID- 33169244
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - COVID-19 from Wellington New Zealand.
PG  - 633-638
LID - 10.1007/s11673-020-10038-3 [doi]
AB  - This paper examines the role of bioethics in the successful control of COVID-19
      in New Zealand. After the severe acute respiratory syndrome (SARS) coronavirus
      episode in Toronto researchers developed a framework of values and principles to 
      articulate values that were already commonly accepted "in the community of its
      intended users," to be used to inform decision-making. New Zealand subsequently
      developed its own framework that was embedded in its Pandemic Influenza Plan.
      These formed the basis of the New Zealand response to COVID-19. This paper
      illustrates the ways in which the bioethical framework was reflected in the
      decisions and actions made by the government.
FAU - Gray, Ben
AU  - Gray B
AUID- ORCID: http://orcid.org/0000-0001-7647-9474
AD  - Primary Health Care and General Practice, University of Otago, Wellington,
      Wellington, 6021, New Zealand. ben.gray@otago.ac.nz.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/*epidemiology/*prevention & control
MH  - Communicable Disease Control/*organization & administration
MH  - Humans
MH  - New Zealand/epidemiology
MH  - Pandemics
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - Social Values
PMC - PMC7651798
OTO - NOTNLM
OT  - COVID-19
OT  - Descriptive ethics
OT  - Pandemic planning
EDAT- 2020/11/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/10 05:46
PHST- 2020/05/02 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/10 05:46 [entrez]
AID - 10.1007/s11673-020-10038-3 [doi]
AID - 10.1007/s11673-020-10038-3 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):633-638. doi: 10.1007/s11673-020-10038-3. Epub 2020 
      Nov 9.


PMID- 33168581
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 68
IP  - 8
DP  - 2020 Dec
TI  - Academic collaborations with industry: lessons for the future.
PG  - 1305-1308
LID - 10.1136/jim-2020-001636 [doi]
AB  - Academic centers and industry partners have had love-hate relationships for more 
      than a century. Despite many examples of socially beneficial collaborations
      between academia and industry, it has become increasingly difficult to find an
      arrangement where neither clinicians/researchers working with industry nor
      industry itself is demonized. Regardless, we must incentivize innovation.
      Preclinical research is primarily funded by the government, whereas 70% of
      clinical research is supported by industry. Due to external political pressure
      and industry's concern about lack of control over content, industry's support of 
      continuing medical education (CME) has shrunk to 10% from 40% and has led to
      diversion of funding to non-CME events. Despite scrutiny of clinical faculty
      members' interactions with industry, corporate philanthropy is much sought after 
      by academic institutions. Developing new therapeutics requires both academia and 
      industry to transparently and ethically partner with creation of innovative
      start-ups, sharing of non-proprietary clinical trial data, and in postmarketing
      surveillance. The search continues for truly symbiotic relationships between
      academia and industry.
CI  - (c) American Federation for Medical Research 2020. No commercial re-use. See
      rights and permissions. Published by BMJ.
FAU - Reddy, S Sethu K
AU  - Reddy SSK
AUID- ORCID: 0000-0003-2944-5436
AD  - Medicine, Central Michigan University College of Medicine, Mount Pleasant,
      Michigan, USA sethu.k.reddy@gmail.com.
FAU - Chao, Shing
AU  - Chao S
AD  - College of Medicine, Central Michigan University, Saginaw, Michigan, USA.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American
      Federation for Clinical Research
JID - 9501229
SB  - IM
MH  - Big Data
MH  - *Cooperative Behavior
MH  - Drug Discovery
MH  - Humans
MH  - *Industry
MH  - Product Surveillance, Postmarketing
MH  - *Universities
OTO - NOTNLM
OT  - *academic medical centers
OT  - *drug discovery
OT  - *education
OT  - *industry
OT  - *medical
OT  - *translational medical research
COIS- Competing interests: None declared.
EDAT- 2020/11/11 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/11/10 05:38
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/11/10 05:38 [entrez]
AID - jim-2020-001636 [pii]
AID - 10.1136/jim-2020-001636 [doi]
PST - ppublish
SO  - J Investig Med. 2020 Dec;68(8):1305-1308. doi: 10.1136/jim-2020-001636. Epub 2020
      Nov 9.


PMID- 33168560
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 9
TI  - The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol
      for an intervention study to enhance the HCV cascade of care for people who
      inject drugs (T'N'T HepC).
PG  - e039724
LID - 10.1136/bmjopen-2020-039724 [doi]
AB  - INTRODUCTION: Injecting drug use is the primary driver of hepatitis C virus (HCV)
      infection in Europe. Despite the need for more engagement with care, people who
      inject drugs (PWID) are hard to reach with HCV testing and treatment. We
      initiated a study to evaluate the efficacy for testing and linkage to care among 
      PWID consulting peer-based testing at a mobile clinic in Copenhagen, Denmark.
      METHODS AND ANALYSIS: In this intervention study, we will recruit participants at
      a single community-based, peer-run mobile clinic. In a single visit, we will
      first offer participants a point-of-care HCV antibody test, and if they test
      positive, then they will receive an HCV RNA test. If they are HCV-RNA+, we will
      administer facilitated referrals to designated 'fast-track' clinics at a hospital
      or an addiction centre for treatment. The primary outcomes for this study are the
      number of tested and treated individuals. Secondary outcomes include individuals 
      lost at each step in the care cascade. ETHICS AND DISSEMINATION: The results of
      this study could provide a model for targeting PWID for HCV testing and treatment
      in Demark and other settings, which could help achieve WHO HCV elimination
      targets. The Health Research Ethics Committee of Denmark and the Danish Data
      Protection Agency confirmed (December 2018/January 2019) that this study did not 
      require their approval. Study findings will be disseminated through peer-reviewed
      publications, conference presentations and social media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lazarus, Jeffrey Victor
AU  - Lazarus JV
AUID- ORCID: 0000-0001-9618-2299
AD  - Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of 
      Barcelona, Barcelona, Spain jeffrey.lazarus@isglobal.org.
FAU - Ovrehus, Anne
AU  - Ovrehus A
AD  - Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
FAU - Demant, Jonas
AU  - Demant J
AD  - Users Academy, Copenhagen, Denmark.
FAU - Krohn-Dehli, Louise
AU  - Krohn-Dehli L
AD  - Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre,
      Denmark.
FAU - Weis, Nina
AU  - Weis N
AUID- ORCID: 0000-0002-3133-2724
AD  - Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre,
      Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Adolescent
MH  - Antiviral Agents/therapeutic use
MH  - COVID-19
MH  - Europe
MH  - Hepacivirus
MH  - *Hepatitis C/diagnosis/drug therapy/epidemiology
MH  - Humans
MH  - Mobile Health Units
MH  - Pandemics
MH  - Pharmaceutical Preparations
MH  - SARS-CoV-2
MH  - Substance Abuse, Intravenous/drug therapy
MH  - World Health Organization
PMC - PMC7654134
OTO - NOTNLM
OT  - *Hepatology
OT  - *Infectious diseases
OT  - *People who inject drugs
OT  - *Public health
OT  - *Viral hepatitis
COIS- Competing interests: JVL reports grants, personal fees and other from AbbVie and 
      Gilead Sciences, personal fees from CEPHEID, GSK, Intercept and Janssen, and
      grants and personal fees from MSD, outside the submitted work. AO reports grants,
      personal fees and other from AbbVie, Gilead Sciences and MSD, outside the
      submitted work. JD reports grants from AbbVie, Gilead Sciences and MSD, outside
      the submitted work. LK-D has nothing to disclose. NW reports unrestricted grants 
      and personal fees from AbbVie and Gilead Sciences, grants and personal fees from 
      MSD and grants from Bristol Myers Squibb, outside the submitted work.
EDAT- 2020/11/11 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/10 05:38
PHST- 2020/11/10 05:38 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-039724 [pii]
AID - 10.1136/bmjopen-2020-039724 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 9;10(11):e039724. doi: 10.1136/bmjopen-2020-039724.


PMID- 33168558
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 9
TI  - Effect of particulate matter exposure on patients with COPD and risk reduction
      through behavioural interventions: the protocol of a prospective panel study.
PG  - e039394
LID - 10.1136/bmjopen-2020-039394 [doi]
AB  - INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) are
      vulnerable to particulate matter (PM) exposure which can increase acute
      exacerbations and hospitalisation. Interventions to avoid PM exposure are
      important but evidence-based guidance is lacking. This study aims to assess the
      impact of PM on lung function, quality of life and exacerbations in patients with
      COPD using a panel design study; it will also provide evidence for interventional
      measures to reduce harm from PM exposure. METHODS AND ANALYSIS: A prospective
      panel study of patients with COPD aged >/=40 years will be conducted. Patients
      will be required to have a forced expiratory volume in one second <80% of the
      predicted value at enrolment. A total of 120 patients from three different
      regions will be enrolled, 60 from the metropolitan area, 30 from an
      industrialised area and 30 from a clean rural area. Clinical outcomes will be
      assessed through COPD assessment test scores, the St. George's Respiratory
      Questionnaire for patients with COPD and pulmonary function testing. Indoor and
      outdoor PM in the patients' environments will be measured using gravimetric and
      light scattering platforms. To estimate the individual dose of PM exposure, a
      time-activity diary, Geographic Information System and land use regression model 
      will be combined in every season for 1 year. The correlation between PM exposure 
      and the health status of patients with COPD will be evaluated. In addition, 40
      patients with the lowest score of life behaviour score to reduce environmental PM
      exposure will be randomised to a control or intervention group, who will receive 
      in-depth education on risk-reducing behaviours. ETHICS AND DISSEMINATION: This
      study was approved by the Institutional Review Board of each site. The
      participants received comprehensive information and provided informed consent.
      The result of this study will be discussed in the form of conference
      presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER:
      NCT04020237.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Park, Shinhee
AU  - Park S
AD  - Pulmonary, Allergy and Critical Care medicine, Gangneung Asan Hospital,
      University of Ulsan College of Medicine, Gangneung, Republic of Korea.
FAU - Ra, Seung Won
AU  - Ra SW
AD  - Department of Internal Medicine, Ulsan University Hospital, University of Ulsan
      College of Medicine, Ulsan, Republic of Korea.
FAU - Kang, Sung Yoon
AU  - Kang SY
AD  - Department of Internal Medicine, Gachon University Gil Medical Center, Incheon,
      Republic of Korea.
FAU - Kim, Hwan-Cheol
AU  - Kim HC
AD  - Department of Occupational and Environmental Medicine, Inha University College of
      Medicine, Incheon, Republic of Korea seiwon@amc.seoul.kr carpediem@inha.ac.kr.
FAU - Lee, Sei Won
AU  - Lee SW
AUID- ORCID: 0000-0003-4814-6730
AD  - Department of Pulmonology and Critical Care Medicine, Asan Medical Center,
      University of Ulsan College of Medicine, Seoul, Republic of Korea
      seiwon@amc.seoul.kr carpediem@inha.ac.kr.
LA  - eng
SI  - ClinicalTrials.gov/NCT04020237
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Particulate Matter)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Particulate Matter/adverse effects
MH  - Prospective Studies
MH  - *Pulmonary Disease, Chronic Obstructive/prevention & control
MH  - Quality of Life
MH  - Risk Reduction Behavior
PMC - PMC7654133
OTO - NOTNLM
OT  - *adult thoracic medicine
OT  - *chronic airways disease
OT  - *thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/11 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/10 05:38
PHST- 2020/11/10 05:38 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-039394 [pii]
AID - 10.1136/bmjopen-2020-039394 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 9;10(11):e039394. doi: 10.1136/bmjopen-2020-039394.


PMID- 33168556
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 9
TI  - What older adults and their caregivers need for making better health-related
      decisions at home: a participatory mixed methods protocol.
PG  - e039102
LID - 10.1136/bmjopen-2020-039102 [doi]
AB  - INTRODUCTION: Shared decision making is an interpersonal process whereby
      healthcare providers collaborate with and support patients in decision-making.
      Older adults receiving home care need support with decision-making. We will
      explore what older adults receiving home care and their caregivers need for
      making better health-related decisions. METHODS AND ANALYSIS: This two-phase
      sequential exploratory mixed methods study will be conducted in a pan-Canadian
      healthcare organisation, SE Health. First, we will create a participant advisory 
      group to advise us throughout the research process. In phase 1 (qualitative), we 
      will recruit a convenience sample of 15-30 older adults and caregivers receiving 
      home care to participate in open-ended semi-structured interviews. Phase 1
      participants will be invited to share what health-related decisions they face at 
      home and what they need for making better decisions. In phase 2 (quantitative),
      interdisciplinary health and social care providers will be invited to answer a
      web-based survey to share their views on the decisional needs of older adults and
      their caregivers. The survey will include questions informed by findings from
      qualitative interviews in phase 1, and a workbook for assessing decisional needs 
      based on the Ottawa Decision Support Framework. Finally, qualitative and
      quantitative results will be triangulated (by methods, investigator, theory and
      source) to develop a comprehensive understanding of decision-making needs from
      the perspective of older adults, caregivers and health and social care providers.
      We will use the quality of mixed methods studies in health services research
      guidelines and the Checklist for Reporting the Results of Internet E-Surveys
      checklist. ETHICS AND DISSEMINATION: Ethics approval was obtained from the
      research ethics boards at Southlake Regional Health Centre and Universite Laval. 
      This study will inform the design of decision support interventions. Further
      dissemination plans include summary briefs for study participants, tailored
      reports for home care decision makers and policy makers, and peer-reviewed
      publications. TRIAL REGISTRATION NUMBER: NCT04327830.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lai, Claudia
AU  - Lai C
AD  - Tier 1 Canada Research in Shared Decision Making and Knowledge Translation,
      Universite Laval Primary Care Research Centre (CERSSPL-UL), Quebec City, Quebec, 
      Canada.
AD  - SE Research Centre, SE Health, Markham, Ontario, Canada.
FAU - Holyoke, Paul
AU  - Holyoke P
AD  - SE Research Centre, SE Health, Markham, Ontario, Canada.
FAU - Plourde, Karine V
AU  - Plourde KV
AD  - Tier 1 Canada Research in Shared Decision Making and Knowledge Translation,
      Universite Laval Primary Care Research Centre (CERSSPL-UL), Quebec City, Quebec, 
      Canada.
AD  - Department of Family Medicine and Emergency Medicine, Universite Laval, Quebec
      City, Quebec, Canada.
FAU - Decary, Simon
AU  - Decary S
AD  - Tier 1 Canada Research in Shared Decision Making and Knowledge Translation,
      Universite Laval Primary Care Research Centre (CERSSPL-UL), Quebec City, Quebec, 
      Canada.
AD  - Department of Family Medicine and Emergency Medicine, Universite Laval, Quebec
      City, Quebec, Canada.
FAU - Legare, France
AU  - Legare F
AUID- ORCID: 0000-0002-2296-6696
AD  - Tier 1 Canada Research in Shared Decision Making and Knowledge Translation,
      Universite Laval Primary Care Research Centre (CERSSPL-UL), Quebec City, Quebec, 
      Canada france.legare@mfa.ulaval.ca.
AD  - Department of Family Medicine and Emergency Medicine, Universite Laval, Quebec
      City, Quebec, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04327830
GR  - FDN-159931/CIHR/Canada
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Caregivers
MH  - *Decision Making
MH  - Humans
MH  - Reproducibility of Results
PMC - PMC7654109
OTO - NOTNLM
OT  - *epidemiology
OT  - *geriatric medicine
OT  - *primary care
COIS- Competing interests: This study will be conducted in SE Health, one of the
      largest social enterprises offering home care services across Canada.
EDAT- 2020/11/11 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/10 05:38
PHST- 2020/11/10 05:38 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-039102 [pii]
AID - 10.1136/bmjopen-2020-039102 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 9;10(11):e039102. doi: 10.1136/bmjopen-2020-039102.


PMID- 33168550
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 9
TI  - Protocol for a systematic review and meta-analysis of culturally adapted
      internet- and mobile-based health promotion interventions.
PG  - e037698
LID - 10.1136/bmjopen-2020-037698 [doi]
AB  - INTRODUCTION: High rates of immigration pose challenges for the healthcare
      systems of many countries to offer high-quality care to diverse populations.
      Advancing health interventions with incorporating the cultural background of
      diverse populations can be helpful to overcome this challenge. First studies
      suggest that culturally diverse populations might benefit from culturally adapted
      internet-based and mobile-based interventions (IMI) to promote health behaviours.
      However, the effectiveness of culturally adapted IMIs for health promotion
      interventions has not been evaluated systematically. Therefore, the aim of this
      review is to assess the effectiveness of culturally adapted IMIs regarding health
      promotion. Additionally, the cultural adaptation features of these interventions 
      will be outlined. METHODS AND ANALYSIS: Randomised controlled trials (RCTs)
      investigating the effectiveness of culturally adapted IMIs to promote health
      behaviours in the field of healthy eating, smoking cessation, alcohol
      consumption, physical activity and sexual health behaviour will be identified via
      a systematic search of the databases MEDLINE, Embase, PsycINFO, CENTRAL. The
      preliminary search has been conducted on the 26 August 2019 and will be updated
      in the process. Data will be pooled meta-analytically in case of at least three
      included studies reporting on the same outcome. Moreover, a narrative synthesis
      of the included studies will be conducted. The risk of bias will be assessed
      using the Cochrane Collaboration's tool for the Quality Assessment of RCTs V.
      2.0. Publication bias will be assessed using funnel plots. ETHICS AND
      DISSEMINATION: Ethical approval is not required for this study. The results of
      this study will be published in a peer-reviewed international journal. PROSPERO
      REGISTRATION NUMBER: PROSPERO; CRD42020152939.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Balci, Sumeyye
AU  - Balci S
AUID- ORCID: 0000-0001-8219-6163
AD  - Department of Clinical Psychology and Psychotherapy, Institute of Psychology and 
      Education, University of Ulm, Ulm, Germany sumeyye.balci@uni-ulm.de.
FAU - Spanhel, Kerstin
AU  - Spanhel K
AD  - Department of Rehabilitation Psychology and Psychotherapy, Institute of
      Psychology, Albert-Ludwigs-Universitat Freiburg, Freiburg im Breisgau,
      Baden-Wurttemberg, Germany.
FAU - Sander, Lasse
AU  - Sander L
AD  - Department of Rehabilitation Psychology and Psychotherapy, Institute of
      Psychology, Albert-Ludwigs-Universitat Freiburg, Freiburg im Breisgau,
      Baden-Wurttemberg, Germany.
FAU - Baumeister, Harald
AU  - Baumeister H
AD  - Department of Clinical Psychology and Psychotherapy, Institute of Psychology and 
      Education, University of Ulm, Ulm, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Exercise
MH  - *Health Promotion
MH  - Humans
MH  - Internet
MH  - Meta-Analysis as Topic
MH  - Smoking Cessation
MH  - Systematic Reviews as Topic
MH  - *Telemedicine
PMC - PMC7654131
OTO - NOTNLM
OT  - *psychiatry
OT  - *public health
OT  - *social medicine
COIS- Competing interests: HB received consultancy fees, reimbursement of congress
      attendance and travel costs as well as payments for lectures from Psychotherapy
      and Psychiatry Associations as well as Psychotherapy Training Institutes in the
      context of E-Mental-Health topics. He has been the beneficiary of study support
      (third-party funding) from several public funding organisations. LS reported
      receiving personal fees from Psychotherapy Training Institutes and clinics in the
      context of e-mental-health and supervision outside the submitted work.
EDAT- 2020/11/11 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/10 05:38
PHST- 2020/11/10 05:38 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - bmjopen-2020-037698 [pii]
AID - 10.1136/bmjopen-2020-037698 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 9;10(11):e037698. doi: 10.1136/bmjopen-2020-037698.


PMID- 33168403
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1545-1534 (Electronic)
IS  - 1080-6032 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Dec
TI  - Morbidity Among Athletes Presenting for Medical Care During 3 Iterations of an
      Ultratrail Race in the Himalayas.
PG  - 437-440
LID - S1080-6032(20)30131-9 [pii]
LID - 10.1016/j.wem.2020.08.001 [doi]
AB  - INTRODUCTION: Although ultratrail races are increasing in popularity, there is a 
      dearth of data regarding illnesses and medical care at these events. Data about
      injuries and illnesses for races taking place in the Himalayas, where the nearest
      medical facility can be hundreds of miles away, are even harder to find. This
      study aimed to describe the injuries and illnesses befalling the participants of 
      a 7-stage 212 km (132 mi) trail race at high altitude. METHODS: Ethical approval 
      was obtained from Nepal Research Health Council. A retrospective study of the
      record of medical encounters among the 100 participants competing in the Manaslu 
      trail race in Nepal from 2014 to 2016 was performed. Diagnoses were classified
      into various categories. Informed consent was taken from all participants.
      RESULTS: Acute diarrhea was the most common ailment reported among the
      participants (18%), followed closely by musculoskeletal problems (17%). Altitude 
      illness made up 6% of care provided. Approximately 35% of the athletes were using
      acetazolamide as prophylaxis for high altitude illnesses. The 1 case needing
      evacuation in the 3 iterations was high altitude pulmonary edema. CONCLUSIONS:
      Ultratrail races at high altitude pose a challenge in terms of provision of
      medical care in a remote setting with limited resources. However, most of the
      illnesses are minor in nature and easily managed by the race doctor. Knowledge of
      common illnesses among travelers to the area can help aid in preparation and
      provision of proper care, especially in remote settings with limited resources.
CI  - Copyright (c) 2020 Wilderness Medical Society. Published by Elsevier Inc. All
      rights reserved.
FAU - Dawadi, Suvash
AU  - Dawadi S
AD  - CIWEC Hospital and Travel Medicine, Center/Mountain Medicine Society of Nepal,
      Kathmandu, Nepal. Electronic address: suvashdawa@gmail.com.
FAU - Basyal, Bikash
AU  - Basyal B
AD  - Abington Jefferson Health/Mountain Medicine Society of Nepal, Kathmandu, Nepal.
FAU - Subedi, Yogesh
AU  - Subedi Y
AD  - MedStar Union Memorial Hospital/Mountain Medicine Society of Nepal, Kathmandu,
      Nepal.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - United States
TA  - Wilderness Environ Med
JT  - Wilderness & environmental medicine
JID - 9505185
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - O3FX965V0I (Acetazolamide)
RN  - Pulmonary edema of mountaineers
SB  - IM
MH  - Acetazolamide/administration & dosage/pharmacology
MH  - Adult
MH  - Altitude
MH  - Altitude Sickness/*diagnosis/prevention & control/therapy
MH  - *Athletic Injuries
MH  - Carbonic Anhydrase Inhibitors/administration & dosage/pharmacology
MH  - Diarrhea
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary
MH  - Male
MH  - Marathon Running/*injuries
MH  - Nepal
OTO - NOTNLM
OT  - Nepal
OT  - athletic injuries
OT  - high altitude
OT  - trail running
EDAT- 2020/11/11 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/11/10 05:37
PHST- 2019/12/27 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
PHST- 2020/11/10 05:37 [entrez]
AID - S1080-6032(20)30131-9 [pii]
AID - 10.1016/j.wem.2020.08.001 [doi]
PST - ppublish
SO  - Wilderness Environ Med. 2020 Dec;31(4):437-440. doi: 10.1016/j.wem.2020.08.001.
      Epub 2020 Nov 7.


PMID- 33168083
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 10
TI  - How the logics of the market, bureaucracy, professionalism and care are
      reconciled in practice: an empirical ethics approach.
PG  - 1024
LID - 10.1186/s12913-020-05870-7 [doi]
AB  - BACKGROUND: In the Netherlands, the for-profit sector has gained a substantial
      share of nursing home care within just a few years. The ethical question that
      arises from the growth of for-profit care is whether the market logic can be
      reconciled with the provision of healthcare. This question relates to the debate 
      on the Moral Limits of Markets (MLM) and commodification of care. METHODS: The
      contribution of this study is twofold. Firstly, we construct a theoretical
      framework from existing literature; this theoretical framework differentiates
      four logics: the market, bureaucracy, professionalism, and care. Secondly, we
      follow an empirical ethics approach; we used three for-profit nursing homes as
      case studies and conducted qualitative interviews with various stakeholders.
      RESULTS: Four main insights emerge from our empirical study. Firstly, there are
      many aspects of the care relationship (e.g. care environment, personal
      relationships, management) and every aspect of the relationship should be
      considered because the four logics are reconciled differently for each aspect.
      The environment and conditions of for-profit nursing homes are especially
      commodified. Secondly, for-profit nursing homes pursue a different professional
      logic from the traditional, non-profit sector - one which is inspired by the
      logic of care and which contrasts with bureaucratic logic. However, insofar as
      professionals in for-profit homes are primarily responsive to residents' wishes, 
      the market logic also prevails. Thirdly, a multilevel approach is necessary to
      study the MLM in the care sector since the degree of commodification differs by
      level. Lastly, it is difficult for the market to engineer social cohesion among
      the residents of nursing homes. CONCLUSIONS: The for-profit nursing home sector
      does embrace the logic of the market but reconciles it with other logics (i.e.
      logic of care and logic of professionalism). Importantly, for-profit nursing
      homes have created an environment in which care professionals can provide
      person-oriented care, thereby reconciling the logic of the market with the logic 
      of care.
FAU - Kruse, Florien M
AU  - Kruse FM
AUID- ORCID: https://orcid.org/0000-0003-3850-9331
AD  - Radboud University Medical Center, Radboud Institute for Health Sciences, IQ
      healthcare, Nijmegen, The Netherlands. florien.kruse@radboudumc.nl.
FAU - Ligtenberg, Wieke M R
AU  - Ligtenberg WMR
AD  - Radboud University Medical Center, Radboud Institute for Health Sciences, IQ
      healthcare, Nijmegen, The Netherlands.
FAU - Oerlemans, Anke J M
AU  - Oerlemans AJM
AD  - Radboud University Medical Center, Radboud Institute for Health Sciences, IQ
      healthcare, Nijmegen, The Netherlands.
FAU - Groenewoud, Stef
AU  - Groenewoud S
AD  - Radboud University Medical Center, Radboud Institute for Health Sciences, IQ
      healthcare, Nijmegen, The Netherlands.
FAU - Jeurissen, Patrick P T
AU  - Jeurissen PPT
AD  - Radboud University Medical Center, Radboud Institute for Health Sciences, IQ
      healthcare, Nijmegen, The Netherlands.
AD  - Ministry of Health, Welfare and Sport, The Hague, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - *Delivery of Health Care
MH  - *Health Care Sector
MH  - Humans
MH  - Long-Term Care
MH  - Models, Theoretical
MH  - Netherlands
MH  - Nursing Homes/economics
MH  - Organizations, Nonprofit
MH  - Privatization/*ethics
MH  - *Professionalism
PMC - PMC7654039
OTO - NOTNLM
OT  - Commodification
OT  - Empirical ethics
OT  - Long-term care
OT  - Moral limits of markets
EDAT- 2020/11/11 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/11/10 05:33
PHST- 2020/05/13 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/10 05:33 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - 10.1186/s12913-020-05870-7 [doi]
AID - 10.1186/s12913-020-05870-7 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Nov 10;20(1):1024. doi: 10.1186/s12913-020-05870-7.


PMID- 33168081
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 9
TI  - Negative pressure wound therapy (NPWT) on closed incisions to prevent surgical
      site infection in high-risk patients in hepatopancreatobiliary surgery: study
      protocol for a randomized controlled trial-the NP-SSI trial.
PG  - 918
LID - 10.1186/s13063-020-04831-z [doi]
AB  - BACKGROUND: Incisional surgical site infections (iSSI) in hepatopancreatobiliary 
      (HPB) surgery usually lead to prolonged hospital stays, consume valuable
      resources, and impact on patients' outcome. Prophylactic closed incision negative
      pressure wound therapy (ciNPWT) to decrease wound complications has become
      available. Owing to an increasing number of studies, evidence for superiority in 
      many indication areas has accumulated; however, in general surgery, there are a
      few data and those have shown contradictory results. METHODS: In this
      monocentric, prospective, randomized, controlled, two-armed study, the influence 
      of ciNPWT on incisional surgical site infection rates after HPB operations will
      be investigated. A total of 222 patients will be randomized 1:1 to an
      interventional group (7-day treatment with ciNPWT) or a control group (treated
      with gauze dressing). The primary parameter to evaluate efficacy is the rate of
      incisional SSIs within 30 days after surgery. Additionally, several clinically
      relevant secondary outcomes will be assessed. DISCUSSION: A reduction in the rate
      of incisional SSIs would not only lead to a significant cost reduction and
      shorter postoperative length of stay, but may also improve postoperative quality 
      of life for patients. While earlier publications have shown advantages for
      ciNPWT, recent studies did not confirm a positive effect regarding iSSI rate.
      Even if iSSI rate is not reduced, findings obtained from the secondary endpoints 
      may be of clinical relevance, such as reduction of wound complication rates.
      TRIAL REGISTRATION: This trial has been registered in the German Clinical Trials 
      Register, DRKS 00015136 . Registered on 19 February 2019 and has been approved by
      the local ethics committee of the University of Regensburg: 18-1225-101.
FAU - Brennfleck, Frank W
AU  - Brennfleck FW
AUID- ORCID: http://orcid.org/0000-0001-8055-9282
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany. frank.brennfleck@klinik.uni-regensburg.de.
FAU - Linsenmeier, Lena
AU  - Linsenmeier L
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Junger, Henrik H G
AU  - Junger HHG
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Schmidt, Katharina M
AU  - Schmidt KM
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Werner, Jens M
AU  - Werner JM
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Woehl, Daniel
AU  - Woehl D
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Zeman, Florian
AU  - Zeman F
AD  - Center for Clinical Trials, University Hospital Regensburg,
      Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
FAU - Mutzbauer, Ingrid
AU  - Mutzbauer I
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Hutchinson, James A
AU  - Hutchinson JA
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Geissler, Edward K
AU  - Geissler EK
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Schlitt, Hans J
AU  - Schlitt HJ
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
FAU - Brunner, Stefan M
AU  - Brunner SM
AD  - Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 
      11, 93053, Regensburg, Germany.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201109
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Humans
MH  - *Negative-Pressure Wound Therapy/adverse effects
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Surgical Wound Infection/diagnosis/prevention & control
MH  - Wound Healing
PMC - PMC7654160
OTO - NOTNLM
OT  - HPB surgery
OT  - Incision management
OT  - NP-SSI
OT  - NPWT
OT  - Prevena
OT  - Randomized controlled trial
OT  - SSI
OT  - Wound infection
OT  - ciNPWT
EDAT- 2020/11/11 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/10 05:33
PHST- 2019/05/16 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/10 05:33 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04831-z [doi]
AID - 10.1186/s13063-020-04831-z [pii]
PST - epublish
SO  - Trials. 2020 Nov 9;21(1):918. doi: 10.1186/s13063-020-04831-z.


PMID- 33168072
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20210914
IS  - 1756-994X (Electronic)
IS  - 1756-994X (Linking)
VI  - 12
IP  - 1
DP  - 2020 Nov 9
TI  - Genomics in the era of COVID-19: ethical implications for clinical practice and
      public health.
PG  - 95
LID - 10.1186/s13073-020-00792-9 [doi]
AB  - Genomic studies of patients with COVID-19, or exposed to it, are underway to
      delineate host factors associated with variability in susceptibility,
      infectivity, and disease severity. Here, we highlight the ethical
      implications-both potential benefits and harms-of genomics for clinical practice 
      and public health in the era of COVID-19.
FAU - Geller, Gail
AU  - Geller G
AUID- ORCID: 0000-0003-4856-1942
AD  - Berman Institute of Bioethics, Johns Hopkins University, Deering Hall, Room 202, 
      1809 Ashland Ave., Baltimore, MD, 21205, USA. ggeller@jhu.edu.
AD  - Johns Hopkins University School of Medicine, Baltimore, MD, USA. ggeller@jhu.edu.
AD  - Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD,
      21205, USA. ggeller@jhu.edu.
FAU - Duggal, Priya
AU  - Duggal P
AD  - Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD,
      21205, USA.
FAU - Thio, Chloe L
AU  - Thio CL
AD  - Johns Hopkins University School of Medicine, Baltimore, MD, USA.
AD  - Johns Hopkins School of Medicine Hepatitis Center, 855 N. Wolfe St. Rangos Room
      533, Baltimore, MD, 21205, USA.
FAU - Mathews, Debra
AU  - Mathews D
AD  - Berman Institute of Bioethics, Johns Hopkins University, Deering Hall, Room 202, 
      1809 Ashland Ave., Baltimore, MD, 21205, USA.
AD  - Johns Hopkins University School of Medicine, Baltimore, MD, USA.
FAU - Kahn, Jeffrey P
AU  - Kahn JP
AD  - Berman Institute of Bioethics, Johns Hopkins University, Deering Hall, Room 202, 
      1809 Ashland Ave., Baltimore, MD, 21205, USA.
AD  - Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD,
      21205, USA.
FAU - Maragakis, Lisa L
AU  - Maragakis LL
AD  - Johns Hopkins University School of Medicine, Baltimore, MD, USA.
AD  - Johns Hopkins School of Medicine Infection Control, 600 N. Wolfe St., Osler 425, 
      Baltimore, MD, 21205, USA.
FAU - Garibaldi, Brian T
AU  - Garibaldi BT
AD  - Johns Hopkins University School of Medicine, Baltimore, MD, USA.
AD  - Johns Hopkins University School of Medicine Pulmonology, 5501 Hopkins Bayview
      Circle, Baltimore, MD, 21224, USA.
LA  - eng
GR  - RM1 HG009038/HG/NHGRI NIH HHS/United States
GR  - RM1HG009038/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201109
PL  - England
TA  - Genome Med
JT  - Genome medicine
JID - 101475844
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/methods
MH  - Coronavirus Infections/*pathology/therapy
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genetic Testing/*ethics
MH  - Genomics/*ethics/methods
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*pathology/therapy
MH  - Public Health/*ethics/methods
MH  - SARS-CoV-2
PMC - PMC7649891
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Host genomics
EDAT- 2020/11/11 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/10 05:33
PHST- 2020/07/28 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/10 05:33 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1186/s13073-020-00792-9 [doi]
AID - 10.1186/s13073-020-00792-9 [pii]
PST - epublish
SO  - Genome Med. 2020 Nov 9;12(1):95. doi: 10.1186/s13073-020-00792-9.


PMID- 33168062
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Nov 9
TI  - Evidence of integrated primary-secondary health care in low-and middle-income
      countries: protocol for a scoping review.
PG  - 260
LID - 10.1186/s13643-020-01514-3 [doi]
AB  - BACKGROUND: Integrated care is a people-centered health delivery approach that
      ensures the comprehensiveness, quality, and continuity of service across the
      settings and levels of health systems. The World Health Organization (WHO)
      recommends integration across levels and building-blocks of health systems as a
      prerequisite of Universal Health Coverage (UHC). While health systems of low- and
      middle-income countries (LMICs) are often fragmented and led by siloed service
      delivery structure, several LMICs-including India-have attempted health system
      integration. Several systematic reviews of evidence on healthcare integration
      from developed countries exist, but no synthesis from LMICs was reported to date.
      This review will overview the existing evidence of primary-secondary care
      integration (PSI) in the context of LMICs, aiming to support policy decisions for
      the effective integration of health delivery systems in India. METHODS: The
      review will be conducted following the six steps recommend by Arksey and
      O'Malley. Scientific and grey literature will be systematically selected from
      PubMed, Embase, Scopus, Web of Science, Global Index Medicus, and electronic
      repositories (such as WHO, World Bank, Health Policy Plus, and OpenGrey). Using a
      comprehensive search strategy, literature written in English and published
      between 2000 and 2020 will be selected, and two independent authors will screen
      their titles and abstracts. The result will be charted using a data extraction
      form and reported using tables, figures, and narrative forms. DISCUSSION: No
      ethical approval is necessary for the review. The final report will be developed 
      with the consultation of other stakeholders and disseminated through workshops,
      conference papers, and peer review articles. The review will serve as a guiding
      tool to approach, implement, and test the PSI models in India and other LMICs.
      SCOPING REVIEW REGISTRATION: https://osf.io/kjhzt .
FAU - Hasan, Md Zabir
AU  - Hasan MZ
AUID- ORCID: 0000-0001-8730-0054
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA. zabir.hasan@gmail.com.
FAU - Singh, Shalini
AU  - Singh S
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
FAU - Arora, Dinesh
AU  - Arora D
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
FAU - Jain, Nishant
AU  - Jain N
AD  - Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ), New Delhi, India.
FAU - Gupta, Shivam
AU  - Gupta S
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - Delivery of Health Care
MH  - *Developing Countries
MH  - Health Policy
MH  - Humans
MH  - *Poverty
MH  - Primary Health Care
MH  - Review Literature as Topic
PMC - PMC7654598
OTO - NOTNLM
OT  - *Ayushman Bharat
OT  - *Health systems
OT  - *India
OT  - *Integrated care
OT  - *Integrated primary-secondary care
OT  - *Low- and middle-income countries
OT  - *Scoping review
EDAT- 2020/11/11 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/10 05:33
PHST- 2020/03/26 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/10 05:33 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01514-3 [doi]
AID - 10.1186/s13643-020-01514-3 [pii]
PST - epublish
SO  - Syst Rev. 2020 Nov 9;9(1):260. doi: 10.1186/s13643-020-01514-3.


PMID- 33167935
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 10
TI  - Influencing factors for prevention of postpartum hemorrhage and early detection
      of childbearing women at risk in Northern Province of Rwanda: beneficiary and
      health worker perspectives.
PG  - 678
LID - 10.1186/s12884-020-03389-7 [doi]
AB  - BACKGROUND: Reduction of maternal mortality and morbidity is a major global
      health priority. However, much remains unknown regarding factors associated with 
      postpartum hemorrhage (PPH) among childbearing women in the Rwandan context. The 
      aim of this study is to explore the influencing factors for prevention of PPH and
      early detection of childbearing women at risk as perceived by beneficiaries and
      health workers in the Northern Province of Rwanda. METHODS: A qualitative
      descriptive exploratory study was drawn from a larger sequential
      exploratory-mixed methods study. Semi-structured interviews were conducted with
      11 women who experienced PPH within the 6 months prior to interview. In addition,
      focus group discussions were conducted with: women's partners or close relatives 
      (2 focus groups), community health workers (CHWs) in charge of maternal health (2
      focus groups) and health care providers (3 focus groups). A socio ecological
      model was used to develop interview guides describing factors related to early
      detection and prevention of PPH in consideration of individual attributes,
      interpersonal, family and peer influences, intermediary determinants of health
      and structural determinants. The research protocol was approved by the University
      of Rwanda, College of Medicine and Health Sciences Institutional Ethics Review
      Board. RESULTS: We generated four interrelated themes: (1) Meaning of PPH:
      beliefs, knowledge and understanding of PPH: (2) Organizational factors; (3)
      Caring and family involvement and (4) Perceived risk factors and barriers to PPH 
      prevention. The findings from this study indicate that PPH was poorly understood 
      by women and their partners. Family members and CHWs feel that their role for the
      prevention of PPH is to get the woman to the health facility on time. The main
      factors associated with PPH as described by participants were multiparty and
      retained placenta. Low socioeconomic status and delays to access health care were
      identified as the main barriers for the prevention of PPH. CONCLUSIONS:
      Addressing the identified factors could enhance early prevention of PPH among
      childbearing women. Placing emphasis on developing strategies for early detection
      of women at higher risk of developing PPH, continuous professional development of
      health care providers, developing educational materials for CHWs and family
      members could improve the prevention of PPH. Involvement of all levels of the
      health system was recommended for a proactive prevention of PPH. Further
      quantitative research, using case control design is warranted to develop a
      screening tool for early detection of PPH risk factors for a proactive
      prevention.
FAU - Bazirete, Oliva
AU  - Bazirete O
AUID- ORCID: http://orcid.org/0000-0002-8476-3448
AD  - College of Medicine and Health Sciences, University of Rwanda, 3286, Kigali,
      Rwanda. baziretoliva@gmail.com.
FAU - Nzayirambaho, Manasse
AU  - Nzayirambaho M
AD  - College of Medicine and Health Sciences, University of Rwanda, 3286, Kigali,
      Rwanda.
FAU - Umubyeyi, Aline
AU  - Umubyeyi A
AD  - College of Medicine and Health Sciences, University of Rwanda, 3286, Kigali,
      Rwanda.
FAU - Uwimana, Marie Chantal
AU  - Uwimana MC
AD  - College of Medicine and Health Sciences, University of Rwanda, 3286, Kigali,
      Rwanda.
FAU - Evans, Marilyn
AU  - Evans M
AD  - University of Western Ontario, Arthur Labatt Family School of Nursing, 1151
      Richmond St, London, ON, N6A 3K7, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
RN  - 0 (Oxytocics)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Community Health Workers/*psychology/statistics & numerical data
MH  - Female
MH  - Focus Groups
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Maternal Mortality
MH  - Mothers/*psychology
MH  - Oxytocics/administration & dosage
MH  - Parity
MH  - Postpartum Hemorrhage/epidemiology/*prevention & control
MH  - Pregnancy
MH  - Qualitative Research
MH  - Risk Assessment/methods
MH  - Risk Factors
MH  - Rwanda/epidemiology
MH  - Social Determinants of Health
MH  - Surveys and Questionnaires/statistics & numerical data
MH  - Young Adult
PMC - PMC7654175
OTO - NOTNLM
OT  - Beneficiaries
OT  - Early detection
OT  - Health workers
OT  - Influencing factors
OT  - Postpartum hemorrhage
OT  - Prevention
EDAT- 2020/11/11 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/11/10 05:32
PHST- 2020/05/20 00:00 [received]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/10 05:32 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.1186/s12884-020-03389-7 [doi]
AID - 10.1186/s12884-020-03389-7 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Nov 10;20(1):678. doi: 10.1186/s12884-020-03389-7.


PMID- 33167922
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 10
TI  - Willingness to perform induced abortion and associated factors among graduating
      midwifery, medical, nursing, and public health officer students of University of 
      Gondar, Northwest Ethiopia: institution based cross sectional study.
PG  - 676
LID - 10.1186/s12884-020-03382-0 [doi]
AB  - BACKGROUND: In developing countries, abortion is often unsafe and a significant
      cause of maternal morbidity and mortality accounting for about 8% (4.7-13.2%) of 
      maternal mortality worldwide. Internationally, safe abortion services are
      recognized as reducing maternal mortality, and liberalized abortion laws are
      associated with reduced mortality resulting from unsafe abortion procedures.
      However, health care providers have moral, social and gender-based reservations
      that affects their willingness towards providing induced abortion services. The
      purpose of this study was to assess willingness to perform induced abortion and
      associated factors among graduating Midwifery, Medical, Nursing, and Public
      health officer students of University of Gondar. METHODS: Institution based cross
      sectional study was conducted from March 29 to May 30, 2019. All graduating
      students available during data collection period were considered as study
      population. Stratified simple random sampling technique was used to select 424
      study participants. Pre tested, semi- structured, self-administered questionnaire
      was used to collect data. Data analysis was done using SPSS version 20. Ethical
      clearance was obtained from School of midwifery under the delegation of
      institutional review board of university of Gondar. RESULTS: Two hundred ninety
      students out of 424 students were willing to perform induced abortion for
      indications supported by Ethiopian abortion law, making a proportion of 68.4%
      (95%Cl: 64.2, 72.9). Sex (Being male (AOR = 4.89, 95%CI: 3.02, 7.89)), religion
      (being orthodox than protestant (AOR = 10.41, 95%CI: 3.02, 21.57)), being Muslim 
      than protestant (AOR = 5.73, 95%CI: 1.37, 15.92)) and having once or less a week 
      religious attendance (AOR = 2.00, 95% CI: 1.20, 3.34) were factors associated
      with willingness towards performing induced abortion. CONCLUSIONS: According to
      this study willingness of students towards providing induced abortion services
      was good. However female students, protestant followers and those students with
      more than once a week religious attendance should be encouraged to support
      women's access to induced abortion services by referring them to other health
      care professionals willing to provide induced abortion services.
FAU - Enyew, Mihretu Molla
AU  - Enyew MM
AUID- ORCID: http://orcid.org/0000-0001-8051-7779
AD  - Department of Clinical Midwifery, School of Midwifery, College of Medicine and
      Health Sciences, University of Gondar, PO box 196, Gondar, Ethiopia.
      mihretumolla143@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201110
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Abortion, Induced/ethics/legislation & jurisprudence/*psychology
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Ethiopia
MH  - Female
MH  - Humans
MH  - Male
MH  - Midwifery/*education
MH  - Pregnancy
MH  - Public Health/education
MH  - Religion
MH  - Schools, Health Occupations/statistics & numerical data
MH  - Sex Factors
MH  - Students, Medical/*psychology/statistics & numerical data
MH  - Students, Nursing/*psychology/statistics & numerical data
MH  - Students, Public Health/*psychology/statistics & numerical data
MH  - Surveys and Questionnaires/statistics & numerical data
MH  - Universities/statistics & numerical data
MH  - Young Adult
PMC - PMC7654038
OTO - NOTNLM
OT  - Ethiopian abortion law
OT  - Graduating students
OT  - Induced abortion
OT  - Willingness
EDAT- 2020/11/11 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/11/10 05:31
PHST- 2020/06/15 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/10 05:31 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.1186/s12884-020-03382-0 [doi]
AID - 10.1186/s12884-020-03382-0 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Nov 10;20(1):676. doi: 10.1186/s12884-020-03382-0.


PMID- 33167771
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1758-1095 (Electronic)
IS  - 0141-0768 (Linking)
VI  - 113
IP  - 11
DP  - 2020 Nov
TI  - Reducing bias and improving transparency in medical research: a critical overview
      of the problems, progress and suggested next steps.
PG  - 433-443
LID - 10.1177/0141076820956799 [doi]
AB  - In recent years there has been increasing awareness of problems that have
      undermined trust in medical research. This review outlines some of the most
      important issues including research culture, reporting biases, and statistical
      and methodological issues. It examines measures that have been instituted to
      address these problems and explores the success and limitations of these
      measures. The paper concludes by proposing three achievable actions which could
      be implemented to deliver significantly improved transparency and mitigation of
      bias. These measures are as follows: (1) mandatory registration of interests by
      those involved in research; (2) that journals support the 'registered reports'
      publication format; and (3) that comprehensive study documentation for all
      publicly funded research be made available on a World Health Organization
      research repository. We suggest that achieving such measures requires a
      broad-based campaign which mobilises public opinion. We invite readers to
      feedback on the proposed actions and to join us in calling for their
      implementation.
FAU - Bradley, Stephen H
AU  - Bradley SH
AUID- ORCID: 0000-0002-2038-2056
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds LS2 9JT, UK.
FAU - DeVito, Nicholas J
AU  - DeVito NJ
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford
      OX2 6GG, UK.
FAU - Lloyd, Kelly E
AU  - Lloyd KE
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds LS2 9JT, UK.
FAU - Richards, Georgia C
AU  - Richards GC
AUID- ORCID: 0000-0003-0244-5620
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford
      OX2 6GG, UK.
FAU - Rombey, Tanja
AU  - Rombey T
AD  - Institute for Research in Operative Medicine, Witten/Herdecke University,
      Alfred-Herrhausen-Straue 50, 58448 Witten, Germany.
FAU - Wayant, Cole
AU  - Wayant C
AD  - Centre for Health Sciences, Oklahoma State University, Tulsa 74107, USA.
FAU - Gill, Peter J
AU  - Gill PJ
AUID- ORCID: 0000-0002-6253-1312
AD  - Department of Paediatrics, University of Toronto, Toronto M5G 1X8, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J R Soc Med
JT  - Journal of the Royal Society of Medicine
JID - 7802879
SB  - IM
MH  - Access to Information
MH  - Bias
MH  - Biomedical Research/*standards
MH  - Humans
MH  - *Quality Improvement
MH  - Registries
MH  - Research Design
PMC - PMC7673265
OTO - NOTNLM
OT  - *Research and publication ethics
OT  - *statistics and research methods
EDAT- 2020/11/11 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/11/10 05:30
PHST- 2020/11/10 05:30 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1177/0141076820956799 [doi]
PST - ppublish
SO  - J R Soc Med. 2020 Nov;113(11):433-443. doi: 10.1177/0141076820956799.


PMID- 33167533
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20210902
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - The Role of Natural Killer (NK) Cells in Acute Coronary Syndrome: A Comprehensive
      Review.
LID - E1514 [pii]
LID - 10.3390/biom10111514 [doi]
AB  - With poor outcomes and an immense financial burden, acute coronary syndrome (ACS)
      and its ischemic repercussions still present a major global health problem.
      Unfavorable outcomes seem to be mainly due to adverse cardiac remodeling. Since
      the inflammatory response takes an important role in remodeling secondary to
      myocardial infarction (MI), and as inflammation in this manner has not been
      completely elucidated, we attempted to give rise to a further understanding of
      ACS pathophysiology. Hence, in this review, we integrated current knowledge of
      complex communication networks between natural killer (NK) cells and immune and
      resident heart cells in the context of ACS. Based on available data, the role of 
      NK cells seems to be important in the infarcted myocardium, where it affects
      heart remodeling. On the other hand, in atherosclerotic plaque, NK cells seem to 
      be mere passers-by, except in the case of chronic infections by atherogenic
      pathogens. In that case, NK cells seem to support proinflammatory milieu. NK cell
      research is challenging due to ethical reasons, convergent evolution, and
      phenotypic diversity among individuals. Therefore, we argue that further research
      of NK cells in ACS is valuable, given their therapeutic potential in improving
      postischemic heart remodeling.
FAU - Kumric, Marko
AU  - Kumric M
AD  - Department of Pathophysiology, University of Split School of Medicine, Soltanska 
      2, 21000 Split, Croatia.
FAU - Kurir, Tina Ticinovic
AU  - Kurir TT
AD  - Department of Pathophysiology, University of Split School of Medicine, Soltanska 
      2, 21000 Split, Croatia.
AD  - Endocrinology Clinic, University Hospital of Split, Spinciceva 1, 21000 Split,
      Croatia.
FAU - Borovac, Josip A
AU  - Borovac JA
AD  - Department of Pathophysiology, University of Split School of Medicine, Soltanska 
      2, 21000 Split, Croatia.
AD  - Institute of Emergency Medicine of Split-Dalmatia County (ZHM SDZ), Spinciceva 1,
      21000 Split, Croatia.
FAU - Bozic, Josko
AU  - Bozic J
AUID- ORCID: 0000-0003-1634-0635
AD  - Department of Pathophysiology, University of Split School of Medicine, Soltanska 
      2, 21000 Split, Croatia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201105
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
SB  - IM
MH  - Acute Coronary Syndrome/*immunology/therapy
MH  - Animals
MH  - Humans
MH  - Killer Cells, Natural/*immunology
PMC - PMC7694449
OTO - NOTNLM
OT  - *acute myocardial infarction
OT  - *cardiac remodeling
OT  - *coronary artery disease
OT  - *heart failure
OT  - *inflammation
OT  - *natural killer cells
EDAT- 2020/11/11 06:00
MHDA- 2021/09/03 06:00
CRDT- 2020/11/10 01:05
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/31 00:00 [revised]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/10 01:05 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
AID - biom10111514 [pii]
AID - 10.3390/biom10111514 [doi]
PST - epublish
SO  - Biomolecules. 2020 Nov 5;10(11). pii: biom10111514. doi: 10.3390/biom10111514.


PMID- 33167429
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Appraising the Welfare of Thoroughbred Racehorses in Training in Queensland,
      Australia: The Incidence and Type of Musculoskeletal Injuries Vary between
      Two-Year-Old and Older Thoroughbred Racehorses.
LID - E2046 [pii]
LID - 10.3390/ani10112046 [doi]
AB  - Musculoskeletal injuries (MSI) remain a concerning cause of racehorse morbidity
      and mortality with important ethical and welfare consequences. Previous research 
      examining risk factors for MSI report inconsistent findings. Age is thought to
      affect MSI risk, but, to date, there have been no prospective studies comparing
      MSI in two-year-old versus older horses. This study aimed to: (1) determine the
      incidence of MSI for two-year-old and older horses, and whether this was affected
      by training track, season, or rainfall, and (2) determine the types of MSI
      affecting two-year-old and older horses, and whether horses trialled or raced
      after injury. A prospective survey was conducted with data collected through
      personal structured weekly interviews with participating trainers over a 13-month
      period. Data were analysed using Poisson regression. The incidence of MSI in the 
      current study was low (0.6%). The incidence of MSI in two-year-old horses was
      higher than older horses (p < 0.001). Types of MSI varied between two-year-old
      and older horses (p < 0.001) and affected whether horses subsequently trailed or 
      raced from 11 to 23 months after injury (p < 0.001). A larger proportion of
      two-year-old horses had dorsal metacarpal disease and traumatic lacerations. A
      smaller proportion of two-year-old horses had suspensory ligament desmitis,
      superficial digital flexor tendonitis, proximal sesamoid bone fractures, and
      fetlock joint injuries than older horses. Training track and rainfall did not
      affect MSI. The season affected MSI in two-year-old horses (p < 0.001) but not
      older horses. The major limitation was that trainers in this study were
      metropolitan (city) and our findings may not be generalisable to racehorses in
      regional (country) areas. Another significant limitation was the assumption that 
      MSI was the reason for failure to trial or race after injury. In conclusion, the 
      incidence of MSI was low in the current study and the types and the risk factors 
      for MSI are different for two-year-old and older horses.
FAU - Crawford, Kylie L
AU  - Crawford KL
AUID- ORCID: 0000-0002-9403-0096
AD  - School of Veterinary Science, The University of Queensland, 4343 Gatton,
      Australia.
AD  - School of Public Health, The University of Queensland, 4006 Herston, Australia.
FAU - Finnane, Anna
AU  - Finnane A
AD  - School of Public Health, The University of Queensland, 4006 Herston, Australia.
FAU - Greer, Ristan M
AU  - Greer RM
AD  - Torus Research, 4035 Bridgeman Downs, Australia.
AD  - School of Medicine, The University of Queensland, 4006 Herston, Australia.
FAU - Phillips, Clive J C
AU  - Phillips CJC
AUID- ORCID: 0000-0002-1926-6357
AD  - Curtin University Sustainability Policy (CUSP) Institute, Curtin University, 6845
      Perth, Australia.
FAU - Woldeyohannes, Solomon M
AU  - Woldeyohannes SM
AD  - School of Veterinary Science, The University of Queensland, 4343 Gatton,
      Australia.
FAU - Perkins, Nigel R
AU  - Perkins NR
AD  - School of Veterinary Science, The University of Queensland, 4343 Gatton,
      Australia.
FAU - Ahern, Benjamin J
AU  - Ahern BJ
AD  - School of Veterinary Science, The University of Queensland, 4343 Gatton,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7694396
OTO - NOTNLM
OT  - epidemiology
OT  - injury
OT  - musculoskeletal
OT  - racehorse
OT  - thoroughbred
OT  - wastage
EDAT- 2020/11/11 06:00
MHDA- 2020/11/11 06:01
CRDT- 2020/11/10 01:05
PHST- 2020/09/29 00:00 [received]
PHST- 2020/10/29 00:00 [revised]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/10 01:05 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2020/11/11 06:01 [medline]
AID - ani10112046 [pii]
AID - 10.3390/ani10112046 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Nov 5;10(11). pii: ani10112046. doi: 10.3390/ani10112046.


PMID- 33167409
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 5
TI  - The Interplay between Cancer Biology and the Endocannabinoid System-Significance 
      for Cancer Risk, Prognosis and Response to Treatment.
LID - E3275 [pii]
LID - 10.3390/cancers12113275 [doi]
AB  - The various components of the endocannabinoid system (ECS), such as the
      cannabinoid receptors (CBRs), cannabinoid ligands, and the signalling network
      behind it, are implicated in several tumour-related states, both as favourable
      and unfavourable factors. This review analyses the ECS's complex involvement in
      the susceptibility to cancer, prognosis, and response to treatment, focusing on
      its relationship with cancer biology in selected solid cancers (breast,
      gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, CNS
      tumours, and melanoma). Changes in the expression and activation of CBRs, as well
      as their ability to form distinct functional heteromers affect the cell's
      tumourigenic potential and their signalling properties, leading to
      pharmacologically different outcomes. Thus, the same ECS component can exert both
      protective and pathogenic effects in different tumour subtypes, which are often
      pathologically driven by different biological factors. The use of endogenous and 
      exogenous cannabinoids as anti-cancer agents, and the range of effects they might
      induce (cell death, regulation of angiogenesis, and invasion or anticancer
      immunity), depend in great deal on the tumour type and the specific ECS component
      that they target. Although an attractive target, the use of ECS components in
      anti-cancer treatment is still interlinked with many legal and ethical issues
      that need to be considered.
FAU - Moreno, Estefania
AU  - Moreno E
AUID- ORCID: 0000-0002-2491-5753
AD  - Department of Biochemistry and Molecular Biomedicine, Faculty of Biology,
      University of Barcelona, and Institute of Biomedicine of the University of
      Barcelona (IBUB), 08028 Barcelona, Spain.
FAU - Cavic, Milena
AU  - Cavic M
AUID- ORCID: 0000-0002-7604-9295
AD  - Department of Experimental Oncology, Institute for Oncology and Radiology of
      Serbia, Pasterova 14, 11000 Belgrade, Serbia.
FAU - Krivokuca, Ana
AU  - Krivokuca A
AUID- ORCID: 0000-0002-1698-6981
AD  - Department of Experimental Oncology, Institute for Oncology and Radiology of
      Serbia, Pasterova 14, 11000 Belgrade, Serbia.
FAU - Canela, Enric I
AU  - Canela EI
AD  - Department of Biochemistry and Molecular Biomedicine, Faculty of Biology,
      University of Barcelona, and Institute of Biomedicine of the University of
      Barcelona (IBUB), 08028 Barcelona, Spain.
AD  - Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas
      (CIBERNED), 28031 Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201105
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7694406
OTO - NOTNLM
OT  - anti-cancer treatment
OT  - cancer risk
OT  - cannabinoid receptors
OT  - cannabinoids
EDAT- 2020/11/11 06:00
MHDA- 2020/11/11 06:01
CRDT- 2020/11/10 01:05
PHST- 2020/10/06 00:00 [received]
PHST- 2020/11/02 00:00 [revised]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/10 01:05 [entrez]
PHST- 2020/11/11 06:00 [pubmed]
PHST- 2020/11/11 06:01 [medline]
AID - cancers12113275 [pii]
AID - 10.3390/cancers12113275 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Nov 5;12(11). pii: cancers12113275. doi:
      10.3390/cancers12113275.


PMID- 33166989
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Using a Respectful Approach to Child-centred Healthcare (ReACH) in a paediatric
      clinical trial: A feasibility study.
PG  - e0241764
LID - 10.1371/journal.pone.0241764 [doi]
AB  - BACKGROUND: There is a growing momentum in paediatric ethics to develop
      respectful research and healthcare protocols. We developed, tested and refined
      our 'Respectful Approach to Child-centred Healthcare' (ReACH), to underpin
      respectful participant interactions in a clinical trial. OBJECTIVE: To determine 
      whether a ReACH-based approach is acceptable to children and parents, and
      effective in obtaining compliance with common healthcare assessments in a
      clinical trial of healthy 4-6-year-old children. METHODS: ReACH-based child
      assessments were evaluated at two baseline clinics and one post-intervention,
      using mixed methods. Children (n = 49; 46.9% female; mean age = 5.24+/-0.88 years
      at baseline) and their parents provided independent evaluation, via customised
      5-point Likert scales and qualitative feedback. A dedicated child researcher
      evaluated adherence to the study ReACH principles. RESULTS: Children achieved
      compliance rates of 95% for body composition (BodPod) assessments; 89% for blood 
      pressure measurements, and 92% (baseline) and 87% (post-intervention) for blood
      draws. Adherence to ReACH principles during clinic visits was positively
      associated with child compliance, significantly for baseline BodPod (p = 0.002)
      and blood test (p = 0.009) clinics. Satisfaction with BodPod protocols was
      positively associated with compliance, for children at baseline (p = 0.029) and
      for parents post-intervention (p <0.001). Parents rated the study itself very
      highly, with 91.7% satisfied at baseline and 100% post-intervention. Qualitative 
      feedback reflected an enjoyable study experience for both parents and children.
      CONCLUSIONS: Adherence to our emerging ReACH approach was associated with high
      child compliance rates for common healthcare assessments, although no causality
      can be inferred at this preliminary stage of development. Participants expressed 
      satisfaction with all aspects of the study. Our use of child-centred methods
      throughout a research intervention appears feasible and acceptable to children
      and their parents.
FAU - Nicholl, Analise
AU  - Nicholl A
AUID- ORCID: 0000-0003-4970-8096
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, 
      Western Australia, Australia.
FAU - Evelegh, Kate
AU  - Evelegh K
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, 
      Western Australia, Australia.
FAU - Deering, Kane Evan
AU  - Deering KE
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, 
      Western Australia, Australia.
FAU - Russell, Kate
AU  - Russell K
AD  - Peaceful Parents, Confident Kids, Toowoomba, Queensland, Australia.
FAU - Lawrence, David
AU  - Lawrence D
AD  - Faculty of Arts, Business, Law and Education, Graduate School of Education,
      University of Western Australia, Perth, Western Australia, Australia.
FAU - Lyons-Wall, Philippa
AU  - Lyons-Wall P
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, 
      Western Australia, Australia.
FAU - O'Sullivan, Therese Anne
AU  - O'Sullivan TA
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, 
      Western Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201109
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Child
MH  - Child Day Care Centers/statistics & numerical data
MH  - Child, Preschool
MH  - Delivery of Health Care/*methods
MH  - Double-Blind Method
MH  - Feasibility Studies
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
PMC - PMC7652280
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/10 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/11/09 20:20
PHST- 2019/12/30 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/09 20:20 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
AID - 10.1371/journal.pone.0241764 [doi]
AID - PONE-D-19-35472 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 9;15(11):e0241764. doi: 10.1371/journal.pone.0241764.
      eCollection 2020.


PMID- 33166819
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2210-2612 (Print)
IS  - 2210-2612 (Linking)
VI  - 77
DP  - 2020
TI  - Triphallia (triple penis), the first reported case in human.
PG  - 198-200
LID - S2210-2612(20)31024-5 [pii]
LID - 10.1016/j.ijscr.2020.11.008 [doi]
AB  - INTRODUCTION: Supernumerary penises is an extremely rare congenital anomaly which
      affects one in every 5-6 million live births. Affected patients may have only a
      rudimentary penis, supernumerary penile glances or complete duplication or
      triplication of penises. Some patients may have some other associated congenital 
      anomalies. PRESENTATION OF CASE: A 3-month-old child presented because of left
      side hydrocele. There were evidence of two supernumerary penises in the perineum,
      the first one was about 2 cm in length with a glans and was attached to the root 
      of the penis, and the third one was about 1 cm and was below the scrotum.
      Hydrocelectomy was performed. The two supernumerary penises were extending to
      perineal region and were attached to original penis, both had corpora cavernosum 
      and spongiosum with no urethra inside. Both supernumerary penises were excised
      and both corpora were sutured with a fine slowly absorbable suture material. The 
      patient was discharged with no postoperative events and follow up was done for
      one years with no reported adverse events. CONCLUSION: Triphallia (three penises)
      is unreported condition in human until now. Patients with supernumerary penises
      have unique presentation and no cases are identical. The position of the penis
      may be ectopic or orthotopic. Treatment is difficult because it poses medical,
      ethical, and cosmetic aspects. A combined multidisciplinary team is required for 
      the management and long term follow up is required. Excision or reconstruction of
      the duplicate penis is required depending on the corporal development and anatomy
      of the urethra.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Jabali, Shakir Saleem
AU  - Jabali SS
AD  - Department of Surgery, College of Medicine, University of Duhok, Kurdistan
      Region, Iraq.
FAU - Mohammed, Ayad Ahmad
AU  - Mohammed AA
AD  - Department of Surgery, College of Medicine, University of Duhok, Kurdistan
      Region, Iraq. Electronic address: ayad.mohammed@uod.ac.
LA  - eng
PT  - Case Reports
DEP - 20201104
PL  - Netherlands
TA  - Int J Surg Case Rep
JT  - International journal of surgery case reports
JID - 101529872
PMC - PMC7652711
OTO - NOTNLM
OT  - Diphallia
OT  - Multiple penises
OT  - Supernumerary penises
OT  - Triphallia
OT  - Urogenital anomalies
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 20:16
PHST- 2020/10/02 00:00 [received]
PHST- 2020/10/31 00:00 [revised]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
PHST- 2020/11/09 20:16 [entrez]
AID - S2210-2612(20)31024-5 [pii]
AID - 10.1016/j.ijscr.2020.11.008 [doi]
PST - ppublish
SO  - Int J Surg Case Rep. 2020;77:198-200. doi: 10.1016/j.ijscr.2020.11.008. Epub 2020
      Nov 4.


PMID- 33166197
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20211110
IS  - 2473-4276 (Electronic)
IS  - 2473-4276 (Linking)
VI  - 4
DP  - 2020 Nov
TI  - Joint Imaging Platform for Federated Clinical Data Analytics.
PG  - 1027-1038
LID - 10.1200/CCI.20.00045 [doi]
AB  - PURPOSE: Image analysis is one of the most promising applications of artificial
      intelligence (AI) in health care, potentially improving prediction, diagnosis,
      and treatment of diseases. Although scientific advances in this area critically
      depend on the accessibility of large-volume and high-quality data, sharing data
      between institutions faces various ethical and legal constraints as well as
      organizational and technical obstacles. METHODS: The Joint Imaging Platform (JIP)
      of the German Cancer Consortium (DKTK) addresses these issues by providing
      federated data analysis technology in a secure and compliant way. Using the JIP, 
      medical image data remain in the originator institutions, but analysis and AI
      algorithms are shared and jointly used. Common standards and interfaces to local 
      systems ensure permanent data sovereignty of participating institutions. RESULTS:
      The JIP is established in the radiology and nuclear medicine departments of 10
      university hospitals in Germany (DKTK partner sites). In multiple complementary
      use cases, we show that the platform fulfills all relevant requirements to serve 
      as a foundation for multicenter medical imaging trials and research on large
      cohorts, including the harmonization and integration of data, interactive
      analysis, automatic analysis, federated machine learning, and extensibility and
      maintenance processes, which are elementary for the sustainability of such a
      platform. CONCLUSION: The results demonstrate the feasibility of using the JIP as
      a federated data analytics platform in heterogeneous clinical information
      technology and software landscapes, solving an important bottleneck for the
      application of AI to large-scale clinical imaging data.
FAU - Scherer, Jonas
AU  - Scherer J
AUID- ORCID: 0000-0001-8608-6252
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
FAU - Nolden, Marco
AU  - Nolden M
AUID- ORCID: 0000-0001-9629-0564
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Pattern Analysis and Learning Group, Radio-oncology and Clinical Radiotherapy,
      Heidelberg University Hospital, Heidelberg, Germany.
FAU - Kleesiek, Jens
AU  - Kleesiek J
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Division of Radiology, German Cancer Research Center, Heidelberg, Germany.
FAU - Metzger, Jasmin
AU  - Metzger J
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
FAU - Kades, Klaus
AU  - Kades K
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
FAU - Schneider, Verena
AU  - Schneider V
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Division of Radiology, German Cancer Research Center, Heidelberg, Germany.
FAU - Bach, Michael
AU  - Bach M
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Division of Radiology, German Cancer Research Center, Heidelberg, Germany.
FAU - Sedlaczek, Oliver
AU  - Sedlaczek O
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Division of Radiology, German Cancer Research Center, Heidelberg, Germany.
AD  - Klinik Diagnostische und Interventionelle Radiologie der Universitat Heidelberg, 
      Heidelberg, Germany.
FAU - Bucher, Andreas M
AU  - Bucher AM
AUID- ORCID: 0000-0001-9194-5955
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum 
      Frankfurt, Frankfurt, Germany.
FAU - Vogl, Thomas J
AU  - Vogl TJ
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum 
      Frankfurt, Frankfurt, Germany.
FAU - Grunwald, Frank
AU  - Grunwald F
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Frankfurt, Frankfurt, Germany.
FAU - Kuhn, Jens-Peter
AU  - Kuhn JP
AUID- ORCID: 0000-0003-3258-930X
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut und Poliklinik fur Diagnostische und Interventionelle Radiologie,
      Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Germany.
FAU - Hoffmann, Ralf-Thorsten
AU  - Hoffmann RT
AUID- ORCID: 0000-0003-3150-4263
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut und Poliklinik fur Diagnostische und Interventionelle Radiologie,
      Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Germany.
FAU - Kotzerke, Jorg
AU  - Kotzerke J
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Universitatsklinikum Carl Gustav Carus 
      Dresden, Dresden, Germany.
FAU - Bethge, Oliver
AU  - Bethge O
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Medical Faculty, Department of Diagnostic and Interventional Radiology,
      University Dusseldorf, Dusseldorf, Germany.
FAU - Schimmoller, Lars
AU  - Schimmoller L
AUID- ORCID: 0000-0001-7476-292X
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Medical Faculty, Department of Diagnostic and Interventional Radiology,
      University Dusseldorf, Dusseldorf, Germany.
FAU - Antoch, Gerald
AU  - Antoch G
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Medical Faculty, Department of Diagnostic and Interventional Radiology,
      University Dusseldorf, Dusseldorf, Germany.
FAU - Muller, Hans-Wilhelm
AU  - Muller HW
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Dusseldorf, Dusseldorf, Germany.
FAU - Daul, Andreas
AU  - Daul A
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Tubingen, Tubingen, Germany.
FAU - Nikolaou, Konstantin
AU  - Nikolaou K
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Tubingen, Tubingen, Germany.
FAU - la Fougere, Christian
AU  - la Fougere C
AUID- ORCID: 0000-0001-7519-0417
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin und Klinische Molekulare Bildgebung,
      Universitatsklinikum Tubingen, Tubingen, Germany.
FAU - Kunz, Wolfgang G
AU  - Kunz WG
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Department of Radiology, University Hospital, Ludwig Maximilian University
      Munich, Munich, Germany.
FAU - Ingrisch, Michael
AU  - Ingrisch M
AUID- ORCID: 0000-0003-0268-9078
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Department of Radiology, University Hospital, Ludwig Maximilian University
      Munich, Munich, Germany.
FAU - Schachtner, Balthasar
AU  - Schachtner B
AUID- ORCID: 0000-0002-8712-3948
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Department of Radiology, University Hospital, Ludwig Maximilian University
      Munich, Munich, Germany.
AD  - German Center of Lung Research, Giessen, Germany.
FAU - Ricke, Jens
AU  - Ricke J
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Department of Radiology, University Hospital, Ludwig Maximilian University
      Munich, Munich, Germany.
FAU - Bartenstein, Peter
AU  - Bartenstein P
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Klinikum der Universitat Munchen,
      Munchen, Germany.
FAU - Nensa, Felix
AU  - Nensa F
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie und Neuroradiologie,
      Universitatsklinikum Essen AoR, Essen, Germany.
FAU - Radbruch, Alexander
AU  - Radbruch A
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie und Neuroradiologie,
      Universitatsklinikum Essen AoR, Essen, Germany.
FAU - Umutlu, Lale
AU  - Umutlu L
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie und Neuroradiologie,
      Universitatsklinikum Essen AoR, Essen, Germany.
FAU - Forsting, Michael
AU  - Forsting M
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie und Neuroradiologie,
      Universitatsklinikum Essen AoR, Essen, Germany.
FAU - Seifert, Robert
AU  - Seifert R
AUID- ORCID: 0000-0001-5985-7701
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Essen AoR, Essen, Germany.
FAU - Herrmann, Ken
AU  - Herrmann K
AUID- ORCID: 0000-0002-9662-7259
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Essen AoR, Essen, Germany.
FAU - Mayer, Philipp
AU  - Mayer P
AUID- ORCID: 0000-0003-1957-1594
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik Diagnostische und Interventionelle Radiologie der Universitat Heidelberg, 
      Heidelberg, Germany.
FAU - Kauczor, Hans-Ulrich
AU  - Kauczor HU
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik Diagnostische und Interventionelle Radiologie der Universitat Heidelberg, 
      Heidelberg, Germany.
AD  - German Center of Lung Research, Giessen, Germany.
FAU - Penzkofer, Tobias
AU  - Penzkofer T
AUID- ORCID: 0000-0001-9591-8575
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Radiologie (mit dem Bereich Kinderradiologie), Charite
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Hamm, Bernd
AU  - Hamm B
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Radiologie (mit dem Bereich Kinderradiologie), Charite
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Brenner, Winfried
AU  - Brenner W
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Kloeckner, Roman
AU  - Kloeckner R
AUID- ORCID: 0000-0001-5492-4792
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Diagnostische und Interventionelle Radiologie,
      Universitatsmedizin Mainz, Mainz, Germany.
FAU - Duber, Christoph
AU  - Duber C
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Diagnostische und Interventionelle Radiologie,
      Universitatsmedizin Mainz, Mainz, Germany.
FAU - Schreckenberger, Mathias
AU  - Schreckenberger M
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Universitatsmedizin Mainz, Mainz,
      Germany.
FAU - Braren, Rickmer
AU  - Braren R
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie, Klinikum Rechts der
      Isar, Technical University of Munich, Munich, Germany.
FAU - Kaissis, Georgios
AU  - Kaissis G
AUID- ORCID: 0000-0001-8382-8062
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Pattern Analysis and Learning Group, Radio-oncology and Clinical Radiotherapy,
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie, Klinikum Rechts der
      Isar, Technical University of Munich, Munich, Germany.
AD  - Department of Computing, Imperial College London, London, United Kingdom.
FAU - Makowski, Marcus
AU  - Makowski M
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Institut fur Diagnostische und Interventionelle Radiologie, Klinikum Rechts der
      Isar, Technical University of Munich, Munich, Germany.
FAU - Eiber, Matthias
AU  - Eiber M
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Klinikum Rechts der Isar, Technical
      University of Munich, Munich, Germany.
FAU - Gafita, Andrei
AU  - Gafita A
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Klinikum Rechts der Isar, Technical
      University of Munich, Munich, Germany.
FAU - Trager, Rupert
AU  - Trager R
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Klinikum Rechts der Isar, Technical
      University of Munich, Munich, Germany.
FAU - Weber, Wolfgang A
AU  - Weber WA
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik und Poliklinik fur Nuklearmedizin, Klinikum Rechts der Isar, Technical
      University of Munich, Munich, Germany.
FAU - Neubauer, Jakob
AU  - Neubauer J
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Freiburg, Freiburg, Germany.
FAU - Reisert, Marco
AU  - Reisert M
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Freiburg, Freiburg, Germany.
FAU - Bock, Michael
AU  - Bock M
AUID- ORCID: 0000-0001-9720-3506
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Freiburg, Freiburg, Germany.
FAU - Bamberg, Fabian
AU  - Bamberg F
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Freiburg, Freiburg, Germany.
FAU - Hennig, Jurgen
AU  - Hennig J
AUID- ORCID: 0000-0002-2273-3497
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Diagnostische und Interventionelle Radiologie, Universitatsklinikum
      Freiburg, Freiburg, Germany.
FAU - Meyer, Philipp Tobias
AU  - Meyer PT
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Freiburg, Freiburg, Germany.
FAU - Ruf, Juri
AU  - Ruf J
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Freiburg, Freiburg, Germany.
FAU - Haberkorn, Uwe
AU  - Haberkorn U
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Klinische Kooperationseinheit Nuklearmedizin, Deutsches Krebsforschungszentrum
      Heidelberg, Heidelberg, Germany.
FAU - Schoenberg, Stefan O
AU  - Schoenberg SO
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Universitatsmedizin Mannheim, Medizinische Fakultat Mannheim der Universitat
      Heidelberg, Heidelberg, Germany.
FAU - Kuder, Tristan
AU  - Kuder T
AUID- ORCID: 0000-0001-6439-8124
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Medizinische Physik in der Radiologie, Deutsches Krebsforschungszentrum
      Heidelberg, Heidelberg, Germany.
FAU - Neher, Peter
AU  - Neher P
AUID- ORCID: 0000-0002-5285-7554
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
FAU - Floca, Ralf
AU  - Floca R
AUID- ORCID: 0000-0003-3218-3377
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Pattern Analysis and Learning Group, Radio-oncology and Clinical Radiotherapy,
      Heidelberg University Hospital, Heidelberg, Germany.
FAU - Schlemmer, Heinz-Peter
AU  - Schlemmer HP
AD  - Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.
AD  - German Cancer Consortium, Heidelberg, Germany.
AD  - Division of Radiology, German Cancer Research Center, Heidelberg, Germany.
FAU - Maier-Hein, Klaus
AU  - Maier-Hein K
AUID- ORCID: 0000-0002-6626-2463
AD  - Division of Medical Image Computing, German Cancer Research Center, Heidelberg,
      Germany.
AD  - Pattern Analysis and Learning Group, Radio-oncology and Clinical Radiotherapy,
      Heidelberg University Hospital, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JCO Clin Cancer Inform
JT  - JCO clinical cancer informatics
JID - 101708809
SB  - IM
MH  - *Artificial Intelligence
MH  - Data Science
MH  - Delivery of Health Care
MH  - Germany
MH  - Humans
MH  - *Radiology
PMC - PMC7713526
EDAT- 2020/11/10 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/11/09 17:10
PHST- 2020/11/09 17:10 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
AID - 10.1200/CCI.20.00045 [doi]
PST - ppublish
SO  - JCO Clin Cancer Inform. 2020 Nov;4:1027-1038. doi: 10.1200/CCI.20.00045.


PMID- 33166070
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - Ethics of Midwifery Care During the COVID-19 Pandemic.
PG  - 731-732
LID - 10.1111/jmwh.13187 [doi]
FAU - Kantrowitz-Gordon, Ira
AU  - Kantrowitz-Gordon I
AUID- ORCID: 0000-0002-8531-6965
LA  - eng
PT  - Editorial
DEP - 20201109
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - Beneficence
MH  - COVID-19/*epidemiology
MH  - Decision Making, Shared
MH  - Female
MH  - Health Policy
MH  - Health Status Disparities
MH  - Humans
MH  - Midwifery/*ethics
MH  - *Pandemics
MH  - Personal Autonomy
MH  - Pregnancy
MH  - Prenatal Care
MH  - Social Justice
MH  - Telemedicine
MH  - United States/epidemiology
EDAT- 2020/11/10 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/11/09 14:32
PHST- 2020/10/19 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/11/09 14:32 [entrez]
AID - 10.1111/jmwh.13187 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):731-732. doi: 10.1111/jmwh.13187. Epub 
      2020 Nov 9.


PMID- 33165882
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 1731-2531 (Electronic)
IS  - 1642-5758 (Linking)
VI  - 52
IP  - 4
DP  - 2020
TI  - Triage during the COVID-19 pandemic.
PG  - 312-315
LID - 42319 [pii]
LID - 10.5114/ait.2020.100564 [doi]
AB  - The coronavirus disease (COVID-19) was previously unknown, and we are learning
      about it day by day, but pandemic-associated ethical dilemmas have been studied
      and discussed for years. Triage means not only ranking in terms of importance
      (prioritisation) but also allocation of limited medical resources. Survival, post
      epidemic-quality of life, and consumption of medical resources required to
      achieve the set goal are crucial for making triage decisions. The pandemic triage
      decisions should be based on a protocol, considering the need for medical
      measures and therapy benefits. The first step is to consider the exclusion
      criteria and the risk of death. The next step is sequential clinical assessment, 
      repeatable at defined intervals. It seems that the preferable solution is to
      triage all the patients and give priority to those who would benefit more. A
      prerequisite for allocating insufficient medical resources is public trust in the
      criteria for allocation.
FAU - Kucewicz-Czech, Ewa
AU  - Kucewicz-Czech E
AD  - Department of Cardiac Anaesthesia and Intensive Care, Leszek Giec Upper-Silesian 
      Medical Centre, Medical University of Silesia, Katowice, Poland.
FAU - Damps, Maria
AU  - Damps M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Anaesthesiol Intensive Ther
JT  - Anaesthesiology intensive therapy
JID - 101472620
SB  - IM
MH  - COVID-19
MH  - Clinical Decision-Making
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Triage/statistics & numerical data/*trends
OTO - NOTNLM
OT  - * COVID-19
OT  - * triage
OT  - *pandemic
EDAT- 2020/11/10 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/09 14:28
PHST- 2020/11/09 14:28 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 42319 [pii]
AID - 10.5114/ait.2020.100564 [doi]
PST - ppublish
SO  - Anaesthesiol Intensive Ther. 2020;52(4):312-315. doi: 10.5114/ait.2020.100564.


PMID- 33165559
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Participant compensation in global health research: a case study.
PG  - 524-532
LID - 10.1093/inthealth/ihaa064 [doi]
AB  - BACKGROUND: Compensation for research participants can be provided for reasons
      including reimbursement of costs; compensation for time lost, discomfort or
      inconvenience; or expression of appreciation for participation. This compensation
      involves numerous ethical complexities, at times entailing competing risks. In
      the context of transnational research, often incorporating contexts of economic
      inequality, power differentials and post-colonialism, these issues extend into
      wider questions of ethical research conduct. METHODS: We describe experiences of 
      conducting a community-based study of air pollution in southern Malawi
      incorporating ethnographic, participatory and air quality monitoring elements.
      Decisions surrounding participant compensation evolved in response to changing
      circumstances in the field. RESULTS: Attention to careful researcher-participant 
      relationships and responsiveness to community perspectives allowed dynamic,
      contextualised decision-making around participant compensation. Despite widely
      cited risks, including but not restricted to undue influence of monetary
      compensation on participation, we learned that failure to adequately recognise
      and compensate participants has its own risks, notably the possibility of 'ethics
      dumping'. CONCLUSIONS: We recommend active engagement with research participants 
      and communities with integration of contextual insights throughout, including
      participant compensation, as for all elements of research conduct. Equitable
      research relationships encompass four central values: fairness, care, honesty and
      respect.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Saleh, Sepeedeh
AU  - Saleh S
AD  - Malawi-Liverpool-Wellcome Trust, Queen Elizabeth Central Hospital, College of
      Medicine, P.O. Box 30096, Chichiri, Blantyre 3, Malawi.
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
FAU - Sambakunsi, Henry
AU  - Sambakunsi H
AD  - Malawi-Liverpool-Wellcome Trust, Queen Elizabeth Central Hospital, College of
      Medicine, P.O. Box 30096, Chichiri, Blantyre 3, Malawi.
FAU - Nyirenda, Deborah
AU  - Nyirenda D
AD  - Malawi-Liverpool-Wellcome Trust, Queen Elizabeth Central Hospital, College of
      Medicine, P.O. Box 30096, Chichiri, Blantyre 3, Malawi.
FAU - Kumwenda, Moses
AU  - Kumwenda M
AD  - Malawi-Liverpool-Wellcome Trust, Queen Elizabeth Central Hospital, College of
      Medicine, P.O. Box 30096, Chichiri, Blantyre 3, Malawi.
FAU - Mortimer, Kevin
AU  - Mortimer K
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
FAU - Chinouya, Martha
AU  - Chinouya M
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
LA  - eng
GR  - 203919/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 16/136/35/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Anthropology, Cultural
MH  - *Global Health
MH  - Humans
MH  - Malawi
MH  - *Research Personnel
PMC - PMC7651450
OTO - NOTNLM
OT  - *ethics dumping
OT  - *global health
OT  - *participant compensation
OT  - *research ethics
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/05/04 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962068 [pii]
AID - 10.1093/inthealth/ihaa064 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):524-532. doi: 10.1093/inthealth/ihaa064.


PMID- 33165558
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Ethical research in global health emergencies: making the case for a broader
      understanding of 'research ethics'.
PG  - 515-517
LID - 10.1093/inthealth/ihaa053 [doi]
AB  - The ethical challenges of global health research become particularly acute in
      emergency contexts, and are exacerbated by historic inequities and imbalances in 
      power and influence. Drawing on the findings of an international working group
      established by the Nuffield Council on Bioethics, this article argues for the
      need to take a broader approach to 'research ethics' as traditionally understood,
      to include the role of 'duty-bearers' such as funders, governments, research
      institutions and journals. An 'ethical compass' of three core values (equal
      respect, fairness and helping reduce suffering) supports ethical reflection at
      the level of policy, as well as on the ground.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Wright, Katharine S
AU  - Wright KS
AD  - Nuffield Council on Bioethics, 28 Bedford Square, London WC1B 3JS, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - *Bioethics
MH  - Emergencies
MH  - Ethics, Research
MH  - *Global Health
MH  - Humans
PMC - PMC7651111
OTO - NOTNLM
OT  - *emergencies
OT  - *ethics
OT  - *global health
OT  - *research
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/05/21 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962067 [pii]
AID - 10.1093/inthealth/ihaa053 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):515-517. doi: 10.1093/inthealth/ihaa053.


PMID- 33165557
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Decolonising global health: transnational research partnerships under the
      spotlight.
PG  - 518-523
LID - 10.1093/inthealth/ihaa073 [doi]
AB  - There are increasing calls to decolonise aspects of science, and global health is
      no exception. The decolonising global health movement acknowledges that global
      health research perpetuates existing power imbalances and aims to identify
      concrete ways in which global health teaching and research can overcome its
      colonial past and present. Using the context of clinical trials implemented
      through transnational research partnerships (TRPs) as a case study, this
      narrative review brings together perspectives from clinical research and social
      science to lay out specific ways in which TRPs build on and perpetuate colonial
      power relations. We will explore three core components of TRPs: participant
      experience, expertise and infrastructure, and authorship. By combining a critical
      perspective with recently published literature we will recommend specific ways in
      which TRPs can be decolonised. We conclude by discussing decolonising global
      health as a potential practice and object of research. By doing this we intend to
      frame the decolonising global health movement as one that is accessible to
      everyone and within which we can all play an active role.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Lawrence, David S
AU  - Lawrence DS
AD  - Department of Clinical Research, Faculty of Infectious and Tropical Diseases, The
      London School of Hygiene and Tropical Medicine, London, UK.
AD  - Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
FAU - Hirsch, Lioba A
AU  - Hirsch LA
AD  - Department of Public Health, Environments and Society, Faculty of Public Health
      and Policy, London School of Hygiene and Tropical Medicine, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - *Global Health
MH  - *Health Education
MH  - Humans
PMC - PMC7651076
OTO - NOTNLM
OT  - *authorship
OT  - *decolonisation
OT  - *ethics
OT  - *global health
OT  - *transnational research partnerships
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/06/01 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962065 [pii]
AID - 10.1093/inthealth/ihaa073 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):518-523. doi: 10.1093/inthealth/ihaa073.


PMID- 33165556
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Participant understanding of informed consent in a multidisease community-based
      health screening and biobank platform in rural South Africa.
PG  - 560-566
LID - 10.1093/inthealth/ihaa072 [doi]
AB  - BACKGROUND: In low- and middle-income settings, obtaining informed consent for
      biobanking may be complicated by socio-economic vulnerability and
      context-specific power dynamics. We explored participants experiences and
      perceptions of the research objectives in a community-based multidisease
      screening and biospecimen collection platform in rural KwaZulu-Natal, South
      Africa. METHODS: We undertook semi-structured in-depth interviews to assess
      participant understanding of the informed consent, research objectives and
      motivation for participation. RESULTS: Thirty-nine people participated
      (individuals who participated in screening/biospecimen collection and those who
      did not and members of the research team). Some participants said they understood
      the information shared with them. Some said they participated due to the
      perceived benefits of the reimbursement and convenience of free healthcare. Most 
      who did not participate said it was due to logistical rather than ethical
      concerns. None of the participants recalled aspects of biobanking and genetics
      from the consent process. CONCLUSIONS: Although most people understood the study 
      objectives, we observed challenges to identifying language appropriate to explain
      biobanking and genetic testing to our target population. Engagement with
      communities to adopt contextually relevant terminologies that participants can
      understand is crucial. Researchers need to be mindful of the impact of
      communities' socio-economic status and how compensation can be potentially
      coercive.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Ngwenya, Nothando
AU  - Ngwenya N
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Division of Infection and Immunity, University College London, London, UK.
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, KwaZulu-Natal, South Africa.
FAU - Luthuli, Manono
AU  - Luthuli M
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
FAU - Gunda, Resign
AU  - Gunda R
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Division of Infection and Immunity, University College London, London, UK.
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, KwaZulu-Natal, South Africa.
FAU - Gumede, Ntombizonke A
AU  - Gumede NA
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
FAU - Adeagbo, Oluwafemi
AU  - Adeagbo O
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Division of Infection and Immunity, University College London, London, UK.
AD  - Department of Sociology, University of Johannesburg, Johannesburg, South Africa.
FAU - Nkosi, Busisiwe
AU  - Nkosi B
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Division of Infection and Immunity, University College London, London, UK.
FAU - Gareta, Dickman
AU  - Gareta D
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
FAU - Koole, Olivier
AU  - Koole O
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Global Health and Development Department, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Siedner, Mark
AU  - Siedner M
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
FAU - Wong, Emily B
AU  - Wong EB
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Division of Infection and Immunity, University College London, London, UK.
AD  - Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
FAU - Seeley, Janet
AU  - Seeley J
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Global Health and Development Department, London School of Hygiene and Tropical
      Medicine, London, UK.
CN  - Vukuzazi team
LA  - eng
GR  - K08 AI118538/AI/NIAID NIH HHS/United States
GR  - 096527/WT_/Wellcome Trust/United Kingdom
GR  - 082384/Z/07/Z/WT_/Wellcome Trust/United Kingdom
GR  - R01 AI152149/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - *Biological Specimen Banks
MH  - Comprehension
MH  - Humans
MH  - *Informed Consent
MH  - Research Personnel
MH  - South Africa
PMC - PMC7651191
OTO - NOTNLM
OT  - *South Africa
OT  - *demographic surveillance
OT  - *ethics
OT  - *informed consent
IR  - Surujdeen A
FIR - Surujdeen, Ashmika
IR  - Khumalo H
FIR - Khumalo, Hlolisile
IR  - Mhlongo N
FIR - Mhlongo, Ngcebo
IR  - Bucibo S
FIR - Bucibo, Sanah
IR  - Gumbi S
FIR - Gumbi, Sibahle
IR  - Mthembu L
FIR - Mthembu, Lindani
IR  - Mchunu S
FIR - Mchunu, Seneme
IR  - Phakamani M
FIR - Phakamani, Mkhwanazi
IR  - Anele M
FIR - Anele, Mkhwanazi
IR  - Ntombiyenhlanhla M
FIR - Ntombiyenhlanhla, Mkhwanazi
IR  - Rose M
FIR - Rose, Myeni
IR  - Mandlakayise Z
FIR - Mandlakayise, Zikhali
IR  - Fezeka M
FIR - Fezeka, Mfeka
IR  - Hlobisile G
FIR - Hlobisile, Gumede
IR  - Nozipho M
FIR - Nozipho, Mbonambi
IR  - Hloniphile N
FIR - Hloniphile, Ngubane
IR  - Thokozani S
FIR - Thokozani, Simelane
IR  - Bongumenzi N
FIR - Bongumenzi, Ndlovu
IR  - Talente N
FIR - Talente, Ntimbane
IR  - Mbali M
FIR - Mbali, Mbuyisa
IR  - Xolani M
FIR - Xolani, Mkhize
IR  - Melusi S
FIR - Melusi, Sibiya
IR  - Ntombela N
FIR - Ntombela, Ntombiyenkosi
IR  - Dlamini M
FIR - Dlamini, Mandisi
IR  - Nkosi T
FIR - Nkosi, Thengokwakhe
IR  - Mkhwanazi S
FIR - Mkhwanazi, Sibusiso
IR  - Skhumbuzo M
FIR - Skhumbuzo, Mthombeni
IR  - Hlobisile C
FIR - Hlobisile, Chonco
IR  - Hlengiwe D
FIR - Hlengiwe, Dlamini
IR  - Doctar M
FIR - Doctar, Mlambo
IR  - Nonhlanhla M
FIR - Nonhlanhla, Mzimela
IR  - Zinhle B
FIR - Zinhle, Buthelezi
IR  - Mpumelelo S
FIR - Mpumelelo, Steto
IR  - Sibusiso M
FIR - Sibusiso, Mhlongo
IR  - Bongani M
FIR - Bongani, Magwaza
IR  - Siyabonga N
FIR - Siyabonga, Nsibande
IR  - Nombuyiselo Z
FIR - Nombuyiselo, Zondi
IR  - Khanyisani B
FIR - Khanyisani, Buthelezi
IR  - Sibusiso N
FIR - Sibusiso, Nsibande
IR  - Mfeka N
FIR - Mfeka, Nonceba
IR  - Zungu A
FIR - Zungu, Ayanda
IR  - Gumede H
FIR - Gumede, Hlobisile
IR  - Mfekayi N
FIR - Mfekayi, Nonhlanhla
IR  - Zulu S
FIR - Zulu, Smangaliso
IR  - Buthelezi M
FIR - Buthelezi, Mzamo
IR  - Senzeni M
FIR - Senzeni, Mkhwanazi
IR  - Dube M
FIR - Dube, Mlungisi
IR  - Mthembu WP
FIR - Mthembu, Welcome Petros
IR  - Mthembu SC
FIR - Mthembu, Sphiwe Clement
IR  - Mthembu Z
FIR - Mthembu, Zinhle
IR  - Thokozani B
FIR - Thokozani, Bhengu
IR  - Mthembu S
FIR - Mthembu, Sandile
IR  - Mthethwa P
FIR - Mthethwa, Phumelele
IR  - Mbatha Z
FIR - Mbatha, Zamashandu
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/05/27 00:00 [received]
PHST- 2020/08/29 00:00 [accepted]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962058 [pii]
AID - 10.1093/inthealth/ihaa072 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):560-566. doi: 10.1093/inthealth/ihaa072.


PMID- 33165554
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20220531
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Comparative ethnographies of medical research: materiality, social relations,
      citizenship and hope in Tanzania and Sierra Leone.
PG  - 575-583
LID - 10.1093/inthealth/ihaa071 [doi]
AB  - In this paper we bring together ethnographic research carried out during two
      clinical prevention trials to explore identities, relations and political
      imaginations that were brought to life by these different technologies. We
      highlight the ways in which critical anthropological engagement in clinical
      trials can help us radically reconsider the parameters and standards of medical
      research. In the paper we analyse the very different circumstances that made
      these two trials possible, highlighting the different temporalities and politics 
      of HIV and Ebola as epidemics. We then describe four themes revealed by
      ethnographic research with participants and their communities but mediated by the
      specific sociopolitical contexts in which the trials were taking place. In both
      countries we found materiality and notions of exchange to be important to
      participants' understanding of the value of medical research and their role
      within it. These dynamics were governed through social relations and moral
      economies that also underpinned challenges to Western notions of research ethics.
      The clinical trials offered a language to express both disaffection and
      disillusionment with the political status quo (often through rumours and
      anxieties) while at the same time setting the foundations for alternative visions
      of citizenship. Attached to these were expressions of 'uncertainty and hope'
      steeped in locally distinctive notions of destiny and expectations of the future.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Lees, Shelley
AU  - Lees S
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK.
FAU - Enria, Luisa
AU  - Enria L
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK.
LA  - eng
GR  - G0100137/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Anthropology, Cultural
MH  - *Biomedical Research
MH  - Clinical Trials as Topic
MH  - *Epidemics
MH  - *Hemorrhagic Fever, Ebola/epidemiology
MH  - Humans
MH  - Sierra Leone
MH  - Tanzania
PMC - PMC7650898
OTO - NOTNLM
OT  - *Africa
OT  - *Ebola
OT  - *HIV
OT  - *anthropology
OT  - *clinical trials
OT  - *comparative
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/07/06 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962055 [pii]
AID - 10.1093/inthealth/ihaa071 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):575-583. doi: 10.1093/inthealth/ihaa071.


PMID- 33165553
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20220129
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Managing ancillary care in resource-constrained settings: Dilemmas faced by
      frontline HIV prevention researchers in a rural area in South Africa.
PG  - 543-550
LID - 10.1093/inthealth/ihaa045 [doi]
AB  - BACKGROUND: We describe the findings from a research ethics case study, linked
      with a team evaluating a package of intervention services to prevent HIV
      infection in adolescent girls and young women (AGYW) living in a rural and poor
      setting of KwaZulu-Natal, South Africa. METHODS: We conducted qualitative
      interviews (n=77) with members of the linked research team evaluating the
      intervention programme, programme implementing staff, AGYW enrolled in the
      intervention programme, caregivers, ethics committee members, Public Engagement
      officers, community advisory board members and community stakeholders. Data were 
      analysed iteratively using thematic framework analysis. Themes were determined by
      the study aims combined with an inductive development of codes emerging from the 
      data. RESULTS: The findings show that the burden of providing ancillary care fell
      primarily on the shoulders of frontline researchers and programme staff. Dilemmas
      around responding to gender-based violence illustrated the limits of 'referral to
      services' as a solution for meeting ancillary care obligations in contexts with
      barriers to basic health and social services. CONCLUSION: Our findings show
      important gaps in meeting ancillary care needs. Participants' needs required
      social and economic support which frontline researchers and implementing partners
      were not able to meet, causing moral distress.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Nkosi, Busisiwe
AU  - Nkosi B
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Institute for Global Health, University College London, London, UK.
FAU - Seeley, Janet
AU  - Seeley J
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - London School of Hygiene and Tropical Medicine, UK.
FAU - Chimbindi, Natsayi
AU  - Chimbindi N
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Institute for Global Health, University College London, London, UK.
FAU - Zuma, Thembelihle
AU  - Zuma T
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Institute for Global Health, University College London, London, UK.
FAU - Kelley, Maureen
AU  - Kelley M
AD  - Ethox Centre and Wellcome Centre for Ethics & Humanities, Nuffield Department of 
      Population Health, University of Oxford, UK.
FAU - Shahmanesh, Maryam
AU  - Shahmanesh M
AD  - Africa Health Research Institute, KwaZulu-Natal, South Africa.
AD  - Institute for Global Health, University College London, London, UK.
LA  - eng
GR  - 096527/WT_/Wellcome Trust/United Kingdom
GR  - R01 MH114560/MH/NIMH NIH HHS/United States
GR  - 203132/WT_/Wellcome Trust/United Kingdom
GR  - MC_PC_16025/MRC_/Medical Research Council/United Kingdom
GR  - 200344/Z/15/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Adolescent
MH  - Caregivers
MH  - Counseling
MH  - Female
MH  - *HIV Infections/prevention & control
MH  - Humans
MH  - Rural Population
MH  - South Africa
PMC - PMC7651306
OTO - NOTNLM
OT  - *South Africa
OT  - *ancillary care
OT  - *referral process
OT  - *vulnerability
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/06/01 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962054 [pii]
AID - 10.1093/inthealth/ihaa045 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):543-550. doi: 10.1093/inthealth/ihaa045.


PMID- 33165552
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Cohorts as collections of bodies and communities of persons: insights from the
      SEARCH010/RV254 research cohort.
PG  - 584-590
LID - 10.1093/inthealth/ihaa060 [doi]
AB  - Longitudinal research cohorts are uniquely suited to answer research questions
      about morbidity and mortality. Cohorts may be comprised of individuals identified
      by specific conditions or other shared traits. We argue that research cohorts are
      more than simply aggregations of individuals and their associated data to meet
      research objectives. They are social communities comprised of members,
      investigators and organizations whose own interests, identities and cultures
      interact and evolve over time. The literature describes a range of scientific and
      ethical challenges and opportunities associated with cohorts. To advance these
      deliberations, we report examples from the literature and our own research on the
      Thai SEARCH010/RV254 cohort, comprising individuals diagnosed with human
      immunodeficiency virus (HIV) during acute infection. We reflect on the impact of 
      cohort experiences and identity, and specifically how people incorporate cohort
      participation into meaning making associated with their diagnosis, the influence 
      of cohort participation on decision making for early-phase clinical trials
      recruited from within the cohort, and the impact of the relationships that exist 
      between researchers and participants. These data support the concept of cohorts
      as communities of persons, where identity is shaped, in part, through cohort
      experiences. The social meanings associated with cohorts have implications for
      the ethics of cohort-based research, as social contexts inevitably affect the
      ways that ethical concerns manifest.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Henderson, Gail E
AU  - Henderson GE
AD  - Department of Social Medicine, University of North Carolina School of Medicine,
      347A MacNider, 333 South Columbia Street, Chapel Hill, NC 27599-7240, USA.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - Department of Social Medicine, University of North Carolina School of Medicine,
      347A MacNider, 333 South Columbia Street, Chapel Hill, NC 27599-7240, USA.
FAU - Corneli, Amy
AU  - Corneli A
AD  - Departments of Population Health Sciences and Medicine, School of Medicine, Duke 
      Clinical Research Institute, Duke University, 215 Morris Street, Durham, NC
      27701.
FAU - Peay, Holly L
AU  - Peay HL
AD  - RTI International, 3040 E Cornwallis Rd, Research Triangle Park, NC 27709.
LA  - eng
GR  - R01 AI127024/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Cohort Studies
MH  - *HIV Infections
MH  - Humans
MH  - Informed Consent
MH  - Thailand
PMC - PMC7650957
OTO - NOTNLM
OT  - *HIV
OT  - *cohort studies
OT  - *cure trials
OT  - *ethics
OT  - *informed consent
OT  - *social sciences
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/06/19 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962053 [pii]
AID - 10.1093/inthealth/ihaa060 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):584-590. doi: 10.1093/inthealth/ihaa060.


PMID- 33165551
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20220531
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Recommendations from Thai stakeholders about protecting HIV remission ('cure')
      trial participants: report from a participatory workshop.
PG  - 567-574
LID - 10.1093/inthealth/ihaa067 [doi]
AB  - BACKGROUND: The social/behavioral HIV Decision-Making Study (DMS) assesses
      informed consent and trial experiences of individuals in HIV remission trials in 
      Thailand. We convened a 1-d multi-stakeholder participatory workshop in Bangkok. 
      We provide a meeting summary and reactions from DMS investigators. METHODS:
      Workshop members viewed de-identified interview excerpts from DMS participants.
      They deliberated on the findings and made recommendations regarding informed
      choice for remission trials. Notes and recordings were used to create a summary
      report, which was reviewed by members and refined. RESULTS: Workshop members'
      recommendations included HIV education and psychosocial support to establish the 
      basis for informed choice, key trial information to be provided in everyday
      language, supportive decision-making processes and psychosocial care during and
      after the trial. Concerns included participant willingness to restart
      antiretrovirals after trial-mandated treatment interruption, unintended influence
      of the research team on decision-making and seemingly altruistic motivations for 
      trial participation that may signal attempts to atone for stigmatized behavior.
      CONCLUSIONS: The workshop highlighted community perspectives and resulted in
      recommendations for supporting informed choice and psychosocial and physical
      health. These are the first such recommendations arising from a deliberative
      process. Although some elements are rooted in the Thai context, most are
      applicable across remission trials.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Peay, Holly L
AU  - Peay HL
AD  - RTI International, Research Triangle Park, USA.
FAU - Ormsby, Nuchanart Q
AU  - Ormsby NQ
AD  - University of North Carolina at Chapel Hill, Department of Social Medicine, USA.
FAU - Henderson, Gail E
AU  - Henderson GE
AD  - University of North Carolina at Chapel Hill, Department of Social Medicine, USA.
FAU - Jupimai, Thidarat
AU  - Jupimai T
AD  - Center of Excellence in Pediatric Infectious Diseases and Vaccines Faculty of
      Medicine, Chulalongkorn University, Thailand.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - University of North Carolina at Chapel Hill, Department of Social Medicine, USA.
AD  - University of North Carolina at Chapel Hill, Center for Bioethics, USA.
FAU - Siripassorn, Krittaecho
AU  - Siripassorn K
AD  - Bamrasnaradura Infectious Diseases Institute, Thailand.
FAU - Kanchawee, Kunakorn
AU  - Kanchawee K
AD  - Center of Excellence in Research on Gender, Sexuality and Health, Faculty of
      Social Sciences and Humanities, Mahidol University, Thailand.
FAU - Isaacson, Sinead
AU  - Isaacson S
AD  - University of North Carolina at Chapel Hill, Department of Social Medicine, USA.
AD  - University of North Carolina at Chapel Hill, Department of Epidemiology, USA.
FAU - Cadigan, R Jean
AU  - Cadigan RJ
AD  - University of North Carolina at Chapel Hill, Department of Social Medicine, USA.
AD  - University of North Carolina at Chapel Hill, Center for Bioethics, USA.
FAU - Kuczynski, Kriste
AU  - Kuczynski K
AD  - University of North Carolina at Chapel Hill, Department of Social Medicine, USA.
FAU - Likhitwonnawut, Udom
AU  - Likhitwonnawut U
AD  - Thailand National CAB on HIV research, Thailand.
LA  - eng
GR  - R01 AI127024/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - *Clinical Trials as Topic
MH  - *HIV Infections/drug therapy/prevention & control
MH  - Humans
MH  - Informed Consent
MH  - Language
MH  - *Research Report
MH  - Thailand
PMC - PMC7650909
OTO - NOTNLM
OT  - *HIV
OT  - *cure trials
OT  - *ethics
OT  - *informed consent
OT  - *stakeholder engagement
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/06/08 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962052 [pii]
AID - 10.1093/inthealth/ihaa067 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):567-574. doi: 10.1093/inthealth/ihaa067.


PMID- 33165550
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Towards a fair and transparent research participant compensation and
      reimbursement framework in Vietnam.
PG  - 533-540
LID - 10.1093/inthealth/ihaa066 [doi]
AB  - BACKGROUND: Providing compensation for participants in clinical research is well 
      established and while international guidelines exist, defining a context-specific
      and fair compensation for participants in low-resource settings is challenging
      due to ethical concerns and the lack of practical, national compensation and
      reimbursement frameworks. METHODS: We reviewed Oxford University Clinical
      Research Unit (OUCRU) internal reimbursement documentation over a 10-y period and
      conducted a scoping literature review to expand our knowledge of compensation and
      reimbursement practices including ethical concerns. We developed a preliminary
      reimbursement framework that was presented to community advisory boards (CAB) and
      clinical investigators to assess its applicability, fairness and transparency.
      RESULTS: The main topics discussed at the workshops centered on fairness and
      whether the reimbursements could be perceived as financial incentives. Other
      decisive factors in the decision-making process were altruism and the loss of
      caregivers' earnings. Investigators raised the issue of additional burdens,
      whereas the CAB members were focused on non-monetary elements such as the
      healthcare quality the patients would receive. All elements discussed were
      reviewed and, where possible, incorporated into the final framework. CONCLUSION: 
      Our new reimbursement framework provides a consistent, fair and transparent
      decision-making process and will be implemented across all future OUCRU clinical 
      research in Vietnam.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Sansom, Lucy J
AU  - Sansom LJ
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
FAU - Minh, Trang Pham Nguyen
AU  - Minh TPN
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
FAU - Hill, Iona E
AU  - Hill IE
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
AD  - Department of Pure and Applied Chemistry, Technology and Innovation Centre,
      University of Strathclyde, 99 George St, Glasgow G1 1RD, UK.
FAU - Ha, Quyen Nguyen Than
AU  - Ha QNT
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
FAU - Trong, Thuan Dang
AU  - Trong TD
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
FAU - Vidaillac, Celine
AU  - Vidaillac C
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
AD  - Centre for Tropical Medicine and Global Health, New Richards Building, Old Road
      Campus, Roosevelt Drive, Oxford, OX3 7LG, UK.
FAU - Quynh, Nhu Dong
AU  - Quynh ND
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
FAU - Turner, Hugo C
AU  - Turner HC
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
AD  - Centre for Tropical Medicine and Global Health, New Richards Building, Old Road
      Campus, Roosevelt Drive, Oxford, OX3 7LG, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, Department of Infectious
      Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial
      College London, Level 2, Faculty Building South Kensington Campus, London SW7
      2AZ, UK.
FAU - Van Nuil, Jennifer Ilo
AU  - Van Nuil JI
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
AD  - Centre for Tropical Medicine and Global Health, New Richards Building, Old Road
      Campus, Roosevelt Drive, Oxford, OX3 7LG, UK.
FAU - Phuong, Dung Nguyen Thi
AU  - Phuong DNT
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
FAU - Kestelyn, Evelyne
AU  - Kestelyn E
AD  - Oxford University Clinical Research Unit, University of Oxford, Centre for
      Tropical Medicine, 764, Vo Van Kiet, Ho Chi Minh City, Vietnam.
AD  - Centre for Tropical Medicine and Global Health, New Richards Building, Old Road
      Campus, Roosevelt Drive, Oxford, OX3 7LG, UK.
LA  - eng
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
GR  - 106680/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - 096527/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Humans
MH  - Income
MH  - *Motivation
MH  - *Research Personnel
MH  - Vietnam
PMC - PMC7651161
OTO - NOTNLM
OT  - *LMICs
OT  - *Vietnam
OT  - *ethics
OT  - *participant compensation
OT  - *participant reimbursement
OT  - *remuneration framework
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/06/08 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/08/06 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962051 [pii]
AID - 10.1093/inthealth/ihaa066 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):533-540. doi: 10.1093/inthealth/ihaa066.


PMID- 33165549
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20220129
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Research ethics in context: understanding the vulnerabilities, agency and
      resourcefulness of research participants living along the Thai-Myanmar border.
PG  - 551-559
LID - 10.1093/inthealth/ihaa052 [doi]
AB  - BACKGROUND: Research ethics guidelines set a high bar for conducting research
      with vulnerable populations, often resulting in their exclusion from beneficial
      research. Our study aims to better characterise participants' vulnerabilities,
      agency, resourcefulness and sources of support. METHODS: We undertook qualitative
      research around two clinical studies involving migrant women living along the
      Thai-Myanmar border. We conducted 32 in-depth interviews and 10 focus group
      discussions with research participants, families, researchers and key informants.
      RESULTS: We found that being 'undocumented' is at the core of many structural
      vulnerabilities, reflecting political, economic, social and health needs.
      Although migrant women lead challenging lives, they have a support network that
      includes family, employers, community leaders, non-governmental organisations and
      research networks. Migrant women choose to participate in research to access
      quality healthcare, gain knowledge and obtain extra money. However, research has 
      the potential to exacerbate existing vulnerabilities, such as the burdens of
      cross-border travel, foregoing work and being more visible as migrants.
      CONCLUSIONS: Our study confirms that research is important to provide
      evidence-based care and was viewed by participants as offering many benefits, but
      it also has hidden burdens. Migrant women exercised agency and resourcefulness
      when navigating challenges in their lives and research participation.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Khirikoekkong, Napat
AU  - Khirikoekkong N
AD  - Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University,
      Mae Sot, Thailand.
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, Thailand.
FAU - Jatupornpimol, Nattapat
AU  - Jatupornpimol N
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, Thailand.
FAU - Nosten, Suphak
AU  - Nosten S
AD  - Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University,
      Mae Sot, Thailand.
FAU - Asarath, Supa-At
AU  - Asarath SA
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, Thailand.
FAU - Hanboonkunupakarn, Borimas
AU  - Hanboonkunupakarn B
AD  - Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
      University, Bangkok, Thailand.
FAU - McGready, Rose
AU  - McGready R
AD  - Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University,
      Mae Sot, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Nosten, Francois
AU  - Nosten F
AD  - Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University,
      Mae Sot, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Roest, Jennifer
AU  - Roest J
AD  - Wellcome Centre for Ethics & Humanities, Nuffield Department of Population
      Health, University of Oxford, Oxford, UK.
AD  - The Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      Oxford, UK.
FAU - Parker, Michael
AU  - Parker M
AD  - Wellcome Centre for Ethics & Humanities, Nuffield Department of Population
      Health, University of Oxford, Oxford, UK.
AD  - The Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      Oxford, UK.
FAU - Kelley, Maureen
AU  - Kelley M
AD  - Wellcome Centre for Ethics & Humanities, Nuffield Department of Population
      Health, University of Oxford, Oxford, UK.
AD  - The Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      Oxford, UK.
FAU - Cheah, Phaik Yeong
AU  - Cheah PY
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - The Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      Oxford, UK.
LA  - eng
GR  - 096527/WT_/Wellcome Trust/United Kingdom
GR  - 106698/WT_/Wellcome Trust/United Kingdom
GR  - 203132/WT_/Wellcome Trust/United Kingdom
GR  - MC_PC_16025/MRC_/Medical Research Council/United Kingdom
GR  - 200344/Z/15/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Ethics, Research
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Myanmar
MH  - Qualitative Research
MH  - Thailand
MH  - *Transients and Migrants
PMC - PMC7651704
OTO - NOTNLM
OT  - *agency
OT  - *consent
OT  - *migrants
OT  - *pregnant women
OT  - *research ethics
OT  - *vulnerability
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/06/01 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/07/20 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962050 [pii]
AID - 10.1093/inthealth/ihaa052 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):551-559. doi: 10.1093/inthealth/ihaa052.


PMID- 33165548
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20220129
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Experiences of research ethics committee members and scientists of the research
      protocol review process in Uganda: a case study.
PG  - 541-542
LID - 10.1093/inthealth/ihaa047 [doi]
AB  - BACKGROUND: We investigated how relevant and responsive scientists and research
      ethics committee (REC) members considered the research protocol review processes 
      for health research practice in Uganda. METHODS: Interviews were conducted with
      five scientists and five REC members. Data were analysed thematically. RESULTS:
      How much to compensate for time, the amount of study information shared with
      volunteers and sample storage for future unknown research were areas of concern
      for REC members. Delays in getting feedback concerned scientists. CONCLUSIONS:
      Researchers and REC members need to hold regular discussions to ensure the review
      process is relevant and responsive.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Ssali, Agnes
AU  - Ssali A
AD  - MRC/UVRI & LSHTM Uganda Research Unit, P.O. Box 49, Entebbe.
FAU - Poland, Fiona
AU  - Poland F
AD  - University of East Anglia, Norwich UK Norwich Research Park, Norwich NR4 7TJ, UK.
FAU - Seeley, Janet
AU  - Seeley J
AD  - MRC/UVRI & LSHTM Uganda Research Unit, P.O. Box 49, Entebbe.
AD  - London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London
      WC1H 7SH, UK.
LA  - eng
GR  - MC_UU_00027/4/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - *Research Personnel
MH  - Uganda
PMC - PMC7651429
OTO - NOTNLM
OT  - *Uganda
OT  - *ethics committee
OT  - *process
OT  - *protocol
OT  - *research
OT  - *review
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/05/20 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962049 [pii]
AID - 10.1093/inthealth/ihaa047 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):541-542. doi: 10.1093/inthealth/ihaa047.


PMID- 33165547
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov 9
TI  - Competing ethics in a pilot strategy to implement parasitology training and
      research in post-Ebola Sierra Leone.
PG  - 509-514
LID - 10.1093/inthealth/ihaa065 [doi]
AB  - Much of the focus of public health research post-Ebola in Sierra Leone has been
      on rebuilding the healthcare system. However, very little attention has focused
      on capacity building in knowledge necessary for (bio)medical research,
      specifically around emerging opportunistic human pathogens that contribute to the
      high morbidity and mortality rates in Sierra Leone. In collaboration with
      academic staff from the University of Makeni, we engaged in a small-scale pilot
      intervention to strengthen medical parasitology teaching and research. The
      cultural competencies and ethical expertise provided by Sierra Leonean academics 
      was critical to work in local communities and ensuring consent to undertake
      research. Yet, at the end of a day of collecting samples, in small pieces of
      conversation, the staff also explained ethical constraints they experienced
      taking part in research collaborations. They illustrate that, while on the
      surface all may seem well with a project, there can be harmful effects in terms
      of accessibility, ownership, cultural responsiveness and accountability, which
      should be taken into consideration when establishing networks and collaborations 
      with universities from low-income countries.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Pena-Fernandez, Antonio
AU  - Pena-Fernandez A
AD  - Leicester School of Allied Health Sciences, Faculty of Health and Life Sciences, 
      De Montfort University, The Gateway, Leicester LE1 9BH, UK.
FAU - Anjum, Umar
AU  - Anjum U
AD  - Leicester School of Allied Health Sciences, Faculty of Health and Life Sciences, 
      De Montfort University, The Gateway, Leicester LE1 9BH, UK.
FAU - Wadoum, Raoul Emeric Guetiya
AU  - Wadoum REG
AD  - Department of Public Health, Microbiology and Immunology, Ernest Bai Koroma
      University of Science and Technology, Makeni, Sierra Leone.
AD  - Department of Public Health, University of Makeni, Makeni, Sierra Leone.
FAU - Koroma, Sylvester
AU  - Koroma S
AD  - Department of Public Health, University of Makeni, Makeni, Sierra Leone.
FAU - Berghs, Maria
AU  - Berghs M
AD  - Leicester School of Allied Health Sciences, Faculty of Health and Life Sciences, 
      De Montfort University, The Gateway, Leicester LE1 9BH, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
SB  - IM
MH  - Capacity Building
MH  - *Hemorrhagic Fever, Ebola
MH  - Humans
MH  - Public Health
MH  - Sierra Leone
PMC - PMC7650977
OTO - NOTNLM
OT  - *Sierra Leone
OT  - *capacity building
OT  - *ethics
OT  - *intervention
OT  - *parasitology
OT  - *research challenges
EDAT- 2020/11/10 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/11/09 14:25
PHST- 2020/05/04 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/11/09 14:25 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 5962048 [pii]
AID - 10.1093/inthealth/ihaa065 [doi]
PST - ppublish
SO  - Int Health. 2020 Nov 9;12(6):509-514. doi: 10.1093/inthealth/ihaa065.


PMID- 33165392
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201112
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Linking)
VI  - 65
IP  - 5
DP  - 2020 Sep-Oct
TI  - The Ethics of Machine Learning in Medical Sciences: Where Do We Stand Today?
PG  - 358-364
LID - 10.4103/ijd.IJD_419_20 [doi]
AB  - Advances in Machine Learning and availability of state-of-the-art computational
      resources, along with digitized healthcare data, have set the stage for extensive
      application of artificial intelligence in the realm of diagnosis, prognosis,
      clinical decision support, personalized treatment options, drug development, and 
      the field of biomedicine. Here, we discuss the application of Machine Learning
      algorithms in patient healthcare and dermatological domains along with the
      ethical complexities that are involved. In scientific studies, ethical challenges
      were initially not addressed proportionally (as assessed by keyword counts in
      PubMed) and just more recently (since 2016) this has started to improve. Few
      pioneering countries have created regulatory guidelines around how to respect
      matters of (1) privacy, (2) fairness, (3) accountability, (4) transparency and
      (5) conflict of interest when developing novel medical Machine Learning
      applications. While there is a strong promise of emerging medical applications to
      ultimately benefit both the patients and the medical practitioners, it is
      important to raise awareness on the five key ethical issues and incorporate them 
      into medical practice in the near future.
CI  - Copyright: (c) 2020 Indian Journal of Dermatology.
FAU - Basu, Treena
AU  - Basu T
AD  - Department of Mathematics, Occidental College, Los Angeles, USA.
FAU - Engel-Wolf, Sebastian
AU  - Engel-Wolf S
AD  - Systems Biotechnology Group, Technical University of Munich, Boltzmannstr. 15,
      Garching, Germany.
FAU - Menzer, Olaf
AU  - Menzer O
AD  - Department of Geography, University of California, Santa Barbara, Newport Beach, 
      CA, USA.
AD  - Technology Department, Retirement Solutions Division, Pacific Life, Newport
      Beach, CA, USA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC7640783
OTO - NOTNLM
OT  - Best practices
OT  - electronic health records
OT  - ethics
OT  - machine learning
COIS- There are no conflicts of interest.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 14:24
PHST- 2020/11/09 14:24 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.4103/ijd.IJD_419_20 [doi]
AID - IJD-65-358 [pii]
PST - ppublish
SO  - Indian J Dermatol. 2020 Sep-Oct;65(5):358-364. doi: 10.4103/ijd.IJD_419_20.


PMID- 33165343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 0019-5545 (Print)
IS  - 0019-5545 (Linking)
VI  - 62
IP  - 4
DP  - 2020 Jul-Aug
TI  - Does electroconvulsive therapy cause brain damage: An update.
PG  - 339-353
LID - 10.4103/psychiatry.IndianJPsychiatry_239_19 [doi]
AB  - Electroconvulsive therapy (ECT) is an effective modality of treatment for a
      variety of psychiatric disorders. However, it has always been accused of being a 
      coercive, unethical, and dangerous modality of treatment. The dangerousness of
      ECT has been mainly attributed to its claimed ability to cause brain damage. This
      narrative review aims to provide an update of the evidence with regard to whether
      the practice of ECT is associated with damage to the brain. An accepted
      definition of brain damage remains elusive. There are also ethical and technical 
      problems in designing studies that look at this question specifically. Thus, even
      though there are newer technological tools and innovations, any review attempting
      to answer this question would have to take recourse to indirect methods. These
      include structural, functional, and metabolic neuroimaging; body fluid
      biochemical marker studies; and follow-up studies of cognitive impairment and
      incidence of dementia in people who have received ECT among others. The review of
      literature and present evidence suggests that ECT has a demonstrable impact on
      the structure and function of the brain. However, there is a lack of evidence at 
      present to suggest that ECT causes brain damage.
CI  - Copyright: (c) 2020 Indian Journal of Psychiatry.
FAU - Jolly, Amal Joseph
AU  - Jolly AJ
AD  - Department of Psychiatry, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Singh, Shubh Mohan
AU  - Singh SM
AD  - Department of Psychiatry, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200727
PL  - India
TA  - Indian J Psychiatry
JT  - Indian journal of psychiatry
JID - 0013255
PMC - PMC7597699
OTO - NOTNLM
OT  - Adverse effect
OT  - brain damage
OT  - electroconvulsive therapy
COIS- There are no conflicts of interest.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 14:24
PHST- 2019/04/09 00:00 [received]
PHST- 2019/06/23 00:00 [revised]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/11/09 14:24 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.4103/psychiatry.IndianJPsychiatry_239_19 [doi]
AID - IJPsy-62-339 [pii]
PST - ppublish
SO  - Indian J Psychiatry. 2020 Jul-Aug;62(4):339-353. doi:
      10.4103/psychiatry.IndianJPsychiatry_239_19. Epub 2020 Jul 27.


PMID- 33165329
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 164
DP  - 2020 Oct 23
TI  - Measuring Post-Stroke Cerebral Edema, Infarct Zone and Blood-Brain Barrier
      Breakdown in a Single Set of Rodent Brain Samples.
LID - 10.3791/61309 [doi]
AB  - One of the most common causes of morbidity and mortality worldwide is ischemic
      stroke. Historically, an animal model used to stimulate ischemic stroke involves 
      middle cerebral artery occlusion (MCAO). Infarct zone, brain edema and
      blood-brain barrier (BBB) breakdown are measured as parameters that reflect the
      extent of brain injury after MCAO. A significant limitation to this method is
      that these measurements are normally obtained in different rat brain samples,
      leading to ethical and financial burdens due to the large number of rats that
      need to be euthanized for an appropriate sample size. Here we present a method to
      accurately assess brain injury following MCAO by measuring infarct zone, brain
      edema and BBB permeability in the same set of rat brains. This novel technique
      provides a more efficient way to evaluate the pathophysiology of stroke.
FAU - Frank, Dmitry
AU  - Frank D
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev.
FAU - Gruenbaum, Benjamin F
AU  - Gruenbaum BF
AD  - Department of Anesthesiology, Yale University School of Medicine.
FAU - Grinshpun, Julia
AU  - Grinshpun J
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev.
FAU - Melamed, Israel
AU  - Melamed I
AD  - Department of Neurosurgery, Soroka University Medical Center and the Faculty of
      Health Sciences, Ben-Gurion University of the Negev.
FAU - Severynovska, Olena
AU  - Severynovska O
AD  - Department of Physiology, Faculty of Biology, Ecology and Medicine,
      Dnepropetrovsk State University.
FAU - Kuts, Ruslan
AU  - Kuts R
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev.
FAU - Semyonov, Michael
AU  - Semyonov M
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev.
FAU - Brotfain, Evgeni
AU  - Brotfain E
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev.
FAU - Zlotnik, Alexander
AU  - Zlotnik A
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev.
FAU - Boyko, Matthew
AU  - Boyko M
AD  - Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion
      University of the Negev; matthewboykoresearch@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20201023
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
SB  - IM
MH  - Animals
MH  - Blood-Brain Barrier/*metabolism
MH  - Brain Edema/*complications/*metabolism
MH  - Brain Infarction/*complications
MH  - Disease Models, Animal
MH  - Infarction, Middle Cerebral Artery/complications
MH  - Male
MH  - Permeability
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2020/11/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/09 14:24
PHST- 2020/11/09 14:24 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.3791/61309 [doi]
PST - epublish
SO  - J Vis Exp. 2020 Oct 23;(164). doi: 10.3791/61309.


PMID- 33164959
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1875-8894 (Electronic)
IS  - 1874-5393 (Linking)
VI  - 13
IP  - 3
DP  - 2020
TI  - Navigating the ethical Scylla and Charybdis of the COVID vaccine.
PG  - 229-231
LID - 10.3233/PRM-200025 [doi]
FAU - Vercler, Christian
AU  - Vercler C
LA  - eng
PT  - Editorial
PL  - Netherlands
TA  - J Pediatr Rehabil Med
JT  - Journal of pediatric rehabilitation medicine
JID - 101490944
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Beneficence
MH  - COVID-19
MH  - *COVID-19 Vaccines/supply & distribution
MH  - Humans
MH  - Mandatory Programs/*ethics
MH  - Pandemics
MH  - Resource Allocation/*ethics
MH  - Vaccination Refusal/*ethics
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - coronavirus
OT  - vaccine
EDAT- 2020/11/10 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/11/09 14:23
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/11/09 14:23 [entrez]
AID - PRM200025 [pii]
AID - 10.3233/PRM-200025 [doi]
PST - ppublish
SO  - J Pediatr Rehabil Med. 2020;13(3):229-231. doi: 10.3233/PRM-200025.


PMID- 33164899
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2291-9694 (Print)
VI  - 8
IP  - 11
DP  - 2020 Nov 9
TI  - Multidimensional Machine Learning Personalized Prognostic Model in an Early
      Invasive Breast Cancer Population-Based Cohort in China: Algorithm Validation
      Study.
PG  - e19069
LID - 10.2196/19069 [doi]
AB  - BACKGROUND: Current online prognostic prediction models for breast cancer, such
      as Adjuvant! Online and PREDICT, are based on specific populations. They have
      been well validated and widely used in the United States and Western Europe;
      however, several validation attempts in non-European countries have revealed
      suboptimal predictions. OBJECTIVE: We aimed to develop an advanced breast cancer 
      prognosis model for disease progression, cancer-specific mortality, and all-cause
      mortality by integrating tumor, demographic, and treatment characteristics from a
      large breast cancer cohort in China. METHODS: This study was approved by the
      Clinical Test and Biomedical Ethics Committee of West China Hospital, Sichuan
      University on May 17, 2012. Data collection for this project was started in May
      2017 and ended in March 2019. Data on 5293 women diagnosed with stage I to III
      invasive breast cancer between 2000 and 2013 were collected. Disease progression,
      cancer-specific mortality, all-cause mortality, and the likelihood of disease
      progression or death within a 5-year period were predicted. Extreme gradient
      boosting was used to develop the prediction model. Model performance was assessed
      by calculating the area under the receiver operating characteristic curve
      (AUROC), and the model was calibrated and compared with PREDICT. RESULTS: The
      training, test, and validation sets comprised 3276 (499 progressions, 202 breast 
      cancer-specific deaths, and 261 all-cause deaths within 5-year follow-up), 1405
      (211 progressions, 94 breast cancer-specific deaths, and 129 all-cause deaths),
      and 612 (109 progressions, 33 breast cancer-specific deaths, and 37 all-cause
      deaths) women, respectively. The AUROC values for disease progression,
      cancer-specific mortality, and all-cause mortality were 0.76, 0.88, and 0.82 for 
      training set; 0.79, 0.80, and 0.83 for the test set; and 0.79, 0.84, and 0.88 for
      the validation set, respectively. Calibration analysis demonstrated good
      agreement between predicted and observed events within 5 years. Comparable AUROC 
      and calibration results were confirmed in different age, residence status, and
      receptor status subgroups. Compared with PREDICT, our model showed similar AUROC 
      and improved calibration values. CONCLUSIONS: Our prognostic model exhibits high 
      discrimination and good calibration. It may facilitate prognosis prediction and
      clinical decision making for patients with breast cancer in China.
CI  - (c)Xiaorong Zhong, Ting Luo, Ling Deng, Pei Liu, Kejia Hu, Donghao Lu, Dan Zheng,
      Chuanxu Luo, Yuxin Xie, Jiayuan Li, Ping He, Tianjie Pu, Feng Ye, Hong Bu, Bo Fu,
      Hong Zheng. Originally published in JMIR Medical Informatics
      (http://medinform.jmir.org), 09.11.2020.
FAU - Zhong, Xiaorong
AU  - Zhong X
AUID- ORCID: https://orcid.org/0000-0003-1812-7213
AD  - Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China
      Hospital, Sichuan University, Chengdu, China.
FAU - Luo, Ting
AU  - Luo T
AUID- ORCID: https://orcid.org/0000-0002-9670-4031
AD  - Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China
      Hospital, Sichuan University, Chengdu, China.
FAU - Deng, Ling
AU  - Deng L
AUID- ORCID: https://orcid.org/0000-0002-6614-5515
AD  - Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast,
      West China Hospital, Sichuan University, Chengdu, China.
FAU - Liu, Pei
AU  - Liu P
AUID- ORCID: https://orcid.org/0000-0002-3795-6140
AD  - Big Data Research Center, School of Computer Science and Engineering, University 
      of Electronic Science and Technology of China, Chengdu, China.
FAU - Hu, Kejia
AU  - Hu K
AUID- ORCID: https://orcid.org/0000-0001-6680-8107
AD  - Department of Medical Epidemiology & Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Lu, Donghao
AU  - Lu D
AUID- ORCID: https://orcid.org/0000-0002-4186-8661
AD  - Department of Medical Epidemiology & Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Zheng, Dan
AU  - Zheng D
AUID- ORCID: https://orcid.org/0000-0002-8066-328X
AD  - Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast,
      West China Hospital, Sichuan University, Chengdu, China.
FAU - Luo, Chuanxu
AU  - Luo C
AUID- ORCID: https://orcid.org/0000-0002-2761-9394
AD  - Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast,
      West China Hospital, Sichuan University, Chengdu, China.
FAU - Xie, Yuxin
AU  - Xie Y
AUID- ORCID: https://orcid.org/0000-0001-5431-365X
AD  - Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China
      Hospital, Sichuan University, Chengdu, China.
FAU - Li, Jiayuan
AU  - Li J
AUID- ORCID: https://orcid.org/0000-0002-6965-8877
AD  - Department of Epidemiology and Biostatistics, West China School of Public Health,
      Sichuan University, Chengdu, China.
FAU - He, Ping
AU  - He P
AUID- ORCID: https://orcid.org/0000-0002-1631-9409
AD  - Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China
      Hospital, Sichuan University, Chengdu, China.
FAU - Pu, Tianjie
AU  - Pu T
AUID- ORCID: https://orcid.org/0000-0001-6452-3650
AD  - Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Ye, Feng
AU  - Ye F
AUID- ORCID: https://orcid.org/0000-0003-2486-1801
AD  - Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Bu, Hong
AU  - Bu H
AUID- ORCID: https://orcid.org/0000-0001-7472-6443
AD  - Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Fu, Bo
AU  - Fu B
AUID- ORCID: https://orcid.org/0000-0003-1632-028X
AD  - Big Data Research Center, School of Computer Science and Engineering, University 
      of Electronic Science and Technology of China, Chengdu, China.
FAU - Zheng, Hong
AU  - Zheng H
AUID- ORCID: https://orcid.org/0000-0001-5802-330X
AD  - Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast,
      West China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - Canada
TA  - JMIR Med Inform
JT  - JMIR medical informatics
JID - 101645109
PMC - PMC7683252
OTO - NOTNLM
OT  - breast cancer
OT  - machine learning
OT  - prediction model
OT  - prognosis
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 14:23
PHST- 2020/04/05 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/08/07 00:00 [revised]
PHST- 2020/11/09 14:23 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - v8i11e19069 [pii]
AID - 10.2196/19069 [doi]
PST - epublish
SO  - JMIR Med Inform. 2020 Nov 9;8(11):e19069. doi: 10.2196/19069.


PMID- 33164729
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 2046-4924 (Electronic)
IS  - 1366-5278 (Linking)
VI  - 24
IP  - 56
DP  - 2020 Nov
TI  - An interactive website to aid young women's choice of contraception: feasibility 
      and efficacy RCT.
PG  - 1-44
LID - 10.3310/hta24560 [doi]
AB  - BACKGROUND: Effective use of contraception can reduce numbers of unintended
      pregnancies, but misunderstandings and concerns about contraception abound.
      Increasingly, women seek health-care information online. OBJECTIVES: To develop
      an interactive website to aid informed choice of contraceptive method, including 
      long-acting reversible contraception (Phase I), and test its effectiveness in a
      parallel, single-blind randomised trial (Phase II). Approval came from London -
      Camden & King's Cross Research Ethics Committee (reference 17/LO/0112). SETTING
      AND PARTICIPANTS: For both phases, women aged 15-30 years were recruited from
      general practice, sexual health services, maternity services, community
      pharmacies and an abortion service. DESIGN: In Phase I, we conducted three
      systematic literature reviews, a review of YouTube (YouTube, LLC, San Bruno, CA, 
      USA) videos about contraception, and focus groups and interviews with young women
      to explore barriers to and concerns and misperceptions about contraception. We
      then iteratively co-designed an interactive website, Contraception Choices [URL: 
      www.contraceptionchoices.org (accessed June 2020)], with young women and a
      software company. In Phase II, we evaluated the website through a randomised
      trial that began as a feasibility trial. Early demand for Contraception Choices
      stimulated a design change from a feasibility to an efficacy trial, with
      follow-up for clinical outcomes at 3 and 6 months. A randomisation list was
      incorporated into the trial software program to allocate participants to the
      intervention (website) or control group (standard care). INTERVENTION:
      Contraception Choices is a co-designed, evidence-based, interactive website to
      aid informed choice of contraception. It provides information about different
      methods, addresses common concerns and offers tailored contraceptive options in
      response to individual preferences. MAIN OUTCOME MEASURES: Qualitative -
      participant views and experience of the intervention, assessed through
      qualitative interviews. Quantitative primary outcomes - follow-up rate at 6
      months in the initial feasibility trial, using a long-acting reversible
      contraception method, and satisfaction with contraceptive method at 6 months in
      the efficacy trial. RESULTS: A total of 927 women were randomised online to the
      website (n = 464) or control group (n = 463), of whom 739 (80%) provided
      follow-up data at 6 months [786 women (85%) provided data at 3 and/or 6 months
      that were included in the analysis of primary outcomes]. There was little
      difference between groups in the proportion using long-acting reversible
      contraception at 6 months [30.4% intervention vs. 31.0% control, adjusted odds
      ratio after imputation 0.87 (95% confidence interval 0.60 to 1.27)] or in
      satisfaction with contraceptive method [proportion being 'satisfied' or 'very
      satisfied', 82.6% intervention vs. 82.1% control, adjusted odds ratio 0.93 (95%
      confidence interval 0.69 to 1.25)]. Qualitative evaluation indicated highly
      positive views about the website and increased knowledge of contraceptive methods
      that could dispel misperceptions. Women appreciated having information tailored
      to their specific needs and felt better prepared before consultations.
      LIMITATIONS: We did not include intermediate measures, such as knowledge of
      contraceptive methods, intention to change method or confidence in discussing
      contraception with a health-care professional, which may have indicated other
      benefits of using the website. In future, the website should be studied in
      different settings (e.g. schools and in routine practice) to see whether or not
      it improves the quality or efficiency of contraceptive consultations.
      CONCLUSIONS: Our systematic review indicated wide-ranging influences on women's
      use of contraception globally. The website, Contraception Choices, was very
      popular with young women and contraception service providers. It was not
      associated with statistically significant differences in use of long-acting
      reversible contraception or satisfaction with contraceptive method at 6 months.
      TRIAL REGISTRATION: Current Controlled Trials ISRCTN13247829. FUNDING: This
      project was funded by the National Institute for Health Research (NIHR) Health
      Technology Assessment programme and will be published in full in Health
      Technology Assessment; Vol. 24, No. 56. See the NIHR Journals Library website for
      further project information.
FAU - Stephenson, Judith
AU  - Stephenson J
AUID- ORCID: 0000-0002-8852-0881
AD  - UCL Elizabeth Garrett Anderson Institute for Women's Health, University College
      London, London, UK.
FAU - Bailey, Julia V
AU  - Bailey JV
AUID- ORCID: 0000-0002-5001-0122
AD  - Department of Primary Care and Population Health, University College London,
      Royal Free Hospital, London, UK.
FAU - Blandford, Ann
AU  - Blandford A
AUID- ORCID: 0000-0002-3198-7122
AD  - UCL Interaction Centre (UCLIC), University College London, London, UK.
FAU - Brima, Nataliya
AU  - Brima N
AUID- ORCID: 0000-0002-6930-5166
AD  - Institute for Global Health, University College London, London, UK.
FAU - Copas, Andrew
AU  - Copas A
AUID- ORCID: 0000-0001-8968-5963
AD  - Institute for Global Health, University College London, London, UK.
FAU - D'Souza, Preethy
AU  - D'Souza P
AUID- ORCID: 0000-0003-3604-2280
AD  - Department of Social Science, UCL Institute of Education, University College
      London, London, UK.
FAU - Gubijev, Anasztazia
AU  - Gubijev A
AUID- ORCID: 0000-0003-4317-5866
AD  - UCL Elizabeth Garrett Anderson Institute for Women's Health, University College
      London, London, UK.
FAU - Hunter, Rachael
AU  - Hunter R
AUID- ORCID: 0000-0002-7447-8934
AD  - Health Economics, University College London, London, UK.
FAU - Shawe, Jill
AU  - Shawe J
AUID- ORCID: 0000-0002-2766-7302
AD  - Institute of Health and Community, University of Plymouth, Plymouth, UK.
FAU - Rait, Greta
AU  - Rait G
AUID- ORCID: 0000-0002-7216-7294
AD  - PRIMENT Clinical Trials Unit, Department of Primary Care and Population Health,
      University College London, Royal Free Hospital, London, UK.
FAU - Oliver, Sandy
AU  - Oliver S
AUID- ORCID: 0000-0001-9571-269X
AD  - Department of Social Science, UCL Institute of Education, University College
      London, London, UK.
AD  - Africa Centre for Evidence, Faculty of Humanities, University of Johannesburg,
      Johannesburg, South Africa.
LA  - eng
SI  - ISRCTN/ISRCTN13247829
GR  - 11/3009/04/DH_/Department of Health/United Kingdom
GR  - 13/79/09/DH_/Department of Health/United Kingdom
GR  - G0701749/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Choice Behavior
MH  - Community Pharmacy Services/statistics & numerical data
MH  - Contraception/*methods
MH  - Feasibility Studies
MH  - Female
MH  - General Practice/statistics & numerical data
MH  - Health Education/*methods
MH  - Humans
MH  - *Internet
MH  - Long-Acting Reversible Contraception/methods
MH  - Maternal Health Services/statistics & numerical data
MH  - Patient Preference
MH  - Reproductive Health Services/statistics & numerical data
MH  - Single-Blind Method
MH  - United Arab Emirates
MH  - Young Adult
PMC - PMC7681569
OAB - WHAT WAS THE QUESTION?: Choosing between types of contraception can be
      challenging, so can a website help women make the right choice for them? WHAT DID
      WE DO?: We asked women what they think about contraception. We looked at other
      studies and YouTube (YouTube, LLC, San Bruno, CA, USA) videos. We then designed
      the Contraception Choices website with young women [URL:
      www.contraceptionchoices.org (accessed January 2020)]. The website describes each
      type of contraception and compares them side by side. When users answer questions
      about what matters to them, the website suggests three types of contraception
      they might like. A total of 927 women helped us test the website in an online
      trial. We asked everyone what contraception they were using and how satisfied
      they were with it 6 months later. WHAT DID WE FIND?: Women really liked the
      website. Ninety-seven per cent of participants found it helpful or very helpful
      for 'getting useful information about contraception' and 87% responded that it
      was helpful or very helpful for 'finding a method of contraception that is right 
      for you'. Comments included: However, seeing the website did not mean that women 
      used a more reliable type of contraception. Women were just as satisfied with
      their contraception whether or not they had seen the website. We think that this 
      is because many other factors are involved; for example, some women found it
      difficult to access long-acting contraception methods from health services. WHAT 
      DOES THIS MEAN?: Young women liked the Contraception Choices website and found it
      useful. Women can be put off by contraception side effects and the views of
      partners, friends, family and others. On its own, the Contraception Choices
      website was not enough to help more women use the most reliable contraception
      methods.
OABL- eng
OTO - NOTNLM
OT  - *CONTRACEPTION
OT  - *CONTRACEPTIVE METHODS
OT  - *DIGITAL HEALTH
OT  - *INTERACTIVE DIGITAL INTERVENTION
OT  - *RANDOMISED CONTROLLED TRIAL
EDAT- 2020/11/10 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/11/09 13:51
PHST- 2020/11/09 13:51 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - 10.3310/hta24560 [doi]
PST - ppublish
SO  - Health Technol Assess. 2020 Nov;24(56):1-44. doi: 10.3310/hta24560.


PMID- 33164471
OWN - NLM
STAT- Publisher
LR  - 20201109
IS  - 2047-9018 (Electronic)
IS  - 0029-6570 (Linking)
DP  - 2020 Nov 9
TI  - Understanding the relevance of human rights in healthcare and nursing practice.
LID - 10.7748/ns.2020.e11490 [doi]
AB  - While the NHS aims to respect the human rights of every individual, it also has a
      wider social duty to promote equality in the services it provides. This means
      that the rights of individual patients are not absolute, because the aim of the
      NHS is to improve the overall health and well-being of the nation. For example,
      certain treatments may be withheld from individuals because of the excessive cost
      to the NHS, or concerns about its clinical effectiveness. This article explains
      the origins of human rights and their function, and examines the relationship
      between nursing care and human rights.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Terry, Louise
AU  - Terry L
AD  - London South Bank University, London, England.
FAU - Newham, Roger
AU  - Newham R
AD  - School of Nursing, Institute of Clinical Sciences, College of Medical and Dental 
      Sciences, University of Birmingham, Birmingham, England.
LA  - eng
PT  - Journal Article
DEP - 20201109
PL  - England
TA  - Nurs Stand
JT  - Nursing standard (Royal College of Nursing (Great Britain) : 1987)
JID - 9012906
OTO - NOTNLM
OT  - Human Rights Act
OT  - ethical issues
OT  - ethical practice
OT  - human rights
OT  - legal issues
OT  - professional
COIS- None declared
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:00
CRDT- 2020/11/09 05:40
PHST- 2019/10/29 00:00 [accepted]
PHST- 2020/11/09 05:40 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:00 [medline]
AID - 10.7748/ns.2020.e11490 [doi]
AID - e11490 [pii]
PST - aheadofprint
SO  - Nurs Stand. 2020 Nov 9. pii: e11490. doi: 10.7748/ns.2020.e11490.


PMID- 33164033
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 0304-4602 (Print)
IS  - 0304-4602 (Linking)
VI  - 49
IP  - 8
DP  - 2020 Aug
TI  - Triage of ICU Resources in a Pandemic Surge: Good Ethics Depends on Good Data.
PG  - 605-607
FAU - Anantham, Devanand
AU  - Anantham D
AD  - Department of Respiratory and Critical Care Medicine, Singapore General Hospital,
      Singapore.
FAU - Sewa, Duu Wen
AU  - Sewa DW
FAU - Ng, Shin Yi
AU  - Ng SY
FAU - Phua, Ghee Chee
AU  - Phua GC
LA  - eng
PT  - Letter
PL  - Singapore
TA  - Ann Acad Med Singap
JT  - Annals of the Academy of Medicine, Singapore
JID - 7503289
SB  - IM
MH  - Humans
MH  - *Influenza, Human/epidemiology/therapy
MH  - Intensive Care Units
MH  - Pandemics
MH  - *Triage
EDAT- 2020/11/10 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/09 05:36
PHST- 2020/11/09 05:36 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PST - ppublish
SO  - Ann Acad Med Singap. 2020 Aug;49(8):605-607.


PMID- 33163669
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210212
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 10
DP  - 2020 Oct
TI  - Infection control in dentistry during COVID - 19 pandemic: what has changed?
PG  - e05402
LID - 10.1016/j.heliyon.2020.e05402 [doi]
AB  - The novel coronavirus (COVID-19) pandemic has emerged disrupting many
      socio-economical and healthcare aspects across the world. This virus can be
      transmitted by symptomatic and asymptomatic individuals through saliva and
      contact. Due to its airborne transmission, aerosols created by natural activities
      and during dental treatment of infected individuals have become a potential
      vehicle of transmission and threat. The objective of this review was to assess
      the existing infection control measures taken in dental health-care settings and 
      suggest modifications to reduce the transmission of novel coronavirus. This is a 
      general review publication. Literature search was made at National Library of
      Medicine, Pubmed using key words such as "dentistry and COVID", "dentistry and
      COVID and infection control". Publications related to behaviour, education,
      ethics, treatment and childcare were excluded. Publications describing general
      aspects of infection control were reviewed. Keyword "Dentistry and COVID and
      Infection control" generated 70 publications which were reviewed. Infection
      control measures in dentistry are designed to minimise cross transmission mainly 
      of blood borne pathogens. The unique nature of COVID-19 including highly
      infectious and transmissibility, and the ability to survive for a long time in
      the environment requires special attention and modification to the existing
      infection control measures which are highlighted here. In conclusion, a modified 
      infection prevention and control (IPC) regime will protect the dental
      practitioner, assistant and staff, patients and the community. During the
      pandemic, drastic measures are necessary, however, during an endemic period
      measures can be remodified as necessary.
CI  - (c) 2020 The Author(s).
FAU - Patel, Mrudula
AU  - Patel M
AD  - Department of Clinical Microbiology and Infectious Diseases, School of Pathology,
      Faculty of Health Sciences, University of the Witwatersrand, and Infection
      Control Services, National Health Laboratory Services, Johannesburg, South
      Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201030
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7640357
OTO - NOTNLM
OT  - COVID-19
OT  - Dentistry
OT  - IPC
OT  - Infection control
OT  - Microbiology
OT  - SARS-CoV-2
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:34
PHST- 2020/07/14 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/09 05:34 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e05402 [doi]
AID - S2405-8440(20)32245-3 [pii]
PST - epublish
SO  - Heliyon. 2020 Oct 30;6(10):e05402. doi: 10.1016/j.heliyon.2020.e05402.
      eCollection 2020 Oct.


PMID- 33163583
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2349-3259 (Electronic)
IS  - 2349-3240 (Linking)
VI  - 7
IP  - 2
DP  - 2020 Apr-Jun
TI  - Management of fast breathing pneumonia in young infants aged 7 to 59 days by
      community level health workers: protocol for a multi-centre cluster randomized
      controlled trial.
PG  - 83-93
LID - 10.18203/2349-3259.ijct20201715 [doi]
AB  - BACKGROUND: WHO does not recommend community-level health workers (CLHWs) using
      integrated community case management (iCCM) to treat 7-59 days old infants with
      fast breathing with oral amoxicillin, whereas World Health Organization (WHO)
      integrated management of childhood illness (IMCI) recommends it. We want to
      collect evidence to help harmonization of both protocols. METHODS: A cluster,
      randomized, open-label trial will be conducted in Africa and Asia (Ethiopia,
      Malawi, Bangladesh and India) using a common protocol with the same study design,
      inclusion criteria, intervention, comparison, and outcomes to contribute to the
      overall sample size. This trial will also identify hypoxaemia in young infants
      with fast breathing. CLHWs will assess infants for fast breathing, which will be 
      confirmed by a study supervisor. Enrolled infants in the intervention clusters
      will be treated with oral amoxicillin, whereas in the control clusters they will 
      be managed as per existing iCCM protocol. An independent outcome assessor will
      assess all enrolled infants on days 6 and 14 of enrolment for the study outcomes 
      in both intervention and control clusters. Primary outcome will be clinical
      treatment failure by day 6. This trial will obtain approval from the WHO and site
      institutional ethics committees. CONCLUSIONS: If the research shows that CLHWs
      can effectively and safely treat fast breathing pneumonia in 7-59 days old young 
      infants, it will increase access to pneumonia treatment substantially for infants
      living in communities with poor access to health facilities. Additionally, this
      evidence will contribute towards the review of the current iCCM protocol and its 
      harmonization with IMCI protocol. TRIAL REGISTRATION: The trial is registered at 
      AZNCTR International Trial Registry as ACTRN12617000857303.
CN  - Enhanced Management of Pneumonia in Community (EMPIC) Study Group
FAU - Mothabbir, Golam
AU  - Mothabbir G
AD  - Save the Children US, Bangladesh Office.
FAU - Rana, Shohel
AU  - Rana S
AD  - Save the Children US, Bangladesh Office.
FAU - Baqui, Abdullah H
AU  - Baqui AH
AD  - Johns Hopkins University, USA.
FAU - Ahmed, Salahuddin
AU  - Ahmed S
AD  - Johns Hopkins University-Bangladesh.
FAU - Ahmed, Asm Nawshad
AU  - Ahmed AN
AD  - Child Health Research Foundation, Bangladesh.
FAU - Taneja, Sunita
AU  - Taneja S
AD  - Center for Health Research and Development, Society for Applied Studies.
FAU - Mundra, Sudarshan
AU  - Mundra S
AD  - Center for Health Research and Development, Society for Applied Studies.
FAU - Bhandari, Nita
AU  - Bhandari N
AD  - Center for Health Research and Development, Society for Applied Studies.
FAU - Dalpath, Suresh
AU  - Dalpath S
AD  - State Health System Resource Centre, Haryana, India.
FAU - Tigabu, Zemene
AU  - Tigabu Z
AD  - University of Gondar, Gondar.
FAU - Andargie, Gashaw
AU  - Andargie G
AD  - University of Gondar, Gondar.
FAU - Teklu, Alemayehu
AU  - Teklu A
AD  - University of Gondar, Gondar.
FAU - Tazebew, Ashenafi
AU  - Tazebew A
AD  - University of Gondar, Gondar.
FAU - Alemu, Kassahun
AU  - Alemu K
AD  - University of Gondar, Gondar.
FAU - Awoke, Tadese
AU  - Awoke T
AD  - University of Gondar, Gondar.
FAU - Gebeyehu, Abebaw
AU  - Gebeyehu A
AD  - Amhara Regional Health Bureau.
FAU - Jenda, Gomezgani
AU  - Jenda G
AD  - Save the Children, US, Malawi Office.
FAU - Nsona, Humphreys
AU  - Nsona H
AD  - Ministry of Health, Malawi.
FAU - Mathanga, Don
AU  - Mathanga D
AD  - College of Medicine, Blantyre, Malawi.
FAU - Nisar, Yasir Bin
AU  - Nisar YB
AD  - Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World
      Health Organization, Geneva, Switzerland.
FAU - Bahl, Rajiv
AU  - Bahl R
AD  - Department of Maternal, Newborn, Child and Adolescent Health and Ageing.
FAU - Sadruddin, Salim
AU  - Sadruddin S
AD  - Retired WHO staff.
FAU - Muhe, Lulu
AU  - Muhe L
AD  - Retired WHO staff.
FAU - Moschovis, Peter
AU  - Moschovis P
AD  - Pediatric Pulmonary Medicine, Pediatric Global Health, Massachusetts General
      Hospital, Harvard Medical School, USA.
FAU - Aboubaker, Samira
AU  - Aboubaker S
AD  - Retired WHO staff.
FAU - Qazi, Shamim
AU  - Qazi S
AD  - Retired WHO staff.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
GR  - K23 ES030399/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PL  - India
TA  - Int J Clin Trials
JT  - International journal of clinical trials
JID - 101724850
PMC - PMC7644113
MID - NIHMS1599331
OTO - NOTNLM
OT  - Amoxicillin
OT  - Community level health worker
OT  - Enhanced case management
OT  - Fast breathing pneumonia
OT  - Pulse oximeter
OT  - Young infant
OT  - iCCM
COIS- Conflict of interest: None declared
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:34
PHST- 2020/11/09 05:34 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.18203/2349-3259.ijct20201715 [doi]
PST - ppublish
SO  - Int J Clin Trials. 2020 Apr-Jun;7(2):83-93. doi: 10.18203/2349-3259.ijct20201715.


PMID- 33163500
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201110
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Editorial: Medicine and Society.
PG  - 570551
LID - 10.3389/fmed.2020.570551 [doi]
FAU - Ghezzi, Pietro
AU  - Ghezzi P
AD  - Brighton and Sussex Medical School, Brighton, United Kingdom.
FAU - Shahvisi, Arianne
AU  - Shahvisi A
AD  - Brighton and Sussex Medical School, Brighton, United Kingdom.
FAU - Stevens, Hilde
AU  - Stevens H
AD  - Institute for Interdisciplinary Innovation in Healthcare, Universite libre de
      Bruxelles, Brussels, Belgium.
LA  - eng
PT  - Editorial
DEP - 20201014
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7591592
OTO - NOTNLM
OT  - ethics
OT  - genetic testing
OT  - health information
OT  - patient involvement
OT  - pseudoscience
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:33
PHST- 2020/06/08 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/11/09 05:33 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.3389/fmed.2020.570551 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Oct 14;7:570551. doi: 10.3389/fmed.2020.570551.
      eCollection 2020.


PMID- 33163499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201112
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Ethical Considerations for Treating Cancer Patients During the SARS-CoV-2 Virus
      Crisis: To Treat or Not to Treat? A Literature Review and Perspective From a
      Cancer Center in Low-Middle Income Country.
PG  - 561168
LID - 10.3389/fmed.2020.561168 [doi]
AB  - Providing routine healthcare to patients with serious health illnesses represents
      a challenge to healthcare providers amid the SARS-CoV-2 pandemic. Treating cancer
      patients during this pandemic is even more complex due to their heightened
      vulnerability, as both cancer and cancer treatment weaken the immune system
      leading to a higher risk of both infections and severe complications. In addition
      to the need to protect cancer patients from unnecessary exposure to SARS-CoV-2
      infection during their routine care, interruption, and discontinuation of cancer 
      treatment can result in negative consequences on patients' health, in addition to
      the ghost of rationing healthcare resources in high demand during a global health
      crisis. This article aims to explore the ethical dilemmas faced by
      decision-makers and healthcare providers caring for cancer patients during the
      SARS-CoV-2 pandemic. This includes setting triage criteria for non-infected
      cancer patients, fairly allocating limited healthcare resources between cancer
      patients and SARS-CoV-2 patients, prioritizing SARS-CoV-2 treatment or vaccine,
      once developed, for cancer patients and non-cancer patients, patient-physician
      communication on matters such as end-of-life and do-not-resuscitate (DNR), and
      lastly, shifting physicians' priorities from treating their own cancer patients
      to treating critically ill SARS-CoV-2 infected patients. Ultimately, no
      straightforward decision can be easily made at such exceptionally difficult
      times. Applying different ethical principles can result in very different
      scenarios and consequences. In the end, we will briefly share the experience of
      the King Hussein Cancer Center (KHCC), the only standalone comprehensive cancer
      center in the region.
CI  - Copyright (c) 2020 Al-Tabba', Al-Hussaini, Mansour, Sultan, Abdel-Razeq and
      Mansour.
FAU - Al-Tabba', Amal
AU  - Al-Tabba' A
AD  - Independent Researcher, Amman, Jordan.
FAU - Al-Hussaini, Maysa
AU  - Al-Hussaini M
AD  - Department of Pathology and Laboratory Medicine, King Hussein Cancer Center,
      Amman, Jordan.
AD  - Human Research Participants Protection Office, King Hussein Cancer Center, Amman,
      Jordan.
FAU - Mansour, Razan
AU  - Mansour R
AD  - Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman,
      Jordan.
FAU - Sultan, Hala
AU  - Sultan H
AD  - University of Jordan School of Medicine, Amman, Jordan.
FAU - Abdel-Razeq, Hikmat
AU  - Abdel-Razeq H
AD  - University of Jordan School of Medicine, Amman, Jordan.
AD  - Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan.
FAU - Mansour, Asem
AU  - Mansour A
AD  - Human Research Participants Protection Office, King Hussein Cancer Center, Amman,
      Jordan.
AD  - King Hussein Cancer Center, Amman, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7580805
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - cancer care
OT  - ethics
OT  - guidelines
OT  - pandemic
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:33
PHST- 2020/05/11 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/11/09 05:33 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.3389/fmed.2020.561168 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Oct 7;7:561168. doi: 10.3389/fmed.2020.561168.
      eCollection 2020.


PMID- 33163019
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20220418
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 20
IP  - 2
DP  - 2020 Jun
TI  - Prevalence of hepatitis B and C virus co-infection in HIV positive patients
      attending a health institution in southeast Nigeria.
PG  - 579-586
LID - 10.4314/ahs.v20i2.5 [doi]
AB  - BACKGROUND: The health of people living with HIV/AIDS becomes progressively worse
      when co-infected with hepatitis B virus (HBV) and hepatitis C virus (HCV),
      resulting in shortened life span. The modes of transmission of HIV, HBV and HCV
      are similar. OBJECTIVE: To determine the prevalence of HBV and HCV co-infection
      in HIV patients. METHOD: This was a retrospective study of serology test results 
      for hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti-HCV) of HIV
      positive patients registered from 2008-2013 (6years) at the University of Nigeria
      Teaching Hospital. Adult patients with confirmed HIV seropositivity were
      included. Ethical approval was obtained and confidentiality of the patient
      information was maintained. Laboratory records were reviewed to obtain HBsAg,
      anti-HCV, and CD4 T-lymphocyte results. Prevalence was determined by the number
      of positive results over total number of patients tested. Chi-square test was
      used to determine relationships and p<0.05 was considered to be statistically
      significant. RESULTS: 4663 HIV patient records were included comprising 3024
      (65%) females and 1639 (35%) males. Serology results showed 365/4663 (7.8%)
      tested HBsAg-positive only; 219/4663 (4.7%) tested anti-HCV-positive only; and
      27/4663 (0.58%) tested both HBsAg and anti-HCV-positive. Correlation of age and
      sex were statistically significant with HBV and HCV (p<0.05) but not CD4 count
      (p>0.05). CONCLUSION: HBV co-infection was more prevalent than HCV, and triple
      infection was also observed. Screening for these viral infections in the HIV
      population is necessary for early identification to enable appropriate, holistic 
      management of these patients.
CI  - (c) 2020 Nnakenyi ID et al.
FAU - Nnakenyi, Ifeyinwa Dorothy
AU  - Nnakenyi ID
AD  - University of Nigeria Nsukka, Department of Chemical Pathology.
AD  - University of Nigeria Teaching Hospital, Department of Chemical Pathology.
FAU - Uchechukwu, Chisom
AU  - Uchechukwu C
AD  - University of Nigeria Nsukka, Department of Chemical Pathology.
AD  - University of Nigeria Nsukka, Department of Chemical Pathology.
FAU - Nto-Ezimah, Uloaku
AU  - Nto-Ezimah U
AD  - University of Nigeria Nsukka, Department of Chemical Pathology.
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis C Antibodies)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adult
MH  - CD4 Lymphocyte Count
MH  - Coinfection/*epidemiology/virology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HIV/genetics
MH  - HIV Infections/blood/*epidemiology
MH  - Hepacivirus/genetics/*isolation & purification
MH  - Hepatitis B/blood/*epidemiology
MH  - Hepatitis B Surface Antigens/analysis/blood
MH  - Hepatitis B virus/genetics/*isolation & purification
MH  - Hepatitis C/blood/*epidemiology
MH  - Hepatitis C Antibodies/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - Prevalence
MH  - RNA, Viral/analysis
MH  - Retrospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
PMC - PMC7609124
OTO - NOTNLM
OT  - HIV
OT  - Hepatitis B virus
OT  - Hepatitis C virus
OT  - co-infection
EDAT- 2020/11/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/09 05:31
PHST- 2020/11/09 05:31 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.4314/ahs.v20i2.5 [doi]
PST - ppublish
SO  - Afr Health Sci. 2020 Jun;20(2):579-586. doi: 10.4314/ahs.v20i2.5.


PMID- 33163000
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
PG  - 585354
LID - 10.3389/fimmu.2020.585354 [doi]
AB  - A novel coronavirus, which has been designated as severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan
      China and causes the highly infectious disease referred to as COVID-19. COVID-19 
      has now spread worldwide to become a global pandemic affecting over 24 million
      people as of August 26th, 2020 and claimed the life of more than 800,000 people
      worldwide. COVID-19 is asymptomatic for some individuals and for others it can
      cause symptoms ranging from flu-like to acute respiratory distress syndrome
      (ARDS), pneumonia and death. Although it is anticipated that an effective vaccine
      will be available to protect against COVID-19, at present the world is relying on
      social distancing and hygiene measures and repurposed drugs. There is a worldwide
      effort to develop an effective vaccine against SARS-CoV-2 and, as of late August 
      2020, there are 30 vaccines in clinical trials with over 200 in various stages of
      development. This review will focus on the eight vaccine candidates that entered 
      Phase 1 clinical trials in mid-May, including AstraZeneca/Oxford's AZD1222,
      Moderna's mRNA-1273 and Sinovac's CoronaVac vaccines, which are currently in
      advanced stages of vaccine development. In addition to reviewing the different
      stages of vaccine development, vaccine platforms and vaccine candidates, this
      review also discusses the biological and immunological basis required of a
      SARS-CoV-2 vaccine, the importance of a collaborative international effort, the
      ethical implications of vaccine development, the efficacy needed for an
      immunogenic vaccine, vaccine coverage, the potential limitations and challenges
      of vaccine development. Although the demand for a vaccine far surpasses the
      production capacity, it will be beneficial to have a limited number of vaccines
      available for the more vulnerable population by the end of 2020 and for the rest 
      of the global population by the end of 2021.
CI  - Copyright (c) 2020 Sharma, Sultan, Ding and Triggle.
FAU - Sharma, Omna
AU  - Sharma O
AD  - Weill Cornell Medicine-Qatar, Doha, Qatar.
FAU - Sultan, Ali A
AU  - Sultan AA
AD  - Department of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Cornell 
      University, Doha, Qatar.
FAU - Ding, Hong
AU  - Ding H
AD  - Departments of Medical Education and Pharmacology, Weill Cornell Medicine-Qatar, 
      Education City, Doha, Qatar.
FAU - Triggle, Chris R
AU  - Triggle CR
AD  - Departments of Medical Education and Pharmacology, Weill Cornell Medicine-Qatar, 
      Education City, Doha, Qatar.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201014
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (Vaccines, DNA)
RN  - 0 (Vaccines, Inactivated)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - Antibodies, Neutralizing/immunology
MH  - Antibodies, Viral/immunology
MH  - COVID-19/*prevention & control/virology
MH  - COVID-19 Vaccines/adverse effects/*immunology
MH  - Drug Development/methods
MH  - Female
MH  - Host-Pathogen Interactions/immunology
MH  - Humans
MH  - Immunogenicity, Vaccine
MH  - Male
MH  - Middle Aged
MH  - SARS-CoV-2/*immunology
MH  - Spike Glycoprotein, Coronavirus/*immunology
MH  - Vaccines, DNA/adverse effects/*immunology
MH  - Vaccines, Inactivated/immunology
PMC - PMC7591699
OTO - NOTNLM
OT  - *COVID-19 pandemic
OT  - *DNA vaccine
OT  - *RNA vaccine
OT  - *SARS-CoV-2
OT  - *inactivated virus particle vaccine
OT  - *neutralizing antibodies
OT  - *non-replication viral vector vaccine
OT  - *vaccine development
EDAT- 2020/11/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/09 05:31
PHST- 2020/07/20 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/11/09 05:31 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.3389/fimmu.2020.585354 [doi]
PST - epublish
SO  - Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection
      2020.


PMID- 33162869
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1541-4094 (Print)
IS  - 1541-4094 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Jul
TI  - Sexuality and Gender in Psychiatry: Ethical and Clinical Issues.
PG  - 304-306
LID - 10.1176/appi.focus.20200019 [doi]
FAU - Saenz, Samuel Ricardo
AU  - Saenz SR
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University School of
      Medicine, Stanford, California.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - United States
TA  - Focus (Am Psychiatr Publ)
JT  - Focus (American Psychiatric Publishing)
JID - 101156081
PMC - PMC7587911
OTO - NOTNLM
OT  - Ethics
OT  - Gender Differences
OT  - LGBTQ+
OT  - gender
OT  - sexuality
COIS- Dr. Saenz reports no financial relationships with commercial interests.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:30
PHST- 2020/11/09 05:30 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.1176/appi.focus.20200019 [doi]
AID - FOC_20200019 [pii]
PST - ppublish
SO  - Focus (Am Psychiatr Publ). 2020 Jul;18(3):304-306. doi:
      10.1176/appi.focus.20200019. Epub 2020 Aug 7.


PMID- 33162859
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210402
IS  - 1541-4094 (Print)
IS  - 1541-4094 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Apr
TI  - Ethical Issues in the Evaluation and Treatment of Depression.
PG  - 201-204
LID - 10.1176/appi.focus.20200006 [doi]
FAU - Rogol, Alissa Megan
AU  - Rogol AM
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, 
      California.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - United States
TA  - Focus (Am Psychiatr Publ)
JT  - Focus (American Psychiatric Publishing)
JID - 101156081
PMC - PMC7587885
OTO - NOTNLM
OT  - Depression
OT  - Ethics
COIS- Dr. Rogol reports no financial relationships with commercial interests.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:30
PHST- 2020/11/09 05:30 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.1176/appi.focus.20200006 [doi]
AID - FOC_20200006 [pii]
PST - ppublish
SO  - Focus (Am Psychiatr Publ). 2020 Apr;18(2):201-204. doi:
      10.1176/appi.focus.20200006. Epub 2020 Apr 23.


PMID- 33162855
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210402
IS  - 1541-4094 (Print)
IS  - 1541-4094 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Apr
TI  - Real-Time Monitoring: A Key Element in Personalized Health and Precision Health.
PG  - 175-180
LID - 10.1176/appi.focus.20190042 [doi]
AB  - Current management of psychiatric disorders relies heavily on retrospective,
      subjective reports provided by patients and their families. Consequently,
      psychiatric services are often provisioned inefficiently and with suboptimal
      outcomes. Recent advances in computing and sensor technologies have enabled the
      development of real-time monitoring systems for the diagnosis and management of
      psychiatric disorders. The state of these technologies is rapidly evolving, with 
      passive monitoring and predictive modeling as two areas that have great potential
      to affect psychiatric care. Although outpatient psychiatry probably stands to
      benefit the most from the use of real-time monitoring technologies, there are
      also several ways in which inpatient psychiatry may also benefit. As the
      capabilities of these technologies increase and their use becomes more common,
      many ethical and legal issues will need to be considered. The role of
      governmental regulatory bodies and nongovernmental organizations in providing
      oversight of the implementation of these technologies is an active area of
      discussion.
CI  - Copyright (c) by the American Psychiatric Association.
FAU - Zulueta, John
AU  - Zulueta J
AD  - Department of Psychiatry, College of Medicine (all authors), and Department of
      Bioengineering and Computer Science, College of Engineering (Leow), all at the
      University of Illinois at Chicago.
FAU - Leow, Alex D
AU  - Leow AD
AD  - Department of Psychiatry, College of Medicine (all authors), and Department of
      Bioengineering and Computer Science, College of Engineering (Leow), all at the
      University of Illinois at Chicago.
FAU - Ajilore, Olusola
AU  - Ajilore O
AD  - Department of Psychiatry, College of Medicine (all authors), and Department of
      Bioengineering and Computer Science, College of Engineering (Leow), all at the
      University of Illinois at Chicago.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - United States
TA  - Focus (Am Psychiatr Publ)
JT  - Focus (American Psychiatric Publishing)
JID - 101156081
PMC - PMC7587889
OTO - NOTNLM
OT  - Biological Markers
OT  - mHealth
OT  - patient-specific modeling
OT  - phenotype
COIS- Dr. Leow reports serving on the advisory board for Buoy Health and being a
      cofounder of KeyWise. Dr. Ajilore reports serving on the advisory board of
      Embodied Labs and Blueprint Health, being a cofounder of KeyWise, and being a
      consultant for Quartet Health. Dr. Zulueta reports no financial relationship with
      commercial interests.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:30
PHST- 2020/11/09 05:30 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.1176/appi.focus.20190042 [doi]
AID - FOC_20190042 [pii]
PST - ppublish
SO  - Focus (Am Psychiatr Publ). 2020 Apr;18(2):175-180. doi:
      10.1176/appi.focus.20190042. Epub 2020 Apr 23.


PMID- 33162652
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0377-1237 (Print)
IS  - 0377-1237 (Linking)
VI  - 76
IP  - 4
DP  - 2020 Oct
TI  - Hair transplantation by follicular unit extraction for male androgenetic
      alopecia: A retrospective observational study from two centers.
PG  - 430-437
LID - 10.1016/j.mjafi.2019.11.001 [doi]
AB  - BACKGROUND: Follicular unit extraction (FUE) is the most popular method of hair
      transplantation in today's world. Hair transplantation in androgenetic alopecia
      (AGA) in males can restore the frontal hairline and provide hair density in
      alopecic areas to the satisfaction of most patients. METHODS: Consecutive male
      patients of AGA who underwent hair transplantation by FUE method in two centers
      between the period of January 2016 and June 2017 have been included in this study
      based on inclusion and exclusion criteria. Photographic images, trichoscopy and
      Likert's scale were used to assess patient's improvement in hair density after
      the transplantation procedure. Statistical methods using SPSS software was used
      to analyze the results. Institutional ethical clearance and patients' written
      consent for procedure and images was obtained. The study was an observational
      retrospective study using data and images from records for which consent and
      ethical clearance was obtained from patients and the institution. RESULTS:
      Average number of follicular units transplanted in patients was 1290 (improvement
      in hair density: of 30.61 follicular units/sq cm). There was a statistically
      significant difference in improvement in hair density in patients younger than 33
      years and in patients with Norwood classification below stage 4a. Forty-nine
      patients were satisfied with the results after assessment by the Likert scale.
      CONCLUSION: Hair transplantation by follicular extraction method provides good
      hair cover in AGA in males. This modern dermatosurgical technique with its many
      innovations is a very helpful technique to improve quality of life in male
      pattern baldness.
CI  - (c) 2020 Director General, Armed Forces Medical Services. Published by Elsevier, 
      a division of RELX India Pvt. Ltd.
FAU - Vasudevan, Biju
AU  - Vasudevan B
AD  - Senior Advisor (Dermatology), Base Hospital Lucknow, UP, 226002, India.
FAU - Neema, Shekhar
AU  - Neema S
AD  - Classified Specialist (Dermatology), Command Hospital (Southern Command), Pune
      411040, India.
FAU - Ghosh, Kunal
AU  - Ghosh K
AD  - Brigadier Administration, Base Hospital Delhi Cantt, Delhi, India.
FAU - Singh, Sehdev
AU  - Singh S
AD  - Senior Advisor (Dermatology), Command Hospital (Eastern Command), Kolkatta,
      India.
FAU - Khera, Anurag
AU  - Khera A
AD  - Commanding Officer, 421 Field Hospital, C/o 99 APO, India.
LA  - eng
PT  - Journal Article
DEP - 20200312
PL  - India
TA  - Med J Armed Forces India
JT  - Medical journal, Armed Forces India
JID - 7602492
PMC - PMC7606102
OTO - NOTNLM
OT  - Androgenetic alopecia
OT  - Follicles
OT  - Follicular unit extraction
OT  - Hair density
OT  - Hair transplantation
OT  - Implantation
COIS- The authors have none to declare.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:29
PHST- 2018/08/16 00:00 [received]
PHST- 2019/11/22 00:00 [accepted]
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.1016/j.mjafi.2019.11.001 [doi]
AID - S0377-1237(19)30126-1 [pii]
PST - ppublish
SO  - Med J Armed Forces India. 2020 Oct;76(4):430-437. doi:
      10.1016/j.mjafi.2019.11.001. Epub 2020 Mar 12.


PMID- 33162647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201112
IS  - 0377-1237 (Print)
IS  - 0377-1237 (Linking)
VI  - 76
IP  - 4
DP  - 2020 Oct
TI  - Is written informed consent 'cast in iron' even during a pandemic?
PG  - 367-369
LID - 10.1016/j.mjafi.2020.10.007 [doi]
FAU - Gupta, Pooja
AU  - Gupta P
AD  - Associate Professor (Pharmacology) & Member Secretary, IEC Subcommittee, AIIMS,
      New Delhi, India.
FAU - Naeem, Syed Shariq
AU  - Naeem SS
AD  - Assistant Professor (Pharmacology), Aligarh Muslim University, Aligarh, UP,
      India.
FAU - Mohan, Prafull
AU  - Mohan P
AD  - Professor, Department of Pharmacology, Armed Forces Medical College, Pune, India.
FAU - Banerjee, Amitav
AU  - Banerjee A
AD  - Professor & Head (Community Medicine), Dr. DY Patil Medical College, Hospital &
      Research Centre, Pune & Chairperson, Institutional Ethics Committee, AFMC, Pune, 
      India.
LA  - eng
PT  - Editorial
DEP - 20201029
PL  - India
TA  - Med J Armed Forces India
JT  - Medical journal, Armed Forces India
JID - 7602492
PMC - PMC7598424
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Informed consent
OT  - Pandemic
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:29
PHST- 2020/09/30 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.1016/j.mjafi.2020.10.007 [doi]
AID - S0377-1237(20)30196-9 [pii]
PST - ppublish
SO  - Med J Armed Forces India. 2020 Oct;76(4):367-369. doi:
      10.1016/j.mjafi.2020.10.007. Epub 2020 Oct 29.


PMID- 33162599
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - Suppl 3
DP  - 2020 Aug
TI  - A randomised controlled trial to study Bispectral guided induction of general
      anaesthesia using propofol and etomidate infusion.
PG  - S180-S185
LID - 10.4103/ija.IJA_221_20 [doi]
AB  - BACKGROUND AND AIMS: The present prospective, randomised study was done to
      evaluate induction characteristics with bispectral (BIS) index guided infusion of
      propofol and etomidate. MATERIALS AND METHODS: After institutional ethical
      committee approval, 70 patients, aged 18-60 years, American Society of
      Anaesthesiologists (ASA) I and II scheduled for elective surgery were included.
      Patients were randomly allocated into one of the two groups. In Group E, patients
      received etomidate infusion at a rate of 0.07 mg kg(-1) min(-1) and in Group P,
      received propofol infusion of 0.7 mg kg(-1) min(-1). Time from start of infusion 
      to loss of palpebral reflex (TP), loss of verbal command (TV), BIS to reach 50
      (TBIS50), mean induction dose and incremental dose of each drug required to keep 
      BIS50., haemodynamic parameters and adverse effects like pain, myoclonus, apnoea 
      and postoperative nausea and vomiting (PONV) were also noted. RESULTS: TP,TV, and
      TBIS 50 was faster in E as compared to P group and was statistically significant 
      for all parameters. Mean induction dose of drug required till BIS 50 was 2.68 +/-
      0.56 mg kg(-1) and 0.242 +/- 0.11 mg kg(-1) in group P and E, respectively. There
      was a significant difference between the groups with group E requiring
      incremental dose in a significant proportion of patients (P = 0.004). There was a
      significant decrease in MAP in P group as compared to E. In group P, more number 
      of patients experienced pain and had apnoea episode as compared to group E. (P < 
      0.001). Myoclonus was observed in group E only (P = 0.016). CONCLUSION:
      BIS-guided titration of propofol and etomidate infusion for induction did not
      result in reduction of the dose, haemodynamic variations and other effects.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Saini, Savita
AU  - Saini S
AD  - Department of Anaesthesiologyand Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Bhardwaj, Mamta
AU  - Bhardwaj M
AD  - Department of Anaesthesiologyand Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Sharma, Asha
AU  - Sharma A
AD  - Department of Anaesthesiologyand Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Taxak, Susheela
AU  - Taxak S
AD  - Department of Anaesthesiologyand Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
LA  - eng
PT  - Journal Article
DEP - 20200815
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7641050
OTO - NOTNLM
OT  - Bispectral index
OT  - etomidate
OT  - infusion
OT  - myoclonus
OT  - propofol
COIS- There are no conflicts of interest.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:29
PHST- 2020/03/09 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.4103/ija.IJA_221_20 [doi]
AID - IJA-64-180 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Aug;64(Suppl 3):S180-S185. doi: 10.4103/ija.IJA_221_20.
      Epub 2020 Aug 15.


PMID- 33162574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 9
DP  - 2020 Sep
TI  - Evaluation of segmental epidural blockade following standard test dose versus
      test dose with addition of saline in abdominal surgeries.
PG  - 790-795
LID - 10.4103/ija.IJA_310_20 [doi]
AB  - BACKGROUND AND AIMS: Epidural analgesia is widely used for pain relief but
      confirmation of accurate epidural placement is poorly understood. We proposed
      that sensory blockade to cold sensation would predict the accurate placement of
      epidural. The primary outcome was the assessment of sensory blockade at 5 and 10 
      min with a standard epidural test dose versus test dose with additional saline.
      We looked at haemodynamic changes following administration as secondary outcomes.
      METHODS: Following Ethics Committee approval, 161 patients presenting for
      elective abdominal surgery needing epidural analgesia with general anaesthesia
      were randomly allocated into Group 1 receiving standard test dose (3 ml of 2%
      lignocaine with 1:2,00,000 adrenaline) or Group 2 (standard test dose with 6 ml
      of saline) epidurally. The blockade to cold sensation was assessed at 5 and 10
      min. The heart rate (HR), systolic blood pressure (SBP), and mean arterial
      pressure (MAP) were recorded at baseline, 1, 5, and 10 min following epidural
      dosing. Statistical analysis was performed with Chi-square test for categorical
      and Student's t-test for continuous variables. RESULTS: The sensory blockade at 5
      min was 69.5% versus 82.3% (P = 0.059), and at 10 min 85.4% versus 97.5% (P =
      0.01) in Groups 1 and 2, respectively. The MAP at 5 min (P = 0.032) and the HR
      and MAP at 10 min (P = 0.015, 0.04) were significantly lower in Group 2.
      CONCLUSION: An epidural test dose of 3 ml followed by additional 6 ml saline
      accurately predicted sensory blockade to cold at 10 min in comparison to the
      standard dose of 3 ml but was associated with a decrease in the HR and MAP.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Joseph, Nandhini
AU  - Joseph N
AD  - Department of Anesthesiology and Critical Care, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
FAU - Kumar, Lakshmi
AU  - Kumar L
AD  - Department of Anesthesiology and Critical Care, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
FAU - Shyamsundar, P
AU  - Shyamsundar P
AD  - Department of Anesthesiology and Critical Care, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
FAU - Balakrishnan, Sindhu
AU  - Balakrishnan S
AD  - Department of Anesthesiology and Critical Care, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
FAU - Kesavan, Rajesh
AU  - Kesavan R
AD  - Department of Anesthesiology and Critical Care, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
FAU - Rajan, Sunil
AU  - Rajan S
AD  - Department of Anesthesiology and Critical Care, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, India.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7641068
OTO - NOTNLM
OT  - Adrenaline
OT  - analgesia
OT  - epidural
OT  - lidocaine
OT  - saline
COIS- There are no conflicts of interest.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:29
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.4103/ija.IJA_310_20 [doi]
AID - IJA-64-790 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Sep;64(9):790-795. doi: 10.4103/ija.IJA_310_20. Epub 2020 
      Sep 1.


PMID- 33162573
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 9
DP  - 2020 Sep
TI  - A randomised controlled trial to evaluate the peri-operative role of
      intraoperative dexmedetomidine infusion in robotic-assisted laparoscopic
      oncosurgeries.
PG  - 784-789
LID - 10.4103/ija.IJA_664_20 [doi]
AB  - BACKGROUND: Robotic and minimal invasive surgeries pose challenges to the
      anaesthesiologists. Dexmedetomidine (dexmed), with distinct properties of
      sedation and analgesia has emerged as a promising drug. Our primary aim, in this 
      double-blinded study, was to evaluate reduction in the intraoperative opioid
      requirement with the use of intravenous dexmed infusion. Secondary objectives
      included effect on intraoperative anaesthetic and postoperative analgesic
      requirement. METHODOLOGY: After approval from Ethics board and registration of
      the trial, 46 eligible patients planned for robotic oncosurgeries (abdomen) were 
      included. As per computer generated randomisation chart, patients were randomised
      into either dexmed or saline group. Five minutes after insufflation of the
      abdomen, the study drug bolus-saline or dexmed (1 mug/kg) was given over 10 min
      and was followed by maintenance infusion (0.2 mug/kg/h) until release of
      pneumoperitoneum. Study drug titration, fentanyl boluses, and changes in minimum 
      alveolar concentration (MAC) of inhalational agent were protocolised. RESULTS:
      The mean intraoperative fentanyl requirement was significantly lower in the
      dexmed group 192.6 mug (+/-66.4) versus the saline group 260.7 mug (+/-88.6), P =
      0.013. The MAC requirement of inhalational agent was significantly lower in the
      dexmed group. Intraoperative episodes of hypotension and bradycardia were similar
      in both groups. First analgesic request, 24 h postoperative pain scores and side 
      effects profile were comparable in both groups. CONCLUSION: Intraoperative dexmed
      (bolus of 1 mug/kg followed by 0.2 mug/kg/h infusion) has an opioid and
      inhalational anaesthetic sparing role during robotic oncosurgeries. However, no
      benefit of the infusion is seen in the postoperative period.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Bakshi, Sumitra G
AU  - Bakshi SG
AD  - Department of Anesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi
      Bhabha National Institute, Mumbai, Maharashtra, India.
FAU - Paulin, Susan V
AU  - Paulin SV
AD  - Department of Anesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi
      Bhabha National Institute, Mumbai, Maharashtra, India.
FAU - Bhawalkar, Pranay
AU  - Bhawalkar P
AD  - Department of Anesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi
      Bhabha National Institute, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7641074
OTO - NOTNLM
OT  - Dexmedetomidine
OT  - peri-operative care
OT  - pneumoperitoneum
OT  - robotic surgical procedures
COIS- There are no conflicts of interest.
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:29
PHST- 2020/06/02 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - 10.4103/ija.IJA_664_20 [doi]
AID - IJA-64-784 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Sep;64(9):784-789. doi: 10.4103/ija.IJA_664_20. Epub 2020 
      Sep 1.


PMID- 33161953
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 1953-8022 (Electronic)
IS  - 1246-7820 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Nov
TI  - COVID-19, transfusion, and publishing ethics.
PG  - 201-202
LID - S1246-7820(20)30126-9 [pii]
LID - 10.1016/j.tracli.2020.10.002 [doi]
FAU - Garraud, O
AU  - Garraud O
AD  - Inserm_U_1059, faculty of medicine, university of Saint-Etienne, 42000
      Saint-Etienne, France; Institut national de la transfusion sanguine, 75015 Paris,
      France. Electronic address: Olivier.garraud@univ-st-etienne.fr.
LA  - eng
PT  - Editorial
PL  - France
TA  - Transfus Clin Biol
JT  - Transfusion clinique et biologique : journal de la Societe francaise de
      transfusion sanguine
JID - 9423846
SB  - IM
EDAT- 2020/11/10 06:00
MHDA- 2020/11/10 06:01
CRDT- 2020/11/09 05:23
PHST- 2020/11/09 05:23 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2020/11/10 06:01 [medline]
AID - S1246-7820(20)30126-9 [pii]
AID - 10.1016/j.tracli.2020.10.002 [doi]
PST - ppublish
SO  - Transfus Clin Biol. 2020 Nov;27(4):201-202. doi: 10.1016/j.tracli.2020.10.002.


PMID- 33161655
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 0869-866X (Print)
IS  - 0869-866X (Linking)
VI  - 28
IP  - 5
DP  - 2020 Sep
TI  - [Euthanasia as a worldwide dilemma of modern times].
PG  - 867-876
LID - 10.32687/0869-866X-2020-28-5-867-876 [doi]
AB  - Nowadays, the most important place in medicine is occupied by ethical and legal
      aspects of organization of medical care and the provision of qualitative medical 
      services to citizens. The main mechanism of functioning of the patient-centric
      health care system is implementation of the rights of patients as described in
      our country within the framework of international legal acts, the Constitution of
      the Russian Federation, the Civil, the Civil Procedure and Criminal Codes of the 
      Russian Federation, as well as the Legislation on the protection of health of
      citizen. Since the mid of twentieth century, in many countries was widely
      discussed possibility of ensuring one of the most controversial and non-obvious
      rights of patient - the right to death. In medical practice, the mechanisms
      implementing this right are the acts of euthanasia, the assisted suicide, the
      voluntary death (refusal of water and food), "murder out of sympathy", terminal
      sedation and the phenomenon of "double effect" as well. The article presents
      review of scientific publications presented in national and international
      databases, highlighting prerequisites of implementation of euthanasia into
      practice and international experience of applying this mechanism of demise as
      well.
FAU - Moskvicheva, L I
AU  - Moskvicheva LI
AD  - The P. A. Hertsen Moscow Research Oncologic Institute, the Branch of The Federal 
      State Budget Institution "The National Medical Research Center of Radiology" of
      Minzdrav of Russia, 125284, Moscow, Russia, ludamed16@mail.ru.
FAU - Agamov, Z Kh
AU  - Agamov ZK
AD  - N. A. Semashko National Research Institute of Public Health, 105064, Moscow,
      Russia.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med
JT  - Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny
JID - 101270373
SB  - IM
MH  - *Criminals
MH  - Delivery of Health Care
MH  - *Euthanasia
MH  - Humans
MH  - Russia
MH  - *Suicide, Assisted
OTO - NOTNLM
OT  - assisted suicide
OT  - euthanasia
OT  - the Constitution of the Russian Federation
OT  - the Criminal Code of the Russian Federation
OT  - the Legislation on the protection of health of citizen
EDAT- 2020/11/09 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/11/08 20:40
PHST- 2020/03/04 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/11/08 20:40 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.32687/0869-866X-2020-28-5-867-876 [doi]
PST - ppublish
SO  - Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2020 Sep;28(5):867-876. doi: 
      10.32687/0869-866X-2020-28-5-867-876.


PMID- 33161617
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 0745-5194 (Print)
IS  - 0745-5194 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Dec
TI  - Plantation Politics, Paranoia, and Public Health on the Frontlines of America's
      COVID-19 Response.
PG  - 578-590
LID - 10.1111/maq.12623 [doi]
AB  - "Plantation politics" pervade multiple institutions in the United States,
      including public health. Drawing from my experience working as a volunteer at
      drive-thru COVID testing sites in the United States, I critically examine the
      relationship between public health, the military, and capitalism when racial
      slavery serves as the sociopolitical backdrop of everyday life. I ponder what it 
      means for Black people to toil for a country, in the midst of an emergent
      communicable disease outbreak, that would weeks later launch into protests for
      and debates about their entitlements to freedom, safety, and security. Starting
      from experiences of Black women on the frontlines, I reveal complexities that
      underlie and undermine notions of care as altruistic, natural, or ethical "in the
      wake" of chattel slavery and in the midst of racial capitalism.
CI  - (c) 2020 by the American Anthropological Association.
FAU - Oyarzun, Yesmar
AU  - Oyarzun Y
AUID- ORCID: 0000-0003-0023-7078
AD  - Department of Anthropology, Rice University.
LA  - eng
PT  - Journal Article
DEP - 20201108
PL  - United States
TA  - Med Anthropol Q
JT  - Medical anthropology quarterly
JID - 8405037
SB  - IM
MH  - *African Americans
MH  - Anthropology, Medical
MH  - COVID-19/*epidemiology
MH  - *Communicable Disease Control
MH  - Enslavement
MH  - Humans
MH  - *Politics
MH  - Public Health Administration/*standards
MH  - *SARS-CoV-2
MH  - United States/epidemiology
MH  - Volunteers
OTO - NOTNLM
OT  - *COVID-19
OT  - *plantation politics
OT  - *public health workers
OT  - *racial paranoia
OT  - *racism
EDAT- 2020/11/09 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/11/08 20:39
PHST- 2020/06/29 00:00 [received]
PHST- 2020/08/08 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/11/08 20:39 [entrez]
AID - 10.1111/maq.12623 [doi]
PST - ppublish
SO  - Med Anthropol Q. 2020 Dec;34(4):578-590. doi: 10.1111/maq.12623. Epub 2020 Nov 8.


PMID- 33161388
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20201218
IS  - 1788-6120 (Electronic)
IS  - 0030-6002 (Linking)
VI  - 161
IP  - 45
DP  - 2020 Nov 8
TI  - COVID-19 and the ethical issues of justice and rationing in health care, with
      particular regard to the Italian experience
PG  - 1899-1907
LID - 10.1556/650.2020.32043 [doi]
AB  - Osszefoglalo. A 2020. ev elejen kirobbant COVID-19-vilagjarvany tobbek kozott
      rairanyitotta a figyelmet az eletmento-eletfenntarto kezelesek igazsagos
      elosztasanak erzekeny kerdesere is. Europan belul elsokent Olaszorszagot sujtotta
      a katasztrofa, a valsaghelyzetben pedig az erzestelenites, fajdalomcsillapitas,
      ujraelesztes es intenziv ellatas teruleten tevekenykedo szakemberek olasz
      tarsasaga, a SIAARTI 2020. marcius 6-an kozzetett egy 15 pontos ajanlast. E
      szerint utilitarista megkozelitessel a rendelkezesre allo szukos eroforrasokat
      azon betegek kezelesere kellene forditani, akik tulelesi eselye nagyobb, valamint
      tobb eletevre szamithatnak a jovoben, mert ez biztosithatja a leheto legtobb
      ember szamara a leheto legnagyobb hasznot. A javaslat komoly szakmai vitat
      robbantott ki, amely egyertelmuve tette, hogy az orvosi eszkozok igazsagos
      elosztasara vonatkozo diskurzust feltetlenul folytatni kell, nemcsak
      Olaszorszagon belul, hanem a pandemiatol sujtott tobbi allamban is. Orv Hetil.
      2020; 161(45): 1899-1907. Summary. Among other queries, the explosion of the
      COVID-19 pandemic at the beginning of 2020 has firmly put in focus the sensitive 
      issue of how to allocate scarcely available life-saving treatments in a fair and 
      just manner. The first European country to face an emergency caused by the
      pandemic was Italy. In a rapidly escalating crisis, on 6th March 2020, the
      Italian Society of Anaesthesia, Analgesia, Resuscitation, and Intensive Care
      (SIAARTI) issued a series of 15 recommendations, suggesting that a utilitarian
      approach should be adopted in Italian health care and the extremely scarce
      resources should be reserved for patients with a greater probability of survival 
      and life expectancy, in order to maximize the benefits for the largest possible
      number of people. The recommendations generated a heated debate among health care
      professionals, thereby evidencing that similar discussions must be initiated and 
      pursued in all countries affected by the pandemic. Orv Hetil. 2020; 161(45):
      1899-1907.
FAU - Peter, Orsolya Marta
AU  - Peter OM
AD  - 1Altalanos Orvostudomanyi Kar, Magatartastudomanyi Intezet, Semmelweis Egyetem,
      Budapest, Nagyvarad ter 4., 1089.
LA  - hun
PT  - Journal Article
TT  - Az igazsagossag es a besorolas etikai problemai az egeszsegugyben, kulonos
      tekintettel a COVID-19-jarvany olaszorszagi tapasztalataira.
DEP - 20201108
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Italy
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - SARS-CoV-2
MH  - *Social Justice
OTO - NOTNLM
OT  - *COVID-19
OT  - *COVID-19
OT  - *Italy
OT  - *Olaszorszag
OT  - *besorolas
OT  - *health care rationing
OT  - *medical ethics
OT  - *orvosi etika
OT  - *selection criteria
OT  - *szelekcios kriteriumok
EDAT- 2020/11/09 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/11/08 20:36
PHST- 2020/08/25 00:00 [received]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/11/08 20:36 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1556/650.2020.32043 [doi]
PST - epublish
SO  - Orv Hetil. 2020 Nov 8;161(45):1899-1907. doi: 10.1556/650.2020.32043. Print 2020 
      Nov 8.


PMID- 33160601
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20201218
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
VI  - 65
IP  - 848
DP  - 2020 Sep
TI  - [The philosophical clinical approach to burnout in caregivers in the light of
      Covid-19].
PG  - 62-64
LID - S0038-0814(20)30192-4 [pii]
LID - 10.1016/S0038-0814(20)30192-4 [doi]
AB  - The crisis caused by the Covid-19 pandemic has highlighted the risks of burnout
      in caregivers and more specifically the question of ethical suffering. A
      philosophical clinical approach to burnout enables it to be analysed as a form of
      existential suffering linked to our shared vulnerability, as well as to more
      socio-organisational failings.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Fleury, Cynthia
AU  - Fleury C
AD  - Conservatoire national des arts et metiers, 292, rue Saint-Martin, 75141 Paris
      cedex 03, France; GHU Paris Psychiatrie et neurosciences, 1, rue Cabanis, 75014
      Paris, France. Electronic address: cynthia.fleury-perkins@lecnam.net.
FAU - Gateau, Valerie
AU  - Gateau V
AD  - GHU Paris Psychiatrie et neurosciences, 1, rue Cabanis, 75014 Paris, France.
LA  - fre
PT  - Journal Article
TT  - La clinique philosophique du burn out des soignants a la lumiere de la Covid-19.
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
MH  - Betacoronavirus
MH  - *Burnout, Psychological
MH  - COVID-19
MH  - Caregivers/*psychology
MH  - Coronavirus Infections/*psychology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19
OT  - burn out
OT  - burnout
OT  - caregiver
OT  - ethical suffering
OT  - ethics of care
OT  - organisation
OT  - soignant
OT  - souffrance ethique
OT  - vulnerability
OT  - vulnerabilite
OT  - ethique du care
EDAT- 2020/11/09 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/11/08 20:23
PHST- 2020/11/08 20:23 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - S0038-0814(20)30192-4 [pii]
AID - 10.1016/S0038-0814(20)30192-4 [doi]
PST - ppublish
SO  - Soins. 2020 Sep;65(848):62-64. doi: 10.1016/S0038-0814(20)30192-4.


PMID- 33160515
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 114
IP  - 5
DP  - 2020 Nov
TI  - Data sharing: using blockchain and decentralized data technologies to unlock the 
      potential of artificial intelligence: What can assisted reproduction learn from
      other areas of medicine?
PG  - 927-933
LID - S0015-0282(20)32402-X [pii]
LID - 10.1016/j.fertnstert.2020.09.160 [doi]
AB  - The extension of blockchain use for nonfinancial domains has revealed
      opportunities to the health care sector that answer the need for efficient and
      effective data and information exchanges in a secure and transparent manner.
      Blockchain is relatively novel in health care and particularly for data
      analytics, although there are examples of improvements achieved. We provide a
      systematic review of blockchain uses within the health care industry, with a
      particular focus on the in vitro fertilization (IVF) field. Blockchain technology
      in the fertility sector, including data sharing collaborations compliant with
      ethical data handling within confines of international law, allows for
      large-scale prospective cohort studies to proceed at an international scale.
      Other opportunities include gamete donation and matching, consent sharing, and
      shared resources between different clinics.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Hickman, Cristina Fontes Lindemann
AU  - Hickman CFL
AD  - Apricity, Paris, France; Institute of Reproduction and Developmental Biology,
      Imperial College London, London, United Kingdom; TMRW Life Sciences, New York,
      New York.
FAU - Alshubbar, Hoor
AU  - Alshubbar H
AD  - Apricity, Paris, France; Institute of Reproduction and Developmental Biology,
      Imperial College London, London, United Kingdom.
FAU - Chambost, Jerome
AU  - Chambost J
AD  - Apricity, Paris, France.
FAU - Jacques, Celine
AU  - Jacques C
AD  - Apricity, Paris, France.
FAU - Pena, Chris-Alexandre
AU  - Pena CA
AD  - Apricity, Paris, France.
FAU - Drakeley, Andrew
AU  - Drakeley A
AD  - Hewitt Fertility Centre, Liverpool Women's Hospital, Liverpool, United Kingdom.
FAU - Freour, Thomas
AU  - Freour T
AD  - Service de Medecine et Biologie de la Reproduction, CHU de Nantes, Nantes,
      France; Centre de Recherche en Transplantation et Immunologie, INSERM, Universite
      de Nantes, Nantes, France.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
MH  - *Artificial Intelligence/statistics & numerical data
MH  - *Blockchain/statistics & numerical data
MH  - Databases, Factual/statistics & numerical data
MH  - Fertilization in Vitro/methods/statistics & numerical data
MH  - Humans
MH  - Information Dissemination/*methods
MH  - *Reproductive Techniques, Assisted/statistics & numerical data
OTO - NOTNLM
OT  - *Blockchain
OT  - *IVF
OT  - *federated learning
OT  - *fertility
OT  - *systematic literature review
EDAT- 2020/11/09 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/11/08 20:22
PHST- 2020/09/25 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/11/08 20:22 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
AID - S0015-0282(20)32402-X [pii]
AID - 10.1016/j.fertnstert.2020.09.160 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Nov;114(5):927-933. doi: 10.1016/j.fertnstert.2020.09.160.


PMID- 33160412
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20201218
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Nov 7
TI  - Assessing the effects of exposure to a SARS-CoV-2 re-positive patient in
      healthcare personnel.
PG  - 511
LID - 10.1186/s13104-020-05365-y [doi]
AB  - OBJECTIVE: To evaluate whether patients with COVID-19 who have tested re-positive
      with the PCR test for the SARS-CoV-2 virus are infectious is a challenge in the
      current circumstances. A follow-up survey was conducted with healthcare personnel
      (HCP) who were exposed to a patient whose PCR test results for SARS-CoV-2 were
      re-positive 18 days after the initial confirmation of negative PCR results.
      RESULTS: We studied a total of 15 HCP who had contact exposures (15/15) and
      aerosol exposures (7/15). None of them tested positive for IgG against SARS-CoV-2
      on blood examination. None of them had any symptoms during 10 days of active
      isolation. All PCR tests conducted using the nasopharyngeal swabs collected from 
      the HCP on day 10 were negative. No apparent infection was found in any of the
      HCP who had contact exposure with and/or aerosol exposure to the patient whose
      PCR test results for SARS-CoV-2 were re-positive 18 days after the initial
      confirmation of negative results of PCR tests for SARS-CoV-2. CLINICAL TRIAL:
      Trial Registration: No. 170, approved June 10th, 2020 by the ethics committee of 
      Sakai City Medical Center.
FAU - Ogawa, Yoshihiko
AU  - Ogawa Y
AUID- ORCID: http://orcid.org/0000-0002-6823-8475
AD  - Department of Infectious Diseases, Sakai City Medical Center, Ebaraji 1-1-1,
      Sakai, Osaka, Japan. hikoichi.ogw@gmail.com.
AD  - Treatment Team for COVID-19, Sakai City Medical Center, Ebaraji 1-1-1, Sakai,
      Osaka, Japan. hikoichi.ogw@gmail.com.
FAU - Nishida, Koji
AU  - Nishida K
AD  - Treatment Team for COVID-19, Sakai City Medical Center, Ebaraji 1-1-1, Sakai,
      Osaka, Japan.
AD  - Department of Respiratory Medicine, Sakai City Medical Center, Ebaraji 1-1-1,
      Sakai, Osaka, Japan.
FAU - Gohma, Iwao
AU  - Gohma I
AD  - Treatment Team for COVID-19, Sakai City Medical Center, Ebaraji 1-1-1, Sakai,
      Osaka, Japan.
AD  - Department of Respiratory Medicine, Sakai City Medical Center, Ebaraji 1-1-1,
      Sakai, Osaka, Japan.
FAU - Kasahara, Kei
AU  - Kasahara K
AD  - Center for Infectious Diseases, Nara Medical University, Shijo-cho 840,
      Kashihara, Nara, Japan.
FAU - Yano, Hisakazu
AU  - Yano H
AD  - Department of Microbiology and Infectious Diseases, Nara Medical University,
      Shijo-cho 840, Kashihara, Nara, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20201107
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/blood/immunology
MH  - Betacoronavirus/immunology
MH  - COVID-19
MH  - Coronavirus Infections/*transmission
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/blood/immunology
MH  - Infectious Disease Transmission, Patient-to-Professional/*statistics & numerical 
      data
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*transmission
MH  - Polymerase Chain Reaction
MH  - SARS-CoV-2
MH  - Young Adult
PMC - PMC7648555
OTO - NOTNLM
OT  - COVID-19
OT  - Healthcare personnel
OT  - PCR re-positive
OT  - SARS-CoV-2
EDAT- 2020/11/09 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/11/08 20:21
PHST- 2020/08/29 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/08 20:21 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - 10.1186/s13104-020-05365-y [doi]
AID - 10.1186/s13104-020-05365-y [pii]
PST - epublish
SO  - BMC Res Notes. 2020 Nov 7;13(1):511. doi: 10.1186/s13104-020-05365-y.


PMID- 33160397
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20201201
IS  - 2050-7283 (Electronic)
IS  - 2050-7283 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Nov 7
TI  - The Dark Triad of personality and attitudes toward cognitive enhancement.
PG  - 119
LID - 10.1186/s40359-020-00486-2 [doi]
AB  - BACKGROUND: Cognitive enhancement (CE) refers to the voluntary improvement of
      human cognitive capabilities. Few studies have examined the general attitude of
      the public towards CE. Such studies have suggested that the use of CE is
      considered largely unacceptable by the public. In parallel, past research
      indicates that individuals scoring high on the Dark Triad of personality
      (Machiavellianism, narcissism, and psychopathy) and competitiveness have atypical
      views of ethical questions. In this study, we examined (a) whether attitudes
      towards CE are associated with individual differences in the Dark Triad of
      personality as well as in trait and contextual competitiveness and (b) whether
      the Dark Triad moderates the effect of trait and contextual competitiveness on
      attitudes towards CE. METHOD: US employees (N = 326) were recruited using
      Mechanical Turk. Participants completed a web survey. Data were analyzed by means
      of (robust) hierarchical regression and (robust) ANCOVAs. RESULTS: The Dark Triad
      of personality and one of its subscales, Machiavellianism, predicted positive
      attitudes towards CE. Neither trait competitiveness nor contextual
      competitiveness were linked to general attitudes towards CE, but the DT was a
      positive moderator of the association between contextual competitiveness and
      positive attitudes. CONCLUSION: Our findings extend the incipient knowledge about
      the factors relating to favourable views of CE by highlighting the role of dark
      personality traits in shaping such views. Our study further shows contextual
      factors can play a differentiated role with respect to such attitudes depending
      upon dark personality traits. Implications for policy-making are discussed.
FAU - Mayor, Eric
AU  - Mayor E
AUID- ORCID: http://orcid.org/0000-0001-9441-7592
AD  - Department of Clinical Psychology and Epidemiology, University of Basel, 4055,
      Basel, Switzerland. ericmarcel.mayor@unibas.ch.
FAU - Daehne, Maxime
AU  - Daehne M
AD  - Institute of Work and Organizational Psychology, University of Neuchatel, 2000
      Neuchatel, Switzerland.
FAU - Bianchi, Renzo
AU  - Bianchi R
AD  - Institute of Work and Organizational Psychology, University of Neuchatel, 2000
      Neuchatel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201107
PL  - England
TA  - BMC Psychol
JT  - BMC psychology
JID - 101627676
RN  - 0 (Nootropic Agents)
SB  - IM
MH  - Antisocial Personality Disorder/*psychology
MH  - *Attitude
MH  - Cognition/drug effects
MH  - Competitive Behavior
MH  - Humans
MH  - *Machiavellianism
MH  - *Narcissism
MH  - *Nootropic Agents/pharmacology
PMC - PMC7648998
OTO - NOTNLM
OT  - Cognitive enhancement
OT  - Competitiveness
OT  - Dark triad of personality
OT  - Ethical views
OT  - Public attitudes
EDAT- 2020/11/09 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/11/08 20:21
PHST- 2020/08/25 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/08 20:21 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
AID - 10.1186/s40359-020-00486-2 [doi]
AID - 10.1186/s40359-020-00486-2 [pii]
PST - epublish
SO  - BMC Psychol. 2020 Nov 7;8(1):119. doi: 10.1186/s40359-020-00486-2.


PMID- 33160361
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 7
TI  - Perceptions of education quality and influence of language barrier: graduation
      survey of international medical students at four universities in China.
PG  - 410
LID - 10.1186/s12909-020-02340-w [doi]
AB  - BACKGROUND: As the number of Asian and African students studying medicine in
      China increases, it is imperative to evaluate the educational experiences of
      these international medical students (IMSs). This study was intended to
      investigate opinions of China-educated IMSs towards the medical curriculum and
      the impact of Chinese language capability on their clinical studies. METHODS: A
      self-administered questionnaire was circulated to the final-year IMSs during the 
      graduation time from May 2019 to July 2019 in 4 universities in China. The
      questionnaire asked IMSs to assess the quality of medical education and provide a
      self-evaluation of their Chinese language capability. One-way Analysis of
      Variance (ANOVA) was used to determine whether IMSs' Chinese language capability 
      was associated with their clinical experiences and clinical competence. RESULTS: 
      Overall, we received 209 valid responses, of which 76.1% were satisfied with the 
      quality of medical education. Genetics, physics, and mathematics were perceived
      as the least relevant basic courses for medical practice, and 21.5% of student
      reported that community-oriented medicine was a neglected subject. Notably, 58.9%
      of students had positive views about discussions on ethical topics during their
      clerkships, and 71.3% believed they had acquired sufficient clinical skills to
      begin a residency program. Chinese speaking skills and communication initiatives 
      were found to be critical factors in influencing students' clinical experiences
      and competence. CONCLUSION: This study presents the perceptions of China-educated
      IMSs towards medical curriculum from various aspects. Results show that language 
      influences the education experiences of IMSs. Collectively, these results
      indicate that the curriculum for IMSs in China should be more problem-based and
      community-engaged to improve IMSs' learning experiences and preparation for
      community deployment. Furthermore, training curriculum for the oral Chinese
      should be improved to equip IMSs with sufficient language competence to enable
      them to efficiently carry out clinical clerkship and rotations. Our findings
      provide evidence for benchmarking medical curricular codifications tailored for
      Asian and African students.
FAU - Li, Wen
AU  - Li W
AD  - School of International Education, Xuzhou Medical University, No.209 of Tongshan 
      Road, Yunlong District, Xuzhou, Jiangsu, China.
FAU - Liu, Chang
AU  - Liu C
AD  - School of International Education, Xuzhou Medical University, No.209 of Tongshan 
      Road, Yunlong District, Xuzhou, Jiangsu, China.
FAU - Liu, Shenjun
AU  - Liu S
AD  - School of International Education, Xuzhou Medical University, No.209 of Tongshan 
      Road, Yunlong District, Xuzhou, Jiangsu, China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - School of literature, Dali University, Dali, China.
FAU - Shi, Rong-Gen
AU  - Shi RG
AD  - College of International Studies, Nanjing Medical University, Nanjing, China.
FAU - Jiang, Hailan
AU  - Jiang H
AD  - School of International Education, Nanjing Medical University, Nanjing, China.
FAU - Ling, Yi
AU  - Ling Y
AD  - Department of Obstetrics and Gynaecology, First Affiliated Hospital of Hainan
      Medical University, Haikou, China.
FAU - Sun, Hong
AU  - Sun H
AUID- ORCID: http://orcid.org/0000-0003-3858-4315
AD  - School of International Education, Xuzhou Medical University, No.209 of Tongshan 
      Road, Yunlong District, Xuzhou, Jiangsu, China. sunh@xzhmu.edu.cn.
LA  - eng
GR  - 2018SJA0960/Philosophy and Social Sciences Fund Project of Jiangsu Provincial
      Department of Education
PT  - Journal Article
DEP - 20201107
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - China
MH  - Communication Barriers
MH  - Curriculum
MH  - Humans
MH  - Perception
MH  - *Students, Medical
MH  - Surveys and Questionnaires
MH  - Universities
PMC - PMC7648950
OTO - NOTNLM
OT  - Africa
OT  - Asia
OT  - Curriculum evaluation
OT  - Graduation questionnaire
OT  - International medical student
OT  - Language barrier
OT  - Medical education in China
OT  - Students' perceptions
EDAT- 2020/11/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/08 20:21
PHST- 2020/05/03 00:00 [received]
PHST- 2020/10/29 00:00 [accepted]
PHST- 2020/11/08 20:21 [entrez]
PHST- 2020/11/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02340-w [doi]
AID - 10.1186/s12909-020-02340-w [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Nov 7;20(1):410. doi: 10.1186/s12909-020-02340-w.


PMID- 33159651
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - Suppl 1
DP  - 2020 Dec
TI  - Infection control measures in times of antimicrobial resistance: a matter of
      solidarity.
PG  - 47-55
LID - 10.1007/s40592-020-00119-9 [doi]
AB  - Control measures directed at carriers of multidrug-resistant organisms are
      traditionally approached as a trade-off between public interests on the one hand 
      and individual autonomy on the other. We propose to reframe the ethical issue and
      consider control measures directed at carriers an issue of solidarity. Rather
      than asking "whether it is justified to impose strict measures", we propose
      asking "how to best care for a person's carriership and well-being in ways that
      do not imply an unacceptable risk for others?". A solidarity approach could
      include elevating baseline levels of precaution measures and accepting certain
      risks in cases where there is exceptionally much at stake. A generous national
      compensation policy that also covers for costs related to dedicated care is
      essential in a solidarity approach. An additional benefit of reframing the
      questions is that it helps to better acknowledge that being subjected to control 
      measures is a highly personal matter.
FAU - Rump, Babette
AU  - Rump B
AUID- ORCID: http://orcid.org/0000-0002-6573-0333
AD  - National Coordination Centre for Communicable Disease Control, RIVM-Centre for
      Communicable Diseases, Postbus 1, 3720 BA, Bilthoven, The Netherlands.
      info@rivm.nl.
AD  - Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute
      for Health Sciences, Radboud university medical center, Nijmegen, The
      Netherlands. info@rivm.nl.
FAU - Timen, Aura
AU  - Timen A
AD  - National Coordination Centre for Communicable Disease Control, RIVM-Centre for
      Communicable Diseases, Bilthoven, The Netherlands.
AD  - Athena institute for Research on Innovation and Communication in Health and Life 
      Sciences, VU University Amsterdam, Amsterdam, The Netherlands.
FAU - Hulscher, Marlies
AU  - Hulscher M
AD  - Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute
      for Health Sciences, Radboud university medical center, Nijmegen, The
      Netherlands.
FAU - Verweij, Marcel
AU  - Verweij M
AD  - Section Communication, Philosophy and Technology, Wageningen University,
      Wageningen, The Netherlands. marcel.verweij@wur.nl.
LA  - eng
GR  - ZonMw/731010011/ZonMw
GR  - V/150013/18/ED/Ministerie van Volksgezondheid, Welzijn en Sport
PT  - Journal Article
DEP - 20201107
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - *Carrier State
MH  - *Drug Resistance, Bacterial
MH  - *Ethical Analysis
MH  - Humans
MH  - *Infection Control
PMC - PMC7648233
OTO - NOTNLM
OT  - Amr
OT  - Ethics
OT  - Infection control measures
OT  - Isolation
OT  - Justification
OT  - Solidarity
EDAT- 2020/11/08 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/11/07 12:06
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/11/07 12:06 [entrez]
AID - 10.1007/s40592-020-00119-9 [doi]
AID - 10.1007/s40592-020-00119-9 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(Suppl 1):47-55. doi: 10.1007/s40592-020-00119-9.
      Epub 2020 Nov 7.


PMID- 33158835
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Barriers and facilitators associated with steps of the HIV care cascade for
      migrants in OECD countries: a systematic mixed studies review protocol.
PG  - e040646
LID - 10.1136/bmjopen-2020-040646 [doi]
AB  - INTRODUCTION: In 2019, the United Nations signalled a substantial rise in the
      number of international migrants, up to 272 million globally, about half of which
      move to only 10 countries, including 8 member nations of the Organization for
      Economic Co-operation and Development (OECD). Migrants in OECD countries are
      often at higher risk for acquiring HIV and have a higher frequency of delayed HIV
      diagnosis. The barriers and facilitators that migrant people living with HIV
      (PLWH) in OECD countries face in relation to HIV care are insufficiently
      understood. The five-step HIV Care Cascade Continuum (HCCC) is an effective model
      to identify gaps, barriers and facilitators associated with HIV care. The purpose
      of this study is to generate a comprehensive, multilevel understanding of
      barriers and facilitators regarding the five steps of the HCCC model in OECD
      countries by migration status. METHODS AND ANALYSIS: A systematic mixed studies
      review using a data-based convergent design will be conducted. Medline, Embase,
      Scopus, CINAHL and the Cochrane Library will be searched on 25 March 2020.
      Screening and critical appraisal will be conducted independently by the first
      author. Authors 3-5 will act as second reviewers, each independently conducting
      33% of the screening and appraisal. Quantitative data will be transformed to
      qualitative data and be synthesised using thematic analysis. The Mixed Methods
      Appraisal Tool will be used for quality assessment. An advisory committee,
      composed of four migrant PLWH, will be involved in screening and appraising 5% of
      articles to build knowledge and experience with systematic reviews. They will
      also be involved in analysis and dissemination. ETHICS AND DISSEMINATION: Ethics 
      approval was obtained from the McGill University Health Centre (15-188-MUHC,
      2016-1697, eReviews 4688). Publications arising from this study will be
      open-access. PROSPERO REGISTRATION NUMBER: CRD42020172122.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arora, Anish
AU  - Arora A
AUID- ORCID: 0000-0003-3710-8704
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill
      University, Montreal, Quebec, Canada anish.arora@mail.mcgill.ca.
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical
      Trials, Canadian Institutes of Health Research, Montreal, Quebec, Canada.
FAU - Quesnel-Vallee, Amelie
AU  - Quesnel-Vallee A
AD  - Department of Sociology, Faculty of Arts, McGill University, Montreal, Quebec,
      Canada.
AD  - Department of Epidemiology, Biostatistics and Occupational Health, Faculty of
      Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
FAU - Lessard, David
AU  - Lessard D
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical
      Trials, Canadian Institutes of Health Research, Montreal, Quebec, Canada.
FAU - Mate, Kedar
AU  - Mate K
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill
      University, Montreal, Quebec, Canada.
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical
      Trials, Canadian Institutes of Health Research, Montreal, Quebec, Canada.
FAU - Rodriguez-Cruz, Adriana
AU  - Rodriguez-Cruz A
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill
      University, Montreal, Quebec, Canada.
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical
      Trials, Canadian Institutes of Health Research, Montreal, Quebec, Canada.
FAU - Kronfli, Nadine
AU  - Kronfli N
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Department of Medicine, Chronic Viral Illness Service, Division of Infectious
      Diseases, McGill University Health Centre, Montreal, Quebec, Canada.
FAU - Engler, Kim
AU  - Engler K
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical
      Trials, Canadian Institutes of Health Research, Montreal, Quebec, Canada.
FAU - Vedel, Isabelle
AU  - Vedel I
AUID- ORCID: 0000-0002-6873-1681
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill
      University, Montreal, Quebec, Canada.
FAU - Lebouche, Bertrand
AU  - Lebouche B
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill
      University, Montreal, Quebec, Canada.
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
AD  - Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical
      Trials, Canadian Institutes of Health Research, Montreal, Quebec, Canada.
AD  - Department of Medicine, Chronic Viral Illness Service, Division of Infectious
      Diseases, McGill University Health Centre, Montreal, Quebec, Canada.
CN  - Antiviral Speed Access Program (ASAP) Migrant Advisory Committee
LA  - eng
GR  - Canadian Institutes for Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *HIV Infections/diagnosis
MH  - Humans
MH  - Mass Screening
MH  - Organisation for Economic Co-Operation and Development
MH  - Systematic Reviews as Topic
MH  - *Transients and Migrants
PMC - PMC7651739
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *health policy
OT  - *international health services
OT  - *organisation of health services
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040646 [pii]
AID - 10.1136/bmjopen-2020-040646 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e040646. doi: 10.1136/bmjopen-2020-040646.


PMID- 33158833
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Implementation of the Assistive Product List (APL) in Malawi through development 
      of appropriate policy and systems: an action research protocol.
PG  - e040281
LID - 10.1136/bmjopen-2020-040281 [doi]
AB  - INTRODUCTION: Assistive technology (AT) is important for the achievement of the
      sustainable development goals (SDGs) for persons with disabilities (PWD).
      Increasingly, studies suggest a significant gap between the need for and demand
      for and provisions of AT for PWD in low-income and middle-income settings.
      Evidence from high income countries highlights the importance of robust AT
      policies to the achievement of the recommendations of the World Health Assembly
      on AT. In Malawi, there is no standalone AT policy. The objectives of the
      Assistive Product List Implementation Creating Enablement of inclusive SDGs
      (APPLICABLE) project, are to propose and facilitate the development of a
      framework for creating effective national AT policy and specify a system capable 
      of implementing such policies in low-income countries such as Malawi. METHOD AND 
      ANALYSIS: We propose an action research process with stakeholders in AT in
      Malawi. APPLICABLE will adopt an action research paradigm, through developing a
      shared research agenda with stakeholders and including users of AT. This involves
      the formation of an Action Research Group that will specify the priorities for
      practice-and policy-based evidence, in order to facilitate the development of
      contextually realistic and achievable policy aspirations on AT in Malawi and
      provide system strengthening recommendations that will ensure that the policy is 
      implementable for their realisation. We will undertake an evaluation of this
      policy by measuring supply and support for specific AT prior to, and following
      the implementation of the policy recommendations. ETHICS AND DISSEMINATION: The
      study protocol was approved by Maynooth University Research Ethics Committee
      (SRESC-2019-2378566) and University of Malawi Research Ethics Committee
      (P.01/20/10). Findings from the study will be disseminated by publication in
      peer-reviewed journals, presentations to stakeholders in Malawi, Ireland and
      international audiences at international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ebuenyi, Ikenna D
AU  - Ebuenyi ID
AUID- ORCID: 0000-0002-3329-6296
AD  - Assisting Living & Learning (ALL) Institute, Department of Psychology, Maynooth
      University, Maynooth, Ireland ikenna.ebuenyi@mu.ie.
FAU - Smith, Emma M
AU  - Smith EM
AUID- ORCID: 0000-0003-2541-5723
AD  - Assisting Living & Learning (ALL) Institute, Department of Psychology, Maynooth
      University, Maynooth, Ireland.
FAU - Kafumba, Juba
AU  - Kafumba J
AD  - Centre for Social Research, University of Malawi, Zomba, Malawi.
FAU - Jamali, Monica Z
AU  - Jamali MZ
AD  - Centre for Social Research, University of Malawi, Zomba, Malawi.
FAU - Munthali, Alister
AU  - Munthali A
AD  - Centre for Social Research, University of Malawi, Zomba, Malawi.
FAU - MacLachlan, Malcolm
AU  - MacLachlan M
AUID- ORCID: 0000-0001-6672-9206
AD  - Assisting Living & Learning (ALL) Institute, Department of Psychology, Maynooth
      University, Maynooth, Ireland.
AD  - Olomouc University Social Health Institute (OUSHI), Palacky University, Olomouc, 
      Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Global Health
MH  - Health Policy
MH  - Health Services Research
MH  - Humans
MH  - Ireland
MH  - Malawi
MH  - *Sustainable Development
PMC - PMC7651723
OTO - NOTNLM
OT  - *health policy
OT  - *public health
OT  - *rehabilitation medicine
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040281 [pii]
AID - 10.1136/bmjopen-2020-040281 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e040281. doi: 10.1136/bmjopen-2020-040281.


PMID- 33158830
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Protocol for a prospective descriptive prevalence study of catatonia in an acute 
      mental health unit in urban South Africa.
PG  - e040176
LID - 10.1136/bmjopen-2020-040176 [doi]
AB  - INTRODUCTION: Catatonia arises from serious mental, medical, neurological or
      toxic conditions. The prevalence range depends on the setting and the range is
      anything from 7% to 63% in other countries. South African prevalence rates are
      currently unknown. The proposed study is a quantitative descriptive study using
      the Bush Francis Catatonia Screening Instrument as a screening tool with a data
      capturing information sheet to extract clinical information from patient folders.
      The study will investigate: (1) prevalence of catatonia, (2) clinical and
      demographic correlates associated with catatonia, (3) predictors of catatonia,
      (4) response to treatment and (5) subjective experience of catatonia. METHODS AND
      ANALYSIS: The setting is an acute mental health unit (MHU) within a regional,
      general medical hospital in Nelson Mandela Bay, South Africa, which accepts
      referrals from within the hospital and from outlying clinics. Participants will
      be recruited from inpatients in the MHU from beginning of September 2020 to end
      of August 2021. Most admissions are involuntarily, under the Mental Health Care
      Act of 2002 with an age range of 13 to over 65 years. Participants who screen
      positive for catatonia will be followed up after discharge for 3 months to
      measure outcomes. Primary outcomes will include the 12-month prevalence rate of
      catatonia, descriptive and other data on presentation and assessment of catatonia
      in the MHU. Secondary outcomes will include data on treatment response,
      participants' report of their subjective experience of catatonia and predictors
      of catatonia. Descriptive statistics, multivariate binomial logistic regression
      and univariate analyses will be conducted to evaluate associations between
      catatonia and clinical or demographic data which could be predictors of
      catatonia. Survival analysis will be used to examine the time to recovery after
      diagnosis and initiation of treatment. The 95% CI will be used to demonstrate the
      precision of estimates. The level of significance will be p</=0.05. ETHICS AND
      DISSEMINATION: The study has received ethical approval from the Research and
      Ethics Committees of the Eastern Cape Department of Health, Walter Sisulu
      University and Nelson Mandela University. The results will be disseminated as
      follows: at various presentations and feedback sessions; as part of a PhD thesis 
      in Psychology at Nelson Mandela University; and in a manuscript that will be
      submitted to a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zingela, Zukiswa
AU  - Zingela Z
AUID- ORCID: 0000-0002-3425-1145
AD  - Department of Psychiatry and Human Behavioural Sciences, Walter Sisulu
      University, Mthatha, South Africa zzingela@wsu.ac.za.
FAU - Stroud, Louise
AU  - Stroud L
AD  - Department of Psychology, Nelson Mandela University, Port ELizabeth, South
      Africa.
FAU - Cronje, Johan
AU  - Cronje J
AD  - Department of Psychology, Nelson Mandela University, Port ELizabeth, South
      Africa.
FAU - Fink, Max
AU  - Fink M
AD  - Department of Psychiatry, Stony Brook University, Stony Brook, New York, USA.
FAU - van Wyk, Stephanus
AU  - van Wyk S
AD  - Department of Psychiatry and Human Behavioural Sciences, Walter Sisulu
      University, Mthatha, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Catatonia/diagnosis/epidemiology/therapy
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Mental Health
MH  - Prevalence
MH  - Prospective Studies
MH  - South Africa/epidemiology
PMC - PMC7651726
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *child & adolescent psychiatry
OT  - *mental health
OT  - *neurology
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040176 [pii]
AID - 10.1136/bmjopen-2020-040176 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e040176. doi: 10.1136/bmjopen-2020-040176.


PMID- 33158826
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210528
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Using discrete choice experiments to design interventions for heterogeneous
      preferences: protocol for a pragmatic randomised controlled trial of a
      preference-informed, heterogeneity-focused, HIV testing offer for high-risk
      populations.
PG  - e039313
LID - 10.1136/bmjopen-2020-039313 [doi]
AB  - INTRODUCTION: Approximately one million undiagnosed persons living with HIV in
      Southern and Eastern Africa need to test for HIV. Novel approaches are necessary 
      to identify HIV testing options that match the heterogeneous testing preferences 
      of high-risk populations. This pragmatic randomised controlled trial (PRCT) will 
      evaluate the efficacy of a preference-informed, heterogeneity-focused HIV
      counselling and testing (HCT) offer, for improving rates of HIV testing in two
      high-risk populations. METHODS AND ANALYSIS: The study will be conducted in
      Moshi, Tanzania. The PRCT will randomise 600 female barworkers and 600 male
      Kilimanjaro mountain porters across three study arms. All participants will
      receive an HIV testing offer comprised of four preference-informed testing
      options, including one 'common' option-comprising features that are commonly
      available in the area and, on average, most preferred among study
      participants-and three options that are specific to the study arm. Options will
      be identified using mixed logit and latent class analyses of data from a discrete
      choice experiment (DCE). Participants in Arm 1 will be offered the common option 
      and three 'targeted' options that are predicted to be more preferred than the
      common option and combine features widely available in the study area.
      Participants in Arm 2 will be offered the common option and three 'enhanced'
      options, which also include HCT features that are not yet widely available in the
      study area. Participants in Arm 3, an active control arm, will be offered the
      common option and three predicted 'less preferred' options. The primary outcome
      will be uptake of HIV testing. ETHICS AND DISSEMINATION: Ethical approval was
      obtained from the Duke University Health System IRB, the University of South
      Carolina IRB, the Ethics Review Committee at Kilimanjaro Christian Medical
      University College, Tanzania's National Institute for Medical Research, and the
      Tanzania Food & Drugs Authority (now Tanzania Medicines & Medical Devices
      Authority). Findings will be published in peer-reviewed journals. The use of
      rigorous DCE methods for the preference-based design and tailoring of
      interventions could lead to novel policy options and implementation science
      approaches. TRIAL REGISTRATION NUMBER: NCT02714140.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ostermann, Jan
AU  - Ostermann J
AUID- ORCID: 0000-0002-8236-9500
AD  - Department of Health Services Policy & Management, University of South Carolina, 
      Columbia, South Carolina, USA jano@mailbox.sc.edu.
AD  - South Carolina Smart State Center for Healthcare Quality, University of South
      Carolina, Carolina, South Carolina, USA.
AD  - Duke Global Health Institute, Duke University, Durham, North Carolina, USA.
AD  - Center for Health Policy & Inequalities Research, Duke University, Durham, North 
      Carolina, USA.
FAU - Njau, Bernard
AU  - Njau B
AD  - Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
FAU - Hobbie, Amy
AU  - Hobbie A
AD  - Duke Global Health Institute, Duke University, Durham, North Carolina, USA.
AD  - Center for Health Policy & Inequalities Research, Duke University, Durham, North 
      Carolina, USA.
FAU - Mtuy, Tara
AU  - Mtuy T
AD  - Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Masaki, Martha L
AU  - Masaki ML
AD  - Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
FAU - Shayo, Aisa
AU  - Shayo A
AD  - Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
FAU - van Zwetselaar, Marco
AU  - van Zwetselaar M
AUID- ORCID: 0000-0002-5953-0060
AD  - Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
FAU - Masnick, Max
AU  - Masnick M
AD  - Selway Labs, LLC, Barrington, Rhode Island, USA.
FAU - Flaherty, Brian
AU  - Flaherty B
AD  - Department of Psychology, University of Washington, Seattle, Washington, USA.
FAU - Brown, Derek S
AU  - Brown DS
AD  - Brown School, Washington University in St. Louis, St. Louis, Missouri, USA.
FAU - Muhlbacher, Axel C
AU  - Muhlbacher AC
AD  - Center for Health Policy & Inequalities Research, Duke University, Durham, North 
      Carolina, USA.
AD  - Institut Gesundheitsokonomie und Medizinmanagement, Hochschule Neubrandenburg,
      Neubrandenburg, Germany.
AD  - Department of Population Health Sciences, Duke University, Durham, North
      Carolina, USA.
FAU - Thielman, Nathan M
AU  - Thielman NM
AD  - Duke Global Health Institute, Duke University, Durham, North Carolina, USA.
AD  - Center for Health Policy & Inequalities Research, Duke University, Durham, North 
      Carolina, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02714140
GR  - P30 AI064518/AI/NIAID NIH HHS/United States
GR  - R01 MH106388/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Counseling
MH  - Female
MH  - *HIV Infections/diagnosis
MH  - *HIV Testing
MH  - Humans
MH  - Male
MH  - Tanzania
PMC - PMC7651730
OTO - NOTNLM
OT  - *health economics
OT  - *hiv & aids
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-039313 [pii]
AID - 10.1136/bmjopen-2020-039313 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e039313. doi: 10.1136/bmjopen-2020-039313.


PMID- 33158825
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Pharmaceutical management of elderly high-risk patients in perioperative settings
      (PHAROS): protocol of a pilot sequential intervention study.
PG  - e039094
LID - 10.1136/bmjopen-2020-039094 [doi]
AB  - INTRODUCTION: With increasing age, the risk of complications after surgery rises 
      in elderly patients. Furthermore, the prevalence of multimorbidity and
      polypharmacy rises with age, making this elderly population especially vulnerable
      for drug-related problems and posing an additional risk for postoperative
      complications. Still, only few studies have concentrated on investigating how
      medication safety can be improved in these patients. The aim of this pilot study 
      is to examine the impact of a comprehensive intervention (interprofessional
      systematic medication therapy management) on medication appropriateness in
      elderly polymedicated, multimorbid patients during hospital stay for elective
      surgery. METHODS AND ANALYSIS: This pilot study will include a total number of
      140 patients. Surgical high-risk patients >/=65 years taking more than five
      chronic systemic drugs will be recruited consecutively for 9 months in the
      control group capturing usual care regarding medication history and in-hospital
      medication therapy management without any study intervention. Recruitment of the 
      intervention group will be conducted for another 9 months. The intervention
      consists of the following components: an additional medication history by a
      hospital pharmacist before admission, a subsequent medication review,
      optimisation of the long-term medication and recommendations to the patient's
      general practitioner. A follow-up will be performed 3 months after surgery. As
      the primary study outcome, medication appropriateness will be measured using the 
      Medication Appropriateness Index.Secondary outcomes are postoperative
      complications, incidence and frequency of adverse drug reactions and potentially 
      inappropriate medication in the elderly, satisfaction with inpatient and
      outpatient care, medication reconciliation and health-related quality of life.
      Multivariable analyses will be used to analyse all quantitative research
      questions. ETHICS AND DISSEMINATION: Ethics approval was obtained by the medical 
      ethics committee of the Medical Chamber of Hamburg (study ID: PV5754). Data will 
      be published in peer-reviewed journals and presented at conferences. TRIAL
      REGISTRATION NUMBER: The study is registered at www.drks.de: DRKS00014621.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Richter, Julia
AU  - Richter J
AD  - Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Schonfeld, Moritz Sebastian
AU  - Schonfeld MS
AUID- ORCID: 0000-0002-8611-8717
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany mo.schoenfeld@uke.de.
FAU - Langebrake, Claudia
AU  - Langebrake C
AD  - Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
AD  - Department of Stem Cell Transplantation, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Bergelt, Corinna
AU  - Bergelt C
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Kriston, Levente
AU  - Kriston L
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Olotu, Cynthia
AU  - Olotu C
AUID- ORCID: 0000-0001-9272-7386
AD  - Department of Anaesthesiology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Kiefmann, Rainer
AU  - Kiefmann R
AD  - Department of Anaesthesiology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
LA  - eng
SI  - DRKS/DRKS00014621
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Inappropriate Prescribing
MH  - Pharmaceutical Preparations
MH  - Pilot Projects
MH  - Polypharmacy
MH  - *Quality of Life
MH  - Reproducibility of Results
PMC - PMC7651720
OTO - NOTNLM
OT  - *adverse events
OT  - *clinical pharmacology
OT  - *clinical trials
OT  - *geriatric medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-039094 [pii]
AID - 10.1136/bmjopen-2020-039094 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e039094. doi: 10.1136/bmjopen-2020-039094.


PMID- 33158824
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Feasibility and acceptability of e-PROMs data capture and feedback among patients
      receiving haemodialysis in the Symptom monitoring WIth Feedback Trial (SWIFT)
      pilot: protocol for a qualitative study in Australia.
PG  - e039014
LID - 10.1136/bmjopen-2020-039014 [doi]
AB  - INTRODUCTION: People receiving haemodialysis experience a high symptom burden and
      impaired quality of life. The use of patient-reported outcome measures (PROMs) is
      increasing in nephrology care, however their acceptability, utility and impacts
      are not well understood. METHODS AND ANALYSIS: We describe a protocol for a
      qualitative study to evaluate the feasibility and acceptability of
      electronic-PROMs (e-PROMs) data capture and feedback in haemodialysis following
      the pilot Symptom monitoring WIth Feedback Trial (SWIFT). SWIFT involves linkage 
      of e-PROMs data, including symptoms and health-related quality of life, to the
      Australia and New Zealand Dialysis and Transplant Registry with feedback to
      patients' treating nephrologists and nurse unit managers. Focus groups and
      semistructured interviews will be conducted with nephrologists (n=15), dialysis
      nurses (n=24) and patients receiving haemodialysis (n=24) from six dialysis units
      in Australia. Question topics will include the technical and clinical feasibility
      and acceptability of e-PROMs reporting and feedback (including the barriers and
      enablers to uptake) and perceived impact on patient care and outcomes.
      Transcripts will be analysed thematically and guided by Normalisation Process
      Theory. ETHICS AND DISSEMINATION: Ethics approval was obtained from the relevant 
      hospital Human Research Ethics Committees (HREC/18/CALHN/481; HREC/MML/54599).
      The findings from the SWIFT pilot and qualitative evaluation will inform the
      implementation of the SWIFT main trial, and more broadly, the use of e-PROMs in
      clinical settings and registries. TRIAL REGISTRATION NUMBER:
      ANZCTRN12618001976279.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Duncanson, Emily
AU  - Duncanson E
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute, Adelaide, South Australia,
      Australia.
FAU - Bennett, Paul N
AU  - Bennett PN
AD  - Faculty of Health Medicine Nursing and Behavioural Sciences, Deakin University,
      Burwood, Victoria, Australia.
FAU - Viecelli, Andrea
AU  - Viecelli A
AD  - School of Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland,
      Australia.
FAU - Dansie, Kathryn
AU  - Dansie K
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute, Adelaide, South Australia,
      Australia.
FAU - Handke, William
AU  - Handke W
AD  - Consumer representative, Private citizen, Canberra, ACT, Australia.
FAU - Tong, Allison
AU  - Tong A
AD  - Sydney School of Public Health, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Palmer, Suetonia
AU  - Palmer S
AD  - Department of Medicine, University of Otago, Christchurch, New Zealand.
FAU - Jesudason, Shilpanjali
AU  - Jesudason S
AD  - Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal 
      Adelaide Hospital, Adelaide, South Australia, Australia.
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - McDonald, Stephen P
AU  - McDonald SP
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute, Adelaide, South Australia,
      Australia.
AD  - Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal 
      Adelaide Hospital, Adelaide, South Australia, Australia.
FAU - Morton, Rachael L
AU  - Morton RL
AUID- ORCID: 0000-0001-7834-0572
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South
      Wales, Australia Rachael.morton@ctc.usyd.edu.au.
CN  - Symptom monitoring WIth Feedback Trial (SWIFT) Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Feasibility Studies
MH  - Feedback
MH  - Humans
MH  - New Zealand
MH  - Patient Reported Outcome Measures
MH  - Pilot Projects
MH  - Qualitative Research
MH  - *Quality of Life
MH  - *Renal Dialysis
PMC - PMC7651719
OTO - NOTNLM
OT  - *adult nephrology
OT  - *chronic renal failure
OT  - *dialysis
OT  - *nephrology
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-039014 [pii]
AID - 10.1136/bmjopen-2020-039014 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e039014. doi: 10.1136/bmjopen-2020-039014.


PMID- 33158823
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Added value of assessing medical students' reflective writings in communication
      skills training: a longitudinal study in four academic centres.
PG  - e038898
LID - 10.1136/bmjopen-2020-038898 [doi]
AB  - OBJECTIVES: This study describes the development and implementation of a model to
      assess students' communication skills highlighting the use of reflective writing.
      We aimed to evaluate the usefulness of the students' reflections in the
      assessment of communication skills. DESIGN: Third-year and fourth-year medical
      students enrolled in an elective course on clinical communication skills
      development were assessed using different assessment methods. SETTING AND
      PARTICIPANTS: The communication skills course was offered at four universities
      (three in Brazil and one in Portugal) and included 69 students. OUTCOME MEASURES:
      The students were assessed by a Multiple-Choice Questionnaire (MCQ), an objective
      structured clinical examination (OSCE) and reflective writing narratives. The
      Cronbach's alpha, dimensionality and the person's correlation were applied to
      evaluate the reliability of the assessment methods and their correlations.
      Reflective witting was assessed by applying the Reflection Evaluation for
      Enhanced Competencies Tool Rubric (Reflect Score (RS)) to measure reflections'
      depth, and the Thematic Score (TS) to map and grade reflections' themes. RESULTS:
      The Cronbach alpha for the MCQ, OSCE global score, TS and RS were, respectively, 
      0.697, 0.633, 0.784 and 0.850. The interobserver correlation for the TS and RS
      were, respectively, 0.907 and 0.816. The assessment of reflection using the TS
      was significantly correlated with the MCQ (r=0.412; p=0.019), OSCE (0.439;
      p=0.012) and RS (0.410; p=0.020). The RS did not correlate with the MCQ and OSCE.
      CONCLUSIONS: Assessing reflection through mapping the themes and analysing the
      depth of reflective writing expands the assessment of communication skills. While
      the assessment of reflective themes is related to the cognitive and behavioural
      domains of learning, the reflective depth seems to be a specific competence, not 
      correlated with other assessment methods-possibly a metacognitive domain.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ament Giuliani Franco, Camila
AU  - Ament Giuliani Franco C
AD  - Medicine School, Pontifical Catholic University of Parana, Curitiba, Brazil.
FAU - Franco, Renato Soleiman
AU  - Franco RS
AD  - Medicine School and Post-Graduate Program in Bioethics, Pontifical Catholic
      University of Parana, Curitiba, Brazil.
FAU - Cecilio-Fernandes, Dario
AU  - Cecilio-Fernandes D
AUID- ORCID: 0000-0002-8746-1680
AD  - Department of Medical Psychology and Psychiatry, School of Medical Sciences,
      University of Campinas, Campinas, Brazil.
FAU - Severo, Milton
AU  - Severo M
AD  - Department of Clinical Epidemiology, Predictive Medicine and Public Health and
      Public Health and Forensic Sciences, and Medical Education Department, University
      of Porto Medical School, Porto, Portugal.
FAU - Ferreira, Maria Amelia
AU  - Ferreira MA
AD  - Public Health and Forensic Sciences, and Medical Education Department, University
      of Porto Faculty of Medicine, Porto, Portugal.
FAU - de Carvalho-Filho, Marco Antonio
AU  - de Carvalho-Filho MA
AUID- ORCID: 0000-0001-7008-4092
AD  - Internal Medicine, University of Minho School of Medicine, Braga, Portugal
      m.a.de.carvalho.filho@umcg.nl.
AD  - CEDAR - Center for Educational Development and Research in Health Sciences,
      University Medical Center Groningen, Groningen, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brazil
MH  - Clinical Competence
MH  - Communication
MH  - Educational Measurement
MH  - Humans
MH  - Longitudinal Studies
MH  - Portugal
MH  - Reproducibility of Results
MH  - *Students, Medical
MH  - Writing
PMC - PMC7651724
OTO - NOTNLM
OT  - *medical education & training
OT  - *medical ethics
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-038898 [pii]
AID - 10.1136/bmjopen-2020-038898 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e038898. doi: 10.1136/bmjopen-2020-038898.


PMID- 33158822
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Association between vitamin D and uterine fibroids: a study protocol of an
      open-label, randomised controlled trial.
PG  - e038709
LID - 10.1136/bmjopen-2020-038709 [doi]
AB  - INTRODUCTION: Uterine fibroids are the most common pelvic benign tumour with no
      satisfactory long-term medical treatment. Recent studies have demonstrated that
      vitamin D significantly inhibited the growth of fibroids in vitro, vivo and a
      small-sample clinical trial. Therefore, the aim of this randomised clinical trial
      (RCT) is to evaluate whether supplementation with vitamin D could reduce the risk
      and inhibit the growth of uterine fibroids in reproductive stage women. METHODS
      AND ANALYSIS: The open-label, RCT comprises two parts, including parts I and II. 
      In part I, 2230 vitamin D deficiency or vitamin D insufficiency patients without 
      uterine fibroids will be randomly assigned to two groups: intervention group
      (according to the level of serum 25-hydroxyvitamin D3, receive 1600 or 800 IU/day
      of vitamin D3 for 2 years) and control group (followed up at the same time
      points). By using gynaecological ultrasound examinations, the incidence of
      uterine fibroids will be employed to measure the outcome in different groups. In 
      part II, 360 uterine fibroids patients with vitamin D deficiency or vitamin D
      insufficiency will be randomly assigned to intervention group or control group.
      According to the level of serum 25-hydroxyvitamin D3, 180 patients will receive
      1600 or 800 IU/day of vitamin D3 for 2 years. Control group will receive regular 
      follow-up. The outcome measure will be conducted using gynaecological ultrasound 
      examinations to detect the growth of uterine fibroids in each group. ETHICS AND
      DISSEMINATION: This study has been approved by the institutional review board of 
      the Second Affiliated Hospital of Wenzhou Medical University (No. LCKY2018-35).
      TRIAL REGISTRATION NUMBERS: NCT03586947 and NCT03584529.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sheng, Bo
AU  - Sheng B
AD  - Obstetrics and Gynecology, Wenzhou Medical University Second Affiliated Hospital,
      Wenzhou, China.
FAU - Song, Yizuo
AU  - Song Y
AD  - Obstetrics and Gynecology, Wenzhou Medical University Second Affiliated Hospital,
      Wenzhou, China.
FAU - Liu, Yi
AU  - Liu Y
AD  - Obstetrics and Gynecology, Wenzhou Medical University Second Affiliated Hospital,
      Wenzhou, China.
FAU - Jiang, Chenchen
AU  - Jiang C
AD  - Clinical Research Center, Wenzhou Medical University Second Affiliated Hospital, 
      Wenzhou, China.
FAU - Zhu, Xueqiong
AU  - Zhu X
AUID- ORCID: 0000-0002-8389-928X
AD  - Obstetrics and Gynecology, Wenzhou Medical University Second Affiliated Hospital,
      Wenzhou, China zjwzzxq@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03584529
SI  - ClinicalTrials.gov/NCT03586947
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vitamins)
RN  - 1406-16-2 (Vitamin D)
RN  - 1C6V77QF41 (Cholecalciferol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Cholecalciferol/therapeutic use
MH  - Diabetes Mellitus, Type 2
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Leiomyoma/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Vitamin D
MH  - Vitamin D Deficiency/complications/drug therapy
MH  - Vitamins
MH  - Young Adult
PMC - PMC7651728
OTO - NOTNLM
OT  - *clinical trials
OT  - *gynaecological oncology
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/11/08 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-038709 [pii]
AID - 10.1136/bmjopen-2020-038709 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e038709. doi: 10.1136/bmjopen-2020-038709.


PMID- 33158819
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 6
TI  - Protocol for a feasibility study of smoking cessation in the surgical pathway
      before major lung surgery: Project MURRAY.
PG  - e036568
LID - 10.1136/bmjopen-2019-036568 [doi]
AB  - INTRODUCTION: Smoking prior to major thoracic surgery is the biggest risk factor 
      for development of postoperative pulmonary complications, with one in five
      patients continuing to smoke before surgery. Current guidance is that all
      patients should stop smoking before elective surgery yet very few are offered
      specialist smoking cessation support. Patients would prefer support within the
      thoracic surgical pathway. No study has addressed the effectiveness of such an
      intervention in this setting on cessation. The overall aim is to determine in
      patients who undergo major elective thoracic surgery whether an intervention
      integrated (INT) into the surgical pathway improves smoking cessation rates
      compared with usual care (UC) of standard community/hospital based NHS smoking
      support. This pilot study will evaluate feasibility of a substantive trial.
      METHODS AND ANALYSIS: Project MURRAY is a trial comparing the effectiveness of
      INT and UC on smoking cessation. INT is pharmacotherapy and a hybrid of
      behavioural support delivered by the trained healthcare practitioners (HCPs) in
      the thoracic surgical pathway and a complimentary web-based application. This
      pilot study will evaluate the feasibility of a substantive trial and study
      processes in five adult thoracic centres including the University Hospitals
      Birmingham NHS Foundation Trust. The primary objective is to establish the
      proportion of those eligible who agree to participate. Secondary objectives
      include evaluation of study processes. Analyses of feasibility and
      patient-reported outcomes will take the form of simple descriptive statistics and
      where appropriate, point estimates of effects sizes and associated 95% CIs.
      ETHICS AND DISSEMINATION: The study has obtained ethical approval from NHS
      Research Ethics Committee (REC number 19/WM/0097). Dissemination plan includes
      informing patients and HCPs; engaging multidisciplinary professionals to support 
      a proposal of a definitive trial and submission for a full application dependent 
      on the success of the study. TRIAL REGISTRATION NUMBER: NCT04190966.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lugg, Sebastian T
AU  - Lugg ST
AUID- ORCID: 0000-0002-7861-9108
AD  - Birmingham Acute Care Research Group, Institute of Inflammation and Ageing,
      University of Birmingham, Birmingham, UK.
FAU - Kerr, Amy
AU  - Kerr A
AD  - Department of Thoracic Surgery, University Hospitals Birmingham NHS Foundation
      Trust, Birmingham, UK.
FAU - Kadiri, Salma
AU  - Kadiri S
AD  - Department of Thoracic Surgery, University Hospitals Birmingham NHS Foundation
      Trust, Birmingham, UK.
FAU - Budacan, Alina-Maria
AU  - Budacan AM
AD  - Department of Thoracic Surgery, University Hospitals Birmingham NHS Foundation
      Trust, Birmingham, UK.
FAU - Farley, Amanda
AU  - Farley A
AD  - Insitute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Perski, Olga
AU  - Perski O
AD  - Institute of Epidemiology & Health, University College London, London, UK.
FAU - West, Robert
AU  - West R
AD  - Institute of Epidemiology & Health, University College London, London, UK.
FAU - Brown, Jamie
AU  - Brown J
AD  - Institute of Epidemiology & Health, University College London, London, UK.
FAU - Thickett, David R
AU  - Thickett DR
AD  - Birmingham Acute Care Research Group, Institute of Inflammation and Ageing,
      University of Birmingham, Birmingham, UK.
FAU - Naidu, Babu
AU  - Naidu B
AD  - Birmingham Acute Care Research Group, Institute of Inflammation and Ageing,
      University of Birmingham, Birmingham, UK b.naidu@bham.ac.uk.
AD  - Department of Thoracic Surgery, University Hospitals Birmingham NHS Foundation
      Trust, Birmingham, UK.
CN  - Project MURRAY Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT04190966
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201106
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Feasibility Studies
MH  - Humans
MH  - Lung/*surgery
MH  - Pilot Projects
MH  - Smoking
MH  - *Smoking Cessation
PMC - PMC7651715
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *adult thoracic medicine
OT  - *cardiothoracic surgery
COIS- Competing interests: None declared.
IR  - Shackcloth M
FIR - Shackcloth, Michael
IR  - Feeney S
FIR - Feeney, Sarah
IR  - Murphy L
FIR - Murphy, Lindsey
IR  - Black M
FIR - Black, Magenta
IR  - Rathinam S
FIR - Rathinam, Sridhar
IR  - Boyles R
FIR - Boyles, Rebecca
IR  - Qadri S
FIR - Qadri, Syed
IR  - Dobbs K
FIR - Dobbs, Karen
IR  - Shackleford H
FIR - Shackleford, Helen
IR  - Jalal Z
FIR - Jalal, Zara
IR  - Jordan C
FIR - Jordan, Christine
IR  - Skirth B
FIR - Skirth, Ben
EDAT- 2020/11/08 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/11/07 05:28
PHST- 2020/11/07 05:28 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2019-036568 [pii]
AID - 10.1136/bmjopen-2019-036568 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 6;10(11):e036568. doi: 10.1136/bmjopen-2019-036568.


PMID- 33158270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Human-Animal Interactions in Zoos: What Can Compassionate Conservation,
      Conservation Welfare and Duty of Care Tell Us about the Ethics of Interacting,
      and Avoiding Unintended Consequences?
LID - E2037 [pii]
LID - 10.3390/ani10112037 [doi]
AB  - Human-animal interactions (HAIs) in zoos can be rewarding for both humans and
      animals, but can also be fraught with ethical and welfare perils. Contact with
      animals can be beneficial for all parties involved, and can indeed lead to
      pro-conservation and respect for nature behaviours being adopted by humans after 
      so-called "profound experiences" of connecting or interacting with animals. Yet, 
      human-animal interactions may also increase certain individuals' desires for
      inappropriate wild-animal 'pet' ownership, and can convey a false sense of
      acceptability of exploiting animals for "cheap titillation". Indeed, this has
      been reflected in a recent research review conducted on animal-visitor
      interactions in zoos from a number of different countries and global regions.
      These are unintended consequences that "modern, ethical zoos" would try to
      minimise, or avoid completely where possible, though most zoos still offer
      close-contact experiences with their animals. Three ethical frameworks that may
      be beneficial for ethically run zoos to incorporate when considering human-animal
      interactions are: Compassionate Conservation, Conservation Welfare and Duty of
      Care. These three ethical frameworks are concerned with the welfare state and
      outcomes for individual animals, not just the population or species. Human-animal
      interactions in zoos may be acceptable in many circumstances and may be
      beneficial to both animal and human participants; however, they must be closely
      monitored through welfare tracking tools. The World Association of Zoos and
      Aquariums (WAZA) has published guidelines for human-animal interactions that are 
      mandatory for member institutions to adhere to, although whether these guidelines
      are taken as mandatory or suggestions at individual institutions is unknown. Some
      suggestions for relevant extensions to the guidelines are suggested herein.
      Melding Duty of Care and the two Conservation ethical frameworks would be ideal
      for assessing the ethical acceptability of such interactions as they currently
      occur, and for considering how they should be modified to occur (or not) into the
      future in zoological settings.
FAU - Learmonth, Mark James
AU  - Learmonth MJ
AUID- ORCID: 0000-0002-2237-0665
AD  - Animal Welfare Science Centre, The University of Melbourne, Parkville, Victoria
      3010, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7694286
OTO - NOTNLM
OT  - animal ethics
OT  - animal-visitor interactions
OT  - compassionate conservation
OT  - conservation welfare
OT  - duty of care
OT  - human-animal interactions
OT  - zoo animals
EDAT- 2020/11/08 06:00
MHDA- 2020/11/08 06:01
CRDT- 2020/11/07 01:03
PHST- 2020/10/14 00:00 [received]
PHST- 2020/10/30 00:00 [revised]
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/07 01:03 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/08 06:01 [medline]
AID - ani10112037 [pii]
AID - 10.3390/ani10112037 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Nov 4;10(11). pii: ani10112037. doi: 10.3390/ani10112037.


PMID- 33157993
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - Safety and efficacy of complementary and alternative medicine in the treatment of
      autism spectrum disorder: A protocol for systematic review and meta-analysis.
PG  - e23128
LID - 10.1097/MD.0000000000023128 [doi]
AB  - INTRODUCTION: The purpose of this study is to evaluate the efficacy and safety of
      complementary and alternative medicine in the treatment of autism spectrum
      disorder. METHODS AND ANALYSIS: We will electronically search Pubmed, Medline,
      Embase, Web of Science, the Cochrane Central Register of Controlled Trial, China 
      National Knowledge Infrastructure, China Biomedical Literature Database, China
      Science Journal Database, and Wan-fang Database from their inception. Also, we
      will manually retrieve other resources, including reference lists of identified
      publications, conference articles, and gray literature. The clinical randomized
      controlled trials or quasi-randomized controlled trials related to complementary 
      and alternative medicine treating autism spectrum disorder will be included in
      the study. The language is limited to Chinese and English. Research selection,
      data extraction, and research quality assessment will be independently completed 
      by 2 researchers. Data were synthesized by using a fixed-effect model or
      random-effect model depend on the heterogeneity test. The Childhood Autism Rating
      Scale (CARS) and Autism Behavior Checklist (ABC) scores will be the primary
      outcomes. The scores of the Autism Treatment Evaluation Checklist and the
      Ritvo-Freeman Real Life Rating Scale will also be assessed as secondary outcomes.
      RevMan V.5.3 statistical software will be used for meta-analysis, and the level
      of evidence will be assessed by Grading of Recommendations Assessment,
      Development, and Evaluation (GRADE). Continuous data will be expressed in the
      form of weighted mean difference or standardized mean difference with 95%
      confidence intervals (CIs), whereas dichotomous data will be expressed in the
      form of relative risk with 95% CIs. ETHICS AND DISSEMINATION: The protocol of
      this systematic review does not require ethical approval because it does not
      involve humans. We will publish this article in peer-reviewed journals and
      presented at relevant conferences. SYSTEMATIC REVIEW REGISTRATION: OSF
      Registries, DOI: 10.17605/OSF.IO/ HA97R (https://osf.io/ha97r).
FAU - Shuai, Biqin
AU  - Shuai B
AD  - The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi
      Medical University), Huichuan District, Zunyi, Guizhou 563000, China.
FAU - Jin, Hongjiao
AU  - Jin H
FAU - Lin, Yong
AU  - Lin Y
AUID- ORCID: 0000-0002-5682-3036
FAU - Duan, Renrong
AU  - Duan R
FAU - Zhao, Ning
AU  - Zhao N
FAU - Li, Zhu
AU  - Li Z
FAU - Mao, Jiao
AU  - Mao J
FAU - Luo, Yan
AU  - Luo Y
FAU - Shi, Mengyu
AU  - Shi M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Autism Spectrum Disorder/*therapy
MH  - Child
MH  - *Complementary Therapies/adverse effects
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7647561
EDAT- 2020/11/08 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1097/MD.0000000000023128 [doi]
AID - 00005792-202011060-00087 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e23128. doi: 10.1097/MD.0000000000023128.


PMID- 33157989
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - Predictive value of MEP1A in cancer prognosis: A protocol for systematic review
      and meta-analysis.
PG  - e23120
LID - 10.1097/MD.0000000000023120 [doi]
AB  - BACKGROUND: Meprin is a member of the astaxanthin family; it performs many
      functions through a wide range of proteolytic enzyme activities during health and
      disease, including tumors and inflammatory conditions. The purpose of this
      systematic review was to evaluate the predictive value of MEP1A in tumor
      prognosis. METHODS: A comprehensive search was conducted on PubMed, Cochrane
      library, and Web of Science Database using a developed search strategy. The
      Newcastle-Ottawa Scale (NOS) or the Cochrane Collaboration's tool for assessing
      risk of bias will be used to access the methodological quality of included
      studies, and GRADE will be applied to evaluate evidence quality of outcomes. All 
      analyses were performed by Stata 15.0. RESULTS: The results will systematically
      summarize and display the currently collected evidence on the predictive value of
      MEP1A in different tumor prognosis. CONCLUSION: This study may play a certain
      role in predicting the prognosis of cancer patients in the future, and may prompt
      clinicians to make necessary treatment or prevention plans as soon as possible.
      ETHICS AND COMMUNICATION: It is not necessary because the present systematic
      review is based on published studies. INPLASY REGISTRATION NUMBER:
      INPLASY2020100005.
FAU - Chen, Yong
AU  - Chen Y
AD  - The First Hospital of Lanzhou University.
FAU - Wu, Fangfang
AU  - Wu F
AD  - Evidence-Based Nursing Center, School of Nursing, Lanzhou University.
FAU - Zhang, Li
AU  - Zhang L
AD  - The Third Ward of Cardiovascular Clinical Medical Center, Affiliated Hospital of 
      Gansu University of Chinese Medicine.
FAU - Du, Li
AU  - Du L
AD  - The Third People's Hospital of Lanzhou City, Lanzhou, China.
FAU - Yan, Xiang
AU  - Yan X
AUID- ORCID: 0000-0002-2267-0713
AD  - The First Hospital of Lanzhou University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.18 (meprin A)
SB  - IM
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Metalloendopeptidases/*blood
MH  - Neoplasms/*blood/*mortality
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - *Research Design
MH  - Survival Rate
MH  - *Systematic Reviews as Topic
PMC - PMC7647559
EDAT- 2020/11/08 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1097/MD.0000000000023120 [doi]
AID - 00005792-202011060-00083 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e23120. doi: 10.1097/MD.0000000000023120.


PMID- 33157974
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - The efficacy of gelatin sponge combined with moist wound-healing nursing
      intervention for the treatment of pressure ulcers: A randomized controlled trial 
      protocol.
PG  - e23079
LID - 10.1097/MD.0000000000023079 [doi]
AB  - OBJECTIVE: The objective of this current research is to investigate the
      effectiveness of the nursing intervention of combination gelatin sponge and moist
      wound healing in treating the pressure ulcers (PUs). METHODS: This is a
      randomized controlled trial to be carried out from January 2021 to May 2021. This
      trial is implemented in accordance with the SPIRIT Checklist for the randomized
      researches and was granted through the Ethics Committee of 5th Medical Center of 
      Chinese PLA General Hospital (No. 0624876). This study includes 80 PU
      participants. The patients meet the following criteria will be included. All
      participants meet the diagnostic criteria recommended via the National Pressure
      Ulcer Advisory Panel Society: complete skin defect, no bones, tendons and muscles
      exposure, no subcutaneous tunnel or scale; the patients selected are between 40
      and 60 years old. The patients with the following criteria will be excluded:
      receiving other treatments that may influence the healing, for instance,
      radiation therapy and corticosteroids; patients with the complications of
      infection, malignant tumors, as well as peripheral vascular disease; and patients
      with serious diseases, containing kidney, cardiac, and liver diseases. The
      patients are randomly divided into 2 groups, the control group and study group,
      with 40 members in each group. In control group, the patients are given the
      routine nursing care. And in study group, the patients are given the nursing of
      gelatin sponge combined with moist wound-healing. After 28 days, the state of the
      patients healing is observed closely, containing the dressing change frequency,
      curative effects, and the end-point efficiency. On the basis of the Pressure
      Ulcer Healing Scale developed by the American pressure sore expert group, the
      quantitative scoring can be implemented, and therapeutic effects are assessed.
      RESULTS: The variables of clinical result among the groups are illustrated in the
      Table. CONCLUSION: The nursing intervention of gelatin sponge combined with the
      moist wound- healing may evidently increase the healing efficiency of PU. TRIAL
      REGISTRATION NUMBER: researchregistry 6091.
FAU - Huang, Shun
AU  - Huang S
AD  - Department of Nursing.
FAU - Yang, Ying
AU  - Yang Y
AD  - Department of Nursing.
FAU - Yu, Xiaoli
AU  - Yu X
AD  - Liver Cirrhosis Diagnosis and Treatment Center.
FAU - Wang, Yonggang
AU  - Wang Y
AUID- ORCID: 0000-0001-7181-9986
AD  - Intensive Care Center, 5th Medical Center of Chinese PLA General Hospital,
      Beijing, PR China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hemostatics)
SB  - IM
MH  - Adult
MH  - Combined Modality Therapy
MH  - Gelatin Sponge, Absorbable/*therapeutic use
MH  - Hemostatics/*therapeutic use
MH  - Humans
MH  - Humidity
MH  - Middle Aged
MH  - Pressure Ulcer/*nursing/therapy
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Treatment Outcome
MH  - *Wound Healing
PMC - PMC7647604
EDAT- 2020/11/08 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1097/MD.0000000000023079 [doi]
AID - 00005792-202011060-00068 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e23079. doi: 10.1097/MD.0000000000023079.


PMID- 33157956
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - The efficacy and adverse effects of PARP inhibitor combined with chemotherapy
      compared with chemotherapy alone in the treatment of cancer patient: A protocol
      for systematic review.
PG  - e23040
LID - 10.1097/MD.0000000000023040 [doi]
AB  - BACKGROUND: There search of PARP inhibitors has made great breakthroughs and
      progress. Become a new type of medicine for cancer treatment,bringing hope to
      more advanced cancer patients.The purpose of this systematic review is to
      evaluate the clinical efficacy and adverse effects of PARP inhibitorscombined
      with chemotherapy and chemotherapy alone in the treatment of cancer patients.
      METHODS: We searched the following 4 databases, including: PubMed, EMBASE, Web of
      Science, and Cochrane Library. The search will also be conducted at the clinical 
      trial centers: ClinicalTrials.gov, ISRCTN Registry, WHO International Clinical
      Trials Registration Platform. The search date is as of September 22, 2020. There 
      is no language restriction during this search, and the latest documents are kept 
      updated through settings. The subject search terms were identified as "PARP
      Inhibitor", "Neoplasms" and "Dug therapy". The Phase 2 and Phase 3 clinical
      trials comparing PARP inhibitor combined with chemotherapy and chemotherapy alone
      were included. The results include overall survival (OS), progression-free
      survival (PFS), objective response rate (ORR) and adverse events. Two researchers
      separately completed the article inclusion, data extraction and quality
      evaluation of this study. The assessment of the risk of bias and data will be
      conducted using Review Manager. ETHICS AND DISSEMINATION: All articles are
      published and do not require the approval of the ethics committee and the signed 
      informed consent form. The results of this systematic review will be published
      through peer-reviewed publications. REGISTERED: Registered on INPLASY and the
      registration number is INPLASY202090087.
FAU - Zhao, Suyue
AU  - Zhao S
AD  - The First Clinical Medical College of Lanzhou University.
FAU - Fang, Tao
AU  - Fang T
AD  - The First Clinical Medical College of Lanzhou University.
FAU - Yao, Li
AU  - Yao L
AD  - The First Clinical Medical College of Lanzhou University.
FAU - Zheng, Ying
AU  - Zheng Y
AD  - The First Clinical Medical College of Lanzhou University.
FAU - Zhang, Ling
AU  - Zhang L
AD  - The First Clinical Medical College of Lanzhou University.
FAU - Zhu, Kexiang
AU  - Zhu K
AUID- ORCID: 0000-0002-7041-6066
AD  - The First Hospital of Lanzhou University, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Data Management
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy/mortality
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*adverse effects/therapeutic use
MH  - Progression-Free Survival
MH  - Treatment Outcome
PMC - PMC7647544
EDAT- 2020/11/08 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - 10.1097/MD.0000000000023040 [doi]
AID - 00005792-202011060-00050 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e23040. doi: 10.1097/MD.0000000000023040.


PMID- 33157949
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - Effects of Qigong, Tai Chi, acupuncture, and Tuina on cancer-related fatigue for 
      breast cancer patients: A protocol of systematic review and meta-analysis.
PG  - e23016
LID - 10.1097/MD.0000000000023016 [doi]
AB  - BACKGROUNDS: Cancer-related fatigue (CRF) is one of the most common and disabling
      outcomes in patients with breast cancer (BC). Traditional Chinese medicine (TCM) 
      nonpharmacological interventions are becoming increasingly popular for cancer
      treatment and rehabilitation interventions. However, their efficacy and safety
      remain unclear and there is no systematic review or meta-analysis focusing fully 
      on this issue. We aim to evaluate the effects of representative TCM
      nonpharmacological interventions, including Qigong, Tai Chi, acupuncture, and
      Tuina, on CRF in BC patients. METHODS: Published randomized controlled trials
      (RCTs) that assessed the efficacy of these interventions on CRF for BC patients
      will be included. We will search from the following electronic databases: PubMed,
      Cochrane Library, EMBASE, MEDLINE, Web of Science, Scopus, PsycINFO, PSYINDEX,
      CINAHL, China National Knowledge Infrastructure (CNKI), WanFang Database, and
      Chinese Biomedical Literature Database (CBM). The primary outcomes are the
      improvement of CRF, which will be evaluated by the Piper Fatigue Scale (PFS), the
      Functional Assessment of Cancer Therapy (FACT)-Fatigue Scale, Schwartz Cancer
      Fatigue Scale (SCFS), the Multidimensional Fatigue Inventory (MFI). The secondary
      outcomes are quality of life and safety. The meta-analysis will be performed
      using RevMan ver 5.3(Cochrane) statistical software. RESULTS: We will provide
      more practical results investigating the efficacy of Qigong, Tai Chi,
      acupuncture, Tuina for BC patients with CRF from several respects including the
      improvement of fatigue, quality of life, and safety. CONCLUSIONS: This review
      will generate more stronger evidence in BC patients for TCM nonpharmacological
      interventions, including Qigong, Tai Chi, acupuncture, Tuina, in the treatment of
      CRF and help to inform clinicians and policymakers. ETHICS DISSEMINATION: Ethical
      approval is not necessary because all of the study base in our review will be
      based on published research. We will submit our results to a peer-reviewed
      journal. STUDY REGISTRATION NUMBER: The study is priorly registered through
      International Platform of Registered Systematic Review and Meta-analysis Protocol
      on October 2, 2020 (INPLASY 2020100003).
FAU - Li, Xue
AU  - Li X
AUID- ORCID: 0000-0002-0642-6622
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
FAU - Wang, Xueqian
AU  - Wang X
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
FAU - Song, Lijun
AU  - Song L
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
FAU - Tian, Jiayue
AU  - Tian J
AD  - School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
FAU - Ma, Xuejiao
AU  - Ma X
AD  - School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
FAU - Mao, Qiyuan
AU  - Mao Q
AD  - School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
FAU - Lin, Hongsheng
AU  - Lin H
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Breast Neoplasms/*complications
MH  - China/epidemiology
MH  - Fatigue/*etiology/psychology/*therapy
MH  - Female
MH  - Humans
MH  - Medicine, Chinese Traditional/methods
MH  - Qigong/methods
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Tai Ji/methods
MH  - Treatment Outcome
PMC - PMC7647542
EDAT- 2020/11/08 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - 10.1097/MD.0000000000023016 [doi]
AID - 00005792-202011060-00043 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e23016. doi: 10.1097/MD.0000000000023016.


PMID- 33157948
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - Clinical, inflammatory, and immune differences between COVID-19 patients with and
      without cancer: A protocol for systematic review and meta-analysis.
PG  - e23015
LID - 10.1097/MD.0000000000023015 [doi]
AB  - INTRODUCTION: The World Health Organization announce that novel coronavirus
      (COVID-19) is pandemic worldwide on March 11, 2020. In this pandemic, cancer
      patients are prone to become critically ill after being infected with COVID-19
      due to special immune conditions, and cannot effectively benefit from the
      treatment plan designed for normal people. However, only a few literatures report
      the differences between cancer patients and normal people after being infected
      with COVID-19. There is no systematic review to evaluate the clinical,
      inflammatory, and immune differences between COVID-19 patients with and without
      cancer. The systematic review aims to summarize and analyze the clinical,
      inflammatory, and immune differences between them. METHODS AND ANALYSIS: We plan 
      to conduct a systematic review according to the Preferred Reporting Items for
      Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines. Several
      databases (PubMed/MEDLINE, Embase, Web of Science, The Cochrane Library, CNKI,
      CBM, VIP, WanFang) were searched for relevant eligible observational studies on
      COVID-19 patients with cancer published from December 2019 to September 2020. Two
      researchers (Y.ZY and W.PP) will independently complete search strategy
      formulation, literature selecting, Information extraction, data collation, and
      quality assessment. The primary outcome will be the clinical characteristics
      differences between COVID-19 patients with and without cancer. Secondary outcomes
      will include immune function regulation characteristics such as T cell subset
      status, inflammation and other factors for COVID-19 patients with cancer. We
      intend to perform a meta-analysis of studies calculating odds ratio differences
      (Hedge g) for comparison in Forest plots and subgroup analysis after assessment
      of heterogeneity using I statistics based on compatibility on the basis of
      population and outcomes. ETHICS AND DISSEMINATION: We will use the information
      from published researches with no need for ethical assessment. Our findings will 
      be published in a peer-reviewed journal according to the PRISMA guidelines.
      PROSPERO REGISTRATION NUMBER: CRD42020204417.
FAU - Yu, Zhongyang
AU  - Yu Z
AUID- ORCID: 0000-0001-9148-0895
AD  - Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine,
      Fangguyuan Rd.
FAU - Wang, Peipei
AU  - Wang P
AD  - School of Life Sciences, Beijing University of Chinese Medicine.
FAU - Chen, Bailin
AU  - Chen B
AD  - School of TCM, Beijing University of Chinese Medicine, Sunshine South Street,
      Fangshan District, Beijing.
FAU - Zhang, Zihao
AU  - Zhang Z
AD  - School of TCM, Beijing University of Chinese Medicine, Sunshine South Street,
      Fangshan District, Beijing.
FAU - Jiang, Jun
AU  - Jiang J
AD  - Gynecology Department, Zhejiang University of Traditional Chinese Medicine First 
      Affiliated Hospital, Youdian Rd, Shangcheng District, Hangzhou City, Zhejiang
      Province, China.
FAU - Zhuang, Yulong
AU  - Zhuang Y
AD  - Gynecology Department, Zhejiang University of Traditional Chinese Medicine First 
      Affiliated Hospital, Youdian Rd, Shangcheng District, Hangzhou City, Zhejiang
      Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*diagnosis/*immunology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neoplasms/*complications
MH  - Observational Studies as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/*immunology
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
PMC - PMC7647537
EDAT- 2020/11/08 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1097/MD.0000000000023015 [doi]
AID - 00005792-202011060-00042 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e23015. doi: 10.1097/MD.0000000000023015.


PMID- 33157935
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - Effects of arsenic trioxide combined with platinum drugs in treatment of cervical
      cancer: A protocol for systematic review and meta-analysis of randomized
      controlled trials.
PG  - e22950
LID - 10.1097/MD.0000000000022950 [doi]
AB  - INTRODUCTION: Cervical cancer is the second largest tumor disease threatening
      female reproductive tract health. AS2O3 is a multi-directional and multi-target
      anti-cervical cancer drug. It can be combined with platinum drugs to treat
      cervical cancer. The literatures of AS2O3 combined with platinum drugs related to
      cervical cancer have shown inconsistent results, and there is currently no high
      quality of systematic review to evaluate the effects of AS2O3 combined with
      platinum drugs in cervical cancer patients. METHODS AND ANALYSIS: English and
      Chinese literature about AS2O3 combined with platinum drugs treatment for
      cervical cancer published before August 31, 2020 will be systematic searched in
      PubMed, Embase, Web of Science, Cochrane Library, Open Grey, Clinicaltrials.gov, 
      Chinese Clinical Trial Registry, WANFANG, VIP Chinese Science and Technology
      Journal Database, CNKI, Chinese biomedical document service system (SinoMed).
      Only randomized controlled trials (RCTs) of patients with cervical cancer will be
      included. Literature screening, data extraction, and the assessment of risk of
      bias will be independently conducted by 2 reviewers, and the 3rd reviewer will be
      consulted if any different opinions existed. Clinical total effective rate,
      adverse events, SCCAg, CYFRA21-1, quality of life, and immune function will be
      evaluated. Systematic review and meta-analysis will be produced by RevMan 5.3 and
      Stata 14.0. This protocol reported in accordance with the Preferred Reporting
      Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) statement, and
      we will report the systematic review by following the PRISMA statement. RESULTS: 
      The current study is a protocol for systematic review and meta-analysis without
      results, and data analysis will be carried out after the protocol. We will share 
      our findings in the fourth quarter of 2021. CONCLUSION: Efficacy and safety of
      AS2O3 combined with platinum drugs in the treatment of cervical cancer will be
      assessed. The results will be published in a public issue journal to provide
      evidence-based medical evidence for Obstetrician and Gynecologists to make
      clinical decisions. ETHICS AND DISSEMINATION: Ethical approval is not required as
      the review is a secondary study based on published literature. The results of the
      study will be published in peer-reviewed publications and disseminated
      electronically or in print. PROTOCOL REGISTRATION NUMBER: INPLASY202080130.
FAU - Zhang, Yawen
AU  - Zhang Y
AUID- ORCID: 0000-0002-5927-1281
AD  - The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 
      Guangdong Province, P.R. China.
FAU - Pan, Di
AU  - Pan D
FAU - Yang, Haishi
AU  - Yang H
FAU - Huang, Jiaxin
AU  - Huang J
FAU - He, Zeyang
AU  - He Z
FAU - Li, Haiying
AU  - Li H
FAU - Li, Daocheng
AU  - Li D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platinum Compounds)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Arsenic Trioxide/*administration & dosage
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Platinum Compounds/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Uterine Cervical Neoplasms/*drug therapy
PMC - PMC7647570
EDAT- 2020/11/08 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1097/MD.0000000000022950 [doi]
AID - 00005792-202011060-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e22950. doi: 10.1097/MD.0000000000022950.


PMID- 33157928
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - The effects of traditional Chinese medicine combined with chemotherapy on immune 
      function and quality of life in patients with non-small cell lung cancer: A
      protocol for systematic review and meta-analysis.
PG  - e22859
LID - 10.1097/MD.0000000000022859 [doi]
AB  - BACKGROUND: This article will evaluate the effects of traditional Chinese
      medicine (TCM) combined with chemotherapy on the immune function and quality of
      life of patients with non-small cell lung cancer (NSCLC), and evaluate the
      published side effects. METHODS: The systematic review and meta-analysis will be 
      conducted in accordance with the Preferred Reporting Items for Systematic Review 
      and Meta-Analysis guidelines. The databases we will search include: PubMed,
      EMBASE, Cochrane Library, Web of Science, China National Knowledge
      Infrastructure, China Biomedicine, Wan fang Data, and Technology Periodical
      Database. The search date is from inception to June 30, 2020. There are no
      restrictions on the document language. The literatures included in this study are
      randomized controlled trials. The main results include ratio of CD3, CD4, CD8,
      CD4/CD8, NK cells, the level of IgA, IgG, IgM, and Karnofsky performance status
      score. The secondary result is to evaluate various side effects during treatment.
      We will use the Cochrane Collaboration tool to evaluate each study and use Review
      Manager software (RevMan, version 5.3) to merge and analyze the data. The 2
      researchers will independently cross-screen the literature, extract data, and
      evaluate the quality. If there are differences, we will resolve them through
      discussion or consultation with a third reviewer. RESULTS: The results of this
      study will provide high-quality evidence for the effect of TCM combined with
      chemotherapy on the immune function and quality of life of patients with NSCLC.
      CONCLUSION: This article will comprehensively evaluate the effects of TCM
      combined with chemotherapy on the immune function and quality of life of patients
      with NSCLC, and provide evidence-based evidence for clinical practice. ETHICS:
      Since the data used in this study is based on previous trials and does not
      involve patient privacy, ethical approval is not required. STUDY REGISTRATION
      NUMBER: INPLASY202070071.
FAU - Zhao, Li-Na
AU  - Zhao LN
AUID- ORCID: 0000-0001-9417-149
AD  - School of Health Preservation and Rehabilitation.
FAU - Yang, Yin-Qing
AU  - Yang YQ
AD  - School of Management, Chengdu University of Traditional Chinese Medicine,
      Sichuan, China.
FAU - Wang, Wen-Wen
AU  - Wang WW
AD  - School of Health Preservation and Rehabilitation.
FAU - Li, Qian
AU  - Li Q
AD  - School of Health Preservation and Rehabilitation.
FAU - Xiao, Hua
AU  - Xiao H
AUID- ORCID: 0000-0003-3425-3148
AD  - School of Health Preservation and Rehabilitation.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CD3 Complex)
RN  - 0 (Immunoglobulin Isotypes)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - CD3 Complex/metabolism
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/blood/*therapy
MH  - Humans
MH  - Immunoglobulin Isotypes/blood
MH  - Killer Cells, Natural/metabolism
MH  - Lung Neoplasms/blood/*therapy
MH  - *Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - *Quality of Life
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7647523
EDAT- 2020/11/08 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1097/MD.0000000000022859 [doi]
AID - 00005792-202011060-00022 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e22859. doi: 10.1097/MD.0000000000022859.


PMID- 33157927
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - Rapid rehabilitation nursing improves clinical outcomes in postoperative patients
      with colorectal carcinoma: A protocol for randomized controlled trial.
PG  - e22857
LID - 10.1097/MD.0000000000022857 [doi]
AB  - BACKGROUND: Colorectal carcinoma has a high incidence rate and the high mortality
      rate has always been an important global health challenge. Surgical treatment is 
      widely performed in patients with colorectal carcinoma. Fast track surgery (FTS) 
      applies evidence-based medical concept to optimize the management during the
      operation, so as to reduce the psychological and physical trauma stress of
      surgical patients and make them recover rapidly. We perform this protocol for
      randomized controlled study to evaluate the efficacy of a rapid rehabilitation
      care in colorectal carcinoma surgery. METHODS: It is a single-center randomized
      controlled study to be conducted from January 2021 to December 2021. It was
      authorized via the Ethics Committee of the Huzhou Central Hospital (20191127-01).
      Eighty participants who undergo colorectal carcinoma surgery will be included in 
      this research. Patients are randomly assigned to control group (standard
      management group, including 40 samples) and study group (the FTS group, including
      40 samples). The main results are times of postoperative exhaust, first
      defecation, ambulation, first eating, and postoperative hospital stay. Secondary 
      outcomes are incidence of nausea and emesis, wound infection, urinary tract
      infection, lung infection, deep vein thrombosis, and rehospitalization rate among
      the 2 groups. All analyses are conducted using the SPSS for Windows Release 15.0.
      RESULTS: Figure 1 shows the clinical results between groups. CONCLUSION: The
      research can offer a reliable basis for the effectiveness of a rapid recovery
      nursing program in patients with colorectal carcinoma. TRIAL REGISTRATION: This
      study protocol was registered in Research Registry (researchregistry6038).
FAU - Zhu, Genying
AU  - Zhu G
AD  - Department of Gastrointestinal Surgery, Huzhou Central Hospital (Affiliated
      Central Hospital of HuZhou University), Zhejiang, China.
FAU - Wu, Chen
AU  - Wu C
FAU - Shen, Xiaoying
AU  - Shen X
AUID- ORCID: 0000-0002-6798-4900
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Colorectal Neoplasms/*rehabilitation/*surgery
MH  - Humans
MH  - *Postoperative Care
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Rehabilitation Nursing
PMC - PMC7647534
EDAT- 2020/11/08 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1097/MD.0000000000022857 [doi]
AID - 00005792-202011060-00021 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e22857. doi: 10.1097/MD.0000000000022857.


PMID- 33157521
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210130
IS  - 2152-7202 (Electronic)
IS  - 2152-7202 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec 14
TI  - Does a Pandemic Preempt Participatory Medicine?
PG  - e23860
LID - 10.2196/23860 [doi]
AB  - For those of us who believe deeply in a collaborative relationship between
      patients and doctors, the chaos created by the COVID-19 pandemic has brought an
      uncomfortable question to the fore: Is participatory medicine still relevant
      during a pandemic? Drawing liberally upon the Jewish tradition of Talmudic
      reasoning, I would like to offer 3 considered replies: "Yes," "no," and "it
      depends." Sometimes, patients may have no choice but to cede control to medical
      professionals, even though patients are still the experts on their own lives.
      Other times, the shared control of participatory medicine is both an ethical and 
      clinical imperative. However, as the worldwide toll exacted by COVID-19 has made 
      us grimly aware, no one is really in control. That is why, in these uncertain
      times, the path forward requires maintaining mutual trust between health care
      providers and patients, whatever the circumstances. After all, it is our bodies
      and our selves at stake.
CI  - (c)Michael Louis Millenson. Originally published in Journal of Participatory
      Medicine (http://jopm.jmir.org), 14.12.2020.
FAU - Millenson, Michael Louis
AU  - Millenson ML
AUID- ORCID: https://orcid.org/0000-0001-8364-1927
AD  - Health Quality Advisors LLC, United States.
AD  - Feinberg School of Medicine, Northwestern University, Evanston, IL, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20201214
PL  - Canada
TA  - J Particip Med
JT  - Journal of participatory medicine
JID - 101539422
PMC - PMC7744137
OTO - NOTNLM
OT  - COVID-19
OT  - DETECT study, Body Politic
OT  - Fitbit
OT  - pandemic
OT  - participatory medicine
OT  - patient-generated health data
OT  - sensors
OT  - shared decision making
OT  - wearables
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 20:20
PHST- 2020/08/26 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/10/13 00:00 [revised]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
PHST- 2020/11/06 20:20 [entrez]
AID - v12i4e23860 [pii]
AID - 10.2196/23860 [doi]
PST - epublish
SO  - J Particip Med. 2020 Dec 14;12(4):e23860. doi: 10.2196/23860.


PMID- 33157370
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 133
DP  - 2020 Dec
TI  - Diagnostic accuracy of dual-energy CT virtual non-calcium images with different
      related contrast material values for the detection of bone marrow edema in knee.
PG  - 109385
LID - S0720-048X(20)30575-1 [pii]
LID - 10.1016/j.ejrad.2020.109385 [doi]
AB  - PURPOSE: The purpose of this study was to evaluate the diagnostic accuracy of
      different related contrast material (Rel.CM) values in dual-energy computed
      tomography (DECT) virtual non-calcium (VNCa) images for the detection of bone
      marrow edema (BME) in knee. METHOD: This prospective study was approved by the
      institutional research ethics board, and written informed consent was obtained
      from all participants. Twenty-three patients (24 knees) who underwent dual-energy
      CT and MRI within three weeks from July 2018 to June 2019 with a definite history
      of trauma were enrolled. Each knee was divided into 12 regions. First, MR images 
      served as the reference standard, Receiver operating characteristic (ROC) curve
      was used and diagnostic accuracy of VNCa images corresponding to different Rel.CM
      values (1.25, 1.35, 1.45, 1.55, 1.65, 1.75) were analyzed, aimed to select an
      optimal Rel.CM value of VNCa images for detecting BME. Then, CT values of the
      normal areas and BME areas were measured on the VNCa images corresponding to the 
      optimal Rel.CM value for preliminary quantitative analysis. The rank-sum test was
      used to compare the differences of CT values between BME areas and normal bone
      marrow areas on the VNCa images. RESULTS: The 24 knees were divided into 288
      areas. MR Imaging showed BME in 121 areas. The areas under the ROC curve with
      different Rel.CM values (1.25, 1.35, 1.45, 1.55, 1.65, and 1.75) were 0.633,
      0.674, 0.882, 0.684, 0.651, and 0.649, respectively. On the VNCa images of Rel.CM
      = 1.45, the diagnostic accuracy was the highest (up to 89.2 %), the CT values of 
      the BME area and the normal area were -67.9 (1.7 approximately -100.1) HU and
      -94.5 (-69.7 approximately -144.9) HU, respectively, with statistical
      significance (Z=-9.804, P < 0.05). CONCLUSIONS: The VNCa images with a Rel.CM
      value of 1.45 is optimal for the detection of BME in knee.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Liang, Jianchao
AU  - Liang J
AD  - Department of Radiology, the Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai, 519000, China; Department of Radiology, Zhuhai People's Hospital, Zhuhai,
      519000, China.
FAU - Fang, Yijie
AU  - Fang Y
AD  - Department of Radiology, the Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai, 519000, China.
FAU - Jiang, Yunping
AU  - Jiang Y
AD  - Department of Radiology, the Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai, 519000, China.
FAU - Zhan, Yingying
AU  - Zhan Y
AD  - Department of Radiology, the Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai, 519000, China.
FAU - Hong, Guobin
AU  - Hong G
AD  - Department of Radiology, the Fifth Affiliated Hospital, Sun Yat-Sen University,
      Zhuhai, 519000, China. Electronic address: honggb@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
RN  - 0 (Contrast Media)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - *Bone Marrow/diagnostic imaging
MH  - Calcium
MH  - *Contrast Media
MH  - Edema/diagnostic imaging
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Bone marrow edema (BME)
OT  - Dual-energy CT (DECT)
OT  - Knee
OT  - Related contrast material
OT  - Tomography
OT  - X-ray computed
EDAT- 2020/11/07 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/11/06 20:13
PHST- 2020/02/23 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/11/06 20:13 [entrez]
AID - S0720-048X(20)30575-1 [pii]
AID - 10.1016/j.ejrad.2020.109385 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 Dec;133:109385. doi: 10.1016/j.ejrad.2020.109385. Epub 2020
      Nov 2.


PMID- 33156936
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1460-2237 (Electronic)
IS  - 0268-1080 (Linking)
VI  - 35
IP  - Supplement_2
DP  - 2020 Nov 1
TI  - Guiding principles for quality, ethical standards and ongoing learning in
      implementation research: multicountry learnings from participatory action
      research to strengthen health systems.
PG  - ii137-ii149
LID - 10.1093/heapol/czaa123 [doi]
AB  - Global health gains can be achieved through strengthening health systems to
      identify and address implementation challenges in low- and middle-income
      countries. Participatory research, that promotes joint problem and solution
      finding between communities and different health systems actors, supports policy 
      implementation analysis at all levels. Within the neglected tropical disease
      programmes in Liberia and Nigeria, we applied participatory action research (PAR)
      to address programmatic and health system bottlenecks with health systems
      strengthening embedded. This paper shares learning from 20 interviews with
      co-researchers, from national and sub-national levels and academic researchers
      who worked collaboratively to understand challenges, co-create solutions and
      advocate for policy change. Through analysis and reflections of existing PAR
      principles, we inductively identified five additional guiding principles for
      quality, ethical standards and ongoing learning within PAR projects that aim to
      strengthen health systems. (1) Recognize communities as units of identity and
      define stakeholder participation to ensure equitable engagement of all actors;
      (2) enable flexible action planning that builds on existing structures whilst
      providing opportunities for embedding change; (3) address health systems and
      research power differentials that can impede co-production of knowledge and
      solution development; (4) embed relational practices that lead to new political
      forms of participation and inquiry within health systems and (5) develop
      structures for ongoing learning at multiple levels of the health system. PAR can 
      strengthen health systems by connecting and co-creating potentially sustainable
      solutions to implementation challenges. Additional research to explore how these 
      five additional principles can support the attainment of quality and ethical
      standards within implementation research using a PAR framework for health systems
      strengthening is needed.
CI  - (c) The Author(s) 2020. Published by Oxford University Press in association with 
      The London School of Hygiene and Tropical Medicine.
FAU - Ozano, Kim
AU  - Ozano K
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L35QA, UK.
FAU - Dean, Laura
AU  - Dean L
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L35QA, UK.
FAU - Adekeye, Oluwatosin
AU  - Adekeye O
AD  - Sightsavers, Nigeria Country Office, Golf Course Road, City Centre, Kaduna,
      Nigeria.
FAU - Bettee, Anthony K
AU  - Bettee AK
AD  - Ministry of Health, Government of Liberia, SKD Boulevard, Monrovia, Liberia.
FAU - Dixon, Ruth
AU  - Dixon R
AD  - Sightsavers, 35 Perrymount Rd, Haywards Heath RH16 3BZ, UK.
FAU - Gideon, Ntuen Uduak
AU  - Gideon NU
AD  - Ministry of Health, Government of Nigeria, Federal Secretariat, Complex Garki
      PMB, 83 Abuja, Nigeria.
FAU - Gwani, Noela
AU  - Gwani N
AD  - Sightsavers, Nigeria Country Office, Golf Course Road, City Centre, Kaduna,
      Nigeria.
FAU - Isiyaku, Sunday
AU  - Isiyaku S
AD  - Sightsavers, Nigeria Country Office, Golf Course Road, City Centre, Kaduna,
      Nigeria.
FAU - Kollie, Karsor
AU  - Kollie K
AD  - Ministry of Health, Government of Liberia, SKD Boulevard, Monrovia, Liberia.
FAU - Lar, Luret
AU  - Lar L
AD  - Sightsavers, Nigeria Country Office, Golf Course Road, City Centre, Kaduna,
      Nigeria.
FAU - Oluwole, Akinola
AU  - Oluwole A
AD  - Sightsavers, Nigeria Country Office, Golf Course Road, City Centre, Kaduna,
      Nigeria.
FAU - Piotrowski, Helen
AU  - Piotrowski H
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L35QA, UK.
FAU - Siakeh, Alice
AU  - Siakeh A
AD  - Pacific Institute for Research and Evaluation UL-PIRE Africa Center, University
      of Liberia, Capitol Hill Liberia.
FAU - Thomson, Rachael
AU  - Thomson R
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L35QA, UK.
FAU - Yashiyi, James
AU  - Yashiyi J
AD  - Sightsavers, Nigeria Country Office, Golf Course Road, City Centre, Kaduna,
      Nigeria.
FAU - Zawolo, Georgina
AU  - Zawolo G
AD  - Pacific Institute for Research and Evaluation UL-PIRE Africa Center, University
      of Liberia, Capitol Hill Liberia.
FAU - Theobald, Sally
AU  - Theobald S
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L35QA, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Health Policy Plan
JT  - Health policy and planning
JID - 8610614
MH  - *Government Programs
MH  - *Health Services Research
MH  - Humans
MH  - Liberia
MH  - Nigeria
MH  - Policy Making
PMC - PMC7646736
OTO - NOTNLM
OT  - Implementation research
OT  - ethical standards
OT  - health systems strengthening
OT  - participatory action research
OT  - quality
EDAT- 2020/11/07 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/06 17:35
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/11/06 17:35 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 5959260 [pii]
AID - 10.1093/heapol/czaa123 [doi]
PST - ppublish
SO  - Health Policy Plan. 2020 Nov 1;35(Supplement_2):ii137-ii149. doi:
      10.1093/heapol/czaa123.


PMID- 33156811
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210709
IS  - 2368-7959 (Print)
IS  - 2368-7959 (Linking)
VI  - 7
IP  - 12
DP  - 2020 Dec 22
TI  - Ethics of Digital Mental Health During COVID-19: Crisis and Opportunities.
PG  - e23776
LID - 10.2196/23776 [doi]
AB  - Social distancing measures due to the COVID-19 pandemic have accelerated the
      adoption and implementation of digital mental health tools. Psychiatry and
      therapy sessions are being conducted via videoconferencing platforms, and the use
      of digital mental health tools for monitoring and treatment has grown. This rapid
      shift to telehealth during the pandemic has given added urgency to the ethical
      challenges presented by digital mental health tools. Regulatory standards have
      been relaxed to allow this shift to socially distanced mental health care. It is 
      imperative to ensure that the implementation of digital mental health tools,
      especially in the context of this crisis, is guided by ethical principles and
      abides by professional codes of conduct. This paper examines key areas for an
      ethical path forward in this digital mental health revolution: privacy and data
      protection, safety and accountability, and access and fairness.
CI  - (c)Nicole Martinez-Martin, Ishan Dasgupta, Adrian Carter, Jennifer A Chandler,
      Philipp Kellmeyer, Karola Kreitmair, Anthony Weiss, Laura Y Cabrera. Originally
      published in JMIR Mental Health (http://mental.jmir.org), 22.12.2020.
FAU - Martinez-Martin, Nicole
AU  - Martinez-Martin N
AUID- ORCID: https://orcid.org/0000-0001-9345-0462
AD  - Department of Pediatrics, Center for Biomedical Ethics, School of Medicine,
      Stanford University, Stanford, CA, United States.
FAU - Dasgupta, Ishan
AU  - Dasgupta I
AUID- ORCID: https://orcid.org/0000-0002-5748-1840
AD  - Department of Philosophy, University of Washington, Seattle, WA, United States.
FAU - Carter, Adrian
AU  - Carter A
AUID- ORCID: https://orcid.org/0000-0002-3593-0772
AD  - School of Psychological Sciences and the Turner Institute for Brain and Mental
      Health, Monash University, Melbourne, Australia.
FAU - Chandler, Jennifer A
AU  - Chandler JA
AUID- ORCID: https://orcid.org/0000-0001-9471-4626
AD  - Faculty of Law, Centre for Health Law, Policy & Ethics, University of Ottawa,
      Ottawa, ON, Canada.
FAU - Kellmeyer, Philipp
AU  - Kellmeyer P
AUID- ORCID: https://orcid.org/0000-0001-5538-373X
AD  - Neuroethics and AI Ethics Lab Department of Neurosurgery, University Medical
      Center Freiburg, Freiburg, Germany.
FAU - Kreitmair, Karola
AU  - Kreitmair K
AUID- ORCID: https://orcid.org/0000-0002-6808-9713
AD  - Department of Medical History and Bioethics, School of Medicine and Public
      Health, University of Wisconsin, Madison, WI, United States.
FAU - Weiss, Anthony
AU  - Weiss A
AUID- ORCID: https://orcid.org/0000-0002-4597-6598
AD  - Department of Psychiatry and Center for Bioethics, Harvard Medical School,
      Boston, MA, United States.
FAU - Cabrera, Laura Y
AU  - Cabrera LY
AUID- ORCID: https://orcid.org/0000-0002-6220-7096
AD  - Center for Ethics & Humanities in the Life Sciences, Department of Translational 
      Neuroscience, Michigan State University, East Lansing, MI, United States.
LA  - eng
GR  - K01 MH118375/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20201222
PL  - Canada
TA  - JMIR Ment Health
JT  - JMIR mental health
JID - 101658926
PMC - PMC7758081
OTO - NOTNLM
OT  - COVID-19
OT  - crisis
OT  - digital mental health
OT  - ethics
OT  - implementation
OT  - mental health
OT  - neuroethics
OT  - online tool
OT  - opportunity
OT  - telehealth
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 17:34
PHST- 2020/08/22 00:00 [received]
PHST- 2020/10/31 00:00 [accepted]
PHST- 2020/10/11 00:00 [revised]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
PHST- 2020/11/06 17:34 [entrez]
AID - v7i12e23776 [pii]
AID - 10.2196/23776 [doi]
PST - epublish
SO  - JMIR Ment Health. 2020 Dec 22;7(12):e23776. doi: 10.2196/23776.


PMID- 33155574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 6
TI  - A Short Intervention Followed by an Interactive E-Learning Module to Motivate
      Medical Students to Enlist as First Responders: Protocol for a Prospective
      Implementation Study.
PG  - e24664
LID - 10.2196/24664 [doi]
AB  - BACKGROUND: In Geneva, Switzerland, basic life support (BLS) maneuvers are
      provided in only 40% of out-of-hospital cardiac arrests (OHCAs) cases. As OHCA
      outcomes are markedly improved when BLS maneuvers are swiftly applied, a
      "first-responder" system was introduced in 2019. When emergency dispatchers
      identify a possible OHCA, first responders receive an alert message on a specific
      app (Save-a-Life) installed on their smartphones. Those nearest to the victim and
      immediately available are sent the exact location of the intervention. First-year
      medical students only have limited knowledge regarding BLS procedures but might
      nevertheless need to take care of OHCA victims. Medical students responding to
      out-of-hospital emergencies are off-duty in half of these situations, and
      offering junior medical students the opportunity to enlist as first responders
      might therefore not only improve OHCA outcomes but also foster a greater
      recognition of the role medical students can hold in our society. OBJECTIVE: Our 
      aim is to determine whether providing first-year medical students with a short
      intervention followed by an interactive e-learning module can motivate them to
      enlist as first responders. METHODS: After obtaining the approval of the regional
      ethics committee and of the vice-dean for undergraduate education of the
      University of Geneva Faculty of Medicine (UGFM), 2 senior medical students will
      present the project to their first-year colleagues at the beginning of a lecture.
      First-year students will then be provided with a link to an interactive
      e-learning module which has been designed according to the Swiss Resuscitation
      Council's first aid guidelines. After answering a first questionnaire and
      completing the module, students will be able to register for practice sessions.
      Those attending and successfully completing these sessions will receive a
      training certificate which will enable them to enlist as first responders. The
      primary outcome will be the proportion of first-year medical students enlisting
      as first responders at the end of the study period. Secondary outcomes will be
      the proportion of first-year medical students electing to register on the
      platform, to begin the e-learning module, to complete the e-learning module, to
      register for practice sessions, to attend the practice sessions, and to obtain a 
      certificate. The reasons given by medical students for refusing to participate
      will be analyzed. We will also assess how comfortable junior medical students
      would feel to be integrated into the first responders system at the end of the
      training program and whether it affects the registration rate. RESULTS: The
      regional ethics committee (Req-2020-01143) and the UGFM vice-dean for
      undergraduate education have given their approval to the realization of this
      study, which is scheduled to begin in January 2021. CONCLUSIONS: This study
      should determine whether a short intervention followed by an interactive
      e-learning module can motivate first-year medical students to enlist as first
      responders. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      PRR1-10.2196/24664.
CI  - (c)Laurent Suppan, Tara Herren, Victor Taramarcaz, Simon Regard, Sebastien
      Martin-Achard, Ido Zamberg, Robert Larribau, Marc Niquille, Francois Mach,
      Melanie Suppan, Eduardo Schiffer. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 06.11.2020.
FAU - Suppan, Laurent
AU  - Suppan L
AUID- ORCID: https://orcid.org/0000-0001-6989-6421
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Herren, Tara
AU  - Herren T
AUID- ORCID: https://orcid.org/0000-0001-9277-0093
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Taramarcaz, Victor
AU  - Taramarcaz V
AUID- ORCID: https://orcid.org/0000-0002-6325-6551
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Regard, Simon
AU  - Regard S
AUID- ORCID: https://orcid.org/0000-0002-3979-7593
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Martin-Achard, Sebastien
AU  - Martin-Achard S
AUID- ORCID: https://orcid.org/0000-0002-2766-032X
AD  - Save a Life, Swiss Emergency Responders Association, Geneva, Switzerland.
FAU - Zamberg, Ido
AU  - Zamberg I
AUID- ORCID: https://orcid.org/0000-0003-4534-4635
AD  - Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, 
      Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty
      of Medicine, Geneva, Switzerland.
AD  - Unit of Development and Research in Medical Education, Faculty of Medicine,
      University of Geneva, Geneva, Switzerland.
AD  - School of Education, Johns Hopkins University, Baltimore, MD, United States.
FAU - Larribau, Robert
AU  - Larribau R
AUID- ORCID: https://orcid.org/0000-0002-5200-4199
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Niquille, Marc
AU  - Niquille M
AUID- ORCID: https://orcid.org/0000-0002-2671-6889
AD  - Division of Emergency Medicine, Department of Anesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, University of Geneva
      Hospitals and Faculty of Medicine, Geneva, Switzerland.
FAU - Mach, Francois
AU  - Mach F
AUID- ORCID: https://orcid.org/0000-0003-3178-9131
AD  - Cardiology Department, University of Geneva Hospitals and Faculty of Medicine,
      Geneva, Switzerland.
FAU - Suppan, Melanie
AU  - Suppan M
AUID- ORCID: https://orcid.org/0000-0002-8807-9619
AD  - Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, 
      Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty
      of Medicine, Geneva, Switzerland.
FAU - Schiffer, Eduardo
AU  - Schiffer E
AUID- ORCID: https://orcid.org/0000-0002-7415-4315
AD  - Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, 
      Intensive Care and Emergency Medicine, University of Geneva Hospitals and Faculty
      of Medicine, Geneva, Switzerland.
AD  - Unit of Development and Research in Medical Education, Faculty of Medicine,
      University of Geneva, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201106
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7679213
OTO - NOTNLM
OT  - basic life support
OT  - cardiopulmonary resuscitation
OT  - medical students
OT  - out-of-hospital cardiac arrest
OT  - undergraduate medical education
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 08:40
PHST- 2020/10/02 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/10/26 00:00 [revised]
PHST- 2020/11/06 08:40 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
AID - v9i11e24664 [pii]
AID - 10.2196/24664 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 6;9(11):e24664. doi: 10.2196/24664.


PMID- 33155449
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220531
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 75
IP  - 11
DP  - 2020 Nov
TI  - [Forensic Psychiatry in Belgium in 2020].
PG  - 742-747
AB  - Forensic psychiatry is a medical (sub-) speciality covering a variety of
      different fields, such as general psychiatry, criminology, law, anthropology and 
      sociology. Experts in forensic psychiatry are required to have a base of specific
      training, eclectic knowledge and correct ethical and professional practice. The
      cross-disciplinary nature of forensic psychiatry means that it demands
      flexibility, procedural rigour and a continuous dialogue between the medical
      field and the legal profession. The aim of this article is to provide an overview
      of the evolution in this field, which is very specific and also essential to
      today's democracy. Indeed, forensic psychiatry can be traced all the way back to 
      Antiquity, but it has undergone profound changes in the last few years, with the 
      field gaining recognition and its practices becoming increasingly
      professionalised. This is indeed excellent news.
FAU - Leistedt, S
AU  - Leistedt S
AD  - SPF Justice, Belgique,Faculte de Medecine, UMons,Belgique,Hopital psychiatrique
      securise (HPS), CRP Les Marronniers, Tournai, Belgique.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - La psychiatrie legale en Belgique en 2020.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
SB  - IM
MH  - Belgium
MH  - *Forensic Psychiatry
MH  - Humans
OTO - NOTNLM
OT  - Criminology
OT  - Medical Law
OT  - Psychopathology
OT  - Forensic Psychiatry
EDAT- 2020/11/07 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/11/06 06:05
PHST- 2020/11/06 06:05 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PST - ppublish
SO  - Rev Med Liege. 2020 Nov;75(11):742-747.


PMID- 33155257
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 20
DP  - 2020 Oct
TI  - Assisted suicide: article 17 of the Italian Code of Medical Ethics follows in the
      footsteps of the Italian Constitutional Court's landmark ruling.
PG  - 10309-10312
LID - 23376 [pii]
LID - 10.26355/eurrev_202010_23376 [doi]
FAU - Marinelli, E
AU  - Marinelli E
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Italy. f.busardo@univpm.it.
FAU - Busardo, F P
AU  - Busardo FP
LA  - eng
PT  - Letter
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - Italy
MH  - *Jurisprudence
MH  - Suicide, Assisted/*legislation & jurisprudence
EDAT- 2020/11/07 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/11/06 06:02
PHST- 2020/11/06 06:02 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 10.26355/eurrev_202010_23376 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10309-10312. doi:
      10.26355/eurrev_202010_23376.


PMID- 33154842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201107
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 2
TI  - Psychiatric Manifestations in Fahr's Syndrome: A Case Report.
PG  - e10770
LID - 10.7759/cureus.10770 [doi]
AB  - Fahr's syndrome is a rare neurological entity, primarily impacting basal ganglia 
      with bilateral intracranial calcium deposition. It mainly manifests motor and
      psychiatric symptoms in affected individuals. After the patient and her family
      members' consent and proper ethical clearance from the institutional ethical
      committee, we here report a case presented with a few motor symptoms, features of
      delirium, and prominent psychiatric symptoms such as disorganized behavior,
      auditory hallucinations, and delusions. The imaging study found bilateral basal
      ganglia calcification and edema in the parietal region, primarily on the right
      side. Laboratory studies revealed mildly low parathyroid hormone and calcium
      levels, but no significant findings in other investigational tests. Her past
      medical and psychiatric history were negative, except for her well-adjusted
      pre-morbid personality. Our aim through this case is to highlight the psychiatric
      manifestation of a rare neurological syndrome. It also showcases the importance
      of ruling out medical causes when a patient presents primarily with behavioral
      symptoms.
CI  - Copyright (c) 2020, Kumar et al.
FAU - Kumar, Prerak
AU  - Kumar P
AD  - Psychiatry and Behavioral Sciences, Lady Hardinge Medical College, Smt Sucheta
      Kriplani Hospital, New Delhi, IND.
FAU - Singh, Romil
AU  - Singh R
AD  - Internal Medicine, Metropolitan Hospital, Jaipur, IND.
FAU - Shah, Kaushal
AU  - Shah K
AD  - Psychiatry, Griffin Memorial Hospital, Norman, USA.
LA  - eng
PT  - Case Reports
DEP - 20201002
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7606226
OTO - NOTNLM
OT  - basal ganglia
OT  - calcification
OT  - fahr's syndrome
OT  - paranoia
OT  - psychosis
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 06:00
PHST- 2020/11/06 06:00 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
AID - 10.7759/cureus.10770 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 2;12(10):e10770. doi: 10.7759/cureus.10770.


PMID- 33154650
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - The OPTION Scale: Measuring Patients' Perceptions of Shared Decision-Making in
      the Kingdom of Saudi Arabia.
PG  - 1337-1346
LID - 10.2147/JMDH.S273340 [doi]
AB  - BACKGROUND: Involving patients in the decision-making process is now widely
      accepted as appropriate and ethical during consultations, particularly when
      several options are available. The aim of this study is to measure the patients' 
      perceptions of shared decision-making practices during clinical encounters in
      Saudi Arabia. METHODS: This study employs a quantitative cross-sectional design. 
      The OPTION scale was translated to Arabic. The questionnaire's content validity
      was assessed using an expert panel review. The questionnaire was then
      administered to 291 participants through online recruitment. RESULTS:
      Participants reported positive perceptions of shared decision-making practices in
      Saudi Arabia. The lowest perceived shared decision-making scores were from
      patients who visited the internal medicine department (f = 2.163, P = 0.009).
      Participants who received care from female physicians reported significantly
      higher levels of involvement in the shared decision-making process compared to
      male physicians (t = -2.732, P = 0.007). Although the majority of the
      participants in the study were from Eastern Province, this province documented
      the lowest mean perceived decision-making score by the patients compared to other
      provinces within Saudi Arabia (f = 3.613, P = 0.007). Female participants in the 
      study had a higher shared decision-making score than the male participants (t =
      -3.644, P < 0.0001). CONCLUSION: Generally, the study results confirmed that
      shared decision-making in the Saudi health system includes significant patient
      involvement. Interventions that enhance the culture of shared decision-making in 
      Saudi Arabia are necessary to ensure better adherence to treatment plans and thus
      better health outcomes.
CI  - (c) 2020 Alrawiai et al.
FAU - Alrawiai, Sumaiah
AU  - Alrawiai S
AUID- ORCID: 0000-0002-0251-0616
AD  - Department of Health Information Management & Technology, College of Public
      Health, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
FAU - Aljaffary, Afnan
AU  - Aljaffary A
AUID- ORCID: 0000-0001-6656-3306
AD  - Department of Health Information Management & Technology, College of Public
      Health, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
FAU - Al-Rayes, Saja
AU  - Al-Rayes S
AUID- ORCID: 0000-0001-9908-7756
AD  - Department of Health Information Management & Technology, College of Public
      Health, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
FAU - Alumran, Arwa
AU  - Alumran A
AUID- ORCID: 0000-0001-6454-3678
AD  - Department of Health Information Management & Technology, College of Public
      Health, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
FAU - Alhuseini, Mishael
AU  - Alhuseini M
AD  - Department of Health Information Management & Technology, College of Public
      Health, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
FAU - Hariri, Bayan
AU  - Hariri B
AD  - Department of Health Information Management & Technology, College of Public
      Health, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7608000
OTO - NOTNLM
OT  - patient experience measure
OT  - patient-centered care
OT  - shared decision-making
COIS- No potential conflicts of interest was reported by the authors.
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 05:59
PHST- 2020/07/23 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/11/06 05:59 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
AID - 10.2147/JMDH.S273340 [doi]
AID - 273340 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Oct 30;13:1337-1346. doi: 10.2147/JMDH.S273340.
      eCollection 2020.


PMID- 33154498
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210415
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Nov 5
TI  - Cardiac adverse events associated with chloroquine and hydroxychloroquine
      exposure in 20 years of drug safety surveillance reports.
PG  - 19199
LID - 10.1038/s41598-020-76258-0 [doi]
AB  - Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health
      Organization's List of Essential Medications for treating non-resistant malaria, 
      rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition,
      both drugs are currently used off-label in hospitals worldwide and in numerous
      clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ
      use has been associated with cardiac side effects, which is of concern due to the
      higher risk of COVID-19 complications in patients with heart related disorders,
      and increased mortality associated with COVID-19 cardiac complications. In this
      study we analyzed over thirteen million adverse event reports form the United
      States Food and Drug Administration Adverse Event Reporting System to confirm and
      quantify the association of cardiac side effects of CQ and HCQ. Additionally, we 
      identified several confounding factors, including male sex, NSAID
      coadministration, advanced age, and prior diagnoses contributing to drug related 
      cardiotoxicity. These findings may help guide therapeutic decision making and
      ethical trial design for COVID-19 treatment.
FAU - Cohen, Isaac V
AU  - Cohen IV
AD  - Clinical Pharmacology and Therapeutics (CPT) Postdoctoral Training Program,
      University of California San Francisco, San Francisco, CA, USA.
FAU - Makunts, Tigran
AU  - Makunts T
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
      San Diego, La Jolla, CA, USA.
AD  - Oak Ridge Institute of Science and Education (ORISE), Clinical Pharmacology and
      Machine Learning Fellowship, Center for Drug Evaluation and Research, United
      States Food and Drug Administration, Silver Spring, MD, USA.
FAU - Moumedjian, Talar
AU  - Moumedjian T
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
      San Diego, La Jolla, CA, USA.
FAU - Issa, Masara A
AU  - Issa MA
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
      San Diego, La Jolla, CA, USA.
FAU - Abagyan, Ruben
AU  - Abagyan R
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
      San Diego, La Jolla, CA, USA. rabagyan@health.ucsd.edu.
LA  - eng
GR  - R35 GM131881/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20201105
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 886U3H6UFF (Chloroquine)
SB  - IM
MH  - COVID-19
MH  - Chloroquine/*adverse effects/therapeutic use
MH  - Cohort Studies
MH  - Coronavirus Infections/drug therapy
MH  - Female
MH  - Heart/*drug effects
MH  - Humans
MH  - Hydroxychloroquine/*adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/drug therapy
MH  - *Product Surveillance, Postmarketing
MH  - *Safety
PMC - PMC7644696
EDAT- 2020/11/07 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/06 05:56
PHST- 2020/05/15 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/11/06 05:56 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1038/s41598-020-76258-0 [doi]
AID - 10.1038/s41598-020-76258-0 [pii]
PST - epublish
SO  - Sci Rep. 2020 Nov 5;10(1):19199. doi: 10.1038/s41598-020-76258-0.


PMID- 33154346
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201218
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Nov 6
TI  - [Ethical considerations during health crisis: about SARS-CoV-2 coronavirus
      pandemic.]
LID - e202011149 [pii]
AB  - In 2009, the H1N1 pandemic raised a series of ethical considerations that
      influenced the approach to the crisis. In the framework of the SARS-CoV-2
      coronavirus pandemic, these issues have been repeated, and the analysis of what
      happened in 2009 can be seen as a warning. The principles of justice, solidarity,
      equity, transparency and reciprocity should be included in future pandemic
      response plans, including lessons learned.
FAU - Santillan-Garcia, Azucena
AU  - Santillan-Garcia A
AD  - Hospital Universitario. Burgos. Espana.
FAU - Ferrer-Arnedo, Carmen
AU  - Ferrer-Arnedo C
AD  - Hospital Central de Cruz Roja. Madrid. Espana.
AD  - Vicepresidenta de la Sociedad Madrilena de Etica Enfermera. Madrid. Espana.
LA  - spa
PT  - Journal Article
TT  - Consideraciones eticas durante las crisis sanitarias: a proposito de la pandemia 
      por el coronavirus SARS-CoV-2.
DEP - 20201106
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/methods
MH  - Coronavirus Infections/*epidemiology
MH  - *Ethics, Medical
MH  - *Health Equity
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype
MH  - Influenza, Human/epidemiology
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Spain/epidemiology
OTO - NOTNLM
OT  - Covid-19
OT  - Ethics
OT  - Health crisis
OT  - Pandemic
OT  - Spain
EDAT- 2020/11/07 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/11/06 05:52
PHST- 2020/06/02 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/06 05:52 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Nov 6;94.


PMID- 33154291
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20220418
IS  - 1117-1936 (Print)
VI  - 27
IP  - 4
DP  - 2020 Oct-Dec
TI  - Tympanometric findings among Nigerian prison inmates: A cross-sectional survey.
PG  - 365-370
LID - 10.4103/npmj.npmj_96_20 [doi]
AB  - BACKGROUND: Prisoners, due to confinement, are isolated from contact with society
      and access to many of the facilities, including medical care. There is paucity of
      data on the middle ear function of prison inmates in the English literature
      globally. We aimed to assess the middle ear function of prison inmates in Kaduna,
      Nigeria. PARTICIPANTS AND METHODS: This was a cross-sectional comparative study
      of prison inmates at the Kaduna convict prison. Ethical approval was obtained
      from the Kaduna State Ministry of Health and the Nigerian Prison Service. Prison 
      inmates aged 18-55 years in the Kaduna convict prison with an equal number of age
      and sex-matched controls from the community were enrolled. Consent was obtained
      from the participants. Data were collected using a structured pre-tested
      questionnaire. Participants had a thorough physical examination of the ears.
      Tympanometry was conducted on suitable participants to assess the middle ear
      function. Statistical Product and Service Solutions version 20.0 was used to
      analyse the data. RESULTS: Four hundred and thirty inmates with an equal number
      of controls were enrolled for the study. The mean age for the inmates and
      controls was 30.2 +/- 7.51 and 30.4 +/- 8.02 years, respectively. There were 47
      female and 383 males, with a female: male of 1:8.1. Forty-six (46/397, 11.6%) of 
      the inmates and 15 (15/423, 3.5%) of the controls had abnormal tympanograms on
      the right while on the left, it was 12.4% and 3.8%, respectively. The difference 
      between the two groups was statistically significant (chi(2) = 40.071, P =
      0.0001). CONCLUSION: : Middle ear abnormalities are more prevalent among prison
      inmates than the general population. Middle ear effusion and ossicular chain
      disruption were the most common middle ear abnormalities affecting the prison
      inmates.
FAU - Kirfi, Abdullahi Musa
AU  - Kirfi AM
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Abubakar Tafawa Balewa 
      University Teaching Hospital, Bauchi, Nigeria.
FAU - Fufore, Mohammed Bello
AU  - Fufore MB
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Federal Medical Center,
      Yola, Nigeria.
FAU - Quadri, Oladeji Raheem
AU  - Quadri OR
AD  - Department of Otorhinolaryngology, Gombe State University, Gombe, Nigeria.
FAU - Kodiya, Aliyu Mohammed
AU  - Kodiya AM
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University of Maiduguri
      Teaching Hospital, University of Maiduguri, Maiduguri, Nigeria.
FAU - Benjamin Nwaorgu, Onyekwere George
AU  - Benjamin Nwaorgu OG
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, University College
      Hospital, Ibadan and College of Medicine, University of Ibadan, Ibadan, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Niger Postgrad Med J
JT  - The Nigerian postgraduate medical journal
JID - 9613595
SB  - IM
MH  - *Acoustic Impedance Tests
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria
MH  - *Prisoners
MH  - Prisons
MH  - Young Adult
OTO - NOTNLM
OT  - Kaduna
OT  - Nigeria
OT  - middle ear function
OT  - prison inmates
COIS- None
EDAT- 2020/11/07 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/11/06 05:52
PHST- 2020/11/06 05:52 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - NigerPostgradMedJ_2020_27_4_365_299920 [pii]
AID - 10.4103/npmj.npmj_96_20 [doi]
PST - ppublish
SO  - Niger Postgrad Med J. 2020 Oct-Dec;27(4):365-370. doi: 10.4103/npmj.npmj_96_20.


PMID- 33154213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0970-2113 (Print)
IS  - 0970-2113 (Linking)
VI  - 37
IP  - 6
DP  - 2020 Nov-Dec
TI  - Prognostic factors for sarcomatoid carcinomas of lung: A single-centre
      experience.
PG  - 506-510
LID - 10.4103/lungindia.lungindia_525_19 [doi]
AB  - BACKGROUND: Although lung sarcomatoid carcinomas (LSCa) arised from the
      epithelial tissue, they have very distinctive features than other non-small cell 
      lung carcinomas in terms of histopathology and survival. It constitutes 0.1%-0.4%
      of all lung cancers. The aim of our study is to evaluate the survival analysis of
      LSCa in a single thoracic surgery clinic and to determine the prognostic factors.
      MATERIALS AND METHODS: It was a retrospective cohort study. After the approval of
      the local ethics committee, a total of 34 patients who were operated in our
      department between January 2010 and December 2018, whose pathologies were
      reported as sarcomatoid carcinoma was included in the study. The patients were
      analyzed by age, gender, presence of necrosis in the histopathological
      examination, tumor stage, tumor diameter, and tumor location. RESULTS: There were
      28 males and 6 females. The median age was 60 years (range: 36-80 years). The
      median survival was 42 months (32.6-52.2 months), and the 5-year overall survival
      was 33.6%. Significantly negative prognostic factors were tumor diameter and
      tumor stage (P = 0.003 and 0.001, respectively). Median disease-free interval
      (DFI) was 38 months (27.3-49.1 months), and 5-year DFI was 32.6%. CONCLUSION:
      LSCa are highly heterogeneous epithelial malignancies, and it has worse survival 
      than other epithelial cancers. Relatively, satisfactory results can be obtained
      in these tumors with surgical treatment.
FAU - Sayan, Muhammet
AU  - Sayan M
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Bas, Aynur
AU  - Bas A
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Valiyev, Elgun
AU  - Valiyev E
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Celik, Ali
AU  - Celik A
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Kurul, Ismail Cuneyt
AU  - Kurul IC
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Aribas, Olgun Kadir
AU  - Aribas OK
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Tastepe, Abdullah Irfan
AU  - Tastepe AI
AD  - Department of Thoracic Surgery, School of Medicine, Gazi University, Ankara,
      Turkey.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC7879877
OTO - NOTNLM
OT  - Giant cell
OT  - pleomorphic carcinoma
OT  - sarcomatoid carcinoma
OT  - spindle cell
COIS- None
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 05:52
PHST- 2020/11/06 05:52 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
AID - LungIndia_2020_37_6_506_299665 [pii]
AID - 10.4103/lungindia.lungindia_525_19 [doi]
PST - ppublish
SO  - Lung India. 2020 Nov-Dec;37(6):506-510. doi: 10.4103/lungindia.lungindia_525_19.


PMID- 33154208
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 0970-2113 (Print)
IS  - 0970-2113 (Linking)
VI  - 37
IP  - 6
DP  - 2020 Nov-Dec
TI  - Sarcopenia in patients with chronic obstructive pulmonary disease: A study of
      prevalence and associated factors in Western Greek population.
PG  - 479-484
LID - 10.4103/lungindia.lungindia_143_20 [doi]
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with a
      progressive loss of muscle mass and function and a systemic inflammatory process 
      that can cause sarcopenia. OBJECTIVE: The objective of this study is to estimate 
      the prevalence rate of sarcopenia in COPD patients and to determine the factors
      associated with sarcopenic patients living in Western Greece. METHODS: European
      Working Group on Sarcopenia in Older People criteria were applied to 69
      outpatients with stable COPD. Body composition, exercise capacity, functional
      performance, physical activity, and health status were also assessed. COPD
      disease severity (COPD stage) was evaluated with the Global Initiative for
      chronic obstructive lung disease. The study protocol was approved by the Ethical 
      Committee of the Technological Educational Institute of Western Greece. RESULTS: 
      The sample comprised 69 patients (59 women and 10 men), with a mean age of 71.33 
      +/- 7.48 years. The prevalence of sarcopenia was 24.6% (n = 17). A high
      percentage (82.6%; n = 57) of the 69 Greek participants did not perform any
      regular exercise. The findings of this study demonstrated that sarcopenia was
      positively associated with COPD, age, body mass index, skeletal muscle mass, hand
      grip strength, and 4 m test. CONCLUSIONS: In conclusion, there is a 24.6%
      prevalence of sarcopenia in patients with COPD. Further research with larger
      samples would be indicated to clarify the precise association of specific
      characteristics of patients with sarcopenia and COPD.
FAU - Tsekoura, Maria
AU  - Tsekoura M
AD  - Department of Physiotherapy, School of Health Rehabilitation Sciences, University
      of Patras, Patras, Greece.
FAU - Tsepis, Elias
AU  - Tsepis E
AD  - Department of Physiotherapy, School of Health Rehabilitation Sciences, University
      of Patras, Patras, Greece.
FAU - Billis, Evdokia
AU  - Billis E
AD  - Department of Physiotherapy, School of Health Rehabilitation Sciences, University
      of Patras, Patras, Greece.
FAU - Gliatis, John
AU  - Gliatis J
AD  - Department of Medicine, School of Health Sciences, University of Patras, Patras, 
      Greece.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC7879857
OTO - NOTNLM
OT  - Airway obstruction
OT  - lung disease
OT  - sarcopenia
OT  - skeletal muscle mass
COIS- None
EDAT- 2020/11/07 06:00
MHDA- 2020/11/07 06:01
CRDT- 2020/11/06 05:52
PHST- 2020/11/06 05:52 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/11/07 06:01 [medline]
AID - LungIndia_2020_37_6_479_299653 [pii]
AID - 10.4103/lungindia.lungindia_143_20 [doi]
PST - ppublish
SO  - Lung India. 2020 Nov-Dec;37(6):479-484. doi: 10.4103/lungindia.lungindia_143_20.


PMID- 33154153
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 6
DP  - 2020 Dec
TI  - When a Family Seeks to Exclude Residents From Their Child's Care.
LID - e2020011007 [pii]
LID - 10.1542/peds.2020-011007 [doi]
AB  - A primary goal of our medical education system is to produce physicians qualified
      to promote health, prevent and treat disease, and relieve suffering. Although
      some aspects of the practice of medicine can be learned in classrooms, from
      textbooks, or with simulators, other aspects can only be learned through the
      direct provision of patient care. Residency programs therefore offer essential
      educational experiences that support residents' acquisition of knowledge, skills,
      and professional judgment through the assumption of progressive responsibility
      under an appropriate level of supervision. Yet, ethical questions can arise when 
      medical education is integrated with patient care. How should we balance the
      educational needs of residents and the social benefits of medical education
      against obligations to patients and families? In this article, we present the
      case of a child whose family requests that residents not be allowed to perform
      any procedures on their child and then ask experts (a pediatric residency program
      director, a pediatrics resident, and an ethicist) to comment.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Largent, Emily A
AU  - Largent EA
AD  - Perelman School of Medicine, University of Pennsylvania, Philadelphia,
      Pennsylvania; elargent@pennmedicine.upenn.edu.
FAU - Newman, Ross
AU  - Newman R
AD  - Children's Mercy Kansas City, Kansas, Missouri; and.
FAU - Gaw, Christopher E
AU  - Gaw CE
AD  - Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
FAU - Lantos, John D
AU  - Lantos JD
AD  - Children's Mercy Kansas City, Kansas, Missouri; and.
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20201105
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Child Care/*ethics/psychology
MH  - Child, Preschool
MH  - Family/*psychology
MH  - Female
MH  - Humans
MH  - Internship and Residency/*ethics
MH  - Pyelonephritis/*therapy
MH  - Students, Medical/*psychology
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/11/07 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/11/06 05:51 [entrez]
AID - peds.2020-011007 [pii]
AID - 10.1542/peds.2020-011007 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Dec;146(6). pii: peds.2020-011007. doi:
      10.1542/peds.2020-011007. Epub 2020 Nov 5.


PMID- 33154091
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Commentary on 'Payment in challenge studies: ethics, attitudes and a new payment 
      for risk model'.
PG  - 829-830
LID - 10.1136/medethics-2020-106975 [doi]
FAU - Payne, Ruth
AU  - Payne R
AD  - Department of Infection, Immunity and Cardiovascular Disease, University of
      Sheffield, Sheffield, UK r.o.payne@sheffield.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20201105
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Dec;46(12):815-826. PMID: 32978306
CIN - J Med Ethics. 2020 Dec;46(12):837-839. PMID: 33234546
MH  - *Attitude
MH  - Humans
MH  - *Motivation
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/10/03 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/11/06 05:51 [entrez]
AID - medethics-2020-106975 [pii]
AID - 10.1136/medethics-2020-106975 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):829-830. doi: 10.1136/medethics-2020-106975. Epub
      2020 Nov 5.


PMID- 33154089
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Should practice and policy be revised to allow for risk-proportional payment to
      human challenge study participants?
PG  - 835-836
LID - 10.1136/medethics-2020-106900 [doi]
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AUID- ORCID: 0000-0001-5940-602X
AD  - Monash Bioethics Centre, Monash University, Clayton, Victoria, Australia
      zeb.jamrozik@monash.edu.
AD  - Ethox & Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, 
      United Kingdom.
AD  - Royal Melbourne Hospital Department of Medicine, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AUID- ORCID: 0000-0003-3496-2884
AD  - Monash Bioethics Centre, Monash University, Clayton, Victoria, Australia.
LA  - eng
GR  - 210551/Z/18/Z/WT_/Wellcome Trust/United Kingdom
GR  - 203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 216355/Z/19/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20201105
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Dec;46(12):815-826. PMID: 32978306
CIN - J Med Ethics. 2020 Dec;46(12):837-839. PMID: 33234546
MH  - Attitude
MH  - *Ethics Committees, Research
MH  - Humans
MH  - *Motivation
MH  - Policy
MH  - Research Design
PMC - PMC7719901
OTO - NOTNLM
OT  - *clinical trials
OT  - *ethics
OT  - *public health ethics
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/10/18 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/11/06 05:51 [entrez]
AID - medethics-2020-106900 [pii]
AID - 10.1136/medethics-2020-106900 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):835-836. doi: 10.1136/medethics-2020-106900. Epub
      2020 Nov 5.


PMID- 33154065
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE
      project.
PG  - e043634
LID - 10.1136/bmjopen-2020-043634 [doi]
AB  - OBJECTIVE: To provide guidance to researchers, funders, regulators and study
      delivery teams to ensure that research on COVID-19 is inclusive, particularly of 
      groups disproportionately affected by COVID-19 and who may have been historically
      under-served by research. SUMMARY OF KEY POINTS: Groups who are
      disproportionately affected by COVID-19 include (but are not limited to) older
      people, people with multiple long-term conditions, people with disabilities,
      people from Black, Asian and Ethnic minority groups, people living with obesity, 
      people who are socioeconomically deprived and people living in care homes. All
      these groups are under-served by clinical research, and there is an urgent need
      to rectify this if COVID-19 research is to deliver relevant evidence for these
      groups who are most in need. We provide a framework and checklists for addressing
      key issues when designing and delivering inclusive COVID-19 research, based on
      the National Institute for Health Research INnovations in CLinical trial design
      and delivery for the UnDEr-served project roadmap. Strong community engagement,
      codevelopment and prioritisation of research questions and interventions are
      essential. Under-served groups should be represented on funding panels and ethics
      committees, who should insist on the removal of barriers to participation.
      Exclusion criteria should be kept to a minimum; intervention delivery and outcome
      measurement should be simple, flexible and tailored to the needs of different
      groups, and local advice on the best way to reach and engage with under-served
      communities should be taken by study delivery teams. Data on characteristics that
      allow identification of under-served groups must be collected, analyses should
      include these data to enable subgroup comparisons and results should be shared
      with under-served groups at an early stage. CONCLUSION: Inclusive COVID-19
      research is a necessity, not a luxury, if research is to benefit all the
      communities it seeks to serve. It requires close engagement with under-served
      groups and attention to aspects of study topic, design, delivery, analysis and
      dissemination across the research life cycle.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Witham, Miles D
AU  - Witham MD
AUID- ORCID: 0000-0002-1967-0990
AD  - NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon
      Tyne, UK miles.witham@newcastle.ac.uk.
AD  - NIHR Clinical Research Network Cluster E, Newcastle University, Newcastle upon
      Tyne, Tyne and Wear, UK.
FAU - Anderson, Eleanor
AU  - Anderson E
AD  - NIHR Clinical Research Network Cluster E, Newcastle University, Newcastle upon
      Tyne, Tyne and Wear, UK.
FAU - Carroll, Camille B
AU  - Carroll CB
AUID- ORCID: 0000-0001-7472-953X
AD  - Faculty of Health, University of Plymouth, Plymouth, Devon, UK.
FAU - Dark, Paul M
AU  - Dark PM
AD  - NIHR Manchester Biomedical Research Centre, The University of Manchester and
      Northern Care Alliance NHS Group, Manchester, UK.
FAU - Down, Kim
AU  - Down K
AD  - NIHR Clinical Research Network Cluster E, Newcastle University, Newcastle upon
      Tyne, Tyne and Wear, UK.
FAU - Hall, Alistair S
AU  - Hall AS
AD  - Cardiology Department, Leeds General Infirmary Department of Cardiology, Leeds,
      West Yorkshire, UK.
FAU - Knee, Joanna
AU  - Knee J
AD  - NIHR Clinical Research Network Coordinating Centre, University of Leeds, Leeds,
      West Yorkshire, UK.
FAU - Maher, Eamonn R
AU  - Maher ER
AD  - Department of Medical Genetics, University of Cambridge and NIHR Cambridge
      Biomedical Research Centre, Cambridge, UK.
FAU - Maier, Rebecca H
AU  - Maier RH
AD  - Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, Tyne
      and Wear, UK.
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      Tyne and Wear, UK.
FAU - Mountain, Gail A
AU  - Mountain GA
AD  - Centre for Applied Dementia Studies, University of Bradford, Bradford, West
      Yorkshire, UK.
FAU - Nestor, Gary
AU  - Nestor G
AD  - NIHR Clinical Research Network Cluster E, Newcastle University, Newcastle upon
      Tyne, Tyne and Wear, UK.
FAU - O'Brien, John T
AU  - O'Brien JT
AD  - Department of Psychiatry, University of Cambridge, Cambridge, Cambridgeshire, UK.
FAU - Oliva, Laurie
AU  - Oliva L
AD  - NIHR Clinical Research Network Coordinating Centre, Guy's and St Thomas' NHS
      Foundation Trust, London, UK.
FAU - Wason, James
AU  - Wason J
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      Tyne and Wear, UK.
AD  - MRC Biostatistics Unit, University of Cambridge, Cambridge, Cambridgeshire, UK.
FAU - Rochester, Lynn
AU  - Rochester L
AD  - NIHR Clinical Research Network Cluster E, Newcastle University, Newcastle upon
      Tyne, Tyne and Wear, UK.
AD  - Brain and Movement Group, Translational Clinical Research Institute, Newcastle
      University, Newcastle upon Tyne, Tyne and Wear, UK.
CN  - NIHR CRN INCLUDE Steering Group
LA  - eng
GR  - MC_UU_00002/6/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Biomedical Research/*organization & administration
MH  - COVID-19/*epidemiology
MH  - Humans
MH  - *Minority Groups
MH  - *SARS-CoV-2
PMC - PMC7646322
OTO - NOTNLM
OT  - *COVID-19
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - bmjopen-2020-043634 [pii]
AID - 10.1136/bmjopen-2020-043634 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e043634. doi: 10.1136/bmjopen-2020-043634.


PMID- 33154062
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Associations between vision impairment and driving and the effectiveness of
      vision-related interventions: protocol for a systematic review and meta-analysis.
PG  - e040881
LID - 10.1136/bmjopen-2020-040881 [doi]
AB  - INTRODUCTION: Driving is one of the main modes of transport with safe driving
      requiring a combination of visual, cognitive and physical skills. With population
      ageing, the number of people living with vision impairment is set to increase in 
      the decades ahead. Vision impairment may negatively impact an individual's
      ability to safely drive. The association between vision impairment and motor
      vehicle crash involvement or driving participation has yet to be systematically
      investigated. Further, the evidence for the effectiveness of vision-related
      interventions aimed at decreasing crashes and driving errors has not been
      synthesised. METHODS AND ANALYSIS: A search will be conducted for relevant
      studies on Medline (Ovid), EMBASE and Global Health from their inception to March
      2020 without date or geographical restrictions. Two investigators will
      independently screen abstracts and full texts using Covidence software with
      conflicts resolved by a third investigator. Data extraction will be conducted on 
      all included studies, and their quality assessed to determine the risk of bias
      using the Joanna Briggs Institute Critical Appraisal Tools. Outcome measures
      include crash risk, driving cessation and surrogate measures of driving safety
      (eg, driving errors and performance). The results of this review will be reported
      using the Preferred Reporting Items for Systematic Review and Meta-Analysis
      guideline. Meta-analysis will be undertaken for outcomes with sufficient data and
      reported following the Meta-analyses of Observational Studies in Epidemiology
      guideline. Where statistical pooling is not feasible or appropriate, narrative
      summaries will be presented following the Synthesis Without Meta-analysis in
      systematic reviews guideline. ETHICS AND DISSEMINATION: This review will only
      report on published data thus no ethics approval is required. Results will be
      included in the Lancet Global Health Commission on Global Eye Health, published
      in a peer-reviewed journal and presented at relevant conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020172153.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Nguyen, Helen
AU  - Nguyen H
AUID- ORCID: 0000-0002-5285-1507
AD  - School of Optometry and Vision Science, Faculty of Science, University of New
      South Wales, Sydney, New South Wales, Australia.
FAU - Di Tanna, Gian Luca
AU  - Di Tanna GL
AD  - The George Institute for Global Health, Faculty of Medicine, The University of
      New South Wales, Sydney, New South Wales, Australia.
FAU - Coxon, Kristy
AU  - Coxon K
AUID- ORCID: 0000-0003-4820-0397
AD  - School of Health Sciences, and the Translational Health Research Institute,
      Western Sydney University, Penrith, New South Wales, Australia.
FAU - Brown, Julie
AU  - Brown J
AD  - The George Institute for Global Health, Faculty of Medicine, The University of
      New South Wales, Sydney, New South Wales, Australia.
FAU - Ren, Kerrie
AU  - Ren K
AD  - School of Optometry and Vision Science, Faculty of Science, University of New
      South Wales, Sydney, New South Wales, Australia.
FAU - Ramke, Jacqueline
AU  - Ramke J
AUID- ORCID: 0000-0002-5764-1306
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, United Kingdom.
AD  - School of Optometry and Vision Science, University of Auckland, Auckland, New
      Zealand.
FAU - Burton, Matthew J
AU  - Burton MJ
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, United Kingdom.
AD  - Moorfields Eye Hospital, London, United Kingdom.
FAU - Gordon, Iris
AU  - Gordon I
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, United Kingdom.
FAU - Zhang, Justine H
AU  - Zhang JH
AUID- ORCID: 0000-0001-8385-2003
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, United Kingdom.
AD  - Manchester Royal Eye Hospital, Manchester, United Kingdom.
FAU - Furtado, Joao M
AU  - Furtado JM
AD  - Division of Ophthalmology, Ribeirao Preto Medical School, University of Sao
      Paulo, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Mdala, Shaffi
AU  - Mdala S
AD  - Opthalmology Department, Queen Elizabeth Central Hospital, Blantyre, Malawi.
FAU - Kitema, Gatera Fiston
AU  - Kitema GF
AD  - Ophthalmology Department, School of Health Sciences, University of Rwanda,
      Kigali, Rwanda.
FAU - Keay, Lisa
AU  - Keay L
AD  - School of Optometry and Vision Science, Faculty of Science, University of New
      South Wales, Sydney, New South Wales, Australia l.keay@unsw.edu.au.
AD  - The George Institute for Global Health, Faculty of Medicine, The University of
      New South Wales, Sydney, New South Wales, Australia.
LA  - eng
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Accidents, Traffic/prevention & control
MH  - *Automobile Driving
MH  - Global Health
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
MH  - Vision, Ocular
PMC - PMC7646345
OTO - NOTNLM
OT  - *epidemiology
OT  - *ophthalmology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040881 [pii]
AID - 10.1136/bmjopen-2020-040881 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e040881. doi: 10.1136/bmjopen-2020-040881.


PMID- 33154058
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Rotator cuff-related shoulder pain: does the type of exercise influence the
      outcomes? Protocol of a randomised controlled trial.
PG  - e039976
LID - 10.1136/bmjopen-2020-039976 [doi]
AB  - INTRODUCTION: Lifetime prevalence of shoulder pain is 70%, and approximately 50% 
      of people with shoulder pain will experience pain for more than a year. Rotator
      cuff-related shoulder pain (RCRSP) is the most common shoulder condition and the 
      main non-surgical intervention is exercise therapy. For approximately 30% of
      people with RCRSP, this approach does not lead to a significant reduction in
      symptoms. This may be due to an inappropriate dosage or choice of exercises. The 
      aim of this investigation is to compare the short, mid and long-term effects, in 
      terms of symptoms, functional limitations, kinesiophobia and pain
      catastrophising, of three different shoulder rehabilitation approaches
      (education, strengthening, motor control) in adults with RCRSP. METHODS AND
      ANALYSIS: In this single-blind (assessor), parallel-group, randomised clinical
      trial, 123 adults presenting with RCRSP will take part in a 12-week
      rehabilitation programme. They will be randomly assigned to one of three groups
      (education only, strengthening approach or motor control-focused approach).
      Abbreviated version of the Disabilities of the Arm, Shoulder and Hand
      Questionnaire, the primary outcome, Western Ontario Rotator Cuff Index and Brief 
      Pain Inventory will evaluate symptoms and functional limitations, while Tampa
      Scale of Kinesiophobia and Pain Catastrophizing Scale will evaluate pain-related 
      fear and catastrophising at baseline and at 3, 6, 12 and 24 weeks.
      Ultrasonographic acromiohumeral distances and tendon thickness will be assessed
      at baseline and 12 weeks. Intervention groups will be compared on outcomes with
      intention-to-treat analyses using two-way repeated measures analysis of variance 
      if the data are normally distributed or non-parametric analysis of longitudinal
      data if they are not. ETHICS AND DISSEMINATION: Ethics approval was obtained from
      the Sectorial Rehabilitation and Social Integration Research Ethics Committee of 
      the Centre Integre Universitaire de Sante et de Services Sociaux de la Capitale
      Nationale (CIUSSS-CN). Results will be disseminated through international
      publications in peer-reviewed journals, in addition to international conference
      presentations. TRIAL REGISTRATION NUMBER: NCT03892603; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dube, Marc-Olivier
AU  - Dube MO
AUID- ORCID: 0000-0002-5676-2982
AD  - Department of Rehabilitation, Faculty of Medicine, Universite Laval, Quebec City,
      Quebec, Canada.
AD  - Center for Interdisciplinary Research in Rehabilitation and Social Integration,
      Quebec City, Quebec, Canada.
FAU - Desmeules, Francois
AU  - Desmeules F
AD  - School of Rehabilitation, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec, Canada.
AD  - Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada.
FAU - Lewis, Jeremy
AU  - Lewis J
AD  - School of Health and Social Work, University of Hertfordshire, Hatfield, UK.
AD  - Therapy Department, Central London Community Healthcare NHS Trust, London, UK.
AD  - Department of Physical Therapy & Rehabilitation Science, College of Health
      Sciences, Qatar University, Doha, Qatar.
FAU - Roy, Jean-Sebastien
AU  - Roy JS
AD  - Department of Rehabilitation, Faculty of Medicine, Universite Laval, Quebec City,
      Quebec, Canada jean-sebastien.roy@fmed.ulaval.ca.
AD  - Center for Interdisciplinary Research in Rehabilitation and Social Integration,
      Quebec City, Quebec, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03892603
GR  - CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Exercise Therapy
MH  - Humans
MH  - Ontario
MH  - Randomized Controlled Trials as Topic
MH  - *Rotator Cuff/diagnostic imaging
MH  - *Rotator Cuff Injuries/complications/therapy
MH  - Shoulder Pain/therapy
MH  - Single-Blind Method
PMC - PMC7646354
OTO - NOTNLM
OT  - *elbow & shoulder
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *shoulder
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039976 [pii]
AID - 10.1136/bmjopen-2020-039976 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e039976. doi: 10.1136/bmjopen-2020-039976.


PMID- 33154057
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Chemotherapy-based split stereotactic body radiation therapy for borderline
      resectable and locally advanced pancreatic cancer: study protocol of a
      prospective, single-arm phase II trial.
PG  - e039900
LID - 10.1136/bmjopen-2020-039900 [doi]
AB  - INTRODUCTION: The question of how to administer adequate chemotherapy to
      synchronise stereotactic body radiation therapy (SBRT) treatment strategy to
      maximise the benefits of neoadjuvant therapy for the improved prognosis of
      patients with borderline resectable (BRPC) and locally advanced (LAPC) pancreatic
      cancer is a challenging and debatable issue. No studies have yet evaluated the
      efficacy of split-course SBRT as the neoadjuvant chemoradiotherapy regimen. We
      aimed to study whether neoadjuvant chemotherapy plus split-course SBRT results in
      better outcomes in BRPC and LAPC patients. METHODS AND ANALYSIS: Treatment-naive 
      patients with radiographically confirmed BRPC or LAPC, supporting biopsy results 
      and no severe comorbidities will be enrolled. They will be treated with
      nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT, 
      followed by an investigator's choice of continuation of treatment with nab-P+Gem 
      or surgery. nab-P+Gem chemotherapy will commence on day 1 for each of six cycles:
      nab-paclitaxel 125 mg/m(2) intravenous infusion over approximately 30-45 min,
      followed by gemcitabine 1000 mg/m(2) intravenous infusion over about 30 min on
      days 1 and 15 of each 28-day cycle. During the first and second cycles of
      chemotherapy, SBRT will be given as a single irradiation of 10 Gy four times
      (days 2 and 16 of each 28-day cycle). The primary endpoint is progression-free
      survival; while the secondary outcomes are the time to treatment failure, disease
      control rate, overall response rate, overall survival, R0 resection rate and
      incidence of adverse effects. ETHICS AND DISSEMINATION: The study protocol was
      approved by the Ethics Committee of Xiehe Affiliated Hospital of Fujian Medical
      University (No. 2019YF015-01). Results from our study will be disseminated in
      international peer-reviewed journals. All study procedures were developed in
      order to assure data protection and confidentiality. TRIAL REGISTRATION NUMBER:
      NCT04289792.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zheng, Rong
AU  - Zheng R
AUID- ORCID: 0000-0002-9605-450X
AD  - Department of Radiation Oncology, Fujian Medical University Union Hospital,
      Fuzhou, Fujian, China.
FAU - Wang, Congfei
AU  - Wang C
AD  - Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Huang, Xiaoxue
AU  - Huang X
AD  - Department of Radiation Oncology, Fujian Medical University Union Hospital,
      Fuzhou, Fujian, China.
FAU - Lin, Qingliang
AU  - Lin Q
AD  - Department of Radiation Oncology, Fujian Medical University Union Hospital,
      Fuzhou, Fujian, China.
FAU - Huang, Daxin
AU  - Huang D
AD  - Department of Radiation Oncology, Fujian Medical University Union Hospital,
      Fuzhou, Fujian, China.
FAU - Li, Xiao-Bo
AU  - Li XB
AD  - Department of Radiation Oncology, Fujian Medical University Union Hospital,
      Fuzhou, Fujian, China.
FAU - Huang, Heguang
AU  - Huang H
AD  - Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China benhuaxu@163.com hhuang2@aliyun.com.
FAU - Xu, Benhua
AU  - Xu B
AUID- ORCID: 0000-0003-1397-6195
AD  - Department of Radiation Oncology, Fujian Medical University Union Hospital,
      Fuzhou, Fujian, China benhuaxu@163.com hhuang2@aliyun.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04289792
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - *Pancreatic Neoplasms/drug therapy
MH  - Prospective Studies
MH  - *Radiosurgery
PMC - PMC7646341
OTO - NOTNLM
OT  - *chemotherapy
OT  - *pancreatic disease
OT  - *radiation oncology
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039900 [pii]
AID - 10.1136/bmjopen-2020-039900 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e039900. doi: 10.1136/bmjopen-2020-039900.


PMID- 33154056
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Expanding the upper age limit for cervical cancer screening: a protocol for a
      nationwide non-randomised intervention study.
PG  - e039636
LID - 10.1136/bmjopen-2020-039636 [doi]
AB  - INTRODUCTION: Cervical cancer screening ceases between the ages of 60 and 65 in
      most countries. Yet, a relatively high proportion of cervical cancers are
      diagnosed in women above the screening age. This study will evaluate if screening
      of women aged 65-69 years may result in increased detection of cervical
      intraepithelial neoplasia grade 2 or worse (CIN2+) compared with women not
      invited to screening. Invited women may choose between general practitioner
      (GP)-based screening or cervico-vaginal self-sampling. Furthermore, the study
      will assess if self-sampling is superior to GP-based screening in reaching
      long-term unscreened women. METHODS AND ANALYSIS: This population-based
      non-randomised intervention study will include 10 000 women aged 65-69 years,
      with no record of a cervical cytology sample or screening invitation in the 5
      years before inclusion. Women who have opted-out of the screening programme or
      have a record of hysterectomy or cervical amputation are excluded. Women residing
      in the Central Denmark Region (CDR) are allocated to the intervention group,
      while women residing in the remaining four Danish regions are allocated to the
      reference group. The intervention group is invited for human papillomavirus-based
      screening by attending routine screening at the GP or by requesting a
      self-sampling kit. The reference group receives standard care which is the
      opportunity to have a cervical cytology sample obtained at the GP or by a
      gynaecologist. The study started in April 2019 and will run over the next 4.5
      years. The primary outcome will be the proportion of CIN2+ detected in the
      intervention and reference groups. In the intervention group, the proportion of
      long-term unscreened women attending GP-based screening or self-sampling will be 
      compared. ETHICS AND DISSEMINATION: The study has been submitted to the Ethical
      Committee in the CDR which deemed that the study was not notifiable to the
      Committee and informed consent is therefore not required. The study is approved
      by the Danish Data Protection Regulation and the Danish Patient Safety Authority.
      Results will be disseminated in peer-reviewed journals. TRIAL REGISTRATION
      NUMBER: NCT04114968.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tranberg, Mette
AU  - Tranberg M
AUID- ORCID: 0000-0002-6285-6694
AD  - Department of Public Health Programmes, Randers Regional Hospital, Randers,
      Denmark mettrani@rm.dk.
FAU - Petersen, Lone Kjeld
AU  - Petersen LK
AD  - Department of Obstetrics and Gynecology, Odense University Hospital, Odense,
      Denmark.
AD  - OPEN, Department of Clinical Medicine, University of Southern Denmark, Odense,
      Denmark.
FAU - Elfstrom, Klara Miriam
AU  - Elfstrom KM
AD  - Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
AD  - Regional Cancer Center of Stockholm-Gotland, Stockholm, Sweden.
FAU - Hammer, Anne
AU  - Hammer A
AD  - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
AD  - Department of Obstetrics and Gynecology, Regionshospitalet Herning, Herning,
      Denmark.
FAU - Blaakaer, Jan
AU  - Blaakaer J
AD  - Department of Obstetrics and Gynecology, Odense University Hospital, Odense,
      Denmark.
AD  - OPEN, Department of Clinical Medicine, University of Southern Denmark, Odense,
      Denmark.
FAU - Bennetsen, Mary Holten
AU  - Bennetsen MH
AD  - Department of Pathology, Regional Hospital Randers, Randers, Denmark.
FAU - Jensen, Jorgen Skov
AU  - Jensen JS
AUID- ORCID: 0000-0002-7464-7435
AD  - Research Unit for Reproductive Microbiology, Statens Serum Institut, Copenhagen, 
      Denmark.
FAU - Andersen, Berit
AU  - Andersen B
AD  - Department of Public Health Programmes, Randers Regional Hospital, Randers,
      Denmark.
AD  - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04114968
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Cervical Intraepithelial Neoplasia/diagnosis
MH  - Clinical Trials as Topic
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Mass Screening
MH  - Papillomaviridae
MH  - Papillomavirus Infections/diagnosis
MH  - *Uterine Cervical Neoplasms/diagnosis
MH  - Vaginal Smears
PMC - PMC7646343
OTO - NOTNLM
OT  - *cytopathology
OT  - *epidemiology
OT  - *gynaecology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: Roche sponsors the Cobas HPV-DNA test kits and CINtec Plus
      test kits for the study. According to the contract between Roche and the
      Department of Public Health Programmes, Randers Regional Hospital, Roche has
      commented on the protocol article, but had no influence on the scientific process
      and no editorial rights pertaining to this manuscript. The authors retained the
      right to submit the manuscript. MT, JB, JSJ and BA have participated in other
      studies with HPV test kits sponsored by Roche and self-sampling devices sponsored
      by Axlab. MT has received honoraria from Roche Diagnostics and AstraZeneca for
      lectures on HPV self-sampling and HPV triage-methods, respectively. AH has
      received lecture fees from AstraZeneca. All authors declare no conflicts of
      interest.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - bmjopen-2020-039636 [pii]
AID - 10.1136/bmjopen-2020-039636 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e039636. doi: 10.1136/bmjopen-2020-039636.


PMID- 33154055
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Protocol for development and validation of a clinical prediction model for
      adverse pregnancy outcomes in women with gestational diabetes.
PG  - e038845
LID - 10.1136/bmjopen-2020-038845 [doi]
AB  - INTRODUCTION: Gestational diabetes (GDM) is a common yet highly heterogeneous
      condition. The ability to calculate the absolute risk of adverse pregnancy
      outcomes for an individual woman with GDM would allow preventative and
      therapeutic interventions to be delivered to women at high-risk, sparing women at
      low-risk from unnecessary care. The Prediction for Risk-Stratified care for women
      with GDM (PeRSonal GDM) study will develop, validate and evaluate the clinical
      utility of a prediction model for adverse pregnancy outcomes in women with GDM.
      METHODS AND ANALYSIS: We undertook formative research to conceptualise and design
      the prediction model. Informed by these findings, we will conduct a model
      development and validation study using a retrospective cohort design with
      participant data collected as part of routine clinical care across three
      hospitals. The study will include all pregnancies resulting in births from 1 July
      2017 to 31 December 2018 coded for a diagnosis of GDM (estimated sample size 2430
      pregnancies). We will use a temporal split-sample development and validation
      strategy. A multivariable logistic regression model will be fitted. The
      performance of this model will be assessed, and the validated model will also be 
      evaluated using decision curve analysis. Finally, we will explore modes of model 
      presentation suited to clinical use, including electronic risk calculators.
      ETHICS AND DISSEMINATION: This study was approved by the Human Research Ethics
      Committee of Monash Health (RES-19-0000713 L). We will disseminate results via
      presentations at scientific meetings and publication in peer-reviewed journals.
      TRIAL REGISTRATION DETAILS: Systematic review proceeding this work was registered
      on PROSPERO (CRD42019115223) and the study was registered on the Australian and
      New Zealand Clinical Trials Registry (ACTRN12620000915954); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cooray, Shamil D
AU  - Cooray SD
AUID- ORCID: 0000-0002-6825-4440
AD  - Monash Centre for Health Research and Implementation, School of Public Health and
      Preventative Medicine, Monash University, Clayton, Victoria, Australia.
AD  - Diabetes Unit, Monash Health, Clayton, Victoria, Australia.
FAU - Boyle, Jacqueline A
AU  - Boyle JA
AUID- ORCID: 0000-0002-3616-1637
AD  - Monash Centre for Health Research and Implementation, School of Public Health and
      Preventative Medicine, Monash University, Clayton, Victoria, Australia.
AD  - Monash Women's Program, Monash Health, Clayton, Victoria, Australia.
FAU - Soldatos, Georgia
AU  - Soldatos G
AD  - Monash Centre for Health Research and Implementation, School of Public Health and
      Preventative Medicine, Monash University, Clayton, Victoria, Australia.
AD  - Diabetes and Endocrinology Units, Monash Health, Clayton, Victoria, Australia.
FAU - Zamora, Javier
AU  - Zamora J
AUID- ORCID: 0000-0003-4901-588X
AD  - CIBER Epidemiology and Public Health, Madrid, Comunidad de Madrid, Spain.
AD  - Clinical Biostatistics Unit, Hospital Ramon y Cajal, Madrid, Madrid, Spain.
FAU - Fernandez Felix, Borja M
AU  - Fernandez Felix BM
AUID- ORCID: 0000-0002-8798-019X
AD  - CIBER Epidemiology and Public Health, Madrid, Comunidad de Madrid, Spain.
AD  - Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, Madrid,
      Madrid, Spain.
FAU - Allotey, John
AU  - Allotey J
AUID- ORCID: 0000-0003-4134-6246
AD  - WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and
      Systems Research, University of Birmingham, Birmingham, Birmingham, UK.
FAU - Thangaratinam, Shakila
AU  - Thangaratinam S
AUID- ORCID: 0000-0002-4254-460X
AD  - WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and
      Systems Research, University of Birmingham, Birmingham, Birmingham, UK.
FAU - Teede, Helena J
AU  - Teede HJ
AUID- ORCID: 0000-0001-7609-577X
AD  - Monash Centre for Health Research and Implementation, School of Public Health and
      Preventative Medicine, Monash University, Clayton, Victoria, Australia
      Helena.Teede@monash.edu.
AD  - Diabetes and Endocrinology Units, Monash Health, Clayton, Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12620000915954
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Diabetes, Gestational/diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - New Zealand
MH  - Pregnancy
MH  - Pregnancy Outcome/epidemiology
MH  - Retrospective Studies
PMC - PMC7646337
OTO - NOTNLM
OT  - *diabetes in pregnancy
OT  - *obstetrics
OT  - *public health
COIS- Competing interests: SDC reports grants from the National Health and Medical
      Research Council (NHMRC), Diabetes Australia, the Australian Academy of Science
      and the Australian Government Department of Education and Training during the
      conduct of the study; JB reports grants from the NHMRC during the conduct of the 
      study; BFF reports grants from CIBER (Biomedical Research Network in Epidemiology
      and Public Health, Madrid, Spain) during the conduct of the study and HJT reports
      grants from the NHMRC and the Medical Research Future Fund during the conduct of 
      the study; no other relationships or activities that could appear to have
      influenced the submitted work.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - bmjopen-2020-038845 [pii]
AID - 10.1136/bmjopen-2020-038845 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e038845. doi: 10.1136/bmjopen-2020-038845.


PMID- 33154053
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Evaluating the intended and unintended consequences of opioid-prescribing
      interventions on primary care in British Columbia, Canada: protocol for a
      retrospective population-based cohort study.
PG  - e038724
LID - 10.1136/bmjopen-2020-038724 [doi]
AB  - INTRODUCTION: Between 2015 and 2018, there were over 40 000 opioid-related
      overdose events and 4551 deaths among residents in British Columbia (BC). During 
      this time the province mobilised a variety of policy levers to encourage
      physicians to expand access to opioid agonist treatment and the College of
      Physicians and Surgeons of British Columbia (CPSBC) released a practice standard 
      establishing legally enforceable minimum thresholds of professional behaviour in 
      the hopes of curtailing overdose events. Our goal is to conduct a comprehensive
      investigation of the intended and unintended consequences of these policy
      changes. Specifically, we aim to understand the effects of these measures on
      physician prescribing behaviours, identify physician characteristics associated
      with uptake of the new measures, and measure the effects of the policy changes on
      patients' access to quality primary care. METHODS AND ANALYSIS: This is a
      population-level, retrospective cohort study of all BC primary care physicians
      who prescribed any opioid medication for opioid-use disorder or chronic
      non-cancer pain during the study period, and their patients. The study period is 
      1 January 2013-31 December 2018, with a 1-year wash-in period (1 January 2012-31 
      December 2012) to exclude patients who initiated long-term opioid treatment prior
      to our study period or whose pain type (ie, 'chronic non-cancer', 'acute',
      'cancer or palliative', or 'other') cannot be confirmed. The project combines
      five administrative health datasets under the authority of the BC Ministry of
      Health, with the CPSBC's Physician Registry, BC Cancer Agency's Cancer Registry
      and Vital Statistics' Mortality data. We will create measures of prescribing
      concordance, access, continuity, and comprehensiveness to assess primary care
      delivery and quality at both the physician and patient level. We will use
      generalised estimating equations, interrupted time series, mixed effects models, 
      and funnel plots to identify factors related to changes in prescribing and
      evaluate the impact of the changes to prescribing policies. Results will be
      reported using appropriate Enhancing the QUAlity and Transparency Of health
      Research guidelines (eg, STrengthening the Reporting of OBservational studies in 
      Epidemiology). ETHICS AND DISSEMINATION: This study has been approved by McGill
      University's Institutional Review Board (#A11-M55-19A), and the University of
      British Columbia's Research Ethics Board (#H19-03537). We will disseminate
      results via a combination of open access peer-reviewed journal publications,
      conferences, lay summaries and OpEds.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Panagiotoglou, Dimitra
AU  - Panagiotoglou D
AUID- ORCID: 0000-0002-6175-3634
AD  - Department of Epidemiology, Biostatistics and Occupational Health, McGill
      University, Montreal, Quebec, Canada dimitra.panagiotoglou@mcgill.ca.
FAU - McCracken, Rita
AU  - McCracken R
AUID- ORCID: 0000-0002-2962-0364
AD  - Department of Family Practice, University of British Columbia Faculty of
      Medicine, Vancouver, British Columbia, Canada.
FAU - Lavergne, M Ruth
AU  - Lavergne MR
AUID- ORCID: 0000-0002-4205-4600
AD  - Centre for Applied Research in Mental Health and Addiction, Simon Fraser
      University, Burnaby, British Columbia, Canada.
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia,
      Canada.
FAU - Strumpf, Erin C
AU  - Strumpf EC
AD  - Department of Epidemiology, Biostatistics and Occupational Health, McGill
      University, Montreal, Quebec, Canada.
AD  - Department of Economics, McGill University, Montreal, Quebec, Canada.
FAU - Gomes, Tara
AU  - Gomes T
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - Institute for Clinical Evaluative Sciences, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Fischer, Benedikt
AU  - Fischer B
AD  - Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New
      Zealand.
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental,
      University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Brackett, Austyn
AU  - Brackett A
AD  - Patient Voices Network, Vancouver, British Columbia, Canada.
FAU - Johnson, Cheyenne
AU  - Johnson C
AD  - British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
AD  - School of Nursing, University of British Columbia, Vancouver, British Columbia,
      Canada.
FAU - Kendall, Perry
AU  - Kendall P
AD  - British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/therapeutic use
MH  - British Columbia
MH  - Chronic Pain
MH  - Humans
MH  - Practice Patterns, Physicians'
MH  - *Primary Health Care
MH  - Retrospective Studies
PMC - PMC7646336
OTO - NOTNLM
OT  - *health policy
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - bmjopen-2020-038724 [pii]
AID - 10.1136/bmjopen-2020-038724 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e038724. doi: 10.1136/bmjopen-2020-038724.


PMID- 33154049
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Respiratory function and respiratory complications in spinal cord injury:
      protocol for a prospective, multicentre cohort study in high-income countries.
PG  - e038204
LID - 10.1136/bmjopen-2020-038204 [doi]
AB  - INTRODUCTION: Pneumonia is one of the leading complications and causes of death
      after a spinal cord injury (SCI). After a cervical or thoracic lesion, impairment
      of the respiratory muscles decreases respiratory function, which increases the
      risk of respiratory complications. Pneumonia substantially reduces patient's
      quality of life, may prolong inpatient rehabilitation time, increase healthcare
      costs or at worse, lead to early death. Respiratory function and coughing can be 
      improved through various interventions after SCI, but the available evidence as
      to which aspect of respiratory care should be optimised is inconclusive.
      Furthermore, ability of respiratory function parameters to predict pneumonia risk
      is insufficiently established. This paper details the protocol for a large-scale,
      multicentre research project that aims to evaluate the ability of parameters of
      respiratory function to predict and understand variation in inpatient risk of
      pneumonia in SCI. METHODS AND ANALYSIS: RESCOM, a prospective cohort study, began
      recruitment in October 2016 across 10 SCI rehabilitation centres from Australia, 
      Austria, Germany, the Netherlands and Switzerland. Inpatients with acute SCI,
      with complete or incomplete cervical or thoracic lesions, 18 years or older and
      not/no more dependent on 24-hour mechanical ventilation within the first 3 months
      after injury are eligible for inclusion. The target sample size is 500
      participants. The primary outcome is an occurrence of pneumonia; secondary
      outcomes include pneumonia-related mortality and quality of life. We will use the
      longitudinal data for prognostic models on inpatient pneumonia risk factors.
      ETHICS AND DISSEMINATION: The study has been reviewed and approved by all local
      ethics committees of all participating centres. Study results will be
      disseminated to the scientific community through peer-reviewed journals and
      conference presentations, to the SCI community, other stakeholders and via social
      media, newsletters and engagement activities. TRIAL REGISTRATION DETAILS:
      ClinicalTrials.gov NCT02891096.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Raab, Anja M
AU  - Raab AM
AUID- ORCID: 0000-0002-4139-2173
AD  - Clinical Trial Unit, Swiss Paraplegic Center, Nottwil, Switzerland.
FAU - Brinkhof, Martin W G
AU  - Brinkhof MWG
AUID- ORCID: 0000-0002-9319-665X
AD  - Life Course Epidemiology Group, Swiss Paraplegic Research, Nottwil, Switzerland.
FAU - Berlowitz, David J
AU  - Berlowitz DJ
AUID- ORCID: 0000-0003-2543-8722
AD  - Department of Respiratory and Sleep Medicine, Institute for Breathing and Sleep, 
      Heidelberg, Victoria, Australia.
AD  - Department of Physiotherapy, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Postma, Karin
AU  - Postma K
AUID- ORCID: 0000-0002-0729-6778
AD  - Department of Rehabilitation Medicine, Rijndam Rehabilitation and Erasmus MC,
      University Medical Center Rotterdam, Rotterdam, The Netherlands.
FAU - Gobets, David
AU  - Gobets D
AUID- ORCID: 0000-0003-0270-5672
AD  - Department of Rehabilitation Medicine, Heliomare Rehabilitation Center, Wijk aan 
      Zee, The Netherlands.
FAU - Hirschfeld, Sven
AU  - Hirschfeld S
AD  - Department of Spinal Cord Medicine, BG Trauma Hospital, Hamburg, Germany.
FAU - Hopman, Maria T E
AU  - Hopman MTE
AUID- ORCID: 0000-0001-9504-5452
AD  - Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 
      The Netherlands.
FAU - Huber, Burkhart
AU  - Huber B
AD  - Trauma Surgery, AUVA Rehabilitation Center Haring, Bad Haring, Austria.
FAU - Hund-Georgiadis, Margret
AU  - Hund-Georgiadis M
AUID- ORCID: 0000-0002-4415-2888
AD  - Clinic for neurorehabilitation and paraplegiology, REHAB Basel, Basel,
      Switzerland.
FAU - Jordan, Xavier
AU  - Jordan X
AUID- ORCID: 0000-0003-3389-0057
AD  - Spinal Cord Unit, Clinique romande de readaptation, Sion, Switzerland.
FAU - Schubert, Martin
AU  - Schubert M
AD  - Spinal Cord Injury Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Wildburger, Renate
AU  - Wildburger R
AUID- ORCID: 0000-0001-9820-3823
AD  - Allgemeine Unfallversicherungsanstalt, AUVA Rehabilitation Clinic Tobelbad,
      Tobelbad, Austria.
FAU - Mueller, Gabi
AU  - Mueller G
AUID- ORCID: 0000-0001-6391-3737
AD  - Clinical Trial Unit, Swiss Paraplegic Center, Nottwil, Switzerland
      gabi.mueller@paraplegie.ch.
LA  - eng
SI  - ClinicalTrials.gov/NCT02891096
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - COVID-19
MH  - Developed Countries
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - *Spinal Cord Injuries/complications/epidemiology
PMC - PMC7646333
OTO - NOTNLM
OT  - *epidemiology
OT  - *rehabilitation medicine
OT  - *respiratory infections
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - bmjopen-2020-038204 [pii]
AID - 10.1136/bmjopen-2020-038204 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e038204. doi: 10.1136/bmjopen-2020-038204.


PMID- 33154047
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic
      recurrence in resected stage III melanoma: study protocol.
PG  - e037857
LID - 10.1136/bmjopen-2020-037857 [doi]
AB  - INTRODUCTION: In the new era of effective systemic therapies for advanced
      melanoma, early detection of lower volume recurrent disease using surveillance
      imaging can improve survival. However, intensive imaging follow-up strategies are
      likely to increase costs to health systems and may pose risks to patients. The
      objective of this study is to estimate from the Australian health system
      perspective the cost-effectiveness of four follow-up strategies in resected stage
      III melanoma over a 5-year period following surgical treatment with curative
      intent. METHODS AND ANALYSIS: A decision-analytic model will be built to estimate
      the costs and benefits of (1) 12 monthly, (2) 6 monthly, (3) 3-4 monthly positron
      emission tomography/CT imaging for 5 years, compared with (4) no imaging
      follow-up. The model will be populated with probabilities of disease recurrence, 
      test performance measures using data from >1000 consecutive resected stage III
      melanoma patients from Melanoma Institute Australia diagnosed between 2000 and
      2017. Healthcare resource use, including surveillance imaging, doctor's visits,
      subsequent tests and procedures to investigate suspicious findings, will be
      quantified from detailed patient records and valued using Australian reference
      pricing. Economic outcomes include cost per new distant melanoma recurrence
      detected and cost per diagnostic error avoided, for no imaging compared with the 
      other strategies.Deterministic sensitivity analyses will examine the robustness
      of model results. ETHICS AND DISSEMINATION: This study was approved by the Sydney
      Local Health District, Sydney Local Health District Ethics Review Committee (RPAH
      Zone), AU/1/830638 and the Australian Institute of Health and Welfare
      (EO2019-1-454). The results of this study will be published in peer-reviewed
      medical and health economics journals and will inform melanoma management
      guidelines.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dieng, Mbathio
AU  - Dieng M
AD  - NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of
      Sydney, Camperdown, New South Wales, Australia mbathio.dieng@sydney.edu.au.
FAU - Khanna, Nikita
AU  - Khanna N
AUID- ORCID: 0000-0002-4052-3610
AD  - NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of
      Sydney, Camperdown, New South Wales, Australia.
FAU - Nguyen, Mai Thi Hoang
AU  - Nguyen MTH
AD  - NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of
      Sydney, Camperdown, New South Wales, Australia.
FAU - Turner, Robin
AU  - Turner R
AD  - Biostatistics, University of Otago Dunedin School of Medicine, Dunedin, New
      Zealand.
FAU - Lord, Sarah J
AU  - Lord SJ
AD  - NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of
      Sydney, Camperdown, New South Wales, Australia.
FAU - Menzies, Alexander M
AU  - Menzies AM
AD  - Melanoma Institute Australia, The University of Sydney, North Sydney, New South
      Wales, Australia.
AD  - Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney,
      New South Wales, Australia.
FAU - Allen, Jay
AU  - Allen J
AD  - Melanoma Institute Australia, The University of Sydney, North Sydney, New South
      Wales, Australia.
FAU - Saw, Robyn
AU  - Saw R
AD  - Melanoma Institute Australia, The University of Sydney, North Sydney, New South
      Wales, Australia.
FAU - Nieweg, Omgo E
AU  - Nieweg OE
AD  - Melanoma Institute Australia, The University of Sydney, North Sydney, New South
      Wales, Australia.
AD  - Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital,
      Sydney, New South Wales, Australia.
FAU - Thompson, John
AU  - Thompson J
AD  - Surgical Oncology, Melanoma Institute of Australia, North Sydney, New South
      Wales, Australia.
AD  - Sydney Medical School, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Morton, Rachael L
AU  - Morton RL
AUID- ORCID: 0000-0001-7834-0572
AD  - NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of
      Sydney, Camperdown, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - *Melanoma/diagnostic imaging/surgery
MH  - Neoplasm Recurrence, Local/diagnostic imaging
MH  - Neoplasm Staging
MH  - *Positron Emission Tomography Computed Tomography
MH  - Recurrence
PMC - PMC7646332
OTO - NOTNLM
OT  - *health economics
OT  - *oncology
OT  - *radiology & imaging
OT  - *risk management
COIS- Competing interests: RS received honoraria from Novartis and MSD for an advisory 
      capacity.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - bmjopen-2020-037857 [pii]
AID - 10.1136/bmjopen-2020-037857 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e037857. doi: 10.1136/bmjopen-2020-037857.


PMID- 33154043
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 5
TI  - Psychotherapy versus treatment as usual and other control interventions in
      children and adolescents with overweight and obesity: a protocol for systematic
      review with meta-analysis and Trial Sequential Analysis.
PG  - e036058
LID - 10.1136/bmjopen-2019-036058 [doi]
AB  - INTRODUCTION: The prevalence of children with overweight and obesity is
      increasing worldwide. Multicomponent interventions incorporating diet, physical
      activity and behavioural change have shown limited improvement to body mass index
      (BMI). However, the impact of psychotherapy is poorly explored. This systematic
      review aims to assess the effects of psychotherapeutic approaches for children
      with all degrees of overweight. METHODS AND ANALYSIS: We will include randomised 
      clinical trials involving children and adolescents between 0 and 18 years with
      overweight and obesity, irrespective of publication type, year, status or
      language up to April 2020. Psychotherapy will be compared with no intervention;
      wait list control; treatment as usual; sham psychotherapy or pharmaceutical
      placebo. The following databases will be searched: Cochrane Central Register of
      Controlled Trials, Cochrane Database of Systematic Reviews, MEDLINE, Embase,
      PsycINFO, PubMed, Web of Science, CINAHL and LILACS. Primary outcomes will be BMI
      z-score, quality of life measured by a validated scale and proportion of patients
      with serious adverse events. Secondary outcomes will be body weight, self-esteem,
      anxiety, depression and proportion of patients with non-serious adverse events.
      Exploratory outcomes will be body fat, muscle mass and serious adverse events.
      Study inclusion, data extraction and bias risk assessments will be conducted
      independently by at least two authors. We will assess risk of bias according to
      Cochrane guidelines and the Cochrane Effective Practice and Organisation of Care 
      guidance. We will use meta-analysis and control risks of random errors with Trial
      Sequential Analysis. The quality of the evidence will be assessed using Grading
      of Recommendations Assessment, Development and Evaluation Tool. The systematic
      review will be reported according to Preferred Reporting Items for Systematic
      Reviews and Meta-Analyses and Cochrane guidelines. ETHICS AND DISSEMINATION: As
      individual patient data will not be included, we do not require ethics approval. 
      This review will be published in a peer review journal. PROSPERO REGISTRATION
      NUMBER: CRD42018086458.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rashid, Rajeeb
AU  - Rashid R
AUID- ORCID: 0000-0003-3765-1213
AD  - Child Life and Health, University of Edinburgh, Edinburgh, UK
      rajeeb.rashid@nhslothian.scot.nhs.uk.
FAU - Condon, Laura
AU  - Condon L
AD  - School of Medicine, University of Nottingham, Nottingham, UK.
FAU - Gluud, Christian
AU  - Gluud C
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Jakobsen, Janus C
AU  - Jakobsen JC
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
AD  - Department of Cardiology, Holbaek Sygehus, Holbaek, Sjaelland, Denmark.
FAU - Lindschou, Jane
AU  - Lindschou J
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Lissau, Inge
AU  - Lissau I
AUID- ORCID: 0000-0002-2225-9975
AD  - Clinical Research Centre, University Hospital Copenhagen, Copenhagen, Hvidovre,
      Denmark.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201105
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Body Mass Index
MH  - Child
MH  - Humans
MH  - *Overweight/therapy
MH  - *Pediatric Obesity/therapy
MH  - Psychotherapy
MH  - *Quality of Life
PMC - PMC7646330
OTO - NOTNLM
OT  - *adolescents
OT  - *children
OT  - *intervention
OT  - *obesity
OT  - *overweight
OT  - *psychotherapy
OT  - *randomised control trial
OT  - *treatment
COIS- Competing interests: None declared.
EDAT- 2020/11/07 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/11/06 05:51
PHST- 2020/11/06 05:51 [entrez]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - bmjopen-2019-036058 [pii]
AID - 10.1136/bmjopen-2019-036058 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 5;10(11):e036058. doi: 10.1136/bmjopen-2019-036058.


PMID- 33153874
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210911
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 265
DP  - 2020 Nov
TI  - The Amish health culture and culturally sensitive health services: An exhaustive 
      narrative review.
PG  - 113466
LID - S0277-9536(20)30685-7 [pii]
LID - 10.1016/j.socscimed.2020.113466 [doi]
AB  - As the Amish population is growing, researcher and practitioner interest in the
      Amish health culture is also growing. This is largely due to demand from
      practitioners for population-specific cultural guidance. Once a small area of
      study, health-themed publications in Amish studies (n = 246) now account for
      approximately one-fourth of all peer-reviewed publications, and a sizeable
      percentage address the health culture, i.e. Amish beliefs, practices, attitudes, 
      decision-making processes, financing, and values. In this article, we provide a
      first-ever exhaustive narrative review of the Amish health culture literature
      (addressing Amish health conditions elsewhere). Specifically, we address Amish
      use of modern medicine, complementary & alternative medicine, cultural norms for 
      birthing and intercourse, support and care for the sick and aged, health
      knowledge, payment for services, barriers to service access, service provider
      effectiveness, health programming, and ethical conflicts. Our goal is to organize
      the literature, synthesize findings, identify orienting perspectives, and clarify
      research questions and directions. Following our synthesis, we reflect on the
      current state of Amish health culture research, drawing particular attention to
      strengths and limitations of the oft-used cultural competency paradigm, and
      recommending more rigorous social scientific theorization of the Amish health
      culture.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Anderson, Cory
AU  - Anderson C
AD  - Population Research Institute, Pennsylvania State University, State College, PA, 
      717-330-1766, USA. Electronic address: dranderson@amishstudies.org.
FAU - Potts, Lindsey
AU  - Potts L
AD  - Truman State University, 100 E. Normal Ave, Kirksville, MO, 63501, USA.
LA  - eng
GR  - P2C HD041025/HD/NICHD NIH HHS/United States
GR  - T32 HD007514/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201021
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Aged
MH  - *Amish
MH  - *Complementary Therapies
MH  - Cultural Competency
MH  - Culture
MH  - Health Services
MH  - Humans
PMC - PMC8431948
MID - NIHMS1720770
OTO - NOTNLM
OT  - *Complementary and alternative health
OT  - *Cultural competency
OT  - *Ethics
OT  - *Ethnicity and health
OT  - *Plain Anabaptist
OT  - *Religion and health
EDAT- 2020/11/07 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/11/06 05:43
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/10/18 00:00 [accepted]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/11/06 05:43 [entrez]
AID - S0277-9536(20)30685-7 [pii]
AID - 10.1016/j.socscimed.2020.113466 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Nov;265:113466. doi: 10.1016/j.socscimed.2020.113466. Epub 2020
      Oct 21.


PMID- 33152653
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20210127
IS  - 1872-8243 (Electronic)
IS  - 1386-5056 (Linking)
VI  - 143
DP  - 2020 Nov
TI  - REVISITING HEALTH INFORMATION TECHNOLOGY ETHICAL, LEGAL, and SOCIAL ISSUES and
      EVALUATION: TELEHEALTH/TELEMEDICINE and COVID-19.
PG  - 104239
LID - S1386-5056(20)30938-2 [pii]
LID - 10.1016/j.ijmedinf.2020.104239 [doi]
AB  - BACKGROUND: Information technologies have been vital during the COVID-19
      pandemic. Telehealth and telemedicine services, especially, fulfilled their
      promise by allowing patients to receive advice and care at a distance, making it 
      safer for all concerned. Over the preceding years, professional societies,
      governments, and scholars examined ethical, legal, and social issues (ELSI)
      related to telemedicine and telehealth. Primary concerns evident from reviewing
      this literature have been quality of care, access, consent, and privacy.
      OBJECTIVES: To identify and summarize ethical, legal, and social issues related
      to information technology in healthcare, as exemplified by telehealth and
      telemedicine. To expand on prior analyses and address gaps illuminated by the
      COVID-19 experience. To propose future research directions. METHODS: Literature
      was identified through searches, forward and backward citation chaining, and the 
      author's knowledge of scholars and works in the area. EU and professional
      organizations' guidelines, and nineteen scholarly papers were examined and
      categories created to identify ethical, legal, and social issues they addressed. 
      A synthesis matrix was developed to categorize issues addressed by each source.
      RESULTS: A synthesis matrix was developed and issues categorized as: quality of
      care, consent and autonomy, access to care and technology, legal and regulatory, 
      clinician responsibilities, patient responsibilities, changed relationships,
      commercialization, policy, information needs, and evaluation, with subcategories 
      that fleshed out each category. The literature primarily addressed quality of
      care, access, consent, and privacy. Other identified considerations were little
      discussed. These and newer concerns include: usability, tailoring services to
      each patient, curriculum and training, implementation, commercialization, and
      licensing and liability. The need for interoperability, data availability,
      cybersecurity, and informatics infrastructure also is more apparent. These issues
      are applicable to other information technologies in healthcare. CONCLUSIONS:
      Clinicians and organizations need updated guidelines for ethical use of
      telemedicine and telehealth care, and decision- and policy-makers need evidence
      to inform decisions. The variety of newly implemented telemedicine services is an
      on-going natural experiment presenting an unparalleled opportunity to develop an 
      evidence-based way forward. The paper recommends evaluation using an applied
      ethics, context-sensitive approach that explores interactions among multiple
      factors and considerations. It suggests evaluation questions to investigate
      ethical, social, and legal issues through multi-method, sociotechnical,
      interpretive and ethnographic, and interactionist evaluation approaches. Such
      evaluation can help telehealth, and other information technologies, be integrated
      into healthcare ethically and effectively.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Kaplan, Bonnie
AU  - Kaplan B
AD  - Yale Center for Medical Informatics, Yale Interdisciplinary Center for Bioethics,
      Yale Information Society Project, Yale Solomon Center for Health Law and Policy, 
      Yale University, 238 Prospect St, New Haven, CT 06511, USA. Electronic address:
      Bonnie.Kaplan@yale.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200731
PL  - Ireland
TA  - Int J Med Inform
JT  - International journal of medical informatics
JID - 9711057
SB  - IM
MH  - *COVID-19
MH  - Computer Security
MH  - Delivery of Health Care/methods
MH  - Humans
MH  - Medical Informatics/*ethics/*legislation & jurisprudence
MH  - Pandemics
MH  - Privacy
MH  - SARS-CoV-2
MH  - Telemedicine/*ethics/*legislation & jurisprudence
PMC - PMC7831568
OTO - NOTNLM
OT  - *Ethics
OT  - *Evaluation
OT  - *Health information technology
OT  - *Telehealth
OT  - *Telemedicine
OT  - *eHealth
EDAT- 2020/11/06 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/11/05 20:18
PHST- 2020/06/16 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/11/05 20:18 [entrez]
AID - S1386-5056(20)30938-2 [pii]
AID - 10.1016/j.ijmedinf.2020.104239 [doi]
PST - ppublish
SO  - Int J Med Inform. 2020 Nov;143:104239. doi: 10.1016/j.ijmedinf.2020.104239. Epub 
      2020 Jul 31.


PMID- 33152202
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 2590-7379 (Electronic)
IS  - 0120-4157 (Linking)
VI  - 40
IP  - Supl. 2
DP  - 2020 Oct 30
TI  - Ethical guidelines on cardiopulmonary resuscitation in the context of the
      COVID-19 pandemic in Colombia
PG  - 180-187
LID - 10.7705/biomedica.5762 [doi]
AB  - The pandemic caused by COVID19 is associated with an increase in the number of
      cases of cardiorespiratory arrest, which has resulted in ethical concerns
      regarding the enforceability of cardiopulmonary resuscitation, as well as the
      conditions to carry it out. The risk of aerosol transmission and the clinical
      uncertainties about the efficacy, the potential sequelae, and the circumstances
      that could justify limiting this procedure during the pandemic have multiplied
      the ethical doubts on how to proceed in these cases. Based on ethical and legal
      grounds, this paper offers a practical guide on how to proceed in the clinical
      setting in cases of cardiopulmonary arrest during the pandemic. The criteria of
      justice, benefit, no harm, respect for autonomy, precaution, integrity, and
      transparency are asserted in an organized and practical framework for
      decision-making regarding cardiopulmonary resuscitation.
FAU - Rueda, Eduardo A
AU  - Rueda EA
AD  - nternational Bioethics Committee - UNESCO, Red Latinoamericana y del Caribe de
      Educacion en Bioetica; Facultad de Derecho y Ciencias Politicas, Universidad
      Nacional de Colombia, Bogota, D.C., Colombia. eruedab@gmail.com.
FAU - Suarez, Edilma
AU  - Suarez E
AD  - Facultad de Enfermeria, Pontificia Universidad Javeriana, Bogota, D.C., Colombia.
      edilmasuarezcastro@gmail.com.
FAU - Gempeler, Fritz E
AU  - Gempeler FE
AD  - Facultad de Medicina, Pontificia Universidad Javeriana, Bogota, D.C., Colombia;
      Servicio de Etica, Hospital Universitario de San Ignacio, Bogota, D.C., Colombia.
      gempeler@gmail.com.
FAU - Torregrosa, Lilian
AU  - Torregrosa L
AD  - Facultad de Medicina, Pontificia Universidad Javeriana, Bogota, D.C., Colombia;
      Servicio de Etica, Hospital Universitario de San Ignacio, Bogota, D.C., Colombia;
      Asociacion Colombiana de Cirugia, Bogota, D.C., Colombia; Departamento de
      Cirugia, Hospital Universitario San Ignacio, Bogota, D.C., Colombia.
      lilian.torregrosa@gmail.com.
FAU - Caballero, Andrea
AU  - Caballero A
AD  - Clinica Campo Abierto, EPS Sanitas, Bogota, D.C., Colombia.
      andrea@caballero.com.co.
FAU - Bernal, Diana
AU  - Bernal D
AD  - Facultad de Jurisprudencia, Universidad del Rosario, Bogota, D.C., Colombia;
      Consejo Nacional de Bioetica de Colombia, Bogota, D.C., Colombia.
      diana.bernalc@hotmail.com.
FAU - Badoui, Nora
AU  - Badoui N
AD  - Facultad de Medicina, Pontificia Universidad Javeriana, Bogota, D.C., Colombia;
      Facultad de Medicina, Universidad Nacional de Colombia, Bogota, D.C., Colombia.
      nora.badoui@javeriana.edu.co.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - [Pautas eticas para la reanimacion cardiopulmonar en el contexto de la pandemia
      de COVID-19 en Colombia].
DEP - 20201030
PL  - Colombia
TA  - Biomedica
JT  - Biomedica : revista del Instituto Nacional de Salud
JID - 8205605
RN  - 0 (Aerosols)
SB  - IM
MH  - Advance Directives
MH  - Aerosols
MH  - Air Microbiology
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiopulmonary Resuscitation/*ethics/methods
MH  - Clinical Decision-Making
MH  - Colombia/epidemiology
MH  - Coronavirus Infections/*complications/epidemiology/prevention &
      control/transmission
MH  - Heart Arrest/etiology/*therapy
MH  - Humans
MH  - Infection Control/methods
MH  - Infectious Disease Transmission, Patient-to-Professional/prevention & control
MH  - Medical Futility
MH  - Occupational Exposure
MH  - *Pandemics/prevention & control
MH  - Personal Autonomy
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*complications/epidemiology/prevention & control/transmission
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Social Justice
PMC - PMC7676840
OTO - NOTNLM
OT  - *Coronavirus infections
OT  - *cardiopulmonary resuscitation
OT  - *codes of ethics
OT  - *practice guideline
EDAT- 2020/11/06 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/05 17:15
PHST- 2020/08/01 00:00 [received]
PHST- 2020/11/05 17:15 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.7705/biomedica.5762 [doi]
PST - epublish
SO  - Biomedica. 2020 Oct 30;40(Supl. 2):180-187. doi: 10.7705/biomedica.5762.


PMID- 33152039
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - First do no harm: An exploration of researchers' ethics of conduct in Big Data
      behavioral studies.
PG  - e0241865
LID - 10.1371/journal.pone.0241865 [doi]
AB  - Research ethics has traditionally been guided by well-established documents such 
      as the Belmont Report and the Declaration of Helsinki. At the same time, the
      introduction of Big Data methods, that is having a great impact in behavioral
      research, is raising complex ethical issues that make protection of research
      participants an increasingly difficult challenge. By conducting 39
      semi-structured interviews with academic scholars in both Switzerland and United 
      States, our research aims at exploring the code of ethics and research practices 
      of academic scholars involved in Big Data studies in the fields of psychology and
      sociology to understand if the principles set by the Belmont Report are still
      considered relevant in Big Data research. Our study shows how scholars generally 
      find traditional principles to be a suitable guide to perform ethical data
      research but, at the same time, they recognized and elaborated on the challenges 
      embedded in their practical application. In addition, due to the growing
      introduction of new actors in scholarly research, such as data holders and
      owners, it was also questioned whether responsibility to protect research
      participants should fall solely on investigators. In order to appropriately
      address ethics issues in Big Data research projects, education in ethics,
      exchange and dialogue between research teams and scholars from different
      disciplines should be enhanced. In addition, models of consultancy and shared
      responsibility between investigators, data owners and review boards should be
      implemented in order to ensure better protection of research participants.
FAU - Favaretto, Maddalena
AU  - Favaretto M
AUID- ORCID: 0000-0003-2647-301X
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - De Clercq, Eva
AU  - De Clercq E
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Gaab, Jens
AU  - Gaab J
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
FAU - Elger, Bernice Simone
AU  - Elger BS
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Behavioral Sciences/*ethics
MH  - Big Data
MH  - Data Mining/*ethics
MH  - Data Science/*ethics
MH  - Ethics, Research
MH  - Female
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - Middle Aged
MH  - Research Personnel
MH  - Stakeholder Participation/psychology
MH  - Switzerland
MH  - United States
PMC - PMC7644008
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/06 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/05 17:13
PHST- 2020/07/22 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/05 17:13 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1371/journal.pone.0241865 [doi]
AID - PONE-D-20-22705 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 5;15(11):e0241865. doi: 10.1371/journal.pone.0241865.
      eCollection 2020.


PMID- 33151771
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 6
DP  - 2020 Oct
TI  - Professional and Psychological Impacts of the COVID-19 Pandemic on Oncology
      Residents: A National Survey.
PG  - 1674-1683
LID - 10.1200/GO.20.00376 [doi]
AB  - PURPOSE: The COVID-19 pandemic has severely affected clinical practice in
      oncology, leading to organizational, ethical, and medical issues. In particular, 
      it has raised challenges in the context of competing care priorities between
      COVID-19 and cancer treatment. Residents on the front line face difficulties
      related to increasing care needs and urgent reorganization of health care systems
      while managing psychological stress and uncertainty. We aimed to evaluate the
      impact of the COVID-19 pandemic on oncology residents. METHODS AND MATERIALS: We 
      conducted a national survey (39 questions) in France among oncology and radiation
      therapy residents to determine the psychological impact and professional
      difficulties (eg, reassignment, training/research time, supervision, teleworking,
      management of patients) associated with the first peak of the COVID-19 pandemic. 
      RESULTS: Overall, 222 residents (medical oncologists, 61%; radiation therapists, 
      39%) participated in our survey, representing approximately one third of all
      residents and fellows in France. One third of respondents had been reassigned to 
      a COVID-19 ward. Training and research activity decreased for 89% and 41% of
      respondents, respectively. Two thirds (70%) of respondents declared that they had
      faced ethical issues, 35% felt worried about their own health, and 23%
      experienced psychological distress. According to the Hospital Anxiety and
      Depression Scale, 32% were anxious and 17% depressed. Consumption of tobacco,
      psychostimulants, and alcohol increased in 31%, 24%, and 29% of respondents,
      respectively. CONCLUSION: French oncology residents were highly affected by the
      first peak of the COVID-19 pandemic in terms of professional activity and
      psychological impact. This national survey can be used as a basis for improved
      management, medical reorganization, and training of residents during the ongoing 
      COVID-19 pandemic.
FAU - Hilmi, Marc
AU  - Hilmi M
AUID- ORCID: 0000-0003-4762-6740
AD  - Department of Medical Oncology, Institut Curie Saint-Cloud, Saint-Cloud, France.
AD  - Association pour l'Enseignement et la Recherche des Internes d'Oncologie, Paris, 
      France.
FAU - Boileve, Alice
AU  - Boileve A
AD  - Association pour l'Enseignement et la Recherche des Internes d'Oncologie, Paris, 
      France.
AD  - Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
FAU - Ducousso, Anabelle
AU  - Ducousso A
AD  - Association pour l'Enseignement et la Recherche des Internes d'Oncologie, Paris, 
      France.
FAU - Michalet, Morgan
AU  - Michalet M
AD  - Societe Francaise des Jeunes Oncologues Radiotherapeutes, Paris, France.
AD  - Department of Radiation Oncology, Institut du Cancer de Montpellier, Montpellier,
      France.
FAU - Turpin, Anthony
AU  - Turpin A
AD  - Department of Medical Oncology, Centre Hopital-Universitaire Lille, Lille,
      France.
FAU - Neuzillet, Cindy
AU  - Neuzillet C
AD  - Department of Medical Oncology, Institut Curie Saint-Cloud, Saint-Cloud, France.
FAU - Naoun, Natacha
AU  - Naoun N
AD  - Association pour l'Enseignement et la Recherche des Internes d'Oncologie, Paris, 
      France.
AD  - Department of Medical Oncology, Institut de Cancerologie de Lorraine, Nancy,
      France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
SB  - IM
MH  - COVID-19/complications/epidemiology/pathology/*psychology
MH  - Delivery of Health Care
MH  - France/epidemiology
MH  - Humans
MH  - Medical Oncology/*trends
MH  - Neoplasms/complications/epidemiology/*psychology/virology
MH  - Oncologists/psychology
MH  - *Pandemics
MH  - SARS-CoV-2/pathogenicity
MH  - Stress, Psychological/epidemiology
PMC - PMC7713519
EDAT- 2020/11/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/05 17:11
PHST- 2020/11/05 17:11 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1200/GO.20.00376 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2020 Oct;6:1674-1683. doi: 10.1200/GO.20.00376.


PMID- 33151763
OWN - NLM
STAT- Publisher
LR  - 20220422
IS  - 1748-3115 (Electronic)
IS  - 1748-3107 (Linking)
DP  - 2020 Nov 5
TI  - Moral distress and ethical decision-making of eldercare professionals involved in
      digital service transformation.
PG  - 1-10
LID - 10.1080/17483107.2020.1839579 [doi]
AB  - AIM: Technology affects almost all aspects of modern eldercare. Ensuring ethical 
      decision-making is essential as eldercare becomes more digital; each decision
      affects a patient's life, self-esteem, health and wellness. METHODS: We conducted
      a survey and interviews with eldercare professionals to better understand the
      behavioural ethics and decision making involved in the digital transition of
      eldercare. CONCLUSION: Our qualitative analysis showed three recurrent roles
      among eldercare professionals in regard to digital service transformation;
      makers, implementers and maintainers. All three encountered challenging and
      stressful ethical dilemmas due to uncertainty and a lack of control. The matter
      of power relations, the attempts to standardize digital solutions and the
      conflict between cost efficiency and if digital care solutions add value for
      patients, all caused moral dilemmas for eldercare professionals. The findings
      suggest a need for organizational infrastructure that promotes ethical conduct
      and behaviour, ethics training and access to related resources.Implications for
      rehabilitationThe transition to digital care service is not neutral, but
      value-laden. Digital transformation affects ethical behaviour and
      decision-making.The decision as to which digital services should be developed and
      deployed must include eldercare professionals and not lay solely in the hands of 
      managers, technologists and economists.We must move away from attempting to fit
      standardized solutions to a heterogenous group of older patients; accommodating
      the pluralism of patients' needs and wants protects their dignity, autonomy and
      independence.As digital care practices evolve, so too must organizational
      structures that promote ethical conduct.
FAU - Frennert, Susanne
AU  - Frennert S
AUID- ORCID: https://orcid.org/0000-0002-9522-5469
AD  - Department of Computer Science and Media Technology, Internet of Things and
      People Research Center, Malmo University, Malmo, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - England
TA  - Disabil Rehabil Assist Technol
JT  - Disability and rehabilitation. Assistive technology
JID - 101255937
SB  - IM
OTO - NOTNLM
OT  - Ethics
OT  - digital care services
OT  - eldercare professionals
OT  - ethical decision-making
OT  - moral distress
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/11/05 17:11
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2020/11/05 17:11 [entrez]
AID - 10.1080/17483107.2020.1839579 [doi]
PST - aheadofprint
SO  - Disabil Rehabil Assist Technol. 2020 Nov 5:1-10. doi:
      10.1080/17483107.2020.1839579.


PMID- 33151535
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1938-3800 (Electronic)
IS  - 0742-3225 (Linking)
VI  - 52
IP  - 10
DP  - 2020 Nov
TI  - Mock Trial as a Learning Tool in a Family Medicine Residency.
PG  - 741-744
LID - 10.22454/FamMed.2020.405328 [doi]
AB  - BACKGROUND AND OBJECTIVES: Mock trials have been used to teach medical learners
      about malpractice litigation, ethics, legal concepts, and evidence-based
      practice. Although 5.2% of family physicians are sued for malpractice annually,
      there is no formal requirement nor curriculum for educating our residents about
      malpractice, and mock trial has not been reported as an education modality in a
      family medicine residency. We developed a mock trial experience to educate family
      medicine residents about malpractice litigation and evaluated the resident
      experience over 3 years. METHODS: This is a retrospective, single-site study
      evaluating resident experience in our mock trials. We assessed perceived value
      using a 5-point Likert scale; and we assessed knowledge with free-text answers to
      both open and closed questions. We used descriptive statistics to describe data. 
      RESULTS: Residents found the mock trial effective and engaging, giving the
      experience an overall evaluation of 4.9/5+/-0.3; 86.4% identified the importance 
      of documentation as a learning outcome; 72.7% of residents identified negligence 
      as necessary to justify a lawsuit, but they demonstrated limited mastery of the
      four elements of negligence, with 45.5% correctly listing harm, 40.9% causation, 
      13.6% breach of duty, and 0% duty owed. CONCLUSIONS: Mock trial is an enjoyable
      and effective tool to engage residents and provide a general understanding of
      malpractice litigation. It is less effective in conveying nuanced details of
      negligence. It may also be effective in teaching practice management techniques.
FAU - Lennon, Robert P
AU  - Lennon RP
AD  - Penn State College of Medicine, Department of Family and Community Medicine,
      Hershey, PA.
FAU - Clebak, Karl T
AU  - Clebak KT
AD  - Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
FAU - Stepanian, Jonathan B
AU  - Stepanian JB
AD  - Dickinson School of Law, Pennsylvania State University.
FAU - Riley, Timothy D
AU  - Riley TD
AD  - Department of Family and Community Medicine, Pennsylvania State University,
      Hershey, PA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fam Med
JT  - Family medicine
JID - 8306464
SB  - IM
MH  - Curriculum
MH  - Family Practice
MH  - Humans
MH  - *Internship and Residency
MH  - *Malpractice
MH  - Retrospective Studies
EDAT- 2020/11/06 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/05 12:15
PHST- 2020/11/05 12:15 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.22454/FamMed.2020.405328 [doi]
PST - ppublish
SO  - Fam Med. 2020 Nov;52(10):741-744. doi: 10.22454/FamMed.2020.405328.


PMID- 33151427
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - Harm Reduction: A Misnomer.
PG  - 324-334
LID - 10.1007/s10728-020-00413-x [doi]
AB  - 'Harm reduction' programs are usually justified on the utilitarian grounds that
      they aim to reduce the net harms of a behavior. In this paper, I contend that (1)
      the historical genesis of harm reduction programs, and the crucial moral
      imperative that distinguishes these programs from other interventions and
      policies, are not utilitarian; (2) the practical implementation of harm reduction
      programs is not, and probably cannot be, utilitarian; and (3) the continued
      justification of harm reduction on utilitarian grounds is untenable and may
      itself cause harm. Promoting harm reduction programs as utilitarian in the public
      arena disregards their deeper prioritarian impulses. 'Harm reduction' is a
      misnomer, and the name should be abandoned sooner rather than later.
FAU - King, Nicholas B
AU  - King NB
AUID- ORCID: http://orcid.org/0000-0002-2093-3380
AD  - Biomedical Ethics Unit, McGill University, Montreal, Canada.
      nicholas.king@mcgill.ca.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - *Ethical Theory
MH  - *Harm Reduction
MH  - Humans
MH  - *Morals
MH  - Philosophy
MH  - Social Justice
PMC - PMC7679315
OTO - NOTNLM
OT  - Ethics
OT  - Harm reduction
OT  - Justice
OT  - Philosophy
OT  - Utilitarianism
EDAT- 2020/11/06 06:00
MHDA- 2021/08/18 06:00
CRDT- 2020/11/05 12:14
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2020/11/05 12:14 [entrez]
AID - 10.1007/s10728-020-00413-x [doi]
AID - 10.1007/s10728-020-00413-x [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Dec;28(4):324-334. doi: 10.1007/s10728-020-00413-x. Epub
      2020 Nov 5.


PMID- 33151160
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 5
TI  - Sella Turcica Morphology in Patients With Genetic Syndromes: Protocol for a
      Systematic Review.
PG  - e16633
LID - 10.2196/16633 [doi]
AB  - BACKGROUND: The sella turcica is an important anatomical reference used in
      orthodontics and the evaluation of craniofacial growth. Studies have found an
      association between variations in sella turcica morphology in patients with
      certain syndromes affecting the craniofacial complex. It is hypothesized that
      each related syndrome or pathological condition is associated with a specific
      pattern of malformation of the sella turcica. OBJECTIVE: This study outlines the 
      protocol for a systematic review that aims to determine if genetic syndromes
      involving the craniofacial complex are associated with abnormal radiographic
      sella turcica morphology and if there is a pattern of malformation that is
      consistent with each syndrome. METHODS: An electronic database search was
      conducted using a planned search strategy to identify relevant studies. We
      included primary studies evaluating the morphology of the sella turcica based on 
      imaging from a lateral view. Specifically, only studies with postnatal human
      participants with genetic syndromes involving the craniofacial complex were
      included in this review. We placed no restrictions on the language or time frame 
      of these studies. Based on the search findings, studies were further screened for
      relevance and eligibility by two independent reviewers. Data were extracted from 
      the selected studies. We assessed the selected studies for risk of bias and
      quality by using risk of bias tools from the Joanna Briggs Institute. We will
      provide a narrative synthesis of our findings and a structured summary based on
      prespecified themes. RESULTS: The protocol is registered with PROSPERO
      (#CRD42019148060) and approved by the University of Western Cape Biomedical
      Science Research Ethics Committee (BM205/3). The literature search was conducted 
      in September 2019 and updated in July 2020. The study was completed in August
      2020, and the findings will be published in an open-access journal. CONCLUSIONS: 
      The results of this systematic review are expected to provide a comprehensive
      list of morphological variations of the sella turcica, which will aid in the
      identification of syndromes associated with the craniofacial complex. We also
      expect to identify patterns of sella turcica morphology that highlight
      genotype-phenotype correlations, thus adding to the body of evidence relating to 
      genetics and craniofacial malformations. TRIAL REGISTRATION: PROSPERO
      International Prospective Register of Systematic Reviews CRD42019148060;
      https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=148060.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/16633.
CI  - (c)Imaan Amina Roomaney, Manogari Chetty. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 05.11.2020.
FAU - Roomaney, Imaan Amina
AU  - Roomaney IA
AUID- ORCID: https://orcid.org/0000-0001-6789-5484
AD  - Department of Oral Biology and Dental Genetics, Faculty of Dentistry, University 
      of Western Cape, Cape Town, South Africa.
FAU - Chetty, Manogari
AU  - Chetty M
AUID- ORCID: https://orcid.org/0000-0002-1176-8539
AD  - Department of Oral Biology and Dental Genetics, Faculty of Dentistry, University 
      of Western Cape, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7677016
OTO - NOTNLM
OT  - cephalometrics
OT  - craniofacial malformations
OT  - craniofacial syndrome
OT  - sella turcica
OT  - systematic review
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:01
CRDT- 2020/11/05 12:12
PHST- 2019/10/09 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/11/05 12:12 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:01 [medline]
AID - v9i11e16633 [pii]
AID - 10.2196/16633 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 5;9(11):e16633. doi: 10.2196/16633.


PMID- 33151152
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 11
DP  - 2020 Nov 5
TI  - A Digitally Competent Health Workforce: Scoping Review of Educational Frameworks.
PG  - e22706
LID - 10.2196/22706 [doi]
AB  - BACKGROUND: Digital health technologies can be key to improving health outcomes, 
      provided health care workers are adequately trained to use these technologies.
      There have been efforts to identify digital competencies for different health
      care worker groups; however, an overview of these efforts has yet to be
      consolidated and analyzed. OBJECTIVE: The review aims to identify and study
      existing digital health competency frameworks for health care workers and provide
      recommendations for future digital health training initiatives and framework
      development. METHODS: A literature search was performed to collate digital health
      competency frameworks published from 2000. A total of 6 databases including gray 
      literature sources such as OpenGrey, ResearchGate, Google Scholar, Google, and
      websites of relevant associations were searched in November 2019. Screening and
      data extraction were performed in parallel by the reviewers. The included
      evidence is narratively described in terms of characteristics, evolution, and
      structural composition of frameworks. A thematic analysis was also performed to
      identify common themes across the included frameworks. RESULTS: In total, 30
      frameworks were included in this review, a majority of which aimed at nurses,
      originated from high-income countries, were published since 2016, and were
      developed via literature reviews, followed by expert consultations. The thematic 
      analysis uncovered 28 digital health competency domains across the included
      frameworks. The most prevalent domains pertained to basic information technology 
      literacy, health information management, digital communication, ethical, legal,
      or regulatory requirements, and data privacy and security. The Health Information
      Technology Competencies framework was found to be the most comprehensive
      framework, as it presented 21 out of the 28 identified domains, had the highest
      number of competencies, and targeted a wide variety of health care workers.
      CONCLUSIONS: Digital health training initiatives should focus on competencies
      relevant to a particular health care worker group, role, level of seniority, and 
      setting. The findings from this review can inform and guide digital health
      training initiatives. The most prevalent competency domains identified represent 
      essential interprofessional competencies to be incorporated into health care
      workers' training. Digital health frameworks should be regularly updated with
      novel digital health technologies, be applicable to low- and middle-income
      countries, and include overlooked health care worker groups such as allied health
      professionals.
CI  - (c)Nuraini Nazeha, Deepali Pavagadhi, Bhone Myint Kyaw, Josip Car, Geronimo
      Jimenez, Lorainne Tudor Car. Originally published in the Journal of Medical
      Internet Research (http://www.jmir.org), 05.11.2020.
FAU - Nazeha, Nuraini
AU  - Nazeha N
AUID- ORCID: 0000-0002-1935-5499
AD  - Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore, Singapore.
FAU - Pavagadhi, Deepali
AU  - Pavagadhi D
AUID- ORCID: 0000-0003-4337-8137
AD  - Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore, Singapore.
FAU - Kyaw, Bhone Myint
AU  - Kyaw BM
AUID- ORCID: 0000-0002-1750-0330
AD  - Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore, Singapore.
FAU - Car, Josip
AU  - Car J
AUID- ORCID: 0000-0001-8969-371X
AD  - Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore, Singapore.
AD  - Department of Primary Care and Public Health, School of Public Health, Imperial
      College London, London, United Kingdom.
FAU - Jimenez, Geronimo
AU  - Jimenez G
AUID- ORCID: 0000-0002-1304-426X
AD  - Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore, Singapore.
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Netherlands, Netherlands.
FAU - Tudor Car, Lorainne
AU  - Tudor Car L
AUID- ORCID: 0000-0001-8414-7664
AD  - Department of Primary Care and Public Health, School of Public Health, Imperial
      College London, London, United Kingdom.
AD  - Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore, Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201105
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Clinical Competence/*standards
MH  - Curriculum
MH  - Health Personnel/*education
MH  - Health Workforce/*standards
MH  - Humans
PMC - PMC7677019
OTO - NOTNLM
OT  - *competency
OT  - *digital competency
OT  - *digital health
OT  - *eHealth
OT  - *framework
OT  - *health professions education
OT  - *medical education
OT  - *review
EDAT- 2020/11/06 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/11/05 12:11
PHST- 2020/07/22 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/11/05 12:11 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - v22i11e22706 [pii]
AID - 10.2196/22706 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Nov 5;22(11):e22706. doi: 10.2196/22706.


PMID- 33150808
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1532-7655 (Electronic)
IS  - 0737-0016 (Linking)
VI  - 37
IP  - 4
DP  - 2020 Oct-Dec
TI  - A Critical Ethnography of Outreach Nursing for People Experiencing Homelessness.
PG  - 189-202
LID - 10.1080/07370016.2020.1809858 [doi]
AB  - People experiencing homelessness have a high prevalence of substance abuse and
      mental and physical problems. Although they have very complex health needs, they 
      face many barriers that reduce their access to health care and social services.
      Several research studies have shown the need to implement adapted nursing
      interventions to address these crucial access issues. In this article, we present
      the results of a critical ethnography of outreach nurses who work with homeless
      people (n = 12). Robert Castel's theoretical model, which focuses on the process 
      of social disaffiliation, provided the conceptual underpinnings for this
      research. Our qualitative data analysis revealed four categories, namely 1) the
      professional role and identity of nurses; 2) the social function of outreach
      nursing; 3) clinical realities and 4) disaffiliation and stigmatization. Our
      findings highlight the need to raise awareness among health care providers about 
      the ethical, clinical and organizational issues of homelessness, particularly the
      mechanisms of exclusion and stigmatization in health care settings that affect
      people experiencing homelessness.
FAU - Paradis-Gagne, Etienne
AU  - Paradis-Gagne E
AUID- ORCID: https://orcid.org/0000-0001-6524-4346
AD  - Faculty of Nursing, Universite de Montreal , Quebec, Canada.
FAU - Pariseau-Legault, Pierre
AU  - Pariseau-Legault P
AUID- ORCID: https://orcid.org/0000-0001-9833-0187
AD  - Department of Nursing, Universite du Quebec en Outaouais, Saint-Jerome , Quebec, 
      Canada.
FAU - Villemure, Midori
AU  - Villemure M
AD  - Department of Nursing, Universite du Quebec a Trois-Rivieres , Quebec, Canada.
FAU - Chauvette, Simon
AU  - Chauvette S
AD  - Department of Nursing, Universite du Quebec a Trois-Rivieres , Quebec, Canada.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Community Health Nurs
JT  - Journal of community health nursing
JID - 8411341
SB  - IM
MH  - Anthropology, Cultural/methods/statistics & numerical data
MH  - Community-Institutional Relations/*trends
MH  - Health Services Accessibility/standards/statistics & numerical data
MH  - Homeless Persons/*statistics & numerical data
MH  - Humans
MH  - Nursing/instrumentation/*methods/trends
MH  - Ontario
MH  - Qualitative Research
MH  - Quebec
EDAT- 2020/11/06 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/11/05 08:37
PHST- 2020/11/05 08:37 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 10.1080/07370016.2020.1809858 [doi]
PST - ppublish
SO  - J Community Health Nurs. 2020 Oct-Dec;37(4):189-202. doi:
      10.1080/07370016.2020.1809858.


PMID- 33149770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1758-8340 (Print)
IS  - 1758-8340 (Linking)
VI  - 12
DP  - 2020
TI  - Identification of the risks in CAR T-cell therapy clinical trials in China: a
      Delphi study.
PG  - 1758835920966574
LID - 10.1177/1758835920966574 [doi]
AB  - AIMS: Within the past few years, there has been tremendous growth in clinical
      trials of chimeric antigen receptor (CAR) T-cell therapies. Unlike those of many 
      small-molecule pharmaceuticals, CAR T-cell therapy clinical trials are fraught
      with risks due to the use of live cell products. The aim of this study is to
      reach a consensus with experts on the most relevant set of risks that practically
      occur in CAR T-cell therapy clinical trials. METHODS: A Delphi method of
      consensus development was used to identify the risks in CAR T-cell therapy
      clinical trials, comprising three survey rounds. The expert panel consisted of
      principal investigators, clinical research physicians, members of institutional
      ethics committees, and Good Clinical Practice managers. RESULTS: Of the 24
      experts invited to participate in this Delphi study, 20 participants completed
      Round 1, Round 2, and Round 3. Finally, consensus (defined as >80% agreement) was
      achieved for 54 risks relating to CAR T-cell clinical trials. Effective
      interventions related to these risks are needed to ensure the proper protection
      of subject health and safety. CONCLUSION: The Delphi method was successful in
      gaining a consensus on risks relevant to CAR T-cell clinical trials in a
      geographically diverse expert association. It is hoped that this work can benefit
      future risk-based quality management in clinical trials and can potentially
      promote the better development of CAR T-cell therapy products.
CI  - (c) The Author(s), 2020.
FAU - Wu, Weijia
AU  - Wu W
AD  - Department of Clinical Pharmacy and Pharmaceutical Management, School of
      Pharmacy, Fudan University, Shanghai, China.
FAU - Huo, Yan
AU  - Huo Y
AD  - National Institution of Food and Drug Control, National Medical Products
      Administration, Beijing, China.
FAU - Ding, Xueying
AU  - Ding X
AD  - Engineering Technology Research Center of Cell Therapy and Clinical Translation, 
      Shanghai Science and Technology Committee.
FAU - Zhou, Yuhong
AU  - Zhou Y
AD  - Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai,
      China.
FAU - Gu, Shengying
AU  - Gu S
AD  - Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong
      University School of Medicine, Shanghai, China.
FAU - Gao, Yuan
AU  - Gao Y
AD  - Department of Clinical Pharmacy and Pharmaceutical Management, School of
      Pharmacy, Fudan University, Pudong District, Shanghai, 200433, China.
LA  - eng
PT  - Journal Article
DEP - 20201017
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC7580145
OTO - NOTNLM
OT  - CAR T-cell therapy
OT  - Delphi study
OT  - clinical trial
OT  - risk identification
OT  - subject protection
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:01
CRDT- 2020/11/05 06:07
PHST- 2020/01/31 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/11/05 06:07 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:01 [medline]
AID - 10.1177/1758835920966574 [doi]
AID - 10.1177_1758835920966574 [pii]
PST - epublish
SO  - Ther Adv Med Oncol. 2020 Oct 17;12:1758835920966574. doi:
      10.1177/1758835920966574. eCollection 2020.


PMID- 33149671
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Outcomes of 596 Advanced Gastric Cancer Patients with Different Numbers of
      Chemotherapy Lines: The More Chemotherapy Lines, the Better Survival.
PG  - 10631-10638
LID - 10.2147/CMAR.S275990 [doi]
AB  - OBJECTIVE: Many large-sample prospective randomized clinical trials investigating
      advanced gastric cancer (AGC) have confirmed the survival advantages of
      first-line, second-line, or third-line chemotherapy compared with their
      respective control groups. However, due to the ethical concerns of prospective
      clinical trials, it is impossible to conduct a randomized comparative study of
      patients who do not receive chemotherapy and those who receive a second-line or
      above chemotherapy. Few research reports have addressed the relationship between 
      the number of chemotherapy lines and overall survival (OS) in patients with AGC. 
      In the present study, we analyzed the impact of the number of chemotherapy lines 
      on OS in AGC patients using real-world data. PATIENTS AND METHODS: This study
      collected the medical records of patients with AGC diagnosed at Shandong Cancer
      Hospital from December 2007 to December 2017. According to the treatment
      received, AGC patients were divided into groups that did not receive
      chemotherapy, those who received only 1 line, 2 lines, or 3 lines and above.
      Kaplan-Meier analysis was used to assess patient survival. RESULTS: A total of
      596 AGC patients were included in this study. The following patients were
      enrolled: 0 lines (did not receive chemotherapy), 77 (12.9%); 1 line, 235 (39.4%)
      patients; 2 lines, 185 (31.1%) patients; and >/=3 lines 99 (16.6%) patients. OS
      was significantly correlated with the number of chemotherapy lines (P<0.001),
      with a median OS from diagnosis of 3.3, 8.6, 15.6, and 21.0 months for patients
      receiving 0, 1, 2, >/=3 lines of chemotherapy, respectively. CONCLUSION: This
      study showed that the more chemotherapy lines AGC patients received, the longer
      the OS. This study not only confirmed the impact of chemotherapy lines on OS but 
      it also supplements the results of prospective clinical trials that cannot be
      completed due to the ethical implications.
CI  - (c) 2020 Sun et al.
FAU - Sun, Li
AU  - Sun L
AD  - Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan,
      People's Republic of China.
FAU - Wang, Huijun
AU  - Wang H
AD  - Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan,
      People's Republic of China.
FAU - Liu, Zhen
AU  - Liu Z
AD  - Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan,
      People's Republic of China.
FAU - Meng, Ying
AU  - Meng Y
AD  - Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan,
      People's Republic of China.
FAU - Qiu, Meiqing
AU  - Qiu M
AD  - Department of Oncology, Zaozhuang Municipal Hospital, Zaozhuang, People's
      Republic of China.
FAU - Ju, Yafei
AU  - Ju Y
AD  - Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan,
      People's Republic of China.
FAU - Zhang, Shu
AU  - Zhang S
AUID- ORCID: 0000-0002-9869-8026
AD  - Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan,
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7602914
OTO - NOTNLM
OT  - advanced gastric cancer
OT  - number of chemotherapy lines
OT  - overall survival
OT  - real world data
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:01
CRDT- 2020/11/05 06:06
PHST- 2020/08/10 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/11/05 06:06 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:01 [medline]
AID - 10.2147/CMAR.S275990 [doi]
AID - 275990 [pii]
PST - epublish
SO  - Cancer Manag Res. 2020 Oct 27;12:10631-10638. doi: 10.2147/CMAR.S275990.
      eCollection 2020.


PMID- 33149349
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210502
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 11
DP  - 2020 Nov
TI  - Veterinary Medical Ethics.
PG  - 1137-1138
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7560768
EDAT- 2020/11/06 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/11/05 06:05
PHST- 2020/11/05 06:05 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_11_1137 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Nov;61(11):1137-1138.


PMID- 33148859
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20201106
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 73
IP  - 9 cz. 2
DP  - 2020
TI  - REPRODUCTIVE CHOICE: INTERNATIONAL ETHICAL STANDARDS AND PROSPECTS FOR LEGAL
      REGULATION IN CERTAIN EUROPEAN COUNTRIES.
PG  - 2056-2061
AB  - OBJECTIVE: The aim: The article is aimed at elucidating the prospects for the
      formation of universal ethical and legal standards in the work of medical workers
      in order to ensure the reproductive choice of a person according to the analysis 
      of international documents, court practice of the ECHR, and the national
      legislation of individual European countries. PATIENTS AND METHODS: Materials and
      methods: Research materials include scientific developments of both domestic and 
      Western theorists and human rights defenders in the field of medical law in the
      aspect of reproductive choice. The recommendations of the Center for Reproductive
      Rights in the USA, the World Health Organization, the United Nations, and the
      ECHR practices were of great importance. This article used the methods of
      searching, analyzing, organizing, and summarizing information. CONCLUSION:
      Conclusions: It is necessary to ensure the provision and guarantee of
      reproductive choice for everyone at the level of the Constitution. Given the
      public debate about the contradictions of individual manifestations of
      reproductive autonomy, it is proposed at the first stage of legal regulation to
      develop national principles and ethical standards for medical workers in this
      area.
FAU - Nykolyna, Kateryna V
AU  - Nykolyna KV
AD  - TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV, KYIV, UKRAINE.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
SB  - IM
MH  - Europe
MH  - Humans
MH  - *Moral Obligations
MH  - Morals
MH  - *Reproductive Rights
OTO - NOTNLM
OT  - informed consent-
OT  - post-mortal reproduction-
OT  - reproductive choice-
OT  - reproductive rights -
EDAT- 2020/11/06 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2020;73(9 cz. 2):2056-2061.


PMID- 33148790
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 2054-4774 (Print)
IS  - 2054-4774 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Nov
TI  - Burnout and work-related stressors in gastroenterology: a protocol for a
      multinational observational study in the ASEAN region.
LID - e000534 [pii]
LID - 10.1136/bmjgast-2020-000534 [doi]
AB  - BACKGROUND: Clinician burnout is an important occupational hazard that may be
      exacerbated by the novel COVID-19 pandemic. Within Southeast Asia, burnout in
      gastroenterology is understudied. The primary objective of this study is to
      estimate the prevalence of burnout symptoms within gastroenterology, in member
      states of the Associations of Southeast Asian Nations (ASEAN), during and after
      the COVID-19 pandemic. The secondary objective is to identify work-related
      stressors that contribute to burnout in ASEAN gastroenterologists. METHODS AND
      ANALYSIS: This is an observational study that will use anonymised online surveys 
      to estimate the prevalence of burnout symptoms at two time points: during the
      COVID-19 pandemic in 2020 and in 2022 (assumed to be after the pandemic).
      Gastroenterologists from Singapore, Malaysia, Thailand, Indonesia, Philippines
      and Brunei will be invited to participate in the online survey through their
      national gastroenterology and endoscopy societies. Burnout will be assessed using
      the Maslach Burnout Inventory-Human Services Survey tool. Supplementary questions
      will collect demographic and qualitative data. Associations between demographic
      characteristics and burnout will be tested by multiple regression. RESULTS: The
      prevalence of burnout symptoms in gastroenterology during the COVID-19 pandemic, 
      and the baseline prevalence after COVID-19, will be established in the
      above-mentioned countries. Work-related stressors commonly associated with
      burnout will be identified, allowing the introduction of preventative measures to
      reduce burnout in the future. ETHICS AND DISSEMINATION: Ethical approval was
      granted by the Singhealth Centralised Institutional Review Board (2020/2709).
      Results will be submitted for publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ong, John
AU  - Ong J
AUID- ORCID: 0000-0001-5103-7311
AD  - Department of Medicine, National University of Singapore, Singapore
      jo401@cam.ac.uk.
AD  - Department of Engineering, University of Cambridge, Cambridge, United Kingdom.
FAU - Ong, Andrew Ming Liang
AU  - Ong AML
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore.
FAU - Ong, Sharon
AU  - Ong S
AD  - Department of Surgical Intensive Care, Singapore General Hospital, Singapore.
AD  - Department of Surgical Intensive Care, Sengkang General Hospital, Singapore.
FAU - Xin, Xiaohui
AU  - Xin X
AD  - Department of Health Services Research, Singapore General Hospital, Singapore.
FAU - Lee, Yeong Yeh
AU  - Lee YY
AD  - School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.
FAU - Pausawasdi, Nonthalee
AU  - Pausawasdi N
AD  - Department of Medicine, Division of Gastroenterology, Faculty of Medicine Siriraj
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - De Lusong, Mark Anthony
AU  - De Lusong MA
AD  - Department of Medicine, Philippine General Hospital, Manila, Philippines.
FAU - Makmun, Dadang
AU  - Makmun D
AD  - Department of Internal Medicine, Division of Gastroenterology, Faculty of
      Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital,
      Central Jakarta, Indonesia.
FAU - Chong, Vui Heng
AU  - Chong VH
AD  - Department of Gastroenterology, UBD PAPRSB Institute of Health Sciences, Gadong, 
      Brunei Darussalam.
FAU - Ho, Shiaw Hooi
AU  - Ho SH
AUID- ORCID: 0000-0003-4992-7627
AD  - Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Lim, Wan Yen
AU  - Lim WY
AUID- ORCID: 0000-0002-0335-0255
AD  - Department of Anaesthesia, Singapore General Hospital, Singapore.
FAU - Koh, Calvin Jianyi
AU  - Koh CJ
AD  - Department of Gastroenterology and Hepatology, National University Hospital,
      Singapore.
FAU - Ong, David
AU  - Ong D
AD  - Department of Gastroenterology and Hepatology, National University Hospital,
      Singapore.
FAU - Khor, Christopher
AU  - Khor C
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore.
FAU - Dan, Yock Young
AU  - Dan YY
AD  - Department of Medicine, National University of Singapore, Singapore.
AD  - Department of Gastroenterology and Hepatology, National University Hospital,
      Singapore.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Gastroenterol
JT  - BMJ open gastroenterology
JID - 101660690
SB  - IM
MH  - Adult
MH  - Asia/epidemiology
MH  - *Betacoronavirus
MH  - Burnout, Professional/*epidemiology
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Female
MH  - *Gastroenterology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Stress, Psychological/*epidemiology
PMC - PMC7643491
OTO - NOTNLM
OT  - *environmental health
OT  - *epidemiology
OT  - *health service research
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/08/31 00:00 [received]
PHST- 2020/09/14 00:00 [revised]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjgast-2020-000534 [pii]
AID - 10.1136/bmjgast-2020-000534 [doi]
PST - ppublish
SO  - BMJ Open Gastroenterol. 2020 Nov;7(1). pii: bmjgast-2020-000534. doi:
      10.1136/bmjgast-2020-000534.


PMID- 33148776
OWN - NLM
STAT- Publisher
LR  - 20220506
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Nov 4
TI  - Ethics of pursuing targets in public health: the case of voluntary medical male
      circumcision for HIV-prevention programs in Kenya.
LID - medethics-2020-106293 [pii]
LID - 10.1136/medethics-2020-106293 [doi]
AB  - The use of targets to direct public health programmes, particularly in global
      initiatives, has become widely accepted and commonplace. This paper is an ethical
      analysis of the utilisation of targets in global public health using our
      fieldwork on and experiences with voluntary medical male circumcision (VMMC)
      initiatives in Kenya. Among the many countries involved in VMMC for HIV
      prevention, Kenya is considered a success story, its programmes having medically 
      circumcised nearly 2 million men since 2007. We describe ethically problematic
      practices in Kenyan VMMC programmes revealed by our fieldwork, how the problems
      are related to the pursuit of targets and discuss possible approaches to their
      management. Although the establishment and pursuit of targets in public health
      can have many benefits, assessments of target-driven programmes tend to focus on 
      quantifiable outcomes rather than the processes by which the outcomes are
      obtained. However, in order to speak more robustly about programmatic 'success', 
      and to maintain community trust, it is vital to ethically evaluate how a public
      health initiative is actually implemented in the pursuit of its targets.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - UNC Center for Bioethics, University of North Carolina at Chapel Hill, Chapel
      Hill, North Carolina, USA.
AD  - Department of Social Medicine, University of North Carolina at Chapel Hill,
      Chapel Hill, North Carolina, USA.
FAU - Gilbertson, Adam
AU  - Gilbertson A
AUID- ORCID: http://orcid.org/0000-0002-4396-3638
AD  - Pacific Institute for Research and Evaluation, Chapel Hill Center, Chapel Hill,
      North Carolina, USA adamgilbertson@outlook.com.
FAU - Hallfors, Denise
AU  - Hallfors D
AD  - Retired, Pacific Institute for Research and Evaluation, Chapel Hill Center,
      Chapel Hill, North Carolina, USA.
FAU - Luseno, Winnie K
AU  - Luseno WK
AD  - Pacific Institute for Research and Evaluation, Chapel Hill Center, Chapel Hill,
      North Carolina, USA.
LA  - eng
GR  - P30 AI050410/AI/NIAID NIH HHS/United States
GR  - R01 MH102125/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8144939
MID - NIHMS1703908
OTO - NOTNLM
OT  - HIV infection and AIDS
OT  - circumcision
OT  - ethics
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/05/18 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - medethics-2020-106293 [pii]
AID - 10.1136/medethics-2020-106293 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Nov 4. pii: medethics-2020-106293. doi:
      10.1136/medethics-2020-106293.


PMID- 33148765
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Accuracy of signs, symptoms and blood tests for diagnosing acute bacterial
      rhinosinusitis and CT-confirmed acute rhinosinusitis in adults: protocol of an
      individual patient data meta-analysis.
PG  - e040988
LID - 10.1136/bmjopen-2020-040988 [doi]
AB  - INTRODUCTION: This protocol outlines a diagnostic individual patient data (IPD)
      meta-analysis aimed at developing simple prediction models based on readily
      available signs, symptoms and blood tests to accurately predict acute bacterial
      rhinosinusitis and CT-confirmed (fluid level or total opacification in any sinus)
      acute rhinosinusitis (ARS) in adults presenting to primary care with clinically
      diagnosed ARS, target conditions associated with antibiotic benefit. METHODS AND 
      ANALYSIS: The systematic searches of PubMed and Embase of a review on the
      accuracy of signs and symptoms for diagnosing ARS in ambulatory care will be
      updated to April 2020 to identify relevant studies. Authors of eligible studies
      will be contacted and invited to provide IPD. Methodological quality of the
      studies will be assessed using the Quality Assessment of Diagnostic Accuracy
      Studies-2 tool. Candidate predictor selection will be based on knowledge from
      existing literature, clinical reasoning and availability. Multivariable logistic 
      regression analyses will be used to develop prediction models aimed at
      calculating absolute risk estimates. Large unexplained between-study
      heterogeneity in predictive accuracy of the models will be explored and may lead 
      to either model adjustment or derivation of separate context-specific models.
      Calibration and discrimination will be evaluated to assess the models'
      performance. Bootstrap resampling techniques will be used to assess internal
      validation and to inform on possible adjustment for overfitting. In addition, we 
      aim to perform internal-external cross-validation procedures. ETHICS AND
      DISSEMINATION: In this IPD meta-analysis, no identifiable patient data will be
      used. As such, the Medical Research Involving Humans Subject Act does not apply, 
      and official ethical approval is not required. Findings will be published in
      international peer-reviewed journals and presented at scientific conferences.
      PROSPERO REGISTRATION NUMBER: PROSPERO CRD42020175659.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Venekamp, Roderick
AU  - Venekamp R
AUID- ORCID: 0000-0002-1446-9614
AD  - Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht
      University, Utrecht, The Netherlands r.p.venekamp@umcutrecht.nl.
FAU - Hansen, Jens Georg
AU  - Hansen JG
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Reitsma, Johannes B
AU  - Reitsma JB
AD  - Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - Ebell, Mark H
AU  - Ebell MH
AUID- ORCID: 0000-0003-3228-2877
AD  - Department of Epidemiology and Biostatistics, University of Georgia College of
      Public Health, Athens, Georgia, USA.
FAU - Lindbaek, Morten
AU  - Lindbaek M
AD  - Department of General Practice, Institute for Health and Society, University of
      Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Hematologic Tests
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Review Literature as Topic
MH  - *Rhinitis/diagnosis
MH  - *Sinusitis/diagnosis
MH  - Tomography, X-Ray Computed
PMC - PMC7640527
OTO - NOTNLM
OT  - *epidemiology
OT  - *otolaryngology
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040988 [pii]
AID - 10.1136/bmjopen-2020-040988 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e040988. doi: 10.1136/bmjopen-2020-040988.


PMID- 33148764
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Tranexamic ACid during PancereaticoDuodenectomy (TAC-PD): study protocol for a
      multicentre randomised, blind, placebo-controlled trial.
PG  - e040914
LID - 10.1136/bmjopen-2020-040914 [doi]
AB  - INTRODUCTION: Pancreaticoduodenectomy (PD) is a major gastroenterological surgery
      that results in a substantial amount of blood loss. Several studies have
      demonstrated that major blood loss during PD is associated with both short-term
      and long-term poor outcomes. Administration of perioperative tranexamic acid
      (TXA) has been reported to reduce intraoperative blood loss in various surgeries,
      including cardiovascular surgery and orthopaedic surgery. Nevertheless, the
      effect of perioperative TXA use in patients undergoing PD has not been
      investigated. This study aims to investigate the effect of TXA on blood loss
      during PD. METHODS AND ANALYSIS: A multicentre (six hospitals), randomised, blind
      (patient-blinded, surgeon-blinded, anaesthesiologist-blinded, monitor-blinded),
      placebo-controlled trial of TXA during PD was started in September 2019. Patients
      undergoing PD for biliary, duodenal or pancreatic diseases are randomly assigned 
      to the TXA or placebo group. The stratification factors are the institutions and 
      preoperative clinical diagnosis. Before skin incision, the participants in TXA
      group are administrated 1 g TXA as a loading infusion followed by a maintenance
      infusion of 125 mg/hour TXA until the end of surgery or 8 hours from the
      incision. Participants in the placebo group are administrated the same volume of 
      saline that is indistinguishable from the TXA. The primary outcome is blood loss 
      during PD. The secondary outcomes are intraoperative and postoperative (up to day
      2) blood transfusions, operation time, anaesthesia time, postoperative laboratory
      variables, length of hospital stay, in-hospital and 90-day mortality and
      postoperative complications occurring within 28 days of surgery or requiring
      readmission. To date, 115 patients of a planned 220 have been enrolled in the
      study. ETHICS AND DISSEMINATION: This protocol was approved by the Nagoya
      University Clinical Research Review Board and is registered with Japan Registry
      of Clinical Trials on 15 August 2019. The results of this trial will be
      disseminated through peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      jRCTs041190062.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ishii, Kenta
AU  - Ishii K
AUID- ORCID: 0000-0001-6491-5224
AD  - Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
      ishiikenta0701@gmail.com.
FAU - Yokoyama, Yukihiro
AU  - Yokoyama Y
AD  - Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
FAU - Yonekawa, Yoshihiko
AU  - Yonekawa Y
AD  - Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
FAU - Ebata, Tomoki
AU  - Ebata T
AD  - Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
SB  - IM
MH  - *Antifibrinolytic Agents/therapeutic use
MH  - Blood Loss, Surgical/prevention & control
MH  - Double-Blind Method
MH  - Humans
MH  - Japan
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Tranexamic Acid
MH  - Treatment Outcome
PMC - PMC7640528
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *adult gastroenterology
OT  - *bleeding disorders & coagulopathies
OT  - *clinical trials
OT  - *hepatobiliary surgery
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040914 [pii]
AID - 10.1136/bmjopen-2020-040914 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e040914. doi: 10.1136/bmjopen-2020-040914.


PMID- 33148763
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Acceptability of bisphosphonates among patients, clinicians and managers: a
      systematic review and framework synthesis.
PG  - e040634
LID - 10.1136/bmjopen-2020-040634 [doi]
AB  - OBJECTIVE: To explore the acceptability of different bisphosphonate regimens for 
      the treatment of osteoporosis among patients, clinicians and managers, payers and
      academics. DESIGN: A systematic review of primary qualitative studies. Seven
      databases were searched from inception to July 2019. Screening, data extraction
      and quality assessment of full-articles selected for inclusion were performed
      independently by two authors. A framework synthesis was applied to extracted data
      based on the theoretical framework of acceptability (TFA). The TFA includes seven
      domains relating to sense-making, emotions, opportunity costs, burden, perceived 
      effectiveness, ethicality and self-efficacy. Confidence in synthesis findings was
      assessed. SETTING: Any developed country healthcare setting. PARTICIPANTS:
      Patients, healthcare professionals, managers, payers and academics. INTERVENTION:
      Experiences and views of oral and intravenous bisphosphonates. RESULTS:
      Twenty-five studies were included, mostly describing perceptions of oral
      bisphosphonates. We identified, with high confidence, how patients and healthcare
      professionals make sense (coherence) of bisphosphonates by balancing perceptions 
      of need against concerns, how uncertainty prevails about bisphosphonate perceived
      effectiveness and a number of individual and service factors that have potential 
      to increase self-efficacy in recommending and adhering to bisphosphonates. We
      identified, with moderate confidence, that bisphosphonate taking induces concern,
      but has the potential to engender reassurance, and that both side effects and
      special instructions for taking oral bisphosphonates can result in treatment
      burden. Finally, we identified with low confidence that multimorbidity plays a
      role in people's perception of bisphosphonate acceptability. CONCLUSION: By using
      the lens of acceptability, our findings demonstrate with high confidence that a
      theoretically informed, whole-system approach is necessary to both understand and
      improve adherence. Clinicians and patients need supporting to understand the need
      for bisphosphonates, and clinicians need to clarify to patients what constitutes 
      bisphosphonate treatment success. Further research is needed to explore
      perspectives of male patients and those with multimorbidity receiving
      bisphosphonates, and patients receiving intravenous treatment. PROSPERO
      REGISTRATION NUMBER: CRD42019143526.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Paskins, Zoe
AU  - Paskins Z
AD  - School of Medicine, Keele University, Keele, UK z.paskins@keele.ac.uk.
AD  - Haywood Academic Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, UK.
FAU - Crawford-Manning, Fay
AU  - Crawford-Manning F
AUID- ORCID: 0000-0002-9768-1695
AD  - School of Medicine, Keele University, Keele, UK.
AD  - Haywood Academic Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, UK.
FAU - Cottrell, Elizabeth
AU  - Cottrell E
AUID- ORCID: 0000-0002-5757-1854
AD  - School of Medicine, Keele University, Keele, UK.
FAU - Corp, Nadia
AU  - Corp N
AD  - School of Medicine, Keele University, Keele, UK.
FAU - Wright, Jenny
AU  - Wright J
AD  - School of Medicine, Keele University, Keele, UK.
FAU - Jinks, Clare
AU  - Jinks C
AD  - School of Medicine, Keele University, Keele, UK.
FAU - Bishop, Simon
AU  - Bishop S
AD  - Centre for Health Innovation, Leadership and Learning, University of Nottingham, 
      Nottingham, UK.
FAU - Doyle, Alison
AU  - Doyle A
AD  - Operations and Clinical Practice, Royal Osteoporosis Society, Bath, UK.
FAU - Ong, Terence
AU  - Ong T
AD  - Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Gittoes, Neil
AU  - Gittoes N
AD  - Centre for Endocrinology Diabetes and Metabolism, University of Birmingham,
      Birmingham, UK.
FAU - Leonardi-Bee, Jo
AU  - Leonardi-Bee J
AD  - Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK.
FAU - Langley, Tessa
AU  - Langley T
AD  - Division of Epidemiology and Public Health, University of Nottingham, Nottingham,
      UK.
FAU - Horne, Robert
AU  - Horne R
AD  - School of Pharmacy, University College London, London, UK.
FAU - Sahota, Opinder
AU  - Sahota O
AD  - Department of Geriatric Medicine, Nottingham University Hospitals NHS Trust,
      Nottingham, UK.
LA  - eng
GR  - CS-2018-18-ST2-010/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
SB  - IM
MH  - *Bone Density Conservation Agents/therapeutic use
MH  - Diphosphonates/therapeutic use
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - *Osteoporosis/drug therapy
MH  - Qualitative Research
PMC - PMC7640526
OTO - NOTNLM
OT  - *bone diseases
OT  - *musculoskeletal disorders
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040634 [pii]
AID - 10.1136/bmjopen-2020-040634 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e040634. doi: 10.1136/bmjopen-2020-040634.


PMID- 33148762
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - MAPPinfo, mapping quality of health information: study protocol for a validation 
      study of an assessment instrument.
PG  - e040572
LID - 10.1136/bmjopen-2020-040572 [doi]
AB  - INTRODUCTION: Health information is a prerequisite of informed decision-making.
      Criteria for development, content and presentation have recently been published
      in a corresponding guideline. Within a systematic search, 27 relevant checklists 
      were identified, none of them, however, complying with the guideline or providing
      reasonably operationalised measurement items. Therefore, a draft of a checklist
      with 19 criteria was drafted. The current study aims at developing and validating
      this measure of quality. METHODS AND ANALYSIS: The validation design consists of 
      five single studies to be conducted at the University of Halle-Wittenberg/Germany
      and Graz/Austria. (1) Achieving content validity through expert reviews of the
      first draft, (2) achieving feasibility using 'think aloud' in piloting with
      untrained users, (3) pretesting the instrument applied to health information
      materials without use of secondary sources: determining inter-rater reliability
      and criterion validity, (4) determining construct validity using information on
      proceedings and methods in the development process provided by the developers and
      (5) determining divergent validity in comparison with the Ensuring Quality
      Information for Patients (EQUIP) (expanded) Scale. The substudies will use
      varying samples of experts, students and developers and will apply the instrument
      to materials of various domains. Sample sizes will be adjusted to the particular 
      research designs and questions. Analyses will employ qualitative methods, such as
      content analyses and discourse within the expert panel, and correlation-based
      methods both for determining inter-rater reliability and validity. ETHICS AND
      DISSEMINATION: The project is approved by the ethics committee of the Martin
      Luther University Halle-Wittenberg (approval number: 2019 115). Results will be
      published, and the instrument made accessible on public health platforms. It is
      meant to become a certification standard. MAPPinfo can be used as a screening
      instrument without training or secondary sources. Although developed in the
      German language, the instrument will be applicable also in other languages. TRIAL
      REGISTRATION NUMBER: AsPredected22546; date of registration: 24 July 2019.
      PROTOCOL VERSION: July 2020.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kasper, Jurgen
AU  - Kasper J
AD  - Faculty of Health Sciences, Department of Health and Caring Sciences, University 
      of Tromso, Tromso, Norway Juergen.Kasper@uit.no.
AD  - Oslo Metropolitan University, Faculty of Health Sciences, Oslo, Norway.
FAU - Luhnen, Julia
AU  - Luhnen J
AD  - Health and Nursing Science, Martin Luther University Halle Wittenberg, Halle,
      Germany.
FAU - Hinneburg, Jana
AU  - Hinneburg J
AD  - Health and Nursing Science, Martin Luther University Halle Wittenberg, Halle,
      Germany.
FAU - Siebenhofer, Andrea
AU  - Siebenhofer A
AUID- ORCID: 0000-0002-6980-2103
AD  - Medical University Graz, Institute of General Practice and Evidence-Based Health 
      Services Research, Graz, Austria.
AD  - Goethe University, Institute for General Practice, Frankfurt, Germany.
FAU - Posch, Nicole
AU  - Posch N
AD  - Institute of General Practice and Evidence-Based Health Services Research,
      Medizinische Universitat Graz, Graz, Austria.
FAU - Berger-Hoger, Birte
AU  - Berger-Hoger B
AD  - Health and Nursing Science, Martin Luther University Halle Wittenberg, Halle,
      Germany.
FAU - Grafe, Alexander
AU  - Grafe A
AD  - MSH Medical School Hamburg, Hamburg, Germany.
FAU - Keppler, Jan
AU  - Keppler J
AD  - Institute of Psychology, Christian-Albrechts-Universitat zu Kiel, Kiel, Germany.
FAU - Steckelberg, A
AU  - Steckelberg A
AUID- ORCID: 0000-0002-8687-3149
AD  - Health and Nursing Science, Martin Luther University Halle Wittenberg, Halle,
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Austria
MH  - *Checklist
MH  - Humans
MH  - Reproducibility of Results
PMC - PMC7640523
OTO - NOTNLM
OT  - *health & safety
OT  - *information management
OT  - *information technology
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040572 [pii]
AID - 10.1136/bmjopen-2020-040572 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e040572. doi: 10.1136/bmjopen-2020-040572.


PMID- 33148760
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Impact of surgical margin status on the survival outcome after surgical resection
      of gastric cancer: a protocol for systematic review and meta-analysis.
PG  - e040282
LID - 10.1136/bmjopen-2020-040282 [doi]
AB  - INTRODUCTION: Generally, complete resection with cancer cell negative (R0) margin
      has been accepted as the most effective treatment of gastric cancer and positive 
      resection (R1/R2) margin has been associated with decreased survival to varied
      degrees. However, the independent impact of microscopical positive (R1) margin on
      long-term survival may be confounded. No meta-analysis has worked at the
      association between R1 margin and outcomes of gastric cancer and the available
      evidence are scant. Therefore, we plan to conduct a systematic review and
      meta-analysis to quantitatively explore the role of R1 margin on gastric
      (including oesophagogastric junction) cancer survival after curative intent
      resection. METHODS AND ANALYSIS: The protocol was conducted according to
      Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
      guideline. A systematic search of PubMed, Embase and the Cochrane Central
      Register of Controlled Trials databases will be performed from their inceptions
      to 30 April 2020 to identify randomised controlled trials (RCTs), cohort studies 
      and case-control studies focusing on the impact of R1 margin on survival of
      gastric cancer after curative intent resection. The primary outcome will be the
      overall survival (OS) and disease-free survival (DFS) and the secondary outcomes 
      will be 5-year OS rate and 5-year DFS rate. The Cochrane tool for bias assessment
      in randomised trials and Risk Of Bias In Non-randomised Studies-I for the
      assessment of bias in non-randomised studies (NRS) will be used. Statistical
      heterogeneity will be assessed by visual inspection of forest plots and measured 
      using the I(2) statistics. A fixed-effect model will be used when heterogeneity
      is low, otherwise, a random-effect model will be chosen. Publication bias will be
      assessed by funnel plots, subgroup analysis and sensitivity analysis will be
      performed in the right context. For each outcome, we will perform data synthesis 
      separately for RCTs and NRS using Rev Man V.5.3 software and compile 'summary of 
      findings' tables separately for RCTs and NRS using GRADEpro software. Grading of 
      Recommendations, Assessment, Development and Evaluations considerations will also
      be used to make an overall assessment of the quality of evidence. ETHICS AND
      DISSEMINATION: There is no requirement for ethics approval because no patient
      data will be collected at an individual level in this systematic review and
      meta-analysis.The results of this systematic review will be published in a
      peer-reviewed journal and presented at relevant conferences, any deviations from 
      the protocol will be clearly documented and explained in its final report.
      PROSPERO REGISTRATION NUMBER: CRD42020165110.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jiang, Zhiyuan
AU  - Jiang Z
AUID- ORCID: 0000-0003-2483-3413
AD  - Department of Gastrointestinal Surgery, Sichuan University West China Hospital,
      Chengdu, Sichuan, China.
FAU - Cai, Zhaolun
AU  - Cai Z
AUID- ORCID: 0000-0002-3706-6703
AD  - Department of Gastrointestinal Surgery, Sichuan University West China Hospital,
      Chengdu, Sichuan, China.
FAU - Yin, Yuan
AU  - Yin Y
AD  - Department of Gastrointestinal Surgery, Sichuan University West China Hospital,
      Chengdu, Sichuan, China.
FAU - Shen, Chaoyong
AU  - Shen C
AD  - Department of Gastrointestinal Surgery, Sichuan University West China Hospital,
      Chengdu, Sichuan, China.
FAU - Huang, Jinming
AU  - Huang J
AD  - Department of Rehabilitation Medicine, Sichuan University West China Hospital,
      Chengdu, Sichuan, China.
FAU - Yin, Yiqiong
AU  - Yin Y
AD  - Department of Gastrointestinal Surgery, Sichuan University West China Hospital,
      Chengdu, Sichuan, China hxwcwk@126.com yiqiong489@163.com.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Gastrointestinal Surgery, Sichuan University West China Hospital,
      Chengdu, Sichuan, China hxwcwk@126.com yiqiong489@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Margins of Excision
MH  - Meta-Analysis as Topic
MH  - Publication Bias
MH  - Research Design
MH  - *Stomach Neoplasms/surgery
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7643516
OTO - NOTNLM
OT  - *Survival
OT  - *gastrointestinal tumours
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040282 [pii]
AID - 10.1136/bmjopen-2020-040282 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e040282. doi: 10.1136/bmjopen-2020-040282.


PMID- 33148756
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Impact of SARS-CoV-2 (COVID-19) on pregnancy: a systematic review and
      meta-analysis protocol.
PG  - e039933
LID - 10.1136/bmjopen-2020-039933 [doi]
AB  - INTRODUCTION: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been
      growing at an accelerating rate, and has become a public health emergency.
      Pregnant women and their fetuses are susceptible to viral infection, and outcomes
      in this population need to be investigated. METHODS AND ANALYSIS: PubMed, Web of 
      Science, Embase, CINAHAL, Latin American and Caribbean Health Sciences
      Literature, clinicaltrials.gov, SCOPUS, Google Scholar and Cochrane Central
      Controlled Trials Registry will be searched for observational studies (cohort and
      control cases) published from December 2019 to present. This systematic review
      and meta-analysis will include studies of pregnant women at any gestational stage
      diagnosed with COVID-19. The primary outcomes will be maternal and foetal
      morbidity and mortality. Three independent reviewers will select the studies and 
      extract data from the original publications. The risk of bias will be assessed
      using the Newcastle-Ottawa Scale for observational studies. To evaluate the
      strength of evidence from the included data, we will use Grading of
      Recommendation Assessment, Development, and Evaluation method. Data synthesis
      will be performed using Review Manager software V.5.2.3. To assess heterogeneity,
      we will compute the I(2) statistics. Additionally, a quantitative synthesis will 
      be performed if the included studies are sufficiently homogenous. ETHICS AND
      DISSEMINATION: This study will be a review of the published data, and thus it is 
      not necessary to obtain ethical approval. The findings of this systematic review 
      will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      PROSPERO 2020: CRD42020181519.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Medeiros, Kleyton Santos
AU  - Medeiros KS
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Sarmento, Ayane Cristine Alves
AU  - Sarmento ACA
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Martins, Erico Silva
AU  - Martins ES
AD  - Oncology School, Liga Norte Riograndense Contra o Cancer, Natal, Rio Grande do
      Norte, Brazil.
FAU - Costa, Ana Paula Ferreira
AU  - Costa APF
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil.
FAU - Eleuterio, Jose Jr
AU  - Eleuterio J Jr
AD  - Motherhood and Child Department, Universidade Federal do Ceara, Fortaleza,
      Brazil.
FAU - Goncalves, Ana Katherine
AU  - Goncalves AK
AUID- ORCID: 0000-0002-8351-5119
AD  - Postgraduate Program in Health Sciences, Federal University of Rio Grande do
      Norte, Natal, Brazil anakatherine_ufrnet@yahoo.com.br.
LA  - eng
PT  - Journal Article
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - Birth Weight
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Female
MH  - Fetal Diseases
MH  - Fetal Distress
MH  - *Fetal Mortality
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Newborn, Diseases
MH  - *Maternal Mortality
MH  - Meta-Analysis as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious
MH  - *Pregnancy Outcome
MH  - SARS-CoV-2
MH  - Stillbirth
MH  - Systematic Reviews as Topic
PMC - PMC7640522
OTO - NOTNLM
OT  - *gynaecology
OT  - *infection control
OT  - *infectious diseases
OT  - *neonatology
OT  - *obstetrics
OT  - *virology
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjopen-2020-039933 [pii]
AID - 10.1136/bmjopen-2020-039933 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e039933. doi: 10.1136/bmjopen-2020-039933.


PMID- 33148754
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Defining timeliness in care for patients with lung cancer: protocol for a scoping
      review.
PG  - e039660
LID - 10.1136/bmjopen-2020-039660 [doi]
AB  - INTRODUCTION: Cancer is the second leading cause of death worldwide, and lung
      cancer is the single leading cause of cancer mortality worldwide. Early diagnosis
      of lung cancer is the key to better prognosis and longer survival. While there
      are substantial literature reporting delays in cancer diagnosis, there is a lack 
      of consensus in the definitions and terms used to describe 'delay' in the
      treatment pathway. The aim of this scoping review is to identify and critically
      synthesise the operational definitions and terminologies used to describe the
      timely initiation of care and consequent treatments over the care pathway for
      patients with lung cancer. This scoping review will also compare how timeliness
      was operationalised in Western and Asian countries. METHODS AND ANALYSIS: The
      scoping review will use the methodology described by Arksey and O'Malley and
      endorsed by the Joanna Briggs Institute. MEDLINE, EMBASE, CINAHL and PsycINFO
      electronic databases will be searched. Grey literature sources and the reference 
      lists of key studies will be used to identify additional relevant studies. The
      scoping review will include all studies, irrespective of study methodology and
      quality. Two reviewers will independently screen all titles and abstracts to
      identify eligible studies for inclusion. The full texts of identified studies
      will be further examined and charted using a data extraction form. A narrative
      synthesis will be performed to assess and categorise available definitions of
      timeliness. ETHICS AND DISSEMINATION: Ethical approval is not needed as this
      scoping review will be reviewing already published articles. The results produced
      from this review will be submitted to a scientific peer-reviewed journal for
      publication and will be presented at scientific meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ansar, Adnan
AU  - Ansar A
AUID- ORCID: 0000-0001-6052-8657
AD  - College of Science, Health and Engineering, La Trobe University, Melbourne,
      Victoria, Australia ansar.a@students.latrobe.edu.au.
FAU - Lewis, Virginia
AU  - Lewis V
AD  - Australian Institute for Primary Care and Aging, La Trobe University, Bundoora,
      Victoria, Australia.
FAU - McDonald, Christine Faye
AU  - McDonald CF
AD  - Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia.
FAU - Liu, Chaojie
AU  - Liu C
AUID- ORCID: 0000-0003-0877-0424
AD  - School of Psychology and Public Health, La Trobe University, Bundoora, Victoria, 
      Australia.
FAU - Rahman, Aziz
AU  - Rahman A
AD  - School of Health, Federation University Australia, Berwick, Victoria, Australia.
AD  - School of Nursing and Midwifery, La Trobe University, Melbourne, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Asia
MH  - Delivery of Health Care
MH  - Humans
MH  - *Lung Neoplasms/diagnosis/therapy
MH  - Peer Review
MH  - *Research Design
PMC - PMC7643508
OTO - NOTNLM
OT  - *preventive medicine
OT  - *protocols & guidelines
OT  - *public health
OT  - *respiratory tract tumours
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-039660 [pii]
AID - 10.1136/bmjopen-2020-039660 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e039660. doi: 10.1136/bmjopen-2020-039660.


PMID- 33148753
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Effects of temperature, humidity, air quality and anthropic activities on the
      transmission of SARS-CoV-2: a systematic review protocol.
PG  - e039623
LID - 10.1136/bmjopen-2020-039623 [doi]
AB  - INTRODUCTION: The current global pandemic of the virus that emerged from Hubei
      province in China has caused coronavirus disease in 2019 (COVID-19), which has
      affected a total number of 900 036 people globally, involving 206 countries and
      resulted in a cumulative of 45 693 deaths worldwide as of 3 April 2020. The mode 
      of transmission is identified through airdrops from patients' body fluids such as
      during sneezing, coughing and talking. However, the relative importance of
      environmental effects in the transmission of the virus has not been vastly
      studied. In addition, the role of temperature and humidity in air-borne
      transmission of infection is presently still unclear. This study aims to identify
      the effect of temperature, humidity and air quality in the transmission of
      SARS-CoV-2. METHODS AND ANALYSIS: We will systematically conduct a comprehensive 
      literature search using various databases including PubMed, EMBASE, Scopus,
      CENTRAL and Google Scholar to identify potential studies. The search will be
      performed for any eligible articles from the earliest published articles up to
      latest available studies in 2020. We will include all the observational studies
      such as cohort case-control and cross-sectional studies that explains or measures
      the effects of temperature and/or humidity and/or air quality and/or anthropic
      activities that is associated with SARS-CoV-2. Study selection and reporting will
      follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      (PRISMA) guidelines and Meta-Analysis of Observational Studies in Epidemiology
      guideline. All data will be extracted using a standardised data extraction form
      and quality of the studies will be assessed using the Newcastle-Ottawa Scale
      guideline. Descriptive and meta-analysis will be performed using a random effect 
      model in Review Manager File. ETHICS AND DISSEMINATION: No primary data will be
      collected, and thus no formal ethical approval is required. The results will be
      disseminated through a peer-reviewed publication and conference presentation.
      PROSPERO REGISTRATION NUMBER: CRD42020176756.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jeevananthan, Chandrika
AU  - Jeevananthan C
AUID- ORCID: 0000-0003-1161-0720
AD  - Department of Community Health, Faculty of Medicine, Universiti Kebangsaan
      Malaysia, Kuala Lumpur, Malaysia chandrika.jeevananthan@gmail.com.
AD  - Sector for Evidence-based Healthcare,National Institutes of Health, Ministry of
      Health, Shah Alam, Selangor, Malaysia.
FAU - Muhamad, Nor Asiah
AU  - Muhamad NA
AUID- ORCID: 0000-0002-7772-2103
AD  - Sector for Evidence-based Healthcare,National Institutes of Health, Ministry of
      Health, Shah Alam, Selangor, Malaysia.
FAU - Jaafar, Mohd Hasni
AU  - Jaafar MH
AUID- ORCID: 0000-0003-0007-6008
AD  - Department of Community Health, Faculty of Medicine, Universiti Kebangsaan
      Malaysia, Kuala Lumpur, Malaysia.
FAU - Hod, Rozita
AU  - Hod R
AUID- ORCID: 0000-0001-8645-1723
AD  - Department of Community Health, Faculty of Medicine, Universiti Kebangsaan
      Malaysia, Kuala Lumpur, Malaysia.
FAU - Ab Ghani, Rimah Melati
AU  - Ab Ghani RM
AD  - Sector for Evidence-based Healthcare,National Institutes of Health, Ministry of
      Health, Shah Alam, Selangor, Malaysia.
FAU - Md Isa, Zaleha
AU  - Md Isa Z
AUID- ORCID: 0000-0003-4850-901X
AD  - Department of Community Health, Faculty of Medicine, Universiti Kebangsaan
      Malaysia, Kuala Lumpur, Malaysia.
CN  - Review Team Members
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Air Pollution
MH  - Air Pollution, Indoor
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*transmission
MH  - *Human Activities
MH  - Humans
MH  - *Humidity
MH  - Pandemics
MH  - Pneumonia, Viral/*transmission
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - *Temperature
PMC - PMC7643413
OTO - NOTNLM
OT  - *epidemiology
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
IR  - Jeevananthan C
FIR - Jeevananthan, Chandrika
IR  - Muhamad NA
FIR - Muhamad, Nor Asiah
IR  - Jaafar MH
FIR - Jaafar, Mohd Hasni
IR  - Hod R
FIR - Hod, Rozita
EDAT- 2020/11/06 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - bmjopen-2020-039623 [pii]
AID - 10.1136/bmjopen-2020-039623 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e039623. doi: 10.1136/bmjopen-2020-039623.


PMID- 33148752
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Clinical communication in inflammatory bowel disease: a systematic literature
      review protocol.
PG  - e039503
LID - 10.1136/bmjopen-2020-039503 [doi]
AB  - INTRODUCTION: Evidence regarding effective communication between clinicians and
      patients with inflammatory bowel disease (IBD) is limited. Studies that
      investigate clinical communication in IBD are much fewer in number than studies
      that investigate the perceptions of patients and clinicians about communication
      in clinical encounters. The current review aims to identify, organise and
      summarise systematically what is currently known about (1) the characteristics of
      interactions between clinicians who manage IBD and patients with IBD, and (2) how
      clinical discussion affects health outcomes in IBD. METHODS AND ANALYSIS: Scopus,
      PubMed, Embase, Communication Abstracts, Health & Society, Linguistics and
      Language Behavior Abstracts and PsycINFO will be systematically searched for
      studies that investigate the characteristics of IBD clinical interactions during 
      recorded consultations, from earliest available dates within each database to May
      2020. A specifically developed quality assessment tool, grounded in linguistic
      theory, will be used to critically assess the evidence. In addition, a data
      extraction template will be developed and utilised to provide a description of
      the characteristics of IBD clinical communication as well as an estimation of its
      effect on health outcomes in a narrative synthesis. ETHICS AND DISSEMINATION:
      Ethical review and approval is not required for this systematic review as no
      primary data will be collected. The results will be published in peer-reviewed
      journals and presented at academic conferences. PROSPERO REGISTRATION NUMBER:
      International Prospective Register of Systematic Reviews (PROSPERO) on 28 April
      2020 (registration number: CRD42020169657).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Karimi, Neda
AU  - Karimi N
AUID- ORCID: 0000-0002-2841-637X
AD  - Faculty of Medicine, South Western Sydney Clinical School, University of New
      South Wales, Sydney, New South Wales, Australia Neda.Karimi@unsw.edu.au.
AD  - Gastroenterology Research Group, The Ingham Institute for Applied Medical
      Research, Liverpool, New South Wales, Australia.
FAU - Moore, Alison Rotha
AU  - Moore AR
AD  - Faculty of Law Humanities and the Arts, School of Humanities and Social Inquiry, 
      University of Wollongong, Wollongong, New South Wales, Australia.
FAU - Lukin, Annabelle
AU  - Lukin A
AD  - Faculty of Medicine, Health and Human Sciences, Department of Linguistics,
      Macquarie University, Sydney, New South Wales, Australia.
FAU - Kanazaki, Ria
AU  - Kanazaki R
AUID- ORCID: 0000-0002-8866-1078
AD  - Faculty of Medicine, South Western Sydney Clinical School, University of New
      South Wales, Sydney, New South Wales, Australia.
AD  - Department of Gastroenterology, Liverpool Hospital, Liverpool, New South Wales,
      Australia.
FAU - Williams, Astrid-Jane
AU  - Williams AJ
AD  - Faculty of Medicine, South Western Sydney Clinical School, University of New
      South Wales, Sydney, New South Wales, Australia.
AD  - Department of Gastroenterology, Liverpool Hospital, Liverpool, New South Wales,
      Australia.
FAU - Connor, Susan
AU  - Connor S
AD  - Faculty of Medicine, South Western Sydney Clinical School, University of New
      South Wales, Sydney, New South Wales, Australia.
AD  - Department of Gastroenterology, Liverpool Hospital, Liverpool, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Communication
MH  - Humans
MH  - *Inflammatory Bowel Diseases
PMC - PMC7643514
OTO - NOTNLM
OT  - *clinical communication
OT  - *clinical encounter
OT  - *communication
OT  - *inflammatory bowel disease
OT  - *systematic review
COIS- Competing interests: NK, ARM and AL have received grant support from Janssen. RK 
      has received research and educational support from Pfizer, Abbvie, Takeda and
      Janssen. AW has received Honoraria from Takeda, Ferring, Janssen and Abbvie. SC
      has received Honoraria, speaker fees, educational support and/or research support
      from AbbVie, Celgene, Ferring, Gilead, Janssen, MSD, Novartis, Orphan/Aspen,
      Pfizer, Shire and Takeda.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-039503 [pii]
AID - 10.1136/bmjopen-2020-039503 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e039503. doi: 10.1136/bmjopen-2020-039503.


PMID- 33148744
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Co-production of an educational package for the universal human papillomavirus
      (HPV) vaccination programme tailored for schools with low uptake: a participatory
      study protocol.
PG  - e039029
LID - 10.1136/bmjopen-2020-039029 [doi]
AB  - AIM: To co-produce with young people an educational package about the human
      papillomavirus (HPV) vaccine that is tailored to increase vaccine uptake in
      schools and populations with lower uptake. INTRODUCTION: Persistent infection
      with HPV can result in cancers affecting men and especially women. From September
      2019, the English-schools-based HPV vaccination programme was expanded to include
      young men (in addition to young women) aged 12-13 years. Some young people
      attending schools with lower uptake of the vaccine have unmet information needs. 
      We hypothesise that mechanisms to address information needs and increase young
      people's autonomy in consent procedures will result in higher uptake. METHODS AND
      ANALYSIS: The Medical Research Council's framework for development and evaluation
      of complex interventions will inform intervention development. Recruitment of
      young people aged 12-15 years and key stakeholders (National Health Service
      commissioners, school staff, immunisation nurses and youth workers/practitioners)
      will be facilitated through existing links with healthcare organisations, schools
      and youth organisations in areas with lower uptake of the HPV vaccination
      programme. The proposed research will comprise three phases: (1) a rapid review
      of adolescent immunisation materials and preliminary qualitative interviews with 
      young people and key stakeholders, (2) theory development and co-production of
      HPV vaccine communication materials through an iterative process with young
      people and (iii) testing delivery mechanisms and acceptability of the educational
      package in four schools with lower uptake. ETHICS AND DISSEMINATION: The
      University of Bristol's Faculty of Health Sciences and London School of Hygiene
      and Tropical Medicine's Research Ethics Committees provided approvals for the
      study. A dissemination event for young people and key stakeholders and webinar
      with the National Immunisation Network will be organised. The study findings will
      be published in peer-reviewed journals and presented at conferences.
      Recommendations for a future larger scale study will be made.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fisher, Harriet
AU  - Fisher H
AUID- ORCID: 0000-0002-5639-0955
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK Harriet.Fisher@bristol.ac.uk.
FAU - Audrey, Suzanne
AU  - Audrey S
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Chantler, Tracey
AU  - Chantler T
AUID- ORCID: 0000-0001-7776-7339
AD  - Department of Global Health and Development, London School of Hygiene & Tropical 
      Medicine, London, UK.
FAU - Finn, Adam
AU  - Finn A
AD  - Division of Clinical Sciences, University of Bristol, Bristol, UK.
FAU - Letley, Louise
AU  - Letley L
AD  - National Infection Service, Public Health England, London, UK.
FAU - Mounier-Jack, Sandra
AU  - Mounier-Jack S
AD  - Department of Global Health and Development, London School of Hygiene & Tropical 
      Medicine, London, UK.
FAU - Thomas, Clare
AU  - Thomas C
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Yates, Julie
AU  - Yates J
AD  - Public Health England, Taunton, UK.
FAU - Hickman, Matthew
AU  - Hickman M
AUID- ORCID: 0000-0001-9864-459X
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
LA  - eng
GR  - MR/T027150/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - *Alphapapillomavirus
MH  - Child
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - London
MH  - Male
MH  - *Papillomavirus Infections/prevention & control
MH  - *Papillomavirus Vaccines
MH  - Schools
MH  - State Medicine
MH  - Uterine Cervical Neoplasms
MH  - Vaccination
PMC - PMC7643513
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *paediatric infectious disease & immunisation
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-039029 [pii]
AID - 10.1136/bmjopen-2020-039029 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e039029. doi: 10.1136/bmjopen-2020-039029.


PMID- 33148743
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Psychometric properties of patient-reported outcome measures of self-management
      for cancer survivors: a systematic review protocol using COSMIN methodology.
PG  - e038983
LID - 10.1136/bmjopen-2020-038983 [doi]
AB  - INTRODUCTION: Self-management is an important strategy for cancer survivors.
      Evaluating self-management is essential for planning nursing interventions that
      promote self-management and for measuring the contribution of nursing to health
      outcomes. Many patient-reported outcome measures (PROMs) have been designed and
      used to assess self-management in cancer survivors. However, it is unclear which 
      PROM has the best reliability and validity. Therefore, the goal is to
      systematically review the psychometric properties of existing self-management
      PROMs and determine which PROM is best for cancer survivors. METHODS AND
      ANALYSIS: This systematic review will be conducted according to the
      COnsensus-based Standards for the selection of health Measurement INstruments
      (COSMIN) guidelines for systematic reviews of PROMs. Ten electronic literature
      databases (PubMed, EMBASE and so on) and two websites for PROMs will be searched 
      from inception to 1 March 2020. Studies testing the psychometric properties of
      PROMs assessing self-management for cancer survivors, published in either English
      or Chinese, will be included. Two independent reviewers determined the
      eligibility of the studies and will independently extract the data. Risk of bias 
      will be assessed using the COSMIN risk-of-bias checklist, and the quality of the 
      results will be assessed using specific COSMIN quality criteria. ETHICS AND
      DISSEMINATION: It is not necessary to obtain ethical approval for this systematic
      review protocol. The results will be published in a peer-reviewed journal and
      presented at a relevant conference. PROSPERO REGISTRATION NUMBER: CRD42020149120.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Peng, Jian
AU  - Peng J
AUID- ORCID: 0000-0003-1953-0709
AD  - School of Nursing, Fudan University, Shanghai, China.
FAU - Chen, Yiting
AU  - Chen Y
AD  - School of Nursing, Fudan University, Shanghai, China.
FAU - Shen, Lanjun
AU  - Shen L
AD  - School of Nursing, Fudan University, Shanghai, China.
FAU - Zhu, Zheng
AU  - Zhu Z
AD  - School of Nursing, Fudan University, Shanghai, China.
FAU - Xing, Weijie
AU  - Xing W
AD  - School of Nursing, Fudan University, Shanghai, China.
FAU - Jin, Guodong
AU  - Jin G
AD  - Nursing department, Xi'an Jiaotong University Medical College First Affiliated
      Hospital, Xi'an, Shaanxi, China.
FAU - Hu, Yan
AU  - Hu Y
AD  - School of Nursing, Fudan University, Shanghai, China huyan@fudan.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cancer Survivors
MH  - Humans
MH  - *Neoplasms/therapy
MH  - Patient Reported Outcome Measures
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - *Self-Management
PMC - PMC7640513
OTO - NOTNLM
OT  - *health & safety
OT  - *oncology
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - bmjopen-2020-038983 [pii]
AID - 10.1136/bmjopen-2020-038983 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e038983. doi: 10.1136/bmjopen-2020-038983.


PMID- 33148738
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy
      followed by robot-assisted radical prostatectomy for treating locally advanced
      prostate cancer: protocol for an open-label, dose-escalation, single-centre,
      phase I clinical trial.
PG  - e038678
LID - 10.1136/bmjopen-2020-038678 [doi]
AB  - INTRODUCTION: Patients with locally advanced prostate cancer are at high risk of 
      recurrence after definitive treatment. There are emerging data that radical
      prostatectomy can delay the progression of castration resistance and potentially 
      prolong survival. Neoadjuvant radiation therapy improves local control and has
      shown survival benefit with favourable toxicity profiles in several other
      malignancies. We have designed this trial to investigate whether this
      combination, which theoretically maximises local control, is a safe and feasible 
      approach for treating locally advanced prostate cancer. METHODS AND ANALYSIS:
      This study is a phase I, open-label study to investigate the safety and
      feasibility of neoadjuvant hormone and radiation therapy followed by
      robot-assisted radical prostatectomy by a traditional 3+3 dose-escalation design 
      with four planned radiation dose levels (39.6 Gy/22F, 45 Gy/25F, 50.4 Gy/28F and 
      54 Gy/30F). Locally advanced prostate cancer patients with positive pelvic and/or
      retroperitoneal lymph nodes will be recruited. The primary objective is to
      determine the adverse events and maximal tolerable dose (MTD) of neoadjuvant
      radiotherapy. Toxicity will be assessed using the National Cancer Institute
      Common Toxicity Criteria V.5.0. ETHICS AND DISSEMINATION: This protocol was
      approved by the Institutional Review Board of Shanghai Changhai Hospital (ref.
      CHEC2019-070 and CHEC2019-082). The study will be performed in compliance with
      applicable local legislation and in accordance with the ethical principles
      developed by the World Medical Association in the Declaration of Helsinki 2013.
      Study results will be disseminated through conferences and peer-reviewed
      scientific journals. TRIAL REGISTRATION NUMBERS: ChiCTR1900022716;
      ChiCTR1900022754.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xiao, Yu-Tian
AU  - Xiao YT
AUID- ORCID: 0000-0002-3039-8342
AD  - Department of Urology, Shanghai Changhai Hospital, Shanghai, China.
FAU - Zhao, Xianzhi
AU  - Zhao X
AUID- ORCID: 0000-0003-4096-3349
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Shanghai, China.
FAU - Chang, Yifan
AU  - Chang Y
AD  - Department of Urology, Shanghai Changhai Hospital, Shanghai, China.
FAU - Lu, Xiaojun
AU  - Lu X
AD  - Department of Urology, Shanghai Changhai Hospital, Shanghai, China.
FAU - Wang, Ye
AU  - Wang Y
AD  - Department of Urology, Shanghai Changhai Hospital, Shanghai, China.
FAU - Zhang, Huojun
AU  - Zhang H
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Shanghai, China
      chyyzhj@163.com renshancheng@gmail.com.
FAU - Ren, Shancheng
AU  - Ren S
AD  - Department of Urology, Shanghai Changhai Hospital, Shanghai, China
      chyyzhj@163.com renshancheng@gmail.com.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Androgen Antagonists)
RN  - 0 (Hormones)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Androgen Antagonists
MH  - China
MH  - Feasibility Studies
MH  - Hormones
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Positron Emission Tomography Computed Tomography
MH  - Prostatectomy
MH  - *Prostatic Neoplasms/radiotherapy/surgery
MH  - Quality of Life
MH  - Robotic Surgical Procedures
MH  - Young Adult
PMC - PMC7640530
OTO - NOTNLM
OT  - *radiation oncology
OT  - *surgery
OT  - *urological tumours
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - bmjopen-2020-038678 [pii]
AID - 10.1136/bmjopen-2020-038678 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e038678. doi: 10.1136/bmjopen-2020-038678.


PMID- 33148737
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Effects of exergames training on postural balance in patients who had a chronic
      stroke: study protocol for a randomised controlled trial.
PG  - e038593
LID - 10.1136/bmjopen-2020-038593 [doi]
AB  - INTRODUCTION: Exergames training, as an additional therapy to standard care, has 
      been widely used for motor recovery after patients who had a stroke, and it is a 
      valuable and positive tool in the rehabilitation of this population. This study
      describes a single-blind randomised clinical trial that will aim to investigate
      the effects of exergames training on postural balance in patients with chronic
      stroke. METHODS AND ANALYSIS: Forty-two individuals with chronic stroke (>6
      months), aged 20-75 years, will be randomised into two groups: the experimental
      group, which will be subjected to an exergames protocol, and control group, which
      will undergo a kinesiotherapy protocol. Both protocols are based on postural
      balance. The intervention will consist of 40-minute sessions two times per week
      for 10 consecutive weeks. The volunteers will be evaluated before the treatment, 
      at the end of the interventions and 8 weeks thereafter. The primary outcome will 
      be postural balance (Berg Balance Scale, Functional Reach Test, Timed Up and Go
      test and Centre of Pressure variables) and secondary outcomes will include gait
      (6 m timed walk and Kinovea Software), cortical activation patterns
      (electroencephalography Emotiv EPOC), functional independence (Functional
      Independence Measure), quality of life (Stroke-Specific Quality of Life Scale)
      and motivation (Intrinsic Motivation Inventory). ETHICS AND DISSEMINATION: This
      protocol was approved by the Ethics Committee of the Federal University of Rio
      Grande do Norte (number 3.434.350). The results of the study will be disseminated
      to participants through social networks and will be submitted to a peer-reviewed 
      journal and scientific meetings. TRIAL REGISTRATION NUMBER: Brazilian Registry of
      Clinical Trials (RBR-78v9hx).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bessa, Nathalia Priscilla Oliveira Silva
AU  - Bessa NPOS
AUID- ORCID: 0000-0002-3160-8102
AD  - Departament of Physical Therapy, Federal University of Rio Grande do Norte,
      Natal, Brazil nathyzinhasilva@gmail.com.
FAU - Lima Filho, Bartolomeu Fagundes de
AU  - Lima Filho BF
AD  - Departament of Physical Therapy, Federal University of Rio Grande do Norte,
      Natal, Brazil.
FAU - Medeiros, Candice Simoes Pimenta de
AU  - Medeiros CSP
AD  - Departament of Physical Therapy, Federal University of Rio Grande do Norte,
      Natal, Brazil.
FAU - Ribeiro, Tatiana Souza
AU  - Ribeiro TS
AUID- ORCID: 0000-0002-9611-1076
AD  - Departament of Physical Therapy, Federal University of Rio Grande do Norte,
      Natal, Brazil.
FAU - Campos, Tania Fernandes
AU  - Campos TF
AD  - Departament of Physical Therapy, Federal University of Rio Grande do Norte,
      Natal, Brazil.
FAU - Cavalcanti, Fabricia Azevedo da Costa
AU  - Cavalcanti FADC
AD  - Departament of Physical Therapy, Federal University of Rio Grande do Norte,
      Natal, Brazil.
LA  - eng
SI  - ReBec/RBR-78v9hx
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brazil
MH  - Exercise Therapy
MH  - Humans
MH  - Middle Aged
MH  - Postural Balance
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Single-Blind Method
MH  - *Stroke/therapy
MH  - *Stroke Rehabilitation
MH  - Time and Motion Studies
MH  - Young Adult
PMC - PMC7643507
OTO - NOTNLM
OT  - *neurology
OT  - *rehabilitation medicine
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-038593 [pii]
AID - 10.1136/bmjopen-2020-038593 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e038593. doi: 10.1136/bmjopen-2020-038593.


PMID- 33148730
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Intensive care units follow-up: a scoping review protocol.
PG  - e037725
LID - 10.1136/bmjopen-2020-037725 [doi]
AB  - INTRODUCTION: Increasing numbers of patients are surviving critical illness,
      leading to growing concern about the potential impact of the long-term
      consequences of intensive care on patients, families and society as a whole.
      These long-term effects are together known as postintensive care syndrome and
      their presence can be evaluated at intensive care unit (ICU) follow-up
      consultations. However, the services provided by these consultations vary across 
      hospitals and units, in part because there is no validated standard model to
      evaluate patients and their quality of life after ICU discharge. We describe a
      protocol for a scoping review focusing on models of ICU follow-up and the impact 
      of such strategies on improving patient quality of life. METHODS AND ANALYSIS: In
      this scoping review, we will search the literature systematically using
      electronic databases (MEDLINE - from database inception to June 15th 2020) and a 
      grey literature search. We will involve stakeholders as recommended by the Joanna
      Briggs Institute approach developed by Peters et al. The research will be
      conducted in accordance with the Preferred Reporting Items for Systematic Reviews
      and Meta-Analyses Extension for Scoping Reviews guidelines. ETHICS AND
      DISSEMINATION: This study does not require ethics approval, because data will be 
      obtained through a review of published primary studies. The results of our
      evaluation will be published in a peer-reviewed journal and will also be
      disseminated through presentations at national and international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Prevedello, Danielle
AU  - Prevedello D
AUID- ORCID: 0000-0003-3945-0757
AD  - Department of Intensive Care Medicine, Erasme University Hospital, Brussels,
      Belgium danielle.prevedello@erasme.ulb.ac.be.
FAU - Fiore, Marco
AU  - Fiore M
AD  - Department of Intensive Care Medicine, Erasme University Hospital, Brussels,
      Belgium.
FAU - Creteur, Jacques
AU  - Creteur J
AD  - Department of Intensive Care Medicine, Erasme University Hospital, Brussels,
      Belgium.
FAU - Preiser, J C
AU  - Preiser JC
AD  - Department of Intensive Care Medicine, Erasme University Hospital, Brussels,
      Belgium.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - postintensive care syndrome
SB  - IM
MH  - Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - *Peer Review
MH  - Quality of Life
PMC - PMC7643502
OTO - NOTNLM
OT  - *health services administration & management
OT  - *intensive & critical care
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-037725 [pii]
AID - 10.1136/bmjopen-2020-037725 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e037725. doi: 10.1136/bmjopen-2020-037725.


PMID- 33148727
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Enhancing early detection of neurological and developmental disorders and
      provision of intervention in low-resource settings in Uttar Pradesh, India: study
      protocol of the G.A.N.E.S.H. programme.
PG  - e037335
LID - 10.1136/bmjopen-2020-037335 [doi]
AB  - INTRODUCTION: Around 9% of India's children under six are diagnosed with
      neurodevelopmental disorders. Low-resource, rural communities often lack
      programmes for early identification and intervention. The Prechtl General
      Movement Assessment (GMA) is regarded as the best clinical tool to predict
      cerebral palsy in infants <5 months. In addition, children with developmental
      delay, intellectual disabilities, late detected genetic disorders or autism
      spectrum disorder show abnormal general movements (GMs) during infancy. General
      Movement Assessment in Neonates for Early Identification and Intervention, Social
      Support and Health Awareness (G.A.N.E.S.H.) aims to (1) provide evidence as to
      whether community health workers can support the identification of infants at
      high-risk for neurological and developmental disorders and disabilities, (2)
      monitor further development in those infants and (3) initiate early and targeted 
      intervention procedures. METHODS: This 3-year observational cohort study will
      comprise at least 2000 infants born across four districts of Uttar Pradesh,
      India. Community health workers, certified for GMA, video record and assess the
      infants' GMs twice, that is, within 2 months after birth and at 3-5 months. In
      case of abnormal GMs and/or reduced MOSs, infants are further examined by a
      paediatrician and a neurologist. If necessary, early intervention strategies
      (treatment as usual) are introduced. After paediatric and neurodevelopmental
      assessments at 12-24 months, outcomes are categorised as normal or
      neurological/developmental disorders. Research objective (1): to relate the GMA
      to the outcome at 12-24 months. Research objective (2): to investigate the impact
      of predefined exposures. Research objective (3): to evaluate the interscorer
      agreement of GMA. ETHICS AND DISSEMINATION: G.A.N.E.S.H. received ethics approval
      from the Indian Government Chief Medical Officers of Varanasi and Mirzapur and
      from the Ramakrishna Mission Home of Service in Varanasi. GMA is a worldwide used
      diagnostic tool, approved by the Ethics Committee of the Medical University of
      Graz, Austria (27-388 ex 14/15). Apart from peer-reviewed publications, we are
      planning to deploy G.A.N.E.S.H. in other vulnerable settings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Toldo, Moreno
AU  - Toldo M
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Varishthananda, Swami
AU  - Varishthananda S
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Einspieler, Christa
AU  - Einspieler C
AUID- ORCID: 0000-0002-7875-0632
AD  - Division of Phoniatrics, Research Unit iDN (Interdisciplinary Developmental
      Neuroscience), Medical University of Graz, Graz, Austria
      christa.einspieler@medunigraz.at.
FAU - Tripathi, Neeraj
AU  - Tripathi N
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Singh, Anshu
AU  - Singh A
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Verma, Surendra K
AU  - Verma SK
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Vishwakarma, Kanchan
AU  - Vishwakarma K
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Zhang, Dajie
AU  - Zhang D
AD  - Division of Phoniatrics, Research Unit iDN (Interdisciplinary Developmental
      Neuroscience), Medical University of Graz, Graz, Austria.
AD  - Department of Child and Adolescent Psychiatry and Psychotherapy, University
      Medical Center Gottingen, Gottingen, Germany.
AD  - Leibniz ScienceCampus Primate Cognition, Goettingen, Germany.
FAU - Dwivedi, Agyeya
AU  - Dwivedi A
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Gupta, Ritika
AU  - Gupta R
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Karn, Sanjay
AU  - Karn S
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Kerketta, Nirmal
AU  - Kerketta N
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Narayan, Ram
AU  - Narayan R
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Nikam Singh, Karuna
AU  - Nikam Singh K
AD  - Joints n Motion (JnM) Academy, Mumbai, India.
FAU - Rani, Sumitra
AU  - Rani S
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Singh, Akanksha
AU  - Singh A
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Singh, Divyanshu
AU  - Singh D
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Singh, Krishna Pratap
AU  - Singh KP
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Singh, Navin
AU  - Singh N
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Singh, Neeraj
AU  - Singh N
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Singh, Rishi
AU  - Singh R
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Singh, Shyam P
AU  - Singh SP
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Srivastava, Rakesh
AU  - Srivastava R
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Srivastava, Sandeep
AU  - Srivastava S
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Srivastava, Sanjeev
AU  - Srivastava S
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Yadav, Gopal
AU  - Yadav G
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Yadav, Preeti
AU  - Yadav P
AD  - Department of Medical Rehabilitation, Kiran Society for Rehabilitation and
      Education of Children with Disabilities, Varanasi, India.
FAU - Yadav, Sheshnath
AU  - Yadav S
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Yadav, Sujata
AU  - Yadav S
AD  - Department of Community Medicine, Ramakrishna Mission Home of Service, Varanasi, 
      India.
FAU - Marschik, Peter B
AU  - Marschik PB
AD  - Division of Phoniatrics, Research Unit iDN (Interdisciplinary Developmental
      Neuroscience), Medical University of Graz, Graz, Austria.
AD  - Department of Child and Adolescent Psychiatry and Psychotherapy, University
      Medical Center Gottingen, Gottingen, Germany.
AD  - Leibniz ScienceCampus Primate Cognition, Goettingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Austria
MH  - *Autism Spectrum Disorder/diagnosis
MH  - *Cerebral Palsy
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - India
MH  - Infant
MH  - Infant, Newborn
MH  - Pregnancy
PMC - PMC7640505
OTO - NOTNLM
OT  - *community child health
OT  - *developmental neurology & neurodisability
OT  - *paediatric neurology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: The GM Trust supports G.A.N.E.S.H. CE is a GM Trust tutor
      for GMA, and PBM is president of the GM Trust (honorary function), both of whom
      have contributed to G.A.N.E.S.H. on an honorary basis.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - bmjopen-2020-037335 [pii]
AID - 10.1136/bmjopen-2020-037335 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e037335. doi: 10.1136/bmjopen-2020-037335.


PMID- 33148723
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - WeChat-based health education to improve health knowledge in three major
      infectious diseases among residents: a multicentre case-controlled protocol.
PG  - e037046
LID - 10.1136/bmjopen-2020-037046 [doi]
AB  - INTRODUCTION: Health literacy (HL) in infectious diseases is inadequate in China.
      Since the first nationwide survey of HL conducted in China, great efforts have
      been made. However, the rate of HL in infectious diseases was 16.06% in 2017. In 
      contrast, with an HL rate of 15.85% in 2008, no significant effect was observed
      over 10 years. With an increasing number of internet users, we aim to assess the 
      effects of WeChat-based health education for the promotion of partial HL-health
      knowledge in infectious diseases. METHODS AND ANALYSIS: A total of 2160 residents
      aged 15-69 years old will be enrolled in this study. The primary outcome measures
      will be the rate of health knowledge in infectious disease. The follow-up period 
      is 3 years. ETHICS AND DISSEMINATION: The study protocol was approved by the
      Research Ethics Committee of the First Affiliated Hospital, College of Medicine, 
      Zhejiang University. The findings of this study will be submitted to a
      peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Qiu, Yan
AU  - Qiu Y
AUID- ORCID: 0000-0001-7996-4109
AD  - General Practice Department, The First Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou, China.
FAU - Qin, Hongli
AU  - Qin H
AD  - General Practice Department, The First Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou, China.
FAU - Ying, Meike
AU  - Ying M
AD  - General Practice Department, The First Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou, China.
FAU - Xu, Kaijin
AU  - Xu K
AD  - State Key Laboratory for Diagnosis and Treatment Of Infectious Diseases, National
      Clinical Research Center for Infectious Diseases, Collaborative Innovation Center
      for Diagnosis and Treatment of Infectious Diseases, The First Affiliated
      Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
FAU - Ren, Jingjing
AU  - Ren J
AD  - General Practice Department, The First Affiliated Hospital, School of Medicine,
      Zhejiang University, Hangzhou, China 3204092@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - China
MH  - *Communicable Diseases/epidemiology
MH  - Female
MH  - Health Education
MH  - *Health Literacy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7643496
OTO - NOTNLM
OT  - *hepatobiliary disease
OT  - *hiv & aids
OT  - *infectious diseases
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-037046 [pii]
AID - 10.1136/bmjopen-2020-037046 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e037046. doi: 10.1136/bmjopen-2020-037046.


PMID- 33148722
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 4
TI  - Rationale and study protocol of the Physical Activity and Dietary intervention in
      women with OVArian cancer (PADOVA) study: a randomised controlled trial to
      evaluate effectiveness of a tailored exercise and dietary intervention on body
      composition, physical function and fatigue in women with ovarian cancer
      undergoing chemotherapy.
PG  - e036854
LID - 10.1136/bmjopen-2020-036854 [doi]
AB  - INTRODUCTION: As a consequence of ovarian cancer and its treatment, many women
      with ovarian cancer have to deal with reduced physical function, fatigue, and
      loss of weight and/or muscle mass, compromising quality of life. Exercise and
      dietary interventions can positively influence body composition, physical fitness
      and function, and fatigue in patients with cancer. However, there are no data
      from randomised controlled trials on the effectiveness of exercise and dietary
      interventions in patients with ovarian cancer. Due to a complex disease
      trajectory, a relatively poor survival and distinct disease-induced and
      treatment-induced side effects, it is unclear whether exercise and dietary
      interventions that were shown to be feasible and effective in other types of
      cancer produce comparable results in patients with ovarian cancer. The aim of
      this article is to present the design of the multicentre randomised controlled
      Physical Activity and Dietary intervention in OVArian cancer trial and to
      describe how the exercise and dietary intervention is tailored to specific
      comorbidities and disease-induced and treatment-induced adverse effects in
      patients with ovarian cancer. METHODS AND ANALYSIS: Adult women with primary
      epithelial ovarian cancer who are scheduled to undergo first-line (neo)adjuvant
      chemotherapy (n=122) are randomly allocated to a combined exercise and dietary
      intervention or a usual care control group during chemotherapy. Primary outcomes 
      are body composition, physical function and fatigue. Outcome measures will be
      assessed before the start of chemotherapy, 3 weeks after completion of
      chemotherapy and 12 weeks later. The exercise and dietary intervention was
      tailored to ovarian cancer-specific comorbidities and adverse effects of ovarian 
      cancer and its treatment following the i3-S strategy. ETHICS AND DISSEMINATION:
      This study has been approved by the medical ethical committee of the Amsterdam
      UMC (reference: 018). Results of the study will be published in international
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: Netherlands Trial Registry
      (NTR6300).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Stelten, Stephanie
AU  - Stelten S
AD  - Epidemiology and Biostatistics, Amsterdam Public Health research institute,
      Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 
      The Netherlands.
AD  - Physiology, Radboud Institute of Health Sciences, Radboudumc, Nijmegen, The
      Netherlands.
FAU - Hoedjes, Meeke
AU  - Hoedjes M
AD  - Medical and Clinical Psychology, Center of Research on Psychology in Somatic
      diseases, Tilburg University, Tilburg, The Netherlands.
FAU - Kenter, Gemma G
AU  - Kenter GG
AD  - Obstetrics and Gynaecology, Cancer Center Amsterdam, Center for Gynaecologic
      Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam,
      Amsterdam, The Netherlands.
AD  - Obstetrics and Gynaecology, Amsterdam UMC, Univ(ersity) of Amsterdam, Amsterdam, 
      Netherlands.
AD  - Gynaecology, Center for Gynaecologic Oncology Amsterdam (CGOA), The Netherlands
      Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
FAU - Kampman, Ellen
AU  - Kampman E
AD  - Human Nutrition and Health, Wageningen University and Research, Wageningen, The
      Netherlands.
FAU - Huijsmans, Rosalie J
AU  - Huijsmans RJ
AD  - Rehabilitation Medicine, Amsterdam UMC, Vrije Universiteit van Amsterdam,
      Amsterdam, The Netherlands.
FAU - van Lonkhuijzen, Luc Rcw
AU  - van Lonkhuijzen LR
AD  - Obstetrics and Gynaecology, Amsterdam UMC, Univ(ersity) of Amsterdam, Amsterdam, 
      Netherlands.
FAU - Buffart, L M
AU  - Buffart LM
AUID- ORCID: 0000-0002-8095-436X
AD  - Epidemiology and Biostatistics, Amsterdam Public Health research institute,
      Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 
      The Netherlands laurien.buffart@radboudumc.nl.
AD  - Physiology, Radboud Institute of Health Sciences, Radboudumc, Nijmegen, The
      Netherlands.
LA  - eng
SI  - NTR/NTR6300
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Body Composition
MH  - Carcinoma, Ovarian Epithelial
MH  - *Exercise
MH  - Exercise Therapy
MH  - Fatigue/etiology
MH  - Female
MH  - Humans
MH  - Netherlands
MH  - *Ovarian Neoplasms/complications/drug therapy
MH  - *Quality of Life
PMC - PMC7643503
OTO - NOTNLM
OT  - *epidemiology
OT  - *gynaecological oncology
OT  - *nutrition & dietetics
OT  - *nutritional support
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - bmjopen-2020-036854 [pii]
AID - 10.1136/bmjopen-2020-036854 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 4;10(11):e036854. doi: 10.1136/bmjopen-2020-036854.


PMID- 33148720
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov 3
TI  - Physical activity coaching for adults with mobility limitations: protocol for the
      ComeBACK pragmatic hybrid effectiveness-implementation type 1 randomised
      controlled trial.
PG  - e034696
LID - 10.1136/bmjopen-2019-034696 [doi]
AB  - INTRODUCTION: Mobility limitation is common and often results from neurological
      and musculoskeletal health conditions, ageing and/or physical inactivity. In
      consultation with consumers, clinicians and policymakers, we have developed two
      affordable and scalable intervention packages designed to enhance physical
      activity for adults with self-reported mobility limitations. Both are based on
      behaviour change theories and involve tailored advice from physiotherapists.
      METHODS AND ANALYSIS: This pragmatic hybrid effectiveness-implementation type 1
      randomised control trial (n=600) will be undertaken among adults with
      self-reported mobility limitations. It aims to estimate the effects on physical
      activity of: (1) an enhanced 6-month intervention package (one face-to-face
      physiotherapy assessment, tailored physical activity plan, physical activity
      phone coaching from a physiotherapist, informational/motivational resources and
      activity monitors) compared with a less intensive 6-month intervention package
      (single session of tailored phone advice from a physiotherapist, tailored
      physical activity plan, unidirectional text messages, informational/motivational 
      resources); (2) the enhanced intervention package compared with no intervention
      (6-month waiting list control group); and (3) the less intensive intervention
      package compared with no intervention (waiting list control group). The primary
      outcome will be average steps per day, measured with the StepWatch Activity
      Monitor over a 1-week period, 6 months after randomisation. Secondary outcomes
      include other physical activity measures, measures of health and functioning,
      individualised mobility goal attainment, mental well-being, quality of life, rate
      of falls, health utilisation and intervention evaluation. The hybrid
      effectiveness-implementation design (type 1) will be used to enable the
      collection of secondary implementation outcomes at the same time as the primary
      effectiveness outcome. An economic analysis will estimate the cost-effectiveness 
      and cost-utility of the interventions compared with no intervention and to each
      other. ETHICS AND DISSEMINATION: Ethical approval has been obtained by Sydney
      Local Health District, Royal Prince Alfred Zone. Dissemination will be via
      publications, conferences, newsletters, talks and meetings with health managers. 
      TRIAL REGISTRATION NUMBER: ACTRN12618001983291.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hassett, Leanne
AU  - Hassett L
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - Discipline of Physiotherapy, Sydney School of Health Sciences, University of
      Sydney, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Tiedemann, Anne
AU  - Tiedemann A
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Hinman, Rana S
AU  - Hinman RS
AD  - Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Crotty, Maria
AU  - Crotty M
AD  - College of Medicine and Public Health, Flinders University, Adelaide, South
      Australia, Australia.
FAU - Hoffmann, Tammy
AU  - Hoffmann T
AD  - Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland,
      Australia.
FAU - Harvey, Lisa
AU  - Harvey L
AD  - John Walsh Centre for Rehabilitation Research, Northern Clinical School, The
      University of Sydney, St Leonards, New South Wales, Australia.
FAU - Taylor, Nicholas F
AU  - Taylor NF
AD  - School of Allied Health, Human Services and Sport, La Trobe University,
      Melbourne, New South Wales, Australia.
FAU - Greaves, Colin
AU  - Greaves C
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, UK.
FAU - Treacy, Daniel
AU  - Treacy D
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
AD  - Prince of Wales Hospital, South Eastern Sydney Local Health District, Sydney, New
      South Wales, Australia.
FAU - Jennings, Matthew
AU  - Jennings M
AD  - Liverpool Hospital, South Western Sydney Local Health District, Sydney, New South
      Wales, Australia.
FAU - Milat, Andrew
AU  - Milat A
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
AD  - NSW Ministry of Health, Liverpool, New South Wales, Australia.
FAU - Bennell, Kim L
AU  - Bennell KL
AD  - Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Howard, Kirsten
AU  - Howard K
AUID- ORCID: 0000-0002-0918-7540
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - van den Berg, Maayken
AU  - van den Berg M
AD  - College of Nursing and Health Sciences, Flinders University, Adelaide, South
      Australia, Australia.
FAU - Pinheiro, Marina
AU  - Pinheiro M
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - Discipline of Physiotherapy, Sydney School of Health Sciences, University of
      Sydney, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Wong, Siobhan
AU  - Wong S
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Kirkham, Catherine
AU  - Kirkham C
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Ramsay, Elizabeth
AU  - Ramsay E
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - O'Rourke, Sandra
AU  - O'Rourke S
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Sherrington, Catherine
AU  - Sherrington C
AUID- ORCID: 0000-0001-8934-4368
AD  - Institute for Musculoskeletal Health, University of Sydney/ Sydney Local Health
      District, Sydney, New South Wales, Australia cathie.sherrington@sydney.edu.au.
AD  - School of Public Health, University of Sydney, Camperdown, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201103
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Accidental Falls
MH  - *Exercise
MH  - Fear
MH  - Humans
MH  - *Mentoring
MH  - Quality of Life
PMC - PMC7640503
OTO - NOTNLM
OT  - *clinical trials
OT  - *geriatric medicine
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/06 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/11/05 05:58
PHST- 2020/11/05 05:58 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - bmjopen-2019-034696 [pii]
AID - 10.1136/bmjopen-2019-034696 [doi]
PST - epublish
SO  - BMJ Open. 2020 Nov 3;10(11):e034696. doi: 10.1136/bmjopen-2019-034696.


PMID- 33148299
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220418
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 4
TI  - Evaluation of the efficacy and safety of fire needle compared to filiform needle 
      on knee osteoarthritis: study protocol for a randomized controlled trial.
PG  - 911
LID - 10.1186/s13063-020-04827-9 [doi]
AB  - BACKGROUND: Knee osteoarthritis is a common clinical chronic degenerative disease
      associated with high morbidity and long-term disability. Previous studies have
      confirmed the efficacy of acupuncture on knee osteoarthritis. Fire needle
      acupuncture is a combination of heat and acupuncture, which may be more effective
      than the commonly used filiform needle acupuncture. This study is designed as a
      randomized controlled trial to evaluate the efficacy and safety of fire needle
      acupuncture compared to filiform needle acupuncture in knee osteoarthritis
      patients. METHODS AND ANALYSIS: This is a prospective randomized controlled
      superiority clinical trial to evaluate the efficacy and safety of fire needle
      acupuncture compared to filiform needle acupuncture for knee osteoarthritis. A
      total of 100 participants will be randomly assigned to two different groups.
      Participants will receive fire needle acupuncture treatment in the fire needle
      group, while participants in the filiform needle group will be treated with a
      filiform needle at the same acupuncture points as the fire needle group. All
      participants will receive 6 weeks of treatment (2 times per week). The primary
      outcome is the change of the Western Ontario and McMaster Universities
      Osteoarthritis Index, and the secondary outcomes include the change of the visual
      analog scale and 12-item Short Form Health Survey from baseline to endpoint.
      ETHICS AND DISSEMINATION: Ethical approval of this study was granted by the
      Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine
      Affiliated to Capital Medical University (2018SB-066). Written informed consent
      will be obtained from all participants. Outcomes of the trial will be
      disseminated through peer-reviewed publications. TRIAL REGISTRATION: Chinese
      Clinical Trial Registry ChiCTR1800019579 . Registered on November 18, 2018.
FAU - Gao, Yuanjie
AU  - Gao Y
AUID- ORCID: http://orcid.org/0000-0003-0014-7718
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Liu, Lu
AU  - Liu L
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
AD  - Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical
      Sciences, Beijing, China.
FAU - Li, Bin
AU  - Li B
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Guo, Jing
AU  - Guo J
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Liu, Huilin
AU  - Liu H
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Wang, Shaosong
AU  - Wang S
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Ji, Xu
AU  - Ji X
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Fu, Yuanbo
AU  - Fu Y
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Wang, Yizhan
AU  - Wang Y
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China.
FAU - Sun, Jingqing
AU  - Sun J
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China. sjq100037@sina.com.
FAU - Yuan, Fang
AU  - Yuan F
AD  - Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese
      Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture
      Neuromodulation, Beijing, China. alicef531@163.com.
LA  - eng
GR  - PZ2019019/Beijing Municipal Administration of Hospitals
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Acupuncture Therapy/adverse effects
MH  - Humans
MH  - Needles
MH  - *Osteoarthritis, Knee/diagnosis/therapy
MH  - Pain Measurement
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7640691
EDAT- 2020/11/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/05 05:36
PHST- 2020/02/03 00:00 [received]
PHST- 2020/10/17 00:00 [accepted]
PHST- 2020/11/05 05:36 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04827-9 [doi]
AID - 10.1186/s13063-020-04827-9 [pii]
PST - epublish
SO  - Trials. 2020 Nov 4;21(1):911. doi: 10.1186/s13063-020-04827-9.


PMID- 33148239
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 4
TI  - Assessment of immunization data quality of routine reports in Ho municipality of 
      Volta region, Ghana.
PG  - 1013
LID - 10.1186/s12913-020-05865-4 [doi]
AB  - BACKGROUND: Immunization has been an important public health intervention for
      preventing and reducing child morbidity and mortality over the years and coverage
      has increased in the past decades. However, the validity of the data from
      immunization coverages is usually disputed. Immunization data from health
      facilities show poor concordance between tallied registers and monthly reports as
      they are reported to higher levels of the health system. The study assessed the
      quality of data from routine immunization of some health facilities in the Ho
      central municipality in the Volta region of Ghana. METHODS: A descriptive
      cross-sectional study was used to review routine immunization data in tallied
      registers and reports submitted to the Municipal Health Directorate (MHD) from
      January to December, 2015. Simple random sampling was used to select three health
      facilities in Ho central municipality. The World Health Organization (WHO) Data
      Quality Self-assessment (DQS) tool was the main instrument used to present and
      analyze data for accuracy and discrepancy level between the tallied registers and
      reports. A template was created in Microsoft excel which automatically presented 
      accuracy and discrepancy levels when data was entered. Ethical approval for the
      study was obtained from Ghana Health Service Ethics Review Committee. RESULTS:
      The result showed discrepancies between recounted tallies at the facilities and
      reports submitted to the MHD. Accuracy ratios of 102, 64 and 94% for Bacillus
      Calmette Guerin (BCG), Pentavalent (Penta) vaccine dose 3 and Measles 2
      respectively indicating underreporting for BCG and over reporting for the rest
      were obtained. There was 460 over reported data to the municipal level
      representing accuracy ratio of 80% and discrepancy level of 20%. CONCLUSIONS:
      Immunization data was characterized by underreporting and overreporting, hence
      not accurate and lacked quality. Immunization data quality should be a priority
      among health staff at health facilities.
FAU - Ziema, Sorengmen Amos
AU  - Ziema SA
AD  - Department of Epidemiology, and Biostatistics, School of Public Health,
      University of Health and Allied Sciences, Ho, Volta Region, Ghana.
FAU - Asem, Livingstone
AU  - Asem L
AUID- ORCID: http://orcid.org/0000-0003-1483-819X
AD  - Department of Public Administration and Health Services Management, Business
      School, University of Ghana, Legon, Accra, Ghana. lasem@st.ug.edu.gh.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Child
MH  - Cross-Sectional Studies
MH  - *Data Accuracy
MH  - Ghana/epidemiology
MH  - Humans
MH  - Immunization
MH  - *Immunization Programs
MH  - Infant
PMC - PMC7643460
OTO - NOTNLM
OT  - Data quality
OT  - Expanded program on immunization
OT  - Immunization data
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:36
PHST- 2020/06/29 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/05 05:36 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12913-020-05865-4 [doi]
AID - 10.1186/s12913-020-05865-4 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Nov 4;20(1):1013. doi: 10.1186/s12913-020-05865-4.


PMID- 33148233
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Nov 4
TI  - Medical students' affective reactions to workplace experiences: qualitative
      investigation in a Chinese cultural context.
PG  - 404
LID - 10.1186/s12909-020-02335-7 [doi]
AB  - BACKGROUND: Compassion fatigue, unprofessional behavior, and burnout are
      prompting educators to examine medical students' affective reactions to workplace
      experiences. Attributes of both students and learning environments are influenced
      by their socio-cultural backgrounds. To prevent 'educational cultural hegemony', 
      opinion leaders have advocated research in under-represented cultural contexts,
      of which Asia is a prime example. This study aimed to broaden the discourse of
      medical education by answering the question: how do students react affectively to
      workplace experiences in a Chinese cultural context? METHODS: In 2014, the
      authors recruited five female and seven male Taiwanese clerkship students to make
      1-2 audio-diary recordings per week for 12 weeks describing affective
      experiences, to which they had consciously reacted. The authors analyzed
      transcripts of these recordings thematically in the original Mandarin and
      prepared a thick description of their findings, including illustrative extracts. 
      An English-speaking education researcher helped them translate this into English,
      constantly comparing the interpretation with the original, untranslated data.
      RESULTS: (Mis) matches between their visions of future professional life and
      clerkship experiences influenced participants' affective reactions, thoughts, and
      behaviors. Participants managed these reactions by drawing on a range of personal
      and social resources, which influenced the valence, strength, and nature of their
      reactions. This complex set of interrelationships was influenced by culturally
      determined values and norms, of which this report provides a thick description.
      CONCLUSION: To avoid educational cultural hegemony, educators need to understand 
      professional behavior in terms of complex interactions between
      culturally-specific attributes of individual students and learning environments. 
      TRIAL REGISTRATION: The ethics committee of the National Taiwan University (NTU) 
      Hospital gave research ethics approval ( 20130864RINB ).
FAU - Yeh, Huei-Ming
AU  - Yeh HM
AD  - Department of Anesthesiology, National Taiwan University Hospital, Taipei,
      Taiwan.
FAU - Chien, Wan-Hsi
AU  - Chien WH
AD  - Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital,
      Taipei, Taiwan.
FAU - Tsai, Daniel Fu-Chang
AU  - Tsai DF
AD  - Research Institute of Medical Education & Bioethics, National Taiwan University
      College of Medicine, and Attending Physician, Department of Medical Research,
      National Taiwan University Hospital, Taipei, Taiwan.
FAU - Dornan, Tim
AU  - Dornan T
AD  - Centre for Medical Education, Queen's University Belfast, Belfast, UK.
AD  - Maastricht University, Maastricht, The Netherlands.
FAU - Lai, Ling-Ping
AU  - Lai LP
AD  - Department of Cardiology, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Chu, Chun-Lin
AU  - Chu CL
AUID- ORCID: http://orcid.org/0000-0001-9122-4437
AD  - Department of Anesthesiology, National Taiwan University Hospital Yun-Lin Branch,
      No 579, Sec 2 Yun-Lin Road, Douliu, YunLin, Taiwan, ROC. genie0818@gmail.com.
LA  - eng
GR  - 102-2511-002-001-MY2/Ministry of Science and Technology, Taiwan
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Asia
MH  - China
MH  - Female
MH  - Humans
MH  - Male
MH  - Qualitative Research
MH  - *Students, Medical
MH  - Taiwan
MH  - Workplace
PMC - PMC7610235
OTO - NOTNLM
OT  - Affective reaction
OT  - Cultural hegemony
OT  - Oral diary
OT  - Workplace experience
EDAT- 2020/11/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/05 05:36
PHST- 2020/01/30 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/05 05:36 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02335-7 [doi]
AID - 10.1186/s12909-020-02335-7 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Nov 4;20(1):404. doi: 10.1186/s12909-020-02335-7.


PMID- 33148222
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220716
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 4
TI  - Do solidarity and reciprocity obligations compel African researchers to feedback 
      individual genetic results in genomics research?
PG  - 112
LID - 10.1186/s12910-020-00549-4 [doi]
AB  - BACKGROUND: A key ethical question in genomics research relates to whether
      individual genetic research results should be disclosed to research participants 
      and if so, which results are to be disclosed, by whom and when. Whilst this issue
      has received only scarce attention in African bioethics discourse, the extension 
      of genomics research to the African continent has brought it into sharp focus.
      METHODS: In this qualitative study, we examined the views of adolescents, parents
      and caregivers participating in a paediatric and adolescent HIV-TB genomic study 
      in Botswana on how solidarity and reciprocity obligations could guide decisions
      about feedback of individual genetic research results. Data were collected using 
      deliberative focus group discussions and in-depth interviews. RESULTS: Findings
      from 93 participants (44 adolescents and 49 parents and caregivers) demonstrated 
      the importance of considering solidarity and reciprocity obligations in decisions
      about the return of individual genetic research results to participants.
      Participants viewed research participation as a mutual relationship and expressed
      that return of research results would be one way in which research participation 
      could be reciprocated. They noted that when reciprocity obligations are
      respected, participants feel valued and not respecting reciprocity expectations
      could undermine participant trust and participation in future studies.
      CONCLUSIONS: We conclude that expectations of solidarity and reciprocity could
      translate into an obligation to feedback selected individual genetic research
      results in African genomics research.
FAU - Ralefala, Dimpho
AU  - Ralefala D
AUID- ORCID: 0000-0001-9074-0405
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, 7925, South Africa. dnjadingwe@gmail.com.
AD  - Office of Research and Development, University of Botswana, Gaborone, Botswana.
      dnjadingwe@gmail.com.
FAU - Kasule, Mary
AU  - Kasule M
AD  - Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.
FAU - Wonkam, Ambroise
AU  - Wonkam A
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, 7925, South Africa.
AD  - Deputy Dean's Office, Faculty of Health Sciences, Groote Schuur Hospital, Cape
      Town, South Africa.
FAU - Matshaba, Mogomotsi
AU  - Matshaba M
AD  - Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.
AD  - Baylor College of Medicine, Houston, TX, USA.
FAU - de Vries, Jantina
AU  - de Vries J
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, 7925, South Africa.
LA  - eng
GR  - U24 HL135600/HL/NHLBI NIH HHS/United States
GR  - U54 HG009790/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201104
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Adolescent
MH  - Botswana
MH  - Child
MH  - Feedback
MH  - Genetic Research
MH  - *Genomics
MH  - Humans
MH  - *Research Personnel
PMC - PMC7640670
OTO - NOTNLM
OT  - *Africa
OT  - *Botswana
OT  - *Feedback
OT  - *Genetic research results
OT  - *Genomics research
OT  - *Individual
OT  - *Reciprocity
OT  - *Solidarity
EDAT- 2020/11/06 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/05 05:36
PHST- 2020/06/25 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/05 05:36 [entrez]
PHST- 2020/11/06 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00549-4 [doi]
AID - 10.1186/s12910-020-00549-4 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Nov 4;21(1):112. doi: 10.1186/s12910-020-00549-4.


PMID- 33147394
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201218
IS  - 1851-8265 (Electronic)
IS  - 1669-2381 (Linking)
VI  - 16
DP  - 2020 Oct 29
TI  - [Essay on Pandementia: when the characters and microbes of science fiction jump
      off the screen and invade the planet].
PG  - e2995
LID - 10.18294/sc.2020.2995 [doi]
AB  - This essay intends to carry out an ethical and philosophical reflection on the
      effects of the emergency contingencies of the COVID-19 pandemic. With a focus on 
      Brazil, it seeks to understand, critique, and attribute meaning to references to 
      the pandemic, in particularly dramatic moments brought about by the synergy
      produced between the serious disease affecting the country and the world and a
      government that stands out for its remarkable unwillingness and inability to deal
      with this calamity. This text was written during the Brazilian "quarantine,"
      which lasted from mid-March to late April, 2020. During this period, we were
      bombarded by facts that never ceased to haunt us, and lived each day under the
      terrible dominion of the pandemic. Therefore, this text was written in the midst 
      of a social context marked by control efforts, with great attention directed at
      the health of those affected, despite the complex political framework and serious
      economic difficulties facing the country.
FAU - Castiel, Luis David
AU  - Castiel LD
AD  - Medico. Doctor en Salud Publica. Investigador, Departamento de Epidemiologia e
      Metodos Quantitativos em Saude, Escola Nacional de Saude Publica Sergio Arouca,
      Fundacao Oswaldo Cruz, Rio de Janeiro, Brasil. luis.castiel@ensp.fiocruz.br.
LA  - spa
PT  - Journal Article
TT  - Ensayo sobre la pandemencia: cuando los personajes y microbios de la ciencia
      ficcion salen de la pelicula.
DEP - 20201029
PL  - Argentina
TA  - Salud Colect
JT  - Salud colectiva
JID - 101276038
SB  - IM
MH  - Attitude to Health
MH  - Brazil/epidemiology
MH  - COVID-19
MH  - *Coronavirus Infections/economics/epidemiology/prevention & control/psychology
MH  - Federal Government
MH  - *Health Policy
MH  - Humans
MH  - *Pandemics/economics/prevention & control
MH  - *Pneumonia, Viral/economics/epidemiology/prevention & control/psychology
MH  - *Quarantine/economics/methods/psychology
MH  - Risk
OTO - NOTNLM
OT  - *COVID-19
OT  - *Communicable Diseases
OT  - *Epidemiology
OT  - *Health Risks
OT  - *Pandemics
EDAT- 2020/11/05 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/04 17:12
PHST- 2020/07/15 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/04 17:12 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.18294/sc.2020.2995 [doi]
PST - epublish
SO  - Salud Colect. 2020 Oct 29;16:e2995. doi: 10.18294/sc.2020.2995.


PMID- 33147213
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20201218
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Public attitudes toward allocating scarce resources in the COVID-19 pandemic.
PG  - e0240651
LID - 10.1371/journal.pone.0240651 [doi]
AB  - The general public is subject to triage policies that allocate scarce lifesaving 
      resources during the COVID-19 pandemic, one of the worst public health
      emergencies in the past 100 years. However, public attitudes toward ethical
      principles underlying triage policies used during this pandemic are not well
      understood. Three experiments (preregistered; online samples; N = 1,868; U.S.
      residents) assessed attitudes toward ethical principles underlying triage
      policies. The experiments evaluated assessments of utilitarian, egalitarian,
      prioritizing the worst-off, and social usefulness principles in conditions
      arising during the COVID-19 pandemic, involving resource scarcity, resource
      reallocation, and bias in resource allocation toward at-risk groups, such as the 
      elderly or people of color. We found that participants agreed with allocation
      motivated by utilitarian principles and prioritizing the worst-off during initial
      distribution of resources and disagreed with allocation motivated by egalitarian 
      and social usefulness principles. At reallocation, participants agreed with
      giving priority to those patients who received the resources first. Lastly,
      support for utilitarian allocation varied when saving the greatest number of
      lives resulted in disadvantage for at-risk or historically marginalized groups.
      Specifically, participants expressed higher levels of agreement with policies
      that shifted away from maximizing benefits to one that assigned the same priority
      to members of different groups if this mitigated disadvantage for people of
      color. Understanding these attitudes can contribute to developing triage
      policies, increase trust in health systems, and assist physicians in achieving
      their goals of patient care during the COVID-19 pandemic.
FAU - Buckwalter, Wesley
AU  - Buckwalter W
AD  - Department of Philosophy, University of Manchester, Manchester, United Kingdom.
FAU - Peterson, Andrew
AU  - Peterson A
AUID- ORCID: 0000-0001-5192-3348
AD  - Department of Philosophy, Institute for Philosophy and Public Policy, George
      Mason University, Fairfax, Virginia, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201104
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Attitude
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*psychology
MH  - Emergencies/psychology
MH  - Female
MH  - Health Care Rationing/statistics & numerical data
MH  - Health Resources/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/*psychology
MH  - Public Health/statistics & numerical data
MH  - Public Opinion
MH  - Triage/statistics & numerical data
MH  - Young Adult
PMC - PMC7641460
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/05 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/11/04 17:11
PHST- 2020/06/28 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/11/04 17:11 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1371/journal.pone.0240651 [doi]
AID - PONE-D-20-19914 [pii]
PST - epublish
SO  - PLoS One. 2020 Nov 4;15(11):e0240651. doi: 10.1371/journal.pone.0240651.
      eCollection 2020.


PMID- 33146856
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - Collateral Paternalism and Liberal Critiques of Public Health Policy: Diminishing
      Theoretical Demandingness and Accommodating the Devil in the Detail.
PG  - 372-381
LID - 10.1007/s10728-020-00417-7 [doi]
AB  - Critical literatures, and public discourses, on public health policies and
      practices often present fixated concerns with paternalism. In this paper, rather 
      than focus on the question of whether and why intended instances of paternalistic
      policy might be justified, we look to the wider, real-world socio-political
      contexts against which normative evaluations of public health must take place. We
      explain how evaluative critiques of public health policy and practice must be
      sensitive to the nuance and complexity of policy contexts. This includes
      sensitivity to the 'imperfect' reach and application of policy, leading to
      collateral effects including collateral paternalism. We argue that theoretical
      critiques must temper their demandingness to real-world applicability, allowing
      for the detail of social and policy contexts, including harm reduction: apparent 
      knock-down objections of paternalism cannot hold if they are limited to an
      abstract or artificially-isolated evaluation of the reach of a public health
      intervention.
FAU - Coggon, John
AU  - Coggon J
AD  - Centre for Health, Law, and Society, Bristol Population Health Science Institute,
      University of Bristol Law School, 8-10 Berkeley Square, Bristol, BS8 1HH, UK.
FAU - Viens, A M
AU  - Viens AM
AUID- ORCID: http://orcid.org/0000-0002-2379-4523
AD  - School of Global Health, York University, Victor Dahdaleh Building, 88 The Pond
      Road, Toronto, M3J 2S5, Canada. amviens@yorku.ca.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - Harm Reduction
MH  - *Health Policy
MH  - Humans
MH  - *Paternalism
MH  - *Politics
MH  - *Public Health
OTO - NOTNLM
OT  - Collateral paternalism
OT  - Harm reduction
OT  - Public health ethics
OT  - Public policy
EDAT- 2020/11/05 06:00
MHDA- 2021/08/18 06:00
CRDT- 2020/11/04 12:14
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2020/11/04 12:14 [entrez]
AID - 10.1007/s10728-020-00417-7 [doi]
AID - 10.1007/s10728-020-00417-7 [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Dec;28(4):372-381. doi: 10.1007/s10728-020-00417-7. Epub
      2020 Nov 4.


PMID- 33146787
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Plagiarism, Fake Peer-Review, and Duplication: Predominant Reasons Underlying
      Retractions of Iran-Affiliated Scientific Papers.
PG  - 3455-3463
LID - 10.1007/s11948-020-00274-6 [doi]
AB  - Retractions of scientific papers published by some Iran-affiliated scientists in 
      the preceding decade have attracted much attention and publicity; however, the
      reasons for these retractions have not been documented. We searched the
      Retraction Watch Database to enumerate the retracted Iran-affiliated papers from 
      December 2001 to December 2019 and aimed to outline the predominant reasons for
      retractions. The reasons included fake peer-review, authorship dispute,
      fabricated data, plagiarism, conflict of interest, erroneous data, and
      duplication. The Fisher's exact test was used to investigate the associations
      between retractions and their underlying reasons. We selected P < 0.05 to
      indicate the statistically significant differences. We found 697 retracted
      papers. Duplication (27%), plagiarism (26%), and fake peer-review (21%) were the 
      most frequent reasons for retractions. Our study highlights the importance of
      urgent intervention to prevent the misconduct and questionable research practices
      that lead to retractions in Iran. Continually educating the scientists and
      postgraduate students about the ethics and norms of scientific publishing is an
      important measure to ensure publication of reliable, worthy, and impactful
      papers.
FAU - Kamali, Negin
AU  - Kamali N
AUID- ORCID: http://orcid.org/0000-0002-8718-2614
AD  - Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares
      University, 25529, Tehran, Iran.
FAU - Talebi Bezmin Abadi, Amin
AU  - Talebi Bezmin Abadi A
AUID- ORCID: http://orcid.org/0000-0001-5209-6436
AD  - Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares
      University, 25529, Tehran, Iran. Amin.talebi@modares.ac.ir.
FAU - Rahimi, Farid
AU  - Rahimi F
AUID- ORCID: http://orcid.org/0000-0002-0920-8188
AD  - Research School of Biology, The Australian National University, Canberra, ACT,
      2601, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Authorship
MH  - Humans
MH  - Iran
MH  - Peer Review
MH  - *Plagiarism
MH  - *Scientific Misconduct
OTO - NOTNLM
OT  - Duplication
OT  - Ethics in publishing
OT  - Fake peer-review
OT  - Iran
OT  - Manuscript
OT  - Retraction of publication
EDAT- 2020/11/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/11/04 12:14
PHST- 2020/01/12 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/11/04 12:14 [entrez]
AID - 10.1007/s11948-020-00274-6 [doi]
AID - 10.1007/s11948-020-00274-6 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3455-3463. doi: 10.1007/s11948-020-00274-6. Epub
      2020 Nov 4.


PMID- 33146475
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 2047-8941 (Electronic)
IS  - 1472-0795 (Linking)
VI  - 32
IP  - 6
DP  - 2020 Nov 24
TI  - Sexually speaking: person-centred conversations with people living with a
      dementia.
PG  - 33-42
LID - 10.7748/nop.2020.e1207 [doi]
AB  - While sexuality is integral to being human and supporting sexual expression is
      fundamental to delivering person-centred care, many nurses find this area
      challenging. This is particularly true when working with people living with a
      dementia, irrespective of their age. However, it can be especially challenging in
      older adults. This article aims to support nurses in their work with individuals 
      and couples living with a dementia. After briefly defining the term 'sexuality'
      and acknowledging the effects of the most common types of dementia, the article
      discusses the importance of person-centred conversations. It details a new
      person-centred paradigm that can assist nurses to learn about people's sexuality 
      and sexual wishes. Through enhanced understanding and increased objectivity,
      nurses can be better equipped to support people to continue living fulfilled
      sexual lives according to their choices and priorities. The article concludes by 
      summarising the legal and professional context and nursing responsibilities
      involved in addressing sexuality with people living with a dementia, specifically
      when mental capacity becomes an issue.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Lipinska, Danuta
AU  - Lipinska D
AD  - My Home Life, counsellor and supervisor in private practice, Norwich, England.
FAU - Heath, Hazel
AU  - Heath H
AD  - Loughton, Essex, England.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - Nurs Older People
JT  - Nursing older people
JID - 101084156
MH  - Aged
MH  - *Communication
MH  - Dementia/*nursing
MH  - Humans
MH  - Patient-Centered Care
MH  - Sexual Behavior
MH  - *Sexuality
OTO - NOTNLM
OT  - care homes
OT  - clinical
OT  - consent
OT  - dementia
OT  - diversity
OT  - ethical issues
OT  - mental capacity
OT  - neurology
OT  - nursing homes
OT  - older people
OT  - professional
OT  - sexuality
COIS- None declared
EDAT- 2020/11/05 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/11/04 08:45
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/11/04 08:45 [entrez]
AID - 10.7748/nop.2020.e1207 [doi]
AID - e1207 [pii]
PST - ppublish
SO  - Nurs Older People. 2020 Nov 24;32(6):33-42. doi: 10.7748/nop.2020.e1207. Epub
      2020 Nov 4.


PMID- 33146418
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1365-2184 (Electronic)
IS  - 0960-7722 (Linking)
VI  - 53
IP  - 12
DP  - 2020 Dec
TI  - General requirements for stem cells.
PG  - e12926
LID - 10.1111/cpr.12926 [doi]
AB  - The standard 'General requirements for stem cells' is the first set of general
      guidelines for stem cell research and production in China, jointly drafted and
      agreed upon by experts from the Chinese Society for Stem Cell Research. This
      standard specifies the classification, ethical requirements, quality
      requirements, quality control requirements, detection control requirements and
      waste disposal requirements of stem cells, which is applicable to stem cell
      research and production. It was firstly released by the Chinese Society for Cell 
      Biology on 1 August 2017 and was further revised on 30 April 2020. We hope that
      publication of these guidelines will promote institutional establishment,
      acceptance, and execution of proper protocols, and accelerate the international
      standardization of stem cells for clinical development and therapeutic
      applications.
CI  - (c) 2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.
FAU - Hao, Jie
AU  - Hao J
AUID- ORCID: https://orcid.org/0000-0002-7739-1850
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Ma, Aijin
AU  - Ma A
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
AD  - China National Institute of Standardization, Beijing, China.
AD  - Beijing Technology and Business University, Beijing, China.
FAU - Wang, Lei
AU  - Wang L
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Cao, Jiani
AU  - Cao J
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Chen, Si
AU  - Chen S
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Wang, Liu
AU  - Wang L
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Fu, Boqiang
AU  - Fu B
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
AD  - China National Institute of Metrology, Beijing, China.
FAU - Zhou, Jiaxi
AU  - Zhou J
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Pei, Xuetao
AU  - Pei X
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Xiang, Peng
AU  - Xiang P
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Hu, Shijun
AU  - Hu S
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Li, Qiyuan
AU  - Li Q
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Zhang, Yong
AU  - Zhang Y
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Xia, Yingjie
AU  - Xia Y
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Zhu, Huanxin
AU  - Zhu H
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Stacey, Glyn
AU  - Stacey G
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
FAU - Zhou, Qi
AU  - Zhou Q
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
FAU - Zhao, Tongbiao
AU  - Zhao T
AUID- ORCID: https://orcid.org/0000-0003-1429-5818
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, National Stem Cell
      Resource Center, Institute for Stem Cell and Regeneration, Institute of Zoology, 
      Chinese Academy of Sciences, Beijing, China.
AD  - Chinese Society for Stem Cell Research, Shanghai, China.
LA  - eng
GR  - 2018YFA0108401/National Key R&D Program of China
GR  - 2018YFE0204400/National Key R&D Program of China
GR  - 2018GGFZ-CN010/Standard Advancement Program
GR  - XDA16040501/Strategic Priority Research Program of the Chinese Academy of
      Sciences
GR  - 2019GGFZ-CN01/Model Society of Science and Technology for Group Standard
      Development Program
PT  - Journal Article
PT  - Review
DEP - 20201104
PL  - England
TA  - Cell Prolif
JT  - Cell proliferation
JID - 9105195
SB  - IM
MH  - Cell Differentiation/*physiology
MH  - Cell Lineage/physiology
MH  - Embryonic Stem Cells/cytology
MH  - Humans
MH  - Pluripotent Stem Cells/*cytology
MH  - *Stem Cell Transplantation
MH  - Stem Cells/*cytology
PMC - PMC7705904
OTO - NOTNLM
OT  - detection control
OT  - general requirements
OT  - quality control
OT  - stem cells
OT  - waste disposal
EDAT- 2020/11/05 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/11/04 08:44
PHST- 2020/09/24 00:00 [received]
PHST- 2020/09/27 00:00 [accepted]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/11/04 08:44 [entrez]
AID - 10.1111/cpr.12926 [doi]
PST - ppublish
SO  - Cell Prolif. 2020 Dec;53(12):e12926. doi: 10.1111/cpr.12926. Epub 2020 Nov 4.


PMID- 33146266
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73Suppl 3
IP  - Suppl 3
DP  - 2020
TI  - Meaning of well-being of older institutionalized persons in abandonment
      situation.
PG  - e20200123
LID - S0034-71672020001500180 [pii]
LID - 10.1590/0034-7167-2020-0123 [doi]
AB  - OBJECTIVE: To understand the meaning of well-being of older persons in situation 
      of abandonment. METHODS: a qualitative phenomenological study, carried out in a
      nursing home in Tepic, Nayarit, from 2017 to 2019. Intentional sampling with 12
      older persons aged 60 and above. Data collection occurred by phenomenological
      interview. The ethical criteria of the General Health Law were respected.
      Participants signed the Informed Consent Form. Data analysis took place through
      phenomenological analysis. RESULTS: four themes have emerged: 1. Living
      Activities of Daily Living; 2. Attention to physical needs; 3. Coexistence; 4.
      Spirituality experience. CONCLUSION: for older persons, living institutionalized 
      implies a process of adaptation and transformation to their context and state of 
      life, restructuring their needs that provide well-being. It is important to
      approach these scenarios to establish ways of experiencing aging that favor a
      full quality of life.
FAU - Martinez, Wendy Sindy Nallely Flores
AU  - Martinez WSNF
AUID- ORCID: http://orcid.org/0000-0001-8347-9640
AD  - Universidad de Guanajuato, Division de Ciencias de Salud e Ingenierias. Celaya,
      Guanajuato, Mexico.
FAU - Gonzalez, Maria de Jesus Jimenez
AU  - Gonzalez MJJ
AUID- ORCID: http://orcid.org/0000-0003-3806-0714
AD  - Universidad de Guanajuato, Division de Ciencias de Salud e Ingenierias. Celaya,
      Guanajuato, Mexico.
FAU - Perez, Norma Elvira Moreno
AU  - Perez NEM
AUID- ORCID: http://orcid.org/0000-0003-1829-3916
AD  - Universidad de Guanajuato, Division de Ciencias de Salud e Ingenierias. Celaya,
      Guanajuato, Mexico.
FAU - Guerrero-Castaneda, Raul Fernando
AU  - Guerrero-Castaneda RF
AUID- ORCID: http://orcid.org/0000-0003-3996-5208
AD  - Universidad de Guanajuato, Division de Ciencias de Salud e Ingenierias. Celaya,
      Guanajuato, Mexico.
LA  - eng
LA  - spa
PT  - Journal Article
DEP - 20201102
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - *Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*psychology
MH  - Female
MH  - Homes for the Aged
MH  - Humans
MH  - Institutionalization
MH  - Male
MH  - Middle Aged
MH  - Nursing Homes
MH  - Qualitative Research
MH  - *Quality of Life
MH  - *Spirituality
EDAT- 2020/11/05 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/11/04 08:43
PHST- 2020/04/24 00:00 [received]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/11/04 08:43 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - S0034-71672020001500180 [pii]
AID - 10.1590/0034-7167-2020-0123 [doi]
PST - epublish
SO  - Rev Bras Enferm. 2020 Nov 2;73Suppl 3(Suppl 3):e20200123. doi:
      10.1590/0034-7167-2020-0123. eCollection 2020.


PMID- 33145054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2072-1439 (Print)
IS  - 2072-1439 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep
TI  - Fluorescence navigation with indocyanine green for identification of
      intersegmental planes using a photodynamic eye camera.
PG  - 4817-4824
LID - 10.21037/jtd-20-1448 [doi]
AB  - BACKGROUND: Pulmonary segmentectomy is an important surgical option for complete 
      resection in patients with poor lung function. However, correctly recognizing the
      intersegmental plane for accurate segmentectomy is sometimes difficult. We
      therefore developed a novel method that allows the detection of intersegmental
      planes using an indocyanine green (ICG) fluorescence imaging device, photodynamic
      eye (PDE) camera, PDE-neo. METHODS: As a prospective study, we performed
      bronchial ICG-guided segmentectomy using PDE-neo. The patients were placed in a
      lateral position under general anesthesia, and we performed a combined
      muscle-sparing minithoracotomy with video assistance. The pulmonary artery,
      pulmonary vein, and segmental bronchi were separated, and ICG mixed with
      autologous blood was introduced by spraying through the resected segment bronchi 
      to enable visualization of the intersegmental surface with PDE-neo. This study
      protocol was approved by the Research Ethics Board of Hamamatsu University School
      of Medicine, Japan. Written informed consent was obtained from all patients.
      RESULTS: Overall, 10 lung malignancy patients, including 8 males and 2 females,
      participated in this study from March 2011 to October 2013. The median age was 69
      years (range, 29-76 years). Pathologic diagnoses were 7 adenocarcinomas, 1
      adenosquamous carcinoma, 1 carcinoid tumor, and 1 lung metastasis from the
      parotid gland cancer. The intersegmental planes of 8 cases could be identified by
      this method using a PDE-neo, whereas those of 2 cases did not show clear
      demarcations. The reason was that because of severe emphysema, air flowed from
      the resected segment to the surrounding segments, obliterating the demarcation
      between the two segmental planes. There were no recurrent cases and only two
      deaths due to other diseases were observed; and the 5-year cause-specific
      survival rate was 100%. CONCLUSIONS: Intersegmental planes could be more easily
      identified using ICG fluorescence imaging during segmentectomy. This method is
      feasible and effective and has a good long-term prognosis.
CI  - 2020 Journal of Thoracic Disease. All rights reserved.
FAU - Funai, Kazuhito
AU  - Funai K
AD  - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
FAU - Kawase, Akikazu
AU  - Kawase A
AD  - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
FAU - Shimizu, Kei
AU  - Shimizu K
AD  - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
FAU - Sekihara, Keigo
AU  - Sekihara K
AD  - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
FAU - Yamashita, Takashi
AU  - Yamashita T
AD  - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
FAU - Shiiya, Norihiko
AU  - Shiiya N
AD  - First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC7578513
OTO - NOTNLM
OT  - Emphysema
OT  - fluorescence imaging
OT  - indocyanine green (ICG)
OT  - lung neoplasms
OT  - segmentectomy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/jtd-20-1448). The authors have no
      conflicts of interest to declare.
EDAT- 2020/11/05 06:00
MHDA- 2020/11/05 06:01
CRDT- 2020/11/04 05:44
PHST- 2020/11/04 05:44 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/05 06:01 [medline]
AID - 10.21037/jtd-20-1448 [doi]
AID - jtd-12-09-4817 [pii]
PST - ppublish
SO  - J Thorac Dis. 2020 Sep;12(9):4817-4824. doi: 10.21037/jtd-20-1448.


PMID- 33144536
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20220418
IS  - 0004-0614 (Print)
IS  - 0004-0614 (Linking)
VI  - 73
IP  - 9
DP  - 2020 Nov
TI  - Is Thiol/Disulphide homeostasis important in prostate cancer diagnosis?
PG  - 819-825
AB  - OBJECTIVES: To assess the relationship between prostate cancer and
      thiol/disulphide homeostasisas an important indicator of oxidative stress.
      METHODS: After ethics committee approval (546/2015); 388 patients aged between
      46-75 years who underwent transrectal ultrasound guided prostatebiopsy in three
      different centers between July 2015-2016 owing to serum prostate specific antigen
      (PSA) levels >/=2.5 ng/ml and/or abnormal digital rectal examination were
      involved in this study. The plasma levels of thiol/disulphide homeostasis
      parameters were compared in patients with and without prostate cancer. RESULTS:
      The mean age of the patients was 62.9+/-7 years. In patients with prostate cancer
      (n=130, 33.5% ) the mean plasma levels of native thiol and total thiol were lower
      (332.9 vs 362.1 mumol/L and 363 vs 392.6 mumol/L, p=0.001). Plasma disulphide
      levels were not statistically different between the groups (15 vs 15.3 mumol/L,
      p=0.936). In prostate cancer group; patients with Gleason score >/=7 had lower
      plasma native thiol levels than patients with Gleason score<7 (321.3 vs 342.6
      mumol/L, p=0.029) while there were no significant differences in total thiol and 
      disulphide levels (352.3 vs 371.9 mumol/L, ptotal Thiol =0.064 and 15.5 vs 14.6
      mumol/L, pdisulphide =0.933). CONCLUSIONS: Lower plasma levels of thiol in
      patients with prostate cancer and high Gleason score is an oteworthy result. We
      believe that our results should be supported by further studies.
FAU - Senel, Cagdas
AU  - Senel C
AD  - Department of Urology. University of Health Sciences. Ankara Numune Research and 
      Training Hospital. Ankara. Turkey.
FAU - Aslan, Yilmaz
AU  - Aslan Y
AD  - Department of Urology. University of Health Sciences. Ankara Numune Research and 
      Training Hospital. Ankara. Turkey.
FAU - Imamoglu, M Abdurrahim
AU  - Imamoglu MA
AD  - Department of Urology. University of Health Sciences. Diskapi Research and
      Training Hospital. Ankara. Turkey.
FAU - Karakoyunlu, A Nihat
AU  - Karakoyunlu AN
AD  - Department of Urology. University of Health Sciences. Diskapi Research and
      Training Hospital. Ankara. Turkey.
FAU - Altinova, Serkan
AU  - Altinova S
AD  - Department of Urology. Ataturk Research and Training Hospital. Ankara. Turkey.
FAU - Ozcan, M Fuat
AU  - Ozcan MF
AD  - Department of Urology. Ataturk Research and Training Hospital. Ankara. Turkey.
FAU - Erdogan, Serpil
AU  - Erdogan S
AD  - Department of Clinical Biochemistry. Ataturk Research and Training Hospital.
      Ankara. Turkey.
FAU - Balci, Melih
AU  - Balci M
AD  - Department of Urology. University of Health Sciences. Ankara Numune Research and 
      Training Hospital. Ankara. Turkey.
FAU - Tuncel, Altug
AU  - Tuncel A
AD  - Department of Urology. University of Health Sciences. Ankara Numune Research and 
      Training Hospital. Ankara. Turkey.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Es importante la homeostasis del Tiol/Disulfito en el diagnostico del cancer de
      prostata?
PL  - Spain
TA  - Arch Esp Urol
JT  - Archivos espanoles de urologia
JID - 0064757
RN  - 0 (Disulfides)
RN  - 0 (Sulfhydryl Compounds)
SB  - IM
MH  - Aged
MH  - *Disulfides
MH  - Homeostasis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Prostatic Neoplasms/diagnosis
MH  - Sulfhydryl Compounds
OTO - NOTNLM
OT  - Cancer de prostata
OT  - Diagnosis
OT  - Diagnostico
OT  - Dynamic thiol-disulphide homeostasis
OT  - Estres oxidativo
OT  - Homeostasis dinamica tiol/ disulfito
OT  - Oxidative stress
OT  - Prostate cancer
EDAT- 2020/11/05 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/11/04 05:37
PHST- 2020/11/04 05:37 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 2020-73-9-d0e2352b0a1a12bfc6d914959cc48486603a63f0 [pii]
PST - ppublish
SO  - Arch Esp Urol. 2020 Nov;73(9):819-825.


PMID- 33144275
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201218
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 26
TI  - The Role of Demoralization and Meaning in Life (DEMIL) in Influencing Suicidal
      Ideation Among Patients Affected by Chronic Pain: Protocol of a Single-Center,
      Observational, Case-Control Study.
PG  - e24882
LID - 10.2196/24882 [doi]
AB  - BACKGROUND: Chronic pain is a significant risk factor for suicidal ideation (SI) 
      and suicidal behavior (SB), including a 20%-40% prevalence rate of SI, a
      prevalence between 5% and 14% of suicide attempts, and a doubled risk of death by
      suicide in patients with chronic pain compared to controls. In most studies,
      associations between chronic pain and suicidality are robust, even after
      adjusting for the effect of sociodemographics and psychiatric comorbidity, and
      particularly for depressive conditions. A number of specific conditions that can 
      modulate suicidality risk in patients with chronic pain have been investigated,
      but there is a need for their more specific characterization. Numerous recent
      studies have shown that demoralization and meaning in life (MiL) constructs
      affect suicidality as risk and protective factors, respectively. These constructs
      have been mainly investigated in patients with somatic illness and in
      community-dwelling individuals who may present with SI or SB independently of a
      psychiatric diagnosis of depression. However, a paucity of studies investigated
      them in suicidal patients affected by chronic pain. OBJECTIVE: The primary
      objective of this project is to investigate the relationship between
      demoralization and MiL on SI risk in patients with chronic pain. The secondary
      objectives are (1) to test whether demoralization can occur independently of
      depression in patients with chronic pain and SI, (2) to examine whether the
      expected association between demoralization and SI may be explained by a sole
      dimension of demoralization: hopelessness, (3) to examine whether the presence of
      MiL, but not the search for MiL, is associated with less SI, and (4) to explore
      whether previously described MiL profiles (ie, high presence-high search, high
      presence-low search, moderate presence-moderate search, low presence-low search, 
      and low presence-high search) emerge in our cohort. METHODS: This project is a
      single-center, observational, case-control study-the Demoralization and Meaning
      in Life (DEMiL) study-conducted by the Division of Clinical Pharmacology and
      Toxicology, the Multidisciplinary Pain Centre, and the Service of Liaison
      Psychiatry and Crisis Intervention at the Geneva University Hospitals. Self- and 
      hetero-administered questionnaires were conducted among patients and controls,
      matched by age and gender. The Ethics Committee of the Canton of Geneva approved 
      the scientific utilization of collected data (project No. 2017-02138; decision
      dated January 25, 2018). Data have been analyzed with SPSS, version 23.0,
      software (IBM Corp). RESULTS: From March 1, 2018, to November 30, 2019, 70
      patients and 70 controls were enrolled. Statistical analyses are still in
      progress and are expected to be finalized in November 2020. To date, we did not
      observe any unfavorable event for which a causal relationship with the collection
      of health-related personal data could be ruled out. Results of this study are
      expected to form the basis for possible prevention and psychotherapeutic
      interventions oriented toward demoralization and MiL constructs for suicidal
      patients with chronic pain. CONCLUSIONS: The interest in exploring demoralization
      and MiL in chronic pain patients with SI arises from the common clinical
      observation that experiencing chronic pain often requires a revision of one's
      life goals and expectations. Hence, the impact of chronic pain is not limited to 
      patients' biopsychosocial functioning, but it affects the existential domain as
      well. The major clinical implications in suicidal patients with chronic pain
      consist in trying to (1) delineate a more precise and individualized suicide risk
      profile, (2) improve detection and prevention strategies by investigating SI also
      in individuals who do not present with a clinically diagnosed depression, and (3)
      enhance the panel of interventions by broadening supportive or psychotherapeutic 
      actions, taking into consideration the existential condition of a person who
      suffers and strives to deal with his or her suffering. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/24882.
CI  - (c)Alessandra Costanza, Vasileios Chytas, Viridiana Mazzola, Valerie Piguet,
      Jules Desmeules, Guido Bondolfi, Christine Cedraschi. Originally published in
      JMIR Research Protocols (http://www.researchprotocols.org), 26.11.2020.
FAU - Costanza, Alessandra
AU  - Costanza A
AUID- ORCID: https://orcid.org/0000-0001-6387-6462
AD  - Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
AD  - Department of Psychiatry, Santi Antonio e Biagio e Cesare Arrigo Hospital,
      Alessandria, Italy.
FAU - Chytas, Vasileios
AU  - Chytas V
AUID- ORCID: https://orcid.org/0000-0002-1897-3578
AD  - Division of Clinical Pharmacology and Toxicology, Multidisciplinary Pain Center, 
      Geneva University Hospitals, Geneva, Switzerland.
FAU - Mazzola, Viridiana
AU  - Mazzola V
AUID- ORCID: https://orcid.org/0000-0001-7151-3450
AD  - Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
AD  - Department of Psychiatry, Service of Liaison Psychiatry and Crisis Intervention, 
      Geneva University Hospitals, Geneva, Switzerland.
FAU - Piguet, Valerie
AU  - Piguet V
AUID- ORCID: https://orcid.org/0000-0001-5830-9252
AD  - Division of Clinical Pharmacology and Toxicology, Multidisciplinary Pain Center, 
      Geneva University Hospitals, Geneva, Switzerland.
FAU - Desmeules, Jules
AU  - Desmeules J
AUID- ORCID: https://orcid.org/0000-0003-2702-1795
AD  - Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
AD  - Division of Clinical Pharmacology and Toxicology, Multidisciplinary Pain Center, 
      Geneva University Hospitals, Geneva, Switzerland.
FAU - Bondolfi, Guido
AU  - Bondolfi G
AUID- ORCID: https://orcid.org/0000-0002-4352-5531
AD  - Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
AD  - Department of Psychiatry, Service of Liaison Psychiatry and Crisis Intervention, 
      Geneva University Hospitals, Geneva, Switzerland.
FAU - Cedraschi, Christine
AU  - Cedraschi C
AUID- ORCID: https://orcid.org/0000-0002-3743-5644
AD  - Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva,
      Switzerland.
AD  - Division of Clinical Pharmacology and Toxicology, Multidisciplinary Pain Center, 
      Geneva University Hospitals, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7728536
OTO - NOTNLM
OT  - chronic pain
OT  - demoralization
OT  - meaning in life
OT  - study protocol
OT  - suicidal ideation
OT  - suicide
OT  - suicide attempt
OT  - suicide behavior
EDAT- 2020/11/05 06:00
MHDA- 2020/11/05 06:01
CRDT- 2020/11/04 05:35
PHST- 2020/10/08 00:00 [received]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/03 00:00 [revised]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/05 06:01 [medline]
PHST- 2020/11/04 05:35 [entrez]
AID - v9i11e24882 [pii]
AID - 10.2196/24882 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 26;9(11):e24882. doi: 10.2196/24882.


PMID- 33143724
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220531
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Nov 3
TI  - The awareness of women on prostate cancer: a mixed-methods systematic review
      protocol.
PG  - 253
LID - 10.1186/s13643-020-01513-4 [doi]
AB  - BACKGROUND: Prostate cancer accounts for about 10% of cancers affecting and
      claiming the lives of men. Studies have reported that women are better than men
      in recognition of the early manifestations of various cancers. Besides, women
      have been recognized to show a profound interest in their partners' health and
      hence, make observations that men do not know. Several studies have reported on
      the knowledge gaps of prostate cancer among patients and the general population. 
      It is vital to comprehensively review the available evidence and identify
      research gaps in our current understanding of knowledge of women on prostate
      cancer. METHODS: A search of bibliographic databases, MEDLINE (EBSCOhost), CINAHL
      (EBSCOhost), PsycINFO (EBSCOhost), Web of Science, and EMBASE (Ovid) will be
      undertaken from January 1999 to December 2019. The search will be limited to
      studies published in the English language. Duplication of studies will be removed
      using the EndNote citation manager. After deduplication, citations will be
      screened independently by two authors according to prespecified criteria. Data
      extraction and quality assessment of the selected studies will be done
      independently by two authors. Meta-analytic methods will be used where
      appropriate. The convergent segregated method of synthesis will be adopted in
      this review. ETHICS AND DISSEMINATION: Primary data collection will not be
      involved in this study, hence formal ethical clearance will not be needed. The
      results of the study will be presented through a peer-reviewed journal and
      conference presentation. PATIENT AND PUBLIC INVOLVEMENT: Patients or the public
      will not be engaged in the conduct of this study. TRIAL REGISTRATION: Open
      Science Framework (OSF) registration DOI: https://doi.org/10.17605/OSF.IO/EYHF2.
FAU - Wiafe, Ebenezer
AU  - Wiafe E
AUID- ORCID: 0000-0002-0496-5737
AD  - University of KwaZulu-Natal, Durban, South Africa. weben38@mail.com.
FAU - Mensah, Kofi Boamah
AU  - Mensah KB
AD  - University of KwaZulu-Natal, Durban, South Africa.
AD  - Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
FAU - Mensah, Adwoa Bemah Boamah
AU  - Mensah ABB
AD  - Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
FAU - Bangalee, Varsha
AU  - Bangalee V
AD  - University of KwaZulu-Natal, Durban, South Africa.
FAU - Oosthuizen, Frasia
AU  - Oosthuizen F
AD  - University of KwaZulu-Natal, Durban, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201103
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - Humans
MH  - Male
MH  - *Prostatic Neoplasms
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7641856
EDAT- 2020/11/05 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/04 05:31
PHST- 2020/07/07 00:00 [received]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/04 05:31 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01513-4 [doi]
AID - 10.1186/s13643-020-01513-4 [pii]
PST - epublish
SO  - Syst Rev. 2020 Nov 3;9(1):253. doi: 10.1186/s13643-020-01513-4.


PMID- 33143168
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20211008
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 21
DP  - 2020 Oct 30
TI  - Facilitators and Barriers in the Organ Donation Process: A Qualitative Study
      among Nurse Transplant Coordinators.
LID - E7996 [pii]
LID - 10.3390/ijerph17217996 [doi]
AB  - BACKGROUND: Spain is the world leader in organ donation, with a rate of 49.0
      donations per million population. Nurse transplant coordinators fulfill key roles
      for the success of the complex donation process. Our aims were: (a) to describe
      the experience of nurse transplant coordinators and (b) to identify barriers and 
      facilitators during the process of organ donation. METHODS: A qualitative
      phenomenological study was conducted within the National Transplant Organization.
      A purposive sampling method was used, and data collection methods included
      semistructured interviews, researcher field notes, and participants' personal
      letters. A systematic text condensation analysis was performed. The study was
      approved by the Clinical Research Ethics Committee. RESULTS: A total of 16
      participants were recruited and four themes were identified: (a) a different job 
      for nurses, (b) facilitators and barriers of the coordinator's job, (c) not a job
      for a novice nurse, and (d) coordinators facing a paradigm shift. Coordinators
      described their job as being characterized with uncertainty and having to face
      emotional and institutional barriers. The facilitators identified were high
      educational level and training, and feelings of pride for being part of the
      National Transplant Organization. CONCLUSIONS: The organ donation process
      requires specialized training to avoid organizational barriers.
FAU - Fernandez-Alonso, Victor
AU  - Fernandez-Alonso V
AUID- ORCID: 0000-0002-4018-9931
AD  - Gregorio Maranon Sanitary Research Institute (IiSGM), International Doctoral
      School, Universidad Rey Juan Carlos, 28922 Madrid, Spain.
FAU - Palacios-Cena, Domingo
AU  - Palacios-Cena D
AUID- ORCID: 0000-0003-0669-6339
AD  - Research Group of Humanities and Qualitative Research in Health Science of
      Universidad Rey Juan Carlos (Hum&QRinHS), Universidad Rey Juan Carlos, Alcorcon, 
      28922 Madrid, Spain.
FAU - Silva-Martin, Celia
AU  - Silva-Martin C
AD  - Gregorio Maranon Sanitary Reasearch Institute (IsSGM), 28007 Madrid, Spain.
FAU - Garcia-Pozo, Ana
AU  - Garcia-Pozo A
AD  - General University Hospital Gregorio Maranon, Gregorio Maranon Sanitary Research 
      Institute (IiSGM), 28007 Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Attitude of Health Personnel
MH  - Humans
MH  - Nurses
MH  - *Organ Transplantation
MH  - Qualitative Research
MH  - Spain
MH  - *Tissue and Organ Procurement
PMC - PMC7662326
OTO - NOTNLM
OT  - *nursing
OT  - *nursing care
OT  - *organ transplantation
OT  - *qualitative research
OT  - *supervisory
OT  - *tissue donor
EDAT- 2020/11/05 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/04 01:03
PHST- 2020/09/10 00:00 [received]
PHST- 2020/10/26 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/04 01:03 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - ijerph17217996 [pii]
AID - 10.3390/ijerph17217996 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 30;17(21). pii: ijerph17217996. doi:
      10.3390/ijerph17217996.


PMID- 33143093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Oct 30
TI  - Freezing Weakens the Barrier Function of Reconstructed Human Epidermis as
      Evidenced by Raman Spectroscopy and Percutaneous Permeation.
LID - E1041 [pii]
LID - 10.3390/pharmaceutics12111041 [doi]
AB  - The development and characterization of reconstructed human epidermis (RHE) is an
      active area of R&D. RHE can replace animal tissues in pharmaceutical,
      toxicological and cosmetic sciences, yielding scientific and ethical advantages. 
      RHEs remain costly, however, due to consumables and time required for their
      culture and a short shelf-life. Storing, i.e., freezing RHE could help reduce
      costs but to date, little is known on the effects of freezing on the barrier
      function of RHE. We studied such effects using commercial EpiSkin RHE stored at
      -20, -80 and -150 degrees C for 1 and 10 weeks. We acquired intrinsic Raman
      spectra in the stratum corneum (SC) of the RHEs as well as spectra obtained
      following topical application of resorcinol in an aqueous solution. In parallel, 
      we quantified the effects of freezing on the permeation kinetics of resorcinol
      from time-dependent permeation experiments. Principal component analyses
      discriminated the intrinsic SC spectra and the spectra of resorcinol-containing
      RHEs, in each case on the basis of the freezing conditions. Permeation of
      resorcinol through the frozen RHE increased 3- to 6-fold compared to fresh RHE,
      with the strongest effect obtained from freezing at -20 degrees C for 10 weeks.
      Due to the extensive optimization and standardization of EpiSkin RHE, the effects
      observed in our work may be expected to be more pronounced with other RHEs.
FAU - Dancik, Yuri
AU  - Dancik Y
AD  - Le STUDIUM Institute of Advanced Studies, 1 rue Dupanloup, 45000 Orleans, France.
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
FAU - Kichou, Hichem
AU  - Kichou H
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
FAU - Eklouh-Molinier, Christophe
AU  - Eklouh-Molinier C
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
FAU - Souce, Martin
AU  - Souce M
AUID- ORCID: 0000-0002-6627-9660
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
FAU - Munnier, Emilie
AU  - Munnier E
AUID- ORCID: 0000-0002-6691-4484
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
FAU - Chourpa, Igor
AU  - Chourpa I
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
FAU - Bonnier, Franck
AU  - Bonnier F
AD  - Faculte de Pharmacie, Universite de Tours, 31 Avenue Monge, EA 6295
      NanoMedicaments et NanoSondes, 37200 Tours, France.
LA  - eng
GR  - N/A/Le STUDIUM Institute of Advanced Studies
GR  - 2017-00118114/Region Centre-Val de Loire - MISTIC project ARD 2020
      Cosmetosciences
GR  - N/A/European Regional Development Fund
PT  - Journal Article
DEP - 20201030
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC7694161
OTO - NOTNLM
OT  - EpiSkin
OT  - Raman spectroscopy
OT  - freezing
OT  - permeation
OT  - reconstructed human epidermis
OT  - resorcinol
OT  - skin barrier
OT  - storage
EDAT- 2020/11/05 06:00
MHDA- 2020/11/05 06:01
CRDT- 2020/11/04 01:03
PHST- 2020/09/25 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/04 01:03 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/05 06:01 [medline]
AID - pharmaceutics12111041 [pii]
AID - 10.3390/pharmaceutics12111041 [doi]
PST - epublish
SO  - Pharmaceutics. 2020 Oct 30;12(11). pii: pharmaceutics12111041. doi:
      10.3390/pharmaceutics12111041.


PMID- 33141451
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - The role of community engagement in addressing bystander risks in research: The
      case of a Zika virus controlled human infection study.
PG  - 883-892
LID - 10.1111/bioe.12806 [doi]
AB  - There is limited guidance on how to assess the ethical acceptability of research 
      risks that extend beyond research participants to third parties (or "research
      bystanders"). Community or stakeholder engagement has been proposed as one way to
      address potential harms to community members, including bystanders. Despite
      widespread agreement on the importance of community engagement in biomedical
      research, this umbrella term includes many different goals and approaches,
      agreement on which is ethically required or recommended for a particular context.
      We analyse the case of a potential Zika virus human challenge trial to assess
      whether and how community engagement can help promote the ethical acceptability
      of research posing risks to bystanders. We conclude that, in addition to having
      intrinsic value, community engagement can improve the identification of bystander
      risks, effective approaches to minimizing them, and transparency about bystander 
      risks for host communities.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Shah, Seema K
AU  - Shah SK
AUID- ORCID: 0000-0001-7726-1186
AD  - Lurie Children's Hospital and Northwestern Feinberg School of Medicine.
FAU - Miller, Franklin
AU  - Miller F
AD  - Cornell Weill School of Medicine.
FAU - Fernandez Lynch, Holly
AU  - Fernandez Lynch H
AUID- ORCID: 0000-0001-7813-9879
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania.
LA  - eng
GR  - 1 R01 AI114617-01A1/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201103
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Biomedical Research
MH  - Humans
MH  - Research Design
MH  - Stakeholder Participation
MH  - *Zika Virus
MH  - *Zika Virus Infection/prevention & control
OTO - NOTNLM
OT  - *Zika
OT  - *bystanders
OT  - *community engagement
OT  - *human challenge studies
OT  - *research ethics
OT  - *risk
EDAT- 2020/11/04 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/11/03 12:51
PHST- 2018/12/21 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/11/03 12:51 [entrez]
AID - 10.1111/bioe.12806 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):883-892. doi: 10.1111/bioe.12806. Epub 2020 Nov 3.


PMID- 33140740
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20220418
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Nov 3
TI  - [Ethics Committee experience during COVID-19 emergency. A brief report.]
LID - e202011146 [pii]
AB  - OBJECTIVE: The health crisis caused by COVID-19 required the prompt launch of
      research in order to generate scientific evidence pertaining to the new disease
      oriented to control its devastating effects and continuous spread. Therefore, it 
      was essential to adapt the work flow of Research Ethics Committees, to prioritize
      and to accelerate the evaluation of projects related to this disease. METHODS:
      This work analyses the evaluation conducted by our Regional Ethics Committees
      during the initial period of the health emergency (between 13th March and 28th
      May 2020). RESULTS: 81 research projects were evaluated, 73 of them of regional
      scope (62 single-centre), 4 national and 4 international. 57 projects obtained a 
      favourable opinion, 4 were withdrawn by the sponsors, 6 did not require ethics
      approval and 14 did not respond to the clarifications requested up to the date of
      the study's closure. CONCLUSIONS: The most important research procedures to be
      analysed in this context are those related to the methodology and informed
      consent process. It is also essential to address aspects related to the privacy
      of personal data, and to take into account the workload of the researchers. As an
      improvement proposal, we think that greater collaboration between the different
      research teams should be encourage to obtain more robust results.
FAU - Bugarin Gonzalez, Rosendo
AU  - Bugarin Gonzalez R
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Romero-Yuste, Susana Maria
AU  - Romero-Yuste SM
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Lopez Vazquez, Paula M feminine
AU  - Lopez Vazquez PM
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Casariego Roson, Juan
AU  - Casariego Roson J
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Carballeda Feijoo, Nuria
AU  - Carballeda Feijoo N
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Cruz Del Rio, Juana M feminine
AU  - Cruz Del Rio JM
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Cueva Banuelos, Juan Fernando
AU  - Cueva Banuelos JF
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Fernandez Rial, Jose Alvaro
AU  - Fernandez Rial JA
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Fernandez Trisac, Jose Luis
AU  - Fernandez Trisac JL
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Ferreira Diaz, M feminine Jose
AU  - Ferreira Diaz MJ
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Millan Calenti, Rafael Alvaro
AU  - Millan Calenti RA
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Pia Morandeira, Agustin
AU  - Pia Morandeira A
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Prado Casal, Jorge
AU  - Prado Casal J
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Rodriguez-Tenreiro Sanchez, Carmen
AU  - Rodriguez-Tenreiro Sanchez C
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Santos Garcia, Diego
AU  - Santos Garcia D
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Vazquez Lago, Juan Manuel
AU  - Vazquez Lago JM
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Verdejo Gonzalez, M feminine Asuncion
AU  - Verdejo Gonzalez MA
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
FAU - Zarra Ferro, Irene
AU  - Zarra Ferro I
AD  - Comite de Etica de la Investigacion con medicamentos de Galicia (CEIm-G). Servizo
      Galego de Saude. Espana.
LA  - spa
PT  - Journal Article
TT  - Experiencia de un Comite de Etica de la Investigacion durante la pandemia por
      COVID-19.
DEP - 20201103
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Informed Consent
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Research Design/*standards
MH  - SARS-CoV-2
MH  - Spain
MH  - *Workflow
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics Committees
OT  - Research
OT  - Spain
EDAT- 2020/11/04 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/11/03 08:38
PHST- 2020/07/08 00:00 [received]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/11/03 08:38 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Nov 3;94.


PMID- 33140408
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 61
IP  - 12
DP  - 2020 Dec
TI  - Twin pregnancy in women with epilepsy.
PG  - 2748-2753
LID - 10.1111/epi.16727 [doi]
AB  - OBJECTIVE: We report data from the Raoul Wallenberg Australian Register of
      Antiepileptic Drugs in Pregnancy (APR) to see if there are significant
      differences in relation to the courses and outcomes of the twin pregnancies
      contained in the register, as compared with the singleton ones. METHODS: The APR 
      has been under the oversight of Melbourne institutional Human Ethics Research
      Committees; all women enrolled in the APR have provided written informed consent.
      Data from the APR were transferred to a spreadsheet and then analyzed using
      simple statistical techniques including logistic regression. RESULTS: The
      population studied comprised 44 twin and 2261 singleton pregnancies; thus, twin
      pregnancies accounted for 1.91% of all pregnancies studied. The women carrying
      twins tended to be older than the women with singleton pregnancies to a
      statistically significant extent, their pregnancies more often originated from
      assisted fertilization techniques, and their babies were more often delivered by 
      cesarean section. There were no statistically significant differences in relation
      to antiepileptic drug (AED) therapy. Individual twins had statistically
      significantly lower mean birthweights than singleton babies and they were
      statistically significantly more often involved structurally malformed foetuses. 
      In the first year of life, the twin pregnancies statistically significantly more 
      often produced offspring that were affected by seizures in infancy. SIGNIFICANCE:
      The data suggest that there may be an increased hazard of fetal malformation in
      the offspring of twin pregnancy in women with epilepsy, but that with
      contemporary standards of management of epilepsy and pregnancy, there is unlikely
      to be an increased hazard of seizure-affected pregnancy.
CI  - (c) 2020 International League Against Epilepsy.
FAU - Vajda, Frank J E
AU  - Vajda FJE
AUID- ORCID: 0000-0001-5570-7538
AD  - Department of Medicine and Neurosciences, Royal Melbourne Hospital and University
      of Melbourne, Parkville, Vic, Australia.
AD  - Department of Neurology, Alfred Hospital, Melbourne, Vic, Australia.
AD  - Department of Neuroscience, Monash University, Clayton, Vic, Australia.
FAU - O'Brien, Terence J
AU  - O'Brien TJ
AD  - Department of Neurology, Alfred Hospital, Melbourne, Vic, Australia.
AD  - Department of Neuroscience, Monash University, Clayton, Vic, Australia.
FAU - Graham, Janet E
AU  - Graham JE
AUID- ORCID: 0000-0003-2140-2351
AD  - Department of Medicine and Neurosciences, Royal Melbourne Hospital and University
      of Melbourne, Parkville, Vic, Australia.
FAU - Hitchcock, Alison A
AU  - Hitchcock AA
AD  - Department of Medicine and Neurosciences, Royal Melbourne Hospital and University
      of Melbourne, Parkville, Vic, Australia.
FAU - Perucca, Piero
AU  - Perucca P
AD  - Department of Medicine and Neurosciences, Royal Melbourne Hospital and University
      of Melbourne, Parkville, Vic, Australia.
AD  - Department of Neurology, Alfred Hospital, Melbourne, Vic, Australia.
AD  - Department of Neuroscience, Monash University, Clayton, Vic, Australia.
FAU - Lander, Cecilie M
AU  - Lander CM
AD  - Royal Brisbane and Women's Hospital and School of Medicine and Biomedical
      Science, University of Queensland, Brisbane, Qld, Australia.
FAU - Eadie, Mervyn J
AU  - Eadie MJ
AD  - Royal Brisbane and Women's Hospital and School of Medicine and Biomedical
      Science, University of Queensland, Brisbane, Qld, Australia.
LA  - eng
GR  - Epilepsy Society of Australia
GR  - UCB
GR  - Eisai
GR  - Royal Melbourne Hospital Neuroscience Foundation
GR  - Sanofi Genzyme
GR  - National Health and Medical Research Council
GR  - Epilepsy Action Australia
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201102
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
SB  - IM
MH  - Australia/epidemiology
MH  - Case-Control Studies
MH  - Cesarean Section/statistics & numerical data
MH  - Congenital Abnormalities/epidemiology
MH  - Epilepsy/*complications
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications/*pathology
MH  - Pregnancy Outcome
MH  - *Pregnancy, Twin/statistics & numerical data
MH  - Registries
OTO - NOTNLM
OT  - *antiepileptic medication
OT  - *foetal malformations
OT  - *pregnancy
OT  - *seizures
OT  - *twins
EDAT- 2020/11/04 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/11/03 05:49
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
PHST- 2020/11/03 05:49 [entrez]
AID - 10.1111/epi.16727 [doi]
PST - ppublish
SO  - Epilepsia. 2020 Dec;61(12):2748-2753. doi: 10.1111/epi.16727. Epub 2020 Nov 2.


PMID- 33140180
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20220218
IS  - 1432-1238 (Electronic)
IS  - 0342-4642 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Extracorporeal life support for adults with acute respiratory distress syndrome.
PG  - 2464-2476
LID - 10.1007/s00134-020-06290-1 [doi]
AB  - Extracorporeal life support (ECLS) can support gas exchange in patients with the 
      acute respiratory distress syndrome (ARDS). During ECLS, venous blood is drained 
      from a central vein via a cannula, pumped through a semipermeable membrane that
      permits diffusion of oxygen and carbon dioxide, and returned via a cannula to a
      central vein. Two related forms of ECLS are used. Venovenous extracorporeal
      membrane oxygenation (ECMO), which uses high blood flow rates to both oxygenate
      the blood and remove carbon dioxide, may be considered in patients with severe
      ARDS whose oxygenation or ventilation cannot be maintained adequately with best
      practice conventional mechanical ventilation and adjunctive therapies, including 
      prone positioning. Extracorporeal carbon dioxide removal (ECCO2R) uses lower
      blood flow rates through smaller cannulae and provides substantial CO2
      elimination (~ 20-70% of total CO2 production), albeit with marginal improvement 
      in oxygenation. The rationale for using ECCO2R in ARDS is to facilitate
      lung-protective ventilation by allowing a reduction of tidal volume, respiratory 
      rate, plateau pressure, driving pressure and mechanical power delivered by the
      mechanical ventilator. This narrative review summarizes physiological concepts
      related to ECLS, as well as the rationale and evidence supporting ECMO and ECCO2R
      for the treatment of ARDS. It also reviews complications, limitations, and the
      ethical dilemmas that can arise in treating patients with ECLS. Finally, it
      discusses future key research questions and challenges for this technology.
FAU - Combes, Alain
AU  - Combes A
AUID- ORCID: 0000-0002-6030-3957
AD  - Sorbonne Universite, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and
      Nutrition, 75013, Paris, France. alain.combes@aphp.fr.
AD  - Service de Medecine Intensive-Reanimation, Institut de Cardiologie, APHP Sorbonne
      Universite Hopital Pitie-Salpetriere, 75013, Paris, France. alain.combes@aphp.fr.
FAU - Schmidt, Matthieu
AU  - Schmidt M
AD  - Sorbonne Universite, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and
      Nutrition, 75013, Paris, France.
AD  - Service de Medecine Intensive-Reanimation, Institut de Cardiologie, APHP Sorbonne
      Universite Hopital Pitie-Salpetriere, 75013, Paris, France.
FAU - Hodgson, Carol L
AU  - Hodgson CL
AD  - Australian and New Zealand Intensive Care-Research Centre, Monash University,
      Melbourne, Australia.
FAU - Fan, Eddy
AU  - Fan E
AD  - Interdepartmenal Division of Critical Care Medicine, University of Toronto,
      Toronto, ON, Canada.
AD  - Department of Medicine, Division of Respirology, University Health Network,
      Toronto, ON, Canada.
FAU - Ferguson, Niall D
AU  - Ferguson ND
AD  - Department of Medicine, Division of Respirology, University Health Network,
      Toronto, ON, Canada.
AD  - Interdepartmental Division of Critical Care Medicine and Department of Medicine, 
      University of Toronto, Toronto, ON, Canada.
FAU - Fraser, John F
AU  - Fraser JF
AD  - Critical Care Research Group, Adult Intensive Care Services, Northside Medical
      School, The Prince Charles Hospital, University of Queensland, Brisbane,
      Australia.
FAU - Jaber, Samir
AU  - Jaber S
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), Centre
      National de la Recherche Scientifique (CNRS), From the PhyMedExp, University of
      Montpellier, Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier,
      France.
AD  - Departement d'Anesthesie-Reanimation, Hopital Saint-Eloi, Montpellier Cedex,
      France.
FAU - Pesenti, Antonio
AU  - Pesenti A
AD  - Department of Anesthesia, Critical Care and Emergency, Department of
      Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale
      Maggiore Policlinico, University of Milan, Milan, Italy.
FAU - Ranieri, Marco
AU  - Ranieri M
AD  - Intensive Care Unit, Policlinico di Sant'Orsola, Alma Mater Studiorum University 
      of Bologna, Bologna, Italy.
FAU - Rowan, Kathryn
AU  - Rowan K
AD  - Clinical Trials Unit, Intensive Care National Audit and Research Centre (ICNARC),
      London, UK.
FAU - Shekar, Kiran
AU  - Shekar K
AD  - Adult Intensive Care Services, Critical Care Research Group, the Prince Charles
      Hospital, Brisbane, QLD, Australia.
AD  - Queensland University of Technology, University of Queensland, Brisbane, QLD,
      Australia.
FAU - Slutsky, Arthur S
AU  - Slutsky AS
AD  - Interdepartmental Division of Critical Care Medicine, University of Toronto,
      Toronto, ON, Canada.
AD  - Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, Unity
      Health Toronto, St Michael's Hospital, Toronto, ON, Canada.
FAU - Brodie, Daniel
AU  - Brodie D
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University
      College of Physicians and Surgeons, NewYork-Presbyterian Hospital, New York, USA.
AD  - Center for Acute Respiratory Failure, NewYork-Presbyterian Hospital, New York,
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201102
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
SB  - IM
MH  - Adult
MH  - Extracorporeal Circulation
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - Respiration, Artificial
MH  - *Respiratory Distress Syndrome/therapy
MH  - Tidal Volume
PMC - PMC7605473
OTO - NOTNLM
OT  - *Acute respiratory failure
OT  - *Extracorporeal membrane oxygenation
OT  - *Mechanical ventilation
OT  - *Outcome
EDAT- 2020/11/04 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/11/03 05:48
PHST- 2020/09/22 00:00 [received]
PHST- 2020/10/10 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/11/03 05:48 [entrez]
AID - 10.1007/s00134-020-06290-1 [doi]
AID - 10.1007/s00134-020-06290-1 [pii]
PST - ppublish
SO  - Intensive Care Med. 2020 Dec;46(12):2464-2476. doi: 10.1007/s00134-020-06290-1.
      Epub 2020 Nov 2.


PMID- 33140036
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 24
DP  - 2020
TI  - Current state and future perspectives of telemedicine use in surgery during the
      COVID-19 pandemic: A scoping review protocol.
PG  - 17-20
LID - 10.1016/j.isjp.2020.10.002 [doi]
AB  - INTRODUCTION: The biggest concerns in the current pandemic are enormous workload 
      pressure, psychological distress, caregiver burnout, and, even worse,
      transmission of the virus among healthcare workers. One of the potentially
      beneficial tools in reducing the above-mentioned risks for overwhelming the
      healthcare system is telemedicine. Although the role of telemedicine and related 
      interventions as a crisis management tool has increased, the current state of the
      implementation of telemedicine in surgery and surgical subspecialties has not
      been adequately evaluated. OBJECTIVE AND SIGNIFICANCE: The objective of this
      review is to screen the literature, extract expert opinions, qualitative, and
      quantitative data on the current use and future directions in the implementation 
      of telemedicine in surgery and surgical subspecialties during the COVID-19
      pandemic. The findings would potentially help in understanding the challenges and
      future directions of telemedicine use in surgery. METHODS AND ANALYSIS: The
      databases to be searched include PubMed, EMBASE, and MEDLINE (via Ovid). In
      addition, ClinicalTrials.gov and medRxiv.org will be searched for any ongoing
      and/or unpublished studies. The reference lists of articles included in the
      review will be screened to assess the sensitivity of the search. Literature
      search, quality assessment, followed by data extraction will be performed by two 
      independent researchers. The findings of the data synthesis will be reported in
      diagrams, tables, and text. This review will consider reports that include expert
      opinions, qualitative and quantitative data on the implementation of telemedicine
      in surgery and surgical subspecialties (including patients with surgical disease 
      of any age) during the COVID-19 pandemic. In addition, future perspectives
      reported based either on the evidence provided by the data or on expert opinions 
      will be considered. ETHICS AND DISSEMINATION: This study does not require an
      institutional review board approval given its summary design nature. Findings of 
      this systematic review will be published in a peer-reviewed journal. SYSTEMATIC
      REVIEW REGISTRATION NUMBER: PROSPERO does not currently accept registrations for 
      scoping reviews, literature reviews or mapping reviews.
CI  - (c) 2020 The Author(s).
FAU - Gachabayov, Mahir
AU  - Gachabayov M
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY, United States.
FAU - Latifi, Lulejeta A
AU  - Latifi LA
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY, United States.
FAU - Parsikia, Afshin
AU  - Parsikia A
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY, United States.
FAU - Latifi, Rifat
AU  - Latifi R
AD  - Department of Surgery, Westchester Medical Center, New York Medical College,
      Valhalla, NY, United States.
LA  - eng
PT  - Journal Article
DEP - 20201024
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7584517
OTO - NOTNLM
OT  - Breast cancer
OT  - COVID-19
OT  - Endocrine therapy
OT  - SARS-Co-V-2
OT  - Surgery
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/11/04 06:00
MHDA- 2020/11/04 06:01
CRDT- 2020/11/03 05:47
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/11/03 05:47 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2020/11/04 06:01 [medline]
AID - 10.1016/j.isjp.2020.10.002 [doi]
AID - S2468-3574(20)30031-0 [pii]
PST - ppublish
SO  - Int J Surg Protoc. 2020;24:17-20. doi: 10.1016/j.isjp.2020.10.002. Epub 2020 Oct 
      24.


PMID- 33139649
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201226
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Nov 1
TI  - The Motion of the Italian National Bioethics Committee on Aggressive Treatment
      towards Children with Limited Life Expectancy.
LID - E448 [pii]
LID - 10.3390/healthcare8040448 [doi]
AB  - The motion of the Italian National Bioethics Committee entitled "Aggressive
      treatment or therapeutic obstinacy on young children with limited life
      expectancy" comprises a premise that rejects therapeutic obstinacy and makes 12
      recommendations. Recommendation no. 1 states the general rules: it ascribes a
      cardinal role to a shared care plan, it supports pain management therapy and pain
      relief, it opposes ineffective and disproportionate clinical treatment and
      defensive medicine. The other recommendations are correlated to the enacting of a
      national law establishing clinical ethics committees in paediatric hospitals;
      participation of parents and their fiduciaries in the decision-making processes; 
      recourse to courts only as extrema ratio in the event of irremediable
      disagreement between the medical team and the family members; accompaniment at
      the end of life also through continuous deep sedation combined with pain therapy;
      access to palliative care; the need to reinforce research on pain and suffering
      in children; clinical trials and research studies conducted in children; the
      training of doctors, healthcare personnel and psychologists, to support parents
      in emotional and practical terms; the facilitation of the closeness of parents to
      children in extremely precarious clinical conditions; the relevant role of the
      associations of parents of sick children. Comments are made, in particular, about
      the innovative recommendations respectively relating to the adoption of care
      planning, the establishment, by law, of clinical ethics committees in paediatric 
      hospitals and the limitation of recourse to courts-only as extrema ratio-in the
      event of irremediable disagreement between the medical team and the family
      members.
FAU - Bolcato, Matteo
AU  - Bolcato M
AUID- ORCID: 0000-0002-8784-8463
AD  - Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.
FAU - Russo, Marianna
AU  - Russo M
AD  - Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.
FAU - Feola, Alessandro
AU  - Feola A
AUID- ORCID: 0000-0002-9666-2636
AD  - Department of Experimental Medicine, University of Campania "Luigi Vanvitelli",
      80138 Naples, Italy.
FAU - Della Pietra, Bruno
AU  - Della Pietra B
AD  - Department of Experimental Medicine, University of Campania "Luigi Vanvitelli",
      80138 Naples, Italy.
FAU - Tettamanti, Camilla
AU  - Tettamanti C
AUID- ORCID: 0000-0002-7410-3198
AD  - Department of Health Sciences, Section of Legal and Forensic Medicine, University
      of Genova, 16126 Genova, Italy.
FAU - Bonsignore, Alessandro
AU  - Bonsignore A
AUID- ORCID: 0000-0001-6616-0347
AD  - Department of Health Sciences, Section of Legal and Forensic Medicine, University
      of Genova, 16126 Genova, Italy.
FAU - Ciliberti, Rosagemma
AU  - Ciliberti R
AD  - Department of Health Sciences, Section of History of Medicine and Bioethics,
      University of Genova, 16126 Genova, Italy.
FAU - Rodriguez, Daniele
AU  - Rodriguez D
AD  - Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.
FAU - Aprile, Anna
AU  - Aprile A
AD  - Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7712670
OTO - NOTNLM
OT  - Italian National Bioethics Committee
OT  - aggressive treatments
OT  - short life expectancy
OT  - therapeutic obstinacy
OT  - young children
EDAT- 2020/11/04 06:00
MHDA- 2020/11/04 06:01
CRDT- 2020/11/03 05:40
PHST- 2020/10/13 00:00 [received]
PHST- 2020/10/27 00:00 [revised]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/11/03 05:40 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2020/11/04 06:01 [medline]
AID - healthcare8040448 [pii]
AID - 10.3390/healthcare8040448 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Nov 1;8(4). pii: healthcare8040448. doi:
      10.3390/healthcare8040448.


PMID- 33139622
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20211204
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 21
DP  - 2020 Nov 1
TI  - Vitamin D Knowledge, Attitudes, and Behaviors in Young Danish Women with a
      Non-Western Ethnic Minority Background-A Questionnaire Survey.
LID - E8053 [pii]
LID - 10.3390/ijerph17218053 [doi]
AB  - The prevalence of vitamin D deficiency in women with a non-Western ethnic
      minority background in Nordic countries is high. The aim of this study was to
      assess vitamin D knowledge, attitudes, and behaviors in women with a non-Western 
      ethic minority background living in Denmark. A validated vitamin D knowledge,
      attitudes, and behaviors' questionnaire was translated into Danish, piloted, and 
      distributed via relevant Facebook groups. The responses were analyzed using
      parametric and non-parametric tests for descriptive and bivariate analyses. In
      total, 254 women who considered themselves having a non-Western ethnic minority
      background responded to the questionnaire. The median age (IQR) was 25 (23-33)
      years old; 32% had a professional bachelor's, 28% had high school, and 22% had a 
      master's or higher university education. Participants scored higher on vitamin D 
      general knowledge (scores above 80 on the scale 0-100) compared to vitamin D
      nutrition knowledge or vitamin D attitudes and behaviors (scores around 60 on the
      scale 0-100). In conclusion, the vitamin D knowledge among study
      participants-i.e., young well-educated non-Western ethnic minority women in
      Denmark-was pretty good. The further examination of vitamin D knowledge,
      attitudes, and behaviors should explore specifics related to nationality and
      religion and focus on less-educated non-Western ethnic minority women in Denmark 
      and other Nordic countries.
FAU - Ozel, Erdinc
AU  - Ozel E
AD  - Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark.
FAU - Cantarero-Arevalo, Lourdes
AU  - Cantarero-Arevalo L
AD  - Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark.
AD  - WHO Collaborating Center for Research and Training in Patient Perspective on
      Medicines Use, Department of Pharmacy, University of Copenhagen, 2100 Copenhagen,
      Denmark.
FAU - Jacobsen, Ramune
AU  - Jacobsen R
AUID- ORCID: 0000-0002-8142-9807
AD  - Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark.
AD  - WHO Collaborating Center for Research and Training in Patient Perspective on
      Medicines Use, Department of Pharmacy, University of Copenhagen, 2100 Copenhagen,
      Denmark.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Denmark
MH  - Ethnicity/*statistics & numerical data
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Middle Aged
MH  - Minority Groups/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - *Vitamin D
MH  - Vitamin D Deficiency/ethnology
MH  - Young Adult
PMC - PMC7662621
OTO - NOTNLM
OT  - *Denmark
OT  - *ethnicity
OT  - *knowledge
OT  - *vitamin D
EDAT- 2020/11/04 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/11/03 05:40
PHST- 2020/09/14 00:00 [received]
PHST- 2020/10/28 00:00 [revised]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/03 05:40 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - ijerph17218053 [pii]
AID - 10.3390/ijerph17218053 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Nov 1;17(21). pii: ijerph17218053. doi:
      10.3390/ijerph17218053.


PMID- 33139403
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 96
IP  - 1141
DP  - 2020 Nov
TI  - Medical informed choice: understanding the element of time to meet the standard
      of care for valid informed consent.
PG  - 708-710
LID - 10.1136/postgradmedj-2019-137278 [doi]
AB  - Medical informed choice is essential for a physician meeting their fiduciary duty
      when proposing medical and surgical actions, and necessary for a patient to
      consent or cull the outlined therapeutic approaches. Informed choice, as part of 
      a shared decision-making model, allows widespread give-and-take of ideas between 
      the patient and physician. This sharing of ideas results in a partnership for
      decision-making and a responsibility for medical and surgical outcomes.Informed
      choice is indispensible to the patient education process that meets the desired
      outcome of any covenant-an offer of and acceptance of the proposed treatment. The
      covenant anchors a true patient-physician partnership with parity and equality in
      decision-making and medical/surgical outcomes.Medical informed choice flows from 
      ethical and legal principles necessary to meet the acknowledged standard of care.
      This is codified by statute and fortified in general common law. This espouses a 
      fiduciary relationship where the patient and physician understand and accede to
      the degree of autonomy the patient requests.The growth of an equal
      patient-physician relationship requires time. There is no alternative to the time
      variable when developing a physician-patient relationship. Despite physicians
      being under pressures to perform more clinical and administrative duties in less 
      time in the corporate model of medicine, time remains the most critical variable 
      when considering informed choice and shared decision-making. Videos, pamphlets
      and alternate healthcare providers cannot and should not substitute for physician
      time.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Paterick, Zachary R
AU  - Paterick ZR
AD  - Law, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Paterick, Timothy Edward
AU  - Paterick TE
AUID- ORCID: http://orcid.org/0000-0002-7054-5976
AD  - Cardiology, Aurora, Hobart, Wisconsin, USA tpaterick@gmail.com.
FAU - Paterick, Barb Block
AU  - Paterick BB
AD  - Law, University Of Wisconsin Colleges, Madison, Wisconsin, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
MH  - Choice Behavior
MH  - Decision Making, Shared
MH  - Disclosure/ethics/standards
MH  - Humans
MH  - *Information Dissemination/ethics/methods
MH  - *Informed Consent/ethics/psychology/standards
MH  - *Moral Obligations
MH  - *Patient Care Management/ethics/legislation & jurisprudence/standards
MH  - Physician-Patient Relations
MH  - *Standard of Care
MH  - Time Factors
OTO - NOTNLM
OT  - health & safety
OT  - medical education & training
OT  - medical ethics
OT  - medical law
COIS- Competing interests: None declared.
EDAT- 2020/11/04 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/11/03 05:38
PHST- 2019/11/01 00:00 [received]
PHST- 2019/11/24 00:00 [revised]
PHST- 2019/12/09 00:00 [accepted]
PHST- 2020/11/03 05:38 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
AID - postgradmedj-2019-137278 [pii]
AID - 10.1136/postgradmedj-2019-137278 [doi]
PST - ppublish
SO  - Postgrad Med J. 2020 Nov;96(1141):708-710. doi: 10.1136/postgradmedj-2019-137278.


PMID- 33138847
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Nov 2
TI  - Parental perspectives long term after neonatal clinical trial participation: a
      survey.
PG  - 907
LID - 10.1186/s13063-020-04787-0 [doi]
AB  - BACKGROUND: Although recruiting newborns is ethically challenging, clinical
      trials remain essential to improve neonatal care. There is a lack of empirical
      data on the parental perspectives following participation of their neonate in a
      clinical trial, especially at long term. The objective of this study is to assess
      experiences and emotions of parents, long term after trial participation in an
      interventional drug trial. METHODS: Parents of former participants of five
      neonatal interventional drug trials were surveyed at long term (3-13 years ago)
      after participation. The survey assessed parental contentment with trial
      participation, perceived influence of the trial on care and health, emotional
      consequences of participation, and awareness of typical clinical trial
      characteristics on 6-point Likert scales. RESULTS: Complete responses were
      received from 123 parents (52% of involved families). Twenty percent of parents
      did not remember participation. Those who remembered participation reported high 
      contentment with overall trial participation (median 5.00), but not with
      follow-up (median 3.00). Most parents did not perceive any influence of the trial
      on care (median 2.00) and health (median 2.43). Almost all parents reported
      satisfaction and pride (median 4.40), while a minority of parents reported
      anxiety and stress (median 1.44) or guilt (median 1.33) related to trial
      participation. A relevant minority was unaware of typical trial characteristics
      (median 4.20; 27% being unaware). CONCLUSIONS: Overall, parents reported positive
      experiences and little emotional distress long term after participation. Future
      efforts to improve the practice of neonatal clinical trials should focus on
      ensuring effective communication about the concept and characteristics of a
      clinical trial during consent discussions and on the follow-up after the trial.
FAU - Salaets, Thomas
AU  - Salaets T
AUID- ORCID: http://orcid.org/0000-0002-0971-5147
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
      thomas.salaets@kuleuven.be.
FAU - Lavrysen, Emilie
AU  - Lavrysen E
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
FAU - Smits, Anne
AU  - Smits A
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
FAU - Vanhaesebrouck, Sophie
AU  - Vanhaesebrouck S
AD  - Department of Internal Medicine and Pediatrics, UGent, Ghent, Belgium.
FAU - Rayyan, Maissa
AU  - Rayyan M
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
FAU - Ortibus, Els
AU  - Ortibus E
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
FAU - Toelen, Jaan
AU  - Toelen J
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
FAU - Claes, Laurence
AU  - Claes L
AD  - Faculty of Psychology and Educational Studies, Unit of Clinical Psychology,
      KULeuven, Leuven, Belgium.
FAU - Allegaert, Karel
AU  - Allegaert K
AD  - Department of Development and Regeneration, KULeuven, Leuven, Belgium.
AD  - Department of Pharmaceutical and Pharmacological Sciences, KULeuven, Leuven,
      Belgium.
AD  - Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands.
LA  - eng
GR  - SBO 130033/Agentschap voor Innovatie door Wetenschap en Technologie
PT  - Journal Article
DEP - 20201102
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Anxiety
MH  - *Emotions
MH  - Humans
MH  - Infant, Newborn
MH  - *Parents
MH  - Surveys and Questionnaires
PMC - PMC7607657
OTO - NOTNLM
OT  - Clinical bio-ethics
OT  - Neonatal clinical trials
EDAT- 2020/11/04 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/03 05:32
PHST- 2020/05/01 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/11/03 05:32 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04787-0 [doi]
AID - 10.1186/s13063-020-04787-0 [pii]
PST - epublish
SO  - Trials. 2020 Nov 2;21(1):907. doi: 10.1186/s13063-020-04787-0.


PMID- 33138843
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1743-8977 (Electronic)
IS  - 1743-8977 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Nov 2
TI  - Translocation of (ultra)fine particles and nanoparticles across the placenta; a
      systematic review on the evidence of in vitro, ex vivo, and in vivo studies.
PG  - 56
LID - 10.1186/s12989-020-00386-8 [doi]
AB  - Fetal development is a crucial window of susceptibility in which exposure may
      lead to detrimental health outcomes at birth and later in life. The placenta
      serves as a gatekeeper between mother and fetus. Knowledge regarding the barrier 
      capacity of the placenta for nanoparticles is limited, mostly due to technical
      obstacles and ethical issues. We systematically summarize and discuss the current
      evidence and define knowledge gaps concerning the maternal-fetal transport and
      fetoplacental accumulation of (ultra)fine particles and nanoparticles. We
      included 73 studies on placental translocation of particles, of which 21 in
      vitro/ex vivo studies, 50 animal studies, and 2 human studies on transplacental
      particle transfer. This systematic review shows that (i) (ultra)fine particles
      and engineered nanoparticles can bypass the placenta and reach fetal units as
      observed for all the applied models irrespective of the species origin (i.e.,
      rodent, rabbit, or human) or the complexity (i.e., in vitro, ex vivo, or in
      vivo), (ii) particle size, particle material, dose, particle dissolution,
      gestational stage of the model, and surface composition influence maternal-fetal 
      translocation, and (iii) no simple, standardized method for nanoparticle
      detection and/or quantification in biological matrices is available to date.
      Existing evidence, research gaps, and perspectives of maternal-fetal particle
      transfer are highlighted.
FAU - Bongaerts, Eva
AU  - Bongaerts E
AD  - Centre for Environmental Sciences, Hasselt University, Agoralaan Building D,
      3590, Diepenbeek, Belgium.
FAU - Nawrot, Tim S
AU  - Nawrot TS
AD  - Centre for Environmental Sciences, Hasselt University, Agoralaan Building D,
      3590, Diepenbeek, Belgium.
AD  - Department of Public Health and Primary Care, KU Leuven, Herestraat 49, Box 703, 
      3000, Leuven, Belgium.
FAU - Van Pee, Thessa
AU  - Van Pee T
AD  - Centre for Environmental Sciences, Hasselt University, Agoralaan Building D,
      3590, Diepenbeek, Belgium.
FAU - Ameloot, Marcel
AU  - Ameloot M
AD  - Biomedical Research Institute, Hasselt University, Agoralaan Building C, 3590,
      Diepenbeek, Belgium.
FAU - Bove, Hannelore
AU  - Bove H
AUID- ORCID: 0000-0001-7185-3746
AD  - Centre for Environmental Sciences, Hasselt University, Agoralaan Building D,
      3590, Diepenbeek, Belgium. hannelore.bove@uhasselt.be.
AD  - Biomedical Research Institute, Hasselt University, Agoralaan Building C, 3590,
      Diepenbeek, Belgium. hannelore.bove@uhasselt.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201102
PL  - England
TA  - Part Fibre Toxicol
JT  - Particle and fibre toxicology
JID - 101236354
RN  - 0 (Particulate Matter)
SB  - IM
MH  - Animals
MH  - Female
MH  - Fetus
MH  - Humans
MH  - *Maternal-Fetal Exchange
MH  - *Nanoparticles
MH  - Particle Size
MH  - *Particulate Matter
MH  - Placenta
MH  - Pregnancy
MH  - Rabbits
PMC - PMC7607677
OTO - NOTNLM
OT  - *(ultra)fine particles
OT  - *Engineered
OT  - *Maternal-fetal transfer
OT  - *Nanoparticles
OT  - *Placenta
OT  - *Pregnancy
EDAT- 2020/11/04 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/11/03 05:32
PHST- 2020/06/09 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/03 05:32 [entrez]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 10.1186/s12989-020-00386-8 [doi]
AID - 10.1186/s12989-020-00386-8 [pii]
PST - epublish
SO  - Part Fibre Toxicol. 2020 Nov 2;17(1):56. doi: 10.1186/s12989-020-00386-8.


PMID- 33136355
STAT- Publisher
DA  - 20201103
PB  - Oxford University Press
CTI - Wellcome Trust-Funded Monographs and Book Chapters
DP  - 2020 May
TI  - Consciousness and Morality
BTI - Oxford Handbook of the Philosophy of Consciousness
AB  - It is well known that the nature of consciousness is elusive, and that attempts
      to understand it generate problems in metaphysics, philosophy of mind,
      psychology, and neuroscience. Less appreciated are the important - even if still 
      elusive - connections between consciousness and issues in ethics. In this chapter
      we consider three such connections. First, we consider the relevance of
      consciousness for questions surrounding an entity's moral status. Second, we
      consider the relevance of consciousness for questions surrounding moral
      responsibility for action. Third, we consider the relevance of consciousness for 
      the acquisition of moral knowledge.
CI  - (c)Joshua Shepherd 2020.
FED - Kriegel, Uriah
ED  - Kriegel U
FAU - Shepherd, Joshua
AU  - Shepherd J
FAU - Levy, Neil
AU  - Levy N
LA  - eng
GR  - 104347/Wellcome Trust/United Kingdom
PT  - Review
PT  - Book Chapter
PL  - Oxford (UK)
EDAT- 2020/11/03 06:01
MHDA- 2020/11/03 06:01
CDAT- 2020/11/03 06:01
AID - NBK563591 [bookaccession]


PMID- 33137849
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - The Japan Geriatrics Society consensus statement "recommendations for older
      persons to receive the best medical and long-term care during the COVID-19
      outbreak-considering the timing of advance care planning implementation".
PG  - 1112-1119
LID - 10.1111/ggi.14075 [doi]
AB  - Since the end of 2019, a life-threatening infectious disease (coronavirus disease
      2019: COVID-19) has spread globally, and numerous victims have been reported. In 
      particular, older persons tend to suffer more severely when infected with a novel
      coronavirus (SARS-CoV-2) and have higher case mortality rates; additionally,
      outbreaks frequently occur in hospitals and long-term care facilities where most 
      of the residents are older persons. Unfortunately, it has been stated that the
      COVID-19 pandemic has caused a medical collapse in some countries, resulting in
      the depletion of medical resources, such as ventilators, and triage based on
      chronological age. Furthermore, as some COVID-19 cases show a rapid deterioration
      of clinical symptoms and accordingly, the medical and long-term care staff cannot
      always confirm the patient's values and wishes in time, we are very concerned as 
      to whether older patients are receiving the medical and long-term care services
      that they wish for. It was once again recognized that it is vital to implement
      advance care planning as early as possible before suffering from COVID-19. To
      this end, in August 2020, the Japan Geriatrics Society announced ethical
      recommendations for medical and long-term care for older persons and emphasized
      the importance of conducting advance care planning at earlier stages. Geriatr
      Gerontol Int 2020; 20: 1112-1119.
CI  - (c) 2020 Japan Geriatrics Society.
CN  - Japan Geriatrics Society Subcommittee on End-of-Life Issues and New Coronavirus
      Countermeasure Team
FAU - Kuzuya, Masafumi
AU  - Kuzuya M
AUID- ORCID: https://orcid.org/0000-0002-6134-9578
AD  - Department of Community Healthcare & Geriatrics, Nagoya University Graduate
      School of Medicine, Nagoya, Japan.
AD  - Institutes of Innovation for Future Society, Nagoya University, Nagoya, Japan.
FAU - Aita, Kaoruko
AU  - Aita K
AD  - Uehiro Division, Center for Death & Life Studies and Practical Ethics, Graduate
      School of Humanities and Sociology, The University of Tokyo, Tokyo, Japan.
FAU - Katayama, Yoko
AU  - Katayama Y
AD  - Department of Nursing, Kagawa Prefectural University of Health Sciences,
      Takamatsu, Japan.
FAU - Katsuya, Tomohiro
AU  - Katsuya T
AD  - Katsuya Clinic, Amagasaki, Japan/Department of Clinical Gene Therapy, Osaka
      University Graduate School of Medicine, Suita, Japan.
FAU - Nishikawa, Mitsunori
AU  - Nishikawa M
AD  - Department of Palliative Care, National Center for Geriatrics and Gerontology,
      Obu, Japan.
FAU - Hirahara, Satoshi
AU  - Hirahara S
AD  - Training/Research Center, Tokyo Fureai Medical & Cooperative Society, Tokyo,
      Japan.
FAU - Miura, Hisayuki
AU  - Miura H
AUID- ORCID: https://orcid.org/0000-0002-4780-9857
AD  - Department of Home Care and Regional Liaison Promotion, National Center for
      Geriatrics and Gerontology, Obu, Japan.
FAU - Yanagawa, Madoka
AU  - Yanagawa M
AD  - Toyota East Rehabilitation Hospital, Toyota, Japan.
FAU - Arai, Hidenori
AU  - Arai H
AUID- ORCID: https://orcid.org/0000-0002-9000-6849
AD  - National Center for Geriatrics and Gerontology, Obu, Japan.
FAU - Iijima, Katsuya
AU  - Iijima K
AUID- ORCID: https://orcid.org/0000-0003-1339-5681
AD  - Institute of Gerontology, The University of Tokyo, Tokyo, Japan.
FAU - Okochi, Jiro
AU  - Okochi J
AD  - Tatsumanosato Geriatric Health Services Facility, Daito, Japan.
FAU - Kozaki, Koichi
AU  - Kozaki K
AD  - Department of Geriatric Medicine, Kyorin University, School of Medicine, Mitaka, 
      Japan.
FAU - Yamaguchi, Yasuhiro
AU  - Yamaguchi Y
AUID- ORCID: https://orcid.org/0000-0002-6899-4406
AD  - Department of Respiratory Medicine, Jichi Medical University Saitama Medical
      Center, Saitama, Japan.
FAU - Rakugi, Hiromi
AU  - Rakugi H
AUID- ORCID: https://orcid.org/0000-0001-6508-4338
AD  - Department of Geriatric and General Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Akishita, Masahiro
AU  - Akishita M
AD  - Department of Geriatric Medicine, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20201102
PL  - Japan
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
SB  - IM
MH  - *Advance Care Planning/ethics
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/epidemiology/mortality/prevention & control/*therapy
MH  - Consensus
MH  - Decision Making/ethics
MH  - Geriatrics/standards
MH  - Health Resources/economics
MH  - Humans
MH  - Japan
MH  - Long-Term Care/*ethics
MH  - Pandemics/ethics
MH  - Triage/ethics
OTO - NOTNLM
OT  - COVID-19
OT  - advance care planning
OT  - ethics
OT  - older persons
OT  - shared decision-making
EDAT- 2020/11/03 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/11/02 20:21
PHST- 2020/09/07 00:00 [received]
PHST- 2020/10/02 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/11/02 20:21 [entrez]
AID - 10.1111/ggi.14075 [doi]
PST - ppublish
SO  - Geriatr Gerontol Int. 2020 Dec;20(12):1112-1119. doi: 10.1111/ggi.14075. Epub
      2020 Nov 2.


PMID- 33136899
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210208
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 31
IP  - 8
DP  - 2020 Nov/Dec
TI  - International Cleft Surgery Educational Initiatives: Ethical Challenges and
      Solutions.
PG  - 2379-2380
LID - 10.1097/SCS.0000000000007041 [doi]
FAU - Kantar, Rami S
AU  - Kantar RS
AD  - Global Smile Foundation, Norwood, MA, Department of Surgery, The University of
      Maryland Medical System/Shock Trauma Center, Baltimore, MD.
FAU - Chahine, Elsa M
AU  - Chahine EM
AD  - Global Smile Foundation, Norwood, MA.
FAU - Alfonso, Allyson R
AU  - Alfonso AR
AD  - Global Smile Foundation, Norwood, MA, Hansjorg Wyss Department of Plastic
      Surgery, NYU Langone Health, NY.
FAU - Nader, Marie K
AU  - Nader MK
AD  - Global Smile Foundation, Norwood, MA, Yale New Haven Children's Hospital, Yale,
      CT.
FAU - Annan, Beyhan
AU  - Annan B
AD  - Global Smile Foundation, Norwood, MA.
FAU - Haddad, Anthony G
AU  - Haddad AG
AD  - Global Smile Foundation, Norwood, MA, Department of Surgery, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, MA.
FAU - Hamdan, Usama S
AU  - Hamdan US
AD  - Global Smile Foundation, Norwood, MA, Otology and Laryngology, Harvard Medical
      School Boston, MA, Otolaryngology, Tufts University School of Medicine, Boston,
      MA, Otolaryngology, Boston University School of Medicine. Boston, MA.
LA  - eng
PT  - Letter
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 17:13
PHST- 2020/11/02 17:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1097/SCS.0000000000007041 [doi]
AID - 00001665-202012000-00067 [pii]
PST - ppublish
SO  - J Craniofac Surg. 2020 Nov/Dec;31(8):2379-2380. doi:
      10.1097/SCS.0000000000007041.


PMID- 33136333
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Nov
TI  - Ethical Considerations When Using a Mobile Eye Tracker in a Patient-Facing Area: 
      Lessons from an Intensive Care Unit Observational Protocol.
PG  - 2-13
LID - 10.1002/eahr.500068 [doi]
AB  - This article describes the process of designing, approving, and conducting an
      investigator-initiated protocol to use an eye-tracking device in a health care
      setting. Participants wore the device, which resembles eyeglasses, in a
      front-facing manner in an intensive care unit for the study of personnel gaze
      patterns, producing a visual record of workflow. While the data of interest for
      our study was not specifically the health information protected by the privacy
      rule of the Health Insurance Portability and Accountability Act (HIPAA), a wide
      variety of such data was captured by the eye-tracking device, and the prospective
      consent of all people who might have been incidentally videotaped was not
      feasible. The protocol therefore required attention to unique ethical
      considerations-including consent, privacy and confidentiality, HIPAA compliance, 
      institutional liability, and the use of secondary data. The richness of
      eye-tracker data suggests various beneficial applications in health care
      occupational research and quality improvement. Therefore, sharing our study's
      successful design and execution, including proactive researcher-institutional
      review board communication, can inform and encourage similarly valuable, ethical,
      and innovative audiovisual research techniques.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Larsen, Ethan P
AU  - Larsen EP
AD  - Human factors engineer at the Children's Hospital of Philadelphia and was a
      postdoctoral fellow at the Houston Methodist Hospital's Center for Outcomes
      Research when this study was conducted.
FAU - Kolman, Jacob M
AU  - Kolman JM
AD  - Senior scientific writer at the Houston Methodist Hospital's Center for Outcomes 
      Research (and was a senior research assistant there when the study was conducted)
      and is a research associate in the Department of Industrial and Systems
      Engineering at Texas A&M University.
FAU - Masud, Faisal N
AU  - Masud FN
AD  - Mary A. and M. Samuel Daffin, Sr., Centennial Chair in Anesthesia and Critical
      Care and the medical director of the Center for Critical Care at Houston
      Methodist Hospital and a professor of clinical anesthesiology at Weill Cornell
      Medical College.
FAU - Sasangohar, Farzan
AU  - Sasangohar F
AD  - Assistant professor in the Department of Industrial and Systems Engineering at
      Texas A&M University as well as a scientist and an assistant professor of
      outcomes research at Houston Methodist Hospital's Center for Outcomes Research.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Confidentiality/*ethics
MH  - Ethics Committees, Research/*standards
MH  - *Eye-Tracking Technology
MH  - Health Insurance Portability and Accountability Act/legislation & jurisprudence
MH  - Humans
MH  - *Intensive Care Units
MH  - Nursing Staff, Hospital/psychology
MH  - *Privacy
MH  - Prospective Studies
MH  - Research Design/*standards
MH  - United States
MH  - Video Recording
OTO - NOTNLM
OT  - HIPAA Privacy Rule
OT  - audiovisual research
OT  - health personnel
OT  - human subjects research
OT  - intensive care units
OT  - mobile eye tracker
OT  - patient rights
EDAT- 2020/11/03 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/02 12:13
PHST- 2020/11/02 12:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1002/eahr.500068 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Nov;42(6):2-13. doi: 10.1002/eahr.500068.


PMID- 33136332
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Nov
TI  - Loopholes in the Research Ethics System? Informed Consent Waivers in Cluster
      Randomized Trials with Individual-Level Intervention.
PG  - 21-28
LID - 10.1002/eahr.500071 [doi]
AB  - Individual-cluster trials randomize groups of individuals but deliver study
      interventions directly to individual participants. We examine three arguments
      that might justify the perception that the bar for a waiver of consent should be 
      lower in such trials than for individually randomized trials. We contend that if 
      these arguments are treated as sufficient to grant a waiver of consent, then a
      loophole emerges in research oversight. Such loopholes are morally hazardous for 
      study participants, the integrity of science, and public trust in the research
      enterprise. We conclude by articulating the standards that research ethics
      committees should use to evaluate requests for waivers of consent in
      individual-cluster trials.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - London, Alex John
AU  - London AJ
AD  - Clara L. West Professor of Ethics and Philosophy in the Department of Philosophy 
      at Carnegie Mellon University.
FAU - Taljaard, Monica
AU  - Taljaard M
AD  - Senior scientist in the clinical epidemiology program at the Ottawa Hospital
      Research Institute and an associate professor in the School of Epidemiology and
      Public Health at the University of Ottawa.
FAU - Weijer, Charles
AU  - Weijer C
AD  - Professor in the Departments of Medicine, Epidemiology & Biostatistics, and
      Philosophy at Western University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Ethics Committees, Research/*standards
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Randomized Controlled Trials as Topic/*ethics
MH  - Research Design/*standards
OTO - NOTNLM
OT  - cluster randomized trials
OT  - human research ethics
OT  - individual-cluster trials
OT  - informed consent
OT  - informed consent waivers
EDAT- 2020/11/03 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/02 12:13
PHST- 2020/11/02 12:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1002/eahr.500071 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Nov;42(6):21-28. doi: 10.1002/eahr.500071.


PMID- 33136331
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Nov
TI  - Benefit Sharing for Human Genomics Research: Awareness and Expectations of
      Genomics Researchers in Sub-Saharan Africa.
PG  - 14-20
LID - 10.1002/eahr.500069 [doi]
AB  - Benefit sharing is an ethical issue that underscores the need to find a balance
      between access to genetic resources and the provision of fair benefits in
      exchange for access. The Human Genome Organisation (HUGO) is one of the few
      initiatives to have engaged with the topic of benefit sharing in human genomics. 
      However, there is a lack of clarity on what benefit sharing entails in human
      genomics research and how it could be implemented in practice. This paper reports
      on a qualitative study that explored the views and expectations of benefit
      sharing by a group of genomics researchers in sub-Saharan Africa. Overall, while 
      there was little awareness of benefit sharing among the researchers, there was
      support for benefit sharing in human genetics, and this was based on principles
      of fairness, solidarity, and reciprocity. This in-depth explorative study
      demonstrates the need for genomics research consortia in Africa to have open
      discussions on benefit sharing and to develop ethics frameworks for benefit
      sharing in population genomics studies in Africa. HUGO's statement on benefit
      sharing and the Nagoya Protocol could provide guidance.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Munung, Nchangwi Syntia
AU  - Munung NS
AD  - Faculty of health sciences in the Department of Medicine and in the Division of
      Human Genetics at the University of Cape Town in South Africa.
FAU - de Vries, Jantina
AU  - de Vries J
AD  - Faculty of health sciences in the Department of Medicine at the University of
      Cape Town in South Africa.
LA  - eng
GR  - WT099313MA/WT_/Wellcome Trust/United Kingdom
GR  - 1U01HG008226-01/Stigma in African Genomics H3Africa Award
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Africa South of the Sahara
MH  - *Awareness
MH  - Biological Specimen Banks/ethics
MH  - Biomedical Research/*ethics
MH  - Capacity Building
MH  - Genome, Human/*genetics
MH  - Genomics/*ethics
MH  - Humans
MH  - Interviews as Topic
MH  - *Motivation
MH  - Qualitative Research
MH  - Research Personnel/*ethics
OTO - NOTNLM
OT  - Human Genome Organisation
OT  - benefit sharing
OT  - biobanking
OT  - genomics research
OT  - research ethics
OT  - sub-Saharan Africa
EDAT- 2020/11/03 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/02 12:13
PHST- 2020/11/02 12:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1002/eahr.500069 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Nov;42(6):14-20. doi: 10.1002/eahr.500069.


PMID- 33136330
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Nov
TI  - Ethical and Practical Concerns about IRB Restrictions on the Use of Research
      Data.
PG  - 29-34
LID - 10.1002/eahr.500072 [doi]
AB  - In response to researcher noncompliance with ethical and regulatory provisions
      governing research with humans, protocol deviations, and unanticipated problems
      with research, institutional review boards (IRBs) or institutions sometimes
      impose restrictions on the use of research data, although specific cases in which
      this happens are unlikely to be known publicly. We review IRB policies at top
      research institutions in the United States about restrictions on the use of
      research data and describe potential reasons for restricting the use of such data
      in the context of ensuring compliance with human subjects research standards. We 
      also discuss ethical considerations related to restricting the use of research
      data and argue that IRBs have limited regulatory authority to take such actions. 
      Finally, we offer recommendations regarding decision-making about restricting the
      use of research data and call for additional guidance in this area.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Barnes, Mark
AU  - Barnes M
AD  - Partner at Ropes & Gray LLP.
FAU - Carrithers, Judith
AU  - Carrithers J
AD  - Director of regulatory affairs at the commercial institutional review board
      Advarra.
FAU - Sugarman, Jeremy
AU  - Sugarman J
AD  - Harvey M. Meyerhoff Professor of Bioethics and Medicine at the Berman Institute
      of Bioethics and in the Department of Medicine at Johns Hopkins University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Data Collection/*standards
MH  - Ethics Committees, Research/*standards
MH  - Humans
MH  - *Research Design
MH  - Research Subjects
MH  - United States
OTO - NOTNLM
OT  - human subjects research
OT  - institutional review boards
OT  - research compliance
OT  - research data
OT  - research ethics
EDAT- 2020/11/03 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/02 12:13
PHST- 2020/11/02 12:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1002/eahr.500072 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Nov;42(6):29-34. doi: 10.1002/eahr.500072.


PMID- 33136329
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Nov
TI  - Thought Leader Comparisons of Risks in Precision Medicine Research.
PG  - 35-40
LID - 10.1002/eahr.500059 [doi]
AB  - Biomedical research is increasingly capitalizing on an array of data to
      illuminate the interplay between "omics," lifestyle, and health. Leveraging this 
      information presents opportunities to advance knowledge but also poses risks to
      research participants. In interviews with thought leaders, we asked which data
      type associated with a hypothetical precision medicine research endeavor was
      riskiest: 42% chose ongoing access to electronic health records, 17% chose
      genomic analyses of biospecimens, and 15% chose streaming data from mobile
      devices. Other responses included "It depends" (15%), the three types are equally
      risky (8%), and the combination of data types together is riskiest (3%). When
      asked to consider the hypothetical study overall, 60% rated the likelihood of the
      risks materializing as low, but 20% rated the potential consequences as severe.
      These results have implications for study design and informed consent, including 
      placing appropriate emphasis on the risks and protections for the full range of
      data.
CI  - (c) 2020 The Authors. Ethics & Human Research published by Wiley Periodicals LLC 
      on behalf of The Hastings Center.
FAU - Beskow, Laura M
AU  - Beskow LM
AD  - Ann Geddes Stahlman Chair in Medical Ethics and a professor of health policy at
      the Center for Biomedical Ethics and Society at the Vanderbilt University Medical
      Center.
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Associate in health policy at the Center for Biomedical Ethics and Society at the
      Vanderbilt University Medical Center.
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Research assistant professor at the Center for Biomedical Ethics and Society at
      the Vanderbilt University Medical Center at the time of this work.
LA  - eng
GR  - R01-HG-007733/National Human Genome Research Institute (NHGRI)
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - *Biomedical Research
MH  - Electronic Health Records/*standards
MH  - Humans
MH  - Informed Consent/ethics
MH  - *Leadership
MH  - *Precision Medicine
MH  - *Research Design
MH  - *Risk Assessment
PMC - PMC7702072
OTO - NOTNLM
OT  - big data
OT  - electronic health records
OT  - genomic research
OT  - informed consent
OT  - research ethics
EDAT- 2020/11/03 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/11/02 12:13
PHST- 2020/11/02 12:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
AID - 10.1002/eahr.500059 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Nov;42(6):35-40. doi: 10.1002/eahr.500059.


PMID- 33136103
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2050-7518 (Electronic)
IS  - 2050-750X (Linking)
VI  - 8
IP  - 46
DP  - 2020 Dec 14
TI  - Advanced biomedical applications based on emerging 3D cell culturing platforms.
PG  - 10487-10501
LID - 10.1039/d0tb01658f [doi]
AB  - It is of great value to develop reliable in vitro models for cell biology and
      toxicology. However, ethical issues and the decreasing number of donors restrict 
      the further use of traditional animal models in various fields, including the
      emerging fields of tissue engineering and regenerative medicine. The huge gap
      created by the restrictions in animal models has pushed the development of the
      increasingly recognized three-dimensional (3D) cell culture, which enables cells 
      to closely simulate authentic cellular behaviour such as close cell-to-cell
      interactions and can achieve higher functionality. Furthermore, 3D cell culturing
      is superior to the traditional 2D cell culture, which has obvious limitations and
      cannot closely mimic the structure and architecture of tissues. In this study, we
      review several methods used to form 3D multicellular spheroids. The extracellular
      microenvironment of 3D spheroids plays a role in many aspects of biological
      sciences, including cell signalling, cell growth, cancer cell generation, and
      anti-cancer drugs. More recently, they have been explored as basic construction
      units for tissue and organ engineering. We review this field with a focus on the 
      previous research in different areas using spheroid models, emphasizing aqueous
      two-phase system (ATPS)-based techniques. Multi-cellular spheroids have great
      potential in the study of biological systems and can closely mimic the in vivo
      environment. New technologies to form and analyse spheroids such as the aqueous
      two-phase system and magnetic levitation are rapidly overcoming the technical
      limitations of spheroids and expanding their applications in tissue engineering
      and regenerative medicine.
FAU - Wang, Anheng
AU  - Wang A
AD  - Department of Chemistry, University of Hull, Hull, HU6 7RX, UK.
      V.N.Paunov@hull.ac.uk.
FAU - Madden, Leigh A
AU  - Madden LA
FAU - Paunov, Vesselin N
AU  - Paunov VN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201102
PL  - England
TA  - J Mater Chem B
JT  - Journal of materials chemistry. B
JID - 101598493
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Animals
MH  - Biomedical Engineering/*methods/trends
MH  - Cell Culture Techniques/*methods/trends
MH  - Coculture Techniques
MH  - Humans
MH  - *Lab-On-A-Chip Devices/trends
MH  - Pharmaceutical Preparations/administration & dosage
MH  - Spheroids, Cellular/drug effects/*physiology
EDAT- 2020/11/03 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/11/02 12:10
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PHST- 2020/11/02 12:10 [entrez]
AID - 10.1039/d0tb01658f [doi]
PST - ppublish
SO  - J Mater Chem B. 2020 Dec 14;8(46):10487-10501. doi: 10.1039/d0tb01658f. Epub 2020
      Nov 2.


PMID- 33136053
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201121
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Nov 2
TI  - Integrating a Mobile Health Device Into a Community Youth Mental Health Team to
      Manage Severe Mental Illness: Protocol for a Randomized Controlled Trial.
PG  - e19510
LID - 10.2196/19510 [doi]
AB  - BACKGROUND: Symptoms of mental illness are often triggered by stress, and
      individuals with mental illness are sensitive to these effects. The development
      of mobile health (mHealth) devices allows continuous recording of biometrics
      associated with activity, sleep, and arousal. Deviations in these measures could 
      indicate a stressed state requiring early intervention. This paper describes a
      protocol for integrating an mHealth device into a community mental health team to
      enhance management of severe mental illness in young adults. OBJECTIVE: The aim
      of this study is to examine (1) whether an mHealth device integrated into a
      community mental health team can improve outcomes for young adults with severe
      mental illness and (2) whether the device detects periods of mental health versus
      deterioration. METHODS: This study examines whether physiological information
      from an mHealth device prevents mental deterioration when shared with the
      participant and clinical team versus with the participant alone. A randomized
      controlled trial (RCT) will allocate 126 young adults from community mental
      health services for 6 months to standard case management combined with an
      integrated mHealth device (ie, physiological information is viewed by both
      participant and case manager: unWIRED intervention) or an unintegrated mHealth
      device (ie, participant alone self-monitors: control). Participants will wear the
      Empatica Embrace2 device, which continuously records electrodermal activity and
      actigraphy (ie, rest and activity). The study also examines whether the Embrace2 
      can detect periods of mental health versus deterioration. A variety of
      measurements will be taken, including physiological data from the Embrace2;
      participant and case manager self-report regarding symptoms, functioning, and
      quality of life; chart reviews; and ecological momentary assessments of stress in
      real time. Changes in each participant's Clinical Global Impression Scale scores 
      will be assessed by blinded raters as the primary outcome. In addition,
      participants and case managers will provide qualitative data regarding their
      experience with the integrated mHealth device, which will be thematically
      analyzed. RESULTS: The study has received ethical approval from the Western
      Sydney Local Health District Human Research Ethics Committee. It is due to start 
      in October 2020 and conclude in October 2022. CONCLUSIONS: The RCT will provide
      insight as to whether an integrated mHealth device enables case managers and
      participants to pre-emptively manage early warning signs and prevent relapse. We 
      anticipate that unWIRED will enhance early intervention by improving detection of
      stress and allowing case managers and patients to better engage and respond to
      symptoms. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry
      (ANZCTR) ACTRN12620000642987; https://www.anzctr.org.au/ACTRN12620000642987.aspx.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/19510.
CI  - (c)Simon Byrne, Beth Kotze, Fabio Ramos, Achim Casties, Jean Starling, Anthony
      Harris. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 02.11.2020.
FAU - Byrne, Simon
AU  - Byrne S
AUID- ORCID: https://orcid.org/0000-0002-2729-1907
AD  - Western Sydney Local Health District Mental Health Service, Sydney, NSW,
      Australia.
AD  - Westmead Institute for Medical Research, Sydney, Australia.
FAU - Kotze, Beth
AU  - Kotze B
AUID- ORCID: https://orcid.org/0000-0002-9794-1688
AD  - Rivendell Child Adolescent and Family Unit, Sydney, Australia.
FAU - Ramos, Fabio
AU  - Ramos F
AUID- ORCID: https://orcid.org/0000-0002-2996-2188
AD  - School of Computer Science, University of Sydney, Sydney, Australia.
FAU - Casties, Achim
AU  - Casties A
AUID- ORCID: https://orcid.org/0000-0003-3312-2357
AD  - Westmead Institute for Medical Research, Sydney, Australia.
FAU - Starling, Jean
AU  - Starling J
AUID- ORCID: https://orcid.org/0000-0002-3761-4810
AD  - Concord Centre for Mental Health, Sydney, Australia.
AD  - Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney,
      Australia.
FAU - Harris, Anthony
AU  - Harris A
AUID- ORCID: https://orcid.org/0000-0002-8617-4962
AD  - Western Sydney Local Health District Mental Health Service, Sydney, NSW,
      Australia.
AD  - Westmead Institute for Medical Research, Sydney, Australia.
AD  - Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7669449
OTO - NOTNLM
OT  - actigraphy
OT  - anxiety
OT  - electrodermal activity
OT  - mHealth device
OT  - psychosis
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 12:09
PHST- 2020/06/12 00:00 [received]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/10/02 00:00 [revised]
PHST- 2020/11/02 12:09 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - v9i11e19510 [pii]
AID - 10.2196/19510 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Nov 2;9(11):e19510. doi: 10.2196/19510.


PMID- 33135445
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 2049-4408 (Electronic)
IS  - 2049-4394 (Linking)
VI  - 102-B
IP  - 11
DP  - 2020 Nov
TI  - Early to medium-term outcomes of uncemented ceramic-bearing total hip
      arthroplasty in teenagers for paediatric hip conditions.
PG  - 1491-1496
LID - 10.1302/0301-620X.102B11.BJJ-2020-0668.R1 [doi]
AB  - AIMS: Despite advances in the treatment of paediatric hip disease, adolescent and
      young adult patients can develop early onset end-stage osteoarthritis. The aims
      of this study were to address the indications and medium-term outcomes for total 
      hip arthroplasty (THA) with ceramic bearings for teenage patients. METHODS:
      Surgery was performed by a single surgeon working in the paediatric orthopaedic
      unit of a tertiary referral hospital. Databases were interrogated from 2003 to
      2017 for all teenage patients undergoing THA with a minimum 2.3 year follow-up.
      Data capture included patient demographics, the underlying hip pathology, number 
      of previous surgeries, and THA prostheses used. Institutional ethical approval
      was granted to contact patients for prospective clinical outcomes and obtain
      up-to-date radiographs. In total, 60 primary hips were implanted in 51 patients
      (35 female, 16 male) with nine bilateral cases. The mean age was 16.7 years (12
      to 19) and mean follow-up was 9.3 years (2.3 to 16.8). RESULTS: The most common
      indication for teenage hip arthroplasty was avascular necrosis secondary to
      slipped upper femoral epiphysis (31%; n = 16). Overall, 64% of patients (n = 33) 
      had undergone multiple previous operations. The survival at follow-up was 97%;
      two patients required revision for aseptic loosening (one femoral stem, one
      acetabular component). Both patients had fused hips noted at the time of
      arthroplasty. A further two patients had radiolucent lines but were asymptomatic.
      At latest follow-up the mean Oxford Hip Score was 44 (31 to 48) and a Visual
      Analogue Scale measurement of 1.5, indicating satisfactory function. CONCLUSION: 
      Operating on this cohort can be complicated by multiple previous surgeries and
      distorted anatomy, which in some cases require custom-made prostheses. We have
      demonstrated a good outcome with low revision rate in this complex group of
      patients. Cite this article: Bone Joint J 2020;102-B(11):1491-1496.
FAU - Buddhdev, Pranai K
AU  - Buddhdev PK
AD  - Catterall Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, UK.
FAU - Vanhegan, Ivor S
AU  - Vanhegan IS
AD  - Catterall Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, UK.
FAU - Khan, Tahir
AU  - Khan T
AD  - Catterall Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, UK.
FAU - Hashemi-Nejad, Aresh
AU  - Hashemi-Nejad A
AD  - Catterall Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bone Joint J
JT  - The bone & joint journal
JID - 101599229
RN  - 0 (Bone Cements)
SB  - IM
MH  - Adolescent
MH  - *Arthroplasty, Replacement, Hip
MH  - Bone Cements
MH  - Cementation
MH  - Ceramics
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Hip Joint/surgery
MH  - *Hip Prosthesis
MH  - Humans
MH  - Male
MH  - Osteoarthritis, Hip/etiology/*surgery
MH  - Prosthesis Design
MH  - Prosthesis Failure
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Adolescent
OT  - Arthroplasty
OT  - Ceramic-bearing
OT  - Hip replacement
OT  - Outcomes
OT  - Paediatric
OT  - Paediatric hip conditions
OT  - Paediatric hip pathology
OT  - Teenage hip
OT  - Uncemented
EDAT- 2020/11/03 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/11/02 08:39
PHST- 2020/11/02 08:39 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.1302/0301-620X.102B11.BJJ-2020-0668.R1 [doi]
PST - ppublish
SO  - Bone Joint J. 2020 Nov;102-B(11):1491-1496. doi:
      10.1302/0301-620X.102B11.BJJ-2020-0668.R1.


PMID- 33135092
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - Re-assessing the Triadic Model of Care for Trans Patients Using a Harm-Reduction 
      Approach.
PG  - 415-423
LID - 10.1007/s10728-020-00416-8 [doi]
AB  - The World Professional Association for Transgender Health's Standards of Care
      (WPATH SOC), now in its seventh edition, is a frequently cited, internationally
      recognized, evidence-based document that details a comprehensive framework for
      gender-related care of trans people. However, the WPATH SOC still relies heavily 
      in some cases on gatekeeping practices, dubbed "triadic therapy," or a process
      where a trans patient is encouraged to seek out psychotherapy, and hormone
      therapy, and only then be able to engage in surgical options for transitioning. I
      use G. Alan Marlatt's harm reduction framework to argue that the triadic process 
      creates its own set of harms that trans people have to contend with, especially
      insofar as it focuses on resolving gender dysphoria in a demanding, moralizing,
      and top-down way as opposed to enriching trans lives by reducing harms that
      prevent us from flourishing. Using Marlatt's criterion that harm reduction ought 
      to be bottom-up, low threshold, and not moralizing, I develop a list of
      suggestions for what ought to be centrally considered in treating trans patients.
FAU - Gruenewald, A F
AU  - Gruenewald AF
AUID- ORCID: http://orcid.org/0000-0003-0647-8761
AD  - Department of Philosophy, University of Waterloo, 200 University Avenue West,
      Waterloo, ON, N2L 3G1, Canada. afgruenewald@uwaterloo.ca.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - Gender Dysphoria/*therapy
MH  - Harm Reduction/*ethics
MH  - Health Services for Transgender Persons/*standards
MH  - Humans
MH  - *Psychotherapy
MH  - Transgender Persons/psychology/*statistics & numerical data
MH  - Transsexualism/surgery
OTO - NOTNLM
OT  - Applied ethics
OT  - Harm reduction
OT  - Philosophy of medicine
OT  - Trans patients
OT  - WPATH SOC
EDAT- 2020/11/03 06:00
MHDA- 2021/08/18 06:00
CRDT- 2020/11/02 06:24
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2020/11/02 06:24 [entrez]
AID - 10.1007/s10728-020-00416-8 [doi]
AID - 10.1007/s10728-020-00416-8 [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Dec;28(4):415-423. doi: 10.1007/s10728-020-00416-8. Epub
      2020 Nov 1.


PMID- 33134913
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 2632-1297 (Electronic)
IS  - 2632-1297 (Linking)
VI  - 2
IP  - 2
DP  - 2020
TI  - Artificial intelligence for clinical decision support in neurology.
PG  - fcaa096
LID - 10.1093/braincomms/fcaa096 [doi]
AB  - Artificial intelligence is one of the most exciting methodological shifts in our 
      era. It holds the potential to transform healthcare as we know it, to a system
      where humans and machines work together to provide better treatment for our
      patients. It is now clear that cutting edge artificial intelligence models in
      conjunction with high-quality clinical data will lead to improved prognostic and 
      diagnostic models in neurological disease, facilitating expert-level clinical
      decision tools across healthcare settings. Despite the clinical promise of
      artificial intelligence, machine and deep-learning algorithms are not a
      one-size-fits-all solution for all types of clinical data and questions. In this 
      article, we provide an overview of the core concepts of artificial intelligence, 
      particularly contemporary deep-learning methods, to give clinician and
      neuroscience researchers an appreciation of how artificial intelligence can be
      harnessed to support clinical decisions. We clarify and emphasize the data
      quality and the human expertise needed to build robust clinical artificial
      intelligence models in neurology. As artificial intelligence is a rapidly
      evolving field, we take the opportunity to iterate important ethical principles
      to guide the field of medicine is it moves into an artificial intelligence
      enhanced future.
CI  - (c) The Author(s) (2020). Published by Oxford University Press on behalf of the
      Guarantors of Brain.
FAU - Pedersen, Mangor
AU  - Pedersen M
AUID- ORCID: 0000-0002-9199-1916
AD  - The Florey Institute of Neuroscience and Mental Health, The University of
      Melbourne, Heidelberg, VIC 3084, Australia.
AD  - Department of Psychology, Auckland University of Technology (AUT), Auckland,
      0627, New Zealand.
FAU - Verspoor, Karin
AU  - Verspoor K
AUID- ORCID: 0000-0002-8661-1544
AD  - School of Computing and Information Systems, The University of Melbourne,
      Parkville, VIC 3010, Australia.
FAU - Jenkinson, Mark
AU  - Jenkinson M
AUID- ORCID: 0000-0001-6043-0166
AD  - Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of
      Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.
AD  - South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA
      5000, Australia.
AD  - Australian Institute for Machine Learning (AIML), The University of Adelaide,
      Adelaide, SA 5000, Australia.
FAU - Law, Meng
AU  - Law M
AUID- ORCID: 0000-0001-8414-1991
AD  - Department of Radiology, Alfred Hospital, Melbourne, VIC 3181, Australia.
AD  - Department of Electrical and Computer Systems Engineering, Monash University,
      Melbourne, VIC 3181, Australia.
AD  - Department of Neuroscience, Monash School of Medicine, Nursing and Health
      Sciences, Melbourne, VIC 3181, Australia.
FAU - Abbott, David F
AU  - Abbott DF
AUID- ORCID: 0000-0002-7259-8238
AD  - The Florey Institute of Neuroscience and Mental Health, The University of
      Melbourne, Heidelberg, VIC 3084, Australia.
AD  - Department of Medicine Austin Health, The University of Melbourne, Heidelberg,
      VIC 3084, Australia.
FAU - Jackson, Graeme D
AU  - Jackson GD
AUID- ORCID: 0000-0002-7917-5326
AD  - The Florey Institute of Neuroscience and Mental Health, The University of
      Melbourne, Heidelberg, VIC 3084, Australia.
AD  - Department of Medicine Austin Health, The University of Melbourne, Heidelberg,
      VIC 3084, Australia.
AD  - Department of Neurology, Austin Health, Heidelberg, VIC 3084, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200709
PL  - England
TA  - Brain Commun
JT  - Brain communications
JID - 101755125
PMC - PMC7585692
OTO - NOTNLM
OT  - artificial intelligence
OT  - augmented intelligence
OT  - deep learning
OT  - ethics
OT  - neurology
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:23
PHST- 2020/05/19 00:00 [received]
PHST- 2020/05/19 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/11/02 06:23 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1093/braincomms/fcaa096 [doi]
AID - fcaa096 [pii]
PST - epublish
SO  - Brain Commun. 2020 Jul 9;2(2):fcaa096. doi: 10.1093/braincomms/fcaa096.
      eCollection 2020.


PMID- 33134557
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201104
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Harnessing consumer smartphone and wearable sensors for clinical cancer research.
PG  - 140
LID - 10.1038/s41746-020-00351-x [doi]
AB  - As smartphones and consumer wearable devices become more ubiquitous, there is a
      growing opportunity to capture rich mobile sensor data continuously, passively,
      and in real-world settings with minimal burden. In the context of cancer, changes
      in these passively sensed digital biomarkers may reflect meaningful variation in 
      functional status, symptom burden, quality of life, and risk for adverse clinical
      outcomes. These data could enable real-time remote monitoring of patients between
      clinical encounters and more proactive, comprehensive, and personalized care.
      Over the past few years, small studies across a variety of cancer populations
      support the feasibility and potential clinical value of mobile sensors in
      oncology. Barriers to implementing mobile sensing in clinical oncology care
      include the challenges of managing and making sense of continuous sensor data,
      patient engagement issues, difficulty integrating sensor data into existing
      electronic health systems and clinical workflows, and ethical and privacy
      concerns. Multidisciplinary collaboration is needed to develop mobile sensing
      frameworks that overcome these barriers and that can be implemented at
      large-scale for remote monitoring of deteriorating health during or after cancer 
      treatment or for promotion and tailoring of lifestyle or symptom management
      interventions. Leveraging digital technology has the potential to enrich
      scientific understanding of how cancer and its treatment affect patient lives, to
      use this understanding to offer more timely and personalized support to patients,
      and to improve clinical oncology outcomes.
CI  - (c) The Author(s) 2020.
FAU - Low, Carissa A
AU  - Low CA
AUID- ORCID: 0000-0002-3318-7495
AD  - Department of Medicine, University of Pittsburgh, 3347 Forbes Avenue, Suite 200, 
      Pittsburgh, PA 15213 USA.grid.21925.3d0000 0004 1936 9000
LA  - eng
GR  - K07 CA204380/CA/NCI NIH HHS/United States
GR  - R37 CA242545/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201027
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7591557
OTO - NOTNLM
OT  - Cancer
OT  - Palliative care
OT  - Quality of life
OT  - Risk factors
COIS- Competing interestsThe author declares no competing interests.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:21
PHST- 2020/06/05 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/11/02 06:21 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1038/s41746-020-00351-x [doi]
AID - 351 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Oct 27;3:140. doi: 10.1038/s41746-020-00351-x. eCollection
      2020.


PMID- 33134493
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2373-8731 (Print)
IS  - 2373-8731 (Linking)
VI  - 6
IP  - 11
DP  - 2020 Nov
TI  - Ethical Decision Diagrams on Donation After Cardiocirculatory Death Heart
      Transplantation Considering Organ Preservation Techniques.
PG  - e617
LID - 10.1097/TXD.0000000000001075 [doi]
AB  - BACKGROUND: To overcome organ shortage, some centers accept hearts from
      cardiocirculatory determined death (DCD) donors for heart transplantation (HTx). 
      DCD-HTx is attached with special ethical conflicts on the donor, family, and
      recipient side. Ethically motivated decisions also have to be made considering
      organ preservation techniques. However, ethical decision diagrams, which can be
      applied to find a final answer on the complex field of ethical questions, have
      not been developed yet. METHODS: In an interdisciplinary group of clinical
      ethicists, transplantation surgeons, transplantation researchers, and
      perfusionists, after review of relevant literature, we focused on crucial ethical
      aspects on DCD-HTx in general and separated ethical conflicts with regard to the 
      individual perspective of the donor, family, and recipient. RESULTS: The leading 
      aspect of discussion in the donor perspective mainly deals with the standoff
      period and with the definition of death. The perspective of recipients focuses on
      the wish to say farewell after the patient is deceased. In the recipient
      perspective ethical questions regarding organ procurement techniques occur.
      CONCLUSIONS: Ethical decision-making on DCD-HTx is complex, but it can be
      processed in a structured way by applying the decision diagrams that we have
      developed.
CI  - Copyright (c) 2020 The Author(s). Transplantation Direct. Published by Wolters
      Kluwer Health, Inc.
FAU - Saemann, Lars
AU  - Saemann L
AD  - Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
AD  - Faculty Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen,
      Germany.
FAU - Karck, Matthias
AU  - Karck M
AD  - Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
FAU - Korkmaz-Icoz, Sevil
AU  - Korkmaz-Icoz S
AD  - Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
FAU - Wenzel, Folker
AU  - Wenzel F
AD  - Faculty Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen,
      Germany.
FAU - Szabo, Gabor
AU  - Szabo G
AD  - Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
AD  - Department of Cardiac Surgery, University of Halle, Halle, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - United States
TA  - Transplant Direct
JT  - Transplantation direct
JID - 101651609
PMC - PMC7575185
COIS- The authors declare no funding or conflicts of interest. L.S. is a fellow of the 
      Josef Guttler Stipendium of the German Society for Cardiovascular
      Engineering/Deutsche Gesellschaft fur Kardiotechnik (DGfK).
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:21
PHST- 2020/08/07 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/11/02 06:21 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1097/TXD.0000000000001075 [doi]
PST - epublish
SO  - Transplant Direct. 2020 Oct 19;6(11):e617. doi: 10.1097/TXD.0000000000001075.
      eCollection 2020 Nov.


PMID- 33134442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2352-3409 (Electronic)
IS  - 2352-3409 (Linking)
VI  - 33
DP  - 2020 Dec
TI  - LogiKEy workbench: Deontic logics, logic combinations and expressive ethical and 
      legal reasoning (Isabelle/HOL dataset).
PG  - 106409
LID - 10.1016/j.dib.2020.106409 [doi]
AB  - The LogiKEy workbench and dataset for ethical and legal reasoning is presented.
      This workbench simultaneously supports development, experimentation, assessment
      and deployment of formal logics and ethical and legal theories at different
      conceptual layers. More concretely, it comprises, in form of a dataset
      (Isabelle/HOL theory files), formal encodings of multiple deontic logics, logic
      combinations, deontic paradoxes and normative theories in the higher-order proof 
      assistant system Isabelle/HOL. The data were acquired through application of the 
      LogiKEy methodology, which supports experimentation with different normative
      theories, in different application scenarios, and which is not tied to specific
      logics or logic combinations. Our workbench consolidates related research
      contributions of the authors and it may serve as a starting point for further
      studies and experiments in flexible and expressive ethical and legal reasoning.
      It may also support hands-on teaching of non-trivial logic formalisms in lecture 
      courses and tutorials. The LogiKEy methodology and framework is discussed in more
      detail in the companion research article titled "Designing Normative Theories for
      Ethical and Legal Reasoning: LogiKEy Framework, Methodology, and Tool Support"
      [5].
CI  - (c) 2020 The Author(s). Published by Elsevier Inc.
FAU - Benzmuller, Christoph
AU  - Benzmuller C
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
AD  - Freie Universitat Berlin, Berlin, Germany.
FAU - Farjami, Ali
AU  - Farjami A
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
FAU - Fuenmayor, David
AU  - Fuenmayor D
AD  - Freie Universitat Berlin, Berlin, Germany.
FAU - Meder, Paul
AU  - Meder P
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
FAU - Parent, Xavier
AU  - Parent X
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
FAU - Steen, Alexander
AU  - Steen A
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
FAU - van der Torre, Leendert
AU  - van der Torre L
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
AD  - Zhejiang University, Hangzhou, China.
FAU - Zahoransky, Valeria
AU  - Zahoransky V
AD  - University of Luxembourg, Esch sur Alzette, Luxembourg.
AD  - University of Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Netherlands
TA  - Data Brief
JT  - Data in brief
JID - 101654995
PMC - PMC7586073
OTO - NOTNLM
OT  - Automated theorem proving
OT  - Higher-order logic
OT  - Knowledge representation and reasoning
OT  - Model finding
OT  - Normative reasoning
OT  - Normative systems
OT  - Semantical embedding
OT  - Trustworthy and responsible AI
COIS- Benzmuller was funded by the VolkswagenStiftung under grant CRAP (Consistent
      Rational Argumentation in Politics). Parent and van der Torre were supported by
      the European Union's Horizon 2020 research and innovation programme under the
      Marie Sklodowska-Curie grant agreement MIREL (MIning and REasoning with Legal
      texts) No 690974.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:21
PHST- 2020/06/22 00:00 [received]
PHST- 2020/10/08 00:00 [revised]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/11/02 06:21 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1016/j.dib.2020.106409 [doi]
AID - S2352-3409(20)31291-9 [pii]
PST - epublish
SO  - Data Brief. 2020 Oct 15;33:106409. doi: 10.1016/j.dib.2020.106409. eCollection
      2020 Dec.


PMID- 33134232
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Fostering Vicarious Resilience for Perinatal Palliative Care Professionals.
PG  - 572933
LID - 10.3389/fped.2020.572933 [doi]
AB  - Background: The demands on healthcare professionals caring for families grappling
      with a life-limiting condition in an unborn or newly born child can be
      overwhelming. Clinicians working in emergency/trauma, hospice, and pediatric
      settings are already at high risk for burnout and compassion fatigue, which can
      leave healthcare institutions increasingly vulnerable to poor retention,
      absenteeism, and waning quality of care. The provision of exemplary palliative
      care requires a cohesive interdisciplinary team of seasoned professionals
      resilient to daily challenges. In September 2019, the American College of
      Gynecology, in a committee opinion, published standard of care guidelines for
      perinatal palliative care. This has created an impetus for exceptional caregiving
      and a greater demand for both physician and interdisciplinary healthcare provider
      education, training, and ongoing support that promotes truly beneficent care for 
      pregnant patients confronted with life-limiting fetal conditions. Methods: A
      scoping review of the research literature was conducted in order to distinguish
      the barriers and facilitators of professional resiliency in perinatal palliative 
      care. PubMed, Medline, CINAHL, and EBSCO Psychology & Behavioral Sciences
      Collections were systematically reviewed. Because of the paucity of studies
      specific to perinatal palliative care, several interviews of nurses and
      physicians in that field were conducted and analyzed for content distinctly
      pertaining to personal practices or workplace factors that support or hinder
      professional resiliency. Results: The research indicated that medical
      professionals often cite a lack of knowledge, inexperience using effective
      communication skills related to perinatal palliative care and bereavement,
      challenges with interdisciplinary collaboration, misconceptions about the role
      and function of palliative care in the perinatal or neonatal settings, moral
      distress, and workload challenges as encumbrances to professional satisfaction.
      Strategic implementation of facility-wide bereavement care training, effective
      communication modalities, and evidenced-based practical applications are critical
      components for a thriving perinatal palliative care team. Authentic formal and
      informal debriefing, peer mentoring, adequate caseloads, robust provider
      self-care practices, exceptional relational efficacy, and cultural and spiritual 
      humility can foster personal growth and even vicarious resilience for perinatal
      palliative care professionals. Conclusions: Support should be strategic and
      multifaceted. The onus to implement salient measures to cultivate resilience in
      the perinatal palliative caregiver should not be only upon the individuals
      themselves but also upon prevailing regulatory governing bodies and healthcare
      institutions.
CI  - Copyright (c) 2020 Grauerholz, Fredenburg, Jones and Jenkins.
FAU - Grauerholz, Kathryn R
AU  - Grauerholz KR
AD  - Life Perspectives, San Diego, CA, United States.
FAU - Fredenburg, Michaelene
AU  - Fredenburg M
AD  - Life Perspectives, San Diego, CA, United States.
FAU - Jones, Premala Tara
AU  - Jones PT
AD  - Life Perspectives, San Diego, CA, United States.
AD  - Counseling and Testing Center, University of Akron, Akron, OH, United States.
FAU - Jenkins, Kristy N
AU  - Jenkins KN
AD  - Life Perspectives, San Diego, CA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201008
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7579417
OTO - NOTNLM
OT  - burnout
OT  - compassion
OT  - ethical
OT  - grief
OT  - palliative
OT  - perinatal
OT  - resiliency
OT  - self-care
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:20
PHST- 2020/06/15 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/11/02 06:20 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.3389/fped.2020.572933 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Oct 8;8:572933. doi: 10.3389/fped.2020.572933. eCollection
      2020.


PMID- 33134039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 2198-9834 (Print)
VI  - 7
IP  - 3
DP  - 2020
TI  - Spiritual, Moral and Ethical Dilemmata for Healthcare Professionals During
      Covid-19 Times.
PG  - 197-198
LID - 10.1007/s40737-020-00205-5 [doi]
FAU - Chaturvedi, Santosh K
AU  - Chaturvedi SK
AD  - National Institute of Mental Health and Neurosciences, Bangalore,
      India.grid.416861.c0000 0001 1516 2246
LA  - eng
PT  - Editorial
DEP - 20201027
PL  - India
TA  - J Psychosoc Rehabil Ment Health
JT  - Journal of psychosocial rehabilitation and mental health
JID - 101662774
PMC - PMC7588584
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:19
PHST- 2020/10/07 00:00 [received]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
PHST- 2020/11/02 06:19 [entrez]
AID - 10.1007/s40737-020-00205-5 [doi]
AID - 205 [pii]
PST - ppublish
SO  - J Psychosoc Rehabil Ment Health. 2020;7(3):197-198. doi:
      10.1007/s40737-020-00205-5. Epub 2020 Oct 27.


PMID- 33133904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201104
IS  - 2169-7574 (Print)
IS  - 2169-7574 (Linking)
VI  - 8
IP  - 5
DP  - 2020 May
TI  - Articulating the "So, What?" in Clinical Research: Insight from the M-CHOIR
      Group.
PG  - e2848
LID - 10.1097/GOX.0000000000002848 [doi]
AB  - With the academic culture of "publish or perish," authors must ensure that they
      are delivering high-quality data with a meaningful impact on clinical practice.
      Even for physician-scientists at the top of their fields, establishing the
      relevance of a study to clinical practice is a challenge. Thus, it is essential
      that research proposals ask questions that are clinically important, use
      appropriate methodologies, and examine outcomes that are relevant to both the
      physicians and the patients. The question of "so, what?" or in other words, "who 
      cares?" is one that can make or break a study's impact on clinical practice.
      Researchers should use models such as PICOS (Population, Intervention,
      Comparison, Outcomes, and Study design) and FINER (Feasible, Interesting, Novel, 
      Ethical, Relevant) and ask why readers will care about their study's findings
      before the study is conducted. By doing so, researchers can ensure the successful
      execution of their study and a meaningful impact of their findings, in both
      academia and clinical practice. This Special Topic article aims to guide
      researchers in producing relevant, impactful conclusions of their studies by
      providing input and resources from the Michigan Center for Hand Outcomes and
      Innovation (M-CHOIR) group.
CI  - Copyright (c) 2020 The Authors. Published by Wolters Kluwer Health, Inc. on
      behalf of The American Society of Plastic Surgeons.
FAU - Kim, You J
AU  - Kim YJ
AD  - Section of Plastic Surgery, Department of Surgery, University of Michigan Medical
      School, Ann Arbor, Mich.
FAU - Mack, Shale J
AU  - Mack SJ
AD  - Section of Plastic Surgery, Department of Surgery, University of Michigan Medical
      School, Ann Arbor, Mich.
FAU - Chung, Kevin C
AU  - Chung KC
AD  - Section of Plastic Surgery, Department of Surgery, University of Michigan Medical
      School, Ann Arbor, Mich.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Plast Reconstr Surg Glob Open
JT  - Plastic and reconstructive surgery. Global open
JID - 101622231
PMC - PMC7572177
COIS- Disclosure: Dr. Chung receives funding from the National Institutes of Health and
      book royalties from Wolters Kluwer and Elsevier. He has received financial
      support from Axogen to attend conferences. The other authors have no financial
      interest to declare.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:19
PHST- 2020/03/04 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/11/02 06:19 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1097/GOX.0000000000002848 [doi]
PST - epublish
SO  - Plast Reconstr Surg Glob Open. 2020 May 21;8(5):e2848. doi:
      10.1097/GOX.0000000000002848. eCollection 2020 May.


PMID- 33133898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2169-7574 (Print)
IS  - 2169-7574 (Linking)
VI  - 8
IP  - 5
DP  - 2020 May
TI  - Barriers to Obtaining Informed Consent on Shortterm Surgical Missions.
PG  - e2823
LID - 10.1097/GOX.0000000000002823 [doi]
AB  - Short-term surgical missions (STSMs) enable visiting surgeons to help address
      inequalities in the provision of surgical care in resource-limited settings. One 
      criticism of STSMs is a failure to obtain informed consent from patients before
      major surgical interventions. We aim to use collective evidence to establish the 
      barriers to obtaining informed consent on STSMs and in resource-limited settings 
      and suggest practical solutions to overcome them. METHODS: A systematic review
      was performed using PubMed and Web of Science databases and following Preferred
      Reporting Items for Systematic Review and Meta-Analysis guidelines. In addition
      to the data synthesized from the systematic review, we also include pertinent
      data from a recent long-term follow-up study in Ethiopia. RESULTS: Of the 72
      records screened, 11 studies were included in our review. The most common barrier
      to obtaining informed consent was a paternalistic approach to medicine and
      patient education. Other common barriers were a lack of ethics education among
      surgeons in low-income and middle-income countries, cultural beliefs toward
      healthcare, and language barriers between the surgeons and patients. Our
      experience of a decade of reconstructive surgery missions in Ethiopia
      corroborates this. In a long-term follow-up study of our head-and-neck patients, 
      informed consent was obtained for 85% (n = 68) of patients over a 14-year period.
      CONCLUSIONS: This study highlights the main barriers to obtaining informed
      consent on STSMs and in the resource-limited setting. We propose a checklist that
      incorporates practical solutions to the most common barriers surgeons will
      experience, aimed to improve the process of informed consent on STSMs.
CI  - Copyright (c) 2020 The Authors. Published by Wolters Kluwer Health, Inc. on
      behalf of The American Society of Plastic Surgeons.
FAU - Cebron, Urska
AU  - Cebron U
AD  - Department of Hand, Plastic, Reconstructive and Burn Surgery, University of
      Tubingen, Tubingen, Germany.
FAU - Honeyman, Calum
AU  - Honeyman C
AD  - Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe
      Hospital, Oxford, United Kingdom.
FAU - Berhane, Meklit
AU  - Berhane M
AD  - Department of Plastic and Reconstructive Surgery, ALERT Hospital, Addis Ababa,
      Ethiopia.
FAU - Patel, Vinod
AU  - Patel V
AD  - Department of Oral Surgery, Guy's & St Thomas' NHS Foundation Trust, London,
      United Kingdom.
FAU - Martin, Dominique
AU  - Martin D
AD  - Department of Plastic & Reconstructive Surgery, University of Bordeaux, Bordeaux,
      France.
FAU - McGurk, Mark
AU  - McGurk M
AD  - Department of Oral & Maxillofacial Surgery, University College London Hospitals
      NHS Foundation Trust, London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Plast Reconstr Surg Glob Open
JT  - Plastic and reconstructive surgery. Global open
JID - 101622231
PMC - PMC7571941
COIS- Disclosure: The authors have no financial interest to declare in relation to the 
      content of this article.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:19
PHST- 2020/01/12 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/11/02 06:19 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1097/GOX.0000000000002823 [doi]
PST - epublish
SO  - Plast Reconstr Surg Glob Open. 2020 May 21;8(5):e2823. doi:
      10.1097/GOX.0000000000002823. eCollection 2020 May.


PMID- 33133867
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 29
TI  - A Novel Skin Closure Technique for the Management of Lacerations in Thin-Skinned 
      Individuals.
PG  - e10702
LID - 10.7759/cureus.10702 [doi]
AB  - Suturing thin, fragile skin, particularly in elderly patients, is often
      problematic and presents a challenge to many clinicians. We describe a novel
      technique that re-enforces the edges of such thin fragile skin, with the use of
      topical skin adhesive, 2-octyl cyanoacrylate (Dermabond; Ethicon, Somerville,
      NJ). This allows secure suture placement and application of tension to facilitate
      wound closure.
CI  - Copyright (c) 2020, Joyce et al.
FAU - Joyce, Kenneth
AU  - Joyce K
AD  - Department of Plastic, Reconstructive, and Aesthetic Surgery, Mater Misericordiae
      Hospital, Dublin, IRL.
FAU - Potter, Shirley
AU  - Potter S
AD  - Department of Plastic, Reconstructive and Aesthetic Surgery, Mater Misericordiae 
      Hospital, Dublin, IRL.
LA  - eng
PT  - Case Reports
DEP - 20200929
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7594668
OTO - NOTNLM
OT  - surgical glue
OT  - wound therapy
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:18
PHST- 2020/11/02 06:18 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.7759/cureus.10702 [doi]
PST - epublish
SO  - Cureus. 2020 Sep 29;12(9):e10702. doi: 10.7759/cureus.10702.


PMID- 33133801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 26
TI  - Pattern and Outcome of Thoracic Injuries in a Busy Tertiary Care Unit.
PG  - e11181
LID - 10.7759/cureus.11181 [doi]
AB  - INTRODUCTION: Thoracic traumas are one of the most commonly encountered injuries 
      in the emergency room. They range from blunt chest injuries due to road traffic
      accidents to penetrating chest injuries. Immediate medical and surgical
      interventions are essential to improve the outcome. This study was conducted to
      assess the pattern of thoracic trauma presenting to the emergency room, their
      outcome and factors contributing to it. METHODS: This prospective, observational,
      cross-sectional study was conducted in the Department of Thoracic Surgery, Jinnah
      Post Graduate Medical Center, Karachi from January 1 until July 31, 2020, with
      institutional ethical approval. Patients age >/=12 years presenting with
      traumatic thoracic injury with or without associated injuries were included.
      Characteristics of their injuries and management outcome were studied. All data
      was processed through Statistical Package for Social Sciences (SPSS) Statistics
      version 22 (IBM Corp., Armonk, NY, USA). RESULTS: A total of 199 patients were
      included; 154 (77.4%) patients were male and 45 (22.6%) patients were female. The
      most common age group presenting with trauma was the middle age (30-60 years),
      which included 101 (50.8%) patients. Out of the total, 126 (63.3%) had blunt
      chest injuries and 73 (36.6%) had penetrating chest injuries. Road traffic
      accidents were the most common cause of blunt chest injuries seen in 83 (65.8%)
      patients, whereas gunshot was the most common mode of penetrating chest injuries 
      encountered in 41 (56.2%) cases. Tube thoracostomies were performed in 166
      (83.4%) patients and thoracotomies in seven (3.51%) patients. Out of the total,
      57 (28.6%) patients required mechanical ventilation and it was associated with
      blunt trauma, hemothorax, rib fracture, abdominal and head injuries (p </=0.05). 
      Mortality was seen in 22 (11.1%), which was associated with hemothorax, head
      injuries, mechanical ventilation and severe blood loss (p </=0.05). CONCLUSION:
      Traumatic thoracic injuries are a preventable cause of mortality. Blunt chest
      injuries are more common than penetrating chest injuries. Proper implementation
      of public safety measures ensures less frequent and severe outcomes. Emergency
      department team and specialized thoracic surgeons must come together to manage
      these critical patients with utmost care.
CI  - Copyright (c) 2020, Mazcuri et al.
FAU - Mazcuri, Misauq
AU  - Mazcuri M
AD  - Thoracic Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Ahmad, Tanveer
AU  - Ahmad T
AD  - Thoracic Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Abid, Ambreen
AU  - Abid A
AD  - Thoracic Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Thapaliya, Pratikshya
AU  - Thapaliya P
AD  - Thoracic Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Ali, Mansab
AU  - Ali M
AD  - General Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Ali, Nadir
AU  - Ali N
AD  - Thoracic Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7593122
OTO - NOTNLM
OT  - blunt chest injuries
OT  - hemothorax
OT  - mortality
OT  - penetrating chest injuries
OT  - thoracic trauma
OT  - tube thoracostomies
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:18
PHST- 2020/11/02 06:18 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.7759/cureus.11181 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 26;12(10):e11181. doi: 10.7759/cureus.11181.


PMID- 33133692
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2090-1305 (Print)
IS  - 2090-1305 (Linking)
VI  - 2020
DP  - 2020
TI  - The Attitudes of Relatives of ICU Patients toward Informed Consent for Clinical
      Research.
PG  - 2760168
LID - 10.1155/2020/2760168 [doi]
AB  - BACKGROUND: Informed consent is a key ethical requirement for biomedical research
      that is implemented to ensure autonomy and voluntary participation. However,
      patients in the intensive care unit (ICU) may be unconscious or severely ill and 
      thus lack the capacity for decisions about research participation. Thus,
      relatives or guardians are usually asked to provide informed consent prior to the
      inclusion of ICU patients in research. AIMS: This study aimed to assess the
      attitudes and preferences of relatives of ICU patients toward informed consent in
      biomedical research in Jordan. Subjects and Methods. A sample of 184 relatives
      with a critically ill next of kin in the ICU was anonymously surveyed regarding
      their attitudes and preferences toward giving informed consent for biomedical
      research on behalf of their patients. RESULTS: The study showed that the majority
      of relatives had a positive attitude toward the informed consent process on
      behalf of their patients in the ICU (72.3%). The perception that participation in
      research would be directly beneficial to their patient was the most significant
      reason to provide informed consent among relatives. The degree of relatedness to 
      the patient was significantly associated with the decision to provide informed
      consent on behalf of the patients in the ICU. Additionally, more than 70% of the 
      relatives strongly agreed to take part in clinical research if they were to be
      unconscious patients in the ICU. Moreover, the majority of the respondents agreed
      that their first-degree relatives would give consent on their behalf. CONCLUSION:
      Relatives with a critically ill next of kin in the ICU had positive attitudes
      toward providing informed consent on behalf of their patients. This was motivated
      by the direct benefit from the research to their patient.
CI  - Copyright (c) 2020 Rania Mahafzah et al.
FAU - Mahafzah, Rania
AU  - Mahafzah R
AD  - Dept. of Clinical Pharmacy, Jordan University of Science and Technology, Irbid
      22110, Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AUID- ORCID: https://orcid.org/0000-0002-2808-5099
AD  - Dept. of Clinical Pharmacy, Jordan University of Science and Technology, Irbid
      22110, Jordan.
FAU - Khabour, Omar F
AU  - Khabour OF
AD  - Dept. of Medical Laboratory Sciences, Jordan University of Science and
      Technology, Irbid 22110, Jordan.
LA  - eng
GR  - R25 TW010026/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20201009
PL  - Egypt
TA  - Crit Care Res Pract
JT  - Critical care research and practice
JID - 101539357
PMC - PMC7568781
COIS- No potential conflicts of interest were reported by the authors.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:18
PHST- 2020/05/29 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/02 06:18 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1155/2020/2760168 [doi]
PST - epublish
SO  - Crit Care Res Pract. 2020 Oct 9;2020:2760168. doi: 10.1155/2020/2760168.
      eCollection 2020.


PMID- 33133658
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2080-4806 (Print)
IS  - 2080-4806 (Linking)
VI  - 73
IP  - 3
DP  - 2020
TI  - A four month squatting-based pelvic exercise regime cures day/night enuresis and 
      bowel dysfunction in children aged 7-11 years.
PG  - 307-314
LID - 10.5173/ceju.2020.0044 [doi]
AB  - INTRODUCTION: In 2004, Patricia Skilling developed a new squatting-based pelvic
      floor rehabilitation method based on strengthening the three reflex pelvic
      muscles and ligaments hypothesized to control the closure and micturition
      reflexes. We adapted these methods to test our hypothesis that day/night enuresis
      was due to the inability of these muscles/ligaments to control an inappropriately
      activated micturition reflex. MATERIAL AND METHODS: The trial commenced as a
      randomized control trial to be conducted over 4 months, but was converted to a
      prospective trial at 4 weeks by order of the Ethics Committee. A total of 48
      children, 7.6 +/-2.5 years, 34 females, 14 males, had strictly supervised
      exercises twice daily, 10 squats, 10 bridge, fitball exercises involving
      proprioception exercises with surface perineal electromyogram (EMG) once a
      week.Eligibility criteria were daytime urine leakage plus night-time bedwetting. 
      Exclusion criterion was refusal to sign consent forms. Assessment was done by
      intention to treat. The criterion for cure was complete dryness. RESULTS: At
      1(st) review (4 weeks) 12/24 in the treatment group reported total cure of
      wetting; 41/48 children (86%) were cured of both daytime/nighttime enuresis (p
      <0.001) at 4 months. There were no adverse events. Secondary outcomes were
      concomitant cure of constipation, fecal incontinence, urinary retention as
      predicted by the underlying integral theory of incontinence. CONCLUSIONS: We
      believe our methods accelerated normal childhood strengthening of
      muscles/ligaments which control inappropriate activation of the micturition
      reflex which we hypothesize is the basis for daytime/nighttime enuresis. This is 
      a simple treatment, needs diligent application and validation by others.
CI  - Copyright by Polish Urological Association.
FAU - Garcia-Fernandez, Angel
AU  - Garcia-Fernandez A
AD  - Universidad Nacional de Cordoba, Department of Pediatric Surgery, Cordoba,
      Argentina.
FAU - Petros, Peter Emanuel
AU  - Petros PE
AD  - University of NSW Professorial, Department of Surgery, St Vincent's Hospital,
      Sydney, Australia.
AD  - School of Mechanical and Chemical Engineering, University of Western Australia,
      Perth, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Poland
TA  - Cent European J Urol
JT  - Central European journal of urology
JID - 101587101
CIN - J Urol. 2021 Apr;205(4):1212-1214. PMID: 33467895
PMC - PMC7587486
OTO - NOTNLM
OT  - bedwetting
OT  - constipation
OT  - daytime/nighttime enuresis
OT  - fecal incontinence
OT  - urinary retention
COIS- The authors declare no conflicts of interest.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:18
PHST- 2020/03/05 00:00 [received]
PHST- 2020/04/19 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/11/02 06:18 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.5173/ceju.2020.0044 [doi]
AID - 0044 [pii]
PST - ppublish
SO  - Cent European J Urol. 2020;73(3):307-314. doi: 10.5173/ceju.2020.0044. Epub 2020 
      Jul 20.


PMID- 33133234
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - Addressing obstacles to the inclusion of palliative care in humanitarian health
      projects: a qualitative study of humanitarian health professionals' and policy
      makers' perceptions.
PG  - 70
LID - 10.1186/s13031-020-00314-9 [doi]
AB  - BACKGROUND: Humanitarian non-governmental organizations provide assistance to
      communities affected by war, disaster and epidemic. A primary focus of healthcare
      provision by these organizations is saving lives; however, curative care will not
      be sufficient, appropriate, or available for some patients. In these instances,
      palliative care approaches to ease suffering and promote dignity are needed.
      Though several recent initiatives have increased the probability of palliative
      care being included in humanitarian healthcare response, palliative care remains 
      minimally integrated in humanitarian health projects. METHODS: We conducted a
      qualitative study using interpretive description methodology to investigate
      humanitarian policy-makers' and health care professionals' experiences and
      perceptions of palliative care during humanitarian crises. In this article, we
      report on the analysis of in-depth interviews with 24 participants related to
      their perceptions of obstacles to providing palliative care in humanitarian
      crises, and opportunities for overcoming these obstacles. Among the participants,
      23 had experience as humanitarian health professionals, and 12 had experience
      with policy development and organizational decision-making. RESULTS: Participants
      discussed various obstacles to the provision of palliative care in humanitarian
      crises. More prominent obstacles were linked to the life-saving ethos of
      humanitarian organizations, priority setting of scarce resources, institutional
      and donor funding, availability of guidance and expertise in palliative care,
      access to medication, and cultural specificity around death and dying. Less
      prominent obstacles related to continuity of care after project closure, equity, 
      security concerns, and terminology. CONCLUSION: Opportunities exist for
      overcoming the obstacles to providing palliative care in humanitarian crises.
      Doing so is necessary to ensure that humanitarian healthcare can fulfill its
      objectives not only of saving lives, but also of alleviating suffering and
      promoting dignity of individuals who are ill or injured during a humanitarian
      crises, including persons who are dying or likely to die.
CI  - (c) The Author(s) 2020.
FAU - Hunt, Matthew
AU  - Hunt M
AUID- ORCID: 0000-0003-4190-0163
AD  - School of Physical and Occupational Therapy, McGill University; Researcher,
      Centre for Interdisciplinary Research on Rehabilitation, 3654 Prom Sir William
      Osler, Montreal, QC H3G 1Y5 Canada.grid.14709.3b0000 0004 1936 8649
FAU - Nouvet, Elysee
AU  - Nouvet E
AD  - School of Health Studies, Western University, HSB 339 1151 Richmond St, London,
      ON N6A 5B9 Canada.grid.39381.300000 0004 1936 8884
FAU - Chenier, Ani
AU  - Chenier A
AD  - Humanitarian Health Ethics Research Group, Western University, School of Health
      Studies, Western University, School of Health Studies, HSB 339, 1151 Richmond St,
      London, ON N6A 5B9 Canada.grid.39381.300000 0004 1936 8884
FAU - Krishnaraj, Gautham
AU  - Krishnaraj G
AD  - Humanitarian Health Ethics Research Group, McMaster University, CRL Building,
      1280 Main Street West, Hamilton, Ontario L8S 4K1 Canada.grid.25073.330000 0004
      1936 8227
FAU - Bernard, Carrie
AU  - Bernard C
AD  - Department of Community and Family Medicine, University of Toronto, 500
      University Ave, Toronto, ON M5G 1V7 Canada.grid.17063.330000 0001 2157 2938
AD  - Department of Family Medicine, McMaster University 100 Main Street West, 6th
      Floor, Hamilton, ON L8P 1H6 Canada.grid.25073.330000 0004 1936 8227
FAU - Bezanson, Kevin
AU  - Bezanson K
AD  - Northern Ontario School of Medicine, Lakehead University, Thunder Bay Regional
      Health Sciences Centre, 980 Oliver Rd, Thunder Bay, Ontario P7B 6V4
      Canada.grid.258900.60000 0001 0687 7127
FAU - de Laat, Sonya
AU  - de Laat S
AD  - Global Health, McMaster University, 1280 Main Street West, MDCL 3500, Hamilton,
      ON L8S 4K1 Canada.grid.25073.330000 0004 1936 8227
FAU - Schwartz, Lisa
AU  - Schwartz L
AD  - Department of Health Research Methods & Impact, McMaster University, CRL
      Building, 1280 Main Street West, Hamilton, Ontario L8S 4K1
      Canada.grid.25073.330000 0004 1936 8227
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7592183
OTO - NOTNLM
OT  - Armed conflict
OT  - Disasters
OT  - Ebola virus disease, end of life
OT  - Ethics, humanitarian action, non-governmental organizations, palliative care
OT  - Public health emergencies
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:16
PHST- 2020/04/23 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/11/02 06:16 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.1186/s13031-020-00314-9 [doi]
AID - 314 [pii]
PST - epublish
SO  - Confl Health. 2020 Oct 28;14:70. doi: 10.1186/s13031-020-00314-9. eCollection
      2020.


PMID- 33132955
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Dilemma Tales as African Knowledge Practice: An Example From Research on
      Obligations of Support.
PG  - 546330
LID - 10.3389/fpsyg.2020.546330 [doi]
AB  - This contribution to the Frontiers research topic collection on African Cultural 
      Models considers dilemma tales: an African knowledge practice in which narrators 
      present listeners with a difficult choice that usually has ethical or moral
      implications. We adapted the dilemma tale format to create research tasks. We
      then used these research tasks to investigate conceptions of care, support, and
      relationality among participants in Ghanaian, African American, and European
      American settings that vary in affordances for embedded interdependence vs.
      modern individualism. Results revealed hypothesized patterns, such that judgments
      about the inappropriateness of institutionalized eldercare (vs. home elder care) 
      and prioritization of material support to parent (over spouse) were greater among
      Ghanaian participants than European American participants. Responses of African
      American participants were more ambiguous, resembling European American
      acceptance of institutionalized eldercare relative to Ghanaian participants, but 
      resembling Ghanaian tendencies to prioritize support to parent (over spouse)
      relative to European American participants. Results illuminate that standard
      patterns of hegemonic psychological science (e.g., tendencies to prioritize
      obligations to spouse over mother) are the particular product of WEIRD cultural
      ecologies rather than context-general characteristics.
CI  - Copyright (c) 2020 Esiaka, Adams and Osei-tutu.
FAU - Esiaka, Darlingtina
AU  - Esiaka D
AD  - Department of Psychology, Union College, Schenectady, NY, United States.
FAU - Adams, Glenn
AU  - Adams G
AD  - Department of Psychology, University of Kansas, Lawrence, KS, United States.
FAU - Osei-Tutu, Annabella
AU  - Osei-Tutu A
AD  - Department of Psychology, University of Ghana, Accra, Ghana.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7561668
OTO - NOTNLM
OT  - African cultural models
OT  - dilemma tales
OT  - eldercare
OT  - family
OT  - interdependence
OT  - obligation
OT  - relationality
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:14
PHST- 2020/03/27 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/11/02 06:14 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.3389/fpsyg.2020.546330 [doi]
PST - epublish
SO  - Front Psychol. 2020 Oct 2;11:546330. doi: 10.3389/fpsyg.2020.546330. eCollection 
      2020.


PMID- 33132748
OWN - NLM
STAT- Publisher
LR  - 20220218
IS  - 1388-1957 (Print)
IS  - 1388-1957 (Linking)
DP  - 2020 Oct 26
TI  - Responsible innovation in synthetic biology in response to COVID-19: the role of 
      data positionality.
PG  - 1-9
LID - 10.1007/s10676-020-09565-9 [doi]
AB  - Synthetic biology, as an engineering approach to biological systems, has the
      potential to disruptively innovate the development of vaccines, therapeutics, and
      diagnostics. Data accessibility and differences in data-usage capabilities are
      important factors in shaping this innovation landscape. In this paper, the data
      that underpin synthetic biology responses to the COVID-19 pandemic are analyzed
      as positional information goods-goods whose value depends on exclusivity. The
      positionality of biological data impacts the ability to guide innovations toward 
      societally preferred goals. From both an ethical and economic point of view,
      positionality can lead to suboptimal as well as beneficial situations. When
      aiming for responsible innovation (i.e. embedding societal deliberation in the
      innovation process), it is important to consider hurdles and facilitators in data
      access and use. Central governance and knowledge commons provide routes to
      mitigate the negative effects of data positionality.
CI  - (c) The Author(s) 2020.
FAU - Bruynseels, Koen
AU  - Bruynseels K
AUID- ORCID: 0000-0001-7133-3978
AD  - Philosophy Department, Technology Policy & Management, T.U. Delft, Jaffalaan 5,
      2628 BX Delft, The Netherlands.grid.5292.c0000 0001 2097 4740
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Netherlands
TA  - Ethics Inf Technol
JT  - Ethics and information technology
JID - 101248311
PMC - PMC7585993
OTO - NOTNLM
OT  - COVID-19
OT  - Data frictions
OT  - Knowledge commons
OT  - Pandemic
OT  - Positionality
OT  - Responsible innovation
OT  - Synthetic biology
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/11/02 06:13
PHST- 2020/11/02 06:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1007/s10676-020-09565-9 [doi]
AID - 9565 [pii]
PST - aheadofprint
SO  - Ethics Inf Technol. 2020 Oct 26:1-9. doi: 10.1007/s10676-020-09565-9.


PMID- 33132575
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 9
DP  - 2020 Sep
TI  - Cardiopulmonary Resuscitation during COVID-19 Pandemic: Outcomes, Risks, and
      Protective Strategies for the Healthcare Workers and Ethical Considerations.
PG  - 868-872
LID - 10.5005/jp-journals-10071-23544 [doi]
AB  - The crisis caused by Coronavirus disease-2019 (COVID-19) pandemic has led us to
      safeguard ourselves and our colleagues against transmission of this highly
      contagious infection, while aiming for the same goals of care. In spite of the
      stringent measures adopted by affected countries, rising number of healthcare
      workers (HCWs) are getting infected, dwindling the scarce manpower at our
      disposal. In the pre-COVID-19 times, cardiopulmonary resuscitation (CPR) was
      offered unhesitantly to all patients, who had even a slim chance of achieving
      return of spontaneous circulation. In COVID-19 era, CPR, due to some components
      being high aerosol-generating procedures (AGPs), has become high-risk procedure
      for the HCWs. Instead of "Primum non nocere" (first do no harm), we are forced to
      change to "Primum non nocere ad te" (first do no harm to yourself). The challenge
      is therefore to provide best possible chance of survival to deserving patients,
      whose COVID-19 status might be unknown, without causing harm to the HCWs. In this
      review, we discuss the current data regarding infected HCWs, outcomes of
      inhospital and out-of-hospital cardiac arrests, components of CPR which are
      high-risk AGPs, how to safeguard the HCWs while offering CPR, and the ethical
      considerations when CPR is considered, in this COVID-19 era. We wish to emphasize
      here that there is NO EMERGENCY in a pandemic, and time must be made for donning 
      appropriate PPE. We feel that clear policies need to be developed by the
      institutions to deliver CPR to correct population, in this challenging period.
      How to cite this article: Kulkarni AP, Singh Y, Garg H, Jha S. Cardiopulmonary
      Resuscitation during COVID-19 Pandemic: Outcomes, Risks, and Protective
      Strategies for the Healthcare Workers and Ethical Considerations. Indian J Crit
      Care Med 2020;24(9):868-872.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Kulkarni, Atul P
AU  - Kulkarni AP
AD  - Division of Critical Care Medicine, Department of Anesthesia, Critical Care and
      Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Parel (E), Mumbai, 
      Maharashtra, India.
FAU - Singh, Yudhyavir
AU  - Singh Y
AD  - Department of Anesthesiology, Critical Care and Pain Medicine, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Garg, Heena
AU  - Garg H
AD  - Department of Anesthesiology, Critical Care and Pain Medicine, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Jha, Simant
AU  - Jha S
AD  - Department of Critical Care, Pushpawati Singhania Research Institute, New Delhi, 
      India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7584834
OTO - NOTNLM
OT  - Aerosol-generating medical procedures
OT  - COVID-19
OT  - Cardiopulmonary resuscitation
OT  - Personal protective equipment
OT  - Transmission of infection
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:13
PHST- 2020/11/02 06:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.5005/jp-journals-10071-23544 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Sep;24(9):868-872. doi:
      10.5005/jp-journals-10071-23544.


PMID- 33132572
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 9
DP  - 2020 Sep
TI  - Ethical Issues in Intensive Care Units during the COVID-19 Pandemic.
PG  - 855-856
LID - 10.5005/jp-journals-10071-23543 [doi]
AB  - Coronavirus disease-2019 (COVID-19) outbreak began in December 2019 in China and 
      has spread rapidly across the world. The healthcare system of each country has
      been affected from this situation. Undoubtedly, during this period several
      ethical issues have been raised. In this commentary, we aimed to make a
      discussion regarding the ethical issues that could be raised in the treatment of 
      patients in the intensive care units during the COVID-19 pandemic. The objective 
      of this article is to contribute to the wide current discussion regarding the
      appropriate measures that should be taken to protect the health and ensure the
      safety of the staff that comes in close contact with patients who are suspected
      or confirmed of having COVID-19. How to cite this article: Karampelias V,
      Spanidis Y, Roussakou E. Ethical Issues in Intensive Care Units during the
      COVID-19 Pandemic. Indian J Crit Care Med 2020;24(9):855-856.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Karampelias, Vasileios
AU  - Karampelias V
AD  - Department of Surgery, School of Medicine, University of Patras, Patras, Greece.
FAU - Spanidis, Ypatios
AU  - Spanidis Y
AD  - Department of Surgery, School of Medicine, University of Patras, Patras, Greece.
FAU - Roussakou, Elpida
AU  - Roussakou E
AD  - Mediterranean College, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7584844
OTO - NOTNLM
OT  - Ethical issues
OT  - Intensive care unit
OT  - Surgical intensive care unit
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
CRDT- 2020/11/02 06:13
PHST- 2020/11/02 06:13 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
AID - 10.5005/jp-journals-10071-23543 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Sep;24(9):855-856. doi:
      10.5005/jp-journals-10071-23543.


PMID- 33132095
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 1877-0568 (Electronic)
IS  - 1877-0568 (Linking)
VI  - 106
IP  - 8
DP  - 2020 Dec
TI  - Rate of publication in predatory journals by orthopedic surgeons members of the
      French orthopedic and traumatology society (SOFCOT): A follow-up note.
PG  - 1457-1461
LID - S1877-0568(20)30292-9 [pii]
LID - 10.1016/j.otsr.2020.03.042 [doi]
AB  - BACKGROUND: France ranks 9th worldwide for scientific publication in orthopedics 
      and the increase in both the quantity and the quality of its scientific
      production has been described in detail. On the other hand, publishing by French 
      orthopedic surgeons in predatory journals is more obscure. The journals in
      question are difficult to identify but are based on an open-access model with
      article processing charges (APC), except in rare cases that are difficult to
      specify, as they are not stated at the time of submission. The increase in the
      number of predatory journals over the last 10 years led us to attempt to assess
      the rate at which French orthopedic surgeons publish in them, as revealed by
      investigation of the SIGAPS bibliometric database. HYPOTHESIS: Over the period
      2008-2017, the rate of publications by French orthopedic surgeons in predatory
      journals was less than 5%. MATERIAL AND METHOD: The SIGAPS database contains the 
      detail of publications by French orthopedic surgeons members of the French
      Society of Orthopedic Surgery and Traumatology (SoFCOT) and was used to analyse
      all such articles (journal article, review or editorial) so as to isolate
      articles with PubMed-Not-MEDLINE status falling in the SIGAPS non-classified (NC)
      category and to determine the predatory status of the journal using established
      lists, such as Beall's list or that drawn up by StopPredatoryJournals. In case of
      difficulty in determining predatory status, we applied the criteria defined by
      Beall and the Committee on Publication Ethics (COPE). RESULTS: Out of 6056
      articles in the SIGAPS database published by French orthopedic surgeons between
      2008 and 2017, 323 could be suspected of being published in a predatory journal, 
      but only 33 were so confirmed: i.e., 0.55% of French orthopedic scientific output
      over the study period. Eleven appeared in journals whose publishers were listed
      as predatory by Beall, 21 appeared in journals whose publishers had been listed
      as predatory on Beall's list in 2012 with the dubious editorial practices defined
      by Beall, and one article appeared in a journal found to be predatory on analysis
      of its editorial board. More than half of these articles (58%) were subject to
      APCs averaging $400. DISCUSSION: Despite a strong increase in the number of
      predatory journals over the last decade, very few French orthopedic surgeons
      resort to them to publish their work. Difficulty of identification and authors'
      lack of knowledge about this type of journals may account for some of these
      submissions. Scientific teams need to check certain criteria before submitting to
      a journal: short time to publication and low APC should be taken as warning
      signs, and any demand for payment after acceptance certainly raises the question 
      of the journal's predatory nature. LEVEL OF EVIDENCE: IV; retrospective study
      without control group.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Dartus, Julien
AU  - Dartus J
AD  - Universite de Lille Nord de France, 59000 Lille, France; Service d'orthopedie,
      CHU de Lille, Hopital Roger-Salengro, 59000 Lille, France. Electronic address:
      juliendartus@gmail.com.
FAU - Saab, Marc
AU  - Saab M
AD  - Universite de Lille Nord de France, 59000 Lille, France; Service d'orthopedie,
      CHU de Lille, Hopital Roger-Salengro, 59000 Lille, France.
FAU - Martinot, Pierre
AU  - Martinot P
AD  - Universite de Lille Nord de France, 59000 Lille, France; Service d'orthopedie,
      CHU de Lille, Hopital Roger-Salengro, 59000 Lille, France.
FAU - Putman, Sophie
AU  - Putman S
AD  - Universite de Lille Nord de France, 59000 Lille, France; Service d'orthopedie,
      CHU de Lille, Hopital Roger-Salengro, 59000 Lille, France.
FAU - Erivan, Roger
AU  - Erivan R
AD  - CNRS, SIGMA Clermont, ICCF, Universite Clermont-Auvergne, CHU Clermont-Ferrand,
      63000 Clermont-Ferrand, France.
FAU - Devos, Patrick
AU  - Devos P
AD  - Service d'orthopedie, CHU de Lille, Hopital Roger-Salengro, 59000 Lille, France; 
      University of Lille, CHU of Lille, ULR 2694-METRICS: evaluation des technologies 
      de sante et des pratiques medicales, 59000 Lille, France.
LA  - eng
PT  - Journal Article
DEP - 20201031
PL  - France
TA  - Orthop Traumatol Surg Res
JT  - Orthopaedics & traumatology, surgery & research : OTSR
JID - 101494830
SB  - IM
MH  - Follow-Up Studies
MH  - France
MH  - Humans
MH  - Orthopedic Surgeons
MH  - *Orthopedics
MH  - *Periodicals as Topic
MH  - Retrospective Studies
MH  - *Traumatology
OTO - NOTNLM
OT  - Bibliometrics
OT  - France
OT  - Impact factor
OT  - Predatory journal
OT  - Scientific literature
EDAT- 2020/11/03 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/11/02 05:39
PHST- 2020/02/16 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
PHST- 2020/11/02 05:39 [entrez]
AID - S1877-0568(20)30292-9 [pii]
AID - 10.1016/j.otsr.2020.03.042 [doi]
PST - ppublish
SO  - Orthop Traumatol Surg Res. 2020 Dec;106(8):1457-1461. doi:
      10.1016/j.otsr.2020.03.042. Epub 2020 Oct 31.


PMID- 33130836
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 41
IP  - 11
DP  - 2020 Nov
TI  - The emergence of new trends in clinical laboratory diagnosis.
PG  - 1175-1180
LID - 10.15537/smj.2020.11.25455 [doi]
AB  - Diagnostic processes typically rely on traditional and laborious methods, that
      are prone to human error, resulting in frequent misdiagnosis of diseases.
      Computational approaches are being increasingly used for more precise diagnosis
      of the clinical pathology, diagnosis of genetic and microbial diseases, and
      analysis of clinical chemistry data. These approaches are progressively used for 
      improving the reliability of testing, resulting in reduced diagnostic errors.
      Artificial intelligence (AI)-based computational approaches mostly rely on
      training sets obtained from patient data stored in clinical databases. However,
      the use of AI is associated with several ethical issues, including patient
      privacy and data ownership. The capacity of AI-based mathematical models to
      interpret complex clinical data frequently leads to data bias and reporting of
      erroneous results based on patient data. In order to improve the reliability of
      computational approaches in clinical diagnostics, strategies to reduce data bias 
      and analyzing real-life patient data need to be further refined.
FAU - Alaidarous, Mohammed A
AU  - Alaidarous MA
AD  - Department of Medical Laboratory Sciences, College of Applied Medical Sciences,
      Majmaah University, Majmaah, Kingdom of Saudi Arabia. E-mail.
      m.alaidarous@mu.edu.sa.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
SB  - IM
MH  - *Artificial Intelligence/ethics
MH  - Chemistry, Clinical
MH  - Clinical Laboratory Techniques/*methods/*trends
MH  - Confidentiality
MH  - Databases as Topic
MH  - Diagnostic Errors/*prevention & control
MH  - Humans
MH  - Models, Theoretical
MH  - Reproducibility of Results
PMC - PMC7804231
EDAT- 2020/11/02 06:00
MHDA- 2021/04/23 06:00
CRDT- 2020/11/01 20:42
PHST- 2020/11/01 20:42 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
AID - 10.15537/smj.2020.11.25455 [doi]
PST - ppublish
SO  - Saudi Med J. 2020 Nov;41(11):1175-1180. doi: 10.15537/smj.2020.11.25455.


PMID- 33130626
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 49
IP  - 5
DP  - 2020 Nov
TI  - The ethical and legal status of neurosurgical guidelines: the neurosurgeon's
      golden fleece or Achilles' heel?
PG  - E14
LID - 10.3171/2020.8.FOCUS20597 [doi]
LID - 2020.8.FOCUS20597 [pii]
AB  - Neurosurgical guidelines are fundamental for evidence-based practice and have
      considerably increased both in number and content over the last decades. Yet,
      guidelines in neurosurgery are not without limitations, as they are
      overwhelmingly based on low-level evidence. Such recommendations have in the past
      been occasionally overturned by well-designed randomized controlled trials
      (RCTs), demonstrating the volatility of poorly underpinned evidence. Furthermore,
      even RCTs in surgery come with several limitations; most notably, interventions
      are often insufficiently standardized and assume a homogeneous patient
      population, which is not always applicable to neurosurgery. Lastly, guidelines
      are often outdated by the time they are published and smaller fields such as
      neurosurgery may lack a sufficient workforce to provide regular updates. These
      limitations raise the question of whether it is ethical to use low-level evidence
      for guideline recommendations, and if so, how strictly guidelines should be
      adhered to from an ethical and legal perspective. This article aims to offer a
      critical approach to the ethical and legal status of guidelines in neurosurgery. 
      To this aim, the authors discuss: 1) the current state of neurosurgical
      guidelines and the evidence they are based on; 2) the degree of implementation of
      these guidelines; 3) the legal status of guidelines in medical disciplinary
      cases; and 4) the ethical balance between confident and critical use of
      guidelines. Ultimately, guidelines are neither laws that should always be
      followed nor purely academic efforts with little practical use. Every patient is 
      unique, and tailored treatment defined by the surgeon will ensure optimal care;
      guidelines play an important role in creating a solid base that can be adhered to
      or deviated from, depending on the situation. From a research perspective, it is 
      inevitable to rely on weaker evidence initially in order to generate more robust 
      evidence later, and clinician-researchers have an ethical duty to contribute to
      generating and improving neurosurgical guidelines.
FAU - Tewarie, Ishaan Ashwini
AU  - Tewarie IA
AD  - 1Computational Neurosciences Outcomes Center, Department of Neurosurgery, Brigham
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
AD  - 2Department of Neurosurgery, Haaglanden Medical Center, The Hague.
AD  - 3Department of Neurosurgery, Leiden Medical Center, Leiden.
FAU - Hulsbergen, Alexander F C
AU  - Hulsbergen AFC
AD  - 1Computational Neurosciences Outcomes Center, Department of Neurosurgery, Brigham
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
AD  - 2Department of Neurosurgery, Haaglanden Medical Center, The Hague.
AD  - 3Department of Neurosurgery, Leiden Medical Center, Leiden.
FAU - Volovici, Victor
AU  - Volovici V
AD  - 4Department of Neurosurgery, Erasmus Medical Center, Rotterdam; and.
AD  - 5Center for Medical Decision Making, Department of Public Health, Erasmus Medical
      Center, Rotterdam, The Netherlands.
FAU - Broekman, Marike L D
AU  - Broekman MLD
AD  - 1Computational Neurosciences Outcomes Center, Department of Neurosurgery, Brigham
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
AD  - 2Department of Neurosurgery, Haaglanden Medical Center, The Hague.
AD  - 3Department of Neurosurgery, Leiden Medical Center, Leiden.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
SB  - IM
MH  - Humans
MH  - *Neurosurgeons
MH  - *Neurosurgery
MH  - Neurosurgical Procedures
OTO - NOTNLM
OT  - *IONM = intraoperative neuromonitoring
OT  - *RCT = randomized controlled trial
OT  - *TBI = traumatic brain injury
OT  - *clinical practice guidelines
OT  - *ethics
OT  - *evidence-based medicine
OT  - *malpractice
OT  - *medicolegal environment
EDAT- 2020/11/02 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/11/01 20:41
PHST- 2020/06/30 00:00 [received]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/11/01 20:41 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.3171/2020.8.FOCUS20597 [doi]
AID - 2020.8.FOCUS20597 [pii]
PST - ppublish
SO  - Neurosurg Focus. 2020 Nov;49(5):E14. doi: 10.3171/2020.8.FOCUS20597.


PMID- 33130625
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 49
IP  - 5
DP  - 2020 Nov
TI  - Medical malpractice in spine surgery: a review.
PG  - E16
LID - 10.3171/2020.8.FOCUS20602 [doi]
LID - 2020.8.FOCUS20602 [pii]
AB  - Medical malpractice is an important but often underappreciated topic within
      neurosurgery, particularly for surgeons in the early phases of practice. The
      practice of spinal neurosurgery involves substantial risk for litigation, as both
      the natural history of the conditions being treated and the operations being
      performed almost always carry the risk of permanent damage to the spinal cord or 
      nerve roots, a cardiopulmonary event, death, or other dire outcomes. In this
      review, the authors discuss important topics related to medical malpractice in
      spine surgery, including tort reform, trends and frequency of litigation claims
      in spine surgery, wrong-level and wrong-site surgery, catastrophic outcomes
      including spinal cord injury and death, and ethical considerations.
FAU - Medress, Zachary A
AU  - Medress ZA
FAU - Jin, Michael C
AU  - Jin MC
FAU - Feng, Austin
AU  - Feng A
FAU - Varshneya, Kunal
AU  - Varshneya K
FAU - Veeravagu, Anand
AU  - Veeravagu A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
SB  - IM
MH  - Humans
MH  - *Malpractice
MH  - *Neurosurgery
MH  - Neurosurgical Procedures/adverse effects
MH  - Spine
MH  - *Surgeons
OTO - NOTNLM
OT  - *CES = cauda equina syndrome
OT  - *JC = Joint Commission on Accreditation of Healthcare Organizations
OT  - *UK = United Kingdom
OT  - *UP = Universal Protocol
OT  - *ethics
OT  - *medical malpractice
OT  - *medicolegal
OT  - *spine surgery
OT  - *tort reform
EDAT- 2020/11/02 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/11/01 20:41
PHST- 2020/06/30 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/11/01 20:41 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.3171/2020.8.FOCUS20602 [doi]
AID - 2020.8.FOCUS20602 [pii]
PST - ppublish
SO  - Neurosurg Focus. 2020 Nov;49(5):E16. doi: 10.3171/2020.8.FOCUS20602.


PMID- 33130611
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 49
IP  - 5
DP  - 2020 Nov
TI  - Informed consent in neurosurgery: a systematic review.
PG  - E6
LID - 10.3171/2020.8.FOCUS20611 [doi]
LID - 2020.8.FOCUS20611 [pii]
AB  - OBJECTIVE: Informed consent has served as a main principle of medical ethics and 
      laws in the United States. The 1986 American Association of Neurological Surgeons
      Code of Ethics implied medicolegal liability for the failure to obtain informed
      consent without providing practical guidance regarding the application of
      informed consent to individual patient encounters in a medicolegal environment.
      Here, the authors aimed to identify baseline patient recall after discussions
      with neurosurgeons and their capacity to provide informed consent, describe the
      effects of interventions to improve patient comprehension, and elucidate the role
      of informed consent in malpractice litigation in neurosurgery. Their findings may
      guide neurosurgeons in discussions to properly inform patients and reduce the
      risk of litigation. METHODS: A systematic review was conducted to explore
      informed consent within neurosurgery and its application to medicolegal liability
      using the PubMed, Embase, and Scopus databases. Titles and abstracts from
      articles identified in the search were read and selected for full-text review.
      Studies meeting prespecified inclusion criteria were reviewed in full and
      analyzed for study design, aim, population, interventions, and outcomes. RESULTS:
      Of 1428 resultant articles, 21 were included in the review. Baseline patient
      recall was low, particularly for risks and alternatives of treatments, and even
      decreased over time. Cognitive impairment was noted as a factor limiting the
      ability to provide informed consent. Interventions incorporating a combination of
      modalities in informed consent discussions, a specialized consent form with
      points for neurosurgeons to check off upon discussion, interactive websites,
      question prompt lists, and illustrations were found to be effective in improving 
      patient knowledge. Lack of informed consent was a common factor for malpractice
      litigation. Spine surgery was particularly prone to costly lawsuits. Payments
      were generally greater for plaintiff verdicts than for settlements. CONCLUSIONS: 
      The application of informed consent to patient encounters is an important facet
      of clinical practice. Neurosurgeons have a duty to provide patients with all
      pertinent information to allow them to make decisions about their care. The
      authors examined baseline patient comprehension and capacity, interventions to
      improve informed consent, and malpractice litigation; it appears that determining
      the proper capacity to provide informed consent and considering informed consent 
      as a process that depends on the setting are important. There is room to improve 
      the informed consent process centered on baseline patient health literacy and
      understanding as well as clear communication using multiple modalities.
FAU - Shlobin, Nathan A
AU  - Shlobin NA
AD  - 1Department of Neurological Surgery, Northwestern University Feinberg School of
      Medicine, Division of Pediatric Neurosurgery, Anne and Robert H. Lurie Children's
      Hospital, Chicago.
FAU - Sheldon, Mark
AU  - Sheldon M
AD  - 2Department of Philosophy, Northwestern University, Evanston; and.
AD  - 3Center for Bioethics and Medical Humanities, Northwestern University Feinberg
      School of Medicine, Chicago, Illinois.
FAU - Lam, Sandi
AU  - Lam S
AD  - 1Department of Neurological Surgery, Northwestern University Feinberg School of
      Medicine, Division of Pediatric Neurosurgery, Anne and Robert H. Lurie Children's
      Hospital, Chicago.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
SB  - IM
MH  - Humans
MH  - Informed Consent
MH  - *Malpractice
MH  - Neurosurgeons
MH  - *Neurosurgery
MH  - Neurosurgical Procedures
MH  - United States
OTO - NOTNLM
OT  - *decision-making
OT  - *informed consent
OT  - *medical malpractice
OT  - *medicolegal
OT  - *neurosurgery
EDAT- 2020/11/02 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/11/01 20:41
PHST- 2020/07/01 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/11/01 20:41 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.3171/2020.8.FOCUS20611 [doi]
AID - 2020.8.FOCUS20611 [pii]
PST - ppublish
SO  - Neurosurg Focus. 2020 Nov;49(5):E6. doi: 10.3171/2020.8.FOCUS20611.


PMID- 33130572
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 31
TI  - Health service needs and perspectives of remote forest communities in Papua New
      Guinea: study protocol for combined clinical and rapid anthropological
      assessments with parallel treatment of urgent cases.
PG  - e041784
LID - 10.1136/bmjopen-2020-041784 [doi]
AB  - INTRODUCTION: Our project follows community requests for health service
      incorporation into conservation collaborations in the rainforests of Papua New
      Guinea (PNG). This protocol is for health needs assessments, our first step in
      coplanning medical provision in communities with no existing health data. METHODS
      AND ANALYSIS: The study includes clinical assessments and rapid anthropological
      assessment procedures (RAP) exploring the health needs and perspectives of
      partner communities in two areas, conducted over 6 weeks fieldwork. First, in
      Wanang village (population c.200), which is set in lowland rainforest. Second, in
      six communities (population c.3000) along an altitudinal transect up the highest 
      mountain in PNG, Mount Wilhelm. Individual primary care assessments incorporate
      physical examinations and questioning (providing qualitative and quantitative
      data) while RAP includes focus groups, interviews and field observations
      (providing qualitative data). Given absence of in-community primary care,
      treatments are offered alongside research activity but will not form part of the 
      study. Data are collected by a research fellow, primary care clinician and two
      PNG research technicians. After quantitative and qualitative analyses, we will
      report: ethnoclassifications of disease, causes, symptoms and perceived
      appropriate treatment; community rankings of disease importance and service
      needs; attitudes regarding health service provision; disease burdens and
      associations with altitudinal-related variables and cultural practices. To aid
      wider use study tools are in online supplemental file, and paper and ODK versions
      are available free from the corresponding author. ETHICS AND DISSEMINATION:
      Challenges include supporting informed consent in communities with low literacy
      and diverse cultures, moral duties to provide treatment alongside research in
      medically underserved areas while minimising risks of therapeutic misconception
      and inappropriate inducement, and PNG research capacity building. Brighton and
      Sussex Medical School (UK), PNG Institute of Medical Research and PNG Medical
      Research Advisory Committee have approved the study. Dissemination will be via
      journals, village meetings and plain language summaries.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Middleton, Jo
AU  - Middleton J
AUID- ORCID: 0000-0001-5951-6608
AD  - Primary Care and Public Health, and NIHR Global Health Research Unit on Neglected
      Tropical Diseases, Brighton and Sussex Medical School, Falmer, UK
      J.Middleton@bsms.ac.uk.
AD  - Evolution, behaviour and environment, School of Life Sciences, University of
      Sussex, Falmer, UK.
FAU - Abdad, Mohammad Yazid
AU  - Abdad MY
AD  - Papua New Guinea Institute of Medical Research, Goroka/Madang, Papua New Guinea.
AD  - Infectious Disease Research Laboratory, National Centre for Infectious Diseases, 
      Singapore.
FAU - Beauchamp, Emilie
AU  - Beauchamp E
AD  - International Institute for Environment and Development, London, UK.
FAU - Colthart, Gavin
AU  - Colthart G
AD  - Primary Care and Public Health, Brighton and Sussex Medical School, Falmer, UK.
AD  - Medicine, James Cook University, Townsville, North Queensland, Australia.
FAU - Cooper, Maxwell J F
AU  - Cooper MJF
AD  - Primary Care and Public Health, Brighton and Sussex Medical School, Falmer, UK.
FAU - Dem, Francesca
AU  - Dem F
AD  - New Guinea Binatang Research Centre, Nagada, Papua New Guinea.
FAU - Fairhead, James
AU  - Fairhead J
AD  - Anthropology, School of Global Studies, University of Sussex, Falmer, UK.
FAU - Grundy, Caroline L
AU  - Grundy CL
AD  - Sussex Sustainability Research Programme, University of Sussex, Falmer, UK.
FAU - Head, Michael G
AU  - Head MG
AD  - Faculty of Medicine and Global Health Research Institute, University of
      Southampton, Southampton, UK.
FAU - Inacio, Joao
AU  - Inacio J
AD  - School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton,
      UK.
AD  - Global Health and Tropical Medicine, New University of Lisbon Institute of
      Hygiene and Tropical Medicine, Lisboa, Portugal.
FAU - Jimbudo, Mavis
AU  - Jimbudo M
AD  - New Guinea Binatang Research Centre, Nagada, Papua New Guinea.
FAU - Jones, Christopher Iain
AU  - Jones CI
AUID- ORCID: 0000-0001-7065-1157
AD  - Medical Statistics, Brighton and Sussex Medical School, Falmer, UK.
FAU - Konecna, Martina
AU  - Konecna M
AD  - Zoology, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech
      Republic.
FAU - Laman, Moses
AU  - Laman M
AD  - Papua New Guinea Institute of Medical Research, Goroka/Madang, Papua New Guinea.
FAU - MacGregor, Hayley
AU  - MacGregor H
AD  - Institute of Development Studies, Falmer, UK.
FAU - Novotny, Vojtech
AU  - Novotny V
AD  - Zoology, Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech
      Republic.
AD  - Ecology, Biology Centre, Institute of Entomology, Ceske Budejovice, Czech
      Republic.
FAU - Peck, Mika
AU  - Peck M
AD  - Evolution, behaviour and environment, School of Life Sciences, University of
      Sussex, Falmer, UK.
FAU - Paliau, Jason
AU  - Paliau J
AD  - New Guinea Binatang Research Centre, Nagada, Papua New Guinea.
FAU - Philip, Jonah
AU  - Philip J
AD  - New Guinea Binatang Research Centre, Nagada, Papua New Guinea.
FAU - Pomat, Willie
AU  - Pomat W
AD  - Papua New Guinea Institute of Medical Research, Goroka/Madang, Papua New Guinea.
FAU - Roberts, Chrissy H
AU  - Roberts CH
AD  - Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
FAU - Sui, Shen
AU  - Sui S
AD  - New Guinea Binatang Research Centre, Nagada, Papua New Guinea.
FAU - Stewart, Alan J
AU  - Stewart AJ
AD  - Evolution, behaviour and environment, School of Life Sciences, University of
      Sussex, Falmer, UK.
FAU - Walker, Stephen L
AU  - Walker SL
AUID- ORCID: 0000-0002-2034-8376
AD  - Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
AD  - Hospital for Tropical Diseases and Department of Dermatology, University College 
      London Hospitals NHS Foundation Trust, London, UK.
FAU - Cassell, Jackie A
AU  - Cassell JA
AUID- ORCID: 0000-0003-0777-0385
AD  - Primary Care and Public Health, and NIHR Global Health Research Unit on Neglected
      Tropical Diseases, Brighton and Sussex Medical School, Falmer, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201031
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Dec 10;10(12):e041784corr1. PMID: 33303473
MH  - Anthropology, Cultural
MH  - Forests
MH  - *Health Services
MH  - Humans
MH  - Needs Assessment
MH  - Papua New Guinea
MH  - Rural Health
PMC - PMC7733180
OTO - NOTNLM
OT  - *anthropology
OT  - *epidemiology
OT  - *primary care
OT  - *protocols & guidelines
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/11/02 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/11/01 20:40
PHST- 2020/11/01 20:40 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-041784 [pii]
AID - 10.1136/bmjopen-2020-041784 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 31;10(10):e041784. doi: 10.1136/bmjopen-2020-041784.


PMID- 33130571
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 31
TI  - Effect of backward walking training on knee osteoarthritis: protocol of a
      systematic review and meta-analysis.
PG  - e040726
LID - 10.1136/bmjopen-2020-040726 [doi]
AB  - INTRODUCTION: Backward walking (BW) is otherwise known as retrowalking. As
      opposed to forward walking, BW is a countersequential exercise and is a common
      method of rehabilitation training and disease-assisted treatment. Studies have
      shown that BW has a helpful effect on improving lower limb proprioception, gait
      synergy and improving limb balance. Many studies have concluded that BW can
      improve the symptoms of patients with knee osteoarthritis (KOA) and can be used
      for rehabilitation and adjunctive treatment of KOA, but there is a lack of
      evidence-based medical evidence.This research aims to provide an update to the
      most recent available evidence on the effect of BW on patients with KOA . METHODS
      AND ANALYSES: Electronic databases, such as Ovid/MEDLINE, EMBASE, CINAHL, Scopus,
      Web of Science and PubMed, will be searched by us. We will include studies
      identified from citation until 12 May 2020 and will not be restricted by
      geographical setting. The search will not be limited to the language of the
      publication, but the study of human subjects. Randomised controlled trials (RCTs)
      on the BW training of KOA will be included, with outcome measures including pain,
      knee function or balance function. The quality of included RCTs will be evaluated
      according to the Cochrane Collaboration's risk of bias tool. A meta-analysis or
      systematic review will be performed to summarise the effects of BW training. We
      will perform sensitivity analysis on the sample size of RCTs, meta-regression
      analysis of the follow-up periods, dosages and baselines of outcome measures, and
      publication bias analysis. ETHICS AND DISSEMINATION: Ethical approval is not
      required as this study will not involve confidential personal data. The results
      of this study will be disseminated through a peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42020185694.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wu, Yuxuan
AU  - Wu Y
AD  - Department of Orthopedics, People's Hospital of Deyang City, Deyang, China.
FAU - Lei, Cheng
AU  - Lei C
AUID- ORCID: 0000-0003-1311-515X
AD  - Department of Orthopedics, People's Hospital of Deyang City, Deyang, China
      lifecool_lc@163.com 2081322034@qq.com.
FAU - Huangfu, Zhimin
AU  - Huangfu Z
AD  - College of Basic Medical Sciences, Chongqing Medical University, Chongqing,
      China.
FAU - Sunzi, Kejimu
AU  - Sunzi K
AD  - Department of Orthopedics, People's Hospital of Deyang City, Deyang, China.
FAU - Yang, Changmei
AU  - Yang C
AD  - Department of Neurosurgery, The Affiliated Hospital of Southwest Medical
      University, Luzhou, China lifecool_lc@163.com 2081322034@qq.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201031
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Exercise
MH  - Exercise Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Osteoarthritis, Knee/therapy
MH  - Proprioception
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - *Walking
PMC - PMC7783601
OTO - NOTNLM
OT  - *knee
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/02 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/11/01 20:40
PHST- 2020/11/01 20:40 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-040726 [pii]
AID - 10.1136/bmjopen-2020-040726 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 31;10(10):e040726. doi: 10.1136/bmjopen-2020-040726.


PMID- 33130570
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 31
TI  - Exercise training in the treatment of paroxysmal atrial fibrillation: study
      protocol of the Cologne ExAfib Trial.
PG  - e040054
LID - 10.1136/bmjopen-2020-040054 [doi]
AB  - INTRODUCTION: Atrial fibrillation (AF) is the most common form of cardiac
      arrhythmia and is associated with a number of comorbidities such as coronary
      artery disease and heart failure. While physical activity is already implemented 
      in current international guidelines for the prevention and treatment of AF, the
      precise role of different types of exercise in the management of AF remains to be
      elucidated. The primary aim of the Cologne ExAfib Trial is to assess the
      feasibility and safety of different exercise modes in patients diagnosed with
      paroxysmal AF. Secondary outcomes include assessments of physical function, AF
      burden, quality of life and inflammation, as well as morphological and cardiac
      adaptations. METHODS AND ANALYSIS: The study opened for recruitment in September 
      2019. In the initial pilot phase of this four-armed randomised controlled trial, 
      we aim to enrol 60 patients between 60 years and 80 years of age with paroxysmal 
      AF. After screening and pretesting, patients are randomised into one of the
      following groups: high-intensity interval training (4x4 min at 75%-85% peak power
      output (PPO)), moderate-intensity continuous training (25 min at 55%-65% PPO),
      strength training (whole body, 3 sets of 6-12 repetitions at 70%-90% one
      repetition maximum [1RM]) or a usual-care control group. Training is performed
      two times per week for 12 weeks. If the feasibility and safety can be confirmed
      through the initial pilot phase, the recruitment will be continued and powered
      for a clinical endpoint.Feasibility and safety are assessed by measures of
      recruitment and completion, programme tolerance and adherence as well as reported
      adverse events, including hospitalisation rates. Secondary endpoints are assessed
      by measures of peak oxygen consumption and the 1RM of selected muscle groups,
      questionnaires concerning quality of life and AF burden, serum blood samples for 
      the analysis of C reactive protein, interleukin-6, tumour necrosis factor alpha
      and N-terminal pro-brain natriuretic peptide concentrations and ultrasound for
      muscle and heart morphology as well as cardiac function. ETHICS AND
      DISSEMINATION: Ethics approval was obtained from the ethics committee of the
      German Sport University Cologne (No.: 175/2018). All procedures performed in
      studies involving human participants are in accordance with the ethical standards
      of the institutional and/or national research committee and with the 1964
      Declaration of Helsinki and its later amendments or comparable ethical standards.
      Manuscripts will be written based on international authorship guidelines. No
      professional writers will be commissioned for manuscript drafting. The findings
      of this study will be published in peer-reviewed journals and presented at
      leading exercise and medicine conferences TRIAL REGISTRATION NUMBER: The study is
      registered both at the German and at the WHO trial registers (DRKS00016637);
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zacher, Jonas
AU  - Zacher J
AD  - Department of Preventive and Rehabilitative Sports Medicine, Institute of
      Cardiovascular Research and Sports Medicine, German Sport University, Cologne,
      Germany j.zacher@dshs-koeln.de.
FAU - Dillschnitter, Katrin
AU  - Dillschnitter K
AUID- ORCID: 0000-0002-0842-9886
AD  - Department of Preventive and Rehabilitative Sports Medicine, Institute of
      Cardiovascular Research and Sports Medicine, German Sport University, Cologne,
      Germany.
FAU - Freitag, Nils
AU  - Freitag N
AD  - Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular
      Research and Sports Medicine, German Sport University, Cologne, Germany.
FAU - Kreutz, Thorsten
AU  - Kreutz T
AD  - IST University of Applied Sciences, Dusseldorf, Germany.
FAU - Bjarnason-Wehrens, Birna
AU  - Bjarnason-Wehrens B
AD  - Department of Preventive and Rehabilitative Sports Medicine, Institute of
      Cardiovascular Research and Sports Medicine, German Sport University, Cologne,
      Germany.
FAU - Bloch, Wilhelm
AU  - Bloch W
AD  - Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular
      Research and Sports Medicine, German Sport University, Cologne, Germany.
FAU - Predel, Hans-Georg
AU  - Predel HG
AD  - Department of Preventive and Rehabilitative Sports Medicine, Institute of
      Cardiovascular Research and Sports Medicine, German Sport University, Cologne,
      Germany.
FAU - Schumann, Moritz
AU  - Schumann M
AD  - Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular
      Research and Sports Medicine, German Sport University, Cologne, Germany.
LA  - eng
SI  - DRKS/DRKS00016637
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201031
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adaptation, Physiological
MH  - *Atrial Fibrillation/therapy
MH  - *Cardiac Rehabilitation
MH  - Exercise
MH  - *Exercise Therapy
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7783621
OTO - NOTNLM
OT  - *adult cardiology
OT  - *atrial fibrillation
OT  - *echocardiography
OT  - *medical education & training
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/11/02 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/11/01 20:40
PHST- 2020/11/01 20:40 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-040054 [pii]
AID - 10.1136/bmjopen-2020-040054 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 31;10(10):e040054. doi: 10.1136/bmjopen-2020-040054.


PMID- 33130569
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 31
TI  - Study protocol of a pilot study evaluating feasibility and acceptability of a
      psychosexual intervention for couples postallogeneic haematopoietic stem cell
      transplantation.
PG  - e039300
LID - 10.1136/bmjopen-2020-039300 [doi]
AB  - INTRODUCTION: Sexual dysfunction is one of the most common side effects of
      allogeneic haematopoietic stem cell transplantation (HSCT) for haematological
      cancers. Problems can persist between 5 and 10 years post-transplant and impact
      mood, couple intimacy and relationship satisfaction. Few intervention studies,
      however, target sexual dysfunction in patients post-HSCT. This pilot study aims
      to examine the feasibility and acceptability of implementing a psychosexual
      intervention for HSCT survivors and their partners post-transplantation. METHODS 
      AND ANALYSIS: Fifteen allogeneic HSCT survivors and their partners will be
      recruited. Patients who are more than 3 months post-transplantation will be sent 
      invitation letters describing the couples' psychosexual intervention that will be
      offered through this study. The intervention will comprise two components: (1)
      psychosexual education about medical and behavioural treatment options for sexual
      dysfunction delivered by a haematology nurse consultant; (2) emotionally focused 
      therapy-based relationship education programme for couples delivered by a
      clinical psychologist (four sessions of 1.5 hours each). Couples who consent to
      participate will be administered a series of measures assessing mood,
      relationship satisfaction and sexual dysfunction preintervention and
      post-intervention, as well as satisfaction with the intervention
      postintervention. Feasibility of the intervention will be examined via recording 
      enrolment rate, adherence, compliance with completing outcome measures and
      fidelity of intervention delivery. ETHICS AND DISSEMINATION: Ethics approval has 
      been obtained at the Peter MacCallum Cancer Centre in Melbourne, Australia.
      Results will be presented at national and international conferences and published
      in a peer-reviewed journal so that in can be accessed by clinicians involved in
      the care of allogeneic HSCT patients. If this intervention is found to be
      feasible and acceptable, its impact will be examined in a future randomised
      controlled trial and subsequently implemented as part of routine care in the
      allogeneic HSCT population.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pillay, Brindha
AU  - Pillay B
AUID- ORCID: 0000-0002-2142-1002
AD  - Psychosocial Oncology Program, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia brindha.pillay@petermac.org.
FAU - Ftanou, Maria
AU  - Ftanou M
AD  - Psychosocial Oncology Program, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Ritchie, David
AU  - Ritchie D
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal
      Melbourne Hospital, Melbourne, Victoria, Australia.
FAU - Panek-Hudson, Yvonne
AU  - Panek-Hudson Y
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal
      Melbourne Hospital, Melbourne, Victoria, Australia.
FAU - Jefford, Michael
AU  - Jefford M
AD  - Australian Cancer Survivorship Centre, Peter MacCallum Cancer Centre, Melbourne, 
      Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Garcia, Teresa
AU  - Garcia T
AD  - Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal
      Melbourne Hospital, Melbourne, Victoria, Australia.
FAU - Shields, Cassandra
AU  - Shields C
AD  - School of Psychology, University of Queensland, Brisbane, Queensland, Australia.
AD  - The Australian Centre for Emotionally Focused Therapy, Brisbane, Queensland,
      Australia.
FAU - Gniel, Jo
AU  - Gniel J
AD  - Landscape of Life, Melbourne, Victoria, Australia.
FAU - Phipps-Nelson, Jo
AU  - Phipps-Nelson J
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Cancer Experiences Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, 
      Australia.
FAU - Drosdowsky, Allison
AU  - Drosdowsky A
AD  - Cancer Experiences Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, 
      Australia.
FAU - Blaschke, Sarah
AU  - Blaschke S
AD  - Cancer Experiences Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, 
      Australia.
FAU - Ellen, Steve
AU  - Ellen S
AD  - Psychosocial Oncology Program, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201031
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Feasibility Studies
MH  - Hematologic Neoplasms/therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Pilot Projects
MH  - *Sexual Dysfunction, Physiological
MH  - Survivors
PMC - PMC7783613
OTO - NOTNLM
OT  - *bone marrow transplantation
OT  - *oncology
OT  - *sexual dysfunction
COIS- Competing interests: None declared.
EDAT- 2020/11/02 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/11/01 20:40
PHST- 2020/11/01 20:40 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-039300 [pii]
AID - 10.1136/bmjopen-2020-039300 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 31;10(10):e039300. doi: 10.1136/bmjopen-2020-039300.


PMID- 33130566
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 31
TI  - Adaptation and piloting of an integrated intervention model for alcohol use
      disorders in primary healthcare in rural Tanzania: a study protocol.
PG  - e038615
LID - 10.1136/bmjopen-2020-038615 [doi]
AB  - INTRODUCTION: Integration of evidence-based interventions for alcohol use
      disorders (AUDs) into primary healthcare has potential to increase coverage and
      reduce population burden. However, these interventions are rarely implemented in 
      low- and middle-income countries and there is little existing guidance on how
      this could be achieved. The aim of the proposed study is to adapt and pilot an
      integrated model for AUDs in Tanzanian primary healthcare. METHODS AND ANALYSIS: 
      The study design will include a situational analysis, a qualitative study, a
      series of participatory Theory of Change (ToC) workshops and pilot intervention
      study. The evidence-based packages of care for AUD from the WHO mental health Gap
      Intervention Guide will form the basis of intervention. The situation analysis
      will use publicly available data to identify existing resources and system
      functioning. In-depth interviews will be conducted with key stakeholders (people 
      with lived experience of substance use problems, health workers, health planners 
      and community-based organisations) to identify barriers and facilitators to
      integration and recommended implementation strategies. Thematic analysis will be 
      used. Triangulation of findings will inform the ToC map for the adapted model of 
      integrated services for AUDs. This model will then be piloted. Change in
      knowledge, skills and attitudes of health workers will be measured
      pre-implementation and post-implementation. Interrupted time series analysis will
      be used to identify change in the rate of identification of AUDs beyond that
      observed due to secular trends or by chance. The integrated model will be
      finalised for future implementation and larger-scale evaluation. ETHICS AND
      DISSEMINATION: Ethical approval was obtained from Addis Ababa University College 
      of Health Science Institutional Review Board and Muhimbili University of Health
      and Allied Sciences Institutional Review Board. Findings will be disseminated to 
      inform strategies for scale up of integrated interventions for people with AUDs
      in Tanzania and similar contexts.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mushi, Dorothy Peter
AU  - Mushi DP
AUID- ORCID: 0000-0003-3659-0957
AD  - Department of Psychiatry and Mental Health, School of Medicine,Muhimbili
      University of Health and Allied Sciences, Dar es Salaam, Tanzania
      dorrymush@yahoo.com.
AD  - Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and
      Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa
      University, Addis Ababa, Ethiopia.
AD  - Centre for Innovative Drug Development and Therapeutics Trial for Africa
      (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa,
      Ethiopia.
FAU - Hanlon, Charlotte
AU  - Hanlon C
AUID- ORCID: 0000-0002-7937-3226
AD  - Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and
      Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa
      University, Addis Ababa, Ethiopia.
AD  - Centre for Innovative Drug Development and Therapeutics Trial for Africa
      (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa,
      Ethiopia.
AD  - Centre for Global Mental Health, Institute of Psychiatry, Psychology and
      Neuroscience, King's College London, London, UK.
FAU - Francis, Joel Msafiri
AU  - Francis JM
AUID- ORCID: 0000-0003-1902-2683
AD  - Department of Family Medicine and Primary Care, School of Clinical Medicine,
      Faculty of Health Sciences, University of the Witwatersrand, Johannesburg South
      Africa, Johannesburg, South Africa.
AD  - Department of Epidemiology and Biostatistics, Muhimbili University of Health and 
      Allied Sciences, Dar es Salaam, Tanzania, United Republic of.
FAU - Teferra, Solomon
AU  - Teferra S
AD  - Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and
      Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa
      University, Addis Ababa, Ethiopia.
AD  - Department of Epidemiology, Harvard, Harvard T.H. Chan School of Public Health,
      Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201031
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Alcoholism/therapy
MH  - Cross-Sectional Studies
MH  - Ethiopia
MH  - Female
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - *Primary Health Care
MH  - Tanzania
PMC - PMC7783617
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *mental health
OT  - *primary care
OT  - *psychiatry
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/11/02 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/11/01 20:40
PHST- 2020/11/01 20:40 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-038615 [pii]
AID - 10.1136/bmjopen-2020-038615 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 31;10(10):e038615. doi: 10.1136/bmjopen-2020-038615.


PMID- 33130558
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 31
TI  - Reference architectures for ambient assisted living: a scoping review protocol.
PG  - e033758
LID - 10.1136/bmjopen-2019-033758 [doi]
AB  - INTRODUCTION: For the first time in human history, the number of older people
      will be higher than the number of children. The prevalence of chronic diseases,
      such as hypertension, cardiovascular disease, diabetes and mental disorders in
      older adults is high. Given that, it is essential to make usage of related
      technology to provide improved health conditions and reduce the costs for
      promoting ageing in place, and that is precisely the aim of Ambient Assisted
      Living technology. Considering that these systems provide significant benefit to 
      a vast number of stakeholders, can be applied to the functional diversity of
      application domains and have high economic and social impacts, it is essential to
      create reusable and interoperable platforms and standards that are able to deal
      with the heterogeneity of applications and domains. In this sense, reference
      architectures have been proposed and evaluated. A comprehensive scoping review
      concerning the reference architectures must clarify specific aspects, such as
      what the main domains are and how the solutions effectively deal with them.
      METHODS: This scoping review will follow the methodology framework defined in
      'Scoping studies: advancing the methodology'. In this methodological framework,
      six stages are proposed for scoping review studies: identifying the research
      question; identifying relevant studies; study selection; charting the data;
      collating, summarising and reporting the results; and consultation. The research 
      questions aim to investigate what are the motivations, stakeholders, benefits,
      domains, approaches, architectural components and governance aspects of the
      proposed reference architectures and models. The team will focus on the Scopus
      Document Search, PubMed (MEDLINE), IEEE Xplore Digital Library, ACM Digital
      Library and Science Direct electronic research databases. The search query is a
      combination of terms related to Ambient Assisted Living AND Reference
      Architecture. ETHICS AND DISSEMINATION: This is a scoping review study and there 
      is no requirement for ethical approval, as primary data will not be collected.
      The results from this scoping review will be published in a peer-reviewed journal
      and reported at scientific meetings. We intend to share the results with the
      International Standards and Conformity Assessment - SyC AAL from Canada to use
      the review as a basis for establishing an assessment model of reference
      architectures.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bublitz, Frederico
AU  - Bublitz F
AUID- ORCID: 0000-0003-1711-5392
AD  - Department of Computing, State University of Paraiba, Campina Grande, Brazil.
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Sahota, Naman K
AU  - Sahota NK
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Oetomo, Arlene
AU  - Oetomo A
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Fadrique, Laura
AU  - Fadrique L
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Morita, Plinio P
AU  - Morita PP
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada plinio.morita@uwaterloo.ca.
LA  - eng
PT  - Journal Article
DEP - 20201031
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Ambient Intelligence
MH  - Canada
MH  - Child
MH  - Humans
MH  - Independent Living
MH  - *Mental Disorders
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7783615
OTO - NOTNLM
OT  - *AAL
OT  - *ambient assisted living
OT  - *independent living
OT  - *old age assistance
OT  - *reference architecture
OT  - *scoping review
COIS- Competing interests: None declared.
EDAT- 2020/11/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/11/01 20:40
PHST- 2020/11/01 20:40 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033758 [pii]
AID - 10.1136/bmjopen-2019-033758 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 31;10(10):e033758. doi: 10.1136/bmjopen-2019-033758.


PMID- 33130325
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1724-191X (Electronic)
IS  - 1120-1797 (Linking)
VI  - 79
DP  - 2020 Nov
TI  - X-rays for medical imaging: Radiation protection, governance and ethics over 125 
      years.
PG  - 47-64
LID - S1120-1797(20)30228-3 [pii]
LID - 10.1016/j.ejmp.2020.09.012 [doi]
AB  - Starting from Rontgen's discovery and the first radiograph of his wife's hand,
      the curtain was raised on a new technique with remarkable possibilities for
      contributing to human health. While growth in applications proceeded rapidly, it 
      was accompanied by significant harms to those involved and by inappropriate
      opportunistic application. This paper places the attempts to deal with the harms 
      and inappropriate activities side by side with the positive developments. It
      attempts a narrative on the development of medical radiation protection over the 
      125-year period and places it in the context of a commentary on governance and
      ethics. The substance of the narrative is based on the recommendations of ICRP as
      they developed and altered over time. The governance commentary is based on
      assessing the independence of ICRP and its attention to medical exposures. In
      terms of ethics, the recommendations at each stage are reviewed in the light of
      values that are deemed appropriate to both medical ethics and radiation
      protection. The paper, while celebrating Rontgen-125, also hopefully provides a
      perspective for discussion as ICRP's centenary in 2028 approaches. This is an
      important part of ensuring continued acceptance and confident use of X-Rays, and 
      helps underwrite the possibility of further developments in the area.
CI  - Copyright (c) 2020 Associazione Italiana di Fisica Medica. Published by Elsevier 
      Ltd. All rights reserved.
FAU - Malone, Jim
AU  - Malone J
AD  - School of Medicine, Trinity College Dublin, Dublin D02 NW44, Ireland. Electronic 
      address: jfmalone@tcd.ie.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201030
PL  - Italy
TA  - Phys Med
JT  - Physica medica : PM : an international journal devoted to the applications of
      physics to medicine and biology : official journal of the Italian Association of 
      Biomedical Physics (AIFB)
JID - 9302888
SB  - IM
MH  - Humans
MH  - *Radiation Protection
MH  - Radiography
MH  - X-Rays
OTO - NOTNLM
OT  - Ethics
OT  - Governance
OT  - Marie Curie
OT  - Radiation protection
EDAT- 2020/11/02 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/01 20:32
PHST- 2020/08/19 00:00 [received]
PHST- 2020/09/05 00:00 [revised]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/11/01 20:32 [entrez]
AID - S1120-1797(20)30228-3 [pii]
AID - 10.1016/j.ejmp.2020.09.012 [doi]
PST - ppublish
SO  - Phys Med. 2020 Nov;79:47-64. doi: 10.1016/j.ejmp.2020.09.012. Epub 2020 Oct 30.


PMID- 33130015
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2352-5568 (Electronic)
IS  - 2352-5568 (Linking)
VI  - 39
IP  - 6
DP  - 2020 Dec
TI  - French legal approach to patient consent in clinical research.
PG  - 883-885
LID - S2352-5568(20)30259-9 [pii]
LID - 10.1016/j.accpm.2020.10.012 [doi]
FAU - Toulouse, Elisabeth
AU  - Toulouse E
AD  - Magistrat de l'ordre judiciaire conseillere a la Cour d'Appel de Nimes, Chargee
      du contentieux de la premiere chambre civile, Cour d'Appel de Nimes, Avenue des
      arenes, 30000 Nimes, France; Comite de protection des personnes Sud Mediterranee 
      3, Site de Serre Cavalier, CHU de Nimes, Place du Pr Robert Debre, 30029 Nimes
      cedex 9, France.
FAU - Lafont, Brigitte
AU  - Lafont B
AD  - Direction de la Recherche Clinique et de l'Innovation, CHU de Nimes, Universite
      de Montpellier, Nimes, France. Electronic address: brigitte.lafont@chu-nimes.fr.
FAU - Granier, Sophie
AU  - Granier S
AD  - Direction de la Recherche Clinique et de l'Innovation, CHU de Nimes, Universite
      de Montpellier, Nimes, France.
FAU - Mcgurk, Gordon
AU  - Mcgurk G
AD  - Human Research Ethics Committee, Royal Brisbane and Women's Hospital, Butterfield
      St, Herston, QLD 4029, Australia.
FAU - Bazin, Jean-Etienne
AU  - Bazin JE
AD  - CHU de Clermont-Ferrand, Pole de Medecine Perioperatoire (MPO), F-63000
      Clermont-Ferrand, France, Universite Clermont Auvergne, F-63000 Clermont-Ferrand,
      France; CPP Sud Est 6, CHU de Clermont-Ferrand, Universite Clermont Auvergne,
      F-63000 Clermont-Ferrand, France.
LA  - eng
PT  - Letter
DEP - 20201028
PL  - France
TA  - Anaesth Crit Care Pain Med
JT  - Anaesthesia, critical care & pain medicine
JID - 101652401
SB  - IM
MH  - *Biomedical Research
MH  - France
MH  - Humans
MH  - *Informed Consent
OTO - NOTNLM
OT  - *Clinical research
OT  - *Consent
OT  - *Ethics
OT  - *France
OT  - *Law
EDAT- 2020/11/02 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/11/01 20:30
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/11/01 20:30 [entrez]
AID - S2352-5568(20)30259-9 [pii]
AID - 10.1016/j.accpm.2020.10.012 [doi]
PST - ppublish
SO  - Anaesth Crit Care Pain Med. 2020 Dec;39(6):883-885. doi:
      10.1016/j.accpm.2020.10.012. Epub 2020 Oct 28.


PMID- 33129719
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1879-307X (Electronic)
IS  - 1364-6613 (Linking)
VI  - 24
IP  - 12
DP  - 2020 Dec
TI  - Machine Thinking, Fast and Slow.
PG  - 1019-1027
LID - S1364-6613(20)30222-9 [pii]
LID - 10.1016/j.tics.2020.09.007 [doi]
AB  - Machines do not 'think fast and slow' in the sense that humans do in dual-process
      models of cognition. However, the people who create the machines may attempt to
      emulate or simulate these fast and slow modes of thinking, which will in turn
      affect the way end users relate to these machines. In this opinion article we
      consider the complex interplay in the way various stakeholders (engineers, user
      experience designers, regulators, ethicists, and end users) can be inspired,
      challenged, or misled by the analogy between the fast and slow thinking of humans
      and the Fast and Slow Thinking of machines.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Bonnefon, Jean-Francois
AU  - Bonnefon JF
AD  - Toulouse School of Economics (TSM-R), CNRS, Universite Toulouse Capitole,
      Toulouse, France. Electronic address: jean-francois.bonnefon@tse-fr.eu.
FAU - Rahwan, Iyad
AU  - Rahwan I
AD  - Center for Humans and Machines, Max-Planck Institute for Human Development,
      Berlin, Germany. Electronic address: rahwan@mpib-berlin.mpg.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201028
PL  - England
TA  - Trends Cogn Sci
JT  - Trends in cognitive sciences
JID - 9708669
SB  - IM
MH  - Humans
MH  - Machine Learning
MH  - *Technology
MH  - *Thinking
OTO - NOTNLM
OT  - *algorithm aversion
OT  - *artificial intelligence
OT  - *dual-process
OT  - *machine behavior
OT  - *machine ethics
OT  - *trust
EDAT- 2020/11/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/11/01 20:28
PHST- 2020/06/10 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/11/01 20:28 [entrez]
AID - S1364-6613(20)30222-9 [pii]
AID - 10.1016/j.tics.2020.09.007 [doi]
PST - ppublish
SO  - Trends Cogn Sci. 2020 Dec;24(12):1019-1027. doi: 10.1016/j.tics.2020.09.007. Epub
      2020 Oct 28.


PMID- 33129706
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 2212-0289 (Electronic)
IS  - 1865-9217 (Linking)
VI  - 158-159
DP  - 2020 Dec
TI  - Bonus agreements of senior physicians in Switzerland - A qualitative interview
      study.
PG  - 39-46
LID - S1865-9217(20)30139-2 [pii]
LID - 10.1016/j.zefq.2020.09.002 [doi]
AB  - In Switzerland a legal prohibition of volume-based bonus agreements has been
      initiated which is expected to take force at the beginning of 2021. Bonus
      agreements for physicians pose a risk to unbiased indication, possibly leading to
      over-, under- and misuse of medical care. In order to investigate physicians'
      perceptions of bonus agreements and reflect on them from an ethical point of
      view, we conducted a qualitative interview study with Swiss senior physicians.
      The remuneration system is complex and diverse so that the interviewed physicians
      were not always able to explain in detail to which targets the variable
      components of their salary were linked. Study participants were aware of their
      ethical responsibility regarding non-biased indication and cost-effective
      medicine. All rejected volume-based bonus agreements. Target agreements should
      generally have a clear, comprehensible function and always contain a component
      related to the quality of care delivered. Critical attention should go beyond a
      narrow focus on volume-based bonus agreements to include other volume-oriented
      target agreements and reimbursement systems that have the potential to negatively
      affect patient care.
CI  - Copyright (c) 2020. Published by Elsevier GmbH.
FAU - Fassler, Margrit
AU  - Fassler M
AD  - Institute of Biomedical Ethics and History of Medicine (IBME), University of
      Zurich, Zurich, Switzerland.
FAU - Jobges, Susanne
AU  - Jobges S
AD  - Institute of Biomedical Ethics and History of Medicine (IBME), University of
      Zurich, Zurich, Switzerland.
FAU - Biller-Andorno, Nikola
AU  - Biller-Andorno N
AD  - Institute of Biomedical Ethics and History of Medicine (IBME), University of
      Zurich, Zurich, Switzerland. Electronic address: biller-andorno@ibme.uzh.ch.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Netherlands
TA  - Z Evid Fortbild Qual Gesundhwes
JT  - Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen
JID - 101477604
SB  - IM
MH  - Germany
MH  - Humans
MH  - *Medicine
MH  - *Physicians
MH  - Qualitative Research
MH  - Switzerland
OTO - NOTNLM
OT  - Bonus
OT  - Ethical issues
OT  - Ethics
OT  - Ethik
OT  - Qualitative Interviewstudie
OT  - Qualitative interview study
OT  - Resources
OT  - Ressourcen
OT  - Target agreements
OT  - Zielvereinbarungen
EDAT- 2020/11/02 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/11/01 20:28
PHST- 2020/04/22 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/11/01 20:28 [entrez]
AID - S1865-9217(20)30139-2 [pii]
AID - 10.1016/j.zefq.2020.09.002 [doi]
PST - ppublish
SO  - Z Evid Fortbild Qual Gesundhwes. 2020 Dec;158-159:39-46. doi:
      10.1016/j.zefq.2020.09.002. Epub 2020 Oct 29.


PMID- 33129607
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 50
DP  - 2020 Nov 25
TI  - A clinical perspective of the U.S. anti-vaccination epidemic: Considering
      marginal costs and benefits, CDC best practices guidelines, free riders, and herd
      immunity.
PG  - 7877-7879
LID - S0264-410X(20)31388-8 [pii]
LID - 10.1016/j.vaccine.2020.10.068 [doi]
FAU - Anderson, Michael G
AU  - Anderson MG
AD  - American College of Legal Medicine, Inc., Chicago, United States; University of
      Illinois College of Medicine, Chicago, Rockford, IL, United States; Magistrate
      Court of Cherokee County, GA, United States. Electronic address:
      mander10@uic.edu.
FAU - Ballinger, Eric A
AU  - Ballinger EA
AD  - Magistrate Court of Cherokee County, GA, United States.
FAU - Benjamin, David
AU  - Benjamin D
AD  - Northeastern University School of Pharmacy, Boston, MA, United States.
FAU - Frenkel, Lawrence D
AU  - Frenkel LD
AD  - University of Illinois College of Medicine, Chicago, Rockford, IL, United States.
FAU - Hinnant, C William Jr
AU  - Hinnant CW Jr
AD  - American College of Legal Medicine, Inc., Chicago, United States; Clemson
      University, Department of Public Health Sciences, Clemson, SC, United States;
      Limestone College, Department of Health Sciences, Gaffney, SC, United States.
FAU - Zucker, Karin W
AU  - Zucker KW
AD  - Baylor University, Hankamer School of Business, Army Med. Dept., Waco, TX, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
SB  - IM
MH  - Advisory Committees
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Cost-Benefit Analysis
MH  - *Epidemics
MH  - *Immunity, Herd
MH  - Immunization Schedule
MH  - United States/epidemiology
MH  - Vaccination
OTO - NOTNLM
OT  - *ACIP
OT  - *Anti-vaccination
OT  - *Bio-ethics
OT  - *Counter-marketing
OT  - *Empathy
OT  - *Free-riders
OT  - *Hesitant
OT  - *Immunization guidelines
OT  - *Public health
OT  - *Risk-selection incentives
OT  - *Vaccine performance ratio
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/11/02 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/11/01 20:27
PHST- 2020/05/26 00:00 [received]
PHST- 2020/10/18 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/11/01 20:27 [entrez]
AID - S0264-410X(20)31388-8 [pii]
AID - 10.1016/j.vaccine.2020.10.068 [doi]
PST - ppublish
SO  - Vaccine. 2020 Nov 25;38(50):7877-7879. doi: 10.1016/j.vaccine.2020.10.068. Epub
      2020 Oct 28.


PMID- 33129429
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 31
IP  - 11
DP  - 2020 Nov
TI  - Publishing Ethics and Misconduct in the Journal of Vascular and Interventional:
      Radiology: An Editor's Perspective.
PG  - 1792-1794
LID - S1051-0443(20)30812-5 [pii]
LID - 10.1016/j.jvir.2020.09.026 [doi]
FAU - Haskal, Ziv J
AU  - Haskal ZJ
AD  - Department of Radiology and Medical Imaging/Interventional Radiology, University 
      of Virginia School of Medicine, Charlottesville, VA. Electronic address:
      ziv1@mac.com.
LA  - eng
PT  - Editorial
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
SB  - IM
MH  - Biomedical Research/*ethics
MH  - Conflict of Interest
MH  - Duplicate Publications as Topic
MH  - *Editorial Policies
MH  - Humans
MH  - Periodicals as Topic/*ethics
MH  - Plagiarism
MH  - Radiography, Interventional/*ethics
MH  - Scientific Misconduct/*ethics
EDAT- 2020/11/02 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/11/01 20:25
PHST- 2020/09/21 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/11/01 20:25 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - S1051-0443(20)30812-5 [pii]
AID - 10.1016/j.jvir.2020.09.026 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2020 Nov;31(11):1792-1794. doi: 10.1016/j.jvir.2020.09.026.


PMID- 33129403
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 329
DP  - 2020 Jul - Aug
TI  - [Respecting the religion or the spirituality of the elderly person with mental
      health issues].
PG  - 31-35
LID - S0241-6972(20)30084-0 [pii]
LID - 10.1016/S0241-6972(20)30084-0 [doi]
AB  - Mental health facilities, despite the evolution of recent decades, remain in part
      places in which patients are deprived of their liberty. For elderly people with
      mental health issues, spirituality and freedom of expression are even more
      legitimate. Religious tolerance is a challenge for caregivers, and a patient's
      request to practise their religion must be acknowledged. The provision of
      dedicated spaces and the presence of chaplains must favour the respect of
      cultural liberties.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Hazif-Thomasa, Cyril
AU  - Hazif-Thomasa C
AD  - Service de psychiatrie du sujet age, Spurbo, EA 7479, CHRU de Brest, route de
      Ploudalmezeau, 29820 Bohars, France. Electronic address:
      cyril.hazifthomas@chu-brest.fr.
FAU - Thomasb, Philippe
AU  - Thomasb P
AD  - Centre de recherches semiotiques (Ceres), EA 3648, universite de Limoges, 39 rue 
      Camille-Guerin, 87000 Limoges, France.
LA  - fre
PT  - Journal Article
TT  - Respecter la religion ou la spiritualite de la personne agee en souffrance
      mentale.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - Aged
MH  - *Caregivers/psychology
MH  - Humans
MH  - *Mental Disorders/therapy
MH  - *Professional-Patient Relations
MH  - *Religion
MH  - *Respect
MH  - Spirituality
OTO - NOTNLM
OT  - autonomie
OT  - autonomy
OT  - care
OT  - deprivation of liberty
OT  - ethics
OT  - institution psychiatrique
OT  - pratique religieuse
OT  - privation de liberte
OT  - psychiatric institution
OT  - religious practice
OT  - soin
OT  - vulnerability
OT  - vulnerabilite
OT  - ethique
EDAT- 2020/11/02 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/11/01 20:24
PHST- 2020/11/01 20:24 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - S0241-6972(20)30084-0 [pii]
AID - 10.1016/S0241-6972(20)30084-0 [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 Jul - Aug;41(329):31-35. doi:
      10.1016/S0241-6972(20)30084-0.


PMID- 33129328
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 31
TI  - Just say "no": Can dentists refuse care on the basis of finances? A survey using 
      an ethical vignette in an Iranian Dental School.
PG  - 109
LID - 10.1186/s12910-020-00554-7 [doi]
AB  - BACKGROUND: Decision making when patients ask a dentist for fee reduction is a
      real ethical dilemma at dental settings. The aim of this study was to evaluate
      how dental students and tutors think about their position for, or against fee
      reduction at dental offices. METHOD: It was a questionnaire-based survey, which
      examined the ethical attitudes of students and tutors of an Iranian Dental
      School. The questionnaire included a vignette about an ethical dilemma at a
      dental office. Different ethical approaches, i.e. duty-based, virtue-oriented and
      consequentialist arguments, for or against fee reduction at dental office were
      suggested. Respondents were asked to rank those ethical options. Data was entered
      and analyzed in SPSS 16.0. RESULT: 121 dental students and thirty-six faculty
      members (dental specialists) participated in this study. It revealed that a
      majority of dental students and tutors (68%) are in favor of charging patients
      less, when facing an imagined request at dental office, using either
      virtue-oriented (54%) or consequentialist (14%) argument for fee reduction. The
      difference between rankings of four options was statistically significant, while 
      no statistically significant difference exists neither between male and female
      respondents, nor students and tutors. CONCLUSION: This case study provides a
      basis for fruitful discussions in ethics courses for dental students. Our study
      suggests that financial issues should be considered as a part of ethical training
      within the dental student's curriculum.
FAU - Kazemian, Ali
AU  - Kazemian A
AUID- ORCID: 0000-0002-9531-0102
AD  - Department of Community Oral Health, School of Dentistry, Mashhad University of
      Medical Sciences, Vakilabad Blvd, P.O. Box 984, Mashhad, Iran.
      kazemiana@mums.ac.ir.
FAU - Fayyazi, Mahsa
AU  - Fayyazi M
AD  - School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Shafiee, Shahrzad
AU  - Shafiee S
AD  - School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201031
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Curriculum
MH  - Dentists
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - *Schools, Dental
MH  - Surveys and Questionnaires
PMC - PMC7603726
OTO - NOTNLM
OT  - *Dental Education
OT  - *Ethics
OT  - *Financial Management
OT  - *Questionnaire
EDAT- 2020/11/02 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/11/01 20:23
PHST- 2020/06/05 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/11/01 20:23 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00554-7 [doi]
AID - 10.1186/s12910-020-00554-7 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 31;21(1):109. doi: 10.1186/s12910-020-00554-7.


PMID- 33129261
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 31
TI  - A three-armed cognitive-motor exercise intervention to increase spatial
      orientation and life-space mobility in nursing home residents: study protocol of 
      a randomized controlled trial in the PROfit project.
PG  - 437
LID - 10.1186/s12877-020-01840-0 [doi]
AB  - BACKGROUND: In nursing home residents, the combination of decreasing mobility and
      declining cognitive abilities, including spatial orientation, often leads to
      reduced physical activity (PA) and life-space (LS) mobility. As a consequence of 
      sedentary behavior, there is a lack of social interaction and cognitive
      stimulation, resulting in low quality of life. It has not yet been examined
      whether cognitive-motor training including spatial cognitive tasks is suitable to
      improve spatial orientation and, as a consequence, to enlarge LS mobility, and
      increase well-being and general cognitive-motor functioning. Therefore, the
      overall goal of this multicentric randomized controlled trial (RCT) is to compare
      the effect of three different intervention approaches including functional
      exercise and orientation tasks on PA, LS and spatial orientation in nursing home 
      residents. METHODS: A three-arm single-blinded multicenter RCT with a wait-list
      control group will be conducted in a sample of 513 individuals (needed according 
      to power analysis) in three different regions in Germany. In each nursing home,
      one of three different intervention approaches will be delivered to participating
      residents for 12 weeks, twice a week for 45 min each: The PROfit basic group will
      perform functional strength, balance, flexibility, and walking exercises always
      at the same location, whereas the PROfit plus group changes the location three
      times while performing similar/the same exercises as the PROfit basic group. The 
      PROfit orientation group receives navigation tasks in addition to the relocation 
      during the intervention. Physical and cognitive functioning as well as
      psychological measures will be assessed in all study groups at baseline.
      Participants will then be randomized into either the intervention group or the
      wait-list control group. After 12 weeks, and after 24 weeks the measures will be 
      repeated. DISCUSSION: This study evaluates whether the three different
      interventions are feasible to reduce the decline of or even improve PA, LS, and
      spatial orientation in nursing home residents. By adding different training
      locations in PROfit plus, the program is expected to be superior to PROfit basic 
      in increasing physical and cognitive parameters. Moreover, we expect the PROfit
      orientation intervention to be most effective in terms of PA, LS, and spatial
      orientation due to two mechanisms: (1) increased physical and cognitive activity 
      will enhance cognitive-motor capacity and (2) the spatial training will help to
      build up cognitive strategies to compensate for age-related loss of spatial
      orientation abilities and related limitations. TRIAL REGISTRATION: The trial was 
      prospectively registered at DRKS.de with registration number DRKS00021423 on
      April 16, 2020 and was granted permission by the Technical University Berlin
      local ethics committee (No. GR_14_20191217).
FAU - Wollesen, Bettina
AU  - Wollesen B
AUID- ORCID: 0000-0002-1082-9141
AD  - Department of Biological Psychology and Neuroergonomics, TU Berlin, Fasanenstr.
      1, 10623, Berlin, Germany. bettina.wollesen@uni-hamburg.de.
AD  - Department of Human Movement Science, University of Hamburg, Mollerstrasse 10,
      20148, Hamburg, Germany. bettina.wollesen@uni-hamburg.de.
FAU - Fricke, Madeleine
AU  - Fricke M
AD  - Department of Biological Psychology and Neuroergonomics, TU Berlin, Fasanenstr.
      1, 10623, Berlin, Germany.
FAU - Jansen, Carl-Philipp
AU  - Jansen CP
AD  - Network Aging Research, Heidelberg University, Bergheimer Str. 20, 69115,
      Heidelberg, Germany.
FAU - Gordt, Katharina
AU  - Gordt K
AD  - Institute of Sports and Sports Sciences, Heidelberg University, Im Neuenheimer
      Feld 720, 69120, Heidelberg, Germany.
FAU - Schwenk, Michael
AU  - Schwenk M
AD  - Network Aging Research, Heidelberg University, Bergheimer Str. 20, 69115,
      Heidelberg, Germany.
AD  - Institute of Sports and Sports Sciences, Heidelberg University, Im Neuenheimer
      Feld 720, 69120, Heidelberg, Germany.
FAU - Muehlbauer, Thomas
AU  - Muehlbauer T
AD  - Division of Movement and Training Sciences/Biomechanics of Sport, University of
      Duisburg-Essen, Gladbecker Str. 182, 45141, Essen, Germany.
FAU - Morawietz, Christina
AU  - Morawietz C
AD  - Division of Movement and Training Sciences/Biomechanics of Sport, University of
      Duisburg-Essen, Gladbecker Str. 182, 45141, Essen, Germany.
FAU - Kruse, Adele
AU  - Kruse A
AD  - Department of Human Movement Science, University of Hamburg, Mollerstrasse 10,
      20148, Hamburg, Germany.
FAU - Gramann, Klaus
AU  - Gramann K
AD  - Department of Biological Psychology and Neuroergonomics, TU Berlin, Fasanenstr.
      1, 10623, Berlin, Germany.
AD  - School of Software, University of Technology Sydney, Sydney, 2007, Australia.
LA  - eng
GR  - no number/no number/International
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201031
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Cognition
MH  - Exercise
MH  - *Exercise Therapy
MH  - Humans
MH  - Nursing Homes
MH  - *Orientation, Spatial
PMC - PMC7603752
OTO - NOTNLM
OT  - *Cognitive functioning
OT  - *Life-space
OT  - *Multi-modal intervention
OT  - *Nursing home
OT  - *Physical activity
OT  - *Spatial navigation
EDAT- 2020/11/02 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/11/01 20:23
PHST- 2020/06/15 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/11/01 20:23 [entrez]
PHST- 2020/11/02 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1186/s12877-020-01840-0 [doi]
AID - 10.1186/s12877-020-01840-0 [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Oct 31;20(1):437. doi: 10.1186/s12877-020-01840-0.


PMID- 35155762
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2377-9608 (Electronic)
IS  - 2377-9608 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Competency of Academic Nurse Educators.
PG  - 2377960820969389
LID - 10.1177/2377960820969389 [doi]
AB  - BACKGROUND: In the face of a rapidly changing social environment and increasing
      demand for health care services, there is a global concern that academic nurse
      educators should have expert-level competencies and should improve the level of
      nursing education. OBJECTIVE: This study aimed to investigate the elements that
      constitute competency in academic nurse educators. METHODS: A cross-sectional
      self-completed online survey was conducted involving academic nurse educators
      working at universities in Japan. We invited 277 nursing universities to
      participate in the survey and to provide academic nurse educators with
      information about the research by contacting the dean of each university's
      nursing department. In total, 372 educators completed the survey (response rate
      4.03%), and after excluding those with incomplete data, 367 were analyzed (valid 
      response rate 3.97%). The data were analyzed by exploratory-factor analysis, with
      the least-squares method and promax rotation performed. RESULTS: An exploratory
      analysis yielded five competency factors: "facilitating active learning,"
      "engaging in academic research activities," "participating in university
      management," "undertaking self-directed learning based on professional ethics,"
      and "practicing education autonomously." CONCLUSIONS: The competencies identified
      in the present study are essential for academic nurse educators, and the five
      factors are in accord with the findings of previous studies. Support systems for 
      academic nursing educators should be established to improve their competencies
      comprehensively. However, further research is needed to develop the competencies 
      of academic nurse educators into more comprehensive and sophisticated
      competencies.
CI  - (c) The Author(s) 2020.
FAU - Satoh, Miho
AU  - Satoh M
AUID- ORCID: https://orcid.org/0000-0001-8939-5595
AD  - Department of Fundamental Nursing, Yokohama City University, Yokohama, Japan.
FAU - Fujimura, Akiko
AU  - Fujimura A
AD  - Department of Clinical Nursing, Tokyo Healthcare University, Tokyo, Japan.
FAU - Sato, Naoko
AU  - Sato N
AD  - Oncology Nursing, Health Sciences, Tohoku University Graduate School of Medicine,
      Sendai, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201102
PL  - United States
TA  - SAGE Open Nurs
JT  - SAGE open nursing
JID - 101724853
PMC - PMC8832301
OTO - NOTNLM
OT  - academic nurse educator
OT  - competency
OT  - higher education
OT  - nurse education
OT  - professional development
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/11/02 00:00
MHDA- 2020/11/02 00:01
CRDT- 2022/02/14 05:36
PHST- 2020/04/07 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/10/04 00:00 [accepted]
PHST- 2022/02/14 05:36 [entrez]
PHST- 2020/11/02 00:00 [pubmed]
PHST- 2020/11/02 00:01 [medline]
AID - 10.1177/2377960820969389 [doi]
AID - 10.1177_2377960820969389 [pii]
PST - epublish
SO  - SAGE Open Nurs. 2020 Nov 2;6:2377960820969389. doi: 10.1177/2377960820969389.
      eCollection 2020 Jan-Dec.


PMID- 33128559
OWN - NLM
STAT- Publisher
LR  - 20201031
IS  - 1930-613X (Electronic)
IS  - 0026-4075 (Linking)
DP  - 2020 Oct 30
TI  - The Code of Military Ethics Requires an End to "Executive Medicine" in Military
      Treatment Facilities.
LID - usaa280 [pii]
LID - 10.1093/milmed/usaa280 [doi]
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
SB  - IM
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:00
CRDT- 2020/10/31 17:07
PHST- 2020/07/22 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/10/31 17:07 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:00 [medline]
AID - 5948059 [pii]
AID - 10.1093/milmed/usaa280 [doi]
PST - aheadofprint
SO  - Mil Med. 2020 Oct 30. pii: 5948059. doi: 10.1093/milmed/usaa280.


PMID- 33128092
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 2090-911X (Electronic)
IS  - 1110-2608 (Linking)
VI  - 72
IP  - 1
DP  - 2020 Oct 30
TI  - Prospective associations between ECG abnormalities and death or myocardial
      infarction in a cohort of 980 employed, middle-aged Swedish men.
PG  - 75
LID - 10.1186/s43044-020-00114-9 [doi]
AB  - BACKGROUND: In 1993, 1000 randomly selected employed Swedish men aged 45-50 years
      were invited to a nurse-led health examination with a survey on life style,
      fasting lab tests, and a 12-lead ECG. A repeat examination was offered in 1998.
      The ECGs were classified according to the Minnesota Code. Upon ethical approval, 
      endpoints in terms of MI and death over 25 years were collected from Swedish
      national registers with the purpose of analyzing the independent association of
      ECG abnormalities as risk factors for myocardial infarction and death. RESULTS:
      Seventy-nine of 977 participants had at least one ECG abnormality 1993 or 1998.
      One hundred participants had a first MI over the 25 years. Odds ratio for having 
      an MI in the group that had one or more ECG abnormality compared with the group
      with two normal ECGs was estimated to 3.16. 95%CI (1.74; 5.73), p value 0.0001.
      One hundred fifty-seven participants had died before 2019. For death, similarly
      no statistically significant difference was shown, OR 1.52, 95%CI (0.83; 2.76).
      CONCLUSIONS: Our study suggests that presence of ST- and R-wave changes is
      associated with an independent 3-4-fold increased risk of MI after 25 years
      follow-up, but not of death. A 12-lead resting ECG should be included in any MI
      risk calculation on an individual level.
FAU - Dimberg, Lennart
AU  - Dimberg L
AUID- ORCID: https://orcid.org/0000-0002-8241-0032
AD  - Department of Public Health and Community Medicine, the Sahlgrenska Academy,
      University of Gothenburg, Box 454, SE-405 30, Gothenburg, Sweden.
      Ldimberg@aol.com.
FAU - Eriksson, Bo
AU  - Eriksson B
AD  - Department of Health Metrics, the Sahlgrenska Academy, University of Gothenburg, 
      Gothenburg, Sweden.
FAU - Enqvist, Per
AU  - Enqvist P
AD  - Department of Public Health and Community Medicine, the Sahlgrenska Academy,
      University of Gothenburg, Box 454, SE-405 30, Gothenburg, Sweden.
LA  - eng
GR  - H92:37/Volvo Research and Educational Foundations
PT  - Journal Article
DEP - 20201030
PL  - Germany
TA  - Egypt Heart J
JT  - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of
      Cardiology
JID - 9106952
PMC - PMC7599283
OTO - NOTNLM
OT  - Cohort study
OT  - Middle-aged men
OT  - Mortality
OT  - Myocardial infarction
OT  - Resting ECG
OT  - Risk factors
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:01
CRDT- 2020/10/31 05:35
PHST- 2020/08/15 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/10/31 05:35 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:01 [medline]
AID - 10.1186/s43044-020-00114-9 [doi]
AID - 10.1186/s43044-020-00114-9 [pii]
PST - epublish
SO  - Egypt Heart J. 2020 Oct 30;72(1):75. doi: 10.1186/s43044-020-00114-9.


PMID- 33127766
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 187
IP  - 9
DP  - 2020 Oct 31
TI  - Veterinary ethicist sued by acupuncturist.
PG  - 336-337
LID - 10.1136/vr.m4193 [doi]
LA  - eng
PT  - News
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
SB  - IM
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:01
CRDT- 2020/10/31 05:30
PHST- 2020/10/31 05:30 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:01 [medline]
AID - vr.m4193 [pii]
AID - 10.1136/vr.m4193 [doi]
PST - ppublish
SO  - Vet Rec. 2020 Oct 31;187(9):336-337. doi: 10.1136/vr.m4193.


PMID- 33127638
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 30
TI  - Improving quality in clinical placement studies in nursing homes
      (QUALinCLINstud): the study protocol of a participatory mixed-methods multiple
      case study design.
PG  - e040491
LID - 10.1136/bmjopen-2020-040491 [doi]
AB  - INTRODUCTION: Improved quality in clinical supervision and assessment of student 
      nurses in nursing home clinical placements is vitally important to effective
      recruitment and preparation for this healthcare sector. Knowledge regarding
      supervision and assessment practices within these settings is limited. Also,
      knowledge of evolving e-learning tools on the quality and effectiveness of these 
      educational practices seems to be absent. METHODS AND ANALYSIS: The aim of the
      "Improving quality in clinical placement studies in nursing homes"
      (QUALinCLINstud) study is to develop and evaluate how a web-based programme can
      optimise supervision, assessment and learning during nursing home placements. The
      study applies a participatory, mixed-methods case study design, organised in four
      work packages (WPs). WP1 will explore how the nurse education institution address
      the quality of student nurses' clinical placements in nursing homes. In WP2,
      clinical supervision and assessment practices will be explored, and described
      from multiple stakeholder perspectives. In WP3, based on the findings from WP1
      and WP2, a web-based pedagogical supervision and assessment programme will be
      developed through a developmental co-productive process between nurse education
      institutions, practice settings and student nurses. In WP4, the web-based
      programme will be pilot-tested and evaluated through a mixed-methods approach. A 
      range of data collection procedures will be used throughout the project, for
      example, questionnaires, interviews, observations and workshops. ETHICS AND
      DISSEMINATION: The ethical conduct of the study is approved by the Norwegian
      Centre for Research Data (2018/61309 and 489776). The results will be
      disseminated through scientific articles, three PhD theses, presentations at
      national and international conferences, and through publicly accessible trade
      journals and newspapers. The results will generate knowledge to inform
      supervision and assessment practices in nursing home placements. Moreover, the
      study will generate knowledge concerning the developmental process of a web-based
      supervision and assessment programme, and the value of e-learning tools applied
      in clinical nursing education.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Laugaland, Kristin Alstveit
AU  - Laugaland KA
AUID- ORCID: 0000-0003-3451-2584
AD  - SHARE-Centre for Resilience in Healthcare, Faculty of Health Sciences, University
      of Stavanger, Stavanger, Norway kristin.a.laugaland@uis.no.
FAU - Thorsen Gonzalez, Marianne
AU  - Thorsen Gonzalez M
AD  - Faculty of Health and Social Sciences, University of South-Eastern Norway-Campus 
      Drammen, Drammen, Buskerud, Norway.
FAU - McCormack, Brendan
AU  - McCormack B
AD  - School of Health Sciences, Queen Margaret University, Edinburgh, UK.
FAU - Skovdahl, Kirsti-Iren
AU  - Skovdahl KI
AD  - Faculty of Health Sciences, University of South-Eastern Norway-Campus Drammen,
      Drammen, Buskerud, Norway.
FAU - Slettebo, Ashild
AU  - Slettebo A
AD  - Department of Health and Nursing Sciences, Faculty of Health and Sport Sciences, 
      University of Agder, Grimstad, Norway.
FAU - Billett, Stephen
AU  - Billett S
AD  - School of Education and Professional Studies, Griffith University, Mount Gravatt,
      Queensland, Australia.
FAU - Akerjordet, Kristin
AU  - Akerjordet K
AD  - SHARE-Centre for Resilience in Healthcare, Faculty of Health Sciences, University
      of Stavanger, Stavanger, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201030
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Education, Nursing
MH  - Humans
MH  - Norway
MH  - Nursing Homes
MH  - Research Design
MH  - *Students, Nursing
PMC - PMC7604860
OTO - NOTNLM
OT  - *clinical placement
OT  - *e-learning tools
OT  - *nursing education
OT  - *nursing homes
OT  - *study protocol
COIS- Competing interests: None declared.
EDAT- 2020/11/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/31 05:29
PHST- 2020/10/31 05:29 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040491 [pii]
AID - 10.1136/bmjopen-2020-040491 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 30;10(10):e040491. doi: 10.1136/bmjopen-2020-040491.


PMID- 33127633
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 30
TI  - Impact of transition programmes for students and new graduate nurses on workplace
      bullying, violence, stress and resilience: a scoping review protocol.
PG  - e038893
LID - 10.1136/bmjopen-2020-038893 [doi]
AB  - INTRODUCTION: The shortage of nurses is projected to grow, and the number of new 
      graduate nurses (NGNs) who are predicted to replace expert nurses has increased. 
      Meanwhile, those NGNs leaving their job within the first year, give various
      reasons for leaving, including workplace bullying and violence. In response, some
      hospitals and universities have developed nurse transition programmes such as
      nurse residency programmes and nurse internship programmes to attract NGNs and to
      assist in their changing status from education to practice. Although these
      programmes have been successful in decreasing the turnover rate for new nurses
      and are cost-effective, their impact on workplace bullying and violence has not
      been systematically reviewed and is yet to be determined. A scoping review will
      be conducted to address this gap. The aim is to identify current knowledge
      regarding the content of transition programmes and their impact in supporting
      NGNs dealing with workplace violence, bullying and stress. METHODS AND ANALYSIS: 
      Arksey and O'Malley's scoping framework and the Joanna Briggs Institute scoping
      review guidance will guide the methodology process of the review. Published
      studies, with no date limit, will be identified through the electronic databases 
      (CINAHL, Scopus, MEDLINE, Web of Science, ASSIA, PsycINFO, Embase, PROSPERO and
      ProQuest Dissertation) and reference lists. Primary key terms will be 'novice
      nurse', 'new graduate nurses' and 'transition programmes'. Two reviewers, guided 
      by standardised procedures, will perform the study selection process
      independently. Data from the selected studies will be extracted using a data
      extraction form. Thematic analysis (for qualitative papers) and descriptive
      summary of the results (for quantitative papers) will be performed. ETHICS AND
      DISSEMINATION: Ethical approval is not required for this review. Findings will be
      used to inform future study designs to evaluate the transition programmes and
      disseminated via peer-reviewed journals and conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alshawush, Khadijah Ali
AU  - Alshawush KA
AUID- ORCID: 0000-0003-1692-4112
AD  - School of Nursing, University of Birmingham, Birmingham, UK
      khadijahalshawosh@yahoo.com.
FAU - Hallett, Nutmeg
AU  - Hallett N
AD  - School of Nursing, University of Birmingham, Birmingham, UK.
FAU - Bradbury-Jones, Caroline
AU  - Bradbury-Jones C
AD  - School of Nursing, University of Birmingham, Birmingham, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201030
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Bullying
MH  - Humans
MH  - Personnel Turnover
MH  - Research Design
MH  - Review Literature as Topic
MH  - Students
MH  - Violence
PMC - PMC7604821
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *ethics (see medical ethics)
OT  - *health services administration & management
COIS- Competing interests: None declared.
EDAT- 2020/11/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/31 05:29
PHST- 2020/10/31 05:29 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038893 [pii]
AID - 10.1136/bmjopen-2020-038893 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 30;10(10):e038893. doi: 10.1136/bmjopen-2020-038893.


PMID- 33127630
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 30
TI  - Study protocol for a prospective, longitudinal cohort study investigating the
      medical and psychosocial outcomes of UK combat casualties from the Afghanistan
      war: the ADVANCE Study.
PG  - e037850
LID - 10.1136/bmjopen-2020-037850 [doi]
AB  - INTRODUCTION: The Afghanistan war (2003-2014) was a unique period in military
      medicine. Many service personnel survived injuries of a severity that would have 
      been fatal at any other time in history; the long-term health outcomes of such
      injuries are unknown. The ArmeD SerVices TrAuma and RehabilitatioN OutComE
      (ADVANCE) study aims to determine the long-term effects on both medical and
      psychosocial health of servicemen surviving this severe combat related trauma.
      METHODS AND ANALYSIS: ADVANCE is a prospective cohort study. 1200
      Afghanistan-deployed male UK military personnel and veterans will be recruited
      and will be studied at 0, 3, 6, 10, 15 and 20 years. Half are personnel who
      sustained combat trauma; a comparison group of the same size has been frequency
      matched based on deployment to Afghanistan, age, sex, service, rank and role.
      Participants undergo a series of physical health tests and questionnaires through
      which information is collected on cardiovascular disease (CVD), CVD risk factors,
      musculoskeletal disease, mental health, functional and social outcomes, quality
      of life, employment and mortality. ETHICS AND DISSEMINATION: The ADVANCE Study
      has approval from the Ministry of Defence Research Ethics Committee (protocol
      no:357/PPE/12) agreed 15 January 2013. Its results will be disseminated through
      manuscripts in clinical/academic journals and presentations at professional
      conferences, and through participant and stakeholder communications. TRIAL
      REGISTRATION NUMBER: The ADVANCE Study is registered at ISRCTN ID:
      ISRCTN57285353.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bennett, Alexander N
AU  - Bennett AN
AD  - Academic Department of Military Rehabilitation, Defence Medical Rehabilitation
      Centre, Stanford Hall, Loughborough, UK alexander.n.bennett@btinternet.com.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Dyball, Daniel Mark
AU  - Dyball DM
AUID- ORCID: 0000-0002-0547-8674
AD  - Academic Department of Military Rehabilitation, Defence Medical Rehabilitation
      Centre, Stanford Hall, Loughborough, UK.
AD  - King's Centre for Military Health Research, King's College London, London, UK.
FAU - Boos, Christopher J
AU  - Boos CJ
AD  - Department of Cardiology, University Hospital Dorset, NHS Trust, Poole, UK.
FAU - Fear, Nicola T
AU  - Fear NT
AUID- ORCID: 0000-0002-5792-2925
AD  - King's Centre for Military Health Research, King's College London, London, UK.
AD  - Academic Department for Military Mental Health, King's College London, London,
      UK.
FAU - Schofield, Susie
AU  - Schofield S
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Bull, Anthony M J
AU  - Bull AMJ
AD  - Centre for Blast Injury Studies, Imperial College London, London, UK.
FAU - Cullinan, Paul
AU  - Cullinan P
AD  - Occupational and Environmental Medicine, National Heart and Lung Institute,
      Imperial College, London, UK.
CN  - ADVANCE Study
LA  - eng
SI  - ISRCTN/ISRCTN57285353
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201030
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Afghan Campaign 2001-
MH  - Afghanistan
MH  - Cohort Studies
MH  - Humans
MH  - *Iraq War, 2003-2011
MH  - Longitudinal Studies
MH  - Male
MH  - Prospective Studies
MH  - *Quality of Life
MH  - United Kingdom/epidemiology
PMC - PMC7604820
OTO - NOTNLM
OT  - *cardiac epidemiology
OT  - *mental health
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
COIS- Competing interests: AB works for the Ministry of Defence. NTF receives funding
      from the MoD and is a trustee of a veteran charity. AMJB directs a research
      centre that receives funding from veteran's charities and is supported by the
      Ministry of Defence.
IR  - Bennett AN
FIR - Bennett, Alexander N
IR  - Cullinan P
FIR - Cullinan, Paul
IR  - Fear NT
FIR - Fear, Nicola T
IR  - Bull AMJ
FIR - Bull, Anthony M J
IR  - Boos CJ
FIR - Boos, Christopher J
IR  - Schofield S
FIR - Schofield, Susie
IR  - Dyball DM
FIR - Dyball, Daniel M
EDAT- 2020/11/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/31 05:29
PHST- 2020/10/31 05:29 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037850 [pii]
AID - 10.1136/bmjopen-2020-037850 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 30;10(10):e037850. doi: 10.1136/bmjopen-2020-037850.


PMID- 33127004
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210209
IS  - 1558-3147 (Electronic)
IS  - 0193-953X (Linking)
VI  - 43
IP  - 4
DP  - 2020 Dec
TI  - Transitioning from Adolescence to Adulthood with Autism Spectrum Disorder: An
      Overview of Planning and Legal Issues.
PG  - 723-733
LID - S0193-953X(20)30055-1 [pii]
LID - 10.1016/j.psc.2020.08.008 [doi]
AB  - The transition to adulthood is complex. It is defined by many objective and
      subjective milestones. Transition from adolescence to young adulthood is
      challenging for both neurotypical individuals and individuals with autism
      spectrum disorders. However, for autistic individuals, this transition is even
      more complicated and poses a range of legal and ethical considerations. This
      article discusses how existing legal and social constructs may exacerbate rather 
      than diminish barriers and access for autistic adults and identifies current and 
      potential legal and policy solutions to reducing current systemic barriers. This 
      article ultimately supports a supported decision-making model for autistic
      adolescents transitioning into adulthood.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Elster, Nanette
AU  - Elster N
AD  - Neiswanger Institute for Bioethics, Loyola University Chicago Stritch School of
      Medicine, 2160 South First Avenue, Maywood, IL 60153, USA. Electronic address:
      nelster@luc.edu.
FAU - Parsi, Kayhan
AU  - Parsi K
AD  - Neiswanger Institute for Bioethics, Loyola University Chicago Stritch School of
      Medicine, 2160 South First Avenue, Maywood, IL 60153, USA. Electronic address:
      https://twitter.com/kayhanparsi.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Psychiatr Clin North Am
JT  - The Psychiatric clinics of North America
JID - 7708110
SB  - IM
RPF - Child Adolesc Psychiatr Clin N Am. 2020 Apr;29(2):399-408. PMID: 32169269
OTO - NOTNLM
OT  - *Adolescence
OT  - *Adulthood
OT  - *Autism
OT  - *Ethical
OT  - *Legal
OT  - *Planning
OT  - *Transition
COIS- Disclosure The authors have nothing to disclose.
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:01
CRDT- 2020/10/31 05:24
PHST- 2020/10/31 05:24 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:01 [medline]
AID - S0193-953X(20)30055-1 [pii]
AID - 10.1016/j.psc.2020.08.008 [doi]
PST - ppublish
SO  - Psychiatr Clin North Am. 2020 Dec;43(4):723-733. doi: 10.1016/j.psc.2020.08.008.


PMID- 33126940
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 10
DP  - 2020 Oct 1
TI  - Introduction of bedaquiline for the treatment of drug-resistant TB in the
      Philippines.
PG  - 1063-1066
LID - 10.5588/ijtld.20.0359 [doi]
AB  - Treatment outcomes in patients with drug-resistant tuberculosis (DR-TB) remains
      unsatisfactory in the Philippines. To address this, we implemented the use of new
      anti-TB drugs and novel regimens. The Philippine National Tuberculosis Control
      Program (NTP) participated in the Bedaquiline (BDQ) Donation Program created by
      the US Agency for International Development and Janssen. Despite availability of 
      donated medicine, there was a delay in the implementation of BDQ, both under
      operational research and programme conditions. The main challenges encountered
      were delayed approval by national and institutional ethics boards; limited
      experience of the NTP in the conduct of operational research into new drugs; and 
      the lack of confidence of healthcare staff in the use of new and re-purposed
      anti-TB drugs. Technical assistance from partners and capacity building on
      clinical management of DR-TB and on pharmacovigilance among health workers were
      vital in overcoming these challenges. Over a 3-year period (from 2016-2018), 448 
      patients were initiated on BDQ-based regimens.
FAU - Santiago, M R
AU  - Santiago MR
AD  - USAID s TB Innovations and Health Systems Strengthening Project, Family Health
      International 360, Makati City.
FAU - Garfin, A M C
AU  - Garfin AMC
AD  - National Tuberculosis Control Program, Department of Health, Manila.
FAU - Balanag, V M
AU  - Balanag VM
AD  - Lung Center of the Philippines, Quezon City, The Philippines.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Antitubercular Agents)
RN  - 0 (Diarylquinolines)
RN  - 78846I289Y (bedaquiline)
SB  - IM
MH  - *Antitubercular Agents/therapeutic use
MH  - Diarylquinolines/therapeutic use
MH  - Humans
MH  - Philippines/epidemiology
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
EDAT- 2020/11/01 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/31 05:23
PHST- 2020/10/31 05:23 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.20.0359 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1063-1066. doi: 10.5588/ijtld.20.0359.


PMID- 33126910
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20220417
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 30
TI  - Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2
      Infection: A structured summary of a study protocol for a randomised controlled
      trial.
PG  - 902
LID - 10.1186/s13063-020-04840-y [doi]
AB  - OBJECTIVES: To assess the impact of adding statin (atorvastatin) and/or aspirin
      on clinical deterioration in patients infected with SARS-CoV-2 who require
      hospitalisation. The safety of these drugs in COVID-19 patients will also be
      evaluated. TRIAL DESIGN: This is a single-centre, prospective, four-arm parallel 
      design, open-label, randomized control trial. PARTICIPANTS: The study will be
      conducted at National Cancer Institute (NCI), Jhajjar, Haryana, which is a part
      of All India Institute of Medical Sciences (AIIMS), New Delhi, and has been
      converted into a dedicated COVID-19 management centre since the outbreak of the
      pandemic. All RT-PCR confirmed cases of SARS-CoV-2 infection with age >/= 40
      years and < 75 years requiring hospital admission (patients with WHO clinical
      improvement ordinal score 3 to 5) will be included in the trial. Written informed
      consent will be taken for all recruited patients. Patients with a critical
      illness (WHO clinical improvement ordinal score > 5), documented significant
      liver disease/dysfunction (aspartate transaminase [AST] / alanine
      aminotransferase [ALT] > 240), myopathy and rhabdomyolysis (creatine
      phosphokinase [CPK] > 5x normal), allergy or intolerance to statins or aspirin,
      prior statin or aspirin use within 30 days, history of active gastrointestinal
      bleeding in past three months, coagulopathy, thrombocytopenia (platelet count <
      100000/ dl), pregnancy, active breastfeeding, or inability to take oral or
      nasogastric medications will be excluded. Patients refusing to give written
      consent and taking drugs that are known to have a significant drug interaction
      with statin or aspirin [including cyclosporine, HIV protease inhibitors,
      hepatitis C protease inhibitor, telaprevir, fibric acid derivatives
      (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole),
      clarithromycin and colchicine] will also be excluded from the trial. INTERVENTION
      AND COMPARATOR: In this study, the benefit and safety of atorvastatin (statin)
      and/or aspirin as adjuvant therapy will be compared with the control group
      receiving usual care for management of COVID-19. Atorvastatin will be prescribed 
      as 40 mg oral tablets once daily for ten days or until discharge, whichever is
      earlier. The dose of aspirin will be 75 mg once daily for ten days or until
      discharge, whichever is earlier. All other therapies will be administered
      according to the institute's COVID-19 treatment protocol and the treating
      physician's clinical judgment. MAIN OUTCOMES: All study participants will be
      prospectively followed up for ten days or until hospital discharge, whichever is 
      longer for outcomes. The primary outcome will be clinical deterioration
      characterized by progression to WHO clinical improvement ordinal score >/= 6
      (i.e., endotracheal intubation, non-invasive mechanical ventilation, pressor
      agents, renal replacement therapy, ECMO requirement, and mortality). The
      secondary outcomes will be change in serum inflammatory markers (C-reactive
      protein and Interleukin-6), Troponin I, and creatine phosphokinase (CPK) from
      time zero to 5th day of study enrolment or 7th day after symptom onset, whichever
      is later. Other clinical outcomes that will be assessed include progression to
      Acute Respiratory Distress Syndrome (ARDS), shock, ICU admission, length of ICU
      admission, length of hospital admission, and in-hospital mortality. Adverse drug 
      effects like myalgia, myopathy, rhabdomyolysis, hepatotoxicity, and bleeding will
      also be examined in the trial to assess the safety of the interventions.
      RANDOMISATION: The study will use a four-arm parallel-group design. A
      computer-generated permuted block randomization with mixed block size will be
      used to randomize the participants in a 1:1:1:1 ratio to group A (atorvastatin
      with conventional therapy), group B (aspirin with conventional therapy), group C 
      (aspirin + atorvastatin with conventional therapy), and group D (control; only
      conventional therapy). BLINDING (MASKING): The study will be an open-label trial.
      NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no existing study that has
      evaluated the role of aspirin and atorvastatin in COVID-19 patients, formal
      sample size calculation has not been done. Patients satisfying the inclusion and 
      exclusion criteria will be recruited during six months of study period. Once the 
      first 200 patients are included in each arm (i.e., total 800 patients), the final
      sample size calculation will be done on the basis of the interim analysis of the 
      collected data. TRIAL STATUS: The institutional ethical committee has approved
      the study protocol (Protocol version 3.0 [June 2020]). Participant recruitment
      starting date: 28(th) July 2020 Participant recruitment ending date: 27(th)
      January 2021 Trial duration: 6 months TRIAL REGISTRATION: The trial has been
      prospectively registered in Clinical Trial Registry - India (ICMR- NIMS):
      Reference no. CTRI/2020/07/026791 (registered on 25 July 2020)]. FULL PROTOCOL:
      The full protocol is attached as an additional file, accessible from the Trials
      website (Additional file 1). In the interest of expediting dissemination of this 
      material, the familiar formatting has been eliminated; this Letter serves as a
      summary of the key elements of the full protocol.
FAU - Ghati, Nirmal
AU  - Ghati N
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Roy, Ambuj
AU  - Roy A
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Bhatnagar, Sushma
AU  - Bhatnagar S
AD  - Department of Onco-Anaesthesia, Dr. B.R.A Institute-Rotary Cancer Hospital, All
      India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Bhati, Sumit
AU  - Bhati S
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Bhushan, Sudha
AU  - Bhushan S
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Mahendran, Manjit
AU  - Mahendran M
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Thakur, Abhishek
AU  - Thakur A
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Tiwari, Pawan
AU  - Tiwari P
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of
      Medical Sciences (AIIMS), New Delhi, India.
FAU - Dwivedi, Tanima
AU  - Dwivedi T
AD  - Department of Laboratory Medicine, National Cancer Institute (Jhajjar, Haryana), 
      All India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Mani, Kalaivani
AU  - Mani K
AD  - Department of Biostatistics, All India Institute of Medical Sciences (AIIMS), New
      Delhi, India.
FAU - Gupta, Ritu
AU  - Gupta R
AD  - Department of Laboratory Oncology, Dr. B.R.A Institute-Rotary Cancer Hospital,
      All India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Mohan, Anant
AU  - Mohan A
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of
      Medical Sciences (AIIMS), New Delhi, India.
FAU - Garg, Rakesh
AU  - Garg R
AD  - Department of Onco-Anaesthesia, Dr. B.R.A Institute-Rotary Cancer Hospital, All
      India Institute of Medical Sciences (AIIMS), New Delhi, India.
FAU - Saxena, Anita
AU  - Saxena A
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India.
FAU - Guleria, Randeep
AU  - Guleria R
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of
      Medical Sciences (AIIMS), New Delhi, India.
FAU - Deepti, Siddharthan
AU  - Deepti S
AUID- ORCID: http://orcid.org/0000-0001-6517-3066
AD  - Department of Cardiology, All India Institute of Medical Sciences (AIIMS), Ansari
      Nagar East, New Delhi, 110029, India. deeptikailath@gmail.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20201030
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A0JWA85V8F (Atorvastatin)
RN  - R16CO5Y76E (Aspirin)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Atorvastatin/adverse effects/*therapeutic use
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/*drug therapy/virology
MH  - Female
MH  - Host-Pathogen Interactions
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - India
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Pneumonia, Viral/diagnosis/*drug therapy/virology
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7598224
OTO - NOTNLM
OT  - Aspirin
OT  - COVID-19
OT  - Mortality
OT  - Protocol
OT  - Randomised control trial
OT  - Statin
EDAT- 2020/11/01 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/31 05:22
PHST- 2020/10/19 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/31 05:22 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.1186/s13063-020-04840-y [doi]
AID - 10.1186/s13063-020-04840-y [pii]
PST - epublish
SO  - Trials. 2020 Oct 30;21(1):902. doi: 10.1186/s13063-020-04840-y.


PMID- 33126906
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Oct 30
TI  - Impact of free maternal health care policy on maternal health care utilization
      and perinatal mortality in Ghana: protocol design for historical cohort study.
PG  - 169
LID - 10.1186/s12978-020-01011-9 [doi]
AB  - BACKGROUND: Ghana introduced what has come to be known as the 'Free' Maternal
      Health Care Policy (FMHCP) in 2008 via the free registration of pregnant women to
      the National Health Insurance Scheme to access healthcare free of charge. The
      policy targeted every pregnant woman in Ghana with a full benefits package
      covering comprehensive maternal healthcare. PURPOSE: This study seeks to measure 
      the contribution of the FMHCP to maternal healthcare utilization; antenatal care 
      uptake, and facility delivery and determine the utilization impact on stillbirth,
      perinatal, and neonatal deaths using quasi-experimental methods. The study will
      also contextualize the findings against funding constraints and operational
      bottlenecks surrounding the policy operations in the Upper East Region of Ghana. 
      METHODS: This study adopts a mixed-method design to estimate the treatment effect
      using variables generated from historical data of Ghana and Kenya Demographic and
      Health Survey data sets of 2008/2014, as treatment and comparison groups
      respectively. As DHS uses complex design, weighting will be applied to the data
      sets to cater for clustering and stratification at all stages of the analysis by 
      setting the data in STATA and prefix Stata commands with 'svy'. Thus, the policy 
      impact will be determined using quasi-experimental designs; propensity score
      matching, and difference-in-differences methods. Prevalence, mean difference, and
      test of association between outcome and exposure variables will be achieved using
      the Rao Scot Chi-square. Confounding variables will be adjusted for using Poisson
      and multiple logistics regression models. Statistical results will be reported in
      proportions, regression coefficient, and risk ratios. This study then employs
      intrinsic-case study technique to explore the current operations of the 'free'
      policy in Ghana, using qualitative methods to obtain primary data from the Upper 
      East Region of Ghana for an in-depth analysis. DISCUSSION: The study discussions 
      will show the contributions of the 'free' policy towards maternal healthcare
      utilization and its performance towards stillbirth, perinatal and neonatal
      healthcare outcomes. The discussions will also centre on policy designs and
      implementation in resource constraints settings showing how SDG3 can be
      achievement or otherwise. Effectiveness of policy proxy and gains in the context 
      of social health insurance within a broader concept of population health and
      economic burden will also be conferred. PROTOCOL APPROVAL: This study protocol is
      registered for implementation by the Ghana Health Service Ethical Review
      Committee, number: GHS-ERC 002/04/19.
FAU - Azaare, John
AU  - Azaare J
AUID- ORCID: http://orcid.org/0000-0001-7167-8175
AD  - Department of Health Policy Planning and Management, University of Ghana School
      of Public Health, Legon, Accra, Ghana. azaarejn@yahoo.com.
FAU - Akweongo, Patricia
AU  - Akweongo P
AD  - Department of Health Policy Planning and Management, University of Ghana School
      of Public Health, Legon, Accra, Ghana.
FAU - Aryeetey, Genevieve Cecilia
AU  - Aryeetey GC
AD  - Department of Health Policy Planning and Management, University of Ghana School
      of Public Health, Legon, Accra, Ghana.
FAU - Dwomoh, Duah
AU  - Dwomoh D
AD  - Department of Biostatistics, University of Ghana School Public Health, Legon,
      Accra, Ghana.
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - England
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Delivery, Obstetric/economics/legislation & jurisprudence/*statistics & numerical
      data
MH  - Female
MH  - Ghana/epidemiology
MH  - *Health Policy
MH  - Health Services Accessibility/economics/*statistics & numerical data
MH  - Humans
MH  - Infant, Newborn
MH  - Kenya
MH  - Maternal Health Services/economics/legislation & jurisprudence/*statistics &
      numerical data
MH  - Patient Acceptance of Health Care/*statistics & numerical data
MH  - Perinatal Death
MH  - *Perinatal Mortality
MH  - Pregnancy
PMC - PMC7597017
OTO - NOTNLM
OT  - Delayed reimbursement
OT  - Impact evaluation
OT  - Stillbirth
OT  - Treatment effect
EDAT- 2020/11/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/31 05:22
PHST- 2019/10/03 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/31 05:22 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s12978-020-01011-9 [doi]
AID - 10.1186/s12978-020-01011-9 [pii]
PST - epublish
SO  - Reprod Health. 2020 Oct 30;17(1):169. doi: 10.1186/s12978-020-01011-9.


PMID- 33126874
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 Oct 30
TI  - Nothing to lose: a grounded theory study of patients' and healthcare
      professionals' perspectives of being involved in the consent process for oncology
      trials with non-curative intent.
PG  - 166
LID - 10.1186/s12904-020-00661-7 [doi]
AB  - BACKGROUND: Clinical cancer research trials may offer little or no direct
      clinical benefit to participants where a cure is no longer possible. As such, the
      decision-making and consent process for patient participation is often
      challenging. AIM: To gain understanding of how patients make decisions regarding 
      clinical trial participation, from the perspective of both the patient and
      healthcare professionals involved. METHODS: In-depth, face to face interviews
      using a grounded theory approach. This study was conducted in a regional Cancer
      Centre in the United Kingdom. Of the 36 interviews, 16 were conducted with
      patients with cancer that had non-curative intent and 18 with healthcare
      professionals involved in the consent process. RESULTS: 'Nothing to lose' was
      identified as the core category that underpinned all other data within the study.
      This highlighted the desperation articulated by participants, who asserted trial 
      participation was the 'only hope in the room'. The decision regarding
      participation was taken within a 'trusting relationship' that was important to
      both patients and professionals. Both were united in their 'fight against
      cancer'. These two categories are critical in understanding the
      decision-making/consent process and are supported by other themes presented in
      the theoretical model. CONCLUSION: This study presents an important insight into 
      the complex and ethically contentious situation of consent in clinical trials
      that have non-curative intent. It confirms that patients with limited options
      trust their doctor and frequently hold unrealistic hopes for personal benefit. It
      highlights a need for further research to develop a more robust and context
      appropriate consent process.
FAU - Murphy, Mary
AU  - Murphy M
AD  - Resuscitation Services, Elliott Dynes Building, Royal Victoria Hospital, Belfast 
      Health and Social Care Trust, Belfast, UK.
FAU - McCaughan, Eilis
AU  - McCaughan E
AD  - School of Nursing and Midwifery, Institute of Nursing and Health Research, Ulster
      University, Coleraine, UK.
FAU - Carson, Matthew A
AU  - Carson MA
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, Belfast, UK.
FAU - Donovan, Monica
AU  - Donovan M
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, Belfast, UK.
FAU - Wilson, Richard H
AU  - Wilson RH
AD  - Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
FAU - Fitzsimons, Donna
AU  - Fitzsimons D
AD  - School of Nursing and Midwifery, Medical Biology Centre, Queen's University
      Belfast, Belfast, UK. d.fitzsimons@qub.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
SB  - IM
MH  - Adult
MH  - Decision Making
MH  - Female
MH  - Grounded Theory
MH  - Health Personnel/*psychology/statistics & numerical data
MH  - Humans
MH  - Informed Consent/*standards/statistics & numerical data
MH  - Interviews as Topic/methods
MH  - Male
MH  - Medical Oncology/instrumentation/methods
MH  - Middle Aged
MH  - Patients/*psychology/statistics & numerical data
MH  - Qualitative Research
MH  - Research/standards/statistics & numerical data
MH  - United Kingdom
PMC - PMC7602307
OTO - NOTNLM
OT  - Cancer
OT  - Clinical trial
OT  - Consent
OT  - Decision-making
OT  - Grounded theory
OT  - Neoplasms
EDAT- 2020/11/01 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/10/31 05:22
PHST- 2020/06/29 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/31 05:22 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 10.1186/s12904-020-00661-7 [doi]
AID - 10.1186/s12904-020-00661-7 [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 Oct 30;19(1):166. doi: 10.1186/s12904-020-00661-7.


PMID- 33126717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210526
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Oct 28
TI  - Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic.
LID - E3170 [pii]
LID - 10.3390/cancers12113170 [doi]
AB  - Pancreatic neuroendocrine tumours (pNETs) are a heterogeneous group of epithelial
      tumours with neuroendocrine differentiation. Although rare (incidence of <1 in
      100,000), they are the second most common group of pancreatic neoplasms after
      pancreatic ductal adenocarcinoma (PDAC). pNET incidence is however on the rise
      and patient outcomes, although variable, have been linked with 5-year survival
      rates as low as 40%. Improvement of diagnostic and treatment modalities strongly 
      relies on disease models that reconstruct the disease ex vivo. A key constraint
      in pNET research, however, is the absence of human pNET models that accurately
      capture the original tumour phenotype. In attempts to more closely mimic the
      disease in its native environment, three-dimensional culture models as well as in
      vivo models, such as genetically engineered mouse models (GEMMs), have been
      developed. Despite adding significant contributions to our understanding of more 
      complex biological processes associated with the development and progression of
      pNETs, factors such as ethical considerations and low rates of clinical
      translatability limit their use. Furthermore, a role for the site-specific
      extracellular matrix (ECM) in disease development and progression has become
      clear. Advances in tissue engineering have enabled the use of tissue constructs
      that are designed to establish disease ex vivo within a close to native ECM that 
      can recapitulate tumour-associated tissue remodelling. Yet, such advanced models 
      for studying pNETs remain underdeveloped. This review summarises the most
      clinically relevant disease models of pNETs currently used, as well as future
      directions for improved modelling of the disease.
FAU - Ney, Alexander
AU  - Ney A
AUID- ORCID: 0000-0003-4868-2832
AD  - Institute for Liver and Digestive Health, University College London, London NW3
      2PF, UK.
FAU - Canciani, Gabriele
AU  - Canciani G
AD  - Institute for Liver and Digestive Health, University College London, London NW3
      2PF, UK.
AD  - School of Medicine, La Sapienza University, 00185 Rome, Italy.
FAU - Hsuan, J Justin
AU  - Hsuan JJ
AD  - Institute for Liver and Digestive Health, University College London, London NW3
      2PF, UK.
FAU - Pereira, Stephen P
AU  - Pereira SP
AUID- ORCID: 0000-0003-0821-1809
AD  - Institute for Liver and Digestive Health, University College London, London NW3
      2PF, UK.
LA  - eng
GR  - G0801588/MRC_/Medical Research Council/United Kingdom
GR  - RG2014_01_PERERIA/PANCREATICCANUK_/Pancreatic Cancer UK/United Kingdom
GR  - 000/UCLH Biomedical Research Centre
GR  - 0/PANCREATICCANUK_/Pancreatic Cancer UK/United Kingdom
GR  - PB-PG-0712-28114/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20201028
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7693644
OTO - NOTNLM
OT  - disease models
OT  - genetically engineered mouse models
OT  - multicellular spheroids
OT  - organoids
OT  - pancreatic cancer
OT  - pancreatic neuroendocrine tumours
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:01
CRDT- 2020/10/31 01:02
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/10/31 01:02 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:01 [medline]
AID - cancers12113170 [pii]
AID - 10.3390/cancers12113170 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Oct 28;12(11). pii: cancers12113170. doi:
      10.3390/cancers12113170.


PMID- 33126670
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Oct 28
TI  - Validation of the Equine Behaviour Assessment and Research Questionnaire
      (E-BARQ): A New Survey Instrument for Exploring and Monitoring the Domestic
      Equine Triad.
LID - E1982 [pii]
LID - 10.3390/ani10111982 [doi]
AB  - The Equine Behaviour Assessment and Research Questionnaire (E-BARQ) was developed
      to obtain quantitative data on the domestic equine triad: training, management
      and behaviour. It can be taken repeatedly, thus collecting longitudinal data to
      enable evaluation of how changes in a horse's training and management are
      reflected in that horse's behaviour over time and how these changes can impact
      horse welfare in the longer term. Questionnaire validation and reliability were
      tested by determining (a) whether an owner's subjective ratings of their horse's 
      problematic behaviours or undesirable temperament traits were reflected in the
      questionnaire scores obtained for that horse (construct validity), (b) whether
      two respondents, equally familiar with a particular horse, reported comparable
      scores for that horse through the questionnaire (inter-rater reliability), and
      (c) whether the same respondent, scoring the same horse after a known interval of
      time, recorded similar responses (intra-rater reliability). Construct validity
      testing of 1923 responses showed significant alignment between owners' reported
      experience of focal horses' behaviour and those horses' E-BARQ scores, with
      scores varying from 1.13 to 1.34 for ridden horse behaviour (all p < 0.001) and
      from 1.06 to 1.43 for non-ridden horse behaviour (all p < 0.001). Inter-rater
      reliability testing of ten horse-rider pairs revealed that 203 of the 215
      question items were significantly aligned (p < 0.001) when tested by two
      independent raters. Of the remaining 19 items, four had fair alignment (k =
      0.174-0.316; p = 0.281) and ten items, largely related to whether the horse shows
      behavioural signs related to anxiety when taken away from home, did not align (k 
      = 0; p = 1). Intra-rater reliability tests showed that the responses
      significantly aligned on all 215 question items tested (p < 0.001). The results
      of these tests confirmed the construct validity and reliability of E-BARQ as a
      standardised behavioural assessment tool for horses.
FAU - Fenner, Kate
AU  - Fenner K
AUID- ORCID: 0000-0002-0649-3278
AD  - Sydney School of Veterinary Science, University of Sydney, Camperdown, NSW 2006, 
      Australia.
FAU - Matlock, Sarah
AU  - Matlock S
AD  - Equine Sciences Program, Colorado State University, Fort Collins, CO 80523, USA.
FAU - Williams, Jane
AU  - Williams J
AUID- ORCID: 0000-0002-0695-3828
AD  - Equine Department, Hartpury University, Gloucester GL19 3BE, UK.
FAU - Wilson, Bethany
AU  - Wilson B
AD  - Sydney School of Veterinary Science, University of Sydney, Camperdown, NSW 2006, 
      Australia.
FAU - McLean, Andrew
AU  - McLean A
AUID- ORCID: 0000-0002-6971-7961
AD  - Equitation Science International, 3 Wonderland Ave, Tuerong, VIC 3915, Australia.
FAU - Serpell, James
AU  - Serpell J
AD  - School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - McGreevy, Paul
AU  - McGreevy P
AUID- ORCID: 0000-0001-7220-8378
AD  - Sydney School of Veterinary Science, University of Sydney, Camperdown, NSW 2006, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7692587
OTO - NOTNLM
OT  - behaviour assessment
OT  - domestic equine triad
OT  - ethical equitation
OT  - horse behaviour
OT  - horse welfare
OT  - rider safety
EDAT- 2020/11/01 06:00
MHDA- 2020/11/01 06:01
CRDT- 2020/10/31 01:02
PHST- 2020/10/05 00:00 [received]
PHST- 2020/10/24 00:00 [revised]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/10/31 01:02 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/01 06:01 [medline]
AID - ani10111982 [pii]
AID - 10.3390/ani10111982 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 28;10(11). pii: ani10111982. doi: 10.3390/ani10111982.


PMID- 33126394
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Auricular acupuncture for migraine: A protocol for systematic review and
      meta-analysis.
PG  - e23036
LID - 10.1097/MD.0000000000023036 [doi]
AB  - INTRODUCTION: Migraines are caused by neurological and vascular dysfunction, with
      a side or both sides of the head pain recurrent attack, often accompanied by
      nausea, vomiting, light, and sound allergy as the characteristics, is the
      clinical common disease, frequently occurring disease. The incidence of migraine 
      is 8.4% to 28% worldwide (highest in Germany), and the lifetime incidence is
      about 14.0%. About 18.2% for women and 6.5% for men, About 23 percent of families
      have at least one migraine sufferer. It can occur at any age, and more than half 
      of patients have headaches that interfere with work or school, while nearly a
      third may miss work or school because of the headache. Therefore, how to relief
      headache immediately and reduce the impact on life and work, becomes the basic
      clinical appeal of many patients. Analgesics are the main treatment for migraine 
      in western medicine, many patients, who worried about the side effects of drugs, 
      often take them only when the pain is unbearable, which can only treat the
      symptoms rather than the root causes. Auricular acupuncture as a form of
      acupuncture therapy which is proved to be effective in RCTs and very suitable for
      patients, has been used in patients who suffer from migraine for a long time,
      therefore a systematic review is necessary to provide available evidence for
      further study. METHODS AND ANALYSIS: The following databases will be searched
      from their inception to September 2020: Electronic database includes PubMed,
      Embase, Cochrane Library, Web of Science, Nature, Science online, VIP medicine
      information, and CNKI (China National Knowledge Infrastructure). Primary
      outcomes: Score of migraine symptoms. Additional outcomes: The overall effective 
      rate. Data will be extracted by two researchers independently, risk of bias of
      the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic
      Reviews of Interventions. All data analysis will be conducted by data statistics 
      software Review Manager V.5.3. and Stata V.12.0. RESULTS: The results of this
      study will systematically evaluate the effectiveness and safety of auricular
      acupuncture intervention for people with migraine. CONCLUSION: The systematic
      review of this study will summarize the current published evidence of auricular
      acupuncture for the treatment of migraine, which can further guide the promotion 
      and application of it. ETHICS AND DISSEMINATION: This study is a systematic
      review, the outcomes are based on the published evidence, so examination and
      agreement by the ethics committee are not required in this study. We intend to
      publish the study results in a journal or conference presentations. OPEN SCIENCE 
      FRA NETWORK (OSF) REGISTRATION NUMBER: October 2, 2020 osf.io/q6arf.
      (https://osf.io/q6arf/.).
FAU - Chen, Yuqin
AU  - Chen Y
AD  - Department of Rehabilitation Medicine of Linyi Central Hospital Linyi, Shandong
      Province, P.R. China.
FAU - Liu, Bingyang
AU  - Liu B
FAU - Gong, Weina
AU  - Gong W
FAU - Liu, Guoqiang
AU  - Liu G
AUID- ORCID: 0000-0001-5053-5239
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture, Ear
MH  - Humans
MH  - Migraine Disorders/*therapy
MH  - Research Design
PMC - PMC7598856
EDAT- 2020/11/01 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1097/MD.0000000000023036 [doi]
AID - 00005792-202010300-00098 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e23036. doi:
      10.1097/MD.0000000000023036.


PMID- 33126393
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Complementary and alternative therapies for knee osteoarthritis: A protocol for
      systematic review and network meta-analysis.
PG  - e23035
LID - 10.1097/MD.0000000000023035 [doi]
AB  - BACKGROUND: Knee osteoarthritis (KOA) is a degenerative disease, making a unique 
      contribution to chronic pain, edema, and limited mobility of knee joint. This
      disease is an important factor affecting the quality of life of middle-aged and
      elderly people. Complementary and alternative medicine (CAM) therapies have been 
      used clinically to treat KOA; however, the selection strategies of different CAM 
      interventions in clinical practice are still uncertain, and the purpose of this
      study is to evaluate the efficacy and acceptability of different CAM therapies
      using systematic review and network meta-analysis. METHODS: According to the
      strategy, the authors will retrieve a total of 7 electronic databases by October 
      2020, including PubMed, the Cochrane Library, EMbase, China National Knowledge
      Infrastructure, China Biological Medicine, Chongqing VIP, and Wan-fang databases 
      After a series of screening, 2 researchers will use Aggregate Data Drug
      Information System and Stata software to analyze the data extracted from the
      randomized controlled trials of CAM therapies for the KOA. Finally, the evidence 
      grade of the results will be evaluated. RESULTS: This study will provide a
      reliable evidence for the selection of CAM therapies for KOA. CONCLUSION: The
      results of this study will provide references for evaluating the influence of
      different CAM therapies for KOA, and provide decision-making references for
      clinical research. ETHICS AND DISSEMINATION: This study does not require ethical 
      approval. The results will be disseminated through a peer-reviewed publication.
      OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/GJMF4.
FAU - Yu, Haiyang
AU  - Yu H
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Chinese
      Medicine.
AD  - Department of Orthopedics.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Department of Acupuncture and Moxibustion, Affiliated Hospital of Gansu
      University of Chinese Medicine, Lanzhou, Gansu Province, China.
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
FAU - Cao, Panju
AU  - Cao P
AD  - Department of Spine, Baoji Hospital of Traditional Chinese Medicine, Baoji,
      Shanxi Province, China.
FAU - Ma, Tao
AU  - Ma T
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Chinese
      Medicine.
FAU - Zhao, Yongli
AU  - Zhao Y
AD  - Department of Orthopedics.
FAU - Xie, Feiyang
AU  - Xie F
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Chinese
      Medicine.
FAU - Yao, Chuanjiang
AU  - Yao C
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Chinese
      Medicine.
FAU - Zhang, Xiaogang
AU  - Zhang X
AUID- ORCID: 0000-0001-7573-2773
AD  - Clinical College of Traditional Chinese Medicine, Gansu University of Chinese
      Medicine.
AD  - Department of Orthopedics.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Complementary Therapies
MH  - Humans
MH  - Network Meta-Analysis
MH  - Osteoarthritis, Knee/*therapy
MH  - Research Design
PMC - PMC7598879
EDAT- 2020/11/01 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1097/MD.0000000000023035 [doi]
AID - 00005792-202010300-00097 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e23035. doi:
      10.1097/MD.0000000000023035.


PMID- 33126377
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Ju Re Ba Du therapy for Postherpetic neuralgia: A protocol for systematic review 
      and meta-analysis.
PG  - e22992
LID - 10.1097/MD.0000000000022992 [doi]
AB  - INTRODUCTION: Postherpetic neuralgia (PHN) is one of the most common types of
      chronic neuropathic pain, which seriously affects quality of the life because of 
      pain severity and poor response to the currently available treatments. Ju Re Ba
      Du therapy as a form of acupuncture therapy which is proved to be effective in
      RCTs and very suitable for patients, has been used in Postherpetic neuralgia in
      patients for a long time, therefore a systematic review is necessary to provide
      available evidence for further study. METHODS AND ANALYSIS: The following
      databases will be searched from their inception to October 2020: Electronic
      database includes PubMed, Embase, Cochrane Library, Web of Science, Nature,
      Science online, VIP medicine information, and CNKI (China National Knowledge
      Infrastructure). PRIMARY OUTCOME: pain intensity assessed on a visual analogue
      scale (VAS); Additional outcomes:Data will be extracted by two researchers
      independently, risk of bias of the meta-analysis will be evaluated based on the
      Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will
      be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. 
      RESULTS: The results of this study will systematically evaluate the effectiveness
      and safety of Ju Re Ba Du therapy intervention for people with Postherpetic
      neuralgia. CONCLUSION: The systematic review of this study will summarize the
      current published evidence of Ju Re Ba Du therapy for the treatment of
      Postherpetic neuralgia, which can further guide the promotion and application of 
      it. ETHICS AND DISSEMINATION: This study is a systematic review, the outcomes are
      based on the published evidence, so examination and agreement by the ethics
      committee are not required in this study. We intend to publish the study results 
      in a journal or conference presentations. OSF REGISTRATION NUMBER: September 29, 
      2020 osf.io/r6y9b. (https://osf.io/r6y9b).
FAU - Huang, Shijie
AU  - Huang S
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Pan, Zhengqi
AU  - Pan Z
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Li, Zimeng
AU  - Li Z
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Zhu, Xinyun
AU  - Zhu X
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Ma, Tingting
AU  - Ma T
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Wu, Jie
AU  - Wu J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Humans
MH  - Neuralgia, Postherpetic/*therapy
MH  - Research Design
PMC - PMC7598878
EDAT- 2020/11/01 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1097/MD.0000000000022992 [doi]
AID - 00005792-202010300-00081 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22992. doi:
      10.1097/MD.0000000000022992.


PMID- 33126375
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Comparison anterior minimally invasive oblique retroperitoneal approach and
      posterior transpedicular approach for debridement fusion in patients with lumbar 
      vertebral osteomyelitis: A randomized controlled trial protocol.
PG  - e22990
LID - 10.1097/MD.0000000000022990 [doi]
AB  - BACKGROUND: Pyogenic osteomyelitis of the spine usually occurs in patients over
      55 years old with acute osteomyelitis. Surgical treatment and fixation can
      relieve pain, enhance spinal balance and nerve function, so that patients can
      walk as soon as possible. Different outcomes of surgical methods include anterior
      minimally invasive oblique retroperitoneal approach (ORA) and posterior
      transpedicular approach (PTA). While, there is no consensus on the best treatment
      for PVO. The goal of the protocol is to compare the clinical consequences between
      PTA and ORA for treating PVO. METHOD: The experiment is a single-center
      randomized clinical research. This experiment was admitted by the Ethics
      Committee of the People's Hospital of Dayi County (Approval number: 1002-084). In
      all, 50 patients with lumbar vertebral osteomyelitis (LVO) who prepares surgical 
      treatment will be included in the study. We contain adult patients (aged over 18 
      years) who accept debridement and spinal stabilization with LVO. Cases are
      removed if there is previous hardware placement, cases who are not confirmed by
      microbiology, or severe renal and liver dysfunction. The primary outcomes are
      intraoperative blood loss, operative time, hospital stay, primary failure and
      recurrence, and bone fusion. The secondary outcomes are postoperative pain score 
      and physical recovery. SPSS Sample Power version 3.0 (IBM, Armonk, NY, USA) is
      used for data analysis. RESULTS: Table 1 will show the outcomes in both groups.
      CONCLUSION: This protocol may offer a reliable basis for the effectiveness of the
      two approaches in the treatment of PVO. TRIAL REGISTRATION NUMBER:
      researchregistry6046.
FAU - Gao, Xiang
AU  - Gao X
AD  - Department of Orthopedics.
FAU - Wan, Shu
AU  - Wan S
AD  - Department of Stomatology, The People's Hospital of Dayi County, Chengdu,
      Sichuan, China.
FAU - Lv, Jie
AU  - Lv J
AD  - Department of Orthopedics.
FAU - Cheng, Wei
AU  - Cheng W
AD  - Department of Orthopedics.
FAU - Zhang, Yangbin
AU  - Zhang Y
AUID- ORCID: 0000-0002-6504-4640
AD  - Department of Orthopedics.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Debridement/*methods
MH  - Humans
MH  - Lumbar Vertebrae/*surgery
MH  - Minimally Invasive Surgical Procedures/*methods
MH  - Osteomyelitis/*surgery
MH  - Randomized Controlled Trials as Topic
MH  - Spinal Diseases/*surgery
MH  - Spinal Fusion/*methods
PMC - PMC7598824
EDAT- 2020/11/01 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1097/MD.0000000000022990 [doi]
AID - 00005792-202010300-00079 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22990. doi:
      10.1097/MD.0000000000022990.


PMID- 33126374
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Clinical nursing pathway improves the nursing satisfaction in patients with acute
      cerebral hemorrhage: A randomized controlled trial protocol.
PG  - e22989
LID - 10.1097/MD.0000000000022989 [doi]
AB  - BACKGROUND: Cerebral hemorrhage (CH) is a very common cerebrovascular disorder in
      clinical practice. More and more studies reported that proper nursing care could 
      promote the rate of treatment, and improve the prognosis after treatment.
      Clinical nursing pathway (CNP) refers to original nursing mode with good quality,
      outstanding efficiency, and low treatment spending. Few articles have reported
      the effect of CNP in patients with acute CH. The program is in urgent need of
      convinced evidence to prove the reliability. Thus, we perform this randomized
      controlled trial protocol and hypothesize that CNP is associated with improved
      outcomes and nursing satisfaction, reduced adverse reactions in patients with
      acute CH. METHOD: It is a single-center randomized controlled study to be
      conducted from October 2020 to October 2021. It was admitted via the Ethics
      Committee of the West China Hospital of Sichuan University (0038842/121). Eighty 
      patients meet diagnostic standards for CH are included. The study group receives 
      the clinical nursing path model. In the control group, patients receive the
      routine care before and after taking to the hospital. The main outcome contains
      the Barthel index score, the patient's degree of satisfaction about care, the
      length of hospital stay, and the risk of complications such as infection,
      bedsores and gastrointestinal function between the 2 groups. Six months after
      admission, the functional independence measure and Fugl Meyer score are recorded.
      All data are analyzed by the IBM SPSS Statistics, version 20 (IBM Corp., Armonk, 
      NY edition). RESULTS: Table 1 shows the clinical outcomes between groups.
      CONCLUSION: CNP may improve the clinical outcomes for patients with acute CH and 
      have a significant value in actual applications. TRIAL REGISTRATION NUMBER:
      researchregistry6061.
FAU - Fu, Su
AU  - Fu S
AD  - Department of Neurological comprehensive ward.
FAU - Han, Hui
AU  - Han H
AD  - Department of Neurological comprehensive ward.
FAU - Fan, Chaofeng
AU  - Fan C
AD  - Department of Neurological comprehensive ward.
FAU - Jiang, Yan
AU  - Jiang Y
AUID- ORCID: 0000-0001-9466-8535
AD  - Department of Nursing, West China Hospital of Sichuan University/West China
      Nursing College, Sichuan, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Cerebral Hemorrhage/*nursing/psychology/therapy
MH  - China
MH  - *Critical Pathways
MH  - Humans
MH  - *Patient Satisfaction
MH  - *Quality Improvement
MH  - Randomized Controlled Trials as Topic
PMC - PMC7598808
EDAT- 2020/11/01 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1097/MD.0000000000022989 [doi]
AID - 00005792-202010300-00078 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22989. doi:
      10.1097/MD.0000000000022989.


PMID- 33126371
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Efficacy of radial extracorporeal shock wave therapy for chronic
      prostatitis/chronic pelvic pain syndrome: A protocol for systematic review.
PG  - e22981
LID - 10.1097/MD.0000000000022981 [doi]
AB  - BACKGROUND: Prostatitis is a common urogenital system disease in men which
      affects 5% to 9% of adult men worldwide and accounts for approximately 8% of
      visits to urologists. In the past years, its pathogenesis is complicated and the 
      classification of it is not clear, so the effect of treatment measures is not
      significant. Recently, the treatment of chronic prostatitis/chronic pelvic pain
      syndrome (CP/CPPS) includes nonsteroidal anti-inflammatory drugs, phytotherapy,
      hormonal therapy, alpha-blockers, anti-anxiolytic, and acupuncture, which provide
      more choice for the urologist. But there still are some limitations. scholars.
      Many studies suggest radial extracorporeal shock wave therapy may be the better
      option in the treatment of CP/CPPS. However, the efficacy and safety of it still 
      lack solid evidence. METHODS AND ANALYSIS: The electronic databases of MEDLINE,
      PubMed, Web of Science, EMBASE, Cochrane Library, Clinicaltrials.org, China
      National Knowledge Infrastructure Database, Wan fang Database, China Biology
      Medicine Database, VIP Science Technology Periodical Database, Chinese Clinical
      Trial Registry will be retrieved. All the randomized controlled trials of radial 
      extracorporeal shock wave therapy (rESWT) for patients with CP/CPPS will be
      included. We will evaluate the outcomes including National Institutes of Health
      Chronic Prostatitis Symptom Index, visual analog scale, international prostate
      symptom score, international index of erectile function-5, and conduct this study
      strictly according to the Cochrane Handbook for Systematic Reviews of
      Interventions. RESULTS: The current study is a protocol for systematic review and
      meta-analysis without results, and data analysis will be carried out after the
      protocol. We will share our findings on October 31st of 2021. CONCLUSION: rESWT
      as a noninvasive treatment with no pain, which will be accepted more easily.
      Although some studies have suggested that rESWT can relieve the symptoms of
      patients, the efficacy and safety of it still lack solid evidence. To address
      this limitation scientifically and systematically, this study will inspect the
      efficacy and safety of the rESWT treatment in patients with CP/CPPS by
      integrating various studies. ETHICS AND DISSEMINATION: Formal ethical approval is
      not required in this protocol. We will collect and analyze data based on
      published studies, and since there are no patients involved in this study,
      individual privacy will not be under concerns. The results of this review will be
      disseminated to peer-reviewed journals or submit to related conferences. PROTOCOL
      REGISTRATION NUMBER: INPLASY202090076.
FAU - Li, Guangsen
AU  - Li G
AUID- ORCID: 0000-0003-0999-1413
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Chang, Degui
AU  - Chang D
FAU - Chen, Di'ang
AU  - Chen D
FAU - Zhang, Peihai
AU  - Zhang P
FAU - You, Yaodong
AU  - You Y
FAU - Huang, Xiaopeng
AU  - Huang X
FAU - Cai, Jian
AU  - Cai J
FAU - Yang, Xuesong
AU  - Yang X
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Chronic Disease
MH  - *Extracorporeal Shockwave Therapy/methods
MH  - Humans
MH  - Male
MH  - Pelvic Pain/etiology/*therapy
MH  - Prostatitis/complications/*therapy
MH  - Syndrome
MH  - Treatment Outcome
PMC - PMC7598797
EDAT- 2020/11/01 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1097/MD.0000000000022981 [doi]
AID - 00005792-202010300-00075 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22981. doi:
      10.1097/MD.0000000000022981.


PMID- 33126364
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Evaluation of competence training for the minimally trained health worker in type
      2 diabetes: A cluster randomized controlled trial.
PG  - e22959
LID - 10.1097/MD.0000000000022959 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus is responsible for high mortality and
      morbidity globally and in India. India has high prevalence of the condition and
      the burden is set to increase exponentially in the next decade. Indians
      traditionally reside in rural or semi-urban areas with limited access to
      healthcare facilities. To overcome this, the government has introduced a cadre of
      health workers called Accredited Social Health Activists (ASHA) for such areas.
      These workers were initially trained to provide maternal & infant care but now
      need improved competence training to improve type 2 diabetes screening &
      management in these locations. The objective of the study is to assess the
      competence training provided to ASHA workers at the chosen study sites.
      METHODOLOGY: A cluster randomized control trial has been designed. It will be
      conducted across 8 centers in Hyderabad & Rangareddy districts of Telangana,
      India. The training will be provided to ASHA workers. The tool used for training 
      will be developed from existing sources with an emphasis on topics which require 
      training. The training will be delivered across 6 months at each center as a
      classroom training. Each participant's baseline competence will be recorded using
      a questionnaire tool and a practical evaluation by trained public health experts.
      The same experts will use the same tools to assess the training post the
      intervention. DISCUSSION: This trial will evaluate the use of health worker
      training as a tool for improving the clinical competence in relation to type 2
      diabetes mellitus. We anticipate that the module will provide a greater
      understanding of type 2 diabetes mellitus, the importance of screening of both
      disease and complications and improved skills for the same. The study has
      received the ethical approval form the Institutional Ethics Committee of the
      Indian Institute of Public Health Hyderabad. The registration number is:
      IIPHH/TRCIEC/218/2020. The trial has also been registered under the Clinical
      trial registry of India (CTRI) on 27 July 2020. The registration number of the
      trial is: CTRI/2020/07/026828. The URL of the registry trial is:
      http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45342&EncHid=&userName=CTRI/2
      020/07/026828.
FAU - Gudlavalleti, Anirudh Gaurang
AU  - Gudlavalleti AG
AUID- ORCID: 0000-0001-7339-5320
AD  - Indian Institute of Public Health Hyderabad, Public Health Foundation of India,
      ANV Arcade, 1 Amar Cooperative Society, Kavuri Hills, Madhapur, Hyderabad, India.
AD  - CAPHRI CaRE and Public Health Research Institute, Maastricht University, PO Box
      616, 6200 MD Maastricht, the Netherlands.
FAU - Babu, Giridhara R
AU  - Babu GR
AD  - Indian Institute of Public Health Hyderabad, Public Health Foundation of India,
      ANV Arcade, 1 Amar Cooperative Society, Kavuri Hills, Madhapur, Hyderabad, India.
FAU - van Schayck, Onno C P
AU  - van Schayck OCP
AD  - CAPHRI CaRE and Public Health Research Institute, Maastricht University, PO Box
      616, 6200 MD Maastricht, the Netherlands.
FAU - Schaper, Nicolaas C
AU  - Schaper NC
AD  - CAPHRI CaRE and Public Health Research Institute, Maastricht University, PO Box
      616, 6200 MD Maastricht, the Netherlands.
FAU - Lewis, Melissa Glenda
AU  - Lewis MG
AD  - Indian Institute of Public Health Hyderabad, Public Health Foundation of India,
      ANV Arcade, 1 Amar Cooperative Society, Kavuri Hills, Madhapur, Hyderabad, India.
FAU - Murthy, G V S
AU  - Murthy GVS
AD  - Indian Institute of Public Health Hyderabad, Public Health Foundation of India,
      ANV Arcade, 1 Amar Cooperative Society, Kavuri Hills, Madhapur, Hyderabad, India.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Clinical Competence/standards
MH  - Community Health Workers/*education
MH  - Diabetes Mellitus, Type 2/diagnosis/prevention & control/*therapy
MH  - Female
MH  - Humans
MH  - India
MH  - Inservice Training/*methods
MH  - Male
MH  - Randomized Controlled Trials as Topic
PMC - PMC7598789
EDAT- 2020/11/01 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1097/MD.0000000000022959 [doi]
AID - 00005792-202010300-00068 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22959. doi:
      10.1097/MD.0000000000022959.


PMID- 33126355
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Diagnosis and treatment of advanced HER2-positive breast cancer in young pregnant
      female: A case report.
PG  - e22929
LID - 10.1097/MD.0000000000022929 [doi]
AB  - RATIONALE: The incidence of pregnancy-associated breast cancer (PABC) is
      increasing nowadays, and its diagnosis and treatment remain complicated due to
      the consideration of the fetus. The available data on PABC are primarily derived 
      from case reports since there are ethical restrictions on conducting randomized
      clinical trials. In the present work, we reported a case of the human epidermal
      growth factor receptor 2 (HER2)-positive PABC and described the diagnosis and
      treatment for such type of breast cancer. PATIENT CONCERNS: A 27-year-old patient
      was admitted to our hospital with the complaints of right breast mass for 3 days,
      and she was a first-time pregnant woman with a single live intrauterine fetus at 
      26 + 3 weeks of gestation. Physical examination of the right breast revealed a
      palpable and hard mass with obscure boundaries (5.0 cm x 4.0 cm) in the upper
      outer quadrant. Significant axillary lymph nodes (2.0 cm) were also present.
      DIAGNOSIS: PABC. INTERVENTION: To protect the fetus, breast ultrasonography was
      used to test her breast mass, a core needle biopsy was adopted to confirm the
      diagnosis, and abdominal ultrasound and chest X-ray were used to evaluate the
      metastasis. The patient was scheduled for neoadjuvant therapy using bi-weekly
      pirarubicin in combination with cyclophosphamide (AC) without anti-HER2 therapy
      for consideration of the fetus's safety. After 4 cycles of AC, the patient
      delivered a healthy male infant. After the delivery, all the treatments were
      carried out according to the standard recommendation for HER2 + breast cancer as 
      non-pregnant patients. OUTCOMES: After the surgery, the disease-free survival for
      the patient was 12 months until brain metastasis was diagnosed. She was still
      undergoing second-line anti-HER2 therapy and currently in a stable situation.
      Besides, the child was also healthy so far. LESSONS: The methods for the
      diagnosis and treatment of PABC that result in teratogenesis should be avoided to
      protect the fetus. Mammogram and chest X-ray were safe approaches for the fetus. 
      Moreover, chemotherapy-based on pirarubicin in combination with cyclophosphamide 
      had no risk to the fetus.
FAU - Tang, Tiantian
AU  - Tang T
AD  - Breast Center, the Fourth Hospital of Hebei Medical University.
FAU - Liu, Yueping
AU  - Liu Y
AD  - Department of Pathology, the Fourth Hospital of Hebei Medical University,
      Shijiazhuang, China.
FAU - Yang, Chao
AU  - Yang C
AD  - Breast Center, the Fourth Hospital of Hebei Medical University.
FAU - Ma, Li
AU  - Ma L
AD  - Breast Center, the Fourth Hospital of Hebei Medical University.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - D58G680W0G (pirarubicin)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/administration & dosage
MH  - Biopsy, Large-Core Needle/methods
MH  - *Breast Neoplasms/metabolism/pathology/therapy
MH  - Cyclophosphamide/*administration & dosage
MH  - Doxorubicin/administration & dosage/*analogs & derivatives
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Mastectomy, Extended Radical/*methods
MH  - Neoplasm Staging
MH  - Postnatal Care/*methods
MH  - Pregnancy
MH  - *Pregnancy Complications, Neoplastic/metabolism/pathology/therapy
MH  - Pregnancy Outcome
MH  - Receptor, ErbB-2/*antagonists & inhibitors
MH  - Trastuzumab/*administration & dosage
MH  - Ultrasonography, Mammary/methods
PMC - PMC7598818
EDAT- 2020/11/01 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.1097/MD.0000000000022929 [doi]
AID - 00005792-202010300-00059 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22929. doi:
      10.1097/MD.0000000000022929.


PMID- 33126351
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Efficacy and safety of Sangbaipi Decoction in patients with acute exacerbation of
      chronic obstructive pulmonary disease: A protocol for systematic review and meta 
      analysis.
PG  - e22917
LID - 10.1097/MD.0000000000022917 [doi]
AB  - BACKGROUND: Chinese medicine Sangbaipi decoction is extensively applied to the
      therapy of acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
      in China. However, owing to the low quality, small sample size, and
      methodological heterogeneity of these studies, this conclusion is not convincing.
      Consequently, it is necessary to systematically evaluate the clinical efficacy
      and safety of Sangbaipi Decoction in the treatment of AECOPD patients, and
      provide high-quality evidence for its clinical application. METHODS: We will
      follow the preferred reporting items for systematic review and meta-analysis
      (PRISMA) for reporting the results of the review in this study. We will utilize
      the Review Manage software V5.3.0 (The Nordic Cochrane Center, The Cochrane
      Collaboration, 2014, Copenhagen, Denmark) to assess the risk of bias and
      visualize the results. We will use Stata software (version 15.0, StataCorp,
      College Station, TX) to perform the meta-analysis. ETHICS AND DISSEMINATION: This
      study is a systematic review and meta-analysis protocol of Sangbaipi decoction on
      AECOPD, participants were not recruited and data were not collected from
      participants, so ethical ratification is not required. RESULTS: This study will
      provide high-quality synthesis of the effectiveness and safety of Sangbaipi
      decoction for AECOPD. Upon completion, the results will be submitted to a
      peer-reviewed journal. CONCLUSION: The efficacy and safety assessment of
      Sangbaipi decoction for AECOPD will be supported by this protocol. REGISTRATION
      NUMBER: PROSPERO CRD 42019138405.
FAU - Li, Jiazhou
AU  - Li J
AD  - School of sport and health of Guangzhou University of Chinese Medicine.
FAU - Jiang, Junlin
AU  - Jiang J
AD  - School of sport and health of Guangzhou University of Chinese Medicine.
FAU - Jing, Chunxiang
AU  - Jing C
AD  - School of sport and health of Guangzhou University of Chinese Medicine.
FAU - Zheng, Wenjiang
AU  - Zheng W
AD  - The First Clinical Medical School of Guangzhou University of Chinese Medicine.
FAU - Pan, Huashan
AU  - Pan H
AUID- ORCID: 0000-0003-4821-8589
AD  - Department of Science and Technology of Guangdong Food and Drug Vocational
      College, Guangzhou, Guangdong Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Meta-Analysis as Topic
MH  - *Morus
MH  - *Pulmonary Disease, Chronic Obstructive/drug therapy/physiopathology
MH  - Research Design
MH  - Symptom Flare Up
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7598796
EDAT- 2020/11/01 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.1097/MD.0000000000022917 [doi]
AID - 00005792-202010300-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22917. doi:
      10.1097/MD.0000000000022917.


PMID- 33126350
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Placebo use and outcome quality: A protocol for systematic review and
      meta-analysis.
PG  - e22915
LID - 10.1097/MD.0000000000022915 [doi]
AB  - BACKGROUND: The Pharmaceutical industry sponsorship, research outcome and quality
      has been already evaluated for clinical trials in order to analyze if this kind
      of sponsorship affects the results of clinical trials. In this sense, this study 
      has the aim to investigate whether placebo use allows positive outcomes regarding
      efficacy and safety compared to synthetic medicines. METHODS: We designed and
      registered a study protocol for a systematic review for methodology data. We will
      only randomized clinical trials that use placebo as comparator. The main outcome 
      will be the evaluation of placebo use regarding the tendency for positive results
      (efficacy and security) when comparing to synthetic medicines. PubMed, Cochrane, 
      LILACS (BVS), Web of Science, Scopus, and Excerpta Medica dataBASE (EMBASE)
      databases will be searched. Gray literature will be identified through the
      databases Proquest (Dissertation and Theses), OpenGrey and Google Scholar. Two
      review authors will independently assess trial quality and will extract data in
      accordance with standard Cochrane methodology. If necessary, we will also contact
      authors for additional information. The Cochrane Collaboration's risk of bias
      tool will be used. If feasible, it means homogenous data, we will conduct random 
      effects meta-analysis. Subgroup analyses will be conducted for different
      justifications for placebo use and for studies sponsored/not sponsored by the
      pharmaceutical industry. RESULTS: Our present findings will indicate the effects 
      of placebo use as comparator regarding efficacy and safety of the oral synthetic 
      medicines. DISCUSSION: This systematic review will identify, summarize, and
      analyze if there is a trend for positive efficacy and safety results for
      synthetic medicines in clinical trials when compared with placebo and if the
      justification for placebo use is considered ethically acceptable. SYSTEMATIC
      REVIEW REGISTRATION: PROSPERO CRD42018110829.
FAU - da Silva, Juliana C R Alves
AU  - da Silva JCRA
AUID- ORCID: 0000-0002-3186-7331
AD  - University of Brasilia, University Campus Darcy Ribeiro Asa Norte, Brasilia,
      Distrito Federal.
FAU - de Azevedo, Kesley Pablo Morais
AU  - de Azevedo KPM
AUID- ORCID: 0000-0002-7849-2661
AD  - Department of Public Health, Postgraduate Program in Public Health, Federal
      University of Rio Grande do Norte, University Campus Lagoa Nova, Natal, Rio
      Grande do Norte.
FAU - Farinasso, Cecilia Menezes
AU  - Farinasso CM
AUID- ORCID: 0000-0002-3612-4422
AD  - Ministry of Health, Esplanade of Ministries, Brasilia, Distrito Federal, Brazil.
FAU - da Silva, Dayde Lane Mendonca
AU  - da Silva DLM
AUID- ORCID: 0000-0001-5653-7411
AD  - University of Brasilia, University Campus Darcy Ribeiro Asa Norte, Brasilia,
      Distrito Federal.
FAU - Stefani, Cristine
AU  - Stefani C
AUID- ORCID: 0000-0003-4712-9779
AD  - University of Brasilia, University Campus Darcy Ribeiro Asa Norte, Brasilia,
      Distrito Federal.
FAU - Figueiredo, Ana Claudia Morais Godoy
AU  - Figueiredo ACMG
AUID- ORCID: 0000-0003-2842-9848
AD  - University of Brasilia, University Campus Darcy Ribeiro Asa Norte, Brasilia,
      Distrito Federal.
FAU - de Souza, Patricia Medeiros
AU  - de Souza PM
AUID- ORCID: 0000-0003-4022-9187
AD  - University of Brasilia, University Campus Darcy Ribeiro Asa Norte, Brasilia,
      Distrito Federal.
FAU - Piuvezam, Grasiela
AU  - Piuvezam G
AUID- ORCID: 0000-0002-2343-7251
AD  - Department of Public Health, Postgraduate Program in Public Health, Federal
      University of Rio Grande do Norte, University Campus Lagoa Nova, Natal, Rio
      Grande do Norte.
FAU - Capucho, Helaine Carneiro
AU  - Capucho HC
AUID- ORCID: 0000-0002-5438-7963
AD  - University of Brasilia, University Campus Darcy Ribeiro Asa Norte, Brasilia,
      Distrito Federal.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Placebos)
SB  - IM
MH  - Data Accuracy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Outcome Assessment, Health Care/ethics/standards
MH  - Pharmaceutical Research/ethics/standards
MH  - Placebos/*pharmacology
MH  - *Randomized Controlled Trials as Topic/ethics/methods/standards
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7598826
EDAT- 2020/11/01 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/10/31 01:01
PHST- 2020/10/31 01:01 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.1097/MD.0000000000022915 [doi]
AID - 00005792-202010300-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22915. doi:
      10.1097/MD.0000000000022915.


PMID- 33126328
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Chinese herbal compound combined with western medicine therapy in the treatment
      of plasma cell mastitis: A protocol for systematic review and meta-analysis.
PG  - e22858
LID - 10.1097/MD.0000000000022858 [doi]
AB  - BACKGROUND: Plasma cell mastitis (PCM) is a benign suppurative disease of the
      breast based on the expansion of mammary ducts and infiltration of plasma cells. 
      It is relatively rare clinically, and its main manifestations include nonperiodic
      breast pain, nipple discharge, areola lump, nipple depression, nipple fistula,
      among others. Modern medicine is mainly surgical treatment, which is easy to
      recur. The clinical practice shows that the overall treatment of patients with
      TCM syndrome differentiation using oral medicine combined with western medicine
      therapy, combined internal and external treatment, can significantly improve the 
      curative effect, prevent recurrence, has a certain therapeutic advantage, but
      lack of evidence of evidence-based medicine. The purpose of this study is to
      study the efficacy and safety of oral traditional Chinese medicine (TCM) combined
      with western medicine therapy in the treatment of PCM. METHODS: Use computer to
      retrieve English databases (PubMed, Embase, Web of Science, the Cochrane Library)
      and Chinese databases (CNKI, Wan Fang, VIP, Chinese biomedical database), from
      the establishment of database to September 2020, for randomized controlled
      trials(RCTs) of oral TCM combined with western medicine therapy in the treatment 
      of PCM, two researchers independently extracted the data and evaluated the
      quality of the included research, and meta-analysis was conducted on the included
      literatures using RevMan5.3 software. RESULTS: This study evaluated the efficacy 
      and safety of oral TCM combined with western medicine therapy in the treatment of
      PCM from the aspects of effective rate, symptom score, recurrence rate, adverse
      reaction rate, and patient satisfaction. CONCLUSION: This study will provide
      reliable evidence-based evidence for the clinical application of oral TCM
      combined with western medicine therapy in the treatment of PCM. ETHICS AND
      DISSEMINATION: The purpose of this study is to sort out and analyze the
      literature. This systematic review also does not involve endangering participant 
      rights. Ethical approval was not required. The results may be published in a
      peer-reviewed journal or disseminated at relevant conferences. OSF REGISTRATION
      NUMBER:: doi 10.17605/OSF.IO/K9A78.
FAU - Zhang, Jindan
AU  - Zhang J
AD  - Changzhi City People's Hospital, Changzhi, Shanxi province, China.
FAU - Xu, Jianzhong
AU  - Xu J
FAU - Zhang, Jiao
AU  - Zhang J
FAU - Ren, Yun
AU  - Ren Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Clinical Protocols
MH  - Drugs, Chinese Herbal/*standards/therapeutic use
MH  - Female
MH  - Humans
MH  - Mastitis/*etiology/physiopathology
MH  - *Meta-Analysis as Topic
MH  - Plasma Cells/*drug effects
MH  - Systematic Reviews as Topic
PMC - PMC7598849
EDAT- 2020/11/01 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/31 01:00
PHST- 2020/10/31 01:00 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1097/MD.0000000000022858 [doi]
AID - 00005792-202010300-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22858. doi:
      10.1097/MD.0000000000022858.


PMID- 33126327
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 44
DP  - 2020 Oct 30
TI  - Guominjian for allergic rhinitis: A protocol for systematic review and
      meta-analysis of randomized clinical trials.
PG  - e22854
LID - 10.1097/MD.0000000000022854 [doi]
AB  - INTRODUCTION: Allergic rhinitis (AR) is an inflammatory disease of nasal mucosa
      caused by IgE mediated inflammatory mediators and various immune active cells and
      cytokines after exposure of specific individuals to allergens. In recent years,
      its prevalence rate has increased gradually. Therefore, we must pay attention to 
      carry out early intervention. However, there are still some side effects in the
      current drug therapy of AR, and the recurrence of AR cannot be well controlled.
      Some Chinese herbs have anti-allergic, anti-inflammatory and immunomodulatory
      effects, and have a better effect on the nasal symptoms of perennial and
      persistent rhinitis. The curative effect of allergic decoction on AR has been
      confirmed clinically. However, due to the lack of reliable evaluation means for
      its safety and effectiveness, it is necessary to carry out a systematic
      evaluation of allergic decoction in the treatment of AR, so as to lay a
      foundation for further research in the future. METHODS AND ANALYSIS: The
      following databases will be searched from their inception to August 2020:
      Electronic database includes PubMed, Embase, Cochrane Library, Web of Science,
      Nature, Science online, Chinese Biomedical Database WanFang, VIP medicine
      information, and China National Knowledge Infrastructure. Primary outcomes: nasal
      symptoms (sneezing, runny nose, nasal itching, and nasal congestion) and ocular
      symptoms (eye itching, foreign body sensation, red eyes, tearing). It can be
      measured by any appropriate scales or other forms of tools, such as the Total
      Nasal Symptom Score. Data will be extracted by 2 researchers independently, risk 
      of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for
      Systematic Reviews of Interventions. All data analysis will be conducted by data 
      statistics software Review Manager V.5.3. and Stata V.12.0. RESULTS: The results 
      of this study will systematically evaluate the efficacy and safety of Guominjian 
      for patients with AR. CONCLUSION: Through the systematic review of this study,
      the evidence of the treatment of AR by Guominjian has been summarized so far, so 
      as to provide guidance for further promoting the application of Guominjian in
      patients with AR. ETHICS AND DISSEMINATION: This study is a systematic review,
      the outcomes are based on the published evidence, so examination and agreement by
      the ethics committee are not required in this study. We intend to publish the
      study results in a journal or conference presentations. OPEN SCIENCE FRA MEWORK
      (OSF) REGISTRATION NUMBER: September 12,
      2020.osf.io/24w8n.(https://osf.io/24w8n).
FAU - Xiong, Yimin
AU  - Xiong Y
AD  - Beijing University of Chinese Medicine, Department of Clinical Medicine, Beijing.
FAU - Li, Haoran
AU  - Li H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
FAU - Zhang, Shu-Nan
AU  - Zhang SN
AD  - China-Japan Friendship Hospital; Department of TCM Pulmonary Diseases, Beijing,
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Clinical Protocols
MH  - Drugs, Chinese Herbal/*standards/therapeutic use
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Rhinitis, Allergic/*drug therapy
MH  - Systematic Reviews as Topic
PMC - PMC7598817
EDAT- 2020/11/01 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/31 01:00
PHST- 2020/10/31 01:00 [entrez]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1097/MD.0000000000022854 [doi]
AID - 00005792-202010300-00031 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 30;99(44):e22854. doi:
      10.1097/MD.0000000000022854.


PMID- 35515484
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220507
IS  - 2056-6697 (Electronic)
IS  - 2056-6697 (Linking)
VI  - 6
IP  - 6
DP  - 2020
TI  - Manifesto for healthcare simulation practice.
PG  - 365-368
LID - 10.1136/bmjstel-2020-000712 [doi]
AB  - A pandemic has sent the world into chaos. It has not only upended our lives;
      hundreds of thousands of lives have already been tragically lost. The global
      crisis has been disruptive, even a threat, to healthcare simulation, affecting
      all aspects of operations from education to employment. While simulationists
      around the world have responded to this crisis, it has also provided a stimulus
      for the continued evolution of simulation. We have crafted a manifesto for
      action, incorporating a more comprehensive understanding of healthcare
      simulation, beyond tool, technique or experience, to understanding it now as a
      professional practice. Healthcare simulation as a practice forms the foundation
      for the three tenets comprising the manifesto: safety, advocacy and leadership.
      Using these three tenets, we can powerfully shape the resilience of healthcare
      simulation practice for now and for the future. Our call to action for all
      simulationists is to adopt a commitment to comprehensive safety, to advocate
      collaboratively and to lead ethically.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Park, Christine S
AU  - Park CS
AUID- ORCID: 0000-0002-5261-9820
AD  - Simulation and Integrative Learning Institute, Department of Medical Education,
      University of Illinois College of Medicine, Chicago, Illinois, USA.
FAU - Clark, Louise
AU  - Clark L
AD  - M Simulation, University of Minnesota Medical School Twin Cities, Minneapolis,
      Minnesota, USA.
FAU - Gephardt, Grace
AU  - Gephardt G
AD  - Arkansas Children's Hospital, Little Rock, Arkansas, USA.
FAU - Robertson, Jamie M
AU  - Robertson JM
AD  - Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Miller, Jane
AU  - Miller J
AD  - Office of Consultation and Research in Medical Education, The University of Iowa 
      Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA.
FAU - Downing, Dayna K
AU  - Downing DK
AD  - Simulation and Technology Education Learning Institute, Children's Health
      Children's Medical Center Dallas, Dallas, Texas, USA.
FAU - Koh, Bee Leng Sabrina
AU  - Koh BLS
AD  - Sengkang General Hospital, Singapore, Singapore.
FAU - Bryant, Kellie D
AU  - Bryant KD
AD  - Columbia University School of Nursing, New York, New York, USA.
FAU - Grant, David
AU  - Grant D
AD  - Bristol Medical Simulation Centre, Bristol, Bristol, UK.
FAU - Pai, Dinker R
AU  - Pai DR
AD  - Simulation, Sri Balaji Vidyapeeth University, Pondicherry, India.
FAU - Gavilanes, Jesika S
AU  - Gavilanes JS
AD  - Oregon Health and Science University, Portland, Oregon, USA.
FAU - Herrera Bastida, Edgar Israel
AU  - Herrera Bastida EI
AD  - Anahuac University Faculty of Health Sciences, Huixquilucan, Mexico.
FAU - Li, Li
AU  - Li L
AUID- ORCID: 0000-0003-4151-967X
AD  - General Practice, Guangzhou First People's Hospital, Guangzhou, Guangdong, China.
FAU - Littlewood, Keith
AU  - Littlewood K
AD  - University of Virginia School of Medicine, Charlottesville, Virginia, USA.
FAU - Escudero, Eliana
AU  - Escudero E
AD  - University Diego Portales, Santiago, Chile.
FAU - Kelly, Michelle Ann
AU  - Kelly MA
AUID- ORCID: 0000-0002-6380-1150
AD  - School of Nursing, Midwifery and Paramedicine, Curtin University, Perth,
      Australia.
FAU - Nestel, Debra
AU  - Nestel D
AUID- ORCID: 0000-0003-2941-2298
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne,
      Australia.
FAU - Rethans, Jan-Joost
AU  - Rethans JJ
AD  - Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht,
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201101
PL  - England
TA  - BMJ Simul Technol Enhanc Learn
JT  - BMJ simulation & technology enhanced learning
JID - 101684779
PMC - PMC8936961
OTO - NOTNLM
OT  - Health Professions Education
OT  - Leadership
OT  - Safety
OT  - Simulation Center Operations/Administration
OT  - Simulation In healthcare
COIS- Competing interests: None declared.
EDAT- 2020/11/01 00:00
MHDA- 2020/11/01 00:01
CRDT- 2022/05/06 05:35
PHST- 2020/06/23 00:00 [received]
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2022/05/06 05:35 [entrez]
PHST- 2020/11/01 00:00 [pubmed]
PHST- 2020/11/01 00:01 [medline]
AID - 10.1136/bmjstel-2020-000712 [doi]
AID - bmjstel-2020-000712 [pii]
PST - epublish
SO  - BMJ Simul Technol Enhanc Learn. 2020 Nov 1;6(6):365-368. doi:
      10.1136/bmjstel-2020-000712. eCollection 2020.


PMID- 35275745
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220602
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 6
DP  - 2020 Nov
TI  - Creating a Global Community of Practice for Oncofertility.
PG  - 317-330
LID - 10.1200/GO.22.00007 [doi]
AB  - Fertility preservation in the cancer setting, known as oncofertility, is a field 
      that requires cross-disciplinary interaction between physicians, basic
      scientists, clinical researchers, ethicists, lawyers, educators, and religious
      leaders. Funded by the National Institutes of Health, the Oncofertility
      Consortium (OC) was formed to be a scientifically grounded, transparent, and
      altruistic resource, both intellectual and monetary, for building this new field 
      of practice capable of addressing the unique needs of young patients with cancer.
      The OC has expanded its attention to include other nonmalignant conditions that
      can threaten fertility, and the work of the OC now extends around the globe,
      involving partners who together have created a community of shared effort,
      resources, and practices. The OC creates materials that are translated,
      disseminated, and amended by all participants in the field, and local programs of
      excellence have developed worldwide to accelerate the pace and improve the
      quality of oncofertility research and practice. Here we review the global
      oncofertility programs and the capacity building activities that strengthen these
      research and clinical programs, ultimately improving patient care.
FAU - Ataman, Lauren M
AU  - Ataman LM
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL.
FAU - Rodrigues, Jhenifer K
AU  - Rodrigues JK
AD  - Brazilian Oncofertility Consortium, Belo Horizonte, Brazil.
AD  - Pro-Criar Medicina Reprodutiva, Belo Horizonte, Brazil.
FAU - Marinho, Ricardo M
AU  - Marinho RM
AD  - Brazilian Oncofertility Consortium, Belo Horizonte, Brazil.
AD  - Pro-Criar Medicina Reprodutiva, Belo Horizonte, Brazil.
AD  - Faculdade de Ciencias Medicas de Minas Gerais, Belo Horizonte, Brazil.
FAU - Caetano, Joao P J
AU  - Caetano JPJ
AD  - Brazilian Oncofertility Consortium, Belo Horizonte, Brazil.
AD  - Pro-Criar Medicina Reprodutiva, Belo Horizonte, Brazil.
AD  - Faculdade de Ciencias Medicas de Minas Gerais, Belo Horizonte, Brazil.
FAU - Chehin, Mauricio B
AU  - Chehin MB
AD  - Brazilian Oncofertility Consortium, Belo Horizonte, Brazil.
AD  - Huntington Reproductive Medicine and Federal University of Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Alves da Motta, Eduardo L
AU  - Alves da Motta EL
AD  - Brazilian Oncofertility Consortium, Belo Horizonte, Brazil.
AD  - Huntington Reproductive Medicine and Federal University of Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Serafini, Paulo
AU  - Serafini P
AD  - Brazilian Oncofertility Consortium, Belo Horizonte, Brazil.
AD  - Huntington Reproductive Medicine and Federal University of Sao Paulo, Sao Paulo, 
      Brazil.
FAU - Suzuki, Nao
AU  - Suzuki N
AD  - St Marianna University School of Medicine, Knagawa, Japan.
FAU - Furui, Tatsuro
AU  - Furui T
AD  - Gifu University Graduate School of Medicine, Gifu, Japan.
FAU - Takae, Seido
AU  - Takae S
AD  - St Marianna University School of Medicine, Knagawa, Japan.
FAU - Sugishita, Yodo
AU  - Sugishita Y
AD  - St Marianna University School of Medicine, Knagawa, Japan.
FAU - Morishige, Ken-Ichiro
AU  - Morishige KI
AD  - Gifu University Graduate School of Medicine, Gifu, Japan.
FAU - Almeida-Santos, Teresa
AU  - Almeida-Santos T
AD  - University Hospital of Coimbra, Coimbra, Portugal.
AD  - University of Coimbra, Coimbra, Portugal.
FAU - Melo, Claudia
AU  - Melo C
AD  - University of Coimbra, Coimbra, Portugal.
FAU - Buzaglo, Karen
AU  - Buzaglo K
AD  - Clinique Ovo, Montreal, Quebec, Canada.
FAU - Irwin, Kate
AU  - Irwin K
AD  - Cancer Knowledge Network, Milton, Ontario, Canada.
FAU - Wallace, W Hamish
AU  - Wallace WH
AD  - Edinburgh Royal Hospital for Sick Children, Edinburgh, United Kingdom.
FAU - Anderson, Richard A
AU  - Anderson RA
AD  - Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United
      Kingdom.
FAU - Mitchell, Roderick T
AU  - Mitchell RT
AD  - Edinburgh Royal Hospital for Sick Children, Edinburgh, United Kingdom.
AD  - Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United
      Kingdom.
FAU - Telfer, Evelyn E
AU  - Telfer EE
AD  - Centres for Fertility Preservation and Integrative Physiology, University of
      Edinburgh, Edinburgh, United Kingdom.
FAU - Adiga, Satish K
AU  - Adiga SK
AD  - Kasturba Medical College, Manipal University, Manipal, India.
FAU - Anazodo, Antoinette
AU  - Anazodo A
AD  - Sydney Children's and Prince of Wales Hospital, Future Fertility, Randwick, New
      South Wales, Australia.
FAU - Stern, Catharyn
AU  - Stern C
AD  - Royal Women's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Sullivan, Elizabeth
AU  - Sullivan E
AD  - University of Technology, Sydney, New South Wales, Australia.
FAU - Jayasinghe, Yasmin
AU  - Jayasinghe Y
AD  - Children's Cancer Centre, Royal Children's Hospital, Parkville, Victoria,
      Australia.
FAU - Orme, Lisa
AU  - Orme L
AD  - Children's Cancer Centre, Royal Children's Hospital, Parkville, Victoria,
      Australia.
FAU - Cohn, Richard
AU  - Cohn R
AD  - Kids Cancer Centre, Sydney Children's Hospital Sydney, New South Wales,
      Australia.
AD  - School of Women's and Children's Health, University of New South Wales, Royal
      Hospital for Women, Sydney, New South Wales, Australia.
FAU - McLachlan, Rob
AU  - McLachlan R
AD  - Monash Institute of Medical Research, Prince Henry's Institute, Clayton,
      Victoria, Australia.
FAU - Deans, Rebecca
AU  - Deans R
AD  - School of Women's and Children's Health, University of New South Wales, Royal
      Hospital for Women, Sydney, New South Wales, Australia.
FAU - Agresta, Franca
AU  - Agresta F
AD  - Royal Women's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Gerstl, Brigitte
AU  - Gerstl B
AD  - Sydney Children's and Prince of Wales Hospital, Future Fertility, Randwick, New
      South Wales, Australia.
FAU - Ledger, William L
AU  - Ledger WL
AD  - School of Women's and Children's Health, University of New South Wales, Royal
      Hospital for Women, Sydney, New South Wales, Australia.
FAU - Robker, Rebecca L
AU  - Robker RL
AD  - Robinson Research Institute, University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - de Meneses E Silva, Joao M
AU  - de Meneses E Silva JM
AD  - Ceara Blood Center, Centro de Hematologia e Hemoterapia do Ceara, Fortaleza,
      Brazil.
AD  - Assis Chateaubri and Maternity School, Federal University of Ceara, Fortaleza,
      Brazil.
FAU - Melo E Silva, Ligia H F
AU  - Melo E Silva LHF
AD  - Federal University of Ceara and Femini Imagem and Ultravida Clinic, Fortaleza,
      Brazil.
FAU - Lunardi, Franciele O
AU  - Lunardi FO
AD  - State University of Ceara, Fortaleza, Brazil.
FAU - Lee, Jung R
AU  - Lee JR
AD  - Seoul National University Bundang Hospital, Seongnam.
AD  - Seoul National University College of Medicine, Seoul, Korea.
FAU - Suh, Chang S
AU  - Suh CS
AD  - Seoul National University Bundang Hospital, Seongnam.
AD  - Seoul National University College of Medicine, Seoul, Korea.
FAU - De Vos, Michael
AU  - De Vos M
AD  - Centre for Reproductive Medicine, Universitair Ziekenhuis (UZ) Brussel, Belgium.
FAU - Van Moer, Ellen
AU  - Van Moer E
AD  - Centre for Reproductive Medicine, Universitair Ziekenhuis (UZ) Brussel, Belgium.
FAU - Stoop, Dominic
AU  - Stoop D
AD  - Centre for Reproductive Medicine, Universitair Ziekenhuis (UZ) Brussel, Belgium.
FAU - Vloeberghs, Veerle
AU  - Vloeberghs V
AD  - Centre for Reproductive Medicine, Universitair Ziekenhuis (UZ) Brussel, Belgium.
FAU - Smitz, Johan
AU  - Smitz J
AD  - Laboratory of Clinical Chemistry and Radioimmunology, UZ Brussel, Brussels,
      Belgium.
FAU - Tournaye, Herman
AU  - Tournaye H
AD  - Centre for Reproductive Medicine, Universitair Ziekenhuis (UZ) Brussel, Belgium.
FAU - Wildt, Ludwig
AU  - Wildt L
AD  - Innsbruck Medical University, Innsbruck, Austria.
FAU - Winkler-Crepaz, Katharina
AU  - Winkler-Crepaz K
AD  - Innsbruck Medical University, Innsbruck, Austria.
FAU - Andersen, Claus Y
AU  - Andersen CY
AD  - Juliane Marie Centre for Women, Children and Reproduction, University Hospital of
      Copenhagen, Copenhagen, Denmark.
FAU - Smith, Brigid M
AU  - Smith BM
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL.
FAU - Smith, Kristin
AU  - Smith K
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL.
FAU - Woodruff, Teresa K
AU  - Woodruff TK
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Corrected and Republished Article
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
SB  - IM
CRF - J Glob Oncol. 2016 Apr;2(2):83-96. PMID: 27284576
EDAT- 2020/11/01 00:00
MHDA- 2020/11/01 00:01
CRDT- 2022/03/11 17:10
PHST- 2022/03/11 17:10 [entrez]
PHST- 2020/11/01 00:00 [pubmed]
PHST- 2020/11/01 00:01 [medline]
AID - 10.1200/GO.22.00007 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2020 Nov;6:317-330. doi: 10.1200/GO.22.00007.


PMID- 33126107
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2468-7812 (Electronic)
IS  - 2468-7812 (Linking)
VI  - 50
DP  - 2020 Dec
TI  - Prevalence of multisite pain and association with work ability - Cross-sectional 
      study.
PG  - 102279
LID - S2468-7812(20)30584-1 [pii]
LID - 10.1016/j.msksp.2020.102279 [doi]
AB  - BACKGROUND: Multisite pain (MSP) has been studied among the working population
      because it is associated with reduced work ability. In Brazil, studies have
      investigated pain without addressing MSP and its interference with work ability. 
      OBJECTIVE: To evaluate the prevalence of MSP among Brazilian workers from
      different occupations and to associate MSP with work ability. METHODS:
      Participants in the BRAzilian eValuation of Occupational health (BRAVO) database 
      were analysed. The BRAVO database contains information about personal data,
      musculoskeletal symptoms (Nordic Musculoskeletal Questionnaire), occupational
      stress (Job Content Questionnaire) and work ability (Work Ability Index). The
      studies were approved by the Ethics Committee and all participants signed an
      informed consent form. Data were analysed using logistic and linear regression.
      Sex, age, comorbidities (hypertension, mild emotional disorder and gastritis),
      type of work (blue and white-collar) and occupational stress were included as
      covariates of the regression models. RESULTS: The prevalence of MSP was 58% (95% 
      CI = 53-62%) among the total sample, 57% (95% CI = 52-62%) in white-collar and
      53% (95% CI = 40-66%) among blue-collar workers. The presence of MSP increases
      the chance of low work ability between 1.8 and 5.1 times. A dose-response
      relationship was found, with the increase in each pain site causing a reduction
      of 0.9-1.2 points in the work ability index. CONCLUSIONS: MSP is highly prevalent
      among Brazilian workers and should be addressed due to its impact on reducing
      work ability.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Souza Mattos de Araujo Vieira, Ludmilla Maria
AU  - Souza Mattos de Araujo Vieira LM
AD  - Department of Physical Therapy, Federal University of Sao Carlos, Sao Carlos, Sao
      Paulo, Brazil.
FAU - de Oliveira Sato, Tatiana
AU  - de Oliveira Sato T
AD  - Department of Physical Therapy, Federal University of Sao Carlos, Sao Carlos, Sao
      Paulo, Brazil. Electronic address: tatisato@ufscar.br.
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - Netherlands
TA  - Musculoskelet Sci Pract
JT  - Musculoskeletal science & practice
JID - 101692753
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Musculoskeletal Pain/epidemiology
MH  - Occupations
MH  - Prevalence
MH  - *Work Capacity Evaluation
OTO - NOTNLM
OT  - *Ergonomics
OT  - *Occupational health
OT  - *Physical therapy
EDAT- 2020/10/31 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/10/30 20:14
PHST- 2020/06/05 00:00 [received]
PHST- 2020/09/09 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/10/30 20:14 [entrez]
AID - S2468-7812(20)30584-1 [pii]
AID - 10.1016/j.msksp.2020.102279 [doi]
PST - ppublish
SO  - Musculoskelet Sci Pract. 2020 Dec;50:102279. doi: 10.1016/j.msksp.2020.102279.
      Epub 2020 Oct 23.


PMID- 33124993
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201120
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 30
TI  - Harmonized One Health Trans-Species and Community Surveillance for Tackling
      Antibacterial Resistance in India: Protocol for a Mixed Methods Study.
PG  - e23241
LID - 10.2196/23241 [doi]
AB  - BACKGROUND: India has the largest burden of drugresistant organisms compared with
      other countries around the world, including multiresistant and extremely
      drugresistant tuberculosis and resistant Gramnegative and Grampositive bacteria. 
      Antibiotic resistant bacteria are found in all living hosts and in the
      environment and move between hosts and ecosystems. An intricate interplay of
      infections, exposure to antibiotics, and disinfectants at individual and
      community levels among humans, animals, birds, and fishes triggers evolution and 
      spread of resistance. The One Health framework proposes addressing antibiotic
      resistance as a complex multidisciplinary problem. However, the evidence base in 
      the Indian context is limited. OBJECTIVE: This multisectoral, trans-species
      surveillance project aims to document the infection and resistance patterns of 7 
      resistant-priority bacteria and the risk factors for resistance following the One
      Health framework and geospatial epidemiology. METHODS: This hospital- and
      community-based surveillance adopts a cross-sectional design with mixed
      methodology (quantitative, qualitative, and spatial) data collection. This study 
      is being conducted at 6 microbiology laboratories and communities in Khurda
      district, Odisha, India. The laboratory surveillance collects data on bacteria
      isolates from different hosts and their resistance patterns. The hosts for
      infection surveillance include humans, animals (livestock, food chain, and pet
      animals), birds (poultry), and freshwater fishes (not crustaceans). For eligible 
      patients, animals, birds and fishes, detailed data from their households or farms
      on health care seeking (for animals, birds and fishes, the illness, and care
      seeking of the caretakers), antibiotic use, disinfection practices, and
      neighborhood exposure to infection risks will be collected. Antibiotic
      prescription and use patterns at hospitals and clinics, and therapeutic and
      nontherapeutic antibiotic and disinfectant use in farms will also be collected.
      Interviews with key informants from animal breeding, agriculture, and food
      processing will explore the perceptions, attitudes, and practices related to
      antibiotic use. The data analysis will follow quantitative (descriptive and
      analytical), qualitative, and geospatial epidemiology principles. RESULTS: The
      study was funded in May 2019 and approved by Institute Ethics Committees in March
      2019. The data collection started in September 2019 and shall continue till March
      2021. As of June 2020, data for 56 humans, 30 animals and birds, and fishes from 
      10 ponds have been collected. Data analysis is yet to be done. CONCLUSIONS: This 
      study will inform about the bacterial infection and resistance epidemiology among
      different hosts, the risk factors for infection, and resistance transmission. In 
      addition, it will identify the potential triggers and levers for further
      exploration and action. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/23241.
CI  - (c) HOTSTAR-India Study Group, Manoja Kumar Das, Ashoka Mahapatra, Basanti Pathi,
      Rajashree Panigrahy, Swetalona Pattnaik, Sudhansu Shekhar Mishra, Samarendra
      Mahapatro, Priyabrat Swain, Jayakrushna Das, Shikha Dixit, Satya Narayan Sahoo,
      Rakesh N Pillai. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 30.10.2020.
CN  - HOTSTAR-India Study Group
AD  - The INCLEN Trust International, New Delhi, India.
FAU - Das, Manoja Kumar
AU  - Das MK
AUID- ORCID: https://orcid.org/0000-0002-8559-5837
AD  - Department of Public Health, The INCLEN Trust International, New Delhi, India.
FAU - Mahapatra, Ashoka
AU  - Mahapatra A
AUID- ORCID: https://orcid.org/0000-0002-4046-7305
AD  - Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar,
      Odisha, India.
FAU - Pathi, Basanti
AU  - Pathi B
AUID- ORCID: https://orcid.org/0000-0001-9112-3249
AD  - Department of Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar,
      Odisha, India.
FAU - Panigrahy, Rajashree
AU  - Panigrahy R
AUID- ORCID: https://orcid.org/0000-0002-4015-4894
AD  - Department of Microbiology, Institute of Medical Sciences and SUM Hospital,
      Bhubaneswar, Odisha, India.
FAU - Pattnaik, Swetalona
AU  - Pattnaik S
AUID- ORCID: https://orcid.org/0000-0001-8681-1215
AD  - Department of Microbiology, Hi-Tech Medical College, Bhubaneswar, Odisha, India.
FAU - Mishra, Sudhansu Shekhar
AU  - Mishra SS
AUID- ORCID: https://orcid.org/0000-0003-3643-5359
AD  - Fish Health Management Division, Central Institute of Freshwater Aquaculture
      (ICAR), Bhubaneswar, Odisha, India.
FAU - Mahapatro, Samarendra
AU  - Mahapatro S
AUID- ORCID: https://orcid.org/0000-0002-9086-0797
AD  - Department of Pediatrics, All India Institute of Medical Sciences, Bhubaneswar,
      Odisha, India.
FAU - Swain, Priyabrat
AU  - Swain P
AUID- ORCID: https://orcid.org/0000-0002-0561-5085
AD  - Fish Health Management Division, Central Institute of Freshwater Aquaculture
      (ICAR), Bhubaneswar, Odisha, India.
FAU - Das, Jayakrushna
AU  - Das J
AUID- ORCID: https://orcid.org/0000-0002-7547-496X
AD  - Department of Veterinary Surgery, College of Veterinary Science and Animal
      Husbandry (OUAT), Bhubaneswar, Odisha, India.
FAU - Dixit, Shikha
AU  - Dixit S
AUID- ORCID: https://orcid.org/0000-0001-5618-5268
AD  - Department of Environmental Health, The INCLEN Trust International, New Delhi,
      India.
FAU - Sahoo, Satya Narayan
AU  - Sahoo SN
AUID- ORCID: https://orcid.org/0000-0002-3426-5512
AD  - Fish Health Management Division, Central Institute of Freshwater Aquaculture
      (ICAR), Bhubaneswar, Odisha, India.
FAU - Pillai, Rakesh N
AU  - Pillai RN
AUID- ORCID: https://orcid.org/0000-0001-8490-2877
AD  - Department of Public Health, The INCLEN Trust International, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7665953
OTO - NOTNLM
OT  - India
OT  - One Health
OT  - antibiotics resistance
OT  - bacterial infection
OT  - drug prescriptions
OT  - sentinel surveillance
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 12:09
PHST- 2020/08/05 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/10/30 12:09 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
AID - v9i10e23241 [pii]
AID - 10.2196/23241 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 30;9(10):e23241. doi: 10.2196/23241.


PMID- 33124935
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210211
IS  - 2042-6313 (Electronic)
IS  - 2042-6305 (Linking)
VI  - 9
IP  - 16
DP  - 2020 Nov
TI  - Six ways to foster community-engaged research during times of societal crises.
PG  - 1101-1104
LID - 10.2217/cer-2020-0206 [doi]
FAU - Edwards, Hillary A
AU  - Edwards HA
AUID- ORCID: 0000-0001-6607-8351
AD  - Department of Pharmaceutical Health Services Research, University of Maryland,
      Baltimore, MD 21201, USA.
FAU - Monroe, Dwyan Y
AU  - Monroe DY
AD  - Institute for Public Health Innovation, Washington, DC 20036, USA.
FAU - Mullins, C Daniel
AU  - Mullins CD
AUID- ORCID: 0000-0003-4322-2490
AD  - Department of Pharmaceutical Health Services Research, University of Maryland,
      Baltimore, MD 21201, USA.
LA  - eng
PT  - Editorial
DEP - 20201030
PL  - England
TA  - J Comp Eff Res
JT  - Journal of comparative effectiveness research
JID - 101577308
SB  - IM
PMC - PMC7668134
OTO - NOTNLM
OT  - * community-based participatory research (CBPR)
OT  - *community-academic partnerships
OT  - *community-engaged research (CEnR)
OT  - *medical ethics
OT  - *stakeholder engagement
OT  - *trust
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 12:09
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
PHST- 2020/10/30 12:09 [entrez]
AID - 10.2217/cer-2020-0206 [doi]
PST - ppublish
SO  - J Comp Eff Res. 2020 Nov;9(16):1101-1104. doi: 10.2217/cer-2020-0206. Epub 2020
      Oct 30.


PMID- 33124658
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210110
IS  - 1873-5843 (Electronic)
IS  - 0887-6177 (Linking)
VI  - 35
IP  - 8
DP  - 2020 Nov 19
TI  - A Teleneuropsychology Consultation Service Model for Children with
      Neurodevelopmental and Acquired Disorders Residing in Rural State Regions.
PG  - 1196-1203
LID - 10.1093/arclin/acaa099 [doi]
AB  - OBJECTIVE: Accessing neuropsychological services, which are often centralized in 
      urban regions, poses unique challenges to children and families in rural regions.
      In 2017, urban neuropsychologists and a pediatrician practicing in a rural region
      of New Mexico started to develop a teleneuropsychology (TeleNP) consultation
      service model to efficiently triage and determine a clinical course of action.
      This pilot project, aimed at expanding clinical access to specialized pediatric
      services in rural areas, evolved over the course of 2 years prior to the
      coronavirus disease 2019 pandemic. METHOD: Providers earned the trust of the
      local community, gained understanding of pertinent sociocultural factors, and
      acquired knowledge of the clinical and educational concerns for the children
      residing in the rural community. The application of a culturally informed
      approach that highlights the importance of community participation and
      collaboration steered the decision to implement a TeleNP consultation model. By
      widening access to neuropsychology, this service helped to determine whether
      neuropsychological testing procedures were medically indicated. RESULTS: We
      summarize the distinct processes that needed to occur at each location to support
      the implementation of telemedicine. We propose a clinical service decision tree
      with specific criteria to help guide providers on how to triage cases in order to
      increase access to specialized healthcare. CONCLUSION: The success of
      implementing a TeleNP consultation service hinges upon ongoing care coordination 
      between providers, clerical staff, patients, and families with clear goals and
      expectations, maintenance of legal and ethical standards, and development of
      specific administrative and clinical processes supporting the use of TeleNP.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights
      reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Sherwood, Andrea R
AU  - Sherwood AR
AD  - University of New Mexico Hospitals, Health Sciences Center, Albuquerque, USA.
FAU - MacDonald, Beatriz
AU  - MacDonald B
AD  - Department of Pediatrics, Section of Psychology, Baylor College of Medicine,
      Houston, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Clin Neuropsychol
JT  - Archives of clinical neuropsychology : the official journal of the National
      Academy of Neuropsychologists
JID - 9004255
SB  - IM
MH  - *COVID-19
MH  - Child
MH  - Humans
MH  - Neuropsychological Tests
MH  - Pilot Projects
MH  - Referral and Consultation
MH  - *Rural Population
PMC - PMC7665470
OTO - NOTNLM
OT  - Cultural Neuropsychology
OT  - Pediatrics
OT  - Telemedicine
OT  - Teleneuropsychology
EDAT- 2020/10/31 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/30 08:39
PHST- 2020/09/23 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/30 08:39 [entrez]
AID - 5942897 [pii]
AID - 10.1093/arclin/acaa099 [doi]
PST - ppublish
SO  - Arch Clin Neuropsychol. 2020 Nov 19;35(8):1196-1203. doi: 10.1093/arclin/acaa099.


PMID- 33124614
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2409-515X (Electronic)
IS  - 2409-515X (Linking)
VI  - 6
IP  - 4
DP  - 2020 Sep 25
TI  - We All Have a Role to Play: Redressing Inequities for Children Living with CAH
      and Other Chronic Health Conditions of Childhood in Resource-Poor Settings.
LID - E76 [pii]
LID - 10.3390/ijns6040076 [doi]
AB  - CLAN (Caring and Living as Neighbours) is an Australian-based non-governmental
      organisation (NGO) committed to equity for children living with chronic health
      conditions in resource-poor settings. Since 2004, CLAN has collaborated with a
      broad range of partners across the Asia Pacific region to improve quality of life
      for children living with congenital adrenal hyperplasia (CAH). This exploratory
      case study uses the Knowledge to Action (KTA) framework to analyse CLAN's
      activities for children living with CAH in the Asia Pacific. The seven stages of 
      the KTA action cycle inform a systematic examination of comprehensive,
      collaborative, sustained actions to address a complex health challenge. The KTA
      framework demonstrates the "how" of CLAN's approach to knowledge creation and
      exchange, and the centrality of community development to multisectoral
      collaborative action across a range of conditions, cultures and countries to
      redressing child health inequities. This includes a commitment to: affordable
      access to essential medicines and equipment; education, research and advocacy;
      optimisation of medical management; encouragement of family support groups;
      efforts to reduce financial burdens; and ethical, transparent program management 
      as critical components of success. Improvements in quality of life and health
      outcomes are achievable for children living with CAH and other chronic health
      conditions in resource-poor settings. CLAN's strategic framework for action
      offers a model for those committed to #LeaveNoChildBehind.
FAU - Armstrong, Kate
AU  - Armstrong K
AUID- ORCID: 0000-0001-5793-4822
AD  - CLAN (Caring & Living As Neighbours), Denistone 2114, Australia.
AD  - College of Medicine & Public Health, Flinders University, Adelaide 5042,
      Australia.
FAU - Benedict Yap, Alain
AU  - Benedict Yap A
AD  - CAHSAPI (Congenital Adrenal Hyperplasia Support Group of the Philippines), Manila
      1000, Philippines.
FAU - Chan-Cua, Sioksoan
AU  - Chan-Cua S
AD  - Department of Pediatrics, Philippines General Hospital, Manila 1000, Philippines.
FAU - Craig, Maria E
AU  - Craig ME
AUID- ORCID: 0000-0001-6004-576X
AD  - Institute of Endocrinology and Diabetes, The Children's Hospital at
      Westmead/Discipline of Child and Adolescent Health, University of Sydney,
      Camperdown 2006, Australia.
AD  - School of Women's and Children's Health, UNSW Medicine, Kensington 2052,
      Australia.
FAU - Cole, Catherine
AU  - Cole C
AD  - CLAN (Caring & Living As Neighbours), Denistone 2114, Australia.
FAU - Chi Dung, Vu
AU  - Chi Dung V
AD  - Department of Pediatric Endocrinology and Metabolism, National Children's
      Hospital, Hanoi 100000, Vietnam.
FAU - Hansen, Joseph
AU  - Hansen J
AD  - CLAN (Caring & Living As Neighbours), Denistone 2114, Australia.
FAU - Ibrahim, Mohsina
AU  - Ibrahim M
AD  - National Institute of Child Health (NICH), Karachi 75510, Pakistan.
FAU - Nadeem, Hassana
AU  - Nadeem H
AD  - National Institute of Child Health (NICH), Karachi 75510, Pakistan.
FAU - Pulungan, Aman
AU  - Pulungan A
AD  - Department of Child Health University of Indonesia, Dr. Cipto Mangunkusumo
      Hospital, Jakarta 10430, Indonesia.
FAU - Raza, Jamal
AU  - Raza J
AD  - National Institute of Child Health (NICH), Karachi 75510, Pakistan.
FAU - Utari, Agustini
AU  - Utari A
AUID- ORCID: 0000-0001-5965-1981
AD  - Department of Pediatrics, Faculty of Medicine, Diponegoro University, Semarang
      50275, Indonesia.
FAU - Ward, Paul
AU  - Ward P
AUID- ORCID: 0000-0002-5559-9714
AD  - College of Medicine & Public Health, Flinders University, Adelaide 5042,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - Switzerland
TA  - Int J Neonatal Screen
JT  - International journal of neonatal screening
JID - 101665400
PMC - PMC7711668
OTO - NOTNLM
OT  - child
OT  - chronic
OT  - community
OT  - community development
OT  - congenital adrenal hyperplasia
OT  - human rights
OT  - inequity
OT  - non-communicable diseases
OT  - parents
OT  - poverty
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 08:39
PHST- 2020/09/01 00:00 [received]
PHST- 2020/09/19 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/30 08:39 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
AID - ijns6040076 [pii]
AID - 10.3390/ijns6040076 [doi]
PST - epublish
SO  - Int J Neonatal Screen. 2020 Sep 25;6(4). pii: ijns6040076. doi:
      10.3390/ijns6040076.


PMID- 33124602
OWN - NLM
STAT- MEDLINE
DCOM- 20220126
LR  - 20220126
IS  - 1361-6498 (Electronic)
IS  - 0952-4746 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Oct 28
TI  - Assessment of the potential impact of embedded radioactive fragments following
      the use of a crude radiological dispersal device ('dirty bomb').
LID - 10.1088/1361-6498/abb14c [doi]
AB  - This work was undertaken to understand what would happen if a high-activity
      radioactive fragment became embedded in an individual following the use of a
      crude radiological dispersal device ('dirty bomb'). Two areas were addressed: how
      would a high-activity fragment be viewed on modern digital x-ray imaging systems;
      and, what would be the impact on medical management for the patient? A set of
      experimental trials were undertaken using an iridium-192 source and a DRagon
      mobile x-ray set equipped with a Canon CXDI-50G portable flat panel digital
      detector plate. In addition, the potential doses to a surgical team were
      calculated and potential doses to a patient were assessed using a Monte Carlo
      code, in which a radioactive point source of nil volume was located within a limb
      of an anthropomorphic voxel phantom. Three distinct effects on the digital
      imaging systems were observed, referred to in this paper as a localised 'bloom'
      effect, a 'discontinuity' effect towards the middle of the image and 'fogging'
      across the entire image. The first two of these effects were unexpected, and
      possible reasons for their appearance are discussed. The Monte Carlo modelling
      showed that the patient exposure can potentially lead to very high localised
      absorbed doses, which may result in symptoms associated with acute radiation
      syndrome. While the dose clearly depends upon the activity of the fragment and
      the length of time that the fragment is present inside the patient, it is clear
      that radiation necrosis of bone, muscle and other tissues may threaten the medium
      term viability of the limb. The dose rates associated with high-activity
      fragments may also restrict the time a surgeon has to operate, leading to
      challenging ethical and surgical decisions. Low-activity fragments allow for
      conventional surgical management to be considered with appropriate control
      measures.
CI  - Creative Commons Attribution license.
FAU - Jones, Laurence
AU  - Jones L
AD  - Dstl, Alverstoke, United Kingdom.
FAU - Moor, Donna
AU  - Moor D
AD  - Dstl, Alverstoke, United Kingdom.
FAU - Peacock, Thomas
AU  - Peacock T
AD  - Dstl, Porton Down, United Kingdom.
FAU - Melley, Thomas
AU  - Melley T
AD  - Dstl, Alverstoke, United Kingdom.
FAU - Foster, Crawford
AU  - Foster C
AD  - Institute of Naval Medicine, Alverstoke, United Kingdom.
FAU - Bland, Steven
AU  - Bland S
AD  - Queen Alexandra Hospital, Cosham, United Kingdom.
FAU - Gibb, Iain
AU  - Gibb I
AD  - Queen Alexandra Hospital, Cosham, United Kingdom.
FAU - Napier, Ian
AU  - Napier I
AUID- ORCID: 0000-0002-9389-3631
AD  - Dstl, Porton Down, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - J Radiol Prot
JT  - Journal of radiological protection : official journal of the Society for
      Radiological Protection
JID - 8809257
SB  - IM
MH  - Humans
MH  - *Nuclear Weapons
MH  - Phantoms, Imaging
MH  - *Radiation Injuries
MH  - *Radioactivity
MH  - Radiographic Image Enhancement
OTO - NOTNLM
OT  - RDD
OT  - digital radiography
OT  - dirty bomb
OT  - radioactive fragment
EDAT- 2020/10/31 06:00
MHDA- 2022/01/27 06:00
CRDT- 2020/10/30 08:38
PHST- 2020/07/21 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2020/10/30 08:38 [entrez]
AID - 10.1088/1361-6498/abb14c [doi]
PST - epublish
SO  - J Radiol Prot. 2020 Oct 28;40(4). doi: 10.1088/1361-6498/abb14c.


PMID- 33124437
OWN - NLM
STAT- Publisher
LR  - 20201030
IS  - 1816-5370 (Electronic)
IS  - 0218-4923 (Linking)
DP  - 2020 Oct 30
TI  - Global health initiatives in cardiothoracic surgery: Ethical considerations and
      guidelines.
PG  - 218492320974504
LID - 10.1177/0218492320974504 [doi]
FAU - Fenton, Kathleen N
AU  - Fenton KN
AD  - Division of Cardiovascular Sciences, Advanced Technologies and Surgery Branch,
      National Heart, Lung, and Blood Institute.
AD  - Department of Bioethics, Clinical Center, National Institutes of Health,
      Bethesda, Md.
AD  - William Novick Global Cardiac Alliance, Memphis, Tenn.
FAU - Novick, William M
AU  - Novick WM
AD  - William Novick Global Cardiac Alliance, Memphis, Tenn.
AD  - University of Tennessee Health Science Center, Global Surgery Institute, Memphis,
      Tenn.
FAU - Entwistle, John W 3rd
AU  - Entwistle JW 3rd
AD  - Division of Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia,
      Pa.
FAU - Moffatt-Bruce, Susan D
AU  - Moffatt-Bruce SD
AD  - Division of Thoracic Surgery, Department of Surgery, Ohio State University,
      Columbus, Ohio.
FAU - Sade, Robert M
AU  - Sade RM
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Institute of Human
      Values in Health Care, Medical University of South Carolina, Charleston, SC.
CN  - Cardiothoracic Ethics Forum
LA  - eng
PT  - Journal Article
DEP - 20201030
PL  - England
TA  - Asian Cardiovasc Thorac Ann
JT  - Asian cardiovascular & thoracic annals
JID - 9503417
SB  - IM
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/30 08:38
PHST- 2020/10/30 08:38 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1177/0218492320974504 [doi]
PST - aheadofprint
SO  - Asian Cardiovasc Thorac Ann. 2020 Oct 30:218492320974504. doi:
      10.1177/0218492320974504.


PMID- 33123514
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - A Systematic Review of the Criminogenic Potential of Synthetic Biology and Routes
      to Future Crime Prevention.
PG  - 571672
LID - 10.3389/fbioe.2020.571672 [doi]
AB  - Synthetic biology has the potential to positively transform society in many
      application areas, including medicine. In common with all revolutionary new
      technologies, synthetic biology can also enable crime. Like cybercrime, that
      emerged following the advent of the internet, biocrime can have a significant
      effect on society, but may also impact on peoples' health. For example, the scale
      of harm caused by the SARS-CoV-2 pandemic illustrates the potential impact of
      future biocrime and highlights the need for prevention strategies. Systematic
      evidence quantifying the crime opportunities posed by synthetic biology has to
      date been very limited. Here, we systematically reviewed forms of crime that
      could be facilitated by synthetic biology with a view to informing their
      prevention. A total of 794 articles from four databases were extracted and a
      three-step screening phase resulted in 15 studies that met our threshold
      criterion for thematic synthesis. Within those studies, 13 exploits were
      identified. Of these, 46% were dependent on technologies characteristic of
      synthetic biology. Eight potential crime types emerged from the studies:
      bio-discrimination, cyber-biocrime, bio-malware, biohacking, at-home drug
      manufacturing, illegal gene editing, genetic blackmail, and neuro-hacking. 14
      offender types were identified. For the most commonly identified offenders (>3
      mentions) 40% were outsider threats. These observations suggest that synthetic
      biology presents substantial new offending opportunities. Moreover, that more
      effective engagement, such as ethical hacking, is needed now to prevent a crime
      harvest from developing in the future. A framework to address the synthetic
      biology crime landscape is proposed.
CI  - Copyright (c) 2020 Elgabry, Nesbeth and Johnson.
FAU - Elgabry, Mariam
AU  - Elgabry M
AD  - Dawes Center for Future Crime, Jill Dando Institute, Department of Security and
      Crime Science, University College London, London, United Kingdom.
AD  - Advanced Centre for Biochemical Engineering, University College London, London,
      United Kingdom.
FAU - Nesbeth, Darren
AU  - Nesbeth D
AD  - Advanced Centre for Biochemical Engineering, University College London, London,
      United Kingdom.
FAU - Johnson, Shane D
AU  - Johnson SD
AD  - Dawes Center for Future Crime, Jill Dando Institute, Department of Security and
      Crime Science, University College London, London, United Kingdom.
LA  - eng
PT  - Systematic Review
DEP - 20201006
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7573185
OTO - NOTNLM
OT  - biocrime
OT  - biosecurity
OT  - crime harvest
OT  - crime science
OT  - cyberbiosecurity
OT  - synthetic biology
OT  - systematic review
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 05:55
PHST- 2020/06/11 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/30 05:55 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
AID - 10.3389/fbioe.2020.571672 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 Oct 6;8:571672. doi: 10.3389/fbioe.2020.571672.
      eCollection 2020.


PMID- 33123381
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2090-214X (Print)
VI  - 2020
DP  - 2020
TI  - Knowledge about COVID-19 and Practices among Hemodialysis Technicians in the
      COVID-19 Pandemic Era.
PG  - 6710503
LID - 10.1155/2020/6710503 [doi]
AB  - INTRODUCTION: Hemodialysis technicians play a crucial role in infection control
      practices in hemodialysis units. Thus, it is important to assess the knowledge
      and attitude towards COVID-19 among hemodialysis technicians in this pandemic
      situation. MATERIALS AND METHODS: An online survey composed of 22 closed-ended
      questions using Google Forms was conducted in the month of April (13th to 19th)
      2020. The survey consisted of questions regarding the knowledge of COVID-19 and
      current hemodialysis practice among hemodialysis technicians. The study was
      approved by the institutional ethics board. The survey was administered online
      through a mobile phone invitation. Basic statistics (mean and standard deviation 
      or total number and percent) were computed for all covariates. RESULTS: Out of
      150, 115 technicians participated in the survey. 80.9% of the participants were
      males. The mean age of respondents was 28.22 + 6.97 years. Most of the
      respondents could correctly identify fever (87.8%), breathlessness (86.08%), and 
      dry cough (81.7%) as the symptoms of COVID-19 infection. 75.7% of the technicians
      were aware that it can be transmitted by asymptomatic persons. 61.1% of the
      technicians were segregating patients who had symptoms such as fever and cough to
      the last shift of the day. 81.1% of the technicians read the guidelines issued by
      the Indian Society of Nephrology-COVID-19 working group. But, only 25.5% of the
      respondents could rightly identify to keep a minimum distance of two meters
      between two beds while dialyzing a suspected patient of COVID-19 along with other
      patients to minimise risk of COVID-19 transmission. 60% of the technicians have
      received hydroxychloroquine as prophylaxis against coronavirus infection.
      CONCLUSION: Our study shows a significant knowledge gap among hemodialysis
      technicians about COVID-19. Effective COVID-19 education campaigns should be
      carried out intensively with relevant information among hemodialysis technicians 
      to address the knowledge gap. A well-informed hemodialysis technician can prove
      to be a great tool to spread the right infection control practices among
      dialysis-dependent patients.
CI  - Copyright (c) 2020 Amit S. Pasari et al.
FAU - Pasari, Amit S
AU  - Pasari AS
AD  - Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha,
      Maharashtra, India.
FAU - Bhawane, Amol
AU  - Bhawane A
AD  - Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha,
      Maharashtra, India.
FAU - Balwani, Manish R
AU  - Balwani MR
AUID- ORCID: https://orcid.org/0000-0003-3923-6953
AD  - Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha,
      Maharashtra, India.
FAU - Tolani, Priyanka
AU  - Tolani P
AD  - Department of Medicine, NKPSIMS, Nagpur, Maharashtra, India.
FAU - Ramteke, Vishal
AU  - Ramteke V
AD  - Department of Nephrology, Kingsway Hospital, Nagpur, Maharashtra, India.
FAU - Deshpande, Nishant
AU  - Deshpande N
AD  - Department of Nephrology, Alexis Hospital, Nagpur, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - United States
TA  - Int J Nephrol
JT  - International journal of nephrology
JID - 101546753
PMC - PMC7585647
COIS- The authors declare that there are no conflicts of interest regarding the
      publication of this paper.
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 05:54
PHST- 2020/04/21 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/10/30 05:54 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
AID - 10.1155/2020/6710503 [doi]
PST - epublish
SO  - Int J Nephrol. 2020 Oct 16;2020:6710503. doi: 10.1155/2020/6710503. eCollection
      2020.


PMID- 33123060
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Does Organizational Cronyism Lead to Lower Employee Performance? Examining the
      Mediating Role of Employee Engagement and Moderating Role of Islamic Work Ethics.
PG  - 579560
LID - 10.3389/fpsyg.2020.579560 [doi]
AB  - In this research, using a time-lagged approach, we investigated the relationship 
      between organizational cronyism and employee performance. Drawing on the
      conservation of resources theory, we tested the mediating role of employee
      engagement in the relationship between organizational cronyism and employee
      performance. We also examined how Islamic work ethics moderated the relationship 
      between organizational cronyism and work engagement. The study, with a total of
      267 participants, was conducted in the healthcare sector of Pakistan. The results
      revealed that organizational cronyism was negatively related to employee
      performance. The analyses confirmed the mediating role of work engagement in the 
      relationship between organizational cronyism and employee performance. Similarly,
      Islamic work ethics moderated the relationship between organizational cronyism
      and work engagement. Implications for future research as well as managerial
      implications of our findings along with the limitations and future research
      directions are also discussed.
CI  - Copyright (c) 2020 Shaheen, Zulfiqar, Saleem and Shehazadi.
FAU - Shaheen, Sadia
AU  - Shaheen S
AD  - Lyallpur Business School, Government College University Faisalabad, Faisalabad,
      Pakistan.
FAU - Zulfiqar, Sehar
AU  - Zulfiqar S
AD  - Department of Management Sciences, National University of Modern Languages,
      Islamabad, Pakistan.
FAU - Saleem, Sharjeel
AU  - Saleem S
AD  - Lyallpur Business School, Government College University Faisalabad, Faisalabad,
      Pakistan.
FAU - Shehazadi, Gulshan
AU  - Shehazadi G
AD  - Lyallpur Business School, Government College University Faisalabad, Faisalabad,
      Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7566910
OTO - NOTNLM
OT  - Islamic work ethics
OT  - conservation of resources theory
OT  - employee performance
OT  - organizational cronyism
OT  - work engagement
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 05:53
PHST- 2020/07/02 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/30 05:53 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
AID - 10.3389/fpsyg.2020.579560 [doi]
PST - epublish
SO  - Front Psychol. 2020 Oct 2;11:579560. doi: 10.3389/fpsyg.2020.579560. eCollection 
      2020.


PMID- 33123042
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Clinical Neuropsychology as a Specialist Profession in European Health Care:
      Developing a Benchmark for Training Standards and Competencies Using the Europsy 
      Model?
PG  - 559134
LID - 10.3389/fpsyg.2020.559134 [doi]
AB  - The prevalence and negative impact of brain disorders are increasing. Clinical
      Neuropsychology is a specialty dedicated to understanding brain-behavior
      relationships, applying such knowledge to the assessment of cognitive, affective,
      and behavioral functioning associated with brain disorders, and designing and
      implementing effective treatments. The need for services goes beyond neurological
      diseases and has increased in areas of neurodevelopmental and psychiatric
      conditions, among others. In Europe, a great deal of variability exists in the
      education and training of Clinical Neuropsychologists. Training models include
      master's programs, continuing education courses, doctoral programs, and/or
      post-doctoral specialization depending on the country, with no common framework
      of requirements, although patients' needs demand equal competencies across
      Europe. In the past 5 years, the Standing Committee on Clinical Neuropsychology
      of the European Federation of Psychologists' Association has conducted a series
      of surveys and interviews with experts in the field representing 30 European
      countries. The information, along with information from the existing literature, 
      is used in presenting an overview of current and relevant topics related to
      policy and guidelines in the training and competencies in Clinical
      Neuropsychology. An option for the way forward is the EuroPsy Specialist
      Certificate, which is currently offered in Work and Organizational Psychology,
      and in psychotherapy. It builds upon the basic certificate and complements
      national standards without overriding them. General principles can be found that 
      can set the basis for a common, solid, and comprehensive specialty
      education/training, sharpening the Neuropsychologists' competencies across
      Europe. The requirements in Clinical Neuropsychology should be comparable to
      those for the existing specialty areas in the EuroPsy model. Despite the
      perceived challenges, developing a specialist certificate appears a step forward 
      for the development of Clinical Neuropsychology. Recommendations are proposed
      toward a shared framework of competencies by the means of a common level of
      education/training for the professionals in Europe. Benchmarking training
      standards and competencies across Europe has the potential of providing
      protection against unqualified and ethically questionable practice, creating
      transparency, raising the general European standard, and promoting mobility of
      both Clinical Neuropsychologists and patients in Europe, for the benefit of the
      professional field and the population.
CI  - Copyright (c) 2020 Hokkanen, Barbosa, Ponchel, Constantinou, Kosmidis, Varako,
      Kasten, Mondini, Lettner, Baker, Persson and Hessen.
FAU - Hokkanen, Laura
AU  - Hokkanen L
AD  - Department of Psychology and Logopedics, Faculty of Medicine, University of
      Helsinki, Helsinki, Finland.
FAU - Barbosa, Fernando
AU  - Barbosa F
AD  - Laboratory of Neuropsychophysiology, Faculty of Psychology and Education
      Sciences, University of Porto, Porto, Portugal.
FAU - Ponchel, Amelie
AU  - Ponchel A
AD  - GHU Paris Psychiatry & Neuroscience, Paris, France.
FAU - Constantinou, Marios
AU  - Constantinou M
AD  - Department of Social Sciences, University of Nicosia, Nicosia, Cyprus.
FAU - Kosmidis, Mary H
AU  - Kosmidis MH
AD  - Lab of Cognitive Neuroscience, School of Psychology, Aristotle University of
      Thessaloniki, Thessaloniki, Greece.
FAU - Varako, Nataliya
AU  - Varako N
AD  - Research Center of Neurology, Lomonosov Moscow State University, Moscow, Russia.
FAU - Kasten, Erich
AU  - Kasten E
AD  - Department of Psychology - Neurosciences, MSH University of Applied Sciences &
      Medical University, Hamburg, Germany.
FAU - Mondini, Sara
AU  - Mondini S
AD  - Department of Philosophy, Sociology, Education and Applied Psychology, University
      of Padova, Padova, Italy.
FAU - Lettner, Sandra
AU  - Lettner S
AD  - Clinical Neuropsychology Unit, Hospital of the Sisters of Charity, Ried, Austria.
FAU - Baker, Gus
AU  - Baker G
AD  - Division of Neurosciences, University of Liverpool, Liverpool, United Kingdom.
FAU - Persson, Bengt A
AU  - Persson BA
AD  - Department of Psychology, Linnaeus University, Vaxjo, Sweden.
FAU - Hessen, Erik
AU  - Hessen E
AD  - Department of Psychology, University of Oslo, Oslo, Norway.
AD  - Department of Neurology, Akershus University Hospital, Lorenskog, Norway.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7573555
OTO - NOTNLM
OT  - EuroPsy
OT  - clinical neuropsychology
OT  - competencies
OT  - guidelines and recommendations
OT  - specialization
OT  - standards
OT  - training
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
CRDT- 2020/10/30 05:53
PHST- 2020/05/05 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/30 05:53 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
AID - 10.3389/fpsyg.2020.559134 [doi]
PST - epublish
SO  - Front Psychol. 2020 Oct 6;11:559134. doi: 10.3389/fpsyg.2020.559134. eCollection 
      2020.


PMID- 33122325
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 29
TI  - Global prevalence of spondyloarthritis in low-income and middle-income countries:
      a systematic review and meta-analysis protocol.
PG  - e041180
LID - 10.1136/bmjopen-2020-041180 [doi]
AB  - INTRODUCTION: In the past decade, the definition of spondyloarthritis (SpA) has
      undergone major modifications with respect to new diagnostic tools and
      classifications. With the advent of biotherapies, treatment possibilities in
      patients with SpA have substantially improved in the last few years. There is
      great interest in obtaining accurate data on the disease prevalence, especially
      in regions where data remains scarce such as low-income and middle-income
      countries (LMICs), in order to measure and understand the needs of their
      healthcare systems. Therefore, through a global systematic review and
      meta-analysis, the current study aims to investigate the prevalence of SpA and
      human leucocyte antigen B27 (HLAB27) and its association with the risk of SpA in 
      the LMIC population. METHODS AND ANALYSIS: We will include cohort, case-control
      and cross-sectional studies performed among adults (>15 years) living in LMICs.
      EMBASE, Medline, Global Index Medicus and Web of Knowledge will be searched for
      relevant records published until 30 April 2020, without any language restriction.
      The review will be reported according to the Meta-analysis Of Observational
      Studies in Epidemiology (MOOSE) guidelines. After screening of titles and
      abstracts, study selection, data extraction and risk of bias assessment by two
      independent reviewers, we shall assess the studies individually for clinical and 
      statistical heterogeneity. Random-effect meta-analysis will be used to pool
      studies judged to be clinically homogeneous. Egger's test and visual inspection
      of funnel plots will be used to assess publication bias. Results will be
      presented by WHO subregions. ETHICS AND DISSEMINATION: Since primary data is not 
      collected in this study, ethical approval is not required. This review is
      expected to provide relevant data on the epidemiology of SpA, HLAB27 and their
      association in the global population of LMICs. The final report will be published
      in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42020163898.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Allado, Edem
AU  - Allado E
AUID- ORCID: 0000-0002-1760-6979
AD  - University Center of Sports Medicine and Adapted Physical Activity, Nancy
      Regional University Hospital Center, Nancy, France e.allado@chru-nancy.fr.
AD  - EA 3450 DevAH, Development, Adaptation and Disadvantage, Cardiorespiratory
      Regulations and Motor Control, Lorraine European University Centre, Nancy,
      France.
FAU - Moussu, Anthony
AU  - Moussu A
AD  - University Center of Sports Medicine and Adapted Physical Activity, Nancy
      Regional University Hospital Center, Nancy, France.
FAU - Bigna, Jean Joel
AU  - Bigna JJ
AUID- ORCID: 0000-0001-8018-6279
AD  - Department of Epidemiology and Public Health, Centre Pasteur of Cameroon,
      Yaounde, Cameroon.
FAU - Hamroun, Sabrina
AU  - Hamroun S
AD  - Rheumatology, Paris University, AP-HP, Cochin Hospital, Paris, Ile-de-France,
      France.
FAU - Camier, Aurore
AU  - Camier A
AD  - Center for Research in Epidemiology and StatisticS (CRESS), Universite de Paris, 
      INSERM, INRA, Sorbonne universite, Paris, Ile-de-France, France.
FAU - Chenuel, Bruno
AU  - Chenuel B
AD  - University Center of Sports Medicine and Adapted Physical Activity, Nancy
      Regional University Hospital Center, Nancy, France.
AD  - EA 3450 DevAH, Development, Adaptation and Disadvantage, Cardiorespiratory
      Regulations and Motor Control, Lorraine European University Centre, Nancy,
      France.
FAU - Hamroun, Aghiles
AU  - Hamroun A
AD  - Center for Research in Epidemiology and Population Health (CESP), Clinical
      Epidemiology Team, National Institute of Health and Medical Research (INSERM),
      Villejuif, Ile-de-France, France.
AD  - Nephrology Dialysis and Kidney Transplantation Department, Lille University
      Hospital Center, Lille, Hauts-de-France, France.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Developing Countries
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Prevalence
MH  - Research Design
MH  - *Spondylarthritis/epidemiology
MH  - Systematic Reviews as Topic
PMC - PMC7597522
OTO - NOTNLM
OT  - *epidemiology
OT  - *immunology
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/10/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/30 05:45
PHST- 2020/10/30 05:45 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041180 [pii]
AID - 10.1136/bmjopen-2020-041180 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 29;10(10):e041180. doi: 10.1136/bmjopen-2020-041180.


PMID- 33122318
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 29
TI  - Conceptualising, operationalising and measuring trust in participatory health
      research networks: a scoping review protocol.
PG  - e038840
LID - 10.1136/bmjopen-2020-038840 [doi]
AB  - INTRODUCTION: A participatory approach to co-creating new knowledge in health
      research has gained significant momentum in recent decades. This is founded on
      the described benefits of community-based participatory research (CBPR), such as 
      increased relevance of research for those who must act on its findings. This has 
      prompted researchers to better understand how CBPR functions to achieve these
      benefits through building sustainable research partnerships. Several studies have
      identified 'trust' as a key mechanism to achieve sustainable partnerships, which 
      themselves constitute social networks. Although existing literature discuss trust
      and CBPR, or trust and social networks, preliminary searches reveal that none
      link all three concepts of trust, CBPR and social networks. Thus, we present our 
      scoping review protocol to systematically review and synthesise the literature
      exploring how trust is conceptualised, operationalised and measured in CBPR and
      social networks. METHODS AND ANALYSIS: This protocol follows guidelines from
      Levac et al (Scoping studies: advancing themethodology. Implement Sci 2010;5:69),
      which follow the methodological framework of Arksey and O'Malley. This scoping
      review explores several electronic databases including Scopus, Medline, PubMed,
      Web of Science, CINAHL, Cochrane Library, Google Scholar and PsychINFO. Grey
      literature such as theses/dissertations and reports will be included. A search
      strategy was identified and agreed on by the team in conjunction with a research 
      librarian. Two independent reviewers will screen articles by title and abstract, 
      then by full text based on pre-determined exclusion/inclusion criteria. A third
      reviewer will arbitrate discrepancies regarding inclusions/exclusions. We plan to
      incorporate a thematic analysis. ETHICS AND DISSEMINATION: Ethics is not required
      for this review specifically. It is a component of a larger study that received
      ethical approval from the University of Limerick research ethics committee
      (#2018_05_12_EHS). Translation of results to key domains is integrated through
      active collaboration of stakeholders from community, health services and academic
      sectors. Findings will be disseminated through academic conferences, and peer
      review publications targeting public and patient involvement in health research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gilfoyle, Meghan
AU  - Gilfoyle M
AUID- ORCID: 0000-0001-5613-0304
AD  - Public and Patient Involvement Research Unit, School of Medicine and Health
      Research Institute (HRI), University of Limerick, Limerick, Ireland.
FAU - MacFarlane, Anne
AU  - MacFarlane A
AUID- ORCID: 0000-0002-9708-5025
AD  - Public and Patient Involvement Research Unit, School of Medicine and Health
      Research Institute (HRI), University of Limerick, Limerick, Ireland.
FAU - Salsberg, Jon
AU  - Salsberg J
AUID- ORCID: 0000-0003-2010-3691
AD  - Public and Patient Involvement Research Unit, School of Medicine and Health
      Research Institute (HRI), University of Limerick, Limerick, Ireland
      jon.salsberg@ul.ie.
LA  - eng
GR  - FDN143237/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201029
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Community-Based Participatory Research
MH  - Delivery of Health Care
MH  - Humans
MH  - Peer Review
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Trust
PMC - PMC7597520
OTO - NOTNLM
OT  - *primary care
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/10/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/30 05:45
PHST- 2020/10/30 05:45 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038840 [pii]
AID - 10.1136/bmjopen-2020-038840 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 29;10(10):e038840. doi: 10.1136/bmjopen-2020-038840.


PMID- 33122316
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 29
TI  - Prevalence and correlates of mental and neurodevelopmental symptoms and disorders
      among deaf children and adolescents: a systematic review protocol.
PG  - e038431
LID - 10.1136/bmjopen-2020-038431 [doi]
AB  - INTRODUCTION: Little is known of the prevalence and correlates of mental and
      neurodevelopmental symptoms and disorders among deaf children and adolescents.
      Research suggests that this is a vulnerable population group at high risk of
      these disorders. However, little is known of correlates of prevalence estimates
      of these mental disorders and it seems that heterogeneous tools have been used to
      derive these estimates. Given the heterogeneity of studies measuring the
      prevalence and correlates of mental and neurodevelopmental symptoms and disorders
      among deaf children and adolescents, we seek to systematically examine and
      synthesise observational epidemiological evidence in this area to articulate a
      more detailed account of these symptoms and disorders and their correlates among 
      this population group. METHODS AND ANALYSIS: We will conduct a systematic search 
      of the following electronic databases to identify published observational
      epidemiological studies examining the prevalence and correlates of mental and
      neurodevelopmental symptoms and disorders among deaf children and adolescents:
      EBSCOhost, ERIC, PsycARTICLES, PsycINFO, PubMED, ScienceDirect, SCOPUS and Web of
      Science. As research in this area is limited, eight databases have been included 
      to widen our search to include as many articles as possible. The search terms
      will be related to mental and neurodevelopmental symptoms and disorders as well
      as deaf children and adolescents. Two reviewers will review and extract data from
      each article independently and, where relevant, discuss differences to reach
      consensus. Additionally, the reviewers will assess overall study quality and risk
      of bias using a quality appraisal scale. Findings from studies will be
      synthesised to produce a quantitative review that summarises existing evidence on
      mental and neurodevelopmental symptoms and disorders among deaf children and
      adolescents and their correlates. The publication date of studies will not be
      restricted so that as much data as possible that fit our inclusion criteria can
      be sourced. We will conduct our searches between August 2020 and March 2021.
      ETHICS AND DISSEMINATION: This systematic review will use publicly available data
      and therefore does not require a direct ethical review. The protocol was however 
      submitted for ethics waiver clearance with Stellenbosch University Health
      Research Ethics Committee. The protocol will be disseminated in a peer-reviewed
      journal. The review protocol was registered with the PROSPERO International
      Prospective Register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO). 
      PROSPERO REGISTRATION NUMBER: CRD42020189403.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Swanepoel, Brandon
AU  - Swanepoel B
AUID- ORCID: 0000-0002-4956-1461
AD  - Faculty of Arts and Social Sciences, Department of Psychology, Stellenbosch
      University, Stellenbosch, Western Cape, South Africa
      psychologistbrandon@gmail.com.
FAU - Swartz, Leslie
AU  - Swartz L
AUID- ORCID: 0000-0003-1741-5897
AD  - Faculty of Arts and Social Sciences, Department of Psychology, Stellenbosch
      University, Stellenbosch, Western Cape, South Africa.
FAU - Gericke, Renate
AU  - Gericke R
AUID- ORCID: 0000-0001-9077-1850
AD  - School of Community and Human Development, Department of Psychology, University
      of the Witwatersrand, Johannesburg, Gauteng, South Africa.
FAU - Mall, Sumaya
AU  - Mall S
AD  - School of Public Health, Division of Epidemiology and Biostatistics, University
      of the Witwatersrand, Johannesburg, Gauteng, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - *Mental Disorders/epidemiology
MH  - Prevalence
MH  - Systematic Reviews as Topic
PMC - PMC7597516
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *deafness
OT  - *epidemiology
OT  - *mental disorders
OT  - *prevalence
COIS- Competing interests: None declared.
EDAT- 2020/10/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/30 05:45
PHST- 2020/10/30 05:45 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038431 [pii]
AID - 10.1136/bmjopen-2020-038431 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 29;10(10):e038431. doi: 10.1136/bmjopen-2020-038431.


PMID- 33122315
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 29
TI  - Periconceptional surveillance for prevention of anaemia and birth defects in
      Southern India: protocol for a biomarker survey in women of reproductive age.
PG  - e038305
LID - 10.1136/bmjopen-2020-038305 [doi]
AB  - INTRODUCTION: Women of reproductive age (WRA) are a high-risk population for
      anaemia and micronutrient deficiencies. Evidence supports the role of
      periconceptional nutrition in the development of adverse pregnancy complications.
      However, in India, there are limited population-based data to guide
      evidence-based recommendations and priority setting. The objective of this study 
      is to conduct a population-based biomarker survey of anaemia and vitamin B12 and 
      folate status in WRA as part of a periconceptional surveillance programme in
      Southern India. METHODS: WRA (15-40 years) who are not pregnant or lactating and 
      reside within 50 km(2) of our community research site in Southern India will be
      screened and invited to participate in the biomarker survey at our research
      facility at Arogyavaram Medical Centre. After informed consent/assent, structured
      interviews will be conducted by trained nurse enumerators to collect
      sociodemographic, dietary, anthropometry, health and reproductive history data.
      Venous blood samples will be collected at enrolment; whole blood will be analysed
      for haemoglobin. Plasma, serum and red blood cells (RBCs) will be processed and
      stored <-80 degrees C until batch analysis. Vitamin B12 concentrations will be
      measured via chemiluminescence, and RBC and serum folate concentrations will be
      evaluated using the World Health Organisation (WHO)-recommended microbiological
      assay at our laboratory in Bangalore. A WHO surveillance system will also be
      established to determine the baseline prevalence of birth defects in this
      setting. ETHICS AND DISSEMINATION: This study has obtained clearance from the
      Health Ministry Screening Committee of the Indian Council of Medical Research.
      The study protocol was reviewed and approved by the Institutional Review Board at
      Cornell University and the Institutional Ethics Committees at Arogyavaram Medical
      Centre and St. John's Research Institute. Findings from this biomarker survey
      will establish the burden of anaemia and micronutrient deficiencies in WRA and
      directly inform a randomised trial for anaemia and birth defects prevention in
      Southern India. The results of this study will be disseminated at international
      research conferences and as published articles in peer-reviewed journals. TRIAL
      REGISTRATION NUMBERS: Clinical trials registration number NCT04048330,
      NCT03853304 and Clinical Trials Registry of India (CTRI) registration number
      REF/2019/03/024479.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Finkelstein, Julia L
AU  - Finkelstein JL
AUID- ORCID: 0000-0001-9512-5559
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA
      jfinkelstein@cornell.edu.
AD  - St. John's Research Institute, Bangalore, Karnataka, India.
FAU - Fothergill, Amy
AU  - Fothergill A
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
FAU - Johnson, Christina B
AU  - Johnson CB
AD  - Arogyavaram Medical Centre, Madanapalle, Andhra Pradesh, India.
FAU - Guetterman, Heather M
AU  - Guetterman HM
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
FAU - Bose, Beena
AU  - Bose B
AD  - St. John's Research Institute, Bangalore, Karnataka, India.
FAU - Jabbar, Shameem
AU  - Jabbar S
AD  - National Center for Environmental Health, Centers for Disease Control and
      Prevention, Atlanta, Georgia, USA.
FAU - Zhang, Mindy
AU  - Zhang M
AD  - National Center for Environmental Health, Centers for Disease Control and
      Prevention, Atlanta, Georgia, USA.
FAU - Pfeiffer, Christine M
AU  - Pfeiffer CM
AD  - National Center for Environmental Health, Centers for Disease Control and
      Prevention, Atlanta, Georgia, USA.
FAU - Qi, Yan Ping
AU  - Qi YP
AD  - National Center on Birth Defects and Developmental Disabilities, Centers for
      Disease Control and Prevention, Atlanta, Georgia, USA.
FAU - Rose, Charles E
AU  - Rose CE
AD  - National Center on Birth Defects and Developmental Disabilities, Centers for
      Disease Control and Prevention, Atlanta, Georgia, USA.
FAU - Krisher, Jesse T
AU  - Krisher JT
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
FAU - Ruth, Caleb J
AU  - Ruth CJ
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
FAU - Mehta, Rajesh
AU  - Mehta R
AD  - World Health Organization Regional Office for South-East Asia, New Delhi, Delhi, 
      India.
FAU - Williams, Jennifer L
AU  - Williams JL
AD  - National Center on Birth Defects and Developmental Disabilities, Centers for
      Disease Control and Prevention, Atlanta, Georgia, USA.
FAU - Bonam, Wesley
AU  - Bonam W
AD  - Arogyavaram Medical Centre, Madanapalle, Andhra Pradesh, India.
FAU - Crider, Krista S
AU  - Crider KS
AD  - National Center on Birth Defects and Developmental Disabilities, Centers for
      Disease Control and Prevention, Atlanta, Georgia, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04048330
SI  - ClinicalTrials.gov/NCT03853304
GR  - 001/WHO_/World Health Organization/International
GR  - T32 HD087137/HD/NICHD NIH HHS/United States
GR  - U19 DD001218/DD/NCBDD CDC HHS/United States
GR  - U19DD001218/ACL/ACL HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20201029
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - *Anemia/epidemiology/prevention & control
MH  - Biomarkers
MH  - Female
MH  - Humans
MH  - India/epidemiology
MH  - *Lactation
MH  - Pregnancy
MH  - Vitamin B 12
PMC - PMC7597478
OTO - NOTNLM
OT  - *anaemia
OT  - *epidemiology
OT  - *gynaecology
OT  - *nutrition & dietetics
OT  - *obstetrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/30 05:45
PHST- 2020/10/30 05:45 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038305 [pii]
AID - 10.1136/bmjopen-2020-038305 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 29;10(10):e038305. doi: 10.1136/bmjopen-2020-038305.


PMID- 33122314
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 29
TI  - Treatments and outcomes of untreated cerebral cavernous malformations in China:
      study protocol of a nationwide multicentre prospective cohort study.
PG  - e037957
LID - 10.1136/bmjopen-2020-037957 [doi]
AB  - INTRODUCTION: The treatment decision and long-term outcomes of previously
      untreated cerebral cavernous malformation (U-CCM) are still controversial.
      Therefore, we are conducting a nationwide multicentre prospective registry study 
      in China to determine the natural history and effect of surgical treatment on
      long-term outcomes in Chinese people with U-CCM. METHODS AND ANALYSIS: This study
      was started on 1 January 2018 and is currently ongoing. It is a cohort follow-up 
      study across a 5-year period. Patients will be followed up for at least 3 years
      after inception. Patients with U-CCM will be enrolled from 24 Grade III, level A 
      hospitals distributed all over China. The cohort size is estimated to be 1200
      patients. Patients are registered in surgically treated group and conservatively 
      treated group. Clinical characteristics, radiology information and laboratory
      data are prospectively collected using an electronic case report form through an 
      electronic data capture system. The primary outcome of this study is poor
      clinical outcome at the last follow-up (modified Rankin Scale score >2 lasting at
      least 1 year). The secondary outcome includes symptomatic haemorrhage, drug
      refractory epilepsy, focal neurological deficits, morbidity and all-cause
      mortality during follow-up. Univariate and multivariate regression analysis will 
      be performed to determine the risk factors for poor outcomes in all patients, and
      to estimate the effect of surgery. Life tables, Kaplan-Meier estimates, log-rank 
      test and proportional hazards Cox regression will be used to analyse the
      follow-up data of conservatively treated patients to determine the natural
      history of U-CCM. Initial presentation and location of U-CCM are prespecified
      subgroup factors. ETHICS AND DISSEMINATION: The study protocol and informed
      consent form have been reviewed and approved by the Research Ethical Committee of
      First Affiliated Hospital of Fujian Medical University (FAHFMU-2018-003).Written 
      informed consent will be obtained from each adult participant or from the
      guardian of each paediatric participant. The final results will be published in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT03467295.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lin, Fuxin
AU  - Lin F
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - He, Qiu
AU  - He Q
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - Gao, Zhuyu
AU  - Gao Z
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - Yu, Lianghong
AU  - Yu L
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - Wang, Dengliang
AU  - Wang D
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - Zheng, Shufa
AU  - Zheng S
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - Lin, Yuanxiang
AU  - Lin Y
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
FAU - Kang, Dezhi
AU  - Kang D
AUID- ORCID: 0000-0002-0906-9456
AD  - Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou, China kdz99988@vip.sina.com.
AD  - Department of Neurosurgery, Fujian Neuromedicine Center, Fuzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03467295
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201029
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Child
MH  - China/epidemiology
MH  - Cohort Studies
MH  - Follow-Up Studies
MH  - *Hemangioma, Cavernous, Central Nervous System
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
PMC - PMC7597476
OTO - NOTNLM
OT  - *clinical trials
OT  - *neurosurgery
OT  - *protocols & guidelines
OT  - *vascular surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/30 05:45
PHST- 2020/10/30 05:45 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037957 [pii]
AID - 10.1136/bmjopen-2020-037957 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 29;10(10):e037957. doi: 10.1136/bmjopen-2020-037957.


PMID- 33121523
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 29
TI  - Practicing outcome-based medical care using pragmatic care trials.
PG  - 899
LID - 10.1186/s13063-020-04829-7 [doi]
AB  - The current separation between medical research and care is an obstacle to
      essential aspects of good medical practice: the verification that care
      interventions actually deliver the good outcomes they promise, and the use of
      scientific methods to optimize care under uncertainty. Pragmatic care trials have
      been designed to address these problems. Care trials are all-inclusive randomized
      trials integrated into care. Every item of trial design is selected in the best
      medical interest of participating patients. Care trials can eventually show what 
      constitutes good medical practice based on patient outcomes. In the meantime,
      care trials give clinicians and patients the scientific methods necessary for
      optimization of medical care when no one really knows what to do.We report the
      progress of 9 randomized care trials that were used to guide the endovascular or 
      surgical management of 1212 patients with acute stroke, intracranial aneurysms,
      and arteriovenous malformations in a single center in an elective or acute care
      context. Care trials were used to address long-standing dilemmas regarding rival 
      medical, surgical, or endovascular management options or to offer innovative
      instead of standard treatments. The trial methodology, by replacing unrepeatable 
      treatment decisions by 1:1 randomized allocation whenever reliable knowledge was 
      not available, had an immediate impact, transforming unverifiable dogmatic
      medical practice into verifiable outcome-based medical care. We believe the
      approach is applicable to all medical or surgical domains, but widespread
      adoption may require the revision of many currently prevalent views regarding the
      role of research in clinical practice.
FAU - Darsaut, Tim E
AU  - Darsaut TE
AD  - Department of Surgery, Division of Neurosurgery, University of Alberta Hospital, 
      Mackenzie Health Sciences Centre, 8440 - 112 Street, Edmonton, Alberta, T6G 2B7, 
      Canada.
FAU - Raymond, Jean
AU  - Raymond J
AUID- ORCID: http://orcid.org/0000-0003-1978-4274
AD  - Department of Radiology, Service of Interventional Neuroradiology, Centre
      Hospitalier de l'Universite de Montreal - CHUM, 1000 Saint-Denis street, room
      D03-5462B, Montreal, QC, H2X 0C1, Canada. jean.raymond@umontreal.ca.
LA  - eng
PT  - Letter
DEP - 20201029
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Humans
MH  - *Intracranial Aneurysm
MH  - Patient Care
MH  - *Stroke
MH  - Uncertainty
PMC - PMC7599099
OTO - NOTNLM
OT  - Clinical research methodology
OT  - Medical ethics
OT  - Pragmatic trials
OT  - Randomized trials
OT  - Research ethics
EDAT- 2020/10/31 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/30 05:33
PHST- 2020/03/28 00:00 [received]
PHST- 2020/10/17 00:00 [accepted]
PHST- 2020/10/30 05:33 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04829-7 [doi]
AID - 10.1186/s13063-020-04829-7 [pii]
PST - epublish
SO  - Trials. 2020 Oct 29;21(1):899. doi: 10.1186/s13063-020-04829-7.


PMID- 33121484
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1472-698X (Electronic)
IS  - 1472-698X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 29
TI  - Behind bars: the burden of being a woman in Brazilian prisons.
PG  - 28
LID - 10.1186/s12914-020-00247-7 [doi]
AB  - BACKGROUND: Brazil has the third largest prison population in the world. In 2016,
      the female prison population totaled 42,000, an increase of 656% over the
      population recorded in the early 2000s. The objective of this study was to
      describe the socialeconomic and reproductive health of women in Brazilian
      prisons, and the specific assistance received within the prison system. METHODS: 
      This is a first of its kind national survey conducted in 15 female prisons in
      eight Brazilian states between 2014 and 2015. The sample consisted of 1327 women 
      in closed or semi-open prison regimes. Data collection used Audio
      Computer-Assisted Self-Interviewing (ACASI). STATA v.15. Was use in analysis. The
      study was submitted to the Research Ethics Committee of the Federal University of
      Ceara, under CEP protocol No. 1,024,053. RESULTS: The population was
      overwhelmingly Black or Brown, poor and little educated. When women worked
      previously, they had worked as domestic servants and were the sole source of
      income for their families. Most were mothers, with 39% having children less than 
      10 years old, now in the care of others. Most were in jail for drug-related
      crimes. Prisons were crowded, with more than 2/3rds of the inmates sharing a cell
      with 6 or more inmates. Services were provide, but women had not had a cervical
      cancer screening within the past 3 years and breast cancer screening was not
      conducted. CONCLUSIONS: Overall, given their backround and prison conditions they
      are unlikely to change the circumstances that brought them to prison in the first
      place.
FAU - de Araujo, Priscila Franca
AU  - de Araujo PF
AUID- ORCID: 0000-0001-7632-6726
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil. ilafranca@yahoo.com.br.
FAU - Kerr, Ligia Regina Franco Sansigolo
AU  - Kerr LRFS
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
FAU - Kendall, Carl
AU  - Kendall C
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
AD  - School of Public Health and Tropical Medicine Tulane University, New Orleans,
      USA.
FAU - Rutherford, George W
AU  - Rutherford GW
AD  - University of California, San Francisco, USA.
FAU - Seal, David W
AU  - Seal DW
AD  - School of Public Health and Tropical Medicine Tulane University, New Orleans,
      USA.
FAU - da Justa Pires Neto, Roberto
AU  - da Justa Pires Neto R
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
FAU - da Costa Pinheiro, Patricia Neyva
AU  - da Costa Pinheiro PN
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
FAU - Galvao, Marli Teresinha Gimeniz
AU  - Galvao MTG
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
FAU - Araujo, Larissa Fortunato
AU  - Araujo LF
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
FAU - Pinheiro, Francisco Marto Leal
AU  - Pinheiro FML
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
FAU - da Silva, Ana Zaira
AU  - da Silva AZ
AD  - Department of Public Health, Federal University of Ceara, Professor Costa Mendes,
      1608 - Didactic Block, 5th floor Neighboor Rodolfo Teofilo, Fortaleza, Ceara,
      60.430-140, Brazil.
LA  - eng
GR  - BRA / K57 PROJECT - # 01/2013/MINISTRY OF HEALTH / SECRETARY OF HEALTH
      SURVEILLANCE / STD, AIDS AND VIRAL HEPATITIS DEPARTMENT
GR  - 405278 / 2012-8/CNPQ
GR  - # 2945/2013/CNPq Science without Borders
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201029
PL  - England
TA  - BMC Int Health Hum Rights
JT  - BMC international health and human rights
JID - 101088678
SB  - IM
EIN - BMC Int Health Hum Rights. 2020 Dec 14;20(1):31. PMID: 33317514
MH  - Adolescent
MH  - Adult
MH  - Brazil
MH  - Cross-Sectional Studies
MH  - *Early Detection of Cancer
MH  - Female
MH  - Health Services Accessibility
MH  - Health Status
MH  - Humans
MH  - Interviews as Topic
MH  - Prisoners/*statistics & numerical data
MH  - *Prisons
MH  - Reproductive Health/*ethnology
MH  - Uterine Cervical Neoplasms/*prevention & control
MH  - Young Adult
PMC - PMC7594946
OTO - NOTNLM
OT  - *Community health
OT  - *Prisons
OT  - *Reproductive health
OT  - *Women
EDAT- 2020/10/31 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/10/30 05:32
PHST- 2020/06/10 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/10/30 05:32 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.1186/s12914-020-00247-7 [doi]
AID - 10.1186/s12914-020-00247-7 [pii]
PST - epublish
SO  - BMC Int Health Hum Rights. 2020 Oct 29;20(1):28. doi: 10.1186/s12914-020-00247-7.


PMID- 33121480
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 29
TI  - A principled ethical approach to intersex paediatric surgeries.
PG  - 108
LID - 10.1186/s12910-020-00550-x [doi]
AB  - BACKGROUND: Surgery for intersex infants should be delayed until individuals are 
      able to decide for themselves, except where it is a medical necessity. In an
      ideal world, this single principle would suffice and such surgeries could be
      totally prohibited. Unfortunately, the world is not perfect, and, in some places,
      intersex neonates are at risk of being abandoned, mutilated or even killed. As
      long as intersex persons are at such high risk in some places, any ethical
      guidelines for intersex surgeries will need to take these extreme risks of harm
      into account. MAIN TEXT: I therefore argue for five basic principles that ought
      to inform ethics guidelines for surgical interventions in intersex children,
      specifically in contexts in which such children are at risk of significant harm. 
      What I set out to come up with is a set of principles that do not completely
      prohibit surgery, but only allow it where a strong case can be made for its
      necessity, in the best interests of the child, and where there is some kind of
      oversight to prevent misuse. The first principle is that interventions as drastic
      as these surgeries should only be performed when there is strong evidence that
      they are beneficial and not harmful. The second principle is that in surgeries
      should normally only be performed in cases of true medical necessity. Principle
      three is that surgeries should normally be delayed until such time as the
      intersex person is mature enough to assent to treatment or decide against it.
      Principle four is that the conventional ethical requirements regarding truth
      telling apply equally to intersex children as to anyone else. The final principle
      is that where physicians or parents think that surgery is in the best interests
      of the child, the burden of proof lies with them. CONCLUSION: It is hoped that
      these principles might help medical teams and parents make better decisions about
      intersex surgeries on children, and they would make such surgeries very rare
      indeed, if they happen at all.
FAU - Behrens, Kevin G
AU  - Behrens KG
AUID- ORCID: 0000-0002-7595-7486
AD  - Steve Biko Centre for Bioethics, School of Clinical Medicine, Faculty of Health
      Sciences, University of the Witwatersrand, Phillip V. Tobias Health Sciences
      Building, 29 Princess of Wales Terrace, Parktown, Johannesburg, 2193, South
      Africa. kevin.behrens@wits.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Child
MH  - *Disorders of Sex Development/surgery
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Morals
MH  - Parents
PMC - PMC7597036
OTO - NOTNLM
OT  - *Intersex
OT  - *Intersex ethics
OT  - *Intersex paediatric surgery
OT  - *Intersex surgery
EDAT- 2020/10/31 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/30 05:32
PHST- 2019/10/18 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/10/30 05:32 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00550-x [doi]
AID - 10.1186/s12910-020-00550-x [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 29;21(1):108. doi: 10.1186/s12910-020-00550-x.


PMID- 33121434
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 29
TI  - Physiotherapists' perceptions of challenges facing evidence-based practice and
      the importance of environmental empowerment in fall prevention in the
      municipality - a qualitative study.
PG  - 432
LID - 10.1186/s12877-020-01846-8 [doi]
AB  - BACKGROUND: Falls in older adults are an increasingly important public-health
      concern. Despite abundant research, fall rates have not been reduced, because
      implementation of evidence-based fall-prevention measures has been slow and
      limited. This study aims to explore physiotherapists' perceptions on external
      factors, such as public policy, organisation and leadership, regarding the
      relation between knowledge translation and the three elements of evidence-based
      practice (EBP) to effectively address barriers and facilitate the uptake of EBP
      in fall prevention. METHODS: We conducted semi-structured interviews with 18
      physiotherapists (men = 7; women = 11) working with fall prevention in the
      primary healthcare system. The physiotherapists ranged in age from 27 to 60 years
      (median 36 years) and had worked as a physiotherapist from 1 to 36 years (median 
      7 years). Data are analysed using thematic analysis. RESULTS: The analysis
      revealed one main theme and four sub-themes. The main theme was 'Environmental
      empowerment enhances physiotherapists' capabilities for using EBP'. A resourceful
      work environment facilitates EBP, having access to information about
      research-based knowledge, supportive leadership, enough human resources and
      opportunities to learn and grow at work. The four sub-themes were as follows: 1) 
      'Tension between attributes of research-based knowledge and organisational
      routines and practices'; 2) 'Evidence must be informed by policymakers-What
      works?'; 3) 'Empowering culture and work environment-A steppingstone to EBP' and 
      4) 'Organisation readiness for EBP, managerial and clinical relations'. Success
      in environmental empowerment depends on the leader's role in creating
      preconditions at the workplace that may lead to important positive personal and
      organisational outcomes for EBP. Two-way communication and
      transfer-of-information are also key factors in the development of positive work 
      engagement when using EBP. CONCLUSION: The findings of this study outline tension
      between policy, leadership, organisational facilitators and EBP. Leadership is
      influenced by policy with ripple effects for the organisation and clinicians.
      Organisational facilitators form structural empowerment, which is the foundation 
      for creating an EBP environment. TRIAL REGISTRATION: 2018/2227/REC south-east C. 
      Registered 19 December 2018, Norwegian Ethics Committee for Medical and Health
      Research Ethics.
FAU - Worum, Hilde
AU  - Worum H
AD  - Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan
      University, Oslo, Norway. hildewor@oslomet.no.
FAU - Lillekroken, Daniela
AU  - Lillekroken D
AD  - Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo
      Metropolitan University, Oslo, Norway.
FAU - Roaldsen, Kirsti Skavberg
AU  - Roaldsen KS
AD  - Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan
      University, Oslo, Norway.
AD  - Department of Neurobiology, Health Sciences and Society, Karolinska Institute,
      Stockholm, Sweden.
AD  - Department of Research, Sunnaas Rehabilitation Hospital, Oslo, Norway.
FAU - Ahlsen, Birgitte
AU  - Ahlsen B
AD  - Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan
      University, Oslo, Norway.
FAU - Bergland, Astrid
AU  - Bergland A
AD  - Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan
      University, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Accidental Falls/prevention & control
MH  - Aged
MH  - Evidence-Based Practice
MH  - Female
MH  - Humans
MH  - Male
MH  - Perception
MH  - *Physical Therapists
MH  - Qualitative Research
PMC - PMC7596977
OTO - NOTNLM
OT  - *Barrier
OT  - *Facilitator
OT  - *Fall prevention
OT  - *Implementation
OT  - *Knowledge translation
OT  - *Leadership
OT  - *Organisation
EDAT- 2020/10/31 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/30 05:32
PHST- 2020/07/13 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/30 05:32 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12877-020-01846-8 [doi]
AID - 10.1186/s12877-020-01846-8 [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Oct 29;20(1):432. doi: 10.1186/s12877-020-01846-8.


PMID- 33120886
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 21
DP  - 2020 Oct 27
TI  - Good Practice Data Linkage (GPD): A Translation of the German Version.
LID - E7852 [pii]
LID - 10.3390/ijerph17217852 [doi]
AB  - The data linkage of different data sources for research purposes is being
      increasingly used in recent years. However, generally accepted methodological
      guidance is missing. The aim of this article is to provide methodological
      guidelines and recommendations for research projects that have been consented to 
      across different German research societies. Another aim is to endow readers with 
      a checklist for the critical appraisal of research proposals and articles. This
      Good Practice Data Linkage (GPD) was already published in German in 2019, but the
      aspects mentioned can easily be transferred to an international context,
      especially for other European Union (EU) member states. Therefore, it is now also
      published in English. Since 2016, an expert panel of members of different German 
      scientific societies have worked together and developed seven guidelines with a
      total of 27 practical recommendations. These recommendations include (1) the
      research objectives, research questions, data sources, and resources; (2) the
      data infrastructure and data flow; (3) data protection; (4) ethics; (5) the key
      variables and linkage methods; (6) data validation/quality assurance; and (7) the
      long-term use of data for questions still to be determined. The authors provide a
      rationale for each recommendation. Future revisions will include new developments
      in science and updates of data privacy regulations.
FAU - March, Stefanie
AU  - March S
AD  - Institute for Social Medicine and Health Systems Research (ISMHSR), Medical
      Faculty, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany.
AD  - Department of Social Work, Health and Media, Magdeburg-Stendal University of
      Applied Sciences, 39114 Magdeburg, Germany.
FAU - Andrich, Silke
AU  - Andrich S
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich-Heine-University Dusseldorf, 40225
      Dusseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center, Leibniz Center for Diabetes Research at the Heinrich-Heine-University
      Dusseldorf, 40225 Dusseldorf, Germany.
FAU - Drepper, Johannes
AU  - Drepper J
AD  - TMF-Technology, Methods, and Infrastructure for Networked Medical Research, 10117
      Berlin, Germany.
FAU - Horenkamp-Sonntag, Dirk
AU  - Horenkamp-Sonntag D
AD  - Techniker Krankenkasse, Healthcare Management, 22305 Hamburg, Germany.
FAU - Icks, Andrea
AU  - Icks A
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich-Heine-University Dusseldorf, 40225
      Dusseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center, Leibniz Center for Diabetes Research at the Heinrich-Heine-University
      Dusseldorf, 40225 Dusseldorf, Germany.
FAU - Ihle, Peter
AU  - Ihle P
AD  - PMV Research Group, University of Cologne, 50931 Cologne, Germany.
FAU - Kieschke, Joachim
AU  - Kieschke J
AD  - Epidemiological Cancer Registry of Lower Saxony, Register Center, 26121
      Oldenburg, Germany.
FAU - Kollhorst, Bianca
AU  - Kollhorst B
AUID- ORCID: 0000-0001-5964-954X
AD  - Leibniz Institute for Prevention Research and Epidemiology-BIPS Department
      Biometry and Data Management, 28359 Bremen, Germany.
FAU - Maier, Birga
AU  - Maier B
AD  - Berlin-Brandenburg Myocardial Infarction Registry e. V., 10317 Berlin, Germany.
FAU - Meyer, Ingo
AU  - Meyer I
AD  - PMV Research Group, University of Cologne, 50931 Cologne, Germany.
FAU - Muller, Gabriele
AU  - Muller G
AD  - Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of
      Medicine Carl Gustav Carus, Technical University of Dresden, 01307 Dresden,
      Germany.
FAU - Ohlmeier, Christoph
AU  - Ohlmeier C
AD  - IGES Institut GmbH, 10117 Berlin, Germany.
FAU - Peschke, Dirk
AU  - Peschke D
AD  - Institute for Public Health and Nursing Research (IPP), University of Bremen,
      28359 Bremen, Germany.
AD  - Department of Applied Health Sciences, University of Health Bochum, 44801 Bochum,
      Germany.
FAU - Richter, Adrian
AU  - Richter A
AUID- ORCID: 0000-0002-3372-2021
AD  - Institute for Community Medicine, Department SHIP-KEF, Greifswald University
      Medical Center, 17475 Greifswald, Germany.
FAU - Rosenbusch, Marie-Luise
AU  - Rosenbusch ML
AD  - Central Research Institute for Ambulatory Healthcare in Germany (Zi), Department 
      of Data Science and Healthcare Analyses, 10587 Berlin, Germany.
FAU - Scholten, Nadine
AU  - Scholten N
AD  - Institute of Medical Sociology, Health Services Research and Rehabilitation
      Science (IMVR), Faculty of Human Sciences and Faculty of Medicine, University of 
      Cologne, 50933 Cologne, Germany.
FAU - Schulz, Mandy
AU  - Schulz M
AD  - Central Research Institute for Ambulatory Healthcare in Germany (Zi), Department 
      of Data Science and Healthcare Analyses, 10587 Berlin, Germany.
FAU - Stallmann, Christoph
AU  - Stallmann C
AUID- ORCID: 0000-0001-8144-5711
AD  - Institute for Social Medicine and Health Systems Research (ISMHSR), Medical
      Faculty, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany.
FAU - Swart, Enno
AU  - Swart E
AUID- ORCID: 0000-0002-3286-2217
AD  - Institute for Social Medicine and Health Systems Research (ISMHSR), Medical
      Faculty, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany.
FAU - Wobbe-Ribinski, Stefanie
AU  - Wobbe-Ribinski S
AD  - DAK Gesundheit, Health Services Research and Innovation, 20097 Hamburg, Germany.
FAU - Wolter, Antke
AU  - Wolter A
AD  - DAK Gesundheit, Health Services Research and Innovation, 20097 Hamburg, Germany.
FAU - Zeidler, Jan
AU  - Zeidler J
AD  - Center for Health Economics Research Hanover (CHERH), Leibniz University Hanover,
      30159 Hanover, Germany.
FAU - Hoffmann, Falk
AU  - Hoffmann F
AUID- ORCID: 0000-0003-0182-5373
AD  - Faculty of Medicine and Health Sciences, Department of Healthcare Research, Carl 
      von Ossietzky University Oldenburg, 26129 Oldenburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Information Storage and Retrieval/*standards
MH  - Language
MH  - *Research Design
MH  - *Translations
PMC - PMC7663300
OTO - NOTNLM
OT  - *epidemiology
OT  - *guidelines
OT  - *health services research
OT  - *personal data
OT  - *record linkage
OT  - *standard
EDAT- 2020/10/31 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/09/17 00:00 [received]
PHST- 2020/10/16 00:00 [revised]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - ijerph17217852 [pii]
AID - 10.3390/ijerph17217852 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 27;17(21). pii: ijerph17217852. doi:
      10.3390/ijerph17217852.


PMID- 33120826
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Implementation of a clinical nursing pathway for percutaneous coronary
      intervention: A randomized controlled trial protocol.
PG  - e22866
LID - 10.1097/MD.0000000000022866 [doi]
AB  - BACKGROUND: Acute myocardial infarction is a very common disease in the emergency
      room. Emergency percutaneous coronary intervention (PCI) is the first choice to
      open infarct-related artery in time to regain the active blood flow of myocardial
      tissue. Clinical nursing pathway (CNP), namely clinical project, is an original
      nursing mode with good quality, outstanding efficiency, and low treatment
      spending, so it has attracted more and more attention. However, few studies have 
      reported the implementation of a CNP in PCIs. The purpose of the protocol is to
      assess the impact of CNP on the clinical efficacy of transradial emergency PCI.
      METHODS: This is a randomized controlled, single center trial which will be
      implemented from January 2021 to June 2021. Hundred samples diagnosed with acute 
      myocardial infarction will be included in this study. It was authorized via the
      Ethics Committee of Changshan County People's Hospital (CCPH002348). Patients are
      assigned to the following groups: control group, given normal routine care; CNP
      group, treated with CNP plan. The time from door to balloon, hospitalization
      expenses, length of stay, postoperative complications, patients' satisfaction
      with treatment are compared and analyzed. All data are collected and analyzed by 
      Social Sciences software version 21.0 (SPSS, Inc., Chicago, IL) program. RESULTS:
      Differences of clinical outcomes between groups (). CONCLUSION: This original
      evidence-based nursing model can be used as the foundation for further research. 
      TRIAL REGISTRATION NUMBER: researchregistry6030.
FAU - Zhang, Zhimin
AU  - Zhang Z
AUID- ORCID: 0000-0002-2453-4299
AD  - Department of Cardiovascular Medicine.
FAU - Bai, Jincheng
AU  - Bai J
AD  - Department of Cardiovascular Medicine.
FAU - Huang, Yongmei
AU  - Huang Y
AD  - Department of Nursing.
FAU - Wang, Lingling
AU  - Wang L
AD  - Department of Radiology, Changshan County People's Hospital, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acute Disease
MH  - Case-Control Studies
MH  - Critical Pathways/*statistics & numerical data
MH  - Emergency Service, Hospital/statistics & numerical data
MH  - Female
MH  - Hospitalization/economics
MH  - Humans
MH  - Length of Stay
MH  - Male
MH  - Myocardial Infarction/diagnosis/physiopathology/*surgery
MH  - Patient Satisfaction
MH  - Percutaneous Coronary Intervention/*methods
MH  - Postoperative Complications/epidemiology
MH  - Radial Artery/*surgery
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7581146
EDAT- 2020/10/31 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1097/MD.0000000000022866 [doi]
AID - 00005792-202010230-00102 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22866. doi:
      10.1097/MD.0000000000022866.


PMID- 33120823
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Comparative effectiveness of East Asian traditional medicine for treatment of
      idiopathic short stature in children: A protocol for systematic review and
      network meta-analysis.
PG  - e22856
LID - 10.1097/MD.0000000000022856 [doi]
AB  - BACKGROUND: There are many East Asian traditional medicine (EATM) therapies that 
      are widely used and effective for idiopathic short stature (ISS) in children.
      However, the comparative effectiveness of these therapies remains unclear. We
      describe the methods that will be used to comparatively evaluate the efficacy and
      safety of EATM therapies for the treatment of pediatric ISS. METHODS AND
      ANALYSIS: Fourteen electronic English, Korean, Chinese, and Japanese databases
      will be searched up to August 2020 for relevant randomized controlled trials of
      various EATMs for the treatment of pediatric ISS, without language or publication
      status restrictions. The primary outcome will be growth-related anthropometric
      indicators, and acceptability, measured through drop-outs that occur during
      treatment for any reason. We will conduct a pairwise meta-analysis for direct
      comparisons if multiple studies use the same types of intervention, comparison,
      and outcome measure. A frequentist network meta-analysis will be performed to
      summarize the available direct and indirect evidence regarding various EATM
      options for pediatric ISS. The risk of bias for the included studies will be
      evaluated using the Cochrane Collaboration's risk of bias tool. CONCLUSIONS: The 
      findings of this review will provide evidence for the comparative effectiveness
      and ranks of current EATMs and help to inform clinical practitioners, patients,
      and policy makers in decision making. ETHICS AND DISSEMINATION: Ethical approval 
      is not required because individual patient data are not included. The findings of
      this systematic review will be disseminated through a peer-reviewed publication
      or conference presentations. PROTOCOL REGISTRATION NUMBER: OSF (URL:
      https://osf.io/s4vp7), PROSPERO CRD42020187160.
FAU - Lee, Boram
AU  - Lee B
AUID- ORCID: 0000-0003-1679-0644
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Yuseong-gu,
      Daejeon.
FAU - Kwon, Chan-Young
AU  - Kwon CY
AD  - Department of Oriental Neuropsychiatry, Dong-eui University College of Korean
      Medicine, Busanjin-gu, Busan, Republic of Korea.
FAU - Jang, Soobin
AU  - Jang S
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Yuseong-gu,
      Daejeon.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Body Height
MH  - Child
MH  - Growth Disorders/*therapy
MH  - Humans
MH  - Medicine, East Asian Traditional/*methods
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
PMC - PMC7581126
EDAT- 2020/10/31 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1097/MD.0000000000022856 [doi]
AID - 00005792-202010230-00099 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22856. doi:
      10.1097/MD.0000000000022856.


PMID- 33120813
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine
      ingredients combined with methotrexate on the progression of bone injury in
      patients with rheumatoid arthritis: A protocol for a systematic review and
      meta-analysis.
PG  - e22841
LID - 10.1097/MD.0000000000022841 [doi]
AB  - BACKGROUND: A large number of clinical studies have confirmed that after
      treatment with traditional Chinese medicine components such as sinomenine (SIN), 
      the matrix -metalloproteinase3 (MMP-3) level of patients with rheumatoid
      arthritis (RA) shows a significant decrease, whereas MMP-3 can be involved in
      degrading bone matrix in humans, so in the progression of bone and joint injury
      in patients with RA, serum MMP-3 can be used as an important biochemical marker. 
      The traditional Chinese medicine components commonly used in clinical practice
      include total glucosides of paeony (TGP), SIN, and tripterygium glycosides, which
      have the characteristics of disease-modifyinganti-rheumatic drugs and
      non-steroidal anti-inflammatory drugs, while they can reduce the toxic side
      effects of methotrexate (MTX), and their combination with other drugs such as MTX
      and leflunomide (HWA486) has become an important regimen for the treatment of RA 
      in clinical practice. Therefore, we designed this study protocol to evaluate the 
      adjuvant effect of commonly used traditional Chinese medicine components combined
      with MTX in the treatment of osteoarticular injury in RA. METHODS: The search
      time was set from January 2000 to September 2020 in this study. EMBASE database, 
      Cochrane Library, PubMed, Web of Science, Science Direct, Chinese National
      Knowledge Infrastructure, China Biology Medicine disc (CBM), Chinese Scientifific
      Journals Database (VIP), and Wanfang Database were used as search sources to
      select the traditional Chinese medicine components that reduce MMP-3 and use MTX 
      in the treatment of RA. Clinical randomized controlled trials were used, and
      inclusion criteria and exclusion criteria were set for screening. In this study, 
      MMP-3, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), cyclic
      peptide containing citrulline (CCP) and rheumatoid factor (RF) were used as the
      main outcomes, and the improvement of Disease Activity Score 28 (DAS28), joint
      bone mineral density, Clinical Disease Activity Index (CDAI), and other
      clinically relevant symptoms was selected as the secondary outcomes. Revman
      software version 5.3 was used for statistical analysis of data and risk
      assessment of deviation in this meta-analysis. In this study, one researcher
      performed study direction selection, literature inquiry, and literature download,
      and 2 independent reviewers performed literature data extraction and literature
      quality assessment. Dichotomized data are expressed as relative risk, continuous 
      data are expressed as mean difference or standard mean difference, and finally
      fixed-effect model or random-effect model is used for synthesis according to the 
      heterogeneity of data. RESULTS: To evaluate the effect of downregulation of MMP-3
      level by traditional Chinese medicine components combined with MTX on the
      progression of bone injury in patients with RA by serum MMP-3, ESR, CRP, CCP, and
      RF. CONCLUSION: This study protocol can be used to evaluate the efficacy and
      safety of traditional Chinese medicine components combined with MTX in the
      treatment of bone injury in patients with RA. ETHICS AND DISSEMINATION: This
      study is a secondary study based on the published clinical research; therefore,
      approval from an ethics committee is not required for this study. In accordance
      with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
      Protocol (PRISMA-P), the results of this study will be published in peer-reviewed
      scientific journals and conference papers. REGISTRATION NUMBER:: is
      INPLASY202090064.
FAU - Sun, Yue
AU  - Sun Y
AD  - College of Basic Medicine.
FAU - Huang, Yucheng
AU  - Huang Y
AD  - College of Clinical Medicine.
FAU - Chen, Tiantian
AU  - Chen T
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine.
FAU - Li, Xueping
AU  - Li X
AD  - College of Basic Medicine.
FAU - Chen, Jiayi
AU  - Chen J
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine.
FAU - Wang, Zhuozhi
AU  - Wang Z
AD  - College of Medical and Life Sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu, P.R. China.
FAU - Lin, Kexin
AU  - Lin K
AD  - College of Clinical Medicine.
FAU - Gao, Yongxiang
AU  - Gao Y
AUID- ORCID: 0000-0002-6921-9006
AD  - College of Basic Medicine.
AD  - College of Clinical Medicine.
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine.
AD  - College of Medical and Life Sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu, P.R. China.
FAU - He, Lisha
AU  - He L
AD  - College of Basic Medicine.
AD  - College of Clinical Medicine.
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine.
AD  - College of Medical and Life Sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu, P.R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antirheumatic Agents/*therapeutic use
MH  - Bone and Bones/drug effects
MH  - Disease Progression
MH  - Down-Regulation/drug effects
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Matrix Metalloproteinase 3/blood/*drug effects
MH  - Medicine, Chinese Traditional/methods
MH  - Methotrexate/*therapeutic use
MH  - Systematic Reviews as Topic
PMC - PMC7581142
EDAT- 2020/10/31 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1097/MD.0000000000022841 [doi]
AID - 00005792-202010230-00089 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22841. doi:
      10.1097/MD.0000000000022841.


PMID- 33120799
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Scalp acupuncture for patients with vascular dementia: A protocol for systematic 
      review and meta-analysis of randomized controlled trails.
PG  - e22798
LID - 10.1097/MD.0000000000022798 [doi]
AB  - BACKGROUND: Vascular dementia (VD) is a kind of acquired intelligence impairment 
      syndrome caused by a series of cerebrovascular factors leading to brain tissue
      damage. Scalp acupuncture is widely used to treating VD. However, there is no a
      systematic review has been used to assess the efficacy and safety of scalp
      acupuncture therapy for VD. Therefore, the purpose of this paper is to
      systematically evaluate the effects of scalp acupuncture on VD. METHODS: We will 
      search the following databases from their inception to July 2020: PubMed, Chinese
      National Knowledge Infrastructure (CNKI), Wan Fang Database, Embase, Medline,
      Chinese Biomedical Literature Database (CBM), EBSCO, Web of Science, Technology
      Periodical Database (VIP), the Chongqing VIP Chinese Science and Cochrane
      Library. At the same time, we will retrieve other resources including conference 
      articles, and gray literature. The randomized controlled trials (RCTs) in English
      or Chinese associated with scalp acupuncture for VD will be included. Our study
      data collection and analysis will be conducted independently by 2 reviewers, and 
      Rev Man V.5.3.5 statistical software will be used to performing meta-analysis.
      RESULTS: This review research will provide a high-quality synthesis to evaluate
      the efficacy and safety of scalp acupuncture for patients with VD. CONCLUSION:
      This study will provide available evidence to judge whether scalp acupuncture is 
      an effective and safe intervention for patients with VD. It also will provide
      reliable evidence for its widespread application. ETHICS AND DISSEMINATION: This 
      systematic review will provide convincing evidence for both patients and
      clinicians. It does not require ethical approval and the results will be
      published in a peer-reviewed journal. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/7CYZR.
FAU - Li, Jie
AU  - Li J
AUID- ORCID: 0000-0001-8457-384
AD  - College of Acupuncture & Massage, Shaanxi University of Chinese Medicine, Shaanxi
      Key Laboratory of Acupuncture & Medicine, Xixian New Area, Shaanxi Province.
FAU - Man, Qiuhong
AU  - Man Q
AD  - Shanghai Fourth People's Hospital Affiliated to Tongji University School of
      Medicine.
FAU - Wang, Wenchun
AU  - Wang W
AD  - The General Hospital of Western Theater Command.
FAU - Pang, Rizhao
AU  - Pang R
AD  - The General Hospital of Western Theater Command.
FAU - Liu, Jiancheng
AU  - Liu J
AD  - The General Hospital of Western Theater Command.
FAU - Zhang, Feng
AU  - Zhang F
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Medicine,
      Chengdu.
FAU - Zhang, Anren
AU  - Zhang A
AD  - Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital
      Affiliated to Tongji University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Activities of Daily Living
MH  - Acupuncture Therapy/adverse effects/*methods
MH  - Dementia, Vascular/*therapy
MH  - Humans
MH  - Mental Status and Dementia Tests
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Scalp
MH  - Severity of Illness Index
PMC - PMC7581174
EDAT- 2020/10/31 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1097/MD.0000000000022798 [doi]
AID - 00005792-202010230-00075 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22798. doi:
      10.1097/MD.0000000000022798.


PMID- 33120783
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20210507
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Continuous adductor canal block provides better performance after total knee
      arthroplasty compared with the single-shot adductor canal block?: An updated
      meta-analysis of randomized controlled trials.
PG  - e22762
LID - 10.1097/MD.0000000000022762 [doi]
AB  - BACKGROUND: Adductor canal block (ACB) has emerged as an attractive alternative
      for femoral nerve blocks (FNB) as the peripheral nerve block of choice for total 
      knee arthroplasty (TKA), preserving quadriceps motor function while providing
      analgesia comparable to FNB. However, its optimal application for TKA remains
      controversial. The objective of this meta-analysis was to compare
      continuous-injection ACB (CACB) vs single-injection ACB (SACB) for postoperative 
      pain control in patients undergoing TKA. METHODS: This study attempts to identify
      the available and relevant randomized controlled trials (RCTs) regarding the
      analgesic effects of CACB compared to SACB in patients undergoing TKA according
      to electronic databases, including PubMed, Medline, Web of Science, EMbase, and
      the Cochrane Library, up to September 2019. Primary outcomes in this regard
      included the use of a visual analogue scale (VAS) pain score with rest or
      activity, while secondary outcomes were cumulative opioid consumption, length of 
      hospital stay (LOS), complications of vomiting and nausea, and rescue analgesia. 
      The corresponding data were analyzed using RevMan v5.3. ETHICAL REVIEW: Because
      all of the data used in this systematic review and meta-analysis has been
      published, the ethical approval was not necessary RESULTS:: This research
      included 9 studies comprised of 739 patients. The analyzed outcomes demonstrated 
      that patients who received CACB had a better at rest-VAS scores at 4 hours (P =
      .007), 8 hors (P < .0001), 12 hours (P < .0001), 24 hours (P = .02),
      mobilization-VAS score at 48 hours (P < .0001), and rescue analgesia (P = .03)
      than those who underwent SACB. Nevertheless, no significant differences were
      present between the 2 strategies in terms of pain VAS scores 48 hours at rest (P 
      = .23) and 24 hours at mobilization (P = .10), complications of vomiting and
      nausea (P = .42), and length of hospital stay (P = .09). CONCLUSION: This
      meta-analysis indicated that CACB is superior to SACB in regard to analgesic
      effect following TKA. However, due to the variation of the included studies, no
      firm conclusions can be drawn. Further investigations into RCT are required for
      verification.
FAU - Yu, Rongguo
AU  - Yu R
AD  - Department of Orthopedics, Fuzhou second Hospital Affiliated to Xiamen
      University, Fujian.
FAU - Wang, Haiyang
AU  - Wang H
AD  - Department of Orthopedics, Fuzhou second Hospital Affiliated to Xiamen
      University, Fujian.
FAU - Zhuo, Youguang
AU  - Zhuo Y
AD  - Department of Orthopedics, Fuzhou second Hospital Affiliated to Xiamen
      University, Fujian.
FAU - Liu, Dongxin
AU  - Liu D
AD  - Hebei North University, Handan Central Hospital Affiliated to Hebei North
      University, China.
FAU - Wu, Chunling
AU  - Wu C
AD  - Department of Orthopedics, Fuzhou second Hospital Affiliated to Xiamen
      University, Fujian.
FAU - Zhang, Yiyuan
AU  - Zhang Y
AD  - Department of Orthopedics, Fuzhou second Hospital Affiliated to Xiamen
      University, Fujian.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Analgesia/*methods
MH  - *Arthroplasty, Replacement, Knee
MH  - Femoral Nerve
MH  - Humans
MH  - Injections
MH  - Nerve Block/*methods
MH  - Pain, Postoperative/*prevention & control
MH  - *Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7581050
EDAT- 2020/10/31 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1097/MD.0000000000022762 [doi]
AID - 00005792-202010230-00059 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22762. doi:
      10.1097/MD.0000000000022762.


PMID- 33120780
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Reduning injection combined with western medicine for pneumonia: A protocol for
      systematic review and meta-analysis.
PG  - e22757
LID - 10.1097/MD.0000000000022757 [doi]
AB  - BACKGROUND: Pneumonia is a common respiratory disease. In severe cases, it can
      induce cardiovascular disease and even life-threatening. In particular, pneumonia
      caused by the new coronavirus (SARS-CoV-2) that broke out at the end of 2019 has 
      seriously affected the health of people in all countries. In recent years, it has
      been treated with the combination of traditional Chinese medicine (TCM) (such as 
      Reduning injection) and Western medicine, and its mortality has decreased
      significantly. But their efficacy has not been scientifically and systematically 
      assessed. Accordingly, it is essential to provide a systematized review program
      to estimate the efficacy and safety of Reduning injection combined with Western
      medicine to treat pneumonia. METHODS: The following databases are retrieved from 
      start to September 2020: Pubmed, Cochrane Library, EMBASE, Web of Science,
      Chinese National Knowledge Infrastructure (CNKI), Wanfang database, the Chongqing
      VIP Chinese Science and Technology Periodical Database (VIP) databases, Chinese
      Biomedical Literature Database (CBM), and other databases, which are absorbed
      into clinical RCTs of pneumonia using western medicine alone or plus Reduning
      injections. The selection of studies, data extraction, and assessment of risk of 
      bias will be performed independently by 2 reviewers. At the same time, Review
      Manager V.5.3.5 (Rev Man V.5.3.5) was used for bias risk assessment and data
      synthesis. RESULTS: The efficacy and safety of Reduning injection combined with
      western medicine in the treatment of pneumonia were evaluated in terms of overall
      effective rate, the patient's antipyretic time, antitussive time, rales
      disappearing time, X-ray recovery time, and the incidence of adverse reactions.
      CONCLUSIONS: This study provides reliable evidence-based support for the clinical
      application of Reduning injection combined with western medicine for pneumonia.
      ETHICS AND DISSEMINATION: Ethical approval is not required in this secondary
      research evidence, and we will publish the results of this study in a journal or 
      relevant conferences. REGISTRATION NUMBER: DOI 10.17605/OSF.IO/VS75Y.
FAU - Cao, Chenggang
AU  - Cao C
AUID- ORCID: 0000-0003-4066-4904
AD  - Chongqing Rongchang District People's Hospital.
FAU - Zhen, Zelong
AU  - Zhen Z
AD  - Chongqing Rongchang District People's Hospital.
FAU - Kuang, Shengnan
AU  - Kuang S
AD  - Chongqing Rongchang District People's Hospital.
FAU - Xu, Tao
AU  - Xu T
AD  - Chongqing Fifth People's Hospital, Chongqing, Chongqing Municipality, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antiviral Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (reduning)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Antiviral Agents/*administration & dosage/therapeutic use
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Protocols
MH  - Coronavirus Infections/drug therapy
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*administration & dosage/therapeutic use
MH  - Humans
MH  - Injections
MH  - *Medicine, Chinese Traditional
MH  - Pandemics
MH  - Pneumonia/*drug therapy
MH  - Pneumonia, Viral/drug therapy
MH  - SARS-CoV-2
PMC - PMC7581155
EDAT- 2020/10/31 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1097/MD.0000000000022757 [doi]
AID - 00005792-202010230-00056 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22757. doi:
      10.1097/MD.0000000000022757.


PMID- 33120779
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - The efficacy of a phone assistance nursing program for functional outcomes in
      patients after shoulder instability surgery: A protocol for randomized controlled
      trial.
PG  - e22756
LID - 10.1097/MD.0000000000022756 [doi]
AB  - OBJECTIVE: We conduct this research protocol for the assessment of the effect of 
      phone-assisted care programs on functional outcomes in patients receiving
      shoulder instability surgery. METHODS: This is a randomized controlled, single
      center trial which will be implemented from October 2020 to December 2021. This
      trial is conducted according to the SPIRIT Checklist of randomized researches. It
      was authorized via the Ethics Committee of the First People's Hospital of
      Xiangyang city affiliated to Hubei Medical College (XY234-026). Ninety
      participants who undergo shoulder instability surgery are analyzed. Patients are 
      randomly divided into control group (standard management group, with 45 patients)
      and study group (the phone program group, with 45 patients). In control group,
      the exercises at home are not monitored. Whereas in study group, patients are
      asked about their at-home activities, and the extra coaching sessions are
      provided to patients on self-care, exercise guidance, and the importance of
      exercise at home, and then answers to their questions. The primary outcome is the
      range of motion of the shoulder joint, and the pain arcs are determined through
      the range of motion. The extra assessments include the shoulder functional
      outcome, pain, and the quality of life. All the analysis needed in this study is 
      implemented with SPSS (IBM, Chicago, USA) for Windows Version 19.0. RESULTS: The 
      clinical outcome variables between groups are shown in Table. CONCLUSION: This
      investigation can offer a reliable basis for the effectiveness of phone
      assistance nursing program in patients after shoulder instability surgery. TRIAL 
      REGISTRATION NUMBER: researchregistry6010.
FAU - Zheng, Yongling
AU  - Zheng Y
AD  - Department of Orthopedics.
FAU - Wang, Hongli
AU  - Wang H
AD  - Department of Operating Room.
FAU - Wang, Huali
AU  - Wang H
AD  - Department of Orthopedics.
FAU - Xu, Junchang
AU  - Xu J
AD  - Department of Orthopedics.
FAU - Chen, Ping
AU  - Chen P
AUID- ORCID: 0000-0002-7745-5527
AD  - Department of Gynaecology and Obstetrics, the First People's Hospital of
      Xiangyang City Affiliated to Hubei Medical College, Hubei, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aftercare/*methods
MH  - *Home Care Services
MH  - Humans
MH  - Joint Instability/*surgery
MH  - Orthopedic Procedures/nursing
MH  - Randomized Controlled Trials as Topic/*methods
MH  - *Self Care
MH  - Shoulder Joint/*surgery
MH  - *Telephone
MH  - Treatment Outcome
PMC - PMC7581063
EDAT- 2020/10/31 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1097/MD.0000000000022756 [doi]
AID - 00005792-202010230-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22756. doi:
      10.1097/MD.0000000000022756.


PMID- 33120767
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Danhong injection for the treatment of early diabetic nephropathy: A protocol of 
      systematic review and meta-analysis.
PG  - e22716
LID - 10.1097/MD.0000000000022716 [doi]
AB  - BACKGROUND: Diabetic nephropathy (DN) is the one that of the most common
      complications of diabetes mellitus (DM). Diabetic patients will experience a high
      mortality rate when DN progress to end-stage. So, it is extremely important to
      early treat DN. Although several interventions have been used to treat DN, a
      conclusive finding has not already been achieved. As one of the most common
      Chinese medicines, danhong injection (DHI) which has been shown to have various
      functions has also been prescribed to be as the alternative treatment option.
      However, no systematic review and meta-analysis has been conducted to objectively
      and comprehensively investigate its effectiveness and safety. Thus, we designed
      the current systematic review and meta-analysis to answer whether DHI can be
      preferably used to timely treat DN. METHODS: We will perform a systematic search 
      to capture any potentially eligible studies in several electronic databases
      including PubMed, Cochrane library, Embase, China National Knowledgement
      Infrastructure (CNKI), Wanfang database, and Chinese sci-tech periodical
      full-text database (VIP) from their inception to August 31, 2020. We will assign 
      2 independent reviewers to select eligible studies, and assess the quality of
      included studies with Cochrane risk of bias assessment tool. We will perform all 
      statistical analyses using RevMan 5.3 software. ETHICS AND DISSEMINATION: We will
      submit our findings to be taken into consideration for publication in a
      peer-reviewed academic journal. Meanwhile, we will also communicate our findings 
      in important conferences. PROTOCOL REGISTRY: The protocol of this systematic
      review and meta-analysis has been registered at the International Plateform of
      Registered Systematic Review and Meta-Analysis Protocols (INPLASY) platform
      (https://inplasy.com/inplasy-2020-9-0005/, registry number: INPLASY202090005) and
      this protocol was funded through a protocol registry.
FAU - Huang, Caixia
AU  - Huang C
AUID- ORCID: 0000-0002-9192-2064
AD  - Department of Nephrology, Beijing Hospital of Integrated Traditional Chinese and 
      Western Medicine, Beijing, China.
FAU - Huang, Cuiling
AU  - Huang C
FAU - Zhou, Guomin
AU  - Zhou G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (danhong)
SB  - IM
MH  - Diabetic Nephropathies/*drug therapy
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Early Medical Intervention
MH  - Humans
MH  - Injections
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
PMC - PMC7581143
EDAT- 2020/10/31 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1097/MD.0000000000022716 [doi]
AID - 00005792-202010230-00043 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22716. doi:
      10.1097/MD.0000000000022716.


PMID- 33120746
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Prostate cancer: a risk factor for COVID-19 in males?: A protocol for systematic 
      review and meta analysis.
PG  - e22591
LID - 10.1097/MD.0000000000022591 [doi]
AB  - INTRODUCTION: COVID-19 is now a global pandemic. Although there are very few
      studies describing the characteristics of SARS-CoV-2 infections in patients with 
      prostate cancer, these patients are likely to be more susceptible to COVID-19
      than healthy people because of their immunosuppressed state. However, there is no
      evidence that prostate cancer is a risk factor for COVID-19. METHODS: We searched
      the Wanfang database, the China Science Journal Citation Report (VIP database),
      the China National Knowledge Infrastructure (CNKI), Web of Science, EMBASE,
      PubMed, and the Cochrane Library for studies related to the topic. We designed a 
      standardized data extraction sheet and used Epidata software 3.1 for data
      extraction. In accordance with the Cochrane 5.1.0 standard, both a quality
      assessment and a risk assessment were carried out for the research meeting the
      inclusion criteria. The data were analyzed using Revman 5.3 and Stata 13.0
      software. RESULTS: The study integrated existing research findings and a
      meta-analysis of the data to investigate the prevalence of prostate cancer in
      males infected with SARS-CoV-2 and the adverse clinical outcomes in male patients
      with or without COVID-19. CONCLUSION: The results of this research may provide a 
      basis for judging if prostate cancer is a risk factor for males infected with
      SARS-CoV-2, and the findings can effectively help to prevent COVID-19 in patients
      with prostate cancer. ETHICS AND DISSEMINATION: Ethics approval is not required
      for this systematic review as it will involve the collection and analysis of
      secondary data. The results of the review will be reported in international
      peer-reviewed journals PRORPERO REGISTRATION NUMBER:: CRD42020194071.
FAU - Mou, Ruiyu
AU  - Mou R
AUID- ORCID: 0000-0003-3494-5240
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - Tianjin Key Laboratory of Translational Research of TCM Prescription and
      Syndrome.
FAU - Jin, Xinyao
AU  - Jin X
AD  - Evidence-based Medicine Center of Tianjin University of Traditional Chinese
      Medicine, Tianjin, China.
FAU - Li, Wenjie
AU  - Li W
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Wu, Mingxin
AU  - Wu M
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Liu, Xiaodi
AU  - Liu X
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Liu, Zhao
AU  - Liu Z
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Guo, Shanqi
AU  - Guo S
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - Tianjin Key Laboratory of Translational Research of TCM Prescription and
      Syndrome.
FAU - Li, Xiaojiang
AU  - Li X
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - Tianjin Key Laboratory of Translational Research of TCM Prescription and
      Syndrome.
FAU - Jia, Yingjie
AU  - Jia Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - Tianjin Key Laboratory of Translational Research of TCM Prescription and
      Syndrome.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Protocols
MH  - Coronavirus Infections/diagnosis/*etiology
MH  - Global Health
MH  - Humans
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/*etiology
MH  - Prevalence
MH  - Prognosis
MH  - Prostatic Neoplasms/*complications/epidemiology
MH  - Risk Assessment
MH  - Risk Factors
MH  - SARS-CoV-2
PMC - PMC7581123
EDAT- 2020/10/31 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1097/MD.0000000000022591 [doi]
AID - 00005792-202010230-00022 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22591. doi:
      10.1097/MD.0000000000022591.


PMID- 33120735
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 43
DP  - 2020 Oct 23
TI  - Platinum versus immunotherapy for early resectable non-small cell lung cancer: A 
      protocol for systematic review and meta analysis.
PG  - e22349
LID - 10.1097/MD.0000000000022349 [doi]
AB  - BACKGROUND: Lung cancer is one of the most common malignant tumors. Non-small
      cell Lung cancer (NSCLC) accounts for about 85% of the total lung cancer. For
      patients with resectable early NSCLC, conventional postoperative adjuvant therapy
      can significantly prolong the overall survival of patients and reduce the risk of
      tumor recurrence. With the emergence and maturity of molecular targeted therapy
      and immunotherapy, the strategy of postoperative chemotherapy for lung cancer
      patients has changed greatly. To evaluate the efficacy of postoperative
      chemotherapy (platinum based chemotherapy and immunotherapy) with or without
      radiotherapy for NSCLC patients, we will conduct a systematic review and
      meta-analysis of published or unpublished randomized controlled trials. METHODS: 
      We will search Pubmed (Medline), Embase, Google Scholar, Cancerlit, and the
      Cochrane Central Register of Controlled Trials for related studies published
      without language restrictions before June 20, 2021. Two review authors will
      search and assess relevant studies independently. Randomized controlled trials
      and quasi-randomized controlled trials studies will be included. we will perform 
      subgroup analysis in different methods of postoperative adjuvant therapy for
      patients with resectable early NSCLC. Because this study will be based on
      published or unpublished records and studies, there is no need for ethics
      approval. INPLASY registration number: INPLASY202080064. RESULTS: The results of 
      this study will be published in a peer-reviewed journal. CONCLUSION: This study
      will compare the efficacy of platinum chemotherapy and immunotherapy in patients 
      with resectable early NSCLC. Since the large sample randomized trials that meet
      the inclusion criteria of this study may be inadequate, we will consider
      incorporating some high quality small sample related tests, which may lead to
      heterogeneity and affect the reliability of the results.
FAU - Tong, Zhangwei
AU  - Tong Z
AD  - Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou,
      China.
FAU - Luo, Fei
AU  - Luo F
FAU - Yang, Xiaojie
AU  - Yang X
FAU - Kang, Mingqiang
AU  - Kang M
FAU - Lin, Jiangbo
AU  - Lin J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Platinum Compounds)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*therapy
MH  - Chemotherapy, Adjuvant
MH  - Humans
MH  - *Immunotherapy
MH  - Lung Neoplasms/*therapy
MH  - Meta-Analysis as Topic
MH  - Molecular Targeted Therapy
MH  - Platinum Compounds/*therapeutic use
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7581118
EDAT- 2020/10/31 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1097/MD.0000000000022349 [doi]
AID - 00005792-202010230-00011 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 23;99(43):e22349. doi:
      10.1097/MD.0000000000022349.


PMID- 33120634
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220417
IS  - 1998-3689 (Electronic)
IS  - 0301-4738 (Linking)
VI  - 68
IP  - 11
DP  - 2020 Nov
TI  - Assessment of psychosocial impact of primary glaucoma and its effect on quality
      of life of patients in Western India.
PG  - 2435-2438
LID - 10.4103/ijo.IJO_2117_19 [doi]
AB  - PURPOSE: : To assess the impact of primary glaucoma of varying severity and
      duration on psychosocial functioning and quality of life of patients. METHODS: A 
      cross-sectional observational study was carried on 200 patients attending the
      glaucoma clinic of a tertiary care hospital in western India. After obtaining
      approval from the institutional ethics committee, written informed consent was
      taken. All patients underwent a thorough ophthalmic examination. Those with
      primary glaucoma were classified as per Hodapp-Parrish-Anderson criteria and
      asked to respond to the National Eye Institute Visual Function Questionnaire
      (NEIVFQ)-25 questionnaire. Responses were analyzed statistically. RESULTS: :
      Overall mean NEIVFQ 25 composite score was 74.4 +/- 18.6. Mean scores were 87.0
      (SD 7.2) for mild, 75.9 (SD 8.1) for moderate, and 47.0 (SD 13.7) for severe
      glaucoma groups. Lower scores were associated with males. Driving (62.2, SD 34.6)
      and ocular pain (63.5, SD 18.7) were maximally affected while color vision (90.1,
      SD 18.7) and social health (86.7, SD 20.1) were least affected. The duration of
      treatment had no effect on mean composite scores with impaired scores seen even
      in newly diagnosed cases. Age of the patient negatively correlated with NEIVFQ 25
      composite score. CONCLUSION: : With disease progression, the psychosocial
      functioning of the patients is negatively affected. This effect is irrespective
      of treatment duration and newly diagnosed cases can have impaired Quality of life
      scores. Quantification of psychosocial status along with education and counseling
      for all patients may play a definitive role in customizing treatment and
      providing patients with a better quality of Life.
FAU - Kalyani, V K S
AU  - Kalyani VKS
AD  - Department of Glaucoma, PBMA's H.V. Desai Eye Hospital, Pune, Maharashtra, India.
FAU - Dayal, Ashutosh
AU  - Dayal A
AD  - Department of Glaucoma, PBMA's H.V. Desai Eye Hospital, Pune, Maharashtra, India.
FAU - Chelerkar, Vidya
AU  - Chelerkar V
AD  - Department of Glaucoma, PBMA's H.V. Desai Eye Hospital, Pune, Maharashtra, India.
FAU - Deshpande, Madan
AU  - Deshpande M
AD  - Department of Glaucoma, PBMA's H.V. Desai Eye Hospital, Pune, Maharashtra, India.
FAU - Chakma, Anwesha
AU  - Chakma A
AD  - Department of Glaucoma, PBMA's H.V. Desai Eye Hospital, Pune, Maharashtra, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Glaucoma/diagnosis/epidemiology
MH  - Humans
MH  - India/epidemiology
MH  - Male
MH  - National Eye Institute (U.S.)
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - United States
PMC - PMC7774162
OTO - NOTNLM
OT  - Glaucoma
OT  - National Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25)
OT  - quality of life
COIS- None
EDAT- 2020/10/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/30 01:01
PHST- 2020/10/30 01:01 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - IndianJOphthalmol_2020_68_11_2435_299044 [pii]
AID - 10.4103/ijo.IJO_2117_19 [doi]
PST - ppublish
SO  - Indian J Ophthalmol. 2020 Nov;68(11):2435-2438. doi: 10.4103/ijo.IJO_2117_19.


PMID- 33120067
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1873-2054 (Electronic)
IS  - 1353-8292 (Linking)
VI  - 66
DP  - 2020 Nov
TI  - Faith-based alcohol treatment in England and Wales: New evidence for policy and
      practice.
PG  - 102457
LID - S1353-8292(20)30273-2 [pii]
LID - 10.1016/j.healthplace.2020.102457 [doi]
AB  - While the historical importance of religion in alcohol treatment is well known,
      the size, scope and significance of contemporary activities remain unclear. Here 
      we begin to address this gap in knowledge by presenting results from a mixed
      methods study of faith-based alcohol treatment in England and Wales. The paper
      begins by mapping location, religious affiliation, organisational structure and
      service provision. We then discuss evidence regarding challenges, opportunities
      and tensions bound up with faith-based organisations 'filling gaps' left by long 
      term restructuring of alcohol service provision, recent 'austerity' funding cuts 
      and relationships between secular and faith-based organisations. In the final
      substantive section, we engage with questions of ethics and care by focusing on
      the internal workings of a subset of faith-based programs that make requirements 
      for religious participation. Drawing on the variegated experiences of
      service-users, we reflect on the ethics of religious conversion in faith-based
      alcohol treatment. The conclusion offers policy and practice relevant insights
      and outlines areas for future research on religion, austerity, and alcohol
      treatment.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Jayne, Mark
AU  - Jayne M
AD  - School of Geography and Planning, Sun Yat-Sen University, 135 West Xingang Road, 
      Guangzhou, Guangdong 510275, PR China. Electronic address:
      jayne@mail.sysu.edu.cn.
FAU - Williams, Andrew
AU  - Williams A
AD  - School of Geography and Planning, Cardiff University, Glamorgan Building, King
      Edward VII Avenue, Cardiff CF10 3WA, Wales, UK. Electronic address:
      WilliamsAPJ@cardiff.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - England
TA  - Health Place
JT  - Health & place
JID - 9510067
MH  - England
MH  - Humans
MH  - *Policy
MH  - *Religion
MH  - Wales
OTO - NOTNLM
OT  - *Alcohol
OT  - *Austerity
OT  - *Faith
OT  - *Policy
OT  - *Treatment
EDAT- 2020/10/30 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/10/29 20:07
PHST- 2020/02/29 00:00 [received]
PHST- 2020/09/30 00:00 [revised]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/10/29 20:07 [entrez]
AID - S1353-8292(20)30273-2 [pii]
AID - 10.1016/j.healthplace.2020.102457 [doi]
PST - ppublish
SO  - Health Place. 2020 Nov;66:102457. doi: 10.1016/j.healthplace.2020.102457. Epub
      2020 Oct 22.


PMID- 33119094
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - Suppl 8
DP  - 2020 Oct 29
TI  - The Role of the Private Sector in Supporting Malaria Control in Resource
      Development Settings.
PG  - S701-S708
LID - 10.1093/infdis/jiaa488 [doi]
AB  - Industrial operations of the private sector, such as extraction, agriculture, and
      construction, can bring large numbers of people into new settlement areas and
      cause environmental change that promotes the transmission of vector-borne
      diseases. Industry-related workers and communities unduly exposed to infection
      risk typically lack the knowledge and means to protect themselves. However, there
      is a strong business rationale for protecting local resident employees through
      integrated vector control programs, as well as an ethical responsibility to care 
      for these individuals and the affected communities. We discuss the role and
      challenges of the private sector in developing malaria control programs, which
      can include extensive collaborations with the public sector that go on to form
      the basis of national vector control programs or more broadly support local
      healthcare systems.
CI  - (c) 2020 World Health Organization; licensee Oxford University Press USA.
FAU - Jones, Robert T
AU  - Jones RT
AD  - Arthropod Control Product Test Centre, London School of Hygiene & Tropical
      Medicine, London, United Kingdom.
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, United Kingdom.
FAU - Tusting, Lucy S
AU  - Tusting LS
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, United Kingdom.
FAU - Smith, Hugh M P
AU  - Smith HMP
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, United Kingdom.
FAU - Segbaya, Sylvester
AU  - Segbaya S
AD  - Johns Hopkins Center for Communication Programs, Accra, Ghana.
FAU - Macdonald, Michael B
AU  - Macdonald MB
FAU - Bangs, Michael J
AU  - Bangs MJ
AD  - lnternational SOS, Ltd., Timika, Papua Province, Indonesia.
AD  - International SOS, Ltd., Kolwesi, Lualaba Province, Democratic Republic of Congo.
FAU - Logan, James G
AU  - Logan JG
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, United Kingdom.
LA  - eng
GR  - MR/N011570/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/N011570/2/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
SB  - IM
MH  - Communicable Disease Control/*organization & administration
MH  - Developing Countries
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Malaria/*prevention & control
MH  - Private Sector
MH  - Quality of Health Care
MH  - Socioeconomic Factors
PMC - PMC7594257
OTO - NOTNLM
OT  - *malaria
OT  - *private sector
OT  - *resource development setting
OT  - *vector-borne disease
EDAT- 2020/10/30 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/10/29 12:12
PHST- 2020/10/29 12:12 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 5942814 [pii]
AID - 10.1093/infdis/jiaa488 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Oct 29;222(Suppl 8):S701-S708. doi: 10.1093/infdis/jiaa488.


PMID- 33118977
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 1181-912X (Print)
IS  - 1181-912X (Linking)
VI  - 30
IP  - 1
DP  - 2020 Winter
TI  - Exploring the challenges of ethical conduct in quality improvement projects.
PG  - 64-68
FAU - Hall, Steven
AU  - Hall S
AD  - Candidate, University of Saskatchewan, College of Nursing, Saskatoon, SK,
      steven.hall@usask.ca.
FAU - Lee, Virginia
AU  - Lee V
AD  - Senior Nursing Research Consultant (interim), Nursing Directorate, Professional
      Practice, Education, Workforce Organization and Research, McGill University
      Health Centre (MUHN), Montreal, QC, virginia.lee@mcgill.ca.
FAU - Haase, Kristen
AU  - Haase K
AD  - Assistant Professor, College of Nursing, University of Saskatchewan, Saskatoon,
      SK, kristen.haase@usask.ca.
LA  - eng
PT  - Journal Article
DEP - 20200101
PL  - Canada
TA  - Can Oncol Nurs J
JT  - Canadian oncology nursing journal = Revue canadienne de nursing oncologique
JID - 9300792
PMC - PMC7585708
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 12:11
PHST- 2020/10/29 12:11 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - conj-30-1-64 [pii]
PST - epublish
SO  - Can Oncol Nurs J. 2020 Jan 1;30(1):64-68. eCollection 2020 Winter.


PMID- 33118935
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 10
DP  - 2020 Oct 29
TI  - Undergraduate Medical Competencies in Digital Health and Curricular Module
      Development: Mixed Methods Study.
PG  - e22161
LID - 10.2196/22161 [doi]
AB  - BACKGROUND: Owing to an increase in digital technologies in health care, recently
      leveraged by the COVID-19 pandemic, physicians are required to use these
      technologies appropriately and to be familiar with their implications on patient 
      care, the health system, and society. Therefore, medical students should be
      confronted with digital health during their medical education. However,
      corresponding teaching formats and concepts are still largely lacking in the
      medical curricula. OBJECTIVE: This study aims to introduce digital health as a
      curricular module at a German medical school and to identify undergraduate
      medical competencies in digital health and their suitable teaching methods.
      METHODS: We developed a 3-week curricular module on digital health for third-year
      medical students at a large German medical school, taking place for the first
      time in January 2020. Semistructured interviews with 5 digital health experts
      were recorded, transcribed, and analyzed using an abductive approach. We obtained
      feedback from the participating students and lecturers of the module through a
      17-item survey questionnaire. RESULTS: The module received overall positive
      feedback from both students and lecturers who expressed the need for further
      digital health education and stated that the field is very important for clinical
      care and is underrepresented in the current medical curriculum. We extracted a
      detailed overview of digital health competencies, skills, and knowledge to teach 
      the students from the expert interviews. They also contained suggestions for
      teaching methods and statements supporting the urgency of the implementation of
      digital health education in the mandatory curriculum. CONCLUSIONS: An elective
      class seems to be a suitable format for the timely introduction of digital health
      education. However, a longitudinal implementation in the mandatory curriculum
      should be the goal. Beyond training future physicians in digital skills and
      teaching them digital health's ethical, legal, and social implications, the
      experience-based development of a critical digital health mindset with openness
      to innovation and the ability to assess ever-changing health technologies through
      a broad transdisciplinary approach to translate research into clinical routine
      seem more important. Therefore, the teaching of digital health should be as
      practice-based as possible and involve the educational cooperation of different
      institutions and academic disciplines.
CI  - (c)Akira-Sebastian Poncette, Daniel Leon Glauert, Lina Mosch, Katarina Braune,
      Felix Balzer, David Back. Originally published in the Journal of Medical Internet
      Research (http://www.jmir.org), 29.10.2020.
FAU - Poncette, Akira-Sebastian
AU  - Poncette AS
AUID- ORCID: 0000-0003-4627-7016
AD  - Department of Anesthesiology and Intensive Care Medicine, Charite -
      Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
AD  - Einstein Center Digital Future, Berlin, Germany.
FAU - Glauert, Daniel Leon
AU  - Glauert DL
AUID- ORCID: 0000-0001-8583-8811
AD  - Department of Anesthesiology and Intensive Care Medicine, Charite -
      Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
FAU - Mosch, Lina
AU  - Mosch L
AUID- ORCID: 0000-0003-3154-2745
AD  - Department of Anesthesiology and Intensive Care Medicine, Charite -
      Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
FAU - Braune, Katarina
AU  - Braune K
AUID- ORCID: 0000-0001-6590-245X
AD  - Department of Paediatric Endocrinology and Diabetes, Charite -
      Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
FAU - Balzer, Felix
AU  - Balzer F
AUID- ORCID: 0000-0003-1575-2056
AD  - Department of Anesthesiology and Intensive Care Medicine, Charite -
      Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
AD  - Einstein Center Digital Future, Berlin, Germany.
FAU - Back, David Alexander
AU  - Back DA
AUID- ORCID: 0000-0001-7552-7753
AD  - Department of Traumatology and Orthopaedics, Septic and Reconstructive Surgery,
      Bundeswehr Hospital Berlin, Berlin, Germany
AD  - Dieter Scheffner Center for Medical Education and Educational Research, Charite -
      Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
EIN - J Med Internet Res. 2020 Dec 7;22(12):e25738. PMID: 33284785
MH  - COVID-19
MH  - Coronavirus Infections
MH  - *Curriculum
MH  - Education, Medical, Undergraduate/*methods
MH  - Feedback
MH  - Germany
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - *Schools, Medical
MH  - *Students, Medical
MH  - Surveys and Questionnaires
MH  - *Telemedicine
PMC - PMC7661229
OTO - NOTNLM
OT  - *curriculum, medical school, digital health mindset
OT  - *digital health
OT  - *digital health education
OT  - *eHealth
OT  - *eHealth education
OT  - *elective module
OT  - *interview
OT  - *mHealth
OT  - *qualitative research
OT  - *survey
EDAT- 2020/10/30 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/29 12:11
PHST- 2020/07/10 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/10/29 12:11 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - v22i10e22161 [pii]
AID - 10.2196/22161 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Oct 29;22(10):e22161. doi: 10.2196/22161.


PMID- 33118846
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1947-5543 (Electronic)
IS  - 1947-5543 (Linking)
VI  - 18
IP  - 6
DP  - 2020 Dec
TI  - Diverse Responses of the Biobanks in Indo-Pacific Rim Region During the COVID-19 
      Pandemic: Case Scenarios from Two Low- and Middle-Income Countries and Two
      High-Income Countries in the Indo-Pacific Rim Region.
PG  - 525-532
LID - 10.1089/bio.2020.0078 [doi]
AB  - Background: Biobankers have been unexpectedly involved in the pandemic of
      COVID-19 since early 2020. Although specific guidance was not available, the
      International Society for Biological and Environmental Repositories (ISBER) Best 
      Practices and the ISO 20387 document have been utilized to deal with the pandemic
      disaster. The ISO experts and best practice experts in ISBER teamed up to share
      the available information and learn the experiences of biobanks concerning
      COVID-19 through organizing webinars, surveys, and town hall meetings. Four ISBER
      regional ambassadors (RAs) from the Indo-Pacific Rim (IPR) region were also
      actively involved at one of the town hall meetings. These RAs, who are from
      Australia, India, Indonesia, and Japan, and the Director-at-Large of the region, 
      have summarized their experiences in this article. Materials and Methods: The
      ISBER Standards Committee COVID-19 Task Force has kindly provided the survey
      results. The extracted glossary from the results was categorized into 10 factors:
      (1) crisis management; (2) sample-related issues; (3) logistics-related issues;
      (4) equipment-related issues; (5) ethical, legal, and social implication-related 
      issues; (6) operation-related issues; (7) personnel-related issues; (8)
      management-related issues; (9) infection-related issues; and (10)
      research-related issues. Each IPR RA has provided a case considering these 10
      factors. Results and Discussion: Two key points have emerged from the scenarios, 
      which are as follows: (1) impacts of the biobanks in low- and middle-income
      countries (LMICs) are similar to those in high-income countries (HICs) and (2)
      tolerance of the biobanks in LMICs is not so robust as those in HICs.
      Furthermore, communication strategies with internal and external stakeholders are
      critical for a biobank to manage this crisis. This article summarizes the
      impacts, indicates the opportunities that COVID-19 has brought to the biobank
      community, and highlights the usefulness of the network beyond biobank services. 
      Lastly, the biobanks need to turn the challenges into opportunities to overcome
      the crisis.
FAU - Yadav, Birendra Kumar
AU  - Yadav BK
AD  - National Liver Disease Biobank, ILBS, New Delhi, India.
FAU - Ng, Wayne
AU  - Ng W
AD  - Victorian Cancer Biobank, Melbourne, Australia.
FAU - Fachiroh, Jajah
AU  - Fachiroh J
AD  - Biobank Development Team/Histology and Cell Biology, Faculty of Medicine, Public 
      Health and Nursing Universitas Gadjah Mada, Yogyakarta, Indonesia.
FAU - Tsuruyama, Tatsuaki
AU  - Tsuruyama T
AD  - Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
AD  - Kyoto University Hospital, Clinical Bioresource Center, Kyoto, Japan.
FAU - Furuta, Koh
AU  - Furuta K
AD  - Urayasu Warakuen Clinic, Urayasu, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - United States
TA  - Biopreserv Biobank
JT  - Biopreservation and biobanking
JID - 101507284
SB  - IM
MH  - *Biological Specimen Banks
MH  - *Biomedical Research
MH  - *COVID-19/epidemiology/metabolism
MH  - Developed Countries
MH  - Developing Countries
MH  - Humans
MH  - *Pandemics
MH  - SARS-CoV-2/*metabolism
OTO - NOTNLM
OT  - COVID-19
OT  - Indo-Pacific Rim (IPR) biobank
OT  - pandemic impact
EDAT- 2020/10/30 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/29 12:10
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/10/29 12:10 [entrez]
AID - 10.1089/bio.2020.0078 [doi]
PST - ppublish
SO  - Biopreserv Biobank. 2020 Dec;18(6):525-532. doi: 10.1089/bio.2020.0078. Epub 2020
      Oct 28.


PMID- 33118497
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 182
IP  - 43
DP  - 2020 Oct 19
TI  - [The Nordic kidneyexchangeprogramme].
LID - V04200209 [pii]
AB  - This review describes the ScandiaTransplant Kidney Exchange Programme and the
      background of renal exchange programmes gaining popularity worldwide,
      possibilities and limitations of the programmes, the ethical aspects and
      perspectives. The first kidney exchanges between Danish and Swedish countries
      were performed in 2019, and until now 23 exchanges and transplantations have been
      performed. All surgical procedures have been performed simultaneously and/or
      coordinated at different hospitals in Scandinavia, and the kidney grafts were
      transported between the participating units.
FAU - Skov, Karin
AU  - Skov K
AD  - karin.skov@rm.dk.
FAU - Weinreich, Ilse Duus
AU  - Weinreich ID
FAU - Bruunsgaard, Helle
AU  - Bruunsgaard H
FAU - Bistrup, Claus
AU  - Bistrup C
FAU - Sorensen, Soren Schwartz
AU  - Sorensen SS
FAU - Koefoed-Nielsen, Pernille
AU  - Koefoed-Nielsen P
FAU - Wennberg, Lars
AU  - Wennberg L
FAU - Lindner, Per
AU  - Lindner P
FAU - Andersson, Tommy
AU  - Andersson T
LA  - dan
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
SB  - IM
MH  - Humans
MH  - Kidney
MH  - *Kidney Transplantation
MH  - Scandinavian and Nordic Countries
MH  - *Tissue Donors
EDAT- 2020/10/30 06:00
MHDA- 2021/06/11 06:00
CRDT- 2020/10/29 08:39
PHST- 2020/10/29 08:39 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
AID - V04200209 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2020 Oct 19;182(43). pii: V04200209.


PMID- 33117961
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Transcutaneous tibial nerve stimulation for the treatment of bladder storage
      symptoms in people with multiple sclerosis: Protocol of a single-arm feasibility 
      study.
PG  - 66
LID - 10.12688/hrbopenres.13107.1 [doi]
AB  - Background: Neurogenic lower urinary tract dysfunction (NLUTD) is common among
      people with multiple sclerosis (MS) with a pooled prevalence of 68.41% using
      self-report measures and 63.95% using urodynamic studies. Transcutaneous tibial
      nerve stimulation (TTNS) is a non-invasive option to manage bladder storage
      symptoms; however, the potential efficacy of TTNS among people with MS is based
      on a small number of studies with the absence of high-quality evidence relating
      to efficacy, and lack of clarity of the optimal electrical stimulation parameters
      and frequency, duration and number of treatment sessions. This study aims to
      assess whether TTNS is feasible and acceptable as a treatment for bladder storage
      symptoms in people with MS. Methods: We will use a single-arm experimental study 
      to explore the feasibility and acceptability of TTNS in the treatment of bladder 
      storage symptoms in MS. The CONSORT extension for pilot and feasibility studies
      will be followed to standardise the conduct and reporting of the study. The
      recruitment plan is twofold: 1) Open recruitment for people with MS through MS
      Ireland's communication channels; 2) recruitment from a convenience sample of
      people with MS who have previously participated in a qualitative interview study 
      of urinary symptoms. We will assess recruitment/retention rates, the urinary
      symptoms changes and the effect on quality of life pre and post intervention
      using ICIQ-OAB, 3-day bladder diary, King's Health Questionnaire and collect
      self-reported data on adherence and adverse events. Acceptability of using TTNS
      will be evaluated at the end of intervention. This study has been reviewed and
      approved by the Education and Health Science's Faculty Research Ethics Committee,
      University of Limerick [2020_06_07_EHS]. Conclusion: It is anticipated that
      assessing the feasibility and acceptability of TTNS for storage bladder symptoms 
      in MS will inform the development of a definitive randomised trial. Trial
      registration: ClinicalTrials.gov NCT04528784 27/08/2020.
CI  - Copyright: (c) 2020 Al Dandan HB et al.
FAU - Al Dandan, Hawra B
AU  - Al Dandan HB
AUID- ORCID: https://orcid.org/0000-0002-0807-7323
AD  - School of Allied Health, Faculty of Education and Health Sciences, Clinical
      therapies, University of Limerick, Limerick, County Limerick, Ireland.
AD  - College of Applied Medical Sciences, Physiotherapy, Imam Abdulrahman Bin Faisal
      University, Dammam, Saudi Arabia.
FAU - Galvin, Rose
AU  - Galvin R
AUID- ORCID: https://orcid.org/0000-0002-8171-224X
AD  - School of Allied Health, Faculty of Education and Health Sciences, Clinical
      therapies, University of Limerick, Limerick, County Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, County Limerick,
      Ireland.
AD  - Aging Research Centre, University of Limerick, Limerick, County Limerick,
      Ireland.
FAU - Robinson, Katie
AU  - Robinson K
AUID- ORCID: https://orcid.org/0000-0003-1008-9857
AD  - School of Allied Health, Faculty of Education and Health Sciences, Clinical
      therapies, University of Limerick, Limerick, County Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, County Limerick,
      Ireland.
AD  - Aging Research Centre, University of Limerick, Limerick, County Limerick,
      Ireland.
FAU - McClurg, Dorren
AU  - McClurg D
AD  - Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow
      Caledonian University, Glasgow, UK.
FAU - Coote, Susan
AU  - Coote S
AUID- ORCID: https://orcid.org/0000-0001-7077-0164
AD  - School of Allied Health, Faculty of Education and Health Sciences, Clinical
      therapies, University of Limerick, Limerick, County Limerick, Ireland.
AD  - Health Research Institute, University of Limerick, Limerick, County Limerick,
      Ireland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04528784
PT  - Journal Article
DEP - 20200916
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7578569
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - Neurogenic bladder
OT  - Tibial nerve stimulation.
OT  - feasibility study
OT  - urinary symptoms
COIS- No competing interests were disclosed.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:54
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/10/29 05:54 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.12688/hrbopenres.13107.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Sep 16;3:66. doi: 10.12688/hrbopenres.13107.1. eCollection
      2020.


PMID- 33117886
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Oct 19
TI  - Genetic Testing and Counseling in Metabolic Liver Disease: An Interactive Lecture
      for Medical Students.
PG  - 10996
LID - 10.15766/mep_2374-8265.10996 [doi]
AB  - Introduction: Medical students have limited opportunities to learn about current 
      genetic testing. This session provided exposure to different types of testing and
      the complex issues that physicians may encounter when counseling patients on
      proper testing and interpreting results. Methods: We designed a 1-hour
      interactive lecture for second-year medical students. We presented an overview of
      the topic, then applied the concepts to specific disorders and cases. Students
      were asked to answer questions regarding cases using an audience response system,
      and we used their responses as the basis for our in-class discussion. This
      session has been held twice, with 25 students attending in 2018 and 31 students
      in 2019. The session was also recorded so that additional students not in
      attendance could watch, and was available to 151 students in 2018 and 333
      students in 2019. Results: Students answered questions via audience response
      system. There was a range of 47%-100% of students giving the correct answers in
      2018, and 55%-93% in 2019. Exam questions covering genetic counseling issues were
      answered correctly by 66% and 77% of students in 2018, and 70% and 68% of
      students in 2019. Discussion: This session provided an opportunity for medical
      students to be exposed to some of the complex ethical and psychosocial issues
      that may arise with genetic testing for liver disease and to consider how to
      navigate them. Using an audience response system during the lecture made the
      session more interactive and allowed the teacher to correct errors and teach
      based on the responses.
CI  - (c) 2020 McPheron et al.
FAU - McPheron, Molly A
AU  - McPheron MA
AUID- ORCID: 0000-0003-2133-1987
AD  - Assistant Professor, Medical and Molecular Genetics, Indiana University School of
      Medicine.
FAU - Craven, Hannah J
AU  - Craven HJ
AD  - Assistant Librarian, Ruth Lilly Medical Library, Indiana University School of
      Medicine.
FAU - Molleston, Jean P
AU  - Molleston JP
AD  - Professor of Clinical Pediatrics, Department of Pediatrics, Indiana University
      School of Medicine.
FAU - Dilly, Christen K
AU  - Dilly CK
AD  - Assistant Professor, Department of Medicine, Indiana University School of
      Medicine; Roudebush VA Medical Center.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - Counseling
MH  - Genetic Testing
MH  - Humans
MH  - Learning
MH  - *Liver Diseases
MH  - *Students, Medical
PMC - PMC7586753
OTO - NOTNLM
OT  - *Biochemistry & Cell Biology
OT  - *Case-Based Learning
OT  - *Ethics/Bioethics
OT  - *Gastroenterology
OT  - *Genetic Counseling
OT  - *Genetic Testing
OT  - *Medical Genetics
OT  - *Metabolic Liver Disease
OT  - *Pediatric Gastroenterology
EDAT- 2020/10/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/29 05:54
PHST- 2020/10/29 05:54 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10996 [doi]
AID - 10996 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Oct 19;16:10996. doi: 10.15766/mep_2374-8265.10996.


PMID- 33117827
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - The Everyday Life of Patients With Tuberculosis in the Concentration Camp of
      Mittelbau-Dora (1943-1945).
PG  - 526839
LID - 10.3389/fmed.2020.526839 [doi]
AB  - The everyday life of patients with tuberculosis in the main prisoner infirmary of
      the Mittelbau-Dora concentration camp is analyzed historically-critically by
      medical records, documents of the Schutzstaffel (SS) physicians, contemporary
      medical textbooks and memoirs of former inmates from partly international
      archives. To compare the medical treatment in the three phases of the
      concentration camp, the representative months of February 1944, July 1944 and
      January 1945 were examined. The analysis shows that SS hygienists inspected the
      place for fear of a collapse of the V-2 rocket production. The primitive medical 
      infrastructure was slowly expanded after its founding in 1943. SS physicians and 
      medics led and supervised the treatment provided by inmates. These were in an
      ethical dilemma between cooperation with the SS and commitment to the sick
      prisoners. The Tuberculosis Department was used for isolation. Sputum diagnostics
      and X-ray equipment were utilized as selection tools. Infectious patients laid
      usually for weeks in the same bed with two other patients. Significantly more
      resources were available, however, for non-infectious tuberculosis patients. The 
      therapy was based on the medical expert opinion of the time and was mainly
      symptomatic such as fever reduction. Rest and vitamins should make prisoners fit 
      for the armament industry. Patients with tuberculosis had a high death rate. The 
      prisoners who survived were discharged, but often did not recover. Several
      thousand prisoners were selected for transports, which led to special
      concentration camps for seriously ill prisoners (Lublin-Majdanek, Bergen-Belsen) 
      and the subcamp Boelcke-Kaserne. There, they often died of catastrophic
      conditions or were killed.
CI  - Copyright (c) 2020 Kiosze and Steger.
FAU - Kiosze, Philipp
AU  - Kiosze P
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University, Ulm,
      Germany.
FAU - Steger, Florian
AU  - Steger F
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University, Ulm,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7577410
OTO - NOTNLM
OT  - World War II
OT  - concentration camps
OT  - lung diseases
OT  - medical records
OT  - medical staff
OT  - national socialism
OT  - prisoners
OT  - tuberculosis
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:54
PHST- 2020/01/17 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/10/29 05:54 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.3389/fmed.2020.526839 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Sep 25;7:526839. doi: 10.3389/fmed.2020.526839.
      eCollection 2020.


PMID- 33117659
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2230-2034 (Electronic)
IS  - 2230-2034 (Linking)
VI  - 11
DP  - 2020
TI  - Managing Welfare and Antimicrobial-Resistance Issues in Treating Foot-and-Mouth
      Disease Lesions: A New Therapeutic Approach.
PG  - 99-107
LID - 10.2147/VMRR.S273788 [doi]
AB  - INTRODUCTION: Foot-and-mouth disease (FMD) causes negative impacts on global food
      security, the livestock trade, national economies, and farming-family
      livelihoods, particularly in resource-poor developing countries with inadequate
      biosecurity and low levels of vaccination from inadequate veterinary services. As
      smallholder farmers have limited understanding of disease-risk management, their 
      focus in FMD outbreaks is on accessing clinically effective therapies. However,
      most are provided inappropriate traditional treatments and/or topical or
      parenteral antibiotics, often delivered by paraveterinarians inadequately trained
      in antimicrobial custodianship. This results in negative financial impacts on
      livelihoods plus risks of food safety and development of antimicrobial
      resistance. We report the use of a novel pain-relief therapy for FMD. METHODS:
      Clinical examinations in an outbreak of suspected FMD in April 2019 in Muang Khay
      village in Luang Prabang province, Laos confirmed signs and lesions of severe,
      subacute, ulcerative glossitis and interdigital dermatitis, typical of FMD. All
      affected buffalo (n=99) and cattle (n=37) presented for treatment in a population
      of 238 large ruminants, from 15 of 136 households, were administered a topical
      anesthetic pain-relief product (PRP) wound gel by spray-on (10-30 mL per animal) 
      formulation developed for aversive husbandry procedures (Tri-Solfen, Animal
      Ethics, Australia). RESULTS: Treatment with PRP resulted in immediate improvement
      in demeanor and locomotion, and no adverse events were observed. On follow-up
      interview, all owners confirmed that their animals were eating within 2 days and 
      lesions had healed within 5 days. Having experienced the positive clinical
      impacts of PRP on affected animals, these and surrounding farmers were keen to
      purchase the PRP for future use. The veterinary authorities rapidly registered
      the PRP for FMD therapy in Laos due to the observed efficacy. DISCUSSION: These
      findings suggest a potential paradigm shift from treating FMD with expensive
      antimicrobials, which risks antimicrobial resistance, to a new, less expensive
      therapeutic approach that reduces animal suffering and may motivate farmers to
      report disease to access treatment. Use of the PRP is suggested as an innovation 
      that may improve future FMD management, particularly in developing countries.
CI  - (c) 2020 Windsor et al.
FAU - Windsor, Peter
AU  - Windsor P
AUID- ORCID: 0000-0001-5629-3517
AD  - The University of Sydney, Sydney School of Veterinary Science, Camden, NSW, 2570,
      Australia.
FAU - Khounsy, Syseng
AU  - Khounsy S
AD  - Department of Livestock and Fisheries, Ministry of Livestock and Fisheries,
      Vientiane, Lao People's Democratic Republic.
FAU - Earp, Francesca
AU  - Earp F
AUID- ORCID: 0000-0002-9454-2550
AD  - The University of Sydney, Sydney School of Veterinary Science, Camden, NSW, 2570,
      Australia.
FAU - MacPhillamy, Isabel
AU  - MacPhillamy I
AD  - The University of Sydney, Sydney School of Veterinary Science, Camden, NSW, 2570,
      Australia.
FAU - Young, James
AU  - Young J
AD  - The University of Sydney, Sydney School of Veterinary Science, Camden, NSW, 2570,
      Australia.
FAU - Bush, Russell
AU  - Bush R
AD  - The University of Sydney, Sydney School of Veterinary Science, Camden, NSW, 2570,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - New Zealand
TA  - Vet Med (Auckl)
JT  - Veterinary medicine (Auckland, N.Z.)
JID - 101724251
PMC - PMC7549654
OTO - NOTNLM
OT  - Laos
OT  - antisepsis
OT  - buffalo
OT  - cattle
OT  - therapy
OT  - topical anesthesia
COIS- The authors report no conflicts of interest in this work. The extensive studies
      evaluating Tri-Solfen and other therapies for aversive animal-husbandry
      interventions that occurred prior to this study were funded by an Australian
      Research Council Linkage Grant from the Australian government with financial
      contributions from Animal Ethics Australia and Bayer Animal Health Australia.
      However, this study did not receive funding from either of these companies, nor
      did they have a role in study design, data collection and analysis, decision to
      publish, or preparation of the manuscript.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:53
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/29 05:53 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.2147/VMRR.S273788 [doi]
AID - 273788 [pii]
PST - epublish
SO  - Vet Med (Auckl). 2020 Oct 8;11:99-107. doi: 10.2147/VMRR.S273788. eCollection
      2020.


PMID- 33117633
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2210-9099 (Print)
IS  - 2210-9099 (Linking)
VI  - 11
IP  - 5
DP  - 2020 Oct
TI  - Primary Healthcare Under Transformation in 3 Eastern European Countries: Quality 
      Satisfaction as Rated by Students.
PG  - 286-295
LID - 10.24171/j.phrp.2020.11.5.04 [doi]
AB  - OBJECTIVES: This study aimed to determine the reasons for student dissatisfaction
      with the quality of primary healthcare (PHC) in countries under healthcare system
      transformation (Belarus, Poland, and Ukraine) to identify reserves and make
      improvements. METHODS: A comparative multipopulation survey was translated,
      verified, and completed during face-to-face interviews during March 2019 to May
      2019. There were 700 Humanities students included in this study to determine
      satisfaction with the quality of PHC provided by the family doctor. Satisfaction 
      was assessed according to the availability of the doctor, the level of
      organization of the institution, the service process, the quality of the
      interaction with the doctor, adherence to the rights of patients, and any
      additional financial expense incurred by the patient. RESULTS: Politeness and
      attentiveness of doctors were rated highly. Dissatisfaction was associated with
      the negative attitude of medical personnel towards the patient. One in 10
      respondents replied that medical confidentiality was not observed. More than 65% 
      of students had paid for diagnostic tests/or treatments, and some respondents
      from Poland and Ukraine were asked by the doctor to pay for services without a
      receipt. CONCLUSION: Dissatisfaction with the quality of PHC in countries under
      transformation of the health system was largely due to ethical aspects of the
      doctor-patient relationship. Therefore, ethical standards need to be upheld and
      patients need to be aware of these standards using medical education materials
      covering the moral aspects of the relationship between medical personnel and
      patient.
CI  - Copyright (c)2020, Korea Centers for Disease Control and Prevention.
FAU - Ahiyevets, Sviatlana
AU  - Ahiyevets S
AUID- ORCID: https://orcid.org/0000-0002-5944-1340
AD  - Institute of Legal Research, National Centre of Legislation and Legal Research of
      the Republic of Belarus, Minsk, Belarus.
FAU - Shpakou, Andrei
AU  - Shpakou A
AUID- ORCID: https://orcid.org/0000-0003-4340-5211
AD  - Yanka Kupala State University of Grodno, Grodno, Belarus.
FAU - Baj-Korpak, Joanna
AU  - Baj-Korpak J
AUID- ORCID: https://orcid.org/0000-0002-6379-2485
AD  - Pope John Paul II State School of Higher Education Department of Physiotherapy,
      Biala Podlaska, Poland.
FAU - Kleszczewska, Ewa
AU  - Kleszczewska E
AUID- ORCID: https://orcid.org/0000-0001-8163-1477
AD  - Edward F. Szczepanik State School of Higher Professional Education in Suwalki,
      Suwalki, Poland.
FAU - Rzatkiewicz, Katarzyna
AU  - Rzatkiewicz K
AUID- ORCID: https://orcid.org/0000-0003-2134-9116
AD  - Edward F. Szczepanik State School of Higher Professional Education in Suwalki,
      Suwalki, Poland.
FAU - Mancewicz, Krzysztof
AU  - Mancewicz K
AUID- ORCID: https://orcid.org/0000-0002-0997-451X
AD  - University of Medical Science in Bialystok, Bialystok, Poland.
FAU - Stetsenko, Valentina
AU  - Stetsenko V
AUID- ORCID: https://orcid.org/0000-0003-3650-4975
AD  - National Pedagogical Drahomanov University, capital KA, Cyrilliciev, Ukraine.
FAU - Stetsenko, Semen
AU  - Stetsenko S
AUID- ORCID: https://orcid.org/0000-0002-4350-2321
AD  - Supreme Court, Kiev, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Osong Public Health Res Perspect
JT  - Osong public health and research perspectives
JID - 101563309
PMC - PMC7577384
OTO - NOTNLM
OT  - primary healthcare
OT  - satisfaction
OT  - students
COIS- Conflicts of Interest The authors have no conflicts of interest to declare.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:53
PHST- 2020/10/29 05:53 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.24171/j.phrp.2020.11.5.04 [doi]
AID - ophrp-11-286 [pii]
PST - ppublish
SO  - Osong Public Health Res Perspect. 2020 Oct;11(5):286-295. doi:
      10.24171/j.phrp.2020.11.5.04.


PMID- 33117502
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Ebola, quarantine, and the need for a new ethical framework.
PG  - 9
LID - 10.18502/jmehm.v13i9.4078 [doi]
AB  - Quarantine is a broad public health strategy used to control infectious diseases 
      outbreaks. An arguably most aggressive public health intervention, quarantine
      limits the asymptomatic individuals' liberty and can result in significant harm. 
      Quarantine was used in an attempt to control several Ebola outbreaks during the
      Ebola epidemic in West Africa in 2014. The most concerning quarantine
      intervention occurred at West Point, a slum of 75,000 people in the capital
      Liberian capital, Monrovia. This work critically reviews present ethical
      frameworks in public health for the examination of outbreaks in West Africa. This
      work utilizes the nine public health ethical principles described by Kerridge,
      Lowe and Stewart to argue that the quarantine at West Point was not ethically
      justified; and, it concludes that a new ethical framework for quarantine is
      required to address future outbreaks in the West African context.
CI  - (c) 2020 Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences. All rights reserved.
FAU - Moore, Corey Benjamin
AU  - Moore CB
AD  - School of Public Health and Community Medicine, University of New South Wales,
      Sydney, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7575914
OTO - NOTNLM
OT  - Ebola virus.
OT  - Ethics
OT  - Quarantine
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:52
PHST- 2019/05/18 00:00 [received]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/10/29 05:52 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.18502/jmehm.v13i9.4078 [doi]
AID - JMEHM-13-9 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Aug 26;13:9. doi: 10.18502/jmehm.v13i9.4078.
      eCollection 2020.


PMID- 33117501
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Policy considerations to achieve practical ethics: closing the gap between
      ethical theory and practic.
PG  - 8
LID - 10.18502/jmehm.v13i8.4075 [doi]
AB  - Social and professional behaviors are driven by extrinsic as well as intrinsic
      factors including executive rules and regulations enacted by extrinsic agents
      through coercion, police force and penalties. Despite their effectiveness, these 
      mechanisms undermine the fact that ethics is an intrinsic human quality. The
      present study seeks strategies to apply extrinsic coercion as an incentive to
      direct ethics as an intrinsic value. Ethical behaviors driven by intrinsic
      motivations are more permanent and less costly. Legal force can either strengthen
      or weaken intrinsic requirements. Extrinsic conditions such as considering the
      interests, attitudes and preferences of others, involving people in the
      regulation and execution of law, justification of law, avoiding excessive
      punishment or rewards, and indirect support of ethics by establishing the
      appropriate social context can help boost intrinsic requirements in individuals. 
      Ethics will not be practically established unless we harness individuals'
      'willingness to act' as an essential determinant for ethical behavior. This
      requires adoption of a more psychological approach to ethics. If this aspect of
      ethical behavior is considered in regulations and executive processes, extrinsic 
      forces can strengthen intrinsic requirements and spread ethics.
CI  - (c) 2020 Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences. All rights reserved.
FAU - Madani, Mansure
AU  - Madani M
AD  - PhD Candidate in Medical Ethics, Medical Ethics and History of Medicine Research 
      Center, Tehran University of Medical Sciences, Tehran, Iran; PhD Candidate in
      Medical Ethics, Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences, Tehran, Iran; Department of Medical Ethics,
      School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Ghasemzadeh, Nazafarin
AU  - Ghasemzadeh N
AD  - Researcher, Department of Medical Ethics, Faculty of Medicine, Urmia University
      of Medical Sciences, Urmia, Iran.
FAU - Dizani, Ali
AU  - Dizani A
AD  - Researcher, Qom Seminary and Department of Islamic Knowledge and Humanities,
      Amirkabir University of Technology, Tehran, Iran.
FAU - Gharamaleki, Ahad Faramarz
AU  - Gharamaleki AF
AD  - Professor, Department of Islamic Theology and Philosophy, University of Tehran,
      Tehran, Iran.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Professor, Endocrinology and Metabolism Research Center, Endocrinology and
      Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences,
      Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7575913
OTO - NOTNLM
OT  - Ethics and law interaction
OT  - Intrinsic and extrinsic coercion
OT  - Policies and intrinsic motivation
OT  - Social ethics.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:52
PHST- 2019/11/11 00:00 [received]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/10/29 05:52 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.18502/jmehm.v13i8.4075 [doi]
AID - JMEHM-13-8 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Aug 25;13:8. doi: 10.18502/jmehm.v13i8.4075.
      eCollection 2020.


PMID- 33117498
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Comparison of the importance and observance of the patient's bill of rights from 
      the perspectives of patients and personnel of hospitals in Kerman.
PG  - 5
LID - 10.18502/jmehm.v13i5.4070 [doi]
AB  - Patients' rights are among the most important criteria for evaluating the quality
      of health services. The current study aimed to determine the importance and
      observance of the patient's bill of rights. This cross-sectional study was done
      in Kerman, Iran. The research samples were 217 patients and 204 personnel. The
      data collection tool was a researcher-made questionnaire in the scope of the
      patient's bill of rights, and data were analyzed by SPSS 15. The results showed a
      significant difference between patients and the personnel on the subject of the
      patient's bill of rights and most of its dimensions (P < 0.01). However, no
      significant difference was found between their views on the observance of the
      patient's bill of rights and its dimensions. Also, 35.9% of patients as well as
      25% of personnel considered the observance of patients' rights unfavorable. The
      participants were aware of the importance of the patient's bill of rights. It is 
      necessary, however, to codify and approve the laws related to the rights of
      patients.
CI  - (c) 2020 Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences. All rights reserved.
FAU - Dehghan, Mahlagha
AU  - Dehghan M
AD  - Assistant Professor, Nursing Research Center, Kerman University of Medical
      Sciences, Kerman, Iran.
FAU - Mehdipour-Rabori, Roghayeh
AU  - Mehdipour-Rabori R
AD  - Assistant Professor, Nursing Research Center, Kerman University of Medical
      Sciences, Kerman, Iran.
FAU - Rayani, Masoud
AU  - Rayani M
AD  - Assistant Professor, Nursing Research Center, Kerman University of Medical
      Sciences, Kerman, Iran.
FAU - Zakeri, Mohammad Ali
AU  - Zakeri MA
AD  - Researcher, Non-Communicable Diseases Research Center, Rafsanjan University of
      Medical Sciences, Rafsanjan, Iran.
FAU - Mobasher, Mina
AU  - Mobasher M
AD  - Assistant Professor of Medical Ethics, Faculty of Iranian Traditional Medicine,
      Kerman University of Medical Sciences, Kerman, Iran.
FAU - Iranmanesh, Maryam
AU  - Iranmanesh M
AD  - Researcher, Nursing Research Center, Kerman University of Medical Sciences,
      Kerman, Iran.
FAU - Rezai, Narges
AU  - Rezai N
AD  - Researcher, Nursing Research Center, Kerman University of Medical Sciences,
      Kerman, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7575912
OTO - NOTNLM
OT  - Clinical ethics
OT  - Patients' bill of rights.
OT  - Patients' rights
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:52
PHST- 2019/05/18 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/10/29 05:52 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.18502/jmehm.v13i5.4070 [doi]
AID - JMEHM-13-5 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Jun 2;13:5. doi: 10.18502/jmehm.v13i5.4070.
      eCollection 2020.


PMID- 33117041
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-7258 (Print)
IS  - 1179-7258 (Linking)
VI  - 11
DP  - 2020
TI  - "A Taste of Real Medicine": Third Year Medical Students' Report Experiences of
      Early Workplace Encounters.
PG  - 717-725
LID - 10.2147/AMEP.S230946 [doi]
AB  - INTRODUCTION: Medical students extend their preparatory learning on entering the 
      clinical work environment, by joining their clinical team as peripheral
      participants and start to care for "real" patients. This learning is situated,
      experiential, varied, mainly unstructured, highly dependent on clinical
      opportunities (affordances), and students' motivation to learn (learner agency). 
      Students ideally contribute to workplace activities, which allow their practical 
      skills, confidence and professional identity to evolve. This study sought to
      investigate senior students' perspectives in their early stages of workplace
      learning, by using social learning theory as a framework. The focus is on team
      integration, practical skills performance, professional development and their
      evolving professional identity. METHODS: Between 2015 and 2018, we conducted five
      focus groups, with a total of 36 volunteers, out of a possible 200 (18% Stage 3
      (Year 3)) medical students. Each focus group session was audio recorded and
      transcribed verbatim. Participants were de-identified, and framework analysis
      used the theoretical frameworks of communities of practice, and workplace
      affordances to gain insight into their work-place learning experience during the 
      first two months of their clinical rotation. RESULTS: Thirty-six students out of 
      200 (18%) attended focus groups over a four-year period. The results are
      presented using the theoretical frameworks of community of practice and workplace
      affordances and presented as themes of: meaning, "learning as experience",
      practice, "learning as doing" community, "learning as belonging", and identity,
      "learning as becoming". DISCUSSION: Participants reported many positive examples 
      of workplace learning while dealing directly with patients. Students were also
      exposed to ethical dilemmas and unexpected risks in the workplace. These included
      lack of site orientation, unsupportive teams, lack of supervision, and students' 
      inability to initiate agency, all of which contributed to their workplace
      uncertainty. Performing manageable tasks for their team provided a role in their 
      community of practice, strengthening their identity as evolving doctors. Exposure
      to both positive and negative role models allowed students to reflect on ethical 
      issues, further extending their own professional identities. SUMMARY:
      Participants were quick to observe and report workplace dynamics as they were
      exposed to the positive and negative aspects of the hidden curriculum. This
      allowed them to reflect on patient safety, and ethical concerns promoting the
      development of their professional identity.
CI  - (c) 2020 McKenzie et al.
FAU - McKenzie, Susan
AU  - McKenzie S
AD  - Central Clinical School, Sydney Medical School, The University of Sydney, Sydney,
      NSW, Australia.
FAU - Burgess, Annette
AU  - Burgess A
AUID- ORCID: 0000-0001-9617-3819
AD  - Education Office, Sydney Medical School, The University of Sydney, Sydney, NSW,
      Australia.
FAU - Mellis, Craig
AU  - Mellis C
AD  - Central Clinical School, Sydney Medical School, The University of Sydney, Sydney,
      NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - New Zealand
TA  - Adv Med Educ Pract
JT  - Advances in medical education and practice
JID - 101562700
PMC - PMC7547787
OTO - NOTNLM
OT  - communities of practice
OT  - professional identity
OT  - role modelling
OT  - third-year medicine
OT  - workplace learning
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:50
PHST- 2019/09/13 00:00 [received]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/10/29 05:50 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.2147/AMEP.S230946 [doi]
AID - 230946 [pii]
PST - epublish
SO  - Adv Med Educ Pract. 2020 Oct 6;11:717-725. doi: 10.2147/AMEP.S230946. eCollection
      2020.


PMID- 33116992
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-1594 (Print)
IS  - 1179-1594 (Linking)
VI  - 13
DP  - 2020
TI  - Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review.
PG  - 2125-2148
LID - 10.2147/RMHP.S260641 [doi]
AB  - BACKGROUND: Rare or orphan diseases have become an important target of healthcare
      activities all over the world. The study aims to identify ethical questions
      linked to rare diseases and orphan drugs and ethical principles or approaches
      applied to solve them. METHODS: Relevant peer-reviewed articles were identified
      by means of a systematic review. The literature was searched from 20 May 2020 to 
      20 June 2020. The search included the databases PubMed, Scopus and Web of Science
      (2010 - April 2020). A total of 4,139 papers related to rare diseases were
      identified; with 1,205 papers obtained from Scopus; 2,476 papers from PubMed; and
      458 from Web of Science with keyword search "ethics" AND "rare" AND "disease",
      "ethical" AND "orphan", "ethical" AND "orphan" AND "drug", and "ethical" AND
      "rare" AND "disease". Finally, XX studies were chosen for further analysis.
      RESULTS: The main findings reveal five main ethical issues. The most essential
      one shows that funding research and development in the field of orphan drugs
      poses an almost impossible dilemma. Other issues include the significance of
      non-economic values like compassion and beneficence in decision-making related to
      orphan drugs and rare diseases; the identification of limits to labelling
      diseases as rare; barriers to global, supranational and international
      cooperation; and last but not least, determining and establishing panels of
      decision-makers. CONCLUSIONS: A strictly global approach would be the most
      appropriate way to deal with rare diseases. Nonetheless, international, let alone
      global, cooperation seems to be completely beyond the reach of the current
      international community, although the EU, for instance, has a centralized
      procedure for labelling orphan drugs. This deficit in international cooperation
      can be partly explained by the fact that the current technologically globalized
      world still lacks globally accepted ethical values and rules. This is further
      aggravated by unresolved international and intercultural conflicts. In addition, 
      the sub-interests of various parties as well as the lack of desire to deal with
      other people's problems need to be taken into account. The aforementioned
      problems are difficult to avoid. Nevertheless, let us be cautiously optimistic.
      At least, there are people who raise ethical questions about rare diseases and
      orphan drugs.
CI  - (c) 2020 Kacetl et al.
FAU - Kacetl, Jaroslav
AU  - Kacetl J
AUID- ORCID: 0000-0002-9327-8268
AD  - Department of Linguistics, Faculty of Informatics and Management, University of
      Hradec Kralove, Hradec Kralove, Czech Republic.
FAU - Maresova, Petra
AU  - Maresova P
AUID- ORCID: 0000-0002-1218-501X
AD  - Department of Economics, Faculty of Informatics and Management, University of
      Hradec Kralove, Hradec Kralove, Czech Republic.
FAU - Maskuriy, Raihan
AU  - Maskuriy R
AD  - Malaysia Japan International Institute of Technology (MJIIT), Universiti
      Teknologi Malaysia Kuala Lumpur, Kuala Lumpur, Malaysia.
AD  - Department of Architecture, Faculty of Design and Architecture, Universiti Putra 
      Malaysia (UPM), Serdang, Malaysia.
FAU - Selamat, Ali
AU  - Selamat A
AUID- ORCID: 0000-0001-9746-8459
AD  - Media and Games Center of Excellence (MagicX), Universiti Teknologi Malaysia,
      Skudai, Malaysia.
AD  - School of Computing, Faculty of Engineering, Universiti Teknologi Malaysia (UTM),
      Skudai, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - England
TA  - Risk Manag Healthc Policy
JT  - Risk management and healthcare policy
JID - 101566264
PMC - PMC7568613
OTO - NOTNLM
OT  - ethical aspects
OT  - ethical principles
OT  - orphan drugs
OT  - rare disease
COIS- The authors report no conflicts of interest for this work.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:50
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/10/29 05:50 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.2147/RMHP.S260641 [doi]
AID - 260641 [pii]
PST - epublish
SO  - Risk Manag Healthc Policy. 2020 Oct 13;13:2125-2148. doi: 10.2147/RMHP.S260641.
      eCollection 2020.


PMID- 33116941
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-142X (Print)
IS  - 1179-142X (Linking)
VI  - 13
DP  - 2020
TI  - Long Term Follow-Up of Prototheca keratitis: A Case Report.
PG  - 503-506
LID - 10.2147/IMCRJ.S268696 [doi]
AB  - BACKGROUND: Prototheca spp. are rare human pathogens, and only three cases of
      Prototheca keratitis have been reported. They were treated with anti-fungal drugs
      and surgical excision. Two of the three cases were successful, and the case of an
      immunocompromised patient was not successful. Thus, the best treatment of
      Prototheca keratitis is still undetermined, and further investigations are
      needed. The purpose of this report is to present our findings in a case of
      Prototheca keratitis that was successfully treated with topical medications
      without surgical excision. METHODS: This study was performed in accordance with
      the Declaration of Helsinki and was approved by the Ethics Committee of Hidaka
      Medical Center, Toyooka Hospital. A written informed consent was obtained from
      the patient before beginning the medical treatments. CASE REPORT: A 75-year-old
      man with a history of stage 4 prostate carcinoma and bilateral limbal stem cell
      deficiency had undergone keratoepithelioplasty on his left eye for the
      deficiency. Postoperatively, a greyish-white epithelial opacity was noted on the 
      central cornea of his left eye, and he had been treated with topical
      fluorometholone and oral dexamethasone together with a therapeutic contact lens. 
      Corneal smears and contact lens swabs were positive for Prototheca spp. He
      required a continuous treatment with amphotericin B (AMPH-B) ointment, topical
      fluconazole (FLCZ), and voriconazole (VRCZ). This treatment protocol was
      effective, but recurrences developed when his general condition worsened.
      CONCLUSION: Our findings indicate that Prototheca keratitis can be successfully
      treated but not cured with topical AMPH-B, FLCZ, and VRCZ without surgical
      treatment. However, recurrences can develop when the general condition of the
      patient worsens. Thus, continuous monitoring and treatment are necessary in cases
      of Prototheca keratitis.
CI  - (c) 2020 Minato et al.
FAU - Minato, Kazumi
AU  - Minato K
AUID- ORCID: 0000-0001-9957-3236
AD  - Department of Ophthalmology, Eye Center, Hidaka Medical Center, Toyooka Hospital,
      Toyooka City, Hyogo 669-5392, Japan.
FAU - Yoshikawa, Munemitsu
AU  - Yoshikawa M
AUID- ORCID: 0000-0003-0919-1387
AD  - Department of Ophthalmology, Eye Center, Hidaka Medical Center, Toyooka Hospital,
      Toyooka City, Hyogo 669-5392, Japan.
FAU - Nakanishi, Hideo
AU  - Nakanishi H
AUID- ORCID: 0000-0002-0158-8278
AD  - Department of Ophthalmology, Eye Center, Hidaka Medical Center, Toyooka Hospital,
      Toyooka City, Hyogo 669-5392, Japan.
FAU - Hasegawa, Kaori
AU  - Hasegawa K
AD  - Department of Microbiology, Toyooka Hospital, Toyooka City, Hyogo 668-0065,
      Japan.
LA  - eng
PT  - Case Reports
DEP - 20201009
PL  - New Zealand
TA  - Int Med Case Rep J
JT  - International medical case reports journal
JID - 101566269
PMC - PMC7555245
OTO - NOTNLM
OT  - Prototheca spp.
OT  - cornea
OT  - infection
OT  - treatment
COIS- The authors report no conflicts of interest for this work.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:50
PHST- 2020/06/29 00:00 [received]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/10/29 05:50 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.2147/IMCRJ.S268696 [doi]
AID - 268696 [pii]
PST - epublish
SO  - Int Med Case Rep J. 2020 Oct 9;13:503-506. doi: 10.2147/IMCRJ.S268696.
      eCollection 2020.


PMID- 33116781
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Linking)
VI  - 13
DP  - 2020
TI  - The Increasing Role of Artificial Intelligence in Health Care: Will Robots
      Replace Doctors in the Future?
PG  - 891-896
LID - 10.2147/IJGM.S268093 [doi]
AB  - Artificial intelligence (AI) pertains to the ability of computers or
      computer-controlled machines to perform activities that demand the cognitive
      function and performance level of the human brain. The use of AI in medicine and 
      health care is growing rapidly, significantly impacting areas such as medical
      diagnostics, drug development, treatment personalization, supportive health
      services, genomics, and public health management. AI offers several advantages;
      however, its rampant rise in health care also raises concerns regarding legal
      liability, ethics, and data privacy. Technological singularity (TS) is a
      hypothetical future point in time when AI will surpass human intelligence. If it 
      occurs, TS in health care would imply the replacement of human medical
      practitioners with AI-guided robots and peripheral systems. Considering the pace 
      at which technological advances are taking place in the arena of AI, and the pace
      at which AI is being integrated with health care systems, it is not be
      unreasonable to believe that TS in health care might occur in the near future and
      that AI-enabled services will profoundly augment the capabilities of doctors, if 
      not completely replace them. There is a need to understand the associated
      challenges so that we may better prepare the health care system and society to
      embrace such a change - if it happens.
CI  - (c) 2020 Shuaib et al.
FAU - Shuaib, Abdullah
AU  - Shuaib A
AUID- ORCID: 0000-0003-2072-5634
AD  - Department of General Surgery, Jahra Hospital, Jahra, Kuwait.
FAU - Arian, Husain
AU  - Arian H
AD  - Department of General Surgery, Jahra Hospital, Jahra, Kuwait.
FAU - Shuaib, Ali
AU  - Shuaib A
AUID- ORCID: 0000-0002-6145-8440
AD  - Biomedical Engineering Unit, Department of Physiology, Faculty of Medicine,
      Kuwait University, Kuwait City, Kuwait.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC7585503
OTO - NOTNLM
OT  - artificial intelligence
OT  - health care system
OT  - technological singularity
COIS- The authors declare there are no conflicts of interest.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:49
PHST- 2020/06/17 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/29 05:49 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.2147/IJGM.S268093 [doi]
AID - 268093 [pii]
PST - epublish
SO  - Int J Gen Med. 2020 Oct 19;13:891-896. doi: 10.2147/IJGM.S268093. eCollection
      2020.


PMID- 33116756
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1178-7058 (Print)
IS  - 1178-7058 (Linking)
VI  - 13
DP  - 2020
TI  - Inpatient Dialysis Planning During the COVID-19 Pandemic: A Single-Center
      Experience and Review of the Literature.
PG  - 253-259
LID - 10.2147/IJNRD.S275075 [doi]
AB  - BACKGROUND: COVID-19 has created havoc in healthcare systems worldwide, including
      shortages in equipment and supplies for dialysis in the acute setting. METHODS:
      We compared our planning and experience at a tertiary care academic medical
      center to recommendations in the literature. RESULTS: Published literature and
      our experience underscored the need to plan for adequate dialysis equipment,
      particularly for continuous renal replacement therapy in the ICU setting,
      adequate nursing, and flexible scheduling of chronic patients to accommodate the 
      surge in acute patients. We discovered other "shortages" not mentioned in the
      literature: shortages in the number of portable reverse osmosis (RO) machines
      needed to prepare dialysis water, inadequate number of rooms in units designated 
      for COVID-19 patients with plumbing for dialysis, and lack of temperature
      blending valves on sinks that necessitated using cold water only, and damaging
      the RO membranes. We identified the need for cooperation between nephrology and
      critical care medicine, hospital-based and community nephrologists and community 
      dialysis units as well as nephrologists at other hospitals in the region. We
      turned to guidance from the hospital ethics committee. CONCLUSION: Planning for
      an expected surge in hospitalized patients requiring RRT demands coordination
      between critical care, dialysis and nursing services as well as community and
      hospital providers to make certain there are adequate dialysis resources. Our
      experience suggests that continuous dialysis is in greatest demand early in the
      illness, and that plans to increase supplies should be put in place. But,
      planning should also focus on unforeseen hospital-specific infrastructure
      shortages that can develop over time and hamper intermittent dialysis delivery to
      all patients who require treatment.
CI  - (c) 2020 Mitchell et al.
FAU - Mitchell, Kevin R
AU  - Mitchell KR
AD  - Division of Kidney Diseases and Hypertension, Brown Medicine, Providence, RI,
      USA.
AD  - Alpert Medical School, Brown University, Providence, RI, USA.
AD  - Department of Medicine, Rhode Island Hospital, Providence, RI, USA.
FAU - Bomm, Alison
AU  - Bomm A
AUID- ORCID: 0000-0001-8274-9135
AD  - Department of Medicine, Rhode Island Hospital, Providence, RI, USA.
AD  - Department of Nursing, Rhode Island Hospital, Providence, RI, USA.
FAU - Shea, Barry S
AU  - Shea BS
AUID- ORCID: 0000-0002-3205-026X
AD  - Alpert Medical School, Brown University, Providence, RI, USA.
AD  - Department of Medicine, Rhode Island Hospital, Providence, RI, USA.
AD  - Division of Pulmonary and Critical Care Medicine, Brown Medicine, Providence, RI,
      USA.
FAU - Shemin, Douglas
AU  - Shemin D
AD  - Division of Kidney Diseases and Hypertension, Brown Medicine, Providence, RI,
      USA.
AD  - Alpert Medical School, Brown University, Providence, RI, USA.
AD  - Department of Medicine, Rhode Island Hospital, Providence, RI, USA.
FAU - Bayliss, George
AU  - Bayliss G
AUID- ORCID: 0000-0002-7508-9762
AD  - Division of Kidney Diseases and Hypertension, Brown Medicine, Providence, RI,
      USA.
AD  - Alpert Medical School, Brown University, Providence, RI, USA.
AD  - Department of Medicine, Rhode Island Hospital, Providence, RI, USA.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - New Zealand
TA  - Int J Nephrol Renovasc Dis
JT  - International journal of nephrology and renovascular disease
JID - 101550217
PMC - PMC7585817
OTO - NOTNLM
OT  - coordination
OT  - dialysis
OT  - disaster
OT  - planning
COIS- The authors confirm that they have no conflicts of interest and that the contents
      of this paper have not been published elsewhere in full or in abstract form.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 05:49
PHST- 2020/08/01 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/10/29 05:49 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - 10.2147/IJNRD.S275075 [doi]
AID - 275075 [pii]
PST - epublish
SO  - Int J Nephrol Renovasc Dis. 2020 Oct 21;13:253-259. doi: 10.2147/IJNRD.S275075.
      eCollection 2020.


PMID- 33116292
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201222
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 586
IP  - 7831
DP  - 2020 Oct
TI  - Africa's people must be able to write their own genomics agenda.
PG  - 644
LID - 10.1038/d41586-020-03028-3 [doi]
LA  - eng
PT  - Editorial
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Nature. 2020 Oct;586(7831):741-748. PMID: 33116287
MH  - Africa
MH  - *Genomics
MH  - *Human Migration
MH  - Humans
MH  - Writing
OTO - NOTNLM
OT  - *Ethics
OT  - *Genetics
OT  - *Genomics
OT  - *Society
EDAT- 2020/10/30 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/29 05:46
PHST- 2020/10/29 05:46 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1038/d41586-020-03028-3 [doi]
AID - 10.1038/d41586-020-03028-3 [pii]
PST - ppublish
SO  - Nature. 2020 Oct;586(7831):644. doi: 10.1038/d41586-020-03028-3.


PMID- 33115905
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 28
TI  - Predicting pain recovery in patients with acute low back pain: a study protocol
      for a broad validation of a prognosis prediction model.
PG  - e040785
LID - 10.1136/bmjopen-2020-040785 [doi]
AB  - BACKGROUND: The clinical course of acute low back pain (LBP) is generally
      favourable; however, there is significant variability in the prognosis of these
      patients. A clinical prediction model to predict the likelihood of pain recovery 
      at three time points for patients with acute LBP has recently been developed. The
      aim of this study is to conduct a broad validation test of this clinical
      prediction model, by testing its performance in a new sample of patients and a
      different setting. METHODS: The validation study with a prospective cohort design
      will recruit 420 patients with recent onset non-specific acute LBP, with moderate
      pain intensity, seeking care in the emergency departments of hospitals in Sao
      Paulo, Brazil. The primary outcome measure will be days to recovery from pain.
      The predicted probability of pain recovery for each individual will be computed
      based on predictions of the development model and this will be used to test the
      performance (calibration and discrimination) in the validation dataset.
      DISCUSSION: The findings of this study will better inform about the performance
      of the clinical prediction model, helping both clinicians and patients. If the
      model's performance is acceptable, then future research should evaluate the
      impact of the prediction model, assessing whether it produces a change in
      clinicians' behaviour and/or an improvement in patient outcomes. ETHICS AND
      DISSEMINATION: Ethics were granted by the Research Ethics Committee of the
      Universidade Cidade de Sao Paulo, #20310419.4.0000.0064. Study findings will be
      disseminated widely through peer-reviewed publications and conference
      presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Silva, Fernanda Goncalves
AU  - Silva FG
AUID- ORCID: 0000-0002-5116-6751
AD  - Physiotherapy, UNICID, Sao Paulo, Brazil nanda_fgs94@hotmail.com.
FAU - Mota da Silva, Tatiane
AU  - Mota da Silva T
AD  - Physiotherapy, UNICID, Sao Paulo, Brazil.
FAU - Palomo, Gabriele Alves
AU  - Palomo GA
AD  - Physiotherapy, UNICID, Sao Paulo, Brazil.
FAU - Hancock, Mark Jonathan
AU  - Hancock MJ
AD  - Health Professions Department, Macquarie University, Sydney, New South Wales,
      Australia.
FAU - Costa, Luciola da Cunha Menezes
AU  - Costa LDCM
AD  - Masters and Doctoral Programs in Physical Therapy, Universidade Cidade de Sao
      Paulo, Sao Paulo, Brazil.
FAU - Costa, Leonardo Oliveira Pena
AU  - Costa LOP
AD  - Masters and Doctoral Programs in Physical Therapy, Universidade Cidade de Sao
      Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201028
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brazil
MH  - Humans
MH  - *Low Back Pain/diagnosis/therapy
MH  - *Models, Statistical
MH  - Pain Measurement
MH  - Prognosis
MH  - Prospective Studies
PMC - PMC7594364
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *back pain
OT  - *epidemiology
OT  - *musculoskeletal disorders
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/10/29 05:41
PHST- 2020/10/29 05:41 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - bmjopen-2020-040785 [pii]
AID - 10.1136/bmjopen-2020-040785 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 28;10(10):e040785. doi: 10.1136/bmjopen-2020-040785.


PMID- 33115902
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 28
TI  - NutriQuebec: a unique web-based prospective cohort study to monitor the
      population's eating and other lifestyle behaviours in the province of Quebec.
PG  - e039889
LID - 10.1136/bmjopen-2020-039889 [doi]
AB  - INTRODUCTION: The epidemic of non-communicable diseases including cardiovascular 
      diseases and type 2 diabetes is attributable in large part to unhealthy eating
      and physical inactivity. In the fall of 2016, the Quebec government launched its 
      first-ever Government Health Prevention Policy (Politique gouvernementale de
      prevention en sante (PGPS)) to influence factors that lead to improved health
      status and quality of life as well as reduced social inequalities in health in
      the population of Quebec. NutriQuebec is a web-based prospective open cohort
      study whose primary aim is to provide essential data for the evaluation of the
      PGPS on the Quebec population's eating and other lifestyle behaviours over time. 
      METHODS AND ANALYSIS: Over a first phase of 3 years, NutriQuebec will enrol 20
      000 adults living in the province of Quebec in Canada through a multimedia
      campaign designed to reach different segments of the population, including
      subgroups with lower socioeconomic status. Participants will be invited to
      complete on a web platform nine core questionnaires on a yearly basis.
      Questionnaires will assess several dimensions related to lifestyle, including
      eating and physical activity behaviours, as well as a large number of personal
      characteristics and global health status. Temporal trends in eating and lifestyle
      behaviours will be analysed in relation to the implementation of the PGPS to
      provide essential data for its evaluation at a population level. Data analyses
      will use sociodemographic weights to adjust responses of participants to achieve,
      so far as is possible, representativeness of the adult Quebec population. ETHICS 
      AND DISSEMINATION: Universite Laval Research Ethics Board approved the
      NutriQuebec project. Data analysis, presentations in conferences and publication 
      of manuscripts are scheduled to start in 2020. TRIAL REGISTRATION NUMBER:
      NCT04140071.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lapointe, Annie
AU  - Lapointe A
AUID- ORCID: 0000-0001-7081-4809
AD  - Centre NUTRISS, INAF, Universite Laval, Quebec City, Quebec, Canada.
FAU - Laramee, Catherine
AU  - Laramee C
AD  - Centre NUTRISS, INAF, Universite Laval, Quebec City, Quebec, Canada.
FAU - Belanger-Gravel, Ariane
AU  - Belanger-Gravel A
AD  - Centre NUTRISS, INAF, Universite Laval, Quebec City, Quebec, Canada.
AD  - Department of Information and Communication, Universite Laval, Quebec city,
      Quebec, Canada.
AD  - Quebec Heart and Lung Institute, Quebec city, Quebec, Canada.
FAU - Buckeridge, David L
AU  - Buckeridge DL
AD  - School of Population and Global Health, McGill University, Montreal, Quebec,
      Canada.
FAU - Desroches, Sophie
AU  - Desroches S
AD  - Centre NUTRISS, INAF, Universite Laval, Quebec City, Quebec, Canada.
AD  - School of Nutrition, Universite Laval, Quebec City, Quebec, Canada.
FAU - Garriguet, Didier
AU  - Garriguet D
AD  - Health Analysis Division, Statistics Canada, Ottawa, Ontario, Canada.
FAU - Gauvin, Lise
AU  - Gauvin L
AD  - Centre de recherche du CHUM, Centre Hospitalier de l'Universite de Montreal,
      Montreal, Quebec, Canada.
AD  - Department of Social and Preventive Medicine, Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Lemieux, Simone
AU  - Lemieux S
AD  - Centre NUTRISS, INAF, Universite Laval, Quebec City, Quebec, Canada.
AD  - School of Nutrition, Universite Laval, Quebec City, Quebec, Canada.
FAU - Plante, Celine
AU  - Plante C
AD  - Institut national de sante publique du Quebec, Quebec City, Quebec, Canada.
FAU - Lamarche, Benoit
AU  - Lamarche B
AD  - Centre NUTRISS, INAF, Universite Laval, Quebec City, Quebec, Canada
      benoit.lamarche@fsaa.ulaval.ca.
AD  - School of Nutrition, Universite Laval, Quebec City, Quebec, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04140071
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201028
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - *Diet/statistics & numerical data
MH  - *Exercise
MH  - Female
MH  - *Health Behavior
MH  - *Health Status
MH  - Humans
MH  - *Internet
MH  - Life Style
MH  - Male
MH  - Prospective Studies
MH  - Quality of Life
MH  - Quebec/epidemiology
PMC - PMC7594370
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *public health
OT  - *world wide web technology
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/10/29 05:41
PHST- 2020/10/29 05:41 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - bmjopen-2020-039889 [pii]
AID - 10.1136/bmjopen-2020-039889 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 28;10(10):e039889. doi: 10.1136/bmjopen-2020-039889.


PMID- 33115901
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 28
TI  - Conditionally positive: a qualitative study of public perceptions about using
      health data for artificial intelligence research.
PG  - e039798
LID - 10.1136/bmjopen-2020-039798 [doi]
AB  - OBJECTIVES: Given widespread interest in applying artificial intelligence (AI) to
      health data to improve patient care and health system efficiency, there is a need
      to understand the perspectives of the general public regarding the use of health 
      data in AI research. DESIGN: A qualitative study involving six focus groups with 
      members of the public. Participants discussed their views about AI in general,
      then were asked to share their thoughts about three realistic health AI research 
      scenarios. Data were analysed using qualitative description thematic analysis.
      SETTINGS: Two cities in Ontario, Canada: Sudbury (400 km north of Toronto) and
      Mississauga (part of the Greater Toronto Area). PARTICIPANTS: Forty-one
      purposively sampled members of the public (21M:20F, 25-65 years, median age 40). 
      RESULTS: Participants had low levels of prior knowledge of AI and mixed, mostly
      negative, perceptions of AI in general. Most endorsed using data for health AI
      research when there is strong potential for public benefit, providing that
      concerns about privacy, commercial motives and other risks were addressed.
      Inductive thematic analysis identified AI-specific hopes (eg, potential for
      faster and more accurate analyses, ability to use more data), fears (eg, loss of 
      human touch, skill depreciation from over-reliance on machines) and conditions
      (eg, human verification of computer-aided decisions, transparency). There were
      mixed views about whether data subject consent is required for health AI
      research, with most participants wanting to know if, how and by whom their data
      were used. Though it was not an objective of the study, realistic health AI
      scenarios were found to have an educational effect. CONCLUSIONS: Notwithstanding 
      concerns and limited knowledge about AI in general, most members of the general
      public in six focus groups in Ontario, Canada perceived benefits from health AI
      and conditionally supported the use of health data for AI research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McCradden, Melissa D
AU  - McCradden MD
AD  - Department of Bioethics, Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Sarker, Tasmie
AU  - Sarker T
AD  - Health Team, Vector Institute, Toronto, Ontario, Canada.
FAU - Paprica, P Alison
AU  - Paprica PA
AUID- ORCID: 0000-0001-6362-7087
AD  - Health Team, Vector Institute, Toronto, Ontario, Canada
      alison.paprica@utoronto.ca.
AD  - Institute for Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201028
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Artificial Intelligence
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - *Medical Informatics
MH  - Middle Aged
MH  - Ontario
MH  - *Public Opinion
MH  - Qualitative Research
PMC - PMC7594363
OTO - NOTNLM
OT  - *ethics (see medical ethics)
OT  - *health informatics
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/10/29 05:41
PHST- 2020/10/29 05:41 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - bmjopen-2020-039798 [pii]
AID - 10.1136/bmjopen-2020-039798 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 28;10(10):e039798. doi: 10.1136/bmjopen-2020-039798.


PMID- 33115898
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 28
TI  - Tailored smartphone intervention to promote healthy eating among Brazilian
      adolescents: a randomised controlled trial protocol.
PG  - e038896
LID - 10.1136/bmjopen-2020-038896 [doi]
AB  - INTRODUCTION: Adolescent eating patterns are characterised by high consumption of
      unhealthy foods, which has resulted in an increasing prevalence of overweight and
      chronic diseases. It is crucial to promote healthy eating habits, and nutritional
      interventions based on the transtheoretical model have been found to be
      especially effective. Mobile health strategies also seem promising for
      adolescents. This study aims to outline a smartphone intervention via WhatsApp
      for adolescents to promote healthy eating consumption, better nutritional
      knowledge, self-efficacy in the adoption of healthy practices and progress
      through the stages of change. METHODS AND ANALYSIS: There will be three distinct 
      groups in this randomised study: a general intervention group (GG), in which the 
      participants will receive the same healthy eating messages, based on the
      Brazilian food guide; a tailored intervention group (TG), in which the
      participants will receive healthy eating messages based on their stage of change;
      and a control group (CG), in which participants will receive messages on a
      different theme. Possession of a smartphone, use of WhatsApp and being a senior
      student (16-19 years) from a public school of the Federal District of Brazil will
      be the study's inclusion criteria. Rural schools will be excluded. The sample
      size estimated is 390 individuals: 38 in the GG, 314 in the TG and 38 in the CG. 
      The intervention will last 6 weeks, with a daily message sent to the students. We
      will investigate nutritional knowledge, self-efficacy in the adoption of healthy 
      eating practices, food consumption and stages of change using preintervention and
      postintervention questionnaires. Memorisation of the messages will be also
      assessed. ETHICS AND DISSEMINATION: The study was approved by the University of
      Brasilia, School of Health Sciences and Research Ethics Committee. At the end of 
      the study, the participating schools will receive a printed report with the main 
      results of the intervention. TRIAL REGISTRATION NUMBER: RBR-5b9jk7.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Melo, Giselle Rhaisa
AU  - Melo GR
AUID- ORCID: 0000-0003-4918-8377
AD  - NESNUT- Department of Nutrition, University of Brasilia, Brasilia, Federal
      District, Brazil giselle-melo1502@hotmail.com.
FAU - Correa Lima, Stefany
AU  - Correa Lima S
AD  - NESNUT- Department of Nutrition, University of Brasilia, Brasilia, Federal
      District, Brazil.
FAU - M Dos Santos Chagas, Carolina
AU  - M Dos Santos Chagas C
AD  - NESNUT- Department of Nutrition, University of Brasilia, Brasilia, Federal
      District, Brazil.
AD  - Department of Nutrition, Federal University of Lavras, Lavras, Minas Gerais,
      Brazil.
FAU - Nakano, Eduardo Y
AU  - Nakano EY
AD  - Statistics Department, University of Brasilia, Brasilia, Federal District,
      Brazil.
FAU - Toral, Natacha
AU  - Toral N
AD  - NESNUT- Department of Nutrition, University of Brasilia, Brasilia, Federal
      District, Brazil.
LA  - eng
SI  - ReBec/RBR-5b9jk7
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201028
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Brazil
MH  - *Diet, Healthy
MH  - *Feeding Behavior/psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mobile Applications
MH  - Psychology, Adolescent
MH  - Randomized Controlled Trials as Topic
MH  - *School Health Services
MH  - Schools
MH  - *Smartphone
MH  - Young Adult
PMC - PMC7594362
OTO - NOTNLM
OT  - *adolescent
OT  - *food and nutrition education
OT  - *mobile health
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/10/29 05:41
PHST- 2020/10/29 05:41 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - bmjopen-2020-038896 [pii]
AID - 10.1136/bmjopen-2020-038896 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 28;10(10):e038896. doi: 10.1136/bmjopen-2020-038896.


PMID- 33115860
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 10
DP  - 2020 Oct
TI  - Bridging research integrity and global health epidemiology (BRIDGE) guidelines:
      explanation and elaboration.
LID - e003237 [pii]
LID - 10.1136/bmjgh-2020-003237 [doi]
AB  - Over the past decade, two movements have profoundly changed the environment in
      which global health epidemiologists work: research integrity and research
      fairness. Both ought to be equally nurtured by global health epidemiologists who 
      aim to produce high quality impactful research. Yet bridging between these two
      aspirations can lead to practical and ethical dilemmas. In the light of these
      reflections we have proposed the BRIDGE guidelines for the conduct of fair global
      health epidemiology, targeted at stakeholders involved in the commissioning,
      conduct, appraisal and publication of global health research. The guidelines
      follow the conduct of a study chronologically from the early stages of study
      preparation until the dissemination and communication of findings. They can be
      used as a checklist by research teams, funders and other stakeholders to ensure
      that a study is conducted in line with both research integrity and research
      fairness principles. In this paper we offer a detailed explanation for each item 
      of the BRIDGE guidelines. We have focused on practical implementation issues,
      making this document most of interest to those who are actually conducting the
      epidemiological work.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alba, Sandra
AU  - Alba S
AUID- ORCID: 0000-0003-2435-624X
AD  - Health, KIT Royal Tropical Insititute, Amsterdam, The Netherlands s.alba@kit.nl.
FAU - Lenglet, Annick
AU  - Lenglet A
AD  - Medecins Sans Frontieres, Amsterdam, North Holland, The Netherlands.
FAU - Verdonck, Kristien
AU  - Verdonck K
AD  - Tropical diseases, Institute of Tropical Medicine, Antwerp, Belgium.
FAU - Roth, Johanna
AU  - Roth J
AD  - European and Developing Countries Clinical Trials Partnership, The Hague, South
      Holland, The Netherlands.
FAU - Patil, Rutuja
AU  - Patil R
AUID- ORCID: 0000-0001-6390-4363
AD  - Vadu Rural Health Program, KEM Hospital Research Centre, Pune, Maharashtra,
      India.
FAU - Mendoza, Walter
AU  - Mendoza W
AD  - United Nations Population Fund, Lima, Peru.
FAU - Juvekar, Sanjay
AU  - Juvekar S
AD  - Vadu Rural Health Program, KEM Hospital Research Centre, Pune, Maharashtra,
      India.
FAU - Rumisha, Susan F
AU  - Rumisha SF
AD  - National Institute for Medical Research, Dar es Salaam, United Republic of
      Tanzania.
AD  - Big Data Institute, University of Oxford, Oxford, Oxfordshire, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *Checklist
MH  - Communication
MH  - *Global Health
MH  - Humans
PMC - PMC7594201
OTO - NOTNLM
OT  - *epidemiology
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/29 05:41
PHST- 2020/06/24 00:00 [received]
PHST- 2020/08/30 00:00 [revised]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/29 05:41 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-003237 [pii]
AID - 10.1136/bmjgh-2020-003237 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Oct;5(10). pii: bmjgh-2020-003237. doi:
      10.1136/bmjgh-2020-003237.


PMID- 33115859
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 10
DP  - 2020 Oct
TI  - Bridging research integrity and global health epidemiology (BRIDGE) statement:
      guidelines for good epidemiological practice.
LID - e003236 [pii]
LID - 10.1136/bmjgh-2020-003236 [doi]
AB  - BACKGROUND: Research integrity and research fairness have gained considerable
      momentum in the past decade and have direct implications for global health
      epidemiology. Research integrity and research fairness principles should be
      equally nurtured to produce high-quality impactful research-but bridging the two 
      can lead to practical and ethical dilemmas. In order to provide practical
      guidance to researchers and epidemiologist, we set out to develop good
      epidemiological practice guidelines specifically for global health epidemiology, 
      targeted at stakeholders involved in the commissioning, conduct, appraisal and
      publication of global health research. METHODS: We developed preliminary
      guidelines based on targeted online searches on existing best practices for
      epidemiological studies and sought to align these with key elements of global
      health research and research fairness. We validated these guidelines through a
      Delphi consultation study, to reach a consensus among a wide representation of
      stakeholders. RESULTS: A total of 45 experts provided input on the first round of
      e-Delphi consultation and 40 in the second. Respondents covered a range of
      organisations (including for example academia, ministries, NGOs, research
      funders, technical agencies) involved in epidemiological studies from countries
      around the world (Europe: 19; Africa: 10; North America: 7; Asia: 5;
      South-America: 3 Australia: 1). A selection of eight experts were invited for a
      face-to-face meeting. The final guidelines consist of a set of 6 standards and 42
      accompanying criteria including study preparation, protocol development, data
      collection, data management, data analysis, dissemination and communication.
      CONCLUSION: While guidelines will not by themselves guard global health from
      questionable and unfair research practices, they are certainly part of a
      concerted effort to ensure not only mutual accountability between individual
      researchers, their institutions and their funders but most importantly their
      joint accountability towards the communities they study and society at large.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alba, Sandra
AU  - Alba S
AUID- ORCID: 0000-0003-2435-624X
AD  - Health, KIT Royal Tropical Institute, Amsterdam, The Netherlands s.alba@kit.nl.
FAU - Verdonck, Kristien
AU  - Verdonck K
AD  - Tropical Diseases, Institute of Tropical Medicine, Antwerp, Belgium.
FAU - Lenglet, Annick
AU  - Lenglet A
AD  - Medecins Sans Frontieres, Amsterdam, The Netherlands.
AD  - Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlands.
FAU - Rumisha, Susan F
AU  - Rumisha SF
AD  - National Institute for Medical Research, Dar es Salaam, Tanzania, United Republic
      of.
AD  - Big Data Institute, University of Oxford, Oxford, UK.
FAU - Wienia, Martijn
AU  - Wienia M
AD  - NWO-WOTRO Science for Global Development, The Hague, The Netherlands.
FAU - Teunissen, Imre
AU  - Teunissen I
AD  - Health, KIT Royal Tropical Institute, Amsterdam, The Netherlands.
FAU - Straetemans, Masja
AU  - Straetemans M
AD  - Health, KIT Royal Tropical Institute, Amsterdam, The Netherlands.
FAU - Mendoza, Walter
AU  - Mendoza W
AD  - United Nations Population Fund, Lima, Peru.
FAU - Jeannetot, Daniel
AU  - Jeannetot D
AD  - Health, KIT Royal Tropical Institute, Amsterdam, The Netherlands.
FAU - Weibel, Daniel
AU  - Weibel D
AD  - EDCTP, The Hague, The Netherlands.
FAU - Mayanja-Kizza, Harriet
AU  - Mayanja-Kizza H
AD  - School of Medicine, Makerere University, Kampala, Uganda.
FAU - Juvekar, Sanjay
AU  - Juvekar S
AD  - Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Africa
MH  - Europe
MH  - *Global Health
MH  - Humans
PMC - PMC7594207
OTO - NOTNLM
OT  - *epidemiology
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/29 05:41
PHST- 2020/06/26 00:00 [received]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/10/29 05:41 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-003236 [pii]
AID - 10.1136/bmjgh-2020-003236 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Oct;5(10). pii: bmjgh-2020-003236. doi:
      10.1136/bmjgh-2020-003236.


PMID- 33115756
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 2046-6390 (Electronic)
IS  - 2046-6390 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 28
TI  - Publishing ethics in the era of paper mills.
LID - bio056556 [pii]
LID - 10.1242/bio.056556 [doi]
FAU - Hackett, Rachel
AU  - Hackett R
AUID- ORCID: 0000-0002-7511-3953
AD  - The Company of Biologists, Bidder Building, Station Road, Cambridge CB24 9LF, UK 
      rachel.hackett@biologists.com steven.kelly@plants.ox.ac.uk.
FAU - Kelly, Steven
AU  - Kelly S
AD  - Department of Plant Sciences, University of Oxford, South Parks Road, Oxford OX1 
      3RB, UK rachel.hackett@biologists.com steven.kelly@plants.ox.ac.uk.
LA  - eng
PT  - Editorial
DEP - 20201028
PL  - England
TA  - Biol Open
JT  - Biology open
JID - 101578018
SB  - IM
MH  - Ethics, Research
MH  - Humans
MH  - Publications/ethics/standards
MH  - Publishing/*ethics
PMC - PMC7648613
EDAT- 2020/10/30 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/10/29 05:40
PHST- 2020/10/29 05:40 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
AID - 9/10/bio056556 [pii]
AID - 10.1242/bio.056556 [doi]
PST - epublish
SO  - Biol Open. 2020 Oct 28;9(10). pii: 9/10/bio056556. doi: 10.1242/bio.056556.


PMID- 33115712
OWN - NLM
STAT- Publisher
LR  - 20201029
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
DP  - 2020 Oct 28
TI  - Prerequisites to support high-quality clinical trials in children and young
      people.
LID - archdischild-2019-318677 [pii]
LID - 10.1136/archdischild-2019-318677 [doi]
AB  - Children have the right to treatment based on the same quality of information
      that guides treatment in adults. Without the proper evaluation of medicinal
      products and devices in paediatric clinical trials that are designed to meet the 
      rigorous standards of the competent authorities, children are discriminated from 
      advances in medicine. There are regulatory, scientific and ethical incentives to 
      address the knowledge gap regarding efficacy and safety of medicines in the
      paediatric population. High-quality clinical trials involving children of all
      ages can generate data that will ultimately close the knowledge gaps and support 
      decision making.For clinical trials that enrol children, the needs are
      specialised and often resource intensive. Prerequisites for successful paediatric
      clinical trials are personnel with training in both paediatrics and neonatology
      and expertise in clinical trials in these populations. Moreover, national and
      international networks for efficient collaboration, dissemination of information,
      and sharing of resources and expertise are also needed, together with competent, 
      efficient and high-quality local infrastructure with effective processes.
      Monitoring and oversight bodies with the relevant competence, including expertise
      in paediatrics, is also an important prerequisite for paediatric clinical trials.
      Compromise in any of these components will compromise the downstream results.This
      paper discusses the structures and competences needed in order to perform
      effective, high-quality paediatric clinical trials with the ultimate goal of
      better medicines and treatments for children. We propose a model of examining the
      process as a series of components that each has to be optimised, then all the
      components are actively optimised to function together as an ecosystem, and the
      resulting ecosystem functions well with the general research system and the
      healthcare delivery system.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hirschfeld, Steven
AU  - Hirschfeld S
AD  - Uniformed Services University of the Health Sciences, 4201 Jones Bridge Road,
      Bethesda, Maryland, 20814 USA.
FAU - Lagler, Florian B
AU  - Lagler FB
AD  - Institute for Inherited Metabolic Diseases and Department of Pediatrics,
      Paracelsus Medical University, Clinical Research Center Salzburg GmbH,
      Strubergasse 21, 5020 Salzburg, Austria.
AD  - European Society of Developmental, Perinatal and Pediatric Pharmacology (ESDPPP) 
      Council, Leuven, Belgium.
FAU - Kindblom, Jenny M
AU  - Kindblom JM
AUID- ORCID: http://orcid.org/0000-0001-8437-0639
AD  - European Society of Developmental, Perinatal and Pediatric Pharmacology (ESDPPP) 
      Council, Leuven, Belgium jenny.kindblom@vgregion.se.
AD  - Pediatric Clinical Research Center, Queen Silvia Children's Hospital, Sahlgrenska
      University Hospital, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201028
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
SB  - IM
OTO - NOTNLM
OT  - evidence based medicine
OT  - general paediatrics
OT  - outcomes research
COIS- Competing interests: None declared.
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/10/29 05:40
PHST- 2020/02/07 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/10/29 05:40 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - archdischild-2019-318677 [pii]
AID - 10.1136/archdischild-2019-318677 [doi]
PST - aheadofprint
SO  - Arch Dis Child. 2020 Oct 28. pii: archdischild-2019-318677. doi:
      10.1136/archdischild-2019-318677.


PMID- 33115702
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1950-6112 (Electronic)
IS  - 0003-3898 (Linking)
VI  - 78
IP  - 6
DP  - 2020 Dec 1
TI  - [Ethics and confidentiality of a patient in a medical biology laboratory].
PG  - 665-670
LID - 10.1684/abc.2020.1597 [doi]
AB  - Confidentiality is based on principles of deontology and ethics, which are
      included in French regulations and supported by the professional orders. It
      contributes to the respect and dignity of the patient. If this consideration of
      the human person is old, it has been updated to build the framework imposed by
      the accreditation of medical biology laboratories. Confidentiality is thus
      reflected in a charter of ethics, a model of which we propose here. It reflects
      the commitments of healthcare professionals in the processing of biological
      samples from patients. Confidentiality is thus applied, in a practical way, at
      each phase of the laboratory's activity. In the pre-analytical phase, it
      organizes the reception of the patient and the taking of samples, taking into
      account the particular case of minors. In the analytical phase, confidentiality
      imposes limited access to the technical premises and the organization of the flow
      of personnel from outside the laboratory. Finally, in the post-analytical phase, 
      the reporting of results is regulated, depending on the type of analyses
      performed and the person to whom the results are to be reported (patient or
      prescriber). The particular case of spermiology illustrates all these points.
      Finally, during these phases of sample processing, document management is also a 
      matter of confidentiality and data protection. Confidentiality is essential to
      the functioning of a health care structure, but it is restrictive in its
      day-to-day implementation. Nevertheless, it must be combined with an awareness of
      all staff to address the ethical issue of human dignity.
FAU - Boulliat, Caroline
AU  - Boulliat C
AD  - Hopital d'instruction des armees Desgenettes, Lyon, France.
FAU - Melki, Gilles
AU  - Melki G
AD  - Service qualite, Unilians Biogroup, Decines-Charpieu, France.
FAU - Targe, Francois
AU  - Targe F
AD  - Laboratoire de biologie medicale, Unilians-Biogroup, Decines-Charpieu, France.
FAU - Massoubre, Bernard
AU  - Massoubre B
AD  - Hopital d'instruction des armees Desgenettes, Lyon, France.
LA  - fre
PT  - Journal Article
TT  - L'ethique et la confidentialite du patient au laboratoire de biologie medicale.
PL  - France
TA  - Ann Biol Clin (Paris)
JT  - Annales de biologie clinique
JID - 2984690R
RN  - 0 (Medical Waste Disposal)
SB  - IM
MH  - Biology/ethics/standards
MH  - Clinical Laboratory Techniques/*ethics/standards
MH  - Computer Security/ethics/legislation & jurisprudence/standards
MH  - *Confidentiality/ethics/legislation & jurisprudence
MH  - Disclosure/ethics/legislation & jurisprudence/standards
MH  - *Ethics, Medical
MH  - Female
MH  - Humans
MH  - Laboratories/*ethics/standards
MH  - Male
MH  - Medical Waste Disposal/ethics/legislation & jurisprudence/methods/standards
MH  - Pre-Analytical Phase/ethics/standards
MH  - Referral and Consultation/ethics/organization & administration/standards
MH  - Spermatozoa/chemistry/physiology
MH  - Workplace/organization & administration/standards
OTO - NOTNLM
OT  - RGPD
OT  - accreditation standard iso 15189
OT  - confidentiality
OT  - deontology
OT  - medical ethics
OT  - spermiology
EDAT- 2020/10/30 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/10/29 05:40
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/10/29 05:40 [entrez]
AID - abc.2020.1597 [pii]
AID - 10.1684/abc.2020.1597 [doi]
PST - ppublish
SO  - Ann Biol Clin (Paris). 2020 Dec 1;78(6):665-670. doi: 10.1684/abc.2020.1597.


PMID- 33115541
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220531
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 28
TI  - Rationale and design of repeated cross-sectional studies to evaluate the
      reporting quality of trial protocols: the Adherence to SPIrit REcommendations
      (ASPIRE) study and associated projects.
PG  - 896
LID - 10.1186/s13063-020-04808-y [doi]
AB  - BACKGROUND: Clearly structured and comprehensive protocols are an essential
      component to ensure safety of participants, data validity, successful conduct,
      and credibility of results of randomized clinical trials (RCTs). Funding
      agencies, research ethics committees (RECs), regulatory agencies, medical
      journals, systematic reviewers, and other stakeholders rely on protocols to
      appraise the conduct and reporting of RCTs. In response to evidence of poor
      protocol quality, the Standard Protocol Items: Recommendations for Interventional
      Trials (SPIRIT) guideline was published in 2013 to improve the accuracy and
      completeness of clinical trial protocols. The impact of these recommendations on 
      protocol completeness and associations between protocol completeness and
      successful RCT conduct and publication remain uncertain. OBJECTIVES AND METHODS: 
      Aims of the Adherence to SPIrit REcommendations (ASPIRE) study are to investigate
      adherence to SPIRIT checklist items of RCT protocols approved by RECs in the UK, 
      Switzerland, Germany, and Canada before (2012) and after (2016) the publication
      of the SPIRIT guidelines; determine protocol features associated with
      non-adherence to SPIRIT checklist items; and assess potential differences in
      adherence across countries. We assembled an international cohort of RCTs based on
      450 protocols approved in 2012 and 402 protocols approved in 2016 by RECs in
      Switzerland, the UK, Germany, and Canada. We will extract data on RCT
      characteristics and adherence to SPIRIT for all included protocols. We will use
      multivariable regression models to investigate temporal changes in SPIRIT
      adherence, differences across countries, and associations between SPIRIT
      adherence of protocols with RCT registration, completion, and publication of
      results. We plan substudies to examine the registration, premature
      discontinuation, and non-publication of RCTs; the use of patient-reported
      outcomes in RCT protocols; SPIRIT adherence of RCT protocols with non-regulated
      interventions; the planning of RCT subgroup analyses; and the use of routinely
      collected data for RCTs. DISCUSSION: The ASPIRE study and associated substudies
      will provide important information on the impact of measures to improve the
      reporting of RCT protocols and on multiple aspects of RCT design, trial
      registration, premature discontinuation, and non-publication of RCTs observing
      potential changes over time.
FAU - Gryaznov, Dmitry
AU  - Gryaznov D
AUID- ORCID: http://orcid.org/0000-0002-2361-6794
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland. dmitry.gryaznov@usb.ch.
FAU - Odutayo, Ayodele
AU  - Odutayo A
AD  - Applied Health Research Centre, Li Ka Shing Knowledge Instiute of St Michael's
      Hospital, Toronto, Canada.
AD  - Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine,
      Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - von Niederhausern, Belinda
AU  - von Niederhausern B
AD  - Department of Clinical Research, Clinical Trial Unit, University Hospital Basel
      and University of Basel, Basel, Switzerland.
AD  - Roche Pharma AG, Grenzach-Wyhlen, Germany.
FAU - Speich, Benjamin
AU  - Speich B
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine,
      Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Kasenda, Benjamin
AU  - Kasenda B
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
AD  - iOMEDICO AG, Research & Development, Freiburg, Germany.
FAU - Ojeda-Ruiz, Elena
AU  - Ojeda-Ruiz E
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Preventive Medicine Department, Osakidetza Basque Health Service, Bioaraba Health
      Research Institute, Health Prevention, Promotion and Care Area, Araba University 
      Hospital, Vitoria-Gasteiz, Spain.
FAU - Blumle, Anette
AU  - Blumle A
AD  - Institute for Evidence in Medicine, Medical Center - University of Freiburg,
      Faculty of Medicine, University of Freiburg, Freiburg, Germany.
AD  - Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.
FAU - Schandelmaier, Stefan
AU  - Schandelmaier S
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
FAU - Mertz, Dominik
AU  - Mertz D
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
FAU - Tomonaga, Yuki
AU  - Tomonaga Y
AD  - Epidemiology, Biostatistics and Prevention Institute, University of Zurich,
      Zurich, Switzerland.
FAU - Amstutz, Alain
AU  - Amstutz A
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Swiss Tropical and Public Health Institute, University of Basel, Basel,
      Switzerland.
AD  - Department of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Basel, Basel, Switzerland.
FAU - Pauli-Magnus, Christiane
AU  - Pauli-Magnus C
AD  - Department of Clinical Research, Clinical Trial Unit, University Hospital Basel
      and University of Basel, Basel, Switzerland.
FAU - Gloy, Viktoria
AU  - Gloy V
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Bischoff, Karin
AU  - Bischoff K
AD  - Institute for Evidence in Medicine, Medical Center - University of Freiburg,
      Faculty of Medicine, University of Freiburg, Freiburg, Germany.
AD  - Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.
FAU - Wollmann, Katharina
AU  - Wollmann K
AD  - Institute for Evidence in Medicine, Medical Center - University of Freiburg,
      Faculty of Medicine, University of Freiburg, Freiburg, Germany.
AD  - Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.
FAU - Rehner, Laura
AU  - Rehner L
AD  - Institute for Evidence in Medicine, Medical Center - University of Freiburg,
      Faculty of Medicine, University of Freiburg, Freiburg, Germany.
AD  - Department of Epidemiology and Community Health, Institute for Community
      Medicine, University Medicine Greifswald, Greifswald, Germany.
FAU - Lohner, Szimonetta
AU  - Lohner S
AD  - Cochrane Hungary, Clinical Centre of the University of Pecs, Medical School,
      University of Pecs, Pecs, Hungary.
FAU - Meerpohl, Joerg J
AU  - Meerpohl JJ
AD  - Institute for Evidence in Medicine, Medical Center - University of Freiburg,
      Faculty of Medicine, University of Freiburg, Freiburg, Germany.
AD  - Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.
FAU - Nordmann, Alain
AU  - Nordmann A
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Klatte, Katharina
AU  - Klatte K
AD  - Department of Clinical Research, Clinical Trial Unit, University Hospital Basel
      and University of Basel, Basel, Switzerland.
FAU - Ghosh, Nilabh
AU  - Ghosh N
AD  - Department of Neurosurgery and Department of Biomedicine, University Hospital
      Basel, University of Basel, Basel, Switzerland.
FAU - Heravi, Ala Taji
AU  - Heravi AT
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Wong, Jacqueline
AU  - Wong J
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
FAU - Chow, Ngai
AU  - Chow N
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
FAU - Hong, Patrick Jiho
AU  - Hong PJ
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
AD  - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto,
      Canada.
FAU - Cord, Kimberly Mc
AU  - Cord KM
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Sricharoenchai, Sirintip
AU  - Sricharoenchai S
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Busse, Jason W
AU  - Busse JW
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
AD  - Department of Anesthesia, McMaster University, Hamilton, Canada.
FAU - Agarwal, Arnav
AU  - Agarwal A
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
FAU - Saccilotto, Ramon
AU  - Saccilotto R
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Schwenkglenks, Matthias
AU  - Schwenkglenks M
AD  - Epidemiology, Biostatistics and Prevention Institute, University of Zurich,
      Zurich, Switzerland.
AD  - Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel,
      Switzerland.
FAU - Moffa, Giusi
AU  - Moffa G
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Department of Mathematics and Computer Science, University of Basel, Basel,
      Switzerland.
FAU - Hemkens, Lars G
AU  - Hemkens LG
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
FAU - Hopewell, Sally
AU  - Hopewell S
AD  - Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine,
      Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - von Elm, Erik
AU  - von Elm E
AD  - Cochrane Switzerland, Centre for Primary Care and Public Health (Unisante),
      University of Lausanne, Lausanne, Switzerland.
FAU - Briel, Matthias
AU  - Briel M
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University Hospital Basel and University of Basel, Spitalstrasse
      12, 4031, Basel, Switzerland.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Canada
MH  - *Clinical Trial Protocols as Topic
MH  - *Cross-Sectional Studies
MH  - Ethics Committees, Research
MH  - Germany
MH  - Humans
MH  - Switzerland
PMC - PMC7594472
OTO - NOTNLM
OT  - Randomized clinical trials
OT  - Registration
OT  - Reporting guideline adherence
OT  - Reporting quality
OT  - Trial discontinuation
OT  - Trial protocol
EDAT- 2020/10/30 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/29 05:30
PHST- 2020/06/10 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/29 05:30 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04808-y [doi]
AID - 10.1186/s13063-020-04808-y [pii]
PST - epublish
SO  - Trials. 2020 Oct 28;21(1):896. doi: 10.1186/s13063-020-04808-y.


PMID- 33115456
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 28
TI  - Redundant trials can be prevented, if the EU clinical trial regulation is applied
      duly.
PG  - 107
LID - 10.1186/s12910-020-00536-9 [doi]
AB  - The problem of wasteful clinical trials has been debated relentlessly in the
      medical community. To a significant extent, it is attributed to redundant trials 
      - studies that are carried out to address questions, which can be answered
      satisfactorily on the basis of existing knowledge and accessible evidence from
      prior research. This article presents the first evaluation of the potential of
      the EU Clinical Trials Regulation 536/2014, which entered into force in 2014 but 
      is expected to become applicable at the end of 2021, to prevent such trials.
      Having reviewed provisions related to the trial authorisation, we propose how
      certain regulatory requirements for the assessment of trial applications can and 
      should be interpreted and applied by national research ethics committees and
      other relevant authorities in order to avoid redundant trials and, most
      importantly, preclude the unnecessary recruitment of trial participants and their
      unjustified exposure to health risks.
FAU - Kim, Daria
AU  - Kim D
AUID- ORCID: 0000-0002-1422-9522
AD  - Research Fellow, Max Planck Institute for Innovation and Competition,
      Marstallplatz 1, 81545, Munich, Germany. daria.kim@ip.mpg.de.
FAU - Hasford, Joerg
AU  - Hasford J
AD  - Ludwig-Maximilians-University of Munich, The Institute for Medical Information
      Processing, Biometry, and Epidemiology, and Chairman of the Permanent Working
      Party of Research Ethics Committees in Germany, Scharnitzerstasse 7, 82166,
      Grafelfing, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
PMC - PMC7592564
OTO - NOTNLM
OT  - *Clinical trials
OT  - *EU clinical trials regulation
OT  - *Research ethics
OT  - *Research ethics committees
OT  - *Research redundancy
OT  - *Systematic review
OT  - *Trial authorisation
OT  - *Trial methodology
EDAT- 2020/10/30 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/29 05:29
PHST- 2019/09/23 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/10/29 05:29 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00536-9 [doi]
AID - 10.1186/s12910-020-00536-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 28;21(1):107. doi: 10.1186/s12910-020-00536-9.


PMID- 33115423
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 28
TI  - Influential role of lean soft tissue in the association between training volume
      and bone mineral density among male adolescent practitioners of impact-loading
      sports: ABCD Growth study.
PG  - 496
LID - 10.1186/s12887-020-02402-4 [doi]
AB  - BACKGROUND: Training volume is associated with direct and indirect pathways of
      bone adaptations. In addition, training volume is a training variable associated 
      with lean soft tissue (LST), which has been shown to be an important predictor of
      areal bone mineral density (aBMD). Thus, the aim of this study is to investigate 
      the influential role of lean soft tissue (LST) in the association between
      training volume and aBMD in male adolescent athletes. METHODS: This
      cross-sectional study was composed of 299 male adolescent athletes, mean age 14.1
      (1.8) years, from 9 different weight-bearing modalities. The Ethical Board
      approved the investigation. The adolescents reported the number of days per week 
      they trained and the time spent training and, from this, the training volume
      (h/wk) was estimated. The LST and aBMD were assessed by dual-energy x-ray
      absorptiometry. Somatic maturation was estimated by the peak of height velocity. 
      Mediation analysis was performed to investigate the role of LST in the
      association between training volume and aBMD. Level of significance was set at p 
      < 0.05. RESULTS: LST partially explained the association between training volume 
      and aBMD in all body segments: upper limbs (58.37%; beta = 0.00142), lower limbs 
      (28.35%; beta = 0.00156), spine (33.80%; beta = 0.00124), and whole body (41.82%,
      beta = 0.00131). There was no direct effect of training volume on aBMD in upper
      limbs (CI -0.00085 to 0.00287). CONCLUSION: The association between training
      volume and aBMD is influenced by LST in different body segments, mainly upper
      limbs, demonstrating that interventions aiming to enhance aBMD should also
      consider LST as an important variable to be managed.
FAU - Narciso, Pedro Henrique
AU  - Narciso PH
AD  - Department of Physical Education, Sao Paulo State University (UNESP), Roberto
      Simonsen Avenue, 305. Educational Center, SP, CEP: 19060-900, Presidente
      Prudente, Brazil. pedro.narciso@unesp.br.
FAU - Werneck, Andre Oliveira
AU  - Werneck AO
AD  - School of Public Health, University of Sao Paulo (USP), Sao Paulo, Brazil.
FAU - Luiz-de-Marco, Rafael
AU  - Luiz-de-Marco R
AD  - Department of Physical Education, Post-Graduation Program in Movement Sciences,
      Sao Paulo State University (UNESP), Presidente Prudente, Brazil.
FAU - Ventura Faustino-da-Silva, Yuri da Silva
AU  - Ventura Faustino-da-Silva YDS
AD  - Department of Physical Education, Post-Graduation Program in Movement Sciences,
      Sao Paulo State University (UNESP), Presidente Prudente, Brazil.
FAU - Maillane-Vanegas, Santiago
AU  - Maillane-Vanegas S
AD  - Department of Physical Therapy, Post-Graduation Program in Physical Therapy, Sao 
      Paulo State University (UNESP), Presidente Prudente, Brazil.
FAU - Agostinete, Ricardo Ribeiro
AU  - Agostinete RR
AD  - Department of Physical Education, Post-Graduation Program in Movement Sciences,
      Sao Paulo State University (UNESP), Presidente Prudente, Brazil.
FAU - Fernandes, Romulo Araujo
AU  - Fernandes RA
AD  - Department of Physical Education, Sao Paulo State University (UNESP), Roberto
      Simonsen Avenue, 305. Educational Center, SP, CEP: 19060-900, Presidente
      Prudente, Brazil.
LA  - eng
GR  - 2018/21935-1/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/International
GR  - 2015/19710-3/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201028
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adolescent
MH  - Athletes
MH  - Body Composition
MH  - *Bone Density
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Male
MH  - *Sports
PMC - PMC7592582
OTO - NOTNLM
OT  - *body composition
OT  - *bone tissue
OT  - *muscle mass
EDAT- 2020/10/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/29 05:29
PHST- 2020/04/15 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/29 05:29 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12887-020-02402-4 [doi]
AID - 10.1186/s12887-020-02402-4 [pii]
PST - epublish
SO  - BMC Pediatr. 2020 Oct 28;20(1):496. doi: 10.1186/s12887-020-02402-4.


PMID- 33114680
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 21
DP  - 2020 Oct 26
TI  - The Performance Implications of Job Insecurity: The Sequential Mediating Effect
      of Job Stress and Organizational Commitment, and the Buffering Role of Ethical
      Leadership.
LID - E7837 [pii]
LID - 10.3390/ijerph17217837 [doi]
AB  - Although previous works have examined how job insecurity affects the perceptions,
      attitudes, and behaviors of members in an organization, those studies have not
      paid enough attention to the relationship between job insecurity and performance 
      or the mediating processes in that relationship. Considering that organizational 
      performance is a fundamental target or purpose, investigating it is greatly
      needed. This research examines both mediating factors and a moderator in the link
      between job insecurity and organizational performance by building a moderated
      sequential mediation model. To be specific, we hypothesize that the degree of an 
      employee's job stress and organizational commitment sequentially mediate the
      relationship between job insecurity and performance. Furthermore, ethical
      leadership could moderate the association between job insecurity and job stress. 
      Using a three-wave data set gathered from 301 currently working employees in
      South Korea, we reveal that not only do job stress and organizational commitment 
      sequentially mediate the job insecurity-performance link, but also that ethical
      leadership plays a buffering role of in the job insecurity-job stress link. Our
      findings suggest that the degree of job stress and organizational commitment (as 
      mediators), as well as ethical leadership (as a moderator), function as
      intermediating mechanisms in the job insecurity-performance link.
FAU - Kim, Min-Jik
AU  - Kim MJ
AD  - Institute of Finance and Banking, Seoul National University, 1 Kwanak-ro, Seoul
      08826, Korea.
FAU - Kim, Byung-Jik
AU  - Kim BJ
AD  - College of Business Administration, University of Ulsan, Ulsan 44610, Korea.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Employment/*psychology
MH  - Female
MH  - Humans
MH  - *Job Satisfaction
MH  - *Leadership
MH  - Male
MH  - Middle Aged
MH  - Morals
MH  - *Occupational Stress/epidemiology
MH  - Republic of Korea
MH  - Young Adult
PMC - PMC7663293
OTO - NOTNLM
OT  - *ethical leadership
OT  - *job insecurity
OT  - *job stress
OT  - *moderated sequential mediation model
OT  - *organizational commitment
OT  - *organizational performance
EDAT- 2020/10/30 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/10/29 01:04
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2020/10/29 01:04 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - ijerph17217837 [pii]
AID - 10.3390/ijerph17217837 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 26;17(21). pii: ijerph17217837. doi:
      10.3390/ijerph17217837.


PMID- 33114653
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2309-608X (Electronic)
IS  - 2309-608X (Linking)
VI  - 6
IP  - 4
DP  - 2020 Oct 26
TI  - Aspergillus fumigatus and Aspergillus flavus-Specific IgG Cut-Offs for the
      Diagnosis of Chronic Pulmonary Aspergillosis in Pakistan.
LID - E249 [pii]
LID - 10.3390/jof6040249 [doi]
AB  - Despite a high burden of chronic pulmonary aspergillosis (CPA) in Pakistan,
      Aspergillus-specific IgG testing is currently not available. Establishing
      cut-offs for Aspergillus-specific IgG for CPA diagnosis is crucial due to
      geographical variation. In settings such as Pakistan, where non-Aspergillus
      fumigatus (mainly A. flavus) Aspergillus species account for the majority of CPA 
      cases, there is a need to explore additional benefit of Aspergillus
      flavus-specific IgG detection along with A. fumigatus-specific IgG detection.
      This study was conducted at the Aga Khan University, Karachi, Pakistan after
      ethical approval. Serum for IgG detection were collected after informed consent
      from healthy controls (n = 21), diseased controls (patients with lung diseases, n
      = 18), and CPA patients (n = 21). A. fumigatus and A. flavus IgG were detected
      using Siemens immulite assay. The sensitivity and specificity of A.
      fumigatus-specific IgG were 80.95% and 82.05%, respectively at a cut-off of 20
      mg/L. The sensitivity and specificity of A. flavus-specific IgG were 80.95% and
      79.49% at a cut-off of 30 mg/L. We report, for the first time, performance of A. 
      flavus-specific IgG for CPA diagnosis. Although there was no statistically
      significant difference between the performance of both antigens, it seems
      contextually relevant to include A. flavus IgG in the CPA diagnostic algorithm in
      regions with higher non-A. fumigatus CPA infections.
FAU - Jabeen, Kauser
AU  - Jabeen K
AUID- ORCID: 0000-0003-2497-7847
AD  - Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi
      74800, Pakistan.
FAU - Farooqi, Joveria
AU  - Farooqi J
AUID- ORCID: 0000-0002-9921-4660
AD  - Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi
      74800, Pakistan.
FAU - Iqbal, Nousheen
AU  - Iqbal N
AUID- ORCID: 0000-0001-5026-9874
AD  - Section of Pulmonary Medicine, Department of Medicine, Aga Khan University,
      Karachi 74800, Pakistan.
AD  - Department of Medicine, Jinnah Medical and Dental College, Karachi 75400,
      Pakistan.
FAU - Wahab, Khalid
AU  - Wahab K
AD  - Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi
      74800, Pakistan.
FAU - Irfan, Muhammad
AU  - Irfan M
AUID- ORCID: 0000-0002-5796-2548
AD  - Section of Pulmonary Medicine, Department of Medicine, Aga Khan University,
      Karachi 74800, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Switzerland
TA  - J Fungi (Basel)
JT  - Journal of fungi (Basel, Switzerland)
JID - 101671827
PMC - PMC7711809
OTO - NOTNLM
OT  - Aspergillus IgG
OT  - Aspergillus flavus
OT  - Aspergillus fumigatus
OT  - Pakistan
OT  - Siemens immulite
OT  - chronic pulmonary aspergillosis
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 01:04
PHST- 2020/09/10 00:00 [received]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/10/29 01:04 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - jof6040249 [pii]
AID - 10.3390/jof6040249 [doi]
PST - epublish
SO  - J Fungi (Basel). 2020 Oct 26;6(4). pii: jof6040249. doi: 10.3390/jof6040249.


PMID- 33114528
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct 26
TI  - Ethical Considerations about Genomic Medicine Implementation: Lessons Learned
      from the eMERGE III Study.
LID - E195 [pii]
LID - 10.3390/jpm10040195 [doi]
AB  - The development of high-throughput techniques has permitted the accumulation of
      enormous amounts of genomic information. As increasing numbers of studies aim to 
      utilize individual genomic information for diagnostic, preventive, or therapeutic
      purposes, Institutional Review Boards (IRBs) have a greater opportunity to review
      such types of study protocols. An article published in the Journal of
      Personalized Medicine titled, "Ethical Considerations Related to Return of
      Results from Genomic Medicine Projects: The eMERGE Network (Phase III)
      Experience" identified the common concerns of IRBs in the process of reviewing
      such studies, and some concerns included the readability of informed consent
      materials, potential risks to participants, information sharing with family
      members, options for withdrawal or receiving limited results, and provisions to
      clear participant questions. Since there is an increase in the number of genomic 
      medicine implementation studies worldwide, the insights provided by this study
      would assist future researchers in protocol preparation as well as aid project
      review by IRB members.
FAU - Inamura, Kentaro
AU  - Inamura K
AUID- ORCID: 0000-0001-6444-3861
AD  - Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer
      Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
LA  - eng
GR  - 19K07426/JSPS KAKENHI
GR  - Not applicable/The Mochida Memorial Foundation for Medical and Pharmaceutical
      Research
GR  - Not applicable/Takeda Science Foundation
GR  - Not applicable/The Ichiro Kanehara Foundation
GR  - Not applicable/Grant for Lung Cancer Research
GR  - Not applicable/Suzuki Foundation for Urological Medicine
PT  - Editorial
DEP - 20201026
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC7712392
OTO - NOTNLM
OT  - biobank
OT  - bioethics
OT  - electronic health record
OT  - electronic medical record
OT  - genetic testing
OT  - next-generation sequencing
OT  - personalized medicine
OT  - precision medicine
OT  - research ethics
OT  - return of results
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 01:03
PHST- 2020/10/09 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2020/10/29 01:03 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - jpm10040195 [pii]
AID - 10.3390/jpm10040195 [doi]
PST - epublish
SO  - J Pers Med. 2020 Oct 26;10(4). pii: jpm10040195. doi: 10.3390/jpm10040195.


PMID- 33114408
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Oct 24
TI  - The Development of a Novel Questionnaire Approach to the Investigation of Horse
      Training, Management, and Behaviour.
LID - E1960 [pii]
LID - 10.3390/ani10111960 [doi]
AB  - The Equine Behaviour Assessment and Research Questionnaire (E-BARQ) is a
      questionnaire instrument developed to obtain quantitative data on the domestic
      equine triad of training, management, and behaviour of horses. The E-BARQ was
      developed to identify how changes in training and management impact behaviour
      over time, to define normal behaviour in horses, and to discover how to improve
      rider safety and horse welfare, leading to ethical equitation. During the
      development of the E-BARQ, we also investigated how best to motivate stakeholders
      to engage with this citizen science project. The pilot version of the E-BARQ
      collected qualitative data on respondents' experience of the questionnaire. The
      pilot questionnaire was developed with the assistance of an international panel
      (with professional expertise in horse training, equitation science, veterinary
      science, equestrian coaching, welfare, animal behaviour, and elite-level riding),
      and was used to collect data on 1320 horses from approximately 1194
      owner/caregiver respondents, with an option for respondents to provide free-text 
      feedback. A Rotated Principal Component Analysis of the 218 behavioural,
      management, and training questionnaire items extracted a total of 65 rotated
      components. Thirty-six of the 65 rotated components demonstrated high internal
      reliability. Of the 218 questionnaire items, 43 items failed to reach the Rotated
      Principal Component Analysis criteria and were not included in the final version 
      of the E-BARQ. Survey items that failed the Rotated Principal Component Analysis 
      inclusion criteria were discarded if found to have a less than 85% response rate,
      or a variance of less than 1.3. Of those that survived the Rotated Principal
      Component Analysis, items were further assigned to horse temperament (17 rotated 
      components), equitation (11 rotated components), and management and equipment (8 
      rotated components) groups. The feedback from respondents indicated the need for 
      further items to be added to the questionnaire, resulting in a total of 214 items
      for the final E-BARQ survey. Many of these items were further grouped into
      question matrices, and the demographic items for horse and handler included,
      giving a final total of 97 questions on the E-BARQ questionnaire. These results
      provided content validity, showing that the questionnaire items were an
      acceptable representation of the entire horse training, management, and
      behavioural domain for the development of the final E-BARQ questionnaire.
FAU - Fenner, Kate
AU  - Fenner K
AUID- ORCID: 0000-0002-0649-3278
AD  - Sydney School of Veterinary Science, University of Sydney, Camperdown NSW 2006,
      Australia.
FAU - Dashper, Katherine
AU  - Dashper K
AUID- ORCID: 0000-0002-2415-2290
AD  - School of Events, Tourism and Hospitality Management, Leeds Beckett University,
      Leeds LS1 3HE, UK.
FAU - Serpell, James
AU  - Serpell J
AD  - School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
      19104, USA.
FAU - McLean, Andrew
AU  - McLean A
AUID- ORCID: 0000-0002-6971-7961
AD  - Equitation Science International, 3 Wonderland Ave, Tuerong, Victoria 3915,
      Australia.
FAU - Wilkins, Cristina
AU  - Wilkins C
AD  - Saddletops Pty Ltd., Gatton, Queensland 4343, Australia.
FAU - Klinck, Mary
AU  - Klinck M
AD  - Dre Mary Klinck, m.v., consultante en comportement, Sainte-Anne-de-Bellevue, QC
      H9X0A6, Canada.
FAU - Wilson, Bethany
AU  - Wilson B
AD  - Sydney School of Veterinary Science, University of Sydney, Camperdown NSW 2006,
      Australia.
FAU - McGreevy, Paul
AU  - McGreevy P
AUID- ORCID: 0000-0001-7220-8378
AD  - Sydney School of Veterinary Science, University of Sydney, Camperdown NSW 2006,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201024
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7693391
OTO - NOTNLM
OT  - behavioural evaluation
OT  - citizen science
OT  - ethical equitation
OT  - horse welfare
OT  - rider safety
OT  - the domestic equine triad
EDAT- 2020/10/30 06:00
MHDA- 2020/10/30 06:01
CRDT- 2020/10/29 01:03
PHST- 2020/10/02 00:00 [received]
PHST- 2020/10/17 00:00 [revised]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/10/29 01:03 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2020/10/30 06:01 [medline]
AID - ani10111960 [pii]
AID - 10.3390/ani10111960 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 24;10(11). pii: ani10111960. doi: 10.3390/ani10111960.


PMID- 33114007
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1424-8220 (Electronic)
IS  - 1424-8220 (Linking)
VI  - 20
IP  - 21
DP  - 2020 Oct 23
TI  - A Novel Fetal Movement Simulator for the Performance Evaluation of Vibration
      Sensors for Wearable Fetal Movement Monitors.
LID - E6020 [pii]
LID - 10.3390/s20216020 [doi]
AB  - Fetal movements (FM) are an important factor in the assessment of fetal health.
      However, there is currently no reliable way to monitor FM outside clinical
      environs. While extensive research has been carried out using accelerometer-based
      systems to monitor FM, the desired accuracy of detection is yet to be achieved. A
      major challenge has been the difficulty of testing and calibrating sensors at the
      pre-clinical stage. Little is known about fetal movement features, and clinical
      trials involving pregnant women can be expensive and ethically stringent. To
      address these issues, we introduce a novel FM simulator, which can be used to
      test responses of sensor arrays in a laboratory environment. The design uses a
      silicon-based membrane with material properties similar to that of a gravid
      abdomen to mimic the vibrations due to fetal kicks. The simulator incorporates
      mechanisms to pre-stretch the membrane and to produce kicks similar to that of a 
      fetus. As a case study, we present results from a comparative study of an
      acoustic sensor, an accelerometer, and a piezoelectric diaphragm as candidate
      vibration sensors for a wearable FM monitor. We find that the acoustic sensor and
      the piezoelectric diaphragm are better equipped than the accelerometer to
      determine durations, intensities, and locations of kicks, as they have a
      significantly greater response to changes in these conditions than the
      accelerometer. Additionally, we demonstrate that the acoustic sensor and the
      piezoelectric diaphragm can detect weaker fetal movements (threshold wall
      displacements are less than 0.5 mm) compared to the accelerometer (threshold wall
      displacement is 1.5 mm) with a trade-off of higher power signal artefacts.
      Finally, we find that the piezoelectric diaphragm produces better signal-to-noise
      ratios compared to the other two sensors in most of the cases, making it a
      promising new candidate sensor for wearable FM monitors. We believe that the FM
      simulator represents a key development towards enabling the eventual translation 
      of wearable FM monitoring garments.
FAU - Ghosh, Abhishek Kumar
AU  - Ghosh AK
AUID- ORCID: 0000-0001-7846-0793
AD  - Department of Mechanical Engineering, Imperial College London, London SW7 2AZ,
      UK.
FAU - Burniston, Sonny F
AU  - Burniston SF
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Krentzel, Daniel
AU  - Krentzel D
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Roy, Abhishek
AU  - Roy A
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Sheikh, Adil Shoaib
AU  - Sheikh AS
AUID- ORCID: 0000-0002-4274-4951
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Siddiq, Talha
AU  - Siddiq T
AUID- ORCID: 0000-0003-3145-2088
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Trinh, Paula Mai Phuong
AU  - Trinh PMP
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Velazquez, Marta Mambrilla
AU  - Velazquez MM
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Vielle, Hei-Ting
AU  - Vielle HT
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Nowlan, Niamh C
AU  - Nowlan NC
AD  - Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.
FAU - Vaidyanathan, Ravi
AU  - Vaidyanathan R
AD  - Department of Mechanical Engineering, Imperial College London, London SW7 2AZ,
      UK.
LA  - eng
GR  - BDCS-2018-46/Commonwealth Scholarship Commission
GR  - DST-UKIERI-2016-17-0103/UK-India Education and Research Initiative (UKIERI)
PT  - Journal Article
DEP - 20201023
PL  - Switzerland
TA  - Sensors (Basel)
JT  - Sensors (Basel, Switzerland)
JID - 101204366
SB  - IM
MH  - Female
MH  - Fetal Monitoring
MH  - *Fetal Movement
MH  - Humans
MH  - Movement
MH  - Pregnancy
MH  - Vibration
MH  - *Wearable Electronic Devices
PMC - PMC7660296
OTO - NOTNLM
OT  - accelerometer
OT  - acoustic sensor
OT  - fetal movement monitor
OT  - fetal movement simulator
OT  - maternal abdomen model
OT  - piezoelectric diaphragm
EDAT- 2020/10/30 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/10/29 01:02
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/15 00:00 [revised]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/10/29 01:02 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - s20216020 [pii]
AID - 10.3390/s20216020 [doi]
PST - epublish
SO  - Sensors (Basel). 2020 Oct 23;20(21). pii: s20216020. doi: 10.3390/s20216020.


PMID- 33113978
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 21
DP  - 2020 Oct 23
TI  - A Case-Centered Approach to Nursing Ethics Education: A Qualitative Study.
LID - E7748 [pii]
LID - 10.3390/ijerph17217748 [doi]
AB  - Nurses deal with ethical decisions as they protect patients' rights, but a
      consensus on effective approaches to nursing ethics education is lacking. The
      "four topics" method can facilitate decision-making when nurses experience
      ethical dilemmas in practice. This study aimed to describe nursing students'
      perspectives on and experiences of a case-centered approach to nursing ethics
      education using the four topics method. This qualitative study consisted of two
      phases. First, we delivered case-centered nursing ethics education sessions to
      nursing students using the four topics method. Then, we conducted two focus group
      discussions that explored students' perspectives on and experiences of nursing
      ethics education. Data were analyzed using conventional content analysis. Four
      themes were identified: the importance of ethics education as perceived by
      nursing students, problems in current nursing ethics education, the experience of
      case-centered nursing ethics education using the four topics approach, and
      suggestions for improving nursing ethics education. The case-centered approach
      using the four topics method is effective in enhancing nursing students' nursing 
      ethics ability. It is crucial to understand that nursing students would like to
      set up their own ethical standards and philosophy. Continuous efforts to
      encourage students' participation and to provide ethical reflection opportunities
      during clinical practice are needed to better connect theory with clinical
      practice.
FAU - Lee, Won
AU  - Lee W
AD  - Department of Nursing, Chung-Ang University, Seoul 06974, Korea.
FAU - Choi, Sungkyoung
AU  - Choi S
AD  - Department of Medical Humanities and Social Sciences, Yonsei University College
      of Medicine, Seoul 06974, Korea.
FAU - Kim, Sujeong
AU  - Kim S
AD  - Department of Family Health Nursing, College of Nursing, The Catholic University 
      of Korea, Seoul 06974, Korea.
FAU - Min, Ari
AU  - Min A
AUID- ORCID: 0000-0002-5151-0559
AD  - Department of Nursing, Chung-Ang University, Seoul 06974, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201023
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - *Education, Nursing
MH  - *Ethics, Nursing
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - Qualitative Research
MH  - *Students, Nursing
MH  - Young Adult
PMC - PMC7660290
OTO - NOTNLM
OT  - *four topics approach
OT  - *nursing education
OT  - *nursing ethics
OT  - *nursing student
OT  - *qualitative research
EDAT- 2020/10/30 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/10/29 01:02
PHST- 2020/09/17 00:00 [received]
PHST- 2020/10/16 00:00 [revised]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/29 01:02 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - ijerph17217748 [pii]
AID - 10.3390/ijerph17217748 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 23;17(21). pii: ijerph17217748. doi:
      10.3390/ijerph17217748.


PMID- 32789008
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Controlled administration of cannabis to mitigate cannabis-attributable harm
      among recreational users: a quasi-experimental study in Germany.
PG  - 201
LID - 10.12688/f1000research.22612.2 [doi]
AB  - Background: New approaches are required to slow down or reverse increasing trends
      of levels of delta-9-tetrahydrocannabinol (THC) and cannabis-attributable
      hospitalizations in Germany. Legal access to cannabis may constitute one viable
      effective policy response; however, available evidence does not suffice to inform
      a regulation model for Germany. The proposed study aims to reduce harm for
      cannabis users through legal access to herbal cannabis through pharmacies.
      Protocol: A quasi-experimental study comparing cannabis users with legal access
      to herbal cannabis (Berlin, intervention group) to those without legal access
      (Hamburg, control group) (total N=698). As the primary outcome, we hypothesize
      that: 1) illegal THC consumption will reduce by at least 50% in the intervention 
      group and 2) total THC exposure in the intervention group will be reduced by at
      least 10% lower than that of the control group, taking into account baseline
      values. Secondary outcomes comprise measures of frequency of use, THC-impaired
      driving, and mode of administration. Paired t-tests and multilevel regression
      models will be performed for statistical analyses. Discussion: This study
      proposal is currently being reviewed by the 'Federal Institute for Drugs and
      Medical Devices' - the body responsible for approving research studies on
      classified substances, including cannabis. Upon approval and prior to the start
      of the study, a full ethical review will be undertaken. Results may inform a
      regulation model for Germany and other jurisdictions and are expected to deepen
      the understanding of the effects of legal access to cannabis. Pre-registration:
      German Clinical Trials Register (DRKS), DRKS00020829.
CI  - Copyright: (c) 2020 Manthey J et al.
FAU - Manthey, Jakob
AU  - Manthey J
AUID- ORCID: 0000-0003-1231-3760
AD  - Institute of Clinical Psychology and Psychotherapy, Technische Universitat
      Dresden, Dresden, Germany.
AD  - Centre for Interdisciplinary Addiction Research, Department of Psychiatry,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Kalke, Jens
AU  - Kalke J
AD  - Centre for Interdisciplinary Addiction Research, Department of Psychiatry,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Rehm, Jurgen
AU  - Rehm J
AUID- ORCID: 0000-0001-5665-0385
AD  - Institute of Clinical Psychology and Psychotherapy, Technische Universitat
      Dresden, Dresden, Germany.
AD  - Centre for Interdisciplinary Addiction Research, Department of Psychiatry,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
AD  - Institute for Mental Health Policy Research and Campbell Family Mental Health
      Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
AD  - Dalla Lana School of Public Health and Department of Psychiatry, University of
      Toronto, Toronto, ON, Canada.
AD  - Department of International Health Projects, Institute for Leadership and Health 
      Management, I.M. Sechenov First Moscow State Medical University, Moscow, Russian 
      Federation.
FAU - Rosenkranz, Moritz
AU  - Rosenkranz M
AUID- ORCID: 0000-0002-0851-6330
AD  - Centre for Interdisciplinary Addiction Research, Department of Psychiatry,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Verthein, Uwe
AU  - Verthein U
AD  - Centre for Interdisciplinary Addiction Research, Department of Psychiatry,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
SI  - figshare/10.6084/m9.figshare.11903301.v1
SI  - DRKS/DRKS00020829
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200323
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - 0 (Medical Marijuana)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Cannabis/adverse effects
MH  - Dronabinol/*analysis
MH  - Germany
MH  - Humans
MH  - Marijuana Use
MH  - Medical Marijuana/*therapeutic use
MH  - *Recreational Drug Use
PMC - PMC7400698
OTO - NOTNLM
OT  - *Cannabis
OT  - *Germany
OT  - *Marihuana
OT  - *THC
OT  - *legal
OT  - *model study
OT  - *pharmacy
OT  - *prohibition
COIS- No competing interests were disclosed.
EDAT- 2020/10/30 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/10/29 05:52
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/10/29 05:52 [entrez]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - 10.12688/f1000research.22612.2 [doi]
PST - epublish
SO  - F1000Res. 2020 Mar 23;9:201. doi: 10.12688/f1000research.22612.2. eCollection
      2020.


PMID- 33112530
STAT- Publisher
DA  - 20201029
PB  - Canadian Agency for Drugs and Technologies in Health
CTI - CADTH Rapid Response Reports
DP  - 2020 Apr 21
BTI - Primary Care Initiated Gender-Affirming Therapy for Gender Dysphoria: A Review of
      Evidence Based Guidelines
AB  - "Transgender" is an umbrella term used to describe individuals with gender
      diversity. Transgender people include those whose gender identity or expression
      differs from that assigned at birth.(1) Gender dysphoria refers to the discomfort
      or distress caused by the discrepancy between a person's gender identity (their
      psychological sense of themselves as men or women) and the sex assigned at birth 
      and the associated primary or secondary sexual characteristics and/or expected
      social gender role.(2) Changes to social role and presentation are typically
      observed in transgender people. Individuals with gender dysphoria may identify as
      men and women, or as gender variant, transgender, transsexual, transvestite,
      non-gender, pangender, polygender, gender queer, androgyne, neutrois or many
      other terms. The current population estimates of transgender and gender
      nonconforming people range from 0.17 to 1,333 per 100,000 worldwide.(3) In
      British Columbia, the number of transgender people was estimated to be over
      23,157 (based on a prevalence of 0.5%) in 2014.(4) However, the proportion of
      this population is likely underestimated.(5) The pressures associated with
      unmanaged dysphoria and/or the social stigma that can accompany gender diagnosis 
      and transition may result in clinically significant levels of distress that would
      require medical assistance, in particular, specialist experience of the field.(2)
      Historically, medical care for transgender people has been provided in highly
      specialized gender centers, where mental health professionals, endocrinologists
      or other specialists carried out appropriate assessment and subsequent treatment 
      if necessary. These treatments can include a combination of medical (cross-sex
      hormone therapy), surgical (genital reassignment surgery and non-genital surgical
      procedures), mental health and other related treatments and services (e.g. speech
      and voice therapy).(2)(,)(6)(,)(7) However, delayed treatment initiation and
      barriers to access are common, because the specialists are usually located in
      major centers. According to a project in Ontario, approximately 70% of
      transgender people live outside the Greater Toronto Area, although urban centers 
      are often sought out by those who wish to access healthcare.(8) Since the last
      decade, there has been increasing recognition that people with gender dysphoria
      may be well-served in primary care settings and, with additional training, family
      physicians and nurse practitioners may provide some gender-affirming
      services.(2)(,)(7) The role of primary care providers may include performing
      initial examinations, working with referring psychiatrists (to make sure there is
      support available between referral and appointment if needed). Also in the longer
      term, in a primary care setting, physicians can be responsible for the life-long 
      monitoring of their patient's wellbeing, which involves conducting simple
      monitoring tests, examinations and medication reviews as recommended by the
      specialists.(2) In addition to transgender-specific care, transgender people also
      require ongoing primary and preventive care, such as the need for cervical
      screening in transmen and breast cancer screening in transwomen.(6) In this way, 
      transgender-specific healthcare needs are assumed to be addressed in a timely and
      effective manner in the context of primary care.(8) Survey results from a group
      of 11 adult transgender patients in Ontario echoed that most transgender people
      expected care to be delivered by family physicians when it is possible.(9) In
      another interview with 13 physicians from Ontario, the doctors identified
      barriers when providing healthcare services to transgender patients, such as
      challenges accessing resources, a lack of knowledge, ethical considerations
      regarding medical transitioning treatments, or the process of diagnosing gender
      identity disorder.(10) The objective of this report is to review and critically
      appraise the evidence-based clinical practice guidelines regarding primary
      care-initiated gender-affirming therapy for adults with gender dysphoria.
CI  - Copyright (c) 2020 Canadian Agency for Drugs and Technologies in Health.
FAU - Chen, Stella
AU  - Chen S
FAU - Loshak, Hannah
AU  - Loshak H
LA  - eng
PT  - Review
PT  - Book
PL  - Ottawa (ON)
EDAT- 2020/10/29 06:01
MHDA- 2020/10/29 06:01
CDAT- 2020/10/29 06:01
AID - NBK563451 [bookaccession]


PMID- 33113044
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210127
IS  - 1432-1963 (Electronic)
IS  - 0172-8113 (Linking)
VI  - 41
IP  - Suppl 2
DP  - 2020 Dec
TI  - [Perspectives on CAR T-cell treatment].
PG  - 149-154
LID - 10.1007/s00292-020-00819-3 [doi]
AB  - CARTs (T-cells with a chimeric antigen receptor) are one of the most innovative
      and exciting developments in cancer medicine. In August 2018, two novel drugs
      were approved in the European Union, both for the treatment of relapsed and
      refractory aggressive lymphoma, one of them also for the treatment of acute
      lymphoblastic leukemia in children and young adults up to 25 years. In the
      foreseeable future, further approvals are expected, e.g., in mantle cell lymphoma
      and multiple myeloma. Clinical trials with new constructs are ongoing in almost
      all cancer entities. The introduction of this completely new principle implicates
      unusual challenges: (1) The use of genetically modified "living drugs" is
      challenging from a regulatory point of view and might require a lifelong
      surveillance of the patient, (2) companies and authorities make high demands on
      the quality management at the sites, (3) the price of about 280,000euro for the
      approved treatments rises new socioeconomic and ethical questions. However, CARTs
      will change the therapeutic landscape in many cancers in upcoming years.
FAU - Viardot, Andreas
AU  - Viardot A
AD  - Klinik fur Innere Medizin III, Universitatsklinik , Albert-Einstein-Allee 23,
      89081, Ulm, Deutschland. andreas.viardot@uniklinik-ulm.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Perspektiven der CAR-T-Zell-Therapie.
PL  - Germany
TA  - Pathologe
JT  - Der Pathologe
JID - 8006541
RN  - 0 (Antigens, CD19)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Antigens, CD19
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Receptors, Antigen, T-Cell
MH  - Receptors, Chimeric Antigen
MH  - *T-Lymphocytes
OTO - NOTNLM
OT  - Aggressive lymphoma
OT  - Chimeric antigen receptor
OT  - Cytokine release syndrome
OT  - Neurotoxicity
EDAT- 2020/10/29 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/10/28 17:18
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2020/10/28 17:18 [entrez]
AID - 10.1007/s00292-020-00819-3 [doi]
AID - 10.1007/s00292-020-00819-3 [pii]
PST - ppublish
SO  - Pathologe. 2020 Dec;41(Suppl 2):149-154. doi: 10.1007/s00292-020-00819-3.


PMID- 33112829
OWN - NLM
STAT- MEDLINE
DCOM- 20210928
LR  - 20210928
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 27
IP  - 12
DP  - 2020 Dec
TI  - Adiponectin receptor activation inhibits prostate cancer xenograft growth.
PG  - 711-729
LID - 10.1530/ERC-20-0297 [doi]
LID - ERC-20-0297 [pii]
AB  - Adiponectin is an adipokine originally identified as dysregulated in obesity,
      with a key role in insulin sensitisation and in maintaining systemic energy
      balance. However, adiponectin is progressively emerging as having aberrant
      signalling in multiple disease states, including prostate cancer (PCa).
      Circulating adiponectin is lower in patients with PCa than in non-malignant
      disease, and inversely correlates with cancer severity. More severe
      hypoadiponectinemia is observed in advanced PCa than in organ-confined disease.
      Given the crossover between adiponectin signalling and several cancer hallmark
      pathways that influence PCa growth and progression, we hypothesised that
      targeting dysregulated adiponectin signalling may inhibit tumour growth and
      progression. We, therefore, aimed to test the efficacy of correcting the
      hypoadiponectinemia and dysregulated adiponectin signalling observed in PCa, a
      world-first PCa therapeutic approach, using peptide adiponectin receptor (ADIPOR)
      agonist ADP355 in mice bearing subcutaneous LNCaP xenografts. We demonstrate
      significant evidence for PCa growth inhibition by ADP355, which slowed tumour
      growth and delayed progression of serum PCa biomarker, prostate-specific antigen 
      (PSA), compared to vehicle. ADP355 conferred a significant advantage by
      increasing time on treatment with a delayed ethical endpoint. mRNA sequencing and
      protein expression analyses of tumours revealed ADP355 PCa growth inhibition may 
      be through altered cellular energetics, cellular stress and protein synthesis,
      which may culminate in apoptosis, as evidenced by the increased apoptotic marker 
      in ADP355-treated tumours. Our findings highlight the efficacy of ADP355 in
      targeting classical adiponectin-associated signalling pathways in vivo and
      provide insights into the promising future for modulating adiponectin signalling 
      through ADIPOR agonism as a novel anti-tumour treatment modality.
FAU - Philp, Lisa K
AU  - Philp LK
AUID- ORCID: 0000-0001-8365-295X
AD  - Australian Prostate Cancer Research Centre - Queensland, Institute of Health and 
      Biomedical Innovation, School of Biomedical Sciences, Faculty of Health,
      Queensland University of Technology, Princess Alexandra Hospital, Translational
      Research Institute, Brisbane, Queensland, Australia.
FAU - Rockstroh, Anja
AU  - Rockstroh A
AD  - Australian Prostate Cancer Research Centre - Queensland, Institute of Health and 
      Biomedical Innovation, School of Biomedical Sciences, Faculty of Health,
      Queensland University of Technology, Princess Alexandra Hospital, Translational
      Research Institute, Brisbane, Queensland, Australia.
FAU - Lehman, Melanie
AU  - Lehman M
AD  - Australian Prostate Cancer Research Centre - Queensland, Institute of Health and 
      Biomedical Innovation, School of Biomedical Sciences, Faculty of Health,
      Queensland University of Technology, Princess Alexandra Hospital, Translational
      Research Institute, Brisbane, Queensland, Australia.
AD  - Vancouver Prostate Centre, Department of Urologic Sciences, University of British
      Columbia, Vancouver, Canada.
FAU - Sadowski, Martin C
AU  - Sadowski MC
AD  - Australian Prostate Cancer Research Centre - Queensland, Institute of Health and 
      Biomedical Innovation, School of Biomedical Sciences, Faculty of Health,
      Queensland University of Technology, Princess Alexandra Hospital, Translational
      Research Institute, Brisbane, Queensland, Australia.
FAU - Bartonicek, Nenad
AU  - Bartonicek N
AD  - Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
FAU - Wade, John D
AU  - Wade JD
AD  - Florey Institute of Neuroscience and Mental Health, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - School of Chemistry, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Otvos, Laszlo
AU  - Otvos L
AD  - OLPE, LLC, Audubon, Pennsylvania, USA.
AD  - Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary.
FAU - Nelson, Colleen C
AU  - Nelson CC
AD  - Australian Prostate Cancer Research Centre - Queensland, Institute of Health and 
      Biomedical Innovation, School of Biomedical Sciences, Faculty of Health,
      Queensland University of Technology, Princess Alexandra Hospital, Translational
      Research Institute, Brisbane, Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - 0 (Receptors, Adiponectin)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Prostatic Neoplasms/*therapy
MH  - Receptors, Adiponectin/*therapeutic use
OTO - NOTNLM
OT  - *ADP355
OT  - *adiponectin
OT  - *adiponectin receptor agonist
OT  - *peptide drug
OT  - *prostate cancer
EDAT- 2020/10/29 06:00
MHDA- 2021/09/29 06:00
CRDT- 2020/10/28 17:16
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/09/29 06:00 [medline]
PHST- 2020/10/28 17:16 [entrez]
AID - 10.1530/ERC-20-0297 [doi]
AID - ERC-20-0297.R1 [pii]
PST - ppublish
SO  - Endocr Relat Cancer. 2020 Dec;27(12):711-729. doi: 10.1530/ERC-20-0297.


PMID- 33112758
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 11
DP  - 2020 Nov 19
TI  - Status of Institutional Review Board Meetings Conducted Through Web Conference
      Systems in Japanese National University Hospitals During the COVID-19 Pandemic:
      Questionnaire Study.
PG  - e22302
LID - 10.2196/22302 [doi]
AB  - BACKGROUND: With the global proliferation of the novel COVID-19 disease,
      conventionally conducting institutional review board (IRB) meetings has become a 
      difficult task. Amid concerns about the suspension of drug development due to
      delays within IRBs, it has been suggested that IRB meetings should be temporarily
      conducted via the internet. OBJECTIVE: This study aimed to elucidate the current 
      status of IRB meetings conducted through web conference systems. METHODS: A
      survey on conducting IRB meetings through web conference systems was administered
      to Japanese national university hospitals. Respondents were in charge of
      operating IRB offices at different universities. This study was not a randomized 
      controlled trial. RESULTS: The survey was performed at 42 facilities between the 
      end of May and early June, 2020, immediately after the state of emergency was
      lifted in Japan. The survey yielded a response rate of 74% (31/42). Additionally,
      while 68% (21/31) of facilities introduced web conference systems for IRB
      meetings, 13% (4/31) of the surveyed facilities postponed IRB meetings.
      Therefore, we conducted a further survey of 21 facilities that implemented web
      conference systems for IRB meetings. According to 71% (15/21) of the respondents,
      there was no financial burden for implementing these systems, as they were free
      of charge. In 90% (19/21) of the facilities, IRB meetings through web conference 
      systems were already being conducted with personal electronic devices.
      Furthermore, in 48% (10/21) of facilities, a web conference system was used in
      conjunction with face-to-face meetings. CONCLUSIONS: Due to the COVID-19
      pandemic, the number of reviews in clinical trial core hospitals has decreased.
      This suggests that the development of pharmaceuticals has stagnated because of
      COVID-19. According to 71% (15/21) of the respondents who conducted IRB meetings 
      through web conference systems, the cost of introducing such meetings was US $0, 
      showing a negligible financial burden. Moreover, it was shown that online
      deliberations could be carried out in the same manner as face-to-face meetings,
      as 86% (18/21) of facilities stated that the number of comments made by board
      members did not change. To improve the quality of IRB meetings conducted through 
      web conference systems, it is necessary to further examine camera use and the
      content displayed on members' screens during meetings. Further examination of all
      members who use web conference systems is required. Our measures for addressing
      the requests and problems identified in our study could potentially be considered
      protocols for future IRB meetings, when the COVID-19 pandemic has passed and
      face-to-face meetings are possible again. This study also highlights the
      importance of developing web conference systems for IRB meetings to respond to
      future unforeseen pandemics.
CI  - (c)Kenta Yagi, Kazuki Maeda, Satoshi Sakaguchi, Masayuki Chuma, Yasutaka Sato,
      Chikako Kane, Akiyo Akaishi, Keisuke Ishizawa, Hiroaki Yanagawa. Originally
      published in the Journal of Medical Internet Research (http://www.jmir.org),
      19.11.2020.
FAU - Yagi, Kenta
AU  - Yagi K
AUID- ORCID: 0000-0003-0869-5786
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Maeda, Kazuki
AU  - Maeda K
AUID- ORCID: 0000-0002-3930-2052
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Sakaguchi, Satoshi
AU  - Sakaguchi S
AUID- ORCID: 0000-0002-8916-636X
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Chuma, Masayuki
AU  - Chuma M
AUID- ORCID: 0000-0002-5755-283X
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Sato, Yasutaka
AU  - Sato Y
AUID- ORCID: 0000-0001-8179-2211
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Kane, Chikako
AU  - Kane C
AUID- ORCID: 0000-0001-9455-1505
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Akaishi, Akiyo
AU  - Akaishi A
AUID- ORCID: 0000-0002-3621-5156
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
FAU - Ishizawa, Keisuke
AU  - Ishizawa K
AUID- ORCID: 0000-0003-1971-7696
AD  - Department of Clinical Pharmacology and Therapeutics, Tokushima University
      Graduate School of Biomedical Sciences, Kuramoto-cho, Tokushima, Japan.
AD  - Department of Pharmacy, Tokushima University Hospital, Kuramoto-cho, Tokushima,
      Japan.
FAU - Yanagawa, Hiroaki
AU  - Yanagawa H
AUID- ORCID: 0000-0002-6734-2262
AD  - Clinical Research Center for Developmental Therapeutics, Tokushima University
      Hospital, Tokushima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201119
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Ethics Committees, Research/organization & administration/*statistics & numerical
      data
MH  - *Hospitals, University
MH  - Humans
MH  - *Internet
MH  - Japan/epidemiology
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - *Surveys and Questionnaires
MH  - Videoconferencing/organization & administration/*statistics & numerical data
PMC - PMC7683025
OTO - NOTNLM
OT  - *COVID-19
OT  - *IRB
OT  - *Institutional Review Board
OT  - *Japan
OT  - *REB
OT  - *Research Ethics Board
OT  - *clinical trial
OT  - *drug development
OT  - *hospital
OT  - *survey
OT  - *teleconference
OT  - *web conference
EDAT- 2020/10/29 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/10/28 17:15
PHST- 2020/07/08 00:00 [received]
PHST- 2020/10/26 00:00 [accepted]
PHST- 2020/08/06 00:00 [revised]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/10/28 17:15 [entrez]
AID - v22i11e22302 [pii]
AID - 10.2196/22302 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Nov 19;22(11):e22302. doi: 10.2196/22302.


PMID- 33112204
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Dec
TI  - A Revolution by Stealth: A Legal-Ethical Analysis of the Rise of Pre-Conception
      Authorization of Surrogacy Agreements.
PG  - 351-371
LID - 10.1080/20502877.2020.1836464 [doi]
AB  - This article offers a legal-ethical analysis of recent UK and Dutch proposals to 
      regulate surrogacy proactively through a national system of pre-conception
      authorization of surrogacy agreements. Within such a system, authorities are
      already before conception called upon to examine and assess contractual
      arrangements between the intending parents and the prospective surrogate mother. 
      This regulatory approach is presented by its advocates as a win-win for all
      parties involved; as bringing family law in line with the changed social reality 
      of creating families; and as maintaining a non-permissive approach toward
      commercial surrogacy. In this article, we critically examine these claims. Our
      analysis suggests that the proposed systems may result in the facilitation of
      surrogacy practices with commercial, commodifying and exploitative dimensions.
      Moreover, although these frameworks are presented as merely regulating something 
      that is already taking place, they silently introduce a radically new and, as we 
      shall argue, highly problematic legal-ethical approach to surrogacy.
FAU - van Beers, Britta
AU  - van Beers B
AUID- ORCID: https://orcid.org/0000-0002-4766-1709
AD  - Department of Legal Philosophy, Faculty of Law, Vrije Universiteit, Amsterdam,
      Netherlands.
FAU - Bosch, Laura
AU  - Bosch L
AD  - Independent researcher on children's rights, Utrecht, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - *Ethical Analysis
MH  - Female
MH  - Humans
MH  - Morals
MH  - Pregnancy
MH  - Prospective Studies
MH  - *Surrogate Mothers
OTO - NOTNLM
OT  - commodification
OT  - contract
OT  - regulation
OT  - reproductive market
OT  - surrogacy
EDAT- 2020/10/29 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/10/28 12:10
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/10/28 12:10 [entrez]
AID - 10.1080/20502877.2020.1836464 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Dec;26(4):351-371. doi: 10.1080/20502877.2020.1836464. Epub 2020
      Oct 28.


PMID- 33111409
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210528
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 10
DP  - 2020 Oct
TI  - Death, dying and donation: community perceptions of brain death and their
      relationship to decisions regarding withdrawal of vital organ support and organ
      donation.
PG  - 1192-1201
LID - 10.1111/imj.15028 [doi]
AB  - Despite brain death (BD) being established as a definition of death for over 50
      years, the concept remains controversial. Little is known about public perception
      of death determination in decision-making about withdrawal of organ support and
      organ donation (OD), and the importance of the 'Dead Donor Rule' (DDR). We
      examined perceptions about death in a BD patient and their relationship to
      decisions about withdrawal of vital organ support, OD and the DDR, using an
      online survey of 1017 Australian adults. A BD patient scenario was presented,
      followed by a series of questions. Statistically significant differences in
      responses were determined using repeated measures analyses of variance and t
      tests. Seven hundred and fourteen respondents (70.2%) agreed that a hypothetical 
      BD patient was dead. Those disagreeing most commonly cited the presence of
      heartbeat and breathing. Seven hundred and seventy (75.7%) favoured removal of
      'life support', including 136 (13.3%) who had not agreed the patient was dead.
      Support for OD was high, but most favoured organ removal only after heartbeat and
      breathing had ceased. Where OD was in keeping with the patient's known wishes,
      464 (45.6%) agreed that organs could be removed even if this caused death.
      Forty-one (20%) of those who had indicated they considered the patient was not
      dead agreed to organ removal even if it caused death. Australian public views on 
      BD, withdrawal of 'life support' and OD are complex. Emphasis on prognosis and
      the impact of significant brain injury may be more appropriate in these
      situations, rather than focussing on death determination and upholding the DDR.
CI  - (c) 2020 Royal Australasian College of Physicians.
FAU - Skowronski, George
AU  - Skowronski G
AUID- ORCID: 0000-0002-1748-1897
AD  - Sydney Health Ethics, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - O'Leary, Michael J
AU  - O'Leary MJ
AD  - Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
FAU - Critchley, Christine
AU  - Critchley C
AD  - School of Health Sciences, Swinburne University of Technology, Melbourne,
      Victoria, Australia.
FAU - O'Reilly, Lisa
AU  - O'Reilly L
AD  - South East Sydney Local Health District, Kogarah, New South Wales, Australia.
FAU - Forlini, Cynthia
AU  - Forlini C
AD  - School of Medicine, Deakin University, Geelong, Victoria, Australia.
FAU - Ghinea, Narcyz
AU  - Ghinea N
AD  - Sydney Health Ethics, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Sheahan, Linda
AU  - Sheahan L
AD  - Sydney Health Ethics, University of Sydney, Camperdown, New South Wales,
      Australia.
FAU - Stewart, Cameron
AU  - Stewart C
AD  - Law School, University of Sydney, Camperdown, New South Wales, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, University of Sydney, Camperdown, New South Wales,
      Australia.
LA  - eng
GR  - Sydney Medical School Foundation
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
CIN - Intern Med J. 2021 Apr;51(4):626. PMID: 33890373
MH  - Adult
MH  - Australia/epidemiology
MH  - *Brain Death
MH  - Death
MH  - Humans
MH  - Perception
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *brain death
OT  - *ethics
OT  - *intensive care
OT  - *organ donation
OT  - *transplantation
EDAT- 2020/10/29 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/28 05:45
PHST- 2020/05/26 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/10/28 05:45 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1111/imj.15028 [doi]
PST - ppublish
SO  - Intern Med J. 2020 Oct;50(10):1192-1201. doi: 10.1111/imj.15028.


PMID- 33111347
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1938-3711 (Electronic)
IS  - 0022-5002 (Linking)
VI  - 114
IP  - 3
DP  - 2020 Nov
TI  - Single-case experimental designs for behavioral neuroscience.
PG  - 447-467
LID - 10.1002/jeab.633 [doi]
AB  - Single-case experimental designs (SCEDs) are commonly used in behavior analytic
      research but rarely used in behavioral neuroscience research. The recent
      development of technologies that allow control of the timing of neurobiological
      events such as gene expression and neuronal firing enable the fruitful
      application of SCEDs for the study of brain-behavior relations. There are at
      least 3 benefits expected from applying SCEDs to study how neurobiological events
      affect behavior. First, SCEDs entail direct within- and across-subject
      assessments of reliability, likely increasing the probability of replication
      across studies and encouraging a search for the causes of replication failure
      when they occur. Second, SCEDs focus on behavior in individual organisms
      producing a body of knowledge that applies to individuals rather than population 
      parameters. Finally, SCEDs require fewer animals, decreasing costs and effort and
      addressing the ethical obligation to reduce the number of animals used for
      research. Examples are provided using hypothetical data generated based on
      published research. Collaborations between behavior analysts and behavioral
      neuroscientists will bring the world within the skin under direct experimental
      control and broaden our understanding of the determinants of behavior.
CI  - (c) 2020 Society for the Experimental Analysis of Behavior.
FAU - Soto, Paul L
AU  - Soto PL
AUID- ORCID: 0000-0003-2930-6479
AD  - Department of Psychology, Louisiana State University.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - United States
TA  - J Exp Anal Behav
JT  - Journal of the experimental analysis of behavior
JID - 0203727
SB  - IM
MH  - Animals
MH  - Behavior, Animal
MH  - Behavioral Research/*methods
MH  - Cross-Over Studies
MH  - Gene Expression
MH  - Gene Transfer Techniques
MH  - Genetic Engineering
MH  - Humans
MH  - Neurosciences/*methods
MH  - Optogenetics
MH  - Reproducibility of Results
MH  - Single-Case Studies as Topic/*methods
OTO - NOTNLM
OT  - *DREADD
OT  - *behavioral neuroscience
OT  - *gene expression
OT  - *optogenetic
OT  - *single-case experimental designs
EDAT- 2020/10/29 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/10/28 05:44
PHST- 2020/05/29 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/04 00:00 [accepted]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/10/28 05:44 [entrez]
AID - 10.1002/jeab.633 [doi]
PST - ppublish
SO  - J Exp Anal Behav. 2020 Nov;114(3):447-467. doi: 10.1002/jeab.633. Epub 2020 Oct
      27.


PMID- 33110842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug
TI  - Knowledge & awareness of burn first aid among health-care workers in Saudi
      Arabia: Are health-care workers in need for an effective educational program?
PG  - 4259-4264
LID - 10.4103/jfmpc.jfmpc_811_20 [doi]
AB  - OBJECTIVE: The objective of this study was to assess the level of awareness and
      knowledge of first aid for burns among healthcare workers in Saudi Arabia.
      METHODS: We conducted a cross-sectional study between September 2 and December 5,
      2019, via a self-administered online questionnaire among healthcare workers at a 
      university hospital. The questionnaire comprised 24 questions divided into two
      sections pertaining to demographics and first aid for burns. This study was
      approved by the Research Ethics Committee. RESULTS: We included 1,438 respondents
      in this study. Females comprised 68.2% (982) of the respondents. A total of 513
      respondents (35.7%) were medical students. The mean burn knowledge score of all
      respondents was 8.07 +/- 2.03 out of 13. Interestingly, 940 individuals (65.4%)
      used traditional medications on the burn area. Knowledge regarding antibiotic use
      in burn injuries was poor-1,199 (82.3%) study participants agreed that
      antibiotics are beneficial in the case of burns, which is a wrong act. The mean
      knowledge score was significantly different across groups of different ages,
      sexes, nationalities, marital statuses, and job positions (P < 0.001).
      CONCLUSION: The level of awareness of first aid for burn patients among
      healthcare workers was insufficient, and the unnecessary use of traditional
      medicines and antibiotics in burn patients being high. Moreover, this study
      confirmed the need for an effective educational program among healthcare workers.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Mortada, Hatan
AU  - Mortada H
AD  - Department of Plastic Surgery and Burn Unit, King Saud Medical City, Riyadh,
      Saudi Arabia.
FAU - Malatani, Nader
AU  - Malatani N
AD  - Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Aljaaly, Hattan
AU  - Aljaaly H
AD  - Division of Plastic and Reconstructive Surgery, Department of Surgery, King
      Abdulaziz University, Jeddah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7586629
OTO - NOTNLM
OT  - Assessment: traditional remedies
OT  - awareness
OT  - burn first aid
OT  - healthcare workers
OT  - knowledge
COIS- There are no conflicts of interest.
EDAT- 2020/10/29 06:00
MHDA- 2020/10/29 06:01
CRDT- 2020/10/28 05:41
PHST- 2020/05/09 00:00 [received]
PHST- 2020/06/14 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/10/28 05:41 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/10/29 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_811_20 [doi]
AID - JFMPC-9-4259 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Jun 25;9(8):4259-4264. doi:
      10.4103/jfmpc.jfmpc_811_20. eCollection 2020 Aug.


PMID- 33110840
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug
TI  - Preparedness, perceived impact and concerns of health care workers in a teaching 
      hospital during coronavirus disease 2019 (COVID-19).
PG  - 4247-4251
LID - 10.4103/jfmpc.jfmpc_799_20 [doi]
AB  - OBJECTIVE: Coronavirus Disease 2019 is a new threat to human lives worldwide.
      Preparedness of institutions during epidemic outbreak has a pivotal role in
      saving lives and preventing further spread. At the same time, these pandemics
      impact badly on professional and personal life of Health care workers. The
      objective of this study is to find the opinion of Health care workers regarding
      their level of preparedness, concerns and perceived impact related to this
      pandemic outbreak. MATERIALS AND METHODS: In this study, random samples of
      doctors and nurses was provided with a self-administered questionnaire regarding 
      their preparedness, work and non-work related concerns and impact on their lives 
      during Covid-19 outbreak. RESULTS: Most of the Health Care Workers believed that 
      their institute preparation to fight Covid-19 pandemic is better than prior to
      onset of this crisis (P < 0.001). Work related stress was seen more commonly in
      nurses whereas higher frequency of non-work related stress was observed among
      doctors. Nurses (75.55%) faith in their employer was more than doctors faith
      (46.66%) regarding their medical needs. There was more acceptance of
      hydroxychloroquine as a prophylactic drug for Covid-19 in doctors compared to
      nurses (P < 0.01). CONCLUSIONS: Though this institute was more prepared at the
      time of pandemic spread, substantial opportunity of improvement remains. The
      consistency of work and non work related anxiety and stress in health care
      workers is very high in present study group. Concerns and risks of Health Care
      Workers should be addressed ethically and adequately by strengthening safety
      measures and building trust in the system they work.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Saurabh, Kumar
AU  - Saurabh K
AD  - Department of Pediatrics, Government Medical College, Bettiah, Bihar, India.
FAU - Ranjan, Shilpi
AU  - Ranjan S
AD  - Department of Community Medicine, Nalanda Medical College and Hospital, Patna,
      Bihar, India.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7586576
OTO - NOTNLM
OT  - Anxiety
OT  - COVID-19
OT  - HCW
OT  - hydroxychloroquine
OT  - pandemic
OT  - preparedness
OT  - stress
COIS- There are no conflicts of interest.
EDAT- 2020/10/29 06:00
MHDA- 2020/10/29 06:01
CRDT- 2020/10/28 05:41
PHST- 2020/05/07 00:00 [received]
PHST- 2020/06/14 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/10/28 05:41 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/10/29 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_799_20 [doi]
AID - JFMPC-9-4247 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Aug 25;9(8):4247-4251. doi:
      10.4103/jfmpc.jfmpc_799_20. eCollection 2020 Aug.


PMID- 33110806
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug
TI  - Hypertension in pediatric patients admitted to inpatient ward at King Abdulaziz
      Universty Hospital in Saudi Arabia: Prevalence, causes, and outcomes.
PG  - 4031-4038
LID - 10.4103/jfmpc.jfmpc_214_20 [doi]
AB  - BACKGROUND: The secondary hypertension (HTN) is the predominant form of HTN in
      pediatrics. Renal diseases and renovascular anomalies are the most commonly
      reported causes. In this study, we aimed to identify the prevalence, causes, and 
      outcomes of secondary HTN in Saudi Arabia. METHODS: A retrospective study was
      conducted among 3,640 pediatric patients aged between 0 and 18 years, admitted to
      the pediatric nephrology ward at King Abdulaziz University Hospital, Jeddah,
      Saudi Arabia. The study has been approved by the ethics review committee of King 
      Abdulaziz University. RESULTS: Prevalence of secondary HTN due to renal disease
      was (77.0%). Most of the cases were diagnosed with stage 5 renal disease (78.3%).
      Small kidney size was frequently diagnosed (n = 29, 11.9%), followed by large
      kidney size (n = 26, 10.7%). One third of the cases (n = 79, 32.4%) were under
      control, 49 (20.1%) lost follow-up, and 24 (10.1%) deceased. A total of 61
      (33.1%) patients progressed to end-stage renal disease and patientswere managed
      by different types of treatments. CONCLUSION: The prevalence of secondary HTN due
      to renal disease is considered to be high in pediatric patients admitted to King 
      Abdulaziz University. Several renal diseases in the renal system are associated
      with secondary HTN mostly attriubuted to renal malformation. In addition, renal
      affection, cerebral infarction, bleeding, left ventricular hypertrophy, and
      valvular lesion are the highest reported complications in our population.
      Follow-up with ECHO and brain CT is highly recommended in pediatric HTN. Future
      studies on a larger sample and vigorous follow-up are recommended.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Safdar, Osama
AU  - Safdar O
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - AlJehani, Reham
AU  - AlJehani R
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - Aljuhani, Mohammed
AU  - Aljuhani M
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - AlGhamdi, Hajar
AU  - AlGhamdi H
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - Asiri, Arub
AU  - Asiri A
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - AlGhofaily, Oyoon
AU  - AlGhofaily O
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - Hisan, Fatimah
AU  - Hisan F
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - Altabsh, Ghidah
AU  - Altabsh G
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7586632
OTO - NOTNLM
OT  - Hypertension
OT  - inpatient
OT  - outcomes
OT  - pediatric
COIS- There are no conflicts of interest.
EDAT- 2020/10/29 06:00
MHDA- 2020/10/29 06:01
CRDT- 2020/10/28 05:41
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/10/28 05:41 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/10/29 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_214_20 [doi]
AID - JFMPC-9-4031 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Aug 25;9(8):4031-4038. doi:
      10.4103/jfmpc.jfmpc_214_20. eCollection 2020 Aug.


PMID- 33110720
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201029
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 22
TI  - Role of Serum Markers in Combination as a Diagnostic Tool for Acute Pulmonary
      Embolism: Cross-Sectional Study.
PG  - e10584
LID - 10.7759/cureus.10584 [doi]
AB  - Background and objective Acute pulmonary embolism (APE) is a serious
      cardiovascular emergency, mainly secondary to deep vein thrombosis (DVT), which
      causes death. The goal of the current study was to determine the levels of
      different serum markers in combination among patients with and without acute
      pulmonary embolism in order to use them as a diagnostic tool. Methodology A
      sample of 96 patients was kept with a 90% power of study and a 5% level of
      significance in the current study. It was carried from January to June 2020 in
      the Department of Medicine, Bahawal Victoria Hospital, Bahawalpur, after the
      hospital's Ethical Committee approval. Written informed consent was taken. Serum 
      levels of C-reactive protein (CRP), D-dimer, fibrinogen, and Troponin-I between
      both groups were done once enrolled. SPSS software, version 25 (IBM Corp. Armonk,
      NY) was used to analyze the collected data. Results Patients with acute pulmonary
      embolism had a mean age of 50.4 +/- 10.4 years. All serum markers were
      significantly raised in patients suffering from acute pulmonary embolism with a
      p-value of <0.05. Conclusion We concluded that all these serum markers can be
      used together as a tool in making the correct diagnosis of acute pulmonary
      embolism in our setup.
CI  - Copyright (c) 2020, Yousuf et al.
FAU - Yousuf, Muhammad Sr
AU  - Yousuf M Sr
AD  - Pathology, Quaid-e-Azam Medical College, Bahawalpur, PAK.
FAU - Reza, Sara
AU  - Reza S
AD  - Pathology, Quaid-e-Azam Medical College, Bahawalpur, PAK.
FAU - Zafar, Saleha
AU  - Zafar S
AD  - Pathology, Quaid-e-Azam Medical College, Bahawalpur, PAK.
FAU - Noor, Shehnaz
AU  - Noor S
AD  - Pathology, Quaid-e-Azam Medical College, Bahawalpur, PAK.
FAU - Sarfraz, Lubna
AU  - Sarfraz L
AD  - Pathology, Quaid-e-Azam Medical College, Bahawalpur, PAK.
FAU - Iqbal, Muhammad
AU  - Iqbal M
AD  - Cardiology, Cardiac Centre, Bahawalpur, PAK.
FAU - Laique, Talha
AU  - Laique T
AD  - Pharmacology, Lahore Medical and Dental College, Lahore, PAK.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7580984
OTO - NOTNLM
OT  - acute pulmonary embolism
OT  - serum markers
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/29 06:00
MHDA- 2020/10/29 06:01
CRDT- 2020/10/28 05:41
PHST- 2020/10/28 05:41 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/10/29 06:01 [medline]
AID - 10.7759/cureus.10584 [doi]
PST - epublish
SO  - Cureus. 2020 Sep 22;12(9):e10584. doi: 10.7759/cureus.10584.


PMID- 33110524
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 2047-2986 (Electronic)
IS  - 2047-2978 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Dec
TI  - Addressing methodological and ethical issues in practicing health economic
      evaluation in China.
PG  - 020322
LID - 10.7189/jogh.10.020322 [doi]
FAU - Jiang, Shan
AU  - Jiang S
AD  - School of Population and Public Health, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Chen, Zhuo
AU  - Chen Z
AD  - Department of Health Policy and Management, College of Public Health, University 
      of Georgia, Athens, Georgia, USA.
AD  - School of Economics, Faculty of Humanities and Social Sciences, University of
      Nottingham Ningbo China, Ningbo, China.
FAU - Wu, Jing
AU  - Wu J
AD  - School of Pharmaceutical Science and Technology, Tianjin University, Tianjin,
      China.
FAU - Zang, Xiao
AU  - Zang X
AD  - Department of Epidemiology, School of Public Health, Brown University,
      Providence, Rhode Island, USA.
FAU - Jiang, Yawen
AU  - Jiang Y
AD  - School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Scotland
TA  - J Glob Health
JT  - Journal of global health
JID - 101578780
SB  - IM
MH  - China
MH  - *Cost-Benefit Analysis
MH  - Health Care Sector/*economics
MH  - Humans
PMC - PMC7561214
COIS- Competing interests: ZC has a consulting agreement with Janssen Scientific
      Affairs (Project #: 1021RR771080). The sponsor had no roles in this research. The
      authors completed the ICMJE Unified Competing Interest form (available upon
      request from the corresponding author) and declare no further conflicts of
      interest.
EDAT- 2020/10/29 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/10/28 05:40
PHST- 2020/10/28 05:40 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
AID - 10.7189/jogh.10.020322 [doi]
AID - jogh-10-020322 [pii]
PST - ppublish
SO  - J Glob Health. 2020 Dec;10(2):020322. doi: 10.7189/jogh.10.020322.


PMID- 33110502
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201218
IS  - 2047-2986 (Electronic)
IS  - 2047-2978 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Dec
TI  - The ethics and value of contact tracing apps: International insights and
      implications for Scotland's COVID-19 response.
PG  - 020103
LID - 10.7189/jogh.10.020103 [doi]
AB  - The COVID-19 pandemic has put health systems, economies and societies under
      unprecedented strain, calling for innovative approaches. Scotland's government,
      like those elsewhere, is facing difficult decisions about how to deploy digital
      technologies and data to help contain, control and manage the disease, while also
      respecting citizens' rights. This paper explores the ethical challenges presented
      by these methods, with particular emphasis on mobile apps associated with contact
      tracing. Drawing on UK and international experiences, it examines issues such as 
      public trust, data privacy and technology design; how changing disease threats
      and contextual factors can affect the balance between public benefits and risks; 
      and the importance of transparency, accountability and stakeholder participation 
      for the trustworthiness and good-governance of digital systems and strategies.
      Analysis of recent technology debates, controversial programmes and emerging
      outcomes in comparable countries implementing contact tracing apps, reveals
      sociotechnical complexities and unexpected paradoxes that warrant further study
      and underlines the need for holistic, inclusive and adaptive strategies. The
      paper also considers the potential role of these apps as Scotland transitions to 
      the 'new normal', outlines challenges and opportunities for public engagement,
      and poses a set of ethical questions to inform decision-making at multiple
      levels, from software design to institutional governance.
CI  - Copyright (c) 2020 by the Journal of Global Health. All rights reserved.
FAU - Pagliari, Claudia
AU  - Pagliari C
AD  - Usher Institute/Edinburgh Global Health Academy, The University of Edinburgh,
      Edinburgh, UK.
LA  - eng
PT  - Editorial
PL  - Scotland
TA  - J Glob Health
JT  - Journal of global health
JID - 101578780
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Contact Tracing/*ethics/methods
MH  - Coronavirus Infections/prevention & control
MH  - Disease Transmission, Infectious/*ethics/prevention & control
MH  - Government
MH  - Human Rights/*ethics
MH  - Humans
MH  - Mobile Applications/*ethics
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/prevention & control
MH  - SARS-CoV-2
MH  - Scotland/epidemiology
MH  - Stakeholder Participation
MH  - Technology/ethics
PMC - PMC7510337
COIS- Competing interests: The author is an advisor to the Scottish Government and
      chairs the national expert group on Digital Ethics. She is also an advisor to the
      World Health Organisation on Digital Health and a theme leader of the NHS Digital
      Academy. Interpretations and opinions expressed in this paper are her own. The
      author has completed the ICMJE Unified Competing Interest form (available upon
      request) and declares no further conflicts of interest.
EDAT- 2020/10/29 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/28 05:40
PHST- 2020/10/28 05:40 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.7189/jogh.10.020103 [doi]
AID - jogh-10-020103 [pii]
PST - ppublish
SO  - J Glob Health. 2020 Dec;10(2):020103. doi: 10.7189/jogh.10.020103.


PMID- 33110258
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201222
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 586
IP  - 7831
DP  - 2020 Oct
TI  - Can lab-grown brains become conscious?
PG  - 658-661
LID - 10.1038/d41586-020-02986-y [doi]
FAU - Reardon, Sara
AU  - Reardon S
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Cell Stem Cell. 2019 Oct 3;25(4):558-569.e7. PMID: 31474560
MH  - Brain
MH  - *Consciousness
MH  - Humans
MH  - *Organoids
OTO - NOTNLM
OT  - *Ethics
OT  - *Neuroscience
OT  - *Philosophy
EDAT- 2020/10/29 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/10/28 05:38
PHST- 2020/10/28 05:38 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 10.1038/d41586-020-02986-y [doi]
AID - 10.1038/d41586-020-02986-y [pii]
PST - ppublish
SO  - Nature. 2020 Oct;586(7831):658-661. doi: 10.1038/d41586-020-02986-y.


PMID- 33110257
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 586
IP  - 7831
DP  - 2020 Oct
TI  - Myanmar amber fossils: a legal as well as ethical quagmire.
PG  - 674
LID - 10.1038/d41586-020-03006-9 [doi]
FAU - Barrett, Paul M
AU  - Barrett PM
FAU - Johanson, Zerina
AU  - Johanson Z
LA  - eng
PT  - Letter
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 0 (Amber)
SB  - IM
MH  - *Amber
MH  - Animals
MH  - *Fossils
MH  - Myanmar
MH  - Paleontology/*ethics/*legislation & jurisprudence
MH  - Primates
OTO - NOTNLM
OT  - *Palaeontology
OT  - *Politics
OT  - *Publishing
EDAT- 2020/10/29 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/10/28 05:38
PHST- 2020/10/28 05:38 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 10.1038/d41586-020-03006-9 [doi]
AID - 10.1038/d41586-020-03006-9 [pii]
PST - ppublish
SO  - Nature. 2020 Oct;586(7831):674. doi: 10.1038/d41586-020-03006-9.


PMID- 33109679
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Efficacy and safety of oral hydroxyurea in transfusion-dependent
      beta-thalassaemia: a protocol for randomised double-blind controlled clinical
      trial.
PG  - e041958
LID - 10.1136/bmjopen-2020-041958 [doi]
AB  - INTRODUCTION: Despite being one of the first diseases to be genetically
      characterised, beta-thalassaemia remains a disorder without a cure in a majority 
      of patients. Most patients with beta-thalassaemia receive only supportive
      treatment and therefore have a poor quality of life and shorter life spans.
      Hydroxyurea, which has shown to induce fetal haemoglobin synthesis in human
      erythroid cells, is currently recommended for the treatment of sickle cell
      disease. However, its clinical usefulness in transfusion-dependent
      beta-thalassaemia is unclear. Here, we present a protocol for a randomised
      double-blind controlled clinical trial to evaluate the efficacy and safety of
      oral hydroxyurea in transfusion-dependent beta-thalassaemia. METHODS AND
      ANALYSIS: This single-centre randomised double-blind placebo-controlled clinical 
      trial is conducted at the Thalassaemia Centre of Colombo North Teaching Hospital,
      Ragama, Sri Lanka. Adult and adolescent patients with haematologically and
      genetically confirmed transfusion-dependent beta-thalassaemia are enrolled and
      randomised into the intervention or control group. The intervention group
      receives oral hydroxyurea 10-20 mg/kg daily for 6 months, while the control group
      receives a placebo which is identical in size, shape and colour to hydroxyurea
      without its active ingredient. Transfused blood volume, pretransfusion
      haemoglobin level, fetal haemoglobin percentage and adverse effects of treatment 
      are monitored during treatment and 6 months post-treatment. Cessation or
      reduction of blood transfusions during the treatment period will be the primary
      outcome measure. The statistical analysis will be based on intention to treat.
      ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Ethics
      Committee of Faculty of Medicine, University of Kelaniya (P/116/05/2018) and the 
      trial is approved by the National Medicinal Regulatory Authority of Sri Lanka.
      Results of the trial will be disseminated in scientific publications in reputed
      journals. TRIAL REGISTRATION NUMBER: SLCTR/2018/024; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yasara, Nirmani
AU  - Yasara N
AD  - Department of Paediatrics, University of Kelaniya, Ragama, Sri Lanka.
FAU - Wickramarathne, Nethmi
AU  - Wickramarathne N
AD  - Department of Paediatrics, University of Kelaniya, Ragama, Sri Lanka.
FAU - Mettananda, Chamila
AU  - Mettananda C
AD  - Department of Pharmacology, University of Kelaniya, Ragama, Sri Lanka.
FAU - Manamperi, Aresha
AU  - Manamperi A
AD  - Molecular Medicine Unit, University of Kelaniya, Ragama, Sri Lanka.
FAU - Premawardhena, Anuja
AU  - Premawardhena A
AD  - Department of Medicine, University of Kelaniya, Ragama, Sri Lanka.
AD  - Colombo North Teaching Hospital, Ragama, Sri Lanka.
FAU - Mettananda, Sachith
AU  - Mettananda S
AUID- ORCID: 0000-0002-0760-0418
AD  - Department of Paediatrics, University of Kelaniya, Ragama, Sri Lanka
      sachith.mettananda@kln.ac.lk.
AD  - Colombo North Teaching Hospital, Ragama, Sri Lanka.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Double-Blind Method
MH  - Humans
MH  - Hydroxyurea
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Sri Lanka
MH  - *Thalassemia
MH  - *beta-Thalassemia/drug therapy
PMC - PMC7592299
OTO - NOTNLM
OT  - *anaemia
OT  - *clinical trials
OT  - *genetics
OT  - *haematopathology
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041958 [pii]
AID - 10.1136/bmjopen-2020-041958 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e041958. doi: 10.1136/bmjopen-2020-041958.


PMID- 33109675
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Surgical treatment for colorectal cancer: analysis of the influence of an
      enhanced recovery programme on long-term oncological outcomes-a study protocol
      for a prospective, multicentre, observational cohort study.
PG  - e040316
LID - 10.1136/bmjopen-2020-040316 [doi]
AB  - INTRODUCTION: The evidence currently available from enhanced recovery after
      surgery (ERAS) programmes concerns their benefits in the immediate postoperative 
      period, but there is still very little evidence as to whether their correct
      implementation benefits patients in the long term. The working hypothesis here is
      that, due to the lower response to surgical aggression and lower rates of
      postoperative complications, ERAS protocols can reduce colorectal cancer-related 
      mortality. The main objective of this study is to analyse the impact of an ERAS
      programme for colorectal cancer on 5-year survival. As secondary objectives, we
      propose to analyse the weight of each of the predefined items in the oncological 
      results as well as the quality of life. METHODS AND ANALYSIS: A multicentre
      prospective cohort study was conducted in patients older than 18 years of age who
      are scheduled to undergo surgery for colorectal cancer. The study involved 12
      hospitals with an implemented enhanced recovery protocol according to the
      guidelines published by the Spanish National Health Service. The intervention
      group includes patients with a minimum implementation level of 70%, and the
      control group includes those who fail to reach this level. Compliance will be
      studied using 18 key performance indicators, and the results will be analysed
      using cancer survival indicators, including overall survival, cancer-specific
      survival and relapse-free survival. The time to recurrence, perioperative
      morbidity and mortality, hospital stay and quality of life will also be studied, 
      the latter using the validated EuroQol Five questionnaire. The propensity index
      method will be used to create comparable treatment and control groups, and a
      multivariate regression will be used to study each variable. The Kaplan-Meier
      estimator will be used to estimate survival and the log-rank test to make
      comparisons. A p value of less than 0.05 (two-tailed) will be considered to be
      significant. ETHICS AND DISSEMINATION: Ethical approval for this study was
      obtained from the Aragon Ethical Committee (C.P.-C.I. PI20/086) on 4 March 2020. 
      The findings of this study will be submitted to peer-reviewed journals (BMJ Open,
      JAMA Surgery, Annals of Surgery, British Journal of Surgery). Abstracts will be
      submitted to relevant national and international meetings. TRIAL REGISTRATION
      NUMBER: NCT04305314.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ramirez-Rodriguez, Jose-M
AU  - Ramirez-Rodriguez JM
AUID- ORCID: 0000-0001-7964-1166
AD  - Lozano Blesa University Clinical Hospital, Zaragoza, Aragon, Spain
      jramirez@unizar.es.
AD  - Aragon Health Sciences Institute, Zaragoza, Aragon, Spain.
FAU - Martinez-Ubieto, Javier
AU  - Martinez-Ubieto J
AD  - Miguel Servet University Hospital, Zaragoza, Aragon, Spain.
FAU - Munoz-Rodes, Jose-L
AU  - Munoz-Rodes JL
AD  - Miguel Hernandez University of Elche, Elche, Valenciana, Spain.
FAU - Rodriguez-Fraile, Jose-R
AU  - Rodriguez-Fraile JR
AD  - Health Service of Castilla-La Mancha, Guadalajara, Castilla-La Mancha, Spain.
FAU - Garcia-Erce, Jose-A
AU  - Garcia-Erce JA
AD  - Navarre Health Service, Pamplona, Navarra, Spain.
FAU - Blanco-Gonzalez, Javier
AU  - Blanco-Gonzalez J
AD  - La Ribera Hospital, Alzira, Valenciana, Spain.
FAU - Del Valle-Hernandez, Emilio
AU  - Del Valle-Hernandez E
AD  - General University Hospital Gregorio Maranon, Madrid, Spain.
FAU - Abad-Gurumeta, Alfredo
AU  - Abad-Gurumeta A
AD  - Hospital Universitario Infanta Leonor, Madrid, Spain.
FAU - Centeno-Robles, Eugenia
AU  - Centeno-Robles E
AD  - Complejo Asistencial de Palencia, Palencia, Spain.
FAU - Martinez-Perez, Carolina
AU  - Martinez-Perez C
AD  - General University Hospital Consortium of Valencia, Valencia, Comunitat
      Valenciana, Spain.
FAU - Leon-Arellano, Miguel
AU  - Leon-Arellano M
AD  - Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Echazarreta-Gallego, Estibaliz
AU  - Echazarreta-Gallego E
AD  - Hospital of Barbastro, Barbastro, Aragon, Spain.
FAU - Elia-Guedea, Manuela
AU  - Elia-Guedea M
AD  - Lozano Blesa University Clinical Hospital, Zaragoza, Aragon, Spain.
FAU - Pascual-Bellosta, Ana
AU  - Pascual-Bellosta A
AD  - Miguel Servet University Hospital, Zaragoza, Aragon, Spain.
FAU - Miranda-Tauler, Elena
AU  - Miranda-Tauler E
AD  - Miguel Hernandez University of Elche, Elche, Valenciana, Spain.
FAU - Manuel-Vazquez, Alba
AU  - Manuel-Vazquez A
AD  - Health Service of Castilla-La Mancha, Guadalajara, Castilla-La Mancha, Spain.
FAU - Balen-Rivera, Enrique
AU  - Balen-Rivera E
AD  - Navarre Health Service, Pamplona, Navarra, Spain.
FAU - Alvarez-Martinez, David
AU  - Alvarez-Martinez D
AD  - La Ribera Hospital, Alzira, Valenciana, Spain.
FAU - Perez-Pena, Jose
AU  - Perez-Pena J
AD  - General University Hospital Gregorio Maranon, Madrid, Spain.
FAU - Abad-Motos, Ane
AU  - Abad-Motos A
AD  - Hospital Universitario Infanta Leonor, Madrid, Spain.
FAU - Redondo-Villahoz, Elisabeth
AU  - Redondo-Villahoz E
AD  - Complejo Asistencial de Palencia, Palencia, Spain.
FAU - Biosta-Perez, Elena
AU  - Biosta-Perez E
AD  - General University Hospital Consortium of Valencia, Valencia, Comunitat
      Valenciana, Spain.
FAU - Guadalajara-Labajo, Hector
AU  - Guadalajara-Labajo H
AD  - Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Ripolles-Melchor, Javier
AU  - Ripolles-Melchor J
AD  - Hospital Universitario Infanta Leonor, Madrid, Spain.
FAU - Latre-Saso, Cristina
AU  - Latre-Saso C
AD  - Hospital of Barbastro, Barbastro, Aragon, Spain.
FAU - Cordoba-Diaz de Laspra, Elena
AU  - Cordoba-Diaz de Laspra E
AD  - Lozano Blesa University Clinical Hospital, Zaragoza, Aragon, Spain.
FAU - Sanchez-Guillen, Luis
AU  - Sanchez-Guillen L
AD  - Miguel Hernandez University of Elche, Elche, Valenciana, Spain.
FAU - Cabellos-Olivares, Mercedes
AU  - Cabellos-Olivares M
AD  - Health Service of Castilla-La Mancha, Guadalajara, Castilla-La Mancha, Spain.
FAU - Longas-Valien, Javier
AU  - Longas-Valien J
AD  - Lozano Blesa University Clinical Hospital, Zaragoza, Aragon, Spain.
FAU - Ortega-Lucea, Sonia
AU  - Ortega-Lucea S
AD  - Miguel Servet University Hospital, Zaragoza, Aragon, Spain.
FAU - Ocon-Breton, Julia
AU  - Ocon-Breton J
AD  - Lozano Blesa University Clinical Hospital, Zaragoza, Aragon, Spain.
FAU - Arroyo-Sebastian, Antonio
AU  - Arroyo-Sebastian A
AD  - Miguel Hernandez University of Elche, Elche, Valenciana, Spain.
FAU - Garcia-Olmo, Damian
AU  - Garcia-Olmo D
AD  - Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.
AD  - Universidad Autonoma de Madrid, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04305314
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - *Colorectal Neoplasms/surgery
MH  - Humans
MH  - Length of Stay
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local
MH  - Observational Studies as Topic
MH  - Postoperative Complications/epidemiology
MH  - Prospective Studies
MH  - *Quality of Life
MH  - State Medicine
PMC - PMC7597515
OTO - NOTNLM
OT  - *change management
OT  - *colorectal surgery
OT  - *gastrointestinal tumours
COIS- Competing interests: J-MR-R reports grants from Instituto de Investigacion Carlos
      III, during the conduct of the study. J-AG-E reports grants and personal fees
      from Vifor Pharma, Zambon and Sandoz, outside the submitted work. JR-M reports
      personal fees from Fresenius Kabi, Edwards Lifesciences, Dextera Medical and MSD,
      outside the submitted work
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040316 [pii]
AID - 10.1136/bmjopen-2020-040316 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e040316. doi: 10.1136/bmjopen-2020-040316.


PMID- 33109669
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Effect of female sex work-targeted community-based interventions along the HIV
      treatment cascade in sub-Saharan Africa: a systematic review protocol.
PG  - e039495
LID - 10.1136/bmjopen-2020-039495 [doi]
AB  - INTRODUCTION: Female sex workers (FSWs) are a known high-risk group that are at
      increased risk of HIV transmission due to exposure to multiple sexual partners
      and inability to negotiate safe sex attributed to challenging economic
      circumstances. Previous systematic reviews have examined the effectiveness of HIV
      interventions prioritising FSWs and have shown that targeted interventions
      improve access to HIV prevention and treatment services. Interventions that
      increase FSWs' uptake of services are well documented; however, evidence on
      specific interventions aimed at improving FSWs' continuity in HIV care along the 
      treatment cascade is lacking. This systematic review aims to document the
      performance of community-based interventions along the HIV treatment cascade.
      METHODS AND ANALYSIS: We will use a sensitive search strategy for electronic
      bibliographic databases, bibliographies of included articles and grey literature 
      sources. In addition, the Joint United Nations Programme on HIV/AIDS and the WHO 
      websites, peer-reviewed conference papers and grey literature sources will be
      searched for additional reports of sex work programmes. We will include
      randomised controlled trials, cross-sectional surveys and cohort interventions
      where community-based HIV services were provided to FSWs and measure the
      performance of the HIV intervention on one or more cascade stages. We will
      conduct a systematic review of studies published from 2004 to present within the 
      sub-Saharan Africa region. We will report quantitative study outcomes of HIV
      testing and diagnosis, linkage to care, initiation on antiretroviral therapy and 
      viral suppression. We will analyse the data using the random-effects
      meta-analysis method, and funnel plots will be used to assess the publication
      bias. ETHICS AND DISSEMINATION: This systematic review will not require ethical
      approval; we will publish data from manuscripts. The results of this study will
      be disseminated in peer-reviewed journals and conference presentations. PROSPERO 
      REGISTRATION NUMBER: CRD42020157623.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Atuhaire, Lydia
AU  - Atuhaire L
AUID- ORCID: 0000-0002-6683-0862
AD  - Division of Epidemiology & Biostatistics, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa latuhaire@gmail.com.
FAU - Adetokunboh, Olatunji
AU  - Adetokunboh O
AD  - Division of Epidemiology & Biostatistics, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
AD  - DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), 
      Stellenbosch University, Cape town, South Africa.
FAU - Shumba, Constance
AU  - Shumba C
AD  - School of Nursing and Midwifery, Aga Khan University East Africa, Nairobi, Kenya.
AD  - Department of Population Health, Aga Khan University East Africa, Nairobi, Kenya.
FAU - Nyasulu, Peter S
AU  - Nyasulu PS
AUID- ORCID: 0000-0003-2757-0663
AD  - Division of Epidemiology & Biostatistics, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
AD  - School of Public Health, Faculty of Medicine and Health Sciences, University of
      the Witwatersrand, Johannesburg, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa South of the Sahara
MH  - Cross-Sectional Studies
MH  - Female
MH  - *HIV Infections/drug therapy/prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Sex Work
MH  - *Sex Workers
MH  - Systematic Reviews as Topic
PMC - PMC7592303
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *infectious disease/HIV
OT  - *public health
OT  - *virology
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039495 [pii]
AID - 10.1136/bmjopen-2020-039495 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e039495. doi: 10.1136/bmjopen-2020-039495.


PMID- 33109667
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210517
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Personalising Outcomes after Child Cardiac Arrest (POCCA): design and recruitment
      challenges of a multicentre, observational study.
PG  - e039323
LID - 10.1136/bmjopen-2020-039323 [doi]
AB  - INTRODUCTION: Blood and imaging biomarkers show promise in prognosticating
      outcomes after paediatric cardiac arrest in pilot studies. We describe the
      methods and early recruitment challenges and solutions for an ongoing multicentre
      (n=14) observational trial, Personalising Outcomes following Child Cardiac Arrest
      to validate clinical, blood and imaging biomarkers individually and together in a
      clinically relevant panel. METHODS AND ANALYSIS: Children (n=164) between 48
      hours and 17 years of age who receive chest compressions irrespective of
      provider, duration, or event location and are admitted to an intensive care unit 
      are eligible. Blood samples will be taken on days 1-3 for the measurement of
      brain-focused biomarkers analysed to predict the outcome. Clinically indicated
      and timed brain MRI and spectroscopy biomarkers will be analysed to predict the
      outcome. The primary outcome for the trial is survival with favourable (Vineland 
      Adaptive Behavioural Scale score >70) outcome at 1 year. Secondary outcomes
      include mortality and pre-event and postdischarge measures of emotional,
      cognitive, physical and family functioning and health-related quality of life.
      Early enrollment targets were not met due to prolonged regulatory and subcontract
      processes. Multiple, simultaneous interventions including modification to
      inclusion criteria, additional sites and site visits were implemented with
      successful improvement in recruitment. Study procedures including outcomes and
      biomarker analysis are ongoing. ETHICS AND DISSEMINATION: Twelve of 14 sites will
      use the centralised Institutional Review Board (IRB) at the University of
      Pittsburgh (PRO14030712). Two sites will use individual IRBs: Children's
      Healthcare of Atlanta Institutional Review Board and Children's Hospital of
      Wisconsin IRB. Parents and/or guardians are consented and children assented (when
      possible) by the site Primary investigator (PI) or research coordinator for
      enrollment. Study findings will be disseminated through scientific conferences,
      peer-reviewed journal publications, public study website materials and invited
      lectures. TRIAL REGISTRATION NUMBER: NCT02769026.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fink, Ericka L
AU  - Fink EL
AUID- ORCID: 0000-0002-3683-4571
AD  - Critical Care Medicine, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA finkel@ccm.upmc.edu.
FAU - Clark, Robert S B
AU  - Clark RSB
AD  - Critical Care Medicine, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Panigrahy, Ashok
AU  - Panigrahy A
AD  - Radiology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical 
      Center, Pittsburgh, Pennsylvania, USA.
FAU - Berger, Rachel
AU  - Berger R
AD  - Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical
      Center, Pittsburgh, Pennsylvania, USA.
FAU - Wisnowski, Jessica
AU  - Wisnowski J
AD  - Radiology, USC Keck School of Medicine, Los Angeles, California, USA.
FAU - Bluml, Stefan
AU  - Bluml S
AD  - Radiology, USC Keck School of Medicine, Los Angeles, California, USA.
FAU - Maloney, David
AU  - Maloney D
AD  - Critical Care Medicine, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Rubin, Pamela
AU  - Rubin P
AD  - Critical Care Medicine, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Haller, Tamara
AU  - Haller T
AD  - Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Bayir, Hulya
AU  - Bayir H
AD  - Critical Care Medicine, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Beers, Sue R
AU  - Beers SR
AD  - Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Kochanek, Patrick M
AU  - Kochanek PM
AD  - Critical Care Medicine, Children's Hospital of Pittsburgh of University of
      Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
FAU - Fabio, Anthony
AU  - Fabio A
AD  - Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
CN  - POCCA Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02769026
GR  - K23 HD099309/HD/NICHD NIH HHS/United States
GR  - R01 NS096714/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Nov 30;10(11):1. PMID: 33257478
MH  - Aftercare
MH  - *COVID-19
MH  - Child
MH  - *Heart Arrest/therapy
MH  - Humans
MH  - Patient Discharge
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - Wisconsin
PMC - PMC7592297
OTO - NOTNLM
OT  - *magnetic resonance imaging
OT  - *neurological injury
OT  - *paediatric intensive & critical care
COIS- Competing interests: None declared.
IR  - Kochanek P
FIR - Kochanek, Patrick
IR  - Clark R
FIR - Clark, Robert
IR  - Bayir H
FIR - Bayir, Hulya
IR  - Panigrahy A
FIR - Panigrahy, Ashok
IR  - Berger R
FIR - Berger, Rachel
IR  - Beers S
FIR - Beers, Sue
IR  - Fabio T
FIR - Fabio, Tony
IR  - Walson K
FIR - Walson, Karen
IR  - Topjian A
FIR - Topjian, Alexis
IR  - Newth CJ
FIR - Newth, Christopher Jl
IR  - Hunt E
FIR - Hunt, Elizabeth
IR  - Duval-Arnould J
FIR - Duval-Arnould, Jordan
IR  - Balakrishnan B
FIR - Balakrishnan, Binod
IR  - Meyer MT
FIR - Meyer, Michael T
IR  - Chung MG
FIR - Chung, Melissa G
IR  - Willyerd A
FIR - Willyerd, Anthony
IR  - Smith L
FIR - Smith, Lincoln
IR  - Wenger J
FIR - Wenger, Jesse
IR  - Friess S
FIR - Friess, Stuart
IR  - Pineda J
FIR - Pineda, Jose
IR  - Siems A
FIR - Siems, Ashley
IR  - Patregnani J
FIR - Patregnani, Jason
IR  - Diddle J
FIR - Diddle, John
IR  - Maddux A
FIR - Maddux, Aline
IR  - Doughty L
FIR - Doughty, Lesley
IR  - Piantino J
FIR - Piantino, Juan
IR  - Desai B
FIR - Desai, Beena
IR  - Richardson MG
FIR - Richardson, Maureen G
IR  - Bates C
FIR - Bates, Cynthia
IR  - Parikh D
FIR - Parikh, Darshana
IR  - Prodell J
FIR - Prodell, Janice
IR  - Winters M
FIR - Winters, Maddie
IR  - Smith K
FIR - Smith, Katie
IR  - Kwok J
FIR - Kwok, Jeni
IR  - Cabrales A
FIR - Cabrales, Adriana
IR  - Adewale R
FIR - Adewale, Ronke
IR  - Melvin P
FIR - Melvin, Pam
IR  - Shad S
FIR - Shad, Sadaf
IR  - Siegel K
FIR - Siegel, Katherine
IR  - Murkowski K
FIR - Murkowski, Katherine
IR  - Kasch M
FIR - Kasch, Mary
IR  - Hensley J
FIR - Hensley, Josey
IR  - Steele L
FIR - Steele, Lisa
IR  - Brown D
FIR - Brown, Danielle
IR  - Burrows B
FIR - Burrows, Brian
IR  - Hlivka L
FIR - Hlivka, Lauren
IR  - Rich D
FIR - Rich, Deana
IR  - Tutundzic A
FIR - Tutundzic, Amila
IR  - Day T
FIR - Day, Tina
IR  - Barganier L
FIR - Barganier, Lori
IR  - Wolfe A
FIR - Wolfe, Ashley
IR  - Little M
FIR - Little, Mackenzie
IR  - Tomanio E
FIR - Tomanio, Elyse
IR  - Patel N
FIR - Patel, Neha
IR  - Hession D
FIR - Hession, Diane
IR  - Sierra Y
FIR - Sierra, Yamila
IR  - Grosskreuz R
FIR - Grosskreuz, Ruth
IR  - Kevin Van BS
FIR - Kevin Van, B S
IR  - Jones R
FIR - Jones, Rhonda
IR  - Benken L
FIR - Benken, Laura
IR  - Dyar B
FIR - Dyar, Beata
IR  - Mishler L
FIR - Mishler, Laura
IR  - Elmer J
FIR - Elmer, Jonathan
IR  - Subramanian S
FIR - Subramanian, Subramanian
IR  - Wallace J
FIR - Wallace, Julia
IR  - Robinson T
FIR - Robinson, Tami
IR  - Frank A
FIR - Frank, Andrew
IR  - Bluml S
FIR - Bluml, Stefan
IR  - Wisnowski J
FIR - Wisnowski, Jessica
IR  - Feldman K
FIR - Feldman, Keri
IR  - Vemulapalli A
FIR - Vemulapalli, Avinash
IR  - Ryan L
FIR - Ryan, Linda
IR  - Szypulski S
FIR - Szypulski, Scott
IR  - Keys C
FIR - Keys, Christopher
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039323 [pii]
AID - 10.1136/bmjopen-2020-039323 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e039323. doi: 10.1136/bmjopen-2020-039323.


PMID- 33109665
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 26
TI  - Quality of life and experiences of sarcoma trajectories (the QUEST study):
      protocol for an international observational cohort study on diagnostic pathways
      of sarcoma patients.
PG  - e039309
LID - 10.1136/bmjopen-2020-039309 [doi]
AB  - INTRODUCTION: Sarcomas are rare tumours with considerable heterogeneity. Early
      and accurate diagnosis is important to optimise patient outcomes in terms of
      local disease control, overall survival (OS) and health-related quality of life
      (HRQoL). Time to diagnosis is variable in bone as well as soft tissue sarcoma.
      Possible factors for a long time from first symptom to diagnosis (the total
      interval) include patient, tumour and healthcare characteristics, but until now
      the most relevant risk factors and its association with outcomes remain unknown. 
      Our study aims to (1) quantify total interval, the time interval from first
      symptom until (histological) diagnosis; (2) identify factors associated with
      interval length and (3) determine the association between total interval and
      HRQoL, stage and tumour size at diagnosis, progression-free survival (PFS) and
      OS. METHODS AND ANALYSIS: We will conduct a longitudinal, prospective,
      international, multicentre cohort study among patients aged >/=18 years with
      newly diagnosed bone or soft tissue sarcoma at eight centres (three in UK, five
      in The Netherlands). Patients will be asked to complete questionnaires at five
      points in time; one at diagnosis and at follow-up points of 3, 6, 12 and 24
      months. Questionnaire data is collected within the Patient Reported Outcomes
      Following Initial treatment and Long term Evaluation of Survivorship (PROFILES)
      registry: an international data management system for collection of
      patient-reported outcomes. Clinical data will be extracted from patient records. 
      The primary endpoint is HRQoL at diagnosis, measured with the EORTC QLQ-C30.
      Secondary endpoints are stage and tumour size at diagnosis, PFS, OS, additional
      patient-reported outcomes, such as quality-adjusted life years and psychological 
      distress. ETHICS AND DISSEMINATION: Ethical approval was given by the Health
      Research Authority and Research Ethics Committee for the United Kingdom
      (18/WA/0096) and medical ethical committee of Radboudumc for The Netherlands
      (2017-3881). Results will be presented in peer-reviewed journals and presented at
      meetings. TRIAL REGISTRATION NUMBER: NCT03441906.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Soomers, Vicky
AU  - Soomers V
AUID- ORCID: 0000-0003-0019-3968
AD  - Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Desar, Ingrid Me
AU  - Desar IM
AD  - Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - van de Poll-Franse, Lonneke V
AU  - van de Poll-Franse LV
AD  - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer
      Institute, Amsterdam, The Netherlands.
AD  - Department of Research, Netherlands Comprehensive Cancer organization (IKNL),
      Utrecht, The Netherlands.
AD  - Department of Medical and Clinical Psychology, CoRPS - Centre of Research on
      Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands.
FAU - Husson, Olga
AU  - Husson O
AD  - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer
      Institute, Amsterdam, The Netherlands olga.husson@icr.ac.uk.
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
AD  - Division of Clinical Studies, Institute of Cancer Research, London, UK.
FAU - van der Graaf, Winette Ta
AU  - van der Graaf WT
AD  - Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
AD  - Department of medical oncology, Royal Marsden NHS Foundation Trust, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03441906
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Humans
MH  - Netherlands/epidemiology
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - *Sarcoma/diagnosis/epidemiology
MH  - United Kingdom/epidemiology
PMC - PMC7592281
OTO - NOTNLM
OT  - *bone diseases
OT  - *health policy
OT  - *oncology
OT  - *sarcoma
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-039309 [pii]
AID - 10.1136/bmjopen-2020-039309 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 26;10(10):e039309. doi: 10.1136/bmjopen-2020-039309.


PMID- 33109663
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Effects of oil-soluble versus water-soluble contrast media at
      hysterosalpingography on pregnancy outcomes in women with a low risk of tubal
      disease: study protocol for a randomised controlled trial.
PG  - e039166
LID - 10.1136/bmjopen-2020-039166 [doi]
AB  - INTRODUCTION: In recent years, due to various factors, the rate of infertility in
      China has increased and now affects over 10% of women of reproductive age.
      Hysterosalpingography (HSG) is a common diagnostic procedure during fertility
      examinations. However, there is no consensus on the choice of contrast agents and
      their effects. As the largest multicentre, randomised controlled trial (H2Oil
      trial from the Netherlands) has shown that oil-soluble contrast at HSG can
      enhance fertility compared with water-soluble contrast, we propose this study to 
      examine whether the use of oil-soluble contrast media results in increased rates 
      of pregnancy in Chinese women undergoing HSG. METHODS AND ANALYSIS: This study is
      a single-centre, randomised, controlled, parallel-group, superiority trial.
      Patients with low risk of tubal disease will be randomised to undergo HSG using
      iodinated oil injection (OSCM group, oil-soluble contrast media) or ioversol
      injection (WSCM group, water-soluble contrast media). To evaluate the potential
      superiority of the OSCM group, with 1:1 allocation ratio, 90% statistical power
      and a two-sided significance level of 5%, we have calculated a sample of 520
      women per group to be enrolled, for a total of 1040 including 10% loss to
      follow-up or protocol variation. The primary outcome is the rate of ongoing
      pregnancy during 6 months after randomisation. The secondary outcomes will
      consist of thyroid function of patients and newborns, pain scores during HSG,
      rate of live birth, clinical pregnancies, miscarriages, ectopic pregnancy, time
      to ongoing pregnancy, time to live birth, cost calculations of the OSCM
      group/WSCM group, and assisted reproductive technology treatments between the two
      groups. ETHICS AND DISSEMINATION: This protocol received authorisation from the
      Medical Research Ethics Committee of International Peace Maternity and Child
      Health Hospital on 18 January 2020 (approval no GKLW2020-02). The findings will
      be reported in peer-reviewed publications and presentations at international
      scientific meetings. TRIAL REGISTRATION NUMBER: ChiCTR2000031612.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liang, Guiling
AU  - Liang G
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,
      China.
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - Zhu, Qian
AU  - Zhu Q
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,
      China.
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - He, Xiaoqing
AU  - He X
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,
      China.
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - Wang, Xiaofeng
AU  - Wang X
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,
      China.
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - Jiang, Ling
AU  - Jiang L
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
AD  - Department of Radiology, International Peace Maternity and Child Health Hospital,
      School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
FAU - Zhu, Chenfeng
AU  - Zhu C
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,
      China.
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
FAU - Xie, Li
AU  - Xie L
AUID- ORCID: 0000-0003-1892-2217
AD  - Clinical Research Institute, Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Qian, Zhaoxia
AU  - Qian Z
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China
      zhaoxiaqian@163.com zhangjian_sjtu@126.com.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
AD  - Department of Radiology, International Peace Maternity and Child Health Hospital,
      School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
FAU - Zhang, Jian
AU  - Zhang J
AUID- ORCID: 0000-0003-3664-5807
AD  - Department of Obstetrics and Gynecology, International Peace Maternity and Child 
      Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,
      China zhaoxiaqian@163.com zhangjian_sjtu@126.com.
AD  - Shanghai Key Laboratory Embryo Original Diseases, Shanghai, China.
AD  - Shanghai Municipal Key Clinical Specialty, Shanghai, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Contrast Media)
RN  - 059QF0KO0R (Water)
SB  - IM
MH  - Child
MH  - China
MH  - Contrast Media/adverse effects
MH  - Female
MH  - Humans
MH  - *Hysterosalpingography
MH  - Infant, Newborn
MH  - *Infertility, Female
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Pregnancy Rate
MH  - Randomized Controlled Trials as Topic
MH  - Water
PMC - PMC7597517
OTO - NOTNLM
OT  - *diagnostic radiology
OT  - *gynaecology
OT  - *subfertility
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039166 [pii]
AID - 10.1136/bmjopen-2020-039166 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e039166. doi: 10.1136/bmjopen-2020-039166.


PMID- 33109662
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Social determinants of health associated with the development of sepsis in
      adults: a scoping review protocol.
PG  - e039146
LID - 10.1136/bmjopen-2020-039146 [doi]
AB  - INTRODUCTION: Sepsis, the life-threatening immune response to infection, affects 
      millions of people annually. Understanding of the factors associated with the
      development of sepsis is crucial for improving population health and public
      health efforts; in particular, literature exploring the relationship between
      sepsis and social determinants of health is lacking. This review seeks to
      establish and amalgamate existing evidence of the relationships between sepsis
      and the following social determinants: frailty, registration with a family
      physician, mental illness, alcohol abuse, social support levels, smoking status, 
      illicit drug use disorders, socioeconomic status, gender and race/ethnicity.
      METHODS AND ANALYSIS: This study will analyse qualitative and quantitative
      studies using standard processes. The selected social determinants of health and 
      their potential link to adult sepsis will be analysed separately under distinct
      headings. Findings will be consolidated in a final discussion. PubMed and Medline
      will be searched for articles published between 1970 and 2020 using search
      strings combining 'sepsis' and other variations, such as 'septicaemia' with each 
      social determinant of interest. 'Sepsis' and at least one social determinant of
      interest must be present in a study's title for inclusion in the review; the
      results of the initial search will be filtered based on predetermined inclusion
      and exclusion criteria. Evidence from this scoping review will provide
      information on the impact of social determinants of health on the risk of
      developing adult sepsis, which can inform clinicians of the various risk factors 
      to consider when admitting patients. ETHICS AND DISSEMINATION: Approval from a
      research ethics board is not needed for this amalgamation of information from
      studies for which the primary investigators have obtained their own, respective
      ethics board approval. Once completed, the review will be submitted for
      publication in a peer-reviewed journal, and findings will be presented in local
      and national forums.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Machon, Christina
AU  - Machon C
AD  - Health Sciences Programme, McMaster University, Hamilton, Ontario, Canada.
FAU - Sheikh, Fatima
AU  - Sheikh F
AD  - Life Sciences Programme, McMaster University, Hamilton, Ontario, Canada.
FAU - Fox-Robichaud, Alison
AU  - Fox-Robichaud A
AUID- ORCID: 0000-0001-9912-3606
AD  - Medicine, McMaster University, Hamilton, Ontario, Canada afoxrob@mcmaster.ca.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Humans
MH  - Public Health
MH  - Review Literature as Topic
MH  - *Sepsis/epidemiology
MH  - Social Determinants of Health
MH  - Social Support
MH  - *Substance-Related Disorders
PMC - PMC7592284
OTO - NOTNLM
OT  - *infectious diseases
OT  - *public health
OT  - *social medicine
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039146 [pii]
AID - 10.1136/bmjopen-2020-039146 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e039146. doi: 10.1136/bmjopen-2020-039146.


PMID- 33109660
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Public managers' role in creating workplace social capital (WSC) and its effect
      on employees' well-being and health: a protocol of a longitudinal cohort study
      (PUMA-WSC).
PG  - e039027
LID - 10.1136/bmjopen-2020-039027 [doi]
AB  - INTRODUCTION: Workplace social capital (WSC) has been shown to affect employees' 
      well-being and health, yet it is not clear how public managers can create WSC and
      which forms of WSC are most important. This study is the first prospective cohort
      study to examine the relationship between management behaviour, WSC, well-being
      and sickness absence. It uses a validated and detailed scale on WSC, which can
      distinguish between bonding, bridging, linking and organisational WSC over time. 
      The study thereby provides rich data giving a much-needed detailed image of how
      WSC impacts on public employees' well-being and health. Additionally, the study
      pays special attention to the fact that these relationships can be different for 
      different types of employees and therefore tests a set of relevant employee and
      context-related variables. METHODS AND ANALYSIS: Project preparations in terms of
      agreements and data preparation of existing data started in 2019. This
      prospective cohort study considers and collects organisational data from 2016 to 
      2025. Annual employee surveys of more than 8000 employees (in a large Danish
      municipality) will be combined with register data in all years. This generates a 
      unique cohort of public employees in different professions that are traceable
      over several years. The annual surveys include information on the management
      behaviour, WSC and employee outcomes. Fine-grained information on sickness
      absences will be matched for all employees and years under study. Moreover,
      confounders and the nested nature of the data will be considered. ETHICS AND
      DISSEMINATION: Approval has been obtained from The Regional Committee on Health
      Research Ethics from Southern Denmark and from the University of Southern
      Denmark. The results will be presented at conferences and published in
      international peer-reviewed journals and in a practice-oriented monography
      targeted at public managers. The result will furthermore be disseminated to the
      involved employees through seminars and workshops in the participating
      organisations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pihl-Thingvad, Signe
AU  - Pihl-Thingvad S
AD  - Department of Political Science and Public Management, University of Southern
      Denmark, Odense, Denmark.
FAU - Hansen, Sune W
AU  - Hansen SW
AD  - Department of Political Science and Public Management, University of Southern
      Denmark, Odense, Denmark.
FAU - Winter, Vera
AU  - Winter V
AUID- ORCID: 0000-0001-7087-2400
AD  - Department of Political Science and Public Management, University of Southern
      Denmark, Odense, Denmark winter@wiwi.uni-wuppertal.de.
AD  - Department of Health Care Management, Schumpeter School of Business and
      Economics, University of Wuppertal, Wuppertal, Germany.
FAU - Hansen, Michelle S
AU  - Hansen MS
AD  - Department of Political Science and Public Management, University of Southern
      Denmark, Odense, Denmark.
FAU - Willems, Jurgen
AU  - Willems J
AD  - Department of Political Science and Public Management, University of Southern
      Denmark, Odense, Denmark.
AD  - Institute for Public Management und Governance, Department of Management, WU
      Wien, Wien, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Health Status
MH  - Humans
MH  - Longitudinal Studies
MH  - *Mental Health
MH  - Prospective Studies
MH  - *Social Capital
MH  - *Workplace
PMC - PMC7592307
OTO - NOTNLM
OT  - *human resource management
OT  - *social medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039027 [pii]
AID - 10.1136/bmjopen-2020-039027 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e039027. doi: 10.1136/bmjopen-2020-039027.


PMID- 33109659
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - The Brabant study: design of a large prospective perinatal cohort study among
      pregnant women investigating obstetric outcome from a biopsychosocial
      perspective.
PG  - e038891
LID - 10.1136/bmjopen-2020-038891 [doi]
AB  - BACKGROUND: Pregnancy is characterised by many biological and psychosocial
      changes. Adequate maternal thyroid function is important for the developing fetus
      throughout gestation. Latent class analyses recently showed three different
      patterns of change in thyroid function throughout pregnancy with different
      associations with obstetric outcome. Maternal distress during the pregnancy
      (anxiety and depression) negatively affects obstetric outcome. Pregnancy distress
      in turn may be affected by personality traits and attachment styles. Moreover,
      during the pregnancy, substantial social changes occur in the partner
      relationship and work experience. The aim of the Brabant study is to investigate 
      the association between thyroid function trajectories and obstetric outcomes.
      Moreover, within the Brabant study, we will investigate how different
      trajectories of pregnancy distress are related to obstetric outcome, and the role
      of personality in this association. We will evaluate the possible role of
      maternal distress and attachment style on maternal-fetal bonding. Finally, we
      will study social changes in the perinatal period regarding partner relationship 
      and well-being and performance at work. METHODS AND ANALYSIS: The Brabant study
      is a longitudinal, prospective cohort study of an anticipated 4000 pregnant
      women. Women will be recruited at 8-10 weeks gestation among community midwife
      practices in South-East Brabant in the Netherlands. Thyroid function parameters
      (TSH and fT4), thyroid peroxidase antibody and human chorionic gonadotrophin will
      be assessed at 12, 20 and 28 weeks gestation. Moreover, at these three time
      points women will fill out questionnaires assessing demographic and obstetric
      features, life style habits and psychological and social variables, such as
      depressive symptoms, personality, partner relationship quality and burnout. Data 
      from the obstetric records will also be collected. ETHICS AND DISSEMINATION: The 
      study has been approved by the Medical Ethical Committee of the Maxima Medical
      Center Veldhoven. Results will be submitted to peer-reviewed journals in the
      relevant fields and presented on national and international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Meems, Margreet
AU  - Meems M
AUID- ORCID: 0000-0002-0938-3840
AD  - CoRPS - Center of Research on Psychological and Somatic disorders, Department of 
      Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands.
FAU - Hulsbosch, Lianne
AU  - Hulsbosch L
AD  - CoRPS - Center of Research on Psychological and Somatic disorders, Department of 
      Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands.
FAU - Riem, Madelon
AU  - Riem M
AD  - CoRPS - Center of Research on Psychological and Somatic disorders, Department of 
      Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands.
FAU - Meyers, Christina
AU  - Meyers C
AD  - Department of Human Resource Studies, Tilburg University, Tilburg, The
      Netherlands.
FAU - Pronk, Tila
AU  - Pronk T
AD  - Department of Social Psychology, Tilburg University, Tilburg, The Netherlands.
FAU - Broeren, Maarten
AU  - Broeren M
AD  - Laboratory of Clinical Chemistry and Hematology, Maxima Medical Center,
      Veldhoven, The Netherlands.
FAU - Nabbe, Karin
AU  - Nabbe K
AD  - Clinical Laboratory, Diagnostiek voor U, Eindhoven, The Netherlands.
FAU - Oei, Guid
AU  - Oei G
AD  - Department of Obstetrics and Gynecology, Maxima Medical Center, Eindhoven, The
      Netherlands.
FAU - Bogaerts, Stefan
AU  - Bogaerts S
AD  - Department of Developmental Psychology, Tilburg University, Tilburg, The
      Netherlands.
FAU - Pop, Victor
AU  - Pop V
AD  - CoRPS - Center of Research on Psychological and Somatic disorders, Department of 
      Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands
      V.J.M.Pop@tilburguniversity.edu.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Netherlands
MH  - Pregnancy
MH  - *Pregnancy Complications/epidemiology
MH  - *Pregnant Women
MH  - Prospective Studies
PMC - PMC7592269
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *maternal medicine
OT  - *thyroid disease
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038891 [pii]
AID - 10.1136/bmjopen-2020-038891 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e038891. doi: 10.1136/bmjopen-2020-038891.


PMID- 33109658
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - A protocol for the economic evaluation of the smoking Cessation in Pregnancy
      Incentives Trial III (CPIT III).
PG  - e038827
LID - 10.1136/bmjopen-2020-038827 [doi]
AB  - INTRODUCTION: Smoking results in an average 10-year loss of life, but smokers who
      permanently quit before age 40 can expect a near normal lifespan. Pregnancy poses
      a good opportunity to help women to stop; around 80% of women in the UK have a
      baby, most of whom are less than 40 years of age. Smoking prevalence during
      pregnancy is high: 17%-23% in the UK. Smoking during pregnancy causes low birth
      weight and increases the risk of premature birth. After birth, passive smoking is
      linked to sudden infant death syndrome, respiratory diseases and increased
      likelihood of taking up smoking. These risks impact the long-term health of the
      child with associated increase in health costs. Emerging evidence suggests that
      offering financial incentives to pregnant women to quit is highly cost
      effective.This protocol describes the economic evaluation of a multi-centre
      randomised controlled trial (Cessation in Pregnancy Incentives Trial III, CPIT
      III) designed to establish whether offering financial incentives, in addition to 
      usual care, is effective and cost effective in helping pregnant women to quit.
      METHODS AND ANALYSIS: The economic evaluation will identify, measure and value
      resource use and outcomes from CPIT III, comparing participants randomised to
      either usual care or usual care plus up to pound400 financial incentives.
      Within-trial and long-term analyses will be conducted from a National Health
      Service and Personal Social Services perspective; the outcome for both analyses
      will be quality adjusted life-years measured using EQ-5D-5L. Patient level data
      collected during the trial will be used for the within-trial analysis, with an
      additional outcome of cotinine validated quit rates at 34-38 weeks gestation and 
      6 months postpartum. The long-term model will be informed by data from the trial 
      and published literature. ETHICS AND DISSEMINATION: TRIAL REGISTRATION NUMBER:
      ISRCTN15236311; Pre-results (https://doi.org/10.1186/ISRCTN15236311).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - McMeekin, Nicola
AU  - McMeekin N
AUID- ORCID: 0000-0003-2918-8820
AD  - Health Economics and Health Technology Assessment, Institute of Health and
      Wellbeing, University of Glasgow, Glasgow, UK nicola.mcmeekin@glasgow.ac.uk.
FAU - Sinclair, Lesley
AU  - Sinclair L
AD  - Usher Institute of Population Health Sciences and Informatics, The University of 
      Edinburgh, Edinburgh, UK.
FAU - Bauld, Linda
AU  - Bauld L
AD  - Usher Institute of Population Health Sciences and Informatics, The University of 
      Edinburgh, Edinburgh, UK.
FAU - Tappin, David Michael
AU  - Tappin DM
AD  - Scottish Cot Death Trust, West Glasgow Ambulatory Care Hospital, University of
      Glasgow, Glasgow, UK.
FAU - Mitchell, Alex
AU  - Mitchell A
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Boyd, Kathleen Anne
AU  - Boyd KA
AD  - Health Economics and Health Technology Assessment, Institute of Health and
      Wellbeing, University of Glasgow, Glasgow, UK.
LA  - eng
SI  - ISRCTN/ISRCTN15236311
GR  - C48006/A20863/CRUK_/Cancer Research UK/United Kingdom
GR  - HIPS/16/1/Chief Scientist Office Scottish/International
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Child
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Health Behavior
MH  - Humans
MH  - Infant, Newborn
MH  - *Motivation
MH  - Multicenter Studies as Topic
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - *Smoking Cessation
MH  - State Medicine
PMC - PMC7592273
OTO - NOTNLM
OT  - *health economics
OT  - *maternal medicine
OT  - *public health
COIS- Competing interests: None declared
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038827 [pii]
AID - 10.1136/bmjopen-2020-038827 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e038827. doi: 10.1136/bmjopen-2020-038827.


PMID- 33109657
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 26
TI  - Resilience in Healthcare (RiH): a longitudinal research programme protocol.
PG  - e038779
LID - 10.1136/bmjopen-2020-038779 [doi]
AB  - INTRODUCTION: Over the past three decades, extensive research has been undertaken
      to understand the elements of what constitutes high quality in healthcare. Yet,
      much of this research has been conducted on individual elements and their
      specific challenges. Hence, goals other than understanding the complex of factors
      and elements that comprises quality in healthcare have been privileged. This lack
      of progress has led to the conclusion that existing approaches to research are
      not able to address the inherent complexity of healthcare systems as
      characterised by a significant degree of performance variability within and
      across system levels, and what makes them resilient. A shift is, therefore,
      necessary in such approaches. Resilience in Healthcare (RiH) adopts an approach
      comprising a comprehensive research programme that models the capacity of
      healthcare systems and stakeholders to adapt to changes, variations and/or
      disruptions: that is, resilience. As such, RiH offers a fresh approach capable of
      capturing and illuminating the complexity of healthcare and how high-quality care
      can be understood and advanced. METHODS AND ANALYSIS: Methodologically, to
      illuminate what constitutes quality in healthcare, it is necessary to go beyond
      single-site, case-based studies. Instead, there is a need to engage in
      multi-site, cross-national studies and engage in long-term multidisciplinary
      collaboration between national and international researchers interacting with
      multiple healthcare stakeholders. By adopting such processes, multiple partners
      and a multidisciplinary orientation, the 5-year RiH research programme aims to
      confront these challenges and accelerate current understandings about and
      approaches to researching healthcare quality.The RiH research programme adopts a 
      longitudinal collaborative interactive design to capture and illuminate
      resilience as part of healthcare quality in different healthcare settings in
      Norway and in five other countries. It combines a meta-analysis of detailed
      empirical research in Norway with cross-country comparison from Australia, Japan,
      Netherlands, Switzerland and the UK. Through establishing an RiH framework, the
      programme will identify processes with outcomes that aim to capture how
      high-quality healthcare provisions are achieved. A collaborative learning
      framework centred on engagement aims to systematically translate research
      findings into practice through co-construction processes with partners and
      stakeholders. ETHICS AND DISSEMINATION: The RiH research programme is approved by
      the Norwegian Centre for Research Data (No. 864334). The empirical projects
      selected for inclusion in this longitudinal research programme have been approved
      by the Norwegian Centre for Research Data or the Regional Committees for Medical 
      and Health Research Ethics. The RiH research programme has an embedded
      publication and dissemination strategy focusing on the progressive sharing of
      scientific knowledge, information and results, and on engaging with the public,
      including relevant patient and stakeholder representatives. The findings will be 
      disseminated through scientific articles, PhD dissertations, presentations at
      national and international conferences, and through social media, newsletters and
      the popular media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aase, Karina
AU  - Aase K
AUID- ORCID: 0000-0002-5363-5152
AD  - SHARE - Centre for Resilience in Healthcare, University of Stavanger, Stavanger, 
      Norway karina.aase@uis.no.
FAU - Guise, Veslemoy
AU  - Guise V
AUID- ORCID: 0000-0002-9124-1664
AD  - SHARE - Centre for Resilience in Healthcare, University of Stavanger, Stavanger, 
      Norway.
FAU - Billett, Stephen
AU  - Billett S
AD  - School of Education and Professional Studies, Griffith University, Nathan,
      Queensland, Australia.
FAU - Sollid, Stephen Johan Mikal
AU  - Sollid SJM
AD  - SHARE - Centre for Resilience in Healthcare, University of Stavanger, Stavanger, 
      Norway.
AD  - Department for Research and Development, Norwegian Air Ambulance Foundation,
      Oslo, Norway.
FAU - Nja, Ove
AU  - Nja O
AD  - Faculty of Science and Technology, University of Stavanger, Stavanger, Norway.
FAU - Roise, Olav
AU  - Roise O
AUID- ORCID: 0000-0003-4931-7001
AD  - SHARE - Centre for Resilience in Healthcare, University of Stavanger, Stavanger, 
      Norway.
AD  - Division of Orthopedic Surgery, Oslo University Hospital, Oslo, Norway.
FAU - Manser, Tanja
AU  - Manser T
AD  - School of Applied Psychology, University of Applied Sciences and Arts
      Northwestern Switzerland, Olten, Switzerland.
FAU - Anderson, Janet E
AU  - Anderson JE
AD  - SHARE - Centre for Resilience in Healthcare, University of Stavanger, Stavanger, 
      Norway.
AD  - Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's
      College London, London, UK.
FAU - Wiig, Siri
AU  - Wiig S
AD  - SHARE - Centre for Resilience in Healthcare, University of Stavanger, Stavanger, 
      Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Delivery of Health Care
MH  - *Health Services Research
MH  - Humans
MH  - Japan
MH  - Longitudinal Studies
MH  - Netherlands
MH  - Norway
MH  - Quality of Health Care
MH  - Switzerland
PMC - PMC7592282
OTO - NOTNLM
OT  - *health & safety
OT  - *health policy
OT  - *organisation of health services
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-038779 [pii]
AID - 10.1136/bmjopen-2020-038779 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 26;10(10):e038779. doi: 10.1136/bmjopen-2020-038779.


PMID- 33109655
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Health risk behaviours among migrants by duration of residence: protocol for a
      systematic review and meta-analysis.
PG  - e038388
LID - 10.1136/bmjopen-2020-038388 [doi]
AB  - INTRODUCTION: International migrants' health has often been found to deteriorate 
      in new countries, partly due to changes in health risk behaviours such as alcohol
      consumption, tobacco use, physical inactivity, and poor dietary habits. However, 
      limited efforts have been made to comprehensively evaluate the extent to which
      migrants adopt unhealthy risk behaviours with longer duration of residence. This 
      systematic review and meta-analysis will summarise evidence on international
      migrants' behavioural patterns by duration of residence in multiple country
      contexts. METHODS AND ANALYSIS: PubMed/MEDLINE, Web of Science and ProQuest
      databases will be searched for quantitative or mixed-method observational studies
      published in peer-reviewed scientific journals between 1 January 2000 and 31
      December 2019. Studies comparing foreign-born individuals by duration of
      residence will be included. Information on study characteristics, descriptive
      statistics and measures of effect will be extracted. All included studies will be
      quality assessed using a modified Newcastle-Ottawa scale. The review will include
      narrative synthesis and, if sufficient and comparable data are available, random 
      effects meta-analyses. The review will be conducted in compliance with the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
      ETHICS AND DISSEMINATION: Ethical approval is not required since previously
      published information from peer-reviewed studies will be assessed. The results of
      this review will be published in peer-reviewed journals and presented at
      scientific conferences. Other forms of dissemination will include communication
      to broader audiences using well-established channels, including through
      university-based press releases. Progress will be regularly updated on the
      International Prospective Register of Systematic Reviews to ensure full
      transparency. PROSPERO REGISTRATION NUMBER: CRD42018108881.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Berg, Lisa
AU  - Berg L
AUID- ORCID: 0000-0002-8707-180X
AD  - Department of Public Health Sciences, Stockholm University, Stockholm, Sweden
      lisa.berg@su.se.
AD  - Centre for Health Equity Studies, Stockholm University/Karolinska Institutet,
      Stockholm, Sweden.
FAU - Gustafsson, Nina-Katri
AU  - Gustafsson NK
AD  - Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
AD  - Centre for Health Equity Studies, Stockholm University/Karolinska Institutet,
      Stockholm, Sweden.
FAU - Honkaniemi, Helena
AU  - Honkaniemi H
AD  - Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
AD  - Centre for Health Equity Studies, Stockholm University/Karolinska Institutet,
      Stockholm, Sweden.
FAU - Juarez, Sol Pia
AU  - Juarez SP
AD  - Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
AD  - Centre for Health Equity Studies, Stockholm University/Karolinska Institutet,
      Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Health Risk Behaviors
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Time Factors
MH  - *Transients and Migrants
PMC - PMC7592271
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038388 [pii]
AID - 10.1136/bmjopen-2020-038388 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e038388. doi: 10.1136/bmjopen-2020-038388.


PMID- 33109654
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 26
TI  - Effects of active referral combined with a small financial incentive on smoking
      cessation: study protocol for a cluster randomised controlled trial.
PG  - e038351
LID - 10.1136/bmjopen-2020-038351 [doi]
AB  - INTRODUCTION: Evidence-based smoking cessation treatments are effective but
      underutilised, accentuating the need for novel approaches to increase use. This
      trial investigates the effects of active referral combined with a financial
      incentive to use smoking cessation services on smoking abstinence among community
      smokers. METHODS AND ANALYSIS: This ongoing study is a two-arm, assessor-blinded,
      pragmatic, cluster randomised controlled trial with follow-ups at 1, 2, 3 and 6
      months after randomisation. We aim to enrol 1134 daily smokers from 70 community 
      sites (clusters) in Hong Kong. All participants receive Ask, Warn, Advise, Refer,
      Do-it-again (AWARD) guided advice and a self-help booklet at baseline.
      Additionally, participants in the intervention group receive an offer of referral
      to smoking cessation services at baseline and a small financial incentive (HK$300
      approximately US$38) contingent on using any of such services within 3 months.
      The primary outcomes are bioverified abstinence (exhaled carbon monoxide <4 ppm
      and salivary cotinine <10 ng/mL) at 3 and 6 months. Secondary outcomes include
      self-reported 7-day point prevalence of abstinence, smoking reduction rate, quit 
      attempts and the use of smoking cessation services at 3 and 6 months.
      Intention-to-treat approach and regression models will be used in primary
      analyses. ETHICS AND DISSEMINATION: This protocol has been approved by the
      Institutional Review Board of the University of Hong Kong/Hospital Authority Hong
      Kong West Cluster (IRB reference number: UW 18-318). The results of this trial
      will be submitted for publication in peer-reviewed journals, and the key findings
      will be presented at national and international conferences. TRIAL REGISTRATION
      NUMBER: ClinicalTrials.gov Registry NCT03565796.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Weng, Xue
AU  - Weng X
AUID- ORCID: 0000-0002-9564-4284
AD  - School of Nursing, University of Hong Kong, Hong Kong, China.
FAU - Wang, Man Ping
AU  - Wang MP
AUID- ORCID: 0000-0003-4000-2388
AD  - School of Nursing, University of Hong Kong, Hong Kong, China mpwang@hku.hk.
FAU - Li, Ho Cheung William
AU  - Li HCW
AUID- ORCID: 0000-0002-2562-769X
AD  - School of Nursing, University of Hong Kong, Hong Kong, China.
FAU - Cheung, Yee Tak Derek
AU  - Cheung YTD
AUID- ORCID: 0000-0002-5850-5349
AD  - School of Nursing, University of Hong Kong, Hong Kong, China.
FAU - Lau, Ching Yin
AU  - Lau CY
AD  - School of Nursing, University of Hong Kong, Hong Kong, China.
FAU - Kwong, Antonio Cho Shing
AU  - Kwong ACS
AD  - Hong Kong Council on Smoking and Health, Hong Kong, China.
FAU - Lai, Vienna Wai Yin
AU  - Lai VWY
AD  - Hong Kong Council on Smoking and Health, Hong Kong, China.
FAU - Chan, Sophia Siu Chee
AU  - Chan SSC
AD  - School of Nursing, University of Hong Kong, Hong Kong, China.
FAU - Lam, Tai Hing
AU  - Lam TH
AD  - School of Public Health, University of Hong Kong, Hong Kong, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03565796
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Motivation
MH  - Randomized Controlled Trials as Topic
MH  - *Referral and Consultation
MH  - Smokers/psychology
MH  - *Smoking Cessation/methods/psychology
PMC - PMC7592296
OTO - NOTNLM
OT  - *clinical trials
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - bmjopen-2020-038351 [pii]
AID - 10.1136/bmjopen-2020-038351 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 26;10(10):e038351. doi: 10.1136/bmjopen-2020-038351.


PMID- 33109653
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Uncovering motivation and self-regulated learning skills in integrated medical
      MOOC learning: a mixed methods research protocol.
PG  - e038235
LID - 10.1136/bmjopen-2020-038235 [doi]
AB  - INTRODUCTION: Massive Open Online Courses (MOOCs) are informal learning
      environments. Since a few years, MOOCs are being reused and integrated in formal 
      medical education. However, what constitutes optimal integration is still
      unclear. In this mixed methods study protocol we describe how we will investigate
      three MOOC integration designs using the same MOOC. THIS STUDY HOLDS MULTIPLE
      OBJECTIVES: (1) Describe motivation profiles in medical students that learn in
      integrated MOOCs, and discern if motivation profiles are associated with specific
      MOOC integration designs; (2) investigate how psychological needs of medical
      students are satisfied or frustrated in different MOOC integration designs; (3)
      investigate the relationship between autonomous motivation to learn in an
      integrated MOOC and use of self-regulated learning skills in that MOOC; (4)
      uncover processes that are involved in goal acceptance or rejection of medical
      students in integrated medical MOOC designs with assigned learning goals; and (5)
      identify obstacles medical students encounter when learning with assigned
      learning goals in integrated medical MOOCs. METHODS AND ANALYSIS: Objectives 1
      and 2 will be pursued with a cross-sectional study design, objective 3 with an
      observational cohort study design and objectives 4 and 5 with a qualitative
      interview study design. All medical students in one of three MOOC integration
      designs at Leiden University Medical Center (LUMC) will be invited to
      participate. Primary endpoints for objectives 1 and 2 are motivation profiles,
      and variety in need satisfaction and frustration. For objective 3 the primary
      endpoints are autonomous motivation and self-regulated online learning. For
      objectives 4 and 5 primary endpoints are process themes regarding goal acceptance
      or rejection, and perceived obstacles when working with assigned online learning 
      goals. ETHICS AND DISSEMINATION: This study has been approved by the Educational 
      Research Review Board of the LUMC. Planned dissemination of findings include
      three presentations at (inter)national conferences and three research articles.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hendriks, Renee A
AU  - Hendriks RA
AUID- ORCID: 0000-0002-1932-6428
AD  - Center for Innovation in Medical Education, Leiden University Medical Center,
      Leiden, The Netherlands r.a.hendriks@lumc.nl.
FAU - de Jong, Peter G M
AU  - de Jong PGM
AD  - Center for Innovation in Medical Education, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - Admiraal, Wilfried F
AU  - Admiraal WF
AD  - ICLON Leiden University Graduate School of Teaching, Leiden University, Leiden,
      The Netherlands.
FAU - Reinders, Marlies E J
AU  - Reinders MEJ
AD  - Department of Internal Medicine, Leiden University Medical Center, Leiden, The
      Netherlands.
AD  - Department of Internal Medicine, Erasmus University Medical Center, Rotterdam,
      The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Education, Distance
MH  - *Education, Medical
MH  - Humans
MH  - Learning
MH  - Motivation
MH  - Observational Studies as Topic
PMC - PMC7592287
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *medical education & training
OT  - *world wide web technology
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038235 [pii]
AID - 10.1136/bmjopen-2020-038235 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e038235. doi: 10.1136/bmjopen-2020-038235.


PMID- 33109651
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Factors influencing maternal health in indigenous communities with presence of
      traditional midwifery in the Americas: protocol for a scoping review.
PG  - e037922
LID - 10.1136/bmjopen-2020-037922 [doi]
AB  - INTRODUCTION: Indigenous mothers often receive culturally unsafe services that do
      not fully respond to their needs. The objective of this scoping review is to
      collate and assess evidence that identifies factors, including the role and
      influence of traditional midwives, that affect maternal health in indigenous
      communities in the Americas. The results will map Western perspectives reflected 
      in published and unpublished literature to indicate the complex network of
      factors that influence maternal outcomes. These maps will allow for comparison
      with local stakeholder knowledge and discussion to identify what needs to change 
      to promote culturally safe care. METHODS AND ANALYSIS: A librarian will search
      studies with iterative and documented adjustments in CINAHL, Scopus, Latin
      American and Caribbean Health Sciences Literature (LILACS), MEDLINE, Embase and
      Google Scholar without any time restrictions, and use Google search engine for
      grey literature. Included studies will be empirical (quantitative, qualitative or
      mixed); address maternal health issues among indigenous communities in the
      Americas; and report on the role or influence of traditional midwives. Two
      researchers will independently screen and blindly select the included studies.
      The quality assessment of included manuscripts will rely on the Mixed Methods
      Appraisal Tool (MMAT). Two independent researchers will extract data on factors
      promoting or reducing maternal health in indigenous communities, including the
      role or influence of traditional midwives. Fuzzy cognitive mapping will summarise
      the findings as a list of relationships between identified factors and outcomes
      with weights indicating strength of the relationship and the evidence supporting 
      this. ETHICS AND DISSEMINATION: This review is part of a proposal approved by the
      ethics committees at McGill University and the Centro de Investigacion de
      Enfermedades Tropicales in Guerrero. Participating indigenous communities in
      Guerrero State approved the study in 2015. The results of the scoping review will
      contribute to the field of cultural safety and intercultural dialogue for the
      promotion of maternal health in indigenous communities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sarmiento, Ivan
AU  - Sarmiento I
AUID- ORCID: 0000-0003-2871-1464
AD  - CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Quebec,
      Canada ivan.sarmiento@mail.mcgill.ca.
AD  - Grupo de Estudios en Sistemas Tradicionales de Salud (GESTS), Universidad del
      Rosario, Bogota, Cundinamarca, Colombia.
FAU - Paredes-Solis, Sergio
AU  - Paredes-Solis S
AUID- ORCID: 0000-0002-3015-3038
AD  - Centro de Investigacion de Enfermedades Tropicales (CIET), Universidad Autonoma
      de Guerrero, Acapulco, Mexico.
FAU - Morris, Martin
AU  - Morris M
AD  - Schulich Library of Physical Sciences, Life Sciences and Engineering, McGill
      University, Montreal, Quebec, Canada.
FAU - Pimentel, Juan
AU  - Pimentel J
AD  - CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Quebec,
      Canada.
AD  - Grupo de Estudios en Sistemas Tradicionales de Salud (GESTS), Universidad del
      Rosario, Bogota, Cundinamarca, Colombia.
FAU - Cockcroft, Anne
AU  - Cockcroft A
AD  - CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Quebec,
      Canada.
FAU - Andersson, Neil
AU  - Andersson N
AD  - CIET-PRAM, Department of Family Medicine, McGill University, Montreal, Quebec,
      Canada.
AD  - Centro de Investigacion de Enfermedades Tropicales (CIET), Universidad Autonoma
      de Guerrero, Acapulco, Mexico.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Americas
MH  - Caribbean Region
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - Maternal Health
MH  - *Midwifery
MH  - Pregnancy
MH  - Review Literature as Topic
PMC - PMC7592283
OTO - NOTNLM
OT  - *maternal medicine
OT  - *primary care
OT  - *public health
OT  - *reproductive medicine
OT  - *social medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037922 [pii]
AID - 10.1136/bmjopen-2020-037922 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e037922. doi: 10.1136/bmjopen-2020-037922.


PMID- 33109646
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 26
TI  - Awareness of cognitive abilities in the execution of activities of daily living
      after acquired brain injury: an evaluation protocol.
PG  - e037542
LID - 10.1136/bmjopen-2020-037542 [doi]
AB  - INTRODUCTION: One of the main limitations that can be observed after acquired
      brain injury (ABI) is the alteration of the awareness of the deficits that can
      occur in the cognitive skills necessary for performing activities of daily living
      (ADL). According to the Dynamic Comprehensive Model of Awareness (DCMA),
      consciousness is composed of offline component, which contains the information
      stored about characteristics of the tasks and stable beliefs about one's own
      capabilities and online awareness, which is activated in the context of the
      performance of a specific task. The main objective of this project was to
      generate and validate a detailed cognitive assessment protocol within the context
      of ADL to evaluate the components of DCMA. METHODS AND ANALYSIS: The proposed
      protocol consists of two ecological tools: The Cog-Awareness ADL Scale to measure
      offline component and the Awareness ADL-task: Basic and Instrumental ADL
      performance-based test to measure online awareness. The aim is to identify the
      presence of cognitive deficits and anosognosia in patients with ABI within the
      context of everyday life activities. These two measures will be administered to a
      group of patients with ABI. In addition, these participants will complete another
      series of classic tests on anosognosia and cognitive functions in order to find
      the convergent validity of the two tests proposed in this protocol. The external 
      validity of the Cog-Awareness ADL Scale and the relationships between awareness
      components within the same ADL domain will be also analysed. ETHICS AND
      DISSEMINATION: This study was approved by the Ethics Committee of Biomedical
      Research of Andalusia, on 13 January /2017 (Proceeding 1/2017). All participants 
      are required to provide written informed consent. The findings from this will be 
      disseminated via scientific publication. TRIAL REGISTRATION NUMBER: NCT03712839.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Merchan-Baeza, Jose Antonio
AU  - Merchan-Baeza JA
AD  - Research group on Methodology, Methods, Models and Outcomes of Health and Social 
      Sciences (M3O), Faculty of Health Science and Welfare, Centre for Health and
      Social Care Research (CESS), University of Vic-Central University of Catalonia
      (UVIC-UCC), Vic (Barcelona), Spain.
FAU - Rodriguez-Bailon, Maria
AU  - Rodriguez-Bailon M
AUID- ORCID: 0000-0001-6658-7658
AD  - Departament of Physiotherapy (Occupational Therapy), University of Malaga,
      Malaga, Spain mariarbailon@uma.es.
FAU - Ricchetti, Giorgia
AU  - Ricchetti G
AD  - Departament of Experimental Psychology; Mind, Brain and Behavior Research Center 
      (CIMCYC-UGR), University of Granada, Granada, Spain.
FAU - Navarro-Egido, Alba
AU  - Navarro-Egido A
AD  - Departament of Experimental Psychology; Mind, Brain and Behavior Research Center 
      (CIMCYC-UGR), University of Granada, Granada, Spain.
FAU - Funes, Maria Jesus
AU  - Funes MJ
AD  - Departament of Experimental Psychology; Mind, Brain and Behavior Research Center 
      (CIMCYC-UGR), University of Granada, Granada, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03712839
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - *Brain Injuries
MH  - Cognition
MH  - *Cognitive Dysfunction
MH  - Humans
PMC - PMC7592290
OTO - NOTNLM
OT  - *adult neurology
OT  - *neurological injury
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037542 [pii]
AID - 10.1136/bmjopen-2020-037542 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 26;10(10):e037542. doi: 10.1136/bmjopen-2020-037542.


PMID- 33109644
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 26
TI  - Consequences of health condition labelling: protocol for a systematic scoping
      review.
PG  - e037392
LID - 10.1136/bmjopen-2020-037392 [doi]
AB  - INTRODUCTION: When health conditions are labelled it is often to classify and
      communicate a set of symptoms. While diagnostic labelling can provide explanation
      for an individual's symptoms, it can also impact how individuals and others view 
      those symptoms. Despite existing research regarding the effects of labelling
      health conditions, a synthesis of these effects has not occurred. We will conduct
      a systematic scoping review to synthesise the reported consequences and impact of
      being given a label for a health condition from an individual, societal and
      health practitioner perspective and explore in what context labelling of health
      conditions is considered important. METHODS AND ANALYSIS: The review will adhere 
      to the Joanna Briggs Methodology for Scoping Reviews. Searches will be conducted 
      in five electronic databases (PubMed, Embase, PsycINFO, Cochrane, CINAHL).
      Reference lists of included studies will be screened and forward and backward
      citation searching of included articles will be conducted. We will include
      reviews and original studies which describe the consequences for individuals
      labelled with a non-cancer health condition. We will exclude hypothetical
      research designs and studies focused on the consequences of labelling cancer
      conditions, intellectual disabilities and/or social attributes. We will conduct
      thematic analyses for qualitative data and descriptive or meta-analyses for
      quantitative data where appropriate. ETHICS AND DISSEMINATION: Ethical approval
      is not required for a scoping review. Results will be disseminated via
      publication in a peer-reviewed journal, conference presentations and lay-person
      summaries on various online platforms. Findings from this systematic scoping
      review will identify gaps in current understanding of how, when, why and for whom
      a diagnostic label is important and inform future research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sims, Rebecca
AU  - Sims R
AUID- ORCID: 0000-0002-1604-8354
AD  - Institute for Evidence-Based Healthcare, Bond University Faculty of Health
      Sciences and Medicine, Gold Coast, Queensland, Australia.
FAU - Kazda, Luise
AU  - Kazda L
AUID- ORCID: 0000-0003-4105-0402
AD  - Sydney School of Public Health, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Michaleff, Zoe A
AU  - Michaleff ZA
AUID- ORCID: 0000-0002-0360-4956
AD  - Institute for Evidence-Based Healthcare, Bond University Faculty of Health
      Sciences and Medicine, Gold Coast, Queensland, Australia.
FAU - Glasziou, Paul
AU  - Glasziou P
AUID- ORCID: 0000-0001-7564-073X
AD  - Institute for Evidence-Based Healthcare, Bond University Faculty of Health
      Sciences and Medicine, Gold Coast, Queensland, Australia.
FAU - Thomas, Rae
AU  - Thomas R
AUID- ORCID: 0000-0002-2165-5917
AD  - Institute for Evidence-Based Healthcare, Bond University Faculty of Health
      Sciences and Medicine, Gold Coast, Queensland, Australia rthomas@bond.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Intellectual Disability
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7592274
OTO - NOTNLM
OT  - *public health
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037392 [pii]
AID - 10.1136/bmjopen-2020-037392 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 26;10(10):e037392. doi: 10.1136/bmjopen-2020-037392.


PMID- 33109642
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 26
TI  - Selenium and bone health: a protocol for a systematic review and meta-analysis.
PG  - e036612
LID - 10.1136/bmjopen-2019-036612 [doi]
AB  - INTRODUCTION: Bone health affects the ability of human body to stay active, and
      its degradation can cause considerable morbidity and mortality. The factors
      related to bone health play an important role in preventing osteoporosis and its 
      adverse consequences. However, the risk factors for osteoporosis have not been
      fully elucidated. Deficiency in the trace element selenium may be one of the risk
      factors for the development of osteoporosis. Previous studies have investigated
      the effects of selenium on osteoporosis; however, the results are inconclusive.
      Therefore, the present study aimed to systematically examine the existing
      literature on the associations between dietary or serum selenium and bone mineral
      density (BMD), osteoporosis or osteoporotic fractures, and to quantify such
      associations through meta-analysis. METHODS AND ANALYSIS: PubMed, Embase and
      Cochrane Library will be searched using a specified search strategy to identify
      relevant studies up to October 2019. Both interventional and observational
      studies in humans will be included. The outcomes will include BMD and the
      prevalence or incidence of osteoporosis and osteoporotic fractures. For dietary
      or serum selenium and BMD, osteoporosis or osteoporotic fractures pooled
      analyses, estimates will be expressed as the mean difference, and the pooled OR, 
      relative risk, HR or beta coefficient, and corresponding 95% CIs. Heterogeneity
      of the studies and publication bias will be investigated accordingly. To assess
      the quality and the risk of bias of the included studies, the Newcastle-Ottawa
      Quality Scale or the Cochrane risk of bias assessment tool will be used where
      appropriate. ETHICS AND DISSEMINATION: Since no private and confidential patient 
      data will be included in the reporting, approval from an ethics committee is not 
      required. The results will be published in a peer-reviewed journal. The study
      raises no ethical issues. PROSPERO REGISTRATION NUMBER: CRD42019147188.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Ning
AU  - Wang N
AD  - Department of Orthopaedics, Xiangya Hospital Central South University, Changsha, 
      Hunan, China.
FAU - Xie, Dongxing
AU  - Xie D
AD  - Department of Orthopaedics, Xiangya Hospital Central South University, Changsha, 
      Hunan, China.
FAU - Wu, Jing
AU  - Wu J
AD  - Department of Epidemiology and Health Statistics, Central South University
      Xiangya School of Public Health, Changsha, Hunan, China.
FAU - Wu, Ziying
AU  - Wu Z
AD  - Department of Orthopaedics, Xiangya Hospital Central South University, Changsha, 
      Hunan, China.
FAU - He, Hongyi
AU  - He H
AD  - Department of Orthopaedics, Xiangya Hospital Central South University, Changsha, 
      Hunan, China.
FAU - Yang, Zidan
AU  - Yang Z
AD  - Department of Epidemiology and Health Statistics, Central South University
      Xiangya School of Public Health, Changsha, Hunan, China.
FAU - Yang, Tuo
AU  - Yang T
AD  - Health Management Center, Xiangya Hospital Central South University, Changsha,
      Hunan, China.
FAU - Wang, Yilun
AU  - Wang Y
AUID- ORCID: 0000-0002-9468-4110
AD  - Department of Orthopaedics, Xiangya Hospital Central South University, Changsha, 
      Hunan, China yilun_Wang@csu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - H6241UJ22B (Selenium)
SB  - IM
MH  - Bone Density
MH  - Bone and Bones
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Osteoporosis/epidemiology/prevention & control
MH  - *Osteoporotic Fractures
MH  - *Selenium
PMC - PMC7592280
OTO - NOTNLM
OT  - *bone diseases
OT  - *orthopaedic & trauma surgery
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036612 [pii]
AID - 10.1136/bmjopen-2019-036612 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 26;10(10):e036612. doi: 10.1136/bmjopen-2019-036612.


PMID- 33109641
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 27
TI  - Duloxetine combined with intra-articular injection versus intra-articular
      injection alone for pain relief in knee osteoarthritis: a study protocol for a
      randomised controlled trial.
PG  - e036447
LID - 10.1136/bmjopen-2019-036447 [doi]
AB  - INTRODUCTION: Intra-articular (IA) injection of hyaluronic acid (HA) and
      corticosteroid (CS) is a common treatment for osteoarthritis (OA) of the knee. As
      a drug treatment for patients with depression, duloxetine has been shown in many 
      studies to effectively relieve the pain of OA and improve function of the knee
      joint. However, evidence regarding the efficacy of IA injection of HA+CS combined
      with duloxetine for pain management in patients with OA of the knee is lacking.
      The aim of this study was to test the hypothesis that IA injection of HA+CS
      combined with duloxetine could achieve pain management superior to that of IA
      injection of HA+CS alone in patients experiencing knee OA pain. METHODS: This
      study will adopt a prospective, randomised, open-label blind endpoint study
      design. In total, 150 patients with OA of the knee will be enrolled in the study.
      The participants will be randomly allocated to receive either a single IA
      injection of HA+CS combined with duloxetine or a single IA injection of HA+CS
      alone, and both groups will complete a 24-week follow-up to assess pain and
      functional improvements. The primary outcome measure is the change in the weekly 
      mean of the 24 hours average pain scores from baseline to the end of 24 weeks in 
      patients with OA of the knee, and the secondary outcomes include the response to 
      treatment, changes from baseline in the brief pain inventory, improvement in the 
      Western Ontario and McMaster Universities Osteoarthritis index scores, patient
      global impression of improvement scale, Hospital Anxiety and Depression Scale and
      adverse events during the 24-week follow-up. The data will be analysed by the
      intention-to-treat principle. ETHICS APPROVAL AND DISSEMINATION: This study was
      approved by the institutional ethics committee of the Beijing Tiantan Hospital
      (approval number: KY 2019-086-02). The results of the study will be published in 
      peer-reviewed journals, and the findings will be presented at scientific
      meetings. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04117893; 
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Duo Yi
AU  - Li DY
AUID- ORCID: 0000-0002-2151-548X
AD  - Department of Anesthesiology, Beijing Children's Hospital, Capital Medical
      University, National Center for Children's Health, Beijing, China.
FAU - Han, Rong
AU  - Han R
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, China.
FAU - Zhao, Zhi Gang
AU  - Zhao ZG
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, China luofangwt@yahoo.com 1022zzg@sina.com.
FAU - Luo, Fang
AU  - Luo F
AD  - Department of Pain Management, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China luofangwt@yahoo.com 1022zzg@sina.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04117893
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201027
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 9044SC542W (Duloxetine Hydrochloride)
SB  - IM
MH  - Duloxetine Hydrochloride/therapeutic use
MH  - Humans
MH  - Hyaluronic Acid/therapeutic use
MH  - Injections, Intra-Articular
MH  - *Osteoarthritis, Knee/complications/drug therapy
MH  - Pain
MH  - Pain Management
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7592275
OTO - NOTNLM
OT  - *anaesthetics
OT  - *knee
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036447 [pii]
AID - 10.1136/bmjopen-2019-036447 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 27;10(10):e036447. doi: 10.1136/bmjopen-2019-036447.


PMID- 33109628
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2059-7029 (Electronic)
IS  - 2059-7029 (Linking)
VI  - 5
IP  - 5
DP  - 2020 Oct
TI  - Late decisions about treatment limitation in patients with cancer: empirical
      analysis of end-of-life practices in a haematology and oncology unit at a German 
      university hospital.
PG  - e000950
LID - S2059-7029(20)32722-8 [pii]
LID - 10.1136/esmoopen-2020-000950 [doi]
AB  - BACKGROUND: Decisions to limit treatment (DLTs) are important to protect patients
      from overtreatment but constitute one of the most ethically challenging
      situations in oncology practice. In the Ethics Policy for Advance Care Planning
      and Limiting Treatment study (EPAL), we examined how often DLT preceded a
      patient's death and how early they were determined before (T1) and after (T2) the
      implementation of an intrainstitutional ethics policy on DLT. METHODS: This
      prospective quantitative study recruited 1.134 patients with
      haematological/oncological neoplasia in a period of 2x6 months at the University 
      Hospital of Munich, Germany. Information on admissions, discharges, diagnosis,
      age, DLT, date and place of death, and time span between the initial
      determination of a DLT and the death of a patient was recorded using a
      standardised form. RESULTS: Overall, for 21% (n=236) of the 1.134 patients, a DLT
      was made. After implementation of the policy, the proportion decreased (26%
      T1/16% T2). However, the decisions were more comprehensive, including more often 
      the combination of 'Do not resuscitate' and 'no intense care unit' (44% T1/64%
      T2). The median time between the determination of a DLT and the patient's death
      was similarly short with 6 days at a regular ward (each T1/T2) and 10.5/9 (T1/T2)
      days at a palliative care unit. For patients with solid tumours, the DLTs were
      made earlier at both regular and palliative care units than for the deceased with
      haematological neoplasia. CONCLUSION: Our results show that an ethics policy on
      DLT could sensitise for treatment limitations in terms of frequency and extension
      but had no significant impact on timing of DLT. Since patients with
      haematological malignancies tend to undergo intensive therapy more often during
      their last days than patients with solid tumours, special attention needs to be
      paid to this group. To support timely discussions, we recommend the concept of
      advance care planning.
CI  - (c) Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. Published by BMJ on behalf of the European Society for Medical
      Oncology.
FAU - Mehlis, Katja
AU  - Mehlis K
AD  - Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg,
      Germany. Electronic address: Katja.Mehlis@med.uni-heidelberg.de.
FAU - Bierwirth, Elena
AU  - Bierwirth E
AD  - Institut fur physikalische und rehabilitative Medizin, Klinikum Ingolstadt GmbH, 
      Ingolstadt, Germany.
FAU - Laryionava, Katsiaryna
AU  - Laryionava K
AD  - Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg,
      Germany.
FAU - Mumm, Friederike
AU  - Mumm F
AD  - Department of Medicine III, University Hospital Munich, Munich, Germany.
FAU - Heussner, Pia
AU  - Heussner P
AD  - Zentrum Innere Medizin, Klinikum Garmisch-Partenkirchen GmbH,
      Garmisch-Partenkirchen, Germany.
FAU - Winkler, Eva C
AU  - Winkler EC
AD  - Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg,
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
SB  - IM
MH  - Death
MH  - *Hematology
MH  - Hospitals, University
MH  - Humans
MH  - *Neoplasms/therapy
MH  - Prospective Studies
PMC - PMC7592262
OTO - NOTNLM
OT  - *advanced cancer
OT  - *end-of-life
OT  - *life-prolonging measures
OT  - *treatment limitation
COIS- Competing interests: None declared.
EDAT- 2020/10/29 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/07/28 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - S2059-7029(20)32722-8 [pii]
AID - 10.1136/esmoopen-2020-000950 [doi]
PST - ppublish
SO  - ESMO Open. 2020 Oct;5(5):e000950. doi: 10.1136/esmoopen-2020-000950.


PMID- 33109513
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201029
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 371
DP  - 2020 Oct 27
TI  - Covid-19: Doctors question ethics of treating adults in paediatric ICUs.
PG  - m4144
LID - 10.1136/bmj.m4144 [doi]
FAU - Dyer, Clare
AU  - Dyer C
AD  - The BMJ.
LA  - eng
PT  - Journal Article
DEP - 20201027
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
EDAT- 2020/10/29 06:00
MHDA- 2020/10/29 06:01
CRDT- 2020/10/28 05:31
PHST- 2020/10/28 05:31 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/10/29 06:01 [medline]
AID - 10.1136/bmj.m4144 [doi]
PST - epublish
SO  - BMJ. 2020 Oct 27;371:m4144. doi: 10.1136/bmj.m4144.


PMID- 33109490
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 1877-0568 (Electronic)
IS  - 1877-0568 (Linking)
VI  - 106
IP  - 8
DP  - 2020 Dec
TI  - Want a better h-index? - All you need to know about copyright and open access.
PG  - 1475-1480
LID - S1877-0568(20)30273-5 [pii]
LID - 10.1016/j.otsr.2020.05.015 [doi]
AB  - INTRODUCTION: Physicians, whether in the public or private sector, are
      increasingly bound to "publish or perish". Although researchers have become aware
      of certain ethical concerns relating to the concept of authorship, clinicians
      still tend to neglect issues of copyright. The present study aims: 1) to explain 
      to orthopedic surgeons what exactly is protected by copyright in a scientific
      article; 2) to assess the legal implications of publishing contracts; and 3) to
      specify the means of publication that best boost the author's h-index. MATERIAL
      AND METHODS: The study was based on intellectual property legislation and
      jurisprudence and the underlying principles. The European and American medical
      and legal literature was analyzed. RESULTS: It is vital to understand the basic
      principles of copyright and the legal implications of publishing contracts. A
      scientific article is protected by copyright as soon as it has been written. This
      confers both moral and property rights. "Moral" rights protect the person of the 
      author and are inalienable; unlike property rights, they cannot be transferred.
      Publishing contracts can only concern property and other derivative rights. Most 
      scientific articles are published in open access via Creative Commons (CC)
      licenses. The greater the freedom of use provided for in the CC license, the more
      easily other authors can use the article, adding to it or altering it. As all CC 
      licenses include an attribution clause, authors publishing under a relatively
      unrestrictive CC license increase the chances of boosting their h-index.
      CONCLUSION: Forewarned is forearmed. Mastering the means of publication enables
      authors to make the most of their publications in boosting their h-index, and
      also to contribute to the new Open Science paradigm: abandoning some intellectual
      property in favor of innovation and knowledge sharing rather than clinging to
      data protection. LEVEL OF EVIDENCE: IV.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Masson SAS.. All rights
      reserved.
FAU - Favre, Janelise
AU  - Favre J
AD  - Archipel, route de Chene, 11, 1207 Geneva, Switzerland.
FAU - Germond, Tania
AU  - Germond T
AD  - PACTT, route de la Corniche, 9b, 1066 Epalinges, Switzerland.
FAU - Clavert, Philippe
AU  - Clavert P
AD  - Service de chirurgie du membre superieur, CCOM, CHRU de Strasbourg, avenue
      Baumann, 67400 Illkirch, France.
FAU - Collin, Philippe
AU  - Collin P
AD  - Centre hospitalier prive Saint-Gregoire (Vivalto Sante), 6, boulevard de la
      Boutiere, 35760 Saint-Gregoire, France.
FAU - Michelet, Aude
AU  - Michelet A
AD  - ReSurg SA, rue Saint-Jean, 2, 1260 Nyon, Switzerland.
FAU - Ladermann, Alexandre
AU  - Ladermann A
AD  - Orthopaedic Surgery Department, hopital de La Tour, Geneva, Switzerland; Faculty 
      of Medicine, University of Geneva, Geneva, Switzerland; Orthopedics and Trauma
      Service, University Hospitals of Geneva, rue Gabrielle-Perret-Gentil, 4, 1205
      Geneva, Switzerland. Electronic address: alexandre.laedermann@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201024
PL  - France
TA  - Orthop Traumatol Surg Res
JT  - Orthopaedics & traumatology, surgery & research : OTSR
JID - 101494830
SB  - IM
MH  - *Access to Information
MH  - *Copyright
MH  - Humans
MH  - United States
OTO - NOTNLM
OT  - Authorship
OT  - Citation
OT  - Copyright protection
OT  - Creative commons
OT  - H-index
OT  - Open Access
OT  - Plagiarism
OT  - Publication
OT  - Research
OT  - Science
OT  - Scientific work
EDAT- 2020/10/29 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/10/28 05:31
PHST- 2020/01/24 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
PHST- 2020/10/28 05:31 [entrez]
AID - S1877-0568(20)30273-5 [pii]
AID - 10.1016/j.otsr.2020.05.015 [doi]
PST - ppublish
SO  - Orthop Traumatol Surg Res. 2020 Dec;106(8):1475-1480. doi:
      10.1016/j.otsr.2020.05.015. Epub 2020 Oct 24.


PMID- 33109285
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201207
IS  - 1477-1128 (Electronic)
IS  - 1463-4236 (Linking)
VI  - 21
DP  - 2020 Oct 28
TI  - Awareness of family physician residents of their roles in disaster health
      management: a cross-sectional study in Turkey.
PG  - e47
LID - 10.1017/S146342362000047X [doi]
AB  - AIM: Family physicians are role models for their societies in disaster management
      and have an important place in it. This study was carried out during the
      specialty training of the residents, who are currently family physicians fighting
      against COVID-19 in the field, and was aimed to identify the awareness levels of 
      residents regarding the roles and duties of family physicians before, during, and
      after disasters and to increase their awareness of disaster medicine and
      management. BACKGROUND: The duties and responsibilities of a family physician in 
      disasters should be a part of their specialty training. This study has
      contributed to the limited literature, increased awareness, and opened a new
      avenue of research for studies to be conducted with family physicians by
      demonstrating the current situation of family physicians in disaster management. 
      METHODS: This is an observational and descriptive study. The knowledge,
      experience, opinions, willingness, attitudes of the residents, and the awareness 
      levels of the residents regarding their roles and duties in a disaster were
      evaluated along with their sociodemographic information. The surveys were applied
      in the family medicine clinics of the all residents by the interview method (n = 
      233). FINDINGS: Only 9.2% of the residents stated that they had received training
      on disaster medicine where they currently work. The knowledge level of the
      residents on this subject was found as 'Unsure'. In total, 80% of the residents
      stated that family physicians should have a role in disasters. It was found that 
      83.3% of the residents had never joined a disaster drill, 94.3% had never
      participated in making or applying a disaster plan, and 97.7% had never worked in
      any disaster. CONCLUSION: The residents participating in the study lacked not
      only information on disaster management but also experience. The residents'
      willingness to receive training, work voluntarily, significantly question the
      curriculum, and specialize in disaster medicine were a positive outcome.
FAU - Yilmaz, Tarik Eren
AU  - Yilmaz TE
AUID- ORCID: 0000-0003-2745-9527
AD  - Department of Family Medicine, Ankara Numune Training and Research Hospital,
      University of Health Sciences, Ankara, Turkey.
FAU - Yilmaz, Tugba
AU  - Yilmaz T
AD  - Department of Family Medicine, Ankara Numune Training and Research Hospital,
      University of Health Sciences, Ankara, Turkey.
FAU - Ornek Buken, Nuket
AU  - Ornek Buken N
AD  - Department of History of Medicine and Medical Ethics, Faculty of Medicine,
      University of Hacettepe, Ankara, Turkey.
FAU - Ozkara, Adem
AU  - Ozkara A
AD  - Department of Family Medicine, Ankara Numune Training and Research Hospital,
      University of Health Sciences, Ankara, Turkey.
FAU - Altintas, Kerim Hakan
AU  - Altintas KH
AD  - Department of Public Health, Faculty of Medicine, University of Hacettepe,
      Ankara, Turkey.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201028
PL  - England
TA  - Prim Health Care Res Dev
JT  - Primary health care research & development
JID - 100897390
SB  - IM
MH  - Adult
MH  - Clinical Competence/*statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Disaster Medicine/*methods
MH  - Female
MH  - Humans
MH  - Internship and Residency/*statistics & numerical data
MH  - Male
MH  - *Physician's Role
MH  - Physicians, Family/*statistics & numerical data
MH  - Turkey
MH  - Young Adult
PMC - PMC7681159
OTO - NOTNLM
OT  - *disaster ethics
OT  - *disaster management
OT  - *disaster medicine
OT  - *family physician
OT  - *pandemic ethics
EDAT- 2020/10/29 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/28 05:29
PHST- 2020/10/28 05:29 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - S146342362000047X [pii]
AID - 10.1017/S146342362000047X [doi]
PST - epublish
SO  - Prim Health Care Res Dev. 2020 Oct 28;21:e47. doi: 10.1017/S146342362000047X.


PMID- 33109281
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
VI  - 37
DP  - 2020 Oct 28
TI  - How does HTA addresses current social expectations? An international survey.
PG  - e9
LID - 10.1017/S0266462320000793 [doi]
AB  - OBJECTIVES: Integration of ethics into technology assessment in healthcare (HTA) 
      reports is directly linked to the need of decision makers to provide rational
      grounds justifying their social choices. In a decision-making paradigm, facts and
      values are intertwined and the social role of HTA reports is to provide relevant 
      information to decision makers. Since 2003, numerous surveys and discussions have
      addressed different aspects of the integration of ethics into HTA. This study
      aims to clarify how HTA professionals consider the integration of ethics into
      HTA, so an international survey was conducted in 2018 and the results are
      reported here. METHODS: A survey comprising twenty-two questions was designed and
      carried out from April 2018 to July 2018. Three hundred and twenty-eight HTA
      agencies from seventy-five countries were invited to participate in this survey. 
      RESULTS: Eighty-nine participants completed the survey, representing a
      participation rate of twenty-seven percent. As to how HTA reports should fulfill 
      their social role, over 84 percent of respondents agreed upon the necessity to
      address this role for decision makers, patients, and citizens. At a lower level, 
      the same was found regarding the necessity to make value-judgments explicit in
      different report sections, including ethical analysis. This contrasts with the
      response-variability obtained on the status of ethical analysis with the
      exception of the expertise required. Variability in stakeholder-participation
      usefulness was also observed. CONCLUSIONS: This study reveals the importance of a
      three-phase approach, including assessment, contextual data, and recommendations,
      and highlights the necessity to make explicit value-judgments and have a
      systematic ethical analysis in order to fulfill HTA's social role in guiding
      decision makers.
FAU - Gagnon, Hubert
AU  - Gagnon H
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
FAU - Legault, Georges-Auguste
AU  - Legault GA
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Faculte de Droit, Universite de Sherbrooke, 2500 Boul. de l'Universite,
      Sherbrooke, QC, Canada, J1K 2R1.
FAU - Bellemare, Christian A
AU  - Bellemare CA
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Centre Integre Universitaire de Sante et Services Sociaux (CIUSSS) de l'Estrie - 
      Centre Hospitalier de l'Universite de Sherbrooke (CHUS), 580 rue Bowen sud,
      Sherbrooke, QC, Canada.
FAU - Parent, Monelle
AU  - Parent M
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
FAU - Dagenais, Pierre
AU  - Dagenais P
AUID- ORCID: https://orcid.org/0000-0001-5058-6941
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Centre Integre Universitaire de Sante et Services Sociaux (CIUSSS) de l'Estrie - 
      Centre Hospitalier de l'Universite de Sherbrooke (CHUS), Centre de Recherche
      Clinique du CHUS, 3001, 12e Avenue nord Sherbrooke, QC, Canada, J1H 5N4.
AD  - Faculte de Medecine et des Sciences de la Sante de l'Universite de Sherbrooke,
      Sherbrooke, QC, Canada, J1K 2R1.
FAU - K-Bedard, Suzanne
AU  - K-Bedard S
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Centre Integre Universitaire de Sante et Services Sociaux (CIUSSS) de l'Estrie - 
      Centre Hospitalier de l'Universite de Sherbrooke (CHUS), 580 rue Bowen sud,
      Sherbrooke, QC, Canada.
FAU - Tapin, Danielle
AU  - Tapin D
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
FAU - Bernier, Louise
AU  - Bernier L
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Faculte de Droit, Universite de Sherbrooke, 2500 Boul. de l'Universite,
      Sherbrooke, QC, Canada, J1K 2R1.
FAU - Beland, Jean-Pierre
AU  - Beland JP
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Unite d'Enseignement en Ethique, Departement des Sciences Humaines, Universite du
      Quebec a Chicoutimi (UQAC), Chicoutimi, QC, Canada, G7X 2B1.
FAU - Daniel, Charles-Etienne
AU  - Daniel CE
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Faculte de Droit, Universite de Sherbrooke, 2500 Boul. de l'Universite,
      Sherbrooke, QC, Canada, J1K 2R1.
FAU - Patenaude, Johane
AU  - Patenaude J
AUID- ORCID: https://orcid.org/0000-0001-6721-9697
AD  - Institut Interdisciplinaire d'Innovation Technologique (3IT) de l'Universite de
      Sherbrooke, Parc Innovation P2, 3000 boulevard de l'Universite Sherbrooke,
      Sherbrooke, QC, Canada, J1K 0A5.
AD  - Faculte de Medecine et des Sciences de la Sante de l'Universite de Sherbrooke,
      Sherbrooke, QC, Canada, J1K 2R1.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
SB  - IM
MH  - Decision Making
MH  - Humans
MH  - Judgment
MH  - Professional Role
MH  - *Social Responsibility
MH  - Technology Assessment, Biomedical/*ethics/*organization & administration
OTO - NOTNLM
OT  - Ethics
OT  - health technology assessment
OT  - social needs
OT  - survey
OT  - value judgments
EDAT- 2020/10/29 06:00
MHDA- 2021/10/06 06:00
CRDT- 2020/10/28 05:29
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
PHST- 2020/10/28 05:29 [entrez]
AID - 10.1017/S0266462320000793 [doi]
AID - S0266462320000793 [pii]
PST - epublish
SO  - Int J Technol Assess Health Care. 2020 Oct 28;37:e9. doi:
      10.1017/S0266462320000793.


PMID- 33109271
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 27
TI  - Group Post-Admission Cognitive Therapy for Suicidality vs Individual Supportive
      Therapy for the prevention of repeat suicide attempts: a randomized controlled
      trial.
PG  - 889
LID - 10.1186/s13063-020-04816-y [doi]
AB  - BACKGROUND: Suicide is a serious public health problem. The development and use
      of effective treatments for people hospitalized for suicide attempts remain a
      priority. Regarding psychosocial treatment, the evidence for treatments that
      effectively prevent suicide repetition of suicide attempts is extremely thin.
      There is some evidence that cognitive behavioural therapy may be effective for
      reducing suicide behaviour. The primary aim of this study is to compare Group
      Post-Admission Cognitive Therapy for Suicidality (GPACTS) versus Individual
      Supportive Therapy (IST) for preventing suicide. METHODS: In total, 240
      participants with a high suicide risk score according to a Mini International
      Neuropsychiatric Interview (MINI) will be randomized to either GPACTS or IST.
      This is a multicentre, parallel group, randomized (1:1 ratio),
      two-tailed-superiority trial with endpoint-assessor blinding. Patients meeting
      inclusion criteria during a screening visit will be enrolled in the study and
      randomized into two groups: one group will undergo 6 weeks of GPACTS, and the
      second group will undergo 6 weeks of IST. Following 6 weeks of interventional
      therapy, patients are followed up for 12 months. Follow-up for both groups is
      identical and includes the administration of questionnaires at baseline and then 
      within 10 days after the end of therapy sessions and then at 3, 6 and 12 months
      following the end of GPACTS/IST sessions. DISCUSSION: To our knowledge, this is
      the first RCT of its kind to be conducted in France, and so far, there are no
      studies in the literature on group psychotherapy for the treatment of individuals
      who have attempted suicide. The outcomes will provide clear guidance for
      professionals to apply psychological intervention with suicide attempts. The
      protocol respects ethical principles, and ethical approval was obtained from the 
      local ethics committee. The results will be disseminated through an original
      research published as original research in peer-reviewed manuscript, through a
      therapist manual for cognitive therapy, and presentations at research
      conferences. TRIAL REGISTRATION: ClinicalTrials.gov NCT02664701 . Registered on
      January 27, 2017.
FAU - Chaib, Laurent S
AU  - Chaib LS
AUID- ORCID: http://orcid.org/0000-0002-9309-9817
AD  - Department of Adult Psychiatry, University Hospital, Place du Pr. R. Debre,
      30029, Nimes, Cedex 9, France. laurent.chaib@chu-nimes.fr.
AD  - Epsylon Laboratory (EA 4556) Dynamic of Human Abilities & Health Behaviors,
      University of Montpellier 3, Montpellier, France. laurent.chaib@chu-nimes.fr.
FAU - Lopez-Castroman, Jorge
AU  - Lopez-Castroman J
AD  - Department of Adult Psychiatry, University Hospital, Place du Pr. R. Debre,
      30029, Nimes, Cedex 9, France.
AD  - CIBERSAM (Centro de Investigacion en Salud Mental), Carlos III Institute of
      Health, Madrid, Spain.
AD  - INSERM U1061, University of Montpellier, Neuropsychiatry: Epidemiological and
      Clinical Research, Montpellier, France.
AD  - Montpellier University, Montpellier, France.
FAU - Abbar, Mocrane
AU  - Abbar M
AD  - Department of Adult Psychiatry, University Hospital, Place du Pr. R. Debre,
      30029, Nimes, Cedex 9, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT02664701
GR  - 14-0241/clinical research hospital program, government fund, health ministry
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20201027
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Cognitive Behavioral Therapy
MH  - France
MH  - Humans
MH  - *Psychotherapy, Group
MH  - *Suicide
MH  - Suicide, Attempted
PMC - PMC7590693
OTO - NOTNLM
OT  - Psychosocial interventions
OT  - Randomized controlled trial
OT  - Repeat suicide attempts
EDAT- 2020/10/29 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/28 05:29
PHST- 2019/07/23 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/28 05:29 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04816-y [doi]
AID - 10.1186/s13063-020-04816-y [pii]
PST - epublish
SO  - Trials. 2020 Oct 27;21(1):889. doi: 10.1186/s13063-020-04816-y.


PMID- 33109181
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 27
TI  - Ethics and the marketing authorization of pharmaceuticals: what happens to
      ethical issues discovered post-trial and pre-marketing authorization?
PG  - 103
LID - 10.1186/s12910-020-00543-w [doi]
AB  - BACKGROUND: In the EU, clinical assessors, rapporteurs and the Committee for
      Medicinal Products for Human Use are obliged to assess the ethical aspects of a
      clinical development program and include major ethical flaws in the marketing
      authorization deliberation processes. To this date, we know very little about the
      manner that these regulators put this obligation into action. In this paper, we
      intend to look into the manner and the extent that ethical issues discovered
      during inspection have reached the deliberation processes. METHODS: To gather
      data, we used the Dutch Medicines Evaluation Board database and first searched
      for the inspections, and their accompanying site inspection reports and
      integrated inspection reports, related to central marketing authorization
      applications (henceforth, application/s) of drugs submitted to the European
      Medicines Agency (EMA) from 2011 to 2015. We then extracted inspection findings
      that were purely of ethical nature, i.e., those that did not affect the
      benefit/risk balance of the study (issues related to informed consent, research
      ethics committees, and respect for persons). Only findings graded at least major 
      by the inspectorate were included. Lastly, to identify how many of the ethically 
      relevant findings (ERFs) reach the application deliberation processes, we
      extracted the relevant joint response assessment reports and reviewed the
      sections that discussed inspection findings. RESULTS: From 2011 to 2015, there
      were 390 processed applications, of which 65 had inspection reports and
      integrated inspection reports accessible via the database of the Dutch Medicines 
      Evaluation Board. Of the 65, we found ERFs in 37 (56.9%). The majority of the
      ERFs were graded as major and half of the time it was informed-consent related. A
      third of these findings were related to research ethics committee processes and
      requirements. Of the 37 inspections with ERFs, 30 were endorsed in the integrated
      inspection reports as generally GCP compliant. Day 150 joint response assessment 
      reports and Day 180 list of outstanding issues were reviewed for all 37
      inspections, and none of the ERFs were carried over in any of the assessment
      reports or list of outstanding issues. CONCLUSION: None of the ethically relevant
      findings, all of which were graded as major or critical in integrated inspection 
      reports, were explicitly carried over to the joint assessment reports. This calls
      for more transparency in EMA application deliberations on how ERFs are
      considered, if at all, in the decision-making processes.
FAU - Bernabe, Rosemarie D L C
AU  - Bernabe RDLC
AUID- ORCID: 0000-0002-4999-3117
AD  - Faculty of Health and Social Sciences, University of South-Eastern Norway,
      Kongsberg, Norway. r_bernabe@yahoo.com.
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Oslo, Norway. r_bernabe@yahoo.com.
FAU - van Thiel, Ghislaine J M W
AU  - van Thiel GJMW
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Breekveldt, Nancy S
AU  - Breekveldt NS
AD  - Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
FAU - Gispen, Christine C
AU  - Gispen CC
AD  - Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
FAU - van Delden, Johannes J M
AU  - van Delden JJM
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Ethics Committees, Research
MH  - Humans
MH  - Informed Consent
MH  - *Marketing
MH  - *Pharmaceutical Preparations
MH  - Risk Assessment
PMC - PMC7590474
EDAT- 2020/10/29 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/28 05:28
PHST- 2019/04/24 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/10/28 05:28 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00543-w [doi]
AID - 10.1186/s12910-020-00543-w [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 27;21(1):103. doi: 10.1186/s12910-020-00543-w.


PMID- 33109174
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 27
TI  - An ethical issue: nurses' conscientious objection regarding induced abortion in
      South Korea.
PG  - 106
LID - 10.1186/s12910-020-00552-9 [doi]
AB  - BACKGROUND: The Constitutional Court of South Korea declared that an abortion ban
      was unconstitutional on April 11, 2019. The National Health Care System will
      provide abortion care across the country as a formal medical service.
      Conscientious objection is an issue raised during the construction of legal
      reforms. METHODS: One hundred sixty-seven perioperative nurses responded to the
      survey questionnaire. Nurses' perception about conscientious objection, support
      of legislation regarding conscientious objection, and intention to object were
      measured. Logistic regression was used to explore the factors associated with
      support of the legislation and the intention to conscientiously object. RESULTS: 
      Only 28.8% of the responding nurses were aware of health care professionals'
      conscientious objection. The majority (68.7%) felt that patients' rights should
      be prioritized over health care professionals' conscientious objection. On the
      other hand, 45.8% supported the legislation on conscientious objection to
      abortion, and 42.5% indicated a willingness to refuse to participate in an
      abortion case if conscientious objection was permitted. Religion, awareness of
      conscientious objection, and prioritizing of nurses' right to conscientious
      objection were significantly associated with supporting the legislation.
      Moreover, religion and prioritizing nurses' rights were significantly associated 
      with the intention to conscientiously object. CONCLUSIONS: This study provides
      information necessary for further discussion of nurses' conscientious objection. 
      Nursing leaders, researchers, and educators should appeal to nurses and involve
      them in making policies that balance a women's right to non-discrimination and to
      receiving appropriate care with nurses' rights to maintain their moral integrity 
      without compromising their professional obligation.
FAU - Ko, Chung Mee
AU  - Ko CM
AD  - College of Nursing, Sungshin Women's University, 55, Dobong-ro 76ga-gil,
      Gangbuk-gu, Seoul, 01133, Republic of Korea.
FAU - Koh, Chin Kang
AU  - Koh CK
AUID- ORCID: 0000-0002-9588-1888
AD  - College of Nursing, The Research Institute of Nursing Science, Seoul National
      University, 103 Daehakro, Jongrogu, Seoul, 03080, Republic of Korea.
      ckoh@snu.ac.kr.
FAU - Lee, Ye Sol
AU  - Lee YS
AD  - College of Nursing, Seoul National University, 103 Daehakro, Jongrogu, Seoul,
      03080, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Abortion, Induced
MH  - Conscience
MH  - Female
MH  - Humans
MH  - Morals
MH  - *Nurses
MH  - Pregnancy
MH  - Refusal to Treat
MH  - Republic of Korea
MH  - Women's Rights
PMC - PMC7590714
OTO - NOTNLM
OT  - *Abortion
OT  - *Conscientious objection
OT  - *Legal reform
OT  - *Nursing ethics
OT  - *Women's health
EDAT- 2020/10/29 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/28 05:28
PHST- 2020/06/09 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/10/28 05:28 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00552-9 [doi]
AID - 10.1186/s12910-020-00552-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 27;21(1):106. doi: 10.1186/s12910-020-00552-9.


PMID- 33109165
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 27
TI  - "It gets people through the door": a qualitative case study of the use of
      incentives in the care of people at risk or living with HIV in British Columbia, 
      Canada.
PG  - 105
LID - 10.1186/s12910-020-00548-5 [doi]
AB  - BACKGROUND: There has been growing interest in the use of incentives to increase 
      the uptake of health-related behaviours and achieve desired health outcomes at
      the individual and population level. However, the use of incentives remains
      controversial for ethical reasons. An area in which incentives have been not only
      proposed but used is HIV prevention, testing, treatment and care-each one
      representing an interconnecting step in the "HIV Cascade." METHODS: The main
      objective of this qualitative case study was to document the experiences of
      health care and service providers tasked with administrating incentivized HIV
      testing, treatment, and care in British Columbia, Canada. A second objective was 
      to explore the ethical and professional tensions that arise from the use of
      incentives as well as strategies used by providers to mitigate them. We conducted
      interviews with 25 providers and 6 key informants, which were analyzed using
      applied thematic analysis. We also collected documents and took field notes.
      RESULTS: Our findings suggest that incentives target populations believed to pose
      the most risk to public health. As such, incentives are primarily used to close
      the gaps in the HIV Cascade by getting the "right populations" to test, start
      treatment, stay on treatment, and, most importantly, achieve (and sustain) viral 
      suppression. Participants considered that incentives work because they "bring
      people through the door." However, they believed the effectiveness of incentives 
      to be superficial, short-lived and one-dimensional-thus, failing to address
      underlying structural barriers to care and structural determinants of health.
      They also raised concerns about the unintended consequences of incentives and the
      strains they may put on the therapeutic relationship. They had developed
      strategies to mitigate the ensuing ethical and professional tensions and to make 
      their work feel relational rather than transactional. CONCLUSIONS: We identify an
      urgent need to problematize the use of incentives as a part of the "HIV Cascade" 
      agenda and interrogate the ethics of engaging in this practice from the
      perspective of health care and service providers. More broadly, we question the
      introduction of market logic into the realm of health care-an area of life
      previously not subject to monetary exchanges.
FAU - Gagnon, Marilou
AU  - Gagnon M
AUID- ORCID: 0000-0003-4214-3088
AD  - Canadian Institute for Substance Use Research, University of Victoria, 2300
      McKenzie Ave, Victoria, BC, V8N 5M8, Canada. marilougagnon@uvic.ca.
FAU - Guta, Adrian
AU  - Guta A
AD  - School of Social Work, University of Windsor, 167 Ferry Street, Windsor, ON, N9A 
      0C5, Canada.
FAU - Upshur, Ross
AU  - Upshur R
AD  - Dalla Lana Chair in Clinical Public Health, Dalla Lana School of Public Health,
      678-155 College Street, Toronto, ON, M5T 3M7, Canada.
FAU - Murray, Stuart J
AU  - Murray SJ
AD  - Canada Research Chair in Rhetoric and Ethics, Department of English Language and 
      Literature, Carleton University, 1125 Colonel By Drive, Ottawa, ON, K1S 5B6,
      Canada.
FAU - Bungay, Vicky
AU  - Bungay V
AD  - Canada Research Chair in Gender, Equity and Community Engagement, School of
      Nursing, University of British Columbia, T201-2211 Wesbrook Mall, Vancouver, BC, 
      V6T2B5, Canada.
LA  - eng
GR  - 159826/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome
MH  - British Columbia
MH  - *HIV Infections/prevention & control
MH  - Humans
MH  - Motivation
MH  - Qualitative Research
PMC - PMC7590593
OTO - NOTNLM
OT  - *AIDS
OT  - *Behavioural economics
OT  - *Canada
OT  - *Case study
OT  - *Ethics
OT  - *HIV
OT  - *Incentives
OT  - *Qualitative
EDAT- 2020/10/29 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/28 05:28
PHST- 2020/05/04 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/28 05:28 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00548-5 [doi]
AID - 10.1186/s12910-020-00548-5 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 27;21(1):105. doi: 10.1186/s12910-020-00548-5.


PMID- 33109160
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 27
TI  - The relationship between the perception of open disclosure of patient safety
      incidents, perception of patient safety culture, and ethical awareness in nurses.
PG  - 104
LID - 10.1186/s12910-020-00546-7 [doi]
AB  - BACKGROUND: Scientific advances have resulted in more complex medical systems,
      which in turn have led to an increase in the number of patient safety incidents
      (PSIs). In this environment, the importance of honest disclosure of PSIs is
      rising, which highlight the need to settle a reliable system. This study aimed to
      investigate the effects of patient safety culture and ethical awareness on open
      disclosure of PSIs. METHODS: Data were collected from 389 nurses using
      self-reported perceptions of open disclosure of PSIs, perceptions of patient
      safety culture, and ethical awareness. RESULTS: Perception of open disclosure of 
      PSIs was significantly correlated with ethical awareness and perception of
      patient safety culture. Ethical awareness had the greatest impact on perception
      of PSIs, and two components of the perception of patient safety culture, namely
      overall knowledge about patient safety and staffing, were found to have
      significant effects. CONCLUSIONS: To enhance nurses' perception of open
      disclosure of PSIs, educational curriculum and programs that teach and practice
      fundamental ethical values are needed. Furthermore, it also calls for effort on
      the part of healthcare institutions and the government, as well as people's
      trust, to implement a legal safety net and foster patient safety culture to
      promote honest disclosure of PSIs to patients.
FAU - Kim, Yujeong
AU  - Kim Y
AD  - College of Nursing, Research Institute of Nursing Science, Kyungpook National
      University, 680 Gukchabosangro, Jung-gu, Daegu, 41944, Republic of Korea.
FAU - Lee, Eunmi
AU  - Lee E
AUID- ORCID: 0000-0003-1998-6925
AD  - Department of Nursing, Research Institute for Basic Science, Hoseo University,
      20, Hoseo-ro79beon-gil, Baebang-eup, Asan-si, Chungcheongnam-do, 31499, Republic 
      of Korea. sweetbear2@hanmail.net.
LA  - eng
GR  - 2017R1C1B 5073718/the National Research Foundation of Korea/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201027
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Disclosure
MH  - Humans
MH  - *Nurses
MH  - *Patient Safety
MH  - Perception
MH  - Safety Management
PMC - PMC7590671
OTO - NOTNLM
OT  - *Disclosure
OT  - *Ethical awareness
OT  - *Patient safety
OT  - *Principle-based ethics
EDAT- 2020/10/29 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/28 05:28
PHST- 2019/10/03 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/10/28 05:28 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00546-7 [doi]
AID - 10.1186/s12910-020-00546-7 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 27;21(1):104. doi: 10.1186/s12910-020-00546-7.


PMID- 33108928
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2052-286X (Electronic)
IS  - 1357-6321 (Linking)
VI  - 26
IP  - 7
DP  - 2020 Oct 2
TI  - Methodological and ethical challenges while conducting qualitative research on
      spirituality and end of life in a Muslim context: a guide to novice researchers.
PG  - 362-370
LID - 10.12968/ijpn.2020.26.7.362 [doi]
AB  - Abstract Spirituality could be understood as a personal belief, a relation with
      sacred, divine experience, a sense of purpose and meaning towards life,
      authenticity and connectedness. It is a continually evolving, highly complex,
      contextual, subjective, and sensitive construct. A continuous development is seen
      around understanding about spirituality and spiritual concepts, such as spiritual
      experiences, spiritual pain and spiritual distress, especially among patients and
      families at the end of life. The concepts, values, attitudes, and beliefs around 
      spirituality, spiritual needs and expressions vary among different individuals,
      cultures, and religions. There is a dearth of literature around spirituality,
      especially among Muslim patients and families at the end of life. The
      complexities around the concept of spirituality in the literature raise several
      ethical and methodological concerns for a novice researcher while planning and
      conducting a study on spirituality during end-of-life care in a hospice setting, 
      especially among a Muslim population. This paper aims to share some of the
      methodological and ethical challenges that can be faced by qualitative
      researchers while conducting research around spirituality and end-of-life care in
      an Islamic/Muslim context. Major challenges include defining the term
      spirituality, spirituality and culture, communication, power relations, language 
      and translation, recruitment and selection of the participants, emotional
      distress, and reflexivity and reciprocity. Having an in-depth understanding of
      these challenges can guide researchers to address these issues adequately in
      their spirituality research in a Muslim context.
FAU - Lalani, Nasreen
AU  - Lalani N
AD  - Assistant Professor, Purdue University, West Lafayette, Indiana, USA.
FAU - Ali, Gulnar
AU  - Ali G
AD  - Consultant in Spirituality and Existential Care, New School of Psychotherapy and 
      Counselling, London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Palliat Nurs
JT  - International journal of palliative nursing
JID - 9506762
MH  - Death
MH  - *Ethics, Research
MH  - Humans
MH  - *Islam
MH  - *Qualitative Research
MH  - *Spirituality
MH  - *Terminal Care
OTO - NOTNLM
OT  - End-of-life care
OT  - Ethical challenges
OT  - Muslim traditions of thought
OT  - Qualitative research
OT  - Spirituality
EDAT- 2020/10/29 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/10/28 05:27
PHST- 2020/10/28 05:27 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 10.12968/ijpn.2020.26.7.362 [doi]
PST - ppublish
SO  - Int J Palliat Nurs. 2020 Oct 2;26(7):362-370. doi: 10.12968/ijpn.2020.26.7.362.


PMID- 33108925
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2052-286X (Electronic)
IS  - 1357-6321 (Linking)
VI  - 26
IP  - 7
DP  - 2020 Oct 2
TI  - Characterisation of palliative sedation use in inpatients at a medium-stay
      palliative care unit.
PG  - 341-345
LID - 10.12968/ijpn.2020.26.7.341 [doi]
AB  - BACKGROUND: Palliative sedation has been used to refer to the practice of
      providing symptom control through the administration of sedative drugs. The
      objective of this article was to characterise palliative sedation use in
      inpatients at a medium-stay palliative care unit. MATERIAL AND METHODS: A
      cross-sectional study was conducted on 125 randomly selected patients (aged 15 or
      older) who had died in 2014. The Palliative Performance Scale was used to
      evaluate the functional status. RESULTS: Palliative sedation was documented in
      34.4% of the patients and midazolam was the most commonly used sedative agent
      (86.0%). More than half (53.5%) of those who recieved sedation presented with
      delirium. Liver dysfunction was more frequent in the sedated patients (p=0.033)
      and patients with heart disease were less likely (p=0.026) to be sedated.
      CONCLUSION: Palliative sedation is an ethically accepted practice. It was
      commonly midazolam-induced, and differences were documented, among sedated and
      non-sedated patients, in terms of liver dysfunction and heart disease.
FAU - Murillo-Zamora, Efren
AU  - Murillo-Zamora E
AD  - PhD, Departamento de Epidemiologia, Unidad de Medicina Familiar No 19, Instituto 
      Mexicano del Seguro Social, Colima, Mexico.
FAU - Garcia-Lopez, Nallely A
AU  - Garcia-Lopez NA
AD  - MPC, Departamento Clinico, Unidad de Medicina Familiar No. 19, Instituto Mexicano
      del Seguro Social, Colima, Mexico.
FAU - de Santiago-Ruiz, Ana
AU  - de Santiago-Ruiz A
AD  - MD, Hospital Centro de Cuidados Laguna, Fundacion Vianorte-Laguna, Madrid, Spain.
FAU - Chavez-Lira, Alcira Emperatriz
AU  - Chavez-Lira AE
AD  - MD, Residencia Orpea Aravaca, Madrid, Espana.
FAU - Mendoza-Cano, Oliver
AU  - Mendoza-Cano O
AD  - Facultad de Ingenieria Civil, Universidad de Colima, Colima, Mexico.
FAU - Guzman-Esquivel, Jose
AU  - Guzman-Esquivel J
AD  - PhD, Unidad de Investigacion en Epidemiologia Clinica, Instituto Mexicano del
      Seguro Social, Colima, Mexico and Facultad de Medicina, Universidad de Colima,
      Colima, Mexico.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Palliat Nurs
JT  - International journal of palliative nursing
JID - 9506762
RN  - 0 (Hypnotics and Sedatives)
RN  - R60L0SM5BC (Midazolam)
MH  - Cross-Sectional Studies
MH  - *Hospice and Palliative Care Nursing
MH  - Humans
MH  - *Hypnotics and Sedatives/therapeutic use
MH  - Inpatients
MH  - Midazolam/therapeutic use
MH  - *Palliative Care
OTO - NOTNLM
OT  - Hypnotics and sedatives
OT  - Inpatients
OT  - Midazolam
OT  - Palliative care
EDAT- 2020/10/29 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/10/28 05:27
PHST- 2020/10/28 05:27 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 10.12968/ijpn.2020.26.7.341 [doi]
PST - ppublish
SO  - Int J Palliat Nurs. 2020 Oct 2;26(7):341-345. doi: 10.12968/ijpn.2020.26.7.341.


PMID- 33108922
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2052-286X (Electronic)
IS  - 1357-6321 (Linking)
VI  - 26
IP  - 7
DP  - 2020 Oct 2
TI  - Experience of communication among cervical cancer patients in Kenya.
PG  - 346-352
LID - 10.12968/ijpn.2020.26.7.346 [doi]
AB  - Communication influences patient disclosure, treatment adherence, and outcome,
      adaptation to illness, and bereavement. Different cancer patients and caregivers 
      communicate their various experiences in unique ways. These distinctive
      experiences are necessary to be told, because it empowers both the teller and
      everyone who hears and shares that experience. However, there is little research 
      documenting the experiences of cervical cancer patients and caregivers in Kenya
      and the rest of Africa. This study therefore sought to assess the communication
      experience among cervical cancer patients and their caregivers. This study was a 
      qualitative study employing the phenomenological method to obtain data from
      cervical patients and caregivers. It was carried out in Uasin Gishu County,
      Kenya, where a range of in-depth interviews were held with eight patients and
      eight caregivers purposively sampled. Data from the interviews were analysed
      thematically and presented in narrative form using paraphrases and quotations.
      Ethical issues such as informed consent, confidentiality and official
      authorisation were observed at all levels. To enrich this study, hermeneutic
      theory, which explains more about the individual's experience, was used. The
      findings of the study indicated that communication is therapeutic, although most 
      of the patients and the caregivers were reluctant to talk about their illness.
      The findings of this study will be of interest to scholars, policy-makers and
      caregivers of terminally ill patients.
FAU - Caren, Jerop
AU  - Caren J
AD  - Student Alupe University College, Alupe, Kenya.
FAU - Mose, George
AU  - Mose G
AD  - Lecturer, School of Information, Kisii University, Nairobi, Kenya.
FAU - Kurgat, Kibiwott
AU  - Kurgat K
AD  - Professor, School of Information, Kisii University, Nairobi, Kenya.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Palliat Nurs
JT  - International journal of palliative nursing
JID - 9506762
MH  - *Caregivers
MH  - *Communication
MH  - Female
MH  - Humans
MH  - Kenya
MH  - Qualitative Research
MH  - *Uterine Cervical Neoplasms
OTO - NOTNLM
OT  - Caregivers
OT  - Cervical cancer patients
OT  - Experience
OT  - Health communication
EDAT- 2020/10/29 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/10/28 05:27
PHST- 2020/10/28 05:27 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 10.12968/ijpn.2020.26.7.346 [doi]
PST - ppublish
SO  - Int J Palliat Nurs. 2020 Oct 2;26(7):346-352. doi: 10.12968/ijpn.2020.26.7.346.


PMID- 33107966
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1306-696X (Print)
VI  - 26
IP  - 6
DP  - 2020 Nov
TI  - The protective role of probiotics in sepsis-induced rats.
PG  - 843-846
LID - 10.14744/tjtes.2020.70440 [doi]
AB  - BACKGROUND: Probiotic ingestion is associated with an increase in intestinal
      flora of useful bacteria, which contributes to the known protective effects it
      has on the intestinal barrier and thereby reducing infection. The present study
      aims to investigate the protective effect of Lactobacillus rhamnosus gg (LGG) as 
      an important probiotic with gastrointestinal barrier strengthening effect in
      sepsis. METHODS: Our study was conducted in the Animal Experiments Laboratory
      after obtaining ethicalapproval to conduct this study.Twenty-four rats were
      randomly divided into threegroups and group 1 (control group n=8), group 2
      (sepsis group, n=8), group 3 (sepsis + probiotic group, n=8) were planned as
      double-blind. LGG was used as a probiotic. For the sepsis model, E. coli (0111:
      B4) was injected intraperitoneally, and the rats were sacrificed 48 hours after
      treatment. Blood samples were collected from all animals before sacrification and
      sent to the biochemistry laboratory to evaluate oxidant and antioxidant
      parameters. RESULTS: CRP values of Group 1 were significantly lower than Group 2,
      and CRP values of Group 3 were significantly lower. While total thiol levels of
      Group 2 were significantly lower than Group 1, total thiol levels of Group 3 were
      significantly higher than Group 2. There was no statistically significant
      difference between the groups for eNOS, GPX, PON1 and MDA levels. CONCLUSION:
      Prophylactic use of probiotics, such as LGG to reduce bacterial translocation and
      strengthen the immune system, is an inexpensive and effective method of
      treatment, and we recommend the repetition of studies supported by prospective
      clinical trials.
FAU - Yilmaz, Mustafa
AU  - Yilmaz M
AD  - Department of Biochemistry, Adnan Menderes University Faculty of Medicine,
      Aydin-Turkey.
FAU - Erdem, Ali Onur
AU  - Erdem AO
AD  - Department of Pediatric Surgery, Adnan Menderes University Faculty of Medicine,
      Aydin-Turkey.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial, Veterinary
TT  - Sepsis olusturulan sicanlarda probiyotiklerin koruyucu rolu.
PL  - Turkey
TA  - Ulus Travma Acil Cerrahi Derg
JT  - Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency
      surgery : TJTES
JID - 101274231
RN  - 0 (Antioxidants)
RN  - 0 (Protective Agents)
RN  - 0 (Sulfhydryl Compounds)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Animals
MH  - Antioxidants/analysis
MH  - C-Reactive Protein/analysis
MH  - Double-Blind Method
MH  - Lactobacillus rhamnosus
MH  - Male
MH  - Oxidative Stress/drug effects
MH  - Probiotics/*pharmacology
MH  - Protective Agents/*pharmacology
MH  - Rats
MH  - Sepsis/*metabolism
MH  - Sulfhydryl Compounds/blood
EDAT- 2020/10/28 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/10/27 12:14
PHST- 2020/10/27 12:14 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.14744/tjtes.2020.70440 [doi]
PST - ppublish
SO  - Ulus Travma Acil Cerrahi Derg. 2020 Nov;26(6):843-846. doi:
      10.14744/tjtes.2020.70440.


PMID- 33107406
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20201218
IS  - 1942-6038 (Electronic)
IS  - 1942-602X (Linking)
VI  - 35
IP  - 6
DP  - 2020 Nov
TI  - Reopening Schools During COVID-19: School Nurse Ethical Conflicts and Moral
      Dilemmas.
PG  - 308-312
LID - 10.1177/1942602X20963522 [doi]
FAU - Combe, Laurie G
AU  - Combe LG
LA  - eng
PT  - Letter
PL  - United States
TA  - NASN Sch Nurse
JT  - NASN school nurse (Print)
JID - 101528330
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Education, Distance/*ethics
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Moral Obligations
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Psychological Distance
MH  - Quarantine/organization & administration
MH  - SARS-CoV-2
MH  - School Nursing/*organization & administration
MH  - United States
EDAT- 2020/10/28 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/27 08:40
PHST- 2020/10/27 08:40 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1177/1942602X20963522 [doi]
PST - ppublish
SO  - NASN Sch Nurse. 2020 Nov;35(6):308-312. doi: 10.1177/1942602X20963522.


PMID- 33107311
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Linking)
VI  - 23
IP  - 10
DP  - 2020 Oct 1
TI  - Evaluation of Iranian Medical Journals from the Perspective of Publication
      Ethics.
PG  - 697-703
LID - 10.34172/aim.2020.88 [doi]
AB  - BACKGROUND: Scientific journals will gain real credit when they meet publication 
      ethics standards. This study seeks to evaluate the current status of medical
      journals' adherence to some ethical standards. METHODS: The 412 scientific
      journals approved by the Ministry of Health and Medical Education were included
      in this study. The process of downloading articles and data extraction for seven 
      general and specific indicators related to publication ethics was conducted by
      trained researchers. Different methods were implemented by the team of colleagues
      to prevent possible errors in data extraction. After data integration, data
      analysis was performed using SPSS version 23. RESULTS: Overall, 408 journals and 
      3948 articles met the inclusion criteria. The distribution of journals according 
      to the highest journal index was 5.4%, 13.7%, 8.3%, 8.1% and 64.5% for ISI, ESCI,
      PubMed, Scopus and Other indexes, respectively. In 27.7% of the articles, the
      review process took over 6 months. According to the results, 6.6% and 31.7% of
      the articles belonged to the journals' editors and owner universities,
      respectively. Journal self-citation was seen in 19.2% of articles and in fewer
      than half of the articles (45.5%), the status of conflict of interest was
      declared. In 36.9% of the articles, the code of ethics or university ethics
      committee approval, and in 36.5% of clinical trial articles, the clinical trial
      registration code was reported. CONCLUSION: Modifying processes or introducing
      new rules for indicators of publication ethics by trustee organizations can
      improve the current status. These seven indicators can also be used to rank
      journals.
CI  - (c) 2020 The Author(s). This is an open-access article distributed under the
      terms of the Creative Commons Attribution License
      (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
      distribution, and reproduction in any medium, provided the original work is
      properly cited.
FAU - Shamsi-Gooshki, Ehsan
AU  - Shamsi-Gooshki E
AUID- ORCID: 0000-0003-2405-0873
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Bagheri, Hasan
AU  - Bagheri H
AUID- ORCID: 0000-0003-2895-6189
AD  - Chemical Injuries Research Center, Systems Biology and Poisonings Institute,
      Baqiyatallah University of Medical Sciences, Tehran, Iran.
FAU - Salesi, Mahmood
AU  - Salesi M
AUID- ORCID: 0000-0003-3042-2143
AD  - Chemical Injuries Research Center, Systems Biology and Poisonings Institute,
      Baqiyatallah University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
SB  - IM
MH  - *Bioethical Issues
MH  - Conflict of Interest
MH  - Editorial Policies
MH  - Ethics Committees
MH  - Humans
MH  - Iran
MH  - Periodicals as Topic/*ethics
MH  - Publishing/*ethics
OTO - NOTNLM
OT  - *Ethics
OT  - *Indicators
OT  - *Medical journals
OT  - *Publications
EDAT- 2020/10/28 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/10/27 08:40
PHST- 2020/01/26 00:00 [received]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/10/27 08:40 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
AID - 10.34172/aim.2020.88 [doi]
PST - epublish
SO  - Arch Iran Med. 2020 Oct 1;23(10):697-703. doi: 10.34172/aim.2020.88.


PMID- 33107306
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Linking)
VI  - 23
IP  - 10
DP  - 2020 Oct 1
TI  - Developing "Code of Ethics for Medical Professionals, Medical Council of Islamic 
      Republic of Iran".
PG  - 658-664
LID - 10.34172/aim.2020.83 [doi]
AB  - BACKGROUND: The medical profession has always been an inspiration for human
      societies throughout its diverse history. This position and historical authority 
      in the field of ethics has had a different and higher status, in such a way that 
      many of the norms of general ethics and professional ethics, especially
      principles, such as trust, confidentiality and respect for human dignity, have
      been developed by medical professionals. Developing guidelines of general and
      professional ethics is one of the inherent duties of the Medical Council of the
      Islamic Republic of Iran (IRIMC) as a professional organization. In this regard, 
      the Supreme Council of IRIMC has approved the "Code of Ethics for Medical
      Professionals" and, in accordance with its legal authority, has annexed it to the
      disciplinary regulations of IRIMC. METHODS: A draft document, the result of
      extensive literature review, was discussed in 27 expert panel meetings and after 
      receiving and endorsing the stakeholders' point of view, was approved by the
      IRIMC Supreme Council. RESULTS: The first edition of "Code of Ethics for Medical 
      Professionals, Medical Council of Islamic Republic of Iran" was developed on July
      6, 2017 by the Supreme Council of IRIMC. The guideline was set to take effect one
      year after its enactment. The first edition was revised and completed and final
      edition was adopted on August 9, 2018 by IRIMC in 13 chapters and 140 articles
      (original full text is available in the Supplementary file 1). CONCLUSION:
      According to the approved decision by the Supreme Council of IRIMC on May 10,
      2018, the final edition takes effect as of October 7, 2018.
CI  - (c) 2020 The Author(s). This is an open-access article distributed under the
      terms of the Creative Commons Attribution License
      (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
      distribution, and reproduction in any medium, provided the original work is
      properly cited.
FAU - Shamsi-Gooshki, Ehsan
AU  - Shamsi-Gooshki E
AUID- ORCID: 0000-0003-2405-0873
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
AD  - Department of Medical Ethics, Faculty of Medicine, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Parsapoor, Alireza
AU  - Parsapoor A
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
AD  - Department of Medical Ethics, Faculty of Medicine, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Asghari, Fariba
AU  - Asghari F
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Parsa, Mojtaba
AU  - Parsa M
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
AD  - Department of Medical Ethics, Faculty of Medicine, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Saeedinejad, Yasaman
AU  - Saeedinejad Y
AD  - Department of Criminology and Criminal Law, Faculty of Law, Shahid Beheshti
      University, Tehran, Iran.
FAU - Biroudian, Saeed
AU  - Biroudian S
AD  - Headquarters for the Promotion of Medical Ethics of Medical Council of the
      Islamic Republic of Iran, Tehran, Iran.
FAU - Fadavi, Mohsen
AU  - Fadavi M
AD  - Medical Ethics Department, Faculty of Traditional Medicine, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Khalajzadeh, Majid Reza
AU  - Khalajzadeh MR
AD  - Department of Medical Ethics, Iran University of Medical Sciences, Tehran, Iran.
FAU - Namazi, Hamid Reza
AU  - Namazi HR
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
AD  - Department of Medical Ethics, Faculty of Medicine, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Ghasemzadeh, Nazafarin
AU  - Ghasemzadeh N
AD  - Department of Medical Ethics, Faculty of Medicine, Urmia University of Medical
      Sciences, Urmia, Iran.
FAU - Omani Samani, Reza
AU  - Omani Samani R
AD  - Department of Medical Ethics and Law, Reproductive Biomedicine Research Center,
      Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
FAU - Milanifar, Alireza
AU  - Milanifar A
AD  - Bioethics and Law department, Avicenna Research Institute, ACECR, Tehran, Iran.
FAU - Raoofi, Azam
AU  - Raoofi A
AD  - Department of Health Management and Economics, School of Public Health, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Rouhbakhsh Halvaei, Sanaz
AU  - Rouhbakhsh Halvaei S
AD  - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mousavi, Maryam Sadat
AU  - Mousavi MS
AD  - Medical Ethics and Professionalism Office, Shariati Hospital, Tehran University
      of Medical Sciences, Tehran, Iran.
FAU - Zali, Alireza
AU  - Zali A
AUID- ORCID: 0000-0002-2298-2290
AD  - Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive
      Neurosurgical Center of Excellence, Shahid Beheshti University of Medical
      Sciences, Tehran, Iran.
FAU - Fazel, Iraj
AU  - Fazel I
AD  - Shahid Beheshti University of Medical Sciences; Tehran, Iran.
AD  - Iran Assembly for Scientific Medical Associations, Tehran, Iran.
FAU - Zafarghandi, Mohammad Reza
AU  - Zafarghandi MR
AUID- ORCID: 0000-0002-5993-0830
AD  - Tehran University of Medical Sciences, Tehran, Iran.
AD  - Medical Council of the Islamic Republic of Iran, Tehran, Iran.
FAU - Idani, Esmaeil
AU  - Idani E
AUID- ORCID: 0000-0002-0327-7107
AD  - National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Moin, Mostafa
AU  - Moin M
AUID- ORCID: 0000-0002-6150-9009
AD  - Immunology and Asthma and Allergy Research Institute, Tehran University of
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
SB  - IM
MH  - *Codes of Ethics
MH  - Guidelines as Topic
MH  - Humans
MH  - Iran
MH  - Patient Rights
MH  - Societies, Medical
OTO - NOTNLM
OT  - *Codes of ethics
OT  - *Iran
OT  - *Medical councils
EDAT- 2020/10/28 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/10/27 08:40
PHST- 2020/06/08 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/10/27 08:40 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
AID - 10.34172/aim.2020.83 [doi]
PST - epublish
SO  - Arch Iran Med. 2020 Oct 1;23(10):658-664. doi: 10.34172/aim.2020.83.


PMID- 33106383
OWN - NLM
STAT- Publisher
LR  - 20201027
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 26
TI  - US direct-to-consumer medical service advertisements fail to provide adequate
      information on quality and cost of care.
LID - medethics-2020-106458 [pii]
LID - 10.1136/medethics-2020-106458 [doi]
AB  - BACKGROUND: In the 1970s, the Federal Trade Commission declared that allowing
      medical providers to advertise directly to consumers would be "providing the
      public with truthful information about the price, quality or other aspects of
      their service." However, our understanding of the advertising content is highly
      limited. OBJECTIVE: To assess whether direct-to-consumer medical service
      advertisements provide relevant information on access, quality and cost of care, 
      a content analysis was conducted. METHOD: Television and online advertisements
      for medical services directly targeting consumers were collected in two major
      urban centres in Nevada, USA, identifying 313 television advertisements and 200
      non-duplicate online advertisements. RESULTS: Both television and online
      advertisements reliably conveyed information about the services provided and how 
      to make an appointment. At the same time, less than half of the advertisements
      featured insurance information and hours of operation and less than a quarter of 
      them contained information regarding the quality and price of care. The claims of
      quality were substantiated in even fewer advertisements. The scarcity of quality 
      and cost information was more severe in television advertisements. CONCLUSION:
      There is little evidence that medical service advertising, in its current form,
      would contribute to lower prices or improved quality of care by providing
      valuable information to consumers.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Park, Sung-Yeon
AU  - Park SY
AUID- ORCID: http://orcid.org/0000-0001-5205-7963
AD  - School of Community Health Sciences, University of Nevada Reno, Reno, Nevada, USA
      syp@unr.edu.
FAU - Yun, Gi Woong
AU  - Yun GW
AD  - Reynold School of Journalism, University of Nevada Reno, Reno, Nevada, USA.
FAU - Friedman, Sarah
AU  - Friedman S
AD  - School of Community Health Sciences, University of Nevada Reno, Reno, Nevada,
      USA.
FAU - Hill, Kylie
AU  - Hill K
AD  - School of Community Health Sciences, University of Nevada Reno, Reno, Nevada,
      USA.
AD  - Center for Biobehavioral Health, Nationwide Children's Hospital, Columbus, Ohio, 
      USA.
FAU - Ryu, So Young
AU  - Ryu SY
AD  - School of Community Health Sciences, University of Nevada Reno, Reno, Nevada,
      USA.
FAU - Schwenk, Thomas L
AU  - Schwenk TL
AD  - Dean, University of Nevada School of Medicine, Reno, Nevada, USA.
FAU - Coppes, Max J
AU  - Coppes MJ
AD  - Physician-in-Chief, Renown Childrens' Hospital, Reno, Nevada, USA.
AD  - Pediatrics, University of Nevada School of Medicine, Reno, Nevada, USA.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - codes of/position statements on professional ethics
OT  - ethics
OT  - journalism/mass media
COIS- Competing interests: None declared.
EDAT- 2020/10/28 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/10/27 05:41
PHST- 2020/05/17 00:00 [received]
PHST- 2020/09/25 00:00 [revised]
PHST- 2020/09/27 00:00 [accepted]
PHST- 2020/10/27 05:41 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
AID - medethics-2020-106458 [pii]
AID - 10.1136/medethics-2020-106458 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 26. pii: medethics-2020-106458. doi:
      10.1136/medethics-2020-106458.


PMID- 33106184
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 2045-4015 (Electronic)
IS  - 2045-4015 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Oct 26
TI  - Assisted life termination and truth telling to terminally ill patients - a
      cross-sectional study of public opinions in Israel.
PG  - 57
LID - 10.1186/s13584-020-00419-9 [doi]
AB  - BACKGROUND: End-of-life decisions are highly complex socio-normative and ethical 
      phenomena. The goal of this study was to provide an assessment of public opinions
      in Israel concerning aspects of end-of-life decisions. METHODS: An online cross
      sectional study was performed in February 2020. The primary tool including items 
      pertaining to death assistance and truth telling to patients. A sample of 515
      participants representative of the adult Israeli population was obtained.
      RESULTS: The majority of participants (71%) supports telling the entire truth to 
      patients even in harsh conditions. Support for truth telling decreases with
      affiliation to religion, with as little as 40% support among ultra-orthodox.
      People with vocational education are the least supportive of truth telling.
      Concerning doctor assisted death, almost half (49%) of the sample were
      supportive. Opposition is positively associated with religiosity, with 90% of
      ultra-orthodox and 58% of religious participants opposing doctor-assisted death, 
      compared to only 18% among seculars. Non-Jews were 3.35 times (95%CI: 1.90, 5.91)
      more likely to oppose doctor assisted death than Jews (p < .0001). An
      Interrelationship analysis crossing between attitudes revealed that the largest
      group (39%) was comprised of participants who support both ("autonomists").
      CONCLUSIONS: Israelis are overwhelmingly supportive of truth telling to patients.
      In contrast, Israeli public opinions on doctor assisted death are divided. For
      both attitudes, religiousness plays a crucial role as a catalyst for conservatism
      and opposition to change. Almost a half of the public is also supportive of an
      autonomist approach that would allow patients to decide on ending their own
      lives.
FAU - Bodas, Moran
AU  - Bodas M
AUID- ORCID: 0000-0002-6182-6362
AD  - Israel National Center for Trauma & Emergency Medicine Research, The Gertner
      Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel 
      Hashomer, 5265601, Ramat-Gan, Israel. Moranb@gertner.health.gov.il.
AD  - The Department of Emergency Management & Disaster Medicine, School of Public
      Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel. 
      Moranb@gertner.health.gov.il.
FAU - Velan, Baruch
AU  - Velan B
AD  - Israel National Center for Trauma & Emergency Medicine Research, The Gertner
      Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel 
      Hashomer, 5265601, Ramat-Gan, Israel.
FAU - Kaplan, Giora
AU  - Kaplan G
AD  - Israel National Center for Trauma & Emergency Medicine Research, The Gertner
      Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel 
      Hashomer, 5265601, Ramat-Gan, Israel.
FAU - Ziv, Arnona
AU  - Ziv A
AD  - Israel National Center for Trauma & Emergency Medicine Research, The Gertner
      Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel 
      Hashomer, 5265601, Ramat-Gan, Israel.
FAU - Rubin, Carmit
AU  - Rubin C
AD  - Israel National Center for Trauma & Emergency Medicine Research, The Gertner
      Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel 
      Hashomer, 5265601, Ramat-Gan, Israel.
FAU - Peleg, Kobi
AU  - Peleg K
AD  - Israel National Center for Trauma & Emergency Medicine Research, The Gertner
      Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel 
      Hashomer, 5265601, Ramat-Gan, Israel.
AD  - The Department of Emergency Management & Disaster Medicine, School of Public
      Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - Isr J Health Policy Res
JT  - Israel journal of health policy research
JID - 101584158
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Decision Making
MH  - Female
MH  - Humans
MH  - Israel
MH  - Jews/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Physician's Role
MH  - Public Opinion
MH  - Religion
MH  - Suicide, Assisted/*psychology
MH  - Terminal Care/*psychology
MH  - Terminally Ill/*psychology
MH  - *Truth Disclosure
MH  - Young Adult
PMC - PMC7586668
OTO - NOTNLM
OT  - *Autonomy
OT  - *Doctor-assisted-death
OT  - *End-of-life
OT  - *Truth-telling
EDAT- 2020/10/28 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/10/27 05:35
PHST- 2020/09/10 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/10/27 05:35 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
AID - 10.1186/s13584-020-00419-9 [doi]
AID - 10.1186/s13584-020-00419-9 [pii]
PST - epublish
SO  - Isr J Health Policy Res. 2020 Oct 26;9(1):57. doi: 10.1186/s13584-020-00419-9.


PMID- 33106170
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220418
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 26
TI  - BCG revaccination of health workers in Brazil to improve innate immune responses 
      against COVID-19: A structured summary of a study protocol for a randomised
      controlled trial.
PG  - 881
LID - 10.1186/s13063-020-04822-0 [doi]
AB  - OBJECTIVES: The BCG vaccine, widely used in Brazil in new-borns, induces adjuvant
      protection for several diseases, including childhood virus infections. BCG
      activates monocytes and innate memory NK cells which are crucial for the
      antiviral immune response. Therefore, strategies to prevent COVID-19 in health
      workers (HW) should be carried out to prevent them becoming unwell so that they
      can continue to work during the pandemic. The hypothesis is that BCG will improve
      the innate immune response and prevent symptomatic infection or COVID-19
      severity. The primary objective is to verify the effectiveness and safety of the 
      BCG vaccine to prevent or reduce incidence of severe acute respiratory syndrome
      coronavirus-2 (SARS-CoV-2) infection in the city of Goiania (Brazil) among HW
      previously vaccinated with BCG and also its severity and mortality during the
      pandemic of the disease. Secondary objectives are to estimate the incidence of
      COVID-19 among these professionals and the innate immune response elicited to
      BCG. TRIAL DESIGN: This a phase II trial for repositioning BCG as a preventive
      strategy against COVID-19. The trial is an open-label, parallel-group randomised 
      clinical trial, comparing HW vaccinated with BCG and HW not vaccinated.
      PARTICIPANTS: The trial will recruit 800 HW of Goiania - Goias, Brazil to reach a
      total of 400 HW included after comorbidities questioning and laboratorial
      evaluation. Eligibility criteria: Any HW presenting BCG vaccination scar with
      direct contact with suspected COVID-19 patients for at least 8 hours per week,
      whether in hospital beds, ICU, or in transportation or admission (nurses,
      doctors, physiotherapists, nutritionists, receptionists, etc.) who have negative 
      IgM and IgG COVID-19 test. Participants with any of the following characteristics
      will be excluded: - Have had in the last fifteen days any signs or symptoms of
      virus infection, including COVID-19; - Have had fever in the last fifteen days; -
      Have been vaccinated fifteen days before the inclusion; - Have a history or
      confirmation of any immunosuppressive disease such as HIV, presented solid tumour
      in the last two years or autoimmune diseases; - Are under preventive medication
      with antibiotics, steroid anti-inflammatories, or chemotherapy; - Have less than 
      500 neutrophils per mL of blood; - Have previously been diagnosed with
      tuberculosis; - Are breastfeeding or pregnant; - Are younger than 18 years old; -
      Are participating as an investigator in this clinical trial. INTERVENTION AND
      COMPARATOR: HW will be randomized into the BCG vaccinated group or the BCG
      unvaccinated control group. The BCG vaccinated group will receive in the right
      arm, intradermally, a one off dose of 0.1 mL corresponding to approximately 2
      x10(5) to 8 x10(5) CFU of live, freeze-dried, attenuated BCG Moscow 361-I,
      Bacillus Calmette Guerin vaccine (Serum Institute of India PVT. LTD.). The
      unvaccinated control group will not be vaccinated. The HW allocated in both
      groups will be followed up at specific times points until 180 days post
      inclusion. The vaccinated and control groups will be compared according to
      COVID-19 related outcomes. MAIN OUTCOMES: The primary outcomes are the incidence 
      coefficient of infection by SARS-CoV-2 determined by RT-PCR of naso-oropharyngeal
      swab specimen or rapid lateral flow IgG and IgM test, and presence of general
      COVID-19 symptoms, disease severity and admission to hospital during the 180 days
      of follow up. The secondary outcome is the innate immune response elicited 15-20 
      days after vaccination. RANDOMISATION: The vaccine vial contains approximately 10
      doses. In order to optimize the vaccine use, the randomisation was performed in
      blocks of 20 participants using the platform randomization.com [
      http://www.jerrydallal.com/random/permute.htm ]. The randomization was prepared
      before any HW inclusion. The results were printed and inserted in sealed
      envelopes that were numbered with BCG-001 to BCG-400. The printed results as well
      the envelopes had the same numbers. At the time of the randomisation, each
      participant that meets the inclusion criteria will receive a consecutive
      participant number [BCG-001-BCG-400]. The sealed envelope with the assigned
      number, blinded to the researchers, will be opened in front of the participant
      and the arm allocation will be known. BLINDING (MASKING): There is no masking for
      the participants or for the healthcare providers. The study will be blinded to
      the laboratory researchers and to those who will be evaluating the outcomes and
      performing the statistical analyses. In this case, only the participant
      identification number will be available. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 
      Four hundred heath workers will be randomised in two groups. Two hundred
      participants will be vaccinated, and 200 participants will not be vaccinated.
      TRIAL STATUS: The protocol approved by the Brazilian Ethical Committee is the
      seventh version, number CAAE: 31783720.0.0000.5078. The trial has been recruiting
      since September 20(th), 2020. The clinical trial protocol was registered on
      August 5(th), 2020. It is estimated that recruitment will finish by March 2021.
      TRIAL REGISTRATION: The protocol number was registered on August 5(th), 2020 at
      REBEC (Registro Brasileiro de Ensaios Clinicos). Register number: RBR-4kjqtg and 
      WHO trial registration number UTN: U1111-1256-3892. FULL PROTOCOL: The full
      protocol is attached as an additional file, accessible from the Trials website
      (Additional file 1). In the interest in expediting dissemination of this
      material, the familiar formatting has been eliminated; this Letter serves as a
      summary of the key elements of the full protocol.
FAU - Junqueira-Kipnis, Ana Paula
AU  - Junqueira-Kipnis AP
AUID- ORCID: http://orcid.org/0000-0002-4200-6617
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil. ana_kipnis@ufg.br.
FAU - Dos Anjos, Laura Raniere Borges
AU  - Dos Anjos LRB
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - Barbosa, Lilia Cristina de Souza
AU  - Barbosa LCS
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - da Costa, Adeliane Castro
AU  - da Costa AC
AD  - Faculdade Estacio de Sa de Goias - FESGO, Goiania, Goias, Brazil.
FAU - Borges, Kellen Christina Malheiros
AU  - Borges KCM
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - Cardoso, Amanda da Rocha Oliveira
AU  - Cardoso ADRO
AD  - Faculty of Medicine, Federal University of Goias, Goiania, Goias, Brazil.
FAU - Ribeiro, Kaio Mota
AU  - Ribeiro KM
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - Rosa, Sarah Brena Aparecida
AU  - Rosa SBA
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - Souza, Carine de Castro
AU  - Souza CC
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - das Neves, Rogerio Coutinho
AU  - das Neves RC
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - Saraiva, Guylherme
AU  - Saraiva G
AD  - Faculty of Medicine, Federal University of Goias, Goiania, Goias, Brazil.
FAU - da Silva, Sueli Meira
AU  - da Silva SM
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
FAU - Silveira, Erika Aparecida
AU  - Silveira EA
AD  - Faculty of Medicine, Federal University of Goias, Goiania, Goias, Brazil.
FAU - Rabahi, Marcelo Fouad
AU  - Rabahi MF
AD  - Faculty of Medicine, Federal University of Goias, Goiania, Goias, Brazil.
FAU - Conte, Marcus Barreto
AU  - Conte MB
AD  - Centro Universitario Arthur Sa Earp Neto. - UNIFASE- Petropolis, Rio de Janeiro, 
      Brazil.
FAU - Kipnis, Andre
AU  - Kipnis A
AD  - Institute of Tropical Pathology and Public Health, Federal University of Goias,
      Goiania, Goias, Brazil.
LA  - eng
GR  - 401206/2020-3/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
GR  - 001/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
GR  - 302974/2017-2/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
GR  - 303671/2019-0/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
GR  - 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
PT  - Clinical Trial, Phase II
PT  - Letter
PT  - Randomized Controlled Trial
DEP - 20201026
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (BCG Vaccine)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
SB  - IM
EIN - Trials. 2020 Nov 24;21(1):967. PMID: 33234139
MH  - BCG Vaccine/*administration & dosage
MH  - Betacoronavirus/immunology
MH  - Brazil/epidemiology
MH  - COVID-19
MH  - Case-Control Studies
MH  - Coronavirus Infections/epidemiology/immunology/*prevention & control/virology
MH  - Cross Protection/immunology
MH  - Follow-Up Studies
MH  - Health Personnel/statistics & numerical data
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Immunity, Innate/*immunology
MH  - Immunization, Secondary/methods
MH  - Immunoglobulin G/blood
MH  - Immunoglobulin M/blood
MH  - Incidence
MH  - Injections, Intradermal
MH  - Killer Cells, Natural/immunology
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/immunology/*prevention & control/virology
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - SARS-CoV-2
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7586662
OTO - NOTNLM
OT  - BCG revaccination
OT  - COVID-19
OT  - NK
OT  - Randomised controlled trial
OT  - cross-protection
OT  - health workers
OT  - innate immune response
OT  - macrophages
OT  - protocol
EDAT- 2020/10/28 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/27 05:35
PHST- 2020/09/30 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/27 05:35 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1186/s13063-020-04822-0 [doi]
AID - 10.1186/s13063-020-04822-0 [pii]
PST - epublish
SO  - Trials. 2020 Oct 26;21(1):881. doi: 10.1186/s13063-020-04822-0.


PMID- 32090174
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210914
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Cellular agriculture in the UK: a review.
PG  - 12
LID - 10.12688/wellcomeopenres.15685.2 [doi]
AB  - This review details the core activity in cellular agriculture conducted in the UK
      at the end of 2019, based upon a literature review by, and community contacts of 
      the authors. Cellular agriculture is an emergent field in which agricultural
      products-most typically animal-derived agricultural products-are produced through
      processes operating at the cellular level, as opposed to (typically farm-based)
      processes operating at the whole organism level. Figurehead example technologies 
      include meat, leather and milk products manufactured from a cellular level.
      Cellular agriculture can be divided into two forms: 'tissue-engineering based
      cellular agriculture' and 'fermentation-based cellular agriculture'. Products
      under development in this category are typically valued for their environmental, 
      ethical, and sometimes health and safety advantages over the animal-derived
      versions. There are university laboratories actively pursuing research on meat
      products through cellular agriculture at the universities of Bath, Newcastle,
      Aberystwyth, and Aston University in Birmingham. A cellular agriculture approach 
      to producing leather is being pursued at the University of Manchester, and work
      seeking to produce a palm oil substitute is being conducted at the University of 
      Bath. The UK cellular agriculture companies working in the meat space are Higher 
      Steaks, Cellular Agriculture Ltd, CellulaRevolution, Multus Media and Biomimetic 
      Solutions. UK private investors include CPT Capital, Agronomics Ltd, Atomico,
      Backed VCs, and Breakoff Capital. The UK also has a strong portfolio of social
      science research into diverse aspects of cellular agriculture, with at least ten 
      separate projects being pursued over the previous decade. Three analyses of the
      environmental impact of potential cellular agriculture systems have been
      conducted in the UK. The first dedicated third-sector group in this sector in the
      UK is Cultivate (who produced this report) followed by Cellular Agriculture UK.
      International groups New Harvest and the Good Food Institute also have a UK
      presence.
CI  - Copyright: (c) 2020 Stephens N and Ellis M.
FAU - Stephens, Neil
AU  - Stephens N
AUID- ORCID: https://orcid.org/0000-0003-3871-0887
AD  - Social and Political Sciences, Brunel University London, Uxbridge, UB8 3PH, UK.
FAU - Ellis, Marianne
AU  - Ellis M
AUID- ORCID: https://orcid.org/0000-0003-4155-0853
AD  - Department of Chemical Engineering, University of Bath, Bath, BA2 7AY, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 208198/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20201012
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7014924
OTO - NOTNLM
OT  - Cell-based meat
OT  - Cellular agriculture
OT  - Clean meat
OT  - Cultivated meat
OT  - Cultured meat
OT  - Palm oil
OT  - UK
COIS- Competing interests: NS is a founding member of Cultivate, a third sector
      multi-voiced forum for discussing cellular agriculture from UK perspectives, and 
      this publication forms part of the work of Cultivate. ME is a founding member of 
      Cultivate, a third sector multi-voiced forum for discussing cellular agriculture 
      from UK perspectives, and this publication forms part of the work of Cultivate.
      ME is also of co-founder of Cellular Agriculture Ltd, a start-up company active
      in cellular agriculture.
EDAT- 2020/10/28 06:00
MHDA- 2020/10/28 06:01
CRDT- 2020/10/27 05:47
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/10/27 05:47 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2020/10/28 06:01 [medline]
AID - 10.12688/wellcomeopenres.15685.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Oct 12;5:12. doi: 10.12688/wellcomeopenres.15685.2.
      eCollection 2020.


PMID- 33105272
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20211203
IS  - 1531-698X (Electronic)
IS  - 1040-8703 (Linking)
VI  - 32
IP  - 6
DP  - 2020 Dec
TI  - Ethical and legal considerations related to disorders of consciousness.
PG  - 765-771
LID - 10.1097/MOP.0000000000000961 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to describe ethical and legal
      issues that arise in the management of patients with disorders of consciousness
      ranging from the minimally conscious state to the coma state, as well as brain
      death. RECENT FINDINGS: The recent literature highlights dilemmas created by
      diagnostic and prognostic uncertainties in patients with disorders of
      consciousness. The discussion also reveals the challenges experienced by the
      disability community, which includes individuals with severe brain injury who are
      classified as having a disorder of consciousness. We review current guidelines
      for management of patients with disorders of consciousness including discussions 
      around diagnosis, prognosis, consideration of neuropalliation, and decisions
      around life sustaining medical treatment. SUMMARY: In the setting of uncertainty,
      this review describes the utility of applying a disability rights perspective and
      shared decision-making process to approach medical decision-making for patients
      with disorders of consciousness. We outline approaches to identifying surrogate
      decision makers, standards for decision-making and decision-making processes,
      specifically addressing the concept of futility as a less useful framework for
      making decisions. We also highlight special considerations for research,
      innovative and controversial care, brain death, organ donation, and child abuse
      and neglect.
FAU - Rissman, Lauren
AU  - Rissman L
AD  - Ann & Robert H. Lurie Children's Hospital of Chicago.
AD  - Northwestern University Feinberg School of Medicine.
FAU - Paquette, Erin Talati
AU  - Paquette ET
AD  - Ann & Robert H. Lurie Children's Hospital of Chicago.
AD  - Northwestern University Feinberg School of Medicine.
AD  - Northwestern University Pritzker School of Law (by courtesy), Chicago, Illinois, 
      USA.
LA  - eng
GR  - K12 HD047349/HD/NICHD NIH HHS/United States
GR  - K23 HD098289/HD/NICHD NIH HHS/United States
GR  - L40 HD089260/HD/NICHD NIH HHS/United States
GR  - K12 HD043449/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Pediatr
JT  - Current opinion in pediatrics
JID - 9000850
SB  - IM
MH  - *Consciousness Disorders/therapy
MH  - *Ethics, Medical
MH  - Humans
MH  - *Legislation, Medical
PMC - PMC8204725
MID - NIHMS1651615
EDAT- 2020/10/27 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/10/26 20:17
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/10/26 20:17 [entrez]
AID - 10.1097/MOP.0000000000000961 [doi]
AID - 00008480-202012000-00010 [pii]
PST - ppublish
SO  - Curr Opin Pediatr. 2020 Dec;32(6):765-771. doi: 10.1097/MOP.0000000000000961.


PMID- 33105200
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Dec
TI  - Ethical and societal challenges in penis transplantation.
PG  - 594-600
LID - 10.1097/MOT.0000000000000820 [doi]
AB  - PURPOSE OF REVIEW: To review the current understanding of the ethical and
      societal difficulties of penile transplantation. RECENT FINDINGS: Penile
      transplantation, as with other forms of vascularized composite
      allotransplantation, has increasing acceptance in society but is still not
      entirely accepted. Guidelines aiming to help guide future penile transplant
      programs in an ethical and scientific safe manner were created. Controversies
      regarding the economic impact, patient safety, and the rights of the patients
      choosing penile transplant remains. SUMMARY: Penile transplantation has excellent
      functional and cosmetic results in the short-term and medium-term. The penis,
      similar to the face in facial transplantation, carries emotional gravity that
      relates to visible body parts of another that live forth in a tangible manner
      contributing to psychological and ethical challenges for both the individual and 
      society more broadly, healthcare administrators, and healthcare workers. In the
      context of these challenges, controversies emerge related to issues of judgment
      about what society can and wants to afford. Effects of toxic immunosuppression in
      a nonlife saving life-enhancing procedure, as well as costs, become arguments
      that have to be considered in the context of ethical and societal challenges.
FAU - van der Merwe, Andre
AU  - van der Merwe A
AD  - Division of Urology.
FAU - Moosa, Mogamat R
AU  - Moosa MR
AD  - Department of Internal Medicine.
FAU - Barsdorf, Nicola
AU  - Barsdorf N
AD  - Health Research Ethics, Division of Research Development and Support, Faculty of 
      Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South
      Africa.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Ethics
MH  - Humans
MH  - Male
MH  - Penis/*transplantation
EDAT- 2020/10/27 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/10/26 20:17
PHST- 2020/10/26 20:17 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
AID - 10.1097/MOT.0000000000000820 [doi]
AID - 00075200-202012000-00012 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Dec;25(6):594-600. doi:
      10.1097/MOT.0000000000000820.


PMID- 33104893
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210517
IS  - 1432-1963 (Electronic)
IS  - 0172-8113 (Linking)
VI  - 41
IP  - Suppl 2
DP  - 2020 Dec
TI  - [Report of the working group History and Ethics of Pathology for the 104th annual
      meeting of the German Society of Pathology in 2020].
PG  - 165-166
LID - 10.1007/s00292-020-00818-4 [doi]
FAU - Braunschweig, T
AU  - Braunschweig T
AD  - Institut fur Pathologie, Universitatsklinikum RWTH Aachen, Aachen, Deutschland.
      tbraunschweig@ukaachen.de.
FAU - Schierle, K
AU  - Schierle K
AD  - Institut fur Pathologie, Universitatsklinikum Leipzig, Leipzig, Deutschland.
LA  - ger
PT  - Journal Article
TT  - Bericht der Arbeitsgemeinschaft Geschichte und Ethik der Pathologie fur die 104. 
      Jahrestagung der Deutschen Gesellschaft fur Pathologie 2020.
PL  - Germany
TA  - Pathologe
JT  - Der Pathologe
JID - 8006541
SB  - IM
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 17:14
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
PHST- 2020/10/26 17:14 [entrez]
AID - 10.1007/s00292-020-00818-4 [doi]
AID - 10.1007/s00292-020-00818-4 [pii]
PST - ppublish
SO  - Pathologe. 2020 Dec;41(Suppl 2):165-166. doi: 10.1007/s00292-020-00818-4.


PMID- 33104691
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 10
DP  - 2020
TI  - The effects of idealism and relativism on the moral judgement of social vs.
      environmental issues, and their relation to self-reported pro-environmental
      behaviours.
PG  - e0239707
LID - 10.1371/journal.pone.0239707 [doi]
AB  - Many studies have demonstrated that moral philosophies, such as idealism and
      relativism, could be used as robust predictors of judgements and behaviours
      related to common moral issues, such as business ethics, unethical beliefs,
      workplace deviance, marketing practices, gambling, etc. However, little
      consideration has been given to using moral philosophies to predict
      environmentally (un)friendly attitudes and behaviours, which could also be
      classified as moral. In this study, we have assessed the impact of idealism and
      relativism using the Ethics Position Theory. We have tested its capacity to
      predict moral identity, moral judgement of social vs. environmental issues, and
      self-reported pro-environmental behaviours. The results from an online MTurk
      study of 432 US participants revealed that idealism had a significant impact on
      all the tested variables, but the case was different with relativism.
      Consistently with the findings of previous studies, we found relativism to be a
      strong predictor of moral identity and moral judgement of social issues. In
      contrast, relativism only weakly interacted with making moral judgements of
      environmental issues, and had no effects in predicting pro-environmental
      behaviours. These findings suggest that Ethics Position Theory could have a
      strong potential for defining moral differences between environmental attitudes
      and behaviours, capturing the moral drivers of an attitude-behaviour gap, which
      continuously stands as a barrier in motivating people to become more
      pro-environmental.
FAU - Zaikauskaite, Laura
AU  - Zaikauskaite L
AUID- ORCID: 0000-0001-9943-8747
AD  - Department of Clinical, Educational and Health Psychology, Division of Psychology
      and Language Sciences, University College London, London, United Kingdom.
FAU - Chen, Xinyu
AU  - Chen X
AD  - Department of Clinical, Educational and Health Psychology, Division of Psychology
      and Language Sciences, University College London, London, United Kingdom.
FAU - Tsivrikos, Dimitrios
AU  - Tsivrikos D
AD  - Department of Clinical, Educational and Health Psychology, Division of Psychology
      and Language Sciences, University College London, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Conservation of Natural Resources/methods
MH  - Environmental Health/*ethics
MH  - Female
MH  - Humans
MH  - Judgment/*ethics
MH  - Male
MH  - *Morals
MH  - Social Behavior
PMC - PMC7588084
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/27 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/10/26 17:13
PHST- 2020/04/29 00:00 [received]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2020/10/26 17:13 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1371/journal.pone.0239707 [doi]
AID - PONE-D-20-12480 [pii]
PST - epublish
SO  - PLoS One. 2020 Oct 26;15(10):e0239707. doi: 10.1371/journal.pone.0239707.
      eCollection 2020.


PMID- 33104433
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20220417
IS  - 0966-0461 (Print)
IS  - 0966-0461 (Linking)
VI  - 29
IP  - 19
DP  - 2020 Oct 22
TI  - SECUREment bundles to prevent peripheral intravenous catheter failure-the
      SECURE-PIVC trial: study protocol for a pilot randomized controlled trial.
PG  - S40-S46
LID - 10.12968/bjon.2020.29.19.S40 [doi]
AB  - INTRODUCTION: Peripheral intravenous catheters (PIVCs) are widely used, but
      failure is unacceptably common with up to 69% failing before treatment is
      complete. PIVC securement reduces failure, but the optimal way to achieve this is
      unclear. Tapes and supplementary securement products are widely used, however
      rigorous testing of these to reduce PIVC failure remains unexplored. METHODS AND 
      ANALYSIS: In adult medical-surgical wards at a tertiary hospital, this pilot
      randomized controlled trial tests standard care (bordered polyurethane dressing
      plus nonsterile tape over the extension tubing) against two securement
      interventions (intervention one: standard care plus two sterile tape strips over 
      the PIVC hub; intervention two: intervention one plus a tubular bandage).
      Patients >18 years of age requiring a PIVC for >24 hours are eligible. Patients
      with laboratory-confirmed positive blood cultures within 24 hours of screening,
      known allergy to study products, current or high-risk of skin tear, or
      non-English speaking without interpreter are excluded. Sample size is 35 per
      trial arm, and central randomization is computer-generated with allocation
      concealed until entry. Patients and clinical staff cannot be blinded to treatment
      allocation. However, infection outcomes are assessed by a blinded investigator.
      Primary outcome is study feasibility. Secondary outcomes (PIVC failure, dwell
      time, skin adverse events, PIVC colonization, and cost) are compared between
      groups. Feasibility outcomes are reported descriptively. ETHICS AND TRIAL
      COMMENCEMENT: Ethical approvals were received from Royal Brisbane and Women's
      Hospital (HREC/18/QRBW/44571) and Griffith University (2018/1000). Trial
      commencement was May 2019. Trial registration: ACTRN12619000026123.
FAU - Corley, Amanda
AU  - Corley A
AD  - Adjunct Senior Research Fellow position with the AVATAR group at Menzies Health
      Institute QLD, Griffith University.
FAU - Ullman, Amanda J
AU  - Ullman AJ
AD  - NHMRC Fellow and Associate Professor at Griffith University, and Honorary
      Research Fellow at the Queensland Children's Hospital and the Royal Brisbane and 
      Women's Hospital.
FAU - Marsh, Nicole
AU  - Marsh N
AD  - Nursing Director, Research, The Royal Brisbane and Women's Hospital.
FAU - Emily N, Larsen
AU  - Emily N L
AD  - Senior Research Assistant with the AVATAR Group, Griffith University, Australia.
FAU - Mihala, Gabor
AU  - Mihala G
AD  - Centre for Applied Health Economics (CAHE) and the AVATAR Group.
FAU - Harris, Patrick N A
AU  - Harris PNA
AD  - Infectious Disease Physician, Medical Microbiologist and NHMRC Early Career
      Fellow at The University of Queensland Centre for Clinical Research (UQCCR).
FAU - Rickard, Claire M
AU  - Rickard CM
AD  - AVATAR Group.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - England
TA  - Br J Nurs
JT  - British journal of nursing (Mark Allen Publishing)
JID - 9212059
RN  - 0 (Polyurethanes)
MH  - Adult
MH  - Bandages
MH  - *Catheterization, Peripheral/adverse effects
MH  - Catheters
MH  - Female
MH  - Humans
MH  - Pilot Projects
MH  - Polyurethanes
MH  - Randomized Controlled Trials as Topic
EDAT- 2020/10/27 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/10/26 17:12
PHST- 2020/10/26 17:12 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
AID - 10.12968/bjon.2020.29.19.S40 [doi]
PST - ppublish
SO  - Br J Nurs. 2020 Oct 22;29(19):S40-S46. doi: 10.12968/bjon.2020.29.19.S40.


PMID- 33104084
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 1188-4169 (Print)
IS  - 1188-4169 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep 3
TI  - Vaccine Injury Compensation Programs:Rationale and an overview of the Quebec
      program.
PG  - 305-308
LID - 10.14745/ccdr.v46i09a09 [doi]
AB  - Vaccines are among the safest therapeutic agents, and serious adverse events
      rarely occur. When they do occur, an individual may have to bear some or all of
      the costs associated with their injuries, seek compensation through litigation
      or, if available, seek compensation from a publicly-supported Vaccine Injury
      Compensation Program (VIC Programs). The VIC Programs are "no-fault" compensation
      schemes in which governments compensate individuals who are harmed by properly
      manufactured vaccines. There are ethical, legal and practical rationales to
      support these programs. Worldwide there are 19 countries that have implemented
      VIC Programs; in the majority of these countries, vaccines are not mandatory.
      They all have similar processes with respect to process, standard of proof and
      elements of compensation. In Canada, only the province of Quebec has a VIC
      Program, which has been running successfully since 1985. Concerns with VIC
      Programs include cost, difficulties assessing causality and concern that such
      programs may undermine public trust in vaccines; but these concerns can be
      addressed, especially in high-income countries that can bear the costs and have
      the capacity to manage the program.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - Canada
TA  - Can Commun Dis Rep
JT  - Canada communicable disease report = Releve des maladies transmissibles au Canada
JID - 9303729
PMC - PMC7556198
OTO - NOTNLM
OT  - compensation
OT  - ethical considerations
OT  - no-fault insurance
OT  - vaccine injury
COIS- Competing interests: E Dube received grants from the Public Health Agency of
      Canada, the Quebec Ministry of Health and Social Services, les Fonds de recherche
      du Quebec-Sante, the Canadian Institutes of Health Research, the Canadian
      Immunization Research Network and the Social Sciences and Humanities Research
      Council of Canada. She is a member of the Canadian Vaccination Evidence Resource 
      and Exchange Centre (CANVax) Team. NE MacDonald received grants from the Public
      Health Agency of Canada, the World Health Organization, the Nova Scotia Health
      Research Foundation, the Canadian Institutes of Health Research, the Canadian
      Immunization Research Network and the Social Sciences and Humanities Research
      Council of Canada. She is a member of the CANVax Team.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.14745/ccdr.v46i09a09 [doi]
AID - 460909 [pii]
PST - epublish
SO  - Can Commun Dis Rep. 2020 Sep 3;46(9):305-308. doi: 10.14745/ccdr.v46i09a09.
      eCollection 2020 Sep 3.


PMID- 33104051
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1875-8894 (Electronic)
IS  - 1874-5393 (Linking)
VI  - 13
IP  - 3
DP  - 2020
TI  - Disparities and ethical considerations for children with tracheostomies during
      the COVID-19 pandemic.
PG  - 371-376
LID - 10.3233/PRM-200749 [doi]
AB  - The COVID-19 pandemic is exacerbating longstanding challenges facing children
      with tracheostomies and their families. Myriad ethical concerns arising in the
      long-term care of children with tracheostomies during the COVID-19 pandemic
      revolve around inadequate access to care, healthcare resources, and
      rehabilitation services. Marginalized communities such as those from Black and
      Hispanic origins face disproportionate chronic illness because of racial and
      other underlying disparities. In this paper, we describe how these disparities
      also present challenges to children who are technology-dependent, such as those
      with tracheostomies and discuss the emerging ethical discourse regarding
      healthcare and resource access for this population during the pandemic.
FAU - Kana, Lulia A
AU  - Kana LA
AD  - University of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Shuman, Andrew G
AU  - Shuman AG
AD  - University of Michigan Medical School, Ann Arbor, MI, USA.
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Michigan
      Medical School, Ann Arbor, MI, USA.
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan
      Medical School, Ann Arbor, MI, USA.
FAU - Helman, Jennifer
AU  - Helman J
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Michigan
      Medical School, Ann Arbor, MI, USA.
FAU - Krawcke, Kelly
AU  - Krawcke K
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Michigan
      Medical School, Ann Arbor, MI, USA.
FAU - Brown, David J
AU  - Brown DJ
AD  - University of Michigan Medical School, Ann Arbor, MI, USA.
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Michigan
      Medical School, Ann Arbor, MI, USA.
AD  - Office for Health Equity and Inclusion, Michigan Medicine, Ann Arbor, MI, USA.
LA  - eng
PT  - Letter
PL  - Netherlands
TA  - J Pediatr Rehabil Med
JT  - Journal of pediatric rehabilitation medicine
JID - 101490944
SB  - IM
MH  - COVID-19/*epidemiology/therapy
MH  - Child
MH  - *Health Status Disparities
MH  - Humans
MH  - Long-Term Care/*methods
MH  - *Pandemics
MH  - *SARS-CoV-2
MH  - Tracheostomy/*ethics
OTO - NOTNLM
OT  - COVID-19
OT  - chronic disability
OT  - ethics
OT  - pediatric tracheostomy
EDAT- 2020/10/27 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/10/26 12:09 [entrez]
AID - PRM200749 [pii]
AID - 10.3233/PRM-200749 [doi]
PST - ppublish
SO  - J Pediatr Rehabil Med. 2020;13(3):371-376. doi: 10.3233/PRM-200749.


PMID- 33103986
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - An Evaluation of the Pipeline Framework for Ethical Considerations in Machine
      Learning Healthcare Applications: The Case of Prediction from Functional
      Neuroimaging Data.
PG  - 56-58
LID - 10.1080/15265161.2020.1820110 [doi]
FAU - Overton, Dawson J
AU  - Overton DJ
AD  - University of Toronto.
AD  - Schulich School of Medicine and Dentistry, Western University.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Functional Neuroimaging
MH  - Humans
MH  - *Machine Learning
MH  - Morals
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820110 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):56-58. doi: 10.1080/15265161.2020.1820110.


PMID- 33103985
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20211102
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - A Framework to Evaluate Ethical Considerations with ML-HCA Applications-Valuable,
      Even Necessary, but Never Comprehensive.
PG  - W6-W10
LID - 10.1080/15265161.2020.1827695 [doi]
FAU - Char, Danton
AU  - Char D
AD  - Stanford University School of Medicine.
FAU - Abramoff, Michael
AU  - Abramoff M
AD  - University of Iowa.
AD  - Digital Diagnostics.
FAU - Feudtner, Chris
AU  - Feudtner C
AD  - The University of Pennsylvania.
AD  - The Children's Hospital of Philadelphia.
LA  - eng
GR  - K01 HG008498/HG/NHGRI NIH HHS/United States
GR  - P30 EY025580/EY/NEI NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Delivery of Health Care
MH  - Humans
MH  - Machine Learning
MH  - *Morals
PMC - PMC7714002
MID - NIHMS1648283
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1827695 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):W6-W10. doi: 10.1080/15265161.2020.1827695.


PMID- 33103983
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20211102
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - AI Ethics Is Not a Panacea.
PG  - 20-22
LID - 10.1080/15265161.2020.1819470 [doi]
FAU - McLennan, Stuart
AU  - McLennan S
AUID- ORCID: 0000-0002-2019-6253
AD  - Technical University of Munich.
AD  - University of Basel.
FAU - Lee, Meredith M
AU  - Lee MM
AUID- ORCID: 0000-0002-1405-577X
AD  - UC Berkeley Division of Computing, Data Science, and Society.
FAU - Fiske, Amelia
AU  - Fiske A
AUID- ORCID: 0000-0001-7207-6897
AD  - Technical University of Munich.
FAU - Celi, Leo Anthony
AU  - Celi LA
AUID- ORCID: 0000-0001-6712-6626
AD  - Beth Israel Deaconess Medical Center.
AD  - Harvard-Massachusetts Institute of Technology.
AD  - Harvard T.H. Chan School of Public Health.
LA  - eng
GR  - R01 EB017205/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - Humans
MH  - *Machine Learning
MH  - *Morals
PMC - PMC8034825
MID - NIHMS1689545
EDAT- 2020/10/27 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - 10.1080/15265161.2020.1819470 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):20-22. doi: 10.1080/15265161.2020.1819470.


PMID- 33103982
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - An Ethical Framework to Nowhere.
PG  - 30-32
LID - 10.1080/15265161.2020.1820109 [doi]
FAU - Swirsky, Eric S
AU  - Swirsky ES
AUID- ORCID: 0000-0002-8949-1103
AD  - University of Illinois at Chicago.
FAU - Gu, Carol
AU  - Gu C
AD  - University of Illinois at Chicago.
FAU - Boyd, Andrew D
AU  - Boyd AD
AUID- ORCID: 0000-0002-3459-9379
AD  - University of Illinois at Chicago.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Ethical Analysis
MH  - Humans
MH  - Machine Learning
MH  - *Morals
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820109 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):30-32. doi: 10.1080/15265161.2020.1820109.


PMID- 33103981
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201029
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Where Bioethics Meets Machine Ethics.
PG  - 22-24
LID - 10.1080/15265161.2020.1819471 [doi]
FAU - Lewis, Anna C F
AU  - Lewis ACF
AD  - Harvard University.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
EIN - Am J Bioeth. 2021 Jan;21(1):W7. PMID: 33289454
MH  - *Bioethics
MH  - Ethical Theory
MH  - Humans
MH  - Machine Learning
MH  - Morals
EDAT- 2020/10/27 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - 10.1080/15265161.2020.1819471 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):22-24. doi: 10.1080/15265161.2020.1819471.


PMID- 33103980
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Accountability in the Machine Learning Pipeline: The Critical Role of Research
      Ethics Oversight.
PG  - 40-42
LID - 10.1080/15265161.2020.1820111 [doi]
FAU - McCradden, Melissa D
AU  - McCradden MD
AUID- ORCID: 0000-0002-6476-2165
AD  - The Hospital for Sick Children.
FAU - Anderson, James A
AU  - Anderson JA
AD  - The Hospital for Sick Children.
FAU - Zlotnik Shaul, Randi
AU  - Zlotnik Shaul R
AD  - The Hospital for Sick Children.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Ethics Committees, Research
MH  - *Ethics, Research
MH  - Humans
MH  - Machine Learning
MH  - Social Responsibility
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820111 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):40-42. doi: 10.1080/15265161.2020.1820111.


PMID- 33103978
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Embedded Ethics Could Help Implement the Pipeline Model Framework for Machine
      Learning Healthcare Applications.
PG  - 32-35
LID - 10.1080/15265161.2020.1820101 [doi]
FAU - Fiske, Amelia
AU  - Fiske A
AUID- ORCID: 0000-0001-7207-6897
AD  - Technical University of Munich.
FAU - Tigard, Daniel
AU  - Tigard D
AUID- ORCID: 0000-0003-3633-3563
AD  - Technical University of Munich.
FAU - Muller, Ruth
AU  - Muller R
AD  - Technical University of Munich.
FAU - Haddadin, Sami
AU  - Haddadin S
AUID- ORCID: 0000-0001-7696-4955
AD  - Technical University of Munich.
FAU - Buyx, Alena
AU  - Buyx A
AUID- ORCID: 0000-0002-5726-7633
AD  - Technical University of Munich.
FAU - McLennan, Stuart
AU  - McLennan S
AUID- ORCID: 0000-0002-2019-6253
AD  - Technical University of Munich.
AD  - University of Basel.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Machine Learning
MH  - Morals
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820101 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):32-35. doi: 10.1080/15265161.2020.1820101.


PMID- 33103974
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Machine Learning in Healthcare: Exceptional Technologies Require Exceptional
      Ethics.
PG  - 48-51
LID - 10.1080/15265161.2020.1820103 [doi]
FAU - Baeroe, Kristine
AU  - Baeroe K
AUID- ORCID: 0000-0002-4626-7232
AD  - University of Bergen.
FAU - Jansen, Maarten
AU  - Jansen M
AD  - Radboud University Nijmegen.
FAU - Kerasidou, Angeliki
AU  - Kerasidou A
AD  - University of Oxford.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Machine Learning
MH  - Morals
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820103 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):48-51. doi: 10.1080/15265161.2020.1820103.


PMID- 33103973
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20211207
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - It is Time for Bioethicists to Enter the Arena of Machine Learning Ethics.
PG  - 18-20
LID - 10.1080/15265161.2020.1820115 [doi]
FAU - Hardt, Michaela
AU  - Hardt M
AD  - Independent Scholar.
FAU - Chin, Marshall H
AU  - Chin MH
AD  - University of Chicago.
LA  - eng
GR  - P30 DK092949/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Ethicists
MH  - *Ethics Consultation
MH  - Humans
MH  - Machine Learning
MH  - Morals
PMC - PMC8647714
MID - NIHMS1759235
EDAT- 2020/10/27 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - 10.1080/15265161.2020.1820115 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):18-20. doi: 10.1080/15265161.2020.1820115.


PMID- 33103972
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Machine Learning Healthcare Applications (ML-HCAs) Are No Stand-Alone Systems but
      Part of an Ecosystem - A Broader Ethical and Health Technology Assessment
      Approach is Needed.
PG  - 46-48
LID - 10.1080/15265161.2020.1820104 [doi]
FAU - Gerhards, Helene
AU  - Gerhards H
AUID- ORCID: 0000-0001-9795-2689
AD  - OTH Regensburg.
FAU - Weber, Karsten
AU  - Weber K
AUID- ORCID: 0000-0001-8875-2386
AD  - OTH Regensburg.
FAU - Bittner, Uta
AU  - Bittner U
AD  - Heinrich Heine University Dusseldorf.
FAU - Fangerau, Heiner
AU  - Fangerau H
AUID- ORCID: 0000-0001-9065-3395
AD  - Heinrich Heine University Dusseldorf.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - Delivery of Health Care
MH  - *Ecosystem
MH  - Humans
MH  - Machine Learning
MH  - Morals
MH  - *Technology Assessment, Biomedical
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820104 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):46-48. doi: 10.1080/15265161.2020.1820104.


PMID- 33103970
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Deepening the Normative Evaluation of Machine Learning Healthcare Application by 
      Complementing Ethical Considerations with Regulatory Governance.
PG  - 43-45
LID - 10.1080/15265161.2020.1820106 [doi]
FAU - Ho, Calvin Wai-Loon
AU  - Ho CW
AUID- ORCID: 0000-0002-8328-1308
AD  - University of Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Nov;20(11):7-17. PMID: 33103967
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Machine Learning
MH  - Morals
EDAT- 2020/10/27 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1080/15265161.2020.1820106 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):43-45. doi: 10.1080/15265161.2020.1820106.


PMID- 33103967
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20211102
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Identifying Ethical Considerations for Machine Learning Healthcare Applications.
PG  - 7-17
LID - 10.1080/15265161.2020.1819469 [doi]
AB  - Along with potential benefits to healthcare delivery, machine learning healthcare
      applications (ML-HCAs) raise a number of ethical concerns. Ethical evaluations of
      ML-HCAs will need to structure the overall problem of evaluating these
      technologies, especially for a diverse group of stakeholders. This paper outlines
      a systematic approach to identifying ML-HCA ethical concerns, starting with a
      conceptual model of the pipeline of the conception, development, implementation
      of ML-HCAs, and the parallel pipeline of evaluation and oversight tasks at each
      stage. Over this model, we layer key questions that raise value-based issues,
      along with ethical considerations identified in large part by a literature
      review, but also identifying some ethical considerations that have yet to receive
      attention. This pipeline model framework will be useful for systematic ethical
      appraisals of ML-HCA from development through implementation, and for
      interdisciplinary collaboration of diverse stakeholders that will be required to 
      understand and subsequently manage the ethical implications of ML-HCAs.
FAU - Char, Danton S
AU  - Char DS
AD  - Stanford University School of Medicine.
FAU - Abramoff, Michael D
AU  - Abramoff MD
AD  - University of Iowa.
AD  - Digital Diagnostics.
FAU - Feudtner, Chris
AU  - Feudtner C
AD  - The University of Pennsylvania.
AD  - The Children's Hospital of Philadelphia.
LA  - eng
GR  - K01 HG008498/HG/NHGRI NIH HHS/United States
GR  - P30 EY025580/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Nov;20(11):1-3. PMID: 33103968
CIN - Am J Bioeth. 2020 Nov;20(11):27-30. PMID: 33103969
CIN - Am J Bioeth. 2020 Nov;20(11):43-45. PMID: 33103970
CIN - Am J Bioeth. 2020 Nov;20(11):37-40. PMID: 33103971
CIN - Am J Bioeth. 2020 Nov;20(11):46-48. PMID: 33103972
CIN - Am J Bioeth. 2020 Nov;20(11):18-20. PMID: 33103973
CIN - Am J Bioeth. 2020 Nov;20(11):48-51. PMID: 33103974
CIN - Am J Bioeth. 2020 Nov;20(11):25-27. PMID: 33103975
CIN - Am J Bioeth. 2020 Nov;20(11):35-37. PMID: 33103976
CIN - Am J Bioeth. 2020 Nov;20(11):32-35. PMID: 33103978
CIN - Am J Bioeth. 2020 Nov;20(11):54-56. PMID: 33103979
CIN - Am J Bioeth. 2020 Nov;20(11):40-42. PMID: 33103980
CIN - Am J Bioeth. 2020 Nov;20(11):22-24. PMID: 33103981
CIN - Am J Bioeth. 2020 Nov;20(11):30-32. PMID: 33103982
CIN - Am J Bioeth. 2020 Nov;20(11):20-22. PMID: 33103983
CIN - Am J Bioeth. 2020 Nov;20(11):51-53. PMID: 33103984
CIN - Am J Bioeth. 2020 Nov;20(11):W6-W10. PMID: 33103985
CIN - Am J Bioeth. 2020 Nov;20(11):56-58. PMID: 33103986
MH  - Delivery of Health Care
MH  - Humans
MH  - *Machine Learning
MH  - *Morals
PMC - PMC7737650
MID - NIHMS1648280
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *effectiveness
OT  - *ethics
OT  - *machine learning
OT  - *safety
OT  - *test characteristics
EDAT- 2020/10/27 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/10/26 12:09
PHST- 2020/10/26 12:09 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1819469 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Nov;20(11):7-17. doi: 10.1080/15265161.2020.1819469.


PMID- 33103813
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Study bystanders and ethical treatment of study participants-A proof of concept.
PG  - 941-947
LID - 10.1111/bioe.12825 [doi]
AB  - The ethics of research on human subjects is often construed as a fine balance
      between the interests of patients in need of novel health interventions, and
      those of study participants who should remain safe in the process. But there is a
      third group in the mix. Some people belong to neither category, yet research can 
      affect or jeopardize them. Call such people "bystanders." This article shows that
      thinking about bystander protection can question whether there is an upper limit 
      on the risks that studies may legitimately visit upon their participants. Thus,
      thinking about appropriate bystander protection can shed light on the appropriate
      protection of study participants. Core research ethics, which focuses on the
      latter, must consider the former as well.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Eyal, Nir
AU  - Eyal N
AUID- ORCID: 0000-0003-1056-6609
AD  - Center for Population-Level Bioethics (IFH), Department of Health Behavior,
      Society, and Policy (SPH) and Department of Pilosophy (SAS), Rutgers University, 
      New Brunswick, New Jersey.
LA  - eng
GR  - 1 R01 AI114617-01A1/NH/NIH HHS/United States
GR  - 208766/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201026
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Ethics, Research
MH  - Humans
MH  - Research Design
MH  - *Research Subjects
OTO - NOTNLM
OT  - *minimal risk
OT  - *research ethics review
OT  - *research subjects
OT  - *risk threshold
OT  - *risk-adapted regulation
OT  - *subject protection
EDAT- 2020/10/27 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/26 08:45
PHST- 2019/01/15 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/10/26 08:45 [entrez]
AID - 10.1111/bioe.12825 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):941-947. doi: 10.1111/bioe.12825. Epub 2020 Oct 26.


PMID- 33103654
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201218
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 10
DP  - 2020 Oct 1
TI  - Indigenous Apocalypse and Transgenerational Trauma.
PG  - E898-903
LID - amajethics.2020.898 [pii]
LID - 10.1001/amajethics.2020.898 [doi]
AB  - The disproportionate negative impact of the COVID-19 pandemic on Native
      communities is a result of transgenerational traumas-mental and physical-which
      have been ongoing and developing for centuries. This article considers
      19th-century American visual and narrative representations of Native experiences 
      of and responses to transgenerational trauma. This article also suggests ethical 
      implications for Native American health of interpreting those representations and
      suggests an obligation to look on 19th-century White American artists'
      romanticizations of Native experiences with humility.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Ramos, Sam
AU  - Ramos S
AD  - Associate director of innovation and creativity in the Department of Learning and
      Public Engagement at the Art Institute of Chicago in Illinois.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Art/history
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/epidemiology/virology
MH  - Family Characteristics
MH  - Historical Trauma/*complications/ethnology
MH  - *Historiography
MH  - History, 19th Century
MH  - Humans
MH  - Indians, North American/*psychology
MH  - Narration
MH  - Pandemics
MH  - Pneumonia, Viral/*complications/epidemiology/virology
MH  - *Population Health
MH  - SARS-CoV-2
MH  - United States
MH  - *Violence/ethics/history/psychology
EDAT- 2020/10/27 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/26 08:43
PHST- 2020/10/26 08:43 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - amajethics.2020.898 [pii]
AID - 10.1001/amajethics.2020.898 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Oct 1;22(10):E898-903. doi: 10.1001/amajethics.2020.898.


PMID- 33103653
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201218
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 10
DP  - 2020 Oct 1
TI  - Paintings From Spain's COVID-19 Pandemic.
PG  - E893-897
LID - amajethics.2020.893 [pii]
LID - 10.1001/amajethics.2020.893 [doi]
AB  - Artist Francisca Lita Saez considers experience of physicians during Spain's
      COVID-19 pandemic. Three acrylic and pastel paintings convey defenseless human
      beings' confrontations with the novel SARS-CoV-2 virus, which is not yet
      controlled, leaving suffering and death in its wake. A physician-artist
      collaboration offers a visual representation of the clinical and ethical
      magnitude of the pandemic and humanity's fight for survival.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Vicente-Herrero, Teofila
AU  - Vicente-Herrero T
AD  - Specialist in occupational medicine in Valencia, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/virology
MH  - Humans
MH  - *Medicine in the Arts
MH  - *Paintings
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/virology
MH  - SARS-CoV-2
MH  - Spain
EDAT- 2020/10/27 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/26 08:43
PHST- 2020/10/26 08:43 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - amajethics.2020.893 [pii]
AID - 10.1001/amajethics.2020.893 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Oct 1;22(10):E893-897. doi: 10.1001/amajethics.2020.893.


PMID- 33103650
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20211204
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 10
DP  - 2020 Oct 1
TI  - Racialization as a Barrier to Achieving Health Equity for Native Americans.
PG  - E874-881
LID - amajethics.2020.874 [pii]
LID - 10.1001/amajethics.2020.874 [doi]
AB  - Racial identity is a complex idea, particularly for American Indian and Alaska
      Native (AI/AN) populations. The idea of a single AI/AN race developed from a
      European-American view of phenotypic and cultural differences. It continues to
      have significant consequences for AI/AN populations within the clinical-medical
      context. For clinicians, using this flawed category in medical decision making
      poses ethical challenges and has implications for patient autonomy and justice.
      This article briefly traces the development of the idea of an AI/AN race, the
      concerns raised in using this identity marker, and the ethical implications of
      employing the categorization.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Gampa, Vikas
AU  - Gampa V
AD  - Fellow in the Massachusetts General Hospital Fellowship Program in Rural Health
      Leadership in Boston.
FAU - Bernard, Kenneth
AU  - Bernard K
AD  - Founder of the Native American Emergency Medicine Consortium and a co-organizer
      of the Native American and Rural Emergency Medicine Conference.
FAU - Oldani, Michael J
AU  - Oldani MJ
AD  - Professor of pharmaceutical sciences and administration and the director of
      Interprofessional Practice and Education at Concordia University Wisconsin in
      Mequon.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Alaskan Natives
MH  - American Indians or Alaska Natives
MH  - *Health Equity
MH  - Humans
MH  - *Indians, North American
MH  - Minority Groups
EDAT- 2020/10/27 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/26 08:43
PHST- 2020/10/26 08:43 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.874 [pii]
AID - 10.1001/amajethics.2020.874 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Oct 1;22(10):E874-881. doi: 10.1001/amajethics.2020.874.


PMID- 33103648
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20211204
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 10
DP  - 2020 Oct 1
TI  - Effects of Substance Use Disorder Criminalization on American Indian Pregnant
      Individuals.
PG  - E862-867
LID - amajethics.2020.862 [pii]
LID - 10.1001/amajethics.2020.862 [doi]
AB  - Individuals with substance use disorders (SUDs) are at markedly elevated risk of 
      involvement in the criminal legal system. Over the past 30 years, substance use
      during pregnancy has been criminalized through laws on the federal, state, and
      tribal level. American Indian (AI) individuals are disproportionately affected by
      these laws due to their race, socioeconomic status, and limited access to SUD
      treatment. This article aims to educate readers on laws criminalizing substance
      use during pregnancy and on how AI individuals are disproportionately affected by
      these laws. It also discusses how these laws conflict with the ethical principles
      of autonomy, nonmaleficence, and justice. Finally, this article recommends that
      clinicians advocate for the decriminalization of SUDs during pregnancy and for
      improvement in access to comprehensive, evidence-based SUDs care.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Simon, Rachel
AU  - Simon R
AD  - Addiction medicine fellow at Massachusetts General Hospital in Boston.
FAU - Giroux, Jennifer
AU  - Giroux J
AD  - Medical epidemiologist for the Great Plains Area Indian Health Service
      intermittently from 2004 through 2019.
FAU - Chor, Julie
AU  - Chor J
AD  - Assistant professor of obstetrics and gynecology at the University of Chicago in 
      Illinois, where she also serves as assistant director of the MacLean Center for
      Clinical Medical Ethics.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - American Indians or Alaska Natives
MH  - *Criminals
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Substance-Related Disorders
EDAT- 2020/10/27 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/26 08:43
PHST- 2020/10/26 08:43 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.862 [pii]
AID - 10.1001/amajethics.2020.862 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Oct 1;22(10):E862-867. doi: 10.1001/amajethics.2020.862.


PMID- 33103647
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201218
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 10
DP  - 2020 Oct 1
TI  - Three Levels of Autonomy and One Long-Term Solution for Native American Health
      Care.
PG  - E856-861
LID - amajethics.2020.856 [pii]
LID - 10.1001/amajethics.2020.856 [doi]
AB  - Native Americans have twice the poverty rate of the general US population, suffer
      significant health inequity, and are chronically underrepresented, at only 0.08%,
      in the US physician workforce. The COVID-19 pandemic has illuminated key ethical,
      clinical, and economic complexities in health decision making among Native
      patients. This article discusses 3 levels of autonomy relevant to health
      decisions, including taking care of our own by increasing numbers of Native
      medical students.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Wescott, Siobhan
AU  - Wescott S
AD  - Assistant professor in family and community medicine and the assistant director
      of Indians Into Medicine at the University of North Dakota in Grand Forks.
FAU - Mittelstet, Beth
AU  - Mittelstet B
AD  - Pediatrician pursuing a career in Native health.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy/virology
MH  - Decision Making
MH  - *Education, Medical
MH  - *Health Equity
MH  - *Health Services, Indigenous
MH  - *Health Workforce
MH  - Humans
MH  - *Indians, North American
MH  - *Pandemics
MH  - Personal Autonomy
MH  - *Physicians
MH  - *Pneumonia, Viral/epidemiology/therapy/virology
MH  - SARS-CoV-2
EDAT- 2020/10/27 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/26 08:43
PHST- 2020/10/26 08:43 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - amajethics.2020.856 [pii]
AID - 10.1001/amajethics.2020.856 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Oct 1;22(10):E856-861. doi: 10.1001/amajethics.2020.856.


PMID- 33103633
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 1748-2631 (Electronic)
IS  - 1748-2623 (Linking)
VI  - 15
IP  - sup1
DP  - 2020 Dec
TI  - Welfare technology, ethics and well-being a qualitative study about the
      implementation of welfare technology within areas of social services in a Swedish
      municipality.
PG  - 1835138
LID - 10.1080/17482631.2020.1835138 [doi]
AB  - Purpose: Digitalization and e-health have potential to generate good quality,
      equal health, well-being and to develop and strengthen individuals' resources
      with the goal of increased independence and participation in society. The
      implementation of welfare technology requires knowledge of digitalization, as
      well as an awareness of its meaning in terms of ethical principles and ethical
      analysis. The purpose of this study was to describe ethical analysis concerning
      the implementation of welfare technology, in terms of both strategies and tools, 
      within areas of social services in a Swedish municipality. Method: We followed a 
      working model that focused on increased knowledge and experience in the
      implementation of welfare technology from an ethical perspective. In the data
      collection were observations, a questionnaire with open-ended questions and focus
      group discussions used. Results: The analysis showed that when welfare technology
      was introduced and implemented within the area of social services in a
      municipality, ethical awareness resulting from the conflicts between various
      interests and values had to be addressed. Conclusions: The ethical analysis
      improved implementation of strategies and tools in terms of facts and values, and
      invisible underlying values to the concept of well-being.
FAU - Cuesta, Marta
AU  - Cuesta M
AD  - School of Health and Welfare, Halmstad University , Halmstad, Sweden.
FAU - German Millberg, Lena
AU  - German Millberg L
AD  - School of Health and Welfare, Halmstad University , Halmstad, Sweden.
FAU - Karlsson, Staffan
AU  - Karlsson S
AUID- ORCID: https://orcid.org/0000-0002-6624-9963
AD  - School of Health and Welfare, Halmstad University , Halmstad, Sweden.
FAU - Arvidsson, Susann
AU  - Arvidsson S
AUID- ORCID: https://orcid.org/0000-0001-5647-086X
AD  - School of Health and Welfare, Halmstad University , Halmstad, Sweden.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Qual Stud Health Well-being
JT  - International journal of qualitative studies on health and well-being
JID - 101256506
SB  - IM
MH  - Adult
MH  - Awareness
MH  - Cities
MH  - Digital Technology/ethics
MH  - Disabled Persons
MH  - *Ethical Analysis
MH  - Female
MH  - Focus Groups
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - *Quality of Life
MH  - Social Values
MH  - Social Welfare/*ethics
MH  - Social Work/*ethics
MH  - Stakeholder Participation
MH  - Surveys and Questionnaires
MH  - Sweden
MH  - Technology/*ethics
MH  - Telemedicine/ethics
MH  - Urban Population
PMC - PMC7594863
OTO - NOTNLM
OT  - Ethical analysis
OT  - health spaces
OT  - welfare technology
OT  - well-being
OT  - working model
EDAT- 2020/10/27 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/10/26 08:42
PHST- 2020/10/26 08:42 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
AID - 10.1080/17482631.2020.1835138 [doi]
PST - ppublish
SO  - Int J Qual Stud Health Well-being. 2020 Dec;15(sup1):1835138. doi:
      10.1080/17482631.2020.1835138.


PMID- 33103142
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2667-677X (Print)
IS  - 2149-276X (Linking)
VI  - 48
IP  - 5
DP  - 2020 Oct
TI  - A Prospective Observational Study to Determine the Predictors of Increased Number
      of Attempts at Labour Epidural Placement.
PG  - 379-384
LID - 10.5152/TJAR.2020.47600 [doi]
AB  - OBJECTIVE: Multiple attempts at labour epidural placement result in patient
      discomfort and high incidence of complications. Identifying the factors that lead
      to more than one attempt would help anaesthesiologists prepare in advance such as
      getting expert help and additional equipment, patient counselling or planning
      alternative management. METHODS: This prospective observational study was
      conducted on 500 patients from July 2017 to June 2018 after obtaining approval
      from the institutional Ethics Review Committee. The study patients consisted of
      full-term parturient women who were admitted in the labour room suite of Aga Khan
      Hospital requesting for labour epidural and consented to participate in the
      study. A predesigned form was used to collect the following data: number of
      attempts at epidural insertion and factors such as patients' demographics,
      cervical dilatation, anatomical grading of spine according to visibility and
      palpation of spinous process and vertebral interspace, experience level of the
      anaesthesiologist, patient satisfaction and pain score during labour. RESULTS:
      The average age of the patients was 28.11+/-4.02 years. The total number of
      epidural attempts varied between one and four; the median number of attempts was 
      1 [IQR=1-2]. Anatomical grade of the spine was the only factor that was
      significantly associated with more than one attempt at epidural insertion
      (p=0.0005). Patient satisfaction was negatively associated with the number of
      attempts (p=0.04), but mean pain difference at different time points during the
      course of labour was not statistically significant between patients with one
      attempt and those with more than one attempt. CONCLUSION: Determining the
      anatomical grade of the spine is the most reliable method for predicting a
      technically difficult neuraxial block that requires more than one attempt at
      epidural insertion.
CI  - (c) Copyright 2020 by Turkish Anaesthesiology and Intensive Care Society.
FAU - Ismail, Samina
AU  - Ismail S
AUID- ORCID: https://orcid.org/0000-0001-6138-1810
AD  - Department of Anaesthesiology, Aga Khan University, Karachi, Pakistan.
FAU - Raza, Syed Amir
AU  - Raza SA
AUID- ORCID: https://orcid.org/0000-0003-3970-8236
AD  - Department of Anaesthesiology, Aga Khan University, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200217
PL  - Turkey
TA  - Turk J Anaesthesiol Reanim
JT  - Turkish journal of anaesthesiology and reanimation
JID - 101680817
PMC - PMC7556642
OTO - NOTNLM
OT  - Difficulty
OT  - grade of spine
OT  - labour epidural
OT  - number of attempts
OT  - predictors
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:29
PHST- 2019/07/25 00:00 [received]
PHST- 2019/09/25 00:00 [accepted]
PHST- 2020/10/26 05:29 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.5152/TJAR.2020.47600 [doi]
AID - tjar-48-5-379 [pii]
PST - ppublish
SO  - Turk J Anaesthesiol Reanim. 2020 Oct;48(5):379-384. doi: 10.5152/TJAR.2020.47600.
      Epub 2020 Feb 17.


PMID- 33102854
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 10
DP  - 2020 Oct
TI  - Survey of reasons why women utilize honey therapeutically, and reasons for not
      utilizing honey.
PG  - e05231
LID - 10.1016/j.heliyon.2020.e05231 [doi]
AB  - There are various situations when honey can be reasonably used in cases of
      disease, for example radiotherapy and/or chemotherapy-induced oral mucositis. We 
      investigated the underlying reasons why women eat honey and why some would refuse
      to use honey even if it was reasonable to do so. In order to answer these
      questions, we asked 201 women to answer various questions related to the
      consumption of honey. We found that the preferred routes of administration change
      when honey is used as a remedy. Most importantly, we identified "organic
      beekeeping" and a second factor related to the perception of honey regarding
      price, handling and health by principal component analysis as relevant regarding 
      the refusal of the use of honey even when scientifically reasonable. If honey is 
      to become an acceptable treatment option, it seems important to address all
      aspects of ethical beekeeping in the production of medicinal bee products.
CI  - (c) 2020 Published by Elsevier Ltd.
FAU - Munstedt, Karsten
AU  - Munstedt K
AD  - Ortenau Klinikum Offenburg-Kehl, Ebertplatz 12, 77654 Offenburg, Germany.
FAU - Mannle, Heidrun
AU  - Mannle H
AD  - Ortenau Klinikum Offenburg-Kehl, Ebertplatz 12, 77654 Offenburg, Germany.
FAU - Riepen, Thomas
AU  - Riepen T
AD  - Practice for Gynecology, Konrad-Adenauer-Strasse 2, 35781 Weilburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7569232
OTO - NOTNLM
OT  - Food science
OT  - Honey
OT  - Medical use
OT  - Preferences
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:28
PHST- 2020/04/25 00:00 [received]
PHST- 2020/06/07 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/10/26 05:28 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e05231 [doi]
AID - S2405-8440(20)32074-0 [pii]
PST - epublish
SO  - Heliyon. 2020 Oct 15;6(10):e05231. doi: 10.1016/j.heliyon.2020.e05231.
      eCollection 2020 Oct.


PMID- 33102656
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2352-3409 (Electronic)
IS  - 2352-3409 (Linking)
VI  - 33
DP  - 2020 Dec
TI  - Response time and eye tracking datasets for activities demanding varying
      cognitive load.
PG  - 106389
LID - 10.1016/j.dib.2020.106389 [doi]
AB  - The dataset contains the following three measures that are widely used to
      determine cognitive load in humans: Detection Response Task - response time,
      pupil diameter, and eye gaze. These measures were recorded from 28 participants
      while they underwent tasks that are designed to permeate three different
      cognitive difficulty levels. The dataset will be useful to those researchers who 
      seek to employ low cost, non-invasive sensors to detect cognitive load in humans 
      and to develop algorithms for human-system automation. One such application is
      found in Advanced Driver Assistance Systems where eye-trackers are employed to
      monitor the alertness of the drivers. The dataset would also be helpful to
      researchers who are interested in employing machine learning algorithms to
      develop predictive models of humans for applications in human-machine system
      automation. The data is collected by the authors at the Department of Electrical 
      & Computer Engineering in collaboration with the Faculty of Human Kinetics at the
      University of Windsor under the guidance of their Research Ethics Board.
CI  - (c) 2020 The Authors.
FAU - Pillai, Prarthana
AU  - Pillai P
AD  - Department of Electrical and Computer Engineering, University of Windsor, 401
      Sunset Avenue, Windsor, ON, N9G 3P4, Canada.
FAU - Ayare, Prathamesh
AU  - Ayare P
AD  - Department of Electrical and Computer Engineering, University of Windsor, 401
      Sunset Avenue, Windsor, ON, N9G 3P4, Canada.
FAU - Balasingam, Balakumar
AU  - Balasingam B
AD  - Department of Electrical and Computer Engineering, University of Windsor, 401
      Sunset Avenue, Windsor, ON, N9G 3P4, Canada.
FAU - Milne, Kevin
AU  - Milne K
AD  - Faculty of Human Kinetics, University of Windsor, 401 Sunset Avenue, Windsor, ON 
      N9G 3P4, Canada.
FAU - Biondi, Francesco
AU  - Biondi F
AD  - Faculty of Human Kinetics, University of Windsor, 401 Sunset Avenue, Windsor, ON 
      N9G 3P4, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - Netherlands
TA  - Data Brief
JT  - Data in brief
JID - 101654995
PMC - PMC7578673
OTO - NOTNLM
OT  - Cognitive load detection
OT  - Detection
OT  - Detection response task (DRT)
OT  - Eye-tracking
OT  - Human-computer interface
OT  - Machine learning
OT  - Psychological signals
OT  - Pupil dilation
OT  - Signal processing
COIS- The authors declare that they have no known competing financial interests or
      personal relationships which have, or could be perceived to have, influenced the 
      work reported in this article.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:27
PHST- 2020/07/23 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/26 05:27 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1016/j.dib.2020.106389 [doi]
AID - S2352-3409(20)31268-3 [pii]
PST - epublish
SO  - Data Brief. 2020 Oct 8;33:106389. doi: 10.1016/j.dib.2020.106389. eCollection
      2020 Dec.


PMID- 33102385
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2319-9644 (Print)
IS  - 2279-042X (Linking)
VI  - 9
IP  - 2
DP  - 2020 Apr-Jun
TI  - Intravenous Drug Incompatibilities in the Intensive Care Unit of a Tertiary Care 
      Hospital in India: Are they Preventable?
PG  - 106-111
LID - 10.4103/jrpp.JRPP_20_11 [doi]
AB  - OBJECTIVE: The main aim of the study was to identify the physical and chemical
      incompatibilities among the drugs administered intravenously to patients admitted
      to the Intensive Care Unit (ICU) of a 1000 bedded hospital. The study also
      envisaged establishing pharmaceutical guidelines for the administration of
      incompatible medications. METHODS: This prospective cross-sectional study was
      conducted from January to July 2018 in the ICU after getting approval from the
      Hospital Ethics Committee. A total of 104 medication charts were collected, and
      their data were analyzed. Compatibility of the selected drug with a second drug, 
      when given together, was then analyzed using the Micromedex health-care series,
      Trissel's handbook of injectable drugs, and Manufacturer's product information.
      The pharmaceutical intervention was performed by preparing. The drug
      compatibility chart of selected drugs and the same was reported to the study
      department. FINDINGS: Of 104 medication charts reviewed, 66 charts had
      incompatibility, accounting for 90 incompatibilities. Incompatibility between two
      intravenous (IV) bolus drugs constituted 68.8% with pantoprazole and ondansetron 
      (85.4%) being the most frequent combination. Incompatibility between
      infusion-bolus was found to be 26.6%. Meropenem (infusion) and pantoprazole
      (bolus) constituted 16.6%. Incompatibility between two infusions in the same IV
      line was found to be 4.4%. A drug compatibility chart containing 19 selected
      drugs was prepared and submitted to the study department for their perusal.
      CONCLUSION: The current study showed that a significant number of drug
      incompatibilities occur in hospitalized critically ill patients in our tertiary
      care hospital. These incompatibilities could generally be prevented by adhering
      to proper medication administration techniques like flushing the line using
      compatible fluid or through a multi-lumen catheter or multiple IV access.
CI  - Copyright: (c) 2020 Journal of Research in Pharmacy Practice.
FAU - Sriram, Shanmugam
AU  - Sriram S
AD  - Department of Pharmacy Practice, Sri Ramakrishna Institute of Paramedical
      Sciences, Coimbatore, Tamil Nadu, India.
FAU - Aishwarya, S
AU  - Aishwarya S
AD  - Department of Pharmacy Practice, PharmD Intern, Sri Ramakrishna Institute of
      Paramedical Sciences, Coimbatore, Tamil Nadu, India.
FAU - Moithu, Akhila
AU  - Moithu A
AD  - Department of Pharmacy Practice, PharmD Intern, Sri Ramakrishna Institute of
      Paramedical Sciences, Coimbatore, Tamil Nadu, India.
FAU - Sebastian, Akshaya
AU  - Sebastian A
AD  - Department of Pharmacy Practice, PharmD Intern, Sri Ramakrishna Institute of
      Paramedical Sciences, Coimbatore, Tamil Nadu, India.
FAU - Kumar, Ajith
AU  - Kumar A
AD  - Department of Pharmacy Practice, PharmD Intern, Sri Ramakrishna Institute of
      Paramedical Sciences, Coimbatore, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - India
TA  - J Res Pharm Pract
JT  - Journal of research in pharmacy practice
JID - 101614023
PMC - PMC7547742
OTO - NOTNLM
OT  - Critically ill patients
OT  - drug-related problems
OT  - intensive care unit
OT  - intravenous drug incompatibilities
COIS- There are no conflicts of interest.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:26
PHST- 2019/11/06 00:00 [received]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/10/26 05:26 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.4103/jrpp.JRPP_20_11 [doi]
AID - JRPP-9-106 [pii]
PST - epublish
SO  - J Res Pharm Pract. 2020 Jun 26;9(2):106-111. doi: 10.4103/jrpp.JRPP_20_11.
      eCollection 2020 Apr-Jun.


PMID- 33102314
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul
TI  - Post cholecystectomy common bile duct dilatation and associated symptomatology.
PG  - 3464-3469
LID - 10.4103/jfmpc.jfmpc_694_20 [doi]
AB  - BACKGROUND: Relationship between postcholecystectomy bile duct dilatation and
      associated symptomatology is a potential dilemma for treating surgeon for which
      various studies with variable results have been documented. MATERIALS AND
      METHODS: This study is a 1 year prospective study conducted at IGMC, Shimla after
      taking proper consent and ethical approval from institutional ethical committee. 
      Total 50 cases of symptomatic cholelithiasis belonging to either sex admitted in 
      surgical wards of IGMC, Shimla for elective surgery were selected for present
      study. Cholecystectomy was done in all cases after doing all investigations.
      RESULTS: Postoperatively within 48 h symptoms were observed in 29 patients. Out
      of these, flatulence was present in 1, nausea and vomiting in 7 and 8,
      respectively. Combined flatulence vomiting in 5 and flatulence-reflux-nausea in 1
      patient. After 1 month of interval, all patients were symptom free. CONCLUSION:
      Symptoms which were present in the postoperative patients were unrelated to
      dilatation of common bile duct. Either these symptoms were the persistent
      symptoms present before the operation or related to anaesthetic drugs.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Sood, Rajan
AU  - Sood R
AD  - Assistant Professor, Department of General Surgery, Dr. Yashwant Singh Parmar
      Govt. Medical College & Hospital, Nahan, Himachal Pradesh, India.
FAU - Sharma, Dinesh
AU  - Sharma D
AD  - Assistant Professor, Department of Radiodiagnosis & Imaging, Dr. Yashwant Singh
      Parmar Govt. Medical College & Hospital, Nahan, Himachal Pradesh, India.
FAU - Sharma, Girish
AU  - Sharma G
AD  - Professor & Head, Department of Anaesthesiology, Dr. Yashwant Singh Parmar Govt. 
      Medical College & Hospital, Nahan, Himachal Pradesh, India.
FAU - Kaushik, Shailendra
AU  - Kaushik S
AD  - Senior Resident, Department of General Surgery, Dr. Yashwant Singh Parmar Govt.
      Medical College & Hospital, Nahan, Himachal Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7567239
OTO - NOTNLM
OT  - Bile duct
OT  - cholecystectomy
OT  - post-operative
OT  - symptoms
COIS- There are no conflicts of interest.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:26
PHST- 2020/04/24 00:00 [received]
PHST- 2020/04/26 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/10/26 05:26 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_694_20 [doi]
AID - JFMPC-9-3464 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Jul 30;9(7):3464-3469. doi:
      10.4103/jfmpc.jfmpc_694_20. eCollection 2020 Jul.


PMID- 33101792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 18
TI  - Bioethical Implications in Vaccine Development, a COVID-19 Challenge.
PG  - e10530
LID - 10.7759/cureus.10530 [doi]
AB  - Introduction In the last 18 years, on three occasions, coronavirus has
      represented a challenge for global health. Between 2002 and 2003 with Severe
      Acute Respiratory Syndrome, in 2012 with Middle East Respiratory Syndrome, and
      since the end of 2019 with severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) pandemic, which has 
      challenged health care models and the way of doing research, placing bioethics at
      the center of discussion. Methods On August 19, 2020, a webinar organized by the 
      Research Institute of Medical Science (IICIMED, for its acronym in Spanish),
      entitled 'Bioethical Implications in Vaccine Development, a COVID-19 Challenge'
      took place. Three experts spoke about the importance of bioethics in the race to 
      develop a COVID-19 vaccine, the risk involved in shortening the terms of the
      clinical trial phases, and how the associated risks can be minimized, in order to
      expedite research results. Conclusion With the novel SARS-CoV-2 coronavirus,
      critical challenges have been posed not only for public health but for research
      and the scientific community. A safe and effective vaccine is urgently needed to 
      prevent COVID-19 transmission, complications, and deaths; the adherence to
      ethical principles required by clinical research is mandatory and closer
      supervision is also essential.
CI  - Copyright (c) 2020, Ospina Henao et al.
FAU - Ospina Henao, Sebastian
AU  - Ospina Henao S
AD  - Instituto de Investigacion en Ciencias Medicas, Universidad de Ciencias Medicas, 
      San Jose, CRI.
FAU - Marin Mora, Alejandro
AU  - Marin Mora A
AD  - Centro de Estudios en Bioderecho, Etica y Salud, Universidad de Murcia, Murcia,
      ESP.
FAU - Chan Solano, Fanny
AU  - Chan Solano F
AD  - Ethics Committee, Universidad de Ciencias Medicas, San Jose, CRI.
FAU - Avila-Aguero, Maria L
AU  - Avila-Aguero ML
AD  - Pediatric Infectious Diseases, Hospital Nacional De Ninos Dr. Carlos Saenz
      Herrera, San Jose, CRI.
AD  - Pediatric Infectious Diseases, Center for Infectious Disease Modeling and
      Analysis, Yale School of Public Health, New Haven, USA.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7575135
OTO - NOTNLM
OT  - bioethics
OT  - clinical trial
OT  - covid-19
OT  - social value
OT  - vaccine
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:24
PHST- 2020/10/26 05:24 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.7759/cureus.10530 [doi]
PST - epublish
SO  - Cureus. 2020 Sep 18;12(9):e10530. doi: 10.7759/cureus.10530.


PMID- 33101788
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 15
TI  - Correlation Between Body Mass Index and Blood Pressure Levels Among Hypertensive 
      Patients: A Gender-Based Comparison.
PG  - e10974
LID - 10.7759/cureus.10974 [doi]
AB  - Objective Blood pressure (BP) has been found to rise among populations due to the
      high body mass index (BMI). Overweight and persons who have high BP are prone to 
      develop heart diseases. The objective of this study was to evaluate the
      correlation between BMI and BP among hypertensive patients in both males and
      females aged 18 years and above. Methodology A cross-sectional study was carried 
      out among patients with a self-reported history of hypertension and
      anti-hypertensive medication. After taking ethical approval, a total of 337
      patients aged 18 or above were selected by using convenience sampling. The
      duration of the study was six months. A detailed history was taken from each
      patient about hypertension associated symptoms with the help of a self-designed
      questionnaire. The BMI of the patients was assessed. Statistical Package for
      Social Sciences (SPSS) Version 20.0 (IBM Corp., Armonk, NY, USA) was used to
      analyze the collected data. Spearman correlation was used, and p-value <0.05 was 
      considered significant. Results In a total of 337 patients, the mean age of the
      patients was 45.87+/-13.38 years. In which 176 (52.2%) were males and 161 (47.8%)
      were females. Their mean BMI level was 26.83+/-5.83 kg/m(2), and the mean
      systolic blood pressure level was 141.78+/-13.00 mm Hg whereas the diastolic
      blood pressure was 85.21+/-10.03 mm Hg. The results also showed that among males 
      the BMI had a significant negative correlation with both systolic blood pressure 
      level (rho = -0.212, p = 0.011) and diastolic blood pressure level (rho = -0.208,
      p = 0.013), while in females the correlation was insignificant. Conclusion Our
      study results concluded that the BMI of the patients had a significant weak
      negative correlation with both systolic blood pressure level and diastolic blood 
      pressure level in males; however, no significant correlation was found in
      females.
CI  - Copyright (c) 2020, Khalid et al.
FAU - Khalid, Faran
AU  - Khalid F
AD  - Internal Medicine, Dow University Hospital, Dow University of Health Sciences,
      Karachi, PAK.
FAU - Siddique, Abubakkar
AU  - Siddique A
AD  - Physiology, Islamic International Medical College, Rawalpindi, PAK.
FAU - Siddiqui, Jamil Ahmed
AU  - Siddiqui JA
AD  - Biochemistry, Fazaia Ruth Pfau Medical College, Karachi, PAK.
AD  - Biochemistry, Al-Tibri Medical College, Karachi, PAK.
FAU - Panhwar, Ghazala
AU  - Panhwar G
AD  - Biochemistry, Al-Tibri Medical College and Hospital, Karachi, PAK.
FAU - Singh, Simran
AU  - Singh S
AD  - Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
FAU - Anwar, Adnan
AU  - Anwar A
AD  - Physiology, Al-Tibri Medical College, Karachi, PAK.
AD  - Stereotactic Radiosurgery/Radiation Oncology, Al-Tibri Medical College, Karachi, 
      PAK.
FAU - Hashmi, Atif A
AU  - Hashmi AA
AD  - Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7575319
OTO - NOTNLM
OT  - blood pressure
OT  - body mass index
OT  - diastolic blood pressure
OT  - systolic
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:24
PHST- 2020/10/26 05:24 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.7759/cureus.10974 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 15;12(10):e10974. doi: 10.7759/cureus.10974.


PMID- 33101716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2071-9736 (Electronic)
IS  - 1025-9848 (Linking)
VI  - 25
DP  - 2020
TI  - Psychologists' experience of a malpractice complaint: Their relationship with and
      processes at the regulator.
PG  - 1384
LID - 10.4102/hsag.v25i0.1384 [doi]
AB  - BACKGROUND: Professional malpractice complaints in the South African health arena
      have increased over the last decade. There is a lack of research on how South
      African health practitioners experience professional malpractice complaints and
      complaint processes. AIM: This article reports on one aspect of the findings in a
      more extensive study relating to the complaint experience of psychology
      practitioners, namely how a group of psychology practitioners experienced their
      relationship with and the processes at the regulator during a malpractice
      complaint. The regulator refers to the professional registration body which
      manages complaints against practitioners. SETTING: The study included 10
      registered South African psychologists who experienced a malpractice complaint.
      METHODS: After sampling, semi-structured interviews were conducted,
      audio-recorded and transcribed. The data were managed using interpretative
      phenomenological analysis (IPA) to elicit the personal, subjective experience of 
      the individual participants. FINDINGS: Two superordinate themes and related
      subthemes emerged from the analysis. First, relating to the experience of the
      complaint procedures and processes, participants experienced an extended
      timeframe for complaint management, a lack of communication during complaint
      management, legal challenges during some disciplinary proceedings and some
      complaints as unjustified and frivolous. Second, participants were unsure of
      their relationship with the regulator. Their responses denoted instances of
      vulnerability and inequality during proceedings. CONCLUSIONS: The findings call
      for closer collaboration between the registration body and practitioners during
      complaints management, to eliminate vexatious complaints, to streamline processes
      and to encourage guidance of and support for the professional.
CI  - (c) 2020. The Authors.
FAU - Kirkcaldy, Hanle
AU  - Kirkcaldy H
AUID- ORCID: https://orcid.org/0000-0001-9797-2655
AD  - School of Psychosocial and Behavioural Sciences, North-West University,
      Potchefstroom, South Africa.
FAU - van Rensburg, Esme
AU  - van Rensburg E
AUID- ORCID: https://orcid.org/0000-0002-5961-4416
AD  - School of Psychosocial and Behavioural Sciences, North-West University,
      Potchefstroom, South Africa.
FAU - du Plooy, Kobus
AU  - du Plooy K
AUID- ORCID: https://orcid.org/0000-0003-2573-5866
AD  - School of Psychosocial and Behavioural Sciences, North-West University,
      Potchefstroom, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - South Africa
TA  - Health SA
JT  - Health SA = SA Gesondheid
JID - 101213385
PMC - PMC7564922
OTO - NOTNLM
OT  - disciplinary action
OT  - ethics
OT  - malpractice complaints
OT  - psychologists
OT  - registration body
OT  - regulator
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:24
PHST- 2019/12/01 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/10/26 05:24 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.4102/hsag.v25i0.1384 [doi]
AID - HSAG-25-1384 [pii]
PST - epublish
SO  - Health SA. 2020 Oct 12;25:1384. doi: 10.4102/hsag.v25i0.1384. eCollection 2020.


PMID- 33101714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2071-9736 (Electronic)
IS  - 1025-9848 (Linking)
VI  - 25
DP  - 2020
TI  - A model to facilitate self-management of human immunodeficiency virus in students
      within a university setting and promoting their mental health.
PG  - 1069
LID - 10.4102/hsag.v25i0.1069 [doi]
AB  - BACKGROUND: The introduction of antiretroviral treatment (ART) has resulted in
      people with HIV living longer. Antiretroviral treatment demands a lifelong
      commitment from patients not only in terms of adherence to the medication but
      also in relation to lifestyle changes in general. This poses a challenge to a
      student living with HIV (SLHIV) who only spends a few years at university before 
      entering the workplace and relocating. It also means that the care, support and
      treatment received at the university will no longer be available to them as these
      services are only offered to enrolled students. It is imperative for
      practitioners at universities to help SLHIV effectively manage their illness.
      AIM: The aim of the article is to illustrate the process followed to develop a
      model that could serve as a frame of reference to facilitate the management of
      HIV as an integral part of the mental health of SLHIV within a university.
      SETTING: The model is designed for professional practitioners in university
      settings who support students living with HIV in managing their illness. METHODS:
      A theory-generative, qualitative, exploratory, descriptive and contextual study
      design was utilised. The central concept was derived from the experiences of
      practitioners and SLHIV by conducting individual interviews using appreciative
      inquiry. The common themes and categories identified in the interviews served as 
      a basis for the identification of the central concept for the study. The process 
      included the identification, definition and classification of the central concept
      and essential attributes. The conceptual framework was then described. Measures
      to ensure trustworthiness were also adhered to in the study and approval for the 
      study was granted (Ethical clearance #2014-071). RESULTS: The central concept was
      identified as the 'facilitation of self-management'. It was defined and
      classified, and these definitions and classifications were used as the basis for 
      the model. Thereafter, the model was described. CONCLUSION: The model can be used
      as a frame of reference to assist SLHIV in effectively managing their illness.
CI  - (c) 2020. The Authors.
FAU - Diedricks, Teolene G
AU  - Diedricks TG
AUID- ORCID: https://orcid.org/0000-0002-8747-6129
AD  - Department of Educational Psychology, University of Johannesburg, Johannesburg,
      South Africa.
FAU - Myburgh, Chris P H
AU  - Myburgh CPH
AUID- ORCID: https://orcid.org/0000-0003-4182-4244
AD  - Department of Educational Psychology, University of Johannesburg, Johannesburg,
      South Africa.
FAU - Poggenpoel, Marie
AU  - Poggenpoel M
AUID- ORCID: https://orcid.org/0000-0001-7515-8695
AD  - Department of Nursing Sciences, University of Johannesburg, Johannesburg, South
      Africa.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - South Africa
TA  - Health SA
JT  - Health SA = SA Gesondheid
JID - 101213385
PMC - PMC7564683
OTO - NOTNLM
OT  - HIV
OT  - mental health
OT  - self-management
OT  - students
OT  - university
COIS- The authors declare that they have no financial or personal relationships, which 
      may have inappropriately influenced them in writing this article.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:24
PHST- 2018/01/18 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/10/26 05:24 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.4102/hsag.v25i0.1069 [doi]
AID - HSAG-25-1069 [pii]
PST - epublish
SO  - Health SA. 2020 Sep 25;25:1069. doi: 10.4102/hsag.v25i0.1069. eCollection 2020.


PMID- 33101602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220210
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Dec
TI  - ABA Finding Its Heart During a Pandemic: An Exploration in Social Validity.
PG  - 757-766
LID - 10.1007/s40617-020-00517-9 [doi]
AB  - The COVID-19 pandemic has presented practitioners of applied behavior analysis
      (ABA) with new and uncharted challenges. Upholding ethical responsibilities while
      navigating an international public health crisis has opened areas of uncertainty 
      that have no precedent. Although there is general guidance on how to respond
      ethically from the Behavior Analyst Certification Board (BACB) in their
      publication specific to the COVID-19 crisis (BACB, 2020, March 29, Ethics
      Guidance for ABA Providers During COVID-19 Pandemic, retrieved from
      https://www.bacb.com/ethics-guidance-for-aba-providers-during-covid-19-pandemic-2
      /), there remains a huge responsibility on the individual practitioner to make
      potentially life-changing decisions. In that regard, practitioners are urged to
      ensure that they rely on socially significant and valid decision-making
      processes. The goal of this article is to provide an exercise in accounting for
      stakeholder feedback and connecting with patients and families regarding their
      input on the acceptability of treatment during the COVID-19 pandemic. The
      exercise is in the form of a structured parent interview to help practitioners
      account for the setting variables and social validity of treatment during a
      crisis. It is our ethical responsibility to remember this critical dimension of
      our science and practice.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - Nicolson, Amanda C
AU  - Nicolson AC
AUID- ORCID: 0000-0002-1695-4306
AD  - Center for Applied Behavior Analysis, Malibu, CA USA.
AD  - Fresno, CA USA.
FAU - Lazo-Pearson, Junelyn F
AU  - Lazo-Pearson JF
AD  - Advanced Behavioral Health, Huntington Beach, CA USA.
FAU - Shandy, Jackie
AU  - Shandy J
AD  - B.E.S.T. Consulting, Inc., Sacramento, CA USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201016
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7567003
OTO - NOTNLM
OT  - Autism
OT  - COVID-19
OT  - Clinical decision making
OT  - Consumer feedback
OT  - Social significance
OT  - Social validity
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:23
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
PHST- 2020/10/26 05:23 [entrez]
AID - 10.1007/s40617-020-00517-9 [doi]
AID - 517 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Oct 16;13(4):757-766. doi: 10.1007/s40617-020-00517-9.
      eCollection 2020 Dec.


PMID- 33101500
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220211
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - The Infectious Diseases Act and Resource Allocation during the COVID-19 Pandemic 
      in Bangladesh.
PG  - 491-502
LID - 10.1007/s41649-020-00149-9 [doi]
AB  - The Infectious Diseases (Prevention, Control and Eradication) Act entered into
      force officially on 14 November 2018 in Bangladesh. The Act is designed to raise 
      awareness of, prevent, control, and eradicate infectious or communicable diseases
      to address public health emergencies and reduce health risks. A novel coronavirus
      disease (COVID-19) was first identified in Bangladesh on 8 March 2020, and the
      Ministry of Health and Family Welfare issued a gazette on 23 March, listing
      COVID-19 as an infectious disease and addressing COVID-19 as a public health
      emergency. The gazette empowers the government to monitor the spread of
      infection. Despite there being an infrastructure of research ethics committees in
      almost all hospitals in Bangladesh, a lack of such committees in the clinical
      setting often forces healthcare professionals to allocate scarce healthcare
      resources to the task. These personnel are often either influenced by
      materialistic matters or guided by the emergency policies, without reaching a
      consensus on how to allocate scarce resources in times of need, especially in the
      time of the COVID-19 pandemic. Ethical dilemmas often arise when a number of
      patients with COVID-19, especially in poor and middle-class areas, are denied
      care while elites are prioritized to receive such scarce resources. Resource
      allocation in healthcare during the COVID-19 pandemic in Bangladesh appears to be
      unethical and in direct conflict with the biomedical principles of
      non-maleficence and procedural justice. The findings of this study suggest that
      the Act needs substantive changes in the stipulation of policy directing
      hospitals in the provision of resource allocation framework. Furthermore,
      parliament should produce guidance outlining how to successfully implement the
      law with the aim of protecting public health in times of emergency, especially
      the COVID-19 pandemic.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Siraj, Md Sanwar
AU  - Siraj MS
AUID- ORCID: https://orcid.org/0000-0001-6303-4660
AD  - Department of Government and Politics, Jahangirnagar University, Savar, Dhaka,
      Bangladesh.grid.411808.40000 0001 0664 5967
FAU - Dewey, Rebecca Susan
AU  - Dewey RS
AUID- ORCID: https://orcid.org/0000-0002-6888-3298
AD  - Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham,
      UK.grid.4563.40000 0004 1936 8868
FAU - Hassan, A S M Firoz Ul
AU  - Hassan ASMFU
AD  - Department of Government and Politics, Jahangirnagar University, Savar, Dhaka,
      Bangladesh.grid.411808.40000 0001 0664 5967
LA  - eng
PT  - Journal Article
DEP - 20201017
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7568013
OTO - NOTNLM
OT  - Bangladesh
OT  - Coronavirus
OT  - Infectious diseases
OT  - Pandemic
OT  - Resource allocation
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:23
PHST- 2020/07/09 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
PHST- 2020/10/26 05:23 [entrez]
AID - 10.1007/s41649-020-00149-9 [doi]
AID - 149 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Oct 17;12(4):491-502. doi: 10.1007/s41649-020-00149-9.
      eCollection 2020 Dec.


PMID- 33101315
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Airway Natural Killer Cells and Bacteria in Health and Disease.
PG  - 585048
LID - 10.3389/fimmu.2020.585048 [doi]
AB  - Natural killer (NK) cells are innate lymphoid cells at the interface between
      innate and adaptive immunity and mostly studied for their important roles in
      viral infections and malignant tumors. They can kill diseased cells and produce
      cytokines and chemokines, thereby shaping the adaptive immune response. Nowadays,
      NK cells are considered as a strong weapon for cancer immunotherapy and can for
      example be transduced to express tumor-specific chimeric antigen receptors or
      harnessed with therapeutic antibodies such as the so-called NK engagers. Whereas 
      a large body of literature exists about the antiviral and antitumoral properties 
      of NK cells, their potential role in bacterial infections is not that well
      delineated. Furthermore, NK cells are much more heterogeneous than previously
      thought and have tissue-characteristic features and phenotypes. This review gives
      an overview of airway NK cells and their position within the immunological army
      dressed against bacterial infections in the upper and predominantly the lower
      respiratory tracts. Whereas it appears that in several infections, NK cells play 
      a non-redundant and protective role, they can likewise act as rather detrimental.
      The use of mouse models and the difficulty of access to human airway tissues for 
      ethical reasons might partly explain the divergent results. However, new methods 
      are appearing that are likely to reduce the heterogeneity between studies and to 
      give a more coherent picture in this field.
CI  - Copyright (c) 2020 Theresine, Patil and Zimmer.
FAU - Theresine, Maud
AU  - Theresine M
AD  - CG I Group, Department of Infection and Immunity, Luxembourg Institute of Health,
      Esch-sur-Alzette, Luxembourg.
FAU - Patil, Neha D
AU  - Patil ND
AD  - CG I Group, Department of Infection and Immunity, Luxembourg Institute of Health,
      Esch-sur-Alzette, Luxembourg.
FAU - Zimmer, Jacques
AU  - Zimmer J
AD  - CG I Group, Department of Infection and Immunity, Luxembourg Institute of Health,
      Esch-sur-Alzette, Luxembourg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200925
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Animals
MH  - Bacterial Infections/*immunology
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Lung/*immunology
MH  - Respiratory Tract Infections/*immunology
PMC - PMC7546320
OTO - NOTNLM
OT  - *airways
OT  - *bacteria
OT  - *chronic obstructive pulmonary disease
OT  - *infection
OT  - *lungs
OT  - *natural killer cells
OT  - *pathogenesis
EDAT- 2020/10/27 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/10/26 05:22
PHST- 2020/07/19 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/26 05:22 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 10.3389/fimmu.2020.585048 [doi]
PST - epublish
SO  - Front Immunol. 2020 Sep 25;11:585048. doi: 10.3389/fimmu.2020.585048. eCollection
      2020.


PMID- 33100469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0300-1652 (Print)
IS  - 0300-1652 (Linking)
VI  - 61
IP  - 3
DP  - 2020 May-Jun
TI  - Effect of Blood Donor Educational intervention on the knowledge and Attitude
      towards Voluntary Blood Donation among Medical Students at a Nigerian University.
PG  - 163-168
LID - 10.4103/nmj.NMJ_177_19 [doi]
AB  - BACKGROUND: Blood is a veritable tool in many life-saving situations. Despite the
      increased demand for blood, the supply of safe blood has been inadequate. This
      study was aimed to determine the effect of educational intervention on the
      knowledge and attitude of medical students of a Nigerian University to voluntary 
      blood donation. MATERIALS AND METHODS: This was a cross-sectional study involving
      158 undergraduate medical students of Ebonyi State University in South-East
      Nigeria. Participants were recruited by stratified sampling technique. A
      pretested semi-structured participant administered questionnaire was used to
      baseline knowledge and attitude to voluntary blood donation. This was followed by
      educational intervention in the form of a workshop by experts in blood
      transfusion medicine. Then, postintervention assessment was done using the
      initial questionnaire 30 days later. The study was approved by the Research and
      Ethics Committee of Ebonyi State University, Abakaliki. Data obtained were
      analyzed using SPSS 20 software, and P value was set at </=0.05. RESULTS: Of the 
      158 medical students who participated in the study, there were 90 (57%) males and
      68 (43%) females. Baseline proportion of the participants who had good knowledge 
      was high (72.8%), while baseline attitude of the participants was positive to
      most aspects of voluntary blood donation. Post intervention, the level of
      knowledge about voluntary blood donation increased to 99.4%, and similarly
      attitude to voluntary blood donation improved. CONCLUSION: Educational
      intervention was effective in improving the knowledge and attitude towards
      voluntary blood donation among medical students. Continuous enlightenment will
      influence potential blood donors to have better knowledge and positive attitude
      toward voluntary blood donation.
CI  - Copyright: (c) 2020 Nigerian Medical Journal.
FAU - Ugwu, Ngozi Immaculata
AU  - Ugwu NI
AD  - Department of Haematology and Immunology, Faculty of Clinical Medicine, College
      of Health Sciences, Ebonyi State University, Abakaliki, Nigeria.
FAU - Uneke, Chigozie Jesse
AU  - Uneke CJ
AD  - African Institute for Health Policy and Health Systems, Ebonyi State University, 
      Abakaliki, Nigeria.
FAU - Ugwu, Collins Nwachi
AU  - Ugwu CN
AD  - Department of Internal Medicine, Faculty of Clinical Medicine, Ebonyi State
      University, Abakaliki, Nigeria.
FAU - Oti, Wilberforce John Otu
AU  - Oti WJO
AD  - Department of Industrial Chemistry, Faculty of Sciences, Ebonyi State University,
      Abakaliki, Nigeria.
FAU - Agbo, Urudinachi Nnenne
AU  - Agbo UN
AD  - Department of Community Medicine, Alex Ekwueme Federal University Teaching
      Hospital, Abakaliki, Nigeria.
FAU - Akamike, Ifeyinwa Chizoba
AU  - Akamike IC
AD  - Department of Community Medicine, Alex Ekwueme Federal University Teaching
      Hospital, Abakaliki, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200704
PL  - Nigeria
TA  - Niger Med J
JT  - Nigerian medical journal : journal of the Nigeria Medical Association
JID - 0315137
PMC - PMC7547758
OTO - NOTNLM
OT  - Attitude
OT  - blood donation
OT  - educational intervention
OT  - knowledge
OT  - medical students
COIS- There are no conflicts of interest.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:18
PHST- 2019/09/29 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/10/26 05:18 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.4103/nmj.NMJ_177_19 [doi]
AID - NMJ-61-163 [pii]
PST - ppublish
SO  - Niger Med J. 2020 May-Jun;61(3):163-168. doi: 10.4103/nmj.NMJ_177_19. Epub 2020
      Jul 4.


PMID- 33100395
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 4
DP  - 2020 Nov
TI  - Patient Data-Sharing for AI: Ethical Challenges, Catholic Solutions.
PG  - 471-481
LID - 10.1177/0024363920922690 [doi]
AB  - Recent news of Catholic and secular healthcare systems sharing electronic health 
      record (EHR) data with technology companies for the purposes of developing
      artificial intelligence (AI) applications has drawn attention to the ethical and 
      social challenges of such collaborations, including threats to patient privacy
      and confidentiality, undermining of patient consent, and lack of corporate
      transparency. Although the United States Catholic Conference of Bishops' Ethical 
      and Religious Directives for Health Care Services (ERDs) address collaborations
      between US Catholic healthcare providers and other entities, the ERDs do not
      adequately address the novel concerns seen in EHR data-sharing for AI
      development. Neither does the Health Insurance Portability and Accountability Act
      (HIPAA) privacy rule. This article describes ethical and social problems observed
      in recent patient data-sharing collaborations with AI companies and analyzes them
      in light of the guiding principles of the ERDs as well as the 2020 Rome Call to
      AI Ethics (RCAIE) document recently released by the Vatican. While both the ERDs 
      and RCAIE guiding principles can inform future collaborations, we suggest that
      the next revision of the ERDs should consider addressing data-sharing and AI more
      directly. SUMMARY: Electronic health record data-sharing with artificial
      intelligence developers presents unique ethical and social challenges that can be
      addressed with updated United States Catholic Conference of Bishops' Ethical and 
      Religious Directives and guidance from the Vatican's 2020 Rome Call to AI Ethics.
CI  - (c) Catholic Medical Association 2020.
FAU - Baric-Parker, Jean
AU  - Baric-Parker J
AUID- ORCID: https://orcid.org/0000-0001-6744-4982
AD  - St. Bernard's School of Theology and Ministry, Rochester, NY, USA.
FAU - Anderson, Emily E
AU  - Anderson EE
AD  - Neiswanger Institute for Bioethics, Stritch School of Medicine, Loyola University
      Chicago, Maywood, IL, USA.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7551527
OTO - NOTNLM
OT  - Artificial intelligence (AI)
OT  - Catholic health care
OT  - Data-sharing
OT  - Electronic health records (EHR)
OT  - Ethical and Religious Directives (ERDs)
OT  - Ethics
OT  - Patient confidentiality
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:18
PHST- 2020/10/26 05:18 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1177/0024363920922690 [doi]
AID - 10.1177_0024363920922690 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Nov;87(4):471-481. doi: 10.1177/0024363920922690. Epub 2020 May
      15.


PMID- 33100391
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211102
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 4
DP  - 2020 Nov
TI  - Relational Dependence in a Culture of Self-Creation: A Theological Query into the
      Health of the Medical World.
PG  - 438-443
LID - 10.1177/0024363920949785 [doi]
AB  - Half of the medical professionals in the United States are experiencing symptoms 
      of burnout. From the perspective of theological anthropology, this dehumanizing
      aspect of the field is not reducible to ethical failures, for it is rooted in the
      radically new worldview known as self-creation. As an implicit denial of
      Christian understanding of creation, self-creation entails a rejection of
      relationality and dependence-both proper to the Revelation of Jesus Christ. This 
      article proposes that this lost Christian patrimony is intimately connected to
      the increasingly unhealthy dependence we place upon modern medicine. Relying on
      theologian Joseph Ratzinger, we will come to see that a recovery of relational
      dependence is not only necessary for the salvation of man-but the very health of 
      the medical world at large.
CI  - (c) Catholic Medical Association 2020.
FAU - Nepil, John
AU  - Nepil J
AUID- ORCID: https://orcid.org/0000-0003-1890-6073
AD  - St. John Vianney Theological Seminary, Denver, CO, USA.177641
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7551528
OTO - NOTNLM
OT  - Dependence
OT  - Ratzinger
OT  - Relational ontology
OT  - Relationality
OT  - Theological anthropology
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:18
PHST- 2020/10/26 05:18 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1177/0024363920949785 [doi]
AID - 10.1177_0024363920949785 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Nov;87(4):438-443. doi: 10.1177/0024363920949785. Epub 2020 Aug
      31.


PMID- 33100390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 4
DP  - 2020 Nov
TI  - Christian Personalism versus Utilitarianism: An Analysis of Their Approaches to
      Love and Suffering.
PG  - 425-437
LID - 10.1177/0024363920948331 [doi]
AB  - Although Christian ethics and contemporary utilitarian ethics both employ terms
      such as "love" and "compassion" in their efforts to deal with human suffering,
      they are in fact polar opposite ethical views. This fact is not at all easy to
      discern. One key to perceiving the radical opposition between them lies in
      clarifying their respective concepts of love and suffering and the relation
      between the two. In Christian personalism, suffering is always understood as the 
      suffering of individual persons, while in utilitarianism, suffering is primarily 
      understood as a quantifiable entity detached from the individuals who experience 
      it. This detachment of suffering from individuals leads to the depersonalizing
      and commodifying recommendations of utilitarianism. The dignity of persons as
      understood in Christian anthropology serves as the foundation of Christian ethics
      and is the only basis on which ethics can avoid commodifying people. The article 
      begins with an explanation of the utilitarian approach to suffering and its
      concept of love. It then proceeds to express the view of love and suffering that 
      flows from the Christian perspective. The article concludes by exposing the
      inherently self-defeating structure of utilitarian ethics and offers the
      hope-filled, if challenging, approach of Christian personalism. Although
      Christian anthropology and ethics developed within the historical context of
      Christianity, and in fact could only have developed there, the arguments here are
      primarily philosophical elucidations of the differences between the two opposing 
      schools of thought discussed, while here and there including occasional
      theological points. SUMMARY: The article examines the difference between
      Christian ethics and utilitarian ethics, bringing out their stark opposition on
      the topics of love, suffering and the human person.
CI  - (c) Catholic Medical Association 2020.
FAU - Colosi, Peter J
AU  - Colosi PJ
AUID- ORCID: https://orcid.org/0000-0003-1393-1034
AD  - Salve Regina University, Newport, RI, USA.6008
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7551526
OTO - NOTNLM
OT  - Christian personalism
OT  - Dignity
OT  - Ethics
OT  - Love
OT  - Suffering
OT  - Utilitarian
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:18
PHST- 2020/10/26 05:18 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1177/0024363920948331 [doi]
AID - 10.1177_0024363920948331 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Nov;87(4):425-437. doi: 10.1177/0024363920948331. Epub 2020 Aug
      24.


PMID- 33100386
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211102
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 4
DP  - 2020 Nov
TI  - The Human Person, the Physician, and the Physician's Ethics.
PG  - 381-386
LID - 10.1177/0024363920942459 [doi]
FAU - Pellegrino, Edmund
AU  - Pellegrino E
LA  - eng
PT  - Journal Article
DEP - 20201009
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7551537
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:18
PHST- 2020/10/26 05:18 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1177/0024363920942459 [doi]
AID - 10.1177_0024363920942459 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Nov;87(4):381-386. doi: 10.1177/0024363920942459. Epub 2020 Oct
      9.


PMID- 33100385
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 4
DP  - 2020 Nov
TI  - Fertility Technology Research and the Use of Human Beings as Property.
PG  - 376-380
LID - 10.1177/0024363920947263 [doi]
AB  - In January 2020, an article in the Journal of Human Reproduction exploring
      whether human embryos could be obtained via uterine lavage and to compare their
      quality to embryos created via in vitro fertilization. Any embryo that was not
      removed via lavage was either prevented from implanting by giving the women
      injections of gonadotropin releasing hormone antagonists or aborted with either
      methotrexate or uterine curettage. This research was done using women in Mexico, 
      who were paid the equivalent of over two months' wages and who signed away their 
      rights to their embryos, including agreeing to have an abortion if implantation
      did occur. Not only is this another instance of human beings being treated as
      property but is against the dignity of these women by turning them into, as one
      ethicist says, "human petri dishes." SUMMARY: Researchers continue to use people 
      as objects to obtain their goals. In this case, it was poor women in Mexico and
      their embryos. The Editors of Journal of Human Reproduction enabled this by
      publishing the report.
CI  - (c) Catholic Medical Association 2020.
FAU - Jones-Nosacek, Cynthia
AU  - Jones-Nosacek C
AUID- ORCID: https://orcid.org/0000-0001-5129-8626
AD  - The Ohio State University, Columbus, OH, USA.2647
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7551536
OTO - NOTNLM
OT  - Abortion
OT  - Applied ethics
OT  - Beneficence
OT  - Bioethics
OT  - Dignity of the human person
OT  - Distributive justice
OT  - Ethics
OT  - Ethics of reproduction
OT  - Human dignity
OT  - Infertility therapies
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
CRDT- 2020/10/26 05:18
PHST- 2020/10/26 05:18 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
AID - 10.1177/0024363920947263 [doi]
AID - 10.1177_0024363920947263 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Nov;87(4):376-380. doi: 10.1177/0024363920947263. Epub 2020 Aug
      13.


PMID- 33099712
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - Disagreement, Unenforceability, and Harm Reduction.
PG  - 314-323
LID - 10.1007/s10728-020-00409-7 [doi]
AB  - Talk of harm reduction has expanded horizontally, to apply to an ever-widening
      range of policy domains, and vertically, becoming part of official legal and
      political discourse. This expansion calls for philosophical theorization. What is
      the best way in which to characterize harm reduction? Does it represent a
      distinctive ethical position? How is it best morally justified, and what are its 
      moral limits? I distinguish two varieties of harm reduction. One of them,
      technocratic harm reduction, is premised on the fact of non-enforceability of
      prohibitionist policies. The second, deliberative harm reduction, is premised on 
      the fact of reasonable disagreement, grounded in the fact that reasonable persons
      disagree about a range of controversial behaviours. I argue that deliberative
      harm reduction better accounts for some of harm reduction's most attractive
      features, and provides a plausible way of accounting for harm reductions's
      justificatory grounds and limits.
FAU - Weinstock, Daniel M
AU  - Weinstock DM
AD  - Institute for Health and Social Policy, Faculty of Law, McGill University,
      Montreal, Canada. Daniel.weinstock2@mcgill.ca.
LA  - eng
PT  - Journal Article
DEP - 20201024
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - *Harm Reduction
MH  - Humans
MH  - Law Enforcement
MH  - Needle-Exchange Programs
MH  - *Negotiating
MH  - *Policy
MH  - Sex Work
MH  - Suicide, Assisted
PMC - PMC7585486
OTO - NOTNLM
OT  - Consequentialism
OT  - Disagreement
OT  - Enforcement
OT  - Harm reduction
OT  - Policy
EDAT- 2020/10/26 06:00
MHDA- 2021/08/18 06:00
CRDT- 2020/10/25 20:15
PHST- 2020/10/10 00:00 [accepted]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2020/10/25 20:15 [entrez]
AID - 10.1007/s10728-020-00409-7 [doi]
AID - 10.1007/s10728-020-00409-7 [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Dec;28(4):314-323. doi: 10.1007/s10728-020-00409-7. Epub
      2020 Oct 24.


PMID- 33099502
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 23
TI  - Effects of infrapatellar fat pad preservation versus resection on clinical
      outcomes after total knee arthroplasty in patients with knee osteoarthritis
      (IPAKA): study protocol for a multicentre, randomised, controlled clinical trial.
PG  - e043088
LID - 10.1136/bmjopen-2020-043088 [doi]
AB  - INTRODUCTION: The infrapatellar fat pad (IPFP) is commonly resected during total 
      knee arthroplasty (TKA) for better exposure. However, our previous studies have
      suggested that IPFP size was protective against, while IPFP signal intensity
      alteration was detrimental on knee symptoms and structural abnormalities. We
      hypothesise that an IPFP with normal qualities, rather than abnormal qualities,
      should be preserved during TKA. The aim of this study is to compare, over a
      1-year period, the postoperative clinical outcomes of IPFP preservation versus
      resection after TKA in patients with normal or abnormal IPFP signal intensity
      alteration on MRI. METHODS AND ANALYSIS: Three hundred and sixty people with
      end-stage knee osteoarthritis and on the waiting list for TKA will be recruited
      and identified as normal IPFP quality (signal intensity alteration score </=1) or
      abnormal IPFP quality (signal intensity alteration score >/=2). Patients in each 
      hospital will then be randomly allocated to IPFP resection group or preservation 
      group. The primary outcomes are the summed score of self-reported Knee Injury and
      Osteoarthritis Outcome Score (KOOS), KOOS subscales assessing function in daily
      activities and function in sport and recreation. Secondary endpoints will be
      included: KOOS subscales (pain, symptoms and quality of life), Knee Society
      Score, 100 mm Visual Analogue Scale (VAS) Pain, timed up-and-go test, patellar
      tendon shortening, 100 mm VAS self-reported efficacy of reduced pain and
      increased quality of life, and Insall-Salvati index assessed on plain X-ray.
      Adverse events will be recorded. Intention-to-treat analyses will be used. ETHICS
      AND DISSEMINATION: The study is approved by the local Medical Ethics Committee
      (Zhujiang Hospital Ethics Committee, reference number 2017-GJGBK-001) and will be
      conducted according to the principle of the Declaration of Helsinki (64th, 2013) 
      and the Good Clinical Practice standard, and in compliance with the Medical
      Research Involving Human Subjects Act . Data will be published in peer-reviewed
      journals and presented at conferences, both nationally and internationally. TRIAL
      REGISTRATION NUMBER: This trial was registered at Clinicaltrial.gov website on 19
      October 2018 with identify number NCT03763448.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhu, Zhaohua
AU  - Zhu Z
AUID- ORCID: 0000-0003-3913-2564
AD  - Clinical Research Centre, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China.
AD  - Department of Orthopaedics, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
      Australia.
FAU - Han, Weiyu
AU  - Han W
AD  - Clinical Research Centre, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China.
AD  - Department of Orthopaedics, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
      Australia.
FAU - Lu, Ming
AU  - Lu M
AD  - Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical
      University, Hefei, China.
FAU - Lin, Jianhao
AU  - Lin J
AD  - Arthritis Clinical and Research Center, Peking University People's Hospital,
      Beijing, China.
FAU - Yin, Zongsheng
AU  - Yin Z
AD  - Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical
      University, Hefei, China.
FAU - Shang, Xifu
AU  - Shang X
AD  - Department of Orthopaedic Surgery, Anhui Provincial Hospital, Hefei, China.
FAU - Weng, Xisheng
AU  - Weng X
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Peking 
      Union Medical College, Chinese Academy of Medical Science, Beijing, China.
FAU - Zha, Zhengang
AU  - Zha Z
AD  - Institute of Orthopaedic Diseases and Center for Joint Surgery and Sports
      Medicine, The First Affiliated Hospital, Jinan University, Guangzhou, China.
FAU - Tian, Jin
AU  - Tian J
AD  - Department of Orthopaedics, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China.
FAU - Lei, Guanghua
AU  - Lei G
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha,
      Hunan, China.
FAU - Hunter, David J
AU  - Hunter DJ
AUID- ORCID: 0000-0003-3197-752X
AD  - Institute of Bone and Joint Research, Kolling Institute, Sydney, New South Wales,
      Australia.
AD  - Department of Rheumatology, Royal North Shore Hospital, University of Sydney,
      Sydney, New South Wales, Australia.
FAU - Ding, Changhai
AU  - Ding C
AD  - Clinical Research Centre, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China Changhai.Ding@utas.edu.au.
AD  - Department of Orthopaedics, Zhujiang Hospital, Southern Medical University,
      Guangzhou, China.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
      Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03763448
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201023
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adipose Tissue
MH  - *Arthroplasty, Replacement, Knee
MH  - Humans
MH  - Knee Joint/diagnostic imaging/surgery
MH  - Multicenter Studies as Topic
MH  - *Osteoarthritis, Knee/diagnostic imaging/surgery
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7590360
OTO - NOTNLM
OT  - *infrapatellar fat pad
OT  - *osteoarthritis
OT  - *randomised controlled trial
OT  - *total knee arthroplasty
COIS- Competing interests: None declared.
EDAT- 2020/10/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/25 20:14
PHST- 2020/10/25 20:14 [entrez]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-043088 [pii]
AID - 10.1136/bmjopen-2020-043088 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 23;10(10):e043088. doi: 10.1136/bmjopen-2020-043088.


PMID- 33099499
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 23
TI  - Evaluating the association between unmet healthcare needs and subsequent clinical
      outcomes: protocol for the Addressing Post-Intensive Care Syndrome-01 (APICS-01) 
      multicentre cohort study.
PG  - e040830
LID - 10.1136/bmjopen-2020-040830 [doi]
AB  - INTRODUCTION: As short-term mortality declines for critically ill patients, a
      growing number of survivors face long-term physical, cognitive and/or mental
      health impairments. After hospital discharge, many critical illness survivors
      require an in-depth plan to address their healthcare needs. Early after hospital 
      discharge, numerous survivors experience inadequate care or a mismatch between
      their healthcare needs and what is provided. Many patients are readmitted to the 
      hospital, have substantial healthcare resource use and experience long-lasting
      morbidity. The objective of this study is to investigate the gap in healthcare
      needs occurring immediately after hospital discharge and its association with
      hospital readmissions or death for survivors of acute respiratory failure (ARF). 
      METHODS AND ANALYSIS: In this multicentre prospective cohort study, we will enrol
      200 survivors of ARF in the intensive care unit (ICU) who are discharged directly
      home from their acute care hospital stay. Unmet healthcare needs, the primary
      exposure of interest, will be evaluated as soon as possible within 1 to 4 weeks
      after hospital discharge, via a standardised telephone assessment. The primary
      outcome, death or hospital readmission, will be measured at 3 months after
      discharge. Secondary outcomes (eg, quality of life, cognitive impairment,
      depression, anxiety and post-traumatic stress disorder) will be measured as part 
      of 3-month and 6-month telephone-based follow-up assessments. Descriptive
      statistics will be reported for the exposure and outcome variables along with a
      propensity score analysis, using inverse probability weighting for the primary
      exposure, to evaluate the relationship between the primary exposure and outcome. 
      ETHICS AND DISSEMINATION: The study received ethics approval from Vanderbilt
      University Medical Center Institutional Review Board (IRB) and the University of 
      Utah IRB (for the Veterans Affairs site). These results will inform both clinical
      practice and future interventional trials in the field. We plan to disseminate
      the results in peer-reviewed journals, and via national and international
      conferences. TRIAL REGISTRATION DETAILS: ClinicalTrials.gov (NCT03738774).
      Registered before enrollment of the first patient.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Akhlaghi, Narjes
AU  - Akhlaghi N
AUID- ORCID: 0000-0002-8702-1845
AD  - Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins
      University, Baltimore, MD, USA.
AD  - Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
FAU - Needham, Dale M
AU  - Needham DM
AD  - Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins
      University, Baltimore, MD, USA.
AD  - Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
AD  - Department of Physical Medicine and Rehabilitation, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
FAU - Bose, Somnath
AU  - Bose S
AD  - Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center
      and Harvard Medical School, Boston, MA, USA.
FAU - Banner-Goodspeed, Valerie M
AU  - Banner-Goodspeed VM
AD  - Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center
      and Harvard Medical School, Boston, MA, USA.
FAU - Beesley, Sarah J
AU  - Beesley SJ
AD  - Center for Humanizing Critical Care and Pulmonary/Critical Care Medicine,
      Intermountain Medical Center, Murray, UT, USA.
AD  - Pulmonary and Critical Care Medicine, University of Utah School of Medicine, Salt
      Lake City, UT, USA.
FAU - Dinglas, Victor D
AU  - Dinglas VD
AD  - Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins
      University, Baltimore, MD, USA.
AD  - Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
FAU - Groat, Danielle
AU  - Groat D
AD  - Center for Humanizing Critical Care and Pulmonary/Critical Care Medicine,
      Intermountain Medical Center, Murray, UT, USA.
FAU - Greene, Tom
AU  - Greene T
AD  - Division of Epidemiology Biostatistics, University of Utah, Salt Lake City, UT,
      USA.
FAU - Hopkins, Ramona O
AU  - Hopkins RO
AD  - Center for Humanizing Critical Care and Pulmonary/Critical Care Medicine,
      Intermountain Medical Center, Murray, UT, USA.
AD  - Psychology and Neuroscience, Brigham Young University, Provo, UT, USA.
FAU - Jackson, James
AU  - Jackson J
AD  - Vanderbilt University Medical Center, Nashville, TN, USA.
FAU - Mir-Kasimov, Mustafa
AU  - Mir-Kasimov M
AD  - Pulmonary and Critical Care Medicine, University of Utah School of Medicine, Salt
      Lake City, UT, USA.
AD  - George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City,
      UT, USA.
FAU - Sevin, Carla M
AU  - Sevin CM
AD  - Vanderbilt University Medical Center, Nashville, TN, USA.
FAU - Wilson, Emily
AU  - Wilson E
AD  - Center for Humanizing Critical Care and Pulmonary/Critical Care Medicine,
      Intermountain Medical Center, Murray, UT, USA.
FAU - Brown, Samuel M
AU  - Brown SM
AD  - Center for Humanizing Critical Care and Pulmonary/Critical Care Medicine,
      Intermountain Medical Center, Murray, UT, USA samuel.brown@imail.org.
AD  - Pulmonary and Critical Care Medicine, University of Utah School of Medicine, Salt
      Lake City, UT, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03738774
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201023
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - postintensive care syndrome
SB  - IM
MH  - Cohort Studies
MH  - *Critical Illness
MH  - Delivery of Health Care
MH  - Humans
MH  - Intensive Care Units
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - *Quality of Life
PMC - PMC7590359
OTO - NOTNLM
OT  - *Adult intensive & critical care
OT  - *REHABILITATION MEDICINE
OT  - *RESPIRATORY MEDICINE (see Thoracic Medicine)
COIS- Competing interests: Samuel M. Brown reports grants from National Institutes of
      Health, Department of Defense, Intermountain Research and Medical Foundation, and
      Janssen and consulting fees paid to his employer from Faron and Sedana, outside
      the submitted work. He also reports payments for DSMB service from Hamilton,
      outside the submitted work.
EDAT- 2020/10/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/25 20:14
PHST- 2020/10/25 20:14 [entrez]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040830 [pii]
AID - 10.1136/bmjopen-2020-040830 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 23;10(10):e040830. doi: 10.1136/bmjopen-2020-040830.


PMID- 33099491
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 23
TI  - Study protocol: a multicentre, prospective, phase II trial of isotoxic
      hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer.
PG  - e036295
LID - 10.1136/bmjopen-2019-036295 [doi]
AB  - INTRODUCTION: Concurrent chemoradiotherapy with conventional fractionation has
      been acknowledged as one of the standard treatments for locally advanced
      non-small cell lung cancer (NSCLC). The radiotherapy dose of 60 Gy is far from
      enough for local tumour control. Due to this fact, hypofractionated radiotherapy 
      can shorten the total treatment duration, partially counteract the accelerated
      repopulation of tumour cells and deliver a higher biological effective dose, it
      has been increasingly used for NSCLC. In theory, concurrent hypofractionated
      chemoradiotherapy can result in an enhanced curative effect. To date, the vast
      majority of radiotherapy prescriptions assign a uniform radiotherapy dose to all 
      patients. However this kind of uniform radiotherapy prescription may lead to two 
      consequences: excess damage to normal tissues for large tumours and insufficient 
      dose for small tumours. Our study aims to evaluate whether delivering
      individualised radiotherapy dose is feasible using intensity-modulated
      radiotherapy. METHODS AND ANALYSIS: Our study of individualised radiotherapy is a
      multicenter phase II trial. From April 2019, a total of 30 patients from three
      Chinese centres, with a proven histological or cytological diagnosis of
      inoperable NSCLC, will be recruited. The dose of radiation will be increased
      until one or more of the organs at risk tolerance or the maximum dose of 69 Gy is
      reached. The primary end point is feasibility, with response rates,
      progression-free survival and overall survival as secondary end points. The
      concurrent chemotherapy regimen will be docetaxel plus lobaplatin. ETHICS AND
      DISSEMINATION: The study has been approved by medical ethics committees from
      three research centres. The trial is conducted in accordance with the Declaration
      of Helsinki.The trial results will be disseminated through academic conference
      presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER:
      NCT03606239.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liu, Yue-E
AU  - Liu YE
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Xue, Xiao-Ying
AU  - Xue XY
AD  - Department of Radiotherapy, Second Hospital of Hebei Medical University,
      Shijiazhuang, Hebei, China.
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Chen, Xue-Ji
AU  - Chen XJ
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Ding, Yu-Xia
AU  - Ding YX
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Liu, Chao-Xing
AU  - Liu CX
AD  - Department of Oncology, No.1 Hospital of Shijiazhuang City, Shijiazhuang, Hebei, 
      China.
FAU - Qin, Yue-Liang
AU  - Qin YL
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Li, Wei-Qian
AU  - Li WQ
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Ren, Xiao-Cang
AU  - Ren XC
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China.
FAU - Lin, Qiang
AU  - Lin Q
AUID- ORCID: 0000-0001-9599-4121
AD  - Department of Oncology, North China Petroleum Bureau General Hospital, Hebei
      Medical University, Renqiu, Hebei, China billhappy001@163.com.
AD  - Hebei Medical University, Shijiazhuang, Hebei, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03606239
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201023
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Chemoradiotherapy/adverse effects
MH  - Clinical Trials, Phase II as Topic
MH  - Dose Fractionation, Radiation
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
PMC - PMC7590348
OTO - NOTNLM
OT  - *oncology
OT  - *radiotherapy
OT  - *respiratory tract tumours
COIS- Competing interests: None declared.
EDAT- 2020/10/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/25 20:14
PHST- 2020/10/25 20:14 [entrez]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036295 [pii]
AID - 10.1136/bmjopen-2019-036295 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 23;10(10):e036295. doi: 10.1136/bmjopen-2019-036295.


PMID- 33099459
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210101
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 8
TI  - The Swiss Prison Study (SWIPS): Protocol for Establishing a Public Health
      Registry of Prisoners in Switzerland.
PG  - e23973
LID - 10.2196/23973 [doi]
AB  - BACKGROUND: The health aspects, disease frequencies, and specific health
      interests of prisoners and refugees are poorly understood. Importantly, access to
      the health care system is limited for this vulnerable population. There has been 
      no systematic investigation to understand the health issues of inmates in
      Switzerland. Furthermore, little is known on how recent migration flows in Europe
      may have affected the health conditions of inmates. OBJECTIVE: The Swiss Prison
      Study (SWIPS) is a large-scale observational study with the aim of establishing a
      public health registry in northern-central Switzerland. The primary objective is 
      to establish a central database to assess disease prevalence (ie, International
      Classification of Diseases-10 codes [German modification]) among prisoners. The
      secondary objectives include the following: (1) to compare the 2015 versus 2020
      disease prevalence among inmates against a representative sample from the local
      resident population, (2) to assess longitudinal changes in disease prevalence
      from 2015 to 2020 by using cross-sectional medical records from all inmates at
      the Police Prison Zurich, Switzerland, and (3) to identify unrecognized health
      problems to prepare successful public health strategies. METHODS: Demographic and
      health-related data such as age, sex, country of origin, duration of
      imprisonment, medication (including the drug name, brand, dosage, and release),
      and medical history (including the International Classification of Diseases-10
      codes [German modification] for all diagnoses and external results that are part 
      of the medical history in the prison) have been deposited in a central register
      over a span of 5 years (January 2015 to August 2020). The final cohort is
      expected to comprise approximately 50,000 to 60,000 prisoners from the Police
      Prison Zurich, Switzerland. RESULTS: This study was approved on August 5, 2019 by
      the ethical committee of the Canton of Zurich with the registration code KEK-ZH
      No. 2019-01055 and funded in August 2020 by the "Walter and Gertrud Siegenthaler"
      foundation and the "Theodor and Ida Herzog-Egli" foundation. This study is
      registered with the International Standard Randomized Controlled Trial Number
      registry. Data collection started in August 2019 and results are expected to be
      published in 2021. Findings will be disseminated through scientific papers as
      well as presentations and public events. CONCLUSIONS: This study will construct a
      valuable database of information regarding the health of inmates and refugees in 
      Swiss prisons and will act as groundwork for future interventions in this
      vulnerable population. TRIAL REGISTRATION: ISRCTN registry ISRCTN11714665;
      http://www.isrctn.com/ISRCTN11714665. INTERNATIONAL REGISTERED REPORT IDENTIFIER 
      (IRRID): DERR1-10.2196/23973.
CI  - (c)Thomas Gaisl, Naser Musli, Patrick Baumgartner, Marc Meier, Silvana K Rampini,
      Eva Blozik, Edouard Battegay, Malcolm Kohler, Shekhar Saxena. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      08.12.2020.
FAU - Gaisl, Thomas
AU  - Gaisl T
AUID- ORCID: https://orcid.org/0000-0002-9017-6143
AD  - Global Health and Population, Harvard T H Chan School of Public Health, Boston,
      MA, United States.
AD  - Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.
AD  - Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Musli, Naser
AU  - Musli N
AUID- ORCID: https://orcid.org/0000-0001-9076-938X
AD  - Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.
FAU - Baumgartner, Patrick
AU  - Baumgartner P
AUID- ORCID: https://orcid.org/0000-0003-4096-7438
AD  - Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Meier, Marc
AU  - Meier M
AUID- ORCID: https://orcid.org/0000-0002-3183-1144
AD  - Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.
FAU - Rampini, Silvana K
AU  - Rampini SK
AUID- ORCID: https://orcid.org/0000-0002-4788-438X
AD  - Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.
FAU - Blozik, Eva
AU  - Blozik E
AUID- ORCID: https://orcid.org/0000-0002-0620-6873
AD  - Department of Health Sciences, Helsana Insurance Group, Zurich, Switzerland.
FAU - Battegay, Edouard
AU  - Battegay E
AUID- ORCID: https://orcid.org/0000-0001-9202-5034
AD  - Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.
FAU - Kohler, Malcolm
AU  - Kohler M
AUID- ORCID: https://orcid.org/0000-0003-1800-8003
AD  - Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
FAU - Saxena, Shekhar
AU  - Saxena S
AUID- ORCID: https://orcid.org/0000-0001-7048-4416
AD  - Global Health and Population, Harvard T H Chan School of Public Health, Boston,
      MA, United States.
LA  - eng
PT  - Journal Article
DEP - 20201208
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7755536
OTO - NOTNLM
OT  - epidemiology
OT  - health register
OT  - prison medicine
OT  - public health
EDAT- 2020/10/26 06:00
MHDA- 2020/10/26 06:01
CRDT- 2020/10/25 20:14
PHST- 2020/08/30 00:00 [received]
PHST- 2020/10/25 00:00 [accepted]
PHST- 2020/10/04 00:00 [revised]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2020/10/26 06:01 [medline]
PHST- 2020/10/25 20:14 [entrez]
AID - v9i12e23973 [pii]
AID - 10.2196/23973 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 8;9(12):e23973. doi: 10.2196/23973.


PMID- 33099243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220616
IS  - 1873-426X (Electronic)
IS  - 0008-6215 (Linking)
VI  - 498
DP  - 2020 Dec
TI  - Retraction notice to "2D NMR assisted structure elucidation of three
      cyanoethylated cellulose derivatives and correlated with their properties"
      [Carbohydr. Res. 487(2020) 107861].
PG  - 108177
LID - S0008-6215(20)30548-6 [pii]
LID - 10.1016/j.carres.2020.108177 [doi]
AB  - This article has been retracted: please see Elsevier Policy on Article Withdrawal
      (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This
      article has been retracted at the request of the Editor-in-Chief who would like
      to withdraw this accepted article, due to serious errors in authorship and
      affiliations which breach the journal's ethical policies.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China.
FAU - Shen, Xiaofei
AU  - Shen X
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China.
FAU - Qian, Hao
AU  - Qian H
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China.
FAU - Song, Lei
AU  - Song L
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China.
FAU - Xie, Kaiyun
AU  - Xie K
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China.
FAU - Zhang, Mingtao
AU  - Zhang M
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China.
FAU - Wang, Huiqing
AU  - Wang H
AD  - Department of Polymer Science and Engineering, School of Chemistry and Chemical
      Engineering, Hefei University of Technology, Hefei, Anhui Province, 230009,
      China. Electronic address: huiqing.wang@hfut.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Retraction of Publication
DEP - 20201021
PL  - Netherlands
TA  - Carbohydr Res
JT  - Carbohydrate research
JID - 0043535
SB  - IM
ROF - Carbohydr Res. 2020 Jan;487:107861. PMID: 31759323
EDAT- 2020/10/26 06:00
MHDA- 2020/10/26 06:01
CRDT- 2020/10/25 00:09
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2020/10/26 06:01 [medline]
PHST- 2020/10/25 00:09 [entrez]
AID - S0008-6215(20)30548-6 [pii]
AID - 10.1016/j.carres.2020.108177 [doi]
PST - ppublish
SO  - Carbohydr Res. 2020 Dec;498:108177. doi: 10.1016/j.carres.2020.108177. Epub 2020 
      Oct 21.


PMID- 33098755
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20210225
IS  - 1474-4465 (Electronic)
IS  - 1474-4422 (Linking)
VI  - 19
IP  - 12
DP  - 2020 Dec
TI  - Informed consent procedures for emergency interventional research in patients
      with traumatic brain injury and ischaemic stroke.
PG  - 1033-1042
LID - S1474-4422(20)30276-3 [pii]
LID - 10.1016/S1474-4422(20)30276-3 [doi]
AB  - Health-care professionals and researchers have a legal and ethical responsibility
      to inform patients before carrying out diagnostic tests or treatment
      interventions as part of a clinical study. Interventional research in emergency
      situations can involve patients with some degree of acute cognitive impairment,
      as is regularly the case in traumatic brain injury and ischaemic stroke. These
      patients or their proxies are often unable to provide informed consent within
      narrow therapeutic time windows. International regulations and national laws are 
      criticised for being inconclusive or restrictive in providing solutions.
      Currently accepted consent alternatives are deferred consent, exception from
      consent, or waiver of consent. However, these alternatives appear under-utilised 
      despite being ethically permissible, socially acceptable, and regulatorily
      compliant. We anticipate that, when the requirements for medical urgency are
      properly balanced with legal and ethical conduct, the increased use of these
      alternatives has the potential to improve the efficiency and quality of future
      emergency interventional studies in patients with an inability to provide
      informed consent.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kompanje, Erwin J O
AU  - Kompanje EJO
AD  - Department of Intensive Care Adult, Erasmus Medical Center, University Medical
      Center, Rotterdam, The Netherlands; Department of Ethics and Philosophy of
      Medicine, Erasmus University, Rotterdam, The Netherlands. Electronic address:
      e.j.o.kompanje@erasmusmc.nl.
FAU - van Dijck, Jeroen T J M
AU  - van Dijck JTJM
AD  - University Neurosurgical Center Holland, Leiden University Medical Center,
      Haaglanden Medical Center & Haga Teaching Hospital, Leiden and The Hague, The
      Netherlands.
FAU - Chalos, Vicky
AU  - Chalos V
AD  - Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, The Netherlands; Department of Neurology, Erasmus Medical Center,
      University Medical Center, Rotterdam, The Netherlands; Department of Radiology
      and Nuclear Science, Erasmus Medical Center, University Medical Center,
      Rotterdam, The Netherlands.
FAU - van den Berg, Sophie A
AU  - van den Berg SA
AD  - Department of Neurology, Erasmus Medical Center, University Medical Center,
      Rotterdam, The Netherlands; Department of Neurology, Amsterdam UMC, The
      Netherlands.
FAU - Janssen, Paula M
AU  - Janssen PM
AD  - Department of Neurology, Erasmus Medical Center, University Medical Center,
      Rotterdam, The Netherlands.
FAU - Nederkoorn, Paul J
AU  - Nederkoorn PJ
AD  - Department of Neurology, Amsterdam UMC, The Netherlands.
FAU - van der Jagt, Mathieu
AU  - van der Jagt M
AD  - Department of Intensive Care Adult, Erasmus Medical Center, University Medical
      Center, Rotterdam, The Netherlands.
FAU - Citerio, Giuseppe
AU  - Citerio G
AD  - School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
FAU - Stocchetti, Nino
AU  - Stocchetti N
AD  - Department of Physiopathology and Transplantation, Milan University, Milan,
      Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Dippel, Diederik W J
AU  - Dippel DWJ
AD  - Department of Neurology, Erasmus Medical Center, University Medical Center,
      Rotterdam, The Netherlands.
FAU - Peul, Wilco C
AU  - Peul WC
AD  - University Neurosurgical Center Holland, Leiden University Medical Center,
      Haaglanden Medical Center & Haga Teaching Hospital, Leiden and The Hague, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201021
PL  - England
TA  - Lancet Neurol
JT  - The Lancet. Neurology
JID - 101139309
SB  - IM
CIN - Lancet Neurol. 2020 Dec;19(12):968-969. PMID: 33098756
CIN - Lancet Neurol. 2021 Mar;20(3):170. PMID: 33609468
CIN - Lancet Neurol. 2021 Mar;20(3):170-171. PMID: 33609469
EIN - Lancet Neurol. 2021 Apr;20(4):e3. PMID: 33581051
MH  - Brain Injuries, Traumatic/*therapy
MH  - *Clinical Studies as Topic/ethics/legislation & jurisprudence
MH  - *Emergency Medical Services/ethics/legislation & jurisprudence
MH  - Humans
MH  - *Informed Consent/ethics/legislation & jurisprudence
MH  - Ischemic Stroke/*therapy
EDAT- 2020/10/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/25 00:00
PHST- 2020/02/08 00:00 [received]
PHST- 2020/07/20 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/25 00:00 [entrez]
AID - S1474-4422(20)30276-3 [pii]
AID - 10.1016/S1474-4422(20)30276-3 [doi]
PST - ppublish
SO  - Lancet Neurol. 2020 Dec;19(12):1033-1042. doi: 10.1016/S1474-4422(20)30276-3.
      Epub 2020 Oct 21.


PMID- 33098488
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - Disgust or Dignity? The Moral Basis of Harm Reduction.
PG  - 343-351
LID - 10.1007/s10728-020-00412-y [doi]
AB  - Harm reduction has been advocated to address a diverse range of public health
      concerns. The moral justification of harm reduction is usually presumed to be
      consequentialist because the goal of harm reduction is to reduce the harmful
      health consequences of risky behaviors, such as substance use. Harm reduction is 
      contrasted with an abstinence model whose goal is to eradicate or reduce the
      prevalence of such behaviors. The abstinence model is often thought to be
      justified by 'deontological' considerations: it is claimed that many risky
      behaviors are morally unacceptable, and therefore that we have a moral obligation
      to recommend abstinence. Because harm reduction is associated with a
      consequentialist justification and the abstinence model is associated with a
      deontological justification, the potential for a deontological justification of
      harm reduction has been overlooked. This paper addresses this gap. It argues that
      the moral duty to protect autonomy and dignity that has been advocated in other
      areas of medical ethics also justifies the public health policy of harm
      reduction. It offers two examples-the provision of supervised injection sites and
      the Housing First policy to address homelessness-to illustrate the argument.
FAU - Stoljar, Natalie
AU  - Stoljar N
AUID- ORCID: http://orcid.org/0000-0001-5068-041X
AD  - Department of Philosophy and Institute for Health and Social Policy, McGill
      University, 855 Sherbrooke St, W., Montreal, QC, H3A 2T7, Canada.
      natalie.stoljar@mcgill.ca.
LA  - eng
PT  - Journal Article
DEP - 20201024
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - *Disgust
MH  - Ethical Theory
MH  - *Harm Reduction
MH  - Humans
MH  - *Morals
MH  - Needle-Exchange Programs
MH  - *Respect
OTO - NOTNLM
OT  - Dignity
OT  - Harm reduction
OT  - Medical ethics
OT  - Relational autonomy
EDAT- 2020/10/25 06:00
MHDA- 2021/08/18 06:00
CRDT- 2020/10/24 12:06
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/10/25 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
PHST- 2020/10/24 12:06 [entrez]
AID - 10.1007/s10728-020-00412-y [doi]
AID - 10.1007/s10728-020-00412-y [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Dec;28(4):343-351. doi: 10.1007/s10728-020-00412-y. Epub
      2020 Oct 24.


PMID- 33097576
OWN - NLM
STAT- Publisher
LR  - 20201024
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 23
TI  - Consent and living organ donation.
LID - medethics-2020-106570 [pii]
LID - 10.1136/medethics-2020-106570 [doi]
AB  - This paper focuses on voluntary consent in the context of living organ donation. 
      Arguing against three dominant views, I claim that voluntariness must not be
      equated with willingness, that voluntariness does not require the exercise of
      relational moral agency, and that, in cases of third-party pressure,
      voluntariness critically depends on the role of the surgeon and the medical team,
      and not just on the pressure from other people. I therefore argue that an
      adequate account of voluntary consent cannot understand voluntariness as a purely
      psychological concept, that it has to be consistent with people pursuing various 
      different conceptions of the good and that it needs to make the interaction
      between the person giving consent and the person (or people) receiving consent
      central to its approach.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kiener, Maximilian
AU  - Kiener M
AD  - Philosophy, University of Oxford, Oxford, UK
      maximilian.kiener@philosophy.ox.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - autonomy
OT  - ethics
OT  - informed consent
OT  - vital organ donation
COIS- Competing interests: None declared.
EDAT- 2020/10/25 06:00
MHDA- 2020/10/25 06:00
CRDT- 2020/10/24 05:29
PHST- 2020/06/10 00:00 [received]
PHST- 2020/08/30 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/24 05:29 [entrez]
PHST- 2020/10/25 06:00 [pubmed]
PHST- 2020/10/25 06:00 [medline]
AID - medethics-2020-106570 [pii]
AID - 10.1136/medethics-2020-106570 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 23. pii: medethics-2020-106570. doi:
      10.1136/medethics-2020-106570.


PMID- 33097519
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20220531
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 371
DP  - 2020 Oct 23
TI  - The ethics of transferring adult patients to paediatric services.
PG  - m4089
LID - 10.1136/bmj.m4089 [doi]
FAU - Hampton, Thomas
AU  - Hampton T
AD  - Alder Hey Children's NHS Foundation Trust, Liverpool L14 5AB, UK.
FAU - Sadlers, Victoria
AU  - Sadlers V
AD  - Alder Hey Children's NHS Foundation Trust, Liverpool L14 5AB, UK.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20201023
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
CON - BMJ. 2020 Sep 29;370:m3747. PMID: 32994215
MH  - Adult
MH  - Child
MH  - Humans
MH  - *Pediatrics/ethics
COIS- Competing interests: TH receives grant funding from the Wellcome Trust. Neither
      author has any other conflict of interest, financial or otherwise.
EDAT- 2020/10/25 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/24 05:28
PHST- 2020/10/24 05:28 [entrez]
PHST- 2020/10/25 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.1136/bmj.m4089 [doi]
PST - epublish
SO  - BMJ. 2020 Oct 23;371:m4089. doi: 10.1136/bmj.m4089.


PMID- 33097227
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20210110
IS  - 1528-3968 (Electronic)
IS  - 0029-6554 (Linking)
VI  - 68
IP  - 6
DP  - 2020 Nov - Dec
TI  - Nurses confronting the coronavirus: Challenges met and lessons learned to date.
PG  - 838-844
LID - S0029-6554(20)30659-X [pii]
LID - 10.1016/j.outlook.2020.08.018 [doi]
AB  - Registered nurses are an essential workforce group across the globe. They use
      their expertise and skill sets every day in clinical practice to protect,
      promote, and advocate on behalf of patients and families under their care. In
      this article we discuss the physical, emotional, and moral stresses that nurses
      are experiencing in their day-to-day practice settings created by the novel
      coronavirus. We consider the demands placed on nurses by unexpected patient
      surges within hospital environments and inadequate personal protective equipment 
      and other critical resources, challenging nurses' ability to meet their
      professional and ethical obligations. We also share our thoughts on supporting
      nurses and others now, and ideas for needed healing for both individuals and
      organizations as we move forward. Finally, we argue for the need for substantive 
      reform of institutional processes and systems that can deliver quality care in
      the future when faced with another devastating humanitarian and public health
      crises.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ulrich, Connie M
AU  - Ulrich CM
AD  - University of Pennsylvania School of Nursing and Perelman School of Medicine; New
      Courtland Center for Transitions and Health. Electronic address:
      culrich@nursing.upenn.edu.
FAU - Rushton, Cynda H
AU  - Rushton CH
AD  - Johns Hopkins University School of Nursing and Berman Insitute of Bioethics.
FAU - Grady, Christine
AU  - Grady C
AD  - Department of Bioethics, National Institutes of Health Clinical Center.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - Nurs Outlook
JT  - Nursing outlook
JID - 0401075
SB  - IM
MH  - Adult
MH  - COVID-19/*nursing
MH  - Coronavirus
MH  - Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nurses/*psychology
MH  - Nursing Care/*ethics/*psychology
MH  - Nursing Staff, Hospital/*ethics/*psychology
MH  - Occupational Stress
MH  - Pandemics
MH  - Quality of Health Care/*ethics
MH  - United States
PMC - PMC7462465
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Lessons Learned
OT  - *Nurses
EDAT- 2020/10/25 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/24 05:26
PHST- 2020/05/27 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/10/25 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/24 05:26 [entrez]
AID - S0029-6554(20)30659-X [pii]
AID - 10.1016/j.outlook.2020.08.018 [doi]
PST - ppublish
SO  - Nurs Outlook. 2020 Nov - Dec;68(6):838-844. doi: 10.1016/j.outlook.2020.08.018.
      Epub 2020 Sep 1.


PMID- 33096686
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201030
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - An Anglocentric History of Anaesthetics and Analgesics in the Refinement of
      Animal Experiments.
LID - E1933 [pii]
LID - 10.3390/ani10101933 [doi]
AB  - Previous histories of animal experimentation, e.g., Franco (2013) have focused on
      ethics, the law and the personalities involved, but not on the involvement of
      anaesthetics or analgesics. Given that these were major subjects of (UK)
      Parliamentary debates on vivisection in the mid-19th century and viewed as
      "indisputable refinements in animal experimentation" (Russell and Burch 1959), it
      seemed that an analysis of their role was overdue. This commentary has, in
      interweaving the history of animal experimentation in the UK with the evolution
      of anaesthesia, attempted to: (1) clarify the evidence for Russell and Burch's
      view; and (2) evaluate anaesthesia's ongoing contribution to experimental
      refinement. The history that emerges reveals that the withholding or misuse of
      anaesthetics and, or analgesics from laboratory animals in the UK has had a
      profound effect on scientists and indirectly on the attitudes of the British
      public in general, becoming a major driver for the establishment of the
      anti-vivisection movement and subsequently, the Cruelty to Animals Act (1876)-the
      world's first legislation for the regulation of animal experimentation. In 1902, 
      the mismanaged anaesthetic of a dog in the Department of Physiology, University
      College London resulted in numerous events of public disorder initiated by
      medical students against the police and a political coalition of
      anti-vivisectionists, trade unionists, socialists, Marxists, liberals and
      suffragettes. The importance of anaesthesia in animal experiments was sustained
      over the following 150 years as small mammalian species gradually replaced dogs
      and cats as the principle subjects for vivisection. In discussing experimental
      refinement in their 1959 report, "The Principles of Humane Experimental
      Technique" Russell and Burch described anaesthetics as "... the greatest single
      advance in humane technique, (which) has at the same time been virtually
      indispensable for the advance of experimental biology". Since then, the role of
      anaesthetics and in particular analgesics has become an unavoidable consideration
      whenever animal experiments are planned and conducted. This has been accompanied 
      by a proliferation of training and educational programmes in laboratory animal
      anaesthesia.
FAU - Clutton, R Eddie
AU  - Clutton RE
AD  - The Wellcome Trust Critical Care Laboratory for Large Animals, Roslin Institute, 
      Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG, UK.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7589666
OTO - NOTNLM
OT  - anaesthesia
OT  - analgesia
OT  - animal research
OT  - animal testing
OT  - biomedical research
OT  - history of science
EDAT- 2020/10/25 06:00
MHDA- 2020/10/25 06:01
CRDT- 2020/10/24 01:00
PHST- 2020/09/14 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/10/24 01:00 [entrez]
PHST- 2020/10/25 06:00 [pubmed]
PHST- 2020/10/25 06:01 [medline]
AID - ani10101933 [pii]
AID - 10.3390/ani10101933 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 21;10(10). pii: ani10101933. doi: 10.3390/ani10101933.


PMID- 33095701
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1558-1756 (Electronic)
IS  - 0272-1716 (Linking)
VI  - 40
IP  - 6
DP  - 2020 Nov-Dec
TI  - Designing Technology for Sociotechnical Problems: Challenges and Considerations.
PG  - 76-87
LID - 10.1109/MCG.2020.3017405 [doi]
AB  - Designing technology for sociotechnical problems is challenging due to the
      heterogeneity of stakeholders' needs, the diversity among their values and
      perspectives, and the disparity in their technical skills. Careful considerations
      are needed to ensure that data collection is inclusive and representative of the 
      target populations. It is also important to employ data analysis methods that are
      compatible with users' technical skills and are capable of drawing a
      representative picture of people's values, priorities, and needs. However,
      current technical solutions often fail to meet these critical requirements. In
      this article, we present a set of empirically-driven design considerations for
      building technological interventions to address sociotechnical issues. We then
      discuss open challenges and tradeoffs around privacy, ethics, bias, uncertainty, 
      and trust. We conclude with a call to action for researchers to advance the
      domain knowledge and improve our technological arsenal for addressing
      sociotechnical problems.
FAU - Mahyar, Narges
AU  - Mahyar N
FAU - Jasim, Mahmood
AU  - Jasim M
FAU - Sarvghad, Ali
AU  - Sarvghad A
FAU - Tory, Melanie
AU  - Tory M
FAU - Keefe, Daniel F
AU  - Keefe DF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - IEEE Comput Graph Appl
JT  - IEEE computer graphics and applications
JID - 9881869
SB  - IM
EDAT- 2020/10/24 06:00
MHDA- 2020/10/24 06:01
CRDT- 2020/10/23 17:09
PHST- 2020/10/23 17:09 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/10/24 06:01 [medline]
AID - 10.1109/MCG.2020.3017405 [doi]
PST - ppublish
SO  - IEEE Comput Graph Appl. 2020 Nov-Dec;40(6):76-87. doi: 10.1109/MCG.2020.3017405.


PMID- 33095667
OWN - NLM
STAT- Publisher
LR  - 20201023
IS  - 1541-3764 (Electronic)
IS  - 0030-2228 (Linking)
DP  - 2020 Oct 23
TI  - Nurses' Opinions on Do-Not-Resuscitate Orders.
PG  - 30222820969317
LID - 10.1177/0030222820969317 [doi]
AB  - The aim of this study was to determine nurses' opinions on Do Not Resuscitate
      (DNR) orders. This is a descriptive study. A total of 1250 nurses participated in
      this study. The mean age of participants was 34.5 +/- 7.7 years; 92.6% were
      women; 56.4% had bachelor's degrees, and 28.8% were intensive care, oncology, or 
      palliative care nurses. Most participants (94.3%) agreed that healthcare
      professionals involved in DNR decision-making processes should have ethical
      competence, while they were mostly undecided (43%) about the statement whether or
      not DNR should be legal. More than half the participants (60.2%) disagreed with
      the idea that DNR implementation causes an ethical dilemma. Participants'
      opinions on DNR decisions significantly differed according to the number of years
      of employment and unit of duty. The results showed that most of the nurses had
      positive attitudes towards DNR orders despite it being illegal. Future studies
      are needed to better understand family members' and decision makers' perceptions 
      of DNR orders for patients.
FAU - Gul, Senay
AU  - Gul S
AUID- ORCID: https://orcid.org/0000-0002-8808-5760
AD  - Faculty of Nursing, Hacettepe University, Ankara, Turkey.
FAU - Bagcivan, Gulcan
AU  - Bagcivan G
AD  - School of Nursing, Koc University, Istanbul, Turkey.
FAU - Aksu, Miray
AU  - Aksu M
AD  - Gulhane Training and Research Hospital, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20201023
PL  - United States
TA  - Omega (Westport)
JT  - Omega
JID - 1272106
SB  - IM
OTO - NOTNLM
OT  - Do-Not-Resuscitate orders
OT  - decision-making
OT  - end of life
OT  - nurses
EDAT- 2020/10/24 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/23 17:09
PHST- 2020/10/23 17:09 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1177/0030222820969317 [doi]
PST - aheadofprint
SO  - Omega (Westport). 2020 Oct 23:30222820969317. doi: 10.1177/0030222820969317.


PMID- 33095490
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Sep
TI  - Between Crisis and Convention: How Should We Address Contingency?
PG  - 17-19
LID - 10.1002/hast.1181 [doi]
AB  - The Covid-19 pandemic has brought about renewed conversation about equality and
      equity in the distribution of medical resources. Much of the recent conversation 
      has focused on creating and implementing policies in times of crisis when
      resources are exhausted. Depending on how the pandemic develops, some communities
      may implement crisis measures, but many health care facilities are currently
      experiencing shortages of staff and materials even if the facilities have not
      implemented crisis standards. There is a need for shared conversation about
      equality and equity in these times of contingency between conventional and crisis
      medicine. To respond well to these challenges, I recommend that institutions rely
      on policy, professional education, and ethics consultation. As is the case with
      crisis policies, creating contingency policies requires that health care
      professionals decide on how, specifically, to achieve equity. A policy is only as
      effective as its implementation; therefore, institutions should invest in
      context-specific education on contingency policies. Finally, ethics consultation 
      should be available for questions that contingency policies cannot address.
CI  - (c) 2020 The Hastings Center.
FAU - Bibler, Trevor
AU  - Bibler T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - *Disaster Medicine/ethics/standards
MH  - Ethics Consultation
MH  - *Health Care Rationing/ethics/methods
MH  - *Health Equity
MH  - Health Policy
MH  - Health Resources/*supply & distribution
MH  - *Healthcare Disparities
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Resource Allocation
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Covid-19 pandemic
OT  - *allocation
OT  - *equity
OT  - *ethics consultation
OT  - *health policy
OT  - *justice
EDAT- 2020/10/24 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/23 12:13
PHST- 2020/10/23 12:13 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.1002/hast.1181 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Sep;50(5):17-19. doi: 10.1002/hast.1181.


PMID- 33095488
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Sep
TI  - "Reproductive Negligence": A Necessary and Sufficient Remedy?
PG  - 44-45
LID - 10.1002/hast.1186 [doi]
AB  - This book review essay discusses Birth Rights and Wrongs: How Medicine and
      Technology Are Remaking Reproduction and the Law (2019), by Dov Fox.
CI  - (c) 2020 The Hastings Center.
FAU - Zacharias, Rachel L
AU  - Zacharias RL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
OTO - NOTNLM
OT  - fertility industry
OT  - reproductive autonomy
OT  - reproductive ethics
OT  - reproductive harm
OT  - tort law
EDAT- 2020/10/24 06:00
MHDA- 2020/10/24 06:01
CRDT- 2020/10/23 12:13
PHST- 2020/10/23 12:13 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/10/24 06:01 [medline]
AID - 10.1002/hast.1186 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Sep;50(5):44-45. doi: 10.1002/hast.1186.


PMID- 33095487
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Sep
TI  - Words Matter.
PG  - 2
LID - 10.1002/hast.1175 [doi]
AB  - The lead article in this, the September-October 2020, issue of the Hastings
      Center Report considers the use of metaphors in communications with clinicians
      and patients.
CI  - (c) 2020 The Hastings Center.
FAU - Kaebnick, Gregory E
AU  - Kaebnick GE
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Communication
MH  - Humans
MH  - Metaphor
MH  - Professional-Patient Relations
MH  - *Semantics
OTO - NOTNLM
OT  - *clinical ethics
OT  - *clinician-patient relationship
OT  - *fatness
OT  - *genetic essentialism
OT  - *metaphor
EDAT- 2020/10/24 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/23 12:13
PHST- 2020/10/23 12:13 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.1002/hast.1175 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Sep;50(5):2. doi: 10.1002/hast.1175.


PMID- 33095486
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Sep
TI  - Your Father's a Fighter; Your Daughter's a Vegetable: A Critical Analysis of the 
      Use of Metaphor in Clinical Practice.
PG  - 20-29
LID - 10.1002/hast.1182 [doi]
AB  - There are two widespread beliefs about the use of metaphors in clinical medicine.
      The first is that military metaphors are harmful to patients and should be
      discouraged in medical practice. The second is that the metaphors of clinical
      practice can be judged by and standardized in reference to neutral criteria. In
      this article, I evaluate both these beliefs, exposing their shared flawed logic. 
      This logic underwrites the false empiricist assumptions that metaphorical
      language and literal language are fundamentally distinct, play separate roles in 
      communication, and therefore can be independently analyzed, systematized, and
      prescribed. Next, using the resources of ordinary language philosophy, I lay out 
      a theoretical view of medical metaphors that is grounded in metaphor use within
      clinician-patient relationships. Finally, drawing on the work of philosopher Max 
      Black, I diagram a practical conceptual framework for clinicians to use when they
      consider whether a metaphor is appropriate for a specific patient encounter.
CI  - (c) 2020 The Hastings Center.
FAU - Tate, Tyler
AU  - Tate T
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
CON - JAMA. 2017 Aug 1;318(5):482-483. PMID: 28763546
MH  - Fathers
MH  - Humans
MH  - Language
MH  - Male
MH  - *Metaphor
MH  - Nuclear Family
MH  - *Vegetables
OTO - NOTNLM
OT  - *clinical ethics
OT  - *communication
OT  - *metaphor
OT  - *narrative
OT  - *patient-clinician relationship
OT  - *philosophy of language
EDAT- 2020/10/24 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/10/23 12:13
PHST- 2020/10/23 12:13 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.1002/hast.1182 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Sep;50(5):20-29. doi: 10.1002/hast.1182.


PMID- 33095485
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Sep
TI  - Can We Do without Respect and Justice in Animal Research Ethics?
PG  - 46-47
LID - 10.1002/hast.1187 [doi]
AB  - This book review essay discusses Principles of Animal Research Ethics (2020), by 
      Tom L. Beauchamp and David DeGrazia.
CI  - (c) 2020 The Hastings Center.
FAU - Walker, Rebecca L
AU  - Walker RL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
OTO - NOTNLM
OT  - animal research ethics
OT  - animal welfare
OT  - justice
OT  - respect
OT  - social benefit
EDAT- 2020/10/24 06:00
MHDA- 2020/10/24 06:01
CRDT- 2020/10/23 12:13
PHST- 2020/10/23 12:13 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/10/24 06:01 [medline]
AID - 10.1002/hast.1187 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Sep;50(5):46-47. doi: 10.1002/hast.1187.


PMID- 33095479
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Sep
TI  - A Matter of Justice: "Fat" Is Not Necessarily a Bad Word.
PG  - 11-16
LID - 10.1002/hast.1180 [doi]
AB  - This essay argues that the discrimination that fat patients face is an issue of
      health justice. Insofar as this is the case, bioethicists and health care
      providers should not only care about it but also work to dismantle the
      systematic, institutional, social, and individual factors that are contributing
      to it to ensure that fat patients receive high-quality health care, free of
      stigma and discrimination. The essay discusses a variety of ways in which fat
      patients are discriminated against and considers the false assumptions that fuel 
      such discrimination. It concludes by considering the structural and social issues
      that contribute to fatness and pushes health care providers to abandon the
      assumption that being fat is an individual moral failing. Ultimately, the paper
      argues, "fat" is not necessarily a bad word, nor one that health care providers
      should avoid.
CI  - (c) 2020 The Hastings Center.
FAU - Freeman, Lauren
AU  - Freeman L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Ethical Theory
MH  - Human Rights
MH  - Humans
MH  - Overweight/*psychology
MH  - Patient Rights/*ethics/standards
MH  - Prejudice/*ethics/psychology
MH  - Social Justice
MH  - Social Stigma
MH  - Terminology as Topic
OTO - NOTNLM
OT  - *clinical ethics
OT  - *delivery of health care
OT  - *fatness
OT  - *health justice
OT  - *weight stigma
EDAT- 2020/10/24 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/23 12:13
PHST- 2020/10/23 12:13 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.1002/hast.1180 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Sep;50(5):11-16. doi: 10.1002/hast.1180.


PMID- 33095270
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20211204
IS  - 1661-8564 (Electronic)
IS  - 1661-8556 (Linking)
VI  - 65
IP  - 9
DP  - 2020 Dec
TI  - Knowledge translation strategies designed for public health decision-making
      settings: a scoping review.
PG  - 1571-1580
LID - 10.1007/s00038-020-01506-z [doi]
AB  - OBJECTIVES: To review and describe available Knowledge Translation (KT)
      strategies that are designed for or applied in public health decision-making
      settings. INTRODUCTION: KT is the exchange, synthesis, and ethically sound
      application of knowledge. This review proposes that KT strategies in public
      health settings should be understood as action plans that promote evidence use
      and facilitate evidence-informed decision-making. METHODS: This scoping review
      included studies that reported on KT strategies applied in public health
      settings, published between 2010 and 2017. Studies were searched using Medline,
      online KT database, and citation tracing. Data from 305 included studies were
      synthesized using a coding form and conceptually mapped to identify KT strategies
      used in public health settings. RESULTS: A total of 124 unique examples of KT
      methods or tools were identified and summarized into 38 recommended and promising
      KT strategies. Built on the lists of recommended strategies, this review
      synthesized a framework that matched all 38 KT strategies to 10 key components of
      the evidence-informed decision-making process. CONCLUSIONS: The public health KT 
      strategies summarized and organized by this review promote a better understanding
      and more effective use of KT strategies.
FAU - Zhao, Naisi
AU  - Zhao N
AD  - Department of Public Health and Community Medicine, School of Medicine, Tufts
      University, 136 Harrison Ave, Boston, MA, 02111, USA.
FAU - Koch-Weser, Susan
AU  - Koch-Weser S
AD  - Department of Public Health and Community Medicine, School of Medicine, Tufts
      University, 136 Harrison Ave, Boston, MA, 02111, USA.
FAU - Lischko, Amy
AU  - Lischko A
AD  - Department of Public Health and Community Medicine, School of Medicine, Tufts
      University, 136 Harrison Ave, Boston, MA, 02111, USA.
FAU - Chung, Mei
AU  - Chung M
AUID- ORCID: http://orcid.org/0000-0002-5583-2870
AD  - Department of Public Health and Community Medicine, School of Medicine, Tufts
      University, 136 Harrison Ave, Boston, MA, 02111, USA. mei_chun.chung@tufts.edu.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201023
PL  - Switzerland
TA  - Int J Public Health
JT  - International journal of public health
JID - 101304551
SB  - IM
MH  - Decision Making
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Public Health
MH  - Translational Research, Biomedical/*organization & administration
OTO - NOTNLM
OT  - Knowledge Translation
OT  - Knowledge-to-action gap
OT  - Public health decision-making
OT  - Public health policy
EDAT- 2020/10/24 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/10/23 12:11
PHST- 2020/04/06 00:00 [received]
PHST- 2020/10/03 00:00 [accepted]
PHST- 2020/09/24 00:00 [revised]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/10/23 12:11 [entrez]
AID - 10.1007/s00038-020-01506-z [doi]
AID - 10.1007/s00038-020-01506-z [pii]
PST - ppublish
SO  - Int J Public Health. 2020 Dec;65(9):1571-1580. doi: 10.1007/s00038-020-01506-z.
      Epub 2020 Oct 23.


PMID- 33094947
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2575-3126 (Electronic)
IS  - 2575-3126 (Linking)
VI  - 14
IP  - 12
DP  - 2020 Oct
TI  - Low-Volume Local Anesthetics for C5 and Supraclavicular Nerve Blocks for Mid and 
      Lateral Clavicle Surgery: A Case Series.
PG  - e01322
LID - 10.1213/XAA.0000000000001322 [doi]
AB  - After institutional ethics committee approval and informed consent, 20 patients
      with clavicle fractures were recruited. An ultrasound-guided C5 root block was
      performed by injecting 3 mL of 0.5% bupivacaine with a subsequent
      ultrasound-guided supraclavicular nerve (SCN) block with 3 mL of 0.5%
      bupivacaine. A combination of low-volume C5 root block and SCN block provided
      reliable awake anesthesia and postoperative analgesia in patients with fractured 
      clavicles. This technique can avoid a general anesthesia for fractures of the mid
      and lateral clavicle. Further studies should focus on the optimal volume of local
      anesthetics required for the success of this technique.
FAU - Diwan, Sandeep
AU  - Diwan S
AD  - From the Department of Anesthesiology, Sancheti Hospital, Pune, Maharashtra,
      India.
FAU - Nair, Abhijit
AU  - Nair A
AD  - Department of Anesthesiology, Basavatarakam Indo-American Cancer Hospital and
      Research Institute, Hyderabad, Telangana, India.
FAU - Sermeus, Luc A
AU  - Sermeus LA
AD  - Department of Anaesthesiology, Cliniques Universitaires Saint Luc, Universite
      Catholique de Louvain, Brussels, Belgium.
FAU - Patil, Atul A
AU  - Patil AA
AD  - Department of Orthopedics, Sancheti Hospital, Pune, Maharashtra, India.
FAU - Attarde, Dheeraj Somnath
AU  - Attarde DS
AD  - Department of Orthopedics, Sancheti Hospital, Pune, Maharashtra, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - A A Pract
JT  - A&A practice
JID - 101714112
RN  - 0 (Anesthetics, Local)
SB  - IM
MH  - Anesthetics, Local
MH  - *Brachial Plexus/diagnostic imaging
MH  - *Brachial Plexus Block
MH  - Clavicle/surgery
MH  - Humans
MH  - Ultrasonography, Interventional
EDAT- 2020/10/24 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/23 11:51
PHST- 2020/10/23 11:51 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1213/XAA.0000000000001322 [doi]
AID - 02054229-202010000-00006 [pii]
PST - ppublish
SO  - A A Pract. 2020 Oct;14(12):e01322. doi: 10.1213/XAA.0000000000001322.


PMID- 33094905
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1612-1880 (Electronic)
IS  - 1612-1872 (Linking)
VI  - 17
IP  - 12
DP  - 2020 Dec
TI  - Characterization of beta-Cryptoxanthin and Other Carotenoid Derivatives from
      Rhodotorula taiwanensis, A Novel Yeast Isolated from Traditional Starter Culture 
      of Assam.
PG  - e2000198
LID - 10.1002/cbdv.202000198 [doi]
AB  - The present investigation was intended to characterize pigments for the first
      time from Rhodotorula taiwanensis (LC011412) yeast isolated from the ethic
      fermentation starter culture source meant to evaluate its carotenoid contents for
      beneficial applications. The pigments were extracted by an optimized solvent
      system, purified by flash chromatography and were identified by TLC and UV/VIS
      spectroscopy. The absorbance spectra confirmed the presence of beta-carotene,
      beta-cryptoxanthin, torulene and torularhodin that showed maximum absorbance
      (lambdamax ) within the ranges. The fractions were further characterized by LC/MS
      and analyzed through FT-IR and NMR for structure elucidation. Spectral analyses
      also confirmed the presence of the compounds mentioned above. These compounds
      promise great commercial value and could be useful for large scale production
      anticipated for potential applications in food, nutraceutical, pharmaceutical and
      cosmetic sectors. It is pertinent that the characterized carotenoid pigments from
      the isolate have incredible prospects in industrial applications which require
      profound attention.
CI  - (c) 2020 Wiley-VHCA AG, Zurich, Switzerland.
FAU - Parasar, Deep Prakash
AU  - Parasar DP
AD  - Microbial Communication and Fungal Biology Group, Department of Biotechnology,
      Gauhati University, 781014, Guwahati, Assam, India.
AD  - Department of Biotechnology, Assam Down Town University, 781026, Panikhaiti,
      Guwahati, Assam, India.
FAU - Ramakrishnan, Elancheran
AU  - Ramakrishnan E
AD  - Drug Discovery Lab, Department of Chemistry, Annamalai University, Annamalai
      Nagar, 608002, Tamil Nadu, India.
FAU - Kabilan, Senthamaraikannan
AU  - Kabilan S
AD  - Drug Discovery Lab, Department of Chemistry, Annamalai University, Annamalai
      Nagar, 608002, Tamil Nadu, India.
FAU - Kotoky, Jibon
AU  - Kotoky J
AD  - Drug Discovery Laboratory, Life Science Division, Institute of Advanced Study in 
      Science and Technology (IASST), Paschim Boragaon, 781035, Guwahati, Assam, India.
FAU - Sarma, Hridip Kumar
AU  - Sarma HK
AUID- ORCID: http://orcid.org/0000-0002-0786-9222
AD  - Microbial Communication and Fungal Biology Group, Department of Biotechnology,
      Gauhati University, 781014, Guwahati, Assam, India.
LA  - eng
GR  - Mishing community
GR  - Banaras Hindu University
GR  - Gauhati University
GR  - NEHU-SAIF
GR  - IASST
GR  - Guwahati Biotech Park
GR  - Institutional Biotech Hub of Gauhati University
GR  - Department of Botany, Gauhati University
GR  - BSR-UGC fellowship
GR  - CSIR
GR  - DST PURSE Phase-II
GR  - Annamalai University
GR  - BT/303/TBP/2012/Department of Biotechnology, Ministry of Science and Technology, 
      Govt. of India
PT  - Journal Article
DEP - 20201126
PL  - Switzerland
TA  - Chem Biodivers
JT  - Chemistry & biodiversity
JID - 101197449
RN  - 0 (Beta-Cryptoxanthin)
RN  - 36-88-4 (Carotenoids)
RN  - Rhodotorula taiwanensis
SB  - IM
MH  - Beta-Cryptoxanthin/*chemistry
MH  - Carotenoids/*chemistry
MH  - Chromatography, Liquid/methods
MH  - Magnetic Resonance Spectroscopy/methods
MH  - Mass Spectrometry/methods
MH  - Rhodotorula/*metabolism
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Yeasts/*isolation & purification
OTO - NOTNLM
OT  - Assam
OT  - Rhodotorula taiwanensis
OT  - carotenoid derivatives
OT  - ethnic community
OT  - traditional fermentation
EDAT- 2020/10/24 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/10/23 08:40
PHST- 2020/03/18 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/10/23 08:40 [entrez]
AID - 10.1002/cbdv.202000198 [doi]
PST - ppublish
SO  - Chem Biodivers. 2020 Dec;17(12):e2000198. doi: 10.1002/cbdv.202000198. Epub 2020 
      Nov 26.


PMID- 33094378
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 2092-9293 (Electronic)
IS  - 1976-9571 (Linking)
VI  - 42
IP  - 12
DP  - 2020 Dec
TI  - CRISPR: a journey of gene-editing based medicine.
PG  - 1369-1380
LID - 10.1007/s13258-020-01002-x [doi]
AB  - CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) is one of the
      hallmark of biological tools, contemplated as a valid and hopeful alternatives to
      genome editing. Advancements in CRISPR-based technologies have empowered
      scientists with an editing kit that allows them to employ their knowledge for
      deleting, replacing and lately "Gene Surgery", and provides unique control over
      genes in broad range of species, and presumably in humans. These fast-growing
      technologies have high strength and flexibility and are becoming an adaptable
      tool with implementations that are altering organism's genome and easily used for
      chromatin manipulation. In addition to the popularity of CRISPR in genome
      engineering and modern biology, this major tool authorizes breakthrough
      discoveries and methodological advancements in science. As scientists are
      developing new types of experiments, some of the applications are raising
      questions about what CRISPR can enable. The results of evidence-based research
      strongly suggest that CRISPR is becoming a practical tool for genome-engineering 
      and to create genetically modified eukaryotes, which is needed to establish
      guidelines on new regulatory concerns for scientific communities.
FAU - Golkar, Zhabiz
AU  - Golkar Z
AUID- ORCID: 0000-0002-0512-012X
AD  - Division of Academic Affairs, Voorhees College, Denmark, SC, USA.
      zgolkar@voorhees.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201022
PL  - Korea (South)
TA  - Genes Genomics
JT  - Genes & genomics
JID - 101481027
SB  - IM
MH  - Animals
MH  - *CRISPR-Cas Systems
MH  - Gene Editing/*methods
MH  - Humans
MH  - Precision Medicine
PMC - PMC7679360
OTO - NOTNLM
OT  - *Adaptive immunity
OT  - *Bacteria
OT  - *CRISPR
OT  - *Cas
OT  - *DNA
OT  - *Ethic
OT  - *Gene-editing
OT  - *Medicine
EDAT- 2020/10/24 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/10/23 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2020/10/23 06:00 [entrez]
AID - 10.1007/s13258-020-01002-x [doi]
AID - 10.1007/s13258-020-01002-x [pii]
PST - ppublish
SO  - Genes Genomics. 2020 Dec;42(12):1369-1380. doi: 10.1007/s13258-020-01002-x. Epub 
      2020 Oct 22.


PMID- 33094158
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Oct 16
TI  - An Interactive Approach to Teaching the Clinical Applications of Autonomy and
      Justice in the Context of Discharge Decision-Making.
PG  - 10992
LID - 10.15766/mep_2374-8265.10992 [doi]
AB  - Introduction: Students are taught the basics of medical ethics during their
      pre-clinical education, but need additional instruction on how to apply these
      principles to patient situations they may encounter during their clinical
      rotations. The ethical principles of autonomy and justice become especially
      pertinent to patient care in the setting of discharge decision-making. Third-year
      medical students would therefore benefit from an interactive educational activity
      that allows them to practice applying these principles within the context of
      discharge decision-making. Methods: This session was designed for third-year
      medical students completing their required rotation in neurology. Students
      participated in a 1-hour, facilitator-led, interactive, small-group, ethics-based
      activity meant to simulate the typical 4-day post-stroke hospital stay. Learning 
      objectives for the activity were to enhance students' understanding of the
      principles of autonomy, justice, competence, and capacity. Students were given
      pretest to gauge prior knowledge of activity learning objectives; their knowledge
      was again assessed afterwards, and they were surveyed on the usefulness and value
      of the activity. Results: Twenty-three third-year medical students completed the 
      activity over three sessions. The average improvement between pre- and posttest
      score was 40%. Lastly, on the qualitative feedback form, a majority of students
      strongly agreed that the activity was useful and presented new information, with 
      18 of 23 students giving the activity the highest possible rating of excellent.
      Discussion: A large majority of the students found the activity to be valuable,
      and the activity was shown to be effective at improving students' knowledge of a 
      key aspect of successful medical practice.
CI  - (c) 2020 Palanisamy and Xiong.
FAU - Palanisamy, Divya
AU  - Palanisamy D
AD  - Fourth-Year Medical Student, Case Western Reserve University School of Medicine.
FAU - Xiong, Wei
AU  - Xiong W
AD  - Assistant Dean for Clerkship Education, Case Western Reserve University School of
      Medicine; Core Clerkship Director and Assistant Professor, Department of
      Neurology, University Hospitals Cleveland Medical Center.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - Ethics, Medical
MH  - Humans
MH  - Patient Discharge
MH  - Problem-Based Learning
MH  - *Social Justice
MH  - *Students, Medical
PMC - PMC7566224
OTO - NOTNLM
OT  - *Autonomy
OT  - *Clinical Reasoning/Diagnostic Reasoning
OT  - *Clinical Teaching/Bedside Teaching
OT  - *Competence and Capacity
OT  - *Discharge Planning
OT  - *Ethics
OT  - *Ethics/Bioethics
OT  - *Feedback
OT  - *Justice
OT  - *Multimedia
OT  - *Neurology
OT  - *Qualitative Research
OT  - *Quality Improvement/Patient Safety
OT  - *Quantitative Research
EDAT- 2020/10/24 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/23 05:58
PHST- 2020/10/23 05:58 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10992 [doi]
AID - 10992 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Oct 16;16:10992. doi: 10.15766/mep_2374-8265.10992.


PMID- 33093965
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1999-768X (Print)
IS  - 1999-768X (Linking)
VI  - 35
IP  - 5
DP  - 2020 Sep
TI  - Modulation of Interleukin-8 Production by Vitamin D Supplementation in Indonesian
      Patients with Diabetic Polyneuropathy: A Randomized Clinical Trial.
PG  - e168
LID - 10.5001/omj.2020.110 [doi]
AB  - OBJECTIVES: We sought to assess the modulation of interleukin-8 (IL-8) production
      by vitamin D supplementation in Indonesian patients with diabetic polyneuropathy 
      (DPN). METHODS: We conducted a cohort prospective, randomized,
      placebo-controlled, double-blind trial. This study was approved by the Local
      Ethical Committee and conducted from July 2018 to February 2019. We recruited 50 
      subjects with type 2 diabetes mellitus attending Haji Adam Malik General Hospital
      Medan, and divided them into two groups. The groups were treated for 10 weeks,
      either with placebo or vitamin D (D3) supplementation of 50 000 IU/week. They
      were evaluated by routine nerve conduction study (NCS) in the upper and lower
      limbs, and their serum vitamin 25-hydroxyvitamin D (25(OH)D) and IL-8 levels
      before and 10 weeks after placebo or vitamin D supplementation were measured. The
      role of IL-8 and vitamin D supplementation on the NCS was analyzed using linear
      regression. RESULTS: There was a significant difference between the mean vitamin 
      25(OH)D (p = 0.001) and IL-8 levels (p = 0.002) before and after vitamin D
      supplementation. There was no significant correlation between changes in vitamin 
      25(OH)D and IL-8 levels (p = 0.743). There was significant role of IL-8 on
      amplitude of the sensory sural nerve (p = 0.047; B = -0.009) and the nerve
      conduction velocity (NCV) of the motor tibial nerve (p = 0.007; B = -0.027).
      There was a significant role of vitamin D supplementation on NCSs. CONCLUSIONS:
      Higher IL-8 levels were correlated with poorer amplitude of the sensory sural
      nerve and the NCV of motor tibial nerves. Lower vitamin 25(OH)D levels were
      correlated with poorer distal latencies, amplitudes, and NCVs. There was no
      significant correlation between vitamin 25(OH)D and IL-8 levels. Thus, no
      sufficient evidence that vitamin D supplementation modulates IL-8 in Indonesian
      patients with DPN. Vitamin D3 improved NCSs in diabetic patients.
CI  - The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.
FAU - Fitri, Aida
AU  - Fitri A
AD  - Department of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Medan, 
      Indonesia.
FAU - Sjahrir, Hasan
AU  - Sjahrir H
AD  - Department of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Medan, 
      Indonesia.
FAU - Bachtiar, Adang
AU  - Bachtiar A
AD  - Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
FAU - Ichwan, Muhammad
AU  - Ichwan M
AD  - Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas
      Sumatera Utara, Medan, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - Oman
TA  - Oman Med J
JT  - Oman medical journal
JID - 101526350
PMC - PMC7560522
OTO - NOTNLM
OT  - Calcifediol
OT  - Diabetic Neuropathies
OT  - Indonesia
OT  - Interleukin-8
EDAT- 2020/10/24 06:00
MHDA- 2020/10/24 06:01
CRDT- 2020/10/23 05:58
PHST- 2019/08/21 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/10/23 05:58 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/10/24 06:01 [medline]
AID - 10.5001/omj.2020.110 [doi]
AID - OMJ-35-05-1900136 [pii]
PST - epublish
SO  - Oman Med J. 2020 Sep 30;35(5):e168. doi: 10.5001/omj.2020.110. eCollection 2020
      Sep.


PMID- 33093363
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1536-4801 (Electronic)
IS  - 0277-2116 (Linking)
VI  - 71
IP  - 5
DP  - 2020 Nov
TI  - The Ethics of Feeding the Aspirating Child in an Age of Increasing Patient
      Complexity.
PG  - 586-588
LID - 10.1097/MPG.0000000000002919 [doi]
FAU - Rosen, Rachel
AU  - Rosen R
AD  - Division of Gastroenterology, Hepatology and Nutrition.
FAU - Kamin, Daniel
AU  - Kamin D
AD  - Division of Gastroenterology, Hepatology and Nutrition.
FAU - Simoneau, Tregony
AU  - Simoneau T
AD  - Division of Pulmonary and Respiratory Diseases.
FAU - Larson, Kara
AU  - Larson K
AD  - Division of Otolaryngology.
FAU - Hotz, Arda
AU  - Hotz A
AD  - Division of General Pediatrics, Complex Care Service, Boston Children's Hospital,
      Boston, MA.
FAU - Mauskar, Sangeeta
AU  - Mauskar S
AD  - Division of General Pediatrics, Complex Care Service, Boston Children's Hospital,
      Boston, MA.
FAU - Kahn, Stacy A
AU  - Kahn SA
AD  - Division of Gastroenterology, Hepatology and Nutrition.
LA  - eng
GR  - R01 DK097112/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Pediatr Gastroenterol Nutr
JT  - Journal of pediatric gastroenterology and nutrition
JID - 8211545
SB  - IM
MH  - Child
MH  - *Family
MH  - Humans
EDAT- 2020/10/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/23 05:51
PHST- 2020/10/23 05:51 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1097/MPG.0000000000002919 [doi]
AID - 00005176-202011000-00003 [pii]
PST - ppublish
SO  - J Pediatr Gastroenterol Nutr. 2020 Nov;71(5):586-588. doi:
      10.1097/MPG.0000000000002919.


PMID- 33093266
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201101
IS  - 1226-4512 (Print)
IS  - 1226-4512 (Linking)
VI  - 24
IP  - 6
DP  - 2020 Nov 1
TI  - Trends in the development of human stem cell-based non-animal drug testing
      models.
PG  - 441-452
LID - 10.4196/kjpp.2020.24.6.441 [doi]
AB  - In vivo animal models are limited in their ability to mimic the extremely complex
      systems of the human body, and there is increasing disquiet about the ethics of
      animal research. Many authorities in different geographical areas are considering
      implementing a ban on animal testing, including testing for cosmetics and
      pharmaceuticals. Therefore, there is a need for research into systems that can
      replicate the responses of laboratory animals and simulate environments similar
      to the human body in a laboratory. An in vitro two-dimensional cell culture model
      is widely used, because such a system is relatively inexpensive, easy to
      implement, and can gather considerable amounts of reference data. However, these 
      models lack a real physiological extracellular environment. Recent advances in
      stem cell biology, tissue engineering, and microfabrication techniques have
      facilitated the development of various 3D cell culture models. These include
      multicellular spheroids, organoids, and organs-on-chips, each of which has its
      own advantages and limitations. Organoids are organ-specific cell clusters
      created by aggregating cells derived from pluripotent, adult, and cancer stem
      cells. Patient-derived organoids can be used as models of human disease in a
      culture dish. Biomimetic organ chips are models that replicate the physiological 
      and mechanical functions of human organs. Many organoids and organ-on-a-chips
      have been developed for drug screening and testing, so competition for patents
      between countries is also intensifying. We analyzed the scientific and
      technological trends underlying these cutting-edge models, which are developed
      for use as non-animal models for testing safety and efficacy at the nonclinical
      stages of drug development.
FAU - Lee, Su-Jin
AU  - Lee SJ
AD  - Department of Predictive Toxicology, Korea Institute of Toxicology, Korea
      Research Institute of Chemical Technology, Daejeon 34114, Korea.
FAU - Lee, Hyang-Ae
AU  - Lee HA
AD  - Department of Predictive Toxicology, Korea Institute of Toxicology, Korea
      Research Institute of Chemical Technology, Daejeon 34114, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Korean J Physiol Pharmacol
JT  - The Korean journal of physiology & pharmacology : official journal of the Korean 
      Physiological Society and the Korean Society of Pharmacology
JID - 9709505
PMC - PMC7585597
OTO - NOTNLM
OT  - In vitro model
OT  - Non-clinical testing
OT  - Organ-on-a-chip
OT  - Organoid
OT  - Stem cell
EDAT- 2020/10/24 06:00
MHDA- 2020/10/24 06:01
CRDT- 2020/10/23 05:50
PHST- 2020/08/18 00:00 [received]
PHST- 2020/08/31 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/10/23 05:50 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/10/24 06:01 [medline]
AID - kjpp.2020.24.6.441 [pii]
AID - 10.4196/kjpp.2020.24.6.441 [doi]
PST - ppublish
SO  - Korean J Physiol Pharmacol. 2020 Nov 1;24(6):441-452. doi:
      10.4196/kjpp.2020.24.6.441.


PMID- 33093038
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 22
TI  - Impact of non-pharmaceutical interventions for reducing transmission of COVID-19:
      a systematic review and meta-analysis protocol.
PG  - e041383
LID - 10.1136/bmjopen-2020-041383 [doi]
AB  - INTRODUCTION: Implementing non-pharmaceutical interventions (NPIs) protect the
      public from COVID-19. However, the impact of NPIs has been inconsistent and
      remains unclear. This study, therefore, aims to measure the impact of major NPIs 
      (social distancing, social isolation and quarantine) on reducing COVID-19
      transmission. METHODS AND ANALYSIS: We will conduct a systematic review and
      meta-analysis research of both randomised and non-randomised controlled trials.
      We will undertake a systematic search of: MEDLINE, Embase, Allied & Complementary
      Medicine, COVID-19 Research, WHO database on COVID-19, ClinicalTrails.Gov for
      clinical trials on COVID-19, Cochrane Resources on Coronavirus (COVID-19), Oxford
      COVID-19 Evidence Service and Google Scholar for published and unpublished
      literatures on COVID-19 including preprint engines such as medRxiv, bioRxiv,
      Litcovid and SSRN for unpublished studies on COVID-19 and will be reported in
      accordance with Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses. Outcomes of interest for impact analysis will include the
      reduction of COVID-19 transmission, avoiding crowds and restricting movement,
      isolating ill and psychological impacts. The Preferred Reporting Items for
      Systematic Review and Meta-Analysis Protocols checklist has been used for this
      protocol. For quality of included studies, we will use the Cochrane
      Collaboration's tool for assessing risk of bias for randomised controlled trials 
      and the Newcastle-Ottawa Scale for observational studies. The Grading of
      Recommendations Assessment, Development and Evaluation approach will grade the
      certainty of the evidence for all outcome measures across studies. Random-effects
      model for meta-analysis will measure the effect size of NPIs or the strengths of 
      relationships. For quantitative data, risk ratio or OR, absolute risk difference 
      (for dichotomous outcome data), or mean difference or standardised mean
      difference (for continuous data) and their 95% CIs will be calculated. Where
      statistical pooling is not possible, a narrative synthesis will be conducted for 
      the included studies. To assess the heterogeneity of effects, I(2) together with 
      the observed effects will be evaluated to provide the true effects in the
      analysis. ETHICS AND DISSEMINATION: Formal ethical approval from an institutional
      review board or research ethics committee is not required as primary data will
      not be collected. The final results of this study will be published in an
      open-access peer-reviewed journal, and abstract will be presented at suitable
      national/international conferences or workshops. We will also share important
      information with public health authorities as well as with the WHO. In addition, 
      we may post the submitted manuscript under review to medRxiv, or other relevant
      preprint servers. TRIAL REGISTRATION NUMBER: CRD42020207338.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Regmi, Krishna
AU  - Regmi K
AUID- ORCID: 0000-0002-1408-1978
AD  - Institute for Health Research, Faculty of Health and Social Sciences, University 
      of Bedfordshire, Luton, UK Krishna.r.regmi@gmail.com.
FAU - Lwin, Cho Mar
AU  - Lwin CM
AD  - Department of Rheumatology, University of Medicine Mandalay, Mandalay, Myanmar.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/methods
MH  - *Coronavirus Infections/epidemiology/prevention & control/transmission
MH  - Disease Transmission, Infectious/*prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control/transmission
MH  - Public Health/methods/statistics & numerical data
MH  - Quarantine/*methods
MH  - Research Design
MH  - SARS-CoV-2
MH  - *Social Isolation
MH  - Systematic Reviews as Topic
PMC - PMC7582337
OTO - NOTNLM
OT  - *COVID-19
OT  - *epidemiology
OT  - *infection control
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/24 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/23 05:49
PHST- 2020/10/23 05:49 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - bmjopen-2020-041383 [pii]
AID - 10.1136/bmjopen-2020-041383 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 22;10(10):e041383. doi: 10.1136/bmjopen-2020-041383.


PMID- 33093037
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 22
TI  - Assessing care trajectories of adolescent females seeking early induced abortion 
      in New South Wales: multistage, mixed-methods study protocol.
PG  - e039819
LID - 10.1136/bmjopen-2020-039819 [doi]
AB  - INTRODUCTION: In Australia, New South Wales (NSW), abortion has recently been
      removed from the criminal code. Previous research from Australia and other
      high-income countries has focused on adult women's access to abortion services.
      This protocol describes a five-stage mixed-methods study to determine the care
      trajectories and experiences of adolescent females, aged 16-19 years, seeking an 
      early induced abortion in NSW. The aims are to (1) explore the needs and
      perspectives of adolescent females seeking sexual and reproductive health
      services in NSW and (2) develop a framework for abortion service provision for
      adolescents in NSW. METHODS AND ANALYSIS: This study comprises: (1)
      semistructured qualitative interviews with key informants, individuals with
      diverse, in-depth experience of providing and/or supporting abortion care in NSW;
      (2) a cross-sectional online survey of adolescent females residing in NSW; (3)
      case study interviews with adolescents females who have accessed an abortion
      service in NSW; (4) a co-design workshop with adolescents who took part in stage 
      3 to develop relevant knowledge and recommendations and (5) a knowledge
      dissemination forum with key stakeholders. ETHICS AND DISSEMINATION: Ethics
      approval has been received from the University of Technology Sydney Human
      Research Ethics Committee for this study. Data collection commenced in March 2019
      and will continue until the end of 2020. This study aims to develop a deep
      understanding of adolescent abortion care trajectories and experiences of
      abortion services in NSW. The study will deliver co-produced recommendations to
      improve adolescent access to abortion information and services.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Assifi, Anisa Rojanapenkul
AU  - Assifi AR
AUID- ORCID: 0000-0001-5295-4074
AD  - School of Public Health, Faculty of Health, University of Technology Sydney,
      Sydney, New South Wales, Australia anisamra@gmail.com.
FAU - Kang, Melissa
AU  - Kang M
AUID- ORCID: 0000-0002-9438-2518
AD  - School of Public Health, Faculty of Health, University of Technology Sydney,
      Sydney, New South Wales, Australia.
FAU - Sullivan, Elizabeth
AU  - Sullivan E
AUID- ORCID: 0000-0002-8718-2753
AD  - Office of the PVC Health and Medicine, Faculty of Health and Medicine, The
      University of Newcastle, Callaghan, New South Wales, Australia.
FAU - Dawson, Angela J
AU  - Dawson AJ
AUID- ORCID: 0000-0003-0926-2202
AD  - School of Public Health, Faculty of Health, University of Technology Sydney,
      Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201022
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Abortion, Induced
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Health Services Accessibility
MH  - Humans
MH  - New South Wales
MH  - Pregnancy
MH  - Young Adult
PMC - PMC7583066
OTO - NOTNLM
OT  - *health services administration & management
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/23 05:49
PHST- 2020/10/23 05:49 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039819 [pii]
AID - 10.1136/bmjopen-2020-039819 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 22;10(10):e039819. doi: 10.1136/bmjopen-2020-039819.


PMID- 33093035
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 22
TI  - Histopathological features of prostate cancer conspicuity on multiparametric MRI:
      protocol for a systematic review and meta-analysis.
PG  - e039735
LID - 10.1136/bmjopen-2020-039735 [doi]
AB  - INTRODUCTION: Multiparametric MRI (mpMRI) has improved risk stratification for
      men with suspected prostate cancer. Indeed, mpMRI-visible tumours tend to be
      larger and of higher pathological grade than mpMRI-invisible tumours; however,
      concern remains around significant cancer that is undetected by mpMRI. There has 
      been considerable recent interest to investigate whether tumour conspicuity on
      mpMRI is associated with additional histopathological features (including
      cellular density, microvessel density and unusual prostate cancer subtypes),
      which may have important clinical implications in both diagnosis and prognosis.
      Furthermore, analysis of these features may help reveal the radiobiology that
      underpins the actual mechanisms of mpMRI visibility (and invisibility) of
      prostate tumours. Here, we describe a protocol for a systematic review of the
      histopathological basis of prostate cancer conspicuity on mpMRI. METHODS AND
      ANALYSIS: A systematic search of the MEDLINE, PubMed, Embase and Cochrane
      databases will be conducted. The Preferred Reporting Items for Systematic Reviews
      and Meta-Analyses (PRISMA) guidelines will be used to guide screening, thematic
      reporting and conclusions drawn from all eligible studies. Included papers will
      be full-text, English-language articles, comparing the histopathological
      characteristics of mpMRI-visible lesions and mpMRI-invisible tumours. All studies
      published between January 1950 and January 2020 will be eligible for inclusion.
      Studies using confirmatory immunohistochemistry for the identification of immune 
      subsets or structural components will be included. Study bias and quality will be
      assessed using a modified Newcastle-Ottawa scale. To ensure methodological
      rigour, this protocol is written in accordance with the PRISMA Protocol 2015
      checklist. If appropriate, a meta-analysis will be conducted comparing
      histopathological feature frequency between mpMRI-visible and mpMRI-invisible
      disease. ETHICS AND DISSEMINATION: No ethical approval will be required as this
      is an academic review of published literature. Findings will be disseminated
      through publications in peer-reviewed journals and presentations at national and 
      international conferences. PROSPERO REGISTRATION NUMBER: CRD42020176049.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Norris, Joseph M
AU  - Norris JM
AUID- ORCID: 0000-0003-2294-0303
AD  - UCL Division of Surgery and Interventional Science, University College London,
      London, UK joseph.norris@ucl.ac.uk.
FAU - Carmona Echeverria, Lina M
AU  - Carmona Echeverria LM
AD  - UCL Division of Surgery and Interventional Science, University College London,
      London, UK.
FAU - Simpson, Benjamin S
AU  - Simpson BS
AUID- ORCID: 0000-0003-3685-6110
AD  - UCL Division of Surgery and Interventional Science, University College London,
      London, UK.
FAU - Ball, Rhys
AU  - Ball R
AD  - Department of Pathology, University College London Hospitals NHS Foundation
      Trust, London, UK.
FAU - Freeman, Alex
AU  - Freeman A
AD  - Department of Pathology, University College London Hospitals NHS Foundation
      Trust, London, UK.
FAU - Kelly, Daniel
AU  - Kelly D
AUID- ORCID: 0000-0002-1847-0655
AD  - School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, South Glamorgan, UK.
FAU - Kirkham, Alex
AU  - Kirkham A
AD  - Department of Radiology, University College London Hospitals NHS Foundation
      Trust, London, UK.
FAU - Whitaker, Hayley C
AU  - Whitaker HC
AD  - UCL Division of Surgery and Interventional Science, University College London,
      London, UK.
FAU - Emberton, Mark
AU  - Emberton M
AD  - UCL Division of Surgery and Interventional Science, University College London,
      London, UK.
LA  - eng
GR  - MR/S00680X/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201022
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - *Multiparametric Magnetic Resonance Imaging
MH  - *Prostatic Neoplasms/diagnostic imaging
PMC - PMC7583062
OTO - NOTNLM
OT  - *MRI
OT  - *histopathology
OT  - *prostate disease
OT  - *urological tumours
COIS- Competing interests: JMN received funding from the MRC. BSSS received funding
      from the Rosetrees Trust. LMCE received funding from PCUK. HCW received funding
      from PCUK, the Urology Foundation and the Rosetrees Trust. AK, AF and ME have
      stock interest in Nuada Medical. ME received funding from NIHR-i4i, MRC,
      Sonacare, Trod Medical, Cancer Vaccine Institute and Sophiris Biocorp for trials 
      in prostate cancer. ME is a medical consultant to Sonacare, Sophiris Biocorp,
      Steba Biotech, GSK, Exact Imaging and Profound Medical. Travel allowance was
      previously provided from Sanofi Aventis, Astellas, GSK and Sonacare. ME is a
      proctor for HIFU with Sonacare Inc. and paid for training other surgeons in this 
      procedure.
EDAT- 2020/10/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/23 05:49
PHST- 2020/10/23 05:49 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039735 [pii]
AID - 10.1136/bmjopen-2020-039735 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 22;10(10):e039735. doi: 10.1136/bmjopen-2020-039735.


PMID- 33093034
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 22
TI  - The role of concomitant ligament injury in the development of post-traumatic
      osteoarthritis after distal radius fractures: a protocol for a systematic review.
PG  - e039591
LID - 10.1136/bmjopen-2020-039591 [doi]
AB  - INTRODUCTION: Treatment of distal radius fractures (DRFs) aims to restore
      anatomic position of the fracture fragments and congruity of the articular
      surface to optimise functional outcomes and prevent osteoarthritis in the long
      term. While ligament injury of the wrist is often associated with DRFs and sole
      ligament injuries of the wrist lead to osteoarthritis, it is plausible that
      concomitant ligament injury in DRFs may aggravate degenerative changes of the
      wrist. The relationship between concomitant ligament injury and post-traumatic
      osteoarthritis in patients with DRFs is unclear. This study aims to identify the 
      types of associated ligament injury in patients with a DRF and to elucidate the
      association of ligament injury on the development of post-traumatic
      osteoarthritis. METHODS AND ANALYSIS: This protocol is written in accordance with
      the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol
      (PRISMA-P) guidelines. An electronic search in MEDLINE, Embase, Web of Science,
      Cochrane Central Register of Trials and Google Scholar has been created and
      performed by a Health Sciences librarian with expertise in systematic review
      searching. Original research articles in English literature, which report on
      concomitant ligament injury of the wrist in relation to post-traumatic
      osteoarthritis, patient-reported outcome measures or clinician-reported outcome
      measures in patients (aged >/=18 years) with DRFs will be included. Two reviewers
      will independently screen and appraise articles and perform data extraction. In
      case of any disagreements, a third reviewer will be consulted. A systematic
      qualitative synthesis will be performed using text and tables. ETHICS AND
      DISSEMINATION: No ethical approval is required, since this is a protocol for a
      systematic review. The systematic review will be submitted for publication in a
      peer-reviewed scientific journal and for presentation at relevant conferences.
      PROSPERO REGISTRATION NUMBER: CRD42020165007.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Slichter, Malou E
AU  - Slichter ME
AUID- ORCID: 0000-0002-7085-8622
AD  - Department of Orthopaedic Surgery, Reinier de Graaf Hospital, Delft, The
      Netherlands m.slichter@rdgg.nl.
FAU - Kraan, Gerald A
AU  - Kraan GA
AD  - Department of Orthopaedic Surgery, Reinier de Graaf Hospital, Delft, The
      Netherlands.
FAU - Bramer, Wichor M
AU  - Bramer WM
AD  - Medical Library, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Colaris, Joost W
AU  - Colaris JW
AD  - Department of Orthopaedic Surgery, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Mathijssen, Nina M C
AU  - Mathijssen NMC
AD  - Department of Orthopaedic Surgery, Reinier de Graaf Hospital, Delft, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201022
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Delivery of Health Care
MH  - Humans
MH  - Ligaments
MH  - Meta-Analysis as Topic
MH  - *Osteoarthritis/etiology
MH  - *Radius Fractures/complications
MH  - Research Design
PMC - PMC7583071
OTO - NOTNLM
OT  - *adult surgery
OT  - *hand & wrist
OT  - *musculoskeletal disorders
OT  - *orthopaedic & trauma surgery
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/10/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/23 05:49
PHST- 2020/10/23 05:49 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039591 [pii]
AID - 10.1136/bmjopen-2020-039591 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 22;10(10):e039591. doi: 10.1136/bmjopen-2020-039591.


PMID- 33093033
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 22
TI  - Protocol for a prospective, observational, hospital-based multicentre study of
      nosocomial SARS-CoV-2 transmission: NOSO-COR Project.
PG  - e039088
LID - 10.1136/bmjopen-2020-039088 [doi]
AB  - INTRODUCTION: The newly identified SARS-CoV-2 can cause serious acute respiratory
      infections such as pneumonia. In France, mortality rate in the general population
      was approximately 10% and could reach higher levels at the hospital. In the
      current context of high incidence rates of SARS-CoV-2 in the community, a
      significant increase in the rate of nosocomial transmission is expected. The risk
      of nosocomial transmission could even be higher in low-income countries that have
      fragile healthcare systems. This protocol is intended to estimate the prevalence 
      and incidence of suspected or confirmed cases of nosocomial SARS-CoV-2 infection,
      the clinical spectrum and the determinants (risk factors/protective) at
      participating hospitals. METHODS AND ANALYSIS: This will be an international
      multicentre prospective, observational, hospital-based study in adults and
      children. It will include volunteer patients and healthcare professionals in
      France and hospitals affiliated with the GABRIEL network. Demographic and
      clinical data will be collected using case report forms designed especially for
      the purpose of the project. A nasopharyngeal swab will be collected and tested
      for SARS-CoV-2 by reverse-transcriptase PCR. Characteristics of the study
      participants, the proportion of confirmed nosocomial SARS-CoV-2 infections
      relative to all patients with syndromes suggestive of SARS-CoV-2 infection, will 
      be analysed. Appropriate multivariate modelling will be used to identify the
      determinants associated with nosocomial onset. ETHICS AND DISSEMINATION: This
      study was approved by the clinical research and committee of all participating
      countries. The findings will be submitted to peer-reviewed journal for
      publication and shared with national health authorities. TRIAL REGISTRATION
      NUMBER: NCT04290780.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Saadatian-Elahi, Mitra
AU  - Saadatian-Elahi M
AUID- ORCID: 0000-0003-1265-8806
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
AD  - Service Hygiene, Epidemiologie et Prevention, Centre Hospitalier Edouard Herriot,
      Hospices Civils de Lyon, Lyon, France.
FAU - Picot, Valentina
AU  - Picot V
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
AD  - Fondation Merieux, Lyon, Rhone-Alpes, France.
FAU - Henaff, Laetitia
AU  - Henaff L
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
FAU - Pradel, Florence K
AU  - Pradel FK
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
AD  - Fondation Merieux, Lyon, Rhone-Alpes, France.
FAU - Escuret, Vanessa
AU  - Escuret V
AD  - Laboratoire de Virologie, Institut des Agents Infectieux, Hopital de la
      Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
AD  - Virpath, Grippe, de l'emergence au controle, Centre International de Recherche en
      Infectiologie (CIRI), Inserm U111, CNRS 5308, ENS, UCBL1, Faculte de Medecine RTH
      Laennec, Lyon, France.
FAU - Dananche, Cedric
AU  - Dananche C
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
AD  - Service Hygiene, Epidemiologie et Prevention, Centre Hospitalier Edouard Herriot,
      Hospices Civils de Lyon, Lyon, France.
FAU - Elias, Christelle
AU  - Elias C
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
AD  - Service Hygiene, Epidemiologie et Prevention, Centre Hospitalier Edouard Herriot,
      Hospices Civils de Lyon, Lyon, France.
FAU - Endtz, Hubert P
AU  - Endtz HP
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France.
AD  - Fondation Merieux, Lyon, Rhone-Alpes, France.
FAU - Vanhems, Philippe
AU  - Vanhems P
AD  - Laboratoire des Pathogenes Emergents, Fondation Merieux, Centre International de 
      Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, Lyon, France
      philippe.vanhems@chu-lyon.fr.
AD  - Service Hygiene, Epidemiologie et Prevention, Centre Hospitalier Edouard Herriot,
      Hospices Civils de Lyon, Lyon, France.
AD  - Inserm, F-CRIN, Lyon center of Innovative Clinical Research Network in
      Vaccinology (I REIVAC), CIC 1417, Paris, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04290780
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20201022
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/epidemiology/*transmission
MH  - Cross Infection/*epidemiology
MH  - Female
MH  - France/epidemiology
MH  - Hospitals/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology/*transmission
MH  - Prospective Studies
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Young Adult
PMC - PMC7582335
OTO - NOTNLM
OT  - *epidemiology
OT  - *infection control
OT  - *infectious diseases
OT  - *protocols and guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/24 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/10/23 05:49
PHST- 2020/10/23 05:49 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - bmjopen-2020-039088 [pii]
AID - 10.1136/bmjopen-2020-039088 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 22;10(10):e039088. doi: 10.1136/bmjopen-2020-039088.


PMID- 33093030
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 22
TI  - 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled 
      clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the
      pharyngeal carriage of meningococci in adolescents.
PG  - e037358
LID - 10.1136/bmjopen-2020-037358 [doi]
AB  - INTRODUCTION: Capsular group B Neisseria meningitidis (MenB) is the most common
      cause of invasive meningococcal disease (IMD) in many parts of the world. A MenB 
      vaccine directed against the polysaccharide capsule remains elusive due to poor
      immunogenicity and safety concerns. The vaccines licensed for the prevention of
      MenB disease, 4CMenB (Bexsero) and MenB-fHbp (Trumenba), are serogroup B
      'substitute' vaccines, comprised of subcapsular proteins and are designed to
      provide protection against most MenB disease-causing strains. In many high-income
      countries, such as the UK, adolescents are at increased risk of IMD and have the 
      highest rates of meningococcal carriage. Beginning in the late 1990s,
      immunisation of this age group with the meningococcal group C conjugate vaccine
      reduced asymptomatic carriage and disrupted transmission of this organism,
      resulting in lower group C IMD incidence across all age groups. Whether
      vaccinating teenagers with the novel 'MenB' protein-based vaccines will prevent
      acquisition or reduce duration of carriage and generate herd protection was
      unknown at the time of vaccine introduction and could not be inferred from the
      effects of the conjugate vaccines. 4CMenB and MenB-fHbp may also impact on
      non-MenB disease-causing capsular groups as well as commensal Neisseria spp. This
      study will evaluate the impact of vaccination with 4CMenB or MenB-fHbp on
      oropharyngeal carriage of pathogenic meningococci in teenagers, and consequently 
      the potential for these vaccines to provide broad community protection against
      MenB disease. METHODS AND ANALYSIS: The 'Be on the TEAM' (Teenagers Against
      Meningitis) Study is a pragmatic, partially randomised controlled trial of 24 000
      students aged 16-19 years in their penultimate year of secondary school across
      the UK with regional allocation to a 0+6 month schedule of 4CMenB or MenB-fHbp or
      to a control group. Culture-confirmed oropharyngeal carriage will be assessed at 
      baseline and at 12 months, following which the control group will be eligible for
      4CMenB vaccination. The primary outcome is the carriage prevalence of potentially
      pathogenic meningococci (defined as those with genogroups B, C, W, Y or X), in
      each vaccine group compared separately to the control group at 12 months
      post-enrolment, that is, 12 months after the first vaccine dose and 6 months
      after the second vaccine dose. Secondary outcomes include impact on carriage of: 
      genogroup B meningococci; hyperinvasive meningococci; all meningococci; those
      meningococci expressing vaccine antigens and; other Neisseria spp. A sample size 
      of 8000 in each arm will provide 80% power to detect a 30% reduction in
      meningococcal carriage, assuming genogroup B, C, W, Y or X meningococci carriage 
      of 3.43%, a design effect of 1.5, a retention rate of 80% and a significance
      level of 0.05. Study results will be available in 2021 and will inform the UK and
      international immunisation policy and future vaccine development. ETHICS AND
      DISSEMINATION: This study is approved by the National Health Service South
      Central Research Ethics Committee (18/SC/0055); the UK Health Research Authority 
      (IRAS ID 239091) and the UK Medicines and Healthcare products Regulatory Agency. 
      Publications arising from this study will be submitted to peer-reviewed journals.
      Study results will be disseminated in public forums, online, presented at local
      and international conferences and made available to the participating schools.
      TRIAL REGISTRATION NUMBERS: ISRCTN75858406; Pre-results, EudraCT 2017-004609-42.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Carr, Jeremy
AU  - Carr J
AUID- ORCID: 0000-0002-2729-0920
AD  - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
      jeremy.carr@paediatrics.ox.ac.uk.
FAU - Plested, Emma
AU  - Plested E
AD  - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
      UK.
AD  - National Institute for Health Research Oxford Biomedical Research Centre, Oxford,
      Oxfordshire, UK.
FAU - Aley, Parvinder
AU  - Aley P
AD  - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
      UK.
AD  - National Institute for Health Research Oxford Biomedical Research Centre, Oxford,
      Oxfordshire, UK.
FAU - Camara, Susana
AU  - Camara S
AD  - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
      UK.
AD  - National Institute for Health Research Oxford Biomedical Research Centre, Oxford,
      Oxfordshire, UK.
FAU - Davis, Kimberly
AU  - Davis K
AD  - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
      UK.
FAU - MacLennan, Jenny M
AU  - MacLennan JM
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Gray, Steve
AU  - Gray S
AD  - Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, 
      Manchester, UK.
FAU - Faust, Saul N
AU  - Faust SN
AUID- ORCID: 0000-0003-3410-7642
AD  - NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical
      Research Centre, University of Southampton and University Hospital Southampton
      NHS Foundation Trust, Southampton, UK.
AD  - Faculty of Medicine and Institute of Life Sciences, University of Southampton,
      Southampton, UK.
FAU - Borrow, Ray
AU  - Borrow R
AD  - Meningococcal Reference Unit, Public Health England, Manchester Royal Infirmary, 
      Manchester, UK.
FAU - Christensen, Hannah
AU  - Christensen H
AD  - School of Population Health Sciences, Bristol Medical School, University of
      Bristol, Bristol, UK.
FAU - Trotter, Caroline
AU  - Trotter C
AUID- ORCID: 0000-0003-4000-2708
AD  - Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
FAU - Maiden, Martin C J
AU  - Maiden MCJ
AUID- ORCID: 0000-0001-6321-5138
AD  - Department of Zoology, University of Oxford, Oxford, UK.
FAU - Finn, Adam
AU  - Finn A
AUID- ORCID: 0000-0003-1756-5668
AD  - School of Population Health Sciences, Bristol Medical School, University of
      Bristol, Bristol, UK.
FAU - Snape, Matthew D
AU  - Snape MD
AD  - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
      UK.
AD  - National Institute for Health Research Oxford Biomedical Research Centre, Oxford,
      Oxfordshire, UK.
CN  - 'Be on the TEAM' investigators
LA  - eng
SI  - ISRCTN/ISRCTN75858406
SI  - EudraCT/2017-004609-42
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201022
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Meningococcal Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Humans
MH  - *Meningitis
MH  - *Meningococcal Infections/epidemiology/prevention & control
MH  - *Meningococcal Vaccines
MH  - *Neisseria meningitidis
MH  - *Neisseria meningitidis, Serogroup B
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
MH  - Vaccination
MH  - Young Adult
PMC - PMC7583083
OTO - NOTNLM
OT  - *Paediatric infectious disease and immunisation
OT  - *Paediatric intensive and critical care
OT  - *infectious diseases
OT  - *paediatrics
COIS- Competing interests: AF reports grants from the Department of Health, during the 
      conduct of the study; grants from Pfizer, grants from GSK, outside the submitted 
      work. HC reports other from Sanofi Pasteur, other from IMS Health, grants from
      National Institute for Health Research, other from AstraZeneca, grants and other 
      from GSK, outside the submitted work. MS reports grants from National Institute
      for Health Research (NIHR), non-financial support from Pfizer, during the conduct
      of the study; grants from Pfizer, grants from MCM, grants from GlaxoSmithKline,
      grants from Novavax, grants from Medimmune, grants from Janssen, outside the
      submitted work. SC reports salary contribution from the study NIHR grant, during 
      the conduct of the study. SF reports personal fees were paid to his institution
      (with no personal payment of any kind) from AstraZeneca/Medimmune, Sanofi,
      Pfizer, Seqirus, Sandoz, Merck, GSK, Alios, Johnson & Johnson and Merck, outside 
      the submitted work. RB reports grants from University of Oxford via a NIHR grant,
      during the conduct of the study; contract research on behalf of Public Health
      England for GSK, Pfizer and Sanofi Pasteur, outside the submitted work.
IR  - Smith A
FIR - Smith, Andrew
IR  - Williams C
FIR - Williams, Christopher
IR  - Zipitis C
FIR - Zipitis, Christos
IR  - Cameron C
FIR - Cameron, Claire
IR  - Baxter D
FIR - Baxter, David
IR  - Orr D
FIR - Orr, David
IR  - Turner D
FIR - Turner, David
IR  - Whittaker E
FIR - Whittaker, Elizabeth
IR  - Fidler K
FIR - Fidler, Katy
IR  - Raman M
FIR - Raman, Mala
IR  - Heath P
FIR - Heath, Paul
IR  - Gowda R
FIR - Gowda, Rohit
IR  - Hughes S
FIR - Hughes, Stephen
IR  - Khajuria S
FIR - Khajuria, Sujata
EDAT- 2020/10/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/23 05:49
PHST- 2020/10/23 05:49 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037358 [pii]
AID - 10.1136/bmjopen-2020-037358 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 22;10(10):e037358. doi: 10.1136/bmjopen-2020-037358.


PMID- 33092776
OWN - NLM
STAT- MEDLINE
DCOM- 20211208
LR  - 20211214
IS  - 1877-1300 (Electronic)
IS  - 1877-1297 (Linking)
VI  - 12
IP  - 12
DP  - 2020 Dec
TI  - "Providing care across a language barrier" - A program at the intersection of
      inter-professional education and co-curricular engagement.
PG  - 1461-1469
LID - S1877-1297(20)30256-2 [pii]
LID - 10.1016/j.cptl.2020.07.016 [doi]
AB  - BACKGROUND AND PURPOSE: As the number of patients with limited English
      proficiency (LEP) in the United States grows, so does the importance of finding
      solutions for the unique challenges that may arise in the healthcare arena. The
      need for culturally and linguistically appropriate services (CLAS) is clear, and 
      this topic provides fertile ground for interprofessional collaboration both in
      practice and education. EDUCATIONAL ACTIVITY AND SETTING: The authors present a
      description of a six-hour interdisciplinary program offered as a dual continuing 
      education and co-curricular opportunity for faculty, preceptors, and students in 
      health professional programs at one university. The program covered topics
      related to CLAS, such as Spanish language basics, ethical considerations when
      language barriers are present, common misconceptions that exist, and strategies
      and resources to improve care for LEP patients. FINDINGS: A total of 24
      participants (four nurses, two nurse practitioners, six pharmacists, two nursing 
      students, and 10 pharmacy students) completed the program. Post-evaluation
      responses revealed that 94% of participants would change how they cared for
      patients as a result of the home study, with 80% concordance for each of the live
      sessions. DISCUSSION: Responses provided helpful feedback for integration of
      these topics into coursework and on the value of resources for current
      practitioners, ultimately highlighting the value of an inter-professional
      training module for delivery of the content. This program was a positively
      received offering that enhanced inter-professional education and co-curricular
      offerings on an important topic.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Greene, Elisa
AU  - Greene E
AD  - Pharmacy Practice, Belmont University College of Pharmacy, 1900 Belmont Blvd,
      Nashville, TN 37212, United States. Electronic address: Elisa.greene@belmont.edu.
FAU - Adam, Jamie
AU  - Adam J
AD  - Nursing, Belmont University College of Health Sciences, 1900 Belmont Blvd,
      Nashville, TN 37212, United States. Electronic address: Jamie.adam@belmont.edu.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - United States
TA  - Curr Pharm Teach Learn
JT  - Currents in pharmacy teaching & learning
JID - 101560815
SB  - IM
MH  - Communication Barriers
MH  - *Education, Professional
MH  - Health Personnel/education
MH  - Humans
MH  - *Students, Nursing
MH  - *Students, Pharmacy
MH  - United States
OTO - NOTNLM
OT  - *Co-curriculum
OT  - *Continuing professional development
OT  - *Inter-professional education
OT  - *Limited English proficiency, cross-cultural care
COIS- Declaration of Competing Interest None
EDAT- 2020/10/24 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/10/23 05:35
PHST- 2019/10/04 00:00 [received]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/10/23 05:35 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - S1877-1297(20)30256-2 [pii]
AID - 10.1016/j.cptl.2020.07.016 [doi]
PST - ppublish
SO  - Curr Pharm Teach Learn. 2020 Dec;12(12):1461-1469. doi:
      10.1016/j.cptl.2020.07.016. Epub 2020 Aug 6.


PMID- 33092593
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 22
TI  - "Can virtue be taught?": a content analysis of medical students' opinions of the 
      professional and ethical challenges to their professional identity formation.
PG  - 380
LID - 10.1186/s12909-020-02313-z [doi]
AB  - BACKGROUND: Efforts have begun to characterize the ethical and professional
      issues encountered by medical students in their clinical years. By applying
      previously identified taxonomies to a national sample of medical students, this
      study seeks to develop generalizable insights that can inform professional
      identity formation across various clerkships and medical institutions. METHODS:
      In a national survey of medical students, participants answered an open-ended
      survey item that asked them to describe a clinical experience involving an
      ethical or professional issue. We conducted a content analysis with these
      responses using the Kaldjian taxonomy of ethical and professionalism themes in
      medical education through an iterative, consensus-building process. Noting the
      emerging virtues-based approach to ethics and professionalism, we also reexamined
      the data using a taxonomy of virtues. RESULTS: The response rate to this survey
      item was 144 out of 499 eligible respondents (28.9%). All 144 responses were
      successfully coded under one or more themes in the original taxonomy of ethical
      and professional issues, resulting in a total of 173 coded responses.
      Professional duties was the most frequently coded theme (29.2%), followed by
      Communication (26.4%), Quality of care (18.8%), Student-specific issues of moral 
      distress (16.7%), Decisions regarding treatment (16.0%), and Justice (13.2%). In 
      the virtues taxonomy, 180 total responses were coded from the 144 original
      responses, and the most frequent virtue coded was Wisdom (23.6%), followed by
      Respectfulness (20.1%) and Compassion or Empathy (13.9%). CONCLUSIONS: Originally
      developed from students' clinical experiences in one institution, the Kaldjian
      taxonomy appears to serve as a useful analytical framework for categorizing a
      variety of clinical experiences faced by a national sample of medical students.
      This study also supports the development of virtue-based programs that focus on
      cultivating the virtue of wisdom in the practice of medicine.
FAU - Hawking, Michael
AU  - Hawking M
AD  - Hematology and Oncology, The University of Chicago, Chicago, IL, USA.
FAU - Kim, Jenny
AU  - Kim J
AD  - Department of Biological Sciences, The University of Chicago, Chicago, IL, USA.
FAU - Jih, Melody
AU  - Jih M
AD  - Department of Economics, The University of Chicago, Chicago, IL, USA.
FAU - Hu, Chelsea
AU  - Hu C
AD  - Department of Economics and the Department of Political Science, The University
      of Chicago, Chicago, IL, USA.
FAU - Yoon, John D
AU  - Yoon JD
AUID- ORCID: http://orcid.org/0000-0002-4877-0704
AD  - MacLean Center for Clinical Medical Ethics, Department of Medicine, The
      University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
      jdyoon@uchicago.edu.
LA  - eng
GR  - T32 CA009566/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20201022
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - *Education, Medical
MH  - Ethics, Medical
MH  - Humans
MH  - Morals
MH  - Professionalism
MH  - *Students, Medical
MH  - Virtues
PMC - PMC7584068
OTO - NOTNLM
OT  - Clinical ethics
OT  - Kaldjian taxonomy
OT  - Professional identity formation
OT  - Professionalism
OT  - Virtue ethics
OT  - Wisdom
EDAT- 2020/10/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/23 05:31
PHST- 2020/08/20 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/23 05:31 [entrez]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02313-z [doi]
AID - 10.1186/s12909-020-02313-z [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Oct 22;20(1):380. doi: 10.1186/s12909-020-02313-z.


PMID- 33091572
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1532-0480 (Electronic)
IS  - 1532-0464 (Linking)
VI  - 112
DP  - 2020 Dec
TI  - Reducing waiting time for remote patients in telemedicine with considering
      treated patients in emergency department based on body sensors technologies and
      hybrid computational algorithms: Toward scalable and efficient real time
      healthcare monitoring system.
PG  - 103592
LID - S1532-0464(20)30221-5 [pii]
LID - 10.1016/j.jbi.2020.103592 [doi]
AB  - BACKGROUND: Scalability challenge in real time healthcare monitoring system
      relates to several issues. One of the insistent issues is the increasing in the
      number of patients. Increasing in the patients' number causes long queue and
      increase the waiting time for the patients in their seeking for healthcare
      services. Thus, an ethical issue raises as the healthcare providers should
      provide fast services for all patients. Recent studies have proposed scalable
      models that are limited to (1) triaging remote patients for the optimal emergency
      level and (2) prioritizing remote patients with the highest triage level to
      receive immediate healthcare services. However, these studies have shown
      limitations, that is, (1) they have not addressed the waiting time for all
      patients with different triage levels in the same waiting queue; and (2) they
      have not considered Emergency Department EDs patients. Therefore, considering the
      remote patients with the treated patients in EDs in one healthcare system is a
      demand, to efficiently handle all the patients' requests and productively manage 
      the medical resources. OBJECTIVE: This study aims to reduce the waiting time for 
      the remote patients in telemedicine with considering treated patients in EDs. The
      study presents a scalable telemedicine model to improve the ability of real time 
      healthcare monitoring system in accommodating the increasing number of patients
      with chronic heart disease by reducing their waiting time for healthcare
      services, prioritizing the patients who have the most emergency cases and provide
      all the patients by fast healthcare services. The proposed model called Triaging 
      and Prioritizing Model "TPM". METHOD: The proposed model "TPM" considers triaging
      and prioritizing all patients (remote and EDs patients) as two sequential
      processes. The TPM was formulated to triage the patients based on hybrid
      algorithms which combine Evidence-Theory with Fuzzy Cluster Means (FCM) and then 
      prioritize the patients based on dedicated computational algorithm. A simulation,
      on 580 chronic heart diseases patients, was implemented. The patients considered 
      as they have different emergency levels based on four vital data acquisition
      tools: electrocardiogram sensor, blood pressure sensor, oxygen saturation sensor 
      and a text input as non-sensory based acquisition tool. RESULTS: Computational
      results show the superiority of the proposed model (TPM) in accommodating large
      numbers of patients and reducing their waiting time for services compared with
      relevant benchmark studies. In 1,185 min, TPM managed the (580) patients'
      requests. By contrast, the benchmark managed only 256 patients at the same amount
      of time. In addition to that, TPM shows improvements in terms of waiting time and
      services provisioning rates compared with benchmark methods. CONCLUSION: All
      patients with the different emergency levels receive services with less waiting
      time compared with the relevant studies. The proposed model (TPM) model considers
      both of remote patients and treated patients in EDs efficiently. TPM improves
      response time for the medical services, reduces waiting time for all patients and
      consequently, saves more lives.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Salman, Omar Hussein
AU  - Salman OH
AD  - Network Department, Faculty of Engineering, AL Iraqia University Baghdad, Iraq.
      Electronic address: omarwsn@gmail.com.
FAU - Aal-Nouman, Mohammed Imad
AU  - Aal-Nouman MI
AD  - College of Information Engineering, Al-Nahrain University, Baghdad, Iraq.
FAU - Taha, Zahraa K
AU  - Taha ZK
AD  - Network Department, Faculty of Engineering, AL Iraqia University Baghdad, Iraq.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - United States
TA  - J Biomed Inform
JT  - Journal of biomedical informatics
JID - 100970413
SB  - IM
MH  - Algorithms
MH  - Emergency Service, Hospital
MH  - Humans
MH  - *Telemedicine
MH  - Triage
MH  - *Waiting Lists
OTO - NOTNLM
OT  - *Chronic disease
OT  - *Disaster
OT  - *Emergency Department ED
OT  - *Healthcare services
OT  - *Patient monitoring
OT  - *Sensor
EDAT- 2020/10/23 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/22 20:12
PHST- 2020/07/05 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/10/22 20:12 [entrez]
AID - S1532-0464(20)30221-5 [pii]
AID - 10.1016/j.jbi.2020.103592 [doi]
PST - ppublish
SO  - J Biomed Inform. 2020 Dec;112:103592. doi: 10.1016/j.jbi.2020.103592. Epub 2020
      Oct 19.


PMID- 33090500
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Bystanders and ethical review of research: Proceed with caution.
PG  - 937-940
LID - 10.1111/bioe.12823 [doi]
AB  - Scientists seeking to conduct research with human subjects must first submit
      their proposals to research ethics committees (Institutional Review Boards
      [IRBs], in the United States). Some of these studies pose risks to "bystanders," 
      i.e., people who may be affected by the research but who are not enrolled as
      study subjects. Should IRBs expand their scope to include oversight over possible
      harms to bystanders as well as research subjects? This paper presents arguments
      against this step. Prior review of research with human subjects, despite its
      evident burden on the research enterprise, is a necessary caution, because the
      tension between the objectives of humane treatment of research subjects and sound
      scientific design and procedure has in the past led to serious abuses. This
      rationale is inapplicable in the case of bystanders. Moreover, in view of the
      many and varied effects of both research practices and scientific advances on the
      broader public over time, those who may be considered to be "bystanders" may
      potentially expand without limit; requiring IRBs to anticipate these distant and 
      long-term effects as part of prior ethical review could greatly increase its
      burden and its deterrent effect on research. While conducting research without
      concern for serious potential harm to bystanders may be irresponsible and
      unethical, expanding the scope of prior review by IRBs to include risks to
      bystanders is not required by the principles governing human subjects research,
      and the costs and burdens of this expansion may outweigh any expected gains.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Wikler, Daniel
AU  - Wikler D
AUID- ORCID: 0000-0001-9760-0309
AD  - Department of Global Health and Population, Harvard School of Public Health,
      Boston, Massachusetts.
LA  - eng
GR  - 1 R01 AI114617-01A1/NH/NIH HHS/United States
GR  - 208766/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201022
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Ethical Review
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Research Design
MH  - Research Subjects
MH  - United States
OTO - NOTNLM
OT  - *IRBs
OT  - *bystanders
OT  - *ethical review
OT  - *research ethics
OT  - *research risk
OT  - *risk
EDAT- 2020/10/23 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/22 12:19
PHST- 2019/01/28 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/10/22 12:19 [entrez]
AID - 10.1111/bioe.12823 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):937-940. doi: 10.1111/bioe.12823. Epub 2020 Oct 22.


PMID- 33090216
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201218
IS  - 1465-3648 (Electronic)
IS  - 0268-1153 (Linking)
VI  - 35
IP  - 5
DP  - 2020 Oct 1
TI  - How do Nigerian newspapers report COVID-19 pandemic? The implication for
      awareness and prevention.
PG  - 471-480
LID - 10.1093/her/cyaa031 [doi]
AB  - This study examined media coverage of COVID-19 in Nigeria with attention to the
      frequency and depth of coverage, story format, news sources, media tone and
      themes. Four widely read newspapers were content analysed between February 2020
      and April 2020. Focus was on Daily Sun, Vanguard, Daily Trust and Leadership.
      Results indicated that the Nigerian media performed well in terms of covering the
      pandemic, which in turn created awareness. However, the coverage was not in-depth
      as most of the reported stories were short and were predominantly straight news. 
      It was also observed that the media cited more of the Nigeria Centre for Disease 
      Control (NCDC) and government officials. Further findings disclosed that most of 
      the stories were alarming and induced panic. Most common topics were coverage of 
      cases in Nigeria, death rates and concerns about Nigeria's preparedness. Public
      sensitization and education were sparingly covered. Ethics healthcare workers
      could adhere to received minimal attention. The media should focus more on
      sensitizing and educating the public on the necessary steps to take in curbing
      the virus. They should refrain from over usage of alarming and panic tone in
      presenting the stories of COVID-19 pandemic in Nigeria.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights
      reserved. For permissions, please email: journals.permissions@oup.com.
FAU - Apuke, Oberiri Destiny
AU  - Apuke OD
AD  - School of Communication, Universiti Sains Malaysia, 11800 USM, Pulau Pinang,
      Malaysia.
AD  - Department of Mass Communication, Taraba State University, PMB 1167 Jalingo ,
      Nigeria.
FAU - Omar, Bahiyah
AU  - Omar B
AD  - School of Communication, Universiti Sains Malaysia, 11800 USM, Pulau Pinang,
      Malaysia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Health Educ Res
JT  - Health education research
JID - 8608459
MH  - Awareness
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Humans
MH  - Mass Media
MH  - Newspapers as Topic
MH  - Nigeria
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
PMC - PMC7665478
EDAT- 2020/10/23 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/10/22 12:18
PHST- 2020/05/03 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/10/22 12:18 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - 5935539 [pii]
AID - 10.1093/her/cyaa031 [doi]
PST - ppublish
SO  - Health Educ Res. 2020 Oct 1;35(5):471-480. doi: 10.1093/her/cyaa031.


PMID- 33090194
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 324
IP  - 20
DP  - 2020 Nov 24
TI  - Scientific and Ethical Principles Underlying Recommendations From the Advisory
      Committee on Immunization Practices for COVID-19 Vaccination Implementation.
PG  - 2025-2026
LID - 10.1001/jama.2020.20847 [doi]
FAU - Bell, Beth P
AU  - Bell BP
AD  - Department of Global Health, University of Washington, Seattle.
FAU - Romero, Jose R
AU  - Romero JR
AD  - University of Arkansas for Medical Sciences, Little Rock.
AD  - Arkansas Department of Health, Little Rock.
FAU - Lee, Grace M
AU  - Lee GM
AD  - Stanford University School of Medicine, Stanford Children's Health, Stanford,
      California.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Advisory Committees
MH  - COVID-19/*prevention & control
MH  - COVID-19 Vaccines/administration & dosage
MH  - Health Care Rationing/ethics
MH  - Health Plan Implementation/*ethics
MH  - Humans
MH  - Immunization Programs/ethics
MH  - Pandemics
MH  - United States
MH  - Vaccination/*ethics
EDAT- 2020/10/23 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/22 12:17
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/22 12:17 [entrez]
AID - 2772326 [pii]
AID - 10.1001/jama.2020.20847 [doi]
PST - ppublish
SO  - JAMA. 2020 Nov 24;324(20):2025-2026. doi: 10.1001/jama.2020.20847.


PMID- 33090120
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 73
IP  - 4
DP  - 2020 May 7
TI  - Ethical Considerations in Animal Research: The Principle of 3R's.
PG  - 199-209
LID - 10.24875/RIC.20000380 [doi]
AB  - In the last century, progress in the knowledge of human diseases, their diagnosis
      and treatment have grown exponentially, due in large part to the introduction and
      use of laboratory animals. Along with this important progress, the need to
      provide training and guidance to the scientific community in all aspects related 
      to the proper use of experimental animals has been indispensable. Animal research
      committees play a primary role in evaluating experimental research protocols,
      from their feasibility to the rational use of animals, but above all in seeking
      animal welfare. The Institutional Committee for the Care and Use of Animals
      (IACUC) has endeavored to share several relevant aspects in conducting research
      with laboratory animals. Here, we present and discuss the topics that we consider
      of utmost importance to take in the account during the design of any experimental
      research protocol, so we invite researchers, technicians, and undergraduate and
      graduate students to dive into the fascinating subject of proper animal care and 
      use for experimentation. The main intention of these contributions is to
      sensitize users of laboratory animals for the proper and rational use of them in 
      experimental research, as well as to disseminate the permitted and unpermitted
      procedures in laboratory animals. In the first part, the significance of
      experimental research, the main functions of IACUC, and the principle of the
      three R's (replacement, reduction, and refinement) are addressed.
FAU - Diaz, Lorenza
AU  - Diaz L
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Zambrano, Elena
AU  - Zambrano E
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Flores, Maria E
AU  - Flores ME
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City; Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Contreras, Mariela
AU  - Contreras M
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Crispin, Jose C
AU  - Crispin JC
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Aleman, Gabriela
AU  - Aleman G
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Bravo, Cesar
AU  - Bravo C
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Armenta, Alejandra
AU  - Armenta A
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Valdes, Victor J
AU  - Valdes VJ
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto de
      Fisiologia Celular, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Tovar, Armando
AU  - Tovar A
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Gamba, Gerardo
AU  - Gamba G
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City; Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Barrios-Payan, Jorge
AU  - Barrios-Payan J
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Bobadilla, Norma A
AU  - Bobadilla NA
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City; Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la
      Nutricion
JID - 9421552
SB  - IM
MH  - *Animal Care Committees
MH  - *Animal Experimentation/ethics
MH  - *Animal Welfare
MH  - Animals
MH  - Animals, Laboratory
MH  - Research Design
OTO - NOTNLM
OT  - *Institutional Animal Care and Use Committee
OT  - *Reduction
OT  - *Refinement
OT  - *Replacement
EDAT- 2020/10/23 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/10/22 12:16
PHST- 2020/10/22 12:16 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.24875/RIC.20000380 [doi]
PST - epublish
SO  - Rev Invest Clin. 2020 May 7;73(4):199-209. doi: 10.24875/RIC.20000380.


PMID- 33090113
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201118
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 22
TI  - Understanding the Uptake of Big Data in Health Care: Protocol for a Multinational
      Mixed-Methods Study.
PG  - e16779
LID - 10.2196/16779 [doi]
AB  - BACKGROUND: Despite the high potential of big data, their applications in health 
      care face many organizational, social, financial, and regulatory challenges. The 
      societal dimensions of big data are underrepresented in much medical research.
      Little is known about integrating big data applications in the corporate routines
      of hospitals and other care providers. Equally little is understood about
      embedding big data applications in daily work practices and how they lead to
      actual improvements for health care actors, such as patients, care professionals,
      care providers, information technology companies, payers, and the society.
      OBJECTIVE: This planned study aims to provide an integrated analysis of big data 
      applications, focusing on the interrelations among concrete big data experiments,
      organizational routines, and relevant systemic and societal dimensions. To
      understand the similarities and differences between interactions in various
      contexts, the study covers 12 big data pilot projects in eight European
      countries, each with its own health care system. Workshops will be held with
      stakeholders to discuss the findings, our recommendations, and the
      implementation. Dissemination is supported by visual representations developed to
      share the knowledge gained. METHODS: This study will utilize a mixed-methods
      approach that combines performance measurements, interviews, document analysis,
      and cocreation workshops. Analysis will be structured around the following four
      key dimensions: performance, embedding, legitimation, and value creation. Data
      and their interrelations across the dimensions will be synthesized per
      application and per country. RESULTS: The study was funded in August 2017. Data
      collection started in April 2018 and will continue until September 2021. The
      multidisciplinary focus of this study enables us to combine insights from several
      social sciences (health policy analysis, business administration, innovation
      studies, organization studies, ethics, and health services research) to advance a
      holistic understanding of big data value realization. The multinational character
      enables comparative analysis across the following eight European countries:
      Austria, France, Germany, Ireland, the Netherlands, Spain, Sweden, and the United
      Kingdom. Given that national and organizational contexts change over time, it
      will not be possible to isolate the factors and actors that explain the
      implementation of big data applications. The visual representations developed for
      dissemination purposes will help to reduce complexity and clarify the relations
      between the various dimensions. CONCLUSIONS: This study will develop an
      integrated approach to big data applications that considers the interrelations
      among concrete big data experiments, organizational routines, and relevant
      systemic and societal dimensions. INTERNATIONAL REGISTERED REPORT IDENTIFIER
      (IRRID): DERR1-10.2196/16779.
CI  - (c)Rik Wehrens, Vikrant Sihag, Sandra Sulz, Hilco van Elten, Erik van Raaij,
      Antoinette de Bont, Anne Marie Weggelaar-Jansen. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 22.10.2020.
FAU - Wehrens, Rik
AU  - Wehrens R
AUID- ORCID: https://orcid.org/0000-0002-6141-9863
AD  - Erasmus School of Health Policy & Management, Erasmus University Rotterdam,
      Rotterdam, Netherlands.
FAU - Sihag, Vikrant
AU  - Sihag V
AUID- ORCID: https://orcid.org/0000-0003-4299-5467
AD  - Rotterdam School of Management, Erasmus University Rotterdam, Rotterdam,
      Netherlands.
AD  - Department of Industrial Engineering & Innovation Sciences, Eindhoven University 
      of Technology, Eindhoven, Netherlands.
FAU - Sulz, Sandra
AU  - Sulz S
AUID- ORCID: https://orcid.org/0000-0002-2354-1307
AD  - Erasmus School of Health Policy & Management, Erasmus University Rotterdam,
      Rotterdam, Netherlands.
FAU - van Elten, Hilco
AU  - van Elten H
AUID- ORCID: https://orcid.org/0000-0003-3909-5521
AD  - Erasmus School of Health Policy & Management, Erasmus University Rotterdam,
      Rotterdam, Netherlands.
FAU - van Raaij, Erik
AU  - van Raaij E
AUID- ORCID: https://orcid.org/0000-0002-3758-5431
AD  - Erasmus School of Health Policy & Management, Erasmus University Rotterdam,
      Rotterdam, Netherlands.
AD  - Rotterdam School of Management, Erasmus University Rotterdam, Rotterdam,
      Netherlands.
FAU - de Bont, Antoinette
AU  - de Bont A
AUID- ORCID: https://orcid.org/0000-0002-0745-4537
AD  - Erasmus School of Health Policy & Management, Erasmus University Rotterdam,
      Rotterdam, Netherlands.
FAU - Weggelaar-Jansen, Anne Marie
AU  - Weggelaar-Jansen AM
AUID- ORCID: https://orcid.org/0000-0002-7786-6326
AD  - Erasmus School of Health Policy & Management, Erasmus University Rotterdam,
      Rotterdam, Netherlands.
AD  - School of Medical Physics and Engineering, University of Technology Eindhoven,
      Eindhoven, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7644380
OTO - NOTNLM
OT  - balance score card
OT  - big data
OT  - business modeling
OT  - ethics
OT  - governmental regulation
OT  - implementation
OT  - innovation
OT  - legitimacy
OT  - performance
OT  - regulation
OT  - social sciences
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 12:16
PHST- 2019/10/24 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/10/22 12:16 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - v9i10e16779 [pii]
AID - 10.2196/16779 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 22;9(10):e16779. doi: 10.2196/16779.


PMID- 33089678
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - Vol. 31
IP  - 1
DP  - 2020 Sep 14
TI  - Chapter 6. French and Chinese regulatory approaches to end-of-life and
      euthanasia.
PG  - 63-83
LID - 10.3917/jibes.311.0063 [doi]
AB  - For patients in critical or terminal situations, the approach to death is a
      situation that raises many ethical and legal issues of importance. Health
      professionals and families of the person at the end-of-life are obviously at the 
      forefront of the concerns generated by these situations, all wishing to act in
      the best interest of the patient. Some States have regulated the various
      situations encountered on the ground in order to provide stakeholders with clear 
      and appropriate procedures to ensure human dignity in practice by elaborating the
      rules of an end-of-life ethics aimed at supporting health professionals involved 
      in carrying out certain acts while setting limits in respect of the persons
      concerned. What are the alternatives? Is euthanasia tolerable? What role for
      health professionals? And for the family? The content of the regulations differs 
      according to countries, to cultural sensitivities and ethical and legal
      traditions, like the political will to regulate this topic. The regulatory
      experience of countries like France and China can be useful to other countries
      and serve as a basis for discussing the topic. Therefore, we analyze the current 
      French framework and the situation in China in order to highlight main elements
      of ethical discussions, adopted positions and rules, eventual joint
      considerations, remaining issues and challenges in a comparative approach.
FAU - Wu, Tao
AU  - Wu T
FAU - Chassang, Gauthier
AU  - Chassang G
LA  - eng
PT  - Journal Article
TT  - Chapter 6. French and Chinese regulatory approaches to end-of-life and
      euthanasia.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - China
MH  - Euthanasia/*ethics
MH  - France
MH  - Humans
MH  - Morals
MH  - *Personhood
EDAT- 2020/10/23 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/22 06:16
PHST- 2020/10/22 06:16 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.3917/jibes.311.0063 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Sep 14;Vol. 31(1):63-83. doi:
      10.3917/jibes.311.0063.


PMID- 33089117
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2589-5370 (Electronic)
IS  - 2589-5370 (Linking)
VI  - 26
DP  - 2020 Sep
TI  - The effects of sedation cessation within the first four hours of intensive care
      unit admission in mechanically ventilated critically ill patients - a quality
      improvement study.
PG  - 100486
LID - 10.1016/j.eclinm.2020.100486 [doi]
AB  - BACKGROUND: Early deep sedation in mechanically ventilated patients during the
      first 48 h of intensive care unit (ICU) admission can be associated with adverse 
      outcomes. We hypothesised that moving the 'daily sedation break' process
      forwards, might allow earlier titration of sedation to target levels - an 'early 
      sedation cessation' (ESC). METHODS: We commenced a quality improvement project
      with the primary outcome being to stop sedation completely, within 4 h of ICU
      admission, in 95% of eligible patients. This was done by small, step-wise tests
      of change. No ethical approval was required. FINDINGS: Between 1 February 2014
      and 31 January 2018, 1787 intubated patients were included. 1052 received an
      'ESC' within 4 h ('Yes'), 545 were excluded ('Excluded'), and 190 were
      inadvertently omitted from 'ESC' ('No'). The primary aim was achieved for the
      first time after 12 months. Compared to the 'Yes' group, the 'Excluded' group
      received 38% more propofol in the first 48 h of admission (IRR 1.38 (1.31-1.47), 
      p<0.001), while the 'No' group received 32% more (IRR 1.32 (1.22-1.43), p<0.001).
      At four hours, 19.6% (12.9-27.9) of the 'Yes' group had attained a target RASS of
      -1, 0 or 1, compared to 13.6% (8.0-21.0) of those in the 'No' group. This
      proportion increased to 55.6% (46.1-64.9) at 24 h compared with 44.9% (35.6-54.4)
      in the 'No' group. INTERPRETATION: Ceasing sedative infusions as soon as
      possible, is safe and feasible, in both medical and surgical patients, and can be
      implemented into 'real life' with no additional staffing.
CI  - Crown Copyright (c) 2020 Published by Elsevier Ltd.
FAU - Cuthill, Jennifer A
AU  - Cuthill JA
AD  - Intensive Care Department, Glasgow Royal Infirmary, Alexandra Parade, Glasgow, G4
      0SF, United Kingdom.
FAU - Jarvie, Lyndsey
AU  - Jarvie L
AD  - Intensive Care Department, Glasgow Royal Infirmary, Alexandra Parade, Glasgow, G4
      0SF, United Kingdom.
FAU - McGovern, Christopher
AU  - McGovern C
AD  - Intensive Care Department, Glasgow Royal Infirmary, Alexandra Parade, Glasgow, G4
      0SF, United Kingdom.
FAU - Shaw, Martin
AU  - Shaw M
AD  - Department of Clinical Physics, Glasgow Royal Infirmary, Alexandra Parade,
      Glasgow G4 0SF, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - EClinicalMedicine
JT  - EClinicalMedicine
JID - 101733727
PMC - PMC7564524
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:40
PHST- 2020/05/05 00:00 [received]
PHST- 2020/07/16 00:00 [revised]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/10/22 05:40 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.1016/j.eclinm.2020.100486 [doi]
AID - S2589-5370(20)30230-3 [pii]
PST - epublish
SO  - EClinicalMedicine. 2020 Jul 31;26:100486. doi: 10.1016/j.eclinm.2020.100486.
      eCollection 2020 Sep.


PMID- 33088986
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 2424-8002 (Electronic)
IS  - 2424-8002 (Linking)
VI  - 6
IP  - 3
DP  - 2020
TI  - Bioethical and Legal Issues in 3D Bioprinting.
PG  - 272
LID - 10.18063/ijb.v6i3.272 [doi]
AB  - Bioethical and legal issues of three-dimensional (3D) bioprinting as the emerging
      field of biotechnology have not yet been widely discussed among bioethicists
      around the world, including Russia. The scope of 3D bioprinting includes not only
      the issues of the advanced technologies of human tissues and organs printing but 
      also raises a whole layer of interdisciplinary problems of modern science,
      technology, bioethics, and philosophy. This article addresses the ethical and
      legal issues of bioprinting of artificial human organs.
CI  - Copyright: (c) 2020 Kirillova, et al.
FAU - Kirillova, Anastasia
AU  - Kirillova A
AD  - National Medical Research Center for Obstetrics, Gynecology and Perinatology
      Named After Academician V.I. Kulakov of the Ministry of Healthcare of Russian
      Federation, Moscow, 117513, Russia.
FAU - Bushev, Stanislav
AU  - Bushev S
AD  - Department of Philosophy, Lomonosov Moscow State University, Moscow, 119991,
      Russia.
FAU - Abubakirov, Aydar
AU  - Abubakirov A
AD  - National Medical Research Center for Obstetrics, Gynecology and Perinatology
      Named After Academician V.I. Kulakov of the Ministry of Healthcare of Russian
      Federation, Moscow, 117513, Russia.
FAU - Sukikh, Gennady
AU  - Sukikh G
AD  - National Medical Research Center for Obstetrics, Gynecology and Perinatology
      Named After Academician V.I. Kulakov of the Ministry of Healthcare of Russian
      Federation, Moscow, 117513, Russia.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - Singapore
TA  - Int J Bioprint
JT  - International journal of bioprinting
JID - 101709763
PMC - PMC7557521
OTO - NOTNLM
OT  - Artificial ovary
OT  - Bioethics
OT  - Ethical issues
OT  - Oncofertility
OT  - Regulatory concerns
OT  - Three-dimensional printing
COIS- No conflicts of interest are reported by the authors.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:39
PHST- 2020/02/16 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/10/22 05:39 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.18063/ijb.v6i3.272 [doi]
AID - IJB-6-3-272 [pii]
PST - epublish
SO  - Int J Bioprint. 2020 Apr 28;6(3):272. doi: 10.18063/ijb.v6i3.272. eCollection
      2020.


PMID- 33088745
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2229-516X (Print)
IS  - 2229-516X (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - Introduction and Implementation of Early Clinical Exposure in Undergraduate
      Medical Training to Enhance Learning.
PG  - 205-209
LID - 10.4103/ijabmr.IJABMR_270_20 [doi]
AB  - CONTEXT: Conventional medical curricula have created an impenetrable wall between
      the preclinical and clinical years of training, thus submerging relevance of
      basic sciences in clinical setup. Recently, the Medical Council of India has
      introduced a number of changes and updates in the medical education, including
      "early clinical exposure" (ECE) in newly proposed competency-based medical
      education. ECE does not replace the basic and clinical sciences but enriches and 
      contextualizes that learning, therefore motivating the students to develop a
      better insight into medical profession. AIMS: (1) To develop a protocol for the
      introduction of ECE in undergraduate medical training, (2) to validate and to
      deliver it to the 1(st) year MBBS students and assess their perceptions. SETTINGS
      AND DESIGN: It was a prospective, nonrandomized, interventional study. SUBJECTS
      AND METHODS: After taking permission from the institutional research committee
      and institutional ethical committee, a protocol for the introduction of ECE in
      Biochemistry was developed. The feedback questionnaire for the students and the
      faculty and retro-preself-efficacy questionnaire for the students were designed
      and validated. The ECE protocol was delivered to 143 1(st)-year MBBS students,
      and perceptions of concerned were collected and analyzed. STATISTICAL ANALYSIS
      USED: Collected data were analyzed in terms of percentages, medians, and
      satisfaction index and were represented in graphs. RESULTS: Students reported
      that the ECE session was an enjoyable, satisfactory, and effective learning tool,
      with the improvement in knowledge, retention, attention, and motivation. Students
      also reported that this method of teaching-learning should be implemented in
      other topics as well as in other subjects of the first professional course.
      CONCLUSIONS: ECE protocol was perceived as very satisfactory by the students, and
      it helped in improvement of knowledge and to understand the relevance of
      preclinical subject in clinical setup.
CI  - Copyright: (c) 2020 International Journal of Applied and Basic Medical Research.
FAU - Gupta, Kapil
AU  - Gupta K
AD  - Department of Biochemistry, Adesh Institute of Medical Sciences and Research,
      Bathinda, Punjab, India.
FAU - Gill, Gurpreet Singh
AU  - Gill GS
AD  - Department of General Surgery, Adesh Institute of Medical Sciences and Research, 
      Bathinda, Punjab, India.
FAU - Mahajan, Rajiv
AU  - Mahajan R
AD  - Department of Pharmacology, Adesh Institute of Medical Sciences and Research,
      Bathinda, Punjab, India.
LA  - eng
PT  - Journal Article
DEP - 20200711
PL  - India
TA  - Int J Appl Basic Med Res
JT  - International journal of applied & basic medical research
JID - 101579831
PMC - PMC7534714
OTO - NOTNLM
OT  - Biochemistry
OT  - MBBS first professional
OT  - early clinical exposure
OT  - perceptions
COIS- There are no conflicts of interest.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:38
PHST- 2020/03/05 00:00 [received]
PHST- 2020/05/22 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/10/22 05:38 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.4103/ijabmr.IJABMR_270_20 [doi]
AID - IJABMR-10-205 [pii]
PST - ppublish
SO  - Int J Appl Basic Med Res. 2020 Jul-Sep;10(3):205-209. doi:
      10.4103/ijabmr.IJABMR_270_20. Epub 2020 Jul 11.


PMID- 33088467
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 11
DP  - 2020
TI  - Thai CV Risk Score and Primary Prevention in Impaired Fasting Plasma Glucose or
      Diabetes Mellitus versus Normoglycemia in Patients with Metabolic Syndrome.
PG  - 139
LID - 10.4103/ijpvm.IJPVM_12_19 [doi]
AB  - BACKGROUND: Impaired fasting plasma glucose (IFG) as well as diabetes mellitus
      (DM) may influence the presence of another metabolic syndrome (MetS) components
      resulting in the different risk of cardiovascular (CV) morbidity and mortality.
      This study aimed to determine the impact of IFG as well as DM on the 10-year CV
      risk using Thai CV risk score and primary prevention in complying with CV risk
      score in these patients. METHODS: This cross-sectional study was conducted at the
      internal medicine clinic, Pathum Thani Hospital, Thailand. The study was approved
      by the hospital ethics committee and written informed consent was obtained from
      all patients. Patients having MetS according to the criteria of the International
      Diabetes Federation were enrolled while those with a history of CVD were
      excluded. The 10-year CV risk was assessed using the Thai CV risk score. RESULTS:
      The total of 112 patients were enrolled in the study. They were in old age and
      female sex was a significantly higher proportion (61.70% vs 35.50%, P = 0.013).
      Of these, 72.32% had IFG or DM. Proportions of patients with moderate and high CV
      risk score were significantly greater in IFG/DM group and only 34.48% and 79.31% 
      of patients with moderate or high CV risk score received aspirin and statin. IFG 
      or DM significantly elevated CV risk score (OR = 6.66, 95% CI = 2.29, 19.58).
      CONCLUSIONS: IFG/DM significantly elevated CV risk score in these patients with
      the strongest impact. The assessment of CV risk is highly recommended for primary
      prevention and long-term CVD benefit.
CI  - Copyright: (c) 2020 International Journal of Preventive Medicine.
FAU - Duangrithi, Duangjai
AU  - Duangrithi D
AD  - Head of General Pharmacy Practice Division, Department of Pharmaceutical Care,
      College of Pharmacy, Rangsit University, Pathumtani, Thailand.
FAU - Wattanasermkit, Ruja
AU  - Wattanasermkit R
AD  - Department of Pharmaceutical Care, College of Pharmacy, Rangsit University,
      Pathumtani, Thailand.
FAU - Rungwijee, Sudarat
AU  - Rungwijee S
AD  - Department of Pharmaceutical Care, College of Pharmacy, Rangsit University,
      Pathumtani, Thailand.
FAU - Khunsom, Natthanicha
AU  - Khunsom N
AD  - Department of Pharmaceutical Care, College of Pharmacy, Rangsit University,
      Pathumtani, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20200905
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC7554559
OTO - NOTNLM
OT  - Cardiovascular diseases
OT  - diabetes mellitus
OT  - metabolic syndrome
OT  - risk assessment
COIS- There are no conflicts of interest.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:37
PHST- 2019/01/17 00:00 [received]
PHST- 2019/08/29 00:00 [accepted]
PHST- 2020/10/22 05:37 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.4103/ijpvm.IJPVM_12_19 [doi]
AID - IJPVM-11-139 [pii]
PST - epublish
SO  - Int J Prev Med. 2020 Sep 5;11:139. doi: 10.4103/ijpvm.IJPVM_12_19. eCollection
      2020.


PMID- 33088431
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - What is hidden in hidden curriculum? a qualitative study in medicine.
PG  - 4
LID - 10.18502/jmehm.v13i4.2843 [doi]
AB  - The hidden curriculum is considered to be between the designed and experienced
      curricula. One of the challenges that medical educators face is to understand
      what students learn in real clinical settings. The aim of the present study was
      to answer this question: What is hidden in hidden medical curriculum? This study 
      was a qualitative content analysis. Participants were selected through purposive 
      sampling. Data collection was performed through unstructured interviews and
      continued until data saturation. Data were analyzed simultaneously with data
      collection using MAXQDA10 software. Data validity was confirmed based on the
      proposed Lincoln and Guba criteria. The main theme that emerged in this study was
      implicit learning. Professional ethics, spiritual, social and cultural issues,
      and clinical skills are the five major themes that were presented in this study. 
      These themes and their subthemes are transferred during an implicit learning
      experience in hidden curriculum. Since a wide range of issues are mostly
      transferred by hidden curriculum, it is essential to have a dynamic approach to
      educational environments. This is especially important in clinical settings, as
      the process of learning is constantly happening in the backyard.
CI  - (c) 2020 Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences. All rights reserved.
FAU - Yazdani, Shahram
AU  - Yazdani S
AD  - Professor, School of Medical Education Sciences, Shahid Beheshti University of
      Medical Sciences, Tehran, Iran.
FAU - Andarvazh, Mohammad Reza
AU  - Andarvazh MR
AD  - PhD Graduate of Medical Education, School of Medical Education, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran; Assistant Professor, Nasibeh School
      of Nursing and Midwifery, Educational Development Center, Mazandaran University
      of Medical Sciences, Sari, Iran.
FAU - Afshar, Leila
AU  - Afshar L
AD  - Associate Professor, Department of Medical Ethics, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200510
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7569532
OTO - NOTNLM
OT  - Content analysis
OT  - Hidden curriculum
OT  - Implicit learning
OT  - Medical education
OT  - Professional ethics
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:37
PHST- 2019/01/17 00:00 [received]
PHST- 2020/04/29 00:00 [received]
PHST- 2020/10/22 05:37 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.18502/jmehm.v13i4.2843 [doi]
AID - JMEHM-13-4 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 May 10;13:4. doi: 10.18502/jmehm.v13i4.2843.
      eCollection 2020.


PMID- 33088429
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 2008-0387 (Print)
IS  - 2008-0387 (Linking)
VI  - 13
DP  - 2020
TI  - Ethical considerations and challenges of sex education for adolescents in Iran: a
      qualitative study.
PG  - 2
LID - 10.18502/jmehm.v13i2.2664 [doi]
AB  - Adolescence is a period in one's lifetime during which sexual maturation occurs. 
      Major changes and increased sexual instinct raise many questions in the minds of 
      adolescents. Receiving wrong education or inappropriate information can affect
      adolescents' life and future deeply. Obviously, ethical considerations cannot be 
      ignored in nationwide macro policies and educational programs on such a sensitive
      issue. In this qualitative study, we attempted to explore the ethical
      considerations and challenges of sex education for adolescents. The study was
      conducted between May 2015 and March 2017. Data were collected through
      semi-structured in-depth interviews with 25 participants, and MAXQDA 11 was used 
      for coding. Six hundred sixty-two codes (662) were extracted and classified into 
      four categories: 1) the potential risks of sex education for adolescents; 2) the 
      advantages of sex education for adolescents, and the approaches; 3) the
      challenges in the interval between sexual maturation and marriage, and the role
      of religion; and 4) the measures implemented in Iran. Shame, embarrassment, and
      some cultural beliefs surrounding the subject of sex education are obstacles to
      providing adolescents with the necessary information. According to the principles
      of medical ethics, the main principle in sex education is beneficence, and
      sometimes infringement of confidentiality has its advantages.
CI  - (c) 2020 Medical Ethics and History of Medicine Research Center, Tehran
      University of Medical Sciences. All rights reserved.
FAU - Joodaki, Kobra
AU  - Joodaki K
AD  - PhD Candidate in Medical Ethics, Department of Medical Ethics, School of
      Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Nedjat, Saharnaz
AU  - Nedjat S
AD  - Professor, Department of Epidemiology and Biostatistics, Knowledge Utilization
      Research Center, School of Public Health, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Vahid Dastjerdi, Marziyeh
AU  - Vahid Dastjerdi M
AD  - Associated Professor, Department of Obstetrics and Gynecology, School of
      Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Professor, Endocrinology and Metabolism Research Center, Endocrinology and
      Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences,
      Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - Iran
TA  - J Med Ethics Hist Med
JT  - Journal of medical ethics and history of medicine
JID - 101606442
PMC - PMC7569533
OTO - NOTNLM
OT  - Adolescent
OT  - Ethical considerations
OT  - Medical ethics
OT  - Reproductive ethics
OT  - Sex education
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:37
PHST- 2018/12/25 00:00 [received]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/10/22 05:37 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.18502/jmehm.v13i2.2664 [doi]
AID - JMEHM-13-2 [pii]
PST - epublish
SO  - J Med Ethics Hist Med. 2020 Apr 11;13:2. doi: 10.18502/jmehm.v13i2.2664.
      eCollection 2020.


PMID- 33088291
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Linking)
VI  - 44
DP  - 2020
TI  - Theoretical and practical challenges of proportionate universalism: a review.
PG  - e110
LID - 10.26633/RPSP.2020.110 [doi]
AB  - OBJECTIVE: In 2010, the principle of proportionate universalism (PU) has been
      proposed as a solution to reduce health inequalities. It had a great resonance
      but does not seem to have been widely applied and no guidelines exist on how to
      implement it.The two specific objectives of this scoping review were: (1) to
      describe the theoretical context in which PU was established, (2) to describe how
      researchers apply PU and related methodological issues. METHODS: We searched for 
      all articles published until 6(th) of February 2020, mentioning "Proportionate
      Universalism" or its synonyms "Targeted universalism" OR "Progressive
      Universalism" as a topic in all Web of Science databases. RESULTS: This review of
      55 articles allowed us a global vision around the question of PU regarding its
      theoretical foundations and practical implementation. PU principle is rooted in
      the social theories of universalism and targeting. It proposes to link these two 
      aspects in order to achieve an effective reduction of health inequalities.
      Regarding practical implementation, PU interventions were rare and led to
      different interpretations. There are still many methodological and ethical
      challenges regarding conception and evaluation of PU interventions, including how
      to apply proportionality, and identification of needs. CONCLUSION: This review
      mapped available scientific literature on PU and its related concepts. PU
      principle originates from social theories. As highlighted by authors who
      implemented PU interventions, application raises many challenges from design to
      evaluation. Analysis of PU applications provided in this review answered to some 
      of them but remaining methodological challenges could be addressed in further
      research.
FAU - Francis-Oliviero, Florence
AU  - Francis-Oliviero F
AD  - University of Bordeaux Bordeaux France University of Bordeaux, Bordeaux, France.
FAU - Cambon, Linda
AU  - Cambon L
AD  - University of Bordeaux Bordeaux France University of Bordeaux, Bordeaux, France.
FAU - Wittwer, Jerome
AU  - Wittwer J
AD  - University of Bordeaux Bordeaux France University of Bordeaux, Bordeaux, France.
FAU - Marmot, Michael
AU  - Marmot M
AD  - Institute of Health Equity at the University College London London United Kingdom
      Institute of Health Equity at the University College London, London, United
      Kingdom.
FAU - Alla, Francois
AU  - Alla F
AD  - University of Bordeaux Bordeaux France University of Bordeaux, Bordeaux, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201015
PL  - United States
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC7556407
OTO - NOTNLM
OT  - Health equity
OT  - health policy
OT  - socioeconomic factors
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:36
PHST- 2020/04/24 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/10/22 05:36 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.26633/RPSP.2020.110 [doi]
AID - RPSP.2020.110 [pii]
PST - epublish
SO  - Rev Panam Salud Publica. 2020 Oct 15;44:e110. doi: 10.26633/RPSP.2020.110.
      eCollection 2020.


PMID- 33088098
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0973-1075 (Print)
IS  - 0973-1075 (Linking)
VI  - 26
IP  - Suppl 1
DP  - 2020 Jun
TI  - Concerns and Coping Strategies of Persons Under Institutional Quarantine During
      SARS-CoV-2 Pandemic.
PG  - S99-S105
LID - 10.4103/IJPC.IJPC_176_20 [doi]
AB  - INTRODUCTION: The World Health Organization has declared severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) as a pandemic. The interventions employed by 
      various health authorities in combating the infection may help in eliminating the
      threat; however, they have long-term cognitive and mental health effects on the
      population. AIMS: The primary objective was to assess the prevalent concerns and 
      coping strategies and perspectives in persons suspected of SARS-CoV-2 infection
      under institutional quarantine in India during the period from April 2020 to May 
      2020. SETTING AND DESIGN: Its a cross-sectional observational study conducted in 
      the National Cancer Institute, Jhajjar, India. METHODOLOGY: After ethical
      clearance, convenience sampling was done. Relevant demographic details were
      obtained. Health-care professionally administered questionnaire to assess
      psychological concerns and coping mechanisms. All statistics are deemed to be
      descriptive only. RESULTS: The most common physical concern was fever seen in 37%
      of respondents, followed by cough in 31% and sore throat in 29%. In terms of
      emotional concerns, 55.3% of respondents were worried and 43% were anxious and
      33% were sad. About 80.6% of participants selected support from family and
      friends helped them cope during the institutional quarantine. 57% maintained a
      daily routine, 70% selected praying, and 45% used music as a coping strategy.
      Only 2% felt that they were unable to cope. CONCLUSION: It highlights that the
      psychological impact of illness on affected individuals should not be overlooked 
      as it may have the potential to cause major psychiatric morbidity. It also
      provides a crucial assessment of their coping mechanisms.
CI  - Copyright: (c) 2020 Indian Journal of Palliative Care.
FAU - Singh, Neha
AU  - Singh N
AD  - Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRA-IRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Kumar, Sanjeev
AU  - Kumar S
AD  - Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRA-IRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Rathore, Puneet
AU  - Rathore P
AD  - Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRA-IRCH, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Vig, Saurabh
AU  - Vig S
AD  - Department of Onco-Anaesthesia and Palliative Medicine, National Cancer
      Institute, All India Institute of Medical Sciences, New Delhi, India.
FAU - Vallath, Nandini
AU  - Vallath N
AD  - Palliative Care, BARC Hospital, Mumbai, Maharashtra, India.
FAU - Mohan, Anant
AU  - Mohan A
AD  - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of
      Medical Sciences, New Delhi, India.
FAU - Bhatnagar, Sushma
AU  - Bhatnagar S
AD  - Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRA-IRCH, All India
      Institute of Medical Sciences, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - United States
TA  - Indian J Palliat Care
JT  - Indian journal of palliative care
JID - 101261221
PMC - PMC7534984
OTO - NOTNLM
OT  - Coping
OT  - SARS-CoV-2
OT  - emotional
OT  - psychological
OT  - quarantine
OT  - symptom
COIS- There are no conflicts of interest.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:36
PHST- 2020/05/23 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/10/22 05:36 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.4103/IJPC.IJPC_176_20 [doi]
AID - IJPC-26-99 [pii]
PST - ppublish
SO  - Indian J Palliat Care. 2020 Jun;26(Suppl 1):S99-S105. doi:
      10.4103/IJPC.IJPC_176_20. Epub 2020 Jun 30.


PMID- 33088081
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0973-1075 (Print)
IS  - 0973-1075 (Linking)
VI  - 26
IP  - Suppl 1
DP  - 2020 Jun
TI  - Concerns of Health Care Professionals Managing non-COVID Patients during The
      COVID-19 Pandemic: A Descriptive Cross- Sectional Study.
PG  - S21-S26
LID - 10.4103/IJPC.IJPC_155_20 [doi]
AB  - CONTEXT: The coronavirus pandemic has put an unprecedented burden on the
      health-care workers who are the cornerstone of the work system, preparing to
      mitigate its effects. Due to the lack of protective equipments, guidelines for
      managing patients, or proper training and education regarding the same, health
      care professionals (HCPs) working in non-COVID areas may face even greater
      problems than those working in COVID areas of a hospital. Our aim was to find out
      the concerns of HCPs working in non-COVID areas. SUBJECTS AND METHODS: After
      obtaining institutional ethics approval, a descriptive cross-sectional study was 
      planned. An online Google-based questionnaire was rolled out to all doctors
      through various social media platforms who were dealing with COVID-negative
      patients. RESULTS: We received a total of 110 responses. 84.5% of participants
      were concerned about the risk of infection to self and family, 67.3% were
      concerned by the disruption of their daily activities. 56.4% of HCPs were
      disturbed by the lack of any concrete protocol for patient management. Less staff
      availability, delay in discharging duties toward their patients, and increased
      workload were other concerns. More than half of the doctors received N-95 masks
      whenever required and were trained in donning and doffing of Personal protective 
      equipment. Sixty-eight percemt of our respondents labeled their current quality
      of life as stressful. CONCLUSION: It is the need of the hour to develop a
      comprehensive strategy focussing on the above challenges that HCPs working in
      non-COVID areas are facing. This will go a long way in not only providing
      holistic care to the patients but also in controlling this pandemic.
CI  - Copyright: (c) 2020 Indian Journal of Palliative Care.
FAU - Sarma, Riniki
AU  - Sarma R
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Vig, Saurabh
AU  - Vig S
AD  - Department of Onco-Anaesthesia and Palliative Medicine, NCI, AIIMS, New Delhi,
      India.
FAU - Rathore, Puneet
AU  - Rathore P
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Pushpam, Deepam
AU  - Pushpam D
AD  - Department of Medical Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India.
FAU - Mishra, Seema
AU  - Mishra S
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Gupta, Nishkarsh
AU  - Gupta N
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Garg, Rakesh
AU  - Garg R
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Kumar, Vinod
AU  - Kumar V
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Bharati, Sachidanand Jee
AU  - Bharati SJ
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
FAU - Bhatnagar, Sushma
AU  - Bhatnagar S
AD  - Department of Onco-Anaesthesia and Palliative Medicine, AIIMS, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - United States
TA  - Indian J Palliat Care
JT  - Indian journal of palliative care
JID - 101261221
PMC - PMC7534988
OTO - NOTNLM
OT  - Challenges
OT  - health care professionals
OT  - non COVID
OT  - pandemic
COIS- There are no conflicts of interest.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 05:36
PHST- 2020/05/21 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/10/22 05:36 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - 10.4103/IJPC.IJPC_155_20 [doi]
AID - IJPC-26-21 [pii]
PST - ppublish
SO  - Indian J Palliat Care. 2020 Jun;26(Suppl 1):S21-S26. doi:
      10.4103/IJPC.IJPC_155_20. Epub 2020 Jun 30.


PMID- 33087650
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 0369-4305 (Print)
IS  - 0369-4305 (Linking)
VI  - 76
IP  - 10
DP  - 2020
TI  - [13. Research Ethics and Prevention of Research Fraud].
PG  - 1047-1051
LID - 10.6009/jjrt.2020_JSRT_76.10.1047 [doi]
FAU - Takei, Hiroyuki
AU  - Takei H
AD  - Department of Radiology, Gunma University Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Hoshasen Gijutsu Gakkai Zasshi
JT  - Nihon Hoshasen Gijutsu Gakkai zasshi
JID - 7505722
SB  - IM
MH  - *Biomedical Research
MH  - Ethics, Research
MH  - *Fraud
EDAT- 2020/10/23 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/22 05:29
PHST- 2020/10/22 05:29 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.6009/jjrt.2020_JSRT_76.10.1047 [doi]
PST - ppublish
SO  - Nihon Hoshasen Gijutsu Gakkai Zasshi. 2020;76(10):1047-1051. doi:
      10.6009/jjrt.2020_JSRT_76.10.1047.


PMID- 33087615
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 273
DP  - 2020 Sep 4
TI  - Evaluations of Decision Support Tools Are Preference-Sensitive and
      Interest-Conflicted: The Case of Deliberation Aids.
PG  - 217-222
LID - 10.3233/SHTI200643 [doi]
AB  - The questions 'What constitutes a good health care decision?', and, by extension,
      'What constitutes good healthcare decision support?' continue to be asked. The
      most developed answers focus largely, often exclusively, on the quality of the
      'deliberation' component as the determinant of the quality of the decision or
      decision aid. We argue that these answers and resulting aids reflect the
      preferences of healthcare professionals and aid developers and that these
      preferences are closely aligned with their interests. Some interests are
      material, but many professional, institutional, intellectual, methodological, and
      ethical. Successful promotion of a particular preference-sensitive,
      interest-conflicted decision aid does not change its ontological nature.
      Conflicts of interest are therefore universal and of concern only when this
      ontology is denied and if aids based on alternative interest-based preferences,
      such as technologies involving numerical analytic calculation, are subjected to
      discrimination.
FAU - Dowie, Jack
AU  - Dowie J
AD  - London School of Hygiene and Tropical Medicine.
AD  - University of Southern Denmark.
FAU - Kaltoft, Mette Kjer
AU  - Kaltoft MK
AD  - University of Southern Denmark.
FAU - Rajput, Vije Kumar
AU  - Rajput VK
AD  - Stonydelph Health Centre, Tamworth, UK.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Conflict of Interest
MH  - *Decision Support Techniques
MH  - Delivery of Health Care
OTO - NOTNLM
OT  - Decision quality
OT  - conflict of interest
OT  - decision aid
OT  - deliberation
OT  - evaluation
OT  - preference-sensitive
OT  - three-talk-model
EDAT- 2020/10/23 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/22 05:29
PHST- 2020/10/22 05:29 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - SHTI200643 [pii]
AID - 10.3233/SHTI200643 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Sep 4;273:217-222. doi: 10.3233/SHTI200643.


PMID- 33087613
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 273
DP  - 2020 Sep 4
TI  - The STAR-C Intelligent Coach: A Cross-Disciplinary Design Process of a Behavior
      Change Intervention in Primary Care.
PG  - 203-208
LID - 10.3233/SHTI200640 [doi]
AB  - A broad range of aspects are needed to be taken into consideration in the design 
      and development of personalized coaching systems based on artificial intelligence
      methodologies. This research presents the initial phase of joining different
      professional and stakeholder perspectives on behavior change technologies into a 
      flexible design proposal for a digital coaching system. The diversity and
      sometimes opposed views on content, behavior, purposes and context were managed
      using a structured argument-based design approach, which also feed into the
      behavior of the personalized system. Results include a set of personalization
      strategies that will be further elaborated with the target user group to manage
      sensitive issues such as ethics, social norms, privacy, motivation, autonomy and 
      social relatedness.
FAU - Lindgren, Helena
AU  - Lindgren H
AD  - Department of Computing Science, Umea University, Sweden.
FAU - Guerrero, Esteban
AU  - Guerrero E
AD  - Department of Computing Science, Umea University, Sweden.
FAU - Jingar, Monika
AU  - Jingar M
AD  - Department of Computing Science, Umea University, Sweden.
FAU - Lindvall, Kristina
AU  - Lindvall K
AD  - Department of Epidemiology and Global Health, Umea University.
FAU - Ng, Nawi
AU  - Ng N
AD  - Department of Epidemiology and Global Health, Umea University.
FAU - Richter Sundberg, Linda
AU  - Richter Sundberg L
AD  - Department of Epidemiology and Global Health, Umea University.
FAU - Santosa, Ailiana
AU  - Santosa A
AD  - Department of Epidemiology and Global Health, Umea University.
FAU - Weinehall, Lars
AU  - Weinehall L
AD  - Department of Epidemiology and Global Health, Umea University.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Artificial Intelligence
MH  - *Mentoring
MH  - Motivation
MH  - Primary Health Care
MH  - Privacy
OTO - NOTNLM
OT  - argumentation theory
OT  - behavior change
OT  - cardiovascular diseases
OT  - intelligent agents
OT  - participatory action design
OT  - personalization
OT  - persuasive technology
EDAT- 2020/10/23 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/22 05:29
PHST- 2020/10/22 05:29 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - SHTI200640 [pii]
AID - 10.3233/SHTI200640 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Sep 4;273:203-208. doi: 10.3233/SHTI200640.


PMID- 33087590
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 273
DP  - 2020 Sep 4
TI  - Application of Industry 4.0 Concept to Health Care.
PG  - 23-37
LID - 10.3233/SHTI200613 [doi]
AB  - The paper describes the concept of the Industry 4.0 and its reflection in health 
      care. Industry 4.0 connects intelligent production concepts with external
      factors, including those linked with the production and those linked more with
      human, as for example intelligent homes or social web systems. Communication,
      data and information play an important role in the whole system. After explaining
      basic characteristics of the Industry 4.0 concept and its main parts, we show how
      they can be utilized in the health care sector and what their advantages are. Key
      technologies and techniques include Internet of Things, big data, artificial
      intelligence, data integration, robotization, virtual reality, and 3D printing.
      Finally, we identify the main challenges and research directions. Among the most 
      important ones are interoperability, standardization, reliability, security and
      privacy, ethical and legal issues.
FAU - Lhotska, Lenka
AU  - Lhotska L
AD  - Czech Institute of Informatics, Robotics and Cybernetics.
AD  - Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, 
      Czech Republic.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Artificial Intelligence
MH  - Big Data
MH  - *Delivery of Health Care
MH  - Humans
MH  - Industry
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Health 4.0
OT  - Industry 4.0
OT  - Internet of Things
OT  - Virtual Reality
OT  - artificial intelligence
OT  - monitoring
EDAT- 2020/10/23 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/22 05:29
PHST- 2020/10/22 05:29 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - SHTI200613 [pii]
AID - 10.3233/SHTI200613 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Sep 4;273:23-37. doi: 10.3233/SHTI200613.


PMID- 33087539
OWN - NLM
STAT- Publisher
LR  - 20201022
IS  - 2633-3775 (Electronic)
IS  - 2633-3767 (Linking)
DP  - 2020 Oct 21
TI  - Experiences of medical practitioners in the Australian Defence Force on live
      tissue trauma training.
LID - bmjmilitary-2020-001550 [pii]
LID - 10.1136/bmjmilitary-2020-001550 [doi]
AB  - INTRODUCTION: Care of battle casualties is a central role of military medical
      practitioners. Historically, certain trauma procedural skills have been learnt
      through live tissue training. However, faced with opposition from community
      members and academics, who argue equivalence of non-animal alternatives, this is 
      now being phased out. This study explores Australian military medical
      practitioners' experiences of and attitudes towards live tissue training. METHOD:
      We performed a phenomenologically driven qualitative exploration of individuals' 
      experiences of live tissue trauma training. 32 medical officers volunteered for
      the study. In-depth interviews were conducted with 15 practitioners (60% Army,
      20% Air Force, 20% Navy; 33% surgical, 53% critical care, 13% general practice). 
      Qualitative data were subjected to content analysis, with key themes identified
      using manual and computer-assisted coding. RESULTS: Live tissue training was
      valued by military medical practitioners, particularly because of the realistic
      feel of tissues and physiological responsiveness to treatment. Learner-perceived 
      value of live tissue training was higher for complex skills and those requiring
      delicate tissue handling. 100% of surgeons and critical care doctors regarded
      live tissue as the only suitable model for learning repair of penetrating cardiac
      injury. Live tissue training was felt to enhance self-efficacy, particularly for 
      rarely applied skills. Though conscious of the social and ethical context of live
      tissue training, >90% of participants reported positive emotional responses to
      live tissue training. CONCLUSION: In contrast to published research, live tissue 
      training was thought by participants to possess characteristics that are not yet 
      replicable using alternative learning aids. The experienced positive values of
      live tissue training should inform the decision to move towards non-animal
      alternatives.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Mahoney, Adam
AU  - Mahoney A
AUID- ORCID: http://orcid.org/0000-0002-3097-7096
AD  - 2nd General Health Battalion, Australian Army, Brisbane, Queensland, Australia
      adam.mahoney@defence.gov.au.
FAU - Reade, M C
AU  - Reade MC
AUID- ORCID: http://orcid.org/0000-0003-1570-0707
AD  - Joint Health Command, Australian Defence Force, Herston, Queensland, Australia.
AD  - Burns, Trauma and Critical Care Research Centre, University of Queensland,
      Herston, Queensland, Australia.
FAU - Moffat, M
AU  - Moffat M
AD  - Centre for Medical Education, University of Dundee College of Medicine, Dentistry
      and Nursing, Dundee, UK.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - England
TA  - BMJ Mil Health
JT  - BMJ military health
JID - 101761581
SB  - IM
OTO - NOTNLM
OT  - medical education & training
OT  - surgery
OT  - trauma management
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/10/22 05:29
PHST- 2020/05/29 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/10/22 05:29 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
AID - bmjmilitary-2020-001550 [pii]
AID - 10.1136/bmjmilitary-2020-001550 [doi]
PST - aheadofprint
SO  - BMJ Mil Health. 2020 Oct 21. pii: bmjmilitary-2020-001550. doi:
      10.1136/bmjmilitary-2020-001550.


PMID- 33087409
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20220220
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Identity, well-being and autonomy in ongoing puberty suppression for non-binary
      adults: a response to the commentaries.
PG  - 761-762
LID - 10.1136/medethics-2020-106942 [doi]
FAU - Notini, Lauren
AU  - Notini L
AUID- ORCID: 0000-0001-5055-9505
AD  - Melbourne Law School, University of Melbourne, Melbourne, Victoria, Australia
      lauren.notini@unimelb.edu.au.
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Parkville, Victoria, Australia.
FAU - Earp, Brian D
AU  - Earp BD
AUID- ORCID: 0000-0001-9691-2888
AD  - Yale-Hastings Program in Ethics and Health Policy, Yale University, New Haven,
      Connecticut, United States and The Hastings Center, Garrison, New York, United
      States.
AD  - The Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford,
      United Kingdom.
FAU - Gillam, Lynn
AU  - Gillam L
AUID- ORCID: 0000-0001-6481-5004
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Children's Bioethics Centre, The Royal Children's Hospital Melbourne, Parkville, 
      Victoria, Australia.
FAU - Savulescu, Julian
AU  - Savulescu J
AUID- ORCID: 0000-0003-1691-6403
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Parkville, Victoria, Australia.
AD  - The Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford,
      United Kingdom.
AD  - University of Oxford, Oxford, United Kingdom.
AD  - University of Melbourne, Melbourne, Victoria, Australia.
FAU - Telfer, Michelle
AU  - Telfer M
AUID- ORCID: 0000-0002-3000-5297
AD  - Department of Adolescent Medicine, The Royal Children's Hospital Melbourne,
      Parkville, Victoria, Australia.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Pang, Ken C
AU  - Pang KC
AUID- ORCID: 0000-0002-6881-775X
AD  - Department of Adolescent Medicine, The Royal Children's Hospital Melbourne,
      Parkville, Victoria, Australia.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
AD  - The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria,
      Australia.
LA  - eng
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - WT203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - WT104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20201021
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):743-752. PMID: 32709753
CON - J Med Ethics. 2020 Nov;46(11):759-760. PMID: 32839229
CON - J Med Ethics. 2020 Nov;46(11):757-758. PMID: 32878919
CON - J Med Ethics. 2020 Nov;46(11):755-756. PMID: 32883708
CON - J Med Ethics. 2020 Nov;46(11):753-754. PMID: 33033114
MH  - Adult
MH  - *Gender Identity
MH  - Humans
MH  - *Puberty
OTO - NOTNLM
OT  - *autonomy
OT  - *clinical ethics
OT  - *concept of health
OT  - *philosophy of the health professions
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/09/24 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/10/22 05:28 [entrez]
AID - medethics-2020-106942 [pii]
AID - 10.1136/medethics-2020-106942 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):761-762. doi: 10.1136/medethics-2020-106942. Epub
      2020 Oct 21.


PMID- 33087383
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - Understanding and responding to COVID-19 in Wales: protocol for a
      privacy-protecting data platform for enhanced epidemiology and evaluation of
      interventions.
PG  - e043010
LID - 10.1136/bmjopen-2020-043010 [doi]
AB  - INTRODUCTION: The emergence of the novel respiratory SARS-CoV-2 and subsequent
      COVID-19 pandemic have required rapid assimilation of population-level data to
      understand and control the spread of infection in the general and vulnerable
      populations. Rapid analyses are needed to inform policy development and target
      interventions to at-risk groups to prevent serious health outcomes. We aim to
      provide an accessible research platform to determine demographic, socioeconomic
      and clinical risk factors for infection, morbidity and mortality of COVID-19, to 
      measure the impact of COVID-19 on healthcare utilisation and long-term health,
      and to enable the evaluation of natural experiments of policy interventions.
      METHODS AND ANALYSIS: Two privacy-protecting population-level cohorts have been
      created and derived from multisourced demographic and healthcare data. The C20
      cohort consists of 3.2 million people in Wales on the 1 January 2020 with
      follow-up until 31 May 2020. The complete cohort dataset will be updated monthly 
      with some individual datasets available daily. The C16 cohort consists of 3
      million people in Wales on the 1 January 2016 with follow-up to 31 December 2019.
      C16 is designed as a counterfactual cohort to provide contextual comparative
      population data on disease, health service utilisation and mortality. Study
      outcomes will: (a) characterise the epidemiology of COVID-19, (b) assess
      socioeconomic and demographic influences on infection and outcomes, (c) measure
      the impact of COVID-19 on short -term and longer-term population outcomes and (d)
      undertake studies on the transmission and spatial spread of infection. ETHICS AND
      DISSEMINATION: The Secure Anonymised Information Linkage-independent Information 
      Governance Review Panel has approved this study. The study findings will be
      presented to policy groups, public meetings, national and international
      conferences, and published in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lyons, Jane
AU  - Lyons J
AUID- ORCID: 0000-0002-4407-770X
AD  - Population Data Science, Swansea University Medical School, Swansea, UK
      j.lyons@swansea.ac.uk.
FAU - Akbari, Ashley
AU  - Akbari A
AUID- ORCID: 0000-0003-0814-0801
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Torabi, Fatemeh
AU  - Torabi F
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Davies, Gareth I
AU  - Davies GI
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - North, Laura
AU  - North L
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Griffiths, Rowena
AU  - Griffiths R
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Bailey, Rowena
AU  - Bailey R
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Hollinghurst, Joseph
AU  - Hollinghurst J
AUID- ORCID: 0000-0002-3556-2017
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Fry, Richard
AU  - Fry R
AUID- ORCID: 0000-0002-7968-6679
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Turner, Samantha L
AU  - Turner SL
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Thompson, Daniel
AU  - Thompson D
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Rafferty, James
AU  - Rafferty J
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Mizen, Amy
AU  - Mizen A
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Orton, Chris
AU  - Orton C
AUID- ORCID: 0000-0002-9561-2493
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Thompson, Simon
AU  - Thompson S
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Au-Yeung, Lee
AU  - Au-Yeung L
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Cross, Lynsey
AU  - Cross L
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Gravenor, Mike B
AU  - Gravenor MB
AD  - Institute of Life Sciences, Swansea University Medical School, Swansea, UK.
FAU - Brophy, Sinead
AU  - Brophy S
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Lucini, Biagio
AU  - Lucini B
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - John, Ann
AU  - John A
AUID- ORCID: 0000-0002-5657-6995
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
FAU - Szakmany, Tamas
AU  - Szakmany T
AD  - Department of Anaesthesia, Intensive Care and Pain Medicine, Division of
      Population Medicine, Cardiff University, Cardiff, UK.
AD  - Aneurin Bevan University Health Board, Newport, UK.
FAU - Davies, Jan
AU  - Davies J
AD  - Members of the public, Swansea, UK.
FAU - Davies, Chris
AU  - Davies C
AD  - Members of the public, Swansea, UK.
FAU - Thomas, Daniel Rh
AU  - Thomas DR
AD  - Public Health Wales NHS Trust, Cardiff, Cardiff, UK.
FAU - Williams, Christopher
AU  - Williams C
AD  - Public Health Wales NHS Trust, Cardiff, Cardiff, UK.
FAU - Emmerson, Chris
AU  - Emmerson C
AD  - Public Health Wales NHS Trust, Cardiff, Cardiff, UK.
FAU - Cottrell, Simon
AU  - Cottrell S
AD  - Public Health Wales NHS Trust, Cardiff, Cardiff, UK.
FAU - Connor, Thomas R
AU  - Connor TR
AD  - School of Biosciences, Cardiff University, Cardiff, South Glamorgan, UK.
FAU - Taylor, Chris
AU  - Taylor C
AD  - School of Social Sciences, Cardiff University, Cardiff, South Glamorgan, UK.
FAU - Pugh, Richard J
AU  - Pugh RJ
AD  - Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Rhyl, UK.
FAU - Diggle, Peter
AU  - Diggle P
AD  - Faculty of Health and Medicine, Lancaster University, Lancaster, Lancashire, UK.
AD  - Epidemiology and Population Health, University of Liverpool, Liverpool,
      Merseyside, UK.
FAU - John, Gareth
AU  - John G
AD  - NHS Wales Informatics Service, Cardiff, Wales, UK.
FAU - Scourfield, Simon
AU  - Scourfield S
AD  - NHS Wales Informatics Service, Cardiff, Wales, UK.
FAU - Hunt, Joe
AU  - Hunt J
AD  - NHS Wales Informatics Service, Cardiff, Wales, UK.
FAU - Cunningham, Anne M
AU  - Cunningham AM
AD  - NHS Wales Informatics Service, Cardiff, Wales, UK.
FAU - Helliwell, Kathryn
AU  - Helliwell K
AD  - Welsh Government, Cardiff, Cardiff, UK.
FAU - Lyons, Ronan
AU  - Lyons R
AUID- ORCID: 0000-0001-5225-000X
AD  - Population Data Science, Swansea University Medical School, Swansea, UK.
LA  - eng
GR  - MR/V028367/1/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_20029/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
GR  - MR/S027750/1/MRC_/Medical Research Council/United Kingdom
GR  - HCRW_SCF-18-1504/HCRW/HCRW_/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Delivery of Health Care/*standards
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Wales/epidemiology
PMC - PMC7580065
OTO - NOTNLM
OT  - *COVID-19
OT  - *epidemiology
OT  - *health informatics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - bmjopen-2020-043010 [pii]
AID - 10.1136/bmjopen-2020-043010 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e043010. doi: 10.1136/bmjopen-2020-043010.


PMID- 33087380
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for 
      a prospective observational multicentre cohort study in inflammatory bowel
      disease and irritable bowel syndrome.
PG  - e041733
LID - 10.1136/bmjopen-2020-041733 [doi]
AB  - INTRODUCTION: Gut microbiome and diet may be important in irritable bowel
      syndrome (IBS), inflammatory bowel disease (IBD) and comorbid psychiatric
      conditions, but the mechanisms are unclear. We will create a large cohort of
      patients with IBS, IBD and healthy controls, and follow them over time,
      collecting dietary and mental health information and biological samples, to
      assess their gastrointestinal (GI) and psychological symptoms in association with
      their diet, gut microbiome and metabolome. METHODS AND ANALYSIS: This 5-year
      observational prospective cohort study is recruiting 8000 participants from 15
      Canadian centres. Persons with IBS who are 13 years of age and older or IBD >/=5 
      years will be recruited. Healthy controls will be recruited from the general
      public and from friends or relatives of those with IBD or IBS who do not have GI 
      symptoms. Participants answer surveys and provide blood, urine and stool samples 
      annually. Surveys assess disease activity, quality of life, physical pain,
      lifestyle factors, psychological status and diet. The main outcomes evaluated
      will be the association between the diet, inflammatory, genetic, microbiome and
      metabolomic profiles in those with IBD and IBS compared with healthy controls
      using multivariate logistic regression. We will also compare these profiles in
      those with active versus quiescent disease and those with and without
      psychological comorbidity. ETHICS AND DISSEMINATION: Approval has been obtained
      from the institutional review boards of all centres taking part in the study. We 
      will develop evidence-based knowledge translation initiatives for patients,
      clinicians and policymakers to disseminate results to relevant stakeholders.Trial
      registration number: NCT03131414.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Moayyedi, Paul
AU  - Moayyedi P
AUID- ORCID: 0000-0002-3616-9292
AD  - Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario,
      Canada moayyep@mcmaster.ca.
FAU - MacQueen, Glenda
AU  - MacQueen G
AD  - Medicine, University of Calgary, Calgary, Alberta, Canada.
FAU - Bernstein, Charles N
AU  - Bernstein CN
AD  - Gastroenterology, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Vanner, Stephen
AU  - Vanner S
AD  - Medicine, Queen's University, Kingston, Ontario, Canada.
FAU - Bercik, Premysl
AU  - Bercik P
AD  - Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario,
      Canada.
FAU - Madsen, Karen L
AU  - Madsen KL
AD  - Medicine, University of Alberta, Edmonton, Ontario, Canada.
FAU - Surette, Michael
AU  - Surette M
AD  - McMaster University Faculty of Health Sciences, Hamilton, Alberta, Canada.
FAU - Rioux, John D
AU  - Rioux JD
AD  - Universite de Montreal, Montreal, Ontario, Canada.
FAU - Dieleman, Levinus A
AU  - Dieleman LA
AD  - Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta,
      Canada.
FAU - Verdu, Elena
AU  - Verdu E
AD  - Division of Gastroenterology, McMaster University Faculty of Health Sciences,
      Hamilton, Ontario, Canada.
FAU - de Souza, Russell J
AU  - de Souza RJ
AD  - Department of Clinical Epidemiology and Biostatistics, McMaster University
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
FAU - Otley, Anthony
AU  - Otley A
AD  - Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Targownik, Laura
AU  - Targownik L
AD  - Mount Sinai Hospital, Toronto, Ontario, Canada.
FAU - Lavis, John
AU  - Lavis J
AD  - McMaster University Faculty of Health Sciences, Hamilton, Alberta, Canada.
FAU - Cunningham, Jennifer
AU  - Cunningham J
AUID- ORCID: 0000-0001-8137-6779
AD  - Population Health Research Institute, McMaster University Faculty of Health
      Sciences, Hamilton, Ontario, Canada.
FAU - Marshall, Deborah A
AU  - Marshall DA
AUID- ORCID: 0000-0002-8467-8008
AD  - Department of Community Health Sciences, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Zelinsky, Sandra
AU  - Zelinsky S
AD  - PaCER Innovates, University of Calgary, Calgary, Alberta, Canada.
FAU - Fernandes, Aida
AU  - Fernandes A
AD  - Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario,
      Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03131414
GR  - RN279389-35803/Canadian Institute of Health Research /International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Canada
MH  - Cohort Studies
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - *Inflammatory Bowel Diseases/epidemiology/microbiology
MH  - *Irritable Bowel Syndrome/epidemiology/microbiology
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Young Adult
PMC - PMC7580069
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *functional bowel disorders
OT  - *inflammatory bowel disease
OT  - *microbiology
OT  - *nutritional support
COIS- Competing interests: PM holds the Audrey Campbell Chair in Ulcerative Colitis
      Research. PM, PB and AF have no conflicts of interest. CNB is supported in part
      by the Bingham Chair in Gastroenterology. He is on Advisory Boards for AbbVie
      Canada, Janssen Canada, Takeda Canada, Pfizer Canada. He is a consultant for
      Mylan Pharmaceuticals. He is receiving educational grants from AbbVie Canada,
      Pfizer Canada, Shire Canada, Takeda Canada, Janssen Canada. Speaker's panel for
      AbbVie Canada, Janssen Canada, Takeda Canada, and Medtronic Canada. Received
      research funding from AbbVie Canada. JDR receives research funding from Pfizer.
      LAD is on the Advisory Boards for Janssen Canada, AbbVie Canada, Pfizer Canada
      and Takeda Canada. DAM holds a Canada Research Chair (2008-2018) and the Arthur
      J.E. Child Chair and receives travel reimbursement through Illumina for meetings 
      of the Global Economics and Evaluation of Clinical Genomics Sequencing Working
      Group. SV was supported by an educational grant from Allergan. SZ is a patient
      research partner and received a grant from Takeda Canada.
EDAT- 2020/10/23 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-041733 [pii]
AID - 10.1136/bmjopen-2020-041733 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e041733. doi: 10.1136/bmjopen-2020-041733.


PMID- 33087379
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - Reproductive patterns, pregnancy outcomes and parental leave practices of women
      physicians in Ontario, Canada: the Dr Mom Cohort Study protocol.
PG  - e041281
LID - 10.1136/bmjopen-2020-041281 [doi]
AB  - INTRODUCTION: Surveys and qualitative studies suggest that women physicians may
      delay childbearing, be at increased risk of adverse peripartum complications when
      they do become pregnant, and face discrimination and lower earnings as a result
      of parenthood. Observational studies enrolling large, representative samples of
      women physicians are needed to accurately evaluate their reproductive patterns,
      pregnancy outcomes, parental leave practices and earnings. This protocol provides
      a detailed research plan for such studies. METHODS AND ANALYSIS: The Dr Mom
      Cohort Study encompasses a series of retrospective observational studies of women
      physicians in Ontario, Canada. All practising physicians in Ontario are
      registered with the College of Physicians and Surgeons of Ontario (CPSO). By
      linking a dataset of physicians from the CPSO to existing provincial
      administrative databases, which hold health data and physician billing records,
      we will be able to retrospectively assess the healthcare utilisation, work
      practices and pregnancy outcomes of women physicians at the population level.
      Specific outcomes of interest include: (1) rates and timing of pregnancy; (2)
      pregnancy-related care and complications; and (3) duration of parental leave and 
      subsequent earnings, each of which will be evaluated with regression methods
      appropriate to the form of the outcome. We estimate that, at minimum, 5000 women 
      physicians will be eligible for inclusion. ETHICS AND DISSEMINATION: This
      protocol has been approved by the Research Ethics Board at St. Michael's Hospital
      in Toronto, Ontario, Canada (#18-248). We will disseminate findings through
      several peer-reviewed publications, presentations at national and international
      meetings, and engagement of physicians, residency programmes, department heads
      and medical societies.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cusimano, Maria C
AU  - Cusimano MC
AUID- ORCID: 0000-0002-1661-4846
AD  - Department of Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, 
      Canada.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
FAU - Baxter, Nancy N
AU  - Baxter NN
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - Melbourne School of Population and Global Heath, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
FAU - Sutradhar, Rinku
AU  - Sutradhar R
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
AD  - Division of Biostatistics, Dalla Lana School of Public Health, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Ray, Joel G
AU  - Ray JG
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
AD  - Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
FAU - Garg, Amit X
AU  - Garg AX
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
AD  - Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.
FAU - McArthur, Eric
AU  - McArthur E
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
FAU - Vigod, Simone
AU  - Vigod S
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
AD  - Department of Psychiatry, Women's College Hospital, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, Women's College Research Institute, Women's College
      Hospital, Toronto, Ontario, Canada.
FAU - Simpson, Andrea N
AU  - Simpson AN
AD  - Department of Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, 
      Canada Andrea.Simpson@unityhealth.to.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - ICES (Formerly the Institute for Clinical Evaluative Sciences), Toronto, Ontario,
      Canada.
AD  - Department of Obstetrics & Gynaecology, St. Michael's Hospital/Unity Health
      Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Observational Studies as Topic
MH  - Ontario
MH  - *Parental Leave
MH  - *Physicians, Women
MH  - Pregnancy
MH  - Pregnancy Outcome/epidemiology
MH  - Retrospective Studies
PMC - PMC7580071
OTO - NOTNLM
OT  - *epidemiology
OT  - *general medicine (see Internal Medicine)
OT  - *maternal medicine
OT  - *medical education & training
OT  - *obstetrics
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-041281 [pii]
AID - 10.1136/bmjopen-2020-041281 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e041281. doi: 10.1136/bmjopen-2020-041281.


PMID- 33087375
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - Retrospective chart review and survey to identify adverse safety events in the
      emergency medical services care of children with out-of-hospital cardiac arrest
      in the USA: a study protocol.
PG  - e039215
LID - 10.1136/bmjopen-2020-039215 [doi]
AB  - INTRODUCTION: Efforts to improve the quality of emergency medical services (EMS) 
      care for adults with out-of-hospital cardiac arrest (OHCA) have led to improved
      survival over time. Similar improvements have not been observed for children with
      OHCA, who may be at increased risk for preventable adverse safety events during
      prehospital care. The purpose of this study is to identify patient and
      organisational factors that are associated with adverse safety events during the 
      EMS care of paediatric OHCA. METHODS AND ANALYSIS: This is a large multisite EMS 
      study in the USA consisting of chart reviews and agency surveys to measure,
      characterise and evaluate predictors of our primary outcome severe adverse safety
      events in paediatric OHCA. Using the previously validated Paediatric prehospital 
      adverse Event Detection System tool, we will review EMS charts for 1500 children 
      with OHCA from 2013 to 2019 to collect details of each case and identify severe
      adverse safety events (ASEs). Cases will be drawn from over 40 EMS agencies in at
      least five states in geographically diverse areas of the USA. EMS agencies
      providing charts will also be invited to complete an agency survey to capture
      organisational characteristics. We will describe the frequency and proportion of 
      severe ASEs in paediatric OHCA across geographic regions and clinical domains,
      and identify patient and EMS organisational characteristics associated with
      severe ASEs using logistic regression. ETHICS AND DISSEMINATION: This study has
      been approved by the Oregon Health & Science University Institutional Review
      Board (IRB Approval# 00018748). Study results will be disseminated through
      scientific publications and presentations, and to EMS leaders and staff through
      local EMS medical directors, quality and training officers and community
      engagement activities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Eriksson, Carl
AU  - Eriksson C
AUID- ORCID: 0000-0002-1885-4800
AD  - Pediatrics, Oregon Health and Science University, Portland, Oregon, USA
      eriksson@ohsu.edu.
FAU - Schoonover, Amanda
AU  - Schoonover A
AD  - Obstetrics and Gynecology, Oregon Health and Science University, Portland,
      Oregon, USA.
FAU - Harrod, Tabria
AU  - Harrod T
AUID- ORCID: 0000-0002-5005-3667
AD  - Obstetrics and Gynecology, Oregon Health and Science University, Portland,
      Oregon, USA.
FAU - Meckler, Garth
AU  - Meckler G
AUID- ORCID: 0000-0002-6057-0465
AD  - Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Hansen, Matt
AU  - Hansen M
AUID- ORCID: 0000-0003-2958-6423
AD  - Emergency Medicine, Oregon Health and Science University, Portland, Oregon, USA.
FAU - Yanez, David
AU  - Yanez D
AUID- ORCID: 0000-0002-2501-5028
AD  - Anesthesiology, Yale University, New Haven, Connecticut, USA.
FAU - Daya, Mo
AU  - Daya M
AUID- ORCID: 0000-0002-6910-8293
AD  - Emergency Medicine, Oregon Health and Science University, Portland, Oregon, USA.
FAU - Jui, Jonathan
AU  - Jui J
AUID- ORCID: 0000-0002-9663-6542
AD  - Emergency Medicine, Oregon Health and Science University, Portland, Oregon, USA.
FAU - Guise, Jeanne-Marie
AU  - Guise JM
AUID- ORCID: 0000-0002-8961-488X
AD  - Obstetrics and Gynecology, Oregon Health and Science University, Portland,
      Oregon, USA.
LA  - eng
GR  - R01 HL141429/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiopulmonary Resuscitation
MH  - Child
MH  - *Emergency Medical Services
MH  - Female
MH  - Humans
MH  - Male
MH  - Oregon
MH  - *Out-of-Hospital Cardiac Arrest/therapy
MH  - Registries
MH  - Retrospective Studies
MH  - United States/epidemiology
PMC - PMC7580068
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *epidemiology
OT  - *health & safety
OT  - *paediatric A&E and ambulatory care
OT  - *paediatrics
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-039215 [pii]
AID - 10.1136/bmjopen-2020-039215 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e039215. doi: 10.1136/bmjopen-2020-039215.


PMID- 33087374
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - Valuation study for a preference-based quality of life measure for dental caries 
      (Dental Caries Utility Index - DCUI) among Australian adolescents - study
      protocol.
PG  - e038626
LID - 10.1136/bmjopen-2020-038626 [doi]
AB  - INTRODUCTION: A new health state classification system has been developed for
      dental caries - Dental Caries Utility Index (DCUI) to facilitate the assessment
      of oral health interventions in the cost-utility analysis (CUA). This paper
      reports the protocol for a valuation study, which aims to generate a
      preference-based algorithm for the classification system for the DCUI. METHODS
      AND ANALYSIS: Discrete choice experiments (DCEs) will be conducted to value
      health states generated by the DCUI classification system and preferences for
      these health states will be modelled to develop a utility algorithm. DCEs produce
      utility values on a latent scale and these values will be anchored into the full 
      health-dead scale to calculate the quality-adjusted life years in CUA. There is
      no previous evidence for the most suitable anchoring method for dental caries
      health state valuation. Hence, we will first conduct pilot studies with two
      anchoring approaches; DCE including duration attribute and DCE anchoring to worst
      heath state in Visual Analogue Scale. Based on the pilot studies, the most
      suitable anchoring method among two approaches will be used in the main valuation
      survey, which will be conducted as an online survey among a representative sample
      of 2000 adults from the Australian general population. Participants will be asked
      to complete a set of DCE choice tasks along with anchoring tasks, basic
      social-demographic questions, DCUI, a generic preference-based measure and oral
      health quality of life instrument. ETHICS AND DISSEMINATION: Ethical approval for
      this study was obtained from the Human Research Ethics Committee, Griffith
      University (reference number HREC/2019/550). The generated algorithm will
      facilitate the use of the new dental caries preference-based measure in economic 
      evaluations of oral health interventions. The results will be disseminated
      through journal articles and professional conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hettiarachchi, Ruvini
AU  - Hettiarachchi R
AUID- ORCID: 0000-0003-3501-2645
AD  - Centre for Applied Health Economics, School of Medicine, Griffith University,
      Nathan, Queensland, Australia ruvini.hettiarachchi@griffithuni.edu.au.
AD  - Menzies Health Institute Queensland, Griffith University, Nathan, Queensland,
      Australia.
FAU - Kularatna, Sanjeewa
AU  - Kularatna S
AUID- ORCID: 0000-0001-5650-154X
AD  - Australian Centre for Health Services Innovation, Queensland University of
      Technology, Institute of Health and Biomedical Innovation, Kelvin Grove,
      Queensland, Australia.
FAU - Byrnes, Joshua
AU  - Byrnes J
AD  - Centre for Applied Health Economics, School of Medicine, Griffith University,
      Nathan, Queensland, Australia.
AD  - Menzies Health Institute Queensland, Griffith University, Nathan, Queensland,
      Australia.
FAU - Mulhern, Brendan
AU  - Mulhern B
AD  - Centre for Health Economics Research and Evaluation, University of Technology
      Sydney, Sydney, New South Wales, Australia.
FAU - Chen, Gang
AU  - Chen G
AD  - Centre for Health Economics, Monash University, Clayton, Victoria, Australia.
FAU - Scuffham, Paul A
AU  - Scuffham PA
AD  - Centre for Applied Health Economics, School of Medicine, Griffith University,
      Nathan, Queensland, Australia.
AD  - Menzies Health Institute Queensland, Griffith University, Nathan, Queensland,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia
MH  - Child
MH  - *Dental Caries
MH  - Health Status
MH  - Humans
MH  - *Quality of Life
MH  - Quality-Adjusted Life Years
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7580066
OTO - NOTNLM
OT  - *health economics
OT  - *oral medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038626 [pii]
AID - 10.1136/bmjopen-2020-038626 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e038626. doi: 10.1136/bmjopen-2020-038626.


PMID- 33087371
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - Violence against women during pregnancy and postpartum period: a mixed methods
      study protocol.
PG  - e037522
LID - 10.1136/bmjopen-2020-037522 [doi]
AB  - INTRODUCTION: Violence against women is a public health problem that poses
      serious consequences for victims and their environments. The healthcare system
      struggles to assess this phenomenon during prenatal and postpartum care because
      of pregnant and postpartum women's potential vulnerabilities. The research
      protocol presents the aims to evaluate the prevalence of violence, the period(s) 
      in which it occurs, aggressors and forms it takes as well as to explore how
      violence against women is perceived among pregnant and postpartum women. METHODS 
      AND ANALYSIS: This mixed methods study protocol uses an explanatory sequential
      design and is based on the establishment of meta-inferences that result from the 
      combination of quantitative and qualitative approaches. Probabilistic sampling
      will be used to select the study participants: 584 women attending prenatal
      and/or postpartum care outpatient services at the University of Campinas Women's 
      Hospital, Brazil. The quantitative approach will consist of four validated
      questionnaires, and the qualitative approach will use focus groups that serve to 
      deepen the understanding of participants' views about the study topic. To create 
      the focus groups, 72 study participants will be invited and divided into 6 groups
      (3 adolescents and 3 adults) based on age and pregnancy/postpartum condition.
      Descriptive analysis of sociodemographic characteristics and questionnaire
      results will be used to identify the prevalence and forms of violence experienced
      by women during the pregnancy-puerperal cycle, the relationships between women
      and their aggressors, and the existence of a history of violence. A bivariate and
      multivariate analysis will be performed to identify the association between
      sociodemographic factors and violence as an outcome. Qualitative data will be
      analysed through Grounded Theory to understand women's perceptions of the
      phenomenon studied. ETHICS AND DISSEMINATION: The research protocol was approved 
      by the Research Ethics Committee of the University of Campinas, Brazil number
      CAAE: 13426819.1.0000.5404. The results will be disseminated to the health
      science community.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sanchez, Odette Del Risco
AU  - Sanchez ODR
AUID- ORCID: 0000-0002-7094-0378
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Bonas, Mariana Kerche
AU  - Bonas MK
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Grieger, Isabella
AU  - Grieger I
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Baquete, Aline Geovanna Lima
AU  - Baquete AGL
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Nogueira Vieira, Daniella Aparecida
AU  - Nogueira Vieira DA
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Contieri Bozzo Campos, Bianca
AU  - Contieri Bozzo Campos B
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Guerazzi Pousa Pereira, Carla Grazielle
AU  - Guerazzi Pousa Pereira CG
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil.
FAU - Surita, Fernanda G
AU  - Surita FG
AUID- ORCID: 0000-0003-4335-0337
AD  - Department of Obstetrics & Gynecology, State University of Campinas, Campinas,
      Brazil surita@unicamp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brazil/epidemiology
MH  - Female
MH  - Humans
MH  - *Postpartum Period
MH  - Pregnancy
MH  - *Pregnancy Complications
MH  - Prevalence
MH  - Violence
PMC - PMC7580047
OTO - NOTNLM
OT  - *primary care
OT  - *public health
OT  - *qualitative research
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037522 [pii]
AID - 10.1136/bmjopen-2020-037522 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e037522. doi: 10.1136/bmjopen-2020-037522.


PMID- 33087369
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 21
TI  - Living with a left ventricular assist device: psychological burden and coping:
      protocol for a cross-sectional and longitudinal qualitative study.
PG  - e037017
LID - 10.1136/bmjopen-2020-037017 [doi]
AB  - INTRODUCTION: Due to technological progress and persistent shortage of donor
      hearts, left ventricular assist devices (LVADs) have become established in the
      treatment of advanced heart failure. Accordingly, more patients live with LVADs
      for prolonged periods. Related research focused primarily on clinical issues and 
      little is known about psychosocial aspects of living with an LVAD. This study
      aims to explore psychological burden and coping following LVAD implantation.
      METHODS AND ANALYSIS: An exploratory qualitative study with cross-sectional and
      longitudinal elements will be carried out. At least 18 patients with LVAD who
      have the device implanted from a few weeks to more than 3 years will be
      interviewed in the cross-sectional component using an interview guide. A
      subsample of patients who live with the LVAD for up to 3 months when recruited
      will be interviewed two additional times in the following year. The
      cross-sectional interviews will be analysed using an inductive qualitative
      content analysis to describe psychological burden, coping resources and behaviour
      from the patient's perspective. Based on the findings, the longitudinal
      interviews will be analysed with a deductive content analysis to explore
      psychological adjustment during the first year after implantation. The findings
      will provide a deeper understanding of the complex and specific situation of
      patients with LVAD and of psychological adjustment to living with a
      life-sustaining implant. This can help clinicians in considering individual
      aspects to promote patient outcomes and is the basis for further research on
      healthcare interventions or technical solutions to reduce burden and for
      developing rehabilitation measures to promote psychosocial outcomes. ETHICS AND
      DISSEMINATION: Ethical approval was obtained from the ethics committee of the
      School of Medicine and Health Sciences at the University of Oldenburg (2019-023).
      Study findings will be disseminated at national and international conferences and
      through peer-reviewed journals. TRIAL REGISTRATION NUMBER: German Clinical Trials
      Register (DRKS00016883).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Levelink, Michael
AU  - Levelink M
AUID- ORCID: 0000-0002-2024-8295
AD  - Department of Health Services Research, University of Oldenburg School of
      Medicine and Health Sciences, Oldenburg, Germany michael.levelink1@uol.de.
FAU - Eichstaedt, Harald Christian
AU  - Eichstaedt HC
AD  - Department of Cardiac Surgery, Klinikum Oldenburg AoR, Oldenburg, Niedersachsen, 
      Germany.
FAU - Meyer, Sven
AU  - Meyer S
AD  - Department of Cardiology, Klinikum Oldenburg AoR, Oldenburg, Niedersachsen,
      Germany.
FAU - Brutt, Anna Levke
AU  - Brutt AL
AD  - Department of Health Services Research, University of Oldenburg School of
      Medicine and Health Sciences, Oldenburg, Germany.
LA  - eng
SI  - DRKS/DRKS00016883
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adaptation, Psychological
MH  - Cross-Sectional Studies
MH  - *Heart Failure/therapy
MH  - *Heart Transplantation
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Quality of Life
MH  - Tissue Donors
PMC - PMC7580038
OTO - NOTNLM
OT  - *heart failure
OT  - *qualitative research
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037017 [pii]
AID - 10.1136/bmjopen-2020-037017 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 21;10(10):e037017. doi: 10.1136/bmjopen-2020-037017.


PMID- 33087336
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 2632-1009 (Electronic)
IS  - 2632-1009 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Oct
TI  - Students' perceptions on their use of an EHR: pilot questionnaire study.
LID - e100163 [pii]
LID - 10.1136/bmjhci-2020-100163 [doi]
AB  - INTRODUCTION: Many clinical education programmes have not incorporated the use of
      the electronic health record (EHR) into their curriculum. It is important to
      incorporate technologies that will be used in real-world settings to better
      prepare students for clinical practice. OBJECTIVES: To undertake a review of
      literature to identify a training evaluation framework; to conduct a
      self-completion survey, pretraining and post-training, to determine students'
      perceptions on the benefit of using EHR training system. SETTING: Nursing School,
      University, North West England, UK; University Ethic Committee Approval Received.
      PARTICIPANTS: Registered nurses undertaking a validated return to practice
      course; 24 participants for the first cohort who completed pretraining
      questionnaire and 23 for the second post-training cohort. RESULTS: The
      statistical results show that the students perceived that the training improved
      their capability in employing digital systems with statistically significant
      difference in the assessed preproficiency and post proficiency in the use of
      digital clinical systems (premedians and post medians are 2 and 5 on 10-point
      Likert scale, p=0.041). There was also an indication of an improvement in the
      knowledge of EHR systems although not statistically significant. Most students
      perceived it increased their knowledge on digital systems. CONCLUSION: Students
      perceived an increase in proficiency with the EHR. There was evidence of
      improvement in confidence in the use of the EHR, but this confidence would be
      enhanced by additional use of the system. Some desire to increase confidence
      further and to develop knowledge of digital systems was expressed.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ellis, Beverley S
AU  - Ellis BS
AUID- ORCID: http://orcid.org/0000-0003-0938-1172
AD  - Faculty of Health and Social Care, University of Central Lancashire, Preston,
      Lancashire, UK.
FAU - Quayle, Susan
AU  - Quayle S
AD  - School of Nursing, University of Central Lancashire, Preston, Lancashire, UK
      SQuayle2@uclan.ac.uk.
FAU - Bailey, Ian
AU  - Bailey I
AD  - Emis Health, Leeds, UK.
FAU - Tishkovskaya, Svetlana
AU  - Tishkovskaya S
AD  - Academic Research Support Team, University of Central Lancashire, Preston,
      Lancashire, UK.
FAU - Spencer, Joseph
AU  - Spencer J
AD  - Academic Research Support Team, University of Central Lancashire, Preston,
      Lancashire, UK.
FAU - Richardson, Robin
AU  - Richardson R
AD  - Faculty of Health and Social Care, University of Central Lancashire, Preston,
      Lancashire, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Health Care Inform
JT  - BMJ health & care informatics
JID - 101745500
SB  - IM
MH  - Curriculum
MH  - *Electronic Health Records/statistics & numerical data
MH  - Humans
MH  - *Nurses/statistics & numerical data
MH  - Nursing Evaluation Research/statistics & numerical data
MH  - Perception
MH  - *Students/statistics & numerical data
MH  - Surveys and Questionnaires
PMC - PMC7580040
OTO - NOTNLM
OT  - BMJ Health Informatics
OT  - nursing
COIS- Competing interests: None declared.
EDAT- 2020/10/23 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/10/22 05:28
PHST- 2020/04/21 00:00 [received]
PHST- 2020/08/13 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/10/22 05:28 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - bmjhci-2020-100163 [pii]
AID - 10.1136/bmjhci-2020-100163 [doi]
PST - ppublish
SO  - BMJ Health Care Inform. 2020 Oct;27(3). pii: bmjhci-2020-100163. doi:
      10.1136/bmjhci-2020-100163.


PMID- 33087161
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 21
TI  - Letter on Predicting the number of sites needed to deliver a multicentre clinical
      trial within a limited time frame in the UK.
PG  - 873
LID - 10.1186/s13063-020-04798-x [doi]
AB  - When planning a multicentre clinical trial, it can be difficult to predict the
      time needed to open individual sites, and this in turn impacts on the total
      number of sites needed, the budget and the time frame for a clinical trial to be 
      delivered successfully. This is of particular importance for funding applications
      with a limited time frame and budget such as NIHR RfPB. It is more efficient and 
      cost-effective to open the total number of sites needed at the outset of a trial,
      rather than to respond later to slow site opening and recruitment. Here, we share
      our experience of successfully delivering a multicentre clinical trial for a rare
      disease within a limited time frame and budget by approximately doubling the
      number of sites initially predicted to be needed. We initially predicted 20 sites
      would be needed to deliver the clinical trial, but early on in the trial, the
      number of sites was more than doubled to allow successful recruitment of the
      target sample size within the desired time frame. Of the 48 ethically approved
      sites, the median time from ethical approval of a site to opening for recruitment
      was 182 days (95% confidence interval [143 to 245 days]) and ranged from 18 to
      613 days. In four (9%) of these sites, part of the delay was due to pharmacy sign
      off not being given when R&D had issued capacity and capability (C&C). Delays due
      to pharmacy sign off varied from 10 days to over 3 months delay in two sites (94 
      days and 102 days). A mathematical solution to the problem of planning a study
      with a short recruitment window has been given to support the planning and
      costing of grants with fixed time constraints: number of sites = required sample 
      size divided by (number of eligible patients per site per month times recruitment
      rate times (the number of months accrual minus 6 months)). We expect these
      results to help others who are planning multicentre clinical trials in the UK.
      Ethical approval from NRES Committee South West (IRAS number 225959). TRIAL
      REGISTRATION: EudraCT Number 2017-001171-23 . Registered on 26 June 2017.
FAU - Greenwood, Rosemary
AU  - Greenwood R
AD  - School of Translational Health Sciences, University of Bristol, Bristol, UK.
AD  - University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
FAU - Pell, Julie
AU  - Pell J
AD  - Cardiff University Centre for Trials Research, Cardiff, UK.
FAU - Foscarini-Craggs, Paula
AU  - Foscarini-Craggs P
AD  - Cardiff University Centre for Trials Research, Cardiff, UK.
FAU - Wale, Katharine
AU  - Wale K
AD  - University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
FAU - Thomas, Ian
AU  - Thomas I
AD  - Cardiff University Centre for Trials Research, Cardiff, UK.
FAU - Bradbury, Charlotte
AU  - Bradbury C
AUID- ORCID: http://orcid.org/0000-0001-5248-8165
AD  - School of Translational Health Sciences, University of Bristol, Bristol, UK.
      c.bradbury@bristol.ac.uk.
AD  - University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
      c.bradbury@bristol.ac.uk.
LA  - eng
GR  - PB-PG-0815-20016/National Institute for Health Research
PT  - Letter
PT  - Multicenter Study
DEP - 20201021
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Sample Size
MH  - *Time Factors
MH  - United Kingdom
PMC - PMC7579882
OTO - NOTNLM
OT  - Multicentre randomised controlled trials
EDAT- 2020/10/23 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/22 05:26
PHST- 2020/05/19 00:00 [received]
PHST- 2020/10/10 00:00 [accepted]
PHST- 2020/10/22 05:26 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04798-x [doi]
AID - 10.1186/s13063-020-04798-x [pii]
PST - epublish
SO  - Trials. 2020 Oct 21;21(1):873. doi: 10.1186/s13063-020-04798-x.


PMID- 33087123
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210910
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 21
TI  - A qualitative study of big data and the opioid epidemic: recommendations for data
      governance.
PG  - 101
LID - 10.1186/s12910-020-00544-9 [doi]
AB  - BACKGROUND: The opioid epidemic has enabled rapid and unsurpassed use of big data
      on people with opioid use disorder to design initiatives to battle the public
      health crisis, generally without adequate input from impacted communities.
      Efforts informed by big data are saving lives, yielding significant benefits.
      Uses of big data may also undermine public trust in government and cause other
      unintended harms. OBJECTIVES: We aimed to identify concerns and recommendations
      regarding how to use big data on opioid use in ethical ways. METHODS: We
      conducted focus groups and interviews in 2019 with 39 big data stakeholders
      (gatekeepers, researchers, patient advocates) who had interest in or knowledge of
      the Public Health Data Warehouse maintained by the Massachusetts Department of
      Public Health. RESULTS: Concerns regarding big data on opioid use are rooted in
      potential privacy infringements due to linkage of previously distinct data
      systems, increased profiling and surveillance capabilities, limitless lifespan,
      and lack of explicit informed consent. Also problematic is the inability of
      affected groups to control how big data are used, the potential of big data to
      increase stigmatization and discrimination of those affected despite data
      anonymization, and uses that ignore or perpetuate biases. Participants support
      big data processes that protect and respect patients and society, ensure justice,
      and foster patient and public trust in public institutions. Recommendations for
      ethical big data governance offer ways to narrow the big data divide (e.g.,
      prioritize health equity, set off-limits topics/methods, recognize blind spots), 
      enact shared data governance (e.g., establish community advisory boards),
      cultivate public trust and earn social license for big data uses (e.g., institute
      safeguards and other stewardship responsibilities, engage the public, communicate
      the greater good), and refocus ethical approaches. CONCLUSIONS: Using big data to
      address the opioid epidemic poses ethical concerns which, if unaddressed, may
      undermine its benefits. Findings can inform guidelines on how to conduct ethical 
      big data governance and in ways that protect and respect patients and society,
      ensure justice, and foster patient and public trust in public institutions.
FAU - Evans, Elizabeth A
AU  - Evans EA
AUID- ORCID: 0000-0002-3478-9957
AD  - Department of Health Promotion and Policy, School of Public Health and Health
      Sciences, University of Massachusetts Amherst, 312 Arnold House, 715 North
      Pleasant Street, Amherst, MA, 01003, USA. eaevans@umass.edu.
FAU - Delorme, Elizabeth
AU  - Delorme E
AD  - Department of Health Promotion and Policy, School of Public Health and Health
      Sciences, University of Massachusetts Amherst, 312 Arnold House, 715 North
      Pleasant Street, Amherst, MA, 01003, USA.
FAU - Cyr, Karl
AU  - Cyr K
AD  - Department of Health Promotion and Policy, School of Public Health and Health
      Sciences, University of Massachusetts Amherst, 312 Arnold House, 715 North
      Pleasant Street, Amherst, MA, 01003, USA.
FAU - Goldstein, Daniel M
AU  - Goldstein DM
AD  - Department of Health Promotion and Policy, School of Public Health and Health
      Sciences, University of Massachusetts Amherst, 312 Arnold House, 715 North
      Pleasant Street, Amherst, MA, 01003, USA.
LA  - eng
GR  - UG1 DA050067/DA/NIDA NIH HHS/United States
GR  - 1UG1DA050067-01/DA/NIDA NIH HHS/United States
GR  - 1H79T1081387-01/TI/CSAT SAMHSA HHS/United States
GR  - UG3 DA044830/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20201021
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - *Analgesics, Opioid/adverse effects
MH  - *Big Data
MH  - Data Anonymization
MH  - Humans
MH  - Opioid Epidemic
MH  - Qualitative Research
PMC - PMC7576981
OTO - NOTNLM
OT  - *Big data
OT  - *Data governance
OT  - *Opioid epidemic
OT  - *Public health ethics
OT  - *Qualitative methods
EDAT- 2020/10/23 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/22 05:26
PHST- 2020/06/09 00:00 [received]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/10/22 05:26 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00544-9 [doi]
AID - 10.1186/s12910-020-00544-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 21;21(1):101. doi: 10.1186/s12910-020-00544-9.


PMID- 33087101
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 21
TI  - Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an
      ethical analysis.
PG  - 102
LID - 10.1186/s12910-020-00545-8 [doi]
AB  - BACKGROUND: Genetic testing is moving from targeted investigations of monogenetic
      diseases to broader testing that may provide more information. For example,
      recent health economic studies of genetic testing for an increased risk of breast
      cancer suggest that it is associated with higher cost-effectiveness to screen for
      pathogenic variants in a seven gene panel rather than the usual two gene test for
      variants in BRCA1 and BRCA2. However, irrespective of the extent to which the
      screening of the panel is cost-effective, there may be ethical reasons to not
      screen for pathogenic variants in a panel, or to revise the way in which testing 
      and disclosing of results are carried out. MAIN TEXT: In this paper we discuss
      the ethical aspects of genetic testing for an increased risk of breast cancer
      with a special focus on the ethical differences between screening for pathogenic 
      variants in BRCA1/2 and a seven gene panel. The paper identifies that the panel
      increases the number of secondary findings as well as the number of variants of
      uncertain significance as two specific issues that call for ethical reflection.
      CONCLUSIONS: We conclude that while the problem of handling secondary findings
      should not be overstated with regard to the panel, the fact that the panel also
      generate more variants of uncertain significance, give rise to a more complex set
      of problems that relate to the value of health as well as the value of autonomy. 
      Therefore, it is insufficient to claim that the seven gene panel is preferable by
      only referring to the higher cost effectiveness of the panel.
FAU - Gustavsson, Erik
AU  - Gustavsson E
AUID- ORCID: 0000-0001-5448-9209
AD  - Division of Society and Health, Department of Health, Medicine and Caring
      Sciences, Linkoping University, 581 83, Linkoping, Sweden.
      erik.gustavsson@liu.se.
AD  - Centre for Applied Ethics, Department of Culture and Society, Linkoping
      University, Linkoping, Sweden. erik.gustavsson@liu.se.
FAU - Galvis, Giovanni
AU  - Galvis G
AD  - Division of Society and Health, Department of Health, Medicine and Caring
      Sciences, Linkoping University, 581 83, Linkoping, Sweden.
FAU - Juth, Niklas
AU  - Juth N
AD  - LIME, Stockholm Centre for Healthcare Ethics, Karolinska Institutet, Stockholm,
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
SB  - IM
MH  - BRCA1 Protein/genetics
MH  - *Breast Neoplasms/genetics
MH  - Ethical Analysis
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Humans
MH  - Mutation
PMC - PMC7579789
OTO - NOTNLM
OT  - *Breast cancer
OT  - *Ethics
OT  - *Genetic testing
OT  - *Secondary findings
OT  - *Variants of uncertain significance
EDAT- 2020/10/23 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/22 05:26
PHST- 2019/10/10 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/10/22 05:26 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00545-8 [doi]
AID - 10.1186/s12910-020-00545-8 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 21;21(1):102. doi: 10.1186/s12910-020-00545-8.


PMID- 33086648
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 19
TI  - An Assessment of the Novel COVISTRESS Questionnaire: COVID-19 Impact on Physical 
      Activity, Sedentary Action and Psychological Emotion.
LID - E3352 [pii]
LID - 10.3390/jcm9103352 [doi]
AB  - Globally the COVID-19 pandemic outbreak has triggered an economic downturn and a 
      rise in unemployment. As a result, global communities have had to face physical, 
      health, psychological and socio-economical related stressors. The purpose of this
      study was to assess and report the impact of isolation and effect of coronavirus 
      on selected psychological correlates associated with emotions. Following ethical 
      approval, a mixed methods observational study was conducted using the validated
      COVISTRESS questionnaire. Two observational study scenarios were evaluated namely
      "Prior" to the COVID-19 outbreak and "Currently", i.e., during the COVID-19
      pandemic. 10,121 participants from 67 countries completed the COVISTRESS
      questionnaire. From the questionnaire responses only questions that covered the
      participant's occupation; sociodemographic details, isolation and impact of
      coronavirus were selected. Further analyses were performed on output measures
      that included leisure time, physical activity, sedentary time and emotions. All
      output measures were evaluated using the Visual Analogue Scale (VAS) with an
      intensity ranging from 0-100. Descriptive statistics, Wilcoxon signed-rank test
      and Spearman correlational analysis were applied to the leisure time, physical
      activity, sedentary time and emotional feeling datasets; p = 0.05 was set as the 
      significance level. Both males and females displayed similar output measures. The
      Wilcoxon signed rank test showed significant differences with respect to "Prior" 
      COVID-19 and "Currently" for sedentary activity (Z = -40.462, p < 0.001),
      physical activity (Z = -30.751, p < 0.001) and all other emotional feeling output
      measures. A moderate correlation between "Prior" COVID-19 and "Currently" was
      observed among the Males (r = 0.720) in comparison to the Females (r = 0.639) for
      sedentary activity while weaker correlations (r < 0.253) were observed for
      physical activity and emotional feeling measurements, respectively. Our study
      reported incremental differences in the physical and psychological output
      measures reported, i.e., "Prior" COVID-19 and "Currently". "Prior" COVID-19 and
      "Currently" participants increased their sedentary habits by 2.98%, and the level
      of physical activity reduced by 2.42%, depression levels increased by 21.62%,
      anxiety levels increased by 16.71%, and stress levels increased by 21.8%. There
      were no correlations (r) between leisure, physical activity and sedentary action 
      (i.e., "Prior" = -0.071; "Currently" = -0.097); no correlations (r) between
      leisure physical activity and emotion (i.e., -0.071 > r > 0.081) for "Prior"; and
      poor correlations (r) between leisure, physical activity and sedentary action
      (i.e., -0.078 > r > 0.167) for "Current". The correlations (r) between sedentary 
      action and emotion for "Prior" and "Currently" were (-0.100 > r > 0.075) and
      (-0.040 > r > 0.041) respectively. The findings presented here indicate that the 
      COVISTRESS project has created awareness in relation to the physical and
      psychological impact resulting from the COVID-19 pandemic. The findings have also
      highlighted individual distress caused by COVID-19 and associated health
      consequences for the global community.
FAU - Ugbolue, Ukadike Chris
AU  - Ugbolue UC
AD  - Faculty of Sports Science, Ningbo University, Ningbo 315211, China.
AD  - Institute for Clinical Exercise & Health Science, School of Health and Life
      Sciences, University of the West of Scotland, South Lanarkshire G72 0LH,
      Scotland, UK.
AD  - Department of Biomedical Engineering, University of Strathclyde, Glasgow G11XQ,
      UK.
FAU - Duclos, Martine
AU  - Duclos M
AUID- ORCID: 0000-0002-7158-386X
AD  - Department of Sport Medicine and Functional Exploration, University Hospital CHU 
      G. Montpied, INRA, UNH, CRNH Auvergne, Clermont Auvergne University,
      Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
FAU - Urzeala, Constanta
AU  - Urzeala C
AUID- ORCID: 0000-0003-1977-5722
AD  - Sports and Motor Performance Department, Faculty of Physical Education and
      Sports, National University of Physical Education and Sports, 060057 Bucharest,
      Romania.
FAU - Berthon, Mickael
AU  - Berthon M
AD  - LaPSCo, Catech, Universite Clermont Auvergne, CNRS, F-63000 Clermont-Ferrand,
      France.
FAU - Kulik, Keri
AU  - Kulik K
AD  - Health and Physical Education Program, Indiana University of Pennsylvania,
      Bloomington, IN 47405-1006, USA.
FAU - Bota, Aura
AU  - Bota A
AD  - Department of Teaching Staff Training, Faculty of Physical Education and Sports, 
      National University of Physical Education and Sports, 060057 Bucharest, Romania.
FAU - Thivel, David
AU  - Thivel D
AD  - Laboratory of Metabolic Adaptations to Exercise under Physiological and
      Pathological conditions (AME2P), Universite Clermont Auvergne, CRNH Auvergne,
      F-63000 Clermont-Ferrand, France.
FAU - Bagheri, Reza
AU  - Bagheri R
AD  - Department of Exercise Physiology, University of Isfahan, 8174673441 Isfahan,
      Iran.
FAU - Gu, Yaodong
AU  - Gu Y
AUID- ORCID: 0000-0003-2187-9440
AD  - Faculty of Sports Science, Ningbo University, Ningbo 315211, China.
FAU - Baker, Julien S
AU  - Baker JS
AUID- ORCID: 0000-0002-9093-7897
AD  - Faculty of Sports Science, Ningbo University, Ningbo 315211, China.
AD  - Department of Sport, Physical Education and Health, Centre for Health and
      Exercise Science Research, Hong Kong Baptist University, Kowloon Tong 999077,
      Hong Kong, China.
FAU - Andant, Nicolas
AU  - Andant N
AD  - Biostatistics Unit, DRCI, University Hospital of Clermont-Ferrand, CHU
      Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
FAU - Pereira, Bruno
AU  - Pereira B
AUID- ORCID: 0000-0003-3778-7161
AD  - Biostatistics Unit, DRCI, University Hospital of Clermont-Ferrand, CHU
      Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
FAU - Rouffiac, Karine
AU  - Rouffiac K
AD  - Preventive and Occupational Medicine, University Hospital of Clermont-Ferrand,
      CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France.
FAU - Clinchamps, Maelys
AU  - Clinchamps M
AUID- ORCID: 0000-0003-4756-6928
AD  - Physiological and Psychosocial Stress, LaPSCo, CNRS, Preventive and Occupational 
      Medicine, WittyFit, University Hospital of Clermont-Ferrand, CHU
      Clermont-Ferrand, Universite Clermont Auvergne, F-63000 Clermont-Ferrand, France.
FAU - Dutheil, Frederic
AU  - Dutheil F
AD  - Physiological and Psychosocial Stress, LaPSCo, CNRS, Preventive and Occupational 
      Medicine, WittyFit, University Hospital of Clermont-Ferrand, CHU
      Clermont-Ferrand, Universite Clermont Auvergne, F-63000 Clermont-Ferrand, France.
FAU - On Behalf Of The Covistress Network
AU  - On Behalf Of The Covistress Network
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7603364
OTO - NOTNLM
OT  - COVID-19
OT  - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
OT  - anxiety
OT  - depression
OT  - distress
OT  - stress
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 01:02
PHST- 2020/09/06 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/10/22 01:02 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - jcm9103352 [pii]
AID - 10.3390/jcm9103352 [doi]
PST - epublish
SO  - J Clin Med. 2020 Oct 19;9(10). pii: jcm9103352. doi: 10.3390/jcm9103352.


PMID- 33086638
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Traumatic Stress of Frontline Workers in Culling Livestock Animals in South
      Korea.
LID - E1920 [pii]
LID - 10.3390/ani10101920 [doi]
AB  - The last decade brought several devastating outbreaks of foot and mouth disease
      and avian influenza in South Korea, which had been handled through preventive
      culling, despite the controversy surrounding its efficiency and ethical
      considerations. Notably, the lack of regulations on culling processes has exposed
      the workers to extremely harsh working conditions. This study investigates the
      effect of culling jobs on the mental health of the frontline workers, based on
      200 samples collected through a web-based survey conducted on participants with
      experience of culling tasks. Culling was found to have a powerful negative effect
      on the workers' mental health, including high depression rates. Of those
      surveyed, 83.7% answered that the working conditions were intense, and 74.5%
      showed scores above the cutoff point for post-traumatic stress disorder (PTSD). A
      regression analysis revealed that individual's attitudes toward animals mediated 
      the effect of culling experience on PTSD symptoms. However, mental health care
      for the workers has been insufficient: 70.2% of the respondents were willing to
      get mental treatment to deal with the distress they underwent from culling. We
      conclude that engagement in culling has a detrimental effect on the workers'
      mental health, and that they should be provided with systematic mental health
      care.
FAU - Park, Hyomin
AU  - Park H
AD  - Department of Urban Sociology, University of Seoul, 163 Seoulsiripdaero,
      Dongdaemun-gu, Seoul 02504, Korea.
FAU - Chun, Myung Sun
AU  - Chun MS
AUID- ORCID: 0000-0002-0658-2895
AD  - Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul 
      National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.
FAU - Joo, Yunjeong
AU  - Joo Y
AD  - The Institute for Social Development and Policy, Seoul National University, 1
      Gwanak-ro, Gwanak-gu, Seoul 08826, Korea.
LA  - eng
GR  - NRF-2019S1A5A2A03047987/National Research Foundation of Korea
GR  - none/National Human Rights Commission of Korea
PT  - Journal Article
DEP - 20201019
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7603362
OTO - NOTNLM
OT  - AAS
OT  - PANAS
OT  - PTSD
OT  - animal attitude scale
OT  - animal disease
OT  - animal ethics
OT  - culling
OT  - depression
OT  - mental health
OT  - post-traumatic stress disorder
EDAT- 2020/10/23 06:00
MHDA- 2020/10/23 06:01
CRDT- 2020/10/22 01:01
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/16 00:00 [revised]
PHST- 2020/10/17 00:00 [accepted]
PHST- 2020/10/22 01:01 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2020/10/23 06:01 [medline]
AID - ani10101920 [pii]
AID - 10.3390/ani10101920 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 19;10(10). pii: ani10101920. doi: 10.3390/ani10101920.


PMID- 33086620
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 20
DP  - 2020 Oct 19
TI  - Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical
      Applications.
LID - E7730 [pii]
LID - 10.3390/ijms21207730 [doi]
AB  - Perinatal stem cells have been regarded as an attractive and available cell
      source for medical research and clinical trials in recent years. Multiple stem
      cell types have been identified in the human placenta. Recent advances in
      knowledge on placental stem cells have revealed that human amniotic epithelial
      stem cells (hAESCs) have obvious advantages and can be used as a novel potential 
      cell source for cellular therapy and clinical application. hAESCs are known to
      possess stem-cell-like plasticity, immune-privilege, and paracrine properties. In
      addition, non-tumorigenicity and a lack of ethical concerns are two major
      advantages compared with embryonic stem cells (ESCs) and induced pluripotent stem
      cells (iPSCs). All of the characteristics mentioned above and other additional
      advantages, including easy accessibility and a non-invasive application
      procedure, make hAESCs a potential ideal cell type for use in both research and
      regenerative medicine in the near future. This review article summarizes current 
      knowledge on the characteristics, therapeutic potential, clinical advances and
      future challenges of hAESCs in detail.
FAU - Qiu, Chen
AU  - Qiu C
AD  - MOE Laboratory of Biosystems Homeostasis & Protection and College of Life
      Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, College of Life
      Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Ge, Zhen
AU  - Ge Z
AD  - Institute of Materia Medica, Hangzhou Medical College, Hangzhou 310013, China.
FAU - Cui, Wenyu
AU  - Cui W
AD  - MOE Laboratory of Biosystems Homeostasis & Protection and College of Life
      Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, College of Life
      Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Yu, Luyang
AU  - Yu L
AD  - MOE Laboratory of Biosystems Homeostasis & Protection and College of Life
      Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, College of Life
      Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Li, Jinying
AU  - Li J
AUID- ORCID: 0000-0001-7434-674X
AD  - MOE Laboratory of Biosystems Homeostasis & Protection and College of Life
      Sciences-iCell Biotechnology Regenerative Biomedicine Laboratory, College of Life
      Sciences, Zhejiang University, Hangzhou 310058, China.
LA  - eng
GR  - 2018YFA0800504/the National Key R&D Program of China
GR  - 91839104, 81770444, 81600354, 81970372/the National Natural Science Foundation of
      China
GR  - LZ20H020002/the Zhejiang Provincial Natural Science Foundation of China
GR  - 201704020214/the Project of Health Collaborative Innovation of Guangzhou City
GR  - 2019M662036/the China Postdoctoral Science Foundation
PT  - Journal Article
PT  - Review
DEP - 20201019
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Culture Media, Serum-Free)
SB  - IM
MH  - Amnion/*cytology
MH  - Cell Plasticity/drug effects
MH  - Culture Media, Serum-Free/pharmacology
MH  - Epithelial Cells/*cytology
MH  - Humans
MH  - Stem Cell Transplantation
MH  - Stem Cells/*cytology
PMC - PMC7594030
OTO - NOTNLM
OT  - cell therapy
OT  - clinical application
OT  - human amniotic epithelial stem cells
OT  - low immunogenicity
OT  - paracrine effect
OT  - perinatal stem cells
OT  - plasticity
EDAT- 2020/10/23 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/10/22 01:01
PHST- 2020/08/31 00:00 [received]
PHST- 2020/10/14 00:00 [revised]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/10/22 01:01 [entrez]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - ijms21207730 [pii]
AID - 10.3390/ijms21207730 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Oct 19;21(20). pii: ijms21207730. doi: 10.3390/ijms21207730.


PMID- 34898824
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220107
IS  - 2773-1073 (Electronic)
IS  - 0445-7706 (Linking)
VI  - 52
IP  - 3
DP  - 2020 Oct 23
TI  - The National Commission for Allied and Health Care Professions Bill 2020:
      Implications for Occupational Therapists and the AIOTA.
PG  - 104-107
LID - 10.4103/ijoth.ijoth_40_20 [doi]
AB  - The new National Commission for Allied and Health Care professions (NCAHCP) bill 
      2020 is introduced by the Government of India on September 15, 2020, to
      streamline the cadres in the country for allied and health-care professions
      within its health systems for the greater public good. It is very pertinent to
      understand the implications of the NCAHCP bill for All India Occupational
      therapists Association (AIOTA) and occupational therapists in India. The
      implications for AIOTA are (1) development of state councils and enabling their
      functioning in all the states of India, (2) radical revision of the OT curriculum
      incorporating policies and programs of the Indian health system, and (3)
      developing and strengthening the existing systems for OT practice. For
      occupational therapists, the implications are (1) registering to independently
      practice OT in India and (2) documenting professional practice for ethical
      integrity. Forming an advisory board to develop strategies for a smooth
      transition to the opportunities that the NCAHCP bill provides, must hold the
      top-most priority for AIOTA.
FAU - Kamalakannan, Sureshkumar
AU  - Kamalakannan S
AD  - Department of Public Health and Disability, Indian Institute of Public Health,
      Hyderabad, Telangana, India.
FAU - Chockalingam, Manigandan
AU  - Chockalingam M
AD  - Department of Occupational Therapy, School of Health Sciences, National
      University of Ireland Galway, Galway, Ireland.
LA  - eng
GR  - IA/CPHE/16/1/502650/WTDBT_/DBT-Wellcome Trust India Alliance/India
PT  - Journal Article
PL  - India
TA  - Indian J Occup Ther
JT  - The Indian journal of occupational therapy
JID - 17540030R
PMC - PMC7612084
MID - EMS128335
OTO - NOTNLM
OT  - All India Occupational Therapists Association
OT  - India
OT  - National Commission for Allied and Health Care Professions Bill 2020
OT  - Occupational Therapy
OT  - Persons with Disabilities
COIS- Conflicts of Interest There are no conflicts of interest.
EDAT- 2020/10/23 00:00
MHDA- 2020/10/23 00:01
CRDT- 2021/12/13 17:46
PHST- 2021/12/13 17:46 [entrez]
PHST- 2020/10/23 00:00 [pubmed]
PHST- 2020/10/23 00:01 [medline]
AID - 10.4103/ijoth.ijoth_40_20 [doi]
PST - ppublish
SO  - Indian J Occup Ther. 2020 Oct 23;52(3):104-107. doi: 10.4103/ijoth.ijoth_40_20.


PMID- 33085946
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1540-9597 (Electronic)
IS  - 0276-3869 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Oct-Dec
TI  - Social Media and Online Professionalism Integrated into Year 3 OB/GYN
      Clerkship().
PG  - 359-369
LID - 10.1080/02763869.2020.1826226 [doi]
AB  - A curriculum-integrated course developed and taught by Library faculty was
      introduced into the Library's undergraduate medical education (UME) informatics
      longitudinal theme in 2014 to address growing concerns about the role of social
      media in medicine. Literature, social media content, and case-based discussion
      were used to meet educational objectives and facilitate interactivity. Most
      students indicated that their online behaviors would change as a result of the
      class. They became alert to potential negative and positive effects of social
      media use in their professional and personal lives. Since implementation, the
      curriculum has expanded within UME and graduate studies programs.
FAU - Geyer, Enid
AU  - Geyer E
AUID- ORCID: https://orcid.org/0000-0002-0777-3263
AD  - Schaffer Library of Health Sciences, Albany Medical College, New York, USA.
FAU - Irish, Elizabeth
AU  - Irish E
AUID- ORCID: https://orcid.org/0000-0003-0993-4195
AD  - Schaffer Library of Health Sciences, Albany Medical College, New York, USA.
FAU - Hagzan, Amanda
AU  - Hagzan A
AD  - New York State Technology Enterprises Corporation, Albany, USA.
FAU - Wiczulis, Alicia
AU  - Wiczulis A
AD  - Department of Obstetrics and Gynecology, Albany Medical College, New York, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Ref Serv Q
JT  - Medical reference services quarterly
JID - 8219208
MH  - Adult
MH  - Clinical Clerkship/*organization & administration
MH  - *Curriculum
MH  - Education, Distance/*organization & administration
MH  - Education, Medical, Undergraduate/*organization & administration
MH  - Female
MH  - Gynecology/*education
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obstetrics/*education
MH  - *Social Media
MH  - South Carolina
OTO - NOTNLM
OT  - Curriculum
OT  - ethics
OT  - integrated
OT  - online behavior
OT  - professionalism
OT  - social media
EDAT- 2020/10/22 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/10/21 17:04
PHST- 2020/10/21 17:04 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - 10.1080/02763869.2020.1826226 [doi]
PST - ppublish
SO  - Med Ref Serv Q. 2020 Oct-Dec;39(4):359-369. doi: 10.1080/02763869.2020.1826226.


PMID- 33085928
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1467-9280 (Electronic)
IS  - 0956-7976 (Linking)
VI  - 31
IP  - 11
DP  - 2020 Nov
TI  - The Worst-Motive Fallacy: A Negativity Bias in Motive Attribution.
PG  - 1430-1438
LID - 10.1177/0956797620954492 [doi]
AB  - In this article, we describe a hitherto undocumented fallacy-in the sense of a
      mistake in reasoning-constituted by a negativity bias in the way that people
      attribute motives to others. We call this the "worst-motive fallacy," and we
      conducted two experiments to investigate it. In Experiment 1 (N = 323),
      participants expected protagonists in a variety of fictional vignettes to pursue 
      courses of action that satisfy the protagonists' worst motive, and furthermore,
      participants significantly expected the protagonist to pursue a worse course of
      action than they would prefer themselves. Experiment 2 (N = 967) was a
      preregistered attempted replication of Experiment 1, including a bigger range of 
      vignettes; the first effect was not replicated for the new vignettes tested but
      was for the original set. Also, we once again found that participants expected
      protagonists to be more likely than they were themselves to pursue courses of
      action that they considered morally bad. We discuss the worst-motive fallacy's
      relation to other well-known biases as well as its possible evolutionary origins 
      and its ethical (and meta-ethical) consequences.
FAU - Walmsley, Joel
AU  - Walmsley J
AD  - Department of Philosophy, University College Cork.
FAU - O'Madagain, Cathal
AU  - O'Madagain C
AD  - Departement d'Etudes Cognitives, Ecole Normale Superieure.
AD  - School of Collective Intelligence, Universite Mohammed VI Polytechnique.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201021
PL  - United States
TA  - Psychol Sci
JT  - Psychological science
JID - 9007542
SB  - IM
MH  - Bias
MH  - Humans
MH  - Judgment
MH  - *Morals
MH  - *Motivation
MH  - Social Perception
OTO - NOTNLM
OT  - *attribution
OT  - *cognitive bias
OT  - *experimental philosophy
OT  - *meta-ethics
OT  - *moral intuitions
OT  - *moral judgment
OT  - *motives
OT  - *open data
OT  - *open materials
OT  - *preregistered
EDAT- 2020/10/22 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/21 17:03
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/10/21 17:03 [entrez]
AID - 10.1177/0956797620954492 [doi]
PST - ppublish
SO  - Psychol Sci. 2020 Nov;31(11):1430-1438. doi: 10.1177/0956797620954492. Epub 2020 
      Oct 21.


PMID- 33085884
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201218
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 383
IP  - 20
DP  - 2020 Nov 12
TI  - Covid-19 Vaccine Trials and Incarcerated People - The Ethics of Inclusion.
PG  - 1897-1899
LID - 10.1056/NEJMp2025955 [doi]
FAU - Strassle, Camila
AU  - Strassle C
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
FAU - Jardas, E
AU  - Jardas E
AUID- ORCID: 0000-0002-6168-6398
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
FAU - Ochoa, Jorge
AU  - Ochoa J
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
FAU - Berkman, Benjamin E
AU  - Berkman BE
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
FAU - Danis, Marion
AU  - Danis M
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
FAU - Rid, Annette
AU  - Rid A
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
FAU - Taylor, Holly A
AU  - Taylor HA
AUID- ORCID: 0000-0001-6811-9356
AD  - From the Department of Bioethics, National Institutes of Health, Bethesda, MD.
LA  - eng
PT  - Journal Article
DEP - 20201021
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/immunology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - *Prisoners
MH  - *Research Subjects
MH  - SARS-CoV-2
MH  - Viral Vaccines/*immunology
EDAT- 2020/10/22 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/21 15:37
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/10/21 15:37 [entrez]
AID - 10.1056/NEJMp2025955 [doi]
PST - ppublish
SO  - N Engl J Med. 2020 Nov 12;383(20):1897-1899. doi: 10.1056/NEJMp2025955. Epub 2020
      Oct 21.


PMID- 33083775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210415
IS  - 2589-871X (Electronic)
IS  - 2589-871X (Linking)
VI  - 2
DP  - 2020
TI  - Perspectives on the establishment of a canadian human taphonomic facility: The
      experience of REST[ES].
PG  - 287-292
LID - 10.1016/j.fsisyn.2020.09.001 [doi]
AB  - REST[ES] is the first Canadian human taphonomic facility (HTF) dedicated to
      research and training relating to human decomposition in a northern temperate
      climate. The following paper outlines the measures taken to successfully
      establish, open and operate this novel Canadian HTF with particular focus on:
      project team and partnerships, facility location, approvals and permits,
      infrastructure and social acceptability. It is intended that our experience of
      establishing REST[ES] may serve as an example to help others with the
      establishment of future HTFs, thus contributing to the expansion in the global
      accessibility to human decomposition research and training.
CI  - (c) 2020 The Authors.
FAU - Pecsi, Emily L
AU  - Pecsi EL
AD  - Departement d'Anatomie, Universite du Quebec a Trois-Rivieres, 3351 Boulevard des
      Forges, Trois-Rivieres, Quebec, G8Z 4M3, Canada.
FAU - Bronchti, Gilles
AU  - Bronchti G
AD  - Departement d'Anatomie, Universite du Quebec a Trois-Rivieres, 3351 Boulevard des
      Forges, Trois-Rivieres, Quebec, G8Z 4M3, Canada.
FAU - Crispino, Frank
AU  - Crispino F
AD  - Departement de Chimie, Biochimie et Physique, Laboratoire de Recherche en
      Criminalistique, Universite du Quebec a Trois-Rivieres, 3351 Boulevard des
      Forges, Trois-Rivieres, Quebec, G8Z 4M3, Canada.
FAU - Forbes, Shari L
AU  - Forbes SL
AD  - Departement de Chimie, Biochimie et Physique, Laboratoire de Recherche en
      Criminalistique, Universite du Quebec a Trois-Rivieres, 3351 Boulevard des
      Forges, Trois-Rivieres, Quebec, G8Z 4M3, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Netherlands
TA  - Forensic Sci Int Synerg
JT  - Forensic science international. Synergy
JID - 101766849
PMC - PMC7554357
OTO - NOTNLM
OT  - Body donation
OT  - Forensic taphonomy
OT  - Human decomposition
OT  - Human ethics
OT  - Social acceptability
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:05
PHST- 2020/05/28 00:00 [received]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/21 06:05 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
AID - 10.1016/j.fsisyn.2020.09.001 [doi]
AID - S2589-871X(20)30056-5 [pii]
PST - epublish
SO  - Forensic Sci Int Synerg. 2020 Sep 8;2:287-292. doi: 10.1016/j.fsisyn.2020.09.001.
      eCollection 2020.


PMID- 33083573
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Validation of the Sexual Knowledge Picture Instrument as a diagnostic instrument 
      for child sexual abuse: study protocol.
PG  - e000799
LID - 10.1136/bmjpo-2020-000799 [doi]
AB  - BACKGROUND: The consequences of child sexual abuse (CSA) can be significant and
      can affect short-term and long-term mental, sexual and physical health. In order 
      to offer timely and appropriate care for the child, early recognition of CSA is
      necessary. The lack of specific physical and psychological signs and barriers to 
      abuse disclosure that these young victims face makes it difficult for medical and
      psychological professionals to recognise and confirm CSA signs. We aimed to
      validate the Sexual Knowledge Picture Instrument (SKPI) as a diagnostic
      instrument for CSA. METHODS AND ANALYSIS: An observational study to quantify the 
      intraobserver and interobserver reliability and diagnostic accuracy of the SKPI
      will be performed. A total of 250 subjects from three groups will be included in 
      the study: (1) a group of suspected CSA victims, recruited from three academic
      paediatric hospitals; (2) a case group of (proven) victims of CSA, recruited in
      cooperation with the Dutch Police Vice Squad; and (3) a control group of
      children, recruited from preschools and primary schools. All children will be
      interviewed using the SKPI, and to investigate reliability, video recordings will
      be assessed and reassessed by the same and a different blinded rater,
      respectively. Within 1 year, the results of the SKPI will be compared with the
      conclusions from the independent child protective services or police reports. If 
      necessary, the SKPI will be modified to improve its reliability and accuracy.
      ETHICS AND DISSEMINATION: This validation study of the SKPI is necessary for
      obtaining a reliable diagnostic tool, which will enable medical and psychological
      professionals to detect CSA in young victims at an early age and start
      intervention/treatment. TRIAL REGISTRATION NUMBER: NL 50903.018.15.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - van Ham, Kirsten
AU  - van Ham K
AUID- ORCID: 0000-0001-6328-7123
AD  - Paediatrics, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
FAU - Brilleslijper-Kater, Sonja
AU  - Brilleslijper-Kater S
AD  - Paediatrics, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
FAU - van der Lee, Hanneke
AU  - van der Lee H
AD  - Epidemiology, Kennisinstituut van Medisch Specialisten, Utrecht, The Netherlands.
FAU - van Rijn, Rick
AU  - van Rijn R
AD  - Paediatric Radiology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
FAU - van Goudoever, Hans
AU  - van Goudoever H
AD  - Paediatrics, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
FAU - Teeuw, Rian
AU  - Teeuw R
AD  - Paediatrics, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7526291
OTO - NOTNLM
OT  - child abuse
OT  - epidemiology
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:04
PHST- 2020/07/15 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/10/21 06:04 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
AID - 10.1136/bmjpo-2020-000799 [doi]
AID - bmjpo-2020-000799 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Sep 29;4(1):e000799. doi: 10.1136/bmjpo-2020-000799.
      eCollection 2020.


PMID- 33083563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220105
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Social license for the use of big data in the COVID-19 era.
PG  - 128
LID - 10.1038/s41746-020-00342-y [doi]
AB  - Strategies to enable the reopening of businesses and schools in countries
      emerging from social-distancing measures revolve around knowledge of who has
      COVID-19 or is displaying recognized symptoms, the people with whom they have had
      physical contact, and which groups are most likely to experience adverse
      outcomes. Efforts to clarify these issues are drawing on the collection and use
      of large datasets about peoples' movements and their health. In this Comment, we 
      outline the importance of earning social license for public approval of big data 
      initiatives, and specify principles of data law and data governance practices
      that can promote social license. We provide illustrative examples from the United
      States, Canada, and the United Kingdom.
CI  - (c) The Author(s) 2020.
FAU - Shaw, James A
AU  - Shaw JA
AUID- ORCID: 0000-0002-9522-0756
AD  - Joint Centre for Bioethics, University of Toronto, Toronto, ON Canada.
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      University of Toronto, Toronto, ON Canada.
FAU - Sethi, Nayha
AU  - Sethi N
AD  - Centre for Biomedicine, Self and Society, Usher Institute, University of
      Edinburgh, Edinburgh, Scotland.
FAU - Cassel, Christine K
AU  - Cassel CK
AD  - University of California San Francisco, San Francisco, CA USA.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7532144
OTO - NOTNLM
OT  - *Health policy
OT  - *Medical ethics
COIS- Competing interestsThe authors declare that there are no competing interests.
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:04
PHST- 2020/06/11 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/10/21 06:04 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
AID - 10.1038/s41746-020-00342-y [doi]
AID - 10.1038/s41746-020-00342-y [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Oct 2;3:128. doi: 10.1038/s41746-020-00342-y. eCollection
      2020.


PMID- 33083211
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201027
IS  - 2211-6095 (Print)
IS  - 2211-6095 (Linking)
VI  - 59
DP  - 2020
TI  - Feasibility and acceptability of an online response inhibition cognitive training
      program for youth with Williams syndrome.
PG  - 107-134
LID - 10.1016/bs.irrdd.2020.09.002 [doi]
AB  - Williams syndrome (WS) is a genetic neurodevelopmental disorder often accompanied
      by inhibitory difficulties. Online cognitive training programs show promise for
      improving cognitive functions. No such interventions have been developed for
      individuals with WS, but to explore the practicality of large-scale online
      cognitive training for this population, we must first investigate whether
      families of those with WS find these programs feasible and acceptable. Twenty
      individuals aged 10-17 years with WS, along with parents, participated in a pilot
      online cognitive training program supervised in real time using videoconference
      software. We evaluated the feasibility and acceptability of this response
      inhibition training using three parent questionnaires. Descriptive data are
      reported for the measures of feasibility and acceptability. Overall, the online
      procedures received a positive reaction from families. Parents were likely to
      recommend the study to others. They indicated training was ethical and acceptable
      despite feeling neutral about effectiveness. The frequency and duration of
      sessions were acceptable to families (two 20-to-30-min sessions per week; 10
      sessions total). Families provided feedback and offered suggestions for
      improvement, such as more flexibility in scheduling and decreasing time spent in 
      review of procedures.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Brei, Natalie G
AU  - Brei NG
AD  - Catholic Social Services of Southern Nebraska, Lincoln, NE, United States.
FAU - Raicu, Ana-Maria
AU  - Raicu AM
AD  - Michigan State University, East Lansing, MI, United States.
FAU - Lee, Han Joo
AU  - Lee HJ
AD  - University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
FAU - Klein-Tasman, Bonita P
AU  - Klein-Tasman BP
AD  - University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - Netherlands
TA  - Int Rev Res Dev Disabil
JT  - International review of research in developmental disabilities
JID - 101603421
PMC - PMC7560495
OTO - NOTNLM
OT  - Acceptability
OT  - Cognitive training
OT  - Feasibility
OT  - Internet-delivered training
OT  - Response inhibition
OT  - Williams syndrome
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:03
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
PHST- 2020/10/21 06:03 [entrez]
AID - 10.1016/bs.irrdd.2020.09.002 [doi]
AID - S2211-6095(20)30010-5 [pii]
PST - ppublish
SO  - Int Rev Res Dev Disabil. 2020;59:107-134. doi: 10.1016/bs.irrdd.2020.09.002. Epub
      2020 Oct 15.


PMID- 33083178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 15
TI  - Current Knowledge of Breastfeeding Among Health Workers in a Developing Country
      Setting: A Survey in Calabar, Nigeria.
PG  - e10476
LID - 10.7759/cureus.10476 [doi]
AB  - Background Health workers are in a strategic position to provide correct
      information to mothers on breastfeeding practice. This study assessed knowledge
      of breastfeeding among health workers in health facilities in Calabar. Methods
      This was a cross-sectional descriptive study. A 45-item self-administered
      questionnaire was used to obtain data. Ethical clearance for the study was
      obtained from the Cross River State Research and Ethics Committee. Data were
      analyzed using SPSS version 21.0 (SPSS, Inc., Chicago, USA). A knowledge score of
      at least 90% was considered satisfactory. Factors associated with the level of
      knowledge were determined using chi-square. The p-value was set at 0.05. Result
      Two hundred and twenty-five healthcare professionals were surveyed, with a mean
      age of 37.5 +/- 9.4 years, ranging from 20 to 65 years. The commonest age group
      was 41 to 50 years (43.1%). Females (80.9%) formed a larger proportion of
      participants with a female-male ratio of 4:1. The mean percentage of knowledge
      score was 85.1 +/- 9.0%. A satisfactory level of knowledge was found in 27.1% of 
      respondents. About one-third (33.7%) and one-fifth (21.8%) of health workers were
      not aware of the weight control benefit and protection against osteoporosis of
      breastmilk, respectively. Approximately one-fifth (22.2%) of respondents had
      misconceptions concerning the effects of colostrum on the prevention of neonatal 
      jaundice. Nurses with diploma level of training had a satisfactory level of
      knowledge, compared with other professions (p < 0.05). Conclusion Health workers'
      knowledge of breastfeeding was generally good though suboptimal. Health-related
      professions should provide current information on the best breastfeeding
      practices.
CI  - Copyright (c) 2020, Ikobah et al.
FAU - Ikobah, Joanah M
AU  - Ikobah JM
AD  - Hepatology and Nutrition Division, Department of Paediatrics, University of
      Calabar/University of Calabar Teaching Hospital, Calabar, NGA.
FAU - Ikpeme, Offiong
AU  - Ikpeme O
AD  - Department of Paediatrics, University of Calabar/University of Calabar Teaching
      Hospital, Calabar, NGA.
FAU - Omoronyia, Ogban
AU  - Omoronyia O
AD  - Department of Community Medicine, University of Calabar/University of Calabar
      Teaching Hospital, Calabar, NGA.
FAU - Ekpenyong, Nnette
AU  - Ekpenyong N
AD  - Department of Community Medicine, University of Calabar/University of Calabar
      Teaching Hospital, Calabar, NGA.
FAU - Udoh, Ekong
AU  - Udoh E
AD  - Department of Paediatrics, University of Uyo/University of Uyo Teaching Hospital,
      Uyo, NGA.
LA  - eng
PT  - Journal Article
DEP - 20200915
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7567322
OTO - NOTNLM
OT  - breastfeeding
OT  - child survival
OT  - health workers
OT  - knowledge
OT  - nigeria
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:03
PHST- 2020/10/21 06:03 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
AID - 10.7759/cureus.10476 [doi]
PST - epublish
SO  - Cureus. 2020 Sep 15;12(9):e10476. doi: 10.7759/cureus.10476.


PMID- 33083175
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 15
TI  - Moving From Organ Donation to Knowledge Donation: A Novel Opportunity for
      Surgical Education Following Organ Donation.
PG  - e10473
LID - 10.7759/cureus.10473 [doi]
AB  - The objective of this article is to share how our institution implemented the use
      of organ donors for surgical education following organ recovery. Despite
      technological advances, realistic surgical simulation models are lacking, leaving
      little opportunity to practice a procedure prior to performance on a living
      patient. Utilization of organ donors following organ donation offers an
      opportunity for life-like surgical simulation. We developed a pathway to use
      organ donor tissue in the post-recovery period for robotic simulation. We
      obtained support from our local Institutional Review Board, Ethics Committee, and
      organ procurement organization to create a "knowledge donor" program. Our
      knowledge donation program provided learners hands-on experience with a novel
      procedure and also provided organ donors another opportunity to express their
      altruism. We found that the process was well accepted by donor families and
      learners. We implemented a knowledge donation program at our hospital that
      provides valuable surgical experience. We discuss future directions for knowledge
      donation at our institution.
CI  - Copyright (c) 2020, Wu et al.
FAU - Wu, Peter
AU  - Wu P
AD  - Surgery, St. Joseph's Hospital and Medical Center, Phoenix, USA.
FAU - Rieger, Rebecca
AU  - Rieger R
AD  - Surgery, St. Joseph's Hospital and Medical Center, Phoenix, USA.
FAU - McBride, Margaret M
AU  - McBride MM
AD  - Mission Integration, St. Joseph's Hospital and Medical Center, Phoenix, USA.
FAU - Gray, Kayla
AU  - Gray K
AD  - Research Projects Coordinator, Donor Network of Arizona, Phoenix, USA.
FAU - Mankin, James
AU  - Mankin J
AD  - Surgery, St. Joseph's Hospital and Medical Center, Phoenix, USA.
LA  - eng
PT  - Journal Article
DEP - 20200915
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7567310
OTO - NOTNLM
OT  - knowledge donation
OT  - organ donation
OT  - organ donor
OT  - organ harvesting
OT  - organ procurement
OT  - organ recovery
OT  - organ retrieval
OT  - surgical education
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:03
PHST- 2020/10/21 06:03 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
AID - 10.7759/cureus.10473 [doi]
PST - epublish
SO  - Cureus. 2020 Sep 15;12(9):e10473. doi: 10.7759/cureus.10473.


PMID- 33083040
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1999-768X (Print)
IS  - 1999-768X (Linking)
VI  - 35
IP  - 5
DP  - 2020 Sep
TI  - Medical Liability of Healthcare Professionals Under Omani Law: A Primer.
PG  - e182
LID - 10.5001/omj.2020.123 [doi]
AB  - Professionals in healthcare face, not infrequently, medical liability issues in
      their practice. Worldwide, patient safety has become a major medical, legal,
      ethical, political, and economic concern. Oman has witnessed a leap in its
      medical and legal spheres over the last half a century. Developments in
      healthcare services in the country have taken place in parallel with developments
      in legal awareness regarding patient safety and bodily integrity. However, many
      healthcare practitioners remain unaware of medical liability essentials in their 
      daily practice. Neither basic medical education nor professional development
      education incorporates medical law in general and, specifically, medical
      liability in their courses and curricula. Hence, this article attempts to present
      the essentials of medical liability in healthcare practice in accordance with
      existing Omani legislation. It defines medical liability and identifies four
      types of liability that healthcare practitioners might be prone to penal, civil, 
      disciplinary, and administrative liabilities. Each of these forms of liability is
      discussed with examples illustrating it from enacted Omani laws. This paper
      concludes by recommending a further focus on medical law in basic and
      professional education of healthcare practitioners in Oman.
CI  - The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.
FAU - Al-Azri, Nasser Hammad
AU  - Al-Azri NH
AD  - Emergency Department, Ibri Hospital, Ministry of Health, A'Dhahirah, Oman.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200930
PL  - Oman
TA  - Oman Med J
JT  - Oman medical journal
JID - 101526350
PMC - PMC7548508
OTO - NOTNLM
OT  - Education, Medical
OT  - Liability, Legal
OT  - Malpractice
OT  - Oman
OT  - Patient Safety
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:01
CRDT- 2020/10/21 06:02
PHST- 2019/10/20 00:00 [received]
PHST- 2019/12/23 00:00 [accepted]
PHST- 2020/10/21 06:02 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:01 [medline]
AID - 10.5001/omj.2020.123 [doi]
AID - OMJ-35-05-1900154 [pii]
PST - epublish
SO  - Oman Med J. 2020 Sep 30;35(5):e182. doi: 10.5001/omj.2020.123. eCollection 2020
      Sep.


PMID- 33082524
OWN - NLM
STAT- Publisher
LR  - 20201021
IS  - 1476-5373 (Electronic)
IS  - 0007-0610 (Linking)
DP  - 2020 Oct 20
TI  - Plagiarism in dentistry - a systematic review.
LID - 10.1038/s41415-020-2026-4 [doi]
AB  - Objective Following a survey of the literature, a systematic review was carried
      out with the aim of answering the following questions: 1) What is 'acceptable
      plagiarism'?; 2) Who carries out plagiarism?; 3) What factors could encourage
      plagiarism?; 4) How can plagiarism be managed?Data source and selection Following
      PRISMA guidelines, data were gathered by searching Scopus, PubMed and Web of
      Science. After removal of duplicates, 345 titles were identified. Then, having
      satisfied a priori eligibility criteria, 29 papers were interrogated. The quality
      of relevant papers (n = 23) was assessed using the Joanna Briggs Critical
      Appraisal Tool.Data extraction There was no clear threshold as to what is
      'acceptable plagiarism'. Despite this lack of clarity, it is argued consistently 
      that males, and those who wrote in a language that is not their mother tongue,
      were more likely to plagiarise.Conclusion Plagiarism is all but inescapable due
      to various reasons: 1) there is no agreed threshold as to what is 'acceptable
      plagiarism'; 2) the internet; 3) institutional; and 4) societal expectations.
      Plagiarism could be mitigated in the student domain by grammar support and, for
      example, non-written submissions such as presenting work by video. Academic fraud
      is fundamentally undermined by valuing original and creative scholarship and
      sound ethical principles.
FAU - Farook, Taseef Hasan
AU  - Farook TH
AD  - School of Dental Sciences, Universiti Sains Malaysia, Kelantan, 16150, Malaysia.
FAU - Radford, John
AU  - Radford J
AD  - School of Dentistry, University of Dundee, Park Place, Dundee, DD1 4HN, Scotland,
      UK.
FAU - Alam, Mohammad Khursheed
AU  - Alam MK
AD  - College of Dentistry, Jouf University, Sakaka, 72721, Saudi Arabia.
      dralam@gmail.com.
FAU - Jamayet, Nafij Bin
AU  - Jamayet NB
AD  - School of Dental Sciences, Universiti Sains Malaysia, Kelantan, 16150, Malaysia. 
      dr.nafij@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - Br Dent J
JT  - British dental journal
JID - 7513219
SB  - IM
EDAT- 2020/10/22 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/10/21 05:59
PHST- 2019/11/04 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/10/21 05:59 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1038/s41415-020-2026-4 [doi]
AID - 10.1038/s41415-020-2026-4 [pii]
PST - aheadofprint
SO  - Br Dent J. 2020 Oct 20. pii: 10.1038/s41415-020-2026-4. doi:
      10.1038/s41415-020-2026-4.


PMID- 33082195
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Maternal age at delivery and risk of allergy and asthma in the offspring: a
      systematic review and meta-analysis protocol.
PG  - e039288
LID - 10.1136/bmjopen-2020-039288 [doi]
AB  - INTRODUCTION: While several perinatal factors have been linked to the risk of
      developing asthma and allergy in childhood, the role of maternal age at delivery 
      remains uncertain. Some studies suggest that young maternal age at delivery may
      increase the risk, while other studies suggested a reduced risk. To provide a
      clearer appreciation of the underlying evidence, we plan to undertake a
      systematic review to synthesise previous studies that have investigated the
      association between maternal age at delivery and the risk of asthma and allergy
      in the offspring. METHODS AND ANALYSIS: We will search PubMed, EMBASE, ISI Web of
      Science, Scopus and Google Scholar to identify relevant studies on the topic
      published in the databases from inception until October 2020. We will search
      databases of proceedings of international conferences, contact authors who have
      published on the topic and search the reference lists of the included studies in 
      order to identify additional studies. Two investigators will independently screen
      the identified studies, perform data extraction and examine the risk of bias in
      the studies; a third investigator will arbitrate throughout these processes. We
      will use the Effective Public Health Practice Project tool for assessment of the 
      risk of bias in included studies. We will perform random-effects meta-analysis to
      combine effect estimates from included studies judged to be homogeneous. ETHICS
      AND DISSEMINATION: Only data from the published literature will be included in
      this study, therefore no ethics approval is required. Our findings will be
      published in a peer-reviewed journal. PROTOCOL REGISTRATION: The protocol has
      been submitted for registration on PROSPERO, University of York, and Centre for
      Review and Dissemination, now awaiting the assignment of a registration number.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Amera, Yohannes Tesfaye
AU  - Amera YT
AUID- ORCID: 0000-0003-2798-0267
AD  - School of Public Health and Community Medicine, Institute of Medicine, University
      of Gothenburg, Gothenburg, Sweden yoyetes20@gmail.com.
FAU - Baldeh, Abdoulie K
AU  - Baldeh AK
AD  - School of Public Health and Community Medicine, Institute of Medicine, University
      of Gothenburg, Gothenburg, Sweden.
FAU - Ali, Mohamed Mustafa
AU  - Ali MM
AD  - School of Public Health and Community Medicine, Institute of Medicine, University
      of Gothenburg, Gothenburg, Sweden.
FAU - Goksor, Emma
AU  - Goksor E
AD  - Department of Paediatrics, University of Gothenburg, Gothenburg, Sweden.
FAU - Wennergren, Goran
AU  - Wennergren G
AD  - Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden.
FAU - Nwaru, Bright I
AU  - Nwaru BI
AD  - Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Asthma/epidemiology/etiology
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - *Hypersensitivity/epidemiology/etiology
MH  - Maternal Age
MH  - Meta-Analysis as Topic
MH  - Pregnancy
MH  - Systematic Reviews as Topic
PMC - PMC7577063
OTO - NOTNLM
OT  - *allergy
OT  - *asthma
OT  - *chronic airways disease
OT  - *community child health
OT  - *eczema
OT  - *emphysema
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039288 [pii]
AID - 10.1136/bmjopen-2020-039288 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e039288. doi: 10.1136/bmjopen-2020-039288.


PMID- 33082193
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Cardio-ankle vascular index (CAVI) measured by a new device: protocol for a
      validation study.
PG  - e038581
LID - 10.1136/bmjopen-2020-038581 [doi]
AB  - INTRODUCTION: Cardio-ankle vascular index (CAVI) is a new marker of arterial
      stiffness (AS) that can assess vascular wall stiffness in the aorta, femoral
      artery and tibial artery. CAVI is less affected by blood pressure at the time of 
      measurement than the gold standard method (carotid-femoral pulse wave velocity
      (PWV)). Our group has developed a device called VOPITB (Velocidad Onda de Pulso
      Indice Tobillo Brazo) that uses the oscillometric method and easily and
      accurately measures the PWV in the arms and legs separately, allowing new AS
      indices to be studied. This article describes the research protocol to determine 
      CAVI using VOPITB and to validate the device against a reference device (VaSera
      VS-1500) and assess its clinical utility. METHODS AND ANALYSES: A
      cross-sectional, descriptive and observational study will be conducted. In all,
      120 subjects (a minimum of 40% of subjects from any one gender) will be
      evaluated. CAVI will be determined from the measurement by VOPITB and VaSera
      VS-1500. For each subject, the average of the three readings taken with each
      device will be calculated. The Bland-Altman plot will be used to determine
      whether any bias exists in the data-that is, a tendency of the size of the
      difference to vary with the mean. The participants will be divided roughly
      equally between the following age bands: <30, 30-60 and >60 years. ETHICS AND
      DISSEMINATION: The study has been approved by the ethics committee of the
      Hospital San Pedro de Alcantara, Caceres, Spain. The participants will be
      required to sign an informed consent form before inclusion in the study, in
      accordance with the Declaration of Helsinki and WHO standards for observational
      studies. The dissemination plan of the research study results will be through
      presentations in relevant national and international conferences and scientific
      publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04303546.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rico Martin, Sergio
AU  - Rico Martin S
AUID- ORCID: 0000-0003-4932-1940
AD  - Department of Nursing, Nursing and Occupational Therapy College. Universidad de
      Extremadura, Caceres, Spain sergiorico@unex.es.
AD  - Iberian Network on Arterial Structure, Central Hemodynamics and Neurocognition,
      Caceres, Spain.
FAU - Vassilenko, Valentina
AU  - Vassilenko V
AD  - Iberian Network on Arterial Structure, Central Hemodynamics and Neurocognition,
      Caceres, Spain.
AD  - Laboratory of Instrumentation, Biomedical Engineering and Radiation Physics
      (LIBPhys-UNL), NOVA School of Science and Technology, NOVA University Lisbon,
      Caprica, Portugal.
FAU - de Nicolas Jimenez, Jorge M
AU  - de Nicolas Jimenez JM
AD  - Iberian Network on Arterial Structure, Central Hemodynamics and Neurocognition,
      Caceres, Spain.
AD  - Zona Centro Health Center, Extremadura Health Service, Caceres, Spain.
FAU - Rey Sanchez, Purificacion
AU  - Rey Sanchez P
AD  - Department of Nursing, Nursing and Occupational Therapy College. Universidad de
      Extremadura, Caceres, Spain.
FAU - Serrano, Andreia
AU  - Serrano A
AD  - Iberian Network on Arterial Structure, Central Hemodynamics and Neurocognition,
      Caceres, Spain.
AD  - Laboratory of Instrumentation, Biomedical Engineering and Radiation Physics
      (LIBPhys-UNL), NOVA School of Science and Technology, NOVA University Lisbon,
      Caprica, Portugal.
FAU - Martinez Alvarez, Mariana
AU  - Martinez Alvarez M
AD  - Deparment of Nursing, Faculty of Medicine, Universidad de Extremadura, Badajoz,
      Spain.
FAU - Calderon Garcia, Julian F
AU  - Calderon Garcia JF
AD  - Department of Nursing, Nursing and Occupational Therapy College. Universidad de
      Extremadura, Caceres, Spain.
AD  - Iberian Network on Arterial Structure, Central Hemodynamics and Neurocognition,
      Caceres, Spain.
FAU - Sanchez Munoz-Torrero, Juan F
AU  - Sanchez Munoz-Torrero JF
AD  - Iberian Network on Arterial Structure, Central Hemodynamics and Neurocognition,
      Caceres, Spain.
AD  - Department of Internal Medicine, Hospital San Pedro de Alcantara, Caceres, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04303546
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ankle
MH  - Blood Pressure
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - *Pulse Wave Analysis
MH  - Spain
MH  - *Vascular Stiffness
PMC - PMC7577065
OTO - NOTNLM
OT  - *epidemiology
OT  - *ischaemic heart disease
OT  - *vascular medicine
COIS- Competing interests: JFSM-T has property rights over the patented VOPITB
      invention (Oficina Espanola de Patentes y Marcas; number of concession:
      P201130872; publication number: 2400134) and is consultant for MSD, Astra, Pfizer
      and Boehringer Ingelheim.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038581 [pii]
AID - 10.1136/bmjopen-2020-038581 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e038581. doi: 10.1136/bmjopen-2020-038581.


PMID- 33082192
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Osseointegrated reconstruction and rehabilitation of transtibial amputees: the
      Osseointegration Group of Australia surgical technique and protocol for a
      prospective cohort study.
PG  - e038346
LID - 10.1136/bmjopen-2020-038346 [doi]
AB  - INTRODUCTION: Lower extremity amputation uniformly impairs a person's vocational,
      social and recreational capacity. Rehabilitation in traditional socket prostheses
      (TSP) is associated with a spectrum of complications involving the
      socket-residuum interface which lead to reduced prosthetic use and quality of
      life. Osseointegration has recently emerged as a novel concept to overcome these 
      complications by eliminating this interface and anchoring the prosthesis directly
      to bone. Though the complications of TSPs affect both transfemoral and
      transtibial amputees, Osseointegration has been predominantly performed in
      transfemoral ones assuming a greater benefit/risk ratio. However, as the safety
      of the procedure has been established, we intend to extend the concept to
      transtibial amputees and document the outcomes. METHODS AND ANALYSIS: This is
      protocol for a prospective cohort study, with patient enrolment started in 2014
      and expected to be completed by 2022. The inclusion criteria are age over 18
      years, unilateral, bilateral and mixed transtibial amputation and experiencing
      socket-related problems. All patients receive osseointegrated implants, the type 
      of which depend on the length of the residuum and quality of bone, which are
      press-fitted into the residual bone. Objective functional outcomes comprising
      6-Minute Walk Test, Timed Up-and-Go test and K-level, subjective
      patient-reported-quality-of-life outcomes (Short Form Health Survey 36, daily
      prosthetic wear hours, prosthetic wear satisfaction) and adverse events are
      recorded preoperatively and at postoperative follow-up intervals of 3, 6, 12
      months and yearly, and compared with the preoperative values using appropriate
      statistical tests. Multivariable multilevel logistic regression will be performed
      with a focus to identify factors associated with outcomes and adverse events,
      specifically infection, periprosthetic fracture, implant fracture and aseptic
      loosening. ETHICS AND DISSEMINATION: The Ethics approval for the study has been
      received from the University of Notre Dame, Sydney, Australia (014153S). The
      outcomes of this study will be disseminated by publications in peer-reviewed
      academic journals and scientific presentations at relevant orthopaedic
      conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Haque, Russel
AU  - Haque R
AD  - Department of Orthopaedic Surgery, Macquarie University Hospital, North Ryde BC, 
      New South Wales, Australia.
AD  - The Limb Reconstruction Discipline, Macquarie University Hospital, North Ryde BC,
      New South Wales, Australia.
FAU - Al-Jawazneh, Shakib
AU  - Al-Jawazneh S
AD  - Department of Orthopaedic Surgery, Macquarie University Hospital, North Ryde BC, 
      New South Wales, Australia.
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Hoellwarth, Jason
AU  - Hoellwarth J
AD  - Department of Orthopaedic Surgery, Macquarie University Hospital, North Ryde BC, 
      New South Wales, Australia.
FAU - Akhtar, Muhammad Adeel
AU  - Akhtar MA
AD  - Department of Orthopaedic Surgery, NHS Fife, Kirkcaldy, UK.
FAU - Doshi, Karan
AU  - Doshi K
AD  - Department of Orthopaedic Surgery, Macquarie University Hospital, North Ryde BC, 
      New South Wales, Australia.
FAU - Tan, Yao Chang
AU  - Tan YC
AD  - Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, 
      Macquarie University, Sydney, New South Wales, Australia.
FAU - Lu, William Yenn-Ru
AU  - Lu WY
AUID- ORCID: 0000-0001-6919-8367
AD  - Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, 
      Macquarie University, Sydney, New South Wales, Australia
      research@osseointegrationaustralia.com.au.
FAU - Roberts, Claudia
AU  - Roberts C
AD  - The Limb Reconstruction Discipline, Macquarie University Hospital, North Ryde BC,
      New South Wales, Australia.
FAU - Al Muderis, Munjed
AU  - Al Muderis M
AD  - Department of Orthopaedic Surgery, Macquarie University Hospital, North Ryde BC, 
      New South Wales, Australia.
AD  - The Limb Reconstruction Discipline, Macquarie University Hospital, North Ryde BC,
      New South Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Amputees
MH  - Australia
MH  - Humans
MH  - Osseointegration
MH  - Prospective Studies
MH  - Prosthesis Design
MH  - Quality of Life
MH  - Treatment Outcome
PMC - PMC7577069
OTO - NOTNLM
OT  - *limb reconstruction
OT  - *orthopaedic & trauma surgery
OT  - *plastic & reconstructive surgery
OT  - *rehabilitation medicine
COIS- Competing interests: MAM receives royalties for design contributions for the
      Osseointegrated Prosthetic Limb (OPL; Permedica s.p.a; Milan, Italy) implant
      system.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038346 [pii]
AID - 10.1136/bmjopen-2020-038346 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e038346. doi: 10.1136/bmjopen-2020-038346.


PMID- 33082191
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - (Rad 8)Caffeine prophylaxis to improve intermittent hypoxaemia in infants born
      late preterm: a randomised controlled dosage trial (Latte Dosage Trial).
PG  - e038271
LID - 10.1136/bmjopen-2020-038271 [doi]
AB  - INTRODUCTION: Infants born late preterm (34+0 to 36+6 weeks' gestational age)
      have frequent episodes of intermittent hypoxaemia compared with term infants.
      Caffeine citrate reduces apnoea and intermittent hypoxaemia and improves
      long-term neurodevelopmental outcomes in infants born very preterm and may have
      similar effects in late preterm infants. Clearance of caffeine citrate increases 
      with gestational age and late preterm infants are likely to need a higher dose
      than very preterm infants. Our aim is to determine the most effective and
      best-tolerated dose of caffeine citrate to reduce transient intermittent
      hypoxaemia events in late preterm infants. METHODS AND ANALYSIS: A phase IIB,
      double-blind, five-arm, parallel, randomised controlled trial to compare the
      effect of four doses of oral caffeine citrate versus placebo on the frequency of 
      intermittent hypoxaemia. Late preterm infants will be enrolled within 72 hours of
      birth and randomised to receive 5, 10, 15 or 20 mg/kg/day caffeine citrate or
      matching placebo daily until term corrected age. The frequency of intermittent
      hypoxaemia (events/hour where oxygen saturation concentration is >/=10% below
      baseline for </=2 min) will be assessed with overnight oximetry at baseline, 2
      weeks after randomisation (primary outcome) and at term corrected age. Growth
      will be measured at these timepoints, and effects on feeding and sleeping will be
      assessed by parental report. Data will be analysed using generalised linear mixed
      models. ETHICS AND DISSEMINATION: This trial has been approved by the Health and 
      Disability Ethics Committees of New Zealand (reference 18/NTA/129) and the local 
      institutional research review committees. Findings will be disseminated to
      peer-reviewed journals to clinicians and researchers at local and international
      conferences and to the public. The findings of the trial will inform the design
      of a large multicentre trial of prophylactic caffeine in late preterm infants, by
      indicating the most appropriate dose to use and providing information on
      feasibility. TRIAL REGISTRATION NUMBER: ACTRN12618001745235; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oliphant, Elizabeth Anne
AU  - Oliphant EA
AUID- ORCID: 0000-0002-3660-4127
AD  - Department of Paediatrics: Child and Youth Health, The University of Auckland,
      Auckland, New Zealand e.oliphant@auckland.ac.nz.
AD  - Newborn Services, Starship Children's Health, Auckland District Health Board,
      Auckland, New Zealand.
FAU - McKinlay, Christopher J D
AU  - McKinlay CJD
AD  - Liggins Institute, The University of Auckland, Auckland, New Zealand.
AD  - Kidz First Neonatal Care, Counties Manukau Health, Auckland, New Zealand.
FAU - McNamara, David G
AU  - McNamara DG
AD  - Paediatrics Respiratory Services, Starship Children's Health, Auckland District
      Health Board, Auckland, New Zealand.
FAU - Alsweiler, Jane Marie
AU  - Alsweiler JM
AUID- ORCID: 0000-0002-0874-6654
AD  - Department of Paediatrics: Child and Youth Health, The University of Auckland,
      Auckland, New Zealand.
LA  - eng
SI  - ANZCTR/ACTRN12618001745235
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 3G6A5W338E (Caffeine)
SB  - IM
EIN - BMJ Open. 2020 Nov 6;10(11):1. PMID: 33158841
MH  - Apnea
MH  - *Caffeine
MH  - Female
MH  - Humans
MH  - Hypoxia/prevention & control
MH  - Infant
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - New Zealand
MH  - Pregnancy
PMC - PMC7577061
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *neonatology
OT  - *paediatric thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038271 [pii]
AID - 10.1136/bmjopen-2020-038271 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e038271. doi: 10.1136/bmjopen-2020-038271.


PMID- 33082190
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Protocol for a scoping review to understand what is known about how GPs make
      decisions with, for and on behalf of patients who lack capacity.
PG  - e038032
LID - 10.1136/bmjopen-2020-038032 [doi]
AB  - INTRODUCTION: General Practitioners (GPs) and allied healthcare professionals
      working in primary care are regularly required to make decisions with, for and on
      behalf of patients who lack capacity. In England and Wales, these decisions are
      made for incapacitated adult patients under the Mental Capacity Act 2005, which
      primarily requires that decisions are made in the patient's 'best interests'.
      Regarding children, decisions are also made in their best interests but are done 
      so under the Children Act 1989, which places paramount importance on the welfare 
      of the child. Decisions for children are usually made by parents, but a GP may
      become involved if he or she feels a parent is not acting in the best interests
      of the child. Internationally, including elsewhere in the UK, different
      approaches are taken. We hypothesise that, despite the legislation and
      professional guidelines, there are many different approaches taken by GPs and
      allied healthcare professionals in England and Wales when making these complex
      decisions with, for and on behalf of patients who lack capacity. To better
      understand what is known about how these decisions are made, we plan to undertake
      a scoping review and directed content analysis of the literature. While the
      majority of decisions made in primary care are made by GPs, for completeness,
      this review will include all allied healthcare professionals working in primary
      care. METHODS AND ANALYSIS: To ensure a wide breadth of literature is captured, a
      scoping review will be undertaken as described by Arksey and O'Malley (2005). A
      five-stage approach will be taken when conducting this review: (1) identifying
      the research question; (2) identifying relevant papers; (3) study selection; (4) 
      data extraction and (5) summarising and synthesis. The final stage will include a
      directed content analysis of the data to help establish the cross-cutting themes.
      ETHICS AND DISSEMINATION: The scoping review will be disseminated through
      conferences and peer-reviewed publications. This scoping review is the first
      (mapping) phase in a proposed larger study to explore how GPs make decisions
      with, for and on behalf of those who lack capacity. Qualitative research with
      GPs, patients and their families will follow, before all the results are
      synthesised using an 'empirical bioethics' methodology.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ogden, Simon Jack
AU  - Ogden SJ
AUID- ORCID: 0000-0002-6447-7903
AD  - Centre for Ethics in Medicine, University of Bristol, Bristol, UK
      jack.ogden@bristol.ac.uk.
FAU - Huxtable, Richard
AU  - Huxtable R
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
FAU - Ives, Jonathan
AU  - Ives J
AD  - Centre for Ethics in Medicine, University of Bristol, Bristol, UK.
LA  - eng
GR  - 204813/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Child
MH  - England
MH  - Female
MH  - *General Practitioners
MH  - Humans
MH  - Male
MH  - Parents
MH  - Qualitative Research
MH  - Research Design
MH  - Review Literature as Topic
MH  - Wales
PMC - PMC7577062
OTO - NOTNLM
OT  - *medical ethics
OT  - *primary care
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038032 [pii]
AID - 10.1136/bmjopen-2020-038032 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e038032. doi: 10.1136/bmjopen-2020-038032.


PMID- 33082189
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Cerebrovascular accident and acute coronary syndrome and perioperative outcomes
      (CAPO) study protocol: a 10-year database linkage between Hospital Episode
      Statistics Admitted Patient Care, Myocardial Infarction National Audit Project
      and Office for National Statistics registries for time-dependent risk analysis of
      perioperative outcomes in English NHS hospitals.
PG  - e037904
LID - 10.1136/bmjopen-2020-037904 [doi]
AB  - INTRODUCTION: An increasing number of people who have a history of acute coronary
      syndrome or cerebrovascular accident (termed cardiovascular events) are being
      considered for surgery. Up-to-date evidence of the impact of these prior events
      is needed to inform person-centred decision making. While perioperative risk for 
      major adverse cardiac events immediately after a cardiovascular event is known to
      be elevated, the duration of time after the event for which the perioperative
      risk is increased is not clear. METHODS AND ANALYSIS: This is an individual
      patient-level database linkage study of all patients in England with at least one
      operation between 2007 and 2017 in the Hospital Episode Statistics Admitted
      Patient Care database. Data will be linked to mortality data from the Office for 
      National Statistics up to 2018, for 30-day, 90-day and 1-year mortality and to
      the Myocardial Ischaemia National Audit Project, a UK registry of acute coronary 
      syndromes. The primary outcome will be the association between time from
      cardiovascular event to index surgery and 30-day all-cause mortality. Additional 
      associations we will report are all unplanned readmissions, prolonged length of
      stay, 30-day hospital free survival and incidence of new cardiovascular events
      within one postoperative year. Important subgroups will be surgery specific
      (invasiveness, urgency and subspecialty), type of acute coronary syndrome (ST or 
      non-ST elevation myocardial infarction) and type of cerebrovascular accident
      (ischaemic or haemorrhagic stroke). ETHICS AND DISSEMINATION: Ethical approval
      for this observational study has been obtained from East Midlands-Nottingham 1
      Research Ethics Committee; REC reference: 18/EM0403. The results of the study
      will be made available through peer-reviewed publications and via the Health
      Services Research Centre of the Royal College of Anaesthetists, London.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Luney, Matthew Stephen
AU  - Luney MS
AD  - Anaesthesia and Critical Care Section, Division of Clinical Neuroscience,
      University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Lindsay, William
AU  - Lindsay W
AD  - Anaesthesia and Critical Care Section, Division of Clinical Neuroscience,
      University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - McKeever, Tricia M
AU  - McKeever TM
AD  - Division of Epidemiology and Public Health, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Moppett, Iain Keith
AU  - Moppett IK
AUID- ORCID: 0000-0003-3750-6067
AD  - Anaesthesia and Critical Care Section, Division of Clinical Neuroscience,
      University of Nottingham, Nottingham, Nottinghamshire, UK
      iain.moppett@nottingham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acute Coronary Syndrome/epidemiology
MH  - England/epidemiology
MH  - Hospitals
MH  - Humans
MH  - London
MH  - *Myocardial Infarction/epidemiology
MH  - Observational Studies as Topic
MH  - Registries
MH  - Risk Assessment
MH  - State Medicine
MH  - *Stroke/epidemiology
PMC - PMC7577058
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *myocardial infarction
OT  - *stroke
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037904 [pii]
AID - 10.1136/bmjopen-2020-037904 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e037904. doi: 10.1136/bmjopen-2020-037904.


PMID- 33082186
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Anticoagulation strategies in critical care for the treatment of atrial
      fibrillation: a protocol for a systematic review and meta-analysis.
PG  - e037591
LID - 10.1136/bmjopen-2020-037591 [doi]
AB  - INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia in
      critically ill patients and is associated with an increased risk of
      thromboembolic events and mortality. Oral anticoagulation for thromboembolism
      prophylaxis is a key component of managing AF in the general population and is
      recommended by National Institute for Health and Care Excellence guidelines.
      However, assessment tools used to aid decision making about anticoagulation have 
      not yet been validated in the critical care setting. There is a paucity of data
      assessing the impact of anticoagulation strategies on clinical outcomes in
      critically ill patients with AF. We present a protocol for a systematic review
      and meta-analysis to evaluate the effectiveness of anticoagulation strategies for
      AF used specifically in critical care. METHODS AND ANALYSIS: We will conduct a
      systematic review of the literature by searching MEDLINE, EMBASE, CENTRAL and
      PubMed databases for articles published from January 1990 to October 2019.
      Studies reporting anticoagulation strategies for AF in adults (>18 years)
      admitted to a general critical care setting will be assessed for inclusion.
      Outcomes of interest will include (1) percentage of patients started on
      anticoagulation in critical care for AF, (2) incidence of thromboembolism, (3)
      incidence of bleeding events, (4) intensive care unit (ICU) mortality, (5)
      hospital mortality, (6) ICU length of stay and (7) hospital length of stay. We
      will conduct a meta-analysis of trials. Risk of bias will be assessed using the
      Cochrane Risk of Bias tool for randomised trials or the Newcastle-Ottawa Risk of 
      Bias assessment tool for non-randomised studies. This protocol and subsequent
      systematic review will be reported following the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses checklist. ETHICS AND DISSEMINATION: This
      proposed systematic review will include data extracted from published studies;
      therefore, ethical approval is not required. The results of this review will be
      published in clinical specialty journals and presented at international meetings 
      and conferences. TRIAL REGISTRATION NUMBER: CRD42020158237.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Johnston, Brian
AU  - Johnston B
AUID- ORCID: 0000-0003-1634-3297
AD  - Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
      brian.johnston@liverpool.ac.uk.
FAU - Nelson, Alexandra
AU  - Nelson A
AD  - Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
FAU - Waite, Alicia C
AU  - Waite AC
AD  - Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
FAU - Lemma, Gedeon
AU  - Lemma G
AD  - Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
FAU - Welters, Ingeborg
AU  - Welters I
AUID- ORCID: 0000-0002-3408-8798
AD  - Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - *Atrial Fibrillation/complications/drug therapy
MH  - Critical Care
MH  - Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7577029
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *anticoagulation
OT  - *cardiology
OT  - *intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037591 [pii]
AID - 10.1136/bmjopen-2020-037591 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e037591. doi: 10.1136/bmjopen-2020-037591.


PMID- 33082181
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - While you're waiting, a waiting room-based, cardiovascular disease-focused
      educational program: protocol for a randomised controlled trial.
PG  - e036780
LID - 10.1136/bmjopen-2020-036780 [doi]
AB  - INTRODUCTION: Patients with cardiovascular disease (CVD) frequently attend
      outpatient clinics and spend a significant amount of time in waiting rooms.
      Currently, this time is poorly used. This study aims to investigate whether
      providing CVD and cardiopulmonary resuscitation (CPR) education to waiting
      patients in a cardiology clinic of a large referral hospital improves motivation 
      to change health behaviours, CPR knowledge, behaviours and clinic satisfaction
      post clinic, and whether there is any impact on reported CVD lifestyle behaviours
      or relevant CPR outcomes at 30 days. METHODS AND ANALYSIS: Randomised controlled 
      trial with parallel design to be conducted among 330 patients in the waiting room
      of a chest pain clinic in a tertiary referral hospital. Intervention (n=220)
      participants will receive a tablet-delivered series of educational videos catered
      to self-reported topics of interest (physical activity, blood pressure, diet,
      medications, smoking and general health) and level of health knowledge. Control
      (n=110) participants will receive usual care. In a substudy, intervention
      participants will be randomised 1:1 to receive an extra video on CPR or no extra 
      video. The primary outcome will be the proportion of intervention and control
      participants who report high motivation to improve physical activity, diet and
      blood pressure monitoring at end of clinic. The primary outcome of the CPR study 
      will be confidence to perform CPR post clinic. Secondary analysis will examine
      impact on clinic satisfaction, lifestyle behaviours, CPR knowledge and
      willingness to perform CPR post clinic and at 30-day follow-up. ETHICS AND
      DISSEMINATION: Ethics approval has been received from the Western Sydney Local
      Health District Human Research Ethics Committee. All patients will provide
      informed consent via a tablet-based eConsent framework. Study results will be
      disseminated via the usual channels including peer-reviewed publications and
      presentations at national and international conferences. TRIAL REGISTRATION
      NUMBER: ANZCTR12618001725257.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mcintyre, Daniel
AU  - Mcintyre D
AUID- ORCID: 0000-0003-4854-4050
AD  - Westmead Applied Research Centre, University of Sydney, Westmead, New South
      Wales, Australia daniel.mcintyre@sydney.edu.au.
FAU - Thiagalingam, Aravinda
AU  - Thiagalingam A
AD  - Westmead Applied Research Centre, University of Sydney, Westmead, New South
      Wales, Australia.
AD  - Cardiology Department, Westmead Hospital, Westmead, New South Wales, Australia.
FAU - Chow, Clara
AU  - Chow C
AD  - Westmead Applied Research Centre, University of Sydney, Westmead, New South
      Wales, Australia.
AD  - Cardiology Department, Westmead Hospital, Westmead, New South Wales, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiovascular Diseases/prevention & control
MH  - Health Education
MH  - Humans
MH  - Life Style
MH  - Motivation
MH  - Randomized Controlled Trials as Topic
MH  - Waiting Rooms
PMC - PMC7577035
OTO - NOTNLM
OT  - *cardiology
OT  - *clinical trials
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036780 [pii]
AID - 10.1136/bmjopen-2020-036780 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e036780. doi: 10.1136/bmjopen-2020-036780.


PMID- 33082180
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Availability and use of mHealth for disease diagnosis and treatment support by
      health workers in sub-Saharan Africa: a scoping review protocol.
PG  - e036641
LID - 10.1136/bmjopen-2019-036641 [doi]
AB  - INTRODUCTION: Improving healthcare for all is one of the global health
      priorities, particularly in disease burdened settings such as sub-Saharan Africa 
      (SSA). Considering the high penetration rate of mobile phones in SSA, mobile
      health (mHealth) could be used to achieve universal health coverage. The proposed
      study will map evidence on the availability and use of mHealth for disease
      diagnosis and treatment support by health workers in SSA. METHODS AND ANALYSIS:
      This review will be guided by Arksey and O'Malley's scoping review framework and 
      Levac et al's recommendations and guidelines from the Joanna Briggs Institute. A 
      scoping review will be conducted to explore what is known about mHealth for
      disease diagnosis and treatment support by health workers in SSA and to identify 
      areas for future research. In addition to searching the grey literature, the
      following databases will be explored from PubMed, MEDLINE and CINAHL with full
      text via EBSCOhost and ScienceDirect databases. A search in Google Scholar will
      be considered as an additional information source. The literature search will
      involve published studies from 2000 to 2020 in any language. This review will
      cover mHealth for disease diagnosis and treatment support by health workers in
      SSA. The primary investigator will conduct the title screening, and subsequently,
      two reviewers will independently conduct abstract and full article screening and 
      data extraction. The results of this proposed review will be presented using the 
      Preferred Reporting Items for Systematic Reviews and Meta-analysis: Extension for
      Scoping Review guidelines. ETHICS AND DISSEMINATION: Ethical approval is not
      required for the scoping review, which is the first stage in a PhD study in
      public health on accessing mHealth for disease diagnosis and treatment support by
      health workers in Ghana. The final review will be submitted for publications to a
      scientific journal, and our results will be presented at appropriate conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Osei, Ernest
AU  - Osei E
AUID- ORCID: 0000-0002-8536-545X
AD  - Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban,
      South Africa ernestosei56@gmail.com.
FAU - Kuupiel, Desmond
AU  - Kuupiel D
AUID- ORCID: 0000-0001-7780-1955
AD  - Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban,
      South Africa.
AD  - Research for Sustainable Development Consult, Sunyani, Bono Region, Ghana.
FAU - Mashamba-Thompson, Tivani Phosa
AU  - Mashamba-Thompson TP
AUID- ORCID: 0000-0002-4193-2416
AD  - Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban,
      South Africa.
AD  - Public Health, University of Limpopo, Polokwane, Limpopo Province, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Ghana
MH  - Health Personnel
MH  - Health Workforce
MH  - Humans
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
MH  - *Telemedicine
PMC - PMC7577031
OTO - NOTNLM
OT  - *health informatics
OT  - *information management
OT  - *public health
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036641 [pii]
AID - 10.1136/bmjopen-2019-036641 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e036641. doi: 10.1136/bmjopen-2019-036641.


PMID- 33082177
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 20
TI  - Nodding syndrome: bridging the gap-a scoping review protocol.
PG  - e035269
LID - 10.1136/bmjopen-2019-035269 [doi]
AB  - INTRODUCTION: Nodding syndrome (NS) is an encephalopathy of unknown origin that
      affects children aged between 3 and 15 years old. Cases have been reported since 
      the 1950 in Tanzania and South Sudan, the most heavily affected population is the
      Acholi community in Uganda. In response to the high incidence of the disease, the
      Ugandan Government has developed a management algorithm, but access to such
      measures in affected communities is limited. There is little funding for research
      on the disease, consequently, few studies have been conducted to date.
      Nevertheless, the number of scientific publications on NS has increased since
      2013, reporting several aetiological hypotheses, management algorithms and cases 
      of stigmatisation; however, none has obtained conclusive results.This document
      describes a protocol for a scoping review of NS to date aimed at obtaining a
      broad overview of the disease. The results will identify gaps in knowledge in
      order to better guide future research, intervention strategies, health policies
      in areas at risk and cooperation and development programmes. METHODS AND
      ANALYSIS: To identify the relevant data, we will conduct a literature search
      using the electronic databases PubMed/Medline, Embase, Social Science Citation
      Index Scopus, Scientific Electronic Library Online (SciELO), Literatura
      Latinoamericana y del Caribe en Ciencias de la Salud (LILACS), Social Science
      Citation Index Expanded and The Cochrane Library. We will also include grey
      literature. The search strategy will be designed by a librarian.Two members of
      the team will work independently to identify studies for inclusion and perform
      data extraction. The search results will be assessed by two independent reviewers
      and data from the included studies will be charted and summarised in duplicate.
      The data will be summarised in tables and figures to present the research
      landscape and describe and map gaps. ETHICS AND DISSEMINATION: Ethical approval
      is not required. The scoping review will adhere to the Preferred Reporting Items 
      for Systematic Reviews andMeta-Analyses-ScR guidelines. The results will be
      disseminated at scientific congresses and meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - De Castro, Ana Cristina
AU  - De Castro AC
AUID- ORCID: 0000-0002-5924-0100
AD  - Facultad de Medicina y Ciencias de la Salud. Departamento de Enfermeria,
      Universidad de Alcala, Alcala de Henares, Madrid, Spain.
FAU - Ortega-Deballon, Ivan
AU  - Ortega-Deballon I
AD  - Facultad de Medicina y Ciencias de la Salud. Departamento de Enfermeria,
      Universidad de Alcala, Alcala de Henares, Madrid, Spain iviortega@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - *Nodding Syndrome/epidemiology
MH  - Population Groups
MH  - Review Literature as Topic
MH  - South Sudan
MH  - Systematic Reviews as Topic
MH  - Tanzania
MH  - Uganda/epidemiology
PMC - PMC7577026
OTO - NOTNLM
OT  - *community child health
OT  - *health policy
OT  - *neurology
OT  - *pathology
OT  - *tropical medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:53
PHST- 2020/10/21 05:53 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035269 [pii]
AID - 10.1136/bmjopen-2019-035269 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 20;10(10):e035269. doi: 10.1136/bmjopen-2019-035269.


PMID- 33081823
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220531
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 20
TI  - Effectiveness and safety of tenosynovitis of the long head of the biceps brachii 
      with acupuncture: a protocol for a systematic review and meta-analysis.
PG  - 869
LID - 10.1186/s13063-020-04800-6 [doi]
AB  - BACKGROUND: Tenosynovitis of the long head of the biceps (LHB) brachii is a
      common disease in patients over 40 years old. It can always result in chronic
      anterior shoulder pain and limited function. Acupuncture is one of most popular
      conservative treatment methods, and increasing studies indicate that it has
      remarkable therapeutic effects on the tenosynovitis of LHB brachii. However, the 
      effectiveness and safety of acupuncture for treating tenosynovitis of LHB brachii
      remain largely uncertain. In our study, we will perform the first systematic
      review and meta-analysis to explore the effectiveness and safety of acupuncture
      on the tenosynovitis of LHB brachii. METHODS: We will search the randomized
      controlled trial (RCT) literatures involving acupuncture for treating
      tenosynovitis of LHB brachii in eight electric databases, including PubMed, Web
      of Science, EMBASE, the Cochrane Library, Chinese National Knowledge
      Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang
      Database, and Technology Periodical Database (VIP). We will define the visual
      analog scale (VAS), the Melle score of shoulder joint functional activity, and
      the ability assessment of daily living activities (ADL) as the primary outcomes. 
      Besides quality of life, adverse events caused by acupuncture will be regarded as
      the secondary outcomes. Quality assessment of the included studies will be
      independently performed according to the Cochrane Risk of Bias tool. Meanwhile,
      the level of evidence for results will be assessed by using the Grading of
      Recommendations Assessment, Development, and Evaluation (GRADE) method. All
      analyses will be conducted by using the RevMan software V5.3. RESULTS: From the
      study, we will ascertain the effectiveness and safety of acupuncture treatment on
      tenosynovitis of LHB brachii. CONCLUSION: The conclusion of this study will
      confirm the effectiveness and safety of acupuncture in the treatment of
      tenosynovitis of LHB brachii, which can provide new evidence to guide appropriate
      interventions on tenosynovitis of LHB brachii with acupuncture in the future.
      ETHICS AND DISSEMINATION: Ethical approval is not required because no individual 
      patient data are collected. This review will be published in a peer-reviewed
      journal and presented at an international academic conference for dissemination. 
      TRIAL REGISTRATION: PROSPERO registration number CRD42020167434 . Registered on
      April 28, 2020.
FAU - Li, Rongrong
AU  - Li R
AD  - Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third
      Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou City,
      310053, Zhejiang Province, China.
FAU - Jiang, Yongliang
AU  - Jiang Y
AD  - Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third
      Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou City,
      310053, Zhejiang Province, China.
FAU - Hu, Renjie
AU  - Hu R
AD  - Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third
      Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou City,
      310053, Zhejiang Province, China.
FAU - He, Xiaofen
AU  - He X
AD  - Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third
      Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou City,
      310053, Zhejiang Province, China.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - Key Laboratory of Acupuncture and Neurology of Zhejiang Province, The Third
      Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou City,
      310053, Zhejiang Province, China. fangjianqiao7532@163.com.
LA  - eng
GR  - NO.2018YFC1704600/Key Technologies Research and Development Program
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Activities of Daily Living
MH  - *Acupuncture Therapy/adverse effects
MH  - Adult
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - *Tenosynovitis
MH  - Visual Analog Scale
PMC - PMC7576742
OTO - NOTNLM
OT  - Acupuncture
OT  - Brachii
OT  - LHB
OT  - Meta-analysis
OT  - Tenosynovitis
EDAT- 2020/10/22 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/21 05:38
PHST- 2020/05/12 00:00 [received]
PHST- 2020/10/10 00:00 [accepted]
PHST- 2020/10/21 05:38 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04800-6 [doi]
AID - 10.1186/s13063-020-04800-6 [pii]
PST - epublish
SO  - Trials. 2020 Oct 20;21(1):869. doi: 10.1186/s13063-020-04800-6.


PMID- 33081796
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Oct 20
TI  - Allogeneic administration of human umbilical cord-derived mesenchymal
      stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four
      Vietnamese infants.
PG  - 398
LID - 10.1186/s12967-020-02568-6 [doi]
AB  - BACKGROUND: Bronchopulmonary dysplasia (BPD) is a severe condition in premature
      infants that compromises lung function and necessitates oxygen support. Despite
      major improvements in perinatal care minimizing the devastating effects, BPD
      remains the most frequent complication of extreme preterm birth. Our study
      reports the safety of the allogeneic administration of umbilical cord-derived
      mesenchymal stem/stromal cells (allo-UC-MSCs) and the progression of lung
      development in four infants with established BPD. METHODS: UC tissue was
      collected from a healthy donor, followed by propagation at the Stem Cell Core
      Facility at Vinmec Research Institute of Stem Cell and Gene Technology. UC-MSC
      culture was conducted under xeno- and serum-free conditions. Four patients with
      established BPD were enrolled in this study between May 25, 2018, and December
      31, 2018. All four patients received two intravenous doses of allo-UC-MSCs (1
      million cells/kg patient body weight (PBW) per dose) with an intervening interval
      of 7 days. Safety and patient conditions were evaluated during hospitalization
      and at 7 days and 1, 6 and 12 months postdischarge. RESULTS: No
      intervention-associated severe adverse events or prespecified adverse events were
      observed in the four patients throughout the study period. At the time of this
      report, all patients had recovered from BPD and were weaned off of oxygen
      support. Chest X-rays and CT scans confirmed the progressive reductions in
      fibrosis. CONCLUSIONS: Allo-UC-MSC administration is safe in preterm infants with
      established BPD. Trial registration This preliminary study was approved by the
      Vinmec International Hospital Ethics Board (approval number: 88/2019/QD-VMEC;
      retrospectively registered March 12, 2019).
FAU - Nguyen, Liem Thanh
AU  - Nguyen LT
AD  - Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare
      System, Hanoi, Vietnam.
FAU - Trieu, Thai T H
AU  - Trieu TTH
AD  - Vinmec International Hospital-Times City, Vinmec Healthcare System, Hanoi,
      Vietnam.
FAU - Bui, Hue T H
AU  - Bui HTH
AD  - Vinmec Hi-Tech Center, Times City, Vinmec Healthcare System, Hanoi, Vietnam.
FAU - Hoang, Van T
AU  - Hoang VT
AD  - Cellular Manufacturing Department, Vinmec Research Institute of Stem Cell and
      Gene Technology, 458 Minh Khai, Hai Ba Trung Ward, Hanoi, Vietnam.
FAU - Nguyen, Anh T T
AU  - Nguyen ATT
AD  - Vinmec Hi-Tech Center, Times City, Vinmec Healthcare System, Hanoi, Vietnam.
FAU - Trinh, Nhung T H
AU  - Trinh NTH
AD  - Vinmec Hi-Tech Center, Times City, Vinmec Healthcare System, Hanoi, Vietnam.
FAU - Nguyen, Kien T
AU  - Nguyen KT
AD  - Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare
      System, Hanoi, Vietnam.
FAU - Hoang, Duc M
AU  - Hoang DM
AUID- ORCID: 0000-0001-5444-561X
AD  - Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare
      System, Hanoi, Vietnam. v.duchm3@vinmec.com.
AD  - Cellular Manufacturing Department, Vinmec Research Institute of Stem Cell and
      Gene Technology, 458 Minh Khai, Hai Ba Trung Ward, Hanoi, Vietnam.
      v.duchm3@vinmec.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
SB  - IM
MH  - Aftercare
MH  - Asians
MH  - *Bronchopulmonary Dysplasia/therapy
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Patient Discharge
MH  - Pregnancy
MH  - *Premature Birth
MH  - Umbilical Cord
PMC - PMC7576694
OTO - NOTNLM
OT  - *Allogeneic mesenchymal stem cell administration
OT  - *Bronchopulmonary dysplasia
OT  - *Umbilical cord tissue
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/21 05:38
PHST- 2020/07/02 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/10/21 05:38 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12967-020-02568-6 [doi]
AID - 10.1186/s12967-020-02568-6 [pii]
PST - epublish
SO  - J Transl Med. 2020 Oct 20;18(1):398. doi: 10.1186/s12967-020-02568-6.


PMID- 33081119
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 16
TI  - Beyond Fish Oil Supplementation: The Effects of Alternative Plant Sources of
      Omega-3 Polyunsaturated Fatty Acids upon Lipid Indexes and Cardiometabolic
      Biomarkers-An Overview.
LID - E3159 [pii]
LID - 10.3390/nu12103159 [doi]
AB  - Cardiovascular diseases remain a global challenge, and lipid-associated
      biomarkers can predict cardiovascular events. Extensive research on
      cardiovascular benefits of omega-3 polyunsaturated fatty acids (n3-PUFAs) is
      geared towards fish oil supplementation and fish-rich diets. Nevertheless,
      vegetarianism and veganism are becoming more popular across all segments of
      society, due to reasons as varied as personal, ethical and religious values,
      individual preferences and environment-related principles, amongst others. Due to
      the essentiality of PUFAs, plant sources of n3-PUFAs warrant further
      consideration. In this review, we have critically appraised the efficacy of
      plant-derived n3-PUFAs from foodstuffs and supplements upon lipid profile and
      selected cardiometabolic markers. Walnuts and flaxseed are the most common plant 
      sources of n3-PUFAs, mainly alpha-linolenic acid (ALA), and feature the strongest
      scientific rationale for applicability into clinical practice. Furthermore,
      walnuts and flaxseed are sources of fibre, potassium, magnesium, and
      non-essential substances, including polyphenols and sterols, which in conjunction
      are known to ameliorate cardiovascular metabolism. ALA levels in rapeseed and
      soybean oils are only slight when compared to flaxseed oil. Spirulina and
      Chlorella, biomasses of cyanobacteria and green algae, are important sources of
      n3-PUFAs; however, their benefits upon cardiometabolic markers are plausibly
      driven by their antioxidant potential combined with their n3-PUFA content. In
      humans, ALA is not sufficiently bioconverted into eicosapentaenoic and
      docosahexaenoic acids. However, evidence suggests that plant sources of ALA are
      associated with favourable cardiometabolic status. ALA supplementation, or
      increased consumption of ALA-rich foodstuffs, combined with reduced omega-6 (n6) 
      PUFAs intake, could improve the n3/n6 ratio and improve cardiometabolic and lipid
      profile.
FAU - Santos, Heitor O
AU  - Santos HO
AD  - School of Medicine, Federal University of Uberlandia (UFU), Uberlandia 38408-100,
      Brazil.
FAU - Price, James C
AU  - Price JC
AD  - College of Health, Life and Environmental Sciences, University of Worcester,
      Worcester WR2 6AJ, UK.
FAU - Bueno, Allain A
AU  - Bueno AA
AUID- ORCID: 0000-0002-9456-8558
AD  - College of Health, Life and Environmental Sciences, University of Worcester,
      Worcester WR2 6AJ, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201016
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Antioxidants)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0RBV727H71 (alpha-Linolenic Acid)
SB  - IM
MH  - Antioxidants
MH  - Cardiovascular Diseases/metabolism/*prevention & control
MH  - Chlorella/chemistry
MH  - *Dietary Supplements
MH  - Fatty Acids, Omega-3/*administration & dosage/isolation &
      purification/pharmacology
MH  - Flax/chemistry
MH  - Food Analysis
MH  - Humans
MH  - Juglans/chemistry
MH  - *Lipid Metabolism
MH  - *Phytotherapy
MH  - Spirulina/chemistry
MH  - alpha-Linolenic Acid/administration & dosage
PMC - PMC7602731
OTO - NOTNLM
OT  - alpha-linolenic acid
OT  - flaxseed
OT  - lipids
OT  - omega-3
OT  - walnuts
EDAT- 2020/10/22 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/10/21 01:02
PHST- 2020/09/27 00:00 [received]
PHST- 2020/10/11 00:00 [revised]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/10/21 01:02 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - nu12103159 [pii]
AID - 10.3390/nu12103159 [doi]
PST - epublish
SO  - Nutrients. 2020 Oct 16;12(10). pii: nu12103159. doi: 10.3390/nu12103159.


PMID- 33080745
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Safety and effectiveness of acupuncture for POSEIDON patients in IVF/ICSI: A
      protocol for systematic review and meta-analysis.
PG  - e22768
LID - 10.1097/MD.0000000000022768 [doi]
AB  - INTRODUCTION: The purpose of this paper is to evaluate the efficacy and safety of
      acupuncture for POSEIDON patients undergoing IVF/ICSI. METHODS: and analysis We
      will electronically search Pubmed, Medline, Embase, Web of Science, the Cochrane 
      Central Register of Controlled Trial, China National Knowledge Infrastructure,
      China Biomedical Literature Database, China Science Journal Database and Wan-fang
      Database from their inception. Also, we will manually retrieve other resources,
      including reference lists of identified publications, conference articles, and
      grey literature. The clinical randomized controlled trials or quasi randomized
      controlled trials related to acupuncture treatment for POSEIDON patients in
      IVF/ICSI will be included in the study. The language is limited to Chinese and
      English. Research selection, data extraction, and research quality assessment
      will be independently completed by two researchers. Data were synthesized by
      using a fixed effect model or random effect model depend on the heterogeneity
      test. The clinical pregnancy rate (CPR) and live birth rate (LBR) will be the
      primary outcomes. The ongoing pregnancy, miscarriage rate (MR) and adverse events
      will also be assessed as secondary outcomes. RevMan V.5.3 statistical software
      will be used for meta-analysis, and the level of evidence will be assessed by
      Grading of Recommendations Assessment, Development, and Evaluation (GRADE).
      Continuous data will be expressed in the form of weighted mean difference or
      standardized mean difference with 95% confidence intervals (CIs), while
      dichotomous data will be expressed in the form of relative risk with 95% CIs.
      ETHICS AND DISSEMINATION: The protocol of this systematic review (SR) does not
      require ethical approval because it does not involve humans. We will publish this
      article in peer-reviewed journals and presented at relevant conferences.
      SYSTEMATIC REVIEW REGISTRATION: OSF Registries, DOI: 10.17605/OSF.IO/6WP2F
      (https://osf.io/6wp2f).
FAU - Zhu, Xinyun
AU  - Zhu X
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Yang, Lijie
AU  - Yang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, China.
FAU - Li, Zimeng
AU  - Li Z
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Pan, Zhengqi
AU  - Pan Z
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Huang, Shijie
AU  - Huang S
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Xiong, Yueheng
AU  - Xiong Y
AD  - Acupuncture and Moxibustion School Chengdu University of Traditional Chinese
      Medicine.
FAU - Wu, Jie
AU  - Wu J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Female
MH  - *Fertilization in Vitro
MH  - Humans
MH  - Infertility/therapy
MH  - *Meta-Analysis as Topic
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Research Design
MH  - *Sperm Injections, Intracytoplasmic
MH  - *Systematic Reviews as Topic
PMC - PMC7571989
EDAT- 2020/10/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1097/MD.0000000000022768 [doi]
AID - 00005792-202010160-00078 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22768. doi:
      10.1097/MD.0000000000022768.


PMID- 33080733
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Efficacy and safety of acupoint injection therapy for allergic rhinitis: A
      protocol for systematic review and meta-analysis.
PG  - e22737
LID - 10.1097/MD.0000000000022737 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR), characterized by nasal itching, sneezing, and
      congestion, is a common disorder of nose. In the United States, AR affects 10% to
      20% of adults. The negative impact of the high prevalence of AR has caused a
      great economic burdens worldwide. Modern Western Medicine mainly treats AR with
      antihistamine drugs, glucocorticoids, allergic immunotherapy (AIT), but it
      seriously affects patients compliance because of its long course of treatment,
      high medical costs and side effect. And now, as an important mean of treating AR,
      acupoint injection has been widely used in clinics, and has achieved significant 
      efficacy. METHODS AND ANALYSIS: The following databases will be searched for
      relevant information before July 2020: PubMed, Embase, Cochrane Library, Web of
      Science, and CNKI. MAJOR RESULTS: scores of Rhinitis Quality of Life (RQLQ),
      Rhinitis Total Symptom Scores (RTSS). Secondary results: levels of
      antigen-specific serum immunoglobulin E (IgE), total effective rate, adverse
      event. Data will be collected independently by 2 researchers, and the risk of
      bias in meta-analysis will be evaluated according to "Cochrane Handbook for
      Systematic Reviews of Interventions". All data analysis will be conducted using
      Review Manager V.5.3. and Stata V.12.0. RESULTS: The curative effect and safety
      of acupoint injection treatment for AR patients will be evaluated systematically.
      CONCLUSION: The systematic review of this study will summarize the currently
      published evidence of acupoint injection treatment for AR to further guide its
      promotion and application. ETHICS AND DISSEMINATION: The private information from
      individuals will not be published. This systematic review also will not involve
      endangering participant rights. Ethical approval is not required. The results may
      be published in a peer-reviewed journal or disseminated in relevant
      conferences.Open Science Framework (OSF) registration number:
      https://osf.io/fa9dq.
FAU - Chen, Zhenfeng
AU  - Chen Z
AUID- ORCID: 0000-0002-4820-6089
AD  - Guangxi university of Traditional Chinese Medicine.
FAU - Xing, Shasha
AU  - Xing S
AD  - Ruikang Hospital affiliated to Guangxi University of Chinese Medicine, Nanning,
      Guangxi Province.
FAU - Huang, Yingzhuan
AU  - Huang Y
AD  - Guangxi university of Traditional Chinese Medicine.
FAU - Zeng, Qifeng
AU  - Zeng Q
AD  - Guangxi university of Traditional Chinese Medicine.
FAU - Xu, Donghan
AU  - Xu D
AD  - Macau University of Science and Technology, College of Traditional Chinese
      Medicine Macau.
FAU - He, Qiumei
AU  - He Q
AD  - Guangxi university of Traditional Chinese Medicine.
FAU - Qin, Huangguan
AU  - Qin H
AD  - Guangxi university of Traditional Chinese Medicine.
FAU - Luo, Xiaofan
AU  - Luo X
AD  - Guangxi university of Traditional Chinese Medicine.
FAU - Li, Renfeng
AU  - Li R
AUID- ORCID: 0000-0001-5893-1463
AD  - The first Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning,
      Guangxi Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Research Design
MH  - Rhinitis, Allergic/*therapy
MH  - *Systematic Reviews as Topic
PMC - PMC7572024
EDAT- 2020/10/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1097/MD.0000000000022737 [doi]
AID - 00005792-202010160-00066 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22737. doi:
      10.1097/MD.0000000000022737.


PMID- 33080731
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Compound Xuanju Capsule combined with western medicine for the treatment of male 
      oligoasthenotspermia: A protocol for systematic review and meta-analysis.
PG  - e22733
LID - 10.1097/MD.0000000000022733 [doi]
AB  - BACKGROUND: Oligoasthenotspermia is a condition in which the number and motility 
      of sperm in the semen of fertile men are lower than the normal level.
      Oligoasthenotspermia not only causes damage to the reproductive system, but also 
      causes infertility in severe cases. Compound Xuanju capsule is a kind of Chinese 
      patent medicine. Traditional medicine believes that compound Xuanju capsule can
      nourish kidney Yang, benefit kidney essence, improve semen quality, and treat
      infertility caused by oligoasthenotspermia. Clinical practice shows that compound
      Xuanju capsule combined with western medicine has a good therapeutic effect on
      male oligoasthenotspermia, but there is no evidence of evidence-based medicine.
      The purpose of this study is to systematically evaluate the efficacy and safety
      of compound Xuanju capsule combined with western medicine in the treatment of
      male oligoasthenotspermia, and to improve the evidence-based basis for the
      clinical application of compound Xuanju capsule in the treatment of male
      oligoasthenotspermia. METHODS: A systematic search was performed by retrieving on
      English database (PubMed, Embase, Web of Science, and The Cochrane Library) and
      Chinese database (CNKI, Wanfang, Weipu (VIP), CBM). Besides, manually search for 
      Google and Baidu academic of compound XuanJu capsule combined western medicine in
      the treatment of male oligoasthenotspermia in randomized controlled clinical
      research. The retrieval time limit was from the establishment of the database to 
      July 2020. Two researchers independently extracted and evaluated the quality of
      the data in the included study. A meta-analysis was performed using RevMan5.3
      software, no language restrictions. RESULTS: In this study, the efficacy and
      safety of compound Xuanju capsule combined with western medicine in the treatment
      of male oligoasthenotspermia were evaluated by the total effective rate, semen
      parameters and other indexes. CONCLUSIONS: This study will provide reliable
      evidence-based evidence for the clinical application of compound Xuanju capsule
      combined with western medicine in the treatment of male oligoasthenotspermia.
      ETHICS AND DISSEMINATION: Private information from individuals will not be
      published. This systematic review also does not involve endangering participant
      rights. Ethical approval was not required. The results may be published in a
      peer-reviewed journal or disseminated at relevant conferences.OSF Registration
      number: DOI 10.17605/OSF.IO/2PM8T.
FAU - Chen, Lili
AU  - Chen L
AUID- ORCID: 0000-0003-3456-734
AD  - Department of Reproductive Medicine, Yantai Yuhuangding Hospital, Affiliated
      Hospital of Qingdao University, Yantai, Shandong province.
FAU - Lan, Hongyi
AU  - Lan H
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Zhang, Yuyan
AU  - Zhang Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Zhang, Xiaoyan
AU  - Zhang X
AD  - Department of Reproductive Medicine, Yantai Yuhuangding Hospital, Affiliated
      Hospital of Qingdao University, Yantai, Shandong province.
FAU - Liu, Yu
AU  - Liu Y
AD  - Department of Reproductive Medicine, Yantai Yuhuangding Hospital, Affiliated
      Hospital of Qingdao University, Yantai, Shandong province.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Capsules)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Capsules
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Humans
MH  - Male
MH  - *Medicine, Chinese Traditional
MH  - Oligospermia/*drug therapy
MH  - Semen Analysis
PMC - PMC7572002
EDAT- 2020/10/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1097/MD.0000000000022733 [doi]
AID - 00005792-202010160-00064 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22733. doi:
      10.1097/MD.0000000000022733.


PMID- 33080720
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Chinese herbal compound prescription for Endometriosis: A protocol for systematic
      review and meta-analysis.
PG  - e22698
LID - 10.1097/MD.0000000000022698 [doi]
AB  - BACKGROUND: Endometriosis (EMT) is one of the common diseases of women of
      childbearing age. EMT destroys the anatomical structure of the pelvis, which
      leads to abnormal ovulation and endocrine abnormalities. It also affects embryo
      implantation and makes patients infertile. Recently, it is confirmed that Chinese
      medicine also have an excellent clinical efficacy on EMT. Compared with the
      conventional western medicine treatment, it effectively relieve pain and other
      concomitant symptoms. METHODS AND ANALYSIS: The following databases will be
      searched for relevant information before July 2020: PubMed, Embase, Cochrane
      Library, Web of Science, and CNKI. MAJOR RESULTS: the overall effective rate, VAS
      score. SECONDARY OUTCOMES: blood serum estradiol (E2), progesterone (P),
      Follicle-Stimulating Hormone (FSH), adverse events. Data will be collected
      independently by 2 researchers, and the risk of bias in meta-analysis will be
      evaluated according to "Cochrane Handbook for Systematic Reviews of
      Interventions". All data analysis will be conducted using Review Manager V.5.3.
      and Stata V.12.0. RESULTS: The curative effect and safety of Chinese herbal
      compound prescription treatment for EMT patients will be evaluated
      systematically. CONCLUSION: The systematic review of this study will summarize
      the currently published evidence of Chinese herbal compound prescription
      treatment for EMT to further guide its promotion and application. ETHICS AND
      DISSEMINATION: The private information from individuals will not be published.
      This systematic review also will not involve endangering participant rights.
      Ethical approval is not required. The results may be published in a peer-reviewed
      journal or disseminated in relevant conferences. OPEN SCIENCE FRAMEWORK (OSF)
      REGISTRATION NUMBER:: https://osf.io/p5nrk.
FAU - Tang, Xiusong
AU  - Tang X
AD  - Guangxi university of Traditional Chinese Medicine, Nanning, Guangxi Province,
      China.
FAU - Chen, Jing
AU  - Chen J
FAU - Ou, Peiqi
AU  - Ou P
FAU - Chen, Jingqin
AU  - Chen J
FAU - Lan, Shaohang
AU  - Lan S
FAU - Luo, Jiajing
AU  - Luo J
FAU - Luo, Yehao
AU  - Luo Y
FAU - Shang, Yuzhi
AU  - Shang Y
FAU - Fang, Gang
AU  - Fang G
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Databases, Factual
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Endometriosis/*drug therapy
MH  - Female
MH  - Humans
MH  - *Medicine, Chinese Traditional
PMC - PMC7571967
EDAT- 2020/10/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1097/MD.0000000000022698 [doi]
AID - 00005792-202010160-00053 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22698. doi:
      10.1097/MD.0000000000022698.


PMID- 33080719
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Risk factors and prevalence of diabetic retinopathy: A protocol for
      meta-analysis.
PG  - e22695
LID - 10.1097/MD.0000000000022695 [doi]
AB  - BACKGROUND: Diabetic retinopathy (DR) is one of the serious complications of
      diabetes mellitus. Without further treatment, it can evolve into the stage of
      proliferation, which will lead to the formation of new blood vessels, vitreous
      hemorrhage, or anterior retinal hemorrhage, which will lead to severe vision loss
      and increase the risk of blindness. METHODS: The research literature on the risk 
      factors of diabetic retinopathy published as of July 1, 2020 was searched through
      MEDLINE, Embase, ovid, Web of Science, Wanfang, CNKI, and other databases, The
      search strategy has been first developed in MEDLINE using MeSH subject headings
      combined with free-text terms and Stata12.0 software was used for meta-analysis. 
      RESULTS: This study is ongoing and the results will be submitted to a
      peer-reviewed journal for publication. ETHICS AND DISSEMINATION: Ethical approval
      is not applicable, since this is an overview based on published articles.
      PROTOCOL REGISTRATION NUMBER: The registration number is INPLASY202070107, the
      DOI number is 10.37766/inplasy2020.7.0107.
FAU - Hou, Yuying
AU  - Hou Y
AD  - The First Affiliated Hospital of Henan University of Science and Technology,
      Luoyang, Henan.
FAU - Cai, Yitong
AU  - Cai Y
AD  - The school of Nursing, Lanzhou University, Lanzhou, Gansu, China.
FAU - Jia, Zhumin
AU  - Jia Z
AD  - The First Affiliated Hospital of Henan University of Science and Technology,
      Luoyang, Henan.
FAU - Shi, Suling
AU  - Shi S
AD  - The First Affiliated Hospital of Henan University of Science and Technology,
      Luoyang, Henan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Diabetic Retinopathy/*epidemiology/etiology
MH  - Humans
MH  - Prevalence
MH  - Risk Factors
PMC - PMC7571993
EDAT- 2020/10/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1097/MD.0000000000022695 [doi]
AID - 00005792-202010160-00052 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22695. doi:
      10.1097/MD.0000000000022695.


PMID- 33080718
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Traditional Chinese medicine on treating premenstrual syndrome and premenstrual
      dysphoric disorder: A protocol for systematic review and meta-analysis.
PG  - e22694
LID - 10.1097/MD.0000000000022694 [doi]
AB  - BACKGROUND: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder
      (PMDD) are common disorders that manifest themselves in the late luteal phase,
      and significantly interfere with an individual's daily activities. Clinical
      evidence suggests that traditional Chinese medicine (TCM) may ease PMS/PMDD
      symptoms. Here, we review a protocol for exploring the effectiveness and safety
      of TCM in PMS/PMDD management. METHODS: We will conduct a literature search for
      randomized controlled trials (RCT) for TCM use in PMS/PMDD on PubMed, web of
      science, EMBASE, the Cochrane central register of controlled trials (Cochrane
      Library), Chinese national knowledge infrastructure, Chinese VIP Information,
      Wanfang, as well as Chinese biomedical literature database. The search included
      all relevant reports for up to June 1, 2020. The search results were
      independently analyzed by 2 reviewers who extracted the data. RCT quality will be
      assessed using the risk-of-bias tool. The evidence will be inspected using the
      grading of recommendations assessment development and evaluation (GRADE). We will
      utilize Stata and Revman for systematic review and meta-analysis and analysis of 
      direct and indirect evidence. RESULTS: Based on current evidence, this study will
      elucidate the rationale for the utilization of TCM in PMS/PMDD treatment.
      CONCLUSION: Conclusions from this study will inform about the effectiveness and
      safety of TCM in PMS/PMDD management. TRIAL REGISTRATION NUMBER: CRD42020192822. 
      ETHICS AND DISSEMINATION: Since all data utilized in this systematic review and
      meta-analysis are published, ethical approval is not needed. Additionally, in the
      trial of the review process, all data will be evaluated anonymously.
FAU - Gao, Mingzhou
AU  - Gao M
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine, Jinan, Shandong Province.
AD  - Research and Innovation team of Emotional Diseases and Syndromes in Shandong
      University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
FAU - Sun, Hui
AU  - Sun H
AD  - School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, Hubei
      Province.
FAU - Sun, Wenjun
AU  - Sun W
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine, Jinan, Shandong Province.
AD  - Research and Innovation team of Emotional Diseases and Syndromes in Shandong
      University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
FAU - Gao, Dongmei
AU  - Gao D
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine, Jinan, Shandong Province.
AD  - Research and Innovation team of Emotional Diseases and Syndromes in Shandong
      University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
FAU - Qiao, Mingqi
AU  - Qiao M
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine, Jinan, Shandong Province.
AD  - Research and Innovation team of Emotional Diseases and Syndromes in Shandong
      University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Databases, Factual
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Premenstrual Dysphoric Disorder/*drug therapy
MH  - Premenstrual Syndrome/*drug therapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7571909
EDAT- 2020/10/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1097/MD.0000000000022694 [doi]
AID - 00005792-202010160-00051 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22694. doi:
      10.1097/MD.0000000000022694.


PMID- 33080674
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Erchen decoction for hyperlipemia: Protocol for a systematic review and
      meta-analysis.
PG  - e22374
LID - 10.1097/MD.0000000000022374 [doi]
AB  - BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated
      levels of blood lipids and lipoproteins and a major pathogenic factor of
      atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat
      hyperlipidemia. However, there is no systematic review found. In order to
      evaluate the efficacy and safety of ECD in the treatment of hyperlipidemia, we
      need to conduct a meta-analysis and systematic evaluation. METHODS: We will
      enroll the randomized controlled trials (RCTs) evaluating the effectiveness and
      safety of ECD in the treatment of hyperlipidemia. Data come mainly from 4 Chinese
      databases (China national knowledge infrastructure, Wanfang, Chinese biomedical
      literature database, and VIP Database) and 4 English databases (Pubmed, Embase
      excerpt medica database, Cochrane Library, and Web of science). The enrollment of
      RCTs is from the starting date of database establishment till September 30, 2020.
      Low density lipoprotein cholesterol is considered as the main indicator of the
      dyslipidemia, while the serum concentrations of total cholesterol, triglyceride, 
      high density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B are 
      regarded as the secondary indicators. There are Safety indicators including liver
      enzyme, kidney function and fasting blood glucose. The work such as selection of 
      literature, data collection, quality evaluation of included literature, and
      assessment of publication bias will be conducted by 2 independent researchers.
      Meta-analysis will be performed by RevMan 5.0 software. RESULTS: This study will 
      provide high-quality evidence for the effectiveness and safety of ECD in the
      treatment of hyperlipidemia. CONCLUSION: The results of the study will help us
      determine whether ECD can effectively treat hyperlipidemia. ETHICS AND
      DISSEMINATION: This study does not require ethical approval. We will disseminate 
      our findings by publishing results in a peer-reviewed journal. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/GZ69F.
FAU - Luo, Huan
AU  - Luo H
AUID- ORCID: 0000-0003-4765-1487
AD  - College of basic medicine, Chengdu university of Traditional Chinese Medicine,
      Chengdu, Sichuan 611137, China.
FAU - Xiong, Min
AU  - Xiong M
FAU - Zhu, Wenyu
AU  - Zhu W
FAU - Shen, Tao
AU  - Shen T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Hyperlipidemias/*drug therapy
MH  - Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7572033
EDAT- 2020/10/22 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.1097/MD.0000000000022374 [doi]
AID - 00005792-202010160-00007 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22374. doi:
      10.1097/MD.0000000000022374.


PMID- 33080670
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - Banxia Xiexin Decoction in the treatment of chronic atrophic gastritis: A
      protocol for systematic review and meta-analysis.
PG  - e22110
LID - 10.1097/MD.0000000000022110 [doi]
AB  - BACKGROUND: Chronic atrophic gastritis (CAG) is a common digestive disease.
      Without active treatment, it may induce gastric cancer. Western medicine has a
      certain effect on chronic atrophic gastritis, but there are many adverse
      reactions after long-term medication, and the disease is prone to relapse after
      treatment, which will affect the health and life of patients. Traditional Chinese
      medicine has obvious advantages in the treatment of chronic stomach diseases with
      reliable effect. A number of clinical data have also confirmed that Banxia Xiexin
      decoction has significant effect in the treatment of chronic atrophic gastritis, 
      but there is no evidence of evidence-based medicine. Therefore, this study aims
      to explore the clinical efficacy and safety of Banxia Xiexin decoction in the
      treatment of chronic atrophic gastritis by means of systematic evaluation.
      METHOD: Databases including PubMed, The Cochrance Library, Embase, Web of
      Science, CNKI, VIP, and Wanfang were searched by computer. Besides, Baidu Scholar
      and Google Scholar were manually searched, and all randomized controlled trials
      of Banxia xiexin decoction for the treatment of chronic atrophic gastritis were
      collected. The retrieval time was from the establishment of the database to July 
      31, 2020. After 2 reviewers independently screened the literature, extracted the 
      data and evaluated the bias risk of the included study, RevMan5.3 software
      (developed by the UK's International Cochrane Collaboration) was used to analyze 
      the data. RESULTS: In this study, the effectiveness and safety of Banxia Xiexin
      decoction for the treatment of chronic atrophic gastritis were evaluated by the
      clinical efficiency, traditional Chinese medicine syndrome score (traditional
      Chinese medicine syndrome score), quality of life score, gastrin level, epidermal
      growth factor, eradication rate of helicobacter pylori and incidence of adverse
      reactions. CONCLUSION: This study will provide reliable evidence for the clinical
      application of Banxia Xiexin decoction in the treatment of chronic atrophic
      gastritis. ETHICS AND DISSEMINATION: The private information from individuals
      will not be published. This systematic review also will not involve endangering
      participant rights. Ethical approval is not required. The results may be
      published in a peer-reviewed journal or disseminated in relevant conferences. OSF
      REGISTRATION NUMBER: DOI 10.17605/OSF.IO/7K6QW.
FAU - Ji, Qing
AU  - Ji Q
AD  - College of Nursing, School of Medicine and Health of Anyang Vocational and
      Technical college, Anyang.
FAU - Yang, Ying
AU  - Yang Y
AD  - Department of Rehabilitation Medicine, the People's Hospital of SND, Suzhou.
FAU - Song, Xiaolei
AU  - Song X
AD  - Department of Orthopedics, Angang Staff General Hospital, Anyang.
FAU - Han, Xu
AU  - Han X
AD  - Department of TCM, National Medical Hall of Nanjing University of Traditional
      Chinese Medicine.
FAU - Wang, Wenlin
AU  - Wang W
AD  - Department of TCM, Nanjing University of Science and Technology Hospital,
      Nanjing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (banxia xiexin decoction)
SB  - IM
MH  - Chronic Disease
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Gastritis, Atrophic/*drug therapy
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7572018
EDAT- 2020/10/22 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.1097/MD.0000000000022110 [doi]
AID - 00005792-202010160-00003 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22110. doi:
      10.1097/MD.0000000000022110.


PMID- 33080390
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1873-488X (Electronic)
IS  - 1056-8719 (Linking)
VI  - 106
DP  - 2020 Nov - Dec
TI  - Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4
      activity sheep hepatic microsomes.
PG  - 106934
LID - S1056-8719(20)30265-3 [pii]
LID - 10.1016/j.vascn.2020.106934 [doi]
AB  - INTRODUCTION: Ex vivo studies of human fetal hepatic drug metabolism are uncommon
      as it requires access to functional liver tissue and therefore raises practical
      and ethical concerns. Large animal models provide an alternative opportunity to
      study changes in cytochrome P450 (CYP) activity in the mother and fetus during
      pregnancy. We aimed to develop methods to determine the activity of CYP1A2,
      CYP2C9, CYP2D6 and CYP3A4 in sheep hepatic microsomes. METHODS: We identified
      optimal conditions to determine the activity of CYP1A2 (using the probe drug
      phenacetin), CYP2C9 (diclofenac), CYP2D6 (dextromethorphan) and CYP3A4
      (midazolam) by varying techniques for microsome extraction, probe drug
      concentration, incubation time and microsome concentration. The specificity of
      each probe drug was assessed by determining the rate of metabolism when specific 
      CYP enzyme inhibitors were included in the reaction. RESULTS: The optimum
      incubation time and probe drug concentration was six hours with 5 muM phenacetin 
      (CYP1A2), four hours with 10 muM diclofenac (CYP2C9), 30 min with 1 muM of
      midazolam (CYP3A4) and 10 min with 1 muM dextromethorphan (CYP2D6). For both
      CYP2D6 and CYP3A4 reactions required 20 mug of microsomal protein, whereas for
      CYP1A2 and CYP2C9, reactions required 40 mug of microsomal protein. Metabolism of
      phenacetin, dextromethorphan and midazolam was reduced by specific enzyme
      inhibitors, but the specific CYP2C9 inhibitor sulfaphenazole did not
      substantially inhibit diclofenac metabolism. DISCUSSION: This study identifies
      the optimal conditions for determining CYP activity in maternal sheep hepatic
      microsomes. In doing so, we have developed a standardised protocol for assessment
      of microsomal activity of CYP3A4, CYP1A2 and CYP2D6, but we were unable to
      optimise conditions for assessment of CYP2C9. This approach can be applied to
      investigate the impact of pregnancy complications on maternal and fetal hepatic
      drug metabolism.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - McBride, Grace M
AU  - McBride GM
AD  - Early Origins of Adult Health Research Group, Australia; UniSA: Clinical and
      Health Sciences, University of South Australia, Adelaide 5000, Australia.
FAU - Soo, Jia Yin
AU  - Soo JY
AD  - Early Origins of Adult Health Research Group, Australia; UniSA: Clinical and
      Health Sciences, University of South Australia, Adelaide 5000, Australia.
FAU - Varcoe, Tamara
AU  - Varcoe T
AD  - Early Origins of Adult Health Research Group, Australia; UniSA: Clinical and
      Health Sciences, University of South Australia, Adelaide 5000, Australia.
FAU - Morrison, Janna L
AU  - Morrison JL
AD  - Early Origins of Adult Health Research Group, Australia; UniSA: Clinical and
      Health Sciences, University of South Australia, Adelaide 5000, Australia.
FAU - Wiese, Michael D
AU  - Wiese MD
AD  - UniSA: Clinical and Health Sciences, University of South Australia, Adelaide
      5000, Australia. Electronic address: Michael.Wiese@unisa.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20201018
PL  - United States
TA  - J Pharmacol Toxicol Methods
JT  - Journal of pharmacological and toxicological methods
JID - 9206091
RN  - 0 (Cytochrome P-450 Enzyme Inhibitors)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 7355X3ROTS (Dextromethorphan)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - ER0CTH01H9 (Phenacetin)
RN  - R60L0SM5BC (Midazolam)
SB  - IM
MH  - Animals
MH  - Cell Fractionation/methods
MH  - Cytochrome P-450 Enzyme Inhibitors/*pharmacology
MH  - Cytochrome P-450 Enzyme System/analysis/*metabolism
MH  - Dextromethorphan/pharmacokinetics
MH  - Diclofenac/pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Assays/*methods
MH  - Feasibility Studies
MH  - Female
MH  - Maternal-Fetal Exchange
MH  - Microsomes, Liver/drug effects/*enzymology
MH  - Midazolam/pharmacokinetics
MH  - Phenacetin/pharmacokinetics
MH  - Pregnancy
MH  - Pregnancy Complications/drug therapy/*metabolism
MH  - Sheep
OTO - NOTNLM
OT  - CYP1A2
OT  - CYP2C9
OT  - CYP2D6
OT  - CYP3A4
OT  - Cytochrome P450
OT  - Drug metabolism
OT  - Fetal
OT  - Microsomes
OT  - Sheep
EDAT- 2020/10/21 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/10/20 20:08
PHST- 2020/04/29 00:00 [received]
PHST- 2020/09/03 00:00 [revised]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/10/20 20:08 [entrez]
AID - S1056-8719(20)30265-3 [pii]
AID - 10.1016/j.vascn.2020.106934 [doi]
PST - ppublish
SO  - J Pharmacol Toxicol Methods. 2020 Nov - Dec;106:106934. doi:
      10.1016/j.vascn.2020.106934. Epub 2020 Oct 18.


PMID- 33079799
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1550-5073 (Electronic)
IS  - 0893-2190 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Oct/Dec
TI  - Screening for the Social Determinants of Health: An Ethical Imperative.
PG  - 289-291
LID - 10.1097/JPN.0000000000000518 [doi]
FAU - Johnson, Darci
AU  - Johnson D
AD  - Brown University School of Public Health Providence, Rhode Island.
FAU - Howard, Elisabeth D
AU  - Howard ED
AD  - Director of Midwifery Women and Infants Hospital Associate Professor Obstetrics
      and Gynecology (Clinical) Alpert Medical School of Brown University Providence,
      Rhode Island.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Perinat Neonatal Nurs
JT  - The Journal of perinatal & neonatal nursing
JID - 8801387
MH  - *Health Status Disparities
MH  - *Healthcare Disparities/ethics/ethnology
MH  - Humans
MH  - *Mass Screening/ethics/methods
MH  - *Maternal-Child Health Services/ethics/organization & administration
MH  - Maternal-Child Nursing/ethics/methods
MH  - Patient Outcome Assessment
MH  - *Patient-Centered Care/methods/standards
MH  - *Social Determinants of Health/ethics/ethnology
MH  - United States/epidemiology
EDAT- 2020/10/21 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/10/20 17:09
PHST- 2020/10/20 17:09 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
AID - 10.1097/JPN.0000000000000518 [doi]
AID - 00005237-202010000-00003 [pii]
PST - ppublish
SO  - J Perinat Neonatal Nurs. 2020 Oct/Dec;34(4):289-291. doi:
      10.1097/JPN.0000000000000518.


PMID- 33079793
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1538-9804 (Electronic)
IS  - 0162-220X (Linking)
VI  - 43
IP  - 6
DP  - 2020 Nov/Dec
TI  - How the COVID-19 Pandemic Could Reshape Palliative Care Into High-Tech and
      High-Touch Care: An Ethics of Care Perspective.
PG  - 429-430
LID - 10.1097/NCC.0000000000000883 [doi]
FAU - Ho, Calvin Wai-Loon
AU  - Ho CW
AD  - Department of Law and Centre for Medical Ethics and Law The University of Hong
      Kong, Hong Kong Editorial Board Member, CANCER NURSING School of Nursing, Li Ka
      Shing Faculty of Medicine The University of Hong Kong, Hong Kong.
FAU - Lin, Chia-Chin
AU  - Lin CC
LA  - eng
PT  - Editorial
PL  - United States
TA  - Cancer Nurs
JT  - Cancer nursing
JID - 7805358
SB  - IM
EDAT- 2020/10/21 06:00
MHDA- 2020/10/21 06:01
CRDT- 2020/10/20 17:09
PHST- 2020/10/20 17:09 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/10/21 06:01 [medline]
AID - 10.1097/NCC.0000000000000883 [doi]
AID - 00002820-202011000-00001 [pii]
PST - ppublish
SO  - Cancer Nurs. 2020 Nov/Dec;43(6):429-430. doi: 10.1097/NCC.0000000000000883.


PMID- 33079768
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1550-512X (Electronic)
IS  - 1525-5794 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Oct/Dec
TI  - Building an Ethical Organizational Culture.
PG  - 168-174
LID - 10.1097/HCM.0000000000000304 [doi]
AB  - The success of a health care institution-as defined by delivering high-quality,
      high-value care, positive patient outcomes, and financial solvency-is
      inextricably tied to the culture within that organization. The ability to achieve
      and sustain alignment between its mission, values, and everyday practices defines
      a positive organizational culture. An institution that has a diminished
      organizational culture, reflected in the failure to consistently align management
      and clinical decisions and practices with its mission and values, will struggle. 
      The presence of misalignment or of ethics gaps affects the quality of care being 
      delivered, the morale of the staff, and the organization's image in the
      community. Transforming an organizational culture will provide a foundation for
      success and a framework for daily ethics-grounded operations in any organization.
      However, building an ethics-grounded organization is a challenging process
      requiring strong organization leadership and planning. Using a case study, the
      authors provide a multiyear, continuous step-by-step strategy consisting of
      identifying ethics culture gaps, establishing an ethics taskforce, clarifying and
      prioritizing the problems, developing strategy for change, implementing the
      strategy, and evaluating outcomes. This process will assist organizations in
      aligning its actions with its mission and values, to find success on all fronts.
FAU - Nelson, William A
AU  - Nelson WA
AD  - Reprinted from Nelson WA, Taylor E, Walsh T. Building an ethical organizational
      culture. Health Care Manag. 2014;33(2):158-164. doi:10.1097/HCM.0000000000000008.
      Author Affiliations: Dartmouth Institute for Health Policy and Clinical Practice 
      (Drs Nelson, Taylor, and Walsh), Dartmouth Center for Health Care Delivery
      Science (Drs Nelson and Walsh), Community and Family Medicine (Dr Nelson), and
      Master of Health Care Delivery Science Program (Dr Walsh), Geisel School of
      Medicine at Dartmouth, Hanover, New Hampshire.
FAU - Taylor, Emily
AU  - Taylor E
FAU - Walsh, Thom
AU  - Walsh T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Health Care Manag (Frederick)
JT  - The health care manager
JID - 100896672
MH  - Delivery of Health Care
MH  - *Ethics, Institutional
MH  - Humans
MH  - *Leadership
MH  - Organizational Case Studies
MH  - *Organizational Culture
MH  - *Organizational Objectives
EDAT- 2020/10/21 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/20 17:09
PHST- 2020/10/20 17:09 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1097/HCM.0000000000000304 [doi]
AID - 00126450-202010000-00005 [pii]
PST - ppublish
SO  - Health Care Manag (Frederick). 2020 Oct/Dec;39(4):168-174. doi:
      10.1097/HCM.0000000000000304.


PMID- 33079766
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1550-512X (Electronic)
IS  - 1525-5794 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Oct/Dec
TI  - Ethical Issues and the Electronic Health Record.
PG  - 150-161
LID - 10.1097/HCM.0000000000000302 [doi]
AB  - Ethical issues related to electronic health records (EHRs) confront health
      personnel. Electronic health records create conflict among several ethical
      principals. Electronic health records may represent beneficence because they are 
      alleged to increase access to health care, improve the quality of care and
      health, and decrease costs. Research, however, has not consistently demonstrated 
      access for disadvantaged persons, the accuracy of EHRs, their positive effects on
      productivity, nor decreased costs. Should beneficence be universally
      acknowledged, conflicts exist with other ethical principles. Autonomy is
      jeopardized when patients' health data are shared or linked without the patients'
      knowledge. Fidelity is breached by the exposure of thousands of patients' health 
      data through mistakes or theft. Lack of confidence in the security of health data
      may induce patients to conceal sensitive information. As a consequence, their
      treatment may be compromised. Justice is breached when persons, because of their 
      socioeconomic class or age, do not have equal access to health information
      resources and public health services. Health personnel, leaders, and policy
      makers should discuss the ethical implications of EHRs before the occurrence of
      conflicts among the ethical principles. Recommendations to guide health
      personnel, leaders, and policy makers are provided.
FAU - Layman, Elizabeth J
AU  - Layman EJ
AD  - Reprinted from Layman EJ. Ethical issues and the electronic health record. Health
      Care Manag. 2008;27(2):165-176. doi:10.1097/01.HCM.0000285044.19666.a8. Author
      Affiliations: Department of Health Services and Information Management, College
      of Allied Health Sciences, East Carolina University, Greenville, New North
      Carolina.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Health Care Manag (Frederick)
JT  - The health care manager
JID - 100896672
MH  - *Computer Security
MH  - Data Mining/standards
MH  - *Delivery of Health Care
MH  - Electronic Health Records/*ethics
MH  - Health Personnel/*ethics
MH  - Health Services Accessibility
MH  - Humans
MH  - *Medical Informatics
EDAT- 2020/10/21 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/20 17:09
PHST- 2020/10/20 17:09 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1097/HCM.0000000000000302 [doi]
AID - 00126450-202010000-00003 [pii]
PST - ppublish
SO  - Health Care Manag (Frederick). 2020 Oct/Dec;39(4):150-161. doi:
      10.1097/HCM.0000000000000302.


PMID- 33079472
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 18
IP  - 10
DP  - 2020 Oct
TI  - Clinical management, ethics and informed consent related to multi-gene
      panel-based high throughput sequencing testing for platelet disorders:
      Communication from the SSC of the ISTH.
PG  - 2751-2758
LID - 10.1111/jth.14993 [doi]
AB  - Molecular diagnostics of inherited platelet disorders (IPD) has been
      revolutionized by the implementation of high-throughput sequencing (HTS)
      approaches. A conclusive diagnosis using HTS tests can be obtained quickly and
      cost-effectively in many, but not all patients. The expanding use of HTS tests
      has raised concerns regarding complex variant interpretation and the ethical
      implications of detecting unsolicited findings such as variants in IPD genes
      RUNX1, ETV6, and ANKRD26, which are associated with increased leukemic risk. This
      guidance document has been developed and written by a multidisciplinary team of
      researchers and clinicians, with expertise in hematology, clinical and molecular 
      genetics, and bioethics, alongside a RUNX1 patient advocacy representative. We
      recommend that for clinical diagnostics, HTS for IPD should use a multigene panel
      of curated diagnostic-grade genes. Critically, we advise that an HTS test for
      clinical diagnostics should only be ordered by a clinical expert that is: (a)
      fully aware of the complexity of genotype-phenotype correlations for IPD; (b)
      able to discuss these complexities with a patient and family members before the
      test is initiated; and (c) able to interpret and appropriately communicate the
      results of a HTS diagnostic report, including the implication of variants of
      uncertain clinical significance. Each patient should know what an HTS test could 
      mean for his or her clinical management before initiating a test. We hereby
      propose an exemplified informed consent document that includes information on
      these ethical concerns and can be used by the community for implementation of HTS
      of IPD in a clinical diagnostic setting. This paper does not include
      recommendations for HTS of IPD in a research setting.
CI  - (c) 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley
      Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
FAU - Downes, Kate
AU  - Downes K
AD  - East Genomic Laboratory Hub, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge, UK.
AD  - Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, 
      Cambridge, UK.
FAU - Borry, Pascal
AU  - Borry P
AD  - Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
FAU - Ericson, Katrin
AU  - Ericson K
AD  - The RUNX1 Research Program, Santa Barbara, CA, USA.
FAU - Gomez, Keith
AU  - Gomez K
AUID- ORCID: 0000-0002-8934-0700
AD  - Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust,
      London, UK.
FAU - Greinacher, Andreas
AU  - Greinacher A
AUID- ORCID: 0000-0001-8343-7336
AD  - Institut fur Immunologie und Transfusionsmedizin, Universitatsmedizin Greifswald,
      Greifswald, Germany.
FAU - Lambert, Michele
AU  - Lambert M
AD  - Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia,
      PA, USA.
AD  - Department of Pediatrics, Perelman School of Medicine at the University of
      Pennsylvania, Philadelphia, PA, USA.
FAU - Leinoe, Eva
AU  - Leinoe E
AD  - Department of Haematology, Rigshospitalet, National University Hospital,
      Copenhagen, Denmark.
FAU - Noris, Patrizia
AU  - Noris P
AD  - IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
FAU - Van Geet, Chris
AU  - Van Geet C
AD  - Department of Cardiovascular Sciences, Center or Molecular and Vascular Biology, 
      KU Leuven, Leuven, Belgium.
FAU - Freson, Kathleen
AU  - Freson K
AUID- ORCID: 0000-0002-4381-2442
AD  - Department of Cardiovascular Sciences, Center or Molecular and Vascular Biology, 
      KU Leuven, Leuven, Belgium.
CN  - Subcommittee on Genomics in Thrombosis, Hemostasis
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
SB  - IM
MH  - *Blood Platelet Disorders/diagnosis/genetics
MH  - Communication
MH  - Female
MH  - Genetic Association Studies
MH  - *High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Informed Consent
PMC - PMC7589386
OTO - NOTNLM
OT  - *blood platelet disorders
OT  - *consent forms
OT  - *ethics
OT  - *high-throughput nucleotide sequencing
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 12:15
PHST- 2020/04/21 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/10/20 12:15 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1111/jth.14993 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2020 Oct;18(10):2751-2758. doi: 10.1111/jth.14993.


PMID- 33079342
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Ethical Issues with Simulating the Bridge Problem in VR.
PG  - 3313-3331
LID - 10.1007/s11948-020-00267-5 [doi]
AB  - We aim to generate a dilemma for virtual reality-based research that we motivate 
      through an extended case study of Thomson's (Yale Law J 94(6):1395-1415, 1985)
      Bridge variant of the trolley problem. Though the problem we generate applies
      more broadly than the Bridge problem, we believe it makes a good exemplar of the 
      kind of case we believe is problematic. First, we argue that simulations of these
      thought experiments run into a practicality horn that makes it practically
      impossible to produce them. These problems revolve around concepts that we call
      "perspectival fidelity" and "context realism." Moral dilemmas that include
      features present in the Bridge variant will, as a result, be practically
      impossible to simulate. We also argue that, should we be wrong about the
      practical impossibility of creating a VR simulation of Bridge, such a simulation 
      must face an ethical horn which renders these simulations ethically impermissible
      to develop or use. For these reasons, we argue that it is virtually impossible to
      simulate the bridge problem (and other thought experiments with similar features)
      both practically and ethically in VR.
FAU - Ramirez, Erick Jose
AU  - Ramirez EJ
AUID- ORCID: http://orcid.org/0000-0001-9042-6942
AD  - Philosophy Department, Santa Clara University, Santa Clara, USA.
      ejramirez@scu.edu.
FAU - LaBarge, Scott
AU  - LaBarge S
AD  - Philosophy Department, Santa Clara University, Santa Clara, USA.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Computer Simulation
MH  - Morals
MH  - *Virtual Reality
OTO - NOTNLM
OT  - Applied ethics
OT  - Moral psychology
OT  - Philosophy of technology
OT  - Simulation ethics
OT  - Virtual reality
EDAT- 2020/10/21 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/20 12:14
PHST- 2020/01/29 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/10/20 12:14 [entrez]
AID - 10.1007/s11948-020-00267-5 [doi]
AID - 10.1007/s11948-020-00267-5 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3313-3331. doi: 10.1007/s11948-020-00267-5. Epub
      2020 Oct 20.


PMID- 33079219
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20220218
IS  - 1433-044X (Electronic)
IS  - 0177-5537 (Linking)
VI  - 123
IP  - 11
DP  - 2020 Nov
TI  - [Economic aspects of digitalization in orthopedics and trauma surgery].
PG  - 856-861
LID - 10.1007/s00113-020-00891-7 [doi]
AB  - INTRODUCTION: In addition to the advantages for patients and physicians, the
      progression of digitalization will also have economic implications for healthcare
      systems in toto worldwide. The integration of digital innovations enables
      healthcare institutions to transform their current activities and processes and
      to create a new form of patient care. IMPORTANT ECONOMIC TOPICS OF
      DIGITALIZATION: Using digital applications process optimization can be achieved
      by increased efficiency and therefore a reduction in costs in the healthcare
      system. Improved processes can in turn achieve an increase in quality in the
      treatment of patients. Simultaneously, a duplication of investigations can be
      avoided through digital interfaces and the communication among the healthcare
      professions involved can be improved, which would result in a conservation of
      resources. Finally, these influences can lead to more precision in medicine,
      acceleration of healing processes and represent an advantage for all parties
      involved. PERSPECTIVES: Economic redistribution due to digitalization of medicine
      will become increasingly apparent in the future. Ethical considerations as well
      as data protection will be important topics. At the same time investments and
      digital innovations must be sponsored by the government and industry. Scientific 
      studies are necessary to secure the evidence of new methods for practice in
      orthopedics and trauma surgery.
FAU - Pforringer, Dominik
AU  - Pforringer D
AD  - Klinik und Poliklinik fur Unfallchirurgie, Klinikum rechts der Isar, Technische
      Universitat Munchen, Ismaninger Str. 22, 81675, Munchen, Deutschland.
      dominik.pfoerringer@mri.tum.de.
FAU - Matusiewicz, David
AU  - Matusiewicz D
AD  - Institut fur Gesundheit und Soziales (ifgs), FOM Hochschule fur Oekonomie und
      Management, Essen, Deutschland.
FAU - Tsitsilonis, Serafeim
AU  - Tsitsilonis S
AD  - Centrum fur Muskuloskeletale Chirurgie, Charite - Universitatsmedizin Berlin,
      Berlin, Deutschland.
FAU - Gehlen, Tobias
AU  - Gehlen T
AD  - Centrum fur Muskuloskeletale Chirurgie, Charite - Universitatsmedizin Berlin,
      Berlin, Deutschland.
FAU - Back, David A
AU  - Back DA
AD  - Klinik fur Unfallchirurgie und Orthopadie, Bundeswehrkrankenhaus Berlin, Berlin, 
      Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Okonomische Aspekte der Digitalisierung in Orthopadie und Unfallchirurgie.
PL  - Germany
TA  - Unfallchirurg
JT  - Der Unfallchirurg
JID - 8502736
SB  - IM
MH  - Delivery of Health Care
MH  - Health Resources
MH  - Humans
MH  - *Orthopedic Procedures
MH  - *Orthopedics/economics
MH  - Patient Care
PMC - PMC7574668
OTO - NOTNLM
OT  - Economic development
OT  - Health resources
OT  - Precision medicine
OT  - Process optimization
OT  - Quality of health care
EDAT- 2020/10/21 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/20 12:12
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/10/20 12:12 [entrez]
AID - 10.1007/s00113-020-00891-7 [doi]
AID - 10.1007/s00113-020-00891-7 [pii]
PST - ppublish
SO  - Unfallchirurg. 2020 Nov;123(11):856-861. doi: 10.1007/s00113-020-00891-7.


PMID- 33079069
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 20
TI  - Determinants of Medical Practice Variation Among Primary Care Physicians:
      Protocol for a Three Phase Study.
PG  - e18673
LID - 10.2196/18673 [doi]
AB  - BACKGROUND: One of the greatest challenges of modern health systems is the choice
      and use of resources needed to diagnose and treat patients. Medical practice
      variation (MPV) is a broad term which entails the differences between health care
      providers inclusive of both the overuse and underuse. In this paper, we describe 
      a 3-phase research protocol examining MPV in primary care. OBJECTIVE: We aim to
      identify the potential targets for behavioral modification interventions to
      reduce the variation in practice patterns and thus improve health care, decrease 
      costs, and prevent disparities in care. METHODS: The first phase will delineate
      the variation in primary care practice over a wide range of services and long
      follow-up period (2003-2017), the second will examine the 3 determinants of
      variation (ie, patient, physician, and clinic characteristics), and attempt to
      derive the unexplained variance. In the third phase, we will assess a novel
      component that might contribute to the previously unexplained variance - the
      physicians' personal behavioral characteristics (such as risk aversion, fear of
      malpractice, stress from uncertainty, empathy, and burnout). RESULTS: This work
      was supported by the research grant from Israel National Institute for Health
      Policy Research (Grant No. 2014/134). Soroka University Medical Center
      Institutional Ethics Committee has approved the updated version of the study
      protocol (SOR-14-0063) in February 2019. All relevant data for phases 1 and 2,
      including patient, physician, and clinic, were collected from the Clalit Health
      Services data set in 2019 and are currently being analyzed. The evaluation of the
      individual physician characteristics (eg, risk aversion) by the face-to-face
      questionnaires was started on 2018 and remains in progress. We intend to publish 
      the results during 2020-2021. CONCLUSIONS: Based on the results of our study, we 
      aim to propose a list of potential targets for focused behavioral intervention.
      Identifying new targets for such an intervention can potentially lead to a
      decrease in the unwarranted variation in the medical practice. We suggest that
      such an intervention will result in optimization of the health system,
      improvement of health outcomes, reduction of disparities in care and savings in
      cost. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18673.
CI  - (c)Sagi Shashar, Shlomi Codish, Moriah Ellen, Ehud Davidson, Victor Novack.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 20.10.2020.
FAU - Shashar, Sagi
AU  - Shashar S
AUID- ORCID: https://orcid.org/0000-0002-2386-8027
AD  - Clinical Research Center, Soroka University Medical Center and Faculty of Health 
      Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
FAU - Codish, Shlomi
AU  - Codish S
AUID- ORCID: https://orcid.org/0000-0002-1980-0441
AD  - Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion
      University of the Negev, Beer-Sheva, Israel.
FAU - Ellen, Moriah
AU  - Ellen M
AUID- ORCID: https://orcid.org/0000-0001-7127-7283
AD  - Department of Health Services Management, Guilford Glazer Faculty of Business and
      Management, Ben Gurion University, Beer-Sheva, Israel.
AD  - Institute of Health Policy Management and Evaluation, Dalla Lana School of Public
      Health, University of Toronto, Toronto, ON, Canada.
AD  - McMaster Health Forum, McMaster University, Hamilton, ON, Canada.
FAU - Davidson, Ehud
AU  - Davidson E
AUID- ORCID: https://orcid.org/0000-0002-3087-0408
AD  - General Management, Clalit Health Services, Tel Aviv, Israel.
FAU - Novack, Victor
AU  - Novack V
AUID- ORCID: https://orcid.org/0000-0001-8706-9622
AD  - Clinical Research Center, Soroka University Medical Center and Faculty of Health 
      Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7609196
OTO - NOTNLM
OT  - medical practice variation
OT  - personal behavioral characteristics
OT  - primary care physicians
OT  - variation determinants
EDAT- 2020/10/21 06:00
MHDA- 2020/10/21 06:01
CRDT- 2020/10/20 12:11
PHST- 2020/03/16 00:00 [received]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/10/20 12:11 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/10/21 06:01 [medline]
AID - v9i10e18673 [pii]
AID - 10.2196/18673 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 20;9(10):e18673. doi: 10.2196/18673.


PMID- 33078879
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20211203
IS  - 1468-0009 (Electronic)
IS  - 0887-378X (Linking)
VI  - 98
IP  - 4
DP  - 2020 Dec
TI  - Ethical and Legal Implications of Remote Monitoring of Medical Devices.
PG  - 1257-1289
LID - 10.1111/1468-0009.12481 [doi]
AB  - Policy Points Millions of life-sustaining implantable devices collect and relay
      massive amounts of digital health data, increasingly by using user-downloaded
      smartphone applications to facilitate data relay to clinicians via manufacturer
      servers. Our analysis of health privacy laws indicates that most US patients may 
      have little access to their own digital health data in the United States under
      the Health Insurance Portability and Accountability Act Privacy Rule, whereas the
      EU General Data Protection Regulation and the California Consumer Privacy Act
      grant greater access to device-collected data. Our normative analysis argues for 
      consistently granting patients access to the raw data collected by their
      implantable devices. CONTEXT: Millions of life-sustaining implantable devices
      collect and relay massive amounts of digital health data, increasingly by using
      user-downloaded smartphone applications to facilitate data relay to clinicians
      via manufacturer servers. Whether patients have either legal or normative claims 
      to data collected by these devices, particularly in the raw, granular format
      beyond that summarized in their medical records, remains incompletely explored.
      METHODS: Using pacemakers and implantable cardioverter-defibrillators (ICDs) as a
      clinical model, we outline the clinical ecosystem of data collection, relay,
      retrieval, and documentation. We consider the legal implications of US and
      European privacy regulations for patient access to either summary or raw device
      data. Lastly, we evaluate ethical arguments for or against providing patients
      access to data beyond the summaries presented in medical records. FINDINGS: Our
      analysis of applicable health privacy laws indicates that US patients may have
      little access to their raw data collected and held by device manufacturers in the
      United States under the Health Insurance Portability and Accountability Act
      Privacy Rule, whereas the EU General Data Protection Regulation (GDPR) grants
      greater access to device-collected data when the processing of personal data
      falls under the GDPR's territorial scope. The California Consumer Privacy Act,
      the "little sister" of the GDPR, also grants greater rights to California
      residents. By contrast, our normative analysis argues for consistently granting
      patients access to the raw data collected by their implantable devices.
      Smartphone applications are increasingly involved in the collection, relay,
      retrieval, and documentation of these data. Therefore, we argue that smartphone
      user agreements are an emerging but potentially underutilized opportunity for
      clarifying both legal and ethical claims for device-derived data. CONCLUSIONS:
      Current health privacy legislation incompletely supports patients' normative
      claims for access to digital health data.
CI  - (c) 2020 Milbank Memorial Fund.
FAU - Cohen, I Glenn
AU  - Cohen IG
AD  - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard
      Law School, Harvard University.
FAU - Gerke, Sara
AU  - Gerke S
AD  - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard
      Law School, Harvard University.
FAU - Kramer, Daniel B
AU  - Kramer DB
AD  - Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth
      Israel Deaconess Medical Center, Harvard Medical School.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - United States
TA  - Milbank Q
JT  - The Milbank quarterly
JID - 8607003
SB  - IM
CIN - Milbank Q. 2020 Dec;98(4):1027-1032. PMID: 33377289
MH  - Electronic Health Records/ethics/*legislation & jurisprudence
MH  - Ethics, Medical
MH  - Europe
MH  - Health Insurance Portability and Accountability Act
MH  - Humans
MH  - *Pacemaker, Artificial
MH  - *Patient Rights
MH  - United States
PMC - PMC7772635
OTO - NOTNLM
OT  - *GDPR
OT  - *HIPAA
OT  - *health policy
OT  - *implantable cardioverter-defibrillators
OT  - *pacemakers
EDAT- 2020/10/21 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/10/20 08:38
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/10/20 08:38 [entrez]
AID - 10.1111/1468-0009.12481 [doi]
PST - ppublish
SO  - Milbank Q. 2020 Dec;98(4):1257-1289. doi: 10.1111/1468-0009.12481. Epub 2020 Oct 
      20.


PMID- 33078757
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 57
IP  - 4
DP  - 2020 Oct-Dec
TI  - A tale of two springs.
PG  - 478-480
LID - 10.4103/ijc.IJC_614_19 [doi]
AB  - Palliative care, which is more than just terminal care, is still unknown in most 
      parts of India. This narrative highlights how early integration of palliative
      medicine can help the patient and their family to make the most of their time
      together. Besides, excellent clinical acumen is required while looking after the 
      sickest and the most critical patients, proper communication skills, and an
      ethical and holistic approach enables a good doctor-patient relationship. Good
      pain relief, symptom control, attention to nursing issues, providing information 
      sensitively to empower patients and families for joint decision making, and
      advance care planning can help bring about a decent death and bereavement.
      Healing is brought about not only for the caregivers but also for the healthcare 
      professionals.
FAU - Butola, Savita
AU  - Butola S
AD  - Central Armed Police Composite Hospital, Border Security Force Academy, Tekanpur,
      Gwalior, Madhya Pradesh, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
SB  - IM
MH  - Advance Care Planning/*statistics & numerical data
MH  - Caregivers/*psychology
MH  - Humans
MH  - Neoplasms/*therapy
MH  - Palliative Care/*psychology
MH  - Prognosis
MH  - *Stress, Psychological
MH  - Terminal Care/*psychology
OTO - NOTNLM
OT  - Advance planning
OT  - India
OT  - pain-relief
OT  - palliative care
OT  - terminal
COIS- None
EDAT- 2020/10/21 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/10/20 08:37
PHST- 2020/10/20 08:37 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - IndianJournalofCancer_2020_57_4_478_291413 [pii]
AID - 10.4103/ijc.IJC_614_19 [doi]
PST - ppublish
SO  - Indian J Cancer. 2020 Oct-Dec;57(4):478-480. doi: 10.4103/ijc.IJC_614_19.


PMID- 33078673
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1552-681X (Electronic)
IS  - 0272-989X (Linking)
VI  - 40
IP  - 8
DP  - 2020 Nov
TI  - Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized
      Controlled Trial.
PG  - 1034-1040
LID - 10.1177/0272989X20961095 [doi]
AB  - Microsimulation models are often used to predict long-term outcomes and guide
      policy decisions regarding cancer screening. The United Kingdom Flexible
      Sigmoidoscopy Screening (UKFSS) Trial examines a one-time intervention of
      flexible sigmoidoscopy that was implemented before a colorectal cancer (CRC)
      screening program was established. Long-term study outcomes, now a full 17 y
      following randomization, have been published. We use the outcomes from this trial
      to validate 3 microsimulation models for CRC to long-term study outcomes. We find
      that 2 of 3 models accurately predict the relative effect of screening (the
      hazard ratios) on CRC-specific incidence 17 y after screening. We find that all 3
      models yield predictions of the relative effect of screening on CRC incidence and
      mortality (i.e., the hazard ratios) that are reasonably close to the UKFSS
      results. Two of the 3 models accurately predict the relative reduction in CRC
      incidence 17 y after screening. One model accurately predicted the absolute
      incidence and mortality rates in the screened group. The models differ in their
      estimates related to adenoma detection at screening. Although high-quality
      screening results help to inform models, trials are expensive, last many years,
      and can be complicated by ethical issues and technological changes across the
      duration of the trial. Thus, well-calibrated and validated models are necessary
      to predict outcomes for which data are not available. The results from this
      validation demonstrate the utility of models in predicting long-term outcomes and
      in collaborative modeling to account for uncertainty.
FAU - DeYoreo, Maria
AU  - DeYoreo M
AUID- ORCID: 0000-0002-3847-1030
AD  - RAND Corporation, Santa Monica, CA, USA.
FAU - Lansdorp-Vogelaar, Iris
AU  - Lansdorp-Vogelaar I
AD  - Department of Public Health, Erasmus MC, Rotterdam, Zuid-Holland, the
      Netherlands.
FAU - Knudsen, Amy B
AU  - Knudsen AB
AD  - Institute for Technology Assessment and Harvard Medical School, Massachusetts
      General Hospital, Boston, MA, USA.
FAU - Kuntz, Karen M
AU  - Kuntz KM
AD  - Department of Health Policy and Management, University of Minnesota, School of
      Public Health, Minneapolis, MN, USA.
FAU - Zauber, Ann G
AU  - Zauber AG
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, NY, USA.
FAU - Rutter, Carolyn M
AU  - Rutter CM
AUID- ORCID: 0000-0002-4396-8594
AD  - RAND Corporation, Santa Monica, CA, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U01 CA199335/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20201020
PL  - United States
TA  - Med Decis Making
JT  - Medical decision making : an international journal of the Society for Medical
      Decision Making
JID - 8109073
SB  - IM
MH  - Colorectal Neoplasms/*complications/epidemiology/mortality
MH  - Computer Simulation
MH  - Early Detection of Cancer/methods
MH  - Humans
MH  - Incidence
MH  - Models, Theoretical
MH  - Risk Assessment/methods/*standards/statistics & numerical data
MH  - *Time
MH  - Time Factors
PMC - PMC7665984
MID - NIHMS1626190
OTO - NOTNLM
OT  - *colorectal cancer
OT  - *colorectal cancer screening
OT  - *microsimulation model
OT  - *model validation
EDAT- 2020/10/21 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/10/20 08:37
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/10/20 08:37 [entrez]
AID - 10.1177/0272989X20961095 [doi]
PST - ppublish
SO  - Med Decis Making. 2020 Nov;40(8):1034-1040. doi: 10.1177/0272989X20961095. Epub
      2020 Oct 20.


PMID- 33078574
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1547-5069 (Electronic)
IS  - 1527-6546 (Linking)
VI  - 52
IP  - 6
DP  - 2020 Nov
TI  - Nursing Journal Policies on Disclosure and Management of Conflicts of Interest.
PG  - 680-687
LID - 10.1111/jnu.12605 [doi]
AB  - PURPOSE: Concerns about conflicts of interest (COIs) in research and health care 
      are well known, but recent reports of authors failing to disclose potential COIs 
      in journal articles threatens the integrity of the scholarly literature. While
      many nursing journals have published editorials on this topic, review of nursing 
      journal policies on and experiences with COIs has not been reported. The purposes
      of this study were to examine the extent to which nursing journals have COI
      policies and require disclosures by authors, peer reviewers, editorial board
      members, and editors who have a role in journal content decisions. DESIGN: This
      cohort study addressed top-ranked nursing journal policies about and experiences 
      with COIs in scholarly publications. METHODS: An analysis of COI policies in the 
      instructions for authors of 118 journals listed in the nursing category of
      Clarivate Analytics Journal Citation Reports was completed in 2019. An electronic
      survey of the editors was also conducted to determine their awareness and
      experience with COI policies for their journals. Characteristics of the journals 
      and policies were assessed. Information on polices about COIs for editors and
      peer reviewers were also reviewed. A content analysis of the policies included
      assessment of best practices and gaps in requirements. FINDINGS: For the journal 
      policy assessment, 116 journals that publish only in the English language were
      eligible. The majority (n = 113; 97.4%) of journals had a statement on COI
      policies for authors, but only 42 (36.2%) had statements for peer reviewers and
      only 37 (31.9%) had statements for editors. A total of 117 journal editors were
      sent the survey. One declined to participate, leaving a total of 116 eligible
      editors; 82 (70.6%) responded and 34 did not respond. Sixty-seven (81.7%) of the 
      82 editors indicated that their journal had a policy about COIs for authors.
      Seventy-four editors (63.7%) responded to the question about their journal having
      a policy about COIs for peer reviewers and editors. Thirty-three (44.5%) of the
      respondents indicated their journal had a COI policy for peer reviewers, and 29
      (39.1%) stated they had a policy for editors. Few editors (n = 7; 9%) indicated
      that they had encountered problems pertaining to author COIs. CONCLUSIONS:
      Findings from this study may help promote ethical publication practices through
      comprehensive policies on disclosure and management of nursing journal authors,
      peer reviewers, and editors. CLINICAL RELEVANCE: Declarations of potential
      conflicts of interest promote transparency and allows the consumer of research to
      take that into consideration when considering the findings of a study.
CI  - (c) 2020 Sigma Theta Tau International.
FAU - Barnsteiner, Jane
AU  - Barnsteiner J
AUID- ORCID: 0000-0002-9462-9306
AD  - Xi, Professor Emerita, University of Pennsylvania School of Nursing, Editor,
      Translational Research and Quality Improvement, American Journal of Nursing,
      Miramar Beach, FL, USA.
FAU - Shawn Kennedy, Maureen
AU  - Shawn Kennedy M
AD  - Upsilon, Editor-In-Chief, American Journal of Nursing, New York, NY, USA.
FAU - Flanagin, Annette
AU  - Flanagin A
AD  - Gamma Phi, Executive Managing Editor, JAMA and JAMA Network, Chicago, IL, USA.
FAU - Sietmann, Caroline
AU  - Sietmann C
AD  - Author Outreach Program Manager, JAMA and JAMA Network, Chicago, IL, USA.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - United States
TA  - J Nurs Scholarsh
JT  - Journal of nursing scholarship : an official publication of Sigma Theta Tau
      International Honor Society of Nursing
JID - 100911591
SB  - IM
MH  - *Conflict of Interest
MH  - *Disclosure
MH  - *Editorial Policies
MH  - Humans
MH  - *Nursing
MH  - *Periodicals as Topic
OTO - NOTNLM
OT  - *Competing interests
OT  - *conflicts of interest
OT  - *disclosure and conflicts of interest
OT  - *financial conflicts of interest
EDAT- 2020/10/21 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/10/20 06:30
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/10/20 06:30 [entrez]
AID - 10.1111/jnu.12605 [doi]
PST - ppublish
SO  - J Nurs Scholarsh. 2020 Nov;52(6):680-687. doi: 10.1111/jnu.12605. Epub 2020 Oct
      19.


PMID- 33078074
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 60
DP  - 2020 Dec
TI  - Does elective orthopaedic surgery in pandemic era increase risk of developing
      COVID-19? A combined analysis of retrospective and prospective study at Cipto
      Mangunkusumo Hospital, Jakarta, Indonesia.
PG  - 87-91
LID - 10.1016/j.amsu.2020.10.015 [doi]
AB  - BACKGROUND: To date, no recommendations have been published on when and how to
      start again carrying out elective, non-urgent surgery on COVID-19-negative
      patients after the epidemic peak has been reached in a given country or region
      and the pressure on healthcare facilities, healthcare workers and resources has
      been released by so far that elective surgery procedures can be safely and
      ethically programmed again. This study aims to investigate whether elective
      orthopaedic surgery will increase the risk of developing COVID-19. MATERIALS AND 
      METHODS: This was a combined retrospective and prospective studies performed at a
      national tertiary hospital in Jakarta, Indonesia. Subjects were patients who
      underwent elective orthopaedic surgeries at our institution from April to May
      2020. Those who were previously infected with COVID-19 from polymerase chain
      reaction (PCR) reverse transcriptase (RT) examination obtained via nasopharynx
      and oropharynx swab, as well as those who were reluctant to participate were
      excluded from the study. RESULTS: A total of 35 subjects (mean age 32.89 +/-
      17.42) were recruited. Fifteen (42.9%) subjects were male, and 20 subjects
      (57.1%) were female. Mean duration of surgery was 240 min with the longest and
      shortest duration of 690 and 40 min, respectively. General anaesthesia was
      performed in the majority of cases in 18 surgeries (51.4%) with local anaesthesia
      as the least in 2 surgeries (5.7%). Length of stay of our study was 6 days of
      average. None of the patients developed symptoms suggestive of COVID-19
      infection. CONCLUSION: We found that elective orthopaedic surgery may not be
      associated with increased cases of COVID-19 cases. However, our study was limited
      by short duration of follow-up. Further studies are required in order to
      investigate the affect of undergoing elective surgery and the number of COVID-19 
      cases.
CI  - (c) 2020 The Authors.
FAU - Kamal, A F
AU  - Kamal AF
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Widodo, W
AU  - Widodo W
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Kuncoro, M W
AU  - Kuncoro MW
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Karda, I W A M
AU  - Karda IWAM
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Prabowo, Y
AU  - Prabowo Y
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Singh, G
AU  - Singh G
AD  - Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia,
      Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Liastuti, L D
AU  - Liastuti LD
AD  - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Trimartani
AU  - Trimartani
AD  - Department of Ear, Nose, and Throat, Faculty of Medicine, Universitas Indonesia, 
      Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Hutagalung, E U
AU  - Hutagalung EU
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Saleh, I
AU  - Saleh I
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Tobing, S D A L
AU  - Tobing SDAL
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Gunawan, B
AU  - Gunawan B
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Dilogo, I H
AU  - Dilogo IH
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Lubis, A M T
AU  - Lubis AMT
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Kurniawan, A
AU  - Kurniawan A
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Rahyussalim, A J
AU  - Rahyussalim AJ
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Oesman, I
AU  - Oesman I
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Ifran, N N P P S
AU  - Ifran NNPPS
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Latief, W
AU  - Latief W
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Wijaya, M T
AU  - Wijaya MT
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Ivansyah, M D
AU  - Ivansyah MD
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Primaputra, M R A
AU  - Primaputra MRA
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Reksoprodjo, A Y
AU  - Reksoprodjo AY
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Hendriarto, A
AU  - Hendriarto A
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Novriandi, K M A
AU  - Novriandi KMA
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Alaztha, Z
AU  - Alaztha Z
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Canintika, A F
AU  - Canintika AF
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Sitanggang, A H R
AU  - Sitanggang AHR
AD  - Department of Orthopaedics and Traumatology, Faculty of Medicine Universitas
      Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7557301
OTO - NOTNLM
OT  - COVID-19
OT  - Elective surgery
OT  - Orthopaedic surgery
COIS- None.
EDAT- 2020/10/21 06:00
MHDA- 2020/10/21 06:01
CRDT- 2020/10/20 06:25
PHST- 2020/09/05 00:00 [received]
PHST- 2020/10/08 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/10/21 06:01 [medline]
PHST- 2020/10/20 06:25 [entrez]
AID - 10.1016/j.amsu.2020.10.015 [doi]
AID - S2049-0801(20)30369-1 [pii]
PST - ppublish
SO  - Ann Med Surg (Lond). 2020 Dec;60:87-91. doi: 10.1016/j.amsu.2020.10.015. Epub
      2020 Oct 15.


PMID- 33078004
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 10
DP  - 2020 Oct
TI  - [Bureaucracy gives way to science. What good the pandemic has left.]
PG  - 565-567
LID - 10.1701/3453.34414 [doi]
AB  - The CoViD-19 pandemic has pointed out the the need for an efficient, timely,
      ethically correct clinical research, in order to find rapid and reliable
      responses to health challenges. The guidelines published by the Agenzia Italiana 
      del Farmaco during the pandemic have shown that some useful changes for
      simplifying and speeding-up clinical research in Italy are feasible, while
      maintaining high levels of quality. In this perspective, a reflection is a must: 
      perhaps we are ready to detach ourselves from that image of a slow and
      bureaucratic country now widespread in Europe. Perhaps the pandemic has left us
      something good. Maybe we are really able of working much better, even in
      non-emergency conditions.
FAU - Cagnazzo, Celeste
AU  - Cagnazzo C
AD  - SC Oncoematologia Pediatrica, AOU Citta della Salute e della Scienza, Presidio
      Ospedaliero Infantile Regina Margherita, Torino - Dipartimento di Scienze della
      Sanita Pubblica e Pediatriche, Universita di Torino.
FAU - Fagioli, Franca
AU  - Fagioli F
AD  - SC Oncoematologia Pediatrica, AOU Citta della Salute e della Scienza, Presidio
      Ospedaliero Infantile Regina Margherita, Torino - Dipartimento di Scienze della
      Sanita Pubblica e Pediatriche, Universita di Torino.
LA  - ita
PT  - Journal Article
TT  - La burocrazia cede il passo alla scienza. Quel che di buono ci ha lasciato la
      pandemia.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - Biomedical Research/*organization & administration
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/therapy
MH  - Humans
MH  - Italy
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/therapy
MH  - *Practice Guidelines as Topic
EDAT- 2020/10/21 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/20 06:24
PHST- 2020/10/20 06:24 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.1701/3453.34414 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Oct;111(10):565-567. doi: 10.1701/3453.34414.


PMID- 33077840
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Oct 19
TI  - Low prevalence of end plate junction failure in danish patients with lumbar disc 
      herniation.
PG  - 17652
LID - 10.1038/s41598-020-74690-w [doi]
AB  - The present study was undertaken to determine the prevalence of endplate junction
      failure in a smaller cohort of Danish patients with lumbar disk herniation and
      compare this to the previously published data from India. Consecutive patients
      seen in a large regional hospital spine-care unit, with a clinical presentation
      suggesting a lumbar disk herniation with concomitant radiculopathy and
      confirmatory recent MRI were included. Additional imaging by CT was performed as 
      part of the study and these were analyzed with specific attention to endplate
      junction failures. For ethical reasons, the number of participants was kept to a 
      minimum and a total of 26 patients were included. The prevalence (n = 5) of
      endplate junction failure was found to be statistically significantly lower than 
      that previously reported. Our findings do not echo those previously reported in
      an Indian population: Endplate junction failure was indeed observed, but at a
      significantly lower rate. We discuss potential reasons for the difference in
      findings with due attention to the weaknesses of the current study.
FAU - O'Neill, Soren Francis Dyhrberg
AU  - O'Neill SFD
AD  - Spinecenter of Southern Denmark, Lillebaelt Hospital, Middelfart, DK5750,
      Denmark. soeren.oneill@rsyd.dk.
AD  - University of Southern Denmark, Institute of Regional Health Science Research,
      Odense, DK5230, Denmark. soeren.oneill@rsyd.dk.
FAU - Fidelman, Jonas Morten
AU  - Fidelman JM
AD  - Department of Sport Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, DK5230, Denmark.
AD  - Department of Radiology, University Hospital of Southern Denmark, Vejle, DK7100, 
      Denmark.
FAU - Haarup, Linne Steinar
AU  - Haarup LS
AD  - Department of Sport Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, DK5230, Denmark.
AD  - Spinecenter Djursland, Grena, DK8500, Denmark.
FAU - Lund, Christian
AU  - Lund C
AD  - Department of Radiology, University Hospital of Southern Denmark, Vejle, DK7100, 
      Denmark.
FAU - Konner, Mikkel Brunsgaard
AU  - Konner MB
AD  - Spinecenter of Southern Denmark, Lillebaelt Hospital, Middelfart, DK5750,
      Denmark.
AD  - University of Southern Denmark, Institute of Regional Health Science Research,
      Odense, DK5230, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Annulus Fibrosus/pathology
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Intervertebral Disc Displacement/drug therapy/etiology/*pathology
MH  - *Lumbar Vertebrae/diagnostic imaging/pathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Radiculopathy/etiology/pathology
MH  - Tomography, X-Ray Computed
PMC - PMC7573575
EDAT- 2020/10/21 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/10/20 06:20
PHST- 2020/03/13 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/10/20 06:20 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - 10.1038/s41598-020-74690-w [doi]
AID - 10.1038/s41598-020-74690-w [pii]
PST - epublish
SO  - Sci Rep. 2020 Oct 19;10(1):17652. doi: 10.1038/s41598-020-74690-w.


PMID- 33077571
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Kids' Outcomes And Long-term Abilities (KOALA): protocol for a prospective,
      longitudinal cohort study of mild traumatic brain injury in children 6 months to 
      6 years of age.
PG  - e040603
LID - 10.1136/bmjopen-2020-040603 [doi]
AB  - INTRODUCTION: Mild traumatic brain injury (mTBI) is highly prevalent, especially 
      in children under 6 years. However, little research focuses on the consequences
      of mTBI early in development. The objective of the Kids' Outcomes And Long-term
      Abilities (KOALA) study is to document the impact of early mTBI on children's
      motor, cognitive, social and behavioural functioning, as well as on quality of
      life, stress, sleep and brain integrity. METHODS AND ANALYSES: KOALA is a
      prospective, multicentre, longitudinal cohort study of children aged 6 months to 
      6 years at the time of injury/recruitment. Children who sustain mTBI (n=150) or
      an orthopaedic injury (n=75) will be recruited from three paediatric emergency
      departments (PEDs), and compared with typically developing children (community
      controls, n=75). A comprehensive battery of prognostic and outcome measures will 
      be collected in the PED, at 10 days, 1, 3 and 12 months postinjury. Biological
      measures, including measures of brain structure and function (magnetic resonance 
      imaging, MRI), stress (hair cortisol), sleep (actigraphy) and genetics (saliva), 
      will complement direct testing of function using developmental and
      neuropsychological measures and parent questionnaires. Group comparisons and
      predictive models will test the a priori hypotheses that, compared with children 
      from the community or with orthopaedic injuries, children with mTBI will (1)
      display more postconcussive symptoms and exhibit poorer motor, cognitive, social 
      and behavioural functioning; (2) show evidence of altered brain structure and
      function, poorer sleep and higher levels of stress hormones. A combination of
      child, injury, socioenvironmental and psychobiological factors are expected to
      predict behaviour and quality of life at 1, 3 and 12 months postinjury. ETHICS
      AND DISSEMINATION: The KOALA study is approved by the Sainte-Justine University
      Hospital, McGill University Health Centre and University of Calgary Conjoint
      Health Research Ethics Boards. Parents of participants will provide written
      consent. Dissemination will occur through peer-reviewed journals and an
      integrated knowledge translation plan.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Beauchamp, Miriam H
AU  - Beauchamp MH
AUID- ORCID: 0000-0002-8637-6361
AD  - Psychology, Universite de Montreal, Montreal, Quebec, Canada
      miriam.beauchamp@umontreal.ca.
AD  - Sainte-Justine Hospital Research Center, Montreal, Quebec, Canada.
FAU - Degeilh, Fanny
AU  - Degeilh F
AD  - Psychology, Universite de Montreal, Montreal, Quebec, Canada.
AD  - Sainte-Justine Hospital Research Center, Montreal, Quebec, Canada.
AD  - Psychiatry, LMU Munchen, Munchen, Bayern, Germany.
FAU - Yeates, Keith
AU  - Yeates K
AUID- ORCID: 0000-0001-7680-2892
AD  - Psychology, University of Calgary, Calgary, Alberta, Canada.
AD  - Research Institute, Alberta Children's Hospital, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
FAU - Gagnon, Isabelle
AU  - Gagnon I
AD  - School of Physical and Occupational Therapy, McGill University, Montreal, Quebec,
      Canada.
AD  - Trauma, Montreal Children's Hospital, Montreal, Quebec, Canada.
FAU - Tang, Ken
AU  - Tang K
AD  - Clinical Research Unit, Children's Hospital of Eastern Ontario Research
      Institute, Ottawa, Ontario, Canada.
FAU - Gravel, Jocelyn
AU  - Gravel J
AD  - Pediatric Emergency Medicine, CHU Sainte-Justine, Montreal, Quebec, Canada.
FAU - Stang, Antonia
AU  - Stang A
AD  - Pediatrics, University of Calgary, Calgary, Alberta, Canada.
AD  - Pediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
FAU - Burstein, Brett
AU  - Burstein B
AD  - Pediatric Emergency Medicine, Montreal Children's Hospital, McGill University
      Health Center, Montreal, Quebec, Canada.
FAU - Bernier, Annie
AU  - Bernier A
AD  - Psychology, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Lebel, Catherine
AU  - Lebel C
AD  - Research Institute, Alberta Children's Hospital, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
AD  - Radiology, University of Calgary, Calgary, Alberta, Canada.
FAU - El Jalbout, Ramy
AU  - El Jalbout R
AD  - Radiology, CHU Sainte-Justine, Montreal, Quebec, Canada.
FAU - Lupien, Sonia
AU  - Lupien S
AD  - Psychiatry, Universite de Montreal, Montreal, Quebec, Canada.
FAU - de Beaumont, Louis
AU  - de Beaumont L
AD  - Surgery, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Zemek, Roger
AU  - Zemek R
AUID- ORCID: 0000-0001-7807-2459
AD  - Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
FAU - Dehaes, Mathieu
AU  - Dehaes M
AD  - Psychology, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Deschenes, Sylvain
AU  - Deschenes S
AD  - Radiology, CHU Sainte-Justine, Montreal, Quebec, Canada.
CN  - PERC KOALA Project
LA  - eng
GR  - FDN148417/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Animals
MH  - *Brain Concussion/diagnosis
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - *Phascolarctidae
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC7574946
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *developmental neurology & neurodisability
OT  - *magnetic resonance imaging
OT  - *neurological injury
OT  - *neuroradiology
OT  - *paediatric neurology
COIS- Competing interests: CL's spouse is an employee of General Electric Healthcare.
      The other authors report no biomedical financial interests or potential conflicts
      of interest.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 06:17
PHST- 2020/10/20 06:17 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040603 [pii]
AID - 10.1136/bmjopen-2020-040603 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e040603. doi: 10.1136/bmjopen-2020-040603.


PMID- 33077567
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Efficacy and safety of exogenous surfactant therapy in patients under 12 months
      of age invasively ventilated for severe bronchiolitis (SURFABRON): protocol for a
      multicentre, randomised, double-blind, controlled, non-profit trial.
PG  - e038780
LID - 10.1136/bmjopen-2020-038780 [doi]
AB  - INTRODUCTION: Some evidence indicates that exogenous surfactant therapy may be
      effective in infants with acute viral bronchiolitis, even though more
      confirmatory data are needed. To date, no large multicentre trials have evaluated
      the effectiveness and safety of exogenous surfactant in severe cases of
      bronchiolitis requiring invasive mechanical ventilation (IMV). METHODS AND
      ANALYSIS: This is a multicentre randomised, placebo-controlled, double-blind
      study, performed in 19 Italian paediatric intensive care units (PICUs). Eligible 
      participants are infants under the age of 12 months hospitalised in a PICU,
      suffering from severe acute hypoxaemic bronchiolitis, requiring IMV. We adopted a
      more restrictive definition of bronchiolitis, including only infants below 12
      months of age, to maintain the population as much homogeneous as possible. The
      primary outcome is to evaluate whether exogenous surfactant therapy (Curosurf,
      Chiesi Pharmaceuticals, Italy) is effective compared with placebo (air) in
      reducing the duration of IMV in the first 14 days of hospitalisation, in infants 
      suffering from acute hypoxaemic viral bronchiolitis. Secondary outcomes are
      duration of non-invasive mechanical ventilation in the post-extubation phase,
      number of cases requiring new intubation after previous extubation within 14 days
      from randomisation, PICU and hospital length of stay (LOS), duration of oxygen
      dependency, effects on oxygenation and ventilatory parameters during invasive
      mechanical respiratory support, need for repeating treatment within 24 hours of
      first treatment, use of other interventions (eg, high-frequency oscillatory
      ventilation, nitric oxide, extracorporeal membrane oxygenation), mortality within
      the first 14 days of PICU stay and before hospital discharge, side effects and
      serious adverse events. ETHICS AND DISSEMINATION: The trial design and protocol
      have received approval by the Italian National Agency for Drugs (AIFA) and by the
      Regional Ethical Committee of Verona University Hospital (1494CESC). Findings
      will be disseminated through publication in peer-reviewed journals,
      conference/meeting presentations and media. TRIAL REGISTRATION NUMBER:
      Clinicaltrials.gov, issue date 22 May 2019. NCT03959384.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Biban, Paolo
AU  - Biban P
AUID- ORCID: 0000-0001-7073-6265
AD  - Department of Neonatal and Paediatric Critical Care, Azienda Ospedaliera
      Universitaria Integrata Verona, Verona, Italy paolo.biban@aovr.veneto.it.
FAU - Conti, Giorgio
AU  - Conti G
AD  - Paediatric Anesthesia and Intensive Care, Policlinico Universitario Agostino
      Gemelli, Roma, Italy.
FAU - Wolfler, Andrea Michele
AU  - Wolfler AM
AUID- ORCID: 0000-0001-6389-3692
AD  - Paediatric Anesthesia and Intensive Care, Ospedale dei Bambini Vittore Buzzi,
      Milano, Italy.
FAU - Carlassara, Silvia
AU  - Carlassara S
AD  - Department of Neonatal and Paediatric Critical Care, Azienda Ospedaliera
      Universitaria Integrata Verona, Verona, Italy.
FAU - Gitto, Eloisa
AU  - Gitto E
AD  - Neonatal and Paediatric Intensive Care, Azienda Ospedaliera Universitaria G.
      Martino, Messina, Italy.
FAU - Rulli, Immacolata
AU  - Rulli I
AD  - Neonatal and Paediatric Intensive Care, Azienda Ospedaliera Universitaria G.
      Martino, Messina, Italy.
FAU - Moscatelli, Andrea
AU  - Moscatelli A
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Giannina Gaslini, Genova,
      Italy.
FAU - Micalizzi, Camilla
AU  - Micalizzi C
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Giannina Gaslini, Genova,
      Italy.
FAU - Savron, Fabio
AU  - Savron F
AD  - Paediatric Anesthesia and Intensive Care, IRCCS Materno Infantile Burlo Garofolo,
      Trieste, Italy.
FAU - Sagredini, Raffaella
AU  - Sagredini R
AD  - Paediatric Anesthesia and Intensive Care, IRCCS Materno Infantile Burlo Garofolo,
      Trieste, Italy.
FAU - Genoni, Giulia
AU  - Genoni G
AD  - Neonatal and Paediatric Intensive Care, Azienda Ospedaliero-Universitaria
      Maggiore della Carita, Novara, Italy.
FAU - Binotti, Marco
AU  - Binotti M
AD  - Neonatal and Paediatric Intensive Care, Azienda Ospedaliero-Universitaria
      Maggiore della Carita, Novara, Italy.
FAU - Caramelli, Fabio
AU  - Caramelli F
AD  - Paediatric Anesthesia and Intensive Care, Azienda Ospedaliera-Universitaria
      Sant'Orsola-Malpighi, Bologna, Italy.
FAU - Fae, Monica
AU  - Fae M
AD  - Paediatric Anesthesia and Intensive Care, Azienda Ospedaliera-Universitaria
      Sant'Orsola-Malpighi, Bologna, Italy.
FAU - Pettenazzo, Andrea
AU  - Pettenazzo A
AD  - Paediatric Intensive Care, Azienda Ospedaliera Universitaria Padova, Padua,
      Italy.
FAU - Stritoni, Valentina
AU  - Stritoni V
AD  - Paediatric Intensive Care, Azienda Ospedaliera Universitaria Padova, Padua,
      Italy.
FAU - D'Amato, Luigia
AU  - D'Amato L
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Pediatrico Santobbono, Napoli,
      Italy.
FAU - Zito Marinosci, Geremia
AU  - Zito Marinosci G
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Pediatrico Santobbono, Napoli,
      Italy.
FAU - Calderini, Edoardo
AU  - Calderini E
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Maggiore Policlinico, Milano, 
      Italy.
FAU - Scalia Catenacci, Stefano
AU  - Scalia Catenacci S
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Maggiore Policlinico, Milano, 
      Italy.
FAU - Berardi, Alberto
AU  - Berardi A
AD  - Neonatal Intensive Care, Azienda Ospedaliero-Universitaria Policlinico, Modena,
      Italy.
FAU - Torcetta, Francesco
AU  - Torcetta F
AD  - Neonatal Intensive Care, Azienda Ospedaliero-Universitaria Policlinico, Modena,
      Italy.
FAU - Bonanomi, Ezio
AU  - Bonanomi E
AD  - Paediatric Anesthesia and Intensive Care, ASST Papa Giovanni XXIII, Bergamo,
      Italy.
FAU - Bonacina, Daniele
AU  - Bonacina D
AD  - Paediatric Anesthesia and Intensive Care, ASST Papa Giovanni XXIII, Bergamo,
      Italy.
FAU - Ivani, Giorgio
AU  - Ivani G
AD  - Paediatric Anesthesia and Intensive Care, Ospedale Infantile Regina Margherita
      Sant'Anna, Torino, Italy.
FAU - Santuz, Pierantonio
AU  - Santuz P
AD  - Department of Neonatal and Paediatric Critical Care, Azienda Ospedaliera
      Universitaria Integrata Verona, Verona, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT03959384
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Surface-Active Agents)
SB  - IM
MH  - *Bronchiolitis/drug therapy
MH  - Child
MH  - Double-Blind Method
MH  - Humans
MH  - Infant
MH  - Italy
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Respiration, Artificial
MH  - *Surface-Active Agents
PMC - PMC7574934
OTO - NOTNLM
OT  - *clinical trials
OT  - *paediatric infectious disease & immunisation
OT  - *paediatric intensive & critical care
OT  - *paediatric thoracic medicine
COIS- Competing interests: PB has received speaker fees from Chiesi Group. AW has
      received speaker fee from Takeda. FC and PS received travel funding by Chiesi.
      All other authors (SSC, EG, IR, AM, CM, FS, RS, GG, MB, MF, AP, VS, LD, GZM, EC, 
      SSC, AB, FT, EB, DB, GI) report no competing interests.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 06:17
PHST- 2020/10/20 06:17 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038780 [pii]
AID - 10.1136/bmjopen-2020-038780 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e038780. doi: 10.1136/bmjopen-2020-038780.


PMID- 33077564
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Impact of expanding smoke-free policies beyond enclosed public places and
      workplaces on children's tobacco smoke exposure and respiratory health: protocol 
      for a systematic review and meta-analysis.
PG  - e038234
LID - 10.1136/bmjopen-2020-038234 [doi]
AB  - INTRODUCTION: Tobacco smoke exposure (TSE) has considerable adverse respiratory
      health impact among children. Smoke-free policies covering enclosed public places
      are known to reduce child TSE and benefit child health. An increasing number of
      jurisdictions are now expanding smoke-free policies to also cover outdoor areas
      and/or (semi)private spaces (indoor and/or outdoor). We aim to systematically
      review the evidence on the impact of these 'novel smoke-free policies' on
      children's TSE and respiratory health. METHODS AND ANALYSIS: 13 electronic
      databases will be searched by two independent reviewers for eligible studies. We 
      will consult experts from the field and hand-search references and citations to
      identify additional published and unpublished studies. Study designs recommended 
      by the Cochrane Effective Practice and Organisation of Care (EPOC) group are
      eligible, without restrictions on the observational period, publication date or
      language. Our primary outcomes are: self-reported or parental-reported TSE in
      places covered by the policy; unplanned hospital attendance for wheezing/asthma
      and unplanned hospital attendance for respiratory infections. We will assess risk
      of bias of individual studies following the EPOC or Risk Of Bias In
      Non-randomised Studies of Interventions tool, as appropriate. We will conduct
      separate random effects meta-analyses for smoke-free policies covering (1) indoor
      private places, (2) indoor semiprivate places, (3) outdoor (semi)private places
      and (4) outdoor public places. We will assess whether the policies were
      associated with changes in TSE in other locations (eg, displacement). Subgroup
      analyses will be conducted based on country income classification (ie, high,
      middle or low income) and by socioeconomic status. Sensitivity analyses will be
      undertaken via broadening our study design eligibility criteria (ie, including
      non-EPOC designs) or via excluding studies with a high risk of bias. This review 
      will inform policymakers regarding the implementation of extended smoke-free
      policies to safeguard children's health. ETHICS AND DISSEMINATION: Ethical
      approval is not required. Findings will be disseminated to academics and the
      general public. PROSPERO REGISTRATION NUMBER: CRD42020190563.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Rado, Marta K
AU  - Rado MK
AUID- ORCID: 0000-0002-1676-5951
AD  - Department of Paediatrics, Erasmus MC - Sophia Children's Hospital, University
      Medical Centre Rotterdam, Rotterdam, Netherlands.
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, Netherlands.
FAU - Molenberg, Famke Jm
AU  - Molenberg FJ
AUID- ORCID: 0000-0002-5305-9730
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, Netherlands.
FAU - Sheikh, Aziz
AU  - Sheikh A
AD  - Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom.
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Millett, Christopher
AU  - Millett C
AUID- ORCID: 0000-0002-0793-9884
AD  - Public Health Policy Evaluation Unit, School of Public Health, Imperial College
      London, London, United Kingdom.
FAU - Bramer, Wichor M
AU  - Bramer WM
AUID- ORCID: 0000-0003-2681-9180
AD  - Medical Library, Erasmus MC, University Medical Centre Rotterdam, Rotterdam,
      Netherlands.
FAU - Burdorf, Alex
AU  - Burdorf A
AUID- ORCID: 0000-0003-3129-2862
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, Netherlands.
FAU - van Lenthe, Frank J
AU  - van Lenthe FJ
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, Netherlands.
FAU - Been, Jasper V
AU  - Been JV
AUID- ORCID: 0000-0002-4907-6466
AD  - Department of Paediatrics, Erasmus MC - Sophia Children's Hospital, University
      Medical Centre Rotterdam, Rotterdam, Netherlands j.been@erasmusmc.nl.
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Tobacco Smoke Pollution)
SB  - IM
MH  - Child
MH  - Child Health
MH  - Family
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Review Literature as Topic
MH  - *Smoke-Free Policy
MH  - *Tobacco Smoke Pollution
MH  - Workplace
PMC - PMC7577335
OTO - NOTNLM
OT  - *child protection
OT  - *community child health
OT  - *health policy
OT  - *public health
OT  - *respiratory infections
COIS- Competing interests: None declared.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 06:16
PHST- 2020/10/20 06:16 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038234 [pii]
AID - 10.1136/bmjopen-2020-038234 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e038234. doi: 10.1136/bmjopen-2020-038234.


PMID- 33077562
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - First trimester screening for pre-eclampsia and intrauterine growth restriction
      using three-dimensional Doppler angiography (SPIRIT): protocol for a multicentre 
      prospective study in nulliparous pregnant women.
PG  - e037751
LID - 10.1136/bmjopen-2020-037751 [doi]
AB  - INTRODUCTION: Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are
      two major pregnancy complications, related to chronic uteroplacental
      hypoperfusion. Nowadays, there is no screening or diagnostic test for
      uteroplacental vascularisation deficiency in pregnant women. Since 2004, 3
      three-imensional power Doppler (3DPD) angiography has been used for the
      evaluation of uteroplacental vascularisation and three vascular indices are
      usually calculated: Vascularisation Index (VI), Flow Index (FI) and
      vascularisation-FI (VFI). A high intraobserver and interobserver reproducibility 
      and a potential interest for placental function study were reported by our team
      and others.The main objective of our study is to determine differences in 3DPD
      indices at first trimester between pregnancies defined at their outcome as
      uncomplicated pregnancy, PE (mild and severe) and IUGR in nulliparous women.
      METHODS AND ANALYSIS: This is a national multicentre prospective cohort study
      conducted in four French maternity units. We expect to include 2200 women in a
      period of 36 months. The nulliparous pregnant women will be recruited during
      their first trimester consultation (11-13+6 gestation week (GW)).The 3DPD and
      uterine artery Doppler acquisition will be included in the current routine
      11-13+6 GW ultrasound. Also, additional blood samples will be taken for biomarker
      analysis (PAPP-A and P1GF) and biological collection. Uteroplacental VIs (FI and 
      VFI) will be measured. For each subgroup (uncomplicated pregnancy, PE and IUGR), 
      mean values in 3DPD indices will be computed and compared using a pairwise t test
      with a Bonferroni correction p value adjustment. ETHICS AND DISSEMINATION: The
      study was approved by the French Ethics Committee, the Comite de Protection des
      Personnes SUD MEDITERRANEE IV on 13 February 2018 with reference number 17 12 03.
      The results of this study will be published in a peer-reviewed journal and will
      be presented at relevant conferences. TRIAL REGISTRATION NUMBER: NCT03342014;
      Pre-results. PHRCN-16-0567.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bertholdt, Charline
AU  - Bertholdt C
AUID- ORCID: 0000-0001-9297-5363
AD  - Obstetric and Fetal Medicine Unit, CHRU Nancy, Nancy, France
      charline.bertholdt@gmail.com.
AD  - Inserm IADI, Universite de Lorraine, Nancy, France.
FAU - Hossu, Gabriela
AU  - Hossu G
AD  - Inserm IADI, Universite de Lorraine, Nancy, France.
AD  - Inserm CIC-IT, CHRU Nancy, Nancy, France.
FAU - Banasiak, Claire
AU  - Banasiak C
AD  - Inserm CIC-IT, CHRU Nancy, Nancy, France.
FAU - Beaumont, Marine
AU  - Beaumont M
AD  - Inserm IADI, Universite de Lorraine, Nancy, France.
AD  - Inserm CIC-IT, CHRU Nancy, Nancy, France.
FAU - Morel, Olivier
AU  - Morel O
AD  - Obstetric and Fetal Medicine Unit, CHRU Nancy, Nancy, France.
AD  - Inserm IADI, Universite de Lorraine, Nancy, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03342014
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Angiography
MH  - Female
MH  - *Fetal Growth Retardation/diagnostic imaging
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Multicenter Studies as Topic
MH  - Placenta/diagnostic imaging
MH  - *Pre-Eclampsia/diagnostic imaging
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnant Women
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Ultrasonography, Doppler
MH  - Ultrasonography, Prenatal
PMC - PMC7574950
OTO - NOTNLM
OT  - *fetal medicine
OT  - *prenatal diagnosis
OT  - *ultrasonography
OT  - *ultrasound
COIS- Competing interests: None declared.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 06:16
PHST- 2020/10/20 06:16 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037751 [pii]
AID - 10.1136/bmjopen-2020-037751 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e037751. doi: 10.1136/bmjopen-2020-037751.


PMID- 33077560
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Group-based intervention to improve developmental status among children age 6-18 
      months in rural Shanxi province, China: a study protocol for a cluster randomised
      controlled trial.
PG  - e037156
LID - 10.1136/bmjopen-2020-037156 [doi]
AB  - INTRODUCTION: Early childhood development (ECD) is a critical component for
      building the foundation of future physical and emotional health and subsequent
      academic success. The quality of the home environment to promote development is
      an important factor in ECD. Since large rural-urban disparities in the home
      environment exist in China, there is a critical need to develop and evaluate
      interventions to promote ECD in rural areas. Individual center-based or
      home-based interventions dominate the current ECD programmes in rural China.
      However, group-based interventions offer potential advantages in terms of both
      effectiveness and cost. Thus, we aim to: (1) evaluate the effectiveness of an
      integrated group-based intervention, the Care Group Intervention, in enhancing
      ECD among children age 6-18 months and (2) conduct a cost-effectiveness analysis.
      METHODS AND ANALYSIS: The Care Group Intervention uses a cluster (by township)
      randomised controlled trial conducted in Fenxi county, Shanxi province, China,
      from July 2019, for 1 year. The intervention focuses on five key components of
      nurturing care including good health, adequate nutrition, responsive caregiving, 
      security and safety, and opportunities for early learning. The intervention
      comprises small groups of 3-10 children within a certain age range and their
      primary caregivers that are led by well-trained local facilitators. Outcomes
      includes infants' developmental quotient (Bayley Scales of Infant Development
      III, Ages & Stages Questionnaire: Social-Emotional, second edition); anaemia
      (HemoCue Hb 301+); nurturing environment (Infant/Toddler Home Observation for
      Measurement of the Environment), parent-child interaction (Teaching Scale) and
      caregiver depression (Center for Epidemiological Studies Depression). Cost data
      are collected throughout the entire study to carry out a cost-effectiveness
      analysis. ETHICS AND DISSEMINATION: This study was approved by the Ethical
      Committee of Capital Institute of Pediatrics, Beijing, China on 10 July 2018
      (SHERLL2018014). Findings and results from this project will be disseminated via 
      publications and presentations. TRIAL REGISTRATION NUMBER: Chinese Clinical
      Trials Registry: ChiCTR1900022894. Registered on 30 April 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Mengxue
AU  - Xu M
AD  - Department of Integrated Early Childhood Development, Capital Institute of
      Pediatrics, Beijing, China.
FAU - Liu, Aihua
AU  - Liu A
AD  - Department of Integrated Early Childhood Development, Capital Institute of
      Pediatrics, Beijing, China.
FAU - Zhao, Chunxia
AU  - Zhao C
AD  - UNICEF China Office, Beijing, China.
FAU - Fang, Hai
AU  - Fang H
AD  - China Center for Health Development Studies, Peking University, Beijing, China.
FAU - Huang, Xiaona
AU  - Huang X
AD  - UNICEF China Office, Beijing, China.
FAU - Berman, Stephen
AU  - Berman S
AD  - Center for Global Health (CGH), Colorado School of Public Health, Aurora,
      Colorado, USA.
FAU - Guan, Hongyan
AU  - Guan H
AUID- ORCID: 0000-0002-8153-1676
AD  - Department of Integrated Early Childhood Development, Capital Institute of
      Pediatrics, Beijing, China cip_ghy@yeah.net.
AD  - Beijing Municipal Key Laboratory of Child Development and Nutriomics, Beijing,
      China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Beijing
MH  - Child
MH  - *Child Development
MH  - Child, Preschool
MH  - China
MH  - Humans
MH  - Infant
MH  - Learning
MH  - Randomized Controlled Trials as Topic
MH  - *Rural Population
PMC - PMC7574939
OTO - NOTNLM
OT  - *community child health
OT  - *health economics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 06:16
PHST- 2020/10/20 06:16 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037156 [pii]
AID - 10.1136/bmjopen-2020-037156 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e037156. doi: 10.1136/bmjopen-2020-037156.


PMID- 33077559
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 19
TI  - Effectiveness of negative pressure wound therapy in the prevention of surgical
      wound complications in the cesarean section at-risk population: a parallel group 
      randomised multicentre trial-the CYGNUS protocol.
PG  - e035727
LID - 10.1136/bmjopen-2019-035727 [doi]
AB  - INTRODUCTION: Caesarean delivery is steadily becoming one of the more common
      surgical procedures in Australia with over 100 000 caesarean sections performed
      each year. Over the last 10 years in Australia, the caesarean section rate has
      increased from 28% in 2003 to 33% in 2013. On the international stage, the
      Australian caesarean delivery rates are higher than the average for the
      Organisation for Economic Co-operation and Development, Australia ranked as 8 out
      of 33 and is second to the USA. Postoperative surgical site infections (SSIs) and
      wound complications are the most common and costly event following a caesarean
      section. Globally, complication rates following a caesarean delivery vary from
      4.9% to 9.8%. Complications such as infection and wound breakdown affect the
      postpartum mother's health and well-being, and contribute to healthcare costs for
      clinical management that often spans the acute, community and primary healthcare 
      settings. Published level one studies using advanced wound dressings in the
      identified 'at-risk' population prior to surgery for prophylactic intervention
      are yet to be forthcoming. METHODS AND ANALYSIS: A parallel group randomised
      control trial of 448 patients will be conducted across two metropolitan hospitals
      in Perth, Western Australia, which provide obstetric and midwifery services. We
      will recruit pregnant women in the last trimester, prior to their admission into 
      the healthcare facility for delivery of their child. We will use a
      computer-generated block sequence to randomise the 448 participants to either the
      interventional (negative pressure wound therapy (NPWT) dressing, n=224) or
      comparator arm (non-NPWT dressing, n=224). The primary outcome measure is the
      occurrence of surgical wound dehiscence (SSWD) or SSI. The Centres for Disease
      Control reporting definition of either superficial or deep infection at 30 days
      will be used as the outcome measure definition. SWD will be classified as per the
      World Union of Wound Healing Societies grading system (grade I-IV). We will
      assess recruitment rate, and adherence to intervention and follow-up. We will
      assess the potential effectiveness of NPWT in the prevention of postpartum
      surgical wound complications at three time points during the study; postoperative
      days 5, 14 and 30, after which the participant will be closed out of the trial.
      We will use statistical methods to determine efficacy, and risk stratification
      will be conducted to determine the SWD risk profile of the participant. Follow-up
      at day 30 will assess superficial and deep infection, and wound dehiscence (grade
      I-IV) and the core outcome data set for wound complications. This study will
      collect health-related quality of life (European Quality of Life 5-Dimensions
      5-Level Scale), mortality and late complications such as further surgery with a
      cost analysis conducted. The primary analysis will be by intention-to-treat. This
      clinical trial protocol follows the Standard Protocol Items: Recommendations for 
      Interventional Trials (SPIRIT) and the Consolidated Standards of Reporting Trials
      guidelines. ETHICS AND DISSEMINATION: Ethics approval was obtained through St
      John of God Health Care (HREC1409), Western Australia Department of Health King
      Edward Memorial Hospital (HREC3111). Study findings will be published in
      peer-reviewed journals and presented at international conferences. We used the
      SPIRIT checklist when writing our study protocol. TRIAL REGISTRATION NUMBER:
      Australian and New Zealand Clinical Trials Registry (ACTRN12618002006224p).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sandy-Hodgetts, Kylie
AU  - Sandy-Hodgetts K
AUID- ORCID: 0000-0001-6848-2526
AD  - Skin Integrity Research Institute, School of Biomedical Sciences, University of
      Western Australia, Crawley, Western Australia, Australia
      kylie.sandy-hodgetts@uwa.edu.au.
FAU - Parsons, Richard
AU  - Parsons R
AD  - School of Occupational Therapy, Social Work and Speech Pathology, Curtin
      University Faculty of Health Sciences, Perth, Western Australia, Australia.
FAU - Norman, Richard
AU  - Norman R
AD  - School of Public Health, Curtin University Faculty of Health Sciences, Perth,
      Western Australia, Australia.
FAU - Fear, Mark W
AU  - Fear MW
AD  - Burn Injury Research Unit, School of Biomedical Sciences, University of Western
      Australia, Crawley, Western Australia, Australia.
FAU - Wood, Fiona M
AU  - Wood FM
AD  - Fiona Stanley and Princess Margaret Hospitals, Burns Service of Western
      Australia, Perth, Western Australia, Australia.
FAU - White, Scott W
AU  - White SW
AD  - Department of Obstetrics and Gynaecology, The University of Western Australia
      Faculty of Health and Medical Sciences, Perth, Western Australia, Australia.
AD  - Maternal Fetal Medicine Service, King Edward Memorial Hospital, Subiaco, Western 
      Australia, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201019
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Cesarean Section/adverse effects
MH  - Child
MH  - Female
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Negative-Pressure Wound Therapy
MH  - New Zealand
MH  - Pregnancy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Surgical Wound/therapy
MH  - Surgical Wound Infection/epidemiology/prevention & control
MH  - Western Australia
PMC - PMC7574944
OTO - NOTNLM
OT  - *clinical trials
OT  - *obstetrics
OT  - *surgery
OT  - *wound management
COIS- Competing interests: None declared.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/20 06:16
PHST- 2020/10/20 06:16 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035727 [pii]
AID - 10.1136/bmjopen-2019-035727 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 19;10(10):e035727. doi: 10.1136/bmjopen-2019-035727.


PMID- 33077510
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 70
IP  - 700
DP  - 2020 Nov
TI  - Supporting GPs around euthanasia requests from people with dementia: a
      qualitative analysis of Dutch nominal group meetings.
PG  - e833-e842
LID - 10.3399/bjgp20X713093 [doi]
AB  - BACKGROUND: Euthanasia has been regulated by law under strict conditions in the
      Netherlands since 2002. Since then the number of euthanasia cases has constantly 
      increased, and increased exponentially for patients with dementia (PWD). The
      number of euthanasia requests by such patients is even higher. Recently, an
      interview study showed that physicians who are confronted with a PWD's euthanasia
      request experience problems with communication, pressure from relatives,
      patients, and society, workload, interpretation of the law, and ethical
      considerations. Moreover, if honoured, the physician and patient may interpret
      the right moment for euthanasia differently. AIM: To identify ways of supporting 
      GPs confronted with a PWD's euthanasia request. DESIGN AND SETTING: Two expert
      nominal group meetings were organised with Dutch care physicians for older
      people, GPs, legal experts, a healthcare chaplain, a palliative care consultant, 
      and a psychologist. METHOD: A total of 15 experts participated in the meetings.
      Both meetings were audio-recorded, transcribed verbatim, and analysed using
      thematic analysis. RESULTS: Four themes emerged from the meetings: support
      provided by healthcare professionals, influencing public opinion, educational
      activities, and managing time and work pressure. The need for support was
      considered highest for GPs for all of these themes. CONCLUSION: Consensus was
      reached with the help of experts on support needs for GPs confronted with
      euthanasia requests from PWD. A concise and clear explanation of the law is
      strongly desired. Changing public opinion seems the most challenging and a
      long-term aim. Communication training for finding the right balance between the
      physician's professional responsibility and the patient's autonomy should be made
      available, as a short-term aim.
CI  - (c)The Authors.
FAU - Schuurmans, Jaap
AU  - Schuurmans J
AD  - Department of Anaesthesiology, Pain and Palliative Medicine.
FAU - Vos, Stephanie
AU  - Vos S
AD  - Radboud University, Nijmegen, the Netherlands.
FAU - Vissers, Pim
AU  - Vissers P
AD  - Radboud University, Nijmegen, the Netherlands.
FAU - Tilburgs, Bram
AU  - Tilburgs B
AD  - Radboud University, Nijmegen, the Netherlands.
FAU - Engels, Yvonne
AU  - Engels Y
AD  - Radboud University, Nijmegen, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
MH  - Aged
MH  - Decision Making
MH  - *Dementia
MH  - *Euthanasia
MH  - Group Processes
MH  - Humans
MH  - Netherlands
MH  - Qualitative Research
PMC - PMC7575404
OTO - NOTNLM
OT  - *dementia
OT  - *euthanasia requests
OT  - *general practitioners
OT  - *health services, primary health care
OT  - *support
EDAT- 2020/10/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/20 06:16
PHST- 2019/09/25 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/10/20 06:16 [entrez]
AID - bjgp20X713093 [pii]
AID - 10.3399/bjgp20X713093 [doi]
PST - epublish
SO  - Br J Gen Pract. 2020 Oct 29;70(700):e833-e842. doi: 10.3399/bjgp20X713093. Print 
      2020 Nov.


PMID- 33077342
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210206
IS  - 1545-7214 (Electronic)
IS  - 1064-7481 (Linking)
VI  - 28
IP  - 12
DP  - 2020 Dec
TI  - Ethical Issues in the Management of Patients With Behavioral and Psychological
      Symptoms of Dementia During COVID-19 Containment: Examples From Institutions in
      France.
PG  - 1332-1333
LID - S1064-7481(20)30509-1 [pii]
LID - 10.1016/j.jagp.2020.10.001 [doi]
FAU - Nkodo, Jacques-Alexis
AU  - Nkodo JA
AD  - Division of Geriatric Medicine, CHRU de Tours, Tours, France; Clinique
      Psychiatrique Universitaire, CHRU de Tours, Tours, France. Electronic address:
      j.nkodo@chu-tours.fr.
FAU - Camus, Vincent
AU  - Camus V
AD  - Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; INSERM U1253 
      & Universite de Tours, Tours, France.
FAU - Fougere, Bertrand
AU  - Fougere B
AD  - Division of Geriatric Medicine, CHRU de Tours, Tours, France; Education, Ethics, 
      Health (EA 7505), Universite de Tours, Tours, France.
LA  - eng
PT  - Letter
DEP - 20201006
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American
      Association for Geriatric Psychiatry
JID - 9309609
SB  - IM
MH  - Aged
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/prevention & control/psychology
MH  - *Dementia/epidemiology/psychology
MH  - France/epidemiology
MH  - Humans
MH  - Infection Control/organization & administration
MH  - Needs Assessment
MH  - Organizational Innovation
MH  - *Pandemics/ethics/prevention & control
MH  - *Patient Care Management/ethics/organization & administration/trends
MH  - *Pneumonia, Viral/epidemiology/prevention & control/psychology
MH  - *Problem Behavior
MH  - Public Health
MH  - SARS-CoV-2
PMC - PMC7537620
EDAT- 2020/10/21 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/10/20 05:45
PHST- 2020/07/30 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/10/20 05:45 [entrez]
AID - S1064-7481(20)30509-1 [pii]
AID - 10.1016/j.jagp.2020.10.001 [doi]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2020 Dec;28(12):1332-1333. doi:
      10.1016/j.jagp.2020.10.001. Epub 2020 Oct 6.


PMID- 33076972
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Oct 19
TI  - Environmental assessment of cytotoxic drugs in healthcare settings: protocol for 
      a systematic review and meta-analysis.
PG  - 242
LID - 10.1186/s13643-020-01494-4 [doi]
AB  - BACKGROUND: Occupational exposure to cytotoxic drugs is associated with various
      unfavorable health outcomes. This protocol reports a methodology for a systematic
      review and meta-analysis that aims to systematically review the published
      literature and quantify the level of environmental contamination of healthcare
      settings with cytotoxic drugs. METHODS: This protocol is developed in accordance 
      with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      Protocol-2015 (PRISMA-P) guidelines. Six electronic databases (PubMed, Web of
      Science, Scopus, Cochrane Library, CINAHL, and EMBASE) will be searched with no
      restrictions on publication period. Eligible studies will be identified and data 
      will be extracted using a predefined data extraction form by at least two
      independent reviewers following best practice. Eligible studies should report
      calculated or calculable estimates on the proportion of positive samples tested
      for cytotoxic drugs and/or estimates on the concentration of the cytotoxic
      drug(s) in the tested samples. Risk of bias (RoB) will be assessed by using the
      RoB in Studies estimating Prevalence of Exposure to Occupational risk factors
      (RoB-SPEO) tool, which developed by the World Health Organization (WHO) and
      International Labour Organization (ILO) for environmental and occupational health
      systematic reviews. The random-effects model will be used to perform
      meta-analyses. DISCUSSION: Occupational exposure to cytotoxic drugs is associated
      with short- and long-term adverse health outcomes. Following this protocol, the
      review to be carried out will be the first to fill an evidence gap on the
      environmental contamination of healthcare settings with cytotoxic drugs. The
      findings of this review will help in the understanding of the risk of
      occupational exposure of healthcare workers to cytotoxic drugs and facilitate the
      identification of priority areas for specific interventions. ETHICS AND
      DISSEMINATION: The systematic review methodology does not require ethics approval
      due to the nature of the study design. The results of the systematic review will 
      be published in a peer-reviewed journal and will be publicly available.
      SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020162780 , dated July 14, 2020.
FAU - Al Alawi, Laila
AU  - Al Alawi L
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
FAU - Soteriades, Elpidoforos S
AU  - Soteriades ES
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
AD  - Department of Environmental Health, Environmental and Occupational Medicine and
      Epidemiology (EOME), Harvard School of Public Health, Boston, MA, USA.
FAU - Paulo, Marilia Silva
AU  - Paulo MS
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
AD  - Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical,
      Universidade Nova de Lisboa, Lisbon, Portugal.
FAU - Ostlundh, Linda
AU  - Ostlundh L
AD  - National Medical Library, College of Medicine and Health Sciences, United Arab
      Emirates University, Al Ain, United Arab Emirates.
FAU - Grivna, Michal
AU  - Grivna M
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
FAU - Al Maskari, Fatima
AU  - Al Maskari F
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
AD  - Zayed Center for Health Sciences, United Arab Emirates University, Al Ain, United
      Arab Emirates.
FAU - Al-Rifai, Rami H
AU  - Al-Rifai RH
AUID- ORCID: 0000-0001-6102-0353
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates.
      rrifai@uaeu.ac.ae.
AD  - Zayed Center for Health Sciences, United Arab Emirates University, Al Ain, United
      Arab Emirates. rrifai@uaeu.ac.ae.
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Cost of Illness
MH  - Delivery of Health Care
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Occupational Diseases
MH  - *Occupational Exposure/analysis
MH  - *Pharmaceutical Preparations
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7574301
OTO - NOTNLM
OT  - *Cytotoxic drugs
OT  - *Environmental assessment
OT  - *Meta-analysis
OT  - *Systematic review
EDAT- 2020/10/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/20 05:40
PHST- 2020/05/14 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/20 05:40 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01494-4 [doi]
AID - 10.1186/s13643-020-01494-4 [pii]
PST - epublish
SO  - Syst Rev. 2020 Oct 19;9(1):242. doi: 10.1186/s13643-020-01494-4.


PMID- 33076209
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 747
DP  - 2020 Dec 10
TI  - Development and application of species-specific cell-based bioassays to assess
      toxicity in green sea turtles.
PG  - 142095
LID - S0048-9697(20)35624-2 [pii]
LID - 10.1016/j.scitotenv.2020.142095 [doi]
AB  - Despite the detection of a wide range of contaminants in the blood of green
      turtle populations foraging in three locations of northern Queensland - Upstart
      Bay, Cleveland Bay and the Howick Group of Reefs, little is known about the
      effects of these contaminants on turtle health. Newly developed cell-based
      bioassays using green turtle primary cell cultures provide an ethical,
      reproducible, and high-throughput method for assessing the risk of chemical
      exposure sea turtles. In this project, the toxicity of six priority metals (Mn,
      Co, Mo, As, Sb, Cu) and blood extracts from foraging turtles were tested in two
      bioassays adapted to green turtle primary skin and liver cells. Cytotoxicity of
      metals and blood extracts was measured in primary skin fibroblast cells using a
      resazurin assay. Glutathione-S-transferase (GST) activity was measured in primary
      skin fibroblasts and primary liver epithelial cells following exposure to metals 
      and blood extracts. Arsenic, molybdenum, cobalt and copper were found to be
      cytotoxic to green turtle skin cells. Only manganese, cobalt and copper were
      found to alter GST activity, predominantly in skin cells, indicating a higher
      sensitivity of green turtle skin cells compared to liver cells. Effect
      concentrations of metals in both bioassays were above concentrations found in
      turtle blood. Turtle blood extracts from the three foraging grounds showed
      differences in cytotoxicity and GST activity. In both assays, blood extracts of
      turtles from Upstart Bay were the most toxic, followed by those from Cleveland
      Bay, then the Howick Reefs, suggesting turtles from Upstart Bay and Cleveland Bay
      may be at risk from current concentrations of organic contaminants. This study
      demonstrates that species-specific cell-based bioassays can be used effectively
      to assess chemical risk in sea turtles and their foraging grounds, and could be
      applied to assess chemical risk in other marine wildlife.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Finlayson, Kimberly A
AU  - Finlayson KA
AD  - Australian Rivers Institute, Griffith University, Australia. Electronic address: 
      kimberly.finlayson@griffithuni.edu.au.
FAU - Madden Hof, Christine A
AU  - Madden Hof CA
AD  - World Wildlife Fund for Nature, Australia.
FAU - van de Merwe, Jason P
AU  - van de Merwe JP
AD  - Australian Rivers Institute, Griffith University, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - Animals
MH  - Biological Assay
MH  - Primary Cell Culture
MH  - Queensland
MH  - *Turtles
MH  - *Water Pollutants, Chemical/analysis/toxicity
OTO - NOTNLM
OT  - Exposure
OT  - Metals
OT  - Organics
OT  - QuEChERS
OT  - Sea turtle
OT  - in vitro bioassay
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/10/21 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/10/20 01:02
PHST- 2020/06/08 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/08/29 00:00 [accepted]
PHST- 2020/10/20 01:02 [entrez]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - S0048-9697(20)35624-2 [pii]
AID - 10.1016/j.scitotenv.2020.142095 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Dec 10;747:142095. doi: 10.1016/j.scitotenv.2020.142095. 
      Epub 2020 Sep 1.


PMID- 33074630
STAT- Publisher
DA  - 20201020
ISBN- 9780309677707
ISBN- 030967770X
PB  - National Academies Press (US)
CTI - The National Academies Collection: Reports funded by National Institutes of
      Health
DP  - 2020 Sep 2
BTI - Roundtable on Data Science Postsecondary Education: A Compilation of Meeting
      Highlights
LID - 10.17226/25804 [doi]
AB  - Established in December 2016, the National Academies of Sciences, Engineering,
      and Medicine's Roundtable on Data Science Postsecondary Education was charged
      with identifying the challenges of and highlighting best practices in
      postsecondary data science education. Convening quarterly for 3 years,
      representatives from academia, industry, and government gathered with other
      experts from across the nation to discuss various topics under this charge. The
      meetings centered on four central themes: foundations of data science; data
      science across the postsecondary curriculum; data science across society; and
      ethics and data science. This publication highlights the presentations and
      discussions of each meeting.
CI  - Copyright 2020 by the National Academy of Sciences. All rights reserved.
CN  - National Academies of Sciences, Engineering, and Medicine; Division of Behavioral
      and Social Sciences and Education; Division on Engineering and Physical Sciences;
      Board on Science Education; Computer Science and Telecommunications Board;
      Committee on Applied and Theoretical Statistics; Board on Mathematical Sciences
      and Analytics
FED - Casola, Linda
ED  - Casola L
LA  - eng
GR  - HHSN263201200074I/NIH HHS/United States
PT  - Review
PT  - Book
PL  - Washington (DC)
EDAT- 2020/10/20 06:01
MHDA- 2020/10/20 06:01
CDAT- 2020/10/20 06:01
AID - NBK562965 [bookaccession]
AID - 10.17226/25804 [doi]


PMID- 33075122
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20220531
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 120
IP  - 12
DP  - 2020 Dec 1
TI  - An Evaluation of Reporting Guidelines and Clinical Trial Registry Requirements
      Among Addiction Medicine Journals.
PG  - 823-830
LID - 10.7556/jaoa.2020.148 [doi]
AB  - CONTEXT: Robust methodology and ethical reporting are paramount for quality
      scientific research, but recently, that quality in addiction research has been
      questioned. Avenues to improve such research quality include adherence to
      reporting guidelines and proper usage of clinical trial registries. Reporting
      guidelines and clinical trial registries have been shown to lead researchers to
      more ethical and transparent methodology. OBJECTIVES: To investigate the
      reporting guideline and clinical trial registration policies of addiction
      research journals and identify areas of improvement. METHODS: We used Google
      Scholar Metrics' h-5 index to identify the top 20 addiction research journals. We
      then examined the instructions for authors from each journal to identify whether 
      they required, recommended, or made no mention of trial registration and
      reporting guidelines, including the Consolidated Standards of Reporting Trials
      (CONSORT), Meta-Analysis of Observational Studies in Epidemiology (MOOSE),
      Quality of Reporting of Meta-analyses (QUOROM), Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses (PRISMA), Standards for Reporting Diagnostic
      Accuracy Studies (STARD), Strengthening the Reporting of Observational Studies in
      Epidemiology (STROBE), Animal Research: Reporting of In Vivo Experiments
      (ARRIVE), Case Reports (CARE), Consolidated Health Economic Evaluation Reporting 
      Standards (CHEERS), Standards for Reporting Qualitative Research (SRQR),
      Standards for Quality Improvement Reporting Excellence (SQUIRE), Standard
      Protocol Items: Recommendations for Interventional Trials (SPIRIT), Consolidated 
      Criteria for Reporting Qualitative Research (COREQ), Transparent Reporting of a
      Multivariate Prediction Model for Individual Prognosis or Diagnosis (TRIPOD),
      Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
      (PRISMA-P), and the International Committee of Medical Journal Editors (ICMJE)
      guidelines. We performed the same analysis regarding requirements for clinical
      trial registration. RESULTS: Of the 20 journals included in this study, 10
      journals (50%) did not require adherence to any reporting guidelines. Trial
      registration followed a similar trend; 15 journals (75%) did not mention any form
      of trial or systematic review registration, and ClinicalTrials.gov was only
      recommended by only 1 journal (5%). CONCLUSIONS: Among top addiction medicine
      journals, required adherence to reporting guidelines and clinical trial registry 
      policies remains substandard. A step toward fulfilling the National Institute on 
      Drug Abuses' call for improvement in transparency and reproducibility within
      addiction research should include all journals adopting a strict reporting
      guideline and clinical trial registry adherence policy.
FAU - Cooper, Craig M
AU  - Cooper CM
FAU - Gray, Harrison
AU  - Gray H
FAU - Barcenas, Leslie
AU  - Barcenas L
FAU - Torgerson, Trevor
AU  - Torgerson T
FAU - Checketts, Jake X
AU  - Checketts JX
FAU - Vassar, Matt
AU  - Vassar M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
SB  - IM
MH  - *Addiction Medicine
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Editorial Policies
MH  - Guideline Adherence
MH  - Guidelines as Topic
MH  - *Periodicals as Topic
MH  - Registries
MH  - Reproducibility of Results
EDAT- 2020/10/20 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/10/19 17:12
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/10/19 17:12 [entrez]
AID - 2765295 [pii]
AID - 10.7556/jaoa.2020.148 [doi]
PST - ppublish
SO  - J Am Osteopath Assoc. 2020 Dec 1;120(12):823-830. doi: 10.7556/jaoa.2020.148.


PMID- 33075059
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 10
DP  - 2020
TI  - The inclusion of blastomeres into the inner cell mass in early-stage human
      embryos depends on the sequence of cell cleavages during the fourth division.
PG  - e0240936
LID - 10.1371/journal.pone.0240936 [doi]
AB  - The fate of the ICM in humans is still unknown, due to the ethical difficulties
      surrounding experimentation in this field. In this study we have explored the
      existing time-lapse recording data of embryos in the early stages of development,
      taking advantage of the large refractile bodies (RBs) within blastomeres as
      cellular markers. Our study found that the cellular composition of the ICM in
      humans is largely determined at the time of the fourth division and blastomeres
      which cleave first to fourth, during the fourth division from 8 cells to 16
      cells, have the potential to be incorporated in the ICM.
FAU - Otsuki, Junko
AU  - Otsuki J
AUID- ORCID: 0000-0002-8183-8651
AD  - Assisted Reproductive Technology Center, Okayama University, Okayama, Japan.
AD  - Hanabusa Women's Clinic, Kobe, Hyogo, Japan.
FAU - Iwasaki, Toshiroh
AU  - Iwasaki T
AD  - Hanabusa Women's Clinic, Kobe, Hyogo, Japan.
FAU - Enatsu, Noritoshi
AU  - Enatsu N
AD  - Hanabusa Women's Clinic, Kobe, Hyogo, Japan.
FAU - Katada, Yuya
AU  - Katada Y
AD  - Hanabusa Women's Clinic, Kobe, Hyogo, Japan.
FAU - Furuhashi, Kohyu
AU  - Furuhashi K
AD  - Hanabusa Women's Clinic, Kobe, Hyogo, Japan.
FAU - Shiotani, Masahide
AU  - Shiotani M
AD  - Hanabusa Women's Clinic, Kobe, Hyogo, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201019
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Blastocyst Inner Cell Mass/*physiology
MH  - Blastomeres/*physiology
MH  - Cell Division
MH  - Embryonic Development
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Reproductive Techniques, Assisted
MH  - Retrospective Studies
MH  - Time-Lapse Imaging/*methods
MH  - Video Recording
PMC - PMC7571684
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/19 17:12
PHST- 2020/05/13 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/19 17:12 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1371/journal.pone.0240936 [doi]
AID - PONE-D-20-14274 [pii]
PST - epublish
SO  - PLoS One. 2020 Oct 19;15(10):e0240936. doi: 10.1371/journal.pone.0240936.
      eCollection 2020.


PMID- 33074890
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210125
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 6
DP  - 2020 Dec
TI  - Ethics of Codes and Codes of Ethics: When Is It Ethical to Provide
      Cardiopulmonary Resuscitation During the COVID-19 Pandemic?
PG  - 930-934
LID - 10.1097/SLA.0000000000004318 [doi]
AB  - OBJECTIVE: Our study aims to provide a paradigm when it is ethical to perform
      cardiopulmonary resuscitation (CPR) on patients during the COVID-19 pandemic.
      SUMMARY BACKGROUND DATA: Hospitals around the nation are enacting systems to
      limit CPR in caring for COVID+ patients for a variety of legitimate reasons and
      based on concepts of medical futility and allocation of scarce resources. No
      ethical framework, however, has been proposed as a standard to guide care in this
      crucial matter. METHODS: Our analysis begins with definitions of ethically
      relevant terms. We then cycle an illustrative clinical vignette through the
      mathematically permissible possibilities to account for all conceivable
      scenarios. Scenarios with ethical tension are examined. RESULTS: Patients have
      the negative right to refuse care including CPR, but they do not have the
      positive right to demand it. Our detailed ethical analysis and recommendations
      support CPR if and only if 1) CPR is judged medically beneficial, and in line
      with the patient's and values and goals, 2) allocations or scarce resources
      follow a just and transparent triage system, and 3) providers are protected from 
      contracting the disease. CONCLUSIONS: CPR is an intervention like any other, with
      attendant risks and benefits and with responsibility for the utilization of
      limited resources. Our ethical analysis advocates for a systematic approach to
      codes that respects the important ethical considerations in caring for the
      critically ill and facilitates patient-centered, evidence-based, and fair
      treatment to all.
FAU - Kopar, Piroska K
AU  - Kopar PK
AD  - Department of Surgery, Washington University in St. Louis School of Medicine,
      Saint Louis, MO.
FAU - Brown, Douglas E
AU  - Brown DE
FAU - Turnbull, Isaiah R
AU  - Turnbull IR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
MH  - *Bioethical Issues
MH  - COVID-19/*therapy
MH  - Cardiopulmonary Resuscitation/*ethics
MH  - Codes of Ethics
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - *SARS-CoV-2
MH  - Terminology as Topic
PMC - PMC7668330
EDAT- 2020/10/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/19 17:11
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/19 17:11 [entrez]
AID - 10.1097/SLA.0000000000004318 [doi]
AID - 00000658-202012000-00013 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Dec;272(6):930-934. doi: 10.1097/SLA.0000000000004318.


PMID- 33074352
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 2509-8020 (Electronic)
IS  - 2509-8020 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Oct 19
TI  - Development and evaluation of the Singapore Caregiver Quality of Life Scale -
      Dementia.
PG  - 84
LID - 10.1186/s41687-020-00252-3 [doi]
AB  - PURPOSE: To develop and evaluate a measurement scale for multi-domain assessment 
      of the quality of life of family caregivers of persons with dementia (PWD) in
      Singapore, a multi-ethic society in South-East Asia where English is the lingua
      franca. METHODS: Items from the Singapore Caregiver Quality of Life Scale
      (SCQOLS), which was originally developed in the context of advanced cancers, were
      adopted as candidate items. Furthermore, a multi-disciplinary panel reviewed
      dementia-specific caregiver quality of life scales to identified items not
      covered in SCQOLS for inclusion as candidate items. A pilot study of 31 family
      caregivers of PWD was conducted to solicit inputs on candidate items; 102 family 
      caregivers of PWD were surveyed for evaluation of the scale's measurement
      properties. RESULTS: Factor analysis confirmed a 5-domain structure of the 63
      candidate items. The Root Mean Square Error of Approximation was 0.056 and
      Comparative Fit Index was 0.928. Convergent validity of the total and domain
      scores was demonstrated in terms of correlation with the Brief Assessment Scale
      for Caregivers and its sub-scales. The scores also showed an expected pattern of 
      correlation with hours spent on caregiving per week. Known-group validity was
      demonstrated by differences in mean scores between functional staging groups.
      Cronbach's alpha of the total and domain scores ranged from 0.89 to 0.95.
      Test-retest reliability (intraclass correlation coefficient) ranged from 0.77 to 
      0.92. CONCLUSIONS: The Singapore Caregiver Quality of Life Scale - Dementia
      (SCQOLS-D) is a quality of life measurement scale for family caregivers of
      persons with dementia that is valid and reliable.
FAU - Cheung, Yin Bun
AU  - Cheung YB
AUID- ORCID: http://orcid.org/0000-0003-0517-7625
AD  - Program in Health Services & Systems Research and Centre for Quantitative
      Medicine, Duke-NUS Medical School, Level 6, Academia, 20 College Road, Singapore,
      169856, Singapore. yinbun.cheung@duke-nus.edu.sg.
AD  - Centre for Child Health Research, Tampere University, Tampere, Finland.
      yinbun.cheung@duke-nus.edu.sg.
FAU - Teo, Irene
AU  - Teo I
AD  - Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Center, Singapore,
      Singapore.
FAU - Lim, Wee Shiong
AU  - Lim WS
AD  - Department of Geriatric Medicine, Institute of Geriatrics and Active Aging, Tan
      Tock Seng Hospital, Singapore, Singapore.
FAU - Hum, Allyn
AU  - Hum A
AD  - Department of Geriatric Medicine, Institute of Geriatrics and Active Aging, Tan
      Tock Seng Hospital, Singapore, Singapore.
AD  - Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore.
FAU - Neo, Shirlyn H S
AU  - Neo SHS
AD  - Division of Supportive and Palliative Care, National Cancer Center, Singapore,
      Singapore.
FAU - Yang, Grace M
AU  - Yang GM
AD  - Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Center, Singapore,
      Singapore.
FAU - Lee, Geok Ling
AU  - Lee GL
AD  - Department of Social Work, Faculty of Arts and Social Sciences, National
      University of Singapore, Singapore, Singapore.
FAU - Tan, Gretchen
AU  - Tan G
AD  - Program in Health Services & Systems Research and Centre for Quantitative
      Medicine, Duke-NUS Medical School, Level 6, Academia, 20 College Road, Singapore,
      169856, Singapore.
FAU - Seow, Dennis C C
AU  - Seow DCC
AD  - Department of Geriatric Medicine, Singapore General Hospital, Singapore,
      Singapore.
LA  - eng
GR  - LCPC-IN18-0001/Lien Center for Palliative Care
GR  - Salary support/Lien Center for Palliative Care
PT  - Journal Article
DEP - 20201019
PL  - Germany
TA  - J Patient Rep Outcomes
JT  - Journal of patient-reported outcomes
JID - 101722688
PMC - PMC7572987
OTO - NOTNLM
OT  - Caregivers
OT  - Dementia
OT  - Measurement scale
OT  - Quality of life
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 12:23
PHST- 2020/07/08 00:00 [received]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/10/19 12:23 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.1186/s41687-020-00252-3 [doi]
AID - 10.1186/s41687-020-00252-3 [pii]
PST - epublish
SO  - J Patient Rep Outcomes. 2020 Oct 19;4(1):84. doi: 10.1186/s41687-020-00252-3.


PMID- 33073737
OWN - NLM
STAT- MEDLINE
DCOM- 20210309
LR  - 20220330
IS  - 1654-9880 (Electronic)
IS  - 1654-9880 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Dec 31
TI  - Implementation of accelerated research: strategies for implementation as applied 
      in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in
      Uganda.
PG  - 1829829
LID - 10.1080/16549716.2020.1829829 [doi]
AB  - BACKGROUND: The 2013-2016 Ebola epidemic in West Africa is the worst ever caused 
      by Ebolaviruses with over 28,000 human cases and 11,325 deaths. The World Health 
      Organisation (WHO) declared the epidemic a public health crisis that required
      accelerated development of novel interventions including vaccines. The Medical
      Research Council/Uganda Virus Research Institute and London School of Hygiene and
      Tropical Medicine Uganda Research Unit (MRC/UVRI & LSHTM Uganda Research Unit)
      was among the African research sites that implemented the VAC52150EBL1004 Ebola
      vaccine trial. OBJECTIVE: We report on the strategies utilised by the Unit and
      sponsor in ensuring expedited clinical trial approval and accelerated conduct.
      METHODS: Janssen Vaccines and Prevention B.V. conducted a phase 1 trial to
      evaluate the safety, tolerability, and immunogenicity of heterologous two-dose
      vaccination regimens using Ad26.ZEBOV and MVA-BN-Filo, in healthy adults in
      Africa. Accelerated implementation strategies are hereby presented. RESULTS:
      Strategies included: holding the African Vaccine Regulatory Forum (AVAREF) joint 
      review meeting; expedited review by institutional ethics and country-specific
      regulatory bodies; competitive recruitment between sites; electronic data capture
      (EDC); frequent study monitoring schedule; involvement of a community advisory
      board (CAB); and utilization of a 'phased' study information-sharing approach in 
      community engagement and participant recruitment. These strategies enabled the
      site to acquire approvals within 2 months and enrol 47 participants within a
      spurn of five. The same milestone is usually acquired in at least 1 year without 
      accelerated implementation. CONCLUSION: The use of well-thought strategies by
      sponsors and research sites can enable the implementation of accelerated
      research. We recommend the use of similar strategies in other settings.
FAU - Kitonsa, Jonathan
AU  - Kitonsa J
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Ggayi, Abu-Baker
AU  - Ggayi AB
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Anywaine, Zacchaeus
AU  - Anywaine Z
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Kisaakye, Eva
AU  - Kisaakye E
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Nsangi, Laura
AU  - Nsangi L
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Basajja, Vincent
AU  - Basajja V
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Nyantaro, Mary
AU  - Nyantaro M
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
FAU - Watson-Jones, Deborah
AU  - Watson-Jones D
AD  - London School of Hygiene and Tropical Medicine , London, UK.
FAU - Shukarev, Georgi
AU  - Shukarev G
AD  - Janssen Vaccines and Prevention B.V., Clinical Development , Leiden, The
      Netherlands.
FAU - Ilsbroux, Ine
AU  - Ilsbroux I
AD  - Janssen Research & Development, Portfolio Delivery Operations, Global Development
      , Beerse, Belgium.
FAU - Robinson, Cynthia
AU  - Robinson C
AD  - Janssen Vaccines and Prevention B.V., Clinical Development , Leiden, The
      Netherlands.
FAU - Kaleebu, Pontiano
AU  - Kaleebu P
AD  - Medical Research Council, Uganda Virus Research Institute and London School of
      Hygiene and Tropical Medicine Uganda Research Unit , Entebbe, Uganda.
LA  - eng
GR  - MC_UU_00027/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Glob Health Action
JT  - Global health action
JID - 101496665
RN  - 0 (Ebola Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Africa, Western
MH  - Ebola Vaccines/*administration & dosage/*immunology
MH  - Ebolavirus
MH  - Epidemics
MH  - Female
MH  - Hemorrhagic Fever, Ebola/*epidemiology/*prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Research Design
MH  - Single-Blind Method
MH  - Uganda
MH  - Young Adult
PMC - PMC7594841
OTO - NOTNLM
OT  - *Ebola virus disease
OT  - *accelerated conduct
OT  - *expedited approval
OT  - *vaccine research
EDAT- 2020/10/20 06:00
MHDA- 2021/03/10 06:00
CRDT- 2020/10/19 08:40
PHST- 2020/10/19 08:40 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/03/10 06:00 [medline]
AID - 10.1080/16549716.2020.1829829 [doi]
PST - ppublish
SO  - Glob Health Action. 2020 Dec 31;13(1):1829829. doi:
      10.1080/16549716.2020.1829829.


PMID- 33073273
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1364-548X (Electronic)
IS  - 1359-7345 (Linking)
VI  - 56
IP  - 88
DP  - 2020 Nov 14
TI  - Reactivity prediction in aza-Michael additions without transition state
      calculations: the Ames test for mutagenicity.
PG  - 13661-13664
LID - 10.1039/d0cc05681b [doi]
AB  - Animal testing remains a contentious ethical issue in predictive toxicology.
      Thus, a fast, versatile, low-cost quantum chemical model is presented for
      predicting the risk of Ames mutagenicity in a series of 1,4 Michael acceptor type
      compounds. This framework eliminates the need for transition state calculations, 
      and uses an intermediate structure to probe the reactivity of aza-Michael
      acceptors. This model can be used in a variety of settings e.g., the design of
      targeted covalent inhibitors and polyketide biosyntheses.
FAU - Townsend, Piers A
AU  - Townsend PA
AD  - Centre for Sustainable Chemical Technologies, University of Bath, Claverton Down,
      Bath, BA2 7AY, UK.
FAU - Grayson, Matthew N
AU  - Grayson MN
LA  - eng
PT  - Journal Article
DEP - 20201019
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Mutagens)
SB  - IM
MH  - Anti-Bacterial Agents/*chemistry/pharmacology
MH  - Density Functional Theory
MH  - *Models, Chemical
MH  - Molecular Structure
MH  - Mutagens/*chemistry/pharmacology
MH  - Quantitative Structure-Activity Relationship
MH  - Salmonella typhimurium/drug effects
EDAT- 2020/10/20 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/10/19 06:01
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/10/19 06:01 [entrez]
AID - 10.1039/d0cc05681b [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2020 Nov 14;56(88):13661-13664. doi: 10.1039/d0cc05681b. Epub
      2020 Oct 19.


PMID- 33073256
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2666-3899 (Electronic)
IS  - 2666-3899 (Linking)
VI  - 1
IP  - 7
DP  - 2020 Oct 9
TI  - High Tech, High Risk: Tech Ethics Lessons for the COVID-19 Pandemic Response.
PG  - 100102
LID - 10.1016/j.patter.2020.100102 [doi]
AB  - The COVID-19 pandemic has, in a matter of a few short months, drastically
      reshaped society around the world. Because of the growing perception of machine
      learning as a technology capable of addressing large problems at scale, machine
      learning applications have been seen as desirable interventions in mitigating the
      risks of the pandemic disease. However, machine learning, like many tools of
      technocratic governance, is deeply implicated in the social production and
      distribution of risk and the role of machine learning in the production of risk
      must be considered as engineers and other technologists develop tools for the
      current crisis. This paper describes the coupling of machine learning and the
      social production of risk, generally, and in pandemic responses specifically. It 
      goes on to describe the role of risk management in the effort to institutionalize
      ethics in the technology industry and how such efforts can benefit from a deeper 
      understanding of the social production of risk through machine learning.
CI  - (c) 2020 The Authors.
FAU - Moss, Emanuel
AU  - Moss E
AD  - Data & Society Research Institute, New York, NY 10010, USA.
AD  - CUNY Graduate Center, New York, NY 10016, USA.
FAU - Metcalf, Jacob
AU  - Metcalf J
AD  - Data & Society Research Institute, New York, NY 10010, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Patterns (N Y)
JT  - Patterns (New York, N.Y.)
JID - 101767765
PMC - PMC7546204
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 06:01
PHST- 2020/10/19 06:01 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.1016/j.patter.2020.100102 [doi]
AID - S2666-3899(20)30136-7 [pii]
PST - ppublish
SO  - Patterns (N Y). 2020 Oct 9;1(7):100102. doi: 10.1016/j.patter.2020.100102.


PMID- 33073032
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210728
IS  - 2409-515X (Electronic)
IS  - 2409-515X (Linking)
VI  - 6
IP  - 2
DP  - 2020 Jun
TI  - Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot
      Screening for Cystic Fibrosis.
PG  - 40
LID - 10.3390/ijns6020040 [doi]
LID - 40 [pii]
AB  - Newborn bloodspot screening for cystic fibrosis is a valid public health strategy
      for populations with a high incidence of this inherited condition. There are a
      wide variety of approaches to screening and in this paper, we propose that a
      bioethical framework is required to determine the most appropriate screening
      protocol for a population. This framework depends on the detailed evaluation of
      the ethical consequences of all screening outcomes and placing these in the
      context of the genetic profile of the population screened, the geography of the
      region and the healthcare resources available.
CI  - (c) 2020 by the authors.
FAU - Armstrong, Rachael E
AU  - Armstrong RE
AD  - Department of Women's and Children's Health, University of Liverpool, Liverpool
      L12 2AP, UK; r.armstrong3@doctors.org.uk.
FAU - Frith, Lucy
AU  - Frith L
AD  - Institute of Population Health, University of Liverpool, Liverpool L69 3GL, UK;
      frith@liverpool.ac.uk.
FAU - Ulph, Fiona M
AU  - Ulph FM
AUID- ORCID: 0000-0003-3590-6542
AD  - Division of Psychology & Mental Health, School of Health Sciences, Faculty of
      Biology, Medicine and Health, University of Manchester, Manchester Academic
      Health Science Centre, Manchester M13 9PL, UK; Fiona.Ulph@manchester.ac.uk.
FAU - Southern, Kevin W
AU  - Southern KW
AD  - Department of Women's and Children's Health, University of Liverpool, Liverpool
      L12 2AP, UK; r.armstrong3@doctors.org.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200526
PL  - Switzerland
TA  - Int J Neonatal Screen
JT  - International journal of neonatal screening
JID - 101665400
PMC - PMC7422997
OTO - NOTNLM
OT  - *bioethics
OT  - *cystic fibrosis
OT  - *cystic fibrosis screen positive
OT  - *inconclusive diagnosis (CFSPID)
OT  - *newborn bloodspot screening
COIS- Conflicts of InterestThe authors declare no conflict of interest.
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/10/19 06:00 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.3390/ijns6020040 [doi]
AID - ijns6020040 [pii]
PST - epublish
SO  - Int J Neonatal Screen. 2020 May 26;6(2):40. doi: 10.3390/ijns6020040. eCollection
      2020 Jun.


PMID- 33072818
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201120
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 5
DP  - 2020 Nov
TI  - Changes from COVID-19. A perspective from internal pediatric medicine.
PG  - 343.e1-343.e8
LID - 10.1016/j.anpede.2020.06.003 [doi]
AB  - The SARS-CoV2 pandemic dimension has affected the Hospital Pediatrics Medicine
      assistance in our country. New challenges generated by COVID-19 require a series 
      of proactive measures, based on existing scientific knowledge and standards of
      good practice, that allow the Pediatric Hospital services readiness and
      operability. Hospital Internal Pediatrics, as responsible of integral care of the
      hospitalized child, plays a leading role in the new hospital model emerging from 
      this crisis. This review analyzes the impact of the current SARS-CoV2 epidemic on
      pediatric care, and perspective of new COVID-19 outbreaks in coexistence with
      other viral infections. Changes secondary to pandemic involved in Hospital
      pediatric units must be analyzed, and how to prepare for future epidemics, also
      the involvement of pediatric units in adult care and the possible opportunities
      for improvement. Assistance of patients with chronic complex conditions in
      epidemic circumstances, safety aspects, opportunities for teaching and ethical
      considerations are reviewed. The Spanish Society of Hospital Pediatrics Medicine 
      offers with this article a series of resources for Internal pediatric Medicine
      practitioners responsible to face next challenges in pediatric hospitalization
      units.
CI  - (c) 2020 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L.U.
FAU - Alcala Minagorre, Pedro J
AU  - Alcala Minagorre PJ
AD  - Unidad de Hospitalizacion Pediatrica, Hospital General Universitario de Alicante,
      Alicante, Spain.
FAU - Villalobos Pinto, Enrique
AU  - Villalobos Pinto E
AD  - Servicio de Pediatria, Hospital Nino Jesus, Madrid, Spain.
FAU - Ramos Fernandez, Jose Miguel
AU  - Ramos Fernandez JM
AD  - Servicio de Pediatria, Hospital Regional Universitario Materno-Infantil de
      Malaga, Malaga, Spain.
FAU - Rodriguez-Fernandez, Rosa
AU  - Rodriguez-Fernandez R
AD  - Seccion de Pediatria Hospitalaria, Hospital Gregorio Maranon, Madrid, Spain.
FAU - Vazquez Ronco, Miguel
AU  - Vazquez Ronco M
AD  - Seccion Pediatria Hospitalaria, Hospital Universitario Cruces, Barakaldo,
      Bizkaia, Spain.
FAU - Escosa-Garcia, Luis
AU  - Escosa-Garcia L
AD  - Servicio de Pediatria Hospitalaria, Enfermedades Infecciosas y Tropicales,
      Hospital Universitario La Paz, Madrid, Spain.
FAU - Montiano Jorge, Juan Ignacio
AU  - Montiano Jorge JI
AD  - Servicio de Pediatria, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
FAU - Garcia Garcia, Juan Jose
AU  - Garcia Garcia JJ
AD  - Unidad de Hospitalizacion Pediatrica, Hospital Sant Joan de Deu, Esplugues de
      Llobregat, Barcelona, Spain.
CN  - en representacion de la Sociedad Espanola de Pediatria Hospitalaria (SEPHO)
LA  - eng
PT  - Journal Article
DEP - 20201010
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
PMC - PMC7547609
OTO - NOTNLM
OT  - COVID-19
OT  - Hospital medicine
OT  - Internal pediatric medicine
OT  - Pediatric hospitals
OT  - SARS-CoV-2
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:59
PHST- 2020/05/16 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
PHST- 2020/10/19 05:59 [entrez]
AID - 10.1016/j.anpede.2020.06.003 [doi]
AID - S2341-2879(20)30184-8 [pii]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Nov;93(5):343.e1-343.e8. doi:
      10.1016/j.anpede.2020.06.003. Epub 2020 Oct 10.


PMID- 33072715
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Editorial: How Can Genomic Biobanks Provide the Bridge for Implementation of
      Effective Clinical Therapy?
PG  - 581490
LID - 10.3389/fpubh.2020.581490 [doi]
FAU - Przygodzki, Ronald M
AU  - Przygodzki RM
AD  - Office of Research & Development, Washington, DC, United States.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
DEP - 20200922
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *Biological Specimen Banks
MH  - *Biomedical Research
MH  - Genomics
PMC - PMC7537097
OTO - NOTNLM
OT  - *biobanking & biorepositories
OT  - *database
OT  - *ethic
OT  - *genomic
OT  - *policy
OT  - *standards
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:58
PHST- 2020/07/08 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/10/19 05:58 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.3389/fpubh.2020.581490 [doi]
PST - epublish
SO  - Front Public Health. 2020 Sep 22;8:581490. doi: 10.3389/fpubh.2020.581490.
      eCollection 2020.


PMID- 33072701
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Lessons From Italy's and Sweden's Policies in Fighting COVID-19: The Contribution
      of Biomedical and Social Competences.
PG  - 563397
LID - 10.3389/fpubh.2020.563397 [doi]
AB  - We start (section The COVID-19 Pandemic and Italy's Response to It) by focusing
      on Italy's "tough" response to COVID-19 pandemic, which included total lockdown
      with very limited possibility of movement for over 60 million individuals. We
      analyse (section Sweden's Softer Approach) Sweden's softer approach, which is
      based on relatively lax measures and tends to safeguard fundamental
      constitutional rights. We problematise (section General Disagreement Among
      Experts: A Pressing Epistemic Problem) around the stalemate that arises as a
      consequence of the implementation of these different approaches, both
      epistemically grounded and equally justified, in the face of an unknown virus, in
      society. We point out that in some cases, like the one we discuss here, the
      epistemic justification that underlies scientific expertise is not enough to
      direct public debates and that politicians shouldn't exclusively focus on it. We 
      claim that, especially in situations of emergency when experts disagree, decision
      makers ought to promote broad discussions, with attention to public reason as
      well as to constitutional rights, in the attempt to find a shared procedural and 
      democratic agreement on how to act. On these grounds (section The Need of More
      Public Discourse in Fighting Covid-19) we call for an increase role of different 
      types of expertise in public debates thus for the inclusion of ethicists,
      bioethicists, economists, psychologists, moral and legal philosophers in any
      scientific committee responsible for taking important decisions for public
      health, especially during situations like pandemics. Likewise, in the interest of
      public reason and representativeness, we also claim that it may be fruitful to
      bring in non-experts, or experts whose expertise is not based solely on
      "epistemic status," but rather on either experience or political advocacy, of
      either the homeless, the immigrant, or other disenfranchised groups. This, in
      expanding the epistemic-expert pool, may also make it "more representative of
      society as a whole."
CI  - Copyright (c) 2020 Farina and Lavazza.
FAU - Farina, Mirko
AU  - Farina M
AD  - Institute for Humanities and Social Sciences, Innopolis University, Innopolis,
      Russia.
AD  - Institute of Philosophy, Saint Petersburg State University, Saint Petersburg,
      Russia.
AD  - Department of Philosophy, King's College, London, United Kingdom.
FAU - Lavazza, Andrea
AU  - Lavazza A
AD  - Centro Universitario Internazionale, Arezzo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *COVID-19
MH  - Communicable Disease Control
MH  - Humans
MH  - Italy/epidemiology
MH  - *Pandemics
MH  - Policy
MH  - SARS-CoV-2
MH  - Social Skills
MH  - Sweden/epidemiology
PMC - PMC7536320
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *expertise
OT  - *public health
OT  - *science
OT  - *scientific disagreement
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:58
PHST- 2020/05/18 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/10/19 05:58 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.3389/fpubh.2020.563397 [doi]
PST - epublish
SO  - Front Public Health. 2020 Sep 22;8:563397. doi: 10.3389/fpubh.2020.563397.
      eCollection 2020.


PMID- 33072375
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2054-1058 (Print)
IS  - 2054-1058 (Linking)
VI  - 7
IP  - 6
DP  - 2020 Nov
TI  - A survey of clinical competence of new nurses working in emergency department in 
      Iran: A descriptive, cross-sectional study.
PG  - 1896-1901
LID - 10.1002/nop2.579 [doi]
AB  - Aims: This article reports on a study investigating the self-assessed clinical
      competence of new nurses working in emergency departments. Design: A quantitative
      approach using descriptive cross-sectional survey design was employed. Methods:
      The clinical competency of the participants was assessed using the Competency
      Inventory for Registered Nurse questionnaire, which contains the seven dimensions
      of clinical care, leadership, interpersonal relations, legal/ethical,
      professional development, teaching/coaching and critical thinking/research
      aptitude. Data from 115 new nurses employed in emergency departments of nine
      selected university hospitals in the northwest of Iran were collected by the
      Competency Inventory for Registered Nurse (CIRN) from December 2018-May 2019 and 
      analysed. Results: The mean clinical competency for the total scale was 155.7 (SD
      32.9), indicating a moderate competency. The most highly self-rated competency
      was legal/ethical practice, and the least rated was critical thinking-research
      aptitude.
CI  - (c) 2020 The Authors. Nursing Open published by John Wiley & Sons Ltd.
FAU - Vand Tamadoni, Behjat
AU  - Vand Tamadoni B
AD  - Department of Medical-Surgical Nursing Faculty of Nursing and Midwifery Tabriz
      University of Medical Sciences Tabriz Iran.
FAU - Shahbazi, Shahla
AU  - Shahbazi S
AUID- ORCID: 0000-0002-4146-9425
AD  - Department of Medical-Surgical Nursing Faculty of Nursing and Midwifery and Sina 
      Hospital Tabriz University of Medical Sciences Tabriz Iran.
FAU - Seyedrasooli, Alehe
AU  - Seyedrasooli A
AD  - Department of Medical-Surgical Nursing Faculty of Nursing and Midwifery Tabriz
      University of Medical Sciences Tabriz Iran.
FAU - Gilani, Neda
AU  - Gilani N
AD  - Department of Statistics and Epidemiology Faculty of Health Tabriz university of 
      medical sciences Tabriz Iran.
AD  - Emergency Medicine Research Team Tabriz University of Medical Sciences Tabriz
      Iran.
FAU - Gholizadeh, Leila
AU  - Gholizadeh L
AUID- ORCID: 0000-0002-6711-3312
AD  - IMPACCT Faculty of Health University of Technology Sydney Sydney NSW Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - United States
TA  - Nurs Open
JT  - Nursing open
JID - 101675107
MH  - Clinical Competence
MH  - Cross-Sectional Studies
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Iran
MH  - *Nurses
MH  - *Nursing Staff, Hospital
MH  - Surveys and Questionnaires
PMC - PMC7544866
OTO - NOTNLM
OT  - *Iran
OT  - *competency
OT  - *emergency department
OT  - *emergency nursing
OT  - *nurse competence
OT  - *nursing
COIS- Authors declare no conflict of interest.
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:57
PHST- 2019/08/26 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/10/19 05:57 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.1002/nop2.579 [doi]
AID - NOP2579 [pii]
PST - epublish
SO  - Nurs Open. 2020 Jul 28;7(6):1896-1901. doi: 10.1002/nop2.579. eCollection 2020
      Nov.


PMID- 33071895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The 2020 Coronavirus Pandemic as a Change-Event in Sport Performers' Careers:
      Conceptual and Applied Practice Considerations.
PG  - 567966
LID - 10.3389/fpsyg.2020.567966 [doi]
AB  - The Coronavirus experience (CE) presents a highly challenging period for sport
      performers (e.g., athletes, coaches, referees), with potential effects on their
      lives and career trajectories. In this article, we initially conceptualize the CE
      using the scheme of change for sport psychology practice (Samuel and Tenenbaum,
      2011a). Within this framework, the CE is understood as a longitudinal,
      multifaceted, unpredicted, non-controlled change-event, with four distinct
      stages: (a) a pre-Coronavirus stage with unique career contextual conditions
      (i.e., stable engagement or a transitional period), (b) Coronavirus stage-A
      accompanied by instability and confusion, emotional response, and cognitive
      appraisal, (c) Coronavirus stage-B characterized by active coping or regression, 
      and (d) Coronavirus stage-C; instability endures or decreases, depending on
      career trajectory. The CE presents sport performers with modifications in various
      dimensions, including physical and physiological, motor skills, psycho-social and
      self-identity, relationships, performance and achievement, motivation and
      aspirations, organizational-occupational, and micro- and macro-cultural issues.
      Sport performers can exhibit several emotional responses (i.e., positive,
      negative, neutral), and consequential coping endeavors. The development of the
      change process is underlined by key decisions, manifested in sport performers'
      attempts to implement responsive change in these dimensions (e.g., adapt their
      diets, sleep routines, and exercise regimen). The second part of the article
      discusses applied practice considerations, presenting various techniques and
      methodologies which practitioners can apply while consulting from a change-based 
      perspective. Ethical issues pertaining to the formation of effective therapeutic 
      relationships during this period are also assessed. The conclusions offer future 
      avenues for researchers and practitioners when attempting to evaluate and cope
      with this global phenomenon.
CI  - Copyright (c) 2020 Samuel, Tenenbaum and Galily.
FAU - Samuel, Roy David
AU  - Samuel RD
AD  - Interdisciplinary Center Herzliya, Herzliya, Israel.
FAU - Tenenbaum, Gershon
AU  - Tenenbaum G
AD  - Interdisciplinary Center Herzliya, Herzliya, Israel.
FAU - Galily, Yair
AU  - Galily Y
AD  - Interdisciplinary Center Herzliya, Herzliya, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7540073
OTO - NOTNLM
OT  - COVID-19
OT  - athletes
OT  - coaches
OT  - detraining
OT  - quarantine
OT  - referees
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:55
PHST- 2020/05/31 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/19 05:55 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.3389/fpsyg.2020.567966 [doi]
PST - epublish
SO  - Front Psychol. 2020 Sep 23;11:567966. doi: 10.3389/fpsyg.2020.567966. eCollection
      2020.


PMID- 33071548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210421
IS  - 1321-8719 (Print)
IS  - 1321-8719 (Linking)
VI  - 27
IP  - 3
DP  - 2020
TI  - Structuring the debate about research ethics in the psychology and law field: an 
      international perspective.
PG  - 397-411
LID - 10.1080/13218719.2020.1742243 [doi]
AB  - Forensic psychologists' role is well established, and they are rightly well
      regulated because their decisions and behaviour can have a significant impact on 
      people's rights and interests. Their ethical integrity, however, partly hinges on
      the psycholegal research products (data, methods and instruments) that they and
      others use. The ethical regulation of researchers who produce products and their 
      research processes is, however, fragmented, limited and narrow and largely
      focuses on domestic research. Relatively few scholars have examined the
      regulation of psycholegal research or commented on the ethical implications of
      recent court decisions. The purpose of this paper is to start a debate about the 
      ethical regulation of researchers in the psycholegal field and consider methods
      of improving it to maintain society's trust in the field.
CI  - (c) 2020 The Australian and New Zealand Association of Psychiatry, Psychology and
      Law.
FAU - Allan, Alfred
AU  - Allan A
AUID- ORCID: https://orcid.org/0000-0001-7039-797X
AD  - School of Arts and Humanities, Edith Cowan University, Joondalup, WA, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - England
TA  - Psychiatr Psychol Law
JT  - Psychiatry, psychology, and law : an interdisciplinary journal of the Australian 
      and New Zealand Association of Psychiatry, Psychology and Law
JID - 9433511
PMC - PMC7534332
OTO - NOTNLM
OT  - Ethics
OT  - editor
OT  - institutional committee
OT  - law
OT  - psychology
OT  - research
OT  - review
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:53
PHST- 2020/10/19 05:53 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
AID - 10.1080/13218719.2020.1742243 [doi]
AID - 1742243 [pii]
PST - epublish
SO  - Psychiatr Psychol Law. 2020 Apr 21;27(3):397-411. doi:
      10.1080/13218719.2020.1742243. eCollection 2020.


PMID- 33071472
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 0951-5666 (Print)
IS  - 0951-5666 (Linking)
VI  - 35
IP  - 4
DP  - 2020
TI  - Ethics of engagement.
PG  - 783-793
LID - 10.1007/s00146-020-01079-8 [doi]
FAU - Gill, Karamjit S
AU  - Gill KS
AD  - University of Brighton, Brighton, UK.grid.12477.370000000121073784
LA  - eng
PT  - Editorial
DEP - 20201010
PL  - Germany
TA  - AI Soc
JT  - AI & society
JID - 9883157
PMC - PMC7547559
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
CRDT- 2020/10/19 05:53
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
PHST- 2020/10/19 05:53 [entrez]
AID - 10.1007/s00146-020-01079-8 [doi]
AID - 1079 [pii]
PST - ppublish
SO  - AI Soc. 2020;35(4):783-793. doi: 10.1007/s00146-020-01079-8. Epub 2020 Oct 10.


PMID- 33071276
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1349-8029 (Electronic)
IS  - 0470-8105 (Linking)
VI  - 60
IP  - 11
DP  - 2020 Nov 15
TI  - Genome Medicine for Brain Tumors: Current Status and Future Perspectives.
PG  - 531-542
LID - 10.2176/nmc.ra.2020-0175 [doi]
AB  - As a result of rapid progress in genome medicine technologies, such as the
      evolution of DNA sequencing and the development of molecular targeted drugs, the 
      era of precision cancer medicine has begun. In 2019, a nationwide genome medicine
      system was established and cancer gene panel sequencing began being covered by
      national health insurance in Japan. However, patients with brain tumors have not 
      benefited much from genome medicine, even though gliomas contain many potential
      molecular targets, such as alterations in EGFR, IDH1/2, BRAF, and Histone H3K27. 
      Targeted therapies for these molecules are currently under enthusiastic
      development; however, such attempts have not yet achieved remarkable success. To 
      date, only a limited number of targeted drugs for brain tumors such as immune
      checkpoint, neurotrophic tyrosine receptor kinase (NTRK), and Bruton tyrosine
      kinase (BTK) inhibitors are available, and only in limited cases. Several
      obstacles remain in the development of drugs to treat brain tumors, including the
      difficulties in conducting clinical trials because of the relatively rare
      incidence and in drug delivery through the blood-brain barrier (BBB).
      Furthermore, general problems for numerous types of cancer, such as tumor
      heterogeneity, also exist for brain tumors. We hope that overcoming these issues 
      could enable precision genome medicine to be more beneficial for patients with
      brain tumors such as malignant gliomas. In addition, careful consideration of
      ethical, legal, and social issues (ELSIs) is important as it is indispensable for
      maintaining good relationships with patients, which is one of the keys for genome
      medicine promotion.
FAU - Mukasa, Akitake
AU  - Mukasa A
AD  - Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto
      University.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201016
PL  - Japan
TA  - Neurol Med Chir (Tokyo)
JT  - Neurologia medico-chirurgica
JID - 0400775
SB  - IM
MH  - Brain Neoplasms/*genetics/*therapy
MH  - *Genetic Techniques
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Precision Medicine
MH  - Sequence Analysis, DNA
PMC - PMC7788271
OTO - NOTNLM
OT  - brain tumor
OT  - gene
OT  - glioma
OT  - precision medicine
OT  - targeted therapy
EDAT- 2020/10/20 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/10/19 05:52
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2020/10/19 05:52 [entrez]
AID - 10.2176/nmc.ra.2020-0175 [doi]
PST - ppublish
SO  - Neurol Med Chir (Tokyo). 2020 Nov 15;60(11):531-542. doi:
      10.2176/nmc.ra.2020-0175. Epub 2020 Oct 16.


PMID- 33070881
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 79
DP  - 2020 Sep
TI  - Tele-robotics and artificial-intelligence in stroke care.
PG  - 129-132
LID - S0967-5868(20)31352-7 [pii]
LID - 10.1016/j.jocn.2020.04.125 [doi]
AB  - In the last forty years, the field of medicine has experienced dramatic shifts in
      technology-enhanced surgical procedures - from its initial use in 1985 for
      neurosurgical biopsies to current implementation of systems such as
      magnetic-guided catheters for endovascular procedures. Systems such as the Niobe 
      Magnetic Navigation system and CorPath GRX have allowed for utilization of a
      fully integrated surgical robotic systems for perioperative manipulation, as well
      as tele-controlled manipulation systems for telemedicine. These robotic systems
      hold tremendous potential for future implementation in cerebrovascular
      procedures, but lack of relevant clinical experience and uncharted ethical and
      legal territory for real-life tele-robotics have stalled their adoption for
      neurovascular surgery, and might present significant challenges for future
      development and widespread implementation. Yet, the promise that these
      technologies hold for dramatically improving the quality and accessibility of
      cerebrovascular procedures such as thrombectomy for acute stroke, drives the
      research and development of surgical robotics. These technologies, coupled with
      artificial intelligence (AI) capabilities such as machine learning,
      deep-learning, and outcome-based analyses and modifications, have the capability 
      to uncover new dimensions within the realm of cerebrovascular surgery.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Rabinovich, Emily P
AU  - Rabinovich EP
AD  - University of Virginia School of Medicine, 1215 Lee Street, Charlottesville, VA
      22908, USA.
FAU - Capek, Stepan
AU  - Capek S
AD  - Department of Neurological Surgery, University of Virginia, 1215 Lee Street,
      Charlottesville, VA 22908, USA; 2nd Faculty of Medicine, Charles University in
      Prague, Prague, Czech Republic.
FAU - Kumar, Jeyan S
AU  - Kumar JS
AD  - Department of Neurological Surgery, University of Virginia, 1215 Lee Street,
      Charlottesville, VA 22908, USA.
FAU - Park, Min S
AU  - Park MS
AD  - Department of Neurological Surgery, University of Virginia, 1215 Lee Street,
      Charlottesville, VA 22908, USA. Electronic address:
      MP2TQ@hscmail.mcc.virginia.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200805
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
SB  - IM
MH  - Artificial Intelligence/*trends
MH  - Endovascular Procedures/instrumentation/*trends
MH  - Humans
MH  - Robotic Surgical Procedures/methods/*trends
MH  - Stroke/*surgery
MH  - Telemedicine/instrumentation/methods/*trends
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Cerebrovascular
OT  - Endovascular
OT  - Robotic surgery
OT  - Tele-surgery
OT  - Telerobotics
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/10/20 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/10/19 05:28
PHST- 2020/02/25 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/10/19 05:28 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - S0967-5868(20)31352-7 [pii]
AID - 10.1016/j.jocn.2020.04.125 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Sep;79:129-132. doi: 10.1016/j.jocn.2020.04.125. Epub 2020 
      Aug 5.


PMID- 33069989
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1872-6283 (Electronic)
IS  - 0379-0738 (Linking)
VI  - 317
DP  - 2020 Dec
TI  - Men at war, recovery and analysis of soldiers' remains from the WWI and WWII
      Italian Front.
PG  - 110533
LID - S0379-0738(20)30395-9 [pii]
LID - 10.1016/j.forsciint.2020.110533 [doi]
AB  - Italy was hit hard by the World Wars, still today the discovery of human remains 
      dating back to 20th century is a common phenomenon, in particular on Alpine
      glaciers, due to climate changes. The authors will describe the Italian scenario 
      in terms of legislation, scientific procedures and related disciplines involved, 
      then the difficulties in the identification of human remains of soldiers, but
      also potential issues related to uncontrolled "scavenging" activities and
      consequent ethical aspects. The interdisciplinarity, used as systematic approach 
      to deal with complex cases, allowed the presumptive identification of a WWI
      soldier recovered after one century from the glaciers of the Adamello mountain,
      as described. Putting aside the national perspective, the authors endorse and
      encourage the establishment of an international working group in order to share
      common issues, to exchange experience and to build global best-practices.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Gaudio, Daniel
AU  - Gaudio D
AD  - Department of Anthropology, Faculty of Science, Masaryk University, Brno, Czech
      Republic; LABANOF - Laboratorio di Antropologia e Odontologia Forense, Sezione di
      Medicina Legale del Dipartimento di Scienze Biomediche per la Salute, Universita 
      degli Studi di Milano, Italy. Electronic address: danielgaudio@sci.muni.cz.
FAU - Cattaneo, Cristina
AU  - Cattaneo C
AD  - LABANOF - Laboratorio di Antropologia e Odontologia Forense, Sezione di Medicina 
      Legale del Dipartimento di Scienze Biomediche per la Salute, Universita degli
      Studi di Milano, Italy.
FAU - Galassi, Andrea
AU  - Galassi A
AD  - U.O. Medicina Legale AULSS8 Berica, Vicenza, Italy.
FAU - Nicolis, Franco
AU  - Nicolis F
AD  - Ufficio Beni Archeologici, Soprintendenza Per i Beni Culturali, Provincia
      Autonoma di Trento, Trento, Italy.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20201003
PL  - Ireland
TA  - Forensic Sci Int
JT  - Forensic science international
JID - 7902034
SB  - IM
MH  - Archaeology
MH  - *Body Remains
MH  - Forensic Anthropology/ethics/*organization & administration
MH  - History, 20th Century
MH  - Humans
MH  - Italy
MH  - *Military Personnel/history
MH  - World War I
MH  - World War II
OTO - NOTNLM
OT  - Archaeology
OT  - Forensic Anthropology
OT  - Italian Front
OT  - Soldiers' identification
OT  - World War
COIS- Declaration of Competing Interest The authors report no declarations of interest.
EDAT- 2020/10/19 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/10/18 20:28
PHST- 2020/08/12 00:00 [received]
PHST- 2020/09/25 00:00 [revised]
PHST- 2020/09/26 00:00 [accepted]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2020/10/18 20:28 [entrez]
AID - S0379-0738(20)30395-9 [pii]
AID - 10.1016/j.forsciint.2020.110533 [doi]
PST - ppublish
SO  - Forensic Sci Int. 2020 Dec;317:110533. doi: 10.1016/j.forsciint.2020.110533. Epub
      2020 Oct 3.


PMID- 33069960
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 266
DP  - 2020 Dec
TI  - Developing an Innu framework for health research: The canoe trip as a metaphor
      for a collaborative approach centered on valuing Indigenous knowledges.
PG  - 113409
LID - S0277-9536(20)30628-6 [pii]
LID - 10.1016/j.socscimed.2020.113409 [doi]
AB  - Indigenous communities increasingly assert their right to self-determination by
      requiring that participatory research approaches be used, valuing and
      prioritizing Indigenous knowledges, for the purpose of improving Indigenous
      health. While frameworks that focus on Indigenous knowledges are being developed,
      these must be adapted or developed by Indigenous communities because their
      knowledge is specific to place and inherent to their lived experience. No
      community-based participatory research (CBPR) framework for health research has
      been developed with the Labrador Innu. In addition, while the literature
      emphasizes the importance of relationship in research with Indigenous
      communities, the process of establishing relationships is underspecified. Within 
      this context, we describe our experience in developing a CBPR framework for
      health research in a study that is community-initiated and fitting within Innu
      self-determination. We highlight the importance of paying attention to the
      theoretical roots of CBPR, arguing that this helps researchers focus on the
      centrality of Indigenous knowledges (in this case, Innu knowledge). This requires
      that non-Indigenous researchers question assumptions of universality regarding
      their own knowledge and see all knowledges as equitable. Such posture of humility
      allows non-Indigenous researchers to enter relational spaces that join
      researchers and Indigenous communities. Within these spaces, a true collaborative
      approach is enabled and Indigenous knowledges are uncovered and become
      foundational in the inquiry process. We illustrate these ideas by describing a
      model for opening relational spaces that include Indigenous and non-Indigenous
      researchers. We then present a framework that uses the metaphor of canoeing
      together to capture our CBPR approach for use in Innu health research. We outline
      the behaviors of non-Indigenous researchers to build and solidify relationships
      with Indigenous community researchers over time. This article is useful for
      non-Indigenous researchers interested in relational approaches to research with
      Indigenous communities, and for Indigenous leaders and researchers who seek
      community solutions through research.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Ward, Leonor M
AU  - Ward LM
AD  - Population Health PhD Program, Faculty of Health Science, University of Ottawa,
      Ottawa, Canada. Electronic address: lzuni008@uottawa.ca.
FAU - Hill, Mary Janet
AU  - Hill MJ
AD  - Sheshatshiu Innu First Nation, Innu Nation of Labrador, Sheshatshiu, Newfoundland
      and Labrador, Canada. Electronic address: maryjanethill@gmail.com.
FAU - Chreim, Samia
AU  - Chreim S
AD  - Population Health PhD Program, Faculty of Health Science, University of Ottawa,
      Ottawa, Canada; Telfer School of Management, University of Ottawa, Ottawa,
      Canada. Electronic address: Chreim@telfer.uottawa.ca.
FAU - Poker, Christine
AU  - Poker C
AD  - Mushuau Innu First Nation, Innu Nation of Labrador, Natuashish, Newfoundland and 
      Labrador, Canada. Electronic address: christinepoker11@gmail.com.
FAU - Olsen Harper, Anita
AU  - Olsen Harper A
AD  - National Aboriginal Circle Against Family Violence, Kahnawake, Quebec, Canada.
      Electronic address: a_oharper@bell.net.
FAU - Wells, Samantha
AU  - Wells S
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research
      Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada;
      Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario,
      Canada; Department of Epidemiology and Biostatistics, Schulich School of Medicine
      and Dentistry, Western University, Ontario, London; School of Psychology, Deakin 
      University, Burwood, Victoria, Australia. Electronic address:
      Samantha.wells@camh.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - *Community-Based Participatory Research
MH  - Humans
MH  - *Metaphor
MH  - Newfoundland and Labrador
MH  - Personal Autonomy
MH  - Research Personnel
OTO - NOTNLM
OT  - *CBPR
OT  - *Canada
OT  - *Collaborative research approaches
OT  - *Ethical research with Indigenous communities
OT  - *Indigenous health research
OT  - *Innu health research framework
OT  - *Labrador Innu
OT  - *Relational spaces
EDAT- 2020/10/19 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/18 20:27
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/10/18 20:27 [entrez]
AID - S0277-9536(20)30628-6 [pii]
AID - 10.1016/j.socscimed.2020.113409 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Dec;266:113409. doi: 10.1016/j.socscimed.2020.113409. Epub 2020
      Oct 6.


PMID- 33069658
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 13
IP  - 21
DP  - 2020 Nov 9
TI  - CT-Determined Tricuspid Annular Dilatation Is Associated With Increased 2-Year
      Mortality in TAVR Patients.
PG  - 2497-2507
LID - S1936-8798(20)31377-7 [pii]
LID - 10.1016/j.jcin.2020.06.027 [doi]
AB  - OBJECTIVES: The aim of this study was to investigate the prevalence and
      prognostic impact of tricuspid annular dilatation (TAD) measured in multislice
      computed tomography datasets in patients undergoing transfemoral transcatheter
      aortic valve replacement for severe aortic stenosis. BACKGROUND: TAD is an
      increasingly recognized entity associated with poor outcomes in patients with
      valvular heart disease. METHODS: The maximal septolateral diameter of the
      tricuspid annulus was measured in consecutive patients with 3-dimensional
      multidetector row computed tomographic datasets undergoing transfemoral
      transcatheter aortic valve replacement. Receiver-operating curve characteristic
      analysis was performed to obtain an ideal, body surface area-normalized cutoff
      for TAD. Ethical approval was obtained from the institutional ethics board.
      RESULTS: The study included 1,137 patients, of whom 299 died within a mean
      follow-up period of 1.8 +/- 1.0 years. TAD was identified in 446 patients (39.2%)
      on the basis of a receiver-operating characteristic cutoff of 23 mm/m(2). TAD had
      no impact on procedural outcomes, including device failure defined according to
      Valve Academic Research Consortium-2 criteria. Patients with TAD experienced
      significantly greater mortality (hazard ratio: 1.99; 95% confidence interval:
      1.59 to 2.51; p < 0.001). Multivariate analysis including clinical and
      echocardiographic parameters confirmed the predictive value of TAD (hazard ratio:
      1.78; 95% confidence interval: 1.33 to 2.38; p < 0.001), while echocardiographic 
      variables, including estimated pulmonary artery pressure and the severity of
      tricuspid regurgitation, did not reach statistical significance. The predictive
      value of TAD was incremental to a baseline model of clinical and
      echocardiographic parameters (continuous net reclassification improvement 0.204; 
      p < 0.01) and incremental to the Society of Thoracic Surgeons score (continuous
      net reclassification improvement 0.209; p < 0.001). CONCLUSIONS: TAD is an
      independent predictor of all-cause mortality in patients with severe aortic
      stenosis undergoing transcatheter aortic valve replacement.
CI  - Copyright (c) 2020 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
FAU - Deseive, Simon
AU  - Deseive S
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany. Electronic
      address: simon.deseive@med.uni-muenchen.de.
FAU - Steffen, Julius
AU  - Steffen J
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Beckmann, Markus
AU  - Beckmann M
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
FAU - Jochheim, David
AU  - Jochheim D
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Orban, Mathias
AU  - Orban M
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Zadrozny, Magda
AU  - Zadrozny M
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Gschwendtner, Sarah
AU  - Gschwendtner S
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Braun, Daniel
AU  - Braun D
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Rizas, Konstantinos
AU  - Rizas K
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Curta, Adrian
AU  - Curta A
AD  - Klinik und Poliklinik fur Radiologie, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
FAU - Hagl, Christian
AU  - Hagl C
AD  - Herzchirurgische Klinik und Poliklinik, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
FAU - Theiss, Hans D
AU  - Theiss HD
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Mehilli, Julinda
AU  - Mehilli J
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Massberg, Steffen
AU  - Massberg S
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
FAU - Hausleiter, Jorg
AU  - Hausleiter J
AD  - Medizinische Klinik und Poliklinik I, Klinikum der Universitat,
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; German Centre for
      Cardiovascular Research, partner site Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
SB  - IM
CIN - JACC Cardiovasc Interv. 2020 Nov 9;13(21):2508-2509. PMID: 33069659
MH  - Aortic Valve/surgery
MH  - Aortic Valve Stenosis/surgery
MH  - *Dilatation
MH  - Humans
MH  - Multidetector Computed Tomography
MH  - Severity of Illness Index
MH  - *Transcatheter Aortic Valve Replacement
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *aortic stenosis
OT  - *transcatheter aortic valve replacement
OT  - *tricuspid annular dilatation
OT  - *tricuspid regurgitation
COIS- Author Relationship With Industry Dr. Mehilli has received an institutional
      research grant from Boston Scientific; and has received lecture fees from Edwards
      Lifesciences, Medtronic, Boston Scientific, Bristol Myers Squibb, and
      AstraZeneca. Drs. Hausleiter and Braun have received speaking and consulting
      honoraria from Abbott Vascular and Edwards Lifesciences. All other authors have
      reported that they have no relationships relevant to the contents of this paper
      to disclose.
EDAT- 2020/10/19 06:00
MHDA- 2021/08/12 06:00
CRDT- 2020/10/18 20:24
PHST- 2020/02/25 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2020/10/18 20:24 [entrez]
AID - S1936-8798(20)31377-7 [pii]
AID - 10.1016/j.jcin.2020.06.027 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2020 Nov 9;13(21):2497-2507. doi:
      10.1016/j.jcin.2020.06.027. Epub 2020 Oct 14.


PMID- 33069493
OWN - NLM
STAT- Publisher
LR  - 20211203
IS  - 2529-993X (Electronic)
IS  - 2529-993X (Linking)
DP  - 2020 Sep 10
TI  - The vaccine against COVID-19 and institutional trust.
LID - S0213-005X(20)30266-4 [pii]
LID - 10.1016/j.eimc.2020.08.001 [doi]
AB  - Major public and private laboratories have entered into a race to find an
      effective COVID-19 vaccine. When that vaccine arrives, the governments will have 
      to implement vaccination programs to achieve the necessary immunization levels to
      prevent the disease transmission. In this context, the ethical dilemma of
      compulsory vaccination vs. voluntary vaccination will be raised. Underlying this 
      dilemma, lies the problem of the ethical models on which the political decisions 
      of governments in matters of health are based. The article proposes and argues
      the need to base health policy decisions on an ethical <<first person>> model,
      based on responsibility, that allows us to move from a normative ethic to an
      ethic of responsible behavior. This change in the ethical model, together with
      certain proposals for political action, will help us to restore institutional
      trust so that the necessary levels of collective immunity against COVID-19 can be
      achieved through the voluntary vaccination of the citizens.
CI  - Copyright (c) 2020 Sociedad Espanola de Enfermedades Infecciosas y Microbiologia 
      Clinica. Publicado por Elsevier Espana, S.L.U. All rights reserved.
FAU - Gonzalez-Melado, Fermin Jesus
AU  - Gonzalez-Melado FJ
AD  - Departamento de Teologia Moral y Bioetica, Centro Superior de Estudios Teologicos
      (Badajoz), Universidad Pontificia de Salamanca, Salamanca, Espana. Electronic
      address: fjgonzalezme@upsa.es.
FAU - Di Pietro, Maria Luisa
AU  - Di Pietro ML
AD  - Sezione di Igiene, Dipartimento Universitario Scienze della Vita e Sanita
      Pubblica, Universita Cattolica del Sacro Cuore, Rome, Italy.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - La vacuna frente a la COVID-19 y la confianza institucional.
DEP - 20200910
PL  - Spain
TA  - Enferm Infecc Microbiol Clin (Engl Ed)
JT  - Enfermedades infecciosas y microbiologia clinica (English ed.)
JID - 101777541
SB  - IM
PMC - PMC7834478
OTO - NOTNLM
OT  - COVID-19
OT  - Confianza institucional
OT  - Ethics of responsibility
OT  - Institutional trust
OT  - Prevencion
OT  - Prevention
OT  - Vaccination
OT  - Vacunacion
OT  - Etica de la responsabilidad
EDAT- 2020/10/19 06:00
MHDA- 2020/10/19 06:00
CRDT- 2020/10/18 20:23
PHST- 2020/05/13 00:00 [received]
PHST- 2020/08/12 00:00 [revised]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/10/18 20:23 [entrez]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2020/10/19 06:00 [medline]
AID - S0213-005X(20)30266-4 [pii]
AID - 10.1016/j.eimc.2020.08.001 [doi]
PST - aheadofprint
SO  - Enferm Infecc Microbiol Clin (Engl Ed). 2020 Sep 10. pii: S0213-005X(20)30266-4. 
      doi: 10.1016/j.eimc.2020.08.001.


PMID- 33069414
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210210
IS  - 1525-3198 (Electronic)
IS  - 0022-0302 (Linking)
VI  - 103
IP  - 12
DP  - 2020 Dec
TI  - Consumer perception of the sustainability of dairy products and plant-based dairy
      alternatives.
PG  - 11228-11243
LID - S0022-0302(20)30822-5 [pii]
LID - 10.3168/jds.2020-18406 [doi]
AB  - Plant-based dairy alternative beverage sales have increased in recent years.
      Plant-based dairy alternatives often advertise on a platform of sustainability
      and environmental commitment. To successfully position and market dairy products 
      in this competitive environment, dairy companies must understand the consumer
      definition of and importance placed on sustainability, as well as communicate
      sustainability information effectively. The objective of this study was to
      characterize consumer perception of the sustainability of milk and dried dairy
      ingredients and their respective plant-based alternatives. Focus groups and 2
      online surveys were conducted. In the first survey, maximum difference scaling
      was used to rank the importance of specific dairy product attributes to
      sustainability, along with an exercise in which respondents selected whether a
      fluid milk or protein powder product was sustainable. A follow-up survey included
      2 exercises in which respondents selected whether generic dairy products or dried
      dairy ingredients were sustainable, natural, healthy, trustworthy, or ethical.
      Over half of dairy product consumers reported that they looked for
      sustainability-related information. Consumers who purchased both plant-based
      dairy alternative and dairy products placed a higher self-reported importance on 
      sustainability than those who purchased dairy products only. Focus group and
      survey maximum difference scaling results identified 5 key attributes for
      sustainability: minimal carbon footprint/greenhouse gas emissions, few/no
      preservatives, animal happiness and welfare, and simple/minimal ingredients.
      Plant-based dairy alternatives followed by fluid milk and protein powders were
      considered more sustainable than dairy products, but package type and organic
      status also played a role in consumer sustainability perception. Product labels
      were the most common source of sustainability information, although consumers
      also sought information on websites affiliated and unaffiliated with dairy
      companies. There was cognitive overlap among the terms sustainable, natural,
      healthy, ethical, and trustworthy as they relate to dairy products, but consumers
      used the terms distinctly. Consumers perceived differences in these terms between
      general categories of dairy as well as among products in a specific dairy
      category. Dairy companies may be able to differentiate themselves by helping
      consumers make these choices by simplifying sustainability-related messaging and 
      by maintaining open, transparent communication regarding sustainability.
CI  - Copyright (c) 2020 American Dairy Science Association. Published by Elsevier Inc.
      All rights reserved.
FAU - Schiano, A N
AU  - Schiano AN
AD  - Department of Food, Bioprocessing and Nutrition Sciences, Southeast Dairy Foods
      Research Center, North Carolina State University, Raleigh 27695.
FAU - Harwood, W S
AU  - Harwood WS
AD  - Department of Food, Bioprocessing and Nutrition Sciences, Southeast Dairy Foods
      Research Center, North Carolina State University, Raleigh 27695.
FAU - Gerard, P D
AU  - Gerard PD
AD  - School of Mathematical and Statistical Sciences, Clemson University, Clemson, SC 
      29634.
FAU - Drake, M A
AU  - Drake MA
AD  - Department of Food, Bioprocessing and Nutrition Sciences, Southeast Dairy Foods
      Research Center, North Carolina State University, Raleigh 27695. Electronic
      address: mdrake@ncsu.edu.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - United States
TA  - J Dairy Sci
JT  - Journal of dairy science
JID - 2985126R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Animal Welfare
MH  - Animals
MH  - *Carbon Footprint
MH  - Commerce
MH  - *Consumer Behavior
MH  - Dairy Products/*standards
MH  - Diet, Vegetarian
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Milk/chemistry/*standards
MH  - Perception
MH  - *Program Evaluation
MH  - Qualitative Research
MH  - Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - consumer surveys
OT  - milk
OT  - plant-based dairy alternatives
OT  - qualitative research
OT  - sustainability
EDAT- 2020/10/19 06:00
MHDA- 2021/02/11 06:00
CRDT- 2020/10/18 20:22
PHST- 2020/02/20 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
PHST- 2020/10/18 20:22 [entrez]
AID - S0022-0302(20)30822-5 [pii]
AID - 10.3168/jds.2020-18406 [doi]
PST - ppublish
SO  - J Dairy Sci. 2020 Dec;103(12):11228-11243. doi: 10.3168/jds.2020-18406. Epub 2020
      Oct 15.


PMID- 33069227
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 17
TI  - Potential research ethics violations against an indigenous tribe in Ecuador: a
      mixed methods approach.
PG  - 100
LID - 10.1186/s12910-020-00542-x [doi]
AB  - BACKGROUND: Biomedical and ethnographic studies among indigenous people are
      common practice in health and geographical research. Prior health research
      misconduct has been documented, particularly when obtaining genetic material. The
      objective of this study was to crossmatch previously published data with the
      perceptions of the Waorani peoples about the trading of their genetic material
      and other biological samples. METHODS: We conducted a mixed methods study design 
      using a tailored 15-item questionnaire in 72 participants and in-depth interviews
      in 55 participants belonging to 20 Waorani communities about their experiences
      and perceptions of participating in biomedical research projects. Additionally,
      we conducted a systematic review of the literature in order to crossmatch the
      published results of studies stating the approval of an ethics committee and
      individual consent within their work. RESULTS: A total of 40 men (60%) and 32
      women (40%), with a mean age of 57 +/- 15 years agreed to be interviewed for
      inclusion. Five main categories around the violation of good clinical practices
      were identified, concerning the obtention of blood samples from a recently
      contacted Waorani native community within the Amazonian region of Ecuador. These 
      themes are related to the lack of adequate communication between community
      members and researchers as well as the voluntariness to participate in health
      research. Additionally, over 40 years, a total of 38 manuscripts related to the
      use of biological samples in Waorani indigenous people were published. The
      majority of the studies (68%) did not state within their article obtaining
      research ethics board approval, and 71% did not report obtaining the informed
      consent of the participants prior to the execution of the project. CONCLUSION:
      Clinical Research on the Waorani community in the Ecuadorian Amazon basin has
      been performed on several occasions. Unfortunately, the majority of these
      projects did not follow the appropriate ethical and professional standards in
      either reporting the results or fulfilling them. The results of our investigation
      suggest that biological material, including genetic material, has been used by
      researchers globally, with some omitting the minimum information required to
      guarantee transparency and good clinical practices. We highlight the importance
      of stating ethics within research to avoid breaches in research transparency.
FAU - Ortiz-Prado, Esteban
AU  - Ortiz-Prado E
AUID- ORCID: 0000-0002-1895-7498
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas,
      Ecuador Calle de los Colimes y Avenida De los Granados, Quito, 170137, Ecuador.
      e.ortizprado@gmail.com.
FAU - Simbana-Rivera, Katherine
AU  - Simbana-Rivera K
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas,
      Ecuador Calle de los Colimes y Avenida De los Granados, Quito, 170137, Ecuador.
FAU - Gomez-Barreno, Lenin
AU  - Gomez-Barreno L
AD  - One Health Research Group, Faculty of Medicine, Universidad de Las Americas,
      Ecuador Calle de los Colimes y Avenida De los Granados, Quito, 170137, Ecuador.
FAU - Tamariz, Leonardo
AU  - Tamariz L
AD  - Division of Population Health and Computational Medicine, University of Miami,
      Florida, USA.
FAU - Lister, Alex
AU  - Lister A
AD  - Public Health Program, Faculty of Medicine, University of Southampton,
      Southampton, England.
FAU - Baca, Juan Carlos
AU  - Baca JC
AD  - Grassland Group, Technical University of Munich, Munich, Germany.
FAU - Norris, Alegria
AU  - Norris A
AD  - Ministerio de Biodiversidad, Quito, Ecuador.
FAU - Adana-Diaz, Lila
AU  - Adana-Diaz L
AD  - Faculty of Psychology, Universidad de Las Americas, Quito, Ecuador.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201017
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Ecuador
MH  - Ethics Committees
MH  - Ethics Committees, Research
MH  - *Ethics, Research
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Informed Consent
MH  - Male
MH  - Research Design
PMC - PMC7568418
OTO - NOTNLM
OT  - *Consent
OT  - *Ecuador
OT  - *Indigenous populations
OT  - *Research ethics board
OT  - *Waorani
EDAT- 2020/10/19 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/18 20:19
PHST- 2019/12/31 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/18 20:19 [entrez]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00542-x [doi]
AID - 10.1186/s12910-020-00542-x [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 17;21(1):100. doi: 10.1186/s12910-020-00542-x.


PMID- 33069219
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201218
IS  - 1472-6831 (Electronic)
IS  - 1472-6831 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 17
TI  - Association between early childhood oral health impact scale (ECOHIS) scores and 
      pediatric dental surgery wait times.
PG  - 285
LID - 10.1186/s12903-020-01263-8 [doi]
AB  - BACKGROUND: Severe Early Childhood Caries (S-ECC) is an aggressive form of tooth 
      decay that often requires pediatric dental rehabilitative surgery. The Early
      Childhood Oral Health Impact Scale (ECOHIS) measures oral health-related quality 
      of life (OHRQL). The purpose of this study was to determine whether there is an
      association between ECOHIS scores and surgery wait times for children undergoing 
      dental treatment for S-ECC under general anesthesia (GA). METHODS: The hypothesis
      was that there is no present association between wait times and ECOHIS score.
      Children under 72 months of age with S-ECC were recruited on the day of their
      slated dental surgery under GA. Parents/caregivers completed a questionnaire that
      included the ECOHIS. Data were merged with other ECOHIS scores from a previous
      study. Wait times were acquired from the Patient Access Registry Tool (PART)
      database. Data analysis included descriptive statistics and bivariate analyses. A
      p-value of </=0.05 was considered statistically significant; 95% confidence
      intervals (CIs) were reported for each correlation coefficient. This study was
      approved by the University of Manitoba's Health Research Ethics Board. RESULTS:
      Overall, 200 children participated, the majority of whom were Indigenous (63%)
      and resided in Winnipeg (52.5%). The mean age was 47.6 +/- 13.8 months and 50.5% 
      were female. Analyses showed ECOHIS scores were not significantly correlated with
      children's wait times. Observed correlations between ECOHIS and children's wait
      times were low and not statistically significant, ranging from rho = 0.11 for
      wait times and child impact section (CIS) scores (95% CI: - 0.04, 0.26; p =
      0.14), rho = - 0.08 for family impact section (FIS) scores (95% CI: - 0.23, 0.07;
      p = 0.28), and rho = 0.04 for total ECOHIS scores (95% CI: - 0.11, 0.19; p =
      0.56). CONCLUSION: No significant associations were observed between ECOHIS
      scores and wait times. In fact, those with worse OHRQL appeared to wait longer
      for surgery. ECOHIS scores could, however, still be used to help prioritize
      children for dental surgery to ensure that they receive timely access to dental
      care under GA. This is essential given the challenges posed by COVID-19 on timely
      access to surgical care.
FAU - Lee, Victor H K
AU  - Lee VHK
AD  - Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry,
      Rady Faculty of Health Sciences, University of Manitoba, 507 - 715 McDermot
      Avenue, Winnipeg, Manitoba, R3E 3P4, Canada.
AD  - Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Grant, Cameron G
AU  - Grant CG
AD  - Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry,
      Rady Faculty of Health Sciences, University of Manitoba, 507 - 715 McDermot
      Avenue, Winnipeg, Manitoba, R3E 3P4, Canada.
FAU - Mittermuller, Betty-Anne
AU  - Mittermuller BA
AD  - Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry,
      Rady Faculty of Health Sciences, University of Manitoba, 507 - 715 McDermot
      Avenue, Winnipeg, Manitoba, R3E 3P4, Canada.
AD  - Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Singh, Sarbjeet
AU  - Singh S
AD  - Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry,
      Rady Faculty of Health Sciences, University of Manitoba, 507 - 715 McDermot
      Avenue, Winnipeg, Manitoba, R3E 3P4, Canada.
AD  - Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Weiss, Brenda
AU  - Weiss B
AD  - Shared Health, Winnipeg, Manitoba, Canada.
FAU - Edwards, Jeanette M
AU  - Edwards JM
AD  - Shared Health, Winnipeg, Manitoba, Canada.
FAU - Schroth, Robert J
AU  - Schroth RJ
AUID- ORCID: 0000-0002-6262-5378
AD  - Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry,
      Rady Faculty of Health Sciences, University of Manitoba, 507 - 715 McDermot
      Avenue, Winnipeg, Manitoba, R3E 3P4, Canada. robert.schroth@umanitoba.ca.
AD  - Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
      robert.schroth@umanitoba.ca.
AD  - Department of Pediatrics and Child Health, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
      robert.schroth@umanitoba.ca.
AD  - Section of Pediatric Dentistry, Winnipeg Regional Health Authority, Winnipeg,
      Manitoba, Canada. robert.schroth@umanitoba.ca.
LA  - eng
GR  - Embedded Clinician Researcher Award/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201017
PL  - England
TA  - BMC Oral Health
JT  - BMC oral health
JID - 101088684
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Child, Preschool
MH  - Coronavirus Infections/epidemiology
MH  - Dental Caries/*diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Oral Health/*statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology
MH  - Quality of Life/*psychology
MH  - SARS-CoV-2
MH  - *Waiting Lists
PMC - PMC7568462
OTO - NOTNLM
OT  - *COVID-19
OT  - *ECOHIS
OT  - *Early childhood caries
OT  - *Oral health-related quality of life, wait times
OT  - *Preschool child
EDAT- 2020/10/19 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/18 20:19
PHST- 2020/05/25 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/18 20:19 [entrez]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.1186/s12903-020-01263-8 [doi]
AID - 10.1186/s12903-020-01263-8 [pii]
PST - epublish
SO  - BMC Oral Health. 2020 Oct 17;20(1):285. doi: 10.1186/s12903-020-01263-8.


PMID- 33069208
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 17
TI  - Evaluation of alveolar recruitment maneuver on respiratory resistance during
      general anesthesia: a prospective observational study.
PG  - 264
LID - 10.1186/s12871-020-01182-9 [doi]
AB  - BACKGROUND: Alveolar recruitment maneuvers enable easily reopening nonaerated
      lung regions via a transient elevation in transpulmonary pressure. To evaluate
      the effect of these maneuvers on respiratory resistance, we used an oscillatory
      technique during mechanical ventilation. This study was conducted to assess the
      effect of the alveolar recruitment maneuvers on respiratory resistance under
      routine anesthesia. We hypothesized that respiratory resistance at 5 Hz (R5)
      after the maneuver would be decreased after the lung aeration. METHODS: After
      receiving the ethics committee's approval, we enrolled 33 patients who were
      classified with an American Society of Anesthesiologists physical status of 1, 2 
      or 3 and were undergoing general anesthesia for transurethral resection of a
      bladder tumor within a 12-month period from 2017 to 2018. The recruitment
      maneuver was performed 30 min after endotracheal intubation. The maneuver
      consisted of sustained manual inflation of the anesthesia reservoir bag to a peak
      inspiratory pressure of 40 cmH2O for 15 s, including 5 s of gradually increasing 
      the peak inspiratory pressure. Respiratory resistance was measured using the
      forced oscillation technique before and after the maneuver, and the mean R5 was
      calculated during the expiratory phase. The respiratory resistance and ventilator
      parameter results were analyzed using paired Student's t-tests, and p < 0.05 was 
      considered statistically significant. RESULTS: We analyzed 31 patients (25 men
      and 6 women). R5 was 7.3 +/- 1.6 cmH2O/L/sec before the recruitment maneuver
      during mechanical ventilation and was significantly decreased to 6.4 +/- 1.7
      cmH2O/L/sec after the maneuver. Peak inspiratory pressure and plateau pressure
      were significantly decreased, and pulmonary compliance was increased, although
      the values were not clinically relevant. CONCLUSION: The recruitment maneuver
      decreased respiratory resistance and increased lung compliance during mechanical 
      ventilation. TRIAL REGISTRATION: Name of registry: Japan Medical Association
      Center for Clinical Trials. TRIAL REGISTRATION NUMBER: reference JMA-IIA00136.
      Date of registration: 2 September 2013. URL of trial registry record:
      https://dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=
      3&seqno=3582.
FAU - Nakahira, Junko
AU  - Nakahira J
AUID- ORCID: 0000-0002-8896-356X
AD  - Department of Anesthesiology, Osaka Medical College, 2-7 Daigaku-machi,
      Takatsuki, Osaka, 569-8686, Japan. ane052@osaka-med.ac.jp.
FAU - Nakano, Shoko
AU  - Nakano S
AD  - Department of Anesthesiology, Osaka Medical College, 2-7 Daigaku-machi,
      Takatsuki, Osaka, 569-8686, Japan.
FAU - Minami, Toshiaki
AU  - Minami T
AD  - Department of Anesthesiology, Osaka Medical College, 2-7 Daigaku-machi,
      Takatsuki, Osaka, 569-8686, Japan.
LA  - eng
GR  - 17K16761/KAKENHI (Grants-in-Aid for Scientific Research) from the Japan Society
      for the Promotion of Science/International
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201017
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
SB  - IM
MH  - Aged
MH  - Airway Resistance/*physiology
MH  - Anesthesia, General/*methods
MH  - Female
MH  - Humans
MH  - Lung Compliance
MH  - Male
MH  - Middle Aged
MH  - *Positive-Pressure Respiration
MH  - Prospective Studies
MH  - Pulmonary Alveoli/*physiology
PMC - PMC7568405
OTO - NOTNLM
OT  - *Alveolar recruitment maneuver
OT  - *Forced oscillation technique
OT  - *Respiratory resistance
EDAT- 2020/10/19 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/10/18 20:19
PHST- 2020/03/06 00:00 [received]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/10/18 20:19 [entrez]
PHST- 2020/10/19 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.1186/s12871-020-01182-9 [doi]
AID - 10.1186/s12871-020-01182-9 [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 Oct 17;20(1):264. doi: 10.1186/s12871-020-01182-9.


PMID- 33068093
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201218
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Lifestyle, behavior, perception and practices of Nepalese during lockdown due to 
      COVID-19 pandemic.
PG  - 690-695
LID - 10.31729/jnma.5284 [doi]
AB  - INTRODUCTION: COVID-19 infection is caused by a new strain of SARS CoV-2 virus,
      which transmits directly from person-to-person and has become a pandemic. To
      counteract this, actions related to mass quarantines or stay-at-home orders have 
      been used termed as lockdown. This study aims to study lifestyle, behaviour,
      perception and practice of people regarding during the lockdown. METHODS: An
      online survey was conducted with structured questionnaire in Google forms after
      ethical approval from Nepal Health Research Council (Ref-2631). The attributes of
      knowledge, attitude and practices were explored using multiple-choice questions
      and results were statistically analysed using Microsoft excel. RESULTS: Five
      hundred fifty-five respondents completed the survey with 280 (50.5%) males and
      275 (49.5%) female. The knowledge regarding viral pandemic was increased in 496
      (89.3%) respondents. 424 (76.4%) people developed stress due to pandemic. Three
      hundred fifty three (63.6%) were adversely affected by professional works or
      suffered economic loss in business. More than 42% participants are using their
      time for study in personal development, online classes etc. Conclusions: The
      knowledge of viral pandemic as well as personal hygiene habits have improved in
      majority of people but many also developed stress. They were convinced that
      lockdown lowered transmission of infection which in turn affected lifestyle
      behaviour and practices. Practicing social distancing becomes too difficult for
      the poor in the absence of proper social security system and government support. 
      E-Learning has become more acceptable due to lockdown. Further studies with
      in-person interviews are warranted.
FAU - Kandel, Samikshya
AU  - Kandel S
AD  - Nepal Academy of Science and Technology, Khumaltar, Lalitpur, Nepal.
FAU - Lamsal, Mahesh
AU  - Lamsal M
AD  - Central Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu,
      Nepal.
FAU - Yadav, Saroj Adhikari
AU  - Yadav SA
AD  - Patan Academy of Health Sciences, Lalitpur, Kathmandu, Nepal.
FAU - Bhandari, Dipak
AU  - Bhandari D
AD  - Pokhara Biological Sciences and Technology Centre, Pokhara, Nepal.
FAU - Adhikari, Ganesh
AU  - Adhikari G
AD  - Central Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu,
      Nepal.
FAU - Poudel, Sagar
AU  - Poudel S
AD  - All India Institute of Medical Sciences, New Delhi, India.
FAU - Sharma, Pawan
AU  - Sharma P
AD  - B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Gautam, Swotantra
AU  - Gautam S
AD  - B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Hand Sanitizers)
SB  - IM
MH  - Adult
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Economic Status
MH  - Education, Distance
MH  - Employment
MH  - Female
MH  - Gloves, Protective
MH  - Hand Hygiene
MH  - Hand Sanitizers
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Hygiene
MH  - Male
MH  - Masks
MH  - Middle Aged
MH  - Nepal
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Quarantine
MH  - SARS-CoV-2
MH  - Stress, Psychological/psychology
MH  - Young Adult
PMC - PMC7580336
OTO - NOTNLM
OT  - COVID-19; lockdown; Nepal; Pandemic.
EDAT- 2020/10/18 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/08/14 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.31729/jnma.5284 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):690-695. doi: 10.31729/jnma.5284.


PMID- 33068092
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Postpartum Maternal Morbidity Requiring Hospital Admission in A Teaching
      Hospital: A Descriptive Cross-sectional Study.
PG  - 686-689
LID - 10.31729/jnma.5125 [doi]
AB  - INTRODUCTION: Major concern shifts from mother to newborn in postnatal period.
      Postpartum complications contribute to a lot of maternal morbidity and mortality.
      This study aims to determine the prevalence of morbidities in women following
      delivery at Manipal Teaching Hospital so as to identify and improve maternal
      quality care. METHODS: This is a descriptive cross-sectional study conducted at
      department of Obstetrics and Gynaecology, Manipal Teaching Hospital from
      September 2018 to March 2020 after ethical approval from the institutional review
      committee with reference number 1296. All the women presenting to the department 
      during the study period were included in the study. Women who were admitted to
      accompany and nurse their babies for neonatal problems were excluded.Point
      estimate at 95% Confidence Interval was calculated along with frequency and
      proportion for binary data. Data were entered in Excel and analysed in SPSS.
      RESULTS: Among 3510 cases, 104 women were admitted with various postpartum
      morbidities. The prevalence of postpartum morbidity was found to be 104 (2.96%)
      at 95% Confidence Interval (2.67-3.25). Puerperal sepsis was diagnosed in 23
      (22.11%), preeclampsia in 20(19.23%) eclampsia in 14 (13.46%) and haemorrhage in 
      14 (13.46%) respectively. Majority of patients, 83.65% belonged to age group of
      20-34 years. Nine patients (8.65%) were teenage mothers. CONCLUSIONS: Puerperal
      sepsis, preeclampsia, eclampsia and haemorrhage were the major postpartum
      complications requiring admissions in hospital.
FAU - Shrestha, Pravin
AU  - Shrestha P
AD  - Department of Obstetrics and Gynecology, Manipal College of Medical Sciences,
      Pokhara, Nepal.
FAU - Mahato, Vibha
AU  - Mahato V
AD  - Department of Obstetrics and Gynecology, Manipal College of Medical Sciences,
      Pokhara, Nepal.
FAU - Karmacharya, Smita Shrestha
AU  - Karmacharya SS
AD  - Nobel College, Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - *Cesarean Section
MH  - Cross-Sectional Studies
MH  - *Eclampsia
MH  - Female
MH  - Hospitals, Teaching
MH  - Humans
MH  - Infant, Newborn
MH  - Postpartum Period
MH  - Pregnancy
MH  - Young Adult
PMC - PMC7580332
OTO - NOTNLM
OT  - hospital admission; maternal morbidity; postpartum.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/06/22 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5125 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):686-689. doi: 10.31729/jnma.5125.


PMID- 33068089
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Safe Abortion among Underprivileged Group Married Women of Low Resource Country: 
      A Descriptive Cross-sectional Study.
PG  - 672-676
LID - 10.31729/jnma.5298 [doi]
AB  - INTRODUCTION: Unsafe Abortion is one of the leading causes of maternal death. The
      unhygienic and dangerous practice has been encountered in various geographical
      areas of Nepal. Despite its legalization, many women are still being not
      concerned and well informed regarding safe abortion and become victims of it. The
      main aim of this study was to assess the knowledge and practice regarding safe
      abortion among married women of reproductive (14 to 49) years of an
      underprivileged group of low resource country, Nepal. METHODS: A descriptive
      cross-sectional study design was done in Rajbanshi community of Jhapa District.
      Data collection was done after taking ethical approval. Study population was
      selected conveniently. Data was collected by using a semi-structured
      questionnaire via face to face interviews among 420 married women of reproductive
      (14-49) years. All the extracted data were entered and analyzed using Statistical
      Package for the Social Services version 20. Descriptive analysis was doneand
      presented using frequency and percentage. RESULTS: Out of 420 respondents, 388
      respondents (92.4%) found to have poor knowledge, regarding safe abortion.
      Likewise, only 44 respondents (10.05%) had practiced abortion, of which only 2
      respondents (0.05%) had an unsafe abortion and 42 respondents (10%) had practiced
      safe abortion. CONCLUSIONS: Practices of unsafe abortion were prevalent.
      Respondents with poor knowledge werefound to have done abortion. In this context,
      it can be concluded that knowledge regarding safe abortion can be increased by
      educating and providing awareness to the people of society.
FAU - Budathoki, Sapana
AU  - Budathoki S
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Mali, Prajita
AU  - Mali P
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Khadka, Rakshya
AU  - Khadka R
AD  - Centre for Mental Health and Counselling Service-Nepal, Nepal.
FAU - Rajbhandari, Bibek
AU  - Rajbhandari B
AD  - Nepal Police Hospital, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Abortion, Induced
MH  - *Abortion, Legal
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Nepal/epidemiology
MH  - Pregnancy
PMC - PMC7580325
OTO - NOTNLM
OT  - abortion; Nepal; reproductive.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/08/18 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5298 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):672-676. doi: 10.31729/jnma.5298.


PMID- 33068087
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Spectrum of Injury Presenting to Emergency Department in A Tertiary Care Hospital
      in Nepal: A Descriptive Cross-sectional Study.
PG  - 664-667
LID - 10.31729/jnma.5248 [doi]
AB  - INTRODUCTION: Injury is one of the major global public health problems causing
      significant number of death and disability. The study aims to study the
      epidemiological and clinical profile of patients presented in emergency
      department with injury. METHODS: This was a descriptive cross-sectional study
      conducted in a tertiary care hospital from September 2019 to February 2020 after 
      obtaining ethical approval from Institutional review board (reference number
      007-076/077). A convenient sampling method was applied. Epidemiological factors, 
      chronological factors, causes of injury, anatomical distribution, pattern of
      injury were studied. Statistical analysis was done using statistical package for 
      the social sciences version 20. Point estimate at 95% Confidence Interval was
      calculated along with frequency and proportion for binary data. RESULTS: Out of
      197 patients, 72 (36.5%) patients had fall followed by road traffic accident 57
      (28.9%). Of total, 80 (40.6%) had injury at home and 80 (40.6%) had cut injury.
      Head and neck accounted for 66 (33.5%) of total injury followed by upper
      Extremities 50 (25.4%) and lower extremities 47 (23.9%). Eighty-seven (44.2%) of 
      the patients visited emergency within 30 minutes of sustained injury.
      CONCLUSIONS: The top three leading causes of injuries visiting emergency
      department were: fall, Road Traffic Accident and physical assaults respectively. 
      The most common mode was fall being cut as most common pattern. Head and neck was
      the most commonest site of injury. The common place of injury was home.
FAU - Thapa, Sameer
AU  - Thapa S
AD  - Department of Emergency Medicine and General Practice, Nepal Medical College and 
      Teaching Hospital, Attarkhel, Kathmandu, Nepal.
FAU - Upreti, Anup Raj
AU  - Upreti AR
AD  - Clinical Pharmacist, Nepal Medical College and Teaching Hospital, Attarkhel,
      Kathmandu, Nepal.
FAU - Dawadi, Bishow Raj
AU  - Dawadi BR
AD  - Department of Emergency Medicine and General Practice, Grande International
      Hospital, Dhapasi, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Accidents, Traffic
MH  - Cross-Sectional Studies
MH  - *Emergency Service, Hospital
MH  - Humans
MH  - Nepal/epidemiology
MH  - Tertiary Care Centers
PMC - PMC7580327
OTO - NOTNLM
OT  - fall; injury; road traffic accident.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/08/04 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5248 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):664-667. doi: 10.31729/jnma.5248.


PMID- 33068085
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Prevalence of Thyroid Dysfunction Among Depression Patients in a Tertiary Care
      Centre.
PG  - 654-658
LID - 10.31729/jnma.5296 [doi]
AB  - INTRODUCTION: Patients with thyroid disorders are more prone to develop
      depressive symptoms and conversely depression may be accompanied by various
      subtle thyroid abnormalities. The aim of the study was to estimate the prevalence
      of thyroid dysfunction in depression. METHODS: This is a descriptive
      cross-sectional study conducted at Devdaha Medical College and Research Institute
      employing a simple random sampling technique during the period of August
      2019-January 2020. The research was approved by the Ethical Committee of the
      Institutional Review Board of Devdaha Medical College and Research Institute. The
      protocol approval number is 009/019. Data analysis was done in Statistical
      Package for the Social Sciences (Version 23). Results were presented as
      frequencies and percentages where required. RESULTS: Among 263 patients with
      depression, 69 (26.2%) had abnormal thyroid status with most common being
      subclinical hypothyroidism 32 (12.2%), 13 (4.9%) overt hypothyroidism and 7
      (2.7%) overt hyperthyroidism. CONCLUSIONS: The prevalence of thyroid dysfunction 
      is high among patients with depression. We recommend to conduct routine thyroid
      function tests for all the patients with depression.
FAU - Kafle, Bikram
AU  - Kafle B
AD  - Department of Psychiatry, Devdaha Medical College, Rupandehi, Nepal.
FAU - Khadka, Bikram
AU  - Khadka B
AD  - Department of Biochemistry, Devdaha Medical College, Rupandehi, Nepal.
FAU - Tiwari, Mohan Lal
AU  - Tiwari ML
AD  - Department of Medicine, Devdaha Medical College, Rupandehi, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Depression/epidemiology
MH  - Humans
MH  - Prevalence
MH  - Tertiary Care Centers
MH  - *Thyroid Gland
PMC - PMC7580338
OTO - NOTNLM
OT  - depression; hyperthyroidism; hypothyroidism.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/08/17 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5296 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):654-658. doi: 10.31729/jnma.5296.


PMID- 33068084
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Prevalence of Repeat Cesarean Section in a Tertiary Care Hospital.
PG  - 650-653
LID - 10.31729/jnma.5375 [doi]
AB  - INTRODUCTION: Cesarean section is the surgical delivery of a baby through an
      incision made in the mother's abdomen and uterus. Repeat cesarean section has
      recently increased, partly because of concern about increased risk of uterine
      rupture in women attempting vaginal birth after cesarean delivery. Among the
      women who underwent cesarean section in their first delivery, 80-96% had a second
      surgical delivery. Therefore, the present study aimed to describe the prevalence 
      of repeat cesarean section among Nepali women presented at Kathmandu Medical
      College and Teaching Hospital who had a previous cesarean section. METHODS: This 
      was a descriptive cross-sectional study conducted in Kathmandu Medical College
      and Teaching Hospital from 1st of February to 31st of May 2020. Ethical approval 
      was taken from the Institutional Review Committee of the Kathmandu Medical
      College. Convenient sampling was done. All pregnant patients between gestational 
      ages of 37-40 weeks with previous cesarean section admitted for safe confinement 
      were included in the study. RESULTS: Among the 104 women, who had prior cesarean 
      section, 99 (95.19%) had second cesarean section and 5 (4.81%) had vaginal birth 
      after cesarean. The most common indication for the first cesarean section was
      fetal distress 31 (29.81%) while the indication for the second cesarean section
      among previously cesarean section women was cephalo pelvic disproportion 39
      (39.40%). CONCLUSIONS: The proportion of cesarean section in both first and
      subsequent delivery is quite high. This high rate may compromise the reproductive
      future of the women who underwent consecutive cesarean section with possible
      consequent complications.
FAU - Sharma, Jyotshna
AU  - Sharma J
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College, Sinamangal, 
      Kathmandu, Nepal.
FAU - Tiwari, Sanjeeb
AU  - Tiwari S
AD  - Department of General Practice and Emergency Medicine, Maharajgunj Medical
      Campus, Institute of Medicine, T.U., Maharajgunj, Kathmandu, Nepal.
FAU - Padhye, Saraswati M
AU  - Padhye SM
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College, Sinamangal, 
      Kathmandu, Nepal.
FAU - Mahato, Bidya
AU  - Mahato B
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College, Sinamangal, 
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cesarean Section
MH  - Cesarean Section, Repeat/adverse effects
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Pregnancy
MH  - Prevalence
MH  - Risk Factors
MH  - Tertiary Care Centers
MH  - *Uterine Rupture/epidemiology/etiology/surgery
MH  - *Vaginal Birth after Cesarean
PMC - PMC7580334
OTO - NOTNLM
OT  - birth; cesarean section; vaginal birth after cesarean.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/09/11 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5375 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):650-653. doi: 10.31729/jnma.5375.


PMID- 33068083
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Ringer's Lactate Hydration and Incidence of Post ERCP Pancreatitis: A Descriptive
      Cross-sectional Study.
PG  - 645-649
LID - 10.31729/jnma.5435 [doi]
AB  - INTRODUCTION: Endoscopic retrograde cholangiopancreatography is one of the most
      frequently used treatment modality for various pancreatobiliary problems.
      Frequent complications of endoscopic retrograde cholangiopancreatography include 
      pancreatitis, cholangitis, hemorrhage and perforation. This study was done to see
      the prevalence of post endoscopic retrograde cholangiopancreatography
      pancreatitis in patient aggressively hydrated with Ringer's Lactate solution.
      METHODS: A descriptive cross sectional study was carried out on patient
      undergoing endoscopic retrograde cholangiopancreatography at Bharatpur Hospital
      from June 2018 to August 2020. Ethical clearance was taken from Institutional
      Review Committee Bharatpur Hospital (reference number 16/076/77). The convenient 
      sampling method was applied. Data were collected and analyzed in statistical
      package for the social sciences version 16. Point estimate at 95% confidence
      interval was calculated along with frequency and proportion for binary data.
      RESULTS: Pain abdomen was assessed using Visual Analogue Scale and it was found
      that 8.1% of patients (15 patients) complained of pain abdomen with visual
      analogue scale> 3. Serum amylase was sent only in those patients who complained
      of pain abdomen and only in three patients (1.6%) serum amylase was increased
      more than 3 times the upper limit of normal value suggestive of pancreatitis. All
      three patients who had pancreatitis had precut sphincterotomy. CONCLUSIONS: In
      this study we found that incidence of pancreatitis slumped after aggressive
      hydration with Ringer's lactate solution and adjunct use of other prophylactic
      measures for prevention of post endoscopic retrograde cholangiopancreatography
      pancreatitis might yield further better results.
FAU - Pun, Ashis
AU  - Pun A
AD  - Department of Surgery, Bharatpur Hospital, Bharatpur, Chitwan, Nepal.
FAU - Dhungana, Amit
AU  - Dhungana A
AD  - Department of Anaesthesiology, Bharatpur Hospital, Bharatpur, Chitwan, Nepal.
FAU - Neupane, Dipendra
AU  - Neupane D
AD  - Department of Surgery, Bharatpur Hospital, Bharatpur, Chitwan, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Ringer's Lactate)
SB  - IM
MH  - *Cholangiopancreatography, Endoscopic Retrograde/adverse effects
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Incidence
MH  - *Pancreatitis/epidemiology/etiology
MH  - Ringer's Lactate
PMC - PMC7580329
OTO - NOTNLM
OT  - endoscopic retrograde cholangiopancreatography; pancreatitis; ringer's lactate.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/09/26 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5435 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):645-649. doi: 10.31729/jnma.5435.


PMID- 33068082
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Excessive Daytime Sleepiness among First to Fourth Year Undergraduate Students of
      a Medical College in Nepal: A Descriptive Cross-sectional Study.
PG  - 640-644
LID - 10.31729/jnma.5297 [doi]
AB  - INTRODUCTION: Excessive Daytime Sleepiness is a significant health problem among 
      medical students worldwide which can impair their cognitive and academic
      performances. Our study aims to determine the prevalence of Excessive Daytime
      Sleepiness among the first to fourth year undergraduate students of the Nepalese 
      Army Institute of Health Sciences-College of Medicine. METHODS: Following the
      ethical approval from the Institutional Review Committee with registration no.
      317, a descriptive cross-sectional study was conducted among the first to fourth 
      year medical students of the Nepalese Army Institute of Health Sciences-College
      of Medicine from 4" to 10" August 2020. Two hundred and thirty-two students were 
      selected for the study using the stratified random sampling technique. Epworth
      Sleepiness Scale was used to obtain data on daytime sleepiness among the study
      participants. The data were entered into Google spreadsheets and later analyzed. 
      Point estimate at 95% Confidence Interval was calculated along with the frequency
      and proportion for binary data. RESULTS: The prevalence of Excessive Daytime
      Sleepiness among the first to fourth year undergraduate students of the Nepalese 
      Army Institute of Health Sciences-College of Medicine is found to be 67 (31.02%) 
      at 95% Confidence Interval (24.85-37.19). It was found to be highly prevalent
      among the fourth year undergraduate medical students 20 (35.09%) and least
      prevalent among the first year students 13 (26.00%). Excessive Daytime Sleepiness
      was found to be slightly higher among females 23 (34.85%) than males 44 (29.33%).
      CONCLUSIONS: Excessive Daytime Sleepinessis highly prevalent among medical
      students in our study as suggested by various international studies.
FAU - Roka, Kumar
AU  - Roka K
AD  - Department of Internal Medicine, Shree Birendra Hospital, Chhauni, Kathmandu,
      Nepal.
FAU - Khadka, Sabina
AU  - Khadka S
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Dahal, Sanju
AU  - Dahal S
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Yadav, Meenakshi
AU  - Yadav M
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Thapa, Puja
AU  - Thapa P
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Kc, Rubina
AU  - Kc R
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Disorders of Excessive Somnolence/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Surveys and Questionnaires
MH  - Universities
PMC - PMC7580330
OTO - NOTNLM
OT  - Epworth Sleepiness Scale; Excessive Daytime Sleepiness; medical students; Nepal; 
      prevalence.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/08/18 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5297 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):640-644. doi: 10.31729/jnma.5297.


PMID- 33068081
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Prevalence of Intracranial Artery Stenosis in Patients with Acute Ischemic Stroke
      in a Tertiary Care Hospital of China.
PG  - 634-639
LID - 10.31729/jnma.5201 [doi]
AB  - INTRODUCTION: Intracranial artery stenosis is the most common cause of acute
      ischemic stroke, especially among people in Asia. About its epidemiology, however
      little is understood. The goal of our research is to establish the prevalence of 
      intracranial artery stenosis in patients with acute ischemic stroke in a tertiary
      care hospital. METHODS: A descriptive cross-sectional study was done in 1006
      acute ischemic stroke patients at Affiliated Zhongda Hospital, School of
      Medicine, Southeast University China from May 2018 to May 2019. Ethical approval 
      was taken from the Ethical review committee of the institution. A convenient
      sampling method was done. Intracranial artery stenosis was diagnosed when
      evidence of acute ischemic stroke was found in the territory of approximately 2
      50% stenosis identified by Transcranial Doppler ultrasound and confirmed by
      magnetic resonance angiography or computed tomography. Statistical analysis was
      done using the Statistical Package for the Social Sciences version 20. RESULTS:
      The prevalence of intracranial artery stenosis was found in 331 (32.90%) patients
      at 95% Confidence interval (0.24-0.42%). Among 331 cases the anterior circulation
      artery stenosis was present on 201 (19.98%) patients, followed by posterior
      circulation artery stenosis on 80 (7.95%) patients, then anterior plus posterior 
      circulation artery stenosis on 50 (4.97%) patients. CONCLUSIONS: Intracranial
      artery stenosis is one of the most causes of acute ischemic stroke in China. The 
      proportion of anterior circulation artery stenosis was higher than that in the
      posterior circulation.
FAU - Jaiswal, Sandip Kumar
AU  - Jaiswal SK
AD  - Department of Neurology, Affiliated Zhongda Hospital, School of Medicine,
      Southeast University China.
FAU - Fuling, Yan
AU  - Fuling Y
AD  - Department of Neurology, Affiliated Zhongda Hospital, School of Medicine,
      Southeast University China.
FAU - Li, Min
AU  - Li M
AD  - Department of Cardiology, Affiliated Zhongda Hospital, School of Medicine,
      Southeast University China.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Arteries
MH  - Asia
MH  - *Brain Ischemia/epidemiology
MH  - China/epidemiology
MH  - Constriction, Pathologic
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Ischemic Stroke
MH  - Prevalence
MH  - *Stroke/epidemiology
MH  - Tertiary Care Centers
PMC - PMC7580323
OTO - NOTNLM
OT  - acute ischemic stroke; intracranial artery stenosis; transcranial Doppler
      ultrasound.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/07/18 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5201 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):634-639. doi: 10.31729/jnma.5201.


PMID- 33068080
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 229
DP  - 2020 Sep 27
TI  - Right Ventricular Dimensions and Tricuspid Annular Plane Systolic Excursion among
      Medical Students of Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 630-633
LID - 10.31729/jnma.5302 [doi]
AB  - INTRODUCTION: The change in morphology and functions of the right ventricle is an
      important predictor of heart and lung disease. There is limited data on the
      normal dimension of the right ventricle. The study aimed to find the right
      ventricular diameter, its thickness, and tricuspid annular plane systolic
      excursion in healthy male medical students of a tertiary care hospital. METHODS: 
      It is a descriptive cross-sectional study conducted in healthy medical students
      of Kathmandu Medical College and Teaching Hospital, from February-April, 2019.
      Ethical approval was taken from the institutional review committee (reference
      number 120720193). Convenient sampling method was used. We measured various
      dimensions of the right ventricle in different views. The data was analyzed in
      the Statistical Package for the Social Sciences. RESULTS: In the 96 male students
      included in the study, the mean right ventricular basal diameter was 36.45+/-3.49
      mm, right ventricular mid cavity diameter was 29+/-3.63 mm, right ventricular
      longitudinal dimension was 65.72+/-7.52 mm, right ventricular outflow tract in
      parasternal long-axis view was 27.07+/-2.12 mm, proximal and distal right
      ventricular outflow in parasternal short-axis view was 25.33+/-2.57 mm and
      20.08+/-1.99 mm, right ventricular thickness was 4.20+/-0.54 mm, and tricuspid
      annular plane systolic excursion was 23.02+/-3.54 mm. CONCLUSIONS: The study
      found that the values of right ventricular dimensions and the right ventricle's
      tricuspid annular plane systolic excursion among male medical students of a
      tertiary care hospital to be in accordance with the guidelines by the American
      Society of Echocardiography. The upper limits of the normal values of the right
      ventricle could be very helpful in clinical practice in determining the right
      ventricle dimension.
FAU - Poudel, Nimesh
AU  - Poudel N
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Bhattarai, Mahesh
AU  - Bhattarai M
AD  - Department of Cardiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Bhatt, Laxmi Raj
AU  - Bhatt LR
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Karki, Dambar Bahadur
AU  - Karki DB
AD  - Department of Cardiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Echocardiography
MH  - *Heart Ventricles/diagnostic imaging
MH  - Humans
MH  - Male
MH  - *Students, Medical
MH  - Tertiary Care Centers
PMC - PMC7580333
OTO - NOTNLM
OT  - echocardiography; heart; right ventricle.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/17 12:04
PHST- 2020/08/21 00:00 [received]
PHST- 2020/10/17 12:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5302 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Sep 27;58(229):630-633. doi: 10.31729/jnma.5302.


PMID- 33067664
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201112
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 11
DP  - 2020 Nov
TI  - [Studies on novel immune therapies: challenges from an ethical point of view].
PG  - 1424-1430
LID - 10.1007/s00103-020-03232-6 [doi]
AB  - Novel immune therapies are more and more based on the molecular differentiation
      of disease patterns and related clinical studies are thus more often
      characterized by so-called adaptive study designs (umbrella or basket studies
      including platform studies), which are continuously adjusted based on novel
      results. This paper analyses new study designs beyond the often-postulated need
      for regulation in order to identify ethical problems based on typical structural 
      features and to - whenever possible - suggest solutions. Additionally to the
      relationship between social and scientific values of a study as well as aspects
      of the scientific validity of new forms of evidence, the inclusion of study
      subjects under the condition of relative uncertainty, specific challenges in the 
      process of ethical approval, as well as ethical and practical challenges in the
      process of informing patients and receiving informed consent will be addressed.
FAU - Paul, Norbert W
AU  - Paul NW
AD  - Institut fur Geschichte, Theorie und Ethik der Medizin, Universitatsmedizin
      Mainz, Am Pulverturm 13, 55131, Mainz, Deutschland. norbert.paul@uni-mainz.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Studien zu neuen Immuntherapien: Herausforderungen aus Sicht der Ethik.
DEP - 20201016
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - Germany
MH  - Humans
MH  - *Informed Consent
MH  - *Morals
MH  - Research Design
PMC - PMC7647972
OTO - NOTNLM
OT  - Adaptive study design
OT  - Basket studies
OT  - Ethics
OT  - Risk-benefit analysis
OT  - Umbrella studies
EDAT- 2020/10/18 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/17 05:30
PHST- 2020/05/08 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/10/17 05:30 [entrez]
AID - 10.1007/s00103-020-03232-6 [doi]
AID - 10.1007/s00103-020-03232-6 [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Nov;63(11):1424-1430. doi: 10.1007/s00103-020-03232-6. Epub 2020 Oct 16.


PMID- 33067315
OWN - NLM
STAT- Publisher
LR  - 20201017
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 16
TI  - Triage and justice in an unjust pandemic: ethical allocation of scarce medical
      resources in the setting of racial and socioeconomic disparities.
LID - medethics-2020-106457 [pii]
LID - 10.1136/medethics-2020-106457 [doi]
AB  - Shortages of life-saving medical resources caused by COVID-19 have prompted
      hospitals, healthcare systems, and governmentsto develop crisis standards of
      care, including 'triage protocols' to potentially ration medical supplies during 
      the public health emergency. At the same time, the pandemic has highlighted and
      exacerbated racial, ethnic, and socioeconomic health disparities that together
      constitute a form of structural racism. These disparities pose a critical ethical
      challenge in developing fair triage systems that will maximize lives saved
      without perpetuating systemic inequities. Here we review alternatives to
      'utilitarian' triage, including first-come first-served, egalitarian, and
      prioritarian systems of allocating scarce medical resources. We assess the
      comparative advantages and disadvantages of these allocation schemes. Ultimately,
      we argue that while triage protocols should not exacerbate disparities, they are 
      not an adequate mechanism for redressing systemic health inequities. Entrenched
      health disparities must be addressed through broader social change.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Tolchin, Benjamin
AU  - Tolchin B
AUID- ORCID: http://orcid.org/0000-0002-9099-0022
AD  - Neurology, Yale School of Medicine, New Haven, Connecticut, USA
      benjamin.tolchin@yale.edu.
AD  - Epilepsy Center of Excellence, VA Connecticut Healthcare System, West Haven,
      Connecticut, USA.
AD  - Adult Ethics Committee, Yale New Haven Hospital, New Haven, Connecticut, USA.
FAU - Hull, Sarah C
AU  - Hull SC
AD  - Cardiology, Yale School of Medicine, New Haven, Connecticut, USA.
AD  - Program for Biomedical Ethics, Yale School of Medicine, New Haven, Connecticut,
      USA.
FAU - Kraschel, Katherine
AU  - Kraschel K
AD  - Solomon Center for Health Law & Policy, Yale Law School, New Haven, Connecticut, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - legal aspects
OT  - minorities
OT  - resource allocation
OT  - social aspects
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2020/10/18 06:00
CRDT- 2020/10/17 05:25
PHST- 2020/05/18 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/10/17 05:25 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/10/18 06:00 [medline]
AID - medethics-2020-106457 [pii]
AID - 10.1136/medethics-2020-106457 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 16. pii: medethics-2020-106457. doi:
      10.1136/medethics-2020-106457.


PMID- 33067314
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - COVID-19 and beyond: the ethical challenges of resetting health services during
      and after public health emergencies.
PG  - 715-716
LID - 10.1136/medethics-2020-106965 [doi]
FAU - Baines, Paul
AU  - Baines P
AUID- ORCID: 0000-0001-9045-4054
AD  - Division of Health Science, Warwick Medical School, University of Warwick,
      Coventry, UK.
FAU - Draper, Heather
AU  - Draper H
AUID- ORCID: 0000-0002-0020-4252
AD  - Division of Health Science, Warwick Medical School, University of Warwick,
      Coventry, UK.
FAU - Chiumento, Anna
AU  - Chiumento A
AUID- ORCID: 0000-0002-0526-0173
AD  - Department of Primary Care and Mental Health, University of Liverpool, Liverpool,
      UK.
FAU - Fovargue, Sara
AU  - Fovargue S
AD  - Law School, Lancaster University, Lancaster, UK.
FAU - Frith, Lucy
AU  - Frith L
AUID- ORCID: 0000-0002-8506-0699
AD  - Institute of Population Health, University of Liverpool, Liverpool, UK
      L.J.Frith@liverpool.ac.uk.
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/therapy/virology
MH  - Decision Making/*ethics
MH  - Delivery of Health Care/*ethics
MH  - Emergencies
MH  - *Ethics, Clinical
MH  - Health Equity
MH  - Health Planning/ethics
MH  - Health Services/*ethics
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/epidemiology/therapy/virology
MH  - Public Health/*ethics
MH  - Resource Allocation/ethics
MH  - SARS-CoV-2
PMC - PMC7656144
OTO - NOTNLM
OT  - *ethics
OT  - *public health ethics
OT  - *public policy
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/17 05:25
PHST- 2020/10/01 00:00 [received]
PHST- 2020/10/04 00:00 [accepted]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/10/17 05:25 [entrez]
AID - medethics-2020-106965 [pii]
AID - 10.1136/medethics-2020-106965 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):715-716. doi: 10.1136/medethics-2020-106965. Epub
      2020 Oct 16.


PMID- 33067305
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - The Food provision, cUlture and Environment in secondary schooLs (FUEL) study:
      protocol of a mixed methods evaluation of national School Food Standards
      implementation in secondary schools and their impact on pupils' dietary intake
      and dental health.
PG  - e042931
LID - 10.1136/bmjopen-2020-042931 [doi]
AB  - INTRODUCTION: Excess free sugar intake is associated with obesity and poor dental
      health. Adolescents consume substantially more free sugar than is recommended.
      National (UK) School Food Standards (SFS) are in place but are not mandatory in
      all schools, and their impact on the diets of secondary school pupils is unknown.
      We aim to evaluate how SFS and wider healthy eating recommendations (from the
      national School Food Plan (SFP)) are implemented in secondary schools and how
      they influence pupils' diets and dental health. METHODS AND ANALYSIS:
      Secondary-level academies/free schools in the West Midlands, UK were divided into
      two groups: SFS mandated and SFS non-mandated. Using propensity scores to guide
      sampling, we aim to recruit 22 schools in each group. We will compare data on
      school food provision and sales, school food culture and environment, and the
      food curriculum from each group, collected through: school staff, governor,
      pupil, parent surveys; school documents; and observation. We will explore the
      implementation level for the SFS requirements and SFP recommendations and develop
      a school food typology. We aim to recruit 1980 pupils aged 11-15 years across the
      44 schools and collect dietary intake (24-hour recall) and dental health data
      through self-completion surveys. We will compare free sugar/other dietary intake 
      and dental health across the two SFS groups and across the identified school
      types. School type will be further characterised in 4-8 case study schools
      through school staff interviews and pupil focus groups. Evaluation of economic
      impact will be through a cost-consequence analysis and an exploratory
      cost-utility analysis. ETHICS AND DISSEMINATION: Ethical approval was obtained
      from the University of Birmingham Ethical Review Committee (ERN_18-1738).
      Findings will be disseminated to key national and local agencies, schools and the
      public through reports, presentations, the media and open access publications.
      TRIAL REGISTRATION NUMBER: ISRCTN 68757496 (registered 17 October 2019).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Murphy, Marie
AU  - Murphy M
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Pallan, Miranda
AU  - Pallan M
AUID- ORCID: 0000-0002-2868-4892
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK
      m.j.pallan@bham.ac.uk.
FAU - Lancashire, Emma
AU  - Lancashire E
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Duff, Rhona
AU  - Duff R
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Adamson, Ashley J
AU  - Adamson AJ
AD  - Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle 
      University, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Bartington, Suzanne
AU  - Bartington S
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Frew, Emma
AU  - Frew E
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Griffin, Tania
AU  - Griffin T
AD  - Department for Health, University of Bath, Bath, UK.
FAU - Hurley, Kiya L
AU  - Hurley KL
AD  - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham,
      UK.
FAU - Parry, Jayne
AU  - Parry J
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Passmore, Sandra
AU  - Passmore S
AD  - Services for Education Ltd, Birmingham, UK.
FAU - Ravaghi, Vahid
AU  - Ravaghi V
AD  - School of Dentistry, University of Birmingham, Birmingham, UK.
FAU - Sitch, Alice J
AU  - Sitch AJ
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
AD  - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS
      Foundation Trust, Birmingham, UK.
FAU - Spence, Suzanne
AU  - Spence S
AD  - Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle 
      University, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Rowland, Maisie K
AU  - Rowland MK
AD  - Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle 
      University, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Wheeldon, Scott
AU  - Wheeldon S
AD  - Wheelers Lane Technology College, Birmingham, UK.
FAU - Adab, Peymane
AU  - Adab P
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
LA  - eng
SI  - ISRCTN/ISRCTN68757496
GR  - MR/K02325X/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Diet
MH  - Diet, Healthy
MH  - Eating
MH  - *Food
MH  - Humans
MH  - *Schools
PMC - PMC7569925
OTO - NOTNLM
OT  - *epidemiology
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: MP, EL, AJA, SB, EF, TG, KH, JP, SP, VR, AJS and PA hold
      grants from the UK National Institute for Health Research (NIHR). PA is Chair of 
      the NIHR Public Health Research Funding Committee. AJA is Director of the NIHR
      School for Public Health Research, a NIHR Senior Investigator and a member of
      both the School Food Plan Alliance and UK Prevention Research Partnership network
      Generating Excellent Nutrition in UK Schools (GENIUS). JP is Chair of a NIHR
      Fellowships selection committee. AJS is a grant holder for the Birmingham NIHR
      Biomedical Research Centre. SB is an elected member of Oxfordshire County
      Council.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:25
PHST- 2020/10/17 05:25 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042931 [pii]
AID - 10.1136/bmjopen-2020-042931 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e042931. doi: 10.1136/bmjopen-2020-042931.


PMID- 33067301
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Effect of wheelchair-modified rowing exercise on cardiometabolic risk factors in 
      spinal cord injured wheelchair users: protocol for a randomised controlled trial.
PG  - e040727
LID - 10.1136/bmjopen-2020-040727 [doi]
AB  - INTRODUCTION: Cardiovascular and metabolic diseases are a growing concern for
      individuals with spinal cord injury (SCI). Physical inactivity contributes to
      cardiometabolic morbidity and mortality in the SCI population. However, previous 
      studies have shown mixed results regarding the effects of exercise on
      cardiometabolic risk factors in individuals with SCI. This discrepancy could be
      influenced by insufficient exercise stimuli. Recent guidelines recommend 30 min
      of moderate-to-vigorous intensity aerobic exercise, three times per week, for
      improvement in cardiometabolic health in individuals with SCI. However, to date, 
      no studies have implemented an exercise intervention matching the new
      recommendations to examine the effects on cardiometabolic risk factors.
      Therefore, the primary objective of this study is to determine the effects of 12 
      weeks of wheelchair user-modified upper-body rowing exercise on both traditional 
      (constituents of the metabolic syndrome) and novel (eg, vascular structure and
      function) cardiometabolic risk factors in manual wheelchair users with SCI.
      METHODS AND ANALYSIS: A randomised controlled trial will compare 12 weeks of
      upper-body rowing exercise, 30 min three times per week, with a control group
      continuing their normal lifestyle. Outcome measurements will be performed
      immediately before (baseline), after 6 weeks (halfway), 12 weeks of training
      (post) and 6 months after the termination of the intervention period (follow-up).
      Outcomes will include inflammatory (eg, C reactive protein) and metabolic
      biomarkers determined from venous blood (with serum fasting insulin as primary
      outcome), body composition, arterial blood pressure, cardiorespiratory fitness
      level, brachial artery vascular structure and function and autonomic nervous
      system function. ETHICS AND DISSEMINATION: This trial is reported to the Danish
      Data Protection Agency (J.nr. 2019-899/10-0406) and approved by the Committees on
      Health Research Ethics in The North Denmark Region on 12 December 2019 (J.nr.
      N-20190053). The principal investigator will collect written informed consent
      from all participants prior to inclusion. Irrespective of study outcomes, the
      results will be submitted to peer-reviewed scientific journals for publication.
      TRIAL REGISTRATION NUMBER: NCT04390087.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hansen, Rasmus Kopp
AU  - Hansen RK
AUID- ORCID: 0000-0001-8515-8779
AD  - Sport Sciences - Performance and Technology, Department of Health Science and
      Technology, Aalborg University, Aalborg, Denmark rkopp@hst.aau.dk.
AD  - Department of Research and Development, University College of Northern Jutland
      (UCN), Aalborg, Denmark.
FAU - Samani, Afshin
AU  - Samani A
AD  - Sport Sciences - Performance and Technology, Department of Health Science and
      Technology, Aalborg University, Aalborg, Denmark.
FAU - Laessoe, Uffe
AU  - Laessoe U
AD  - Department of Research and Development, University College of Northern Jutland
      (UCN), Aalborg, Denmark.
AD  - Physical Therapy Department, University College of Northern Jutland (UCN),
      Aalborg, Denmark.
FAU - Handberg, Aase
AU  - Handberg A
AD  - Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg,
      Denmark.
AD  - Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
FAU - Larsen, Ryan Godsk
AU  - Larsen RG
AD  - Sport Sciences - Performance and Technology, Department of Health Science and
      Technology, Aalborg University, Aalborg, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04390087
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cardiometabolic Risk Factors
MH  - Exercise
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Spinal Cord
MH  - *Spinal Cord Injuries
MH  - *Water Sports
MH  - *Wheelchairs
PMC - PMC7569950
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *neurological injury
OT  - *physiology
OT  - *public health
OT  - *rehabilitation medicine
OT  - *ultrasonography
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:25
PHST- 2020/10/17 05:25 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040727 [pii]
AID - 10.1136/bmjopen-2020-040727 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e040727. doi: 10.1136/bmjopen-2020-040727.


PMID- 33067298
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Protocol for a definitive randomised controlled trial and economic evaluation of 
      a community-based rehabilitation programme following hip fracture: fracture in
      the elderly multidisciplinary rehabilitation-phase III (FEMuR III).
PG  - e039791
LID - 10.1136/bmjopen-2020-039791 [doi]
AB  - INTRODUCTION: Proximal femoral (hip) fracture is common, serious and costly.
      Rehabilitation may improve functional recovery but evidence of effectiveness and 
      cost-effectiveness are lacking. An enhanced rehabilitation intervention was
      previously developed and a feasibility study tested the methods used for this
      randomised controlled trial (RCT). The objectives are to compare the
      effectiveness and cost-effectiveness of the enhanced rehabilitation programme
      following surgical repair of proximal femoral fracture in older people compared
      with usual care. METHODS AND ANALYSIS: Protocol for phase III, parallel-group,
      two-armed, superiority, pragmatic RCT with 1:1 allocation ratio; allocation
      sequence by minimisation programme with a built-in random element; secure
      web-based allocation concealment. The two treatments will be usual care (control)
      and usual care plus an enhanced rehabilitation programme (intervention). The
      enhanced rehabilitation will consist of a patient-held information workbook, goal
      setting diary and up to six additional therapy sessions. Outcome assessment and
      statistical analysis will be performed blind; patient and carer participants will
      be unblinded. Outcomes will be measured at baseline, 17 and 52 weeks' follow-up. 
      Primary outcome at 52 weeks will be the Nottingham Extended Activities of Daily
      Living scale. Secondary outcomes will measure anxiety and depression, health
      utility, cognitive status, hip pain intensity, falls self-efficacy, fear of
      falling, grip strength and physical function. Carer strain, anxiety and
      depression will be measured in carers. All safety events will be recorded, and
      serious adverse events will be assessed to determine whether they are related to 
      the intervention and expected. Concurrent economic evaluation will be a
      cost-utility analysis from a health service and personal social care perspective.
      An embedded process evaluation will determine the mechanisms and processes that
      explain the implementation and impacts of the enhanced rehabilitation programme. 
      ETHICS AND DISSEMINATION: National Health Service research ethics approval
      reference 18/NE/0300. Results will be disseminated by peer-reviewed publication. 
      TRIAL REGISTRATION NUMBER: ISRCTN28376407; Pre-results registered on 23 November 
      2018.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Williams, Nefyn
AU  - Williams N
AUID- ORCID: 0000-0002-8078-409X
AD  - Department of Primary Care and Mental Health, University of Liverpool Faculty of 
      Health and Life Sciences, Liverpool, UK nefyn.williams@liverpool.ac.uk.
FAU - Dodd, Susanna
AU  - Dodd S
AD  - Liverpool Clinical Trials Centre, University of Liverpool Faculty of Health and
      Life Sciences, Liverpool, UK.
FAU - Hardwick, Ben
AU  - Hardwick B
AD  - Liverpool Clinical Trials Centre, University of Liverpool Faculty of Health and
      Life Sciences, Liverpool, UK.
FAU - Clayton, Dannii
AU  - Clayton D
AD  - Liverpool Clinical Trials Centre, University of Liverpool Faculty of Health and
      Life Sciences, Liverpool, UK.
FAU - Edwards, Rhiannon Tudor
AU  - Edwards RT
AD  - Centre for Health Economics & Medicines Evaluation, Bangor University College of 
      Human Sciences, Bangor, Gwynedd, UK.
FAU - Charles, Joanna Mary
AU  - Charles JM
AD  - Centre for Health Economics & Medicines Evaluation, Bangor University College of 
      Human Sciences, Bangor, Gwynedd, UK.
FAU - Logan, Phillipa
AU  - Logan P
AD  - Division of Rehabilitation and Ageing, University of Nottingham Faculty of
      Medicine and Health Sciences, Nottingham, UK.
FAU - Busse, Monica
AU  - Busse M
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Lewis, Ruth
AU  - Lewis R
AD  - North Wales Centre for Primary Care Research, Bangor University College of Human 
      Sciences, Bangor, Gwynedd, UK.
FAU - Smith, Toby O
AU  - Smith TO
AD  - School of Health Sciences, University of East Anglia Faculty of Medicine and
      Health Sciences, Norwich, Norfolk, UK.
FAU - Sackley, Catherine
AU  - Sackley C
AD  - University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.
FAU - Morrison, Val
AU  - Morrison V
AD  - School of Psychology, Bangor University College of Human Sciences, Bangor,
      Gwynedd, UK.
FAU - Lemmey, Andrew
AU  - Lemmey A
AD  - School of Sports, Health and Exercise Science, Bangor University College of Human
      Sciences, Bangor, Gwynedd, UK.
FAU - Masterson-Algar, Patricia
AU  - Masterson-Algar P
AUID- ORCID: 0000-0001-6344-1346
AD  - School of Healthcare Sciences, Bangor University College of Human Sciences,
      Bangor, Gwynedd, UK.
FAU - Howard, Lola
AU  - Howard L
AD  - Liverpool Clinical Trials Centre, University of Liverpool Faculty of Health and
      Life Sciences, Liverpool, UK.
FAU - Hennessy, Sophie
AU  - Hennessy S
AD  - Liverpool Clinical Trials Centre, University of Liverpool Faculty of Health and
      Life Sciences, Liverpool, UK.
FAU - Soady, Claire
AU  - Soady C
AD  - Liverpool Clinical Trials Centre, University of Liverpool Faculty of Health and
      Life Sciences, Liverpool, UK.
FAU - Ralph, Penelope
AU  - Ralph P
AD  - Department of Primary Care and Mental Health, University of Liverpool Faculty of 
      Health and Life Sciences, Liverpool, UK.
FAU - Dobson, Susan
AU  - Dobson S
AD  - Department of Primary Care and Mental Health, University of Liverpool Faculty of 
      Health and Life Sciences, Liverpool, UK.
FAU - Dorkenoo, Shanaz
AU  - Dorkenoo S
AD  - Involving People Network, Health and Care Research Wales, Cardiff, UK.
LA  - eng
SI  - ISRCTN/ISRCTN28376407
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Accidental Falls
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Cost-Benefit Analysis
MH  - Femur
MH  - *Hip Fractures/surgery
MH  - Humans
MH  - Randomized Controlled Trials as Topic
PMC - PMC7569930
OTO - NOTNLM
OT  - *clinical trials
OT  - *health economics
OT  - *hip
OT  - *qualitative research
OT  - *rehabilitation medicine
COIS- Competing interests: NHW reports additional grants from NIHR HS&DR outside the
      submitted work and membership of the NIHR HTA programme funding committee
      (commissioned research).
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:25
PHST- 2020/10/17 05:25 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039791 [pii]
AID - 10.1136/bmjopen-2020-039791 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039791. doi: 10.1136/bmjopen-2020-039791.


PMID- 33067297
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Protocol of a prospective, multicentre phase I study to evaluate the safety,
      tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in
      patients with castration-resistant prostate carcinoma.
PG  - e039639
LID - 10.1136/bmjopen-2020-039639 [doi]
AB  - INTRODUCTION: Prostate cancer is the second most common cancer in men worldwide. 
      When the disease becomes resistant to androgen-deprivation therapy, treatment
      options are sparse. To address the high medical need in castration-resistant
      prostate cancer (CRPC), we generated a novel PSMAxCD3 bispecific antibody termed 
      CC-1. CC-1 binds to prostate-specific membrane antigen that is expressed on
      prostate cancer cells and tumour vessels, thereby allowing a dual anticancer
      effect. METHODS AND ANALYSIS: This first in human clinical study is a prospective
      and multicentre trial which enrols patients with metastatic CRPC after failure of
      established third-line therapy. CC-1 is applied after prophylactic interleukin-6 
      receptor blockade with tocilizumab (once 8 mg/kg body weight). Each patient
      receives at least one cycle of CC-1 over a time course of 7 days in an inpatient 
      setting. If clinical benefit is observed, up to five additional cycles of CC-1
      can be applied. The study is divided in two parts: (1) a dose escalation phase
      with intraindividual dose increase from 28 microg to the target dose of 1156
      microg based on a modified fast titration design by Simon et al to determine
      safety, tolerability and the maximum tolerated dose (MTD) as primary endpoints
      and (2) a dose expansion phase with additional 14 patients on the MTD level of
      part (1) to identify first signs of efficacy. Secondary endpoints compromise
      overall safety, tumour response, survival and a translational research programme 
      with, among others, the analysis of CC-1 half-life, the induced immune response, 
      as well as the molecular profiling in liquid biopsies. ETHICS AND DISSEMINATION: 
      The PSMAxCD3 study was approved by the Ethics Committee of The University
      Hospital Tubingen (100/2019AMG1) and the Paul-Ehrlich-Institut (3684/02).
      Clinical trial results will be published in peer-reviewed journals. TRIAL
      REGISTRATION NUMBERS: ClinicalTrials.gov Registry (NCT04104607) and
      ClinicalTrials.eu Registry (EudraCT2019-000238-20).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Heitmann, Jonas S
AU  - Heitmann JS
AUID- ORCID: 0000-0002-7305-8620
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
AD  - Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed
      Tumor Therapies', University of Tubingen, Tubingen, Germany.
FAU - Walz, Juliane S
AU  - Walz JS
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
AD  - Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed
      Tumor Therapies', University of Tubingen, Tubingen, Germany.
FAU - Pflugler, Martin
AU  - Pflugler M
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen,
      Tubingen, Germany.
FAU - Kauer, Joseph
AU  - Kauer J
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen,
      Tubingen, Germany.
FAU - Schlenk, Richard F
AU  - Schlenk RF
AD  - National Center of Tumor Diseases-Trial Center, National Center of Tumor
      Diseases, German Cancer Research Center, Heidelberg, Germany.
AD  - Department of Internal Medicine VI, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg,
      Germany.
FAU - Jung, Gundram
AU  - Jung G
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen,
      Tubingen, Germany.
FAU - Salih, Helmut R
AU  - Salih HR
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, Tubingen, 
      Germany helmut.salih@med.uni-tuebingen.de.
AD  - Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed
      Tumor Therapies', University of Tubingen, Tubingen, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT04104607
SI  - EudraCT/2019-000238-20
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Androgen Antagonists)
SB  - IM
MH  - Androgen Antagonists
MH  - *Carcinoma
MH  - Castration
MH  - Clinical Trials, Phase I as Topic
MH  - Humans
MH  - Male
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - *Prostatic Neoplasms, Castration-Resistant/drug therapy
PMC - PMC7569941
OTO - NOTNLM
OT  - *adult oncology
OT  - *immunology
OT  - *urological tumours
COIS- Competing interests: GJ and HRS are listed as inventors on the patent application
      'Novel PSMA binding antibody and uses thereof', EP16151281 and others, with the
      German Cancer Research Center (DKFZ), Heidelberg, Germany, as applicant. The
      other authors declare no competing interests.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:25
PHST- 2020/10/17 05:25 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039639 [pii]
AID - 10.1136/bmjopen-2020-039639 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039639. doi: 10.1136/bmjopen-2020-039639.


PMID- 33067295
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Internet-based patient- primary care physician-cardiologist integrated management
      model of hypertension in China: study protocol for a multicentre randomised
      controlled trial.
PG  - e039447
LID - 10.1136/bmjopen-2020-039447 [doi]
AB  - INTRODUCTION: The control rate of hypertension is low in China, especially in
      rural, western and minority areas. This is related to poor medical skills among
      physicians in primary care institutions and low levels of trust among patients.
      However, primary healthcare institutions are the main battleground for the
      prevention and treatment of hypertension. It is worth exploring how to most
      effectively integrate patients, primary care physicians and cardiologists in
      tertiary hospitals, to build a long-term mechanism for the prevention and
      treatment of hypertension. In this study, we aim to evaluate the clinical
      effectiveness and conduct a health economic evaluation of an internet-based
      patient-primary care physician-cardiologist integrated management model of
      hypertension in areas of China with different socioeconomic levels. METHODS AND
      ANALYSIS: This is a 12-month, multicentre, randomised controlled trial involving 
      patients with hypertension in urban communities and rural areas of Sichuan
      Province, China. Each primary healthcare institution will cooperate with their
      tertiary hospital through the Red Shine Chronic Disease Management System
      (RSCDMS). Patients will be randomly assigned 1:1 to two groups: (1) a traditional
      care group; (2) an intervention group in which primary care physicians and
      cardiologists can share patient data and manage patients together through the
      RSCDMS. Patients can upload their blood pressure (BP) values and communicate with
      physicians using the system. The primary outcome is the change in systolic BP
      over a 12-month period. Secondary outcomes are changes in diastolic BP, BP
      control rate, values of 24-hour ambulatory BP monitoring, difference in
      cost-effectiveness between the groups, patient satisfaction, medication adherence
      and home BP monitoring compliance. All data will be recorded and stored in the
      RSCDMS and analysed using IBM SPSS V.26.0. ETHICS AND DISSEMINATION: This study
      has been approved by the Biomedical Research Ethics Committee of the West China
      Hospital of Sichuan University in Sichuan, China (No. 2020-148). Written informed
      consent will be obtained from all participants. The results of this study will be
      disseminated to the public through academic conferences and peer-reviewed
      journals. TRIAL REGISTRATION NUMBER: ChiCTR2000030677.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ye, Runyu
AU  - Ye R
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Shi, Rufeng
AU  - Shi R
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Liu, Kai
AU  - Liu K
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Wang, Si
AU  - Wang S
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Liao, Hang
AU  - Liao H
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Li, Xinran
AU  - Li X
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Gou, Qiling
AU  - Gou Q
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Rong, Xi
AU  - Rong X
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Zhang, Zhipeng
AU  - Zhang Z
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Yang, Changqiang
AU  - Yang C
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Yang, Xiangyu
AU  - Yang X
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China.
FAU - Chen, Xiaoping
AU  - Chen X
AUID- ORCID: 0000-0001-7714-3403
AD  - Cardiology, West China Hospital of Sichuan University, Chengdu, Sichaun, China
      xiaopingchen15@126.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiologists
MH  - China
MH  - Humans
MH  - *Hypertension/prevention & control
MH  - Internet
MH  - Multicenter Studies as Topic
MH  - *Physicians, Primary Care
MH  - Randomized Controlled Trials as Topic
PMC - PMC7569994
OTO - NOTNLM
OT  - *hypertension
OT  - *primary care
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039447 [pii]
AID - 10.1136/bmjopen-2020-039447 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039447. doi: 10.1136/bmjopen-2020-039447.


PMID- 33067294
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Uptake and effectiveness of a tailor-made online lifestyle programme targeting
      modifiable risk factors for dementia among middle-aged descendants of people with
      recently diagnosed dementia: study protocol of a cluster randomised controlled
      trial (Demin study).
PG  - e039439
LID - 10.1136/bmjopen-2020-039439 [doi]
AB  - INTRODUCTION: Descendants of patients with dementia have a higher risk to develop
      dementia. This study aims to investigate the uptake and effectiveness of an
      online tailor-made lifestyle programme for dementia risk reduction (DRR) among
      middle-aged descendants of people with recently diagnosed late-onset dementia.
      METHODS AND ANALYSIS: Demin is a cluster randomised controlled trial, aiming to
      include 21 memory clinics of which 13 will be randomly allocated to the passive
      (poster and flyer in a waiting room) and 8 to the active recruitment strategy
      (additional personal invitation by members of the team of the memory clinic). We 
      aim to recruit 378 participants (40-60 years) with a parent who is recently
      diagnosed with Alzheimer's disease or vascular dementia at one of the
      participating memory clinics. All participants receive a dementia risk assessment
      (online questionnaire, physical examination and blood sample) and subsequently an
      online tailor-made lifestyle advice regarding protective (Mediterranean diet,
      low/moderate alcohol consumption and high cognitive activity) and risk factors
      (physical inactivity, smoking, loneliness, cardiovascular diseases (CVD),
      hypertension, high cholesterol, diabetes, obesity, renal dysfunction and
      depression) for dementia. The primary outcome is the difference in uptake between
      the two recruitment strategies. Secondary outcomes are change(s) in (1) the
      Lifestyle for Brain Health score, (2) individual health behaviours, (3) health
      beliefs and attitudes towards DRR and (4) compliance to the tailor-made lifestyle
      advice. Outcomes will be measured at 3, 6, 9 and 12 months after baseline. The
      effectiveness of this online tailor-made lifestyle programme will be evaluated by
      comparing Demin participants to a matched control group (lifelines cohort).
      ETHICS AND DISSEMINATION: This study has been approved by the Dutch Ministry of
      Health, Welfare and Sport according to the Population Screening Act. All
      participants have to give online informed consent using SMS-tan (transaction
      authentication number delivered via text message). Findings will be disseminated 
      through peer-reviewed journals and (inter)national conferences. TRIAL
      REGISTRATION NUMBER: NTR7434.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Vrijsen, Joyce
AU  - Vrijsen J
AUID- ORCID: 0000-0003-1506-2266
AD  - Department of Epidemiology, University of Groningen, University Medical Centre
      Groningen, Groningen, The Netherlands j.vrijsen@umcg.nl.
FAU - Abu-Hanna, Ameen
AU  - Abu-Hanna A
AD  - Department of Medical Informatics, University of Amsterdam, Amsterdam UMC,
      Amsterdam, The Netherlands.
FAU - Maeckelberghe, Els Lm
AU  - Maeckelberghe EL
AD  - Wenckebach Institute for Training and Education, University of Groningen,
      University Medical Centre Groningen, Groningen, The Netherlands.
FAU - De Deyn, Peter Paul
AU  - De Deyn PP
AD  - Department of Neurology and Alzheimer Centre Groningen, University of Groningen, 
      University Medical Centre Groningen, Groningen, The Netherlands.
FAU - de Winter, Andrea F
AU  - de Winter AF
AD  - Department of Health Sciences, University of Groningen, University Medical Centre
      Groningen, Groningen, The Netherlands.
FAU - Reesink, Fransje E
AU  - Reesink FE
AD  - Department of Neurology and Alzheimer Centre Groningen, University of Groningen, 
      University Medical Centre Groningen, Groningen, The Netherlands.
FAU - Oude Voshaar, Richard C
AU  - Oude Voshaar RC
AD  - Department of Psychiatry, University of Groningen, University Medical Centre
      Groningen, Groningen, The Netherlands.
FAU - Buskens, Erik
AU  - Buskens E
AD  - Department of Epidemiology, University of Groningen, University Medical Centre
      Groningen, Groningen, The Netherlands.
FAU - de Rooij, Sophia E
AU  - de Rooij SE
AD  - Medical School Twente, Medical Spectrum Twente, Enschede, The Netherlands.
FAU - Smidt, Nynke
AU  - Smidt N
AD  - Department of Epidemiology, University of Groningen, University Medical Centre
      Groningen, Groningen, The Netherlands.
CN  - Demin consortium
LA  - eng
SI  - NTR/NTR7434
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Dementia/prevention & control
MH  - Health Behavior
MH  - Humans
MH  - *Life Style
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Risk Reduction Behavior
PMC - PMC7569992
OTO - NOTNLM
OT  - *dementia
OT  - *epidemiology
OT  - *preventive medicine
OT  - *public health
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039439 [pii]
AID - 10.1136/bmjopen-2020-039439 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039439. doi: 10.1136/bmjopen-2020-039439.


PMID- 33067293
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - School-based, two-arm, parallel, controlled trial of a culturally adapted
      resilience intervention to improve adolescent mental health in Vietnam: study
      protocol.
PG  - e039343
LID - 10.1136/bmjopen-2020-039343 [doi]
AB  - INTRODUCTION: The Resourceful Adolescent Program (RAP) is an evidence-based
      resilience intervention for adolescents. Operating in a strength-focused
      paradigm, the programme uses an integration of cognitive behavioural therapy and 
      interpersonal psychotherapy to improve coping skills and build resilience. This
      study aims to establish whether a culturally and linguistically adapted
      intervention informed by RAP principles is effective in increasing resilience,
      enhancing coping skills and preventing symptoms of depression and anxiety.
      METHODS AND ANALYSIS: We will translate, back-translate and culturally adapt the 
      RAP for adolescents and training materials for facilitators, and the adapted
      intervention will be called Happy House. A two-arm parallel controlled trial will
      be conducted in eight high schools in the north of Vietnam. In each of the
      selected schools, all students from four randomly selected grade 10 classes (an
      estimation of about 1204 students) will be invited to participate. The control
      group will receive the usual curriculum. The intervention group will receive six 
      weekly 90 min school-based group sessions of Happy House in addition to the usual
      curriculum. The primary outcome, depressive symptoms, will be measured using a
      locally validated version of the Centre for Epidemiologic Studies Depression
      Scale Revised. Secondary outcomes are mental well-being, coping self-efficacy,
      school connectedness, anger management and health risk behaviours. Data will be
      collected at recruitment, and at two weeks and six months post intervention.
      Mixed-effect logistic regression for the main outcome and mixed-effect linear and
      logistic regression models for the secondary outcomes will be conducted to
      estimate the effects of the intervention on the outcomes. ETHICS AND
      DISSEMINATION: This trial has been approved by Monash University Human Research
      Ethics Committee (No. 21455) and the Institutional Review Board of the Hanoi
      School of Public Health (488/2019/YTCC-HD3). Dissemination of findings will
      include peer-reviewed publications, international and national conferences,
      seminar and media presentations, national policy briefings in Vietnam, local
      language reports and lay language summaries for participants. TRIAL REGISTRATION 
      NUMBERS: Registered with the Australian New Zealand Clinical Trials Registry,
      registration number: ACTRN12620000088943 (3/2/2020).WHO Universal Trial Number:
      U1111-1246-4079.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tran, Thach
AU  - Tran T
AUID- ORCID: 0000-0002-4686-8601
AD  - Global and Women's Health, Public Health and Preventive Medicine, Monash
      University, Melbourne, Victoria, Australia.
FAU - Nguyen, Huong Thanh
AU  - Nguyen HT
AD  - Department of Health Education, Faculty of Social Science, Behavior and Health
      Education, Hanoi University of Public Health, Hanoi, Vietnam.
FAU - Shochet, Ian
AU  - Shochet I
AUID- ORCID: 0000-0002-4666-2128
AD  - School of Psychology and Counselling, Queensland University of Technology,
      Brisbane, Queensland, Australia.
FAU - Wurfl, Astrid
AU  - Wurfl A
AD  - School of Psychology and Counselling, Queensland University of Technology,
      Brisbane, Queensland, Australia.
FAU - Orr, Jayne
AU  - Orr J
AD  - School of Psychology and Counselling, Queensland University of Technology,
      Brisbane, Queensland, Australia.
FAU - Nguyen, Nga
AU  - Nguyen N
AD  - Department of Health Education, Faculty of Social Science, Behavior and Health
      Education, Hanoi University of Public Health, Hanoi, Vietnam.
FAU - La, Nga
AU  - La N
AD  - Department of Health Education, Faculty of Social Science, Behavior and Health
      Education, Hanoi University of Public Health, Hanoi, Vietnam.
FAU - Nguyen, Hau
AU  - Nguyen H
AD  - Global and Women's Health, Public Health and Preventive Medicine, Monash
      University, Melbourne, Victoria, Australia.
FAU - Stocker, Ruby
AU  - Stocker R
AD  - Global and Women's Health, Public Health and Preventive Medicine, Monash
      University, Melbourne, Victoria, Australia.
FAU - Nguyen, Trang
AU  - Nguyen T
AD  - Global and Women's Health, Public Health and Preventive Medicine, Monash
      University, Melbourne, Victoria, Australia.
FAU - Le, Minh
AU  - Le M
AD  - Global and Women's Health, Public Health and Preventive Medicine, Monash
      University, Melbourne, Victoria, Australia.
FAU - Fisher, Jane
AU  - Fisher J
AUID- ORCID: 0000-0002-1959-6807
AD  - Global and Women's Health, Public Health and Preventive Medicine, Monash
      University, Melbourne, Victoria, Australia jane.fisher@monash.edu.
LA  - eng
SI  - ANZCTR/ACTRN12620000088943
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Anxiety
MH  - Australia
MH  - Humans
MH  - *Mental Health
MH  - Randomized Controlled Trials as Topic
MH  - *Schools
MH  - Vietnam
PMC - PMC7574926
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039343 [pii]
AID - 10.1136/bmjopen-2020-039343 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039343. doi: 10.1136/bmjopen-2020-039343.


PMID- 33067291
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Advanced consent for participation in acute care randomised control trials:
      protocol for a scoping review.
PG  - e039172
LID - 10.1136/bmjopen-2020-039172 [doi]
AB  - INTRODUCTION: Informed consent is essential to clinical research, though
      obtaining informed consent for participation in research for emergency conditions
      is challenging. Adapted consent methods include consent from a
      substitute-decision maker, deferral of consent and waiver of consent. A novel
      approach is to use advanced consent, where a potential participant provides
      consent in the present in the event that they become eligible for enrolment into 
      a future study. This scoping review will map and synthesise the literature on the
      use of advanced consent for participation and enrolment in randomised control
      trials for emergency conditions. METHODS AND ANALYSIS: Guided by Arksey and
      O'Malley's scoping review methodology framework, we will search electronic
      databases (Medline, Embase, Web of Science and the Cochrane Register of Clinical 
      Trials), the grey literature sources and reference lists of relevant studies.
      Eligible studies will include English language articles that discuss, examine or 
      employ the use of advanced consent for enrolment in randomised control trials,
      specifically related to emergency conditions or emergency treatment. Diverse
      types of articles will be eligible for inclusion, including peer-reviewed
      qualitative and quantitative studies such as randomised control trials,
      observational studies, surveys, systematic reviews, as well as narrative reviews 
      and ethics papers. Studies will be screened by two independent reviewers to
      determine eligibility for inclusion. Data on bibliographic information, study
      characteristics and methodology, and reported results, specifically author
      disposition, will be extracted and described using qualitative analysis. ETHICS
      AND DISSEMINATION: Formal ethics review is not required as primary data will not 
      be collected. The findings of this study will be disseminated through a
      peer-reviewed publication. The findings of this study will help identify
      knowledge gaps that may guide areas for future research and may aid in the design
      of future clinical trials using advanced consent.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Niznick, Naomi
AU  - Niznick N
AUID- ORCID: 0000-0003-0935-9135
AD  - Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa,
      Ontario, Canada naniznick@toh.ca.
FAU - Lun, Ronda
AU  - Lun R
AD  - Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa,
      Ontario, Canada.
FAU - Dewar, Brian
AU  - Dewar B
AD  - Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Dowlatshahi, Dar
AU  - Dowlatshahi D
AD  - Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa,
      Ontario, Canada.
AD  - Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Shamy, Michel
AU  - Shamy M
AD  - Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa,
      Ontario, Canada.
AD  - Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Informed Consent
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7569993
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *medical ethics
OT  - *neurology
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039172 [pii]
AID - 10.1136/bmjopen-2020-039172 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039172. doi: 10.1136/bmjopen-2020-039172.


PMID- 33067290
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Platelet transfusion for neonates with thrombocytopaenia: protocol for a
      systematic review.
PG  - e039132
LID - 10.1136/bmjopen-2020-039132 [doi]
AB  - INTRODUCTION: Thrombocytopaenia is one of the most common haemostatic
      abnormalities among neonates. It affects approximately one-quarter of neonates
      admitted into neonatal intensive care units and may lead to a high risk of
      bleeding and mortality, which are substantial causes for concern by
      neonatologists. Platelet transfusion (PT) is a specific treatment for
      thrombocytopaenia. To date, PT thresholds are diverse since the associations
      between low platelet count and negative outcomes are not clear. We propose this
      protocol for a systematic review to collect and assess evidence concerning the
      best PT threshold to reduce mortality, bleeding and major morbidity among
      neonates with thrombocytopaenia. METHODS AND ANALYSIS: The systematic review will
      be performed according to the Cochrane Handbook for Systematic Review of
      Interventions, the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses statement, and the Grading of Recommendations Assessment,
      Development and Evaluation system. Two independent researchers will perform the
      study selection, data extraction/coding, quality assessment and further analyses 
      of the included studies, with disagreements being resolved by a third researcher.
      A systematic search of the literature will be conducted in the PubMed, Cochrane
      Library and Embase databases from database inception through 13 October 2020. All
      randomised controlled trials, cohort studies and case-control studies will be
      included without any restrictions regarding publication date or language. The
      primary outcomes will comprise in-hospital mortality and bleeding episodes.
      Endnote X9 and Review Manager V.5.3 software will be used to manage the selection
      process and statistical analysis, respectively. If the included studies are
      sufficient and homogeneous for any of the outcomes, a quantitative synthesis
      (meta-analysis) may be performed. Otherwise, we will conduct a narrative
      systematic review of the results. ETHICS AND DISSEMINATION: Ethical approval is
      not required for this study because the data will be obtained from published
      studies and will not include individual patient data. The results of this study
      are anticipated to be published in a peer-reviewed journal. PROSPERO REGISTRATION
      NUMBER: CRD42020169262.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liu, Dengjun
AU  - Liu D
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Sichuan University, Chengdu, China.
FAU - Wu, Jinlin
AU  - Wu J
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Sichuan University, Chengdu, China.
FAU - Xiong, Tao
AU  - Xiong T
AUID- ORCID: 0000-0001-5255-6324
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China tao_xiong@126.com.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Sichuan University, Chengdu, China.
FAU - Yue, Yan
AU  - Yue Y
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Sichuan University, Chengdu, China.
FAU - Tang, Jun
AU  - Tang J
AUID- ORCID: 0000-0003-4884-4248
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Case-Control Studies
MH  - Hospital Mortality
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - *Platelet Transfusion
MH  - Research Design
MH  - *Thrombocytopenia/therapy
PMC - PMC7569922
OTO - NOTNLM
OT  - *bleeding disorders & coagulopathies
OT  - *blood bank & transfusion medicine
OT  - *neonatal intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039132 [pii]
AID - 10.1136/bmjopen-2020-039132 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e039132. doi: 10.1136/bmjopen-2020-039132.


PMID- 33067283
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Hospital readmission after anterior cruciate ligament reconstruction: protocol
      for a systematic review and meta-analysis.
PG  - e037888
LID - 10.1136/bmjopen-2020-037888 [doi]
AB  - INTRODUCTION: Anterior cruciate ligament (ACL) injury is one of the most common
      injuries of the knee. ACL reconstruction (ACLR) has been widely performed as a
      safe and effective treatment for ACL injuries. As there is an increasing trend in
      the incidence of ACL injury, hospital readmission after ACLR has attracted
      renewed attention for the financial burden to both patients and the healthcare
      system. However, information about hospital readmission after ACLR remains
      fragmented. Therefore, we plan to systematically review the literature to
      investigate the rate of, causes and risk factors for hospital readmission after
      ACLR, and summarise interventions to reduce hospital readmission. This article is
      to provide the protocol for an upcoming systematic review and meta-analysis on
      this important issue. METHODS AND ANALYSIS: Reporting of this protocol follows
      the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
      (PRISMA-P) checklist. Electronic databases, including PubMed, Embase and the
      Cochrane Library, will be systematically searched from inception to June 2020. No
      language restrictions will be applied. Studies will be included if they reported 
      hospital readmission or explored the associated potential causes and risk factors
      for hospital readmission after ACLR. The primary outcome will be the number and
      time frame of hospital readmission after ACLR. Secondary outcomes will be reasons
      for readmission, number and types of complications, risk factors for readmission 
      and preventive measures for readmission after ACLR. Quality assessments will be
      performed by using the Newcastle-Ottawa Scale (NOS). If possible, study results
      will be summarised in a forest plot, and heterogeneity will be tested by using
      the Cochran's Q and I(2) statistics. ETHICS AND DISSEMINATION: No ethical
      approval is required because our study is not related to patients or animals. The
      results will be published in a peer-reviewed journal. PROSPERO REGISTRATION
      NUMBER: CRD42020058624.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shao, Long
AU  - Shao L
AD  - Department of Orthopaedic Surgery, Ningbo No.6 Hospital, Ningbo, Zhejiang, China.
FAU - Wu, Di
AU  - Wu D
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
FAU - Li, Jia-Ying
AU  - Li JY
AD  - Departments of Nephrology, Peking Union Medical College Hospital, Chinese Academy
      of Medical Sciences & Peking Union Medical College, Beijing, China.
FAU - Wu, Xiang-Dong
AU  - Wu XD
AUID- ORCID: 0000-0002-3920-4372
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
AD  - Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing
      Medical University, Chongqing, China.
FAU - Zhou, Xi
AU  - Zhou X
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
FAU - Qiu, Gui-Xing
AU  - Qiu GX
AUID- ORCID: 0000-0001-7137-1843
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese
      Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
FAU - Luo, Changqi
AU  - Luo C
AD  - Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing
      Medical University, Chongqing, China.
FAU - Xiao, Peng-Cheng
AU  - Xiao PC
AD  - Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing
      Medical University, Chongqing, China.
FAU - Liu, Jia-Cheng
AU  - Liu JC
AD  - Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing
      Medical University, Chongqing, China.
FAU - Huang, Wei
AU  - Huang W
AUID- ORCID: 0000-0002-8894-0982
AD  - Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing
      Medical University, Chongqing, China drhuangwei68@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Anterior Cruciate Ligament Injuries/surgery
MH  - *Anterior Cruciate Ligament Reconstruction
MH  - Humans
MH  - Knee Joint/surgery
MH  - Meta-Analysis as Topic
MH  - Patient Readmission
MH  - Treatment Outcome
PMC - PMC7569989
OTO - NOTNLM
OT  - *health & safety
OT  - *knee
OT  - *quality in health care
OT  - *risk management
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037888 [pii]
AID - 10.1136/bmjopen-2020-037888 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e037888. doi: 10.1136/bmjopen-2020-037888.


PMID- 33067281
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Cohort protocol: Guangzhou High-Risk Infant Cohort study.
PG  - e037829
LID - 10.1136/bmjopen-2020-037829 [doi]
AB  - INTRODUCTION: Despite the increase in the survival rate of high-risk infants
      (HRIs) worldwide, the prevalence of motor and neurodevelopmental sequelae in such
      newborns has not shown concomitant improvement. Meanwhile, there are few cohorts 
      that explore factors related to the development of HRIs in China. Therefore, the 
      Guangzhou High-Risk Infant Cohort (GHRIC) has been designed to examine the
      complex relationships among a myriad of factors influencing growth and
      development in such children. METHODS AND ANALYSIS: The GHRIC study is a
      prospective cohort study that by the year 2023 will enrol an estimated total of
      3000 HRIs from Guangzhou Women and Children's Medical Center (GWCMC) in
      Guangzhou, China. This study is designed to assess the growth and cognitive
      characteristics of HRIs and the risk factors affecting their development and
      prognoses. Data on risk factors, neurodevelopmental and cognitive-function
      evaluations, laboratory results, and specimens will be collected and analysed.
      Information on perinatal and clinical interventions for these infants will also
      be recorded during regular follow-up visits until age 6. ETHICS AND
      DISSEMINATION: The protocol for this study has been approved by the Research
      Ethics Committee of GWCMC, which accepted responsibility for supervising all of
      the aspects of the study (No. 2017102712). Study outcomes will be disseminated
      through conference presentations, peer-reviewed publications, the Internet and
      social media. TRIAL REGISTRATION NUMBER: ChiCTR-EOC-17013236.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hu, Pian
AU  - Hu P
AUID- ORCID: 0000-0002-0525-8911
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Han, Azhu
AU  - Han A
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Hu, Yan
AU  - Hu Y
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Wen, Yuqi
AU  - Wen Y
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Liang, Jingjing
AU  - Liang J
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Xiao, Wanqi
AU  - Xiao W
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Lin, Suifang
AU  - Lin S
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Song, Yanyan
AU  - Song Y
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China yansong84@126.com.
FAU - Tan, Xuying
AU  - Tan X
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Zhao, Xiaopeng
AU  - Zhao X
AD  - Neonatal Unit, The Neonatal Medical Center, Guangzhou Women and Children's
      Medical Center, Guangzhou Medical University, Guangzhou, China.
FAU - Dong, Haipeng
AU  - Dong H
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Liu, Qianyun
AU  - Liu Q
AD  - Department of Child Health Care, Guangzhou Women and Children's Medical Center,
      Guangzhou Medical University, Guangzhou, China.
FAU - Zhang, Huayan
AU  - Zhang H
AD  - Neonatal Unit, The Neonatal Medical Center, Guangzhou Women and Children's
      Medical Center, Guangzhou Medical University, Guangzhou, China.
AD  - Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia,
      Pennsylvania, USA.
FAU - Tao, Li
AU  - Tao L
AD  - Neonatal Unit, The Neonatal Medical Center, Guangzhou Women and Children's
      Medical Center, Guangzhou Medical University, Guangzhou, China.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Neonatal Unit, The Neonatal Medical Center, Guangzhou Women and Children's
      Medical Center, Guangzhou Medical University, Guangzhou, China.
LA  - eng
SI  - ChiCTR/ChiCTR-EOC-17013236
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - China/epidemiology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Prospective Studies
MH  - *Research Design
MH  - Risk Factors
PMC - PMC7569926
OTO - NOTNLM
OT  - *epidemiology
OT  - *neonatology
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037829 [pii]
AID - 10.1136/bmjopen-2020-037829 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e037829. doi: 10.1136/bmjopen-2020-037829.


PMID- 33067279
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Effects of sulforaphane on cognitive function in patients with frontal brain
      damage: study protocol for a randomised controlled trial.
PG  - e037543
LID - 10.1136/bmjopen-2020-037543 [doi]
AB  - INTRODUCTION: Many patients with frontal brain damage show serious cognitive
      function deficits, which hamper their quality of life and result in poor clinical
      outcomes. Preclinical research has shown that sulforaphane can significantly
      improve spatial localisation and working memory impairment after brain injury.
      The primary aim of this double-blind randomised controlled clinical trial is to
      assess the efficacy of sulforaphane for improving cognitive function in patients 
      with frontal brain damage. METHODS AND ANALYSIS: Ninety eligible patients will be
      randomly allocated to an active treatment or a placebo group in a 2:1 ratio.
      Participants will undergo a series of cognitive and neuropsychiatric tests at
      baseline (week 0) and after 12 weeks to determine the effect of sulforaphane on
      cognition. Magnetic resonance spectrum of the brain will be studied using the 3T 
      MRIs of the brain to detect brain metabolites markers, including N-acetyl
      aspartate, glutamate (Glu), glutathione (GSH) and gamma-aminobutyric acid (GABA).
      Blood brain-derived neurotrophic factor, Glu, GSH and GABA levels and gut
      microbiota will also be assessed over this period. This study will also evaluate 
      long-term outcomes of brain trauma, brain tumours and cerebrovascular disease via
      exploratory analyses. The primary outcome will be the difference in scores of a
      battery of cognitive tests after 12 weeks of sulforaphane treatment. The
      secondary outcomes will be changes in the Functional Activities Questionnaire
      (FAQ), the Patient Health Questionnaire (PHQ-9), the Self-Rating Anxiety Scale,
      the changes in T1-weighted MRI and resting-state functional MRI findings, and
      changes in brain and blood metabolic markers and gut microbiota at weeks 0 and
      12. We expect that sulforaphane will yield favourable results in treating memory 
      and learning deficits for patients with frontal brain damage. Cognitive
      functional treatment may also improve brain trauma, brain tumours and
      cerebrovascular outcomes. ETHICS AND DISSEMINATION: The study protocol has been
      approved by the Medical Ethics committee of the Xiangya Hospital of Central South
      University (No. 2017121019). The results will be disseminated in peer-reviewed
      journals and at international conferences. TRIAL REGISTRATION NUMBER: This trial 
      was registered on Clinicaltrials.gov on 31 January 2020 (NCT04252261). The
      protocol version is V.1.0 (20 December 2019).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liu, Fangkun
AU  - Liu F
AD  - Department of Neurosurgery, Central South University (CSU), 410008, Changsha,
      Hunan, China.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      410011, Changsha, Hunan, China; Mental Health Institute of the Second Xiangya
      Hospital, Central South University, Chinese National Clinical Research Center on 
      Mental Disorders (Xiangya), Chinese National Technology Institute on Mental
      Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, 410011,
      Changsha, Hunan, China.
FAU - Hei, Gangrui
AU  - Hei G
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      410011, Changsha, Hunan, China; Mental Health Institute of the Second Xiangya
      Hospital, Central South University, Chinese National Clinical Research Center on 
      Mental Disorders (Xiangya), Chinese National Technology Institute on Mental
      Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, 410011,
      Changsha, Hunan, China.
FAU - Wu, Renrong
AU  - Wu R
AUID- ORCID: 0000-0002-5804-6648
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      410011, Changsha, Hunan, China; Mental Health Institute of the Second Xiangya
      Hospital, Central South University, Chinese National Clinical Research Center on 
      Mental Disorders (Xiangya), Chinese National Technology Institute on Mental
      Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, 410011,
      Changsha, Hunan, China zhixiongliu@csu.edu.cn wurenrong@csu.edu.cn.
FAU - Liu, Zhixiong
AU  - Liu Z
AUID- ORCID: 0000-0003-3733-7259
AD  - Department of Neurosurgery, Central South University (CSU), 410008, Changsha,
      Hunan, China zhixiongliu@csu.edu.cn wurenrong@csu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT04252261
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Isothiocyanates)
RN  - 0 (Sulfoxides)
RN  - GA49J4310U (sulforaphane)
SB  - IM
MH  - Brain/diagnostic imaging
MH  - *Brain Injuries
MH  - Cognition
MH  - Humans
MH  - Isothiocyanates
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Sulfoxides
PMC - PMC7569949
OTO - NOTNLM
OT  - *clinical trials
OT  - *delirium & cognitive disorders
OT  - *neurological injury
OT  - *neurosurgery
OT  - *protocols & guidelines
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037543 [pii]
AID - 10.1136/bmjopen-2020-037543 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e037543. doi: 10.1136/bmjopen-2020-037543.


PMID- 33067278
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Effect of 12-week pulmonary rehabilitation on cognitive function in patients with
      stable chronic obstructive pulmonary disease: study protocol for a single-center 
      randomised controlled trial.
PG  - e037307
LID - 10.1136/bmjopen-2020-037307 [doi]
AB  - INTRODUCTION: Cognitive impairment, an important complication in patients with
      chronic obstructive pulmonary disease (COPD), seriously affects self-management
      of the disease and quality of life (QoL). As an exercise-based intervention
      programme, pulmonary rehabilitation (PR)-especially aerobic exercise (mainly
      mind-body exercise) and resistance exercise (RE)-has been proposed for its
      potential effectiveness in improving cognitive function. However, there is still 
      a lack of strong evidence for PR's effectiveness. In this study, we expect to
      clarify the effects of pulmonary-based Qigong exercise and elastic band-based RE 
      on cognitive function in patients with COPD and to fill in the relevant evidence 
      blanks. METHODS AND ANALYSIS: This study is a single-centre randomised controlled
      trial with assessor and data analyst blinding. We will recruit 108 participants
      with stable COPD starting on 23 December 2019, and randomly allocate them into
      the pulmonary-based Qigong exercise group, elastic band-based RE group,
      pulmonary-based Qigong exercise and elastic band-based RE combined group, or
      control group at a 1:1:1:1 ratio. Participants in intervention groups will
      perform 30 min of exercise two times per day, 5 days a week, for 12 weeks. The
      primary outcome will be the global cognitive function as assessed by the Montreal
      Cognitive Assessment and auditory event-related potential P300. Secondary
      outcomes will include the specific cognitive domains-attention, memory, executive
      function, verbal fluency and mental-processing speed; psychological functions and
      QoL. Exploratory outcomes will include grey matter volume and levels of
      inflammatory mediators. Outcomes will be measured before and after the
      interventions. ETHICS AND DISSEMINATION: Ethics approval has been granted by the 
      Ethics Committee of Yue-Yang Integrative Medicine Hospital, an affiliate of
      Shanghai University of Traditional Chinese Medicine, Shanghai, China (Grant No.
      2019-141). Written informed consent will be obtained from each participant before
      any procedures are performed. The findings will be published in peer-reviewed
      journals and presented at academic conferences. TRIAL REGISTRATION NUMBER:
      ChiCTR1900026869; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Duan, Hongxia
AU  - Duan H
AUID- ORCID: 0000-0001-7925-8925
AD  - School of Rehabilitation Science, Shanghai University of Traditional Chinese
      Medicine, Shanghai, China.
FAU - Li, Peijun
AU  - Li P
AD  - Department of Sports Medicine, Shanghai University of Sport, Shanghai, China.
FAU - Wang, Zhenwei
AU  - Wang Z
AD  - Department of Respiratory Medicine, Shanghai University of Traditional Chinese
      Medicine Yueyang Hospital of Integrated Traditional Chinese Medicine and Western 
      Medicine, Shanghai, China.
FAU - Chen, Haixia
AU  - Chen H
AD  - Department of Sports Medicine, Shanghai University of Sport, Shanghai, China.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of Sports Medicine, Shanghai University of Sport, Shanghai, China.
FAU - Wu, Weibing
AU  - Wu W
AD  - Department of Sports Medicine, Shanghai University of Sport, Shanghai, China.
FAU - Liu, Xiaodan
AU  - Liu X
AUID- ORCID: 0000-0002-8379-0292
AD  - School of Rehabilitation Science, Shanghai University of Traditional Chinese
      Medicine, Shanghai, China hzhp403@126.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - Cognition
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive
MH  - *Qigong
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7569932
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *delirium & cognitive disorders
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037307 [pii]
AID - 10.1136/bmjopen-2020-037307 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e037307. doi: 10.1136/bmjopen-2020-037307.


PMID- 33067277
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 16
TI  - Exploring and understanding the scope and value of the Parkinson's nurse in the
      UK (The USP Project): a realist economic evaluation protocol.
PG  - e037224
LID - 10.1136/bmjopen-2020-037224 [doi]
AB  - INTRODUCTION: There are multiple configurations of specialist nurses working in
      the field of Parkinson's. Parkinson's Nurse Specialists (PNSs) are recognised as 
      playing a pivotal role; however, there is little published evidence to
      demonstrate their effectiveness. Further evidence is needed to establish which
      aspects of the PNSs provide the greatest benefit to people with Parkinson's and
      their families, and the cost-effectiveness of different models of care. METHODS
      AND ANALYSIS: Realist approaches explain how and why programmes work (or not)
      through striving to answer the question: what works, for whom and under what
      circumstances. This research uses a realist evaluation and aims to integrate an
      economic analysis within the realist framework. We refer to this as 'realist
      economic evaluation'. It comprises four phases: (1) developing resource-sensitive
      initial programme theories (IPTs) using surveys to gain a better understanding of
      the role and impact (costs and benefits) of the PNSs; (2) testing the IPTs
      through qualitative interviews and quantitative data analysis; (3) evaluating the
      cost and resource use implications alongside the benefits associated with the
      role of the PNSs and (4) iteratively refining the IPTs throughout the project.
      The IPTs will draw on both quantitative and qualitative data. The result of the
      study will be a series of refined programme theories, which will explain how
      specialist nurses work in the field of Parkinson's in the UK, what impact they
      have on people with Parkinson's and their families and carers, and at what cost. 
      ETHICS AND DISSEMINATION: Northumbria University, the Health Research Authority
      and Health and Care Research Wales have approved this study. Key findings will be
      disseminated throughout the duration of the project online and through social
      media, and via annual and regional Parkinson's meetings and the Parkinson's UK
      Excellence Network. Academic dissemination will occur through publication and
      conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brown, Sarah
AU  - Brown S
AUID- ORCID: 0000-0002-7078-0984
AD  - Nursing, Midwifery and Health, Northumbria University, Newcastle Upon Tyne, UK.
FAU - Dalkin, Sonia Michelle
AU  - Dalkin SM
AUID- ORCID: 0000-0002-3266-5926
AD  - Faculty of Health and Life Sciences, Northumbria University, Newcastle Upon Tyne,
      UK.
FAU - Bate, Angela
AU  - Bate A
AD  - Nursing, Midwifery and Health, Northumbria University, Newcastle Upon Tyne, UK.
FAU - Bradford, Russ
AU  - Bradford R
AD  - Parkinson's Concierge, London, UK.
FAU - Allen, Charlotte
AU  - Allen C
AD  - Parkinson's Concierge, London, UK.
FAU - Brittain, Katie
AU  - Brittain K
AD  - Department of Nursing, Midwifery and Health, Northumbria University, Newcastle
      Upon Tyne, UK.
FAU - Clarke, Amanda
AU  - Clarke A
AD  - Health and Life Sciences, Northumbria University, Newcastle Upon Tyne, UK.
FAU - Hand, Annette
AU  - Hand A
AUID- ORCID: 0000-0002-9364-757X
AD  - Nursing, Midwifery and Health, Northumbria University, Newcastle Upon Tyne, UK
      a.hand@northumbria.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - *Parkinson Disease
MH  - Research Design
MH  - United Kingdom
MH  - Wales
PMC - PMC7569928
OTO - NOTNLM
OT  - *health economics
OT  - *neurology
OT  - *parkinson's disease
COIS- Competing interests: None declared.
EDAT- 2020/10/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/17 05:24
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037224 [pii]
AID - 10.1136/bmjopen-2020-037224 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 16;10(10):e037224. doi: 10.1136/bmjopen-2020-037224.


PMID- 33067240
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2375-2548 (Electronic)
IS  - 2375-2548 (Linking)
VI  - 6
IP  - 42
DP  - 2020 Oct
TI  - Does inappropriate behavior hurt or stink? The interplay between neural
      representations of somatic experiences and moral decisions.
LID - eaat4390 [pii]
LID - 10.1126/sciadv.aat4390 [doi]
AB  - Embodied models suggest that moral judgments are strongly intertwined with
      first-hand somatic experiences, with some pointing to disgust, and others arguing
      for a role of pain/harm. Both disgust and pain are unpleasant, arousing
      experiences, with strong relevance for survival, but with distinctive sensory
      qualities and neural channels. Hence, it is unclear whether moral cognition
      interacts with sensory-specific properties of one somatic experience or with
      supramodal dimensions common to both. Across two experiments, participants
      evaluated ethical dilemmas and subsequently were exposed to disgusting
      (olfactory) or painful (thermal) stimulations of matched unpleasantness. We found
      that moral scenarios enhanced physiological and neural activity to subsequent
      disgust (but not pain), as further supported by an independently validated
      whole-brain signature of olfaction. This effect was mediated by activity in the
      posterior cingulate cortex triggered by dilemma judgments. Our results thus speak
      in favor of an association between moral cognition and sensory-specific
      properties of disgust.
CI  - Copyright (c) 2020 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0
      (CC BY-NC).
FAU - Sharvit, G
AU  - Sharvit G
AUID- ORCID: 0000-0002-0464-4642
AD  - Laboratory of Behavioural Neurology and Imaging of Cognition, Department of
      Neuroscience, University Medical Center, University of Geneva, Geneva,
      Switzerland.
AD  - Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland.
AD  - Haas School of Business, University of California, Berkeley, Berkeley, CA, USA.
FAU - Lin, E
AU  - Lin E
AUID- ORCID: 0000-0003-4604-7050
AD  - Laboratory of Behavioural Neurology and Imaging of Cognition, Department of
      Neuroscience, University Medical Center, University of Geneva, Geneva,
      Switzerland.
AD  - Department of Management, Technology, and Economics, ETH, 8006, Zurich,
      Switzerland.
FAU - Vuilleumier, P
AU  - Vuilleumier P
AUID- ORCID: 0000-0002-8198-9214
AD  - Laboratory of Behavioural Neurology and Imaging of Cognition, Department of
      Neuroscience, University Medical Center, University of Geneva, Geneva,
      Switzerland.
AD  - Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland.
AD  - Geneva Neuroscience Center, University of Geneva, Geneva, Switzerland.
FAU - Corradi-Dell'Acqua, C
AU  - Corradi-Dell'Acqua C
AUID- ORCID: 0000-0002-7512-9023
AD  - Laboratory of Behavioural Neurology and Imaging of Cognition, Department of
      Neuroscience, University Medical Center, University of Geneva, Geneva,
      Switzerland. corrado.corradi@unige.ch.
AD  - Geneva Neuroscience Center, University of Geneva, Geneva, Switzerland.
AD  - Theory of Pain Laboratory, Department of Psychology, Faculty of Psychology and
      Educational Sciences (FPSE), University of Geneva, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - United States
TA  - Sci Adv
JT  - Science advances
JID - 101653440
SB  - IM
PMC - PMC7567598
EDAT- 2020/10/18 06:00
MHDA- 2020/10/18 06:01
CRDT- 2020/10/17 05:24
PHST- 2020/01/08 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/10/17 05:24 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/10/18 06:01 [medline]
AID - 6/42/eaat4390 [pii]
AID - 10.1126/sciadv.aat4390 [doi]
PST - epublish
SO  - Sci Adv. 2020 Oct 16;6(42). pii: 6/42/eaat4390. doi: 10.1126/sciadv.aat4390.
      Print 2020 Oct.


PMID- 33066818
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1750-1172 (Electronic)
IS  - 1750-1172 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Oct 16
TI  - European expert network on rare communicable diseases and other rare diseases
      linked to mobility and globalisation focused on health care provision (EURaDMoG):
      a feasibility study.
PG  - 291
LID - 10.1186/s13023-020-01534-1 [doi]
AB  - INTRODUCTION: In the current mobility and globalization context, there is a
      growing need to identify potential changes on the pattern of diseases in the
      European Union (EU)/European Economic Area (EEA) and provide accurate diagnosis
      and treatment for the population. The pattern of rare communicable diseases that 
      can affect people returning to EU/EEA from travel abroad, visiting EU/EEA or
      establishing in the EU/EEA is of special relevance. The objective of this
      manuscript is to give an overview about the EURaDMoG study and discuss the
      feasibility of establishing a European network on rare communicable diseases and 
      other rare conditions linked to mobility and globalization. METHODS: We undertook
      a three-steps process where we first conducted a narrative review to estimate the
      prevalence and incidence and to list rare communicable and non-communicable
      diseases linked to mobility and globalization in the EU/EEA; second, we organized
      an international consultation workshop with experts in the diseases previously
      selected; and finally, the feasibility study analysed how successful a European
      expert network on rare diseases linked to mobility and globalization focused on
      health care provision would be, accounting for different operational and also
      sustainability criteria. RESULTS: First, considering the areas or topics that the
      network should cover, it was concluded that communicable and non-communicable
      rare diseases linked to mobility and globalization should be differentiated.
      Second, since all non-communicable rare diseases linked to mobility and
      globalization identified are already covered by different European Reference
      Networks (ERNs), there is no need for them to be included in a new European
      network. Three scenarios were considered for establishing a potential European
      network for rare communicable diseases linked to Mobility and Globalisation with 
      a focus on Health Care provision: 1) To maintain the current situation "Status
      Quo" scenario; 2) to create a specific European expert network (EEN) on rare
      communicable diseases linked to mobility and globalisation; 3) to develop a new
      ERN on communicable rare diseases linked to mobility and globalisation.
      CONCLUSIONS: Since the focus is the provision of health care, an ERN could have
      the potential to better boost the quality of care being facilitated by
      technological tools and online platforms that permit the safe and ethically
      acceptable exchange of data. However, this potential new network should not
      eclipse current existing networks and they should be complementary.
FAU - Requena-Mendez, Ana
AU  - Requena-Mendez A
AUID- ORCID: 0000-0002-4422-241X
AD  - Barcelona Institute for Global Health (Hospital Clinic- Universitat de
      Barcelona), Barcelona, Spain. ana.requena@isglobal.org.
AD  - Department of Medicine, Karolinska Institutet, Solna, 17176, Stockholm, Sweden.
      ana.requena@isglobal.org.
FAU - Bisoffi, Zeno
AU  - Bisoffi Z
AD  - Department of Infectious - Tropical Diseases and Microbiology, IRCCS Sacro Cuore 
      Don Calabria Hospital, Negrar (Verona), Italy.
AD  - Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
FAU - Vives-Corrons, Joan-Lluis
AU  - Vives-Corrons JL
AD  - Institute for Leukaemia Research Josep Carreras (IJC), Badalona (Barcelona),
      Spain.
FAU - Gascon, Joaquim
AU  - Gascon J
AD  - Barcelona Institute for Global Health (Hospital Clinic- Universitat de
      Barcelona), Barcelona, Spain.
FAU - Plasencia, Antoni
AU  - Plasencia A
AD  - Barcelona Institute for Global Health (Hospital Clinic- Universitat de
      Barcelona), Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201016
PL  - England
TA  - Orphanet J Rare Dis
JT  - Orphanet journal of rare diseases
JID - 101266602
SB  - IM
MH  - *Communicable Diseases/epidemiology
MH  - Delivery of Health Care
MH  - Europe
MH  - European Union
MH  - Feasibility Studies
MH  - Humans
MH  - *Rare Diseases/epidemiology
PMC - PMC7563907
OTO - NOTNLM
OT  - *Communicable diseases
OT  - *Globalisation
OT  - *Imported diseases
OT  - *Mobility
OT  - *Rare diseases
OT  - *Rare infections
EDAT- 2020/10/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/17 05:19
PHST- 2019/12/16 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/10/17 05:19 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13023-020-01534-1 [doi]
AID - 10.1186/s13023-020-01534-1 [pii]
PST - epublish
SO  - Orphanet J Rare Dis. 2020 Oct 16;15(1):291. doi: 10.1186/s13023-020-01534-1.


PMID- 33066811
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 16
TI  - Therapeutic benefits of music-based synchronous finger tapping in Parkinson's
      disease-an fNIRS study protocol for randomized controlled trial in Dalian, China.
PG  - 864
LID - 10.1186/s13063-020-04770-9 [doi]
AB  - BACKGROUND: Music therapy improves neuronal activity and connectivity of healthy 
      persons and patients with clinical symptoms of neurological diseases like
      Parkinson's disease, Alzheimer's disease, and major depression. Despite the
      plethora of publications that have reported the positive effects of music
      interventions, little is known about how music improves neuronal activity and
      connectivity in afflicted patients. METHODS: For patients suffering from
      Parkinson's disease (PD), we propose a daily 25-min music-based synchronous
      finger tapping (SFT) intervention for 8 weeks. Eligible participants with PD are 
      split into two groups: an intervention group and a control arm. In addition, a
      third cohort of healthy controls will be recruited. Assessment of finger tapping 
      performances, the Unified Parkinson's Disease Rating Scale (UPDRS), an n-back
      test, the Montreal Cognitive Assessment (MoCA), as well as oxygenated hemoglobin 
      (HbO2), deoxygenated hemoglobin (HbR), and total hemoglobin activation collected 
      by functional near-infrared spectroscopy (fNIRS) are measured at baseline, week 4
      (during), week 8 (post), and week 12 (retention) of the study. Data collected
      from the two PD groups are compared to baseline performances from healthy
      controls. DISCUSSION: This exploratory prospective trial study investigates the
      cortical neuronal activity and therapeutic effects associated with an auditory
      external cue used to induce automatic and implicit synchronous finger tapping in 
      patients diagnosed with PD. The extent to which the intervention is effective may
      be dependent on the severity of the disease. The study's findings are used to
      inform larger clinical studies for optimization and further exploration of the
      therapeutic effects of movement-based music therapy on neural activity in
      neurological diseases. TRIAL REGISTRATION: ClinicalTrials.gov NCT04212897 .
      Registered on December 30, 2019. The participant recruitment and study protocol
      have received ethical approval from the First Affiliated Hospital of Dalian
      Medical University. The hospital Protocol Record number is PJ-KY-2019-123. The
      protocol was named "fNIRS Studies of Music Intervention of Parkinson's Disease." 
      The current protocol is version 1.1, revised on September 1, 2020.
FAU - Pu, Lanlan
AU  - Pu L
AD  - Department of Neurology, the First Affiliated Hospital of Dalian Medical
      University, Dalian, Liaoning Province, China.
FAU - Qureshi, Nauman Khalid
AU  - Qureshi NK
AD  - School of Biomedical Engineering, Faculty of Electronic Information and
      Electrical Engineering, Dalian University of Technology, Dalian, Liaoning
      Province, China.
FAU - Ly, Joanne
AU  - Ly J
AD  - Department of Biomedical Engineering, University of California, Irvine, CA, USA.
FAU - Zhang, Bingwei
AU  - Zhang B
AD  - Department of Neurology, the First Affiliated Hospital of Dalian Medical
      University, Dalian, Liaoning Province, China.
FAU - Cong, Fengyu
AU  - Cong F
AD  - School of Biomedical Engineering, Faculty of Electronic Information and
      Electrical Engineering, Dalian University of Technology, Dalian, Liaoning
      Province, China.
AD  - Faculty of Information Technology, University of Jyvaskyla, Jyvaskyla, Finland.
FAU - Tang, William C
AU  - Tang WC
AD  - Department of Biomedical Engineering, University of California, Irvine, CA, USA. 
      wctang@uci.edu.
FAU - Liang, Zhanhua
AU  - Liang Z
AD  - Department of Neurology, the First Affiliated Hospital of Dalian Medical
      University, Dalian, Liaoning Province, China. zhanhualiang@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04212897
GR  - LNCCC-C06-2015/Health and Family Planning Commission of Liaoning Province
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201016
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - China
MH  - Humans
MH  - *Music
MH  - *Parkinson Disease/diagnosis/therapy
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Spectroscopy, Near-Infrared
PMC - PMC7568348
OTO - NOTNLM
OT  - Explicit and implicit timing
OT  - Motor-control
OT  - Music therapy
OT  - Parkinson's disease
OT  - Randomized controlled trials
OT  - Synchronous finger tapping
OT  - fNIRS
EDAT- 2020/10/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/17 05:19
PHST- 2020/02/25 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/17 05:19 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04770-9 [doi]
AID - 10.1186/s13063-020-04770-9 [pii]
PST - epublish
SO  - Trials. 2020 Oct 16;21(1):864. doi: 10.1186/s13063-020-04770-9.


PMID- 33066771
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 16
TI  - Forgoing life-sustaining treatment - a comparative analysis of regulations in
      Japan, Korea, Taiwan, and England.
PG  - 99
LID - 10.1186/s12910-020-00535-w [doi]
AB  - BACKGROUND: Regulations on forgoing life-sustaining treatment (LST) have
      developed in Asian countries including Japan, Korea and Taiwan. However, other
      countries are relatively unaware of these due to the language barrier. This
      article aims to describe and compare the relevant regulatory frameworks, using
      the (more familiar) situation in England as a point of reference. We undertook
      literature reviews to ascertain the legal and regulatory positions on forgoing
      LST in Japan, Korea, Taiwan, and England. MAIN TEXT: Findings from a literature
      review are first presented to describe the development of the regulatory
      frameworks surrounding the option of forgoing LST in each country. Based on the
      findings from the four countries, we suggest five ethically important points,
      reflection on which should help to inform the further development of regulatory
      frameworks concerning end-of-life care in these countries and beyond. There
      should be reflection on: (1) the definition of - and reasons for defining - the
      'terminal stage' and associated criteria for making such judgements; Korea and
      Taiwan limit forgoing LST to patients in this stage, but there are risks
      associated with defining this too narrowly or broadly; (2) foregoing LST for
      patients who are not in this stage, as is allowed in Japan and England, because
      here too there are areas of controversy, including (in England) whether the law
      in this area does enough to respect the autonomy of (now) incapacitated patients;
      (3) whether 'foregoing' LST should encompass withholding and withdrawing
      treatment; this is also an ethically disputed area, particularly in the Asian
      countries we examine; (4) the family's role in end-of-life decision-making,
      particularly as, compared with England, the three Asian countries traditionally
      place a greater emphasis on families and communities than on individuals; and (5)
      decision-making with and for those incapacitated patients who lack families,
      surrogate decision-makers or ADs. CONCLUSION: Comparison of, and reflection on,
      the different legal positions that obtain in Japan, Korea, Taiwan, and England
      should prove informative and we particularly invite reflection on five areas, in 
      the hope the ensuing discussions will help to establish better end-of-life
      regulatory frameworks in these countries and elsewhere.
FAU - Tanaka, Miho
AU  - Tanaka M
AUID- ORCID: 0000-0003-4230-9391
AD  - Japan Medical Association Research Institute, 2-28-16 Honkomagome, Bunkyo-ku,
      Tokyo, 113-8621, Japan. mipomipo-tky@umin.ac.jp.
FAU - Kodama, Satoshi
AU  - Kodama S
AD  - Graduate School of Letters, Kyoto University, Yoshida Honmachi, Sakyo-ku, Kyoto, 
      606-8501, Japan.
FAU - Lee, Ilhak
AU  - Lee I
AD  - College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722,
      South Korea.
FAU - Huxtable, Richard
AU  - Huxtable R
AD  - Centre for Ethics in Medicine, Population Health Sciences, Medical School,
      University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
FAU - Chung, Yicheng
AU  - Chung Y
AD  - Tokyo Branch of Otani University, Shin Buddhist Comprehensive Research Institute,
      2-19-11 Yushima, Bunkyo-ku, Tokyo, 113-0034, Japan.
LA  - eng
GR  - 2018A-002/Sasakawa Memorial Health Foundation (JP)/International
GR  - NRF-2017S1A2A2040014/Global Research Network program through the Ministry of
      Education of the Republic of Korea and the National Research Foundation of
      Korea/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Decision Making
MH  - England
MH  - Humans
MH  - Japan
MH  - Republic of Korea
MH  - Taiwan
MH  - *Withholding Treatment
PMC - PMC7563900
OTO - NOTNLM
OT  - *End-of-life care
OT  - *England
OT  - *Forgoing (withholding and withdrawing) life-sustaining treatment
OT  - *Guideline
OT  - *Japan
OT  - *Korea
OT  - *Law
OT  - *Taiwan
EDAT- 2020/10/18 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/17 05:19
PHST- 2019/08/20 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/10/17 05:19 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00535-w [doi]
AID - 10.1186/s12910-020-00535-w [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 16;21(1):99. doi: 10.1186/s12910-020-00535-w.


PMID- 33066551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 14
TI  - Pre-Liver Transplant ROTEM Clot Lysis Index Is Associated with 30-Day Mortality, 
      But Is Not a Measure for Fibrinolysis.
LID - E3298 [pii]
LID - 10.3390/jcm9103298 [doi]
AB  - Complex alterations of the coagulation system in end stage liver disease lead to 
      an increased risk of bleeding and mortality. In the present study, we
      investigated; 1. the association of pre-liver transplant rotational
      thrombelastometry (ROTEM) variables with bleeding as well as 30-day-mortality and
      2. the underlying pathophysiology. After approval from the local ethics
      committee, rotational thrombelastometry variables, conventional laboratory
      coagulation values, MELD score (model of end-stage liver disease), red blood cell
      loss, blood product use, coagulation factors, underlying disease, and demographic
      data were retrospectively analysed. Pre-transplant thrombelastometry clot lysis
      index (CLI) and MELD were the only variables associated with mortality, bleeding 
      and blood product use, respectively. Mortality was 4.2%, when CLI was <85%, and
      increased to 25.7% when the CLI was >95%. Multivariate analysis including CLI and
      MELD score identified the CLI as an independent and the best predictor of
      30-day-mortality. Interestingly, the inhibition of fibrinolysis did neither
      affect CLI nor the association of the variable with mortality. Thus, fibrinolysis
      can be excluded as the reason for low CLI values. In conclusion, low CLI values
      measured before the beginning of liver transplantation are associated with
      reduced bleeding and mortality, but do not indicate fibrinolysis.
FAU - Hartmann, Matthias
AU  - Hartmann M
AUID- ORCID: 0000-0003-1596-0613
AD  - Klinik fur Anasthesiologie und Intensivmedizin, Universitatsklinikum Essen,
      Universitat Duisburg-Essen, 45122 Essen, Germany.
FAU - Craciun, Bogdan
AU  - Craciun B
AD  - Klinik fur Anasthesiologie und Intensivmedizin, Universitatsklinikum Essen,
      Universitat Duisburg-Essen, 45122 Essen, Germany.
FAU - Paul, Andreas
AU  - Paul A
AD  - Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie,
      Universitatsklinikum Essen, Universitat Duisburg-Essen, 45122 Essen, Germany.
FAU - Brenner, Thorsten
AU  - Brenner T
AD  - Klinik fur Anasthesiologie und Intensivmedizin, Universitatsklinikum Essen,
      Universitat Duisburg-Essen, 45122 Essen, Germany.
FAU - Saner, Fuat H
AU  - Saner FH
AUID- ORCID: 0000-0002-9157-4573
AD  - Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie,
      Universitatsklinikum Essen, Universitat Duisburg-Essen, 45122 Essen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7602159
OTO - NOTNLM
OT  - ROTEM
OT  - clot lysis index
OT  - fibrinolysis
OT  - liver transplantation
EDAT- 2020/10/18 06:00
MHDA- 2020/10/18 06:01
CRDT- 2020/10/17 01:04
PHST- 2020/09/08 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/17 01:04 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/10/18 06:01 [medline]
AID - jcm9103298 [pii]
AID - 10.3390/jcm9103298 [doi]
PST - epublish
SO  - J Clin Med. 2020 Oct 14;9(10). pii: jcm9103298. doi: 10.3390/jcm9103298.


PMID- 33066392
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 20
DP  - 2020 Oct 14
TI  - Organizational Solutions to the Moral Risks of Policing.
LID - E7461 [pii]
LID - 10.3390/ijerph17207461 [doi]
AB  - In addition to the physical and emotional challenges faced by law enforcement
      professionals, the job confronts officers with numerous moral risks. The moral
      risks include moral distress, moral injury, ethical exhaustion, compassion
      fatigue, and practices that lead to lapses in ethical decision-making. The paper 
      focuses on what police agencies can do to better address the moral risks of
      policing. These moral risks are central to officer wellness and, thus, a crucial 
      component of officers' operational readiness. Strategies are presented that will 
      improve prevention efforts, including recruiting and hiring, training,
      supervision, and promotional practices. Additionally, the paper offers
      recommendations for effective approaches to intervention with officers who have
      displayed the effects of these moral risks. Finally, the paper highlights the
      kind of law enforcement leaders who are best able to implement strategies
      designed to prevent negative outcomes associated with the moral risks of
      policing.
FAU - Blumberg, Daniel M
AU  - Blumberg DM
AUID- ORCID: 0000-0001-8925-8689
AD  - California School of Professional Psychology, Alliant International University,
      San Diego, CA 92129, USA.
FAU - Papazoglou, Konstantinos
AU  - Papazoglou K
AUID- ORCID: 0000-0002-8644-2437
AD  - Department of Criminal Justice, New Jersey City University, Jersey City, NJ
      07305, USA.
FAU - Schlosser, Michael D
AU  - Schlosser MD
AUID- ORCID: 0000-0003-0910-7237
AD  - Police Training Institute, University of Illinois at Urbana-Champaign, Champaign,
      IL 61820, USA.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Humans
MH  - *Law Enforcement
MH  - *Morals
MH  - *Police
MH  - Risk
PMC - PMC7602265
OTO - NOTNLM
OT  - *moral risks
OT  - *police leadership
OT  - *police misconduct
OT  - *police wellness
EDAT- 2020/10/18 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/10/17 01:03
PHST- 2020/09/23 00:00 [received]
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/10/11 00:00 [accepted]
PHST- 2020/10/17 01:03 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - ijerph17207461 [pii]
AID - 10.3390/ijerph17207461 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 14;17(20). pii: ijerph17207461. doi:
      10.3390/ijerph17207461.


PMID- 33066272
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210715
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 13
TI  - Animal Research beyond the Laboratory: Report from a Workshop on Places Other
      than Licensed Establishments (POLEs) in the UK.
LID - E1868 [pii]
LID - 10.3390/ani10101868 [doi]
AB  - Research involving animals that occurs outside the laboratory raises an array of 
      unique challenges. With regard to UK legislation, however, it receives only
      limited attention in terms of official guidelines, support, and statistics, which
      are unsurprisingly orientated towards the laboratory environment in which the
      majority of animal research takes place. In September 2019, four social
      scientists from the Animal Research Nexus program gathered together a group of 13
      experts to discuss nonlaboratory research under the Animals (Scientific
      Procedures) Act (A(SP)A) of 1986 (mirroring European Union (EU) Directive
      2010/63/EU), which is the primary mechanism for regulating animal research in the
      UK. Such nonlaboratory research under the A(SP)A often occurs at Places Other
      than Licensed Establishments (POLEs). The primary objective of the workshop was
      to assemble a diverse group with experience across a variety of POLEs (e.g.,
      wildlife field sites, farms, fisheries, veterinary clinics, zoos) to explore the 
      practical, ethical, and regulatory challenges of conducting research at POLEs.
      While consensus was not sought, nor reached on every point of discussion, we
      collectively identified five key areas that we propose require further discussion
      and attention. These relate to: (1) support and training; (2) ethical review; (3)
      cultures of care, particularly in nonregulated research outside of the
      laboratory; (4) the setting of boundaries; and (5) statistics and transparency.
      The workshop generated robust discussion and thereby highlighted the value of
      focusing on the unique challenges posed by POLEs, and the need for further
      opportunities for exchanging experiences and sharing best practice relating to
      research projects outside of the laboratory in the UK and elsewhere.
FAU - Palmer, Alexandra
AU  - Palmer A
AD  - School of Geography and the Environment, University of Oxford, Oxford OX1 3QY,
      UK.
FAU - Greenhough, Beth
AU  - Greenhough B
AUID- ORCID: 0000-0002-7351-2619
AD  - School of Geography and the Environment, University of Oxford, Oxford OX1 3QY,
      UK.
FAU - Hobson-West, Pru
AU  - Hobson-West P
AD  - School of Sociology and Social Policy, University of Nottingham, Nottingham NG7
      2RD, UK.
FAU - Message, Reuben
AU  - Message R
AUID- ORCID: 0000-0001-8779-3282
AD  - School of Geography and the Environment, University of Oxford, Oxford OX1 3QY,
      UK.
FAU - Aegerter, James N
AU  - Aegerter JN
AD  - National Wildlife Management Centre, Animal and Plant Health Agency, Sand Hutton,
      York YO41 1LZ, UK.
FAU - Belshaw, Zoe
AU  - Belshaw Z
AD  - PDSA Nottingham, Dunkirk Road, Nottingham NG7 2PH, UK.
FAU - Dennison, Ngaire
AU  - Dennison N
AD  - Biological Services, University of Dundee, Dundee DD1 5EH, UK.
FAU - Dickey, Roger
AU  - Dickey R
AD  - Army Ornithological Society (AOS), Aldershot GU11 1PS, UK.
FAU - Lane, Julie
AU  - Lane J
AD  - National Wildlife Management Centre, Animal and Plant Health Agency, Sand Hutton,
      York YO41 1LZ, UK.
FAU - Lorimer, Jamie
AU  - Lorimer J
AD  - School of Geography and the Environment, University of Oxford, Oxford OX1 3QY,
      UK.
FAU - Millar, Kate
AU  - Millar K
AD  - Centre for Applied Bioethics, School of Biosciences and School of Veterinary
      Medicine and Science (SVMS), University of Nottingham, Nottingham LE12 5PF, UK.
FAU - Newman, Chris
AU  - Newman C
AD  - Wildlife Conservation Research Unit, The Recanati-Kaplan Centre, Department of
      Zoology, University of Oxford, Oxford OX13 5QL, UK.
FAU - Pullen, Kirsten
AU  - Pullen K
AD  - Wild Planet Trust, Paignton Zoo, Totnes Road, Paignton TQ4 7EU, UK.
FAU - Reynolds, S James
AU  - Reynolds SJ
AUID- ORCID: 0000-0001-5017-1324
AD  - Army Ornithological Society (AOS), Aldershot GU11 1PS, UK.
AD  - School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK.
FAU - Wells, Dominic J
AU  - Wells DJ
AD  - Department of Comparative Biomedical Sciences, Royal Veterinary College, London
      NW1 0TU, UK.
FAU - Witt, Matthew J
AU  - Witt MJ
AUID- ORCID: 0000-0002-9498-5378
AD  - College of Life and Environmental Sciences, University of Exeter, Exeter EX4 4QD,
      UK.
FAU - Wolfensohn, Sarah
AU  - Wolfensohn S
AUID- ORCID: 0000-0002-0985-3603
AD  - School of Veterinary Medicine, University of Surrey, Guildford GU2 7AL, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - WT205393/A/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - KSRG07/Keble College, University of Oxford
PT  - Journal Article
DEP - 20201013
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7602001
OTO - NOTNLM
OT  - animal research
OT  - animal welfare
OT  - farms
OT  - fisheries
OT  - governance
OT  - policy
OT  - veterinary medicine
OT  - wildlife
OT  - zoos
EDAT- 2020/10/18 06:00
MHDA- 2020/10/18 06:01
CRDT- 2020/10/17 01:03
PHST- 2020/09/09 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/10/17 01:03 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/10/18 06:01 [medline]
AID - ani10101868 [pii]
AID - 10.3390/ani10101868 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 13;10(10). pii: ani10101868. doi: 10.3390/ani10101868.


PMID- 33066133
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Linking)
VI  - 7
IP  - 10
DP  - 2020 Oct 13
TI  - Preliminary Study on the Echo-Assisted Intersphincteric Autologous
      Microfragmented Adipose Tissue Injection to Control Fecal Incontinence in
      Children Operated for Anorectal Malformations.
LID - E181 [pii]
LID - 10.3390/children7100181 [doi]
AB  - AIM OF THE STUDY: To assess the efficacy of a novel technique (echo-assisted
      intersphincteric autologous microfragmented adipose tissue injection, also called
      "anal-lipofilling") in the management of non-responsive fecal incontinence in
      children born with anorectal malformations (ARMs). METHODS: Following ethical
      committee approval (CHPED-MAR-18-02), anal-lipofilling was proposed to patients
      with fecal incontinence not responsive to medications or bowel management (bowel 
      enema and/or transanal irrigation automatic systems), then a prospective study
      was conducted. Anal-lipofilling consisted of three phases: lipoaspiration from
      the abdominal wall, processing of the lipoaspirate with a Lipogems system and
      intersphincteric injection of the processed fat tissue via endosonographic
      assistance. A questionnaire based on Krickenbeck's scale (KS) was administered to
      the patients to evaluate the clinical outcome. MAIN RESULTS: Four male patients
      (three recto-urethral fistula, and one recto-perineal fistula) underwent the
      anal-lipofilling procedure at a mean age of 13.0 +/- 4.2 yrs. There were no
      complications during or after the procedure. From an initial assessment of the
      patients there was an improvement in the bowel function at a median follow up of 
      6 months, with better scores at KS (100% Soiling grade three pre-treatment vs.
      75% grade one post-treatment). CONCLUSIONS: Even if our Study is preliminary,
      echo-assisted anal-lipofilling could be considered as a feasible and safe
      alternative technique in the management of the fecal incontinence in
      non-responding ARMs patients. More studies are still necessary to support the
      validity of the implant of autologous adipose tissue in the anal sphincter as a
      therapy for fecal incontinence in children born with ARMs.
FAU - Parente, Giovanni
AU  - Parente G
AUID- ORCID: 0000-0002-7119-651X
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - Pinto, Valentina
AU  - Pinto V
AD  - Plastic Surgery, Sant'Orsola-Malpighi University Hospital, 40138 Bologna, Italy.
FAU - Di Salvo, Neil
AU  - Di Salvo N
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - D'Antonio, Simone
AU  - D'Antonio S
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - Libri, Michele
AU  - Libri M
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - Gargano, Tommaso
AU  - Gargano T
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - Catania, Vincenzo Davide
AU  - Catania VD
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - Ruggeri, Giovanni
AU  - Ruggeri G
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
FAU - Lima, Mario
AU  - Lima M
AD  - Pediatric Surgery Department, Sant'Orsola-Malpighi University Hospital, 40138
      Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC7656299
OTO - NOTNLM
OT  - anal-lipofilling
OT  - anorectal malformation
OT  - bowel management
OT  - endoanal ultrasound
OT  - fecal incontinence
EDAT- 2020/10/18 06:00
MHDA- 2020/10/18 06:01
CRDT- 2020/10/17 01:02
PHST- 2020/09/08 00:00 [received]
PHST- 2020/10/06 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/10/17 01:02 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2020/10/18 06:01 [medline]
AID - children7100181 [pii]
AID - 10.3390/children7100181 [doi]
PST - epublish
SO  - Children (Basel). 2020 Oct 13;7(10). pii: children7100181. doi:
      10.3390/children7100181.


PMID- 33065985
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20210415
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 13
TI  - Genomics in Personalized Nutrition: Can You "Eat for Your Genes"?
LID - E3118 [pii]
LID - 10.3390/nu12103118 [doi]
AB  - Genome-wide single nucleotide polymorphism (SNP) data are now quickly and
      inexpensively acquired, raising the prospect of creating personalized dietary
      recommendations based on an individual's genetic variability at multiple SNPs.
      However, relatively little is known about most specific gene-diet interactions,
      and many molecular and clinical phenotypes of interest (e.g., body mass index
      [BMI]) involve multiple genes. In this review, we discuss direct to consumer
      genetic testing (DTC-GT) and the current potential for precision nutrition based 
      on an individual's genetic data. We review important issues such as dietary
      exposure and genetic architecture addressing the concepts of penetrance,
      pleiotropy, epistasis, polygenicity, and epigenetics. More specifically, we
      discuss how they complicate using genotypic data to predict phenotypes as well as
      response to dietary interventions. Then, several examples (including caffeine
      sensitivity, alcohol dependence, non-alcoholic fatty liver disease,
      obesity/appetite, cardiovascular, Alzheimer's disease, folate metabolism,
      long-chain fatty acid biosynthesis, and vitamin D metabolism) are provided
      illustrating how genotypic information could be used to inform nutritional
      recommendations. We conclude by examining ethical considerations and practical
      applications for using genetic information to inform dietary choices and the
      future role genetics may play in adopting changes beyond population-wide healthy 
      eating guidelines.
FAU - Mullins, Veronica A
AU  - Mullins VA
AD  - Department of Nutritional Sciences, University of Arizona, Tucson, AZ 85719, USA.
FAU - Bresette, William
AU  - Bresette W
AUID- ORCID: 0000-0003-3360-0355
AD  - Department of Nutritional Sciences, University of Arizona, Tucson, AZ 85719, USA.
FAU - Johnstone, Laurel
AU  - Johnstone L
AD  - The BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA.
FAU - Hallmark, Brian
AU  - Hallmark B
AD  - The BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA.
FAU - Chilton, Floyd H
AU  - Chilton FH
AD  - Department of Nutritional Sciences, University of Arizona, Tucson, AZ 85719, USA.
AD  - The BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA.
LA  - eng
GR  - R01 AT008621/NH/NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201013
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
MH  - *Diet, Healthy/standards
MH  - Eating/*physiology
MH  - Female
MH  - Genetic Testing
MH  - Humans
MH  - Male
MH  - *Nutrigenomics
MH  - Nutritional Physiological Phenomena/*genetics/*physiology
MH  - Polymorphism, Single Nucleotide
MH  - *Precision Medicine
MH  - *Recommended Dietary Allowances
PMC - PMC7599709
OTO - NOTNLM
OT  - diet
OT  - genetics
OT  - nutrients
OT  - nutrigenetics
OT  - nutrigenomics
OT  - personalized
OT  - precision nutrition
EDAT- 2020/10/18 06:00
MHDA- 2021/04/16 06:00
CRDT- 2020/10/17 01:02
PHST- 2020/09/16 00:00 [received]
PHST- 2020/10/05 00:00 [revised]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/10/17 01:02 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
AID - nu12103118 [pii]
AID - 10.3390/nu12103118 [doi]
PST - epublish
SO  - Nutrients. 2020 Oct 13;12(10). pii: nu12103118. doi: 10.3390/nu12103118.


PMID- 33065486
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1532-2238 (Electronic)
IS  - 1096-6374 (Linking)
VI  - 55
DP  - 2020 Dec
TI  - Childhood growth hormone deficiency, a diagnosis in evolution: The intersection
      of growth hormone history and ethics.
PG  - 101358
LID - S1096-6374(20)30067-8 [pii]
LID - 10.1016/j.ghir.2020.101358 [doi]
AB  - In 1958 the first recorded case of a patient treated with human growth hormone
      for growth hormone deficiency was published. Since that time, the source and
      availability of human growth hormone have changed. With the increased
      availability of growth hormone, there has been an uptrend in the level below
      which childhood growth hormone deficiency is diagnosed based on provocative GH
      stimulation testing. This increase is despite better specificity of growth
      hormone assays in addition to a lack of supportive evidence regarding appropriate
      normal values. With these trends the diagnosis of childhood growth hormone
      deficiency is evolving, and clinicians should be aware that this may have
      potential ethical implications.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Henry, Rohan K
AU  - Henry RK
AD  - Section of Endocrinology, Department of Pediatrics, Nationwide Children's
      Hospital/The Ohio State University College of Medicine, Columbus, OH 43205, USA. 
      Electronic address: rohan.henry@nationwidechildrens.org.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - Scotland
TA  - Growth Horm IGF Res
JT  - Growth hormone & IGF research : official journal of the Growth Hormone Research
      Society and the International IGF Research Society
JID - 9814320
RN  - 12629-01-5 (Human Growth Hormone)
SB  - IM
MH  - Child
MH  - Diagnostic Tests, Routine/*ethics
MH  - Growth Disorders/blood/*diagnosis
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Human Growth Hormone/*blood/*deficiency/history
MH  - Humans
OTO - NOTNLM
OT  - *Growth hormone deficiency (GHD)
OT  - *Growth hormone stimulation test
OT  - *Human growth hormone
EDAT- 2020/10/17 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/10/16 20:17
PHST- 2020/07/31 00:00 [received]
PHST- 2020/09/23 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/10/16 20:17 [entrez]
AID - S1096-6374(20)30067-8 [pii]
AID - 10.1016/j.ghir.2020.101358 [doi]
PST - ppublish
SO  - Growth Horm IGF Res. 2020 Dec;55:101358. doi: 10.1016/j.ghir.2020.101358. Epub
      2020 Oct 6.


PMID- 33064838
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
IP  - 35-36
DP  - 2020 Aug 24
TI  - Attitudes and acceptance of patients undergoing visceral surgery towards an open 
      access electronic medical record - a Swiss-German single-centre study.
PG  - w20328
LID - 10.4414/smw.2020.20328 [doi]
LID - Swiss Med Wkly. 2020;150:w20328 [pii]
AB  - INTRODUCTION: With the digitalisation of patient medical records, providing
      patients with free access to their electronic medical record (EMR) has become an 
      important topic of debate in many countries. Recent studies show that the quality
      of treatment in healthcare may be improved by encouraging patients to take an
      active part in their care. Providing patients with access to their EMR may also
      improve the patient-doctor relationship, adherence to treatment and patient
      satisfaction. In June 2015, the Swiss government passed a law to set the
      framework for a nationally coordinated EMR system. A major stipulation to this
      legislation is that patients and doctors must consent to having an open access
      EMR (oEMR). The aim of this study was to assess patients' attitudes towards an
      oEMR. METHODS: Consecutive patients attending the outpatient clinic of our
      department within two months were included in this study. Patients were asked to 
      complete a questionnaire consisting of 43 items, including amongst others disease
      characteristics, their expectations regarding an oEMR and its implementation.
      This study was approved by the ethics committee of the Canton Zurich (BASEC-Nr.
      Req-2016-00383). RESULTS: 149 patients were included with a mean age of 52
      (standard deviation 17) years. 42% suffered from abdominal diseases (benign or
      malignant), 26% from hernias, and 17% from anorectal disorders. 76% of the
      responding patients fully supported an oEMR. Among all items, a higher
      educational degree (odds ratio [OR] 55, 95% confidence interval [CI] 39-70),
      patients with general or half-private insurance (OR 10, 95% CI 0.99-100) and
      patients with suspected cancer (OR 6, 95% CI 0.93-42) were independent predictors
      for a positive attitude regarding an oEMR on multivariate analysis. CONCLUSION:
      To our knowledge, this is the first study conducted in a hospital in the
      German-speaking part of Switzerland evaluating patients' opinions regarding an
      oEMR. Overall a large majority of the patients support an oEMR. Patients with
      cancer, a higher educational degree and general or half-private insured patients 
      were more likely to support an oEMR. An important next step would be to conduct
      studies investigating opinions of medical professionals during the implementation
      of an oEMR.
FAU - Bindschadler, Patrick
AU  - Bindschadler P
AD  - Department of Surgery, Cantonal Hospital Winterthur, Switzerland
FAU - Frei, Lina
AU  - Frei L
AD  - Department of Surgery, Cantonal Hospital Winterthur, Switzerland
FAU - Raptis, Dimitri A
AU  - Raptis DA
AD  - Department of Surgery, Royal Free Hospital London, United Kingdom
FAU - Tschuor, Christoph
AU  - Tschuor C
AD  - Department of Surgery, Cantonal Hospital Winterthur, Switzerland
FAU - Breitenstein, Stefan
AU  - Breitenstein S
AD  - Department of Surgery, Cantonal Hospital Winterthur, Switzerland
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - Access to Information/*psychology
MH  - Adolescent
MH  - *Digestive System Surgical Procedures
MH  - *Electronic Health Records
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Patient Satisfaction
MH  - Physician-Patient Relations
MH  - Switzerland
EDAT- 2020/10/17 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/10/16 17:11
PHST- 2020/10/16 17:11 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
AID - 10.4414/smw.2020.20328 [doi]
AID - Swiss Med Wkly. 2020;150:w20328 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Sep 1;150(35-36):w20328. doi: 10.4414/smw.2020.20328.
      eCollection 2020 Aug 24.


PMID- 33064707
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 72
IP  - 4
DP  - 2020
TI  - THE ROLE OF RESEARCH ETHICS COMMITTEES IN OBSERVATIONAL STUDIES: EPIDEMIOLOGICAL 
      REGISTRIES, CASE REPORTS, INTERVIEWS, AND RETROSPECTIVE STUDIES.
PG  - 259
LID - 10.24875/RIC.20000166 [doi]
FAU - Maldonado-Castellanos, Isaac
AU  - Maldonado-Castellanos I
AD  - Postgraduate Program in Bioethics, Postgraduate Unit, Universidad Nacional
      Autonoma de Mexico (UNAM), Mexico City, Mexico.
FAU - Mora-Magana, Ignacio
AU  - Mora-Magana I
AD  - Sub-directorate of Evaluation and Educational Programming, Instituto Nacional de 
      Pediatria, Mexico City, Mexico.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la
      Nutricion
JID - 9421552
SB  - IM
CON - Rev Invest Clin. 2019;71(3):149-156. PMID: 31184330
CIN - Rev Invest Clin. 2020;72(4):260. PMID: 33064713
MH  - *Ethics Committees, Research
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Registries
MH  - Retrospective Studies
MH  - *Uterine Cervical Neoplasms
EDAT- 2020/10/17 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/10/16 17:10
PHST- 2020/10/16 17:10 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
AID - j72/4/259 [pii]
AID - 10.24875/RIC.20000166 [doi]
PST - ppublish
SO  - Rev Invest Clin. 2020;72(4):259. doi: 10.24875/RIC.20000166.


PMID- 33064107
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2152-7202 (Electronic)
IS  - 2152-7202 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Mar 30
TI  - Influence of Community and Culture in the Ethical Allocation of Scarce Medical
      Resources in a Pandemic Situation: Deliberative Democracy Study.
PG  - e18272
LID - 10.2196/18272 [doi]
AB  - BACKGROUND: Stark gaps exist between projected health needs in a pandemic
      situation and the current capacity of health care and medical countermeasure
      systems. Existing pandemic ethics discussions have advocated to engage the public
      in scarcity dilemmas and attend the local contexts and cultural perspectives that
      shape responses to a global health threat. This public engagement study thus
      considers the role of community and culture in the ethical apportionment of
      scarce health resources, specifically ventilators, during an influenza pandemic. 
      It builds upon a previous exploration of the values and preferences of Maryland
      residents regarding how a finite supply of mechanical ventilators ought to be
      allocated during a severe global outbreak of influenza. An important finding of
      this earlier research was that local history and place within the state
      engendered different ways of thinking about scarcity. OBJECTIVE: Given the
      intrastate variation in the themes expressed by Maryland participants, the
      project team sought to examine interstate differences by implementing the same
      protocol elsewhere to answer the following questions. Does variation in ethical
      frames of reference exist within different regions of the United States? What
      practical implications does evidence of sameness and difference possess for
      pandemic planners and policymakers at local and national levels? METHODS:
      Research using the same deliberative democracy process from the Maryland study
      was conducted in Central Texas in March 2018 among 30 diverse participants, half 
      of whom identified as Hispanic or Latino. Deliberative democracy provides a
      moderated process through which community members can learn facts about a public 
      policy matter from experts and explore their own and others' views. RESULTS:
      Participants proposed that by evenly distributing supplies of ventilators and
      applying clear eligibility criteria consistently, health authorities could enable
      fair allocation of scarce lifesaving equipment. The strong identification,
      attachment, and obligation of persons toward their nuclear and extended families 
      emerged as a distinctive regional and ethnic core value that has practical
      implications for the substance, administration, and communication of allocation
      frameworks. CONCLUSIONS: Maryland and Central Texas residents expressed a common,
      overriding concern about the fairness of allocation decisions. Central Texas
      deliberants, however, more readily expounded upon family as a central
      consideration. In Central Texas, family is a principal, culturally inflected lens
      through which life and death matters are often viewed. Conveners of other
      pandemic-related public engagement exercises in the United States have advocated 
      the benefits of transparency and inclusivity in developing an ethical allocation 
      framework; this study demonstrates cultural competence as a further advantage.
CI  - (c)Monica Schoch-Spana, Emily K Brunson, Howard Gwon, Alan Regenberg, Eric S
      Toner, Elizabeth L Daugherty-Biddison. Originally published in Journal of
      Participatory Medicine (http://jopm.jmir.org), 30.03.2020.
FAU - Schoch-Spana, Monica
AU  - Schoch-Spana M
AUID- ORCID: https://orcid.org/0000-0002-8397-8367
AD  - Johns Hopkins Center for Health Security, Bloomberg School of Public Health,
      Johns Hopkins University, Baltimore, MD, United States.
FAU - Brunson, Emily K
AU  - Brunson EK
AUID- ORCID: https://orcid.org/0000-0001-6321-1882
AD  - Department of Anthropology, Texas State University, San Marcos, TX, United
      States.
FAU - Gwon, Howard
AU  - Gwon H
AUID- ORCID: https://orcid.org/0000-0003-3318-1699
AD  - Department of Environmental Sciences, Bloomberg School of Public Health, Johns
      Hopkins University, Baltimore, MD, United States.
FAU - Regenberg, Alan
AU  - Regenberg A
AUID- ORCID: https://orcid.org/0000-0003-0604-9596
AD  - Johns Hopkins Berman Institute of Bioethics, Johns Hopkins University, Baltimore,
      MD, United States.
FAU - Toner, Eric S
AU  - Toner ES
AUID- ORCID: https://orcid.org/0000-0001-5292-9450
AD  - Johns Hopkins Center for Health Security, Bloomberg School of Public Health,
      Johns Hopkins University, Baltimore, MD, United States.
FAU - Daugherty-Biddison, Elizabeth L
AU  - Daugherty-Biddison EL
AUID- ORCID: https://orcid.org/0000-0003-2504-3552
AD  - Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns
      Hopkins University, Baltimore, MD, United States.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - Canada
TA  - J Particip Med
JT  - Journal of participatory medicine
JID - 101539422
PMC - PMC7141421
OTO - NOTNLM
OT  - COVID19
OT  - culture
OT  - disaster
OT  - ethics
OT  - influenza
OT  - pandemic
OT  - preparedness
OT  - scarce resources
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 12:09
PHST- 2020/02/20 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/10/16 12:09 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - v12i1e18272 [pii]
AID - 10.2196/18272 [doi]
PST - epublish
SO  - J Particip Med. 2020 Mar 30;12(1):e18272. doi: 10.2196/18272.


PMID- 33064101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 16
TI  - High-Intensity Interval Aerobic Resistance Training to Counteract Low Relative
      Appendicular Lean Soft Tissue Mass in Middle Age: Study Protocol for a Randomized
      Controlled Trial.
PG  - e22989
LID - 10.2196/22989 [doi]
AB  - BACKGROUND: Sarcopenia is the age-related loss of skeletal muscle mass and
      function and may exist in early middle age. Previous research in this area has
      focused on resistance training in older individuals; however, there is a lack of 
      intervention trials in middle-aged adults with low relative appendicular lean
      soft tissue mass who may be at risk for sarcopenia in older age. OBJECTIVE: This 
      randomized controlled trial aims to determine the effects of a high-intensity
      interval aerobic resistance training intervention on appendicular lean soft
      tissue mass in middle-aged adults with low relative appendicular lean soft tissue
      mass. METHODS: We will conduct a 40-week, single-blinded randomized controlled
      trial in 84 middle-aged adults with low appendicular lean soft tissue mass in the
      wider Dunedin area, New Zealand. We will randomly allocate participants to
      receive either a group-based, 20-week high-intensity interval aerobic resistance 
      training intervention program or a single, 60-minute education session on current
      exercise recommendations. After the first 20 weeks, both groups will be given a
      20-week home program. The study will assess primary and secondary outcome
      measures, including body composition (regional and whole-body lean soft tissue
      mass, fat mass, percentage body fat, measured by dual x-ray absorptiometry),
      blood biomarkers (cortisol, creatinine, C-reactive protein, lipid profile,
      hemoglobin), physical fitness (maximum oxygen consumption, blood pressure),
      physical activity (accelerometry), physical function (handgrip strength,
      sit-to-stand, gait speed, quadriceps strength), and self-reported questionnaires 
      (health outcomes, self-efficacy, perceived enjoyment of physical activity, and
      multifactorial lifestyle), at baseline, 20 weeks, and 40 weeks. Physical function
      and self-reported questionnaires will also be measured at 10 weeks. We will
      assess the primary outcome measure, total body lean soft tissue mass, at
      baseline, 20 weeks, and 40 weeks. Analyses will be performed using
      intention-to-treat principles, comparing the outcomes resulting from the
      intervention, using linear mixed models. RESULTS: We obtained ethical approval
      for this study from The University of Otago Human Ethics Committee on December
      10, 2018. Participant recruitment started on February 11, 2019 and was completed 
      on May 14, 2019. Data collection started on February 25, 2019 and was completed
      on February 28, 2020. We expect to publish the results in January 2021.
      CONCLUSIONS: High-intensity interval aerobic resistance training is a
      time-efficient form of exercise, enabling busy middle-aged adults to meet
      physical activity recommendations while maximizing training results. The findings
      can inform the development of future prevention-focused interventions aimed at
      counteracting the high prevalence of sarcopenia in the aging population. TRIAL
      REGISTRATION: Australian New Zealand Clinical Trials Registry
      (ACTRN12618001778279); https://tinyurl.com/y555z6fz. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/22989.
CI  - (c)Lara Vlietstra, Debra L Waters, Lynnette M Jones, Kim Meredith-Jones.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 16.10.2020.
FAU - Vlietstra, Lara
AU  - Vlietstra L
AUID- ORCID: https://orcid.org/0000-0001-7397-1308
AD  - Department of Medicine, Otago Medical School, Dunedin Campus, University of
      Otago, Dunedin, New Zealand.
AD  - School of Physiotherapy, University of Otago, Dunedin, New Zealand.
FAU - Waters, Debra L
AU  - Waters DL
AUID- ORCID: https://orcid.org/0000-0001-7982-2370
AD  - Department of Medicine, Otago Medical School, Dunedin Campus, University of
      Otago, Dunedin, New Zealand.
AD  - School of Physiotherapy, University of Otago, Dunedin, New Zealand.
FAU - Jones, Lynnette M
AU  - Jones LM
AUID- ORCID: https://orcid.org/0000-0002-4980-4064
AD  - School of Physical Education, Sport & Exercise Sciences, University of Otago,
      Dunedin, New Zealand.
FAU - Meredith-Jones, Kim
AU  - Meredith-Jones K
AUID- ORCID: https://orcid.org/0000-0002-5445-4871
AD  - Department of Medicine, Otago Medical School, Dunedin Campus, University of
      Otago, Dunedin, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20201016
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7600005
OTO - NOTNLM
OT  - high-intensity interval training
OT  - randomized controlled trial
OT  - sarcopenia
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 12:09
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/03 00:00 [revised]
PHST- 2020/10/16 12:09 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - v9i10e22989 [pii]
AID - 10.2196/22989 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 16;9(10):e22989. doi: 10.2196/22989.


PMID- 33063912
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 34
IP  - 12
DP  - 2020 Dec
TI  - The impact of religiously tailored and ethically balanced education on intention 
      for living organ donation among Muslim Americans.
PG  - e14111
LID - 10.1111/ctr.14111 [doi]
AB  - We tested the efficacy of religiously tailored and ethically balanced education
      upon living kidney organ donation intent among Muslim Americans. Pre-post changes
      in participant stage of change, preparedness, and likelihood judged efficacy.
      Among 137 participants, mean stage of change toward donation appeared to improve 
      (0.59; SD +/- 1.07, P < .0001), as did the group's preparedness to make a
      donation decision (0.55; SD +/- 0.86, P < .0001), and likelihood to donate a
      kidney (0.39; SD +/- 0.85, P < .0001). Mean change in likelihood to encourage a
      loved one, a co-worker, or a mosque community member with ESRD to seek a living
      donor also increased (0.22; SD +/- 0.84, P = .0035, 0.23; SD +/- 0.82, P = .0021,
      0.33; SD +/- 0.79, P < .0001 respectively). Multivariate ordered logistic
      regression models revealed that gains in biomedical knowledge regarding organ
      donation increased odds for positive change in preparedness (OR = 1.20; 95% CI
      1.01-1.41, P = .03), while increasing age associated with lower odds of positive 
      change in stage of change (OR = 0.98, 95% CI 0.96-0.998, P = .03), and prior
      registration as an organ donor lowered odds for an increase in likelihood to
      donate a kidney (OR = 0.22; 95% CI 0.08-0.60, P = .003). Our intervention appears
      to enhance living kidney donation-related intent among Muslim Americans
      [Clinicaltrials.gov number: NCT04443114].
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Padela, Aasim I
AU  - Padela AI
AUID- ORCID: 0000-0003-4834-2889
AD  - Initiative on Islam and Medicine, University of Chicago, Chicago, IL, USA.
AD  - Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee, WI,
      USA.
AD  - Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
FAU - Duivenbode, Rosie
AU  - Duivenbode R
AUID- ORCID: 0000-0001-5399-3534
AD  - Initiative on Islam and Medicine, University of Chicago, Chicago, IL, USA.
FAU - Saunders, Milda R
AU  - Saunders MR
AUID- ORCID: 0000-0002-9276-2066
AD  - Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
FAU - Quinn, Michael
AU  - Quinn M
AUID- ORCID: 0000-0003-3857-1573
AD  - Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
FAU - Koh, Elizabeth
AU  - Koh E
AD  - Initiative on Islam and Medicine, University of Chicago, Chicago, IL, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04443114
PT  - Journal Article
DEP - 20201101
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
SB  - IM
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Intention
MH  - Islam
MH  - *Organ Transplantation
MH  - Surveys and Questionnaires
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *behavior change
OT  - *bioethics
OT  - *islam
OT  - *organ transplantation
EDAT- 2020/10/17 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/10/16 08:40
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/10/16 08:40 [entrez]
AID - 10.1111/ctr.14111 [doi]
PST - ppublish
SO  - Clin Transplant. 2020 Dec;34(12):e14111. doi: 10.1111/ctr.14111. Epub 2020 Nov 1.


PMID- 33063114
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20211204
IS  - 1527-974X (Electronic)
IS  - 1067-5027 (Linking)
VI  - 27
IP  - 12
DP  - 2020 Dec 9
TI  - A systematic literature review of Native American and Pacific Islanders'
      perspectives on health data privacy in the United States.
PG  - 1987-1998
LID - 10.1093/jamia/ocaa235 [doi]
AB  - BACKGROUND: Privacy-related concerns can prevent equitable participation in
      health research by US Indigenous communities. However, studies focused on these
      communities' views regarding health data privacy, including systematic reviews,
      are lacking. METHODS: We conducted a systematic literature review analyzing
      empirical, US-based studies involving American Indian/Alaska Native (AI/AN) and
      Native Hawaiian or other Pacific Islander (NHPI) perspectives on health data
      privacy, which we define as the practice of maintaining the security and
      confidentiality of an individual's personal health records and/or biological
      samples (including data derived from biological specimens, such as personal
      genetic information), as well as the secure and approved use of those data.
      RESULTS: Twenty-one studies involving 3234 AI/AN and NHPI participants were
      eligible for review. The results of this review suggest that concerns about the
      privacy of health data are both prevalent and complex in AI/AN and NHPI
      communities. Many respondents raised concerns about the potential for misuse of
      their health data, including discrimination or stigma, confidentiality breaches, 
      and undesirable or unknown uses of biological specimens. CONCLUSIONS:
      Participants cited a variety of individual and community-level concerns about the
      privacy of their health data, and indicated that these deter their willingness to
      participate in health research. Future investigations should explore in more
      depth which health data privacy concerns are most salient to specific AI/AN and
      NHPI communities, and identify the practices that will make the collection and
      use of health data more trustworthy and transparent for participants.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association.
FAU - Taitingfong, Riley
AU  - Taitingfong R
AD  - Department of Communication, University of California San Diego, La Jolla,
      California, USA.
FAU - Bloss, Cinnamon S
AU  - Bloss CS
AD  - Department of Family Medicine and Public Health, School of Medicine, University
      of California San Diego, La Jolla, California, USA.
AD  - Department of Psychiatry, School of Medicine, University of California San Diego,
      La Jolla, California, USA.
AD  - Center for Wireless and Population Health Systems, Calit2, University of
      California San Diego, La Jolla, California, USA.
FAU - Triplett, Cynthia
AU  - Triplett C
AD  - Qualcomm Institute Calit2, University of California San Diego, La Jolla,
      California, USA.
FAU - Cakici, Julie
AU  - Cakici J
AD  - San Diego Joint Doctoral Program in Public Health, San Diego State
      University/University of California, San Diego, California, USA.
FAU - Garrison, Nanibaa'
AU  - Garrison N
AD  - Institute for Society and Genetics, University of California, Los Angeles,
      California, USA.
AD  - Institute for Precision Health, David Geffen School of Medicine, University of
      California, Los Angeles, California, USA.
AD  - Division of General Internal Medicine and Health Services Research, David Geffen 
      School of Medicine, University of California, Los Angeles, California, USA.
FAU - Cole, Shelley
AU  - Cole S
AD  - Texas Biomedical Research Institute, San Antonio, Texas, USA.
FAU - Stoner, Julie A
AU  - Stoner JA
AD  - Department of Biostatistics and Epidemiology, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA.
FAU - Ohno-Machado, Lucila
AU  - Ohno-Machado L
AD  - Department of Biomedical Informatics, School of Medicine, University of
      California, San Diego, La Jolla, California, USA.
LA  - eng
GR  - R01 HG008753/HG/NHGRI NIH HHS/United States
GR  - R01 HL136835/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
PL  - England
TA  - J Am Med Inform Assoc
JT  - Journal of the American Medical Informatics Association : JAMIA
JID - 9430800
SB  - IM
MH  - *American Indians or Alaska Natives
MH  - Attitude to Health/*ethnology
MH  - Biological Specimen Banks
MH  - *Confidentiality/ethics
MH  - Ethics, Research
MH  - Genetic Privacy
MH  - Health Records, Personal
MH  - Humans
MH  - *Native Hawaiian or Other Pacific Islander
MH  - *Privacy
MH  - United States
PMC - PMC7727344
OTO - NOTNLM
OT  - *Indigenous populations
OT  - *health information
OT  - *personal genetic information, research ethics
OT  - *privacy
EDAT- 2020/10/17 06:00
MHDA- 2021/04/16 06:00
CRDT- 2020/10/16 05:58
PHST- 2020/07/14 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
PHST- 2020/10/16 05:58 [entrez]
AID - 5924605 [pii]
AID - 10.1093/jamia/ocaa235 [doi]
PST - ppublish
SO  - J Am Med Inform Assoc. 2020 Dec 9;27(12):1987-1998. doi: 10.1093/jamia/ocaa235.


PMID- 33062894
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2382-1205 (Print)
IS  - 2382-1205 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - A Case for Transformative Learning in Medical Ethics Education.
PG  - 2382120520931059
LID - 10.1177/2382120520931059 [doi]
AB  - In this article, we discuss the current state of medical ethics education. In
      Higher Education, ethics is taught predominantly through discussion and case
      study-based teaching formats. At present, however, only little can be said about 
      the adequacy of these teaching methods in attaining complex educational
      objectives as ethics education poses challenges regarding meaningful student
      assessment and evaluation of educational methods. Output-oriented evaluation and 
      assessment paradigms that centre quantified student performance fail to
      meaningfully capture the learning of ethics. Currently, we argue that
      comparatively small efforts are being devoted to the advancement of innovative
      and adequate approaches to teaching and assessment in ethics education. In
      response to these shortcomings, drawing from educational traditions that focus on
      preparatory activities, we work towards a new approach to evaluate teaching
      methods and assessing the learning in ethics.
CI  - (c) The Author(s) 2020.
FAU - Gille, Felix
AU  - Gille F
AUID- ORCID: https://orcid.org/0000-0002-2847-4633
AD  - Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH
      Zurich, Zurich, Switzerland.
FAU - Nardo, Aline
AU  - Nardo A
AD  - Department of Humanities, Social and Political Sciences, ETH Zurich, Zurich,
      Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - J Med Educ Curric Dev
JT  - Journal of medical education and curricular development
JID - 101690298
PMC - PMC7536470
OTO - NOTNLM
OT  - Medical ethics
OT  - course development
OT  - productive failure
OT  - transformative learning
COIS- Declaration of Conflicting Interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 05:57
PHST- 2020/04/01 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/10/16 05:57 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - 10.1177/2382120520931059 [doi]
AID - 10.1177_2382120520931059 [pii]
PST - epublish
SO  - J Med Educ Curric Dev. 2020 Oct 1;7:2382120520931059. doi:
      10.1177/2382120520931059. eCollection 2020 Jan-Dec.


PMID- 33062753
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Competences of academic librarians in providing health research services: A
      qualitative study.
PG  - 220
LID - 10.4103/jehp.jehp_254_20 [doi]
AB  - BACKGROUND: One of the most important responsibilities of today's university
      libraries is supporting research activities. The present research is aimed at
      explaining the librarians' competencies in providing research services for
      researchers of Isfahan University of Medical Sciences. MATERIALS AND METHODS:
      This study was performed in 2018 with a qualitative approach and conventional
      content analysis. The participants were 18 faculty members, students, and
      librarians selected by purposive sampling. Data collection was done by 18
      semi-structured interviews. Continuous data analysis was performed by
      conventional content analysis. RESULTS: According to the participants'
      experiences, two major categories were recognized, including "general
      competencies" and "specialized competencies." The general competencies category
      included three subcategories of communication skill, professional ethics, and
      basic abilities. The specialized competencies category included six subcategories
      of information resource retrieval and evaluation, using research software,
      research assistance, intellectual property literacy, scientific publication
      literacy, scientometrics, and altmetrics. CONCLUSION: According to the
      participants' experiences, university librarians need specialized competencies in
      addition to basic and transdisciplinary abilities. It is suggested for research
      managers and policymakers to plan for empowering librarians regarding the results
      of the present study.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Esmailzadeh, Maedeh
AU  - Esmailzadeh M
AD  - Department of Medical Library and Information Sciences, Isfahan University of
      Medical Sciences, Isfahan, Iran.
FAU - Bahrami, Masoud
AU  - Bahrami M
AD  - Nursing and Midwifery Care Research Center, Isfahan University of Medical
      Sciences, Isfahan, Iran.
FAU - Soleymani, Mohammad Reza
AU  - Soleymani MR
AD  - Health Information Technology Research Center, Isfahan University of Medical
      Sciences, Isfahan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7530421
OTO - NOTNLM
OT  - Isfahan University of Medical Sciences
OT  - librarians
OT  - research competencies
OT  - research services
OT  - researchers
COIS- There are no conflicts of interest.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 05:56
PHST- 2020/03/28 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/10/16 05:56 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - 10.4103/jehp.jehp_254_20 [doi]
AID - JEHP-9-220 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Aug 31;9:220. doi: 10.4103/jehp.jehp_254_20.
      eCollection 2020.


PMID- 33062735
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Predictors of high achievers in Indian medical undergraduates: Association with
      emotional intelligence and perceived stress.
PG  - 202
LID - 10.4103/jehp.jehp_263_20 [doi]
AB  - BACKGROUND: Today's Bachelor in Medicine, Bachelor in Surgery (MBBS) students
      will become Indian Medical Graduates in future. Emotional intelligence (EI) is an
      essential component in the making of an Indian Medical Graduate. There is
      increasing stress during medical training. The study was conducted to compare the
      association of EI score and perceived stress scale (PSS) among average and
      excellent undergraduate medical students. The secondary objective was to find the
      predictors of excellent academic performance. MATERIALS AND METHODS: This
      descriptive cross-sectional study was conducted after institutional ethics
      committee approval. All 522 consented students studying in 2(nd), 4(th), 7(th),
      and 9(th) semesters filled up established pre-validated questionnaires ;
      Schutteself report EI test and Cohen's perceived stress scale. Sociodemographic
      details of the respondents were collected. Average attendance and marks of
      previous semester examinations of all included students were collected from
      academic cell of the institution. All students were grouped into three groups:
      average, good, and excellent performers from the marks collected. Comparison of
      EI scores and PSS scores was done between students in excellent and average
      groups using unpaired t-test. RESULTS: Of the 94.9% of respondents, 78.2% of the 
      students were included in the study. The mean EI and PSS scores were 123 +/- 14.5
      and 22.8 +/- 13.9, respectively. There was no statistically significant
      difference in EI scores between average and excellent performers ([123.8 +/-
      18.7] vs. [127.7 +/- 16]; P - 0.089). Perceived stress was lower in excellent
      performers ([20.9 +/- 11.1] vs. [24.8 +/- 15.0]; P - 0.01). EI was associated
      with better performance in clinical year students. EI was negatively correlated
      to perceived stress. CONCLUSION: Our study provides predictors of excellent
      academic performances among Indian medical undergraduates. This study suggests
      introduction of extracurricular activities in ongoing undergraduate curricular
      syllabus. It imparts awareness among students about the importance of attending
      classes. This study bestows higher EI and lower perceived stress to better
      academic performance.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Manjareeka, Magna
AU  - Manjareeka M
AD  - Department of Physiology, Kalinga Institute of Medical Sciences, KIIT University,
      Bhubaneswar, Odisha, India.
FAU - Yadav, Srijan
AU  - Yadav S
AD  - Department of Seventh Semester Student, Kalinga Institute of Medical Sciences,
      KIIT University, Bhubaneswar, Odisha, India.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7530425
OTO - NOTNLM
OT  - Academic achievement
OT  - Indian Medical Graduate
OT  - MBBS
OT  - better performance
OT  - predictors
COIS- There are no conflicts of interest.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 05:56
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/10/16 05:56 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - 10.4103/jehp.jehp_263_20 [doi]
AID - JEHP-9-202 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Aug 31;9:202. doi: 10.4103/jehp.jehp_263_20.
      eCollection 2020.


PMID- 33061738
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-7258 (Print)
IS  - 1179-7258 (Linking)
VI  - 11
DP  - 2020
TI  - The Hidden Curriculum Challenges in Learning Professional Ethics Among Iranian
      Medical Students: A Qualitative Study.
PG  - 673-681
LID - 10.2147/AMEP.S258723 [doi]
AB  - BACKGROUND: Medical ethics is a vital quality for the doctors which has been
      seriously taken into consideration in recent years. Identifying the factors
      affecting medical ethics may help to develop more effective ways to promote this 
      quality in medical education. This study was aimed to explain the challenges of
      hidden curriculum in learning the professional ethics among Iranian medical
      students. MATERIALS AND METHODS: This qualitative study was performed on 15
      medical interns of Kermanshah University of Medical Sciences in 2019 using
      grounded theory (GT). Sampling was started by purposive sampling and continued
      through theoretical sampling until complete data saturation. Data collection and 
      analysis were done simultaneously. Data were interpreted by the constant
      comparative method according to Strauss and Corbin's approach. RESULTS: The
      results showed that the challenges of hidden curriculum for learning the
      professional ethics by medical students included a number of key concepts.
      Analyzing these concepts and taking into account the commonalities, we obtained
      six subthemes using a reduction inductive method, the main theme of which was
      "the challenge of hidden curriculum in learning the professional medical ethics".
      The subthemes included "decreased interest in medicine", "false beliefs",
      "curriculum weakness", "materialism and economic problems", "avoidance of
      responsibility", and "underlying problems of the medical profession". CONCLUSION:
      The findings indicated six challenges in the hidden curriculum for learning the
      professional medical ethics. These challenges can be considered a threat or an
      obstacle to achieving the goals of professional ethics. Therefore, curriculum
      planners, education policymakers, and teachers should plan and implement the
      professional ethics curriculum based on these factors.
CI  - (c) 2020 Safari et al.
FAU - Safari, Yahya
AU  - Safari Y
AUID- ORCID: 0000-0002-6763-5225
AD  - Research Center for Environmental Determinants of Health (RCEDH), Health
      Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
FAU - Khatony, Alireza
AU  - Khatony A
AUID- ORCID: 0000-0003-3552-5539
AD  - Clinical Research Development Center, Imam Reza Hospital, Kermanshah University
      of Medical Sciences, Kermanshah, Iran.
FAU - Tohidnia, Mohammad Rasoul
AU  - Tohidnia MR
AD  - Department of Radiology and Nuclear Medicine, School of Paramedical Sciences,
      Kermanshah University of Medical Sciences, Kermanshah, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - New Zealand
TA  - Adv Med Educ Pract
JT  - Advances in medical education and practice
JID - 101562700
PMC - PMC7523179
OTO - NOTNLM
OT  - curriculum
OT  - medical education
OT  - professional ethics
OT  - professionalism
COIS- The authors report no conflicts of interest for this work.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 05:52
PHST- 2020/05/15 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/10/16 05:52 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - 10.2147/AMEP.S258723 [doi]
AID - 258723 [pii]
PST - epublish
SO  - Adv Med Educ Pract. 2020 Sep 24;11:673-681. doi: 10.2147/AMEP.S258723.
      eCollection 2020.


PMID- 33061093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0973-7723 (Electronic)
IS  - 0970-9134 (Linking)
VI  - 36
IP  - 1
DP  - 2020 Jan
TI  - Chest wall reconstruction: success of a team approach-a 12-year experience from a
      tertiary care institution.
PG  - 44-51
LID - 10.1007/s12055-019-00841-y [doi]
AB  - BACKGROUND: The thoracic cavity was considered as a forbidden area in the past
      and anyone attempting to meddle with it was expected to be doomed. But the past
      several decades have seen a marked improvement in the management and
      reconstruction of complex chest wall defects. This study was undertaken to review
      our experience in chest wall reconstruction during the past 12 years and to
      stress upon the importance of a multidisciplinary team approach to this complex
      problem. METHODS: After obtaining the necessary clearance from institutional
      ethics committee, we did a retrospective review of all case records of chest wall
      reconstructions (CWR) performed in our institution during a 12-year period from
      May 2005 to September 2016. Patient characteristics, co-morbidities, operative
      data and post-operative complications and outcomes were reviewed. RESULTS: During
      the study period, a total of 32 patients underwent CWR. All patients were
      assessed, planned, operated and managed by a team consisting of thoracic
      surgeons, plastic surgeons, intensivists and pulmonologists. Patients were in the
      age group of 14-72 with a male:female ratio of 15:17. Indications for CWR were
      neoplasms (n = 13-40.62%), post-sternotomy wound dehiscence (n = 12-37.5%),
      osteoradionecrosis (n = 4-12.5%), tuberculosis (n = 2-6.25%) and osteomyelitis
      rib (1/32-3.125%). Inflammatory defects were mostly closed with soft tissue alone
      whereas skeletal stabilisation with soft tissue cover was required in tumour
      resections. All were pedicled flaps, the most common being pectoralis major (PM) 
      muscle flap (n = 12). Others include latissimus dorsi (LD) muscle (n = 9); rectus
      abdominis (RA) muscle (n = 2); transverse rectus abdominis musculocutaneous flap 
      (TRAM) (n = 2), deltopectoral (DP) (n = 1), omentum (n = 3) and breast flap (n = 
      3). Post-operative complications include wound dehiscence (12%), wound infection 
      (21%) and recurrent sinus formation (7%). One partial flap failure was recorded. 
      Post-operative mortality was 3%. CONCLUSION: Chest wall reconstruction is a
      complex procedure and each defect needs an individualised approach for optimum
      outcome. Extensive chest wall resections can be safely undertaken with the
      support of the reconstructive surgeon and with good critical care back up.
CI  - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2019.
FAU - Malathi, Lekshmi
AU  - Malathi L
AUID- ORCID: 0000-0002-0970-355X
AD  - Department of Plastic Surgery, Government Medical College Kottayam, Kottayam,
      Kerala India.grid.413229.f0000 0004 1766 4073
FAU - Das, Sankar
AU  - Das S
AD  - Department of Plastic Surgery, Government Medical College Kottayam, Kottayam,
      Kerala India.grid.413229.f0000 0004 1766 4073
FAU - Nair, Jayakumar Thanathu Krishnan
AU  - Nair JTK
AD  - Department of Cardiovascular and Thoracic Surgery, Government Medical College
      Kottayam, Kottayam, Kerala India.grid.413229.f0000 0004 1766 4073
FAU - Rajappan, Aniraj
AU  - Rajappan A
AD  - Department of Plastic Surgery, Government Medical College Kottayam, Kottayam,
      Kerala India.grid.413229.f0000 0004 1766 4073
LA  - eng
PT  - Journal Article
DEP - 20190709
PL  - India
TA  - Indian J Thorac Cardiovasc Surg
JT  - Indian journal of thoracic and cardiovascular surgery
JID - 8700105
PMC - PMC7525737
OTO - NOTNLM
OT  - Chest wall reconstruction
OT  - Osteoradionecrosis of sternum
OT  - Sternal wound dehiscence
COIS- Conflict of interestThe authors declare that they have no conflict of interest.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
CRDT- 2020/10/16 05:50
PHST- 2019/02/27 00:00 [received]
PHST- 2019/05/16 00:00 [revised]
PHST- 2019/05/24 00:00 [accepted]
PHST- 2020/10/16 05:50 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
AID - 10.1007/s12055-019-00841-y [doi]
AID - 841 [pii]
PST - ppublish
SO  - Indian J Thorac Cardiovasc Surg. 2020 Jan;36(1):44-51. doi:
      10.1007/s12055-019-00841-y. Epub 2019 Jul 9.


PMID- 33060250
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20210927
IS  - 0886-6708 (Print)
IS  - 0886-6708 (Linking)
VI  - 35
IP  - 5
DP  - 2020 Oct 1
TI  - Experiences of Jewish and Arab Healthcare Practitioners Treating Terrorists in
      Israel.
PG  - 674-689
LID - 10.1891/VV-D-19-00098 [doi]
AB  - The growing number of terror attacks worldwide draws attention to the
      difficulties that healthcare practitioners experience when they treat terrorists 
      or suspected terrorists. Research literature on the challenges faced by
      healthcare practitioners treating terrorists in conflict areas is limited.
      In-depth interviews were conducted during 2016-2017 with 50 Jewish and Arab
      healthcare practitioners (managers, physicians, and nurses) employed in 11 public
      hospitals in Israel, who treat Palestinian terrorists and security prisoners, in 
      the context of a prolonged and violent national conflict. Jewish practitioners
      find it emotionally difficult to treat terrorists and security prisoners. They
      face an ethical dilemma when called upon to save the lives of those who took life
      and find themselves identifying with the victims. Arab practitioners identify
      with both sides of the conflict. Three coping strategies were described:
      maintaining a humanistic standpoint; adherence to a standard of detached
      professionalism; and refusal to treat terrorists and security prisoners.
CI  - (c) Copyright 2020 Springer Publishing Company, LLC.
FAU - Keshet, Yael
AU  - Keshet Y
AD  - Western Galilee Academic College, Akko, Israel yaelk@wgalil.ac.il.
FAU - Popper-Giveon, Ariela
AU  - Popper-Giveon A
AD  - David Yellin Academic College, Jerusalem, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Violence Vict
JT  - Violence and victims
JID - 8916436
SB  - IM
MH  - Adult
MH  - Arabs/*psychology
MH  - *Attitude of Health Personnel
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Israel
MH  - Jews/*psychology
MH  - Male
MH  - *Prisoners
MH  - *Terrorism
OTO - NOTNLM
OT  - *Arabs
OT  - *Israel
OT  - *detached professionalism
OT  - *hospital
OT  - *terror
EDAT- 2020/10/17 06:00
MHDA- 2021/09/28 06:00
CRDT- 2020/10/16 05:40
PHST- 2020/10/16 05:40 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
AID - 35/5/674 [pii]
AID - 10.1891/VV-D-19-00098 [doi]
PST - ppublish
SO  - Violence Vict. 2020 Oct 1;35(5):674-689. doi: 10.1891/VV-D-19-00098.


PMID- 33060187
OWN - NLM
STAT- Publisher
LR  - 20201016
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 15
TI  - Equity in access to facial transplantation.
LID - medethics-2020-106129 [pii]
LID - 10.1136/medethics-2020-106129 [doi]
AB  - We examine ethical considerations in access to facial transplantation (FT), with 
      implications for promoting health equity. As a form of vascularised composite
      allotransplantation, FT is still considered innovative with a relatively low
      volume of procedures performed to date by a small number of active FT programmes 
      worldwide. However, as numbers continue to increase and institutions look to
      establish new FT programmes, we anticipate that attention will shift from
      feasibility towards ensuring the benefits of FT are equitably available to those 
      in need. This manuscript assesses barriers to care and their ethical implications
      across a number of considerations, with the intent of mapping various factors
      relating to health equity and fair access to FT. Evidence is drawn from an
      evolving clinical experience as well as published scholarship addressing several 
      dimensions of access to FT. We also explore novel concerns that have yet to be
      mentioned in the literature.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kimberly, Laura L
AU  - Kimberly LL
AD  - Hansjorg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY,
      United States laura.kimberly@nyulangone.org.
AD  - Division of Medical Ethics, Department of Population Health, NYU Langone Health, 
      New York, NY, United States.
FAU - Ramly, Elie P
AU  - Ramly EP
AD  - Hansjorg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY,
      United States.
FAU - Alfonso, Allyson R
AU  - Alfonso AR
AD  - Hansjorg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY,
      United States.
FAU - Diep, Gustave K
AU  - Diep GK
AD  - Hansjorg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY,
      United States.
FAU - Berman, Zoe P
AU  - Berman ZP
AD  - Hansjorg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY,
      United States.
FAU - Rodriguez, Eduardo D
AU  - Rodriguez ED
AD  - Hansjorg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY,
      United States.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - ethics
OT  - transplantation
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/02/05 00:00 [received]
PHST- 2020/09/26 00:00 [revised]
PHST- 2020/09/26 00:00 [accepted]
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:00 [medline]
AID - medethics-2020-106129 [pii]
AID - 10.1136/medethics-2020-106129 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 15. pii: medethics-2020-106129. doi:
      10.1136/medethics-2020-106129.


PMID- 33060092
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210402
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Cluster-randomised trial of community-based screening for eye disease in adults
      in Nepal: the Village-Integrated Eye Worker Trial II (VIEW II) trial protocol.
PG  - e040219
LID - 10.1136/bmjopen-2020-040219 [doi]
AB  - INTRODUCTION: The majority of blindness worldwide could be prevented or reversed 
      with early diagnosis and treatment, yet identifying at-risk and prevalent cases
      of eye disease and linking them with care remain important obstacles to
      addressing this burden. Leading causes of blindness like glaucoma, diabetic
      retinopathy and age-related macular degeneration have detectable early
      asymptomatic phases and can cause irreversible vision loss. Mass screening for
      such diseases could reduce visual impairment at the population level. METHODS AND
      ANALYSIS: This protocol describes a parallel-group cluster-randomised trial
      designed to determine whether community-based screening for glaucoma, diabetic
      retinopathy and age-related macular degeneration reduces population-level visual 
      impairment in Nepal. A door-to-door population census is conducted in all study
      communities. All adults aged >/=60 years have visual acuity tested at the census 
      visit, and those meeting referral criteria are referred to a local eye care
      facility for further diagnosis and management. Communities are subsequently
      randomised to a community-based screening programme or to no additional
      intervention. The intervention consists of a single round of screening including 
      intraocular pressure and optical coherence tomography assessment of all adults
      >/=60 years old with enhanced linkage to care for participants meeting referral
      criteria. Four years after implementation of the intervention, masked outcome
      assessors conduct a repeat census to collect data on the primary outcome, visual 
      acuity. Individuals with incident visual impairment receive a comprehensive
      ophthalmological examination to determine the cause of visual impairment.
      Outcomes are compared by treatment arm according to the originally assigned
      intervention. ETHICS AND DISSEMINATION: The trial has received ethical approval
      from the University of California San Francisco Institutional Review Board, Nepal
      Netra Jyoti Sangh and the Nepal Health Research Council. Results of this trial
      will be disseminated through publication in peer-reviewed journals and
      presentation at local and international meetings. TRIAL REGISTRATION NUMBER:
      NCT03752840.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - O'Brien, Kieran S
AU  - O'Brien KS
AD  - Francis I Proctor Foundation, University of California San Francisco, San
      Francisco, California, USA.
FAU - Stevens, Valerie M
AU  - Stevens VM
AUID- ORCID: 0000-0003-4482-2519
AD  - Francis I Proctor Foundation, University of California San Francisco, San
      Francisco, California, USA.
FAU - Byanju, Raghunandan
AU  - Byanju R
AD  - Bharatpur Eye Hospital, Bharatpur, Nepal.
FAU - Kandel, Ram Prasad
AU  - Kandel RP
AD  - Seva Foundation, Bharatpur, Nepal.
FAU - Bhandari, Gopal
AU  - Bhandari G
AD  - Bharatpur Eye Hospital, Bharatpur, Nepal.
FAU - Bhandari, Sadhan
AU  - Bhandari S
AD  - Bharatpur Eye Hospital, Bharatpur, Nepal.
FAU - Melo, Jason S
AU  - Melo JS
AD  - Francis I Proctor Foundation, University of California San Francisco, San
      Francisco, California, USA.
FAU - Porco, Travis C
AU  - Porco TC
AD  - Francis I Proctor Foundation, University of California San Francisco, San
      Francisco, California, USA.
AD  - Department of Ophthalmology, University of California San Francisco, San
      Francisco, California, USA.
FAU - Lietman, Thomas M
AU  - Lietman TM
AD  - Francis I Proctor Foundation, University of California San Francisco, San
      Francisco, California, USA.
AD  - Department of Ophthalmology, University of California San Francisco, San
      Francisco, California, USA.
FAU - Keenan, Jeremy D
AU  - Keenan JD
AUID- ORCID: 0000-0002-7118-1457
AD  - Francis I Proctor Foundation, University of California San Francisco, San
      Francisco, California, USA jeremy.keenan@ucsf.edu.
AD  - Department of Ophthalmology, University of California San Francisco, San
      Francisco, California, USA.
CN  - Group Information for the VIEW II Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03752840
GR  - UG1 EY028097/EY/NEI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Humans
MH  - *Mass Screening
MH  - Middle Aged
MH  - Nepal
MH  - Randomized Controlled Trials as Topic
MH  - San Francisco
MH  - *Vision, Low/diagnosis
PMC - PMC7566737
OTO - NOTNLM
OT  - *age-related macular degeneration
OT  - *diabetic retinopathy
OT  - *glaucoma
OT  - *mass screening
OT  - *randomised controlled trial
COIS- Competing interests: None declared.
IR  - Acharaya P
FIR - Acharaya, Prakriti
IR  - Adhikari M
FIR - Adhikari, Manmohan
IR  - Adihikari SK
FIR - Adihikari, Shree Kanta
IR  - Bhattarai D
FIR - Bhattarai, Deepak
IR  - Bhattarai R
FIR - Bhattarai, Rabin
IR  - Bhandari G
FIR - Bhandari, Gopal
IR  - Bhandari S
FIR - Bhandari, Sadhan
IR  - Byanju R
FIR - Byanju, Raghunandan
IR  - Chaudhary A
FIR - Chaudhary, Ajaya
IR  - Chaudhary B
FIR - Chaudhary, Bhagiram
IR  - Chaudhary DS
FIR - Chaudhary, Daya Shankar
IR  - Chaudhary K
FIR - Chaudhary, Kishor
IR  - Dharel KR
FIR - Dharel, Krishna Raj
IR  - Gautam M
FIR - Gautam, Maria
IR  - Gautam SK
FIR - Gautam, Shree Krishna
IR  - Ghimire A
FIR - Ghimire, Aakriti
IR  - Ghimire B
FIR - Ghimire, Bishwash
IR  - Ghimire N
FIR - Ghimire, Narayan
IR  - Ghimire R
FIR - Ghimire, Ramesh
IR  - Giri G
FIR - Giri, Gaurav
IR  - Giri P
FIR - Giri, Puspa
IR  - Gurau D
FIR - Gurau, Dhanmaya
IR  - Gurung R
FIR - Gurung, Ramesh
IR  - Kandel D
FIR - Kandel, Deepak
IR  - Khadka S
FIR - Khadka, Simanta
IR  - Lamichhane B
FIR - Lamichhane, Benju
IR  - Mahato P
FIR - Mahato, Pappu
IR  - Neupane P
FIR - Neupane, Pratikshya
IR  - Panday RJ
FIR - Panday, Ram Janaki
IR  - Parajuli S
FIR - Parajuli, Sabina
IR  - Poudel RD
FIR - Poudel, Radhika Devi
IR  - Poudel S
FIR - Poudel, Susmita
IR  - Pradhan S
FIR - Pradhan, Sangita
IR  - Pun S
FIR - Pun, Suchan
IR  - Ranabhat B
FIR - Ranabhat, Bishaka
IR  - Ranabhat S
FIR - Ranabhat, Sudha
IR  - Rimal G
FIR - Rimal, Gaurav
IR  - Sapkota G
FIR - Sapkota, Gopal
IR  - Sapkota S
FIR - Sapkota, Subit
IR  - Shah R
FIR - Shah, Ranjeet
IR  - Shrestha M
FIR - Shrestha, Manisha
IR  - Silwal S
FIR - Silwal, Saraswati
IR  - Subedi A
FIR - Subedi, Amisha
IR  - Subedi P
FIR - Subedi, Pradeep
IR  - Tamang A
FIR - Tamang, Alish
IR  - Tandukar D
FIR - Tandukar, Dilip
IR  - Wagle NS
FIR - Wagle, Nischal Sharma
IR  - Yadav NK
FIR - Yadav, Nilam Kumari
IR  - Mishra S
FIR - Mishra, Sailesh
IR  - Chase H
FIR - Chase, Heidi
IR  - Gilbert S
FIR - Gilbert, Suzanne
IR  - Jesudason L
FIR - Jesudason, Lauren
IR  - Tenzing C
FIR - Tenzing, Chundak
IR  - Chaudhary S
FIR - Chaudhary, Shravan
IR  - Dhakwha P
FIR - Dhakwha, Parami
IR  - Kandel RP
FIR - Kandel, Ram Prasad
IR  - Sharma P
FIR - Sharma, Prasanna
IR  - Shrestha A
FIR - Shrestha, Apsara
IR  - Keenan J
FIR - Keenan, Jeremy
IR  - Lietman T
FIR - Lietman, Thomas
IR  - Melo J
FIR - Melo, Jason
IR  - O'Brien K
FIR - O'Brien, Kieran
IR  - Porco T
FIR - Porco, Travis
IR  - Schwartz D
FIR - Schwartz, Daniel
IR  - Shrestha R
FIR - Shrestha, Riju
IR  - Stamper R
FIR - Stamper, Robert
IR  - Stevens V
FIR - Stevens, Valerie
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-040219 [pii]
AID - 10.1136/bmjopen-2020-040219 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e040219. doi: 10.1136/bmjopen-2020-040219.


PMID- 33060089
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Protocol description of the HOVON 141/VISION trial: a prospective, multicentre,
      randomised phase II trial of ibrutinib plus venetoclax in patients with
      creatinine clearance >/=30 mL/min who have relapsed or refractory chronic
      lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
PG  - e039168
LID - 10.1136/bmjopen-2020-039168 [doi]
AB  - INTRODUCTION: Literature is scarce on the combination treatment of ibrutinib and 
      venetoclax (IV) is scarce in relapsed or refractory chronic lymphocytic leukaemia
      (RR-CLL). Especially, the possibility of stopping ibrutinib in RR-CLL patients in
      deep remission is unclear. METHODS AND ANALYSIS: In the HOVON 141/VISION trial,
      patients with RR-CLL are treated with 12 cycles of IV after a short induction
      with ibrutinib. Patients reaching undetectable minimal residual disease (uMRD)
      after 12 cycles of IV are randomised 1:2 to continue ibrutinib or stop treatment.
      The persistence of uMRD after stopping IV is studied. In addition, in patients
      who become positive for MRD again after stopping, IV treatment is reinitiated.
      The efficacy of this approach with regard to progression-free survival 12 months 
      after randomisation is the primary endpoint of the study. ETHICS AND
      DISSEMINATION: This protocol respects the Helsinki declaration and has been
      approved by the ethical committee of the Amsterdam Medical Center. Study findings
      will be disseminated through peer-reviewed papers. All patients who fulfil the
      inclusion criteria and no-exclusion criteria, and have signed the informed
      consent form are included in the study. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT03226301).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Levin, Mark-David
AU  - Levin MD
AUID- ORCID: 0000-0003-2139-3547
AD  - Department of Internal Medicine, Albert Schweitzer Hospital Location Dordwijk,
      Dordrecht, Zuid-Holland, The Netherlands.
FAU - Kater, Arnon P
AU  - Kater AP
AD  - Department of Hematology, Amsterdam UMC - Locatie AMC, Amsterdam, North Holland, 
      The Netherlands a.p.kater@amsterdamumc.nl.
FAU - Mattsson, Mattias
AU  - Mattsson M
AD  - Department of Hematology, Uppsala Universitet, Uppsala, Sweden.
FAU - Kersting, Sabina
AU  - Kersting S
AD  - Department of Hematology, Haga Hospital, Den Haag, Zuid-Holland, The Netherlands.
FAU - Ranti, Juha
AU  - Ranti J
AD  - Department of Hematology, University of Turku, Turku, Finland.
FAU - Thi Tuyet Tran, Hoa
AU  - Thi Tuyet Tran H
AD  - Department of Hematology, Akershus University Hospital, Lorenskog, Norway.
FAU - Nasserinejad, Kazem
AU  - Nasserinejad K
AD  - HOVON Data Center, Department of Hematology, Erasmus MC, Rotterdam, Zuid-Holland,
      The Netherlands.
FAU - Niemann, Carsten Utoft
AU  - Niemann CU
AD  - Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03226301
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Piperidines)
RN  - 0 (Sulfonamides)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 1X70OSD4VX (ibrutinib)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 2.7.10.1 (ROR1 protein, human)
RN  - EC 2.7.10.1 (Receptor Tyrosine Kinase-like Orphan Receptors)
RN  - JAC85A2161 (Adenine)
RN  - N54AIC43PW (venetoclax)
SB  - IM
MH  - Adenine/*analogs & derivatives/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bridged Bicyclo Compounds, Heterocyclic
MH  - Creatinine
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
MH  - *Piperidines/therapeutic use
MH  - Prospective Studies
MH  - Receptor Tyrosine Kinase-like Orphan Receptors
MH  - Recurrence
MH  - Sulfonamides
MH  - Tumor Suppressor Protein p53
PMC - PMC7566731
OTO - NOTNLM
OT  - *clinical trials
OT  - *leukaemia
OT  - *lymphoma
OT  - *toxicity
COIS- Competing interests: M-DL: Advisory board compensation from Janssen, AbbVie and
      Roche; travel reimbursement from Janssen, AbbVie and Roche. AK: Received research
      grants from Celgene, Janssen, AbbVie, Roche/Genentech, AstraZeneca; speakers fee 
      from AbbVie and AstraZeneca, and participated in advisory boards of AbbVie,
      Janssen, AstraZeneca and Roche. CUN: Research grant from AbbVie and Janssen;
      advisory board compensation from AbbVie, Janssen, Gilead, Roche, AstraZeneca,
      Acerta and Sunesis; travel reimbursement from Gilead, Roche and Novartis;
      consultancy compensation from CSL Behring. MM: Lecture remuneration from Janssen 
      and advisory board compensation from AbbVie. JR: Received consultancy fees from
      AbbVie and Janssen. HTTT: Consultancy fees from Janssen-Cilag, AbbVie, Bayer,
      Novartis and AstraZeneca.
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-039168 [pii]
AID - 10.1136/bmjopen-2020-039168 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e039168. doi: 10.1136/bmjopen-2020-039168.


PMID- 33060088
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Ghost ileostomy versus conventional loop ileostomy in patients undergoing low
      anterior resection for rectal cancer (DRKS00013997): protocol for a randomised
      controlled trial.
PG  - e038930
LID - 10.1136/bmjopen-2020-038930 [doi]
AB  - INTRODUCTION: Anastomotic leakage is the most important complication in
      colorectal surgery occurring in up to 20% after low anterior rectal resection.
      Therefore, a diverting ileostomy is usually created during low anterior resection
      to protect the anastomosis or rather to diminish the consequences in case of
      anastomotic leakage. The so-called virtual or ghost ileostomy is a pre-stage
      ostomy that can be easily exteriorised, if anastomotic leakage is suspected, in
      order to avoid the severe consequences of anastomotic leakage. On the other hand,
      an actual ileostomy can be avoided in patients, who do not develop anastomotic
      leakage. METHODS AND ANALYSIS: The GHOST trial is a randomised controlled pilot
      trial comparing ghost ileostomy with conventional loop ileostomy in patients
      undergoing low anterior resection with total mesorectal excision for rectal
      cancer. After screening for eligibility and obtaining informed consent, a total
      of 60 adult patients are included in the trial. Patients are intraoperatively
      randomised to the trial groups in a 1:1 ratio after assuring that none of the
      intraoperative exclusion criteria are present. The main outcome parameter is the 
      comprehensive complication index as a measure of safety. Further outcomes include
      specific complications, stoma-related complications, complications of ileostomy
      closure, frequency of transformation of ghost ileostomy into conventional
      ileostomy, frequency of terminal ostomy creation, proportion of patients with an 
      ostomy at 6 months after index surgery, anorectal function (Wexner score) and
      quality of life assessed by the European Organisation for Research and Treatment 
      of Cancer (EORTC) QLQ-C30 and CR29 questionnaires. Follow-up for each individual 
      patient will be 6 months. ETHICS AND DISSEMINATION: The GHOST trial has been
      approved by the Medical Ethics Committee of Heidelberg University (reference
      number S-694/2017). If the intervention proves to be safe, loop ileostomy could
      be spared in a large proportion of patients, thus also avoiding stoma-related
      complications and a second operation (ileostomy closure) with its inherent
      complications in these patients. TRIAL REGISTRATION NUMBER: German Clinical
      Trials Registry (DRKS00013997); Universal Trial Number: U1111-1208-9742.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huttner, Felix J
AU  - Huttner FJ
AUID- ORCID: 0000-0002-2299-964X
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Probst, Pascal
AU  - Probst P
AUID- ORCID: 0000-0002-0895-4015
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Mihaljevic, Andre
AU  - Mihaljevic A
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
FAU - Contin, Pietro
AU  - Contin P
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
FAU - Dorr-Harim, Colette
AU  - Dorr-Harim C
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Ulrich, Alexis
AU  - Ulrich A
AD  - Surgical Department I, Stadtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss,
      Germany.
FAU - Schneider, Martin
AU  - Schneider M
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany markus.buechler@med.uni-heidelberg.de.
FAU - Diener, Markus K
AU  - Diener MK
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Knebel, Phillip
AU  - Knebel P
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
LA  - eng
SI  - DRKS/DRKS00013997
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Anastomosis, Surgical/adverse effects
MH  - Anastomotic Leak/etiology
MH  - Humans
MH  - *Ileostomy/adverse effects
MH  - Postoperative Complications
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Rectal Neoplasms/surgery
PMC - PMC7566726
OTO - NOTNLM
OT  - *colorectal surgery
OT  - *gastrointestinal tumours
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038930 [pii]
AID - 10.1136/bmjopen-2020-038930 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e038930. doi: 10.1136/bmjopen-2020-038930.


PMID- 33060087
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Towards a multilevel governance framework on the implementation of patient rights
      in health facilities: a protocol for a systematic scoping review.
PG  - e038927
LID - 10.1136/bmjopen-2020-038927 [doi]
AB  - INTRODUCTION: Patient rights are "those rights that are attributed to a person
      seeking healthcare". Patient rights have implications for quality of healthcare
      and acts as a key accountability tool. It can galvanise structural improvements
      in the health system and reinforces ethical healthcare. States are duty bound to 
      respect, protect and promote patient rights. The rhetoric on patient rights is
      burgeoning across the globe. With changing modes of governance arrangements, a
      number of state and non-state actors and institutions at various levels play a
      role in the design and implementation of (patient rights) policies. However,
      there is limited understanding on the multilevel institutional mechanisms for
      patient rights implementation in health facilities. We attempt to fill this gap
      by analysing the available scholarship on patient rights through a critical
      interpretive synthesis approach in a systematic scoping review. METHODS: The
      review question is 'how do the multilevel actors, institutional structures,
      processes interact and influence the patient rights implementation in healthcare 
      facilities? How do they work at what level and in which contexts?" Three
      databases PubMed, LexisNexis and Web of Science will be systematically searched
      until 30(th) April 2020, for empirical and non-empirical literature in English
      from both lower middle-income countries and high-income countries. Targeted
      search will be performed in grey literature and through citation and reference
      tracking of key records. Using the critical interpretive synthesis approach, a
      multilevel governance framework on the implementation of patient rights in health
      facilities which is grounded in the data will be developed. ETHICS AND
      DISSEMINATION: The review uses published literature hence ethics approval is not 
      required. The findings of the review will be published in a peer-reviewed
      journal. REGISTRATION NUMBER: PROSPERO 2020 CRD42020176939.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Putturaj, Meena
AU  - Putturaj M
AUID- ORCID: 0000-0002-7029-1144
AD  - Centre for Local Health Traditions and Policy, The University of
      Trans-disciplinary Health Sciences and Technology, Bengaluru, India
      meenaputturaj@gmail.com.
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
AD  - Department of Health, Ethics and Society, Maastricht University, Maastricht,
      Netherlands.
AD  - Health Equity Cluster, Institute of Public Health, Bengaluru, India.
FAU - Van Belle, Sara
AU  - Van Belle S
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
FAU - Criel, Bart
AU  - Criel B
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
FAU - Engel, Nora
AU  - Engel N
AD  - Department of Health, Ethics and Society, Maastricht University, Maastricht,
      Netherlands.
FAU - Krumeich, Anja
AU  - Krumeich A
AD  - Department of Health, Ethics and Society, Maastricht University, Maastricht,
      Netherlands.
FAU - B Nagendrappa, Prakash
AU  - B Nagendrappa P
AD  - Centre for Local Health Traditions and Policy, The University of
      Trans-disciplinary Health Sciences and Technology, Bengaluru, India.
FAU - Prashanth, N S
AU  - Prashanth NS
AD  - Health Equity Cluster, Institute of Public Health, Bengaluru, India.
LA  - eng
GR  - IA/CPHI/16/1/502648/WTDBT_/DBT-Wellcome Trust India Alliance/India
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - *Developing Countries
MH  - Government Programs
MH  - *Health Facilities
MH  - Humans
MH  - *Patient Rights
PMC - PMC7566736
OTO - NOTNLM
OT  - *health policy
OT  - *medical ethics
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038927 [pii]
AID - 10.1136/bmjopen-2020-038927 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e038927. doi: 10.1136/bmjopen-2020-038927.


PMID- 33060086
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210304
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Couples-based approach to HIV prevention for transgender women and their
      partners: study protocol for a randomised controlled trial testing the efficacy
      of the 'It Takes Two' intervention.
PG  - e038723
LID - 10.1136/bmjopen-2020-038723 [doi]
AB  - INTRODUCTION: HIV transmission and acquisition risk among transgender women is
      particularly high in the context of primary partnerships. This project extends a 
      previous pilot couples-focused HIV intervention programme, which was shown to be 
      feasible, acceptable and promising in reducing sexual risk behaviour among
      transgender women and their partners. This randomised controlled trial (RCT)
      tests the efficacy of this culturally sensitive HIV prevention programme for
      HIV-serodiscordant and HIV-negative seroconcordant transgender women and their
      partners. METHODS AND ANALYSIS: To finalise the protocol for trial, we used
      qualitative methods to hone eligibility criteria, refine the intervention and
      control manuals, and name and brand the intervention ('It Takes Two'). The RCT
      investigates the effects of the It Takes Two intervention on Composite Risk for
      HIV (CR-HIV) among 100 couples. CR-HIV is a binary indicator of couple HIV risk
      using validated measures of sexual behaviour, pre-exposure prophylaxis use among 
      HIV-negative participants and viral suppression among participants living with
      HIV. Using a two-arm RCT, we will examine intervention effects on CR-HIV at
      12-month follow-up comparing transgender women and their partners randomised to
      the intervention versus control (HIV prevention information only). ETHICS AND
      DISSEMINATION: This study has been reviewed and approved by the University of
      California, San Francisco (19-28624) and the University of Michigan (HUM00147690)
      Institutional Review Boards. Participants provide informed consent before taking 
      part of the study activities. Results will be published in peer-reviewed journals
      and presented at scientific conferences. We will make our results available to
      the community of researchers and general public interested in transgender health 
      to avoid unintentional duplication of research, as well as to others in the
      health and social services community, including LGBT community-based
      organisations, AIDS service organisations and other transgender-serving
      organisations. The full de-identified dataset and codebook will be shared at the 
      University of Michigan Digital Repository. TRIAL REGISTRATION NUMBER:
      NCT04067661.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gamarel, Kristi E
AU  - Gamarel KE
AD  - Department of Health Behavior and Health Education, University of Michigan School
      of Public Health, Ann Arbor, Michigan, USA.
FAU - Sevelius, Jae M
AU  - Sevelius JM
AD  - Center for AIDS Prevention Studies, University of California, San Francisco,
      California, USA.
AD  - Division of Prevention Science, University of California, San Francisco,
      California, USA.
FAU - Neilands, Torsten B
AU  - Neilands TB
AD  - Center for AIDS Prevention Studies, University of California, San Francisco,
      California, USA.
AD  - Division of Prevention Science, University of California, San Francisco,
      California, USA.
FAU - Kaplan, Rachel L
AU  - Kaplan RL
AD  - Department of Obstetrics, Gynecology, & Reproductive Sciences, University of
      California, San Francisco, California, USA.
FAU - Johnson, Mallory O
AU  - Johnson MO
AD  - Center for AIDS Prevention Studies, University of California, San Francisco,
      California, USA.
AD  - Division of Prevention Science, University of California, San Francisco,
      California, USA.
FAU - Nemoto, Tooru
AU  - Nemoto T
AD  - Public Health Institute, Oakland, California, USA.
FAU - Darbes, Lynae A
AU  - Darbes LA
AD  - Department of Health Behavior and Biological Sciences, University of Michigan
      School of Nursing, Ann Arbor, Michigan, USA.
FAU - Operario, Don
AU  - Operario D
AUID- ORCID: 0000-0003-2467-5048
AD  - Department of Behavioral and Social Sciences, Brown University School of Public
      Health, Providence, Rhode Island, USA Don_Operario@brown.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT04067661
GR  - R25 MH067127/MH/NIMH NIH HHS/United States
GR  - R01 MH115765/MH/NIMH NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome
MH  - Female
MH  - *HIV Infections/prevention & control
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - San Francisco
MH  - *Transgender Persons
MH  - *Transsexualism
PMC - PMC7566735
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038723 [pii]
AID - 10.1136/bmjopen-2020-038723 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e038723. doi: 10.1136/bmjopen-2020-038723.


PMID- 33060085
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter,
      Observational Study of Patients with Heart Failure with Preserved Ejection
      Fraction.
PG  - e038294
LID - 10.1136/bmjopen-2020-038294 [doi]
AB  - INTRODUCTION: Neither the pathophysiology nor an effective treatment for heart
      failure with preserved ejection fraction (HFpEF) has been elucidated to date. The
      purpose of this ongoing study is to elucidate the pathophysiology and prognostic 
      factors for patients with HFpEF admitted to participating institutes. We also aim
      to obtain insights into the development of new diagnostic and treatment methods
      by analysing patient background factors, clinical data and follow-up information.
      METHODS AND ANALYSIS: This study is a prospective, multicentre, observational
      study of patients aged >/=20 years admitted due to acute decompensated heart
      failure with preserved left ventricular ejection fraction (>/=50%) and elevated
      N-terminal-pro brain natriuretic peptide (NT-proBNP) (>/=400 pg/mL). The study
      began in June 2016, with the participation of Osaka University Hospital and 31
      affiliated facilities. We will collect data on history in detail, accompanying
      diseases, quality of life, frailty score, medication history, and laboratory and 
      echocardiographic data. We will follow-up each patient for 5 years, and collect
      outcome data on mortality, cause of death, and the number and cause of
      hospitalisation. The target number of registered cases is 1500 cases in 5 years. 
      ETHICS AND DISSEMINATION: The protocol was approved by the Institutional Review
      Board (IRB) of Osaka University Hospital on 24 February 2016 (ID: 15471), and by 
      the IRBs of the all participating facilities. The findings will be disseminated
      through peer-reviewed publications and conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Suna, Shinichiro
AU  - Suna S
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Hikoso, Shungo
AU  - Hikoso S
AUID- ORCID: 0000-0003-2284-1970
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan hikoso@cardiology.med.osaka-u.ac.jp.
FAU - Yamada, Takahisa
AU  - Yamada T
AD  - Division of Cardiology, Osaka General Medical Center, Osaka, Japan.
FAU - Uematsu, Masaaki
AU  - Uematsu M
AD  - Cardiovascular Division, National Hospital Organization Osaka National Hospital, 
      Osaka, Japan.
FAU - Yasumura, Yoshio
AU  - Yasumura Y
AD  - Division of Cardiovascular Medicine, Amagasaki Chuo Hospital, Amagasaki, Japan.
FAU - Nakagawa, Akito
AU  - Nakagawa A
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
AD  - Division of Cardiovascular Medicine, Amagasaki Chuo Hospital, Amagasaki, Japan.
FAU - Takeda, Toshihiro
AU  - Takeda T
AD  - Department of Medical Informatics, Osaka University Graduate School of Medicine, 
      Osaka, Japan.
FAU - Kojima, Takayuki
AU  - Kojima T
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Kida, Hirota
AU  - Kida H
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Oeun, Bolrathanak
AU  - Oeun B
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Sunaga, Akihiro
AU  - Sunaga A
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Kitamura, Tetsuhisa
AU  - Kitamura T
AD  - Department of Social and Environmental Medicine, Osaka University Graduate School
      of Medicine, Suita, Japan.
FAU - Dohi, Tomoharu
AU  - Dohi T
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Okada, Katsuki
AU  - Okada K
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Mizuno, Hiroya
AU  - Mizuno H
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Nakatani, Daisaku
AU  - Nakatani D
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Iso, Hiroyasu
AU  - Iso H
AUID- ORCID: 0000-0002-9241-7289
AD  - Public Health, Department of Social Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Matsumura, Yasushi
AU  - Matsumura Y
AD  - Department of Medical Informatics, Osaka University Graduate School of Medicine, 
      Osaka, Japan.
FAU - Sakata, Yasushi
AU  - Sakata Y
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
CN  - OCVC-Heart Failure Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Activities of Daily Living
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - *Heart Failure/diagnosis
MH  - Humans
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
MH  - Prognosis
MH  - Prospective Studies
MH  - Quality of Life
MH  - Stroke Volume
MH  - *Ventricular Function, Left
MH  - Young Adult
PMC - PMC7566724
OTO - NOTNLM
OT  - *cardiac epidemiology
OT  - *cardiology
OT  - *heart failure
COIS- Competing interests: SS has received personal fees from Nihon Medi-Physics and
      FUJIFILM Toyama Chemical. SH has received personal fees from Daiichi Sankyo
      Company, Bayer, Astellas Pharma, Pfizer Pharmaceuticals and Boehringer Ingelheim 
      Japan, and grants from Roche Diagnostics, FUJIFILM Toyama Chemical and Actelion
      Pharmaceuticals. AN has received personal fees from AstraZeneca and Otsuka
      Pharmaceutical. YM has a leadership position and stock of MKS, and has received a
      grant from MKS. HM has received personal fees from Daiichi Sankyo Company, Kowa
      Company, Bayer and Pfizer Pharmaceuticals, and a grant from Terumo. DN has
      received a personal fee from Daiichi Sankyo Company. YS has received personal
      fees from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo Company,
      Mitsubishi Tanabe Pharma Corporation and Actelion Pharmaceuticals, and grants
      from Roche Diagnostic, FUJIFILM Toyama Chemical, Abbott Medical Japan, Otsuka
      Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation and 
      Biotronik.
IR  - Sakata Y
FIR - Sakata, Yasushi
IR  - Hikoso S
FIR - Hikoso, Shungo
IR  - Nakatani D
FIR - Nakatani, Daisaku
IR  - Mizuno H
FIR - Mizuno, Hiroya
IR  - Suna S
FIR - Suna, Shinichiro
IR  - Okada K
FIR - Okada, Katsuki
IR  - Dohi T
FIR - Dohi, Tomoharu
IR  - Kojima T
FIR - Kojima, Takayuki
IR  - Sunaga A
FIR - Sunaga, Akihiro
IR  - Kida H
FIR - Kida, Hirota
IR  - Bolrathanak O
FIR - Bolrathanak, Oeun
IR  - Tamaki S
FIR - Tamaki, Shunsuke
IR  - Fukunami M
FIR - Fukunami, Masatake
IR  - Hayashi T
FIR - Hayashi, Takaharu
IR  - Higuchi Y
FIR - Higuchi, Yoshiharu
IR  - Masuda M
FIR - Masuda, Masaharu
IR  - Asai M
FIR - Asai, Mitsutoshi
IR  - Mano T
FIR - Mano, Toshiaki
IR  - Fuji H
FIR - Fuji, Hisakazu
IR  - Masuda D
FIR - Masuda, Daisaku
IR  - Takeda Y
FIR - Takeda, Yoshihiro
IR  - Nagai Y
FIR - Nagai, Yoshiyuki
IR  - Yamashita S
FIR - Yamashita, Shizuya
IR  - Sairyo M
FIR - Sairyo, Masami
IR  - Nakagawa Y
FIR - Nakagawa, Yusuke
IR  - Nozaki S
FIR - Nozaki, Shuichi
IR  - Abe H
FIR - Abe, Haruhiko
IR  - Ueda Y
FIR - Ueda, Yasunori
IR  - Koretsune Y
FIR - Koretsune, Yukihiro
IR  - Nagai K
FIR - Nagai, Kunihiko
IR  - Yano M
FIR - Yano, Masamichi
IR  - Nishino M
FIR - Nishino, Masami
IR  - Tanouchi J
FIR - Tanouchi, Jun
IR  - Arita Y
FIR - Arita, Yoh
IR  - Hasegawa S
FIR - Hasegawa, Shinji
IR  - Ishizu T
FIR - Ishizu, Takamaru
IR  - Ichikawa M
FIR - Ichikawa, Minoru
IR  - Takano Y
FIR - Takano, Yuzuru
IR  - Rin E
FIR - Rin, Eisai
IR  - Watanabe T
FIR - Watanabe, Tetsuya
IR  - Hoshida S
FIR - Hoshida, Shiro
IR  - Izumi M
FIR - Izumi, Masahiro
IR  - Yamamoto H
FIR - Yamamoto, Hiroyoshi
IR  - Kato H
FIR - Kato, Hiroyasu
IR  - Nakatani K
FIR - Nakatani, Kazuhiro
IR  - Hiraoka H
FIR - Hiraoka, Hisatoyo
IR  - Nishio M
FIR - Nishio, Mayu
IR  - Hirooka K
FIR - Hirooka, Keiji
IR  - Yoshimura T
FIR - Yoshimura, Takahiro
IR  - Yasuoka Y
FIR - Yasuoka, Yoshinori
IR  - Tani A
FIR - Tani, Akihiro
IR  - Okumoto Y
FIR - Okumoto, Yasushi
IR  - Akagi H
FIR - Akagi, Hideharu
IR  - Makino Y
FIR - Makino, Yasunaka
IR  - Ohnishi T
FIR - Ohnishi, Toshinari
IR  - Iwakura K
FIR - Iwakura, Katsuomi
IR  - Nishikawa N
FIR - Nishikawa, Nagahiro
IR  - Kijima Y
FIR - Kijima, Yoshiyuki
IR  - Kitao T
FIR - Kitao, Takashi
IR  - Kanai H
FIR - Kanai, Hideyuki
IR  - Shioyama W
FIR - Shioyama, Wataru
IR  - Fujita M
FIR - Fujita, Masashi
IR  - Harada K
FIR - Harada, Koichiro
IR  - Kumada M
FIR - Kumada, Masahiro
IR  - Nakagawa O
FIR - Nakagawa, Osamu
IR  - Araki R
FIR - Araki, Ryo
IR  - Yamada T
FIR - Yamada, Takayuki
IR  - Maruyama T
FIR - Maruyama, Takao
IR  - Sera F
FIR - Sera, Fusako
IR  - Nakamoto K
FIR - Nakamoto, Kei
IR  - Kioka H
FIR - Kioka, Hidetaka
IR  - Ohtani T
FIR - Ohtani, Tomohito
IR  - Manabe S
FIR - Manabe, Shirou
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038294 [pii]
AID - 10.1136/bmjopen-2020-038294 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e038294. doi: 10.1136/bmjopen-2020-038294.


PMID- 33060084
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Psychiatric epidemiological survey of university students in Botswana: rationale 
      and methods of the Youth Mental Health Study (YMHS).
PG  - e038175
LID - 10.1136/bmjopen-2020-038175 [doi]
AB  - BACKGROUND: While the burden of disease attributable to mental disorders in
      low/middle-income countries (LMICs) is lower than high-income countries, there is
      recognition that the dearth of evidence from the LMICs may underestimate the
      actual prevalence and burden associated with mental disorders. Such is likely the
      case for Botswana where there has been no nationally representative data on the
      prevalence of symptoms of mental disorders or even a subgroup estimation of
      mental disorders in the country. Thus, the Youth Mental Health Study (YMHS) aims 
      to estimate the prevalence and identify predictors of symptoms of mental
      disorders among university students in Botswana to add to the evidence and
      contribute to the country's health service planning. METHODS: The YMHS is a
      cross-sectional study of youth (18-29 years) attending six large universities
      (accounting for nearly half of the tertiary student population) in Botswana. A
      stratified sampling procedure with proportionate allocation and selection is used
      to select a representative sample of 1308 participants. An online survey
      comprising of a battery of reliable and validated self-report measures of
      symptoms of mental disorders is used. A developmental psychopathology framework
      is used in identifying the risk factors of mental disorders. Participant
      recruitment will span over 4 months beginning in February 2020. ETHICS AND
      DISSEMINATION: The study has received ethics approval from the University of
      Botswana Institutional Review Board, and the Ministry of Health and Wellness.
      Participants will be provided with feedback of their own results. Aggregated
      findings will be disseminated to stakeholders in the tertiary education and
      health sector in Botswana, and through peer-reviewed journals, conference
      presentations and the media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Maphisa, J Maphisa
AU  - Maphisa JM
AUID- ORCID: 0000-0003-0716-5812
AD  - Department of Psychology, University of Botswana, Gaborone, Botswana
      maphisa.maphisa@mopipi.ub.bw.
FAU - Mogotsi, Opelo Petunia
AU  - Mogotsi OP
AD  - Department of Psychology, University of Botswana, Gaborone, Botswana.
FAU - Machola, Olorato Khumo
AU  - Machola OK
AD  - Department of Psychology, University of Botswana, Gaborone, Botswana.
FAU - Maswabi, Keamogetse Metlha
AU  - Maswabi KM
AD  - Department of Psychology, University of Botswana, Gaborone, Botswana.
FAU - Motsamai, Tiro Bright
AU  - Motsamai TB
AD  - Department of Psychology, University of Botswana, Gaborone, Botswana.
FAU - Mosupiemang, Boitshepo
AU  - Mosupiemang B
AD  - Department of Psychology, University of Botswana, Gaborone, Botswana.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Botswana/epidemiology
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Mental Disorders/epidemiology
MH  - *Mental Health
MH  - Students
MH  - Universities
PMC - PMC7566732
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *mental health
OT  - *substance misuse
OT  - *suicide & self-harm
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038175 [pii]
AID - 10.1136/bmjopen-2020-038175 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e038175. doi: 10.1136/bmjopen-2020-038175.


PMID- 33060083
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Identifying factors associated with high use of acute care in Canada: protocol of
      a population-based retrospective cohort study.
PG  - e038008
LID - 10.1136/bmjopen-2020-038008 [doi]
AB  - INTRODUCTION: High-cost users (HCUs) account for a small proportion of the
      population but use a disproportionately large share of healthcare resources.
      Although HCUs exist in all healthcare types, acute care is the most expensive
      type of service and the most significant contributor to expenditures among HCUs. 
      This study aims to determine demographic, socioeconomic and clinical factors
      associated with being HCUs in adult patients (>/=18 years) receiving acute care
      in Canada. METHODS AND ANALYSIS: This is a population-based analysis using a
      national linked dataset. Adult patients who had at least one interaction with
      acute care facilities each year from 2011 to 2014 were captured in the dataset,
      and those living in institutions or other collective residences were not covered.
      The primary outcome is HCU of acute care (yes/no), which is defined as whether a 
      patient is within the top 10% of the highest acute care cost users in his/her
      province. Multilevel logistic regression will be used to identify factors
      associated with HCU and to examine the provincial variations of these identified 
      risk factors. Sensitivity analyses investigating the influences of different high
      user definitions and missing data on the study results will also be performed.
      ETHICS AND DISSEMINATION: All researchers will follow the codes and rules set by 
      Statistics Canada and the Research Data Centre and give priority to the
      confidentiality of the data during and after this study. The study findings will 
      be published in peer-review journals and disseminated at academic conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Mengmeng
AU  - Zhang M
AUID- ORCID: 0000-0001-9431-9909
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Ma, Jinhui
AU  - Ma J
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Xie, Feng
AU  - Xie F
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Centre for Health Economics and Policy Analysis (CHEPA), McMaster University,
      Hamilton, Ontario, Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada thabanl@mcmaster.ca.
AD  - Biostatistics Unit/FSORC, Saint Joseph's Healthcare Hamilton, Hamilton, Ontario, 
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Canada
MH  - Child
MH  - Cohort Studies
MH  - *Delivery of Health Care
MH  - Female
MH  - *Health Expenditures
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Retrospective Studies
PMC - PMC7566720
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health economics
OT  - *health policy
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - bmjopen-2020-038008 [pii]
AID - 10.1136/bmjopen-2020-038008 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e038008. doi: 10.1136/bmjopen-2020-038008.


PMID- 33060082
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - EnDPoINT: protocol for an implementation research study to integrate a holistic
      package of physical health, mental health and psychosocial care for podoconiosis,
      lymphatic filariasis and leprosy into routine health services in Ethiopia.
PG  - e037675
LID - 10.1136/bmjopen-2020-037675 [doi]
AB  - INTRODUCTION: Neglected tropical diseases (NTDs) causing lower limb lymphoedema
      such as podoconiosis, lymphatic filariasis (LF) and leprosy are common in
      Ethiopia. Routine health services for morbidity management and disability
      prevention (MMDP) of lymphoedema caused by these conditions are still lacking,
      even though it imposes a huge burden on affected individuals and their
      communities in terms of physical and mental health, and psychosocial and economic
      outcomes. This calls for an integrated, holistic approach to MMDP across these
      three diseases. METHODS AND ANALYSIS: The 'Excellence in Disability Prevention
      Integrated across NTDs' (EnDPoINT) implementation research study aims to assess
      the integration and scale-up of a holistic package of care-including physical
      health, mental health and psychosocial care-into routine health services for
      people with lymphoedema caused by podoconiosis, LF and leprosy in selected
      districts in Awi zone in the North-West of Ethiopia. The study is being carried
      out over three phases using a wide range of mixed methodologies. Phase 1 involves
      the development of a comprehensive holistic care package and strategies for its
      integration into the routine health services across the three diseases, and to
      examine the factors that influence integration and the roles of key health system
      actors. Phase 2 involves a pilot study conducted in one subdistrict in Awi zone, 
      to establish the care package's adoption, feasibility, acceptability, fidelity,
      potential effectiveness, its readiness for scale-up, costs of the interventions
      and the suitability of the training and training materials. Phase 3 involves
      scale-up of the care package in three whole districts, as well as its evaluation 
      in regard to coverage, implementation, clinical (physical health, mental health
      and psychosocial) and economic outcomes. ETHICS AND DISSEMINATION: Ethics
      approval for the study has been obtained in the UK and Ethiopia. The results will
      be disseminated through publications in scientific journals, conference
      presentations, policy briefs and workshops.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Semrau, Maya
AU  - Semrau M
AUID- ORCID: 0000-0003-0366-1093
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, 
      UK m.semrau@bsms.ac.uk.
FAU - Ali, Oumer
AU  - Ali O
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, 
      UK.
AD  - Center for Innovative Drug Development and Therapeutic Trials for Africa
      (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Deribe, Kebede
AU  - Deribe K
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, 
      UK.
AD  - School of Public Health, College of Health Sciences, Addis Ababa University,
      Addis Ababa, Ethiopia.
FAU - Mengiste, Asrat
AU  - Mengiste A
AD  - Center for Innovative Drug Development and Therapeutic Trials for Africa
      (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Tesfaye, Abraham
AU  - Tesfaye A
AD  - Center for Innovative Drug Development and Therapeutic Trials for Africa
      (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Kinfe, Mersha
AU  - Kinfe M
AD  - Center for Innovative Drug Development and Therapeutic Trials for Africa
      (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Bremner, Stephen A
AU  - Bremner SA
AD  - Department of Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, UK.
FAU - Hounsome, Natalia
AU  - Hounsome N
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, 
      UK.
FAU - Kelly-Hope, Louise A
AU  - Kelly-Hope LA
AD  - Centre for Neglected Tropical Diseases, Department of Tropical Disease Biology,
      Liverpool School of Tropical Medicine, Liverpool, UK.
FAU - MacGregor, Hayley
AU  - MacGregor H
AD  - Health and Development Cluster, Institute of Development Studies, University of
      Sussex, Brighton, UK.
FAU - Taddese, Henock B
AU  - Taddese HB
AD  - Faculty of Medicine, School of Public Health, Imperial College London, London,
      UK.
FAU - Banteyerga, Hailom
AU  - Banteyerga H
AD  - College of Humanities, Language Studies, Journalism and Communication, Addis
      Ababa University, Addis Ababa, Ethiopia.
FAU - HaileMariam, Damen
AU  - HaileMariam D
AD  - School of Public Health, College of Health Sciences, Addis Ababa University,
      Addis Ababa, Ethiopia.
FAU - Negussu, Nebiyu
AU  - Negussu N
AD  - Neglected Tropical Diseases, Disease Prevention and Control Directorate, Federal 
      Ministry of Health, Addis Ababa, Ethiopia.
FAU - Fekadu, Abebaw
AU  - Fekadu A
AUID- ORCID: 0000-0003-2219-0952
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, 
      UK.
AD  - Center for Innovative Drug Development and Therapeutic Trials for Africa
      (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Davey, Gail
AU  - Davey G
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, 
      UK.
LA  - eng
GR  - 201900/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - MR/M025470/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Elephantiasis/prevention & control
MH  - *Elephantiasis, Filarial/prevention & control
MH  - Ethiopia
MH  - Health Services
MH  - Humans
MH  - *Leprosy/prevention & control
MH  - Mental Health
MH  - Pilot Projects
MH  - *Psychiatric Rehabilitation
PMC - PMC7566734
OTO - NOTNLM
OT  - *implementation research
OT  - *leprosy
OT  - *lymphatic filariasis
OT  - *lymphoedema
OT  - *mental health
OT  - *podoconiosis
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037675 [pii]
AID - 10.1136/bmjopen-2020-037675 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e037675. doi: 10.1136/bmjopen-2020-037675.


PMID- 33060081
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Publication bias in pediatric emergence delirium: a cross-sectional analysis of
      ClinicalTrials.gov and ClinicalTrialsRegister.eu.
PG  - e037346
LID - 10.1136/bmjopen-2020-037346 [doi]
AB  - OBJECTIVES: Emergence delirium (ED) is a frequent and potentially serious
      complication of general anaesthesia in children. Although there are various
      treatment strategies, no general management recommendations can be made.
      Selective reporting of study results may impair clinical decision-making. We,
      therefore, analysed whether the results of completed registered clinical studies 
      in patients with paediatric ED are publicly available or remain unpublished.
      DESIGN: Cross-sectional analysis. SETTING: ClinicalTrials.gov and
      ClinicalTrialsRegister.eu. PARTICIPANTS AND OUTCOME MEASURES: We determined the
      proportion of published and unpublished studies registered at ClinicalTrials.gov 
      and ClinicalTrialsRegister.eu that were marked as completed by 1st September
      2018. The major trial and literature databases were used to search for
      publications. In addition, the study investigators were contacted directly. For
      published trials, time to publication was calculated as the difference in months 
      between study completion date and publication date. RESULTS: Of the 44 registered
      studies on paediatric ED, only 24 (54%) were published by September 2019.
      Published trials contained data from n=2556 patients, whereas n=1644 patients
      were enrolled in unpublished trials. Median time to publication was 19 months.
      Studies completed in recent years were published faster, but still only 9 of 24
      trials were published within 12 months of completion. CONCLUSION: There is a
      distinct publication gap in clinical research in paediatric ED that may have an
      impact on meta-analyses and clinical practice.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Meyburg, Jochen
AU  - Meyburg J
AD  - Department of General Pediatrics and Pediatric Intensive Care, Center for
      Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Ries, Markus
AU  - Ries M
AUID- ORCID: 0000-0002-5054-5741
AD  - Department of Pediatric Neurology and Metabolic Medicine, Center for Pediatric
      and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
      markus.ries@uni-heidelberg.de.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Clinical Decision-Making
MH  - *Clinical Trials as Topic
MH  - Cross-Sectional Studies
MH  - Databases, Factual
MH  - *Emergence Delirium
MH  - Humans
MH  - Publication Bias
MH  - *Registries
PMC - PMC7566730
OTO - NOTNLM
OT  - *medical ethics
OT  - *paediatric anaesthesia
OT  - *paediatric intensive & critical care
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037346 [pii]
AID - 10.1136/bmjopen-2020-037346 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e037346. doi: 10.1136/bmjopen-2020-037346.


PMID- 33060077
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 15
TI  - Efficacy of neoadjuvant atezolizumab treatment in patients with advanced
      urothelial bladder cancer according to the BASQ classification: a study protocol 
      for an open-label, two-cohort, phase II trial.
PG  - e035530
LID - 10.1136/bmjopen-2019-035530 [doi]
AB  - INTRODUCTION: Atezolizumab is a programmed death ligand-1 inhibitor for
      urothelial bladder cancer treatment. Atezolizumab has become the standard therapy
      for patients with urothelial bladder cancer who are not responding to
      cisplatin-based chemotherapy and is also used as a first-line treatment in
      cisplatin-ineligible patients. However, the efficacy of atezolizumab as a
      neoadjuvant chemotherapy for radical cystectomy has not yet been published and is
      still under study. This trial investigates the effectiveness of
      basal/squamous-like (BASQ) classification in the selection of an effective target
      group of patients with muscle-invasive bladder cancer (MIBC) for neoadjuvant
      atezolizumab treatment. METHODS AND ANALYSIS: This study is an open-label,
      two-cohort, phase II trial. It was designed to evaluate the efficacy of
      neoadjuvant atezolizumab treatment in patients with MIBC (T2-4N0M0) pathological 
      responses after neoadjuvant chemotherapy and radical cystectomy. According to the
      molecular subtype characteristics of previous transurethral resection of the
      bladder specimens, patients are divided into two groups: luminal type
      (KRT5/6-KRT14-FOXA1+GATA3+) and basal type (KRT5/6+KRT14+FOXA1-GATA3-). Every 3
      weeks, atezolizumab is administered at a dose of 1200 mg for three cycles prior
      to radical cystectomy in patients with MIBC. The primary end point is objective
      pathological responses in the intention-to-treat patients. The secondary end
      point is a 1-year progression-free survival difference according to the BASQ
      classification in patients who underwent neoadjuvant atezolizumab treatment.
      ETHICS AND DISSEMINATION: The study protocol was approved by the Institutional
      Review Board of Seoul National University Hospital, Seoul, Republic of Korea (H
      1806-051-950). The trial is registered at ClinicalTrials.gov. The trial results
      will be published in peer-reviewed journals and at conferences. TRIAL
      REGISTRATION NUMBER: NCT03577132.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yuk, Hyeong Dong
AU  - Yuk HD
AD  - Urology, Seoul National University Hospital, Seoul, The Republic of Korea.
AD  - College of Medicine, Seoul National University, Seoul, The Republic of Korea.
FAU - Jeong, Chang Wook
AU  - Jeong CW
AD  - Urology, Seoul National University Hospital, Seoul, The Republic of Korea.
AD  - College of Medicine, Seoul National University, Seoul, The Republic of Korea.
FAU - Kwak, Cheol
AU  - Kwak C
AD  - Urology, Seoul National University Hospital, Seoul, The Republic of Korea.
AD  - College of Medicine, Seoul National University, Seoul, The Republic of Korea.
FAU - Kim, Hyeon
AU  - Kim H
AD  - Urology, Seoul National University Hospital, Seoul, The Republic of Korea.
AD  - College of Medicine, Seoul National University, Seoul, The Republic of Korea.
FAU - Moon, Kyung Chul
AU  - Moon KC
AD  - College of Medicine, Seoul National University, Seoul, The Republic of Korea.
AD  - Pathology, Seoul National University Hospital, Seoul, The Republic of Korea.
FAU - Ku, Ja Hyeon
AU  - Ku JH
AUID- ORCID: 0000-0002-0391-2342
AD  - Urology, Seoul National University Hospital, Seoul, The Republic of Korea
      kuuro70@snu.ac.kr.
AD  - College of Medicine, Seoul National University, Seoul, The Republic of Korea.
LA  - eng
SI  - ClinicalTrials.gov/NCT03577132
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 52CMI0WC3Y (atezolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Clinical Trials, Phase II as Topic
MH  - Cystectomy
MH  - Humans
MH  - *Neoadjuvant Therapy
MH  - Republic of Korea
MH  - Seoul
MH  - Treatment Outcome
MH  - *Urinary Bladder Neoplasms/drug therapy/surgery
PMC - PMC7566723
OTO - NOTNLM
OT  - *genitourinary medicine
OT  - *immunology
OT  - *urological tumours
COIS- Competing interests: None declared.
EDAT- 2020/10/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/16 05:39
PHST- 2020/10/16 05:39 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035530 [pii]
AID - 10.1136/bmjopen-2019-035530 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 15;10(10):e035530. doi: 10.1136/bmjopen-2019-035530.


PMID- 33059766
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Oct 15
TI  - Application of human amniotic epithelial cells in regenerative medicine: a
      systematic review.
PG  - 439
LID - 10.1186/s13287-020-01951-w [doi]
AB  - Human amniotic epithelial cells (hAECs) derived from placental tissues have
      gained considerable attention in the field of regenerative medicine. hAECs
      possess embryonic stem cell-like proliferation and differentiation capabilities, 
      and adult stem cell-like immunomodulatory properties. Compared with other types
      of stem cell, hAECs have special advantages, including easy isolation, plentiful 
      numbers, the obviation of ethical debates, and non-immunogenic and
      non-tumorigenic properties. During the past two decades, the therapeutic
      potential of hAECs for treatment of various diseases has been extensively
      investigated. Accumulating evidence has demonstrated that hAEC transplantation
      helps to repair and rebuild the function of damaged tissues and organs by
      different molecular mechanisms. This systematic review focused on summarizing the
      biological characteristics of hAECs, therapeutic applications, and recent
      advances in treating various tissue injuries and disorders. Relevant studies
      published in English from 2000 to 2020 describing the role of hAECs in diseases
      and phenotypes were comprehensively sought out using PubMed, MEDLINE, and Google 
      Scholar. According to the research content, we described the major hAEC
      characteristics, including induced differentiation plasticity, homing and
      differentiation, paracrine function, and immunomodulatory properties. We also
      summarized the current status of clinical research and discussed the prospects of
      hAEC-based transplantation therapies. In this review, we provide a comprehensive 
      understanding of the therapeutic potential of hAECs, including their use for cell
      replacement therapy as well as secreted cytokine and exosome biotherapy.
      Moreover, we showed that the powerful immune-regulatory function of hAECs reveals
      even more possibilities for their application in the treatment of immune-related 
      diseases. In the future, establishing the optimal culture procedure, achieving
      precise and accurate treatment, and enhancing the therapeutic potential by
      utilizing appropriate preconditioning and/or biomaterials would be new challenges
      for further investigation.
FAU - Zhang, Qiuwan
AU  - Zhang Q
AD  - The International Peace Maternity and Child Health Hospital, School of Medicine, 
      Shanghai Jiao Tong University; Shanghai Key Laboratory of Embryo Original
      Diseases; Shanghai Municipal Key Clinical Speciality, 145, Guang-Yuan Road,
      Shanghai, 200030, People's Republic of China.
FAU - Lai, Dongmei
AU  - Lai D
AUID- ORCID: 0000-0003-3810-2136
AD  - The International Peace Maternity and Child Health Hospital, School of Medicine, 
      Shanghai Jiao Tong University; Shanghai Key Laboratory of Embryo Original
      Diseases; Shanghai Municipal Key Clinical Speciality, 145, Guang-Yuan Road,
      Shanghai, 200030, People's Republic of China. laidongmei@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20201015
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Amnion
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Epithelial Cells
MH  - Female
MH  - Humans
MH  - *Placenta
MH  - Pregnancy
MH  - *Regenerative Medicine
PMC - PMC7559178
OTO - NOTNLM
OT  - *Cell transplantation
OT  - *Differentiation
OT  - *Human amniotic/amnion epithelial cells
OT  - *Immunomodulation
OT  - *Paracrine properties
OT  - *Regenerative medicine
EDAT- 2020/10/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/16 05:34
PHST- 2020/07/01 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/16 05:34 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-01951-w [doi]
AID - 10.1186/s13287-020-01951-w [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Oct 15;11(1):439. doi: 10.1186/s13287-020-01951-w.


PMID- 33059727
OWN - NLM
STAT- MEDLINE
DCOM- 20210826
LR  - 20210826
IS  - 1824-7288 (Electronic)
IS  - 1720-8424 (Linking)
VI  - 46
IP  - 1
DP  - 2020 Oct 15
TI  - Autosomal recessive polycystic kidney disease: case report of a newborn with rare
      PKHD1 mutation, rapid renal enlargement and early fatal outcome.
PG  - 154
LID - 10.1186/s13052-020-00922-4 [doi]
AB  - INTRODUCTION: Autosomal recessive polycystic kidney disease (ARPKD; MIM#263200)
      is one of the most frequent pediatric renal cystic diseases, with an incidence of
      1:20,000. It is caused by mutations of the PKHD1 gene, on chromosome 6p12. The
      clinical spectrum is highly variable, ranging from late-onset milder forms to
      severe perinatal manifestations. The management of newborns with severe pulmonary
      insufficiency is challenging, and causes of early death are sepsis or respiratory
      failure. In cases of massive renal enlargement, early bilateral nephrectomy and
      peritoneal dialysis may reduce infant mortality. However, there is no conclusive 
      data on the role of surgery, and decision-making is driven by patient's clinical 
      condition and expertise of the center. PATIENT PRESENTATION: We hereby describe a
      preterm female newborn with perinatal, rapid and bilateral, abnormal growth of
      both kidneys, respiratory failure and initial signs of liver disease. She was
      subsequently confirmed to be affected by a rare and severe homozygous mutation of
      the PKHD1 gene, inherited from both her consanguineous parents. Our patient died 
      78 days after birth, due to a fungal sepsis which worsened her respiratory
      insufficiency. CONCLUSIONS: This patient report shows some of the clinical and
      ethical issues of neonatal ARPKD, and the need of multidisciplinary approach and 
      good communication with the family. Target next generation sequencing (NGS)
      techniques may guide and support clinicians, as well as guarantee to these
      patients the most appropriate clinical management, avoiding unnecessary and/or
      disproportionate treatments.
FAU - Serra, Gregorio
AU  - Serra G
AUID- ORCID: http://orcid.org/0000-0002-2918-9826
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy. gregorioserra1984@libero.it.
FAU - Corsello, Giovanni
AU  - Corsello G
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy.
FAU - Antona, Vincenzo
AU  - Antona V
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy.
FAU - D'Alessandro, Maria Michela
AU  - D'Alessandro MM
AD  - Department of Pediatric Nephrology, Children's Hospital "G. Di Cristina",
      Palermo, Italy.
FAU - Cassata, Nicola
AU  - Cassata N
AD  - Department of Pediatrics, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo,
      Italy.
FAU - Cimador, Marcello
AU  - Cimador M
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy.
FAU - Giuffre, Mario
AU  - Giuffre M
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy.
FAU - Schierz, Ingrid Anne Mandy
AU  - Schierz IAM
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy.
FAU - Piro, Ettore
AU  - Piro E
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and
      Medical Specialties "G. D'Alessandro", University Hospital "P.Giaccone", Palermo,
      Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - Ital J Pediatr
JT  - Italian journal of pediatrics
JID - 101510759
RN  - 0 (PKHD1 protein, human)
RN  - 0 (Receptors, Cell Surface)
SB  - IM
MH  - Consanguinity
MH  - Fatal Outcome
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Mutation
MH  - Polycystic Kidney, Autosomal Recessive/*genetics
MH  - Receptors, Cell Surface
PMC - PMC7560064
OTO - NOTNLM
OT  - ARPKD
OT  - Ethics
OT  - Genotype-phenotype correlation
OT  - Next generation sequencing
OT  - Potter sequence
EDAT- 2020/10/17 06:00
MHDA- 2021/08/27 06:00
CRDT- 2020/10/16 05:34
PHST- 2020/07/24 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/16 05:34 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2021/08/27 06:00 [medline]
AID - 10.1186/s13052-020-00922-4 [doi]
AID - 10.1186/s13052-020-00922-4 [pii]
PST - epublish
SO  - Ital J Pediatr. 2020 Oct 15;46(1):154. doi: 10.1186/s13052-020-00922-4.


PMID- 33059674
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201218
IS  - 1475-9276 (Electronic)
IS  - 1475-9276 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Oct 15
TI  - Ethics, pandemic and environment; looking at the future of low middle income
      countries.
PG  - 182
LID - 10.1186/s12939-020-01296-z [doi]
AB  - COVID-19 which started in Wuhan, China and swiftly expanded geographically
      worldwide, including to Low to Middle Income Countries (LMICs). This in turn
      raised numerous ethical concerns in preparedness, knowledge sharing, intellectual
      property rights, environmental health together with the serious constraints
      regarding readiness of health care systems in LMICs to respond to this enormous
      public health crisis. From the restrictions on public freedom and burgeoning
      socio-economic impacts to the rationing of scarce medical resources, the spread
      of COVID-19 is an extraordinary ethical dilemma for resource constrained nations 
      with less developed health and research systems. In the current crisis,
      scientific knowledge and technology has an important role to play in effective
      response. Emergency preparedness is a shared responsibility of all countries with
      a moral obligation to support each other. This review discusses the ethical
      concerns regarding the national capacities and response strategies in LMICs to
      deal with the COVID-19 pandemic as well as the deep link between the environment 
      and the increasing risk of pandemics.
FAU - Tanveer, Faouzia
AU  - Tanveer F
AD  - Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.
FAU - Khalil, Ali Talha
AU  - Khalil AT
AD  - Department of Pathology, Lady Reading Hospital (MTI), Peshawar, Pakistan.
      alitalha.khalil@lrh.edu.pk.
FAU - Ali, Muhammad
AU  - Ali M
AD  - Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.
FAU - Shinwari, Zabta Khan
AU  - Shinwari ZK
AD  - Pakistan Academy of Sciences, Islamabad, Pakistan.
AD  - Department of Plant Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201015
PL  - England
TA  - Int J Equity Health
JT  - International journal for equity in health
JID - 101147692
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - *Developing Countries
MH  - *Environment
MH  - *Ethics
MH  - Forecasting
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
PMC - PMC7557237
OTO - NOTNLM
OT  - *Coronavirus
OT  - *Environment
OT  - *Ethics
OT  - *LMICs
OT  - *Pandemic
EDAT- 2020/10/17 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/10/16 05:33
PHST- 2020/06/05 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/16 05:33 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1186/s12939-020-01296-z [doi]
AID - 10.1186/s12939-020-01296-z [pii]
PST - epublish
SO  - Int J Equity Health. 2020 Oct 15;19(1):182. doi: 10.1186/s12939-020-01296-z.


PMID- 33058705
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - 12
DP  - 2020 Dec
TI  - Dental Radiographs for Age Estimation in US Asylum Seekers: Methodological,
      Ethical, and Health Issues.
PG  - 1786-1789
LID - 10.2105/AJPH.2020.305918 [doi]
AB  - Unaccompanied migrant children seeking asylum status in the United States are
      often forced to undergo dental radiographs, or x-rays, to verify that they are
      younger than 18 years.The application of third molar dental radiographs is
      methodologically flawed and should not be employed as a determinant of
      chronological age. Furthermore, the use of such tests without obtaining informed 
      consent from either the youth or an objective advocate is unethical.Finally, the 
      legal and health consequences of these inappropriately applied tests are severe
      and jeopardize the safety and security of these vulnerable minors.
FAU - Kapadia, Farzana
AU  - Kapadia F
AD  - Farzana Kapadia, Deputy Editor at AJPH, is with the Department of Epidemiology,
      School of Global Public Health, New York University, New York, NY. Jacqueline
      Stevens is with the Department of Political Science and the Deportation Research 
      Clinic, Northwestern University, Evanston, IL. Diana Silver is with the School of
      Global Public Health, New York University.
FAU - Stevens, Jacqueline
AU  - Stevens J
AD  - Farzana Kapadia, Deputy Editor at AJPH, is with the Department of Epidemiology,
      School of Global Public Health, New York University, New York, NY. Jacqueline
      Stevens is with the Department of Political Science and the Deportation Research 
      Clinic, Northwestern University, Evanston, IL. Diana Silver is with the School of
      Global Public Health, New York University.
FAU - Silver, Diana
AU  - Silver D
AD  - Farzana Kapadia, Deputy Editor at AJPH, is with the Department of Epidemiology,
      School of Global Public Health, New York University, New York, NY. Jacqueline
      Stevens is with the Department of Political Science and the Deportation Research 
      Clinic, Northwestern University, Evanston, IL. Diana Silver is with the School of
      Global Public Health, New York University.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
MH  - Adolescent
MH  - Age Determination by Teeth/*methods
MH  - Child
MH  - Humans
MH  - Molar, Third/diagnostic imaging
MH  - Radiography, Dental/adverse effects/*ethics/methods
MH  - *Refugees
MH  - Third-Party Consent/ethics
PMC - PMC7661996
EDAT- 2020/10/16 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/10/15 17:58
PMCR- 2022/12/01 00:00
PHST- 2022/12/01 00:00 [pmc-release]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/10/15 17:58 [entrez]
AID - 10.2105/AJPH.2020.305918 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Dec;110(12):1786-1789. doi: 10.2105/AJPH.2020.305918.
      Epub 2020 Oct 15.


PMID- 33058704
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210304
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - 12
DP  - 2020 Dec
TI  - COVID-19 and the Rise of Participatory SIGINT: An Examination of the Rise in
      Government Surveillance Through Mobile Applications.
PG  - 1780-1785
LID - 10.2105/AJPH.2020.305912 [doi]
AB  - The COVID-19 pandemic has triggered a significant growth in government
      surveillance techniques globally, primarily through the use of cell phone
      applications. However, although these applications can have actionable effects on
      public health efforts to control pandemics, the participatory or voluntary nature
      of these measures is obscuring the relationship between health information and
      traditional government surveillance techniques, potentially preventing effective 
      oversight. Public health measures have traditionally been resistant to the
      integration of government-led intelligence techniques, such as signals
      intelligence (SIGINT), because of ethical and legal issues arising from the
      nature of surveillance techniques.We explore this rise of participatory SIGINT
      and its nature as an extension of biosurveillance through 3 drivers: the rise of 
      surveillance capitalism, the exploitation of a public health crisis to obscure
      state of exception politics with a moral imperative, and the historically
      enduring nature of emergency-implemented surveillance measures.We conclude that
      although mobile applications may indeed be useful in containing pandemics, they
      should be subject to similar oversight and regulation as other government
      intelligence collection techniques.
FAU - Bernard, Rose
AU  - Bernard R
AD  - All authors are with the Conflict and Health Research Group, Kings College
      London, London, UK.
FAU - Bowsher, Gemma
AU  - Bowsher G
AD  - All authors are with the Conflict and Health Research Group, Kings College
      London, London, UK.
FAU - Sullivan, Richard
AU  - Sullivan R
AD  - All authors are with the Conflict and Health Research Group, Kings College
      London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
CIN - Am J Public Health. 2021 Mar;111(3):369-370. PMID: 33566643
MH  - COVID-19/*epidemiology
MH  - Contact Tracing/methods
MH  - Government Programs/*methods
MH  - Humans
MH  - *Mobile Applications
MH  - Pandemics
MH  - Politics
MH  - Public Health Surveillance/*methods
MH  - Quarantine/methods
MH  - SARS-CoV-2
PMC - PMC7661974
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Global Health
OT  - *Government
OT  - *Human Rights
OT  - *SUBJECT CODES
OT  - *Social Science
EDAT- 2020/10/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/15 17:58
PMCR- 2022/12/01 00:00
PHST- 2022/12/01 00:00 [pmc-release]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/15 17:58 [entrez]
AID - 10.2105/AJPH.2020.305912 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Dec;110(12):1780-1785. doi: 10.2105/AJPH.2020.305912.
      Epub 2020 Oct 15.


PMID- 33058598
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 6
DP  - 2020 Jun
TI  - [Towards a new derogation from medical confidentiality in the event of immediate 
      danger ?]
PG  - 605-608
AB  - Towards a new derogation from medical confidentiality in the event of immediate
      danger? In the relationship between the patient and the healthcare professional, 
      medical confidentiality is an essential principle. However, there are exceptions,
      all provided for by law. In recent years, the question has arisen of whether to
      add to these derogations when the patient poses a significant risk to a third
      party, or even when the patient himself is at risk. A bill in the process of
      being voted on tends to lift secrecy to protect the victim of domestic violence. 
      The implementation of such a mandatory exemption will never be easy for the
      doctor concerned.
FAU - Bergoignan Esper, Claudine
AU  - Bergoignan Esper C
AD  - Membre de l'Academie nationale de medecine ; professeur honoraire, faculte de
      droit, universite Paris-Descartes, Paris, France.
LA  - fre
PT  - Journal Article
TT  - Vers une nouvelle derogation au secret medical en cas de danger immediat ?
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Confidentiality
MH  - *Domestic Violence
MH  - Health Personnel
MH  - Humans
MH  - *Physicians
OTO - NOTNLM
OT  - Disclosure
OT  - Health sector reform
OT  - Medical ethics
COIS- L'auteur declare n'avoir aucun lien d'interets.
EDAT- 2020/10/16 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/15 17:48
PHST- 2020/10/15 17:48 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Jun;70(6):605-608.


PMID- 33058232
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
VI  - 76
IP  - 12
DP  - 2020 Dec
TI  - The CRIAA Program complex intervention in primary care to support women and their
      families in breastfeeding: Study protocol for a pilot trial.
PG  - 3641-3653
LID - 10.1111/jan.14534 [doi]
AB  - AIM: To report a pilot study protocol to assess the feasibility of a complex
      intervention, in the primary healthcare context, to support women and their
      families in breastfeeding. DESIGN: A pilot/feasibility trial with control and
      intervention groups. METHODS: The study will be conducted in two primary
      healthcare centres with 40 childbearing women (20 control group; 20 intervention 
      group), with their partner/meaningful person and their respective healthcare
      professionals. Intervention group participants will receive the intervention: (a)
      in a breastfeeding workshop during their third trimester of pregnancy; and (b)
      via virtual breastfeeding support for six months postpartum. Health professionals
      will be trained to deliver the intervention. The control group will receive
      standard care in the outpatient clinic. The pilot will help determine the
      intervention's feasibility. Data collected pre-intervention, 10-days postpartum
      and two-, four-, and six-months postpartum will provide estimates of the
      intervention's preliminary effects on self-efficacy and main outcomes. Research
      Ethics Committee approval was obtained in April 2019. DISCUSSION: Breastfeeding
      support is a complex reality influenced by multiple factors. Therefore,
      approaches to breastfeeding are also, requiring interventions that address its
      multidimensional nature, including all actors involved. The proposed intervention
      will be applied by an interdisciplinary professional health team, allowing for
      its incorporation into standard practice and its perpetual maintenance. IMPACT:
      The study will produce an original, comprehensive, complex intervention
      addressing contextual, and organizational factors to promote breastfeeding
      support using an interdisciplinary and family-based approach; breastfeeding
      self-efficacy is the core concept. The program evaluation and feasibility study
      will permit exploration of the integration of the intervention's novel aspects
      into the daily work of professionals and reveal how to better use existing
      resources in a full-scale clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov 
      ID: NCT03944642.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Lucchini-Raies, Camila
AU  - Lucchini-Raies C
AUID- ORCID: https://orcid.org/0000-0001-5704-9778
AD  - School of Nursing, Pontificia Universidad Catolica de Chile, Santiago, Chile.
AD  - Universidad de Navarra, Pamplona, Spain.
FAU - Marquez-Doren, Francisca
AU  - Marquez-Doren F
AUID- ORCID: https://orcid.org/0000-0001-8093-4687
AD  - School of Nursing, Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Beca, Paulina
AU  - Beca P
AD  - School of Medicine, Family Health Center San Alberto Hurtado ANCORA, Pontificia
      Universidad Catolica de Chile, Santiago, Chile.
FAU - Perez, J Carola
AU  - Perez JC
AD  - Faculty of Psychology, Universidad del Desarrollo, Santiago, Chile.
FAU - Campos, Solange
AU  - Campos S
AD  - School of Nursing, Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Lopez-Dicastillo, Olga
AU  - Lopez-Dicastillo O
AUID- ORCID: https://orcid.org/0000-0001-7375-8072
AD  - Faculty of Health Science, Universidad Publica de Navarra, Pamplona, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03944642
GR  - PIEM04-19/Interdisciplinary Research Fund 2018. School of Nursing and School of
      Medicine. Pontificia Universidad Catolica de Chile
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
MH  - *Breast Feeding
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Pilot Projects
MH  - *Postnatal Care
MH  - Pregnancy
MH  - Primary Health Care
OTO - NOTNLM
OT  - breastfeeding self-efficacy
OT  - breastfeeding support
OT  - complex intervention
OT  - midwives
OT  - nursing
OT  - pilot study
OT  - primary health care
EDAT- 2020/10/16 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/15 17:41
PHST- 2020/04/17 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/15 17:41 [entrez]
AID - 10.1111/jan.14534 [doi]
PST - ppublish
SO  - J Adv Nurs. 2020 Dec;76(12):3641-3653. doi: 10.1111/jan.14534. Epub 2020 Oct 15.


PMID- 33058226
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Ethics of controlled human infection studies: Past, present and future.
PG  - 745-748
LID - 10.1111/bioe.12801 [doi]
FAU - Shah, Seema K
AU  - Shah SK
AD  - Division of Academic General Pediatrics, Lurie Children's Hospital and Department
      of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago,
      Illinois.
FAU - Rid, Annette
AU  - Rid A
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      Bethesda, Maryland.
LA  - eng
PT  - Editorial
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Ethics
MH  - *Ethics, Medical
MH  - Forecasting
MH  - Humans
EDAT- 2020/10/16 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/15 17:41
PHST- 2020/10/15 17:41 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 10.1111/bioe.12801 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):745-748. doi: 10.1111/bioe.12801.


PMID- 33058122
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 0189-160X (Print)
IS  - 0189-160X (Linking)
VI  - 37
IP  - 5
DP  - 2020 Oct
TI  - Determinants of Health-related Quality of Life in Persons with Epilepsy Seen at a
      Tertiary Hospital in North Western Nigeria.
PG  - 475-480
AB  - INTRODUCTION: There is a growing global concern about the effect of epilepsy on
      the Health-Related Quality of Life (HRQoL) of the sufferers. AIM: This study
      assessed the determinants of HRQoL in persons with epilepsy (PWE) in a tertiary
      hospital in North Western Nigeria. METHODOLOGY: A cross-sectional study was
      carried out on 103 patients with epilepsy aged >/= 18 years attending Neurology
      clinic. Ethical clearance was obtained from the Health Research Ethics Committee 
      of the institution. The short version of the World Health Organization Quality of
      Life questionnaire (WHOQOL-BREF) was administered to the participants.
      Statistical significance was set with p value at 0.05. The determinants of HRQoL 
      was obtained by using univariate and subsequent multivariate logistic regression 
      analysis. RESULT: The mean age of patients was 33.4+/-15.8 years. There were
      54(52.4%) males and 49 (47.6%) females. The significant determinants of
      HRQoLfound were time of last seizure episode (OR = 7.50, 95% CI = 1.36 -41.20, p 
      = 0.021) and social support (OR = 21.5, 95% CI = 3.67 - 125.68, p = 0.001).
      Following multivariate logistic regression analysis, social support (OR = 29.51, 
      95% CI = 2.87 - 302.66, p = 0.004) appeared as the independent determinant of
      HRQoLin PWE. CONCLUSION: Social support was the main determining factor of HRQoL 
      in epilepsy patients in this study. Therefore there is the need to ensure a
      comprehensive care which should include health education, adequate seizure
      control and social support for epilepsy patients to improve their HRQoL.
FAU - Iwuozo, E U
AU  - Iwuozo EU
AD  - Neurology Unit, Medicine Department, Benue State University Teaching Hospital,
      Makurdi, Benue State.
FAU - Obiako, O R
AU  - Obiako OR
AD  - Neurology Unit, Department of Medicine, Ahmadu Bello University Teaching
      Hospital, Shika-Zaria, Kaduna State.
FAU - Onyemocho, A
AU  - Onyemocho A
AD  - Department of Community Medicine and Epidemiology Benue State University,
      Makurdi, Benue State.
FAU - Ogunniyi, A
AU  - Ogunniyi A
AD  - Neurology Unit, Department of Medicine, University College Hospital, Ibadan, Oyo 
      State.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - West Afr J Med
JT  - West African journal of medicine
JID - 8301891
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Epilepsy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
MH  - Young Adult
EDAT- 2020/10/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/15 17:40
PHST- 2020/10/15 17:40 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PST - ppublish
SO  - West Afr J Med. 2020 Oct;37(5):475-480.


PMID- 33057957
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1742-6316 (Electronic)
IS  - 0391-9714 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Oct 14
TI  - Making the anaesthetised animal into a boundary object: an analysis of the 1875
      Royal Commission on Vivisection.
PG  - 50
LID - 10.1007/s40656-020-00344-9 [doi]
AB  - This paper explores how, at the 1875 Royal Commission on Vivisection, the
      anaesthetised animal was construed as a boundary object around which "cooperation
      without consensus" (Star, in: Esterbrook (ed) Computer supported cooperative
      work: cooperation or conflict? Springer, London, 1993) could form, serving the
      interests of both scientists and animals. Advocates of anaesthesia presented it
      as benevolently intervening between the scientific agent and animal patient. Such
      articulations of 'ethical' vivisection through anaesthesia were then mandated in 
      the 1876 Cruelty to Animals Act, and thus have had significant downstream effects
      on the regulation of laboratory animals in Britain and beyond. Constructing this 
      'consensus' around the anaesthetised animal, however, required first excluding
      abolitionists and inhumane scientists, and secondly limiting the interests of
      experimental animals to the avoidance of pain through anaesthesia and euthanasia,
      thereby circumventing the issue of their possible interest in future life. This
      consensus also served to secure the interests of vivisecting scientists and to
      limit the influence of public opinion in the laboratory to administrative
      procedure and scheduled inspection. The focus on anaesthesia was connected with
      discussions of what supporting infrastructures were required to ensure proper
      ethical procedure was carried out by scientists. In contrast to the much studied 
      polarisation in British society between pro- and antivivisectionists after 1876, 
      we understand the 1875 Commission as a conflict amongst scientists themselves,
      while also being an intra-class conflict amongst the ruling class (French in
      Antivivisection and medical science in Victorian society, Princeton University
      Press, Princeton, 1975).
FAU - Holmes, Tarquin
AU  - Holmes T
AD  - Sociology Department, London School of Economics and Political Science, London,
      UK.
FAU - Friese, Carrie
AU  - Friese C
AUID- ORCID: http://orcid.org/0000-0001-7144-8046
AD  - Sociology Department, London School of Economics and Political Science, London,
      UK. c.friese@lse.ac.uk.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 103320/Z/13/Z/WT_/Wellcome Trust/United Kingdom
PT  - Historical Article
PT  - Journal Article
DEP - 20201014
PL  - Switzerland
TA  - Hist Philos Life Sci
JT  - History and philosophy of the life sciences
JID - 8003052
SB  - IM
MH  - Anesthesia/*veterinary
MH  - Animals
MH  - Biomedical Research/ethics/*history
MH  - History, 19th Century
MH  - United Kingdom
MH  - Vivisection/ethics/*history
PMC - PMC7557452
OTO - NOTNLM
OT  - Anaesthesia
OT  - Boundary objects
OT  - Social worlds
OT  - Vivisection
EDAT- 2020/10/16 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/10/15 17:39
PHST- 2020/05/20 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/15 17:39 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - 10.1007/s40656-020-00344-9 [doi]
AID - 10.1007/s40656-020-00344-9 [pii]
PST - epublish
SO  - Hist Philos Life Sci. 2020 Oct 14;42(4):50. doi: 10.1007/s40656-020-00344-9.


PMID- 33057713
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
VI  - 31
IP  - 5
DP  - 2020 Nov 1
TI  - Rare indications for a lung transplant. A European Society of Thoracic Surgeons
      survey.
PG  - 638-643
LID - 10.1093/icvts/ivaa165 [doi]
AB  - OBJECTIVES: The European Society of Thoracic Surgeons Lung Transplantation
      Working Group promoted a survey to evaluate overall survival in a large cohort of
      patients receiving lung transplants for rare pulmonary diseases. METHODS: We
      conducted a retrospective multicentre study. The primary end point was overall
      survival; secondary end points were survival of patients with the most common
      diagnoses in the context of rare pulmonary diseases and chronic lung allograft
      dysfunction (CLAD)-free survival. Finally, we analysed risk factors for overall
      survival and CLAD-free survival. RESULTS: Clinical records of 674 patients were
      extracted and collected from 13 lung transplant centres; diagnoses included 46
      rare pulmonary diseases. Patients were followed for a median of 3.1 years. The
      median survival after a lung transplant was 8.5 years. The median CLAD-free
      survival was 8 years. The multivariable analysis for mortality identified CLAD as
      a strong negative predictor [hazard ratio (HR) 6.73)], whereas induction therapy 
      was a protective factor (HR 0.68). The multivariable analysis for CLAD occurrence
      identified induction therapy as a protective factor (HR 0.51). When we stratified
      patients by CLAD occurrence in a Kaplan-Meier plot, the survival curves diverged 
      significantly (log-rank test: P < 0.001). Patients with rare diseases who
      received transplants had chronic rejection rates similar to those of the general 
      population who received transplants. CONCLUSIONS: We observed that overall
      survival and CLAD-free survival were excellent. We support the practice of
      allocating lungs to patients with rare pulmonary diseases because a lung
      transplant is both effective and ethically acceptable.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      European Association for Cardio-Thoracic Surgery. All rights reserved.
FAU - Nosotti, Mario
AU  - Nosotti M
AD  - Thoracic Surgery and Lung Transplantation Unit, Foundation IRCCS Ca' Granda
      Ospedale Maggiore Policlinico, Milan, Italy.
FAU - D'Ovidio, Frank
AU  - D'Ovidio F
AD  - Division of Thoracic Surgery, Columbia University Medical Center, New York, NY,
      USA.
FAU - Leiva-Juarez, Miguel
AU  - Leiva-Juarez M
AD  - Division of Thoracic Surgery, Columbia University Medical Center, New York, NY,
      USA.
FAU - Keshavjee, Shaf
AU  - Keshavjee S
AD  - Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada.
FAU - Rackauskas, Mindaugas
AU  - Rackauskas M
AD  - Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada.
FAU - Van Raemdonck, Dirk
AU  - Van Raemdonck D
AD  - Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
FAU - Ceulemans, Laurens J
AU  - Ceulemans LJ
AD  - Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
FAU - Krueger, Thorsten
AU  - Krueger T
AD  - Division of Thoracic Surgery, Lausanne University Hospital, Lausanne,
      Switzerland.
FAU - Koutsokera, Angela
AU  - Koutsokera A
AD  - Lung Transplant Program, Division of Pulmonology, University Hospital of
      Lausanne, Switzerland.
FAU - Schiavon, Marco
AU  - Schiavon M
AD  - Department of Cardio-Thoracic Surgery, Padua University Hospital, Padua, Italy.
FAU - Rea, Federico
AU  - Rea F
AD  - Department of Cardio-Thoracic Surgery, Padua University Hospital, Padua, Italy.
FAU - Iskender, Ilker
AU  - Iskender I
AD  - Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
FAU - Moreno, Paula
AU  - Moreno P
AD  - Thoracic Surgery and Lung Transplantation Unit, University Hospital Reina Sofia, 
      Cordoba, Spain.
FAU - Alvarez, Antonio
AU  - Alvarez A
AD  - Thoracic Surgery and Lung Transplantation Unit, University Hospital Reina Sofia, 
      Cordoba, Spain.
FAU - Luzzi, Luca
AU  - Luzzi L
AD  - Thoracic Surgery, University Hospital of Siena, Siena, Italy.
FAU - Paladini, Piero
AU  - Paladini P
AD  - Thoracic Surgery, University Hospital of Siena, Siena, Italy.
FAU - Rosso, Lorenzo
AU  - Rosso L
AD  - Thoracic Surgery and Lung Transplantation Unit, Foundation IRCCS Ca' Granda
      Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Bertani, Alessandro
AU  - Bertani A
AD  - Thoracic Surgery and Lung Transplantation Unit, IRCCS - ISMETT (Istituto
      Mediterraneo per i Trapianti e Terapie ad alta specializzazione), Palermo, Italy.
FAU - Venuta, Federico
AU  - Venuta F
AD  - Division of Thoracic Surgery, Policlinico Umberto I, Sapienza University, Rome,
      Italy.
FAU - Pecoraro, Ylenia
AU  - Pecoraro Y
AD  - Division of Thoracic Surgery, Policlinico Umberto I, Sapienza University, Rome,
      Italy.
FAU - Al-Kattan, Khaled
AU  - Al-Kattan K
AD  - Department of Surgery, King Faisal Specialist Hospital and Research Center,
      Riyadh, Saudi Arabia.
FAU - Kubisa, Bartosz
AU  - Kubisa B
AD  - Department of Thoracic Surgery and Transplantation, Pomeranian Medical
      University, Szczecin, Poland.
FAU - Inci, Ilhan
AU  - Inci I
AD  - Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Lung Diseases/etiology/mortality/*surgery
MH  - *Lung Transplantation
MH  - Male
MH  - Middle Aged
MH  - *Patient Selection
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate
OTO - NOTNLM
OT  - *Lung diseases
OT  - *Lung transplant
OT  - *Rare diseases
OT  - *Respiratory insufficiency
EDAT- 2020/10/16 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/10/15 17:36
PHST- 2019/12/12 00:00 [received]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/10/15 17:36 [entrez]
AID - 5923813 [pii]
AID - 10.1093/icvts/ivaa165 [doi]
PST - ppublish
SO  - Interact Cardiovasc Thorac Surg. 2020 Nov 1;31(5):638-643. doi:
      10.1093/icvts/ivaa165.


PMID- 33057333
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Linking)
VI  - 17
IP  - 10
DP  - 2020 Oct
TI  - Developing and validating subjective and objective risk-assessment measures for
      predicting mortality after major surgery: An international prospective cohort
      study.
PG  - e1003253
LID - 10.1371/journal.pmed.1003253 [doi]
AB  - BACKGROUND: Preoperative risk prediction is important for guiding clinical
      decision-making and resource allocation. Clinicians frequently rely solely on
      their own clinical judgement for risk prediction rather than objective measures. 
      We aimed to compare the accuracy of freely available objective surgical risk
      tools with subjective clinical assessment in predicting 30-day mortality. METHODS
      AND FINDINGS: We conducted a prospective observational study in 274 hospitals in 
      the United Kingdom (UK), Australia, and New Zealand. For 1 week in 2017,
      prospective risk, surgical, and outcome data were collected on all adults aged 18
      years and over undergoing surgery requiring at least a 1-night stay in hospital. 
      Recruitment bias was avoided through an ethical waiver to patient consent; a
      mixture of rural, urban, district, and university hospitals participated. We
      compared subjective assessment with 3 previously published, open-access objective
      risk tools for predicting 30-day mortality: the Portsmouth-Physiology and
      Operative Severity Score for the enUmeration of Mortality (P-POSSUM), Surgical
      Risk Scale (SRS), and Surgical Outcome Risk Tool (SORT). We then developed a
      logistic regression model combining subjective assessment and the best objective 
      tool and compared its performance to each constituent method alone. We included
      22,631 patients in the study: 52.8% were female, median age was 62 years
      (interquartile range [IQR] 46 to 73 years), median postoperative length of stay
      was 3 days (IQR 1 to 6), and inpatient 30-day mortality was 1.4%. Clinicians used
      subjective assessment alone in 88.7% of cases. All methods overpredicted risk,
      but visual inspection of plots showed the SORT to have the best calibration. The 
      SORT demonstrated the best discrimination of the objective tools (SORT Area Under
      Receiver Operating Characteristic curve [AUROC] = 0.90, 95% confidence interval
      [CI]: 0.88-0.92; P-POSSUM = 0.89, 95% CI 0.88-0.91; SRS = 0.85, 95% CI
      0.82-0.87). Subjective assessment demonstrated good discrimination (AUROC = 0.89,
      95% CI: 0.86-0.91) that was not different from the SORT (p = 0.309). Combining
      subjective assessment and the SORT improved discrimination (bootstrap
      optimism-corrected AUROC = 0.92, 95% CI: 0.90-0.94) and demonstrated continuous
      Net Reclassification Improvement (NRI = 0.13, 95% CI: 0.06-0.20, p < 0.001)
      compared with subjective assessment alone. Decision-curve analysis (DCA)
      confirmed the superiority of the SORT over other previously published models, and
      the SORT-clinical judgement model again performed best overall. Our study is
      limited by the low mortality rate, by the lack of blinding in the 'subjective'
      risk assessments, and because we only compared the performance of clinical risk
      scores as opposed to other prediction tools such as exercise testing or frailty
      assessment. CONCLUSIONS: In this study, we observed that the combination of
      subjective assessment with a parsimonious risk model improved perioperative risk 
      estimation. This may be of value in helping clinicians allocate finite resources 
      such as critical care and to support patient involvement in clinical
      decision-making.
FAU - Wong, Danny J N
AU  - Wong DJN
AUID- ORCID: 0000-0002-3524-1766
AD  - UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine,
      Department for Targeted Intervention, Division of Surgery and Interventional
      Science, University College London, London, United Kingdom.
AD  - Health Services Research Centre, National Institute of Academic Anaesthesia,
      Royal College of Anaesthetists, London, United Kingdom.
FAU - Harris, Steve
AU  - Harris S
AUID- ORCID: 0000-0002-4982-1374
AD  - Bloomsbury Institute of Intensive Care Medicine, University College London,
      London, United Kingdom.
FAU - Sahni, Arun
AU  - Sahni A
AUID- ORCID: 0000-0002-7183-872X
AD  - UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine,
      Department for Targeted Intervention, Division of Surgery and Interventional
      Science, University College London, London, United Kingdom.
AD  - Health Services Research Centre, National Institute of Academic Anaesthesia,
      Royal College of Anaesthetists, London, United Kingdom.
FAU - Bedford, James R
AU  - Bedford JR
AUID- ORCID: 0000-0002-6045-3226
AD  - UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine,
      Department for Targeted Intervention, Division of Surgery and Interventional
      Science, University College London, London, United Kingdom.
AD  - Health Services Research Centre, National Institute of Academic Anaesthesia,
      Royal College of Anaesthetists, London, United Kingdom.
FAU - Cortes, Laura
AU  - Cortes L
AUID- ORCID: 0000-0001-9057-497X
AD  - Health Services Research Centre, National Institute of Academic Anaesthesia,
      Royal College of Anaesthetists, London, United Kingdom.
FAU - Shawyer, Richard
AU  - Shawyer R
AD  - Lay representative, United Kingdom.
FAU - Wilson, Andrew M
AU  - Wilson AM
AD  - Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
FAU - Lindsay, Helen A
AU  - Lindsay HA
AD  - Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
FAU - Campbell, Doug
AU  - Campbell D
AD  - Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
FAU - Popham, Scott
AU  - Popham S
AUID- ORCID: 0000-0003-1234-4655
AD  - Gold Coast University Hospital, Southport, Queensland, Australia.
FAU - Barneto, Lisa M
AU  - Barneto LM
AD  - Wellington Regional Hospital, Capital & Coast District Health Board, Wellington, 
      New Zealand.
FAU - Myles, Paul S
AU  - Myles PS
AUID- ORCID: 0000-0002-3324-5456
AD  - Department of Anaesthesiology and Perioperative Medicine, The Alfred Hospital,
      Melbourne, Victoria, Australia.
CN  - SNAP-2: EPICCS collaborators
FAU - Moonesinghe, S Ramani
AU  - Moonesinghe SR
AD  - UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine,
      Department for Targeted Intervention, Division of Surgery and Interventional
      Science, University College London, London, United Kingdom.
AD  - Health Services Research Centre, National Institute of Academic Anaesthesia,
      Royal College of Anaesthetists, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201015
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia
MH  - Clinical Decision Rules
MH  - *Decision Support Techniques
MH  - Female
MH  - Hospital Mortality/trends
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - New Zealand
MH  - Postoperative Complications/etiology
MH  - Prospective Studies
MH  - ROC Curve
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Surgical Procedures, Operative/*mortality
MH  - United Kingdom
PMC - PMC7561094
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/16 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/15 17:32
PHST- 2019/12/13 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/10/15 17:32 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1371/journal.pmed.1003253 [doi]
AID - PMEDICINE-D-19-04548 [pii]
PST - epublish
SO  - PLoS Med. 2020 Oct 15;17(10):e1003253. doi: 10.1371/journal.pmed.1003253.
      eCollection 2020 Oct.


PMID- 33057189
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 588
IP  - 7837
DP  - 2020 Dec
TI  - Institutions can retool to make research more rigorous.
PG  - 197
LID - 10.1038/d41586-020-02905-1 [doi]
FAU - Dirnagl, Ulrich
AU  - Dirnagl U
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - J Clin Epidemiol. 2019 Nov;115:37-45. PMID: 31195110
MH  - *Academic Medical Centers
MH  - *Research
OTO - NOTNLM
OT  - *Ethics
OT  - *Institutions
OT  - *Research management
EDAT- 2020/10/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/15 17:31
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/15 17:31 [entrez]
AID - 10.1038/d41586-020-02905-1 [doi]
AID - 10.1038/d41586-020-02905-1 [pii]
PST - ppublish
SO  - Nature. 2020 Dec;588(7837):197. doi: 10.1038/d41586-020-02905-1.


PMID- 33055136
OWN - NLM
STAT- Publisher
LR  - 20201015
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 14
TI  - Hope and therapeutic privilege: time for shared prognosis communication.
LID - medethics-2020-106157 [pii]
LID - 10.1136/medethics-2020-106157 [doi]
AB  - Communicating an unfavourable prognosis while maintaining patient hope represents
      a critical challenge for healthcare professionals (HPs). Duty requires respect
      for the right to patient autonomy while at the same time not doing harm by
      causing hopelessness and demoralisation. In some cases, the need for therapeutic 
      privilege is discussed. The primary objectives of this study were to explore HPs'
      perceptions of hope in the prognosis communication and investigate how they
      interpret and operationalise key ethical principles. Sixteen qualitative
      semistructured interviews with HPs from different positions and experience,
      including doctors and nurses in four different departments (intensive care,
      oncology, palliative care, rehabilitation), were conducted in the Ticino Cantonal
      Hospital, Switzerland. The interviews were recorded, transcribed verbatim and
      analysed using thematic analysis. HPs defined prognosis and patient hope as
      interdependent concepts related to future perspectives for subjective quality of 
      life. Two main factors allow HPs to maximise the benefits and minimise the harm
      of their communication: respecting the patient's timing and sharing the patient's
      wishes. Time is required to reframe needs and expectations. Furthermore,
      communication needs to be shared by HPs, patients and their relatives to build
      common awareness and promote a person-centred approach to prognosis. In this
      process, interprofessional collaboration is key: doctors and nurses are
      complementary and can together guarantee that patients and relatives receive
      information in the most appropriate form when they need it. Organisational
      aspects and the HPs' emotional difficulties, particularly in coping with their
      own despair, are barriers to effective communication that need further
      investigation.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Grignoli, Nicola
AU  - Grignoli N
AUID- ORCID: http://orcid.org/0000-0001-6028-2159
AD  - Sasso Corbaro Medical Humanities Foundation, Bellinzona, Switzerland
      nicola.grignoli@ti.ch.
AD  - Consultation-Liaison Psychiatry Service, Organizzazione Sociopsichiatrica
      Cantonale, Mendrisio, Switzerland.
AD  - Clinical Ethics Commission, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
FAU - Wullschleger, Roberta
AU  - Wullschleger R
AD  - Sasso Corbaro Medical Humanities Foundation, Bellinzona, Switzerland.
FAU - Di Bernardo, Valentina
AU  - Di Bernardo V
AD  - Sasso Corbaro Medical Humanities Foundation, Bellinzona, Switzerland.
AD  - Clinical Ethics Commission, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
FAU - Amati, Mirjam
AU  - Amati M
AD  - Department of Health Sciences and Medicine, University of Lucerne and Swiss
      Paraplegic Research, Lucerne/Nottwil, Switzerland.
AD  - Information and Process Management/Supportive Area, Ente Ospedaliero Cantonale,
      Bellinzona, Switzerland.
FAU - Zanini, Claudia
AU  - Zanini C
AD  - Department of Health Sciences and Medicine, University of Lucerne and Swiss
      Paraplegic Research, Lucerne/Nottwil, Switzerland.
AD  - Swiss Paraplegic Research, Nottwil, Switzerland.
FAU - Malacrida, Roberto
AU  - Malacrida R
AD  - Sasso Corbaro Medical Humanities Foundation, Bellinzona, Switzerland.
FAU - Rubinelli, Sara
AU  - Rubinelli S
AD  - Department of Health Sciences and Medicine, University of Lucerne and Swiss
      Paraplegic Research, Lucerne/Nottwil, Switzerland.
AD  - Swiss Paraplegic Research, Nottwil, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - autonomy
OT  - decision-making
OT  - ethics
OT  - professional - professional relationship
COIS- Competing interests: None declared.
EDAT- 2020/10/16 06:00
MHDA- 2020/10/16 06:00
CRDT- 2020/10/15 17:20
PHST- 2020/02/19 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/15 17:20 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/10/16 06:00 [medline]
AID - medethics-2020-106157 [pii]
AID - 10.1136/medethics-2020-106157 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 14. pii: medethics-2020-106157. doi:
      10.1136/medethics-2020-106157.


PMID- 33055135
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 14
TI  - How to reach trustworthy decisions for caesarean sections on maternal request: a 
      call for beneficial power.
LID - medethics-2020-106071 [pii]
LID - 10.1136/medethics-2020-106071 [doi]
AB  - Caesarean delivery is a common and life-saving intervention. However, it involves
      an overall increased risk for short-term and long-term complications for both
      mother and child compared with vaginal delivery. From a medical point of view,
      healthcare professionals should, therefore, not recommend caesarean sections
      without any anticipated medical benefit. Consequently, caesarean sections
      requested by women for maternal reasons can cause conflict between professional
      recommendations and maternal autonomy. How can we assure ethically justified
      decisions in the case of caesarean sections on maternal request in healthcare
      systems that also respect patients' autonomy and aspire for shared decisions? In 
      the maternal-professional relationship, which can be characterised in terms of
      reciprocal obligations and rights, women may not be entitled to demand a
      C-section. Nevertheless, women have a right to respect for their deliberative
      capacity in the decision-making process. How should we deal with a situation of
      non-agreement between a woman and healthcare professional when the woman requests
      a caesarean section in the absence of obvious medical indications? In this paper,
      we illustrate how the maternal-professional relationship is embedded in a nexus
      of power, trust and risk that reinforces a structural inferiority for women. To
      accommodate for beneficial use of power, these decision processes need to be
      trustworthy. We propose a framework, inspired by Lukes' three-dimensional notion 
      of power, which serves to facilitate trust and allows for beneficial power in
      shared processes of decision-making about the delivery mode for women requesting 
      planned C-sections.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Eide, Kristiane T
AU  - Eide KT
AD  - Department of Global Public Health and Primary Care, University of Bergen,
      Bergen, Hordaland, Norway kristiane.eide@uib.no.
FAU - Baeroe, Kristine
AU  - Baeroe K
AD  - Department of Global Public Health and Primary Care, University of Bergen,
      Bergen, Hordaland, Norway.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639926
OTO - NOTNLM
OT  - decision-making
OT  - ethics
OT  - obstetrics and gynaecology
OT  - women
COIS- Competing interests: None declared.
EDAT- 2020/10/16 06:00
MHDA- 2020/10/16 06:00
CRDT- 2020/10/15 17:20
PHST- 2020/01/14 00:00 [received]
PHST- 2020/08/12 00:00 [revised]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/10/15 17:20 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2020/10/16 06:00 [medline]
AID - medethics-2020-106071 [pii]
AID - 10.1136/medethics-2020-106071 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 14. pii: medethics-2020-106071. doi:
      10.1136/medethics-2020-106071.


PMID- 33055122
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 14
TI  - Trial of remote ischaemic preconditioning in vascular cognitive impairment
      (TRIC-VCI): protocol.
PG  - e040466
LID - 10.1136/bmjopen-2020-040466 [doi]
AB  - INTRODUCTION: Cerebral small vessel disease (cSVD) accounts for 20%-25% of
      strokes and is the most common cause of vascular cognitive impairment (VCI). In
      an animal VCI model, inducing brief periods of limb ischaemia-reperfusion reduces
      subsequent ischaemic brain injury with remote and local protective effects, with 
      hindlimb remote ischaemic conditioning (RIC) improving cerebral blood flow,
      decreasing white-matter injury and improving cognition. Small human trials
      suggest RIC is safe and may prevent recurrent strokes. It remains unclear what
      doses of chronic daily RIC are tolerable and safe, whether effects persist after 
      treatment cessation, and what parameters are optimal for treatment response.
      METHODS AND ANALYSIS: This prospective, open-label, randomised controlled trial
      (RCT) with blinded end point assessment and run-in period, will recruit 24
      participants, randomised to one of two RIC intensity groups: one arm treated once
      daily or one arm twice daily for 30 consecutive days. RIC will consistent of 4
      cycles of blood pressure cuff inflation to 200 mm Hg for 5 min followed by 5 min 
      deflation (total 35 min). Selection criteria include: age 60-85 years, evidence
      of cSVD on brain CT/MRI, Montreal Cognitive Assessment (MoCA) score 13-24 and
      preserved basic activities of living. Outcomes will be assessed at 30 days and 90
      days (60 days after ceasing treatment). The primary outcome is adherence
      (completing >/=80% of sessions). Secondary safety/tolerability outcomes include
      the per cent of sessions completed and pain/discomfort scores from patient
      diaries. Efficacy outcomes include changes in cerebral blood flow (per arterial
      spin-label MRI), white-matter hyperintensity volume, diffusion tensor imaging,
      MoCA and Trail-Making tests. ETHICS AND DISSEMINATION: Research Ethics Board
      approval has been obtained. The results will provide information on feasibility, 
      dose, adherence, tolerability and outcome measures that will help design a phase 
      IIb RCT of RIC, with the potential to prevent VCI. Results will be disseminated
      through peer-reviewed publications, organisations and meetings. TRIAL
      REGISTRATION NUMBER: NCT04109963.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ganesh, Aravind
AU  - Ganesh A
AUID- ORCID: 0000-0001-5520-2070
AD  - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Barber, Philip
AU  - Barber P
AD  - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Black, Sandra E
AU  - Black SE
AD  - Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada.
FAU - Corbett, Dale
AU  - Corbett D
AD  - Department of Cellular & Molecular Medicine, University of Ottawa, Ottawa,
      Ontario, Canada.
FAU - Field, Thalia S
AU  - Field TS
AD  - Department of Medicine (Neurology), University of British Columbia, Vancouver,
      British Columbia, Canada.
FAU - Frayne, Richard
AU  - Frayne R
AD  - Seaman Family MR Centre, University of Calgary, Calgary, Alberta, Canada.
AD  - Department of Radiology and Clinical Neurosciences, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Hachinski, Vladimir
AU  - Hachinski V
AD  - Department of Clinical Neurological Sciences, Western University, London,
      Ontario, Canada.
FAU - Ismail, Zahinoor
AU  - Ismail Z
AUID- ORCID: 0000-0002-5529-3731
AD  - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Mai, Lauren M
AU  - Mai LM
AD  - Department of Clinical Neurological Sciences, Western University, London,
      Ontario, Canada.
FAU - McCreary, Cheryl R
AU  - McCreary CR
AUID- ORCID: 0000-0003-1572-010X
AD  - Department of Clinical Neurosciences and Radiology, University of Calgary Faculty
      of Medicine, Calgary, Alberta, Canada.
FAU - Sahlas, Demetrios
AU  - Sahlas D
AD  - Department of Medicine (Neurology), McMaster University Population Health
      Research Institute, Hamilton, Ontario, Canada.
FAU - Sharma, Mukul
AU  - Sharma M
AD  - Department of Medicine (Neurology), McMaster University Population Health
      Research Institute, Hamilton, Ontario, Canada.
FAU - Swartz, Richard H
AU  - Swartz RH
AD  - Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada.
FAU - Smith, Eric E
AU  - Smith EE
AUID- ORCID: 0000-0003-3956-1668
AD  - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta,
      Canada eesmith@ucalgary.ca.
LA  - eng
SI  - ClinicalTrials.gov/NCT04109963
GR  - CNA-163902/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201014
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cognition
MH  - *Cognitive Dysfunction/prevention & control
MH  - Humans
MH  - Ischemia
MH  - *Ischemic Preconditioning
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/prevention & control
PMC - PMC7559076
OTO - NOTNLM
OT  - *clinical trials
OT  - *dementia
OT  - *stroke
COIS- Competing interests: AG has a patent pending for a system to deliver remote
      ischaemic conditioning, not related to the device (or manufacturer) being used in
      this trial. EES reports consulting fees from Alnylam Pharmaceuticals and Biogen; 
      and royalties from UpToDate.
EDAT- 2020/10/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/15 17:20
PHST- 2020/10/15 17:20 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040466 [pii]
AID - 10.1136/bmjopen-2020-040466 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 14;10(10):e040466. doi: 10.1136/bmjopen-2020-040466.


PMID- 33055118
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 14
TI  - Rehabilitative management of back pain in children: protocol for a mixed studies 
      systematic review.
PG  - e038534
LID - 10.1136/bmjopen-2020-038534 [doi]
AB  - INTRODUCTION: Little is known about effective, efficient and acceptable
      management of back pain in children. A comprehensive and updated evidence
      synthesis can help to inform clinical practice. OBJECTIVE: To inform clinical
      practice, we aim to conduct a systematic review of the literature and synthesise 
      the evidence regarding effective, cost-effective and safe rehabilitation
      interventions for children with back pain to improve their functioning and other 
      health outcomes. METHODS AND ANALYSIS: We will search MEDLINE, Embase, PsycINFO, 
      CINAHL, the Index to Chiropractic Literature, the Cochrane Controlled Register of
      Trials and EconLit for primary studies published from inception in all languages.
      We will include quantitative studies (randomised controlled trials, cohort and
      case-control studies), qualitative studies, mixed-methods studies and full
      economic evaluations. To augment our search of the bibliographic electronic
      databases, we will search reference lists of included studies and relevant
      systematic reviews, the WHO International Clinical Trials Registry Platform and
      consult with content experts. We will assess the risk of bias using appropriate
      critical appraisal tools. We will extract data about study and participant
      characteristics, intervention type and comparators, context and setting,
      outcomes, themes and methodological quality assessment. We will use a sequential 
      approach at the review level to integrate data from the quantitative, qualitative
      and economic evidence syntheses. ETHICS AND DISSEMINATION: Ethics approval is not
      required. We will disseminate findings through activities, including (1)
      presentations in national and international conferences; (2) meetings with
      national and international decision makers; (3) publications in peer-reviewed
      journals and (4) posts on organisational websites and social media. PROSPERO
      REGISTRATION NUMBER: CRD42019135009.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cancelliere, Carol
AU  - Cancelliere C
AUID- ORCID: 0000-0003-1883-4970
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada
      carolina.cancelliere@ontariotechu.ca.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
FAU - Wong, Jessica J
AU  - Wong JJ
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Epidemiology Division, Dalla Lana School of Public Health, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Division of Graduate Studies, Canadian Memorial Chiropractic College, Toronto,
      Ontario, Canada.
FAU - Yu, Hainan
AU  - Yu H
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Division of Graduate Studies, Canadian Memorial Chiropractic College, Toronto,
      Ontario, Canada.
FAU - Mior, Silvano
AU  - Mior S
AUID- ORCID: 0000-0001-6575-2797
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Division of Graduate Studies, Canadian Memorial Chiropractic College, Toronto,
      Ontario, Canada.
FAU - Brunton, Ginny
AU  - Brunton G
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - EPPI-Centre, UCL Institute of Education, University College London, England,
      United Kingdom.
AD  - McMaster Midwifery Research Centre, McMaster University, Hamilton, Ontario,
      Canada.
FAU - Shearer, Heather M
AU  - Shearer HM
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Rudoler, David
AU  - Rudoler D
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
FAU - Hestbaek, Lise
AU  - Hestbaek L
AD  - Department of Sport Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
AD  - Nordic Institute of Chiropractic and Clinical Biomechanics, Odense, Denmark.
FAU - Papaconstantinou, Efrosini
AU  - Papaconstantinou E
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
FAU - Cedraschi, Christine
AU  - Cedraschi C
AD  - Division of General Medical Rehabilitation, Geneva University and University
      Hospitals, Geneva, Switzerland.
AD  - Division of Clinical Pharmacology and Toxicology, Multidisciplinary Pain Centre, 
      Geneva University Hospitals, Geneva, Switzerland.
FAU - Swain, Michael
AU  - Swain M
AD  - Department of Chiropractic, Faculty of Science and Engineering, Macquarie
      University, Sydney, New South Wales, Australia.
FAU - Connell, Gaelan
AU  - Connell G
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Rehabilitation Sciences, Faculty of Medicine, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Verville, Leslie
AU  - Verville L
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
FAU - Taylor-Vaisey, Anne
AU  - Taylor-Vaisey A
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Division of Graduate Studies, Canadian Memorial Chiropractic College, Toronto,
      Ontario, Canada.
FAU - Cote, Pierre
AU  - Cote P
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
AD  - Epidemiology Division, Dalla Lana School of Public Health, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201014
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Back Pain
MH  - Case-Control Studies
MH  - Child
MH  - Cost-Benefit Analysis
MH  - Databases, Bibliographic
MH  - Humans
MH  - Qualitative Research
MH  - Systematic Reviews as Topic
PMC - PMC7559046
OTO - NOTNLM
OT  - *back pain
OT  - *health economics
OT  - *protocols & guidelines
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/15 17:20
PHST- 2020/10/15 17:20 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038534 [pii]
AID - 10.1136/bmjopen-2020-038534 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 14;10(10):e038534. doi: 10.1136/bmjopen-2020-038534.


PMID- 33055113
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 14
TI  - Intermittent antegrade warm-blood versus cold-blood cardioplegia in children
      undergoing open heart surgery: a protocol for a randomised controlled study
      (Thermic-3).
PG  - e036974
LID - 10.1136/bmjopen-2020-036974 [doi]
AB  - INTRODUCTION: Surgical repair of congenital heart defects often requires the use 
      of cardiopulmonary bypass (CPB) and cardioplegic arrest. Cardioplegia is used
      during cardiac surgery requiring CPB to keep the heart still and to reduce
      myocardial damage as a result of ischaemia-reperfusion injury. Cold cardioplegia 
      is the prevalent method of myocardial protection in paediatric patients; however,
      warm cardioplegia is used as part of usual care throughout the UK in adults. We
      aim to provide evidence to support the use of warm versus cold blood cardioplegia
      on clinical and biochemical outcomes during and after paediatric congenital heart
      surgery. METHODS AND ANALYSIS: We are conducting a single-centre randomised
      controlled trial in paediatric patients undergoing operations requiring CPB and
      cardioplegic arrest at the Bristol Royal Hospital for Children. We will randomise
      participants in a 1:1 ratio to receive either 'cold-blood cardioplegia' or
      'warm-blood cardioplegia'. The primary outcome will be the difference between
      groups with respect to Troponin T levels over the first 48 postoperative hours.
      Secondary outcomes will include measures of cardiac function; renal function;
      cerebral function; arrythmias during and postoperative hours; postoperative blood
      loss in the first 12 hours; vasoactive-inotrope score in the first 48 hours;
      intubation time; chest and wound infections; time from return from theatre until 
      fit for discharge; length of postoperative hospital stay; all-cause mortality to 
      3 months postoperative; myocardial injury at the molecular and cellular level.
      ETHICS AND DISSEMINATION: This trial has been approved by the London - Central
      Research Ethics Committee. Findings will be disseminated to the academic
      community through peer-reviewed publications and presentation at national and
      international meetings. Patients will be informed of the results through patient 
      organisations and newsletters to participants. TRIAL REGISTRATION NUMBER:
      ISRCTN13467772; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Heys, Rachael
AU  - Heys R
AUID- ORCID: 0000-0002-3957-1287
AD  - Bristol Trials Centre, Clincal Trials and Evaulation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK rh13369@bristol.ac.uk.
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
FAU - Stoica, Serban
AU  - Stoica S
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Angelini, Gianni
AU  - Angelini G
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
AD  - Bristol Heart Institue, University of Bristol, Bristol, UK.
FAU - Beringer, Richard
AU  - Beringer R
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Evans, Rebecca
AU  - Evans R
AD  - Bristol Trials Centre, Clincal Trials and Evaulation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
FAU - Ghorbel, Mohamed
AU  - Ghorbel M
AD  - Bristol Heart Institue, University of Bristol, Bristol, UK.
FAU - Lansdowne, William
AU  - Lansdowne W
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Parry, Andrew
AU  - Parry A
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Pieles, Guido
AU  - Pieles G
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Reeves, Barnaby
AU  - Reeves B
AUID- ORCID: 0000-0002-5101-9487
AD  - Bristol Trials Centre, Clincal Trials and Evaulation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
FAU - Rogers, Chris
AU  - Rogers C
AD  - Bristol Trials Centre, Clincal Trials and Evaulation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
FAU - Saxena, Rohit
AU  - Saxena R
AD  - Cardiac Intensive Care, Great Ormond Street Hospital For Children NHS Foundation 
      Trust, London, UK.
FAU - Sheehan, Karen
AU  - Sheehan K
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Smith, Stella
AU  - Smith S
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
FAU - Walker-Smith, Terrie
AU  - Walker-Smith T
AD  - Bristol Trials Centre, Clincal Trials and Evaulation Unit, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - Tulloh, Robert Mr
AU  - Tulloh RM
AD  - National Institute for Health Research Bristol Biomedical Research Centre,
      University Hospitals Bristol NHS Foundation Trust and University of Bristol,
      Bristol, UK.
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
AD  - Bristol Heart Institue, University of Bristol, Bristol, UK.
FAU - Caputo, Massimo
AU  - Caputo M
AD  - Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation 
      Trust, Bristol, UK.
LA  - eng
SI  - ISRCTN/ISRCTN13467772
GR  - PG/15/33/31394/BHF_/British Heart Foundation/United Kingdom
GR  - CH/1992027/7163/BHF_/British Heart Foundation/United Kingdom
GR  - CH/17/1/32804/BHF_/British Heart Foundation/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201014
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Cardiac Surgical Procedures
MH  - Cardiopulmonary Bypass
MH  - Child
MH  - Heart Arrest, Induced
MH  - *Heart Defects, Congenital/surgery
MH  - Humans
MH  - London
MH  - Randomized Controlled Trials as Topic
PMC - PMC7559029
OTO - NOTNLM
OT  - *cardiac surgery
OT  - *clinical trials
OT  - *congenital heart disease
OT  - *paediatric cardiothoracic surgery
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/15 17:20
PHST- 2020/10/15 17:20 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036974 [pii]
AID - 10.1136/bmjopen-2020-036974 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 14;10(10):e036974. doi: 10.1136/bmjopen-2020-036974.


PMID- 33054303
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
VI  - 112
IP  - 11
DP  - 2020 Nov
TI  - Spanish online survey on informed consent for the performance of paracentesis. Do
      we have it? Do we use it?
PG  - 854-859
LID - 10.17235/reed.2020.7179/2020 [doi]
AB  - INTRODUCTION: informed consent is necessary for invasive procedures as a document
      that guarantees the ethical health relationship and patient safety. AIMS: to
      analyze whether we have and use informed consent documents for paracentesis in
      our hospitals and to obtain data on the technique. METHODS: a descriptive
      observational study was performed during December 2019, via a cross-sectional
      survey disseminated through social networks, aimed at specialists and residents
      of gastroenterology. RESULTS: two hundred and three anonymous surveys were
      included (55.2 % gastroenterologist and 44.8 % residents) from 74 hospitals in 34
      Spanish provinces. Ninety respondents (44.3 %) stated that they had the document 
      in their centers. Of these, 29 (32.2 %) always provided it, 31 (34.4 %) provided 
      it sometimes and 21 (23.3 %) never. Seventy-two professionals (35.5 %) answered
      that they did not have it and 41 (20.5 %) selected "unknown". Of these, 77 (68.1 
      %) considered it was necessary to create this document, 31 (27.4 %) did not think
      it was necessary and five (4.4 %) did not answer. With regards to the technique, 
      173 (85.2 %) performed paracentesis under direct visualization and 30 (14.8 %)
      were eco-guided on most occasions. One hundred and nine (53.7 %) always applied
      local anesthetic, 80 (39.4 %) sometimes and 14 (6.9 %) did not. One hundred and
      sixty-seven respondents (82.3 %) considered it to be a simple technique versus 36
      (17.7 %) who thought that it was of intermediate complexity. In terms of risk,
      150 (73.5 %) considered it was low and 52 (25.6 %), medium. Ninety-nine (48.8 %) 
      experienced minor complications and 37 (18.2 %) experienced major complications. 
      CONCLUSIONS: paracentesis is a common technique in digestive services and could
      be associated with complications, even though it is considered to be simple and
      safe. Due to the important intra- and inter-hospital variability that this
      technique presents, we consider standardized training in this technique is
      necessary, as well as the creation, spread and use of informed consents.
FAU - Jimenez Sanchez, Javier
AU  - Jimenez Sanchez J
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Serrano Diaz, Lidia
AU  - Serrano Diaz L
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Chuni Jimenez, Diana
AU  - Chuni Jimenez D
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Ruiz Moreno, Miguel
AU  - Ruiz Moreno M
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Gallego Perez, Blanca
AU  - Gallego Perez B
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Marin Bernabe, Carmen Maria
AU  - Marin Bernabe CM
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Gomez Lozano, Maria
AU  - Gomez Lozano M
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Garcia Belmonte, Daniel
AU  - Garcia Belmonte D
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Gomez Espin, Rosa
AU  - Gomez Espin R
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Nicolas de Prado, Isabel
AU  - Nicolas de Prado I
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Hernandez Ortuno, Jose Enrique
AU  - Hernandez Ortuno JE
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Egea Simon, Esperanza
AU  - Egea Simon E
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
FAU - Martinez Crespo, Juan Jose
AU  - Martinez Crespo JJ
AD  - Aparato Digestivo, Hospital General Universitario Reina Sofia, Espana.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad
      Espanola de Patologia Digestiva
JID - 9007566
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Informed Consent
MH  - *Paracentesis
MH  - Surveys and Questionnaires
EDAT- 2020/10/16 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/10/15 17:05
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/10/15 17:05 [entrez]
AID - 10.17235/reed.2020.7179/2020 [doi]
PST - ppublish
SO  - Rev Esp Enferm Dig. 2020 Nov;112(11):854-859. doi: 10.17235/reed.2020.7179/2020.


PMID- 33053889
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1424-8220 (Electronic)
IS  - 1424-8220 (Linking)
VI  - 20
IP  - 20
DP  - 2020 Oct 12
TI  - Towards a Personalized Multi-Domain Digital Neurophenotyping Model for the
      Detection and Treatment of Mood Trajectories.
LID - E5781 [pii]
LID - 10.3390/s20205781 [doi]
AB  - The commercial availability of many real-life smart sensors, wearables, and
      mobile apps provides a valuable source of information about a wide range of human
      behavioral, physiological, and social markers that can be used to infer the
      user's mental state and mood. However, there are currently no commercial digital 
      products that integrate these psychosocial metrics with the real-time measurement
      of neural activity. In particular, electroencephalography (EEG) is a
      well-validated and highly sensitive neuroimaging method that yields robust
      markers of mood and affective processing, and has been widely used in mental
      health research for decades. The integration of wearable neuro-sensors into
      existing multimodal sensor arrays could hold great promise for deep digital
      neurophenotyping in the detection and personalized treatment of mood disorders.
      In this paper, we propose a multi-domain digital neurophenotyping model based on 
      the socioecological model of health. The proposed model presents a holistic
      approach to digital mental health, leveraging recent neuroscientific advances,
      and could deliver highly personalized diagnoses and treatments. The technological
      and ethical challenges of this model are discussed.
FAU - Sela, Yaron
AU  - Sela Y
AD  - The Research Center for Internet Psychology (CIP), Sammy Ofer School of
      Communication, Interdisciplinary Centre (IDC), Herzliya 4610101, Israel.
FAU - Santamaria, Lorena
AU  - Santamaria L
AUID- ORCID: 0000-0002-4876-8348
AD  - Cubric, School of Psychology, Cardiff University, Cardiff CF24 4HQ, UK.
FAU - Amichai-Hamburge, Yair
AU  - Amichai-Hamburge Y
AUID- ORCID: 0000-0003-3826-9737
AD  - The Research Center for Internet Psychology (CIP), Sammy Ofer School of
      Communication, Interdisciplinary Centre (IDC), Herzliya 4610101, Israel.
FAU - Leong, Victoria
AU  - Leong V
AUID- ORCID: 0000-0003-0666-9445
AD  - Division of Psychology, Nanyang Technological University, Singapore S639818,
      Singapore.
AD  - Department of Psychology, University of Cambridge, Cambridge CB2 3EB, UK.
LA  - eng
GR  - ES/N006461/1/Economic and Social Research Council
GR  - M4081585.SS0/Nanyang Technological University
GR  - M4012105.SS0/Ministry of Education - Singapore
PT  - Journal Article
DEP - 20201012
PL  - Switzerland
TA  - Sensors (Basel)
JT  - Sensors (Basel, Switzerland)
JID - 101204366
SB  - IM
MH  - *Affect
MH  - *Electroencephalography
MH  - Humans
MH  - Mental Health
MH  - *Mobile Applications
MH  - Technology
PMC - PMC7601670
OTO - NOTNLM
OT  - digital phenotyping
OT  - dual-EEG
OT  - mood disorders
OT  - neurosensors
EDAT- 2020/10/16 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/10/15 01:02
PHST- 2020/08/25 00:00 [received]
PHST- 2020/10/02 00:00 [revised]
PHST- 2020/10/08 00:00 [accepted]
PHST- 2020/10/15 01:02 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - s20205781 [pii]
AID - 10.3390/s20205781 [doi]
PST - epublish
SO  - Sensors (Basel). 2020 Oct 12;20(20). pii: s20205781. doi: 10.3390/s20205781.


PMID- 33053882
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 20
DP  - 2020 Oct 12
TI  - Cytomorphometric Analysis of Inflammation Dynamics in the Periodontium Following 
      the Use of Fixed Dental Prostheses.
LID - E4650 [pii]
LID - 10.3390/molecules25204650 [doi]
AB  - Cytomorphometry is used in the sampling of biological materials and diagnostic
      procedures. The use of cytological studies in periodontal diseases is not well
      described in the literature. Our study aimed to quantitatively assess the
      inflammation dynamics using cytomorphometric analysis of the periodontium before 
      and after the use of fixed dental prostheses. Following ethics approval, a total 
      of 105 subjects were divided in 3 groups as gingivitis (n = 23), periodontitis (n
      = 58), and healthy periodontium (control) (n = 24). The fixed dental prostheses
      (crowns and fixed partial dentures) were fabricated from cobalt-chrome
      metal-ceramic prostheses using the conventional method (C/M-CoCr), cobalt-chrome 
      metal-ceramic prostheses by the computer-aided design and computer-aided
      manufacturing (CAD/CAM) technique (C/C-CoCr), and zirconia-based ceramic
      prostheses by the CAD/CAM technique (C/C-Zr) among subjects with gingivitis and
      periodontitis. The gingival crevicular fluid (GCF) was obtained from subjects
      before and after the use of the prostheses. The total count of epithelial cells
      and the connective tissue cells or polymorphonuclear neutrophils (PMNs) in GCF
      were studied using cytomorphometric analysis. The Statistical Package Tor the
      Social Sciences (SPSS), Version 20 (IBM Company, Chicago, IL, USA) was used to
      analyze the results and the significance level was set at p = 0.05. The data for 
      before and after the use of the prostheses were compared using independent
      t-Tests. Similarly, the results after the use of prostheses in gingivitis,
      periodontitis, and control in each type of prostheses were compared using One-way
      ANOVA with post hoc using Scheffe. The total epithelial cells and the PMNs were
      determined along with the epithelium/leukocyte index. Regardless of the
      prostheses type used, no significant change in the parameters was identified
      among patients with a healthy periodontium, before and after prosthetic
      treatment. In all study groups, a statistically increase (p value < 0.05) was
      observed in the oral epithelial cell counts and a statistically decrease (p <
      0.05) in the PMNs count following the use of the fixed prostheses. Data on
      cytomorphometric analysis could enable the selection of the most appropriate
      prostheses for use in patients with periodontal pathologies. When choosing
      prostheses, changes in the composition of GCF could be considered as a useful
      criterion for their use.
FAU - Heboyan, Artak
AU  - Heboyan A
AUID- ORCID: 0000-0001-8329-3205
AD  - Department of Prosthodontics, Faculty of Stomatology, Yerevan State Medical
      University, Str. Koryun 2, Yerevan 0025, Armenia.
FAU - Syed, Azeem Ul Yaqin
AU  - Syed AUY
AUID- ORCID: 0000-0002-0116-7449
AD  - Department of Prosthodontics and Implantology, College of Dentistry, King Faisal 
      University, Al-Hofuf, Al-Ahsa 31982, Saudi Arabia.
FAU - Rokaya, Dinesh
AU  - Rokaya D
AUID- ORCID: 0000-0002-3854-667X
AD  - Department of Clinical Dentistry, Walailak University International College of
      Dentistry, Walailak University, Bangkok 10400, Thailand.
FAU - Cooper, Paul R
AU  - Cooper PR
AD  - Department of Oral Sciences, University of Otago, Faculty of Dentistry, Sir John 
      Walsh Research Institute, Dunedin 9054, New Zealand.
FAU - Manrikyan, Mikael
AU  - Manrikyan M
AD  - Department of Pediatric Dentistry and Orthodontics, Faculty of Stomatology,
      Yerevan State Medical University, Str. Koryun 2, Yerevan 0025, Armenia.
FAU - Markaryan, Marina
AU  - Markaryan M
AD  - Department of Therapeutic Stomatology, Faculty of Stomatology, Yerevan State
      Medical University, Str. Koryun 2, Yerevan 0025, Armenia.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
SB  - IM
MH  - Adult
MH  - Aged
MH  - Dental Prosthesis/*adverse effects
MH  - Epithelial Cells
MH  - Gingival Crevicular Fluid/immunology/metabolism
MH  - Gingivitis/immunology/metabolism
MH  - Humans
MH  - Inflammation/*immunology/*metabolism
MH  - Middle Aged
MH  - Neutrophils/immunology/metabolism
MH  - Periodontitis/immunology/metabolism
MH  - Periodontium/*immunology/*metabolism
PMC - PMC7587339
OTO - NOTNLM
OT  - CAD/CAM
OT  - epithelial cells
OT  - fixed partial dentures
OT  - gingival crevicular fluid
OT  - periodontium
OT  - polymorphonuclear neutrophils
EDAT- 2020/10/16 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/10/15 01:02
PHST- 2020/09/15 00:00 [received]
PHST- 2020/10/07 00:00 [revised]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/10/15 01:02 [entrez]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - molecules25204650 [pii]
AID - 10.3390/molecules25204650 [doi]
PST - epublish
SO  - Molecules. 2020 Oct 12;25(20). pii: molecules25204650. doi:
      10.3390/molecules25204650.


PMID- 33053578
OWN - NLM
STAT- Publisher
LR  - 20201029
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 72
IP  - 5
DP  - 2020 May 7
TI  - Bioethics in the COVID-19 Pandemic Research: Challenges and Strategies.
PG  - 265-270
LID - 10.24875/RIC.20000258 [doi]
AB  - As all other aspects in times of the coronavirus disease (COVID)-19 pandemic,
      carrying-out quality clinical research has been challenging. Many
      well-established paradigms have shifted as a consequence of the rapid demand for 
      new knowledge. New treatments are fast-moving, informed consent forms are
      difficult to obtain, a competitive invitation from researchers to participate in 
      different studies is common, and non-COVID-19 research protocols are suffering
      continuity. However, these challenges should not imply taking shortcuts or
      accepting deficiencies in bioethical standards, but rather enhance the alertness 
      for rigorous ethical approaches despite these less than ideal circumstances. In
      this manuscript, we point out some interrogates in COVID-19 research and outline 
      possible strategies to overcome the difficult task to continue with high-quality 
      research without violating the ethical principles.
FAU - Gonzalez-Duarte, Alejandra
AU  - Gonzalez-Duarte A
AD  - Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran, Mexico City, Mexico.
FAU - Kaufer-Horwitz, Martha
AU  - Kaufer-Horwitz M
AD  - Obesity and Eating Disorders Clinic, Department of Endocrinology, Instituto
      Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Aguilar-Salinas, Carlos A
AU  - Aguilar-Salinas CA
AD  - Metabolic Diseases Research Unit; Directorate of Nutrition, and 5Department of
      Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion 
      Salvador Zubiran, Mexico City; Tecnologico de Monterrey, School of Medicine and
      Health Sciences, Monterrey, N.L., Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la
      Nutricion
JID - 9421552
SB  - IM
EDAT- 2020/10/15 06:00
MHDA- 2020/10/15 06:00
CRDT- 2020/10/14 20:08
PHST- 2020/10/14 20:08 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/10/15 06:00 [medline]
AID - 10.24875/RIC.20000258 [doi]
PST - aheadofprint
SO  - Rev Invest Clin. 2020 May 7;72(5):265-270. doi: 10.24875/RIC.20000258.


PMID- 33053527
OWN - NLM
STAT- MEDLINE
DCOM- 20201016
LR  - 20201016
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 45
IP  - 8
DP  - 2020 Aug 28
TI  - Ethical guidelines for clinical research related to public health emergencies.
PG  - 881-885
LID - 1672-7347(2020)08-0881-05 [pii]
LID - 10.11817/j.issn.1672-7347.2020.200317 [doi]
AB  - Clinical research is an important part in responding to public health
      emergencies, reducing epidemic hazards, and protecting public health and life
      safety. However, different from the general clinical research, there are many
      uncertainties and knowledge gaps in the clinical research of public health
      emergencies, and there is no unified standard for the clinical research ethics of
      public health emergencies in the world, which poses a new challenge to the
      practice of ethical research in China. In this article, we will combine with the 
      ethical experience of clinical research on public health emergencies in China,
      propose the ethical guidelines for clinical research related to public health
      emergencies, including fast and efficient ethical review mechanism, scientific
      and reasonable research design, a reasonable balance of risk and benefit, adhere 
      to the fundamental value of bioethics, to ensure that fully informed consent, to 
      protect the subject's privacy, and recruiting fairly and reasonably. Further
      emphasized the prioritizing of public health and clinical emergency treatment,
      that is, under the situation of outbreak, all kinds of relevant public health
      clinical research can't affect the priority of epidemic prevention and control
      and clinical supportive treatment measures.
CN  - Professional Committee of Medical Ethics of Hunan Medical Association
CN  - Xiangya Hospital, Central South University
CN  - Center for Medical Humanities Research of Central South University
LA  - eng
LA  - chi
GR  - 160260007/Novel Coronavirus Pneumonia Prevention and Control First Emergency
      Project of Central South University, China
PT  - Journal Article
TT  - .
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University.
      Medical sciences
JID - 101230586
SB  - IM
MH  - China/epidemiology
MH  - *Emergencies
MH  - Humans
MH  - *Public Health
OTO - NOTNLM
OT  - clinical research
OT  - ethical guidelines
OT  - public health emergency
EDAT- 2020/10/15 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/14 20:08
PHST- 2020/10/14 20:08 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 1672-7347(2020)08-0881-05 [pii]
AID - 10.11817/j.issn.1672-7347.2020.200317 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Aug 28;45(8):881-885. doi:
      10.11817/j.issn.1672-7347.2020.200317.


PMID- 33053036
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201218
IS  - 1982-4335 (Electronic)
IS  - 0103-507X (Linking)
VI  - 32
IP  - 3
DP  - 2020 Jul-Sep
TI  - Challenges for the development of alternative low-cost ventilators during
      COVID-19 pandemic in Brazil.
PG  - 444-457
LID - S0103-507X2020000300444 [pii]
LID - 10.5935/0103-507X.20200075 [doi]
AB  - The COVID-19 pandemic has brought concerns to managers, healthcare professionals,
      and the general population related to the potential mechanical ventilators'
      shortage for severely ill patients. In Brazil, there are several initiatives
      aimed at producing alternative ventilators to cover this gap. To assist the teams
      that work in these initiatives, we provide a discussion of some basic concepts on
      physiology and respiratory mechanics, commonly used mechanical ventilation terms,
      the differences between triggering and cycling, the basic ventilation modes and
      other relevant aspects, such as mechanisms of ventilator-induced lung injury,
      respiratory drive, airway heating and humidification, cross-contamination risks, 
      and aerosol dissemination. After the prototype development phase, preclinical
      bench-tests and animal model trials are needed to determine the safety and
      performance of the ventilator, following the minimum technical requirements.
      Next, it is mandatory going through the regulatory procedures as required by the 
      Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria -
      ANVISA). The manufacturing company should be appropriately registered by ANVISA, 
      which also must be notified about the conduction of clinical trials, following
      the research protocol approval by the Research Ethics Committee. The registration
      requisition of the ventilator with ANVISA should include a dossier containing the
      information described in this paper, which is not intended to cover all related
      matters but to provide guidance on the required procedures.
FAU - Suzumura, Erica Aranha
AU  - Suzumura EA
AUID- ORCID: http://orcid.org/0000-0003-1752-6095
AD  - Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de Sao
      Paulo - Sao Paulo (SP), Brasil.
FAU - Zazula, Ana Denise
AU  - Zazula AD
AUID- ORCID: http://orcid.org/0000-0003-0946-3071
AD  - Faculdade de Medicina, Pontificia Universidade Catolica do Parana - Curitiba
      (PR), Brasil.
FAU - Moriya, Henrique Takachi
AU  - Moriya HT
AUID- ORCID: http://orcid.org/0000-0002-1595-1779
AD  - Laboratorio de Engenharia Biomedica, Escola Politecnica, Universidade de Sao
      Paulo - Sao Paulo (SP), Brasil.
FAU - Fais, Cristina Quemelo Adami
AU  - Fais CQA
AD  - Gerencia de Tecnologia em Equipamentos, Gerencia-Geral de Tecnologia em Produtos 
      para a Saude, 3 feminine Diretoria, Agencia Nacional de Vigilancia Sanitaria -
      Brasilia (DF), Brasil.
FAU - Alvarado, Alembert Lino
AU  - Alvarado AL
AUID- ORCID: http://orcid.org/0000-0002-6173-5428
AD  - Laboratorio de Engenharia Biomedica, Escola Politecnica, Universidade de Sao
      Paulo - Sao Paulo (SP), Brasil.
FAU - Cavalcanti, Alexandre Biasi
AU  - Cavalcanti AB
AUID- ORCID: http://orcid.org/0000-0003-2798-6263
AD  - Instituto de Pesquisa, HCor-Hospital do Coracao, Sao Paulo - (SP), Brasil.
FAU - Rodrigues, Ricardo Goulart
AU  - Rodrigues RG
AD  - Servico de Terapia Intensiva, Hospital do Servidor Publico Estadual "Francisco
      Morato de Oliveira" - Sao Paulo (SP), Brasil.
LA  - por
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Desafios para o desenvolvimento de ventiladores alternativos de baixo custo
      durante a pandemia de COVID-19 no Brasil.
PL  - Brazil
TA  - Rev Bras Ter Intensiva
JT  - Revista Brasileira de terapia intensiva
JID - 9506692
SB  - IM
MH  - Animals
MH  - Brazil/epidemiology
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Equipment Design
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Respiration, Artificial/*instrumentation
MH  - Respiratory Mechanics
MH  - Ventilator-Induced Lung Injury/prevention & control
MH  - *Ventilators, Mechanical
PMC - PMC7595729
EDAT- 2020/10/15 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/14 18:00
PHST- 2019/05/27 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/10/14 18:00 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - S0103-507X2020000300444 [pii]
AID - 10.5935/0103-507X.20200075 [doi]
PST - ppublish
SO  - Rev Bras Ter Intensiva. 2020 Jul-Sep;32(3):444-457. doi:
      10.5935/0103-507X.20200075.


PMID- 33052741
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1546-3141 (Electronic)
IS  - 0361-803X (Linking)
VI  - 215
IP  - 6
DP  - 2020 Dec
TI  - Recurrent Hemoptysis After Bronchial Artery Embolization: Prediction Using a
      Nomogram and Artificial Neural Network Model.
PG  - 1490-1498
LID - 10.2214/AJR.20.22775 [doi]
AB  - OBJECTIVE. The purpose of this study was to develop an effective nomogram and
      artificial neural network (ANN) model for predicting recurrent hemoptysis after
      bronchial artery embolization (BAE). MATERIALS AND METHODS. The institutional
      ethics review boards of the two participating hospitals approved this study.
      Patients with hemoptysis who were treated with BAE were allocated to either the
      training cohort (Hospital A) or the validation cohort (Hospital B). The
      predictors of recurrent hemoptysis were identified by univariable and
      multivariable analyses in the training cohort. A nomogram and ANN model were then
      developed, and the accuracy was validated by the Harrell C statistic and ROC
      curves in both the training and validation cohorts. RESULTS. A total of 242
      patients (training cohort, 141; validation cohort, 101) were enrolled in this
      study. The univariable and multivariable analyses revealed that age of 60 years
      old or older (hazard ratio [HR], 3.921; 95% CI, 1.267-12.127; p = 0.018), lung
      cancer (HR, 18.057; 95% CI, 4.124-79.068; p < 0.001), bronchial-pulmonary shunts 
      (HR, 11.981; 95% CI, 2.593-55.356; p = 0.001), and nonbronchial systemic artery
      involvement (HR, 4.194; 95% CI, 1.596-11.024; p = 0.004) were predictors of
      recurrent hemoptysis. The developed nomogram and ANN model had high accuracy,
      with a Harrell C statistic of 0.849 (95% CI, 0.778-0.919) internally (for the
      training cohort) and 0.799 (95% CI, 0.701-0.897) externally (for the validation
      cohort). The optimal cutoff value of the recurrent hemoptysis risk was 0.16.
      CONCLUSION. The nomogram and ANN model could effectively predict the risk for
      recurrent hemoptysis after BAE. Further interventions should be considered for
      patients with a high suspicion of risk (> 0.16) according to the nomogram.
FAU - Xu, Sheng
AU  - Xu S
AD  - Department of Interventional Therapy, Inner Mongolia People's Hospital, 20
      Zhaowuda Rd, Huhhot, 010017, China.
FAU - Guan, Li-Jun
AU  - Guan LJ
AD  - Department of Interventional Radiology, The Affiliated Hospital of Inner Mongolia
      Medical University, Huhhot, China.
FAU - Shi, Bao-Qi
AU  - Shi BQ
AD  - Department of Interventional Therapy, Inner Mongolia People's Hospital, 20
      Zhaowuda Rd, Huhhot, 010017, China.
FAU - Tan, Yong-Sheng
AU  - Tan YS
AD  - Department of Interventional Therapy, Inner Mongolia People's Hospital, 20
      Zhaowuda Rd, Huhhot, 010017, China.
FAU - Zhang, Xue-Jun
AU  - Zhang XJ
AD  - Department of Interventional Therapy, Inner Mongolia People's Hospital, 20
      Zhaowuda Rd, Huhhot, 010017, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201014
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
SB  - IM
MH  - Aged
MH  - *Bronchial Arteries
MH  - *Embolization, Therapeutic
MH  - Female
MH  - Hemoptysis/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Neural Networks, Computer
MH  - Nomograms
MH  - Recurrence
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *bronchial artery embolization
OT  - *hemoptysis
OT  - *prediction
OT  - *recurrence
EDAT- 2020/10/15 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/10/14 17:58
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
PHST- 2020/10/14 17:58 [entrez]
AID - 10.2214/AJR.20.22775 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 2020 Dec;215(6):1490-1498. doi: 10.2214/AJR.20.22775. Epub
      2020 Oct 14.


PMID- 33052391
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20211204
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 324
IP  - 20
DP  - 2020 Nov 24
TI  - Is It Lawful and Ethical to Prioritize Racial Minorities for COVID-19 Vaccines?
PG  - 2023-2024
LID - 10.1001/jama.2020.20571 [doi]
FAU - Schmidt, Harald
AU  - Schmidt H
AD  - Perelman School of Medicine, University of Pennsylvania, Philadelphia.
FAU - Gostin, Lawrence O
AU  - Gostin LO
AD  - O'Neill Institute for National & Global Health Law, Georgetown University,
      Washington, DC.
FAU - Williams, Michelle A
AU  - Williams MA
AD  - Harvard T.H. Chan School of Public Health, Harvard University, Boston,
      Massachusetts.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - COVID-19/*prevention & control
MH  - COVID-19 Vaccines/*administration & dosage
MH  - Health Care Rationing/ethics
MH  - Health Priorities/ethics
MH  - Health Status Disparities
MH  - Humans
MH  - *Minority Groups
MH  - Pandemics
MH  - *Racial Groups
MH  - Vaccination/*ethics
EDAT- 2020/10/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/14 12:44
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/14 12:44 [entrez]
AID - 2771874 [pii]
AID - 10.1001/jama.2020.20571 [doi]
PST - ppublish
SO  - JAMA. 2020 Nov 24;324(20):2023-2024. doi: 10.1001/jama.2020.20571.


PMID- 33052131
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 14
TI  - Comparing Web-Based Mindfulness With Loving-Kindness and Compassion Training for 
      Promoting Well-Being in Pregnancy: Protocol for a Three-Arm Pilot Randomized
      Controlled Trial.
PG  - e19803
LID - 10.2196/19803 [doi]
AB  - BACKGROUND: Promoting psychological well-being and preventing distress among
      pregnant women is an important public health goal. In addition to adversely
      impacting the mother's health and well-being, psychological distress in pregnancy
      increases the risk of poor pregnancy outcomes, compromises infant socioemotional 
      development and bonding, and heightens maternal and child vulnerability in the
      postpartum period. Mindfulness and compassion-based interventions show potential 
      for prevention and early intervention for perinatal distress. As there is an
      established need for accessible, scalable, flexible, and low-cost interventions, 
      there is increased interest in the delivery of these programs on the web. This
      project aims to pilot a three-arm randomized controlled trial (RCT) to determine 
      the feasibility of a full-scale RCT comparing 2 web-based interventions
      (mindfulness vs loving-kindness and compassion) with a web-based active control
      condition (progressive muscle relaxation). OBJECTIVE: The primary objective of
      this study is to assess the feasibility of an RCT protocol comparing the 3
      conditions delivered on the web as a series of instructional materials and brief 
      daily practices over a course of 8 weeks. The second objective is to explore the 
      experiences of women in the different intervention conditions. The third
      objective is to estimate SD values for the outcome measures to inform the design 
      of an adequately powered trial to determine the comparative efficacy of the
      different conditions. METHODS: Pregnant women (n=75) participating in a
      longitudinal birth cohort study (the ORIGINS project) will be recruited to this
      study from 18 weeks of gestational age. We will assess the acceptability and
      feasibility of recruitment and retention strategies and the participants'
      engagement and adherence to the interventions. We will also assess the
      experiences of women in each of the 3 intervention conditions by measuring weekly
      changes in their well-being and engagement with the program and by conducting a
      qualitative analysis of postprogram interviews. RESULTS: This project was funded 
      in September 2019 and received ethics approval on July 8, 2020. Enrollment to the
      study will commence in September 2020. Feasibility of a full-scale RCT will be
      assessed using ADePT (a process for decision making after pilot and feasibility
      trials) criteria. CONCLUSIONS: If the study is shown to be feasible, results will
      be used to inform future full-scale RCTs. Evidence for flexible, scalable, and
      low-cost interventions could inform population health strategies to promote
      well-being and reduce psychological distress among pregnant women. TRIAL
      REGISTRATION: Australian New Zealand Clinical Trials Registry Number
      12620000672954p; http://anzctr.org.au/ACTRN12620000672954p.aspx. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/19803.
CI  - (c)Amy Louise Finlay-Jones, Jacqueline Ann Davis, Amanda O'Donovan, Keerthi
      Kottampally, Rebecca Anne Ashley, Desiree Silva, Jeneva Lee Ohan, Susan L
      Prescott, Jenny Downs. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 14.10.2020.
FAU - Finlay-Jones, Amy Louise
AU  - Finlay-Jones AL
AUID- ORCID: https://orcid.org/0000-0002-1336-4001
AD  - Telethon Kids Institute, Nedlands, Australia.
AD  - Curtin University, Bentley, Australia.
AD  - University of Western Australia, Crawley, Australia.
FAU - Davis, Jacqueline Ann
AU  - Davis JA
AUID- ORCID: https://orcid.org/0000-0003-3590-431X
AD  - Telethon Kids Institute, Nedlands, Australia.
AD  - Curtin University, Bentley, Australia.
AD  - University of Western Australia, Crawley, Australia.
FAU - O'Donovan, Amanda
AU  - O'Donovan A
AUID- ORCID: https://orcid.org/0000-0003-1542-0078
AD  - Murdoch University, Murdoch, Australia.
FAU - Kottampally, Keerthi
AU  - Kottampally K
AUID- ORCID: https://orcid.org/0000-0002-3637-304X
AD  - Telethon Kids Institute, Nedlands, Australia.
AD  - University of Western Australia, Crawley, Australia.
FAU - Ashley, Rebecca Anne
AU  - Ashley RA
AUID- ORCID: https://orcid.org/0000-0002-5437-0002
AD  - Murdoch University, Murdoch, Australia.
FAU - Silva, Desiree
AU  - Silva D
AUID- ORCID: https://orcid.org/0000-0003-4454-466X
AD  - Telethon Kids Institute, Nedlands, Australia.
AD  - University of Western Australia, Crawley, Australia.
AD  - Edith Cowan University, Joondalup, Australia.
AD  - Joondalup Health Campus, Joondalup, Australia.
FAU - Ohan, Jeneva Lee
AU  - Ohan JL
AUID- ORCID: https://orcid.org/0000-0002-4801-4239
AD  - University of Western Australia, Crawley, Australia.
FAU - Prescott, Susan L
AU  - Prescott SL
AUID- ORCID: https://orcid.org/0000-0003-4845-8590
AD  - Telethon Kids Institute, Nedlands, Australia.
AD  - University of Western Australia, Crawley, Australia.
AD  - Perth Children's Hospital, Nedlands, Australia.
FAU - Downs, Jenny
AU  - Downs J
AUID- ORCID: https://orcid.org/0000-0001-7358-9037
AD  - Telethon Kids Institute, Nedlands, Australia.
AD  - Curtin University, Bentley, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7593853
OTO - NOTNLM
OT  - compassion
OT  - intervention
OT  - mental health
OT  - mindfulness
OT  - pregnancy
OT  - public health
OT  - telemedicine
EDAT- 2020/10/15 06:00
MHDA- 2020/10/15 06:01
CRDT- 2020/10/14 12:43
PHST- 2020/05/09 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/10/14 12:43 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/10/15 06:01 [medline]
AID - v9i10e19803 [pii]
AID - 10.2196/19803 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 14;9(10):e19803. doi: 10.2196/19803.


PMID- 33051713
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20211204
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 21
IP  - 7
DP  - 2020 Oct 13
TI  - In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations
      Administered with Drinks and Soft Foods to Infants.
PG  - 282
LID - 10.1208/s12249-020-01825-7 [doi]
AB  - In vitro dissolution testing conditions that reflect and predict in vivo drug
      product performance are advantageous, especially for the development of
      paediatric medicines, as clinical testing in this population is hindered by
      ethical and technical considerations. The aim of this study was to develop an in 
      vivo predictive dissolution test in order to investigate the impact of medicine
      co-administration with soft food and drinks on the dissolution performance of a
      poorly soluble compound. Relevant in vitro dissolution conditions simulating the 
      in vivo gastrointestinal environment of infants were used to establish in
      vitro-in vivo relationships with corresponding in vivo data. Dissolution studies 
      of montelukast formulations were conducted with mini-paddle apparatus on a
      two-stage approach: infant fasted-state simulated gastric fluid (Pi-FaSSGF; for 1
      h) followed by either infant fasted-state or infant fed-state simulated
      intestinal fluid (FaSSIF-V2 or Pi-FeSSIF, respectively; for 3 h). The dosing
      scenarios tested reflected in vivo paediatric administration practices: (i.)
      direct administration of formulation; (ii.) formulation co-administered with
      vehicles (formula, milk or applesauce). Drug dissolution was significantly
      affected by co-administration of the formulation with vehicles compared with
      after direct administration of the formulation. Montelukast dissolution from the 
      granules was significantly higher under fed-state simulated intestinal conditions
      in comparison with the fasted state and was predictive of the in vivo performance
      when the granules are co-administered with milk. This study supports the
      potential utility of the in vitro biorelevant dissolution approach proposed to
      predict in vivo formulation performance after co-administration with vehicles, in
      the paediatric population.
FAU - Martir, J
AU  - Martir J
AD  - Department of Pharmacy and Pharmacology, University of Bath, Claverton Down,
      Bath, BA2 7AY, UK.
FAU - Flanagan, T
AU  - Flanagan T
AD  - Oral Product Development, Pharmaceutical Technology & Development, Operations,
      AstraZeneca, Macclesfield, UK.
AD  - UCB Pharma, Chemin du Foriest, B - 1420, Braine-l'Alleud, Belgium.
FAU - Mann, J
AU  - Mann J
AD  - Oral Product Development, Pharmaceutical Technology & Development, Operations,
      AstraZeneca, Macclesfield, UK.
FAU - Fotaki, N
AU  - Fotaki N
AUID- ORCID: http://orcid.org/0000-0003-1826-7363
AD  - Department of Pharmacy and Pharmacology, University of Bath, Claverton Down,
      Bath, BA2 7AY, UK. n.fotaki@bath.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Acetates)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Cyclopropanes)
RN  - 0 (Pharmaceutical Vehicles)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/*administration & dosage/*chemistry
MH  - Animals
MH  - Anti-Asthmatic Agents/*administration & dosage/*chemistry
MH  - Area Under Curve
MH  - Beverages
MH  - Cyclopropanes
MH  - Drug Compounding
MH  - Fasting
MH  - Food
MH  - Humans
MH  - Infant
MH  - Milk
MH  - Pharmaceutical Vehicles
MH  - Quinolines/*administration & dosage/*chemistry
MH  - Solubility
MH  - Sulfides
PMC - PMC7554011
OTO - NOTNLM
OT  - drug manipulation
OT  - food
OT  - in vitro dissolution
OT  - in vitro-in vivo relationship
OT  - mini-paddle
OT  - paediatric biorelevant media
OT  - paediatrics
EDAT- 2020/10/15 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/10/14 09:17
PHST- 2020/05/06 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/14 09:17 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.1208/s12249-020-01825-7 [doi]
AID - 10.1208/s12249-020-01825-7 [pii]
PST - epublish
SO  - AAPS PharmSciTech. 2020 Oct 13;21(7):282. doi: 10.1208/s12249-020-01825-7.


PMID- 33051635
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2208-7958 (Electronic)
VI  - 49
DP  - 2020 Sep 9
TI  - Australia needs a vaccine injury compensation scheme: Upcoming COVID-19 vaccines 
      make its introduction urgent.
LID - 10.31128/AJGP-COVID-36 [doi]
AB  - There is a strong public health ethical justification to introduce a vaccine
      injury compensation scheme in Australia, and it needs to be in place before
      widespread use of COVID-19 vaccines.
FAU - Wood, Nicholas
AU  - Wood N
AD  - MBBS, PhD, FRACP, Senior Staff Specialist, National Centre for Immunisation
      Research and Surveillance, The Children@s Hospital at Westmead, NSW; Associate
      Professor, The University of Sydney Children@s Hospital Westmead Clinical School,
      NSW.
FAU - Macartney, Kristine
AU  - Macartney K
AD  - MD, FRACP, Professor, Faculty of Medicine and Health, The University of Sydney,
      NSW; Director, The National Centre for Immunisation Research and Surveillance
      (NCIRS), NSW.
FAU - Leask, Julie
AU  - Leask J
AD  - PhD, MPH, Dip Health Sci (Nursing), Professor, Susan Wakil School of Nursing and 
      Midwifery, Faculty of Medicine and Health, The University of Sydney, NSW;
      Visiting Professorial Fellow, National Centre for Immunisation Research and
      Surveillance, NSW.
FAU - McIntyre, Peter
AU  - McIntyre P
AD  - PhD, FRACP, Professorial Fellow, National Centre for Immunisation Research and
      Surveillance (NCIRS), NSW; Professor, Faculty of Medicine and Health, The
      University of Sydney Children@s Hospital Westmead, NSW.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - Australia
TA  - Aust J Gen Pract
JT  - Australian journal of general practice
JID - 101718099
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Vaccines)
SB  - IM
MH  - Australia
MH  - *COVID-19
MH  - COVID-19 Vaccines
MH  - Humans
MH  - SARS-CoV-2
MH  - *Vaccines/adverse effects
EDAT- 2020/10/15 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/14 09:17
PHST- 2020/10/14 09:17 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 10.31128/AJGP-COVID-36 [doi]
PST - epublish
SO  - Aust J Gen Pract. 2020 Sep 9;49. doi: 10.31128/AJGP-COVID-36.


PMID- 33051381
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Compensating for research risk: permissible but not obligatory.
PG  - 827-828
LID - 10.1136/medethics-2020-106829 [doi]
FAU - Fernandez Lynch, Holly
AU  - Fernandez Lynch H
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA
      lynchhf@pennmedicine.upenn.edu.
FAU - Largent, Emily A
AU  - Largent EA
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20201013
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Dec;46(12):815-826. PMID: 32978306
CIN - J Med Ethics. 2020 Dec;46(12):837-839. PMID: 33234546
MH  - Attitude
MH  - *Human Experimentation
MH  - Humans
MH  - *Informed Consent
OTO - NOTNLM
OT  - *clinical trials
OT  - *coercion
OT  - *informed consent
OT  - *research ethics
COIS- Competing interests: Both authors received an honorarium from 1Day Sooner for
      producing an independent report on the ethics of payment for participation in
      human infection challenge studies:
      https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3674548.
EDAT- 2020/10/15 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/10/14 09:12
PHST- 2020/09/14 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/10/14 09:12 [entrez]
AID - medethics-2020-106829 [pii]
AID - 10.1136/medethics-2020-106829 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):827-828. doi: 10.1136/medethics-2020-106829. Epub
      2020 Oct 13.


PMID- 33051380
OWN - NLM
STAT- Publisher
LR  - 20201014
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 13
TI  - Do private German health insurers invest their capital reserves of euro353
      billion according to environmental, social and governance criteria?
LID - medethics-2020-106381 [pii]
LID - 10.1136/medethics-2020-106381 [doi]
AB  - BACKGROUND: To prevent the planet from catastrophic global warming a reduction of
      greenhouse gas emissions to net zero is required. Thus, divestment from fossil
      fuels must be a strategic interest for health insurers. The aim of this study was
      to analyse the implementation of environmental, social and governance (ESG)
      criteria in German private health insurers' investments. METHODS: In 2019 a
      survey about ESG strategies was sent to German private health insurance
      companies. The survey evaluated investment strategies and thresholds for the
      exclusion of sectors and business practices, as well as company strategies for
      sustainable business development. FINDINGS: Given their business reports, German 
      private health insurers manage assets of more than euro350 billion. 11 of 40
      insurance companies provided quantitative data, 10 refused to answer. According
      to quantitative data, euro66 billion of assets is managed according to any ESG
      criteria; this equals an average of 76% of each company's bonds. None of these
      insurers excluded the production and sale of fossil fuels. All excluded coal
      mining but only at high thresholds. For euro226 billion, no data were provided.
      INTERPRETATION: The findings are in contrast to the expected intrinsic economic
      interest of the insurers to stop global warming and improve public health. The
      majority of assets are managed in a highly problematic manner, especially the
      absence of capital allocated in fields contrary to medical ethics (eg, firearms, 
      armour) cannot be presumed. Lack of transparency is a major problem that limits
      clients in choosing the insurer who has the most advanced ESG criteria.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Schneider, Frederick
AU  - Schneider F
AUID- ORCID: http://orcid.org/0000-0002-1952-0124
AD  - Department of Anesthesiology and Intensive Care, TUM School of Medicine,
      Technical University of Munich, Munchen, Germany frederick.schneider@tum.de.
FAU - Gogolewska, Julia
AU  - Gogolewska J
AD  - KLUG-Deutsche Allianz Klimawandel und Gesundheit, Berlin, Germany.
FAU - Ahrend, Klaus-Michael
AU  - Ahrend KM
AD  - Fachbereich Wirtschaft, Hochschule Darmstadt, Darmstadt, Hessen, Germany.
FAU - Hohendorf, Gerrit
AU  - Hohendorf G
AD  - Department of Medical Ethics and History, TUM School of Medicine, Technical
      University of Munich, Munchen, Germany.
FAU - Schneider, Gerhard
AU  - Schneider G
AD  - Department of Anesthesiology and Intensive Care, TUM School of Medicine,
      Technical University of Munich, Munchen, Germany.
FAU - Busse, Reinhard
AU  - Busse R
AD  - Fakultat Wirtschaft und Management, Technische Universitat Berlin, Berlin,
      Germany.
FAU - Schulz, Christian M
AU  - Schulz CM
AD  - Department of Anesthesiology and Intensive Care, TUM School of Medicine,
      Technical University of Munich, Munchen, Germany.
AD  - KLUG-Deutsche Allianz Klimawandel und Gesundheit, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - environmental ethics
OT  - health care economics
OT  - interests of health personnel/institutions
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/10/15 06:00
MHDA- 2020/10/15 06:00
CRDT- 2020/10/14 09:12
PHST- 2020/05/04 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/10/14 09:12 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/10/15 06:00 [medline]
AID - medethics-2020-106381 [pii]
AID - 10.1136/medethics-2020-106381 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 13. pii: medethics-2020-106381. doi:
      10.1136/medethics-2020-106381.


PMID- 33051236
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 13
TI  - Do lifestyle measures to counter COVID-19 affect frailty rates in elderly
      community dwelling? Protocol for cross-sectional and cohort study.
PG  - e040341
LID - 10.1136/bmjopen-2020-040341 [doi]
AB  - INTRODUCTION: Local activities that functioned to prevent frailty in the elderly 
      have been suspended or reduced as a countermeasure against COVID-19. As a result,
      frailty rates are expected to increase, and frailty is expected to worsen as a
      secondary problem associated with COVID-19 countermeasures. Therefore, this study
      aims to determine the extent of frailty in the elderly associated with lifestyle 
      changes implemented as COVID-19 countermeasures, to ascertain actual lifestyle
      changes and clarify the existence of Corona-Frailty. We will also conduct
      Corona-Frailty screening to verify the effect of support provided as feedback to 
      supporters of the elderly. METHODS AND ANALYSIS: The survey target area is
      Takasaki City, Gunma Prefecture, Japan. Phase I aims to verify the short-term
      effects of COVID-19. A questionnaire will be distributed to 465
      community-dwelling elderly people, and responses will be obtained by post.
      Frailty will be evaluated using the Frailty Screening Index. Respondents who are 
      frail and have had many changes in their lifestyle will be screened as high-risk 
      people, and feedback will be provided to local supporters. The aim of Phase II
      will be to verify the long-term effects of COVID-19 and the effect of screening. 
      A similar survey will be distributed twice after the first survey, once after 6
      months and again after 1 year and the frailty rate will be tested. Furthermore,
      out of the subjects identified with frailty in Phase I, the progress of those who
      were screened and those who were not screened will be compared between groups.
      ETHICS AND DISSEMINATION: This study has been approved by the Research Ethics
      Committee of the Takasaki University of Health and Welfare (approval number:
      2009). The results of this study will be reported to the policymaker, presented
      at academic conferences and published in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: UMIN000040335.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shinohara, Tomoyuki
AU  - Shinohara T
AUID- ORCID: 0000-0002-4213-6841
AD  - Department of Physical Therapy, Faculty of Health Care, Takasaki University of
      Health and Welfare, Takasaki, Gunma, Japan shinohara-t@takasaki-u.ac.jp.
FAU - Saida, Kosuke
AU  - Saida K
AD  - Department of Physical Therapy, Faculty of Health Care, Takasaki University of
      Health and Welfare, Takasaki, Gunma, Japan.
FAU - Tanaka, Shigeya
AU  - Tanaka S
AD  - Department of Physical Therapy, Faculty of Health Care, Takasaki University of
      Health and Welfare, Takasaki, Gunma, Japan.
FAU - Murayama, Akihiko
AU  - Murayama A
AD  - Department of Physical Therapy, Faculty of Rehabilitation, Gunma University of
      Health and Welfare, Maebashi, Gunma, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201013
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Aging/physiology
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - Coronavirus Infections/*epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Frail Elderly/*statistics & numerical data
MH  - Frailty/*epidemiology
MH  - Geriatric Assessment/*methods
MH  - Humans
MH  - Independent Living/*statistics & numerical data
MH  - *Life Style
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
PMC - PMC7554407
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *preventive medicine
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/15 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/10/14 09:11
PHST- 2020/10/14 09:11 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - bmjopen-2020-040341 [pii]
AID - 10.1136/bmjopen-2020-040341 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 13;10(10):e040341. doi: 10.1136/bmjopen-2020-040341.


PMID- 33051233
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 13
TI  - Perioperative intravenous lignocaine infusion for postoperative pain control in
      patients undergoing surgery of the spine: protocol for a systematic review and
      meta-analysis.
PG  - e036908
LID - 10.1136/bmjopen-2020-036908 [doi]
AB  - INTRODUCTION: Intravenous lignocaine is an amide local anaesthetic known for its 
      analgesic, antihyperalgesic and anti-inflammatory properties. Administration of
      intravenous lignocaine has been shown to enhance perioperative recovery
      parameters. This is the protocol for a systematic review which intends to
      summarise the evidence base for perioperative intravenous lignocaine
      administration in patients undergoing spinal surgery. METHODS AND ANALYSIS: Our
      primary outcomes include: postoperative pain scores at rest and movement at
      predefined early, intermediate and late time points and adverse events. Other
      outcomes of interest include perioperative opioid consumption, composite
      morbidity, surgical complications and hospital length of stay. We will include
      randomised controlled trials, which compared intravenous lignocaine infusion vs
      standard treatment for perioperative analgesia. We will search electronic
      databases from inception to present; MEDLINE, EMBASE and Cochrane Library
      (Cochrane Database of Systematic Reviews and CENTRAL). Two team members will
      independently screen all citations, full-text articles and abstract data. The
      individual study risk of bias will be appraised using the Cochrane risk of bias
      tool. We will obtain a risk ratio or mean difference (MD) from the intervention
      and control group event rates based on the nature of data. We will correct for
      the variable measurement tools by using the standardised MD (SMD). We will use a 
      random-effects model to synthesise data. We will conduct five subgroup analysis: 
      major versus minor surgery, emergency versus elective surgery, patients with
      chronic pain conditions versus patients without, duration of lignocaine infusion 
      and adult versus paediatric. Confidence in cumulative evidence for will be
      classified according to the Grading of Recommendations, Assessment, Development
      and Evaluation system. We will construct summary of findings tables supported
      detailed evidence profile tables for predefined outcomes. ETHICS AND
      DISSEMINATION: Formal ethical approval is not required as primary data will not
      be collected. The results will be disseminated through a peer-reviewed
      publication. PROSPERO REGISTRATION NUMBER: CRD420201963314.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Licina, Ana
AU  - Licina A
AUID- ORCID: 0000-0001-8897-0156
AD  - Anaesthesia, Austin Health, Heidelberg, Victoria, Australia
      analicina@hotmail.com.
FAU - Silvers, Andrew
AU  - Silvers A
AD  - Anesthesia, Monash Health, Clayton, Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Adult
MH  - Analgesics
MH  - Child
MH  - Humans
MH  - Lidocaine
MH  - Meta-Analysis as Topic
MH  - *Pain, Postoperative/drug therapy
MH  - *Spine
MH  - Systematic Reviews as Topic
PMC - PMC7554463
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *anaesthesia in neurology
OT  - *anaesthesia in orthopaedics
OT  - *neurobiology
OT  - *neurosurgery
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/10/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/14 09:11
PHST- 2020/10/14 09:11 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036908 [pii]
AID - 10.1136/bmjopen-2020-036908 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 13;10(10):e036908. doi: 10.1136/bmjopen-2020-036908.


PMID- 33051228
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 13
TI  - Effect of clindamycin and a live biotherapeutic on the reproductive outcomes of
      IVF patients with abnormal vaginal microbiota: protocol for a double-blind,
      placebo-controlled multicentre trial.
PG  - e035866
LID - 10.1136/bmjopen-2019-035866 [doi]
AB  - INTRODUCTION: Recent studies in in vitro fertilisation (IVF) patients have
      associated abnormal vaginal microbiota (AVM) with poor clinical pregnancy rates
      of 6%-9% per embryo transfer. The biological plausibility for this finding is
      hypothesised to be ascending infection to the endometrium which in turn hampers
      embryo implantation. New molecular based diagnosis may offer advantages compared 
      to microscopical diagnosis of AVM which has huge inter-study variability ranging 
      from 4 to 38%; however, the important question is whether screening and treatment
      of AVM would improve reproductive outcomes in IVF patients. Herein, we describe a
      protocol for an ongoing double-blind, placebo-controlled multicentre trial of IVF
      patients diagnosed with AVM and randomised in three parallel groups 1:1:1.
      METHODS AND ANALYSIS: This is a drug intervention study where IVF patients will
      be screened for AVM, using a qPCR assay targeting Atopobium vaginae and
      Gardnerella vaginalis. If positive, patients will be randomised to one of the
      three study arms. The first arm consists of clindamycin 300 mg x2 daily for 7
      days followed by vaginal Lactobacillus crispatus CTV-05 until clinical pregnancy 
      scan week 7-9. The second arm consists of clindamycin and placebo L. crispatus
      CTV-05, whereas patients in the third arm will be treated with placebo/placebo.
      We used a superiority design to estimate that active treatment in both arms will 
      increase the primary outcome, clinical pregnancy rate per embryo transfer, from
      20% to 40%. A potential difference between the two active arms was considered
      exploratory. With a power of 80% and an alpha at 5%, the sample size is estimated
      to be 333 patients randomised. A pre-planned interim analysis is scheduled at 167
      patients randomised. ETHICS AND DISSEMINATION: All patients have to give informed
      consent. Dissemination of results is ensured in clinical trial agreements whether
      they be positive or not. Ethics committee, Central Denmark Region approved this
      protocol. TRIAL REGISTRATION NUMBER: ICH-GCP monitored trial, EudraCT
      2016-002385-31; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Haahr, Thor
AU  - Haahr T
AUID- ORCID: 0000-0001-9304-5299
AD  - Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark
      thohaa@rm.dk.
AD  - The Fertility Clinic, Skive Regional Hospital, Skive, Denmark.
FAU - Freiesleben, Nina La Cour
AU  - Freiesleben NC
AD  - The Fertility Clinic, Hvidovre University Hospital, Copenhagen, Denmark.
FAU - Pinborg, Anja
AU  - Pinborg A
AD  - The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
      Denmark.
FAU - Nielsen, Henriette Svarre
AU  - Nielsen HS
AD  - The Fertility Clinic, Hvidovre University Hospital, Copenhagen, Denmark.
FAU - Hartvig, Vibeke
AU  - Hartvig V
AD  - Stork Fertility Clinic, Copenhagen, Denmark.
FAU - Mikkelsen, Anne-Lis
AU  - Mikkelsen AL
AD  - The Fertility Clinic, Sjaellands Universitetshospital Koge, Koge, Sjaelland,
      Denmark.
FAU - Parks, Thomas
AU  - Parks T
AD  - Osel Inc, Mountain View, California, USA.
FAU - Uldbjerg, Niels
AU  - Uldbjerg N
AD  - Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark.
AD  - Department of Obstetrics and Gynecology, Aarhus Universitetshospital, Aarhus,
      Denmark.
FAU - Jensen, Jorgen Skov
AU  - Jensen JS
AUID- ORCID: 0000-0002-7464-7435
AD  - Department of Reproductive Microbiology, Statens Serum Institute, Copenhagen,
      Denmark.
FAU - Humaidan, Peter
AU  - Humaidan P
AUID- ORCID: 0000-0001-6884-5366
AD  - Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark.
AD  - The Fertility Clinic, Skive Regional Hospital, Skive, Denmark.
LA  - eng
SI  - EudraCT/2016-002385-31
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201013
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 3U02EL437C (Clindamycin)
RN  - Atopobium vaginae
SB  - IM
MH  - *Actinobacteria
MH  - Clindamycin/therapeutic use
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - *Microbiota
MH  - Multicenter Studies as Topic
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7554508
OTO - NOTNLM
OT  - *Gardnerella
OT  - *IVF
OT  - *Lactobacillus
OT  - *RCT
OT  - *bacterial vaginosis
OT  - *clindamycin
OT  - *microbiota
COIS- Competing interests: PH, JSJ, NU, TP and TH are listed as inventors in an
      international patent application (PCT/US2018/040882), involving the therapeutic
      use of vaginal lactobacilli to improve IVF outcomes. TP is an employee of Osel,
      Inc. Not related to this trial, TH received honoraria for lectures from Ferring, 
      IBSA, Besins and Merck. PH received unrestricted research grants from MSD, Merck 
      and Ferring as well as honoraria for lectures from MSD, Merck, Gedeon-Richter,
      Theramex and IBSA. JSJ received speaker's fee from Hologic, BD, SpeeDx and
      Cepheid and serves on the scientific advisory board of Roche Molecular Systems,
      Abbott Molecular and Cepheid. NLCF received unrestricted research grant from
      Gedeon Richter and honoraria for lectures from Merck. HSN received unrestricted
      research grant from Ferring and honoraria for lectures from Merck, IBSA and
      Ferring.
EDAT- 2020/10/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/14 09:11
PHST- 2020/10/14 09:11 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035866 [pii]
AID - 10.1136/bmjopen-2019-035866 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 13;10(10):e035866. doi: 10.1136/bmjopen-2019-035866.


PMID- 33051226
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 13
TI  - PREventive effect of FENestration with and without clipping on post-kidney
      transplantation lymphatic complications (PREFEN): study protocol for a randomised
      controlled trial.
PG  - e032286
LID - 10.1136/bmjopen-2019-032286 [doi]
AB  - INTRODUCTION: Peritoneal fenestration is an effective preventive method for
      reducing the rate of lymphatic complications in kidney transplantation (KTx). The
      size of the fenestration plays an important role in its effectiveness. A large
      peritoneal window is no longer indicated, due to herniation and difficulties in
      performing biopsies. Small preventive fenestration is effective but will be
      closed too early. The aim of this study is to evaluate whether metal clips around
      the edges of a small fenestration result in optimal effects with minimum
      fenestration size. METHODS AND ANALYSIS: This trial has been initiated in July
      2019 and is expected to last for 2 and a half years. All patients older than 18
      years, who receive kidneys from deceased donors, will be included. The kidney
      recipients will be randomly allocated to either a control arm (small fenestration
      alone) or an intervention arm (small fenestration with clipping). All
      fenestrations will be round, maximum 2 cm, and close to the kidney hilum.
      Clipping will be performed with eight metal clips around the peritoneal window
      (360 degrees ) in every 45 degrees in an oblique position. The primary endpoint
      is the incidence of symptomatic post-KTx lymphatic complications, which require
      interventional treatment within 6 months after KTx. Secondary endpoints are
      intraoperative and postoperative outcomes, including blood loss, operation time, 
      severity grade of lymphocele/lymphorrhea and relative symptoms. ETHICS AND
      DISSEMINATION: This protocol study received approval from the Ethics Committee of
      the University of Heidelberg (Registration Number S-318/2017). A Standard
      Protocol Items: Recommendations for Interventional Trials checklist is available 
      for this protocol. The results will be disseminated through peer-reviewed
      journals and conference presentations. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT03682627).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Golriz, Mohammad
AU  - Golriz M
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Sabagh, Mohammadsadegh
AU  - Sabagh M
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Mohammadi, Sara
AU  - Mohammadi S
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Ghamarnejad, Omid
AU  - Ghamarnejad O
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Khajeh, Elias
AU  - Khajeh E
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Mieth, Markus
AU  - Mieth M
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Al-Saeedi, Mohammed
AU  - Al-Saeedi M
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Diener, Markus K
AU  - Diener MK
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Mihaljevic, Andre L
AU  - Mihaljevic AL
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Morath, Christian
AU  - Morath C
AD  - Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Zeier, Martin
AU  - Zeier M
AD  - Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Kulu, Yakup
AU  - Kulu Y
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Mehrabi, Arianeb
AU  - Mehrabi A
AUID- ORCID: 0000-0001-6163-1525
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
      arianeb.mehrabi@med.uni-heidelberg.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT03682627
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201013
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Incidence
MH  - *Kidney Transplantation/adverse effects
MH  - *Lymphocele/etiology/prevention & control
MH  - Peritoneum/surgery
MH  - Randomized Controlled Trials as Topic
PMC - PMC7554503
OTO - NOTNLM
OT  - *clipping
OT  - *kidney transplantation
OT  - *lymphocele
OT  - *lymphorrhea
OT  - *preventive fenestration
COIS- Competing interests: None declared.
EDAT- 2020/10/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/14 09:11
PHST- 2020/10/14 09:11 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-032286 [pii]
AID - 10.1136/bmjopen-2019-032286 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 13;10(10):e032286. doi: 10.1136/bmjopen-2019-032286.


PMID- 33050945
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20220417
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 13
TI  - The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19
      Patients: A structured summary of a study protocol for a randomised controlled
      trial.
PG  - 848
LID - 10.1186/s13063-020-04773-6 [doi]
AB  - OBJECTIVES: This study aims to investigate the effect of Famotidine on the
      recovery process of COVID-19 patients. TRIAL DESIGN: This phase III randomized
      clinical trial was designed with two parallel arms, placebo-controlled,
      single-blind, and concealed allocation. PARTICIPANTS: All COVID-19 patients
      admitted to Shahid Mohammadi Hospital in Bandar Abbas whose PCR test results are 
      positive for SARS-Cov-2 and sign the written consent of the study are included in
      the study and immunocompromised patients, end-stage renal disease, moderate renal
      failure (clearance Creatinine 30 to 50 ml/min) or stage 4 severe chronic kidney
      disease or need for dialysis (creatinine clearance lesser than 30 ml/min),
      history of liver disease, hepatitis C infection or alcoholism, Glucose 6
      phosphate dehydrogenase deficiency(G6PD), the ratio of Alanine transaminase to
      Aspartate transaminase 5 times above the normal limit, history or evidence of
      long QT segment on Electrocardiogram, psoriasis or porphyria, pregnancy, use of
      oral contraceptives, Dasatinib, Neratinib, Ozanimod, Pazopanib, Rilpivirine,
      Siponimod and/or Tizanidine and allergies to any study drug are excluded.
      INTERVENTION AND COMPARATOR: Intervention group receives standard pharmacotherapy
      according to the treatment protocols of the National Committee of COVID-19 and
      oral famotidine 160 mg (Manufactured by Chemidarou Pharmaceutical Company) four
      times a day until the day of discharge, for a maximum of fourteen days.
      Comparator group receives standard drug therapy according to the treatment
      protocols of the National Committee of COVID-19 and placebo in the same dosage.
      MAIN OUTCOMES: Patients' temperature, respiration rate, oxygen saturation, lung
      infiltration, lactate dehydrogenase and complete blood count were measured at the
      baseline (before the intervention) and on day 14 after the intervention or on the
      discharge day. RANDOMISATION: The person who has no role in admitting patients
      and assigning patients to random codes preparing random sequences using online
      tools and by permuted block randomization method. Eligibility criteria are
      monitored by the person responsible for admitting patients. Codes in a random
      sequence are assigned to patients by the treatment team without knowing that each
      code is in the intervention or comparator group. Patient codes are then matched
      to randomly generated sequence information for interventions. BLINDING (MASKING):
      All participants are unaware of which group of this study they are in and after
      grouping patients in the groups, Patients receive Famotidine in the treatment
      group and receive a placebo in the control group. The lead researcher, care
      givers, data collectors, and outcome assessors are aware of the grouping of
      patients. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no prior work on
      this research question, so no assumptions for the sample size calculation could
      be made. A total of 20 patients participate in this study, which are randomly
      divided into two groups of 10 as intervention or control groups. TRIAL STATUS:
      Version 3 of the protocol was approved by the Deputy of Research and Technology
      and the ethics committee of Hormozgan University of Medical Sciences on August 2,
      2020, with the local code 990245, and the recruitment started on August 17, 2020.
      recruitment ended on August 31, 2020. Since the recruitment ended earlier than
      expected (the expected recruitment end date was 21/12/2020), we submitted post
      recruitment but prior to publication of the results. TRIAL REGISTRATION: The
      protocol was registered before starting subject recruitment under the title: The 
      effect of Famotidine on the improvement of patients with COVID-19,
      IRCT20200509047364N2, at Iranian Registry of clinical trials (
      https://www.irct.ir/trial/49657 ) on 17 August 2020. FULL PROTOCOL: The full
      protocol is attached as an additional file, accessible from the Trials website
      (Additional file 1). In the interest in expediting dissemination of this
      material, the familiar formatting has been eliminated; this Letter serves as a
      summary of the key elements of the full protocol. The study protocol has been
      reported in accordance with the Standard Protocol Items: Recommendations for
      Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
FAU - Samimagham, Hamid Reza
AU  - Samimagham HR
AD  - Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan
      University of Medical Sciences, Bandar Abbas, Iran.
FAU - Hassani Azad, Mehdi
AU  - Hassani Azad M
AD  - Infectious and Tropical Diseases Research Center, Hormozgan Health Institute,
      Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
FAU - Haddad, Maryam
AU  - Haddad M
AD  - Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan
      University of Medical Sciences, Bandar Abbas, Iran.
FAU - Arabi, Mohsen
AU  - Arabi M
AD  - Department of Internal Medicine and Public Health Research Center, Family
      Medicine Department, Iran University of Medical Sciences, Tehran, Iran.
FAU - Hooshyar, Dariush
AU  - Hooshyar D
AD  - Student Research Committee, Faculty of Medicine, Hormozgan University of Medical 
      Sciences, Bandar Abbas, Iran.
FAU - KazemiJahromi, Mitra
AU  - KazemiJahromi M
AD  - Endocrinology and Metabolism Research Center, Hormozgan University of Medical
      Sciences, Bandar Abbas, Iran. mitra.kazemijahromi@gmail.com.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Letter
PT  - Randomized Controlled Trial
DEP - 20201013
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Placebos)
RN  - 5QZO15J2Z8 (Famotidine)
SB  - IM
MH  - Betacoronavirus/*drug effects/genetics
MH  - COVID-19
MH  - Case-Control Studies
MH  - Clinical Protocols
MH  - Coronavirus Infections/*drug therapy/epidemiology/virology
MH  - Famotidine/adverse effects/*therapeutic use
MH  - Histamine H2 Antagonists/adverse effects/*therapeutic use
MH  - Hospitalization/trends
MH  - Humans
MH  - Iran/epidemiology
MH  - Outcome Assessment, Health Care/trends
MH  - Pandemics
MH  - Patient Discharge
MH  - Placebos/administration & dosage
MH  - Pneumonia, Viral/*drug therapy/epidemiology/virology
MH  - SARS-CoV-2
PMC - PMC7552598
OTO - NOTNLM
OT  - COVID-19
OT  - Efficacy
OT  - Famotidine
OT  - Hospitalized
OT  - Randomised controlled trial
OT  - protocol
EDAT- 2020/10/15 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/10/14 08:55
PHST- 2020/09/23 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/14 08:55 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
AID - 10.1186/s13063-020-04773-6 [doi]
AID - 10.1186/s13063-020-04773-6 [pii]
PST - epublish
SO  - Trials. 2020 Oct 13;21(1):848. doi: 10.1186/s13063-020-04773-6.


PMID- 33050924
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20220417
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 13
TI  - Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): 
      A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS)
      Randomized Trial to Evaluate the Efficacy and Tolerability of Several
      Experimental Treatments to Reduce the Risk of Hospitalisation or Death in
      outpatients aged 65 years or older (COVERAGE trial).
PG  - 846
LID - 10.1186/s13063-020-04619-1 [doi]
AB  - OBJECTIVES: To assess the efficacy of several repurposed drugs to prevent
      hospitalisation or death in patients aged 65 or more with recent symptomatic
      SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation. TRIAL
      DESIGN: Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label
      controlled superiority trial. Participants will be randomly allocated 1:1:1:1:1
      to the following strategies: Arm 1: Control arm Arms 2 to 5: Experimental
      treatment arms Planned interim analyses will be conducted at regular intervals.
      Their results will be reviewed by an Independent Data and Safety Monitoring
      Board. Experimental arms may be terminated for futility, efficacy or toxicity
      before the end of the trial. New experimental arms may be added if new evidence
      suggests that other treatments should be tested. A feasibility and acceptability 
      substudy as well as an immunological substudy will be conducted alongside the
      trial. PARTICIPANTS: Inclusion criteria are: 65-year-old or more; Positive test
      for SARS-CoV-2 on a nasopharyngeal swab; Symptoms onset within 3 days before
      diagnosis; No hospitalisation criteria; Signed informed consent; Health
      insurance. Exclusion criteria are: Inability to make an informed decision to
      participate (e.g.: dementia, guardianship); Rockwood Clinical Frailty Scale >/=7;
      Long QT syndrome; QTc interval > 500 ms; Heart rate <50/min; Kalaemia >5.5 mmol/L
      or <3.5 mmol/L; Ongoing treatment with piperaquine, halofantrine, dasatinib,
      nilotinib, hydroxyzine, domperidone, citalopram, escitalopram, potent inhibitors 
      or inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine,
      6-mercaptopurine, theophylline, pyrazinamide, warfarin; Known hypersensitivity to
      any of the trial drugs or to chloroquine and other 4-aminoquinolines,
      amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB; Hepatic
      porphyria; Liver failure (Child-Pugh stage >/=B); Stage 4 or 5 chronic kidney
      disease (GFR <30 mL/min/1.73 m(2)); Dialysis; Hypersentivity to lactose; Lactase 
      deficiency; Abnormalities in galactose metabolism; Malabsorption syndrome;
      Glucose-6-phosphate dehydrogenase deficiency; Symptomatic hyperuricemia; Ileus;
      Colitis; Enterocolitis; Chronic hepatitis B virus disease. The trial is being
      conducted in France in the Bordeaux, Corse, Dijon, Nancy, Paris and Toulouse
      areas as well as in the Grand Duchy of Luxembourg. Participants are recruited
      either at home, nursing homes, general practices, primary care centres or
      hospital outpatient consultations. INTERVENTION AND COMPARATOR: The four
      experimental treatments planned in protocol version 1.2 (April 8(th), 2020) are: 
      (1) Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to
      9; (2) Imatinib 400 mg, 1 tablet QD from day 0 to 9; (3) Favipiravir 200 mg, 12
      tablets BID on day 0, 6 tablets BID from day 1 to 9; (4) Telmisartan 20 mg, 1
      tablet QD from day 0 to 9. The comparator is a complex of vitamins and trace
      elements (AZINC Forme et Vitalite(R)), 1 capsule BID for 10 days, for which there
      is no reason to believe that they are active on the virus. In protocol version
      1.2 (April 8th, 2020): People in the control arm will receive a combination of
      vitamins and trace elements; people in the experimental arms will receive
      hydroxychloroquine, or favipiravir, or imatinib, or telmisartan. MAIN OUTCOME:
      The primary outcome is the proportion of participants with an incidence of
      hospitalisation and/or death between inclusion and day 14 in each arm.
      RANDOMISATION: Participants are randomized in a 1:1:1:1:1 ratio to each arm using
      a web-based randomisation tool. Participants not treated with an ARB or ACEI
      prior to enrolment are randomized to receive the comparator or one of the four
      experimental drugs. Participants already treated with an ARB or ACEI are
      randomized to receive the comparator or one of the experimental drugs except
      telmisartan (i.e.: hydroxychloroquine, imatinib, or favipiravir). Randomisation
      is stratified on ACEI or ARBs treatment at inclusion and on the type of residence
      (personal home vs. nursing home). BLINDING (MASKING): This is an open-label
      trial. Participants, caregivers, investigators and statisticians are not blinded 
      to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 1057
      participants will be enrolled if all arms are maintained until the final analysis
      and no additional arm is added. Three successive futility interim analyses are
      planned, when the number of participants reaches 30, 60 and 102 in the control
      arm. Two efficacy analyses (interim n degrees 3 and final) will be performed
      successively. TRIAL STATUS: This describes the Version 1.2 (April 8(th), 2020) of
      the COVERAGE protocol that was approved by the French regulatory authority and
      ethics committee. The trial was opened for enrolment on April 15(th), 2020 in the
      Nouvelle Aquitaine region (South-West France). Given the current decline of the
      COVID-19 pandemic in France and its unforeseeable dynamic in the coming months,
      new trial sites in 5 other French regions and in Luxembourg are currently being
      opened. A revised version of the protocol was submitted to the regulatory
      authority and ethics committee on June 15(th), 2020. It contains the following
      amendments: (i) Inclusion criteria: age >/=65 replaced by age >/=60; time since
      first symptoms <3 days replaced by time since first symptoms <5 days; (ii)
      Withdrawal of the hydroxychloroquine arm (due to external data); (iii) increase
      in the number of trial sites. TRIAL REGISTRATION: The trial was registered on
      Clinical Trials.gov on April 22(nd), 2020 (Identifier: NCT04356495): and on
      EudraCT on April 10(th), 2020 (Identifier: 2020-001435-27). FULL PROTOCOL: The
      full protocol is attached as an additional file, accessible from the Trials
      website (Additional file 1). In the interest of expediting dissemination of this 
      material, the familiar formatting has been eliminated; this Letter serves as a
      summary of the key elements of the full protocol. The study protocol has been
      reported in accordance with the Standard Protocol Items: Recommendations for
      Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
FAU - Duvignaud, Alexandre
AU  - Duvignaud A
AUID- ORCID: http://orcid.org/0000-0001-7139-2687
AD  - CHU Bordeaux, Department of Infectious Diseases and Tropical Medicine, Division
      of Tropical Medicine and Clinical International Health, F-33000, Bordeaux,
      France. alexandre.duvignaud@chu-bordeaux.fr.
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
      alexandre.duvignaud@chu-bordeaux.fr.
FAU - Lhomme, Edouard
AU  - Lhomme E
AD  - Univ. Bordeaux, Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials
      Platform, F-33000, Bordeaux, France.
AD  - Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
      Research Centre, Inria SISTM, F-33000, Bordeaux, France.
AD  - CHU Bordeaux, Pole de Sante Publique, F-33000, Bordeaux, France.
FAU - Pistone, Thierry
AU  - Pistone T
AD  - CHU Bordeaux, Department of Infectious Diseases and Tropical Medicine, Division
      of Tropical Medicine and Clinical International Health, F-33000, Bordeaux,
      France.
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
FAU - Onaisi, Racha
AU  - Onaisi R
AD  - Department of General Practice, Univ. Bordeaux, F-33000, Bordeaux, France.
FAU - Sitta, Remi
AU  - Sitta R
AD  - Univ. Bordeaux, Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials
      Platform, F-33000, Bordeaux, France.
AD  - CHU Bordeaux, Pole de Sante Publique, F-33000, Bordeaux, France.
FAU - Journot, Valerie
AU  - Journot V
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
FAU - Nguyen, Duc
AU  - Nguyen D
AD  - CHU Bordeaux, Department of Infectious Diseases and Tropical Medicine, Division
      of Tropical Medicine and Clinical International Health, F-33000, Bordeaux,
      France.
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
FAU - Peiffer-Smadja, Nathan
AU  - Peiffer-Smadja N
AD  - CHU Bichat Claude Bernard, Department of Infectious Diseases and Tropical
      Medicine, APHP, F-75000, Paris, France.
AD  - Universite de Paris, IAME, INSERM, F-75018, Paris, France.
AD  - National Institute for Health Research Health Protection Research Unit in
      Healthcare Associated Infections and Antimicrobial Resistance, Imperial College
      London, London, UK.
FAU - Cremer, Antoine
AU  - Cremer A
AD  - Department of Cardiology - Hypertension, CHU Bordeaux, F-33000, Bordeaux, France.
AD  - Inserm U1219, Univ. Bordeaux, F-33000, Bordeaux, France.
FAU - Bouchet, Stephane
AU  - Bouchet S
AD  - Inserm U1219, Univ. Bordeaux, F-33000, Bordeaux, France.
AD  - Department of Pharmacology and Toxicology, CHU Bordeaux, F-33000, Bordeaux,
      France.
FAU - Darnaud, Thomas
AU  - Darnaud T
AD  - Centre Hospitalier de Bastia, Service de Chirurgie Specialisee & Unite de
      Recherche Clinique, F-20200, Bastia, France.
FAU - Poitrenaud, Delphine
AU  - Poitrenaud D
AD  - Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier
      d'Ajaccio, F-20090, Ajaccio, France.
FAU - Piroth, Lionel
AU  - Piroth L
AD  - Department of Infectious Diseases and Tropical Medicine, CHU Dijon, F-21079,
      Dijon, France.
AD  - Inserm U1432, Univ. Bourgogne, F-21000, Dijon, France.
FAU - Binquet, Christine
AU  - Binquet C
AD  - Inserm, CHU Dijon, CIC-EC 1432, F-21000, Dijon, France.
FAU - Michel, Jean-Francois
AU  - Michel JF
AD  - Centre Medical de Steinsel, Steinsel, Luxembourg.
AD  - Formation Specialisee en Medecine Generale (FSMG), Universite de Luxembourg,
      Luxembourg City, Luxembourg.
FAU - Lefevre, Benjamin
AU  - Lefevre B
AD  - Department of Infectious Diseases and Tropical Medicine, CHU Nancy, F-54000,
      Nancy, France.
FAU - Lebeaux, David
AU  - Lebeaux D
AD  - Department of Infectious Diseases and Tropical Medicine, Hopital Europeen Georges
      Pompidou, APHP, F-75000, Paris, France.
FAU - Lebel, Josselin
AU  - Lebel J
AD  - Department of General Practice, Universite de Paris, F-75018, Paris, France.
AD  - UMR 1137, INSERM, IAME, F-75018, Paris, France.
FAU - Dupouy, Julie
AU  - Dupouy J
AD  - MSPU Pins Justaret, F-31860, Pins Justaret, France.
AD  - Department of General Practice, Univ. Paul Sabatier, F-31000, Toulouse, France.
AD  - UMR 1027 Inserm Univ. Paul Sabatier, F-31000, Toulouse, France.
AD  - CHU Toulouse, CIC, F-31000, Toulouse, France.
FAU - Roussillon, Caroline
AU  - Roussillon C
AD  - Clinical Research and Innovation Department, Safety and vigilance, CHU Bordeaux, 
      F-33000, Bordeaux, France.
FAU - Gimbert, Anne
AU  - Gimbert A
AD  - Clinical Research and Innovation Department, CHU Bordeaux, F-33000, Bordeaux,
      France.
FAU - Wittkop, Linda
AU  - Wittkop L
AD  - CHU Bordeaux, Pole de Sante Publique, F-33000, Bordeaux, France.
AD  - Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
      Research Centre, MORPH3EUS, F-33000, Bordeaux, France.
FAU - Thiebaut, Rodolphe
AU  - Thiebaut R
AD  - Univ. Bordeaux, Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials
      Platform, F-33000, Bordeaux, France.
AD  - Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
      Research Centre, Inria SISTM, F-33000, Bordeaux, France.
AD  - CHU Bordeaux, Pole de Sante Publique, F-33000, Bordeaux, France.
FAU - Orne-Gliemann, Joanna
AU  - Orne-Gliemann J
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
FAU - Joseph, Jean-Philippe
AU  - Joseph JP
AD  - Department of General Practice, CIC 1401, Univ. Bordeaux, F-33000, Bordeaux,
      France.
FAU - Richert, Laura
AU  - Richert L
AD  - Univ. Bordeaux, Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials
      Platform, F-33000, Bordeaux, France.
AD  - Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
      Research Centre, Inria SISTM, F-33000, Bordeaux, France.
AD  - CHU Bordeaux, Pole de Sante Publique, F-33000, Bordeaux, France.
FAU - Anglaret, Xavier
AU  - Anglaret X
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
FAU - Malvy, Denis
AU  - Malvy D
AD  - CHU Bordeaux, Department of Infectious Diseases and Tropical Medicine, Division
      of Tropical Medicine and Clinical International Health, F-33000, Bordeaux,
      France.
AD  - Inserm U1219, Univ. Bordeaux, IRD, F-33000, Bordeaux, France.
CN  - COVERAGE study group
LA  - eng
SI  - ClinicalTrials.gov/NCT04356495
GR  - NA/Universite de Bordeaux
GR  - NA/INSERM
GR  - NA/Agence Nationale de la Recherche
GR  - NA/Ministere de la Sante
GR  - NA/EIT Health
PT  - Clinical Trial, Phase III
PT  - Letter
PT  - Randomized Controlled Trial
DEP - 20201013
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Amides)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Antimalarials)
RN  - 0 (Antiviral Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazines)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EW5GL2X7E0 (favipiravir)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Amides/therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Antimalarials/therapeutic use
MH  - Antiviral Agents/therapeutic use
MH  - Betacoronavirus/*genetics
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/epidemiology/virology
MH  - Drug Tolerance
MH  - Feasibility Studies
MH  - France/epidemiology
MH  - Hospitalization/trends
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - Imatinib Mesylate/therapeutic use
MH  - Luxembourg/epidemiology
MH  - Outpatients/*statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/epidemiology/virology
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Pyrazines/therapeutic use
MH  - Risk Reduction Behavior
MH  - SARS-CoV-2
MH  - Telmisartan/therapeutic use
MH  - Therapies, Investigational/*statistics & numerical data
MH  - Treatment Outcome
PMC - PMC7552584
EDAT- 2020/10/15 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/10/14 08:55
PHST- 2020/07/13 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/10/14 08:55 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
AID - 10.1186/s13063-020-04619-1 [doi]
AID - 10.1186/s13063-020-04619-1 [pii]
PST - epublish
SO  - Trials. 2020 Oct 13;21(1):846. doi: 10.1186/s13063-020-04619-1.


PMID- 33050024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Instagranimal: Animal Welfare and Animal Ethics Challenges of Animal-Based
      Tourism.
LID - E1830 [pii]
LID - 10.3390/ani10101830 [doi]
AB  - By animal-based tourism, a host of activities offering passive viewing or active 
      interaction with wild, semi-wild or captive animals is included. The multibillion
      dollar industry is on the rise globally today, offering modes of engagement with 
      animals that trade on increasingly embodied close encounters with non-human
      animals. As new modes of animal-based tourism proliferate, such as sloth selfies,
      visiting cat cafes, swimming with sharks and agri-tourism petting zoos, animal
      welfare standards risk deteriorating. In the following paper, we collate concerns
      over animal welfare into a discussion on the challenges facing animal-based
      tourism. Our synthesis is the first to consider the full spectrum of such
      animal-based tourism: across agri-, hunting, zoo and safari tourism, to name a
      few, and crossing consumptive and non-consumptive boundaries. A literature review
      is first provided. Findings are then presented thematically following workshops
      at an international interdisciplinary symposium of leading tourism, animal
      welfare, ethics and leisure sciences scholars together with practitioners of the 
      industry. It discusses macrolevel drivers to animal-based tourism as an industry,
      the problem of cultural relativism and the role of technology in enhancing or
      promoting the experience. We indicate ways forward toward implementing a
      compassionate animal-based tourism.
FAU - Essen, Erica von
AU  - Essen EV
AUID- ORCID: 0000-0002-9169-0064
AD  - Norwegian Institute for Nature Research Sognsveien 68, 0855 Oslo, Norway.
FAU - Lindsjo, Johan
AU  - Lindsjo J
AD  - Swedish Centre for Animal Welfare, SCAW and Department of Animal Environment and 
      Health, Swedish University of Agricultural Sciences Ulls vag 26, 750 07 Uppsala, 
      Sweden.
FAU - Berg, Charlotte
AU  - Berg C
AUID- ORCID: 0000-0001-5671-5273
AD  - Department of Animal Environment and Health, Swedish University of Agricultural
      Sciences, PO Box 234, 532 23 Skara, Sweden.
LA  - eng
GR  - XX/Sveriges Lantbruksuniversitet
PT  - Journal Article
DEP - 20201008
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7600185
OTO - NOTNLM
OT  - 3Rs
OT  - animal welfare
OT  - compassionate
OT  - cultural relativism
OT  - ethics
OT  - guidelines
OT  - tourism
EDAT- 2020/10/15 06:00
MHDA- 2020/10/15 06:01
CRDT- 2020/10/14 01:03
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/10/14 01:03 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2020/10/15 06:01 [medline]
AID - ani10101830 [pii]
AID - 10.3390/ani10101830 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 8;10(10). pii: ani10101830. doi: 10.3390/ani10101830.


PMID- 33050021
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210702
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 8
TI  - Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility.
LID - E2253 [pii]
LID - 10.3390/cells9102253 [doi]
AB  - Female infertility is a global medical condition that can be caused by various
      disorders of the reproductive system, including premature ovarian failure (POF), 
      polycystic ovary syndrome (PCOS), endometriosis, Asherman syndrome, and
      preeclampsia. It affects the quality of life of both patients and couples.
      Mesenchymal stem cells (MSCs) have received increasing attention as a potential
      cell-based therapy, with several advantages over other cell sources, including
      greater abundance, fewer ethical considerations, and high capacity for
      self-renewal and differentiation. Clinical researchers have examined the
      therapeutic use of MSCs in female infertility. In this review, we discuss recent 
      studies on the use of MSCs in various reproductive disorders that lead to
      infertility. We also describe the role of microRNAs (miRNAs) and exosomal miRNAs 
      in controlling MSC gene expression and driving MSC therapeutic outcomes. The
      clinical application of MSCs holds great promise for the treatment of infertility
      or ovarian insufficiency, and to improve reproductive health for a significant
      number of women worldwide.
FAU - Esfandyari, Sahar
AU  - Esfandyari S
AD  - Department of Surgery, University of Illinois at Chicago, 820 South Wood Street, 
      Chicago, IL 60612, USA.
FAU - Chugh, Rishi Man
AU  - Chugh RM
AD  - Department of Surgery, University of Illinois at Chicago, 820 South Wood Street, 
      Chicago, IL 60612, USA.
FAU - Park, Hang-Soo
AU  - Park HS
AD  - Department of Surgery, University of Illinois at Chicago, 820 South Wood Street, 
      Chicago, IL 60612, USA.
FAU - Hobeika, Elie
AU  - Hobeika E
AD  - Fertility Centers of Illinois, Glenview, IL 60026, USA.
FAU - Ulin, Mara
AU  - Ulin M
AUID- ORCID: 0000-0002-4636-6396
AD  - Department of Surgery, University of Illinois at Chicago, 820 South Wood Street, 
      Chicago, IL 60612, USA.
FAU - Al-Hendy, Ayman
AU  - Al-Hendy A
AD  - Department of Surgery, University of Illinois at Chicago, 820 South Wood Street, 
      Chicago, IL 60612, USA.
AD  - Department of Obstetrics and Gynecology, University of Chicago, 5841 South
      Maryland Ave, Chicago, IL 60637, USA.
LA  - eng
GR  - R01 ES028615/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201008
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (MicroRNAs)
RN  - EC 3.1.- (Exosome Multienzyme Ribonuclease Complex)
SB  - IM
MH  - Exosome Multienzyme Ribonuclease Complex/metabolism
MH  - Female
MH  - Humans
MH  - Infertility, Female/metabolism/*therapy
MH  - Mesenchymal Stem Cell Transplantation/*methods/trends
MH  - Mesenchymal Stem Cells/*metabolism
MH  - MicroRNAs/metabolism
MH  - Ovarian Follicle
MH  - Primary Ovarian Insufficiency/metabolism/therapy
PMC - PMC7599919
OTO - NOTNLM
OT  - *infertility
OT  - *mesenchymal stem cells (MSCs)
OT  - *reproductive system
OT  - *stem-cell therapy
EDAT- 2020/10/15 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/10/14 01:03
PHST- 2020/09/08 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/03 00:00 [accepted]
PHST- 2020/10/14 01:03 [entrez]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
AID - cells9102253 [pii]
AID - 10.3390/cells9102253 [doi]
PST - epublish
SO  - Cells. 2020 Oct 8;9(10). pii: cells9102253. doi: 10.3390/cells9102253.


PMID- 33049287
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1773-0619 (Electronic)
IS  - 0028-3770 (Linking)
VI  - 66
IP  - 6
DP  - 2020 Dec
TI  - Experience using pragmatic care trials to guide neurovascular practice under
      uncertainty.
PG  - 423-428
LID - S0028-3770(20)30400-8 [pii]
LID - 10.1016/j.neuchi.2020.06.136 [doi]
AB  - BACKGROUND: Pragmatic care trials have been designed to provide optimal
      neurovascular care in the presence of uncertainty. The feasibility, benefits, and
      drawbacks of using this novel approach remain unknown. METHODS: We report the
      progress of 9 randomized trials integrated into routine practice to guide the
      endovascular or surgical treatment of intracranial aneurysms, arteriovenous
      malformations, and acute stroke. We review the criticisms and commentaries we
      have received and discuss the corresponding ethical and scientific concepts that 
      need to be revised to practice outcome-based neurovascular care. RESULTS:
      Pragmatic care trials were used to address long standing dilemmas regarding rival
      management options or to offer innovative treatments for 1212 neurovascular
      patients recruited in an elective or acute care context. Adopting care trial
      methodology had an immediate impact on clinical practice, replacing unrepeatable 
      treatment decisions by 1:1 randomized allocation whenever reliable knowledge
      about best management was not available. The care trial approach transformed
      unfounded medical practice into verifiable outcome-based medical care and
      reserved authoritative recommendations for care options that had previously been 
      validated. Criticisms we have encountered include mainly the pragmatic trial
      design choices, with insufficient selection of patients and clinicians,
      too-flexible protocols, lack of funding and feasibility. CONCLUSION: Care trials 
      can be integrated into neurovascular practice. Although they remain a work in
      progress, the approach curtails the practice of unverifiable medicine and offers 
      patients optimal care in the presence of uncertainty.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Darsaut, T E
AU  - Darsaut TE
AD  - University of Alberta Hospital, Mackenzie Health Sciences Centre, Department of
      Surgery, Division of Neurosurgery,8440 112 street, T6G 2B7, Alberta, Canada.
      Electronic address: tdarsaut@ualberta.ca.
FAU - Raymond, J
AU  - Raymond J
AD  - Centre Hospitalier de l'Universite de Montreal-CHUM, Department of Radiology,
      Service of Interventional Neuroradiology, 1000 St-Denis, H2X 0C1 Montreal,
      Canada. Electronic address: jean.raymond@umontreal.ca.
LA  - eng
PT  - Journal Article
DEP - 20201010
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Central Nervous System Vascular Malformations/surgery
MH  - Clinical Decision-Making
MH  - Humans
MH  - Intracranial Aneurysm/surgery
MH  - Neurosurgical Procedures/*methods
MH  - Patient Care Management/*standards
MH  - *Pragmatic Clinical Trials as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Stroke/surgery
MH  - Uncertainty
MH  - Vascular Surgical Procedures/*methods
OTO - NOTNLM
OT  - Clinical research methodology
OT  - Medical ethics
OT  - Pragmatic trials
OT  - Randomized trials
OT  - Research ethics
EDAT- 2020/10/14 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/10/13 20:09
PHST- 2020/04/21 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2020/10/13 20:09 [entrez]
AID - S0028-3770(20)30400-8 [pii]
AID - 10.1016/j.neuchi.2020.06.136 [doi]
PST - ppublish
SO  - Neurochirurgie. 2020 Dec;66(6):423-428. doi: 10.1016/j.neuchi.2020.06.136. Epub
      2020 Oct 10.


PMID- 33049046
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1574-6968 (Electronic)
IS  - 0378-1097 (Linking)
VI  - 367
IP  - 19
DP  - 2020 Oct 21
TI  - Probiotic triangle of success; strain production, clinical studies and product
      development.
LID - fnaa167 [pii]
LID - 10.1093/femsle/fnaa167 [doi]
AB  - The successful development of probiotic foods and dietary supplements rests on
      three pillars; each with their specific challenges and opportunities. First,
      strain production; this depends on selecting the right strain with promising
      technological properties and safety profile. Further the manufacturing of the
      strain in a stable format at sufficiently high yield, following regulatory and
      customer requirements on culture media ingredients and other processing aids. The
      second pillar are the preclinical and clinical studies to document that the
      strain is a probiotic and exerts a health benefit on the host, the consumer.
      Especially when aiming for a regulator approved health claim, clinical studies
      need to be thoroughly performed; following appropriate ethical, scientific and
      regulatory guidelines. Finally, the probiotic will need to be incorporated in a
      product that can be brought to the consumer; a dietary supplement or a functional
      food. Because of the live nature of probiotics, specific challenges may need to
      be dealt with. Although experience from other strains is helpful in the process, 
      the development is strain specific. Commercialisation and marketing of probiotics
      are strictly but differently regulated in most jurisdictions; defining what can
      and cannot be claimed.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.
FAU - Forssten, Sofia D
AU  - Forssten SD
AD  - DuPont Nutrition & Biosciences, Sokeritehtaantie 20, 02460 Kantvik, Finland.
FAU - Laitila, Arja
AU  - Laitila A
AD  - DuPont Nutrition & Biosciences, Sokeritehtaantie 20, 02460 Kantvik, Finland.
FAU - Maukonen, Johanna
AU  - Maukonen J
AD  - DuPont Nutrition & Biosciences, Sokeritehtaantie 20, 02460 Kantvik, Finland.
FAU - Ouwehand, Arthur C
AU  - Ouwehand AC
AD  - DuPont Nutrition & Biosciences, Sokeritehtaantie 20, 02460 Kantvik, Finland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - FEMS Microbiol Lett
JT  - FEMS microbiology letters
JID - 7705721
SB  - IM
MH  - Clinical Studies as Topic
MH  - Dietary Supplements
MH  - Food Microbiology/*trends
MH  - *Probiotics
PMC - PMC7578568
OTO - NOTNLM
OT  - * Bifidobacterium
OT  - * Lactobacillus
OT  - *health benefit
OT  - *probiotics
OT  - *product development
OT  - *strain production
EDAT- 2020/10/14 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/10/13 17:13
PHST- 2020/07/28 00:00 [received]
PHST- 2020/10/11 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/10/13 17:13 [entrez]
AID - 5922720 [pii]
AID - 10.1093/femsle/fnaa167 [doi]
PST - ppublish
SO  - FEMS Microbiol Lett. 2020 Oct 21;367(19). pii: 5922720. doi:
      10.1093/femsle/fnaa167.


PMID- 33048918
OWN - NLM
STAT- Publisher
LR  - 20201013
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 73
IP  - 5
DP  - 2020 May 7
TI  - Ethical Considerations in Animal Research: The Principle of 3R's.
LID - s113961211409 [doi]
AB  - In the last century, progress in the knowledge of human diseases, their diagnosis
      and treatment have grown exponentially, due in large part to the introduction and
      use of laboratory animals. Along with this important progress, the need to
      provide training and guidance to the scientific community in all aspects related 
      to the proper use of experimental animals has been indispensable. Animal research
      committees play a primary role in evaluating experimental research protocols,
      from their feasibility to the rational use of animals, but above all in seeking
      animal welfare. The Institutional Committee for the Care and Use of Animals
      (IACUC) has endeavored to share several relevant aspects in conducting research
      with laboratory animals. Here, we present and discuss the topics that we consider
      of utmost importance to take in the account during the design of any experimental
      research protocol, so we invite researchers, technicians, and undergraduate and
      graduate students to dive into the fascinating subject of proper animal care and 
      use for experimentation. The main intention of these contributions is to
      sensitize users of laboratory animals for the proper and rational use of them in 
      experimental research, as well as to disseminate the permitted and unpermitted
      procedures in laboratory animals. In the first part, the significance of
      experimental research, the main functions of IACUC, and the principle of the
      three R's (replacement, reduction, and refinement) are addressed.
FAU - Diaz, Lorenza
AU  - Diaz L
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Zambrano, Elena
AU  - Zambrano E
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Flores, Maria E
AU  - Flores ME
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City; Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Contreras, Mariela
AU  - Contreras M
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Crispin, Jose C
AU  - Crispin JC
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Aleman, Gabriela
AU  - Aleman G
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Bravo, Cesar
AU  - Bravo C
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Armenta, Alejandra
AU  - Armenta A
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Valdes, Victor J
AU  - Valdes VJ
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; Instituto de
      Fisiologia Celular, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Tovar, Armando
AU  - Tovar A
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Gamba, Gerardo
AU  - Gamba G
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City; Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
FAU - Barrios-Payan, Jorge
AU  - Barrios-Payan J
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Bobadilla, Norma A
AU  - Bobadilla NA
AD  - The Institutional Animal Care and Use Committee, Instituto Nacional de Ciencias
      Medicas y Nutricion Salvador Zubiran, Mexico City; Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la
      Nutricion
JID - 9421552
SB  - IM
EDAT- 2020/10/14 06:00
MHDA- 2020/10/14 06:00
CRDT- 2020/10/13 17:11
PHST- 2020/10/13 17:11 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/10/14 06:00 [medline]
AID - s113961211409 [doi]
PST - aheadofprint
SO  - Rev Invest Clin. 2020 May 7;73(5). doi: s113961211409.


PMID- 33048563
OWN - NLM
STAT- Publisher
LR  - 20201013
IS  - 1939-1463 (Electronic)
IS  - 1082-989X (Linking)
DP  - 2020 Oct 12
TI  - The meaning of scientific objectivity and subjectivity: From the perspective of
      methodologists.
LID - 10.1037/met0000363 [doi]
AB  - Given the challenges to the notion of objectivity posed by social psychological
      research on investigator effects, constructivist and critical epistemological
      perspectives, and the introduction of qualitative research methods in psychology,
      the investigators examined how leading methodologists understand the function of 
      objectivity and subjectivity in psychological science. The aim of the study was
      to learn how contemporary methodologists view these issues so as to communicate
      converging perspectives to the field and inform methods education. A brief
      historical review of the concept of objectivity in psychology is presented to
      contexualize this examination. Eleven accomplished methodologists with expertise 
      in a range of methods and epistemological perspectives were interviewed. Findings
      from a grounded theory analysis demonstrated that all the participants expressed 
      concern about the belief that science is unaffected by scientists' perspectives, 
      believing researchers and educators should problematize this perspective.
      Recommendations from participants included that science be viewed as a
      value-laden endeavor in which scientists systematically conduct research from
      multiple epistemological perspectives, and/or utilize diverse methods tailored to
      address their questions. Scientific procedures were detailed that could curtail
      dangers of either unchecked subjectivity or a false sense of objectivity. A
      functional analysis of these constructs, objectivity and subjectivity, suggested 
      they both serve a similar scientific and an ethical purpose-to prevent the
      premature foreclosure of possible understanding because of the expectations of
      researchers. The mainstreaming of disclosures about the perspectives and
      positions of investigators, as well as their management, and the implementation
      of epistemological and methodological pluralism are encouraged to support this
      ethic. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
FAU - Levitt, Heidi M
AU  - Levitt HM
AUID- ORCID: 0000-0001-9447-1484
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Surace, Francisco I
AU  - Surace FI
AUID- ORCID: 0000-0001-9895-1266
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Wu, Max B
AU  - Wu MB
AUID- ORCID: 0000-0002-3731-0139
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Chapin, Brad
AU  - Chapin B
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Hargrove, Jacqueline G
AU  - Hargrove JG
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Herbitter, Cara
AU  - Herbitter C
AUID- ORCID: 0000-0002-5019-0442
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Lu, Ethan C
AU  - Lu EC
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Maroney, Meredith R
AU  - Maroney MR
AUID- ORCID: 0000-0002-4622-2683
AD  - Department of Psychology, University of Massachusetts Boston.
FAU - Hochman, Alissa L
AU  - Hochman AL
AUID- ORCID: 0000-0002-9032-7079
AD  - Department of Psychology, University of Massachusetts Boston.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - United States
TA  - Psychol Methods
JT  - Psychological methods
JID - 9606928
SB  - IM
EDAT- 2020/10/14 06:00
MHDA- 2020/10/14 06:00
CRDT- 2020/10/13 17:10
PHST- 2020/10/13 17:10 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/10/14 06:00 [medline]
AID - 2020-76120-001 [pii]
AID - 10.1037/met0000363 [doi]
PST - aheadofprint
SO  - Psychol Methods. 2020 Oct 12. pii: 2020-76120-001. doi: 10.1037/met0000363.


PMID- 33048327
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20220218
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Should We Aim to Create a Perfect Healthy Utopia? Discussions of Ethical Issues
      Surrounding the World of Project Itoh's Harmony.
PG  - 3249-3270
LID - 10.1007/s11948-020-00269-3 [doi]
AB  - To consider whether or not we should aim to create a perfect healthy utopia on
      Earth, we focus on the SF novel Harmony (2008), written by Japanese writer
      Project Ito, and analyze various issues in the world established in the novel
      from a bioethical standpoint. In the world depicted in Harmony, preserving health
      and life is a top priority. Super-medicine is realized through highly advanced
      medical technologies. Citizens in Harmony are required to strictly control
      themselves to achieve perfect health and must always disclose their health
      information to the public and continuously prove their health. From a bioethical 
      standpoint, the world in Harmony is governed by a "healthy longevity supremacy"
      principle, with being healthy equated to being good and right. Privacy no longer 
      exists, as it is perceived ethical for citizens to openly communicate
      health-related information to establish one's credibility. Moreover, there is no 
      room for self-determination concerning healthcare because medical interventions
      and care are completely routinized, automated, centralized, and instantly
      provided. This is a situation where the community exhibits extremely powerful and
      effective paternalism. One can argue that healthy longevity is highly preferred. 
      But is it right to aim for a perfectly healthy society at all costs? Should we
      sacrifice freedom, privacy, vivid feelings, and personal dignity to achieve such 
      a world? In our view, the answer is no, as this would require the loss of many
      essential values. We conclude by proposing an alternative governing principle for
      future healthcare, and refer to it as the "do-everything-in-moderation"
      principle.
FAU - Asai, Atsushi
AU  - Asai A
AUID- ORCID: 0000-0001-6698-1452
AD  - Department of Medical Ethics, Tohoku University Graduate School of Medicine, 2-1 
      Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. aasai@med.tohoku.ac.jp.
FAU - Okita, Taketoshi
AU  - Okita T
AD  - Department of Medical Ethics, Tohoku University Graduate School of Medicine, 2-1 
      Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
FAU - Ohnishi, Motoki
AU  - Ohnishi M
AD  - Department of Health and Welfare Public Policy, Laboratory of Public Health,
      Aomori University of Health and Welfare Graduate School of Health Science, 58-1
      oaza hamadate aza mase Aomori, Aomori, 030-8505, Japan.
FAU - Bito, Seiji
AU  - Bito S
AD  - Division of Clinical Epidemiology, National Tokyo Medical Center, National
      Hospital Organization, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8621, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201013
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Delivery of Health Care
MH  - Freedom
MH  - Health Status
MH  - Humans
MH  - Privacy
MH  - *Utopias
PMC - PMC7552577
OTO - NOTNLM
OT  - *Health
OT  - *Moderation
OT  - *Project itoh
OT  - *Science fiction
OT  - *Super-medicine
OT  - *Unethical human experiment
EDAT- 2020/10/14 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/13 12:14
PHST- 2019/10/01 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/10/13 12:14 [entrez]
AID - 10.1007/s11948-020-00269-3 [doi]
AID - 10.1007/s11948-020-00269-3 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3249-3270. doi: 10.1007/s11948-020-00269-3. Epub
      2020 Oct 13.


PMID- 33048325
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Ethical Decision Making in Autonomous Vehicles: The AV Ethics Project.
PG  - 3285-3312
LID - 10.1007/s11948-020-00272-8 [doi]
AB  - The ethics of autonomous vehicles (AV) has received a great amount of attention
      in recent years, specifically in regard to their decisional policies in accident 
      situations in which human harm is a likely consequence. Starting from the
      assumption that human harm is unavoidable, many authors have developed differing 
      accounts of what morality requires in these situations. In this article, a
      strategy for AV decision-making is proposed, the Ethical Valence Theory, which
      paints AV decision-making as a type of claim mitigation: different road users
      hold different moral claims on the vehicle's behavior, and the vehicle must
      mitigate these claims as it makes decisions about its environment. Using the
      context of autonomous vehicles, the harm produced by an action and the
      uncertainties connected to it are quantified and accounted for through
      deliberation, resulting in an ethical implementation coherent with reality. The
      goal of this approach is not to define how moral theory requires vehicles to
      behave, but rather to provide a computational approach that is flexible enough to
      accommodate a number of 'moral positions' concerning what morality demands and
      what road users may expect, offering an evaluation tool for the social
      acceptability of an autonomous vehicle's ethical decision making.
FAU - Evans, Katherine
AU  - Evans K
AUID- ORCID: 0000-0002-1266-941X
AD  - Institut VEDECOM, 21 bis Allee des Marroniers, 78000, Versailles, France.
      katie.d.evans@gmail.com.
AD  - Sciences, Normes, Democratie, Sorbonne Universite, 1 Rue Victor Cousin, 75005,
      Paris, France. katie.d.evans@gmail.com.
FAU - de Moura, Nelson
AU  - de Moura N
AD  - Institut VEDECOM, 21 bis Allee des Marroniers, 78000, Versailles, France.
AD  - ISIR, Sorbonne Universite, 4 Place Jussieu, 75005, Paris, France.
FAU - Chauvier, Stephane
AU  - Chauvier S
AD  - Sciences, Normes, Democratie, Sorbonne Universite, 1 Rue Victor Cousin, 75005,
      Paris, France.
FAU - Chatila, Raja
AU  - Chatila R
AD  - ISIR, Sorbonne Universite, 4 Place Jussieu, 75005, Paris, France.
FAU - Dogan, Ebru
AU  - Dogan E
AD  - Institut VEDECOM, 21 bis Allee des Marroniers, 78000, Versailles, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201013
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Decision Making
MH  - Ethical Theory
MH  - Ethics
MH  - Humans
MH  - *Morals
MH  - Uncertainty
PMC - PMC7755871
OTO - NOTNLM
OT  - *Autonomous vehicles
OT  - *Decision making
OT  - *Ethics
OT  - *Machine ethics
OT  - *Moral reasoning
EDAT- 2020/10/14 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/13 12:14
PHST- 2019/11/21 00:00 [received]
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/10/13 12:14 [entrez]
AID - 10.1007/s11948-020-00272-8 [doi]
AID - 10.1007/s11948-020-00272-8 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3285-3312. doi: 10.1007/s11948-020-00272-8. Epub
      2020 Oct 13.


PMID- 33048059
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210211
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 13
TI  - AQUEDUCT Intervention for Crisis Team Quality and Effectiveness in Dementia:
      Protocol for a Feasibility Study.
PG  - e18971
LID - 10.2196/18971 [doi]
AB  - BACKGROUND: Specialist community teams often support people with dementia who
      experience crisis. These teams may vary in composition and models of practice,
      which presents challenges when evaluating their effectiveness. A best practice
      model for dementia crisis services could be used by teams to improve the quality 
      and effectiveness of the care they deliver. OBJECTIVE: The aim of this study is
      to examine the feasibility of conducting a large-scale randomized controlled
      trial comparing the AQUEDUCT (Achieving Quality and Effectiveness in Dementia
      Using Crisis Teams) Resource Kit intervention to treatment as usual. METHODS:
      This is a multisite feasibility study in preparation for a future randomized
      controlled trial. Up to 54 people with dementia (and their carers) and 40
      practitioners will be recruited from 4 geographically widespread teams managing
      crisis in dementia. Quantitative outcomes will be recorded at baseline and at
      discharge. This study will also involve a nested health economic substudy and
      qualitative research to examine participant experiences of the intervention and
      acceptability of research procedures. RESULTS: Ethical approval for this study
      was granted in July 2019. Participant recruitment began in September 2019, and as
      of September 2020, all data collection has been completed. Results of this study 
      will establish the acceptability of the intervention, recruitment rates, and will
      assess the feasibility and appropriateness of the outcome measures in preparation
      for a large-scale randomized controlled trial. CONCLUSIONS: There is a need to
      evaluate the effectiveness of crisis intervention teams for older people with
      dementia. This is the first study to test the feasibility of an evidence-based
      best practice model for teams managing crisis in dementia. The results of this
      study will assist in the planning and delivery of a large-scale randomized
      controlled trial. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/18971.
CI  - (c)Emma Elizabeth Broome, Donna Maria Coleston-Shields, Tom Dening, Esme
      Moniz-Cook, Fiona Poland, Miriam Stanyon, Martin Orrell. Originally published in 
      JMIR Research Protocols (http://www.researchprotocols.org), 13.10.2020.
FAU - Broome, Emma Elizabeth
AU  - Broome EE
AUID- ORCID: https://orcid.org/0000-0002-1607-0594
AD  - National Institute for Health Research Nottingham Biomedical Research Centre,
      Hearing Sciences, Division of Clinical Neuroscience, University of Nottingham,
      Nottingham, United Kingdom.
FAU - Coleston-Shields, Donna Maria
AU  - Coleston-Shields DM
AUID- ORCID: https://orcid.org/0000-0002-6381-8518
AD  - Division of Psychiatry & Applied Psychology, Institute of Mental Health, School
      of Medicine, University of Nottingham, Nottingham, United Kingdom.
FAU - Dening, Tom
AU  - Dening T
AUID- ORCID: https://orcid.org/0000-0003-3387-4241
AD  - Division of Psychiatry & Applied Psychology, Institute of Mental Health, School
      of Medicine, University of Nottingham, Nottingham, United Kingdom.
FAU - Moniz-Cook, Esme
AU  - Moniz-Cook E
AUID- ORCID: https://orcid.org/0000-0002-7232-4632
AD  - Faculty of Health Sciences, University of Hull, Hull, United Kingdom.
FAU - Poland, Fiona
AU  - Poland F
AUID- ORCID: https://orcid.org/0000-0003-0003-6911
AD  - School of Health Sciences, University of East Anglia, Norwich, United Kingdom.
FAU - Stanyon, Miriam
AU  - Stanyon M
AUID- ORCID: https://orcid.org/0000-0003-4326-0286
AD  - Division of Psychiatry & Applied Psychology, Institute of Mental Health, School
      of Medicine, University of Nottingham, Nottingham, United Kingdom.
FAU - Orrell, Martin
AU  - Orrell M
AUID- ORCID: https://orcid.org/0000-0002-1169-3530
AD  - Division of Psychiatry & Applied Psychology, Institute of Mental Health, School
      of Medicine, University of Nottingham, Nottingham, United Kingdom.
LA  - eng
GR  - RP-PG-0612-20004/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20201013
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7592065
OTO - NOTNLM
OT  - community services
OT  - crisis
OT  - dementia
OT  - feasibility study
OT  - mental health
EDAT- 2020/10/14 06:00
MHDA- 2020/10/14 06:01
CRDT- 2020/10/13 12:11
PHST- 2020/03/30 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/10/13 12:11 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/10/14 06:01 [medline]
AID - v9i10e18971 [pii]
AID - 10.2196/18971 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 13;9(10):e18971. doi: 10.2196/18971.


PMID- 33048058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2369-3762 (Print)
IS  - 2369-3762 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Oct 13
TI  - Identification of Informed Consent in Patient Videos on Social Media: Prospective
      Study.
PG  - e14081
LID - 10.2196/14081 [doi]
AB  - BACKGROUND: The American Medical Association Code of Medical Ethics states that
      any clinical image taken for public education forms part of the patient's
      records. Hence, a patient's informed consent is required to collect, share, and
      distribute their image. Patients must be informed of the intended use of the
      clinical image and the intended audience as part of the informed consent.
      OBJECTIVE: This paper aimed to determine whether a random selection of
      instructional videos containing footage of central venous catheter insertion on
      real patients on YouTube (Google LLC) would mention the presence of informed
      consent to post the video on social media. METHODS: We performed a prospective
      evaluation by 2 separate researchers of the first 125 videos on YouTube with the 
      search term "central line insertion." After duplicates were deleted and exclusion
      criteria applied, 41 videos of patients undergoing central line insertion were
      searched for reference to patient consent. In the case of videos of indeterminate
      consent status, the posters were contacted privately through YouTube to clarify
      the status of consent to both film and disseminate the video on social media. A
      period of 2 months was provided to respond to initial contact. Furthermore,
      YouTube was contacted to clarify company policy. The primary outcome was to
      determine if videos on YouTube were amended to include details of consent at 2
      months postcontact. The secondary outcome was a response to the initial email at 
      2 months. RESULTS: The researchers compiled 143 videos. Of 41 videos that
      contained footage of patient procedures, 41 were of indeterminate consent status 
      and 23 contained identifiable patient footage. From the 41 posters that were
      contacted, 3 responded to initial contact and none amended the video to document 
      consent status. Response from YouTube is pending. CONCLUSIONS: There are
      instructional videos for clinicians on social media that contain footage of
      patients undergoing medical procedures and do not have any verification of
      informed consent. While this study investigated a small sample of available
      videos, the problem appears ubiquitous and should be studied more extensively.
CI  - (c)Jane O'Sullivan, Cathleen McCarrick, Paul Tierney, Donal B O'Connor, Jack
      Collins, Robert Franklin. Originally published in JMIR Medical Education
      (http://mededu.jmir.org), 13.10.2020.
FAU - O'Sullivan, Jane
AU  - O'Sullivan J
AUID- ORCID: https://orcid.org/0000-0002-9447-6100
AD  - Department of Anaesthesia, Letterkenny University Hospital, Donegal, Ireland.
FAU - McCarrick, Cathleen
AU  - McCarrick C
AUID- ORCID: https://orcid.org/0000-0002-9713-9038
AD  - Department of Surgery, Tallaght University Hospital, Dublin, Ireland.
FAU - Tierney, Paul
AU  - Tierney P
AUID- ORCID: https://orcid.org/0000-0002-2647-2861
AD  - Department of Anatomy, Trinity College Dublin, Dublin, Ireland.
FAU - O'Connor, Donal B
AU  - O'Connor DB
AUID- ORCID: https://orcid.org/0000-0001-5475-8675
AD  - Professorial Surgical Unit, Tallaght University Hospital & Trinity College
      Dublin, Dublin, Ireland.
FAU - Collins, Jack
AU  - Collins J
AUID- ORCID: https://orcid.org/0000-0003-0605-5101
AD  - Department of Anaesthesia, Letterkenny University Hospital, Donegal, Ireland.
FAU - Franklin, Robert
AU  - Franklin R
AUID- ORCID: https://orcid.org/0000-0002-5533-4513
AD  - Department of Anaesthesia, Letterkenny University Hospital, Donegal, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - Canada
TA  - JMIR Med Educ
JT  - JMIR medical education
JID - 101684518
EIN - JMIR Med Educ. 2020 Oct 30;6(2):e25045. PMID: 33125336
PMC - PMC7592068
OTO - NOTNLM
OT  - YouTube
OT  - ethics
OT  - medical education
OT  - patient consent
OT  - patient footage
OT  - patient video
OT  - social media
EDAT- 2020/10/14 06:00
MHDA- 2020/10/14 06:01
CRDT- 2020/10/13 12:11
PHST- 2019/03/20 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/10/13 12:11 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/10/14 06:01 [medline]
AID - v6i2e14081 [pii]
AID - 10.2196/14081 [doi]
PST - epublish
SO  - JMIR Med Educ. 2020 Oct 13;6(2):e14081. doi: 10.2196/14081.


PMID- 33047707
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20220417
IS  - 1119-3077 (Print)
VI  - 23
IP  - 10
DP  - 2020 Oct
TI  - Evaluation of the educational environment of a new medical school in southeast
      Nigeria.
PG  - 1462-1469
LID - 10.4103/njcp.njcp_221_20 [doi]
AB  - BACKGROUND: Educational environment (EE) affects transfer/acquisition of
      knowledge and skills needed in training medical students. Evaluation of EE by
      students is paramount to rating the EE of a medical school as well as evaluate
      effects of interventions. Assessing EE of medical schools is a current global
      trend. OBJECTIVES: : To evaluate EE at the new medical school of the Chukwuemeka 
      Odumegwu Ojukwu University Teaching Hospital Awka, Anambra State, Nigeria;
      calculate the total and subscale (Dundee Ready Educational Environment Measure)
      DREEM scores and assess differences in these scores amongst the different
      classes, age groups, and sexes. METHODOLOGY: This was a descriptive
      cross-sectional study using census survey. We administered DREEM questionnaire to
      4(th), 5(th), and 6(th) year medical students in the 2018/2019 academic session
      after ethical approval from Health Research and Ethics Committee (HREC). Data
      entry and analysis done using SPSS. ANOVA was used for association between level 
      of study, age group, and total DREEM/Subscale scores. Test for association
      between sex and mean subscale/total score was done using independent sample
      t-test. P value <0.05 was adjudged significant. Cronbach's alpha for internal
      consistency was calculated. RESULTS: Of 206 students, 185 filled in the
      questionnaire. Total DREEM score was 119.66, Students' perception of teachers
      26.74, Students' academic self Perception 21.94, Students' Perception of Learning
      30.75, Students' Social Self Perception 15.04, Students' Perception of Atmosphere
      25.26. Three items scored above 3 while 11 items scored </=2. Fourth year
      students significantly scored higher than others for all subscale and total DREEM
      score. No significant associations between age or gender and subscale or total
      DREEM scores. Cronbach's alpha for all scores was 0.91. CONCLUSIONS: The EE was
      not excellent but "more positive than negative." Improvements are necessary in
      all domains of DREEM to ensure better quality of the educational environment.
FAU - Ezomike, U O
AU  - Ezomike UO
AD  - Sub-Department of Paediatric Surgery, Faculty of Medical Sciences, College of
      Medicine, University of Nigeria, Ituku, Ozalla Campus, Nigeria.
FAU - Madubogwu, C I
AU  - Madubogwu CI
AD  - Department of Surgery, College of Medicine, Chukwuemeka Odumegwu Ojukwu
      University, Awka, Anambra State, Nigeria.
FAU - Azuike, E C
AU  - Azuike EC
AD  - Department of Community Medicine and Primary Healthcare, University Teaching
      Hospital, Chukwuemeka Odumegwu Ojukwu University, Awka, Anambra State, Nigeria.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Niger J Clin Pract
JT  - Nigerian journal of clinical practice
JID - 101150032
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Education, Medical, Undergraduate
MH  - Female
MH  - Humans
MH  - Learning
MH  - Male
MH  - Nigeria
MH  - Schools, Medical/*organization & administration
MH  - *Self Concept
MH  - *Social Environment
MH  - Students, Medical/*psychology
MH  - Surveys and Questionnaires
MH  - Teaching
MH  - Universities
OTO - NOTNLM
OT  - Educational environment
OT  - evaluation
OT  - new medical school
OT  - southeast Nigeria
COIS- None
EDAT- 2020/10/14 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/13 09:20
PHST- 2020/10/13 09:20 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - NigerJClinPract_2020_23_10_1462_297919 [pii]
AID - 10.4103/njcp.njcp_221_20 [doi]
PST - ppublish
SO  - Niger J Clin Pract. 2020 Oct;23(10):1462-1469. doi: 10.4103/njcp.njcp_221_20.


PMID- 33047613
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1872-969X (Electronic)
IS  - 0146-6453 (Linking)
VI  - 49
IP  - 1_suppl
DP  - 2020 Dec
TI  - The 2018 Bo Lindell Laureate Lecture: Finding common ground between science,
      ethics, and experience.
PG  - 9-31
LID - 10.1177/0146645320946618 [doi]
AB  - The present system of radiological protection has evolved with the advancement of
      science; evolution of ethical and societal values; and the lessons of our
      individual, collective, and historical experience. In communicating with each
      other and members of the public, words are often not enough to completely relay
      thoughts, ideas, or experiences. Art is a shared experience, beyond the spoken
      language, where many can find common ground. This paper provides several examples
      of utilising the visual arts, cinema, and popular culture for communication in
      different contexts, with discussion of how each relates to the ethical values of 
      the system of radiological protection. In this way, we find inter-relationships
      between science, ethics, and experience. Experience improves understanding;
      empathy, or the awareness and feeling of another's experience, can lead to
      similar understanding. Drawing on art and the broader human experience will help 
      us improve our communication, promote transparency, and encourage empathy.
      Through this, we will be more likely to develop trust with stakeholders, which is
      an essential, yet challenging, aspect of radiological protection.
FAU - Martinez, N E
AU  - Martinez NE
AD  - Department of Environmental Engineering and Earth Sciences, Clemson University,
      342 Computer Ct, Clemson, SC 29625, USA; e-mail: nmarti3@clemson.edu.
LA  - eng
PT  - Journal Article
PT  - Lecture
DEP - 20201013
PL  - England
TA  - Ann ICRP
JT  - Annals of the ICRP
JID - 7708044
SB  - IM
MH  - *Communication
MH  - Humans
MH  - *Radiation Protection/instrumentation/methods/standards
OTO - NOTNLM
OT  - Ethics; Art; System of radiological protection
EDAT- 2020/10/14 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/10/13 08:45
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/10/13 08:45 [entrez]
AID - 10.1177/0146645320946618 [doi]
PST - ppublish
SO  - Ann ICRP. 2020 Dec;49(1_suppl):9-31. doi: 10.1177/0146645320946618. Epub 2020 Oct
      13.


PMID- 33047542
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220417
IS  - 1004-5619 (Print)
IS  - 1004-5619 (Linking)
VI  - 36
IP  - 4
DP  - 2020 Aug
TI  - Research Progress on the Forensic Age Estimation in Living Individuals Using MRI.
PG  - 549-548
LID - 10.12116/j.issn.1004-5619.2020.04.022 [doi]
AB  - ABSTRACT: One of the major tasks in the forensic field is age estimation in
      living individuals, especially in adolescents and young adults. The X-ray
      examination of left hand, panoramic radiograph and CT scan of the sternal end of 
      clavicles are mature means that are widely used. However, the X-ray technique has
      great radiation on the human body, and imaging radiation for non-diagnosis and
      treatment purposes does not conform to the current mainstream medical ethics. MRI
      is nonradioactive tomographic imaging and is one of the research and development 
      directions in forensic age estimation in living individuals now. This paper
      summarizes the common indicators and analysis methods of MRI in previous research
      of age estimation, in order to get better understanding of its trends and provide
      a clue for future relevant studies.
CI  - Copyright(c) by the Editorial Department of Journal of Forensic Medicine.
FAU - Lu, T
AU  - Lu T
AD  - West China School of Basic Medical Sciences & Forensic Medicine, Sichuan
      University, Chengdu 610041, China.
FAU - Fan, F
AU  - Fan F
AD  - West China School of Basic Medical Sciences & Forensic Medicine, Sichuan
      University, Chengdu 610041, China.
FAU - Shi, L
AU  - Shi L
AD  - West China School of Basic Medical Sciences & Forensic Medicine, Sichuan
      University, Chengdu 610041, China.
FAU - Deng, Z H
AU  - Deng ZH
AD  - West China School of Basic Medical Sciences & Forensic Medicine, Sichuan
      University, Chengdu 610041, China.
LA  - eng
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Fa Yi Xue Za Zhi
JT  - Fa yi xue za zhi
JID - 9426151
SB  - IM
MH  - Adolescent
MH  - *Age Determination by Skeleton
MH  - Clavicle/diagnostic imaging
MH  - *Forensic Anthropology
MH  - Hand
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Young Adult
OTO - NOTNLM
OT  - forensic anthropology; age determination by skeleton; age determination by teeth;
      magnetic resonance imaging; review
COIS- The authors of this article and the planning committee members and staff have no 
      relevant financial relationships with commercial interests to disclose.
EDAT- 2020/10/14 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/13 05:44
PHST- 2020/03/30 00:00 [received]
PHST- 2020/10/13 05:44 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - j/4/549 [pii]
AID - 10.12116/j.issn.1004-5619.2020.04.022 [doi]
PST - ppublish
SO  - Fa Yi Xue Za Zhi. 2020 Aug;36(4):549-548. doi:
      10.12116/j.issn.1004-5619.2020.04.022.


PMID- 33047188
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20211203
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 12
DP  - 2020 Dec
TI  - Altered evolution: are reproductive endocrinology and infertility specialists
      ready for the genetically engineered future?
PG  - 2949-2954
LID - 10.1007/s10815-020-01963-8 [doi]
AB  - Science, propelled forward by noble aspirations and, at times, human hubris, has 
      the capacity to affect lives and alter the world in unanticipated ways. Even
      seemingly minor discoveries have repeatedly proven to have far reaching
      implications that experts within their respective fields could not have
      predicted. Nuclear technology is both a source of energy and a potential means of
      annihilation. The internet has both seamlessly connected the world but has also
      opened society to the misuse and manipulation of information. Both exemplify how 
      new technologies have the potential for positive and negative outcomes that often
      go beyond what was initially intended. This is not a fault of science and
      innovation but rather an inherent occupational hazard as new discoveries exist
      within a gray zone between ignorance and comprehension. These gaps in our
      knowledge can only be filled over time as our knowledge expands. Innovations that
      were once seen as fringe, over time, become mainstream and that which was once
      revolutionary becomes a part of everyday life. Occasionally, a scientific
      advancement comes along that challenges societal norms and causes us to question 
      what is feasible, acceptable, and ethical. Nowhere in the twenty-first century
      has this been more evident than within the fields of genetics and genetic
      engineering. As we gain a deeper understanding of the source code of life, from
      individual base pairs to epigenetic influences, the implications of new
      discoveries will go far beyond curing genetic diseases, and the possibilities
      will be endless. Reproductive endocrinology and infertility (REI) specialists
      utilize many tools including expanded carrier screening, preimplantation genetic 
      testing, and embryo selection and have become some of the experts at the
      forefront of the ongoing genetic revolution. Now more than ever, there is a need 
      for REIs to be trained in the fundamentals of genetics, exposed to novel gene
      sequencing and editing techniques, and involved in the coming ethical discussions
      in order to be prepared for the genetically engineered future.
FAU - Pavlovic, Zoran J
AU  - Pavlovic ZJ
AUID- ORCID: http://orcid.org/0000-0002-4187-026X
AD  - Department of Obstetrics and Gynecology, Rush University Medical Center, 1653 W. 
      Congress Pkwy, Suite 218 Kellogg, Chicago, IL, 60612, USA.
      zoran.j.pavlovic@gmail.com.
FAU - Sax, Megan R
AU  - Sax MR
AD  - Department of Obstetrics and Gynecology, University of Cincinnati, Medical
      Sciences Building Room 7264, 231 Albert Sabin Way, Mail Location 0526,
      Cincinnati, OH, 45267, USA.
FAU - Kim, Ashley S
AU  - Kim AS
AD  - Department of Obstetrics and Gynecology, Kaiser Permanente Los Angeles Medical
      Center, 4900 Sunset Boulevard, Los Angeles, CA, 90027, USA.
FAU - DeCherney, Alan H
AU  - DeCherney AH
AD  - Program in Adult Endocrinology, Eunice Kennedy Shriver National Institute of
      Child Health and Human Development, National Institutes of Health, 9000 Rockville
      Pike, Bethesda, MD, 20892, USA.
LA  - eng
PT  - Journal Article
DEP - 20201012
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - Endocrinology/*standards
MH  - Female
MH  - *Genetic Engineering
MH  - Genetic Testing/*methods
MH  - Humans
MH  - Infertility/*genetics/*therapy
MH  - Pregnancy
MH  - Preimplantation Diagnosis
MH  - *Reproductive Medicine
MH  - Reproductive Techniques, Assisted/*standards
MH  - Specialization
PMC - PMC7714831
OTO - NOTNLM
OT  - Bioethics
OT  - Broad societal consensus
OT  - CCR5
OT  - CRISPR
OT  - Cas9
OT  - Ethics
OT  - Evolution
OT  - Genetic engineering
OT  - Genetics
OT  - Induced pluripotent stem cells
OT  - Modification
OT  - Moratorium
OT  - PGT
OT  - Yamanaka factors
OT  - iPCS
EDAT- 2020/10/14 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/10/13 05:39
PHST- 2020/04/24 00:00 [received]
PHST- 2020/10/04 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/10/13 05:39 [entrez]
AID - 10.1007/s10815-020-01963-8 [doi]
AID - 10.1007/s10815-020-01963-8 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Dec;37(12):2949-2954. doi:
      10.1007/s10815-020-01963-8. Epub 2020 Oct 12.


PMID- 33047119
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 11
DP  - 2020 Nov 1
TI  - Mild stimulation should be mandatory for oocyte donation.
PG  - 2403-2407
LID - 10.1093/humrep/deaa227 [doi]
AB  - The increasing commercialization of oocyte donation is a source of concern. This 
      evolution is expressed in the fact that oocyte donors' interests are not a
      priority. For decades now, people mention that oocyte donation holds serious
      health risks for donors, as if this is an unavoidable given. However, most of the
      harm is caused by high hormonal stimulation. The risk/benefit balance of high
      stimulation compared to the risk/benefit balance of mild stimulation does not
      justify causing greater harm to donors, especially given the fact that donors
      submit to the procedure without any medical benefit for themselves and to help
      others.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Pennings, Guido
AU  - Pennings G
AD  - Department of Philosophy and Moral Science, Bioethics Institute Ghent (BIG),
      Ghent University, Gent, Belgium.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Confidentiality
MH  - Humans
MH  - *Oocyte Donation
MH  - Oocytes
MH  - *Tissue Donors
OTO - NOTNLM
OT  - *commercialization
OT  - *ethics
OT  - *mild stimulation
OT  - *oocyte donation
OT  - *proportionality principle
EDAT- 2020/10/14 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/13 05:39
PHST- 2020/06/12 00:00 [received]
PHST- 2020/08/08 00:00 [revised]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/10/13 05:39 [entrez]
AID - 5921651 [pii]
AID - 10.1093/humrep/deaa227 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Nov 1;35(11):2403-2407. doi: 10.1093/humrep/deaa227.


PMID- 33046479
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 12
TI  - Achieving universal health coverage for people with stroke in South Africa:
      protocol for a scoping review.
PG  - e041221
LID - 10.1136/bmjopen-2020-041221 [doi]
AB  - INTRODUCTION: Stroke is the second most common cause of death after HIV/AIDS and 
      a significant health burden in South Africa. The extent to which universal health
      coverage (UHC) is achieved for people with stroke in South Africa is unknown.
      Therefore, a scoping review to explore the opportunities and challenges within
      the South African health system to facilitate the achievement of UHC for people
      with stroke is warranted. METHODS AND ANALYSIS: The scoping review will follow
      the approach recommended by Levac, Colquhoun and O'Brien, which includes five
      steps: (1) identifying the research question, (2) identifying relevant studies,
      (3) selecting the studies, (4) charting the data, and (5) collating, summarising 
      and reporting the results. Health Systems Dynamics Framework and WHO Framework on
      integrated people-centred health services will be used to map, synthesise and
      analyse data thematically. ETHICS AND DISSEMINATION: Ethical approval is not
      required for this scoping review, as it will only include published and publicly 
      available data. The findings of this review will be published in an open-access, 
      peer-reviewed journal and we will develop an accessible summary of the results
      for website posting and stakeholder meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - van Niekerk, Sjan-Mari
AU  - van Niekerk SM
AD  - Division of Physiotherapy, Department of Health and Rehabilitation Sciences,
      Stellenbosch University, Cape Town, South Africa smbrown@sun.ac.za.
FAU - Inglis-Jassiem, Gakeemah
AU  - Inglis-Jassiem G
AD  - Division of Physiotherapy, Department of Health and Rehabilitation Sciences,
      Stellenbosch University, Cape Town, South Africa.
FAU - Kamalakannan, Sureshkumar
AU  - Kamalakannan S
AUID- ORCID: 0000-0003-4407-7838
AD  - SACDIR, Public Health Foundation of India, Gurgaon, India.
AD  - International Center for Evidence in Disability, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Fernandes, Silke
AU  - Fernandes S
AD  - Department of Global Health and Development, Faculty of Public Health and Policy,
      London School of Hygiene and Tropical Medicine, London, UK.
FAU - Webster, Jayne
AU  - Webster J
AD  - Department of Disease Control, Faculty of Infectious and Tropical Diseases,
      Stellenbosch University, Cape Town, South Africa.
FAU - English, Rene
AU  - English R
AD  - Division of Health Systems and Public Health, Department of Global Health,
      Faculty of Medicine and Health Sciences, Stellenbosch University, London, UK.
FAU - Smythe, Tracey
AU  - Smythe T
AUID- ORCID: 0000-0003-3408-7362
AD  - International Center for Evidence in Disability, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Louw, Q A
AU  - Louw QA
AD  - Division of Physiotherapy, Department of Health and Rehabilitation Sciences,
      Stellenbosch University, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Government Programs
MH  - Humans
MH  - Medical Assistance
MH  - Review Literature as Topic
MH  - South Africa
MH  - *Stroke/therapy
MH  - *Universal Health Insurance
PMC - PMC7552861
OTO - NOTNLM
OT  - *health policy
OT  - *health system
OT  - *public health
OT  - *stroke
OT  - *universal health coverage
COIS- Competing interests: None declared.
EDAT- 2020/10/14 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/10/13 05:32
PHST- 2020/10/13 05:32 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2020-041221 [pii]
AID - 10.1136/bmjopen-2020-041221 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 12;10(10):e041221. doi: 10.1136/bmjopen-2020-041221.


PMID- 33046478
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210618
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 12
TI  - Protocol of a randomised controlled trial on the efficacy of medication
      optimisation in elderly inpatients: medication optimisation protocol efficacy for
      geriatric inpatients (MPEG) trial.
PG  - e041125
LID - 10.1136/bmjopen-2020-041125 [doi]
AB  - INTRODUCTION: Whether medication optimisation improves clinical outcomes in
      elderly individuals remains unclear. The current study aims to evaluate the
      effect of multidisciplinary team-based medication optimisation on survival,
      rehospitalisation and unscheduled hospital visits in elderly patients. METHODS
      AND ANALYSIS: We report the protocol of a single-centre, open-label, randomised
      controlled trial. The enrolled subjects will be medical inpatients, aged 65 years
      or older, admitted to a community hospital and receiving five or more regular
      medications. The participants will be randomly assigned to receive either an
      intervention for medication optimisation or the usual care. The intervention will
      consist of a multidisciplinary team-based medication review, followed by a
      medication optimisation proposal based on the Screening Tool of Older Persons'
      potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the
      Right Treatment criteria and an implicit medication optimisation protocol.
      Medication optimisation summaries will be sent to primary care physicians and
      community pharmacists on discharge. The primary outcome will be a composite of
      death, unscheduled hospital visits and rehospitalisation until 48 weeks after
      randomisation. Secondary outcomes will include each of the primary endpoints, the
      number of prescribed medications, quality of life score, level of long-term care 
      required, drug-related adverse events, death during hospitalisation and falls.
      Participants will be followed up for 48 weeks with bimonthly telephone interviews
      to assess the primary and secondary outcomes. A log-rank test stratified by
      randomisation factors will be used to compare the incidence of the composite
      endpoint. The study was initiated in 2019 and a minimum of 500 patients will be
      enrolled. ETHICS AND DISSEMINATION: The study protocol has been approved by the
      Institutional Ethical Committee of St. Marianna University School of Medicine
      (No. 4129). The results of the current study will be submitted to a peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: UMIN000035265.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ie, Kenya
AU  - Ie K
AUID- ORCID: 0000-0002-1387-0588
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan kenya.ie@marianna-u.ac.jp.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Hirose, Masanori
AU  - Hirose M
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Sakai, Tsubasa
AU  - Sakai T
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Motohashi, Iori
AU  - Motohashi I
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Aihara, Mari
AU  - Aihara M
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Otsuki, Takuya
AU  - Otsuki T
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Tsuboya, Ayako
AU  - Tsuboya A
AD  - Department of Pharmacy, Kawasaki Municipal Tama Hospital, Kawasaki-shi, Kanagawa,
      Japan.
FAU - Matsumoto, Hiroshi
AU  - Matsumoto H
AD  - Department of Pharmacy, Kawasaki Municipal Tama Hospital, Kawasaki-shi, Kanagawa,
      Japan.
FAU - Hashi, Hikari
AU  - Hashi H
AD  - Department of Pharmacy, Kawasaki Municipal Tama Hospital, Kawasaki-shi, Kanagawa,
      Japan.
FAU - Inoue, Eisuke
AU  - Inoue E
AD  - Showa University Research Administration Center, Showa University, Shinagawa-ku, 
      Tokyo, Japan.
FAU - Takahashi, Masaki
AU  - Takahashi M
AD  - Division of Medical Informatics, St. Marianna University School of Medicine,
      Kawasaki-shi, Kanagawa, Japan.
FAU - Komiya, Eiko
AU  - Komiya E
AD  - Department of Pharmacy, Kawasaki Municipal Tama Hospital, Kawasaki-shi, Kanagawa,
      Japan.
FAU - Itoh, Yuka
AU  - Itoh Y
AD  - Department of Pharmacy, Kawasaki Municipal Tama Hospital, Kawasaki-shi, Kanagawa,
      Japan.
FAU - Tsuchida, Tomoya
AU  - Tsuchida T
AUID- ORCID: 0000-0002-8517-3941
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Kurosu, Eri
AU  - Kurosu E
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Albert, Steven M
AU  - Albert SM
AD  - Department of Behavioral and Community Health Sciences, University of Pittsburgh 
      Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
FAU - Okuse, Chiaki
AU  - Okuse C
AD  - Division of General Internal Medicine, Department of Internal Medicine, Kawasaki 
      Municipal Tama Hospital, Kawasaki-shi, Kanagawa, Japan.
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
FAU - Matsuda, Takahide
AU  - Matsuda T
AD  - Division of General Internal Medicine, Department of Internal Medicine, St
      Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000035265
GR  - P30 AG024827/AG/NIA NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Geriatrics
MH  - Hospitalization
MH  - Humans
MH  - Inappropriate Prescribing
MH  - Inpatients
MH  - *Medication Therapy Management
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7552871
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *geriatric medicine
OT  - *internal medicine
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/10/14 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/10/13 05:32
PHST- 2020/10/13 05:32 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2020-041125 [pii]
AID - 10.1136/bmjopen-2020-041125 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 12;10(10):e041125. doi: 10.1136/bmjopen-2020-041125.


PMID- 33046475
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 12
TI  - Effects of a power strength training using elastic resistance exercises on the
      motor and non-motor symptoms in patients with Parkinson's disease H&Y 1-3: study 
      protocol for a randomised controlled trial (PARK-BAND Study).
PG  - e039941
LID - 10.1136/bmjopen-2020-039941 [doi]
AB  - INTRODUCTION: Parkinson's disease (PD) is the second most common
      neurodegenerative disorder in Brazil. Physical activity is a complementary
      intervention in managing inherent declines associated with the disease like
      strength, balance, gait, and functionality and benefit health-related outcomes.
      Here, we report the PARK-BAND Study protocol, which aims to investigate potential
      benefits of power training using elastic devices in participants with PD. Our
      intervention will be provided in patients with PD using elastic devices like
      elastic bands and tubes. Therefore, we used the term Park from Parkinson's
      disease and band from elastic bands. METHODS AND ANALYSIS: This randomised
      single-blind single-centre two-arm parallel, superiority trial will include 50
      participants with PD attending the clinical setting. Those who meet the
      eligibility criteria and provide consent to participate will be randomised in a
      1:1 ratio to either the exercise group, which will receive power training
      programme or the health education group, which will receive the education
      programme. Randomisation will be performed by permuted block randomisation with a
      block size of eight. Both groups will receive a 12-week intervention. The
      exercise group will have two sessions per week and the health education group
      will have one session per week. Changes from baseline in bradykinesia, as
      assessed by the Unified Parkinson's Disease Rating Scale motor examination
      subscore and physical functional performance, will be the primary outcomes.
      Secondary outcomes include other neurological, neurophysiological and physical
      variables, as well as the quality of life, depression, cognition, sleep quality
      and disturbances, assessed before and after interventions. We hypothesise that
      the exercise group will have greater improvement in primary and secondary
      outcomes than the health education group. ETHICS AND DISSEMINATION: The study is 
      approved by the Research Ethics Committee of Hospital Universitario Walter
      Cantidio and all participants will provide their written informed consent
      (register number 91075318.1.0000.5045).Trial results will be disseminated via
      peer reviewed journal articles and conference presentations, reports for
      organisations involved with PD and for participants. TRIAL REGISTRATION NUMBER:
      Registro Brasileiro de Ensaios Clinicos Registry (RBR-5w2sqt); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lima, Danielle Pessoa
AU  - Lima DP
AUID- ORCID: 0000-0003-4591-727X
AD  - Geriatric Division, Universidade Federal do Ceara, Hospital Universitario Walter 
      Cantidio, Fortaleza, Brazil dra.daniellelima@gmail.com.
AD  - Medical School, Universidade de Fortaleza, Fortaleza, Brazil.
FAU - de Almeida, Samuel Brito
AU  - de Almeida SB
AD  - Clinical Research Unit, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
FAU - Bonfadini, Janine de Carvalho
AU  - Bonfadini JC
AD  - Clinical Research Unit, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
FAU - Sobreira, Emmanuelle Silva Tavares
AU  - Sobreira EST
AD  - Clinical Research Unit, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
FAU - Damasceno, Patricia Gomes
AU  - Damasceno PG
AD  - Division of Neurology, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
FAU - Viana Junior, Antonio Brazil
AU  - Viana Junior AB
AD  - Clinical Research Unit, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
FAU - de Alencar, Madeleine Sales
AU  - de Alencar MS
AD  - Geriatric Division, Universidade Federal do Ceara, Hospital Universitario Walter 
      Cantidio, Fortaleza, Brazil.
FAU - de Luna, Joao Rafael Gomes
AU  - de Luna JRG
AD  - Geriatric Division, Universidade Federal do Ceara, Hospital Universitario Walter 
      Cantidio, Fortaleza, Brazil.
FAU - Rodrigues, Pedro Gustavo Barros
AU  - Rodrigues PGB
AD  - Medical School, Universidade Federal do Ceara, Hospital Universitario Walter
      Cantidio, Fortaleza, Brazil.
FAU - Pereira, Isabelle de Sousa
AU  - Pereira IS
AD  - Medical School, Universidade Federal do Ceara, Hospital Universitario Walter
      Cantidio, Fortaleza, Brazil.
FAU - Gadelha, Andre Luis de Castro
AU  - Gadelha ALC
AD  - Psychology School, Universidade de Fortaleza, Centro de Ciencias da Saude,
      Fortaleza, Brazil.
FAU - de Oliveira, Liliane Maria
AU  - de Oliveira LM
AD  - School of Kinesiology, Universidade Estacio de Sa Sistema Integrado de
      Bibliotecas do Centro Universitario Estacio do Ceara, Fortaleza, Ceara, Brazil.
FAU - Chaves, Erica Carneiro Barbosa
AU  - Chaves ECB
AD  - School of Kinesiology, Universidade Estacio de Sa Sistema Integrado de
      Bibliotecas do Centro Universitario Estacio do Ceara, Fortaleza, Ceara, Brazil.
FAU - Carneiro, Vlademir Gomes
AU  - Carneiro VG
AD  - School of Kinesiology, Universidade Federal da Paraiba, Joao Pessoa, Brazil.
FAU - Monteiro, Rayane Rodrigues
AU  - Monteiro RR
AD  - School of Kinesiology, Universidade Estacio de Sa Sistema Integrado de
      Bibliotecas do Centro Universitario Estacio do Ceara, Fortaleza, Ceara, Brazil.
FAU - Costa, Thatyara Almeida de Macedo
AU  - Costa TAM
AD  - School of Nutrition, Universidade Estacio de Sa Sistema Integrado de Bibliotecas 
      do Centro Universitario Estacio do Ceara, Fortaleza, Ceara, Brazil.
FAU - Helal, Lucas
AU  - Helal L
AD  - School of Kinesiology, Universidade do Extremo Sul Catarinense, Criciuma, Brazil.
FAU - Signorile, Joseph
AU  - Signorile J
AD  - Kinesiology and Sport Sciences, University of Miami, Coral Gables, Florida, USA.
FAU - Lima, Lidiane Andrea Oliveira
AU  - Lima LAO
AD  - Department of Physiotherapy, Universidade Federal do Ceara, Fortaleza, Brazil.
FAU - Sobreira-Neto, Manoel Alves
AU  - Sobreira-Neto MA
AD  - Division of Neurology, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
FAU - Braga-Neto, Pedro
AU  - Braga-Neto P
AUID- ORCID: 0000-0001-9186-9243
AD  - Division of Neurology, Universidade Federal do Ceara, Hospital Universitario
      Walter Cantidio, Fortaleza, Brazil.
AD  - Medical School, Universidade Estadual do Ceara, Curso de Medicina, Fortaleza,
      Brazil.
LA  - eng
SI  - ReBec/RBR-5w2sqt
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Parkinson Disease/therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Resistance Training
MH  - Single-Blind Method
PMC - PMC7552828
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *geriatric medicine
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/14 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/10/13 05:32
PHST- 2020/10/13 05:32 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2020-039941 [pii]
AID - 10.1136/bmjopen-2020-039941 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 12;10(10):e039941. doi: 10.1136/bmjopen-2020-039941.


PMID- 33046474
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 12
TI  - Case-comparison study protocol for gauging effects of neighbourhood trends and
      sickness: examining the perceptions of transit-Induced gentrification in Prince
      George's County.
PG  - e039733
LID - 10.1136/bmjopen-2020-039733 [doi]
AB  - INTRODUCTION: Impoverished neighbourhoods and communities of colour often bear
      the brunt of unintended transit-oriented development (TOD) impacts. These impacts
      have been known to come in the form of transit-induced gentrification (TIG), a
      socioeconomic by-product of TOD defined as a phenomenon that occurs when the
      provision of transit service, particularly light rail transit (LRT), 'up-scales' 
      nearby neighbourhood(s) and displaces existing residents. Consequently, TIG or
      even the perception of TIG can impact health outcomes (eg, anxiety) and social
      determinants of health (SDOH) (eg, crime). METHODS/ANALYSIS: In 2022, the purple 
      line (PL), a 16.2 mile LRT line, is opening in Prince George's County, Maryland, 
      a suburb of Washington, DC, comprised of over 80% African American and Hispanic
      residents. By taking advantage of this natural experiment, we are proposing the
      GENTS (Gauging Effects of Neighborhood Trends and Sickness: Examining the
      Perceptions of Transit-Induced Gentrification in Prince George's County) Study in
      order to evaluate perceived TIG and associated health outcome and SDOH changes,
      at two points in time, among Prince George's County adults in a prospective
      case-comparison design during the pre-PL LRT period. Descriptive analysis and
      latent growth curve modelling will be used to examine these changes over time.
      ETHICS AND DISSEMINATION: Ethics approval has been granted by the University of
      Maryland Institutional Review Board. The GENTS Study will identify temporal
      changes in perceived TIG, health outcomes and SDOH among case and comparison
      residents before the completion and operation of the PL LRT, an under researched 
      period of TOD. The dissemination of GENTS Study findings will be able to address 
      research questions and policy issues that are specifically tailored to PG County 
      while also providing more effective procedural solutions for other regions
      undergoing TOD and TIG risks.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Roberts, Jennifer D
AU  - Roberts JD
AUID- ORCID: 0000-0002-1850-4341
AD  - Kinesiology, University of Maryland at College Park, College Park, Maryland, USA 
      jenrob@umd.edu.
FAU - Tehrani, Shadi O
AU  - Tehrani SO
AD  - School of Architecture and Environmental Design, Iran University of Science and
      Technology, Tehran, Islamic Republic of Iran.
FAU - Isom, Roger Jr
AU  - Isom R Jr
AD  - Kinesiology, University of Maryland at College Park, College Park, Maryland, USA.
FAU - Stone, Eric A
AU  - Stone EA
AD  - Kinesiology, University of Maryland at College Park, College Park, Maryland, USA.
FAU - Brachman, Micah L
AU  - Brachman ML
AD  - Geographical Sciences, University of Maryland at College Park, College Park,
      Maryland, USA.
FAU - Garcia, Valerie Newsome
AU  - Garcia VN
AD  - Medical Education, Morehouse School of Medicine, Atlanta, Georgia, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Humans
MH  - Maryland
MH  - *Perception
MH  - Prospective Studies
MH  - *Residence Characteristics
MH  - Socioeconomic Factors
MH  - Transportation Facilities/*economics
PMC - PMC7552829
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *cardiac epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/14 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/10/13 05:32
PHST- 2020/10/13 05:32 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2020-039733 [pii]
AID - 10.1136/bmjopen-2020-039733 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 12;10(10):e039733. doi: 10.1136/bmjopen-2020-039733.


PMID- 33046472
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 12
TI  - Evaluating the long-term effects of a data-driven approach to reduce variation in
      emergency department pathology investigations: study protocol for evaluation of
      the NSW Health Pathology Atlas of variation.
PG  - e039437
LID - 10.1136/bmjopen-2020-039437 [doi]
AB  - INTRODUCTION: Variation in test ordering is a major issue in Australia and
      globally with significant financial and clinical impacts. There is currently a
      lack of research identifying and remediating variation in the use of pathology
      tests in emergency departments (EDs). In 2019, NSW Health Pathology introduced
      the Pathology Atlas of Variation that uses a data-driven tool (the Atlas
      Analytical Model) to investigate test order variation across New South Wales
      (NSW) and engage with local health districts (LHDs) to reduce variation. The
      objectives of this study are to evaluate whether this data-driven approach is
      associated with: (1) a reduction in test order variation; (2) improvements in
      patient outcomes and (3) cost benefits, for the five most frequent ED
      presentations. METHODS AND ANALYSIS: This is a large multisite study including 45
      major public hospitals across 15 LHDs in NSW, Australia. The Atlas Analytical
      Model is a data analytics and visualisation tool capable of providing analytical 
      insights into variation in pathology investigations across NSW EDs, which will be
      used as feedback to inform LHDs efforts to reduce variation. Interrupted time
      series analyses using 2 years pre Atlas (2017-2018) and 2 years post Atlas
      (2021-2022) data will be conducted. Study data will be obtained by linking
      hospital and laboratory databases. Funnel plots will be used to identify EDs with
      outlying pathology test ordering practices. The outcome measures include changes 
      in test ordering practices, ED length of stay, hospital admission and cost
      benefits (total pathology costs per ED encounter). ETHICS AND DISSEMINATION: The 
      study has received ethical approval from the NSW Population and Health Service
      Research Ethics Committee (reference, 2019/ETH00184). The findings of the study
      will be published in peer-reviewed journals and disseminated via presentations at
      conferences. We will also engage directly with key stakeholders to disseminate
      the findings and to inform policies related to pathology testing in the ED.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Scowen, Craig
AU  - Scowen C
AD  - NSW Health Pathology, Sydney, New South Wales, Australia.
FAU - Wabe, Nasir
AU  - Wabe N
AUID- ORCID: 0000-0002-9740-6319
AD  - Centre for Health Systems and Safety Research, Australian Institute of Health
      Innovation, Macquarie University, North Ryde, New South Wales, Australia
      nasir.wabe@mq.edu.au.
FAU - Eigenstetter, Alex
AU  - Eigenstetter A
AD  - NSW Health Pathology, Sydney, New South Wales, Australia.
FAU - Lindeman, Robert
AU  - Lindeman R
AD  - NSW Health Pathology, Sydney, New South Wales, Australia.
FAU - Miao, Melissa
AU  - Miao M
AD  - Graduate School of Health, University of Technology Sydney, Broadway, New South
      Wales, Australia.
FAU - Westbrook, Johanna I
AU  - Westbrook JI
AD  - Centre for Health Systems and Safety Research, Australian Institute of Health
      Innovation, Macquarie University, North Ryde, New South Wales, Australia.
FAU - Georgiou, Andrew
AU  - Georgiou A
AUID- ORCID: 0000-0002-7619-3668
AD  - Centre for Health Systems and Safety Research, Australian Institute of Health
      Innovation, Macquarie University, North Ryde, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Australia
MH  - *Emergency Service, Hospital/organization & administration/standards
MH  - Hospitals, Public/organization & administration/standards/statistics & numerical 
      data
MH  - Humans
MH  - New South Wales
MH  - *Pathology/methods/organization & administration/standards
PMC - PMC7552857
OTO - NOTNLM
OT  - *health & safety
OT  - *international health services
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/14 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/10/13 05:32
PHST- 2020/10/13 05:32 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2020-039437 [pii]
AID - 10.1136/bmjopen-2020-039437 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 12;10(10):e039437. doi: 10.1136/bmjopen-2020-039437.


PMID- 33046465
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 12
TI  - Effectiveness and cost-effectiveness of a virtual community of practice to
      improve the empowerment of patients with ischaemic heart disease: study protocol 
      of a randomised controlled trial.
PG  - e037374
LID - 10.1136/bmjopen-2020-037374 [doi]
AB  - INTRODUCTION: Virtual Communities of Practice (VCoP) or knowledge-sharing virtual
      communities offer ubiquitous access to information and exchange possibilities for
      people in similar situations, which might be especially valuable for the
      self-management of patients with chronic diseases. In view of the scarce evidence
      on the clinical and economic impact of these interventions on chronic conditions,
      we aim to evaluate the effectiveness and cost-effectiveness of a VCoP in the
      improvement of the activation and other patient empowerment measures in patients 
      with ischaemic heart disease (IHD). METHODS AND ANALYSIS: A pragmatic randomised 
      controlled trial will be performed in Catalonia, Madrid and Canary Islands,
      Spain. Two hundred and fifty patients with a recent diagnosis of IHD attending
      the participating centres will be selected and randomised to the intervention or 
      control group. The intervention group will be offered participation for 12 months
      in a VCoP based on a gamified web 2.0 platform where there is interaction with
      other patients and a multidisciplinary professional team. Intervention and
      control groups will receive usual care. The primary outcome will be measured with
      the Patient Activation Measure questionnaire at baseline, 6, 12 and 18 months.
      Secondary outcomes will include: clinical variables; knowledge (Questionnaire of 
      Cardiovascular Risk Factors), attitudes (Self-efficacy Managing Chronic Disease
      Scale), adherence to the Mediterranean diet (Mediterranean Diet Questionnaire),
      level of physical activity (International Physical Activity Questionnaire),
      depression (Patient Health Questionnaire), anxiety (Hospital Anxiety Scale-A),
      medication adherence (Adherence to Refill Medication Scale), quality of life
      (EQ-5D-5L) and health resources use. Data will be collected from self-reported
      questionnaires and electronic medical records. ETHICS AND DISSEMINATION: The
      trial was approved by Clinical Research Ethics Committee of Gregorio Maranon
      University Hospital in Madrid, Nuestra Senora de Candelaria University Hospital
      in Santa Cruz de Tenerife and IDIAP Jordi Gol in Barcelona. The results will be
      disseminated through workshops, policy briefs, peer-reviewed publications,
      local/international conferences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov
      Registry (NCT03959631). Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gonzalez-Gonzalez, Ana Isabel
AU  - Gonzalez-Gonzalez AI
AUID- ORCID: 0000-0002-1707-0596
AD  - Goethe-Universitat Frankfurt am Main Institut fur Allgemeinmedizin, Frankfurt am 
      Main, Hessen, Germany gonzalezgonzalez@allgemeinmedizin.uni-frankfurt.de.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Gerencia Asistencial de Atencion Primaria, Servicio Madrileno de Madrid, Madrid, 
      Spain.
FAU - Perestelo-Perez, Lilisbeth
AU  - Perestelo-Perez L
AD  - Servicio de Evaluacion y Planificacion del Servicio Canario de la Salud,
      Tenerife, Spain.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Tenerife, Spain.
FAU - Koatz, Debora
AU  - Koatz D
AD  - Avedis Donabedian Research Institute (FAD), Barcelona, Spain.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Barcelona, Spain.
FAU - Ballester, Marta
AU  - Ballester M
AUID- ORCID: 0000-0002-7803-8354
AD  - Avedis Donabedian Research Institute (FAD), Barcelona, Spain.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Barcelona, Spain.
FAU - Pacheco-Huergo, Valeria
AU  - Pacheco-Huergo V
AD  - Avedis Donabedian Research Institute (FAD), Barcelona, Spain.
AD  - Centro de Atencion Primaria Turo, Instituto Catalan de la Salud, Barcelona,
      Spain.
FAU - Ramos-Garcia, Vanesa
AU  - Ramos-Garcia V
AUID- ORCID: 0000-0002-9106-2420
AD  - Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FISC),
      Tenerife, Spain.
FAU - Torres-Castano, Alezandra
AU  - Torres-Castano A
AD  - Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FISC),
      Tenerife, Spain.
FAU - Rivero-Santana, Amado
AU  - Rivero-Santana A
AD  - Servicio de Evaluacion y Planificacion del Servicio Canario de la Salud,
      Tenerife, Spain.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Tenerife, Spain.
FAU - Toledo-Chavarri, Ana
AU  - Toledo-Chavarri A
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Tenerife, Spain.
AD  - Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FISC),
      Tenerife, Spain.
FAU - Valcarcel-Nazco, Cristina
AU  - Valcarcel-Nazco C
AD  - Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FISC),
      Tenerife, Spain.
FAU - Mateos-Rodilla, Juana
AU  - Mateos-Rodilla J
AD  - Escuela Madrilena de Salud, Direccion General de Humanizacion y Atencion al
      Paciente, Madrid, Spain.
FAU - Obaya-Rebollar, Juan Carlos
AU  - Obaya-Rebollar JC
AD  - Centro de Salud Chopera, Gerencia Asistencial de Atencion Primaria, Madrid,
      Spain.
FAU - Garcia-Garcia, Javier
AU  - Garcia-Garcia J
AD  - Unidad de Calidad y Seguridad del Paciente. Hospital Universitario Nuestra Senora
      de Candelaria, Tenerife, Spain.
FAU - Diaz-Sanchez, Santiago
AU  - Diaz-Sanchez S
AD  - Centro de Salud Pintores, Gerencia Asistencial de Atencion Primaria, Madrid,
      Spain.
FAU - Morales-Cobos, Luis
AU  - Morales-Cobos L
AD  - Centro de Salud Las Americas, Gerencia Asistencial de Atencion Primaria, Madrid, 
      Spain.
FAU - Bosch-Fontcuberta, Josep Maria
AU  - Bosch-Fontcuberta JM
AD  - Centro de Atencion Primaria Encants, Instituto Catalan de la Salud, Barcelona,
      Spain.
AD  - Departament de Medicina Area de Medicina, Universitat Autonoma de Barcelona,
      Barcelona, Catalunya, Spain.
FAU - Vallejo-Camazon, Nuria
AU  - Vallejo-Camazon N
AD  - Hospital Germans Trias i Pujol, Badalona, Catalunya, Spain.
FAU - Rodriguez-Almodovar, Ana
AU  - Rodriguez-Almodovar A
AD  - UGC Cardiologia, Hospital Universitario Reina Sofia, Codoba, Spain.
FAU - Del Castillo, Jose Carlos
AU  - Del Castillo JC
AD  - Cardiovascular Area, Hospital San Juan de Dios, Tenerife, Canarias, Spain.
FAU - Munoz-Balsa, Marcos
AU  - Munoz-Balsa M
AD  - Unidad de Apoyo Tecnico, Gerencia Asistencial Atencion Primaria, Servicio
      Madrileno de Salud, Madrid, Spain.
FAU - Del Rey-Granado, Yolanda
AU  - Del Rey-Granado Y
AD  - Unidad de Apoyo Tecnico, Gerencia Asistencial Atencion Primaria, Servicio
      Madrileno de Salud, Madrid, Spain.
FAU - Garrido-Elustondo, Sofia
AU  - Garrido-Elustondo S
AD  - Centre Family and Community Care Teaching Multiprofessional Unit, Comunidad de
      Madrid Consejeria de Sanidad, Madrid, Spain.
FAU - Tello-Bernabe, Maria-Eugenia
AU  - Tello-Bernabe ME
AD  - Centro de Salud El Naranjo, Gerencia Asistencial Atencion Primaria, Servicio
      Madrileno de Salud, Madrid, Spain.
FAU - Ramirez-Puerta, Ana Belen
AU  - Ramirez-Puerta AB
AD  - Unidad de Apoyo Tecnico, Gerencia Asistencial Atencion Primaria, Servicio
      Madrileno de Salud, Madrid, Spain.
FAU - Orrego, Carola
AU  - Orrego C
AUID- ORCID: 0000-0002-2978-6268
AD  - Avedis Donabedian Research Institute (FAD), Barcelona, Spain.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Barcelona, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03959631
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - *Myocardial Ischemia
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Spain
PMC - PMC7552830
OTO - NOTNLM
OT  - *adult cardiology
OT  - *coronary heart disease
OT  - *general medicine (see internal medicine)
OT  - *geriatric medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/13 05:32
PHST- 2020/10/13 05:32 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037374 [pii]
AID - 10.1136/bmjopen-2020-037374 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 12;10(10):e037374. doi: 10.1136/bmjopen-2020-037374.


PMID- 33046074
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 12
TI  - Assessing comfort level of organ donation competencies among pediatric
      intensivists in Saudi Arabia: a national survey.
PG  - 358
LID - 10.1186/s12909-020-02262-7 [doi]
AB  - BACKGROUND: As increasing the number of organ donations presents a global
      challenge, Saudi Arabia is no different. Intensivists can play a major role in
      maximizing the organ donation process and minimize the challenges. The purpose of
      this study was to investigate Saudi pediatric intensivists' comfort and
      importance levels of organ donation competencies. METHODS: We conducted a
      cross-sectional survey whose sampling frame included 100 pediatric intensivists. 
      The pediatrician intensivists were identified through an updated list provided by
      the Saudi Critical Care Society. We assessed 14 competencies categorized into
      four domains: the general donation, donation after brain death (DBD),
      neurological determination of death, and medicolegal, religious, and ethical
      domains. Then we investigated the association between these competencies and
      physicians' characteristics. RESULTS: With a response rate of 76%, we found that 
      40-60% of the surveyed pediatric intensivists rated their comfort in 6 out of 14 
      competencies as high or very high. There was a statistically significant gap in
      the intensivists' rating of 10 competencies (i.e., high importance but low
      comfort levels). Ordinal regression showed that comfort levels with the general
      donation, neurological determination of death, and medicolegal, religious, and
      ethical domains were higher in intensivists who were frequently involved with DBD
      than those who had never been exposed. CONCLUSIONS: Pediatric intensivists
      expressed low comfort levels to organ donation competencies that are essential
      for maximizing donation rates. Adapting mandatory comprehensive donation
      education programs and dedicated physician specialists may be beneficial in
      critical care units aiming to increase donation rates.
FAU - Kazzaz, Yasser M
AU  - Kazzaz YM
AUID- ORCID: http://orcid.org/0000-0003-3590-4547
AD  - Department of Pediatrics, Ministry of National Guards - Health Affairs, Riyadh,
      Kingdom of Saudi Arabia. kazzazy@ngha.med.sa.
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh, Saudi Arabia. kazzazy@ngha.med.sa.
AD  - King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
      kazzazy@ngha.med.sa.
FAU - Da'ar, Omar B
AU  - Da'ar OB
AD  - King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
AD  - Department of Health Systems, College of Public Health and Informatics, King Saud
      bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
LA  - eng
GR  - SP19/107/R/King Abdullah International Medical Research Center
PT  - Journal Article
DEP - 20201012
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Child
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Intensive Care Units
MH  - Saudi Arabia
MH  - Surveys and Questionnaires
MH  - *Tissue and Organ Procurement
PMC - PMC7552448
OTO - NOTNLM
OT  - Donation after brain death
OT  - Intensive care unit physician
OT  - Organ donation
OT  - Saudi Arabia
OT  - Tissue donation
EDAT- 2020/10/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/13 05:27
PHST- 2020/04/20 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/13 05:27 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02262-7 [doi]
AID - 10.1186/s12909-020-02262-7 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Oct 12;20(1):358. doi: 10.1186/s12909-020-02262-7.


PMID- 33045534
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20210110
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 73
DP  - 2020 Nov - Dec
TI  - Mental health, mental capacity, ethics, and the law in the context of COVID-19
      (coronavirus).
PG  - 101632
LID - S0160-2527(20)30091-1 [pii]
LID - 10.1016/j.ijlp.2020.101632 [doi]
AB  - The emergence of the COVID-19 (coronavirus) pandemic in late 2019 and early 2020 
      presented new and urgent challenges to mental health services and legislators
      around the world. This special issue of the International Journal of Law and
      Psychiatry explores mental health law, mental capacity law, and medical and legal
      ethics in the context of COVID-19. Papers are drawn from India, Australia, the
      United Kingdom, Ireland, Germany, Portugal, and the United States. Together,
      these articles demonstrate the complexity of psychiatric and legal issues
      prompted by COVID-19 in terms of providing mental health care, protecting rights,
      exercising decision-making capacity, and a range of other topics. While further
      work is needed in many of these areas, these papers provide a strong framework
      for addressing key issues and meeting the challenges that COVID-19 and, possibly,
      other outbreaks are likely to present in the future.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kelly, Brendan D
AU  - Kelly BD
AD  - Department of Psychiatry, Trinity College Dublin, Trinity Centre for Health
      Sciences, Tallaght University Hospital, Dublin, 24, D24 NR0A, Ireland. Electronic
      address: brendan.kelly@tcd.ie.
FAU - Drogin, Eric
AU  - Drogin E
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - McSherry, Bernadette
AU  - McSherry B
AD  - Melbourne Social Equity Institute, University of Melbourne, 201 Grattan Street,
      Carlton, Vic, 3056, Australia.
FAU - Donnelly, Mary
AU  - Donnelly M
AD  - Law School, University College Cork, Cork, Ireland.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
DEP - 20201001
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - COVID-19/epidemiology/*psychology
MH  - *Commitment of Mentally Ill/ethics/legislation & jurisprudence
MH  - *Human Rights/ethics/legislation & jurisprudence
MH  - Humans
MH  - *Mental Competency/legislation & jurisprudence
MH  - Mental Disorders/epidemiology/*psychology
MH  - *Mental Health
MH  - *Mental Health Services/ethics/legislation & jurisprudence
MH  - Pandemics
MH  - SARS-CoV-2
PMC - PMC7528736
OTO - NOTNLM
OT  - *Coronavirus
OT  - *Covid-19
OT  - *Human rights
OT  - *Mental capacity
OT  - *Mental health legislation
OT  - *Psychiatry
EDAT- 2020/10/13 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/10/12 20:11
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/10/12 20:11 [entrez]
AID - S0160-2527(20)30091-1 [pii]
AID - 10.1016/j.ijlp.2020.101632 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Nov - Dec;73:101632. doi: 10.1016/j.ijlp.2020.101632. 
      Epub 2020 Oct 1.


PMID- 33045018
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20201126
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 10
DP  - 2020
TI  - Grassroots community actors leading the way in the prevention of youth violent
      radicalization.
PG  - e0239897
LID - 10.1371/journal.pone.0239897 [doi]
AB  - Violence-free family ties, non-violent peers or attachment to society have been
      pointed out as protective factors against different types of extremism and
      violent radicalization by international literature. However, more detail needs to
      be provided about which specific aspects within these realms
      (friendship/family/community) are effective in challenging violence and how they 
      operate in practice. Recent research conducted under the framework of the PROTON 
      project (Horizon 2020) has analyzed the social and ethical impacts of
      counter-terrorism and organized crime policies in six European countries. In this
      article we discuss some identified common features among practices that,
      developed by organized actors operating at the local level (e.g.:
      grassroots-based associations, educational institutions, other type of organized 
      networks for prevention, NGOs), are contributing to preventing youth violent
      radicalization, a phenomenon of growing concern in Europe and beyond. Standing on
      a solid rejection to violence, these shared features are the following: a
      bottom-up approach in setting allies with key stakeholders from the community
      or/and family members to intervene; the promotion of trustworthy and healthy
      friendship relationships; debunking the lure surrounding violent subjects ("false
      heroes") and violence in the different contexts, especially in the
      socioeducational one.
FAU - Puigvert, Lidia
AU  - Puigvert L
AD  - Department of Sociology, University of Barcelona, Barcelona, Spain.
AD  - Institute of Criminology, University of Cambridge, Cambridge, United Kingdom.
FAU - Aiello, Emilia
AU  - Aiello E
AD  - Harvard Kennedy School of Government, Harvard University, Cambridge,
      Massachusetts, United States of America.
FAU - Oliver, Esther
AU  - Oliver E
AD  - Department of Sociology, University of Barcelona, Barcelona, Spain.
FAU - Ramis-Salas, Mimar
AU  - Ramis-Salas M
AUID- ORCID: 0000-0002-2820-0122
AD  - Department of Sociology, University of Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201012
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Europe
MH  - Female
MH  - Humans
MH  - Male
MH  - Social Control, Informal/*methods
MH  - *Social Environment
MH  - *Stakeholder Participation
MH  - Violence/*prevention & control/psychology
MH  - Young Adult
PMC - PMC7549796
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/13 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/10/12 17:10
PHST- 2020/04/15 00:00 [received]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/10/12 17:10 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
AID - 10.1371/journal.pone.0239897 [doi]
AID - PONE-D-20-10083 [pii]
PST - epublish
SO  - PLoS One. 2020 Oct 12;15(10):e0239897. doi: 10.1371/journal.pone.0239897.
      eCollection 2020.


PMID- 33044907
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - The Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell
      Disease.
PG  - 195-207
LID - 10.1080/23294515.2020.1818876 [doi]
AB  - BACKGROUND: A first therapeutic target of somatic genome editing (SGE) is sickle 
      cell disease (SCD), the most commonly inherited blood disorders, affecting more
      than 100,000 individuals in the United States. Advancement of SGE is contingent
      on patient participation in first in human clinical trials. However, seriously
      ill patients may be vulnerable to overestimating the benefits of early phase
      studies while underestimating the risks. Therefore, ensuring potential clinical
      trial participants are fully informed prior to participating in a SGE clinical
      trial is critical. Methods: We conducted a mixed-methods study of adults with SCD
      as well as parents and physicians of individuals with SCD. Participants were
      asked to complete a genetic literacy survey, watch an educational video about
      genome editing, complete a two-part survey, and take part in focus group
      discussions. Focus groups addressed topics on clinical trials, ethics of gene
      editing, and what is not understood regarding gene editing. All focus groups were
      audio-recorded, transcribed, and analyzed using conventional content analysis
      techniques to identify major themes. Results: Our study examined the views of SCD
      stakeholders regarding what they want and need to know about genome editing to
      make an informed decision to participate in a SGE clinical trial. Prominent
      themes included stakeholders' desire to understand treatment side effects,
      mechanism of action of SGE, trial qualification criteria, and the impact of SGE
      on quality of life. In addition, some physicians expressed concerns about the
      extent to which their patients would understand concepts related to SGE; however,
      individuals with SCD demonstrated higher levels of genetic literacy than
      estimated by physicians. Conclusions: Designing ethically robust genome editing
      clinical trials for the SCD population will require, at a minimum, addressing the
      expressed information needs of the community through culturally sensitive
      engagement, so that they can make informed decisions to consider participation in
      clinical trials.
FAU - Desine, Stacy
AU  - Desine S
AD  - Social and Behavioral Research Branch, National Human Genome Research Institute, 
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Hollister, Brittany M
AU  - Hollister BM
AUID- ORCID: 0000-0001-9913-4663
AD  - Social and Behavioral Research Branch, National Human Genome Research Institute, 
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Abdallah, Khadijah E
AU  - Abdallah KE
AD  - Social and Behavioral Research Branch, National Human Genome Research Institute, 
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Persaud, Anitra
AU  - Persaud A
AD  - Social and Behavioral Research Branch, National Human Genome Research Institute, 
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Hull, Sara Chandros
AU  - Hull SC
AUID- ORCID: 0000-0001-8742-4997
AD  - Department of Bioethics, Clinical Center, National Institutes of Health,
      Bethesda, Maryland, USA.
AD  - Bioethics Core, National Human Genome Research Institute, National Institutes of 
      Health, Bethesda, Maryland, USA.
FAU - Bonham, Vence L
AU  - Bonham VL
AUID- ORCID: 0000-0002-3649-5442
AD  - Social and Behavioral Research Branch, National Human Genome Research Institute, 
      National Institutes of Health, Bethesda, Maryland, USA.
LA  - eng
GR  - ZIA HG200394/ImNIH/Intramural NIH HHS/United States
GR  - ZIA HG200403/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20201012
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - *Access to Information
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anemia, Sickle Cell/genetics/*therapy
MH  - Attitude
MH  - Child
MH  - Comprehension
MH  - Focus Groups
MH  - *Gene Editing
MH  - *Genetic Therapy
MH  - Health Literacy
MH  - Health Services Needs and Demand
MH  - Humans
MH  - *Informed Consent
MH  - Middle Aged
MH  - Parents
MH  - Patient Participation
MH  - Research Subjects
MH  - Stakeholder Participation
MH  - Young Adult
PMC - PMC7710006
MID - NIHMS1641044
OTO - NOTNLM
OT  - *CRISPR
OT  - *Sickle cell disease
OT  - *clinical trials
OT  - *informed consent
OT  - *somatic genome editing
EDAT- 2020/10/13 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/10/12 17:08
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/10/12 17:08 [entrez]
AID - 10.1080/23294515.2020.1818876 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Oct-Dec;11(4):195-207. doi:
      10.1080/23294515.2020.1818876. Epub 2020 Oct 12.


PMID- 33044549
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 3
IP  - 10
DP  - 2020 Oct 1
TI  - Integration of Catholic Values and Professional Obligations in the Provision of
      Family Planning Services: A Qualitative Study.
PG  - e2020297
LID - 10.1001/jamanetworkopen.2020.20297 [doi]
AB  - Importance: Religious leaders of the Catholic church created guidelines for
      practicing medicine, that involve reproductive care restrictions that may
      conflict with professional obligations. Objective: To explore how Catholic
      obstetrician-gynecologists integrate their religious values and professional
      obligations related to family planning services. Design, Setting, and
      Participants: In this qualitative investigation, in 2018, US-based
      obstetrician-gynecologists were recruited through an online survey and were
      invited to participate in audio-recorded telephone interviews using a
      semistructured interview guide. Participants were obstetrician-gynecologists who 
      self-identified as Catholic and reported providing reproductive health care as
      follows: (1) provide natural family planning only (low practitioners), (2)
      provide additional contraceptive methods (moderate practitioners), and (3)
      provide family planning services including abortion (high practitioners). The
      study purposively sampled those with higher self-reported religiosity. Data were 
      analyzed from November 2018 to February 2019. Main Outcomes and Measures: The
      primary outcome was understanding how participants describe integration of
      Catholic values with family planning service provision. The telephone interviews 
      explored their integration of Catholic values and professional obligations, and 3
      coders analyzed the responses using grounded theory. Results: Among the 34
      Catholic obstetrician-gynecologists interviewed (27 women [79.4%]), there were 10
      low, 15 moderate, and 9 high practitioners from 19 states. Participants'
      description of morality was consistent with Albert Bandura's Social-Cognitive
      Theory of Moral Thought and Action. The findings were used to create a modified
      framework. Within each group of physicians, 3 themes demonstrating their
      reconciliations between Catholic values and professional obligations emerged;
      each of these themes reflected one of the medical ethical principles of autonomy,
      beneficence, nonmaleficence, or justice. All 10 low practitioners primarily
      promoted natural family planning approaches to avoid iatrogenic risks and none
      provided abortion, reflecting nonmaleficence. Alternatively, moderate
      practitioners focused on nonmaleficence by offering contraception to prevent
      abortions. High practitioners primarily promoted patient autonomy by separating
      religious doctrine from medical practice. All had concerns for beneficence. In
      each group, 1 of the 4 medical ethical principles was underrepresented.
      Conclusions and Relevance: In this qualitative analysis, Catholic
      obstetrician-gynecologists establish their family planning care provision
      practices by emphasizing certain moral and/or ethical principles over others.
      These findings highlight how physician morality in the realm of family planning
      service provision often involves certain religious and/or professional
      reconciliations. Understanding the dilemmas Catholic obstetrician-gynecologists
      face can guide professional development efforts and inform ongoing discussions
      about conscientious objection and provision.
FAU - Marchin, Angela
AU  - Marchin A
AD  - Department of Obstetrics and Gynecology, University of Colorado School of
      Medicine, Aurora.
AD  - Now with MEDNAX Health Solutions Partner, Sunrise, Florida.
AD  - Now with Planned Parenthood of the Rocky Mountains, Denver, Colorado.
FAU - Seale, Rebecca
AU  - Seale R
AD  - Department of Obstetrics and Gynecology, University of Colorado School of
      Medicine, Aurora.
FAU - Sheeder, Jeanelle
AU  - Sheeder J
AD  - Department of Obstetrics and Gynecology, University of Colorado School of
      Medicine, Aurora.
FAU - Teal, Stephanie
AU  - Teal S
AD  - Department of Obstetrics and Gynecology, University of Colorado School of
      Medicine, Aurora.
FAU - Guiahi, Maryam
AU  - Guiahi M
AD  - Department of Obstetrics and Gynecology, University of Colorado School of
      Medicine, Aurora.
AD  - Now with Planned Parenthood of the California Central Coast, Santa Barbara,
      California.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - *Catholicism
MH  - Ethics, Medical
MH  - Family Planning Services/*ethics
MH  - Female
MH  - Gynecology/ethics
MH  - Humans
MH  - Male
MH  - Obstetrics/ethics
MH  - Practice Patterns, Physicians'/*ethics
MH  - *Religion and Medicine
MH  - Women's Health/*ethics
PMC - PMC7550969
EDAT- 2020/10/13 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/10/12 12:12
PHST- 2020/10/12 12:12 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 2771378 [pii]
AID - 10.1001/jamanetworkopen.2020.20297 [doi]
PST - epublish
SO  - JAMA Netw Open. 2020 Oct 1;3(10):e2020297. doi:
      10.1001/jamanetworkopen.2020.20297.


PMID- 33044345
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Dec
TI  - The current outcomes and future challenges in pediatric vascularized composite
      allotransplantation.
PG  - 576-583
LID - 10.1097/MOT.0000000000000809 [doi]
AB  - PURPOSE OF REVIEW: We review the outcomes and future challenges associated with
      pediatric vascularized composite allotransplantation, including follow-up data
      from our bilateral pediatric hand-forearm transplantation. RECENT FINDINGS: In
      2015, the first heterologous pediatric upper extremity hand-forearm transplant
      was performed at the Children's Hospital of Philadelphia, and in 2019, the first 
      pediatric neck reconstructive transplantation was performed in Poland. The 5-year
      follow-up of the pediatric upper extremity recipient demonstrates similar growth 
      rates bilaterally, an increase in bone age parallel to chronologic age, and
      perhaps similar overall growth to nontransplant norms. The pediatric upper
      extremity recipient continues to make gains in functional independence. He excels
      academically and participates in various extracurricular activities. Future
      challenges unique to the pediatric population include ethical issues of informed 
      consent, psychosocial implications, limited donor pool, posttransplant compliance
      issues, and greater life expectancy and therefore time to inherit the many
      complications of immunosuppression. SUMMARY: Currently, we recommend pediatric
      vascularized composite allotransplantation (VCA) for bilateral upper extremity
      amputees, preferably on immunosuppression already, and those patients who would
      have the most potential gain not available through standard reconstructive
      techniques while being able to comply with postoperative immunosuppression
      protocols, surveillance, rehabilitation, and follow-up.
FAU - Azoury, Said C
AU  - Azoury SC
AD  - Division of Plastic Surgery, Department of Surgery.
FAU - Lin, Ines
AU  - Lin I
AD  - Division of Plastic Surgery, Department of Surgery.
AD  - Department of Orthopedic Surgery, University of Pennsylvania.
AD  - Hand Transplantation Program, Children's Hospital of Philadelphia.
FAU - Amaral, Sandra
AU  - Amaral S
AD  - Division of Nephrology, The Children's Hospital of Philadelphia, Perelman School 
      of Medicine.
AD  - Division of Biostatistics, Epidemiology and Informatics, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Chang, Benjamin
AU  - Chang B
AD  - Division of Plastic Surgery, Department of Surgery.
AD  - Department of Orthopedic Surgery, University of Pennsylvania.
AD  - Hand Transplantation Program, Children's Hospital of Philadelphia.
FAU - Levin, L Scott
AU  - Levin LS
AD  - Division of Plastic Surgery, Department of Surgery.
AD  - Department of Orthopedic Surgery, University of Pennsylvania.
AD  - Hand Transplantation Program, Children's Hospital of Philadelphia.
LA  - eng
GR  - R01 DK120886/DK/NIDDK NIH HHS/United States
GR  - R01 DK110749/DK/NIDDK NIH HHS/United States
GR  - R01 HD091185/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Vascularized Composite Allotransplantation/*methods
EDAT- 2020/10/13 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/10/12 12:10
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/10/12 12:10 [entrez]
AID - 10.1097/MOT.0000000000000809 [doi]
AID - 00075200-202012000-00010 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Dec;25(6):576-583. doi:
      10.1097/MOT.0000000000000809.


PMID- 33043614
OWN - NLM
STAT- MEDLINE
DCOM- 20210916
LR  - 20210916
IS  - 1757-7861 (Electronic)
IS  - 1757-7853 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Dec
TI  - Anesthetic Management of Patients After Scoliosis Surgery: A Single-Center
      Retrospective Study.
PG  - 1753-1759
LID - 10.1111/os.12798 [doi]
AB  - PURPOSE: To evaluate the effect of anesthetic management on scoliosis surgery and
      review the incidence rate of perioperative adverse events. METHODS: This was a
      retrospective study and approved by the ethics committee. Patients who underwent 
      scoliosis surgery from April 2011 to March 2018 in the Third Hospital of ChengDu 
      were enrolled in this study. Characteristics of patients were obtained from the
      hospital's electronic records. The following information on patients was
      collected: preoperative assessment details, premedication, type of anesthesia and
      operation, the main postoperative outcome, and complications. Data were presented
      as the mean +/- standard deviations (SD) for normally distributed continuous
      variables and numbers for categorical variables. Statistical analyses were
      performed using SPSS version 22.0. RESULTS: In total, 513 patients were enrolled 
      in the present study. The main preoperative complication was cardiopulmonary
      dysfunction (386 cases, 75.24%). Anesthesia induction was performed with
      conscious tracheal intubation after oral surface anesthesia. In total, the common
      postoperative complications involved anesthesia (24 cases, 4.68%), surgery (23
      cases, 4.48%), the respiratory system (138 cases, 26.90%), and the
      gastrointestinal tract (nine cases, 1.75%). The majority of postoperative
      complications were postoperative hypoxemia and hypercapnia, caused by poor
      cardiopulmonary function. Rare and serious complications still occurred. Three
      patients died in hospital. CONCLUSION: Our study demonstrated a high incidence of
      complications in scoliosis surgery, especially postoperative complications.
      Extreme postoperative vigilance is required and high-level monitoring of
      conditions is highly recommended.
CI  - (c) 2020 The Authors. Orthopaedic Surgery published by Chinese Orthopaedic
      Association and John Wiley & Sons Australia, Ltd.
FAU - Li, Qiang
AU  - Li Q
AD  - Department of Anesthesiology, The Third People's Hospital of Chengdu, Southwest
      Jiao Tong University, Chengdu, China.
FAU - Zeng, Fei
AU  - Zeng F
AD  - Center of Cardiac Surgery, Sichuan Academy of Medical Sciences & Sichuan
      Provincial People's Hospital, Chengdu, China.
FAU - Chen, Tao
AU  - Chen T
AD  - Department of Anesthesiology, The Third People's Hospital of Chengdu, Southwest
      Jiao Tong University, Chengdu, China.
FAU - Pu, Chun
AU  - Pu C
AD  - Department of Anesthesiology, The Third People's Hospital of Chengdu, Southwest
      Jiao Tong University, Chengdu, China.
FAU - Liang, Yi-Jian
AU  - Liang YJ
AD  - Department of Orthopaedics, The Third People's Hospital of Chengdu, Southwest
      Jiao Tong University, Chengdu, China.
FAU - Zheng, Chuan-Dong
AU  - Zheng CD
AUID- ORCID: https://orcid.org/0000-0001-9781-5414
AD  - Department of Anesthesiology, The Third People's Hospital of Chengdu, Southwest
      Jiao Tong University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20201011
PL  - Australia
TA  - Orthop Surg
JT  - Orthopaedic surgery
JID - 101501666
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anesthesia/*methods
MH  - Humans
MH  - Postoperative Complications/*etiology
MH  - Reconstructive Surgical Procedures/*methods
MH  - Retrospective Studies
MH  - Scoliosis/*surgery
MH  - Young Adult
PMC - PMC7767771
OTO - NOTNLM
OT  - Anesthetic management
OT  - Postoperative complication
OT  - Scoliosis surgery
EDAT- 2020/10/13 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/10/12 05:38
PHST- 2019/12/30 00:00 [received]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/10/12 05:38 [entrez]
AID - 10.1111/os.12798 [doi]
PST - ppublish
SO  - Orthop Surg. 2020 Dec;12(6):1753-1759. doi: 10.1111/os.12798. Epub 2020 Oct 11.


PMID- 33042961
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201013
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Development of an Improved 3D in vitro Intestinal Model to Perform Permeability
      Studies of Paracellular Compounds.
PG  - 524018
LID - 10.3389/fbioe.2020.524018 [doi]
AB  - The small intestine is the primary site of drug absorption following oral
      administration, making paramount the proper monitoring of the absorption process.
      In vitro tools to predict intestinal absorption are particularly important in
      preclinical drug development since they are less laborious and cost-intensive and
      raise less ethical considerations compared to in vivo studies. The Caco-2 model
      is considered the gold standard of in vitro intestinal models regarding the
      prediction of absorption of orally delivered compounds. However, this model
      presents several drawbacks, such as the expression of tighter tight junctions,
      not being suitable to perform permeability of paracellular compounds. Besides,
      cells are representative of only one intestinal cell type, without considering
      the role of non-absorptive cells on the absorption pathway of drugs. In the
      present study, we developed a new three-dimensional (3D) intestinal model that
      aims to bridge the gap between in vitro tools and animal studies. Our 3D model
      comprises a collagen layer with human intestinal fibroblasts (HIFs) embedded,
      mimicking the intestinal lamina propria and providing 3D support for the
      epithelium, composed of Caco-2 cells and mucus-producing HT29-MTX cells, creating
      a model that can better resemble, both in terms of composition and regarding the 
      outcomes of drug permeability when testing paracellular compounds, the human
      small intestine. The optimization of the collagen layer with HIFs was performed, 
      testing different collagen concentrations and HIF seeding densities in order to
      avoid collagen contraction before day 14, maintaining HIF metabolically active
      inside the collagen disks during time in culture. HIF morphology and
      extracellular matrix (ECM) deposition were assessed, confirming that fibroblasts 
      presented a normal and healthy elongated shape and secreted fibronectin and
      laminin, remodeling the collagen matrix. Regarding the epithelial layer,
      transepithelial electrical resistance (TEER) values decreased when cells were in 
      the 3D configuration, comparing with the 2D analogs (Caco-2 and coculture of
      Caco-2+HT29-MTX models), becoming more similar with in vivo values. The
      permeability assay with fluorescein isothiocyanate (FITC)-Dextran 4 kDa showed
      that absorption in the 3D models is significantly higher than that in the 2D
      models, confirming the importance of using a more biorelevant model when testing 
      the paracellular permeability of compounds.
CI  - Copyright (c) 2020 Macedo, Martinez, Barrias and Sarmento.
FAU - Macedo, Maria Helena
AU  - Macedo MH
AD  - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto, Porto,
      Portugal.
AD  - Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto, Porto,
      Portugal.
FAU - Martinez, Elena
AU  - Martinez E
AD  - Institute for Bioengineering of Catalonia, Barcelona, Spain.
AD  - Consorcio Centro de Investigacion Biomedica en Red de Bioingenieria,
      Biomateriales y Nanomedicina, Madrid, Spain.
AD  - Department of Electronics and Biomedical Engineering, Universitat de Barcelona,
      Barcelona, Spain.
FAU - Barrias, Cristina C
AU  - Barrias CC
AD  - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto, Porto,
      Portugal.
AD  - Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto, Porto,
      Portugal.
FAU - Sarmento, Bruno
AU  - Sarmento B
AD  - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto, Porto,
      Portugal.
AD  - CESPU-Instituto de Investigacao e Formacao Avancada em Ciencias e Tecnologias da 
      Saude, Gandra, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7527803
OTO - NOTNLM
OT  - collagen
OT  - drug absorption
OT  - drug development
OT  - hydrogel
OT  - intestinal model
OT  - paracellular
OT  - permeability
OT  - three-dimensional (3D)
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:32
PHST- 2020/01/01 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/10/12 05:32 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.3389/fbioe.2020.524018 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 Sep 17;8:524018. doi: 10.3389/fbioe.2020.524018.
      eCollection 2020.


PMID- 33042948
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Hazard Prevention, Death and Dignity During COVID-19 Pandemic in Italy.
PG  - 509
LID - 10.3389/fpubh.2020.00509 [doi]
AB  - On 9 March 2020, Italy passed the Prime Minister's Decree n. 648, establishing
      urgent measures to contain the transmission of COVID-19 and prevent biological
      hazards, including very restrictive interventions on public Holy Masses and
      funerals. Italy banned burial procedures based (i) on the recent acknowledgment
      about the virus environmental stability as well as (ii) its national civil
      contingency plan. Hence, only the cremation process is admitted for COVID-19
      deaths. Viewing of the body is permitted only for mourners, which are allowed to 
      perform the prayer at the closing of the coffin and the prayer at the tomb (cf.
      Rite of Succession, first part n. 3 and n. 5). The dead cannot be buried in their
      personal clothes; however, priests have been authorized to put the family clothes
      on top of the corpse, as if they were dressed. Burying personal items is also
      illegal. The dignity of the dead, their cultural and religious traditions, and
      their families should be always respected and protected. Among all the threats,
      COVID-19 epidemic in Italy revealed the fragility of human beings under enforced 
      isolation and, for the first time, the painful deprivation of families to
      accompany their loved ones to the last farewell. Ethics poses new challenges in
      times of epidemics.
CI  - Copyright (c) 2020 Ussai, Armocida, Formenti, Palestra, Calvi and Missoni.
FAU - Ussai, Silvia
AU  - Ussai S
AD  - Directorate General for Food and Health, European Commission, Brussels, Belgium.
FAU - Armocida, Benedetta
AU  - Armocida B
AD  - Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
FAU - Formenti, Beatrice
AU  - Formenti B
AD  - Saluteglobale.it Associazione di Promozione Sociale, Brescia, Italy.
FAU - Palestra, Francesca
AU  - Palestra F
AD  - Saluteglobale.it Associazione di Promozione Sociale, Brescia, Italy.
FAU - Calvi, Marzia
AU  - Calvi M
AD  - Saluteglobale.it Associazione di Promozione Sociale, Brescia, Italy.
FAU - Missoni, Eduardo
AU  - Missoni E
AD  - Saluteglobale.it Associazione di Promozione Sociale, Brescia, Italy.
AD  - Center for Research on Health and Social Care Management (CERGAS), Bocconi
      University, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *COVID-19
MH  - Humans
MH  - Italy/epidemiology
MH  - *Pandemics/prevention & control
MH  - Respect
MH  - SARS-CoV-2
PMC - PMC7530200
OTO - NOTNLM
OT  - *COVID-19
OT  - *deaths
OT  - *hazard & risk
OT  - *policy & institutional actions
OT  - *public health
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:32
PHST- 2020/04/23 00:00 [received]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/10/12 05:32 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.3389/fpubh.2020.00509 [doi]
PST - epublish
SO  - Front Public Health. 2020 Sep 18;8:509. doi: 10.3389/fpubh.2020.00509.
      eCollection 2020.


PMID- 33042894
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2231-0762 (Print)
IS  - 2231-0762 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Jul-Aug
TI  - Assessment of Oral Health-related Quality of Life among Expatriate Working
      Population, Saudi Arabia: A Cross-sectional Study.
PG  - 504-510
LID - 10.4103/jispcd.JISPCD_149_20 [doi]
AB  - BACKGROUND: The expatriate workers (foreign workers) come from various countries 
      having different languages, cultures, and tradition to work in Kingdom of Saudi
      Arabia (KSA); here they adopt to local customs, traditions, and work ethics in
      this new environment. How they perceive their oral health-related quality of life
      (OHRQoL) is important for health-care provider for understanding and planning in 
      patient management. The data of expat workers and their OHRQoL in KSA are meager;
      hence, assessment of OHRQoL among expatriate working population in Al Zulfi,
      Saudi Arabia was planned. MATERIALS AND METHODS: A cross-sectional study was
      conducted on adult expat working population of various nationalities who were
      working in Al Zulfi, KSA. The study sample comprised 600 adult expats. OHRQoL was
      analyzed by using 14-Item Oral Health Impact Profile (OHIP-14) questionnaire as
      instrument. Clinical examination for oral health status was carried out using
      decayed, missing, and filled teeth (DMFT) index and Oral Hygiene Index simplified
      (OHI-S). Student's t test and analysis of variance (ANOVA) were used to compare
      data using Statistical Package for the Social Sciences (SPSS) software program,
      version 20.0 with significance at P </= 0.05. RESULTS: The age of the sample
      population ranged from 19 to 60 years. No significant difference was observed in 
      oral health status among expats of different nationalities. Age and education
      were significantly related to OHRQoL as well as oral health status. The mean
      cumulative scores of OHIP-14 showed that expats from different nationalities had 
      statistically significant differences. CONCLUSION: Overall the impact of OHRQoL
      was less among working expat population in Al Zulfi. Physical pain was the common
      dimension seen among all nationalities. Psychological discomfort and handicap
      dimensions of OHIP-14 were significant among the study sample.
CI  - Copyright: (c) 2020 Journal of International Society of Preventive and Community 
      Dentistry.
FAU - Shaikh, Hidayathulla
AU  - Shaikh H
AD  - Department of Public Health Dentistry, Pacific Academy of Higher Education and
      Research University (PAHER), Udaipur, Rajasthan, India.
FAU - Shilpa, R H
AU  - Shilpa RH
AD  - Department of Public Health Dentistry, MVJ Medical College and Research Hospital,
      Bengaluru, Karnataka, India.
FAU - Fatima, Asiya
AU  - Fatima A
AD  - Department of Orthodontics, Al Badar Dental College & Hospital, Gulbarga,
      Karnataka, India.
FAU - Asawa, Kailash
AU  - Asawa K
AD  - Department of Public Health Dentistry, Pacific Dental College and Hospital,
      Pacific Academy of Higher Education and Research University (PAHER), Udaipur,
      Rajasthan, India.
FAU - Kannan, Karthiga
AU  - Kannan K
AD  - Department of Maxillofacial Diagnostic Sciences, College of Dentistry, Majmaah
      University, Al Zulfi, Kingdom of Saudi Arabia.
FAU - Lankar, Abid
AU  - Lankar A
AD  - Department of Public Health Dentistry, Hail Dental Centre, Hail, Kingdom of Saudi
      Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - India
TA  - J Int Soc Prev Community Dent
JT  - Journal of International Society of Preventive & Community Dentistry
JID - 101618802
PMC - PMC7523926
OTO - NOTNLM
OT  - Expatriates
OT  - KSA
OT  - OHIP-14
OT  - OHRQoL
OT  - oral health
COIS- There are no conflicts of interest.
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:32
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/10/12 05:32 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.4103/jispcd.JISPCD_149_20 [doi]
AID - JISPCD-10-504 [pii]
PST - epublish
SO  - J Int Soc Prev Community Dent. 2020 Aug 6;10(4):504-510. doi:
      10.4103/jispcd.JISPCD_149_20. eCollection 2020 Jul-Aug.


PMID- 33042638
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201012
IS  - 2161-2234 (Electronic)
IS  - 2161-2234 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Sep
TI  - Sincerely, Anonymous.
PG  - 167-176
LID - 10.1002/tht3.455 [doi]
AB  - This paper provides an account of anonymous speech treated as anonymized speech. 
      It is argued that anonymous speech acts are best defined by reference to
      intentional acts of blocking a speaker's identification as opposed to the various
      epistemic effects that imperfectly correlate with these actions. The account is
      used to examine two important subclasses of anonymized speech: speech using
      pseudonyms, and speech anonymized in a specifically communicative manner. Several
      pragmatic and ethical issues with anonymized speech are considered.
CI  - (c) 2020 The Author. Thought: A Journal of Philosophy published by The Thought
      Trust and Wiley Periodicals, Inc.
FAU - Paterson, Grace
AU  - Paterson G
AD  - Department of Philosophy University of Vienna Vienna Austria.
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - United States
TA  - Thought (Hoboken)
JT  - Thought (Hoboken, N.J.)
JID - 101597472
PMC - PMC7539921
OTO - NOTNLM
OT  - anonymity
OT  - anonymous speech
OT  - identifying information
OT  - pseudonyms
OT  - speaker intentions
OT  - speech acts
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:31
PHST- 2019/09/06 00:00 [received]
PHST- 2019/11/05 00:00 [revised]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/10/12 05:31 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.1002/tht3.455 [doi]
AID - THT3455 [pii]
PST - ppublish
SO  - Thought (Hoboken). 2020 Sep;9(3):167-176. doi: 10.1002/tht3.455. Epub 2020 Apr
      27.


PMID- 33042593
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2091-0800 (Print)
VI  - 10
IP  - 3
DP  - 2020 Sep
TI  - Factors associated with awareness and practice about foot care among patients
      admitted with diabetes mellitus: A cross sectional research from a medical
      college hospital of southern India.
PG  - 897-904
LID - 10.3126/nje.v10i3.29213 [doi]
AB  - BACKGROUND: Diabetes Mellitus (DM) causes micro and macro vascular complications.
      One of the complications of DM is diabetic foot that results in amputations and
      decreased quality of life. The aim of this study was to assess the awareness and 
      practice about foot care and associated factors among admitted patients in a
      teaching hospital of coastal Karnataka, India. MATERIAL AND METHODS: A
      cross-sectional study was conducted in a medical college hospital after obtaining
      institutional ethics approval from 24th December 2016 to 21st January 2017.
      Adults with diabetes (N=317) admitted in the hospital were interviewed with a
      validated structured questionnaire for awareness and practice regarding foot
      care. The scores obtained were further graded into good and poor. Data was
      analyzed with SPSS version 22 for descriptive statistics. Bivariate logistic and 
      linear regressions were used to determine the association between variables and
      awareness/practice scores. RESULTS: Mean age of the participants was 56.98
      (+/-10.54) years with males constituting the majority (63.4%). Good awareness and
      practice scores were observed among 69.1% and 41.6% participants, respectively.
      Good awareness scores were associated with male patients (p=0.027), currently not
      married (p=0.044), below poverty line socioeconomic status (p=0.014) and presence
      of foot ulcer (p=0.021). Good practice scores was associated with secondary
      schooling (p=0.003) and receiving insulin (p=0.045). Moderate correlation with
      coefficient 0.493 (p<0.001) was observed between awareness and practice scores.
      CONCLUSION: Seven and four out of 10 study participants had good awareness and
      practice scores about foot care, respectively. A tailor-made health education
      module addressing the lacunae identified in the awareness and practice domains
      needs to be provided to the patients with diabetes mellitus.
CI  - (c) 2020 CEA& INEA.
FAU - Pavithra, H
AU  - Pavithra H
AD  - Department of Community Medicine, Yenepoya Medical College, Yenepoya (Deemed to
      be University), Mangaluru, Karnataka, India, 575018.
FAU - Akshaya, Kibballi Madhukeshwar
AU  - Akshaya KM
AD  - Department of Community Medicine, Yenepoya Medical College, Yenepoya (Deemed to
      be University), Mangaluru, Karnataka, India, 575018.
FAU - Nirgude, Abhay Subashrao
AU  - Nirgude AS
AD  - Department of Community Medicine, Yenepoya Medical College, Yenepoya (Deemed to
      be University), Mangaluru, Karnataka, India, 575018.
FAU - Balakrishna, A G
AU  - Balakrishna AG
AD  - Department of Community Medicine, Yenepoya Medical College, Yenepoya (Deemed to
      be University), Mangaluru, Karnataka, India, 575018.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - Nepal
TA  - Nepal J Epidemiol
JT  - Nepal journal of epidemiology
JID - 101583212
PMC - PMC7538014
OTO - NOTNLM
OT  - Diabetes complications
OT  - Diabetic foot
OT  - Health education
OT  - Knowledge
OT  - Tertiary Care Center
COIS- Competing interests There is no conflict of interest for any author of this
      manuscript.
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:31
PHST- 2020/09/10 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/12 05:31 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.3126/nje.v10i3.29213 [doi]
PST - epublish
SO  - Nepal J Epidemiol. 2020 Sep 30;10(3):897-904. doi: 10.3126/nje.v10i3.29213.
      eCollection 2020 Sep.


PMID- 33042231
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1759-8885 (Print)
IS  - 1759-8885 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Mar
TI  - Ethical Issues in Consenting Older Adults: Academic Researchers and Community
      Perspectives.
PG  - 25-32
LID - 10.1111/jphs.12327 [doi]
AB  - OBJECTIVES: Obtaining informed consents from older adults is surrounded by many
      ethical and practical challenges. The objective of this study was to evaluate
      ethical issues and strategies in consenting older adults in Jordan as perceived
      by academic researchers and older adults. METHODS: An anonymous questionnaire was
      distributed to academic researchers in the Jordanian health sciences colleges,
      and a sample of older adults. The study survey included items eliciting
      demographics, professional characteristics, and perceptions regarding the
      consenting process in older adults, consent-related skills in elderly, and
      strategies to improve the consenting process in older adults. The survey was then
      modified to assess the consent-related ethical issues and challenges as viewed by
      a sample of older adults after explaining the concept of the consenting process
      to them. KEY FINDINGS: A total of 250 academic researchers and 233 older adults
      participated in the study. Both researchers and older adults reported that having
      to sign the written forms and the impact of age-related physical impairments were
      the most challenging obstacles when consenting older adults. Lack of consistency 
      and repeating questions were the most frequently encountered obstacles by
      researchers in consenting older adults. Ensuring privacy
      (anonymity/confidentiality), dedicating more time for the consenting process,
      treating older adults as autonomous individuals and respecting their cultural
      beliefs were the most helpful strategies recommended by both academic researchers
      and older adults. CONCLUSIONS: Obtaining informed consents from older adults is a
      challenging process. Researchers should be aware of the special needs and
      strategies to achieve realistic and ethical informed consents from older adults.
FAU - Altawalbeh, Shoroq M
AU  - Altawalbeh SM
AUID- ORCID: 0000-0001-8345-4048
AD  - Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science
      and Technology, Irbid, Jordan.
FAU - Alkhateeb, Fadi M
AU  - Alkhateeb FM
AD  - Ben and Maytee Fisch College of Pharmacy, The University of Texas at Tyler,
      Texas, United States.
FAU - Attarabeen, Omar F
AU  - Attarabeen OF
AD  - School of Pharmacy, Marshall University, West Virginia, United States.
LA  - eng
GR  - R25 TW010026/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20191030
PL  - England
TA  - J Pharm Health Serv Res
JT  - Journal of pharmaceutical health services research : an official journal of the
      Royal Pharmaceutical Society of Great Britain
JID - 101522005
PMC - PMC7546426
MID - NIHMS1054621
OTO - NOTNLM
OT  - Ethics
OT  - Jordan
OT  - academic researchers
OT  - consent process
OT  - older adults
COIS- Conflict of interest The Author(s) declare(s) that they have no conflicts of
      interest to disclose.
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:29
PHST- 2020/10/12 05:29 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.1111/jphs.12327 [doi]
PST - ppublish
SO  - J Pharm Health Serv Res. 2020 Mar;11(1):25-32. doi: 10.1111/jphs.12327. Epub 2019
      Oct 30.


PMID- 33042218
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - Community engagement and building trust to resolve ethical challenges during
      humanitarian crises: experience from the CAGED study.
PG  - 68
LID - 10.1186/s13031-020-00313-w [doi]
AB  - BACKGROUND: According to the Internal Displacement Monitoring Centre report on
      global human displacement, Ethiopia has the highest number of newly displaced
      people forced to flee their homes. Displaced people have arrived in other
      regions, sometimes leading to conflict. Several regions in Ethiopia experience
      on-going ethnic tensions and violence between tribes, which leaves smallholder
      farmers suspicious of any outside activities in their locale, assuming other
      ethnic groups may harm them. Changes in the central Ethiopian government have
      also led to suspicion of non-local agencies. The Campylobacter Genomics and
      Enteric Dysfunction (CAGED) research project's objective is to improve the
      incomes, livelihoods and nutrition of smallholder farmers and was conducted
      during this period of increasing violence. The project aims to assess the impact 
      of reducing exposure to chicken excreta on young children's gut health and
      growth. This paper does not report empirical findings from CAGED, but is part of 
      a series that aims to identify challenges in humanitarian research and reports on
      mitigation strategies during this research. DISCUSSION: This research is
      important to determine whether Campylobacter infection in chicken's contributes
      to illness and stunting in children. However, violence against other researchers 
      in different parts of Ethiopia led to mistrust and lack of engagement by the
      community with the researchers. Some reactions were so hostile that the team was 
      fearful about returning to some households. As a result, the team designed
      strategies to respond, including establishing two types of community advisory
      boards. One used pre-existing village elder structures and another was composed
      of village youth. Data collection team members received training in principles of
      ethics, consent, and crisis management, and were provided on-going support from
      local and international principal investigators and the study's ethics advisor.
      CONCLUSION: The hostility and mistrust led to fear among the data collectors.
      These and the resulting strategies to address them resulted in delays for the
      research. However, the interventions taken resulted in successful completion of
      the field activities. Moreover, the lessons learned from this project are already
      being implemented with other projects being conducted in various parts of
      Ethiopia.
CI  - (c) The Author(s) 2020.
FAU - Yimer, Getnet
AU  - Yimer G
AUID- ORCID: 0000-0002-1469-837X
AD  - Global One Health initiative, The Ohio State University, Columbus, OH
      USA.grid.261331.40000 0001 2285 7943
FAU - Gebreyes, Wondwossen
AU  - Gebreyes W
AD  - Global One Health initiative, The Ohio State University, Columbus, OH
      USA.grid.261331.40000 0001 2285 7943
FAU - Havelaar, Arie
AU  - Havelaar A
AD  - Department of Animal Sciences, University of Florida, Gainesville, FL
      USA.grid.15276.370000 0004 1936 8091
FAU - Yousuf, Jemal
AU  - Yousuf J
AD  - Department of Rural Development and Agricultural Extension, College of
      Agriculture and Environmental Sciences, Haramaya University, Harar,
      Ethiopia.grid.192267.90000 0001 0108 7468
FAU - McKune, Sarah
AU  - McKune S
AD  - College of public health and Health Professions, University of Florida,
      Gainesville, FL USA.grid.15276.370000 0004 1936 8091
FAU - Mohammed, Abdulmuen
AU  - Mohammed A
AD  - Department of Rural Development and Agricultural Extension, College of
      Agriculture and Environmental Sciences, Haramaya University, Harar,
      Ethiopia.grid.192267.90000 0001 0108 7468
FAU - O'Mathuna, Donal
AU  - O'Mathuna D
AD  - College of Nursing, The Ohio State University, Columbus, OH USA.grid.261331.40000
      0001 2285 7943
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7539377
OTO - NOTNLM
OT  - Community advisory board
OT  - Conflict
OT  - Ethics
OT  - Ethiopia
OT  - Humanitarian research
OT  - Trust
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:29
PHST- 2020/04/25 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/12 05:29 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.1186/s13031-020-00313-w [doi]
AID - 313 [pii]
PST - epublish
SO  - Confl Health. 2020 Oct 6;14:68. doi: 10.1186/s13031-020-00313-w. eCollection
      2020.


PMID- 33041921
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201013
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Defining Leadership in Smart Working Contexts: A Concept Synthesis.
PG  - 556933
LID - 10.3389/fpsyg.2020.556933 [doi]
AB  - This paper begins by considering the importance of leadership to pursue
      behavioral, cultural, technological, and ethical aspirations of smart working
      practices in order to develop a comprehensive understanding of leadership in
      smart working contexts. We adopt a literary approach to the concept synthesis
      method with which to critically analyze and conceptually map a wide set of
      related notions of leadership that are connected with the evolutive dynamics of
      smart working approaches. According to the scope conditions of the research, the 
      role of leadership emerges with the purpose of changing behaviors, creating
      shared meanings, and integrating physical and technology-mediated interactions in
      smart working environments. With this in mind, the iterative integration of smart
      working and leadership literature has gradually begun to detect and classify the 
      main characteristics of leadership in smart working contexts in terms of
      leadership antecedents, attributes, and outcomes. The interpretative synthesis
      results in an overarching conceptualization of "leading in smart working
      contexts" that depicts leadership as a naturally emerging phenomenon that
      combines agile logics and change management practices to align interests at
      different levels of the organization. These premises lead to the alleged
      "triple-win" configuration of smart working approaches. While encouraging
      in-depth discussion about the facilitative and performative function of
      leadership in smart working contexts, this study contributes to advancing
      knowledge on what "being a smart leader" actually means, and how to operatively
      apply this notion in smart working contexts. Together, the concept delineation
      and the operational definition of "smart leadership" offer important insights for
      both managerial action and future directions of research.
CI  - Copyright (c) 2020 Iannotta, Meret and Marchetti.
FAU - Iannotta, Michela
AU  - Iannotta M
AD  - Department of Management, Sapienza University, Rome, Italy.
FAU - Meret, Chiara
AU  - Meret C
AD  - Department of Management, Sapienza University, Rome, Italy.
FAU - Marchetti, Giorgia
AU  - Marchetti G
AD  - Faculty of Economics, Sapienza University, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200916
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7525207
OTO - NOTNLM
OT  - concept synthesis
OT  - e-leadership
OT  - leadership
OT  - smart leadership
OT  - smart working
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:28
PHST- 2020/04/29 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/10/12 05:28 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.3389/fpsyg.2020.556933 [doi]
PST - epublish
SO  - Front Psychol. 2020 Sep 16;11:556933. doi: 10.3389/fpsyg.2020.556933. eCollection
      2020.


PMID- 33041647
OWN - NLM
STAT- Publisher
LR  - 20201012
IS  - 1388-1957 (Print)
IS  - 1388-1957 (Linking)
DP  - 2020 Oct 3
TI  - Improving on and assessing ethical guidelines for digital tracking and tracing
      systems for pandemics.
PG  - 1-4
LID - 10.1007/s10676-020-09561-z [doi]
AB  - So-called digital tracking and tracing systems (DTTSs) have been proposed as a
      means to prevent the spread of SARS-CoV-2. There are ethical guidelines and
      evaluations of such systems available. As part of a research project, I will
      build on and critically evaluate the foundations of such guidelines. The goal is 
      to provide both incremental improvements of the specific requirements for DTTSs
      and to present and discuss more fundamental challenge, the risk for indirect
      effects and slippery slopes. The nature of slippery slopes makes ethical
      guidelines more difficult since it requires a more complex analysis than, for
      example, using a checklist allows for.
CI  - (c) The Author(s) 2020.
FAU - Lundgren, Bjorn
AU  - Lundgren B
AUID- ORCID: 0000-0001-5830-3432
AD  - Department of Historical, Philosophical and Religious Studies, Umea University,
      Umea, Sweden.grid.12650.300000 0001 1034 3451
AD  - Institute for Futures Studies, Stockholm, Sweden.grid.469952.50000 0004 0468 0031
AD  - Department of Philosophy, Stockholm University, Stockholm,
      Sweden.grid.10548.380000 0004 1936 9377
LA  - eng
PT  - Journal Article
DEP - 20201003
PL  - Netherlands
TA  - Ethics Inf Technol
JT  - Ethics and information technology
JID - 101248311
PMC - PMC7532338
OTO - NOTNLM
OT  - COVID-19
OT  - Data protection
OT  - Guidelines
OT  - Pandemic
OT  - Privacy
OT  - SARS-CoV-2
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:00
CRDT- 2020/10/12 05:27
PHST- 2020/10/12 05:27 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:00 [medline]
AID - 10.1007/s10676-020-09561-z [doi]
AID - 9561 [pii]
PST - aheadofprint
SO  - Ethics Inf Technol. 2020 Oct 3:1-4. doi: 10.1007/s10676-020-09561-z.


PMID- 33041608
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1050-8422 (Print)
IS  - 1050-8422 (Linking)
VI  - 30
IP  - 7
DP  - 2020
TI  - "They know what they are getting into:" Researchers confront the benefits and
      challenges of online recruitment for HIV research.
PG  - 481-495
LID - 10.1080/10508422.2019.1692663 [doi]
AB  - Online research has become a critical recruitment modality for understanding and 
      reducing health disparities among hidden populations most at risk for HIV
      infection. There is a lack of consensus and guidelines for the responsible
      conduct of online recruitment for HIV risk populations. Using semi-structured
      phone interviews, this study drew on the experiences of principal investigators
      (PIs) engaged in online HIV research to illuminate scientific and ethical
      benefits and challenges of social media recruitment. Using Thematic Analysis five
      major themes emerged: sampling advantages and disadvantages; challenges of data
      integrity; control of privacy protections; researcher competence and
      responsibility; and resources.
FAU - Bragard, Elise
AU  - Bragard E
AD  - Department of Psychology, Fordham University, Bronx, NY.
FAU - Fisher, Celia B
AU  - Fisher CB
AD  - Center for Ethics Education and Department of Psychology, Fordham University,
      Bronx, NY.
FAU - Curtis, Brenda L
AU  - Curtis BL
AD  - Technology and Translational Research Unit, Intramural Research Program, National
      Institute on Drug Abuse, Baltimore, MD.
LA  - eng
GR  - R25 DA031608/DA/NIDA NIH HHS/United States
GR  - Z99 DA999999/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20191127
PL  - United States
TA  - Ethics Behav
JT  - Ethics & behavior
JID - 9102086
PMC - PMC7539627
MID - NIHMS1543091
OTO - NOTNLM
OT  - HIV
OT  - ethics Internet research
OT  - online recruitment
OT  - privacy
OT  - social media
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:26
PHST- 2020/10/12 05:26 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
AID - 10.1080/10508422.2019.1692663 [doi]
PST - ppublish
SO  - Ethics Behav. 2020;30(7):481-495. doi: 10.1080/10508422.2019.1692663. Epub 2019
      Nov 27.


PMID- 33041541
OWN - NLM
STAT- Publisher
LR  - 20220716
IS  - 0968-6673 (Print)
IS  - 0968-6673 (Linking)
DP  - 2020 Oct 1
TI  - The Ethics of Care and Academic Motherhood amid Covid-19.
LID - 10.1111/gwao.12547 [doi]
AB  - The COVID-19 pandemic has upended the lives of working parents as they strive to 
      meet the conflicting demands of childcare and professional obligations. While
      growing evidence suggests the extraordinary challenges to time and work brought
      by the pandemic, this article explores the pandemic as an opportunity for
      stillness and reflection, a personal and professional recalibration. Through a
      personal narrative describing my experiences as an academic and mother before and
      during the pandemic, framed within the ethics of care, this article brings light 
      to the untenable reality of working mothers pre-pandemic, explores the ways in
      which the pandemic has positively facilitated caring relationships at home as
      well as the reallocation of time and household responsibilities, and argues for
      policy and legislative action at the institutional and societal levels that
      support and value the care work of women and men alike. This article is protected
      by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Miller, Karyn E
AU  - Miller KE
AUID- ORCID: https://orcid.org/0000-0001-6233-6739
AD  - Texas A&M University-Commerce Department of Curriculum and Instruction P.O. Box
      3011 Commerce TX 75429-3011.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - England
TA  - Gend Work Organ
JT  - Gender, work, and organization
JID - 101544781
PMC - PMC7537234
OTO - NOTNLM
OT  - COVID-19
OT  - academic motherhood
OT  - ethics of care
OT  - policy
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:00
CRDT- 2020/10/12 05:26
PHST- 2020/08/04 00:00 [received]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/10/12 05:26 [entrez]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:00 [medline]
AID - 10.1111/gwao.12547 [doi]
AID - GWAO12547 [pii]
PST - aheadofprint
SO  - Gend Work Organ. 2020 Oct 1. pii: GWAO12547. doi: 10.1111/gwao.12547.


PMID- 33041358
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201120
IS  - 0016-3287 (Print)
IS  - 0016-3287 (Linking)
VI  - 124
DP  - 2020 Dec
TI  - Can robots tackle late-life loneliness? Scanning of future opportunities and
      challenges in assisted living facilities.
PG  - 102640
LID - 10.1016/j.futures.2020.102640 [doi]
AB  - This future-oriented study examines the opportunities and challenges offered by
      social robots and communication technology when aiming to decrease emotional and 
      social loneliness in older people residing in assisted living (AL). The paper
      draws on prior literature on loneliness, elder care and social robots. The aim is
      to scan the futures regarding technology support for the frail older people in
      future AL. The analytical frame was built on Robert Weiss' division of relational
      functions: attachment, social integration, opportunity for nurturance,
      reassurance of worth, sense of reliable alliance, and guidance in stressful
      situations, and on a distinction between direct and indirect social robots. Our
      examinations show that social robots could tackle both emotional and social
      loneliness in assisted living by empowering people to engage in different forms
      of social interaction inside and outside the facility. However, ethical concerns 
      of objectification, lack of human contact, and deception need to be thoroughly
      considered when implementing social robots in care for frail older people.
CI  - (c) 2020 The Author(s).
FAU - Pirhonen, Jari
AU  - Pirhonen J
AD  - Faculty of Social Sciences, University of Helsinki, P.O. Box 4, 00014, Finland.
FAU - Tiilikainen, Elisa
AU  - Tiilikainen E
AD  - Department of Social Sciences, University of Eastern Finland, Faculty of Social
      Sciences and Business Studies, 70211 Kuopio, Finland.
FAU - Pekkarinen, Satu
AU  - Pekkarinen S
AD  - School of Engineering Science, Lappeenranta-Lahti University of Technology LUT,
      Mukkulankatu 19, 15210 Lahti, Finland.
FAU - Lemivaara, Marjut
AU  - Lemivaara M
AD  - Faculty of Social Sciences, Tampere University, P.O. Box 100, 33014, Finland.
FAU - Melkas, Helina
AU  - Melkas H
AD  - School of Engineering Science, Lappeenranta-Lahti University of Technology LUT,
      Mukkulankatu 19, 15210 Lahti, Finland.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - Futures
JT  - Futures
JID - 100972611
PMC - PMC7534874
OTO - NOTNLM
OT  - Assisted living
OT  - Exploration
OT  - Futures scanning
OT  - Loneliness
OT  - Older people
OT  - Social robots
EDAT- 2020/10/13 06:00
MHDA- 2020/10/13 06:01
CRDT- 2020/10/12 05:25
PHST- 2020/04/09 00:00 [received]
PHST- 2020/09/06 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/13 06:00 [pubmed]
PHST- 2020/10/13 06:01 [medline]
PHST- 2020/10/12 05:25 [entrez]
AID - 10.1016/j.futures.2020.102640 [doi]
AID - S0016-3287(20)30129-4 [pii]
PST - ppublish
SO  - Futures. 2020 Dec;124:102640. doi: 10.1016/j.futures.2020.102640. Epub 2020 Oct
      5.


PMID- 33040111
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 9
DP  - 2020 Sep
TI  - Applications and impact of computer technologies in management of multimorbidity.
PG  - 1572-1576
LID - 10.5455/JPMA.37601 [doi]
AB  - OBJECTIVE: To highlight clinical scenarios and healthcare practitioners'
      difficulties where computer applications can help in multimorbidity management.
      METHODS: The cross-sectional study was conducted from December 2017 to January
      2019 in the twin cities of Rawalpindi and Islamabad, Pakistan, and comprised
      local physicians/practitioners. Data was collected using a self-generated
      questionnaire which was distributed among the subjects. It identified four
      problems as most commonly faced: treatment/dose management, time management,
      forgetting to ask necessary questions about disease, and 'others', such as bad
      handwriting errors and ethical issues. Data was analysed using SPSS 17. RESULTS: 
      Of the 53 subjects, 33(62%) marked problems related to treatment management,
      35(66%) marked problems related to shortage of time, 34(64%) marked those related
      to difficulty in asking relevant questions about disease, 15(28%) marked the
      'other' option. CONCLUSIONS: Computer technologies are significantly helpful in
      managing the problems of treating multimorbidity by adopting standard database.
FAU - Safdar, Muhammad Farhan
AU  - Safdar MF
AD  - Department of Software Engineering SE, Bahria University Islamabad, Pakistan.
FAU - Bhatti, Shahid Nazir
AU  - Bhatti SN
AD  - Department of Software Engineering SE, Bahria University Islamabad, Pakistan.
FAU - Abbasi, Awais Saeed
AU  - Abbasi AS
AD  - Department of Medicine, Akbar Niazi Teaching Hospital Islamabad, Pakistan.
FAU - Zahra, Fatima Tuz
AU  - Zahra FT
AD  - Department of Medicine, Kahuta Research Laboratories (KRL) Hospital Islamabad,
      Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Computers
MH  - Cross-Sectional Studies
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Multimorbidity
MH  - Pakistan
OTO - NOTNLM
OT  - Multimorbidity, Computer Technologies, Database Integration, SPSS.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10109 [pii]
AID - 10.5455/JPMA.37601 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Sep;70(9):1572-1576. doi: 10.5455/JPMA.37601.


PMID- 33040027
OWN - NLM
STAT- Publisher
LR  - 20220308
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
DP  - 2020 Oct 10
TI  - Violence against doctors: an emerging epidemic amidst COVID-19 pandemic in India.
LID - postgradmedj-2020-138925 [pii]
LID - 10.1136/postgradmedj-2020-138925 [doi]
FAU - Sakthivel, Pirabu
AU  - Sakthivel P
AUID- ORCID: http://orcid.org/0000-0002-6941-9892
AD  - Department of Head and Neck Surgery and Oncology, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Rajeshwari, Madhu
AU  - Rajeshwari M
AD  - Department of Pathology, All India Institute of Medical Sciences, New Delhi,
      India.
FAU - Malhotra, Nipun
AU  - Malhotra N
AD  - Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir
      Medical College and Safdarjung Hospital, New Delhi, India.
FAU - Ish, Pranav
AU  - Ish P
AUID- ORCID: http://orcid.org/0000-0003-1701-4970
AD  - Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir
      Medical College and Safdarjung Hospital, New Delhi, India
      pranavish2512@gmail.com.
LA  - eng
PT  - Letter
DEP - 20201010
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
OTO - NOTNLM
OT  - Ethics (see medical ethics)
OT  - Health policy
OT  - Health services administration & management
OT  - Infectious diseases
OT  - Public health
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2020/10/12 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/08/30 00:00 [accepted]
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2020/10/12 06:00 [medline]
AID - postgradmedj-2020-138925 [pii]
AID - 10.1136/postgradmedj-2020-138925 [doi]
PST - aheadofprint
SO  - Postgrad Med J. 2020 Oct 10. pii: postgradmedj-2020-138925. doi:
      10.1136/postgradmedj-2020-138925.


PMID- 33040016
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210920
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Building community resilience to prevent and mitigate community impact of gun
      violence: conceptual framework and intervention design.
PG  - e040277
LID - 10.1136/bmjopen-2020-040277 [doi]
AB  - INTRODUCTION: The USA has the highest rate of community gun violence of any
      developed democracy. There is an urgent need to develop feasible, scalable and
      community-led interventions that mitigate incident gun violence and its
      associated health impacts. Our community-academic research team received National
      Institutes of Health funding to design a community-led intervention that
      mitigates the health impacts of living in communities with high rates of gun
      violence. METHODS AND ANALYSIS: We adapted 'Building Resilience to Disasters', a 
      conceptual framework for natural disaster preparedness, to guide actions of
      multiple sectors and the broader community to respond to the man-made disaster of
      gun violence. Using this framework, we will identify existing community assets to
      be building blocks of future community-led interventions. To identify existing
      community assets, we will conduct social network and spatial analyses of the gun 
      violence episodes in our community and use these analyses to identify people and 
      neighbourhood blocks that have been successful in avoiding gun violence. We will 
      conduct qualitative interviews among a sample of individuals in the network that 
      have avoided violence (n=45) and those living or working on blocks that have not 
      been a location of victimisation (n=45) to identify existing assets. Lastly, we
      will use community-based system dynamics modelling processes to create a computer
      simulation of the community-level contributors and mitigators of the effects of
      gun violence that incorporates local population-based based data for calibration.
      We will engage a multistakeholder group and use themes from the qualitative
      interviews and the computer simulation to identify feasible community-led
      interventions. ETHICS AND DISSEMINATION: The Human Investigation Committee at
      Yale University School of Medicine (#2000022360) granted study approval. We will 
      disseminate study findings through peer-reviewed publications and academic and
      community presentations. The qualitative interview guides, system dynamics model 
      and group model building scripts will be shared broadly.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Emily A
AU  - Wang EA
AD  - Internal Medicine, Yale University, New Haven, Connecticut, USA
      emily.wang@yale.edu.
AD  - Center for Research Engagement, Yale School of Medicine, New Haven, CT, United
      States.
FAU - Riley, Carley
AU  - Riley C
AUID- ORCID: 0000-0002-3782-0104
AD  - Division of Critical Care, Cincinnati Children's Hospital Medical Center,
      Cincinnati, Ohio, USA.
AD  - Clinical Pediatrics, University of Cincinnati College of Medicine, Cincinnati,
      OH, United States.
FAU - Wood, George
AU  - Wood G
AD  - Northwestern University Institute for Policy Research, Evanston, Illinois, USA.
FAU - Greene, Ann
AU  - Greene A
AD  - Center for Research Engagement, Yale School of Medicine, New Haven, CT, United
      States.
AD  - National Clinician Scholars Program, Yale School of Medicine, New Haven,
      Connecticut, USA.
FAU - Horton, Nadine
AU  - Horton N
AD  - Internal Medicine, Yale University, New Haven, Connecticut, USA.
FAU - Williams, Maurice
AU  - Williams M
AD  - Center for Research Engagement, Yale School of Medicine, New Haven, CT, United
      States.
FAU - Violano, Pina
AU  - Violano P
AD  - Injury Prevention Center, Yale New Haven Hospital, New Haven, CT, United States.
FAU - Brase, Rachel Michele
AU  - Brase RM
AUID- ORCID: 0000-0002-2651-5403
AD  - Social and Behavioral Sciences, Yale University School of Public Health, New
      Haven, Connecticut, USA.
FAU - Brinkley-Rubinstein, Lauren
AU  - Brinkley-Rubinstein L
AD  - Center for Health Equity Research, University of North Carolina, Chapel Hill,
      North Carolina, USA.
FAU - Papachristos, Andrew V
AU  - Papachristos AV
AD  - Northwestern University Institute for Policy Research, Evanston, Illinois, USA.
FAU - Roy, Brita
AU  - Roy B
AUID- ORCID: 0000-0002-3782-0104
AD  - Internal Medicine, Yale University, New Haven, Connecticut, USA.
AD  - Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, United
      States.
LA  - eng
GR  - R01 MD010403/MD/NIMHD NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Computer Simulation
MH  - *Disasters
MH  - *Gun Violence
MH  - Humans
MH  - Residence Characteristics
MH  - Violence/prevention & control
PMC - PMC7552873
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *epidemiology
OT  - *public health
OT  - *statistics & research methods
OT  - *trauma management
COIS- Competing interests: CR and BR report personal fees from Heluna Health, personal 
      fees from the Institute for Healthcare Improvement and grant funding from the
      Robert Wood Johnson Foundation and the Institute for Healthcare Improvement,
      outside the submitted work. BR also reports grant funding from the National
      Heart, Lung, and Blood Institute outside the submitted work. EAW also reports
      funding from the National Heart, Lung, and Blood Institute, National Cancer
      Institute, National Institute on Drug Abuse, the California Health Care
      Foundation and the William T. Grant Foundation. The other authors declare no
      competing interests.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-040277 [pii]
AID - 10.1136/bmjopen-2020-040277 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e040277. doi: 10.1136/bmjopen-2020-040277.


PMID- 33040015
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Effects of in-hospital breast feeding on brain function development in preterm
      infants in China: study protocol for a prospective longitudinal cohort study.
PG  - e038879
LID - 10.1136/bmjopen-2020-038879 [doi]
AB  - INTRODUCTION: Due to immature brain development, preterm infants are more likely 
      to develop neurological developmental defects compared with full-term infants.
      Most preterm infants without neurodevelopmental damage can eventually reach the
      same scholastic level as their same-age peers; however, some show persistent
      impairment. Breast feeding (BF), which is an important public health measure, is 
      of great significance for preterm infants. Various active substances in breast
      milk promote the development of the brain and central nervous system in premature
      infants. We present a protocol for a prospective longitudinal cohort study to
      explore the effect of in-hospital BF on brain development in preterm infants and 
      possible influencing factors. METHODS AND ANALYSIS: This study will enrol 247
      Chinese preterm infants (gestational age: 30-34 weeks) delivered in Women's
      Hospital School of Medicine, Zhejiang University, and transferred to the neonatal
      intensive care unit. Demographic, clinical and in-hospital BF data will be
      collected through electronic medical records. Moreover, follow-up data will be
      obtained by telephone, interview or online. Measurements will be obtained using
      the Breastfeeding Self-Efficacy Scale-Short Form, neuroimaging with functional
      near-infrared spectroscopy, extrauterine growth restriction and the Ages and
      Stages Questionnaire. Follow-up will be performed at 3, 6 and 12 months after
      birth. ETHICS AND DISSEMINATION: This study has been approved by the Women's
      Hospital School of Medicine Zhejiang University Medical Ethics Committee
      (2019-058). The study results are expected to be published in peer-reviewed
      journals and reported at relevant national and international conferences. TRIAL
      REGISTRATION NUMBER: ChiCTR1900027648; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yang, Rui
AU  - Yang R
AD  - Nursing Department, Zhejiang University School of Medicine, Hangzhou, China.
FAU - Zhang, Yao
AU  - Zhang Y
AD  - Nursing College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
FAU - Wang, Hua
AU  - Wang H
AD  - Neonatal Intensive Care Units, Zhejiang University School of Medicine Women's
      Hospital, Hangzhou, Zhejiang, China.
FAU - Xu, Xinfen
AU  - Xu X
AUID- ORCID: 0000-0003-4641-5802
AD  - Nursing Department, Zhejiang University School of Medicine Women's Hospital,
      Hangzhou, Zhejiang, China xuxinf@zju.edu.cn.
AD  - Haining Maternal and Child Health Hospital, Zhejiang University School of
      Medicine Women's Hospital, Haining, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Brain/diagnostic imaging
MH  - Breast Feeding
MH  - China
MH  - Cohort Studies
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - Longitudinal Studies
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7549488
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *neonatal intensive & critical care
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-038879 [pii]
AID - 10.1136/bmjopen-2020-038879 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e038879. doi: 10.1136/bmjopen-2020-038879.


PMID- 33040013
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - MAGNETO cardiography parameters to predict future Sudden Cardiac Death
      (MAGNETO-SCD) or ventricular events from implantable cardioverter defibrillators:
      study protocol, design and rationale.
PG  - e038804
LID - 10.1136/bmjopen-2020-038804 [doi]
AB  - INTRODUCTION: Predicting sudden cardiac death (SCD) is challenging as current
      risk predictors have significant limitations. Evaluating magnetocardiogram (MCG) 
      parameters could be of great value and we plan to assess the capability of a new 
      mobile unshielded MCG device in predicting SCD and ventricular arrhythmias (VA)
      in patients undergoing implantable cardioverter defibrillator (ICD) implantation.
      METHODS AND ANALYSIS: A prospective multicentre (University Hospitals Coventry
      and Warwickshire (UHCW) National Health Service (NHS) Trust/University Hospital
      North Midlands NHS Trust, UK) observational study evaluating the VitalScan MCG
      (Creavo Medical Technologies, UK) to predict future VA risk; 270 patients meeting
      criteria for primary or secondary prevention ICDs (ischaemic or non-ischaemic
      aetiology) are being recruited. The first patient was recruited September 2019
      and the study will be completed at final participant follow-up. The primary
      endpoint is appropriate ICD therapy for VA, secondary endpoint is SCD. Previous
      trials using MCG identified late QRS signals/QRS fragmentation as potential
      indicators of SCD in small samples using large shielded expensive MCG devices
      that were difficult to use clinically. It is hoped the MAGNETO-SCD trial will
      show this new MCG device can provide real world risk stratification for SCD/VA
      risk. The trial has recruited 25 patients (13 with secondary prevention
      indication) from a single site (UHCW) with recruitment starting at the second
      site in March 2020. ETHICS AND DISSEMINATION: Research Ethics Committee,
      Yorkshire and Humber Sheffield Research Ethics Committee UK (Ref: 19/YH/0143) and
      Health Research Authority (IRAS reference 254466, EDGE ID: 123146) approval
      received on 17/07/2019. The Medicines and Healthcare products Regulatory Agency
      approval received 11/07/2019. Results will be disseminated via a peer-reviewed
      publication and presentation at international conferences. TRIAL REGISTRATION
      NUMBERS: ClinicalTrials.gov Registry (NCT04352816) and EU Clinical Trials
      Registry (EudraCT2019-002994-78).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lachlan, Thomas
AU  - Lachlan T
AD  - Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,
      UK.
FAU - He, Hejie
AU  - He H
AD  - Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,
      UK.
FAU - Sharma, Kavi
AU  - Sharma K
AD  - Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,
      UK.
FAU - Khan, Jamal
AU  - Khan J
AD  - Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,
      UK.
FAU - Rajappan, Kim
AU  - Rajappan K
AD  - Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
FAU - Morley-Davies, Adrian
AU  - Morley-Davies A
AD  - Cardiology, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent,
      UK.
FAU - Patwala, Ashish
AU  - Patwala A
AD  - Cardiology, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent,
      UK.
FAU - Randeva, Harpal
AU  - Randeva H
AD  - Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,
      UK.
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Osman, Faizel
AU  - Osman F
AUID- ORCID: 0000-0002-3962-5118
AD  - Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry,
      UK Faizel.osman@warwick.ac.uk.
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04352816
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Death, Sudden, Cardiac/etiology/prevention & control
MH  - *Defibrillators, Implantable
MH  - *Heart Failure
MH  - Humans
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Risk Factors
MH  - State Medicine
PMC - PMC7552867
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiology
OT  - *pacing & electrophysiology
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-038804 [pii]
AID - 10.1136/bmjopen-2020-038804 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e038804. doi: 10.1136/bmjopen-2020-038804.


PMID- 33040012
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Validation of an integrated service model, Health-RESPECT, for older patients in 
      long-term care institution using information and communication technologies:
      protocol of a cluster randomised controlled trial.
PG  - e038598
LID - 10.1136/bmjopen-2020-038598 [doi]
AB  - INTRODUCTION: There is an increased healthcare need to manage institutionalised
      older patients owing to the ageing population. To overcome substantial future
      challenges, the Health-RESPECT (caRE Systems for Patients/Elderly with
      Coordinated care using icT), a new information and communication technologies
      based integrated management service model, was developed to provide effective
      management, enable consultation with distant professionals and share medical
      information between acute care hospitals and long-term care institutions. METHODS
      AND ANALYSIS: A cluster randomised controlled trial will be conducted to examine 
      the effectiveness of the Health-RESPECT in older patients with chronic diseases
      and their medical staff in charge. Intervention involves registration with simple
      comprehensive geriatric assessment, establishment of an individualised care plan 
      for three chronic diseases (hypertension, diabetes and heart failure), medication
      and rehabilitation management, periodic video-conference and in-system assessment
      after intervention period. Primary outcomes are control levels of the three
      chronic diseases, adequacy of drug management and overall functional status.
      Patients will be assessed at before and after study period and 3 months after
      study ended. Analysis will be carried out with an intention-to-treat principle.
      In addition to evaluate intervention effects, clinical usability and economic
      evaluation will be assessed. ETHICS AND DISSEMINATION: The study protocol was
      reviewed and approved by the Seoul National University Bundang Hospital
      Institutional Review Board. Study findings will be published in peer-reviewed
      journals. TRIAL REGISTRATION NUMBER: KCT0004360.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Choi, Jung-Yeon
AU  - Choi JY
AUID- ORCID: 0000-0001-5139-5346
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea (the Republic of).
FAU - Kim, Kwang-Il
AU  - Kim KI
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea (the Republic of) kikim907@snu.ac.kr.
AD  - Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, Korea (the Republic of).
FAU - Kim, Hongsoo
AU  - Kim H
AD  - Department of Public Health Sciences, Seoul National University Graduate School
      of Public Health, Gwanak-gu, Korea (the Republic of).
AD  - Institute of Aging, Seoul National University, Gwanak-gu, Korea (the Republic
      of).
AD  - Institute of Health and Environment, Seoul National University, Seoul, Korea (the
      Republic of).
FAU - Jung, Young-Il
AU  - Jung YI
AD  - Department of Environmental Health, Korea National Open University, Jongno-gu,
      Korea (the Republic of).
FAU - Oh, In-Hwan
AU  - Oh IH
AD  - Department of Preventive Medicine, Kyung Hee University, Seoul, Korea (the
      Republic of).
FAU - Chun, Seungyeon
AU  - Chun S
AD  - Department of Public Health Sciences, Seoul National University Graduate School
      of Public Health, Gwanak-gu, Korea (the Republic of).
FAU - Kim, Gi-Soo
AU  - Kim GS
AD  - Department of Industrial Engineering, Ulsan National Institute of Science and
      Technology, Ulsan, Korea (the Republic of).
FAU - Lim, Jae-Young
AU  - Lim JY
AUID- ORCID: 0000-0002-9454-0344
AD  - Institute of Aging, Seoul National University, Gwanak-gu, Korea (the Republic
      of).
AD  - Department of Rehabilitation Medicine, Seoul National University Bundang
      Hospital, Seongnam, Korea (the Republic of).
AD  - Department of Rehabilitation Medicine, Seoul National University College of
      Medicine, Seoul, Korea (the Republic of).
FAU - Ko, Jin Young
AU  - Ko JY
AD  - Department of Rehabilitation Medicine, Seoul National University Bundang
      Hospital, Seongnam, Korea (the Republic of).
LA  - eng
SI  - CRiS/KCT0004360
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Communication
MH  - Geriatric Assessment
MH  - Humans
MH  - *Long-Term Care
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Seoul
PMC - PMC7552832
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *information technology
OT  - *quality in health care
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-038598 [pii]
AID - 10.1136/bmjopen-2020-038598 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e038598. doi: 10.1136/bmjopen-2020-038598.


PMID- 33040011
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Is arthroplaSty bEtter than interNal fixation for undiSplaced femoral nEck
      fracture? A national pragmatic RCT: the SENSE trial.
PG  - e038442
LID - 10.1136/bmjopen-2020-038442 [doi]
AB  - INTRODUCTION: Undisplaced femoral neck fractures (FNFs) are usually treated by
      internal fixation (IF) but two randomised controlled trials (RCTs) have
      demonstrated advantages of treatment with arthroplasty. The complication rate was
      lowered but there were no clinically improved patient-reported outcome measures
      (PROM), which could be due to underpowering or choice of selected PROM as the
      studies do appear to report a better functional outcome. We will conduct an RCT
      comparing IF with arthroplasties in patients aged over 65 years with an
      undisplaced FNF. METHODS AND ANALYSIS: All hospitals in Denmark treating patients
      with hip fracture can provide patients for this study; therefore, the study can
      be considered a national RCT. Patients over 65 years old with an undisplaced FNF 
      will be screened for eligibility and patients will only be excluded if they are
      unable to understand the study information (due to dementia or language), if they
      have a posterior tilt >20 degrees , a pathological fracture or they cannot walk. 
      Participants will be electronically randomised (in alternating blocks of 4 or 6) 
      into either IF or arthroplasty. Postoperative care will follow the department
      standards.Primary and secondary outcomes and measuring points have been
      established in collaboration with patients with hip fracture by focus group
      interviews. The primary outcome measure is the New Mobility Score assessed after 
      1 year. Secondary outcomes are the Oxford Hip Score, EuroQol 5 domain (EQ-5D-5L),
      degree of posterior tilt, pain Verbal Rating Scale, reoperation and mortality.
      ETHICS AND DISSEMINATION: The study is approved by the Danish Data Protection
      Agency (19/7429) and the scientific ethics committee (S-20180036). All
      participants will sign an informed consent before entering the trial. Because
      this is a national trial, all relevant healthcare professionals in Denmark will
      automatically receive the trial results that will be published in international
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry
      (NCT04075461).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Viberg, Bjarke
AU  - Viberg B
AUID- ORCID: 0000-0001-5169-4282
AD  - Orthopaedic Surgery and Traumatology, Lillebaelt Hospital, University Hospital of
      Southern Denmark, Kolding, Denmark bjarke.viberg@rsyd.dk.
AD  - Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense,
      Denmark.
FAU - Kold, Soren
AU  - Kold S
AD  - Orthopaedic Surgery and Traumatology, Aalborg University Hospital, Aalborg,
      Denmark.
FAU - Brink, Ole
AU  - Brink O
AD  - Orthopaedic Surgery and Traumatology, Aarhus University Hospital, Aarhus,
      Denmark.
FAU - Larsen, Morten Schultz
AU  - Larsen MS
AD  - Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense,
      Denmark.
FAU - Hare, Kristoffer Borbjerg
AU  - Hare KB
AD  - Department of Regional Health Research, University of Southern Denmark, Odense,
      Denmark.
AD  - Department of Orthopaedics, Naestved-Slagelse-Ringsted Hospitals, Slagelse,
      Denmark.
AD  - Department of Physiotherapy and Occupational Therapy, Naestved-Slagelse-Ringsted 
      Hospitals, Slagelse, Denmark.
FAU - Palm, Henrik
AU  - Palm H
AD  - Orthopaedic Surgery and Traumatology, Bispebjerg Hospital, Kobenhavn, Denmark.
CN  - SENSE collaborators
LA  - eng
SI  - ClinicalTrials.gov/NCT04075461
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Arthroplasty, Replacement, Hip
MH  - *Femoral Neck Fractures/surgery
MH  - Fracture Fixation, Internal
MH  - *Hip Fractures/surgery
MH  - Humans
MH  - Reoperation
MH  - Treatment Outcome
PMC - PMC7552868
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *geriatric medicine
OT  - *hip
OT  - *rehabilitation medicine
OT  - *trauma management
COIS- Competing interests: Outside the study, BV has received payment for lectures held
      for Zimmer Biomet and Osmedic Swemac.
IR  - Jensen TG
FIR - Jensen, Thomas Giver
IR  - Nielsen MS
FIR - Nielsen, Mikael Skov
IR  - Thorninger R
FIR - Thorninger, Rikke
IR  - Egendal T
FIR - Egendal, Thomas
IR  - Homilius M
FIR - Homilius, Morten
IR  - Andersen PI
FIR - Andersen, Peter Ivan
IR  - Schonnemann J
FIR - Schonnemann, Jesper
IR  - Krasheninnikoff M
FIR - Krasheninnikoff, Michael
IR  - Ahler-Toftehoj HU
FIR - Ahler-Toftehoj, Hans-Ulrik
IR  - Toquer P
FIR - Toquer, Peter
IR  - Aasvang T
FIR - Aasvang, Tobias
IR  - Alva-Jorgensen JP
FIR - Alva-Jorgensen, Jens Peter
IR  - Molmer M
FIR - Molmer, Michael
IR  - Hasific S
FIR - Hasific, Sead
IR  - Bloch TB
FIR - Bloch, Thomas Brandi
IR  - Pedersen L
FIR - Pedersen, Lasse
IR  - Szephalmi P
FIR - Szephalmi, Peter
IR  - Al-Bayati MA
FIR - Al-Bayati, Mohammed Adel
IR  - Peitz F
FIR - Peitz, Frithjof
IR  - Jensen ST
FIR - Jensen, Steffan Tabori
IR  - Primdahl A
FIR - Primdahl, Annie
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-038442 [pii]
AID - 10.1136/bmjopen-2020-038442 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e038442. doi: 10.1136/bmjopen-2020-038442.


PMID- 33040008
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - The Child and Parent Emotion Study: protocol for a longitudinal study of parent
      emotion socialisation and child socioemotional development.
PG  - e038124
LID - 10.1136/bmjopen-2020-038124 [doi]
AB  - INTRODUCTION: Parents shape child emotional competence and mental health via
      their beliefs about children's emotions, emotion-related parenting, the emotional
      climate of the family and by modelling emotion regulation skills. However, much
      of the research evidence to date has been based on small samples with mothers of 
      primary school-aged children. Further research is needed to elucidate the
      direction and timing of associations for mothers and fathers/partners across
      different stages of child development. The Child and Parent Emotion Study (CAPES)
      aims to examine longitudinal associations between parent emotion socialisation,
      child emotion regulation and socioemotional adjustment at four time points from
      pregnancy to age 12 years. CAPES will investigate the moderating role of parent
      gender, child temperament and gender, and family background. METHODS AND
      ANALYSIS: CAPES recruited 2063 current parents from six English-speaking
      countries of a child 0-9 years and 273 prospective parents (ie, women/their
      partners pregnant with their first child) in 2018-2019. Participants will
      complete a 20-30 min online survey at four time points 12 months apart, to be
      completed in December 2022. Measures include validated parent-report tools
      assessing parent emotion socialisation (ie, parent beliefs, the family emotional 
      climate, supportive parenting and parent emotion regulation) and age-sensitive
      measures of child outcomes (ie, emotion regulation and socioemotional
      adjustment). Analyses will use mixed-effects regression to simultaneously assess 
      associations over three time-point transitions (ie, T1 to T2; T2 to T3; T3 to
      T4), with exposure variables lagged to estimate how past factors predict outcomes
      12 months later. ETHICS AND DISSEMINATION: Ethics approval was granted by the
      Deakin University Human Research Ethics Committee and the Deakin University
      Faculty of Health Human Research Ethics Committee. We will disseminate results
      through conferences and open access publications. We will invite parent end users
      to co-develop our dissemination strategy, and discuss the interpretation of key
      findings prior to publication. TRIAL REGISTERATION: Protocol pre-registration:
      DOI 10.17605/OSF.IO/NGWUY.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Westrupp, Elizabeth M
AU  - Westrupp EM
AUID- ORCID: 0000-0001-6517-6064
AD  - Centre for Social and Early Emotional Development, School of Psychology, Deakin
      University, Geelong, Victoria, Australia elizabeth.westrupp@deakin.edu.au.
AD  - Judith Lumley Centre, La Trobe University, Melbourne, Victoria, Australia.
FAU - Macdonald, Jacqui A
AU  - Macdonald JA
AD  - Centre for Social and Early Emotional Development, School of Psychology, Deakin
      University, Geelong, Victoria, Australia.
AD  - Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences,
      The University of Melbourne, Parkville, Victoria, Australia.
AD  - Centre for Adolescent Health, Murdoch Children's Research Institute, Parkville,
      Victoria, Australia.
FAU - Bennett, Clair
AU  - Bennett C
AD  - Judith Lumley Centre, La Trobe University, Melbourne, Victoria, Australia.
AD  - Columbia Psychiatry, Columbia University Irving Medical Center, New York City,
      New York, USA.
AD  - New York State Psychiatric Institute, New York, United States.
FAU - Havighurst, Sophie
AU  - Havighurst S
AD  - Mindful: Centre for Training and Research in Developmental Health, Department of 
      Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Kehoe, Christiane E
AU  - Kehoe CE
AD  - Mindful: Centre for Training and Research in Developmental Health, Department of 
      Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Foley, Denise
AU  - Foley D
AD  - Centre for Social and Early Emotional Development, School of Psychology, Deakin
      University, Geelong, Victoria, Australia.
FAU - Berkowitz, Tomer S
AU  - Berkowitz TS
AD  - Centre for Social and Early Emotional Development, School of Psychology, Deakin
      University, Geelong, Victoria, Australia.
FAU - King, Gabriella Louise
AU  - King GL
AD  - Centre for Social and Early Emotional Development, School of Psychology, Deakin
      University, Geelong, Victoria, Australia.
FAU - Youssef, George J
AU  - Youssef GJ
AUID- ORCID: 0000-0002-6178-4895
AD  - Centre for Social and Early Emotional Development, School of Psychology, Deakin
      University, Geelong, Victoria, Australia.
AD  - Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences,
      The University of Melbourne, Parkville, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - *Child Development
MH  - Emotions
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Parenting
MH  - Parents
MH  - Pregnancy
MH  - Prospective Studies
MH  - *Socialization
PMC - PMC7552863
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *community child health
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-038124 [pii]
AID - 10.1136/bmjopen-2020-038124 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e038124. doi: 10.1136/bmjopen-2020-038124.


PMID- 33040007
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - 'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives 
      on presymptomatic testing for autosomal dominant polycystic kidney disease: a
      focus group study.
PG  - e038005
LID - 10.1136/bmjopen-2020-038005 [doi]
AB  - BACKGROUND AND OBJECTIVES: Presymptomatic testing is available for early
      diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD).
      However, the complex ethical and psychosocial implications can make
      decision-making challenging and require an understanding of patients' values,
      goals and priorities. This study aims to describe patient and caregiver beliefs
      and expectations regarding presymptomatic testing for ADPKD. DESIGN, SETTING AND 
      PARTICIPANTS: 154 participants (120 patients and 34 caregivers) aged 18 years and
      over from eight centres in Australia, France and Korea participated in 17 focus
      groups. Transcripts were analysed thematically. RESULTS: We identified five
      themes: avoiding financial disadvantage (insecurity in the inability to obtain
      life insurance, limited work opportunities, financial burden); futility in
      uncertainty (erratic and diverse manifestations of disease limiting utility,
      taking preventive actions in vain, daunted by perplexity of results, unaware of
      risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed
      by ambiguous information, medicalising family planning, family pressures);
      seizing control of well-being (gaining confidence in early detection, allowing
      preparation for the future, reassurance in family resilience); and anticipating
      impact on quality of life (reassured by lack of symptoms, judging value of life
      with ADPKD). CONCLUSIONS: For patients with ADPKD, presymptomatic testing
      provides an opportunity to take ownership of their health through family planning
      and preventive measures. However, these decisions can be wrought with tensions
      and uncertainty about prognostic implications, and the psychosocial and financial
      burden of testing. Healthcare professionals should focus on genetic counselling, 
      mental health and providing education to patients' families to support informed
      decision-making. Policymakers should consider the cost burden and risk of
      discrimination when informing government policies. Finally, patients are
      recommended to focus on self-care from an early age.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Logeman, Charlotte
AU  - Logeman C
AUID- ORCID: 0000-0002-8773-1003
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia charlotte.logeman@sydney.edu.au.
AD  - Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Cho, Yeoungjee
AU  - Cho Y
AD  - Australasian Kidney Trials Network, University of Queensland at Princess
      Alexandra Hospital, Brisbane, Queensland, Australia.
AD  - Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Queensland,
      Australia.
FAU - Sautenet, Benedicte
AU  - Sautenet B
AD  - Department of Nephrology Hypertension, Centre Hospitalier Regional Universitaire 
      de Tours, Tours, France.
FAU - Rangan, Gopala K
AU  - Rangan GK
AD  - Centre for Transplant and Renal Research, The Westmead Institute for Medical
      Research, Sydney, New South Wales, Australia.
AD  - Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Gutman, Talia
AU  - Gutman T
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Craig, Jonathan
AU  - Craig J
AD  - College of Medicine and Public Health, Flinders University Faculty of Medicine,
      Nursing and Health Sciences, Adelaide, South Australia, Australia.
FAU - Ong, Albert
AU  - Ong A
AD  - Academic Nephrology Unit, The Henry Wellcome Laboratories for Medical Research,
      University of Sheffield Medical School, Sheffield, UK.
FAU - Chapman, Arlene
AU  - Chapman A
AD  - Department of Medicine, University of Chicago, Chicago, Illinois, USA.
FAU - Ahn, Curie
AU  - Ahn C
AUID- ORCID: 0000-0001-7033-1102
AD  - Internal Medicine, Seoul National University, Seoul, South Korea.
FAU - Coolican, Helen
AU  - Coolican H
AD  - Head Office, Polycystic Kidney Disease Foundation of Australia, Sydney, New South
      Wales, Australia.
FAU - Tze-Wah Kao, Juliana
AU  - Tze-Wah Kao J
AD  - School of Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan.
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei,
      Taiwan.
FAU - Gansevoort, Ron T
AU  - Gansevoort RT
AD  - Faculty of Medical Sciences, University Medical Center Groningen, Groningen, The 
      Netherlands.
FAU - Perrone, Ronald
AU  - Perrone R
AD  - Division of Nephrology, Tufts University School of Medicine, Boston,
      Massachusetts, USA.
FAU - Harris, Tess
AU  - Harris T
AD  - Head Office, PKD International, Geneva, Switzerland.
AD  - London Office, PKD International, London, UK.
FAU - Torres, Vincent
AU  - Torres V
AD  - Department of Nephrology and Hypertension, Mayo Clinic, Rochester, New York, USA.
FAU - Fowler, Kevin
AU  - Fowler K
AD  - Kidney Health Initiative, The Voice of the Patient, Washington, DC, USA.
FAU - Pei, York
AU  - Pei Y
AD  - Divisions of Nephrology and Genomic Medicine, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Kerr, Peter
AU  - Kerr P
AD  - Nephrology, Monash Medical Centre Clayton, Melbourne, Victoria, Australia.
FAU - Ryan, Jessica
AU  - Ryan J
AD  - Nephrology, Monash Medical Centre Clayton, Melbourne, Victoria, Australia.
FAU - Johnson, David
AU  - Johnson D
AD  - Department of Renal Medicine, Princess Alexandra Hospital, Woolloongabba,
      Queensland, Australia.
AD  - Australasian Kidney Trials Network, The University of Queensland, Saint Lucia,
      Queensland, Australia.
FAU - Viecelli, Andrea
AU  - Viecelli A
AD  - Australasian Kidney Trials Network, University of Queensland at Princess
      Alexandra Hospital, Brisbane, Queensland, Australia.
AD  - School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Geneste, Clair
AU  - Geneste C
AD  - Department of Nephrology and Clinical Immunology, Centre Hospitalier Regional
      Universitaire de Tours, Tours, France.
FAU - Kim, Hyunsuk
AU  - Kim H
AD  - Internal Medicine, Seoul National University Hospital, Jongno-gu, South Korea.
FAU - Kim, Yaerim
AU  - Kim Y
AD  - Department of Internal Medicine, Keimyung University College of Medicine, Daegu, 
      South Korea.
FAU - Howell, Martin
AU  - Howell M
AUID- ORCID: 0000-0001-9740-712X
AD  - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, New
      South Wales, Australia.
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Ju, Angela
AU  - Ju A
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Manera, Karine E
AU  - Manera KE
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Teixeira-Pinto, Armando
AU  - Teixeira-Pinto A
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Parasivam, Gayathri
AU  - Parasivam G
AD  - Discipline of Genetic Medicine, The University of Sydney Medical School, Sydney, 
      New South Wales, Australia.
AD  - Clinical Genetics, The Sydney Children's Hospitals Network Randwick and Westmead,
      Westmead, New South Wales, Australia.
FAU - Tong, Allison
AU  - Tong A
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Attitude
MH  - Australia
MH  - *Caregivers
MH  - Focus Groups
MH  - France
MH  - Humans
MH  - *Polycystic Kidney, Autosomal Dominant/diagnosis
MH  - Quality of Life
MH  - Republic of Korea
PMC - PMC7549480
OTO - NOTNLM
OT  - *genetics
OT  - *medical education & training
OT  - *mental health
OT  - *nephrology
OT  - *paediatric nephrology
COIS- Competing interests: GKR declares he is site investigator of clinical trials
      sponsored by Sanofi, Otsuka and Reata, principal investigator of the
      PREVENT-ADPKD clinical trial (funded in part by the NHMRC, Danone
      Nutricia-manufacturer of bottled water-PKD Australia, Westmead Medical Research
      Foundation) and Chair, Scientific Advisory Board, PKD Australia. RP declares he
      is site investigator of clinical trials sponsored by Sanofi, Kadmon, Reata,
      Otsuka and the US Department of Defense (TAME PKD), and section editor for Cystic
      Kidney Disease, UpToDate.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - bmjopen-2020-038005 [pii]
AID - 10.1136/bmjopen-2020-038005 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e038005. doi: 10.1136/bmjopen-2020-038005.


PMID- 33040005
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Barriers and facilitators of rendering HIV services by community health workers
      in sub-Saharan Africa: a meta-synthesis protocol.
PG  - e037876
LID - 10.1136/bmjopen-2020-037876 [doi]
AB  - INTRODUCTION: In sub-Saharan Africa (SSA), Human Immunodeficiency Virus (HIV) is 
      the leading cause of morbidity and mortality. Community healthcare workers (CHWs)
      worldwide have been reported to be effective in strengthening the HIV programme
      by providing services such as adherence support, HIV education and safe sex
      education as part of their roles. The main aim of this meta-synthesis is to
      synthesise qualitative evidence on studies that have been conducted in SSA
      countries to understand the barriers to and facilitators of providing HIV
      services by CHWs across all settings METHODS AND ANALYSIS: This meta-synthesis
      will be guided by Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses. An initial search was conducted on 15 November 2019 for studies
      published between 2009 and 2019 using the population exposure outcome
      nomenclature. We searched the EBSCOHost- (ERIC; Health Source-Nursing/Academic
      Edition), Google Scholar and PubMed databases for the relevant studies. The
      Ritchie and Spencer framework will be used for data synthesis and the Supporting 
      the Use of Research Evidence Framework analysis will be used to analyse data. We 
      will conduct critical appraisal on selected studies using the Qualitative
      Assessment and Review Instrument to limit risk of bias. ETHICS AND DISSEMINATION:
      This review does not involve any human participants and therefore ethical
      approval will not be required. We will publish the protocol as well as the
      findings in any relevant journal and various media namely conferences; symposia, 
      local and international health stakeholders. PROSPERO REGISTRATION NUMBER:
      CRD42020160012. CONCLUSION: Evidence from this review will provide synthesised
      evidence to the utilisation of CHWs in HIV services in SSA.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Khumalo, Gugulethu Eve
AU  - Khumalo GE
AUID- ORCID: 0000-0002-1881-4104
AD  - Discipline of Public Health Medicine, University of KwaZulu-Natal College of
      Health Sciences, Durban, South Africa jcatcalvary@gmail.com.
AD  - Department of Health, KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal, South
      Africa.
FAU - Lutge, Elizabeth
AU  - Lutge E
AD  - KwaZulu Natal Department of Health, South African Government, Durban, KwaZulu
      Natal, South Africa.
FAU - Naidoo, Praba
AU  - Naidoo P
AD  - Library, University of KwaZulu-Natal - Medical School, Durban, South Africa.
FAU - Mashamba-Thompson, Tivani Phosa
AU  - Mashamba-Thompson TP
AUID- ORCID: 0000-0002-4193-2416
AD  - Public Health, University of KwaZulu Natal, Durban, KwaZulu Natal, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa South of the Sahara
MH  - *Community Health Workers
MH  - *HIV Infections
MH  - Humans
MH  - Review Literature as Topic
PMC - PMC7552870
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *international health services
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037876 [pii]
AID - 10.1136/bmjopen-2020-037876 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037876. doi: 10.1136/bmjopen-2020-037876.


PMID- 33040004
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Prevalence of physical health conditions and health risk behaviours in people
      with severe mental illness in South Asia: protocol for a cross-sectional study
      (IMPACT SMI survey).
PG  - e037869
LID - 10.1136/bmjopen-2020-037869 [doi]
AB  - INTRODUCTION: People with severe mental illness (SMI) die on average 10-20 years 
      earlier than the general population. Most of these deaths are due to physical
      health conditions. The aim of this cross-sectional study is to determine the
      prevalence of physical health conditions and their associations with health-risk 
      behaviours, health-related quality of life and various demographic, behavioural, 
      cognitive, psychological and social variables in people with SMI attending
      specialist mental health facilities in South Asia. METHODS AND ANALYSIS: We will 
      conduct a survey of patients with SMI attending specialist mental health
      facilities in Bangladesh, India and Pakistan (n=4500). Diagnosis of SMI will be
      confirmed using the Mini-international neuropsychiatric interview V.6.0. We will 
      collect information about physical health and related health-risk behaviours (WHO
      STEPwise approach to Surveillance (STEPS)); severity of common mental disorders
      (Patient Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder scale
      (GAD-7)) and health-related quality of life (EQ-5D-5L). We will measure blood
      pressure, height, weight and waist circumference according to WHO guidelines. We 
      will also measure glycated haemoglobin, lipid profile, thyroid function, liver
      function, creatinine and haemoglobin. Prevalence rates of physical health
      conditions and health-risk behaviours will be presented and compared with the WHO
      STEPS survey findings in the general population. Regression analyses will explore
      the association between health-risk behaviours, mental and physical health
      conditions. ETHICS AND DISSEMINATION: The study has been approved by the ethics
      committees of the Department of Health Sciences University of York (UK), Centre
      for Injury Prevention and Rehabilitation (Bangladesh), Health Ministry Screening 
      Committee and Indian Council of Medical Research (India) and National Bioethics
      Committee (Pakistan). Findings will be disseminated in peer-reviewed articles, in
      local and international conferences and as reports for policymakers and
      stakeholders in the countries involved. TRIAL REGISTRATION NUMBER:
      ISRCTN88485933; 3 June 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Zavala, Gerardo A
AU  - Zavala GA
AUID- ORCID: 0000-0002-9825-8725
AD  - Department of Health Sciences, University of York, York, UK gzavala@gmail.com.
FAU - Prasad-Muliyala, Krishna
AU  - Prasad-Muliyala K
AD  - Department of Psychiatry, National Institute of Mental Health and Neurosciences
      (NIMHANS), Bangaluru, India.
FAU - Aslam, Faiza
AU  - Aslam F
AD  - Institute of Psychiatry (IOP), Rawalpindi Medical University, Rawalpindi,
      Pakistan.
FAU - Barua, Deepa
AU  - Barua D
AD  - ARK Foundation, Dhaka, Bangladesh.
FAU - Haidar, Asiful
AU  - Haidar A
AD  - ARK Foundation, Dhaka, Bangladesh.
FAU - Hewitt, Catherine
AU  - Hewitt C
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Huque, Rumana
AU  - Huque R
AD  - ARK Foundation, Dhaka, Bangladesh.
FAU - Mansoor, Sonia
AU  - Mansoor S
AD  - Institute of Psychiatry (IOP), Rawalpindi Medical University, Rawalpindi,
      Pakistan.
FAU - Murthy, Pratima
AU  - Murthy P
AD  - Department of Psychiatry, National Institute of Mental Health and Neurosciences
      (NIMHANS), Bangaluru, India.
FAU - Nizami, Asad T
AU  - Nizami AT
AD  - Institute of Psychiatry (IOP), Rawalpindi Medical University, Rawalpindi,
      Pakistan.
FAU - Siddiqi, Najma
AU  - Siddiqi N
AD  - Department of Health Sciences, University of York, York, UK.
AD  - Bradford District Care NHS Foundation Trust, Bradford, UK.
AD  - Hull York Medical School, York, UK.
FAU - Sikander, Siham
AU  - Sikander S
AD  - Global Health Department, Health Services Academy, Islamabad, Pakistan.
FAU - Siddiqi, Kamran
AU  - Siddiqi K
AUID- ORCID: 0000-0003-1529-7778
AD  - Department of Health Sciences, University of York, York, UK.
AD  - Hull York Medical School, York, UK.
FAU - Boehnke, Jan Rasmus
AU  - Boehnke JR
AUID- ORCID: 0000-0003-0249-1870
AD  - Department of Health Sciences, University of York, York, UK.
AD  - School of Health Sciences, University of Dundee, Dundee, UK.
CN  - IMPACT team
LA  - eng
SI  - ISRCTN/ISRCTN88485933
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bangladesh
MH  - Cross-Sectional Studies
MH  - Health Risk Behaviors
MH  - Humans
MH  - India/epidemiology
MH  - *Mental Disorders/epidemiology
MH  - Pakistan/epidemiology
MH  - Prevalence
MH  - *Quality of Life
PMC - PMC7549451
OTO - NOTNLM
OT  - *mental health
OT  - *psychiatry
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037869 [pii]
AID - 10.1136/bmjopen-2020-037869 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037869. doi: 10.1136/bmjopen-2020-037869.


PMID- 33040003
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Rationale and design of a randomised controlled trial testing the effect of
      personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus
      treated with metformin.
PG  - e037859
LID - 10.1136/bmjopen-2020-037859 [doi]
AB  - INTRODUCTION: Metformin and diets aimed at promoting healthy body weight are the 
      first line in treating type 2 diabetes mellitus (T2DM). Clinical practice, backed
      by clinical trials, suggests that many individuals do not reach glycaemic targets
      using this approach alone. The primary aim of the Personalised Medicine in
      Pre-diabetes-Towards Preventing Diabetes in Individuals at Risk (PREDICT) Study
      is to test the efficacy of personalised diet as adjuvant to metformin in
      improving glycaemic control in individuals with dysglycaemia. METHODS AND
      ANALYSIS: PREDICT is a two-arm, parallel group, single-masked randomised
      controlled trial in adults with pre-diabetes or early-stage T2DM (with glycated
      haemoglobin (HbA1c) up to 8.0% (64 mmol/mol)), not treated with glucose-lowering 
      medication. PREDICT is conducted at the Clinical Research Facility at the Garvan 
      Institute of Medical Research (Sydney). Enrolment of participants commenced in
      December 2018 and expected to complete in December 2021. Participants are
      commenced on metformin (Extended Release, titrated to a target dose of 1500
      mg/day) and randomised with equal allocation to either (1) the Personalised
      Nutrition Project algorithm-based diet or (2) low-fat high-dietary fibre diet,
      designed to provide caloric restriction (75%) in individuals with body mass index
      >25 kg/m(2). Treatment duration is 6 months and participants visit the Clinical
      Research Facility five times over approximately 7 months. The primary outcome
      measure is HbA1c. The secondary outcomes are (1) time of interstitial glucose
      <7.8 mmol/L and (2) glycaemic variability (continuous glucose monitoring), (3)
      body weight, (4) fat mass and (5) abdominal visceral fat volume (dual-energy
      X-ray absorptiometry), serum (6) low-density lipoprotein cholesterol (7)
      high-density lipoprotein cholesterol and (8) triglycerides concentrations, (9)
      blood pressure, and (10) liver fat (Fibroscan). ETHICS AND DISSEMINATION: The
      study has been approved by the St Vincent's Hospital Human Research Ethics
      Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional Review 
      Board (File 528-3, Rehovot, Israel). The findings will be published in
      peer-reviewed open access medical journals. TRIAL REGISTRATION NUMBER:
      NCT03558867; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Htet, Thaw D
AU  - Htet TD
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia.
AD  - St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.
AD  - Department of Endocrinology, St Vincent's Hospital, Sydney, New South Wales,
      Australia.
FAU - Godneva, Anastasia
AU  - Godneva A
AD  - Department of Computer Science & Applied Mathematics, Weizmann Institute of
      Science, Rehovot, Israel.
FAU - Liu, Zhixin
AU  - Liu Z
AD  - Mark Wainwright Analytical Centre, UNSW, Sydney, New South Wales, Australia.
FAU - Chalmers, Eliza
AU  - Chalmers E
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia.
FAU - Kolobkov, Dmitry
AU  - Kolobkov D
AD  - Department of Computer Science & Applied Mathematics, Weizmann Institute of
      Science, Rehovot, Israel.
FAU - Snaith, Jennifer R
AU  - Snaith JR
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia.
AD  - St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.
AD  - Department of Endocrinology, St Vincent's Hospital, Sydney, New South Wales,
      Australia.
FAU - Richens, Renee
AU  - Richens R
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia.
FAU - Toth, Krisztina
AU  - Toth K
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia.
FAU - Danta, Mark
AU  - Danta M
AD  - St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.
AD  - Department of Gastroenterology, St Vincent's Hospital, Sydney, New South Wales,
      Australia.
FAU - Hng, Tien-Ming
AU  - Hng TM
AUID- ORCID: 0000-0001-6813-8813
AD  - Diabetes and Endocrinology, Blacktown Mount Druitt Hospital, Sydney, New South
      Wales, Australia.
AD  - Blacktown Clinical School, Western Sydney University, Sydney, New South Wales,
      Australia.
FAU - Elinav, Eran
AU  - Elinav E
AUID- ORCID: 0000-0002-5775-2110
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
FAU - Segal, Eran
AU  - Segal E
AUID- ORCID: 0000-0002-6859-1164
AD  - Department of Computer Science & Applied Mathematics, Weizmann Institute of
      Science, Rehovot, Israel.
FAU - Greenfield, Jerry R
AU  - Greenfield JR
AUID- ORCID: 0000-0002-0866-0973
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia.
AD  - St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.
AD  - Department of Endocrinology, St Vincent's Hospital, Sydney, New South Wales,
      Australia.
FAU - Samocha-Bonet, Dorit
AU  - Samocha-Bonet D
AUID- ORCID: 0000-0001-9422-7852
AD  - Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, New South
      Wales, Australia d.samochabonet@garvan.org.au.
AD  - St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03558867
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Australia
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Diet
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Israel
MH  - *Metformin/therapeutic use
MH  - *Prediabetic State/drug therapy
PMC - PMC7552859
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *nutrition & dietetics
COIS- Competing interests: EE and ES are paid consultants of the company DayTwo. MD has
      received travel support and speaker fees from Gilead, Abbvie and Merck. All other
      authors declare they have no conflict of interest.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037859 [pii]
AID - 10.1136/bmjopen-2020-037859 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037859. doi: 10.1136/bmjopen-2020-037859.


PMID- 33040002
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Rationale and design for Lowering-hyperUricaemia treatment on cardiovascular
      outcoMes In peritoNeal diAlysis patients: a prospective, multicentre,
      double-blind, randomised controlled trial (LUMINA).
PG  - e037842
LID - 10.1136/bmjopen-2020-037842 [doi]
AB  - INTRODUCTION: The prevalence of hyperuricaemia in peritoneal dialysis patients is
      quite high. Studies have demonstrated a correlation between hyperuricaemia and
      cardiovascular disease and treatment of hyperuricaemia reportedly reduces
      cardiovascular risk in patients with chronic kidney disease. However, whether
      hyperuricaemia treatment benefits cardiovascular outcomes in continuous
      ambulatory peritoneal dialysis (CAPD) patients is not yet known. METHODS AND
      ANALYSES: This prospective, multicentre, double-blind, randomised controlled
      trial was designed to evaluate the effects of hyperuricaemia treatment on
      cardiovascular event risk in CAPD patients. Based on a power of 80%, with type I 
      error alpha=0.05, two-sided test and 1:1 parallel control study, considering a
      dropout rate of 20%, a total of 548 eligible patients are expected to be randomly
      assigned to either the hyperuricaemia treatment group (febuxostat) or control
      group (placebo). ETHICS AND DISSEMINATION: This study has been approved by the
      Medical Ethics Committee of the First Affiliated Hospital, Sun Yat-sen University
      and the ethics committees of other participating institutions. Written informed
      consent will be obtained from potential trial participants or authorised
      surrogates.The findings of the study will be disseminated through publications in
      peer-reviewed journals, and presentations at national and international
      conferences. TRIAL REGISTRATION NUMBER: NCT03200210. 25 June 2017. The trial was 
      started on 13 July 2017, and is expected to end by 31 December 2022. Till 20 Jan 
      2020, a total of 548 patients have been recruited. PROTOCOL VERSION: The protocol
      version number and date are YLT-1604-V2.0 and 15 December 2016.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China.
FAU - Huang, Naya
AU  - Huang N
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China.
FAU - Mao, Haiping
AU  - Mao H
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China.
FAU - Yang, Xiao
AU  - Yang X
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China.
FAU - Zhou, Qian
AU  - Zhou Q
AD  - Department of Medical Statistics, Clinical Trials Unit, Sun Yat-sen University
      First Affiliated Hospital, Guangzhou, Guangdong, China.
FAU - Jiang, Lanping
AU  - Jiang L
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China.
FAU - Ding, Jun
AU  - Ding J
AD  - Medical Department, Wanbang Pharmaceutical Marketing and Distribution Co,
      Shanghai, China.
FAU - Feng, Qiong
AU  - Feng Q
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China.
FAU - Yu, Xueqing
AU  - Yu X
AUID- ORCID: 0000-0002-8781-5768
AD  - Department of Nephrology, Sun Yat-sen University First Affiliated
      HospitalNational Health Commission Key Laboratory of Nephrology (Sun Yat-sen
      University), Guangdong Provincial Key Laboratory of Nephrology, Guangzhou,
      Guangdong, China yuxq@mail.sysu.edu.cn.
AD  - Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou,
      Guangdong, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03200210
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 101V0R1N2E (Febuxostat)
SB  - IM
MH  - Double-Blind Method
MH  - Febuxostat
MH  - Humans
MH  - *Hyperuricemia
MH  - *Peritoneal Dialysis, Continuous Ambulatory
MH  - Prospective Studies
PMC - PMC7552848
OTO - NOTNLM
OT  - *cardiology
OT  - *dialysis
OT  - *nephrology
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037842 [pii]
AID - 10.1136/bmjopen-2020-037842 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037842. doi: 10.1136/bmjopen-2020-037842.


PMID- 33040001
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Clinical effectiveness of manipulation and mobilisation interventions for the
      treatment of non-specific neck pain: protocol for a systematic review and
      meta-analysis.
PG  - e037783
LID - 10.1136/bmjopen-2020-037783 [doi]
AB  - INTRODUCTION: Non-specific neck pain (NSNP) is a common musculoskeletal condition
      resulting in pain, physical limitations and associated functional disability.
      Current guidelines recommend manipulation and/or mobilisation as part of the
      multimodal management of NSNP. This study focuses on intervention at the
      articular level and aims to identify whether joint mobilisation or joint
      manipulation has a greater effect on function, range of movement or pain outcomes
      in the management of NSNP. METHODS AND ANALYSIS: A systematic review protocol has
      been designed and is reported in line with the Preferred Reporting Items for
      Systematic Reviews and Meta-Analysis Protocols. A targeted search strategy will
      enable searching of key databases from inception to 31 March 2020: CINAHL, PEDro,
      AMED, EMBASE, OVID, MEDLINE, Web of Science, PubMed and Google Scholar. Key
      journals will be searched using predefined keywords determined from preliminary
      scoping searches for randomised controlled trials of manipulation and
      mobilisation modalities for adults with NSNP in the absence of radiculopathy or
      whiplash, published in English. Grey literature and unpublished studies will also
      be searched. Studies will be screened by title and abstract and full text. Two
      independent reviewers will conduct the searches independently, extract data,
      assess risk of bias (Cochrane Risk of Bias Tool 2) and assess overall strength of
      evidence (Grading of Recommendations, Assessment, Development and Evaluation).
      Meta-analysis will be performed where individual studies measure comparable
      outcomes including performance-based outcome measures such as range of movement
      or patient reported outcome measures such as Neck Disability Index; and where
      interventions are comparable in their delivery such as number of oscillations and
      Maitland grading. Where not possible, data will be presented descriptively.
      ETHICS AND DISSEMINATION: This study does not require ethical approval. Findings 
      will be submitted for publication to relevant peer-reviewed journals and will be 
      presented at profession-specific conferences. PROSPERO REGISTRATION NUMBER:
      CRD42020164457.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bailey, Elizabeth
AU  - Bailey E
AD  - Physiotherapy, University Hospitals Plymouth NHS Trust, Plymouth, UK.
FAU - Heneghan, Nicola R
AU  - Heneghan NR
AUID- ORCID: 0000-0001-7599-3674
AD  - Centre of Precision Rehabilitation for Spinal Pain, School of Sport, Exercise and
      Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Cassidy, Natasha J
AU  - Cassidy NJ
AD  - Physiotherapy, The Royal Orthopaedic Hospital, Birmingham, UK.
FAU - Falla, Deborah
AU  - Falla D
AUID- ORCID: 0000-0003-1689-6190
AD  - Centre of Precision Rehabilitation for Spinal Pain, School of Sport, Exercise and
      Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Rushton, Alison B
AU  - Rushton AB
AUID- ORCID: 0000-0001-8114-7669
AD  - Centre of Precision Rehabilitation for Spinal Pain, School of Sport, Exercise and
      Rehabilitation Sciences, University of Birmingham, Birmingham, UK
      arushto3@uwo.ca.
AD  - School of Physical Therapy, Western University, London, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Chest Pain
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Neck Pain/therapy
MH  - Physical Therapy Modalities
MH  - *Research Design
MH  - Treatment Outcome
PMC - PMC7549443
OTO - NOTNLM
OT  - *clinical trials
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037783 [pii]
AID - 10.1136/bmjopen-2020-037783 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037783. doi: 10.1136/bmjopen-2020-037783.


PMID- 33039998
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Making shared decision-making (SDM) a reality: protocol of a large-scale
      long-term SDM implementation programme at a Northern German University Hospital.
PG  - e037575
LID - 10.1136/bmjopen-2020-037575 [doi]
AB  - INTRODUCTION: Shared decision-making (SDM) is not yet widely used when making
      decisions in German hospitals. Making SDM a reality is a complex task. It
      involves training healthcare professionals in SDM communication and enabling
      patients to actively participate in communication, in addition to providing
      sound, easy to understand information on treatment alternatives in the form of
      evidence-based patient decision aids (EbPDAs). This project funded by the German 
      Innovation Fund aims at designing, implementing and evaluating a multicomponent, 
      large-scale and integrative SDM programme-called SHARE TO CARE (S2C)-at all
      clinical departments of a University Hospital Campus in Northern Germany within a
      4-year time period. METHODS AND ANALYSIS: S2C tackles the aforementioned
      components of SDM: (1) training physicians in SDM communication, (2) activating
      and empowering patients, (3) developing EbPDAs in the most common/relevant
      diseases and (4) training other healthcare professionals in SDM coaching. S2C is 
      designed together with patients and providers. The physicians' training programme
      entails an online and an in situ training module. The decision coach training is 
      based on a similar but less comprehensive approach. The development of online
      EbPDAs follows the International Patient Decision Aid Standards and includes
      written, graphical and video-based information. Validated outcomes of SDM
      implementation are measured in a preintervention and postintervention evaluation 
      design. Process evaluation accompanies programme implementation. Health economic 
      impact of the intervention is investigated using a propensity-score-matched
      approach based on potentially preference-sensitive hospital decisions. ETHICS AND
      DISSEMINATION: Ethics committee review approval has been obtained from Medical
      Ethics Committee of the Medical Faculty of the Christian-Albrechts-University
      Kiel. Project information and results will be disseminated at conferences, on
      project-hosted websites at University Hospital Medical Center Schleswig Holstein 
      and by S2C as well as in peer-reviewed and professional journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Danner, Marion
AU  - Danner M
AUID- ORCID: 0000-0002-0653-4092
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany marion.danner@uksh.de.
FAU - Geiger, Friedemann
AU  - Geiger F
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany.
AD  - SHARE TO CARE, Patientenzentrierte Kommunikation GmbH, Cologne, Germany.
FAU - Wehkamp, Kai
AU  - Wehkamp K
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany.
AD  - SHARE TO CARE, Patientenzentrierte Kommunikation GmbH, Cologne, Germany.
FAU - Rueffer, Jens Ulrich
AU  - Rueffer JU
AD  - SHARE TO CARE, Patientenzentrierte Kommunikation GmbH, Cologne, Germany.
AD  - TAKEPART Media & Sciences GmbH, Cologne, Germany.
FAU - Kuch, Christine
AU  - Kuch C
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany.
FAU - Sundmacher, Leonie
AU  - Sundmacher L
AD  - Ludwig-Maximilians-Universitat Munchen, Munchen, Germany.
FAU - Skjelbakken, Tove
AU  - Skjelbakken T
AD  - Universitetet i Tromso Helsevitenskapelige fakultet Helsefak, Tromso, Norway.
FAU - Rummer, Anne
AU  - Rummer A
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany.
FAU - Novelli, Anna
AU  - Novelli A
AUID- ORCID: 0000-0002-4600-0183
AD  - Ludwig-Maximilians-Universitat Munchen, Munchen, Germany.
FAU - Debrouwere, Marie
AU  - Debrouwere M
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany.
FAU - Scheibler, Fueloep
AU  - Scheibler F
AD  - SHARE TO CARE Team, University Medical Center Schleswig-Holstein Campus Kiel,
      Kiel, Germany.
AD  - SHARE TO CARE, Patientenzentrierte Kommunikation GmbH, Cologne, Germany.
CN  - SHARE TO CARE (S2C) Project Team
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Decision Making
MH  - *Decision Making, Shared
MH  - Germany
MH  - Hospitals, University
MH  - Humans
MH  - *Patient Participation
PMC - PMC7549440
OTO - NOTNLM
OT  - *change management
OT  - *organisation of health services
OT  - *organisational development
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037575 [pii]
AID - 10.1136/bmjopen-2020-037575 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037575. doi: 10.1136/bmjopen-2020-037575.


PMID- 33039994
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Early Parenting Acceptance and Commitment Therapy 'Early PACT' for parents of
      infants with cerebral palsy: a study protocol of a randomised controlled trial.
PG  - e037033
LID - 10.1136/bmjopen-2020-037033 [doi]
AB  - INTRODUCTION: New international clinical practice guidelines exist for
      identifying infants at high risk of cerebral palsy (CP) earlier: between 12 to 24
      weeks corrected age, significantly earlier than previous diagnosis windows in
      Australia at 19 months. The earlier detection of infants at high risk of CP
      creates an opportunity for earlier intervention. The quality of the parent-infant
      relationship impacts various child outcomes, and is leveraged in other forms of
      intervention. This paper presents the protocol of a randomised controlled trial
      of an online parent support programme, Early Parenting Acceptance and Commitment 
      Therapy (Early PACT) for families of infants identified as at high risk of CP. We
      predict that participating in the Early PACT programme will be associated with
      improvements in the parent-infant relationship, in parent mental health and
      well-being as well as infant behaviour and quality of life. METHODS AND ANALYSIS:
      This study aims to recruit 60 parents of infants (0 to 2 years old corrected age)
      diagnosed with CP or identified as at high risk of having CP. Participants will
      be randomly allocated to one of two groups: Early PACT or waitlist control (1:1).
      Early PACT is an online parent support programme grounded in Acceptance and
      Commitment Therapy (ACT). It is delivered as a course on an open source course
      management system called edX. Early PACT is designed to support parental
      adjustment and parent-infant relationship around the time of early diagnosis.
      Assessments will be conducted at baseline, following completion of Early PACT and
      at 6-month follow-up (retention). The primary outcome will be the quality of
      parent-child interactions as measured by the Emotional Availability Scale.
      Standard analysis methods for randomised controlled trial will be used to make
      comparisons between the two groups (Early PACT and waitlist control). Retention
      of effects will be examined at 6-month follow-up. ETHICS AND DISSEMINATION: This 
      study is approved through appropriate Australian and New Zealand ethics
      committees (see in text) with parents providing written informed consent.
      Findings from this trial will be disseminated through peer-reviewed journal
      publications and conference presentations. TRIAL REGISTRATION DETAILS: This trial
      has been prospectively registered on 12 June 2018 to present (ongoing) with the
      Australian New Zealand Clinical Trials Registry (ACTRN12618000986279);
      https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=3 74 896.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Whittingham, Koa
AU  - Whittingham K
AUID- ORCID: 0000-0002-5344-9907
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre (CHRC), Faculty of Medicine, The University of Queensland,
      Brisbane, Queensland, Australia koawhittingham@uq.edu.au.
FAU - Sheffield, Jeanie
AU  - Sheffield J
AD  - School of Psychology, The University of Queensland, Saint Lucia, Queensland,
      Australia.
FAU - Mak, Catherine
AU  - Mak C
AUID- ORCID: 0000-0001-7446-2767
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre (CHRC), Faculty of Medicine, The University of Queensland,
      Brisbane, Queensland, Australia.
FAU - Dickinson, Corrine
AU  - Dickinson C
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre (CHRC), Faculty of Medicine, The University of Queensland,
      Brisbane, Queensland, Australia.
FAU - Boyd, Roslyn N
AU  - Boyd RN
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre (CHRC), Faculty of Medicine, The University of Queensland,
      Brisbane, Queensland, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618000986279
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - Australia
MH  - *Cerebral Palsy/therapy
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - New Zealand
MH  - Parenting
MH  - Parents
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7552872
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *mental health
OT  - *paediatrics
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037033 [pii]
AID - 10.1136/bmjopen-2020-037033 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e037033. doi: 10.1136/bmjopen-2020-037033.


PMID- 33039992
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Multicentre, randomised, open-label, non-inferiority trial comparing the
      effectiveness and safety of ductal lavage versus oral corticosteroids for
      idiopathic granulomatous mastitis: a study protocol.
PG  - e036643
LID - 10.1136/bmjopen-2019-036643 [doi]
AB  - INTRODUCTION: The ideal treatment for idiopathic granulomatous mastitis (IGM)
      remains unclear. In a prospective, single-centre, pilot study, we reported that
      ductal lavage treatment for non-lactational mastitis patients had a 1-year
      clinical complete response (cCR) rate of >90%, without any significant adverse
      events. Thus, in this multicentre, randomised, open-label, non-inferiority trial,
      we will aim to compare the effectiveness and safety of ductal lavage vs oral
      corticosteroids as the first-line treatment for patients with IGM. METHODS AND
      ANALYSIS: The trial will be conducted at the Breast Tumor Center of Sun Yat-sen
      Memorial Hospital in China and at least at one participating regional centre. We 
      plan to recruit 140 eligible IGM patients who will be randomised into the ductal 
      lavage group or oral corticosteroid group with a 1:1 ratio. The patients in the
      oral corticosteroid group will receive meprednisone or prednisone for 6 months.
      The patients in the ductal lavage group will receive ductal lavage and breast
      massage, as previously reported. All the participants will be followed up at the 
      clinic for 1 year post randomisation. The primary endpoint of this trial will be 
      the 1-year cCR rate, and the secondary endpoints will include the time to cCR,
      treatment failure rate, relapse rate and protocol compliance rate. The trial was 
      designed to determine whether ductal lavage is non-inferior to oral
      corticosteroids (1-year cCR rate assumed to be 90%), with a non-inferiority
      margin of 15%. ETHICS AND DISSEMINATION: The ethics committee of Sun Yat-sen
      Memorial Hospital at Sun Yat-sen University approved the study
      (2018-Lun-Shen-Yan-No. 30). The results of the trial will be communicated to the 
      participating primary care practices, published in international journals and
      presented at international clinical and scientific conferences. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03724903); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hu, Tingting
AU  - Hu T
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Li, Shunrong
AU  - Li S
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Huang, Heng
AU  - Huang H
AD  - Department of Mammary Surgery, Lianjiang People's Hospital, Zhanjiang, Guangdong,
      China.
FAU - Huang, Hui
AU  - Huang H
AD  - Department of Mammary Surgery, Maternity and Child Health Care Hospital of
      Jiangmen, Jiangmen, Guangdong, China.
FAU - Tan, Luyuan
AU  - Tan L
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Chen, Yanbo
AU  - Chen Y
AD  - Department of orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Deng, Heran
AU  - Deng H
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Wu, Jiannan
AU  - Wu J
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Zhu, Liling
AU  - Zhu L
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Su, Fengxi
AU  - Su F
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China.
FAU - Chen, Kai
AU  - Chen K
AUID- ORCID: 0000-0002-7052-4681
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
      Guangzhou, Guangdong, China chenkai23@mail.sysu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03724903
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Adrenal Cortex Hormones
MH  - China
MH  - Female
MH  - *Granulomatous Mastitis/drug therapy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Therapeutic Irrigation
PMC - PMC7552910
OTO - NOTNLM
OT  - *breast surgery
OT  - *breast tumours
OT  - *histology
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036643 [pii]
AID - 10.1136/bmjopen-2019-036643 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e036643. doi: 10.1136/bmjopen-2019-036643.


PMID- 33039989
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL
      economic evaluation substudy.
PG  - e036599
LID - 10.1136/bmjopen-2019-036599 [doi]
AB  - INTRODUCTION: Current treatment regimens for multidrug-resistant tuberculosis
      (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the
      costs of treating MDR-TB are much greater than those for treating
      drug-susceptible TB, both for health service and patient-incurred costs. Urgent
      action is needed to identify short, effective, tolerable and cheaper treatments
      for people with both quinolone-susceptible and quinolone-resistant MDR-TB. We
      present the protocol for an economic evaluation (PRACTECAL-EE substudy) alongside
      an ongoing clinical trial (TB-PRACTECAL) aiming to assess the costs to patients
      and providers of new regimens, as well as their cost-effectiveness and impact on 
      participant poverty levels. This substudy is based on data from the three
      countries participating in the main trial. METHODS AND ANALYSIS: Primary cost
      data will be collected from the provider and patient perspectives, following
      economic best practice. We will estimate the probability that new MDR-TB regimens
      containing bedaquiline, pretomanid and linezolid are cost-effective from a
      societal perspective as compared with the standard of care for MDR-TB patients in
      Uzbekistan, South Africa and Belarus. Analysis uses a Markov model populated with
      primary cost and outcome data collected at each study site. We will also estimate
      the impact of new regimens on prevalence of catastrophic patient costs due to TB.
      ETHICS AND DISSEMINATION: Ethical approval has been obtained from the London
      School of Hygiene & Tropical Medicine and Medecins Sans Frontieres. Local ethical
      approval will be sought in each study site. The results of the economic
      evaluation will be shared with the country health authorities and published in a 
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry
      (NCT04207112); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sweeney, Sedona
AU  - Sweeney S
AUID- ORCID: 0000-0003-4233-9080
AD  - Global Health and Development, London School of Hygiene and Tropical Medicine,
      London, UK sedona.sweeney@lshtm.ac.uk.
FAU - Gomez, Gabriela
AU  - Gomez G
AD  - Vaccine Epidemiology and Modelling, Sanofi Pasteur SA, Lyon, France.
FAU - Kitson, Nichola
AU  - Kitson N
AD  - Global Health and Development, London School of Hygiene and Tropical Medicine,
      London, UK.
FAU - Sinha, Animesh
AU  - Sinha A
AUID- ORCID: 0000-0003-3213-7813
AD  - Medecins Sans Frontieres Holland, Minsk, Belarus.
FAU - Yatskevich, Natalia
AU  - Yatskevich N
AD  - Republican Scientific and Practical Centre for Pulmonology and Tuberculosis,
      Minsk, Belarus.
FAU - Staples, Suzanne
AU  - Staples S
AD  - TB and HIV Investigative Network (THINK), Durban, South Africa.
FAU - Moodliar, Ronelle
AU  - Moodliar R
AD  - TB and HIV Investigative Network (THINK), Durban, South Africa.
FAU - Motlhako, Sharon
AU  - Motlhako S
AD  - Helen Joseph Hospital, Clinical HIV Research Unit, Wits Health Consortium,
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Maloma, Matshepo
AU  - Maloma M
AD  - King DinuZulu Hospital, Clinical HIV Research Unit, Wits Health Consortium,
      University of the Witwatersrand, Durban, South Africa.
FAU - Rassool, Mohammed
AU  - Rassool M
AD  - Helen Joseph Hospital, Clinical HIV Research Unit, Wits Health Consortium,
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Ngubane, Nosipho
AU  - Ngubane N
AD  - King DinuZulu Hospital, Clinical HIV Research Unit, Wits Health Consortium,
      University of the Witwatersrand, Durban, South Africa.
FAU - Ndlovu, Ella
AU  - Ndlovu E
AD  - King DinuZulu Hospital, Clinical HIV Research Unit, Wits Health Consortium,
      University of the Witwatersrand, Durban, South Africa.
FAU - Nyang'wa, Bern-Thomas
AU  - Nyang'wa BT
AD  - Manson Unit, Medecins Sans Frontieres, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04207112
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - *Antitubercular Agents/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - London
MH  - Republic of Belarus
MH  - South Africa
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
MH  - Uzbekistan
PMC - PMC7549492
OTO - NOTNLM
OT  - *clinical trials
OT  - *health economics
OT  - *tuberculosis
COIS- Competing interests: The chief investigator of the TB-PRACTECAL trial (B-TN) is a
      full-time employee of Medecins sans Frontieres, the funder of the research. GBG
      is currently employed by Sanofi Pasteur as Regional Lead for vaccine epidemiology
      and modelling on Europe and does not work in any project related to tuberculosis.
      GBG's contribution to this work pertains to activities prior to employment at
      Sanofi Pasteur.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036599 [pii]
AID - 10.1136/bmjopen-2019-036599 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e036599. doi: 10.1136/bmjopen-2019-036599.


PMID- 33039983
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Non-pharmacological approaches to procedural anxiety reduction for patients
      undergoing radiotherapy for cancer: systematic review protocol.
PG  - e035155
LID - 10.1136/bmjopen-2019-035155 [doi]
AB  - INTRODUCTION: Procedural anxiety relates to an affective state of anxiety or fear
      in relation to a medical procedure. Various treatment-related factors may elicit 
      anxiety among oncology patients, including fear of diagnostic imaging (such as
      MRI scans) and impending treatment and medical procedures (such as chemotherapy
      and radiotherapy). It is common in oncology settings to manage acute anxiety
      relating to medical procedures with anxiolytic medication. However,
      pharmacological approaches are not suitable for many patients. Despite this,
      non-pharmacological interventions are infrequently used. The aim of this
      systematic review is to determine whether non-pharmacological interventions
      delivered prior to, or during, radiotherapy are effective in reducing procedural 
      anxiety. METHODS AND ANALYSIS: Data sources will include the bibliographic
      databases CINAHL, MEDLINE, EMBASE, PsycINFO and Cochrane Central Register of
      Controlled trials (CENTRAL) (from inception onward). Eligible studies will
      include adult patients with cancer undergoing radiotherapy treatment. Included
      studies will be those which employ a non-pharmacological intervention, delivered 
      within existing radiotherapy appointments, with the aim of reducing procedural
      anxiety related to radiotherapy. All research designs with a control or other
      comparison group will be included. The primary outcome will be change in levels
      of self-reported procedural anxiety. Secondary outcomes will be changes in scores
      on physiological measures of anxiety and/or changes in treatment completion
      and/or changes in treatment duration and/or changes in psychological distress.
      Two investigators will independently complete title and abstract screening,
      full-text screening, data extraction and assessment of methodological quality. If
      appropriate, a meta-analyses will be performed. Any important amendments to this 
      protocol will be updated in the PROSPERO registration and documented in the
      resulting review publication. ETHICS AND DISSEMINATION: No ethical issues are
      anticipated from this review. The findings will be disseminated through
      peer-reviewed publication and at conferences by presentation. SYSTEMATIC REVIEW
      REGISTRATION: CRD42019112941.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Forbes, Erin
AU  - Forbes E
AUID- ORCID: 0000-0003-0073-4621
AD  - School of Medicine and Public Health, The University of Newcastle Faculty of
      Health and Medicine, Callaghan, New South Wales, Australia.
FAU - Baker, Amanda L
AU  - Baker AL
AD  - School of Medicine and Public Health, The University of Newcastle Faculty of
      Health and Medicine, Callaghan, New South Wales, Australia.
FAU - Britton, Ben
AU  - Britton B
AD  - Department of Consultation Liaison Psychiatry, John Hunter Hospital, New Lambton,
      New South Wales, Australia.
FAU - Clover, Kerrie
AU  - Clover K
AUID- ORCID: 0000-0001-8310-7003
AD  - School of Medicine and Public Health, The University of Newcastle Faculty of
      Health and Medicine, Callaghan, New South Wales, Australia.
AD  - Psycho-Oncology, Calvary Mater Newcastle, Hunter Region Mail Centre, New South
      Wales, Australia.
FAU - Skelton, Eliza
AU  - Skelton E
AD  - School of Medicine and Public Health, The University of Newcastle Faculty of
      Health and Medicine, Callaghan, New South Wales, Australia.
FAU - Oultram, Sharon
AU  - Oultram S
AD  - Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South
      Wales, Australia.
FAU - Oldmeadow, Christopher
AU  - Oldmeadow C
AUID- ORCID: 0000-0001-6104-1322
AD  - CREDITSS-Clinical Research Design, Information Technology and Statistical Support
      Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
FAU - McCarter, Kristen
AU  - McCarter K
AUID- ORCID: 0000-0002-2638-6381
AD  - School of Medicine and Public Health, The University of Newcastle Faculty of
      Health and Medicine, Callaghan, New South Wales, Australia
      Kristen.McCarter@newcastle.edu.au.
AD  - Priority Research Centre for Cancer Research, Innovation and Translation,
      University of Newcastle, Callaghan, New South Wales, Australia.
AD  - Priority Research Centre for Health Behaviour, University of Newcastle,
      Callaghan, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Anxiety/prevention & control
MH  - Fear
MH  - Humans
MH  - *Neoplasms/radiotherapy
MH  - *Psychological Distress
MH  - Self Report
MH  - Systematic Reviews as Topic
PMC - PMC7549444
OTO - NOTNLM
OT  - *adult radiotherapy
OT  - *anxiety disorders
OT  - *radiation oncology
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035155 [pii]
AID - 10.1136/bmjopen-2019-035155 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e035155. doi: 10.1136/bmjopen-2019-035155.


PMID- 33039982
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220322
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Evidence for Better Lives Study: a comparative birth-cohort study on child
      exposure to violence and other adversities in eight low- and middle-income
      countries - foundational research (study protocol).
PG  - e034986
LID - 10.1136/bmjopen-2019-034986 [doi]
AB  - INTRODUCTION: Violence against children is a health, human rights and social
      problem affecting approximately half of the world's children. Its effects begin
      at prenatal stages with long-lasting impacts on later health and well-being. The 
      Evidence for Better Lives Study (EBLS) aims to produce high-quality longitudinal 
      data from cities in eight low- and middle-income countries-Ghana, Jamaica,
      Pakistan, the Philippines, Romania, South Africa, Sri Lanka and Vietnam-to
      support effective intervention to reduce violence against children.
      EBLS-Foundational Research (EBLS-FR) tests critical aspects of the planned EBLS, 
      including participant recruitment and retention, data collection and analysis.
      Alongside epidemiological estimates of levels and predictors of exposure to
      violence and adversity during pregnancy, we plan to explore mechanisms that may
      link exposure to violence to mothers' biological stress markers and subjective
      well-being. METHODS AND ANALYSES: EBLS-FR is a short longitudinal study with a
      sample of 1200 pregnant women. Data are collected during the last trimester of
      pregnancy and 2 to 6 months after birth. The questionnaire for participating
      women has been translated into nine languages. Measures obtained from mothers
      will include, among others, mental and physical health, attitudes to corporal
      punishment, adverse childhood experiences, prenatal intimate partner violence,
      substance use and social/community support. Hair and dry blood spot samples are
      collected from the pregnant women to measure stress markers. To explore research 
      participation among fathers, EBLS-FR is recruiting 300 fathers in the Philippines
      and Sri Lanka. ETHICS AND DISSEMINATION: The study received ethical approvals at 
      all recruiting sites and universities in the project. Results will be
      disseminated through journal publications, conferences and seminar presentations 
      involving local communities, health services and other stakeholders. Findings
      from this work will help to adjust the subsequent stages of the EBLS project.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Valdebenito, Sara
AU  - Valdebenito S
AUID- ORCID: 0000-0001-9361-9379
AD  - Institute of Criminology, University of Cambridge, Cambridge, UK sv331@cam.ac.uk.
FAU - Murray, Aja
AU  - Murray A
AD  - Department of Psychology, The University of Edinburgh, Edinburgh, UK.
FAU - Hughes, Claire
AU  - Hughes C
AD  - Centre for Family Research, University of Cambridge, Cambridge, Cambridgeshire,
      UK.
FAU - Baban, Adriana
AU  - Baban A
AD  - Department of Psychology, Babes-Bolyai University, Cluj-Napoca, Romania.
FAU - Fernando, Asvini D
AU  - Fernando AD
AD  - Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
FAU - Madrid, Bernadette J
AU  - Madrid BJ
AD  - Child Protection Unit, University of the Philippines Manila, Manila, Philippines.
FAU - Ward, Catherine
AU  - Ward C
AD  - Department of Psychology, University of Cape Town, Rondebosch, South Africa.
FAU - Osafo, Joseph
AU  - Osafo J
AD  - Department of Psychology, University of Ghana, Legon, Greater Accra, Ghana.
FAU - Dunne, Michael
AU  - Dunne M
AD  - School of Public Health and Social Work, Queensland University of Technology,
      Kelvin Grove, Queensland, Australia.
FAU - Sikander, Siham
AU  - Sikander S
AD  - Global Health Department, Health Services Academy, Islamabad, Pakistan.
FAU - Walker, Susan P
AU  - Walker SP
AD  - Caribbean Institute for Health Research, University of the West Indies, Kingston,
      Jamaica.
FAU - Thang, Vo Van
AU  - Thang VV
AUID- ORCID: 0000-0003-2018-0371
AD  - Institute for Community Health Research, University of Medicine and Pharmacy, Hue
      University, Hue, Thua Thien-Hue, Viet Nam.
FAU - Tomlinson, Mark
AU  - Tomlinson M
AUID- ORCID: 0000-0001-5846-3444
AD  - Institute for Life Course Health Research, Department of Global Health,
      Stellenbosch University, Cape Town, South Africa.
AD  - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
FAU - Fearon, Pasco
AU  - Fearon P
AD  - Research Department of Clinical, Educational and Health Psychology, University
      College London, London, UK.
FAU - Shenderovich, Yulia
AU  - Shenderovich Y
AUID- ORCID: 0000-0002-0254-3397
AD  - Department of Social Policy and Intervention, University of Oxford, Oxford, UK.
FAU - Marlow, Marguerite
AU  - Marlow M
AD  - Department of Psychology, Stellenbosch University, Stellenbosch, Western Cape,
      South Africa.
FAU - Chathurika, Deshanie
AU  - Chathurika D
AD  - Child Protection Unit, Colombo North Teaching Hospital, Ragama, Sri Lanka.
FAU - Taut, Diana
AU  - Taut D
AD  - Department of Psychology, Babes-Bolyai University, Cluj-Napoca, Romania.
FAU - Eisner, Manuel
AU  - Eisner M
AD  - Institute of Criminology, University of Cambridge, Cambridge, UK.
LA  - eng
GR  - K43 TW010399/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Cohort Studies
MH  - Developing Countries
MH  - *Exposure to Violence
MH  - Female
MH  - Ghana
MH  - Humans
MH  - *Intimate Partner Violence
MH  - Jamaica
MH  - Longitudinal Studies
MH  - Pakistan/epidemiology
MH  - Philippines/epidemiology
MH  - Pregnancy
MH  - Romania
MH  - South Africa/epidemiology
MH  - Sri Lanka/epidemiology
MH  - Vietnam
MH  - Violence
PMC - PMC7552842
OTO - NOTNLM
OT  - *Child protection
OT  - *Community child health
OT  - *EPIDEMIOLOGY
OT  - *MENTAL HEALTH
OT  - *Prenatal diagnosis
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034986 [pii]
AID - 10.1136/bmjopen-2019-034986 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e034986. doi: 10.1136/bmjopen-2019-034986.


PMID- 33039981
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 10
TI  - Effects of walkability on physical activity and obesity: a prospective
      observational study protocol.
PG  - e034882
LID - 10.1136/bmjopen-2019-034882 [doi]
AB  - INTRODUCTION: The prevalence of overweight and obesity is increasing worldwide,
      which could lead to a set of chronic and metabolic diseases. Physical activity is
      a modifiable factor for obesity, which was reported to be correlated with the
      built environment. However, the effects of the built environment on physical
      activity are not consistent. Walkability is a convenient way to assess the built 
      environment. We aim to prospectively explore the relationship among walkability, 
      physical activity and obesity in Chinese participants in Chongqing, a hilly city 
      and provide evidence for future urban planning. METHODS AND ANALYSIS:
      Participants will be recruited from people who receive health examination in the 
      Health Management Centre, the First Affiliated Hospital to Army Medical
      University. Exposure variables are WalkScores calculated within the areas around 
      workplace and residential addresses of participants. The primary outcomes are
      body mass index measured through health examination at baseline and follow-ups,
      and daily walking steps recorded by WeChat mini application for 30 days after
      every time of health examination. Other health-related data of the participants
      will also be collected. Multivariate regression analysis will be performed to
      examine the relationship between exposure variables and outcomes. ETHICS AND
      DISSEMINATION: The Protocol is approved by the Ethics Committee of the First
      Affiliated Hospital to Army Medical University (KY201839). The results will be
      actively disseminated through peer-review journals and conference publications.
      REGISTRATION NUMBER: Chinese Clinical Trial Registry (ChiCTR1800017680).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Yalan
AU  - Zhang Y
AD  - Health Management Centre, First Affiliated Hospital to Army Medical University,
      Chongqing, China.
FAU - Chen, Siyu
AU  - Chen S
AD  - Department of Epidemiology and Biostatistics, First Affiliated Hospital to Army
      Medical University, Chongqing, China.
FAU - Shi, Jiayang
AU  - Shi J
AD  - Health Management Centre, First Affiliated Hospital to Army Medical University,
      Chongqing, China.
FAU - Chen, Zongtao
AU  - Chen Z
AUID- ORCID: 0000-0001-6720-9827
AD  - Health Management Centre, First Affiliated Hospital to Army Medical University,
      Chongqing, China chenzongtao@126.com.
LA  - eng
SI  - ChiCTR/ChiCTR1800017680
PT  - Journal Article
DEP - 20201010
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cities
MH  - *Environment Design
MH  - Exercise
MH  - Humans
MH  - Obesity/epidemiology/prevention & control
MH  - Observational Studies as Topic
MH  - *Residence Characteristics
MH  - Walking
PMC - PMC7554499
OTO - NOTNLM
OT  - *clinical physiology
OT  - *epidemiology
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/11 20:35
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034882 [pii]
AID - 10.1136/bmjopen-2019-034882 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 10;10(10):e034882. doi: 10.1136/bmjopen-2019-034882.


PMID- 33039849
OWN - NLM
STAT- MEDLINE
DCOM- 20211008
LR  - 20211008
IS  - 1879-3320 (Electronic)
IS  - 0960-7404 (Linking)
VI  - 35
DP  - 2020 Dec
TI  - Laparoscopic fluorescence navigation for left-sided colon and rectal cancer:
      Blood flow evaluation, vessel and ureteral navigation, clip marking and
      trans-anal tube insertion.
PG  - 434-440
LID - S0960-7404(20)30409-6 [pii]
LID - 10.1016/j.suronc.2020.10.001 [doi]
AB  - BACKGROUND: Recently, the indocyanine green (ICG) fluorescence navigation method 
      has attracted much attention as a means of intraoperative navigation, especially 
      during laparoscopic surgery. The newly developed near-infrared (NIR) fluorescent 
      resin also emits NIR fluorescence, as does ICG. Presently, new devices made with 
      this resin are being developed. The purpose of this study was to present our
      fluorescence navigation techniques for left-sided colon and rectal cancer.
      METHOD: Fifty-nine patients with left-sided colon and rectal cancer underwent
      laparoscopic surgery with fluorescence navigation between July 2019 and April
      2020. The surgeries included 54 intestinal blood flow (IBF) evaluations using
      ICG, 16 preoperative fluorescence clip marking (FCM) procedures, 7 fluorescence
      ureteral navigation procedures, 4 fluorescence vessel navigation (FVN) procedures
      during lateral lymph node dissection, and 3 fluorescence-guided trans-anal tube
      insertion procedures. Laparoscopic surgery and fluorescence observation were
      performed using a VISERA ELITE 2. In FCM, the Zeoclip FS device was used. In
      ureteral navigation and trans-anal tube insertion, the Near-Infrared Ray Catheter
      (NIRC) fluorescent ureteral catheter (NIRFUC) was used. RESULTS: No complications
      related to the fluorescence navigation techniques, including those involving ICG,
      the Zeoclip FS and the NIRFUC, occurred. In 5 cases, the surgical plan was
      changed according to the IBF evaluation with ICG, and no anastomotic leakage
      occurred in those cases. These fluorescence navigation techniques provide
      previously unavailable visual information regarding the IBF, vessel and ureter
      routes and accurate endoscopic clip and drainage tube locations in the intestinal
      tract. CONCLUSIONS: Technology to visualize blood flow dynamics and structures
      using fluorescence can be considered innovative, especially when applied in
      laparoscopic surgery, which relies on vision. The popularity of fluorescence
      navigation has also appeared to increase the safety of colorectal surgery.
      CLINICAL TRIAL REGISTRATION: Examination of fluorescence navigation for
      laparoscopic colorectal cancer surgery. Research Ethics Committee of the
      Kawaguchi Municipal Medical Center (Saitama, Japan) approval number: 2020-3.
      https://kawaguchi-mmc.org/wp-content/uploads/clinicalresearch-r02.pdf.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Ryu, Shunjin
AU  - Ryu S
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan. Electronic address:
      systematic.ryu1121@gmail.com.
FAU - Ishida, Kota
AU  - Ishida K
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan.
FAU - Okamoto, Atsuko
AU  - Okamoto A
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan.
FAU - Nakashima, Keigo
AU  - Nakashima K
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan.
FAU - Hara, Keigo
AU  - Hara K
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan.
FAU - Ito, Ryusuke
AU  - Ito R
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan.
FAU - Nakabayashi, Yukio
AU  - Nakabayashi Y
AD  - Department of Digestive Surgery, Kawaguchi Municipal Medical Center, 180,
      Nishiaraijuku, Kawaguchi City, Saitama, 333-0833, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - Netherlands
TA  - Surg Oncol
JT  - Surgical oncology
JID - 9208188
RN  - 0 (Fluorescent Dyes)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anal Canal/blood supply/*pathology/surgery
MH  - Anastomotic Leak
MH  - Colonic Neoplasms/blood supply/*pathology/surgery
MH  - Female
MH  - *Fluorescence
MH  - Fluorescent Dyes
MH  - Follow-Up Studies
MH  - Humans
MH  - Laparoscopy/*methods
MH  - Lymph Node Excision
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Rectal Neoplasms/blood supply/*pathology/surgery
MH  - Retrospective Studies
MH  - Surgery, Computer-Assisted/*methods
MH  - Ureter/blood supply/*pathology/surgery
OTO - NOTNLM
OT  - Fluorescence
OT  - Indocyanine green
OT  - Navigation
EDAT- 2020/10/12 06:00
MHDA- 2021/10/09 06:00
CRDT- 2020/10/11 20:30
PHST- 2020/06/25 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/10/09 06:00 [medline]
PHST- 2020/10/11 20:30 [entrez]
AID - S0960-7404(20)30409-6 [pii]
AID - 10.1016/j.suronc.2020.10.001 [doi]
PST - ppublish
SO  - Surg Oncol. 2020 Dec;35:434-440. doi: 10.1016/j.suronc.2020.10.001. Epub 2020 Oct
      6.


PMID- 33039658
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20220531
IS  - 2352-5568 (Electronic)
IS  - 2352-5568 (Linking)
VI  - 39
IP  - 6
DP  - 2020 Dec
TI  - Randomised comparison of Enk and Manujet for emergency tracheal oxygenation with 
      a high-fidelity full-scale simulation.
PG  - 807-812
LID - S2352-5568(20)30224-1 [pii]
LID - 10.1016/j.accpm.2020.01.011 [doi]
AB  - BACKGROUND: We aimed to compare time and difficulties of emergency tracheal
      oxygenation with Enk or Manujet by anaesthesiologists or intensivists, in a
      full-scale cannot ventilate and intubate scenarios on a SimMan3G high-fidelity
      patient simulator. METHODS: After ethical committee approval and written informed
      consent, teams (two to three learners with at least one physician senior)
      participating at a difficult airway training with a massive sublingual haematoma 
      scenario, were randomised in Enk (E) group (29 teams, 76 learners) and Manujet
      (M) group (31 teams, 84 learners) according to the device at disposal. Main
      criterion was time between taking device in hand and first insufflation delay.
      Data were medians [25-75%]. RESULTS: The handling-insufflation time was shorter
      with Enk than with Manujet (74 [54-87] seconds versus 95 [73-123] seconds (s),
      P=0.0112). The team number performing insufflation within one minute after device
      handling was higher in the E group (8, 27.6%) than in the M group (2, 6.4%)
      (P=0.0392) as well as the team number performing insufflation within 90s in the E
      group (22, 75.09%) than in the M group (12, 38.7%) (P=0.0047). In E group, 75% of
      learners reported no difficulty versus 58.8% in M group (P=0.0443). Insufflation 
      frequency was high in both groups and higher than 12min(-1) in 51.7% of the
      teams. CONCLUSION: In a simulation context, Enk use is faster and easier. A high 
      insufflation rate was also in favour of Enk that generates lower airway
      pressures.
CI  - Copyright (c) 2020 Societe francaise d'anesthesie et de reanimation (Sfar).
      Published by Elsevier Masson SAS. All rights reserved.
FAU - Lejus-Bourdeau, Corinne
AU  - Lejus-Bourdeau C
AD  - Service d'Anesthesie Reanimation Chirurgicale, Hotel Dieu - Hopital Mere Enfant, 
      CHU Nantes, Place Alexis Ricordeau, F-44093 Nantes, France; Laboratoire
      Experimental de Simulation de Medecine Intensive de l'Universite (LE SiMU) de
      Nantes, 9, rue Bias, 44001 Nantes, France. Electronic address:
      corinne.lejus@chu-nantes.fr.
FAU - Grillot, Nicolas
AU  - Grillot N
AD  - Service d'Anesthesie Reanimation Chirurgicale, Hotel Dieu - Hopital Mere Enfant, 
      CHU Nantes, Place Alexis Ricordeau, F-44093 Nantes, France; Laboratoire
      Experimental de Simulation de Medecine Intensive de l'Universite (LE SiMU) de
      Nantes, 9, rue Bias, 44001 Nantes, France.
FAU - Dupont, Segolene
AU  - Dupont S
AD  - Service d'Anesthesie Reanimation Chirurgicale, Hotel Dieu - Hopital Mere Enfant, 
      CHU Nantes, Place Alexis Ricordeau, F-44093 Nantes, France; Laboratoire
      Experimental de Simulation de Medecine Intensive de l'Universite (LE SiMU) de
      Nantes, 9, rue Bias, 44001 Nantes, France.
FAU - Robert-Edan, Vincent
AU  - Robert-Edan V
AD  - Service d'Anesthesie Reanimation Chirurgicale, Hotel Dieu - Hopital Mere Enfant, 
      CHU Nantes, Place Alexis Ricordeau, F-44093 Nantes, France; Laboratoire
      Experimental de Simulation de Medecine Intensive de l'Universite (LE SiMU) de
      Nantes, 9, rue Bias, 44001 Nantes, France.
FAU - Bazin, Olivier
AU  - Bazin O
AD  - Laboratoire Experimental de Simulation de Medecine Intensive de l'Universite (LE 
      SiMU) de Nantes, 9, rue Bias, 44001 Nantes, France.
FAU - Viquesnel, Simon
AU  - Viquesnel S
AD  - Laboratoire Experimental de Simulation de Medecine Intensive de l'Universite (LE 
      SiMU) de Nantes, 9, rue Bias, 44001 Nantes, France; Pole Anesthesie Reanimation, 
      CHU Rennes, 2, rue Henri Le Guilloux, 35033 Rennes cedex 9, France.
FAU - Pichenot, Vincent
AU  - Pichenot V
AD  - Service d'Anesthesie Reanimation Chirurgicale, Hotel Dieu - Hopital Mere Enfant, 
      CHU Nantes, Place Alexis Ricordeau, F-44093 Nantes, France; Laboratoire
      Experimental de Simulation de Medecine Intensive de l'Universite (LE SiMU) de
      Nantes, 9, rue Bias, 44001 Nantes, France.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201008
PL  - France
TA  - Anaesth Crit Care Pain Med
JT  - Anaesthesia, critical care & pain medicine
JID - 101652401
SB  - IM
MH  - Emergencies
MH  - Emergency Service, Hospital
MH  - Humans
MH  - *Insufflation
MH  - *Intubation, Intratracheal
MH  - Trachea
OTO - NOTNLM
OT  - *Anaesthesia
OT  - *Difficult airway
OT  - *High-fidelity simulation
OT  - *Intubation
OT  - *Safety
EDAT- 2020/10/12 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/10/11 20:24
PHST- 2019/10/15 00:00 [received]
PHST- 2020/01/03 00:00 [revised]
PHST- 2020/01/23 00:00 [accepted]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/10/11 20:24 [entrez]
AID - S2352-5568(20)30224-1 [pii]
AID - 10.1016/j.accpm.2020.01.011 [doi]
PST - ppublish
SO  - Anaesth Crit Care Pain Med. 2020 Dec;39(6):807-812. doi:
      10.1016/j.accpm.2020.01.011. Epub 2020 Oct 8.


PMID- 33039123
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210110
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 6
DP  - 2020 Dec
TI  - Management practices for postdural puncture headache in obstetrics: a
      prospective, international, cohort study.
PG  - 1045-1055
LID - S0007-0912(20)30741-8 [pii]
LID - 10.1016/j.bja.2020.07.061 [doi]
AB  - BACKGROUND: Accidental dural puncture is an uncommon complication of epidural
      analgesia and can cause postdural puncture headache (PDPH). We aimed to describe 
      management practices and outcomes after PDPH treated by epidural blood patch
      (EBP) or no EBP. METHODS: Following ethics committee approval, patients who
      developed PDPH after accidental dural puncture were recruited from participating 
      countries and divided into two groups, those receiving EBP or no EBP. Data
      registered included patient and procedure characteristics, headache symptoms and 
      intensity, management practices, and complications. Follow-up was at 3 months.
      RESULTS: A total of 1001 patients from 24 countries were included, of which 647
      (64.6%) received an EBP and 354 (35.4%) did not receive an EBP (no-EBP). Higher
      initial headache intensity was associated with greater use of EBP, odds ratio
      1.29 (95% confidence interval 1.19-1.41) per pain intensity unit increase.
      Headache intensity declined sharply at 4 h after EBP and 127 (19.3%) patients
      received a second EBP. On average, no or mild headache (numeric rating score</=3)
      was observed 7 days after diagnosis. Intracranial bleeding was diagnosed in three
      patients (0.46%), and backache, headache, and analgesic use were more common at 3
      months in the EBP group. CONCLUSIONS: Management practices vary between
      countries, but EBP was more often used in patients with greater initial headache 
      intensity. EBP reduced headache intensity quickly, but about 20% of patients
      needed a second EBP. After 7 days, most patients had no or mild headache.
      Backache, headache, and analgesic use were more common at 3 months in patients
      receiving an EBP.
CI  - Copyright (c) 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All
      rights reserved.
FAU - Gupta, Anil
AU  - Gupta A
AD  - Department of Perioperative Medicine and Intensive Care and Institution of
      Physiology and Pharmacology, Karolinska Hospital and Karolinska Institutet,
      Stockholm, Sweden. Electronic address: anil.gupta@sll.se.
FAU - von Heymann, Christian
AU  - von Heymann C
AD  - Department of Anaesthesia, Intensive Care Medicine, Emergency Medicine and Pain
      Therapy, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
FAU - Magnuson, Anders
AU  - Magnuson A
AD  - Clinical Epidemiology and Biostatistics, School of Medical Sciences, Orebro
      University, Orebro, Sweden.
FAU - Alahuhta, Seppo
AU  - Alahuhta S
AD  - Department of Anaesthesiology, Medical Research Center Oulu, University of Oulu, 
      Oulu University Hospital, Oulu, Finland.
FAU - Fernando, Roshan
AU  - Fernando R
AD  - Department of Anesthesiology and Intensive Care Medicine, The Womens Wellness and
      Research Centre, Doha, Qatar.
FAU - Van de Velde, Marc
AU  - Van de Velde M
AD  - Department of Cardiovascular Sciences, KULeuven, Leuven, Belgium.
FAU - Mercier, Frederic J
AU  - Mercier FJ
AD  - Departement d'Anesthesie, Hopital Antoine Beclere, AP-HP, Universite
      Paris-Saclay, France.
FAU - Schyns-van den Berg, Alexandra M J V
AU  - Schyns-van den Berg AMJV
AD  - Department of Anesthesiology, Albert Schweitzer Ziekenhuis, Dordrecht and
      Department of Anesthesiology, Leiden University Medical Centre, Leiden, The
      Netherlands.
CN  - EPiMAP collaborators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20201008
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesia, Epidural/adverse effects
MH  - Blood Patch, Epidural/*methods
MH  - Cohort Studies
MH  - Disease Management
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intracranial Hemorrhages/etiology/therapy
MH  - Middle Aged
MH  - Obstetrics/*methods
MH  - Pain Measurement
MH  - Post-Dural Puncture Headache/*therapy
MH  - Pregnancy
MH  - Prospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - *accidental dural puncture
OT  - *epidural analgesia
OT  - *epidural blood patch
OT  - *obstetrics
OT  - *postdural puncture headache
IR  - Casier I
FIR - Casier, Isabelle
IRAD- AZ Groeninge, Belgium.
IR  - Bryon B
FIR - Bryon, Bart
IRAD- AZ Turnhout, Belgium.
IR  - Soetens F
FIR - Soetens, Filiep
IRAD- AZ Turnhout, Belgium.
IR  - Dewandre PY
FIR - Dewandre, Pierre-Yves
IRAD- CHR Citadelle Liege, Belgium.
IR  - Lambert G
FIR - Lambert, Geraldine
IRAD- CHR Citadelle Liege, Belgium.
IR  - Christiaen J
FIR - Christiaen, Jan
IRAD- GZA SA, Belgium.
IR  - Schepers R
FIR - Schepers, Roel
IRAD- GZA SA, Belgium.
IR  - Van Houwe P
FIR - Van Houwe, Patrick
IRAD- GZA SA, Belgium.
IR  - Kalmar A
FIR - Kalmar, Alain
IRAD- Maria Middelares Hospital, Belgium.
IR  - Vanoverschelde H
FIR - Vanoverschelde, Henk
IRAD- Maria Middelares Hospital, Belgium.
IR  - Bauters M
FIR - Bauters, Monique
IRAD- ZNA Middelheim, Belgium.
IR  - Roofthooft E
FIR - Roofthooft, Eva
IRAD- ZNA Middelheim, Belgium.
IR  - Devroe S
FIR - Devroe, Sarah
IRAD- UZ Leuven, Belgium.
IR  - Van de Velde M
FIR - Van de Velde, Marc
IRAD- UZ Leuven, Belgium.
IR  - Jadrijevic A
FIR - Jadrijevic, Ana
IR  - Jokic A
FIR - Jokic, Aleksandra
IRAD- Clinical Hospital Sveti Duh, Croatia.
IR  - Marin D
FIR - Marin, Damjan
IRAD- Clinical Hospital Sveti Duh, Croatia.
IR  - Sklebar I
FIR - Sklebar, Ivan
IRAD- Clinical Hospital Sveti Duh, Croatia.
IR  - Mihaljevic S
FIR - Mihaljevic, Slobodan
IRAD- Obstetrics and Gynecology Clinic, Croatia.
IR  - Kosinova M
FIR - Kosinova, Martina
IRAD- University Hospital Brno, Czech Republic.
IR  - Stourac P
FIR - Stourac, Petr
IRAD- University Hospital Brno, Czech Republic.
IR  - Adamus M
FIR - Adamus, Milan
IRAD- University Hospital Olomouc, Czech Republic.
IR  - Kufa C
FIR - Kufa, Christian
IRAD- University Hospital Ostrava, Czech Republic.
IR  - Volfova I
FIR - Volfova, Ivana
IRAD- University Hospital Ostrava, Czech Republic.
IR  - Zaoralova B
FIR - Zaoralova, Blazena
IRAD- University Hospital Ostrava, Czech Republic.
IR  - Froeslev-Friis C
FIR - Froeslev-Friis, Christina
IRAD- OUH, Denmark.
IR  - Mygil B
FIR - Mygil, Bjoern
IRAD- OUH, Denmark.
IR  - Krebs Albrechtsen C
FIR - Krebs Albrechtsen, Charlotte
IRAD- Rigshospitalet, Denmark.
IR  - Kavasmaa T
FIR - Kavasmaa, Tomi
IRAD- Central Finland Health Care District, Finland.
IR  - Alahuhta S
FIR - Alahuhta, Seppo
IRAD- Oulu University Hospital, Finland.
IR  - Mayra A
FIR - Mayra, Anne
IRAD- Tampere University Hospital, Finland.
IR  - Mennander S
FIR - Mennander, Susanna
IRAD- Tampere University Hospital, Finland.
IR  - Rautaneva K
FIR - Rautaneva, Kati
IRAD- Tampere University Hospital, Finland.
IR  - Hiekkanen T
FIR - Hiekkanen, Tuula
IRAD- University of Helsinki and Helsinki University Hospital, Jorvi Hospital, Finland.
IR  - Kontinen V
FIR - Kontinen, Vesa
IRAD- University of Helsinki and Helsinki University Hospital, Jorvi Hospital, Finland.
IR  - Linden K
FIR - Linden, Kirsti
IRAD- University of Helsinki and Helsinki University Hospital, Jorvi Hospital, Finland.
IR  - Toivakka S
FIR - Toivakka, Sara
IRAD- University of Helsinki and Helsinki University Hospital, Jorvi Hospital, Finland.
IR  - Boselli E
FIR - Boselli, Emmanuel
IRAD- Centre hospitalier Pierre Oudot, France.
IR  - Greil PE
FIR - Greil, Pierre-Edouard
IRAD- Centre hospitalier Pierre Oudot, France.
IR  - Mascle O
FIR - Mascle, Olivier
IRAD- Centre hospitalier Pierre Oudot, France.
IR  - Courbon A
FIR - Courbon, Aurelie
IRAD- CHER Le Puy en Velay, France.
IR  - Lutz J
FIR - Lutz, Jean
IRAD- CHER Le Puy en Velay, France.
IR  - Simonet T
FIR - Simonet, Therese
IRAD- CHU Caen, France.
IR  - Barbier M
FIR - Barbier, Marie
IRAD- CHU Montpellier, France.
IR  - Hlioua T
FIR - Hlioua, Tarik
IRAD- CHU Montpellier, France.
IR  - Meniolle d'Hauthville F
FIR - Meniolle d'Hauthville, Fleur
IRAD- CHU Montpellier, France.
IR  - Quintin C
FIR - Quintin, Christine
IRAD- CHU Montpellier, France.
IR  - Bouattour K
FIR - Bouattour, Karim
IRAD- Hopital Antoine Beclere, France.
IR  - Lecinq A
FIR - Lecinq, Agnes
IRAD- Hopital Antoine Beclere, France.
IR  - Soued M
FIR - Soued, Mickael
IRAD- Hopital Antoine Beclere, France.
IR  - Bonnet MP
FIR - Bonnet, Marie-Pierre
IRAD- Hopital Cochin-Port Royal, France.
IR  - Carbonniere M
FIR - Carbonniere, Mathieu
IRAD- Hopital Cochin-Port Royal, France.
IR  - Fischer C
FIR - Fischer, Catherine
IRAD- Hopital Cochin-Port Royal, France.
IR  - Picard PC
FIR - Picard, Paola-Carla
IRAD- Hopital Cochin-Port Royal, France.
IR  - Bonnin M
FIR - Bonnin, Martine
IRAD- Hopital Estaing, CHU Clermont-Ferrand, France.
IR  - Storme B
FIR - Storme, Brigitte
IRAD- Hopital Estaing, CHU Clermont-Ferrand, France.
IR  - Bouthors AS
FIR - Bouthors, Anne-Sophie
IRAD- Hopital Jeanne de Flandre CHRU Lille, France.
IR  - Detente T
FIR - Detente, Thomas
IRAD- Hopital Jeanne de Flandre CHRU Lille, France.
IR  - Nguyen Troung M
FIR - Nguyen Troung, Minh
IRAD- Hopital Jeanne de Flandre CHRU Lille, France.
IR  - Keita H
FIR - Keita, Hawa
IRAD- Hopital Louis Mourier, France.
IR  - Nebout S
FIR - Nebout, Sophie
IRAD- Hopital Louis Mourier, France.
IR  - Osse L
FIR - Osse, Lauranne
IRAD- Hopital Louis Mourier, France.
IR  - Delmas A
FIR - Delmas, Anne
IRAD- Hopital Nord, France.
IR  - Vial F
FIR - Vial, Florence
IRAD- Maternite Regionale de Nancy CHU de Nancy, France.
IR  - Kaufner L
FIR - Kaufner, Lutz
IRAD- Charite- Universitatsmedizin Berlin, Germany.
IR  - Hoefing C
FIR - Hoefing, Christoph
IRAD- Gemeinschaftsklinikum Mittelrhein Kemperhof, Germany.
IR  - Mueller S
FIR - Mueller, Stefan
IRAD- Gemeinschaftsklinikum Mittelrhein Kemperhof, Germany.
IR  - Becke K
FIR - Becke, Karin
IRAD- Klinik Hallerwiese, Germany.
IR  - Blobner M
FIR - Blobner, Manfred
IRAD- Klinikum rechts der Isar, Technische Universitat Munchen, Germany.
IR  - Lewald H
FIR - Lewald, Heidrun
IRAD- Klinikum rechts der Isar, Technische Universitat Munchen, Germany.
IR  - Schaller SJ
FIR - Schaller, Stefan Josef
IRAD- Klinikum rechts der Isar, Technische Universitat Munchen, Germany.
IR  - Muggleton E
FIR - Muggleton, Ellis
IRAD- Rotkreuzklinikum Munchen - Frauenklinik, Germany.
IR  - Bette B
FIR - Bette, Birgit
IRAD- University Hospital Bonn, Germany.
IR  - Neumann C
FIR - Neumann, Claudia
IRAD- University Hospital Bonn, Germany.
IR  - Weber S
FIR - Weber, Stefan
IRAD- University Hospital Bonn, Germany.
IR  - Grunewald M
FIR - Grunewald, Matthias
IRAD- University Hospital Schleswig-Holstein, Campus Kiel, Germany.
IR  - Ohnesorge H
FIR - Ohnesorge, Henning
IRAD- University Hospital Schleswig-Holstein, Campus Kiel, Germany.
IR  - Helf A
FIR - Helf, Antonia
IRAD- University Hospital of Wuerzburg, Germany.
IR  - Jelting Y
FIR - Jelting, Yvonne
IRAD- University Hospital of Wuerzburg, Germany.
IR  - Kranke P
FIR - Kranke, Peter
IRAD- University Hospital of Wuerzburg, Germany.
IR  - von Heymann C
FIR - von Heymann, Christian
IRAD- Vivantes Klinikum im Friedrichshain Berlin, Germany.
IR  - Welfle S
FIR - Welfle, Sabine
IRAD- Vivantes Klinikum im Friedrichshain Berlin, Germany.
IR  - Staikou C
FIR - Staikou, Chryssoula
IRAD- Aretaieio Hospital, Medical School, University of Athens, Greece.
IR  - Stavrianopoulou A
FIR - Stavrianopoulou, Antonia
IRAD- Aretaieio Hospital, Medical School, University of Athens, Greece.
IR  - Tsaroucha A
FIR - Tsaroucha, Athanasia
IRAD- Aretaieio Hospital, Medical School, University of Athens, Greece.
IR  - Kalopita K
FIR - Kalopita, Konstantina
IRAD- General Hospital of Athens Alexandra, Greece.
IR  - Loukeri A
FIR - Loukeri, Anastasia
IRAD- General Hospital of Athens Alexandra, Greece.
IR  - Valsamidis D
FIR - Valsamidis, Dimitrios
IRAD- General Hospital of Athens Alexandra, Greece.
IR  - Matsota P
FIR - Matsota, Paraskevi
IRAD- University Hospital Attikon, Greece.
IR  - Thorsteinsson A
FIR - Thorsteinsson, Adalbjorn
IRAD- Landspitali University Hospital, Iceland.
IR  - Tome R
FIR - Tome, Riad
IRAD- Bnai - Zion Medical Center, Israel.
IR  - Eidelman LA
FIR - Eidelman, Leonid A
IRAD- Rabin Medical Center, Israel.
IR  - Davis A
FIR - Davis, Atara
IRAD- Rabin Medical Center, Israel.
IR  - Orbach-Zinger S
FIR - Orbach-Zinger, Sharon
IRAD- Rabin Medical Center, Israel.
IR  - Ioscovich A
FIR - Ioscovich, Alexander
IRAD- Shaare Zedek Medical Center, Israel.
IR  - Ramona I
FIR - Ramona, Iacob
IRAD- Shaare Zedek Medical Center, Israel.
IR  - De Simone L
FIR - De Simone, Luigi
IRAD- Azienda Ospedaliera Universitaria Pisana, Italy.
IR  - Pesetti B
FIR - Pesetti, Barbara
IRAD- Azienda Ospedaliera Universitaria Pisana, Italy.
IR  - Brazzi L
FIR - Brazzi, Luca
IRAD- Citta della Salute e della Scienza, Turin, Italy.
IR  - Zito A
FIR - Zito, Alessandro
IRAD- Citta della Salute e della Scienza, Turin, Italy.
IR  - Camorcia M
FIR - Camorcia, Michela
IRAD- Citta di Roma Hospital, Italy.
IR  - Della Rocca G
FIR - Della Rocca, Giorgio
IRAD- Department of Medical Area, University of Udine, Italy.
IR  - Aversano M
FIR - Aversano, Marco
IRAD- Fatebenefratelli Isola Tiberina, Italy.
IR  - Frigo MG
FIR - Frigo, Maria Grazia
IRAD- Fatebenefratelli Isola Tiberina, Italy.
IR  - Todde C
FIR - Todde, Cristina
IRAD- Fatebenefratelli Isola Tiberina, Italy.
IR  - Morina Q
FIR - Morina, Qamile
IRAD- University Clinical Center of Kosova, Kosovo.
IR  - Macas A
FIR - Macas, Andrius
IRAD- Lithuanian University of Health Sciences Hospital, Lithuania.
IR  - Keraitiene G
FIR - Keraitiene, Grazina
IRAD- Lithuanian University of Health Sciences Hospital, Lithuania.
IR  - Rimaitis K
FIR - Rimaitis, Kestutis
IRAD- Lithuanian University of Health Sciences Hospital, Lithuania.
IR  - Borg F
FIR - Borg, Francis
IRAD- Mater Dei Hospital, Malta.
IR  - Tua C
FIR - Tua, Carl
IRAD- Mater Dei Hospital, Malta.
IR  - Kuijpers-Visser AG
FIR - Kuijpers-Visser, Agnes Geertje
IRAD- Albert Schweitzer Ziekenhuis Dordrecht, Netherlands.
IR  - Schyns-van den Berg A
FIR - Schyns-van den Berg, Alexandra
IRAD- Albert Schweitzer Ziekenhuis Dordrecht, Netherlands.
IR  - Hollmann MW
FIR - Hollmann, Markus W
IRAD- Amsterdam UMC, loc AMC, Netherlands.
IR  - Van den Berg T
FIR - Van den Berg, Tijs
IRAD- Amsterdam UMC, loc AMC, Netherlands.
IR  - Koolen E
FIR - Koolen, Eric
IRAD- Catharina Hospital Eindhoven, Netherlands.
IR  - Dons I
FIR - Dons, Ilse
IRAD- Erasmus MC, Netherlands.
IR  - van der Knijff A
FIR - van der Knijff, Anouk
IRAD- Erasmus MC, Netherlands.
IR  - van der Marel C
FIR - van der Marel, Caroline
IRAD- Erasmus MC, Netherlands.
IR  - Ruysschaert N
FIR - Ruysschaert, Nele
IRAD- Hagaziekenhuis, Netherlands.
IR  - Pelka M
FIR - Pelka, Michal
IRAD- IJsselland Ziekenhuis, Netherlands.
IR  - Pluymakers C
FIR - Pluymakers, Christine
IRAD- IJsselland Ziekenhuis, Netherlands.
IR  - Koopman S
FIR - Koopman, Seppe
IRAD- Maasstad Hospital, Netherlands.
IR  - Teunissen AJ
FIR - Teunissen, Aart-Jan
IRAD- Maasstad Hospital, Netherlands.
IR  - Cornelisse D
FIR - Cornelisse, Dick
IRAD- Reinier De Graaf Gasthuis, Netherlands.
IR  - van Dasselaar N
FIR - van Dasselaar, Nick
IRAD- Reinier De Graaf Gasthuis, Netherlands.
IR  - Verdouw B
FIR - Verdouw, Bastiaan
IRAD- Reinier De Graaf Gasthuis, Netherlands.
IR  - Beenakkers I
FIR - Beenakkers, Ingrid
IRAD- University Medical Centre Utrecht, Netherlands.
IR  - Dahl V
FIR - Dahl, Vegard
IRAD- Akershus University Hospital, Norway.
IR  - Hagen R
FIR - Hagen, Robert
IRAD- Akershus University Hospital, Norway.
IR  - Vivaldi F
FIR - Vivaldi, Francesco
IRAD- Baerum hospital, Norway.
IR  - Eriksen JR
FIR - Eriksen, John Reidar
IRAD- Haukeland University Hospital, Norway.
IR  - Wiszt R
FIR - Wiszt, Radovan
IRAD- Innlandet Hospital Trust Elverum, Norway.
IR  - Aslam Tayyaba N
FIR - Aslam Tayyaba, Naz
IRAD- Vestfold Hospital Trust, Norway.
IR  - Ringvold EM
FIR - Ringvold, Else-Marie
IRAD- Vestfold Hospital Trust, Norway.
IR  - Chutkowski R
FIR - Chutkowski, Radoslaw
IRAD- SPSK CMKP im. prof. W. Orlowskiego, Poland.
IR  - Skirecki T
FIR - Skirecki, Tomasz
IRAD- SPSK CMKP im. prof. W. Orlowskiego, Poland.
IR  - Wodarski B
FIR - Wodarski, Bartlomiej
IRAD- SPSK CMKP im. prof. W. Orlowskiego, Poland.
IR  - Faria MA
FIR - Faria, Maria Aida
IRAD- Centro Hospitalar de Sao Joao EPE, Portugal.
IR  - Ferreira A
FIR - Ferreira, Amelia
IRAD- Centro Hospitalar de Sao Joao EPE, Portugal.
IR  - Sampaio AC
FIR - Sampaio, Ana Catarina
IRAD- Centro Hospitalar de Sao Joao EPE, Portugal.
IR  - Ferreira I
FIR - Ferreira, Irene
IRAD- Centro Hospitalar de Setubal, Portugal.
IR  - Matias B
FIR - Matias, Bernardo
IRAD- Centro Hospitalar de Setubal, Portugal.
IR  - Teixeira J
FIR - Teixeira, Joana
IRAD- Centro Hospitalar de Setubal, Portugal.
IR  - Araujo R
FIR - Araujo, Rita
IRAD- Centro Hospitalar do Porto, EPE, Portugal.
IR  - Cabido H
FIR - Cabido, Herminia
IRAD- Centro Hospitalar do Porto, EPE, Portugal.
IR  - Fortuna R
FIR - Fortuna, Rosario
IRAD- Centro Hospitalar do Porto, EPE, Portugal.
IR  - Lemos P
FIR - Lemos, Paulo
IRAD- Centro Hospitalar do Porto, EPE, Portugal.
IR  - Cardoso C
FIR - Cardoso, Carolina
IRAD- Centro Hospitalar do Tamega e Sousa, EPE, Portugal.
IR  - Moura F
FIR - Moura, Fernando
IRAD- Centro Hospitalar do Tamega e Sousa, EPE, Portugal.
IR  - Pereira C
FIR - Pereira, Cristiana
IRAD- Centro Hospitalar do Tamega e Sousa, EPE, Portugal.
IR  - Pereira S
FIR - Pereira, Sandra
IRAD- Centro Hospitalar do Tamega e Sousa, EPE, Portugal.
IR  - Tavares F
FIR - Tavares, Francisca
IRAD- Centro Hospitalar do Tamega e Sousa, EPE, Portugal.
IR  - Vasconcelos P
FIR - Vasconcelos, Pedro
IRAD- Centro Hospitalar do Tamega e Sousa, EPE, Portugal.
IR  - Abecasis M
FIR - Abecasis, Manuel
IRAD- Centro Hospitalar Universitario Lisboa Norte, Portugal.
IR  - Lanca F
FIR - Lanca, Filipa
IRAD- Centro Hospitalar Universitario Lisboa Norte, Portugal.
IR  - Muchacho P
FIR - Muchacho, Paulo
IRAD- Centro Hospitalar Universitario Lisboa Norte, Portugal.
IR  - Ormonde L
FIR - Ormonde, Lucindo
IRAD- Centro Hospitalar Universitario Lisboa Norte, Portugal.
IR  - Guedes-Araujo I
FIR - Guedes-Araujo, Isabel
IRAD- Centro Hospitalar Tondela-Viseu, Portugal.
IR  - Pinho-Oliveira V
FIR - Pinho-Oliveira, Vitor
IRAD- Centro Hospitalar Tondela-Viseu, Portugal.
IR  - Paredes P
FIR - Paredes, Paulo
IRAD- CHLO - Hospital de Sao Francisco Xavier, Portugal.
IR  - Bentes C
FIR - Bentes, Carla
IRAD- CHVNG-E, Portugal.
IR  - Gouveia F
FIR - Gouveia, Francisco
IRAD- CHVNG-E, Portugal.
IR  - Milheiro A
FIR - Milheiro, Ana
IRAD- CHVNG-E, Portugal.
IR  - Castanheira C
FIR - Castanheira, Claudia
IRAD- Hospital Beatriz Angelo, Portugal.
IR  - Neves M
FIR - Neves, Miriam
IRAD- Hospital Beatriz Angelo, Portugal.
IR  - Pacheco V
FIR - Pacheco, Vania
IRAD- Hospital Beatriz Angelo, Portugal.
IR  - Cortez M
FIR - Cortez, Mara
IRAD- Hospital Central do Funchal, Portugal.
IR  - Tranquada R
FIR - Tranquada, Raquel
IRAD- Hospital Central do Funchal, Portugal.
IR  - Tareco G
FIR - Tareco, Gloria
IRAD- Hospital do Espirito Santo - Evora, EPE, Portugal.
IR  - Furtado I
FIR - Furtado, Ines
IRAD- Hospital Garcia de Orta, Portugal.
IR  - Pereira E
FIR - Pereira, Estela
IRAD- Hospital Garcia de Orta, Portugal.
IR  - Marinho L
FIR - Marinho, Luisa
IRAD- ULSM Matosinhos-Hospital Pedro Hispano, Portugal.
IR  - Seabra M
FIR - Seabra, Manue
IRAD- ULSM Matosinhos-Hospital Pedro Hispano, Portugal.
IR  - Bulasevic A
FIR - Bulasevic, Aleksandra
IRAD- General Hospital Sremska Mitrovica, Serbia.
IR  - Kendrisic M
FIR - Kendrisic, Mirjana
IRAD- General Hospital Sremska Mitrovica, Serbia.
IR  - Jovanovic L
FIR - Jovanovic, Lidija
IRAD- KCV, Obstetric and Gynecology Hospital, Serbia.
IR  - Pujic B
FIR - Pujic, Borislava
IRAD- KCV, Obstetric and Gynecology Hospital, Serbia.
IR  - Kutlesic M
FIR - Kutlesic, Marija
IRAD- University Clinical Center Nis, Center for Anaesthesiology, Serbia.
IR  - Grochova M
FIR - Grochova, Monika
IRAD- University Hospital of L. Pasteur, Slovakia.
IR  - Simonova J
FIR - Simonova, Jana
IRAD- University Hospital of L. Pasteur, Slovakia.
IR  - Pavlovic G
FIR - Pavlovic, Gordana
IRAD- Obstetric and Gynecology Hospital Kranj, Slovenia.
IR  - Rozman A
FIR - Rozman, Ales
IRAD- Obstetric and Gynecology Hospital Kranj, Slovenia.
IR  - Blajic I
FIR - Blajic, Iva
IRAD- University Medical Centre Ljubljana, Slovenia.
IR  - Graovac D
FIR - Graovac, Dragan
IRAD- University Medical Centre Ljubljana, Slovenia.
IR  - Stopar Pintraic T
FIR - Stopar Pintraic, Tatjana
IRAD- University Medical Centre Ljubljana, Slovenia.
IR  - Chiquito T
FIR - Chiquito, Teresa
IRAD- Clinica Universidad de Navarra, Spain.
IR  - Monedero P
FIR - Monedero, Pablo
IRAD- Clinica Universidad de Navarra, Spain.
IR  - Carlos-Errea J
FIR - Carlos-Errea, De Joaquin
IRAD- Complejo Hospitalario de Navarra, Spain.
IR  - Guillen-Casbas R
FIR - Guillen-Casbas, Roque
IRAD- Complejo Hospitalario de Navarra, Spain.
IR  - Veiga-Gil L
FIR - Veiga-Gil, Leonor
IRAD- Complejo Hospitalario de Navarra, Spain.
IR  - Basso M
FIR - Basso, Morena
IRAD- Corporacio Sanitaria Parc Tauli, Spain.
IR  - Garcia Bartolo C
FIR - Garcia Bartolo, Carolina
IRAD- Corporacio Sanitaria Parc Tauli, Spain.
IR  - Hernandez C
FIR - Hernandez, Cristian
IRAD- Corporacio Sanitaria Parc Tauli, Spain.
IR  - Ricol L
FIR - Ricol, Laura
IRAD- Corporacio Sanitaria Parc Tauli, Spain.
IR  - De Santos MP
FIR - De Santos, Maroto Pinar
IRAD- Hospital Clinic of Barcelona, Spain.
IR  - Gracia Solsona JA
FIR - Gracia Solsona, Josep A
IRAD- Hospital Clinic of Barcelona, Spain.
IR  - Lopez-Baamonde M
FIR - Lopez-Baamonde, Manuel
IRAD- Hospital Clinic of Barcelona, Spain.
IR  - Magaldi Mendana M
FIR - Magaldi Mendana, Marta
IRAD- Hospital Clinic of Barcelona, Spain.
IR  - Plaza Moral AM
FIR - Plaza Moral, Ana Maria
IRAD- Hospital Clinic of Barcelona, Spain.
IR  - Vendrell M
FIR - Vendrell, Marina
IRAD- Hospital Clinic of Barcelona, Spain.
IR  - Trillo L
FIR - Trillo, Lourdes
IRAD- Hospital del Mar, Spain.
IR  - Perez Garcia AR
FIR - Perez Garcia, Anibal Ricardo
IRAD- Hospital General de La Palma, Spain.
IR  - Alamillo Salas C
FIR - Alamillo Salas, Clara
IRAD- Hospital General San Jorge, Spain.
IR  - Moret E
FIR - Moret, Enric
IRAD- Hospital Germans Trias i Pujol, Spain.
IR  - Ramio L
FIR - Ramio, Laura
IRAD- Hospital Germans Trias i Pujol, Spain.
IR  - Aguilar Sanchez JL
FIR - Aguilar Sanchez, Jose Luis
IRAD- Hospital Son Llatzer, Spain.
IR  - Soler Pedrola M
FIR - Soler Pedrola, Maria
IRAD- Hospital Son Llatzer, Spain.
IR  - Valldeperas Hernandez MI
FIR - Valldeperas Hernandez, Maria Inmaculada
IRAD- Hospital Son Llatzer, Spain.
IR  - Aldalur G
FIR - Aldalur, Gorka
IRAD- Hospital Universitario Alava, Spain.
IR  - Barcena E
FIR - Barcena, Estibaliz
IRAD- Hospital Universitario Cruces, Spain.
IR  - Herrera J
FIR - Herrera, Julia
IRAD- Hospital Universitario Cruces, Spain.
IR  - Iturri F
FIR - Iturri, Fernando
IRAD- Hospital Universitario Cruces, Spain.
IR  - Martinez A
FIR - Martinez, Alberto
IRAD- Hospital Universitario Cruces, Spain.
IR  - Martinez L
FIR - Martinez, Leire
IRAD- Hospital Universitario Cruces, Spain.
IR  - Serna R
FIR - Serna, Rosa
IRAD- Hospital Universitario Cruces, Spain.
IR  - Gilsanz F
FIR - Gilsanz, Fernando
IRAD- Hospital Universitario La Paz, Spain.
IR  - Guasch Arevalo E
FIR - Guasch Arevalo, Emilia
IRAD- Hospital Universitario La Paz, Spain.
IR  - Iannuccelli F
FIR - Iannuccelli, Fabrizio
IRAD- Hospital Universitario La Paz, Spain.
IR  - Latorre J
FIR - Latorre, Julieta
IRAD- Hospital Universitario La Paz, Spain.
IR  - Rodriguez Roca C
FIR - Rodriguez Roca, Cristina
IRAD- Hospital Universitario La Paz, Spain.
IR  - Perez Pardo OC
FIR - Perez Pardo, Osvaldo Ceferino
IRAD- Hospital Universitario Marques de Valdecilla, Spain.
IR  - Sierra Biddle N
FIR - Sierra Biddle, Natalia
IRAD- Hospital Universitario Marques de Valdecilla, Spain.
IR  - Suarez Cendana C
FIR - Suarez Cendana, Ceferina
IRAD- Hospital Universitario Marques de Valdecilla, Spain.
IR  - Hernandez Gonzalez L
FIR - Hernandez Gonzalez, Lourdes
IRAD- Hospital Universitario Materno-Infantil de Canarias, Spain.
IR  - Remacha Gonzalez C
FIR - Remacha Gonzalez, Caridad
IRAD- Hospital Universitario Materno-Infantil de Canarias, Spain.
IR  - Sanchez Nuez R
FIR - Sanchez Nuez, Raquel
IRAD- Hospital Universitario Materno-Infantil de Canarias, Spain.
IR  - Anta D
FIR - Anta, Diego
IRAD- Sureste University Hospital, Spain.
IR  - Belena JM
FIR - Belena, Jose M
IRAD- Sureste University Hospital, Spain.
IR  - Garcia-Cuadrado C
FIR - Garcia-Cuadrado, Carmen
IRAD- Sureste University Hospital, Spain.
IR  - Garcia I
FIR - Garcia, Irene
IRAD- Vall d'Hebron Hospital, Spain.
IR  - Manrique S
FIR - Manrique, Susana
IRAD- Vall d'Hebron Hospital, Spain.
IR  - Suarez E
FIR - Suarez, Elena
IRAD- Vall d'Hebron Hospital, Spain.
IR  - Hein A
FIR - Hein, Anette
IRAD- Danderyd Hospital, Sweden.
IR  - Arbman E
FIR - Arbman, Elisabet
IRAD- Falu lasarett, Sweden.
IR  - Hansson H
FIR - Hansson, Helena
IRAD- Falu lasarett, Sweden.
IR  - Tillenius M
FIR - Tillenius, Monika
IRAD- Falu lasarett, Sweden.
IR  - Al-Taie R
FIR - Al-Taie, Ruaa
IRAD- Gavle Country Hospital, Sweden.
IR  - Ledin-Eriksson S
FIR - Ledin-Eriksson, Susanne
IRAD- Gavle Country Hospital, Sweden.
IR  - Linden-Sonderso A
FIR - Linden-Sonderso, Anja
IRAD- Helsingborg Hospital, Sweden.
IR  - Rosen O
FIR - Rosen, Ola
IRAD- Helsingborg Hospital, Sweden.
IR  - Austruma E
FIR - Austruma, Evija
IRAD- Kristianstad Centralsjukhus, Sweden.
IR  - Gillberg L
FIR - Gillberg, Lars
IRAD- Kristianstad Centralsjukhus, Sweden.
IR  - Darvish B
FIR - Darvish, Bijan
IRAD- Karolinska University Hospital, Sweden.
IR  - Gupta A
FIR - Gupta, Anil
IRAD- Karolinska University Hospital, Sweden.
IR  - Nordstom JL
FIR - Nordstom, Johan L
IRAD- Karolinska University Hospital, Sweden.
IR  - Persson J
FIR - Persson, Jan
IRAD- Karolinska University Hospital, Huddinge, Sweden.
IR  - Rosenberg J
FIR - Rosenberg, Jan
IRAD- Karolinska University Hospital, Huddinge, Sweden.
IR  - Bruhne L
FIR - Bruhne, Lars
IRAD- NU-sjukvarden, Sweden.
IR  - Forshammar J
FIR - Forshammar, Johan
IRAD- NU-sjukvarden, Sweden.
IR  - Ugarph Edfeldt M
FIR - Ugarph Edfeldt, Malin
IRAD- Orebro University Hospital, Sweden.
IR  - Rolfsson H
FIR - Rolfsson, Hakan
IRAD- Sodersjukhuset, Sweden.
IR  - Hellblom A
FIR - Hellblom, Anna
IRAD- Skane University Hospital Lund, Sweden.
IR  - Levin K
FIR - Levin, Katarina
IRAD- Skane University Hospital Lund, Sweden.
IR  - Rabow S
FIR - Rabow, Sofus
IRAD- Skane University Hospital Lund, Sweden.
IR  - Thorlacius K
FIR - Thorlacius, Karin
IRAD- Skane University Hospital Lund, Sweden.
IR  - Bansch P
FIR - Bansch, Peter
IRAD- University Hospital SUS Malmo, Sweden.
IR  - Robertson Baeriswyl M
FIR - Robertson Baeriswyl, Moira
IRAD- Centre Hospitalier Universitaire Vaudois, Switzerland.
IR  - Stamer U
FIR - Stamer, Ulrike
IRAD- Department of Anaesthesiology and Pain Medicine, Inselspital, University of Bern,
      Switzerland.
IR  - Mathivon S
FIR - Mathivon, Stanislas
IRAD- Geneva University Hospitals, Switzerland.
IR  - Savoldelli G
FIR - Savoldelli, Georges
IRAD- Geneva University Hospitals, Switzerland.
IR  - Auf der Maur P
FIR - Auf der Maur, Pia
IRAD- Kantonsspital St. Gallen, Switzerland.
IR  - Filipovic M
FIR - Filipovic, Miodrag
IRAD- Kantonsspital St. Gallen, Switzerland.
IR  - Dullenkopf A
FIR - Dullenkopf, Alexander
IRAD- Spital Thurgau Frauenfeld, Switzerland.
IR  - Brunner M
FIR - Brunner, Maya
IRAD- University hospital Basel, Switzerland.
IR  - Girard T
FIR - Girard, Thierry
IRAD- University hospital Basel, Switzerland.
IR  - Vonlanthen C
FIR - Vonlanthen, Claudia
IRAD- University hospital Basel, Switzerland.
IR  - Ozbilgin S
FIR - Ozbilgin, Sule
IRAD- Dokuz Eylul University, School of Medicine, Izmir, Turkey.
IR  - Gunaydin D B
FIR - Gunaydin D, Berrin
IRAD- Gazi University School of Medicine, Ankara, Turkey.
IR  - Corman Dincer P
FIR - Corman Dincer, Pelin
IRAD- Marmara University School of Medicine, Turkey.
IR  - Tas Tuna A
FIR - Tas Tuna, Ayca
IRAD- Sakarya Univeristy School of Medicine, Sakarya, Turkey.
EDAT- 2020/10/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/11 20:21
PHST- 2020/04/01 00:00 [received]
PHST- 2020/07/05 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/11 20:21 [entrez]
AID - S0007-0912(20)30741-8 [pii]
AID - 10.1016/j.bja.2020.07.061 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Dec;125(6):1045-1055. doi: 10.1016/j.bja.2020.07.061. Epub
      2020 Oct 8.


PMID- 33039091
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 328
DP  - 2020 May - Jun
TI  - [From empathy to commitment, the ethical approach in psychiatry].
PG  - 34-40
LID - S0241-6972(20)30065-7 [pii]
LID - 10.1016/S0241-6972(20)30065-7 [doi]
AB  - Ethical questioning and reflection are a requirement for the psychiatric
      caregiver, a particular discipline which is both clinical and political. Ethics
      is a safeguard that allows the professional to refocus on the core of their
      profession. It is not synonymous with morality and is situational. It is a combat
      sport against oneself and against those who reduce the patient to a human-machine
      to be repaired.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Touzet, Patrick
AU  - Touzet P
AD  - Centre medico-psychologique, 66 rue de Coumiers, 94130 Nogent-sur-Marne, France. 
      Electronic address: pat.touzet@gmail.com.
LA  - fre
PT  - Journal Article
TT  - De l'empathie a l'engagement, la demarche ethique en psychiatrie.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - Commitment of Mentally Ill/ethics
MH  - Empathy/ethics
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - Psychiatry/*ethics
OTO - NOTNLM
OT  - commitment
OT  - empathie
OT  - empathy
OT  - engagement
OT  - ethics
OT  - habit
OT  - habitude
OT  - humility
OT  - humilite
OT  - morale
OT  - morality
OT  - ethique
EDAT- 2020/10/12 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/11 20:20
PHST- 2020/10/11 20:20 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S0241-6972(20)30065-7 [pii]
AID - 10.1016/S0241-6972(20)30065-7 [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 May - Jun;41(328):34-40. doi:
      10.1016/S0241-6972(20)30065-7.


PMID- 33039088
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 328
DP  - 2020 May - Jun
TI  - [Care programmes: the ambiguity of normality, exception and forms of control].
PG  - 26-29
LID - S0241-6972(20)30062-1 [pii]
LID - 10.1016/S0241-6972(20)30062-1 [doi]
AB  - The care programmes are medical-legal and therapeutic systems that showcase
      different spaces, the law, the patient's clinic, their freedom and their rights. 
      In this context, the patient preserves their freedom to come and go. In applying 
      the care programme, the doctor must acquire their approval, not to say consent.
      Outside hospitalisation, the care programmes bring patients and teams together
      within the city. The matter of social and community psychiatry, a vector of
      catchment-area psychiatry, then makes full sense.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Werner, Mathieu
AU  - Werner M
AD  - Centre medico-psychologique, pole psychiatrie, groupe hospitalier Bretagne Sud,
      espace Kerjegu, 19 place Saint-Michel, 29300 Quimperle, France. Electronic
      address: m.werner@ghbs.bzh.
FAU - Bonvalot, Thierry
AU  - Bonvalot T
AD  - Centre medico-psychologique, pole psychiatrie, groupe hospitalier Bretagne Sud,
      espace Kerjegu, 19 place Saint-Michel, 29300 Quimperle, France.
LA  - fre
PT  - Journal Article
TT  - Programmes de soins : ambiguite de la normalite, exception et formes de controle.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - Community Psychiatry
MH  - Freedom
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - Patient Rights
OTO - NOTNLM
OT  - cadre therapeutique
OT  - care programme
OT  - catchment area psychiatry
OT  - contrainte
OT  - ethics of care
OT  - obligation
OT  - programme de soins
OT  - psychiatrie de secteur
OT  - therapeutic framework
OT  - ethique du soin
EDAT- 2020/10/12 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/11 20:20
PHST- 2020/10/11 20:20 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S0241-6972(20)30062-1 [pii]
AID - 10.1016/S0241-6972(20)30062-1 [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 May - Jun;41(328):26-29. doi:
      10.1016/S0241-6972(20)30062-1.


PMID- 33039085
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 328
DP  - 2020 May - Jun
TI  - [Ethics as a complement to the legal framework].
PG  - 16-18
LID - S0241-6972(20)30059-1 [pii]
LID - 10.1016/S0241-6972(20)30059-1 [doi]
AB  - Management of compulsory care is the source of many legal questions for
      caregivers who have to make decisions. In the eyes of the texts and case law, the
      patient is believed as a subject of law. Thus, no act of care can be applied
      without their free and enlightened consent. In applying the care programme, the
      patient preserves their freedom, and therefore the freedom to continue or not the
      care programme. Faced with complex clinical situations, and to avoid uncertain
      decisions, ethics must make it possible to find the appropriate answers.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Berard, Karine
AU  - Berard K
AD  - Psypro Lyon, 20 rue du General-Dayan, 69100 Villeurbanne, France. Electronic
      address: K.berard@psypro-lyon.fr.
LA  - fre
PT  - Journal Article
TT  - L'ethique comme complement du cadre legal.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - *Ethics, Medical
MH  - Humans
MH  - *Legislation, Medical
OTO - NOTNLM
OT  - compulsory care
OT  - droit des patients
OT  - ethics
OT  - freedom
OT  - liberte
OT  - patient right
OT  - safety of care
OT  - soin sans consentement
OT  - securite des soins
OT  - ethique
EDAT- 2020/10/12 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/11 20:20
PHST- 2020/10/11 20:20 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S0241-6972(20)30059-1 [pii]
AID - 10.1016/S0241-6972(20)30059-1 [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 May - Jun;41(328):16-18. doi:
      10.1016/S0241-6972(20)30059-1.


PMID- 33039066
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1532-8481 (Electronic)
IS  - 8755-7223 (Linking)
VI  - 36
IP  - 5
DP  - 2020 Sep - Oct
TI  - Paying for nursing student clinical placements, ethical considerations.
PG  - 330-333
LID - S8755-7223(20)30025-9 [pii]
LID - 10.1016/j.profnurs.2020.01.008 [doi]
AB  - Ethics is foundational to nursing practice, including the practice of nursing
      education. Many schools of nursing are struggling to find adequate clinical
      placements for students; the root causes of this shortage are complex. Although
      it has not historically been the practice, some schools of nursing are
      considering offering clinical agencies payment for this valuable resource. Given 
      the importance of clinical experience in nursing education, relationships between
      schools of nursing and clinical agencies are crucial. This paper explores some of
      the advantages and disadvantages that may present if schools of nursing pay
      clinical agencies to host nursing students, specifically pre-licensure students. 
      Prior to establishing such relationships, schools of nursing and clinical
      agencies should carefully consider this decision. Questions informed by the
      American Nurses Association Code of Ethics and the National League for Nursing
      Ethical Principles for Nursing Education are provided as examples.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Copeland, Darcy
AU  - Copeland D
AD  - University of Northern Colorado, Campus Box 125, Gunter Hall, Greeley, CO 80639, 
      USA; St Anthony Hospital, 11600 W 2(nd) Place, Lakewood, CO 80228, USA.
      Electronic address: Darcy.copeland@unco.edu.
LA  - eng
PT  - Journal Article
DEP - 20200201
PL  - United States
TA  - J Prof Nurs
JT  - Journal of professional nursing : official journal of the American Association of
      Colleges of Nursing
JID - 8511298
SB  - IM
MH  - *Education, Nursing
MH  - *Education, Nursing, Baccalaureate
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Students, Nursing
OTO - NOTNLM
OT  - Nurse administrator
OT  - Nursing
OT  - Nursing education
OT  - Nursing ethics
COIS- Declaration of competing interest The author has no conflicts of interest to
      declare. This project did not receive any specific grant from funding agencies in
      the public, commercial, or not-for-profit sectors.
EDAT- 2020/10/12 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/10/11 20:20
PHST- 2019/10/18 00:00 [received]
PHST- 2020/01/15 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/10/11 20:20 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
AID - S8755-7223(20)30025-9 [pii]
AID - 10.1016/j.profnurs.2020.01.008 [doi]
PST - ppublish
SO  - J Prof Nurs. 2020 Sep - Oct;36(5):330-333. doi: 10.1016/j.profnurs.2020.01.008.
      Epub 2020 Feb 1.


PMID- 33039028
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1532-3102 (Electronic)
IS  - 0143-4004 (Linking)
VI  - 98
DP  - 2020 Sep 1
TI  - Challenges in preterm birth research: Ghanaian perspective.
PG  - 24-28
LID - S0143-4004(20)30127-2 [pii]
LID - 10.1016/j.placenta.2020.04.016 [doi]
AB  - Preterm birth is highly prevalent in Ghana. It is a major public health concern
      because of the high burden as well as the associated immediate and long-term
      consequences including increased healthcare cost. Studies conducted in
      high-income countries may not be sufficiently generalizable in our context.
      Locally generated evidence-based interventions will be indispensable in improving
      the clinical management and prevention of preterm birth in the country. However, 
      there are limited published literature on preterm birth and prematurity in the
      country. This review seeks to discuss the major challenges associated with
      preterm birth research in Ghana and proposes evidence-based strategies to improve
      biomedical and epidemiological research on preterm birth and prematurity. The
      limited high quality preterm birth research is partly attributable to a variety
      of challenges related to accurate gestational age estimation, research training, 
      capacity and support including funding, efficient ethics committees, local and
      international collaboration as well as effective health management information
      systems. Other related challenges include unavailability of reliable internet
      connectivity, poor compensation for researchers and lack of conductive research
      environment. There is the need to expedite advocacy on implementation of
      practical interventions and strategies aimed at increasing high quality research 
      in the area of preterm birth and prematurity in the country. A paradigm shift in 
      preterm birth research with appropriate integration of concerted
      multidisciplinary research groups should be constituted to put basic science
      research to clinical practice as well as the prevention of preterm birth in the
      country.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Adu-Bonsaffoh, K
AU  - Adu-Bonsaffoh K
AD  - Department of Obstetrics and Gynecology, School of Medicine and Dentistry,
      University of Ghana, Accra, Ghana. Electronic address: kadu-bonsaffoh@ug.edu.gh.
FAU - Oppong, S A
AU  - Oppong SA
AD  - Department of Obstetrics and Gynecology, School of Medicine and Dentistry,
      University of Ghana, Accra, Ghana.
FAU - Dassah, E T
AU  - Dassah ET
AD  - School of Public Health, Kwame Nkrumah University of Science & Technology,
      Kumasi, Ghana; Department of Obstetrics & Gynecology, Komfo Anokye Teaching
      Hospital, Kumasi, Ghana.
FAU - Seffah, J D
AU  - Seffah JD
AD  - Department of Obstetrics and Gynecology, School of Medicine and Dentistry,
      University of Ghana, Accra, Ghana.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200428
PL  - Netherlands
TA  - Placenta
JT  - Placenta
JID - 8006349
SB  - IM
MH  - *Biomedical Research
MH  - Female
MH  - Ghana/epidemiology
MH  - Humans
MH  - Pregnancy
MH  - Premature Birth/*epidemiology
OTO - NOTNLM
OT  - *Challenges
OT  - *Ghana
OT  - *Prematurity
OT  - *Preterm births
OT  - *Research
EDAT- 2020/10/12 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/10/11 20:20
PHST- 2019/11/01 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/10/11 20:20 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S0143-4004(20)30127-2 [pii]
AID - 10.1016/j.placenta.2020.04.016 [doi]
PST - ppublish
SO  - Placenta. 2020 Sep 1;98:24-28. doi: 10.1016/j.placenta.2020.04.016. Epub 2020 Apr
      28.


PMID- 33038722
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 1873-7757 (Electronic)
IS  - 0145-2134 (Linking)
VI  - 109
DP  - 2020 Nov
TI  - What type of survey research questions are identified by adults as upsetting? A
      focus on child maltreatment.
PG  - 104764
LID - S0145-2134(20)30419-1 [pii]
LID - 10.1016/j.chiabu.2020.104764 [doi]
AB  - BACKGROUND: Research on child maltreatment is imperative to inform evidence-based
      prevention and intervention efforts. Nonetheless, researchers continue to face
      barriers due to the perceived sensitivity and possibility of harm when asking
      about these experiences. While studies have started to explore reactions to
      participating in research on sensitive topics, there are notable limitations and 
      fewer have focused on child maltreatment. OBJECTIVE: The objective of this study 
      was to better understand adult respondents' identification of, and reactions to, 
      potentially upsetting questions in the context of a well-being and experiences
      survey, with a focus on child maltreatment. METHODS: Data were from the first
      wave of the Well-Being and Experiences Study in Manitoba, Canada: a computerized 
      self-reported community-based survey of adolescents and their parents/caregivers 
      administered individually at a research facility. The current study focused on
      parents/caregivers' responses (N = 1000). The study utilized a mixed methods
      approach with descriptive statistics and qualitative thematic analyses of
      open-ended responses of their perceptions of upsetting questions. RESULTS:
      Overall, few respondents (15.1 %) identified any questions as upsetting. Ten
      themes emerged in respondents' recall of upsetting questions, including
      maltreatment and other themes often perceived as less sensitive. Only 4%
      identified maltreatment-related questions as upsetting. Among those who
      identified any questions or maltreatment-specific questions as upsetting, most
      felt they were important to ask and should not be removed (92.7 %-97.5 %). These 
      findings suggest that retrospective survey questions about experiences of child
      maltreatment involving adult samples are not associated with major upset and
      should be included in future health and social surveys.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Fortier, Janique
AU  - Fortier J
AD  - Department of Community Health Sciences, University of Manitoba, Canada.
FAU - Stewart-Tufescu, Ashley
AU  - Stewart-Tufescu A
AD  - Departments of Community Health Sciences and Psychiatry, University of Manitoba, 
      Canada.
FAU - Salmon, Samantha
AU  - Salmon S
AD  - Department of Community Health Sciences, University of Manitoba, Canada.
FAU - Garces Davila, Isabel
AU  - Garces Davila I
AD  - Department of Community Health Sciences, University of Manitoba, Canada.
FAU - MacMillan, Harriet L
AU  - MacMillan HL
AD  - Departments of Psychiatry and Behavioural Neurosciences, and of Pediatrics,
      McMaster University, Canada.
FAU - Gonzalez, Andrea
AU  - Gonzalez A
AD  - Department of Psychiatry & Behavioural Neurosciences, McMaster University,
      Canada.
FAU - Mathews, Ben
AU  - Mathews B
AD  - Faculty of Law, Queensland University of Technology, Australia.
FAU - Struck, Shannon
AU  - Struck S
AD  - Department of Community Health Sciences, University of Manitoba, Canada.
FAU - Taillieu, Tamara
AU  - Taillieu T
AD  - Department of Community Health Sciences, University of Manitoba, Canada.
FAU - Afifi, Tracie O
AU  - Afifi TO
AD  - Departments of Community Health Sciences and Psychiatry, University of Manitoba, 
      Canada. Electronic address: Tracie.Afifi@umanitoba.ca.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - Child Abuse Negl
JT  - Child abuse & neglect
JID - 7801702
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Caregivers/*psychology/statistics & numerical data
MH  - Child Abuse/*psychology/statistics & numerical data
MH  - Emotions
MH  - Female
MH  - Humans
MH  - Income
MH  - Male
MH  - Manitoba
MH  - Mental Healing/psychology
MH  - Middle Aged
MH  - Parents/*psychology
MH  - Prevalence
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Child maltreatment
OT  - *Research ethics
OT  - *Responses to research participation
OT  - *Surveys
OT  - *Upsetting questions
EDAT- 2020/10/11 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/10/10 20:15
PHST- 2020/05/14 00:00 [received]
PHST- 2020/09/18 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/10/10 20:15 [entrez]
AID - S0145-2134(20)30419-1 [pii]
AID - 10.1016/j.chiabu.2020.104764 [doi]
PST - ppublish
SO  - Child Abuse Negl. 2020 Nov;109:104764. doi: 10.1016/j.chiabu.2020.104764. Epub
      2020 Oct 7.


PMID- 33038559
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 2352-5568 (Electronic)
IS  - 2352-5568 (Linking)
VI  - 39
IP  - 6
DP  - 2020 Dec
TI  - A simple, low-cost, customisable ultrasound gel-based phantom.
PG  - 888-890
LID - S2352-5568(20)30217-4 [pii]
LID - 10.1016/j.accpm.2020.03.023 [doi]
FAU - Surana, Priyanka
AU  - Surana P
AD  - Department of Anaesthesia, Pain and Palliative Care, State Cancer Institute, GMC,
      India. Electronic address: drpriyankasurana@yahoo.com.
FAU - Narayanan, Madan Kumar
AU  - Narayanan MK
AD  - Department of Anaesthesia, Frimley Park Hospital, Frimley, UK.
FAU - Parikh, Devangi A
AU  - Parikh DA
AD  - Department of Anaesthesia, Lokmanya Tilak Municipal Medical College and Hospital,
      Mumbai, India.
FAU - Deka, Arun
AU  - Deka A
AD  - Department of Anaesthesia, Pain and Palliative Care, State Cancer Institute, GMC,
      India.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - France
TA  - Anaesth Crit Care Pain Med
JT  - Anaesthesia, critical care & pain medicine
JID - 101652401
SB  - IM
MH  - Humans
MH  - Phantoms, Imaging
MH  - *Ultrasonography
OTO - NOTNLM
OT  - *Education
OT  - *Ethics
OT  - *Simulators and models
EDAT- 2020/10/11 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/10/10 20:10
PHST- 2020/03/24 00:00 [received]
PHST- 2020/03/28 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/10/10 20:10 [entrez]
AID - S2352-5568(20)30217-4 [pii]
AID - 10.1016/j.accpm.2020.03.023 [doi]
PST - ppublish
SO  - Anaesth Crit Care Pain Med. 2020 Dec;39(6):888-890. doi:
      10.1016/j.accpm.2020.03.023. Epub 2020 Oct 7.


PMID- 33038425
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210316
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
VI  - 98
IP  - 6
DP  - 2020 Dec
TI  - Ethics of kidney care in the era of COVID-19.
PG  - 1424-1433
LID - S0085-2538(20)31111-X [pii]
LID - 10.1016/j.kint.2020.09.014 [doi]
AB  - The coronavirus disease 2019 pandemic presents significant challenges for health 
      systems globally, including substantive ethical dilemmas that may pose specific
      concerns in the context of care for people with kidney disease. Ethical concerns 
      may arise as changes in policy and practice affect the ability of all health
      professionals to fulfill their ethical duties toward their patients in providing 
      best practice care. In this article, we briefly describe such concerns and
      elaborate on issues of particular ethical complexity in kidney care: equitable
      access to dialysis during pandemic surges; balancing the risks and benefits of
      different kidney failure treatments, specifically with regard to suspending
      kidney transplantation programs and prioritizing home dialysis, and barriers to
      shared decision-making; and ensuring ethical practice when using unproven
      interventions. We present preliminary advice on how to approach these issues and 
      recommend urgent efforts to develop resources that will support health
      professionals and patients in managing them.
CI  - Copyright (c) 2020 International Society of Nephrology. Published by Elsevier
      Inc. All rights reserved.
FAU - Martin, Dominique E
AU  - Martin DE
AD  - School of Medicine, Deakin University, Geelong, Victoria, Australia. Electronic
      address: Dominique.martin@deakin.edu.au.
FAU - Parsons, Jordan A
AU  - Parsons JA
AD  - Bristol Medical School, University of Bristol, Bristol, UK; Instituts fur
      Geschichte und Ethik der Medizin, Martin-Luther-Universitat Halle-Wittenberg,
      Halle, Germany.
FAU - Caskey, Fergus J
AU  - Caskey FJ
AD  - Bristol Medical School, University of Bristol, Bristol, UK; The Richard Bright
      Renal Unit, Southmead Hospital, North Bristol National Health Service Trust,
      Bristol, UK.
FAU - Harris, David C H
AU  - Harris DCH
AD  - Centre for Transplantation and Renal Research, Westmead Institute for Medical
      Research, University of Sydney, Westmead, New South Wales, Australia.
FAU - Jha, Vivekanand
AU  - Jha V
AD  - George Institute for Global Health India, University of New South Wales (UNSW),
      New Delhi, India; School of Public Health, Imperial College, London, UK; Manipal 
      Academy of Higher Education (MAHE), Manipal, Karnataka, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201007
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
SB  - IM
MH  - COVID-19/complications/*therapy
MH  - Clinical Decision-Making/ethics
MH  - Humans
MH  - Kidney Failure, Chronic/complications/*therapy
MH  - Renal Replacement Therapy/*ethics
PMC - PMC7539938
OTO - NOTNLM
OT  - *COVID-19
OT  - *end-stage kidney disease
OT  - *ethics
OT  - *pandemic
OT  - *resource allocation
EDAT- 2020/10/11 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/10 20:09
PHST- 2020/05/08 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/10/10 20:09 [entrez]
AID - S0085-2538(20)31111-X [pii]
AID - 10.1016/j.kint.2020.09.014 [doi]
PST - ppublish
SO  - Kidney Int. 2020 Dec;98(6):1424-1433. doi: 10.1016/j.kint.2020.09.014. Epub 2020 
      Oct 7.


PMID- 33037168
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20210308
IS  - 0972-2823 (Electronic)
IS  - 0022-3859 (Linking)
VI  - 66
IP  - 4
DP  - 2020 Oct-Dec
TI  - The power of subjectivity in competency-based assessment.
PG  - 200-205
LID - 10.4103/jpgm.JPGM_591_20 [doi]
AB  - With the introduction of competency-based undergraduate curriculum in India, a
      paradigm shift in the assessment methods and tools will be the need of the hour. 
      Competencies are complex combinations of various attributes, many of which being 
      not assessable by objective methods. Assessment of affective and communication
      domains has always been neglected for want of objective methods. Areas like
      professionalism, ethics, altruism, and communication-so vital for being an Indian
      Medical Graduate, can be assessed longitudinally applying subjective means only. 
      Though subjectivity has often been questioned as being biased, it has been proven
      time and again that a subjective assessment in expert hands gives comparable
      results as that of any objective assessment. By insisting on objectivity, we may 
      compromise the validity of the assessment and deprive the students of enriched
      subjective feedback and judgement also. This review highlights the importance of 
      subjective assessment in competency-based assessment and ways and means of
      improving the rigor of subjective assessment, with particular emphasis on the
      development and use of rubrics.
FAU - Virk, A
AU  - Virk A
AD  - Adesh Medical College & Hospital, Shahabad (M), Haryana, India.
FAU - Joshi, A
AU  - Joshi A
AD  - Pramukhswami Medical College, Karamsad, Gujarat, India.
FAU - Mahajan, R
AU  - Mahajan R
AD  - Adesh Institute of Medical Sciences & Research, Bathinda, Punjab, India.
FAU - Singh, T
AU  - Singh T
AD  - SGRD Institute of Medical Sciences and Research, Amritsar, Punjab, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Postgrad Med
JT  - Journal of postgraduate medicine
JID - 2985196R
SB  - IM
CIN - J Postgrad Med. 2020 Oct-Dec;66(4):184-186. PMID: 33109781
CIN - J Postgrad Med. 2021 Jan-Mar;67(1):57-58. PMID: 33533743
MH  - Adult
MH  - Clinical Competence/*standards
MH  - Competency-Based Education/*organization & administration
MH  - Curriculum
MH  - Education, Medical/*organization & administration
MH  - Education, Medical, Undergraduate/*methods
MH  - Educational Measurement/*methods
MH  - Female
MH  - Humans
MH  - India
MH  - Male
MH  - Professionalism
MH  - Students, Medical
PMC - PMC7819378
OTO - NOTNLM
OT  - Competency-Based Medical Education
OT  - objectivity
OT  - reliability
OT  - rubrics
OT  - validity
COIS- None
EDAT- 2020/10/11 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/10 05:29
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/10/10 05:29 [entrez]
AID - 297502 [pii]
AID - 10.4103/jpgm.JPGM_591_20 [doi]
PST - ppublish
SO  - J Postgrad Med. 2020 Oct-Dec;66(4):200-205. doi: 10.4103/jpgm.JPGM_591_20.


PMID- 33037037
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 2632-1009 (Electronic)
IS  - 2632-1009 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Oct
TI  - AI enabled suicide prediction tools: a qualitative narrative review.
LID - e100175 [pii]
LID - 10.1136/bmjhci-2020-100175 [doi]
AB  - Background: Suicide poses a significant health burden worldwide. In many cases,
      people at risk of suicide do not engage with their doctor or community due to
      concerns about stigmatisation and forced medical treatment; worse still, people
      with mental illness (who form a majority of people who die from suicide) may have
      poor insight into their mental state, and not self-identify as being at risk.
      These issues are exacerbated by the fact that doctors have difficulty in
      identifying those at risk of suicide when they do present to medical services.
      Advances in artificial intelligence (AI) present opportunities for the
      development of novel tools for predicting suicide.Method: We searched Google
      Scholar and PubMed for articles relating to suicide prediction using artificial
      intelligence from 2017 onwards.Conclusions: This paper presents a qualitative
      narrative review of research focusing on two categories of suicide prediction
      tools: medical suicide prediction and social suicide prediction. Initial evidence
      is promising: AI-driven suicide prediction could improve our capacity to identify
      those at risk of suicide, and, potentially, save lives. Medical suicide
      prediction may be relatively uncontroversial when it pays respect to ethical and 
      legal principles; however, further research is required to determine the validity
      of these tools in different contexts. Social suicide prediction offers an
      exciting opportunity to help identify suicide risk among those who do not engage 
      with traditional health services. Yet, efforts by private companies such as
      Facebook to use online data for suicide prediction should be the subject of
      independent review and oversight to confirm safety, effectiveness and ethical
      permissibility.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - D'Hotman, Daniel
AU  - D'Hotman D
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, United
      Kingdom daniel.dhotman@philosophy.ox.ac.uk.
FAU - Loh, Erwin
AU  - Loh E
AUID- ORCID: http://orcid.org/0000-0001-7157-0826
AD  - Monash Centre for Health Research and Implementation, Monash University, Clayton,
      Victoria, Australia.
AD  - Group Chief Medical Officer, St Vincent's Health Australia Ltd, East Melbourne,
      Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Health Care Inform
JT  - BMJ health & care informatics
JID - 101745500
SB  - IM
MH  - *Artificial Intelligence
MH  - *Global Health
MH  - Humans
MH  - Medical Informatics
MH  - *Protective Factors
MH  - Risk Factors
MH  - Suicide/*prevention & control
PMC - PMC7549453
OTO - NOTNLM
OT  - health care
OT  - information science
OT  - medical informatics
OT  - patient care
COIS- Competing interests: None declared.
EDAT- 2020/10/11 06:00
MHDA- 2021/07/24 06:00
CRDT- 2020/10/10 05:28
PHST- 2020/05/14 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/10/10 05:28 [entrez]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
AID - bmjhci-2020-100175 [pii]
AID - 10.1136/bmjhci-2020-100175 [doi]
PST - ppublish
SO  - BMJ Health Care Inform. 2020 Oct;27(3). pii: bmjhci-2020-100175. doi:
      10.1136/bmjhci-2020-100175.


PMID- 33037032
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Oct
TI  - CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac
      involvement in patients with pulmonary sarcoidosis: protocol for a prospective
      observational cohort study.
LID - e000608 [pii]
LID - 10.1136/bmjresp-2020-000608 [doi]
AB  - INTRODUCTION: Sarcoidosis is a multisystem disease, predominantly affecting the
      lungs but can involve the heart, resulting in cardiac sarcoidosis (CS). Patients 
      require MRI/Positron Emission Tomography (PET) scans for diagnosis.
      Echocardiography, ECG and Holter monitoring may be indicative but not diagnostic 
      alone. Patients can present late with conduction defects, heart failure or sudden
      death. The CASPA (CArdiac Sarcoidosis in PApworth) study protocol aims to (1) use
      MRI to identify CS prevalence; (2) use speckle-tracking echocardiography, signal 
      averaged ECG and Holter monitoring to look for diagnostic pathways; and (3)
      identify serum proteins which may be associated with CS. METHODS AND ANALYSIS:
      Participants with pulmonary sarcoidosis (and no known cardiac disease) from Royal
      Papworth Hospital will have the following: cardiac MRI with late gadolinium,
      two-dimensional transthoracic echocardiography with speckle tracking, signal
      averaged ECG and 24-hour Holter monitor. They will provide a serum sample for
      brain natriuretic peptide levels and proteomics by liquid chromatography coupled 
      to high-resolution mass spectrometry. All data will be collected on OpenClinica
      platform and analysed approximately 6 months after final patient recruitment.
      ETHICS AND DISSEMINATION: The Camden & Kings Cross Research Ethics Committee
      approved the protocol (REC number: 17/LO/0667). Integrated Research Approval
      System (IRAS) 222 720. Dissemination of findings will be via conference
      presentations and submitted to peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Quijano-Campos, Juan Carlos
AU  - Quijano-Campos JC
AUID- ORCID: http://orcid.org/0000-0001-9892-5084
AD  - Interstitial Lung Disease Unit, Royal Papworth Hospital NHS Foundation Trust,
      Cambridge, UK.
AD  - Research & Development, Royal Papworth Hospital NHS Foundation Trust, Cambridge, 
      UK.
FAU - Williams, Lynne
AU  - Williams L
AD  - Department of Cardiology, Royal Papworth Hospital NHS Foundation Trust,
      Cambridge, UK.
FAU - Agarwal, Sharad
AU  - Agarwal S
AD  - Department of Cardiology, Royal Papworth Hospital NHS Foundation Trust,
      Cambridge, UK.
FAU - Tweed, Katharine
AU  - Tweed K
AD  - Department of Radiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge,
      UK.
FAU - Parker, Robert
AU  - Parker R
AD  - The Jenner Institute, University of Oxford, Oxford, UK.
FAU - Lalvani, Ajit
AU  - Lalvani A
AD  - Faculty of Medicine, National Heart and Lung Institute, Imperial College London, 
      London, UK.
FAU - Chiu, Yi-Da
AU  - Chiu YD
AD  - Research & Development, Royal Papworth Hospital NHS Foundation Trust, Cambridge, 
      UK.
AD  - MRC Biostatistic Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, UK.
FAU - Dorey, Kane
AU  - Dorey K
AD  - Interstitial Lung Disease Unit, Royal Papworth Hospital NHS Foundation Trust,
      Cambridge, UK.
AD  - Research & Development, Royal Papworth Hospital NHS Foundation Trust, Cambridge, 
      UK.
FAU - Devine, Thomas
AU  - Devine T
AD  - Research & Development, Royal Papworth Hospital NHS Foundation Trust, Cambridge, 
      UK.
FAU - Stoneman, Victoria
AU  - Stoneman V
AD  - Research & Development, Royal Papworth Hospital NHS Foundation Trust, Cambridge, 
      UK.
FAU - Toshner, Mark
AU  - Toshner M
AD  - Pulmonary Vascular Diseases Unit, Royal Papworth Hospital NHS Foundation Trust,
      Cambridge, UK.
AD  - Department of Medicine, University of Cambridge School of Clinical Medicine,
      Cambridge, UK.
FAU - Thillai, Muhunthan
AU  - Thillai M
AD  - Interstitial Lung Disease Unit, Royal Papworth Hospital NHS Foundation Trust,
      Cambridge, UK muhunthan.thillai@nhs.net.
AD  - Department of Medicine, University of Cambridge School of Clinical Medicine,
      Cambridge, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
SB  - IM
MH  - *Cardiomyopathies/diagnostic imaging
MH  - Electrocardiography, Ambulatory
MH  - Humans
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - *Sarcoidosis/diagnosis
MH  - *Sarcoidosis, Pulmonary/diagnostic imaging
PMC - PMC7549466
OTO - NOTNLM
OT  - *sarcoidosis
COIS- Competing interests: None declared.
EDAT- 2020/10/11 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/10 05:28
PHST- 2020/04/13 00:00 [received]
PHST- 2020/08/22 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/10 05:28 [entrez]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 7/1/e000608 [pii]
AID - 10.1136/bmjresp-2020-000608 [doi]
PST - ppublish
SO  - BMJ Open Respir Res. 2020 Oct;7(1). pii: 7/1/e000608. doi:
      10.1136/bmjresp-2020-000608.


PMID- 33036834
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1872-6232 (Electronic)
IS  - 0378-3782 (Linking)
VI  - 150
DP  - 2020 Nov
TI  - The future of Cochrane Neonatal.
PG  - 105191
LID - S0378-3782(20)30656-3 [pii]
LID - 10.1016/j.earlhumdev.2020.105191 [doi]
AB  - Cochrane Neonatal was first established in 1993, as one of the original review
      groups of the Cochrane Collaboration. In fact, the origins of Cochrane Neonatal
      precede the establishment of the collaboration. In the 1980's, the National
      Perinatal Epidemiology Unit at Oxford, led by Dr. Iain Chalmers, established the 
      "Oxford Database of Perinatal Trials" (ODPT), a register of virtually all
      randomized controlled trials in perinatal medicine to provide a resource for
      reviews of the safety and efficacy of interventions used in perinatal care and to
      foster cooperative and coordinated research efforts in the perinatal field [1].
      An effort that was clearly ahead of its time, ODPT comprised four main elements: 
      a register of published reports of trials; a register of unpublished trials; a
      register of ongoing and planned trials; and data derived from pooled overviews
      (meta-analyses) of trials. This core effort grew into the creation of the seminal
      books, "Effective Care in Pregnancy and Childbirth" as well as "Effective Care of
      the Newborn Infant" [2,3]. As these efforts in perinatal medicine grew, Iain
      Chalmers thought well beyond perinatal medicine into the creation of a worldwide 
      collaboration that became Cochrane [4]. The mission of the Cochrane Collaboration
      is to promote evidence-informed health decision-making by producing high-quality,
      relevant, accessible systematic reviews and other synthesized research evidence
      (www.cochrane.org). Cochrane Neonatal has continued to be one of the most
      productive review groups, publishing between 25 tpo to 40 new or updated
      systematic reviews each year. The impact factor has been steadily increasing over
      four years and now rivals most of the elite journals in pediatric medicine.
      Cochrane Neonatal has been a worldwide effort. Currently, there are 404 reviews
      involving 1206 authors from 52 countries. What has Cochrane done for babies?
      Reviews from Cochrane Neonatal have informed guidelines and recommendations
      worldwide. From January 2018 through June 2020, 77 international guidelines cited
      221 Cochrane Neonatal reviews. These recommendations have included
      recommendations of the use of postnatal steroids, inhaled nitric oxide, feeding
      guidelines for preterm infants and other core aspects of neonatal practice. In
      addition, Cochrane Reviews has been the impetus for important research, including
      the large-scale trial of prophylactic indomethacin therapy, a variety of trials
      of postnatal steroids, trials of emollient ointment and probiotic trials [6].
      While justifiably proud of these accomplishments, one needs to examine the future
      contribution of Cochrane Neonatal to the neonatal community. The future of
      Cochrane Neonatal is inexorably linked to the future of neonatal research.
      Obviously, there is no synthesis of trials data if, as a community, we fail to
      provide the core substrate for that research. As we look at the current trials'
      environment, fewer randomized controlled trial related to neonates are being
      published in recent years. A simple search of PubMed, limiting the search to
      "neonates" and "randomized controlled trials" shows that in the year 2000, 321
      randomized controlled trials were published. These peaked five years ago, in
      2015, with close to 900 trials being published. However, in 2018, only 791
      studies are identified. Does this decrease represent a meaningful change in the
      neonatal research environment? Quite possibly. There are shifting missions of
      clinical neonatology at academic medical institutions, at least in the United
      States, with a focus on business aspects as well as other important competing
      clinical activities. Quality improvement has taken over as one of the major
      activities at both private and academic neonatal practices. Clearly, this is a
      needed improvement. All units at levels need to be dedicated to improving the
      outcomes of the sick and fragile population we care for. However, this need not
      be at the expense of formal clinical trials. It is understandable that this
      approach would be taken. Newer interventions frequently relate to complex systems
      of care and not the simple single interventions. Even trials that might
      traditionally have been done as randomized controlled trials, such as the
      introduction of a new mode of ventilation, are in reality complex challenges to
      the ability of institutions to create systems to adapt to these new technologies.
      Cost of doing trials has always been a barrier. The challenging regulatory and
      ethical environment contributes to these problems as well [7]. Despite these
      barriers, how does the research agenda of the neonatal community move forward in 
      the 21st Century? We need to reassess how we create and disseminate our research 
      findings. Innovative trial designs will allow us to address complex issues that
      we may not have tackled with conventional trials. Adaptive designs may allow us
      to look at potentially life-saving therapies in a way that feel more efficient
      and more ethical [8]. Clarifying issues such as the use of inhaled nitric oxide
      in preterm infants would be greatly served if we even knew whether or not there
      are hypoxemic preterm infant who would benefit from this therapy [9]. Current
      trials do not suggest so, yet current practice tells us that a significant number
      of these babies will receive inhaled nitric oxide [10-13]. Adaptive design, such 
      as those done with trials of extracorporeal membrane oxygenation (ECMO), would
      allow us to quickly assess whether, in fact, these therapies are life-saving and 
      allow us to consider whether or not further trials are needed [14,15]. Our
      understanding that many interventions involve entire systems approaches does not 
      relegate us only to doing quality improvement work. Cluster designs may allow us 
      to test more complex interventions that have usually been under the purview of
      quality improvement [16-18]. Cluster trials are well suited for such
      investigations and can be done with the least interruption to ongoing care.
      Ultimately, quality improvement is the application of the best evidence available
      (evidence-based medicine is "what to do" and evidence-based practice is "how to
      do"). [19,20]. Nascent efforts, such as the statement on "embedding necessary
      research into culture and health" (the ENRICH statement) call for the conduct of 
      large, efficient pragmatic trials to evaluate neonatal outcomes, as in part
      called for in the ALPHA Collaboration [21,22]. This statement envisions an
      international system to identify important research questions by consulting
      regularly with all stakeholders, including patients, public health professionals,
      researchers, providers, policy makers, regulators, funders of industry. The
      ENRICH statement envisions a pathway to enable individuals, educational
      institutions, hospitals and health-care facilities to confirm their status as
      research-friendly by integrating an understanding of trials, other research and
      critical thinking and to teaching learning and culture, as well as an engagement 
      with funders, professional organizations and regulatory bodies and other stake
      holders to raise awareness of the value of efficient international research to
      reduce barriers to large international pragmatic trials and other collaborative
      studies. In the future, if trials are to be done on this scale or trials are
      prospectively designed to be analyzed together, core outcome measures must be
      identified and standardized. That clinical trials supply estimates of outcomes
      that are relevant to patients and their families is critical. In addition,
      current neonatal research evaluates many different outcomes using multiple
      measures. A given measure can have multiple widely used definitions.
      Bronchopulmonary dysplasia (or chronic lung disease just to add to the confusion)
      quickly comes to mind [23,24]. The use of multiple definitions when attempting to
      measure the same outcome prevents synthesis of trial results and meta-analysis
      and hinders efforts to refine our estimates of effects. Towards that end, Webbe
      and colleagues have set out to develop a core outcome set for neonatal research
      [25]. Key stakeholders in the neonatal community reviewed multiple outcomes
      reported in neonatal trials and qualitative studies. Based on consensus, key
      outcome measures were identified, including survival, sepsis, necrotizing
      enterocolitis, brain injury on imaging, retinopathy or prematurity, gross motor
      ability, general cognitive ability, quality of life, adverse events, visual
      impairment or blindness, hearing impairment or deafness, chronic lung
      disease/bronchopulmonary dysplasia. Trials registration has to be a continued
      focus of the neonatal community. Trials registration allows for systematic
      reviewers to understand whether or not reporting bias has occurred [26]. It also 
      allows for transparent incorporation of these core outcome measures. Ultimately, 
      trials registration should include public reporting of all of these core outcomes
      and, in the future, access to data on an individual level such that more
      sophisticated individual patient data meta-analysis could occur. Lastly, there is
      no reason to see clinical trials and quality improvement as separate or exclusive
      activities. In fact, in the first NICQ Collaborative, conducted by Vermont Oxford
      Network, participation in a trial of postnatal steroids was considered part of
      the quality improvement best practices as opposed to simply choosing an as-of-yet
      unproven approach to use of this potent drug [27]. What role will Cochrane
      Neonatal play as we move forward in the 21st Century? As the neonatal community
      moves forward with its' research agenda, Cochrane Neonatal must not only follow
      but also lead with innovative approaches to synthesizing research findings.
      Cochrane Neonatal must continue to work closely with guideline developers. The
      relationship between systematic review production and guideline development is
      clearly outlined in reports from the Institute of Medicine [28,29]. Both are
      essential to guideline development; the systematic review group culling the
      evidence for the benefits and harms of a given intervention and the guideline
      group addressing the contextual issues of cost, feasibility, implementation and
      the values and preferences of individuals and societies. Most national and
      international guidelines groups now routinely use systematic reviews as the
      evidence basis for their guidelines and recommendations. Examples of the
      partnership between Cochrane Neonatal and international guideline development can
      be seen in our support of the World Health Organization (WHO) guidelines on the
      use of vitamin A or the soon to be published recommendations from the
      International Liaison Committee on Resuscitation (ILCOR) on cord management in
      preterm and term infants [30]. In the future, we need to collaborate early in the
      guideline development process so that the reviews are fit for purpose and meet
      the needs of the guideline developers and the end users. Towards this end, all
      Cochrane Neonatal reviews now contain GRADE assessments of the key clinical
      findings reported in the systematic review [31]. Addition of these assessments
      addresses the critical issue of our confidence in the findings. We are most
      confident in evidence provided by randomized controlled trials but this
      assessment can be can be downgraded if the studies that reported on the outcome
      in question had a high risk of bias, indirectness, inconsistency of results, or
      imprecision, or where there is evidence of reporting bias. Information provided
      by GRADE assessments is seen as critical in the process of moving from the
      evidence to formal recommendations [32]. We need to explore complex reviews, such
      as network (NMA) or multiple treatment comparison (MCT) meta-analyses, to address
      issues not formally addressed in clinical trials [33]. In conditions where there 
      are multiple effective interventions, it is rare for all possible interventions
      to have been tested against each other [34]. A solution could be provided by
      network meta-analysis, which allows for comparing all treatments with each other,
      even if randomized controlled trials are not available for some treatment
      comparisons [34]. Network meta-analysis uses both direct (head-to-head)
      randomized clinical trial (RCT) evidence as well as indirect evidence from RCTs
      to compare the relative effectiveness of all included interventions [35].
      However, Mills and colleagues note that the methodological quality of MTCs may be
      difficult for clinicians to interpret because the number of interventions
      evaluated may be large and the methodological approaches may be complex [35].
      Cochrane Neonatal must take a role in both the creation of such analyses and the 
      education of the neonatal community regarding the pitfalls of such an approach.
      The availability of individual patient data will make more sophisticated analyses
      more available to the community. Although the current crop of individual patient 
      data meta-analyses (including the reviews of elective high frequency ventilation,
      inhaled nitric oxide and oxygen targets) have not differed substantially from the
      findings of the trials level reviews (suggesting that, in fact, sick neonates are
      more alike that unalike), there still will be a large role for individual patient
      data meta-analysis, at least to end the unfound conclusions that these therapies 
      are effective in various subgroups (be it issues of sex, disease severity, or
      clinical setting) [36-39]. Future trials should take a lesson from the NeOProM
      Collaborative [37,39]. Given the difficulty in generating significant sample size
      and creating funding in any single environment, trials with similar protocols
      should be conducted in a variety of healthcare settings with an eye towards both 
      study level and individual patient level meta-analysis at the conclusion of those
      trials, allowing for broader contribution to the trials data, more rapid accrual 
      of sample size, and more precise results. We need to educate the neonatal
      community regarding the use and abuse of diagnostic tests. Diagnostic tests are a
      critical component of healthcare but also contribute greatly to the cost of
      medical care worldwide. These costs include the cost of the tests themselves and 
      the costs of misdiagnosis and treatment of individuals who will not benefit from 
      those treatments. Clinicians may have a limited understanding of diagnostic test 
      accuracy, the ability of a diagnostic test to distinguish between patients with
      and without the disease or target condition [41,42]. Efforts such as Choosing
      Wisely have tried to identify these deficiencies [40]. As Cochrane has increased 
      the general literacy of both the medical and general population regarding the
      interpretation of the results of interventions on various diseases, so should
      Cochrane move forward and improve the understanding of diagnostic testing. We
      need to become more efficient at creating and maintaining our reviews. The time
      spent to produce systematic reviews is far too great. In average, it takes
      between 2(1/2) to 6(1/2) years to produce a systematic review, requiring intense 
      time input for highly trained and expensive experts. Innovations in the ways in
      which we produce systematic reviews can make the review process more efficient by
      outsourcing some of the tasks or crowdsourcing to machine learning. We need to
      let the crowd and machine learning innovations help us sort the massive amounts
      of information needed to conduct systematic reviews. It can also allow for "live"
      updating of critical reviews where the research landscape is quickly changing
      [43]. Lastly, Cochrane Neonatal must focus more on users of the reviews and not
      necessarily authors of the reviews. Current Cochrane programming speaks of
      Cochrane training with an eye towards developing the skills of individuals who
      will conduct systematic reviews. While this is clearly needed and laudable, the
      fact of the matter is that most of the community will be "users" of the reviews. 
      Individuals who need to understand how to use and interpret the findings of
      systematic reviews. These review users include clinicians, guideline developers, 
      policy makers and families. Incorporation of GRADE guidelines has been a huge
      step in adding transparency to the level of uncertainty we have in our findings. 
      From a family's perspective, we need to overcome the environment of mistrust or
      misunderstanding of scientific evidence and how we convey what we know, and our
      uncertainty about what we know, to parents and families.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Soll, Roger F
AU  - Soll RF
AD  - Larner College of Medicine at the University of Vermont, Burlington, VT, USA;
      Vermont Oxford Network, Burlington, VT, USA. Electronic address:
      Roger.Soll@uvmhealth.org.
FAU - Ovelman, Colleen
AU  - Ovelman C
AD  - Vermont Oxford Network, Burlington, VT, USA.
FAU - McGuire, William
AU  - McGuire W
AD  - York University, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200912
PL  - Ireland
TA  - Early Hum Dev
JT  - Early human development
JID - 7708381
SB  - IM
MH  - Humans
MH  - Infant, Newborn
MH  - Neonatology/methods/*standards/trends
MH  - Perinatology/methods/*standards/trends
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic/standards
MH  - *Review Literature as Topic
COIS- Declaration of competing interest Roger Soll, Colleen Ovelman and William McGuire
      are editors of Cochrane Neonatal. Roger Soll and Colleen Ovelman are employees of
      the Vermont Oxford Network.
EDAT- 2020/10/11 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/10/10 05:27
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/10/10 05:27 [entrez]
AID - S0378-3782(20)30656-3 [pii]
AID - 10.1016/j.earlhumdev.2020.105191 [doi]
PST - ppublish
SO  - Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub
      2020 Sep 12.


PMID- 33036605
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 9
TI  - Implementation of guidelines on family involvement for persons with psychotic
      disorders in community mental health centres (IFIP): protocol for a cluster
      randomised controlled trial.
PG  - 934
LID - 10.1186/s12913-020-05792-4 [doi]
AB  - BACKGROUND: Family involvement for persons with psychotic disorders is
      under-implemented in mental health care, despite its firm scientific, economic,
      legal and moral basis. This appears to be the case in Norway, despite the
      presence of national guidelines providing both general recommendations on family 
      involvement and support in the health- and care services, and specific guidance
      on family interventions for patients with psychotic disorders. The aim of this
      project is to improve mental health services and the psychosocial health of
      persons with psychotic disorders and their relatives, by implementing selected
      recommendations from the national guidelines in community mental health centres, 
      and to evaluate this process. METHODS: The trial is cluster randomised, where 14 
      outpatient clusters from community mental health centres undergo stratified
      randomisation with an allocation ratio of 1:1. The seven intervention clusters
      will receive implementation support for 18 months, whereas the control clusters
      will receive the same support after this implementation period. The intervention 
      consists of: 1. A basic level of family involvement and support. 2. Family
      psychoeducation in single-family groups. 3. Training and guidance of health care 
      personnel. 4. A family coordinator and 5. Other implementation measures. Fidelity
      to the intervention will be measured four times in the intervention arm and two
      times in the control arm, and the differences in fidelity changes between the
      arms constitute the primary outcomes. In each arm, we aim to include 161 patients
      with psychotic disorders and their closest relative to fill in questionnaires at 
      inclusion, 6 months and 12 months, measuring psychosocial health and satisfaction
      with services. Clinicians will contribute clinical data about patients at
      inclusion and 12 months. Use of health and welfare services and work
      participation, for both patients and relatives, will be retrieved from national
      registries. We will also perform qualitative interviews with patients, relatives,
      health care personnel and leaders. Finally, we will conduct a cost-effectiveness 
      analysis and a political economy analysis. DISCUSSION: This project, with its
      multilevel and mixed methods approach, may contribute valuable knowledge to the
      fields of family involvement, mental health service research and implementation
      science. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03869177 .
      Registered 11.03.19.
FAU - Hestmark, Lars
AU  - Hestmark L
AUID- ORCID: http://orcid.org/0000-0002-3249-0118
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway. lars.hestmark@medisin.uio.no.
FAU - Romoren, Maria
AU  - Romoren M
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway.
FAU - Heiervang, Kristin Sverdvik
AU  - Heiervang KS
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway.
AD  - Division of Mental Health Services, Akershus University Hospital, Sykehusveien
      25, 1474, Nordbyhagen, Norway.
FAU - Weimand, Bente
AU  - Weimand B
AD  - Division of Mental Health Services, Akershus University Hospital, Sykehusveien
      25, 1474, Nordbyhagen, Norway.
AD  - Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
AD  - School of Nursing and Midwifery, Queens University, Belfast, Northern Ireland.
FAU - Ruud, Torleif
AU  - Ruud T
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway.
AD  - Division of Mental Health Services, Akershus University Hospital, Sykehusveien
      25, 1474, Nordbyhagen, Norway.
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Norvoll, Reidun
AU  - Norvoll R
AD  - Work Research Institute, Oslo Metropolitan University, Oslo, Norway.
FAU - Hansson, Kristiane Myckland
AU  - Hansson KM
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway.
FAU - Norheim, Irene
AU  - Norheim I
AD  - Division of Mental Health and Addiction, Vestre Viken Hospital Trust, Lier,
      Norway.
FAU - Aas, Eline
AU  - Aas E
AD  - Department of Health Management and Health Economics, University of Oslo, Oslo,
      Norway.
FAU - Landeweer, Elisabeth Geke Marjan
AU  - Landeweer EGM
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway.
AD  - Department of General Practice and Elderly Care Medicine, University of
      Groningen, University Medical Center Groningen, Groningen, the Netherlands.
FAU - Pedersen, Reidar
AU  - Pedersen R
AD  - Centre for Medical Ethics, University of Oslo, Kirkeveien 166 Fredrik Holsts hus,
      0450, Oslo, Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT03869177
GR  - NFR 262863/Norges Forskningsrad
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201009
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Clinical Protocols
MH  - Community Mental Health Centers/*organization & administration
MH  - Family/*psychology
MH  - Humans
MH  - Norway
MH  - *Practice Guidelines as Topic
MH  - Psychotic Disorders/*therapy
PMC - PMC7547488
OTO - NOTNLM
OT  - Clinical ethics
OT  - Family intervention
OT  - Family involvement
OT  - Family psychoeducation
OT  - Implementation
OT  - Mental health service research
OT  - Psychotic disorders
OT  - Schizophrenia
EDAT- 2020/10/11 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/10/10 05:23
PHST- 2020/01/17 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/10 05:23 [entrez]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1186/s12913-020-05792-4 [doi]
AID - 10.1186/s12913-020-05792-4 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Oct 9;20(1):934. doi: 10.1186/s12913-020-05792-4.


PMID- 33036584
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 9
TI  - Access to institutional delivery services and its associated factors among
      mothers in Jimma Zone, Southwest Ethiopia: a cross-sectional study.
PG  - 1530
LID - 10.1186/s12889-020-09610-8 [doi]
AB  - BACKGROUND: Poor access to institutional delivery services has been known as a
      significant contributory factor to adverse maternal as well as newborn outcomes. 
      Previous studies measured access in terms of utilization while it has different
      dimensions (geographic accessibility, availability, affordability, and
      acceptability) that requires to be measured separately. Therefore, this study was
      conducted to assess the four dimensions of access and factors associated with
      each of these dimensions. METHODS: Community-based cross-sectional study design
      was used, employing both quantitative and qualitative methods. A simple random
      sampling technique was used to select 605 mothers who had given birth in the last
      6 months preceding the study. Multi-variable binary logistic regression was used 
      to select factors associated with the four dimensions of access by using AOR with
      95% CI. Ethical approval was secured from Jimma University Institutional Review
      Board. RESULTS: Five hundred and ninety-three mothers involved in this study,
      resulting in a response rate of 98%. Four hundred five (68%), 273(46%), 279(47%),
      and 273(46%) had geographic, perceived availability, affordability, and
      acceptability access to institutional delivery services, respectively. Antenatal 
      care [AOR = 3.74(1.56, 8.98)], occupation of mother [AOR = 5.10(1.63, 15.88)],
      and residence [AOR = 1.93(1.13, 3.29)] were independently associated with
      geographic accessibility. Household graduation [AOR = 1.46(1.03, 2.06)],
      residence [AOR = 1.74(1.17, 2.59)], and ANC [AOR = 3.80(1.38, 10.50)] were
      independently associated with perceived availability. Moreover, wealth quintile
      [AOR = 11.60(6.02, 22.35)], ANC [AOR = 3.48(1.36, 9.61)], and occupation of
      husband [AOR = 3.63(1.51, 8.74)] were independently associated with
      affordability. Lastly, mother's education [AOR = 2.69(1.42, 5.09)], residence
      [AOR = 2.60(1.66, 4.08)], and household graduation [AOR = 3.12(2.16, 4.50)] were 
      independently associated with acceptability of institutional delivery services.
      CONCLUSIONS: Moderate proportions of mothers have geographic accessibility to
      institutional delivery services, but access to the other three dimensions was
      low. ANC visits of 4 or above, occupation of husband, urban residence, graduation
      of mother's household as a model family, higher wealth quintiles, and maternal
      educational level significantly affect access to institutional delivery services.
      Thus, it was recommended that concerned bodies should give due attention to ANC
      services, female education, training of model families, and enhancement of
      household wealth through job creation opportunities to increase access to
      institutional delivery services.
FAU - Kayrite, Qaro Qanche
AU  - Kayrite QQ
AUID- ORCID: http://orcid.org/0000-0002-8051-2529
AD  - Department of Public Health, College of Health Science, Mizan-Tepi University,
      Mizan-Aman, Ethiopia. qaroqanche@gmail.com.
FAU - Salgedo, Waju Beyene
AU  - Salgedo WB
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
FAU - Weldemarium, Tesfaye Dagne
AU  - Weldemarium TD
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
FAU - Sinkie, Shimeles Ololo
AU  - Sinkie SO
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
FAU - Handalo, Dejene Melese
AU  - Handalo DM
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
FAU - Obola, Teshale Dojamo
AU  - Obola TD
AD  - School of Public Health, College of Medicine and Health Sciences, Hawassa
      University, Hawassa, Ethiopia.
FAU - Kebene, Feyera Gebissa
AU  - Kebene FG
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
FAU - Garedew, Muluneh Getachew
AU  - Garedew MG
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
FAU - Likka, Melaku Haile
AU  - Likka MH
AD  - Department of Health Policy and Management, Faculty of Public Health, Institute
      of Health, Jimma University, Jimma, Ethiopia.
LA  - eng
GR  - Not Applicable/Jimma University
PT  - Journal Article
DEP - 20201009
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Delivery, Obstetric
MH  - Ethiopia
MH  - Female
MH  - Health Facilities
MH  - *Health Services Accessibility
MH  - Humans
MH  - Infant, Newborn
MH  - *Maternal Health Services
MH  - *Mothers
MH  - Pregnancy
MH  - Prenatal Care
MH  - Young Adult
PMC - PMC7547433
OTO - NOTNLM
OT  - Access
OT  - Dimensions
OT  - Institutional delivery services
OT  - Jimma
OT  - Mothers
OT  - Southwest Ethiopia
EDAT- 2020/10/11 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/10 05:23
PHST- 2020/03/29 00:00 [received]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/10 05:23 [entrez]
PHST- 2020/10/11 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1186/s12889-020-09610-8 [doi]
AID - 10.1186/s12889-020-09610-8 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Oct 9;20(1):1530. doi: 10.1186/s12889-020-09610-8.


PMID- 33035930
OWN - NLM
STAT- MEDLINE
DCOM- 20210309
LR  - 20210309
IS  - 1532-2661 (Electronic)
IS  - 0034-5288 (Linking)
VI  - 133
DP  - 2020 Dec
TI  - Am I actually a veterinarian or an economist? Understanding the moral challenges 
      for farm veterinarians in Germany on the basis of a qualitative online survey.
PG  - 246-250
LID - S0034-5288(20)31030-4 [pii]
LID - 10.1016/j.rvsc.2020.09.029 [doi]
AB  - This qualitative online survey (n=123) investigated what farm veterinarians in
      Germany perceive as morally challenging situations. Vital moral challenges can be
      described as conflicts between different actors who make demands on the
      veterinarians, like (a) animals, (b) farmers, (c) politics, (d) society, (e)
      veterinary offices (f) colleagues, supervisors, employees and competitors and (g)
      the veterinarian himself/herself. Or they can be described as the conflict
      between different roles of veterinarians who describe themselves as (a) advocates
      for the animals, (b) entrepreneurs, (c) social workers, (d) part of agriculture, 
      (e) colleagues, supervisors, employees and competitors and (f) private persons.
      It can be deduced that at least some study participants find the described moral 
      challenges a cause for moral distress. The key moral challenge for farm
      veterinarians, from their own viewpoint, are not so much open ethical questions, 
      ethical dilemmas or "duty vs. inclination" conflicts, but rather situations in
      which their personal moral convictions are conflicting with external obstacles.
      Accordingly, a feeling of powerlessness appears in their answers. The extremely
      limited financial scope of animal owners could be identified as the key external 
      obstacle.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Durnberger, Christian
AU  - Durnberger C
AD  - Messerli Research Institute, Unit of Ethics and Human-Animal Studies, Vetmeduni
      Vienna, Veterinarplatz 1, 1210 Vienna, Austria. Electronic address:
      Christian.duernberger@vetmeduni.ac.at.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - England
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
SB  - IM
MH  - Agriculture/economics
MH  - Animals
MH  - Farmers
MH  - Female
MH  - Germany
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morals
MH  - Physician's Role
MH  - Surveys and Questionnaires
MH  - Veterinarians/*economics/*ethics
OTO - NOTNLM
OT  - Farm veterinarians
OT  - Moral conflicts
OT  - Veterinary ethics
EDAT- 2020/10/10 06:00
MHDA- 2021/03/10 06:00
CRDT- 2020/10/09 20:17
PHST- 2020/06/03 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/03/10 06:00 [medline]
PHST- 2020/10/09 20:17 [entrez]
AID - S0034-5288(20)31030-4 [pii]
AID - 10.1016/j.rvsc.2020.09.029 [doi]
PST - ppublish
SO  - Res Vet Sci. 2020 Dec;133:246-250. doi: 10.1016/j.rvsc.2020.09.029. Epub 2020 Sep
      28.


PMID- 33035794
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1872-6283 (Electronic)
IS  - 0379-0738 (Linking)
VI  - 316
DP  - 2020 Nov
TI  - Contrasting insect activity and decomposition of pigs and humans in an Australian
      environment: A preliminary study.
PG  - 110515
LID - S0379-0738(20)30377-7 [pii]
LID - 10.1016/j.forsciint.2020.110515 [doi]
AB  - Non-human vertebrate animals, primarily domestic pigs, have been widely used in
      forensic science research as analogues for humans due to ethical and logistical
      constraints. Yet the suitability of pigs to mimic human decomposition and
      entomological patterns remains largely untested, and explicit comparative
      research in this area is lacking. We compared the decomposition rates and insect 
      communities found at pig and human remains during summer and winter at the
      Australian Facility for Taphonomic Experimental Research (AFTER). Pigs decomposed
      faster than humans, with pigs entering active decay earlier in both summer and
      winter, and humans undergoing desiccation rather than skeletonisation. There was 
      also a delay in the colonisation of humans by both flies and beetles. Species
      richness of these necrophagous taxa was between two and five times higher during 
      the first two weeks of decomposition on pigs compared to humans during both
      summer and winter. Insect species composition was also significantly different
      between pigs and humans in each season. We interpret our findings to mean that
      the difference between humans and pigs, such as their mass, diet, medical
      history, or their microbiomes, might be causing different decomposition processes
      and altered timing or production of chemical cues for insect colonisation.
      Although preliminary, our results suggest that pigs might not be accurate
      substitutes for humans in particular fields of taphonomy and forensic entomology.
      Our findings also have broader implications for the reliability of forensic
      studies using pigs as models for humans, and highlight the need to recognise
      intrinsic differences between animal models and humans.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Dawson, Blake M
AU  - Dawson BM
AD  - Centre for Sustainable Ecosystem Solutions, School of Earth, Atmospheric and Life
      Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia. Electronic 
      address: bmd994@uowmail.edu.au.
FAU - Barton, Philip S
AU  - Barton PS
AD  - Centre for Sustainable Ecosystem Solutions, School of Earth, Atmospheric and Life
      Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia; Federation 
      University Australia, Mount Helen, VIC, 3350, Australia.
FAU - Wallman, James F
AU  - Wallman JF
AD  - Centre for Sustainable Ecosystem Solutions, School of Earth, Atmospheric and Life
      Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia; School of
      Life Sciences, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200917
PL  - Ireland
TA  - Forensic Sci Int
JT  - Forensic science international
JID - 7902034
SB  - IM
MH  - Aged, 80 and over
MH  - Animals
MH  - Australia
MH  - *Coleoptera
MH  - *Diptera
MH  - *Feeding Behavior
MH  - Female
MH  - *Forensic Entomology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postmortem Changes
MH  - Seasons
MH  - Swine
MH  - Temperature
OTO - NOTNLM
OT  - Animal model
OT  - Decomposition
OT  - Forensic entomology
OT  - Necrobiome
OT  - Taphonomy
COIS- Declaration of competing interest None.
EDAT- 2020/10/10 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/10/09 20:12
PHST- 2020/04/08 00:00 [received]
PHST- 2020/09/09 00:00 [revised]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/10/09 20:12 [entrez]
AID - S0379-0738(20)30377-7 [pii]
AID - 10.1016/j.forsciint.2020.110515 [doi]
PST - ppublish
SO  - Forensic Sci Int. 2020 Nov;316:110515. doi: 10.1016/j.forsciint.2020.110515. Epub
      2020 Sep 17.


PMID- 33035654
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1953-8022 (Electronic)
IS  - 1246-7820 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Nov
TI  - Transfusion medicine: Overtime paradigm changes and emerging paradoxes.
PG  - 262-267
LID - S1246-7820(20)30122-1 [pii]
LID - 10.1016/j.tracli.2020.10.001 [doi]
AB  - This essay aims to discuss some aspects of blood transfusion in the perspective
      of the changes that occurred over time as well as modifications of the paradigms 
      that transformed the activities and the organization of blood transfusion
      services. Without specific knowledge, pioneers envisioned precision and
      personalized medicine, rendering transfusion medicine operational. Transfusion
      medicine is like The Picture of Dorian Grey: always young despite being old and
      sometimes appearing old-fashioned. Over the years, the transfusion medicine
      discipline has evolved, and major progress has been achieved, despite some
      troublesome periods (for example, the tainted blood scandal, and-at the time
      being-the offending plasma market and the selling of human parts). Transfusion
      medicine has at all times implemented the rapidly developing biomedical
      technologies to secure blood components. The safety of blood components has now
      reached an exceptional level in economically wealthy countries, especially
      compared to other health care disciplines. Strengthening of the safety has
      mandated that blood donors and recipients are unrelated, an issue which has eased
      preservation and fractionation practices; blood is no longer arm-to-arm
      transfused and neither is whole blood, the commonest component. However, it is
      interesting to note that a revival is occurring as whole blood is back on stage
      for certain specific indications, which is one among the many paradoxes
      encountered while studying this discipline.
CI  - Copyright (c) 2020 Societe francaise de transfusion sanguine (SFTS). Published by
      Elsevier Masson SAS. All rights reserved.
FAU - Garraud, O
AU  - Garraud O
AD  - Universite de Lyon Saint-Etienne, 10, rue Trefilerie, 42023 Saint-Etienne Cedex
      2, France; Institut National de la Transfusion Sanguine, 6, rue Alexandre
      Cabanel, 75015 Paris, France. Electronic address:
      Olivier.garraud@univ-st-etienne.fr.
FAU - Vuk, T
AU  - Vuk T
AD  - Croatian institute of transfusion medicine, Petrova ul. 3, 10000 Zagreb, Croatia.
FAU - Lozano, M
AU  - Lozano M
AD  - Clinic university hospital Barcelona, university of Barcelona, 170C. de
      Villarroel, 08036 Barcelona, Spain.
FAU - Tissot, J-D
AU  - Tissot JD
AD  - Faculte de biologie et de medecine, universite de Lausanne, 21, rue du Bugnon,
      1011 Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - France
TA  - Transfus Clin Biol
JT  - Transfusion clinique et biologique : journal de la Societe francaise de
      transfusion sanguine
JID - 9423846
SB  - IM
MH  - Blood Component Transfusion
MH  - Blood Donors
MH  - Blood Transfusion
MH  - Humans
MH  - *Transfusion Medicine
PMC - PMC7537623
OTO - NOTNLM
OT  - Blood donation
OT  - Blood safety
OT  - Blood transfusion
OT  - Hemovigilance
OT  - Public health
OT  - Quality of medicines
OT  - Transfusion history
OT  - Transfusion services
OT  - ethics
EDAT- 2020/10/10 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/10/09 20:09
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/10/09 20:09 [entrez]
AID - S1246-7820(20)30122-1 [pii]
AID - 10.1016/j.tracli.2020.10.001 [doi]
PST - ppublish
SO  - Transfus Clin Biol. 2020 Nov;27(4):262-267. doi: 10.1016/j.tracli.2020.10.001.
      Epub 2020 Oct 6.


PMID- 33035127
OWN - NLM
STAT- MEDLINE
DCOM- 20210713
LR  - 20211207
IS  - 1552-5732 (Electronic)
IS  - 0890-3344 (Linking)
VI  - 36
IP  - 4
DP  - 2020 Nov
TI  - Advocacy, Strategy and Tactics Used to Confront Corporate Power: The Nestle
      Boycott and International Code of Marketing of Breast-milk Substitutes.
PG  - 568-578
LID - 10.1177/0890334420955158 [doi]
AB  - Douglas A. Johnson began his career as a human rights activist while earning his 
      undergraduate degree in philosophy (1975) at Macalester College in the United
      States. He lived at Gandhi's ashram in India to study nonviolent organizing (1969
      to 1970). He served as the director of the Third World Institute in Minneapolis, 
      MN, USA (1973-1979), which functioned as the international social justice program
      of the Archdiocese of Minneapolis and St. Paul. Johnson's work included creating 
      and running a political collective; leading development study tours into villages
      in Guatemala and Honduras; and investigating how transnational companies (e.g.,
      Nestle) were penetrating the developing world. He was the co-founder of the
      Infant Formula Action Coalition (INFACT), elected national chairperson
      (1977-1985), and appointed as Executive Director (1978-1984). His role included
      representing INFACT before national and international organizations, the human
      milk substitute industry, the US Congress and Executive Branch, and the press. He
      initiated and coordinated the first international grass-roots consumer boycott
      (against Nestle) in ten nations. He was also a co-founder of the International
      Nestle Boycott Committee and the International Baby Food Action Network (IBFAN). 
      He earned a Master's in Public and Private Management at Yale University (1988). 
      Then he became the first Executive Director of the Center for Victims of Torture,
      in Minneapolis (1988-2012), the first treatment center for torture victims in the
      US. Since 2013, he has been teaching human rights theory and practice, and
      sharing lessons he has learned, as a Lecturer in Public Policy at the Harvard
      Kennedy School, Harvard University (US). (This interview was conducted via Zoom
      and transcribed verbatim. It has been edited for ease of readability. DJ refers
      to Doug Johnson and LD refers to Laura Duckett.).
FAU - Johnson, Douglas A
AU  - Johnson DA
AD  - 33574 Carr Center for Human Rights Policy, Harvard Kennedy School, Harvard
      University, Cambridge, MA, USA.
FAU - Duckett, Laura J
AU  - Duckett LJ
AUID- ORCID: https://orcid.org/0000-0003-0873-6381
AD  - 5635 School of Nursing, University of Minnesota-Twin Cities (Emerita), New
      Brighton, MN, USA.
LA  - eng
PT  - Journal Article
DEP - 20201009
PL  - United States
TA  - J Hum Lact
JT  - Journal of human lactation : official journal of International Lactation
      Consultant Association
JID - 8709498
CIN - J Hum Lact. 2021 Nov;37(4):669-671. PMID: 34431741
CIN - J Hum Lact. 2021 Nov;37(4):668. PMID: 34846980
MH  - Developing Countries/statistics & numerical data
MH  - Humans
MH  - Infant
MH  - Infant Nutritional Physiological Phenomena
MH  - Infant, Newborn
MH  - Marketing/ethics/*standards/trends
MH  - Milk Substitutes/metabolism/*standards
MH  - Milk, Human
MH  - *Patient Advocacy
MH  - Professional Corporations/*standards
OTO - NOTNLM
OT  - International Baby Food Action Network
OT  - International Code of Marketing of Breast-milk Substitutes
OT  - Nestle boycott
OT  - UNICEF
OT  - World Health Organization
OT  - breastfeeding
OT  - corporate power
OT  - ethics
OT  - human rights
OT  - oral history
EDAT- 2020/10/10 06:00
MHDA- 2021/07/14 06:00
CRDT- 2020/10/09 17:07
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/07/14 06:00 [medline]
PHST- 2020/10/09 17:07 [entrez]
AID - 10.1177/0890334420955158 [doi]
PST - ppublish
SO  - J Hum Lact. 2020 Nov;36(4):568-578. doi: 10.1177/0890334420955158. Epub 2020 Oct 
      9.


PMID- 33035039
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20210520
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 131
IP  - 3
DP  - 2020 Sep
TI  - Medical Ethics Versus Health Care Workers' Rights: Fight-or-Flee Response.
PG  - e173-e174
LID - 10.1213/ANE.0000000000005060 [doi]
FAU - Subedi, Asish
AU  - Subedi A
AD  - Department of Anesthesiology & Critical Care, BP Koirala Institute of Health
      Sciences, Dharan, Nepal, asishsubedi19@gmail.com; ashish.subedi@bpkihs.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
SB  - IM
CON - Anesth Analg. 2020 Jul;131(1):86-92. PMID: 32243287
CIN - Anesth Analg. 2020 Sep;131(3):e174-e175. PMID: 32541248
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Developing Countries
MH  - Ethics, Medical
MH  - Health Personnel
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7302076
EDAT- 2020/10/10 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/09 15:18
PHST- 2020/10/09 15:18 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1213/ANE.0000000000005060 [doi]
AID - 00000539-202009000-00070 [pii]
PST - ppublish
SO  - Anesth Analg. 2020 Sep;131(3):e173-e174. doi: 10.1213/ANE.0000000000005060.


PMID- 33034047
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2473-4209 (Electronic)
IS  - 0094-2405 (Linking)
VI  - 47
IP  - 12
DP  - 2020 Dec
TI  - Examining gender diversity growth as a model for inclusion of all
      underrepresented persons in medical physics.
PG  - 5976-5985
LID - 10.1002/mp.14524 [doi]
AB  - The labor force of Medical Physics is one of the most gender diverse in the field
      of Physics, as it has attained the proportional achievement of ~30% women
      worldwide (Tsapaki et al. Phys Medica. 2018;55:33-39). While great strides have
      been made toward a gender diverse workforce, women still comprise an
      underrepresented group. Many strategies have been suggested to increase the
      participation of underrepresented persons by addressing unconscious biases,
      increasing opportunities, dedicated hiring policies, and providing support
      networks in science and medicine (Barabino et al. Sci Eng Ethics. 2019; Coe et
      al. Lancet. 2019), yet the personnel landscape remains largely uniform. Herein,
      the conditions, strategies, and approaches that facilitated gender diversity in
      Medical Physics are considered as a means to further the inclusion of other
      underrepresented groups through exemplars of mentorship, addressing unconscious
      biases and the implementation of inclusive practices. Furthermore, the potential 
      for gender diversity to act as a catalyst to create an environment that is more
      accepting of diversity and supports and encourages inclusive practices for the
      participation and inclusion of other underrepresented groups in Medical Physics
      is discussed.
CI  - (c) 2020 American Association of Physicists in Medicine.
FAU - van Zyl, Maxine
AU  - van Zyl M
AD  - Department of Psychology, Faculty of Arts and Social Science, University of
      British Columbia Okanagan, 3333 University Way, Kelowna, BC, V1V 1V7, Canada.
FAU - Haynes, Elijah M K
AU  - Haynes EMK
AD  - School of Health and Exercise Science, Faculty of Health and Social Development, 
      University of British Columbia Okanagan, 3333 University Way, Kelowna, BC, V1V
      1V7, Canada.
FAU - Batchelar, Deidre
AU  - Batchelar D
AD  - Department of Computer Science, Mathematics, Physics and Statistics, Faculty of
      Science, University of British Columbia Okanagan, 3333 University Way, Kelowna,
      BC, V1V 1V7, Canada.
AD  - Department of Medical Physics, BC Cancer - Kelowna, 399 Royal Ave, Kelowna, BC,
      V1Y 5L3, Canada.
FAU - Jakobi, Jennifer M
AU  - Jakobi JM
AD  - School of Health and Exercise Science, Faculty of Health and Social Development, 
      University of British Columbia Okanagan, 3333 University Way, Kelowna, BC, V1V
      1V7, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201112
PL  - United States
TA  - Med Phys
JT  - Medical physics
JID - 0425746
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Physics
PMC - PMC7839666
OTO - NOTNLM
OT  - climate in Medical Physics
OT  - gender diversity
OT  - inclusion
OT  - underrepresented persons
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:41
PHST- 2020/02/04 00:00 [received]
PHST- 2020/08/27 00:00 [revised]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/09 05:41 [entrez]
AID - 10.1002/mp.14524 [doi]
PST - ppublish
SO  - Med Phys. 2020 Dec;47(12):5976-5985. doi: 10.1002/mp.14524. Epub 2020 Nov 12.


PMID- 33033807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2662-2211 (Electronic)
IS  - 2662-2211 (Linking)
VI  - 1
DP  - 2020
TI  - Development and evaluation of a digital, community-based intervention to reduce
      noncommunicable disease risk in a low-resource urban setting in Malaysia: a
      research protocol.
PG  - 87
LID - 10.1186/s43058-020-00080-y [doi]
AB  - BACKGROUND: Noncommunicable disease burden is rising in Malaysia, accounting for 
      72% of all deaths. Urbanization and globalization have contributed to changing
      patterns of diet and physical activity, creating an obesogenic environment that
      increases noncommunicable disease risk, especially in low-income populations.
      Community-based and technological interventions can play an important role in
      addressing structural determinants that influence noncommunicable disease burden.
      The Better Health Programme Malaysia aims to co-create and develop a
      community-based digital intervention for low-income populations to enable
      community stakeholders to address obesogenic environments and improve people's
      knowledge, attitudes, and practices related to noncommunicable disease risk.
      METHODS: This quasi-experimental study will assess community member and community
      health volunteer knowledge, attitudes, and practices on noncommunicable disease
      prevention, risk factors, and health-seeking behavior in three geographical areas
      of Kuala Lumpur, each representing a different ethnicity (Malay, Indian, and
      Chinese). Assessment will take place before and after a 9-month intervention
      period, comparing intervention areas with matched control geographies. We plan to
      engage 2880 community members and 45 community health volunteers across the six
      geographic areas. A digital health needs assessment will inform modification of
      digital health tools to support project aims. Intervention co-creation will use a
      discrete choice experiment to identify community preferences among evidence-based
      intervention options, building from data collected on community knowledge,
      attitudes, and practices. Community health volunteers will work with local
      businesses and other stakeholders to effect change in obesogenic environments and
      NCD risk. The study has been approved by the Malaysian Ministry of Health Medical
      Research Ethical Committee. DISCUSSION: The Better Health Programme Malaysia
      anticipates a bottom-up approach that relies on community health volunteers
      collaborating with local businesses to implement activities that address
      obesogenic environments and improve community knowledge, attitudes, and practices
      related to NCD risk. The planned co-creation process will determine which
      interventions will be most locally relevant, feasible, and needed. The effort
      aims to empower community members and community health volunteers to drive change
      that improves their own health and wellbeing. The learnings can be useful
      nationally and sub-nationally in Malaysia, as well as across similar settings
      that are working with community stakeholders to reduce noncommunicable disease
      risk. TRIAL REGISTRATION: National Medical Research Register, Malaysia;
      NMRR-20-1004-54787 (IIR); July 7, 2020.
CI  - (c) The Author(s) 2020.
FAU - Kataria, Ishu
AU  - Kataria I
AUID- ORCID: 0000-0002-8483-8243
AD  - Center for Global Noncommunicable Diseases, RTI International, New Delhi, India.
FAU - Ngongo, Carrie
AU  - Ngongo C
AD  - Center for Global Noncommunicable Diseases, RTI International, Seattle,
      USA.grid.62562.350000000100301493
FAU - Lim, Shiang Cheng
AU  - Lim SC
AD  - RTI International, Kuala Lumpur, Malaysia.
FAU - Kocher, Erica
AU  - Kocher E
AD  - Center for Global Noncommunicable Diseases, RTI International, Seattle,
      USA.grid.62562.350000000100301493
FAU - Kowal, Paul
AU  - Kowal P
AD  - Better Health Programme Southeast Asia, Yangon, Myanmar.
FAU - Chandran, Arunah
AU  - Chandran A
AD  - Ministry of Health, Putrajaya, Malaysia.grid.415759.b0000 0001 0690 5255
FAU - Kual, Aaron
AU  - Kual A
AD  - British High Commission, Kuala Lumpur, Malaysia.
FAU - Khaw, Fu-Meng
AU  - Khaw FM
AD  - Public Health England, London, UK.grid.271308.f0000 0004 5909 016X
FAU - Mustapha, Feisul Idzwan
AU  - Mustapha FI
AD  - Ministry of Health, Putrajaya, Malaysia.grid.415759.b0000 0001 0690 5255
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - Implement Sci Commun
JT  - Implementation science communications
JID - 101764360
PMC - PMC7538851
OTO - NOTNLM
OT  - Community health volunteer
OT  - Digital health
OT  - Intervention
OT  - KOSPEN
OT  - Malaysia
OT  - Noncommunicable diseases
COIS- Competing interestsThe authors declare that they have no competing interests
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
CRDT- 2020/10/09 05:39
PHST- 2020/09/08 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/09 05:39 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
AID - 10.1186/s43058-020-00080-y [doi]
AID - 80 [pii]
PST - epublish
SO  - Implement Sci Commun. 2020 Oct 7;1:87. doi: 10.1186/s43058-020-00080-y.
      eCollection 2020.


PMID- 33033701
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201010
IS  - 2229-3485 (Print)
IS  - 2229-3485 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Ethics committee meetings - Online or face to face?
PG  - 121-123
LID - 10.4103/picr.PICR_97_20 [doi]
AB  - Ethics committee meetings are held periodically, with all members being
      physically present in the meeting room. During the COVID-19 pandemic, and the
      lockdown, a number of committees have resorted to the use of videoconferencing.
      Online meetings have significant advantages over physical or face-to-face
      meetings, though the guidelines and regulations imply that online meetings should
      not be the norm. Considering the advantages of online meetings in terms of saving
      time and costs, can the regulations and guidelines be tweaked to allow them even 
      after the lockdown is over?
CI  - Copyright: (c) 2020 Perspectives in Clinical Research.
FAU - Ghooi, Ravindra Bhaskar
AU  - Ghooi RB
AD  - Scientia Clinical Services, Pune, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - India
TA  - Perspect Clin Res
JT  - Perspectives in clinical research
JID - 101551517
PMC - PMC7513781
OTO - NOTNLM
OT  - Accreditation
OT  - ethics committee meetings
OT  - face-to-face
OT  - registration
OT  - videoconferencing
COIS- There are no conflicts of interest.
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
CRDT- 2020/10/09 05:39
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/10/09 05:39 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
AID - 10.4103/picr.PICR_97_20 [doi]
AID - PCR-11-121 [pii]
PST - ppublish
SO  - Perspect Clin Res. 2020 Jul-Sep;11(3):121-123. doi: 10.4103/picr.PICR_97_20. Epub
      2020 Jul 6.


PMID- 33033624
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201010
IS  - 2056-6646 (Electronic)
IS  - 2056-6646 (Linking)
VI  - 4
IP  - 10
DP  - 2020 Oct
TI  - Dimensions of Health Security-A Conceptual Analysis.
PG  - 1700003
LID - 10.1002/gch2.201700003 [doi]
AB  - Discussions of the politics and practicalities of confronting health security
      challenges-from infectious disease outbreaks to antimicrobial resistance and the 
      silent epidemic of noncommunicable diseases-hinge on the conceptualization of
      health security. There is no consensus among analysts about the specific
      parameters of health security. This inhibits comparative evaluation and critique,
      and affects the consistency of advice for policymakers. This article aims to
      contribute to debates about the meaning and scope of health security by applying 
      Baldwin's (1997) framework for conceptualizing security with a view to propose an
      alternative framing. Asking Baldwin's concept-defining questions of the health
      security literature highlights how implicit and explicit assumptions currently
      place health security squarely within a narrow traditionalist analytical
      framework. Such framing of health security is inaccurate and constraining, as
      demonstrated by practice and empirical observations. Alternative approaches to
      security propose that security politics can also be multiactor, cooperative, and 
      ethical, while being conscious of postcolonial and feminist critique in search of
      sustainable solutions to existential threats to individuals and communities. A
      broader conceptualization of health security can transform the politics of health
      security, improving health outcomes beyond acute crises and contribute to broader
      security studies' debates.
CI  - (c) 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Stoeva, Preslava
AU  - Stoeva P
AUID- ORCID: https://orcid.org/0000-0002-8626-4079
AD  - Department of Global Health & Development London School of Hygiene and Tropical
      Medicine 15-17 Tavistock Place London WC1H 9SH UK.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - Germany
TA  - Glob Chall
JT  - Global challenges (Hoboken, NJ)
JID - 101705641
PMC - PMC7533848
OTO - NOTNLM
OT  - conceptual framework
OT  - cooperative security
OT  - health security
OT  - security for individuals
COIS- The author declares no conflict of interest.
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
CRDT- 2020/10/09 05:38
PHST- 2017/01/08 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/10/09 05:38 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
AID - 10.1002/gch2.201700003 [doi]
AID - GCH2201700003 [pii]
PST - epublish
SO  - Glob Chall. 2020 Jul 28;4(10):1700003. doi: 10.1002/gch2.201700003. eCollection
      2020 Oct.


PMID- 33033622
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2055-7647 (Print)
IS  - 2055-7647 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - Yoga-based exercise to prevent falls in community-dwelling people aged 60 years
      and over: study protocol for the Successful AGEing (SAGE) yoga randomised
      controlled trial.
PG  - e000878
LID - 10.1136/bmjsem-2020-000878 [doi]
AB  - INTRODUCTION: Falls significantly reduce independence and quality of life in
      older age. Balance-specific exercise prevents falls in people aged 60+ years.
      Yoga is growing in popularity and can provide a high challenge to balance;
      however, the effect of yoga on falls has not been evaluated. This trial aims to
      establish the effect on falls of a yoga exercise programme compared with a yoga
      relaxation programme in community-dwellers aged 60+ years. METHOD AND ANALYSIS:
      This randomised controlled trial will involve 560 community-dwelling people aged 
      60+ years. Participants will be randomised to either: (1) the Successful AGEing
      (SAGE) yoga exercise programme or (2) a yoga relaxation programme. Primary
      outcome is rate of falls in the 12 months post randomisation. Secondary outcomes 
      include mental well-being, physical activity, health-related quality of life,
      balance self-confidence, physical function, pain, goal attainment and sleep
      quality at 12 months after randomisation. The number of falls per person-year
      will be analysed using negative binomial regression models to estimate
      between-group difference in fall rates. Generalised linear models will assess the
      effect of group allocation on the continuously scored secondary outcomes,
      adjusting for baseline scores. An economic analysis will compare the
      cost-effectiveness and cost-utility of the two yoga programmes. ETHICS AND
      DISSEMINATION: Protocol was approved by the Human Research Ethics Committee at
      The University of Sydney, Australia (approval 2019/604). Trial results will be
      disseminated via peer-reviewed articles, conference presentations, lay summaries.
      TRIAL REGISTRATION NUMBER: The protocol for this trial is registered with the
      Australian New Zealand Clinical Trials Registry (ACTRN12619001183178).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oliveira, Juliana S
AU  - Oliveira JS
AD  - Institute for Musculoskeletal Health, Faculty of Medicine and Health, The
      University of Sydney, Camperdown, Australia.
FAU - Sherrington, Catherine
AU  - Sherrington C
AD  - Institute for Musculoskeletal Health, Faculty of Medicine and Health, The
      University of Sydney, Camperdown, Australia.
FAU - Lord, Stephen
AU  - Lord S
AD  - Neuroscience Research Australia, University of New South Wales, Sydney,
      Australia.
FAU - Sesto, Romina
AU  - Sesto R
AD  - Yoga to Go Studio, Petersham, Australia.
FAU - Youkhana, Sabrina
AU  - Youkhana S
AD  - Institute for Musculoskeletal Health, Faculty of Medicine and Health, The
      University of Sydney, Camperdown, Australia.
FAU - Camara, Giane C
AU  - Camara GC
AD  - Institute for Musculoskeletal Health, Faculty of Medicine and Health, The
      University of Sydney, Camperdown, Australia.
FAU - Grunseit, Anne C
AU  - Grunseit AC
AD  - Prevention Research Collaboration, School of Public Health, Faculty of Medicine
      and Health, The University of Sydney, Camperdown, Australia.
FAU - Bauman, Adrian
AU  - Bauman A
AD  - Prevention Research Collaboration, School of Public Health, Faculty of Medicine
      and Health, The University of Sydney, Camperdown, Australia.
FAU - Anstey, Kaarin J
AU  - Anstey KJ
AD  - Neuroscience Research Australia, University of New South Wales, Sydney,
      Australia.
FAU - Shepherd, Roberta B
AU  - Shepherd RB
AD  - School of Health Sciences, Faculty of Medicine and Health, The University of
      Sydney, Camperdown, Australia.
FAU - Tiedemann, Anne
AU  - Tiedemann A
AUID- ORCID: 0000-0003-4076-2870
AD  - Institute for Musculoskeletal Health, Faculty of Medicine and Health, The
      University of Sydney, Camperdown, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMJ Open Sport Exerc Med
JT  - BMJ open sport & exercise medicine
JID - 101681007
PMC - PMC7534729
OTO - NOTNLM
OT  - Aging
OT  - Exercise
OT  - Fall
OT  - Prevention
OT  - Randomised controlled trial
COIS- Competing interests: RS and SY are practicing yoga instructors.
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
CRDT- 2020/10/09 05:38
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/10/09 05:38 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
AID - 10.1136/bmjsem-2020-000878 [doi]
AID - bmjsem-2020-000878 [pii]
PST - epublish
SO  - BMJ Open Sport Exerc Med. 2020 Sep 29;6(1):e000878. doi:
      10.1136/bmjsem-2020-000878. eCollection 2020.


PMID- 33033563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201010
IS  - 1948-0210 (Print)
IS  - 1948-0210 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 26
TI  - Human mesenchymal stem cells derived from umbilical cord and bone marrow exert
      immunomodulatory effects in different mechanisms.
PG  - 1032-1049
LID - 10.4252/wjsc.v12.i9.1032 [doi]
AB  - BACKGROUND: Mesenchymal stem cells (MSCs) are an attractive tool to treat
      graft-versus-host disease because of their unique immunoregulatory properties.
      Although human bone marrow-derived MSCs (BM-MSCs) were the most widely used MSCs 
      in cell therapy until recently, MSCs derived from human umbilical cords (UC-MSCs)
      have gained popularity as cell therapy material for their ethical and noninvasive
      collection. AIM: To investigate the difference in mechanisms of the
      immunosuppressive effects of UC-MSCs and BM-MSCs. METHODS: To analyze soluble
      factors expressed by MSCs, such as indolamine 2,3-dioxygenase, cyclooxygenase-2, 
      prostaglandin E2 and interleukin (IL)-6, inflammatory environments in vitro were 
      reconstituted with combinations of interferon-gamma (IFN-gamma), tumor necrosis
      factor alpha and IL-1beta or with IFN-gamma alone. Activated T cells were
      cocultured with MSCs treated with indomethacin and/or anti-IL-10. To assess the
      ability of MSCs to inhibit T helper 17 cells and induce regulatory T cells,
      induced T helper 17 cells were cocultured with MSCs treated with indomethacin or 
      anti-IL-10. Xenogeneic graft-versus-host disease was induced in NOG mice
      (NOD/Shi-scid/IL-2Rgamma(null)) and UC-MSCs or BM-MSCs were treated as cell
      therapies. RESULTS: Our data demonstrated that BM-MSCs and UC-MSCs shared similar
      phenotypic characteristics and immunomodulation abilities. BM-MSCs expressed more
      indolamine 2,3-dioxygenase after cytokine stimulation with different combinations
      of IFN-gamma, tumor necrosis factor alpha-alpha and IL-1beta or IFN-gamma alone. 
      UC-MSCs expressed more prostaglandin E2, IL-6, programmed death-ligand 1 and 2 in
      the in vitro inflammatory environment. Cyclooxygenase-2 and IL-10 were key
      factors in the immunomodulatory mechanisms of both MSCs. In addition, UC-MSCs
      inhibited more T helper 17 cells and induced more regulatory T cells than
      BM-MSCs. UC-MSCs and BM-MSCs exhibited similar effects on attenuating
      graft-versus-host disease. CONCLUSION: UC-MSCs and BM-MSCs exert similar
      immunosuppressive effects with different mechanisms involved. These findings
      suggest that UC-MSCs have distinct immunoregulatory functions and may substitute 
      BM-MBSCs in the field of cell therapy.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Song, Yunejin
AU  - Song Y
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
FAU - Lim, Jung-Yeon
AU  - Lim JY
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
FAU - Lim, Taekyu
AU  - Lim T
AD  - Division of Hematology Oncology, Department of Internal Medicine, Veterans Health
      Service Medical Center, Seoul 05368, South Korea.
FAU - Im, Keon-Il
AU  - Im KI
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
FAU - Kim, Nayoun
AU  - Kim N
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
FAU - Nam, Young-Sun
AU  - Nam YS
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
FAU - Jeon, Young-Woo
AU  - Jeon YW
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
FAU - Shin, Jong Chul
AU  - Shin JC
AD  - Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA
      University, Seongnam 13496, South Korea.
FAU - Ko, Hyun Sun
AU  - Ko HS
AD  - Department of Obstetrics and Gynecology, College of Medicine, The Catholic
      University of Korea, Seoul 06591, South Korea.
FAU - Park, In Yang
AU  - Park IY
AD  - Department of Obstetrics and Gynecology, College of Medicine, The Catholic
      University of Korea, Seoul 06591, South Korea.
FAU - Cho, Seok-Goo
AU  - Cho SG
AD  - Institute for Translational Research and Molecular Imaging, College of Medicine, 
      The Catholic University of Korea, Seoul 06591, South Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Stem Cells
JT  - World journal of stem cells
JID - 101535826
PMC - PMC7524695
OTO - NOTNLM
OT  - Cell therapy
OT  - Graft-versus-host disease
OT  - Immunomodulation
OT  - Mesenchymal stem cells
OT  - Umbilical cord
OT  - Xenogeneic mouse model
COIS- Conflict-of-interest statement: The authors have nothing to disclose.
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
CRDT- 2020/10/09 05:38
PHST- 2020/03/20 00:00 [received]
PHST- 2020/06/20 00:00 [revised]
PHST- 2020/07/19 00:00 [accepted]
PHST- 2020/10/09 05:38 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
AID - 10.4252/wjsc.v12.i9.1032 [doi]
PST - ppublish
SO  - World J Stem Cells. 2020 Sep 26;12(9):1032-1049. doi: 10.4252/wjsc.v12.i9.1032.


PMID- 33033535
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201010
IS  - 1880-487X (Print)
IS  - 1880-487X (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Factors associated with the awareness of contraceptive methods, understanding the
      prevention of HIV/AIDS and the perception of HIV/AIDS risk among secondary school
      students in Dar es Salaam, Tanzania.
PG  - 155-163
LID - 10.2185/jrm.2020-001 [doi]
AB  - Objective: To assess the awareness of contraceptive methods, understanding of
      HIV/AIDS prevention and the perception of HIV/AIDS risks among secondary school
      students in Tanzania. Methods: An anonymous self-administered questionnaire
      survey was conducted among secondary school students in Tanzania. The
      questionnaire included sociodemographic characteristics, awareness of
      contraceptive methods, an understanding of HIV/AIDS prevention, and the
      perception of HIV/AIDS risks. Three secondary schools were selected by
      considering the gender balance and location, which included the urban and
      surrounding areas. The research objectives, methods, and ethical considerations
      were explained, and the students voluntarily completed the questionnaire.
      Results: A total of 233 responses were collected, and 204 responses were
      considered valid for the analysis. The mean and standard deviation of age were
      18.5 +/- 1.0. Regardless of the gender, age, religion, and major course of study,
      the maternal educational status (adjusted odds ratio [AOR]: 3.129; 95% confidence
      interval [CI]: 1.324, 7.398; P=0.009) and the number of information sources (AOR:
      7.023, 95% CI: 3.166, 15.579, P<0.001) demonstrated associations with the
      awareness of contraceptive methods. Respondents who lived outside a dormitory
      (AOR: 3.782; 95% CI: 1.650, 8.671; P=0.002) and who currently had a partner (AOR:
      3.616; 95% CI: 1.486, 8.800; P=0.005) were associated with a high level of
      understanding of HIV/AIDS prevention regardless of gender, age, religion, and
      major course of study. Respondents with few information sources were associated
      with a high level of perception of HIV/AIDS risks (AOR: 0.293; 95% CI: 0.115,
      0.747; P=0.010), regardless of gender, age, religion, and major course of study. 
      Conclusion: Factors associated with the awareness of contraceptive methods, the
      understanding of HIV/AIDS prevention, and perception of HIV/AIDS risks were not
      consistent. To ensure the improvement of these factors among secondary school
      students, sexual health education should be integrated into educational programs 
      and provided holistically.
CI  - (c)2020 The Japanese Association of Rural Medicine.
FAU - Ohnishi, Mayumi
AU  - Ohnishi M
AD  - Nagasaki University Graduate School of Biomedical Sciences, Japan.
FAU - Leshabari, Sebalda
AU  - Leshabari S
AD  - School of Nursing, Muhimbili University of Health and Allied Sciences, Tanzania.
FAU - Tanaka, Junichi
AU  - Tanaka J
AD  - Nagasaki University Graduate School of Biomedical Sciences, Japan.
FAU - Nishihara, Mika
AU  - Nishihara M
AD  - Nagasaki University Graduate School of Biomedical Sciences, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Japan
TA  - J Rural Med
JT  - Journal of rural medicine : JRM
JID - 101274897
PMC - PMC7530594
OTO - NOTNLM
OT  - HIV/AIDS prevention
OT  - Tanzania
OT  - contraception
OT  - secondary school students
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
CRDT- 2020/10/09 05:38
PHST- 2020/02/04 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/10/09 05:38 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
AID - 10.2185/jrm.2020-001 [doi]
AID - 2020-001 [pii]
PST - ppublish
SO  - J Rural Med. 2020 Oct;15(4):155-163. doi: 10.2185/jrm.2020-001. Epub 2020 Oct 1.


PMID- 33033210
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20201014
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 370
IP  - 6513
DP  - 2020 Oct 9
TI  - Hidden ethical costs of conservation.
PG  - 179-180
LID - 10.1126/science.abe2505 [doi]
FAU - Lynch, Kate E
AU  - Lynch KE
AD  - Department of Philosophy, The University of Sydney, Camperdown, NSW 2006,
      Australia. kate.lynch@sydney.edu.au.
FAU - Blumstein, Daniel T
AU  - Blumstein DT
AD  - Department of Ecology and Evolutionary Biology, Institute of the Environment and 
      Sustainability, University of California, Los Angeles, Los Angeles, CA 90095,
      USA.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
SB  - IM
CON - Science. 2020 Aug 7;369(6504):629-630. PMID: 32764058
CIN - Science. 2020 Oct 9;370(6513):181. PMID: 33033213
MH  - *Animal Welfare
MH  - Animals
MH  - Costs and Cost Analysis
MH  - *Morals
EDAT- 2020/10/10 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/09 05:32
PHST- 2020/10/09 05:32 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 370/6513/179-b [pii]
AID - 10.1126/science.abe2505 [doi]
PST - ppublish
SO  - Science. 2020 Oct 9;370(6513):179-180. doi: 10.1126/science.abe2505.


PMID- 33033114
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Who is Phoenix?
PG  - 753-754
LID - 10.1136/medethics-2020-106822 [doi]
FAU - D'Angelo, Roberto
AU  - D'Angelo R
AD  - The Institute of Contemporary Psychoanalysis, Los Angeles, California, USA
      roberto@robertodangelo.com.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20201008
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):743-752. PMID: 32709753
CIN - J Med Ethics. 2020 Nov;46(11):761-762. PMID: 33087409
MH  - Humans
MH  - *Puberty
PMC - PMC7656143
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/08/19 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/10/09 05:31 [entrez]
AID - medethics-2020-106822 [pii]
AID - 10.1136/medethics-2020-106822 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):753-754. doi: 10.1136/medethics-2020-106822. Epub
      2020 Oct 8.


PMID- 33033101
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV
      infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess
      safety, tolerance, immunological and virological activity.
PG  - e041359
LID - 10.1136/bmjopen-2020-041359 [doi]
AB  - INTRODUCTION: Continuous antiretroviral therapy (ART) suppresses HIV plasma viral
      load (pVL) to very low levels, which allows for some immune recovery.
      Discontinuation of ART leads to pVL rebound from reservoirs of persistence and
      latency, and progressive immunodeficiency. One promising but controversial
      strategy targeting CD4(+) T lymphocytes with a monoclonal antibody (mAb) against 
      alpha4beta7 integrin has shown promise through sustained virological remission of
      pVL (SVR) in SIV239-infected rhesus macaques. We propose to assess the safety and
      tolerability of vedolizumab, a licensed humanised mAb against human alpha4beta7
      integrin, in healthy HIV-infected adults on ART. This study will also assess, by 
      analytical treatment interruption (ATI), whether vedolizumab treatment can induce
      SVR beyond ART and vedolizumab treatment. METHODS AND ANALYSIS: The
      HIV-ART-vedolizumab-ATI (HAVARTI) trial is a single-arm, dose-ranging pilot trial
      in healthy HIV-positive adult volunteers receiving ART. Twelve consenting persons
      will be enrolled in sequential groups of 4 to each serial dosing vedolizumab
      regimen (300 mg, 150 mg, 75 mg). The primary outcomes are: (1) to assess the
      safety and tolerability of seven serial infusions of vedolizumab at each of three
      doses; (2) to identify the immunovirological measures, including pVL and T-cell
      kinetics, that characterise HIV/ART cases before, during, after vedolizumab
      treatment and ATI; and (3) to seek SVR of pVL after ATI. Secondary outcomes will 
      include immune reconstitution and pVL suppression as well as immune
      reconstitution and long-term safety following re-initiation of ART in the absence
      of SVR. ETHICS AND DISSEMINATION: The study protocol was approved by the Ottawa
      Health Science Network-REB and by the Health Canada Therapeutic Products
      Directorate. A Data Safety Monitor will review safety information at regular
      intervals. The final manuscript will be submitted to an open access journal
      within a year of study completion. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov 
      NCT03147859; https://clinicaltrials.gov/ct2/show/NCT03147859.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McGuinty, Michaeline
AU  - McGuinty M
AUID- ORCID: 0000-0002-8724-1733
AD  - Medicine, Division of Infectious Diseases, Ottawa Hospital General Campus,
      Ottawa, Ontario, Canada mimcguinty@toh.on.ca.
FAU - Angel, Jonathan B
AU  - Angel JB
AD  - Medicine, Division of Infectious Diseases, Ottawa Hospital General Campus,
      Ottawa, Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Cooper, Curtis L
AU  - Cooper CL
AUID- ORCID: 0000-0002-3368-3499
AD  - Medicine, Division of Infectious Diseases, Ottawa Hospital General Campus,
      Ottawa, Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Cowan, Juthaporn
AU  - Cowan J
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
AD  - Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - MacPherson, Paul A
AU  - MacPherson PA
AD  - Medicine, Division of Infectious Diseases, Ottawa Hospital General Campus,
      Ottawa, Ontario, Canada.
FAU - Kumar, Ashok
AU  - Kumar A
AD  - Pathology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario,
      Canada.
FAU - Murthy, Sanjay
AU  - Murthy S
AD  - Medicine, Division of Gastroenterology, Ottawa Hospital General Campus, Ottawa,
      Ontario, Canada.
FAU - Sy, Richmond
AU  - Sy R
AD  - Medicine, Division of Gastroenterology, Ottawa Hospital General Campus, Ottawa,
      Ontario, Canada.
FAU - Dennehy, Michelle
AU  - Dennehy M
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Tremblay, Nancy
AU  - Tremblay N
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Byrareddy, Siddappa N
AU  - Byrareddy SN
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, Omaha, Nebraska, USA.
FAU - Cameron, D William
AU  - Cameron DW
AD  - Medicine, Division of Infectious Diseases, Ottawa Hospital General Campus,
      Ottawa, Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03147859
GR  - CTNPT 031/CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201008
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 9RV78Q2002 (vedolizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anti-Retroviral Agents/administration & dosage
MH  - *Antibodies, Monoclonal, Humanized/administration & dosage
MH  - CD4-Positive T-Lymphocytes
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *HIV Infections/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Viral Load
MH  - Young Adult
PMC - PMC7545629
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *clinical trials
OT  - *immunology
OT  - *inflammatory bowel disease
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - bmjopen-2020-041359 [pii]
AID - 10.1136/bmjopen-2020-041359 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 8;10(10):e041359. doi: 10.1136/bmjopen-2020-041359.


PMID- 33033100
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Formative independent evaluation of a digital change programme in the English
      National Health Service: study protocol for a longitudinal qualitative study.
PG  - e041275
LID - 10.1136/bmjopen-2020-041275 [doi]
AB  - INTRODUCTION: Many countries are launching large-scale, digitally enabled change 
      programmes as part of efforts to improve the quality, safety and efficiency of
      care. We have been commissioned to conduct an independent evaluation of a major
      national change programme, the Global Digital Exemplar (GDE) Programme, which
      aims to develop exemplary digital health solutions and encourage their wider
      adoption by creating a learning ecosystem across English National Health Service 
      (NHS) provider organisations. METHODS AND ANALYSIS: This theoretically informed, 
      qualitative, longitudinal formative evaluation comprises five inter-related work 
      packages. We will conduct a combination of 12 in-depth and 24 broader qualitative
      case studies in GDE sites exploring digital transformation, local learning and
      mechanisms of spread of knowledge within the Programme and across the wider NHS. 
      Data will be collected through a combination of semistructured interviews with
      managers, implementation staff (clinical and non-clinical), vendors and
      policymakers, plus non-participant observations of meetings, site visits,
      workshops and documentary analysis of strategic local and national plans. Data
      will be analysed through inductive and deductive methods, beginning with in-depth
      case study sites and testing the findings against data from the wider sample and 
      national stakeholders. ETHICS AND DISSEMINATION: This work is commissioned as
      part of a national change programme and is therefore a service evaluation. We
      have ethical approval from the University of Edinburgh. Results will be
      disseminated at six monthly intervals to national policymakers, and made
      available via our publicly accessible website. We will also identify lessons for 
      the management and evaluation of large-scale evolving digital health change
      programmes that are of international relevance.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Cresswell, Kathrin
AU  - Cresswell K
AUID- ORCID: 0000-0001-6634-9537
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK
      Kathrin.Cresswell@ed.ac.uk.
FAU - Sheikh, Aziz
AU  - Sheikh A
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK.
FAU - Dean Franklin, Bryony
AU  - Dean Franklin B
AD  - School of Pharmacy, University College London, London, UK.
FAU - Krasuska, Marta
AU  - Krasuska M
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK.
FAU - Nguyen, Hung
AU  - Nguyen H
AD  - School of Social and Political Science, University of Edinburgh, Edinburgh, UK.
FAU - Hinder, Susan
AU  - Hinder S
AD  - School of Social and Political Science, University of Edinburgh, Edinburgh, UK.
FAU - Lane, Wendy
AU  - Lane W
AD  - NHS Arden and Greater East Midlands Commissioning Support Unit, Warwick, UK.
FAU - Mozaffar, Hajar
AU  - Mozaffar H
AD  - Business School, University of Edinburgh, Edinburgh, UK.
FAU - Mason, Kathy
AU  - Mason K
AD  - NHS Arden and Greater East Midlands Commissioning Support Unit, Warwick, UK.
FAU - Eason, Sally
AU  - Eason S
AD  - NHS Arden and Greater East Midlands Commissioning Support Unit, Warwick, UK.
FAU - Potts, Henry
AU  - Potts H
AD  - Centre for Health Informatics and Multiprofessional Education, University College
      London, London, UK.
FAU - Williams, Robin
AU  - Williams R
AUID- ORCID: 0000-0002-9044-4611
AD  - School of Social and Political Science, University of Edinburgh, Edinburgh, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201008
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Ecosystem
MH  - Humans
MH  - Longitudinal Studies
MH  - Qualitative Research
MH  - *State Medicine
PMC - PMC7545630
OTO - NOTNLM
OT  - *health informatics
OT  - *health policy
OT  - *qualitative research
COIS- Competing interests: All authors are investigators on the evaluation of the GDE
      Programme (https://www.ed.ac.uk/usher/digital-exemplars). AS was a member of the 
      Working Group that produced Making IT Work, and was an assessor in selecting GDE 
      sites. BDF supervises a PhD student partly funded by Cerner, unrelated to this
      paper.
EDAT- 2020/10/10 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - bmjopen-2020-041275 [pii]
AID - 10.1136/bmjopen-2020-041275 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 8;10(10):e041275. doi: 10.1136/bmjopen-2020-041275.


PMID- 33033098
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Safety and efficacy of larval therapy on treating leg ulcers: a protocol for
      systematic review and meta-analysis.
PG  - e039898
LID - 10.1136/bmjopen-2020-039898 [doi]
AB  - INTRODUCTION: Leg ulcers (LUs) not only seriously affect life and work of
      patients, but also bring huge economic burden to the society. As a potential
      underused biological debridement, larval therapy provides help for the treatment 
      of LUs. The purpose of our research is to assess whether patients with LUs can
      benefit from larval therapy. METHODS AND ANALYSIS: The following electronic
      databases will be searched: PubMed, EMBASE, Web of Science, the Cochrane Library,
      China National Knowledge Infrastructure Database, Wanfang Database and Chinese
      Biological Medicine. Randomised controlled trials are eligible for inclusion.
      There will be no restrictions with respect to language and search date is up to
      June 2020. Primary outcomes investigated are complete healing rate after
      treatment, time to ulcer healing, reduction of wound surface area and adverse
      events. Risk ratios will be used for categorical data; weighted mean difference
      will be used for measurement data. Subgroup analysis and sensitivity analysis
      will be considered if heterogeneity exists. The results of data synthesis will be
      performed by narrative summary and quantitative analysis. ETHICS AND
      DISSEMINATION: This systematic review does not require the approval of the ethics
      committee because individual data on patients are not collected. The results of
      the study will be disseminated in peer-reviewed journals. PROSPERO REGISTRATION
      NUMBER: CRD42020176953.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fan, Weijing
AU  - Fan W
AD  - Peripheral vascular disease department, Shuguang Hospital Affiliated to Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
AD  - Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Yang, Baozhong
AU  - Yang B
AD  - Peripheral vascular disease department, Dongfang Hospital Affiliated to Beijing
      University of Chinese Medicine, Beijing, China 18811023202@126.com
      18601026336@163.com.
FAU - Hu, Xiaoming
AU  - Hu X
AD  - Peripheral vascular disease department, Shuguang Hospital Affiliated to Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
FAU - Yang, Xiao
AU  - Yang X
AD  - Peripheral vascular disease department, Shuguang Hospital Affiliated to Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
FAU - Shi, Chenyan
AU  - Shi C
AD  - Peripheral vascular disease department, Shuguang Hospital Affiliated to Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
FAU - Liu, Guobin
AU  - Liu G
AUID- ORCID: 0000-0002-6598-8545
AD  - Peripheral vascular disease department, Shuguang Hospital Affiliated to Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China 18811023202@126.com
      18601026336@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201008
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Animals
MH  - China
MH  - Humans
MH  - Larva
MH  - *Leg Ulcer/therapy
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
MH  - *Varicose Ulcer
MH  - Wound Healing
PMC - PMC7545619
OTO - NOTNLM
OT  - *diabetic foot
OT  - *vascular surgery
OT  - *wound management
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - bmjopen-2020-039898 [pii]
AID - 10.1136/bmjopen-2020-039898 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 8;10(10):e039898. doi: 10.1136/bmjopen-2020-039898.


PMID- 33033094
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Skin and wound care for individuals with graft versus host disease: a scoping
      review protocol.
PG  - e038567
LID - 10.1136/bmjopen-2020-038567 [doi]
AB  - INTRODUCTION: Graft versus host disease (GVHD) is a major cause of morbidity and 
      mortality following allogenic haematopoietic stem cell transplantation. It is an 
      immunological reaction, involving many organs, leading to a wide range of
      clinical manifestations. Cutaneous manifestations are the most common sign of
      GVHD, as well as pain, vulnerability to infection and impaired quality of
      life.Despite the burdens that cutaneous GVHD presents for patients, their carers 
      and the healthcare system, limited evidence is available to guide day to day
      supportive skin care and wound management. Our objective is to conduct a scoping 
      review to map the evidence for skin and wound management and identify
      evidence-practice gaps for individuals with acute or chronic cutaneous GVHD.
      METHODS AND ANALYSIS: Our review will follow the scoping review methodological
      framework developed by Arksey and O'Malley and further refined by the Joanna
      Briggs Institute Scoping Review Methods Manual. Databases to be searched include;
      PubMed, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials,
      Cumulative Index to Nursing and Allied Health Literature, Web of Science and
      MEDLINE from 1970 to February 2020. Database searches will be supplemented with
      searches from relevant reference lists and grey literature. Descriptive
      statistical analyses will be performed. ETHICS AND DISSEMINATION: This scoping
      review does not require ethical approval. Findings will be disseminated through a
      peer-reviewed publication and conference presentation.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Campbell, Jill
AU  - Campbell J
AUID- ORCID: 0000-0002-1253-8831
AD  - Skin Integrity Service, Royal Brisbane and Women's Hospital, Herston, Queensland,
      Australia jill.campbell@qut.edu.au.
AD  - School of Nursing, Queensland University of Technology, Brisbane, Queensland,
      Australia.
FAU - Gavin, Nicole
AU  - Gavin N
AD  - School of Nursing, Queensland University of Technology, Brisbane, Queensland,
      Australia.
AD  - Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland,
      Australia.
FAU - Button, Elise
AU  - Button E
AD  - School of Nursing, Queensland University of Technology, Brisbane, Queensland,
      Australia.
AD  - Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland,
      Australia.
FAU - Roberts, Natasha
AU  - Roberts N
AD  - Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland,
      Australia.
AD  - School of Public Health and Social Work, Queensland University of Technology,
      Brisbane, Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Cross-Sectional Studies
MH  - *Graft vs Host Disease
MH  - Humans
MH  - Quality of Life
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Skin Care
MH  - Skin Diseases/therapy
PMC - PMC7545636
OTO - NOTNLM
OT  - *adult oncology
OT  - *dermatology
OT  - *wound management
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - bmjopen-2020-038567 [pii]
AID - 10.1136/bmjopen-2020-038567 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 8;10(10):e038567. doi: 10.1136/bmjopen-2020-038567.


PMID- 33033091
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Perioperative patient-controlled regional analgesia versus patient-controlled
      intravenous analgesia for patients with critical limb ischaemia: a study protocol
      for a randomised controlled trial.
PG  - e037879
LID - 10.1136/bmjopen-2020-037879 [doi]
AB  - INTRODUCTION: Both regional analgesia and intravenous analgesia are frequently
      used perioperatively for patients with critical limb ischaemia (CLI).
      Nevertheless, the comparison of perioperative effect of regional and intravenous 
      analgesia has not yet been thoroughly illustrated. This study will
      comprehensively compare patient-controlled regional analgesia (PCRA) and
      patient-controlled intravenous analgesia (PCIA) as two different perioperative
      analgesia approaches for patients with CLI. It investigates their effects on
      analgesia, reperfusion and the quality of recovery perioperatively, also aims to 
      provide clinical evidence to those non-surgical patients with non-reconstructable
      arteries. METHODS AND ANALYSIS: This trial is a randomised, single-centre,
      open-label, parallel trial with target sample size of 52 in total. Eligible
      participants will be randomly allocated to the PCRA group (group R) or the PCIA
      group (group I) after admission. Participants in group R will receive
      ultrasound-guided subgluteal sciatic catheterisation, followed by continuous PCRA
      infusion (0.2% ropivacaine 15 mL as loading dose, 8 mL/hour as background with a 
      patient-controlled bolus of 6 mL). Participants in group I will receive PCIA
      (morphine is given in boluses of 1 mg as needed, background infusion at 1
      mg/hour). Data will be collected at baseline (T0), 2 hours before
      revascularisation treatment (T1) and 2 hours before discharge (T2). The primary
      outcomes include the Numerical Rating Scale pain score at T1 and T2. The
      secondary outcomes include the perioperative transcutaneous oxygen pressure, the 
      Tissue Haemoglobin Index, Hospital Anxiety and Depression Scale at T1 and T2; the
      Patient Global Impression of Change and patient satisfaction at T1 and T2; the
      perioperative cumulative morphine consumption, the length of postoperative
      hospital stay and adverse events. ETHICS AND DISSEMINATION: This study received
      authorisation from the Institutional Review Board of Peking Union Medical College
      Hospital on 21 March 2017 (approval no. ZS-1289X). Study findings will be
      disseminated through presentations at scientific conferences or publications in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial
      Registry (ChiCTR2000029298). PROTOCOL VERSION: V.4CP.B2 (15 June 2020).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Si
AU  - Chen S
AUID- ORCID: 0000-0001-6832-1095
AD  - Department of Anesthesiology, Peking Union Medical College Hospital, Beijing,
      China.
FAU - Xu, Zhonghuang
AU  - Xu Z
AD  - Department of Anesthesiology, Peking Union Medical College Hospital, Beijing,
      China.
FAU - Liu, Hongju
AU  - Liu H
AD  - Department of Anesthesiology, Peking Union Medical College Hospital, Beijing,
      China.
FAU - Zhang, Yuelun
AU  - Zhang Y
AUID- ORCID: 0000-0001-7990-9003
AD  - Medical Research Center, Peking Union Medical College Hospital, Beijing, China.
FAU - Zhang, Jiao
AU  - Zhang J
AD  - Department of Anesthesiology, Peking Union Medical College Hospital, Beijing,
      China.
FAU - Chen, Yuexin
AU  - Chen Y
AD  - Department of Vascular Surgery, Peking Union Medical College Hospital, Beijing,
      China.
FAU - Zheng, Yuehong
AU  - Zheng Y
AUID- ORCID: 0000-0002-0704-5469
AD  - Department of Vascular Surgery, Peking Union Medical College Hospital, Beijing,
      China yuehongzheng@yahoo.com.
FAU - Huang, Yuguang
AU  - Huang Y
AD  - Department of Anesthesiology, Peking Union Medical College Hospital, Beijing,
      China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201008
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anesthetics, Local)
SB  - IM
MH  - Analgesia, Patient-Controlled
MH  - Analgesics, Opioid
MH  - *Anesthetics, Local
MH  - Humans
MH  - Ischemia/drug therapy
MH  - Pain Measurement
MH  - *Pain, Postoperative/drug therapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7545635
OTO - NOTNLM
OT  - *pain management
OT  - *vascular surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037879 [pii]
AID - 10.1136/bmjopen-2020-037879 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 8;10(10):e037879. doi: 10.1136/bmjopen-2020-037879.


PMID- 33033088
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 8
TI  - Effectiveness and cost-effectiveness of a progressive, individualised walking and
      education programme for prevention of low back pain recurrence in adults: study
      protocol for the WalkBack randomised controlled trial.
PG  - e037149
LID - 10.1136/bmjopen-2020-037149 [doi]
AB  - INTRODUCTION: Low back pain (LBP) is recognised globally as a prevalent, costly
      and disabling condition. Recurrences are common and contribute to much of the
      burden of LBP. Current evidence favours exercise and education for prevention of 
      LBP recurrence, but an optimal intervention has not yet been established. Walking
      is a simple, widely accessible, low-cost intervention that has yet to be
      evaluated. This randomised controlled trial (RCT) aims to establish the
      effectiveness and cost-effectiveness of a progressive and individualised walking 
      and education programme (intervention) for the prevention of LBP recurrences in
      adults compared with no treatment (control). METHODS AND ANALYSIS: A pragmatic,
      two-armed RCT comparing walking and education (n=349) with a no treatment control
      group (n=349). Inclusion criteria are adults recovered from an episode of
      non-specific LBP within the last 6 months. Those allocated to the intervention
      group will receive six sessions (three face to face and three telephone
      delivered) with a trained physiotherapist to facilitate a progressive walking
      programme and education over a 6-month period. The primary outcome will be days
      to first recurrence of an episode of activity-limiting LBP. The secondary
      outcomes include days to recurrence of an episode of LBP, days to recurrence of
      an episode of LBP leading to care seeking, disability and quality of life
      measured at 3, 6, 9 and 12 months and costs associated with LBP recurrence. All
      participants will be followed up monthly for a minimum of 12 months. The primary 
      intention-to-treat analysis will assess difference in survival curves (days to
      recurrence) using the log-rank statistic. The cost-effectiveness analysis will be
      conducted from the societal perspective. ETHICS AND DISSEMINATION: Approved by
      Macquarie University Human Research Ethics Committee (Reference: 5201949218164,
      May 2019). Findings will be disseminated through publication in peer-reviewed
      journals and conference presentations. TRIAL REGISTRATION NUMBER:
      ACTRN12619001134112.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pocovi, Natasha Celeste
AU  - Pocovi NC
AUID- ORCID: 0000-0003-0617-7707
AD  - Department of Health Professions, Macquarie University, Sydney, New South Wales, 
      Australia tash.pocovi@mq.edu.au.
FAU - Lin, Chung-Wei C
AU  - Lin CC
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
FAU - Latimer, Jane
AU  - Latimer J
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
FAU - Merom, Dafna
AU  - Merom D
AD  - Department of Physical Activity and Health, Western Sydney University, Sydney,
      New South Wales, Australia.
FAU - Tiedemann, Anne
AU  - Tiedemann A
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
FAU - Maher, Christopher
AU  - Maher C
AUID- ORCID: 0000-0002-1628-7857
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
FAU - van Tulder, Maurits W
AU  - van Tulder MW
AUID- ORCID: 0000-0002-7589-8471
AD  - Health Sciences, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Macaskill, Petra
AU  - Macaskill P
AD  - Sydney School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Clavisi, Ornella
AU  - Clavisi O
AD  - Musculoskeletal Australia, Melbourne, Victoria, Australia.
FAU - Tong, Shuk Yin Kate
AU  - Tong SYK
AD  - Department of Health Professions, Macquarie University, Sydney, New South Wales, 
      Australia.
FAU - Hancock, Mark J
AU  - Hancock MJ
AD  - Department of Health Professions, Macquarie University, Sydney, New South Wales, 
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001134112
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201008
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cost-Benefit Analysis
MH  - Exercise Therapy
MH  - Humans
MH  - *Low Back Pain/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Walking
PMC - PMC7545638
OTO - NOTNLM
OT  - *clinical trial protocol
OT  - *low back pain
OT  - *secondary prevention
OT  - *walking
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037149 [pii]
AID - 10.1136/bmjopen-2020-037149 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 8;10(10):e037149. doi: 10.1136/bmjopen-2020-037149.


PMID- 33033035
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a
      two-centre, double-blind, randomised controlled trial in young children
      undergoing cardiac surgery.
PG  - e042176
LID - 10.1136/bmjopen-2020-042176 [doi]
AB  - INTRODUCTION: Myocardial protection against ischaemic-reperfusion injury is a key
      determinant of heart function and outcome following cardiac surgery in children. 
      However, with current strategies, myocardial injury occurs routinely following
      aortic cross-clamping, as demonstrated by the ubiquitous rise in circulating
      troponin. Remote ischaemic preconditioning, the application of brief, non-lethal 
      cycles of ischaemia and reperfusion to a distant organ or tissue, is a simple,
      low-risk and readily available technique which may improve myocardial protection.
      The Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial will assess
      whether remote ischaemic preconditioning, applied to both lower limbs immediately
      prior to surgery, reduces myocardial injury in cyanotic and acyanotic young
      children. METHODS AND ANALYSIS: The BRICC trial is a two-centre, double-blind,
      randomised controlled trial recruiting up to 120 young children (age 3 months to 
      3 years) undergoing primary repair of tetralogy of Fallot or surgical closure of 
      an isolated ventricular septal defect. Participants will be randomised in a 1:1
      ratio to either bilateral remote ischaemic preconditioning (3x5 min cycles) or
      sham immediately prior to surgery, with follow-up until discharge from hospital
      or 30 days, whichever is sooner. The primary outcome is reduction in area under
      the time-concentration curve for high-sensitivity (hs) troponin-T release in the 
      first 24 hours after aortic cross-clamp release. Secondary outcome measures
      include peak hs-troponin-T, vasoactive inotrope score, arterial lactate and
      central venous oxygen saturations in the first 12 hours, and lengths of stay in
      the paediatric intensive care unit and the hospital. ETHICS AND DISSEMINATION:
      The trial was approved by the West Midlands-Solihull National Health Service
      Research Ethics Committee (16/WM/0309) on 5 August 2016. Findings will be
      disseminated to the academic community through peer-reviewed publications and
      presentation at national and international meetings. Parents will be informed of 
      the results through a newsletter in conjunction with a local charity. TRIAL
      REGISTRATION NUMBER: ISRCTN12923441.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Drury, Nigel E
AU  - Drury NE
AUID- ORCID: 0000-0001-9012-6683
AD  - Paediatric Cardiac Surgery, Birmingham Children's Hospital, Birmingham, West
      Midlands, UK n.e.drury@bham.ac.uk.
AD  - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Bi, Rehana
AU  - Bi R
AD  - Paediatric Cardiac Surgery, Birmingham Children's Hospital, Birmingham, West
      Midlands, UK.
AD  - Paediatric Intensive Care, Birmingham Children's Hospital, Birmingham, West
      Midlands, UK.
FAU - Woolley, Rebecca L
AU  - Woolley RL
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West
      Midlands, UK.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Stickley, John
AU  - Stickley J
AD  - Paediatric Cardiac Surgery, Birmingham Children's Hospital, Birmingham, West
      Midlands, UK.
FAU - Morris, Kevin P
AU  - Morris KP
AD  - Paediatric Intensive Care, Birmingham Children's Hospital, Birmingham, West
      Midlands, UK.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Montgomerie, James
AU  - Montgomerie J
AD  - Paediatric Cardiac Anaesthesia, Birmingham Children's Hospital, Birmingham, West 
      Midlands, UK.
FAU - van Doorn, Carin
AU  - van Doorn C
AD  - Congenital Cardiac Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, West
      Yorkshire, UK.
FAU - Dunn, Warwick B
AU  - Dunn WB
AD  - School of Biosciences, University of Birmingham, Birmingham, West Midlands, UK.
AD  - Phenome Centre Birmingham, University of Birmingham, Birmingham, West Midlands,
      UK.
FAU - Madhani, Melanie
AU  - Madhani M
AD  - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Ives, Natalie J
AU  - Ives NJ
AD  - Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West
      Midlands, UK.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Kirchhof, Paulus
AU  - Kirchhof P
AUID- ORCID: 0000-0002-1881-0197
AD  - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, West 
      Midlands, UK.
AD  - Cardiology, University Heart and Vascular Center, UKE, Hamburg, Germany.
FAU - Jones, Timothy J
AU  - Jones TJ
AD  - Paediatric Cardiac Surgery, Birmingham Children's Hospital, Birmingham, West
      Midlands, UK.
AD  - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, West 
      Midlands, UK.
LA  - eng
SI  - ISRCTN/ISRCTN12923441
GR  - FS/15/49/31612/BHF_/British Heart Foundation/United Kingdom
GR  - AA/18/2/34218/BHF_/British Heart Foundation/United Kingdom
GR  - MR/M009157/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiac Surgical Procedures
MH  - Child
MH  - Double-Blind Method
MH  - Humans
MH  - *Ischemic Preconditioning
MH  - Leg/blood supply
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7542918
OTO - NOTNLM
OT  - *clinical trials
OT  - *congenital heart disease
OT  - *paediatric cardiac surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-042176 [pii]
AID - 10.1136/bmjopen-2020-042176 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e042176. doi: 10.1136/bmjopen-2020-042176.


PMID- 33033031
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Protocol for Project Fizzyo, an analytic longitudinal observational cohort study 
      of physiotherapy for children and young people with cystic fibrosis, with
      interrupted time-series design.
PG  - e039587
LID - 10.1136/bmjopen-2020-039587 [doi]
AB  - INTRODUCTION: Daily physiotherapy is believed to mitigate the progression of
      cystic fibrosis (CF) lung disease. However, physiotherapy airway clearance
      techniques (ACTs) are burdensome and the evidence guiding practice remains weak. 
      This paper describes the protocol for Project Fizzyo, which uses innovative
      technology and analysis methods to remotely capture longitudinal daily data from 
      physiotherapy treatments to measure adherence and prospectively evaluate
      associations with clinical outcomes. METHODS AND ANALYSIS: A cohort of 145
      children and young people with CF aged 6-16 years were recruited. Each
      participant will record their usual physiotherapy sessions daily for 16 months,
      using remote monitoring sensors: (1) a bespoke ACT sensor, inserted into their
      usual ACT device and (2) a Fitbit Alta HR activity tracker. Real-time breath
      pressure during ACTs, and heart rate and daily step counts (Fitbit) are synced
      using specific software applications. An interrupted time-series design will
      facilitate evaluation of ACT interventions (feedback and ACT-driven gaming).
      Baseline, mid and endpoint assessments of spirometry, exercise capacity and
      quality of life and longitudinal clinical record data will also be collected.This
      large dataset will be analysed in R using big data analytics approaches. Distinct
      ACT and physical activity adherence profiles will be identified, using cluster
      analysis to define groups of individuals based on measured characteristics and
      any relationships to clinical profiles assessed. Changes in adherence to
      physiotherapy over time or in relation to ACT interventions will be quantified
      and evaluated in relation to clinical outcomes. ETHICS AND DISSEMINATION: Ethical
      approval for this study (IRAS: 228625) was granted by the London-Brighton and
      Sussex NREC (18/LO/1038). Findings will be disseminated via peer-reviewed
      publications, at conferences and via CF clinical networks. The statistical code
      will be published in the Fizzyo GitHub repository and the dataset stored in the
      Great Ormond Street Hospital Digital Research Environment. TRIAL REGISTRATION
      NUMBER: ISRCTN51624752; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Raywood, Emma
AU  - Raywood E
AUID- ORCID: 0000-0002-0993-5115
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK e.raywood@ucl.ac.uk.
FAU - Douglas, Helen
AU  - Douglas H
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK.
FAU - Kapoor, Kunal
AU  - Kapoor K
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK.
FAU - Filipow, Nicole
AU  - Filipow N
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK.
FAU - Murray, Nicky
AU  - Murray N
AD  - Paediatric Cystic Fibrosis Unit, Royal Brompton and Harefield NHS Foundation
      Trust, London, UK.
FAU - O'Connor, Rachel
AU  - O'Connor R
AD  - Paediatric Cystic Fibrosis Centre, Royal London Hospital, Barts Health NHS Trust,
      London, UK.
FAU - Stott, Lee
AU  - Stott L
AD  - Commercial Software Engineering, Microsoft UK Ltd - Reading, Reading, UK.
FAU - Saul, Greg
AU  - Saul G
AD  - Microsoft Research Lab, Microsoft Research Ltd, Cambridge, UK.
FAU - Kuzhagaliyev, Tim
AU  - Kuzhagaliyev T
AD  - Computer Science Department, UCL, London, UK.
FAU - Davies, Gwyneth
AU  - Davies G
AUID- ORCID: 0000-0001-7937-2728
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK.
FAU - Liakhovich, Olga
AU  - Liakhovich O
AD  - Commercial Software Engineering, Microsoft UK Ltd - Reading, Reading, UK.
FAU - Van Schaik, Tempest
AU  - Van Schaik T
AUID- ORCID: 0000-0001-7745-2249
AD  - Commercial Software Engineering, Microsoft UK Ltd - Reading, Reading, UK.
FAU - Furtuna, Bianca
AU  - Furtuna B
AD  - Commercial Software Engineering, Microsoft UK Ltd - Reading, Reading, UK.
FAU - Booth, John
AU  - Booth J
AD  - Digital Research, Informatics and Virtual Environments (DRIVE) Unit, Great Ormond
      Street Hospital for Children NHS Foundation Trust, London, UK.
FAU - Shannon, Harriet
AU  - Shannon H
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK.
FAU - Bryon, Mandy
AU  - Bryon M
AD  - Department of Paediatric Psychology, Great Ormond Street Hospital for Children
      NHS Foundation Trust, London, UK.
FAU - Main, Eleanor
AU  - Main E
AUID- ORCID: 0000-0002-9739-3167
AD  - Physiotherapy, Respiratory, Critical Care and Anaesthesia Section, UCL Great
      Ormond Street Institute of Child Health, London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN51624752
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Child
MH  - Cohort Studies
MH  - *Cystic Fibrosis/therapy
MH  - Humans
MH  - Longitudinal Studies
MH  - Observational Studies as Topic
MH  - *Physical Therapy Modalities
MH  - Quality of Life
PMC - PMC7542954
OTO - NOTNLM
OT  - *cystic fibrosis
OT  - *data science
OT  - *paediatrics
OT  - *physical activity
OT  - *physiotherapy
COIS- Competing interests: GD reports personal lecture fees from Chiesi Limited for an 
      invited talk on Project Fizzyo at an educational event. All other authors report 
      no conflicts of interest in relation to this protocol.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-039587 [pii]
AID - 10.1136/bmjopen-2020-039587 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e039587. doi: 10.1136/bmjopen-2020-039587.


PMID- 33033029
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Strengthening integration of chronic care in Africa: protocol for the qualitative
      process evaluation of integrated HIV, diabetes and hypertension care in a cluster
      randomised controlled trial in Tanzania and Uganda.
PG  - e039237
LID - 10.1136/bmjopen-2020-039237 [doi]
AB  - INTRODUCTION: In sub-Saharan Africa, the burden of non-communicable diseases
      (NCDs), particularly diabetes mellitus (DM) and hypertension, has increased
      rapidly in recent years, although HIV infection remains a leading cause of death 
      among young-middle-aged adults. Health service coverage for NCDs remains very low
      in contrast to HIV, despite the increasing prevalence of comorbidity of NCDs with
      HIV. There is an urgent need to expand healthcare capacity to provide integrated 
      services to address these chronic conditions. METHODS AND ANALYSIS: This protocol
      describes procedures for a qualitative process evaluation of INTE-AFRICA, a
      cluster randomised trial comparing integrated health service provision for HIV
      infection, DM and hypertension, to the current stand-alone vertical care.
      Interviews, focus group discussions and observations of consultations and other
      care processes in two clinics (in Tanzania, Uganda) will be used to explore the
      experiences of stakeholders. These stakeholders will include health service
      users, policy-makers, healthcare providers, community leaders and members,
      researchers, non-governmental and international organisations. The exploration
      will be carried out during the implementation of the project, alongside an
      understanding of the impact of broader structural and contextual factors. ETHICS 
      AND DISSEMINATION: Ethical approval was granted by the Liverpool School of
      Tropical Medicine (UK), the National Institute of Medical Research (Tanzania) and
      TASO Research Ethics Committee (Uganda) in 2020. The evaluation will provide the 
      opportunity to document the implementation of integration over several timepoints
      (6, 12 and 18 months) and refine integrated service provision prior to scale up. 
      This synergistic approach to evaluate, understand and respond will support
      service integration and inform monitoring, policy and practice development
      efforts to involve and educate communities in Tanzania and Uganda. It will create
      a model of care and a platform of good practices and lessons learnt for other
      countries implementing integrated and decentralised community health services.
      TRIAL REGISTRATION NUMBER: ISRCTN43896688; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Van Hout, Marie-Claire
AU  - Van Hout MC
AUID- ORCID: 0000-0002-0018-4060
AD  - Public Health Institute, Liverpool John Moores University, Liverpool, Merseyside,
      UK M.C.VanHout@ljmu.ac.uk.
FAU - Bachmann, Max
AU  - Bachmann M
AUID- ORCID: 0000-0003-1770-3506
AD  - Norwich Medical School, University of East Anglia Faculty of Medicine and Health 
      Sciences, Norwich, UK.
FAU - Lazarus, Jeffrey V
AU  - Lazarus JV
AUID- ORCID: 0000-0001-9618-2299
AD  - Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of 
      Barcelona, Barcelona, Catalunya, Spain.
FAU - Shayo, Elizabeth Henry
AU  - Shayo EH
AD  - Muhimbili Centre, National Institute for Medical Research, Dar es Salaam, Dar es 
      Salaam, Tanzania, United Republic of.
FAU - Bukenya, Dominic
AU  - Bukenya D
AD  - MRC/UVRI/LSHTM Uganda Research Unit, Medical Research Council Uganda, Entebbe,
      Uganda.
FAU - Picchio, Camila A
AU  - Picchio CA
AD  - Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of 
      Barcelona, Barcelona, Catalunya, Spain.
FAU - Nyirenda, Moffat
AU  - Nyirenda M
AD  - MRC/UVRI/LSHTM Uganda Research Unit, Medical Research Council Uganda, Entebbe,
      Uganda.
FAU - Mfinanga, Sayoki Godfrey
AU  - Mfinanga SG
AD  - Muhimbili Centre, National Institute for Medical Research, Dar es Salaam, Dar es 
      Salaam, Tanzania, United Republic of.
FAU - Birungi, Josephine
AU  - Birungi J
AD  - MRC/UVRI/LSHTM Uganda Research Unit, Medical Research Council Uganda, Entebbe,
      Uganda.
FAU - Okebe, Joseph
AU  - Okebe J
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      Liverpool, Liverpool, UK.
FAU - Jaffar, Shabbar
AU  - Jaffar S
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      Liverpool, Liverpool, UK.
LA  - eng
SI  - ISRCTN/ISRCTN43896688
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Delivery of Health Care, Integrated
MH  - *Diabetes Mellitus/epidemiology/therapy
MH  - *HIV Infections/epidemiology/therapy
MH  - Humans
MH  - *Hypertension/epidemiology/therapy
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Tanzania/epidemiology
MH  - Uganda/epidemiology
PMC - PMC7542920
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *hypertension
OT  - *international health services
OT  - *organisation of health services
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-039237 [pii]
AID - 10.1136/bmjopen-2020-039237 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e039237. doi: 10.1136/bmjopen-2020-039237.


PMID- 33033027
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Acupuncture for chronic cancer-related pain: a systematic review and network
      meta-analysis protocol.
PG  - e039087
LID - 10.1136/bmjopen-2020-039087 [doi]
AB  - INTRODUCTION: Chronic cancer-related pain is one of the most common excruciating 
      symptom that can be caused by the cancer (by the primary tumour or by metastases)
      or by its treatment (surgery, chemotherapy and radiotherapy). Although multiple
      clinical trials and systematic reviews have suggested that acupuncture could be
      effective in treating chronic cancer-related pain, the comparative efficacy and
      safety of these acupuncture methods remains unclear. We, therefore, performed
      this study to evaluate and rank the efficacy and safety of different acupuncture 
      methods for chronic cancer-related pain. METHODS AND ANALYSIS: Seven databases
      will be searched, including Cochrane Library, MEDLINE, Embase, Chinese National
      Knowledge Infrastructure (CNKI), Wanfang Database, the Chongqing VIP Chinese
      Science and Technology Periodical Database and Chinese Biomedical Literature
      Database (CBM) from their inception to March 2020. The primary outcome is the
      change of pain intensity. Bayesian network meta-analysis will be conducted using 
      software R3.5.1. Finally, we will use the Grading of Recommendations Assessment, 
      Development and Evaluation System (GRADE) to assess the quality of evidence.
      ETHICS AND DISSEMINATION: Ethical approval is not required for literature-based
      studies. The results will be disseminated through peer-reviewed publication.
      PROSPERO REGISTRATION NUMBER: CRD42020165747.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yang, Jiao
AU  - Yang J
AUID- ORCID: 0000-0002-0323-2697
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Xu, Guixing
AU  - Xu G
AUID- ORCID: 0000-0002-8040-3656
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Yin, Zihan
AU  - Yin Z
AUID- ORCID: 0000-0002-1543-0551
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Cheng, Ying
AU  - Cheng Y
AUID- ORCID: 0000-0003-3377-171X
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Sun, Sheng Ming
AU  - Sun SM
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Zheng, Qianhua
AU  - Zheng Q
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Chen, Jiao
AU  - Chen J
AUID- ORCID: 0000-0003-0830-6242
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Liang, Fan-Rong
AU  - Liang FR
AUID- ORCID: 0000-0001-8518-9268
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China acuresearch@126.com zhaoling@cdutcm.edu.cn.
FAU - Zhao, Ling
AU  - Zhao L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China acuresearch@126.com zhaoling@cdutcm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - Bayes Theorem
MH  - *Cancer Pain/etiology/therapy
MH  - *Chronic Pain/etiology/therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Neoplasms/complications/therapy
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
PMC - PMC7542929
OTO - NOTNLM
OT  - *anaesthesia in oncology
OT  - *complementary medicine
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-039087 [pii]
AID - 10.1136/bmjopen-2020-039087 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e039087. doi: 10.1136/bmjopen-2020-039087.


PMID- 33033026
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Protocol of a multicentre, prospective cohort study that evaluates
      cost-effectiveness of two perioperative care strategies for potential obstructive
      sleep apnoea in morbidly obese patients undergoing bariatric surgery.
PG  - e038830
LID - 10.1136/bmjopen-2020-038830 [doi]
AB  - INTRODUCTION: Despite the high prevalence of obstructive sleep apnoea (OSA) in
      obese patients undergoing bariatric surgery, OSA is undiagnosed in the majority
      of patients and thus untreated. While untreated OSA is associated with an
      increased risk of preoperative and postoperative complications, no evidence-based
      guidelines on perioperative care for these patients are available. The aim of the
      POPCORN study (Post-Operative Pulse oximetry without OSA sCreening vs
      perioperative continuous positive airway pressure (CPAP) treatment following OSA 
      scReeNing by polygraphy (PG)) is to evaluate which perioperative strategy is the 
      most cost-effective for obese patients undergoing bariatric surgery without a
      history of OSA. METHODS AND ANALYSIS: In this multicentre observational cohort
      study, data from 1380 patients who will undergo bariatric surgery will be
      collected. Patients will receive either postoperative care with pulse oximetry
      monitoring and supplemental oxygen during the first postoperative night, or care 
      that includes preoperative PG and CPAP treatment in case of moderate or severe
      OSA. Local protocols for perioperative care in each participating hospital will
      determine into which cohort a patient is placed. The primary outcome is
      cost-effectiveness, which will be calculated by comparing all healthcare costs
      with the quality-adjusted life-years (QALYs, calculated using EQ-5D
      questionnaires). Secondary outcomes are mortality, complications within 30 days
      after surgery, readmissions, reoperations, length of stay, weight loss, generic
      quality of life (QOL), OSA-specific QOL, OSA symptoms and CPAP adherence.
      Patients will receive questionnaires before surgery and 1, 3, 6 and 12 months
      after surgery to report QALYs and other patient-reported outcomes. ETHICS AND
      DISSEMINATION: Approval from the Medical Research Ethics Committees United was
      granted in accordance with the Dutch law for Medical Research Involving Human
      Subjects Act (WMO) (reference number W17.050). Results will be submitted for
      publication in peer-reviewed journals and presented at (inter)national
      conferences. TRIAL REGISTRATION NUMBER: NTR6991.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - van Veldhuisen, Sophie L
AU  - van Veldhuisen SL
AUID- ORCID: 0000-0002-0044-8441
AD  - Department of Surgery / Vitalys Clinic, Rijnstate Ziekenhuis, Arnhem, The
      Netherlands svanveldhuisen@rijnstate.nl s.l.vanveldhuisen@gmail.com.
FAU - Kuppens, Kim
AU  - Kuppens K
AD  - Department of Pulmonary Medicine, St. Antonius Ziekenhuis, Nieuwegein, The
      Netherlands.
FAU - de Raaff, Christel A L
AU  - de Raaff CAL
AD  - Department of Surgery, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.
FAU - Wiezer, Marinus J
AU  - Wiezer MJ
AD  - Department of Surgery, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.
FAU - de Castro, Steve M M
AU  - de Castro SMM
AD  - Department of Surgery, OLVG, location West, Amsterdam, The Netherlands.
FAU - van Veen, Ruben N
AU  - van Veen RN
AD  - Department of Surgery, OLVG, location West, Amsterdam, The Netherlands.
FAU - Swank, Dingeman J
AU  - Swank DJ
AD  - Department of Surgery, Dutch Obesity Clinic (Nederlandse Obesitas Kliniek), The
      Hague, The Netherlands.
FAU - Demirkiran, Ahmet
AU  - Demirkiran A
AD  - Department of Surgery, Rode Kruis Ziekenhuis, Beverwijk, The Netherlands.
FAU - Boerma, Evert-Jan G
AU  - Boerma EG
AD  - Department of Surgery, Zuyderland Medisch Centrum, Heerlen, The Netherlands.
FAU - Greve, Jan-Willem M
AU  - Greve JM
AD  - Department of Surgery, Zuyderland Medisch Centrum, Heerlen, The Netherlands.
AD  - Department of Surger / Nutrim, Maastricht University, Maastricht, The
      Netherlands.
FAU - van Dielen, Francois M H
AU  - van Dielen FMH
AD  - Department of Surgery, Maxima Medisch Centrum, Eindhoven, The Netherlands.
FAU - Frederix, Geert W J
AU  - Frederix GWJ
AD  - Department of Public Health, Julius Center Research Program Methodology,
      Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
FAU - Hazebroek, Eric J
AU  - Hazebroek EJ
AD  - Department of Surgery / Vitalys Clinic, Rijnstate Ziekenhuis, Arnhem, The
      Netherlands.
AD  - Division of Human Nutrition and Health, Wageningen University and Research,
      Wageningen, Gelderland, The Netherlands.
LA  - eng
SI  - NTR/NTR6991
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - *Bariatric Surgery/economics
MH  - Cohort Studies
MH  - Continuous Positive Airway Pressure/economics
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Obesity, Morbid/complications/economics/surgery/therapy
MH  - Observational Studies as Topic
MH  - Oximetry/economics
MH  - Oxygen/administration & dosage
MH  - Perioperative Care
MH  - Prospective Studies
MH  - Quality of Life
MH  - *Sleep Apnea, Obstructive/economics/etiology/surgery/therapy
PMC - PMC7542938
OTO - NOTNLM
OT  - *adult surgery
OT  - *respiratory medicine (see thoracic medicine)
OT  - *sleep medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-038830 [pii]
AID - 10.1136/bmjopen-2020-038830 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e038830. doi: 10.1136/bmjopen-2020-038830.


PMID- 33033025
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Exercise in older women with breast cancer during systemic therapy: study
      protocol of a randomised controlled trial (BREACE).
PG  - e038674
LID - 10.1136/bmjopen-2020-038674 [doi]
AB  - INTRODUCTION: Exercise interventions have been widely investigated in patients
      with cancer and demonstrate beneficial effects. However, intervention studies
      that include older women with breast cancer exercising during medical treatment
      are scarce. Hence, the aim of this study is to investigate the effect of a
      12-week exercise-based intervention in older women (>/=65 years) with breast
      cancer receiving (neo)adjuvant or first-line or second-line systemic therapy.
      METHODS AND ANALYSIS: This is a single-centre, two-armed randomised controlled
      trial. We anticipate including 100 patients, who will be randomised 1:1 to
      exercise-based intervention or control stratified by treatment setting
      ((neo)adjuvant or metastatic) and treatment (chemotherapy or endocrine therapy + 
      cyclin-dependent kinase (CDK) 4/6 inhibitors). The intervention group will
      receive standard oncological treatment and a 12-week supervised exercise-based
      intervention comprising a progressive resistance exercise programme two times per
      week, a protein supplement after exercise and a home-based walking programme
      based on daily step counts. The control group will receive standard oncological
      treatment. Assessments will be performed at baseline and 6, 12 and 24 weeks after
      start of the intervention. Primary outcome is physical function, measured by the 
      30-second Chair Stand Test. Secondary outcomes are feasibility (compliance and
      adherence to intervention), objective and patient-reported functional measures
      (6-meter and 10-meter gait speed; 6-min Walk Test; Handgrip Strength; Stair Climb
      Test; Physical Activity Questionnaire), symptom burden and well-being (MD
      Anderson Symptom Inventory; Hospital Anxiety and Depression Scale), quality of
      life (European Organization for Research and Treatment of Cancer Quality of Life 
      Questionnaire Core-30 and B23), body composition (dual-energy X-ray
      absorptiometry scan), side effects, inflammatory biomarkers, hospitalisation and 
      survival. ETHICS AND DISSEMINATION: The protocol was reviewed and accepted by the
      Scientific Ethics Review Committee of the Capital Region of Denmark, 17 June 2018
      (VEK ref.: H-18021013). Trial results will be submitted for publication in a
      peer-reviewed journal and presented on conferences, in oncology wards, exercise
      centres in municipalities and patient organisations, ensuring dissemination to
      relevant stakeholders. TRIAL REGISTRATION NUMBER: https://clinicaltrials.gov/ on 
      3 September 2018. Identifier: NCT03656731.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Andersen, Hogni Hammershaimb
AU  - Andersen HH
AUID- ORCID: 0000-0002-4558-8181
AD  - Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte
      University Hospital, Herlev, Denmark hoegni.hammershaimb.andersen@regionh.dk.
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark.
FAU - Mikkelsen, Marta Kramer
AU  - Mikkelsen MK
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark.
AD  - Department of Oncology and Hematology, Rigshospitalet, Copenhagen, Denmark.
FAU - Lundager, Ida
AU  - Lundager I
AD  - Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte
      University Hospital, Herlev, Denmark.
FAU - Lund, Cecilia Margareta
AU  - Lund CM
AD  - Department of Medicine, Herlev and Gentofte University Hospital, Herlev, Denmark.
FAU - Johansen, Julia Sidenius
AU  - Johansen JS
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark.
AD  - Department of Medicine, Herlev and Gentofte University Hospital, Herlev, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Kobenhavn, Denmark.
FAU - Vinther, Anders
AU  - Vinther A
AD  - Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte
      University Hospital, Herlev, Denmark.
AD  - QD-Research Unit, Herlev and Gentofte Hospital, Copenhagen University Hospital,
      Herlev, Denmark.
FAU - Bogh Juhl, Carsten
AU  - Bogh Juhl C
AD  - Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte
      University Hospital, Hellerup, Denmark.
AD  - Institute of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Zerahn, Bo
AU  - Zerahn B
AD  - Department of Clinical Physiology and Nuclear Medicine, Herlev and Gentofte
      Hospital, University of Copenhagen, Herlev, Denmark.
FAU - Ragle, Anne-Mette
AU  - Ragle AM
AD  - Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte
      University Hospital, Herlev, Denmark.
FAU - Nielsen, Dorte Lisbet
AU  - Nielsen DL
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Kobenhavn, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03656731
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Breast Neoplasms/therapy
MH  - Chemotherapy, Adjuvant
MH  - Exercise
MH  - *Exercise Therapy
MH  - Female
MH  - Hand Strength
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7542931
OTO - NOTNLM
OT  - *adult oncology
OT  - *breast tumours
OT  - *chemotherapy
OT  - *oncology
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-038674 [pii]
AID - 10.1136/bmjopen-2020-038674 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e038674. doi: 10.1136/bmjopen-2020-038674.


PMID- 33033024
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Prospective single-centre clinical observational study on electronically
      monitored medication non-adherence, its psychosocial risk factors and lifestyle
      behaviours after heart transplantation: a study protocol.
PG  - e038637
LID - 10.1136/bmjopen-2020-038637 [doi]
AB  - INTRODUCTION: In heart transplant recipients (HTRs), non-adherence (NA) to
      immunosuppressive (IS) medication and to recommended lifestyle behaviours are a
      common phenomenon and associated with higher risk of allograft rejection, organ
      loss and mortality. Risk factors for NA are highly diverse and still
      insufficiently researched. Precise measures of NA and an accurate understanding
      of its aetiology are of undisputable importance to detect patients at risk and
      intervene accordingly. The aim of this study is to assess the accuracy and
      concordance of different measures for NA as well as to determine potential risk
      factors. METHODS AND ANALYSIS: This is a single-centre prospective observational 
      trial. HTRs who are at least aged 18 are no less than 6 months post-transplant
      and receive tacrolimus (Prograf or Advagraf), cyclosporine (Sandimmun) or
      everolimus (Certican) as their prescribed IS medication are eligible for
      participation. We only include patients during the phase of medication
      implementation. At study enrolment, we assess depression, health-related quality 
      of life, self-efficacy, social support, attachment, experiences and attitudes
      towards IS medication, emotional responses after transplantation, satisfaction
      with information about IS medication and perceptions and beliefs about
      medications. We further ask patients to rate their lifestyle behaviours
      concerning alcohol, smoking, diet, physical activity, sun protection and
      appointment keeping via questionnaires. Three different measurement methods for
      NA are applied at T0: self-reports, physician's estimates and IS trough levels.
      NA is monitored prospectively using an electronic multicompartment pillbox (MEMS,
      VAICA) over a 3-month period. Meanwhile, participants receive phone calls every
      second week to obtain additional self-reports, resulting in a total of seven
      measurement points. ETHICS AND DISSEMINATION: The study was approved by the
      Clinical Ethics Committee of the University Hospital Erlangen
      (Friedrich-Alexander-University, Erlangen-Nurnberg). Written informed consent is 
      attained from all participants. The results of this study will be published in
      peer-reviewed journals and presented at conferences. TRIAL REGISTRATION NUMBER:
      DRKS00020496.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lieb, Marietta
AU  - Lieb M
AUID- ORCID: 0000-0002-3688-5141
AD  - Department of Psychosomatic Medicine and Psychotherapy, Friedrich-Alexander
      University Erlangen-Nurnberg, Erlangen, Germany marietta.lieb@uk-erlangen.de.
FAU - Weyand, Michael
AU  - Weyand M
AD  - Department of Cardiac Surgery, University Hospital Erlangen, Erlangen, Germany.
FAU - Seidl, Margot
AU  - Seidl M
AD  - Department of Cardiac Surgery, University Hospital Erlangen, Erlangen, Germany.
FAU - Erim, Yesim
AU  - Erim Y
AD  - Department of Psychosomatic Medicine and Psychotherapy, Friedrich-Alexander
      University Erlangen-Nurnberg, Erlangen, Germany.
LA  - eng
SI  - DRKS/DRKS00020496
PT  - Journal Article
PT  - Observational Study
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Heart Transplantation/psychology
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - *Life Style
MH  - Male
MH  - *Medication Adherence/psychology
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Risk Factors
PMC - PMC7542932
OTO - NOTNLM
OT  - *cardiology
OT  - *statistics & research methods
OT  - *transplant medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-038637 [pii]
AID - 10.1136/bmjopen-2020-038637 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e038637. doi: 10.1136/bmjopen-2020-038637.


PMID- 33033023
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Efficacy and mid/long-term survivorship of mobile-bearing unicompartmental knee
      arthroplasty for medial compartment knee osteoarthritis combined patellofemoral
      joint arthritis: a prospective cohort study protocol.
PG  - e038448
LID - 10.1136/bmjopen-2020-038448 [doi]
AB  - INTRODUCTION: Unicompartmental knee arthroplasty (UKA) is one of the most
      effective surgical procedures for treating isolated medial compartment knee
      osteoarthritis. However, previous studies have regarded patellofemoral
      osteoarthritis as a contraindication for UKA. In contrast, most current research 
      shows that damage to the articular cartilage of the patellofemoral joint, even to
      the extent of full-thickness cartilage loss, has no influence on the outcome of
      UKA. METHODS AND ANALYSIS: Study settings: This study is a prospective cohort
      study that will compare the Forgotten Joint Score and Lonner patellofemoral joint
      score of patients who have undergone UKA; the patients will be divided into two
      groups (with and without patellofemoral joint osteoarthritis (PFJOA)). PRIMARY
      OBJECTIVE: Long-term follow-up will be used to evaluate the effect of the
      operation on the above-mentioned scores in both the groups. SECONDARY OBJECTIVE: 
      We will divide the patients from the with PFJOA group into three subgroups
      according to the localisation of patellofemoral cartilage lesions (medial zone,
      lateral zone and central zone). We aim to compare knee joint scores among these
      groups and clarify the impact of different wear sites on clinical efficacy. We
      will use CT to explore the potential mechanism through which UKA affects
      patellofemoral joint-related parameters (lateral patellar tilt, lateral patellar 
      shift and tibia tuberosity-trochlear groove distance). We will also record
      mid-term/long-term post-surgery complications. ETHICS AND DISSEMINATION: This
      study's protocol is in accordance with the Declaration of Helsinki. This study
      was approved by the Ethics Committee of Xuanwu Hospital. The results of this
      study will be disseminated in international peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: ChiCTR2000030310.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cheng, Jingbo
AU  - Cheng J
AUID- ORCID: 0000-0001-5664-1358
AD  - Department of Orthopaedics, Xuanwu Hospital, Beijing, China.
FAU - Feng, Mingli
AU  - Feng M
AD  - Department of Orthopaedics, Xuanwu Hospital, Beijing, China
      fengmingli6666@163.com.
FAU - Cao, Guanglei
AU  - Cao G
AD  - Department of Orthopaedics, Xuanwu Hospital, Beijing, China.
FAU - Lu, Shibao
AU  - Lu S
AD  - Department of Orthopaedics, Xuanwu Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Arthroplasty, Replacement, Knee
MH  - Cohort Studies
MH  - Humans
MH  - Knee Joint/pathology/surgery
MH  - *Knee Prosthesis
MH  - *Osteoarthritis, Knee/diagnostic imaging/pathology/surgery
MH  - *Patellofemoral Joint/diagnostic imaging/pathology/surgery
MH  - Prospective Studies
MH  - Survivorship
MH  - Treatment Outcome
PMC - PMC7542940
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *knee
OT  - *musculoskeletal disorders
OT  - *orthopaedic & trauma surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-038448 [pii]
AID - 10.1136/bmjopen-2020-038448 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e038448. doi: 10.1136/bmjopen-2020-038448.


PMID- 33033022
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Effective SLOPE: EffectS of Lifestyle interventions in Older PEople with obesity:
      a systematic review and network meta-analysis protocol.
PG  - e038330
LID - 10.1136/bmjopen-2020-038330 [doi]
AB  - INTRODUCTION: Obesity is highly prevalent in older adults aged 65 years or older.
      Different lifestyle interventions (diet, exercise, self-management) are available
      but benefits and harms have not been fully quantified comparing all available
      health promotion interventions. Special consideration must be given to functional
      outcomes and possible adverse effects (loss of muscle and bone mass,
      hypoglycaemia) of weight loss interventions in this age group. The objective of
      this study is to synthesise the evidence regarding the effects of different types
      and modalities of lifestyle interventions, or their combinations, on physical
      function and obesity-related outcomes such as body composition in older adults
      with obesity. METHODS AND ANALYSES: Six databases (Medline, Embase, Cochrane
      Central Register of Controlled Trials, Cumulated Index to Nursing and Allied
      Health Literature (CINAHL), Psychinfo and Web of Science) and two trial
      registries (Clinicaltrials.gov and the WHO International Clinical Trials Registry
      Platform) will be searched for randomised controlled trials of lifestyle
      interventions in older adults with obesity. Screening (title/abstract and
      full-text) and data extraction of references as well as assessment of risk of
      bias and rating of the certainty of evidence (Grading of Recommendations,
      Assessment, Development and Evaluation for network meta-analyses) will be
      performed by two reviewers independently. Frequentist random-effects network
      meta-analyses will be conducted to determine the pooled effects from each
      intervention. ETHICS AND DISSEMINATION: We will submit our findings to
      peer-reviewed journals and present at national and international conferences as
      well as in scientific medical societies. Patient-targeted dissemination will
      involve local and national advocate groups. PROSPERO REGISTRATION NUMBER:
      CRD42019147286.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Torbahn, Gabriel
AU  - Torbahn G
AUID- ORCID: 0000-0003-1463-3119
AD  - Institute for Biomedicine of Aging, Friedrich-Alexander-Universitat
      Erlangen-Nurnberg, Nurnberg, Bayern, Germany gabriel.torbahn@fau.de.
FAU - Schoene, Daniel
AU  - Schoene D
AUID- ORCID: 0000-0003-0717-5746
AD  - Institute of Medical Physics, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 
      Erlangen, Bayern, Germany.
FAU - Schwingshackl, Lukas
AU  - Schwingshackl L
AUID- ORCID: 0000-0003-3407-7594
AD  - Institute for Evidence in Medicine, Faculty of Medicine, Medical Center -
      University of Freiburg, Freiburg, Germany.
FAU - Rucker, Gerta
AU  - Rucker G
AUID- ORCID: 0000-0002-2192-2560
AD  - Institute of Medical Biometry and Medical Informatics, Faculty of Medicine,
      Medical Center - University of Freiburg, Freiburg, Germany.
FAU - Knuttel, Helge
AU  - Knuttel H
AUID- ORCID: 0000-0002-2654-6517
AD  - University Library, University of Regensburg, Regensburg, Germany.
FAU - Kemmler, Wolfgang
AU  - Kemmler W
AUID- ORCID: 0000-0003-3515-0669
AD  - Institute of Medical Physics, University of Erlangen-Nurnberg, Erlangen, Germany.
FAU - Sieber, Cornel C
AU  - Sieber CC
AUID- ORCID: 0000-0002-6271-7459
AD  - Institute for Biomedicine of Aging, Friedrich-Alexander-Universitat
      Erlangen-Nurnberg, Nurnberg, Bayern, Germany.
AD  - Department of Medicine, Kantonsspital Winterthur, Winterthur, Zurich,
      Switzerland.
FAU - Batsis, John A
AU  - Batsis JA
AUID- ORCID: 0000-0002-0845-4416
AD  - Division of Geriatric Medicine, School of Medicine, University of North Carolina 
      at Chapel Hill, Chapel Hill, North Carolina, USA.
AD  - Department of Nutrition, Gillings School of Global Public Health, University of
      North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
FAU - Villareal, Dennis T
AU  - Villareal DT
AUID- ORCID: 0000-0003-1365-7960
AD  - Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine,
      Houston, Texas, USA.
FAU - Stroebele-Benschop, Nanette
AU  - Stroebele-Benschop N
AUID- ORCID: 0000-0002-5835-6945
AD  - Department of Nutritional Psychology, Institute of Nutritional Medicine,
      University of Hohenheim, Stuttgart, Germany.
FAU - Volkert, Dorothee
AU  - Volkert D
AUID- ORCID: 0000-0002-1003-6395
AD  - Institute for Biomedicine of Aging, Friedrich-Alexander-Universitat
      Erlangen-Nurnberg, Nurnberg, Bayern, Germany.
FAU - Kiesswetter, Eva
AU  - Kiesswetter E
AUID- ORCID: 0000-0003-1721-215X
AD  - Institute for Biomedicine of Aging, Friedrich-Alexander-Universitat
      Erlangen-Nurnberg, Nurnberg, Bayern, Germany.
LA  - eng
GR  - K23 AG051681/AG/NIA NIH HHS/United States
GR  - R01 AG067416/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Diet
MH  - Exercise
MH  - Female
MH  - Humans
MH  - *Life Style
MH  - Male
MH  - Middle Aged
MH  - Network Meta-Analysis
MH  - *Obesity/therapy
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7542917
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *nutrition & dietetics
OT  - *sports medicine
COIS- Competing interests: LS is a member of the GRADE working group. JAB is funded by 
      the National Institute on Aging and Office of Dietary Supplements of the National
      Institutes of Health under Award Number K23AG051681, and the R01 AG067416.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-038330 [pii]
AID - 10.1136/bmjopen-2020-038330 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e038330. doi: 10.1136/bmjopen-2020-038330.


PMID- 33033021
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Study protocol for a randomised controlled trial investigating two different
      refeeding formulations to improve safety and efficacy of hospital management of
      adolescent and young adults admitted with anorexia nervosa.
PG  - e038242
LID - 10.1136/bmjopen-2020-038242 [doi]
AB  - INTRODUCTION: Providing effective nutritional rehabilitation to patients
      hospitalised with anorexia nervosa (AN) is challenging, partly due to
      conservative recommendations that advocate feeding patients at low energy
      intakes. An 'underfeeding syndrome' can develop when patients are not provided
      with adequate nutrition during treatment, whereby malnourished patients fail to
      restore weight in a timely matter, and even lose weight. Of particular concern,
      the reintroduction of carbohydrate in a starved patient can increase the risk of 
      developing electrolyte, metabolic and organ dysfunction. The proposed trial
      assesses the efficacy and safety of a lower carbohydrate enteral formula (28%
      carbohydrate) against a standard enteral formula (54% carbohydrate), in
      adolescent and young adult patients (aged 15-25 years), hospitalised with AN.
      METHODS AND ANALYSIS: The study employs a double-blind randomised controlled
      trial design. At admission to hospital, malnourished adolescent and young adults 
      with AN will be randomly allocated to commence feeding on a standard enteral
      feeding formula (1.5 kcal/mL, 54% carbohydrate) or a lower carbohydrate
      isocaloric enteral feeding formula (1.5 kcal/mL, 28% carbohydrate). Assessments
      of nutritional intake, weight and biochemistry (phosphate, magnesium, potassium) 
      will be conducted at baseline and during the first 3 weeks of hospital admission.
      The primary outcome measure will be incidence of hypophosphatemia. Secondary
      outcomes include weight gain, oedema, other electrolyte distortion, length of
      hospital admission, admission to the Intensive Care Unit (ICU) and number of days
      to reach medical stability, using defined parameters. ETHICS AND DISSEMINATION:
      The protocol was approved by the Western Sydney Local Health District Human
      Research Ethics Committee and institutional research governance approvals were
      granted. Written informed consent will be sought prior to study enrolment. Study 
      findings will be widely disseminated through peer-reviewed publications and
      conference presentations. TRIAL REGISTRATION NUMBER: Australian New Zealand
      Clinical Trials Registry (ACTRN12617000342314); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Parker, Elizabeth
AU  - Parker E
AUID- ORCID: 0000-0002-4299-6091
AD  - Department of Dietetics & Nutrition, Westmead Hospital, Westmead, New South
      Wales, Australia elizabeth.parker@health.nsw.gov.au.
AD  - Sydney School of Health Sciences, Faculty of Medicine and Health, The University 
      of Sydney, Sydney, New South Wales, Australia.
FAU - Flood, Victoria
AU  - Flood V
AUID- ORCID: 0000-0001-5310-7221
AD  - Sydney School of Health Sciences, Faculty of Medicine and Health, The University 
      of Sydney, Sydney, New South Wales, Australia.
AD  - Allied Health Research Unit, Western Sydney Local Health District, Westmead
      Hospital, New South Wales, Australia.
FAU - Halaki, Mark
AU  - Halaki M
AD  - Sydney School of Health Sciences, Faculty of Medicine and Health, The University 
      of Sydney, Sydney, New South Wales, Australia.
FAU - Wearne, Christine
AU  - Wearne C
AD  - Department of Medical Psychology, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Anderson, Gail
AU  - Anderson G
AD  - Department of Adolescent & Young Adult Medicine, Westmead Hospital, Westmead, New
      South Wales, Australia.
FAU - Gomes, Linette
AU  - Gomes L
AD  - Department of Adolescent & Young Adult Medicine, Westmead Hospital, Westmead, New
      South Wales, Australia.
FAU - Clarke, Simon
AU  - Clarke S
AD  - Department of Adolescent & Young Adult Medicine, Westmead Hospital, Westmead, New
      South Wales, Australia.
AD  - Centre for Research into Adolescents' Health (CRASH); Department of Adolescent & 
      Young Adult Medicine, Westmead Hospital, Westmead, New South Wales, Australia.
AD  - Sydney School of Medicine, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Wilson, Frances
AU  - Wilson F
AD  - Department of Psychiatry, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Russell, Janice
AU  - Russell J
AD  - Sydney School of Medicine, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
AD  - NSW Statewide Eating Disorder Service, Peter Beumont Unit, Professor Marie Bashir
      Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
FAU - Frig, Elizabeth
AU  - Frig E
AD  - Department of Nutrition and Dietetics, Royal Prince Alfred Hospital, Camperdown, 
      New South Wales, Australia.
FAU - Kohn, Michael
AU  - Kohn M
AD  - Department of Adolescent & Young Adult Medicine, Westmead Hospital, Westmead, New
      South Wales, Australia.
AD  - Centre for Research into Adolescents' Health (CRASH); Department of Adolescent & 
      Young Adult Medicine, Westmead Hospital, Westmead, New South Wales, Australia.
AD  - Sydney School of Medicine, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12617000342314
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Anorexia Nervosa/therapy
MH  - Double-Blind Method
MH  - Enteral Nutrition
MH  - Hospitalization
MH  - Hospitals
MH  - Humans
MH  - *Randomized Controlled Trials as Topic
MH  - Young Adult
PMC - PMC7542921
OTO - NOTNLM
OT  - *clinical trials
OT  - *eating disorders
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - bmjopen-2020-038242 [pii]
AID - 10.1136/bmjopen-2020-038242 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e038242. doi: 10.1136/bmjopen-2020-038242.


PMID- 33033019
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Efficacy and safety of acupuncture for recurrent aphthous stomatitis: a
      systematic review protocol.
PG  - e037603
LID - 10.1136/bmjopen-2020-037603 [doi]
AB  - INTRODUCTION: Recurrent aphthous stomatitis (RAS) is a distressing symptom. There
      are many ways to treat RAS, such as pudilan anti-inflammatory oral liquid and
      doxycycline and laser therapy, but these take a long time to produce positive
      effects and compliance is low. Previous reviews of acupuncture treatment for RAS 
      has been growing, but a systematic review is not available. To assess the
      efficacy and safety of acupuncture for the management of RAS. METHODS AND
      ANALYSIS: The following databases will be searched from their inception to 1
      February 2020: PubMed, Embase, Cochrane Library, CINAHL, Chinese Biomedical
      Literature Database, VIP Database for Chinese Technical Periodicals, China
      National Knowledge Infrastructure and Wanfang. The randomised controlled trials
      in English or Chinese associated with acupuncture for patients with RAS will be
      included. Eligible study conference abstracts and reference lists of manuscripts 
      will also be searched. Two reviewers will select the studies, extract data
      independently. The Cochrane risk of bias tool will be used to assess the risk of 
      bias for the studies. According to heterogeneity testing, data will be
      synthesised using a random-effects model. A meta-analysis will be performed using
      Rev Man V.5.3.5 statistical software for each outcome. Subgroup analysis and
      sensitivity analysis are planned according to clinical evidence. Mean difference 
      or standardised mean difference for continuous data and risk ratio for
      dichotomous data will be calculated. ETHICS AND DISSEMINATION: No ethical
      approval is required. This protocol will not involve individual patient
      information and endangering participant rights. The results will be reported in a
      peer-reviewed journal or disseminated in relevant conferences. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/QASUY.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Feng
AU  - Zhang F
AUID- ORCID: 0000-0002-5557-0129
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zhou, Hao
AU  - Zhou H
AD  - Sub-Health Center, Sichuan Integrative Medicine Hospital, Chengdu, China.
FAU - Ding, Songyi
AU  - Ding S
AD  - Sub-Health Center, Sichuan Integrative Medicine Hospital, Chengdu, China.
FAU - Zhang, Da
AU  - Zhang D
AD  - Sub-Health Center, Sichuan Integrative Medicine Hospital, Chengdu, China.
FAU - Lian, Daoshi
AU  - Lian D
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Chen, Xingliang
AU  - Chen X
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Wang, Chao
AU  - Wang C
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China wangchaotcm@126.com.
AD  - Sub-Health Center, Sichuan Integrative Medicine Hospital, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture
MH  - *Acupuncture Therapy
MH  - Bias
MH  - China
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Stomatitis, Aphthous/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7542930
OTO - NOTNLM
OT  - *health & safety
OT  - *pain management
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037603 [pii]
AID - 10.1136/bmjopen-2020-037603 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e037603. doi: 10.1136/bmjopen-2020-037603.


PMID- 33033018
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - The Seattle Flu Study: a multiarm community-based prospective study protocol for 
      assessing influenza prevalence, transmission and genomic epidemiology.
PG  - e037295
LID - 10.1136/bmjopen-2020-037295 [doi]
AB  - INTRODUCTION: Influenza epidemics and pandemics cause significant morbidity and
      mortality. An effective response to a potential pandemic requires the
      infrastructure to rapidly detect, characterise, and potentially contain new and
      emerging influenza strains at both an individual and population level. The
      objective of this study is to use data gathered simultaneously from community and
      hospital sites to develop a model of how influenza enters and spreads in a
      population. METHODS AND ANALYSIS: Starting in the 2018-2019 season, we have been 
      enrolling individuals with acute respiratory illness from community sites
      throughout the Seattle metropolitan area, including clinics, childcare
      facilities, Seattle-Tacoma International Airport, workplaces, college campuses
      and homeless shelters. At these sites, we collect clinical data and mid-nasal
      swabs from individuals with at least two acute respiratory symptoms.
      Additionally, we collect residual nasal swabs and data from individuals who seek 
      care for respiratory symptoms at four regional hospitals. Samples are tested
      using a multiplex molecular assay, and influenza whole genome sequencing is
      performed for samples with influenza detected. Geospatial mapping and
      computational modelling platforms are in development to characterise the regional
      spread of influenza and other respiratory pathogens. ETHICS AND DISSEMINATION:
      The study was approved by the University of Washington's Institutional Review
      Board (STUDY00006181). Results will be disseminated through talks at conferences,
      peer-reviewed publications and on the study website (www.seattleflu.org).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chu, Helen Y
AU  - Chu HY
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA
      helenchu@uw.edu.
FAU - Boeckh, Michael
AU  - Boeckh M
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington, USA.
FAU - Englund, Janet A
AU  - Englund JA
AD  - Division of Pediatric Infectious Diseases, Allergy, and Rheumatology, University 
      of Washington, Seattle, Washington, USA.
FAU - Famulare, Michael
AU  - Famulare M
AD  - Institute for Disease Modeling, Bellevue, Washington, USA.
FAU - Lutz, Barry
AU  - Lutz B
AD  - Bioengineering, University of Washington, Seattle, Washington, USA.
FAU - Nickerson, Deborah A
AU  - Nickerson DA
AD  - Genome Sciences, University of Washington, Seattle, Washington, USA.
AD  - Brotman Baty Institute, University of Washington, Seattle, Washington, USA.
FAU - Rieder, Mark
AU  - Rieder M
AD  - Brotman Baty Institute, University of Washington, Seattle, Washington, USA.
FAU - Starita, Lea M
AU  - Starita LM
AD  - Genome Sciences, University of Washington, Seattle, Washington, USA.
AD  - Brotman Baty Institute, University of Washington, Seattle, Washington, USA.
FAU - Adler, Amanda
AU  - Adler A
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
FAU - Brandstetter, Elisabeth
AU  - Brandstetter E
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
FAU - Frazer, Chris D
AU  - Frazer CD
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
FAU - Han, Peter D
AU  - Han PD
AD  - Brotman Baty Institute, University of Washington, Seattle, Washington, USA.
FAU - Gulati, Reena K
AU  - Gulati RK
AD  - Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
FAU - Hadfield, James
AU  - Hadfield J
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
FAU - Jackson, Michael
AU  - Jackson M
AD  - Kaiser Permanente, Oakland, California, USA.
FAU - Kiavand, Anahita
AU  - Kiavand A
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
FAU - Kimball, Louise E
AU  - Kimball LE
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington, USA.
FAU - Lacombe, Kirsten
AU  - Lacombe K
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
FAU - Newman, Kira
AU  - Newman K
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
FAU - Sibley, Thomas R
AU  - Sibley TR
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington, USA.
FAU - Logue, Jennifer K
AU  - Logue JK
AUID- ORCID: 0000-0002-7889-8960
AD  - Medicine, University of Washington, Seattle, Washington, USA.
FAU - Lyon, Victoria Rachel
AU  - Lyon VR
AUID- ORCID: 0000-0001-5669-1099
AD  - Family Medicine, University of Washington, Seattle, Washington, USA.
FAU - Wolf, Caitlin R
AU  - Wolf CR
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
FAU - Zigman Suchsland, Monica
AU  - Zigman Suchsland M
AUID- ORCID: 0000-0001-7007-6973
AD  - University of Washington, Seattle, Washington, USA.
FAU - Shendure, Jay
AU  - Shendure J
AD  - Genome Sciences, University of Washington, Seattle, Washington, USA.
AD  - Howard Hughes Medical Institute, Seattle, Washington, USA.
FAU - Bedford, Trevor
AU  - Bedford T
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington, USA.
AD  - Genome Sciences, University of Washington, Seattle, Washington, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Genomics
MH  - Humans
MH  - *Influenza, Human/epidemiology
MH  - Prevalence
MH  - Prospective Studies
MH  - Seasons
PMC - PMC7542952
OTO - NOTNLM
OT  - *influenza
OT  - *protocol
OT  - *respiratory infection
OT  - *surveillance
OT  - *virology
COIS- Competing interests: HYC receives research support from Sanofi, Cepheid and
      Genentech/Roche and is a consultant for Merck. JAE receives research support to
      her institution from AstraZeneca, GlaxoSmithKline, Merck and Novavax and is a
      consultant for Sanofi Pasteur and Meissa Vaccines.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037295 [pii]
AID - 10.1136/bmjopen-2020-037295 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e037295. doi: 10.1136/bmjopen-2020-037295.


PMID- 33033014
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Effect of endotracheal tube plus stylet versus endotracheal tube alone on
      successful first-attempt tracheal intubation among critically ill patients: the
      multicentre randomised STYLETO study protocol.
PG  - e036718
LID - 10.1136/bmjopen-2019-036718 [doi]
AB  - INTRODUCTION: Tracheal intubation is one of the most daily practiced procedures
      performed in intensive care unit (ICU). It is associated with severe
      life-threatening complications, which can lead to intubation-related cardiac
      arrest. Using a preshaped endotracheal tube plus stylet may have potential
      advantages over endotracheal tube without stylet. The stylet is a rigid but
      malleable introducer which fits inside the endotracheal tube and allows for
      manipulation of the tube shape; to facilitate passage of the tube through the
      laryngeal inlet. However, some complications from stylets have been reported
      including mucosal bleeding, perforation of the trachea or oesophagus and sore
      throat. The use of a stylet for first-attempt intubation has never been assessed 
      in ICU and benefit remains to be established. METHODS AND ANALYSIS: The
      endotracheal tube plus stylet to increase first-attempt success during
      orotracheal intubation compared with endotracheal tube alone in ICU patients
      (STYLETO) trial is an investigator-initiated, multicentre, stratified,
      parallel-group unblinded trial with an electronic system-based randomisation.
      Patients will be randomly assigned to undergo the initial intubation attempt with
      endotracheal tube alone (ie,without stylet, control group) or endotracheal tube +
      stylet (experimental group). The primary outcome is the proportion of patients
      with successful first-attempt orotracheal intubation. The single, prespecified,
      secondary outcome is the incidence of complications related to intubation, in the
      hour following intubation. Other outcomes analysed will include safety,
      exploratory procedural and clinical outcomes. ETHICS AND DISSEMINATION: The study
      project has been approved by the appropriate ethics committee
      'Comite-de-Protection-des-Personnes Nord-Ouest3-19.04.26.65808 Cat2
      RECHMPL19_0216/STYLETO2019-A01180-57'". Informed consent is required. The results
      will be submitted for publication in a peer-reviewed journal and presented at one
      or more scientific conferences. If combined use of endotracheal tube plus stylet 
      facilitates tracheal intubation of ICU patients compared with endotracheal tube
      alone, its use will become standard practice, thereby decreasing first-attempt
      intubation failure rates and, potentially, the frequency of intubation-related
      complications. TRIAL REGISTRATION DETAILS: ClinicalTrials.gov Identifier:
      NCT04079387; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jaber, Samir
AU  - Jaber S
AUID- ORCID: 0000-0002-7257-8069
AD  - Department of Anaesthesiology and Critical Care Medicine B (DAR B), Saint-Eloi
      Hospital, University Teaching Hospital of Montpellier, 80 avenue Augustin Fliche,
      34295 Montpellier, France, Universite de Montpellier, Montpellier,
      Languedoc-Roussillon, France s-jaber@chu-montpellier.fr.
AD  - PhyMed Exp, Universite de Montpellier, INSERM U1046 Montpellier, France, Inserm
      U1046, Montpellier, Languedoc-Roussillon, France.
FAU - Rolle, Amelie
AU  - Rolle A
AD  - Intensive Care & Anesthesiology Department, University of Pointe a Pitre
      Hospital. Guadeloupe, France, Universite des Antilles Bibliotheque
      Hospitalo-universitaire de Guadeloupe, Pointe-a-Pitre, Guadeloupe.
FAU - Jung, Boris
AU  - Jung B
AD  - PhyMed Exp, Universite de Montpellier, INSERM U1046 Montpellier, France, Inserm
      U1046, Montpellier, Languedoc-Roussillon, France.
AD  - Departement of Medical Intensive Care, Lapeyronie Teaching Hospital, Montpellier 
      University, 191, Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5,
      Universite de Montpellier, Montpellier, Languedoc-Roussillon, France.
FAU - Chanques, Gerald
AU  - Chanques G
AD  - Department of Anaesthesiology and Critical Care Medicine B (DAR B), Saint-Eloi
      Hospital, University Teaching Hospital of Montpellier, 80 avenue Augustin Fliche,
      34295 Montpellier, France, Universite de Montpellier, Montpellier,
      Languedoc-Roussillon, France.
AD  - PhyMed Exp, Universite de Montpellier, INSERM U1046 Montpellier, France, Inserm
      U1046, Montpellier, Languedoc-Roussillon, France.
FAU - Bertet, Helena
AU  - Bertet H
AD  - IMAG, CNRS, Univ Montpellier, CHU Montpellier, Montpellier, France, Universite de
      Montpellier, Montpellier, Languedoc-Roussillon, France.
FAU - Galeazzi, David
AU  - Galeazzi D
AD  - IMAG, CNRS, Univ Montpellier, CHU Montpellier, Montpellier, France, Universite de
      Montpellier, Montpellier, Languedoc-Roussillon, France.
FAU - Chauveton, Claire
AU  - Chauveton C
AD  - Clinical research department of Montpellier university hospital, Montpellier,
      Universite de Montpellier, Montpellier, Languedoc-Roussillon, France.
FAU - Molinari, Nicolas
AU  - Molinari N
AD  - IMAG, CNRS, Univ Montpellier, CHU Montpellier, Montpellier, France, Universite de
      Montpellier, Montpellier, Languedoc-Roussillon, France.
FAU - De Jong, Audrey
AU  - De Jong A
AD  - Department of Anaesthesiology and Critical Care Medicine B (DAR B), Saint-Eloi
      Hospital, University Teaching Hospital of Montpellier, 80 avenue Augustin Fliche,
      34295 Montpellier, France, Universite de Montpellier, Montpellier,
      Languedoc-Roussillon, France.
AD  - PhyMed Exp, Universite de Montpellier, INSERM U1046 Montpellier, France, Inserm
      U1046, Montpellier, Languedoc-Roussillon, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04079387
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - Intubation, Intratracheal/adverse effects
MH  - *Larynx
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Trachea
PMC - PMC7542923
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *intensive & critical care
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: SJ reports receiving consulting fees from Drager, Fisher &
      Paykel and Xenios.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036718 [pii]
AID - 10.1136/bmjopen-2019-036718 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e036718. doi: 10.1136/bmjopen-2019-036718.


PMID- 33033011
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Comparison of PGS2.0 versus conventional embryo morphology evaluation for
      patients with recurrent pregnancy loss: a study protocol for a multicentre
      randomised trial.
PG  - e036252
LID - 10.1136/bmjopen-2019-036252 [doi]
AB  - INTRODUCTION: Pregnancy loss (PL) is an adverse life event, and there is no
      proven effective treatment for recurrent PL (RPL). Preimplantation genetic
      screening (PGS) can be performed to reduce the risks of PL; however, there is
      still no solid scientific evidence that PGS improves outcomes for couples
      experiencing RPL. Comprehensive chromosome screening (PGS2.0) has become a
      routine practice in in vitro fertilisation (IVF) clinics. Previous studies based 
      on PGS1.0 with a focus on RPL couples where the female is of advanced maternal
      age have reported contradictory results. Hence, a multicentre randomised trial is
      needed to provide evidence for the clinical benefits of PGS2.0 treatment for RPL 
      couples. METHODS AND ANALYSIS: Overall, 268 RPL couples undergoing IVF cycles
      will be enrolled. Couples will be randomised according to a unique grouping
      number generated by a random digital software into (1) PGS2.0 group and (2)
      non-PGS (conventional embryo morphology evaluation) group. This study aims to
      investigate whether the live birth rate (LBR) per initiated cycle after PGS2.0 is
      superior to the LBR per initiated cycle after conventional embryo evaluation
      (non-PGS group). Live birth will be defined as a live baby born after a gestation
      period of >28 weeks, with a birth weight of more than 1000 g. A multivariate
      logistic regression model will be used to adjust for confounding factors. ETHICS 
      AND DISSEMINATION: Ethical approval has been granted by the Ethics Committee of
      Obstetrics and Gynecology Hospital, Fudan University and the participating
      hospitals. Written informed consent will be obtained from each couple before any 
      study procedure is performed. Data from this study will be stored in the Research
      Electronic Data Capture. The results of this trial will be presented and
      published via peer-reviewed publications and presentations at international
      conferences. TRIAL REGISTRATION NUMBER: NCT03214185; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lei, Caixia
AU  - Lei C
AD  - Prenatal Diagnosis Center, Obstetrics and Gynecology Hospital of Fudan
      University, Shanghai, China.
AD  - Department of Genetics, Shanghai JiAi Genetics & IVF Institute, Shanghai, China.
FAU - Sui, Yilun
AU  - Sui Y
AD  - Department of Genetics, Shanghai JiAi Genetics & IVF Institute, Shanghai, China.
FAU - Ye, Jiangfeng
AU  - Ye J
AD  - Clinical Epidemiology, Obstetrics and Gynecology Hospital of Fudan University,
      Shanghai, China.
FAU - Lu, Yao
AU  - Lu Y
AD  - Reproductive Medical Center, Renji Hospital, School of Medicine, Shanghai Jiao
      Tong University, Shanghai, China.
FAU - Xi, Ji
AU  - Xi J
AD  - Reproductive Medical Center, International Peace Maternity and Child Health
      Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
FAU - Sun, Yun
AU  - Sun Y
AD  - Reproductive Medical Center, Renji Hospital, School of Medicine, Shanghai Jiao
      Tong University, Shanghai, China.
FAU - Jin, Li
AU  - Jin L
AD  - Reproductive Medical Center, International Peace Maternity and Child Health
      Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
FAU - Sun, Xiaoxi
AU  - Sun X
AUID- ORCID: 0000-0002-3366-5821
AD  - Department of Genetics, Shanghai JiAi Genetics & IVF Institute, Shanghai, China
      xiaoxi_sun@aliyun.com.
AD  - Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and 
      Gynecology Hospital of Fudan University, Shanghai, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03214185
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Abortion, Habitual
MH  - Birth Rate
MH  - Female
MH  - Fertilization in Vitro
MH  - Genetic Testing
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Pregnancy
MH  - *Preimplantation Diagnosis
MH  - Randomized Controlled Trials as Topic
PMC - PMC7542939
OTO - NOTNLM
OT  - *antenatal
OT  - *prenatal diagnosis
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036252 [pii]
AID - 10.1136/bmjopen-2019-036252 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e036252. doi: 10.1136/bmjopen-2019-036252.


PMID- 33033010
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Do measures of physical function enhance the prediction of persistent pain and
      disability following a whiplash injury? Protocol for a prospective observational 
      study in Spain.
PG  - e035736
LID - 10.1136/bmjopen-2019-035736 [doi]
AB  - INTRODUCTION: Not all factors that predict persistent pain and disability
      following whiplash injury are known. In particular, few physical factors, such as
      changes in movement and muscle behaviour, have been investigated. The aim of this
      study is to identify predictive factors that are associated with the development 
      of persistent pain and disability following a whiplash injury by combining
      contemporary measures of physical function together with established
      psychological and pain-related predictive factors. METHODS AND ANALYSIS: A
      prospective observational study will recruit 150 consecutive eligible patients
      experiencing whiplash-related symptoms, admitted to a private physiotherapy
      clinic in Spain within 15 days of their whiplash injury. Poor outcome will be
      measured using the Neck Disability Index (NDI), defined as an NDI score of 30% or
      greater at 6 months post injury. Candidate predictors, including demographic
      characteristics, injury characteristics, pain characteristics, self-reported
      psychosocial factors and physical factors, will be collected at baseline (within 
      15 days of inception). Regression analyses will be performed to identify factors 
      that are associated with persistent neck pain and disability over the study
      period. ETHICS AND DISSEMINATION: The project has been approved by the Ethics
      Committee of the province of Malaga, Spain (#30052019). The results of this study
      will be published in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alalawi, Ahmed
AU  - Alalawi A
AUID- ORCID: 0000-0001-5667-8150
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Luque-Suarez, Alejandro
AU  - Luque-Suarez A
AD  - Physiotherapy, University of Malaga, Malaga, Spain.
FAU - Fernandez-Sanchez, Manuel
AU  - Fernandez-Sanchez M
AD  - Facultad de Ciencias de la Educacion Enfermeria y Fisioterapia, Universidad De
      Almeria, Almeria, Spain.
FAU - Gallina, Alessio
AU  - Gallina A
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Evans, David
AU  - Evans D
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Falla, Deborah
AU  - Falla D
AUID- ORCID: 0000-0003-1689-6190
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK
      d.falla@bham.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Nov 20;10(11):1. PMID: 33444220
MH  - Disability Evaluation
MH  - Humans
MH  - Neck Pain/etiology
MH  - Observational Studies as Topic
MH  - Physical Examination
MH  - Prospective Studies
MH  - Spain/epidemiology
MH  - *Whiplash Injuries/complications
PMC - PMC7542919
OTO - NOTNLM
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035736 [pii]
AID - 10.1136/bmjopen-2019-035736 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e035736. doi: 10.1136/bmjopen-2019-035736.


PMID- 33033006
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 7
TI  - Can extranodal tumour deposits be diagnosed on MRI? Protocol for a multicentre
      clinical trial (the COMET trial).
PG  - e033395
LID - 10.1136/bmjopen-2019-033395 [doi]
AB  - INTRODUCTION: Tumour deposits (TDs) are a poor prognostic marker when seen on
      pathology, and are worse than lymph node metastases (LNMs). They are now being
      reported on MRI as discontinuous nodules of extramural venous invasion but this
      diagnosis has not been validated and it is unclear how it correlates with the
      diagnosis of TDs on pathology. METHODS AND ANALYSIS: This is a prospective
      interventional clinical trial which aims to directly map the location of TDs on
      MRI and correlate what is seen on MRI with the pathology findings at each
      location. All patients with rectal cancer undergoing resectional surgery are
      eligible (including those undergoing preoperative therapy). The primary outcome
      is the prevalence of TDs seen on pathology. Secondary outcomes are to assess
      radiological and pathological interobserver agreement, assess the effect of TDs
      on prognosis and carry out exploratory work looking at differences between TDs
      and LNMs. The estimated sample size is 100 to detect a twofold increase in the
      pathological diagnosis of TD when MRI mapping is used. ETHICS AND DISSEMINATION: 
      Ethical approval has been granted from the South Central-Hampshire B Research and
      Ethics Committee (IRAS 217627). The study will be carried out under standard
      operative procedures within the Royal Marsden Hospital. TRIAL REGISTRATION
      NUMBER: NCT03303547.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lord, Amy C
AU  - Lord AC
AUID- ORCID: 0000-0001-5579-6171
AD  - Department of General Surgery, Royal Marsden NHS Foundation Trust, London, UK
      amylord@nhs.net.
AD  - Department of General Surgery, Croydon University Hospital, Croydon, UK.
FAU - Moran, Brendan
AU  - Moran B
AD  - Department of General Surgery, Basingstoke and North Hampshire NHS Foundation
      Trust, Basingstoke, UK.
FAU - Abulafi, Muti
AU  - Abulafi M
AD  - Department of General Surgery, Croydon University Hospital, Croydon, UK.
FAU - Rasheed, Shahnawaz
AU  - Rasheed S
AD  - Department of General Surgery, Royal Marsden NHS Foundation Trust, London, UK.
FAU - Nagtegaal, Iris D
AU  - Nagtegaal ID
AD  - Department of Pathology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Terlizzo, Monica
AU  - Terlizzo M
AD  - Department of General Surgery, Royal Marsden NHS Foundation Trust, London, UK.
FAU - Brown, Gina
AU  - Brown G
AD  - Department of Radiology, Royal Marsden NHS Foundation Trust, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03303547
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Extranodal Extension
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Multicenter Studies as Topic
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - *Rectal Neoplasms/diagnostic imaging/pathology
PMC - PMC7542933
OTO - NOTNLM
OT  - *colorectal surgery
OT  - *gastrointestinal imaging
OT  - *gastrointestinal tumours
OT  - *magnetic resonance imaging
OT  - *surgical pathology
COIS- Competing interests: None declared.
EDAT- 2020/10/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/09 05:31
PHST- 2020/10/09 05:31 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033395 [pii]
AID - 10.1136/bmjopen-2019-033395 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 7;10(10):e033395. doi: 10.1136/bmjopen-2019-033395.


PMID- 33032625
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Oct 8
TI  - Translation, cross-cultural adaptation and validation of the Slovenian version of
      Harris Hip Score.
PG  - 335
LID - 10.1186/s12955-020-01592-w [doi]
AB  - INTRODUCTION: The Harris Hip Score is the most widely used outcome measure for
      the assessment of hip pathologies. An official Slovenian version has not been
      culturally adapted and validated. The aim of this study was to create a Slovenian
      valid and reliable version of the HHS. MATERIALS AND METHOD: The HHS was
      translated and modified in Slovenian. The measurement properties of the Slovenian
      HHS were tested in 42 patients suffering from different hip pathologies.
      Reliability, responsiveness, construct validity, convergent/divergent validity
      and content validity of the Slovenian version of the HHS were tested. RESULTS:
      Only minor adaptation was required in the translation process. The internal
      consistency of the HHS expressed by Cronbach's alpha was 0.94. The test-retest
      reliability expressed by the intraclass correlation coefficient was 0.983. The
      correlations of the HHS scale with the WOMAC scale (r = - 0.877) and the VAS
      scale (r = - 0.717) were statistically significant. The highest correlation
      between the HHS and SF-36 was with the General Health dimension (r = 0.61). while
      the lowest correlation was with the SF-36 Mental Health dimension (r = 0.43).
      MDC95% was 10.1. No floor or ceiling effects were found. CONCLUSION: Slovenian
      version of HHS seems to has an acceptable level of reliability and validity.
      Slovenian HHS is short, comprehensible and easy to administer and interpret.
      TRIAL REGISTRATION: Approved by the Slovenian National Medical Ethics Committee
      (0120-46/2019/19).
FAU - Josipovic, Petra
AU  - Josipovic P
AUID- ORCID: http://orcid.org/0000-0001-5121-6715
AD  - Univerza v Ljubljani Medicinska Fakulteta, Vrazov trg 2, Ljubljana, Slovenia.
      petraa.josipovic@gmail.com.
AD  - , Pula, Croatia. petraa.josipovic@gmail.com.
FAU - Moharic, Metka
AU  - Moharic M
AD  - Univerzitetni rehabilitacijski institut SOCA, Linhartova 51, Ljubljana, Slovenia.
FAU - Salamon, Dea
AU  - Salamon D
AD  - Univerza na Primorskem Fakulteta za vede o zdravju, Polje 42, Izola, Slovenia.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20201008
PL  - England
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Cultural Comparison
MH  - Female
MH  - Hip Joint/*physiopathology
MH  - Humans
MH  - Joint Diseases/*physiopathology/psychology
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement/methods
MH  - Quality of Life
MH  - Reproducibility of Results
MH  - Slovakia
MH  - Surveys and Questionnaires/*standards
MH  - Translations
PMC - PMC7545539
OTO - NOTNLM
OT  - Harris hip score
OT  - Hip
OT  - Slovenian
OT  - Translation
OT  - Validation
EDAT- 2020/10/10 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/10/09 05:25
PHST- 2020/04/08 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/09 05:25 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1186/s12955-020-01592-w [doi]
AID - 10.1186/s12955-020-01592-w [pii]
PST - epublish
SO  - Health Qual Life Outcomes. 2020 Oct 8;18(1):335. doi: 10.1186/s12955-020-01592-w.


PMID- 33032616
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201210
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Oct 8
TI  - Lessons learned from COVID-19 for the post-antibiotic future.
PG  - 94
LID - 10.1186/s12992-020-00623-x [doi]
AB  - INTRODUCTION: COVID-19 has rapidly and radically changed the face of human health
      and social interaction. As was the case with COVID-19, the world is similarly
      unprepared to respond to antimicrobial resistance (AMR) and the challenges it
      will produce. COVID-19 presents an opportunity to examine how the international
      community might better respond to the growing AMR threat. MAIN BODY: The impacts 
      of COVID-19 have manifested in health system, economic, social, and global
      political implications. Increasing AMR will also present challenges in these
      domains. As seen with COVID-19, increasing healthcare usage and resource scarcity
      may lead to ethical dilemmas about prioritization of care; unemployment and
      economic downturn may disproportionately impact people in industries reliant on
      human interaction (especially women); and international cooperation may be
      compromised as nations strive to minimize outbreaks within their own borders.
      CONCLUSION: AMR represents a slow-moving disaster that offers a unique
      opportunity to proactively develop interventions to mitigate its impact. The
      world's attention is currently rightfully focused on responding to COVID-19, but 
      there is a moral imperative to take stock of lessons learned and opportunities to
      prepare for the next global health emergency.
FAU - Wilson, Lindsay A
AU  - Wilson LA
AD  - Global Strategy Lab, York University/University of Ottawa, 4700 Keele Street,
      2120 Dahdaleh Building, Toronto, ON, M3J 1P3, Canada.
FAU - Rogers Van Katwyk, Susan
AU  - Rogers Van Katwyk S
AD  - Global Strategy Lab, York University/University of Ottawa, 4700 Keele Street,
      2120 Dahdaleh Building, Toronto, ON, M3J 1P3, Canada.
FAU - Fafard, Patrick
AU  - Fafard P
AD  - Global Strategy Lab, York University/University of Ottawa, 4700 Keele Street,
      2120 Dahdaleh Building, Toronto, ON, M3J 1P3, Canada.
AD  - Graduate School of Public & International Affairs, Faculty of Social Science,
      University of Ottawa, Ottawa, ON, Canada.
FAU - Viens, A M
AU  - Viens AM
AD  - Global Strategy Lab, York University/University of Ottawa, 4700 Keele Street,
      2120 Dahdaleh Building, Toronto, ON, M3J 1P3, Canada.
AD  - School of Global Health, York University, Toronto, ON, Canada.
FAU - Hoffman, Steven J
AU  - Hoffman SJ
AD  - Global Strategy Lab, York University/University of Ottawa, 4700 Keele Street,
      2120 Dahdaleh Building, Toronto, ON, M3J 1P3, Canada.
      steven.hoffman@globalstrategylab.org.
AD  - Dahdaleh Institute for Global Health Research, Faculty of Health and Osgoode Hall
      Law School, York University, Toronto, ON, Canada.
      steven.hoffman@globalstrategylab.org.
AD  - Department of Global Health and Population, Harvard T H Chan School of Public
      Health, Harvard University, Boston, MA, USA.
      steven.hoffman@globalstrategylab.org.
AD  - Department of Health Research Methods, Evidence, and Impact and McMaster Health
      Forum, McMaster University, Hamilton, ON, Canada.
      steven.hoffman@globalstrategylab.org.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
RN  - 0 (Anti-Bacterial Agents)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - COVID-19
MH  - Coronavirus Infections/drug therapy/epidemiology/*prevention & control
MH  - Disaster Planning/organization & administration
MH  - *Drug Resistance, Microbial
MH  - Forecasting
MH  - Global Health
MH  - Humans
MH  - International Cooperation
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
PMC - PMC7542564
OTO - NOTNLM
OT  - *Antimicrobial resistance
OT  - *COVID-19
OT  - *Emergency preparedness
OT  - *International cooperation
EDAT- 2020/10/10 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/09 05:25
PHST- 2020/07/09 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/09 05:25 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1186/s12992-020-00623-x [doi]
AID - 10.1186/s12992-020-00623-x [pii]
PST - epublish
SO  - Global Health. 2020 Oct 8;16(1):94. doi: 10.1186/s12992-020-00623-x.


PMID- 33031342
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20220418
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - Dressing interventions to heal pressure ulcers: A protocol for an overview of
      systematic reviews and meta-analysis.
PG  - e22699
LID - 10.1097/MD.0000000000022699 [doi]
AB  - BACKGROUND: Pressure ulcer (PU) is defined as a lesion or trauma to the skin and 
      underlying tissue resulting from unrelieved pressure, shear, friction, moisture, 
      or a combination of all these, usually appearing over a bony prominence. We aim
      to evaluate the credibility of systematic reviews and meta-analyses that assess
      the effectiveness, safety, and economy of the dressing treatments for PU through 
      an overview. METHODS: We searched the following electronic bibliographic
      databases: PubMed, Embase, Cochrane Library, CINAHL Complete, PsycARTICLES,
      PsycINFO, DynaMed Plus, as well as the Chinese databases without any language
      restriction. We will include meta-analyses that dressings treatments in the
      management of PUs. For each meta-analysis, we will estimate the effect size of a 
      treatment through the random-effect model and the fixed-effect model, and we will
      evaluate between-study heterogeneity (Cochrane's Q and I statistics) and
      small-study effect (Egger's test); we will also estimate the evidence of excess
      significance bias. Methodological quality of each meta-analysis will be evaluated
      by using Assessment of Multiple Systematic Reviews 2. RESULTS: This study is
      ongoing and the results will be submitted to a peer-reviewed journal for
      publication. ETHICS AND DISSEMINATION: Ethical approval is not applicable, since 
      this is an overview based on published articles. PROTOCOL REGISTRATION NUMBER:
      The protocol has been registered on PROSPERO under the number CRD42020161232.
FAU - Geng, Jie
AU  - Geng J
AUID- ORCID: 0000-0003-2619-1012
AD  - Lanzhou University Second Hospital, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Zhao, Yali
AU  - Zhao Y
FAU - Wang, Zheyuan
AU  - Wang Z
FAU - Wang, Mancai
AU  - Wang M
FAU - Wei, Zhihong
AU  - Wei Z
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
EIN - Medicine (Baltimore). 2020 Nov 6;99(45):e23109. PMID: 33157986
MH  - *Bandages
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pressure Ulcer/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7544375
EDAT- 2020/10/09 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/10/08 17:13
PHST- 2020/10/08 17:13 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
AID - 10.1097/MD.0000000000022699 [doi]
AID - 00005792-202010090-00089 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22699. doi: 10.1097/MD.0000000000022699.


PMID- 33031340
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - The efficacy of bilateral intervertebral foramen block for pain management in
      percutaneous endoscopic lumbar discectomy: A protocol for randomized controlled
      trial.
PG  - e22693
LID - 10.1097/MD.0000000000022693 [doi]
AB  - BACKGROUND: Compared with open lumbar microdiscectomy, percutaneous endoscopic
      lumbar discectomy (PELD) has the advantages of remarkable preservation of
      paravertebral structures, less bleeding, shorter operation time and fewer
      complications, it is a common method for the treatment of lumbar disc herniation 
      (LDH). Local anesthesia is recommended during PELD. However, intraoperative pain 
      is sometimes difficult to control satisfactorily. The efficacy of bilateral
      intervertebral foramen block (IFB) for pain management in PELD remains unclear.
      Therefore, this regimen is utilized in a randomized controlled trial for the
      assessment the safety and effectiveness of bilateral IFB for PELD pain control.
      METHOD: This is a single center and randomized controlled trial which will be
      implemented from September 2020 to September 2021. This research protocol is in
      accordance with the items of the Standard Protocol for Randomized Trials, which
      was authorized through the Ethics Committee of Huzhou Central Hospital &
      Affiliated Centre Hospital of Huzhou University (HZCH0465-0864). 100 participants
      who undergo PELD will be analyzed. Inclusion criteria containsThe exclusion
      criteria contains:Patients will be randomly divided into bilateral IFB group
      (with 50 patients) and local infiltration analgesia group (with 50 patients).
      Primary outcomes are pain score at different time points. The secondary outcomes 
      are the operative time, radiation exposure time, length of hospital stay and
      postoperative complications. All the analysis is implemented through applying the
      IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, NY, USA).
      RESULTS: The clinical outcome variables between groups are illustrated in the
      Table 1. CONCLUSION: This investigation can offer a reliable basis for the
      effectiveness and safety of IFB in treating the PELD pain. TRIAL REGISTRATION:
      This study protocol is registered in Research Registry (researchregistry5985).
FAU - Sang, Xiaolan
AU  - Sang X
AD  - Department of operating room, Huzhou Central Hospital & Affiliated Central
      Hospital of Huzhou University.
FAU - Shan, Hanmin
AU  - Shan H
AD  - Department of Anesthesiology.
FAU - Hu, Jiajun
AU  - Hu J
AD  - Department of Anesthesiology.
FAU - Wu, Meng
AU  - Wu M
AD  - Department of Orthopedics and Trauma, Huzhou Central Hospital & Affiliated Centre
      Hospital of Huzhou Unversity, Zhejiang Province, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Anesthesia, Spinal/*methods
MH  - *Diskectomy
MH  - Humans
MH  - Lumbar Vertebrae/*surgery
MH  - Pain Management/*methods
MH  - Randomized Controlled Trials as Topic
PMC - PMC7544323
EDAT- 2020/10/09 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/10/08 17:13
PHST- 2020/10/08 17:13 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
AID - 10.1097/MD.0000000000022693 [doi]
AID - 00005792-202010090-00087 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22693. doi: 10.1097/MD.0000000000022693.


PMID- 33031277
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - Efficacy and safety of traditional Chinese herbal formula combined with western
      medicine for gastroesophageal reflux disease: A protocol for systematic review
      and meta-analysis.
PG  - e22454
LID - 10.1097/MD.0000000000022454 [doi]
AB  - BACKGROUND: The combined therapy of Chinese herbal formula and western medicine
      against gastroesophageal reflux disease (GERD) could significantly improve the
      clinical effect, reduce the recurrence rate and the side effects of western
      medicine, and even reduce the dosage and course of treatment of western medicine.
      This study tried to systematically evaluate the efficacy and safety traditional
      Chinese herbal formula combined with western medicine in the treatment of GERD.
      METHODS: Randomized controlled trials of traditional Chinese herbal formula
      combined with western medicine for GERD patients will be systematically searched 
      using the PubMed, Embase, Medline, Cochrane Library, China National Knowledge
      Infrastructure (CNKI), Wanfang database, Chongqing VIP Chinese Science and
      Technology Periodical Database, and Chinese Biological and Medical database (CMB)
      until Aug. 28, 2020. Two researchers will perform data extraction and risk of
      bias assessment independently. Statistical analysis will be conducted in RevMan
      5.3. RESULTS: This study will summarize the present evidence by exploring the
      efficacy and safety of traditional Chinese herbal formula combined with western
      medicine in the treatment of GERD. CONCLUSIONS: The findings of the study will
      help to determine potential benefits of traditional Chinese herbal formula
      combined with western medicine against GERD. ETHICS AND DISSEMINATION: The
      private information from individuals will not be published. This systematic
      review also will not involve endangering participant rights. Ethical approval is 
      not required. The results may be published in a peer-reviewed journal or
      disseminated in relevant conferences. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/RSAVF.
FAU - Lin, Wuhong
AU  - Lin W
AUID- ORCID: 0000-0003-3073-0779
AD  - The School of Chinese Medicine, Hunan University of Chinese Medicine, Changsha,
      Hunan Province.
FAU - Huang, Guihua
AU  - Huang G
AD  - Department of Spleen, Stomach, and Liver Disease, The First Affiliated Hospital
      of Guangxi University of Chinese Medicine.
FAU - Liu, Xirong
AU  - Liu X
AD  - Department of Spleen, Stomach, and Liver Disease, The First Affiliated Hospital
      of Guangxi University of Chinese Medicine.
FAU - Lin, Huasheng
AU  - Lin H
AD  - Department of Spleen, Stomach, and Liver Disease, The First Affiliated Hospital
      of Guangxi University of Chinese Medicine.
FAU - Zhou, Heng
AU  - Zhou H
AD  - Department of Spleen, Stomach, and Liver Disease, The First Affiliated Hospital
      of Guangxi University of Chinese Medicine.
FAU - Feng, Chunbing
AU  - Feng C
AD  - Emergency Department of Yulin Hospital of Traditional Chinese Medicine.
FAU - Wang, Tingshuai
AU  - Wang T
AD  - The School of Chinese Medicine, Hunan University of Chinese Medicine, Changsha,
      Hunan Province.
FAU - Liang, Renjiu
AU  - Liang R
AD  - Graduate School, Guangxi University of Chinese Medicine, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antacids)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Antacids/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Histamine H2 Antagonists/adverse effects/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7544302
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022454 [doi]
AID - 00005792-202010090-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22454. doi: 10.1097/MD.0000000000022454.


PMID- 33031275
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - The efficacy and safety of sulindac for colorectal polyps: A protocol for
      systematic review and meta-analysis.
PG  - e22402
LID - 10.1097/MD.0000000000022402 [doi]
AB  - BACKGROUND: Sulindac has been used for treating colorectal polyps widely.
      However, the efficacy and safety of sulindac for colorectal polyps are unclear.
      This study aims to evaluate the efficacy and safety of sulindac for colorectal
      polyps. METHODS: Randomized controlled trials of sulindac in the treatment of
      colorectal polyps will be searched in PubMed, EMbase, Cochrane Library, Web of
      Science, China National Knowledge Infrastructure (CNKI), WanFang, the Chongqing
      VIP Chinese Science, and Technology Periodical Database, and China biomedical
      literature database (CBM) from inception to August, 2020. And Baidu Scholar,
      Google Scholar, International Clinical Trials Registry Platform, and Chinese
      Clinical Trials Registry will be searched to obtain more relevant studies
      comprehensively. Two researchers will perform data extraction and risk of bias
      assessment independently. Statistical analysis will be conducted in RevMan 5.3.
      RESULTS: This study will summarize the present evidence by exploring the efficacy
      and safety of sulindac in the treatment of colorectal polyps. CONCLUSION: The
      findings of the study will provide helpful evidence for the efficacy and safety
      of sulindac in the treatment of colorectal polyps, facilitating clinical practice
      and further scientific studies. ETHICS AND DISSEMINATION: The private information
      from individuals will not publish. This systematic review also will not involve
      endangering participant rights. Ethical approval is not required. The results may
      be published in a peer-reviewed journal or disseminated in relevant conferences. 
      OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/N5GDH.
FAU - Long, Qing
AU  - Long Q
AUID- ORCID: 0000-0001-7589-8730
AD  - Department of Traditional Chinese Medicine, The Affiliated Hospital of Southwest 
      Medical University.
FAU - Ao, Liang
AU  - Ao L
AD  - Department of Orthopedics.
FAU - Li, Kuo
AU  - Li K
AD  - Department of Oncology.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Dermatology, Traditional Chinese Medicine Hospital Affiliated to
      Southwest Medical University, Luzhou, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 184SNS8VUH (Sulindac)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Colonic Polyps/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Rectum
MH  - Research Design
MH  - Sulindac/adverse effects/*therapeutic use
MH  - Systematic Reviews as Topic
PMC - PMC7544282
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022402 [doi]
AID - 00005792-202010090-00022 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22402. doi: 10.1097/MD.0000000000022402.


PMID- 33031272
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - Survival difference between brainstem and cerebellum medulloblastoma: the
      surveillance, epidemiology, and end results-based study.
PG  - e22366
LID - 10.1097/MD.0000000000022366 [doi]
AB  - To investigate the prognoses associated with different locations of
      medulloblastoma (MB) in terms of survival through a case-control study and
      evaluate the prognostic factors for MB.The Surveillance, Epidemiology, and End
      Results database was used to identify MB patients diagnosed from 1975 to 2016.
      Each brainstem MB (bMB) patient was matched to a cerebellum MB (cMB) patient by
      propensity score matching based on age, sex, tumor size, extent of metastasis,
      extent of surgical resection, radiotherapy status and chemotherapy status.
      Univariate and multivariate analyses were performed to assess the effect of
      prognostic factors on overall survival. Ethical approval was not necessary as
      this study is based on a public database.A total of 172 bMB patients and 1417 cMB
      patients were included in the study. A total of 144 pairs of patients were
      matched to constitute the matched cohort. Within the matched cohort, the median
      survival times were 213 months and 96 months for cMB and bMB, respectively.
      Within the unmatched cohort, the median survival times were 111 months and 97
      months for cMB and bMB, respectively. Brainstem location detrimentally affected
      the survival time of MB patients in both the matched cohort (hazard ratios =8.14,
      95% confidence interval =5.98-11.08) and the unmatched cohort (hazard ratios
      =1.44, 95% confidence interval =1.20-1.74). Age <5 years and receipt of
      radiotherapy were favorable prognostic factors, whereas gross total resection,
      brainstem location and receipt of chemotherapy were unfavorable prognostic
      factors. Radiotherapy alone was associated with superior outcomes concerning
      adjuvant chemotherapy or radiotherapy.This study uncovers a survival advantage
      for cMB patients versus bMB patients. Additionally, prognostic factors include
      age, extent of surgical resection, and receipt of radiotherapy or chemotherapy.
      Radiotherapy after surgery and rational use of chemotherapy drugs are crucial for
      treatment of MB patients. Further studies of these prognostic factors are
      required to improve the survival time.
FAU - Qin, Qilin
AU  - Qin Q
AUID- ORCID: 0000-0003-4974-4994
AD  - Department of neurosurgery, Second Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Huang, Dezhi
AU  - Huang D
FAU - Jiang, Yugang
AU  - Jiang Y
AUID- ORCID: 0000-0003-1593-6680
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Brain Stem Neoplasms/*mortality/therapy
MH  - Case-Control Studies
MH  - Cerebellar Neoplasms/mortality/therapy
MH  - Child, Preschool
MH  - China/epidemiology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Medulloblastoma/*mortality/therapy
MH  - Prognosis
MH  - Propensity Score
MH  - Registries
MH  - Retrospective Studies
MH  - SEER Program
MH  - Survival Rate
PMC - PMC7544264
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022366 [doi]
AID - 00005792-202010090-00019 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22366. doi: 10.1097/MD.0000000000022366.


PMID- 33031271
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - Treatment of microcirculation dysfunction in type 2 diabetic mellitus with Shenqi
      compound prescription: A protocol of systematic review and meta-analysis of
      randomized clinical trials.
PG  - e22347
LID - 10.1097/MD.0000000000022347 [doi]
AB  - INTRODUCTION: Type 2 diabetic mellitus (T2DM) is a chronic disease. In 2013, the 
      International Diabetes Federation showed that the total number of diabetic
      patients aged 20 to 79 years in China was 89 million, and it is expected to
      increase to 143 million by 2035. The incidence of T2DM and its complications in
      patients with blood glucose is gradually increasing, and there are low awareness 
      rate, low diagnosis rate and high disability rate, which has become a global
      public health problem. Microcirculation Dysfunction in Type 2 diabetic mellitus
      (MDT2DM) plays an important role in the development of diabetic nephropathy,
      diabetic retinopathy, diabetic neuropathy and diabetic foot disease. It is 1 of
      the common etiological mechanisms of diabetic chronic complications. Patients
      with MDT2DM, serious complications, increase the quality of life of patients with
      social impact. Diabetic lower extremity microcirculation disease (dlemd) is the
      main cause of the occurrence, development and difficult healing of diabetic foot.
      Microvascular disease is microcirculation dysfunction. It has been proved that
      Shenqi compound prescription can treat T2DM macrovascular disease and
      microvascular dysfunction. However, due to the lack of evidence and no specific
      methods or suggestions, it is necessary to conduct a systematic evaluation of
      Shenqi compound prescription to provide effective evidence for further research. 
      METHODS AND ANALYSIS: The following databases will be searched from their
      inception to August 2020: Electronic database includes PubMed, Embase, Cochrane
      Library, Web of Science, Nature, Science online, Chinese Biomedical Database
      WanFang, VIP medicine information, and China National Knowledge Infrastructure.
      PRIMARY OUTCOMES:: superoxide dismutase, malondialdehyde, C-reactiveprotein,
      HOMA-IR, advanced glycation end products , FPG, 2hBG, glycosylated hemoglobinA1c,
      fasting insulin ; ADDITIONAL OUTCOMES:: low density lipoprotein, high density
      lipoprotein, triglycerides, total serum cholesterol. Data will be extracted by 2 
      researchers independently, risk of bias of the meta-analysis will be evaluated
      based on the Cochrane Handbook for Systematic Reviews of Interventions. All data 
      analysis will be conducted by data statistics software Review Manager V.5.3. and 
      Stata V.12.0. RESULTS: The results of this study will systematically evaluate the
      efficacy and safety of Shenqi compound prescription in treating patients with
      MDT2DM CONCLUSION:: The systematic review of this study will summarize the
      current published evidence of Shenqi compound prescription in the treatment of
      MDT2DM, and further guide its popularization and application. ETHICS AND
      DISSEMINATION: This study is a systematic review, the outcomes are based on the
      published evidence, so examination and agreement by the ethics committee are not 
      required in this study. We intend to publish the study results in a journal or
      conference presentations. OPEN SCIENCE FRA MEWORK (OSF) REGISTRATION NUMBER:
      August 24, 2020.osf.io/es6z7. (https://osf.io/es6z7).
FAU - Zhong, Min
AU  - Zhong M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Song, Xiaohan
AU  - Song X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhang, Xinxia
AU  - Zhang X
AUID- ORCID: 0000-0003-3124-6110
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Chen, Junmin
AU  - Chen J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Xia, Jia
AU  - Xia J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Tang, Xiaoming
AU  - Tang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Chen, Q I
AU  - Chen QI
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Yang, Botong
AU  - Yang B
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (shenqi)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - *Drugs, Chinese Herbal
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Microcirculation/*drug effects
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7544279
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022347 [doi]
AID - 00005792-202010090-00018 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22347. doi: 10.1097/MD.0000000000022347.


PMID- 33031258
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - The efficacy and safety of auricular point combined with moxibustion for
      insomnia: A protocol for systematic review and meta-analysis.
PG  - e22107
LID - 10.1097/MD.0000000000022107 [doi]
AB  - BACKGROUND: Insomnia is a common sleep disorder, which seriously affects people's
      quality of life and work ability. In China, auricular therapy and moxibustion
      therapy have a long history in treating insomnia. Clinical studies have shown
      that auricular point and moxibustion can effectively improve insomnia symptoms.
      At present, auricular point combined with moxibustion in the treatment of
      insomnia has been widely used in China, but its overall effectiveness and safety 
      are still unclear. There is a lack of systematic evaluation of auricular point
      combined with moxibustion in the treatment of insomnia. This paper aims to
      evaluate the efficacy and safety of auricular point combined with moxibustion in 
      the treatment of insomnia. METHODS: Retrieve randomized controlled trials of
      auricular point combined with moxibustion from PubMed, EMbase, Cochrane Library, 
      Web of Science, China National Knowledge Infrastructure, WanFang, the Chongqing
      VIP Chinese Science and Technology Periodical Database, and China biomedical
      literature database from their establishment to August 2020. Search Baidu
      Scholar, Google Scholar, International Clinical Trials Registry Platform, and
      Chinese Clinical Trials Registry for unpublished gray literature. Two researchers
      independently applied RevMan 5.3 software for data extraction and risk assessment
      of bias. RESULTS: This study evaluated the efficacy and safety of auricular point
      combined with moxibustion in the treatment of insomnia from Pittsburgh sleep
      quality index, Rhone planck sleepiness scale, Traditional Chinese medicine
      syndrome scores, Hamilton anxiety scale (HAMA), Hamilton Depression,
      5-hydroxytryptamine, incidence of adverse reactions, and other aspects.
      CONCLUSION: This study will provide theoretical support for the clinical
      application of auricular point combined with moxibustion in the treatment of
      insomnia. ETHICS AND DISSEMINATION: The private information from individuals will
      not publish. This systematic review also will not involve endangering participant
      rights. Ethical approval is not required. The results may be published in a
      peer-reviewed journal or disseminated in relevant conferences. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/8VZRJ.
FAU - Jin, Rui
AU  - Jin R
AUID- ORCID: 0000-0001-6124-9609
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Wang, Xu
AU  - Wang X
AD  - Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital.
FAU - Lv, Yubing
AU  - Lv Y
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Xu, Guangnan
AU  - Xu G
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Yang, Chen
AU  - Yang C
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Guo, Yang
AU  - Guo Y
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion.
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin, China.
FAU - Li, Xinju
AU  - Li X
AD  - Tianjin University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupressure
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - *Moxibustion
MH  - *Research Design
MH  - Sleep Initiation and Maintenance Disorders/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7544260
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022107 [doi]
AID - 00005792-202010090-00005 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e22107. doi: 10.1097/MD.0000000000022107.


PMID- 33031257
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 41
DP  - 2020 Oct 9
TI  - Traditional Chinese medicine for psoriasis vulgaris: A Protocol of a prospective,
      multicenter cohort study.
PG  - e21913
LID - 10.1097/MD.0000000000021913 [doi]
AB  - INTRODUCTION: The incidence of psoriasis vulgaris is increasing worldwide.
      Chronic recurrence of the disease, as well as accompanying cardiovascular
      disease, metabolic syndrome, and depression has affected the physical and mental 
      health of these patients. Psoriasis vulgaris is a difficult and major disease in 
      the dermatology field. Short-term curative effects using conventional therapy for
      psoriasis vulgaris has made major strides. However, traditional Chinese medicine 
      (TCM) treatment has long-term curative advantages for psoriasis vulgaris but
      lacks the scientific and clinical evidence for its use. This study intends to
      demonstrate and provide scientific and clinical evidence for the use of TCM to
      delay the recurrence of psoriasis vulgaris. METHODS AND ANALYSIS: This will be a 
      prospective, multicenter cohort study. We intend to recruit 1521 psoriasis
      vulgaris patients from 14 hospitals in Beijing, Tianjin, and Hebei. Treatment
      will be based on the diagnosis specifications and clinical practice guidelines of
      TCM and conventional therapy. During inclusion and the subsequent follow-up
      period, doctors through electronic case reports will collect different
      therapeutic TCM regimens and conventional therapy that were administered.
      Information on life condition, skin lesions at each visit, World Health
      Organization Quality of Life Instruments, Zung Self-rating Anxiety Scale, Zung
      Self-assessment of Depression, laboratory examinations, incidence of new rash and
      recurrence during the remission and recurrence stages will be recorded. ETHICS
      AND DISSEMINATION: The clinical trial protocol for this study was approved by the
      ethics committee of the Beijing hospital of TCM affiliated to capital medical
      university (Ethics number: 2019BL02-010-02). We will publish and present our
      results at national and international conferences and in peer-reviewed journals
      specialized in dermatology. TRIAL REGISTRATION: This protocol has been registered
      in clinicaltrials. gov (ChiCTR1900021629).
FAU - Guo, Xinwei
AU  - Guo X
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Zhou, Dongmei
AU  - Zhou D
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University.
FAU - Sun, Liyun
AU  - Sun L
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University.
AD  - Beijing Hospital of Traditional Chinese Medicine Shunyi Branch.
FAU - Wang, Ping
AU  - Wang P
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University.
FAU - Qu, Jianhua
AU  - Qu J
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University.
FAU - Zhang, Cang
AU  - Zhang C
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University.
FAU - Wang, Yan
AU  - Wang Y
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Chen, Zhaoxia
AU  - Chen Z
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Li, Bo
AU  - Li B
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Hu, Jing
AU  - Hu J
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Lin, Zhimiao
AU  - Lin Z
AD  - Peking University First Hospital.
FAU - Shi, Fei
AU  - Shi F
AD  - Air Force General Hospital, PLA.
FAU - Bai, Yanping
AU  - Bai Y
AD  - China-Japan Friendship Hospital.
FAU - Li, Yuanwen
AU  - Li Y
AD  - Dongfang Hospital Beijing University of Chinese Medicine.
FAU - Duan, Xingwu
AU  - Duan X
AD  - Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital.
FAU - Bao, Shentao
AU  - Bao S
AD  - Beijing University of Chinese Medicine Third Affiliated Hospital.
FAU - Lan, Haibing
AU  - Lan H
AD  - Beijing Gulou Hospital of Traditional Chinese Medicine.
FAU - Sun, Xiaoyan
AU  - Sun X
AD  - Beijing Daxing District People's Hospital.
FAU - Wang, Xiong
AU  - Wang X
AD  - Traditional Chinese Medicine hospital of Beijing Miyun.
FAU - Liu, Xiang
AU  - Liu X
AD  - Hebei Province Hospital of Traditional Chinese Medicine.
FAU - Li, Linge
AU  - Li L
AD  - Traditional Chinese Medicine Hospital of Shijiazhuang City.
FAU - Zhang, Litao
AU  - Zhang L
AD  - Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, dermatology 
      department.
FAU - Feng, Fang
AU  - Feng F
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Meng, Yujiao
AU  - Meng Y
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Liu, Qingwu
AU  - Liu Q
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Guo, Xiaoyao
AU  - Guo X
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Guo, Jianning
AU  - Guo J
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Liu, Yu
AU  - Liu Y
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Qi, Cong
AU  - Qi C
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Chen, Jia
AU  - Chen J
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Feng, Shuo
AU  - Feng S
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
FAU - Li, Ping
AU  - Li P
AD  - Beijing Hospital of Traditional Chinese Medicine, Capital Medical University,
      Beijing Institute of Traditional Chinese Medicine.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Psoriasis/*therapy
PMC - PMC7544398
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000021913 [doi]
AID - 00005792-202010090-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 9;99(41):e21913. doi: 10.1097/MD.0000000000021913.


PMID- 33031082
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201218
IS  - 1972-2680 (Electronic)
IS  - 1972-2680 (Linking)
VI  - 14
IP  - 9
DP  - 2020 Sep 30
TI  - Ethical conflicts in COVID-19 times.
PG  - 968-970
LID - 10.3855/jidc.13137 [doi]
AB  - The COVID-19 pandemic has created new challenges on multiple fronts including a
      few ethical concerns. Timely and appropriate access to health services and the
      need to protect vulnerable people are some of them. An important aspect to
      consider, at the global level, is the frailty of health systems in many
      developing countries and the constant threat of these collapsing due to shortage 
      of resources and medical supply. Special attention should be placed towards
      protecting the health of care workers who are highly exposed to SARS-CoV-2
      infection. Research and clinical trials involving COVID-19 patients and healthy
      human volunteers must be done in strict adherence to the fundamental principles
      of bioethics, even if finding a solution is an urgent need. Shared responsibility
      must be assumed as we collectively face a common problem and ethical conflicts
      must be resolved using, as reference, the guidelines developed by the World
      Health Organization and other relevant international and national organizations. 
      This would allow responsible action in the face of the pandemic without harming
      human rights, the individual and collective well-being.
CI  - Copyright (c) 2020 Gilberto Vizcaino, Jose Gilberto Esparza.
FAU - Vizcaino, Gilberto
AU  - Vizcaino G
AD  - Instituto de Investigacion, Universidad Tecnica de Manabi, Portoviejo, Ecuador.
      gilvizcaino@gmail.com.
FAU - Esparza, Jose Gilberto
AU  - Esparza JG
AD  - Institute of Human Virology, University of Maryland School of Medicine,
      Baltimore, MD, United States. jose.esparza5@live.com.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - Italy
TA  - J Infect Dev Ctries
JT  - Journal of infection in developing countries
JID - 101305410
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic/ethics
MH  - Coronavirus Infections/diagnosis/epidemiology/therapy
MH  - Developing Countries
MH  - Global Health/*ethics
MH  - Health Personnel/ethics
MH  - Healthcare Disparities/ethics
MH  - Human Rights/ethics
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/diagnosis/epidemiology/therapy
MH  - SARS-CoV-2
MH  - Triage/ethics
OTO - NOTNLM
OT  - *COVID-19
OT  - *conflicts
OT  - *etichs
COIS- No Conflict of Interest is declared
EDAT- 2020/10/09 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/08 17:12
PHST- 2020/05/26 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/10/08 17:12 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.3855/jidc.13137 [doi]
PST - epublish
SO  - J Infect Dev Ctries. 2020 Sep 30;14(9):968-970. doi: 10.3855/jidc.13137.


PMID- 33030844
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 75
IP  - 10
DP  - 2020 Oct
TI  - [Virginity testing and hymen examination].
PG  - 670-675
AB  - In October 2018, the World Health Organization (WHO) has published a report
      condemning the practice of virginity testing, which are scientifically unfounded 
      and turn out to be harmful for the women who are victims of these. In February
      2019, the Belgian National Council of Physicians Order follows the WHO and has
      recalled that virginity testing is not justified, neither scientifically nor
      ethically. To complete these reports, the present article intends to provide to
      the clinician, whatever its speciality field, an up-to-date and practical guide
      explaining the nature of hymen, its clinical examination, the mechanism leading
      to the onset of the lesions, their description and their forensic interpretation.
      According to the legal and social aspects of forensic medicine, we also would
      like to recall the nature and the inherent dangers of virginity testing, as well 
      as the legal framework of which the clinician must be aware of, in response to
      such a request from a patient.
FAU - Partoune, A
AU  - Partoune A
AD  - Institut medico-legal de Liege, Belgique.
FAU - Dechamps, V
AU  - Dechamps V
AD  - Institut medico-legal de Liege, Belgique.
FAU - Berrendorf, M
AU  - Berrendorf M
AD  - Institut medico-legal de Liege, Belgique.
FAU - Tezel, M
AU  - Tezel M
AD  - Institut medico-legal de Liege, Belgique.
FAU - Boxho, P
AU  - Boxho P
AD  - Institut medico-legal de Liege, Belgique.
LA  - fre
PT  - Journal Article
TT  - Les tests de virginite et l'examen hymeneal.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
SB  - IM
MH  - Female
MH  - Humans
MH  - *Hymen
MH  - Physical Examination
MH  - *Physicians
MH  - Sexual Abstinence
OTO - NOTNLM
OT  - Examination techniques
OT  - Forensic medicine
OT  - Hymen
OT  - Interpretation of injuries
OT  - Virginity testing
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/08 12:25
PHST- 2020/10/08 12:25 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PST - ppublish
SO  - Rev Med Liege. 2020 Oct;75(10):670-675.


PMID- 33030629
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20220218
IS  - 1742-6316 (Electronic)
IS  - 0391-9714 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Oct 8
TI  - COVID-19, other zoonotic diseases and wildlife conservation.
PG  - 45
LID - 10.1007/s40656-020-00345-8 [doi]
AB  - Many experts have warned that environmental degradation is increasing the
      likelihood of future pandemics like COVID-19, as habitat loss and poaching
      increase close contact between wildlife and people. This fact has been framed as 
      a reason to increase wildlife conservation efforts. We have many good reasons to 
      step up conservation efforts, but arguments for doing so on the basis of pandemic
      prevention are rhetorically, ethically, and empricially flawed.
FAU - Santana, Carlos
AU  - Santana C
AUID- ORCID: http://orcid.org/0000-0002-9570-1904
AD  - Department of Philosophy, University of Utah, Salt Lake City, USA.
      c.santana@utah.edu.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - Switzerland
TA  - Hist Philos Life Sci
JT  - History and philosophy of the life sciences
JID - 8003052
SB  - IM
MH  - Animals
MH  - Animals, Wild
MH  - COVID-19
MH  - *Conservation of Natural Resources
MH  - Coronavirus Infections/*epidemiology
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Zoonoses/*epidemiology
PMC - PMC7542570
EDAT- 2020/10/09 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/10/08 12:23
PHST- 2020/08/15 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/08 12:23 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1007/s40656-020-00345-8 [doi]
AID - 10.1007/s40656-020-00345-8 [pii]
PST - epublish
SO  - Hist Philos Life Sci. 2020 Oct 8;42(4):45. doi: 10.1007/s40656-020-00345-8.


PMID- 33030440
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 10
DP  - 2020 Oct 8
TI  - Implementation of Electronic Informed Consent in Biomedical Research and
      Stakeholders' Perspectives: Systematic Review.
PG  - e19129
LID - 10.2196/19129 [doi]
AB  - BACKGROUND: Informed consent is one of the key elements in biomedical research.
      The introduction of electronic informed consent can be a way to overcome many
      challenges related to paper-based informed consent; however, its novel
      opportunities remain largely unfulfilled due to several barriers. OBJECTIVE: We
      aimed to provide an overview of the ethical, legal, regulatory, and user
      interface perspectives of multiple stakeholder groups in order to assist
      responsible implementation of electronic informed consent in biomedical research.
      METHODS: We conducted a systematic literature search using Web of Science (Core
      collection), PubMed, EMBASE, ACM Digital Library, and PsycARTICLES. PRISMA
      (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines
      were used for reporting this work. We included empirical full-text studies
      focusing on the concept of electronic informed consent in biomedical research
      covering the ethical, legal, regulatory, and user interface domains. Studies
      written in English and published from January 2010 onward were selected. We
      explored perspectives of different stakeholder groups, in particular researchers,
      research participants, health authorities, and ethics committees. We critically
      appraised literature included in the systematic review using the Newcastle-Ottawa
      scale for cohort and cross-sectional studies, Critical Appraisal Skills Programme
      for qualitative studies, Mixed Methods Appraisal Tool for mixed methods studies, 
      and Jadad tool for randomized controlled trials. RESULTS: A total of 40 studies
      met our inclusion criteria. Overall, the studies were heterogeneous in the type
      of study design, population, intervention, research context, and the tools used. 
      Most of the studies' populations were research participants (ie, patients and
      healthy volunteers). The majority of studies addressed barriers to achieving
      adequate understanding when using electronic informed consent. Concerns shared by
      multiple stakeholder groups were related to the security and legal validity of an
      electronic informed consent platform and usability for specific groups of
      research participants. CONCLUSIONS: Electronic informed consent has the potential
      to improve the informed consent process in biomedical research compared to the
      current paper-based consent. The ethical, legal, regulatory, and user interface
      perspectives outlined in this review might serve to enhance the future
      implementation of electronic informed consent. TRIAL REGISTRATION: PROSPERO
      International Prospective Register of Systematic Reviews CRD42020158979;
      https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=158979.
CI  - (c)Evelien De Sutter, Drieda Zace, Stefania Boccia, Maria Luisa Di Pietro, David 
      Geerts, Pascal Borry, Isabelle Huys. Originally published in the Journal of
      Medical Internet Research (http://www.jmir.org), 08.10.2020.
FAU - De Sutter, Evelien
AU  - De Sutter E
AUID- ORCID: 0000-0001-6575-2033
AD  - Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and
      Pharmacological Sciences, KU Leuven, Leuven, Belgium.
FAU - Zace, Drieda
AU  - Zace D
AUID- ORCID: 0000-0003-3623-6800
AD  - Section of Hygiene, University Department of Life Sciences and Public Health,
      Universita Cattolica del Sacro Cuore, Roma, Italy.
FAU - Boccia, Stefania
AU  - Boccia S
AUID- ORCID: 0000-0002-1864-749X
AD  - Section of Hygiene, University Department of Life Sciences and Public Health,
      Universita Cattolica del Sacro Cuore, Roma, Italy.
AD  - Department of Woman and Child Health and Public Health, Fondazione Policlinico
      Universitario A Gemelli IRCCS, Roma, Italy.
FAU - Di Pietro, Maria Luisa
AU  - Di Pietro ML
AUID- ORCID: 0000-0002-3893-8788
AD  - Section of Hygiene, University Department of Life Sciences and Public Health,
      Universita Cattolica del Sacro Cuore, Roma, Italy.
FAU - Geerts, David
AU  - Geerts D
AUID- ORCID: 0000-0003-3933-9266
AD  - Meaningful Interactions Lab, KU Leuven, Leuven, Belgium.
FAU - Borry, Pascal
AU  - Borry P
AUID- ORCID: 0000-0002-4931-9560
AD  - Centre for Biomedical Ethics and Law, Department of Public Health and Primary
      Care, KU Leuven, Leuven, Belgium.
FAU - Huys, Isabelle
AU  - Huys I
AUID- ORCID: 0000-0002-4738-8298
AD  - Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and
      Pharmacological Sciences, KU Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201008
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomedical Research/*methods
MH  - Cross-Sectional Studies
MH  - Electronics
MH  - Female
MH  - Humans
MH  - Informed Consent/*standards
MH  - Internet
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - Research Design
MH  - Young Adult
PMC - PMC7582148
OTO - NOTNLM
OT  - *Informed consent
OT  - *biomedical research
OT  - *digital health
OT  - *research ethics
OT  - *systematic review
OT  - *user interface
EDAT- 2020/10/09 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/10/08 12:21
PHST- 2020/04/06 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/08/07 00:00 [revised]
PHST- 2020/10/08 12:21 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - v22i10e19129 [pii]
AID - 10.2196/19129 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Oct 8;22(10):e19129. doi: 10.2196/19129.


PMID- 33030439
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201029
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 8
TI  - The Analgesic Effect of Electroencephalographic Neurofeedback for People With
      Chronic Pain: Protocol for a Systematic Review and Meta-analysis.
PG  - e22821
LID - 10.2196/22821 [doi]
AB  - BACKGROUND: Chronic pain is a global health problem, affecting around 1 in 5
      individuals in the general population. The understanding of the key role of
      functional brain alterations in the generation of chronic pain has led
      researchers to focus on pain treatments that target brain activity.
      Electroencephalographic neurofeedback attempts to modulate the power of
      maladaptive electroencephalography frequency powers to decrease chronic pain.
      Although several studies have provided promising evidence, the effect of
      electroencephalographic neurofeedback on chronic pain is uncertain. OBJECTIVE:
      This systematic review aims to synthesize the evidence from randomized controlled
      trials to evaluate the analgesic effect of electroencephalographic neurofeedback.
      In addition, we will synthesize the findings of nonrandomized studies in a
      narrative review. METHODS: We will apply the search strategy in 5 electronic
      databases (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE,
      PsycInfo, and CINAHL) for published studies and in clinical trial registries for 
      completed unpublished studies. We will include studies that used
      electroencephalographic neurofeedback as an intervention for people with chronic 
      pain. Risk-of-bias tools will be used to assess methodological quality of the
      included studies. We will include randomized controlled trials if they have
      compared electroencephalographic neurofeedback with any other intervention or
      placebo control. The data from randomized controlled trials will be aggregated to
      perform a meta-analysis for quantitative synthesis. The primary outcome measure
      is pain intensity assessed by self-report scales. Secondary outcome measures
      include depressive symptoms, anxiety symptoms, and sleep quality measured by
      self-reported questionnaires. We will investigate the studies for additional
      outcomes addressing adverse effects and resting-state electroencephalography
      analysis. Additionally, all types of nonrandomized studies will be included for a
      narrative synthesis. The intended and unintended effects of nonrandomized studies
      will be extracted and summarized in a descriptive table. RESULTS: Ethics approval
      is not required for a systematic review, as there will be no patient involvement.
      The search for this systematic review commenced in July 2020, and we expect to
      publish the findings in early 2021. CONCLUSIONS: This systematic review will
      provide recommendations for researchers and health professionals, as well as
      people with chronic pain, about the evidence for the analgesic effect of
      electroencephalographic neurofeedback. TRIAL REGISTRATION: International
      Prospective Register of Systematic Reviews (PROSPERO) CRD42020177608;
      https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=177608.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/22821.
CI  - (c)Negin Hesam-Shariati, Wei-Ju Chang, James H McAuley, Andrew Booth, Zina Trost,
      Chin-Teng Lin, Toby Newton-John, Sylvia M Gustin. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 08.10.2020.
FAU - Hesam-Shariati, Negin
AU  - Hesam-Shariati N
AUID- ORCID: https://orcid.org/0000-0003-0829-7016
AD  - Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
AD  - School of Psychology, University of New South Wales, Sydney, Australia.
FAU - Chang, Wei-Ju
AU  - Chang WJ
AUID- ORCID: https://orcid.org/0000-0003-0524-4883
AD  - Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
FAU - McAuley, James H
AU  - McAuley JH
AUID- ORCID: https://orcid.org/0000-0002-0550-828X
AD  - Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia.
FAU - Booth, Andrew
AU  - Booth A
AUID- ORCID: https://orcid.org/0000-0003-4808-3880
AD  - School of Health and Related Research, University of Sheffield, Sheffield, United
      Kingdom.
FAU - Trost, Zina
AU  - Trost Z
AUID- ORCID: https://orcid.org/0000-0002-3345-0337
AD  - Department of Physical Medicine and Rehabilitation, Virginia Commonwealth
      University, Richmond, VA, United States.
FAU - Lin, Chin-Teng
AU  - Lin CT
AUID- ORCID: https://orcid.org/0000-0001-8371-8197
AD  - Australian Artificial Intelligence Institute, Faculty of Engineering and
      Information Technology, University of Technology Sydney, Sydney, Australia.
FAU - Newton-John, Toby
AU  - Newton-John T
AUID- ORCID: https://orcid.org/0000-0003-4219-4985
AD  - Graduate School of Health, University of Technology Sydney, Sydney, Australia.
FAU - Gustin, Sylvia M
AU  - Gustin SM
AUID- ORCID: https://orcid.org/0000-0002-9613-9845
AD  - Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia.
AD  - School of Psychology, University of New South Wales, Sydney, Australia.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7582146
OTO - NOTNLM
OT  - EEG neurofeedback
OT  - chronic pain
OT  - meta-analysis
OT  - systematic review
EDAT- 2020/10/09 06:00
MHDA- 2020/10/09 06:01
CRDT- 2020/10/08 12:21
PHST- 2020/07/23 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/09/14 00:00 [revised]
PHST- 2020/10/08 12:21 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/09 06:01 [medline]
AID - v9i10e22821 [pii]
AID - 10.2196/22821 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 8;9(10):e22821. doi: 10.2196/22821.


PMID- 33029070
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Jun 16
TI  - Global responsibility vs. individual dreams: addressing ethical dilemmas created 
      by the migration of healthcare practitioners.
PG  - 81-89
LID - 10.1080/11287462.2020.1773054 [doi]
AB  - Background The migration of health care professionals from developing to
      developed countries is a trend. This migration benefits the destination countries
      but is quite often devastating to healthcare systems within the home countries.
      Skilled practitioners from developing countries forego opportunities in their
      homelands to migrate to developed countries. This leaves a vacuum of talent,
      weakening the health systems in the 'home' countries. Methods This piece analyzes
      the consequence of such migration through the lens of the four principles of
      Universal Declaration of Bioethics and Human rights (UDBHR): equality, justice
      and equity, solidarity and cooperation, and sharing of benefits. Results In the
      light of moral imagination and moral reflection, we can understand one another as
      global citizens. Policymakers must develop guides to restore balance and ensure
      equitable healthcare worldwide. Incorporating ethics education in medical schools
      and hospitals, implementing temporary migration visas, and helping home countries
      offer attractive compensation can address this concern. Conclusions Health is a
      universal human right; the well-being of all must be addressed without overly
      limiting the rights of practitioners to build the lives they imagine. On the
      other hand, practitioners should consider themselves global citizens and consider
      their ethical obligations when considering their migration.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Hossain, Fahmida
AU  - Hossain F
AUID- ORCID: https://orcid.org/0000-0001-9415-6652
AD  - Center for Healthcare Ethics, Duquesne University, Pittsburgh, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7473311
OTO - NOTNLM
OT  - Health practitioners
OT  - ethics
OT  - global health
OT  - human rights
OT  - migration
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2020/10/09 06:00
MHDA- 2020/10/09 06:01
CRDT- 2020/10/08 05:32
PHST- 2020/10/08 05:32 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/09 06:01 [medline]
AID - 10.1080/11287462.2020.1773054 [doi]
AID - 1773054 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Jun 16;31(1):81-89. doi: 10.1080/11287462.2020.1773054.


PMID- 33028919
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20211007
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Oct 7
TI  - Waist-to-height ratio and skipping breakfast are predictive factors for high
      blood pressure in adolescents.
PG  - 16704
LID - 10.1038/s41598-020-73355-y [doi]
AB  - The purpose of this study was to estimate the prevalence of high blood pressure
      (HBP) in adolescents of the Valencian Autonomous Community (VC) in Spain.
      Besides, its association with other risk factors related to cardiovascular
      disease (CVD) or arterial hypertension (AHT) in order to increase our knowledge
      of public health and to provide advice about healthy diets. We conducted a
      multicentre, observational, cross-sectional, epidemiological study in a sample of
      4402 adolescents from 15 schools during the 2015-2016 school year. The
      participants were aged between 11 and 18 years, and any individuals already
      diagnosed with AHT were excluded. In addition to the Physical Activity
      Questionnaire for Adolescents (PAQ-A), Evaluation of the Mediterranean Diet
      Quality Index (KIDMED), a lifestyle habits survey, the waist-to-height ratio
      (WtHR), and body mass index (BMI) were calculated for each participant. Informed 
      Consent was obtained from Parents of the adolescents involved in the current
      study. The study received approval from the University ethics committee and all
      procedures were conducted in accordance with the tenets of the Declaration of
      Helsinki. Chi-squared, Student t-tests, and ANOVA statistical analyses showed
      that 653 (14.8%) adolescents had previously undiagnosed HBP and that was
      significantly associated with male sex (p < 0.001), age over 15 years (p < 0.05),
      and height, weight, waist circumference, WtHR, BMI, and skipping breakfast. Based
      on the data we obtained in this study, the modifiable factors that influence HBP 
      in adolescents were WtHR, BMI, and skipping breakfast.
FAU - Aparicio-Cercos, C
AU  - Aparicio-Cercos C
AD  - Community Pharmacy, SEFAC, Valencia, Spain.
AD  - Department of Pharmacy, Universidad Cardenal Herrera-CEU, CEU Universities,
      C/Ramon y Cajal s/n, Alfara del Patriarca, 46115, Valencia, Spain.
FAU - Alacreu, M
AU  - Alacreu M
AD  - Embedded Systems and Artificial Intelligence Group, Universidad Cardenal
      Herrera-CEU, CEU Universities, Alfara del Patriarca, Valencia, Spain.
FAU - Salar, L
AU  - Salar L
AD  - Community Pharmacy, SEFAC, Valencia, Spain.
AD  - Department of Pharmacy, Universidad Cardenal Herrera-CEU, CEU Universities,
      C/Ramon y Cajal s/n, Alfara del Patriarca, 46115, Valencia, Spain.
FAU - Moreno Royo, L
AU  - Moreno Royo L
AD  - Department of Pharmacy, Universidad Cardenal Herrera-CEU, CEU Universities,
      C/Ramon y Cajal s/n, Alfara del Patriarca, 46115, Valencia, Spain.
      lmoreno@uchceu.es.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201007
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Adolescent
MH  - Blood Pressure/*physiology
MH  - Body Mass Index
MH  - *Breakfast
MH  - Child
MH  - Cross-Sectional Studies
MH  - Databases, Factual
MH  - Feeding Behavior/*physiology
MH  - Female
MH  - Humans
MH  - Hypertension/*etiology/physiopathology
MH  - Life Style
MH  - Male
MH  - Risk Factors
MH  - *Waist-Height Ratio
PMC - PMC7542155
EDAT- 2020/10/09 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/08 05:29
PHST- 2020/03/10 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/10/08 05:29 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-73355-y [doi]
AID - 10.1038/s41598-020-73355-y [pii]
PST - epublish
SO  - Sci Rep. 2020 Oct 7;10(1):16704. doi: 10.1038/s41598-020-73355-y.


PMID- 33028701
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201218
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 10
DP  - 2020 Oct
TI  - Protecting essential health services in low-income and middle-income countries
      and humanitarian settings while responding to the COVID-19 pandemic.
LID - e003675 [pii]
LID - 10.1136/bmjgh-2020-003675 [doi]
AB  - In health outcomes terms, the poorest countries stand to lose the most from these
      disruptions. In this paper, we make the case for a rational approach to public
      sector health spending and decision making during and in the early recovery phase
      of the COVID-19 pandemic. Based on ethics and equity principles, it is crucial to
      ensure that patients not infected by COVID-19 continue to get access to
      healthcare and that the services they need continue to be resourced. We present a
      list of 120 essential non-COVID-19 health interventions that were adapted from
      the model health benefit packages developed by the Disease Control Priorities
      project.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Blanchet, Karl
AU  - Blanchet K
AUID- ORCID: 0000-0003-0498-8020
AD  - Geneva Centre of Humanitarian Studies, University of Geneva Faculty of Medicine, 
      Geneve, Switzerland karl.blanchet@unige.ch.
FAU - Alwan, Ala
AU  - Alwan A
AD  - Faculty of Public Health and Policy, London School of Hygiene & Tropical
      Medicine, London, UK.
AD  - University of Washington, Seattle, Washington, USA.
FAU - Antoine, Caroline
AU  - Antoine C
AD  - Action Contre la Faim, Paris, France.
FAU - Cros, Marion Jane
AU  - Cros MJ
AD  - Global Financing Facility/World Bank, Addis Ababa, Ethiopia.
FAU - Feroz, Ferozuddin
AU  - Feroz F
AD  - Ministry of Public Health, Kabul, Afghanistan.
FAU - Amsalu Guracha, Tseguaneh
AU  - Amsalu Guracha T
AD  - Global Financing Facility/World Bank, Addis Abab, Ethiopia.
FAU - Haaland, Oystein
AU  - Haaland O
AD  - Department of Global Public Health and Primary Care, University of Bergen,
      Bergen, Norway.
FAU - Hailu, Alemayehu
AU  - Hailu A
AUID- ORCID: 0000-0003-4872-8036
AD  - Department of Global Public Health and Primary Care, University of Bergen,
      Bergen, Norway.
FAU - Hangoma, Peter
AU  - Hangoma P
AUID- ORCID: 0000-0002-6573-5628
AD  - Health Policy and Management, University of Zambia, Lusaka, Zambia.
FAU - Jamison, Dean
AU  - Jamison D
AD  - Global Health Sciences, University of California, San Francisco, California, USA.
FAU - Memirie, Solomon Tessema
AU  - Memirie ST
AD  - Department of Global Public Health and Primary Care, Universitetet i Bergen,
      Bergen, Norway.
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Cambridge, Massachusetts, USA.
FAU - Miljeteig, Ingrid
AU  - Miljeteig I
AUID- ORCID: 0000-0001-5738-017X
AD  - Department of Global Health and Primary Health Care, University of Bergen Faculty
      of Medicine and Dentistry, Bergen, Norway.
AD  - Department of Research and Development, Haukeland University Hospital, Bergen,
      Norway.
FAU - Jan Naeem, Ahmad
AU  - Jan Naeem A
AD  - Ministry of Public Health, Kabul, Afghanistan.
FAU - Nam, Sara L
AU  - Nam SL
AD  - Options Consultancy Services Ltd, London, UK.
FAU - Norheim, Ole Frithjof
AU  - Norheim OF
AD  - Department of Global Public Health and Primary Care, University of Bergen,
      Bergen, Norway.
FAU - Verguet, Stephane
AU  - Verguet S
AUID- ORCID: 0000-0003-4128-0849
AD  - Global Health and Population, Harvard University T H Chan School of Public
      Health, Boston, Massachusetts, USA.
FAU - Watkins, David
AU  - Watkins D
AUID- ORCID: 0000-0001-6341-9595
AD  - University of Washington, Seattle, Washington, USA.
FAU - Johansson, Kjell Arne
AU  - Johansson KA
AUID- ORCID: 0000-0001-8912-8710
AD  - Department of Global Public Health and Primary care, University of Bergen Faculty
      of Medicine and Dentistry, Bergen, Norway.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *Altruism
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Developing Countries
MH  - *Health Services Accessibility/organization & administration/standards
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Poverty
MH  - Public Health
MH  - SARS-CoV-2
PMC - PMC7542611
OTO - NOTNLM
OT  - *control strategies
OT  - *health economics
OT  - *health policies and all other topics
OT  - *health systems
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/08 05:27
PHST- 2020/08/10 00:00 [received]
PHST- 2020/09/14 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/10/08 05:27 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - bmjgh-2020-003675 [pii]
AID - 10.1136/bmjgh-2020-003675 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Oct;5(10). pii: bmjgh-2020-003675. doi:
      10.1136/bmjgh-2020-003675.


PMID- 33028661
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201218
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 5
DP  - 2020 Nov
TI  - COVID-19 Trial Enrollment for Those Who Cannot Consent: Ethical Challenges Posed 
      by a Pandemic.
LID - e2020010728 [pii]
LID - 10.1542/peds.2020-010728 [doi]
AB  - The current coronavirus disease 2019 (COVID-19) pandemic has triggered an intense
      global research effort to inform the life-saving work of frontline clinicians who
      need reliable information as soon as possible. Yet research done in pressured
      circumstances can lead to ethical dilemmas, especially for vulnerable research
      subjects. We present the case of a child with neurocognitive impairment who is
      diagnosed with COVID-19 infection after presenting with fever and a seizure. The 
      child lives in a group home and is in the custody of the state; her parents lost 
      parental rights many years ago. Some members of the health care team want to
      enroll her in a randomized clinical trial evaluating an experimental treatment of
      COVID-19. For minor patients to enroll in this clinical trial, the institutional 
      review board requires assent of patients and consent of guardians. An ethics
      consult is called to help identify relevant concerns in enrollment. In the
      accompanying case discussion, we address historical perspectives on research
      involving people with disabilities; proper management of research participation
      for people with disabilities including consent by proxy, therapeutic
      misconception, and other threats to the ethical validity of clinical trials; and 
      the potentially conflicting obligations of researchers and clinicians.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - House, Samantha A
AU  - House SA
AD  - Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth
      College, Hanover, New Hampshire; samantha.a.house@hitchcock.org.
AD  - Department of Pediatrics, Children's Hospital at Dartmouth-Hitchcock Medical
      Center, Lebanon, New Hampshire.
FAU - Shubkin, Catherine D
AU  - Shubkin CD
AD  - Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth
      College, Hanover, New Hampshire.
AD  - Department of Pediatrics, Children's Hospital at Dartmouth-Hitchcock Medical
      Center, Lebanon, New Hampshire.
FAU - Lahey, Tim
AU  - Lahey T
AD  - Division of Infectious Disease, Larner College of Medicine, The University of
      Vermont and The University of Vermont Medical Center, Burlington, Vermont.
FAU - Brosco, Jeffrey P
AU  - Brosco JP
AD  - Institute for Bioethics and Health Policy, Miller School of Medicine, University 
      of Miami, Miami, Florida; and.
FAU - Lantos, John
AU  - Lantos J
AD  - Bioethics Center, Children's Mercy Hospital, Kansas City, Missouri.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201007
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/complications/*drug therapy
MH  - Female
MH  - Humans
MH  - *Mental Competency
MH  - Neurocognitive Disorders/*complications
MH  - Pandemics
MH  - Pneumonia, Viral/complications/*drug therapy
MH  - Randomized Controlled Trials as Topic/*ethics
MH  - SARS-CoV-2
MH  - Third-Party Consent/*ethics
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/10/09 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/10/08 05:27
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2020/10/08 05:27 [entrez]
AID - peds.2020-010728 [pii]
AID - 10.1542/peds.2020-010728 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Nov;146(5). pii: peds.2020-010728. doi:
      10.1542/peds.2020-010728. Epub 2020 Oct 7.


PMID- 33028625
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Health justice in the Anthropocene: medical ethics and the Land Ethic.
PG  - 791-796
LID - 10.1136/medethics-2020-106855 [doi]
AB  - Industrialisation, urbanisation and economic development have produced
      unprecedented (if unevenly distributed) improvements in human health. They have
      also produced unprecedented exploitation of Earth's life support systems, moving 
      the planet into a new geological epoch, the Anthropocene-one defined by human
      influence on natural systems. The health sector has been complicit in this
      influence. Bioethics, too, must acknowledge its role-the environmental threats
      that will shape human health in this century represent a 'perfect moral storm'
      challenging the ethical theories of the last. The US conservationist Aldo Leopold
      saw this gathering storm more clearly than many, and in his Land Ethic describes 
      the beginnings of a route to safe passage. Its starting point is a
      reinterpretation of the ethical relationship between humanity and the 'land
      community', the ecosystems we live within and depend upon; moving us from
      'conqueror' to 'plain member and citizen' of that community. The justice of the
      Land Ethic questions many presuppositions implicit to discussions of the topic in
      biomedical ethics. By valuing the community in itself-in a way irreducible to the
      welfare of its members-it steps away from the individualism axiomatic in
      contemporary bioethics. Viewing ourselves as citizens of the land community also 
      extends the moral horizons of healthcare from a solely human focus. Taking into
      account the 'stability' of the community requires intergenerational justice. The 
      resulting vision of justice in healthcare-one that takes climate and
      environmental justice seriously-could offer health workers an ethic fit for the
      future.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Wardrope, Alistair
AU  - Wardrope A
AUID- ORCID: 0000-0003-3614-6346
AD  - Academic Neurology Unit, The University of Sheffield, Sheffield, UK
      ajwardrope1@sheffield.ac.uk.
AD  - Department of Neurosciences, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Animal Rights
MH  - *Bioethics
MH  - Ecosystem
MH  - Ethical Theory
MH  - *Ethics, Medical
MH  - Humans
MH  - Morals
MH  - *Social Justice
OTO - NOTNLM
OT  - *distributive justice
OT  - *environmental ethics
OT  - *speciesism
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/10/08 05:27
PHST- 2020/08/29 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2020/10/08 05:27 [entrez]
AID - medethics-2020-106855 [pii]
AID - 10.1136/medethics-2020-106855 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):791-796. doi: 10.1136/medethics-2020-106855. Epub
      2020 Oct 7.


PMID- 33028624
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Integrating philosophy, policy and practice to create a just and fair health
      service.
PG  - 797-802
LID - 10.1136/medethics-2020-106853 [doi]
AB  - To practise 'fairly and justly' a clinician must balance the needs of both the
      many and the few: the individual patient in front of them, and the many unseen
      patients in the waiting room, and in the county. They must consider the immediate
      clinical needs of those in the present, and how their actions will impact on
      future patients. The good medical practice guidance 'Make the care of your
      patient your first concern' provides no guidance on how doctors should act when
      they care for multiple patients with conflicting needs. Moreover, conflicting
      needs extend far past simply those between different patients. At an
      organisational level, financial obligations must be balanced with clinical ones; 
      the system must support those who work within it in a variety of roles; and,
      finally, in order for a healthcare service to be sustainable, the demands of
      current and future generations must be balanced.The central problem, we propose, 
      is that there is no shared philosophical framework on which the provision of care
      or the development of health policy is based, nor is there a practical, fair and 
      transparent process to ensure that the service is equipped to deal justly with
      new challenges as they emerge. Many philosophers have grappled with constructing 
      a set of principles which would lead to a 'good' society which is just to
      different users; prominent among them is Rawls.Four important principles can be
      derived using a Rawlsian approach: equity of access, distributive justice,
      sustainability and openness. However, Rawls' approach is sometimes considered too
      abstract to be applied readily to policymaking; it does not provide clear
      guidance for how individuals working within existing institutions can enact the
      principles of justice. We therefore combine the principles derived from Rawls
      with Scanlonian contractualism: by demanding that decisions are made in a way
      which cannot be 'reasonably rejected' by different stakeholders (including
      'trustees' for those who cannot represent themselves), we ensure that conflicting
      needs are considered robustly.We demonstrate how embedding this framework would
      ensure just policies and fair practice. We illustrate this by using examples of
      how it would help prevent injustice among different socioeconomic groups, prevent
      intergenerational injustice and prevent injustice in a crisis, for example, as we
      respond to new challenges such as COVID-19.Attempts to help individual doctors
      practise fairly and justly throughout their professional lives are best focused
      at an institutional or systemic level. We propose a practical framework:
      combining Scanlonian contractualism with a Rawlsian approach. Adopting this
      framework would equip the workforce and population to contribute to fair
      policymaking, and would ultimately result in a healthcare system whose practice
      and policies-at their core-were just.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fritz, Zoe
AU  - Fritz Z
AUID- ORCID: 0000-0001-9403-409X
AD  - The Healthcare Improvement Studies Institute (THIS Institute), University of
      Cambridge, Cambridge, UK.
AD  - Acute Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge,
      UK.
FAU - Cox, Caitriona L
AU  - Cox CL
AUID- ORCID: 0000-0001-9416-9509
AD  - The Healthcare Improvement Studies Institute (THIS Institute), University of
      Cambridge, Cambridge, UK caitriona.cox@nhs.net.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Delivery of Health Care/ethics/*organization & administration/standards
MH  - Health Care Rationing/organization & administration
MH  - Health Services Accessibility/ethics/organization & administration
MH  - Humans
MH  - Pandemics
MH  - Philosophy, Medical
MH  - *Policy
MH  - SARS-CoV-2
MH  - Socioeconomic Factors
PMC - PMC7719902
OTO - NOTNLM
OT  - *distributive justice
OT  - *ethics
OT  - *political philosophy
OT  - *public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/10/08 05:27
PHST- 2020/09/01 00:00 [received]
PHST- 2020/09/03 00:00 [revised]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/10/08 05:27 [entrez]
AID - medethics-2020-106853 [pii]
AID - 10.1136/medethics-2020-106853 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):797-802. doi: 10.1136/medethics-2020-106853. Epub
      2020 Oct 7.


PMID- 33028566
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Study protocol: azithromycin therapy for chronic lung disease of prematurity
      (AZTEC) - a randomised, placebo-controlled trial of azithromycin for the
      prevention of chronic lung disease of prematurity in preterm infants.
PG  - e041528
LID - 10.1136/bmjopen-2020-041528 [doi]
AB  - INTRODUCTION: Chronic lung disease of prematurity (CLD), also known as
      bronchopulmonary dysplasia (BPD), is a cause of significant respiratory morbidity
      in childhood and beyond. Coupled with lung immaturity, infections (especially by 
      Ureaplasma spp) are implicated in the pathogenesis of CLD through promotion of
      pulmonary inflammation. Azithromycin, which is a highly effective against
      Ureaplasma spp also has potent anti-inflammatory properties. Thus, azithromycin
      therapy may improve respiratory outcomes by targeting infective and inflammatory 
      pathways. Previous trials using macrolides have not been sufficiently powered to 
      definitively assess CLD rates. To address this, the azithromycin therapy for
      chronic lung disease of prematurity (AZTEC) trial aims to determine if a 10-day
      early course of intravenous azithromycin improves rates of survival without CLD
      when compared with placebo with an appropriately powered study. METHODS AND
      ANALYSIS: 796 infants born at less than 30 weeks' gestational age who require at 
      least 2 hours of continuous respiratory support within the first 72 hours
      following birth are being enrolled by neonatal units in the UK. They are being
      randomised to receive a double-blind, once daily dose of intravenous azithromycin
      (20 mg/kg for 3 days, followed by 10 mg/kg for a further 7 days), or placebo. CLD
      is being assessed at 36 weeks' PMA. Whether colonisation with Ureaplasma spp
      prior to randomisation modifies the treatment effect of azithromycin compared
      with placebo will also be investigated. Secondary outcomes include necrotising
      enterocolitis, intraventricular/cerebral haemorrhage, retinopathy of prematurity 
      and nosocomial infections, development of antibiotic resistance and adverse
      reactions will be monitored. ETHICS AND DISSEMINATION: Ethics permission has been
      granted by Wales Research Ethics Committee 2 (Ref 18/WA/0199), and regulatory
      permission by the Medicines and Healthcare Products Regulatory Agency (Clinical
      Trials Authorisation reference 21323/0050/001-0001). The study is registered on
      ISRCTN (ISRCTN11650227). The study is overseen by an independent Data Monitoring 
      Committee and an independent Trial Steering Committee. We shall disseminate our
      findings via national and international peer-reviewed journals, and conferences. 
      A summary of the findings will also be posted on the trial website.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lowe, John
AU  - Lowe J
AD  - Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Gillespie, David
AU  - Gillespie D
AD  - Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Hubbard, Marie
AU  - Hubbard M
AD  - Neonatal Intensive Care Unit, University Hospitals of Leicester NHS Trust,
      Leicester, Leicester, UK.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Child Health, School of Medicine, Cardiff University, Cardiff,
      United Kingdom.
FAU - Kirby, Nigel
AU  - Kirby N
AD  - Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Pickles, Timothy
AU  - Pickles T
AD  - Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Thomas-Jones, Emma
AU  - Thomas-Jones E
AD  - Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Turner, Mark A
AU  - Turner MA
AD  - Institute of Translational Medicine, University of Liverpool, Liverpool, United
      Kingdom.
FAU - Klein, Nigel
AU  - Klein N
AD  - GOS Institute of Child Health, University College London, London, London, UK.
FAU - Marchesi, Julian R
AU  - Marchesi JR
AD  - School of Biosciences, Cardiff University, Cardiff, UK.
FAU - Hood, Kerenza
AU  - Hood K
AD  - Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, UK.
FAU - Berrington, Janet
AU  - Berrington J
AD  - Neonatal Intensive Care Unit, Newcastle Upon Tyne Hospitals NHS Foundation Trust,
      Newcastle Upon Tyne, UK.
FAU - Kotecha, Sailesh
AU  - Kotecha S
AUID- ORCID: 0000-0003-3535-7627
AD  - Department of Child Health, School of Medicine, Cardiff University, Cardiff,
      United Kingdom KotechaS@cardiff.ac.uk.
LA  - eng
SI  - ISRCTN/ISRCTN11650227
GR  - 16/111/106/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glucocorticoids)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 83905-01-5 (Azithromycin)
SB  - IM
MH  - Azithromycin/therapeutic use
MH  - Child
MH  - Chronic Disease
MH  - Dexamethasone
MH  - Glucocorticoids
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - *Infant, Premature, Diseases/drug therapy/prevention & control
MH  - *Lung Diseases/drug therapy/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Wales
PMC - PMC7539578
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *neonatology
OT  - *paediatric thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-041528 [pii]
AID - 10.1136/bmjopen-2020-041528 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e041528. doi: 10.1136/bmjopen-2020-041528.


PMID- 33028562
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general
      population of northern Italy and evaluation of a diagnostic serological ELISA
      test: a cross-sectional study protocol.
PG  - e040036
LID - 10.1136/bmjopen-2020-040036 [doi]
AB  - INTRODUCTION: As of 30 April 2020, the novel betacoronavirus SARS-CoV-2 had
      infected more than 3 172 000 individuals, killing over 224 000 people and
      spreading to more than 200 countries. Italy was the most affected country in
      Europe and the third most affected in the world in terms of the number of cases. 
      Therefore, the aims of this study are: (1) to estimate the prevalence of
      asymptomatic SARS-CoV-2-positive individuals among the general population of
      Verona; (2) to assess the accuracy (sensitivity, specificity and predictive
      values) of an ELISA serological test for the screening of SARS-CoV-2. METHODS AND
      ANALYSIS: The study will be carried out on a random sample of subjects aged at
      least 10 years from the general population of Verona. Participants will undergo
      the measurement of vital parameters (oxygen saturation measured by oximeter,
      respiratory rate and body temperature detected by laser thermometer), the
      administration of a COVID-19-related symptoms questionnaire, the collection of a 
      blood sample and a nasopharyngeal swab. Our evaluation will include the
      statistical technique of Latent Class Analysis, which will be the basis for the
      estimation of prevalence. ETHICS AND DISSEMINATION: The study protocol has been
      approved by the Ethics Committee of Verona and Rovigo provinces on 15 April 2020 
      (internal protocol number 2641CESC). The study results will be submitted for
      publication in international, peer-reviewed journals and the complete dataset
      will be deposited in a public repository. Most relevant data will be made
      available to policy-makers as well as disseminated to stakeholders and to the
      community.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Guerriero, Massimo
AU  - Guerriero M
AUID- ORCID: 0000-0003-1310-539X
AD  - Clinical Research Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di
      Valpolicella, Verona, Italy.
FAU - Bisoffi, Zeno
AU  - Bisoffi Z
AUID- ORCID: 0000-0001-9530-8742
AD  - Department of Diagnostics and Public Health, University of Verona, Verona, Italy 
      zeno.bisoffi@sacrocuore.it.
AD  - Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore
      Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
FAU - Poli, Albino
AU  - Poli A
AD  - Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
FAU - Micheletto, Claudio
AU  - Micheletto C
AD  - Unit of Pneumology, Azienda Ospedaliera Universitaria Integrata Verona, Verona,
      Italy.
FAU - Pomari, Carlo
AU  - Pomari C
AD  - Department of Internal Medicine, Unit of Pneumology, IRCCS Sacro Cuore Don
      Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/blood
MH  - Asymptomatic Infections/*epidemiology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Clinical Protocols
MH  - Coronavirus Infections/blood/*diagnosis/*epidemiology/virology
MH  - Cross-Sectional Studies
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Humans
MH  - Immunoglobulins/blood
MH  - Italy
MH  - Mass Screening/*methods
MH  - *Pandemics
MH  - Pneumonia, Viral/blood/*diagnosis/*epidemiology/virology
MH  - Prevalence
MH  - Research Design
MH  - SARS-CoV-2
MH  - Sensitivity and Specificity
MH  - Serologic Tests/*methods
MH  - Severe Acute Respiratory Syndrome
PMC - PMC7539547
OTO - NOTNLM
OT  - *diagnostic microbiology
OT  - *epidemiology
OT  - *molecular diagnostics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - bmjopen-2020-040036 [pii]
AID - 10.1136/bmjopen-2020-040036 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e040036. doi: 10.1136/bmjopen-2020-040036.


PMID- 33028560
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Effect of joint transition visits on quality of life in adolescents with
      inflammatory bowel diseases: a protocol for a prospective, randomised,
      multicentre, controlled trial (TRANS-IBD).
PG  - e038410
LID - 10.1136/bmjopen-2020-038410 [doi]
AB  - INTRODUCTION: Inflammatory bowel diseases (IBD) are among the most common chronic
      illnesses diagnosed in childhood. Transition from paediatric to adult care is a
      crucial phase. The implementation of joint visits during the transition period in
      IBD is widely recommended, however, strong evidence supporting their benefit is
      still missing. In this trial, we aim to prove the superiority of joint visits
      compared with usual care in improving transition outcomes of adolescents with
      IBD. METHODS AND ANALYSIS: This is a randomised controlled two-arm multicentre
      trial. A minimum of 160 adolescents with IBD aged between 16.75 and 17 years will
      be recruited from Hungarian tertiary IBD centres. After randomisation, eligible
      subjects in the intervention arm attend a total of four joint visits with adult
      and paediatric gastroenterologist between the ages of 17 and 18. In the control
      arm, adolescents meet only the paediatric gastroenterologist, but there is a
      balanced consultation between the two gastroenterologist regarding the patient's 
      treatment plan. Patients in both groups receive the same training and education, 
      the only determinative difference between the two arms is the presence of the
      adult gastroenterologist at the joint visits. Data will be collected at
      inclusion, at transfer and 12 months post-transfer. Primary outcome is the change
      in health-related quality of life measured with the IMPACT-III questionnaire at 1
      year after transfer. Secondary outcomes include the number of patients not lost
      to follow-up, healthcare utilisation, disease activity, medication adherence,
      self-efficacy, transition readiness and patient's satisfaction. To compare the
      results of the two patient groups, two-sample T-test and Mann-Whitney test will
      be applied. ETHICS AND DISSEMINATION: The Scientific and Research Ethics
      Committee of the Hungarian Medical Research Council approved this study
      (50457-2/2019/EKU). Findings will be disseminated at conferences and in medical
      journals. TRIAL REGISTRATION NUMBER: NCT04290156.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Eros, Adrienn
AU  - Eros A
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Pecs,
      Hungary.
AD  - Heim Pal Children's Hospital, Budapest, Hungary, Budapest, Hungary.
AD  - Szentagothai Research Centre, Medical School, University of Pecs, Pecs, Hungary.
FAU - Dohos, Dora
AU  - Dohos D
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Pecs,
      Hungary.
AD  - Szentagothai Research Centre, Medical School, University of Pecs, Pecs, Hungary.
FAU - Veres, Gabor
AU  - Veres G
AD  - First Department of Pediatrics, University of Debrecen, Hungary, Debrecen,
      Hungary.
FAU - Tarnok, Andras
AU  - Tarnok A
AD  - Department of Pediatrics, Medical School, University of Pecs, Pecs, Hungary.
FAU - Vincze, Aron
AU  - Vincze A
AD  - First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary, 
      Pecs, Hungary.
FAU - Teszas, Alexandra
AU  - Teszas A
AD  - Department of Pediatrics, Medical School, University of Pecs, Pecs, Hungary.
FAU - Zadori, Noemi
AU  - Zadori N
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Pecs,
      Hungary.
AD  - Szentagothai Research Centre, Medical School, University of Pecs, Pecs, Hungary.
FAU - Gede, Noemi
AU  - Gede N
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Pecs,
      Hungary.
AD  - Szentagothai Research Centre, Medical School, University of Pecs, Pecs, Hungary.
FAU - Hegyi, Peter
AU  - Hegyi P
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Pecs,
      Hungary.
AD  - Szentagothai Research Centre, Medical School, University of Pecs, Pecs, Hungary.
AD  - First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary, 
      Pecs, Hungary.
AD  - Momentum Gastroenterology Multidisciplinary Research Group, Hungarian Academy of 
      Sciences, University of Szeged, Szeged, Hungary.
FAU - Sarlos, Patricia
AU  - Sarlos P
AUID- ORCID: 0000-0002-5086-9455
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Pecs,
      Hungary sarlosp@gmail.com.
AD  - First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary, 
      Pecs, Hungary.
LA  - eng
SI  - ClinicalTrials.gov/NCT04290156
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Humans
MH  - Hungary
MH  - *Inflammatory Bowel Diseases/therapy
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Transition to Adult Care
PMC - PMC7539589
OTO - NOTNLM
OT  - *adolescents
OT  - *chronic illness
OT  - *inflammatory bowel disease
OT  - *quality of life, randomised controlled trial
OT  - *transitional care
COIS- Competing interests: None declared. Principal investigators of each study sites
      decline any financial and other competing interests.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-038410 [pii]
AID - 10.1136/bmjopen-2020-038410 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e038410. doi: 10.1136/bmjopen-2020-038410.


PMID- 33028559
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced
      by multitargeted kinase inhibitors: protocol of a phase 3 randomised
      self-controlled study.
PG  - e038276
LID - 10.1136/bmjopen-2020-038276 [doi]
AB  - INTRODUCTION: Although topical use of moisturisers is slightly effective for the 
      prevention and avoiding the aggravation of hand-foot syndrome induced by
      multikinase inhibitors, there is still room for improvement. Hydrocolloid
      dressing is a type of wound dressing often used for wounds such as decubitus
      ulcers. The purpose of this study is to verify the usefulness of application of
      hydrocolloid dressings as prophylaxis against development of hand-foot syndrome
      induced by multikinase inhibitors by comparing the effects of this dressing and
      standard supportive care (moisturising care alone) within the same individuals.
      METHODS: This study is a phase 3 randomised, self-controlled study to compare
      prophylactic moisturising care with or without hydrocolloid dressing for
      hand-foot syndrome induced by multikinase inhibitors. Patients with radically
      unresectable advanced or recurrent colorectal carcinoma, gastrointestinal stromal
      tumour and hepatocellular carcinoma who scheduled to receive regorafenib or
      sorafenib therapy are eligible for enrolment.Supportive care for hand-foot
      syndrome will consist of basic moisturising care with or without hydrocolloid
      dressing. If hand-foot syndrome occurs, a steroid ointment will be applied two
      times per day at the affected sites. The primary endpoint is an incidence rate of
      grade 2 or more severe hand-foot syndrome (soles of the feet only) assessed by
      National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
      V.4.0. Grading of hand-foot syndrome will be performed by central review using
      photographs taken weekly by blinded trained physicians. The ethical approval was 
      obtained from National Cancer Center Hospital. The results of this study will be 
      submitted for publication in international peer-reviewed journals and the key
      findings will be presented at international scientific conference. DISCUSSION: If
      the positive results are found in this study, it is shown that hydrocolloid
      dressing is effective not only as a symptom management but also as a prevention
      in hand-foot syndrome induced by multikinase. TRIAL STATUS: The enrolment was
      started in January 2019, and planned to closed in January 2021. As of February
      2020, 26 patients enrolled in this study. TRIAL REGISTRATION NUMBER: UMIN
      Clinical Trial Registry (UMIN000034853). PROTOCOL VERSION: V.1.4, 9 January 2020.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zenda, Sadamoto
AU  - Zenda S
AUID- ORCID: 0000-0002-0421-5805
AD  - Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan
      szenda@east.ncc.go.jp.
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for 
      Public Health Sciences, Tokyo, Japan.
FAU - Ryu, Asako
AU  - Ryu A
AD  - Department of Nursing, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Takashima, Atsuo
AU  - Takashima A
AD  - Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital,
      Chuo-ku, Tokyo, Japan.
FAU - Arai, Michiko
AU  - Arai M
AD  - Department of Nursing, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Takagi, Yusuke
AU  - Takagi Y
AD  - Department of Palliative Medicine, Teikyo University School of Medicine Graduate 
      School of Medicine, Itabashi-ku, Tokyo, Japan.
FAU - Miyaji, Tempei
AU  - Miyaji T
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for 
      Public Health Sciences, Tokyo, Japan.
AD  - Department of Clinical Trial Data Management, Graduate School of Medicine, The
      University of Tokyo, Bunkyo-ku, Japan.
FAU - Mashiko, Tomoe
AU  - Mashiko T
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for 
      Public Health Sciences, Tokyo, Japan.
FAU - Shimizu, Yoichi
AU  - Shimizu Y
AUID- ORCID: 0000-0002-5154-090X
AD  - Department of Nursing, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Yamazaki, Naoya
AU  - Yamazaki N
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku,
      Tokyo, Japan.
FAU - Morizane, Chigusa
AU  - Morizane C
AD  - Department of Hepatobiliary and Pancreatic Oncology Division, National Cancer
      Center Hospital, Tokyo, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Department of Clinical Trial Data Management, Graduate School of Medicine, The
      University of Tokyo, Bunkyo-ku, Japan.
AD  - Division of Biostatistics, Tohoku Graduate School of Medicine, Sendai, Japan.
FAU - Kawaguchi, Takashi
AU  - Kawaguchi T
AD  - Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences,
      Tokyo, Japan.
FAU - Hanai, Akiko
AU  - Hanai A
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for 
      Public Health Sciences, Tokyo, Japan.
FAU - Uchitomi, Yosuke
AU  - Uchitomi Y
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for 
      Public Health Sciences, Tokyo, Japan.
FAU - Oshiba, Fukuko
AU  - Oshiba F
AD  - Department of Nursing, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000034853
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Ointments)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Administration, Topical
MH  - *Bandages, Hydrocolloid
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - *Neoplasm Recurrence, Local
MH  - Ointments
MH  - Randomized Controlled Trials as Topic
MH  - Sorafenib
PMC - PMC7539604
OTO - NOTNLM
OT  - *hand-foot syndrome
OT  - *multi-kinase inhibitor
OT  - *self-controlled study
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-038276 [pii]
AID - 10.1136/bmjopen-2020-038276 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e038276. doi: 10.1136/bmjopen-2020-038276.


PMID- 33028557
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Physical activity and health promotion for nursing staff in elderly care: a study
      protocol for a randomised controlled trial.
PG  - e038202
LID - 10.1136/bmjopen-2020-038202 [doi]
AB  - INTRODUCTION: Nursing staff is burdened by high workload and stress. Furthermore,
      heavy lifting, as well as transferring nursing home residents, cause lumbar
      tissue damage and back pain. Exercise intervention studies to reduce work-related
      problems are rare and the evidence for efficacy of studies among nurses is
      limited. Studies including targeted analysis of requirements are necessary to
      generate effective recommendations and tailored interventions for health
      promotion programmes. The purpose of this multicentred intervention study is to
      identify work-related problems, to implement health promotion programmes and to
      evaluate their effectiveness. METHODS AND ANALYSIS: A randomised controlled trial
      will be conducted, including a total of 48 nursing home facilities in eight
      regions of Germany with an estimated sample size of 700 nurses. Standardised
      ergonomics and posture training (10 weeks, once a week for 20-30 min) and
      subsequently, back-fitness training (12 weeks, once a week for 45-60 min) will be
      administered. Following the implementation of standardised health promotion
      programmes, further demand-oriented interventions can be implemented. The
      perceived exposure to work-related demands, work-related pain in different parts 
      of the body, health-related quality of life, perceived stress, work-related
      patterns of behaviour and experience, presentism behaviour, work environment as
      well as general needs and barriers to health promotion, will be assessed at
      baseline (pre-test), at 10 weeks (post-test, after ergonomics training), at 22
      weeks (post-test, after back-fitness training) and at 34 weeks of the programme
      (follow-up). ETHICS AND DISSEMINATION: The study was reviewed and approved by the
      local ethics committee of the University of Hamburg (AZ: 2018_168). The results
      of the study will be published in open-access and international journals.
      Furthermore, the results will be presented in the participating nursing homes and
      at national and international conferences. TRIAL REGISTRATION NUMBER: DRKS.de
      (DRKS00015241).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Otto, Ann-Kathrin
AU  - Otto AK
AUID- ORCID: 0000-0003-4457-1625
AD  - Department of Human Movement Science, University of Hamburg, Hamburg, Germany
      ann-kathrin.otto@uni-hamburg.de.
FAU - Pietschmann, Juliane
AU  - Pietschmann J
AD  - Department of Sport and Health, University of Paderborn, Paderborn, Germany.
FAU - Appelles, Luisa-Marie
AU  - Appelles LM
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
FAU - Bebenek, Michael
AU  - Bebenek M
AD  - Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nurnberg,
      Erlangen, Germany.
FAU - Bischoff, Laura L
AU  - Bischoff LL
AD  - Department of Human Movement Science, University of Hamburg, Hamburg, Germany.
FAU - Hildebrand, Claudia
AU  - Hildebrand C
AD  - Institute of Sports and Sports Science, Karlsruhe Institute of Technology,
      Karlsruhe, Germany.
FAU - Johnen, Bettina
AU  - Johnen B
AD  - Department of Sports and Exercise Science, University of Stuttgart, Stuttgart,
      Germany.
FAU - Jollenbeck, Thomas
AU  - Jollenbeck T
AD  - Department of Sport and Health, University of Paderborn, Paderborn, Germany.
FAU - Kemmler, Wolfgang
AU  - Kemmler W
AD  - Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nurnberg,
      Erlangen, Germany.
FAU - Klotzbier, Thomas
AU  - Klotzbier T
AD  - Department of Sports and Exercise Science, University of Stuttgart, Stuttgart,
      Germany.
FAU - Korbus, Heide
AU  - Korbus H
AD  - Department of Sports and Exercise Science, University of Stuttgart, Stuttgart,
      Germany.
FAU - Rudisch, Julian
AU  - Rudisch J
AD  - Institute of Sport and Exercise Sciences, University of Munster, Munster,
      Germany.
FAU - Schott, Nadja
AU  - Schott N
AD  - Department of Sports and Exercise Science, University of Stuttgart, Stuttgart,
      Germany.
FAU - Schoene, Daniel
AU  - Schoene D
AD  - Institute of Medical Physics, Friedrich-Alexander University Erlangen-Nurnberg,
      Erlangen, Germany.
FAU - Voelcker-Rehage, Claudia
AU  - Voelcker-Rehage C
AD  - Institute of Sport and Exercise Sciences, University of Munster, Munster,
      Germany.
FAU - Vogel, Oliver
AU  - Vogel O
AD  - Institute of Sports Sciences, Goethe University of Frankfurt, Frankfurt, Germany.
FAU - Vogt, Lutz
AU  - Vogt L
AD  - Institute of Sports Sciences, Goethe University of Frankfurt, Frankfurt, Germany.
FAU - Weigelt, Matthias
AU  - Weigelt M
AD  - Department of Sport and Health, University of Paderborn, Paderborn, Germany.
FAU - Wilke, Jan
AU  - Wilke J
AD  - Institute of Sports Sciences, Goethe University of Frankfurt, Frankfurt, Germany.
FAU - Zwingmann, Katharina
AU  - Zwingmann K
AD  - Institute of Human Movement Science and Health, Chemnitz University of
      Technology, Chemnitz, Germany.
FAU - Wollesen, Bettina
AU  - Wollesen B
AD  - Biological Psychology and Neuroergonomics, Technical University of Berlin,
      Berlin, Germany.
LA  - eng
SI  - DRKS/DRKS00015241
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Exercise
MH  - *Health Promotion
MH  - Humans
MH  - Nursing Homes
MH  - *Nursing Staff
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7539591
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-038202 [pii]
AID - 10.1136/bmjopen-2020-038202 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e038202. doi: 10.1136/bmjopen-2020-038202.


PMID- 33028556
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Assessing the hospital volume-outcome relationship in surgery: a scoping review
      protocol.
PG  - e038201
LID - 10.1136/bmjopen-2020-038201 [doi]
AB  - INTRODUCTION: Even if a positive volume-outcome correlation in surgery is mostly 
      admitted in many surgical fields, the various ways to assess this relationship
      make it difficult for researchers and policymakers to use it. Our aim is
      therefore to provide an overview of the way hospital volume-outcome relationship 
      was assessed. Through this overview, our goal is to identify potential gaps in
      the assessment of this relationship, to help researchers who want to pursue work 
      in this field and, ultimately, to help policy makers interpret such analyses.
      METHODS AND ANALYSIS: This review will be conducted using the six stages of the
      scoping review method: identifying the research question, searching for relevant 
      studies, selecting studies, data extraction, collating, summarising and reporting
      the results and concluding. This review will address all the key questions used
      to assess the volume-outcome relationship in surgery.Primary research papers
      investigating the hospital volume-outcome relationship from 2009 will be
      included. Studies only looking at surgeons' volume-outcome relationship or
      studies were the volume variable is not individualisable will be excluded.Both
      MEDLINE and Scopus will be searched along with grey literature. Two researchers
      will perform all the stages of the review: screen the titles and abstracts,
      review the full text of selected articles to determine final inclusions and
      extract the data. The results will be summarised quantitatively using numerical
      counts. ETHICAL CONSIDERATIONS AND DISSEMINATION: Reviews of published articles
      are considered secondary analysis and do not need ethical approval. The findings 
      will be disseminated through multiple channels like conferences and peer-reviewed
      journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Levaillant, Mathieu
AU  - Levaillant M
AUID- ORCID: 0000-0003-2124-9801
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS : Evaluation des technologies de sante
      et des pratiques medicales, F-59000 Lille, France mathieu.levaillant@gmail.com.
FAU - Marcilly, Romaric
AU  - Marcilly R
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS : Evaluation des technologies de sante
      et des pratiques medicales, INSERM-CIC-IT 1403/Evalab, F-59000 Lille, France.
FAU - Levaillant, Lucie
AU  - Levaillant L
AD  - Department of Pediatric Endocrinology and Diabetology, University Hospital Centre
      Angers, Angers, Pays de la Loire, France.
FAU - Vallet, Benoit
AU  - Vallet B
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS : Evaluation des technologies de sante
      et des pratiques medicales, F-59000 Lille, France.
FAU - Lamer, Antoine
AU  - Lamer A
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS : Evaluation des technologies de sante
      et des pratiques medicales, F-59000 Lille, France.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Hospitals
MH  - Hospitals, High-Volume
MH  - Humans
MH  - Peer Review
MH  - *Research Design
MH  - Review Literature as Topic
MH  - *Surgical Procedures, Operative
PMC - PMC7539612
OTO - NOTNLM
OT  - *health & safety
OT  - *health policy
OT  - *organisation of health services
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-038201 [pii]
AID - 10.1136/bmjopen-2020-038201 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e038201. doi: 10.1136/bmjopen-2020-038201.


PMID- 33028555
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - The efficacy and safety of varenicline alone versus in combination with nicotine 
      lozenges for smoking cessation among hospitalised smokers (VANISH): study
      protocol for a randomised, placebo-controlled trial.
PG  - e038184
LID - 10.1136/bmjopen-2020-038184 [doi]
AB  - INTRODUCTION: Smoking is a leading cause of premature deaths globally. The health
      benefits of smoking cessation are many. However, majority of quit attempts are
      unsuccessful. One way to potentially improve success rates is to evaluate new
      combinations of existing smoking cessation therapies that may work
      synergistically to decrease the intensity of withdrawal symptoms and cravings.
      AIMS: To evaluate the feasibility, efficacy and safety of the combination of
      varenicline and nicotine replacement therapy (NRT) lozenges versus varenicline
      alone in assisting hospitalised smokers to quit. METHODS AND ANALYSIS: This is a 
      multicentre, randomised, placebo-controlled trial. Adults with a history of
      smoking >/=10 cigarettes per day on average in the 4 weeks prior to their
      hospitalisation will be recruited. Participants will be randomly assigned to
      either the intervention group and will receive varenicline and NRT lozenges, or
      the control group and will receive varenicline and placebo lozenges. All
      participants will be actively referred to behavioural support from telephone
      Quitline. Participants are followed up at 1 and 3 weeks and 3, 6 and 12 months
      from the start of treatment. The primary outcome is carbon monoxide validated
      prolonged abstinence from 2 weeks to 6 months after treatment initiation.
      Secondary outcomes include self-reported and biochemically validated prolonged
      and point prevalence abstinence at 3, 6 and 12 months, self-reported adverse
      events, withdrawal symptoms and cravings, adherence to treatment, Quitline
      sessions attended and others. According to the Russell Standard, all randomised
      participants will be accounted for in the primary intention-to-treat analysis.
      ETHICS AND DISSEMINATION: The trial will be conducted in compliance with the
      protocol, the principles of Good Clinical Practice, the National Health and
      Medical Research Council National Statement on Ethical Conduct in Human Research 
      (updated 2015) and the Australian Code for the Responsible Conduct of Research
      (2018). Approval will be sought from the Human Ethics Committees of all the
      participating hospitals and the university. Written informed consent will be
      obtained from each participant at the time of recruitment. TRIAL REGISTRATION
      NUMBER: Australia New Zealand Clinical Trials Registry (ACTRN12618001792213).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gobarani, Rukshar Kaizerali
AU  - Gobarani RK
AUID- ORCID: 0000-0002-7027-7887
AD  - Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical
      Sciences, Monash University, Parkville, Victoria, Australia.
FAU - Abramson, Michael J
AU  - Abramson MJ
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Victoria, Australia.
FAU - Bonevski, Billie
AU  - Bonevski B
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan, New
      South Wales, Australia.
FAU - Weeks, Gregory R
AU  - Weeks GR
AD  - Pharmacy Department, Barwon Health, Geelong, Victoria, Australia.
FAU - Dooley, Michael J
AU  - Dooley MJ
AD  - Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical
      Sciences, Monash University, Parkville, Victoria, Australia.
AD  - Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia.
FAU - Smith, Brian J
AU  - Smith BJ
AD  - General and Respiratory Medicine, Bendigo Health, Bendigo, Victoria, Australia.
FAU - Veale, Antony
AU  - Veale A
AD  - Department of Respiratory Medicine, The Queen Elizabeth Hospital, Woodville
      South, South Australia, Australia.
FAU - Webb, Ashley
AU  - Webb A
AD  - Department of Anaesthesia and Pain Management, Frankston Hospital, Frankston,
      Victoria, Australia.
FAU - Kirsa, Sue
AU  - Kirsa S
AD  - Pharmacy Department, Monash Health, Clayton, Victoria, Australia.
FAU - Thomas, Dennis
AU  - Thomas D
AD  - Priority Research Centre for Healthy Lungs, The University of Newcastle Hunter
      Medical Research Institute, New Lambton, New South Wales, Australia.
FAU - Miller, Alistair
AU  - Miller A
AD  - Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, Victoria,
      Australia.
FAU - Gasser, Rudi
AU  - Gasser R
AD  - Department of General Medicine, Barwon Health, Geelong, Victoria, Australia.
FAU - Paul, Eldho
AU  - Paul E
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Victoria, Australia.
AD  - Clinical Haematology Department, Alfred Health, Melbourne, Victoria, Australia.
FAU - Parkinson, Jacqueline
AU  - Parkinson J
AD  - Pharmacy Department, Monash Health, Clayton, Victoria, Australia.
FAU - Meanger, Darshana
AU  - Meanger D
AD  - Pharmacy Department, Frankston Hospital, Frankston, Victoria, Australia.
FAU - Coward, Lisa
AU  - Coward L
AD  - Department of Anaesthesia, Frankston Hospital, Frankston, Victoria, Australia.
FAU - Kopsaftis, Zoe
AU  - Kopsaftis Z
AD  - Respiratory Medicine and Clinical Practice Unit, The Queen Elizabeth Hospital,
      Woodville South, South Australia, Australia.
FAU - Rofe, Olivia
AU  - Rofe O
AD  - Pharmacy Department, Eastern Health Foundation, Box Hill, Victoria, Australia.
FAU - Lee, Paula
AU  - Lee P
AD  - Pharmacy Department, Eastern Health Foundation, Box Hill, Victoria, Australia.
FAU - George, Johnson
AU  - George J
AD  - Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical
      Sciences, Monash University, Parkville, Victoria, Australia
      johnson.george@monash.edu.
LA  - eng
SI  - ANZCTR/ACTRN12618001792213
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Smoking Cessation Agents)
RN  - W6HS99O8ZO (Varenicline)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Smokers
MH  - *Smoking Cessation
MH  - *Smoking Cessation Agents/therapeutic use
MH  - Tobacco Use Cessation Devices
MH  - *Varenicline/therapeutic use
PMC - PMC7539569
OTO - NOTNLM
OT  - *clinical trials
OT  - *primary care
OT  - *public health
COIS- Competing interests: MA, BB and JG have held investigator-initiated grants from
      Boehringer Ingelheim for an unrelated project. MA has also received assistance
      with conference attendance and conducted an unrelated consultancy for Sanofi. He 
      has also received a speaker's fee from GSK. JG has received honorarium from GSK
      and Pfizer for consultancy and educational grants for unrelated projects.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-038184 [pii]
AID - 10.1136/bmjopen-2020-038184 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e038184. doi: 10.1136/bmjopen-2020-038184.


PMID- 33028554
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - INtravenous Contrast computed tomography versus native computed tomography in
      patients with acute Abdomen and impaired Renal functiOn (INCARO): a multicentre, 
      open-label, randomised controlled trial - study protocol.
PG  - e037928
LID - 10.1136/bmjopen-2020-037928 [doi]
AB  - INTRODUCTION: CT is the primary imaging option for acute abdominal pain in
      adults. Intravenous (IV) contrast media use improves CT quality but may cause
      post-contrast acute kidney injury (PC-AKI). Retrospective studies show no
      association between reduced baseline renal function and IV contrast CT, but, to
      our knowledge, no data from randomised controlled trials exist. METHODS AND
      ANALYSIS: The INCARO (INtravenous Contrast computed tomography versus native
      computed tomography in patients with acute Abdomen and impaired Renal functiOn)
      trial is a multicentre, open-label, parallel group, superiority, individually
      randomised controlled trial comparing IV contrast-enhanced CT to native CT in
      patients requiring emergency abdominal or body CT with impaired renal function
      defined as an estimated glomerular filtration rate (eGFR) of 15 to 45 mL/min/1.73
      m(2). The primary outcome is a composite of all-cause mortality or renal
      replacement therapy (RRT) within 90 days from CT. Secondary outcomes are AKI
      measured by KDIGO (The Kidney Disease: Improving Global Outcomes) criteria within
      72 hours from CT, organ dysfunction defined by mSOFA (modified Sequential Organ
      Failure Assessment) criteria after 48 hours from CT, alive and hospital-free days
      within 90 days after CT, and time from imaging to definitive treatment. All-cause
      mortality, need for RRT and renal transplant in long-term follow-up are also
      measured. The calculated sample size is 994 patients. Patient recruitment is
      estimated to take 3 years. ETHICS AND DISSEMINATION: The Ethics Committee of
      Helsinki University Hospital approved the study. The findings will be
      disseminated in peer-reviewed academic journals. TRIAL REGISTRATION NUMBER:
      NCT04196244.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Raty, Panu
AU  - Raty P
AUID- ORCID: 0000-0001-6088-4547
AD  - Department of Abdominal Surgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Finland.
FAU - Mentula, Panu
AU  - Mentula P
AD  - Department of Abdominal Surgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Finland.
FAU - Lampela, Hanna
AU  - Lampela H
AD  - Department of Abdominal Surgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Finland.
FAU - Nykanen, Taina
AU  - Nykanen T
AD  - Department of Surgery, Hyvinkaa Hospital, Hyvinkaa, Finland.
FAU - Helantera, Ilkka
AU  - Helantera I
AD  - Department of Transplantation and Liver Surgery, University of Helsinki and
      Helsinki University Hospital, Helsinki, Finland.
FAU - Haapio, Mikko
AU  - Haapio M
AD  - Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki,
      Finland.
FAU - Lehtimaki, Tiina
AU  - Lehtimaki T
AD  - Department of Radiology, University of Helsinki and Helsinki University Hospital,
      Helsinki, Finland.
FAU - Skrifvars, Markus B
AU  - Skrifvars MB
AD  - Department of Emergency Care and Services, University of Helsinki and Helsinki
      University Hospital, Helsinki, Finland.
FAU - Vaara, Suvi T
AU  - Vaara ST
AD  - Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care
      and Pain Medicine, University of Helsinki and Helsinki University Hospital,
      Helsinki, Finland.
FAU - Leppaniemi, Ari
AU  - Leppaniemi A
AD  - Department of Abdominal Surgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Finland.
FAU - Sallinen, Ville
AU  - Sallinen V
AD  - Department of Abdominal Surgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Finland ville.sallinen@helsinki.fi.
AD  - Department of Transplantation and Liver Surgery, University of Helsinki and
      Helsinki University Hospital, Helsinki, Finland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04196244
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Abdomen, Acute
MH  - *Acute Kidney Injury/diagnostic imaging/therapy
MH  - Adult
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Renal Replacement Therapy
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed
PMC - PMC7539602
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *acute renal failure
OT  - *adult intensive & critical care
OT  - *adult surgery
OT  - *computed tomography
COIS- Competing interests: AL has received funding from Helsinki University Hospital
      research funds. PR has received a research grant from Orion Research foundation. 
      VS reports grants from the Vatsatautien Tutkimussaatio Foundation, Mary and Georg
      Ehrnrooth's Foundation, Martti I Turunen Foundation, Helsinki University Hospital
      research funds, the Finnish Surgical Society, Finska Lakaresallskapet, Finnish
      Gastroenterological Society, Cancer Foundation, and Academy of Finland, personal 
      lecturing fees from City of Vantaa, Finnish Gastroenterological Society,
      Novartis, and University of Helsinki, and non-financial support from Astellas
      outside of the submitted work. STV has received funding for Clinical Researchers 
      (317061) from the Academy of Finland.
EDAT- 2020/10/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2020-037928 [pii]
AID - 10.1136/bmjopen-2020-037928 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e037928. doi: 10.1136/bmjopen-2020-037928.


PMID- 33028553
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Delirium prevention and treatment in the emergency department (ED): a systematic 
      review protocol.
PG  - e037915
LID - 10.1136/bmjopen-2020-037915 [doi]
AB  - INTRODUCTION: Delirium is a dangerous syndrome of acute brain dysfunction that is
      common in the emergency department (ED), especially among the geriatric
      population. Most systematic reviews of interventions for delirium prevention and 
      treatment have focused on inpatient settings. Best practices of effective
      delirium care in ED settings have not been established. The primary objective of 
      this study is to identify pharmacologic and non-pharmacologic interventions as
      applied by physicians, nursing staff, pharmacists and other ED personnel to
      prevent incident delirium and to shorten the severity and duration of prevalent
      delirium in a geriatric population within the ED. METHODS AND ANALYSIS: Searches 
      using subject headings and keywords will be conducted from database inception
      through June 2020 in MEDLINE, EMBASE, Web of Science, PsychINFO, CINAHL, ProQuest
      Dissertations and Theses Global and Cochrane CENTRAL as well as grey literature. 
      Database searches will not be limited by date or language. Two reviewers will
      identify studies describing any interventions for delirium prevention and/or
      treatment in the ED. Disagreements will be settled by a third reviewer. Pooled
      data analysis will be performed where possible using Review Manager. Risk ratios 
      and weighted difference of means will be used for incidence of delirium and other
      binary outcomes related to delirium, delirium severity or duration of symptoms,
      along with 95% CIs. Heterogeneity will be measured by calculating I (2), and a
      forest plot will be created. If significant heterogeneity is identified,
      metaregression is planned using OpenMeta to identify possible sources of
      heterogeneity. ETHICS AND DISSEMINATION: This is a systematic review of
      previously conducted research; accordingly, it does not constitute human subjects
      research needing ethics review. This review will be prepared as a manuscript and 
      submitted for publication to a peer-reviewed journal, and the results will be
      presented at conferences. PROSPERO TRIAL REGISTRATION NUMBER: CRD42020169654.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dahlstrom, Elijah Blue
AU  - Dahlstrom EB
AUID- ORCID: 0000-0002-0010-4235
AD  - Department of Emergency Medicine, University of Iowa Roy J and Lucille A Carver
      College of Medicine, Iowa City, Iowa, USA.
FAU - Han, Jin Ho
AU  - Han JH
AD  - Department of Emergency Medicine, Vanderbilt University, Nashville, Tennessee,
      USA.
FAU - Healy, Heather
AU  - Healy H
AD  - University of Iowa Libraries, University of Iowa Roy J and Lucille A Carver
      College of Medicine, Iowa City, Iowa, USA.
FAU - Kennedy, Maura
AU  - Kennedy M
AD  - Department of Emergency Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Arendts, Glenn
AU  - Arendts G
AD  - The University of Western Australia, Perth, Western Australia, Australia.
FAU - Lee, Jacques
AU  - Lee J
AD  - University of Toronto, Toronto, Ontario, Canada.
FAU - Carpenter, Chris
AU  - Carpenter C
AD  - Department of Emergency Medicine, Washington University in Saint Louis, Saint
      Louis, Missouri, USA.
FAU - Lee, Sangil
AU  - Lee S
AD  - Department of Emergency Medicine, University of Iowa Hospitals and Clinics, Iowa 
      City, Iowa, USA sangil-lee@uiowa.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Delirium/prevention & control
MH  - *Emergency Service, Hospital
MH  - Humans
MH  - Pharmacists
MH  - Systematic Reviews as Topic
PMC - PMC7539587
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *delirium & cognitive disorders
OT  - *geriatric medicine
COIS- Competing interests: CC: conflicts include SAEM Board of Directors, Geriatric
      Emergency Care Applied Research Network investigator leading cognitive impairment
      core, Clinician-Scientists Transdisciplinary Aging Research Leadership Core,
      Academic Emergency Medicine Deputy Editor-in-Chief, Journal of the American
      Geriatrics Society Associate Editor, Schwartz-Reisman Emergency Medicine
      Institute International Advisory Board Chair, and American Board of Emergency
      Medicine MyEMCert Editor.
EDAT- 2020/10/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037915 [pii]
AID - 10.1136/bmjopen-2020-037915 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e037915. doi: 10.1136/bmjopen-2020-037915.


PMID- 33028552
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Protocol for a scoping review to identify and map intervention components of
      existing school-based interventions for the promotion of physical activity and
      cardiorespiratory fitness among school children aged 6-10 years old.
PG  - e037848
LID - 10.1136/bmjopen-2020-037848 [doi]
AB  - INTRODUCTION: Physical inactivity is known as a leading cause of mortality and
      tracks from childhood to adulthood. Many types of school-based single-component
      and multicomponent interventions to promote physical activity (PA) have been
      undertaken and evaluated, with mixed findings overall. Enlarging the intervention
      areas beyond the school setting is a promising approach. WHO's Health Promoting
      School (WHO HPS) framework is a holistic, setting-based approach where health is 
      promoted through the whole school environment with links to other settings such
      as the home environment and wider community. In this paper, we outline our
      scoping review protocol to systematically review the published literature from
      the last 10 years to identify existing school-based interventions to promote PA
      and cardiorespiratory fitness among children aged 6-10 years old and to map
      intervention components according to the features of this framework. METHODS AND 
      ANALYSIS: Arksey and O'Malley's scoping review methodology framework will guide
      the conduct of this review. We will search Medline, PsycINFO, Cumulative Index to
      Nursing and Allied Health Literature, Sports Medicine & Education Index,
      Education Resources Information Centre and CENTRAL and hand search the reference 
      lists of key studies to identify studies appropriate for inclusion. Any empirical
      study that evaluated the effectiveness of a school-based intervention promoting
      PA and/or cardiorespiratory fitness in children aged 6-10 years old will be
      included. Two reviewers will independently screen all abstracts and full texts
      for inclusion. One reviewer will extract general information, study
      characteristics and intervention contents to classify them according to the
      features of the WHO HPS framework. Results will be synthesised narratively.
      ETHICS AND DISSEMINATION: Findings will be disseminated in conference
      presentations and peer-reviewed publications. A condensed version of the results 
      will be made available for the public. Stakeholder meetings will be arranged to
      discuss and disseminate the findings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Brandes, Berit
AU  - Brandes B
AUID- ORCID: 0000-0002-9313-6593
AD  - Prevention and Evaluation, Leibniz Institute for Prevention Research and
      Epidemiology, BIPS, Bremen, Germany bbrandes@leibniz-bips.de.
FAU - Busse, Heide
AU  - Busse H
AUID- ORCID: 0000-0001-6043-9072
AD  - Prevention and Evaluation, Leibniz Institute for Prevention Research and
      Epidemiology, BIPS, Bremen, Germany.
FAU - Sell, Louisa
AU  - Sell L
AD  - Prevention and Evaluation, Leibniz Institute for Prevention Research and
      Epidemiology, BIPS, Bremen, Germany.
FAU - Christianson, Lara
AU  - Christianson L
AUID- ORCID: 0000-0002-7780-255X
AD  - Clinical Epidemiology, Leibniz Institute for Prevention Research and
      Epidemiology, BIPS, Bremen, Germany.
FAU - Brandes, Mirko
AU  - Brandes M
AUID- ORCID: 0000-0003-2926-4758
AD  - Prevention and Evaluation, Leibniz Institute for Prevention Research and
      Epidemiology, BIPS, Bremen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Cardiorespiratory Fitness
MH  - Child
MH  - Delivery of Health Care
MH  - Exercise
MH  - Humans
MH  - Review Literature as Topic
MH  - Schools
MH  - Young Adult
PMC - PMC7539586
OTO - NOTNLM
OT  - *community child health
OT  - *public health
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037848 [pii]
AID - 10.1136/bmjopen-2020-037848 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e037848. doi: 10.1136/bmjopen-2020-037848.


PMID- 33028548
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - SIZE study: study protocol of a multicentre, randomised controlled trial to
      compare the effectiveness of an interarcuair decompression versus extended
      decompression in patients with intermittent neurogenic claudication caused by
      lumbar spinal stenosis.
PG  - e036818
LID - 10.1136/bmjopen-2020-036818 [doi]
AB  - INTRODUCTION: Intermittent neurogenic claudication (INC) is often caused by
      lumbar spinal stenosis (LSS). Laminectomy is considered a frequently used
      surgical technique for LSS. Previous studies have shown that laminectomy can
      potentially cause lumbar instability. Less invasive techniques, preserving
      midline structures including the bilateral small size interarcuair decompression,
      are currently applied. Due to lack of evidence and consensus, surgeons have to
      rely on their training and own experiences to choose the best surgical techniques
      for their patients. Hence, an observer and patient blinded multicentre,
      randomised controlled trial was designed to determine the effectiveness and
      cost-effectiveness of bilateral interarcuair decompression versus laminectomy for
      LSS. METHODS AND ANALYSIS: 174 patients above 40 years with at least 12 weeks of 
      INC will be recruited. Patients are eligible for inclusion if they have a
      clinical indication for surgery for INC with an MRI showing signs of LSS.
      Patients will be randomised to laminectomy or bilateral interarcuair
      decompression. The primary outcome is functional status measured with the
      Roland-Morris Disability Questionnaire at 12 months. Secondary outcomes consist
      of pain intensity, self-perceived recovery, functional status measured with the
      Oswestry Disability Index and a physical examination. Outcome measurement moments
      will be scheduled at 3 and 6 weeks, and at 3, 6, 12, 18, 24, 36 and 48 months
      after surgery. Physical examination will be performed at 6 weeks, and 12, 24 and 
      48 months. An economic evaluation will be performed and questionnaires will be
      used to collect cost data. ETHICS AND DISSEMINATION: The Medical Ethical
      Committee of the Erasmus Medical Centre Rotterdam approved this study
      (NL.65826.078.18). The results will be published in an international
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov
      (NCT03480893). IRB APPROVAL STATUS: MEC-2018-093.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Arjun Sharma, Jamie
AU  - Arjun Sharma J
AUID- ORCID: 0000-0003-2588-2153
AD  - Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Gadjradj, Pravesh S
AU  - Gadjradj PS
AUID- ORCID: 0000-0001-9672-4238
AD  - Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical 
      Center and The Hague Medical Center, Leiden, The Netherlands, Leiden, The
      Netherlands.
FAU - Peul, Wilco C
AU  - Peul WC
AD  - Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical 
      Center and The Hague Medical Center, Leiden, The Netherlands, Leiden, The
      Netherlands.
FAU - van Tulder, Maurits W
AU  - van Tulder MW
AUID- ORCID: 0000-0002-7589-8471
AD  - Health Sciences, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Moojen, Wouter A
AU  - Moojen WA
AD  - Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical 
      Center and The Hague Medical Center, Leiden, The Netherlands, Leiden, The
      Netherlands.
AD  - Neurosurgery, Medical Centre Haaglanden, Den Haag, The Netherlands.
FAU - Harhangi, Biswadjiet S
AU  - Harhangi BS
AD  - Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
      b.s.harhangi@erasmusmc.nl.
CN  - SIZE-study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03480893
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Decompression, Surgical
MH  - Humans
MH  - Laminectomy
MH  - Lumbar Vertebrae/surgery
MH  - Multicenter Studies as Topic
MH  - Pain Measurement
MH  - Randomized Controlled Trials as Topic
MH  - *Spinal Stenosis/complications/surgery
MH  - Treatment Outcome
PMC - PMC7539610
OTO - NOTNLM
OT  - *neurosurgery
OT  - *spine
COIS- Competing interests: None declared.
IR  - Mauff K
FIR - Mauff, Katya
IR  - Putten HV
FIR - Putten, Hendrikus van
EDAT- 2020/10/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036818 [pii]
AID - 10.1136/bmjopen-2020-036818 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e036818. doi: 10.1136/bmjopen-2020-036818.


PMID- 33028547
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 6
TI  - Mixed-method evaluation of a community-based postpartum support program: a study 
      protocol.
PG  - e036749
LID - 10.1136/bmjopen-2019-036749 [doi]
AB  - INTRODUCTION: Becoming a parent is one of the most significant events an
      individual will experience in their lifetime. The postpartum period can be a
      difficult time, especially for mothers, who may require extra support during this
      challenging time. The proposed study seeks to understand the issue of postpartum 
      support for mothers and their families. It will address this aim by using the
      Mothercraft Ottawa Postpartum Support Drop-in Program as real-life illustration
      of a community-based service organisation delivering these services. METHODS AND 
      ANALYSIS: A three-phased mixed-method programme evaluation guided by the Reach,
      Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) evaluation
      framework and the tenets of community-based participatory research. Instrumental 
      case study methodology will be employed to gain an in-depth understanding of what
      impact(s) the programme is having on mothers, their partners and their families
      (phase I-qualitative). A questionnaire, regression modelling, and geospatial
      analysis will be conducted to gain a deeper understanding of specific programme
      outputs and to generate information that will help inform programme reach (phase 
      II-quantitative). Study phase III will focus on knowledge translation activities 
      to stakeholders and the broader academic community. ETHICS AND DISSEMINATION:
      Ethics approval was granted by the University of Ottawa Research Ethics Board
      (H-12-18-1492). The results of this study will be disseminated at a community
      workshop, in an academic thesis, at academic conferences and in peer-reviewed
      publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Etowa, Josephine
AU  - Etowa J
AD  - School of Nursing, Faculty of Health Sciences, University of Ottawa, Ottawa,
      Ontario, Canada jetowa@uottawa.ca.
FAU - Johnston, Amy
AU  - Johnston A
AUID- ORCID: 0000-0003-1934-7867
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
AD  - Brain and Heart Nexus Research Program, University of Ottawa Heart Institute,
      Ottawa, Ontario, Canada.
FAU - Jama, Zahra
AU  - Jama Z
AD  - School of Nursing, Faculty of Health Sciences, University of Ottawa, Ottawa,
      Ontario, Canada.
FAU - Eccles, Kristin M
AU  - Eccles KM
AD  - Department of Geography, University of Toronto-Mississauga, Mississauga, Ontario,
      Canada.
FAU - Ashton, Alicia
AU  - Ashton A
AD  - Mothercraft Ottawa, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Female
MH  - Humans
MH  - *Postpartum Period
MH  - Program Evaluation
MH  - *Research Design
MH  - Surveys and Questionnaires
PMC - PMC7539575
OTO - NOTNLM
OT  - *maternal medicine
OT  - *mental health
OT  - *public health
COIS- Competing interests: Alicia Ashton is the Executive Director of Mothercraft
      Ottawa but will have no direct involvement in data collection or analysis. As a
      study that follows the tenets of community-based participatory research,
      involvement of those being studied (ie, organisational leadership) is critical to
      shared ownership and uptake of results to improve future programming. All other
      authors report no competing interests.
EDAT- 2020/10/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/08 05:26
PHST- 2020/10/08 05:26 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036749 [pii]
AID - 10.1136/bmjopen-2019-036749 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 6;10(10):e036749. doi: 10.1136/bmjopen-2019-036749.


PMID- 33028410
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1756-3305 (Electronic)
IS  - 1756-3305 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Oct 7
TI  - Assessing the acoustic behaviour of Anopheles gambiae (s.l.) dsxF mutants:
      implications for vector control.
PG  - 507
LID - 10.1186/s13071-020-04382-x [doi]
AB  - BACKGROUND: Release of gene-drive mutants to suppress Anopheles mosquito
      reproduction is a promising method of malaria control. However, many scientific, 
      regulatory and ethical questions remain before transgenic mosquitoes can be
      utilised in the field. At a behavioural level, gene-drive carrying mutants should
      be at least as sexually attractive as the wildtype populations they compete
      against, with a key element of Anopheles copulation being acoustic courtship. We 
      analysed sound emissions and acoustic preference in a doublesex mutant previously
      used to collapse Anopheles gambiae (s.l.) cages. METHODS: Anopheles rely on
      flight tones produced by the beating of their wings for acoustic mating
      communication. We assessed the impact of disrupting a female-specific isoform of 
      the doublesex gene (dsxF) on the wing beat frequency (WBF; measured as flight
      tone) of males (XY) and females (XX) in homozygous dsxF(-) mutants (dsxF(-/-)),
      heterozygous dsxF(-) carriers (dsxF(+/-)) and G3 dsxF(+) controls (dsxF(+/+)). To
      exclude non-genetic influences, we controlled for temperature and wing length. We
      used a phonotaxis assay to test the acoustic preferences of mutant and control
      mosquitoes. RESULTS: A previous study showed an altered phenotype only for
      dsxF(-/-) females, who appear intersex, suggesting that the female-specific dsxF 
      allele is haplosufficient. We identified significant, dose-dependent increases in
      the WBF of both dsxF(-/-) and dsxF(+/-) females compared to dsxF(+/+) females.
      All female WBFs remained significantly lower than male equivalents, though. Males
      showed stronger phonotactic responses to the WBFs of control dsxF(+/+) females
      than to those of dsxF(+/-) and dsxF(-/-) females. We found no evidence of
      phonotaxis in any female genotype. No male genotypes displayed any deviations
      from controls. CONCLUSIONS: A prerequisite for anopheline copulation is the
      phonotactic attraction of males towards female flight tones within mating swarms.
      Reductions in mutant acoustic attractiveness diminish their mating efficiency and
      thus the efficacy of population control efforts. Caged population assessments may
      not successfully reproduce natural mating scenarios. We propose to amend existing
      testing protocols to better reflect competition between mutants and target
      populations. Our findings confirm that dsxF disruption has no effect on males;
      for some phenotypic traits, such as female WBFs, the effects of dsxF appear
      dose-dependent rather than haplosufficient.
FAU - Su, Matthew P
AU  - Su MP
AD  - Ear Institute, University College London, 332 Grays Inn Road, London, WC1X 8EE,
      UK.
AD  - The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
AD  - Division of Biological Science, Nagoya University, Nagoya, 464-8602, Japan.
FAU - Georgiades, Marcos
AU  - Georgiades M
AD  - Ear Institute, University College London, 332 Grays Inn Road, London, WC1X 8EE,
      UK.
AD  - The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
FAU - Bagi, Judit
AU  - Bagi J
AD  - Ear Institute, University College London, 332 Grays Inn Road, London, WC1X 8EE,
      UK.
AD  - The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
FAU - Kyrou, Kyros
AU  - Kyrou K
AD  - Department of Life Sciences, Imperial College London, London, UK.
FAU - Crisanti, Andrea
AU  - Crisanti A
AD  - Department of Life Sciences, Imperial College London, London, UK.
FAU - Albert, Joerg T
AU  - Albert JT
AD  - Ear Institute, University College London, 332 Grays Inn Road, London, WC1X 8EE,
      UK. joerg.albert@ucl.ac.uk.
AD  - The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
      joerg.albert@ucl.ac.uk.
LA  - eng
GR  - AV/PP/0028/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
GR  - 648709/H2020 European Research Council
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - Parasit Vectors
JT  - Parasites & vectors
JID - 101462774
SB  - IM
MH  - Acoustics
MH  - Animal Communication
MH  - Animals
MH  - Animals, Genetically Modified/genetics/physiology
MH  - *Anopheles/genetics/physiology
MH  - Flight, Animal
MH  - Gene Drive Technology/methods
MH  - Hearing
MH  - Mosquito Control/*methods
MH  - Mosquito Vectors/genetics/physiology
MH  - Mutagenesis
MH  - Mutation
MH  - Sexual Behavior, Animal/*physiology
PMC - PMC7539510
OTO - NOTNLM
OT  - Acoustic communication
OT  - Anopheles coluzzii
OT  - Anopheles gambiae (s.l.)
OT  - Doublesex
OT  - Flight tone
OT  - Gene drive
OT  - Hearing
OT  - Mosquito
OT  - Phonotaxis
OT  - Vector control
OT  - Wing beat frequency
EDAT- 2020/10/09 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/10/08 05:25
PHST- 2020/07/14 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/08 05:25 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
AID - 10.1186/s13071-020-04382-x [doi]
AID - 10.1186/s13071-020-04382-x [pii]
PST - epublish
SO  - Parasit Vectors. 2020 Oct 7;13(1):507. doi: 10.1186/s13071-020-04382-x.


PMID- 33028246
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 7
TI  - "I lost my happiness, I felt half dead and half alive" - a qualitative study of
      the long-term aftermath of obstetric near-miss in the urban district of Zanzibar,
      Tanzania.
PG  - 594
LID - 10.1186/s12884-020-03261-8 [doi]
AB  - BACKGROUND: This study aims to explore the stories of three women from Zanzibar, 
      Tanzania, who survived life-threatening obstetric complications. Their narratives
      will increase understanding of the individual and community-level burden masked
      behind the statistics of maternal morbidity and mortality in Tanzania. In line
      with a recent systematic review of women-centred, qualitative maternal morbidity 
      research, this study will contribute to guidance of local and global maternal
      health agendas. METHODS: This two-phased qualitative study was conducted in
      July-August 2017 and July-August 2018, and involved three key informants, who
      were recruited from a maternal near-miss cohort in May 2017 in Mnazi Mmoja
      Hospital, Zanzibar. The used methods were participant observation, interviews
      (informal, unstructured and semi-structured), participatory methods and focus
      group discussions. Data analysis relied primarily on grounded theory, leading to 
      a theoretical model, which was validated repeatedly by the informants and within 
      the study team. The findings were then positioned in the existing literature.
      Approval was granted by Zanzibar's Medical Ethical Research Committee (reference 
      number: ZAMREC/0002/JUN/17). RESULTS: The impact of severe maternal morbidity was
      found to be multi-dimensional and to extend beyond hospital discharge and thus
      institutionalized care. Four key areas impacted by maternal morbidities emerged, 
      namely (1) social, (2) sexual and reproductive, (3) psychological, and (4)
      economic well-being. CONCLUSIONS: This study showed how three women's lives and
      livelihoods were profoundly impacted by the severe obstetric complications they
      had survived, even up to 16 months later. These impacts took a toll on their
      physical, social, economic, sexual and psychological well-being, and affected
      family and community members alike. These findings advocate for a holistic,
      dignified, patient value-based approach to the necessary improvement of maternal 
      health care in low-income settings. Furthermore, it emphasizes the need for
      strategies to be directed not only towards quality of care during pregnancy and
      delivery, but also towards support after obstetric complications.
FAU - Herklots, Tanneke
AU  - Herklots T
AD  - Department of Obstetrics & Gynaecology, Erasmus Medical Center, Rotterdam, the
      Netherlands. tannekeherklots@gmail.com.
FAU - Yussuf, Suhaila Salum
AU  - Yussuf SS
AD  - Department of Obstetrics & Gynaecology, Mnazi Mmoja Hospital, Zanzibar, United
      Republic of Tanzania.
FAU - Mbarouk, Khairat Said
AU  - Mbarouk KS
AD  - Department of Obstetrics & Gynaecology, Mnazi Mmoja Hospital, Zanzibar, United
      Republic of Tanzania.
FAU - O'Meara, Molly
AU  - O'Meara M
AD  - School of Global Health, University of Copenhagen, Copenhagen, Denmark.
FAU - Carson, Emma
AU  - Carson E
AD  - Faculty of Humanities, University Utrecht, Utrecht, the Netherlands.
FAU - Plug, Sebastiaan Beschoor
AU  - Plug SB
AD  - Department of Technology, Policy and Management, Technical University Delft,
      Delft, the Netherlands.
FAU - van Acht, Fleur
AU  - van Acht F
AD  - School of Global Health, University of Copenhagen, Copenhagen, Denmark.
FAU - Terpstra, Pleun
AU  - Terpstra P
AD  - Faculty of Medicine, University Utrecht, Utrecht, the Netherlands.
FAU - Prebevsek, Deja
AU  - Prebevsek D
AD  - Faculty of Medicine, University of Maastricht, Maastricht, the Netherlands.
FAU - Franx, Arie
AU  - Franx A
AD  - Department of Obstetrics & Gynaecology, Erasmus Medical Center, Rotterdam, the
      Netherlands.
FAU - Meguid, Tarek
AU  - Meguid T
AD  - Village Health Centre, Kigutu, Burundi.
FAU - Jacod, Benoit
AU  - Jacod B
AD  - Department of Obstetrics & Gynaecology, Onze Lieve Vrouwe Gasthuis Hospital,
      Amsterdam, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adult
MH  - Attitude to Death
MH  - Family/psychology
MH  - Female
MH  - Focus Groups
MH  - Grounded Theory
MH  - Humans
MH  - Maternal Health Services/*organization & administration
MH  - *Near Miss, Healthcare
MH  - Obstetric Labor Complications/diagnosis/mortality/*psychology
MH  - Pregnancy
MH  - Qualitative Research
MH  - Severity of Illness Index
MH  - Social Support
MH  - Survivors/*psychology
MH  - *Survivorship
MH  - Tanzania
MH  - Young Adult
PMC - PMC7539452
OTO - NOTNLM
OT  - long-term impact
OT  - low-income setting
OT  - maternal morbidity
OT  - obstetric complications
OT  - postpartum period
OT  - value-based health care
EDAT- 2020/10/09 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/10/08 05:24
PHST- 2019/12/22 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/10/08 05:24 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.1186/s12884-020-03261-8 [doi]
AID - 10.1186/s12884-020-03261-8 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Oct 7;20(1):594. doi: 10.1186/s12884-020-03261-8.


PMID- 33028144
OWN - NLM
STAT- Publisher
LR  - 20201008
IS  - 1541-3764 (Electronic)
IS  - 0030-2228 (Linking)
DP  - 2020 Oct 7
TI  - A Reconceptualization of Suicide and Social Workers' Duty to Report.
PG  - 30222820963773
LID - 10.1177/0030222820963773 [doi]
AB  - This paper examines how history and psychiatry have shaped social work approaches
      to suicide prevention. Current social work intervention strategies rely on the
      following four positivist assumptions: (1) suicide is the result of mental
      illness, (2) suicidal individuals are irrational, (3) social workers have more
      knowledge about suicide than their clients, and (4) that preserving life is the
      least harmful outcome. Analysis reveals that these assumptions hold little
      validity and cannot be generalised to all cases. Discussion encourages
      intervention strategies that are informed by the experiences of attempt survivors
      and a broader sociopolitical context. Social workers are encouraged to use
      methods that are not only life-preserving, but life affirming. Finally, community
      specific initiatives to increase resources and decrease isolation and
      marginalization are posited as potential ways to reduce suicide ideation.
FAU - Kumbhare, Shaila
AU  - Kumbhare S
AUID- ORCID: https://orcid.org/0000-0003-2493-6367
AD  - Faculty of Social Work, McMaster University, Hamilton, Ontario, Canada.
AD  - Faculty of Social Work, Ryerson University, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201007
PL  - United States
TA  - Omega (Westport)
JT  - Omega
JID - 1272106
SB  - IM
OTO - NOTNLM
OT  - critical social work
OT  - critical suicidology
OT  - mad studies
OT  - social work and suicide
OT  - suicide and ethics
EDAT- 2020/10/09 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/10/08 05:23
PHST- 2020/10/08 05:23 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1177/0030222820963773 [doi]
PST - aheadofprint
SO  - Omega (Westport). 2020 Oct 7:30222820963773. doi: 10.1177/0030222820963773.


PMID- 33028137
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1556-9535 (Electronic)
IS  - 1556-9527 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Dec
TI  - Dermatological side effects of targeted antineoplastic therapies: a prospective
      study.
PG  - 380-384
LID - 10.1080/15569527.2020.1833028 [doi]
AB  - INTRODUCTION: Epidermal growth factor receptor inhibitors (EGFRs) are
      chemotherapeutic agents used in multiple solid organ malignity. These medications
      have common dermatological side effects, particularly papulopustular (PPL)
      lesions. The management of the diagnosis and treatment processes for such side
      effects may facilitate the continuation of chemotherapy and enhance the patient's
      quality of life. OBJECTIVE: The objective of this study is to report the
      cutaneous side effects of EGFR inhibitors and to share treatment methods for such
      side effects. MATERIALS AND METHODS: In this prospective study, 59 patients using
      EGFR due to breast and colorectal carcinoma at the oncology unit of Haseki
      Training and Research Hospital were assessed. The patients for whom EGFR was
      initiated were examined at the beginning of the treatment at weeks 1 and 2, their
      demographic characteristics were recorded, and the patients who developed a skin 
      rash were followed up from the onset of the lesion. The PPL side effects that
      developed in the patients and other dermatological findings were recorded. The
      PPL side effects were graded, and the treatment plans were reported. The study
      was conducted between February 2016 and February 2018 under the approval of the
      local ethical committee. RESULTS: The mean age of the 59 patients (47 females, 12
      males) taking EGFR inhibitors was 52.4 +/- 12.0 (range: 29-84). Forty-five
      patients had early stage and 14 patients had advanced stage carcinoma. Fourteen
      patients had colorectal carcinoma, three patients had renal cancer, and 42
      patients had breast cancer. Forty-two patients were using trastuzumab (single
      therapy in 29 patients and combined therapy in 13 patients), five patients were
      using cetuximab, three patients were using sunitinib, eight patients were using
      panitumumab, and six patients were using pertuzumab. In 22 patients, PPL side
      effects were observed in the skin; it was G1 in 19 patients and G2 in three
      patients. In seven patients who developed acneiform side effects, systemic
      doxycycline was used, and in others, topical tetracycline and clindamycin were
      used. Except for one patient using trastuzumab, all patients has lesions on the
      face, upper trunk, and back. One patient exhibited an atypical rash, which was
      diagnosed as a granulomatous follicular reaction. Xerosis was present in two
      cases, and paronychia, pyogenic granuloma, trichomegaly, and madarosis were
      observed in one patient each. The patients who developed an acneiform rash were
      treated with topical and systemic antibiotics, light keratolytics, and
      emollients. The skin side effects of all patients were mild to moderate, and all 
      patients completed the chemotherapy process. An acneiform skin rash and other
      dermatological side effects are common with EGFR inhibitors. To treat these side 
      effects, emollients, topical steroids, and local, systemic antibiotics are
      recommended. Clindamycin may be preferred as a topical treatment, and doxycycline
      may be preferred as a systematic treatment.
FAU - Agirgol, Senay
AU  - Agirgol S
AUID- ORCID: https://orcid.org/0000-0002-8000-8883
AD  - Department of Dermatology, Haseki Training and Research Hospital, Istanbul,
      Turkey.
FAU - Caytemel, Ceyda
AU  - Caytemel C
AD  - Department of Dermatology, Haseki Training and Research Hospital, Istanbul,
      Turkey.
FAU - Pilanci, Kezban Nur
AU  - Pilanci KN
AD  - Oncology Department, Haseki Training and Research Hospital, Istanbul, Turkey.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20201020
PL  - England
TA  - Cutan Ocul Toxicol
JT  - Cutaneous and ocular toxicology
JID - 101266892
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects
MH  - Breast Neoplasms/drug therapy
MH  - Colorectal Neoplasms/drug therapy
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Protein Kinase Inhibitors/*adverse effects
MH  - Skin Diseases/*chemically induced
OTO - NOTNLM
OT  - Epidermal growth factor receptor inhibitors
OT  - acneiform eruption
OT  - paronychia
OT  - skin toxicity
OT  - targeted chemotherapy
OT  - trichomegaly
OT  - xerosis
EDAT- 2020/10/09 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/10/08 05:23
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/10/08 05:23 [entrez]
AID - 10.1080/15569527.2020.1833028 [doi]
PST - ppublish
SO  - Cutan Ocul Toxicol. 2020 Dec;39(4):380-384. doi: 10.1080/15569527.2020.1833028.
      Epub 2020 Oct 20.


PMID- 33028122
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 42
IP  - 1
DP  - 2020 Nov
TI  - Non-adherence to hemodialysis regimens among patients on maintenance hemodialysis
      in sub-Saharan Africa: an example from Cameroon.
PG  - 1022-1028
LID - 10.1080/0886022X.2020.1826965 [doi]
AB  - BACKGROUND: Non-adherence (NA) to hemodialysis regimens is one of the
      contributors to the high morbidity and mortality observed in patients with
      end-stage kidney disease (ESKD). We aimed to determine the prevalence and
      predictors of NA to hemodialysis (HD) regimens among patients on maintenance HD
      in Cameroon. METHODS: A cross-sectional study in two HD centers in Cameroon was
      conducted from January to February 2016. Consenting patients on HD for >/=3
      months were included. NA to fluid restriction was defined as a mean interdialytic
      weight gain (IDWG) in the past month >5.7% of the dry weight, NA to dietary
      restriction as a pre dialysis serum phosphorus >5.5 mg/dl in a patient on
      phosphate binders and who is well-nourished, and NA to HD sessions as skipping at
      least one session in the past month. The study was approved by the institutional 
      ethics board. RESULTS: A total of 170 (112 males) participants with a median age 
      of 49 years (range 14-79) were included. The median dialysis vintage was 35
      months (range 3-180 months). The prevalence of NA was 15.3% to fluid restriction,
      26.9% to dietary restriction, and 21.2% to dialysis sessions. Age </=49 years (p 
      = .006, OR: 5.07, 95% CI: 1.59-16.20) and unmarried status (p = .041, OR: 2.63,
      95% CI: 1.04-6.66) were independently associated with NA to fluid restrictions.
      No factor was associated with NA to dietary restrictions and HD sessions.
      CONCLUSIONS: NA to HD regimens is common amongst patients in Cameroon. Younger
      age and being unmarried were the predictors of NA to fluid restriction.
FAU - Halle, Marie Patrice
AU  - Halle MP
AD  - Department of Internal Medicine, Faculty of Medicine and Pharmaceutical Science, 
      Douala General Hospital, University of Douala, Douala, Cameroon.
FAU - Nelson, Musaga
AU  - Nelson M
AD  - Faculty of Health Sciences, University of Buea, Buea, Cameroon.
FAU - Kaze, Folefack Francois
AU  - Kaze FF
AD  - Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde,
      Cameroon.
FAU - Jean Pierre, Nda Mefo'o
AU  - Jean Pierre NM
AD  - Faculty of Medicine and Pharmaceutical Science, University of Douala, Douala,
      Cameroon.
FAU - Denis, Tewafeu
AU  - Denis T
AD  - Faculty of Health Sciences, University of Buea, Buea, Cameroon.
FAU - Fouda, Hermine
AU  - Fouda H
AD  - Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences,
      Douala General Hospital Cameroon, University of Yaounde I, Yaounde, Cameroon.
FAU - Ashuntantang, Enow Gloria
AU  - Ashuntantang EG
AD  - Faculty of Medicine and Biomedical Sciences, Yaounde General Hospital, University
      of Yaounde I, Yaounde, Cameroon.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Phosphates)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cameroon
MH  - Cross-Sectional Studies
MH  - *Diet Therapy
MH  - *Drinking
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/blood/*therapy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Patient Compliance/*statistics & numerical data
MH  - Phosphates/blood
MH  - Potassium/blood
MH  - *Renal Dialysis
MH  - Single Person
MH  - Young Adult
PMC - PMC7580605
OTO - NOTNLM
OT  - Cameroon
OT  - Non-adherence
OT  - hemodialysis
OT  - regimens
OT  - sub-Saharan Africa
EDAT- 2020/10/09 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/10/08 05:23
PHST- 2020/10/08 05:23 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
AID - 10.1080/0886022X.2020.1826965 [doi]
PST - ppublish
SO  - Ren Fail. 2020 Nov;42(1):1022-1028. doi: 10.1080/0886022X.2020.1826965.


PMID- 33027597
OWN - NLM
STAT- Publisher
LR  - 20220423
IS  - 1543-6136 (Electronic)
IS  - 1381-1118 (Linking)
DP  - 2020 Oct 7
TI  - Young Peoples' Perspectives on the Role of Harm Reduction Techniques in the
      Management of Their Self-Harm: A Qualitative Study.
PG  - 1-15
LID - 10.1080/13811118.2020.1823916 [doi]
AB  - OBJECTIVE: Self-harm is a common phenomenon amongst young people, often used to
      regulate emotional distress. Over the last decade harm reduction approaches to
      self-harm have been introduced as a means to minimize risk and reinforce
      alternative coping strategies. However, there is a stark absence of research into
      the perceived usefulness of such techniques amongst adolescents, and previous
      studies have highlighted ethical concerns about advocating 'safer' forms of
      self-harm. This study aimed to investigate the perceived usefulness of harm
      reduction techniques for adolescents who self-harm. METHOD: We purposively
      recruited current clients of a British early intervention program supporting
      young people in managing self-harm. We conducted semi-structured interviews and
      analyzed transcripts using thematic analysis. RESULTS: Eleven interviews with
      service users aged 14-15 years identified three main themes: (1) Controlling the 
      uncontrollable; (2) Barriers to practising safer self-harm; and (3) Developing a 
      broad repertoire of harm reduction techniques. Participants expressed mixed views
      regarding the usefulness of such approaches. Some described greater competence
      and empowerment in self-harm management, whilst others described the utility of
      harm reduction methods as either short-lived or situation-specific, with the
      potential for misuse of anatomical knowledge to cause further harm to high-risk
      adolescents. CONCLUSION: The findings from our sample suggest harm reduction
      techniques have a place in self-harm management for some individuals, but their
      usage should be monitored and offered alongside alternative strategies and
      therapeutic support. Our study highlights the need for further research on who
      would benefit from these techniques and how they can be implemented
      successfully.HIGHLIGHTSHarm reduction can help people who self-harm manage
      distress and maintain autonomyPeople who self-harm have a broad repertoire of
      harm reduction techniquesHarm reduction can help reduce long-term damage and
      frequency of self-harm.
FAU - Davies, Jessica
AU  - Davies J
FAU - Pitman, Alexandra
AU  - Pitman A
FAU - Bamber, Victoria
AU  - Bamber V
FAU - Billings, Joanne
AU  - Billings J
FAU - Rowe, Sarah
AU  - Rowe S
LA  - eng
GR  - G0802441/MRC_/Medical Research Council/United Kingdom
GR  - MR/L501487/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20201007
PL  - England
TA  - Arch Suicide Res
JT  - Archives of suicide research : official journal of the International Academy for 
      Suicide Research
JID - 9504451
SB  - IM
OTO - NOTNLM
OT  - Harm minimization
OT  - harm reduction
OT  - self-harm
OT  - self-injury
OT  - young people
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/10/07 20:04
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
PHST- 2020/10/07 20:04 [entrez]
AID - 10.1080/13811118.2020.1823916 [doi]
PST - aheadofprint
SO  - Arch Suicide Res. 2020 Oct 7:1-15. doi: 10.1080/13811118.2020.1823916.


PMID- 33027384
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20220816
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
VI  - 115
IP  - 3
DP  - 2020 Sep
TI  - Ethics, Artificial Intelligence and Cardiology.
PG  - 579-583
LID - S0066-782X2020001100579 [pii]
LID - 10.36660/abc.20200143 [doi]
FAU - Souza Filho, Erito Marques de
AU  - Souza Filho EM
AUID- ORCID: 0000-0002-0381-3344
AD  - Pos-graduacao em Ciencias Cardiovasculares da Universidade Federal
      Fluminense,Niteroi, RJ - Brasil.
AD  - Universidade Federal Rural do Rio de Janeiro - Departamento de Tecnologias e
      Linguagens,Nova Iguacu, RJ - Brasil.
FAU - Fernandes, Fernando de Amorim
AU  - Fernandes FA
AD  - Pos-graduacao em Ciencias Cardiovasculares da Universidade Federal
      Fluminense,Niteroi, RJ - Brasil.
AD  - Setor de Medicina Nuclear do Servico de Radiologia do Hospital Universitario
      Antonio Pedro (EBESERH-HUAP-UFF),Niteroi, RJ - Brasil.
FAU - Pereira, Nikolas Cunha de Assis
AU  - Pereira NCA
AUID- ORCID: 0000-0002-7186-9876
AD  - Pos-graduacao em Ciencias Cardiovasculares da Universidade Federal
      Fluminense,Niteroi, RJ - Brasil.
FAU - Mesquita, Claudio Tinoco
AU  - Mesquita CT
AUID- ORCID: 0000-0002-1466-9413
AD  - Pos-graduacao em Ciencias Cardiovasculares da Universidade Federal
      Fluminense,Niteroi, RJ - Brasil.
AD  - Setor de Medicina Nuclear do Servico de Radiologia do Hospital Universitario
      Antonio Pedro (EBESERH-HUAP-UFF),Niteroi, RJ - Brasil.
FAU - Gismondi, Ronaldo Altenburg
AU  - Gismondi RA
AUID- ORCID: 0000-0002-0884-4190
AD  - Pos-graduacao em Ciencias Cardiovasculares da Universidade Federal
      Fluminense,Niteroi, RJ - Brasil.
AD  - Hospital Niteroi D or,Niteroi, RJ - Brasil.
LA  - eng
LA  - por
PT  - Journal Article
TT  - Etica, Inteligencia Artificial e Cardiologia.
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
SB  - IM
MH  - Algorithms
MH  - *Artificial Intelligence
MH  - *Cardiology
PMC - PMC9363099
EDAT- 2020/10/08 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/07 17:13
PHST- 2020/02/20 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/10/07 17:13 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S0066-782X2020001100579 [pii]
AID - 10.36660/abc.20200143 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2020 Sep;115(3):579-583. doi: 10.36660/abc.20200143.


PMID- 33027356
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20201218
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 25
IP  - suppl 2
DP  - 2020 Oct
TI  - Where does patient autonomy live, in times of crisis in Portugal?
PG  - 4197-4200
LID - S1413-81232020006804197 [pii]
LID - 10.1590/1413-812320202510.2.26782020 [doi]
AB  - Coronavirus disease 2019 made us question daily practices, such as the simple
      handshake. It also raised some ethical and legal issues. Are the ethical
      principles, that should guide the provision of individualized care, being
      fulfilled? Will we, as health professionals, be able to provide patients with
      instruments so that they can fully exercise their autonomy? The guarantee of
      necessary security solutions, to reduce the risk of contagion in the provision of
      care, safeguards the principle of non-maleficence. However, the risk of contagion
      is impossible to completely eliminate, and there is a residual risk associated
      with the use of physical facilities in healthcare services. But, shouldn't the
      decision to take that risk be the subject of the patient's free and informed
      will? The incorporation of telemedicine platforms is ideal for managing several
      challenges posed by COVID-19, such as the decrease in face-to-face health care
      assistance. Can the patient really decide how he prefers to be consulted, or are 
      we imposing the consultation model? There have been profound changes in
      healthcare systems. However, one must remember that there are ethical principles 
      of biomedicine, that should always prevail?
FAU - Fontes, Ana Filipa
AU  - Fontes AF
AUID- ORCID: http://orcid.org/0000-0002-5474-4748
AD  - Unidade de Saude Familiar 7 fontes, ACeS Cavado I. R. Padre Antonio Freire 7/2
      masculine andar. 4700-395 Braga Portugal. filipafontes@live.com.pt.
FAU - Barbosa, Rita Ribeiro
AU  - Barbosa RR
AUID- ORCID: http://orcid.org/0000-0002-5728-9840
AD  - Unidade de Saude Familiar 7 fontes, ACeS Cavado I. R. Padre Antonio Freire 7/2
      masculine andar. 4700-395 Braga Portugal. filipafontes@live.com.pt.
FAU - Brito, Dinis
AU  - Brito D
AUID- ORCID: http://orcid.org/0000-0002-7547-0053
AD  - Instituto de Investigacao em Ciencias da Vida e Saude, Universidade do Minho.
      Minho Portugal.
LA  - por
LA  - eng
PT  - Journal Article
TT  - Onde mora a autonomia do paciente em tempos de crise em Portugal?
DEP - 20200802
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Confidentiality
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Mass Screening
MH  - Pandemics
MH  - Patient Preference
MH  - *Patient Rights
MH  - *Personal Autonomy
MH  - Pneumonia, Viral/*epidemiology
MH  - Portugal
MH  - SARS-CoV-2
MH  - Telemedicine
EDAT- 2020/10/08 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/07 17:13
PHST- 2020/07/21 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/10/07 17:13 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S1413-81232020006804197 [pii]
AID - 10.1590/1413-812320202510.2.26782020 [doi]
PST - ppublish
SO  - Cien Saude Colet. 2020 Oct;25(suppl 2):4197-4200. doi:
      10.1590/1413-812320202510.2.26782020. Epub 2020 Aug 2.


PMID- 33027191
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Dec
TI  - Risk of disease transmission in an expanded donor population: the potential of
      hepatitis B virus donors.
PG  - 631-639
LID - 10.1097/MOT.0000000000000810 [doi]
AB  - PURPOSE OF REVIEW: Lack of availability of donor organs is a constant challenge
      that patients and providers face in transplantation. To address this shortage,
      donors that test positive for hepatitis B, in particular those with resolved
      infection, have been increasingly utilized in clinical practice. We review here
      the potential risks for the recipient and the advances in hepatitis B management 
      that have made use of these donors a well tolerated and advisable proposition.
      RECENT FINDINGS: As routine administration of antiviral prophylaxis in the
      posttransplant setting among those deemed high risk for transmission, outcomes
      for recipients of hepatitis B donors, including liver transplant recipients, have
      been comparable to uninfected donors. Universal hepatitis B nucleic acid testing 
      of donors has also enhanced our ability to accurately inform recipients regarding
      transmission risk. Appropriate use of prophylaxis and careful monitoring for
      transmission posttransplant is key to ensuring no adverse outcomes occur.
      SUMMARY: Treatment of hepatitis B has evolved over the past two decades.
      Expanding the donor pool with hepatitis B donors is now well tolerated, ethical, 
      and advantageous to the transplant community at large. A clear discussion with
      recipients on the substantial benefit and low harm of using hepatitis B donors
      will lead to greater acceptance and utilization of these organs.
FAU - Zhou, Kali
AU  - Zhou K
AD  - Division of Gastrointestinal and Liver Diseases.
FAU - Zhou, Selena
AU  - Zhou S
AD  - Department of Medicine, Keck School of Medicine at the University of Southern
      California, Los Angeles, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Hepatitis B/*complications
MH  - Hepatitis B virus/*pathogenicity
MH  - Humans
MH  - Tissue Donors
EDAT- 2020/10/08 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/10/07 17:12
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/10/07 17:12 [entrez]
AID - 10.1097/MOT.0000000000000810 [doi]
AID - 00075200-202012000-00018 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Dec;25(6):631-639. doi:
      10.1097/MOT.0000000000000810.


PMID- 33027034
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 26
TI  - Video Consultations for Older Adults With Multimorbidity During the COVID-19
      Pandemic: Protocol for an Exploratory Qualitative Study.
PG  - e22679
LID - 10.2196/22679 [doi]
AB  - BACKGROUND: Multimorbidity, the coexistence of multiple chronic conditions in an 
      individual, is a growing public health challenge. Amidst the COVID-19 pandemic,
      physical distancing remains an indispensable measure to limit the spread of the
      virus. This pertains especially to those belonging to high-risk groups, namely
      older adults with multimorbidity. In-person visits are discouraged for this
      cohort; hence, there is a need for an alternative form of consultation such as
      video consultations to continue the provision of care. OBJECTIVE: The potential
      of video consultations has been explored in several studies. However, the
      emergence of COVID-19 presents us with an unprecedented opportunity to explore
      the use of this technological innovation in a time when physical distancing is
      imperative. This study will evaluate the sustainability of video consultations on
      a micro-, meso-, and macro-level by assessing the views of patients, physicians, 
      and organizational and national policymakers, respectively. METHODS: The NASSS
      (nonadoption, abandonment, scale-up, spread, and sustainability) framework was
      designed as a guide for the development of health care technologies. In this
      study, the implementation of and experiences related to video consultations will 
      be studied using the NASSS framework. Individual in-depth interviews or focus
      group discussions will be conducted with participants using the Zoom platform.
      Data will be analyzed by at least two investigators trained in qualitative
      methodology, organized thematically, and coded in two phases-an initial phase and
      a focused selective phase. All disagreements will be resolved by consulting the
      larger research team until consensus is reached. RESULTS: This study was approved
      for funding from the Geriatric Education and Research Institute. Ethics approval 
      was obtained from the National Healthcare Group Domain Specific Review Board
      (reference #2020/00760). Study recruitment commenced in July 2020. The results of
      the data analysis are expected to be available by the end of the year.
      CONCLUSIONS: This study aims to evaluate the adoption and sustainability of video
      consultations for older adults with multimorbidity during the pandemic as well as
      post COVID-19. The study will yield knowledge that will challenge the current
      paradigm on how care is being delivered for community-dwelling older adults with 
      multimorbidity. Findings will be shared with administrators in the health care
      sector in order to enhance the safety and quality of these video consultations to
      improve patient care for this group of population. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/22679.
CI  - (c)Eng Sing Lee, Poay Sian Sabrina Lee, Evelyn Ai Ling Chew, Gayathri
      Muthulingam, Hui Li Koh, Shu Yun Tan, Yew Yoong Ding. Originally published in
      JMIR Research Protocols (http://www.researchprotocols.org), 26.10.2020.
FAU - Lee, Eng Sing
AU  - Lee ES
AUID- ORCID: https://orcid.org/0000-0003-4963-535X
AD  - Clinical Research Unit, National Healthcare Group Polyclinics, Singapore,
      Singapore.
FAU - Lee, Poay Sian Sabrina
AU  - Lee PSS
AUID- ORCID: https://orcid.org/0000-0002-4660-514X
AD  - Clinical Research Unit, National Healthcare Group Polyclinics, Singapore,
      Singapore.
FAU - Chew, Evelyn Ai Ling
AU  - Chew EAL
AUID- ORCID: https://orcid.org/0000-0003-3837-2195
AD  - Clinical Research Unit, National Healthcare Group Polyclinics, Singapore,
      Singapore.
FAU - Muthulingam, Gayathri
AU  - Muthulingam G
AUID- ORCID: https://orcid.org/0000-0002-9308-4930
AD  - Clinical Research Unit, National Healthcare Group Polyclinics, Singapore,
      Singapore.
FAU - Koh, Hui Li
AU  - Koh HL
AUID- ORCID: https://orcid.org/0000-0002-9093-7707
AD  - Clinical Research Unit, National Healthcare Group Polyclinics, Singapore,
      Singapore.
FAU - Tan, Shu Yun
AU  - Tan SY
AUID- ORCID: https://orcid.org/0000-0003-0307-9546
AD  - Clinical Research Unit, National Healthcare Group Polyclinics, Singapore,
      Singapore.
FAU - Ding, Yew Yoong
AU  - Ding YY
AUID- ORCID: https://orcid.org/0000-0002-3128-8954
AD  - Geriatric Education and Research Institute, Singapore, Singapore.
AD  - Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7592461
OTO - NOTNLM
OT  - COVID-19
OT  - chronic disease
OT  - elderly
OT  - high risk
OT  - morbidity
OT  - multimorbidity
OT  - older adults
OT  - protocol
OT  - qualitative
OT  - telehealth
OT  - telemedicine
OT  - video consultation
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 17:12
PHST- 2020/07/21 00:00 [received]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/09/05 00:00 [revised]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
PHST- 2020/10/07 17:12 [entrez]
AID - v9i10e22679 [pii]
AID - 10.2196/22679 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 26;9(10):e22679. doi: 10.2196/22679.


PMID- 33026488
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1435-1269 (Electronic)
IS  - 0948-6704 (Linking)
VI  - 53
IP  - 7
DP  - 2020 Nov
TI  - [Ethical, legal and social requirements for assistive robots in healthcare :
      Viewpoint of management personnel in hospitals and nursing homes].
PG  - 630-636
LID - 10.1007/s00391-020-01791-6 [doi]
AB  - BACKGROUND: In 2030 there will be 4 million people in need of care in Germany;
      however, the nursing care sector is already suffering from a shortage of skilled 
      workers. Innovative approaches are thus required. One possible solution with high
      future potential is the use of assistive robots that provide support in everyday 
      and work tasks. The aim of this study was to analyze the ethical, legal and
      social aspects of the use of assistance robots in clinics and care facilities in 
      more detail. The empirical survey addressed decision makers in these
      organizations who are responsible for making purchasing decisions in the
      introduction of robotic assistance systems. MATERIAL AND METHODS: Using an online
      survey, decision makers from more than 160 hospitals and care facilities
      throughout Germany were interviewed between October and December 2018. RESULTS:
      The interviewees of the study did not see any absolute exclusion criteria for the
      use of assistance robots in care with respect to ethical, legal and social
      aspects. The majority of the participants were not concerned that assistance
      robots will replace jobs in healthcare. Especially the personalized communication
      with robots was predominantly seen as positive. With respect to data protection
      and the decrease of human contact as a consequence of the introduction of
      assistance robots, the participants were divided. Half of the interviewees also
      expected a behavioral change due to the presence of a robot. CONCLUSION: The
      study showed that from a top management perspective in hospitals and nursing
      homes, a clarification specifically of legal questions on data protection is
      necessary and needs to be addressed by politics. Robot manufacturers should also 
      concentrate on the topics of data protection and data security in order to gain
      acceptance of their solutions.
FAU - Radic, Marija
AU  - Radic M
AD  - Fraunhofer-Zentrum fur Internationales Management und Wissensokonomie IMW,
      Neumarkt 9-19, 04109, Leipzig, Deutschland. marija.radic@imw.fraunhofer.de.
FAU - Vosen, Agnes
AU  - Vosen A
AD  - Fraunhofer-Zentrum fur Internationales Management und Wissensokonomie IMW,
      Neumarkt 9-19, 04109, Leipzig, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Ethische, rechtliche und soziale Anforderungen an Assistenzroboter in der Pflege 
      : Sicht des Fuhrungspersonals in Kliniken und Pflegeeinrichtungen.
DEP - 20201007
PL  - Germany
TA  - Z Gerontol Geriatr
JT  - Zeitschrift fur Gerontologie und Geriatrie
JID - 9506215
SB  - IM
MH  - Attitude of Health Personnel
MH  - Germany
MH  - Hospitals
MH  - Humans
MH  - Nursing Homes
MH  - *Robotics
OTO - NOTNLM
OT  - Behavior change
OT  - Data privacy
OT  - Occupational stress
OT  - Social interaction
OT  - User needs
EDAT- 2020/10/08 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/10/07 12:10
PHST- 2020/05/30 00:00 [received]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/10/07 12:10 [entrez]
AID - 10.1007/s00391-020-01791-6 [doi]
AID - 10.1007/s00391-020-01791-6 [pii]
PST - ppublish
SO  - Z Gerontol Geriatr. 2020 Nov;53(7):630-636. doi: 10.1007/s00391-020-01791-6. Epub
      2020 Oct 7.


PMID- 33026296
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1744-828X (Electronic)
IS  - 1741-0541 (Linking)
VI  - 17
IP  - 6
DP  - 2020 Nov
TI  - Nudges and the meaningful adoption of digital health.
PG  - 429-433
LID - 10.2217/pme-2020-0071 [doi]
FAU - Shah, Neil
AU  - Shah N
AUID- ORCID: 0000-0002-0100-2847
AD  - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania.
FAU - Adusumalli, Srinath
AU  - Adusumalli S
AD  - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania.
AD  - Penn Medicine Nudge Unit, Penn Medicine Center for Healthcare Innovation.
AD  - Office of the Chief Medical Information Officer, University of Pennsylvania
      Health System.
LA  - eng
PT  - Editorial
DEP - 20201007
PL  - England
TA  - Per Med
JT  - Personalized medicine
JID - 101238549
SB  - IM
MH  - Evidence-Based Practice/methods/*trends
MH  - Health Behavior/*physiology
MH  - Humans
MH  - Precision Medicine/methods/trends
MH  - Wearable Electronic Devices/trends
OTO - NOTNLM
OT  - *adherence
OT  - *bioinformatics
OT  - *cardiology
OT  - *economics
OT  - *endocrinology and metabolism
OT  - *ethical issues
OT  - *health record
OT  - *health technology assessment
OT  - *policy issues
OT  - *regulatory issues
EDAT- 2020/10/08 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/10/07 12:09
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/10/07 12:09 [entrez]
AID - 10.2217/pme-2020-0071 [doi]
PST - ppublish
SO  - Per Med. 2020 Nov;17(6):429-433. doi: 10.2217/pme-2020-0071. Epub 2020 Oct 7.


PMID- 33026295
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1744-828X (Electronic)
IS  - 1741-0541 (Linking)
VI  - 17
IP  - 6
DP  - 2020 Nov
TI  - Personalized medicine in Austria: expectations and limitations.
PG  - 423-428
LID - 10.2217/pme-2020-0061 [doi]
FAU - Pot, Mirjam
AU  - Pot M
AUID- ORCID: 0000-0001-9839-8309
AD  - Department of Political Science, University of Vienna, Vienna 1010, Austria.
FAU - Brehme, Marc
AU  - Brehme M
AUID- ORCID: 0000-0003-0694-331X
AD  - Ribbon Biolabs GmbH, Vienna 1030, Austria.
FAU - El-Heliebi, Amin
AU  - El-Heliebi A
AD  - Medical University of Graz, Gottfried Schatz Research Center, Division of Cell
      Biology, Histology and Embryology, Graz 8036, Austria.
AD  - Center for Biomarker Research in Medicine, Graz 8010, Austria.
FAU - Gschmeidler, Brigitte
AU  - Gschmeidler B
AD  - Open Science - Life Sciences in Dialogue, Vienna 1030, Austria.
FAU - Hofer, Philipp
AU  - Hofer P
AD  - Medical University of Vienna, Department of Pathology, Vienna 1090, Austria.
FAU - Kroneis, Thomas
AU  - Kroneis T
AUID- ORCID: 0000-0002-4761-9340
AD  - Medical University of Graz, Gottfried Schatz Research Center, Division of Cell
      Biology, Histology and Embryology, Graz 8036, Austria.
AD  - Center for Biomarker Research in Medicine, Graz 8010, Austria.
FAU - Schirmer, Michael
AU  - Schirmer M
AD  - Department of Internal Medicine, Medical University of Innsbruck, Clinic II,
      Innsbruck 6020, Austria.
FAU - Schumann, Simone
AU  - Schumann S
AD  - Open Science - Life Sciences in Dialogue, Vienna 1030, Austria.
FAU - Prainsack, Barbara
AU  - Prainsack B
AD  - Department of Political Science, University of Vienna, Vienna 1010, Austria.
AD  - Department of Global Health & Social Medicine, King's College London, Strand,
      London WC2R 2LS, United Kingdom.
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201007
PL  - England
TA  - Per Med
JT  - Personalized medicine
JID - 101238549
SB  - IM
MH  - Austria/epidemiology
MH  - Humans
MH  - Precision Medicine/*methods/*trends
OTO - NOTNLM
OT  - *ethical issues
OT  - *legal issues
OT  - *policy issues
EDAT- 2020/10/08 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/10/07 12:09
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/10/07 12:09 [entrez]
AID - 10.2217/pme-2020-0061 [doi]
PST - ppublish
SO  - Per Med. 2020 Nov;17(6):423-428. doi: 10.2217/pme-2020-0061. Epub 2020 Oct 7.


PMID- 33026107
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20211008
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 10
DP  - 2020 Oct 7
TI  - Factors that impact on recruitment to randomised trials in health care: a
      qualitative evidence synthesis.
PG  - MR000045
LID - 10.1002/14651858.MR000045.pub2 [doi]
AB  - BACKGROUND: Randomised trials (also referred to as 'randomised controlled trials'
      or 'trials') are the optimal way to minimise bias in evaluating the effects of
      competing treatments, therapies and innovations in health care. It is important
      to achieve the required sample size for a trial, otherwise trialists may not be
      able to draw conclusive results leading to research waste and raising ethical
      questions about trial participation. The reasons why potential participants may
      accept or decline participation are multifaceted. Yet, the evidence of
      effectiveness of interventions to improve recruitment to trials is not
      substantial and fails to recognise these individual decision-making processes. It
      is important to synthesise the experiences and perceptions of those invited to
      participate in randomised trials to better inform recruitment strategies.
      OBJECTIVES: To explore potential trial participants' views and experiences of the
      recruitment process for participation. The specific objectives are to describe
      potential participants' perceptions and experiences of accepting or declining to 
      participate in trials, to explore barriers and facilitators to trial
      participation, and to explore to what extent barriers and facilitators identified
      are addressed by strategies to improve recruitment evaluated in previous reviews 
      of the effects of interventions including a Cochrane Methodology Review. SEARCH
      METHODS: We searched the Cochrane Library, Medline, Embase, CINAHL,
      Epistemonikos, LILACS, PsycINFO, ORRCA, and grey literature sources. We ran the
      most recent set of searches for which the results were incorporated into the
      review in July 2017. SELECTION CRITERIA: We included qualitative and
      mixed-methods studies (with an identifiable qualitative component) that explored 
      potential trial participants' experiences and perceptions of being invited to
      participate in a trial. We excluded studies that focused only on recruiters'
      perspectives, and trials solely involving children under 18 years, or adults who 
      were assessed as having impaired mental capacity. DATA COLLECTION AND ANALYSIS:
      Five review authors independently assessed the titles, abstracts and full texts
      identified by the search. We used the CART (completeness, accuracy, relevance,
      timeliness) criteria to exclude studies that had limited focus on the phenomenon 
      of interest. We used QSR NVivo to extract and manage the data. We assessed
      methodological limitations using the Critical Skills Appraisal Programme (CASP)
      tool. We used thematic synthesis to analyse and synthesise the evidence. This
      provided analytical themes and a conceptual model. We used the GRADE-CERQual
      (Confidence in the Evidence from Reviews of Qualitative research) approach to
      assess our confidence in each finding. Our findings were integrated with two
      previous intervention effectiveness reviews by juxtaposing the quantitative and
      qualitative findings in a matrix. MAIN RESULTS: We included 29 studies (published
      in 30 papers) in our synthesis. Twenty-two key findings were produced under three
      broad themes (with six subthemes) to capture the experience of being invited to
      participate in a trial and making the decision whether to participate. Most of
      these findings had moderate to high confidence. We identified factors from the
      trial itself that influenced participation. These included how trial information 
      was communicated, and elements of the trial such as the time commitment that
      might be considered burdensome. The second theme related to personal factors such
      as how other people can influence the individual's decision; and how a personal
      understanding of potential harms and benefits could impact on the decision.
      Finally, the potential benefits of participation were found to be key to the
      decision to participate, namely personal benefits such as access to new
      treatments, but also the chance to make a difference and help others. The
      conceptual model we developed presents the decision-making process as a gauge and
      the factors that influence whether the person will, or will not, take part.
      AUTHORS' CONCLUSIONS: This qualitative evidence synthesis has provided
      comprehensive insight into the complexity of factors that influence a person's
      decision whether to participate in a trial. We developed key questions that
      trialists can ask when developing their recruitment strategy. In addition, our
      conceptual model emphasises the need for participant-centred approaches to
      recruitment. We demonstrated moderate to high level confidence in our findings,
      which in some way can be attributed to the large volume of highly relevant
      studies in this field. We recommend that these insights be used to direct or
      influence or underpin future recruitment strategies that are developed in a
      participant-driven way that ultimately improves trial conduct and reduces
      research waste.
CI  - Copyright (c) 2020 The Cochrane Collaboration. Published by John Wiley & Sons,
      Ltd.
FAU - Houghton, Catherine
AU  - Houghton C
AD  - School of Nursing and Midwifery, National University of Ireland Galway, Galway,
      Ireland.
FAU - Dowling, Maura
AU  - Dowling M
AD  - School of Nursing and Midwifery, National University of Ireland, Galway, Galway, 
      Ireland.
FAU - Meskell, Pauline
AU  - Meskell P
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
FAU - Hunter, Andrew
AU  - Hunter A
AD  - School of Nursing and Midwifery, National University of Ireland, Galway, Galway, 
      Ireland.
FAU - Gardner, Heidi
AU  - Gardner H
AD  - Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
FAU - Conway, Aislinn
AU  - Conway A
AD  - School of Nursing and Midwifery, National University of Ireland, Galway, Galway, 
      Ireland.
FAU - Treweek, Shaun
AU  - Treweek S
AD  - Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
FAU - Sutcliffe, Katy
AU  - Sutcliffe K
AD  - Department of Social Science, Social Science Research Unit, UCL Institute of
      Education, London, UK.
FAU - Noyes, Jane
AU  - Noyes J
AD  - Centre for Health-Related Research, Fron Heulog, Bangor University, Bangor, UK.
FAU - Devane, Declan
AU  - Devane D
AD  - School of Nursing and Midwifery, National University of Ireland Galway, Galway,
      Ireland.
FAU - Nicholas, Jane R
AU  - Nicholas JR
AD  - School of Nursing and Midwifery, National University of Ireland, Galway, Galway, 
      Ireland.
FAU - Biesty, Linda M
AU  - Biesty LM
AD  - School of Nursing and Midwifery, National University of Ireland Galway, Galway,
      Ireland.
LA  - eng
GR  - HSRU1/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Systematic Review
DEP - 20201007
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
SB  - IM
MH  - Adult
MH  - Communication
MH  - *Decision Making
MH  - Financial Support
MH  - Humans
MH  - Patient Education as Topic/methods
MH  - *Patient Selection
MH  - Qualitative Research
MH  - Random Allocation
MH  - *Randomized Controlled Trials as Topic
MH  - Research Subjects/*psychology
MH  - Risk Assessment
MH  - Sample Size
MH  - Treatment Refusal/psychology
PMC - PMC8078544
EDAT- 2020/10/08 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/07 08:41
PHST- 2020/10/07 08:41 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1002/14651858.MR000045.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2020 Oct 7;10:MR000045. doi:
      10.1002/14651858.MR000045.pub2.


PMID- 33026053
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 41
IP  - 10
DP  - 2020 Oct
TI  - Screening for body dysmorphic disorder among patients pursuing cosmetic surgeries
      in Saudi Arabia.
PG  - 1111-1120
LID - 10.15537/smj.2020.10.25380 [doi]
AB  - OBJECTIVES: To determine the prevalence of positive screening of body dysmorphic 
      disorder (BDD) among patients seeking cosmetic surgeries in plastic surgery and
      oculoplastic surgery clinics. METHODS: The survey of this cross-sectional study
      was self-administrated and distributed among adults pursuing cosmetic surgeries
      in plastic surgery and oculoplastic surgery clinics at King Abdulaziz University 
      Hospital, Jeddah, Saudi Arabia, between March 2019 and March 2020. The BDD
      questionnaire was validated, and a highly sensitive and specific tool was used to
      identify patients with BDD. Ethical approval was granted by the Research Ethics
      Committee. All analytic studies were performed using IBM SPSS, version 24.
      Results: A total of 344 patients participated in this study with a mean age of
      39.66 +/- 13.76 years. Of these, 296 (86%) were women and 298 (86.6%) were Saudi.
      The prevalence of positive screening for BDD was 19.2%. The most commonly
      requested procedures were abdominoplasty (21.2%) and skin lesion removal (21.2%).
      Smoking was found to be significantly associated with BDD with 21.2% of smokers
      having it (p less than 0.010). CONCLUSION: Body dysmorphic disorder was
      unrecognized among patients pursuing cosmetic surgeries. One-fifth of patients
      requesting cosmetic procedures are potential cases of BDD requiring psychiatric
      evaluation and treatment. We recommend implementing screening protocols to
      identify cases before surgical plans.
FAU - Mortada, Hatan
AU  - Mortada H
AD  - Department of Plastic Surgery & Burn Unit, King Saud Medical City, Riyadh,
      Kingdom of Saudi Arabia. E-mail. Hatanmortada@gmail.com.
FAU - Seraj, Hadeel
AU  - Seraj H
FAU - Bokhari, Amal
AU  - Bokhari A
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
SB  - IM
MH  - Adult
MH  - Body Dysmorphic Disorders/*epidemiology/psychology/*surgery
MH  - Cross-Sectional Studies
MH  - Esthetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Screening/*methods
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Prevalence
MH  - Reconstructive Surgical Procedures/methods/statistics & numerical data
MH  - Saudi Arabia/epidemiology
MH  - *Surgery, Plastic/methods/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7841516
EDAT- 2020/10/08 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/10/07 08:41
PHST- 2020/10/07 08:41 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
AID - 10.15537/smj.2020.10.25380 [doi]
PST - ppublish
SO  - Saudi Med J. 2020 Oct;41(10):1111-1120. doi: 10.15537/smj.2020.10.25380.


PMID- 33025550
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Oct
TI  - Navigating Ethical Practices in the Era of High Cost Hematology.
PG  - 401-407
LID - 10.1007/s11899-020-00599-w [doi]
AB  - PURPOSE OF REVIEW: In this review article, we will highlight ethical issues faced
      by hematologists due to a growing constellation of expensive diagnostics and
      therapeutics in hematology. We outline the important issues surrounding this
      topic including stakeholders, cost considerations, and various ethical challenges
      surrounding access to care, communication about costs, and individual vs.
      societal responsibilities. We review available tools to navigate these ethical
      themes and offer potential solutions. RECENT FINDINGS: We identified several gaps
      in the literature on the topic of ethical issues in hematology treatment and
      supplement by non-hematological cancer and general medical literature. We propose
      proactive solutions to address these problems to include cost transparency,
      utilization of evidence-based decision making tools, application of the four
      quadrant approach to ethical care, and advanced systems-based practice curriculum
      for physician trainees.
FAU - Ertz-Archambault, Natalie
AU  - Ertz-Archambault N
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, 5777 East Mayo Blvd.,
      Phoenix, AZ, 85054, USA. Natalie.Ertz@gmail.com.
FAU - Khera, Nandita
AU  - Khera N
AD  - Division of Hematology and Medical Oncology, Mayo Clinic, 5777 East Mayo Blvd.,
      Phoenix, AZ, 85054, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
SB  - IM
MH  - Clinical Decision-Making/*ethics
MH  - *Conflict of Interest
MH  - Decision Support Techniques
MH  - Evidence-Based Medicine/economics/ethics
MH  - Health Care Costs/*ethics
MH  - Hematology/*economics/*ethics
MH  - Humans
MH  - Patient Participation
MH  - Patient Selection/*ethics
MH  - Quality of Life
MH  - Quality-Adjusted Life Years
MH  - Stakeholder Participation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Biomedical ethics
OT  - *Decision making
OT  - *Ethical analysis
OT  - *Healthcare cost
OT  - *Hematology
EDAT- 2020/10/08 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/07 05:55
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/10/07 05:55 [entrez]
AID - 10.1007/s11899-020-00599-w [doi]
AID - 10.1007/s11899-020-00599-w [pii]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2020 Oct;15(5):401-407. doi: 10.1007/s11899-020-00599-w. 
      Epub 2020 Oct 6.


PMID- 33025400
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20211102
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 11
DP  - 2020 Nov
TI  - Medical research and reproductive medicine in an ethical context: a critical
      commentary on the paper dealing with uterine lavage published by Munne et al.
PG  - 2691-2698
LID - 10.1007/s10815-020-01954-9 [doi]
AB  - A recent study published in Human Reproduction claimed that uterine lavage offers
      a non-surgical, minimally invasive strategy for the recovery of human embryos
      from fertile women who do not want or need IVF for medical reasons but who desire
      preimplantation genetic testing (PGT) for embryos. To prove this hypothesis, the 
      researchers recruited dozens of young Mexican women. The prospective oocyte
      donors underwent ovarian stimulation to induce the production of multiple mature 
      oocytes. Subsequently, these women were inseminated by donor semen. A few days
      later, the developing embryos were collected by uterine lavage (uterine flushing)
      and subjected to genetic testing for aneuploidies (PGT-A). Oocyte donors with
      persistently elevated hCG levels, indicating the implantation of one or more
      embryos after uterine lavage, had to undergo uterine curettage and/or treatment
      with methotrexate. A critical opinion paper discussing the aforementioned study
      was published by De Santis and colleagues and has raised critical issues that are
      largely technical in nature. However, this opinion paper neglects-from our point 
      of view-critical issues of the Mexican study regarding ethical principles and
      moral standards in human research. These aspects are summarized below.
FAU - Murtinger, Maximilian
AU  - Murtinger M
AD  - NEXTCLINIC IVF Zentren Prof. Zech-Bregenz, Bregenz, Austria.
      maximilian.murtinger@ivf.at.
FAU - Wirleitner, Barbara
AU  - Wirleitner B
AD  - NEXTCLINIC IVF Zentren Prof. Zech-Bregenz, Bregenz, Austria.
FAU - Hradecky, Libor
AU  - Hradecky L
AD  - IVF Zentren Prof. Zech-Pilsen, Pilsen, Czech Republic.
FAU - Comploj, Giorgio
AU  - Comploj G
AD  - EuBios Centri Fivet Prof. Zech, Merano, Italy.
FAU - Okhowat, Jasmin
AU  - Okhowat J
AD  - NEXTCLINIC IVF Zentren Prof. Zech-Bregenz, Bregenz, Austria.
FAU - Spitzer, Dietmar
AU  - Spitzer D
AD  - IVF Zentren Prof. Zech-Salzburg, Salzburg, Austria.
FAU - Stadler, Jurgen
AU  - Stadler J
AD  - IVF Zentren Prof. Zech-Salzburg, Salzburg, Austria.
FAU - Haidbauer, Robert
AU  - Haidbauer R
AD  - IVF Zentren Prof. Zech-Salzburg, Salzburg, Austria.
FAU - Schuff, Maximilian
AU  - Schuff M
AD  - NEXTCLINIC IVF Zentren Prof. Zech-Bregenz, Bregenz, Austria.
FAU - Yildirim, Selma
AU  - Yildirim S
AD  - MVZ Kinderwunsch Munsterland, Bocholt, Germany.
FAU - Soepenberg, Therese
AU  - Soepenberg T
AD  - MVZ NEXTCLINICS Kinderwunschzentrum Koln, Cologne, Germany.
FAU - Eibner, Kerstin
AU  - Eibner K
AD  - Medical Department, Kinderwunsch-MVZ Ulm, Ulm, Germany.
FAU - Gagsteiger, Friedrich
AU  - Gagsteiger F
AD  - Medical Department, Kinderwunsch-MVZ Ulm, Ulm, Germany.
LA  - eng
GR  - No award/Not applicable
GR  - No award/No funding
PT  - Journal Article
DEP - 20201006
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - Adult
MH  - Aneuploidy
MH  - Biomedical Research/*ethics
MH  - Embryo Implantation/genetics
MH  - Embryo Transfer/ethics
MH  - Female
MH  - Fertilization in Vitro/ethics
MH  - Humans
MH  - Male
MH  - Oocyte Retrieval/ethics
MH  - Oocytes/cytology/*growth & development
MH  - Pregnancy
MH  - Preimplantation Diagnosis/*ethics
MH  - Reproductive Medicine/*ethics
MH  - Semen/cytology
PMC - PMC7642030
OTO - NOTNLM
OT  - Ethics
OT  - Oocyte donors
OT  - PGT-A
OT  - Publication standards
OT  - Uterine lavage
EDAT- 2020/10/08 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/10/07 05:54
PHST- 2020/06/17 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/10/07 05:54 [entrez]
AID - 10.1007/s10815-020-01954-9 [doi]
AID - 10.1007/s10815-020-01954-9 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Nov;37(11):2691-2698. doi:
      10.1007/s10815-020-01954-9. Epub 2020 Oct 6.


PMID- 33024880
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Contributory factors to the evolution of the concept and practice of informed
      consent in clinical research: A narrative review.
PG  - 100634
LID - 10.1016/j.conctc.2020.100634 [doi]
AB  - Informed consent can be defined as a freely-given decision or agreement following
      disclosure of relevant information. This review explores how legislation
      surrounding informed consent has impacted upon clinical research practices, with 
      a focus on clinical trials involving individuals with the capacity to give
      consent in the non-emergency setting. We also highlight the challenges which
      remain with the informed consent process, including those which exist in the era 
      of data protection legislation and genetic research. Modern ethicists agree that 
      informed consent encompasses three principal factors: disclosure of information, 
      capacity for decision making, and voluntariness. In the context of clinical
      research, informed consent is now required by regulatory and ethical frameworks
      as well as by law, and various guidelines govern the practice of informed
      consent, including the Declaration of Helsinki and the Good Clinical Practice
      Guidelines. Historically, however, researchers acted paternalistically and
      included participants in research without their knowledge or consent. Following
      societal and political revolution, an autonomy model of consent became prevalent,
      and individuals became free to make individual choices about whether to
      participate. Despite this, it is also recognized that an individual's community
      has a role in supporting their decision making, and this may be a strong
      influence, particularly within some societies. Research scandals and
      controversies and whistle-blowers which exposed unethical practices in the area
      of informed consent also contributed to changes in societal attitudes and
      legislation changed as a result. Medical journals also have an established,
      although indirect, role in strengthening good practices surrounding informed
      consent.
CI  - (c) 2020 The Authors.
FAU - O'Sullivan, Lydia
AU  - O'Sullivan L
AD  - School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
AD  - Health Research Board-Trials Methodology Research Network, National University of
      Ireland, Galway, Ireland.
AD  - School of Nursing, Midwifery and Health Systems, University College Dublin,
      Belfield, Dublin 4, Ireland.
FAU - Crowley, Rachel
AU  - Crowley R
AD  - School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
AD  - Department of Endocrinology, Saint Vincent's University Hospital, Elm Park,
      Dublin 4, Ireland.
FAU - McAuliffe, Eilish
AU  - McAuliffe E
AD  - School of Nursing, Midwifery and Health Systems, University College Dublin,
      Belfield, Dublin 4, Ireland.
FAU - Doran, Peter
AU  - Doran P
AD  - School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
AD  - Health Research Board-Trials Methodology Research Network, National University of
      Ireland, Galway, Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200813
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7528065
OTO - NOTNLM
OT  - Clinical research
OT  - Informed consent
OT  - Research ethics
COIS- The authors have no competing interests.
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 05:51
PHST- 2020/05/18 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/10/07 05:51 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
AID - 10.1016/j.conctc.2020.100634 [doi]
AID - S2451-8654(20)30118-6 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Aug 13;19:100634. doi:
      10.1016/j.conctc.2020.100634. eCollection 2020 Sep.


PMID- 33024824
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 2387-0206 (Electronic)
IS  - 2387-0206 (Linking)
VI  - 155
IP  - 8
DP  - 2020 Oct 23
TI  - Clinical and ethical recommendations for decision-making in nursing homes in the 
      context of the COVID-19 crisis.
PG  - 356-359
LID - 10.1016/j.medcle.2020.06.015 [doi]
FAU - Amblas-Novellas, Jordi
AU  - Amblas-Novellas J
AD  - Catedra de Cuidados Paliativos, Centre d'Estudis Sanitaris i Socials (CESS),
      Universitat de Vic - Universitat Central de Catalunya (UVIC-UCC), Vic, Barcelona,
      Spain.
AD  - Grupo de Investigacion en Cronicidad de la Cataluna Central (C3RG), Centre
      d'Estudis Sanitaris i Socials (CESS), Universitat de Vic - Universitat Central de
      Catalunya (UVIC-UCC), Vic, Barcelona, Spain.
AD  - Departament de Salut, Generalitat de Catalunya, Spain.
FAU - Gomez-Batiste, Xavier
AU  - Gomez-Batiste X
AD  - Catedra de Cuidados Paliativos, Centre d'Estudis Sanitaris i Socials (CESS),
      Universitat de Vic - Universitat Central de Catalunya (UVIC-UCC), Vic, Barcelona,
      Spain.
AD  - Grupo de Investigacion en Cronicidad de la Cataluna Central (C3RG), Centre
      d'Estudis Sanitaris i Socials (CESS), Universitat de Vic - Universitat Central de
      Catalunya (UVIC-UCC), Vic, Barcelona, Spain.
AD  - The Qualy Observatory/WHO Collaborating Centre for Public Health Palliative Care 
      Programs (WHOCC), Instituto Catalan de Oncologia, Barcelona, Spain.
CN  - professionals and organizations that have participated in the consensus
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Spain
TA  - Med Clin (Engl Ed)
JT  - Medicina clinica (English ed.)
JID - 101711190
PMC - PMC7528908
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 05:51
PHST- 2020/05/14 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
PHST- 2020/10/07 05:51 [entrez]
AID - 10.1016/j.medcle.2020.06.015 [doi]
AID - S2387-0206(20)30435-6 [pii]
PST - ppublish
SO  - Med Clin (Engl Ed). 2020 Oct 23;155(8):356-359. doi:
      10.1016/j.medcle.2020.06.015. Epub 2020 Oct 1.


PMID- 33024436
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - The Psychonauts' World of Cognitive Enhancers.
PG  - 546796
LID - 10.3389/fpsyt.2020.546796 [doi]
AB  - BACKGROUND: There is growing availability of novel psychoactive substances (NPS),
      including cognitive enhancers (CEs) which can be used in the treatment of certain
      mental health disorders. While treating cognitive deficit symptoms in
      neuropsychiatric or neurodegenerative disorders using CEs might have significant 
      benefits for patients, the increasing recreational use of these substances by
      healthy individuals raises many clinical, medico-legal, and ethical issues.
      Moreover, it has become very challenging for clinicians to keep up-to-date with
      CEs currently available as comprehensive official lists do not exist. METHODS:
      Using a web crawler (NPSfinder((R))), the present study aimed at assessing
      psychonaut fora/platforms to better understand the online situation regarding
      CEs. We compared NPSfinder((R)) entries with those from the European Monitoring
      Centre for Drugs and Drug Addiction (EMCDDA) and from the United Nations Office
      on Drugs and Crime (UNODC) NPS databases up to spring 2019. Any substance that
      was identified by NPSfinder((R)) was considered a CE if it was either described
      as having nootropic abilities by psychonauts or if it was listed among the known 
      CEs by Froestl and colleagues. RESULTS: A total of 142 unique CEs were identified
      by NPSfinder((R)). They were divided into 10 categories, including
      plants/herbs/products (29%), prescribed drugs (17%), image and performance
      enhancing drugs (IPEDs) (15%), psychostimulants (15%), miscellaneous (8%),
      Phenethylamines (6%), GABAergic drugs (5%), cannabimimetic (4%), tryptamines
      derivatives (0.5%), and piperazine derivatives (0.5%). A total of 105 chemically 
      different substances were uniquely identified by NPSfinder((R)). Only one CE was 
      uniquely identified by the EMCDDA; no CE was uniquely identified by the UNODC.
      CONCLUSIONS: These results show that NPSfinder((R)) is helpful as part of an
      Early Warning System, which could update clinicians with the growing numbers and 
      types of nootropics in the increasingly difficult-to-follow internet world.
      Improving clinicians' knowledge of NPS could promote more effective prevention
      and harm reduction measures in clinical settings.
CI  - Copyright (c) 2020 Napoletano, Schifano, Corkery, Guirguis, Arillotta, Zangani
      and Vento.
FAU - Napoletano, Flavia
AU  - Napoletano F
AD  - Department of Mental Health, Homerton University Hospital, East London Foundation
      Trust, London, United Kingdom.
AD  - Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,
      School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
      United Kingdom.
FAU - Schifano, Fabrizio
AU  - Schifano F
AD  - Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,
      School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
      United Kingdom.
FAU - Corkery, John Martin
AU  - Corkery JM
AD  - Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,
      School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
      United Kingdom.
FAU - Guirguis, Amira
AU  - Guirguis A
AD  - Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,
      School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
      United Kingdom.
AD  - Swansea University Medical School, Institute of Life Sciences 2, Swansea
      University, Swansea, United Kingdom.
FAU - Arillotta, Davide
AU  - Arillotta D
AD  - Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,
      School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
      United Kingdom.
AD  - Psychiatry Unit, Department of Clinical and Experimental Medicine, University of 
      Catania, Catania, Italy.
FAU - Zangani, Caroline
AU  - Zangani C
AD  - Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit,
      School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
      United Kingdom.
AD  - Department of Health Sciences, University of Milan, Milan, Italy.
FAU - Vento, Alessandro
AU  - Vento A
AD  - Department of Mental Health, Addictions' Observatory (ODDPSS), Rome, Italy.
AD  - Department of Mental Health, Guglielmo Marconi" University, Rome, Italy.
AD  - Department of Mental Health, ASL Roma 2, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200911
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7516264
OTO - NOTNLM
OT  - cognitive enhancers
OT  - early warning systems
OT  - nootropics
OT  - novel psychoactive substances
OT  - screening
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 05:49
PHST- 2020/03/29 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/10/07 05:49 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
AID - 10.3389/fpsyt.2020.546796 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Sep 11;11:546796. doi: 10.3389/fpsyt.2020.546796.
      eCollection 2020.


PMID- 33024421
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 1541-4612 (Print)
IS  - 1541-4612 (Linking)
VI  - 18
IP  - 6
DP  - 2020 Dec
TI  - Leading Our Frontline HEROES Through Times of Crisis With a Sense of Hope,
      Efficacy, Resilience, and Optimism.
PG  - 592-596
LID - 10.1016/j.mnl.2020.05.011 [doi]
AB  - The coronavirus 2019 (COVID-19) pandemic has changed the trajectory of health
      care delivery in the United States and the whole world. Frontline
      nurses-essential warriors in this fight-complete exhausting shifts and experience
      the moral distress that comes with making difficult ethical decisions. This
      deeply human crisis requires a deeply human response. To augment the mental
      health of their frontline staff, nurse leaders must tap into their staff's
      psychological capital (PsyCap). PsyCap is characterized by having high levels of 
      HERO (i.e., hope, efficacy, resilience, and optimism). In this article, we
      describe strategies that nurse leaders can utilize to foster PsyCap in their
      nurses.
CI  - 2020 by Elsevier Inc. All rights reserved.
FAU - Dimino, Kimberly
AU  - Dimino K
FAU - Horan, Kathleen M
AU  - Horan KM
FAU - Stephenson, Carolene
AU  - Stephenson C
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - United States
TA  - Nurse Lead
JT  - Nurse leader
JID - 101156072
PMC - PMC7529385
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 05:49
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
PHST- 2020/10/07 05:49 [entrez]
AID - 10.1016/j.mnl.2020.05.011 [doi]
AID - S1541-4612(20)30131-2 [pii]
PST - ppublish
SO  - Nurse Lead. 2020 Dec;18(6):592-596. doi: 10.1016/j.mnl.2020.05.011. Epub 2020 Jul
      14.


PMID- 33024377
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 8
DP  - 2020 Aug
TI  - Clinical Utility of the Behavioral Pain Assessment Tool in Patients Admitted in
      the Intensive Care Unit.
PG  - 695-700
LID - 10.5005/jp-journals-10071-23521 [doi]
AB  - INTRODUCTION: Unnoticed and unrelieved pain is one of the main sources of
      psychological and physiological stress for intensive care unit (ICU) patients.
      The eight-item behavior pain assessment tool (BPAT) is a multicountry validated
      tool to assess pain in ICU patients. However, its feasibility and clinical
      utility for ICU patients in India need further research. AIMS AND OBJECTIVES: The
      Aims and objectives of the study were to assess pain using BPAT and its clinical 
      utility in pain assessment and management in ICU patients. MATERIALS AND METHODS:
      Following ethical approval, 400 consecutive adult patients admitted in the ICUs
      in a tertiary care teaching hospital were assessed for pain severity using BPAT
      at intake, baseline pain and procedural pain. Patients <18 years and in deep coma
      on the Glasgow coma scale were excluded from the study. The patients with BPAT
      score >/=4 were given opioid analgesic, and their pain was reassessed after 2-3
      hours. A feedback regarding feasibility and clinical utility was filled by the
      doctors. RESULTS: High interrater agreement for BPAT was observed with excellent 
      kappa coefficients (>0.85) for each item. The BPAT significantly guided the pain 
      management (p < 0.0001). More than 90% of doctors found BPAT easy to understand
      and use. In most of the cases (95.5%), doctors agreed that BPAT can improve the
      clinical management of ICU patients. CONCLUSION: The BPAT is a reliable, brief,
      and an easy-to-use pain assessment tool, which clinicians can use for guiding
      pain assessment and management in the ICU setting on a routine basis. CLINICAL
      SIGNIFICANCE: We recommend implementing BPAT in the clinical practice for better 
      pain assessment and control in ICU patients. HOW TO CITE THIS ARTICLE: Mitra S,
      Jain K, Singh J, Saxena P, Nyima T, Selvam SR, et al. Clinical Utility of the
      Behavioral Pain Assessment Tool in Patients Admitted in the Intensive Care Unit. 
      Indian J Crit Care Med 2020;24(8):695-700.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Mitra, Sukanya
AU  - Mitra S
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Jain, Kompal
AU  - Jain K
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Singh, Jasveer
AU  - Singh J
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Saxena, Puja
AU  - Saxena P
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Nyima, Tenzin
AU  - Nyima T
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Selvam, Selwin R
AU  - Selvam SR
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Walia, Mansi C
AU  - Walia MC
AD  - Department of Anaesthesia and Intensive Care, Government Medical College and
      Hospital, Chandigarh, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7519617
OTO - NOTNLM
OT  - Assessment
OT  - Intensive care unit
OT  - Management
OT  - Pain
OT  - Scale
OT  - Utility
COIS- Source of support: ISCCM. REF. ISCCM/2017-18/42, dated July 20, 2017 Conflict of 
      interest: None
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 05:49
PHST- 2020/10/07 05:49 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
AID - 10.5005/jp-journals-10071-23521 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Aug;24(8):695-700. doi:
      10.5005/jp-journals-10071-23521.


PMID- 33024368
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 8
DP  - 2020 Aug
TI  - A Multicenter Cross-sectional Questionnaire-based Study to Know the Practices and
      Strategies of Ventilatory Management of COVID-19 Patients among the Treating
      Physicians.
PG  - 643-648
LID - 10.5005/jp-journals-10071-23516 [doi]
AB  - INTRODUCTION: COVID-19 has been declared a pandemic by the World Health
      Organization (WHO). Many of the COVID-19 patients develop acute respiratory
      distress syndrome (ARDS) and require ventilatory support based on their severity 
      for which conventional strategies are being used along with few newer strategies.
      We conducted this multicenter survey to know the physician's current ventilation 
      strategies adopted for the care of COVID-19 patients. MATERIALS AND METHODS: The 
      survey was conducted after taking the ethical committee clearance. The web-based 
      multicenter, cross-sectional questionnaire study was sent to physicians, who were
      involved in the management of COVID-19 patients. The questionnaire was segregated
      into three parts: part one consisted of general information and consent form,
      part two was concerned regarding demographic characteristics, and part three was 
      concerned about their practices and strategies for ventilation of COVID-19
      patients. RESULTS: A total of 223 responders replied for the questionnaire; 190
      participated in the study saying that they are involved in the management of
      COVID-19 patients. The answers to the questionnaires were expressed as a
      percentage of total responses. 86% of the respondents said they have a designated
      intensive care unit (ICU) and 89% of the responders said they have an
      intubation/extubation protocol for suspect/confirmed COVID-19 patients. The
      responses of junior residents (JRs), senior residents (SRs), assistant
      professors/junior consultants, and professors/consultants were analyzed
      separately, and a few significant differences were observed. 39% of JRs were
      aware of prone ventilation as the most effective rescue ventilation strategy
      compared to 69% of consultants/professors. Extracorporeal membranous oxygenation 
      (ECMO) strategy was also more significant in consultants/professors (40%) vs JRs 
      (12%). The responders were also diverged based on medical college and corporate
      hospitals, and their responses were noted. Most commonly, responders in the
      corporate hospitals had a facility to ventilate COVID-19 patients in a negative
      pressure isolation facility compared to a nonnegative pressure room isolation
      facility in medical colleges. CONCLUSION: Most of the responders were practicing 
      ventilation strategies in a standard manner. JRs need to undergo further training
      in a few aspects of the ventilatory management, and also, they need to update
      themselves with newer treatment modalities as they keep evolving. Medical
      colleges are providing at par facility compared to corporate hospitals except for
      few advance care facilities. CLINICAL SIGNIFICANCE: This study highlights the
      current practice of ventilatory management of COVID-19 patients, which is
      satisfactory. The survey can be used to develop study tools, to educate resident 
      doctors, to further improve quality of care of critical COVID-19 patients. HOW TO
      CITE THIS ARTICLE: Maddani SS, Deepa HC, Rao S, Chaudhuri S. A Multicenter
      Cross-sectional Questionnaire-based Study to know the Practices and Strategies of
      Ventilatory Management of COVID-19 Patients among the Treating Physicians. Indian
      J Crit Care Med 2020;24(8):643-648.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Maddani, Sagar S
AU  - Maddani SS
AD  - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy
      of Higher Education, Manipal, Karnataka, India.
FAU - Deepa, Hunasaghatta Chandrappa
AU  - Deepa HC
AD  - Department of Pathology, Kasturba Medical College, Manipal Academy of Higher
      Education, Manipal, Karnataka, India.
FAU - Rao, Shwethapriya
AU  - Rao S
AD  - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy
      of Higher Education, Manipal, Karnataka, India.
FAU - Chaudhuri, Souvik
AU  - Chaudhuri S
AD  - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy
      of Higher Education, Manipal, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7519590
OTO - NOTNLM
OT  - COVID-19
OT  - Endotracheal intubation
OT  - Intensive care unit
OT  - Ventilation management
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 05:49
PHST- 2020/10/07 05:49 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
AID - 10.5005/jp-journals-10071-23516 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Aug;24(8):643-648. doi:
      10.5005/jp-journals-10071-23516.


PMID- 33023977
OWN - NLM
STAT- Publisher
LR  - 20201007
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 6
TI  - Public involvement in the governance of population-level biomedical research:
      unresolved questions and future directions.
LID - medethics-2020-106530 [pii]
LID - 10.1136/medethics-2020-106530 [doi]
AB  - Population-level biomedical research offers new opportunities to improve
      population health, but also raises new challenges to traditional systems of
      research governance and ethical oversight. Partly in response to these
      challenges, various models of public involvement in research are being
      introduced. Yet, the ways in which public involvement should meet governance
      challenges are not well understood. We conducted a qualitative study with 36
      experts and stakeholders using the World Cafe method to identify key governance
      challenges and explore how public involvement can meet these challenges. This
      brief report discusses four cross-cutting themes from the study: the need to move
      beyond individual consent; issues in benefit and data sharing; the challenge of
      delineating and understanding publics; and the goal of clarifying justifications 
      for public involvement. The report aims to provide a starting point for making
      sense of the relationship between public involvement and the governance of
      population-level biomedical research, showing connections, potential solutions
      and issues arising at their intersection. We suggest that, in population-level
      biomedical research, there is a pressing need for a shift away from conventional 
      governance frameworks focused on the individual and towards a focus on
      collectives, as well as to foreground ethical issues around social justice and
      develop ways to address cultural diversity, value pluralism and competing
      stakeholder interests. There are many unresolved questions around how this shift 
      could be realised, but these unresolved questions should form the basis for
      developing justificatory accounts and frameworks for suitable collective models
      of public involvement in population-level biomedical research governance.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Erikainen, Sonja
AU  - Erikainen S
AUID- ORCID: http://orcid.org/0000-0002-1442-3050
AD  - Centre for Biomedicine, Self and Society, Usher Institute, The University of
      Edinburgh, Edinburgh, UK sonja.erikainen@ed.ac.uk.
FAU - Friesen, Phoebe
AU  - Friesen P
AD  - Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada.
FAU - Rand, Leah
AU  - Rand L
AD  - Harvard Medical School and PORTAL, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
FAU - Jongsma, Karin
AU  - Jongsma K
AUID- ORCID: http://orcid.org/0000-0001-8135-6786
AD  - Department of Medical Humanities, Julius Center, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
FAU - Dunn, Michael
AU  - Dunn M
AUID- ORCID: http://orcid.org/0000-0002-5603-6200
AD  - The Ethox Centre and Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
FAU - Sorbie, Annie
AU  - Sorbie A
AD  - Mason Institute for Medicine, Life Sciences and the Law, Edinburgh Law School,
      University of Edinburgh, Edinburgh, UK.
FAU - McCoy, Matthew
AU  - McCoy M
AUID- ORCID: http://orcid.org/0000-0002-5273-3877
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman, Philadelphia, Pennsylvania, USA.
FAU - Bell, Jessica
AU  - Bell J
AD  - HeLEX, University of Oxford, Oxford, Oxfordshire, UK.
FAU - Burgess, Michael
AU  - Burgess M
AD  - School of Population and Public Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Chen, Haidan
AU  - Chen H
AD  - School of Health Humanities, Peking University, Beijing, China.
FAU - Chico, Vicky
AU  - Chico V
AD  - School of Law, University of Sheffield, Sheffield, UK.
FAU - Cunningham-Burley, Sarah
AU  - Cunningham-Burley S
AUID- ORCID: http://orcid.org/0000-0002-0009-7653
AD  - Centre for Biomedicine, Self and Society, Usher Institute, The University of
      Edinburgh, Edinburgh, UK.
FAU - Darbyshire, Julie
AU  - Darbyshire J
AUID- ORCID: http://orcid.org/0000-0002-7655-1963
AD  - Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
FAU - Dawson, Rebecca
AU  - Dawson R
AD  - Usher Institute, University of Edinburgh, Edinburgh, UK.
FAU - Evans, Andrew
AU  - Evans A
AD  - Melanoma Patient Network Europe, N/A, UK.
FAU - Fahy, Nick
AU  - Fahy N
AD  - Primary Care Health Sciences, University of Oxford, Oxford, UK.
FAU - Finlay, Teresa
AU  - Finlay T
AD  - Primary Care Health Sciences, University of Oxford, Oxford, UK.
FAU - Frith, Lucy
AU  - Frith L
AUID- ORCID: http://orcid.org/0000-0002-8506-0699
AD  - Institute of Population Health Sciences, University of Liverpool, Liverpool, UK.
FAU - Goldenberg, Aaron
AU  - Goldenberg A
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Hinton, Lisa
AU  - Hinton L
AD  - THIS Institute, University of Cambridge, Cambridge, Cambridgeshire, UK.
FAU - Hoppe, Nils
AU  - Hoppe N
AD  - Centre for Ethics and Law in the Life Sciences, Leibniz University, Hannover,
      Germany.
FAU - Hughes, Nigel
AU  - Hughes N
AD  - Observational Health Data Analytics/Epidemiology, Janssen Research and
      Development, Raritan, New Jersey, USA.
FAU - Koenig, Barbara
AU  - Koenig B
AD  - Department of Political Science, University of Vienna, Vienna, Austria.
FAU - Lignou, Sapfo
AU  - Lignou S
AD  - NeuroSec and Wellcome Centre for Ethics and Humanities, University of Oxford,
      Oxford, UK.
FAU - McGowan, Michelle
AU  - McGowan M
AD  - Ethics Center, Cincinnati Children's Hospital Medical Center Department of
      Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
FAU - Parker, Michael
AU  - Parker M
AD  - The Ethox Centre and Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
FAU - Prainsack, Barbara
AU  - Prainsack B
AD  - Department of Political Science, University of Vienna, Vienna, Austria.
FAU - Shabani, Mahsa
AU  - Shabani M
AD  - Faculty of Criminology, Criminal Law and Social Law, University of Ghent, Ghent, 
      Belgium.
FAU - Staunton, Ciara
AU  - Staunton C
AD  - Middlesex University School of Law, Middlesex University London, London, UK.
FAU - Thompson, Rachel
AU  - Thompson R
AD  - Research Institute for Ethics and Law, Swansea University, Swansea, UK.
FAU - Varnai, Kinga
AU  - Varnai K
AD  - OUH NHS FT and NIHR Oxford Biomedical Research Centre, Oxford, UK.
FAU - Vayena, Effy
AU  - Vayena E
AD  - The Health Ethics and Policy Lab, University of Zurich, Zurich, Switzerland.
FAU - Williams, Oli
AU  - Williams O
AD  - King's College London and THIS Institute, University of Cambridge, Cambridge, UK.
FAU - Williamson, Max
AU  - Williamson M
AD  - University of Oxford, Oxford, UK.
FAU - Chan, Sarah
AU  - Chan S
AD  - Centre for Biomedicine, Self and Society, Usher Institute, The University of
      Edinburgh, Edinburgh, UK.
FAU - Sheehan, Mark
AU  - Sheehan M
AD  - The Ethox Centre and Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - decision-making
OT  - public health ethics
OT  - regulation
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/10/07 05:42
PHST- 2020/05/29 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/10/07 05:42 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - medethics-2020-106530 [pii]
AID - 10.1136/medethics-2020-106530 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 6. pii: medethics-2020-106530. doi:
      10.1136/medethics-2020-106530.


PMID- 33023976
OWN - NLM
STAT- Publisher
LR  - 20201007
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 6
TI  - Frauds in scientific research and how to possibly overcome them.
LID - medethics-2020-106639 [pii]
LID - 10.1136/medethics-2020-106639 [doi]
AB  - Frauds and misconduct have been common in the history of science. Recent events
      connected to the COVID-19 pandemic have highlighted how the risks and
      consequences of this are no longer acceptable. Two papers, addressing the
      treatment of COVID-19, have been published in two of the most prestigious medical
      journals; the authors declared to have analysed electronic health records from a 
      private corporation, which apparently collected data of tens of thousands of
      patients, coming from hundreds of hospitals. Both papers have been retracted a
      few weeks later. When such events happen, the confidence of the population in
      scientific research is likely to be weakened. This paper highlights how the
      current system endangers the reliability of scientific research, and the very
      foundations of the trust system on which modern healthcare is based. Having shed 
      light on the dangers of a system without appropriate monitoring, the proposed
      analysis suggests to strengthen the existing journal policies and improve the
      research process using new technologies supporting control activities by public
      authorities. Among these solutions, we mention the promising aspects of the
      blockchain technology which seems a promising solution to avoid the repetition of
      the mistakes linked to the recent and past history of research.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Boetto, Erik
AU  - Boetto E
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna,
      Italy.
FAU - Golinelli, Davide
AU  - Golinelli D
AUID- ORCID: http://orcid.org/0000-0001-7331-9520
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna,
      Italy davide.golinelli@unibo.it.
FAU - Carullo, Gherardo
AU  - Carullo G
AD  - Department of Italian and Supranational Public Law, University of Milan, Milano, 
      Lombardia, Italy.
FAU - Fantini, Maria Pia
AU  - Fantini MP
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - professional misconduct
OT  - public health ethics
OT  - publication ethics
OT  - research ethics
OT  - scientific research
COIS- Competing interests: None declared.
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/10/07 05:42
PHST- 2020/06/27 00:00 [received]
PHST- 2020/09/19 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/07 05:42 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - medethics-2020-106639 [pii]
AID - 10.1136/medethics-2020-106639 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 6. pii: medethics-2020-106639. doi:
      10.1136/medethics-2020-106639.


PMID- 33023975
OWN - NLM
STAT- Publisher
LR  - 20220408
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Oct 6
TI  - Demonstrating 'respect for persons' in clinical research: findings from
      qualitative interviews with diverse genomics research participants.
LID - medethics-2020-106440 [pii]
LID - 10.1136/medethics-2020-106440 [doi]
AB  - The ethical principle of 'respect for persons' in clinical research has
      traditionally focused on protecting individuals' autonomy rights, but respect for
      participants also includes broader, although less well understood, ethical
      obligations to regard individuals' rights, needs, interests and feelings.
      However, there is little empirical evidence about how to effectively convey
      respect to potential and current participants. To fill this gap, we conducted
      exploratory, qualitative interviews with participants in a clinical genomics
      implementation study. We interviewed 40 participants in English (n=30) or Spanish
      (n=10) about their experiences with respect in the study and perceptions of how
      researchers in a hypothetical observational study could convey respect or a lack 
      thereof. Most interviewees were female (93%), identified as Hispanic/Latino(a)
      (43%) or non-Hispanic white (38%), reported annual household income under US$60
      000 (70%) and did not have a Bachelor's degree (65%); 30% had limited health
      literacy. We identified four key domains for demonstrating respect: (1) personal 
      study team interactions, with an emphasis on empathy, appreciation and
      non-judgment; (2) study communication processes, including following up and
      sharing results with participants; (3) inclusion, particularly ensuring materials
      are understandable and procedures are accessible; and (4) consent and
      authorisation, including providing a neutral informed consent and keeping
      promises regarding privacy protections. While the experience of respect is
      inherently subjective, these findings highlight four key domains that may
      meaningfully demonstrate respect to potential and current research participants. 
      Further empirical and normative work is needed to substantiate these domains and 
      evaluate how best to incorporate them into the practice of research.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kraft, Stephanie A
AU  - Kraft SA
AUID- ORCID: http://orcid.org/0000-0002-2862-7601
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA stephanie.kraft@seattlechildrens.org.
AD  - Pediatrics, University of Washington School of Medicine, Seattle, Washington,
      USA.
FAU - Rothwell, Erin
AU  - Rothwell E
AD  - Obstetrics and Gynecology, The University of Utah School of Medicine, Salt Lake
      City, Utah, USA.
FAU - Shah, Seema K
AU  - Shah SK
AD  - Stanley Manne Children's Research Institute, Ann and Robert H Lurie Children's
      Hospital of Chicago, Chicago, Illinois, USA.
AD  - Pediatrics, Northwestern University Feinberg School of Medicine, Chicago,
      Illinois, USA.
FAU - Duenas, Devan M
AU  - Duenas DM
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
FAU - Lewis, Hannah
AU  - Lewis H
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
FAU - Muessig, Kristin
AU  - Muessig K
AD  - Translational and Applied Genomics, Kaiser Permanente Center for Health Research 
      Northwest Region, Portland, Oregon, USA.
FAU - Opel, Douglas J
AU  - Opel DJ
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
AD  - Pediatrics, University of Washington School of Medicine, Seattle, Washington,
      USA.
FAU - Goddard, Katrina A B
AU  - Goddard KAB
AD  - Translational and Applied Genomics, Kaiser Permanente Center for Health Research 
      Northwest Region, Portland, Oregon, USA.
FAU - Wilfond, Benjamin S
AU  - Wilfond BS
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington, USA.
AD  - Pediatrics, University of Washington School of Medicine, Seattle, Washington,
      USA.
LA  - eng
GR  - K01 HG010361/HG/NHGRI NIH HHS/United States
GR  - U01 HG007307/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8021602
MID - NIHMS1641137
OTO - NOTNLM
OT  - clinical trials
OT  - informed consent
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/10/07 05:42
PHST- 2020/05/12 00:00 [received]
PHST- 2020/08/27 00:00 [revised]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/10/07 05:42 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - medethics-2020-106440 [pii]
AID - 10.1136/medethics-2020-106440 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Oct 6. pii: medethics-2020-106440. doi:
      10.1136/medethics-2020-106440.


PMID- 33023591
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 6
TI  - Human genome editing: how to prevent rogue actors.
PG  - 95
LID - 10.1186/s12910-020-00527-w [doi]
AB  - BACKGROUND: Human genome editing technologies offer much potential benefit.
      However, central to any conversation relating to the application of such
      technologies are certain ethical, legal, and social difficulties around their
      application. The recent misuse, or inappropriate use, by certain Chinese actors
      of the application of genome editing technologies has been, of late, well noted
      and described. Consequently, caution is expressed by various policy experts,
      scientists, bioethicists, and members of the public with regard to the
      appropriate use of human germline genome editing and its possible future effect
      on future generations. MAIN TEXT: As concerns about the applications of heritable
      genome editing have grown, so too have the questions around what is to be done to
      curtail 'rogue actors'. This paper explores various ways in which to regulate
      genomic editing that are socially beneficial, while being cognisant of legal and 
      ethical principles and rights values. This is done by evolving regulatory
      frameworks across jurisdictions in an attempt to raise issues, address common
      principles, and set responsible standards for stewardship of the novel
      technology. CONCLUSIONS: It is suggested that robust and concrete regulatory
      measures be introduced that are culturally and contextually sensitive, inclusive,
      appropriate, and trustworthy - and are based on public empowerment and human
      rights objectives. Doing so will ensure that we are perfectly positioned to
      harness and promote the benefits that novel technologies have to offer, while
      safeguarding public health and curtailing the ambitions of rogue actors. This it 
      is acknowledged is no easy task, so, as a point of departure, this paper sets out
      a path forward by means of certain, practical recommendations - by constructing
      genome editing regulation in a manner that both fulfils the desire to better
      progress human health and that can withstand legal and ethical scrutiny. The
      following observations and recommendations are made: Firstly, that a solution of 
      effective, legitimate governance should consist of a combination of national and 
      supranational legislative regulation or 'hard' law, in combination with 'soft'
      ethics, firmly anchored in and underpinned by human rights values. Second, that
      efforts to support legal and ethical solutions should be rigorous, practical, and
      robust, contribute to a reaffirmation of human rights in a contextually sensitive
      manner, and be transnational in reach. Lastly, that greater harmonisation across 
      jurisdictions and increased public engagement be sought. This it is proposed will
      address the question of how to implement a normative framework which in turn can 
      prevent future rogue actors.
FAU - Townsend, Beverley A
AU  - Townsend BA
AUID- ORCID: 0000-0002-8486-6041
AD  - School of Law, University of KwaZulu-Natal, Durban, South Africa.
      bev@greymatter.co.za.
LA  - eng
GR  - 116275/National Research Foundation (ZA)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201006
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Gene Editing
MH  - *Genome, Human
MH  - Germ Cells
MH  - Human Rights
MH  - Humans
MH  - Morals
PMC - PMC7541231
OTO - NOTNLM
OT  - *CRISPR-Cas9
OT  - *Deliberative public engagement
OT  - *Ethics and law
OT  - *Genome editing technologies
OT  - *Global governance
OT  - *Harmonisation
OT  - *Human rights
EDAT- 2020/10/08 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/07 05:33
PHST- 2020/02/05 00:00 [received]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/10/07 05:33 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00527-w [doi]
AID - 10.1186/s12910-020-00527-w [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 6;21(1):95. doi: 10.1186/s12910-020-00527-w.


PMID- 33023558
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1471-2482 (Electronic)
IS  - 1471-2482 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 6
TI  - Preventing clinically relevant pancreatic fistula with combination of linear
      stapling plus continuous suture of the stump in laparoscopic distal
      pancreatectomy.
PG  - 223
LID - 10.1186/s12893-020-00876-8 [doi]
AB  - BACKGROUND: Pancreatic fistula is one of the serious complications for patients
      undergoing distal pancreatectomy, which leads to significant morbidity. The aim
      of our study is to compare linear stapling closure plus continuous suture with
      linear stapling closure alone during laparoscopic distal pancreatectomy (LDP) in 
      terms of clinically relevant postoperative pancreatic fistula (POPF) rate.
      METHODS: Twenty-two patients underwent LDP at our institution between 2011 and
      2013. Twelve patients had linear stapling closure with peri-firing compression
      (LSC) alone compared with ten patients who had linear stapling closure,
      peri-firing compression plus continuous suture (LSC/CS) for stump closure of
      remnant pancreas in LDP. Biochemical leak and clinically relevant POPF were
      compared between both groups. RESULTS: POPF occurred in 4 of 12 (33.3%) patients 
      with linear stapling closure while no patient developed a clinically relevant
      POPF in the triple combination of linear stapling, peri-firing compression plus
      continuous suture group (p = 0.043).1 patient (8.3%) in the LSC group and 5
      patients (50%) in the LSC/CS group had evidence of a biochemical leak. There were
      no significant differences in operative time (188.3 vs 187.0 min) and blood loss 
      (135 vs. 240 g) between both groups but there was a significantly of shorter
      length of hospital stay (11.9 vs. 19.9 days) in LSC/CS group (p = 0.037). There
      was no mortality in either group. CONCLUSIONS: The triple combination of linear
      stapling, peri-firing compression plus continuous suture in LDP has effectively
      prevented occurrence of clinically relevant ISGPF POPF. TRIAL REGISTRATION: The
      study was retrospectively registered September 30, 2019 at Showa University
      Ethics Committee as IRB protocol numbers 2943.
FAU - Aoki, Takeshi
AU  - Aoki T
AUID- ORCID: http://orcid.org/0000-0002-0503-2525
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan. takejp@med.showa-u.ac.jp.
FAU - Mansour, Doaa A
AU  - Mansour DA
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
AD  - General Surgery Department, Cairo University Hospitals, Kasr Alainy, Al-Saray
      street, El-Manial, Cairo, 11956, Egypt.
FAU - Koizumi, Tomotake
AU  - Koizumi T
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Matsuda, Kazuhiro
AU  - Matsuda K
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Kusano, Tomokazu
AU  - Kusano T
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Wada, Yusuke
AU  - Wada Y
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Hakozaki, Tomoki
AU  - Hakozaki T
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Tomioka, Kodai
AU  - Tomioka K
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Hirai, Takahito
AU  - Hirai T
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Yamazaki, Tatsuya
AU  - Yamazaki T
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Watanabe, Makoto
AU  - Watanabe M
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Otsuka, Koji
AU  - Otsuka K
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
FAU - Gahin, Ahmed Elewa Abbas
AU  - Gahin AEA
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
AD  - General Surgery Department, National Hepatology and Tropical Medicine Research
      Institute, 10. Kasr Alainy street, Cairo, 11562, Egypt.
FAU - Murakami, Masahiko
AU  - Murakami M
AD  - Division of Gastroenterological and General Surgery, Department of Surgery,
      School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo,
      1428666, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - BMC Surg
JT  - BMC surgery
JID - 100968567
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - *Laparoscopy
MH  - Male
MH  - Middle Aged
MH  - Pancreas/surgery
MH  - *Pancreatectomy/adverse effects
MH  - *Pancreatic Fistula/etiology/prevention & control
MH  - Postoperative Complications
MH  - Surgical Stapling
MH  - Suture Techniques
MH  - Sutures
PMC - PMC7541328
OTO - NOTNLM
OT  - Continuous suture for stump closure
OT  - Laparoscopic distal pancreatectomy
OT  - Pancreatic fistula
OT  - Peri-firing compression
OT  - Stapler closure
EDAT- 2020/10/08 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/10/07 05:32
PHST- 2020/04/06 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/07 05:32 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
AID - 10.1186/s12893-020-00876-8 [doi]
AID - 10.1186/s12893-020-00876-8 [pii]
PST - epublish
SO  - BMC Surg. 2020 Oct 6;20(1):223. doi: 10.1186/s12893-020-00876-8.


PMID- 33023523
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 6
TI  - A ten year analysis of maternal deaths in a tertiary hospital using the three
      delays model.
PG  - 585
LID - 10.1186/s12884-020-03262-7 [doi]
AB  - BACKGROUND: Reducing maternal mortality ratios (MMRs) remain an important public 
      health issue in Egypt. The three delays model distinguished three phases of delay
      to be associated with maternal mortality: 1) first phase delay is delay in
      deciding to seek care; 2) second phase delay is delay in reaching health
      facilities; and 3) third phase delay is delay in receiving care in health
      facilities. Increased health services' coverage is thought to be associated with 
      a paradigm shift from first and second phase delays to third phase delay as main 
      factor contributing to MMR. This study aims to examine the contribution of the
      three delays in relation to maternal deaths. METHODS: During a 10 year period
      (2008-2017) 207 maternal deaths were identified in a tertiary hospital in Minia
      governorate, Egypt. Data were obtained through reviewing medical records and
      verbal autopsy for each case. Then data analysis was done in the context of the
      three delays model. RESULTS: From 2008 to 2017 MMR in this hospital was
      186/100.000 live births. Most frequent causes of maternal mortality were
      postpartum hemorrhage, hypertensive disorders of pregnancy and sepsis. Third
      phase delay occurred in 184 deaths (88.9%), second phase delay was observed in
      104 deaths (50%), always together with other phases of delay. First phase delay
      alone was observed in 13 deaths (6.3%) and in 82 deaths (40%) with other phases
      of delay. One fifth of the women had experienced all three phases of delay
      together. Major causes of third phase delay were delayed referral from district
      hospitals, non-availability of skilled staff, lack of blood transfusion
      facilities and shortage of drugs. CONCLUSIONS: There is a paradigm shift from
      first and second phases of delay to the third phase of delay as a major
      contributor to maternal mortality. Reduction of maternal mortality can be
      achieved through improving logistics, infrastructure and health care providers'
      training. TRIAL REGISTRATION: This study is a retrospective study registered
      locally and approved by the ethical committee of the Department of Obstetrics and
      Gynaecology, Minia University Hospital on 1/4/2016 (Registration number:
      MUEOB0002).
FAU - Mohammed, Mo'men M
AU  - Mohammed MM
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - El Gelany, Saad
AU  - El Gelany S
AUID- ORCID: http://orcid.org/0000-0003-1830-3977
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt. Saad.elgelany@yahoo.co.uk.
FAU - Eladwy, Ahmed Rida
AU  - Eladwy AR
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Ali, Essam Ibrahium
AU  - Ali EI
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Gadelrab, Mohamed T
AU  - Gadelrab MT
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Ibrahim, Emad M
AU  - Ibrahim EM
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Khalifa, Eissa M
AU  - Khalifa EM
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Abdelhakium, Ahmed K
AU  - Abdelhakium AK
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Fares, Hashem
AU  - Fares H
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Yousef, Ayman M
AU  - Yousef AM
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Hassan, Heba
AU  - Hassan H
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Goma, Khaled
AU  - Goma K
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Ibrahim, Mahmoud H
AU  - Ibrahim MH
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Gamal, Alaa
AU  - Gamal A
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Khairy, Mohamed
AU  - Khairy M
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Shaban, Ahmed
AU  - Shaban A
AD  - Masr Elhurra Hospital, Minia Directorate of Health, Minia, Egypt.
FAU - Amer, Sahar
AU  - Amer S
AD  - Minia General Hospital, Minia Directorate of Health, Minia, Egypt.
FAU - Abdelraheim, Ahmed R
AU  - Abdelraheim AR
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
FAU - Abdallah, Ameirr A
AU  - Abdallah AA
AD  - Obstetrics and Gynecology Department, Faculty of Medicine, Minia Maternity and
      Children University Hospital, Minia University, Elsalam, Eloboor, Maghaghaga
      City, Minia, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Data Analysis
MH  - Egypt/epidemiology
MH  - Female
MH  - Health Services Accessibility/statistics & numerical data
MH  - Humans
MH  - Maternal Death/*prevention & control/statistics & numerical data
MH  - *Maternal Mortality
MH  - Models, Statistical
MH  - Patient Acceptance of Health Care/statistics & numerical data
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Tertiary Care Centers/*statistics & numerical data
MH  - Time Factors
MH  - Time-to-Treatment/*statistics & numerical data
MH  - Young Adult
PMC - PMC7541230
OTO - NOTNLM
OT  - Egypt
OT  - Maternal mortality
OT  - Minia
OT  - Three delays model
EDAT- 2020/10/08 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/10/07 05:32
PHST- 2019/12/27 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/10/07 05:32 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.1186/s12884-020-03262-7 [doi]
AID - 10.1186/s12884-020-03262-7 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Oct 6;20(1):585. doi: 10.1186/s12884-020-03262-7.


PMID- 33023172
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 19
DP  - 2020 Oct 2
TI  - State of the Art of Family Quality of Life in Early Care and Disability: A
      Systematic Review.
LID - E7220 [pii]
LID - 10.3390/ijerph17197220 [doi]
AB  - Background: In recent years, there has been a growing international interest in
      family quality of life The objective of this systematic review is to understand
      and analyze the conceptualization of the quality of life of families with
      children with disabilities between 0 and 6 years of age, the instruments for
      their measurement and the most relevant research results. Method: A bibliographic
      search was conducted in the Web of Science, Scopus and Eric databases of studies 
      published in English and Spanish from 2000 to July 2019 focused on "family
      quality of life" or "quality of family life" in the disability field. A total of 
      63 studies were selected from a total of 1119 and analyzed for their theoretical 
      and applied contributions to the field of early care. Results: The functional
      conceptualization of family quality of life predominates in this area, and a
      nascent and enriching holistic conceptualization is appreciated. There are three 
      instruments that measure family quality of life in early care, although none of
      them is based on unified theory of FQoL; none of them focus exclusively on the
      age range 0-6 nor do they cover all disabilities. Conclusions: The need to deepen
      the dynamic interaction of family relationships and to understand the ethical
      requirement that the methods used to approach family quality of life respect the 
      holistic nature of the research is noted.
FAU - Francisco Mora, Carmen
AU  - Francisco Mora C
AD  - Faculty of Psychology, Education and Sports Sciences, Ramon Llull University,
      08022 Barcelona, Spain.
FAU - Ibanez, Alba
AU  - Ibanez A
AD  - Faculty of Education, University of Cantabria, 39005 Santander, Spain.
AD  - Group in Health Economics and Management of Health Services, Instituto de
      Investigacion Sanitaria Valdecilla (IDIVAL), 39011 Santander, Spain.
FAU - Balcells-Balcells, Anna
AU  - Balcells-Balcells A
AD  - Faculty of Psychology, Education and Sports Sciences, Ramon Llull University,
      08022 Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20201002
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Art
MH  - Child
MH  - Child, Preschool
MH  - *Disabled Persons
MH  - Family
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Quality of Life
PMC - PMC7578947
OTO - NOTNLM
OT  - *conceptualization
OT  - *disability
OT  - *early childhood intervention
OT  - *family quality of life
OT  - *measurement.
COIS- The authors declare no conflicts of interest.
EDAT- 2020/10/08 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/10/07 01:01
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/19 00:00 [revised]
PHST- 2020/09/27 00:00 [accepted]
PHST- 2020/10/07 01:01 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - ijerph17197220 [pii]
AID - 10.3390/ijerph17197220 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 2;17(19). pii: ijerph17197220. doi:
      10.3390/ijerph17197220.


PMID- 33023041
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 3
TI  - Transitioning of Helicobacter pylori Therapy from Trial and Error to
      Antimicrobial Stewardship.
LID - E671 [pii]
LID - 10.3390/antibiotics9100671 [doi]
AB  - Helicobacter pylori is the only major infection for which antimicrobial therapy
      is not designed using the principles of antimicrobial stewardship. Traditionally,
      antimicrobial therapy is a susceptibility-based therapy, achieves high cure
      rates, and includes surveillance programs to regularly provide updated data
      regarding resistance, outcomes, and treatment guidelines. Current H. pylori
      therapies identified by trial-and-error, and treatment recommendations and
      guidelines are based on comparisons among regimens that rarely take into account 
      the prevalence or effect of resistance. The majority of patients currently
      treated achieve suboptimal results. A paradigm shift is required to abandon
      current approaches and embrace antimicrobial stewardship, and therefore reliably 
      achieve high cure rates; develop, propagate, and update best practice guidelines;
      and provide surveillance of local or regional susceptibility/resistance patterns.
      These also require timely updates to clinicians regarding the current status of
      resistance, antimicrobial effectiveness, and ways to prevent antimicrobial misuse
      to extend the useful life of currently available antibiotics. Here, we discuss
      the differences among current approaches to H. pylori therapy and antimicrobial
      stewardship and identify what is required to achieve the transition.
      Conceptually, the differences are significant, and the transition will likely
      need to be both abrupt and complete. Recommendations for therapy during the
      transition period are given.
FAU - Graham, David Y
AU  - Graham DY
AD  - Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College
      of Medicine, RM 3A-318B (111D), 2002 Holcombe Boulevard, Houston, TX 77030, USA.
LA  - eng
GR  - DK56338/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201003
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC7601139
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - amoxicillin
OT  - antibiotics
OT  - antimicrobial stewardship
OT  - clarithromycin
OT  - ethical trials
OT  - fluoroquinolones
OT  - metronidazole
OT  - proton pump inhibitors
OT  - therapy
EDAT- 2020/10/08 06:00
MHDA- 2020/10/08 06:01
CRDT- 2020/10/07 01:01
PHST- 2020/09/15 00:00 [received]
PHST- 2020/09/28 00:00 [revised]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/10/07 01:01 [entrez]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2020/10/08 06:01 [medline]
AID - antibiotics9100671 [pii]
AID - 10.3390/antibiotics9100671 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2020 Oct 3;9(10). pii: antibiotics9100671. doi:
      10.3390/antibiotics9100671.


PMID- 33022423
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1095-9254 (Electronic)
IS  - 0140-1971 (Linking)
VI  - 84
DP  - 2020 Oct
TI  - Brief report: Gender and ethnicity predict adolescent self-silencing above and
      beyond gender ideology.
PG  - 243-250
LID - S0140-1971(20)30150-0 [pii]
LID - 10.1016/j.adolescence.2020.09.011 [doi]
AB  - INTRODUCTION: Feminist scholars have proposed that adolescents experience a loss 
      of voice termed "self-silencing" due to the internalization of gender norms. A
      growing literature shows that the content and strength of adolescents' gender
      norms is dependent on ethic socialization practices. METHODS: We examined the
      association among self-silencing behaviors and gender ideology, measured both
      explicitly and implicitly, in a racially/ethnically and socioeconomically diverse
      sample of 12-14 year old American adolescents (N = 119, 62 female). RESULTS &
      CONCLUSION: Multiple regression analyses indicated that self-silencing was weakly
      associated with implicit gender ideology, but being White and female were larger 
      risk factors for self-silencing. The internalization of implicit gender norms
      weakly predicted self-silencing when adjusting for ethnicity and gender, but we
      challenge past research by showing gender and ethnicity to be stronger predictors
      than gender ideology. Self-silencing occurred in both boys and girls, but was
      slightly more salient in girls. We report preliminary findings intended for
      replication due to limitations on statistical power and the introduction of an
      implicit measurement tool for assessing gender attitudes with adolescents.
      Implications include clarification of the widely debated association between
      self-silencing and gender ideology and the development of more culturally nuanced
      theories of interpersonal development as it relates to gender and ethnicity
      during adolescence.
CI  - Copyright (c) 2020 The Foundation for Professionals in Services for Adolescents. 
      Published by Elsevier Ltd. All rights reserved.
FAU - Puzio, Angelica
AU  - Puzio A
AD  - New York University, USA. Electronic address: angelicapuzio@nyu.edu.
FAU - Best, Deborah L
AU  - Best DL
AD  - Wake Forest University, USA. Electronic address: best@wfu.edu.
LA  - eng
PT  - Journal Article
DEP - 20201003
PL  - England
TA  - J Adolesc
JT  - Journal of adolescence
JID - 7808986
SB  - IM
MH  - Adolescent
MH  - Adolescent Development
MH  - Child
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Interpersonal Relations
MH  - Male
MH  - *Self Concept
MH  - *Socialization
OTO - NOTNLM
OT  - *Adolescent development
OT  - *Gender socialization
OT  - *Implicit measurement
OT  - *Self-silencing
OT  - *Social development
OT  - *Stereotypes
EDAT- 2020/10/07 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/10/06 20:11
PHST- 2020/05/03 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
PHST- 2020/10/06 20:11 [entrez]
AID - S0140-1971(20)30150-0 [pii]
AID - 10.1016/j.adolescence.2020.09.011 [doi]
PST - ppublish
SO  - J Adolesc. 2020 Oct;84:243-250. doi: 10.1016/j.adolescence.2020.09.011. Epub 2020
      Oct 3.


PMID- 33021898
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 2242-3982 (Electronic)
IS  - 1239-9736 (Linking)
VI  - 79
IP  - 1
DP  - 2020 Dec
TI  - Piecing together the Labrador Inuit food security policy puzzle in Nunatsiavut,
      Labrador (Canada): a scoping review.
PG  - 1799676
LID - 10.1080/22423982.2020.1799676 [doi]
AB  - Inuit in Canada experience greater social and economic inequities than the
      general Canadian population. Food security exemplifies this inequity and is a
      distinct determinant of Inuit health. This scoping review focuses on food
      security-related policies implemented in Nunatsiavut, located in Northern
      Labrador. The primary objective was to identify the range of existing policies
      that pertain to food security in Nunatsiavut. The secondary objective was to
      complete a directed content analysis to map each policy against the applicable
      dimension of food security. This scoping review followed the Johanna Briggs
      methodology. The search strategy included the databases: Medline (via Ovid),
      EMBASE (via Ovid), CINAHL, and Scopus, and a hand search of the relevant
      journals, conference abstracts and grey literature. This search was undertaken
      from April 2019 - October 2019. A content analysis mapped each policy against the
      applicable dimension of food security. Results: The results showed that twenty
      five policies were identified, spanning three levels of government, that
      explicitly or implicitly addressed at least one dimension of food security.
      Accessibility was the most frequent food security dimension identified. The
      Government of Canada developed 60% of policies and the Nunatsiavut Government
      implemented 48% of policies. Most policies focused on proximal factors for food
      security. Identifying distal policies for food security and understanding the
      impact of existing policies in Nunatsiavut remain as areas of further
      investigation. Ethics and Dissemination:This project was reviewed by the
      Nunatsiavut Government Research Advisory Committee.
FAU - Bowers, Renee
AU  - Bowers R
FAU - Turner, Gail
AU  - Turner G
FAU - Graham, Ian D
AU  - Graham ID
AUID- ORCID: 0000-0002-3669-1216
FAU - Furgal, Chris
AU  - Furgal C
FAU - Dubois, Lise
AU  - Dubois L
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Int J Circumpolar Health
JT  - International journal of circumpolar health
JID - 9713056
SB  - IM
MH  - Arctic Regions
MH  - *Food Security
MH  - Government Programs/*organization & administration
MH  - *Health Policy
MH  - Humans
MH  - *Inuits
MH  - Newfoundland and Labrador
MH  - Social Determinants of Health
MH  - Socioeconomic Factors
PMC - PMC7580716
OTO - NOTNLM
OT  - *Inuit
OT  - *food security
OT  - *policy
EDAT- 2020/10/07 06:00
MHDA- 2021/10/06 06:00
CRDT- 2020/10/06 17:11
PHST- 2020/10/06 17:11 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
AID - 10.1080/22423982.2020.1799676 [doi]
PST - ppublish
SO  - Int J Circumpolar Health. 2020 Dec;79(1):1799676. doi:
      10.1080/22423982.2020.1799676.


PMID- 33021826
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1530-8995 (Electronic)
IS  - 1081-0706 (Linking)
VI  - 36
DP  - 2020 Oct 6
TI  - Human Embryogenesis: A Comparative Perspective.
PG  - 411-440
LID - 10.1146/annurev-cellbio-022020-024900 [doi]
AB  - Understanding human embryology has historically relied on comparative approaches 
      using mammalian model organisms. With the advent of low-input methods to
      investigate genetic and epigenetic mechanisms and efficient techniques to assess 
      gene function, we can now study the human embryo directly. These advances have
      transformed the investigation of early embryogenesis in nonrodent species,
      thereby providing a broader understanding of conserved and divergent mechanisms. 
      Here, we present an overview of the major events in human preimplantation
      development and place them in the context of mammalian evolution by comparing
      these events in other eutherian and metatherian species. We describe the advances
      of studies on postimplantation development and discuss stem cell models that
      mimic postimplantation embryos. A comparative perspective highlights the
      importance of analyzing different organisms with molecular characterization and
      functional studies to reveal the principles of early development. This growing
      field has a fundamental impact in regenerative medicine and raises important
      ethical considerations.
FAU - Gerri, Claudia
AU  - Gerri C
AD  - Human Embryo and Stem Cell Laboratory, The Francis Crick Institute, London NW1
      1AT, United Kingdom; email: kathy.niakan@crick.ac.uk.
FAU - Menchero, Sergio
AU  - Menchero S
AD  - Sex Chromosome Biology Laboratory, The Francis Crick Institute, London NW1 1AT,
      United Kingdom; email: james.turner@crick.ac.uk.
FAU - Mahadevaiah, Shantha K
AU  - Mahadevaiah SK
AD  - Sex Chromosome Biology Laboratory, The Francis Crick Institute, London NW1 1AT,
      United Kingdom; email: james.turner@crick.ac.uk.
FAU - Turner, James M A
AU  - Turner JMA
AD  - Sex Chromosome Biology Laboratory, The Francis Crick Institute, London NW1 1AT,
      United Kingdom; email: james.turner@crick.ac.uk.
FAU - Niakan, Kathy K
AU  - Niakan KK
AD  - Human Embryo and Stem Cell Laboratory, The Francis Crick Institute, London NW1
      1AT, United Kingdom; email: kathy.niakan@crick.ac.uk.
LA  - eng
GR  - FC001120 /CRUK_/Cancer Research UK/United Kingdom
GR  - FC001120 /WT_/Wellcome Trust/United Kingdom
GR  - FC001193/MRC_/Medical Research Council/United Kingdom
GR  - FC001193/WT_/Wellcome Trust/United Kingdom
GR  - FC001193/CRUK_/Cancer Research UK/United Kingdom
GR  - FC001120 /MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Annu Rev Cell Dev Biol
JT  - Annual review of cell and developmental biology
JID - 9600627
SB  - IM
MH  - Animals
MH  - *Embryonic Development
MH  - Embryonic Stem Cells/cytology/metabolism
MH  - Humans
MH  - Models, Biological
MH  - Phylogeny
MH  - Zygote/metabolism
OTO - NOTNLM
OT  - *comparative embryology
OT  - *human embryogenesis
OT  - *mammalian development
OT  - *placenta
OT  - *pluripotency
OT  - *stem cell models
EDAT- 2020/10/07 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/10/06 17:10
PHST- 2020/10/06 17:10 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
AID - 10.1146/annurev-cellbio-022020-024900 [doi]
PST - ppublish
SO  - Annu Rev Cell Dev Biol. 2020 Oct 6;36:411-440. doi:
      10.1146/annurev-cellbio-022020-024900.


PMID- 33021777
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1948-7193 (Electronic)
IS  - 1948-7193 (Linking)
VI  - 11
IP  - 20
DP  - 2020 Oct 21
TI  - Polypharmacology or "Pharmacological Promiscuity" In Psychedelic Research: What
      Are We Missing?
PG  - 3191-3193
LID - 10.1021/acschemneuro.0c00614 [doi]
AB  - Research with psychedelic drugs has mainly focused on isolated compounds.
      However, this approach is challenged by the "polypharmacology" paradigm. In this 
      Viewpoint, we suggest that we may be missing something if we do not use the whole
      product in the case of ayahuasca or Psilocybe mushrooms. After describing how
      research on psychedelic drugs can be effectively combined with the
      polypharmacology paradigm, ethical issues are also briefly discussed.
FAU - Ona, Geni S
AU  - Ona GS
AUID- ORCID: 0000-0003-2741-2876
AD  - ICEERS - International Center for Ethnobotanical Education, Research, and
      Services, Barcelona 08015, Spain.
AD  - Medical Anthropology Research Center (MARC), Department of Anthropology,
      Philosophy and Social Work, Universitat Rovira i Virgili, Tarragona 43003, Spain.
FAU - Dos Santos, Rafael G
AU  - Dos Santos RG
AD  - ICEERS - International Center for Ethnobotanical Education, Research, and
      Services, Barcelona 08015, Spain.
AD  - Department of Neuroscience and Behavior, Ribeirao Preto Medical School,
      University of Sao Paulo, Sao Paulo, SP 14049-900, Brazil.
AD  - National Institute for Translational Medicine (INCT-TM), CNPq, Porto Alegre
      90035-003, Brazil.
FAU - Hallak, Jaime E C
AU  - Hallak JEC
AD  - Department of Neuroscience and Behavior, Ribeirao Preto Medical School,
      University of Sao Paulo, Sao Paulo, SP 14049-900, Brazil.
AD  - National Institute for Translational Medicine (INCT-TM), CNPq, Porto Alegre
      90035-003, Brazil.
FAU - Bouso, Jose Carlos
AU  - Bouso JC
AD  - ICEERS - International Center for Ethnobotanical Education, Research, and
      Services, Barcelona 08015, Spain.
AD  - Medical Anthropology Research Center (MARC), Department of Anthropology,
      Philosophy and Social Work, Universitat Rovira i Virgili, Tarragona 43003, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - United States
TA  - ACS Chem Neurosci
JT  - ACS chemical neuroscience
JID - 101525337
RN  - 0 (Hallucinogens)
SB  - IM
MH  - *Agaricales
MH  - *Banisteriopsis
MH  - *Hallucinogens/pharmacology
MH  - Polypharmacology
OTO - NOTNLM
OT  - *Psychedelics
OT  - *ayahuasca
OT  - *polypharmacology
OT  - *psilocybe
OT  - *psilocybin
EDAT- 2020/10/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/06 17:10
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/06 17:10 [entrez]
AID - 10.1021/acschemneuro.0c00614 [doi]
PST - ppublish
SO  - ACS Chem Neurosci. 2020 Oct 21;11(20):3191-3193. doi:
      10.1021/acschemneuro.0c00614. Epub 2020 Oct 6.


PMID- 33021678
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1420-9144 (Electronic)
IS  - 0036-6978 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Dec
TI  - [Modelled Development. Practices of Human Embryology at Gottingen University in
      the Second Half of the Twentieth Century].
PG  - 481-517
LID - 10.1007/s00048-020-00275-3 [doi]
AB  - The Human Embryology Collection at the Centre of Anatomy Gottingen, created
      between 1942 and 1970, represents a unique interrelation of histological
      sectional series of human embryos and large-format physical models open to the
      public based on them. The collection was established long after the heyday of
      human embryology. It is also remarkable in another aspect: while usually models
      within the discipline are considered research objects, Gottingen embryologist
      Erich Blechschmidt (1904-1992) based his understanding on a pedagogical impetus. 
      The article highlights the distinctive and unconventional features of
      Blechschmidt's undertaking against its disciplinary background. My focus lies on 
      the two practices that are central to human embryology-collecting and modelling-,
      as well as the derived collection stocks. The special tension between
      individuality and universality that already characterized the process of their
      creation is also reflected in the later use of the collection. This tension
      allowed Blechschmidt to utilize the models in embryological research and
      anatomical teaching as well as in the broad social debate on abortion and the
      ethical status of human embryos.
FAU - Markert, Michael
AU  - Markert M
AD  - Kunstgeschichtliches Seminar und Kunstsammlung, Professur fur Materialitat des
      Wissens, Georg-August-Universitat Gottingen, Friedlander Weg 2, 37085, Gottingen,
      Deutschland. michael.markert@uni-goettingen.de.
LA  - ger
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Modellierte Individualentwicklung. Humanembryologische Praktiken an der
      Universitat Gottingen in der zweiten Halfte des 20. Jahrhunderts.
PL  - Switzerland
TA  - NTM
JT  - NTM
JID - 0347631
MH  - Abortion, Induced/ethics/*history
MH  - Anatomy/*history
MH  - *Collections as Topic
MH  - *Embryo, Mammalian/anatomy & histology
MH  - Embryology/ethics/*history
MH  - Female
MH  - Germany
MH  - Histology/history
MH  - History, 20th Century
MH  - Humans
MH  - *Models, Biological
MH  - Pregnancy
MH  - Research/history
MH  - Teaching/history
MH  - Universities/*history
PS  - Blechschmidt E
FPS - Blechschmidt, Erich
PMC - PMC7588383
OTO - NOTNLM
OT  - *Academic teaching
OT  - *Human embryology
OT  - *Material culture
OT  - *Practices
OT  - *Research model
EDAT- 2020/10/07 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/10/06 12:22
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/10/06 12:22 [entrez]
AID - 10.1007/s00048-020-00275-3 [doi]
AID - 10.1007/s00048-020-00275-3 [pii]
PST - ppublish
SO  - NTM. 2020 Dec;28(4):481-517. doi: 10.1007/s00048-020-00275-3.


PMID- 33021213
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20220105
IS  - 1752-7163 (Electronic)
IS  - 1752-7155 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Oct 6
TI  - Spatial mapping of VOC exhalation by means of bronchoscopic sampling.
PG  - 046012
LID - 10.1088/1752-7163/abb478 [doi]
AB  - Breath analysis holds promise for non-invasive in vivo monitoring of disease
      related processes. However, physiological parameters may considerably affect
      profiles of exhaled volatile organic substances (VOCs). Volatile substances can
      be released via alveoli, bronchial mucosa or from the upper airways. The aim of
      this study was the systematic investigation of the influence of different
      sampling sites in the respiratory tract on VOC concentration profiles by means of
      a novel experimental setup. After ethical approval, breath samples were collected
      from 25 patients undergoing bronchoscopy for endobronchial ultrasound or
      bronchoscopic lung volume reduction from different sites in the airways. All
      patients had total intravenous anaesthesia under pressure-controlled ventilation.
      If necessary, respiratory parameters were adjusted to keep PETCO2 = 35-45 mm Hg. 
      30 ml gas were withdrawn at six sampling sites by means of gastight glass
      syringes: S1 = Room air, S2 = Inspiration, S3 = Endotracheal tube, S4 = Trachea, 
      S5 = Right B6 segment, S6 = Left B6 segment (S4-S6 through the bronchoscope
      channel). 10 ml were used for VOC analysis, 20 ml for PCO2 determination. Samples
      were preconcentrated by solid-phase micro-extraction (SPME) and analysed by gas
      chromatography-mass spectrometry (GC-MS). PCO2 was determined in a conventional
      blood gas analyser. Statistically significant differences in substance
      concentrations for acetone, isoprene, 2-methyl-pentane and n-hexane could be
      observed between different sampling sites. Increasing substance concentrations
      were determined for acetone (15.3%), 2-methyl-pentane (11.4%) and n-hexane
      (19.3%) when passing from distal to proximal sampling sites. In contrast,
      isoprene concentrations decreased by 9.9% from proximal to more distal sampling
      sites. Blank bronchoscope measurements did not show any contaminations. Increased
      substance concentrations in the proximal respiratory tract may be explained
      through substance excretion from bronchial mucosa while decreased concentrations 
      could result from absorption or reaction processes. Spatial mapping of VOC
      profiles can provide novel insights into substance specific exhalation kinetics
      and mechanisms.
FAU - Fuchs, Patricia
AU  - Fuchs P
AUID- ORCID: 0000-0002-0055-6098
AD  - Department of Anaesthesiology and Intensive Care Medicine, Rostock University
      Medical Centre, ROMBAT, Germany.
FAU - Trautner, Markus
AU  - Trautner M
AD  - Department of Anaesthesiology and Intensive Care Medicine, Rostock University
      Medical Centre, ROMBAT, Germany.
FAU - Sass, Radost
AU  - Sass R
AD  - Department of Anaesthesiology and Intensive Care Medicine, Rostock University
      Medical Centre, ROMBAT, Germany.
FAU - Kamysek, Svend
AU  - Kamysek S
AD  - Department of Anaesthesiology and Intensive Care Medicine, Rostock University
      Medical Centre, ROMBAT, Germany.
FAU - Miekisch, Wolfram
AU  - Miekisch W
AUID- ORCID: 0000-0003-1619-0315
AD  - Department of Anaesthesiology and Intensive Care Medicine, Rostock University
      Medical Centre, ROMBAT, Germany.
FAU - Bier, Andrea
AU  - Bier A
AD  - Department of Pneumology and Interdisciplinary Internal Medicine Intensive Care, 
      Rostock University Medical Centre, Germany.
FAU - Stoll, Paul
AU  - Stoll P
AD  - Department of Pneumology and Interdisciplinary Internal Medicine Intensive Care, 
      Rostock University Medical Centre, Germany.
FAU - Schubert, Jochen K
AU  - Schubert JK
AD  - Department of Anaesthesiology and Intensive Care Medicine, Rostock University
      Medical Centre, ROMBAT, Germany.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - J Breath Res
JT  - Journal of breath research
JID - 101463871
RN  - 0 (Volatile Organic Compounds)
RN  - 142M471B3J (Carbon Dioxide)
SB  - IM
MH  - Breath Tests/*methods
MH  - *Bronchoscopy
MH  - Carbon Dioxide/chemistry
MH  - *Exhalation
MH  - Female
MH  - Humans
MH  - Limit of Detection
MH  - Lung/chemistry
MH  - Male
MH  - Middle Aged
MH  - Partial Pressure
MH  - *Specimen Handling
MH  - Volatile Organic Compounds/*analysis
EDAT- 2020/10/07 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/10/06 08:39
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/10/06 08:39 [entrez]
AID - 10.1088/1752-7163/abb478 [doi]
PST - epublish
SO  - J Breath Res. 2020 Oct 6;14(4):046012. doi: 10.1088/1752-7163/abb478.


PMID- 33021207
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220206
IS  - 1752-7163 (Electronic)
IS  - 1752-7155 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Oct 6
TI  - Breath research in times of a global pandemic and beyond: the game changer.
PG  - 040202
LID - 10.1088/1752-7163/abb99a [doi]
AB  - In contrast to blood and urine samples, breath is invisible and ubiquitous in the
      environment. Different precautions are now necessary beyond the usual 'Universal 
      Precautions'. In the era of COVID-19, breath (especially the aerosol fraction)
      can no longer be considered as harmless in the clinic or laboratory. As Journal
      of Breath Research is a primary resource for breath-related research, we (the
      editors) are presently developing safety guidance applicable to all breath
      research , not just for those projects that involve known COVID-19 infected
      subjects. We are starting this process by implementing requirements on reporting 
      safety precautions in research papers and notes. This editorial announces that
      authors of all new submissions to JBR henceforth must state clearly the
      procedures undertaken for assuring laboratory and clinical safety, much like the 
      existing requirements for disclosing Ethics Committee or Institutional Review
      Board protocols for studies on human subjects. In the following, we additionally 
      make some recommendations based on best practices drawn from our experience and
      input from the JBR Editorial Board.
FAU - Pleil, Joachim D
AU  - Pleil JD
AUID- ORCID: 0000-0001-8211-0796
AD  - Editor-in-Chief, Journal of Breath Research.
FAU - Beauchamp, Jonathan D
AU  - Beauchamp JD
AUID- ORCID: 0000-0003-1405-7625
AD  - Associate Editor, Journal of Breath Research.
FAU - Dweik, Raed A
AU  - Dweik RA
AD  - Associate Editor, Journal of Breath Research.
FAU - Risby, Terence H
AU  - Risby TH
AD  - Associate Editor, Journal of Breath Research.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - England
TA  - J Breath Res
JT  - Journal of breath research
JID - 101463871
RN  - 0 (Aerosols)
SB  - IM
MH  - Aerosols
MH  - Betacoronavirus
MH  - Biomedical Research/standards/*trends
MH  - *Breath Tests
MH  - COVID-19
MH  - *Communicable Disease Control
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Pandemics
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*epidemiology
MH  - Public Health
MH  - Risk
MH  - SARS-CoV-2
MH  - Safety
EDAT- 2020/10/07 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/06 08:39
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/10/06 08:39 [entrez]
AID - 10.1088/1752-7163/abb99a [doi]
PST - epublish
SO  - J Breath Res. 2020 Oct 6;14(4):040202. doi: 10.1088/1752-7163/abb99a.


PMID- 33021191
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - Empirical Investigation of Ethical Challenges Related to the Use of Biological
      Therapies.
PG  - 567-578
LID - 10.1177/1073110520958883 [doi]
AB  - The aim of this study was to investigate the ethical dilemma of prioritising
      financial resources to expensive biological therapies. For this purpose, the four
      principles of biomedical ethics formulated by ethicists Tom Beauchamp and James
      Childress were used as a theoretical framework. Based on arguments of justice,
      Beauchamp and Childress advocate for a health care system organised in line with 
      the Danish system. Notably, our study was carried out in a Danish setting.
FAU - Bladt, Tara
AU  - Bladt T
AD  - Tara Bladt, M.Sc., teaches in the Danish College of Pharmacy Technicians,
      Denmark; Thomas Vorup-Jensen, M.Sc., Ph.D., D.M.Sc., is a Professor in the
      Department of Biomedicine at Aarhus University, Denmark; Eva Saedder, M.D.,
      Ph.D., is an Associate Professor in the Departments of Biomedicine and Clinical
      Pharmacology, Aarhus University and Aarhus University Hospital, Denmark; Mette
      Ebbesen, M.Sc., M.A., Ph.D., is an Associate Professor in the Centre for Science 
      Studies, and Department of Molecular Medicine, Aarhus University, Denmark.
FAU - Vorup-Jensen, Thomas
AU  - Vorup-Jensen T
AD  - Tara Bladt, M.Sc., teaches in the Danish College of Pharmacy Technicians,
      Denmark; Thomas Vorup-Jensen, M.Sc., Ph.D., D.M.Sc., is a Professor in the
      Department of Biomedicine at Aarhus University, Denmark; Eva Saedder, M.D.,
      Ph.D., is an Associate Professor in the Departments of Biomedicine and Clinical
      Pharmacology, Aarhus University and Aarhus University Hospital, Denmark; Mette
      Ebbesen, M.Sc., M.A., Ph.D., is an Associate Professor in the Centre for Science 
      Studies, and Department of Molecular Medicine, Aarhus University, Denmark.
FAU - Saedder, Eva
AU  - Saedder E
AD  - Tara Bladt, M.Sc., teaches in the Danish College of Pharmacy Technicians,
      Denmark; Thomas Vorup-Jensen, M.Sc., Ph.D., D.M.Sc., is a Professor in the
      Department of Biomedicine at Aarhus University, Denmark; Eva Saedder, M.D.,
      Ph.D., is an Associate Professor in the Departments of Biomedicine and Clinical
      Pharmacology, Aarhus University and Aarhus University Hospital, Denmark; Mette
      Ebbesen, M.Sc., M.A., Ph.D., is an Associate Professor in the Centre for Science 
      Studies, and Department of Molecular Medicine, Aarhus University, Denmark.
FAU - Ebbesen, Mette
AU  - Ebbesen M
AD  - Tara Bladt, M.Sc., teaches in the Danish College of Pharmacy Technicians,
      Denmark; Thomas Vorup-Jensen, M.Sc., Ph.D., D.M.Sc., is a Professor in the
      Department of Biomedicine at Aarhus University, Denmark; Eva Saedder, M.D.,
      Ph.D., is an Associate Professor in the Departments of Biomedicine and Clinical
      Pharmacology, Aarhus University and Aarhus University Hospital, Denmark; Mette
      Ebbesen, M.Sc., M.A., Ph.D., is an Associate Professor in the Centre for Science 
      Studies, and Department of Molecular Medicine, Aarhus University, Denmark.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2020 Sep;48(3):579-582. PMID: 33021187
MH  - Beneficence
MH  - *Bioethics
MH  - Biological Therapy/economics/*ethics
MH  - Denmark
MH  - *Ethical Theory
MH  - Female
MH  - Healthcare Financing/*ethics
MH  - Humans
MH  - Male
MH  - Morals
MH  - Personal Autonomy
MH  - Resource Allocation/*ethics
MH  - Social Justice
EDAT- 2020/10/07 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/10/06 08:38
PHST- 2020/10/06 08:38 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1177/1073110520958883 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Sep;48(3):567-578. doi: 10.1177/1073110520958883.


PMID- 33021189
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - An International Review of Health Technology Assessment Approaches to
      Prescription Drugs and Their Ethical Principles.
PG  - 583-594
LID - 10.1177/1073110520958885 [doi]
AB  - In many countries, health technology assessment (HTA) organizations determine the
      economic value of new drugs and make recommendations regarding appropriate
      pricing and coverage in national health systems. In the US, recent policy
      proposals aimed at reducing drug costs would link drug prices to six countries:
      Australia, Canada, France, Germany, Japan, and the UK. We reviewed these
      countries' methods of HTA and guidance on price and coverage recommendations,
      analyzing methods and guidance documents for differences in (1) the methodologies
      HTA organizations use to conduct their evaluations and (2) considerations they
      use when making recommendations. We found important differences in the methods,
      interpretations of HTA findings, and condition-specific carve-outs that HTA
      organizations use to conduct evaluations and make recommendations. These
      variations have ethical implications because they influence the recommendations
      of HTA organizations, which affect access to the drug through national insurance 
      and price negotiations with manufacturers. The differences in HTA approaches
      result from the distinct political, social, and cultural contexts of each
      organization and its value judgments. New cost-containment policies in the US
      should consider the ethical implications of the HTA reviews that they are
      considering relying on to negotiate drug prices and what values should be
      included in US pricing policy.
FAU - Rand, Leah Z
AU  - Rand LZ
AD  - Leah Z. Rand, D.Phil., is a post-doctoral fellow in the Division of
      Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at
      Brigham and Women's Hospital and a research fellow at Harvard Medical School.
      Aaron S. Kesselheim, M.D., J.D., M.P.H., is Professor of Medicine at Harvard
      Medical School, a faculty member of the Division of Pharmacoepidemiology and
      Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital, 
      the Director of the Program on Regulation, Therapeutics, and Law (PORTAL), and a 
      primary care physician. He is the Editor-in-Chief of the Journal of Law, Medicine
      & Ethics.
FAU - Kesselheim, Aaron S
AU  - Kesselheim AS
AD  - Leah Z. Rand, D.Phil., is a post-doctoral fellow in the Division of
      Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at
      Brigham and Women's Hospital and a research fellow at Harvard Medical School.
      Aaron S. Kesselheim, M.D., J.D., M.P.H., is Professor of Medicine at Harvard
      Medical School, a faculty member of the Division of Pharmacoepidemiology and
      Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital, 
      the Director of the Program on Regulation, Therapeutics, and Law (PORTAL), and a 
      primary care physician. He is the Editor-in-Chief of the Journal of Law, Medicine
      & Ethics.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
RN  - 0 (Prescription Drugs)
MH  - Australia
MH  - Canada
MH  - Cost-Benefit Analysis/ethics/*methods/*organization & administration
MH  - *Drug Costs
MH  - France
MH  - Germany
MH  - Government Agencies
MH  - Japan
MH  - Prescription Drugs/*economics
MH  - Technology Assessment, Biomedical/ethics/*methods/*organization & administration
MH  - United Kingdom
MH  - United States
EDAT- 2020/10/07 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/10/06 08:38
PHST- 2020/10/06 08:38 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1177/1073110520958885 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Sep;48(3):583-594. doi: 10.1177/1073110520958885.


PMID- 33021166
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210707
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - Gene Editing Sperm and Eggs (not Embryos): Does it Make a Legal or Ethical
      Difference?
PG  - 619-621
LID - 10.1177/1073110520958891 [doi]
FAU - Cohen, I Glenn
AU  - Cohen IG
AD  - I. Glenn Cohen, J.D., is Deputy Dean and the James A. Attwood and Leslie Williams
      Professor of Law, Harvard Law School, Faculty Director, Petrie-Flom Center for
      Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge,
      MA. Jacob S. Sherkow, J.D., M.A., is Professor of Law, College of Law, and
      Affiliate, Carl R. Woese Institute for Genomic Biology, University of Illinois at
      Urbana-Champaign; Permanent Visiting Professor, Center for Advanced Studies in
      Biomedical Innovation Law, University of Copenhagen Faculty of Law. Eli Y.
      Adashi, M.D., M.S., is a Professor of Medical Science, Warren Alpert Medical
      School, Brown University, Providence, RI.
FAU - Sherkow, Jacob S
AU  - Sherkow JS
AD  - I. Glenn Cohen, J.D., is Deputy Dean and the James A. Attwood and Leslie Williams
      Professor of Law, Harvard Law School, Faculty Director, Petrie-Flom Center for
      Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge,
      MA. Jacob S. Sherkow, J.D., M.A., is Professor of Law, College of Law, and
      Affiliate, Carl R. Woese Institute for Genomic Biology, University of Illinois at
      Urbana-Champaign; Permanent Visiting Professor, Center for Advanced Studies in
      Biomedical Innovation Law, University of Copenhagen Faculty of Law. Eli Y.
      Adashi, M.D., M.S., is a Professor of Medical Science, Warren Alpert Medical
      School, Brown University, Providence, RI.
FAU - Adashi, Eli Y
AU  - Adashi EY
AD  - I. Glenn Cohen, J.D., is Deputy Dean and the James A. Attwood and Leslie Williams
      Professor of Law, Harvard Law School, Faculty Director, Petrie-Flom Center for
      Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge,
      MA. Jacob S. Sherkow, J.D., M.A., is Professor of Law, College of Law, and
      Affiliate, Carl R. Woese Institute for Genomic Biology, University of Illinois at
      Urbana-Champaign; Permanent Visiting Professor, Center for Advanced Studies in
      Biomedical Innovation Law, University of Copenhagen Faculty of Law. Eli Y.
      Adashi, M.D., M.S., is a Professor of Medical Science, Warren Alpert Medical
      School, Brown University, Providence, RI.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2021;49(1):156-157. PMID: 33966662
MH  - Female
MH  - Gene Editing/*ethics/*legislation & jurisprudence/*methods
MH  - Humans
MH  - Male
MH  - Ovum
MH  - Spermatozoa
EDAT- 2020/10/07 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/10/06 08:38
PHST- 2020/10/06 08:38 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1177/1073110520958891 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Sep;48(3):619-621. doi: 10.1177/1073110520958891.


PMID- 33021162
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - Reflections on the Ethics of End-Stage Kidney Disease Care in the U.S.
PG  - 535-537
LID - 10.1177/1073110520958878 [doi]
FAU - Finkelstein, Fredric O
AU  - Finkelstein FO
AD  - Fredric O. Finkelstein, M.D., teaches at the Yale School of Medicine; Alan S.
      Kliger, M.D., teaches at the Yale School of Medicine.
FAU - Kliger, Alan S
AU  - Kliger AS
AD  - Fredric O. Finkelstein, M.D., teaches at the Yale School of Medicine; Alan S.
      Kliger, M.D., teaches at the Yale School of Medicine.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CON - J Law Med Ethics. 2020 Sep;48(3):527-534. PMID: 33021161
MH  - Humans
MH  - *Kidney Failure, Chronic
MH  - *Terminal Care
EDAT- 2020/10/07 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/10/06 08:38
PHST- 2020/10/06 08:38 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1177/1073110520958878 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Sep;48(3):535-537. doi: 10.1177/1073110520958878.


PMID- 33021161
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210512
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - Emergency-Only Hemodialysis Policies: Ethical Critique and Avenues for Reform.
PG  - 527-534
LID - 10.1177/1073110520958877 [doi]
AB  - An estimated 6,500 undocumented immigrants in the United States have been
      diagnosed with end-stage renal disease (ESRD). These individuals are ineligible
      for the federal insurance program that covers dialysis and/or transplantation for
      citizens, and consequently are subject to local or state policies regarding the
      provision of healthcare. In 76% of states, undocumented immigrants are ineligible
      to receive scheduled outpatient dialysis treatments, and typically receive
      dialysis only when presenting to the emergency center with severe
      life-threatening symptoms. 'Emergency-only hemodialysis' (EOHD) is associated
      with higher healthcare costs, higher mortality, and longer hospitalizations. In
      this paper, we present an ethical critique of existing federal policy. We argue
      that EOHD represents a failure of fiduciary and professional obligations,
      contributes to moral distress, and undermines physician obligations to be good
      stewards of medical resources. We then explore potential avenues for reform based
      upon policies introduced at the state level. We argue that, while reform at the
      federal level would ultimately be a more sustainable long-term solution,
      state-based policy reforms can help mitigate the ethical shortcomings of EOHD.
FAU - Lavingia, Richa
AU  - Lavingia R
AD  - Richa Lavingia, B.S., is a medical student at Baylor College of Medicine in
      Houston, TX and an M.P.H. student at the UTHealth School of Public Health in
      Houston, TX. She received her B.S. from Duke University in Durham, NC. Rajeev
      Raghavan, M.D., is an Associate Professor of Medicine at Baylor College of
      Medicine in Houston, TX. He received his B.S. from Case Western Reserve
      University in Cleveland, OH and his M.D. from Baylor College of Medicine in
      Houston, TX. He has published extensively on the experience and care of
      undocumented patients with kidney disease and is a national expert on this topic.
      Stephanie Morain, Ph.D., M.P.H., is an Assistant Professor in the Center for
      Medical Ethics and Health Policy. She received her A.B. from Lafayette College in
      Easton, PA, her M.P.H. from Columbia University's Mailman School of Public Health
      in New York, NY, her Ph.D. in Health Policy from Harvard University in Cambridge,
      MA, and completed her postdoctoral training at the Berman Institute for Bioethics
      at Johns Hopkins University in Baltimore, MD.
FAU - Raghavan, Rajeev
AU  - Raghavan R
AD  - Richa Lavingia, B.S., is a medical student at Baylor College of Medicine in
      Houston, TX and an M.P.H. student at the UTHealth School of Public Health in
      Houston, TX. She received her B.S. from Duke University in Durham, NC. Rajeev
      Raghavan, M.D., is an Associate Professor of Medicine at Baylor College of
      Medicine in Houston, TX. He received his B.S. from Case Western Reserve
      University in Cleveland, OH and his M.D. from Baylor College of Medicine in
      Houston, TX. He has published extensively on the experience and care of
      undocumented patients with kidney disease and is a national expert on this topic.
      Stephanie Morain, Ph.D., M.P.H., is an Assistant Professor in the Center for
      Medical Ethics and Health Policy. She received her A.B. from Lafayette College in
      Easton, PA, her M.P.H. from Columbia University's Mailman School of Public Health
      in New York, NY, her Ph.D. in Health Policy from Harvard University in Cambridge,
      MA, and completed her postdoctoral training at the Berman Institute for Bioethics
      at Johns Hopkins University in Baltimore, MD.
FAU - Morain, Stephanie R
AU  - Morain SR
AD  - Richa Lavingia, B.S., is a medical student at Baylor College of Medicine in
      Houston, TX and an M.P.H. student at the UTHealth School of Public Health in
      Houston, TX. She received her B.S. from Duke University in Durham, NC. Rajeev
      Raghavan, M.D., is an Associate Professor of Medicine at Baylor College of
      Medicine in Houston, TX. He received his B.S. from Case Western Reserve
      University in Cleveland, OH and his M.D. from Baylor College of Medicine in
      Houston, TX. He has published extensively on the experience and care of
      undocumented patients with kidney disease and is a national expert on this topic.
      Stephanie Morain, Ph.D., M.P.H., is an Assistant Professor in the Center for
      Medical Ethics and Health Policy. She received her A.B. from Lafayette College in
      Easton, PA, her M.P.H. from Columbia University's Mailman School of Public Health
      in New York, NY, her Ph.D. in Health Policy from Harvard University in Cambridge,
      MA, and completed her postdoctoral training at the Berman Institute for Bioethics
      at Johns Hopkins University in Baltimore, MD.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2020 Sep;48(3):535-537. PMID: 33021162
MH  - Emergency Service, Hospital/*ethics
MH  - Health Policy/*legislation & jurisprudence
MH  - Health Services Accessibility/*ethics
MH  - Humans
MH  - Kidney Failure, Chronic/*ethnology/*therapy
MH  - Renal Dialysis/*ethics
MH  - Undocumented Immigrants/*legislation & jurisprudence
MH  - United States
EDAT- 2020/10/07 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/10/06 08:38
PHST- 2020/10/06 08:38 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1177/1073110520958877 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Sep;48(3):527-534. doi: 10.1177/1073110520958877.


PMID- 33020834
OWN - NLM
STAT- MEDLINE
DCOM- 20210903
LR  - 20210903
IS  - 1545-6846 (Electronic)
IS  - 0037-8046 (Linking)
VI  - 65
IP  - 4
DP  - 2020 Oct 10
TI  - Advancing Reproductive Justice to Close the Health Gap: A Call to Action for
      Social Work.
PG  - 358-367
LID - 10.1093/sw/swaa034 [doi]
AB  - Reproductive justice is an intersectional social movement, theory, and praxis
      well aligned with social work's mission and values. Yet, advancing reproductive
      justice-the right to have children, to not have children, to parent with safety
      and dignity, and to sexual and bodily autonomy-has not been a signature area of
      scholarship and practice for the field. This article argues that it is critical
      for social work to advance reproductive justice to truly achieve the grand
      challenge of closing the health gap. The article starts by discussing the history
      and tenets of reproductive justice and how it overlaps with social work ethics.
      The authors then highlight some of the ways by which social workers have been
      disruptors of and complicit in the oppression of individuals, families, and
      communities with regard to their reproductive rights and outcomes. The article
      concludes with a call to action and recommendations for social work to foreground
      reproductive justice in research, practice, and education efforts by centering
      marginalized voices while reimagining the field's pursuit of health equity.
CI  - (c) 2020 National Association of Social Workers.
FAU - Gomez, Anu Manchikanti
AU  - Gomez AM
AD  - Sexual Health and Reproductive Equity Program, and associate professor, School of
      Social Welfare, University of California, Berkeley, 110 Haviland Hall MC 7400,
      Berkeley, CA 94720-7400.
FAU - Downey, Margaret Mary
AU  - Downey MM
AD  - Tulane University School of Social Work, New Orleans.
FAU - Carpenter, Emma
AU  - Carpenter E
AD  - University of Texas at Austin.
FAU - Leedham, Usra
AU  - Leedham U
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto.
FAU - Begun, Stephanie
AU  - Begun S
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto.
FAU - Craddock, Jaih
AU  - Craddock J
AD  - School of Social Work, University of Maryland, Baltimore.
FAU - Ely, Gretchen
AU  - Ely G
AD  - School of Social Work, University at Buffalo, State University of New York.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Soc Work
JT  - Social work
JID - 2984852R
SB  - IM
MH  - Female
MH  - Health Status Disparities
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - *Reproductive Rights
MH  - *Social Change
MH  - *Social Justice
MH  - Social Work/*ethics
OTO - NOTNLM
OT  - Grand Challenges for Social Work
OT  - health equity
OT  - reproductive justice
OT  - social work
EDAT- 2020/10/07 06:00
MHDA- 2021/09/04 06:00
CRDT- 2020/10/06 05:33
PHST- 2019/07/11 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/09/04 06:00 [medline]
PHST- 2020/10/06 05:33 [entrez]
AID - 5918214 [pii]
AID - 10.1093/sw/swaa034 [doi]
PST - ppublish
SO  - Soc Work. 2020 Oct 10;65(4):358-367. doi: 10.1093/sw/swaa034.


PMID- 33020798
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20211204
IS  - 1460-2156 (Electronic)
IS  - 0006-8950 (Linking)
VI  - 143
IP  - 11
DP  - 2020 Dec 5
TI  - Recent progress in translational engineered in vitro models of the central
      nervous system.
PG  - 3181-3213
LID - 10.1093/brain/awaa268 [doi]
AB  - The complexity of the human brain poses a substantial challenge for the
      development of models of the CNS. Current animal models lack many essential human
      characteristics (in addition to raising operational challenges and ethical
      concerns), and conventional in vitro models, in turn, are limited in their
      capacity to provide information regarding many functional and systemic responses.
      Indeed, these challenges may underlie the notoriously low success rates of CNS
      drug development efforts. During the past 5 years, there has been a leap in the
      complexity and functionality of in vitro systems of the CNS, which have the
      potential to overcome many of the limitations of traditional model systems. The
      availability of human-derived induced pluripotent stem cell technology has
      further increased the translational potential of these systems. Yet, the adoption
      of state-of-the-art in vitro platforms within the CNS research community is
      limited. This may be attributable to the high costs or the immaturity of the
      systems. Nevertheless, the costs of fabrication have decreased, and there are
      tremendous ongoing efforts to improve the quality of cell differentiation.
      Herein, we aim to raise awareness of the capabilities and accessibility of
      advanced in vitro CNS technologies. We provide an overview of some of the main
      recent developments (since 2015) in in vitro CNS models. In particular, we focus 
      on engineered in vitro models based on cell culture systems combined with
      microfluidic platforms (e.g. 'organ-on-a-chip' systems). We delve into the
      fundamental principles underlying these systems and review several applications
      of these platforms for the study of the CNS in health and disease. Our discussion
      further addresses the challenges that hinder the implementation of advanced in
      vitro platforms in personalized medicine or in large-scale industrial settings,
      and outlines the existing differentiation protocols and industrial cell sources. 
      We conclude by providing practical guidelines for laboratories that are
      considering adopting organ-on-a-chip technologies.
CI  - (c) The Author(s) (2020). Published by Oxford University Press on behalf of the
      Guarantors of Brain.
FAU - Nikolakopoulou, Polyxeni
AU  - Nikolakopoulou P
AD  - AIMES, Center for the Advancement of Integrated Medical and Engineering Sciences,
      Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
FAU - Rauti, Rossana
AU  - Rauti R
AD  - Department of Biomedical Engineering, Faculty of Engineering, Tel Aviv
      University, Tel Aviv, Israel.
FAU - Voulgaris, Dimitrios
AU  - Voulgaris D
AD  - Division of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, 
      Sweden.
FAU - Shlomy, Iftach
AU  - Shlomy I
AD  - Department of Biomedical Engineering, Faculty of Engineering, Tel Aviv
      University, Tel Aviv, Israel.
FAU - Maoz, Ben M
AU  - Maoz BM
AD  - Department of Biomedical Engineering, Faculty of Engineering, Tel Aviv
      University, Tel Aviv, Israel.
AD  - Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
AD  - The Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv,
      Israel.
FAU - Herland, Anna
AU  - Herland A
AD  - AIMES, Center for the Advancement of Integrated Medical and Engineering Sciences,
      Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
AD  - Division of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, 
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Brain
JT  - Brain : a journal of neurology
JID - 0372537
SB  - IM
MH  - Animals
MH  - Engineering
MH  - Humans
MH  - Models, Animal
MH  - *Models, Neurological
MH  - *Nervous System Physiological Phenomena
MH  - *Translational Research, Biomedical
PMC - PMC7719033
OTO - NOTNLM
OT  - * in vitro model
OT  - *CNS models
OT  - *neurodegenerative disease
OT  - *organ-on-a-chip
OT  - *translational medicine
EDAT- 2020/10/07 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/10/06 05:33
PHST- 2019/10/30 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/10/06 05:33 [entrez]
AID - 5918191 [pii]
AID - 10.1093/brain/awaa268 [doi]
PST - ppublish
SO  - Brain. 2020 Dec 5;143(11):3181-3213. doi: 10.1093/brain/awaa268.


PMID- 33020113
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Oct
TI  - Investigating outcome measures for assessing airway clearance techniques in
      adults with cystic fibrosis: protocol of a single-centre randomised controlled
      crossover trial.
LID - e000694 [pii]
LID - 10.1136/bmjresp-2020-000694 [doi]
AB  - INTRODUCTION: Airway clearance techniques (ACTs) are a gold standard of cystic
      fibrosis management; however, the majority of research evidence for their
      efficacy is of low standard; often attributed to the lack of sensitivity from
      outcome measures (OMs) used historically. This randomised controlled trial (RCT) 
      investigates these standard OMs (sputum weight, forced expiratory volume in 1 s) 
      and new OMs (electrical impedance tomography (EIT), multiple breath washout (MBW)
      and impulse oscillometry (IOS)) to determine the most useful measures of ACT.
      METHODS AND ANALYSIS: This is a single-centre RCT with crossover design.
      Participants perform MBW, IOS and spirometry, and then are randomised to either
      rest or supervised ACT lasting 30-60 min. MBW, IOS and spirometry are repeated
      immediately afterwards. EIT and sputum are collected during rest/ACT. On a
      separate day, the OMs are performed with the other intervention. Primary endpoint
      is difference in change in OMs before and after ACT/rest. Sample size was
      calculated with 80% power and significance of 5% for each OM (target n=64).
      ETHICS AND DISSEMINATION: Ethics approval was gained from the London-Chelsea
      Research Ethics Committee (reference 16/LO/0995, project ID 154635).
      Dissemination will involve scientific conference presentation and publication in 
      a peer-reviewed journal. TRIAL REGISTRATION NUMBERS: ISRCTN11220163 and
      NCT02721498.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Stanford, Gemma
AU  - Stanford G
AUID- ORCID: http://orcid.org/0000-0001-6967-6883
AD  - Adult Cystic Fibrosis, Royal Brompton Hospital, London, UK.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Davies, Jane C
AU  - Davies JC
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
AD  - Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK.
FAU - Usmani, Omar
AU  - Usmani O
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
AD  - Research and Development, Royal Brompton Hospital, London, UK.
FAU - Banya, Winston
AU  - Banya W
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
AD  - Research and Development, Royal Brompton Hospital, London, UK.
FAU - Charman, Susan
AU  - Charman S
AD  - Cystic Fibrosis Trust, London, UK.
FAU - Jones, Mandy
AU  - Jones M
AD  - Department of Health Sciences, College of Health, Medicine and Life Scientists,
      Brunel University London, London, UK.
FAU - Simmonds, Nicholas J
AU  - Simmonds NJ
AD  - Adult Cystic Fibrosis, Royal Brompton Hospital, London, UK
      n.simmonds@imperial.ac.uk.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Bilton, Diana
AU  - Bilton D
AD  - Respiratory Medicine, Royal Brompton Hospital, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02721498
GR  - CDRF-2014-05-055/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
SB  - IM
MH  - Adult
MH  - Cross-Over Studies
MH  - *Cystic Fibrosis/therapy
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Randomized Controlled Trials as Topic
MH  - Sputum
PMC - PMC7537140
OTO - NOTNLM
OT  - *cystic fibrosis
OT  - *respiratory measurement
COIS- Competing interests: JD reports other from Algipharma AS; Bayer AG; Boehringer
      Ingelheim Pharma GmbH & Co. KG; Galapagos NV; ImevaX GmbH; Nivalis Therapeutics; 
      ProQR Therapeutics III B.V.; Proteostasis Therapeutics; Raptor Pharmaceuticals;
      Vertex Pharmaceuticals (Europe) Limited; Enterprise; Novartis; Pulmocide;
      Flatley; Teva and grants from CF Trust outside the submitted work. NJS reports
      personal fees from Vertex; Chiesi; Teva; Roche; Pulmocide and Zambon outside the 
      submitted work.
EDAT- 2020/10/07 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/10/06 05:26
PHST- 2020/06/26 00:00 [received]
PHST- 2020/09/09 00:00 [revised]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/10/06 05:26 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 7/1/e000694 [pii]
AID - 10.1136/bmjresp-2020-000694 [doi]
PST - ppublish
SO  - BMJ Open Respir Res. 2020 Oct;7(1). pii: 7/1/e000694. doi:
      10.1136/bmjresp-2020-000694.


PMID- 33020105
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - A multicentre, randomised trial of stabilisation with nasal high flow during
      neonatal endotracheal intubation (the SHINE trial): a study protocol.
PG  - e039230
LID - 10.1136/bmjopen-2020-039230 [doi]
AB  - INTRODUCTION: Neonatal endotracheal intubation is an essential but potentially
      destabilising procedure. With an increased focus on avoiding mechanical
      ventilation, particularly in preterm infants, there are fewer opportunities for
      clinicians to gain proficiency in this important emergency skill. Rates of
      successful intubation at the first attempt are relatively low, and adverse event 
      rates are high, when compared with intubations in paediatric and adult
      populations. Interventions to improve operator success and patient stability
      during neonatal endotracheal intubations are needed. Using nasal high flow
      therapy extends the safe apnoea time of adults undergoing upper airway surgery
      and during endotracheal intubation. This technique is untested in neonates.
      METHODS AND ANALYSIS: The Stabilisation with nasal High flow during Intubation of
      NEonates (SHINE) trial is a multicentre, randomised controlled trial comparing
      the use of nasal high flow during neonatal intubation with standard care (no
      nasal high flow). Intubations are randomised individually, and stratified by
      site, use of premedications, and postmenstrual age (<28 weeks' gestation; >/=28
      weeks' gestation). The primary outcome is the incidence of successful intubation 
      on the first attempt without physiological instability of the infant.
      Physiological instability is defined as an absolute decrease in peripheral oxygen
      saturation >20% from preintubation baseline and/or bradycardia (<100 beats per
      minute). ETHICS AND DISSEMINATION: The SHINE trial received ethical approval from
      the Human Research Ethics Committees of The Royal Women's Hospital, Melbourne,
      Australia and Monash Health, Melbourne, Australia. The trial is currently
      recruiting in these two sites. The findings of this study will be disseminated
      via peer-reviewed journals and presented at national and international
      conferences. TRIAL REGISTRATION NUMBER: ACTRN12618001498280.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hodgson, Kate A
AU  - Hodgson KA
AUID- ORCID: 0000-0002-2908-1049
AD  - Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria,
      Australia kate.hodgson@thewomens.org.au.
AD  - Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Owen, Louise S
AU  - Owen LS
AD  - Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria,
      Australia.
AD  - Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria,
      Australia.
FAU - Kamlin, Camille Omar
AU  - Kamlin CO
AD  - Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria,
      Australia.
AD  - Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria,
      Australia.
FAU - Roberts, Calum T
AU  - Roberts CT
AD  - Monash Newborn, Monash Children's Hospital, Clayton, Victoria, Australia.
AD  - Department of Paediatrics, Monash University, Clayton, Victoria, Australia.
FAU - Donath, Susan M
AU  - Donath SM
AD  - Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research
      Institute, Melbourne, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Davis, Peter G
AU  - Davis PG
AUID- ORCID: 0000-0001-6742-7314
AD  - Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria,
      Australia.
AD  - Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria,
      Australia.
FAU - Manley, Brett James
AU  - Manley BJ
AD  - Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria,
      Australia.
AD  - Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria,
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618001498280
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Australia
MH  - Child
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - *Intubation, Intratracheal/adverse effects
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Respiration, Artificial
PMC - PMC7537449
OTO - NOTNLM
OT  - *intensive & critical care
OT  - *neonatal intensive & critical care
OT  - *neonatology
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039230 [pii]
AID - 10.1136/bmjopen-2020-039230 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e039230. doi: 10.1136/bmjopen-2020-039230.


PMID- 33020103
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Accuracy of potential diagnostic indicators for coeliac disease: a systematic
      review protocol.
PG  - e038994
LID - 10.1136/bmjopen-2020-038994 [doi]
AB  - INTRODUCTION: Coeliac disease (CD) is a systemic immune-mediated disorder
      triggered by gluten in genetically predisposed individuals. CD is diagnosed using
      a combination of serology tests and endoscopic biopsy of the small intestine.
      However, because of non-specific symptoms and heterogeneous clinical
      presentation, diagnosing CD is challenging. Early detection of CD through
      improved case-finding strategies can improve the response to a gluten-free diet, 
      patients' quality of life and potentially reduce the risk of complications.
      However, there is a lack of consensus in which groups may benefit from active
      case-finding. METHODS AND ANALYSIS: We will perform a systematic review to
      determine the accuracy of diagnostic indicators (such as symptoms and risk
      factors) for CD in adults and children, and thus can help identify patients who
      should be offered CD testing. MEDLINE, Embase, Cochrane Library and Web of
      Science will be searched from 1997 until 2020. Screening will be performed in
      duplicate. Data extraction will be performed by one and checked by a second
      reviewer. Disagreements will be resolved through discussion or referral to a
      third reviewer. We will produce a narrative summary of identified prediction
      models. Studies, where 2x2 data can be extracted or reconstructed, will be
      treated as diagnostic accuracy studies, that is, the diagnostic indicators are
      the index tests and CD serology and/or biopsy is the reference standard. For each
      diagnostic indicator, we will perform a bivariate random-effects meta-analysis of
      the sensitivity and specificity. ETHICS AND DISSEMINATION: Results will be
      reported in peer-reviewed journals, academic and public presentations and social 
      media. We will convene an implementation panel to advise on the optimum strategy 
      for enhanced dissemination. We will discuss findings with Coeliac UK to help with
      dissemination to patients. Ethical approval is not applicable, as this is a
      systematic review and no research participants will be involved. PROSPERO
      REGISTRATION NUMBER: CRD42020170766.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Elwenspoek, Martha Maria Christine
AU  - Elwenspoek MMC
AUID- ORCID: 0000-0002-9824-9335
AD  - The National Institute for Health Research Applied Research Collaboration West
      (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol, UK
      martha.elwenspoek@bristol.ac.uk.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Jackson, Joni
AU  - Jackson J
AD  - The National Institute for Health Research Applied Research Collaboration West
      (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Dawson, Sarah
AU  - Dawson S
AD  - The National Institute for Health Research Applied Research Collaboration West
      (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Everitt, Hazel
AU  - Everitt H
AD  - Primary Care, Population Sciences and Medical Education, University of
      Southampton, Southampton, UK.
FAU - Gillett, Peter
AU  - Gillett P
AD  - Paediatric Gastroenterology, Hepatology and Nutrition Department, Royal Hospital 
      for Sick Children, Edinburgh, UK.
FAU - Hay, Alastair D
AU  - Hay AD
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Jones, Hayley E
AU  - Jones HE
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Lane, Deborah L
AU  - Lane DL
AD  - Patient representative, Patient representative, UK.
FAU - Mallett, Susan
AU  - Mallett S
AD  - School of Health and Population Sciences, University of Birmingham, Birmingham,
      West Midlands, UK.
FAU - Robins, Gerry
AU  - Robins G
AD  - Department of Gastroenterology, York Teaching Hospital NHS Foundation Trust,
      York, North Yorkshire, UK.
FAU - Sheppard, Athena Louise
AU  - Sheppard AL
AUID- ORCID: 0000-0003-1564-0740
AD  - Department of Health Sciences, University of Leicester, Leicester,
      Leicestershire, UK.
FAU - Stubbs, Jo
AU  - Stubbs J
AD  - Patient representative, Patient representative, UK.
FAU - Thom, Howard
AU  - Thom H
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Watson, Jessica
AU  - Watson J
AUID- ORCID: 0000-0002-8177-6438
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Whiting, Penny
AU  - Whiting P
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
LA  - eng
GR  - MR/M014533/1/MRC_/Medical Research Council/United Kingdom
GR  - NIHR129020/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Celiac Disease/diagnosis
MH  - Child
MH  - Humans
MH  - Mass Screening
MH  - Meta-Analysis as Topic
MH  - Quality of Life
MH  - Research Design
MH  - Sensitivity and Specificity
MH  - Systematic Reviews as Topic
PMC - PMC7537462
OTO - NOTNLM
OT  - *coeliac disease
OT  - *diagnosis
OT  - *risk factors
OT  - *symptoms
OT  - *systematic review protocol
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038994 [pii]
AID - 10.1136/bmjopen-2020-038994 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e038994. doi: 10.1136/bmjopen-2020-038994.


PMID- 33020102
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Social work leadership competencies in health and mental healthcare: a scoping
      review protocol.
PG  - e038790
LID - 10.1136/bmjopen-2020-038790 [doi]
AB  - INTRODUCTION: Leadership skills are an integral part of effective social work
      practice in health and mental healthcare settings. Social workers require
      critical leadership skills to effectively support, treat and advocate for the
      complex needs of those most vulnerable. Despite an increasing focus on social
      work leadership within the last decade, there has been a paucity of research on
      social work leadership competencies within the realm of health and mental health 
      service provision. To bridge this gap, this scoping review will synthesise and
      map the current literature on social work leadership competencies in health and
      mental healthcare. METHODS AND ANALYSIS: Arksey and O'Malley's five-stage
      framework for scoping reviews will guide our search of six academic databases
      including: PsycINFO, OVID Social Work Abstracts, OVID Medline, Sociological
      Abstracts, Social Services Abstracts and CINAHL Plus with Full Text. Selected
      articles that meet inclusion criteria will then be reviewed and charted.
      Recurrent themes will be reviewed through a qualitative thematic analysis, and
      reported in both text and figures. ETHICS AND DISSEMINATION: Findings will
      highlight key social work leadership competencies as they relate to social work
      practice, team dynamics, and client outcomes within health and mental healthcare.
      Material retrieved in this scoping review was selected from publicly available
      sources, and thus as an obtrusive research method, this review does not warrant
      ethics approval. Findings from this review will be disseminated through published
      scholarly material, as well as presented at conferences pertaining to social work
      research, practice and education.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hussain, Amina
AU  - Hussain A
AUID- ORCID: 0000-0002-8697-0360
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada amina.hussain@mail.utoronto.ca.
FAU - Ashcroft, Rachelle
AU  - Ashcroft R
AUID- ORCID: 0000-0002-5666-1946
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - *Leadership
MH  - *Mental Health Services
MH  - Research Design
MH  - Review Literature as Topic
MH  - Social Work
PMC - PMC7537427
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *mental health
OT  - *primary care
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038790 [pii]
AID - 10.1136/bmjopen-2020-038790 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e038790. doi: 10.1136/bmjopen-2020-038790.


PMID- 33020101
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Incremental effect of non-invasive oscillating device on chest physiotherapy in
      critically ill children: a cross-over randomised trial.
PG  - e038648
LID - 10.1136/bmjopen-2020-038648 [doi]
AB  - INTRODUCTION: Chest physiotherapy (CPT) and intrathoracic percussion ventilation 
      have been recognised as to encourage dislodging the secretions; nonetheless, the 
      tolerance to the procedure and its efficiency have not been proven to be
      sufficient. METHOD AND ANALYSES: This study aims to examine the tolerance,
      feasibility and physiological effects in airway clearance by using a novel
      extrathoracic non-invasive oscillating transducer device (NIOD) in critically ill
      children. A two-stage cross-over randomised controlled study in a paediatric
      intensive care unit in a Canadian Academic Children's Hospital will be applied.
      Children under 24 months old, for whom CPT is prescribed for airway clearance,
      will be included. The study consists of two stages; (1) Stage 1 'Frequency
      Level': we will apply two different frequencies of the NIOD (40 Hz vs 60 Hz) for 
      12 min each, on each patient 3 hours apart, and (2) Stage 2 'NIOD versus CPT': we
      will implement NIOD and CPT alternatingly for 3 hours apart. The order of the
      procedures will be randomly allocated for each case. We will compare the average 
      Deltachanges of tidal lung volume measured by a 3D imaging system and regional
      lung functions using electrical impedance tomography, between the two different
      frequencies and between the NIOD periods and the CPT periods. We will also
      examine tolerance by seeing COMFORT Scales and related complications during the
      procedures. We estimate necessary sample size as 6 for each arm (Total 12 cases) 
      for stage 1 and 48 cases for Stage 2, with power of 0.8 and alpha of 0.05. ETHICS
      AND DISSEMINATION: This study has been approved by the Health Research Ethics
      Board of University of Montreal, Canada (REB number: 2020-2471). We will
      disseminate our findings through peer-reviewed publications and conference
      presentations in paediatric or/and critical care fields. TRIAL REGISTRATION
      NUMBER: ClinicalTrials.gov Registry (NCT03821389).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kawaguchi, Atsushi
AU  - Kawaguchi A
AUID- ORCID: 0000-0002-2209-5835
AD  - Pediatrics, University of Montreal, Montreal, Quebec, Canada.
AD  - Pediatrics, University of Ottawa, Children's Hospital Eastern Ontario, Ottawa,
      Ontario, Canada.
FAU - Bernier, Gabrielle
AU  - Bernier G
AD  - Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
FAU - Adler, Andy
AU  - Adler A
AD  - Systems and Computer Engineering, Carleton University, Ottawa, Ontario, Canada.
FAU - Emeriaud, Guillaume
AU  - Emeriaud G
AD  - Pediatrics, University of Montreal, Montreal, Quebec, Canada.
FAU - Jouvet, Philippe A
AU  - Jouvet PA
AD  - Pediatrics, University of Montreal, Montreal, Quebec, Canada
      philippe.jouvet@umontreal.ca.
LA  - eng
SI  - ClinicalTrials.gov/NCT03821389
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Child
MH  - Child, Preschool
MH  - Critical Care
MH  - *Critical Illness/therapy
MH  - Humans
MH  - Physical Therapy Modalities
MH  - *Respiratory Therapy
PMC - PMC7537431
OTO - NOTNLM
OT  - *chest imaging
OT  - *paediatric intensive & critical care
OT  - *paediatric thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038648 [pii]
AID - 10.1136/bmjopen-2020-038648 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e038648. doi: 10.1136/bmjopen-2020-038648.


PMID- 33020098
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Neuroimaging in the effect of transcranial magnetic stimulation therapy for
      patient with depression: a protocol for a coordinate-based meta-analysis.
PG  - e038099
LID - 10.1136/bmjopen-2020-038099 [doi]
AB  - INTRODUCTION: As a prevalent psychiatric disease, depression is a
      life-threatening mental disorder that may cause work disability and premature
      death. Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation 
      procedure, which has been reported to have a significant effect on antidepressant
      treatment in recent years. However, the parameters of TMS for depression that can
      produce the best clinical benefits remain unknown. In the present study, we will 
      evaluate the effect of TMS treatment for depression from the perspective of
      functional neuroimaging by performing a meta-analysis based on included studies. 
      METHODS AND ANALYSIS: Two independent reviewers will search published studies in 
      the following five databases: PubMed, Web of Science, Embase, China National
      Knowledge Infrastructure and WANGFANG DATA from inception to 1 June 2020. Then we
      will select studies according to predesigned inclusion and exclusion criteria.
      After extracting data from included studies, activation likelihood estimation
      will be applied to data synthesis. Any disagreement will be checked by the third 
      reviewer who will also make the final decision. ETHICS AND DISSEMINATION: This
      work does not require ethics approval as it will be based on published studies.
      This review will be published in peer-reviewed journals.PROSPERO registration
      numberCRD42020165436.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Deng, Yongyan
AU  - Deng Y
AD  - Psychiatric and psychological Neuroimage Lab (PsyNI Lab), Affiliated Brain
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
FAU - Li, Wenyue
AU  - Li W
AD  - Psychiatric and psychological Neuroimage Lab (PsyNI Lab), Affiliated Brain
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
FAU - Zhang, Bin
AU  - Zhang B
AUID- ORCID: 0000-0002-9280-8247
AD  - Psychiatric and psychological Neuroimage Lab (PsyNI Lab), Affiliated Brain
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
      zhang.bin845@foxmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - Depression/therapy
MH  - Humans
MH  - *Mental Disorders
MH  - Meta-Analysis as Topic
MH  - Neuroimaging
MH  - Review Literature as Topic
MH  - *Transcranial Magnetic Stimulation
PMC - PMC7537428
OTO - NOTNLM
OT  - *clinical trials
OT  - *depression & mood disorders
OT  - *magnetic resonance imaging
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038099 [pii]
AID - 10.1136/bmjopen-2020-038099 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e038099. doi: 10.1136/bmjopen-2020-038099.


PMID- 33020095
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - COproduction VALUE creation in healthcare service (CO-VALUE): an international
      multicentre protocol to describe the application of a model of value creation for
      use in systems of coproduced healthcare services and to evaluate the initial
      feasibility, utility and acceptability of associated system-level value creation 
      assessment approaches.
PG  - e037578
LID - 10.1136/bmjopen-2020-037578 [doi]
AB  - INTRODUCTION: Coproduction introduces a fundamental shift in how healthcare
      service is conceptualised. The mechanistic idea of healthcare being a 'product'
      generated by the healthcare system and delivered to patients is replaced by that 
      of a service co-created by the healthcare system and the users of healthcare
      services. Fjeldstad et al offer an approach for conceptualising value creation in
      complex service contexts that we believe is applicable to coproduction of
      healthcare service. We have adapted Fjeldstad's value creation model based on a
      detailed case study of a renal haemodialysis service in Jonkoping, Sweden, which 
      demonstrates coproduction characteristics and key elements of Fjeldstad's model. 
      METHODS AND ANALYSIS: We propose a five-part coproduction value creation model
      for healthcare service: (1) value chain, characterised by a standardised set of
      processes that serve a commonly occurring need; (2) value shop, which offers a
      customised response for unique cases; (3) a facilitated value network, which
      involves groups of individuals struggling with similar challenges; (4)
      interconnection between shop, chain and network elements and (5) leadership. We
      will seek to articulate and assess the value creation model through the work of a
      community of practice comprised of a diverse international workgroup with
      representation from executive, financial and clinical leaders as well as other
      key stakeholders from multiple health systems. We then will conduct pilot studies
      of a qualitative self-assessment process in participating health systems, and
      ultimately develop and test quantitative measures for assessing coproduction
      value creation. ETHICS AND DISSEMINATION: This study has been approved by the
      Dartmouth-Hitchcock Health Institutional Review Board (D-HH IRB) as a minimal
      risk research study. Findings and scholarship will be disseminated broadly
      through continuous engagement with health system stakeholders, national and
      international academic presentations and publications and an internet-based
      electronic platform for publicly accessible study information.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oliver, Brant J
AU  - Oliver BJ
AUID- ORCID: 0000-0002-7399-622X
AD  - Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of
      Medicine at Dartmouth, Lebanon, New Hampshire, USA Brant.j.oliver@dartmouth.edu.
FAU - Batalden, Paul B
AU  - Batalden PB
AD  - Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of
      Medicine at Dartmouth, Lebanon, New Hampshire, USA.
FAU - DiMilia, Peter Rocco
AU  - DiMilia PR
AUID- ORCID: 0000-0001-9305-6393
AD  - Community and Family Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New
      Hampshire, USA.
FAU - Forcino, Rachel C
AU  - Forcino RC
AUID- ORCID: 0000-0001-9938-4830
AD  - Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of
      Medicine at Dartmouth, Lebanon, New Hampshire, USA.
FAU - Foster, Tina C
AU  - Foster TC
AD  - Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of
      Medicine at Dartmouth, Lebanon, New Hampshire, USA.
FAU - Nelson, Eugene C
AU  - Nelson EC
AD  - Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of
      Medicine at Dartmouth, Lebanon, New Hampshire, USA.
FAU - Garre, Boel Anderson
AU  - Garre BA
AD  - Jonkoping Academy School of Health and Social Welfare, Jonkoping, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Delivery of Health Care
MH  - Feasibility Studies
MH  - *Health Services
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Organizations
MH  - Sweden
PMC - PMC7537448
OTO - NOTNLM
OT  - *health services administration & management
OT  - *international health services
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037578 [pii]
AID - 10.1136/bmjopen-2020-037578 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e037578. doi: 10.1136/bmjopen-2020-037578.


PMID- 33020094
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Cognitive behavioural therapy in groups for medicated adults with attention
      deficit hyperactivity disorder: protocol for a randomised controlled trial.
PG  - e037514
LID - 10.1136/bmjopen-2020-037514 [doi]
AB  - INTRODUCTION: Cognitive behavioural therapy (CBT) is an evidence-based treatment 
      for adults with attention deficit hyperactivity disorder (ADHD). However, it is
      still inconsistent whether a combination of CBT would have additive effects in
      medicated ADHD in adulthood. And if CBT would have additional effects, what kind 
      and which dimension would CBT play a part? This study estimates the efficacy of
      CBT in stable medicated adult ADHD, using long-term outcomes and multidimensional
      evaluations. METHODS AND ANALYSIS: It is a two-armed, randomised controlled trial
      on the superiority of the efficacy of 12 weeks of CBT on medicated adult ADHD. We
      compare the short-term and long-term outcomes between CBT combined with
      medication (CBT+M) group and the medication-only (M) group, including ADHD core
      symptoms, emotional symptoms, executive function, self-esteem, life quality and
      brain function using functional near-infrared spectroscopy data. Participants are
      outpatients of the Peking University Sixth Hospital and those recruited online,
      diagnosed as adult ADHD and with stable medication treatment. We estimate ADHD
      core symptoms and combined symptoms at baseline (T1) and week 12 (T2), week 24
      (T3), week 36 (T4) and week 48 (T5). ETHICS AND DISSEMINATION: This trial has
      been approved by the Ethics and Clinical Research Committees of Peking University
      Sixth Hospital and will be performed under the Declaration of Helsinki with the
      Medical Research Involving Human Subjects Act (WMO). The results will be
      disseminated in a peer-reviewed journal and a conference presentation. TRIAL
      REGISTRATION NUMBER: ChiCTR (ChiCTR1900021705).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pan, Mei-Rong
AU  - Pan MR
AD  - Peking University Sixth Hospital, Institute of Mental Health, Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University), National Clinical
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing,
      China.
FAU - Zhao, Meng-Jie
AU  - Zhao MJ
AD  - Peking University Sixth Hospital, Institute of Mental Health, Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University), National Clinical
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing,
      China.
FAU - Liu, Lu
AU  - Liu L
AD  - Peking University Sixth Hospital, Institute of Mental Health, Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University), National Clinical
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing,
      China.
FAU - Li, Hai-Mei
AU  - Li HM
AD  - Peking University Sixth Hospital, Institute of Mental Health, Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University), National Clinical
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing,
      China.
FAU - Wang, Yu-Feng
AU  - Wang YF
AD  - Peking University Sixth Hospital, Institute of Mental Health, Beijing, China.
AD  - NHC Key Laboratory of Mental Health (Peking University), National Clinical
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing,
      China.
FAU - Qian, Qiu-Jin
AU  - Qian QJ
AUID- ORCID: 0000-0001-5060-3772
AD  - Peking University Sixth Hospital, Institute of Mental Health, Beijing, China
      qianqiujin@bjmu.edu.cn.
AD  - NHC Key Laboratory of Mental Health (Peking University), National Clinical
      Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing,
      China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Attention Deficit Disorder with Hyperactivity/therapy
MH  - *Cognitive Behavioral Therapy
MH  - Emotions
MH  - Executive Function
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Self Concept
MH  - Treatment Outcome
PMC - PMC7537466
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *clinical trials
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037514 [pii]
AID - 10.1136/bmjopen-2020-037514 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e037514. doi: 10.1136/bmjopen-2020-037514.


PMID- 33020092
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Patient and public involvement in the development of clinical practice
      guidelines: a scoping review protocol.
PG  - e037327
LID - 10.1136/bmjopen-2020-037327 [doi]
AB  - INTRODUCTION: Clinical practice guidelines (CPGs) are intended to optimise
      patient care by recommending care pathways based on the best available research
      evidence and practice experience. Patient and public involvement (PPI) in
      healthcare is recommended based on the expectation that it will improve the
      quality and relevance of outcomes. There is no consensus on what constitutes
      meaningful and effective PPI in CPG. We will conduct a scoping review to identify
      and synthesise knowledge in four key areas: who have been the patients and public
      previously involved in CPG development, how were they recruited, at what stage in
      the CPG process were they involved and how were they involved. This knowledge
      will inform a general model of PPI in CPG to inform CPGs development. METHODS AND
      ANALYSIS: We will conduct a scoping review using the Methodology for Scoping
      Reviews refined by the Joanna Briggs Institute. Searches will be conducted in
      electronic databases (PubMed, Embase, CINAHL and PsycINFO). National standards
      for developing CPGs from Australia, UK, Canada and the USA will also be
      identified. A forward and backward citation search will be conducted on the
      included studies and national standards. Abstracts and full-text studies will be 
      independently screened by two researchers. Extracted data will include study
      details, type of clinical guideline and the four key areas, which patients and
      public were involved, how were they recruited, at what stage were they included
      and how they were involved. Data will be narratively synthesised. ETHICS AND
      DISSEMINATION: As a scoping review, this study does not require ethics approval. 
      We intend to disseminate the results through publication in a peer-reviewed
      journal and conference presentations. Furthermore, we will use the findings from 
      our scoping review to inform future research to fill key evidence gaps identified
      by this review.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bryant, Elizabeth Ann
AU  - Bryant EA
AUID- ORCID: 0000-0001-9569-7290
AD  - Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland,
      Australia abryant@bond.edu.au.
FAU - Scott, Anna Mae
AU  - Scott AM
AUID- ORCID: 0000-0002-0109-9001
AD  - Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland,
      Australia.
FAU - Thomas, Rae
AU  - Thomas R
AUID- ORCID: 0000-0002-2165-5917
AD  - Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Canada
MH  - Humans
MH  - *Patient Participation
MH  - Peer Review
MH  - *Research Design
MH  - Review Literature as Topic
PMC - PMC7537460
OTO - NOTNLM
OT  - *epidemiology
OT  - *health policy
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037327 [pii]
AID - 10.1136/bmjopen-2020-037327 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e037327. doi: 10.1136/bmjopen-2020-037327.


PMID- 33020091
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Validity of intraoperative imageless navigation (Naviswiss) for component
      positioning accuracy in primary total hip arthroplasty: protocol for a
      prospective observational cohort study in a single-surgeon practice.
PG  - e037126
LID - 10.1136/bmjopen-2020-037126 [doi]
AB  - INTRODUCTION: Optimal outcomes in total hip arthroplasty (THA) are dependent on
      appropriate placement of femoral and acetabular components, with technological
      advances providing a platform for guiding component placement to reduce the risk 
      of malpositioned components during surgery. This study will validate the
      intraoperative data captured using a handheld imageless THA navigation system
      against postoperative measurements of acetabular inclination, acetabular version,
      leg length and femoral offset on CT radiographs. METHODS AND ANALYSIS: This is a 
      prospective observational cohort study conducted within a single-centre,
      single-surgeon private practice. Data will be collected for 35 consecutive
      patients (>18 years) undergoing elective THA surgery, from the research registry 
      established at the surgeon's practice. The primary outcome is the agreement
      between intraoperative component positioning data captured by the navigation
      system compared with postoperative measurements using CT. A total of ten CT scans
      will be reassessed for interobserver and intraobserver reliability. The influence
      of patient and surgical factors on the accuracy of component position will also
      be examined with multivariable linear regression. ETHICS AND DISSEMINATION:
      Ethics approval for this study was provided through a certified ethics committee 
      (Bellberry HREC approval number 2017-07-499). The results of this study will be
      disseminated through peer-reviewed journals and conference presentations. TRIAL
      REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR) Trial 
      ID: ACTRN12620000089932.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ektas, Nalan
AU  - Ektas N
AD  - EBM Analytics, Sydney, New South Wales, Australia.
FAU - Scholes, Corey
AU  - Scholes C
AUID- ORCID: 0000-0001-6592-0738
AD  - EBM Analytics, Sydney, New South Wales, Australia cscholes@ebma.com.au.
FAU - Ruiz, Alejandro M
AU  - Ruiz AM
AD  - Active Surgical, Sydney, New South Wales, Australia.
FAU - Ireland, John
AU  - Ireland J
AD  - Sydney Bone and Joint Clinic, Sydney, New South Wales, Australia.
AD  - School of Medicine, University of Wollongong, Wollongong, New South Wales,
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12620000089932
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acetabulum/surgery
MH  - *Arthroplasty, Replacement, Hip
MH  - Australia
MH  - *Hip Prosthesis
MH  - Humans
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - *Surgeons
MH  - *Surgery, Computer-Assisted
MH  - Treatment Outcome
PMC - PMC7537456
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *hip
OT  - *musculoskeletal disorders
OT  - *orthopaedic & trauma surgery
COIS- Competing interests: No.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037126 [pii]
AID - 10.1136/bmjopen-2020-037126 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e037126. doi: 10.1136/bmjopen-2020-037126.


PMID- 33020090
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Scalable solution for delivery of diabetes self-management education in Thailand 
      (DSME-T): a cluster randomised trial study protocol.
PG  - e036963
LID - 10.1136/bmjopen-2020-036963 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus is among the foremost health challenges
      facing policy makers in Thailand as its prevalence has more than tripled over the
      last two decades, accounting for considerable death, disability and healthcare
      expenditure. Diabetes self-management education (DSME) programmes show promise in
      improving diabetes outcomes, but this is not routinely used in Thailand. This
      study aims to test a culturally tailored DSME model in Thailand, using a
      three-arm cluster randomised controlled trial comparing a nurse-led model, a
      peer-assisted model and standard care. We will test which model is effective and 
      cost effective to improve cardiovascular risk and control of blood glucose among 
      people with diabetes. METHODS AND ANALYSIS: 21 primary care units in northern
      Thailand will be randomised to one of three interventions, enrolling a total of
      693 patients. The primary care units will be randomised (1:1:1) to participate in
      a culturally-tailored DSME intervention for 12 months. The three-arm trial design
      will compare effectiveness of nurse-led, peer-assisted (Thai village health
      volunteers) and standard care. The primary trial outcomes are changes in
      haemoglobin A1c and cardiovascular risk score. A process evaluation and cost
      effectiveness evaluation will be conducted to produce policy relevant guidance
      for the Thai Ministry of Public Health. The planned trial period will start in
      January 2020 and finish October 2021. ETHICS AND DISSEMINATION: Ethical approval 
      has been obtained from Thailand and the UK. We will share our study data with
      other researchers, advertising via our publications and web presence. In
      particular, we are committed to sharing our findings and data with academic
      audiences in Thailand and other low-income and middle-income countries. TRIAL
      REGISTRATION NUMBER: NCT03938233.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Angkurawaranon, Chaisiri
AU  - Angkurawaranon C
AUID- ORCID: 0000-0003-4206-9164
AD  - Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang
      Mai, Thailand chaisiri.a@cmu.ac.th.
FAU - Papachristou Nadal, Iliatha
AU  - Papachristou Nadal I
AD  - Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and 
      Population Health,London School of Hygiene and Tropical Medicine, London, UK.
FAU - Mallinson, Poppy Alice Carson
AU  - Mallinson PAC
AD  - Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and 
      Population Health,London School of Hygiene and Tropical Medicine, London, UK.
FAU - Pinyopornpanish, Kanokporn
AU  - Pinyopornpanish K
AD  - Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang
      Mai, Thailand.
FAU - Quansri, Orawan
AU  - Quansri O
AD  - ASEAN Institute for Health Development, Mahidol University, Salaya, Thailand.
FAU - Rerkasem, Kittipan
AU  - Rerkasem K
AD  - Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai,
      Thailand.
AD  - Research Institute for Health Sciences, Chiang Mai University, Chiang Mai,
      Thailand.
FAU - Srivanichakorn, Supattra
AU  - Srivanichakorn S
AD  - Royal Thai Government Ministry of Public Health, Bangkok, Thailand.
FAU - Techakehakij, Win
AU  - Techakehakij W
AD  - Lampang Hospital, Lampang, Thailand.
FAU - Wichit, Nutchanath
AU  - Wichit N
AD  - Surat Thani Rajabhat University, Surat Thani, Thailand.
FAU - Pateekhum, Chanapat
AU  - Pateekhum C
AD  - Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang
      Mai, Thailand.
FAU - Hashmi, Ahmar H
AU  - Hashmi AH
AD  - Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang
      Mai, Thailand.
FAU - Hanson, Kara
AU  - Hanson K
AD  - Department of Global Health and Development, Faculty of Public Health of Public
      Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
FAU - Khunti, Kamlesh
AU  - Khunti K
AD  - Department of Health Sciences, University of Leicester, Leicester, UK.
FAU - Kinra, Sanjay
AU  - Kinra S
AD  - Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and 
      Population Health,London School of Hygiene and Tropical Medicine, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03938233
GR  - MR/R020876/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Management
MH  - Thailand
PMC - PMC7537447
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *education & training (see medical education & training)
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036963 [pii]
AID - 10.1136/bmjopen-2020-036963 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e036963. doi: 10.1136/bmjopen-2020-036963.


PMID- 33020088
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - AGT-Reha-WK study: protocol for a non-inferiority trial comparing the efficacy
      and costs of home-based telerehabilitation for shoulder diseases with medical
      exercise therapy.
PG  - e036881
LID - 10.1136/bmjopen-2020-036881 [doi]
AB  - INTRODUCTION: Shoulder lesions rank among the top 15 diagnoses accounting for
      days of incapacity to work. Inpatient or full-day outpatient rehabilitation are
      some of the standard therapies. For sustainable rehabilitation, continuation of
      rehabilitation after discharge from a rehabilitation centre is vital. Besides
      medical exercise therapy (MET), home-based physical exercise programmes are used.
      To monitor exercise quantity and quality, AGT-Reha, a health-enabling technology 
      for home rehabilitation, has been developed and evaluated in a pilot study for
      technical feasibility and acceptance. To integrate the digital therapeutic
      AGT-Reha into regular healthcare processes, an efficacy evaluation is required.
      METHODS AND ANALYSIS: AGT-Reha-WK is a prospective, monocentric, non-randomised, 
      unblinded non-inferiority trial. Primary objective is to investigate whether
      AGT-Reha enhanced home-based exercise training is non-inferior to MET as standard
      aftercare. Secondary objective is to compare the costs of both therapies.
      Efficacy as medical success (primary outcome) is examined with regard to ability 
      to work, return to work and sustainability of training (secondary outcomes). The 
      outcome measure for non-inferiority is shoulder function (pain and disability)
      assessed by the standardised Shoulder Pain and Disability Index (SPADI). The
      non-inferiority margin is set to 10 points on SPADI score using a 95% CI.
      Subjects will be recruited at the Rehabilitation Center Bad Pyrmont, Germany. The
      total number of subjects should be 84 (42 per group). Treatment takes 6 months
      per patient. Subjects will be assessed at four time points: pre-baseline
      (admission to rehabilitation centre), baseline (discharge from rehabilitation
      centre), post-therapy and follow-up (3 months post-therapy). ETHICS AND
      DISSEMINATION: Ethics approval was granted by the Ethics Committee of Hannover
      Medical School (ethics approval no: 7313). Results of the trial are planned to be
      published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: German Clinical 
      Trials Register DRKS00011596. Registered 2 June 2017. Recruitment started on 3
      March 2017, and it is expected to continue until December 2020. PROTOCOL VERSION:
      V2.0, 23 May 2018, Amendment 01: improved risk analysis, clarification of
      exclusion criteria to increase reproducibility, additional documentation with
      OpenClinica; these changes have no effect on structural equality.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Steiner, Bianca
AU  - Steiner B
AUID- ORCID: 0000-0002-6762-8973
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Technische Universitat Braunschweig, Braunschweig,
      Germany bianca.steiner@plri.de.
FAU - Elgert, Lena
AU  - Elgert L
AUID- ORCID: 0000-0002-3394-4257
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Hannover, Germany.
FAU - Haux, Reinhold
AU  - Haux R
AUID- ORCID: 0000-0001-5376-8660
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Technische Universitat Braunschweig, Braunschweig,
      Germany.
FAU - Wolf, Klaus-Hendrik
AU  - Wolf KH
AUID- ORCID: 0000-0002-3806-462X
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Hannover, Germany.
LA  - eng
SI  - DRKS/DRKS00011596
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Exercise
MH  - Exercise Therapy
MH  - Germany
MH  - Humans
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Shoulder
MH  - *Telerehabilitation
PMC - PMC7537442
OTO - NOTNLM
OT  - *clinical trials
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *shoulder
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036881 [pii]
AID - 10.1136/bmjopen-2020-036881 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e036881. doi: 10.1136/bmjopen-2020-036881.


PMID- 33020083
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Efficacy and safety of cilostazol-nimodipine combined therapy on delayed cerebral
      ischaemia after aneurysmal subarachnoid haemorrhage: a prospective, randomised,
      double-blinded, placebo-controlled trial protocol.
PG  - e036217
LID - 10.1136/bmjopen-2019-036217 [doi]
AB  - INTRODUCTION: Delayed cerebral ischaemia (DCI) due to cerebral vasospasm (cVS)
      remains the foremost contributor to morbidity and mortality following aneurysmal 
      subarachnoid haemorrhage (aSAH). Past efforts in preventing and treating DCI have
      failed to make any significant progress. To date, our most effective treatment
      involves the use of nimodipine, a calcium channel blocker. Recent studies have
      suggested that cilostazol, a platelet aggregation inhibitor, may prevent cVS.
      Thus far, no study has evaluated the effect of cilostazol plus nimodipine on the 
      rate of DCI following aSAH. METHODS AND ANALYSIS: This is a multicentre,
      double-blinded, randomised, placebo-controlled superiority trial investigating
      the effect of cilostazol on DCI. Data concerning rates of DCI, symptomatic and
      radiographic vasospasm, length of intensive care unit stay, and long-term
      functional and quality-of-life (QoL) outcomes will be recorded. All data will be 
      collected with the aim of demonstrating that the use of cilostazol plus
      nimodipine will safely decrease the incidence of DCI, and decrease the rates of
      both radiographic and symptomatic vasospasm with subsequent improvement in
      long-term functional and QoL outcomes when compared with nimodipine alone. ETHICS
      AND DISSEMINATION: Ethical approval was obtained from all participating hospitals
      by the Ascension Providence Hospital Institutional Review Board. The results of
      this study will be submitted for publication in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: NCT04148105.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dawley, Troy
AU  - Dawley T
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Claus, Chad F
AU  - Claus CF
AUID- ORCID: 0000-0002-2523-8811
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA
      chadfclaus@gmail.com.
FAU - Tong, Doris
AU  - Tong D
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Rajamand, Sina
AU  - Rajamand S
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Sigler, Diana
AU  - Sigler D
AD  - Department of Pharmacy, Ascension Providence Hospital, Michigan State University,
      College of Human Medicine, Southfield, Michigan, USA.
FAU - Bahoura, Matthew
AU  - Bahoura M
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Garmo, Lucas
AU  - Garmo L
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Soo, Teck M
AU  - Soo TM
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Kelkar, Prashant
AU  - Kelkar P
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
FAU - Richards, Boyd
AU  - Richards B
AD  - Division of Neurosurgery, Ascension Providence Hospital, Michigan State
      University, College of Human Medicine, Southfield, Michigan, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04148105
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 57WA9QZ5WH (Nimodipine)
RN  - N7Z035406B (Cilostazol)
SB  - IM
MH  - *Brain Ischemia/drug therapy
MH  - Cilostazol/therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Nimodipine/therapeutic use
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Subarachnoid Hemorrhage/complications
PMC - PMC7537439
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *neurological injury
OT  - *neurology
OT  - *neurosurgery
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036217 [pii]
AID - 10.1136/bmjopen-2019-036217 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e036217. doi: 10.1136/bmjopen-2019-036217.


PMID- 33020081
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Outbreak response intervention models of vaccine-preventable diseases in humans
      and foot-and-mouth disease in livestock: a protocol for a systematic review.
PG  - e036172
LID - 10.1136/bmjopen-2019-036172 [doi]
AB  - INTRODUCTION: Outbreaks of vaccine-preventable diseases continue to threaten
      public health, despite the proven effectiveness of vaccines. Interventions such
      as vaccination, social distancing and palliative care are usually implemented,
      either individually or in combination, to control these outbreaks. Mathematical
      models are often used to assess the impact of these interventions and for
      supporting outbreak response decision making. The objectives of this systematic
      review, which covers all human vaccine-preventable diseases, are to determine the
      relative impact of vaccination compared with other outbreak interventions, and to
      ascertain the temporal trends in the use of modelling in outbreak response
      decision making. We will also identify gaps and opportunities for future research
      through a comparison with the foot-and-mouth disease outbreak response modelling 
      literature, which has good examples of the use of modelling to inform outbreak
      response intervention decision making. METHODS AND ANALYSIS: We searched on
      PubMed, Scopus, Web of Science, Google Scholar and some preprint servers from the
      start of indexing to 15 January 2020. Inclusion: modelling studies, published in 
      English, that use a mechanistic approach to evaluate the impact of an outbreak
      intervention. Exclusion: reviews, and studies that do not describe or use
      mechanistic models or do not describe an outbreak. We will extract data from the 
      included studies such as their objectives, model types and composition, and
      conclusions on the impact of the intervention. We will ascertain the impact of
      models on outbreak response decision making through visualisation of time trends 
      in the use of the models. We will also present our results in narrative style.
      ETHICS AND DISSEMINATION: This systematic review will not require any ethics
      approval since it only involves scientific articles. The review will be
      disseminated in a peer-reviewed journal and at various conferences fitting its
      scope. PROSPERO REGISTRATION NUMBER: CRD42020160803.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Azam, James M
AU  - Azam JM
AUID- ORCID: 0000-0001-5782-7330
AD  - South African DSI-NRF Centre of Excellence in Epidemiological Modelling and
      Analysis (SACEMA), Stellenbosch University, Cape Town, Western Cape, South Africa
      jamesazam@sun.ac.za.
FAU - Are, Elisha B
AU  - Are EB
AUID- ORCID: 0000-0002-0710-7607
AD  - South African DSI-NRF Centre of Excellence in Epidemiological Modelling and
      Analysis (SACEMA), Stellenbosch University, Cape Town, Western Cape, South
      Africa.
FAU - Pang, Xiaoxi
AU  - Pang X
AD  - Department of Mathematics, The University of Manchester, Manchester, UK.
FAU - Ferrari, Matthew J
AU  - Ferrari MJ
AUID- ORCID: 0000-0001-5251-8168
AD  - Center for Infectious Disease Dynamics, Department of Biology, The Pennsylvania
      State University, University Park, Pennsylvania, USA.
FAU - Pulliam, Juliet R C
AU  - Pulliam JRC
AUID- ORCID: 0000-0003-3314-8223
AD  - South African DSI-NRF Centre of Excellence in Epidemiological Modelling and
      Analysis (SACEMA), Stellenbosch University, Cape Town, Western Cape, South
      Africa.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Animals
MH  - Disease Outbreaks/prevention & control
MH  - *Foot-and-Mouth Disease/epidemiology/prevention & control
MH  - Humans
MH  - Livestock
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - *Vaccine-Preventable Diseases
PMC - PMC7537453
OTO - NOTNLM
OT  - *epidemiology
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036172 [pii]
AID - 10.1136/bmjopen-2019-036172 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e036172. doi: 10.1136/bmjopen-2019-036172.


PMID- 33020079
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - Validation study of German inpatient administrative health data for
      epidemiological surveillance and measurement of quality of care for sepsis: the
      OPTIMISE study protocol.
PG  - e035763
LID - 10.1136/bmjopen-2019-035763 [doi]
AB  - INTRODUCTION: Sepsis is a major cause of preventable deaths in hospitals. This
      study aims to investigate if sepsis incidence and quality of care can be assessed
      using inpatient administrative health data (IAHD). METHODS AND ANALYSIS: Design: 
      Retrospective observational validation study using routine data to assess the
      diagnostic accuracy of sepsis coding in IAHD regarding sepsis diagnosis based on 
      medical record review. PROCEDURE: A stratified sample of 10 000 patients with an 
      age >/=15 years treated in between 2015 and 2017 in 10 German hospitals is
      investigated. All available information of medical records is screened by trained
      physicians to identify true sepsis cases ('gold standard') both according to
      current ('sepsis-1') definitions and new ('sepsis-3') definitions. Data from
      medical records are linked to IAHD on patient level using a pseudonym. ANALYSES: 
      Proportions of cases with sepsis according to sepsis-1 and sepsis-3 definitions
      are calculated and compared with estimates from coding of sepsis in IAHD.
      Predictive accuracy (sensitivity, specificity) of different coding abstraction
      strategies regarding the gold standard is estimated. Predictive accuracy of
      mortality risk factors obtained from IAHD regarding the respective risk factors
      obtained from medical records is calculated. An IAHD-based risk model for
      hospital mortality is compared with a record-based risk model regarding model-fit
      and predicted risk of death. Analyses adjust for sampling weights. The obtained
      estimates of sensitivity and specificity for sepsis coding in IAHD are used to
      estimate adjusted incidence proportions of sepsis based on German national IAHD. 
      ETHICS AND DISSEMINATION: The study has been approved by the ethics commission of
      the Jena University Hospital (No. 2018-1065-Daten). The results of the study will
      be discussed in an expert panel to write a memorandum on improving the utility of
      IAHD for epidemiological surveillance and quality management of sepsis care.
      TRIAL REGISTRATION NUMBER: DRKS00017775; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Schwarzkopf, Daniel
AU  - Schwarzkopf D
AUID- ORCID: 0000-0002-1568-8202
AD  - Center for Infectious Diseases and Infection Control, Jena University Hospital,
      Jena, Germany Daniel.Schwarzkopf@med.uni-jena.de.
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
FAU - Fleischmann-Struzek, Carolin
AU  - Fleischmann-Struzek C
AD  - Center for Infectious Diseases and Infection Control, Jena University Hospital,
      Jena, Germany.
AD  - Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
FAU - Schlattmann, Peter
AU  - Schlattmann P
AD  - Institute for Medical Statistics, Computer Science and Data Science, Jena
      University Hospital, Jena, Germany.
FAU - Dorow, Heike
AU  - Dorow H
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
FAU - Ouart, Dominique
AU  - Ouart D
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
FAU - Edel, Andreas
AU  - Edel A
AD  - Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK),
      Charite Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
FAU - Gonnert, Falk A
AU  - Gonnert FA
AD  - Department of Anaesthesiology and Intensive Care Medicine, SRH Wald-Klinikum
      Gera, Gera, Germany.
FAU - Gotz, Jurgen
AU  - Gotz J
AD  - Department of Internal Medicine II - Intensive Care, Klinikum Lippe GmbH,
      Detmold, Germany.
FAU - Grundling, Matthias
AU  - Grundling M
AD  - Department of Anaesthesiology, Intensive Care Medicine, Emergency Medicine and
      Pain Medicine, University Medicine Greifswald, Greifswald, Germany.
FAU - Heim, Markus
AU  - Heim M
AD  - Department of Anaesthesiology and Intensive Care, Technical University of Munich,
      TUM School of Medicine, Klinikum rechts der Isar, Munchen, Germany.
FAU - Jaschinski, Ulrich
AU  - Jaschinski U
AD  - Department of Anaesthesiology and Surgical Intensive Care Medicine,
      Universitatsklinikum Augsburg, Augsburg, Germany.
FAU - Lindau, Simone
AU  - Lindau S
AD  - Department of Anesthesiology, Intensive Care Medicine and Pain Therapy,
      University Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Meybohm, Patrick
AU  - Meybohm P
AUID- ORCID: 0000-0001-5324-981X
AD  - Department of Anaesthesia and Critical Care, University Hospital Wurzburg,
      Wurzburg, Germany.
FAU - Putensen, Christian
AU  - Putensen C
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Hospital
      Bonn, Bonn, Germany.
FAU - Sander, Michael
AU  - Sander M
AD  - Department of Anesthesiology, Intensive Care Medicine and Pain Therapy,
      University Hospital Giessen, UKGM, Justus-Liebig University Giessen, Giessen,
      Germany.
FAU - Reinhart, Konrad
AU  - Reinhart K
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
AD  - Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK),
      Charite Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
CN  - OPTIMISE study group
LA  - eng
SI  - DRKS/DRKS00017775
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Hospital Mortality
MH  - Humans
MH  - Incidence
MH  - *Inpatients
MH  - Retrospective Studies
MH  - *Sepsis/diagnosis/epidemiology/therapy
PMC - PMC7537443
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *epidemiology
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
IR  - Ball A
FIR - Ball, Anja
IR  - Scholtz K
FIR - Scholtz, Kathrin
IR  - Spies C
FIR - Spies, Claudia
IR  - Schewe JC
FIR - Schewe, Jens Christian
IR  - Steinberg V
FIR - Steinberg, Verena
IR  - Behrend S
FIR - Behrend, Susanne
IR  - Michel C
FIR - Michel, Corinna
IR  - Munster S
FIR - Munster, Stefan
IR  - Boden B
FIR - Boden, Beate
IR  - Gockeler A
FIR - Gockeler, Angelika
IR  - Zinn S
FIR - Zinn, Sebastian
IR  - Neb H
FIR - Neb, Holger
IR  - Zacharowski K
FIR - Zacharowski, Kai
IR  - Schmitt E
FIR - Schmitt, Elke
IR  - Helmer P
FIR - Helmer, Philipp
IR  - Ngoc KL
FIR - Ngoc, Khanh Le
IR  - Herzberg M
FIR - Herzberg, Moritz
IR  - Steinsberger FC
FIR - Steinsberger, Ferdinand Cornelius
IR  - Denn SM
FIR - Denn, Sara Marie
IR  - Schneck E
FIR - Schneck, Emmanuel
IR  - Koch C
FIR - Koch, Christian
IR  - Kuhn A
FIR - Kuhn, Anja
IR  - Kuhn SO
FIR - Kuhn, Sven-Olaf
IR  - Scheer C
FIR - Scheer, Christian
IR  - Fuchs C
FIR - Fuchs, Christian
IR  - Schneider G
FIR - Schneider, Gerhard
IR  - Meschede J
FIR - Meschede, Jan
IR  - Holbeck K
FIR - Holbeck, Kirill
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035763 [pii]
AID - 10.1136/bmjopen-2019-035763 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e035763. doi: 10.1136/bmjopen-2019-035763.


PMID- 33020078
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 5
TI  - PartnerCARE-a psycho-oncological online intervention for partners of patients
      with cancer: study protocol for a randomised controlled feasibility trial.
PG  - e035599
LID - 10.1136/bmjopen-2019-035599 [doi]
AB  - INTRODUCTION: Cancer burdens not only the patient but also the partner to a
      comparable extent. Partners of patients with cancer are highly involved in the
      caring process and therefore often experience distress and report a low quality
      of life. Interventions for supporting partners are scarce. Existing ones are
      rarely used by partners because they are often time-consuming per se and offer
      only limited flexibility with regard to schedule and location. The online
      intervention PartnerCARE has been developed on the basis of caregiver needs and
      consists of six consecutive sessions and four optional sessions, which are all
      guided by an e-coach. The study aims to evaluate feasibility and acceptance of
      the online intervention PartnerCARE and the related trial process. In addition,
      first insights of the putative efficacy of PartnerCARE should be gained. METHODS 
      AND ANALYSIS: A two-arm parallel-group randomised controlled trial will be
      conducted to compare the PartnerCARE online intervention with a waitlist control 
      group. The study aims to recruit in total n=60 partners of patients with any type
      of cancer across different access paths (eg, university medical centres, support 
      groups, social media). Congruent with feasibility study objectives, the primary
      outcome comprises recruitment process, study procedure, acceptance and
      satisfaction with the intervention (Client Satisfaction Questionnaire adapted to 
      Internet-based interventions), possible negative effects (Inventory of Negative
      Effects in Psychotherapy) and dropout rates. Secondary outcomes include quality
      of life, distress, depression, anxiety, caregiver burden, fear of progression,
      social support, self-efficacy, coping and loneliness. Online measurements will be
      performed by self-assessment at three time points (baseline/pre-randomisation, 2 
      months and 4 months after randomisation). Data analyses will be based on
      intention-to-treat principle. ETHICS AND DISSEMINATION: Ethics approval has been 
      granted by the Ethics Committee of the University of Ulm (No 390/18). Results
      from this study will be disseminated to relevant healthcare communities, in
      peer-reviewed journals and at scientific and clinical conferences. TRIAL
      REGISTRATION NUMBER: DRKS00017019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bodschwinna, Daniela
AU  - Bodschwinna D
AUID- ORCID: 0000-0002-8618-3324
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Ulm Medical
      Center, Ulm, Germany daniela.bodschwinna@uni-ulm.de.
AD  - Comprehensive Cancer Center Ulm (CCCU), University Ulm Medical Center, Ulm,
      Germany.
FAU - Lorenz, Inga
AU  - Lorenz I
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Ulm Medical
      Center, Ulm, Germany.
FAU - Bauereiss, Natalie
AU  - Bauereiss N
AD  - Department of Clinical Psychology and Psychotherapy, Institute of Psychology and 
      Education, Ulm University, Ulm, Germany.
FAU - Gundel, Harald
AU  - Gundel H
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Ulm Medical
      Center, Ulm, Germany.
FAU - Baumeister, Harald
AU  - Baumeister H
AD  - Department of Clinical Psychology and Psychotherapy, Institute of Psychology and 
      Education, Ulm University, Ulm, Germany.
FAU - Hoenig, Klaus
AU  - Hoenig K
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Ulm Medical
      Center, Ulm, Germany.
AD  - Comprehensive Cancer Center Ulm (CCCU), University Ulm Medical Center, Ulm,
      Germany.
LA  - eng
SI  - DRKS/DRKS00017019
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201005
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Feasibility Studies
MH  - Humans
MH  - *Internet-Based Intervention
MH  - *Neoplasms/therapy
MH  - Psycho-Oncology
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7537440
OTO - NOTNLM
OT  - *adult oncology
OT  - *mental health
OT  - *oncology
COIS- Competing interests: None declared.
EDAT- 2020/10/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/10/06 05:25 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035599 [pii]
AID - 10.1136/bmjopen-2019-035599 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 5;10(10):e035599. doi: 10.1136/bmjopen-2019-035599.


PMID- 33020047
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1879-680X (Electronic)
IS  - 1761-7727 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Dec
TI  - A randomized clinical trial to assess the sagittal effects of Transforce
      transverse appliance (TTA) and NiTi palatal expander (NPE) on skeletal class II
      malocclusion in growing patients during retention phase - A cephalometric study
      using a historical control group.
PG  - 722-731
LID - S1761-7227(20)30109-1 [pii]
LID - 10.1016/j.ortho.2020.08.007 [doi]
AB  - OBJECTIVES: To evaluate and compare the skeletal changes during the retention
      period after expansion with "Transforce Transverse lingual or palatal
      Appliance(R)" (TTA) and "NiTi Palatal Expander(R)" (NPE) in growing subjects with
      class II division 1 malocclusion and to compare these changes with a matched
      historical control. SUBJECTS AND METHODS: A unicentric two arm, parallel
      randomized clinical trial with additional historical control group was conducted 
      over a period of six years. The subjects in the age group of 9-13 years were
      screened and recruited as they reported. The inclusion criteria were: late
      mixed/early permanent dentition, class II or end on molar relationship, posterior
      transverse inter-arch discrepancy 4-8mm, overjet>/=5mm, cephalometrically ANB>4
      degrees and CVMI stage CS2-CS3. Subjects were randomly allocated to two study
      groups (SG), TTA and NPE using block randomization. Appliances in both SG were
      managed and followed by a single clinician with equal standards of care. The
      lateral cephalograms in digital form were obtained at the beginning of the
      treatment (T1), post-expansion (T2) and after ten months retention period (T3).
      Linear positional change>1mm and angular change>0.75 degrees were considered as a
      clinically significant change. Due to the ethical reasons a historical control of
      ten patients (CG) comparable to the SG for age and inclusion criteria was used to
      rule out the growth changes on serial lateral cephalograms. All Cephalometric
      measurements were done by a single operator blinded for the group allocation.
      Operator's measurement error was estimated. The study was single-blinded in
      regard to statistical analysis. Inter-group comparisons between SG were made by
      using an unpaired Student's t-test. ANOVA with post-hoc analysis was used for
      comparison among the study and control groups. RESULTS: A total of 36 subjects
      were recruited, 18 in each SG. Average time required to achieve the desired
      expansion in the TTA and NPE group was 13.6 weeks and 9.8 weeks respectively. The
      TTA group showed significant increase in SNB (1.54+/-0.33 degrees ) when compared
      with the control group (0.53+/-0.37 degrees ) and with the NPE group (0.74+/-0.29
      degrees ) (P<0.0001). Significant differences were observed when post-retention
      changes in SNB, ANB, Wits appraisal, and N perpendicular to Pogonion, were
      compared among the three groups (ANOVA, P<0.0001). Tukey's multiple comparison
      showed that these mandibular sagittal changes were significantly greater in the
      TTA group than in NPE and the control group (P=<0.007, Bonferroni corrected
      value). CONCLUSION: Cephalometrically significant sagittal advancement of
      mandible took place after expansion with TTA and NPE compared to untreated
      control. TTA appears to be more efficient for the sagittal positional changes
      than the NPE. Additional studies with larger samples are warranted to elucidate
      individual variations in skeletal response to the expansion protocol with these
      appliances.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Nagrik, Arun P
AU  - Nagrik AP
AD  - Dr. SC Government medical college and hospital, department of dentistry, 431606
      Nanded, Maharashtra, India. Electronic address: nagrik.arun@gmail.com.
FAU - Bhad, Wasundhara A
AU  - Bhad WA
AD  - Government dental college and hospital, department of orthodontics and
      dentofacial orthopedics, 444003 Nagpur, Maharashtra, India. Electronic address:
      wasundhara.bhad@gmail.com.
FAU - Chavan, Santosh J
AU  - Chavan SJ
AD  - Government dental college and hospital, department of orthodontics and
      dentofacial orthopedics, 444003 Nagpur, Maharashtra, India. Electronic address:
      drsjchavan@gmail.com.
FAU - Doshi, Umal H
AU  - Doshi UH
AD  - CSMSS dental college and hospital, department of orthodontics and dentofacial
      orthopedics, 431136 Aurangabad, Maharashtra, India. Electronic address:
      umal_16@rediffmail.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20201002
PL  - France
TA  - Int Orthod
JT  - International orthodontics
JID - 101184882
RN  - 12035-60-8 (titanium nickelide)
RN  - 7OV03QG267 (Nickel)
RN  - D1JT611TNE (Titanium)
SB  - IM
MH  - Adolescent
MH  - Anatomic Landmarks
MH  - Cephalometry/*methods
MH  - Child
MH  - Control Groups
MH  - Dental Arch/anatomy & histology
MH  - Female
MH  - Humans
MH  - Male
MH  - Malocclusion, Angle Class II/*therapy
MH  - Mandible
MH  - *Maxilla
MH  - *Nickel
MH  - Orthodontic Appliance Design
MH  - Orthodontic Appliances
MH  - Orthodontic Appliances, Fixed
MH  - Orthodontics, Corrective/methods
MH  - Palatal Expansion Technique/*instrumentation
MH  - Prospective Studies
MH  - *Titanium
OTO - NOTNLM
OT  - Class II malocclusion, maxillary transverse discrepancy
OT  - Maxillary expansion
OT  - NiTi palatal expander
OT  - Palatal expansion technique
OT  - TransForce
EDAT- 2020/10/07 06:00
MHDA- 2021/09/15 06:00
CRDT- 2020/10/06 05:25
PHST- 2020/06/26 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2020/10/06 05:25 [entrez]
AID - S1761-7227(20)30109-1 [pii]
AID - 10.1016/j.ortho.2020.08.007 [doi]
PST - ppublish
SO  - Int Orthod. 2020 Dec;18(4):722-731. doi: 10.1016/j.ortho.2020.08.007. Epub 2020
      Oct 2.


PMID- 33019946
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 6
TI  - Bioethics and the use of social media for medical crowdfunding.
PG  - 96
LID - 10.1186/s12910-020-00521-2 [doi]
AB  - BACKGROUND: Social media has globalised compassion enabling requests for
      donations to spread beyond geographical boundaries. The use of social media for
      medical crowdfunding links people with unmet healthcare needs to charitable
      donors. There is no doubt that fundraising campaigns using such platforms
      facilitates access to financial resources to the benefit of patients and their
      caregivers. MAIN TEXT: This paper reports on a critical review of the published
      literature and information from other online resources discussing medical
      crowdfunding and the related ethical questions. The review highlighted the
      benefits of crowdfunding as well as the under-exploration of the risk of having
      patients' desires and human rights undermined during online fundraising
      campaigns. Majority of these campaigns get initiated on behalf of the patients,
      especially the very sick and dependant. The ethical questions raised relate to
      the voluntariness of informed consent and the possibility of patients being used 
      as a means to an end. Vulnerability of patients may expose them to coercion,
      undue influence, manipulation, and violation of their human rights. The success
      of these campaigns is influenced by the digital skills, pre-existing social
      networks and, the emotional potency. Healthcare is a public good, and online
      market forces should not determine access to essential health services. The
      benefits of crowdfunding cannot be subverted, but it can perpetuate unintended
      injustices, especially those arising from socio-economic factors. CONCLUSIONS:
      Policymakers ought to monitor the utilisation of crowdfunding sites to identify
      policy failures and unmet essential health care needs responsible for driving
      individuals to use these platforms. The upholding of human rights and the
      fundamental respect of the individual's wishes is a moral imperative. The need
      for an ethics framework to guide different stakeholders during medical
      crowdfunding needs further examination.
FAU - Kubheka, Brenda Zanele
AU  - Kubheka BZ
AUID- ORCID: 0000-0003-1584-8103
AD  - School of Public Health, Faculty of Health Sciences, University of Witwatersrand,
      Johannesburg, South Africa. brenda.k@wol.co.za.
AD  - Health IQ Consulting, Johannesburg, South Africa. brenda.k@wol.co.za.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Bioethics
MH  - *Crowdsourcing
MH  - *Fund Raising
MH  - Healthcare Financing
MH  - Humans
MH  - *Social Media
PMC - PMC7537104
OTO - NOTNLM
OT  - *Ethics
OT  - *Justice
OT  - *Medical crowdfunding
OT  - *Privacy
OT  - *Social media
OT  - *Undue influence
OT  - *Vulnerability
EDAT- 2020/10/07 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/06 05:23
PHST- 2019/12/13 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/10/06 05:23 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00521-2 [doi]
AID - 10.1186/s12910-020-00521-2 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 6;21(1):96. doi: 10.1186/s12910-020-00521-2.


PMID- 33019886
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 1937-3392 (Electronic)
IS  - 1937-3384 (Linking)
VI  - 26
IP  - 10
DP  - 2020 Oct
TI  - Corneal Recovery Following Rabbit Peripheral Blood Mononuclear Cell-Amniotic
      Membrane Transplantation with Antivascular Endothelial Growth Factor in Limbal
      Stem Cell Deficiency Rabbits.
PG  - 541-552
LID - 10.1089/ten.TEC.2020.0209 [doi]
AB  - Background: Limbal stem cell deficiency (LSCD) is a refractory ocular surface
      disorder characterized by progressive corneal epithelial degeneration,
      conjunctivalization, and neovascularization, potentially leading to blindness.
      There are currently no effective therapeutic options for patients experiencing
      routine symptomatic treatment failure. Transplantation of amniotic membrane (AM) 
      with adherent stem cells (but not bare AM transplantation alone) has shown
      promise in preclinical studies for ocular surface restoration. A major
      limitation, however, is finding a reliable stem cell source. Stem cells can be
      isolated from the peripheral blood mononuclear cell (PBMC) population, and these 
      PBMC-derived stem cells have numerous advantages over allogeneic and other
      autologous stem cell types for therapeutic application, including relative ease
      of acquisition, nonimmunogenicity, and the absence of ethical issues associated
      with embryonic stem cells. Experiment: We examined the efficacy of autologous
      PBMC-AM sheet cultures combined with postoperative antiangiogenesis treatment for
      corneal restoration in LSCD model rabbits. Rabbit PBMCs (rPBMCs) were isolated,
      labeled with EdU for in vivo tracing, and then cultured on AMs in conditioned
      medium before transplantation. Rabbits were transplanted with bare AMs (group 1),
      rPBMC-AM sheets (group 2), or rPBMC-AM sheets plus postoperative treatment with
      the vascular endothelial growth factor antagonist bevacizumab (group 3). Corneal 
      opacity and neovascularization were monitored by slit-lamp imaging for 8 weeks
      and corneas were examined histologically at 1 and 2 months. Results: Corneal
      opacity decreased in all three groups over 8 weeks, but was significantly lower
      in group 2 and even lower in group 3. Corneal neovascularization was
      significantly higher in group 1 throughout the observation period, and
      significantly lower in group 3 than group 1 and 2 by 8 weeks post-transplant. At 
      4 weeks, the corneal surface completed epithelialization (although thinner than
      normal) in group 3 but still patchy in groups 1 and 2. By 8 weeks, the epithelium
      in group 3 was complete and smooth, resembling a normal epithelium. Integrin
      beta1 as a progenitor marker was also generally higher in groups 2 and 3.
      Conclusions: Autologous rPBMC-AM sheets with post-transplant topical bevacizumab 
      can effectively facilitate corneal epithelium recovery in a LSCD model,
      suggesting clinical utility for LSCD-related ocular surface diseases. Impact
      statement Limbal stem cell deficiency (LSCD) increases corneal opacity and
      vascularization, resulting in severe visual impairment or even blindness.
      Traditional surgical limbal transplant is currently the main treatment option for
      LSCD, but carries the risks of rejection and immunosuppressant side effects.
      Autologous stem cell-based therapy is a promising alternative approach, but a
      reliable stem cell source is a major limitation. We report that transplantation
      of autologous rabbit peripheral blood mononuclear cell-amniotic membrane sheets
      plus antivascular endothelial growth factor restored avascular transparent cornea
      in a rabbit LSCD model. These results demonstrate a potentially effective
      approach for ocular surface reconstruction in bilateral LSCD.
FAU - Zhao, Minglei
AU  - Zhao M
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Zhang, Hening
AU  - Zhang H
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Zhen, Dongqin
AU  - Zhen D
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Huang, Mian
AU  - Huang M
AD  - Guangzhou Zoo, GuangZhou, China.
FAU - Li, Weihua
AU  - Li W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Li, Zhiquan
AU  - Li Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Liu, Ying
AU  - Liu Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Xie, Yaojue
AU  - Xie Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Zeng, Baozhu
AU  - Zeng B
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Wang, Zhichong
AU  - Wang Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
FAU - Huang, Bing
AU  - Huang B
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, GuangZhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Tissue Eng Part C Methods
JT  - Tissue engineering. Part C, Methods
JID - 101466663
RN  - 0 (Biomarkers)
RN  - 0 (Endothelial Growth Factors)
RN  - TPY09G7XIR (Fluorescein)
SB  - IM
MH  - Amnion/cytology/*transplantation
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Cell Shape/drug effects
MH  - Cells, Cultured
MH  - Cornea/*physiology
MH  - Endothelial Growth Factors/*pharmacology
MH  - Epithelial Cells/drug effects/metabolism
MH  - Fluorescein/metabolism
MH  - Leukocytes, Mononuclear/*cytology
MH  - Limbus Corneae/*physiology
MH  - Neovascularization, Physiologic/drug effects
MH  - Rabbits
MH  - Stem Cells/drug effects/*metabolism
OTO - NOTNLM
OT  - *amniotic membrane sheets
OT  - *anti-VEGF
OT  - *limbal stem cell deficiency
OT  - *peripheral blood mononuclear cell
OT  - *transplantation
EDAT- 2020/10/07 06:00
MHDA- 2021/10/02 06:00
CRDT- 2020/10/06 05:23
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
PHST- 2020/10/06 05:23 [entrez]
AID - 10.1089/ten.TEC.2020.0209 [doi]
PST - ppublish
SO  - Tissue Eng Part C Methods. 2020 Oct;26(10):541-552. doi:
      10.1089/ten.TEC.2020.0209.


PMID- 33019680
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 19
DP  - 2020 Oct 1
TI  - Developing a Family-Centered Care Model in the Neonatal Intensive Care Unit
      (NICU): A New Vision to Manage Healthcare.
LID - E7197 [pii]
LID - 10.3390/ijerph17197197 [doi]
AB  - Family-centered care (FCC) currently takes a greater role in health care, due to 
      the increasing empowerment parents experience. Within neonatal intensive care
      units (NICUs), family participation has an impact on the humanized care of the
      preterm newborn (PN). This integrative review conducted according to Whittemore
      and Knafl investigated current knowledge of the FCC model and its application in 
      PN care in specific units. The data were collected from PubMed, Cochrane, CINHAL,
      Scopus, and Google Scholar. A total of 46 articles were used, of which 13 were
      selected which met inclusion criteria. Their methodological quality was evaluated
      using the mixed method appraisal tool (MMAT), and after they were analyzed and
      grouped into four thematic blocks: (1) parental participation; (2) health
      parental training; (3) benefits of family empowerment; and (4) humanized care.
      The results revealed that FCCs promote the integration of health equipment and
      family. In addition, parents become the primary caregivers. The benefits of the
      family-PN binomial enable an earlier hospital discharge. Humanized care involves 
      an ethical approach, improving health care. Changes are still needed by health
      managers to adapt health services to the needs of the family and PNs.
FAU - Gomez-Cantarino, Sagrario
AU  - Gomez-Cantarino S
AD  - Department of Nursing, Physical and Occupational Therapy University of
      Castilla-La Mancha, 45071 Campus Toledo, Spain.
FAU - Garcia-Valdivieso, Inmaculada
AU  - Garcia-Valdivieso I
AD  - Mostoles University Hospital (HMOS), Madrid Health Service (SERMAS), Mostoles,
      28935, Spain.
FAU - Moncunill-Martinez, Eva
AU  - Moncunill-Martinez E
AD  - Toledo Hospital Complex (CHT), Neonatal and Pediatric Oncology Unit, Castilla-La 
      Mancha Health Service (SESCAM), Theoretical collaborator University of
      Castilla-La Mancha, 45071 Campus Toledo, Spain.
FAU - Yanez-Araque, Benito
AU  - Yanez-Araque B
AD  - Department of Physical Activity and Sports Sciences, University of Castilla-La
      Mancha, 45071 Campus Toledo, Spain.
FAU - Ugarte Gurrutxaga, M Idoia
AU  - Ugarte Gurrutxaga MI
AD  - Department of Nursing, Physical and Occupational Therapy University of
      Castilla-La Mancha, 45071 Campus Toledo, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201001
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Aftercare
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Intensive Care Units, Neonatal
MH  - Male
MH  - Patient Discharge
MH  - *Patient-Centered Care
MH  - Prospective Studies
PMC - PMC7579288
OTO - NOTNLM
OT  - *child development
OT  - *critical care
OT  - *empowerment
OT  - *family
OT  - *infant
OT  - *newborn
COIS- The authors declare no conflict of interest. The funders had no role in the
      design of the study; in the collection, analyses, or interpretation of data; in
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/10/07 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/10/06 01:08
PHST- 2020/09/14 00:00 [received]
PHST- 2020/09/25 00:00 [revised]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/06 01:08 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - ijerph17197197 [pii]
AID - 10.3390/ijerph17197197 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Oct 1;17(19). pii: ijerph17197197. doi:
      10.3390/ijerph17197197.


PMID- 33019634
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201101
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Wildlife Farms, Stigma and Harm.
LID - E1783 [pii]
LID - 10.3390/ani10101783 [doi]
AB  - Wildlife farming, the commercial breeding and legal sale of non-domesticated
      species, is an increasingly prevalent, persistently controversial, and
      understudied conservation practice. The adoption or rejection of wildlife farms
      is a complex process that incorporates numerous ethical considerations:
      conservation, livelihoods, animal welfare, and cultural practices. This paper
      uses qualitative interview data with key informants (academics) to analyze (a)
      the harms and benefits of wildlife farms and (b) the factors that influence
      whether wildlife farms are stigmatized or accepted. In evaluations of wildlife
      farming's harms and benefits, respondents incorporated multiple considerations:
      animal welfare, environmental impacts, scale disparities between sustenance and
      commercial farms, consumer preferences, species differences, the substitutability
      and accessibility of wildlife products, and governance. The results further
      indicated that the stigmatization or acceptance of wildlife farms is affected by 
      the "wildlife farm" label, if there is a stigma around use of a species, a form
      of production, or the perceived quality of a wildlife product, cultural
      differences in wildlife use, wildlife consumer typology, geopolitical factors,
      and demand reduction efforts. This paper analyzes the complexities of wildlife
      farming such that stakeholders can understand the impacts of this practice on
      species, human communities, individual animals, and the legal and illegal
      wildlife trades.
FAU - Rizzolo, Jessica Bell
AU  - Rizzolo JB
AUID- ORCID: 0000-0002-0941-6956
AD  - Department of Fisheries and Wildlife, Michigan State University, East Lansing, MI
      48824, USA.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7601737
OTO - NOTNLM
OT  - animal welfare
OT  - conservation
OT  - ethics
OT  - stigma
OT  - wildlife farming
OT  - wildlife trade
EDAT- 2020/10/07 06:00
MHDA- 2020/10/07 06:01
CRDT- 2020/10/06 01:07
PHST- 2020/08/25 00:00 [received]
PHST- 2020/09/24 00:00 [revised]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/07 06:01 [medline]
AID - ani10101783 [pii]
AID - 10.3390/ani10101783 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Oct 1;10(10). pii: ani10101783. doi: 10.3390/ani10101783.


PMID- 33019465
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - TCM nonpharmacological interventions for chronic low-back pain: A protocol for
      systematic review and network meta-analysis.
PG  - e22547
LID - 10.1097/MD.0000000000022547 [doi]
AB  - BACKGROUND: chronic low back pain (CLBP) are common symptoms bothering people in 
      daily life. Traditional Chinese medicine (TCM) nonpharmacological interventions
      are gaining an increasing popularity for CLBP. Nevertheless, the evidence of
      efficacy and safety of random controlled trials (RCTs) remains controversial.
      This study aims to evaluate the efficacy and acceptability of different TCM
      nonpharmacological therapies by systematic review and network meta-analysis.
      METHODS: According to the strategy, The authors will retrieve a total of 7
      electronic databases by September 2020, including PubMed, the Cochrane Library,
      EMbase, China National Knowledge Infrastructure, China Biological Medicine,
      Chongqing VIP, and Wan-fang databases After a series of screening, 2 researchers 
      will use Aggregate Data Drug Information System and Stata software to analyze the
      data extracted from the randomized controlled trials of TCM nonpharmacological
      interventions for CLBP. The primary outcome will be the improvement of Pain
      intensity and functional status/disability and the secondary outcomes will
      include lobal improvement, health-related quality of life, satisfaction with
      treatment, and adverse events. Both classical meta-analysis and network
      meta-analysis will be implemented to investigate direct and indirect evidences on
      this topic. The quality of the evidence will be evaluated using the Grading of
      Recommendations Assessment, Development and Evaluation instrument. RESULTS: This 
      study will provide a reliable evidence for the selection of TCM
      nonpharmacological therapies in the treatment of CLBP. CONCLUSION: This study
      will generate evidence for different TCM nonpharmacological therapies for CLBP
      and provide a decision-making reference for clinical research. ETHICS AND
      DISSEMINATION: This study does not require ethical approval. The results will be 
      disseminated through a peer-reviewed publication. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/4H3Y9.
FAU - Yu, Haiyang
AU  - Yu H
AD  - Clinical College of Chinese Medicine, Gansu University of Chinese Medicine.
AD  - Department of Orthopedics.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Department of Acupuncture and Moxibustion, Affiliated Hospital of Gansu
      University of Chinese Medicine, Lanzhou, Gansu Province.
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province, China.
FAU - Ma, Tao
AU  - Ma T
AD  - Clinical College of Chinese Medicine, Gansu University of Chinese Medicine.
FAU - Huang, Ailing
AU  - Huang A
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province, China.
FAU - Lu, Zengpeng
AU  - Lu Z
AD  - Clinical College of Chinese Medicine, Gansu University of Chinese Medicine.
AD  - Department of Orthopedics.
FAU - Zhang, Xiaogang
AU  - Zhang X
AUID- ORCID: 0000-0001-7573-2773
AD  - Clinical College of Chinese Medicine, Gansu University of Chinese Medicine.
AD  - Department of Orthopedics.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupressure/methods
MH  - Acupuncture Therapy/methods
MH  - Clinical Decision-Making
MH  - Cupping Therapy/methods
MH  - Databases, Factual
MH  - Humans
MH  - Low Back Pain/psychology/*therapy
MH  - Medicine, Chinese Traditional/adverse effects/*methods/trends
MH  - Moxibustion/methods
MH  - *Network Meta-Analysis
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Tai Ji/methods
MH  - Treatment Outcome
PMC - PMC7535630
EDAT- 2020/10/07 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022547 [doi]
AID - 00005792-202010020-00087 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22547. doi: 10.1097/MD.0000000000022547.


PMID- 33019433
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - Huang Lian for ulcerative colitis: A protocol of systematic review and
      meta-analysis of randomized clinical trials.
PG  - e22457
LID - 10.1097/MD.0000000000022457 [doi]
AB  - INTRODUCTION: Ulcerative Colitis is a chronic nonspecific inflammatory disease of
      the colon and rectum, which is of global concern. It has the characteristics of a
      long course of disease and repeated attacks, which seriously affects the quality 
      of life and economic and social development of the affected population. The
      treatment of UC by herb Huanglian and compound prescription contain Huanglian
      have been proved. However, due to the lack of evidence, there is no specific
      method or suggestion, it is necessary to systematically evaluate coptidis so as
      to provide effective evidence for further research. METHODS AND ANALYSIS: The
      following databases will be searched from their inception to June 2020:
      Electronic databases included PubMed, Embase, Cochrane Library, Web of Science,
      Nature, Science Online, WanFang China Biomedical Database, VIP Medical
      Information, CNKI (Knowledge Infrastructure of China). MAIN OUTCOMES:
      Colonoscopy, improved condition (tenesmus), stool routine. Additional outcomes:
      Electrocardiogram (ECG), erythrocyte (RBC), leukocyte (WBC), platelet (PLT). Data
      will be extracted by 2 researchers independently, risk of bias of the
      meta-analysis will be evaluated based on the Cochrane Handbook for Systematic
      Reviews of Interventions. All data analysis will be conducted by data statistics 
      software Review Manager V.5.3. and Stata V.12.0. RESULTS: The results of this
      study will systematically evaluate the efficacy and safety of rhizoma coptidis
      intervention in patients with Ulcerative Colitis. CONCLUSION: Through the
      systematic review of this study, the published evidence of rhizoma coptidis on
      the treatment of UC is summarized so as to further guide its promotion and
      application. ETHICS AND COMMUNICATION: This study is a systematic review, the
      outcomes are based on the published evidence, so examination and agreement by the
      ethics committee are not required in this study. We intend to publish the study
      results in a journal or conference presentations. OPEN SCIENCE FRA MEWORK (OSF)
      REGISTRATION NUMBER: August 27, 2020. osf.io/7nh3k (https://osf.io/7nh3k).
FAU - Li, Tinglin
AU  - Li T
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Wu, Mengzhu
AU  - Wu M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Song, Xiaohan
AU  - Song X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Feng, Peimin
AU  - Feng P
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (huanglian)
SB  - IM
MH  - Colitis, Ulcerative/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7535549
EDAT- 2020/10/07 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022457 [doi]
AID - 00005792-202010020-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22457. doi: 10.1097/MD.0000000000022457.


PMID- 33019416
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - Chinese herbal compound prescription for systemic lupus erythematosus: A protocol
      for systematic review and meta-analysis.
PG  - e22404
LID - 10.1097/MD.0000000000022404 [doi]
AB  - BACKGROUND: Systemic lupus erythematosus (SLE), known as lupus, is a chronic
      autoimmune disease and there is no cure for SLE. The western medication can
      improve syndromes to some extent; however, severe adverse drug reactions appear
      at the same time. Recently, it is confirmed that Chinese medicine also can have
      an excellent clinical efficacy on SLE. METHODS AND ANALYSIS: The following
      databases will be searched for relevant information before July 2020: PubMed,
      Embase, Cochrane Library, Web of Science, and China National Knowledge
      Infrastructure. MAJOR RESULTS: levels of total remission rate, SLEDAI. Secondary 
      results: The laboratory index about C3 levels, Hb levels, white blood cell
      levels, and adverse event. Data will be collected independently by 2 researchers,
      and the risk of bias in meta analysis will be evaluated according to "Cochrane
      Handbook for Systematic Reviews of Interventions." All data analysis will be
      conducted using Review Manager V.5.3. and Stata V.12.0. RESULTS: The curative
      effect and safety of Chinese herbal compound prescription treatment for SLE
      patients will be evaluated systematically. CONCLUSION: The systematic review of
      this study will summarize the currently published evidence of Chinese herbal
      compound prescription treatment for SLE to further guide its promotion and
      application. ETHICS AND DISSEMINATION: The private information from individuals
      will not be published. This systematic review also will not involve endangering
      participant rights. Ethical approval is not required. The results may be
      published in a peer-reviewed journal or disseminated in relevant conferences.
      OPEN SCIENCE FRAMEWORK (OSF)REGISTRATION NUMBER:: https://osf.io/wvfrx/.
FAU - Luo, Yehao
AU  - Luo Y
AD  - The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning,
      Guangxi Province.
FAU - Xu, Donghan
AU  - Xu D
AD  - Macau University of Science and Technology, Macau.
FAU - Fu, Yulei
AU  - Fu Y
AD  - Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi Province,
      China.
FAU - Tang, Xiusong
AU  - Tang X
AD  - Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi Province,
      China.
FAU - Chen, Zhenfeng
AU  - Chen Z
AD  - Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi Province,
      China.
FAU - Huang, An
AU  - Huang A
AD  - Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi Province,
      China.
FAU - Pang, Yuzhou
AU  - Pang Y
AD  - Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi Province,
      China.
FAU - Zhang, Yunyan
AU  - Zhang Y
AD  - The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning,
      Guangxi Province.
FAU - Li, Renfeng
AU  - Li R
AUID- ORCID: 0000-0001-5893-1463
AD  - The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning,
      Guangxi Province.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Hemoglobins)
SB  - IM
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Leukocyte Count
MH  - Lupus Erythematosus, Systemic/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Remission Induction
MH  - Research Design
PMC - PMC7535673
EDAT- 2020/10/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MD.0000000000022404 [doi]
AID - 00005792-202010020-00038 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22404. doi: 10.1097/MD.0000000000022404.


PMID- 33019413
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - Effect of large dosage of Fuling on urinary protein of diabetic nephropathy: A
      protocol of systematic review and meta-analysis of randomized clinical trials.
PG  - e22377
LID - 10.1097/MD.0000000000022377 [doi]
AB  - INTRODUCTION: Diabetic nephropathy (DN) is one of the most common and serious
      microvascular complications in patients with diabetes, which seriously affects
      their life quality and survival time. large dose herb Fuling or compound
      prescription contain large dose Fuling for treatment of DN has already been
      confirmed. However, due to the lack of evidence, there is no specific method or
      suggestion, so it is necessary to carry out systematic evaluation on Fuling and
      provide effective evidence for further research. METHODS AND ANALYSIS: The
      following databases will be searched from their inception to June 2020:
      Electronic database includes PubMed, Embase, Cochrane Library, Web of Science,
      Nature, Science online, Chinese Biomedical Database WangFang, VIP medicine
      information, and China National Knowledge Infrastructure (CNKI). Primary
      outcomes:24-hurinary-albumin, Urinary albumin-to-creatinine ratio. Additional
      outcomes: Serum creatinine, Blood urea nitrogen, Glomerular filtration rate,
      Endogenous creatinine clearance rate. Data will be extracted by 2 researchers
      independently, risk of bias of the meta-analysis will be evaluated based on the
      Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will
      be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. 
      RESULTS: The results of this study will systematically evaluate the effectiveness
      and safety of large dose Fuling intervention for people with DN. CONCLUSION: The 
      systematic review of this study will summarize the current published evidence of 
      large dose Fuling for the treatment of DN, which can further guide the promotion 
      and application of it. ETHICS AND DISSEMINATION: This study is a systematic
      review, the outcomes are based on the published evidence, so examination and
      agreement by the ethics committee are not required in this study. We intend to
      publish the study results in a journal or conference presentations. OPEN SCIENCE 
      FRAMEWORK (OSF) REGISTRATION NUMBER: August 24, 2020. osf.io/ym2c6.
      (https://osf.io/ym2c6).
FAU - Xia, Jia
AU  - Xia J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhang, Xinxia
AU  - Zhang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Yang, Botong
AU  - Yang B
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Chen, Qi
AU  - Chen Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhong, Min
AU  - Zhong M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Tang, Xiaoming
AU  - Tang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Albuminuria/metabolism
MH  - Creatinine/blood/urine
MH  - Diabetic Nephropathies/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Wolfiporia
PMC - PMC7535777
EDAT- 2020/10/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MD.0000000000022377 [doi]
AID - 00005792-202010020-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22377. doi: 10.1097/MD.0000000000022377.


PMID- 33019407
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - Erchen decoction combined with Sanziyangqin decoction for chronic obstructive
      pulmonary disease: A protocol for systematic review and meta-analysis.
PG  - e22315
LID - 10.1097/MD.0000000000022315 [doi]
AB  - INTRODUCTION: chronic obstructive pulmonary disease (COPD) is 1 of the leading
      causes of morbidity and mortality worldwide; its economic and social burdens are 
      substantial and increasing. Recent years, an increasing number of study has shown
      the promising advantage of Erchen decoction (ECD) combined with sanziyangqin
      decoction (SZYQD) in treating COPD. However, due to the lack of evidence, there
      is no specific method or suggestion, so it is necessary to provide a protocol for
      a systematic review on ECD combined with SZYQD for COPD and provide effective
      evidence for further clinical use. METHODS AND ANALYSIS: We will conduct a
      Computerized literature searches in the following databases: PubMed, MEDLINE,
      EMBASE, Cochrane Library, China national information network, China biomedical
      literature database (CBM), Chinese Scientific Journals Database and wanfang
      database, from their inception to June 2020, without restrictions of language.
      Study selection, data collection, and evaluation of the quality of evidence will 
      be performed by 2 researchers independently, risk of bias of the meta-analysis
      will be evaluated based on the Cochrane Handbook for Systematic Reviews of
      Interventions. All data analysis will be conducted by data statistics software
      Review Manager V.5.3. and Stata V.12.0. RESULTS: This study will systematically
      evaluate the effectiveness and safety of ECD combined with SZYQD for COPD. The
      results will be published in a peer-reviewed journal. CONCLUSION: This study will
      provide evidence from the current published RCTs of whether ERD combined with
      SZYQD is an effective and safe intervention for COPD. ETHICS AND DISSEMINATION:
      This study is a systematic review, the outcomes are based on the published
      evidence. In this study, no individual data from participants will be involved,
      so ethics approval is not required. OPEN SCIENCE FRAMEWORK(OSF)REGISTRATION
      NUMBER: August 19, 2020; osf.io/zxm24.
FAU - Deng, Lu
AU  - Deng L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Xinyue
AU  - Zhang X
AD  - College of Health Preservation and Rehabilitation, Chengdu University of
      Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
FAU - Dong, Yan
AU  - Dong Y
AUID- ORCID: 0000-0003-1648-900
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Chen, Keling
AU  - Chen K
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zheng, Meiling
AU  - Zheng M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Yang, Zidanqing
AU  - Yang Z
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Tang, Hui
AU  - Tang H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Liao, Wenhao
AU  - Liao W
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Shi, Qunfeng
AU  - Shi Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Respiratory Function Tests
PMC - PMC7535615
EDAT- 2020/10/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MD.0000000000022315 [doi]
AID - 00005792-202010020-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22315. doi: 10.1097/MD.0000000000022315.


PMID- 33019402
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - Acupuncture for thyroid nodule treatment: A protocol of systematic review and
      meta-analysis of randomized clinical trials.
PG  - e22276
LID - 10.1097/MD.0000000000022276 [doi]
AB  - INTRODUCTION: Thyroid nodules are scattered lesions caused by abnormal local
      growth of thyroid cells. In recent years, their prevalence rate has been rising
      gradually, and the probability of cancerations has also been increasing
      gradually. Therefore, we must pay more attention to them and carry out early
      intervention. However, at present, most of the intervention measures for patients
      with thyroid nodules are mainly clinical observation and follow-up, and no clear 
      and effective drug intervention therapy has been proposed. The curative effect of
      acupuncture on thyroid nodules has been proved clinically. However, as there is
      no clear mechanism of action, no specific operation methods or Suggestions, it is
      necessary to make a systematic evaluation of acupuncture therapy, so as to lay a 
      foundation for further research in the future. METHODS AND ANALYSIS: The
      following databases will be searched from their inception to June 2020:
      Electronic database includes PubMed, Embase, Cochrane Library, Web of Science,
      Nature, Science online, Chinese Biomedical Database WanFang, VIP medicine
      information, and China National Knowledge Infrastructure (CNKI). Primary
      outcomes: Color ultrasound of thyroid and cervical lymph nodes, FT3, FT4, TSH,
      TGAB, TPOAB, insulin resistance index (HOMA-IR). Data will be extracted by 2
      researchers independently, risk of bias of the meta-analysis will be evaluated
      based on the Cochrane Handbook for Systematic Reviews of Interventions. All data 
      analysis will be conducted by data statistics software Review Manager V.5.3. and 
      Stata V.12.0. RESULTS: The results of this study will systematically evaluate the
      efficacy and safety of acupuncture therapy for patients with thyroid nodule.
      CONCLUSION: Through the systematic review of this study, the evidence of the
      treatment of thyroid nodule by acupuncture has been summarized so far, so as to
      provide guidance for further promoting the application of acupuncture therapy in 
      patients with thyroid nodule. ETHICS AND DISSEMINATION: This study is a
      systematic review, the outcomes are based on the published evidence, so
      examination and agreement by the ethics committee are not required in this study.
      We intend to publish the study results in a journal or conference presentations. 
      OPEN SCIENCE FRA NETWORK (OSF) REGISTRATION NUMBER: August 18, 2020.
      osf.io/uzck4. (https://osf.io/uzck4).
FAU - Chen, Qi
AU  - Chen Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhang, Xinxia
AU  - Zhang X
AUID- ORCID: 0000-0003-3124-6110
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Yang, Botong
AU  - Yang B
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Xia, Jia
AU  - Xia J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhong, Min
AU  - Zhong M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Tang, Xiaoming
AU  - Tang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/adverse effects/*methods
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Thyroid Function Tests
MH  - Thyroid Nodule/diagnostic imaging/*therapy
MH  - Ultrasonography, Doppler
PMC - PMC7535653
EDAT- 2020/10/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MD.0000000000022276 [doi]
AID - 00005792-202010020-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22276. doi: 10.1097/MD.0000000000022276.


PMID- 33019401
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - Multiple dietary fiber for gestational hyperinsulinism: A protocol of systematic 
      review and meta-analysis of randomized clinical trials.
PG  - e22266
LID - 10.1097/MD.0000000000022266 [doi]
AB  - INTRODUCTION: Gestational hyperinsulinism is a metabolic disease which is widely 
      concerned at home and abroad. It is a clinical consensus that the embryo
      implantation ability of patients with hyperinsulinemia is decreased and the
      abortion rate after implantation is high. The treatment of gestational
      hyperinsulinism with Multiple dietary fiber diets has been proven. However, due
      to the lack of evidence, there is no specific method or recommendation, it is
      necessary to carry out a systematic evaluation of Multiple dietary fiber diet, to
      provide effective evidence for further research. METHODS AND ANALYSIS: The
      following databases will be searched from their inception to August 2020:
      Electronic database includes PubMed, Embase, Cochrane Library, Web of Science,
      Nature, Science online, Chinese Biomedical Database WanFang, VIP medicine
      information, and CNKI. Primary outcomes: Fasting glucose, fasting insulin,
      homeostasis model assessment of insulin resistance, glycosylated hemoglobin.
      Additional outcomes: Low Density Lipoprotein (LDL), High Density Lipoprotein
      (HDL), triglycerides (TG), total serum cholesterol (TC). Data will be extracted
      by 2 researchers independently, risk of bias of the meta-analysis will be
      evaluated based on the Cochrane Handbook for Systematic Reviews (SR) of
      Interventions. All data analysis will be conducted by data statistics software
      Review Manager V.5.3. and Stata V.12.0. RESULTS: The results of this study will
      systematically evaluate the effectiveness and safety of Multiple dietary fiber
      diet interventions in the treatment of gestational hyperinsulinism. CONCLUSION:
      The SR of this study will summarize the current published evidence of Multiple
      dietary fiber for the treatment of gestational hyperinsulinism, which can further
      guide the promotion and application of it. ETHICS AND DISSEMINATION: This study
      is a SR, the outcomes are based on the published evidence, so examination and
      agreement by the ethics committee are not required in this study. We intend to
      publish the study results in a journal or conference presentations. OPEN SCIENCE 
      FRA NETWORK (OSF) REGISTRATION NUMBER: August 19, 2020. osf.io/tbc7z.
      (https://osf.io/tbc7z).
FAU - Yang, Botong
AU  - Yang B
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Wu, Mengzhu
AU  - Wu M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhang, Xinxia
AU  - Zhang X
AUID- ORCID: 0000-0003-3124-6110
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Xia, Jia
AU  - Xia J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Chen, Q I
AU  - Chen QI
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhong, Min
AU  - Zhong M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Tang, Xiaoming
AU  - Tang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Dietary Fiber)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Lipids)
SB  - IM
MH  - Blood Glucose/physiology
MH  - Dietary Fiber/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Hyperinsulinism/*diet therapy
MH  - Insulin Resistance/physiology
MH  - Lipids/blood
MH  - Pregnancy
MH  - Pregnancy Complications/*diet therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7535687
EDAT- 2020/10/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MD.0000000000022266 [doi]
AID - 00005792-202010020-00023 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e22266. doi: 10.1097/MD.0000000000022266.


PMID- 33019384
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 40
DP  - 2020 Oct 2
TI  - The effectiveness of different teaching methods on medical or nursing students:
      Protocol for a systematic review and network meta-analysis.
PG  - e21668
LID - 10.1097/MD.0000000000021668 [doi]
AB  - BACKGROUND: One of the major challenges in nursing and medical education is to
      foster the critical thinking ability and autonomous learning ability for
      students. But the effect of different teaching methods on these abilities of
      nursing or medical students has not been conclusive, and few studies have
      directly compared the differences in the effects of different teaching methods.
      As a result, it is necessary for students to evaluate the impact of different
      teaching methods on critical thinking ability and autonomous learning ability.
      METHODS: A systematic search will be performed using Chinese National Knowledge
      Infrastructure, Wanfang Data (Chinese database), VIP Information (Chinese
      database), Chinese Biomedical Literature, and English language databases,
      including PubMed and Embase, Web of Science, CINAHL Complete (EBSCO0, Cochrane
      library to identify relevant studies from inception to July 10, 2020. We will
      include random controlled trials that evaluated the different teaching methods.
      The Quality Assessment of Diagnostic Accuracy Studies 2 quality assessment tool
      will be used to assess the risk of bias in each study. Standard pairwise
      meta-analysis and network meta-analysis will be performed using STATA V.12.0,
      MetaDiSc 1.40, and R 3.4.1 software to compare the diagnostic efficacy of
      different hormonal biomarkers. RESULTS: The results of this study will be
      published in a peer-reviewed journal. CONCLUSION: This study will summarize the
      direct and indirect evidence to determine the effectiveness of different teaching
      methods for medical or nursing students and attempt to find the most effective
      teaching method. ETHICS AND DISSEMINATION: Ethics approval and patient consent
      are not required, because this study is a meta-analysis based on published
      studies. INPLASY REGISTRATION NUMBER: INPLASY202070017.
FAU - Yun, Bei
AU  - Yun B
AD  - School of nursing, Lanzhou University.
FAU - Su, Qian
AU  - Su Q
AD  - Department of nursing, Gansu Provincial Hospital, China.
FAU - Cai, Yi-Tong
AU  - Cai YT
AD  - School of nursing, Lanzhou University.
FAU - Chen, Lian
AU  - Chen L
AD  - School of nursing, Lanzhou University.
FAU - Qu, Chao-Ran
AU  - Qu CR
AD  - School of nursing, Lanzhou University.
FAU - Han, Lin
AU  - Han L
AUID- ORCID: 0000-0001-7821-5253
AD  - School of nursing, Lanzhou University.
AD  - Department of nursing, Gansu Provincial Hospital, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Curriculum
MH  - Education, Medical/*methods/standards
MH  - Education, Nursing/*methods/standards
MH  - Humans
MH  - Network Meta-Analysis
MH  - Problem-Based Learning/methods
MH  - Systematic Reviews as Topic
MH  - Thinking
PMC - PMC7535560
EDAT- 2020/10/07 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/06 01:07
PHST- 2020/10/06 01:07 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000021668 [doi]
AID - 00005792-202010020-00006 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 2;99(40):e21668. doi: 10.1097/MD.0000000000021668.


PMID- 33019133
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 2694-0604 (Electronic)
IS  - 2375-7477 (Linking)
VI  - 2020
DP  - 2020 Jul
TI  - Evaluation of the Pulse wave in the face for the patients with rotary blood pump 
      (RP) in the Outpatient clinic.
PG  - 5097-6100
LID - 10.1109/EMBC44109.2020.9175425 [doi]
AB  - Rotary blood pump (RP) is one of the most important devices in the treatment of
      profound heart failure and is known to reduce the pulse in the blood pressure
      waveform, especially when it is used for axial flow. In an outpatient clinic,
      checking the pulse of a patient implanted with an RP can help diagnose the
      patient's condition. For that purpose, animal experiments with healthy adult
      goats implanted with the EVAHEART system were carried out after obtaining ethical
      committee approval. Visual imaging of the goats' faces was recorded using a video
      camera. The pulse waves were clearly recorded using the newly developed pulse
      diagnosis system with video imaging and compared with laser Doppler flowmeter and
      time series data. Spectral analysis of the time series data showed the usefulness
      of video imaging from outside the body. Clinical applications are planned, and
      this newly developed method is expected to be a useful diagnostic method for
      evaluating the cardiac function in patients implanted with RPs in the future.
FAU - Yambe, Tomoyuki
AU  - Yambe T
FAU - Yoshizawa, Makoto
AU  - Yoshizawa M
FAU - Shiraishi, Yasuyuki
AU  - Shiraishi Y
FAU - Inoue, Yusuke
AU  - Inoue Y
FAU - Yamada, Akihiro
AU  - Yamada A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Annu Int Conf IEEE Eng Med Biol Soc
JT  - Annual International Conference of the IEEE Engineering in Medicine and Biology
      Society. IEEE Engineering in Medicine and Biology Society. Annual International
      Conference
JID - 101763872
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Animals
MH  - Blood Pressure
MH  - Heart Rate
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Pulsatile Flow
EDAT- 2020/10/07 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/10/06 01:06
PHST- 2020/10/06 01:06 [entrez]
PHST- 2020/10/07 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.1109/EMBC44109.2020.9175425 [doi]
PST - ppublish
SO  - Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:5097-6100. doi:
      10.1109/EMBC44109.2020.9175425.


PMID- 33017433
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 10
DP  - 2020
TI  - Chronic inflammation was a major predictor and determinant factor of anemia in
      lactating women in Sidama zone southern Ethiopia: A cross-sectional study.
PG  - e0240254
LID - 10.1371/journal.pone.0240254 [doi]
AB  - Anemia in women of reproductive age is highly prevalent globally and remains a
      public health problem. In Ethiopia, despite efforts to minimize the burden of
      anemia, it is still a moderate public health problem. Anemia has various
      etiologies including nutritional deficiency, parasitic infection, and
      inflammation. The aim of this study was to examine contributing factors to anemia
      in lactating women. Following ethical approval, and six months after delivery,
      all lactating women (n = 150) were recruited to participate in this study from
      eight randomly selected rural villages. Anthropometric and socio-economic factors
      were assessed. From each, a blood sample was collected for measuring hemoglobin, 
      iron biomarkers, zinc, selenium, and inflammation markers. The median (IQR)
      hemoglobin (Hb) was 132 (123, 139) g/L. Of the women, 19% were anemic and 7% had 
      iron deficiency anemia; 31% were iron deficient and 2% had iron overload. Also,
      8% had functional iron deficit, 6% had acute inflammation, 13% had chronic
      inflammation, and 16% had tissue iron deficiency. The majority (78%) of the women
      had low plasma zinc out of which more than 16% were anemic. Hb was positively
      associated with plasma iron and plasma zinc and negatively associated with
      transferrin receptor (TfR) and alpha-1-acid glycoprotein (AGP). Plasma iron, AGP,
      TfR, hepcidin and plasma zinc were significant predictors of maternal anemia.
      Additionally MUAC and level of education were associated positively with maternal
      hemoglobin. This study showed that maternal anemia was associated with multiple
      factors including nutritional deficiencies, inflammation and limited education.
FAU - Gebreegziabher, Tafere
AU  - Gebreegziabher T
AUID- ORCID: 0000-0001-7666-1110
AD  - Department of Health Sciences, Central Washington University, Ellensburg, WA,
      United States of America.
FAU - Roice, Taylor
AU  - Roice T
AD  - Department of Health Sciences, Central Washington University, Ellensburg, WA,
      United States of America.
FAU - Stoecker, Barbara J
AU  - Stoecker BJ
AD  - Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK,
      United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201005
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Hemoglobins)
RN  - 0 (Receptors, Transferrin)
SB  - IM
MH  - Adult
MH  - Anemia/*epidemiology/*immunology
MH  - Anemia, Iron-Deficiency/genetics
MH  - Anthropometry
MH  - Biomarkers/blood
MH  - Cross-Sectional Studies
MH  - Ethiopia/epidemiology
MH  - Female
MH  - Hemoglobins/genetics
MH  - Humans
MH  - Inflammation/*epidemiology/*immunology
MH  - Lactation
MH  - Receptors, Transferrin/genetics
MH  - Young Adult
PMC - PMC7535025
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/05 17:09
PHST- 2020/06/26 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/05 17:09 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1371/journal.pone.0240254 [doi]
AID - PONE-D-20-19809 [pii]
PST - epublish
SO  - PLoS One. 2020 Oct 5;15(10):e0240254. doi: 10.1371/journal.pone.0240254.
      eCollection 2020.


PMID- 33017375
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1932-8095 (Electronic)
IS  - 1932-8087 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Nov/Dec
TI  - Shared Decision-Making: Grounded in Case Management Ethics.
PG  - 358-360
LID - 10.1097/NCM.0000000000000471 [doi]
FAU - Campagna, Vivian
AU  - Campagna V
AD  - Vivian Campagna, MSN, RN-BC, CCM, is the chief industry relations officer for the
      Commission for Case Manager Certification, the first and largest nationally
      accredited organization that certifies more than 48,000 professional case
      managers and nearly 2,300 disability management specialists. Vivian has been
      involved in case management for more than 25 years and has been a volunteer for
      the Commission in various capacities, including as Chair, before joining in a
      staff role.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prof Case Manag
JT  - Professional case management
JID - 101291585
MH  - *Case Management
MH  - Decision Making
MH  - *Decision Making, Shared
EDAT- 2020/10/06 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/10/05 17:09
PHST- 2020/10/05 17:09 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 10.1097/NCM.0000000000000471 [doi]
AID - 01269241-202011000-00011 [pii]
PST - ppublish
SO  - Prof Case Manag. 2020 Nov/Dec;25(6):358-360. doi: 10.1097/NCM.0000000000000471.


PMID- 33017359
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 32
IP  - 10
DP  - 2020 Oct
TI  - Staying alert to ethical challenges.
PG  - 642-644
LID - 10.1097/JXX.0000000000000512 [doi]
AB  - Please replace the abstract with: Nurse practitioners (NPs) are faced with many
      ethical challenges. It requires moral courage to stand up for ones' beliefs and
      resolve ethical issues. Ethical challenges of NPs are discussed including some
      specific disciplinary situations involving a state board of nursing. Solutions
      that may help NPs stay alert to ethical challenges include ethics courses and
      lifelong mentoring. In this "Year of the Nurse and Midwife," NPs and other nurses
      should ensure that we maintain the designation of most trusted profession.
FAU - Winland-Brown, Jill E
AU  - Winland-Brown JE
AD  - Christine E. Lynn College of Nursing, Florida Atlantic University, Boca Raton,
      Florida.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
MH  - *Ethics, Nursing
MH  - Humans
MH  - Nurse Practitioners/ethics/*psychology/standards
EDAT- 2020/10/06 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/10/05 17:09
PHST- 2020/10/05 17:09 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
AID - 10.1097/JXX.0000000000000512 [doi]
AID - 01741002-202010000-00002 [pii]
PST - ppublish
SO  - J Am Assoc Nurse Pract. 2020 Oct;32(10):642-644. doi:
      10.1097/JXX.0000000000000512.


PMID- 33016834
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Molecular HIV Surveillance and Public Health Ethics: Old Wine in New Bottles.
PG  - 39-41
LID - 10.1080/15265161.2020.1806393 [doi]
FAU - Dawson, Liza
AU  - Dawson L
AD  - Walter Reed Army Institute of Research.
FAU - Latham, Stephen R
AU  - Latham SR
AD  - Yale Interdisciplinary Center for Bioethics.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):10-23. PMID: 32945756
MH  - *HIV Infections
MH  - Humans
MH  - Public Health
MH  - *Social Justice
EDAT- 2020/10/06 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/10/05 12:08
PHST- 2020/10/05 12:08 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1080/15265161.2020.1806393 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):39-41. doi: 10.1080/15265161.2020.1806393.


PMID- 33016832
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Adding a Voice to the Unique Ethical Considerations in Molecular HIV
      Surveillance.
PG  - 34-36
LID - 10.1080/15265161.2020.1806399 [doi]
FAU - Mutenherwa, Farirai
AU  - Mutenherwa F
AUID- ORCID: 0000-0001-7443-7676
AD  - University of KwaZulu-Natal.
AD  - KwaZulu-Natal Research Innovation and Sequencing Platform.
FAU - Wassenaar, Douglas
AU  - Wassenaar D
AUID- ORCID: 0000-0003-0839-9231
AD  - University of KwaZulu-Natal.
AD  - South African Research Ethics Training Initiative, University of KwaZulu-Natal.
FAU - de Oliveira, Tulio
AU  - de Oliveira T
AUID- ORCID: 0000-0002-3027-5254
AD  - University of KwaZulu-Natal.
AD  - KwaZulu-Natal Research Innovation and Sequencing Platform.
AD  - University of Washington.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):10-23. PMID: 32945756
MH  - *HIV Infections
MH  - Humans
MH  - Informed Consent
MH  - Morals
MH  - *Social Justice
EDAT- 2020/10/06 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/10/05 12:08
PHST- 2020/10/05 12:08 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1080/15265161.2020.1806399 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):34-36. doi: 10.1080/15265161.2020.1806399.


PMID- 33016830
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20210110
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Furthering Discussion of Ethical Implementation of HIV Cluster Detection and
      Response.
PG  - 24-26
LID - 10.1080/15265161.2020.1806398 [doi]
FAU - Watson, Meg
AU  - Watson M
AUID- ORCID: 0000-0003-3343-6794
AD  - Centers for Disease Control and Prevention.
FAU - Sweeney, Patricia
AU  - Sweeney P
AD  - Centers for Disease Control and Prevention.
LA  - eng
GR  - CC999999/ImCDC/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):10-23. PMID: 32945756
MH  - *HIV Infections
MH  - Humans
MH  - Morals
MH  - *Social Justice
PMC - PMC7543986
MID - NIHMS1634228
EDAT- 2020/10/06 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/10/05 12:08
PHST- 2020/10/05 12:08 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1080/15265161.2020.1806398 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):24-26. doi: 10.1080/15265161.2020.1806398.


PMID- 33016826
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - An Ethics for Public Health Surveillance.
PG  - 61-63
LID - 10.1080/15265161.2020.1806382 [doi]
FAU - Lee, Lisa M
AU  - Lee LM
AD  - Virginia Tech.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):50-60. PMID: 32945754
MH  - Health Surveys
MH  - Humans
MH  - *Public Health Surveillance
MH  - Students
MH  - *Suicide
EDAT- 2020/10/06 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/10/05 12:08
PHST- 2020/10/05 12:08 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1080/15265161.2020.1806382 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):61-63. doi: 10.1080/15265161.2020.1806382.


PMID- 33016822
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Ethical Convergence and Ethical Possibilities: The Implications of New
      Materialism for Understanding the Molecular Turn in HIV, the Response to
      COVID-19, and the Future of Bioethics.
PG  - 26-29
LID - 10.1080/15265161.2020.1806400 [doi]
FAU - Guta, Adrian
AU  - Guta A
AD  - University of Windsor.
FAU - Gagnon, Marilou
AU  - Gagnon M
AD  - University of Victoria.
FAU - Philbin, Morgan M
AU  - Philbin MM
AD  - Columbia University.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):10-23. PMID: 32945756
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *HIV Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Social Justice
EDAT- 2020/10/06 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/10/05 12:08
PHST- 2020/10/05 12:08 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1080/15265161.2020.1806400 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):26-29. doi: 10.1080/15265161.2020.1806400.


PMID- 33016664
OWN - NLM
STAT- Publisher
LR  - 20201005
IS  - 2046-2344 (Electronic)
IS  - 2046-2336 (Linking)
DP  - 2020 Oct 5
TI  - Biological basis of child health 7: growth, development and the reproductive
      system.
LID - 10.7748/ncyp.2020.e1308 [doi]
AB  - This article is the seventh in a series on the biological basis of child health. 
      It describes early developmental milestones, stages of growth, puberty and the
      development of the reproductive system. It also outlines the methods used to
      assess growth and development, and describes conditions that affect growth and
      development in infants, children and young people. Understanding childhood growth
      and development is crucial for children's nurses, who need to be able to identify
      potential deviations from the norm, since these often reveal underlying
      conditions that require treatment.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Davies, Kate
AU  - Davies K
AD  - London South Bank University and honorary research fellow in paediatric
      endocrinology, Barts and The London School of Medicine and Dentistry, Queen Mary 
      University of London, London, England.
LA  - eng
PT  - Journal Article
DEP - 20201005
PL  - England
TA  - Nurs Child Young People
JT  - Nursing children and young people
JID - 101554473
OTO - NOTNLM
OT  - adolescents
OT  - child development
OT  - child health
OT  - clinical
OT  - ethical issues
OT  - failure to thrive
OT  - genetic disorders
OT  - genetics
OT  - infants
OT  - neonatal
OT  - professional
COIS- None declared
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/10/05 08:45
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/10/05 08:45 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.7748/ncyp.2020.e1308 [doi]
AID - e1308 [pii]
PST - aheadofprint
SO  - Nurs Child Young People. 2020 Oct 5. pii: e1308. doi: 10.7748/ncyp.2020.e1308.


PMID- 33016311
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 2049-632X (Electronic)
IS  - 2049-632X (Linking)
VI  - 78
IP  - 8
DP  - 2020 Nov 11
TI  - UtilisingGalleria mellonella larvae for studying in vivo activity of conventional
      and novel antimicrobial agents.
LID - ftaa059 [pii]
LID - 10.1093/femspd/ftaa059 [doi]
AB  - The immune response of insects displays many structural and functional
      similarities to the innate immune response of mammals. As a result of these
      conserved features, insects may be used for evaluating microbial virulence or for
      testing the in vivo efficacy and toxicity of antimicrobial compounds and results 
      show strong similarities to those from mammals. Galleria mellonella larvae are
      widely used in this capacity and have the advantage of being easy to use,
      inexpensive to purchase and house, and being free from the ethical and legal
      restrictions that relate to the use of mammals in these tests. Galleria
      mellonella larvae may be used to assess the in vivo toxicity and efficacy of
      novel antimicrobial compounds. A wide range of antibacterial and antifungal
      therapies have been evaluated in G. mellonella larvae and results have informed
      subsequent experiments in mammals. While insect larvae are a convenient and
      reproducible model to use, care must be taken in their use to ensure accuracy of 
      results. The objective of this review is to provide a comprehensive account of
      the use of G. mellonella larvae for assessing the in vivo toxicity and efficacy
      of a wide range of antibacterial and antifungal agents.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.
FAU - Piatek, Magdalena
AU  - Piatek M
AD  - SSPC Pharma Research Centre, Department of Biology, Maynooth University, Co.
      Kildare W23 F2H6, Ireland.
FAU - Sheehan, Gerard
AU  - Sheehan G
AD  - Institute of Microbiology and Infection, University of Birmingham, Birmingham B15
      2TT, UK.
FAU - Kavanagh, Kevin
AU  - Kavanagh K
AD  - SSPC Pharma Research Centre, Department of Biology, Maynooth University, Co.
      Kildare W23 F2H6, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Pathog Dis
JT  - Pathogens and disease
JID - 101595366
RN  - 0 (Anti-Infective Agents)
SB  - IM
MH  - Animals
MH  - Anti-Infective Agents/*pharmacology
MH  - Bacteria/*drug effects
MH  - Disease Models, Animal
MH  - Fungi/*drug effects
MH  - Larva/microbiology
MH  - Moths/*microbiology
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - * Galleria
OT  - * in vivo testing
OT  - *antimicrobial
OT  - *bacterial
OT  - *fungal
OT  - *pathogen
EDAT- 2020/10/06 06:00
MHDA- 2021/08/25 06:00
CRDT- 2020/10/05 08:42
PHST- 2020/04/21 00:00 [received]
PHST- 2020/10/02 00:00 [accepted]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
PHST- 2020/10/05 08:42 [entrez]
AID - 5917982 [pii]
AID - 10.1093/femspd/ftaa059 [doi]
PST - ppublish
SO  - Pathog Dis. 2020 Nov 11;78(8). pii: 5917982. doi: 10.1093/femspd/ftaa059.


PMID- 33016096
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201110
IS  - 0310-057X (Print)
IS  - 0310-057X (Linking)
VI  - 48
IP  - 5
DP  - 2020 Sep
TI  - Efficacy of height-based formula to predict insertion depth of left-sided double 
      lumen tube: A prospective observational study.
PG  - 354-357
LID - 10.1177/0310057X20946051 [doi]
AB  - The insertion depth of the left-sided double-lumen tube needs careful positioning
      and bronchoscopic confirmation. Several formulae based on body height have been
      used for estimating the optimal insertion depth of a left-sided double-lumen
      tube. We conducted this prospective study to test the hypothesis that our earlier
      developed height-based formula (0.25 x body height(0.916)) could predict the
      accurate insertion depth of a left-sided double-lumen tube. After obtaining
      ethical approval, 66 patients who underwent thoracic surgery were included. A
      left-sided double-lumen tube was advanced blindly to the predicted depth of
      insertion calculated using our formula. The optimal position of the left-sided
      double-lumen tube was confirmed using a fibreoptic bronchoscope. The primary
      outcome was the percentage of tubes placed in the optimal position without the
      need for further adjustments. The secondary outcomes included the need for
      bronchoscopic adjustments and the final correct insertion depth of the left-sided
      double-lumen tube. The formula resulted in an optimum position of the left-sided 
      double-lumen tube without further adjustments in 45 patients (70%) (95%
      confidence interval 58%-80%). The left-sided double-lumen tube was withdrawn or
      advanced in 18.2% and 12.1%, respectively, to achieve the optimal insertion
      depth. We found that our formula provided satisfactory positioning in about 70%
      of patients and that in the remaining patients, the adjustments required to
      achieve satisfactory positioning under fibreoptic bronchoscope guidance were
      minimal. Nevertheless, as it is not possible to predict which patients will have 
      a satisfactory tube position, bronchoscopic confirmation for the final
      positioning is still required.
FAU - Eldawlatly, Abdelazeem A
AU  - Eldawlatly AA
AD  - Anaesthesia Department, College of Medicine, King Saud University, Riyadh, Saudi 
      Arabia.
FAU - El Tahan, Mohamed R
AU  - El Tahan MR
AUID- ORCID: 0000-0002-9730-6406
AD  - Department of Anaesthesia, College of Medicine, Imam Abdulrahman Bin Faisal
      University, Damman, Saudi Arabia.
FAU - Kanchi, Naveed U
AU  - Kanchi NU
AD  - Anaesthesia Department, King Saud University Medical City, Riyadh, Saudi Arabia.
FAU - Al Qatari, Ahmad
AU  - Al Qatari A
AD  - Anaesthesia Department, Prince Mohamed Ibn Abdulaziz Hospital, Riyadh, Saudi
      Arabia.
FAU - Ahmad, Abdulaziz E
AU  - Ahmad AE
AD  - Department of Anaesthesia, College of Medicine, Imam Abdulrahman Bin Faisal
      University, Damman, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201004
PL  - United States
TA  - Anaesth Intensive Care
JT  - Anaesthesia and intensive care
JID - 0342017
SB  - IM
MH  - Body Height
MH  - Bronchoscopy
MH  - Humans
MH  - *Intubation, Intratracheal
MH  - Prospective Studies
MH  - *Thoracic Surgical Procedures
EDAT- 2020/10/06 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/10/05 08:39
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/10/05 08:39 [entrez]
AID - 10.1177/0310057X20946051 [doi]
PST - ppublish
SO  - Anaesth Intensive Care. 2020 Sep;48(5):354-357. doi: 10.1177/0310057X20946051.
      Epub 2020 Oct 4.


PMID- 33015834
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 10
DP  - 2020 Nov
TI  - Outcomes for children after second liver transplantations are similar to those
      after first transplantations: a binational registry analysis.
PG  - 464-470
LID - 10.5694/mja2.50802 [doi]
AB  - OBJECTIVE: To assess long term graft and patient survival after donor liver
      retransplantation in children in Australia and New Zealand during 1986-2017; to
      determine the factors that influence survival. DESIGN: Retrospective cohort
      analysis (registry data). SETTING, PARTICIPANTS: Australia and New Zealand Liver 
      Transplant Registry data for all liver retransplantations in children (under 18
      years of age), 1986-2017, in all four paediatric and six adult liver
      transplantation centres in the two countries. MAIN OUTCOME MEASURES: Graft and
      patient survival at one, 5, 10 and 15 years. RESULTS: 142 liver
      retransplantations were undertaken in children (59 during 1986-2000, 83 during
      2001-2017). Kaplan-Meier survival analysis indicated that survival was
      significantly greater during 2001-2017 than 1986-2000 (P < 0.001). During
      2001-2017, graft survival one year after retransplantation was 84%, at 5 years
      75%, at 10 years 70%, and at 15 years 54%; patient survival was 89% at one year, 
      87% at 5 years, 87% at 10 years, and 71% at 15 years. Median time between
      transplantations was 0.2 years (IQR, 0.03-1.4 years) during 1986-2000, and 1.8
      years (IQR, 0.1-6.8 years) during 2001-2017 (P = 0.002). The proportion of graft 
      failures that involved split grafts was larger during 2001-2017 (35 of 83, 42%)
      than 1986-2000 (10 of 59, 17%). Graft type, cause of graft failure, and number of
      transplants did not influence survival following retransplantation. CONCLUSION:
      Survival for children following retransplantation is excellent. Graft survival is
      similar for split and whole grafts. Children on the liver waiting list requiring 
      retransplantation should have the same access to donor grafts as children
      requiring a first transplant.
CI  - (c) 2020 AMPCo Pty Ltd.
FAU - Jeffrey, Angus W
AU  - Jeffrey AW
AUID- ORCID: 0000-0002-9137-0204
AD  - Sir Charles Gairdner Hospital, Perth, WA.
FAU - Jeffrey, Gary P
AU  - Jeffrey GP
AD  - Sir Charles Gairdner Hospital, Perth, WA.
AD  - The University of Western Australia, Perth, WA.
FAU - Stormon, Michael
AU  - Stormon M
AD  - Australian National Liver Transplantation Service, Children's Hospital at
      Westmead, Sydney, NSW.
AD  - The University of Sydney, Sydney, NSW.
FAU - Thomas, Gordon
AU  - Thomas G
AD  - Australian National Liver Transplantation Service, Children's Hospital at
      Westmead, Sydney, NSW.
AD  - The University of Sydney, Sydney, NSW.
FAU - O'Loughlin, Edward
AU  - O'Loughlin E
AD  - Australian National Liver Transplantation Service, Children's Hospital at
      Westmead, Sydney, NSW.
AD  - The University of Sydney, Sydney, NSW.
FAU - Shun, Albert
AU  - Shun A
AD  - Australian National Liver Transplantation Service, Children's Hospital at
      Westmead, Sydney, NSW.
AD  - The University of Sydney, Sydney, NSW.
FAU - Hardikar, Winita
AU  - Hardikar W
AD  - Royal Children's Hospital, Melbourne, VIC.
FAU - Jones, Robert
AU  - Jones R
AD  - Victorian Liver Transplant Unit, Austin Hospital, Melbourne, VIC.
AD  - Victorian Liver Transplant Unit, Royal Children's Hospital, Melbourne, VIC.
FAU - McCall, John
AU  - McCall J
AD  - New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.
AD  - Starship Children's Health, Auckland, New Zealand.
FAU - Evans, Helen
AU  - Evans H
AD  - Starship Children's Health, Auckland, New Zealand.
FAU - Starkey, Graham
AU  - Starkey G
AD  - Victorian Liver Transplant Unit, Austin Hospital, Melbourne, VIC.
AD  - Victorian Liver Transplant Unit, Royal Children's Hospital, Melbourne, VIC.
FAU - Hodgkinson, Peter
AU  - Hodgkinson P
AD  - Queensland Liver Transplantation Service, Princess Alexandra Hospital, Brisbane, 
      QLD.
AD  - The University of Queensland, Brisbane, QLD.
FAU - Ee, Looi C
AU  - Ee LC
AD  - Lady Cilento Children's Hospital, Brisbane, QLD.
FAU - Moore, David
AU  - Moore D
AD  - Women's and Children's Hospital, Adelaide, SA.
FAU - Mews, Catherine
AU  - Mews C
AD  - Perth Children's Hospital, Perth, WA.
FAU - McCaughan, Geoff W
AU  - McCaughan GW
AD  - Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital,
      Sydney, NSW.
AD  - Sydney Medical School, , the University of Sydney, Sydney, NSW.
FAU - Angus, Peter W
AU  - Angus PW
AD  - Victorian Liver Transplant Unit, Austin Hospital, Melbourne, VIC.
AD  - Victorian Liver Transplant Unit, Royal Children's Hospital, Melbourne, VIC.
FAU - Wigg, Alan J
AU  - Wigg AJ
AD  - South Australian Liver Transplantation Service, Flinders Medical Centre,
      Adelaide, SA.
FAU - Crawford, Michael
AU  - Crawford M
AD  - The University of Sydney, Sydney, NSW.
AD  - Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital,
      Sydney, NSW.
FAU - Fawcett, Jonathan
AU  - Fawcett J
AD  - Queensland Liver Transplantation Service, Princess Alexandra Hospital, Brisbane, 
      QLD.
AD  - The University of Queensland, Brisbane, QLD.
LA  - eng
PT  - Journal Article
DEP - 20201004
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
CIN - Med J Aust. 2020 Nov;213(10):456-457. PMID: 33089493
MH  - Adult
MH  - Australia/epidemiology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Survival
MH  - Humans
MH  - Infant
MH  - Kaplan-Meier Estimate
MH  - Liver Transplantation/methods/*mortality
MH  - Male
MH  - New Zealand/epidemiology
MH  - Proportional Hazards Models
MH  - Registries
MH  - *Reoperation
MH  - Retrospective Studies
MH  - Tissue Donors
MH  - Treatment Outcome
MH  - Waiting Lists
OTO - NOTNLM
OT  - *Ethics
OT  - *Liver diseases
OT  - *Liver transplantation
OT  - *Tissue and organ procurement
EDAT- 2020/10/06 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/10/05 06:25
PHST- 2020/03/16 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/10/05 06:25 [entrez]
AID - 10.5694/mja2.50802 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Nov;213(10):464-470. doi: 10.5694/mja2.50802. Epub 2020 Oct 4.


PMID- 33015540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Exploring the beliefs and experiences of older Irish adults and family carers
      during the novel coronavirus (COVID-19) pandemic: A qualitative study protocol.
PG  - 16
LID - 10.12688/hrbopenres.13031.1 [doi]
AB  - Background: In December 2019 a novel human coronavirus (COVID-19) was identified 
      in Wuhan, China (Wu et al, 2020). The virus subsequently spread to most countries
      worldwide and the World Health Organisation characterised the outbreak a pandemic
      on March 11 (th) 2020 (WHO, 2020a). Older age is associated with an increased
      risk of mortality in patients with COVID-19 (Chen et al., 2020). In March 2020,
      the Irish Government introduced 'cocooning' as a measure for those over 70 years 
      of age to minimise interactions with others by not leaving their homes (Dept. of 
      Health, 2020). The COVID-19 pandemic presents unique threats to the health and
      well-being of older adults. This study aims to explore the longitudinal
      experiences and beliefs of older adults during the COVID-19 pandemic. Findings
      will be important for tailoring supports, interventions and public health
      information for this population. Methods: A longitudinal exploratory qualitative 
      study will be conducted using repeated semi-structured telephone interviews with 
      a convenient sample of older adults recruited from participants of an older adult
      and family carer stakeholder panel for health services research established by
      the Ageing Research Centre (ARC) at the University of Limerick and through known 
      older adult contacts of ARC academic members. Interviews will be audio recorded, 
      transcribed and analysed using a reflexive approach to thematic analysis.
      Participants will have the opportunity to review and discuss preliminary analysis
      of the interview data and to co-write / design dissemination materials. Ethics
      and Dissemination: Ethical approval has been granted by the Faculty of Education 
      and Health Sciences University of Limerick, Research Ethics Committee
      (2020_03_51_EHS (ER)). Findings will be disseminated through open access journal 
      publications and distribution of lay summaries, a press release and an
      infographic to organisations of and for older people in Ireland, broadcast and
      print media.
CI  - Copyright: (c) 2020 Robinson K et al.
FAU - Robinson, Katie
AU  - Robinson K
AUID- ORCID: https://orcid.org/0000-0003-1008-9857
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
AD  - Ageing Research Centre, Health Research Institute, University of Limerick,
      Limerick, V94 T9PX, Ireland.
FAU - O'Neill, Aoife
AU  - O'Neill A
AUID- ORCID: https://orcid.org/0000-0002-8670-6738
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
AD  - Ageing Research Centre, Health Research Institute, University of Limerick,
      Limerick, V94 T9PX, Ireland.
FAU - Conneely, Mairead
AU  - Conneely M
AUID- ORCID: https://orcid.org/0000-0002-9233-2007
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
FAU - Morrissey, AnnMarie
AU  - Morrissey A
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
AD  - Ageing Research Centre, Health Research Institute, University of Limerick,
      Limerick, V94 T9PX, Ireland.
FAU - Leahy, Siobhan
AU  - Leahy S
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
AD  - Ageing Research Centre, Health Research Institute, University of Limerick,
      Limerick, V94 T9PX, Ireland.
FAU - Meskell, Pauline
AU  - Meskell P
AUID- ORCID: https://orcid.org/0000-0002-0218-5390
AD  - Ageing Research Centre, Health Research Institute, University of Limerick,
      Limerick, V94 T9PX, Ireland.
AD  - Department of Nursing and Midwifery, University of Limerick, Limerick, V94 T9PX, 
      Ireland.
FAU - Pettigrew, Judi
AU  - Pettigrew J
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
FAU - Galvin, Rose
AU  - Galvin R
AUID- ORCID: https://orcid.org/0000-0002-8171-224X
AD  - School of Allied Health, University of Limerick, Limerick, V94 T9PX, Ireland.
AD  - Ageing Research Centre, Health Research Institute, University of Limerick,
      Limerick, V94 T9PX, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7509595
OTO - NOTNLM
OT  - COVID-19
OT  - Older adults
OT  - Public and Patient Involvement
OT  - Qualitative Research
COIS- No competing interests were disclosed.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:23
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/10/05 06:23 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.12688/hrbopenres.13031.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Apr 20;3:16. doi: 10.12688/hrbopenres.13031.1. eCollection
      2020.


PMID- 33015366
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2382-1205 (Print)
IS  - 2382-1205 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Enhancing Mentoring in Palliative Care: An Evidence Based Mentoring Framework.
PG  - 2382120520957649
LID - 10.1177/2382120520957649 [doi]
AB  - BACKGROUND: Growing concerns over ethical issues in mentoring in medicine and
      surgery have hindered efforts to reinitiate mentoring for Palliative Care (PC)
      physicians following the easing of COVID-19 restrictions. Ranging from the
      misappropriation of mentee's work to bullying, ethical issues in mentoring are
      attributed to poor understanding and structuring of mentoring programs,
      underlining the need for a consistent approach to mentoring practices. METHODS:
      Given diverse practices across different settings and the employ of various
      methodologies, a novel approach to narrative reviews (NR)s is proposed to
      summarize, interpret, and critique prevailing data on novice mentoring. To
      overcome prevailing concerns surrounding the reproducibility and transparency of 
      narrative reviews, the Systematic Evidenced Based Approach (SEBA) adopts a
      structured approach to searching and summarizing the included articles and
      employed concurrent content and thematic analysis that was overseen by a team of 
      experts. RESULTS: A total of 18 915 abstracts were reviewed, 62 full text
      articles evaluated and 41 articles included. Ten themes/categories were
      ascertained identified including Nature; Stakeholders; Relationship; Approach;
      Environment; Benefits; Barriers; Assessments; Theories and Definitions.
      CONCLUSION: By compiling and scrutinizing prevailing practice it is possible to
      appreciate the notion of the mentoring ecosystem which sees each mentee, mentor, 
      and host organization brings with them their own microenvironment that contains
      their respective goals, abilities, and contextual considerations. Built around
      competency based mentoring stages, it is possible to advance a flexible yet
      consistent novice mentoring framework.
CI  - (c) The Author(s) 2020.
FAU - Krishna, Lalit Kumar Radha
AU  - Krishna LKR
AUID- ORCID: https://orcid.org/0000-0002-7350-8644
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
AD  - The Palliative Care Centre for Excellence in Research and Education, Singapore.
AD  - Division of Cancer Education, National Cancer Centre Singapore, Singapore.
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, University of Liverpool, Liverpool, UK.
AD  - Duke-NUS Medical School, National University of Singapore, Singapore.
AD  - Centre of Biomedical Ethics, National University of Singapore, Singapore.
FAU - Tan, Lorraine Hui En
AU  - Tan LHE
AUID- ORCID: https://orcid.org/0000-0003-3390-2361
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Ong, Yun Ting
AU  - Ong YT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Tay, Kuang Teck
AU  - Tay KT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Hee, Jia Min
AU  - Hee JM
AD  - National University Hospital, National University Health System, Singapore.
FAU - Chiam, Min
AU  - Chiam M
AD  - Division of Cancer Education, National Cancer Centre Singapore, Singapore.
FAU - Chia, Elisha Wan Ying
AU  - Chia EWY
AUID- ORCID: https://orcid.org/0000-0002-7603-2688
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Sheri, Krish
AU  - Sheri K
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Tan, Xiu Hui
AU  - Tan XH
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Teo, Yao Hao
AU  - Teo YH
AUID- ORCID: https://orcid.org/0000-0003-0439-4097
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Kow, Cheryl Shumin
AU  - Kow CS
AUID- ORCID: https://orcid.org/0000-0002-0809-0771
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore.
FAU - Mason, Stephen
AU  - Mason S
AUID- ORCID: https://orcid.org/0000-0002-4020-6869
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, University of Liverpool, Liverpool, UK.
FAU - Toh, Ying Pin
AU  - Toh YP
AD  - National University Hospital, National University Health System, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200923
PL  - United States
TA  - J Med Educ Curric Dev
JT  - Journal of medical education and curricular development
JID - 101690298
PMC - PMC7517982
OTO - NOTNLM
OT  - Palliative care
OT  - medical school
OT  - medicine
OT  - mentoring
OT  - novice mentoring
OT  - palliative care education
OT  - postgraduate medicine
COIS- Declaration of conflicting interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:22
PHST- 2020/07/23 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1177/2382120520957649 [doi]
AID - 10.1177_2382120520957649 [pii]
PST - epublish
SO  - J Med Educ Curric Dev. 2020 Sep 23;7:2382120520957649. doi:
      10.1177/2382120520957649. eCollection 2020 Jan-Dec.


PMID- 33015359
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Oct 1
TI  - Informed Consent for Academic Surgeons: A Curriculum-Based Update.
PG  - 10985
LID - 10.15766/mep_2374-8265.10985 [doi]
AB  - Introduction: The principles of consent are evolving but remain an important part
      of the surgeon-patient relationship. The goal of this course was a concise,
      contemporary review of the principles of informed consent that would be favorably
      received by academic surgeons. Methods: The curriculum consisted of
      ethicohistorical and legal principles, current requirements, and new consent
      developments. An anonymous, voluntary evaluation tool was used to assess
      strengths and opportunities for improvement. A short postcourse quiz was
      developed to assess understanding. Results: Eighty-five percent of the surgery
      department faculty participated. Evaluations were overwhelmingly positive, all
      elements having weighted averages of greater than 4.5 on a 5-point Likert scale
      (1 = strongly disagree, 5 = strongly agree). Furthermore, a majority of
      respondents for the posttest got the answers correct for all five questions asked
      on the postcourse quiz. Discussion: A proper understanding of informed consent
      remains critically important in the practice of surgery. This short course
      updating surgeons on informed consent quantitatively confirms the favorable
      reception of this approach in terms of attendance and satisfaction, as well as
      understanding of the material.
CI  - (c) 2020 Raper and Joseph.
FAU - Raper, Steven E
AU  - Raper SE
AUID- ORCID: 0000-0001-9191-4681
AD  - Associate Professor and Vice-chair for Quality and Risk Management, Department of
      Surgery, Perelman School of Medicine at the University of Pennsylvania.
FAU - Joseph, Johncy
AU  - Joseph J
AD  - Quality Manager, Department of Surgery, Penn Medicine.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - *Curriculum
MH  - Humans
MH  - Informed Consent
MH  - *Surgeons
PMC - PMC7528671
OTO - NOTNLM
OT  - *Accreditation Council for Continuing Medical Education
OT  - *Clinical/Procedural Skills Training
OT  - *Faculty Education
OT  - *Informed Consent
OT  - *Law of Consent
OT  - *Surgeon-Patient Communication
EDAT- 2020/10/06 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/10/05 06:22
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10985 [doi]
AID - 10985 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Oct 1;16:10985. doi: 10.15766/mep_2374-8265.10985.


PMID- 33015272
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201005
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - [Assisted suicide: When the legislative cannot take the place of the
      existential].
PG  - 100591
LID - 10.1016/j.jemep.2020.100591 [doi]
AB  - The question of the meaning of life arises as much for the young as for the old, 
      as soon as they experience their finitude through some experience of death. To
      explore the issue in retrospect, let's look at death and suicide at different
      scales. If we were to compare suicide to one of the cell deaths, perhaps we would
      compare it to apoptosis as performed by the cell itself. At the animal level,
      survival follows the law of the strongest or the most intelligent. On an
      anthropological scale, civilizations survive in the illusion of their
      immortality. It is certain that suicide is a most intimate act and can, in this
      respect, be considered an act of freedom since it relieves the body's perception 
      of any physical law, perception being abolished by death. The fascination for
      suicide is based on an intellectual exploration, a search for an absolute answer 
      in opposition to all relativism, which paradoxically will take shape in
      annihilation. In times of pandemic and confinement, humanity experiences its
      finiteness. Confinement has re-installed a sense of loneliness in a society that 
      lives on constant hyper-communication. In this text, the author demonstrates that
      suicide must be avoided because it is nonsense for both the individual and the
      community. Thus, living with disability as well as old age should be valued more 
      highly, and public health policies against the causes leading to suicide should
      become state priorities. Finally, far from pathologizing suicide, the question of
      legally recognizing the right to (unassisted) suicide for those who commit it
      must be asked.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Bommier, C
AU  - Bommier C
AD  - Hopital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
AD  - Assistance publique-Hopitaux de Paris, 3, avenue Victoria, 75004 Paris, France.
AD  - Universite de Paris, 12, rue de l'Ecole-de-medecine, 75006 Paris, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Le suicide assiste : quand le legislatif ne peut se substituer a l'existentiel.
DEP - 20200929
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7522007
OTO - NOTNLM
OT  - Assisted suicide
OT  - Ethics
OT  - Euthanasia
OT  - Public health
OT  - Sense
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:22
PHST- 2020/05/24 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1016/j.jemep.2020.100591 [doi]
AID - S2352-5525(20)30129-8 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100591. doi:
      10.1016/j.jemep.2020.100591. Epub 2020 Sep 29.


PMID- 33015271
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201005
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - [New paths or advances in bioethics].
PG  - 100588
LID - 10.1016/j.jemep.2020.100588 [doi]
AB  - This paper examines the impact of the exceptional events of the 2020 pandemic and
      the government containment responses it triggered on two ethical issues that
      arose before the virus took its toll. These two questions - chosen among others -
      were those of the unity of the medical ethics and of the specific nature of the
      pharmacist's ethics. The answers to these questions were deeply changed in
      meaning and value after the events we experienced. When reality intrudes, it does
      not only change practices but it equally changes theory. The questions formerly
      asked continue to be asked, but a certain number of solutions have been
      discredited among those that we thought should be taken into account: a certain
      bureaucracy, in one case, to resolve illusory questions of ethical efficiency; a 
      vague metaphysics of morals in the other, to believe that the distinction between
      a drug and a commodity can be fulfilled cheaply. A reading of Kierkegaard
      appeared to us like a salutary issue in the first case; whereas ethical and
      political research about pharmaceutical matters seemed to be absolutely urgent to
      our eyes, in the second case.
CI  - (c) 2020 Published by Elsevier Masson SAS.
FAU - Clero, J-P
AU  - Clero JP
AD  - Departement de philosophie de l'universite de Rouen, 1, rue Thomas-Beckett, 76821
      Mont-Saint-Aignan, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Nouvelles voies ou avancees en bioethique.
DEP - 20200929
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7521998
OTO - NOTNLM
OT  - Bayesianism
OT  - Death
OT  - Kierkegaard
OT  - Pandemic
OT  - Pharmacy
OT  - Proportionality
OT  - Time
OT  - Unity of ethics
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:22
PHST- 2020/06/14 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1016/j.jemep.2020.100588 [doi]
AID - S2352-5525(20)30126-2 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100588. doi:
      10.1016/j.jemep.2020.100588. Epub 2020 Sep 29.


PMID- 33015270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201005
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - "Death cannot harm the patient: Comparativism and the biased world problem".
PG  - 100578
LID - 10.1016/j.jemep.2020.100578 [doi]
AB  - Premature discussions of patients' rights or duties to death must be put aside to
      focus first on whether death injures the patient who dies. Comparativism argues
      that dying does have impact on this individual, then it may alter our arguments
      on duties or rights to die, as well as on how and whether we should make end of
      life decisions for others. If Comparativism is correct, then there are large
      ramifications for ethics, medicine, and public health. Unfortunately for
      Comparativism, its incorporation of intuitions and possible worlds gives it the
      same undermining biased world problem encountered by Moore's isolation test for
      intrinsic value. Imagining/referring to a possible world whilst in this one
      merely creates the illusion that a decedent's death can benefit or injure her.
      When we select possible worlds or fill in their missing states of affairs, we can
      often impose our own biases into the thought experiment. Thinking about fictions 
      is useful in figuring out what we should do and be, as well as evaluating what
      others did and were, but medical practice and policy affecting end of life issues
      in bioethics should always be based on reality and not subjective partiality.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - R Cooley, Dennis
AU  - R Cooley D
AD  - Director of the Northern Plains Ethics Institute, Professor of Philosophy,
      Ethics, Department of History, Philosophy, and Religious Studies-Dept 2340, North
      Dakota State University, Minard 422 J, P.O Box 6050, Fargo, ND 58108, United
      States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200929
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7522035
OTO - NOTNLM
OT  - Comparativism
OT  - Death
OT  - End-of-life decisions
OT  - Harm
OT  - Patient
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:22
PHST- 2020/05/28 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1016/j.jemep.2020.100578 [doi]
AID - S2352-5525(20)30116-X [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100578. doi:
      10.1016/j.jemep.2020.100578. Epub 2020 Sep 29.


PMID- 33015177
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20220417
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Measurement of Bone Mineral Density in Children with Cerebral Palsy from an
      Ethical Issue to a Diagnostic Necessity.
PG  - 7282946
LID - 10.1155/2020/7282946 [doi]
AB  - INTRODUCTION: Due to concerns about cumulative radiation exposure in the
      pediatric population, it is not standard practice to perform dual-energy X-ray
      absorptiometry (DXA) analysis in the diagnostic process of musculoskeletal
      disorders, such as cerebral palsy (CP). This study aimed to evaluate the bone
      mineral density (BMD) in children with CP and the ethical justification of
      applying DXA analysis in these children. Material and Methods. In this
      monocentric retrospective analysis, data were collected from children and
      adolescents with CP who were treated for a primary illness for three years. A
      clinical examination, which included a DXA analysis, recommended by the
      multidisciplinary team, was performed. After applying inclusion and exclusion
      criteria, 60 scans remained for statistical analysis. BMD and Z-scores for the
      lumbar spine (LS), and hip right and left femoral neck (RFN and LFN,
      respectively), and total hip (TH) were recorded. RESULTS: The average age of
      children with CP when DXA analysis was first performed was about 7 years. The BMD
      (mean +/- SD) at LS (LS-BMD) of all patients was 0.612 +/- 0.12, at RFN 0.555 +/-
      0.11, at LFN 0.572 +/- 0.1, and at TH (TH-BMD) 0.581 +/- 0.13. The values of the 
      Z-score (mean +/- SD) at LS of all patients were -2.5 +/- 0.22, at RFN -2.2 +/-
      0.21, at LFN -2.25 (SD = 0.2), and at TH -2.3 (SD = 0.23). There was no
      statistical significance between age and gender; however, BMI, walking ability,
      fracture history, and pattern of CP had a significant impact on BMD and Z-score
      values of these children. CONCLUSION: The results of our study clearly indicate
      that children with CP have a higher risk of low BMD, osteoporosis, and bone
      fractures, which makes it ethically justifiable to perform the DXA analysis in
      these children.
CI  - Copyright (c) 2020 Jasmin S. Nurkovic et al.
FAU - Nurkovic, Jasmin S
AU  - Nurkovic JS
AUID- ORCID: https://orcid.org/0000-0001-6369-6285
AD  - Center for Regeneration and Rehabilitation, Novi Pazar, Serbia.
AD  - Radiology Department, Faculty of Medical Sciences, University of Kragujevac,
      Serbia.
FAU - Petkovic, Pavle
AU  - Petkovic P
AD  - Radiology Department, Faculty of Medical Sciences, University of Kragujevac,
      Serbia.
AD  - Radiology Department, Clinical Center Kragujevac, Serbia.
FAU - Tiosavljevic, Danijela
AU  - Tiosavljevic D
AD  - Department of Humanities, Medical Faculty, University of Belgrade, Serbia.
FAU - Vojinovic, Radisa
AU  - Vojinovic R
AD  - Radiology Department, Faculty of Medical Sciences, University of Kragujevac,
      Serbia.
AD  - Radiology Department, Clinical Center Kragujevac, Serbia.
LA  - eng
PT  - Journal Article
DEP - 20200919
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Bone Density/*physiology
MH  - Cerebral Palsy/complications/*diagnosis/*physiopathology
MH  - Child
MH  - Child, Preschool
MH  - *Ethics, Medical
MH  - Female
MH  - Fractures, Bone/complications
MH  - Humans
MH  - Male
MH  - Walking
PMC - PMC7525307
COIS- All authors state that they have no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/10/05 06:22
PHST- 2020/06/14 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
AID - 10.1155/2020/7282946 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Sep 19;2020:7282946. doi: 10.1155/2020/7282946. eCollection 
      2020.


PMID- 33015171
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20220417
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Hemodynamics in Shock Patients Assessed by Critical Care Ultrasound and Its
      Relationship to Outcome: A Prospective Study.
PG  - 5175393
LID - 10.1155/2020/5175393 [doi]
AB  - BACKGROUND: Shock is one of the causes of mortality in the intensive care unit
      (ICU). Traditionally, hemodynamics related to shock have been monitored by
      broad-spectrum devices with treatment guided by many inaccurate variables to
      describe the pathophysiological changes. Critical care ultrasound (CCUS) has been
      widely advocated as a preferred tool to monitor shock patients. The purpose of
      this study was to analyze and broaden current knowledge of the characteristics of
      ultrasonic hemodynamic pattern and investigate their relationship to outcome.
      METHODS: This prospective study of shock patients in CCUS was conducted in 181
      adult patients between April 2016 and June 2017 in the Department of Intensive
      Care Unit of West China Hospital. CCUS was performed within the initial 6 hours
      after shock patients were enrolled. The demographic and clinical characteristics,
      ultrasonic pattern of hemodynamics, and outcome were recorded. A stepwise
      bivariate logistic regression model was established to identify the correlation
      between ultrasonic variables and the 28-day mortality. RESULTS: A total of 181
      patients with shock were included in our study (male/female: 113/68). The mean
      age was 58.2 +/- 18.0 years; the mean Acute Physiology and Chronic Health
      Evaluation II (APACHE II score) was 23.7 +/- 8.7, and the 28-day mortality was
      44.8% (81/181). The details of ultrasonic pattern were well represented, and the 
      multivariate analysis revealed that mitral annular plane systolic excursion
      (MAPSE), mitral annular peak systolic velocity (S'-MV), tricuspid annular plane
      systolic excursion (TAPSE), and lung ultrasound score (LUSS) were the independent
      risk factors for 28-day mortality in our study, as well as APACHE II score,
      PaO2/FiO2, and lactate (p = 0.047, 0.041, 0.022, 0.002, 0.027, 0.028, and 0.01,
      respectively). CONCLUSIONS: CCUS exam on admission provided valuable information 
      to describe the pathophysiological changes of shock patients and the mechanism of
      shock. Several critical variables obtained by CCUS were related to outcome, hence
      deserving more attention in clinical decision-making. Trial Registration. The
      study was approved by the Ethics Committee of West China Hospital Review Board
      for human research with the following reference number 201736 and was registered 
      on ClinicalTrials. This trial is registered with NCT03082326 on 3 March 2017
      (retrospectively registered).
CI  - Copyright (c) 2020 Tongjuan Zou et al.
FAU - Zou, Tongjuan
AU  - Zou T
AD  - Department of Critical Care Medicine, West China Hospital/West China School of
      Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
FAU - Yin, Wanhong
AU  - Yin W
AD  - Department of Critical Care Medicine, West China Hospital/West China School of
      Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
FAU - Li, Yi
AU  - Li Y
AD  - Department of Critical Care Medicine, West China Hospital/West China School of
      Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
FAU - Deng, Lijing
AU  - Deng L
AD  - Department of Critical Care Medicine, West China Hospital/West China School of
      Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
FAU - Zhou, Ran
AU  - Zhou R
AD  - Department of Critical Care Medicine, West China Hospital/West China School of
      Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
FAU - Wang, Xiaoting
AU  - Wang X
AD  - Department of Critical Care Medicine, Peking Union Medical College Hospital,
      Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing
      100730, China.
FAU - Chao, Yangong
AU  - Chao Y
AD  - Department of Critical Care Medicine, The First Hospital of Tsinghua University, 
      Beijing 100016, China.
FAU - Zhang, Lina
AU  - Zhang L
AD  - Department of Critical Care Medicine, Xiangya Hospital, Central South University,
      Changsha, Hunan 410008, China.
FAU - Kang, Yan
AU  - Kang Y
AUID- ORCID: https://orcid.org/0000-0002-5715-3900
AD  - Department of Critical Care Medicine, West China Hospital/West China School of
      Medicine, Sichuan University, Chengdu, Sichuan 610041, China.
CN  - Chinese Critical Ultrasound Study Group (CCUSG)
LA  - eng
SI  - ClinicalTrials.gov/NCT03082326
PT  - Journal Article
DEP - 20200915
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Electrocardiography
MH  - Female
MH  - Heart/physiopathology
MH  - *Hemodynamics
MH  - Humans
MH  - *Intensive Care Units
MH  - Lung/diagnostic imaging/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Shock/diagnosis/*diagnostic imaging/mortality/*physiopathology
MH  - Treatment Outcome
MH  - *Ultrasonography
MH  - Young Adult
PMC - PMC7512042
COIS- The authors declare that they have no competing interests.
EDAT- 2020/10/06 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/10/05 06:22
PHST- 2020/02/07 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/10/05 06:22 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
AID - 10.1155/2020/5175393 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Sep 15;2020:5175393. doi: 10.1155/2020/5175393. eCollection 
      2020.


PMID- 33015088
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the
      Course of Chemotherapy in Unresectable Pancreatic Cancer.
PG  - 495
LID - 10.3389/fmed.2020.00495 [doi]
AB  - Background: Malnutrition and cachexia are common in patients with advanced
      pancreatic ductal adenocarcinoma (PDAC) and have a significant influence on the
      tolerance and response to treatments. If timely identified, malnourished PDAC
      patients could be treated to increase their capacity to complete the planned
      treatments and, therefore, possibly, improve their efficacy. Aims: The aim of
      this study is to assess the impact of nutritional status, pancreatic exocrine
      insufficiency (PEI), and other clinical factors on patient outcomes in patients
      with advanced PDAC. Methods: PAncreatic Cancer MAlnutrition and Pancreatic
      Exocrine INsufficiency in the Course of Chemotherapy in Unresectable Pancreatic
      Cancer (PAC-MAIN) is an international multicenter prospective observational
      cohort study. The nutritional status will be determined by means of
      Mini-Nutritional Assessment score and laboratory blood tests. PEI will be defined
      by reduced fecal elastase levels. MAIN OUTCOME: adherence to planned chemotherapy
      in the first 12 weeks following the diagnosis, according to patients' baseline
      nutritional status and quantified and reported as "percent of standard
      chemotherapy dose delivered." SECONDARY OUTCOMES: rate of chemotherapy-related
      toxicity, progression-free survival, survival at 6 months, overall survival,
      quality of life, and the number of hospitalizations. ANALYSIS: chemotherapy
      dosing over the first 12 weeks of therapy (i.e., percent of chemotherapy received
      in the first 12 weeks, as defined above) will be compared between well-nourished 
      and malnourished patients. SAMPLE SIZE: based on an expected percentage of
      chemotherapy delivered of 70% in well-nourished patients, with a type I error of 
      0.05 and a type II error of 0.20, a sample size of 93 patients per group will be 
      required in case of a percentage difference of chemotherapy delivered of 20%
      between well-nourished and malnourished patients, 163 patients per group in case 
      of a difference of 15% between the groups, and 356 patients per group in case of 
      a 10% difference. Centers from Russia, Romania, Turkey, Spain, Serbia, and Italy 
      will participate in the study upon Local Ethics Committee approval. Discussion:
      PAC-MAIN will provide insights into the role of malnutrition and PEI in the
      outcomes of PDAC. The study protocol was registered at clinicaltrials.gov as
      NCT04112836.
CI  - Copyright (c) 2020 Kiriukova, de la Iglesia Garcia, Panic, Bozhychko, Avci,
      Maisonneuve, de-Madaria, Capurso and Sandru.
FAU - Kiriukova, Mariia
AU  - Kiriukova M
AD  - Department of Upper Gastrointestinal, Pancreatic, and Biliary Diseases, Moscow
      Clinical Scientific Center, Moscow, Russia.
FAU - de la Iglesia Garcia, Daniel
AU  - de la Iglesia Garcia D
AD  - Department of Gastroenterology, University Hospital of Santiago de Compostela,
      Santiago de Compostela, Spain.
FAU - Panic, Nikola
AU  - Panic N
AD  - Digestive Endoscopy Department, University Clinic "Dr. Dragisa Misovic-Dedinje", 
      Belgrade, Serbia.
AD  - School of Medicine, University of Belgrade, Belgrade, Serbia.
FAU - Bozhychko, Maryana
AU  - Bozhychko M
AD  - Gastroenterology Department, Alicante University General Hospital, ISABIAL,
      Alicante, Spain.
FAU - Avci, Bartu
AU  - Avci B
AD  - Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Maisonneuve, Patrick
AU  - Maisonneuve P
AD  - Unit of Clinical Epidemiology, Division of Epidemiology and Biostatistics, IEO
      European Institute of Oncology, IRCCS, Milan, Italy.
FAU - de-Madaria, Enrique
AU  - de-Madaria E
AD  - Gastroenterology Department, Alicante University General Hospital, ISABIAL,
      Alicante, Spain.
FAU - Capurso, Gabriele
AU  - Capurso G
AD  - Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational
      and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan,
      Italy.
FAU - Sandru, Vasile
AU  - Sandru V
AD  - Gastroenterology and Interventional Endoscopy Department, Clinical Emergency
      Hospital Bucharest, Bucharest, Romania.
LA  - eng
SI  - ClinicalTrials.gov/NCT04112836
PT  - Journal Article
DEP - 20200903
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7509408
OTO - NOTNLM
OT  - chemotherapy
OT  - dose-intensity
OT  - exocrine pancreatic insufficiency
OT  - locally advanced
OT  - metastatic
OT  - nutritional status
OT  - pancreatic cancer
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:21
PHST- 2019/11/07 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/10/05 06:21 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fmed.2020.00495 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Sep 3;7:495. doi: 10.3389/fmed.2020.00495. eCollection
      2020.


PMID- 33014971
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - A Multi-Domain Intervention Protocol for the Potential Reversal of Cognitive
      Frailty: "WE-RISE" Randomized Controlled Trial.
PG  - 471
LID - 10.3389/fpubh.2020.00471 [doi]
AB  - Following the rapid increase of the aging population, health promotion and
      prevention of physical disability and dementia in older persons are essential for
      healthy aging. For example, there may be a potential to prevent or reverse
      cognitive frailty, the co-existence of both physical frailty and cognitive
      impairment in older persons. However, evidence-based interventions targeting the 
      prevention or potential reversibility of cognitive frailty among community
      dwelling older adults are scarce. In this paper, we described the rationale,
      development and delivery of a multi-domain intervention comprising
      multi-component physical exercise prescription, cognitive training, dietary
      counseling and promotion of psychosocial support, called the WE-RISE trial. The
      aim of WE-RISE intervention is to potentially reverse cognitive frailty. This is 
      a two-armed, single blinded, randomized controlled trial conducted over a
      duration of 6 months, at senior citizen activity centers within the Klang Valley,
      Malaysia. Ambulating, community dwelling older adults aged 60 years and above
      with cognitive frailty are randomized into two groups; (1) intervention group:
      which receives an instructor based "WE-RISE" intervention for the first 3 months,
      and then a home-based "WE-RISE at Home" intervention for the following 3 months; 
      (2) control group: usual care with no modifications to their daily routine.
      Primary outcome is cognitive frailty status and secondary outcome include
      physical function, cognitive performance, nutritional status, psychosocial status
      and quality of life which are obtained during baseline screening and subsequent
      follow ups at 3rd and 6th month. Description of the intervention is done using
      the template for intervention description and replication (TIDieR) checklist.
      This trial protocol has received approval from Research Ethics Committee of
      Universiti Kebangsaan Malaysia (UKM PPI/111/8/JEP-2018-558) and the Department of
      Social Welfare Malaysia (MyResearch Reference: JKMM 100/12/5/2: 2018/405). Trial 
      registration number: ACTRN12619001055190.
CI  - Copyright (c) 2020 Murukesu, Singh, Shahar and Subramaniam.
FAU - Murukesu, Resshaya Roobini
AU  - Murukesu RR
AD  - Physiotherapy Programme and Centre for Healthy Aging and Wellness, Faculty of
      Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
FAU - Singh, Devinder Kaur Ajit
AU  - Singh DKA
AD  - Physiotherapy Programme and Centre for Healthy Aging and Wellness, Faculty of
      Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
FAU - Shahar, Suzana
AU  - Shahar S
AD  - Dietetic Program and Centre for Healthy Aging and Wellness, Faculty of Health
      Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
FAU - Subramaniam, Ponnusamy
AU  - Subramaniam P
AD  - Health Psychology Programme and Centre for Healthy Aging and Wellness, Faculty of
      Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
LA  - eng
SI  - ANZCTR/ACTRN12619001055190
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Aged
MH  - Aged, 80 and over
MH  - Cognition
MH  - Frail Elderly
MH  - *Frailty/therapy
MH  - Humans
MH  - Malaysia/epidemiology
MH  - Middle Aged
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7495818
OTO - NOTNLM
OT  - *cognitive frailty
OT  - *cognitive impairment
OT  - *community dwelling
OT  - *frailty
OT  - *multi-domain intervention
OT  - *older adults
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:21
PHST- 2020/05/06 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/10/05 06:21 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fpubh.2020.00471 [doi]
PST - epublish
SO  - Front Public Health. 2020 Sep 3;8:471. doi: 10.3389/fpubh.2020.00471. eCollection
      2020.


PMID- 33014967
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Earlier Outbreak Detection-A Generic Model and Novel Methodology to Guide Earlier
      Detection Supported by Data From Low- and Mid-Income Countries.
PG  - 452
LID - 10.3389/fpubh.2020.00452 [doi]
AB  - Infectious disease outbreaks can have significant impact on individual health,
      national economies, and social well-being. Through early detection of an
      infectious disease, the outbreak can be contained at the local level, thereby
      reducing adverse effects on populations. Significant time and funding have been
      invested to improve disease detection timeliness. However, current evaluation
      methods do not provide evidence-based suggestions or measurements on how to
      detect outbreaks earlier. Key conditions for earlier detection and their
      influencing factors remain unclear and unmeasured. Without clarity about
      conditions and influencing factors, attempts to improve disease detection remain 
      ad hoc and unsystematic. Methods: We developed a generic five-step disease
      detection model and a novel methodology to use for data collection, analysis, and
      interpretation. Data was collected in two workshops in Southeast Europe (n = 33
      participants) and Southern and East Africa (n = 19 participants), representing
      mid- and low-income countries. Through systematic, qualitative, and quantitative 
      data analyses, we identified key conditions for earlier detection and prioritized
      factors that influence them. As participants joined a workshop format and not an 
      experimental setting, no ethics approval was required. Findings: Our analyses
      suggest that governance is the most important condition for earlier detection in 
      both regions. Facilitating factors for earlier detection are risk communication
      activities such as information sharing, communication, and collaboration
      activities. Impeding factors are lack of communication, coordination, and
      leadership. Interpretation: Governance and risk communication are key influencers
      for earlier detection in both regions. However, inadequate technical capacity,
      commonly assumed to be a leading factor impeding early outbreak detection, was
      not found a leading factor. This insight may be used to pinpoint further
      improvement strategies.
CI  - Copyright (c) 2020 Steele, Orefuwa, Bino, Singer, Lutwama and Dickmann.
FAU - Steele, Lindsay
AU  - Steele L
AD  - New York City Department of Health and Mental Hygiene, New York, NY, United
      States.
AD  - Connecting Organizations for Regional Disease Surveillance (CORDS), Lyon, France.
FAU - Orefuwa, Emma
AU  - Orefuwa E
AD  - Connecting Organizations for Regional Disease Surveillance (CORDS), Lyon, France.
FAU - Bino, Silvia
AU  - Bino S
AD  - Institute of Public Health, Southern European Center for Surveillance and Control
      of Infectious Diseases (SECID), Tirana, Albania.
FAU - Singer, Shepherd Roee
AU  - Singer SR
AD  - Ministry of Health Israel, Jerusalem, Israel.
FAU - Lutwama, Julius
AU  - Lutwama J
AD  - East African Integrated Disease Surveillance Network (EAIDSNet), Kampala, Uganda.
FAU - Dickmann, Petra
AU  - Dickmann P
AD  - Connecting Organizations for Regional Disease Surveillance (CORDS), Lyon, France.
AD  - Department of Anaesthesiology and Intensive Care, Jena University Hospital, Jena,
      Germany.
AD  - Dickmann Risk Communication Drc|, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200911
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Africa, Eastern
MH  - *Animal Diseases
MH  - Animals
MH  - *Communicable Diseases
MH  - Disease Outbreaks
MH  - Europe
MH  - Humans
PMC - PMC7516212
OTO - NOTNLM
OT  - *community-based surveillance
OT  - *detection
OT  - *earlier detection
OT  - *infectious disease outbreaks
OT  - *methodology
OT  - *risk communication
OT  - *surveillance
OT  - *time-to-detection
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:21
PHST- 2019/08/07 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/10/05 06:21 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fpubh.2020.00452 [doi]
PST - epublish
SO  - Front Public Health. 2020 Sep 11;8:452. doi: 10.3389/fpubh.2020.00452.
      eCollection 2020.


PMID- 33014949
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Moral Distress in the Neonatal Intensive Care Unit: What Is It, Why It Happens,
      and How We Can Address It.
PG  - 581
LID - 10.3389/fped.2020.00581 [doi]
AB  - Moral distress is prevalent in the neonatal intensive care unit (NICU), where
      decisions regarding end-of-life care, periviable resuscitation, and medical
      futility are common. Due to its origins in the nursing literature, moral distress
      has primarily been reported among bedside nurses in relation to the hierarchy of 
      the medical team. However, it is increasingly recognized that moral distress may 
      exist in different forms than initially described and that healthcare professions
      outside of nursing experience it. Advances in medical technology have allowed the
      smallest, sickest neonates to survive. The treatment for critically ill infants
      is no longer simply limited by the capability of medical technology but also by
      moral and ethical boundaries of what is right for a given child and family.
      Shared decision-making and the zone of parental discretion can inform and
      challenge the medical team to balance the complexities of patient autonomy
      against harm and suffering. Limited ability to prognosticate and uncertainty in
      outcomes add to the challenges faced with ethical dilemmas. While this does not
      necessarily equate to moral distress, subjective views of quality of life and
      personal values in these situations can lead to moral distress if the plans of
      care and the validity of each path are not fully explored. Differences in
      opinions and approaches between members of the medical team can strain
      relationships and affect each individual differently. It is unclear how the
      various types of moral distress uniquely impact each profession and their role in
      the distinctively challenging decisions made in the NICU environment. The purpose
      of this review is to describe moral distress and the situations that give rise to
      it in the NICU, ways in which various members of the medical team experience it, 
      how it impacts care delivery, and approaches to address it.
CI  - Copyright (c) 2020 Mills and Cortezzo.
FAU - Mills, Manisha
AU  - Mills M
AD  - Division of Neonatal and Pulmonary Biology, Cincinnati Children's Hospital
      Medical Center, Cincinnati, OH, United States.
FAU - Cortezzo, DonnaMaria E
AU  - Cortezzo DE
AD  - Division of Neonatal and Pulmonary Biology, Cincinnati Children's Hospital
      Medical Center, Cincinnati, OH, United States.
AD  - Division of Pain and Palliative Medicine, Cincinnati Children's Hospital Medical 
      Center, Cincinnati, OH, United States.
AD  - Department of Pediatrics, University of Cincinnati College of Medicine,
      Cincinnati, OH, United States.
AD  - Department of Anesthesiology, University of Cincinnati College of Medicine,
      Cincinnati, OH, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200910
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7511509
OTO - NOTNLM
OT  - decision-making
OT  - end-of-life care
OT  - ethical confrontation
OT  - medical futility
OT  - moral distress
OT  - neonatal intensive care
OT  - periviability
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:21
PHST- 2020/06/19 00:00 [received]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/10/05 06:21 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fped.2020.00581 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Sep 10;8:581. doi: 10.3389/fped.2020.00581. eCollection 2020.


PMID- 33014921
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Noninvasive Ventilation in Palliative Care and Ethical Dilemma.
PG  - 483
LID - 10.3389/fped.2020.00483 [doi]
AB  - Significant difference exists between validated indications for noninvasive
      ventilation (NIV) use in children and current real life practice. Lately,
      dedicated centers have reported exponential growth of NIV use in children and
      adolescents. Upper airway obstruction, neuromuscular diseases, chronic
      lung/thoracic conditions, and central respiratory drive failure remain the most
      prevalent indications. However, the need to alleviate respiratory failure related
      distress has been increasingly recognized in several other conditions. Palliative
      care in children with life limiting disorders is a complex continuum of
      activities. In order to provide the most appropriate care for the patients and
      their families, the management often oscillates between actively curative and
      purely supportive actions. Despite unprecedented therapeutic advancements,
      several neurologic, metabolic, hemato-oncologic, respiratory, and other rare
      diseases remain with no curative options. Besides, attentiveness to relive
      suffering, awareness, and availability have moved the boundaries of NIV use
      toward conditions formerly not considered suitable for such care. Still, NIV has 
      limitations and can, if sustained in inappropriate circumstances, fail to provide
      relief. A structured professional frameshift should be available for support and 
      ethical guidance in order to provide confidence to patients, families and all the
      involved caregivers.
CI  - Copyright (c) 2020 Krivec and Caggiano.
FAU - Krivec, Uros
AU  - Krivec U
AD  - Department of Pediatric Pulmology, University Children's Hospital Ljubljana,
      University Medical Center Ljubljana, Ljubljana, Slovenia.
FAU - Caggiano, Serena
AU  - Caggiano S
AD  - Laboratory Pediatric Pulmonology and Respiratory Intermediate Care Unit, Sleep
      and Long Term Ventilation Unit, Academic Department of Pediatrics (DPUO),
      Pediatric Hospital "Bambino Gesu" Research Institute, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200827
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7493667
OTO - NOTNLM
OT  - decision-making
OT  - ethics
OT  - noninvasive ventilation
OT  - palliative care
OT  - pediatric
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:21
PHST- 2020/05/11 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/10/05 06:21 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fped.2020.00483 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Aug 27;8:483. doi: 10.3389/fped.2020.00483. eCollection 2020.


PMID- 33014801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2.
PG  - 1555
LID - 10.3389/fonc.2020.01555 [doi]
AB  - The sudden pandemic of SARS-Cov-2 (also known as novel coronavirus disease 2019, 
      COVID-19) poses a severe threat to hundreds of millions of lives in the world.
      The complete cure of the virus largely relies on the immune system, which becomes
      particularly a challenge for the cancer subjects, whose immunity is generally
      compromised. However, in a constant evolving situation, the clinical data on the 
      prevalence of SARS-Cov-2 for cancer patients is still limited. On top of a wide
      range of medical references and interim guidelines including CDC, NCI, ASCO,
      ESMO, NCCN, AACR, ESMO, and the National Health Commission of China, etc., we
      formed into a guideline based on our experience in our specialized cancer
      hospital in Wuhan, the originally endemic center of the virus. Furthermore, we
      formulated an expert consensus which was developed by all contributors from
      different disciplines after fully discussion based on our understanding and
      analysis of limited information of COVID-19. The consensus highlighted a
      multidisciplinary team diagnostic model with assessment of the balance between
      risks and benefits prior to treatment, individualizing satisfaction of patients' 
      medical needs, and acceptability in ethics and patients' socio-economic
      conditions.
CI  - Copyright (c) 2020 Dong, Luo, Hu, Zhang, Cai, Qian, Ran, Ou, Wang, Huang, Ren,
      Han, Zhang, Wei, Liang, Xu, Wang, Shi, Wei and Hu.
FAU - Dong, Shuang
AU  - Dong S
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Luo, Chenggang
AU  - Luo C
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - The Cancer Quality Control Center of Hubei Province, Wuhan, China.
AD  - Department of Radiological Intervention, Hubei Cancer Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Hu, Xuebo
AU  - Hu X
AD  - Laboratory of Drug Discovery and Molecular Engineering, Department of Medicinal
      Plants, College of Plant Science and Technology, Huazhong Agricultural
      University, Wuhan, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Cai, Qian
AU  - Cai Q
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Qian, Yu
AU  - Qian Y
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Ran, Fengming
AU  - Ran F
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Ou, Wuling
AU  - Ou W
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - The Cancer Quality Control Center of Hubei Province, Wuhan, China.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Huang, Qing
AU  - Huang Q
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Ren, Tianhua
AU  - Ren T
AD  - Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 
      China.
FAU - Han, Guang
AU  - Han G
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - Department of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Tongji
      Medical College, Huazhong University of Science and Technology, Wuhan, China.
AD  - The Administration of Cancer Clinical Trials and GCP, Hubei Cancer Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      China.
FAU - Wei, Wei
AU  - Wei W
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - The Cancer Quality Control Center of Hubei Province, Wuhan, China.
AD  - Radiotherapy Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan, China.
FAU - Liang, Xinjun
AU  - Liang X
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Xu, Huiting
AU  - Xu H
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
FAU - Wang, Sheng
AU  - Wang S
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - Department of Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Shi, Lulu
AU  - Shi L
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - The Cancer Quality Control Center of Hubei Province, Wuhan, China.
AD  - The Administration of Cancer Clinical Trials and GCP, Hubei Cancer Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      China.
FAU - Wei, Shaozhong
AU  - Wei S
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - The Cancer Quality Control Center of Hubei Province, Wuhan, China.
AD  - Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan, China.
AD  - Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Hu, Sheng
AU  - Hu S
AD  - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, China.
AD  - Hubei Provincial Cancer Center, Wuhan, China.
AD  - The Office of Hubei Provincial Cancer Prevention, Wuhan, China.
AD  - The Cancer Quality Control Center of Hubei Province, Wuhan, China.
AD  - Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7462010
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-Cov-2
OT  - cancer
OT  - consensus
OT  - coronavirus
OT  - immunotherapy
OT  - treatment
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:20
PHST- 2020/05/18 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/10/05 06:20 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fonc.2020.01555 [doi]
PST - epublish
SO  - Front Oncol. 2020 Aug 18;10:1555. doi: 10.3389/fonc.2020.01555. eCollection 2020.


PMID- 33014748
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1735-9066 (Print)
IS  - 1735-9066 (Linking)
VI  - 25
IP  - 4
DP  - 2020 Jul-Aug
TI  - Facilitators of Sexual Health Education for Male Adolescents in Iran: A
      Qualitative Study.
PG  - 348-355
LID - 10.4103/ijnmr.IJNMR_299_19 [doi]
AB  - BACKGROUND: Adolescence is a period of rapid physical, social, emotional,
      cognitive, and sexual development. The widening gap between biological maturity
      and social transition to adulthood highlights the importance of adolescents' need
      for education, especially in sexual health. The main objective of this study was 
      to explore the facilitators of Sexual Health Education (SHE) for male adolescents
      in Iran. MATERIALS AND METHODS: In this qualitative content analysis, a total
      number of 45 participants were investigated from June 2018 to July 2019 through
      individual, semi-structured, in-depth interviews in the city of Mashhad, Iran,
      until data saturated. The participants were selected using a purposive sampling
      method. The data were analyzed using a conventional content analysis method based
      on the approach developed by Graneheim and Lundman (2004) using MAXQDA software. 
      RESULTS: In data analysis, 2 main categories and 9 subcategories emerged. The
      main categories included extrapersonal facilitators and intrapersonal
      facilitators. The category of extrapersonal facilitators included the 7
      subcategories of appropriate policy-making, use of religious capacities,
      consideration of native culture, supportive family environment, school
      empowerment, inter-sectoral integration and collaboration, and reinforcement of
      parent-teacher interaction. The category of intrapersonal facilitators comprised 
      of the 2 subcategories of supporting adolescent socialization and using
      distraction techniques in adolescents. CONCLUSIONS: The study revealed that
      having an action plan with a scientific, ethical, legal, religious, and cultural 
      background, establishing a suitable home, school, and community environment,
      strengthening inter-sectoral integration, collaboration, and interpersonal
      coordination, and utilizing the capabilities and potentials of adolescents can
      provide an appropriate SHE for adolescent boys.
CI  - Copyright: (c) 2020 Iranian Journal of Nursing and Midwifery Research.
FAU - Askari, Fariba
AU  - Askari F
AD  - Student Research Committee, Department of Midwifery, School of Nursing and
      Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Mirzaiinajmabadi, Khadigeh
AU  - Mirzaiinajmabadi K
AD  - Associated Professor in Reproductive Health, Nursing and Midwifery Care Research 
      Center, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Rezvani, Mahmood Saeedy
AU  - Rezvani MS
AD  - Associated Professor, Department of Curriculum Studies and Instruction, Faculty
      of Education and Psychology, Ferdowsi University of Mashhad, Mashhad, Iran.
FAU - Asgharinekah, Seyyed-Mohsen
AU  - Asgharinekah SM
AD  - Associated Professor, Department of Educational and Counseling Psychology,
      Faculty of Education and Psychology, Ferdowsi University of Mashhad, Mashhad,
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - India
TA  - Iran J Nurs Midwifery Res
JT  - Iranian journal of nursing and midwifery research
JID - 101558775
PMC - PMC7494163
OTO - NOTNLM
OT  - Adolescent
OT  - education
OT  - male
OT  - qualitative research
OT  - sexual health
COIS- Nothing to declare.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:20
PHST- 2019/12/30 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/10/05 06:20 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.4103/ijnmr.IJNMR_299_19 [doi]
AID - IJNMR-25-348 [pii]
PST - epublish
SO  - Iran J Nurs Midwifery Res. 2020 Jun 17;25(4):348-355. doi:
      10.4103/ijnmr.IJNMR_299_19. eCollection 2020 Jul-Aug.


PMID- 33014378
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2052-0492 (Print)
IS  - 2052-0492 (Linking)
VI  - 8
DP  - 2020
TI  - Linkage of alterations in systemic iron homeostasis to patients' outcome in
      sepsis: a prospective study.
PG  - 76
LID - 10.1186/s40560-020-00495-8 [doi]
AB  - BACKGROUND: Sepsis, a dysregulated host response following infection, is
      associated with massive immune activation and high mortality rates. There is
      still a need to define further risk factors and laboratory parameters predicting 
      the clinical course. Iron metabolism is regulated by both, the body's iron status
      and the immune response. Iron itself is required for erythropoiesis but also for 
      many cellular and metabolic functions. Moreover, iron availability is a critical 
      determinant in infections because it is an essential nutrient for most microbes
      but also impacts on immune function and intravascular oxidative stress. Herein,
      we used a prospective study design to investigate the putative impact of serum
      iron parameters on the outcome of sepsis. METHODS: Serum markers of iron
      metabolism were measured in a prospective cohort of 61 patients (37 males, 24
      females) with sepsis defined by Sepsis-3 criteria in a medical intensive care
      unit (ICU) and compared between survivors and non-survivors. Regulation of iron
      parameters in patients stratified by focus of infection and co-medication as well
      as association of the markers with sepsis severity scores and survival were
      investigated with linear and logistic regression corrected for sex and age
      effects. RESULTS: Positive correlations of increased serum iron and ferritin
      concentrations upon ICU admission with the severity of organ failure (SOFA score)
      and with mortality were observed. Moreover, high TF-Sat, elevated ferritin and
      serum iron levels and low transferrin concentrations were associated with reduced
      survival. A logistic regression model consisting of SOFA and transferrin
      saturation (SOFA-TF-Sat) had the best predictive power for survival in septic ICU
      patients. Of note, administration of blood transfusions prior to ICU admission
      resulted in increased TF-Sat and reduced survival of septic patients.
      CONCLUSIONS: Our study could show an important impact of serum iron parameters on
      the outcome of sepsis. Furthermore, we identified transferrin saturation as a
      stand-alone predictor of sepsis survival and as a parameter of iron metabolism
      which may in a combined model improve the prediction power of the SOFA score.
      TRIAL REGISTRATION: The study was carried out in accordance with the
      recommendations of the Declaration of Helsinki on biomedical research. The study 
      was approved by the institutional ethics review board of the Medical University
      Innsbruck (study AN2013-0006).
CI  - (c) The Author(s) 2020.
FAU - Brandtner, Anna
AU  - Brandtner A
AD  - Division of Intensive Care and Emergency Medicine, Department of Internal
      Medicine I, Medical University of Innsbruck, Innsbruck, Austria.grid.5361.10000
      0000 8853 2677
FAU - Tymoszuk, Piotr
AU  - Tymoszuk P
AD  - Department of Internal Medicine II, Medical University of Innsbruck, Anichstr.
      35, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
FAU - Nairz, Manfred
AU  - Nairz M
AD  - Department of Internal Medicine II, Medical University of Innsbruck, Anichstr.
      35, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
FAU - Lehner, Georg F
AU  - Lehner GF
AD  - Division of Intensive Care and Emergency Medicine, Department of Internal
      Medicine I, Medical University of Innsbruck, Innsbruck, Austria.grid.5361.10000
      0000 8853 2677
FAU - Fritsche, Gernot
AU  - Fritsche G
AD  - Department of Internal Medicine II, Medical University of Innsbruck, Anichstr.
      35, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
FAU - Vales, Anja
AU  - Vales A
AD  - Central Institute for Blood Transfusion and Immunology, Innsbruck, Austria.
FAU - Falkner, Andreas
AU  - Falkner A
AD  - Central Institute for Blood Transfusion and Immunology, Innsbruck, Austria.
FAU - Schennach, Harald
AU  - Schennach H
AD  - Central Institute for Blood Transfusion and Immunology, Innsbruck, Austria.
FAU - Theurl, Igor
AU  - Theurl I
AD  - Department of Internal Medicine II, Medical University of Innsbruck, Anichstr.
      35, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
FAU - Joannidis, Michael
AU  - Joannidis M
AD  - Division of Intensive Care and Emergency Medicine, Department of Internal
      Medicine I, Medical University of Innsbruck, Innsbruck, Austria.grid.5361.10000
      0000 8853 2677
FAU - Weiss, Gunter
AU  - Weiss G
AD  - Department of Internal Medicine II, Medical University of Innsbruck, Anichstr.
      35, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
AD  - Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical
      University of Innsbruck, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
FAU - Pfeifhofer-Obermair, Christa
AU  - Pfeifhofer-Obermair C
AUID- ORCID: 0000-0002-9942-6540
AD  - Department of Internal Medicine II, Medical University of Innsbruck, Anichstr.
      35, Innsbruck, Austria.grid.5361.10000 0000 8853 2677
LA  - eng
GR  - P 28302/FWF_/Austrian Science Fund FWF/Austria
PT  - Journal Article
DEP - 20201001
PL  - England
TA  - J Intensive Care
JT  - Journal of intensive care
JID - 101627304
PMC - PMC7528491
OTO - NOTNLM
OT  - Ferritin
OT  - Infection
OT  - SOFA score
OT  - Transferrin
OT  - Transferrin saturation
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:18
PHST- 2020/06/19 00:00 [received]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/05 06:18 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1186/s40560-020-00495-8 [doi]
AID - 495 [pii]
PST - epublish
SO  - J Intensive Care. 2020 Oct 1;8:76. doi: 10.1186/s40560-020-00495-8. eCollection
      2020.


PMID- 33014207
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 1880-9693 (Print)
IS  - 1880-8190 (Linking)
VI  - 40
DP  - 2020
TI  - Current status and future perspectives of HLA-edited induced pluripotent stem
      cells.
PG  - 23
LID - 10.1186/s41232-020-00132-9 [doi]
AB  - In 2007, Human-induced pluripotent stem cells (iPSCs) were generated by
      transducing four genes (Oct3/4, Sox2, Klf4, c-Myc). Because iPSCs can
      differentiate into any types of cells in the body and have fewer ethical issues
      compared to embryonic stem (ES) cells, application of iPSCs for regenerative
      medicine has been actively examined. In fact, iPSCs have already been used for
      clinical applications, but at present, only autologous iPSC-derived grafts or HLA
      homozygous iPSC-derived grafts are being transplanted into patients following HLA
      matching. HLA is an important molecule that enables the immune system
      differentiates between self and non-self-components; thus, HLA mismatch is a
      major hurdle in the transplantation of iPSCs. To deliver inexpensive
      off-the-shelf iPSC-derived regenerative medicine products to more patients, it is
      necessary to generate universal iPSCs that can be transplanted regardless of the 
      HLA haplotypes. The current strategy to generate universal iPSCs has two broad
      aims: deleting HLA expression and avoiding attacks from NK cells, which are
      caused by HLA deletion. Deletion of B2M and CIITA genes using the CRISPR/Cas9
      system has been reported to suppress the expression of HLA class I and class II, 
      respectively. Transduction of NK inhibitory ligands, such as HLA-E and CD47, has 
      been used to avoid NK cell attacks. Most recently, the HLA-C retaining method has
      been used to generate semi-universal iPSCs. Twelve haplotypes of HLA-C retaining 
      iPSCs can cover 95% of the global population. In future, studying which types of 
      universal iPSCs are most effective for engraftment in various physiological
      conditions is necessary.
CI  - (c) The Author(s) 2020.
FAU - Koga, Keiko
AU  - Koga K
AD  - Takeda-CiRA Joint Program (T-CiRA), 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa
      251-8555 Japan.
AD  - T-CiRA discovery, Takeda Pharmaceutical Company, 2-26-1, Muraoka-Higashi,
      Fujisawa, Kanagawa 251-8555 Japan.grid.419841.10000 0001 0673 6017
FAU - Wang, Bo
AU  - Wang B
AD  - Takeda-CiRA Joint Program (T-CiRA), 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa
      251-8555 Japan.
AD  - Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for
      iPS cell research (CiRA), Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku,
      Kyoto, 606-8507 Japan.grid.258799.80000 0004 0372 2033
FAU - Kaneko, Shin
AU  - Kaneko S
AUID- ORCID: 0000-0003-2291-4586
AD  - Takeda-CiRA Joint Program (T-CiRA), 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa
      251-8555 Japan.
AD  - Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for
      iPS cell research (CiRA), Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku,
      Kyoto, 606-8507 Japan.grid.258799.80000 0004 0372 2033
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201001
PL  - England
TA  - Inflamm Regen
JT  - Inflammation and regeneration
JID - 101479577
PMC - PMC7528263
COIS- Competing interestsShin Kaneko is a founder, shareholder, and chief scientific
      officer of Thyas Co., Ltd. and received research funding from Takeda
      Pharmaceutical Co. Ltd., Kirin Holdings Co., Ltd., Terumo Co. Ltd., TOSOH Co.
      Ltd., and Thyas Co., Ltd. Keiko Koga is an employee of Takeda Pharmaceutical Co. 
      Ltd.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:17
PHST- 2020/05/31 00:00 [received]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/10/05 06:17 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1186/s41232-020-00132-9 [doi]
AID - 132 [pii]
PST - epublish
SO  - Inflamm Regen. 2020 Oct 1;40:23. doi: 10.1186/s41232-020-00132-9. eCollection
      2020.


PMID- 33014119
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1744-859X (Print)
IS  - 1744-859X (Linking)
VI  - 19
DP  - 2020
TI  - Efficacy of nicotine administration on obsessions and compulsions in OCD: a
      systematic review.
PG  - 57
LID - 10.1186/s12991-020-00309-z [doi]
AB  - BACKGROUND: Preliminary studies have tested nicotine as a novel treatment for OCD
      patients who respond partially/incompletely or not at all to first and
      second-line treatment strategies, with the former represented by SSRIs or
      clomipramine, and the latter by switching to another SSRI, or augmentation with
      atypical antipsychotics, and/or combination with/switching to
      cognitive-behavioural therapy. Some studies found nicotine-induced reduction of
      obsessive thoughts and/or compulsive behaviour in OCD patients. We aimed to
      evaluate the efficacy of nicotine administration in OCD patients. METHODS: We
      searched the PubMed, ScienceDirect Scopus, CINHAL, Cochrane,
      PsycINFO/PsycARTICLES, and EMBASE databases from inception to the present for
      relevant papers. The 'Preferred Reporting Items for Systematic Review and
      Meta-Analyses' (PRISMA) standards were used. We included all studies focusing on 
      the effects of nicotine administration on OCD patients' obsessions or
      compulsions. Studies could be open-label, cross-sectional, randomized controlled 
      trials, case series or case reports. RESULTS: A total of five studies could be
      included. Nicotine administration may ameliorate behavioural features and
      recurrent thoughts of severe, treatment-resistant OCD patients; however, in one
      study it was not associated with OC symptom improvement or cognitive enhancement 
      across various executive function subdomains. CONCLUSIONS: Although encouraging, 
      the initial positive response from the use of nicotine in OCD needs testing in
      large controlled studies. This, however, raises ethical issues related to
      nicotine administration, due to its addiction potential, which were not addressed
      in the limited literature we examined. As an alternative, novel treatments with
      drugs able to mimic only the positive effects of nicotine could be implemented.
CI  - (c) The Author(s) 2020.
FAU - Piacentino, Daria
AU  - Piacentino D
AD  - NESMOS Department (Neurosciences, Mental Health, and Sensory Organs), School of
      Medicine and Psychology, Sapienza University, Sant'Andrea Hospital, Rome,
      Italy.grid.7841.a
AD  - Department of Human Neurosciences, Sapienza University, Policlinico Umberto I,
      Rome, Italy.grid.7841.a
AD  - Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, National
      Institute On Drug Abuse Intramural Research Program and National Institute On
      Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological
      Research, National Institutes of Health, Baltimore, MD USA.grid.94365.3d0000 0001
      2297 5165
FAU - Maraone, Annalisa
AU  - Maraone A
AD  - Department of Human Neurosciences, Sapienza University, Policlinico Umberto I,
      Rome, Italy.grid.7841.a
FAU - Roselli, Valentina
AU  - Roselli V
AD  - Department of Human Neurosciences, Sapienza University, Policlinico Umberto I,
      Rome, Italy.grid.7841.a
FAU - Berardelli, Isabella
AU  - Berardelli I
AD  - NESMOS Department (Neurosciences, Mental Health, and Sensory Organs), School of
      Medicine and Psychology, Sapienza University, Sant'Andrea Hospital, Rome,
      Italy.grid.7841.a
FAU - Biondi, Massimo
AU  - Biondi M
AD  - Department of Human Neurosciences, Sapienza University, Policlinico Umberto I,
      Rome, Italy.grid.7841.a
FAU - Kotzalidis, Georgios D
AU  - Kotzalidis GD
AUID- ORCID: 0000-0002-0281-6324
AD  - NESMOS Department (Neurosciences, Mental Health, and Sensory Organs), School of
      Medicine and Psychology, Sapienza University, Sant'Andrea Hospital, Rome,
      Italy.grid.7841.a
FAU - Pasquini, Massimo
AU  - Pasquini M
AD  - Department of Human Neurosciences, Sapienza University, Policlinico Umberto I,
      Rome, Italy.grid.7841.a
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200930
PL  - England
TA  - Ann Gen Psychiatry
JT  - Annals of general psychiatry
JID - 101236515
PMC - PMC7528475
OTO - NOTNLM
OT  - Checking behaviour
OT  - Cognitive functions
OT  - Nicotine
OT  - Obsessive-compulsive disorder
OT  - Treatment
COIS- Competing interestsNone
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:17
PHST- 2020/07/30 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/05 06:17 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1186/s12991-020-00309-z [doi]
AID - 309 [pii]
PST - epublish
SO  - Ann Gen Psychiatry. 2020 Sep 30;19:57. doi: 10.1186/s12991-020-00309-z.
      eCollection 2020.


PMID- 33014070
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 1687-966X (Print)
VI  - 2020
DP  - 2020
TI  - The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as
      Immunomodulatory Agents for COVID-19 Patients.
PG  - 8835986
LID - 10.1155/2020/8835986 [doi]
AB  - A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal
      acute respiratory disease emerged in December 2019. The World Health Organization
      named this disease "COVID-19" and declared it a pandemic on March 11, 2020. Many 
      studies have shown that mesenchymal stem cells (MSCs) and their exosomes
      (MSCs-Exo), which are isolated from allogenic bone marrow stem cells,
      significantly lower the risk of alveolar inflammation and other pathological
      conditions associated with distinct lung injuries. For example, in acute
      respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs
      provide similar healing properties and some clinical trials have used cell-based 
      inhalation therapy which show great promise. MSCs and MSCs-Exo have shown
      potential in clinical trials as a therapeutic tool for severely affected COVID-19
      patients when compared to other cell-based therapies, which may face challenges
      like the cells' sticking to the respiratory tract epithelia during
      administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should
      strictly adhere to the appropriate manufacturing practices, quality control
      measurements, preclinical safety and efficacy data, and the proper ethical
      regulations. This review highlights the available clinical trials that support
      the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19
      patients.
CI  - Copyright (c) 2020 Faisal A. Alzahrani et al.
FAU - Alzahrani, Faisal A
AU  - Alzahrani FA
AUID- ORCID: https://orcid.org/0000-0003-0441-4000
AD  - Department of Biochemistry, Faculty of Science, Embryonic Stem Cell Unit, King
      Fahad Center for Medical Research, King Abdulaziz University, Jeddah, Saudi
      Arabia.
FAU - Saadeldin, Islam M
AU  - Saadeldin IM
AUID- ORCID: https://orcid.org/0000-0002-7633-730X
AD  - Department of Physiology, Faculty of Veterinary Medicine, Zagazig University,
      Zagazig 44519, Egypt.
AD  - Department of Animal Production College of Food and Agriculture Science, King
      Saud University, Riyadh 11451, Saudi Arabia.
FAU - Ahmad, Abrar
AU  - Ahmad A
AUID- ORCID: https://orcid.org/0000-0001-9439-7712
AD  - Department of Biochemistry, Faculty of Science, Embryonic Stem Cell Unit, King
      Fahad Center for Medical Research, King Abdulaziz University, Jeddah, Saudi
      Arabia.
FAU - Kumar, Dipak
AU  - Kumar D
AUID- ORCID: https://orcid.org/0000-0001-6104-9447
AD  - Zoology Department, KKM College, Munger University, Jamui, India.
FAU - Azhar, Esam I
AU  - Azhar EI
AD  - Department of Medical Laboratories, College of Applied Medical Sciences, King
      Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Siddiqui, Arif Jamal
AU  - Siddiqui AJ
AUID- ORCID: https://orcid.org/0000-0002-6236-0920
AD  - Department of Biology, College of Science, University of Hail, Hail, Saudi
      Arabia.
FAU - Kurdi, Bassem
AU  - Kurdi B
AUID- ORCID: https://orcid.org/0000-0002-7169-2337
AD  - Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,
      Saudi Arabia.
FAU - Sajini, Abdulrahim
AU  - Sajini A
AUID- ORCID: https://orcid.org/0000-0002-8600-3899
AD  - Department of Biomedical Engineering, Khalifa University of Science and
      Technology, Abu Dhabi, UAE.
FAU - Alrefaei, Abdulmajeed F
AU  - Alrefaei AF
AUID- ORCID: https://orcid.org/0000-0003-0804-2339
AD  - Jamoum University College, Department of Biology, University of Umm Al-Qura,
      Saudi Arabia.
FAU - Jahan, Sadaf
AU  - Jahan S
AUID- ORCID: https://orcid.org/0000-0002-6976-5672
AD  - College of Applied Medical Science, Majmaah University, Al Majmaah, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200924
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC7512102
COIS- The authors declare that there is no conflict of interests regarding the
      publication of this paper.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:17
PHST- 2020/06/06 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/10/05 06:17 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1155/2020/8835986 [doi]
PST - epublish
SO  - Stem Cells Int. 2020 Sep 24;2020:8835986. doi: 10.1155/2020/8835986. eCollection 
      2020.


PMID- 33014062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1687-8728 (Print)
IS  - 1687-8728 (Linking)
VI  - 2020
DP  - 2020
TI  - Ethical Aspects concerning Instrument Separation and Perforations during
      Endodontic Treatment: A Cross-Sectional Study.
PG  - 8849105
LID - 10.1155/2020/8849105 [doi]
AB  - AIM: During endodontic treatment, dentists may face various unwanted procedural
      accidents, at any stage of the treatment that might compromise endodontic
      treatment outcome and bring obstacles to dentists as well. This study aimed to
      address and analyze several ethical concerns relating to the behavioural conduct 
      of dentists towards endodontic instrument separation as well as perforation of
      the crown and/or root during root canal treatment in Riyadh, Saudi Arabia.
      METHOD: Hundred and eleven questionnaires were distributed among dentists working
      in Riyadh in university clinics and government and private sectors. Data were
      collected, reviewed, and statistically analyzed by Fisher's exact and chi-square 
      tests at a 5% significance level, using SPSS software. RESULTS: 54.5% of the
      respondents have encountered instrument separation. 53.2% stated that they would 
      inform the patient about the instrument separation. 43.6% of the respondents had 
      experienced perforation during root canal treatment, and 54.9% reported that they
      would inform the patient of the accident. CONCLUSION: Within the limitation of
      this survey, we concluded that most of the dental professionals did not hesitate 
      to adhere to the correct ethical conduct, and they would inform the patient if an
      incident occurred.
CI  - Copyright (c) 2020 Raidan Ba-Hattab et al.
FAU - Ba-Hattab, Raidan
AU  - Ba-Hattab R
AUID- ORCID: https://orcid.org/0000-0003-2044-519X
AD  - College of Dental Medicine, Qatar University, Doha, Qatar.
FAU - Rahman, Ishrat
AU  - Rahman I
AD  - Department of Basic Dental Sciences, College of Dentistry, Princess Nourah Bint
      Abdulrahman University, Riyadh, Saudi Arabia.
FAU - Elsayed, Lubna K
AU  - Elsayed LK
AD  - Department of Oral Surgery, Faculty of Dentistry, Suez Canal University,
      Ismaielia, Egypt.
FAU - Alasmari, Wejdan F
AU  - Alasmari WF
AD  - Private Sector, Riyadh, Saudi Arabia.
FAU - Abidia, Randa
AU  - Abidia R
AD  - Department of Preventive Dental Sciences, Dar Al Uloom University, Riyadh, Saudi 
      Arabia.
FAU - Abdelgaffar, Somayah
AU  - Abdelgaffar S
AD  - Private Sector, Jeddah, Saudi Arabia.
FAU - Bahattab, Awsan
AU  - Bahattab A
AUID- ORCID: https://orcid.org/0000-0003-1708-0978
AD  - CRIMEDIM-Research Center in Emergency and Disaster Medicine, Universita Del
      Piemonte Orientale, Novara, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200915
PL  - Egypt
TA  - Int J Dent
JT  - International journal of dentistry
JID - 101524183
PMC - PMC7512109
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:17
PHST- 2020/07/11 00:00 [received]
PHST- 2020/08/29 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/10/05 06:17 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1155/2020/8849105 [doi]
PST - epublish
SO  - Int J Dent. 2020 Sep 15;2020:8849105. doi: 10.1155/2020/8849105. eCollection
      2020.


PMID- 33013706
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - Metabolic Improvement via Enhancing Thermogenic Fat-Mediated Non-shivering
      Thermogenesis: From Rodents to Humans.
PG  - 633
LID - 10.3389/fendo.2020.00633 [doi]
AB  - Brown and beige adipose tissues play a large role in non-shivering thermogenesis 
      (NST) in mammals, and subsequently have been studied for decades as potential
      therapeutic targets to treat obesity and its related metabolic diseases. However,
      the mechanistic regulation of brown/beige adipose tissue induction and
      maintenance in humans is very limited due to the ethical reasons. In fact,
      metabolic signaling has primarily been investigated using rodent models. A better
      understanding of non-shivering thermogenesis in humans is thus vital and urgent
      in order to treat obesity by targeting human brown adipose tissue (BAT). In this 
      review, we summarize the anatomical and physiological differences between rodent 
      and human BAT, current useful and mostly non-invasive methods in studying human
      BAT, as well as recent advancements targeting thermogenic adipocytes as a means
      to combat metabolic diseases in humans. Furthermore, we also discuss several
      novel relevant strategies of therapeutic interventions, which has been attempted 
      in rodent experiments, and possible future investigations in humans in this
      field.
CI  - Copyright (c) 2020 Pan, Zhu, Maretich and Chen.
FAU - Pan, Ruping
AU  - Pan R
AD  - Department of Nuclear Medicine, Tongji Medical College, Tongji Hospital, Huazhong
      University of Science and Technology, Wuhan, China.
FAU - Zhu, Xiaohua
AU  - Zhu X
AD  - Department of Nuclear Medicine, Tongji Medical College, Tongji Hospital, Huazhong
      University of Science and Technology, Wuhan, China.
FAU - Maretich, Pema
AU  - Maretich P
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,
      United States.
FAU - Chen, Yong
AU  - Chen Y
AD  - Department of Endocrinology, Internal Medicine, Tongji Medical College, Tongji
      Hospital, Huazhong University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200910
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Adipose Tissue, Beige/*metabolism
MH  - Adipose Tissue, Brown/*metabolism
MH  - Animals
MH  - Humans
MH  - Rodentia
MH  - Thermogenesis/*physiology
PMC - PMC7511774
OTO - NOTNLM
OT  - *beige adipose tissue
OT  - *brown adipose tissue
OT  - *human
OT  - *non-shivering thermogenesis
OT  - *obesity
OT  - *rodent
EDAT- 2020/10/06 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/10/05 06:15
PHST- 2020/06/02 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/10/05 06:15 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.3389/fendo.2020.00633 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Sep 10;11:633. doi: 10.3389/fendo.2020.00633.
      eCollection 2020.


PMID- 33013666
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Challenges to the Emergence of Telerehabilitation in a Developing Country: A
      Systematic Review.
PG  - 1007
LID - 10.3389/fneur.2020.01007 [doi]
AB  - Background: Despite being known abroad as a viable alternative to face-to-face
      consultation and therapy, telerehabilitation has not fully emerged in developing 
      countries like the Philippines. In the midst of the coronavirus disease 2019
      (COVID-19) pandemic, wherein social distancing disrupted the in-clinic delivery
      of rehabilitation services, Filipinos attempted to explore telerehabilitation.
      However, several hindrances were observed especially during the
      pre-implementation phase of telerehabilitation, necessitating a review of
      existing local evidences. Objective: We aimed to determine the challenges faced
      by telerehabilitation in the Philippines. Method: We searched until March 2020
      through PubMed, Scopus, Embase, Cochrane Library, and HeRDIN for
      telerehabilitation-related publications wherein Filipinos were involved as
      investigator or population. Because of the hypothesized low number of scientific 
      outputs on telerehabilitation locally, we performed handsearching through gray
      literature and included relevant papers from different rehabilitation-related
      professional organizations in the Philippines. We analyzed the papers and
      extracted the human, organizational, and technical challenges to
      telerehabilitation or telehealth in general. Results: We analyzed 21 published
      and 4 unpublished papers, which were mostly reviews (8), feasibility studies (6),
      or case reports/series (4). Twelve out of 25 studies engaged patients and
      physicians in remote teleconsultation, teletherapy, telementoring, or
      telemonitoring. Patients sought telemedicine or telerehabilitation for general
      medical conditions (in 3 studies), chronic diseases (2), mental health issues
      (2), orthopedic problems (2), neurologic conditions (1), communication disorders 
      (1), and cardiac conditions (1). Outcomes in aforementioned studies mostly
      included telehealth acceptance, facilitators, barriers, and satisfaction. Other
      studies were related to telehealth governance, legalities, and ethical issues. We
      identified 18 human, 17 organizational, and 18 technical unique challenges
      related to telerehabilitation in the Philippines. The most common challenges were
      slow internet speed (in 10 studies), legal concerns (9), and skepticism (9).
      Conclusion: There is paucity of data on telerehabilitation in the Philippines.
      Local efforts can focus on exploring or addressing the most pressing human,
      organizational, and technical challenges to the emergence of telerehabilitation
      in the country.
CI  - Copyright (c) 2020 Leochico, Espiritu, Ignacio and Mojica.
FAU - Leochico, Carl Froilan D
AU  - Leochico CFD
AD  - Department of Rehabilitation Medicine, College of Medicine and Philippine General
      Hospital, University of the Philippines Manila, Manila, Philippines.
AD  - Department of Physical Medicine and Rehabilitation, St. Luke's Medical Center,
      Taguig, Philippines.
FAU - Espiritu, Adrian I
AU  - Espiritu AI
AD  - Department of Clinical Epidemiology, College of Medicine, University of the
      Philippines Manila, Manila, Philippines.
AD  - Department of Neurosciences, College of Medicine and Philippine General Hospital,
      University of the Philippines Manila, Manila, Philippines.
FAU - Ignacio, Sharon D
AU  - Ignacio SD
AD  - Department of Rehabilitation Medicine, College of Medicine and Philippine General
      Hospital, University of the Philippines Manila, Manila, Philippines.
AD  - Department of Physical Medicine and Rehabilitation, St. Luke's Medical Center,
      Taguig, Philippines.
FAU - Mojica, Jose Alvin P
AU  - Mojica JAP
AD  - Department of Rehabilitation Medicine, College of Medicine and Philippine General
      Hospital, University of the Philippines Manila, Manila, Philippines.
LA  - eng
PT  - Systematic Review
DEP - 20200908
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7505991
OTO - NOTNLM
OT  - barriers
OT  - developing country
OT  - healthcare delivery
OT  - rehabilitation medicine
OT  - telemedicine
OT  - telerehabilitation
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:15
PHST- 2020/04/24 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/10/05 06:15 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fneur.2020.01007 [doi]
PST - epublish
SO  - Front Neurol. 2020 Sep 8;11:1007. doi: 10.3389/fneur.2020.01007. eCollection
      2020.


PMID- 33013594
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Thinking in a Non-native Language: A New Nudge?
PG  - 549083
LID - 10.3389/fpsyg.2020.549083 [doi]
AB  - The majority of research on learning a non-native language has focused on the
      personal benefits of being bilingual or multilingual. In this paper, we focus on 
      the potential positive effect of actively thinking in a non-native language. Our 
      approach is inspired by recent experimental research suggesting that actively
      thinking in a non-native language leads to improved reasoning and
      decision-making, which is known as the foreign-language effect (FLE). We examine 
      the possibility that one could choose to think in a non-native language in order 
      to reap these potential benefits. Integrating this research with research in
      positive psychology, we explain how doing so might be understood as a type of
      "nudge," or intervention that one could use to increase their chances of making
      autonomous decisions reflecting their own best interest. Nudges have been
      associated with improved outcomes with respect to many aspects of our lives - for
      instance sticking to goals, saving money, exercising more frequently, maintaining
      a healthy diet. It may be that bilinguals can assume an active role in increasing
      their happiness or well-being by making better decisions through strategic
      implementation of a non-native language in decision-making contexts. We also
      discuss the ethics of using the FLE as a nudge when it has beneficial
      consequences, as there are instances when doing so could be beneficial with
      respect to public policy as well. For instance, it has been shown that people are
      less averse to sustainable farming and eating practices (e.g., eating insects)
      when actively thinking in a non-native language. After reviewing the current
      research on the FLE, we suggest that further research needs to be done because
      actively thinking in a non-native language seems to function beneficially in some
      circumstances but may pose cognitive disadvantages in others.
CI  - Copyright (c) 2020 McFarlane, Cipolletti Perez and Weissglass.
FAU - McFarlane, Steven
AU  - McFarlane S
AD  - Department of Philosophy, University of Minnesota at Morris, Morris, MN, United
      States.
FAU - Cipolletti Perez, Heather
AU  - Cipolletti Perez H
AD  - Department of Philosophy and Religion, Broward College, Fort Lauderdale, FL,
      United States.
FAU - Weissglass, Christine
AU  - Weissglass C
AD  - Department of Modern Languages and Literatures, Villanova University, Villanova, 
      PA, United States.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7494810
OTO - NOTNLM
OT  - FLE
OT  - bilingualism
OT  - decision-making
OT  - foreign-language effect
OT  - nudge
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:15
PHST- 2020/04/04 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/10/05 06:15 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fpsyg.2020.549083 [doi]
PST - epublish
SO  - Front Psychol. 2020 Sep 3;11:549083. doi: 10.3389/fpsyg.2020.549083. eCollection 
      2020.


PMID- 33013509
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - When the Underdog Positioning Backfires! The Effects of Ethical Transgressions on
      Attitudes Toward Underdog Brands.
PG  - 1988
LID - 10.3389/fpsyg.2020.01988 [doi]
AB  - This research investigates the novel link between consumers' support for underdog
      brands and their ethical expectations of such brands and finds that the underdog 
      brand positioning may not always be beneficial. Rather, we argue that the
      identification-based supporting motivation for underdog brands may backfire when 
      the accompanying specific moral expectation is not satisfied. Study 1
      demonstrates that the underdog brand falls into an ethical trap in which
      consumers judge the brand more harshly when ethical transgressions are committed.
      In Study 2, the psychological underlying mechanism for this ethical underdog trap
      effect is proved to be perceived betrayal. In Study 3, a boundary condition,
      community-related (vs. autonomy-related) transgressions, is explored. In Study 4,
      the three types of transgressions (autonomy, community, and functional) and the
      mediating effects of perceived betrayal are tested in integrated research design.
      Finally, theoretical and managerial implications are discussed, followed by
      conclusions.
CI  - Copyright (c) 2020 Kim and Park.
FAU - Kim, Yaeri
AU  - Kim Y
AD  - Department of Marketing, College of Business Administration, Sejong University,
      Seoul, South Korea.
AD  - Department of Digital Marketing, School of Management, Sejong Cyber University,
      Seoul, South Korea.
FAU - Park, Kiwan
AU  - Park K
AD  - Department of Marketing, College of Business Administration, Seoul National
      University, Seoul, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20200904
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7498723
OTO - NOTNLM
OT  - consumer brand attitude change
OT  - consumer brand identification
OT  - ethical transgression
OT  - perceived betrayal
OT  - symbolic brand
OT  - underdog backfiring
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:15
PHST- 2019/09/10 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/10/05 06:15 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.3389/fpsyg.2020.01988 [doi]
PST - epublish
SO  - Front Psychol. 2020 Sep 4;11:1988. doi: 10.3389/fpsyg.2020.01988. eCollection
      2020.


PMID- 33013214
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20220417
IS  - 1558-9439 (Electronic)
IS  - 1536-5050 (Linking)
VI  - 108
IP  - 4
DP  - 2020 Oct 1
TI  - Designing a model of professional ethics excellence for clinical librarians.
PG  - 574-583
LID - 10.5195/jmla.2020.893 [doi]
AB  - OBJECTIVE: Developing and promoting professional ethics principles for clinical
      librarians can help the health care system balance the interests of all
      stakeholders, including clinical librarians, health care professionals, and
      patients. Therefore, the goal of this study was to design a model of professional
      ethics excellence for clinical librarians. METHODS: The authors conducted a
      descriptive applied study using literature review and the delphi method. The
      delphi panel included eleven experts in medical librarianship, library and
      information sciences, or information sciences and knowledge studies. RESULTS:
      After the delphi rounds, five concepts and forty-six components were identified
      and confirmed to provide a model of professional ethics excellence for clinical
      librarians. The highest-rated concept was excellence in communication. The
      highest-rated component was mastery in developing search strategies in
      information resources and databases. CONCLUSIONS: Identifying and applying
      principles of professional ethics among clinical librarians can enhance the
      professionalization of clinical librarians and result in better information
      services for physicians. Furthermore, incorporating these principles into the
      curriculum for health sciences library and information sciences students or into 
      workshops for active clinical librarians can further formalize the profession and
      practice of evidence-based medicine.
CI  - Copyright (c) 2020 Hasan Ashrafi-rizi, Zahra Kazempour, Fatemeh Sheikhshoaei,
      Zahra Ghazavi.
FAU - Ashrafi-Rizi, Hasan
AU  - Ashrafi-Rizi H
AUID- ORCID: https://orcid.org/0000-0001-6052-2087
AD  - hassanashrafi@mng.mui.ac.ir, Professor, Health Information Technology Research
      Center, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Kazempour, Zahra
AU  - Kazempour Z
AUID- ORCID: https://orcid.org/0000-0001-6834-2814
AD  - zahrakazempour00@gmail.com, Assistant Professor, Library and Information Science,
      Department of Knowledge and Information Science, Payame Noor University, Tehran, 
      Iran.
FAU - Sheikhshoaei, Fatemeh
AU  - Sheikhshoaei F
AUID- ORCID: https://orcid.org/0000-0001-8804-5403
AD  - (corresponding author), fashoaei@sina.tums.ac.ir, Assistant Professor, Medical
      Library and Information Sciences, School of Allied Medicine, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Ghazavi, Zahra
AU  - Ghazavi Z
AD  - ghazaviz@ymail.com, Iran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Med Libr Assoc
JT  - Journal of the Medical Library Association : JMLA
JID - 101132728
SB  - IM
MH  - *Ethics, Professional
MH  - Humans
MH  - Information Services
MH  - *Librarians
MH  - Library Science/*ethics
PMC - PMC7524624
EDAT- 2020/10/06 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/10/05 06:13
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - 10.5195/jmla.2020.893 [doi]
AID - jmla.2020.893 [pii]
PST - ppublish
SO  - J Med Libr Assoc. 2020 Oct 1;108(4):574-583. doi: 10.5195/jmla.2020.893.


PMID- 33013192
OWN - NLM
STAT- Publisher
LR  - 20220218
IS  - 1388-1957 (Print)
IS  - 1388-1957 (Linking)
DP  - 2020 Sep 29
TI  - Contact tracing apps: an ethical roadmap.
PG  - 1-4
LID - 10.1007/s10676-020-09548-w [doi]
AB  - This research statement presents a roadmap for the ethical evaluation of contact 
      tracing apps. Assuming the possible development of an effective and secure
      contact tracing app, this roadmap explores three ethical concerns-privacy, data
      monopolists and coercion- based on three scenarios. The first scenario envisions 
      and critically evaluates an app that is built on the conceptualization of privacy
      as anonymity and a mere individual right rather than a social value. The second
      scenario sketches and critically discusses an app that adequately addresses
      privacy concerns but is facilitated by data monopolists such as Google and Apple.
      The final scenario discusses the coerced installation and use of a
      privacy-friendly, independently developed contact tracing app. The main worry is 
      coercion through societal exclusion and limited societal participation. The
      statement concludes with three suggestions for designing an ethical contact
      tracing app and a research agenda.
CI  - (c) The Author(s) 2020.
FAU - Lanzing, Marjolein
AU  - Lanzing M
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance, Faculty of
      Philosophy, Theology and Religious Studies, Radboud University Nijmegen, IHub
      19th floor, room 19.06, Houtlaan 4, 6525 Nijmegen, XZ The
      Netherlands.grid.5590.90000000122931605
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - Netherlands
TA  - Ethics Inf Technol
JT  - Ethics and information technology
JID - 101248311
PMC - PMC7524380
OTO - NOTNLM
OT  - Coercion
OT  - Contact tracing apps
OT  - Data monopolists
OT  - Privacy
OT  - Solidarity
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/10/05 06:13
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1007/s10676-020-09548-w [doi]
AID - 9548 [pii]
PST - aheadofprint
SO  - Ethics Inf Technol. 2020 Sep 29:1-4. doi: 10.1007/s10676-020-09548-w.


PMID- 33013191
OWN - NLM
STAT- Publisher
LR  - 20201006
IS  - 1388-1957 (Print)
IS  - 1388-1957 (Linking)
DP  - 2020 Sep 28
TI  - Towards a seamful ethics of Covid-19 contact tracing apps?
PG  - 1-11
LID - 10.1007/s10676-020-09559-7 [doi]
AB  - In the early months of 2020, the deadly Covid-19 disease spread rapidly around
      the world. In response, national and regional governments implemented a range of 
      emergency lockdown measures, curtailing citizens' movements and greatly limiting 
      economic activity. More recently, as restrictions begin to be loosened or lifted 
      entirely, the use of so-called contact tracing apps has figured prominently in
      many jurisdictions' plans to reopen society. Critics have questioned the utility 
      of such technologies on a number of fronts, both practical and ethical. However, 
      little has been said about the ways in which the normative design choices of app 
      developers, and the products that result therefrom, might contribute to ethical
      reflection and wider political debate. Drawing from scholarship in critical
      design and human-computer interaction, this paper examines the development of a
      QR code-based tracking app called Zwaai ('Wave' in Dutch), where its designers
      explicitly positioned the app as an alternative to the predominant Bluetooth and 
      GPS-based approaches. Through analyzing these designers' choices, this paper
      argues that QR code infrastructures can work to surface a set of
      ethical-political seams, two of which are discussed here-responsibilization and
      networked (im)permanence-that more 'seamless' protocols like Bluetooth actively
      aim to bypass, and which may go otherwise unnoticed by existing ethical
      frameworks.
CI  - (c) The Author(s) 2020.
FAU - Hoffman, Andrew S
AU  - Hoffman AS
AUID- ORCID: 0000-0001-6137-4047
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance (iHub), Radboud
      University, Nijmegen, the Netherlands.grid.5590.90000000122931605
AD  - Department of Practical Philosophy, Radboud University, Nijmegen, the
      Netherlands.grid.5590.90000000122931605
FAU - Jacobs, Bart
AU  - Jacobs B
AUID- ORCID: 0000-0002-0740-0336
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance (iHub), Radboud
      University, Nijmegen, the Netherlands.grid.5590.90000000122931605
AD  - Institute for Computing and Information Sciences, Radboud University, Nijmegen,
      the Netherlands.grid.5590.90000000122931605
FAU - van Gastel, Bernard
AU  - van Gastel B
AUID- ORCID: 0000-0002-0974-4634
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance (iHub), Radboud
      University, Nijmegen, the Netherlands.grid.5590.90000000122931605
AD  - Open University, Heerlen, the Netherlands.grid.36120.360000 0004 0501 5439
FAU - Schraffenberger, Hanna
AU  - Schraffenberger H
AUID- ORCID: 0000-0003-1847-2754
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance (iHub), Radboud
      University, Nijmegen, the Netherlands.grid.5590.90000000122931605
FAU - Sharon, Tamar
AU  - Sharon T
AUID- ORCID: 0000-0003-0155-9220
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance (iHub), Radboud
      University, Nijmegen, the Netherlands.grid.5590.90000000122931605
AD  - Department of Practical Philosophy, Radboud University, Nijmegen, the
      Netherlands.grid.5590.90000000122931605
FAU - Pas, Berber
AU  - Pas B
AUID- ORCID: 0000-0002-7563-904X
AD  - Interdisciplinary Hub for Security, Privacy and Data Governance (iHub), Radboud
      University, Nijmegen, the Netherlands.grid.5590.90000000122931605
AD  - Institute for Management Research, School of Management, Radboud University,
      Nijmegen, the Netherlands.grid.5590.90000000122931605
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - Netherlands
TA  - Ethics Inf Technol
JT  - Ethics and information technology
JID - 101248311
PMC - PMC7521862
OTO - NOTNLM
OT  - Contact tracing
OT  - Covid-19
OT  - Critical design
OT  - Digital ethics
OT  - Seamful infrastructure
COIS- Conflict of interestNot applicable.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/10/05 06:13
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1007/s10676-020-09559-7 [doi]
AID - 9559 [pii]
PST - aheadofprint
SO  - Ethics Inf Technol. 2020 Sep 28:1-11. doi: 10.1007/s10676-020-09559-7.


PMID- 33013045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0970-9185 (Print)
IS  - 0970-9185 (Linking)
VI  - 36
IP  - 2
DP  - 2020 Apr-Jun
TI  - Total postoperative analgesia for total knee arthroplasty: Ultrasound guided
      single injection modified 4 in 1 block.
PG  - 261-264
LID - 10.4103/joacp.JOACP_260_19 [doi]
AB  - BACKGROUND AND AIMS: Total pain free outcome following total knee arthroplasty
      has led to the evolution of regional blocks. In this series, the authors have
      revisited and modified Roy et al. 's technique of Ultrasound guided 4 in 1 block 
      for knee and below knee surgeries, to provide a complete comprehensive yet simple
      single injection technique for postoperative analgesia for Total Knee
      Arthroplasty (TKA). MATERIAL AND METHODS: After Instituional ethics approval, we 
      performed the modified 4 in 1 block on 10 consenting patients scheduled to
      undergo total knee arthroplasty. A linear USG-probe was used to identify medial
      femoral condyle, then vastus and sartorius intersection was identified. The probe
      was slid till the descending genicular artery branching from superficial femoral 
      artery was visualized proximal to hiatus. At this point the needle with PNS
      attached, was guided into the Vastus medialis muscle till the stimulation of the 
      nerve to Vastus medialis (0.4-0.5 mA). At this point 5-7 mL of 0.2% Ropivacaine
      was injected. The needle was guided in plane to perivascular region and after
      negative aspiration 0.2%ropivacaine 20-25 ml was injected, visualised to push the
      femoral artery. RESULTS: All ten patients considered in this study had an optimum
      pain score of <5 and were comfortable along with no quadriceps weakness, except
      one patient had a pain score of more than 5 after 36 hr post-operatively and
      required rescue analgesia. CONCLUSION: The addition of USG and PNS guided Vastus 
      medialis nerve block to USG 4-in-1 block in the technique gives good
      post-operative analgesia for TKA.
CI  - Copyright: (c) 2020 Journal of Anaesthesiology Clinical Pharmacology.
FAU - Roy, Ritesh
AU  - Roy R
AD  - Department of Anaesthesia and Pain Management, CARE Hospitals, Bhubaneswar,
      Odisha, India.
FAU - Agarwal, Gaurav
AU  - Agarwal G
AD  - Department of Anaesthesia and Pain Management, CARE Hospitals, Bhubaneswar,
      Odisha, India.
FAU - Pradhan, Chandrasekhar
AU  - Pradhan C
AD  - Department of Anaesthesia and Pain Management, CARE Hospitals, Bhubaneswar,
      Odisha, India.
FAU - Kuanar, Debasis
AU  - Kuanar D
AD  - Department of Anaesthesia and Pain Management, CARE Hospitals, Bhubaneswar,
      Odisha, India.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - India
TA  - J Anaesthesiol Clin Pharmacol
JT  - Journal of anaesthesiology, clinical pharmacology
JID - 9516972
PMC - PMC7480285
OTO - NOTNLM
OT  - Postoperative analgesia
OT  - Total Knee arthroplasty
OT  - modified four in one block
COIS- There are no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:13
PHST- 2019/08/10 00:00 [received]
PHST- 2020/01/07 00:00 [revised]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.4103/joacp.JOACP_260_19 [doi]
AID - JOACP-36-261 [pii]
PST - ppublish
SO  - J Anaesthesiol Clin Pharmacol. 2020 Apr-Jun;36(2):261-264. doi:
      10.4103/joacp.JOACP_260_19. Epub 2020 Jun 15.


PMID- 33013038
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0970-9185 (Print)
IS  - 0970-9185 (Linking)
VI  - 36
IP  - 2
DP  - 2020 Apr-Jun
TI  - Cost identification analysis of general anesthesia.
PG  - 219-226
LID - 10.4103/joacp.JOACP_77_19 [doi]
AB  - BACKGROUND AND AIMS: Rising health costs are challenging anesthesiologists to
      search for cost-effective anesthetic techniques. We conducted a study to estimate
      variable cost per case and cost of drug wastage as percentage of total drug cost 
      associated with different modalities of general anesthesia (GA). MATERIAL AND
      METHODS: This prospective study was carried out after approval by institutional
      ethical committee in 258 adult patients aged 18-60 years of either sex, American 
      Society of Anesthesiologists physical status I or II, with a surgical duration of
      1-4 hours, posted for elective surgery under GA with endotracheal intubation. At 
      the end of surgery, total utilization of each drug, anesthetic gases, and
      consumables were noted and remaining drug was regarded as wastage. Cost was
      recorded as per maximum retail price for that particular brand in the market at
      start of study and total cost was calculated. For purpose of analysis, cases were
      divided into low flow sevoflurane, high flow sevoflurane, high flow isoflurane,
      low flow isoflurane, and total intravenous anesthesia (TIVA). RESULTS: The mean
      variable cost was highest with TIVA (2713.82 +/- 509.57) and lowest with low flow
      isoflurane (1981.62 +/- 335.03; P < 0.001). Drug wastage was 13.1% overall, with 
      highest in low sevoflurane group and lowest in TIVA. CONCLUSION: Low flow
      anesthesia with isoflurane is more cost-effective as compared to high flow
      techniques and TIVA even for short duration surgeries. Rational use of drugs and 
      consumables and minimizing wastage can further reduce anesthesia costs.
CI  - Copyright: (c) 2020 Journal of Anaesthesiology Clinical Pharmacology.
FAU - Malhotra, Rohit
AU  - Malhotra R
AD  - Department of Anaesthesia, Lady Hardinge Medical College Shaheed Bhagat Singh
      Marg, New Delhi, India.
FAU - Kumar, Nishant
AU  - Kumar N
AD  - Department of Anaesthesia, Lady Hardinge Medical College Shaheed Bhagat Singh
      Marg, New Delhi, India.
FAU - Jain, Aruna
AU  - Jain A
AD  - Department of Anaesthesia, Lady Hardinge Medical College Shaheed Bhagat Singh
      Marg, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - India
TA  - J Anaesthesiol Clin Pharmacol
JT  - Journal of anaesthesiology, clinical pharmacology
JID - 9516972
PMC - PMC7480290
OTO - NOTNLM
OT  - Low flow anesthesia
OT  - pharmacoeconomics
OT  - total intravenous anesthesia
COIS- There are no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:13
PHST- 2019/03/21 00:00 [received]
PHST- 2019/05/21 00:00 [revised]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.4103/joacp.JOACP_77_19 [doi]
AID - JOACP-36-219 [pii]
PST - ppublish
SO  - J Anaesthesiol Clin Pharmacol. 2020 Apr-Jun;36(2):219-226. doi:
      10.4103/joacp.JOACP_77_19. Epub 2020 Jun 15.


PMID- 33013032
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0970-9185 (Print)
IS  - 0970-9185 (Linking)
VI  - 36
IP  - 2
DP  - 2020 Apr-Jun
TI  - Cervical epidural analgesia combined with general anesthesia for head and neck
      cancer surgery: A randomized study.
PG  - 182-186
LID - 10.4103/joacp.JOACP_72_19 [doi]
AB  - BACKGROUND AND AIMS: The role of cervical epidural analgesia in head and neck
      cancer surgery is not fully explored. The aim of this study was to evaluate
      cervical epidural analgesia in terms of opioid and anesthetic requirements and
      stress response in patients undergoing head and neck cancer surgery. MATERIAL AND
      METHODS: After institutional ethical committee approval and written informed
      consent, 30 patients undergoing elective head and neck cancer surgery were
      randomized into two groups: Group E (cervical epidural analgesia with general
      anesthesia), and group G (general anesthesia alone). In group E, an 18 gauge
      epidural catheter was placed at cervical (C) 6 - thoracic (T) 1 level. After test
      dose, a bolus of 10 ml of 0.2% ropivacaine was given followed by continuous
      infusion. Technique of general anesthesia and post-operative management was
      standardized in both the groups. Opioid and anesthetic drug requirement was
      observed. Blood glucose and serum cortisol levels were measured at baseline;
      post-incision and after surgery. RESULTS: There was significant reduction in the 
      requirement of morphine (P < 0.001), isoflurane (P = 0.004) and vecuronium (P =
      0.001) in group E. Post-operative, blood glucose and serum cortisol levels were
      significantly reduced (P = 0.0153 and 0.0074, respectively). Early post-operative
      pain was reduced with the lesser requirement of post-operative morphine.
      CONCLUSIONS: The use of combined cervical epidural analgesia with general
      anesthesia reduces opioid, anesthetic drug requirement and stress response as
      compared to general anesthesia alone in patients undergoing head and neck cancer 
      surgery.
CI  - Copyright: (c) 2020 Journal of Anaesthesiology Clinical Pharmacology.
FAU - Kochhar, Anjali
AU  - Kochhar A
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Vardhman Mahavir
      Medical College and Safdarjang Hospital, New Delhi, India.
FAU - Banday, Jahanara
AU  - Banday J
AD  - Department of Anesthesiology and Critical Care, Hamdard Institute of Medical
      Sciences and Research, New Delhi, India.
FAU - Ahmad, Zainab
AU  - Ahmad Z
AD  - Department of Anesthesia, Critical Care and Pain Medicine, University College of 
      Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.
FAU - Panjiar, Pratibha
AU  - Panjiar P
AD  - Department of Anesthesiology and Critical Care, Hamdard Institute of Medical
      Sciences and Research, New Delhi, India.
FAU - Vajifdar, Homay
AU  - Vajifdar H
AD  - Department of Anesthesiology and Critical Care, Hamdard Institute of Medical
      Sciences and Research, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - India
TA  - J Anaesthesiol Clin Pharmacol
JT  - Journal of anaesthesiology, clinical pharmacology
JID - 9516972
PMC - PMC7480315
OTO - NOTNLM
OT  - Anesthesia techniques
OT  - cancer surgery
OT  - cervical epidural
OT  - stress response
COIS- There are no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:13
PHST- 2019/03/14 00:00 [received]
PHST- 2019/12/09 00:00 [revised]
PHST- 2019/12/27 00:00 [accepted]
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.4103/joacp.JOACP_72_19 [doi]
AID - JOACP-36-182 [pii]
PST - ppublish
SO  - J Anaesthesiol Clin Pharmacol. 2020 Apr-Jun;36(2):182-186. doi:
      10.4103/joacp.JOACP_72_19. Epub 2020 Jun 15.


PMID- 33013029
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0970-9185 (Print)
IS  - 0970-9185 (Linking)
VI  - 36
IP  - 2
DP  - 2020 Apr-Jun
TI  - Enhancing cooperation during pediatric ultrasound: Oral midazolam versus
      conventional techniques.
PG  - 166-171
LID - 10.4103/joacp.JOACP_343_17 [doi]
AB  - BACKGROUND AND AIMS: Ultrasound is a safe and non-invasive method for detecting
      numerous pathologies. Pediatric patients are often uncooperative which leads to
      decreased quality and increased time of scan. We compared the conventional means 
      alone and combination of oral midazolam for the above cited purpose. MATERIAL AND
      METHODS: This double blind prospective study (CTRI/2016/06/007030) was conducted 
      after obtaining due approval from institutional ethical committee. One hundred
      Children aged 2-6 years belonging to ASA class 1 or 2, posted for high resolution
      ultrasonography of abdomen were included in the study. They were randomised to
      receive midazolam 0.3 mg/kg mixed in 20 mL of apple juice (Group I) or 20 mL of
      apple juice alone (Group II) 20 minutes prior to the procedure. The parameters
      assessed were level of cooperation, sonologist's satisfaction, total scan time,
      heart rate and SpO2. RESULTS: Out of 100 patients, 44 patients of group I and 42 
      of group II were analysed. The cooperation score was significantly higher in
      Group I (35%) than Group II (19%). Likert scale revealed very satisfied and
      satisfied rating in 61.3% (Group I) and 21.4% (Group II). The time taken by
      sonologist and number of attempts were significantly less in Group I than Group
      II. There was no difference in discharge time between the groups. There was no
      reportable adverse event in either group. CONCLUSION: Oral midazolam is a safe
      and effective agent to aid routine abdominal ultrasonography in pediatric
      patients.
CI  - Copyright: (c) 2020 Journal of Anaesthesiology Clinical Pharmacology.
FAU - Chaurasia, Rachna
AU  - Chaurasia R
AD  - Department of Radiodiagnosis, Maharani Laxmi Bai Medical College, Jhansi, India.
FAU - Jain, Anshul
AU  - Jain A
AD  - Department of Anaesthesiology, Maharani Laxmi Bai Medical College, Jhansi, India.
FAU - Sengar, Narendra Singh
AU  - Sengar NS
AD  - Department of Nephrology, Maharani Laxmi Bai Medical College, Jhansi, India.
FAU - Pandey, Shivali
AU  - Pandey S
AD  - Department of Anaesthesiology, Maharani Laxmi Bai Medical College, Jhansi, India.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - India
TA  - J Anaesthesiol Clin Pharmacol
JT  - Journal of anaesthesiology, clinical pharmacology
JID - 9516972
PMC - PMC7480311
OTO - NOTNLM
OT  - Oral midazolam
OT  - pediatric cooperation
OT  - pediatric sonography
COIS- There are no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:13
PHST- 2017/11/22 00:00 [received]
PHST- 2018/09/10 00:00 [revised]
PHST- 2019/05/10 00:00 [accepted]
PHST- 2020/10/05 06:13 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.4103/joacp.JOACP_343_17 [doi]
AID - JOACP-36-166 [pii]
PST - ppublish
SO  - J Anaesthesiol Clin Pharmacol. 2020 Apr-Jun;36(2):166-171. doi:
      10.4103/joacp.JOACP_343_17. Epub 2020 Jun 15.


PMID- 33012905
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211102
IS  - 0165-1765 (Print)
IS  - 0165-1765 (Linking)
VI  - 196
DP  - 2020 Nov
TI  - Mere Addition is equivalent to avoiding the Sadistic Conclusion in all plausible 
      variable-population social orderings.
LID - 109547 [pii]
LID - 10.1016/j.econlet.2020.109547 [doi]
AB  - Economic policy evaluations require social welfare functions for variable-size
      populations. Two important axioms in the population ethics literature are Mere
      Addition and avoidance of the Sadistic Conclusion, both of which focus on the
      sign of lifetime utility. The population ethics literature treats these axioms as
      closely related but distinct: one influential review calls avoidance of the
      Sadistic Conclusion "less controversial." Here, we provide weak, uncontroversial 
      sufficient conditions for these two principles to be equivalent. Related results 
      exist in prior literature, but these include only same-number utilitarian
      orderings and therefore exclude recent and theoretically important rank-dependent
      social evaluations that we include. [100 words].
FAU - Franz, Nathan
AU  - Franz N
AD  - Population Research Center, University of Texas at Austin.
FAU - Spears, Dean
AU  - Spears D
AD  - Economics Department and Population Research Center, University of Texas at
      Austin; Economics and Planning Unit, Indian Statistical Institute - Delhi Centre;
      IZA.
LA  - eng
GR  - K01 HD098313/HD/NICHD NIH HHS/United States
GR  - P2C HD042849/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200908
PL  - Netherlands
TA  - Econ Lett
JT  - Economics letters
JID - 101084492
PMC - PMC7526863
MID - NIHMS1629052
OTO - NOTNLM
OT  - mere addition
OT  - population ethics
OT  - rank-discounted utilitarianism
OT  - sadistic conclusion
OT  - social welfare
OT  - utilitarianism
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:12
PHST- 2020/10/05 06:12 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
AID - 10.1016/j.econlet.2020.109547 [doi]
PST - ppublish
SO  - Econ Lett. 2020 Nov;196. doi: 10.1016/j.econlet.2020.109547. Epub 2020 Sep 8.


PMID- 33012862
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201218
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 9
DP  - 2020 Sep 1
TI  - The impact of the COVID-19 pandemic response on other health research.
PG  - 625-631
LID - 10.2471/BLT.20.257485 [doi]
AB  - While governments have been focusing on the unprecedented disruption to the
      global economy caused by coronavirus disease 2019 (COVID-19) and the urgent need 
      for COVID-19 research, other health research has become a casualty of the
      pandemic. Major research operations that are unrelated to COVID-19 have been
      significantly diminished or suspended entirely because of either COVID-19-related
      legal restrictions or logistical, staffing or operational concerns. Billions of
      people globally are currently affected by lockdowns or curfews. Since the
      timescale of such restrictive measures is unknown and subject to change, many
      studies are now in limbo and the welfare of tens of thousands of study
      participants is at risk. These circumstances have introduced complex ethical
      challenges that merit urgent attention from international sponsors, researchers
      and regulators. Certain sponsors and regulators have published guidelines on how 
      the COVID-19-related disruptions to clinical research should be managed. Although
      these guidelines provide a good starting point in navigating the challenges of
      the evolving pandemic, they only apply to those researchers funded or governed by
      these bodies. Here, we provide guidelines on managing such disruptions that apply
      beyond these specific settings. We highlight some of the effects of the COVID-19 
      pandemic on other ongoing research projects that are unrelated to COVID-19 and
      provide practical guidance on how the welfare of affected study participants
      should be managed. We conclude that policy-makers, sponsors, researchers and
      regulators must adopt a more flexible approach to ensure participant safety,
      while maintaining data integrity and complying with good clinical practices.
CI  - (c) 2020 The authors; licensee World Health Organization.
FAU - Singh, Jerome Amir
AU  - Singh JA
AD  - Centre for the AIDS Programme of Research in South Africa, University of
      KwaZulu-Natal, Private Bag X13, Congella, Durban 4013, South Africa.
FAU - Bandewar, Sunita Vs
AU  - Bandewar SV
AD  - Health, Ethics and Law Institute of Forum for Medical Ethics Society,
      Mumbai-Pune, India.
FAU - Bukusi, Elizabeth Anne
AU  - Bukusi EA
AD  - Center for Microbiology Research, Kenya Medical Research Institute, Nairobi,
      Kenya.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*economics/*legislation & jurisprudence
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Research Personnel
MH  - Research Subjects
MH  - SARS-CoV-2
PMC - PMC7463185
EDAT- 2020/10/06 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/05 06:12
PHST- 2020/04/01 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/10/05 06:12 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.2471/BLT.20.257485 [doi]
AID - BLT.20.257485 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Sep 1;98(9):625-631. doi: 10.2471/BLT.20.257485.
      Epub 2020 Jul 6.


PMID- 33012817
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 10
DP  - 2020 Oct
TI  - Veterinary Medical Ethics.
PG  - 1035-1036
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7488368
EDAT- 2020/10/06 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/10/05 06:12
PHST- 2020/10/05 06:12 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_10_1035 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Oct;61(10):1035-1036.


PMID- 33012790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0001-4079 (Print)
IS  - 0001-4079 (Linking)
VI  - 204
IP  - 9
DP  - 2020 Dec
TI  - [Novel platelet pharming using human induced pluripotent stem cells].
PG  - 961-970
LID - 10.1016/j.banm.2020.09.040 [doi]
AB  - Ex vivo production of human platelets have been pursued as an alternative measure
      to resolve limitations in the supply and safety of current platelet transfusion
      products. To this end, induced pluripotent stem cells (iPSCs) are considered an
      ideal global source, since they are not only pluripotent and self-renewing, but
      also are available from basically any person, have relatively few ethical issues,
      and are easy to manipulate. From human iPSCs, megakaryocyte (MK) lines with
      robust proliferation capacity have been established by the introduction of
      specified sets of genes. These expandable MKs are also cryopreservable and thus
      would be suitable as master cells for good manufacturing practice (GMP) grade
      production of platelets, assuring availability on demand and safety against
      blood-borne infections. Meanwhile, developments in bioreactors that physically
      mimic the in vivo environment and discovery of substances that promote
      thrombopoiesis have yielded competent platelets with improved efficiency. The
      derivation of platelets from iPSCs could further resolve transfusion-related
      alloimmune complications through the manufacturing of autologous products and
      human leukocyte antigen (HLA)-compatible platelets by manipulation of HLAs and
      human platelet antigens (HPAs). Considering these key advances in the field,
      HLA-deleted platelets could become a universal product that is manufactured at
      industrial level to safely fulfill almost all demands. In this review, we
      overview the ex vivo production of iPSC-derived platelets towards clinical
      applications, a production that would revolutionize the blood transfusion system.
CI  - (c) 2020 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Flahou, C
AU  - Flahou C
AD  - Department of Clinical Application, Center for iPS Cell Research and Application,
      Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.
FAU - Sugimoto, N
AU  - Sugimoto N
AD  - Department of Clinical Application, Center for iPS Cell Research and Application,
      Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.
FAU - Eto, K
AU  - Eto K
AD  - Department of Clinical Application, Center for iPS Cell Research and Application,
      Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.
AD  - Department of Regenerative Medicine, Chiba University Graduate School of
      Medicine, Chiba, Japon.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - La culture de plaquettes a partir de cellules souches pluripotentes induites.
DEP - 20200928
PL  - Netherlands
TA  - Bull Acad Natl Med
JT  - Bulletin de l'Academie nationale de medecine
JID - 7503383
PMC - PMC7521593
OTO - NOTNLM
OT  - Bioreactors
OT  - Induced pluripotent stem cells
OT  - Megakaryocyte
OT  - Platelet transfusion
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
CRDT- 2020/10/05 06:11
PHST- 2020/03/17 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
PHST- 2020/10/05 06:11 [entrez]
AID - 10.1016/j.banm.2020.09.040 [doi]
AID - S0001-4079(20)30516-1 [pii]
PST - ppublish
SO  - Bull Acad Natl Med. 2020 Dec;204(9):961-970. doi: 10.1016/j.banm.2020.09.040.
      Epub 2020 Sep 28.


PMID- 33012402
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1097-6760 (Electronic)
IS  - 0196-0644 (Linking)
VI  - 76
IP  - 4
DP  - 2020 Oct
TI  - Ethical Issues at the End of Life.
PG  - e87
LID - S0196-0644(20)30447-9 [pii]
LID - 10.1016/j.annemergmed.2020.06.008 [doi]
LA  - eng
PT  - Editorial
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
SB  - IM
MH  - Decision Making/*ethics
MH  - Emergency Service, Hospital/ethics/organization & administration/trends
MH  - Humans
MH  - Terminal Care/*ethics/methods
EDAT- 2020/10/06 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/10/05 05:31
PHST- 2020/06/04 00:00 [received]
PHST- 2020/10/05 05:31 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - S0196-0644(20)30447-9 [pii]
AID - 10.1016/j.annemergmed.2020.06.008 [doi]
PST - ppublish
SO  - Ann Emerg Med. 2020 Oct;76(4):e87. doi: 10.1016/j.annemergmed.2020.06.008.


PMID- 33011985
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 1470-8744 (Electronic)
IS  - 0885-4513 (Linking)
VI  - 67
IP  - 6
DP  - 2020 Nov
TI  - Ethical and regulatory issues in human gene editing: Chinese perspective.
PG  - 880-891
LID - 10.1002/bab.2032 [doi]
AB  - This paper focuses on the ethical and regulatory issues raised by gene editing.
      In the introduction of this paper, authors provide the background where the
      ethical and regulatory issues by gene editing have been raised including the
      scientific dimension of gene-editing techniques. In the second part of the paper,
      the authors focus on ethical issues in human gene editing with the start of Huang
      Junjiu case and He Jiankui case. Here, the authors discuss the criteria for
      evaluating action, general ethical issues in gene editing, and try to answer two 
      crucial questions: is it ethically justifiable to use human embryo in ex vivo
      genome editing study and is it ethically justifiable to perform heritable human
      genome editing? In answering the second question, the authors discuss the
      arguments against and for heritable human genome editing, methodological problem,
      and the building of an ethical framework for heritable human genome editing. In
      the third part of the paper, the authors focus on regulatory issues in gene
      editing including proactionary approach versus ethically thinking ahead approach,
      self-regulation versus top-down regulation, transparency versus confidentiality, 
      and education versus punishment.
CI  - (c) 2020 International Union of Biochemistry and Molecular Biology, Inc.
FAU - Lei, Ruipeng
AU  - Lei R
AUID- ORCID: https://orcid.org/0000-0002-5213-4786
AD  - Department of Philosophy, School of the Humanities, Center for Bioethics,
      Huazhong University of Bioethics, Wuhan, People's Republic of China.
FAU - Qiu, Renzong
AU  - Qiu R
AD  - Institute of Philosophy/Center for Applied Ethics, Chinese Academy of Social
      Sciences, Center for Bioethics, Huazhong University of Bioethics, Wuhan, People's
      Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201027
PL  - United States
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
SB  - IM
MH  - *Bioethical Issues
MH  - China
MH  - *Gene Editing/ethics/legislation & jurisprudence
MH  - *Genome, Human
MH  - Humans
OTO - NOTNLM
OT  - confidentiality
OT  - ethically thinking ahead
OT  - gene/genome editing
OT  - heritable gene/genome editing
OT  - human dignity
OT  - human intrinsic value
OT  - informed consent
OT  - intergenerational justice
OT  - proactionary approach
OT  - respect for autonomy
OT  - responsibility for future generation
OT  - risk-benefit ratio
OT  - self-regulation
OT  - top-down regulation
OT  - transparency
EDAT- 2020/10/05 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/10/04 20:35
PHST- 2020/06/08 00:00 [received]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2020/10/05 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
PHST- 2020/10/04 20:35 [entrez]
AID - 10.1002/bab.2032 [doi]
PST - ppublish
SO  - Biotechnol Appl Biochem. 2020 Nov;67(6):880-891. doi: 10.1002/bab.2032. Epub 2020
      Oct 27.


PMID- 33011841
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 4
DP  - 2020 Dec
TI  - Healthcare in Extreme and Austere Environments: Responding to the Ethical
      Challenges.
PG  - 283-291
LID - 10.1007/s10730-020-09427-3 [doi]
AB  - Clinicians may increasingly find themselves practicing, by choice or necessity,
      in resource-poor or extreme environments. This often requires altering typical
      patterns of practice with a different set of medical and ethical considerations
      than are usually faced by clinicians practicing in hospitals in the United States
      and Europe. Practitioners may be required to alter their usual scope of practice 
      or their standard ways of medically treating patients. Limited resources will
      also often place clinicians in the position of having to make decisions about
      fairly allocating healthcare, which will alter the physician-patient
      relationship. This does not absolve physicians and other healthcare practitioners
      of providing the best quality of care that can be given under the circumstances. 
      In addition, the lack of a well-developed healthcare infrastructure and limited
      resources will require working with established providers to determine the needs 
      of the community, and what types of healthcare are feasible given these
      limitations. The essays in this issue of HEC Forum encourage readers to reflect
      on the unique ethical challenges faced in the extreme or austere environment.
FAU - Zientek, David
AU  - Zientek D
AUID- ORCID: http://orcid.org/0000-0001-5531-5550
AD  - Seton Heart Institute, and the University of Texas at Austin Dell, Medical
      School, 1301 W. 38th Street, suite 405, Austin, TX, 78705, USA.
      dzientek@ascension.org.
LA  - eng
PT  - Journal Article
DEP - 20201004
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Developing Countries
MH  - Ethics, Medical
MH  - Health Resources/*ethics/*supply & distribution
MH  - Humans
OTO - NOTNLM
OT  - Ethics of extreme or austere environments
OT  - Ethics of natural or man-made disasters
OT  - Ethics of short-term medical and humanitarian missions
OT  - Medical ethics in resource-poor environments
EDAT- 2020/10/05 06:00
MHDA- 2021/07/01 06:00
CRDT- 2020/10/04 20:34
PHST- 2020/09/30 00:00 [accepted]
PHST- 2020/10/05 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
PHST- 2020/10/04 20:34 [entrez]
AID - 10.1007/s10730-020-09427-3 [doi]
AID - 10.1007/s10730-020-09427-3 [pii]
PST - ppublish
SO  - HEC Forum. 2020 Dec;32(4):283-291. doi: 10.1007/s10730-020-09427-3. Epub 2020 Oct
      4.


PMID- 33011617
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 95
DP  - 2020 Dec
TI  - Changes in anti-fat attitudes among undergraduate nursing students.
PG  - 104584
LID - S0260-6917(20)31434-9 [pii]
LID - 10.1016/j.nedt.2020.104584 [doi]
AB  - BACKGROUND: The number of people with obesity has been increasing significantly
      in recent decades. Nursing students play a role in the care of obese patients,
      but the presence of a stigma regarding this patient group reduces the quality of 
      care due to a climate of mistrust and lack of expectations. OBJECTIVES: To
      analyse if the anti-fat attitudes of nursing students at the Faculty of Nursing, 
      Physiotherapy and Podiatry at Universidad de Sevilla (Spain) change during their 
      degree training. DESIGN: A cross-sectional study was carried out. SETTINGS:
      Undergraduate nursing institution in Spain. PARTICIPANTS: 578 nursing students
      enrolled at the Faculty in all academic years, from the first through the fourth.
      METHODS: Following ethical approval, each participant took part in an individual 
      self-report via the Anti-Fat Attitudes (AFA) Questionnaire, in its validated
      Spanish version. RESULTS: The mean standardised AFA total was 2.29.; by domains: 
      1.29 in Dislike, 2.87 in Fear of fat, and 3.73 in Willpower. Analysis of variance
      tests showed significant differences in the AFA total score and domains by sex
      and academic year. Multiple linear regression analysis demonstrated that the
      highest prejudices were shown by enrolled participants in their first year,
      particularly when the AFA total score was considered. CONCLUSIONS: Nursing
      students at the Faculty do not have many prejudices towards obese people.
      Anti-obesity attitudes among nursing students decrease as the students progress
      in their degree, implying that the specific training received (degree curriculum)
      also enables students to develop their non-technical skills.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Rodriguez-Gazquez, Maria de Los Angeles
AU  - Rodriguez-Gazquez MLA
AD  - Faculty of Nursing, Universidad de Antioquia, C/70 n masculine. 52-21, Medellin, 
      Colombia. Electronic address: maria.rodriguezg@udea.edu.co.
FAU - Ruiz-Iglesias, Ana
AU  - Ruiz-Iglesias A
AD  - Department of Nursing, Faculty of Nursing, Physiotherapy and Podiatry,
      Universidad de Sevilla, Seville, Spain, C/ Avenzoar, n masculine 6, 41009
      Seville, Spain. Electronic address: aruiz33@us.es.
FAU - Gonzalez-Lopez, Jose Rafael
AU  - Gonzalez-Lopez JR
AD  - Department of Nursing, Faculty of Nursing, Physiotherapy and Podiatry,
      Universidad de Sevilla, Seville, Spain, C/ Avenzoar, n masculine 6, 41009
      Seville, Spain. Electronic address: joserafael@us.es.
LA  - eng
PT  - Journal Article
DEP - 20200829
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - *Education, Nursing, Baccalaureate
MH  - Humans
MH  - Spain
MH  - *Students, Nursing
MH  - Surveys and Questionnaires
EDAT- 2020/10/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/04 20:29
PHST- 2019/04/18 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/10/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/04 20:29 [entrez]
AID - S0260-6917(20)31434-9 [pii]
AID - 10.1016/j.nedt.2020.104584 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Dec;95:104584. doi: 10.1016/j.nedt.2020.104584. Epub 2020 
      Aug 29.


PMID- 33011216
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1873-1708 (Electronic)
IS  - 0890-6238 (Linking)
VI  - 98
DP  - 2020 Dec
TI  - Integrating biokinetics and in vitro studies to evaluate developmental
      neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells
      undergoing differentiation towards neuronal and glial cells.
PG  - 174-188
LID - S0890-6238(20)30214-8 [pii]
LID - 10.1016/j.reprotox.2020.09.010 [doi]
AB  - For some complex toxicological endpoints, chemical safety assessment has
      conventionally relied on animal testing. Apart from the ethical issues, also
      scientific considerations have been raised concerning the traditional approach,
      highlighting the importance for considering real life exposure scenario.
      Implementation of flexible testing strategies, integrating multiple sources of
      information, including in vitro reliable test methods and in vitro biokinetics,
      would enhance the relevance of the obtained results. Such an approach could be
      pivotal in the evaluation of developmental neurotoxicity (DNT), especially when
      applied to human cell-based models, mimicking key neurodevelopmental processes,
      relevant to human brain development. Here, we integrated the kinetic behaviour
      with the toxicodynamic alterations of chlorpyrifos (CPF), such as in vitro
      endpoints specific for DNT evaluation, after repeated exposure during
      differentiation of human neural stem cells into a mixed culture of neurons and
      astrocytes. The upregulation of some cytochrome P450 and glutathione
      S-transferase genes during neuronal differentiation and the formation of the two 
      major CPF metabolites (due to bioactivation and detoxification) supported the
      metabolic competence of the used in vitro model. The alterations in the number of
      synapses, neurite outgrowth, brain derived neurotrophic factor, the proportion of
      neurons and astrocytes, as well as spontaneous electrical activity correlated
      well with the CPF ability to enter the cells and be bioactivated to CPF-oxon.
      Overall, our results confirm that combining in vitro biokinetics and assays to
      evaluate effects on neurodevelopmental endpoints in human cells should be
      regarded as a key strategy for a quantitative characterization of DNT effects.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Di Consiglio, Emma
AU  - Di Consiglio E
AD  - Istituto Superiore di Sanita, Environment and Health Department, Mechanisms,
      Biomarkers and Models Unit, Rome, Italy.
FAU - Pistollato, Francesca
AU  - Pistollato F
AD  - European Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic
      address: Francesca.PISTOLLATO@ec.europa.eu.
FAU - Mendoza-De Gyves, Emilio
AU  - Mendoza-De Gyves E
AD  - European Commission, Joint Research Centre (JRC), Ispra, Italy.
FAU - Bal-Price, Anna
AU  - Bal-Price A
AD  - European Commission, Joint Research Centre (JRC), Ispra, Italy.
FAU - Testai, Emanuela
AU  - Testai E
AD  - Istituto Superiore di Sanita, Environment and Health Department, Mechanisms,
      Biomarkers and Models Unit, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - United States
TA  - Reprod Toxicol
JT  - Reproductive toxicology (Elmsford, N.Y.)
JID - 8803591
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Insecticides)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - JCS58I644W (Chlorpyrifos)
SB  - IM
MH  - Biological Assay
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured
MH  - Chlorpyrifos/pharmacokinetics/*toxicity
MH  - Coculture Techniques
MH  - Cytochrome P-450 Enzyme System/genetics
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology
MH  - Insecticides/pharmacokinetics/*toxicity
MH  - Neural Stem Cells/cytology/*drug effects
MH  - Neuroglia/cytology/drug effects
MH  - Neurons/cytology/drug effects
MH  - *Neurotoxicity Syndromes
PMC - PMC7772889
OTO - NOTNLM
OT  - *Biokinetics
OT  - *Chlorpyrifos
OT  - *Developmental neurotoxicity
OT  - *Human iPSC-derived neural stem cells
OT  - *Repeated exposure
EDAT- 2020/10/05 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/10/04 20:22
PHST- 2020/08/06 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/05 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/10/04 20:22 [entrez]
AID - S0890-6238(20)30214-8 [pii]
AID - 10.1016/j.reprotox.2020.09.010 [doi]
PST - ppublish
SO  - Reprod Toxicol. 2020 Dec;98:174-188. doi: 10.1016/j.reprotox.2020.09.010. Epub
      2020 Oct 1.


PMID- 33010668
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 95
DP  - 2020 Dec
TI  - Bioethics education and the development of nursing students' moral competence.
PG  - 104601
LID - S0260-6917(20)31451-9 [pii]
LID - 10.1016/j.nedt.2020.104601 [doi]
AB  - BACKGROUND: The nurse accompanies individuals throughout their lives and, when in
      the hospital environment, provides care to those who face illness or injury.
      Nurses witness numerous situations involving ethical dilemmas that require a
      prompt and effective response based on ethical and moral principles. OBJECTIVES: 
      This study aimed to determine whether bioethics education in nursing influences
      the level of moral competence and opinion of nursing students about three ethical
      dilemmas. METHODS: A longitudinal study was conducted through the application of 
      the MCTxt (Moral Competence Test extended) questionnaire, composed of three
      ethical dilemmas (worker, doctor and judge), on two separate occasions (before
      and after students completed the Bioethics and Nursing Ethics curricular unit,
      which covered a total of 32 h). PARTICIPANTS: 122 s-year students from a
      Portuguese nursing school. RESULTS: Nursing students showed a moral competence
      stagnation (1.2-point difference between the two assessments), although this did 
      not reach statistical significance (p = 0.268). Regarding performance for each of
      the dilemmas, students showed an increase in performance for the worker's and
      judge's dilemmas and a sharp decrease in performance for the doctor's dilemma.
      CONCLUSIONS: The support of students by morally competent teachers and monitors, 
      the development of methods that provide the development of critical judgement and
      decision-making ability, and the increase of hours for the Bioethics course unit 
      seem crucial factors to develop nursing students' moral competence.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Martins, Vera
AU  - Martins V
AD  - Center for Health Technology and Services Research (CINTESIS), R. Dr. Placido da 
      Costa, 4200-450 Porto, Portugal. Electronic address: veritaas@gmail.com.
FAU - Santos, Cristina
AU  - Santos C
AD  - Center for Health Technology and Services Research (CINTESIS), R. Dr. Placido da 
      Costa, 4200-450 Porto, Portugal; Department of Community Medicine, Information
      and Health Decision Sciences, Faculty of Medicine, University of Porto, Al. Prof.
      Hernani Monteiro, 4200- 319 Porto, Portugal.
FAU - Duarte, Ivone
AU  - Duarte I
AD  - Center for Health Technology and Services Research (CINTESIS), R. Dr. Placido da 
      Costa, 4200-450 Porto, Portugal; Department of Community Medicine, Information
      and Health Decision Sciences, Faculty of Medicine, University of Porto, Al. Prof.
      Hernani Monteiro, 4200- 319 Porto, Portugal. Electronic address:
      iduarte@med.up.pt.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - *Bioethics
MH  - *Ethics, Nursing
MH  - Humans
MH  - Longitudinal Studies
MH  - Moral Development
MH  - Morals
MH  - *Students, Nursing
OTO - NOTNLM
OT  - Ethics
OT  - Moral development
OT  - Nursing education
OT  - Nursing students
EDAT- 2020/10/04 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/03 20:16
PHST- 2019/08/22 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/03 20:16 [entrez]
AID - S0260-6917(20)31451-9 [pii]
AID - 10.1016/j.nedt.2020.104601 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Dec;95:104601. doi: 10.1016/j.nedt.2020.104601. Epub 2020 
      Sep 21.


PMID- 33010079
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 29
IP  - 23-24
DP  - 2020 Dec
TI  - Nurses' perspectives on climate change, health and nursing practice.
PG  - 4759-4768
LID - 10.1111/jocn.15519 [doi]
AB  - AIMS AND OBJECTIVES: The purpose of this study was to explore Canadian nurses'
      perspectives on climate change, health, nursing practice and the relationships
      between these concepts. BACKGROUND: Climate change negatively impacts human
      health. With a mandate to promote health, nurses have a professional and ethical 
      responsibility to address climate change. Little is known about Canadian nurses' 
      perspectives on climate change or how they perceive of their professional
      responsibility towards addressing it. METHODS: A focused ethnography was
      conducted in three medicine units and the emergency room at a Canadian hospital. 
      Nurses (n = 22) participated in semi-structured interviews, and observations were
      collected. Data were analysed via thematic analysis. Reporting is in accordance
      with the COREQ guideline. RESULTS: Three themes were identified: muddled
      terminology, climate change and health, and nursing's relationship to climate
      change. CONCLUSION: Participants had varying levels of knowledge about climate
      change and its relationship to health or practice. Climate change was a personal 
      concern, and nursing's role in addressing it was not understood. RELEVANCE TO
      PRACTICE: This study highlighted that practising nurses did not readily recognise
      their role in addressing climate change. More work is needed to clarify this role
      and bring it into the consciousness of every-day nursing practice. Furthermore,
      more work is needed to examine how healthcare organisations can better support
      environmentally responsible nursing practice.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Kalogirou, Maya R
AU  - Kalogirou MR
AUID- ORCID: https://orcid.org/0000-0003-2709-488X
AD  - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada.
FAU - Dahlke, Sherry
AU  - Dahlke S
AUID- ORCID: https://orcid.org/0000-0001-6599-3101
AD  - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada.
FAU - Davidson, Sandra
AU  - Davidson S
AD  - Faculty of Nursing, University of Calgary, Calgary, AB, Canada.
FAU - Yamamoto, Shelby
AU  - Yamamoto S
AUID- ORCID: https://orcid.org/0000-0002-1156-3699
AD  - School of Public Health, University of Alberta, Edmonton, AB, Canada.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
MH  - Canada
MH  - *Climate Change
MH  - *Delivery of Health Care
MH  - Humans
MH  - Morals
MH  - *Nursing
MH  - Qualitative Research
OTO - NOTNLM
OT  - attitudes
OT  - climate change
OT  - environment
OT  - ethnography
OT  - nursing
EDAT- 2020/10/04 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/10/03 12:05
PHST- 2020/08/27 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/10/03 12:05 [entrez]
AID - 10.1111/jocn.15519 [doi]
PST - ppublish
SO  - J Clin Nurs. 2020 Dec;29(23-24):4759-4768. doi: 10.1111/jocn.15519. Epub 2020 Oct
      15.


PMID- 33009784
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 9
DP  - 2020 Sep 1
TI  - What the Activism and Art of Felix Gonzalez-Torres and Gregg Bordowitz Teach Us
      About Health and Human Rights.
PG  - E821-829
LID - amajethics.2020.821 [pii]
LID - 10.1001/amajethics.2020.821 [doi]
AB  - Living through a pandemic and social upheaval suggests the importance of
      revisiting the intersections of the art and activism of Felix Gonzalez-Torres and
      Gregg Bordowitz. These artists' works express their experiences of living through
      a pandemic and subsequent social change and draw out key human rights themes. The
      works' materials, poetics, and invitations to interact offer opportunities for
      audiences to reflect on complex and ethically relevant social and cultural
      dynamics that surface during global crises, such as negotiating personal and
      collective interests, the politics of touch and coexistence, and cultivating
      resilience and strength.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Tavano, Giannella Ysasi
AU  - Tavano GY
AD  - Fellow at the Learning and Public Engagement Department at the Art Institute of
      Chicago in Chicago, Illinois.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Art
MH  - *Human Rights
MH  - Humans
MH  - Politics
MH  - Social Change
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 08:33
PHST- 2020/10/03 08:33 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.821 [pii]
AID - 10.1001/amajethics.2020.821 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Sep 1;22(9):E821-829. doi: 10.1001/amajethics.2020.821.


PMID- 33009783
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 9
DP  - 2020 Sep 1
TI  - Data, Decisions, White Coats.
PG  - E818-820
LID - amajethics.2020.818 [pii]
LID - 10.1001/amajethics.2020.818 [doi]
AB  - White coats are symbols of power that express historically entrenched ideals of
      clinical purity, sterility, and control. These ideals tend to oversimplify
      ethical and clinical complexities inherent in evolutions constantly taking place 
      in health care practice. This pen and ink drawing interrogates these ideals
      visually and reimagines the white coat in the context of more realistic dynamism.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Chen, Christine Lynn
AU  - Chen CL
AD  - Second-year medical student at UT Southwestern Medical School in Dallas, Texas.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
EDAT- 2020/10/04 06:00
MHDA- 2020/10/04 06:01
CRDT- 2020/10/03 08:33
PHST- 2020/10/03 08:33 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2020/10/04 06:01 [medline]
AID - amajethics.2020.818 [pii]
AID - 10.1001/amajethics.2020.818 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Sep 1;22(9):E818-820. doi: 10.1001/amajethics.2020.818.


PMID- 33009781
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 9
DP  - 2020 Sep 1
TI  - Ageism as a Species of Bias.
PG  - E814-815
LID - amajethics.2020.814 [pii]
LID - 10.1001/amajethics.2020.814 [doi]
AB  - Good health care for elders requires acute ethical attention to the role of
      ageism as a pervasive source of bias. A charcoal drawing of one older woman's
      hand visually examines the nature and scope of younger caregivers'
      responsibilities to geriatric patients and their loved ones.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Miller, Elisabeth
AU  - Miller E
AD  - First-year pathology resident at the University of Virginia in Charlottesville.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Aged
MH  - *Ageism
MH  - Bias
MH  - Caregivers
MH  - Female
MH  - Humans
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 08:33
PHST- 2020/10/03 08:33 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.814 [pii]
AID - 10.1001/amajethics.2020.814 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Sep 1;22(9):E814-815. doi: 10.1001/amajethics.2020.814.


PMID- 33009776
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 9
DP  - 2020 Sep 1
TI  - Ethical Choice Architecture in Preabortion Counseling.
PG  - E792-795
LID - amajethics.2020.792 [pii]
LID - 10.1001/amajethics.2020.792 [doi]
AB  - Most women requesting pregnancy termination have already decided to undergo an
      abortion. Physicians are required to obtain informed consent after offering
      objective and accurate descriptions of abortion and its risks and benefits. Some 
      jurisdictions also require concurrent counseling and ultrasound viewing. This
      article discusses potential benefits and harms of providing emotionally charged
      or biased content about abortions at the time of service, considers what
      constitutes ethical content, and explores when ethical content should be part of 
      abortion decision making.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Westbrook, Carol A
AU  - Westbrook CA
AD  - Medical oncologist who spent her academic career at the University of Chicago,
      the University of Illinois, and Boston University.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Abortion, Induced
MH  - Counseling
MH  - Female
MH  - Humans
MH  - Informed Consent
MH  - Morals
MH  - Pregnancy
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 08:33
PHST- 2020/10/03 08:33 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.792 [pii]
AID - 10.1001/amajethics.2020.792 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Sep 1;22(9):E792-795. doi: 10.1001/amajethics.2020.792.


PMID- 33009775
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 9
DP  - 2020 Sep 1
TI  - Sharing Ethics Consultation Notes With Patients Through Online Portals.
PG  - E784-791
LID - amajethics.2020.784 [pii]
LID - 10.1001/amajethics.2020.784 [doi]
AB  - Many health systems have adopted online patient portals that allow patients to
      easily view their health records. As a result, notes written by health care
      professionals are increasingly read by both clinicians and patients, and
      clinicians in specialties that routinely involve sensitive information (eg,
      mental health care) have had to construct notes in a manner that respectfully
      promotes therapeutic relationships with patients. This article discusses whether 
      ethics consultation services should share notes with patients through online
      portals and ways to handle practical implementation challenges. In support of
      sharing notes, this article appeals to an existing right that patients have to
      access their health record and suggests that sharing ethics consultation notes
      might help patients understand key clinical ethics concepts and practices.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Mangino, Dominic R
AU  - Mangino DR
AD  - Postbaccalaureate fellow in the Department of Bioethics at the Clinical Center of
      the National Institutes of Health in Bethesda, Maryland.
FAU - Danis, Marion
AU  - Danis M
AD  - Head of the Section on Ethics and Health Policy in the Department of Bioethics at
      the Clinical Center of the National Institutes of Health (NIH) in Bethesda,
      Maryland, and chief of the Bioethics Consultation Service at the NIH Clinical
      Center.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Electronic Health Records
MH  - *Ethics Consultation
MH  - Humans
MH  - *Patient Portals
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 08:33
PHST- 2020/10/03 08:33 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.784 [pii]
AID - 10.1001/amajethics.2020.784 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Sep 1;22(9):E784-791. doi: 10.1001/amajethics.2020.784.


PMID- 33009772
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 9
DP  - 2020 Sep 1
TI  - Is It Justifiable to Make Self-Determination Illusory to Motivate a Specific
      Health Outcome?
PG  - E767-772
LID - amajethics.2020.767 [pii]
LID - 10.1001/amajethics.2020.767 [doi]
AB  - A nudge is an intervention designed to prompt people to "voluntarily" make the
      choice intended by those who altered the choice environment or situation, and
      therefore using nudges is thought to undermine self-determination. Evidence for
      this assumption is weak, however, and sets aside much of what we know about human
      conduct sociologically. This paper argues that the practical consciousness that
      people have about their own actions and reasons for executing those actions can
      inform our thinking about motivating compliance with treatments in clinical
      settings and the ethical issues involved.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Kelly, Michael P
AU  - Kelly MP
AD  - Visiting fellow at the Institute of Public Health at the University of Cambridge 
      in Cambridge, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Humans
MH  - *Outcome Assessment, Health Care
MH  - *Personal Autonomy
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 08:33
PHST- 2020/10/03 08:33 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.767 [pii]
AID - 10.1001/amajethics.2020.767 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Sep 1;22(9):E767-772. doi: 10.1001/amajethics.2020.767.


PMID- 33009429
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20211002
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Oct 2
TI  - Use of artificial intelligence to recover mandibular morphology after disease.
PG  - 16431
LID - 10.1038/s41598-020-73394-5 [doi]
AB  - Mandibular tumors and radical oral cancer surgery often cause bone dysmorphia and
      defects. Most patients present with noticeable mandibular deformations, and
      doctors often have difficulty determining their exact mandibular morphology. In
      this study, a deep convolutional generative adversarial network (DCGAN) called
      CTGAN is proposed to complete 3D mandibular cone beam computed tomography data
      from CT data. After extensive training, CTGAN was tested on 6 mandibular tumor
      cases, resulting in 3D virtual mandibular completion. We found that CTGAN can
      generate mandibles with different levels and rich morphology, including
      positional and angular changes and local patterns. The completion results are
      shown as tomographic images combining generated and natural areas. The 3D
      generated mandibles have the anatomical morphology of the real mandibles and
      transition smoothly to the portions without disease, showing that CTGAN
      constructs mandibles with the expected patient characteristics and is suitable
      for mandibular morphological completion. The presented modeling principles can be
      applied to other areas for 3D morphological completion from medical
      images.Clinical trial registration: This study is not a clinical trial. Patient
      data were only used for testing in a virtual environment. The use of the digital 
      data used in this study was ethically approved.
FAU - Liang, Ye
AU  - Liang Y
AD  - Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya
      Hospital, Central South University, Changsha, 410008, Hunan Province, China.
AD  - School of Life Sciences, Central South University, Changsha, 410078, Hunan
      Province, China.
FAU - Huan, JingJing
AU  - Huan J
AD  - Xiangya Application Institute, Engineering Research Center of Hunan Province of
      Material Increasing Manufacturing, Central South University, Changsha, 410008,
      Hunan Province, China.
FAU - Li, Jia-Da
AU  - Li JD
AD  - School of Life Sciences, Central South University, Changsha, 410078, Hunan
      Province, China. Lijiada@sklmg.edu.cn.
FAU - Jiang, CanHua
AU  - Jiang C
AD  - Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya
      Hospital, Central South University, Changsha, 410008, Hunan Province, China.
FAU - Fang, ChangYun
AU  - Fang C
AD  - Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya
      Hospital, Central South University, Changsha, 410008, Hunan Province, China.
FAU - Liu, YongGang
AU  - Liu Y
AD  - Xiangya Application Institute, Engineering Research Center of Hunan Province of
      Material Increasing Manufacturing, Central South University, Changsha, 410008,
      Hunan Province, China.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201002
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - *Artificial Intelligence
MH  - Disease
MH  - Female
MH  - Humans
MH  - Male
MH  - Mandible/*anatomy & histology
MH  - Tomography, X-Ray Computed/methods
PMC - PMC7532179
EDAT- 2020/10/04 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/10/03 05:30
PHST- 2019/10/16 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/10/03 05:30 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.1038/s41598-020-73394-5 [doi]
AID - 10.1038/s41598-020-73394-5 [pii]
PST - epublish
SO  - Sci Rep. 2020 Oct 2;10(1):16431. doi: 10.1038/s41598-020-73394-5.


PMID- 33009233
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20211203
IS  - 1528-1132 (Electronic)
IS  - 0009-921X (Linking)
VI  - 478
IP  - 12
DP  - 2020 Dec
TI  - Virtue Ethics in a Value-driven World: It's Always with Me.
PG  - 2714-2716
LID - 10.1097/CORR.0000000000001512 [doi]
FAU - Humbyrd, Casey Jo
AU  - Humbyrd CJ
AD  - C. J. Humbyrd, Associate Professor of Orthopaedic Surgery and Chief, Foot and
      Ankle Division, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 0 (Narcotic Antagonists)
RN  - 36B82AMQ7N (Naloxone)
SB  - IM
MH  - Altruism
MH  - *Attitude of Health Personnel
MH  - Drug Overdose/*drug therapy/mortality
MH  - *Ethics, Medical
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Naloxone/*therapeutic use
MH  - Narcotic Antagonists/*therapeutic use
MH  - *Opioid Epidemic
MH  - Opioid-Related Disorders/*drug therapy/mortality
MH  - *Physician's Role
PMC - PMC7899412
EDAT- 2020/10/04 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/10/03 05:28
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/10/03 05:28 [entrez]
AID - 10.1097/CORR.0000000000001512 [doi]
AID - 00003086-202012000-00006 [pii]
PST - ppublish
SO  - Clin Orthop Relat Res. 2020 Dec;478(12):2714-2716. doi:
      10.1097/CORR.0000000000001512.


PMID- 33009123
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1531-698X (Electronic)
IS  - 1040-8703 (Linking)
VI  - 32
IP  - 6
DP  - 2020 Dec
TI  - A review of current controversies in determining death by neurologic criteria in 
      children.
PG  - 759-764
LID - 10.1097/MOP.0000000000000952 [doi]
AB  - PURPOSE OF REVIEW: Death by neurologic criteria (DNC) is the irreversible
      cessation of all functions of the entire brain, including the brainstem. It is
      legally recognized as equivalent to cardiopulmonary death. Legal and ethical
      controversies surrounding DNC have emerged as a result of several highly
      publicized cases that have eroded public trust in our ability to declare DNC
      accurately. In this review, we focus on recently published primary data about DNC
      and address some of these controversies. RECENT FINDINGS: Approximately 21% of
      children who die in pediatric intensive care units (PICU) are declared DNC.
      Although 60% of physicians report that they have been asked to maintain organ
      support after DNC declaration, less than 1% of patients remain physically present
      in the PICU more than 5 days after DNC declaration. We discuss strategies for
      safely conducting the apnea test, indications and prevalence of ancillary
      testing, and objections to DNC, including issues of consent and requests for
      ongoing organ support. SUMMARY: In order to maintain public trust, published
      guidelines must be followed to accurately and consistently diagnose DNC. We must 
      develop strategies to respond to objections to DNC determination. Ongoing
      research is needed to improve the safety of apnea testing and indications for and
      interpretation of ancillary testing.
FAU - Virupakshaiah, Akash
AU  - Virupakshaiah A
AD  - Department of Neurology.
FAU - Ichord, Rebecca
AU  - Ichord R
AD  - Department of Neurology.
AD  - Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, 
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
      Philadelphia, Pennsylvania, USA.
FAU - Topjian, Alexis A
AU  - Topjian AA
AD  - Department of Anesthesiology and Critical Care Medicine.
AD  - Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, 
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
      Philadelphia, Pennsylvania, USA.
FAU - Kirschen, Matthew P
AU  - Kirschen MP
AD  - Department of Neurology.
AD  - Department of Anesthesiology and Critical Care Medicine.
AD  - Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, 
      Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
      Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Pediatr
JT  - Current opinion in pediatrics
JID - 9000850
SB  - IM
MH  - *Brain Death/diagnosis
MH  - Child
MH  - *Diagnostic Techniques, Neurological
MH  - Humans
MH  - Intensive Care Units, Pediatric
EDAT- 2020/10/04 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/10/03 05:27
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/10/03 05:27 [entrez]
AID - 10.1097/MOP.0000000000000952 [doi]
AID - 00008480-202012000-00009 [pii]
PST - ppublish
SO  - Curr Opin Pediatr. 2020 Dec;32(6):759-764. doi: 10.1097/MOP.0000000000000952.


PMID- 33008958
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 96
IP  - 1141
DP  - 2020 Nov
TI  - Maintaining High Professional Standards, morally, ethically and fairly: what
      doctors need to know right now.
PG  - 711-717
LID - 10.1136/postgradmedj-2020-138851 [doi]
AB  - Facing an investigation into performance concerns can be one of the most
      traumatic events in a doctor's career, and badly handled investigations can lead 
      to severe distress. Yet there is no systematic way for National Health Service
      (NHS) Trusts to record the frequency of investigations, and extremely little data
      on the long-term outcomes of such action for the doctors. The
      document-Maintaining High Professional Standards in the Modern NHS (a framework
      for the initial investigation of concerns about doctors and dentists in the
      NHS)-should protect doctors from facing unfair or mismanaged performance
      management procedures, which include conduct, capability and health. Equally, it 
      provides NHS Trusts with a framework that must be adhered to when managing
      performance concerns regarding doctors. Yet, very few doctors have even heard of 
      it or know about the provisions it contains for their protection, and the
      implementation of the framework appears to be very variable across NHS Trusts. By
      empowering all doctors with the knowledge of what performance management
      procedures exist and how best practice should be implemented, we aim to ensure
      that they are informed participants in any investigation should it occur.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Ataullah, Ifat
AU  - Ataullah I
AD  - Retired Medical Practitioner, Writer, UK ifatataullah@gmail.com.
FAU - Livesey, Alexandra
AU  - Livesey A
AUID- ORCID: http://orcid.org/0000-0003-3991-6959
AD  - Surrey and Borders NHS Foundation Trust, UK.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
MH  - Clinical Competence/*standards
MH  - Humans
MH  - Liability, Legal
MH  - Medical Errors/legislation & jurisprudence/prevention & control
MH  - Personnel Management/methods
MH  - *Physicians/psychology/standards
MH  - *Professional Practice/organization & administration/standards
MH  - *Professionalism/ethics/legislation & jurisprudence/standards
MH  - State Medicine/standards
MH  - United Kingdom
MH  - Work Performance/*standards
MH  - Workforce/organization & administration
OTO - NOTNLM
OT  - Health policy
OT  - Health services administration & management
OT  - Human resource management
OT  - Medical education & training
OT  - Medical law
OT  - Protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/10/04 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/10/03 05:26
PHST- 2020/08/13 00:00 [received]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
PHST- 2020/10/03 05:26 [entrez]
AID - postgradmedj-2020-138851 [pii]
AID - 10.1136/postgradmedj-2020-138851 [doi]
PST - ppublish
SO  - Postgrad Med J. 2020 Nov;96(1141):711-717. doi: 10.1136/postgradmedj-2020-138851.
      Epub 2020 Oct 2.


PMID- 33008586
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 533
IP  - 4
DP  - 2020 Dec 17
TI  - Human iPS cell-derived astrocytes support efficient replication of progressive
      multifocal leukoencephalopathy-type JC polyomavirus.
PG  - 983-987
LID - S0006-291X(20)31870-2 [pii]
LID - 10.1016/j.bbrc.2020.09.117 [doi]
AB  - JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), 
      a demyelinating disease of the central nervous system, in immunocompromised
      patients. Although PML used to be rare, recently the incidence of PML has risen
      due to an increase in immunosuppressive therapy. An in vitro JCPyV infection
      system could be used for anti-drug screening and investigation of tropism
      changes, but study of JCPyV in vitro has been limited due to the difficulty of
      efficiently propagating the virus in cultured cells. PML-type JCPyV efficiently
      propagates in primary human fetal and progenitor cell-derived astrocytes, but the
      preparation of cells from human fetuses is associated with severe ethical
      problems. In this study, human iPS cell-derived astrocytes were exposed to
      PML-type JCPyV. Infection, replication, and VP1 and T antigens of JCPyV were
      detected and confirmed in this culture. The non-coding control region (NCCR) of
      M1-IMRb was conserved in infected cells without point mutations. In addition,
      PML-type JCPyV genomic DNA in infected cells was detected as a single band of
      approximately 5.1 kbp, with no deletions. This is the first demonstration that
      human iPS cell-derived astrocytes efficiently support replication of PML-type
      JCPyV without production of defective interfering particles. These findings
      indicated that a culture system using human iPS cell-derived astrocyte would be
      useful for studies of PML, especially for screening anti-JCPyV drugs.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Shimbo, Emiko
AU  - Shimbo E
AD  - Tokyo Institute of Technology School of Life Science and Technology, 4259
      Nagatsuta-cho, Midori-ku, Yokohama-shi, Kanagawa, 226-8501, Japan.
FAU - Nukuzuma, Souichi
AU  - Nukuzuma S
AD  - Department of Infectious Diseases, Kobe Institute of Health, 4-6-5, Minatojima
      Nakamachi, Chuo-ku, Kobe, 650-0046, Japan.
FAU - Tagawa, Yoh-Ichi
AU  - Tagawa YI
AD  - Tokyo Institute of Technology School of Life Science and Technology, 4259
      Nagatsuta-cho, Midori-ku, Yokohama-shi, Kanagawa, 226-8501, Japan. Electronic
      address: ytagawa@bio.titech.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Antigens, Viral)
RN  - 0 (Antigens, Viral, Tumor)
RN  - 0 (Capsid Proteins)
RN  - 0 (DNA, Viral)
RN  - 0 (VP1 protein, polyomavirus)
SB  - IM
MH  - Animals
MH  - Antigens, Viral/biosynthesis
MH  - Antigens, Viral, Tumor/biosynthesis
MH  - Astrocytes/pathology/*virology
MH  - COS Cells
MH  - Capsid Proteins/biosynthesis/immunology
MH  - Cell Differentiation
MH  - Cell Line
MH  - Chlorocebus aethiops
MH  - DNA, Viral/genetics
MH  - Genome, Viral
MH  - Humans
MH  - Induced Pluripotent Stem Cells/pathology/*virology
MH  - JC Virus/genetics/pathogenicity/*physiology
MH  - Leukoencephalopathy, Progressive Multifocal/etiology/pathology/*virology
MH  - Neural Stem Cells/pathology
MH  - Virus Cultivation/methods
MH  - Virus Replication
OTO - NOTNLM
OT  - *Astrocyte
OT  - *JC polyomavirus
OT  - *M1-IMRb
OT  - *PML
OT  - *iPS cell
COIS- Declaration of competing interest The authors declare no conflicts of interest.
EDAT- 2020/10/04 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/10/03 05:24
PHST- 2020/09/24 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/10/03 05:24 [entrez]
AID - S0006-291X(20)31870-2 [pii]
AID - 10.1016/j.bbrc.2020.09.117 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2020 Dec 17;533(4):983-987. doi:
      10.1016/j.bbrc.2020.09.117. Epub 2020 Sep 30.


PMID- 33008459
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20201218
IS  - 1479-7364 (Electronic)
IS  - 1473-9542 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Oct 2
TI  - Practicing precision medicine with intelligently integrative clinical and
      multi-omics data analysis.
PG  - 35
LID - 10.1186/s40246-020-00287-z [doi]
AB  - Precision medicine aims to empower clinicians to predict the most appropriate
      course of action for patients with complex diseases like cancer, diabetes,
      cardiomyopathy, and COVID-19. With a progressive interpretation of the clinical, 
      molecular, and genomic factors at play in diseases, more effective and
      personalized medical treatments are anticipated for many disorders. Understanding
      patient's metabolomics and genetic make-up in conjunction with clinical data will
      significantly lead to determining predisposition, diagnostic, prognostic, and
      predictive biomarkers and paths ultimately providing optimal and personalized
      care for diverse, and targeted chronic and acute diseases. In clinical settings, 
      we need to timely model clinical and multi-omics data to find statistical
      patterns across millions of features to identify underlying biologic pathways,
      modifiable risk factors, and actionable information that support early detection 
      and prevention of complex disorders, and development of new therapies for better 
      patient care. It is important to calculate quantitative phenotype measurements,
      evaluate variants in unique genes and interpret using ACMG guidelines, find
      frequency of pathogenic and likely pathogenic variants without disease
      indicators, and observe autosomal recessive carriers with a phenotype
      manifestation in metabolome. Next, ensuring security to reconcile noise, we need 
      to build and train machine-learning prognostic models to meaningfully process
      multisource heterogeneous data to identify high-risk rare variants and make
      medically relevant predictions. The goal, today, is to facilitate implementation 
      of mainstream precision medicine to improve the traditional symptom-driven
      practice of medicine, and allow earlier interventions using predictive
      diagnostics and tailoring better-personalized treatments. We strongly recommend
      automated implementation of cutting-edge technologies, utilizing machine learning
      (ML) and artificial intelligence (AI) approaches for the multimodal data
      aggregation, multifactor examination, development of knowledgebase of clinical
      predictors for decision support, and best strategies for dealing with relevant
      ethical issues.
FAU - Ahmed, Zeeshan
AU  - Ahmed Z
AUID- ORCID: 0000-0002-7065-1699
AD  - Institute for Health, Health Care Policy and Aging Research, Rutgers University, 
      112 Paterson Street, New Brunswick, NJ, USA. zahmed@ifh.rutgers.edu.
AD  - Department of Medicine, Robert Wood Johnson Medical School, Rutgers Biomedical
      and Health Sciences, 125 Paterson Street, New Brunswick, NJ, USA.
      zahmed@ifh.rutgers.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201002
PL  - England
TA  - Hum Genomics
JT  - Human genomics
JID - 101202210
SB  - IM
MH  - COVID-19
MH  - Cardiomyopathies
MH  - Coronavirus Infections/epidemiology/*genetics
MH  - Data Analysis
MH  - Diabetes Mellitus/epidemiology/*genetics
MH  - Genomics/trends
MH  - Humans
MH  - Metabolomics/trends
MH  - Neoplasms/epidemiology/*genetics
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*genetics
MH  - Precision Medicine/*trends
MH  - Proteomics/trends
PMC - PMC7530549
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Clinics
OT  - *Genomics
OT  - *Integrative analysis
OT  - *Machine learning
OT  - *Metabolomics
OT  - *Precision medicine
EDAT- 2020/10/04 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/03 05:21
PHST- 2020/04/02 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/10/03 05:21 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1186/s40246-020-00287-z [doi]
AID - 10.1186/s40246-020-00287-z [pii]
PST - epublish
SO  - Hum Genomics. 2020 Oct 2;14(1):35. doi: 10.1186/s40246-020-00287-z.


PMID- 33008387
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 2
TI  - Researchers' views on, and experiences with, the requirement to obtain informed
      consent in research involving human participants: a qualitative study.
PG  - 93
LID - 10.1186/s12910-020-00538-7 [doi]
AB  - BACKGROUND: Informed consent is often cited as the "cornerstone" of research
      ethics. Its intent is that participants enter research voluntarily, with an
      understanding of what their participation entails. Despite agreement on the
      necessity to obtain informed consent in research, opinions vary on the threshold 
      of disclosure necessary and the best method to obtain consent. We aimed to
      investigate Australian researchers' views on, and their experiences with,
      obtaining informed consent. METHODS: Semi-structured interviews were conducted
      with 23 researchers from NSW institutions, working in various fields of research.
      Interviews were analysed and coded to identify themes. RESULTS: Researchers
      reported that consent involved information disclosure, understanding and a
      voluntary decision. They emphasised the variability of consent interactions,
      which were dependent on potential participants' abilities and interests, study
      complexity and context. All researchers reported providing written information to
      potential participants, yet questioned the readability and utility of this
      information. The majority reported using signed consent forms to 'operationalise'
      consent and reported little awareness of, and lack of support in implementing
      more dynamic informed consent procedures, such as verbal informed consent, that
      was fit for the purposes of their studies. Views on Human Research Ethics
      Committees (HRECs) varied. Some reported inconsistent, arduous inputs on the
      information form and consent process. Others expressed reliance on HRECs for
      guidance, viewing them as institutional safeguards. CONCLUSIONS: This study
      highlights the importance of transparent relationships, both between researchers 
      and participants, and between researchers and HRECs. Where the relationship with 
      study participants was reported as more robust, researchers felt that they were
      better able to ensure participants made better, more informed decisions. Where
      the relationship with HRECs was reported as more robust, researchers were more
      likely to view them as institutional safeguards, rather than as bureaucratic
      hindrances. Conscientious and mindful researchers are paramount to ensuring the
      procedure accommodates individual requirements. This study advocates that when
      designing ethical informed consent practices, researchers should be integrated as
      autonomous players with a positive input on the process, rather than, in the
      worst case, predatory recruiters to be curtailed by information forms and
      oversight.
FAU - Xu, Antonia
AU  - Xu A
AD  - School of Medical Sciences, University of NSW, Sydney, NSW, Australia.
AD  - Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital,
      Darlinghurst, NSW, Australia.
FAU - Baysari, Melissa Therese
AU  - Baysari MT
AD  - Discipline of Biomedical Informatics and Digital Health, School of Medical
      Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 
      Australia.
FAU - Stocker, Sophie Lena
AU  - Stocker SL
AD  - Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital,
      Darlinghurst, NSW, Australia.
AD  - St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia.
FAU - Leow, Liang Joo
AU  - Leow LJ
AD  - St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia.
AD  - School of Medicine, University of Notre Dame Australia, Sydney, Australia.
FAU - Day, Richard Osborne
AU  - Day RO
AD  - School of Medical Sciences, University of NSW, Sydney, NSW, Australia.
AD  - Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital,
      Darlinghurst, NSW, Australia.
AD  - St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia.
FAU - Carland, Jane Ellen
AU  - Carland JE
AUID- ORCID: 0000-0002-1456-876X
AD  - Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital,
      Darlinghurst, NSW, Australia. jane.carland@svha.org.au.
AD  - St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia.
      jane.carland@svha.org.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201002
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Australia
MH  - Ethics Committees, Research
MH  - Humans
MH  - *Informed Consent
MH  - Qualitative Research
MH  - *Research Personnel
PMC - PMC7531157
OTO - NOTNLM
OT  - *Ethics
OT  - *Informed consent
OT  - *National Statement
OT  - *Researchers' views
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 05:20
PHST- 2020/10/03 05:20 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00538-7 [doi]
AID - 10.1186/s12910-020-00538-7 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 2;21(1):93. doi: 10.1186/s12910-020-00538-7.


PMID- 33008385
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 2
TI  - An ethics analysis of the rationale for publicly funded plastic surgery.
PG  - 94
LID - 10.1186/s12910-020-00539-6 [doi]
AB  - BACKGROUND: Healthcare systems are increasingly struggling with resource
      constraints, given demographic changes, technological development, and citizen
      expectations. The aim of this article is to normatively analyze different
      suggestions regarding how publicly financed plastic surgery should be delineated 
      in order to identify a well-considered, normative rationale. The scope of the
      article is to discuss general principles and not define specific conditions or
      domains of plastic surgery that should be treated within the publicly financed
      system. METHODS: This analysis uses a reflective equilibrium approach, according 
      to which considered normative judgements in one area should be logically and
      argumentatively coherent with considered normative judgements and background
      theories at large within a system. RESULTS AND CONCLUSIONS: In exploring
      functional versus non-function conditions, we argue that it is difficult to find 
      a principled reason for an absolute priority of functional conditions over
      non-functional conditions. Nevertheless, functional conditions are relatively
      easier to establish objectively, and surgical intervention has a clear causal
      effect on treating a functional condition. Considering non-functional conditions 
      that require plastic surgery [i.e., those related to appearance or symptomatic
      conditions (not affecting function)], we argue that the patient needs to
      experience some degree of suffering (and not only a preference for plastic
      surgery), which must be 'validated' in some form by the healthcare system. This
      validation is required for both functional and non-functional conditions.
      Functional conditions are validated by distinguishing between statistically
      normal and abnormal functioning. Similarly, for non-functional conditions,
      statistical normality represents a potential method for distinguishing between
      what should and should not be publicly funded. However, we acknowledge that such 
      a concept requires further development.
FAU - Sandman, Lars
AU  - Sandman L
AUID- ORCID: 0000-0003-0987-7653
AD  - National Centre for Priorities in Health, Department of Health, Medicine and
      Caring Sciences, Linkoping University, S-581 83, Linkoping, Sweden.
      lars.sandman@liu.se.
AD  - , Vastra Gotaland Region, Sweden. lars.sandman@liu.se.
AD  - Boras University, Boras, Sweden. lars.sandman@liu.se.
FAU - Hansson, Emma
AU  - Hansson E
AD  - Department of Plastic and Reconstructive Surgery, Sahlgrenska University
      Hospital, Grona Straket 8, SE-413 45 Gothenburg, Grona Straket 8, SE-413 45,
      Gothenburg, Sweden.
AD  - The Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201002
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Delivery of Health Care
MH  - Health Services
MH  - Humans
MH  - *Surgery, Plastic
PMC - PMC7531084
OTO - NOTNLM
OT  - *Esthetic surgery
OT  - *Etiology
OT  - *Functional condition
OT  - *Healthcare need
OT  - *Normality
OT  - *Patient experience
OT  - *Plastic surgery
OT  - *Prioritizing
OT  - *Psychosocial condition
OT  - *Rationing
EDAT- 2020/10/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/10/03 05:20
PHST- 2019/10/29 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/03 05:20 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00539-6 [doi]
AID - 10.1186/s12910-020-00539-6 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Oct 2;21(1):94. doi: 10.1186/s12910-020-00539-6.


PMID- 33008128
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 19
DP  - 2020 Sep 30
TI  - The Fate of Transplanted Olfactory Progenitors Is Conditioned by the Cell
      Phenotypes of the Receiver Brain Tissue in Cocultures.
LID - E7249 [pii]
LID - 10.3390/ijms21197249 [doi]
AB  - Among the numerous candidates for cell therapy of the central nervous system
      (CNS), olfactory progenitors (OPs) represent an interesting alternative because
      they are free of ethical concerns, are easy to collect, and allow autologous
      transplantation. In the present study, we focused on the optimization of neuron
      production and maturation. It is known that plated OPs respond to various trophic
      factors, and we also showed that the use of Nerve Growth Factor (NGF) allowed
      switching from a 60/40 neuron/glia ratio to an 80/20 one. Nevertheless, in order 
      to focus on the integration of OPs in mature neural circuits, we cocultured OPs
      in primary cultures obtained from the cortex and hippocampus of newborn mice.
      When dissociated OPs were plated, they differentiated into both glial and
      neuronal phenotypes, but we obtained a 1.5-fold higher viability in cortex/OP
      cocultures than in hippocampus/OP ones. The fate of OPs in cocultures was
      characterized with different markers such as BrdU, Map-2, and Synapsin,
      indicating a healthy integration. These results suggest that the integration of
      transplanted OPs might by affected by trophic factors and the environmental
      conditions/cell phenotypes of the host tissue. Thus, a model of coculture could
      provide useful information on key cell events for the use of progenitors in cell 
      therapy.
FAU - Pourie, Gregory
AU  - Pourie G
AUID- ORCID: 0000-0003-0452-5026
AD  - Inserm UMR1256/NGERE, Faculte de Medecine, 9 Avenue de la Foret de Haye,
      Universite de Lorraine, F-54000 Nancy, France.
AD  - Laboratoire de Neurosciences, Place Leclerc, Universite de Franche-Comte, F-25000
      Besancon, France.
FAU - Akchiche, Nassila
AU  - Akchiche N
AD  - Inserm UMR1256/NGERE, Faculte de Medecine, 9 Avenue de la Foret de Haye,
      Universite de Lorraine, F-54000 Nancy, France.
FAU - Millot, Jean-Louis
AU  - Millot JL
AD  - Laboratoire de Neurosciences, Place Leclerc, Universite de Franche-Comte, F-25000
      Besancon, France.
FAU - Gueant, Jean-Louis
AU  - Gueant JL
AUID- ORCID: 0000-0002-5067-042X
AD  - Inserm UMR1256/NGERE, Faculte de Medecine, 9 Avenue de la Foret de Haye,
      Universite de Lorraine, F-54000 Nancy, France.
FAU - Daval, Jean-Luc
AU  - Daval JL
AD  - Inserm UMR1256/NGERE, Faculte de Medecine, 9 Avenue de la Foret de Haye,
      Universite de Lorraine, F-54000 Nancy, France.
FAU - Bossenmeyer-Pourie, Carine
AU  - Bossenmeyer-Pourie C
AD  - Inserm UMR1256/NGERE, Faculte de Medecine, 9 Avenue de la Foret de Haye,
      Universite de Lorraine, F-54000 Nancy, France.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Animals
MH  - Brain/cytology/growth & development/*metabolism
MH  - Cell Differentiation/genetics
MH  - Cell Lineage/genetics
MH  - Central Nervous System/metabolism
MH  - Coculture Techniques
MH  - Humans
MH  - Mice
MH  - Nerve Growth Factor/genetics
MH  - Neuroglia/cytology/metabolism/transplantation
MH  - Neurons/*metabolism/transplantation
MH  - Olfactory Cortex/cytology/*metabolism/transplantation
MH  - Oligodendroglia/cytology/metabolism/transplantation
MH  - *Stem Cell Transplantation
MH  - Stem Cells/*cytology/metabolism
PMC - PMC7582579
OTO - NOTNLM
OT  - *cellular therapy
OT  - *circuit integration
OT  - *cortex
OT  - *hippocampus
OT  - *olfactory progenitors
EDAT- 2020/10/04 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/10/03 01:02
PHST- 2020/08/05 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/03 01:02 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - ijms21197249 [pii]
AID - 10.3390/ijms21197249 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Sep 30;21(19). pii: ijms21197249. doi: 10.3390/ijms21197249.


PMID- 33007752
OWN - NLM
STAT- Publisher
LR  - 20201002
IS  - 1547-5646 (Electronic)
IS  - 1547-5646 (Linking)
DP  - 2020 Oct 2
TI  - Consensus-based perioperative protocols during the COVID-19 pandemic.
PG  - 1-9
LID - 10.3171/2020.6.SPINE20777 [doi]
LID - 2020.6.SPINE20777 [pii]
AB  - OBJECTIVE: During the COVID-19 pandemic, quaternary-care facilities continue to
      provide care for patients in need of urgent and emergent invasive procedures.
      Perioperative protocols are needed to streamline care for these patients
      notwithstanding capacity and resource constraints. METHODS: A multidisciplinary
      panel was assembled at the University of California, San Francisco, with 26
      leaders across 10 academic departments, including 7 department chairpersons, the 
      chief medical officer, the chief operating officer, infection control officers,
      nursing leaders, and resident house staff champions. An epidemiologist, an
      ethicist, and a statistician were also consulted. A modified two-round, blinded
      Delphi method based on 18 agree/disagree statements was used to build consensus. 
      Significant disagreement for each statement was tested using a one-sided exact
      binomial test against an expected outcome of 95% consensus using a significance
      threshold of p < 0.05. Final triage protocols were developed with unblinded
      group-level discussion. RESULTS: Overall, 15 of 18 statements achieved consensus 
      in the first round of the Delphi method; the 3 statements with significant
      disagreement (p < 0.01) were modified and iteratively resubmitted to the expert
      panel to achieve consensus. Consensus-based protocols were developed using
      unblinded multidisciplinary panel discussions. The final algorithms 1) quantified
      outbreak level, 2) triaged patients based on acuity, 3) provided a checklist for 
      urgent/emergent invasive procedures, and 4) created a novel scoring system for
      the allocation of personal protective equipment. In particular, the authors
      modified the American College of Surgeons three-tiered triage system to
      incorporate more urgent cases, as are often encountered in neurosurgery and spine
      surgery. CONCLUSIONS: Urgent and emergent invasive procedures need to be
      performed during the COVID-19 pandemic. The consensus-based protocols in this
      study may assist healthcare providers to optimize perioperative care during the
      pandemic.
FAU - Mummaneni, Praveen V
AU  - Mummaneni PV
AD  - Departments of1Neurological Surgery.
FAU - Burke, John F
AU  - Burke JF
AD  - Departments of1Neurological Surgery.
FAU - Chan, Andrew K
AU  - Chan AK
AD  - Departments of1Neurological Surgery.
FAU - Sosa, Julie Ann
AU  - Sosa JA
AD  - 2Surgery.
FAU - Lobo, Errol P
AU  - Lobo EP
AD  - 3Anesthesia and Perioperative Medicine.
FAU - Mummaneni, Valli P
AU  - Mummaneni VP
AD  - 3Anesthesia and Perioperative Medicine.
FAU - Antrum, Sheila
AU  - Antrum S
AD  - 4Chancellor's Cabinet; and.
FAU - Berven, Sigurd H
AU  - Berven SH
AD  - 5Orthopedic Surgery.
FAU - Conte, Michael S
AU  - Conte MS
AD  - 2Surgery.
AD  - Divisions of6Vascular and Endovascular Surgery.
FAU - Doernberg, Sarah B
AU  - Doernberg SB
AD  - 7Infectious Diseases.
AD  - 14Medicine, and.
FAU - Goldberg, Andrew N
AU  - Goldberg AN
AD  - 8Otolaryngology Head and Neck Surgery.
FAU - Hess, Christopher P
AU  - Hess CP
AD  - 9Radiology and Biomedical Imaging.
FAU - Hetts, Steven W
AU  - Hetts SW
AD  - 9Radiology and Biomedical Imaging.
AD  - 10Interventional Neuroradiology.
FAU - Josephson, S Andrew
AU  - Josephson SA
AD  - 11Neurology.
FAU - Kohi, Maureen P
AU  - Kohi MP
AD  - 9Radiology and Biomedical Imaging.
AD  - 12Vascular and Interventional Radiology, and.
FAU - Ma, C Benjamin
AU  - Ma CB
AD  - 5Orthopedic Surgery.
FAU - Mahadevan, Vaikom S
AU  - Mahadevan VS
AD  - 13Cardiology.
AD  - 14Medicine, and.
FAU - Molinaro, Annette M
AU  - Molinaro AM
AD  - Departments of1Neurological Surgery.
FAU - Murr, Andrew H
AU  - Murr AH
AD  - 8Otolaryngology Head and Neck Surgery.
FAU - Narayana, Sirisha
AU  - Narayana S
AD  - 14Medicine, and.
FAU - Roberts, John P
AU  - Roberts JP
AD  - 2Surgery.
FAU - Stoller, Marshall L
AU  - Stoller ML
AD  - 15Urology.
FAU - Theodosopoulos, Philip V
AU  - Theodosopoulos PV
AD  - Departments of1Neurological Surgery.
FAU - Vail, Thomas P
AU  - Vail TP
AD  - 5Orthopedic Surgery.
FAU - Wienholz, Sandra
AU  - Wienholz S
AD  - 16Perioperative Care, University of California, San Francisco, California.
FAU - Gropper, Michael A
AU  - Gropper MA
AD  - 3Anesthesia and Perioperative Medicine.
FAU - Green, Adrienne
AU  - Green A
AD  - 14Medicine, and.
FAU - Berger, Mitchel S
AU  - Berger MS
AD  - Departments of1Neurological Surgery.
LA  - eng
PT  - Journal Article
DEP - 20201002
PL  - United States
TA  - J Neurosurg Spine
JT  - Journal of neurosurgery. Spine
JID - 101223545
SB  - IM
OTO - NOTNLM
OT  - ACS = American College of Surgeons
OT  - COVID-19
OT  - ICU = intensive care unit
OT  - MDPC = multidisciplinary perioperative committee
OT  - PAPR = powered air-purifying respirator
OT  - PPE = personal protective equipment
OT  - PUI = inpatients under investigation
OT  - SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
OT  - UCPS = UCSF COVID-19 PPE Score
OT  - UCSF = University of California, San Francisco
OT  - coronavirus disease 19
OT  - infection
OT  - perioperative care
OT  - surgical triage
EDAT- 2020/10/03 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/10/02 20:20
PHST- 2020/05/02 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/10/02 20:20 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - 10.3171/2020.6.SPINE20777 [doi]
AID - 2020.6.SPINE20777 [pii]
PST - aheadofprint
SO  - J Neurosurg Spine. 2020 Oct 2:1-9. doi: 10.3171/2020.6.SPINE20777.


PMID- 33007234
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1875-9777 (Electronic)
IS  - 1875-9777 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Oct 1
TI  - Ethical and Policy Considerations for Human Embryo and Stem Cell Research in
      China.
PG  - 511-514
LID - S1934-5909(20)30456-2 [pii]
LID - 10.1016/j.stem.2020.09.010 [doi]
AB  - China's stem cell research policies are based on a cultural understanding that
      grants special protection to human embryos but does not assign them equivalent
      moral or legal status as fully developed humans. We discuss ethical
      considerations for embryo research and policy changes as China moves toward
      adopting internationally recognized rules.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Peng, Yao-Jin
AU  - Peng YJ
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology,
      Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and
      Regeneration, Chinese Academy of Sciences, Beijing 100101, China; University of
      the Chinese Academy of Sciences, Beijing 100049, China. Electronic address:
      yaojin.peng@ioz.ac.cn.
FAU - Huang, Xiaoru
AU  - Huang X
AD  - School of Marxism Studies, University of the Chinese Academy of Sciences, Beijing
      100049, China.
FAU - Zhou, Qi
AU  - Zhou Q
AD  - State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology,
      Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and
      Regeneration, Chinese Academy of Sciences, Beijing 100101, China; University of
      the Chinese Academy of Sciences, Beijing 100049, China. Electronic address:
      qzhou@ioz.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell Stem Cell
JT  - Cell stem cell
JID - 101311472
SB  - IM
MH  - China
MH  - *Embryo Research
MH  - Humans
MH  - Morals
MH  - Policy
MH  - *Stem Cell Research
EDAT- 2020/10/03 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/02 20:08
PHST- 2020/10/02 20:08 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - S1934-5909(20)30456-2 [pii]
AID - 10.1016/j.stem.2020.09.010 [doi]
PST - ppublish
SO  - Cell Stem Cell. 2020 Oct 1;27(4):511-514. doi: 10.1016/j.stem.2020.09.010.


PMID- 33007202
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20220316
IS  - 2213-6711 (Electronic)
IS  - 2213-6711 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct 13
TI  - The American Public Is Ready to Accept Human-Animal Chimera Research.
PG  - 804-810
LID - S2213-6711(20)30374-X [pii]
LID - 10.1016/j.stemcr.2020.08.018 [doi]
AB  - We report findings from a new survey of US public attitudes toward human-animal
      chimeric embryo (HACE) research, designed to compare with recently reported
      Japanese survey data. We find that 59% of the US public can personally accept the
      process of injecting human induced pluripotent stem cells into genetically
      modified swine embryos and having human tissues produced in a pig's body
      transplanted into a human. This is greater acceptance than in Japan, and there is
      even strong acceptance among those with strong religious affiliations and who
      self-identify as conservatives. We argue that strong public support for HACE
      research, as well as the emerging literature suggesting that humanization of
      research animals is very unlikely, should compel the NIH to lift its current
      moratorium on HACE research.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Crane, Andrew T
AU  - Crane AT
AD  - Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
      Electronic address: atcrane@umn.edu.
FAU - Shen, Francis X
AU  - Shen FX
AD  - University of Minnesota Law School, Minneapolis, MN, USA; Graduate Program in
      Neuroscience, University of Minnesota, Minneapolis, MN, USA; Massachusetts
      General Hospital, Center for Law, Brain, and Behavior, Boston, MA, USA.
      Electronic address: fxshen@umn.edu.
FAU - Brown, Jennifer L
AU  - Brown JL
AD  - University of Minnesota Law School, Minneapolis, MN, USA; Graduate Program in
      Neuroscience, University of Minnesota, Minneapolis, MN, USA.
FAU - Cormack, Warren
AU  - Cormack W
AD  - University of Minnesota Law School, Minneapolis, MN, USA.
FAU - Ruiz-Estevez, Mercedes
AU  - Ruiz-Estevez M
AD  - Recombinetics, Inc., Eagan, MN, USA.
FAU - Voth, Joseph P
AU  - Voth JP
AD  - Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
FAU - Sawai, Tsutomu
AU  - Sawai T
AD  - Institute for the Advanced Study of Human Biology (WPI-ASHBi), KUIAS Kyoto
      University, Kyoto, Japan; Uehiro Research Division for iPS Cell Ethics, Center
      for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
FAU - Hatta, Taichi
AU  - Hatta T
AD  - Uehiro Research Division for iPS Cell Ethics, Center for iPS Cell Research and
      Application, Kyoto University, Kyoto, Japan.
FAU - Fujita, Misao
AU  - Fujita M
AD  - Institute for the Advanced Study of Human Biology (WPI-ASHBi), KUIAS Kyoto
      University, Kyoto, Japan; Uehiro Research Division for iPS Cell Ethics, Center
      for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
FAU - Low, Walter C
AU  - Low WC
AD  - Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA;
      Graduate Program in Neuroscience, University of Minnesota, Minneapolis, MN, USA; 
      Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA.
LA  - eng
GR  - T32 AG052354/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - United States
TA  - Stem Cell Reports
JT  - Stem cell reports
JID - 101611300
SB  - IM
CIN - Stem Cell Reports. 2021 Feb 9;16(2):225-226. PMID: 33567291
MH  - Animals
MH  - Chimera/*physiology
MH  - Humans
MH  - *Public Opinion
MH  - *Research
MH  - Surveys and Questionnaires
MH  - United States
PMC - PMC7562947
OTO - NOTNLM
OT  - *US public attitudes
OT  - *blastocyst complementation
OT  - *ethics and policy
OT  - *gene editing
OT  - *human-animal chimeric embryo
EDAT- 2020/10/03 06:00
MHDA- 2021/07/01 06:00
CRDT- 2020/10/02 20:08
PHST- 2020/04/10 00:00 [received]
PHST- 2020/08/30 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
PHST- 2020/10/02 20:08 [entrez]
AID - S2213-6711(20)30374-X [pii]
AID - 10.1016/j.stemcr.2020.08.018 [doi]
PST - ppublish
SO  - Stem Cell Reports. 2020 Oct 13;15(4):804-810. doi: 10.1016/j.stemcr.2020.08.018. 
      Epub 2020 Oct 1.


PMID- 33006868
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210505
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 10
DP  - 2020 Oct
TI  - Teaching Professional Formation in Response to the COVID-19 Pandemic.
PG  - 1488-1491
LID - 10.1097/ACM.0000000000003434 [doi]
AB  - In response to the COVID-19 pandemic, the Association of American Medical
      Colleges has called for a temporary suspension of clinical teaching activities
      for medical students. Planning for the continued involvement of learners in
      patient care during this pandemic should include teaching learners professional
      formation. The authors provide an ethical framework to guide such teaching, based
      on the ethical principle of beneficence and the professional virtues of courage
      and self-sacrifice from professional ethics in medicine. The authors show that
      these concepts support the conclusion that learners are ethically obligated to
      accept reasonable, but not unreasonable, risk. Based on this ethical framework,
      the authors provide an account of the process of teaching professional formation 
      that medical educators and academic leaders should implement. Medical educators
      and academic leaders should embrace the opportunity that the COVID-19 pandemic
      presents for teaching professional formation. Learners should acquire the
      conceptual vocabulary of professional formation. Learners should recognize that
      risk of infection from patients is unavoidable. Learners should become aware of
      established ethical standards for professional responsibility during epidemics
      from the history of medicine. Learners should master understandable fear. Medical
      educators and academic leaders should ensure that didactic teaching of
      professional formation continues when it becomes justified to end learners'
      participation in the processes of patient care; topics should include the
      professionally responsible management of scarce medical resources. The COVID-19
      pandemic will not be the last major infectious disease that puts learners at
      risk. Professional ethics in medicine provides powerful conceptual tools that can
      be used as an ethical framework to guide medical educators to teach learners, who
      will bear leadership responsibilities in responses to future pandemics,
      professional formation.
FAU - McCullough, Laurence B
AU  - McCullough LB
AD  - L.B. McCullough is professor, Department of Obstetrics and Gynecology, Zucker
      School of Medicine at Hofstra/Northwell, Hempstead, New York, and ethics scholar,
      Lenox Hill Hospital, New York, New York.
FAU - Coverdale, John
AU  - Coverdale J
AD  - J. Coverdale is professor, Department of Psychiatry and Behavioral Sciences and
      Center of Medical Ethics and Health Policy, Baylor College of Medicine, Houston, 
      Texas.
FAU - Chervenak, Frank A
AU  - Chervenak FA
AD  - F.A. Chervenak is professor and chair, Department of Obstetrics and Gynecology,
      and associate dean for international education, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, and chair, Department of Obstetrics and
      Gynecology, Lenox Hill Hospital, New York, New York.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Education, Medical/*ethics
MH  - Ethics, Medical/*education
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - Professionalism/*education/ethics
MH  - SARS-CoV-2
MH  - Schools, Medical
MH  - Societies, Medical
PMC - PMC7179059
EDAT- 2020/10/03 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/02 15:20
PHST- 2020/10/02 15:20 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/ACM.0000000000003434 [doi]
AID - 00001888-202010000-00014 [pii]
PST - ppublish
SO  - Acad Med. 2020 Oct;95(10):1488-1491. doi: 10.1097/ACM.0000000000003434.


PMID- 33006747
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Perception of Organizational Ethical Climate by University Staff and Students in 
      Medicine and Humanities: A Cross Sectional Study.
PG  - 3437-3454
LID - 10.1007/s11948-020-00270-w [doi]
AB  - We assessed students' and employees' perception of ethical climate at a
      university school of medicine compared to that of social sciences and humanities,
      as well as temporal changes in the employees' perception of ethical climate. We
      also explored potential predictors of ethical climate, including moral
      foundations. This cross-sectional questionnaire study was conducted at the
      University of Split School of Medicine and the Faculty of Humanities and Social
      Sciences, in Croatia, from April to September 2019. We used 36-item Ethical
      Climate Questionnaire and 22-item Moral Foundation Questionnaire to survey
      employees, senior and doctoral students. We collected responses using ballot
      boxes as well as online survey. We collected 449 complete responses (response
      rate 36.8%). The dominant ethical climates at two schools were "Company rules and
      procedures" and "Laws and professional codes". We compared our results with a
      study conducted in 2012 and found that the perception of ethical climate had not 
      changed dramatically in last 8 years. Ethical climate, or shared social and
      work-related behaviours, does not seem to change in these institutions even when 
      students and staff are included with faculty in surveys. We provide further
      discussion of why this seems to be the case.
FAU - Vidak, Marin
AU  - Vidak M
AUID- ORCID: 0000-0003-0341-9598
AD  - Department in Research in Biomedicine and Health, School of Medicine, University 
      of Split, Soltanska 2, Split, Croatia. marin.vidak@mefst.hr.
FAU - Buljan, Ivan
AU  - Buljan I
AD  - Department in Research in Biomedicine and Health, School of Medicine, University 
      of Split, Soltanska 2, Split, Croatia.
FAU - Tokalic, Ruzica
AU  - Tokalic R
AD  - Department in Research in Biomedicine and Health, School of Medicine, University 
      of Split, Soltanska 2, Split, Croatia.
FAU - Lunic, Anita
AU  - Lunic A
AD  - Department of Philosophy, Faculty of Humanities and Social Sciences, University
      of Split, Split, Croatia.
FAU - Hren, Darko
AU  - Hren D
AD  - Chair of Psychology, Faculty of Humanities and Social Sciences, University of
      Split, Split, Croatia.
FAU - Marusic, Ana
AU  - Marusic A
AD  - Department in Research in Biomedicine and Health, School of Medicine, University 
      of Split, Soltanska 2, Split, Croatia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201002
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Morals
MH  - Organizational Culture
MH  - Perception
MH  - Students
MH  - Surveys and Questionnaires
MH  - *Universities
OTO - NOTNLM
OT  - *Ethical organizational climate
OT  - *Medical education
OT  - *Moral foundation theory
OT  - *Organizational climate
EDAT- 2020/10/03 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/02 12:09
PHST- 2020/06/16 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/10/02 12:09 [entrez]
AID - 10.1007/s11948-020-00270-w [doi]
AID - 10.1007/s11948-020-00270-w [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3437-3454. doi: 10.1007/s11948-020-00270-w. Epub
      2020 Oct 2.


PMID- 33006496
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 0261-1929 (Print)
IS  - 0261-1929 (Linking)
VI  - 48
IP  - 3
DP  - 2020 May
TI  - The First Rehoming of Laboratory Beagles in Finland: The Complete Process from
      Socialisation Training to Follow-up.
PG  - 116-126
LID - 10.1177/0261192920942135 [doi]
AB  - The fate of experimental animals represents an ethical dilemma and a public
      concern. In the EU, Directive 2010/63/EU allows the rehoming of former
      experimental animals instead of euthanasia. However, to our knowledge, there are 
      no previous reports of rehoming Beagles in Finland. This study aimed to describe 
      the process behind the first rehoming of laboratory Beagles at the University of 
      Helsinki and evaluate its success. In total, 16 former laboratory Beagles were
      rehomed in collaboration with animal protection organisations and the University 
      of Helsinki. The dogs had participated in animal cognition studies and had
      undergone minor procedures during the development of a veterinary drug. While the
      dogs were still in the laboratory, a socialisation training programme lasting
      several months was undertaken. Through surveying of the adoptive owners, and
      interviewing the various stakeholders involved (researchers, animal protection
      organisations and animal caretakers), the overall process was evaluated,
      including: the socialisation training programme; the comparative success of
      rehoming younger compared to older animals; the criteria that were used for the
      selection of the adoptive owners; and the eventual success of rehoming the dogs
      with the new owners. The majority of the dogs adjusted well to their new home
      environment. Euthanasia at the end of their experimental use would have been
      unnecessary and possibly against the objectives of European directives.
FAU - Hanninen, Laura
AU  - Hanninen L
AD  - Research Centre for Animal Welfare, Department of Production Animal Medicine,
      3835University of Helsinki, Helsinki, Finland.
FAU - Norring, Marianna
AU  - Norring M
AD  - Research Centre for Animal Welfare, Department of Production Animal Medicine,
      3835University of Helsinki, Helsinki, Finland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Altern Lab Anim
JT  - Alternatives to laboratory animals : ATLA
JID - 8110074
SB  - IM
MH  - *Animal Welfare
MH  - Animals
MH  - Dogs
MH  - Finland
MH  - Follow-Up Studies
MH  - Ownership
MH  - *Socialization
OTO - NOTNLM
OT  - Beagle
OT  - dog
OT  - laboratory
OT  - rehoming
OT  - welfare
EDAT- 2020/10/03 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/10/02 12:07
PHST- 2020/10/02 12:07 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1177/0261192920942135 [doi]
PST - ppublish
SO  - Altern Lab Anim. 2020 May;48(3):116-126. doi: 10.1177/0261192920942135.


PMID- 33005639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Challenges to the Poultry Industry: Current Perspectives and Strategic Future
      After the COVID-19 Outbreak.
PG  - 516
LID - 10.3389/fvets.2020.00516 [doi]
AB  - Poultry immunity, health, and production are several factors that challenge the
      future growth of the poultry industry. Consumer confidence, product quality and
      safety, types of products, and the emergence and re-emergence of diseases will
      continue to be major challenges to the current situation and the strategic future
      of the industry. Foodborne and zoonotic diseases are strictly linked with
      poultry. Eradication, elimination, and/or control of foodborne and zoonotic
      pathogens present a major challenge to the poultry industry. In addition, the
      public health hazards from consuming foods with high antibiotic residues will
      remain a critical issue. The theory of poultry production described in this
      review will not be limited to considering disease control. Rather, it will also
      incorporate the interconnection of the animals' health, welfare, and immunity. It
      is essential to know that chickens are not susceptible to intranasal infection by
      the SARS-CoV-2 (COVID-19) virus. Nevertheless, the COVID-19 pandemic will affect 
      poultry consumption, transport, and the economics of poultry farming. It will
      also take into consideration economic, ethical, social dimensions, and the
      sustenance of the accomplishment of high environmental security. Stockholders,
      veterinarians, farmers, and all the partners of the chain of poultry production
      need to be more involved in the current situation and the strategic future of the
      industry to fulfill human demands and ensure sustainable agriculture. Thus, the
      present review explores these important tasks.
CI  - Copyright (c) 2020 Hafez and Attia.
FAU - Hafez, Hafez M
AU  - Hafez HM
AD  - Faculty of Veterinary Medicine, Institute of Poultry Diseases, Free University
      Berlin, Berlin, Germany.
FAU - Attia, Youssef A
AU  - Attia YA
AD  - Department of Agriculture, Faculty of Environmental Sciences, King Abdulaziz
      University, Jeddah, Saudi Arabia.
AD  - The Strategic Center to Kingdom Vision Realization, King Abdulaziz University,
      Jeddah, Saudi Arabia.
AD  - Animal and Poultry Production Department, Faculty of Agriculture, Damanhour
      University, Damanhour, Egypt.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200826
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7479178
OTO - NOTNLM
OT  - COVID-19
OT  - Disease control
OT  - SARS-CoV-2
OT  - biosecurity
OT  - consumer protection
OT  - food safety
OT  - poultry disease
EDAT- 2020/10/03 06:00
MHDA- 2020/10/03 06:01
CRDT- 2020/10/02 05:46
PHST- 2020/05/02 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/10/02 05:46 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/03 06:01 [medline]
AID - 10.3389/fvets.2020.00516 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 Aug 26;7:516. doi: 10.3389/fvets.2020.00516. eCollection
      2020.


PMID- 33005454
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2090-0724 (Print)
IS  - 2090-0724 (Linking)
VI  - 2020
DP  - 2020
TI  - Comparison of the Effect of Enteral Feeding through the Bolus and Continuous
      Methods on Serum Phosphorus and Glucose Levels in Patients with Mechanical
      Ventilation: A Randomized Clinical Trial.
PG  - 6428418
LID - 10.1155/2020/6428418 [doi]
AB  - INTRODUCTION: Patients who are under mechanical ventilation in intensive care
      units need to have nutritional support. Also, feeding methods affect serum
      phosphorus and glucose levels, which are very important in weaning patients off
      the ventilator. Thus, this study is to compare the effects of both bolus and
      continuous enteral feeding methods on serum phosphorus and glucose levels in
      patients with mechanical ventilation. METHODS: In this clinical trial study, 34
      patients in the intensive care unit of Imam Khomeini Hospital affiliated to the
      Tehran University of Medical Sciences satisfied inclusion criteria and were
      randomly divided into control and intervention groups. Sampling was done between 
      October and February 2018. The intervention group received continuous enteral
      feeding for one week, and the control group received nutrition by the bolus
      method. The blood glucose level was measured every six hours, and the serum
      phosphorus level was recorded at the beginning and the end of the intervention,
      based on the data entry form with respect to all ethical considerations. Data
      analysis was done by SPSS-20 software. RESULTS: The serum phosphorus level was
      significantly increased in the intervention group (P=0.004) and in the control
      group (P < 0.001) and was compared with the previous intervention. No significant
      difference was found between the intervention and control groups before and after
      the intervention (P=0.22) and also one week after the intervention (P=0.14).
      There was also no significant difference between the glucose levels from day 1 to
      day 7 in the control group (P=0.33) and the intervention group (P=0.086).
      Discussion. Nutritional support in both bolus and continuous methods increased
      the serum phosphorus level. It indicates the importance of the nutritional method
      in controlling the phosphorus level in critically ill patients. However, there
      was no difference between the effects of dietary methods on blood glucose
      control.
CI  - Copyright (c) 2020 Javad Seyyedi et al.
FAU - Seyyedi, Javad
AU  - Seyyedi J
AUID- ORCID: https://orcid.org/0000-0002-6489-0140
AD  - Department of Medical Surgical Nursing, School of Nursing and Midwifery, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Rooddehghan, Zahra
AU  - Rooddehghan Z
AUID- ORCID: https://orcid.org/0000-0002-2068-9533
AD  - School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran,
      Iran.
FAU - Mohammadi, Mostafa
AU  - Mohammadi M
AD  - Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Haghani, Shima
AU  - Haghani S
AD  - MSc in Biostatistics Nursing Care Research Center, Iran University of Medical
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - United States
TA  - J Nutr Metab
JT  - Journal of nutrition and metabolism
JID - 101526296
PMC - PMC7508222
COIS- There were no conflicts of interest in this study to report.
EDAT- 2020/10/03 06:00
MHDA- 2020/10/03 06:01
CRDT- 2020/10/02 05:45
PHST- 2020/02/07 00:00 [received]
PHST- 2020/08/01 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/10/02 05:45 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/03 06:01 [medline]
AID - 10.1155/2020/6428418 [doi]
PST - epublish
SO  - J Nutr Metab. 2020 Sep 8;2020:6428418. doi: 10.1155/2020/6428418. eCollection
      2020.


PMID- 33005190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1687-8450 (Print)
IS  - 1687-8450 (Linking)
VI  - 2020
DP  - 2020
TI  - Efficiency of High and Standard b Value Diffusion-Weighted Magnetic Resonance
      Imaging in Grading of Gliomas.
PG  - 6942406
LID - 10.1155/2020/6942406 [doi]
AB  - BACKGROUND: Glioma is the most common fatal malignant tumor of the CNS. Early
      detection of glioma grades based on diffusion-weighted imaging (DWI) properties
      is considered one of the most recent noninvasive promising tools in the
      assessment of glioma grade and could be helpful in monitoring patient prognosis
      and response to therapy. AIM: This study aimed to investigate the accuracy of DWI
      at both standard and high b values (b = 1000 s/mm(2) and b = 3000 s/mm(2)) to
      distinguish high-grade glioma (HGG) from low-grade glioma (LGG) in clinical
      practice based on histopathological results. MATERIALS AND METHODS: Twenty-three 
      patients with glioma had DWI at l.5 T MR using two different b values (b = 1000
      s/mm(2) and b = 3000 s/mm(2)) at Al-Shifa Medical Complex after obtaining ethical
      and administrative approvals, and data were collected from March 2019 to March
      2020. Minimum, maximum, and mean of apparent diffusion coefficient (ADC) values
      were measured through drawing region of interest (ROI) on a solid part at ADC
      maps. Data were analyzed by using the MedCalc analysis program, version 19.0.4,
      receiver operating characteristic (ROC) curve analysis was done, and optimal
      cutoff values for grading gliomas were determined. Sensitivity and specificity
      were also calculated. RESULTS: The obtained results showed the ADCmean, ADCratio,
      ADCmax, and ADCmin were performed to differentiate between LGG and HGG at both
      standard and high b values. Moreover, ADC values were inversely proportional to
      glioma grade, and these differences are more obvious at high b value. Minimum ADC
      values using standard b value were 1.13 +/- 0.17 x 10(-3) mm(2)/s, 0.89 +/- 0.85 
      x 10(-3) mm(2)/s, and 0.82 +/- 0.17 x 10(-3) mm(2)/s for grades II, III, and IV, 
      respectively. Concerning high b value, ADCmin values were 0.76 +/- 0.07 x 10(-3) 
      mm(2)/s, 0.61 +/- 0.01 x 10(-3) mm(2)/s, and 0.48 +/- 0.07 x 10(-3) mm(2)/s for
      grades II, III, and IV, respectively. ADC values were inversely correlated with
      results of glioma grades, and the correlation was stronger at ADC3000 (r =
      -0.722, P </= 0.001). The ADC3000 achieved the highest diagnostic accuracy with
      an area under the curve (AUC) of 0.618, 100% sensitivity, 85.7% specificity, and 
      85.7% accuracy for glioma grading at a cutoff point of </=0.618 x 10(-3) mm(2)/s.
      The high b value showed stronger agreement with histopathology compared with
      standard b value results (k = 0.89 and 0.79), respectively. CONCLUSION: The ADC
      values decrease with an increase in tumor cellularity. Meanwhile, high b value
      provides better tissue contrast by reflecting more tissue diffusivity. Therefore,
      ADC-derived parameters at high b value are more useful in the grading of glioma
      than those obtained at standard b value. They might be a better surrogate imaging
      sequence in the preoperative evaluation of gliomas.
CI  - Copyright (c) 2020 Mansour Al-Agha et al.
FAU - Al-Agha, Mansour
AU  - Al-Agha M
AUID- ORCID: https://orcid.org/0000-0002-9692-5635
AD  - Radiology Department, Al-Shifa Medical Complex, Ministry of Health, Gaza, State
      of Palestine.
FAU - Abushab, Khaled
AU  - Abushab K
AD  - Medical Imaging Department, Faculty of Applied Medical Sciences, Al Azhar
      University-Gaza, Gaza, State of Palestine.
FAU - Quffa, Khetam
AU  - Quffa K
AD  - Medical Imaging Department, Faculty of Applied Medical Sciences, Al Azhar
      University-Gaza, Gaza, State of Palestine.
FAU - Al-Agha, Samy
AU  - Al-Agha S
AD  - Medical Imaging Department, Faculty of Applied Medical Sciences, Al Azhar
      University-Gaza, Gaza, State of Palestine.
FAU - Alajerami, Yasser
AU  - Alajerami Y
AD  - Medical Imaging Department, Faculty of Applied Medical Sciences, Al Azhar
      University-Gaza, Gaza, State of Palestine.
FAU - Tabash, Mohammed
AU  - Tabash M
AUID- ORCID: https://orcid.org/0000-0003-1170-679X
AD  - Medical Imaging Department, Faculty of Applied Medical Sciences, Al Azhar
      University-Gaza, Gaza, State of Palestine.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC7509551
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/10/03 06:00
MHDA- 2020/10/03 06:01
CRDT- 2020/10/02 05:44
PHST- 2020/05/06 00:00 [received]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/10/02 05:44 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/03 06:01 [medline]
AID - 10.1155/2020/6942406 [doi]
PST - epublish
SO  - J Oncol. 2020 Sep 14;2020:6942406. doi: 10.1155/2020/6942406. eCollection 2020.


PMID- 33005124
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1551-4056 (Electronic)
IS  - 0044-0086 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Sep
TI  - Ethical Aspects of Mental Health Care for Lesbian, Gay, Bi-, Pan-, Asexual, and
      Transgender People: A Case-based Approach.
PG  - 593-602
AB  - The lives of lesbian, gay, bi-, pan-, asexual, and transgender (LGBTA+/LGBT)
      people are not considered to be standard in society, unlike those of heterosexual
      cisgender people. This can lead to prejudices against LGBT people and may
      negatively influence their access to high-quality health care. Medical and mental
      health care have been characterized by attitudes (psycho-)pathologizing LGBT
      lives and therefore supported the stigmatization of LGBT people in the service of
      heteronormativity. Mental health professionals (MHPs) largely have transferred
      principles guiding counseling and psychotherapy with heterosexual (straight)
      cisgender persons to treatment of LGBT individuals without considering the
      specific features of LGBT lives. This is true even if the treatment is not
      exclusively LGBT-related, but can address LGBT-unrelated issues. To counteract
      this, the present paper aims to provide an insight into ethically sound mental
      health care for LGBT people. By applying the principles of biomedical ethics, we 
      have analyzed how LGBT individuals can be discriminated against in mental health 
      care and what MHPs may need to offer LGBT-sensitive high-quality mental health
      care. We argue that MHPs need LGBT-related expertise as well as LGBT-related
      sensitivity. MHPs should acquire specialist knowledge for the diverse lives and
      the challenges of LGBT people. We encourage MHPs to develop an understanding of
      how their own implicit attitudes towards LGBT people can affect treatment.
      However, the demand for special training should not be mistaken as a demand for a
      specific type of mental health care. The principles of general psychotherapy are 
      equally the basis of psychotherapy with LGBT people.
CI  - Copyright (c)2020, Yale Journal of Biology and Medicine.
FAU - Nieder, Timo O
AU  - Nieder TO
AD  - Institute for Sex Research, Sexual Medicine und Forensic Psychiatry, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Guldenring, Annette
AU  - Guldenring A
AD  - Department of Psychiatry, Psychotherapy, and Psychosomatics, Westkustenklinikum
      Heide, Heide, Germany.
FAU - Woellert, Katharina
AU  - Woellert K
AD  - Institute for History and Ethics of Medicine, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Briken, Peer
AU  - Briken P
AD  - Institute for Sex Research, Sexual Medicine und Forensic Psychiatry, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Mahler, Lieselotte
AU  - Mahler L
AD  - Charite University Clinic for Psychiatry and Psychotherapy, Berlin, Germany.
FAU - Mundle, Gotz
AU  - Mundle G
AD  - Zentrum fur Seelische Gesundheit, Oberberg City, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200930
PL  - United States
TA  - Yale J Biol Med
JT  - The Yale journal of biology and medicine
JID - 0417414
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Health
MH  - Sexual Behavior
MH  - *Sexual and Gender Minorities
MH  - Sexuality
MH  - *Transgender Persons
PMC - PMC7513438
OTO - NOTNLM
OT  - *LGBT
OT  - *gender identity
OT  - *heteronormativity
OT  - *psychotherapy
OT  - *sexual orientation
EDAT- 2020/10/03 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/10/02 05:43
PHST- 2020/10/02 05:43 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - yjbm934593 [pii]
PST - epublish
SO  - Yale J Biol Med. 2020 Sep 30;93(4):593-602. eCollection 2020 Sep.


PMID- 33005123
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1551-4056 (Electronic)
IS  - 0044-0086 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Sep
TI  - Ethical Implications of Donor Type for Uterus Transplantation: Why We Should
      Remain Wary of Using Living Donors.
PG  - 587-592
AB  - Over the last few years, research teams have made significant advancements in
      treating absolute uterine factor infertility through uterus transplantation,
      culminating in the birth of the first US baby born from a uterus transplant in
      November 2017. However, studies have differed on the choice of either deceased or
      living donors, with some centers even exploring both methods. As researchers
      continue to investigate the medical feasibility of these approaches, it is also
      important for the medical community to consider how deceased and living uterus
      donation differ ethically. We argue that if living and deceased donation
      demonstrate equivalent clinical efficacy and the deceased donor pool is
      sufficient, living uterus donation should be reevaluated and may no longer be
      ethically justifiable.
CI  - Copyright (c)2020, Yale Journal of Biology and Medicine.
FAU - Bruno, Bethany
AU  - Bruno B
AD  - Cleveland Clinic Lerner College of Medicine, Cleveland, OH.
FAU - Arora, Kavita Shah
AU  - Arora KS
AD  - Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland,
      OH.
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, OH.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200930
PL  - United States
TA  - Yale J Biol Med
JT  - The Yale journal of biology and medicine
JID - 0417414
SB  - IM
MH  - Female
MH  - Humans
MH  - *Infertility, Female
MH  - Living Donors
MH  - Morals
MH  - *Organ Transplantation
MH  - Uterus/transplantation
PMC - PMC7513439
OTO - NOTNLM
OT  - *ethics
OT  - *organ donation
OT  - *uterus transplantation
EDAT- 2020/10/03 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/10/02 05:43
PHST- 2020/10/02 05:43 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - yjbm934587 [pii]
PST - epublish
SO  - Yale J Biol Med. 2020 Sep 30;93(4):587-592. eCollection 2020 Sep.


PMID- 33005113
OWN - NLM
STAT- MEDLINE
DCOM- 20211020
LR  - 20211020
IS  - 1551-4056 (Electronic)
IS  - 0044-0086 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Sep
TI  - Helicobacter Pylori Infection in Amniotic Fluid May Cause Hyperemesis Gravidarum.
PG  - 487-493
AB  - Objectives: Limited data are available from recent trials involving pregnant
      women to guide Helicobacter pylori infection diagnosis. There are no data about
      the presence of H. pylori in the amniotic fluid as well. Furthermore, the
      relation between amniotic fluid H. pylori and hyperemesis gravidarum (HG) has not
      been characterized yet. Materials and Methods: This is a prospective study
      conducted after obtaining approval from the Ethics Committee. Pregnant women
      undergoing amniocentesis were enrolled in the study. The stool antigen test
      assessed the presence of H. pylori in amniotic fluid. A perinatologist
      independently performed an amniocentesis. The obtained amniotic liquid was sent
      to the laboratory to evaluate H. pylori infection by stool H. pylori antigen
      assay. We determined the rate of H. pylori in amniotic fluid and assessed
      relations between H. pylori infection and pregnancy outcome, including HG.
      Results: Between May and September 2017, we enrolled 48 pregnant women who
      underwent amniocentesis to detect possible fetal malformations. Patients were
      divided into two groups regarding the HG status. There were significant
      differences between the groups in terms of H. pylori infection presence. Among
      them, 28 (58.3%) were found to have a positive H. pylori test in their amniotic
      fluid. The rate of HG was significantly higher (71.4%) in patients who tested
      positive for H. pylori in amniocentesis than the H. pylori-negative group (20%), 
      (p<0.001). Conclusions: The study's main new finding is that presence of H.
      pylori in the amniotic fluid is possible. Our data suggest that H.
      pylori-infected amniotic fluid is associated with the experience of past HG. The 
      current study may have important implications for HG detection and help identify 
      patients who would benefit from future preventive strategies.
CI  - Copyright (c)2020, Yale Journal of Biology and Medicine.
FAU - Aydin, Mesut
AU  - Aydin M
AD  - Van Yuzuncu Yil University, School of Medicine, Department of Gastroenterology,
      Van, Turkey.
FAU - Tolunay, Harun Egemen
AU  - Tolunay HE
AD  - Etlik Zubeyde Hanim Maternity and Women's Health Teaching and Research Hospital, 
      Ankara, Turkey.
FAU - Varli, Erol Nadi
AU  - Varli EN
AD  - Etlik Zubeyde Hanim Maternity and Women's Health Teaching and Research Hospital, 
      Ankara, Turkey.
FAU - Boza, Baris
AU  - Boza B
AD  - Mardin State Hospital, Department of Perinatology, Artuklu/Mardin, Turkey.
FAU - Sahin, Ozgur
AU  - Sahin O
AD  - Ufuk University, School of Medicine, Department of Obstetrics and Gynaecology,
      Ankara, Turkey.
FAU - Ozer, Serhat
AU  - Ozer S
AD  - Private Defne Hospital, Department of Gastroenterology, Turkey.
FAU - Dulger, Ahmet Cumhur
AU  - Dulger AC
AD  - Van Yuzuncu Yil University, School of Medicine, Department of Gastroenterology,
      Van, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - United States
TA  - Yale J Biol Med
JT  - The Yale journal of biology and medicine
JID - 0417414
SB  - IM
MH  - Amniotic Fluid
MH  - Female
MH  - *Helicobacter Infections/complications/diagnosis
MH  - *Helicobacter pylori
MH  - Humans
MH  - *Hyperemesis Gravidarum
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious
MH  - Prospective Studies
PMC - PMC7513450
OTO - NOTNLM
OT  - *H. pylori antigen assay
OT  - *Helicobacter pylori
OT  - *amniocentesis
OT  - *amniotic fluid
OT  - *hyperemesis gravidarum
OT  - *stool antigen test
EDAT- 2020/10/03 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/10/02 05:43
PHST- 2020/10/02 05:43 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - yjbm934487 [pii]
PST - epublish
SO  - Yale J Biol Med. 2020 Sep 30;93(4):487-493. eCollection 2020 Sep.


PMID- 33005050
OWN - NLM
STAT- Publisher
LR  - 20211001
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Oct 1
TI  - How we formed a 'journal club' for equity in science.
LID - 10.1038/d41586-020-02794-4 [doi]
FAU - Bachman, Matthew
AU  - Bachman M
FAU - Dickerson, Kathryn C
AU  - Dickerson KC
FAU - Hakimi, Shabnam
AU  - Hakimi S
FAU - Li, Rosa
AU  - Li R
FAU - Yang, Brenda
AU  - Yang B
LA  - eng
PT  - News
DEP - 20201001
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Careers
OT  - Ethics
OT  - Lab life
EDAT- 2020/10/03 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/10/02 05:43
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
PHST- 2020/10/02 05:43 [entrez]
AID - 10.1038/d41586-020-02794-4 [doi]
AID - 10.1038/d41586-020-02794-4 [pii]
PST - aheadofprint
SO  - Nature. 2020 Oct 1. pii: 10.1038/d41586-020-02794-4. doi:
      10.1038/d41586-020-02794-4.


PMID- 33004709
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - Evaluation of ozonized calcium hydroxide as an effective intracanal medicament
      during root canal procedures: an in vitro observational study.
PG  - 122-124
LID - 10.4103/2045-9912.296042 [doi]
AB  - Achieving thorough disinfection is regarded as one of the pillars in endodontics.
      Although calcium hydroxide (CH) is one of the routinely used intracanal
      medicament in endodontics; alternative approaches are gaining popularity to
      mitigate endodontic pathology. However, CH has to be tested for its dissociation 
      which is a rate-limiting attribute essential for its therapeutic action. The
      dissociation of CH into OH(-) and Ca(2+) depends on the vehicle used to prepare
      the paste. This in-vitro study evaluated the use of ozonized olive oil in
      facilitating calcium ion release and change in pH when combined with CH. Fifty
      single rooted extracted human mandibular premolars were instrumented with NiTi
      rotary files (40/6). The teeth were divided into two groups (n = 25 per group) on
      the basis of vehicle: olive oil (CH + olive oil) and ozonized olive oil (CH +
      ozonized olive oil) groups. Both olive and ozonized olive oil vehicles allowed
      the diffusion of ions. However, pastes prepared with ozonized oil showed more ion
      diffusion, with marked calcium ion release after 15 days and alkalinity was
      maintained for complete period of 15 days, depicting better support for CH
      action. The change in calcium ion release and alkalinity were statistically
      significant in ozonized oil vehicle compared to olive oil vehicle. The present
      in-vitro study supports the use of ozonized olive oil as a vehicle to be used
      with CH as an intracanal medicament, considering its anti-microbial potential and
      sustainable release of calcium ions. The study was approved by the Institutional 
      Ethical Committee of Manubhai Patel Dental College (approval No.
      MPDC_130/CONS-25/17) on June 4, 2018.
FAU - Vasavada, Kesha
AU  - Vasavada K
AD  - Conservative Dentistry and Endodontics, Manubhai Patel Dental College and ORI,
      Vadodara, Gujarat, India.
FAU - Kapoor, Sonali
AU  - Kapoor S
AD  - Conservative Dentistry and Endodontics, Manubhai Patel Dental College and ORI,
      Vadodara, Gujarat, India.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Olive Oil)
RN  - 0 (Pharmaceutical Vehicles)
RN  - 0 (Root Canal Filling Materials)
RN  - 66H7ZZK23N (Ozone)
RN  - PF5DZW74VN (Calcium Hydroxide)
SB  - IM
MH  - Calcium Hydroxide/*chemistry/metabolism
MH  - Dental Pulp Cavity
MH  - Humans
MH  - In Vitro Techniques
MH  - Olive Oil/chemistry
MH  - Ozone/*chemistry
MH  - Pharmaceutical Vehicles/*chemistry/metabolism
MH  - Root Canal Filling Materials/*chemistry/metabolism
MH  - Root Canal Therapy
MH  - Treatment Outcome
PMC - PMC8086627
OTO - NOTNLM
OT  - *Candida albicans
OT  - *Enterococcus feacalis
OT  - *atomic absorption spectrophotometer
OT  - *calcium hydroxide
OT  - *endodontic microflora
OT  - *endodontics
OT  - *intracanal disinfection
OT  - *olive oil
OT  - *ozonized olive oil
OT  - *root canal therapy
COIS- None
EDAT- 2020/10/03 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/10/02 05:36
PHST- 2020/10/02 05:36 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - MedGasRes_2020_10_3_122_296042 [pii]
AID - 10.4103/2045-9912.296042 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Jul-Sep;10(3):122-124. doi: 10.4103/2045-9912.296042.


PMID- 33004708
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - Effects of hydrogen-rich water prepared by alternating-current-electrolysis on
      antioxidant activity, DNA oxidative injuries, and diabetes-related markers.
PG  - 114-121
LID - 10.4103/2045-9912.296041 [doi]
AB  - Hydrogen-rich water is conventionally prepared by direct current-electrolysis,
      but has been not or scarcely prepared by alternating current (AC)-electrolysis.
      The AC preparations from tap water for 20-30 minutes exhibit a dissolved hydrogen
      concentration of 1.55 mg/L, which was close to the theoretical maximum value of
      1.6 mg/L. These preparations also displayed an oxidation-reduction potential of
      -270 mV (tap water: +576 mV) and pH of 7.7-7.8, being closer to physiological
      values of body fluids than general types of direct current-electrolytic
      hydrogen-rich water. We examined whether AC-electrolytic hydrogen-water is
      retained for hydrogen-abundance after boiling or for antioxidant abilities, and
      whether the oral administration of this water is clinically effective for
      diabetes and prevention against systemic DNA-oxidative injuries.
      5,5-Dimethyl-1-pyrroline-N-oxide spin trapping and electron spin resonance
      revealed that the hydrogen-rich water generated by AC-electrolysis exhibited
      hydroxyl-radical-scavenging activities. Laser nanoparticle tracking method
      revealed that nanoparticle suspensions as abundant as 5.4 x 10(7)/mL were
      efficiently retained (up to 3.5 x 10(7)/mL) even after boiling for 10 minutes,
      being thermodynamically contrary to Henry's law. Oral intake of hydrogen-rich
      water, 1500 mL per day, lasted for 8 weeks in nine people with the
      diabetes-related serum markers beyond the normal ranges. The subjects exhibited
      significant tendencies for the decreased fasting blood glucose and fructosamine, 
      and for the increased 1,5-anhydro-D-glucitol, concomitantly with significant
      decreases in urinary 8-hydroxy-2-deoxyguanosine contents and its rate of
      generation. Hydrogen-rich water prepared by AC-electrolysis may be effective in
      improving diverse diabetes-related markers and systemic DNA oxidative injuries
      through the formation of abundant heat-resistant nanobubbles and the increased
      hydrogen concentrations. The study protocol was officially approved by the
      Medical Ethics Committee of the Japanese Center for Anti-Aging Medical Sciences
      (approval No. 01S02) on September 15, 2009.
FAU - Asada, Ryoko
AU  - Asada R
AD  - Graduate School of Engineering, Osaka Prefecture University, Osaka, Japan.
FAU - Tazawa, Kenji
AU  - Tazawa K
AD  - School of Medicine, University of Toyama, Toyama, Japan.
FAU - Sato, Shinkichi
AU  - Sato S
AD  - Dlles In Co. Ltd., Tokyo, Japan.
FAU - Miwa, Nobuhiko
AU  - Miwa N
AD  - Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, 
      Hiroshima, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Reactive Oxygen Species)
RN  - 059QF0KO0R (Water)
RN  - 3352-57-6 (Hydroxyl Radical)
RN  - 4429-04-3 (Fructosamine)
RN  - 54BB3B7XMZ (1,5-anhydroglucitol)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - 9G2MP84A8W (Deoxyglucose)
SB  - IM
MH  - Adult
MH  - Antioxidants/*administration & dosage/chemistry/metabolism
MH  - Biomarkers/metabolism
MH  - Blood Glucose/metabolism
MH  - DNA Damage/*drug effects
MH  - Deoxyglucose/metabolism
MH  - Diabetes Mellitus/metabolism
MH  - Electrolysis
MH  - Female
MH  - Fructosamine/metabolism
MH  - Humans
MH  - Hydrogen/*administration & dosage/chemistry/metabolism
MH  - Hydroxyl Radical/chemistry
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Oxidative Stress/*drug effects
MH  - Reactive Oxygen Species/metabolism
MH  - Water/*administration & dosage/chemistry/metabolism
PMC - PMC8086617
OTO - NOTNLM
OT  - *DNA-oxidative injuries
OT  - *alternating current-electrolysis
OT  - *antioxidant activity
OT  - *diabetes
OT  - *hydrogen-rich water
OT  - *reactive oxygen species
COIS- None
EDAT- 2020/10/03 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/10/02 05:36
PHST- 2020/10/02 05:36 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - MedGasRes_2020_10_3_114_296041 [pii]
AID - 10.4103/2045-9912.296041 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Jul-Sep;10(3):114-121. doi: 10.4103/2045-9912.296041.


PMID- 33004707
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - The impact of carbon monoxide inhalation on developing noise-induced hearing loss
      in guinea pigs.
PG  - 110-113
LID - 10.4103/2045-9912.296040 [doi]
AB  - Carbon monoxide (CO) poisoning is one of the most common types of fatal
      poisonings worldwide. Acute exposure to high levels of CO as well as chronic
      exposure to low levels of CO and excessive noise can lead to high frequency
      hearing loss. In this study, twelve guinea pigs were randomly divided into two
      groups: (1) exposed to noise and (2) exposed to noise plus CO. Auditory brainstem
      responses (ABRs) were measured prior to the experiment and immediately, 5, 10 and
      15 days post exposures. There was a significant difference between the ABR
      thresholds before and immediately after exposure to noise at frequencies of 4, 8,
      and 16 kHz and the most threshold shift was observed at 8 kHz. There was also a
      significant difference between the ABR thresholds before and immediately after
      exposure to noise and CO at frequencies of 2, 4, 8, and 16 kHz which demonstrated
      a temporary hearing loss after exposure to noise and CO and the major impact of
      CO on developing noise induced hearing loss occurred at 8 kHz. No significant
      difference was observed between the ABR thresholds recorded before conducting the
      experiments and the ones obtained 5, 10 and 15 days after simultaneous exposure
      to noise and CO at none of frequencies. Simultaneous exposure to noise and CO
      contributes to transient hearing loss in guinea pigs with the most evident
      temporary shift at 8 kHz. The methods were accepted in the Ethics Committee of
      Iran University of Medical Science (registration No. CTRI/2016/01/017170) on
      January 18, 2016.
FAU - Bagheri, Fereshte
AU  - Bagheri F
AD  - Department of Audiology, School of Rehabilitation Sciences, Iran University of
      Medical Sciences, Tehran; Department of Audiology, School of Rehabilitation
      Sciences, Babol University of Medical Sciences, Mazandaran, Iran.
FAU - Sheikhzadeh, Mahbubeh
AU  - Sheikhzadeh M
AD  - Department of Audiology, School of Rehabilitation Sciences, Babol University of
      Medical Sciences, Mazandaran, Iran.
FAU - Raisi, Ahmadreza
AU  - Raisi A
AD  - Department of Chemical Engineering, Amirkabir University of Technology, Tehran,
      Iran.
FAU - Kamali, Mohammad
AU  - Kamali M
AD  - Department of Audiology, School of Rehabilitation Sciences, Iran University of
      Medical Sciences, Tehran, Iran.
FAU - Faridan, Mohammad
AU  - Faridan M
AD  - Department of Occupational Health Engineering and Safety at Work, School of
      Health and Nutrition, Lorestan University of Medical Sciences, Khoramabad, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 7U1EE4V452 (Carbon Monoxide)
SB  - IM
MH  - Acoustic Stimulation
MH  - Administration, Inhalation
MH  - Animals
MH  - Auditory Threshold
MH  - Carbon Monoxide/administration & dosage/*adverse effects
MH  - Evoked Potentials, Auditory, Brain Stem
MH  - Guinea Pigs
MH  - Hearing Loss, High-Frequency/metabolism
MH  - Hearing Loss, Noise-Induced/*metabolism
MH  - Iran
MH  - Male
MH  - Noise
MH  - Signal Transduction
PMC - PMC8086620
OTO - NOTNLM
OT  - *auditory brainstem responses
OT  - *carbon monoxide
OT  - *frequencies
OT  - *guinea pigs
OT  - *noise
OT  - *noise induced hearing loss
OT  - *thresholds
OT  - *transient hearing loss
COIS- None
EDAT- 2020/10/03 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/10/02 05:36
PHST- 2020/10/02 05:36 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - MedGasRes_2020_10_3_110_296040 [pii]
AID - 10.4103/2045-9912.296040 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Jul-Sep;10(3):110-113. doi: 10.4103/2045-9912.296040.


PMID- 33004705
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - Inhalation of molecular hydrogen increases breath acetone excretion during
      submaximal exercise: a randomized, single-blinded, placebo-controlled study.
PG  - 96-102
LID - 10.4103/2045-9912.296038 [doi]
AB  - Aerobic exercise is widely accepted as a beneficial option for reducing fat in
      humans. Recently, it has been suggested that molecular hydrogen (H2) augments
      mitochondrial oxidative phosphorylation. Therefore, the hypothesis that inhaling 
      H2 could facilitate lipid metabolism during aerobic exercise was investigated in 
      the current study by measuring the breath acetone levels, which could be used as 
      non-invasive indicators of lipid metabolism. This study aimed to investigate the 
      effect of inhaling H2 on breath acetone output during submaximal exercise using a
      randomized, single-blinded, placebo-controlled, and cross-over experimental
      design. After taking a 20-minute baseline measurement, breath acetone levels were
      measured in ten male subjects who performed a 60% peak oxygen uptake-intensity
      cycling exercise for 20 minutes while inhaling either 1% H2 or a control gas. In 
      another experiment, six male subjects remained in a sitting position for 45
      minutes while inhaling either 1% H2 or a control gas. H2 significantly augmented 
      breath acetone and enhanced oxygen uptake during exercise (P < 0.01). However, it
      did not significantly change oxidative stress or antioxidant activity responses
      to exercise, nor did it significantly alter the breath acetone or oxygen uptake
      during prolonged resting states. These results suggest that inhaling H2 gas
      promotes an exercise-induced increase in hepatic lipid metabolism. The study was 
      approved by the Ethical Committee of Chubu University, Japan (approved No.
      260086-2) on March 29, 2018.
FAU - Hori, Amane
AU  - Hori A
AD  - Graduate School of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Ichihara, Masatoshi
AU  - Ichihara M
AD  - College of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Kimura, Hayata
AU  - Kimura H
AD  - College of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Ogata, Hisayoshi
AU  - Ogata H
AD  - College of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Kondo, Takaharu
AU  - Kondo T
AD  - College of Life and Health Sciences, Chubu University, Kasugai, Japan.
FAU - Hotta, Norio
AU  - Hotta N
AD  - College of Life and Health Sciences, Chubu University, Kasugai, Japan.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Antioxidants)
RN  - 0 (Placebos)
RN  - 0 (Reactive Oxygen Species)
RN  - 1364PS73AF (Acetone)
RN  - 7YNJ3PO35Z (Hydrogen)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Acetone/chemistry/*metabolism
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Antioxidants/pharmacology
MH  - Breath Tests/*methods
MH  - Drug Elimination Routes
MH  - Exercise/physiology
MH  - Humans
MH  - Hydrogen/*administration & dosage/physiology
MH  - Japan
MH  - Lipid Metabolism/physiology
MH  - Male
MH  - Oxidative Stress/drug effects
MH  - Oxygen/metabolism
MH  - Placebos
MH  - Reactive Oxygen Species/metabolism
MH  - Single-Blind Method
PMC - PMC8086628
OTO - NOTNLM
OT  - *aerobic exercise
OT  - *antioxidant activity
OT  - *hepatic lipid metabolism
OT  - *hydrogen gas
OT  - *ketone bodies
OT  - *mitochondrial oxidative phosphorylation
OT  - *obesity
OT  - *oxidative stress
OT  - *reactive oxygen species
OT  - *seated rest
EDAT- 2020/10/03 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/10/02 05:36
PHST- 2020/10/02 05:36 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - MedGasRes_2020_10_3_96_296038 [pii]
AID - 10.4103/2045-9912.296038 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Jul-Sep;10(3):96-102. doi: 10.4103/2045-9912.296038.


PMID- 33004704
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - Efficacy of dexmedetomidine-ketamine vs. fentanylketamine on saturated oxygen,
      hemodynamic responses and sedation in cystoscopy: a doubleblinded randomized
      controlled clinical trial.
PG  - 91-95
LID - 10.4103/2045-9912.296037 [doi]
AB  - Cystoscopy is a diagnostic and invasive procedure for treatment and follow-up of 
      genitourinary system patients and could be performed with a variety of anesthesia
      techniques. The study aimed to assess the efficacy of dexmedetomidine-ketamine
      vs. fentanyl-ketamine on sedation and analgesia for cystoscopy. This double-blind
      randomized controlled clinical trial enrolled 60 patients undergoing cystoscopy
      in two groups. Patients were assigned randomly by block random allocation method 
      into dexmedetomidine-ketamine group (1 mug/kg dexmedetomidine) and
      fentanyl-ketamine group (2 mug/kg fentanyl) receiving ketamine (0.5 mg/kg).
      Subsequently, mean blood pressure, heart rate, saturated oxygen, respiratory
      rate, pain intensity, Ramsay score for sedation level, cystoscopy duration, and
      urologic satisfaction were measured and compared between two groups. Both the
      groups were similar regarding age, sex and baseline hemodynamic parameters (P >
      0.05). Lower heart rate and pain score were revealed in the
      dexmedetomidine-ketamine group at 25-50 and 30-60 minutes, respectively, after
      cystoscopy (P < 0.05). Moreover, repeated measure test showed that there was
      significant difference in trend of respiratory rate and pain score between two
      groups (P = 0.017) and was lower in dexmedetomidine-ketamine group. The
      dexmedetomidine-ketamine group relieves pain 30 minutes after cystoscopy with
      stable hemodynamic parameters during operation. Therefore,
      dexmedetomidine-ketamine is recommended to be employed for pain relief in
      subjects undergoing cystoscopy. The study was approved by Ethical Committee of
      Arak University of Medical Sciences with IR.ARAKMU.REC.1397.108 on July 2, 2018, 
      and registered in Iranian Registry Clinical Trial center with code
      IRCT20141209020258N105 on April 21, 2019.
FAU - Modir, Hesameddin
AU  - Modir H
AD  - Departments of Anesthesiology and Critical Care, Arak University of Medical
      Sciences, Arak, Iran.
FAU - Moshiri, Esmail
AU  - Moshiri E
AD  - Departments of Anesthesiology and Critical Care, Arak University of Medical
      Sciences, Arak, Iran.
FAU - Yazdi, Bijan
AU  - Yazdi B
AD  - Departments of Anesthesiology and Critical Care, Arak University of Medical
      Sciences, Arak, Iran.
FAU - Kamalpour, Tannaz
AU  - Kamalpour T
AD  - Students Research Committee, Arak University of Medical Sciences, Arak, Iran.
FAU - Goodarzi, Davood
AU  - Goodarzi D
AD  - Department of Urologic Surgery, Arak University of Medical Sciences, Arak, Iran.
FAU - Mohammadbeigi, Abolfazl
AU  - Mohammadbeigi A
AD  - Department of Epidemiology and Biostatistics, Neuroscience Research Center, Qom
      University of Medical Sciences, Qom, Iran.
LA  - eng
SI  - IRCT/IRCT20141209020258N105
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Analgesics)
RN  - 67VB76HONO (Dexmedetomidine)
RN  - 690G0D6V8H (Ketamine)
RN  - S88TT14065 (Oxygen)
RN  - UF599785JZ (Fentanyl)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Analgesics/*administration & dosage
MH  - Anesthesia
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Blood Pressure
MH  - Clinical Trials as Topic
MH  - Cystoscopy/methods
MH  - Data Management
MH  - Dexmedetomidine/*administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Fentanyl/*administration & dosage
MH  - Heart Rate
MH  - Hemodynamics/physiology
MH  - Humans
MH  - Ketamine/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Oxygen/metabolism
MH  - Pain
MH  - Sex Factors
MH  - Time Factors
PMC - PMC8086618
OTO - NOTNLM
OT  - *analgesia; cystoscopy
OT  - *dexmedetomidine; fentanyl; ketamine; sedation
COIS- None
EDAT- 2020/10/03 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/10/02 05:36
PHST- 2020/10/02 05:36 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - MedGasRes_2020_10_3_91_296037 [pii]
AID - 10.4103/2045-9912.296037 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Jul-Sep;10(3):91-95. doi: 10.4103/2045-9912.296037.


PMID- 33004545
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - The carnage of substandard research during the COVID-19 pandemic: a call for
      quality.
PG  - 803-807
LID - 10.1136/medethics-2020-106494 [doi]
AB  - Worldwide there are currently over 1200 research studies being performed on the
      topic of COVID-19. Many of these involve children and adults over age 65 years.
      There are also numerous studies testing investigational vaccines on healthy
      volunteers. No research team is exempt from the pressures and speed at which
      COVID-19 research is occurring. And this can increase the risk of honest error as
      well as misconduct. To date, 33 papers have been identified as unsuitable for
      public use and either retracted, withdrawn, or noted with concern. Asia is the
      source of most of these manuscripts (n=19; 57.6%) with China the largest Asian
      subgroup (n=11; 57.9%). This paper explores these findings and offers guidance
      for responsible research practice during pandemics.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Bramstedt, Katrina A
AU  - Bramstedt KA
AUID- ORCID: 0000-0001-5446-0123
AD  - Luxembourg Agency for Research Integrity, Esch-sur-Alzette, Luxembourg
      txbioethics@yahoo.com.
AD  - Bond University Faculty of Health Sciences and Medicine, Gold Coast, Queensland, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Editorial Policies
MH  - Global Health
MH  - Humans
MH  - Pandemics
MH  - Research/*organization & administration/standards
MH  - Retraction of Publication as Topic
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health ethics
OT  - *research ethics
COIS- Competing interests: The author owns a private consulting company focused on
      bioethics and clinical ethics (AskTheEthicist, LLC).
EDAT- 2020/10/03 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/10/02 05:36
PHST- 2020/05/23 00:00 [received]
PHST- 2020/08/01 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/10/02 05:36 [entrez]
AID - medethics-2020-106494 [pii]
AID - 10.1136/medethics-2020-106494 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):803-807. doi: 10.1136/medethics-2020-106494. Epub
      2020 Oct 1.


PMID- 33004424
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1943-3662 (Electronic)
IS  - 1093-6793 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - COVID-19, Civil Commitment, and Ethics.
PG  - 436-441
LID - 10.29158/JAAPL.200080-20 [doi]
FAU - Sorrentino, Renee M
AU  - Sorrentino RM
AD  - Dr. Sorrentino is Assistant Professor, Department of Psychiatry, Harvard
      University Medical School and the Institute for Sexual Wellness, Boston, MA. Dr. 
      DiCola is Forensic Psychiatry Fellow, Law and Psychiatry Division, Department of 
      Psychiatry, Yale University School of Medicine, New Haven, CT. Dr. Friedman is
      the Phillip J. Resnick Professor of Forensic Psychiatry, and Adjunct Professor of
      Law, Case Western Reserve University, Cleveland, OH. rsorrentino@mgh.harvard.edu.
FAU - DiCola, Laura A
AU  - DiCola LA
AD  - Dr. Sorrentino is Assistant Professor, Department of Psychiatry, Harvard
      University Medical School and the Institute for Sexual Wellness, Boston, MA. Dr. 
      DiCola is Forensic Psychiatry Fellow, Law and Psychiatry Division, Department of 
      Psychiatry, Yale University School of Medicine, New Haven, CT. Dr. Friedman is
      the Phillip J. Resnick Professor of Forensic Psychiatry, and Adjunct Professor of
      Law, Case Western Reserve University, Cleveland, OH.
FAU - Friedman, Susan Hatters
AU  - Friedman SH
AD  - Dr. Sorrentino is Assistant Professor, Department of Psychiatry, Harvard
      University Medical School and the Institute for Sexual Wellness, Boston, MA. Dr. 
      DiCola is Forensic Psychiatry Fellow, Law and Psychiatry Division, Department of 
      Psychiatry, Yale University School of Medicine, New Haven, CT. Dr. Friedman is
      the Phillip J. Resnick Professor of Forensic Psychiatry, and Adjunct Professor of
      Law, Case Western Reserve University, Cleveland, OH.
LA  - eng
PT  - Editorial
DEP - 20201001
PL  - United States
TA  - J Am Acad Psychiatry Law
JT  - The journal of the American Academy of Psychiatry and the Law
JID - 9708963
SB  - IM
MH  - Attitude of Health Personnel
MH  - COVID-19/*therapy
MH  - Commitment of Mentally Ill/ethics
MH  - Dangerous Behavior
MH  - Ethics, Medical
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - Mentally Ill Persons/*statistics & numerical data
MH  - Patient Advocacy/*ethics
OTO - NOTNLM
OT  - *COVID-19
OT  - *civil commitment
OT  - *ethics
OT  - *involuntary hospitalization
OT  - *pandemic
EDAT- 2020/10/03 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/10/02 05:35
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/10/02 05:35 [entrez]
AID - JAAPL.200080-20 [pii]
AID - 10.29158/JAAPL.200080-20 [doi]
PST - ppublish
SO  - J Am Acad Psychiatry Law. 2020 Dec;48(4):436-441. doi: 10.29158/JAAPL.200080-20. 
      Epub 2020 Oct 1.


PMID- 33004398
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Feasibility study of eye movement desensitisation and reprocessing (EMDR) in
      people with an at-risk mental state (ARMS) for psychosis: study protocol.
PG  - e038620
LID - 10.1136/bmjopen-2020-038620 [doi]
AB  - INTRODUCTION: Trauma can play an important role in the development of psychosis, 
      yet no studies have investigated whether a trauma-focused psychological therapy
      could prevent the onset of psychosis in people at high risk of developing this
      condition. This study aims to establish whether it would be feasible to conduct a
      multicentre randomised controlled trial (RCT) to investigate the clinical and
      cost-effectiveness of eye movement desensitisation and reprocessing (EMDR)
      therapy to prevent the onset of psychosis in people with an at-risk mental state 
      (ARMS). METHODS/ANALYSIS: This is a single-arm trial with a nested qualitative
      study where all participants (target n=20) will be offered EMDR. Eligible
      participants are those who meet criteria for ARMS; have experienced a traumatic
      event before the onset of ARMS symptomatology; and have at least one symptom of
      post-traumatic stress disorder (PTSD). Participants will be followed up at 4, 8
      and 12 months after the baseline assessment. The primary outcome measure is
      transition to psychosis, and secondary outcome measures include severity of
      psychotic symptoms, PTSD, depression, anxiety, impaired functioning, health
      status and resource use. The analysis will aim to establish the rates of
      recruitment and retention for a large-scale RCT. Interviews with therapists and
      patients will explore their views of the study and their experiences of
      delivering or receiving EMDR. ETHICS AND DISSEMINATION: This protocol has been
      approved by the South West-Cornwall and Plymouth Research Ethics Committee
      (Reference 18/SW/0037). Findings will be disseminated through journal
      publications, conference presentations and meetings with service users, their
      families, mental health professionals and commissioners. TRIAL REGISTRATION
      NUMBER: ISRCTN31976295.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Strelchuk, Daniela
AU  - Strelchuk D
AUID- ORCID: 0000-0002-1634-2801
AD  - Centre for Academic Mental Health, Population Health Sciences, Bristol Medical
      School, University of Bristol, Bristol, UK daniela.strelchuk@bristol.ac.uk.
AD  - NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS
      Foundation Trust and the University of Bristol, Bristol, UK.
FAU - Wiles, Nicola
AU  - Wiles N
AD  - Centre for Academic Mental Health, Population Health Sciences, Bristol Medical
      School, University of Bristol, Bristol, UK.
AD  - NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS
      Foundation Trust and the University of Bristol, Bristol, UK.
FAU - Turner, Katrina M
AU  - Turner KM
AUID- ORCID: 0000-0002-6375-2918
AD  - Centre for Academic Mental Health, Population Health Sciences, Bristol Medical
      School, University of Bristol, Bristol, UK.
AD  - NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS
      Foundation Trust and the University of Bristol, Bristol, UK.
FAU - Derrick, Catherine
AU  - Derrick C
AD  - Centre for Academic Mental Health, Population Health Sciences, Bristol Medical
      School, University of Bristol, Bristol, UK.
FAU - Zammit, Stan
AU  - Zammit S
AD  - Centre for Academic Mental Health, Population Health Sciences, Bristol Medical
      School, University of Bristol, Bristol, UK.
AD  - Division of Psychological Medicine and Clinical Neuroscience, MRC Centre for
      Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
LA  - eng
SI  - ISRCTN/ISRCTN31976295
GR  - MR/K025643/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/L010305/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Eye Movement Desensitization Reprocessing
MH  - Eye Movements
MH  - Feasibility Studies
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Psychotic Disorders/therapy
MH  - Randomized Controlled Trials as Topic
MH  - *Stress Disorders, Post-Traumatic/prevention & control
PMC - PMC7534702
OTO - NOTNLM
OT  - *clinical trials
OT  - *qualitative research
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038620 [pii]
AID - 10.1136/bmjopen-2020-038620 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e038620. doi: 10.1136/bmjopen-2020-038620.


PMID- 33004397
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Exploring views and experiences of how infections are detected and managed in
      practice by nurses, care workers and manager's in nursing homes in England and
      Sweden: a survey protocol.
PG  - e038390
LID - 10.1136/bmjopen-2020-038390 [doi]
AB  - INTRODUCTION: In order to avoid unnecessary hospital admission and associated
      complications, there is an urgent need to improve the early detection of
      infection in nursing home residents. Monitoring signs and symptoms with
      checklists or aids called decision support tools may help nursing home staff to
      detect infection in residents, particularly during the current COVID-19
      pandemic.We plan to conduct a survey exploring views and experiences of how
      infections are detected and managed in practice by nurses, care workers and
      managers in nursing homes in England and Sweden. METHODS AND ANALYSIS: An
      international cross-sectional descriptive survey, using a pretested
      questionnaire, will be used to explore nurses, care workers and managers views
      and experiences of how infections are detected and managed in practice in nursing
      homes. Data will be analysed descriptively and univariate associations between
      personal and organisational factors explored. This will help identify important
      factors related to awareness, knowledge, attitudes, belief and skills likely to
      affect future implementation of a decision support tool for the early detection
      of infection in nursing home residents. ETHICS AND DISSEMINATION: This study was 
      approved using the self-certification process at the University of Surrey and
      Linkoping University ethics committee (Approval 2018/514-32) in 2018. Study
      findings will be disseminated through community/stakeholder/service user
      engagement events in each country, publication in academic peer-reviewed journals
      and conference presentations. A LAY summary will be provided to participants who 
      indicate they would like to receive this information.This is the first stage of a
      plan of work to revise and evaluate the Early Detection of Infection Scale (EDIS)
      tool and its effect on managing infections and reducing unplanned hospital
      admissions in nursing home residents. Implementation of the EDIS tool may have
      important implications for the healthcare economy; this will be explored in
      cost-benefit analyses as the work progresses.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Carey, N
AU  - Carey N
AUID- ORCID: 0000-0003-2841-1760
AD  - School of Health Sciences, University of Surrey, Guildford, Surrey, UK
      n.carey@surrey.ac.uk.
FAU - Alkhamees, Nouf
AU  - Alkhamees N
AD  - College of Health and Rehabilitation Sciences, Princess Noura Bint Abdul Rahman
      University, Riyadh, Saudi Arabia.
FAU - Cox, Anna
AU  - Cox A
AD  - School of Health Sciences, University of Surrey, Guildford, Surrey, UK.
FAU - Sund-Levander, Marta
AU  - Sund-Levander M
AD  - Division of Nursing, Department of Medical and Health Sciences, Linkoping
      University, Linkoping, Sweden.
FAU - Tingstrom, Pia
AU  - Tingstrom P
AD  - Division of Nursing, Department of Medical and Health Sciences, Linkoping
      University, Linkoping, Sweden.
FAU - Mold, Freda
AU  - Mold F
AD  - School of Health Sciences, University of Surrey, Guildford, Surrey, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Communicable Disease Control/methods/organization & administration
MH  - *Coronavirus Infections/diagnosis/epidemiology/therapy
MH  - Cost-Benefit Analysis
MH  - Cross-Sectional Studies
MH  - England/epidemiology
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Personnel/standards
MH  - Hospitalization
MH  - Humans
MH  - Medical Overuse/*prevention & control
MH  - Nursing Homes/*statistics & numerical data
MH  - *Pandemics
MH  - *Patient Care Management/economics/methods
MH  - *Pneumonia, Viral/diagnosis/epidemiology/therapy
MH  - Practice Management/economics
MH  - Research Design
MH  - SARS-CoV-2
MH  - Skilled Nursing Facilities/*statistics & numerical data
MH  - Sweden/epidemiology
PMC - PMC7534694
OTO - NOTNLM
OT  - *general medicine (see internal medicine)
OT  - *international health services
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - bmjopen-2020-038390 [pii]
AID - 10.1136/bmjopen-2020-038390 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e038390. doi: 10.1136/bmjopen-2020-038390.


PMID- 33004396
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Study protocol for a multicentre implementation trial of monotherapy
      anticoagulation to expedite home treatment of patients diagnosed with venous
      thromboembolism in the emergency department.
PG  - e038078
LID - 10.1136/bmjopen-2020-038078 [doi]
AB  - INTRODUCTION: In the USA, many emergency departments (EDs) have established
      protocols to treat patients with newly diagnosed deep vein thrombosis (DVT) as
      outpatients. Similar treatment of patients with pulmonary embolism (PE) has been 
      proposed, but no large-scale study has been published to evaluate a
      comprehensive, integrated protocol that employs monotherapy anticoagulation to
      treat patients diagnosed with DVT and PE in the ED. METHODS AND ANALYSIS: This
      protocol describes the implementation of the Monotherapy Anticoagulation To
      expedite Home treatment of Venous ThromboEmbolism (MATH-VTE) study at 33
      hospitals in the USA. The study was designed and executed to meet the
      requirements for the Standards for Reporting Implementation Studies guideline.
      The study was funded by investigator-initiated awards from industry, with Indiana
      University as the sponsor. The study principal investigator and study associates 
      travelled to each site to provide on-site training. The protocol identically
      screens patients with both DVT or PE to determine low risk of death using either 
      the modified Hestia criteria or physician judgement plus a negative result from
      the simplified PE severity index. Patients must be discharged from the ED within 
      24 hours of triage and treated with either apixaban or rivaroxaban. Overall
      effectiveness is based upon the primary efficacy and safety outcomes of recurrent
      VTE and bleeding requiring hospitalisation respectively. Target enrolment of 1300
      patients was estimated with efficacy success defined as the upper limit of the
      95% CI for the 30-day frequency of VTE recurrence below 2.0%. Thirty-three
      hospitals in 17 states were initiated in 2016-2017. ETHICS AND DISSEMINATION: All
      sites had Institutional Review Board approval. We anticipate completion of
      enrolment in June 2020; study data will be available after peer-reviewed
      publication. MATH-VTE will provide information from a large multicentre sample of
      US patients about the efficacy and safety of home treatment of VTE with
      monotherapy anticoagulation.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kline, Jeffrey
AU  - Kline J
AUID- ORCID: 0000-0001-7190-3109
AD  - Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana,
      USA jefkline@iu.edu.
FAU - Adler, David
AU  - Adler D
AD  - Emergency Medicine, University of Rochester Medical Center, Rochester, New York, 
      USA.
FAU - Alanis, Naomi
AU  - Alanis N
AUID- ORCID: 0000-0003-2200-315X
AD  - Emergency Medicine, University of North Texas Health Science Center, Fort Worth, 
      Texas, USA.
FAU - Bledsoe, Joseph
AU  - Bledsoe J
AD  - Emergency Medicine, Intermountain Health Care Inc, Salt Lake City, Utah, USA.
FAU - Courtney, Daniel
AU  - Courtney D
AD  - Emergency Medicine, University of Texas Southwestern Medical School, Dallas,
      Texas, USA.
FAU - D'Etienne, James
AU  - D'Etienne J
AD  - Emergency Medicine, John Peter Smith Hospital, Fort Worth, Texas, USA.
FAU - B Diercks, Deborah
AU  - B Diercks D
AD  - Emergency Medicine, University of Texas Southwestern Medical School, Dallas,
      Texas, USA.
FAU - Garrett, John
AU  - Garrett J
AD  - Emergency Medicine, Baylor University Medical Center at Dallas, Dallas, Texas,
      USA.
FAU - Jones, Alan E
AU  - Jones AE
AD  - Emergency Medicine, University of Mississippi Medical Center, Jackson,
      Mississippi, USA.
FAU - MacKenzie, David
AU  - MacKenzie D
AD  - Emergency Medicine, Maine Medical Center, Portland, Maine, USA.
FAU - Madsen, Troy
AU  - Madsen T
AD  - Emergency Medicine, University of Utah, Salt Lake City, Utah, USA.
FAU - Matuskowitz, Andrew
AU  - Matuskowitz A
AD  - Emergency Medicine, Medical University of South Carolina, Charleston, South
      Carolina, USA.
FAU - Mumma, Bryn
AU  - Mumma B
AD  - Emergency Medicine, University of California Davis, Davis, California, USA.
FAU - Nordenholz, Kristen
AU  - Nordenholz K
AD  - Emergency Medicine, University of Colorado Denver, Denver, Colorado, USA.
FAU - Pagenhardt, Justine
AU  - Pagenhardt J
AD  - Emergency Medicine, West Virginia University - Health Sciences Campus,
      Morgantown, West Virginia, USA.
FAU - Runyon, Michael
AU  - Runyon M
AD  - Emergency Medicine, Atrium Health, Charlotte, North Carolina, USA.
FAU - Stubblefield, William
AU  - Stubblefield W
AD  - Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee,
      USA.
FAU - Willoughby, Christopher
AU  - Willoughby C
AD  - Internal Medicine, Louisiana State University, New Orleans, Louisiana, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Indiana
MH  - Multicenter Studies as Topic
MH  - *Pulmonary Embolism/drug therapy
MH  - Risk Factors
MH  - *Venous Thromboembolism/drug therapy
PMC - PMC7534683
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *clinical pharmacology
OT  - *thromboembolism
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038078 [pii]
AID - 10.1136/bmjopen-2020-038078 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e038078. doi: 10.1136/bmjopen-2020-038078.


PMID- 33004395
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Protocol for a process evaluation of Family Planning Elevated: a statewide
      initiative to improve contraceptive access in Utah (USA).
PG  - e038049
LID - 10.1136/bmjopen-2020-038049 [doi]
AB  - INTRODUCTION: Many individuals in the USA do not have access to the contraceptive
      methods they desire. Contraceptive initiatives have emerged at the state and
      national levels to remove barriers to access, and many initiatives have reported 
      success. Other initiatives may want to build on or replicate that success, but
      data are scarce on the details of how and why certain interventions work. This
      paper describes the protocol for the planned process evaluation of Family
      Planning Elevated (FPE), a statewide contraceptive initiative in Utah. METHODS:
      FPE will conduct a process evaluation during the planning and implementation
      phases of the programme. The process evaluation will document (1) the community, 
      state and national contexts in which the programme is implemented, (2) how FPE is
      implemented and (3) the mechanism by which FPE creates impact. We will collect
      qualitative data via interviews with FPE staff, providers and staff participating
      in the programme, and key stakeholders and policy-makers throughout the state.
      The team process evaluator will record FPE decision making and implementation
      activities by taking field notes during weekly FPE meetings. Quantitatively, we
      will collect monthly data reports from FPE-participating clinics, analytics
      reports from the media campaign and survey results from patients in
      FPE-participating clinics. The findings of the process evaluation will allow
      other contraceptive initiatives to learn from FPE's efforts and replicate
      successful components of the programme. ETHICS AND DISSEMINATION: The study
      received approval from the University of Utah's Institutional Review Board.
      Findings from the process evaluation and outcome evaluation will be published,
      shared with other contraceptive initiatives and presented at conferences. TRIAL
      REGISTRATION NUMBER: NCT03877757.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Baayd, Jami
AU  - Baayd J
AUID- ORCID: 0000-0003-4159-4207
AD  - Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah, USA
      jami.baayd@nurs.utah.edu.
FAU - Simmons, Rebecca G
AU  - Simmons RG
AD  - Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03877757
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Contraceptive Agents)
SB  - IM
MH  - *Contraception
MH  - Contraceptive Agents
MH  - *Family Planning Services
MH  - Health Services Accessibility
MH  - Humans
MH  - Utah
PMC - PMC7534679
OTO - NOTNLM
OT  - *Contraception
OT  - *family planning services
OT  - *process evaluation
COIS- Competing interests: The University of Utah Department of Obstetrics and
      Gynecology Program in Family Planning receives research funding from Bayer,
      Bioceptive, Sebela, Medicines 360, Merck, Cooper Surgical, Clinical Innovations
      and Teva.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038049 [pii]
AID - 10.1136/bmjopen-2020-038049 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e038049. doi: 10.1136/bmjopen-2020-038049.


PMID- 33004394
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Nutrition screening and assessment tools for patients with cancer and survivors
      of cancer: a systematic review protocol.
PG  - e037844
LID - 10.1136/bmjopen-2020-037844 [doi]
AB  - INTRODUCTION: Nutritional challenges are common consequences of cancer, and they 
      do not only occur in the hospital setting. They are also frequent after
      completion of treatment, and nutritional interventions in community-based
      post-treatment rehabilitation services are important. The first step towards
      initiating any nutritional intervention is to identify the individual in need
      hereof, but evidence is limited on the applicability of different nutrition
      screening and assessment tools in the post-treatment rehabilitation services. The
      aim is to systematically review and identify nutrition screening and assessment
      tools appropriate for use in patients with cancer and survivors of cancer in
      hospital or community-based healthcare settings. METHODS AND ANALYSIS: In this
      systematic review, the electronic databases PubMed, CINAHL Complete and Embase
      were searched systematically using comprehensive search strategies. Primary
      searches were carried out in August 2018 with updated searches performed in
      November 2019. Clinicaltrials.gov and PROSPERO International Prospective Register
      of Systematic Reviews will be searched for additional relevant studies. Studies
      will be included if they validate a nutrition screening or assessment tool in
      adult patients with cancer or survivors of cancer. No restriction on publication 
      date will be applied, and full-text articles in English, Danish, Norwegian and
      Swedish are eligible for inclusion. Two reviewers will independently conduct
      screening of search results, study selection, data extraction and quality
      assessment. Data will be synthesised narratively. ETHICS AND DISSEMINATION: No
      ethical approval is required. Results will be reported in accordance with the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and 
      published in an international peer-reviewed journal. Furthermore, results will be
      presented in relevant research and clinical fora to facilitate transfer of
      results to clinical practice in benefit of patients. PROSPERO REGISTRATION
      NUMBER: CRD42018096678.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kristensen, Marianne Boll
AU  - Kristensen MB
AUID- ORCID: 0000-0002-7307-7215
AD  - Department of Nursing and Nutrition, University College Copenhagen, Copenhagen,
      Denmark mabk@kp.dk.
AD  - REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense
      University Hospital, and Department of Clinical Research, University of Southern 
      Denmark, Nyborg, Denmark.
FAU - Wessel, Irene
AU  - Wessel I
AUID- ORCID: 0000-0001-9986-5001
AD  - Department of Otorhinolaryngology, Head and Neck Surgery & Audiology,
      Rigshospitalet, Copenhagen, Denmark.
FAU - Ustrup, Kim Skov
AU  - Ustrup KS
AUID- ORCID: 0000-0002-6865-8007
AD  - Department of Nursing and Nutrition, University College Copenhagen, Copenhagen,
      Denmark.
FAU - Dieperink, Karin B
AU  - Dieperink KB
AUID- ORCID: 0000-0003-4766-3242
AD  - Research Unit of Oncology, Department of Oncology, Odense University Hospital,
      Odense, Denmark.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Zwisler, Ann-Dorthe
AU  - Zwisler AD
AUID- ORCID: 0000-0002-9241-2090
AD  - REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense
      University Hospital, and Department of Clinical Research, University of Southern 
      Denmark, Nyborg, Denmark.
FAU - Beck, Anne Marie
AU  - Beck AM
AUID- ORCID: 0000-0003-1210-0167
AD  - Department of Nursing and Nutrition, University College Copenhagen, Copenhagen,
      Denmark.
AD  - Dietetics and Clinical Nutrition Research Unit, Herlev and Gentofte Hospital,
      Herlev, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Early Detection of Cancer
MH  - Humans
MH  - Mass Screening
MH  - *Neoplasms
MH  - Nutritional Status
MH  - Survivors
MH  - Systematic Reviews as Topic
PMC - PMC7534678
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *nutritional support
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037844 [pii]
AID - 10.1136/bmjopen-2020-037844 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e037844. doi: 10.1136/bmjopen-2020-037844.


PMID- 33004392
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Randomised multicentre clinical trial to evaluate voriconazole pre-emptive
      genotyping strategy in patients with risk of aspergillosis: vorigenipharm study
      protocol.
PG  - e037443
LID - 10.1136/bmjopen-2020-037443 [doi]
AB  - INTRODUCTION: Invasive aspergillosis is the most important cause of morbidity and
      mortality in patients with haematological diseases. At present, voriconazole is
      the first-line treatment for invasive fungal disease. The pharmacokinetic
      interindividual variability of voriconazole depends on genetic factors. CYP450 is
      involved in 70%-75% of total metabolism of voriconazole, mainly CYP3A4 and
      CYP2C19, with the remaining 25%-30% of metabolism conducted by monooxygenase
      flavins. CYP2C19 single nucleotide polymorphisms could explain 50%-55% of
      variability in voriconazole metabolism. MATERIALS AND METHODS: The main objective
      is to compare efficiency of pre-emptive voriconazole genotyping with routine
      practice. The primary outcome is serum voriconazole on the fifth day within the
      therapeutic range. The secondary outcome is the combined variables of therapeutic
      failure and adverse events within 90 days of first administration, associated
      with voriconazole. A total of 146 patients at risk of invasive aspergillosis who 
      will potentially receive voriconazole will be recruited, and CYP2C19 will be
      genotyped. If the patient ultimately receives voriconazole, they will be
      randomised (1:1 experimental/control). In the experimental arm, patients will
      receive a dose according to a pharmacogenetic algorithm, including CYP2C19
      genotype and clinical and demographic information. In the control arm, patients
      will receive a dose according to clinical practice guidelines. In addition, a
      Spanish National Healthcare System (NHS) point-of-view cost-effectiveness
      evaluation will be performed. Direct cost calculations for each arm will be
      performed. CONCLUSION: This trial will provide information about the viability
      and cost-effectiveness of the implementation of a pre-emptive voriconazole
      genotyping strategy in the Spanish NHS. ETHICS AND DISSEMINATION: A Spanish
      version of this protocol has been evaluated and approved by the La Paz University
      Hospital Ethics Committee and the Spanish Agency of Medicines and Medical
      Devices. Trial results will be submitted for publication in an open peer-reviewed
      medical speciality-specific publication. TRIAL REGISTRATION NUMBER: Eudra-CT:
      2019-000376-41 and NCT04238884; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Monserrat Villatoro, Jaime
AU  - Monserrat Villatoro J
AD  - Clinical Pharmacology Department, Hospital Universitario La Paz IdiPAZ, Madrid,
      Spain.
FAU - Garcia Garcia, Irene
AU  - Garcia Garcia I
AD  - Clinical Pharmacology Department, Hospital Universitario La Paz IdiPAZ, Madrid,
      Spain.
FAU - Bueno, David
AU  - Bueno D
AD  - Pediatric Oncology and Haematology Department, Hospital Universitario La Paz,
      Madrid, Spain.
FAU - de la Camara, Rafael
AU  - de la Camara R
AD  - Haematology Department, Hospital Universitario de la Princesa, Madrid, Spain.
FAU - Estebanez, Miriam
AU  - Estebanez M
AD  - Internal Medicine Department, Hospital Central de la Defensa Gomez Ulla, Madrid, 
      Spain.
FAU - Lopez de la Guia, Ana
AU  - Lopez de la Guia A
AD  - Haematology Department, Hospital Universitario La Paz, Madrid, Spain.
FAU - Abad-Santos, Francisco
AU  - Abad-Santos F
AD  - Clinical Pharmacology Department, Hospital Universitario de la Princesa, Madrid, 
      Spain.
AD  - Pharmacology Department, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Anton, Cristina
AU  - Anton C
AD  - Health Technology Assessment Department, Universidad Francisco de Vitoria,
      Pozuelo de Alarcon, Madrid, Spain.
FAU - Mejia, Gina
AU  - Mejia G
AD  - Clinical Pharmacology Department, Hospital Universitario de la Princesa, Madrid, 
      Spain.
FAU - Otero, Maria Jose
AU  - Otero MJ
AD  - Haematology Department, Hospital Central de la Defensa Gomez Ulla, Madrid, Spain.
FAU - Ramirez Garcia, Elena
AU  - Ramirez Garcia E
AD  - Clinical Pharmacology Department, Hospital Universitario La Paz IdiPAZ, Madrid,
      Spain.
AD  - Pharmacology Department, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Frias Iniesta, Jesus
AU  - Frias Iniesta J
AD  - Clinical Pharmacology Department, Hospital Universitario La Paz IdiPAZ, Madrid,
      Spain.
AD  - Pharmacology Department, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Carcas, Antonio
AU  - Carcas A
AD  - Clinical Pharmacology Department, Hospital Universitario La Paz IdiPAZ, Madrid,
      Spain.
AD  - Pharmacology Department, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Borobia, Alberto M
AU  - Borobia AM
AUID- ORCID: 0000-0002-8584-3263
AD  - Clinical Pharmacology Department, Hospital Universitario La Paz IdiPAZ, Madrid,
      Spain alberto.borobia@salud.madrid.org.
AD  - Pharmacology Department, Universidad Autonoma de Madrid, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04238884
SI  - EudraCT/2019-000376-41
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - JFU09I87TR (Voriconazole)
SB  - IM
MH  - *Aspergillosis/drug therapy/genetics
MH  - Genotype
MH  - *Hematologic Diseases
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Pharmacogenetics
MH  - Voriconazole/therapeutic use
PMC - PMC7534724
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *clinical trials
OT  - *infectious diseases
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037443 [pii]
AID - 10.1136/bmjopen-2020-037443 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e037443. doi: 10.1136/bmjopen-2020-037443.


PMID- 33004389
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Decolonising qualitative research to explore the experiences of Manitoba's urban 
      Indigenous population living with type 2 diabetes mellitus, obesity and bariatric
      surgery.
PG  - e036595
LID - 10.1136/bmjopen-2019-036595 [doi]
AB  - INTRODUCTION: Obesity and type 2 diabetes mellitus (T2DM) are growing global
      health concerns associated with significant morbidity, mortality and healthcare
      expenditures. Due to histories of colonisation and contemporary marginalisation, 
      Canada's Indigenous populations are disproportionately burdened by obesity, T2DM 
      and many other chronic illnesses. Culturally appropriate research on experiences 
      and outcomes of Indigenous patients undergoing bariatric surgery in Canada is
      scarce. This qualitative study protocol will use a decolonising approach guided
      by an Indigenous Elder to explore the perspectives and experiences of urban
      Indigenous Manitobans with respect to T2DM, obesity and bariatric surgery. This
      knowledge will guide the development and implementation of culturally sensitive
      bariatric care. METHODS AND ANALYSIS: Sequential sharing circles (SSCs) and
      semistructured conversational interviews that have been purposefully designed to 
      be culturally relevant with the guidance of an Indigenous Elder and advisory
      group (IAG) will be carried out in Winnipeg, Manitoba, Canada. Indigenous adults 
      who are obese (body mass index >35 kg/m(2)), have T2DM and live in an urban
      centre will be recruited. Three groups will be investigated: (1) those who have
      had bariatric surgery; (2) those on the wait list for bariatric surgery and (3)
      those not associated with a bariatric surgery programme. Each group of 10-12
      participants will be guided through a semistructured script led by an Indigenous 
      Elder. Elder-facilitated conversational interviews will also be completed
      following the SSCs. All content will be audio recorded and transcribed. Thematic 
      analysis will be used to identify emerging patterns using a constructive grounded
      theory approach. ETHICS AND DISSEMINATION: This study has received ethical
      approval from the University of Manitoba Health Research Ethics Board. Findings
      will inform the development and implementation of culturally sensitive programmes
      at Manitoba's Centre for Metabolic and Bariatric Surgery. Results will be
      disseminated in peer-reviewed scientific journals, at obesity and Indigenous
      health conferences, and knowledge sharing ceremonies.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hardy, Krista
AU  - Hardy K
AUID- ORCID: 0000-0001-7638-7879
AD  - Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada
      umserg99@gmail.com.
FAU - Zmudzinski, Marta
AU  - Zmudzinski M
AD  - Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Fowler-Woods, Melinda
AU  - Fowler-Woods M
AD  - Department of Family Medicine, University of Manitoba, Winnipeg, Manitoba,
      Canada.
AD  - Department of Community Health Sciences, University of Manitoba, Winnipeg,
      Manitoba, Canada.
FAU - Shingoose, Geraldine
AU  - Shingoose G
AD  - Department of Community Health Sciences, University of Manitoba, Winnipeg,
      Manitoba, Canada.
FAU - Fowler-Woods, Amanda
AU  - Fowler-Woods A
AD  - Ongomiizwin Indigenous Institute for Health and Healing, University of Manitoba, 
      Winnipeg, Manitoba, Canada.
FAU - Daeninck, Felicia
AU  - Daeninck F
AD  - Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Hatala, Andrew
AU  - Hatala A
AD  - Department of Community Health Sciences, University of Manitoba, Winnipeg,
      Manitoba, Canada.
FAU - Vergis, Ashley
AU  - Vergis A
AD  - Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Bariatric Surgery
MH  - Canada
MH  - *Diabetes Mellitus, Type 2/surgery
MH  - Humans
MH  - Manitoba
MH  - Obesity/surgery
MH  - Population Groups
MH  - Qualitative Research
PMC - PMC7534700
OTO - NOTNLM
OT  - *general diabetes
OT  - *qualitative research
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036595 [pii]
AID - 10.1136/bmjopen-2019-036595 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e036595. doi: 10.1136/bmjopen-2019-036595.


PMID- 33004387
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Adaptability to acute stress among women survivors of intimate partner violence: 
      protocol for a mixed-methods cross-sectional study in a laboratory setting (BRAW 
      study).
PG  - e036561
LID - 10.1136/bmjopen-2019-036561 [doi]
AB  - INTRODUCTION: Intimate partner violence (IPV) is the most common and alarming
      form of violence against women, affecting around 30% of all women around the
      world. Using an integrative methodology, we approach IPV as a form of chronic
      exposure to severe stress that alters the stress-response system of exposed
      women. The aim of this study is to test the hypothesis that sustained exposure to
      IPV in women confers a vulnerability-to-stress profile characterised by higher
      neuroendocrine and behavioural responsiveness associated with a selective
      attentional processing bias towards threat. METHODS AND ANALYSIS: Women between
      21 and 50 years old from the area of Barcelona (Spain) will be invited to
      participate. A sample of 82 women exposed to IPV and 41 women not exposed to IPV 
      will be included and assessed for attentional bias and response to acute stress
      in a laboratory condition (the Trier Social Stress Task). The study will include 
      quantitative and qualitative measures of cognitive performance, neuroendocrine
      activity and face-to-face interviews to obtain an integrative description of the 
      stress-response profile of these women. Results are expected to help build
      resilience strategies with a long-lasting impression on women's healthy
      functioning. ETHICS AND DISSEMINATION: The study has obtained the approval of the
      local Ethics Committee ('Comite de Etica de Investigacion Parc Tauli de
      Sabadell'; 2 018 551 V.1.2 June 2018). Besides the communication of results in
      peer-reviewed papers and scientific congresses, the project will inform
      guidelines and recommendations through policy-dialogues and workshops with
      relevant regional and national representatives for future work and prevention
      strategies. Participants will be invited to be an active part in the
      dissemination strategy focussed on raising awareness of coping limitations and
      abilities that women themselves will be able to identify throughout the study.
      TRIAL REGISTRATION DETAILS: The study has been registered at the
      ClinicalTrails.gov database (Identifier number: NCT03623555; Pre-results).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Goldberg, Ximena
AU  - Goldberg X
AUID- ORCID: 0000-0001-9681-5826
AD  - Mental Health Department, Neuroscience and Mental Health Research Area, Institut 
      d'Investigacio I Innovacio Parc Tauli I3PT, Universitat Autonoma de Barcelona,
      CIBERSAM, Sabadell, Spain xlgoldberg@tauli.cat.
FAU - Espelt, Carme
AU  - Espelt C
AD  - Mental Health Department, Neuroscience and Mental Health Research Area, Institut 
      d'Investigacio I Innovacio Parc Tauli I3PT, Universitat Autonoma de Barcelona,
      CIBERSAM, Sabadell, Spain.
FAU - Palao, Diego
AU  - Palao D
AD  - Mental Health Department, Neuroscience and Mental Health Research Area, Institut 
      d'Investigacio I Innovacio Parc Tauli I3PT, Universitat Autonoma de Barcelona,
      CIBERSAM, Sabadell, Spain.
FAU - Nadal, Roser
AU  - Nadal R
AD  - Psychobiology Unit (School of Psychology), Institut de Neurociencies, Universitat
      Autonoma de Barcelona, CIBERSAM, Cerdanyola del Valles, Spain.
FAU - Armario, Antonio
AU  - Armario A
AD  - Animal Physiology Unit (School of Biosciences), Institut de Neurociencies,
      Universitat Autonoma de Barcelona, CIBERSAM, Cerdanyola del Valles, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03623555
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Intimate Partner Violence
MH  - *Laboratories
MH  - Middle Aged
MH  - Spain
MH  - Survivors
MH  - Young Adult
PMC - PMC7534674
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *mental health
OT  - *neurobiology
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036561 [pii]
AID - 10.1136/bmjopen-2019-036561 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e036561. doi: 10.1136/bmjopen-2019-036561.


PMID- 33004385
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Strategies to reduce antibiotic use in women with uncomplicated urinary tract
      infection in primary care: protocol of a systematic review and meta-analysis
      including individual patient data.
PG  - e035883
LID - 10.1136/bmjopen-2019-035883 [doi]
AB  - INTRODUCTION: Uncomplicated urinary tract infection (UTI) in women is a common
      reason to present in general practice and is usually treated with antibiotics to 
      reduce symptom severity and duration. Results of recent clinical trials indicate 
      that non-antibiotic treatment approaches can also be effective. However, it
      remains unclear which patients would benefit from antibiotic treatment and which 
      can effectively and safely be treated without antibiotics. This systematic review
      and meta-analysis aims to estimate the effect of treatment strategies to reduce
      antibiotic use in comparison with immediate antibiotic treatment and to identify 
      prognostic factors and moderators of treatment effects. A further aim is to
      identify subgroups of patients benefiting from a specific therapy. METHODS AND
      ANALYSIS: A systematic literature search will be performed to identify randomised
      controlled trials which investigated the effect of treatment strategies to reduce
      antibiotic use in female adults with uncomplicated UTI compared with immediate
      antibiotic treatment. Therefore, the primary outcome of the meta-analysis is
      incomplete recovery. Anonymised individual patient data (IPD) will be collected. 
      Aggregate data will be used for pairwise comparisons of treatment strategies
      using meta-analysis models with random effects accounting for potential
      between-study heterogeneity. Potential effect moderators will be explored in
      meta-regressions. For IPD, generalised linear mixed models will be used, which
      may be adjusted for baseline characteristics. Interactions of baseline variables 
      with treatment effects will be explored. These models will be used to assess
      direct comparisons of treatment, but might be extended to networks. ETHICS AND
      DISSEMINATION: The local institutional review and ethics board judged the project
      a secondary analysis of existing anonymous data which meet the criteria for
      waiver of ethics review. Dissemination of the results will be via published
      scientific papers and presentations. Key messages will be promoted for example,
      via social media or press releases. PROSPERO REGISTRATION NUMBER: CRD42019125804.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Heinz, Judith
AU  - Heinz J
AUID- ORCID: 0000-0001-8331-9137
AD  - Department of Medical Statistics, University Medical Center Goettingen,
      Goettingen, Germany judith.heinz@med.uni-goettingen.de.
FAU - Rover, Christian
AU  - Rover C
AD  - Department of Medical Statistics, University Medical Center Goettingen,
      Goettingen, Germany.
FAU - Furaijat, Ghefar
AU  - Furaijat G
AD  - Department of General Practice, University Medical Center Goettingen, Goettingen,
      Germany.
AD  - Department of Emergency Medicine, University Medical Center Goettingen,
      Goettingen, Germany.
FAU - Kaussner, Yvonne
AU  - Kaussner Y
AD  - Department of General Practice, Julius Maximilians University Wuerzburg Faculty
      of Medicine, Wuerzburg, Germany.
FAU - Hummers, Eva
AU  - Hummers E
AD  - Department of General Practice, University Medical Center Goettingen, Goettingen,
      Germany.
FAU - Debray, Thomas
AU  - Debray T
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Hay, Alastair D
AU  - Hay AD
AD  - Centre for Academic Primary Care, University of Bristol, Bristol, UK.
FAU - Heytens, Stefan
AU  - Heytens S
AD  - Department of Public Health and Primary Care, University of Ghent, Gent, Belgium.
FAU - Vik, Ingvild
AU  - Vik I
AUID- ORCID: 0000-0002-8947-2914
AD  - Department of General Practice, The Antibiotic Centre of Primary Care, Institute 
      of Health and Society, University of Oslo, Oslo, Norway.
AD  - Department of Emergency General Practice, Oslo Accident and Emergency Outpatient 
      Clinic, Oslo, Norway.
FAU - Little, Paul
AU  - Little P
AUID- ORCID: 0000-0003-3664-1873
AD  - Primary Care Population Sciences and Medical Education Unit, University of
      Southampton School of Medicine, Southampton, UK.
FAU - Moore, Michael
AU  - Moore M
AUID- ORCID: 0000-0002-5127-4509
AD  - Primary Care Population Sciences and Medical Education Unit, University of
      Southampton School of Medicine, Southampton, UK.
FAU - Stuart, Beth
AU  - Stuart B
AD  - Primary Care Population Sciences and Medical Education Unit, University of
      Southampton School of Medicine, Southampton, UK.
FAU - Wagenlehner, Florian
AU  - Wagenlehner F
AD  - Clinic for Urology, Pediatric Urology and Andrology, Justus Liebig University
      Giessen Faculty of Medicine, Giessen, Germany.
FAU - Kronenberg, Andreas
AU  - Kronenberg A
AD  - Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
FAU - Ferry, Sven
AU  - Ferry S
AD  - Department of Clinical Microbiology, Bacteriology, Umea University, Umea, Sweden.
FAU - Monsen, Tor
AU  - Monsen T
AD  - Department of Clinical Microbiology, Bacteriology, Umea University, Umea, Sweden.
FAU - Lindbaek, Morten
AU  - Lindbaek M
AD  - Department of General Practice, The Antibiotic Centre of Primary Care, Institute 
      of Health and Society, University of Oslo, Oslo, Norway.
FAU - Friede, Tim
AU  - Friede T
AUID- ORCID: 0000-0001-5347-7441
AD  - Department of Medical Statistics, University Medical Center Goettingen,
      Goettingen, Germany.
FAU - Gagyor, Ildiko
AU  - Gagyor I
AUID- ORCID: 0000-0002-7974-7603
AD  - Department of General Practice, Julius Maximilians University Wuerzburg Faculty
      of Medicine, Wuerzburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adult
MH  - *Anti-Bacterial Agents/therapeutic use
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Primary Health Care
MH  - Systematic Reviews as Topic
MH  - *Urinary Tract Infections/drug therapy
PMC - PMC7534728
OTO - NOTNLM
OT  - *adult urology
OT  - *general medicine (see internal medicine)
OT  - *urinary tract infections
COIS- Competing interests: IG, GF, TF, EH, MM are involved in the following studies:
      'REGATTA-reducing antibiotic use for uncomplicated urinary tract infection in
      general practice by treatment with uva-ursi'. Afshar K, Fleischmann N, Schmiemann
      G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gagyor I.
      'Reducing antibiotic use for uncomplicated urinary tract infection in general
      practice by treatment with uva-ursi (REGATTA)-a double-blind, randomised,
      controlled comparative effectiveness trial'. BMC Complement Altern Med. 2018 Jul 
      3;18(1):203. doi: 10.1186/s12906-018-2266-x). IV was involved in the study: 'Vik 
      I, Bollestad M, Grude N, Baerheim A, Damsgaard E, Neumark T, Bjerrum L, Cordoba
      G, Olsen IC, Lindbaek M. Ibuprofen versus pivmecillinam for uncomplicated urinary
      tract infection in women-a double-blind, randomised non-inferiority trial'. PLoS 
      Med 15;5:e1002569. Doi.org/10.1371/journal.pmed.1002569. MM, ADH and PL are
      coauthors of the study: 'Moore M, Trill J, Simpson C, Webley F, Radford M,
      Stanton L, Maishman T, Glanopoulou A, Flower A, Eyles C, Willcox M, Hay AD, van
      der Werf E, Gibbons S, Lewith G, Little P, Griffiths G. Uva-ursi extract and
      ibuprofen as alternative treatments for uncomplicated urinary tract infection in 
      women (ATAFUTI): a factorial randomised trial. Clinical Microbiology and
      Infection'. Doi.org/10.1016/j.cmi.2019.01.011. SH was involved in the study with 
      the reference number 11. PL and MM were involved in the study with the reference 
      number 12. SF and TM were involved in the study with the reference number 13. IG,
      EH were involved in the studies with the reference numbers 14 and 15. AK was
      involved in the study with the reference number 16.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035883 [pii]
AID - 10.1136/bmjopen-2019-035883 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e035883. doi: 10.1136/bmjopen-2019-035883.


PMID- 33004382
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Oct 1
TI  - Efficacy of low-load blood flow restricted resistance EXercise in patients with
      Knee osteoarthritis scheduled for total knee replacement (EXKnee): protocol for a
      multicentre randomised controlled trial.
PG  - e034376
LID - 10.1136/bmjopen-2019-034376 [doi]
AB  - INTRODUCTION: Up to 20% of patients undergoing total knee replacement (TKR)
      surgery report no or suboptimal pain relief after TKR. Moreover, despite chances 
      of recovering to preoperative functional levels, patients receiving TKR have
      demonstrated persistent deficits in quadriceps strength and functional
      performance compared with healthy age-matched adults. We intend to examine if
      low-load blood flow restricted exercise (BFRE) is an effective preoperative
      method to increase functional capacity, lower limb muscle strength and
      self-reported outcomes after TKR. In addition, the study aims to investigate to
      which extent preoperative BFRE will protect against surgery-related atrophy 3
      months after TKR. METHODS: In this multicentre, randomised controlled and
      assessor blinded trial, 84 patients scheduled for TKR will be randomised to
      receive usual care and 8 weeks of preoperative BFRE or to follow usual care-only.
      Data will be collected before randomisation, 3-4 days prior to TKR, 6 weeks, 3
      months and 12 months after TKR. Primary outcome will be the change in 30 s chair 
      stand test from baseline to 3-month follow-up. Key secondary outcomes will be
      timed up and go, 40 me fast-paced walk test, isometric knee extensor and flexor
      strength, patient-reported outcome and selected myofiber
      properties.Intention-to-treat principle and per-protocol analyses will be
      conducted. A one-way analysis of variance model will be used to analyse between
      group mean changes. Preintervention-to-postintervention comparisons will be
      analysed using a mixed linear model. Also, paired Student's t-test will be
      performed to gain insight into the potential pretraining-to-post-training
      differences within the respective training or control groups and regression
      analysis will be used for analysation of associations between selected outcomes. 
      ETHICAL APPROVAL: The trial has been accepted by the Central Denmark Region
      Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and the Danish
      Data Protection Agency (Journal No 652164). All results will be published in
      international peer-reviewed scientific journals regardless of positive, negative 
      or inconclusive results. TRIAL REGISTRATION NUMBER: NCT04081493.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jorgensen, Stian Langgard
AU  - Jorgensen SL
AUID- ORCID: 0000-0001-8195-8816
AD  - Department of Occupantional and Physical Therapy, Horsens Regional Hospital,
      Horsens, Denmark stiajo@rm.dk.
AD  - H-HIP, Horsens Regional Hospital, Horsens, Denmark.
AD  - Clinical Medicine, Aarhus University, Aarhus, Denmark.
FAU - Bohn, Marie Bagger
AU  - Bohn MB
AD  - Department of Orthopedic Surgery, Horsens Regional Hospital, Horsens, Denmark.
FAU - Aagaard, Per
AU  - Aagaard P
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Odense, Denmark.
FAU - Mechlenburg, Inger
AU  - Mechlenburg I
AD  - Clinical Medicine, Aarhus University, Aarhus, Denmark.
AD  - Department of Orthopedics, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04081493
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Arthroplasty, Replacement, Knee
MH  - Humans
MH  - Knee Joint/surgery
MH  - Multicenter Studies as Topic
MH  - *Osteoarthritis, Knee/surgery
MH  - Randomized Controlled Trials as Topic
MH  - *Resistance Training
MH  - Treatment Outcome
PMC - PMC7534706
OTO - NOTNLM
OT  - *blood flow restriction exercise
OT  - *functional capacity
OT  - *knee osteoarthritis
OT  - *preconditioning
OT  - *total knee replacement surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/02 05:34
PHST- 2020/10/02 05:34 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034376 [pii]
AID - 10.1136/bmjopen-2019-034376 [doi]
PST - epublish
SO  - BMJ Open. 2020 Oct 1;10(10):e034376. doi: 10.1136/bmjopen-2019-034376.


PMID- 33003999
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Oct 1
TI  - Barriers and facilitators to colorectal cancer diagnosis in New Zealand: a
      qualitative study.
PG  - 206
LID - 10.1186/s12875-020-01276-w [doi]
AB  - BACKGROUND: New Zealand (NZ) has high rates of colorectal cancer but low rates of
      early diagnosis. Due to a lack of understanding of the pre-diagnostic experience 
      from the patient's perspective, it is necessary to investigate potential patient 
      and health system factors that contribute to longer diagnostic intervals.
      Previous qualitative studies have discussed delays using The Model of Pathways to
      Treatment, but this has not been explored in the NZ context. This study aimed to 
      understand the patient experience and perception of their general practitioner
      (GP) through the diagnostic process in the Waikato region of NZ. In particular,
      we sought to investigate potential barriers and facilitators that contribute to
      longer diagnostic intervals. METHODS: Ethical approval for this study was granted
      by the New Zealand Health and Disability Ethics Committee. Twenty-eight
      participants, diagnosed with colorectal cancer, were interviewed about their
      experience. Semi-structured interviews were audio recorded, transcribed verbatim 
      and analysed thematically using The Model of Pathways to Treatment framework
      (intervals: appraisal, help-seeking, diagnostic). RESULTS: Participant appraisal 
      of symptoms was a barrier to prompt diagnosis, particularly if symptoms were
      normalised, intermittent, or isolated in occurrence. Successful self-management
      techniques also resulted in delayed help-seeking. However if symptoms worsened,
      disruption to work and daily routines were important facilitators to seeking a GP
      consultation. Participants positively appraised GPs if they showed good technical
      competence and were proactive in investigating symptoms. Negative GP appraisals
      were associated with a lack of physical examinations and misdiagnosis, and left
      participants feeling dehumanised during the diagnostic process. However high
      levels of GP interpersonal competence could override poor technical competence,
      resulting in an overall positive experience, even if the cancer was diagnosed at 
      an advanced stage. Maori participants often appraised symptoms inclusive of their
      sociocultural environment and considered the impact of their symptoms in relation
      to family. CONCLUSIONS: The findings of this study highlight the importance of
      tailored colorectal cancer symptom communication in health campaigns, and
      indicate the significance of the interpersonal competence aspect of GP-patient
      interactions. These findings suggest that interpersonal competence be overtly
      displayed in all GP interactions to ensure a higher likelihood of a positive
      experience for the patient.
FAU - Blackmore, Tania
AU  - Blackmore T
AUID- ORCID: 0000-0002-9411-0440
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
      taniab@waikato.ac.nz.
FAU - Norman, Kimberley
AU  - Norman K
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
FAU - Kidd, Jacquie
AU  - Kidd J
AD  - Auckland University of Technology, Auckland, New Zealand.
FAU - Cassim, Shemana
AU  - Cassim S
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
FAU - Chepulis, Lynne
AU  - Chepulis L
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
FAU - Keenan, Rawiri
AU  - Keenan R
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
FAU - Firth, Melissa
AU  - Firth M
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
FAU - Jackson, Christopher
AU  - Jackson C
AD  - Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
FAU - Stokes, Tim
AU  - Stokes T
AD  - Department of General Practice and Rural Health, University of Otago, Dunedin,
      New Zealand.
FAU - Weller, David
AU  - Weller D
AD  - Centre for Population Health Studies, The University of Edinburgh, Edinburgh,
      Scotland, UK.
FAU - Emery, Jon
AU  - Emery J
AD  - Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, 
      Australia.
FAU - Lawrenson, Ross
AU  - Lawrenson R
AD  - Medical Research Centre, University of Waikato, Hamilton, New Zealand.
LA  - eng
GR  - 17/147/Health Research Council of New Zealand/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
SB  - IM
MH  - *Colorectal Neoplasms/diagnosis
MH  - *General Practitioners
MH  - Humans
MH  - New Zealand
MH  - Qualitative Research
MH  - Referral and Consultation
PMC - PMC7530960
OTO - NOTNLM
OT  - *Colorectal cancer
OT  - *Delays
OT  - *Patient-physician relationship
EDAT- 2020/10/03 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/10/02 05:28
PHST- 2020/05/15 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/10/02 05:28 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
AID - 10.1186/s12875-020-01276-w [doi]
AID - 10.1186/s12875-020-01276-w [pii]
PST - epublish
SO  - BMC Fam Pract. 2020 Oct 1;21(1):206. doi: 10.1186/s12875-020-01276-w.


PMID- 33003677
OWN - NLM
STAT- MEDLINE
DCOM- 20211026
LR  - 20211026
IS  - 2327-2228 (Electronic)
IS  - 0363-7913 (Linking)
VI  - 103
IP  - 8
DP  - 2020 Oct 1
TI  - Implied Yet Unproven: The Digital Pill - Present and Future.
PG  - 23-24
FAU - Hagan, Matthew J
AU  - Hagan MJ
AD  - Alpert Medical School of Brown University, Providence, RI.
FAU - George, Paul
AU  - George P
AD  - Professor of Family Medicine and Medical Science, Alpert Medical School of Brown 
      University, Providence, RI.
FAU - Adashi, Eli Y
AU  - Adashi EY
AD  - Professor of Medical Science, Alpert Medical School of Brown University,
      Providence, RI.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - R I Med J (2013)
JT  - Rhode Island medical journal (2013)
JID - 101605827
SB  - IM
MH  - Humans
MH  - *Medication Adherence
OTO - NOTNLM
OT  - *digital medicine
OT  - *health policy
OT  - *medical device
OT  - *medical ethic
OT  - *patient medication adherence
EDAT- 2020/10/03 06:00
MHDA- 2021/10/27 06:00
CRDT- 2020/10/02 01:02
PHST- 2020/10/02 01:02 [entrez]
PHST- 2020/10/03 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PST - epublish
SO  - R I Med J (2013). 2020 Oct 1;103(8):23-24.


PMID- 33003254
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201218
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Vaccine mandate in long-term care facilities.
PG  - 995-996
LID - 10.1111/ggi.14023 [doi]
FAU - Ino, Hiroyasu
AU  - Ino H
AUID- ORCID: https://orcid.org/0000-0001-5561-0111
AD  - The University of Tokyo Hospital, Tokyo, Japan.
LA  - eng
PT  - Letter
PL  - Japan
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
SB  - IM
MH  - Aged
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Homes for the Aged/*standards
MH  - Humans
MH  - Long-Term Care/standards
MH  - Mandatory Programs
MH  - Nursing Homes/*standards
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Vaccination/*ethics
PMC - PMC7537350
OTO - NOTNLM
OT  - COVID-19
OT  - geriatrics
OT  - long-term care facilities
OT  - medical ethics
OT  - vaccine policy
EDAT- 2020/10/02 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/01 20:23
PHST- 2020/06/30 00:00 [received]
PHST- 2020/07/19 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/10/01 20:23 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1111/ggi.14023 [doi]
PST - ppublish
SO  - Geriatr Gerontol Int. 2020 Oct;20(10):995-996. doi: 10.1111/ggi.14023.


PMID- 33003056
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210208
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 31
IP  - 7
DP  - 2020 Oct
TI  - In Vitro and in Vivo Biocompatibility and Degradability Evaluation of Modified
      Polydioxanone Plate.
PG  - 2059-2062
LID - 10.1097/SCS.0000000000006487 [doi]
AB  - BACKGROUND: Polydioxanone (PDS) has been widely used in the medical field over
      the past 30 years. In the 2000s, PDS plate began to be used for rhinoplasty and
      septoplasty. However, in Asia PDS plates are not widely used due to lack of
      awareness and high prices. The authors devised a method of producing a modified
      PDS (m-PDS; Rhinoblock Material & Design Co., Gyeonggi-do, Sothh Korea) at low
      cost, and compared the biocompatibilities and degradabilities of plates produced 
      with m-PDS and commercial PDS plates (Ethicon, Somerville, NJ) in vivo and in
      vitro. METHODS: The melting point and decomposition rate of m-PDS were determined
      by differential scanning calorimetry and thermogravimetric analysis and its
      tensile strength was also measured. Implants (1 cm x 1 cm x 0.15 mm sized) were
      inserted subcutaneously into mice and harvested en bloc 2, 5, 10, 15, or 25 weeks
      later. Tissues were stained with hematoxylin and eosin or Masson's trichrome to
      evaluate inflammation, extracellular matrix deposition, and vascularization, and 
      plate degradability was also assessed. RESULTS: No significant difference was
      observed between the thermal analysis and tensile test results of m-PDS and PDS
      plates. m-PDS started to degrade in vivo from around 10 weeks, and commercial PDS
      plates from around 15 weeks. After 25 weeks in vivo, both products were
      completely degraded and not observed in tissue slides. Histologic analysis of
      excised specimens showed m-PDS and PDS were similar in terms of inflammation,
      extracellular matrix deposition, and vascularization. CONCLUSION: In vivo and in 
      vitro experiments detected no significant difference between the
      biocompatibilities and degradabilities of modified and commercial PDS plates. The
      results of this study suggest that the modified PDS can be used to produce
      versatile, low cost, absorbable graft materials for rhinoplasty and septoplasty.
FAU - Kim, Sunje
AU  - Kim S
AD  - Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam
      National University, Daejeon.
FAU - Yang, Heesang
AU  - Yang H
AD  - Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam
      National University, Daejeon.
FAU - Kim, Taek-Kyun
AU  - Kim TK
AD  - The PLUS Plastic Surgery, Seoul, South Korea.
FAU - Jeong, Jae-Yong
AU  - Jeong JY
AD  - The PLUS Plastic Surgery, Seoul, South Korea.
FAU - Shin, Chungmin
AU  - Shin C
AD  - Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam
      National University, Daejeon.
FAU - Oh, Sang-Ha
AU  - Oh SH
AD  - Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam
      National University, Daejeon.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
RN  - 31621-87-1 (Polydioxanone)
MH  - Animals
MH  - Asia
MH  - Bone Plates
MH  - Inflammation/chemically induced
MH  - Male
MH  - Materials Testing
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Polydioxanone/chemistry/*metabolism/toxicity
MH  - Republic of Korea
MH  - Rhinoplasty
MH  - Tensile Strength
EDAT- 2020/10/02 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/10/01 20:22
PHST- 2020/10/01 20:22 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
AID - 10.1097/SCS.0000000000006487 [doi]
AID - 00001665-202010000-00049 [pii]
PST - ppublish
SO  - J Craniofac Surg. 2020 Oct;31(7):2059-2062. doi: 10.1097/SCS.0000000000006487.


PMID- 33002875
OWN - NLM
STAT- MEDLINE
DCOM- 20201127
LR  - 20201127
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 49
IP  - 4
DP  - 2020 Oct
TI  - Editorial. Daily neurosurgical experiences with ethics and the elderly.
PG  - E4
LID - 10.3171/2020.7.FOCUS20667 [doi]
LID - 2020.7.FOCUS20667 [pii]
FAU - Hamilton, Mark G
AU  - Hamilton MG
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
SB  - IM
CON - Neurosurg Focus. 2020 Oct;49(4):E3. PMID: 33002872
MH  - Aged
MH  - Humans
MH  - *Neurosurgery
MH  - Neurosurgical Procedures
MH  - Skull
EDAT- 2020/10/02 06:00
MHDA- 2020/11/28 06:00
CRDT- 2020/10/01 20:21
PHST- 2020/10/01 20:21 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/11/28 06:00 [medline]
AID - 10.3171/2020.7.FOCUS20667 [doi]
AID - 2020.7.FOCUS20667 [pii]
PST - ppublish
SO  - Neurosurg Focus. 2020 Oct;49(4):E4. doi: 10.3171/2020.7.FOCUS20667.


PMID- 33002872
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 49
IP  - 4
DP  - 2020 Oct
TI  - Ethical issues in geriatric cranial neurosurgery.
PG  - E3
LID - 10.3171/2020.7.FOCUS20447 [doi]
LID - 2020.7.FOCUS20447 [pii]
AB  - The global demographic shift to an older population has led to the emergence of
      the new field of geriatric neurosurgery. Beyond the complexities of disease
      states and multimorbidity, advanced age brings with it intricate ethical issues
      pertaining to both the practice and provision of medical and surgical care. In
      this paper, the authors describe the central ethical themes seen across the
      spectrum of common neurosurgical conditions in the elderly and highlight the use 
      of foundational ethical principles to help guide treatment decision-making.
FAU - Hachem, Laureen D
AU  - Hachem LD
AD  - 1Division of Neurosurgery, Department of Surgery, University of Toronto; and.
FAU - Bernstein, Mark
AU  - Bernstein M
AD  - 1Division of Neurosurgery, Department of Surgery, University of Toronto; and.
AD  - 2Division of Neurosurgery, Toronto Western Hospital, University Health Network,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
SB  - IM
CIN - Neurosurg Focus. 2020 Oct;49(4):E4. PMID: 33002875
MH  - Aged
MH  - Humans
MH  - *Neurosurgery
MH  - Neurosurgical Procedures
OTO - NOTNLM
OT  - *cSDH = chronic subdural hematoma
OT  - *cranial
OT  - *decision-making
OT  - *ethics
OT  - *geriatric
OT  - *neurosurgery
EDAT- 2020/10/02 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/10/01 20:21
PHST- 2020/05/29 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/10/01 20:21 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.3171/2020.7.FOCUS20447 [doi]
AID - 2020.7.FOCUS20447 [pii]
PST - ppublish
SO  - Neurosurg Focus. 2020 Oct;49(4):E3. doi: 10.3171/2020.7.FOCUS20447.


PMID- 33002746
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 95
DP  - 2020 Dec
TI  - Clinical facilitators' experience of near peer learning in Australian
      undergraduate nursing students: A qualitative study.
PG  - 104602
LID - S0260-6917(20)31452-0 [pii]
LID - 10.1016/j.nedt.2020.104602 [doi]
AB  - BACKGROUND: To mitigate escalating costs in clinical supervision of undergraduate
      nursing students and alleviate clinical facilitators' teaching burden, the
      near-peer learning model has become popular. Studies on near-peer learning have
      been on students' views of the model with a paucity of literature on clinical
      facilitators' experiences. AIM: To explore clinical facilitator experiences of
      the near-peer learning model. DESIGN: A qualitative descriptive design was used
      with a purposeful sample of clinical facilitators involved in near-peer learning 
      of nursing students. SETTING: Two teaching hospitals participated. Two medical
      and two surgical wards were selected from each. PARTICIPANTS: Eleven clinical
      facilitators who had experienced using near-peer learning. METHODS: Focus group
      and individual interviews were conducted with clinical facilitators using a
      semi-structured interview guide following ethics approval. Data were analysed
      using content analysis. RESULTS: Four themes emerged: 1) Congruent student dyad
      characteristics 2) Clinical facilitator attributes of confidence in students'
      knowledge and effective time and conflict management, 3) Availability of suitable
      skills, and 4) Facilitator support and preparation on the model. These themes
      appear to promote optimum learning outcomes of the near-peer model including
      empowering students, junior students gaining practice in foundation skills and
      senior students gaining competence in leadership, mentoring and nurturing skills.
      Barriers included incongruent student characteristics resulting in conflict and
      trust issues, senior student not knowing how to teach, give feedback or teaching 
      inaccurate information; facilitator's lack of confidence in students' knowledge
      level, inadequate time to manage the student dyad and resolve conflict;
      inadequate support and preparation from university staff; and unavailability of
      suitable skills. CONCLUSION: Successful implementation requires careful selection
      of student dyads, appropriate clinical environment and support for clinical
      facilitators. Our findings provide a better understanding of the near-peer model 
      for future implementation.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Henderson, Saras
AU  - Henderson S
AD  - School of Nursing and Midwifery, Griffith University, The Hopkins Centre Research
      for Rehabilitation and Resilience, Women's Wellness Research Group, Menzies
      Health Institute QLD, Australia; School of Nursing and Midwifery, Gold Coast
      campus, Griffith University, Southport, Queensland 4222, Australia. Electronic
      address: s.henderson@griffith.edu.au.
FAU - Needham, Judith
AU  - Needham J
AD  - School of Nursing and Midwifery, Logan campus, Griffith University, University
      Drive, Meadowbrook, Queensland 4131, Australia. Electronic address:
      j.needham@griffith.edu.au.
FAU - van de Mortel, Thea
AU  - van de Mortel T
AD  - School of Nursing and Midwifery, Gold Coast campus, Griffith University,
      Southport, Queensland 4222, Australia. Electronic address:
      t.vandemortel@griffith.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Australia
MH  - *Education, Nursing, Baccalaureate
MH  - Humans
MH  - Learning
MH  - Peer Group
MH  - Qualitative Research
MH  - *Students, Nursing
OTO - NOTNLM
OT  - Clinical education
OT  - Descriptive qualitative research
OT  - Near peer learning model
OT  - Nursing students
EDAT- 2020/10/02 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/01 20:15
PHST- 2020/01/15 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/01 20:15 [entrez]
AID - S0260-6917(20)31452-0 [pii]
AID - 10.1016/j.nedt.2020.104602 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Dec;95:104602. doi: 10.1016/j.nedt.2020.104602. Epub 2020 
      Sep 21.


PMID- 33002434
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1474-5488 (Electronic)
IS  - 1470-2045 (Linking)
VI  - 21
IP  - 10
DP  - 2020 Oct
TI  - Ethical concerns regarding private equity in Right to Try in the USA.
PG  - 1260-1262
LID - S1470-2045(20)30469-1 [pii]
LID - 10.1016/S1470-2045(20)30469-1 [doi]
FAU - Lee, Susannah W
AU  - Lee SW
AD  - Ethics Program, Wellstar Health System, Atlanta, GA 30339, USA. Electronic
      address: susannah.w.lee@gmail.com.
FAU - Hurst, Daniel J
AU  - Hurst DJ
AD  - Department of Family Medicine, Rowan University School of Osteopathic Medicine,
      Stratford, NJ, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet Oncol
JT  - The Lancet. Oncology
JID - 100957246
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - Cancer Care Facilities
MH  - Compassionate Use Trials/*economics/*ethics
MH  - Drugs, Investigational/economics/therapeutic use
MH  - Hospitals, Proprietary
MH  - Humans
MH  - Neoplasms/drug therapy
MH  - United States
EDAT- 2020/10/02 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/10/01 20:10
PHST- 2020/07/23 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/10/01 20:10 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S1470-2045(20)30469-1 [pii]
AID - 10.1016/S1470-2045(20)30469-1 [doi]
PST - ppublish
SO  - Lancet Oncol. 2020 Oct;21(10):1260-1262. doi: 10.1016/S1470-2045(20)30469-1.


PMID- 33002165
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 1938-2421 (Electronic)
IS  - 0148-4834 (Linking)
VI  - 59
IP  - 10
DP  - 2020 Oct 1
TI  - Preparing Nurse Practitioner Students to Practice in Rural Primary Care.
PG  - 581-584
LID - 10.3928/01484834-20200921-08 [doi]
AB  - BACKGROUND: Gaps remain in rural primary care. To fill this gap, nurse practioner
      (NP) graduates may need additional training using a rural-specific curriculum
      framework to be ready to practice in rural primary care. METHOD: Ten NP students 
      participated in a 16-week rural immersion. Preand postsurveys, online journaling,
      self-guided testing, simulation events, and postcourse focus groups were used to 
      evaluate student progress using directed content analysis to identify key themes 
      and to verify, organize, and categorize the collected data. RESULTS: Students
      reported gains in rural culture competence, increased skills in health literacy
      and patient advocacy, improved communication and negotiating ethical issues with 
      patients, and increased awareness of challenges in rural health care and the
      importance of resilience. CONCLUSION: An immersion learning experience with
      targeted didactic content and clinical practicum in rural primary care can help
      to enhance NP students' confidence and technical abilities for providing optimal 
      rural primary care. [J Nurs Educ. 2020;59(10):581-584.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Brommelsiek, Margaret
AU  - Brommelsiek M
FAU - Peterson, Jane A
AU  - Peterson JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nurs Educ
JT  - The Journal of nursing education
JID - 7705432
SB  - IM
MH  - Clinical Competence
MH  - *Curriculum
MH  - *Education, Nursing/methods
MH  - Humans
MH  - *Nurse Practitioners/education
MH  - Preceptorship
MH  - Primary Health Care
MH  - *Rural Population
EDAT- 2020/10/02 06:00
MHDA- 2021/07/01 06:00
CRDT- 2020/10/01 17:16
PHST- 2020/01/10 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/10/01 17:16 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 10.3928/01484834-20200921-08 [doi]
PST - ppublish
SO  - J Nurs Educ. 2020 Oct 1;59(10):581-584. doi: 10.3928/01484834-20200921-08.


PMID- 33001734
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - S3
DP  - 2020 Oct
TI  - Ethical Considerations for Digitally Targeted Public Health Interventions.
PG  - S290-S291
LID - 10.2105/AJPH.2020.305758 [doi]
FAU - Susser, Daniel
AU  - Susser D
AD  - Daniel Susser is an assistant professor in the College of Information Sciences
      and Technology, a research associate in the Rock Ethics Institute, and an
      affiliate faculty member in the Philosophy Department at Penn State University,
      University Park, PA.
LA  - eng
PT  - Editorial
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
MH  - *Communication
MH  - Consumer Health Information/*standards
MH  - *Health Policy
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - *Public Health
MH  - Social Media
PMC - PMC7532326
EDAT- 2020/10/02 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/10/01 17:14
PHST- 2020/10/01 17:14 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.2105/AJPH.2020.305758 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Oct;110(S3):S290-S291. doi: 10.2105/AJPH.2020.305758.


PMID- 33001572
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20220418
IS  - 1741-6787 (Electronic)
IS  - 1545-102X (Linking)
VI  - 17
IP  - 6
DP  - 2020 Dec
TI  - Evidence-Based, Ethical Decision-Making: Using Simulation to Teach the
      Application of Evidence and Ethics in Practice.
PG  - 412-417
LID - 10.1111/wvn.12465 [doi]
AB  - BACKGROUND: Evidence-based practice and ethics should not be taught as isolated
      concepts. Instead, it is imperative to prepare students with the knowledge needed
      to practice ethical, evidence-based decision-making in health care. PURPOSE: The 
      purpose of this project was to describe how a mock hospital ethics committee
      meeting impacted students' learning about the use of evidence to support ethical 
      decision-making in health care. METHOD: A mock hospital ethics committee was
      convened for 121 students from schools of nursing, social work, law, and
      medicine. RESULTS: Thematic content analysis showed a positive impact on nursing 
      students' learning of ethics, group dynamics, discipline-specific
      responsibilities, and EBP. LINKING EVIDENCE TO ACTION: This interprofessional
      education experience showed students how evidence and ethics can be used to guide
      and support practice priorities, responsibilities, and decisions on resource
      utilization and treatment to enable optimal outcomes for patients and
      organizations.
CI  - (c) 2020 Sigma Theta Tau International.
FAU - Opsahl, Angela
AU  - Opsahl A
AUID- ORCID: https://orcid.org/0000-0003-1069-5654
AD  - Indiana University School of Nursing, Bloomington, IN, USA.
FAU - Nelson, Tammi
AU  - Nelson T
AD  - Indiana University School of Social Work, Bloomington, IN, USA.
FAU - Madeira, Jody
AU  - Madeira J
AD  - Indiana University Maurer School of Law, Bloomington, IN, USA.
FAU - Wonder, Amy Hagedorn
AU  - Wonder AH
AD  - Indiana University School of Nursing, Bloomington, IN, USA.
LA  - eng
PT  - Journal Article
DEP - 20201001
PL  - United States
TA  - Worldviews Evid Based Nurs
JT  - Worldviews on evidence-based nursing
JID - 101185267
SB  - IM
MH  - Curriculum/trends
MH  - *Decision Making
MH  - Evidence-Based Practice/*education/*ethics
MH  - Health Personnel/*education
MH  - Humans
MH  - Simulation Training/methods
OTO - NOTNLM
OT  - ethics
OT  - evidence-based practice
OT  - interprofessional education
OT  - nursing education
OT  - teaching strategies
EDAT- 2020/10/02 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/10/01 12:18
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
PHST- 2020/10/01 12:18 [entrez]
AID - 10.1111/wvn.12465 [doi]
PST - ppublish
SO  - Worldviews Evid Based Nurs. 2020 Dec;17(6):412-417. doi: 10.1111/wvn.12465. Epub 
      2020 Oct 1.


PMID- 33001377
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - The Effects of Anti-corruption Campaign on Research Grant Reimbursement:
      Regression Discontinuity Evidence from China.
PG  - 3415-3436
LID - 10.1007/s11948-020-00265-7 [doi]
AB  - Integrity and research ethics are cherished institutions in academic world.
      Although most societies have rules and codes that govern ethical conducts in
      research, few studies have provided quantitative evidence on the impacts of these
      regulations and codes on the behaviors of researchers. In the context of a
      nationwide anti-corruption campaign in China, this paper evaluates the changes of
      principal investigators' reimbursement behavior in a leading university when new 
      reimbursement policies were introduced. Utilizing a novel grant dataset and a
      regression discontinuity design, we find that the new policies lowered PIs'
      monthly average amount of reimbursement from research grants by 35%, which can be
      interpreted as a reduction in grant misuse. Following speculations we argue that 
      institutionalizing orchestrated efforts on grant management, payroll systems, and
      research integrity education is in the right direction toward building China into
      a true scientific power.
FAU - Tang, Li
AU  - Tang L
AD  - School of International Relations and Public Affairs, Fudan University, Shanghai,
      China.
FAU - Cao, Cong
AU  - Cao C
AD  - Faculty of Business, University of Nottingham Ningbo China, Ningbo, China.
FAU - Lien, Donald
AU  - Lien D
AD  - University of Texas, San Antonio, San Antonio, USA.
FAU - Liu, Xiaoou
AU  - Liu X
AUID- ORCID: 0000-0001-7535-9753
AD  - Renmin University of China, Beijing, China. xiaoou.liu@ruc.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201001
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - China
MH  - Humans
MH  - *Morals
MH  - *Research Personnel
OTO - NOTNLM
OT  - *Anti-corruption
OT  - *China
OT  - *Governance
OT  - *Regression discontinuity design
OT  - *Research ethics
EDAT- 2020/10/02 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/10/01 12:15
PHST- 2019/10/22 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/10/01 12:15 [entrez]
AID - 10.1007/s11948-020-00265-7 [doi]
AID - 10.1007/s11948-020-00265-7 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3415-3436. doi: 10.1007/s11948-020-00265-7. Epub
      2020 Oct 1.


PMID- 33001219
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20210115
IS  - 2193-6226 (Electronic)
IS  - 2193-6218 (Linking)
VI  - 115
IP  - 8
DP  - 2020 Nov
TI  - [Medical ethics : The pioneering role of critical care medicine].
PG  - 649-653
LID - 10.1007/s00063-020-00738-4 [doi]
AB  - The development of intensive care medicine started over more than 50 years.
      Effective organ system support for ventilation initially and subsequently for
      circulation, nutrition and renal function resulted in improved outcomes in
      patients with a variety of severe medical conditions. One of the unfortunate
      consequences of this development was that it did not allow dying or prolonged the
      dying process and without the possibility of recovery to a quality of life
      acceptable to the patients. The early realization of this dilemma ultimately led 
      to broad ethical discussions concerning withholding and withdrawal of curative
      therapies in intensive care units, and introducing palliative care.
FAU - Lenz, K
AU  - Lenz K
AD  - Landesverband Hospiz OO, Steingasse 25, 4020, Linz, Osterreich.
      kurt.lenz@meduniwien.ac.at.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Angewandte klinische Ethik : Die Vorreiterrolle der Intensivmedizin.
DEP - 20201001
PL  - Germany
TA  - Med Klin Intensivmed Notfmed
JT  - Medizinische Klinik, Intensivmedizin und Notfallmedizin
JID - 101575086
SB  - IM
MH  - Critical Care
MH  - Decision Making
MH  - Ethics, Medical
MH  - Humans
MH  - Intensive Care Units
MH  - Palliative Care
MH  - *Quality of Life
MH  - *Terminal Care
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Attitude to death
OT  - Critical illness
OT  - Decision making
OT  - Medical ethics
OT  - Terminal care
EDAT- 2020/10/02 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/10/01 12:14
PHST- 2020/01/11 00:00 [received]
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2020/10/01 12:14 [entrez]
AID - 10.1007/s00063-020-00738-4 [doi]
AID - 10.1007/s00063-020-00738-4 [pii]
PST - ppublish
SO  - Med Klin Intensivmed Notfmed. 2020 Nov;115(8):649-653. doi:
      10.1007/s00063-020-00738-4. Epub 2020 Oct 1.


PMID- 33000762
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201120
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 29
TI  - Tobacco-Free Duo Adult-Child Contract for Prevention of Tobacco Use Among
      Adolescents and Parents: Protocol for a Mixed-Design Evaluation.
PG  - e21100
LID - 10.2196/21100 [doi]
AB  - BACKGROUND: Universal tobacco-prevention programs targeting youths usually
      involve significant adults, who are assumed to be important social influences.
      Commitment not to use tobacco, or to quit use, as a formal contract between an
      adolescent and a significant adult is a preventive model that has not been widely
      practiced or explored and has been formally evaluated even less. In this paper,
      we present the rationale and protocol for the evaluation of the Swedish
      Tobacco-free Duo program, a multicomponent school-based program the core of which
      rests on a formal agreement between an adolescent and an adult. The adolescent's 
      commitment mainly concerns avoiding the onset of any tobacco use while the adult 
      commits to support the adolescent in staying tobacco free, being a role model by 
      not using tobacco themselves. OBJECTIVE: To assess (1) whether Tobacco-free Duo
      is superior to an education-only program in preventing smoking onset among
      adolescents and promoting cessation among their parents, (2) whether exposure to 
      core components (adult-child agreement) entails more positive effects than
      exposure to other components, (3) the impact of the program on whole school
      tobacco use, (4) potential negative side effects, and (5) school-level factors
      related to fidelity of the program's implementation. METHODS: A mixed-design
      approach was developed. First, a cluster randomized controlled trial was designed
      with schools randomly assigned to either the comprehensive multicomponent program
      or its educational component only. Primary outcome at the adolescent level was
      identified as not having tried tobacco during the 3-year junior high school
      compulsory grades (12-15 years of age). An intention-to-treat cohort-wise
      approach and an as-treated approach complemented with a whole school repeated
      cross-sectional approach was devised as analytical methods of the trial data.
      Second, an observational study was added in order to compare smoking incidence in
      the schools participating in the experiment with that of a convenience sample of 
      schools that were not part of the experimental study. Diverse secondary outcomes 
      at both adolescent and adult levels were also included. RESULTS: The study was
      approved by the Umea Regional Ethics Review Board (registration number
      2017/255-31) in 2017. Recruitment of schools started in fall 2017 and continued
      until June 2018. In total, 43 schools were recruited to the experimental study,
      and 16 schools were recruited to the observational study. Data collection started
      in the fall 2018, is ongoing, and is planned to be finished in spring 2021.
      CONCLUSIONS: Methodological, ethical, and practical implications of the
      evaluation protocol were discussed, especially the advantage of combining several
      sources of data, to triangulate the study questions. The results of these studies
      will help revise the agenda of this program as well as those of similar programs.
      TRIAL REGISTRATION: International Standard Randomized Controlled Trial Number
      (ISRCTN) 52858080; https://doi.org/10.1186/ISRCTN52858080. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/21100.
CI  - (c)Maria Rosaria Galanti, Anni-Maria Pulkki-Brannstrom, Maria Nilsson. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      29.10.2020.
FAU - Galanti, Maria Rosaria
AU  - Galanti MR
AUID- ORCID: https://orcid.org/0000-0002-7805-280X
AD  - Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
AD  - Centre for Epidemiology and Community Health, Stockholm, Sweden.
FAU - Pulkki-Brannstrom, Anni-Maria
AU  - Pulkki-Brannstrom AM
AUID- ORCID: https://orcid.org/0000-0001-8723-8131
AD  - Department of Epidemiology and Global Health, Umea University, Umea, Sweden.
FAU - Nilsson, Maria
AU  - Nilsson M
AUID- ORCID: https://orcid.org/0000-0003-3036-8546
AD  - Department of Epidemiology and Global Health, Umea University, Umea, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20201029
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7661241
OTO - NOTNLM
OT  - cluster randomized trial
OT  - observational study
OT  - prevention
OT  - public commitment
OT  - school
OT  - social influence
OT  - tobacco use
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 08:37
PHST- 2020/06/05 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
PHST- 2020/10/01 08:37 [entrez]
AID - v9i10e21100 [pii]
AID - 10.2196/21100 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 29;9(10):e21100. doi: 10.2196/21100.


PMID- 33000556
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1445-2197 (Electronic)
IS  - 1445-1433 (Linking)
VI  - 90
IP  - 12
DP  - 2020 Dec
TI  - Part 1: Artificial intelligence technology in surgery.
PG  - 2409-2414
LID - 10.1111/ans.16343 [doi]
AB  - Artificial intelligence (AI) is one of the disruptive technologies of the fourth 
      Industrial Revolution that is changing our work practices. This technology is in 
      use in highly diverse industries including health care, defence, insurance and
      e-commerce. This review focuses on the relevance of AI to surgery. AI will aid
      surgeons with diagnostic decision-making, patient selection for surgery as well
      as improve patient pre- and post-operative care and management. Ethical
      considerations of AI with respect to patient rights and data privacy are
      highlighted. A further challenge is how best to present to national regulators a 
      pragmatic way to assess AI as 'software as a medical device'. This relates to the
      ramifications for the adoption of AI technology in clinical practice, and its
      subsequent public funding support and reimbursement. It is evident that AI
      technology has important applications in surgery in the 21st century. The
      establishment of a key work programme in this area will be important if surgeons 
      are to fully utilize AI in surgery.
CI  - (c) 2020 Royal Australasian College of Surgeons.
FAU - Tan, Lorwai
AU  - Tan L
AUID- ORCID: 0000-0001-8434-2988
AD  - Research, Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Adelaide, South Australia, Australia.
FAU - Tivey, David
AU  - Tivey D
AUID- ORCID: 0000-0003-2213-2576
AD  - Research, Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Adelaide, South Australia, Australia.
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, The University of Adelaide, 
      Adelaide, South Australia, Australia.
FAU - Kopunic, Helena
AU  - Kopunic H
AD  - Research, Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Adelaide, South Australia, Australia.
FAU - Babidge, Wendy
AU  - Babidge W
AUID- ORCID: 0000-0002-7063-7192
AD  - Research, Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Adelaide, South Australia, Australia.
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, The University of Adelaide, 
      Adelaide, South Australia, Australia.
FAU - Langley, Sally
AU  - Langley S
AD  - Plastic and Reconstructive Surgery Department, Christchurch Hospital,
      Christchurch, New Zealand.
FAU - Maddern, Guy
AU  - Maddern G
AD  - Research, Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Adelaide, South Australia, Australia.
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, The University of Adelaide, 
      Adelaide, South Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200930
PL  - Australia
TA  - ANZ J Surg
JT  - ANZ journal of surgery
JID - 101086634
SB  - IM
MH  - *Artificial Intelligence
MH  - Delivery of Health Care
MH  - Humans
MH  - Morals
MH  - *Surgeons
MH  - Technology
OTO - NOTNLM
OT  - *artificial intelligence
OT  - *machine learning
OT  - *surgery
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:42
PHST- 2020/06/28 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/01 05:42 [entrez]
AID - 10.1111/ans.16343 [doi]
PST - ppublish
SO  - ANZ J Surg. 2020 Dec;90(12):2409-2414. doi: 10.1111/ans.16343. Epub 2020 Sep 30.


PMID- 33000297
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1550-7416 (Electronic)
IS  - 1550-7416 (Linking)
VI  - 22
IP  - 6
DP  - 2020 Sep 30
TI  - Successful Extrapolation of Paracetamol Exposure from Adults to Infants After
      Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the 
      Study Dosing Conditions.
PG  - 126
LID - 10.1208/s12248-020-00504-6 [doi]
AB  - Extending licensed drug use to the pediatric population has become an essential
      part of the drug development process. Nonetheless, ethical concerns limit
      clinical testing in pediatric populations and data collected from oral
      bioavailability and food effect studies in adults are often extrapolated to the
      target pediatric (sub)populations. However, based on published information, food 
      effects on drug absorption in infants may not be adequately evaluated by data
      collected in adults. In the present study, a physiologically based
      pharmacokinetic (PBPK) approach for modeling paracetamol suspension data
      collected in adults was proposed with the ultimate aim to investigate whether
      extrapolation to infants is substantially affected by the dosing conditions
      applied to adults. The development of the PBPK model for adults was performed
      using GastroPlus V9.7, and after scaling to infants considering physiological,
      anatomical, and drug clearance changes, extrapolation of the different dosing
      conditions was performed by applying dosing conditions dependent on changes on
      the paracetamol gastric emptying process. Successful simulations of previously
      observed plasma concentration levels in infants were achieved when extrapolating 
      from fasted and infant formula-fed conditions data. Data collected following the 
      reference meal appeared less useful for simulating paracetamol suspension
      performance in infants. The proposed methodology deserves further evaluation
      using high-quality clinical data both in adults and in infants.
FAU - Statelova, Marina
AU  - Statelova M
AD  - Department of Pharmacy, National and Kapodistrian University of Athens,
      Panepistimiopolis, 157 84 Zografou, Athens, Greece.
FAU - Holm, Rene
AU  - Holm R
AD  - Drug Product Development, Janssen Research and Development, Johnson & Johnson,
      Beerse, Belgium.
AD  - Department of Science and Environment, Roskilde University, 4000, Roskilde,
      Denmark.
FAU - Fotaki, Nikoletta
AU  - Fotaki N
AD  - Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
FAU - Reppas, Christos
AU  - Reppas C
AD  - Department of Pharmacy, National and Kapodistrian University of Athens,
      Panepistimiopolis, 157 84 Zografou, Athens, Greece.
FAU - Vertzoni, Maria
AU  - Vertzoni M
AD  - Department of Pharmacy, National and Kapodistrian University of Athens,
      Panepistimiopolis, 157 84 Zografou, Athens, Greece. vertzoni@pharm.uoa.gr.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - United States
TA  - AAPS J
JT  - The AAPS journal
JID - 101223209
RN  - 0 (Suspensions)
RN  - 362O9ITL9D (Acetaminophen)
SB  - IM
MH  - Acetaminophen/administration & dosage/*pharmacokinetics
MH  - Administration, Intravenous
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Biological Availability
MH  - Biopharmaceutics/methods
MH  - Body Size/physiology
MH  - Child
MH  - Child, Preschool
MH  - Computer Simulation
MH  - Datasets as Topic
MH  - Dose-Response Relationship, Drug
MH  - Food-Drug Interactions
MH  - Gastrointestinal Absorption/*physiology
MH  - Humans
MH  - Infant
MH  - Metabolic Clearance Rate/physiology
MH  - *Models, Biological
MH  - Suspensions
OTO - NOTNLM
OT  - *food effect
OT  - *infants
OT  - *oral absorption
OT  - *paracetamol
OT  - *physiologically based pharmacokinetic (PBPK) modeling
EDAT- 2020/10/02 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/10/01 05:40
PHST- 2020/06/29 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/10/01 05:40 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.1208/s12248-020-00504-6 [doi]
AID - 10.1208/s12248-020-00504-6 [pii]
PST - epublish
SO  - AAPS J. 2020 Sep 30;22(6):126. doi: 10.1208/s12248-020-00504-6.


PMID- 33000063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 2688-1152 (Electronic)
IS  - 2688-1152 (Linking)
VI  - 1
IP  - 4
DP  - 2020 Aug
TI  - The role of hospital ethics committees in emergency medicine practice.
PG  - 403-407
LID - 10.1002/emp2.12136 [doi]
AB  - Emergency physicians face real-time ethical dilemmas that may occur at any hour
      of the day or night. Hospital ethics committees and ethics consultation services 
      are not always able to provide immediate responses to emergency physicians'
      consultation requests. When faced with an emergent dilemma, emergency physicians 
      sometimes rely on risk management or hospital counsel to answer legal questions, 
      but may be better served by real-time ethics consultation. When other resources
      are not immediately available, emergency physicians should feel confident in
      making timely decisions, guided by basic principles of medical ethics. We make
      the following recommendations: (1) availability of a member of the hospital
      ethics committee to provide in-person or telephonic consultation concurrent with 
      patient care; (2) appointment to the hospital ethics committee of an emergency
      physician who is familiar with bioethical principles and is available for
      consultation when other ethics consultants are not; and (3) development of
      educational tools by professional societies or similar organizations to assist
      emergency physicians in making reasoned and defensible clinical ethics decisions.
CI  - (c) 2020 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of 
      the American College of Emergency Physicians.
FAU - Baker, Eileen F
AU  - Baker EF
AD  - University of Toledo College of Medicine and Life Sciences Toledo Ohio USA.
AD  - Inc, Riverwood Emergency Services Perrysburg Ohio USA.
FAU - Geiderman, Joel M
AU  - Geiderman JM
AD  - Emergency Medicine Department of Emergency Medicine Ruth and Harry Roman
      Emergency Department Cedars-Sinai Medical Center Los Angeles California USA.
FAU - Kraus, Chadd K
AU  - Kraus CK
AD  - Emergency Medicine Geisinger Medical Center Danville Pennsylvania USA.
FAU - Goett, Rebecca
AU  - Goett R
AD  - Emergency and Palliative Medicine Rutgers New Jersey Medical School Newark New
      Jersey USA.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - United States
TA  - J Am Coll Emerg Physicians Open
JT  - Journal of the American College of Emergency Physicians open
JID - 101764779
PMC - PMC7493501
OTO - NOTNLM
OT  - emergency medicine ethics
OT  - ethical dilemmas
OT  - ethics committee
OT  - ethics consultation
OT  - ethics policy
OT  - hospital policy
OT  - risk management
COIS- The authors declare no conflicts of interest.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:39
PHST- 2020/04/02 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/10/01 05:39 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1002/emp2.12136 [doi]
AID - EMP212136 [pii]
PST - epublish
SO  - J Am Coll Emerg Physicians Open. 2020 Jul 3;1(4):403-407. doi:
      10.1002/emp2.12136. eCollection 2020 Aug.


PMID- 33000043
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 2688-1152 (Electronic)
IS  - 2688-1152 (Linking)
VI  - 1
IP  - 3
DP  - 2020 Jun
TI  - Ethical issues in access to and delivery of emergency department care in an era
      of changing reimbursement and novel payment models.
PG  - 276-280
LID - 10.1002/emp2.12067 [doi]
AB  - Hospital emergency departments (EDs) and the emergency physicians, nurses, and
      other health professionals who provide emergency care in them, are a critical
      component of the United States (US) health care system in the 21st century.
      Although access to emergency care has become a de facto right in the United
      States, funding for emergency care is fragmented and complex, which causes
      confusion and conflict about who should bear the cost of care. This article
      examines the tension between universal access to emergency care in the United
      States and the fragmentary, tenuous, and contentious financial arrangements that 
      make it possible, viewing the issue in context of the historical development,
      legal and moral foundations, current situation, and future challenges of ED care 
      in the United States. It begins with a review of the origins and evolution of
      emergency care and of hospital EDs in the United States. It then examines
      arguments for a right to emergency medical care and for shared obligations of
      patients to seek and of professionals and society to provide that care. Finally, 
      it reviews current strategies and future prospects for protecting access to
      emergency care for patients who require it.
CI  - (c) 2020 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of 
      the American College of Emergency Physicians.
FAU - Kraus, Chadd K
AU  - Kraus CK
AD  - Department of Emergency Medicine Geisinger Health System Danville Pennsylvania.
FAU - Moskop, John C
AU  - Moskop JC
AD  - Department of Internal Medicine Wake Forest School of Medicine Winston-Salem
      North Carolina.
FAU - Marshall, Kenneth D
AU  - Marshall KD
AD  - Department of Emergency Medicine University of Kansas Kansas City Kansas.
FAU - Bookman, Kelly
AU  - Bookman K
AD  - Department of Emergency Medicine University of Colorado Denver Colorado.
CN  - ACEP Ethics Committee
LA  - eng
PT  - Journal Article
DEP - 20200505
PL  - United States
TA  - J Am Coll Emerg Physicians Open
JT  - Journal of the American College of Emergency Physicians open
JID - 101764779
PMC - PMC7493566
COIS- The authors declare no conflicts of interest.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:39
PHST- 2019/10/28 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/10/01 05:39 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1002/emp2.12067 [doi]
AID - EMP212067 [pii]
PST - epublish
SO  - J Am Coll Emerg Physicians Open. 2020 May 5;1(3):276-280. doi:
      10.1002/emp2.12067. eCollection 2020 Jun.


PMID- 33000012
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 2688-1152 (Electronic)
IS  - 2688-1152 (Linking)
VI  - 1
IP  - 1
DP  - 2020 Feb
TI  - Mandatory and permissive reporting laws: obligations, challenges, moral dilemmas,
      and opportunities.
PG  - 38-45
LID - 10.1002/emp2.12011 [doi]
AB  - The duty to report certain conditions to public health or law enforcement
      authorities is one that falls on all physicians and other health care workers as 
      part of their duty to protect the public from harm. In an open society, others,
      such as teachers, clergy, police officers, or simply neighbors, share the
      responsibility of protecting individuals at risk, often by reporting them to
      authorities. The emergency physician and others in the emergency department are
      uniquely positioned to identify people at risk or who pose a risk, and to report 
      them as required or allowed under the law. In some circumstances, these duties
      may conflict with ethical duties such as respect for patient autonomy or to
      protect confidentiality. This article will examine mandatory and permissive
      reporting laws in various states from an ethical perspective. It will also
      explore emerging issues such as the reporting of suspected human trafficking.
CI  - (c) 2020 The Authors. JACEP Open published by Wiley Periodicals, Inc. on behalf
      of the American College of Emergency Physicians.
FAU - Geiderman, Joel M
AU  - Geiderman JM
AD  - Ruth and Harry Roman Emergency Department Department of Emergency Medicine and
      Center for Healthcare Ethics Burns and Allen Research Institute Cedars-Sinai
      Medical Center Los Angeles California USA.
FAU - Marco, Catherine A
AU  - Marco CA
AUID- ORCID: https://orcid.org/0000-0002-6115-1174
AD  - Department of Emergency Medicine Wright State University Boonshoft School of
      Medicine Dayton Ohio USA.
LA  - eng
PT  - Journal Article
DEP - 20200121
PL  - United States
TA  - J Am Coll Emerg Physicians Open
JT  - Journal of the American College of Emergency Physicians open
JID - 101764779
PMC - PMC7493571
OTO - NOTNLM
OT  - ethics
OT  - public health
OT  - reporting
COIS- The authors have no conflicts of interest to report.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:38
PHST- 2019/11/13 00:00 [received]
PHST- 2019/12/03 00:00 [revised]
PHST- 2019/12/10 00:00 [accepted]
PHST- 2020/10/01 05:38 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1002/emp2.12011 [doi]
AID - EMP212011 [pii]
PST - epublish
SO  - J Am Coll Emerg Physicians Open. 2020 Jan 21;1(1):38-45. doi: 10.1002/emp2.12011.
      eCollection 2020 Feb.


PMID- 33000011
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 2688-1152 (Electronic)
IS  - 2688-1152 (Linking)
VI  - 1
IP  - 1
DP  - 2020 Feb
TI  - Assessing psychiatric safety in suicidal emergency department patients.
PG  - 30-37
LID - 10.1002/emp2.12017 [doi]
AB  - We provide a review of the assessment of suicidal emergency department patients
      and includes a legal and ethical perspective. Screening tools and psychiatric
      consultation are important adjuncts to the ED evaluation of potentially suicidal 
      patients. Suicide risk should be assessed, and if positive, an appropriate and
      safe disposition should be arranged. The aim of this article is to review these
      assessment tools and consider ethical issues, such as patient autonomy,
      accountability of the emergency physician, and consultant to Emergency Medical
      Treatment and Labor Act (EMTALA) as well as confidentiality, privacy, and social 
      issues.
CI  - (c) 2020 The Authors. JACEP Open published by Wiley Periodicals, Inc. on behalf
      of the American College of Emergency Physicians.
FAU - Brenner, Jay M
AU  - Brenner JM
AUID- ORCID: https://orcid.org/0000-0002-8489-3322
AD  - Department of Emergency Medicine SUNY-Upstate Medical University Syracuse New
      York.
FAU - Marco, Catherine A
AU  - Marco CA
AD  - Department of Emergency Medicine Wayne State University Dayton Ohio.
FAU - Kluesner, Nicholas H
AU  - Kluesner NH
AD  - Department of Emergency Medicine Unity Point Health System Des Moines Iowa.
FAU - Schears, Raquel M
AU  - Schears RM
AD  - Department of Emergency Medicine University of Central Florida Orlando Florida.
FAU - Martin, Daniel R
AU  - Martin DR
AD  - Department of Emergency Medicine The Ohio State University Columbus Ohio.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200129
PL  - United States
TA  - J Am Coll Emerg Physicians Open
JT  - Journal of the American College of Emergency Physicians open
JID - 101764779
PMC - PMC7493483
OTO - NOTNLM
OT  - ED
OT  - psychiatry
OT  - suicide
COIS- The authors have no conflict of interest to disclose.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:38
PHST- 2019/10/22 00:00 [received]
PHST- 2019/12/20 00:00 [revised]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2020/10/01 05:38 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1002/emp2.12017 [doi]
AID - EMP212017 [pii]
PST - epublish
SO  - J Am Coll Emerg Physicians Open. 2020 Jan 29;1(1):30-37. doi: 10.1002/emp2.12017.
      eCollection 2020 Feb.


PMID- 32999991
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1743-9868 (Print)
IS  - 1743-9868 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Jun 5
TI  - Orthoptic Services in the UK and Ireland During the COVID-19 Pandemic.
PG  - 29-37
LID - 10.22599/bioj.153 [doi]
AB  - AIM: COVID-19 has widely impacted hospital services. The purpose of this study
      was to determine the impact of COVID-19 on Orthoptists and their clinical
      practice in the UK, Ireland, and Channel Islands. METHODS: We conducted a
      prospective survey-based cross-sectional study using an online survey aiming for 
      coverage of orthoptic departments across the UK, Ireland, and Channel Islands. We
      circulated the online survey through the British and Irish Orthoptic Society that
      reaches over 95% of UK and Irish orthoptic services, and through social media and
      orthoptic research networks. RESULTS: The survey response rate was 79%. The
      survey was completed by orthoptic departments, on average 10 days post lockdown. 
      Many orthoptic services were cancelled/paused with remaining services largely
      reserved for emergency cases and urgent care. A substantial rise in
      tele-consultations was reported by 94%, which largely consisted of telephone and 
      video calls and which was regarded generally as working well. Barriers to
      tele-consultations were mainly IT related but with concerns also raised regarding
      ethical and confidentiality issues. Shortage of personal protective equipment
      (PPE) was reported by one third of departments along with issues relating to
      conflicting information about the use of PPE. CONCLUSIONS: We have reported
      information on the changing face of orthoptic clinical practice during the
      COVID-19 pandemic. The survey has highlighted emerging tele-consultation practice
      and the importance of centralised profession-specific guidelines.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Rowe, Fiona
AU  - Rowe F
AD  - University of Liverpool, GB.
FAU - Hepworth, Lauren
AU  - Hepworth L
AD  - University of Liverpool, GB.
FAU - Howard, Claire
AU  - Howard C
AD  - Salford Royal NHS Foundation Trust, GB.
FAU - Lane, Steven
AU  - Lane S
AD  - University of Liverpool, GB.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - Br Ir Orthopt J
JT  - The British and Irish orthoptic journal
JID - 101233819
PMC - PMC7510392
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Orthoptist
OT  - Service delivery
OT  - Survey
COIS- The authors have no competing interests to declare.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:38
PHST- 2020/10/01 05:38 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.22599/bioj.153 [doi]
PST - epublish
SO  - Br Ir Orthopt J. 2020 Jun 5;16(1):29-37. doi: 10.22599/bioj.153.


PMID- 32999916
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2352-8729 (Print)
IS  - 2352-8729 (Linking)
VI  - 12
IP  - 1
DP  - 2020
TI  - Remote cognitive and behavioral assessment: Report of the Alzheimer Society of
      Canada Task Force on dementia care best practices for COVID-19.
PG  - e12111
LID - 10.1002/dad2.12111 [doi]
AB  - INTRODUCTION: Despite the urgent need for remote neurobehavioral assessment of
      individuals with cognitive impairment, guidance is lacking. Our goal is to
      provide a multi-dimensional framework for remotely assessing cognitive,
      functional, behavioral, and physical aspects of people with cognitive impairment,
      along with ethical and technical considerations. METHODS: Literature review on
      remote cognitive assessment and multidisciplinary expert opinion from behavioral 
      neurologists, neuropsychiatrists, neuropsychologists, and geriatricians was
      integrated under the auspices of the Alzheimer Society of Canada Task Force on
      Dementia Care Best Practices for COVID-19. Telephone and video approaches to
      assessments were considered. RESULTS: Remote assessment is shown to be acceptable
      to patients and caregivers. Informed consent, informant history, and attention to
      privacy and autonomy are paramount. A range of screening and domain-specific
      instruments are available for telephone or video assessment of cognition,
      function, and behavior. Some neuropsychological tests administered by
      videoconferencing show good agreement with in-person assessment but still lack
      validation and norms. Aspects of the remote dementia-focused neurological
      examination can be performed reliably. DISCUSSION: Despite challenges, current
      literature and practice support implementation of telemedicine assessments for
      patients with cognitive impairment. Convergence of data across the clinical
      interview, reliable and brief remote cognitive tests, and remote neurological
      exam increase confidence in clinical interpretation and diagnosis.
CI  - (c) 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease
      Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's
      Association.
FAU - Geddes, Maiya R
AU  - Geddes MR
AD  - Department of Neurology and Neurosurgery Montreal Neurological Institute McGill
      University Montreal Canada.
AD  - McGill Center for Studies in Aging McGill University Verdun Canada.
AD  - Departments of Psychiatry and Neurology Brigham and Women's Hospital Harvard
      Medical School Boston USA.
FAU - O'Connell, Megan E
AU  - O'Connell ME
AD  - Department of Psychology University of Saskatchewan Saskatoon Canada.
AD  - Canadian Center for Health & Safety in Agriculture Medicine University of
      Saskatchewan Saskatoon Canada.
FAU - Fisk, John D
AU  - Fisk JD
AD  - Department of Psychiatry Dalhousie University Halifax Canada.
AD  - Department of Psychology and Neuroscience Dalhousie University Halifax Canada.
AD  - Department of Medicine Dalhousie University Halifax Canada.
FAU - Gauthier, Serge
AU  - Gauthier S
AD  - McGill Center for Studies in Aging McGill University Verdun Canada.
FAU - Camicioli, Richard
AU  - Camicioli R
AD  - Neuroscience and Mental Health Institute and Department of Medicine Division of
      Neurology University of Alberta Edmonton Canada.
FAU - Ismail, Zahinoor
AU  - Ismail Z
AD  - Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences 
      Cumming School of Medicine University of Calgary Calgary Alberta Canada.
AD  - Hotchkiss Brain Institute O'Brien Institute for Public Health University of
      Calgary Calgary Alberta Canada.
CN  - Alzheimer Society of Canada Task Force on Dementia Care Best Practices for
      COVID-19
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200922
PL  - United States
TA  - Alzheimers Dement (Amst)
JT  - Alzheimer's & dementia (Amsterdam, Netherlands)
JID - 101654604
PMC - PMC7507991
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - assessment
OT  - cognitive impairment
OT  - dementia
OT  - telehealth
OT  - telemedicine
COIS- The authors have no conflicts of interest to declare.
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:38
PHST- 2020/08/21 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/10/01 05:38 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1002/dad2.12111 [doi]
AID - DAD212111 [pii]
PST - epublish
SO  - Alzheimers Dement (Amst). 2020 Sep 22;12(1):e12111. doi: 10.1002/dad2.12111.
      eCollection 2020.


PMID- 32999730
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - A plea to apply principles of quarantine ethics to prisoners and immigration
      detainees during the COVID-19 crisis.
PG  - lsaa070
LID - 10.1093/jlb/lsaa070 [doi]
FAU - Schotland, Sara D
AU  - Schotland SD
AD  - Justice and Peace Studies and English Departments, Georgetown University.
AD  - Georgetown University Law Center.
AD  - Justice Law and Criminology, American University.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200824
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7499622
OTO - NOTNLM
OT  - COVID-19
OT  - Eighth Amendment
OT  - human rights
OT  - immigration detention
OT  - prisons
OT  - quarantine
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:37
PHST- 2020/07/05 00:00 [received]
PHST- 2020/08/18 00:00 [revised]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/10/01 05:37 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1093/jlb/lsaa070 [doi]
AID - lsaa070 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Aug 24;7(1):lsaa070. doi: 10.1093/jlb/lsaa070. eCollection
      2020 Jan-Jun.


PMID- 32999362
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20210930
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Sep 30
TI  - Efficacy and safety of a single switch from etanercept originator to etanercept
      biosimilar in a cohort of inflammatory arthritis.
PG  - 16178
LID - 10.1038/s41598-020-73183-0 [doi]
AB  - AntiTNF-alpha biosimilars are broadly available for the treatment of inflammatory
      arthritis. There are a lot of data concerning the maintenance of clinical
      efficacy after switching from originators to biosimilars; therefore, such a
      transition is increasingly encouraged both in the US and Europe. However, there
      are reports about flares and adverse events (AE) as a non-medical switch remains 
      controversial due to ethical and clinical implications (efficacy, safety,
      tolerability). The aim of our work was to evaluate the disease activity trend
      after switching from etanercept originator (oETA-Enbrel) to its biosimilar
      (bETA-SP4/Benepali) in a cohort of patients in Turin, Piedmont, Italy. In this
      area, the switch to biosimilars is stalwartly encouraged. We switched 87 patients
      who were in a clinical state of stability from oETA to bETA: 48 patients were
      affected by Rheumatoid Arthritis (RA),26 by Psoriatic Arthritis (PsA) and 13 by
      Ankylosing Spondylitis (AS).We evaluated VAS-pain, Global-Health, CRP, number of 
      swollen and tender joints, Disease Activity Score on 28 joints (DAS28) for RA,
      Disease Activity in Psoriatic Arthritis (DAPSA) for PsA, Health Assessment
      Questionnaire (HAQ) and Health Assessment Questionnaire for the
      spondyloarthropathies (HAQ-S),Bath Ankylosing Spondylitis Disease Activity Index 
      (BASDAI) for AS patients. 11/85 patients (12.6%) stopped treatment after
      switching to biosimilar etanercept. No difference was found between oETA and bETA
      in terms of efficacy. However, some arthritis flare and AE were reported. Our
      data regarding maintenance of efficacy and percentage of discontinuation were in 
      line with the existing literature.
FAU - Ditto, Maria Chiara
AU  - Ditto MC
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy. mariachiaraditto@gmail.com.
AD  - Medical Science, Rheumatology Unit, Azienda Ospedaliera Universitaria di Padova, 
      Padua, Italy. mariachiaraditto@gmail.com.
FAU - Parisi, Simone
AU  - Parisi S
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy.
FAU - Priora, Marta
AU  - Priora M
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy.
FAU - Sanna, Silvia
AU  - Sanna S
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy.
FAU - Peroni, Clara Lisa
AU  - Peroni CL
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy.
FAU - Lagana, Angela
AU  - Lagana A
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy.
FAU - D'Avolio, Antonio
AU  - D'Avolio A
AD  - Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical
      Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy.
FAU - Fusaro, Enrico
AU  - Fusaro E
AD  - Department of General and Specialistic Medicine, Rheumatology Unit, Azienda
      Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Biosimilar Pharmaceuticals/adverse effects/*therapeutic use
MH  - *Drug Substitution
MH  - Etanercept/*therapeutic use
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Spondylitis, Ankylosing/*drug therapy
MH  - Treatment Outcome
PMC - PMC7527334
EDAT- 2020/10/02 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/10/01 05:33
PHST- 2019/07/30 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/10/01 05:33 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1038/s41598-020-73183-0 [doi]
AID - 10.1038/s41598-020-73183-0 [pii]
PST - epublish
SO  - Sci Rep. 2020 Sep 30;10(1):16178. doi: 10.1038/s41598-020-73183-0.


PMID- 32998932
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Single postoperative infusion of zoledronic acid to improve patient-reported
      outcome after hip or knee replacement: study protocol for a randomised,
      controlled, double-blinded clinical trial.
PG  - e040985
LID - 10.1136/bmjopen-2020-040985 [doi]
AB  - INTRODUCTION: In Sweden, roughly 3000 patients are reoperated each year due to
      pain and loss of function related to a loosened hip or knee prosthesis. These
      reoperations are strenuous for the patient, technically demanding and costly for 
      the healthcare system. Any such reoperation that can be prevented would be of
      great benefit. Bisphosphonates are drugs that inhibit osteoclast function.
      Several clinical trials suggest that bisphosphonates lead to improved implant
      fixation and one small study even indicates better functional outcome.
      Furthermore, in epidemiological studies, bisphosphonates have been shown to
      decrease the rate of revision for aseptic loosening by half. Thus, there are
      several indirect indications that bisphosphonates could improve patient-reported 
      outcome, but no firm evidence. METHODS AND ANALYSIS: This is a pragmatic
      randomised, placebo-controlled, double-blinded, academic clinical trial of a
      single postoperative dose of zoledronic acid, in patients younger than 80 years
      undergoing primary total hip or knee replacement for osteoarthritis. Participants
      will be recruited from two orthopaedic departments. All surgeries will be
      performed, and study drugs given at Motala Hospital, Sweden. The primary endpoint
      is to investigate between-group differences in the Hip dysfunction and
      Osteoarthritis Outcome Score and the Knee injury and Osteoarthritis Outcome Score
      at 3-year follow-up. Secondary outcomes will be investigated at 1 year, 3 years
      and 6 years, and stratified for hip and knee implants. These secondary endpoints 
      are supportive, exploratory or explanatory. A total of 1000 patients will be
      included in the study. ETHICS AND DISSEMINATION: The study has been approved by
      the Regional Ethical Review Board in Linkoping (DNR 2015/286-31). The study will 
      be reported in accordance with the Consolidated Standards of Reporting Trials
      statement for pharmacological trials. The results will be submitted for
      publication in peer-reviewed academic journals and disseminated to patient
      organisations and the media. TRIAL REGISTRATION NUMBER: EudraCT: No
      2015-001200-55; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brandt, Jonathan
AU  - Brandt J
AUID- ORCID: 0000-0002-4343-4808
AD  - Department of Orthopaedic Surgery, Capio Specialistvard Motala, Motala, Sweden.
FAU - Ledin, Hakan
AU  - Ledin H
AD  - Department of Orthopaedic Surgery, Capio Specialistvard Motala, Motala, Sweden.
FAU - Ranstam, Jonas
AU  - Ranstam J
AD  - Department of Clinical sciences, Lund University, Lund, Sweden.
FAU - Roos, Ewa
AU  - Roos E
AUID- ORCID: 0000-0001-5425-2199
AD  - Department of Sports Science and Clinical Biomechanics, Syddansk Universitet Det 
      Sundhedsvidenskabelige Fakultet, Odense, Denmark.
FAU - Aspenberg, Per
AU  - Aspenberg P
AD  - Department of Orthopaedic Surgery, Linkoping University Hospital, Linkoping,
      Sweden.
AD  - Department of Biomedical and Clinical Sciences, Faculty of health Sciences,
      Linkoping University, Linkoping, Sweden.
FAU - Schilcher, Jorg
AU  - Schilcher J
AD  - Department of Orthopaedic Surgery, Linkoping University Hospital, Linkoping,
      Sweden jorg.schilcher@liu.se.
AD  - Department of Biomedical and Clinical Sciences, Faculty of health Sciences,
      Linkoping University, Linkoping, Sweden.
AD  - Wallenberg Centre for Molecular Medicine, Linkoping University, Linkoping,
      Sweden.
LA  - eng
SI  - EudraCT/2015-001200-55
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - *Arthroplasty, Replacement, Knee
MH  - Humans
MH  - *Knee Prosthesis
MH  - *Osteoarthritis, Knee/drug therapy/surgery
MH  - Patient Reported Outcome Measures
MH  - Randomized Controlled Trials as Topic
MH  - Sweden
MH  - Treatment Outcome
MH  - Zoledronic Acid
PMC - PMC7528432
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *hip
OT  - *knee
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040985 [pii]
AID - 10.1136/bmjopen-2020-040985 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e040985. doi: 10.1136/bmjopen-2020-040985.


PMID- 32998931
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Pancreatic resection with perioperative drug repurposing of propranolol and
      etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER
      trial.
PG  - e040406
LID - 10.1136/bmjopen-2020-040406 [doi]
AB  - INTRODUCTION: Pancreatic cancer is the fourth-leading cause of cancer-related
      death in developed countries. Despite advances in systemic chemotherapy, the
      mainstay of curative therapy for non-metastatic disease is surgical resection.
      However, the perioperative period is characterised by stress and inflammatory
      reactions that can contribute to metastatic spread and disease recurrence.
      Catecholamines and prostaglandins play a crucial role in these reactions.
      Therefore, a drug repurposing of betablockers and cyclooxygenase inhibitors seems
      reasonable to attenuate tumour-associated inflammation by inhibiting
      psychological, surgical and inflammatory stress responses. This may cause a
      relevant antitumourigenic and antimetastatic effect during the perioperative
      period, a window for cancer-directed therapy that is currently largely
      unexploited. METHODS AND ANALYSIS: This is a prospective, single-centre, two-arm 
      randomised, patient and observer blinded, placebo-controlled, phase-II trial
      evaluating safety and feasibility of combined perioperative treatment with
      propranolol and etodolac in adult patients with non-metastatic cancer of the
      pancreatic head undergoing elective pancreatoduodenectomy. 100 patients
      fulfilling the eligibility criteria will be randomised to perioperative treatment
      for 25 days perioperatively with a combination of propranolol and etodolac or
      placebo. Primary outcome of interest will be safety in terms of serious adverse
      events and reactions within 3 months. Furthermore, adherence to trial medication 
      will be assessed as feasibility outcomes. Preliminary efficacy data will be
      evaluated for the purpose of power calculation for a potential subsequent
      phase-III trial. The clinical trial is accompanied by a translational study
      investigating the mechanisms of action of the combined therapy on a molecular
      basis. ETHICS AND DISSEMINATION: The PROSPER-trial has been approved by the
      German Federal Institute for Drugs and Medical Devices (reference number 4042875)
      and the Ethics Committee of the Medical Faculty of the University of Heidelberg
      (reference number AFmo-385/2018). The final trial results will be published in a 
      peer-reviewed journal and will be presented at appropriate national and
      international conferences. TRIAL REGISTRATION NUMBERS: DRKS00014054; EudraCT
      number: 2018-000415-25.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huttner, Felix J
AU  - Huttner FJ
AUID- ORCID: 0000-0002-2299-964X
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Rooman, Ilse
AU  - Rooman I
AD  - The Anticancer Fund, Brussels, Belgium.
AD  - Laboratory of Medical and Molecular Oncology, Vrije Universiteit Brussel,
      Brussel, Belgium.
FAU - Bouche, Gauthier
AU  - Bouche G
AD  - The Anticancer Fund, Brussels, Belgium.
FAU - Knebel, Phillip
AU  - Knebel P
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Husing, Johannes
AU  - Husing J
AD  - Coordination Center for Clinical Trials, Heidelberg University, Heidelberg,
      Germany.
FAU - Mihaljevic, Andre L
AU  - Mihaljevic AL
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
FAU - Hackert, Thilo
AU  - Hackert T
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
FAU - Strobel, Oliver
AU  - Strobel O
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany markus.buechler@med.uni-heidelberg.de.
FAU - Diener, Markus K
AU  - Diener MK
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Heidelberg, Germany.
LA  - eng
SI  - DRKS/DRKS00014054
SI  - EudraCT/2018-000415-25
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 2M36281008 (Etodolac)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Adult
MH  - Clinical Trials, Phase II as Topic
MH  - Drug Repositioning
MH  - *Etodolac/therapeutic use
MH  - Humans
MH  - Pancreatectomy
MH  - *Propranolol/therapeutic use
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7528424
OTO - NOTNLM
OT  - *adult oncology
OT  - *gastrointestinal tumours
OT  - *pancreatic surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040406 [pii]
AID - 10.1136/bmjopen-2020-040406 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e040406. doi: 10.1136/bmjopen-2020-040406.


PMID- 32998930
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Quantity and quality of conflict of interest policies at German medical schools: 
      a cross-sectional study and survey.
PG  - e039782
LID - 10.1136/bmjopen-2020-039782 [doi]
AB  - OBJECTIVES: To assess the quantity and evaluate the quality of policies and
      curricula focusing on conflicts of interests (COI) at medical schools across
      Germany. DESIGN: Cross-sectional study, survey of medical schools, standardised
      web search. SETTING: Medical schools, Germany. PARTICIPANTS: 38 German medical
      schools. INTERVENTIONS: We collected relevant COI policies, including teaching
      activities, by conducting a search of the websites of all 38 German medical
      schools using standardised keywords for COI policies and teaching. Further, we
      surveyed all medical schools' dean's offices. Finally, we adapted a scoring
      system for results we obtained with 13 categories based on prior similar studies.
      MAIN OUTCOMES AND MEASURES: Presence or absence of COI-related policies,
      including teaching activities at medical school. The secondary outcome was the
      achieved score on a scale from 0 to 26, with high scores representing restrictive
      policies and sufficient teaching activities. RESULTS: We identified relevant
      policies for one medical school via the web search. The response rate of the
      deans' survey was 16 of 38 (42.1%). In total, we identified COI-related policies 
      for 2 of 38 (5.3%) German medical schools, yet no policy was sufficient to
      address all COI-related categories that were assessed in this study. The maximum 
      score achieved was 12 of 26. 36 (94.7%) schools scored 0. No medical school
      reported curricular teaching on COI. CONCLUSIONS: Our results indicate a low
      level of action by medical schools to protect students from undue commercial
      influence. No participating dean was aware of any curriculum or instruction on
      COI at the respective school and only two schools had policies in place. The
      German Medical Students Association and international counterparts have called
      for a stronger focus on COI in the classroom. We conclude that for German medical
      schools, there is still a long way to go.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Grabitz, Peter
AU  - Grabitz P
AUID- ORCID: 0000-0001-5658-2482
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany
      peter.grabitz@charite.de.
AD  - QUEST Center for Transforming Biomedical Research, Berlin Institute of Health
      (BIH),Charite - Universitatsmedizin Berlin, Berlin, Germany.
FAU - Friedmann, Zoe
AU  - Friedmann Z
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Gepp, Sophie
AU  - Gepp S
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Hess, Leonard
AU  - Hess L
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Specht, Lisa
AU  - Specht L
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Struck, Maja
AU  - Struck M
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Tragert, Sophie Kira
AU  - Tragert SK
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Walther, Tobias
AU  - Walther T
AD  - Universities Allied for Essential Medicines Europe e.V, Berlin, Germany.
FAU - Klemperer, David
AU  - Klemperer D
AD  - Faculty of Social and Health Sciences, Regensburg University of Applied Sciences,
      Regensburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Conflict of Interest
MH  - Cross-Sectional Studies
MH  - Curriculum
MH  - Germany
MH  - Humans
MH  - Policy
MH  - *Schools, Medical
PMC - PMC7528426
OTO - NOTNLM
OT  - *health policy
OT  - *medical education & training
OT  - *medical ethics
COIS- Competing interests: All authors have completed the Unified Competing Interest
      form (available on request from the corresponding author) and declare: no
      financial support from any organisation for the submitted work; SG previously
      consulted for Universities Allied for Essential Medicines (UAEM) Europe e.V.; all
      other authors declare no financial relationships with any organisations that
      might have an interest in the submitted work in the previous 3 years and no other
      relationships or activities that could appear to have influenced the submitted
      work.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039782 [pii]
AID - 10.1136/bmjopen-2020-039782 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e039782. doi: 10.1136/bmjopen-2020-039782.


PMID- 32998929
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Determining the level of data sharing, and number of publications, from research 
      databases that have been given a favourable opinion by UK research ethics
      committees.
PG  - e039756
LID - 10.1136/bmjopen-2020-039756 [doi]
AB  - OBJECTIVE: To determine data sharing and number of publications coming from
      research databases that have been given a favourable opinion by UK National
      Health Service (NHS) Research Ethics Committees (RECs). DESIGN: Cohort study.
      INCLUSION CRITERIA & SETTING: All research databases listed on the UK Health
      Research Authority's Assessment Review Portal (HARP) that had received a
      favourable ethics opinion as of January 2018. MAIN OUTCOME MEASURES: Publications
      and data access requests are either listed on HARP or notified through subsequent
      email correspondence. RESULTS: Out of 354 eligible databases, 34% had granted
      access requests and 40% had produced at least one peer-reviewed paper or
      conference abstract/talk. We could not establish contact with 9% of databases,
      and 19% reported no access requests or publications. Only 9% of databases were up
      to date with all annual reports. Email responses from database owners showed a
      range of attitudes towards data sharing. CONCLUSION: Less than half of research
      databases that have received a favourable opinion from NHS research ethics
      committees share their data and produce publications. There is also considerable 
      variability in the operation of research databases and understanding of the
      purpose of research databases. This work was hampered by incomplete records due
      mainly to researchers not submitting annual reports.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Trace, Samantha
AU  - Trace S
AD  - School of Health and Care Professions, University of Portsmouth, Portsmouth,
      Hampshire, UK.
FAU - Bracher, Mike
AU  - Bracher M
AUID- ORCID: 0000-0001-5861-2657
AD  - School of Health Sciences, University of Southampton, Southampton, Hampshire, UK.
FAU - Kolstoe, Simon E
AU  - Kolstoe SE
AUID- ORCID: 0000-0003-1472-3966
AD  - School of Health and Care Professions, University of Portsmouth, Portsmouth,
      Hampshire, UK simon.kolstoe@port.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Attitude
MH  - Cohort Studies
MH  - Ethics Committees
MH  - *Ethics Committees, Research
MH  - Humans
MH  - *Information Dissemination
MH  - State Medicine
MH  - United Kingdom
PMC - PMC7528358
OTO - NOTNLM
OT  - *audit
OT  - *ethics (see medical ethics)
OT  - *information management
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: SEK is chair of the Hampshire A HRA research ethics
      committee, the MOD research ethics committee, and a member of the HRA's
      Confidentiality Advisory Group (CAG). He is also an academic and the ethics
      advisor at the University of Portsmouth. ST is a lay member of the Hampshire B
      HRA research ethics committee. MB has no competing interests.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039756 [pii]
AID - 10.1136/bmjopen-2020-039756 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e039756. doi: 10.1136/bmjopen-2020-039756.


PMID- 32998928
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Impact of preoperative HbA1c on postoperative complications after elective major 
      abdominal surgery: a systematic review protocol.
PG  - e039422
LID - 10.1136/bmjopen-2020-039422 [doi]
AB  - INTRODUCTION: Diabetes has an increasing worldwide prevalence. It is known to be 
      a predisposing factor for postoperative complications. Preoperative glycaemic
      control strategies should be pursued as glycaemic control could serve as a
      modifiable risk factor. Glycated haemoglobin (HbA1c), a marker of 3-month average
      glycaemic control, has been shown in meta-analyses to predict postoperative
      complications in cardiothoracic, bariatric and orthopaedic surgery. However,
      there is no meta-analysis in the major abdominal surgery population, in whom
      morbidity may be higher due to the nature of the surgery. Understanding the
      association between HbA1c and postoperative complications could help in
      preoperative risk prognostication, counselling and glycaemic target selection.
      The aim of this systematic review and meta-analysis is to evaluate all evidence
      on the association between preoperative HbA1c and postoperative complications in 
      elective major abdominal surgery, and to investigate the threshold HbA1c level
      before postoperative complication rates increase. METHODS AND ANALYSIS: This
      review will be performed according to Preferred Reporting Items for Systematic
      Reviews and Meta-Analyses Protocols guidelines. PubMed, Embase, Cochrane Central 
      Register of Controlled Trials, Google Scholar and China National Knowledge
      Infrastructure will be searched for all original studies. Study selection, data
      extraction, risk of bias and quality assessment will be conducted by two
      independent reviewers. The primary outcome is the association between
      preoperative HbA1c and major postoperative complications (Clavien Dindo 3-5), and
      the secondary outcome is the association between HbA1c and overall postoperative 
      complications. Data management and synthesis will be performed using Microsoft
      Excel and Stata to derive pool estimates. ETHICS AND DISSEMINATION: No ethics
      approval is required as only secondary data will be used. Findings will be
      disseminated through peer-reviewed journals and conference presentations.
      PROSPERO REGISTRATION NUMBER: CRD42020167347.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wong, Joanna Kae Ling
AU  - Wong JKL
AUID- ORCID: 0000-0001-5498-2212
AD  - Department of Medicine, Northwick Park Hospital, London, UK.
FAU - Ke, Yuhe
AU  - Ke Y
AD  - Division of Anaesthesiology and Perioperative Medicine, Singapore General
      Hospital, Singapore.
FAU - Ong, Yi Jing
AU  - Ong YJ
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Li, Hui Hua
AU  - Li HH
AD  - Health Services Research Unit, Singapore General Hospital, Singapore.
FAU - Abdullah, Hairil Rizal
AU  - Abdullah HR
AUID- ORCID: 0000-0003-1916-0832
AD  - Division of Anaesthesiology and Perioperative Medicine, Singapore General
      Hospital, Singapore hairil.rizal.abdullah@singhealth.com.sg.
AD  - DukeNUS Medical School, Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - *Blood Glucose
MH  - China
MH  - *Elective Surgical Procedures
MH  - Glycated Hemoglobin A
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Postoperative Complications/epidemiology/etiology
MH  - Systematic Reviews as Topic
PMC - PMC7528368
OTO - NOTNLM
OT  - *anaesthetics
OT  - *diabetes & endocrinology
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039422 [pii]
AID - 10.1136/bmjopen-2020-039422 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e039422. doi: 10.1136/bmjopen-2020-039422.


PMID- 32998927
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Effect of exercise on symptoms of premenstrual syndrome in low and middle-income 
      countries: a protocol for systematic review and meta-analysis.
PG  - e039274
LID - 10.1136/bmjopen-2020-039274 [doi]
AB  - INTRODUCTION: Premenstrual syndrome (PMS) has the potential to affect the quality
      of life adversely. Published guidelines recommend the use of exercise as part of 
      the first-line management interventions for PMS. However, the published evidence 
      related to the effectiveness of physical activity and PMS is inconclusive. This
      review will assess the effectiveness of exercise-based interventions in reducing 
      PMS in women screened or diagnosed with PMS in low and middle-income countries,
      where the prevalence of PMS is high. METHODS AND ANALYSIS: Electronic databases
      will be researched, including Embase, Cochrane Central Register of Controlled
      Trials, MEDLINE, PsycINFO, Web of Science, ClinicalTrials.gov and Google Scholar.
      All the studies published until March 2020 will be included. A standardised data 
      extraction form will be used adapted from the Cochrane Handbook of Systematic
      Reviews of Interventions. Included articles will be assessed using the risk of
      bias tools based on study design. Data will be analysed using Review Manager
      V.5.3. The inverse-variance random-effects method will be used to report the
      standardised mean difference. A meta-analysis will be used only if studies are
      sufficiently homogenous. A narrative synthesis will be undertaken when studies
      are heterogeneous. Methodological heterogeneity between studies will be evaluated
      by considering the study types. Statistical heterogeneity will be tested using
      the I(2) test. Subgroup analyses may be performed only for the primary outcome in
      case of sufficient studies. Sensitivity analysis will be conducted to assess the 
      impact of intervention excluding studies without randomisation and studies with a
      high risk of bias. Funnel plots will be used to assess the potential reporting
      bias and small-study effects only when there are more than 10 studies included in
      the meta-analysis. ETHICS AND DISSEMINATION: This study does not require ethical 
      approval, as the review is entirely based on published studies. The results will 
      be published and/or will be presented at a pertinent conference. PROSPERO
      REGISTRATION NUMBER: CRD42020163377.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pokharel, Pratik
AU  - Pokharel P
AUID- ORCID: 0000-0001-5815-5927
AD  - Forum for Health Research and Development, Dharan, Nepal
      pokharelpratik1921@gmail.com.
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
AD  - Ecole des hautes etudes en sante publique (EHESP), Paris, France.
FAU - Rana, Juwel
AU  - Rana J
AD  - Department of Public Health, North South University, Dhaka, Bangladesh.
AD  - Department of Biostatistics and Epidemiology, University of Massachusetts
      Amherst, Amherst, Massachusetts, USA.
FAU - Moutchia, Jude
AU  - Moutchia J
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
AD  - Ecole des hautes etudes en sante publique (EHESP), Paris, France.
FAU - Uchai, Shreeshti
AU  - Uchai S
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
AD  - Ecole des hautes etudes en sante publique (EHESP), Paris, France.
FAU - Kerri, Aldiona
AU  - Kerri A
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
AD  - Ecole des hautes etudes en sante publique (EHESP), Paris, France.
FAU - Luna Gutierrez, Patricia Lorena
AU  - Luna Gutierrez PL
AD  - Escuela Andaluza de Salud Publica, Granada, Spain.
FAU - Islam, Rakibul M
AU  - Islam RM
AD  - Women's Health Research Program, Monash University, Melbourne, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Developing Countries
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Premenstrual Syndrome
MH  - *Quality of Life
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7528354
OTO - NOTNLM
OT  - *community gynaecology
OT  - *epidemiology
OT  - *pain management
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039274 [pii]
AID - 10.1136/bmjopen-2020-039274 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e039274. doi: 10.1136/bmjopen-2020-039274.


PMID- 32998926
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Treat-to-target strategy with secukinumab as a first-line biological disease
      modifying anti-rheumatic drug compared to standard-of-care treatment in patients 
      with active axial spondyloarthritis: protocol for a randomised open-label phase
      III study, AScalate.
PG  - e039059
LID - 10.1136/bmjopen-2020-039059 [doi]
AB  - INTRODUCTION: In patients with axial spondyloarthritis (axSpA), biological
      disease-modifying anti-rheumatic drugs (bDMARDs) are recommended to those with
      inadequate response or contraindications to non-steroidal anti-inflammatory drugs
      (NSAIDs). In case of failure of the first bDMARD, a switch within the class or to
      other bDMARD is recommended. Despite these treatment options, there is no optimal
      treat-to-target (T2T) strategy. This study aims to evaluate the efficacy of a T2T
      strategy in patients with axSpA, with secukinumab as a first-line bDMARD,
      compared with standard-of-care (SOC) treatment. METHODS AND ANALYSES: This is a
      randomised, parallel-group, open-label, multicentre ongoing study in patients
      with axSpA who are naive to bDMARD and who have had an inadequate response to
      NSAIDs. The study will include an 8-week screening period, a 36-week treatment
      period and a 20-week safety follow-up period. At baseline, patients will be
      randomised (1:1) to T2T or SOC group. In the T2T group, patients will be treated 
      with secukinumab 150 mg subcutaneous (s.c.) weekly until week 4 and then at week 
      8. For non-responders (patients without Ankylosing Spondylitis Disease Activity
      Score [ASDAS] clinically important improvement; change from baseline >/=1.1) at
      week 12, dose will be escalated to 300 mg s.c. every 4 weeks until week 24.
      Non-responders at week 24 will be switched to adalimumab biosimilar 40 mg s.c.
      every 2 weeks until week 34. In the SOC group, patients will receive treatment at
      the discretion of the physician. The primary endpoint is the proportion of
      patients achieving an Assessment in SpondyloArthritis International Society 40%
      (ASAS40) response at week 24. ETHICS AND DISSEMINATION: The study is being
      conducted as per the ethical principles of the Declaration of Helsinki and after 
      approval from independent ethics committees/institutional review boards. The
      first results are expected to be published in early 2022. TRIAL REGISTRATION
      NUMBER: This study is registered with ClinicalTrials.gov, NCT03906136.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Poddubnyy, Denis
AU  - Poddubnyy D
AUID- ORCID: 0000-0002-4537-6015
AD  - Head of the Rheumatology Unit Clinic of Gastroenterology, Infectious Diseases and
      Rheumatology, Charite Universitatsmedizin Berlin, Berlin, Germany
      denis.poddubnyy@charite.de.
AD  - German Rheumatism Research Center Berlin, Berlin, Germany.
FAU - Hammel, Ludwig
AU  - Hammel L
AD  - Deutsche Vereinigung Morbus Bechterew e.V, Schweinfurt, Germany.
FAU - Heyne, Marvin
AU  - Heyne M
AD  - Immunology, Hepatology and Dermatology Franchise, Novartis Pharma GmbH,
      Nuremberg, Germany.
FAU - Veit, Justyna
AU  - Veit J
AD  - Immunology, Hepatology and Dermatology Franchise, Novartis Pharma GmbH,
      Nuremberg, Germany.
FAU - Jentzsch, Claudia
AU  - Jentzsch C
AD  - Immunology, Hepatology and Dermatology Franchise, Novartis Pharma GmbH,
      Nuremberg, Germany.
FAU - Baraliakos, Xenofon
AU  - Baraliakos X
AD  - Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03906136
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - DLG4EML025 (secukinumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - *Antirheumatic Agents/therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Double-Blind Method
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Spondylarthritis/drug therapy
MH  - Treatment Outcome
PMC - PMC7528363
OTO - NOTNLM
OT  - *immunology
OT  - *rheumatology
COIS- Competing interests: DP reports grants and personal fees from Abbvie, Eli Lilly, 
      MSD, Novartis, and Pfizer, personal fees from Roche, BMS, UCB, and Celgene,
      outside the submitted work. XB reports consulting fees, research or institutional
      support and educational grants from AbbVie, BMS, Celgene, Chugai, Galapagos,
      Janssen, Eli Lilly, MSD, Novartis, Pfizer, Sandoz, Sanofi and UCB. LH has no
      conflicts of interest to disclose. MH, JV and CJ are employees of Novartis Pharma
      GmbH.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039059 [pii]
AID - 10.1136/bmjopen-2020-039059 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e039059. doi: 10.1136/bmjopen-2020-039059.


PMID- 32998925
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Management of sleep apnoea syndrome (SAS) in patients with vasovagal syncope
      (VVS): a protocol for the VVS-SAS cohort study.
PG  - e038791
LID - 10.1136/bmjopen-2020-038791 [doi]
AB  - INTRODUCTION: Recurrent vasovagal syncope (VVS) is associated with decreased
      quality-of-life and frequent use of emergency services. The evidence base for
      causality, diagnostic procedures and potential VVS treatments is poor. Scattered 
      observations in the literature suggest a link between respiratory disturbances
      during sleep and VVS. Empirical observations lead us to further hypothesise that 
      the appropriate management of sleep apnoea syndrome (SAS) may help resolve
      comorbid recurrent VVS in certain patients. We therefore designed this pilot
      study to provide a framework for the observation of changes in outcomes
      accompanying the deployment of SAS treatments in patients with VVS. METHODS AND
      ANALYSIS: This is a multicentre, registry-based study whose primary objective is 
      to evaluate the effect of SAS management on the number of syncope/presyncope
      episodes in a population suffering from both VVS and SAS. To this effect, syncope
      rates prior to the treatment of SAS will be compared with those occurring after
      the initiation of the latter. In addition, yearly assessments will collect data
      for echocardiography, polysomnography, Holter monitoring, table tilt tests,
      multiple sleep latency tests, SAS management parameters and questionnaires
      describing fatigue, depression and quality-of-life. Sixty patients will be
      included with a minimum follow-up period of 12 months. The primary analysis will 
      use comparisons of centrality for paired data to describe the changes in syncope 
      rates before versus after the initiation of SAS management. Longitudinal data
      will be analysed using mixed models with patients set as a random effect.
      Subgroup analyses will be performed for SAS-treatment adherence and efficacy.
      ETHICS AND DISSEMINATION: The VVS-SAS registry was approved by an ethics
      committee (Comite pour la Protection des Personnes Ile-de-France VI, Reference
      number CPP/2-18) in accordance with French law. The princeps publication will
      present before-after SAS management results and longitudinal analyses. TRIAL
      REGISTRATION NUMBER: NCT04294524. Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Puel, Vincent
AU  - Puel V
AD  - Pole d'Exploration des Apnees du Sommeil (PEAS), Nouvelle Clinique Bel-Air,
      Bordeaux, France vpuel001@gmail.com.
FAU - Godard, Isabelle
AU  - Godard I
AD  - Pole d'Exploration des Apnees du Sommeil (PEAS), Nouvelle Clinique Bel-Air,
      Bordeaux, France.
FAU - Papaioannou, Georgios
AU  - Papaioannou G
AD  - Department of Cardiology and Hypertension, Hopital Saint-Andre, Centre
      Hospitalier Universitaire de Bordeaux, Bordeaux, France.
FAU - Gosse, Philippe
AU  - Gosse P
AD  - Department of Cardiology and Hypertension, Hopital Saint-Andre, Centre
      Hospitalier Universitaire de Bordeaux, Bordeaux, France.
FAU - Pepin, Jean Louis
AU  - Pepin JL
AD  - Department of Physiology, Sleep and Exercise, Univ Grenoble Alpes, CHU Grenoble, 
      Grenoble, France.
FAU - Thoin, Fabrice
AU  - Thoin F
AD  - Sleep Centre, Bouchard Clinic, Marseille, France.
FAU - Deharo, Jean Claude
AU  - Deharo JC
AD  - Department of Cardiology, Hopital de la Timone, C2VN, APHM, Marseille, France.
FAU - Roche, Frederic
AU  - Roche F
AD  - Department of Clinical Physiology and Excercise, Hopital Nord, Centre Hospitalier
      Universitaire St Etienne, St Etienne, France.
FAU - Zarqane, Naima
AU  - Zarqane N
AD  - Department of Cardiology, Princess Grace Hospital Centre, Monaco.
FAU - Gagnadoux, Frederic
AU  - Gagnadoux F
AD  - Department of Respiratory and Sleep Medicine, Centre Hospitalier Universitaire
      Angers, Angers, France.
FAU - Suehs, Carey Meredith
AU  - Suehs CM
AUID- ORCID: 0000-0002-2175-3496
AD  - Departments of Respiratory Diseases and Medical Information, Centre Hospitalier
      Universitaire de Montpellier, Montpellier, France.
FAU - Molinari, Nicolas
AU  - Molinari N
AD  - Department of Medical Information, IMAG, CNRS, Univ Montpellier, Centre
      Hospitalier Universitaire de Montpellier, Montpellier, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04294524
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - France
MH  - Humans
MH  - Pilot Projects
MH  - *Sleep Apnea Syndromes/complications/therapy
MH  - *Syncope, Vasovagal/diagnosis/therapy
PMC - PMC7528365
OTO - NOTNLM
OT  - *adult cardiology
OT  - *adult thoracic medicine
OT  - *sleep medicine
COIS- Competing interests: VP declares personal fees (outside the submitted work) from 
      Resmed, Lowenstein, Phillips and non-financial support (outside the submitted
      work) from SOS Oxygene and ISIS. FG reports personal fees (outside the submitted 
      work) from Air Liquide Sante, Cidelec, Resmed, Sefam, and non-financial support
      (outside the submitted work) from Air Liquide Sante, Asten Sante, Sefam.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038791 [pii]
AID - 10.1136/bmjopen-2020-038791 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e038791. doi: 10.1136/bmjopen-2020-038791.


PMID- 32998924
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220409
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in
      Nepal: rationale and design of a randomised controlled non-inferiority trial.
PG  - e038066
LID - 10.1136/bmjopen-2020-038066 [doi]
AB  - INTRODUCTION: Fungal infections of the cornea, fungal keratitis (FK), are
      challenging to treat. Current topical antifungals are not always effective and
      are often unavailable, particularly in low-income and middle-income countries
      where most cases occur. Topical natamycin 5% is usually first-line treatment,
      however, even when treated intensively, infections may progress to perforation of
      the eye in around a quarter of cases. Alternative antifungal medications are
      needed to treat this blinding disease.Chlorhexidine is an antiseptic agent with
      antibacterial and antifungal properties. Previous pilot studies suggest that
      topical chlorhexidine 0.2% compares favourably with topical natamycin. Full-scale
      randomised controlled trials (RCTs) of topical chlorhexidine 0.2% are warranted
      to answer this question definitively. METHODS AND ANALYSIS: We will test the
      hypothesis that topical chlorhexidine 0.2% is non-inferior to topical natamycin
      5% in a two-arm, single-masked RCT. Participants are adults with FK presenting to
      a tertiary ophthalmic hospital in Nepal. Baseline assessment includes history,
      examination, photography, in vivo confocal microscopy and cornea scrapes for
      microbiology. Participants will be randomised to alternative topical antifungal
      treatments (topical chlorhexidine 0.2% and topical natamycin 5%; 1:1 ratio, 2-6
      random block size). Patients are reviewed at day 2, day 7 (with reculture), day
      14, day 21, month 2 and month 3. The primary outcome is the best spectacle
      corrected visual acuity (BSCVA) at 3 months. Primary analysis (intention to
      treat) will be by linear regression, with treatment arm and baseline BSCVA
      prespecified covariates. Secondary outcomes include epithelial healing time,
      scar/infiltrate size, ulcer depth, hypopyon size, perforation and/or therapeutic 
      penetrating keratoplasty (corneal transplant), positive reculture rate (day 7)
      and quality of life (EuroQol-5 dimensions, WHO/PBD-VF20, WHOQOL-BREF). ETHICS AND
      DISSEMINATION: The Nepal Health Research Council, the Nepal Department of Drug
      Administration and the London School of Hygiene and Tropical Medicine ethics
      committee have approved the trial. The results will be presented at local and
      international meetings and submitted to peer-reviewed journals for publication.
      TRIAL REGISTRATION NUMBER: ISRCTN14332621; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Hoffman, Jeremy John
AU  - Hoffman JJ
AUID- ORCID: 0000-0001-9454-2131
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK jeremy.hoffman@lshtm.ac.uk.
AD  - Cornea Department, Sagarmatha Choudhary Eye Hospital, Lahan, Nepal.
FAU - Yadav, Reena
AU  - Yadav R
AD  - Cornea Department, Sagarmatha Choudhary Eye Hospital, Lahan, Nepal.
FAU - Das Sanyam, Sandip
AU  - Das Sanyam S
AUID- ORCID: 0000-0002-0554-8441
AD  - Cornea Department, Sagarmatha Choudhary Eye Hospital, Lahan, Nepal.
FAU - Chaudhary, Pankaj
AU  - Chaudhary P
AD  - Cornea Department, Sagarmatha Choudhary Eye Hospital, Lahan, Nepal.
FAU - Roshan, Abhishek
AU  - Roshan A
AD  - Cornea Department, Sagarmatha Choudhary Eye Hospital, Lahan, Nepal.
FAU - Singh, Sanjay Kumar
AU  - Singh SK
AD  - Eastern Region Eye Care Programme, Biratnagar, Nepal.
FAU - Arunga, Simon
AU  - Arunga S
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Mbarara University of Science and Technology Faculty of Medicine, Mbarara,
      Uganda.
FAU - Matayan, Einoti
AU  - Matayan E
AD  - Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi,
      Tanzania.
FAU - Macleod, David
AU  - Macleod D
AD  - MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Weiss, Helen Anne
AU  - Weiss HA
AUID- ORCID: 0000-0003-3547-7936
AD  - MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Leck, Astrid
AU  - Leck A
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Hu, Victor
AU  - Hu V
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Burton, Matthew J
AU  - Burton MJ
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Department of External Eye Disease, Moorfields Eye Hospital NHS Foundation Trust,
      London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN14332621
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 8O0C852CPO (Natamycin)
RN  - JFU09I87TR (Voriconazole)
RN  - R4KO0DY52L (Chlorhexidine)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - *Chlorhexidine
MH  - Humans
MH  - London
MH  - *Natamycin
MH  - Nepal
MH  - Treatment Outcome
MH  - Voriconazole
PMC - PMC7528427
OTO - NOTNLM
OT  - *clinical trials
OT  - *corneal and external diseases
OT  - *mycology
OT  - *ophthalmology
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038066 [pii]
AID - 10.1136/bmjopen-2020-038066 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e038066. doi: 10.1136/bmjopen-2020-038066.


PMID- 32998921
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Dancing to improve balance control, cognitive-motor functions and quality of life
      after stroke: a study protocol for a randomised controlled trial.
PG  - e037039
LID - 10.1136/bmjopen-2020-037039 [doi]
AB  - INTRODUCTION: Dance is an intrinsically motivating activity that includes social 
      interaction, stimulation through music, the pleasure of moving despite
      pathology-induced motor limitations, and it also has good perceived benefits
      among participants. Feeling pleasure while moving is essential to finding the
      motivation to engage in a rehabilitation programme. It is, therefore, urgent to
      provide persons in a poststroke situation with motivating physical activity
      opportunities. Very few studies have examined dance in a stroke context, while it
      is highly adapted and effective for other chronic conditions.Our primary
      objective is to assess the effects of dance programme on patients' balance
      control after stroke. Our secondary objective is to investigate the effects of
      dance on cognitive function, strength, coordination, functional status, balance
      confidence, quality of life, motivation and adherence. Our hypothesis is that
      dance increases balance and motor capacities, and improves poststroke quality of 
      life, adherence and motivation. METHODS AND ANALYSIS: Forty-eight subjects with
      stroke in subacute phase will be randomised into two groups: (1) intervention
      (dance and standard rehabilitation) and (2) control (standard rehabilitation).
      Before intervention, stroke severity, cognitive abilities and motor capacities
      will be assessed. Two baseline tests will be planned to evaluate the stability of
      individuals. Participants will attend a weekly 60-min dance class for 6 weeks.
      Cognitive and motor functions (balance, lower-limbs strength, coordination and
      motor level), quality of life (Stroke-Specific Quality of Life Scale) will be
      measured at weeks 4 and 6 in both groups. Participant satisfaction with regard to
      dance will be tested, as well as adherence and adverse effects. ETHICS AND
      DISSEMINATION: Ethics approval has been granted by the Swiss Ethics Committee of 
      the CER Vaud (2019-01467). Outcomes will be disseminated through publication in
      peer-reviewed journals and presentations at conferences. TRIAL REGISTRATION
      NUMBER: NCT04120467.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Morice, Emmanuel
AU  - Morice E
AD  - Neurorehabilitation, Institution de Lavigny, Lavigny, Vaud, Switzerland.
FAU - Moncharmont, Julien
AU  - Moncharmont J
AD  - Neurorehabilitation, Institution de Lavigny, Lavigny, Vaud, Switzerland.
FAU - Jenny, Clementine
AU  - Jenny C
AD  - Neurorehabilitation, Institution de Lavigny, Lavigny, Vaud, Switzerland.
FAU - Bruyneel, Anne-Violette
AU  - Bruyneel AV
AUID- ORCID: 0000-0003-4764-9336
AD  - Physiotherapy Department, Geneva School of Health Sciences, HES-SO University of 
      Applied Sciences and Arts Western Switzerland, Geneva, Switzerland
      anne-violette.bruyneel@hesge.ch.
LA  - eng
SI  - ClinicalTrials.gov/NCT04120467
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cognition
MH  - Exercise
MH  - Exercise Therapy
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke
MH  - *Stroke Rehabilitation
PMC - PMC7528364
OTO - NOTNLM
OT  - *neurology
OT  - *rehabilitation medicine
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037039 [pii]
AID - 10.1136/bmjopen-2020-037039 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e037039. doi: 10.1136/bmjopen-2020-037039.


PMID- 32998920
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Protocol of DEXPED trial: efficacy of intravenous dexamethasone, administered at 
      the time of analgesic blocking of the lower limb, on postoperative pain in
      children: a randomised, placebo-controlled, double-blind trial.
PG  - e036863
LID - 10.1136/bmjopen-2020-036863 [doi]
AB  - INTRODUCTION: Dexamethasone is a drug used to prolong the postoperative analgesia
      in children after peripheral nerve blockade, although the dose usually used (0.2 
      mg/kg) has not been studied yet. This study is a monocentric, prospective,
      randomised, placebo-controlled, double-blinded study in a university hospital in 
      France. The primary objective of the study is to evaluate the efficacy of 0.2
      mg/kg intravenous dexamethasone on early postoperative pain in children aged 6-15
      years, who require a lower limb peripheral nerve block following general
      anaesthesia. METHODS AND ANALYSIS: Eighty children, aged 6-15 years, undergoing
      surgery for which peripheral nerve lower limb blockade with ropivacaine following
      general anaesthesia are included. The inclusion criteria are: children aged 6-15 
      years, with American Society of Anaesthesiologists physical status I or II and
      scheduled for surgery requiring a peripheral block of the lower limb for
      analgesic purposes, with a preoperative anaesthetic evaluation between 90 and 2
      days before the surgery, with informed consent from legal representatives.
      General anaesthesia is performed. The patient receives, according to his group,
      either 0.2 mg/kg of dexamethasone intravenously at the start of anaesthetic
      induction or the same volume of placebo. Then, the peripheral block of the lower 
      limb is performed with ropivacaine. The primary outcome is the total doses of
      opioid administered (in mg/kg of morphine equivalent) within 24 hours
      postoperatively. The secondary objectives are the evaluation of the effect of a
      single-dose intravenous dexamethasone at the time of anaesthetic induction, on
      the following parameters: onset of postoperative pain, duration of motor block,
      postoperative nausea and vomiting within 24 hours. ETHICS AND DISSEMINATION: This
      study is conducted according to the principles of the Declaration of Helsinki and
      has been approved by the French national ethics committee and the National Drug
      Safety Agency. Findings of this study will be widely disseminated through
      conference presentations, reports, factsheets and academic publications. TRIAL
      REGISTRATION NUMBER: NCT03618173.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vautrin, Nicolas
AU  - Vautrin N
AUID- ORCID: 0000-0003-3628-9208
AD  - Departement d'Anesthesie-Reanimation, Universite de Lorraine, Nancy, Lorraine,
      France nicolas_vautrin@hotmail.fr.
FAU - Thilly, Nathalie
AU  - Thilly N
AD  - Plateforme d'Aide a la Recherche Clinique, Universite de Lorraine, Nancy,
      Lorraine, France.
FAU - Bernard, Yohann
AU  - Bernard Y
AD  - Departement Methodologie Promotion Investigation, Universite de Lorraine, Nancy, 
      Lorraine, France.
FAU - Wurtz, Francois
AU  - Wurtz F
AD  - Departement d'Anesthesie-Reanimation, Universite de Lorraine, Nancy, Lorraine,
      France.
FAU - Meistelman, Claude
AU  - Meistelman C
AD  - Departement d'Anesthesie-Reanimation, Universite de Lorraine, Nancy, Lorraine,
      France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03618173
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics)
RN  - 0 (Anesthetics, Local)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adolescent
MH  - Analgesics
MH  - Anesthetics, Local
MH  - Child
MH  - *Dexamethasone/therapeutic use
MH  - Double-Blind Method
MH  - France
MH  - Humans
MH  - Lower Extremity/surgery
MH  - *Pain, Postoperative/drug therapy
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7528367
OTO - NOTNLM
OT  - *paediatric anaesthesia
OT  - *paediatric orthopaedic & trauma surgery
OT  - *paediatric orthopaedics
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036863 [pii]
AID - 10.1136/bmjopen-2020-036863 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e036863. doi: 10.1136/bmjopen-2020-036863.


PMID- 32998919
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Protocol for development, calibration and validation of the Patient-Reported
      Inventory of Self-Management of Chronic Conditions (PRISM-CC).
PG  - e036776
LID - 10.1136/bmjopen-2020-036776 [doi]
AB  - INTRODUCTION: Assessing and measuring patients' chronic condition self-management
      needs are critical to quality health care and to related research. One in three
      adults around the world live with multiple chronic conditions. While many
      patient-reported measures of self-management have been developed, none has
      emerged as the gold standard, and all have one or more of the following
      limitations: (1) they fail to measure the different domains of self-management
      important to patients, (2) they lack sufficient specificity to support
      patient-centred care or identify the specific components of self-management
      interventions that work and/or (3) they lack suitability for patients with
      multiple chronic conditions. METHODS AND ANALYSIS: The Patient-Reported Inventory
      of Self-Management of Chronic Conditions (PRISM-CC) is being developed to
      overcome these shortcomings. It will measure respondents' perceived success (or
      difficulty) in self-managing seven domains important to patients. The protocol
      has three phases. Phase 1 is conceptual model development and item generation.
      Phase 2 is assessment of the relevance and understanding of items by people with 
      chronic conditions. Phase 3 is item analysis, dimensionality assessment, scaling 
      and preliminary validation of the PRISM-CC using an online survey of people with 
      chronic conditions (n~750). The expected completion date is early 2021. ETHICS
      AND DISSEMINATION: This study will adhere to the Canadian Tri-Council Policy
      Statement on Ethical Conduct for Research Involving Humans. Ethics approval for
      all phases has been obtained from the Nova Scotia Health Authority Research
      Ethics Board. Once completed, the PRISM-CC will be made available for research
      and healthcare at minimal to no cost.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Packer, Tanya
AU  - Packer T
AUID- ORCID: 0000-0003-4831-7691
AD  - Schools of Occupational Therapy and Health Administration, Faculty of Health,
      Dalhousie University, Halifax, Nova Scotia, Canada tanya.packer@dal.ca.
AD  - Rehabilitation Department, Radboud Unversity Medical Centre, Nijmegen,
      Gelderland, The Netherlands.
FAU - Kephart, George
AU  - Kephart G
AUID- ORCID: 0000-0001-7376-9695
AD  - Department of Community Health and Epidemiology, Dalhousie University, Halifax,
      Nova Scotia, Canada.
FAU - Audulv, Asa
AU  - Audulv A
AUID- ORCID: 0000-0003-4456-7853
AD  - Department of Nursing, Umea Universitet Medicinska fakulteten, Umea, Sweden.
FAU - Keddy, America
AU  - Keddy A
AUID- ORCID: 0000-0002-1266-4600
AD  - School of Occupational Therapy, Faculty of Health, Dalhousie University, Halifax,
      Nova Scotia, Canada.
FAU - Warner, Grace
AU  - Warner G
AUID- ORCID: 0000-0001-9865-865X
AD  - School of Occupational Therapy, Faculty of Health, Dalhousie University, Halifax,
      Nova Scotia, Canada.
FAU - Peacock, Kylie
AU  - Peacock K
AUID- ORCID: 0000-0002-3124-7087
AD  - School of Occupational Therapy, Faculty of Health, Dalhousie University, Halifax,
      Nova Scotia, Canada.
FAU - Sampalli, Tara
AU  - Sampalli T
AUID- ORCID: 0000-0002-6459-1503
AD  - Research, Innovation and Discovery, Nova Scotia Health, Halifax, Nova Scotia,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Calibration
MH  - Chronic Disease
MH  - Humans
MH  - Nova Scotia
MH  - Patient Reported Outcome Measures
MH  - *Self-Management
PMC - PMC7528366
OTO - NOTNLM
OT  - *health services administration & management
OT  - *primary care
OT  - *protocols & guidelines
COIS- Competing interests: All authors had financial support from the Canadian
      Institutes of Health Research (CIHR) for the submitted work.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036776 [pii]
AID - 10.1136/bmjopen-2020-036776 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e036776. doi: 10.1136/bmjopen-2020-036776.


PMID- 32998918
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Effectiveness of interventions for the prevention of occupational violence
      against professionals in health services: a protocol for a systematic review.
PG  - e036558
LID - 10.1136/bmjopen-2019-036558 [doi]
AB  - INTRODUCTION: Occupational violence affects several categories of workers;
      however, the health sector category has been considered at a high risk, exposing 
      workers to physical and psychological abuse. Thus, occupational violence has
      decreased the quality of care in health service. This review aims to evaluate the
      effectiveness of interventions for the prevention and reduction of occupational
      violence against health professionals. METHODS AND ANALYSIS: This protocol is
      consistent with the Preferred Reporting Items for Systematic Review and
      Meta-Analysis Protocols. Searches will be conducted in PubMed, Embase, Cochrane
      Library, LILACS, Web of Science, Scopus, CINAHL and LIVIVO along with a
      comprehensive review of grey literature. The search will be conducted on August 1
      st 2020, without language and time restrictions. Following the eligibility
      criteria, two independent reviewers will select the titles and abstracts and
      subsequently screen the full articles. If necessary, a third reviewer will assess
      any disagreements. All references will be imported into EndNote, and any
      duplicates will be removed. The data will be extracted using an extraction-based 
      form from Cochrane. Statistical analyses will be performed using the software
      Cochrane Review Manager, and a meta-analysis will be performed if possible for
      the statistical combination of at least two studies. The risk of bias of the
      randomised clinical trials will be evaluated by the Risk of Bias tool from
      Cochrane, and the risk of bias of the non-randomised intervention studies will be
      evaluated using the Downs and Black scale. The quality of the evidence and
      strength of the classification recommendations will be assessed by the Grading of
      Recommendations, Assessment, Development and Evaluation. ETHICS AND
      DISSEMINATION: This review will not evaluate individual patient information and
      therefore does not require ethical approval. The results will be disseminated
      through publications in peer-reviewed journals, presentations at conferences and 
      the doctoral thesis of the leading author. PROSPERO REGISTRATION NUMBER:
      CRD42018111383.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Okubo, Caroline Vieira Claudio
AU  - Okubo CVC
AUID- ORCID: 0000-0001-8625-8667
AD  - PhD student in Nursing, State University of Londrina, Londrina, Parana, Brazil
      caroline.vieirac@gmail.com.
AD  - Nurse, Federal University of Parana Clinics Hospital, Curitiba, Parana, Brazil.
FAU - Silveira, Renata Cristina Campos Pereira
AU  - Silveira RCCP
AD  - University of Sao Paulo at Ribeirao Preto College of Nursing, Ribeirao Preto, Sao
      Paulo, Brazil.
FAU - Galdino, Maria Jose Quina
AU  - Galdino MJQ
AD  - Department of Nursing, Northern State University of Parana, Bandeirantes, Parana,
      Brazil.
FAU - Fernandes, Daiane Rubinato
AU  - Fernandes DR
AD  - University of Sao Paulo at Ribeirao Preto College of Nursing, Ribeirao Preto, Sao
      Paulo, Brazil.
FAU - Moreira, Aline Aparecida Oliveira
AU  - Moreira AAO
AD  - PhD student in Nursing, State University of Londrina, Londrina, Parana, Brazil.
FAU - Martins, Julia Trevisan
AU  - Martins JT
AD  - Department of Nursing, State University of Londrina, Londrina, PR, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - *Health Personnel
MH  - Health Services
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Research Design
MH  - Review Literature as Topic
MH  - Violence/prevention & control
PMC - PMC7528362
OTO - NOTNLM
OT  - *health & safety
OT  - *international health services
OT  - *medical education & training
OT  - *preventive medicine
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036558 [pii]
AID - 10.1136/bmjopen-2019-036558 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e036558. doi: 10.1136/bmjopen-2019-036558.


PMID- 32998915
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Accuracy of the combined method (auscultation and pH measurement) and
      ultrasonography for confirmation of gastric tube placement: a study protocol for 
      a prospective study.
PG  - e036033
LID - 10.1136/bmjopen-2019-036033 [doi]
AB  - INTRODUCTION: Patients using a nasogastric tube (NGT) are vulnerable to adverse
      events, therefore proper assessment of these patients, verification of the
      correct tube placement and constant monitoring by the nursing staff are
      strategies that can reduce adverse events and risks associated with the care. The
      aim of this study will be to assess the accuracy of the combined method
      (auscultation and pH measurement) and ultrasonography for confirmation of gastric
      tube placement compared with the X-ray method. A further aim will be to measure
      and provide evidence for the direct costs of each method of confirming NGT
      placement and to evaluate the impact of each method on the mean direct cost of
      the patient. METHODS AND ANALYSIS: This is a prospective, single-centre study of 
      diagnostic accuracy. Data will be collected in the clinical and surgical wards,
      intensive care unit and coronary care unit of a Brazilian teaching hospital. The 
      sample will consist of 385 assessments, performed in adult patients that agree to
      participate in the study and that receive an NGT. The combined method and the
      ultrasound will be the index tests and will be performed on all study
      participants for later comparison with an X-ray examination, considered the
      reference standard and the gold standard to distinguish between gastric and
      pulmonary placement. Sensitivity, specificity, positive predictive value and
      negative predictive value will be calculated to assess the diagnostic accuracy of
      the methods investigated in this study, with Cohen's kappa analysis used to
      evaluate the degree of concordance. ETHICS AND DISSEMINATION: The study was
      approved by the Research Ethics Committee of the University of Sao Paulo at
      Ribeirao Preto College of Nursing, registration number: 83087318.4.0000.5393. The
      findings will be reported through academic journals, seminars and conference
      presentations, social media, print media, the internet and community/stakeholder 
      engagement activities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rigobello, Mayara Carvalho Godinho
AU  - Rigobello MCG
AUID- ORCID: 0000-0002-3633-7225
AD  - Departamento de Enfermagem Geral e Especializada, Universidade de Sao Paulo
      Escola de Enfermagem de Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Elias Junior, Jorge
AU  - Elias Junior J
AD  - Departamento de Imagens Medicas, Hematologia e Oncologia Clinica, Universidade de
      Sao Paulo Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto, Sao Paulo,
      Brazil.
FAU - Bonacim, Carlos Alberto Grespan
AU  - Bonacim CAG
AD  - Departamento de Contabilidade, Universidade de Sao Paulo Faculdade de Economia
      Administracao e Contabilidade de Ribeirao Preto, Ribeirao Preto, Sao Paulo,
      Brazil.
FAU - Silveira, Renata Cristina de Campos Pereira
AU  - Silveira RCCP
AD  - Departamento de Enfermagem Geral e Especializada, Universidade de Sao Paulo
      Escola de Enfermagem de Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Bonardi, Fernanda Caroline
AU  - Bonardi FC
AD  - Departamento de Enfermagem Geral e Especializada, Universidade de Sao Paulo
      Escola de Enfermagem de Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Nunes, Roosevelt Santos
AU  - Nunes RS
AD  - Departamento de Cirurgia e Anatomia, Centro de Terapia Intensiva, Universidade de
      Sao Paulo Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto, Sao Paulo,
      Brazil.
FAU - Pereira, Rosana Aparecida
AU  - Pereira RA
AD  - Departamento de Enfermagem Geral e Especializada, Universidade de Sao Paulo
      Escola de Enfermagem de Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Gimenes, Fernanda Raphael Escobar
AU  - Gimenes FRE
AUID- ORCID: 0000-0002-5174-112X
AD  - Departamento de Enfermagem Geral e Especializada, Universidade de Sao Paulo
      Escola de Enfermagem de Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil
      fregimenes@eerp.usp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Auscultation
MH  - Brazil
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Prospective Studies
MH  - Ultrasonography
PMC - PMC7528351
OTO - NOTNLM
OT  - *general medicine (see internal medicine)
OT  - *health & safety
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036033 [pii]
AID - 10.1136/bmjopen-2019-036033 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e036033. doi: 10.1136/bmjopen-2019-036033.


PMID- 32998914
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Protocol for a multicentre, prospective cohort study of clinical, proteomic and
      genomic patterns associated with osteoporosis to develop a multidimensional
      fracture assessment tool: the PoCOsteo Study.
PG  - e035363
LID - 10.1136/bmjopen-2019-035363 [doi]
AB  - INTRODUCTION: The HORIZON 2020 project PoCOsteo aims (1) to develop a
      multidimensional fracture risk assessment tool which would take into account all 
      factors known to be related to an individual's fracture risk. The fracture risk
      model is intended to be developed in two different populations, namely a European
      and a Middle Eastern one; (2) to develop a medical device, which would measure
      and/or quantify proteomic as well as genomic factors as present in whole blood
      samples collected through finger prick; (3) to test the clinical applicability
      and the validity of prototypes of the to be developed point of care device at
      both clinical centres. METHODS AND ANALYSIS: This article presents the protocol
      of this prospective cohort that will be carried out independently at two
      different centres (Division of Endocrinology and Diabetology at the Medical
      University of Graz (MUG) as a clinic-based cohort, and Endocrinology and
      Metabolism Research Institute (EMRI) at the Tehran University of Medical Sciences
      (TUMS) as a population-based cohort). The final aim is to develop a fracture risk
      assessment model, which would include clinical risk factors, biochemical markers 
      of bone turnover, as well as specific genomic factors. The derivation cohorts
      will consist of individuals aged 50 years and above. The period of observation
      for each patient will be 12 months; an extension phase, which would last for
      another 2 years, is also planned. ETHICS AND DISSEMINATION: These studies are
      conducted in accordance with the World Medical Association Declaration of
      Helsinki. The Iranian part was approved by the Research Ethics Committee of EMRI,
      TUMS. The Austrian part was approved by the Ethics Committee of the Medical
      University of Graz. Based on the gathered information, a multidimensional
      fracture assessment tool will be designed which will later be added to the
      PoCOsteo device.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Khashayar, Patricia
AU  - Khashayar P
AD  - Center for Microsystems Technology, Imec & Ghent University, Zwijnaarde - Gent,
      Belgium.
FAU - Dimai, Hans Peter
AU  - Dimai HP
AD  - Department of Internal Medicine, Division of Endocrinology and Diabetology,
      Medical University of Graz, Graz, Steiermark, Austria.
FAU - Moradi, Nahid
AU  - Moradi N
AD  - Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences
      Institute, Tehran University of Medical Sciences, Tehran, Iran (the Islamic
      Republic of).
FAU - Fahimfar, Noushin
AU  - Fahimfar N
AD  - Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences
      Institute, Tehran University of Medical Sciences, Tehran, Iran (the Islamic
      Republic of).
FAU - Gharibzadeh, Safoora
AU  - Gharibzadeh S
AD  - Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, 
      Iran (the Islamic Republic of).
FAU - Ostovar, Afshin
AU  - Ostovar A
AD  - Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences
      Institute, Tehran University of Medical Sciences, Tehran, Iran (the Islamic
      Republic of).
FAU - Nabipour, Iraj
AU  - Nabipour I
AD  - The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf
      Biomedical Sciences Research Institute, Bushehr University of Medical Sciences,
      Bushehr, Iran (the Islamic Republic of).
FAU - Larijani, Bagher
AU  - Larijani B
AUID- ORCID: 0000-0001-5386-7597
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran 
      (the Islamic Republic of) larijanib@tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Austria
MH  - Cohort Studies
MH  - Genomics
MH  - Humans
MH  - Iran
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - *Osteoporosis/genetics
MH  - Prospective Studies
MH  - *Proteomics
PMC - PMC7528352
OTO - NOTNLM
OT  - *calcium & bone
OT  - *general endocrinology
OT  - *geriatric medicine
OT  - *musculoskeletal disorders
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035363 [pii]
AID - 10.1136/bmjopen-2019-035363 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e035363. doi: 10.1136/bmjopen-2019-035363.


PMID- 32998913
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 30
TI  - Intraoperative visualisation and treatment of salivary glands in Sjogren's
      syndrome by contrast-enhanced ultrasound sialendoscopy (CEUSS): protocol for a
      phase I single-centre, single-arm, exploratory study.
PG  - e033542
LID - 10.1136/bmjopen-2019-033542 [doi]
AB  - INTRODUCTION: We established a promising sialendoscopic treatment for in vivo
      enhancement of salivation in salivary glands affected by Sjogren's syndrome (SS).
      In this technique, the ducts of the salivary glands are irrigated with saline and
      steroids. This allows for dilatation of ductal strictures and removal of debris. 
      Unfortunately, it is not possible to assess the delivery and penetration of
      saline or medications in the ductal system and parenchyma. To address this
      problem, we will conduct contrast-enhanced ultrasound sialendoscopy (CEUSS) using
      sulphur hexafluoride microbubbles. To the best of our knowledge, microbubbles
      have never been used for the treatment of salivary glands in SS. It is,
      therefore, imperative to test this application for its safety and feasibility.
      METHODS AND ANALYSIS: A single-arm phase I study will be performed in 10 SS
      patients. Under local anaesthesia, ultrasound (US) guided infusion of the parotid
      and submandibular glands with microbubbles will be performed. Continuous US
      imaging will be used to visualise the glands, including the location of
      strictures and occlusions. Main outcomes will be the evaluation of safety and
      technical feasibility of the experimental treatment. Secondary outcomes will
      consist of determinations of unstimulated whole mouth saliva flow, stimulated
      whole mouth saliva flow, stimulated parotid saliva flow, clinical oral dryness,
      reported pain, xerostomia, disease activity, salivary cytokine profiles and
      clinical SS symptoms. Finally, salivary gland topographical alterations will be
      evaluated by US. ETHICS AND DISSEMINATION: Ethical approval for this study was
      obtained from the Medical Ethics Committee of the Amsterdam University Medical
      Centre, Amsterdam, The Netherlands (NL68283.029.19). data will be presented at
      national and international conferences and published in a peer-reviewed journal. 
      The study will be implemented and reported in line with the Standard Protocol
      Items: Recommendations for Interventional Trials' statement. TRIAL REGISTRATION
      NUMBERS: The Netherlands Trial Register: NL7731, MREC Trial Register:
      NL68283.029.19; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Karagozoglu, K Hakki
AU  - Karagozoglu KH
AUID- ORCID: 0000-0002-6605-6889
AD  - Department of Oral and Maxillofacial Surgery / Oral Pathology, Amsterdam
      University Medical Center (Amsterdam UMC, Location VUmc) and Academic Centre for 
      Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands kh.karagozoglu@amsterdamumc.nl.
FAU - Helder, Marco
AU  - Helder M
AD  - Department of Oral and Maxillofacial Surgery / Oral Pathology, Amsterdam
      University Medical Center (Amsterdam UMC, Location VUmc) and Academic Centre for 
      Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Bot, Joseph
AU  - Bot J
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center
      (Amsterdam UMC, Location VUmc), Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Kamp, Otto
AU  - Kamp O
AD  - Department of Cardiology, Amsterdam University Medical Center (Amsterdam UMC,
      Location VUmc), Amsterdam, The Netherlands.
FAU - Forouzanfar, Tim
AU  - Forouzanfar T
AD  - Department of Oral and Maxillofacial Surgery / Oral Pathology, Amsterdam
      University Medical Center (Amsterdam UMC, Location VUmc) and Academic Centre for 
      Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Brand, Henk S
AU  - Brand HS
AD  - Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam (ACTA), 
      Amsterdam, The Netherlands.
FAU - Cha, Seunghee
AU  - Cha S
AD  - Department of Oral and Maxillofacial Diagnostic Sciences, Division of Oral
      Medicine, University of Florida College of Dentistry, Gainesville, Florida, USA.
FAU - Weisman, Gary
AU  - Weisman G
AD  - Department of Biochemistry, MU Bond Life Sciences Center, University of Missouri,
      Columbia, Missouri, USA.
FAU - Bartelink, Imke
AU  - Bartelink I
AD  - Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical
      Center (Amsterdam UMC, Location VUmc), Amsterdam, The Netherlands.
FAU - Vissink, Arjan
AU  - Vissink A
AD  - Department of Oral and Maxillofacial Surgery, University Medical Center
      Groningen, University of Groningen, Groningen, The Netherlands.
FAU - Jager, Derk Hendrik Jan
AU  - Jager DHJ
AUID- ORCID: 0000-0002-3006-2128
AD  - Department of Oral and Maxillofacial Surgery / Oral Pathology, Amsterdam
      University Medical Center (Amsterdam UMC, Location VUmc) and Academic Centre for 
      Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Trials, Phase I as Topic
MH  - Humans
MH  - Netherlands
MH  - Salivary Glands/diagnostic imaging/surgery
MH  - Salivation
MH  - *Sjogren's Syndrome/diagnostic imaging/therapy
MH  - Xerostomia
PMC - PMC7528357
OTO - NOTNLM
OT  - *Sjogren syndrome
OT  - *Sjogren's syndrome
OT  - *salivary glands
OT  - *sialendoscopy
OT  - *ultrasound
OT  - *ultrasound microbubbles
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/10/01 05:29 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2019-033542 [pii]
AID - 10.1136/bmjopen-2019-033542 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 30;10(9):e033542. doi: 10.1136/bmjopen-2019-033542.


PMID- 32998715
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210820
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 30
TI  - Correction to: Implementing clinical ethics committees as a complex intervention:
      presentation of a feasibility study in community care.
PG  - 92
LID - 10.1186/s12910-020-00534-x [doi]
AB  - An amendment to this paper has been published and can be accessed via the
      original article.
FAU - Magelssen, Morten
AU  - Magelssen M
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Pb. 1130 Blindern, N-0318, Oslo, Norway. magelssen@gmail.com.
FAU - Karlsen, Heidi
AU  - Karlsen H
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Pb. 1130 Blindern, N-0318, Oslo, Norway.
FAU - Pedersen, Reidar
AU  - Pedersen R
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Pb. 1130 Blindern, N-0318, Oslo, Norway.
FAU - Thoresen, Lisbeth
AU  - Thoresen L
AD  - Department of Interdisciplinary Health Sciences, Institute of Health and Society,
      University of Oslo, Oslo, Norway.
LA  - eng
PT  - Published Erratum
DEP - 20200930
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
EFR - BMC Med Ethics. 2020 Sep 1;21(1):82. PMID: 32873310
PMC - PMC7526179
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 05:26
PHST- 2020/10/01 05:26 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - 10.1186/s12910-020-00534-x [doi]
AID - 10.1186/s12910-020-00534-x [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 30;21(1):92. doi: 10.1186/s12910-020-00534-x.


PMID- 32998658
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Black lives matter: Implications for care ethics.
PG  - 1375-1376
LID - 10.1177/0969733020956881 [doi]
FAU - Hodge, David Augustin
AU  - Hodge DA
AD  - 8066Tuskegee University, USA.
FAU - West, Gwendolyn
AU  - West G
AD  - 6223Florida Memorial University, USA.
FAU - Warren, Rueben C
AU  - Warren RC
AD  - 8066Tuskegee University, USA.
LA  - eng
PT  - Editorial
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - African Americans/*ethnology
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Social Justice
MH  - United States/ethnology
EDAT- 2020/10/02 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/10/01 05:26
PHST- 2020/10/01 05:26 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
AID - 10.1177/0969733020956881 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1375-1376. doi: 10.1177/0969733020956881.


PMID- 32998492
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 140
IP  - 13
DP  - 2020 Sep 29
TI  - Doctors' treatment of family and friends.
LID - 10.4045/tidsskr.20.0608 [doi]
FAU - Opsahl, Jan-Henrik
AU  - Opsahl JH
LA  - eng
LA  - nor
PT  - Journal Article
TT  - Legers behandling av familie og venner.
DEP - 20200915
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny
      raekke
JID - 0413423
SB  - IM
MH  - *Friends
MH  - Humans
MH  - Physician-Patient Relations
MH  - *Physicians
OAB - All doctors inevitably receive requests both big and small from family, friends
      and acquaintances in relation to medical advice and treatment. This article
      discusses the ethical, legal and medical aspects of such involvement, and
      suggests what issues to consider before accepting the role of treating physician.
OABL- eng
EDAT- 2020/10/02 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/10/01 04:36
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/10/01 04:36 [entrez]
AID - 20-0608 [pii]
AID - 10.4045/tidsskr.20.0608 [doi]
PST - epublish
SO  - Tidsskr Nor Laegeforen. 2020 Sep 15;140(13). pii: 20-0608. doi:
      10.4045/tidsskr.20.0608. Print 2020 Sep 29.


PMID- 32998350
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Sep 28
TI  - Teaching Research Ethics to Pharmacists: The Practice of Participatory Learning.
LID - E179 [pii]
LID - 10.3390/pharmacy8040179 [doi]
AB  - The research history of community pharmacists in Japan is short, and ethical
      responses may not be mature. Therefore, the Japan Pharmaceutical Association and 
      universities are working on research ethics education to help pharmacists make
      appropriate ethical responses. In this study, we evaluated whether an educational
      program using participatory learning was effective in research ethics education
      for pharmacists. Regarding the educational effects of our workshop, the score for
      motivation to learn about research ethics was high, and that for judgment and
      applied skills related to research ethics was low. Overall, participants'
      assessment of the program contents was extremely favorable, indicating their
      satisfaction. Participatory learning was widely accepted and suggested to be
      effective in improving learning motivation. Additionally, to be able to apply the
      knowledge of research ethics to own research, it was considered necessary to
      continue learning through participatory learning. This will help pharmacists gain
      judgment and applied skills related to research ethics.
FAU - Ogura, Miku
AU  - Ogura M
AUID- ORCID: 0000-0001-6147-4646
AD  - Department of Medical Psychology, Pharmaceutical Education Research Center,
      Kitasato University School of Pharmacy, Tokyo 108-8641, Japan.
FAU - Takehira, Rieko
AU  - Takehira R
AUID- ORCID: 0000-0002-4319-1041
AD  - Department of Medical Psychology, Pharmaceutical Education Research Center,
      Kitasato University School of Pharmacy, Tokyo 108-8641, Japan.
FAU - Arita, Etsuko
AU  - Arita E
AUID- ORCID: 0000-0003-0993-8233
AD  - Department of Medical Psychology, Pharmaceutical Education Research Center,
      Kitasato University School of Pharmacy, Tokyo 108-8641, Japan.
LA  - eng
GR  - JP17K08463/Japan Society for the Promotion of Science
PT  - Journal Article
DEP - 20200928
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC7712191
OTO - NOTNLM
OT  - clinical research
OT  - ethical education
OT  - pharmacy education
OT  - workshop
EDAT- 2020/10/02 06:00
MHDA- 2020/10/02 06:01
CRDT- 2020/10/01 01:00
PHST- 2020/08/26 00:00 [received]
PHST- 2020/09/25 00:00 [revised]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/01 01:00 [entrez]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2020/10/02 06:01 [medline]
AID - pharmacy8040179 [pii]
AID - 10.3390/pharmacy8040179 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2020 Sep 28;8(4). pii: pharmacy8040179. doi:
      10.3390/pharmacy8040179.


PMID- 32998160
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201029
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Quantitative bioluminescence assay for measuring Bacillus cereus nonhemolytic
      enterotoxin complex.
PG  - e0238153
LID - 10.1371/journal.pone.0238153 [doi]
AB  - Bacillus cereus is a foodborne pathogen causing emesis and diarrhea in those
      affected. It is assumed that the non-hemolytic enterotoxin (Nhe) plays a key role
      in B. cereus induced diarrhea. The ability to trace Nhe activity is important for
      food safety. While assays such as PCR and ELISA exist to detect Nhe, those
      methods cannot differentiate between active and inactive forms of Nhe. The
      existing rabbit ileal loop bioassay used to detect Nhe activity is ethically
      disfavored because it uses live experimental animals. Here we present a custom
      built low-cost CCD based luminometer and applied it in conjunction with a
      cell-based assay using Vero cells transduced to express the luciferase enzyme.
      The activity of Nhe was measured as its ability to inhibit synthesis of
      luciferase as quantified by reduction of light emission by the luciferase
      reaction. Emitted light intensity was observed to be inversely proportional to
      Nhe concentration over a range of 7 ng/ml to 125 ng/ml, with a limit of detection
      of 7 ng/ml Nhe.
FAU - Rasooly, Reuven
AU  - Rasooly R
AUID- ORCID: 0000-0001-7458-5804
AD  - Western Regional Research Center, Foodborne Toxin Detection & Prevention Research
      Unit, Agricultural Research Service, United States Department of Agriculture,
      Albany, CA, United States of America.
FAU - Do, Paula
AU  - Do P
AD  - Western Regional Research Center, Foodborne Toxin Detection & Prevention Research
      Unit, Agricultural Research Service, United States Department of Agriculture,
      Albany, CA, United States of America.
FAU - Hernlem, Bradley
AU  - Hernlem B
AD  - Western Regional Research Center, Foodborne Toxin Detection & Prevention Research
      Unit, Agricultural Research Service, United States Department of Agriculture,
      Albany, CA, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200930
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Enterotoxins)
RN  - 0 (enterotoxin, Bacillus cereus)
RN  - EC 1.13.12.- (Luciferases)
SB  - IM
MH  - Animals
MH  - Biocatalysis
MH  - Chlorocebus aethiops
MH  - Enterotoxins/*metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Luciferases/genetics/metabolism
MH  - *Luminescent Measurements
MH  - Vero Cells
PMC - PMC7527251
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/01 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/09/30 20:07
PHST- 2020/05/25 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/30 20:07 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - 10.1371/journal.pone.0238153 [doi]
AID - PONE-D-20-15755 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 30;15(9):e0238153. doi: 10.1371/journal.pone.0238153.
      eCollection 2020.


PMID- 32997842
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 34
IP  - 12
DP  - 2020 Dec
TI  - The structural conundrum of parolees and kidney transplantation.
PG  - e14104
LID - 10.1111/ctr.14104 [doi]
AB  - In the United States, there are a large number of incarcerated individuals,
      resulting in high numbers of previously incarcerated individuals out on parole
      undergoing reentry into society. An aging prison population translates to an
      older parolee population and increased incidence of kidney disease requiring
      either long-term dialysis or transplantation. This paper argues that due to
      challenges specific to the parolee population as well as societal biases and
      priorities, Transplant Centers and healthcare professionals face an ethical
      imperative to attend to the needs of parolees as a class and take steps to
      address challenges related to access to Centers for renal transplantation
      evaluation for this disadvantaged group. It will first review the regulatory
      context of kidney transplantation and highlight the specific ways it effects
      parolees. The paper will then discuss the broader social context of parolee
      reentry into society and barriers faced by parolees in this process. This ethical
      analysis examines the complexity of these issues, and deliberates on ways to
      balance the competing priorities of justice, respect for this patient population 
      as individuals and as a disadvantaged class, and the societal interests regarding
      organ allocation and considerable economic burdens of end-stage renal disease on 
      parolees, the justice system, and the public.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Ahmad, Mahwish U
AU  - Ahmad MU
AUID- ORCID: 0000-0001-6029-5849
AD  - Center for Bioethics, Cleveland Clinic, Cleveland, OH, USA.
AD  - Department of Bioethics, School of Medicine, Case Western Reserve University,
      Cleveland, OH, USA.
FAU - Eves, Margot M
AU  - Eves MM
AD  - Center for Bioethics, Cleveland Clinic, Cleveland, OH, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201012
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
SB  - IM
MH  - Humans
MH  - Incidence
MH  - *Kidney Failure, Chronic/surgery
MH  - *Kidney Transplantation
MH  - Renal Dialysis
MH  - United States
OTO - NOTNLM
OT  - *African American
OT  - *Hispanic
OT  - *access
OT  - *dialysis
OT  - *end-stage renal disease (ESRD)
OT  - *ethics
OT  - *kidney transplantation
OT  - *parolees
OT  - *social support
EDAT- 2020/10/01 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/09/30 17:13
PHST- 2020/06/09 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/30 17:13 [entrez]
AID - 10.1111/ctr.14104 [doi]
PST - ppublish
SO  - Clin Transplant. 2020 Dec;34(12):e14104. doi: 10.1111/ctr.14104. Epub 2020 Oct
      12.


PMID- 32997690
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Coral Gardens Reef, Belize: A refugium in the face of Caribbean-wide Acropora
      spp. coral decline.
PG  - e0239267
LID - 10.1371/journal.pone.0239267 [doi]
AB  - Caribbean Acropora spp. corals have undergone a decline in cover since the second
      half of the twentieth century. Loss of these architecturally complex and
      fast-growing corals has resulted in significant, cascading changes to the
      character, diversity, and available eco-spaces of Caribbean reefs. Few thriving
      Acropora spp. populations exist today in the Caribbean and western North Atlantic
      seas, and our limited ability to access data from reefs assessed via long-term
      monitoring efforts means that reef scientists are challenged to determine
      resilience and longevity of existing Acropora spp. reefs. Here we used multiple
      dating methods to measure reef longevity and determine whether Coral Gardens
      Reef, Belize, is a refuge for Acropora cervicornis against the backdrop of wider 
      Caribbean decline. We used a new genetic-aging technique to identify sample
      sites, and radiocarbon and high-precision uranium-thorium (U-Th) dating
      techniques to test whether one of the largest populations of extant A.
      cervicornis in the western Caribbean is newly established after the 1980s, or
      represents a longer-lived, stable population. We did so with respect for ethical 
      sampling of a threatened species. Our data show corals ranging in age from 1910
      (14C) or 1915 (230Th) to at least November 2019. While we cannot exclude the
      possibility of short gaps in the residence of A. cervicornis earlier in the
      record, the data show consistent and sustained living coral throughout the 1980s 
      and up to at least 2019. We suggest that Coral Gardens has served as a refuge for
      A. cervicornis and that identifying other, similar sites may be critical to
      efforts to grow, preserve, conserve, and seed besieged Caribbean reefs.
FAU - Greer, Lisa
AU  - Greer L
AUID- ORCID: 0000-0001-7350-1947
AD  - Geology Department, Washington and Lee University, Lexington, VA, United States
      of America.
FAU - Clark, Tara
AU  - Clark T
AUID- ORCID: 0000-0002-9648-0867
AD  - School of Earth Atmospheric and Life Sciences, University of Wollongong,
      Wollongong, NSW, Australia.
AD  - Radiogenic Isotope Facility, School of Earth and Environmental Sciences, The
      University of Queensland, Brisbane, QLD, Australia.
FAU - Waggoner, Tanner
AU  - Waggoner T
AD  - Geology Department, Washington and Lee University, Lexington, VA, United States
      of America.
FAU - Busch, James
AU  - Busch J
AD  - Geology Department, Washington and Lee University, Lexington, VA, United States
      of America.
AD  - Department of Earth Sciences, Dartmouth College, Hanover, NH, United States of
      America.
FAU - Guilderson, Thomas P
AU  - Guilderson TP
AD  - Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory,
      Livermore, CA, United States of America.
AD  - Ocean Sciences Department, University of California, Santa Cruz, CA, United
      States of America.
FAU - Wirth, Karl
AU  - Wirth K
AD  - Geology Department, Macalester College, St. Paul, MN, United States of America.
FAU - Zhao, Jian-Xin
AU  - Zhao JX
AD  - Radiogenic Isotope Facility, School of Earth and Environmental Sciences, The
      University of Queensland, Brisbane, QLD, Australia.
FAU - Curran, H Allen
AU  - Curran HA
AD  - Geosciences Department, Smith College, Northampton, MA, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200930
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Anthozoa/*physiology
MH  - Belize
MH  - Caribbean Region
MH  - *Conservation of Natural Resources
MH  - *Coral Reefs
MH  - Endangered Species
MH  - Population Dynamics
MH  - *Refugium
PMC - PMC7526931
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/10/01 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/09/30 17:12
PHST- 2020/04/08 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/30 17:12 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.1371/journal.pone.0239267 [doi]
AID - PONE-D-20-10134 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 30;15(9):e0239267. doi: 10.1371/journal.pone.0239267.
      eCollection 2020.


PMID- 32997483
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201210
IS  - 1210-7778 (Print)
IS  - 1210-7778 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Sep
TI  - Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
PG  - 246-247
LID - 10.21101/cejph.a6464 [doi]
FAU - Allam, Mohamed Farouk
AU  - Allam MF
AD  - Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, 
      Egypt.
FAU - Andraous, Fady
AU  - Andraous F
AD  - Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, 
      Egypt.
LA  - eng
PT  - Letter
PL  - Czech Republic
TA  - Cent Eur J Public Health
JT  - Central European journal of public health
JID - 9417324
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 886U3H6UFF (Chloroquine)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Chloroquine/*therapeutic use
MH  - Coronavirus Infections/*drug therapy
MH  - Drug Therapy/*ethics
MH  - Humans
MH  - Hydroxychloroquine/*therapeutic use
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/*drug therapy
MH  - SARS-CoV-2
EDAT- 2020/10/01 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/09/30 16:09
PHST- 2020/07/01 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/09/30 16:09 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.21101/cejph.a6464 [doi]
PST - ppublish
SO  - Cent Eur J Public Health. 2020 Sep;28(3):246-247. doi: 10.21101/cejph.a6464.


PMID- 32997479
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20201006
IS  - 1210-7778 (Print)
IS  - 1210-7778 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Sep
TI  - Medical tourism: its research and implications for public health.
PG  - 226-229
LID - 10.21101/cejph.a5744 [doi]
AB  - OBJECTIVE: The purpose of this article is to describe current research trends in 
      medical tourism and implications for public health, especially in destination
      countries. METHODS: The methods used for this article include a literature review
      of available sources on the research topic in the world's acknowledged databases 
      Web of Science, Scopus, MEDLINE, and ScienceDirect. RESULTS: The findings
      indicate that there is no consensus on the definition of medical tourism.
      However, there are a few conceptual models which can be used in further medical
      tourism research and practice. The findings also reveal that there are still
      certain issues, which hinder the fast growth of medical tourism, such as unclear 
      impact on healthcare systems, ethical concerns or a lack of effective tools for
      the measurement of quality assurance of the medical tourism services and their
      products. CONCLUSIONS: There is a need for data collection on medical tourism,
      both at national and worldwide level to provide a realistic picture of this
      evolving field of tourism as well as implications for public health in
      destination countries.
FAU - Klimova, Blanka
AU  - Klimova B
AD  - Department of Applied Linguistics, Faculty of Informatics and Management,
      University of Hradec Kralove, Hradec Kralove, Czech Republic.
FAU - Kuca, Kamil
AU  - Kuca K
AD  - Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove,
      Czech Republic.
AD  - Centre for Basic and Applied Research, Faculty of Informatics and Management,
      University of Hradec Kralove, Hradec Kralove, Czech Republic.
LA  - eng
PT  - Journal Article
PL  - Czech Republic
TA  - Cent Eur J Public Health
JT  - Central European journal of public health
JID - 9417324
SB  - IM
MH  - Humans
MH  - *Medical Tourism
MH  - Public Health
MH  - Research/trends
OTO - NOTNLM
OT  - barriers
OT  - implications
OT  - medical tourism
OT  - research
OT  - trends
EDAT- 2020/10/01 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/09/30 16:09
PHST- 2019/03/05 00:00 [received]
PHST- 2020/07/04 00:00 [accepted]
PHST- 2020/09/30 16:09 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
AID - 10.21101/cejph.a5744 [doi]
PST - ppublish
SO  - Cent Eur J Public Health. 2020 Sep;28(3):226-229. doi: 10.21101/cejph.a5744.


PMID- 32997448
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20201218
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 16
IP  - 708
DP  - 2020 Sep 30
TI  - [Ethical questions regarding the medical care of adults with disabilities].
PG  - 1790-1795
AB  - Medical care of adults with disabilities, especially those with intellectual
      disabilities, can be ethically difficult. Several questions arise frequently. Can
      we administer a life-saving treatment that could impact negatively the patient's 
      quality of life when the patient isn't able to give consent? During this Covid-19
      period, can the use of chemical or physical restraints be considered as
      mistreatment, whereas the aim is to protect others? These are situations where
      the ethical question holds a central role. Although each clinical situation is
      unique, this article highlights, through four clinical cases, the ethical
      principles that should guide physicians in their decision-making process.
FAU - Dugerdil, Adeline
AU  - Dugerdil A
AD  - Service de medecine de premier recours, HUG, 1211 Geneve.
FAU - Deriaz, Jonathan
AU  - Deriaz J
AD  - Service de medecine de premier recours, HUG, 1211 Geneve.
FAU - Hurst-Majno, Samia
AU  - Hurst-Majno S
AD  - Institut ethique histoire humanites, Faculte de medecine, Universite de Geneve,
      1211 Geneve 4.
FAU - Dominice Dao, Melissa
AU  - Dominice Dao M
AD  - Service de medecine de premier recours, HUG, 1211 Geneve.
LA  - fre
PT  - Journal Article
TT  - Questions ethiques soulevees par la prise en charge medicale des adultes en
      situation de handicap.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/epidemiology/*psychology/*therapy
MH  - *Disabled Persons
MH  - Humans
MH  - Informed Consent/ethics
MH  - *Intellectual Disability
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*psychology/*therapy
MH  - *Quality of Life
MH  - Restraint, Physical/ethics
COIS- Les auteurs n'ont declare aucun conflit d'interets en relation avec cet article.
EDAT- 2020/10/01 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/09/30 12:19
PHST- 2020/09/30 12:19 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - RMS0708-003 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2020 Sep 30;16(708):1790-1795.


PMID- 32997378
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1399-3046 (Electronic)
IS  - 1397-3142 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Nov
TI  - Genetic disease and intellectual disability as contraindications to transplant
      listing in the United States: A survey of heart, kidney, liver, and lung
      transplant programs.
PG  - e13837
LID - 10.1111/petr.13837 [doi]
AB  - Discrimination based on disability is prohibited in organ transplantation, yet
      studies suggest it continues in listing practices for intellectual disability and
      genetic diseases. It is not known if this differs between adult and pediatric
      programs, or by organ type. We performed an online, forced-choice survey of
      psychosocial listing criteria for adult and pediatric heart, kidney, liver, and
      lung transplant programs in the United States. Of 650 programs contacted, 343
      (52.8%) submitted complete. A minority of programs had formal listing guidelines 
      for any condition considered (Down Syndrome, Duchenne Muscular Dystrophy, Becker 
      Muscular Dystrophy, DiGeorge Syndrome, and Wolf Hirschhorn Syndrome; and mild [IQ
      < 70] and severe [IQ < 35] intellectual disability), although a majority had
      encountered most. Pediatric programs were significantly (P < .02) more lenient in
      the level of contraindication to listing for all genetic conditions considered
      except Duchenne Muscular Dystrophy, and for mild and severe intellectual
      disability. Level of contraindication differed significantly by organ type
      (heart, lung, liver, and kidney) for Duchenne Muscular dystrophy (P = <.001),
      Becker Muscular Dystrophy (P < .001), DiGeorge Syndrome (P < .001),
      Wolf-Hirschhorn syndrome (P = .0012), and severe intellectual disability (P <
      .001). There is significant variation among transplant programs in availability
      of guidelines for as well as listing practices regarding genetic diseases and
      intellectual disability, differing by both adult vs pediatric program, and organ 
      type. Programs with absolute contraindications to listing for specific genetic
      diseases or intellectual disability should reframe their approach, ensuring
      individualized assessments and avoiding elimination of patients based on
      membership in a particular group.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Wall, Anji
AU  - Wall A
AUID- ORCID: 0000-0002-7359-1337
AD  - Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical 
      Center, Dallas, Texas, USA.
FAU - Lee, Gun Ho
AU  - Lee GH
AD  - School of Medicine, Stanford University, Stanford, California, USA.
FAU - Maldonado, Jose
AU  - Maldonado J
AD  - Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, 
      California, USA.
FAU - Magnus, David
AU  - Magnus D
AD  - Departments of Pediatrics and Medicine and Center for Biomedical Ethics, Stanford
      University, Stanford, California, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200930
PL  - Denmark
TA  - Pediatr Transplant
JT  - Pediatric transplantation
JID - 9802574
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Comorbidity
MH  - *Contraindications, Procedure
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Diseases, Inborn/*epidemiology
MH  - Heart Transplantation/adverse effects
MH  - Humans
MH  - Intellectual Disability/*epidemiology
MH  - Kidney Transplantation/adverse effects
MH  - Lung Transplantation/adverse effects
MH  - Male
MH  - Organ Transplantation/*adverse effects
MH  - *Program Evaluation
MH  - Retrospective Studies
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - United States/epidemiology
MH  - *Waiting Lists
MH  - Young Adult
OTO - NOTNLM
OT  - *ethics
OT  - *organ allocation
OT  - *transplantation
EDAT- 2020/10/01 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/09/30 12:18
PHST- 2020/05/23 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2020/09/30 12:18 [entrez]
AID - 10.1111/petr.13837 [doi]
PST - ppublish
SO  - Pediatr Transplant. 2020 Nov;24(7):e13837. doi: 10.1111/petr.13837. Epub 2020 Sep
      30.


PMID- 32996903
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 1857-9655 (Print)
IS  - 1857-9655 (Linking)
VI  - 8
IP  - B
DP  - 2020 Sep 30
TI  - Retraction: Five papers from Open Access Maced J Med Sci. Vol. 7 No. 18 (2019):
      Sep 30 (Global Dermatology).
PG  - 573
LID - 10.3889/oamjms.2020.5492 [doi]
AB  - Editor-in-Chief has retracted the following articles from the special issue Vol. 
      7 No. 18 (2019): Sep 30 (Global Dermatology): (1) DNA Waves and Their
      Applications in Biology - Massimo Fioranelli et al. - Open Access Macedonian
      Journal of Medical Sciences (2019) - DOI: 10.3889/oamjms.2019.767; (2) Recovery
      of Brain in Chick Embryos by Growing Second Heart and Brain - Massimo Fioranelli 
      et al. - Open Access Macedonian Journal of Medical Sciences (2019) - DOI:
      10.3889/oamjms.2019.777; (3) A Mathematical Model for the Signal of Death and
      Emergence of Mind Out of Brain in Izhikevich Neuron Model - Massimo Fioranelli et
      al. - Open Access Macedonian Journal of Medical Sciences (2019) - DOI:
      10.3889/oamjms.2019.774; (4) A Black Hole at the Center of Earth Plays the Role
      of the Biggest System of Telecommunication for Connecting DNAs, Dark DNAs and
      Molecules of Water on 4+N- Dimensional Manifold - Massimo Fioranelli et al. -
      Open Access Macedonian Journal of Medical Sciences (2019) - DOI:
      10.3889/oamjms.2019.776 (5) New System Delivering Microwaves Energy for Inducing 
      Subcutaneous Fat Reduction: In - Vivo Histological and Ultrastructural Evidence -
      Nicola Zerbinati et al., Open Access Macedonian Journal of Medical Sciences
      (2019) - DOI: 10.3889/oamjms.2019.778. An internal investigation has raised
      sufficient evidence that they are not directly connected with the special issue
      Global Dermatology and contain inconsistent results. As such, we retract these
      articles from the literature and by guidelines and best editorial practices from 
      the Committee on Publication Ethics. We apologize to our audience about this
      unfortunate situation.
CI  - Copyright: (c) 2019 Mirko Spiroski.
FAU - Spiroski, Mirko
AU  - Spiroski M
AD  - Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia.
LA  - eng
PT  - Retraction of Publication
DEP - 20200930
PL  - North Macedonia
TA  - Open Access Maced J Med Sci
JT  - Open access Macedonian journal of medical sciences
JID - 101662294
ROF - Open Access Maced J Med Sci. 2019 Aug 30;7(18):2991-2997. PMID: 31850107
ROF - Open Access Maced J Med Sci. 2019 Aug 30;7(18):3073-3080. PMID: 31850126
ROF - Open Access Maced J Med Sci. 2019 Aug 30;7(18):3085-3089. PMID: 31850128
ROF - Open Access Maced J Med Sci. 2019 Sep 11;7(18):3096-3100. PMID: 31850131
ROF - Open Access Maced J Med Sci. 2019 Sep 11;7(18):3121-3126. PMID: 31850137
PMC - PMC7525822
OTO - NOTNLM
OT  - global dermatology
OT  - publication ethics
OT  - retraction
EDAT- 2020/10/01 06:00
MHDA- 2020/10/01 06:01
CRDT- 2020/09/30 12:14
PHST- 2020/08/15 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/09/30 12:14 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/01 06:01 [medline]
AID - 10.3889/oamjms.2020.5492 [doi]
PST - epublish
SO  - Open Access Maced J Med Sci. 2020 Sep 30;8(B):573. doi: 10.3889/oamjms.2020.5492.


PMID- 32996892
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210127
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep 30
TI  - Artificial Intelligence Chatbot Behavior Change Model for Designing Artificial
      Intelligence Chatbots to Promote Physical Activity and a Healthy Diet: Viewpoint.
PG  - e22845
LID - 10.2196/22845 [doi]
AB  - BACKGROUND: Chatbots empowered by artificial intelligence (AI) can increasingly
      engage in natural conversations and build relationships with users. Applying AI
      chatbots to lifestyle modification programs is one of the promising areas to
      develop cost-effective and feasible behavior interventions to promote physical
      activity and a healthy diet. OBJECTIVE: The purposes of this perspective paper
      are to present a brief literature review of chatbot use in promoting physical
      activity and a healthy diet, describe the AI chatbot behavior change model our
      research team developed based on extensive interdisciplinary research, and
      discuss ethical principles and considerations. METHODS: We conducted a
      preliminary search of studies reporting chatbots for improving physical activity 
      and/or diet in four databases in July 2020. We summarized the characteristics of 
      the chatbot studies and reviewed recent developments in human-AI communication
      research and innovations in natural language processing. Based on the identified 
      gaps and opportunities, as well as our own clinical and research experience and
      findings, we propose an AI chatbot behavior change model. RESULTS: Our review
      found a lack of understanding around theoretical guidance and practical
      recommendations on designing AI chatbots for lifestyle modification programs. The
      proposed AI chatbot behavior change model consists of the following four
      components to provide such guidance: (1) designing chatbot characteristics and
      understanding user background; (2) building relational capacity; (3) building
      persuasive conversational capacity; and (4) evaluating mechanisms and outcomes.
      The rationale and evidence supporting the design and evaluation choices for this 
      model are presented in this paper. CONCLUSIONS: As AI chatbots become
      increasingly integrated into various digital communications, our proposed
      theoretical framework is the first step to conceptualize the scope of utilization
      in health behavior change domains and to synthesize all possible dimensions of
      chatbot features to inform intervention design and evaluation. There is a need
      for more interdisciplinary work to continue developing AI techniques to improve a
      chatbot's relational and persuasive capacities to change physical activity and
      diet behaviors with strong ethical principles.
CI  - (c)Jingwen Zhang, Yoo Jung Oh, Patrick Lange, Zhou Yu, Yoshimi Fukuoka.
      Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 30.09.2020.
FAU - Zhang, Jingwen
AU  - Zhang J
AUID- ORCID: 0000-0003-1733-6857
AD  - Department of Communication, University of California, Davis, Davis, CA, United
      States.
AD  - Department of Public Health Sciences, University of California, Davis, Davis, CA,
      United States.
FAU - Oh, Yoo Jung
AU  - Oh YJ
AUID- ORCID: 0000-0002-7829-8535
AD  - Department of Communication, University of California, Davis, Davis, CA, United
      States.
FAU - Lange, Patrick
AU  - Lange P
AUID- ORCID: 0000-0003-3935-663X
AD  - Department of Computer Science, University of California, Davis, Davis, CA,
      United States.
FAU - Yu, Zhou
AU  - Yu Z
AUID- ORCID: 0000-0002-1524-5890
AD  - Department of Computer Science, University of California, Davis, Davis, CA,
      United States.
FAU - Fukuoka, Yoshimi
AU  - Fukuoka Y
AUID- ORCID: 0000-0002-2245-9264
AD  - Department of Physiological Nursing, University of California, San Francisco, San
      Francisco, CA, United States.
LA  - eng
GR  - K24 NR015812/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200930
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Artificial Intelligence/*standards
MH  - Behavior Therapy/*methods
MH  - Communication
MH  - Diet, Healthy/*methods
MH  - Exercise/*physiology
MH  - Humans
MH  - Telemedicine/*methods
PMC - PMC7557439
OTO - NOTNLM
OT  - *artificial intelligence
OT  - *behavior change
OT  - *chatbot
OT  - *communication
OT  - *conversational agent
OT  - *diet
OT  - *intervention
OT  - *natural language processing
OT  - *physical activity
EDAT- 2020/10/01 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/09/30 12:14
PHST- 2020/07/27 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/09/03 00:00 [revised]
PHST- 2020/09/30 12:14 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
AID - v22i9e22845 [pii]
AID - 10.2196/22845 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Sep 30;22(9):e22845. doi: 10.2196/22845.


PMID- 32996891
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201101
IS  - 2561-326X (Electronic)
IS  - 2561-326X (Linking)
VI  - 4
IP  - 9
DP  - 2020 Sep 30
TI  - Phone Calls to Retain Research Participants and Determinants of Reachability in
      an African Setting: Observational Study.
PG  - e19138
LID - 10.2196/19138 [doi]
AB  - BACKGROUND: Long-term retention of research participants in studies is
      challenging. In research in sub-Saharan Africa, phone calls are the most
      frequently used method to distantly engage with participants. OBJECTIVE: We aimed
      to get insight into the effectiveness of phone calls to retain contact with
      participants and evaluated determinants of reachability. METHODS: A
      cross-sectional study was performed using the databases of two randomized
      controlled trials investigating different kinds of antiretroviral therapy in
      HIV-positive patients. One trial finished in 2018 (study 1), and the other
      finished in 2015 (study 2). A random sample size of 200 participants per study
      was obtained. There were up to 3 phone numbers available per participant
      collected during the studies. Participants received a maximum of 3 phone calls on
      every available number on different days and at different times. Voicemails were 
      left, and emails sent wherever possible. We documented how many calls were
      answered, who answered, as well as after how many attempts participants were
      reached. To further increase our understanding of reachability, we conducted a
      short questionnaire assessing factors contributing to reachability. The study was
      approved by the Research Ethics Committee of the University of Witwatersrand,
      Johannesburg, South Africa (reference number M1811107). RESULTS: In our sample
      size of n=200 per study, study 1, with a median time of 11 months since the last 
      visit at the research site, had a response rate of 70.5% (141/200) participants
      while study 2, with a median duration of 55 months since the last visit, had a
      response rate of 50.0% (100/200; P<.001). In study 1, 61.5% (123/200) of calls
      were answered directly by the participant while this was 36.0% (72/200) in study 
      2 (P=.003). The likelihood of reaching a participant decreased with time (odds
      ratio [OR] 0.73, 95% CI 0.63 to 0.84) for every year since the last face-to-face 
      visit. Having more phone numbers per participant increased reachability (OR 2.32,
      95% CI 1.24 to 4.36 for 2 phone numbers and OR 3.03, 95% CI 1.48 to 6.22 for 3
      phone numbers compared with 1 number). A total of 141 of 241 reached participants
      responded to the questionnaire. Of the 93 participants who had changed phone
      numbers, 5% (50/93) had changed numbers because their phone was stolen. The most 
      preferred method of being contacted was direct calling (128/141) with
      participants naming this method followed by WhatsApp (69/141). CONCLUSIONS: Time 
      since last visit and the number of phone numbers listed were the only
      determinants of reachability. Longer follow-up time is accompanied with a
      decrease in reachability by phone while more listed phone numbers increases the
      likelihood that someone can be reached. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT02671383; https://clinicaltrials.gov/ct2/show/NCT02671383 and
      ClinicalTrials.gov NCT02670772; https://clinicaltrials.gov/ct2/show/NCT02670772.
CI  - (c)Melvin Draaijer, Samanta Tresha Lalla-Edward, Willem Daniel Francois Venter,
      Alinda Vos. Originally published in JMIR Formative Research
      (http://formative.jmir.org), 30.09.2020.
FAU - Draaijer, Melvin
AU  - Draaijer M
AUID- ORCID: https://orcid.org/0000-0002-2426-3396
AD  - Department of Global Health, VU Medical Center, Amsterdam University Medical
      Centers, Amsterdam, Netherlands.
AD  - Ezintsha (subdivision of Wits Reproductive Health and HIV Institute), University 
      of Witwatersrand, Johannesburg, South Africa.
FAU - Lalla-Edward, Samanta Tresha
AU  - Lalla-Edward ST
AUID- ORCID: https://orcid.org/0000-0003-3597-1643
AD  - Ezintsha (subdivision of Wits Reproductive Health and HIV Institute), University 
      of Witwatersrand, Johannesburg, South Africa.
FAU - Venter, Willem Daniel Francois
AU  - Venter WDF
AUID- ORCID: https://orcid.org/0000-0002-4157-732X
AD  - Ezintsha (subdivision of Wits Reproductive Health and HIV Institute), University 
      of Witwatersrand, Johannesburg, South Africa.
FAU - Vos, Alinda
AU  - Vos A
AUID- ORCID: https://orcid.org/0000-0002-9551-6223
AD  - Julius Global Health, Julius Center for Health Sciences and Primary Care,
      University Medical Center Utrecht, Utrecht, Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT02670772
SI  - ClinicalTrials.gov/NCT02671383
PT  - Journal Article
DEP - 20200930
PL  - Canada
TA  - JMIR Form Res
JT  - JMIR formative research
JID - 101726394
PMC - PMC7557447
OTO - NOTNLM
OT  - ART
OT  - HIV
OT  - South Africa
OT  - loss to follow-up
OT  - mobile phones
OT  - phone
OT  - retention
EDAT- 2020/10/01 06:00
MHDA- 2020/10/01 06:01
CRDT- 2020/09/30 12:14
PHST- 2020/04/05 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/06/13 00:00 [revised]
PHST- 2020/09/30 12:14 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/01 06:01 [medline]
AID - v4i9e19138 [pii]
AID - 10.2196/19138 [doi]
PST - epublish
SO  - JMIR Form Res. 2020 Sep 30;4(9):e19138. doi: 10.2196/19138.


PMID- 32996058
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - A Taxonomy of Ethical, Legal and Social Implications of Wearable Robots: An
      Expert Perspective.
PG  - 3229-3247
LID - 10.1007/s11948-020-00268-4 [doi]
AB  - Wearable robots and exoskeletons are relatively new technologies designed for
      assisting and augmenting human motor functions. Due to their different possible
      design applications and their intimate connection to the human body, they come
      with specific ethical, legal, and social issues (ELS), which have not been much
      explored in the recent ELS literature. This paper draws on expert consultations
      and a literature review to provide a taxonomy of the most important ethical,
      legal, and social issues of wearable robots. These issues are categorized in (1) 
      wearable robots and the self, (2) wearable robots and the other, and (3) wearable
      robots in society.
FAU - Kapeller, Alexandra
AU  - Kapeller A
AUID- ORCID: 0000-0002-1989-2016
AD  - Department of Thematic Studies: Technology and Social Change, Linkoping
      University, Linkoping, Sweden. alexandra.kapeller@liu.se.
FAU - Felzmann, Heike
AU  - Felzmann H
AD  - Department of Philosophy, National University of Ireland, Galway, Ireland.
FAU - Fosch-Villaronga, Eduard
AU  - Fosch-Villaronga E
AD  - Center for Law and Digital Technologies, Leiden University, Leiden, The
      Netherlands.
FAU - Hughes, Ann-Marie
AU  - Hughes AM
AD  - Faculty of Health Sciences, University of Southampton, Southampton, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humans
MH  - *Morals
MH  - *Wearable Electronic Devices
PMC - PMC7755623
OTO - NOTNLM
OT  - *ELSI
OT  - *Ethical, legal, and societal (ELS) aspects
OT  - *Exoskeleton
OT  - *Taxonomy
OT  - *Wearable robots
EDAT- 2020/10/01 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/30 06:18
PHST- 2020/06/05 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/30 06:18 [entrez]
AID - 10.1007/s11948-020-00268-4 [doi]
AID - 10.1007/s11948-020-00268-4 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3229-3247. doi: 10.1007/s11948-020-00268-4. Epub
      2020 Sep 29.


PMID- 32995624
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 9
DP  - 2020 Sep
TI  - Graduate students reported practices regarding the issue of informed consent and 
      maintaining of data confidentiality in a developing country.
PG  - e04940
LID - 10.1016/j.heliyon.2020.e04940 [doi]
AB  - Research involving human subjects requires strict adherence to ethical
      principles, including informed consent and assuring data confidentiality. Herein,
      a questionnaire was utilized to assess compliance of graduate students who
      conduct research involving human subjects in Jordan with proper practices related
      to informed consent and maintaining of data confidentiality. Among the 251
      respondents, 55.4% were from health-related fields, 61.4% undertook research
      involving humans, and 48.6% did research requiring institutional review board
      approval. Only 37.1% of respondents reported exposure to research ethics
      education during their graduate study. Satisfactory adherence to informed consent
      practices was reported at rates of 56.0%-67.5%. Satisfactory adherence to
      practices related to data confidentiality and study participants' anonymity was
      reported at rates of 67.3%-74.7%. Sharing of data or samples with others was
      reported at a rate of 24.3%. The rates of adherence to proper informed consent
      practices and practices that maintain data confidentiality were less than ideal. 
      Significant policy changes need to be implemented to address these issues.
CI  - (c) 2020 The Authors.
FAU - Swedan, Samer
AU  - Swedan S
AD  - Faculty of Applied Medical Sciences, Dept. of Medical Laboratory Sciences, Jordan
      University of Science and Technology, Irbid 22110, Jordan.
FAU - Khabour, Omar F
AU  - Khabour OF
AD  - Faculty of Applied Medical Sciences, Dept. of Medical Laboratory Sciences, Jordan
      University of Science and Technology, Irbid 22110, Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AD  - Faculty of Pharmacy, Dept. of Clinical Pharmacy, Jordan University of Science and
      Technology, Irbid 22110, Jordan.
FAU - Aljabali, Alaa A A
AU  - Aljabali AAA
AD  - Faculty of Pharmacy, Dept. of Pharmaceutics and Pharmaceutical Technology,
      Yarmouk University, Irbid 21163, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20200919
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7505757
OTO - NOTNLM
OT  - Data confidentiality
OT  - Graduate
OT  - Human studies
OT  - Informed consent
OT  - Jordan
OT  - Research ethics
OT  - Social science
EDAT- 2020/10/01 06:00
MHDA- 2020/10/01 06:01
CRDT- 2020/09/30 06:15
PHST- 2020/06/13 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/09/30 06:15 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/01 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04940 [doi]
AID - S2405-8440(20)31783-7 [pii]
PST - epublish
SO  - Heliyon. 2020 Sep 19;6(9):e04940. doi: 10.1016/j.heliyon.2020.e04940. eCollection
      2020 Sep.


PMID- 32994686
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 26
IP  - 35
DP  - 2020 Sep 21
TI  - Artificial intelligence-assisted esophageal cancer management: Now and future.
PG  - 5256-5271
LID - 10.3748/wjg.v26.i35.5256 [doi]
AB  - Esophageal cancer poses diagnostic, therapeutic and economic burdens in high-risk
      regions. Artificial intelligence (AI) has been developed for diagnosis and
      outcome prediction using various features, including clinicopathologic,
      radiologic, and genetic variables, which can achieve inspiring results. One of
      the most recent tasks of AI is to use state-of-the-art deep learning technique to
      detect both early esophageal squamous cell carcinoma and esophageal
      adenocarcinoma in Barrett's esophagus. In this review, we aim to provide a
      comprehensive overview of the ways in which AI may help physicians diagnose
      advanced cancer and make clinical decisions based on predicted outcomes, and
      combine the endoscopic images to detect precancerous lesions or early cancer.
      Pertinent studies conducted in recent two years have surged in numbers, with
      large datasets and external validation from multi-centers, and have partly
      achieved intriguing results of expert's performance of AI in real time. Improved 
      pre-trained computer-aided diagnosis algorithms in the future studies with larger
      training and external validation datasets, aiming at real-time video processing, 
      are imperative to produce a diagnostic efficacy similar to or even superior to
      experienced endoscopists. Meanwhile, supervised randomized controlled trials in
      real clinical practice are highly essential for a solid conclusion, which meets
      patient-centered satisfaction. Notably, ethical and legal issues regarding the
      black-box nature of computer algorithms should be addressed, for both clinicians 
      and regulators.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Zhang, Yu-Hang
AU  - Zhang YH
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan
      University, Chengdu 610041, Sichuan Province, China.
FAU - Guo, Lin-Jie
AU  - Guo LJ
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan
      University, Chengdu 610041, Sichuan Province, China.
FAU - Yuan, Xiang-Lei
AU  - Yuan XL
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan
      University, Chengdu 610041, Sichuan Province, China.
FAU - Hu, Bing
AU  - Hu B
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan
      University, Chengdu 610041, Sichuan Province, China. hubingnj@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
SB  - IM
MH  - *Adenocarcinoma/therapy
MH  - Artificial Intelligence
MH  - *Barrett Esophagus/therapy
MH  - *Esophageal Neoplasms/diagnosis/therapy
MH  - *Esophageal Squamous Cell Carcinoma
MH  - Humans
PMC - PMC7504247
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Barrett's esophagus
OT  - Computer-aided diagnosis
OT  - Deep learning
OT  - Endoscopy
OT  - Esophageal squamous cell cancer
COIS- Conflict-of-interest statement: All authors declare no conflict of interests.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:12
PHST- 2020/05/25 00:00 [received]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/30 06:12 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.3748/wjg.v26.i35.5256 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2020 Sep 21;26(35):5256-5271. doi:
      10.3748/wjg.v26.i35.5256.


PMID- 32994625
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201218
IS  - 1175-8716 (Electronic)
IS  - 0028-8446 (Linking)
VI  - 133
IP  - 1522
DP  - 2020 Sep 25
TI  - Management of personal protective equipment in New Zealand during the COVID-19
      pandemic: report from the Auditor-General.
PG  - 144-148
AB  - In June 2020 the Office of the Auditor-General released its report on the
      management of personal protective equipment (PPE) in New Zealand during the
      COVID-19 pandemic. The report raises three issues of ethical concern: inadequate 
      stock, inequity and complacency. Acting on the report's recommendations is a
      critical step in strengthening New Zealand's preparedness for future public
      health crises.
FAU - Fenton, Elizabeth
AU  - Fenton E
AD  - Bioethics Centre, University of Otago, Dunedin.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - New Zealand
TA  - N Z Med J
JT  - The New Zealand medical journal
JID - 0401067
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control/transmission
MH  - Humans
MH  - Infection Control/*instrumentation
MH  - Infectious Disease Transmission, Patient-to-Professional/*prevention & control
MH  - New Zealand
MH  - Pandemics/*prevention & control
MH  - Personal Protective Equipment/*supply & distribution
MH  - Pneumonia, Viral/epidemiology/*prevention & control/transmission
MH  - SARS-CoV-2
COIS- Nil.
EDAT- 2020/10/01 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/09/30 06:12
PHST- 2020/09/30 06:12 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
PST - epublish
SO  - N Z Med J. 2020 Sep 25;133(1522):144-148.


PMID- 32994272
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 69
IP  - 12
DP  - 2020 Dec
TI  - The KINGS Ins2 (+/G32S) Mouse: A Novel Model of beta-Cell Endoplasmic Reticulum
      Stress and Human Diabetes.
PG  - 2667-2677
LID - 10.2337/db20-0570 [doi]
AB  - Animal models are important tools in diabetes research because ethical and
      logistical constraints limit access to human tissue. beta-Cell dysfunction is a
      common contributor to the pathogenesis of most types of diabetes. Spontaneous
      hyperglycemia was developed in a colony of C57BL/6J mice at King's College London
      (KCL). Sequencing identified a mutation in the Ins2 gene, causing a
      glycine-to-serine substitution at position 32 on the B chain of the preproinsulin
      2 molecule. Mice with the Ins2 (+/G32S) mutation were named KCL Ins2 G32S (KINGS)
      mice. The same mutation in humans (rs80356664) causes dominantly inherited
      neonatal diabetes. Mice were characterized, and beta-cell function was
      investigated. Male mice became overtly diabetic at approximately 5 weeks of age, 
      whereas female mice had only slightly elevated nonfasting glycemia. Islets showed
      decreased insulin content and impaired glucose-induced insulin secretion, which
      was more severe in males. Transmission electron microscopy and studies of gene
      and protein expression showed beta-cell endoplasmic reticulum (ER) stress in both
      sexes. Despite this, beta-cell numbers were only slightly reduced in older
      animals. In conclusion, the KINGS mouse is a novel model of a human form of
      diabetes that may be useful to study beta-cell responses to ER stress.
CI  - (c) 2020 by the American Diabetes Association.
FAU - Austin, Amazon L F
AU  - Austin ALF
AD  - Department of Diabetes, School of Life Course Sciences, King's College London,
      London, U.K.
FAU - Daniels Gatward, Lydia F
AU  - Daniels Gatward LF
AD  - Department of Diabetes, School of Life Course Sciences, King's College London,
      London, U.K.
FAU - Cnop, Miriam
AU  - Cnop M
AD  - ULB Center for Diabetes Research, Universite Libre de Bruxelles, Brussels,
      Belgium.
AD  - Division of Endocrinology, ULB Erasmus Hospital, Universite Libre de Bruxelles,
      Brussels, Belgium.
FAU - Santos, Gabriel
AU  - Santos G
AUID- ORCID: 0000-0002-5112-1692
AD  - Department of Diabetes, School of Life Course Sciences, King's College London,
      London, U.K.
FAU - Andersson, David
AU  - Andersson D
AD  - Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology, and
      Neuroscience, King's College London, London, U.K.
FAU - Sharp, Sally
AU  - Sharp S
AUID- ORCID: 0000-0001-7451-8548
AD  - Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology, and
      Neuroscience, King's College London, London, U.K.
FAU - Gentry, Clive
AU  - Gentry C
AD  - Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology, and
      Neuroscience, King's College London, London, U.K.
FAU - Bevan, Stuart
AU  - Bevan S
AD  - Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology, and
      Neuroscience, King's College London, London, U.K.
FAU - Jones, Peter M
AU  - Jones PM
AD  - Department of Diabetes, School of Life Course Sciences, King's College London,
      London, U.K.
FAU - King, Aileen J F
AU  - King AJF
AUID- ORCID: 0000-0001-5759-7985
AD  - Department of Diabetes, School of Life Course Sciences, King's College London,
      London, U.K. aileen.king@kcl.ac.uk.
LA  - eng
SI  - figshare/10.2337/figshare.12990821
GR  - MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Insulin)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus/*genetics
MH  - *Disease Models, Animal
MH  - Ecosystem
MH  - Endoplasmic Reticulum Stress/*physiology
MH  - Female
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/blood
MH  - Insulin-Secreting Cells/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Mutation
MH  - Polymorphism, Single Nucleotide
PMC - PMC7679781
EDAT- 2020/10/01 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/05/26 00:00 [received]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/09/30 06:06 [entrez]
AID - db20-0570 [pii]
AID - 10.2337/db20-0570 [doi]
PST - ppublish
SO  - Diabetes. 2020 Dec;69(12):2667-2677. doi: 10.2337/db20-0570. Epub 2020 Sep 29.


PMID- 32994260
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Study protocol for the COPE study: COVID-19 in Older PEople: the influence of
      frailty and multimorbidity on survival. A multicentre, European observational
      study.
PG  - e040569
LID - 10.1136/bmjopen-2020-040569 [doi]
AB  - INTRODUCTION: This protocol describes an observational study which set out to
      assess whether frailty and/or multimorbidity correlates with short-term and
      medium-term outcomes in patients diagnosed with COVID-19 in a European,
      multicentre setting. METHODS AND ANALYSIS: Over a 3-month period we aim to
      recruit a minimum of 500 patients across 10 hospital sites, collecting baseline
      data including: patient demographics; presence of comorbidities; relevant blood
      tests on admission; prescription of ACE inhibitors/angiotensin receptor
      blockers/non-steroidal anti-inflammatory drugs/immunosuppressants; smoking
      status; Clinical Frailty Score (CFS); length of hospital stay; mortality and
      readmission. All patients receiving inpatient hospital care >18 years who receive
      a diagnosis of COVID-19 are eligible for inclusion. Long-term follow-up at 6 and 
      12 months is planned. This will assess frailty, quality of life and medical
      complications.Our primary analysis will be short-term and long-term mortality by 
      CFS, adjusted for age (18-64, 65-80 and >80) and gender. We will carry out a
      secondary analysis of the primary outcome by including additional clinical
      mediators which are determined statistically important using a likelihood ratio
      test. All analyses will be presented as crude and adjusted HR and OR with
      associated 95% CIs and p values. ETHICS AND DISSEMINATION: This study has been
      registered, reviewed and approved by the following: Health Research Authority
      (20/HRA1898); Ethics Committee of Hospital Policlinico Modena, Italy
      (369/2020/OSS/AOUMO); Health and Care Research Permissions Service, Wales; and
      NHS Research Scotland Permissions Co-ordinating Centre, Scotland. All
      participating units obtained approval from their local Research and Development
      department consistent with the guidance from their relevant national
      organisation.Data will be reported as a whole cohort. This project will be
      submitted for presentation at a national or international surgical and geriatric 
      conference. Manuscript(s) will be prepared following the close of the project.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Price, Angeline
AU  - Price A
AUID- ORCID: 0000-0002-4674-270X
AD  - Ageing and Complex Medicine, Salford Royal NHS Trust, Salford, UK
      angeline.price@srft.nhs.uk.
FAU - Barlow-Pay, Fenella
AU  - Barlow-Pay F
AD  - Department of Anaesthetics, Royal Alexandra Hospital, Paisley, Renfrewshire, UK.
FAU - Duffy, Siobhan
AU  - Duffy S
AD  - General Surgery, Royal Alexandra Hospital, Paisley, Renfrewshire, UK.
FAU - Pearce, Lyndsay
AU  - Pearce L
AD  - General Surgery, Salford Royal NHS Foundation Trust, Salford, UK.
FAU - Vilches-Moraga, Arturo
AU  - Vilches-Moraga A
AD  - Ageing and Complex Medicine, Salford Royal NHS Trust, Salford, UK.
FAU - Moug, Susan
AU  - Moug S
AD  - General Surgery, Royal Alexandra Hospital, Paisley, Renfrewshire, UK.
AD  - University of Glasgow, Glasgow, UK.
FAU - Quinn, Terry
AU  - Quinn T
AD  - Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
FAU - Stechman, Michael
AU  - Stechman M
AD  - General Surgery, University Hospital of Wales, Cardiff, UK.
FAU - Braude, Philip
AU  - Braude P
AD  - Medicine for Older People, North Bristol NHS Trust, Westbury on Trym, Bristol,
      UK.
FAU - Mitchell, Emma
AU  - Mitchell E
AD  - Medicine for Older People, North Bristol NHS Trust, Westbury on Trym, Bristol,
      UK.
FAU - Myint, Phyo Kyaw
AU  - Myint PK
AUID- ORCID: 0000-0003-3852-6158
AD  - University of Aberdeen, Aberdeen, UK.
FAU - Verduri, Alessia
AU  - Verduri A
AD  - Hospital Policlinico Modena, Modena, Italy.
FAU - McCarthy, Kathryn
AU  - McCarthy K
AD  - General Surgery, North Bristol NHS Trust, Bristol, United Kingdom.
FAU - Carter, Ben
AU  - Carter B
AD  - Biostatistics and Health Informatics, King's College London, London, UK.
AD  - King's College London, London, UK.
FAU - Hewitt, Jonathan
AU  - Hewitt J
AUID- ORCID: 0000-0002-7924-1792
AD  - Geriatric Medicine, Cardiff University, Cardiff, UK.
CN  - COPE Study Collaborators
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/diagnosis/mortality/therapy
MH  - Correlation of Data
MH  - Europe/epidemiology
MH  - Female
MH  - *Frail Elderly/psychology/statistics & numerical data
MH  - *Frailty/diagnosis/epidemiology
MH  - Geriatric Assessment/methods
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Multicenter Studies as Topic
MH  - *Multimorbidity
MH  - Observational Studies as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral/diagnosis/mortality/therapy
MH  - Public Health/*methods
MH  - *Quality of Life
MH  - SARS-CoV-2
MH  - Survival Analysis
PMC - PMC7526029
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
IR  - Davey C
FIR - Davey, Charlotte
IR  - Jones S
FIR - Jones, Sheila
IR  - Lunstone K
FIR - Lunstone, Kiah
IR  - Cavenagh A
FIR - Cavenagh, Alice
IR  - Silver C
FIR - Silver, Charlotte
IR  - Telford T
FIR - Telford, Thomas
IR  - Simmons R
FIR - Simmons, Rebecca
IR  - Singh S
FIR - Singh, Sandeep
IR  - Paxton D
FIR - Paxton, Dolcie
IR  - Rickard F
FIR - Rickard, Francis
IR  - Holloway M
FIR - Holloway, Mark
IR  - Hesford J
FIR - Hesford, James
IR  - Jichi T
FIR - Jichi, Tarik
IR  - Galbraith N
FIR - Galbraith, Norman
IR  - Edwards J
FIR - Edwards, Jenny
IR  - Bhatti E
FIR - Bhatti, Emma
IR  - Bisset C
FIR - Bisset, Carly
IR  - Alexander R
FIR - Alexander, Ross
IR  - Ingham A
FIR - Ingham, Abigail
IR  - Short R
FIR - Short, Roxanna
IR  - McGovern A
FIR - McGovern, Aine
IR  - Collins J
FIR - Collins, Jemima
IR  - Bruce E
FIR - Bruce, Eilidh
IR  - Einarsson A
FIR - Einarsson, Alice
IR  - Clini E
FIR - Clini, Enrico
IR  - Guaraldi G
FIR - Guaraldi, Giovanni
IR  - Garcia M
FIR - Garcia, Madeline
IR  - Sangani S
FIR - Sangani, Shefali
IR  - Kneen T
FIR - Kneen, Thomas
IR  - Lee T
FIR - Lee, Thomas
IR  - Kyriakopoulos G
FIR - Kyriakopoulos, George
IR  - Thomas M
FIR - Thomas, Michael
IR  - Tan D
FIR - Tan, Denise
EDAT- 2020/10/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - bmjopen-2020-040569 [pii]
AID - 10.1136/bmjopen-2020-040569 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e040569. doi: 10.1136/bmjopen-2020-040569.


PMID- 32994259
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Serial measurements in COVID-19-induced acute respiratory disease to unravel
      heterogeneity of the disease course: design of the Maastricht Intensive Care
      COVID cohort (MaastrICCht).
PG  - e040175
LID - 10.1136/bmjopen-2020-040175 [doi]
AB  - INTRODUCTION: The course of the disease in SARS-CoV-2 infection in mechanically
      ventilated patients is unknown. To unravel the clinical heterogeneity of the
      SARS-CoV-2 infection in these patients, we designed the prospective observational
      Maastricht Intensive Care COVID cohort (MaastrICCht). We incorporated serial
      measurements that harbour aetiological, diagnostic and predictive information.
      The study aims to investigate the heterogeneity of the natural course of
      critically ill patients with a SARS-CoV-2 infection. METHODS AND ANALYSIS:
      Mechanically ventilated patients admitted to the intensive care with a SARS-CoV-2
      infection will be included. We will collect clinical variables, vital parameters,
      laboratory variables, mechanical ventilator settings, chest electrical impedance 
      tomography, ECGs, echocardiography as well as other imaging modalities to assess 
      heterogeneity of the course of a SARS-CoV-2 infection in critically ill patients.
      The MaastrICCht is also designed to foster various other studies and registries
      and intends to create an open-source database for investigators. Therefore, a
      major part of the data collection is aligned with an existing national intensive 
      care data registry and two international COVID-19 data collection initiatives.
      Additionally, we create a flexible design, so that additional measures can be
      added during the ongoing study based on new knowledge obtained from the rapidly
      growing body of evidence. The spread of the COVID-19 pandemic requires the swift 
      implementation of observational research to unravel heterogeneity of the natural 
      course of the disease of SARS-CoV-2 infection in mechanically ventilated
      patients. Our study design is expected to enhance aetiological, diagnostic and
      prognostic understanding of the disease. This paper describes the design of the
      MaastrICCht. ETHICS AND DISSEMINATION: Ethical approval has been obtained from
      the medical ethics committee (Medisch Ethische Toetsingscommissie 2020-1565/3 00 
      523) of the Maastricht University Medical Centre+ (Maastricht UMC+), which will
      be performed based on the Declaration of Helsinki. During the pandemic, the board
      of directors of Maastricht UMC+ adopted a policy to inform patients and ask their
      consent to use the collected data and to store serum samples for COVID-19
      research purposes. All study documentation will be stored securely for fifteen
      years after recruitment of the last patient. The results will be published in
      peer-reviewed academic journals, with a preference for open access journals,
      while particularly considering deposition of the manuscripts on a preprint server
      early. TRIAL REGISTRATION NUMBER: The Netherlands Trial Register (NL8613).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tas, Jeanette
AU  - Tas J
AUID- ORCID: 0000-0002-8914-0960
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - School for Mental Health and Neuroscience (MHeNS), Maastricht University,
      Maastricht, The Netherlands.
FAU - van Gassel, Rob J J
AU  - van Gassel RJJ
AUID- ORCID: 0000-0002-0780-2052
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - School of Nutrition and Translational Research in Metabolism, Maastricht
      University, Maastricht, The Netherlands.
AD  - Department of Surgery, Maastricht University Medical Center+, Maastricht, The
      Netherlands.
FAU - Heines, Serge J H
AU  - Heines SJH
AUID- ORCID: 0000-0001-7672-4177
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Mulder, Mark M G
AU  - Mulder MMG
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Heijnen, Nanon F L
AU  - Heijnen NFL
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Acampo-de Jong, Melanie J
AU  - Acampo-de Jong MJ
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Bels, Julia L M
AU  - Bels JLM
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Bennis, Frank C
AU  - Bennis FC
AUID- ORCID: 0000-0002-6233-9101
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Koelmann, Marcel
AU  - Koelmann M
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Groven, Rald V M
AU  - Groven RVM
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Donkers, Moniek A
AU  - Donkers MA
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - van Rosmalen, Frank
AU  - van Rosmalen F
AUID- ORCID: 0000-0002-9522-3711
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Department of Biomedical Engineering, Maastricht University, Maastricht, The
      Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, The Netherlands.
FAU - Hermans, Ben J M
AU  - Hermans BJM
AUID- ORCID: 0000-0001-7780-4427
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, The Netherlands.
FAU - Meex, Steven Jr
AU  - Meex SJ
AD  - Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht
      University Medical Center+, Maastricht, The Netherlands.
FAU - Mingels, Alma
AU  - Mingels A
AD  - Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht
      University Medical Center+, Maastricht, The Netherlands.
FAU - Bekers, Otto
AU  - Bekers O
AD  - Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht
      University Medical Center+, Maastricht, The Netherlands.
FAU - Savelkoul, Paul
AU  - Savelkoul P
AD  - Department of Medical Microbiology, Maastricht University Medical Centre+,
      Maastricht, The Netherlands.
FAU - Oude Lashof, Astrid M L
AU  - Oude Lashof AML
AD  - Department of Medical Microbiology, Maastricht University Medical Centre+,
      Maastricht, The Netherlands.
FAU - Wildberger, Joachim
AU  - Wildberger J
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, The Netherlands.
AD  - Department of Radiology, Maastricht University Medical Centre+, Maastricht, The
      Netherlands.
FAU - Tijssen, Fabian H
AU  - Tijssen FH
AD  - Department of Anesthesiology, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Buhre, Wolfgang
AU  - Buhre W
AD  - Department of Anesthesiology, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Sels, Jan-Willem E M
AU  - Sels JEM
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Department of Cardiology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
FAU - Ghossein-Doha, Chahinda
AU  - Ghossein-Doha C
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Department of Cardiology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
FAU - Driessen, Rob G H
AU  - Driessen RGH
AUID- ORCID: 0000-0002-8287-6166
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Department of Cardiology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
FAU - Kubben, Pieter L
AU  - Kubben PL
AUID- ORCID: 0000-0002-8059-523X
AD  - Department of Neurosurgery, Maastricht University Medical Centre+, Maastricht,
      The Netherlands.
FAU - Janssen, Marcus L F
AU  - Janssen MLF
AD  - Department of Neurology, Maastricht University Medical Centre+, Maastricht, The
      Netherlands.
FAU - Nicolaes, Gerry A F
AU  - Nicolaes GAF
AD  - Department of Biochemistry, Maastricht University Medical Center+, Maastricht,
      The Netherlands.
FAU - Strauch, Ulrich
AU  - Strauch U
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Geyik, Zafer
AU  - Geyik Z
AUID- ORCID: 0000-0002-6250-3629
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Department of Cardiology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
FAU - Delnoij, Thijs S R
AU  - Delnoij TSR
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Department of Cardiology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
FAU - Walraven, Kim H M
AU  - Walraven KHM
AD  - Department of Pulmonology, Maastricht University Medical Center+, Maastricht, The
      Netherlands.
FAU - Stehouwer, Coen DA
AU  - Stehouwer CD
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, The Netherlands.
AD  - Department of Internal Medicine, Maastricht University Medical Center+,
      Maastricht, The Netherlands.
FAU - Verbunt, Jeanine A M C F
AU  - Verbunt JAMCF
AD  - Department of Rehabilitation Medicine, Maastricht University Medical Centre+,
      Maastricht, The Netherlands.
FAU - Van Mook, Walther N K A
AU  - Van Mook WNKA
AUID- ORCID: 0000-0003-2398-8878
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - van Santen, Susanne
AU  - van Santen S
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Schnabel, Ronny M
AU  - Schnabel RM
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - Aries, Marcel J H
AU  - Aries MJH
AUID- ORCID: 0000-0002-2155-688X
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - School for Mental Health and Neuroscience (MHeNS), Maastricht University,
      Maastricht, The Netherlands.
FAU - van de Poll, Marcel C G
AU  - van de Poll MCG
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - School of Nutrition and Translational Research in Metabolism, Maastricht
      University, Maastricht, The Netherlands.
AD  - Department of Surgery, Maastricht University Medical Center+, Maastricht, The
      Netherlands.
FAU - Bergmans, Dennis
AU  - Bergmans D
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
FAU - van der Horst, Iwan C C
AU  - van der Horst ICC
AUID- ORCID: 0000-0003-3891-8522
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, The Netherlands.
FAU - van Kuijk, Sander
AU  - van Kuijk S
AUID- ORCID: 0000-0003-2796-729X
AD  - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht
      University Medical Center+, Maastricht, The Netherlands.
FAU - van Bussel, Bas C T
AU  - van Bussel BCT
AUID- ORCID: 0000-0003-1621-7848
AD  - Department of Intensive Care, Maastricht University Medical Center+, Maastricht, 
      The Netherlands bas.van.bussel@mumc.nl.
AD  - Care and Public Health Research Institute (CAPHRI), Maastricht University,
      Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Cohort Studies
MH  - *Coronavirus Infections/epidemiology/physiopathology/therapy
MH  - Critical Care/*methods
MH  - *Critical Illness/epidemiology/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging/*methods
MH  - Netherlands/epidemiology
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/physiopathology/therapy
MH  - Prognosis
MH  - Registries/statistics & numerical data
MH  - *Respiration, Artificial/methods/statistics & numerical data
MH  - SARS-CoV-2
MH  - Severity of Illness Index
PMC - PMC7526030
OTO - NOTNLM
OT  - *epidemiology
OT  - *intensive & critical care
OT  - *respiratory infections
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - bmjopen-2020-040175 [pii]
AID - 10.1136/bmjopen-2020-040175 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e040175. doi: 10.1136/bmjopen-2020-040175.


PMID- 32994258
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Lived experiences of social support in Paralympic swimmers: A protocol for a
      qualitative study.
PG  - e039953
LID - 10.1136/bmjopen-2020-039953 [doi]
AB  - INTRODUCTION: Over the past decade, there has been an increase in awareness of
      and investment into disability sport as a result of the 'Paralympic Movement'.
      The provision of personal and professional support to elite athletes is important
      for the well-being and success of the athlete, with various studies advocating a 
      holistic approach to performance enhancement. However, little is known about
      social support experiences in elite para-swimming. Swimming is a popular
      Paralympic sport and the British para swimmers have been very successful in
      recent years, most recently winning 47 medals at Rio 2016. This study will be the
      first to explore the lived experiences of British Paralympic swimmers with
      respect to the personal and professional support available, perceived use of the 
      support network and the influence it has on well-being and performance. METHODS
      AND ANALYSIS: A hermeneutic phenomenological study will be undertaken using a
      subtle-realist paradigmatic view. A purposive sample of British Paralympic
      swimmers will be recruited to enable exploration of social support experiences.
      In-depth semistructured interviews will explore participants' experiences of
      being an elite para-athlete, their support network, the social support available 
      and how they perceive it relates to their well-being and performance. Strategies 
      including reflexivity and member checking will be used to ensure trustworthiness.
      Data will be analysed following the Framework Method; a seven-stage process used 
      for qualitative data analysis. ETHICS AND DISSEMINATION: This study has ethical
      approval (ERN_20-0344) granted by the University of Birmingham in April 2020. The
      findings of this study will be published in a peer-reviewed journal and
      disseminated to key stakeholders in elite para-sport to inform support services
      and improve athlete well-being and performance.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aitchison, Beth
AU  - Aitchison B
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, UK.
FAU - Soundy, Andrew
AU  - Soundy A
AUID- ORCID: 0000-0002-5118-5872
AD  - School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, 
      Birmingham, UK.
FAU - Martin, Paul
AU  - Martin P
AD  - The English Institute of Sport, London, London, UK.
FAU - Rushton, Alison
AU  - Rushton A
AUID- ORCID: 0000-0001-8114-7669
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabiliation Sciences, University of Birmingham, Birmingham, UK.
FAU - Heneghan, Nicola R
AU  - Heneghan NR
AUID- ORCID: 0000-0001-7599-3674
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabiliation Sciences, University of Birmingham, Birmingham, UK
      n.heneghan@bham.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Athletes
MH  - *Disabled Persons
MH  - Humans
MH  - Qualitative Research
MH  - Social Support
MH  - Swimming
PMC - PMC7526310
OTO - NOTNLM
OT  - *rehabilitation medicine
OT  - *social medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039953 [pii]
AID - 10.1136/bmjopen-2020-039953 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e039953. doi: 10.1136/bmjopen-2020-039953.


PMID- 32994255
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Prospective cohort protocol examining the perioperative indicators for
      complications and early mortality following hip fracture surgery in the frail
      patient.
PG  - e038988
LID - 10.1136/bmjopen-2020-038988 [doi]
AB  - INTRODUCTION: The primary aim is to validate earlier suggested risk factors and
      to find new associated risk factors for (30-day) mortality after a hip fracture
      in the frail population. The secondary aim is to determine the factors associated
      with perioperative complications. At last we want to develop and validate a more 
      specific 30-day mortality prediction tool compared with the Nottingham Hip
      Fracture Score. The 30-day mortality prediction can help inform surgical risk and
      guide shared decision-making among patients, family and physicians. METHODS AND
      ANALYSIS: The study is designed as a prospective multicentre cohort study within 
      the area of Rotterdam, the Netherlands starting from January 2018. All patients
      over 65 years of age, with an acute proximal hip fracture, are included.
      Treatment of patients will be by standard practice of care using the latest
      national and international guidelines. Inclusion will be continued at least until
      January 2021 and including at least 2500 patients. In this large cohort we hope
      to have sufficient strength and quality to identify risk factors of 30-day
      mortality and to compare them to known risk factors in literature. Moreover, we
      plan to develop and validate a 30-day mortality prediction tool, which identifies
      patients with a high probability of 30-day mortality. ETHICS AND DISSEMINATION:
      Ethical approval for this protocol was given by the Ethics Committee of the
      Maasstad Hospital (TWOR). Patient data are stored anonymously using the Castor
      data management system. No external funding is used for this study. Results will 
      be published in peer-reviewed publications and at international conferences.
      TRIAL REGISTRATION NUMBER: NL8313.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Jong, Louis
AU  - de Jong L
AUID- ORCID: 0000-0002-4085-6861
AD  - Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands
      dejonglouis@hotmail.com.
FAU - van Rijckevorsel, Veronique
AU  - van Rijckevorsel V
AD  - Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
FAU - Klem, Taco M A L
AU  - Klem TMAL
AD  - Department of Surgery, Franciscus Gasthuis en Vlietland Hospital, Rotterdam, The 
      Netherlands.
FAU - Kuijper, Martijn
AU  - Kuijper M
AD  - Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
FAU - Roukema, Gert R
AU  - Roukema GR
AD  - Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - *Frail Elderly
MH  - *Hip Fractures/surgery
MH  - Humans
MH  - Netherlands/epidemiology
MH  - Postoperative Complications
MH  - Prospective Studies
PMC - PMC7526269
OTO - NOTNLM
OT  - *delirium & cognitive disorders
OT  - *epidemiology
OT  - *hip
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038988 [pii]
AID - 10.1136/bmjopen-2020-038988 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e038988. doi: 10.1136/bmjopen-2020-038988.


PMID- 32994254
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Comparing rates and characteristics of emergency department presentations related
      to pharmaceutical opioid poisoning in Australia: a study protocol for a
      retrospective observational study.
PG  - e038979
LID - 10.1136/bmjopen-2020-038979 [doi]
AB  - INTRODUCTION AND AIMS: Pharmaceutical opioids are an important contributor to the
      global 'opioid crisis', and are implicated in 70% of Australia's opioid-related
      mortality. However, there have been few studies which consider the relative
      contribution of different pharmaceutical opioids to harm.We aim to compare
      commonly used pharmaceutical opioids in terms of (1) rates of harm, and (2)
      demographic and clinical characteristics associated with that harm. METHOD AND
      ANALYSIS: Observational study of emergency department presentations for non-fatal
      poisoning related to pharmaceutical opioid use. Data from 2009 to 2019 will be
      extracted from the Victorian Emergency Minimum Dataset which contains data from
      public hospitals with dedicated emergency departments in Victoria, Australia's
      second most populous state. A combination of free-text and International
      Classification of Diseases 10th Revision codes will be used to identify relevant 
      cases, with manual screening of each case to confirm relevance. We will calculate
      supply-adjusted rates of presentations using Poisson regression for all
      pharmaceutical opioid cases identified, separately for nine commonly prescribed
      pharmaceutical opioids (buprenorphine, codeine, fentanyl, methadone, morphine,
      oxycodone, oxycodone-naloxone, tapentadol, tramadol), and for a multiple opioid
      category. We will use multinomial logistic regression to compare demographic and 
      clinical characteristics, such as triage category, across opioid types. ETHICS
      AND DISSEMINATION: This work is conducted under approval 21427 from the Monash
      University Human Research Ethics Committee for ongoing injury surveillance. As
      per conditions of approval, cells of <5 will not be reported, though zeroes will 
      be preserved. We will present project findings in a peer-reviewed journal article
      as well as at relevant scientific conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lam, Tina
AU  - Lam T
AD  - Monash Addiction Research Centre, Eastern Health Clinical School, Monash
      University, Frankston, Victoria, Australia.
FAU - Hayman, Jane
AU  - Hayman J
AD  - Monash Addiction Research Centre, Eastern Health Clinical School, Monash
      University, Frankston, Victoria, Australia.
AD  - Victorian Injury Surveillance Unit, Monash University Accident Research Centre,
      Monash University, Clayton, Victoria, Australia.
FAU - Berecki-Gisolf, Janneke
AU  - Berecki-Gisolf J
AD  - Monash Addiction Research Centre, Eastern Health Clinical School, Monash
      University, Frankston, Victoria, Australia.
AD  - Victorian Injury Surveillance Unit, Monash University Accident Research Centre,
      Monash University, Clayton, Victoria, Australia.
FAU - Sanfilippo, Paul
AU  - Sanfilippo P
AD  - Monash Addiction Research Centre, Eastern Health Clinical School, Monash
      University, Frankston, Victoria, Australia.
AD  - Turning Point, Eastern Health Clinical School, Monash University, Richmond,
      Victoria, Australia.
FAU - Lubman, Dan I
AU  - Lubman DI
AD  - Monash Addiction Research Centre, Eastern Health Clinical School, Monash
      University, Frankston, Victoria, Australia.
AD  - Turning Point, Eastern Health Clinical School, Monash University, Richmond,
      Victoria, Australia.
FAU - Nielsen, Suzanne
AU  - Nielsen S
AUID- ORCID: 0000-0001-5341-1055
AD  - Monash Addiction Research Centre, Eastern Health Clinical School, Monash
      University, Frankston, Victoria, Australia suzanne.nielsen@monash.edu.
AD  - Turning Point, Eastern Health Clinical School, Monash University, Richmond,
      Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Pharmaceutical Preparations)
RN  - CD35PMG570 (Oxycodone)
SB  - IM
MH  - *Analgesics, Opioid
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Observational Studies as Topic
MH  - Oxycodone
MH  - *Pharmaceutical Preparations
MH  - Victoria
PMC - PMC7526272
OTO - NOTNLM
OT  - *epidemiology
OT  - *pain management
OT  - *psychiatry
OT  - *public health
OT  - *substance misuse
OT  - *suicide & self-harm
COIS- Competing interests: In the past 5 years, SN has been an investigator on untied
      education grants from Indivior, unrelated to the current work. SN has provided
      training to health care professionals on identifying and treating codeine
      dependence for which her institution has received payment from Indivior. DIL has 
      received speaking honoraria from the following: Astra Zeneca, Indivior,
      Janssen-Cilag, Lundbeck, Servier and Shire, and has participated on Advisory
      Boards for Indivior and Lundbeck.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038979 [pii]
AID - 10.1136/bmjopen-2020-038979 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e038979. doi: 10.1136/bmjopen-2020-038979.


PMID- 32994252
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Cognitive impairment and psychopathology in out-of-hospital cardiac arrest
      survivors in Denmark: The REVIVAL cohort study protocol.
PG  - e038633
LID - 10.1136/bmjopen-2020-038633 [doi]
AB  - INTRODUCTION: Cognitive impairment and psychopathology caused by brain hypoxia
      and the traumatic impact of critical illness are common in cardiac arrest
      survivors and can lead to negative consequences of everyday life functioning, and
      further impact mental health in relatives. Most studies have dealt with the mere 
      survival rate after cardiac arrest and not with long-term consequences to mental 
      health in cardiac arrest survivors. Importantly, we face a gap in our knowledge
      about suitable screening tools in the early post-arrest phase for long-term risk 
      prediction of mental health problems. This study aims to evaluate the efficacy of
      a novel screening procedure to predict risk of disabling cognitive impairment and
      psychopathology 3 months after cardiac arrest. Furthermore, the study aims to
      evaluate long-term prevalence of psychopathology in relatives. METHODS AND
      ANALYSES: In this multicentre prospective cohort study, out-of-hospital cardiac
      arrest survivors and their relatives will be recruited. The post-arrest screening
      includes the Montreal Cognitive Assessment (MoCA), the Hospital Anxiety and
      Depression Scale (HADS), the Impact of Event Scale-Revised (IES-R) and the Acute 
      Stress Disorder Interview (ASDI) and is conducted during hospitalisation. In a
      subsample of the patients, functional MRI is done, and cortisol determination
      collected. At 3-month follow-up, the primary study outcomes for 200 survivors
      include the Danish Affective Verbal Learning Test-26 (VAMT-26), Delis-Kaplan
      Executive Function System tests (trail making, colour-word interference, word and
      design fluency), Rey's Complex Figure and Letter-number sequencing subtest of
      Wechsler Adult Intelligence Scale-IV, HADS and IES-R. For the relatives, they
      include HADS and IES-R. ETHICS AND DISSEMINATION: The study is approved by the
      local regional Research Ethics Committee (H-18046155) and the Danish Data
      Protection Agency (RH-2017-325, j.no.05961) and follows the latest version of the
      Declaration of Helsinki. The results will be published in peer-reviewed journals 
      and may impact the follow-up of cardiac arrest survivors.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wagner, Mette Kirstine
AU  - Wagner MK
AUID- ORCID: 0000-0001-9461-1416
AD  - Department of Cardiology, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark mette.kirstine.wagner@regionh.dk.
FAU - Berg, Selina Kikkenborg
AU  - Berg SK
AD  - Department of Cardiology, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Hassager, Christian
AU  - Hassager C
AD  - Department of Cardiology, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Armand, Sophia
AU  - Armand S
AD  - Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark.
FAU - Moller, Jacob Eifer
AU  - Moller JE
AD  - Department of Cardiology, Odense University Hospital, Odense, Denmark.
FAU - Ekholm, Ola
AU  - Ekholm O
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
FAU - Rasmussen, Trine Bernholdt
AU  - Rasmussen TB
AD  - Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark.
FAU - Fisher, Patrick MacDonald
AU  - Fisher PM
AD  - Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark.
AD  - Center for Integrated Molecular Brain Imaging, Copenhagen University Hospital,
      Rigshospitalet, Copenhagen, Denmark.
FAU - Knudsen, Gitte Moos
AU  - Knudsen GM
AD  - Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark.
AD  - Center for Integrated Molecular Brain Imaging, Copenhagen University Hospital,
      Rigshospitalet, Copenhagen, Denmark.
FAU - Stenbaek, Dea Siggaard
AU  - Stenbaek DS
AD  - Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet,
      Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Cognitive Dysfunction/diagnosis/epidemiology/etiology
MH  - Cohort Studies
MH  - Denmark/epidemiology
MH  - Humans
MH  - *Out-of-Hospital Cardiac Arrest
MH  - Prospective Studies
MH  - Survivors
PMC - PMC7526293
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *cardiology
OT  - *depression and mood disorders
OT  - *magnetic resonance imaging
OT  - *mental health
OT  - *neurology
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038633 [pii]
AID - 10.1136/bmjopen-2020-038633 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e038633. doi: 10.1136/bmjopen-2020-038633.


PMID- 32994251
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Evaluation of the efficacy of low concentration fluoride gel using custom trays
      to prevent radiation-related dental caries in patients with head and neck cancer:
      protocol for a randomised controlled phase III trial (FluCar study).
PG  - e038606
LID - 10.1136/bmjopen-2020-038606 [doi]
AB  - INTRODUCTION: The present study is a randomised, multicentre, open-label, phase
      III study, to evaluate the efficacy of low concentration of fluoride gel, applied
      using custom trays, in preventing radiation-related dental caries in patients
      with head and neck cancer who have undergone or are undergoing radiotherapy.
      METHODS AND ANALYSIS: Patients will be randomised into fluoride and control
      groups (1:1 ratio). In the fluoride group, patients will wear custom trays loaded
      with 0.145% fluoride gel after brushing every night while sleeping. In the
      control group, patients will receive oral hygiene instructions as usual. Patients
      in both the groups will be followed up every 3 months for 1 year. The primary
      endpoint is the incidence of newly developed dental caries. Target accrual is 80 
      patients with a two-sided type I error rate of 5% and 80% power to detect 80%
      risk reduction. ETHICS AND DISSEMINATION: This study was approved by the Clinical
      Research Review Board in Nagasaki University The protocol of this study was
      registered at Japan Registry of Clinical Trials (jRCT) and University hospital
      Medical Information Network Clinical Trials Registry (UMIN). The datasets
      generated during the current study will be available from the corresponding
      author on reasonable request. TRIAL REGISTRATION NUMBERS: jRCTs 072190039 and
      UMIN000041426.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Soutome, Sakiko
AU  - Soutome S
AD  - Department of Oral Health, Nagasaki University, Nagasaki, Japan.
FAU - Yanamoto, Souichi
AU  - Yanamoto S
AUID- ORCID: 0000-0003-2372-8347
AD  - Department of Clinical Oral Oncology, Nagasaki University, Nagasaki, Japan
      syana@nagasaki-u.ac.jp.
FAU - Murata, Maho
AU  - Murata M
AD  - Department of Clinical Oral Oncology, Nagasaki University, Nagasaki, Japan.
FAU - Kawashita, Yumiko
AU  - Kawashita Y
AD  - Department of Oral Health, Nagasaki University, Nagasaki, Japan.
FAU - Yoshimatsu, Masako
AU  - Yoshimatsu M
AD  - Oral Care Center, Nagasaki Daigaku Byoin, Nagasaki, Japan.
FAU - Funahara, Madoka
AU  - Funahara M
AD  - School of Oral Health, Kyushu Shika Daigaku, Kitakyushu, Japan.
FAU - Umeda, Masahiro
AU  - Umeda M
AD  - Department of Clinical Oral Oncology, Nagasaki University, Nagasaki, Japan.
FAU - Saito, Toshiyuki
AU  - Saito T
AD  - Department of Oral Health, Nagasaki University, Nagasaki, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - Q80VPU408O (Fluorides)
SB  - IM
MH  - Clinical Trials, Phase III as Topic
MH  - *Dental Caries/prevention & control
MH  - Fluorides
MH  - *Head and Neck Neoplasms/radiotherapy
MH  - Humans
MH  - Japan
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
PMC - PMC7526278
OTO - NOTNLM
OT  - *head & neck tumours
OT  - *oral medicine
OT  - *radiotherapy
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038606 [pii]
AID - 10.1136/bmjopen-2020-038606 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e038606. doi: 10.1136/bmjopen-2020-038606.


PMID- 32994248
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Longitudinal exploration of cancer-related cognitive impairment in patients with 
      newly diagnosed aggressive lymphoma: protocol for a feasibility study.
PG  - e038312
LID - 10.1136/bmjopen-2020-038312 [doi]
AB  - INTRODUCTION: Cancer-related cognitive impairment (CRCI) is a distressing and
      disabling side-effect of cancer treatments affecting up to 75% of patients. For
      some patients, their cognitive impairment may be transient, but for a subgroup,
      these symptoms can be long-standing and have a major impact on the quality of
      life. This paper describes the protocol for a study: (1) to assess the
      feasibility of collecting longitudinal data on cognition via self-report,
      neuropsychological testing, peripheral markers of inflammation and neuroimaging
      and (2) to explore and describe patterns of cancer-related cognitive impairment
      over the course of treatment and recovery in patients with newly diagnosed,
      aggressive lymphoma undergoing standard therapy with curative intent. METHODS AND
      ANALYSIS: This is a prospective, longitudinal, feasibility study in which 30
      newly diagnosed, treatment-naive patients with aggressive lymphoma will be
      recruited over a 12-month period. Patients will complete comprehensive
      assessments at three time points: baseline (time 1, pre-treatment) and two
      post-baseline follow-up assessments (time 2, mid-treatment and time 3, 6-8 weeks 
      post-treatment completion). All patients will be assessed for self-reported
      cognitive difficulties and objective cognitive function using Stroop Colour and
      Word, Trail Making Test Part A and B, Hopkins Verbal Learning Test-Revised,
      Controlled Oral Word Association and Digit Span. Blood cell-based inflammatory
      markers and neuroimaging including a positron emission tomography (PET) with
      (18)F-labelled fluoro-2-deoxyglucose ((18)F-FDG) and CT ((18)F-FDG-PET/CT) and a 
      MRI will explore potential inflammatory and neuroanatomical or functional
      mechanisms and biomarkers related to CRCI. The primary intent of analysis will be
      to assess the feasibility of collecting longitudinal data on cognition using
      subjective reports and objective tasks from patients during treatment and
      recovery for lymphoma. These data will inform the design of a larger-scale
      investigation into the patterns of cognitive change over the course of treatment 
      and recovery, adding to an underexplored area of cancer survivorship research.
      ETHICS AND DISSEMINATION: Ethical approval has been granted by Austin Health
      Human Rights Ethics Committee (HREC) in Victoria Australia. Peer reviewed
      publications and conference presentations will report the findings of this novel 
      study. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry
      (ACTRN12619001649101).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gates, Priscilla
AU  - Gates P
AUID- ORCID: 0000-0002-7978-5802
AD  - Department of Clinical Haematology, Olivia Newton-John Cancer Wellness and
      Research Centre, Austin Health, Melbourne, Victoria, Australia.
AD  - Department of Nursing, Faculty of Medicine, Dentistry & Health Sciences, The
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Gough, Karla
AU  - Gough K
AUID- ORCID: 0000-0003-2819-4217
AD  - Department of Nursing, Faculty of Medicine, Dentistry & Health Sciences, The
      University of Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Cancer Experiences, Peter MacCallum Cancer Centre, Melbourne,
      Victoria, Australia.
FAU - Dhillon, Haryana
AU  - Dhillon H
AUID- ORCID: 0000-0003-4039-5169
AD  - Centre for Medical Psychology & Evidence-based Decision-making, School of
      Psychology, Faculty of Science, The University of Sydney, Sydney, New South
      Wales, Australia haryana.dhillon@sydney.edu.au.
FAU - Wilson, Carlene
AU  - Wilson C
AUID- ORCID: 0000-0002-1883-4690
AD  - Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Melbourne,
      Victoria, Australia.
AD  - School of Psychology and Public Health, LaTrobe University, Melbourne, Victoria, 
      Australia.
FAU - Hawkes, Eliza
AU  - Hawkes E
AUID- ORCID: 0000-0002-0376-2559
AD  - Department of Clinical Haematology, Olivia Newton-John Cancer Wellness and
      Research Centre, Austin Health, Melbourne, Victoria, Australia.
AD  - Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Dore, Vincent
AU  - Dore V
AUID- ORCID: 0000-0002-8051-0558
AD  - Biomedical Imaging, Health & Biosecurity Flagship, The Australian e-Health
      Research Centre, CSIRO Health & Biosecurity, Melbourne, Victoria, Australia.
AD  - Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, 
      Australia.
FAU - Perchyonok, Yuliya
AU  - Perchyonok Y
AUID- ORCID: 0000-0003-3476-8766
AD  - Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Department of Radiology, Austin Health, Melbourne, Victoria, Australia.
FAU - Rowe, Christopher C
AU  - Rowe CC
AUID- ORCID: 0000-0003-3910-2453
AD  - Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria, 
      Australia.
FAU - Walker, Adam K
AU  - Walker AK
AUID- ORCID: 0000-0001-7954-5801
AD  - Laboratory of ImmunoPsychiatry, Neuroscience Research Australia, Sydney, New
      South Wales, Australia.
AD  - School of Psychiatry, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Vardy, Janette L
AU  - Vardy JL
AUID- ORCID: 0000-0002-5739-5790
AD  - Concord Cancer Centre, Concord Repatriation and General Hospital, Concord, New
      South Wales, Australia.
AD  - Concord Clinical School, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - de Ruiter, Michiel
AU  - de Ruiter M
AD  - Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute,
      Amsterdam, The Netherlands.
FAU - Krishnasamy, Meinir
AU  - Krishnasamy M
AUID- ORCID: 0000-0002-3050-4213
AD  - Cancer Nursing Research Group, Department of Nursing/Centre for Cancer Research, 
      School of Health Sciences/University of Melbourne, Faculty of Medicine, Dentistry
      and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
AD  - Academic Nursing Unit, Peter MacCallum Cancer Centre, Melbourne, Victoria,
      Australia.
AD  - Research and Education Nursing, Victorian Comprehensive Cancer Centre, Melbourne,
      Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001649101
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cognitive Dysfunction/diagnosis/etiology
MH  - Feasibility Studies
MH  - Humans
MH  - *Lymphoma/complications
MH  - Positron Emission Tomography Computed Tomography
MH  - Prospective Studies
MH  - Quality of Life
MH  - Victoria
PMC - PMC7526311
OTO - NOTNLM
OT  - *adult neurology
OT  - *delirium & cognitive disorders
OT  - *lymphoma
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038312 [pii]
AID - 10.1136/bmjopen-2020-038312 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e038312. doi: 10.1136/bmjopen-2020-038312.


PMID- 32994245
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Conceptualising cultural safety at an Indigenous-focused midwifery practice in
      Toronto, Canada: qualitative interviews with Indigenous and non-Indigenous
      clients.
PG  - e038168
LID - 10.1136/bmjopen-2020-038168 [doi]
AB  - OBJECTIVE: Cultural safety is an Indigenous concept that can improve how
      healthcare services are delivered to both Indigenous and non-Indigenous peoples
      in Canada. This study explored how Indigenous and non-Indigenous clients at an
      urban, Indigenous-focused midwifery practice in Toronto, Canada (Seventh
      Generation Midwives Toronto, SGMT) conceptualised and experienced culturally safe
      care. DESIGN AND SETTING: Interviews were conducted with former clients of SGMT
      as a part of a larger evaluation of the practice. Participants were purposefully 
      recruited. Interviews were transcribed and analysed thematically using an
      iterative, consensus-based approach and a critical, naturalistic, and
      decolonising lens. PARTICIPANTS: Saturation was reached after 20 interviews (n=9 
      Indigenous participants, n=11 non-Indigenous participants). RESULTS: Three
      domains of cultural safety emerged. Each domain included several themes:
      Relationships and Communication (respect and support for choices; personalised
      and continuous relationships with midwives; and being different from past
      experiences); Sharing Knowledge and Practice (feeling informed about the basics
      of pregnancy, birth, and the postpartum period; and having access to Indigenous
      knowledge and protocols), and Culturally Safe Spaces (feeling at home in
      practice; and having relationships interconnected with the physical space). While
      some ideas were shared across groups, the distinctions between the Indigenous and
      non-Indigenous participants were prominent. CONCLUSION: The Indigenous
      participants conceptualised cultural safety in ways that highlight the survival
      and resurgence of Indigenous values, understandings, and approaches in cities
      like Toronto, and affirm the need for Indigenous midwives. The non-Indigenous
      participants conceptualised cultural safety with both congruence, illuminating
      Black-Indigenous community solidarities in cultural safety, and divergence,
      demonstrating the potential of Indigenous spaces and Indigenous-focused midwifery
      care to also benefit midwifery clients of white European descent. We hope that
      the positive impacts documented here motivate evaluators and healthcare providers
      to work towards a future where 'cultural safety' becomes a standard of care.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Churchill, Mackenzie E
AU  - Churchill ME
AUID- ORCID: 0000-0003-1313-5214
AD  - Well Living House, MAP Centre for Urban Health Solutions (C-UHS), St Michael's
      Hospital, Toronto, Ontario, Canada mackenzie.churchill@gmail.com.
FAU - Smylie, Janet K
AU  - Smylie JK
AD  - Well Living House, MAP Centre for Urban Health Solutions (C-UHS), St Michael's
      Hospital, Toronto, Ontario, Canada.
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Wolfe, Sara H
AU  - Wolfe SH
AD  - Seventh Generation Midwives Toronto (SGMT), Toronto, Ontario, Canada.
FAU - Bourgeois, Cheryllee
AU  - Bourgeois C
AD  - Seventh Generation Midwives Toronto (SGMT), Toronto, Ontario, Canada.
FAU - Moeller, Helle
AU  - Moeller H
AD  - Department of Health Sciences, Lakehead University, Thunder Bay, Ontario, Canada.
FAU - Firestone, Michelle
AU  - Firestone M
AD  - MAP Centre for Urban Health Solutions (C-UHS), St. Michael's Hospital, Toronto,
      Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Female
MH  - Humans
MH  - *Midwifery
MH  - Parturition
MH  - Pregnancy
MH  - Qualitative Research
PMC - PMC7526316
OTO - NOTNLM
OT  - *medical education & training
OT  - *medical ethics
OT  - *obstetrics
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038168 [pii]
AID - 10.1136/bmjopen-2020-038168 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e038168. doi: 10.1136/bmjopen-2020-038168.


PMID- 32994242
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210707
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial
      adaptative platform (REMAP) clinical trial protocol to study interventions to
      improve recovery after surgery in high-risk patients.
PG  - e037690
LID - 10.1136/bmjopen-2020-037690 [doi]
AB  - INTRODUCTION: As the population ages, there is interest in strategies to promote 
      resiliency, especially for frail patients at risk of its complications. The
      physiological stress of surgery in high-risk individuals has been proposed both
      as an important cause of accelerated age-related decline in health and as a model
      testing the effectiveness of strategies to improve resiliency to age-related
      health decline. We describe a randomised, embedded, multifactorial, adaptative
      platform (REMAP) trial to investigate multiple perioperative interventions, the
      first of which is metformin and selected for its anti-inflammatory and
      anti-ageing properties beyond its traditional blood glucose control features.
      METHODS AND ANALYSIS: Within a multihospital, single healthcare system, the Core 
      Protocol for Strategies to Promote ResiliencY (SPRY) will be embedded within both
      the electronic health record (EHR) and the healthcare culture generating a
      continuously self-learning healthcare system. Embedding reduces the
      administrative burden of a traditional trial while accessing and rapidly
      analysing routine patient care EHR data. SPRY-Metformin is a placebo-controlled
      trial and is the first SPRY domain evaluating the effectiveness of three
      metformin dosages across three preoperative durations within a heterogeneous set 
      of major surgical procedures. The primary outcome is 90-day hospital-free days.
      Bayesian posterior probabilities guide interim decision-making with predefined
      rules to determine stopping for futility or superior dosing selection. Using
      response adaptative randomisation, a maximum of 2500 patients allows 77%-92%
      power, detecting >15% primary outcome improvement. Secondary outcomes include
      mortality, readmission and postoperative complications. A subset of patients will
      be selected for substudies evaluating the microbiome, cognition, postoperative
      delirium and strength. ETHICS AND DISSEMINATION: The Core Protocol of SPRY REMAP 
      and associated SPRY-Metformin Domain-Specific Appendix have been ethically
      approved by the Institutional Review Board and are publicly registered. Results
      will be publicly available to healthcare providers, patients and trial
      participants following achieving predetermined platform conclusions. TRIAL
      REGISTRATION NUMBER: NCT03861767.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Reitz, Katherine Moll
AU  - Reitz KM
AUID- ORCID: 0000-0002-9397-321X
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
      reitzkm2@upmc.edu.
FAU - Seymour, Christopher W
AU  - Seymour CW
AD  - Department of Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Vates, Jennifer
AU  - Vates J
AD  - Department of Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Quintana, Melanie
AU  - Quintana M
AD  - Berry Consultants Statistical Innovation, Austin, Texas, USA.
FAU - Viele, Kert
AU  - Viele K
AD  - Berry Consultants Statistical Innovation, Austin, Texas, USA.
FAU - Detry, Michelle
AU  - Detry M
AD  - Berry Consultants Statistical Innovation, Austin, Texas, USA.
FAU - Morowitz, Michael
AU  - Morowitz M
AD  - Department of Surgery, Children's Hospital of Pittsburgh of UPMC, Pittsburgh,
      Pennsylvania, USA.
FAU - Morris, Alison
AU  - Morris A
AD  - Department of Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Methe, Barbara
AU  - Methe B
AD  - Department of Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Kennedy, Jason
AU  - Kennedy J
AD  - Department of Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Zuckerbraun, Brian
AU  - Zuckerbraun B
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Girard, Timothy D
AU  - Girard TD
AD  - Department of Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Marroquin, Oscar C
AU  - Marroquin OC
AD  - Clinical Analytics, UPMC Health System, Pittsburgh, Pennsylvania, USA.
FAU - Esper, Stephen
AU  - Esper S
AD  - Anesthesiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Holder-Murray, Jennifer
AU  - Holder-Murray J
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Newman, Anne B
AU  - Newman AB
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania,
      USA.
FAU - Berry, Scott
AU  - Berry S
AD  - Berry Consultants Statistical Innovation, Austin, Texas, USA.
FAU - Angus, Derek C
AU  - Angus DC
AD  - Department of Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
FAU - Neal, Matthew
AU  - Neal M
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03861767
GR  - L30 AG064730/AG/NIA NIH HHS/United States
GR  - P30 AG024827/AG/NIA NIH HHS/United States
GR  - T32 HL098036/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Bayes Theorem
MH  - Health Personnel
MH  - Humans
MH  - *Metformin/therapeutic use
MH  - *Postoperative Complications
MH  - Randomized Controlled Trials as Topic
PMC - PMC7526307
OTO - NOTNLM
OT  - *adult surgery
OT  - *clinical trials
OT  - *information management
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:06
PHST- 2020/09/30 06:06 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037690 [pii]
AID - 10.1136/bmjopen-2020-037690 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e037690. doi: 10.1136/bmjopen-2020-037690.


PMID- 32994239
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Thymosin alpha 1 in the prevention of infected pancreatic necrosis following
      acute necrotising pancreatitis (TRACE trial): protocol of a multicentre,
      randomised, double-blind, placebo-controlled, parallel-group trial.
PG  - e037231
LID - 10.1136/bmjopen-2020-037231 [doi]
AB  - INTRODUCTION: Infected pancreatic necrosis (IPN) and its related septic
      complications are the major causes of death in patients with acute necrotising
      pancreatitis (ANP). Therefore, the prevention of IPN is of great clinical value, 
      and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study 
      was designed to test the hypothesis that the administration of thymosin alpha 1
      during the acute phase of ANP will result in a reduced incidence of IPN. METHODS 
      AND ANALYSIS: This is a randomised, multicentre, double-blind, placebo-controlled
      study. 520 eligible patients with ANP will be randomised in a 1:1 ratio to
      receive either the thymosin alpha 1 or the placebo using the same mode of
      administration. The primary endpoint is the incidence of IPN during the index
      admission. Most of the secondary endpoints will be registered within the index
      admission including in-hospital mortality, the incidence of new-onset organ
      failure and new-onset persistent organ failure (respiration, cardiovascular and
      renal), receipt of new organ support therapy, requirement for drainage or
      necrosectomy, bleeding requiring intervention, human leucocyte
      antigens-DR(HLA-DR) on day 0, day 7, day 14, and so on and adverse events.
      Considering the possibility of readmission, an additional follow-up will be
      arranged 90 days after enrolment, and IPN and death at day 90 will also be served
      as secondary outcomes. ETHICS AND DISSEMINATION: This study was approved by the
      ethics committee of Jinling Hospital, Nanjing University (Number
      2015NZKY-004-02). The thymosin alpha 1 in the prevention of infected pancreatic
      necrosis following acute necrotising pancreatitis(TRACE) trial was designed to
      test the effect of a new therapy focusing on the immune system in preventing
      secondary infection following ANP. The results of this trial will be disseminated
      in peer-reviewed journals and at scientific conferences. TRIAL REGISTRATION
      NUMBER: ClinicalTrials.gov Registry (NCT02473406).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhou, Jing
AU  - Zhou J
AD  - Center of Severe Acute Pancreatitis (CSAP), Department of General Surgery,
      Jinling Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
FAU - Mao, Wenjian
AU  - Mao W
AD  - Center of Severe Acute Pancreatitis (CSAP), Department of General Surgery,
      Jinling Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
FAU - Ke, Lu
AU  - Ke L
AUID- ORCID: 0000-0001-8093-5073
AD  - Center of Severe Acute Pancreatitis (CSAP), Department of General Surgery,
      Jinling Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
      kkb9832@gmail.com.
FAU - Chen, Tao
AU  - Chen T
AUID- ORCID: 0000-0002-5489-6450
AD  - Tropical Clinical Trials Unit, Department of Clinical Sciences, Liverpool School 
      of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - He, Wenhua
AU  - He W
AD  - Department of Gastroenterology, First Affiliated Hospital of Nanchang University,
      Nanchang, Jiangxi, China.
FAU - Pan, Xinting
AU  - Pan X
AD  - Department of Emergency Intensive Care Unit, The Affiliated Hospital of Qingdao
      University, Qingdao, Shandong, China.
FAU - Chen, Miao
AU  - Chen M
AD  - Department of Intensive Care Unit, Affiliated Hospital of Zunyi Medical College, 
      Zunyi, Guizhou, China.
FAU - He, Chengjian
AU  - He C
AD  - Department of Intensive Care Unit, Affiliated Nanhua Hospital, University of
      South China, Hengyang, Hunan, China.
FAU - Gu, Weili
AU  - Gu W
AD  - Department of Intensive care Unit, Nantong City No 1 People's Hospital and Second
      Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
FAU - Wu, Jingyi
AU  - Wu J
AD  - Department of Intensive Care Unit, Yijishan Hospital of Wannan Medical College,
      Wuhu, Anhui, China.
FAU - Song, Jingchun
AU  - Song J
AD  - Department of Intensive Care Unit, 94th Hospital of PLA, Nanchang, Jiangxi,
      China.
FAU - Ni, Haibin
AU  - Ni H
AD  - Department of Emergency, Jiangsu Provincial Hospital of Integrated Chinese and
      Western Medicine, Nanjing, Jiangsu, China.
FAU - Tu, Jianfeng
AU  - Tu J
AD  - Department of Emergency Medicine, Zhejiang Provincial People's Hospital,
      Hangzhou, Zhejiang, China.
FAU - Sun, Junli
AU  - Sun J
AD  - Department of Intensive Care Unit, Luoyang Center Hospital, Zhengzhou University,
      Zhengzhou, Henan, China.
FAU - Zhang, Guoxiu
AU  - Zhang G
AD  - Department of Intensive Care Unit, Henan University of Science and Technology
      Affiliated First Hospital, Luoyang, Henan, China.
FAU - Chen, Weiwei
AU  - Chen W
AD  - Department of Gastroenterology, Yangzhou University Affiliated Northern Jiangsu
      People's Hospital, Yangzhou City, Jiangsu Province, China.
FAU - Xue, Bing
AU  - Xue B
AD  - Department of Emergency Intensive Care Unit, Shangqiu First People's Hospital,
      Shangqiu, Henan, China.
FAU - Zhao, Xiangyang
AU  - Zhao X
AD  - Department of Intensive Care Unit, Qilu Hospital of Shandong University Qingdao, 
      Qingdao, Shandong, China.
FAU - Shao, Min
AU  - Shao M
AD  - Department of Intensive Care Unit, First Affiliated Hospital of Anhui Medical
      University, Hefei, Anhui, China.
FAU - Liu, Yuxiu
AU  - Liu Y
AD  - Department of Medical Statistics, Jinling Hospital, Nanjing University Medical
      School, Nanjing, Jiangsu, China.
FAU - Tong, Zhihui
AU  - Tong Z
AD  - Center of Severe Acute Pancreatitis (CSAP), Department of General Surgery,
      Jinling Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
FAU - Li, Weiqin
AU  - Li W
AD  - Center of Severe Acute Pancreatitis (CSAP), Department of General Surgery,
      Jinling Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
CN  - Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG)
LA  - eng
SI  - ClinicalTrials.gov/NCT02473406
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - W0B22ISQ1C (Thymalfasin)
SB  - IM
MH  - Double-Blind Method
MH  - Drainage
MH  - Hospitalization
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Pancreatitis, Acute Necrotizing/complications
MH  - Randomized Controlled Trials as Topic
MH  - Thymalfasin
PMC - PMC7526289
OTO - NOTNLM
OT  - *immunology
OT  - *infectious diseases
OT  - *pancreatic disease
COIS- Competing interests: This study is supported by SBE2016750187 of Science and
      technology project, Jiangsu Province, China. SciClone Pharmaceuticals provides
      the study drug for this investigator-initiated study.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:05
PHST- 2020/09/30 06:05 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037231 [pii]
AID - 10.1136/bmjopen-2020-037231 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e037231. doi: 10.1136/bmjopen-2020-037231.


PMID- 32994238
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Documenting and characterising gestational weight gain beliefs and experiences
      among Marshallese pregnant women in Arkansas: a protocol for a longitudinal
      mixed-methods study.
PG  - e037219
LID - 10.1136/bmjopen-2020-037219 [doi]
AB  - INTRODUCTION: Arkansas has the largest population of Marshallese Pacific
      Islanders residing in the continental USA. The Marshallese have higher rates of
      obesity, type 2 diabetes, pre-term births, low birthweight babies, infant
      mortality, and inadequate or no prenatal care. Despite the high rates of
      cardiometabolic and maternal and child health disparities among Marshallese,
      there are no studies documenting gestational weight gain or perceptions about
      gestational weight gain among the Marshallese population residing in the USA.
      METHODS AND ANALYSIS: This paper describes the protocol of a mixed-methods
      concurrent triangulation longitudinal study designed to understand gestational
      weight gain in Marshallese women. The mixed-methods design collects qualitative
      and quantitative data during simultaneous data collection events, at both first
      and third trimester, and then augments that data with postpartum data
      abstraction. Quantitative and qualitative data will be analysed separately and
      then synthesised during the interpretation phase. ETHICS AND DISSEMINATION: The
      study used a community engaged approach approved by the University of Arkansas
      for Medical Sciences Institutional Review Board (#228023). The research team will
      disseminate results to study participants, research stakeholders (clinics,
      faith-based organisations and community-based organisation), the broader
      Marshallese community and fellow researchers. Results will be disseminated to
      study participants through a one-page summary that show the aggregated research
      results using plain language and infographics.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ayers, Britni L
AU  - Ayers BL
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, Arkansas, USA.
FAU - Bogulski, Cari A
AU  - Bogulski CA
AD  - Office of Community Health and Research, University of Arkansas for Medical
      Sciences Northwest, Fayetteville, Arkansas, USA.
FAU - Haggard-Duff, Lauren
AU  - Haggard-Duff L
AD  - College of Nursing, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, Arkansas, USA.
FAU - Andres, Aline
AU  - Andres A
AD  - Department of Pediatrics, University of Arkansas for Medical Sciences, Little
      Rock, Arkansas, USA.
FAU - Borsheim, Elisabet
AU  - Borsheim E
AUID- ORCID: 0000-0002-7842-0625
AD  - Department of Pediatrics, University of Arkansas for Medical Sciences, Little
      Rock, Arkansas, USA.
FAU - McElfish, Pearl A
AU  - McElfish PA
AUID- ORCID: 0000-0002-4033-6241
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, Arkansas, USA pamcelfish@uams.edu.
LA  - eng
GR  - KL2 TR003108/TR/NCATS NIH HHS/United States
GR  - P20 GM109096/GM/NIGMS NIH HHS/United States
GR  - UL1 TR000039/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arkansas
MH  - Child
MH  - Community-Based Participatory Research
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - *Gestational Weight Gain
MH  - Humans
MH  - Language
MH  - Longitudinal Studies
MH  - Pregnancy
MH  - Pregnant Women
PMC - PMC7526321
OTO - NOTNLM
OT  - *gynaecology
OT  - *maternal medicine
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:05
PHST- 2020/09/30 06:05 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037219 [pii]
AID - 10.1136/bmjopen-2020-037219 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e037219. doi: 10.1136/bmjopen-2020-037219.


PMID- 32994236
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 29
TI  - Clinically SUspected ScaPhoid fracturE: treatment with supportive bandage or
      CasT? 'Study protocol of a multicenter randomized controlled trial' (SUSPECT
      study).
PG  - e036998
LID - 10.1136/bmjopen-2020-036998 [doi]
AB  - INTRODUCTION: Some scaphoid fractures become visible on radiographs weeks after a
      trauma which makes normal radiographs directly after trauma unreliable. Untreated
      scaphoid fractures can lead to scaphoid non-union progressing to osteoarthritis. 
      Therefore, the general treatment for patients with a clinically suspected
      scaphoid fracture and normal initial radiographs is immobilisation with
      below-elbow cast for 2 weeks. However, most of these patients are treated
      unnecessarily because eventually less than 10% of them are diagnosed with an
      occult scaphoid fracture. To reduce overtreatment and costs as a result of
      unnecessary cast treatment in patients with a clinically suspected scaphoid
      fracture and normal initial radiographs, we designed a study to compare
      below-elbow cast treatment with supportive bandage treatment. We hypothesise that
      the functional outcome after 3 months is not inferior in patients treated with
      supportive bandage compared to patients treated with below-elbow cast, but with
      lower costs in the supportive bandage group. METHODS AND ANALYSIS: The SUSPECT
      study is an open-labelled multicentre randomised controlled trial with
      non-inferiority design. A total of 180 adult patients with a clinically suspected
      scaphoid fracture and normal initial radiographs are randomised between two
      groups: 3 days of supportive bandage or 2 weeks of below-elbow cast. We aim to
      evaluate the functional outcome and cost-effectiveness of both treatments. The
      primary outcome is the functional outcome after 3 months, assessed with the Quick
      Disability of the Arm, Shoulder and Hand score. Secondary outcomes include
      functional outcome, recovery of function, pain, patient satisfaction, quality of 
      life and cost-effectiveness measured by medical consumption, absence from work or
      decreased productivity. ETHICS AND DISSEMINATION: The Medical Ethics Committee of
      the Erasmus MC Medical Centre, Rotterdam, approved the study protocol
      (MEC-2017-504). We plan to present the results after completion of the study at
      (inter)national conferences and publish in general peer-reviewed journals. TRIAL 
      REGISTRATION NUMBER: NL6976.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Cohen, Abigael
AU  - Cohen A
AUID- ORCID: 0000-0001-9412-1134
AD  - Department of Orthopaedics, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands 
      a.cohen.1@erasmusmc.nl.
FAU - Reijman, Max
AU  - Reijman M
AD  - Department of Orthopaedics, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
FAU - Kraan, Gerald A
AU  - Kraan GA
AD  - Department of Orthopaedics, Reinier de Graaf Hospital, Delft, Zuid-Holland, The
      Netherlands.
FAU - Mathijssen, Nina M C
AU  - Mathijssen NMC
AD  - Department of Orthopaedics, Reinier de Graaf Hospital, Delft, Zuid-Holland, The
      Netherlands.
FAU - Koopmanschap, Marc A
AU  - Koopmanschap MA
AD  - Erasmus School of Health Policy and Management, Erasmus University Rotterdam,
      Rotterdam, Zuid-Holland, The Netherlands.
FAU - Verhaar, Jan A N
AU  - Verhaar JAN
AD  - Department of Orthopaedics, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
FAU - Mol, Sander
AU  - Mol S
AD  - Department of Emergency Medicine, Franciscus Gasthuis en Vlietland, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Colaris, Joost W
AU  - Colaris JW
AD  - Department of Orthopaedics, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
CN  - SUSPECT study group
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200929
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Bandages
MH  - *Fractures, Bone/diagnostic imaging/therapy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Scaphoid Bone/diagnostic imaging
MH  - *Wrist Injuries
PMC - PMC7526317
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *adult orthopaedics
OT  - *hand & wrist
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 06:05
PHST- 2020/09/30 06:05 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036998 [pii]
AID - 10.1136/bmjopen-2020-036998 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 29;10(9):e036998. doi: 10.1136/bmjopen-2020-036998.


PMID- 32994179
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 4
DP  - 2020 Oct
TI  - A Complicated Case of Vaccine Refusal.
LID - e20200768 [pii]
LID - 10.1542/peds.2020-0768 [doi]
AB  - Parents in the United States have a legal right to refuse vaccination for their
      children. There are, however, special circumstances under which the state may
      compel vaccination against parental wishes. In this Ethics Rounds article, we
      present the case of a young boy with sickle cell disease who was partially
      vaccinated against encapsulated bacteria and the ethics of whether to compel
      complete vaccination before splenectomy.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Rossi, Rebecca
AU  - Rossi R
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania.
AD  - Palliative Medicine.
FAU - Rellosa, Neil
AU  - Rellosa N
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania.
AD  - Divisions of Infectious Diseases.
AD  - Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
FAU - Miller, Robin
AU  - Miller R
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania.
AD  - Nemours Center for Cancer and Blood Disorders and.
AD  - Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
FAU - Schultz, Corinna L
AU  - Schultz CL
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania.
AD  - Nemours Center for Cancer and Blood Disorders and.
AD  - Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
FAU - Miller, Jonathan M
AU  - Miller JM
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania.
AD  - General Pediatrics, and.
AD  - Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
FAU - Berman, Loren
AU  - Berman L
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania.
AD  - Departments of Surgery and.
FAU - Miller, Elissa G
AU  - Miller EG
AD  - Thomas Jefferson University, Philadelphia, Pennsylvania;
      elissa.miller@nemours.org.
AD  - Palliative Medicine.
AD  - Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
LA  - eng
PT  - Case Reports
PT  - Letter
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Anemia, Sickle Cell/*therapy
MH  - Antibiotic Prophylaxis
MH  - Child Protective Services
MH  - Child, Preschool
MH  - Erythrocyte Transfusion
MH  - *Ethics Consultation
MH  - Humans
MH  - Immunocompromised Host
MH  - Male
MH  - Opportunistic Infections
MH  - Patient Transfer
MH  - *Professional-Family Relations
MH  - *Splenectomy
MH  - Treatment Refusal
MH  - Trust
MH  - Vaccination Refusal/*ethics
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose
EDAT- 2020/10/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/30 06:05
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/09/30 06:05 [entrez]
AID - peds.2020-0768 [pii]
AID - 10.1542/peds.2020-0768 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Oct;146(4). pii: peds.2020-0768. doi: 10.1542/peds.2020-0768.


PMID- 32993902
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 263
DP  - 2020 Aug - Sep
PG  - 30-31
LID - S1293-8505(20)30237-2 [pii]
LID - 10.1016/S1293-8505(20)30237-2 [doi]
AB  - The body at the boundaries of care and ethics. The body is the site of a variety 
      of explorations, from the most basic to the most sophisticated imaging
      examinations, to provide a diagnosis, monitor the evolution of a pathology or
      decide on a therapy. For the patient, the examination is an ordeal, as is the
      wait for the results. In their role in providing images for clinicians, medical
      imaging professionals must ensure that they adopt an ethical approach showing
      compassion towards the person whose body is undergoing investigation.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Vilmont, Laurence Briois
AU  - Vilmont LB
AD  - c/o La revue de l'infirmiere, 65, rue Camille-Desmoulins, 92130
      Issy-les-Moulineaux,France. Electronic address: laurence.vilmont@freesbee.fr.
LA  - fre
PT  - Journal Article
TT  - Le corps aux confins du soin et de l'ethique.
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - *Empathy
MH  - *Human Body
MH  - Humans
MH  - Patient Care
OTO - NOTNLM
OT  - clinic
OT  - clinique
OT  - communication
OT  - diagnosis
OT  - diagnostic
OT  - ethics
OT  - imagerie medicale
OT  - medical imaging
OT  - ethique
EDAT- 2020/10/01 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/09/30 05:49
PHST- 2020/09/30 05:49 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - S1293-8505(20)30237-2 [pii]
AID - 10.1016/S1293-8505(20)30237-2 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Aug - Sep;69(263):30-31. doi: 10.1016/S1293-8505(20)30237-2.


PMID- 32993841
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1477-1128 (Electronic)
IS  - 1463-4236 (Linking)
VI  - 21
DP  - 2020 Sep 30
TI  - Reasons for the low influenza vaccination rate among nurses in Slovenia.
PG  - e38
LID - 10.1017/S1463423620000419 [doi]
AB  - AIM: This study aimed to identify nurses' views on influenza vaccination and
      factors that might explain why they do not receive influenza vaccinations, and to
      examine any ethical issues encountered in the vaccination process. BACKGROUND:
      All 27 European Union member states and 2 other European countries recommended
      influenza vaccinations for healthcare workers in 2014-15. Data show that the
      influenza vaccination rate among nurses in Slovenia is even lower than in other
      European countries. Slovenian study showed that 41.7% of the respondents had
      received both the pandemic and the seasonal vaccine. Doctors had the highest
      level of vaccine coverage, with 44.1%, followed by registered nurses at 23.4%,
      whereas the lowest level was found among nursing assistants and nursing
      technicians (17%) at a Ljubljana health clinic. METHODS: A qualitative study was 
      carried out. Nineteen nurses who did not receive influenza vaccination took part 
      in the study. Thematic interviews were conducted in December 2018. Interview
      transcripts were read, coded, reviewed and labelled by three independent
      researchers. The collected material was processed using qualitative content
      analysis. FINDINGS: Thirteen categories and four themes were identified and
      coded, which enabled an understanding of the nurses' views regarding influenza
      vaccination. Most of their experiences were positive in one way: they recognised 
      the importance of vaccination and people's awareness of it. However, they did not
      obtain the influenza vaccine themselves. The main barriers to vaccination were
      doubt regarding the vaccine's effectiveness, the potential for side effects, the 
      belief that young healthcare professionals are well protected and not at high
      risk, an overrated trust in their own immune systems, and the belief that
      pharmaceutical industry marketing was targeting them. The nurses suggested
      several ways that vaccination could be promoted and improved vaccination coverage
      achieved. These findings call attention to the importance of recognising both the
      need for targeted information for the nurses and the need for different
      approaches to healthcare provision.
FAU - Pavlic, Danica Rotar
AU  - Pavlic DR
AUID- ORCID: 0000-0001-7575-3195
AD  - Assistant Professor, Faculty of Health Sciences, Health Systems in the European
      Community, Managing and Improving Quality in Nursing, University of Primorska,
      Izola, Slovenia.
FAU - Maksuti, Alem
AU  - Maksuti A
AD  - Institute for Political Management, Dunajska 106, 1000Ljubljana, Slovenia.
FAU - Podnar, Barbara
AU  - Podnar B
AD  - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Kokalj Kokot, Mateja
AU  - Kokalj Kokot M
AD  - Department of Family Medicine, Faculty of Medicine, University of Ljubljana,
      Ljubljana, Slovenia.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - Prim Health Care Res Dev
JT  - Primary health care research & development
JID - 100897390
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Europe
MH  - Female
MH  - Humans
MH  - *Influenza Vaccines
MH  - *Influenza, Human
MH  - Male
MH  - Middle Aged
MH  - *Nurses
MH  - Slovenia
MH  - Vaccination
PMC - PMC7576542
OTO - NOTNLM
OT  - *content analysis
OT  - *influenza
OT  - *nurse
OT  - *qualitative study
OT  - *vaccination rate
EDAT- 2020/10/01 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/09/30 05:48
PHST- 2020/09/30 05:48 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - S1463423620000419 [pii]
AID - 10.1017/S1463423620000419 [doi]
PST - epublish
SO  - Prim Health Care Res Dev. 2020 Sep 30;21:e38. doi: 10.1017/S1463423620000419.


PMID- 32993779
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 29
TI  - Personalised health education against health damage of COVID-19 epidemic in the
      elderly Hungarian population (PROACTIVE-19): protocol of an adaptive randomised
      controlled clinical trial.
PG  - 809
LID - 10.1186/s13063-020-04733-0 [doi]
AB  - BACKGROUND: Early reports indicate that COVID-19 may require intensive care unit 
      (ICU) admission in 5-26% and overall mortality can rise to 11% of the recognised 
      cases, particularly affecting the elderly. There is a lack of evidence-based
      targeted pharmacological therapy for its prevention and treatment. We aim to
      compare the effects of a World Health Organization recommendation-based education
      and a personalised complex preventive lifestyle intervention package (based on
      the same WHO recommendation) on the outcomes of the COVID-19. METHODS:
      PROACTIVE-19 is a pragmatic, randomised controlled clinical trial with adaptive
      "sample size re-estimation" design. Hungarian population over the age of 60 years
      without confirmed COVID-19 will be approached to participate in a telephone
      health assessment and lifestyle counselling voluntarily. Volunteers will be
      randomised into two groups: (A) general health education and (B) personalised
      health education. Participants will go through questioning and recommendation in 
      5 fields: (1) mental health, (2) smoking habits, (3) physical activity, (4)
      dietary habits, and (5) alcohol consumption. Both groups A and B will receive the
      same line of questioning to assess habits concerning these topics. Assessment
      will be done weekly during the first month, every second week in the second
      month, then monthly. The composite primary endpoint will include the rate of ICU 
      admission, hospital admission (longer than 48 h), and mortality in
      COVID-19-positive cases. The estimated sample size is 3788 subjects per study
      arm. The planned duration of the follow-up is a minimum of 1 year. DISCUSSION:
      These interventions may boost the body's cardiovascular and pulmonary reserve
      capacities, leading to improved resistance against the damage caused by COVID-19.
      Consequently, lifestyle changes can reduce the incidence of life-threatening
      conditions and attenuate the detrimental effects of the pandemic seriously
      affecting the older population. TRIAL REGISTRATION: The study has been approved
      by the Scientific and Research Ethics Committee of the Hungarian Medical Research
      Council (IV/2428- 2 /2020/EKU) and has been registered at clinicaltrials.gov (
      NCT04321928 ) on 25 March 2020.
FAU - Eross, Balint
AU  - Eross B
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Translational Medicine Foundation, Szeged, Hungary.
FAU - Molnar, Zsolt
AU  - Molnar Z
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Department of Anaesthesiology and Intensive Therapy, Poznan University for
      Medical Sciences, Poznan, Poland.
FAU - Szakacs, Zsolt
AU  - Szakacs Z
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Zadori, Noemi
AU  - Zadori N
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Szako, Lajos
AU  - Szako L
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Vancsa, Szilard
AU  - Vancsa S
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Juhasz, Mark Felix
AU  - Juhasz MF
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Ocskay, Klementina
AU  - Ocskay K
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Vorhendi, Nora
AU  - Vorhendi N
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Marta, Katalin
AU  - Marta K
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Szentesi, Andrea
AU  - Szentesi A
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Translational Medicine Foundation, Szeged, Hungary.
AD  - Centre for Translational Medicine, Department of Medicine, University of Szeged, 
      Szeged, Hungary.
FAU - Parniczky, Andrea
AU  - Parniczky A
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Heim Pal National Pediatric Institute, Budapest, Hungary.
FAU - Hegyi, Peter J
AU  - Hegyi PJ
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Kiss, Szabolcs
AU  - Kiss S
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Centre for Translational Medicine, Department of Medicine, University of Szeged, 
      Szeged, Hungary.
AD  - Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary.
FAU - Foldi, Maria
AU  - Foldi M
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Centre for Translational Medicine, Department of Medicine, University of Szeged, 
      Szeged, Hungary.
AD  - Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary.
FAU - Dembrovszky, Fanni
AU  - Dembrovszky F
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
FAU - Kanjo, Anna
AU  - Kanjo A
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Heim Pal National Pediatric Institute, Budapest, Hungary.
FAU - Pazmany, Piroska
AU  - Pazmany P
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Heim Pal National Pediatric Institute, Budapest, Hungary.
FAU - Varro, Andras
AU  - Varro A
AD  - Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged,
      Hungary.
FAU - Csatho, Arpad
AU  - Csatho A
AD  - Department of Behavioral Sciences, Medical School, University of Pecs, Pecs,
      Hungary.
FAU - Helyes, Zsuzsanna
AU  - Helyes Z
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Department of Pharmacology and Pharmacotherapy, Medical School, University of
      Pecs, Pecs, Hungary.
FAU - Peterfi, Zoltan
AU  - Peterfi Z
AD  - Division of Infectious Diseases, 1st Department of Medicine, Medical School,
      University of Pecs, Pecs, Hungary.
FAU - Czopf, Laszlo
AU  - Czopf L
AD  - Division of Cardiology, First Department of Medicine, Medical School, University 
      of Pecs, Pecs, Hungary.
FAU - Kiss, Istvan
AU  - Kiss I
AD  - Department of Public Health, Medical School, University of Pecs, Pecs, Hungary.
FAU - Zemplenyi, Antal
AU  - Zemplenyi A
AD  - Health Technology Assessment Center, University of Pecs, Pecs, Hungary.
AD  - Division of Pharmacoeconomics, Department of Pharmaceutics, Faculty of Pharmacy, 
      University of Pecs, Pecs, Hungary.
FAU - Czapari, Dora
AU  - Czapari D
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
FAU - Hegyi, Eszter
AU  - Hegyi E
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Faculty of Law, University of Szeged, Szeged, Hungary.
FAU - Dobszai, Dalma
AU  - Dobszai D
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
FAU - Miklos, Emoke
AU  - Miklos E
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
FAU - Marta, Attila
AU  - Marta A
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
FAU - Toth, Dominika
AU  - Toth D
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
FAU - Farkas, Richard
AU  - Farkas R
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
FAU - Farkas, Nelli
AU  - Farkas N
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary.
AD  - Institute Bioanalysis, Medical School, University of Pecs, Pecs, Hungary.
FAU - Birkas, Bela
AU  - Birkas B
AD  - Department of Behavioral Sciences, Medical School, University of Pecs, Pecs,
      Hungary.
FAU - Pinter, Erika
AU  - Pinter E
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Department of Pharmacology and Pharmacotherapy, Medical School, University of
      Pecs, Pecs, Hungary.
FAU - Petho, Gabor
AU  - Petho G
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
AD  - Department of Pharmacology and Pharmacotherapy, Medical School, University of
      Pecs, Pecs, Hungary.
FAU - Zsigmond, Borbala
AU  - Zsigmond B
AD  - Heim Pal National Pediatric Institute, Budapest, Hungary.
FAU - Sarkozi, Andrea
AU  - Sarkozi A
AD  - Heim Pal National Pediatric Institute, Budapest, Hungary.
FAU - Nagy, Aniko
AU  - Nagy A
AD  - Heim Pal National Pediatric Institute, Budapest, Hungary.
FAU - Hegyi, Peter
AU  - Hegyi P
AD  - Institute for Translational Medicine, Medical School, University of Pecs, Szigeti
      ut 12, Pecs, H-7624, Hungary. p.hegyi@tm-centre.org.
AD  - Translational Medicine Foundation, Szeged, Hungary. p.hegyi@tm-centre.org.
AD  - Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
      p.hegyi@tm-centre.org.
AD  - Centre for Translational Medicine, Department of Medicine, University of Szeged, 
      Szeged, Hungary. p.hegyi@tm-centre.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT04321928
GR  - EFOP 3.6.2-16-2017-00006 - LIVE LONGER/European Regional Development Fund
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Adaptive Clinical Trials as Topic
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Alcohol Drinking/adverse effects
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/mortality/*prevention & control/virology
MH  - Exercise
MH  - Feeding Behavior
MH  - Female
MH  - *Health Education
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Status
MH  - Host-Pathogen Interactions
MH  - Humans
MH  - Hungary
MH  - Male
MH  - Mental Health
MH  - Middle Aged
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/diagnosis/mortality/*prevention & control/virology
MH  - Pragmatic Clinical Trials as Topic
MH  - Protective Factors
MH  - Risk Assessment
MH  - Risk Factors
MH  - *Risk Reduction Behavior
MH  - SARS-CoV-2
MH  - Smoking/adverse effects
PMC - PMC7522906
OTO - NOTNLM
OT  - COVID-19
OT  - Prevention
OT  - Public health
OT  - Randomised controlled trial
OT  - SARS-CoV-2
OT  - nCov-2019
EDAT- 2020/10/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/30 05:48
PHST- 2020/07/24 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/30 05:48 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1186/s13063-020-04733-0 [doi]
AID - 10.1186/s13063-020-04733-0 [pii]
PST - epublish
SO  - Trials. 2020 Sep 29;21(1):809. doi: 10.1186/s13063-020-04733-0.


PMID- 32993736
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201218
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Sep 29
TI  - COVID-19: instruments for the allocation of mechanical ventilators-a narrative
      review.
PG  - 582
LID - 10.1186/s13054-020-03298-3 [doi]
AB  - After the World Health Organization declared COVID-19 to be a pandemic, the
      elaboration of comprehensive and preventive public policies became important in
      order to stop the spread of the disease. However, insufficient or ineffective
      measures may have placed health professionals and services in the position of
      having to allocate mechanical ventilators. This study aimed to identify
      instruments, analyze their structures, and present the main criteria used in the 
      screening protocols, in order to help the development of guidelines and policies 
      for the allocation of mechanical ventilators in the COVID-19 pandemic. The
      instruments have a low level of scientific evidence, and, in general, are
      structured by various clinical, non-clinical, and tiebreaker criteria that
      contain ethical aspects. Few instruments included public participation in their
      construction or validation. We believe that the elaboration of these guidelines
      cannot be restricted to specialists as this question involves ethical
      considerations which make the participation of the population necessary. Finally,
      we propose seventeen elements that can support the construction of screening
      protocols in the COVID-19 pandemic.
FAU - Dos Santos, Marcelo Jose
AU  - Dos Santos MJ
AUID- ORCID: 0000-0001-5123-8797
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil. mjosan1975@usp.br.
AD  - Departamento de Orientacao Profissional, Escola de Enfermagem da Universidade de 
      Sao Paulo, Rua Dr. Eneas de Carvalho Aguiar, 419, CEP - 05403-000 Cerqueira
      Cesar, Sao Paulo, SP, Brazil. mjosan1975@usp.br.
FAU - Martins, Maristela Santini
AU  - Martins MS
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Santana, Fabiana Lopes Pereira
AU  - Santana FLP
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Furtado, Maria Carolina Silvano Pacheco Correa
AU  - Furtado MCSPC
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Miname, Fabiana Cristina Bazana Remedio
AU  - Miname FCBR
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Pimentel, Rafael Rodrigo da Silva
AU  - Pimentel RRDS
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Brito, Agata Nunes
AU  - Brito AN
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Schneider, Patrick
AU  - Schneider P
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Dos Santos, Edson Silva
AU  - Dos Santos ES
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - da Silva, Luciane Hupalo
AU  - da Silva LH
AD  - Research Group "Bioethics and Administration: Teaching and Health Care", Nursing 
      School of University of Sao Paulo, Sao Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200929
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Decision Making
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - Public Health
MH  - *Resource Allocation
MH  - SARS-CoV-2
MH  - Triage/methods
MH  - *Ventilators, Mechanical
PMC - PMC7522926
OTO - NOTNLM
OT  - *Decision making
OT  - *Ethics
OT  - *Health care rationing
OT  - *Pandemics
EDAT- 2020/10/01 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/09/30 05:47
PHST- 2020/06/16 00:00 [received]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/09/30 05:47 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1186/s13054-020-03298-3 [doi]
AID - 10.1186/s13054-020-03298-3 [pii]
PST - epublish
SO  - Crit Care. 2020 Sep 29;24(1):582. doi: 10.1186/s13054-020-03298-3.


PMID- 32993695
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1743-0003 (Electronic)
IS  - 1743-0003 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Sep 29
TI  - Kinematic parameters obtained with the ArmeoSpring for upper-limb assessment
      after stroke: a reliability and learning effect study for guiding parameter use.
PG  - 130
LID - 10.1186/s12984-020-00759-2 [doi]
AB  - BACKGROUND: After stroke, kinematic measures obtained with non-robotic and
      robotic devices are highly recommended to precisely quantify the sensorimotor
      impairments of the upper-extremity and select the most relevant therapeutic
      strategies. Although the ArmeoSpring exoskeleton has demonstrated its
      effectiveness in stroke motor rehabilitation, its interest as an assessment tool 
      has not been sufficiently documented. The aim of this study was to investigate
      the psychometric properties of selected kinematic parameters obtained with the
      ArmeoSpring in post-stroke patients. METHODS: This study involved 30 post-stroke 
      patients (mean age = 54.5 +/- 16.4 years; time post-stroke = 14.7 +/- 26.7 weeks;
      Upper-Extremity Fugl-Meyer Score (UE-FMS) = 40.7 +/- 14.5/66) who participated in
      3 assessment sessions, each consisting of 10 repetitions of the 'horizontal
      catch' exercise. Five kinematic parameters (task and movement time, hand path
      ratio, peak velocity, number of peak velocity) and a global Score were computed
      from raw ArmeoSpring' data. Learning effect and retention were analyzed using a
      2-way repeated-measures ANOVA, and reliability was investigated using the
      intra-class correlation coefficient (ICC) and minimal detectable change (MDC).
      RESULTS: We observed significant inter- and intra-session learning effects for
      most parameters except peak velocity. The measures performed in sessions 2 and 3 
      were significantly different from those of session 1. No additional significant
      difference was observed after the first 6 trials of each session and successful
      retention was also highlighted for all the parameters. Relative reliability was
      moderate to excellent for all the parameters, and MDC values expressed in
      percentage ranged from 42.6 to 102.8%. CONCLUSIONS: After a familiarization
      session, the ArmeoSpring can be used to reliably and sensitively assess motor
      impairment and intervention effects on motor learning processes after a stroke.
      Trial registration The study was approved by the local hospital ethics committee 
      in September 2016 and was registered under number 05-0916.
FAU - Brihmat, Nabila
AU  - Brihmat N
AD  - ToNIC, Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS,
      Toulouse, France.
FAU - Loubinoux, Isabelle
AU  - Loubinoux I
AD  - ToNIC, Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS,
      Toulouse, France.
FAU - Castel-Lacanal, Evelyne
AU  - Castel-Lacanal E
AD  - ToNIC, Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS,
      Toulouse, France.
AD  - Department of Physical and Rehabilitation Medicine, University Hospital of
      Toulouse, Toulouse, France.
FAU - Marque, Philippe
AU  - Marque P
AD  - ToNIC, Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS,
      Toulouse, France.
AD  - Department of Physical and Rehabilitation Medicine, University Hospital of
      Toulouse, Toulouse, France.
FAU - Gasq, David
AU  - Gasq D
AD  - ToNIC, Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS,
      Toulouse, France. gasq.d@chu-toulouse.fr.
AD  - Department of Physiological Explorations, University Hospital of Toulouse,
      Toulouse, France. gasq.d@chu-toulouse.fr.
AD  - Service des Explorations Fonctionnelles Physiologiques, Hopital Rangueil, 1
      Avenue du Pr Poulhes, 31059, Toulouse, France. gasq.d@chu-toulouse.fr.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - J Neuroeng Rehabil
JT  - Journal of neuroengineering and rehabilitation
JID - 101232233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomechanical Phenomena
MH  - *Exoskeleton Device
MH  - Female
MH  - Humans
MH  - Learning
MH  - Male
MH  - Middle Aged
MH  - Psychometrics
MH  - *Recovery of Function
MH  - Reproducibility of Results
MH  - Robotics/*instrumentation
MH  - Stroke
MH  - Stroke Rehabilitation/*instrumentation
MH  - Upper Extremity/physiopathology
PMC - PMC7523068
OTO - NOTNLM
OT  - *ArmeoSpring
OT  - *Exoskeleton device
OT  - *Hemiplegia
OT  - *Learning
OT  - *Psychometrics
EDAT- 2020/10/01 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/09/30 05:47
PHST- 2020/02/11 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/30 05:47 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - 10.1186/s12984-020-00759-2 [doi]
AID - 10.1186/s12984-020-00759-2 [pii]
PST - epublish
SO  - J Neuroeng Rehabil. 2020 Sep 29;17(1):130. doi: 10.1186/s12984-020-00759-2.


PMID- 32993608
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 29
TI  - The role of 3D printed models in the teaching of human anatomy: a systematic
      review and meta-analysis.
PG  - 335
LID - 10.1186/s12909-020-02242-x [doi]
AB  - BACKGROUND: Three-dimensional (3D) printing is an emerging technology widely used
      in medical education. However, its role in the teaching of human anatomy needs
      further evaluation. METHODS: PubMed, Embase, EBSCO, SpringerLink, and Nature
      databases were searched systematically for studies published from January 2011 to
      April 2020 in the English language. GRADEprofiler software was used to evaluate
      the quality of literature. In this study, a meta-analysis of continuous and
      binary data was conducted. Both descriptive and statistical analyses were used.
      RESULTS: Comparing the post-training tests in neuroanatomy, cardiac anatomy, and 
      abdominal anatomy, the standardized mean difference (SMD) of the 3D group and the
      conventional group were 1.27, 0.37, and 2.01, respectively (p < 0.05). For 3D vs.
      cadaver and 3D vs. 2D, the SMD were 0.69 and 1.05, respectively (p < 0.05). For
      answering time, the SMD of the 3D group vs. conventional group was - 0.61 (P <
      0.05). For 3D print usefulness, RR = 2.29(P < 0.05). Five of the six studies
      showed that satisfaction of the 3D group was higher than that of the conventional
      group. Two studies showed that accuracy of answering questions in the 3D group
      was higher than that in the conventional group. CONCLUSIONS: Compared with
      students in the conventional group, those in the 3D printing group had advantages
      in accuracy and answering time. In the test of anatomical knowledge, the test
      results of students in the 3D group were not inferior (higher or equal) to those 
      in the conventional group. The post-training test results of the 3D group were
      higher than those in the cadaver or 2D group. More students in the 3D printing
      group were satisfied with their learning compared with the conventional group.
      The results could be influenced by the quality of the randomized controlled
      trials. In a framework of ethical rigor, the application of the 3D printing model
      in human anatomy teaching is expected to grow further.
FAU - Ye, Zhen
AU  - Ye Z
AD  - Department of Molecular Biology, Basic Medical College, Shandong First Medical
      University & Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China.
FAU - Dun, Aishe
AU  - Dun A
AD  - Department of Anatomy, Basic Medical College, Shandong First Medical University &
      Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China.
FAU - Jiang, Hanming
AU  - Jiang H
AD  - Department of Molecular Biology, Basic Medical College, Shandong First Medical
      University & Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China.
FAU - Nie, Cuifang
AU  - Nie C
AD  - Department of Infectious Disease, Tai'an Central Hospital, Tai'an, Shandong, P.R.
      China.
FAU - Zhao, Shulian
AU  - Zhao S
AD  - Department of Infectious Disease, Tai'an Central Hospital, Tai'an, Shandong, P.R.
      China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Molecular Biology, Basic Medical College, Shandong First Medical
      University & Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China.
FAU - Zhai, Jing
AU  - Zhai J
AD  - Department of Molecular Biology, Basic Medical College, Shandong First Medical
      University & Shandong Academy of Medical Sciences, Tai'an, Shandong, P.R. China. 
      jingzhai66@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200929
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - *Anatomy/education
MH  - Cadaver
MH  - *Education, Medical
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Learning
MH  - Models, Anatomic
MH  - Printing, Three-Dimensional
PMC - PMC7523371
OTO - NOTNLM
OT  - Anatomy
OT  - Medical education
OT  - Three-dimensional printing
EDAT- 2020/10/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/30 05:46
PHST- 2020/01/28 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/30 05:46 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02242-x [doi]
AID - 10.1186/s12909-020-02242-x [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Sep 29;20(1):335. doi: 10.1186/s12909-020-02242-x.


PMID- 32993577
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 29
TI  - Anthropometrical measurements and maternal visceral fat during first half of
      pregnancy: a cross-sectional survey.
PG  - 576
LID - 10.1186/s12884-020-03258-3 [doi]
AB  - BACKGROUND: Determining anthropometric measures that indicate different fat
      deposits can be useful to predict metabolic risk and set specific treatment
      goals, reducing negative consequences for maternal and fetal health. In cases
      where pre-gestational weight measure and subsequent body mass index (BMI) values 
      cannot be determined, other anthropometric measurements may be ideal for
      measuring the nutritional status of pregnant women, especially in low- and
      middle-income countries. This study aims to identify which anthropometric
      measurements correlate better with the maternal fat deposits measured by
      ultrasound. METHODS: A cross-sectional study was conducted with pregnant women
      from the city of Porto Alegre (city), capital of Rio Grande do Sul (state),
      southern Brazil, from October 2016 until January 2018. Anthropometrical variables
      (weight, height, mid-upper arm circumference [MUAC], circumferences of calf and
      neck and triceps skinfolds [TSF] and subscapular skinfolds [SBSF]), and
      ultrasound variables (visceral adipose tissue [VAT] and total adipose tissue
      [TAT]) were collected. To verify the correlation of anthropometric and ultrasound
      measurements, a non-adjusted and adjusted Spearman correlation was used. The
      study was approved by the ethics committees. RESULTS: The age median of the 149
      pregnant women was 25 years [21-31], pre-pregnancy BMI was 26.22 kg/m(2)
      [22.16-31.21] and gestational age was 16.2 weeks [13.05-18.10]. The best
      measurements correlated with VAT and TAT were MUAC and SBSF, both of which showed
      a higher correlation than pre-pregnancy BMI. CONCLUSIONS: It is possible to
      provide a practical and reliable estimate of VAT and TAT from the anthropometric 
      evaluation (MUAC or SBSF) that is low cost, efficient and replicable in an
      outpatient clinic environment, especially in low- and middle-income countries.
FAU - Kretzer, Daniela Cortes
AU  - Kretzer DC
AD  - Faculty of Medicine, Postgraduate Program in Child and Adolescent Health,
      Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2400,
      Santa Cecilia, Rio Grande do Sul, 90035-003, Porto Alegre, Brazil.
      danielakretzer@hotmail.com.
FAU - Matos, Salete
AU  - Matos S
AD  - Faculty of Medicine, Postgraduate Program in Child and Adolescent Health,
      Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2400,
      Santa Cecilia, Rio Grande do Sul, 90035-003, Porto Alegre, Brazil.
FAU - Von Diemen, Lisia
AU  - Von Diemen L
AD  - Postgraduate Program in Psychiatry and Behavioral Sciences, Universidade Federal 
      do Rio Grande do Sul (UFRGS), 90035-003, Porto Alegre, Brazil.
FAU - de Azevedo Magalhaes, Jose Antonio
AU  - de Azevedo Magalhaes JA
AD  - Maternal-Fetal Division (Head), Hospital de Clinicas de Porto Alegre, School of
      Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
FAU - Schoffel, Alice Carvalhal
AU  - Schoffel AC
AD  - Department of Social and Behavioural Health Sciences, Dalla Lana School of Public
      Health, University of Toronto, Toronto, Canada.
FAU - Goldani, Marcelo Zubaran
AU  - Goldani MZ
AD  - Department of Pediatrics, Hospital de Clinicas de Porto Alegre, School of
      Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
FAU - da Silva Rocha, Alexandre
AU  - da Silva Rocha A
AD  - Postgraduate Program in Psychiatry and Behavioral Sciences, Universidade Federal 
      do Rio Grande do Sul (UFRGS), 90035-003, Porto Alegre, Brazil.
FAU - Bernardi, Juliana Rombaldi
AU  - Bernardi JR
AD  - Department of Nutrition, Graduate program in Child and Adolescent Health and
      Graduate Program in Food, Nutrition and Health, Hospital de Clinicas de Porto
      Alegre, School of Medicine, Federal University of Rio Grande do Sul, Porto
      Alegre, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adult
MH  - *Body Weights and Measures
MH  - Correlation of Data
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Intra-Abdominal Fat/*anatomy & histology/diagnostic imaging
MH  - Organ Size
MH  - Pregnancy
MH  - Pregnancy Trimester, First
MH  - Pregnancy Trimester, Second
MH  - Ultrasonography, Prenatal
MH  - Young Adult
PMC - PMC7526141
OTO - NOTNLM
OT  - Anthropometry
OT  - Body mass index
OT  - Mid-upper arm circumference
OT  - Pregnant women
EDAT- 2020/10/01 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/09/30 05:46
PHST- 2019/10/02 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/09/30 05:46 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - 10.1186/s12884-020-03258-3 [doi]
AID - 10.1186/s12884-020-03258-3 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Sep 29;20(1):576. doi: 10.1186/s12884-020-03258-3.


PMID- 32993419
OWN - NLM
STAT- Publisher
LR  - 20200930
IS  - 1541-3764 (Electronic)
IS  - 0030-2228 (Linking)
DP  - 2020 Sep 30
TI  - Nurses' Communication With the Families of Patients at the End-of-Life.
PG  - 30222820959933
LID - 10.1177/0030222820959933 [doi]
AB  - BACKGROUND: Effective communication is important in providing quality care to
      families at the end-of-life. In the end-of-life situations, the nurses' views on 
      how to communicate with the family are not well understood. AIM: This study was
      conducted to explore the nurses' experiences of their communication with families
      of patients at the end-of-life situations. METHODS: The authors used standards
      for reporting qualitative research. The data were analyzed by conventional
      content analysis. Semi-structured interviews were conducted with 24 Iranian
      nurses who had the experiences of dealing with patients' families at the
      end-of-life. RESULTS: Nurses' perceptions of communication with families emerged 
      base on the main theme: "Disrupted communication" consisting of two categories:
      "restricted communication" and "abortive communication." CONCLUSION: The results 
      of this study highlight the need to increase the professional and ethical
      sensitivity of nurses in dealing with patients' families at the end-of-life.
FAU - Norouzadeh, Reza
AU  - Norouzadeh R
AUID- ORCID: https://orcid.org/0000-0002-3044-1910
AD  - Department of Nursing, Nursing and Midwifery Faculty, Shahed University, Tehran, 
      I. R. Iran.
FAU - Anoosheh, Monireh
AU  - Anoosheh M
AUID- ORCID: https://orcid.org/0000-0002-8626-0385
AD  - Department of Nursing, Faculty of Medical Sciences, Tarbiat Modares University,
      Tehran, I. R. Iran.
FAU - Ahmadi, Fazlollah
AU  - Ahmadi F
AD  - Department of Nursing, Faculty of Medical Sciences, Tarbiat Modares University,
      Tehran, I. R. Iran.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - United States
TA  - Omega (Westport)
JT  - Omega
JID - 1272106
SB  - IM
OTO - NOTNLM
OT  - communication
OT  - content analysis
OT  - dying
OT  - end-of-life care
OT  - family
EDAT- 2020/10/01 06:00
MHDA- 2020/10/01 06:00
CRDT- 2020/09/30 05:45
PHST- 2020/09/30 05:45 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/01 06:00 [medline]
AID - 10.1177/0030222820959933 [doi]
PST - aheadofprint
SO  - Omega (Westport). 2020 Sep 30:30222820959933. doi: 10.1177/0030222820959933.


PMID- 32992703
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2076-328X (Print)
IS  - 2076-328X (Linking)
VI  - 10
IP  - 10
DP  - 2020 Sep 25
TI  - Perceptions and Emotional State of Mothers of Children with and without
      Microcephaly after the Zika Virus Epidemic in Rural Caribbean Colombia.
LID - E147 [pii]
LID - 10.3390/bs10100147 [doi]
AB  - Zika virus (ZIKV) infection during pregnancy can cause neurological
      manifestations such as microcephaly. The aim of this study was to explore
      perceptions of ZIKV and mental health in women exposed to ZIKV during pregnancy
      in Colombia. This was a mixed-methods study based on structured interviews and
      psychological tests. Structured interviews were transcribed and analysed with
      Atlas Ti software. A grounded theory approach was applied. Quantitative analysis 
      was performed with Statistical Package for Social Science, SPSS, V. 20. The study
      was approved by the Ethics Committee of the Universidad de Cordoba, Monteria.
      Seventeen women participated in the study; nine of them were mothers of children 
      with microcephaly. Maternal age ranged from 16 to 41 years old. The main themes
      discussed during interviews were: feelings, support, sources of information, and 
      consequences on children's health. Women with children affected by microcephaly
      showed worse mental health compared to women with normocephalic children.
      Maternal mental health worsened after 24 months from giving birth. Perceptions
      regarding disease severity and lack of knowledge were considered to affect
      maternal mental health. Social support and spirituality were key determinants for
      caregivers. Future research is needed to further study coping mechanisms and
      mental health outcomes over time by affected populations.
FAU - Romero-Acosta, Kelly
AU  - Romero-Acosta K
AUID- ORCID: 0000-0002-6568-1316
AD  - Faculty of Humanities and Education, Corporacion Universitaria del Caribe CECAR, 
      Sincelejo 700001, Colombia.
FAU - Marban-Castro, Elena
AU  - Marban-Castro E
AUID- ORCID: 0000-0002-9715-0595
AD  - Department of Maternal, Child, and Reproductive health, ISGlobal, Hospital
      Clinic-Universitat de Barcelona, 08036 Barcelona, Spain.
FAU - Arroyo, Katy
AU  - Arroyo K
AUID- ORCID: 0000-0003-3171-0702
AD  - Faculty of Humanities and Education, Corporacion Universitaria del Caribe CECAR, 
      Sincelejo 700001, Colombia.
FAU - Arrieta, German
AU  - Arrieta G
AD  - Clinica Salud Social SAS, Sincelejo 700002, Colombia.
FAU - Mattar, Salim
AU  - Mattar S
AD  - Instituto de Investigaciones Biologicas del Tropico, Universidad de Cordoba,
      Monteria 230002, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - Switzerland
TA  - Behav Sci (Basel)
JT  - Behavioral sciences (Basel, Switzerland)
JID - 101576826
PMC - PMC7599807
OTO - NOTNLM
OT  - emotional state
OT  - grounded theory
OT  - microcephaly
OT  - perceptions
OT  - women
OT  - zika
EDAT- 2020/10/01 06:00
MHDA- 2020/10/01 06:01
CRDT- 2020/09/30 01:01
PHST- 2020/06/03 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/09/30 01:01 [entrez]
PHST- 2020/10/01 06:00 [pubmed]
PHST- 2020/10/01 06:01 [medline]
AID - bs10100147 [pii]
AID - 10.3390/bs10100147 [doi]
PST - epublish
SO  - Behav Sci (Basel). 2020 Sep 25;10(10). pii: bs10100147. doi: 10.3390/bs10100147.


PMID- 32992153
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 139
DP  - 2020 Nov
TI  - Paediatric Strategy Forum for medicinal product development of epigenetic
      modifiers for children: ACCELERATE in collaboration with the European Medicines
      Agency with participation of the Food and Drug Administration.
PG  - 135-148
LID - S0959-8049(20)30465-2 [pii]
LID - 10.1016/j.ejca.2020.08.014 [doi]
AB  - The fifth multistakeholder Paediatric Strategy Forum focussed on epigenetic
      modifier therapies for children and adolescents with cancer. As most mutations in
      paediatric malignancies influence chromatin-associated proteins or transcription 
      and paediatric cancers are driven by developmental gene expression programs,
      targeting epigenetic mechanisms is predicted to be a very important therapeutic
      approach in paediatric cancer. The Research to Accelerate Cures and Equity (RACE)
      for Children Act FDARA amendments to section 505B of the FD&C Act was implemented
      in August 2020, and as there are many epigenetic targets on the FDA Paediatric
      Molecular Targets List, clinical evaluation of epigenetic modifiers in paediatric
      cancers should be considered early in drug development. Companies are also
      required to submit to the EMA paediatric investigation plans aiming to ensure
      that the necessary data to support the authorisation of a medicine for children
      in EU are of high quality and ethically researched. The specific aims of the
      forum were i) to identify epigenetic targets or mechanisms of action associated
      with epigenetic modification relevant to paediatric cancers and ii) to define the
      landscape for paediatric drug development of epigenetic modifier therapies. DNA
      methyltransferase inhibitors/hypomethylating agents and histone deacetylase
      inhibitors were largely excluded from discussion as the aim was to discuss those 
      targets for which therapeutic agents are currently in early paediatric and adult 
      development. Epigenetics is an evolving field and could be highly relevant to
      many paediatric cancers; the biology is multifaceted and new targets are
      frequently emerging. Targeting epigenetic mechanisms in paediatric malignancy has
      in most circumstances yet to reach or extend beyond clinical proof of concept, as
      many targets do not yet have available investigational drugs developed. Eight
      classes of medicinal products were discussed and prioritised based on the
      existing level of science to support early evaluation in children: inhibitors of 
      menin, DOT1L, EZH2, EED, BET, PRMT5 and LSD1 and a retinoic acid receptor alpha
      agonist. Menin inhibitors should be moved rapidly into paediatric development, in
      view of their biological rationale, strong preclinical activity and ability to
      fulfil an unmet clinical need. A combination approach is critical for successful 
      utilisation of any epigenetic modifiers (e.g. EZH2 and EED) and exploration of
      the optimum combination(s) should be supported by preclinical research and, where
      possible, molecular biomarker validation in advance of clinical translation. A
      follow-up multistakeholder meeting focussing on BET inhibitors will be held to
      define how to prioritise the multiple compounds in clinical development that
      could be evaluated in children with cancer. As epigenetic modifiers are
      relatively early in development in paediatrics, there is a clear opportunity to
      shape the landscape of therapies targeting the epigenome in order that efficient 
      and optimum plans for their evaluation in children and adolescents are developed 
      in a timely manner.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Pearson, Andrew Dj
AU  - Pearson AD
AD  - Accelerate, UK. Electronic address: andy1pearson@btinternet.com.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Dana-Faber Cancer Institute/Harvard Medical School, USA.
FAU - Bourdeaut, Franck
AU  - Bourdeaut F
AD  - Institute Curie, France.
FAU - Reaman, Gregory
AU  - Reaman G
AD  - US Food and Drug Administration, USA.
FAU - Heenen, Delphine
AU  - Heenen D
AD  - KickCancer Foundation, Belgium.
FAU - Meyers, Michael L
AU  - Meyers ML
AD  - Syndax Pharmaceuticals Inc, USA.
FAU - Armstrong, Scott A
AU  - Armstrong SA
AD  - Dana-Faber Cancer Institute/Harvard Medical School, USA.
FAU - Brown, Patrick
AU  - Brown P
AD  - Johns Hopkins Hospital, USA.
FAU - De Carvalho, Daniel
AU  - De Carvalho D
AD  - University Health Network, Canada.
FAU - Jabado, Nada
AU  - Jabado N
AD  - McGill University Health Centre, Canada.
FAU - Marshall, Lynley
AU  - Marshall L
AD  - Royal Marsden NHS Foundation Trust/Institute of Cancer Research, UK.
FAU - Rivera, Miguel
AU  - Rivera M
AD  - Massachusetts General Hospital, USA.
FAU - Smith, Malcolm
AU  - Smith M
AD  - National Cancer Institute, USA.
FAU - Adamson, Peter C
AU  - Adamson PC
AD  - Sanofi US, Emeritus Professor of Paediatrics and Pharmacology, Perelman School of
      Medicine, University of Pennsylvania, USA.
FAU - Barone, Amy
AU  - Barone A
AD  - US Food and Drug Administration, USA.
FAU - Baumann, Christian
AU  - Baumann C
AD  - GlaxoSmithKline, USA.
FAU - Blackman, Samuel
AU  - Blackman S
AD  - Day on Therapeutics Inc, USA.
FAU - Buenger, Vickie
AU  - Buenger V
AD  - Coalition Against Childhood Cancer, USA.
FAU - Donoghue, Martha
AU  - Donoghue M
AD  - US Food and Drug Administration, USA.
FAU - Duncan, Aundrietta D
AU  - Duncan AD
AD  - Salarius Pharma, USA.
FAU - Fox, Elizabeth
AU  - Fox E
AD  - St Jude Children's Research Hospital, USA.
FAU - Gadbaw, Brian
AU  - Gadbaw B
AD  - Novartis Pharmaceuticals Corp, USA.
FAU - Hattersley, Maureen
AU  - Hattersley M
AD  - AstraZeneca, USA.
FAU - Ho, Peter
AU  - Ho P
AD  - Boston Pharmaceuticals, USA.
FAU - Jacobs, Ira
AU  - Jacobs I
AD  - Pfizer, USA.
FAU - Kelly, Michael J
AU  - Kelly MJ
AD  - Syros Pharmaceuticals, USA.
FAU - Kieran, Mark
AU  - Kieran M
AD  - Bristol Myers Squibb, USA.
FAU - Lesa, Giovanni
AU  - Lesa G
AD  - Paediatric Medicines Office, Scientific Evidence Generation Department, Human
      Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
FAU - Ligas, Franca
AU  - Ligas F
AD  - Paediatric Medicines Office, Scientific Evidence Generation Department, Human
      Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
FAU - Ludwinski, Donna
AU  - Ludwinski D
AD  - Solving Kids' Cancer, USA.
FAU - McDonough, Joe
AU  - McDonough J
AD  - The Andrew McDonough B+ Foundation, USA.
FAU - Nikolova, Zariana
AU  - Nikolova Z
AD  - Celgene, Switzerland.
FAU - Norga, Koen
AU  - Norga K
AD  - Antwerp University Hospital, Paediatric Committee of the European Medicines
      Agency, Federal Agency for Medicines and Health Products, Belgium.
FAU - Senderowicz, Adrian
AU  - Senderowicz A
AD  - Constellation Pharma, USA.
FAU - Taube, Tilmann
AU  - Taube T
AD  - Boehringer Ingelheim, Germany.
FAU - Weiner, Susan
AU  - Weiner S
AD  - Children's Cancer Cause, USA.
FAU - Karres, Dominik
AU  - Karres D
AD  - Paediatric Medicines Office, Scientific Evidence Generation Department, Human
      Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
FAU - Vassal, Gilles
AU  - Vassal G
AD  - Gustave Roussy Cancer Centre, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200926
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Child
MH  - Drug Development
MH  - Epigenesis, Genetic/*drug effects
MH  - Epigenomics/methods
MH  - Europe
MH  - Humans
MH  - Medical Oncology/methods
MH  - Neoplasms/*drug therapy
MH  - United States
MH  - United States Food and Drug Administration
OTO - NOTNLM
OT  - *Cancer therapeutics
OT  - *Drug development
OT  - *Epigenetic mechanisms
OT  - *Paediatric oncology
OT  - *Paediatric strategy forum
COIS- Conflicts of interest statement MLM is an employee of Syndax Pharmaceuticals Inc.
      PB is a scientific advisor for Novartis, Syndax and Servier. DDC and MR are
      consultants for Loxo Oncology and receive research support from Advanced Cell
      Diagnostics. PCA is an employee of Sanofi. SB is an employee of Day One
      Therapeutics Inc. ADD is an employee of Salarius Pharma. BG is an employee of
      Novartis. MH is an employee of AstraZeneca. PH is an employee of Boston
      Pharmaceuticals. IJ is an employee of Pfizer. MJK is an employee of Syros
      Pharmaceuticals. MK is an employee of Bristol Myers Squibb. ZN is an employee of 
      Celgene. AS is an employee of Constellation Pharma. TT is an employee of
      Boehringer Ingelheim. ADJP has participated in advisory boards for Novartis,
      Takeda, Merck, Lilly and Celgene. All remaining authors have declared no
      conflicts of interest.
EDAT- 2020/09/30 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/09/29 20:13
PHST- 2020/07/14 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/09/29 20:13 [entrez]
AID - S0959-8049(20)30465-2 [pii]
AID - 10.1016/j.ejca.2020.08.014 [doi]
PST - ppublish
SO  - Eur J Cancer. 2020 Nov;139:135-148. doi: 10.1016/j.ejca.2020.08.014. Epub 2020
      Sep 26.


PMID- 32992106
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 2213-0772 (Electronic)
IS  - 2213-0764 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Dec
TI  - Rethinking ethical oversight in the era of the learning health system.
PG  - 100462
LID - S2213-0764(20)30061-0 [pii]
LID - 10.1016/j.hjdsi.2020.100462 [doi]
AB  - Opportunities to advance science increasingly arise through investigations
      embedded within routine clinical practice in the form of learning health systems.
      Such activities challenge conventional approaches to research regulation that
      have not caught up with those opportunities, often imposing burdens generalized
      from riskier research. We analyze the rules and conventions in the US,
      demonstrating how even those rules are compatible with a much more flexible
      approach to participant risk, institutional oversight, participant consent, and
      disclosure for low-risk learning activities in all jurisdictions.
CI  - Published by Elsevier Inc.
FAU - Asch, David A
AU  - Asch DA
AD  - University of Pennsylvania, Philadelphia, PA, USA; Cpl Michael J Crescenz VA
      Medical Center, Philadelphia, PA, USA. Electronic address:
      asch@wharton.upenn.edu.
FAU - Joffe, Steven
AU  - Joffe S
AD  - University of Pennsylvania, Philadelphia, PA, USA.
FAU - Bierer, Barbara E
AU  - Bierer BE
AD  - Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston,
      MA, USA.
FAU - Greene, Sarah M
AU  - Greene SM
AD  - SG Strategies, Seattle, WA, USA.
FAU - Lieu, Tracy A
AU  - Lieu TA
AD  - Kaiser Permanente Northern California, The Permanente Medical Group, Oakland, CA,
      USA.
FAU - Platt, Jodyn E
AU  - Platt JE
AD  - University of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Whicher, Danielle
AU  - Whicher D
AD  - National Academy of Medicine, Washington, DC, USA.
FAU - Ahmed, Mahnoor
AU  - Ahmed M
AD  - National Academy of Medicine, Washington, DC, USA.
FAU - Platt, Richard
AU  - Platt R
AD  - Harvard Medical School, Boston, MA, USA; Harvard Pilgrim Health Care Institute,
      Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - Healthc (Amst)
JT  - Healthcare (Amsterdam, Netherlands)
JID - 101622189
SB  - IM
MH  - Delivery of Health Care/*ethics/trends
MH  - *Ethical Relativism
MH  - Humans
MH  - Learning Health System/*trends
MH  - Quality Improvement
OTO - NOTNLM
OT  - Ethics
OT  - Learning health system
OT  - Regulation
EDAT- 2020/09/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/09/29 20:11
PHST- 2020/04/13 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/09/29 20:11 [entrez]
AID - S2213-0764(20)30061-0 [pii]
AID - 10.1016/j.hjdsi.2020.100462 [doi]
PST - ppublish
SO  - Healthc (Amst). 2020 Dec;8(4):100462. doi: 10.1016/j.hjdsi.2020.100462. Epub 2020
      Aug 25.


PMID- 32991465
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Chinese herbal medicine for psoriasis: Protocol for an overview of systematic
      reviews.
PG  - e22400
LID - 10.1097/MD.0000000000022400 [doi]
AB  - BACKGROUND: Psoriasis is a chronic recurrent dermatological disease that patents 
      always suffer from different comorbidities. Chinese herbal medicine (CHM) has
      been commonly used in the treatment of psoriasis for a long history. Previous
      systematic reviews (SRs)/meta-analyses (MAs) have shown that CHM may benefit
      patients with psoriasis. This overview aims to summarize the evidence from
      published SRs/MAs for clinical application and to provide several directions for 
      future researches. METHODS: Nine electronic databases (Medline, Embase, Cochrane 
      Library, AMED, CINAHL, CBM, CNKI, VIP Database, Wanfang Databases) will be
      searched from their inceptions to September 2020 without language restrictions.
      At least 2 reviewers will independently conduct the study selection, data
      extraction, and quality assessment. The methodological quality, risk of bias,
      reporting quality, and evidence quality will be respectively evaluated by the
      Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR 2), the Risk
      of Bias in Systematic Reviews, the Preferred Reporting Items for Systematic
      Reviews and Meta-Analyses (PRISMA), and the Grading of Recommendations,
      Assessment, Development and Evaluation (GRADE) system. RESULTS: The results of
      this overview will be submitted to a peer-reviewed journal for publication.
      CONCLUSIONS: We expect to compile current evidence from published SRs/MAs of CHM 
      for patients with psoriasis in an accessible and useful document. ETHICS AND
      DISSEMINATION: This study is a protocol for an overview of SRs/MAs that did not
      involve individual data. Thus, ethical approval is not required. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/VC654.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Yu, Qianying
AU  - Yu Q
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Peng, Li
AU  - Peng L
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Lin, Wenxia
AU  - Lin W
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Qin, Yuesi
AU  - Qin Y
AD  - Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, Sichuan Province, P.
      R. China.
FAU - He, Ying
AU  - He Y
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Guo, Jing
AU  - Guo J
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Xiao, Min
AU  - Xiao M
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Chen, Mingling
AU  - Chen M
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Chronic Disease
MH  - Humans
MH  - Medicine, Chinese Traditional/adverse effects/*methods
MH  - Meta-Analysis as Topic
MH  - Psoriasis/*therapy
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7523869
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022400 [doi]
AID - 00005792-202009250-00067 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22400. doi:
      10.1097/MD.0000000000022400.


PMID- 32991462
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Perioperative analgesia after intrathecal morphine or local infiltration
      anesthesia for total knee replacement: A protocol for randomized controlled
      trial.
PG  - e22394
LID - 10.1097/MD.0000000000022394 [doi]
AB  - OBJECTIVE: We perform this protocol for randomized controlled trial to compare
      the efficacy of intrathecal morphine and local infiltration anesthesia (LIA) in
      the treatment of the postoperative pain after total knee replacement (TKR).
      METHODS: This is a randomized controlled, single center trial which was performed
      from March 2019 to March 2020. This trial is conducted according to the SPIRIT
      Checklist of randomized researches. It is authorized via the Ethics Committee of 
      Beijing Friendship Hospital (2019-P2-050-01). Eighty participants who undergo TKR
      were randomized into 2 groups. Intrathecal morphine group: 0.1 mg of the morphine
      was intrathecally injected, and the spinal anesthetic was injected at the same
      time in the group LIA; In the LIA group: the knee joint was infiltrated with
      epinephrine, ketorologic acid and ropivacaine in the process of operation, and
      the identical mixture was injected 2 bolus through the intraarticular catheter
      after operation. The main outcome variables were the visual analog scale and the 
      consumption amount of opioid every 6-hour interval within 2 days postoperatively.
      The secondary outcome variables were the side effects associated with opioid, the
      length of hospital stay, motion range, and the loss of blood collected by the
      closed suction drainage. All the required analyses were carried out via applying 
      the SPSS for Windows Version 19.0. RESULTS: The clinical outcome variables
      between groups were shown in . CONCLUSION: This protocol will provide the
      evidence on which technique can achieve better analgesia after TKR.
FAU - Qi, Zhengrong
AU  - Qi Z
AD  - Department of Orthopedics, Beijing Friendship Hospital, Capital Medical
      University, Beijing, China.
FAU - Guo, Ai
AU  - Guo A
FAU - Ma, Lifeng
AU  - Ma L
AUID- ORCID: 0000-0001-5756-9810
FAU - Li, Zhiyao
AU  - Li Z
FAU - Yang, Bo
AU  - Yang B
FAU - Zhang, Jingxin
AU  - Zhang J
LA  - eng
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Analgesics, Opioid)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Analgesics, Opioid/*administration & dosage
MH  - *Anesthesia, Local
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Humans
MH  - Injections, Spinal
MH  - Morphine/*administration & dosage
MH  - Pain, Postoperative/etiology/*prevention & control
MH  - Randomized Controlled Trials as Topic
PMC - PMC7523756
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022394 [doi]
AID - 00005792-202009250-00064 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22394. doi:
      10.1097/MD.0000000000022394.


PMID- 32991457
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Non-pharmacological interventions for depressive disorder in patients after
      traumatic brain injury: A protocol for a systematic review and network
      meta-analysis.
PG  - e22375
LID - 10.1097/MD.0000000000022375 [doi]
AB  - BACKGROUND: Depressive disorder has gradually become one of the most commonly
      reported disabling psychiatric complication that occurs after traumatic brain
      injury (TBI). Currently classical antidepressant medications may not have the
      same effectiveness in patients with TBI as in patients without TBI.
      Non-pharmacological interventions have been considered to be effective for
      managing depressive symptoms or treating depressive disorder. But to date the
      comparative effectiveness of various types of non-pharmacological interventions
      has been synthesized in few studies, the evidence remains inconclusive. Thus, the
      purpose of this systematic review and network meta-analyses is to summarize
      high-quality evidence and identify the most effective non-pharmacological
      intervention when applied to treat the depressive disorder in patients after TBI.
      METHODS: The comprehensive literature search in electronic database including
      PubMed, Ovid Medline, Cochrane Library, Web of Science database, Embase Database,
      China National Knowledge Infrastructure (CNKI), and Wanfang Data Chinese database
      from inception to the search date. Only high-quality randomized controlled trials
      (RCTs) that have used non-pharmacological interventions to treat depressive
      disorder after TBI will be considered. Two independent reviewers will identify
      eligible studies, extract and manage data information, and then determine
      methodical quality of included studies. Overall efficacy will be assessed as
      primary outcome. Secondary outcomes involved treatment response, remission rate, 
      overall acceptability, tolerability of treatment, social functioning, occurrence 
      of adverse events, and suicide-related outcome. Cochrane risk of bias assessment 
      tool will be adopted to assess the risk of bias. Study heterogeneity will be
      measured by the I statistic. Traditional pairwise meta-analyses will be performed
      using STATA, while WinBUGS with GeMTC package of R software will be used to carry
      out network meta-analysis. RESULTS: This systematic review will examine the
      relative efficacy, effectiveness, safety, tolerability and acceptability of
      non-pharmacological interventions, and then to identify the most effective
      non-pharmacological intervention for depressive disorder after TBI. EXPECTED
      CONCLUSION: Our work could be used to give clinical recommendations for practice 
      guideline developers, psychiatrist, neurologist, policymakers, researchers as
      well as individual with depressive disorder after TBI, and will also identify
      gaps in knowledge that could be the subject of future research. ETHICS AND
      DISSEMINATION: Neither ethics approval nor patient informed consent is necessary 
      since this protocol was designed based on the existing literature. The results
      will be disseminated electronically or in print through publications in
      peer-reviewed scientific journal. INPLASY REGISTRATION: INPLASY202080022.
FAU - Xu, Mingmin
AU  - Xu M
AD  - School of Acupuncture-Moxibustion and Tuina/The Third Affiliated Hospital,
      Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Guo, Yu
AU  - Guo Y
AUID- ORCID: 0000-0002-1752-1254
AD  - Teaching and Research Section of Acupuncture.
AD  - Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan
      University, Guangzhou.
FAU - Wei, Yulong
AU  - Wei Y
AD  - School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese
      Medicine, Beijing, China.
FAU - Wang, Lu
AU  - Wang L
AD  - School of Acupuncture-Moxibustion and Tuina/The Third Affiliated Hospital,
      Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Feng, Xiumei
AU  - Feng X
AD  - School of Acupuncture-Moxibustion and Tuina/The Third Affiliated Hospital,
      Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Chen, Yue
AU  - Chen Y
AD  - School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese
      Medicine, Beijing, China.
FAU - Yan, Jian
AU  - Yan J
AD  - School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese
      Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Brain Injuries, Traumatic/*complications
MH  - Depressive Disorder/etiology/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7523874
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022375 [doi]
AID - 00005792-202009250-00059 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22375. doi:
      10.1097/MD.0000000000022375.


PMID- 32991451
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Efficacy and safety of Kanglaite injection combined with chemotherapy for
      colorectal cancer: A protocol for systematic review and meta-analysis.
PG  - e22357
LID - 10.1097/MD.0000000000022357 [doi]
AB  - BACKGROUND: The incidence and mortality of colorectal cancer are high.
      Chemotherapy is currently the commonly used therapeutic scheme, but there are
      drug resistance and toxic and side effects. Kanglaite (KLT) injection is a
      broad-spectrum anticancer drug extracted from Semen Coicis (Yi Yi Ren), which has
      been widely used in the treatment of colorectal cancer. Clinical practice shows
      that KLT injection combined with chemotherapy has certain therapeutic advantages,
      but there is a lacking of evidence of evidence-based medicine. The purpose of
      this study is to systematically investigate the efficacy and safety of KLT
      injection combined with chemotherapy in the treatment of colorectal cancer.
      METHODS: Randomized controlled trials of KLT injection combined with chemotherapy
      in the treatment of colorectal cancer were retrieved from English databases
      (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese databases
      (China National Knowledge Infrastructure, Wanfang, Chongqing VIP Chinese Science 
      and Technology Periodical Database, Chinese Biological and Medical database), as 
      well as searching Baidu academic and Google academic manually, and the retrieval 
      time was from their establishment to August 2020. Two researchers independently
      conducted data extraction and literature quality evaluation on the quality of the
      included literatures, and meta-analysis was conducted on the included literatures
      using RevMan 5.3 (developed by the UK's International Cochrane Collaboration).
      RESULTS: This study assessed the efficacy and safety of KLT injection combined
      with chemotherapy in the treatment of colorectal cancer by effective rate,
      Karnofsky Performance Status, Carcinoemybryonic Angtigen remission rate, pain
      remission rate, and incidence of adverse reactions etc. CONCLUSIONS:: This study 
      will provide reliable evidence-based evidence for the clinical application of KLT
      injection combined with chemotherapy in the treatment of colorectal cancer.
      ETHICS AND DISSEMINATION: The private information from individuals will not be
      published. This systematic review also will not involve endangering participant
      rights. Ethical approval is not required. The results may be published in a
      peer-reviewed journal or disseminated in relevant conferences. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/EKVAF.
FAU - Mao, Weili
AU  - Mao W
AUID- ORCID: 0000-0001-5000-5895
AD  - People's Hospital of QuZhou, Quzhou, Zhejiang province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Cheng, Chao
AU  - Cheng C
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Yuan, Xingyu
AU  - Yuan X
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Lan, Tian
AU  - Lan T
AD  - People's Hospital of QuZhou, Quzhou, Zhejiang province.
FAU - Mao, Kaili
AU  - Mao K
AD  - People's Hospital of QuZhou, Quzhou, Zhejiang province.
FAU - Wang, Jun
AU  - Wang J
AD  - People's Hospital of QuZhou, Quzhou, Zhejiang province.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Drugs, Chinese Herbal)
RN  - YCB6D9ELEQ (kang-lai-te)
SB  - IM
MH  - Age Factors
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse
      effects/*therapeutic use
MH  - Cancer Pain/drug therapy
MH  - Carcinoembryonic Antigen/blood
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Karnofsky Performance Status
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7523838
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022357 [doi]
AID - 00005792-202009250-00053 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22357. doi:
      10.1097/MD.0000000000022357.


PMID- 32991439
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Effects of Guizhi decoction for diabetic cardiac autonomic neuropathy: A protocol
      for a systematic review and meta-analysis.
PG  - e22317
LID - 10.1097/MD.0000000000022317 [doi]
AB  - BACKGROUND: Diabetic cardiac autonomic neuropathy (DCAN) is one of the serious
      complications of diabetes. The pathogenesis of DCAN has not been fully
      elucidated. There is currently no effective treatment for such chronic disease.
      Traditional Chinese medicine has a long clinical history for the prevention and
      treatment of diabetes and chronic complications, and it also shows certain
      advantages in the treatment of DCAN. Many clinical studies have confirmed that
      Chinese medicine Guizhi decoction can reduce the clinical symptoms and improve
      neuronal function of patients with DCAN. So we intend to conduct a systematic
      review further clarified the effectiveness and safety of Guizhi decoction for
      DCAN. METHODS: We will search each database from the built-in until July 2020.
      The English literature mainly searches Cochrane Library, PubMed, EMBASE, and Web 
      of Science, while the Chinese literature comes from CNKI, CBM, VIP, and Wangfang 
      database. Simultaneously we will retrieval clinical registration tests and grey
      literatures. In this study, only the clinical randomized controlled trials (RCTs)
      were selected to evaluate the efficacy and safety of Guizhi decoction in the
      treatment of DCAN. The 2 researchers independently conducted literature
      selection, data extraction, and quality assessment. Statistical heterogeneity
      among studies will be evaluated using the Cochran Q test (x) and the I
      statistical value. We will utilize the Review Manage software V5.3.0 (The Nordic 
      Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) to
      statistically analyze all data. ETHICS AND DISSEMINATION: This study is a
      protocol for a systematic review of Guizhi decoction as a treatment of DCAN
      patients. RESULTS: This study will provide high-quality synthesis of
      effectiveness and safety of Guizhi decoction for DCAN. CONCLUSION: This
      systematic review aims to provide new options for Guizhi decoction treatment of
      DCAN in terms of its efficacy and safety. REGISTRATION NUMBER: INPLASY202080018.
FAU - Chen, Junmin
AU  - Chen J
AUID- ORCID: 0000-0002-0086-1607
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Cai, Jiawei
AU  - Cai J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Wei, Mengya
AU  - Wei M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Zhang, Xiaoran
AU  - Zhang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Zhong, Min
AU  - Zhong M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Liu, Min
AU  - Liu M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Yu, Yang
AU  - Yu Y
AD  - College of acupuncture and massage, Chengdu University of Traditional Chinese
      Medicine , No 37 Shi-er-qiao Road, Chengdu, Sichuan Province, PR China.
FAU - Chen, Qiu
AU  - Chen Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (guizhi decoction)
SB  - IM
MH  - Blood Glucose
MH  - Diabetic Neuropathies/*drug therapy
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin A
MH  - Heart Diseases/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7523786
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022317 [doi]
AID - 00005792-202009250-00041 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22317. doi:
      10.1097/MD.0000000000022317.


PMID- 32991427
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Comparative efficacy and safety of traditional Chinese patent medicine for
      anxiety disorders in children or adolescence: A protocol for systematic review
      and network meta-analysis.
PG  - e22274
LID - 10.1097/MD.0000000000022274 [doi]
AB  - BACKGROUND: Anxiety is the most common mental illness among adolescents and
      children, and its incidence is increasing year by year, which has a serious
      adverse effect on the academic and growth of adolescents and children.
      Conventional treatment methods such as oral administration of western medicine
      and psycho-behavioral therapy have obvious limitations. Chinese patent medicines 
      play an irreplaceable role in the treatment of this disease. At present, there is
      no comparison of the safety and effectiveness of various Chinese patent medicines
      curing anxiety in adolescents. So we take advantage of the method of network
      meta-analysis to systematically compare the efficacy of various Chinese patent
      medicines curing this disease. METHODS: We will systematically and
      comprehensively search the following databases, including PubMed, Web of Science,
      EMBASE, The Cochrane Library, China BioMedical Literature (CBM), China National
      Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and 
      Wanfang database. We will include all RCT trials that meet the inclusion
      criteria, starting from the establishment of the database until August 2020. Two 
      researchers will independently screen the literature based on inclusion criteria.
      While extracting data, we also assess the risk of bias in the included studies.
      All the data and evidence obtained will be evaluated by the method of Bayesian
      network meta-analysis. STATA and WinBUGS software will be used. RESULTS: This
      study will evaluate the effectiveness and safety of various TCPMs for anxiety
      disorders in children or adolescence. CONCLUSION: The results of this study will 
      provide valuable references for the clinical application of Traditional Chinese
      patent medicines, and assist clinicians in formulating more reasonable diagnosis 
      and treatment strategies. ETHICS AND DISSEMINATION: This study does not require
      ethical approval. INPLASY REGISTRATION NUMBER: INPLASY202080048.
FAU - Jiang, Zhenyuan
AU  - Jiang Z
AUID- ORCID: 0000-0001-8702-2955
AD  - First College of Clinical Medicine, Shandong University of Traditional Chinese
      Medicine.
FAU - Wang, Jiahao
AU  - Wang J
AD  - First College of Clinical Medicine, Shandong University of Traditional Chinese
      Medicine.
FAU - Yu, Xiaowen
AU  - Yu X
AD  - Affiliated Hospital of Shandong University of Traditional Chinese Medicine,
      Jinan, Shandong Province, China.
FAU - Li, Chuancheng
AU  - Li C
AD  - First College of Clinical Medicine, Shandong University of Traditional Chinese
      Medicine.
FAU - Shao, Yuze
AU  - Shao Y
AD  - First College of Clinical Medicine, Shandong University of Traditional Chinese
      Medicine.
FAU - Wang, Zhonglin
AU  - Wang Z
AD  - Affiliated Hospital of Shandong University of Traditional Chinese Medicine,
      Jinan, Shandong Province, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Nonprescription Drugs)
SB  - IM
MH  - Adolescent
MH  - Anxiety Disorders/*drug therapy
MH  - Bayes Theorem
MH  - Child
MH  - Clinical Protocols/standards
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Network Meta-Analysis
MH  - Nonprescription Drugs/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7523822
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022274 [doi]
AID - 00005792-202009250-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22274. doi:
      10.1097/MD.0000000000022274.


PMID- 32991426
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - The impact of COVID-19 on intestinal flora: A protocol for systematic review and 
      meta analysis.
PG  - e22273
LID - 10.1097/MD.0000000000022273 [doi]
AB  - BACKGROUND: Coronavirus disease (COVID-19) sparked global concern for its
      outbreak and pandemic. It caused severe respiratory tract infections and a
      significant proportion of patients with gastrointestinal symptoms. Several
      studies have investigated the intestinal flora of COVID-19. However, so far there
      has been no evidence demonstrating the evidence on the association of COVID-19
      with intestinal flora through meta-analysis. A systematic and comprehensive
      understanding of their relationship is essential to provide public health
      prevention or treatment strategy. METHODS AND ANALYSIS: This systematic review
      and meta-analysis will be reported following the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses guidelines. Observational studies (cohort
      studies, case-control, and cross-sectional studies) and clinical trials will be
      eligible. Studies eligible for inclusion must contain participants with COVID-19.
      Systematic searches will be conducted in PubMed, EMBASE, Cochrane Library, Ovid, 
      EBSCO, World Health Organization COVID-19 database, China National Knowledge
      Internet, WanFang Data, Chinese Scientific and Technological Journal Database,
      and Chinese Biomedical Databases. A pre-designed search strategy of medical
      subject headings and free text terms for COVID-19 and intestinal flora will be
      used. Two reviewers will independently screen the titles and abstracts, followed 
      by full-text screening. Discrepancies will be resolved by consensus with a third 
      reviewer. The reviewers will then extract data from each eligible article based
      on PECOS (Population, Exposure, Comparator, Outcomes, and Study design). The risk
      of bias and quality of included studies will be assessed using an appropriate
      tool. A random-effects meta-analysis will be considered where there are
      sufficiently homogeneous studies; otherwise, a narrative synthesis will be
      conducted. Heterogeneity among studies will be assessed using I statistics. If
      substantial heterogeneity detected, subgroup analyses and meta-regression will be
      conducted to look for the potential causes. ETHICS AND DISSEMINATION: Ethical
      approval is not required as we will use data from published articles. Findings
      will be published in a peer-reviewed journal.PROSPERO registration number:
      CRD42020191640.
FAU - Li, Fangyuan
AU  - Li F
AD  - College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine Affiliated Hospital.
FAU - Lu, Hua
AU  - Lu H
AD  - College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine Affiliated Hospital.
FAU - Li, Xinyun
AU  - Li X
AD  - College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine Affiliated Hospital.
FAU - Wang, Xinxin
AU  - Wang X
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine Affiliated Hospital.
FAU - Mi, Ling
AU  - Mi L
AD  - Maternal and Child Reproductive Hospital Affiliated to Chengdu University of
      Traditional Chinese Medicine, Chengdu, Sichuan Province, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*pathology
MH  - Gastrointestinal Microbiome/*physiology
MH  - Humans
MH  - Observational Studies as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*pathology
MH  - Research Design
MH  - SARS-CoV-2
PMC - PMC7523765
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022273 [doi]
AID - 00005792-202009250-00028 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22273. doi:
      10.1097/MD.0000000000022273.


PMID- 32991413
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Auricular acupuncture for premature ovarian insufficiency: A protocol for
      systematic review and meta-analysis.
PG  - e22212
LID - 10.1097/MD.0000000000022212 [doi]
AB  - BACKGROUND: A lot of attention has been given to premature ovarian insufficiency 
      (POI) as it poses considerable health risks to women. It is characterized by
      oligomenorrhea, amenorrhea, infertility, autoimmune disorders, and ischemic heart
      disease, with increased mortality. Previous research indicates that auricular
      acupuncture is proven effective in treating POI in clinical practice. However,
      systematic review has not been carried out. Therefore, this study aims at
      evaluating the curative effect and safety of auricular acupuncture treatment for 
      POI through systematic review and meta-analysis. METHODS AND ANALYSIS: The
      following databases will be searched for relevant information before August 2020:
      PubMed, Embase, Cochrane Library, Web of Science, and CNKI. MAJOR RESULTS: levels
      of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estrogen
      (E2). Secondary results: modified Kupperman Index, imaging results including
      ovarian size, antral follicle count, and blood flow changes in the ovary using
      color Doppler ultrasound; total effective rate, adverse event and intervention,
      and hospitalization expenses. Data will be collected independently by 2
      researchers, and the risk of bias in meta-analysis will be evaluated according to
      "Cochrane Handbook for Systematic Reviews of Interventions". All data analysis
      will be conducted using Review Manager V.5.3. and Stata V.12.0. RESULTS: The
      curative effect and safety of auricular acupuncture treatment for POI patients
      will be evaluated systematically. CONCLUSION: In the systematic review, the
      published evidence of auricular acupuncture treatment for POI will be summarized 
      to provide guidance for promotion and application. ETHICS AND DISSEMINATION: The 
      private information from individuals will not be published. This systematic
      review also will not involve endangering participant rights. Ethical approval is 
      not required. The results may be published in a peer-reviewed journal or
      disseminated in relevant conferences.Open Science Framework (OSF) registration
      number: http://osf.io/tg9mw.
FAU - Luo, Yehao
AU  - Luo Y
AD  - Guangxi university of Traditional Chinese Medicine, Nanning, Guangxi Province.
FAU - Xu, Donghan
AU  - Xu D
AD  - Macau University of Science and Technology, Macau.
FAU - Tang, Xiusong
AU  - Tang X
AD  - Guangxi university of Traditional Chinese Medicine, Nanning, Guangxi Province.
FAU - Wei, Luqiu
AU  - Wei L
AD  - Guangxi university of Traditional Chinese Medicine, Nanning, Guangxi Province.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Pang, Yuzhou
AU  - Pang Y
AD  - Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Guangxi
      University of Chinese Medicinee, Nanning, Guangxi Province, China.
FAU - Fang, Gang
AU  - Fang G
AUID- ORCID: 0000-0001-9836-4571
AD  - Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Guangxi
      University of Chinese Medicinee, Nanning, Guangxi Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture, Ear/*methods
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Primary Ovarian Insufficiency/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7523783
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022212 [doi]
AID - 00005792-202009250-00015 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22212. doi:
      10.1097/MD.0000000000022212.


PMID- 32991409
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Effectiveness of psychological interventions for treating chronic
      prostatitis/chronic pelvic pain syndrome: A protocol for systematic review and
      meta-analysis.
PG  - e22151
LID - 10.1097/MD.0000000000022151 [doi]
AB  - INTRODUCTION: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one
      of the most common diseases in urology, which 50% of men are infected at some
      point in their lives. Type III CP/CPPS is the most complex and controversial of
      all types of prostatitis, the highest incidence rate, uncertain efficacy, the
      long-term treatment that affects the patient's psychopathic symptoms, increases
      the psychological burden of patients. Psychological intervention for patients
      with CP/CPPS, which is difficult to treat with drugs and physics, can effectively
      improve clinical efficacy and improve the psychological condition. The
      researchers found a high prevalence of psychosocial problems and catastrophic
      distress in CP/CPPS patients, such as serious mental disorders, especially
      depression, anxiety and stress, and the high incidence of pain-devastating
      illness. In this study, we will evaluate psychological interventions as an
      effective way to relieve chronic prostatitis. METHODS AND ANALYSIS: The databases
      of English databases (PubMed, MEDLINE, EMBASE, Web of Science, Cochrane Library) 
      and Chinese databases (China National Knowledge Infrastructure, China Biology
      Medicine Database, Wanfang Database, VIP Database) will be retrieved. The search 
      strategy that will be run in the PubMed and tailored to the other database when
      necessary is presented in this article. RevMan 5.3 and Stata 11.0 will be used
      for Systematic Review and Meta-analysis. This protocol reported under the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols
      (PRISMA-P) statement, and we will report the systematic review by following the
      PRISMA statement. RESULTS: The study is a protocol for systematic review and
      meta-analysis without results, and data analysis will be carried out after the
      protocol. We will share our findings in the third quarter of 2021. CONCLUSION:
      This systematic review will provide more evidence to assess whether psychological
      is an effective intervention for patients with chronic prostatitis/chronic pelvic
      pain syndrome. Besides, the results will be published in a public issue journal
      and offer the urologists help to make clinical decisions. ETHICS AND
      DISSEMINATION: Formal ethical approval is not required in this protocol. We will 
      collect and analyze data based on published research. Since this research does
      not involve patients, personal privacy will not be affected. The results of this 
      review will be distributed to peer-reviewed journals or submitted to relevant
      conferences. PROTOCOL REGISTRATION NUMBER: INPLASY202080021.
FAU - Xu, Yuanjie
AU  - Xu Y
AUID- ORCID: 0000-0002-7514-8937
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Shen, Yifeng
AU  - Shen Y
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Yao, Hangyu
AU  - Yao H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Yong, Shanshan
AU  - Yong S
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - You, Yaodong
AU  - You Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Age Factors
MH  - Chronic Disease
MH  - Humans
MH  - Male
MH  - Pelvic Pain/*psychology
MH  - Prostatitis/*psychology
MH  - Psychotherapy/*methods
MH  - Qualitative Research
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Severity of Illness Index
MH  - Socioeconomic Factors
PMC - PMC7523870
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000022151 [doi]
AID - 00005792-202009250-00011 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e22151. doi:
      10.1097/MD.0000000000022151.


PMID- 32991400
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 39
DP  - 2020 Sep 25
TI  - Interventions to improve physical performances of older people with cancer before
      complex medico-surgical procedures: Protocol for an umbrella review of systematic
      reviews and meta-analyses.
PG  - e21780
LID - 10.1097/MD.0000000000021780 [doi]
AB  - BACKGROUND: Current demographics lead increasing older cancer patients to undergo
      complex medico-surgical procedures, with substantial risk of decompensations and 
      deconditioning. The Prehabilitation & Rehabilitation in Oncology: Adaptation to
      Disease and Accompaniment of Patients' Trajectories (PROADAPT) project is
      currently being developed with the aim of improving care, through standardized
      care pathways guided by existing evidence and implementation programs. A working 
      group will specifically focus on improvement of physical performances before such
      procedures. These interventions may have been developed in different contexts:
      before surgery in large, before carcinologic surgery or complex medical
      interventions (chemotherapy, radiotherapy), or in primary care for elderly
      patients to prevent sarcopenia and frailty. Post-surgical interventions are out
      of the scope of this review. The objective of this review is to summarize the
      level of evidence to support physical reconditioning interventions and identify
      areas where further work is required. METHODS: This umbrella review will include 
      moderate to high quality systematic reviews, meta-analysis, and pre-existing
      umbrella or meta-reviews. Two reviewers will independently search the following
      databases: PubMed/MedLine, Cochrane Library, Embase, and CINAHL. Research
      strategy will use diverse keywords used to refer to the concepts of
      "prehabilitation," "preoperative exercise," or "preoperative rehabilitation,"
      with prespecified inclusion and exclusion criteria and only systematic reviews
      selection. The distinct types of interventions presented using PRISMA guidelines 
      and a narrative reporting of results. A focus will be made on outcomes such as
      physical performances, quality of life, autonomy in everyday activities, or
      number of hospital bed days. ETHICS AND DISSEMINATION: Ethical approval is not
      required for such an umbrella review. Our review will be submitted for
      publication in a peer-reviewed international journal using open access option if 
      available. It will be complementary to reviews focused on hospital discharge of
      older people. PROSPERO REGISTRATION NUMBER: CRD42020100110.
FAU - Falandry, Claire
AU  - Falandry C
AUID- ORCID: 0000-0001-7267-4723
AD  - Geriatric Unit, Lyon-Sud Hospital.
AD  - CarMeN Laboratory, Inserm U1060, INRA U1397, Universite Claude Bernard Lyon 1,
      INSA Lyon, Charles Merieux Medical School, Lyon University, Oullins.
FAU - Stefani, Laetitia
AU  - Stefani L
AD  - Oncology Department, Centre Hospitalier Annecy Genevois, Pringy.
FAU - Andre, Louise
AU  - Andre L
AD  - Geriatric Unit, Lyon-Sud Hospital.
FAU - Granger, Marion
AU  - Granger M
AD  - Geriatric Unit, Lyon-Sud Hospital.
FAU - Barbavara, Claire
AU  - Barbavara C
AD  - Geriatric Unit, Lyon-Sud Hospital.
FAU - Habchi, Hocine
AU  - Habchi H
AD  - Urology Department, University Hospital Jean Monnet, St. Etienne.
FAU - Bourgeois, Chrystelle
AU  - Bourgeois C
AD  - Oncology Department, Centre Hospitalier Annecy Genevois, Pringy.
FAU - Cure, Herve
AU  - Cure H
AD  - Department of Medical Oncology, CHU de Grenoble, La Tronche.
FAU - Passot, Guillaume
AU  - Passot G
AD  - Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon,
      University of Lyon.
FAU - Gilbert, Thomas
AU  - Gilbert T
AD  - Geriatric Unit, Lyon-Sud Hospital.
AD  - Health Services and Performance Research (HESPER EA7425), Lyon, France.
CN  - PROADAPT working group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - Exercise
MH  - Humans
MH  - Medical Oncology/methods
MH  - Meta-Analysis as Topic
MH  - Neoplasms/*therapy
MH  - *Physical Functional Performance
MH  - Preoperative Care/*methods
MH  - Preoperative Period
MH  - Quality of Life
MH  - Systematic Reviews as Topic
PMC - PMC7523808
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/MD.0000000000021780 [doi]
AID - 00005792-202009250-00002 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 25;99(39):e21780. doi:
      10.1097/MD.0000000000021780.


PMID- 32991328
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Micro and Macro Ethical Considerations of COVID-19.
PG  - 318-325
LID - 2020314318 [pii]
AB  - Micro decisions, made by individuals, during a health crisis in which healthcare 
      resources are particularly in short supply, should not be based only on the age
      of the patients. Ameliorate care is only appreciated when the patient has a
      limited time to live, whatever their age. Macro decisions concern public policy. 
      We must decide now who will pay for the vaccines, who will get them before
      others, whether minorities should be granted priority, and whether the United
      States should join a global distribution system.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Etzioni, Amitai
AU  - Etzioni A
AD  - George Washington University, Washington, District of Columbia USA. icps@gwu.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - *Health Policy
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United States
EDAT- 2020/09/30 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 2020314318 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):318-325.


PMID- 32991327
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Winter
TI  - Developing a Triage Protocol for the COVID-19 Pandemic: Allocating Scarce Medical
      Resources in a Public Health Emergency.
PG  - 303-317
LID - 2020314303 [pii]
AB  - The coronavirus disease-2019 (COVID-19) has caused shortages of life-sustaining
      medical resources, and future waves of the virus may cause further scarcity. The 
      Yale New Haven Health System developed a triage protocol to allocate scarce
      medical resources during the COVID-19 pandemic, with the primary goal of saving
      the most lives possible, and a secondary goal of making triage assessments and
      decisions consistent, transparent, and fair. We outline the process of developing
      the triage protocol, summarize the protocol itself, and discuss the major ethical
      challenges encountered, along with our answers to these challenges. These
      challenges include (1) the role of age and chronic comorbidities; (2) evaluating 
      children and pregnant patients; (3) racial, ethnic, and socioeconomic disparities
      in health; (4) prioritization of healthcare workers; and (5) balancing clinical
      judgment versus protocolized assessments. We conclude with a review of the
      limitations of our protocol and the lessons learned. We hope that a robust public
      discussion of such protocols and the ethical challenges that they raise will
      result in the fairest possible processes, less need for triage, and more lives
      saved during future waves of the COVID-19 pandemic and similar public health
      emergencies.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Tolchin, Benjamin
AU  - Tolchin B
AD  - Department of Neurology, Yale School of Medicine, New Haven, Connecticut USA.
      benjamin.tolchin@yale.edu.
FAU - Latham, Stephen R
AU  - Latham SR
AD  - Yale Interdisciplinary Center for Bioethics, New Haven, Connecticut USA.
      stephen.latham@yale.edu.
FAU - Bruce, Lori
AU  - Bruce L
AD  - Yale Interdisciplinary Center for Bioethics, New Haven, Connecticut USA.
      lori.bruce@yale.edu.
FAU - Ferrante, Lauren E
AU  - Ferrante LE
AD  - Department of Medicine, Yale School of Medicine, New Haven, Connecticut USA.
      lauren.ferrante@yale.edu.
FAU - Kraschel, Katherine
AU  - Kraschel K
AD  - Solomon Center, Yale Law School, New Haven, Connecticut USA.
      katherine.kraschel@yale.edu.
FAU - Jubanyik, Karen
AU  - Jubanyik K
AD  - Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut
      USA. karen.jubanyik@yale.edu.
FAU - Hull, Sarah C
AU  - Hull SC
AD  - Program for Biomedical Ethics, Yale School of Medicine, New Haven, Connecticut
      USA. sarah.hull@yale.edu.
FAU - Herbst, Jennifer L
AU  - Herbst JL
AD  - Quinnipiac University School of Law, Hamden, Connecticut USA.
      jennifer.herbst@quinnipiac.edu.
FAU - Kapo, Jennifer
AU  - Kapo J
AD  - Palliative Medicine, Yale School of Medicine, New Haven, Connecticut USA.
      jennifer.kapo@yale.edu.
FAU - Moritz, Ernest D
AU  - Moritz ED
AD  - Adult Ethics Committee, Yale New Haven Health System, New Haven, Connecticut USA.
      ernest.moritz@ynhh.org.
FAU - Hughes, John
AU  - Hughes J
AD  - Department of Medicine, Yale School of Medicine, New Haven, Connecticut USA.
      hughes.john@yale.edu.
FAU - Siegel, Mark D
AU  - Siegel MD
AD  - Department of Medicine, Yale School of Medicine, New Haven, Connecticut USA.
      mark.siegel@yale.edu.
FAU - Mercurio, Mark R
AU  - Mercurio MR
AD  - Pediatrics and Program for Biomedical Ethics, Yale School of Medicine, in New
      Haven, Connecticut USA. mark.mercurio@yale.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections
MH  - Emergencies
MH  - Female
MH  - Health Care Rationing/*ethics
MH  - Health Resources/*supply & distribution
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - Pregnancy
MH  - Public Health
MH  - SARS-CoV-2
MH  - Triage/*ethics
EDAT- 2020/09/30 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/29 17:13
PHST- 2020/09/29 17:13 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 2020314303 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Winter;31(4):303-317.


PMID- 32991303
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Oct 8
TI  - Coping Skills Mobile App to Support the Emotional Well-Being of Young People
      During the COVID-19 Pandemic: Protocol for a Mixed Methods Study.
PG  - e23716
LID - 10.2196/23716 [doi]
AB  - BACKGROUND: The COVID-19 pandemic is likely to increase anxiety and distress in
      young people worldwide. It is important to prioritize mental health during crisis
      events to mitigate the negative and often long-term effects of the crises on
      young people, families, and society. Mental health and well-being apps represent 
      a scalable approach for improving psychological outcomes in young people and have
      potential to improve the equity of service access. OBJECTIVE: The Whitu: 7 Ways
      in 7 Days well-being app was recently developed by our group to address the
      urgent need for innovative approaches to reach young New Zealanders who are
      struggling to cope with the COVID-19 pandemic. The aim of this study is twofold: 
      to evaluate the acceptability of the prototype app and to examine the
      effectiveness of the refined app at improving mental and emotional well-being and
      reducing depression, anxiety, and stress in young people in New Zealand. METHODS:
      A two-phase mixed methods study will be undertaken to achieve these aims. During 
      the first phase, 20 young people aged 16-30 years (including those of Maori and
      Pacific ethnicity) will participate in a qualitative study to help refine the
      prototype app. During the second phase, 90 young people aged 16-30 years will
      participate in a randomized waitlist-controlled trial (RCT) to evaluate the
      efficacy of the refined Whitu app at 4 weeks and 3 months after baseline.
      Outcomes will be evaluated using validated web-based questionnaires at baseline, 
      4 weeks, and 3 months. RESULTS: The study received ethics approval in May 2020,
      and recruitment for the focus groups commenced in June 2020. Recruitment for the 
      RCT is expected to commence in October 2020. Participants for both study phases
      will be recruited via social media and web-based communities. Data collection for
      the RCT is expected to be completed by January 2021, and analyses are expected to
      be completed by March 2021. Linear mixed modelling will be used to determine
      between-group differences in psychological outcomes. CONCLUSIONS: There is an
      urgent need to develop culturally appropriate, scalable mental health
      interventions to address the psychological consequences of the COVID-19 pandemic.
      In this study, we will develop and test an evidence-based well-being app that, if
      effective, can be made available to all young people in New Zealand and
      internationally. TRIAL REGISTRATION: Australian New Zealand Clinical Trials
      Registry (ACTRN12620000516987);
      https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379597.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/23716.
CI  - (c)Anna Serlachius, Kiralee Schache, Anna Boggiss, David Lim, Kate Wallace-Boyd, 
      Jennifer Brenton-Peters, Elise Buttenshaw, Stephanie Chadd, Alana Cavadino,
      Nicholas Cao, Eva Morunga, Hiran Thabrew. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 08.10.2020.
FAU - Serlachius, Anna
AU  - Serlachius A
AUID- ORCID: https://orcid.org/0000-0002-4797-8351
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Schache, Kiralee
AU  - Schache K
AUID- ORCID: https://orcid.org/0000-0003-0473-9577
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
AD  - Psychological Medicine, Counties Manukau Health, Auckland, New Zealand.
FAU - Boggiss, Anna
AU  - Boggiss A
AUID- ORCID: https://orcid.org/0000-0002-7336-955X
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Lim, David
AU  - Lim D
AUID- ORCID: https://orcid.org/0000-0002-7849-9150
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Wallace-Boyd, Kate
AU  - Wallace-Boyd K
AUID- ORCID: https://orcid.org/0000-0001-8874-4079
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Brenton-Peters, Jennifer
AU  - Brenton-Peters J
AUID- ORCID: https://orcid.org/0000-0002-2370-900X
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Buttenshaw, Elise
AU  - Buttenshaw E
AUID- ORCID: https://orcid.org/0000-0002-1888-0670
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Chadd, Stephanie
AU  - Chadd S
AUID- ORCID: https://orcid.org/0000-0001-8716-7361
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
FAU - Cavadino, Alana
AU  - Cavadino A
AUID- ORCID: https://orcid.org/0000-0002-5709-367X
AD  - Epidemiology and Biostatistics, School of Population Health, University of
      Auckland, Auckland, New Zealand.
FAU - Cao, Nicholas
AU  - Cao N
AUID- ORCID: https://orcid.org/0000-0002-1702-4899
AD  - Tamaki Health, Auckland, New Zealand.
FAU - Morunga, Eva
AU  - Morunga E
AUID- ORCID: https://orcid.org/0000-0002-8050-7201
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
AD  - Auckland District Health Board, Auckland, New Zealand.
FAU - Thabrew, Hiran
AU  - Thabrew H
AUID- ORCID: https://orcid.org/0000-0002-8755-6217
AD  - Department of Psychological Medicine, University of Auckland, Auckland, New
      Zealand.
AD  - Auckland District Health Board, Auckland, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20201008
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7546866
OTO - NOTNLM
OT  - COVID-19
OT  - adolescent
OT  - apps
OT  - coping
OT  - coping skills
OT  - mHealth
OT  - mental health
OT  - mobile applications
OT  - pandemic
OT  - wellbeing
OT  - young adult
EDAT- 2020/09/30 06:00
MHDA- 2020/09/30 06:01
CRDT- 2020/09/29 17:12
PHST- 2020/08/21 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/09/30 06:01 [medline]
PHST- 2020/09/29 17:12 [entrez]
AID - v9i10e23716 [pii]
AID - 10.2196/23716 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Oct 8;9(10):e23716. doi: 10.2196/23716.


PMID- 32990876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201013
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Correction to: Expanding Nallur's Landscape of Machine Implemented Ethics.
PG  - 2411
LID - 10.1007/s11948-020-00263-9 [doi]
AB  - Due to an unfortunate miscommunication with the copy editor an important
      reference was omitted from this recently published article. The reference that
      should be included is.
FAU - Bauer, William A
AU  - Bauer WA
AD  - Department of Philosphy and Religious Studies, North Caroline State University,
      Raleigh, USA. wabauer@ncsu.edu.
LA  - eng
PT  - Published Erratum
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
EFR - Sci Eng Ethics. 2020 Oct;26(5):2401-2410. PMID: 32632782
EDAT- 2020/09/30 06:00
MHDA- 2020/09/30 06:01
CRDT- 2020/09/29 12:38
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/09/30 06:01 [medline]
PHST- 2020/09/29 12:38 [entrez]
AID - 10.1007/s11948-020-00263-9 [doi]
AID - 10.1007/s11948-020-00263-9 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2411. doi: 10.1007/s11948-020-00263-9.


PMID- 32990664
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20220531
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 274
DP  - 2020 Sep 25
TI  - Communication and Public Relations in Healthcare.
PG  - 42-51
LID - 10.3233/SHTI200664 [doi]
AB  - This chapter is written in order to provide the student with a general overview
      of communication and public relations in healthcare. All healthcare institutions 
      have a need for adequate and successful communication with their external and
      internal stakeholders. Every contact of a particular healthcare organization with
      the public represents a unique interface, as an important part of the
      communication strategy. Therefore, it is very important to create strategic
      consistency among all the messages that stakeholders need to receive. The chapter
      will discuss the relationships between the various components of integrated
      marketing communications in healthcare, crisis management in the communications
      sphere and ethics and social responsibility issues.
FAU - Vujadinovic, Nenad
AU  - Vujadinovic N
AD  - University of Donja Gorica, Montenegro.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Communication
MH  - Delivery of Health Care
MH  - Humans
MH  - *Public Relations
OTO - NOTNLM
OT  - Integrated marketing communications
OT  - advertising and PR
OT  - crisis management
OT  - ethics
OT  - media
OT  - social responsibility
OT  - stakeholders (external and internal)
EDAT- 2020/09/30 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/29 12:36
PHST- 2020/09/29 12:36 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - SHTI200664 [pii]
AID - 10.3233/SHTI200664 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Sep 25;274:42-51. doi: 10.3233/SHTI200664.


PMID- 32990662
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20220531
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 274
DP  - 2020 Sep 25
TI  - Mission and Structure of Health Services.
PG  - 19-28
LID - 10.3233/SHTI200661 [doi]
AB  - This chapter aims at providing the student with a general overview of the
      appropriate structure and ethics healthcare organizations are based on, the
      concept of ethical leadership, the importance of having clear statements of
      mission, vision and value in healthcare organizations and the Health Promotion
      Charters implemented in a Globalized World.
FAU - Diomidous, Marianna
AU  - Diomidous M
AD  - National and Kapodistrian University of Athens, Greece.
FAU - Magdalinou, Andriana
AU  - Magdalinou A
AD  - National and Kapodistrian University of Athens, Greece.
FAU - Varga, Orsolya
AU  - Varga O
AD  - University of Debrecen, Hungary.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Bioethics
MH  - Health Promotion
MH  - Humans
MH  - *Leadership
MH  - Morals
OTO - NOTNLM
OT  - Health services
OT  - ethical organization
OT  - mission
OT  - value
OT  - vision
EDAT- 2020/09/30 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/29 12:36
PHST- 2020/09/29 12:36 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - SHTI200661 [pii]
AID - 10.3233/SHTI200661 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Sep 25;274:19-28. doi: 10.3233/SHTI200661.


PMID- 32990477
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - What is changing in chronic migraine treatment? An algorithm for
      onabotulinumtoxinA treatment by the Italian chronic migraine group.
PG  - 1275-1286
LID - 10.1080/14737175.2020.1825077 [doi]
AB  - INTRODUCTION: OnabotulinumtoxinA (OBT-A) and monoclonal antibodies (mAbs)
      targeting the calcitonin gene-related peptide (CGRP) pathway are two of the few
      treatments that ameliorate chronic migraine (CM) in randomized controlled trials 
      and real-life studies. Separate clinical practice guidelines have been developed 
      for the management of CM with OBT-A or CGRP-targeting mAbs. AREAS COVERED:
      Considering the concomitant availability of OBT-A and CGRP-targeting mAbs as
      therapeutic treatment options, Italian migraine experts reviewed the evidence
      supporting the efficacy of OBT-A and CGRP-targeting mAbs in CM in order to
      rationalize the management of CM patients treated with OBT-A. Experts addressed
      everyday practice needs to shape the optimal pharmacological management by
      balancing adherence to regulatory indications, ethical considerations, and
      clinical expertise. Considering the remarkable challenge of improving the health 
      and quality of life of patients with CM, even partial improvements may be
      clinically meaningful, particularly for those who are resistant or intolerant to 
      oral migraine treatments. EXPERT OPINION: In this collaborative effort, we
      propose a treatment algorithm that integrates the relevant aspects of managing
      patients with CM to provide ready-to-use practical guidance regarding the
      appropriate use of OBT-A.
FAU - Sacco, Simona
AU  - Sacco S
AUID- ORCID: 0000-0003-0651-1939
AD  - Neuroscience Section, Department of Biotechnological and Applied Clinical
      Sciences, University of L'Aquila , L'Aquila, Italy.
FAU - Russo, Antonio
AU  - Russo A
AUID- ORCID: 0000-0002-6579-154X
AD  - Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences,
      Headache Center, University of Campania "Luigi Vanvitelli" , Naples, Italy.
FAU - Geppetti, Pierangelo
AU  - Geppetti P
AD  - Department of Health Sciences, Section of Clinical Pharmacology, Headache Center 
      Careggi University Hospital, University of Florence , Florence, Italy.
FAU - Grazzi, Licia
AU  - Grazzi L
AD  - Neuroalgology Unit, Headache Center, Neurological Institute "C. Besta" IRCCS
      Foundation , Milan, Italy.
FAU - Negro, Andrea
AU  - Negro A
AUID- ORCID: 0000-0003-3590-298X
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and
      Psychology, Sant'Andrea Hospital, Sapienza University , Rome, Italy.
FAU - Tassorelli, Cristina
AU  - Tassorelli C
AD  - Headache Science Centre, IRCCS Mondino Foundation , Pavia, PV, Italy.
AD  - Department of Brain and Behavioral Sciences, University of Pavia , Pavia, PV,
      Italy.
FAU - Tedeschi, Gioacchino
AU  - Tedeschi G
AD  - Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences,
      Headache Center, University of Campania "Luigi Vanvitelli" , Naples, Italy.
FAU - Martelletti, Paolo
AU  - Martelletti P
AUID- ORCID: 0000-0002-6556-4128
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and
      Psychology, Sant'Andrea Hospital, Sapienza University , Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200930
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - EC 3.4.24.69 (onabotulinum toxin A)
SB  - IM
MH  - *Algorithms
MH  - Botulinum Toxins, Type A/*therapeutic use
MH  - Chronic Disease/*drug therapy
MH  - Humans
MH  - Italy
MH  - Migraine Disorders/*drug therapy
MH  - Neuromuscular Agents/*therapeutic use
OTO - NOTNLM
OT  - *Chronic migraine
OT  - *GCRP-targeting monoclonal antibodies
OT  - *calcitonin gene-related peptide
OT  - *migraine prophylaxis
OT  - *onabotulinumtoxinA
OT  - *treatment algorithm
EDAT- 2020/09/30 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/09/29 12:33
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/09/29 12:33 [entrez]
AID - 10.1080/14737175.2020.1825077 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2020 Dec;20(12):1275-1286. doi:
      10.1080/14737175.2020.1825077. Epub 2020 Sep 30.


PMID- 32990156
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20201229
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 9
IP  - 21
DP  - 2020 Nov 3
TI  - Derivation and Validation of a Clinical Model to Predict Intensive Care Unit
      Length of Stay After Cardiac Surgery.
PG  - e017847
LID - 10.1161/JAHA.120.017847 [doi]
AB  - Background Across the globe, elective surgeries have been postponed to limit
      infectious exposure and preserve hospital capacity for coronavirus disease 2019
      (COVID-19). However, the ramp down in cardiac surgery volumes may result in
      unintended harm to patients who are at high risk of mortality if their conditions
      are left untreated. To help optimize triage decisions, we derived and
      ambispectively validated a clinical score to predict intensive care unit length
      of stay after cardiac surgery. Methods and Results Following ethics approval, we 
      derived and performed multicenter valida tion of clinical models to predict the
      likelihood of short (</=2 days) and prolonged intensive care unit length of stay 
      (>/=7 days) in patients aged >/=18 years, who underwent coronary artery bypass
      grafting and/or aortic, mitral, and tricuspid value surgery in Ontario, Canada.
      Multivariable logistic regression with backward variable selection was used,
      along with clinical judgment, in the modeling process. For the model that
      predicted short intensive care unit stay, the c-statistic was 0.78 in the
      derivation cohort and 0.71 in the validation cohort. For the model that predicted
      prolonged stay, c-statistic was 0.85 in the derivation and 0.78 in the validation
      cohort. The models, together termed the CardiOttawa LOS Score, demonstrated a
      high degree of accuracy during prospective testing. Conclusions Clinical judgment
      alone has been shown to be inaccurate in predicting postoperative intensive care 
      unit length of stay. The CardiOttawa LOS Score performed well in prospective
      validation and will complement the clinician's gestalt in making more efficient
      resource allocation during the COVID-19 period and beyond.
FAU - Sun, Louise Y
AU  - Sun LY
AD  - Division of Cardiac Anesthesiology University of Ottawa Heart Institute and the
      School of Epidemiology and Public Health University of Ottawa Ontario Canada.
AD  - Institute for Clinical Evaluative Sciences University of Ottawa Heart Institute
      Ottawa Ontario Canada.
FAU - Bader Eddeen, Anan
AU  - Bader Eddeen A
AD  - Institute for Clinical Evaluative Sciences University of Ottawa Heart Institute
      Ottawa Ontario Canada.
FAU - Ruel, Marc
AU  - Ruel M
AD  - Division of Cardiac Surgery University of Ottawa Heart Institute Ottawa Ontario
      Canada.
FAU - MacPhee, Erika
AU  - MacPhee E
AD  - Clinical Operations University of Ottawa Heart Institute Ottawa Ontario Canada.
FAU - Mesana, Thierry G
AU  - Mesana TG
AD  - Division of Cardiac Surgery University of Ottawa Heart Institute Ottawa Ontario
      Canada.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20200929
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cardiac Surgical Procedures/adverse effects
MH  - *Clinical Decision Rules
MH  - Clinical Decision-Making
MH  - Female
MH  - Humans
MH  - *Intensive Care Units
MH  - *Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Ontario
MH  - Predictive Value of Tests
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Triage
PMC - PMC7763427
OTO - NOTNLM
OT  - *COVID-19
OT  - *cardiac surgery
OT  - *intensive care
OT  - *length of stay
OT  - *resource utilization
EDAT- 2020/09/30 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/09/29 08:49
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/09/29 08:49 [entrez]
AID - 10.1161/JAHA.120.017847 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2020 Nov 3;9(21):e017847. doi: 10.1161/JAHA.120.017847. Epub
      2020 Sep 29.


PMID- 32989957
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20210308
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 32
IP  - 2-3
DP  - 2020 Mar Apr May Jun
TI  - [Modelization of recommendation framework advice for children immunization to
      Beninese decision makers].
PG  - 273-278
LID - 10.3917/spub.202.0273 [doi]
AB  - The coverage of immunization against avoidable disease in the Republic of Benin
      as in other West African countries, is declining nowadays. To sustain the
      government effort, National Immunization Technical Advisory Groups (NITAG) were
      created technically and funded by the West African health organization (WAHO) and
      Preventive Medicine Agency in countries of the Economic Community of West African
      States (ECOWAS) including the Republic of Benin. The variation in experts&#8217; 
      methods of analyzing evidence sometimes results in risk error and lack of
      statistical power. This situation does not allow for the comparison of the
      scientific validity of certain recommendations made to policy makers, due to the 
      lack of a rigorous framework. The aim of this paper is to design an improved
      framework to be used in the Republic of Benin in order to encourage a more
      harmonized approach based on evidence used by expert consultative committees.
      This framework shows four fundamental scientific steps including a Ministerial
      referral procedure, recommendation framework, evidence-based data collection,
      model analyses appropriate for expert advice on vaccines and child immunization, 
      as well as three administrative steps including scientific discussion and work
      meetings without forgetting ethical aspects.
FAU - Fourn, Leonard
AU  - Fourn L
LA  - fre
PT  - Journal Article
TT  - Modelisation du cadre conceptuel d'avis de recommandation pour la vaccination des
      enfants aux decideurs beninois.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - *Advisory Committees
MH  - Benin
MH  - Child
MH  - *Health Policy
MH  - Humans
MH  - *Immunization
MH  - *Policy Making
EDAT- 2020/09/30 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/09/29 05:46
PHST- 2020/09/29 05:46 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.3917/spub.202.0273 [doi]
PST - ppublish
SO  - Sante Publique. 2020 Mar Apr May Jun;32(2-3):273-278. doi: 10.3917/spub.202.0273.


PMID- 32989946
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20210308
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 32
IP  - 2-3
DP  - 2020 Mar Apr May Jun
TI  - [Ethical issues of Internet use by pregnant women during their medical care].
PG  - 171-182
LID - 10.3917/spub.202.0171 [doi]
AB  - INTRODUCTION: Pregnant women are heavy users of Internet and this has an impact
      on their medical follow-up. The purpose of this study is to highlight the ethical
      issues related to the use of the Internet by women in their medical care.Methode:
      Through a systematic literature review conducted on PubMed/Medline, Web of
      Science, CINAHL and Embase between June and July 2019, 10&#160;670 results were
      obtained, and 79 articles were included in the post-selection study. A thematic
      analysis was conducted on these articles. RESULTS: More than 90% of pregnant
      women use Internet, particularly to find medical information and social support, 
      mainly on pregnancy and childbirth. This research allows them more equitable
      access to knowledge and develops their empowerment, which modifies the
      relationship between caregiver and patient, through the acquisition of greater
      autonomy for women and the development of experiential knowledge. This access
      offers a central and active role to pregnant women in their medical care.
      However, many authors also agree on the possible abuses of this use:
      misinformation, disproportionate information and the presence of judgment that
      undermine empowerment, but also digital divide and inequity in understanding
      information, stigmatization of women, and risks of privacy breaches on data
      acquired online. CONCLUSION: In order to provide pregnant women with the central 
      and active place they seek, the authors recommend involving caregivers in the
      referral to reliable sites, encouraging them to develop online content, and
      educating pregnant women in the search for health information on Internet.
FAU - Masella, Marie-Alexia
AU  - Masella MA
FAU - Godard, Beatrice
AU  - Godard B
LA  - fre
PT  - Journal Article
TT  - Enjeux ethiques du recours a Internet par les femmes enceintes dans leur suivi de
      grossesse.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - Consumer Health Information/standards
MH  - Female
MH  - Humans
MH  - Information Seeking Behavior
MH  - Internet/*ethics/*statistics & numerical data
MH  - Patient Education as Topic
MH  - Pregnancy
MH  - Pregnant Women/*psychology
MH  - Professional-Patient Relations
MH  - Social Support
EDAT- 2020/09/30 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/09/29 05:46
PHST- 2020/09/29 05:46 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.3917/spub.202.0171 [doi]
PST - ppublish
SO  - Sante Publique. 2020 Mar Apr May Jun;32(2-3):171-182. doi: 10.3917/spub.202.0171.


PMID- 32989753
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Risky research and bystander consent.
PG  - 912-917
LID - 10.1111/bioe.12811 [doi]
AB  - There is no quick and easy answer to the question whether research activities
      that endanger bystanders without their consent ever thereby violate those
      bystanders' rights. We cannot dismiss the idea that bystanders possess strong
      rights against researchers simply on the grounds that they are, after all, merely
      bystanders. Indeed, it is easy to imagine scenarios in which researchers would be
      morally required to gain the informed consent of bystanders whom they risk
      harming. Whether bystander consent is required in any particular real-world case 
      will depend, in part, upon exactly how the research activity endangers them.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Hanser, Matthew
AU  - Hanser M
AUID- ORCID: 0000-0002-5790-4591
AD  - Department of Philosophy, University of California, Santa Barbara, California.
LA  - eng
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200929
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Humans
MH  - *Informed Consent
PMC - PMC7683363
MID - NIHMS1630755
OTO - NOTNLM
OT  - *bystanders
OT  - *informed consent
OT  - *research ethics
OT  - *research risk
OT  - *rights
OT  - *risk
EDAT- 2020/09/30 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/09/29 05:39
PHST- 2018/12/22 00:00 [received]
PHST- 2020/07/10 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/09/29 05:39 [entrez]
AID - 10.1111/bioe.12811 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):912-917. doi: 10.1111/bioe.12811. Epub 2020 Sep 29.


PMID- 32989306
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20210113
IS  - 1750-2799 (Electronic)
IS  - 1750-2799 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - Tutorial: a computational framework for the design and optimization of peripheral
      neural interfaces.
PG  - 3129-3153
LID - 10.1038/s41596-020-0377-6 [doi]
AB  - Peripheral neural interfaces have been successfully used in the recent past to
      restore sensory-motor functions in disabled subjects and for the neuromodulation 
      of the autonomic nervous system. The optimization of these neural interfaces is
      crucial for ethical, clinical and economic reasons. In particular, hybrid models 
      (HMs) constitute an effective framework to simulate direct nerve stimulation and 
      optimize virtually every aspect of implantable electrode design: the type of
      electrode (for example, intrafascicular versus extrafascicular), their insertion 
      position and the used stimulation routines. They are based on the combined use of
      finite element methods (to calculate the voltage distribution inside the nerve
      due to the electrical stimulation) and computational frameworks such as NEURON ( 
      https://neuron.yale.edu/neuron/ ) to determine the effects of the electric field 
      generated on the neural structures. They have already provided useful results for
      different applications, but the overall usability of this powerful approach is
      still limited by the intrinsic complexity of the procedure. Here, we illustrate a
      general, modular and expandable framework for the application of HMs to
      peripheral neural interfaces, in which the correct degree of approximation
      required to answer different kinds of research questions can be readily
      determined and implemented. The HM workflow is divided into the following tasks: 
      identify and characterize the fiber subpopulations inside the fascicles of a
      given nerve section, determine different degrees of approximation for fascicular 
      geometries, locate the fibers inside these geometries and parametrize electrode
      geometries and the geometry of the nerve-electrode interface. These tasks are
      examined in turn, and solutions to the most relevant issues regarding their
      implementation are described. Finally, some examples related to the simulation of
      common peripheral neural interfaces are provided.
FAU - Romeni, Simone
AU  - Romeni S
AUID- ORCID: http://orcid.org/0000-0002-0903-9441
AD  - The Biorobotics Institute and Department of Excellence in Robotics and AI, Scuola
      Superiore Sant'Anna, Pontedera, Italy.
AD  - Bertarelli Foundation Chair in Translational NeuroEngineering, Center for
      Neuroprosthetics and Institute of Bioengineering, Ecole Polytechnique Federale de
      Lausanne (EPFL), Lausanne, Switzerland.
FAU - Valle, Giacomo
AU  - Valle G
AUID- ORCID: http://orcid.org/0000-0002-2637-8007
AD  - The Biorobotics Institute and Department of Excellence in Robotics and AI, Scuola
      Superiore Sant'Anna, Pontedera, Italy.
AD  - Bertarelli Foundation Chair in Translational NeuroEngineering, Center for
      Neuroprosthetics and Institute of Bioengineering, Ecole Polytechnique Federale de
      Lausanne (EPFL), Lausanne, Switzerland.
AD  - Laboratory for Neuroengineering, Department of Health Sciences and Technology,
      Institute for Robotics and Intelligent Systems, ETH Zurich, Zurich, Switzerland.
FAU - Mazzoni, Alberto
AU  - Mazzoni A
AD  - The Biorobotics Institute and Department of Excellence in Robotics and AI, Scuola
      Superiore Sant'Anna, Pontedera, Italy.
FAU - Micera, Silvestro
AU  - Micera S
AUID- ORCID: http://orcid.org/0000-0003-4396-8217
AD  - The Biorobotics Institute and Department of Excellence in Robotics and AI, Scuola
      Superiore Sant'Anna, Pontedera, Italy. silvestro.micera@epfl.ch.
AD  - Bertarelli Foundation Chair in Translational NeuroEngineering, Center for
      Neuroprosthetics and Institute of Bioengineering, Ecole Polytechnique Federale de
      Lausanne (EPFL), Lausanne, Switzerland. silvestro.micera@epfl.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200928
PL  - England
TA  - Nat Protoc
JT  - Nature protocols
JID - 101284307
SB  - IM
MH  - Electric Stimulation/*methods
MH  - Electrodes, Implanted/trends
MH  - Humans
MH  - Implantable Neurostimulators/*trends
MH  - Peripheral Nerves/physiology
MH  - Prostheses and Implants
EDAT- 2020/09/30 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/09/29 05:36
PHST- 2019/07/24 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/09/29 05:36 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
AID - 10.1038/s41596-020-0377-6 [doi]
AID - 10.1038/s41596-020-0377-6 [pii]
PST - ppublish
SO  - Nat Protoc. 2020 Oct;15(10):3129-3153. doi: 10.1038/s41596-020-0377-6. Epub 2020 
      Sep 28.


PMID- 32988951
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 28
TI  - Multicentre, single-blind randomised controlled trial comparing MyndMove
      neuromodulation therapy with conventional therapy in traumatic spinal cord
      injury: a protocol study.
PG  - e039650
LID - 10.1136/bmjopen-2020-039650 [doi]
AB  - INTRODUCTION: This protocol is describing a multicentre, single-blind randomised 
      controlled trial. The objective is to compare the efficacy of MyndMove therapy
      versus conventional therapy (CT) in improving upper extremity function in
      individuals with C4-C7 traumatic, incomplete spinal cord injury (SCI). It is
      being conducted in two US and two Canadian SCI rehabilitation centres. METHODS
      AND ANALYSIS: Sixty people aged 18 years or older with a C4-C7 incomplete (AIS
      B-D) SCI between 4 months and 8 years postinjury are randomised to receive 40
      sessions of MyndMove neuromodulation therapy or CT within a 14-week period of
      time. Therapy sessions are 1 hour in duration with a dose of 3-5 sessions per
      week. Assessments occur prior to randomisation, after 20 sessions, after 40
      sessions and 10 weeks after the last session. The primary outcome measure is the 
      efficacy of MyndMove therapy versus CT in improving upper extremity function as
      measured by Spinal Cord Independence Measure III: Self-Care subscore after 40
      sessions. Secondary outcomes include: (1) improvements in the SCIM mobility
      subscore; (2) upper limb functions measured by Graded Redefined Assessment of
      Strength, Sensibility and Prehension and (3) Toronto Rehab Institute Hand
      Function Test; (4) To assess safety as measured by serious and non-serious
      adverse events recorded for participants in both groups of the study population
      over the duration of the study; (5) to compare the change in quality of life as
      measured by the Spinal Cord Injury-Quality of Life; and (6) to evaluate the
      impact on healthcare resource utilisation. ETHICS AND DISSEMINATION: All ethical 
      approvals were obtained prior to enrolling any participants. Dissemination of the
      results of the study will be made at peer-reviewed academic meetings and through 
      peer-reviewed medical journals TRIAL REGISTRATION NUMBER: NCT03439319.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Anderson, Kim D
AU  - Anderson KD
AUID- ORCID: 0000-0001-9252-161X
AD  - Department of Physical Medicine and Rehabilitation, MetroHealth System,
      Cleveland, Ohio, USA.
AD  - Department of Physical Medicine and Rehabilitation, Case Western Reserve
      University, Cleveland, Ohio, USA.
FAU - Wilson, James R
AU  - Wilson JR
AD  - Department of Physical Medicine and Rehabilitation, MetroHealth System,
      Cleveland, Ohio, USA.
AD  - Department of Physical Medicine and Rehabilitation, Case Western Reserve
      University, Cleveland, Ohio, USA.
FAU - Korupolu, Radha
AU  - Korupolu R
AD  - Department of Physical Medicine and Rehabilitation, University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
AD  - The Institute for Rehabilitation and Research (TIRR), Houston, Texas, USA.
FAU - Pierce, Jacqueline
AU  - Pierce J
AD  - Centre for Neurology Studies, Health Tech Connex, Surrey, British Columbia,
      Canada.
FAU - Bowen, James M
AU  - Bowen JM
AUID- ORCID: 0000-0002-6457-2337
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University 
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
AD  - Toronto Health Economics and Technology Assessment (THETA) Collaborative,
      University of Toronto, Toronto, Ontario, Canada.
FAU - O'Reilly, Daria
AU  - O'Reilly D
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University 
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
AD  - TELUS Health, Toronto, Ontario, Canada.
FAU - Kapadia, Naaz
AU  - Kapadia N
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
FAU - Popovic, Milos R
AU  - Popovic MR
AD  - The KITE Research Institute, University Health Network, Toronto, Ontario, Canada.
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University 
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
AD  - Biostatistics Unit, St. Joseph's Healthcare, Hamilton, Ontario, Canada.
FAU - Musselman, Kristin E
AU  - Musselman KE
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada Kristin.Musselman@uhn.ca.
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03439319
GR  - KL2 TR003168/TR/NCATS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200928
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Humans
MH  - Infant
MH  - Multicenter Studies as Topic
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - *Spinal Cord Injuries/therapy
MH  - Upper Extremity
PMC - PMC7523215
OTO - NOTNLM
OT  - *neuromuscular disease
OT  - *rehabilitation medicine
OT  - *spine
COIS- Competing interests: MyndTec Inc is the contracting organisation of this study
      and through funding provided by US Army Medical Research and Materiel Command,
      researchers are reimbursed for doing this study. All investigators have an
      interest in completing the study.
EDAT- 2020/09/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/29 05:31
PHST- 2020/09/29 05:31 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039650 [pii]
AID - 10.1136/bmjopen-2020-039650 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 28;10(9):e039650. doi: 10.1136/bmjopen-2020-039650.


PMID- 32988948
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 28
TI  - Prognostic factors for outcomes of idiopathic sudden sensorineural hearing loss: 
      protocol for the SeaSHeL national prospective cohort study.
PG  - e038552
LID - 10.1136/bmjopen-2020-038552 [doi]
AB  - INTRODUCTION: The mainstay of treatment for idiopathic sudden sensorineural
      hearing loss (SSNHL) includes oral steroids, intratympanic steroid injections or 
      a combination of both. The National Institute for Health and Care Excellence, in 
      their recent hearing loss guidelines, highlighted the paucity of evidence
      assessing the comparative effectiveness of these treatments; and the National
      Institute for Health Research (NIHR) Health Technology Assessment Programme has
      since released a commissioned call for a trial to identify the most effective
      route of administration of steroids as a first-line treatment for idiopathic
      SSNHL. For such trials to be run effectively, reliable information is needed on
      patients with SSNHL: where they present, numbers, demographics, treatment
      pathways, as well as outcomes. This study will collect these data in a nationwide
      cohort study of patients presenting with SSNHL across 97 National Health Service 
      (NHS) trusts. The study will be delivered through ear, nose and throat (ENT)
      trainee networks, the NIHR Clinical Research Network (CRN) Audiology Champions
      and the NIHR CRN. Importantly, this study will also provide a dataset to develop 
      a prognostic model to predict recovery for patients with idiopathic SSNHL. The
      study objectives are to: (1) map the patient pathway and identify the
      characteristics of adult patients presenting to NHS ENT and hearing services with
      SSNHL, (2) develop a prognostic model to predict recovery for patients with
      idiopathic SSNHL and (3) establish the impact of idiopathic SSNHL on patients'
      quality of life (QoL). METHODS AND ANALYSIS: Study design: national multicentre
      prospective cohort study across 97 NHS trusts. INCLUSION CRITERIA: adult patients
      presenting to NHS ENT and hearing services with SSNHL. OUTCOMES: change in
      auditory function; change in QoL score. ANALYSIS: multivariable prognostic model,
      using prespecified candidate predictors. Mean change in QoL scores will be
      calculated from initial presentation to follow-up. ETHICS AND DISSEMINATION:
      Health Research Authority and NHS Research Ethics Committee approved the study.
      Publication will be on behalf of study sites and collaborators. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04108598).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Mandavia, Rishi
AU  - Mandavia R
AUID- ORCID: 0000-0002-5839-2735
AD  - University College London Hospitals Biomedical Research Centre, National
      Institute for Health Research, London, UK r.mandavia@ucl.ac.uk.
AD  - evidENT, University College London Ear Institute, London, UK.
AD  - SFO UK Students and Foundation Doctors in Otolaryngology, London, UK.
FAU - Hannink, Gerjon
AU  - Hannink G
AD  - Department of Operating Rooms, Radboudumc, Nijmegen, The Netherlands.
FAU - Ahmed, Muhammad Nayeem
AU  - Ahmed MN
AD  - evidENT, University College London Ear Institute, London, UK.
AD  - University of Leeds School of Medicine, Leeds, UK.
FAU - Premakumar, Yaami
AU  - Premakumar Y
AD  - Chelsea and Westminster Hospital, London, UK.
FAU - Chu, Timothy Shun Man
AU  - Chu TSM
AD  - SFO UK Students and Foundation Doctors in Otolaryngology, London, UK.
AD  - Newcastle University School of Clinical Medical Sciences, Newcastle upon Tyne,
      UK.
FAU - Blackshaw, Helen
AU  - Blackshaw H
AD  - University College London Hospitals Biomedical Research Centre, National
      Institute for Health Research, London, UK.
AD  - evidENT, University College London Ear Institute, London, UK.
FAU - Ferdous, Tanjinah
AU  - Ferdous T
AD  - University College London Hospitals Biomedical Research Centre, National
      Institute for Health Research, London, UK.
AD  - evidENT, University College London Ear Institute, London, UK.
FAU - Mehta, Nishchay
AU  - Mehta N
AD  - University College London Hospitals Biomedical Research Centre, National
      Institute for Health Research, London, UK.
AD  - evidENT, University College London Ear Institute, London, UK.
FAU - Manjaly, Joseph
AU  - Manjaly J
AD  - University College London Hospitals Biomedical Research Centre, National
      Institute for Health Research, London, UK.
AD  - evidENT, University College London Ear Institute, London, UK.
FAU - Khan, Maha
AU  - Khan M
AD  - Health Education North West, Manchester, UK.
FAU - Schilder, Anne Gm
AU  - Schilder AG
AD  - University College London Hospitals Biomedical Research Centre, National
      Institute for Health Research, London, UK.
AD  - evidENT, University College London Ear Institute, London, UK.
CN  - SeaSHeL Collaborative
LA  - eng
SI  - ClinicalTrials.gov/NCT04108598
GR  - NIHR-RP-011-045/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200928
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - *Hearing Loss, Sensorineural/drug therapy
MH  - *Hearing Loss, Sudden/drug therapy
MH  - Humans
MH  - Prognosis
MH  - Prospective Studies
MH  - Quality of Life
MH  - State Medicine
PMC - PMC7523222
OTO - NOTNLM
OT  - *adult otolaryngology
OT  - *audiology
OT  - *otolaryngology
COIS- Competing interests: Sensorion is an inner ear disease company and sponsor of the
      NIHR Clinical Research Network Portfolio Study, Audible-S (CPMS 39560, IRAS
      248645).
EDAT- 2020/09/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/29 05:31
PHST- 2020/09/29 05:31 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038552 [pii]
AID - 10.1136/bmjopen-2020-038552 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 28;10(9):e038552. doi: 10.1136/bmjopen-2020-038552.


PMID- 32988945
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 28
TI  - Traditional Chinese medicine injections for heart failure: a protocol for
      systematic review and network meta-analysis of randomised controlled trials.
PG  - e037331
LID - 10.1136/bmjopen-2020-037331 [doi]
AB  - INTRODUCTION: Heart failure (HF) has always been an important issue in global
      public health. The research and development of traditional Chinese medicine (TCM)
      provide more possibilities for improving the prognosis of HF patients. Because
      multiple TCM injections (TCMIs) are being widely applied in clinical work, it is 
      important to choose the right TCMIs for HF patients. The purpose of this study is
      to assess and compare the effect of different TCMIs for HF using network
      meta-analysis (NMA) and further provide references for clinical decision-making. 
      METHODS AND ANALYSIS: The clinical randomised controlled trials (RCTs) and
      meta-analyses of TCMIs for treating HF will be searched in the relevant database,
      including PubMed, EMBASE, Cochrane Library (No. 2 of 2020), Chinese BioMedical
      Literature Database, China National Knowledge Infrastructure, Wan Fang Database
      and Chinese Scientific Journal Database from inception to 29 February 2020. The
      outcomes of interest include all-cause mortality, rehospitalisation rate, left
      ventricular ejection fraction, left ventricular end-diastolic diameter, left
      ventricular end-systolic diameter, brain natriuretic peptide (BNP), N-terminal
      pro-BNP, cardiac output, stroke volume, 6 min walking distance and adverse
      events. The risk of bias assessment of the included RCTs will be conducted
      according to the Cochrane Collaboration's tool for assessing the risk of bias.
      NMA will be performed in a Bayesian hierarchical framework using R V.3.6.1 with
      the gemtc package. Finally, we will rank the efficacy of these treatment
      programmes according to the surface under the cumulative ranking curve, and
      perform quality assessment and recommendation grading of the evidence according
      to the Grading of Recommendations Assessment, Development and Evaluation system. 
      ETHICS AND DISSEMINATION: This study will extract data from the published
      literature and will not involve private information from individuals or
      compromise their rights. Therefore, the study does not require ethical approval. 
      The results will eventually be published in a peer-reviewed journal and
      disseminated at relevant conferences. PROSPERO REGISTRATION NUMBER:
      CRD42020166900.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lin, Shanshan
AU  - Lin S
AUID- ORCID: 0000-0002-0702-6540
AD  - Cardiovascular Department, First Teaching Hospital of Tianjin University of
      Traditional Chinese Medicine, Tianjin, China.
FAU - Shi, Qingyang
AU  - Shi Q
AD  - Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin,
      China.
FAU - Yang, Fengwen
AU  - Yang F
AD  - Evidence-Based Medicine Center, Tianjin University of Traditional Chinese
      Medicine, Tianjin, China.
FAU - Wang, Xianliang
AU  - Wang X
AD  - Cardiovascular Department, First Teaching Hospital of Tianjin University of
      Traditional Chinese Medicine, Tianjin, China jymao@126.com xlwang1981@126.com.
FAU - Mao, Jingyuan
AU  - Mao J
AD  - Cardiovascular Department, First Teaching Hospital of Tianjin University of
      Traditional Chinese Medicine, Tianjin, China jymao@126.com xlwang1981@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200928
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - China
MH  - *Drugs, Chinese Herbal/therapeutic use
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Treatment Outcome
PMC - PMC7523221
OTO - NOTNLM
OT  - *adverse events
OT  - *clinical trials
OT  - *complementary medicine
OT  - *heart failure
OT  - *herbal medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/29 05:31
PHST- 2020/09/29 05:31 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037331 [pii]
AID - 10.1136/bmjopen-2020-037331 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 28;10(9):e037331. doi: 10.1136/bmjopen-2020-037331.


PMID- 32988940
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 28
TI  - Healthy eating and physical activity environments in out-of-school hours care: an
      observational study protocol.
PG  - e036397
LID - 10.1136/bmjopen-2019-036397 [doi]
AB  - INTRODUCTION: Childcare settings have been widely identified as important venues 
      for promoting healthy lifestyles to children. Out-of-school hours care (OSHC) is 
      a rapidly growing childcare service, yet there has been limited research reported
      on healthy eating and physical activity (HEPA) environments within the Australian
      OSHC setting. This research aims to describe the HEPA environments related to
      foods and beverages served, staff behaviours and child physical activity levels
      across two local health districts within New South Wales, Australia. This study
      will provide evidence to support future interventions and policies in Australian 
      OSHC settings. METHODS AND ANALYSIS: A cross-sectional study design will be used 
      to describe the food and beverages provided and child activity levels, and report
      on environmental correlates. OSHC programmes will be visited on non-consecutive
      weekdays between 2018 and 2020. The frequency of foods and beverages offered will
      be observed and categorised into food groups aligned to the Australian Dietary
      Guidelines. Children's physical activity will be measured using ActiGraph
      wGT3X-BT accelerometers. Staff behaviour will be captured via direct observation 
      and the System for Observing Staff Promotion of Activity and Nutrition. Short
      interviews with programme directors will gather contextual information about OSHC
      practices and policies. ETHICS AND DISSEMINATION: Findings will be disseminated
      through peer-reviewed scientific journals, conference presentations and
      individualised feedback to each participating service. Ethical approval was
      granted by the University of Wollongong Human Research Ethics Committee
      (HE17/490).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Crowe, Ruth
AU  - Crowe R
AUID- ORCID: 0000-0003-1439-8681
AD  - School of Medicine, Science Medicine and Health, University of Wollongong,
      Wollongong, New South Wales, Australia rc101@uowmail.edu.au.
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Probst, Yasmine
AU  - Probst Y
AUID- ORCID: 0000-0002-1971-173X
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Norman, Jennifer
AU  - Norman J
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
AD  - Health Promotion Service, Illawarra Shoalhaven Local Health District, Wollongong,
      New South Wales, Australia.
FAU - Furber, Susan
AU  - Furber S
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
AD  - Health Promotion Service, Illawarra Shoalhaven Local Health District, Wollongong,
      New South Wales, Australia.
FAU - Franco, Lisa
AU  - Franco L
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
AD  - Health Promotion Service, Illawarra Shoalhaven Local Health District, Wollongong,
      New South Wales, Australia.
FAU - Stanley, Rebecca M
AU  - Stanley RM
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
AD  - Early Start, School of Education, University of Wollongong, Wollongong, New South
      Wales, Australia.
FAU - Vuong, Cecilia
AU  - Vuong C
AD  - Health Promotion Service, South Western Sydney Local Health District, Liverpool, 
      New South Wales, Australia.
FAU - Wardle, Karen
AU  - Wardle K
AD  - Health Promotion Service, South Western Sydney Local Health District, Liverpool, 
      New South Wales, Australia.
FAU - Davies, Marc
AU  - Davies M
AD  - NSW Healthy Children Initiative, NSW Office of Preventive Health, Liverpool, New 
      South Wales, Australia.
FAU - Ryan, Sarah
AU  - Ryan S
AD  - Early Start, School of Education, University of Wollongong, Wollongong, New South
      Wales, Australia.
FAU - Okely, Anthony D
AU  - Okely AD
AD  - Early Start, School of Education, University of Wollongong, Wollongong, New South
      Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200928
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Child
MH  - *Child Day Care Centers
MH  - Cross-Sectional Studies
MH  - *Diet, Healthy
MH  - Exercise
MH  - Health Promotion
MH  - Humans
MH  - New South Wales
MH  - Observational Studies as Topic
MH  - Schools
PMC - PMC7523195
OTO - NOTNLM
OT  - *child care
OT  - *exercise
OT  - *health promotion
OT  - *healthy eating
OT  - *snacks
COIS- Competing interests: None declared.
EDAT- 2020/09/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/29 05:31
PHST- 2020/09/29 05:31 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036397 [pii]
AID - 10.1136/bmjopen-2019-036397 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 28;10(9):e036397. doi: 10.1136/bmjopen-2019-036397.


PMID- 32988936
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 28
TI  - Mapping the links between climate change and human health in urban areas: how is 
      research conducted? A Scoping review protocol.
PG  - e034667
LID - 10.1136/bmjopen-2019-034667 [doi]
AB  - INTRODUCTION: Scientists from a wide variety of fields of knowledge are
      increasingly interested in climate change issues. The importance given to the
      phenomenon is explained by the uncertainties surrounding it and its consequences 
      not yet fully known. However, there is wide agreement that human activities are
      modifying the Earth's climate beyond the natural cyclical changes and that these 
      changes impact human health. This scoping review aimed to understand how research
      on the links between climate change and human health in urban areas is conducted 
      and how this research is approached holistically or not. METHODS AND ANALYSIS:
      This scoping review is mainly guided by the Arskey and O'Malley scoping review
      framework. A broad range of databases will be used, including PubMed,
      ScienceDirect, Web of Science Core Collection, GreenFILE and Information Science 
      & Technology Abstracts. Predefined inclusion and exclusion criteria will be used,
      with a focus on climate change and human health outcome studies published between
      January 1990 and July 2019. An interdisciplinary team has formulated search
      strategies and the reviewers will independently screen eligible studies for final
      study selection. We will apply a thematic analysis to evaluate and categorise the
      study findings. We expect to map the research according to the scientific
      research methods, the scientific fields and the determinants of health studied.
      Along these lines, we will be able to understand how holistic the research is.
      ETHICS AND DISSEMINATION: No primary data will be collected since all data
      presented in this review are based on published articles and publicly available
      documents. Therefore, ethics committee approval is not a requirement. The
      findings will be disseminated through publication in a peer-reviewed journal,
      presentations at conferences relevant to the field of this research, as well as
      presentations to relevant stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Barbosa, Hiago Pereira
AU  - Barbosa HP
AUID- ORCID: 0000-0002-8628-4491
AD  - Universite de Rennes, EHESP, Inserm, Irset (Research Institute for Environmental 
      and Occupational Health), UMR_S 1085, Rennes, France.
FAU - Roue-Le Gall, Anne
AU  - Roue-Le Gall A
AD  - Universite de Rennes, EHESP, CNRS, ARENES, UMR 6051, F-35000 Rennes, France.
AD  - Department of Environmental and occupational Health, EHESP, Rennes, France.
FAU - Deloly, Clement
AU  - Deloly C
AD  - Department of Environmental and occupational Health, EHESP, Rennes, France.
FAU - Regnaux, Jean-Philippe
AU  - Regnaux JP
AD  - INSERM 1153, CRESS, EpiAgeing Team, Universite de Paris, Paris, France.
AD  - Department of Social Sciences and Health, EHESP, Rennes, France.
FAU - Thomas, Marie-Florence
AU  - Thomas MF
AD  - Universite de Rennes, EHESP, Inserm, Irset (Research Institute for Environmental 
      and Occupational Health), UMR_S 1085, Rennes, France
      marie-florence.thomas@ehesp.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200928
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Climate Change
MH  - Delivery of Health Care
MH  - Humans
MH  - Peer Review
MH  - Research Design
PMC - PMC7523206
OTO - NOTNLM
OT  - *public health
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/09/30 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/29 05:31
PHST- 2020/09/29 05:31 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034667 [pii]
AID - 10.1136/bmjopen-2019-034667 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 28;10(9):e034667. doi: 10.1136/bmjopen-2019-034667.


PMID- 32988831
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 2399-6641 (Electronic)
IS  - 2399-6641 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Sep
TI  - Elective cardiovascular care in the era of the COVID-19 pandemic: managing tragic
      choices.
LID - e001069 [pii]
LID - 10.1136/bmjoq-2020-001069 [doi]
AB  - The COVID-19 pandemic has led to significant morbidity and mortality globally. As
      health systems grapple with caring for patients affected with COVID-19,
      cardiovascular procedures that are deemed 'elective' have been postponed.
      Guidelines concerning which cardiac procedures should be performed during the
      pandemic vary by specialty and geography in the USA. We propose a clinical
      heuristic to guide individual physicians and governing bodies in their decision
      making regarding which cardiac procedures should be performed during the COVID-19
      pandemic using the behavioural economics concept of heuristics and ecological
      rationality.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Berman, Adam E
AU  - Berman AE
AUID- ORCID: 0000-0002-9023-1130
AD  - Division of Cardiology, Medical College of Georgia, Augusta, Georgia, United
      States aberman@augusta.edu.
AD  - Division of Health Economics and Modeling, Medical College of Georgia, Augusta,
      Georgia, United States.
FAU - Miller, Douglas
AU  - Miller D
AD  - Division of Cardiology, Medical College of Georgia, Augusta, Georgia, United
      States.
AD  - Division of Health Policy, Medical College of Georgia, Augusta, Georgia, United
      States.
FAU - Sorrentino, Robert A
AU  - Sorrentino RA
AD  - Division of Cardiology, Medical College of Georgia, Augusta, Georgia, United
      States.
FAU - Mossialos, Elias A
AU  - Mossialos EA
AD  - Department of Health Policy, The London School of Economics and Political
      Science, London, London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BMJ Open Qual
JT  - BMJ open quality
JID - 101710381
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cardiovascular Surgical Procedures/*psychology
MH  - Clinical Decision-Making/*methods
MH  - Contraindications, Procedure
MH  - Coronavirus Infections/*prevention & control
MH  - *Economics, Behavioral
MH  - Elective Surgical Procedures/*psychology
MH  - *Heuristics
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7523154
OTO - NOTNLM
OT  - *clinical
OT  - *decision making
OT  - *decision support
OT  - *ethics
OT  - *health equity
OT  - *health policy
COIS- Competing interests: None declared.
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 05:30
PHST- 2020/06/17 00:00 [received]
PHST- 2020/08/31 00:00 [revised]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/09/29 05:30 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - bmjoq-2020-001069 [pii]
AID - 10.1136/bmjoq-2020-001069 [doi]
PST - ppublish
SO  - BMJ Open Qual. 2020 Sep;9(3). pii: bmjoq-2020-001069. doi:
      10.1136/bmjoq-2020-001069.


PMID- 32988484
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201218
IS  - 1268-6034 (Print)
IS  - 1268-6034 (Linking)
VI  - 25
IP  - 145
DP  - 2020 Sep - Oct
TI  - [Accommodation facility for dependent elderly people, ensuring relational
      proximity after health emergencies].
PG  - 28-30
LID - S1268-6034(20)30118-3 [pii]
LID - 10.1016/j.sger.2020.07.007 [doi]
AB  - The health emergency linked to Covid-19 has been stressful for staff working in
      nursing home, and doubly painful for residents faced with the risk of infection
      and the reality of family separation. We explore in this article some
      psychological consequences resulting from their experience in the waning health
      crisis, hoping that the experience gained will allow greater efficiency in the
      event of a resumption of the pandemic.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Hazif-Thomas, Cyril
AU  - Hazif-Thomas C
AD  - Service de psychiatrie du sujet age, EA 7479, centre hospitalier regional
      universitaire de Brest, route de Ploudalmezeau, 29820 Bohars, France.
FAU - Thomas, Philippe
AU  - Thomas P
AD  - Centre de recherches semiotiques, EA 3648, universite de Limoges, 39 rue
      Camille-Guerin, 87000 Limoges, France. Electronic address:
      philippe.thomas.2008@orange.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Ehpad, pour la proximite relationnelle apres l'urgence sanitaire.
DEP - 20200717
PL  - France
TA  - Soins Gerontol
JT  - Soins. Gerontologie
JID - 9616322
MH  - Aged
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Emergencies/psychology
MH  - Family Relations
MH  - Humans
MH  - Nursing Homes/*organization & administration
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
OTO - NOTNLM
OT  - Covid-19
OT  - confinement
OT  - containment measures
OT  - depression
OT  - depression
OT  - ethics
OT  - pandemic
OT  - pandemie
OT  - psychosocial risks
OT  - risque psychosocial
OT  - ethique
EDAT- 2020/09/30 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/29 05:26
PHST- 2020/09/29 05:26 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - S1268-6034(20)30118-3 [pii]
AID - 10.1016/j.sger.2020.07.007 [doi]
PST - ppublish
SO  - Soins Gerontol. 2020 Sep - Oct;25(145):28-30. doi: 10.1016/j.sger.2020.07.007.
      Epub 2020 Jul 17.


PMID- 32988305
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201001
IS  - 0032-7034 (Print)
IS  - 0032-7034 (Linking)
VI  - 69
IP  - 6
DP  - 2020 Sep
TI  - [Trans-Identity in Minors: Basic Ethical Principles for Individual
      Decision-Making in Healthcare].
PG  - 517-523
LID - 10.13109/prkk.2020.69.6.517 [doi]
AB  - Trans-Identity in Minors: Basic Ethical Principles for Individual Decision-Making
      in Healthcare The treatment of minors with gender incongruence has been the
      subject of controversial discussion for some time. In 2020, the German Ethics
      Council adopted the ad-hoc recommendation "Trans-identity in children and
      adolescents: Therapeutic Controversies - Ethical Orientations" with the aim of
      sensitising to the relevant ethically problematic aspects and of setting out
      orienting guidelines for medical and psychotherapeutic support and treatment.
      According to the Ethics Council, every person has the constitutional right to
      lead a life in accordance with one's own gender identity and to be respected in
      this identity. Healthcare professionals must assess the consequences of treatment
      as well as the consequences of refraining to provide treatment. All interactions 
      with the child must be designed in such a way that the child can participate in
      decision-making and is ultimately enabled to give full informed consent.
      Stigmatisation and discriminatory pathologisation of gender incongruence must be 
      avoided.
FAU - Wiesemann, Claudia
AU  - Wiesemann C
AD  - Institut fur Ethik und Geschichte der Medizin Universitatsmedizin Gottingen
      Humboldtallee 36 37073 Gottingen Deutschland Institut fur Ethik und Geschichte
      der Medizin.
LA  - ger
PT  - Journal Article
TT  - Trans-Identitat bei Kindern und Jugendlichen: Medizinethische Grundsatze fur
      individuelle Behandlungsentscheidungen.
PL  - Germany
TA  - Prax Kinderpsychol Kinderpsychiatr
JT  - Praxis der Kinderpsychologie und Kinderpsychiatrie
JID - 0404246
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Clinical Decision-Making/*ethics
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - Minors/*psychology
OTO - NOTNLM
OT  - Deutscher Ethikrat
OT  - Empfehlungen
OT  - German Ethics Council
OT  - Geschlechtsinkongruenz
OT  - Minderjahrige
OT  - gender incongruence
OT  - guidelines
OT  - minors
EDAT- 2020/09/30 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/29 05:25
PHST- 2020/09/29 05:25 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.13109/prkk.2020.69.6.517 [doi]
PST - ppublish
SO  - Prax Kinderpsychol Kinderpsychiatr. 2020 Sep;69(6):517-523. doi:
      10.13109/prkk.2020.69.6.517.


PMID- 32988192
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20201014
IS  - 0297-2964 (Print)
IS  - 0297-2964 (Linking)
IP  - 141
DP  - 2020 Jun
TI  - [Teaching at hospitals: Between educational and nursing care activities].
PG  - 7-16
LID - 10.3917/rsi.141.0007 [doi]
AB  - This article aims to reveal the ethical framework surrounding hospitalized school
      students, showing that, in the context of disease, traditional ethics do not
      work. From a philosophical perspective, the target audience are teachers and
      volunteers who teach at hospitals, but also nurses and other professionals who
      work with sick children. The development of an ethical framework based on the
      ethics of care (EoC) will enable teachers to guide their activity in hospitals,
      highlighting the need for another ethical framework in order to achieve a
      teaching practice that is fully responsible and compassionate. In an ethical
      framework centered on the sick child, concepts such as "care" and "well-being"
      are mobilized by understanding how they relate to the psychological well-being of
      hospitalized students. I propose that an educational attitude rooted in
      admiration, respect and love can be a good guide for teaching practices in
      hospitals, offering an alternative to the ethical limitations of codes based on a
      universal conception of justice.
FAU - Garcia, Alicia
AU  - Garcia A
LA  - fre
PT  - Journal Article
TT  - L'enseignement en milieu hospitalier : entre education et soins infirmiers.
PL  - France
TA  - Rech Soins Infirm
JT  - Recherche en soins infirmiers
JID - 9715370
MH  - Child
MH  - Child, Hospitalized/*education/psychology
MH  - Humans
MH  - Nursing Care/*ethics
MH  - Students/psychology
MH  - Teaching/*ethics
EDAT- 2020/09/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/29 04:54
PHST- 2020/09/29 04:54 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.3917/rsi.141.0007 [doi]
PST - ppublish
SO  - Rech Soins Infirm. 2020 Jun;(141):7-16. doi: 10.3917/rsi.141.0007.


PMID- 32988185
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201001
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Sep
TI  - [Chapter 4. Bioethics and religion in Latin America]
PG  - 43-47
LID - 10.3917/jibes.311.0043 [doi]
AB  - We want here to examine the challenge of cultural pluralism that the new
      discipline of Bioethics is rising to a Church that wants to leave the sacristy.
      Being herself in the contemporary world, the Church should be involved in those
      issues and should be concerned by the common anguish shared by secularized
      society, which does not share necessarily a religious vision of the world. We
      should question why theology should be interested in bioethics and its problems
      and the way we tackle them. We should also search what may be the perspectives
      for dialogue faced with those challenges such as the health as a right and duty; 
      dilemmas that arise at the beginning and end of life, the role of the theologian 
      and religious persons in the new research ethics committees.
FAU - de Paul de Barchifontaine, Christian
AU  - de Paul de Barchifontaine C
LA  - spa
PT  - Journal Article
TT  - Chapitre 4. Bioetica y religion en America latina.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Bioethics
MH  - *Cultural Diversity
MH  - Humans
MH  - Latin America
MH  - *Religion
MH  - Theology
EDAT- 2020/09/30 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/29 04:52
PHST- 2020/09/29 04:52 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.3917/jibes.311.0043 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Sep;31(1):43-47. doi: 10.3917/jibes.311.0043.


PMID- 32988184
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201001
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Sep
TI  - [Chapter 3. The seven capital sins: genesis, virtues, demons and rights]
PG  - 31-42
LID - 10.3917/jibes.311.0031 [doi]
AB  - Sin in its original form constitutes a deviation from human behavior. Christian
      doctrine incorporates into the Judeo-Christian tradition the deadly sins that we 
      all know (and their demons), as well as the virtues that are supposed to defeat
      or at least neutralize: 1) pride / humility, 2) greed / generosity, 3) lust /
      chastity, 4) anger / patience, 5) gluttony / temperance, 6) envy / charity and 7)
      laziness / diligence. In this same line of thought, to sin would be to abuse the 
      freedom of God. According to John Bossy, the seven deadly sins would be the
      expression of a social and community ethic with which the Catholic Church tried
      at the time to contain violence and heal the troubled medieval society. Sins and 
      their penance were originally a healthy warning of how to manage one&#8217;s
      individual and social behavior (Savater, 2013). That which Modern society allows 
      as lawful or not, has &#8220;overcome&#8221; the conduct and moral republicanism 
      of our days (1). Morality is one of the most sophisticated features of human
      judgment, behavior, and mind. An individual who deviates from violent morality,
      rules and civil rights, even affecting the individual liberties of others,
      sometimes even aggressively. A scientific approach to the origins of evil refers 
      us to the exciting analysis of the molecular, epigenetic, phylogenetic and
      cellular determinants of the neurobiology of sin. This formidable adventure of
      thought constitutes a harmonious path traveled by moral philosophy and the
      neurosciences of that long stretch that is between the error of Prometheus and
      the error of Descartes.
FAU - Estevez M, Edmundo
AU  - Estevez M E
LA  - spa
PT  - Journal Article
TT  - Chapitre 3. Los siete pecados capitales: genesis, virtudes, demonios y derechos.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - Animals
MH  - *Catholicism
MH  - Cattle
MH  - *Christianity
MH  - Humans
MH  - *Morals
MH  - Phylogeny
MH  - *Virtues
EDAT- 2020/09/30 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/29 04:52
PHST- 2020/09/29 04:52 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.3917/jibes.311.0031 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Sep;31(1):31-42. doi: 10.3917/jibes.311.0031.


PMID- 32988183
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201001
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Sep
TI  - [Chapter 1. Ethics and cultural diversity]
PG  - 11-20
LID - 10.3917/jibes.311.0011 [doi]
AB  - Man&#8217;s social nature and capabilities set him up as a creator of culture.
      Culture is inherent to its human nature and encompasses all the dimensions of its
      person, its biology, its intelligence, its affectivity and also its ethical
      dimension. There is no other being in our world that creates and transmits
      culture; culture is of man and for man. Therefore, it unites us to past
      generations and at the same time commits us to the future, since we assume the
      legacy of human history and develop our own to launch it into the future to
      create and participate in cultural advancement and progress.
FAU - Estevez M, Edmundo
AU  - Estevez M E
LA  - fre
PT  - Journal Article
TT  - Chapitre 1. Ethique et diversite culturelle.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Cultural Diversity
MH  - *Ethics
MH  - Humans
MH  - Male
MH  - *Morals
EDAT- 2020/09/30 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/29 04:52
PHST- 2020/09/29 04:52 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.3917/jibes.311.0011 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Sep;31(1):11-20. doi: 10.3917/jibes.311.0011.


PMID- 32987879
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Sep 24
TI  - "They're Not Going to Do Nothing for Me": Research Participants' Attitudes
      towards Elective Genetic Counseling.
LID - E143 [pii]
LID - 10.3390/jpm10040143 [doi]
AB  - As applications of genomic sequencing have expanded, offering genetic counseling 
      support to all patients is arguably no longer practical. Additionally, whether
      individuals desire and value genetic counseling services for genomic screening is
      unclear. We offered elective genetic counseling to 5110 individuals prior to
      undergoing sequencing and 2310 participants who received neutral results to
      assess demand. A total of 0.2% of the study participants accessed genetic
      counseling services prior to sequencing, and 0.3% reached out after receiving
      neutral results. We later conducted 50 interviews with participants to understand
      why they did not access these services. Many interviewees did not recall the
      availability of genetic counseling and were unfamiliar with the profession.
      Interviewees described not needing counseling before sequencing because they
      understood the study and felt that they could cope with any result. Counseling
      was considered equally unnecessary after learning neutral results. Although the
      participants had questions about their results, they did not feel that speaking
      with a genetic counselor would be helpful. Genomic screening efforts that employ 
      opt-in models of genetic counseling may need to clarify the potential value of
      genetic counseling support from the outset and feature genetic counseling
      services more prominently in program materials.
FAU - Sutton, Erica J
AU  - Sutton EJ
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN 55905, USA.
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Beck, Annika T
AU  - Beck AT
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Gamm, Kylie O
AU  - Gamm KO
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - McCormick, Jennifer B
AU  - McCormick JB
AD  - College of Medicine, Department of Humanities, Pennsylvania State University,
      Hershey, PA 17033, USA.
FAU - Kullo, Iftikhar J
AU  - Kullo IJ
AD  - Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Sharp, Richard R
AU  - Sharp RR
AUID- ORCID: 0000-0001-5441-2084
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN 55905, USA.
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
LA  - eng
GR  - U01 HG006379/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20200924
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC7711758
OTO - NOTNLM
OT  - and social implications
OT  - ethical
OT  - genetic counseling
OT  - genomic sequencing
OT  - informed consent
OT  - legal
OT  - patient communication
OT  - patient education
OT  - return of results
EDAT- 2020/09/30 06:00
MHDA- 2020/09/30 06:01
CRDT- 2020/09/29 01:03
PHST- 2020/08/25 00:00 [received]
PHST- 2020/09/12 00:00 [revised]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/09/29 01:03 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/09/30 06:01 [medline]
AID - jpm10040143 [pii]
AID - 10.3390/jpm10040143 [doi]
PST - epublish
SO  - J Pers Med. 2020 Sep 24;10(4). pii: jpm10040143. doi: 10.3390/jpm10040143.


PMID- 35591980
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2296-7745 (Print)
IS  - 2296-7745 (Linking)
VI  - 7
DP  - 2020 Sep 30
TI  - Atlantic Horseshoe Crabs and Endotoxin Testing: Perspectives on Alternatives,
      sustainable Methods, and the 3Rs (Replacement, Reduction, and Refinement).
LID - fmars.2020.582132 [pii]
LID - 10.3389/fmars.2020.582132 [doi]
AB  - Endotoxin testing is a vital part of quality and safety control in pharmaceutical
      production. The primary method for this testing in North America and Europe is
      the limulus amebocyte lysate (LAL) test, a critical component of which is the
      blood of Atlantic horseshoe crabs (Limuius poiyphemus). Procuring blood for LAL
      testing involves capturing and bleeding over 500,000 crabs from wild marine
      populations each year. Whilst efforts are made by manufacturers to return crabs
      to the sea following the collection of blood, there is a level of mortality and
      sub-lethal impact involved, prompting increasing discussions about welfare and
      ethics. The 3Rs - the ambition to where possible, replace, reduce, and refine the
      use of animals - are established and accepted worldwide as the best framework for
      governing animal-dependent science. However, the biomedical utilization of
      horseshoe crabs to produce the LAL test has rarely been viewed through a 3Rs
      framework. More recently, there has been a renewed attention on sustainable
      methods and alternatives to the LAL test. Drawing on in-depth qualitative
      interviews, this article examines stakeholder perspectives on opportunities for
      thinking with the 3Rs, considering current appetites to replace, refine, and
      reduce contemporary biomedical reliance on horseshoe crabs. The shape of
      conversations about the biomedical utilization of horseshoe crabs has shifted
      significantly in recent years, and the 3Rs are an important driver of change,
      offering the potential to advance the use of more sustainable methods, and
      realize the welfare considerations increasingly expected across science and
      society.
FAU - Gorman, Richard
AU  - Gorman R
AD  - Department of Geography, University of Exeter, Exeter, United Kingdom.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 218323/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PL  - Switzerland
TA  - Front Mar Sci
JT  - Frontiers in Marine Science
JID - 101636280
PMC - PMC7612741
MID - EMS116475
OTO - NOTNLM
OT  - 3Rs (replacement, reduction, refinement)
OT  - alternatives to animal testing
OT  - horseshoe crab (Limulus polyphemus)
OT  - limulus amebocyte lysate
OT  - recombinant factor C
OT  - social science and humanities
COIS- Conflict of Interest: The author declares that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a
      potential conflict of interest.
EDAT- 2020/09/30 00:00
MHDA- 2020/09/30 00:01
CRDT- 2022/05/20 02:16
PHST- 2022/05/20 02:16 [entrez]
PHST- 2020/09/30 00:00 [pubmed]
PHST- 2020/09/30 00:01 [medline]
AID - 10.3389/fmars.2020.582132 [doi]
PST - ppublish
SO  - Front Mar Sci. 2020 Sep 30;7. doi: 10.3389/fmars.2020.582132.


PMID- 32987341
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5223 (Electronic)
IS  - 1471-5953 (Linking)
VI  - 48
DP  - 2020 Oct
TI  - The Safe Care Framework: A practical tool for critical thinking.
PG  - 102852
LID - S1471-5953(19)30073-3 [pii]
LID - 10.1016/j.nepr.2020.102852 [doi]
AB  - Safe, effective and ethical clinical decision-making in nursing depends on
      critical thinking, yet there is no consensus on the educational strategies that
      are most effective in developing and refining this foundational skill. A
      qualitative inquiry among graduating Bachelor of Science in Nursing students
      sought to determine whether one such educational strategy, an operationalized
      critical thinking framework, would assist nursing students to better understand
      acute care patients' complex profiles. The Safe Care Framework, consisting of the
      'Concept Map Template' and the 'Priority Setting Tool Template', was developed
      using a constructivist pedagogical approach. The framework illustrates and
      operationalizes the systematic critical thinking processes that expert nurses use
      to provide safe, comprehensive care. Thematic analysis of qualitative survey
      results revealed the following three main themes; (1) greater organization and
      understanding of patient data; (2) guiding of assessments and priorities of care;
      (3) better communication with others, and several subthemes. Thus, the Safe Care 
      Framework may be a practical operational tool that can support novice nurses in
      developing critical thinking skills. This framework adds to the literature on
      innovative pedagogy for nurse educators.
CI  - Copyright (c) 2020 The Author. Published by Elsevier Ltd.. All rights reserved.
FAU - Hundial, Hirpal
AU  - Hundial H
AD  - Vancouver Community College, 1155 East Broadway, Vancouver, B.C, V5T 4V5, Canada.
      Electronic address: hhundial@vcc.ca.
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - Scotland
TA  - Nurse Educ Pract
JT  - Nurse education in practice
JID - 101090848
SB  - IM
MH  - Creativity
MH  - Faculty, Nursing
MH  - Humans
MH  - Qualitative Research
MH  - *Students, Nursing
MH  - *Thinking
OTO - NOTNLM
OT  - Concept map
OT  - Critical thinking
OT  - Patient complexity
OT  - Priority setting
OT  - Safe Care Framework
EDAT- 2020/09/29 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/28 20:16
PHST- 2019/02/06 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/28 20:16 [entrez]
AID - S1471-5953(19)30073-3 [pii]
AID - 10.1016/j.nepr.2020.102852 [doi]
PST - ppublish
SO  - Nurse Educ Pract. 2020 Oct;48:102852. doi: 10.1016/j.nepr.2020.102852. Epub 2020 
      Aug 8.


PMID- 32986726
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Speaking up behavior and cognitive bias in hand hygiene: Competences of
      German-speaking medical students.
PG  - e0239444
LID - 10.1371/journal.pone.0239444 [doi]
AB  - INTRODUCTION: Infection prevention and speaking up on errors are core qualities
      of health care providers. Heuristic effects (e.g. overconfidence) may impair
      behavior in daily routine, while speaking up can be inhibited by hierarchical
      barriers and medical team factors. Aim of this investigation was to determine,
      how medical students experience these difficulties for hand hygiene in daily
      routine. METHODS: On the base of prior investigations we developed a
      questionnaire with 5-point Likert ordinal scaled items and free text entries.
      This was tested for validity and reliability (Cronbach's Alpha 0.89). Accredited 
      German, Swiss and Austrian universities were contacted and medical students asked
      to participated in the anonymous online survey. Quantitative statistics used
      parametric and non-parametric tests and effect size calculations according to
      Lakens. Qualitative data was coded according to Janesick. RESULTS: 1042
      undergraduates of 12 universities participated. All rated their capabilities in
      hand hygiene and feedback reception higher than those of fellow students, nurses 
      and physicians (p<0.001). Half of the participants rating themselves to be best
      educated, realized that faulty hand hygiene can be of lethal effect. Findings
      were independent from age, sex, academic course and university. Speaking-up in
      case of omitted hand hygiene was rated to be done seldomly and most rare on
      persons of higher hierarchic levels. Qualitative results of 164 entries showed
      four main themes: 1) Education methods in hand hygiene are insufficient, 2)
      Hierarchy barriers impair constructive work place culture 3) Hygiene and feedback
      are linked to medical ethics and 4) There is no consequence for breaking hygiene 
      rules. DISCUSSION: Although partially limited by the selection bias, this study
      confirms the overconfidence-effects demonstrated in post-graduates in other
      settings and different professions. The independence from study progress
      suggests, that the effect occurs before start of the academic course with need
      for educational intervention at the very beginning. Qualitative data showed that 
      used methods are insufficient and contradictory work place behavior in hospitals 
      are frustrating. Even 20 years after "To err is human", work place culture still 
      is far away from the desirable.
FAU - Bushuven, Stefan
AU  - Bushuven S
AUID- ORCID: 0000-0001-6272-0714
AD  - Institute for Anesthesiology, Intensive Care, Emergency Medicine and Pain
      Therapy, Hegau-Bodensee Hospital Singen and Hegau Jugendwerk Gailingen,
      Healthcare Association Constance (GLKN), Radolfzell, Germany.
AD  - Institute for Hospital Hygiene and Infection Prevention, Healthcare Association
      Constance (GLKN), Radolfzell, Germany.
AD  - Institute for Didactics and Educational Research in Medicine, Clinic of the
      University Munich, LMU Munich, Munich, Germany.
FAU - Dettenkofer, Markus
AU  - Dettenkofer M
AD  - Institute for Hospital Hygiene and Infection Prevention, Healthcare Association
      Constance (GLKN), Radolfzell, Germany.
FAU - Sippel, Sonia
AU  - Sippel S
AD  - Institute of Medical Teaching and Medical Education Research, University Hospital
      Wuerzburg, Wuerzburg, Germany.
FAU - Koenig, Sarah
AU  - Koenig S
AD  - Institute of Medical Teaching and Medical Education Research, University Hospital
      Wuerzburg, Wuerzburg, Germany.
FAU - Bushuven, Stefanie
AU  - Bushuven S
AD  - Clinic for Orthopedics, Hand- and Trauma surgery, Hegau-Bodensee-Hospital Singen,
      Healthcare Association Constance (GLKN), Radolfzell, Germany.
FAU - Schneider-Brachert, Wulf
AU  - Schneider-Brachert W
AD  - Department of Infection Control and Infectious Diseases, University Hospital
      Regensburg, Regensburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Cognition
MH  - Female
MH  - *Hand Hygiene
MH  - Humans
MH  - *Language
MH  - Male
MH  - Patient Safety
MH  - *Professional Competence
MH  - Students, Medical/*psychology
MH  - Young Adult
PMC - PMC7521694
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/29 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/28 17:12
PHST- 2020/02/04 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/28 17:12 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1371/journal.pone.0239444 [doi]
AID - PONE-D-20-03135 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 28;15(9):e0239444. doi: 10.1371/journal.pone.0239444.
      eCollection 2020.


PMID- 32986455
OWN - NLM
STAT- Publisher
LR  - 20200928
IS  - 1939-148X (Electronic)
IS  - 1541-1559 (Linking)
DP  - 2020 Sep 28
TI  - Dr. Colleen M. Hacker: A certified mental performance consultant (CMPC).
LID - 10.1037/ser0000505 [doi]
AB  - This interview highlighted the atypical career of Dr. Colleen Hacker. She
      discusses her experiences as a mental skills coach, corporate speaker, and
      full-time professor. The convergence of these career paths has led her to be a
      leader in the Olympic and professional sports setting, as well as in academia.
      Dr. Colleen M. Hacker provides critical insights into how she obtained these
      positions and how she manages her day-to-day tasks. Additionally, she discusses
      her knowledge in sport and performance psychology, life as a professor, and her
      experience as a three-time intercollegiate national champion soccer coach.
      Multicultural issues such as geopolitical diversity and the different cultural
      realities among the numerous countries she has traveled are described. Finally,
      Dr. Colleen M. Hacker explains ethical issues and the appealing aspects of her
      career. Her parting advice for young professionals looking to pursue similar
      careers is to be passionate about what you do, pursue excellence, and "be where
      your feet are." (PsycInfo Database Record (c) 2020 APA, all rights reserved).
FAU - Whitmire, Jared
AU  - Whitmire J
AUID- ORCID: 0000-0002-7386-4438
AD  - Department of Psychology & Counseling, University of Central Arkansas.
FAU - Hacker, Colleen M
AU  - Hacker CM
AD  - Department of Kinesiology, Pacific Lutheran University.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - United States
TA  - Psychol Serv
JT  - Psychological services
JID - 101214316
SB  - IM
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/09/28 17:10
PHST- 2020/09/28 17:10 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - 2020-72354-001 [pii]
AID - 10.1037/ser0000505 [doi]
PST - aheadofprint
SO  - Psychol Serv. 2020 Sep 28. pii: 2020-72354-001. doi: 10.1037/ser0000505.


PMID- 32985990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201101
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 28
TI  - Country-Level Assessment of Missed Opportunities for Vaccination in South Africa:
      Protocol for Multilevel Analysis.
PG  - e16672
LID - 10.2196/16672 [doi]
AB  - BACKGROUND: Vaccination is one of the greatest public health interventions of all
      time. Vaccination coverage in South Africa has shown a steady improvement in
      reaching the national target. However, while there is progress nationally, there 
      are districts within the country that are below the set target for vaccination
      coverage. One of the main drivers of suboptimal vaccination coverage is thought
      to be missed opportunities for vaccination. OBJECTIVE: This study aims to
      understand the magnitude and determinants of missed opportunities for vaccination
      in South Africa. METHODS: The 2016 South African Demographic and Health Survey
      will be used to conduct multilevel regression analyses to determine individual
      and contextual factors associated with missed opportunities for vaccination in
      South Africa. The perspectives of parents attending health care facilities in
      South Africa will be explored through exit interviews and focus group
      discussions. Similarly, perspectives of the health care providers will be sought 
      to understand enablers and barriers to vaccination coverage at the facility
      level. Insights to such factors will aid in designing tailor-made interventions
      to improve vaccination coverage in South Africa. RESULTS: Ethical review
      submission is planned for October 2020. Data collection is expected to be
      underway in January 2021. CONCLUSIONS: The extent of missed opportunities in
      South Africa coupled with the associated factors presents an opportunity for
      efforts to increase uptake in districts where vaccination coverage is below the
      national target. Population-level data such as those from the 2016 South African 
      Demographic Health Survey will provide an idea of the magnitude of missed
      opportunities for vaccination in South Africa at the national and subnational
      levels. The findings of the study will inform national and subnational policy
      implementation on vaccinations and help to find context-specific interventions to
      improve vaccination coverage. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      PRR1-10.2196/16672.
CI  - (c)Duduzile Ndwandwe, Ntombenhle J Ngcobo, Abdu A Adamu, Chukwudi Nnaji, Thandiwe
      Mashunye, Arlette M Leufak, Sara Cooper, Olalekan A Uthman, Charles S Wiysonge.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 28.09.2020.
FAU - Ndwandwe, Duduzile
AU  - Ndwandwe D
AUID- ORCID: https://orcid.org/0000-0001-7129-3865
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
FAU - Ngcobo, Ntombenhle J
AU  - Ngcobo NJ
AUID- ORCID: https://orcid.org/0000-0002-9666-6127
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
FAU - Adamu, Abdu A
AU  - Adamu AA
AUID- ORCID: https://orcid.org/0000-0003-3317-1319
AD  - Centre for Evidence-based Health Care, Division of Epidemiology and
      Biostatistics, Department of Global Health, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Nnaji, Chukwudi
AU  - Nnaji C
AUID- ORCID: https://orcid.org/0000-0002-4132-1922
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
FAU - Mashunye, Thandiwe
AU  - Mashunye T
AUID- ORCID: https://orcid.org/0000-0002-3922-439X
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
FAU - Leufak, Arlette M
AU  - Leufak AM
AUID- ORCID: https://orcid.org/0000-0002-0729-6057
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
FAU - Cooper, Sara
AU  - Cooper S
AUID- ORCID: https://orcid.org/0000-0001-9894-236X
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
FAU - Uthman, Olalekan A
AU  - Uthman OA
AUID- ORCID: https://orcid.org/0000-0002-8567-3081
AD  - Centre for Evidence-based Health Care, Division of Epidemiology and
      Biostatistics, Department of Global Health, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
AD  - Warwick-Centre for Applied Health Research and Delivery, Division of Health
      Sciences, University of Warwick Medical School, Coventry, United Kingdom.
FAU - Wiysonge, Charles S
AU  - Wiysonge CS
AUID- ORCID: https://orcid.org/0000-0002-1273-4779
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
AD  - Centre for Evidence-based Health Care, Division of Epidemiology and
      Biostatistics, Department of Global Health, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7551109
OTO - NOTNLM
OT  - South Africa
OT  - implementation science
OT  - missed opportunities for vaccination
OT  - vaccination coverage
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 12:56
PHST- 2019/10/14 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/04/04 00:00 [revised]
PHST- 2020/09/28 12:56 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - v9i9e16672 [pii]
AID - 10.2196/16672 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Sep 28;9(9):e16672. doi: 10.2196/16672.


PMID- 32985844
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201022
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Mar Apr May Jun
TI  - [Modelization of recommendation framework advice for children immunization to
      Beninese decision makers]
PG  - 273-278
LID - 10.3917/spub.202.0273 [doi]
AB  - The coverage of immunization against avoidable disease in the Republic of Benin
      as in other West African countries, is declining nowadays. To sustain the
      government effort, National Immunization Technical Advisory Groups (NITAG) were
      created technically and funded by the West African health organization (WAHO) and
      Preventive Medicine Agency in countries of the Economic Community of West African
      States (ECOWAS) including the Republic of Benin. The variation in experts&#8217; 
      methods of analyzing evidence sometimes results in risk error and lack of
      statistical power. This situation does not allow for the comparison of the
      scientific validity of certain recommendations made to policy makers, due to the 
      lack of a rigorous framework. The aim of this paper is to design an improved
      framework to be used in the Republic of Benin in order to encourage a more
      harmonized approach based on evidence used by expert consultative committees.
      This framework shows four fundamental scientific steps including a Ministerial
      referral procedure, recommendation framework, evidence-based data collection,
      model analyses appropriate for expert advice on vaccines and child immunization, 
      as well as three administrative steps including scientific discussion and work
      meetings without forgetting ethical aspects.
FAU - Fourn, Leonard
AU  - Fourn L
LA  - fre
PT  - Journal Article
TT  - Modelisation du cadre conceptuel d'avis de recommandation pour la vaccination des
      enfants aux decideurs beninois.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - *Advisory Committees
MH  - Benin
MH  - Child
MH  - *Health Policy
MH  - Humans
MH  - *Immunization
EDAT- 2020/09/29 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/09/28 08:52
PHST- 2020/09/28 08:52 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.3917/spub.202.0273 [doi]
PST - ppublish
SO  - Sante Publique. 2020 Mar Apr May Jun;32(2):273-278. doi: 10.3917/spub.202.0273.


PMID- 32985833
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201022
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Mar Apr May Jun
TI  - [Ethical issues of Internet use by pregnant women during their medical care]
PG  - 171-182
LID - 10.3917/spub.202.0171 [doi]
AB  - INTRODUCTION: Pregnant women are heavy users of Internet and this has an impact
      on their medical follow-up. The purpose of this study is to highlight the ethical
      issues related to the use of the Internet by women in their medical care.Methode:
      Through a systematic literature review conducted on PubMed/Medline, Web of
      Science, CINAHL and Embase between June and July 2019, 10&#160;670 results were
      obtained, and 79 articles were included in the post-selection study. A thematic
      analysis was conducted on these articles. RESULTS: More than 90% of pregnant
      women use Internet, particularly to find medical information and social support, 
      mainly on pregnancy and childbirth. This research allows them more equitable
      access to knowledge and develops their empowerment, which modifies the
      relationship between caregiver and patient, through the acquisition of greater
      autonomy for women and the development of experiential knowledge. This access
      offers a central and active role to pregnant women in their medical care.
      However, many authors also agree on the possible abuses of this use:
      misinformation, disproportionate information and the presence of judgment that
      undermine empowerment, but also digital divide and inequity in understanding
      information, stigmatization of women, and risks of privacy breaches on data
      acquired online. CONCLUSION: In order to provide pregnant women with the central 
      and active place they seek, the authors recommend involving caregivers in the
      referral to reliable sites, encouraging them to develop online content, and
      educating pregnant women in the search for health information on Internet.
FAU - Masella, Marie-Alexia
AU  - Masella MA
FAU - Godard, Beatrice
AU  - Godard B
LA  - fre
PT  - Journal Article
PT  - Systematic Review
TT  - Enjeux ethiques du recours a Internet par les femmes enceintes dans leur suivi de
      grossesse.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - Consumer Health Information/standards
MH  - Female
MH  - Humans
MH  - Information Seeking Behavior
MH  - Internet/*ethics/*statistics & numerical data
MH  - Patient Education as Topic
MH  - Pregnancy
MH  - Pregnant Women/*psychology
MH  - Professional-Patient Relations
MH  - Social Support
EDAT- 2020/09/29 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/09/28 08:52
PHST- 2020/09/28 08:52 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.3917/spub.202.0171 [doi]
PST - ppublish
SO  - Sante Publique. 2020 Mar Apr May Jun;32(2):171-182. doi: 10.3917/spub.202.0171.


PMID- 32985203
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 0001-723X (Print)
IS  - 0001-723X (Linking)
VI  - 64
IP  - 3
DP  - 2020
TI  - Obstacles and limitations of transfer factor biological activity assay design.
PG  - 271-275
LID - 10.4149/av_2020_303 [doi]
AB  - Transfer factor (TF) is a heterogeneous mix of low-molecular weight molecules
      obtained from dialyzed leukocyte extract that is capable of transferring
      cell-mediated immunity. As an immunostimulatory drug TF is used to improve
      treatment of infectious diseases, allergies, cancer and immune deficiencies. The 
      main benefit of TF preparations as immunotherapeutic agents is the induction of a
      rapid immune response and the potential of TF as an adjuvant in combination with 
      other drugs might lead to development of novel approaches to combat various
      diseases in the future. The process of TF preparation is rather simple. However, 
      with respect to fact that TF is composed by several multifunction molecules, it
      is likely that during the activity measurement based only on one single
      parameter, other TF biological activities might be overlooked. In addition,
      separated TF components might display synergetic activity effect. According to
      recent European Pharmacopoeia there is no general protocol for immuno-stimulatory
      drugs (including TF) activity measurement available. Nevertheless, for the
      process of TF preparation, control of input material and for final pharmaceutical
      product batches it is inevitable to guaranty proper quality control including
      appropriate in vivo or in vitro test(s) for TF biological activity assay. The
      animal-origin materials and in vivo assays convey a considerable logistic, ethic 
      and economic problem, meanwhile the available in vitro assays have been reported 
      with limited reproducibility and sometimes contradictory results. The currently
      used method for testing biological activity of TF is the in vitro MTT cells
      proliferation assay that is recognized by control authorities in Slovak Republic.
      Keywords: immune system; transfer factor; dialysable leukocyte extract; diseases;
      MTT cells proliferation assay.
FAU - Kempova, V
AU  - Kempova V
FAU - Zatovicova, M
AU  - Zatovicova M
FAU - Kajanova, I
AU  - Kajanova I
FAU - Lenka, L Jelenska
AU  - Lenka LJ
FAU - Klimko, L
AU  - Klimko L
FAU - Kopacek, J
AU  - Kopacek J
FAU - ZelnIk, V
AU  - ZelnIk V
LA  - eng
PT  - Journal Article
PL  - Slovakia
TA  - Acta Virol
JT  - Acta virologica
JID - 0370401
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Transfer Factor)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Biological Assay/*standards
MH  - *Immunity, Cellular
MH  - Reproducibility of Results
MH  - Slovakia
MH  - Transfer Factor/*standards
EDAT- 2020/09/29 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/09/28 08:42
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/09/28 08:42 [entrez]
AID - 10.4149/av_2020_303 [doi]
PST - ppublish
SO  - Acta Virol. 2020;64(3):271-275. doi: 10.4149/av_2020_303.


PMID- 32984747
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2472-7245 (Electronic)
IS  - 2472-7245 (Linking)
VI  - 5
IP  - 3
DP  - 2020 Jul-Sep
TI  - Resident Rotations in Low- and Middle-Income Countries: Motivations, Impact, and 
      Host Perspectives.
LID - e20.00029 [pii]
LID - 10.2106/JBJS.OA.20.00029 [doi]
AB  - Interest in clinical rotations in low- and middle-income countries (LMICs) has
      grown among high-income country (HIC) orthopaedic residents. This study addresses
      the following questions: (1) What motivates HIC surgical residents to rotate in
      LMICs? (2) What is the impact of rotations on HIC residents? (3) What are the
      LMIC partner perceptions of HIC collaboration? MATERIALS AND METHODS: A search
      strategy of multiple databases returned 3,740 unique articles pertaining to HIC
      surgical resident motivations for participating in rotations in LMICs or the LMIC
      host perspective. Data extraction was dually performed using meta-ethnography,
      the qualitative equivalent of meta-analysis. RESULTS: Twenty-one studies were
      included in the final analysis. HIC residents were primarily motivated to rotate 
      in LMICs by altruistic intent, with greatest impact on professional development. 
      LMIC partners mostly valued HIC sustained investment and educational
      opportunities for LMIC partners. From LMIC's perspective, potential harm from
      collaboration arose from system-level and individual-level discordance between
      HIC and LMIC expectations and priorities. HIC priorities included the following: 
      (1) adequate operative time, (2) exposure to varied pathology, and (3)
      mentorship. LMIC priorities included the following: (1) avoiding competition with
      HIC residents for surgical cases, (2) that HIC groups not undermine LMIC internal
      authority, (3) that HIC initiatives address local LMIC needs, and (4) that LMIC
      partners be included as authors on HIC research initiatives. Both HIC and LMIC
      partners raised ethical concerns regarding collaboration and perceived HIC
      residents to be underprepared for their LMIC rotation. DISCUSSION: This study
      synthesizes the available literature on HIC surgical resident motivations for and
      impact of rotating in LMICs and the LMIC host perception of collaboration. Three 
      improvement categories emerged: that residents (1) receive site-specific
      preparation before departure, (2) remain in country long enough to develop
      site-specific skills, and (3) cultivate flexibility and cultural humility.
      Specific suggestions based on synthesized data are offered for each concept and
      can serve as a foundation for mutually beneficial international electives in
      LMICs for HIC orthopaedic trainees.
CI  - Copyright (c) 2020 The Authors. Published by The Journal of Bone and Joint
      Surgery, Incorporated. All rights reserved.
FAU - Donnelley, Claire A
AU  - Donnelley CA
AUID- ORCID: 0000-0001-7316-6368
AD  - Institute for Global Orthopaedics and Traumatology, Department of Orthopaedic
      Surgery, University of California, San Francisco, San Francisco, California.
FAU - Won, Nae
AU  - Won N
AUID- ORCID: 0000-0003-1755-7035
AD  - Institute for Global Orthopaedics and Traumatology, Department of Orthopaedic
      Surgery, University of California, San Francisco, San Francisco, California.
FAU - Roberts, Heather J
AU  - Roberts HJ
AUID- ORCID: 0000-0002-2576-1338
AD  - Department of Orthopaedic Surgery, University of California, San Francisco, San
      Francisco, California.
FAU - von Kaeppler, Ericka P
AU  - von Kaeppler EP
AUID- ORCID: 0000-0002-9495-3755
AD  - Institute for Global Orthopaedics and Traumatology, Department of Orthopaedic
      Surgery, University of California, San Francisco, San Francisco, California.
FAU - Albright, Patrick D
AU  - Albright PD
AUID- ORCID: 0000-0001-7141-9245
AD  - Western Michigan University School of Medicine, Kalamazoo, Michigan.
FAU - Woolley, Pierre Marie
AU  - Woolley PM
AUID- ORCID: 0000-0003-3516-9378
AD  - Department of Orthopedics, University of Notre Dame Haiti School of Medicine,
      Port Au Prince, Haiti.
FAU - Haonga, Billy
AU  - Haonga B
AUID- ORCID: 0000-0001-9342-298X
AD  - Department of Orthopaedics, Muhimbili university of Healthy and Allied sciences, 
      Muhimbili Orthopaedic Institute Orthopaedic Institute, Dar es Salaam, Tanzania.
FAU - Shearer, David W
AU  - Shearer DW
AUID- ORCID: 0000-0002-1356-6391
AD  - Institute for Global Orthopaedics and Traumatology, Department of Orthopaedic
      Surgery, University of California, San Francisco, San Francisco, California.
FAU - Sabharwal, Sanjeev
AU  - Sabharwal S
AUID- ORCID: 0000-0003-3779-1419
AD  - UCSF Benioff Children's Hospital Oakland, Oakland, California and Department of
      Orthopaedic Surgery, University of California, San Francisco, San Francisco,
      California.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - United States
TA  - JB JS Open Access
JT  - JB & JS open access
JID - 101726219
PMC - PMC7480968
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:47
PHST- 2020/09/28 05:47 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.2106/JBJS.OA.20.00029 [doi]
AID - JBJSOA-D-20-00029 [pii]
PST - epublish
SO  - JB JS Open Access. 2020 Jul 31;5(3). pii: JBJSOA-D-20-00029. doi:
      10.2106/JBJS.OA.20.00029. eCollection 2020 Jul-Sep.


PMID- 32984598
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 9
DP  - 2020 Sep
TI  - DNA barcoding reveals mislabeling and commercial fraud in the marketing of
      fillets of the genus Brachyplatystoma Bleeker, 1862, the Amazonian freshwater
      catfishes economically important in Brazil.
PG  - e04888
LID - 10.1016/j.heliyon.2020.e04888 [doi]
AB  - The substitution and mislabeling is facilitated by the processing of fish
      products. We employed a DNA barcoding to authenticate fillets labeled as
      "dourada" (Brachyplatystoma rousseauxii), and "piramutaba" (Brachyplatystoma
      vaillantii) marketed in the Brazil. A 615 bp of the Cytochrome oxidase subunit I 
      (COI) was sequenced from 305 fillets and subsequently identified to species level
      by querying public databases and sequences of reference species. The results
      revealed a global mean substitution rate of 17%. The highest substitution rate
      was detected in "dourada" (26%), the most valuable species, followed by
      "piramutaba" (9%). The most cases of substitutions were by species of lower
      commercial value, suggesting fraud aimed at increased profits. Therefore, we
      suggest the improvement of food-labeling regulation, continued inspection, as
      well as the adoption of the DNA barcode for the molecular authentication of
      processed fish to prevent substitution of these products in Brazil.
CI  - (c) 2020 The Author(s).
FAU - de Carvalho, Soraia Costa
AU  - de Carvalho SC
AD  - Laboratory of Fish Microbiology, Institute of Coastal Studies, Federal University
      of Para, Alameda Leandro Ribeiro s/n, 68600-000, Braganca, Para, Brazil.
FAU - Sampaio, Iracilda
AU  - Sampaio I
AD  - Laboratory of Genetics and Molecular Biology, Institute of Coastal Studies,
      Federal University of Para, Alameda Leandro Ribeiro s/n, 68600-000, Braganca,
      Para, Brazil.
FAU - Santos, Simoni
AU  - Santos S
AD  - Laboratory of Fish Microbiology, Institute of Coastal Studies, Federal University
      of Para, Alameda Leandro Ribeiro s/n, 68600-000, Braganca, Para, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7495058
OTO - NOTNLM
OT  - Commercial fraud
OT  - DNA barcoding
OT  - Ethical issues
OT  - Food analysis
OT  - Food science
OT  - Industry
OT  - Processed fish
OT  - Species substitution
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:47
PHST- 2020/04/17 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/28 05:47 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04888 [doi]
AID - S2405-8440(20)31731-X [pii]
PST - epublish
SO  - Heliyon. 2020 Sep 14;6(9):e04888. doi: 10.1016/j.heliyon.2020.e04888. eCollection
      2020 Sep.


PMID- 32984442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2333-3928 (Electronic)
IS  - 2333-3928 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Ethics and Economics of the COVID-19 Pandemic in the United States.
PG  - 2333392820957661
LID - 10.1177/2333392820957661 [doi]
AB  - The Covid-19 experience provides a natural experiment in personal and social
      ethics. Difficult decisions are routinely made to optimize lives and livelihoods.
      This commentary provides background and insight into the ethical and economic
      foundations underpinning dilemmas of this historic pandemic.
CI  - (c) The Author(s) 2020.
FAU - Hilsenrath, Peter
AU  - Hilsenrath P
AUID- ORCID: https://orcid.org/0000-0002-0866-8043
AD  - Eberhardt School of Business, University of the Pacific, Stockton, CA, USA.
FAU - Borders, Tyrone
AU  - Borders T
AD  - Health Management and Policy, University of Kentucky, Lexington, KY, USA.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - United States
TA  - Health Serv Res Manag Epidemiol
JT  - Health services research and managerial epidemiology
JID - 101654536
PMC - PMC7498963
OTO - NOTNLM
OT  - COVID 19
OT  - Kant
OT  - economics
OT  - ethics
OT  - pandemic
OT  - philosophy
OT  - policy
OT  - public health
OT  - quality-adjusted life year
OT  - utilitarianism
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:46
PHST- 2020/08/07 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/09/28 05:46 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1177/2333392820957661 [doi]
AID - 10.1177_2333392820957661 [pii]
PST - epublish
SO  - Health Serv Res Manag Epidemiol. 2020 Sep 16;7:2333392820957661. doi:
      10.1177/2333392820957661. eCollection 2020 Jan-Dec.


PMID- 32984143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun
TI  - The effect of pain management training in workshop on the knowledge, attitude and
      self-efficacy of pediatric nurses.
PG  - 2880-2884
LID - 10.4103/jfmpc.jfmpc_92_20 [doi]
AB  - BACKGROUND AND AIMS: Pain is the fifth vital sign, and pediatric nurses plays a
      key role in the process of pediatric pain management. The present study aimed to 
      determine the effect of pain management training on the knowledge, attitude and
      self-efficacy of pediatric nurses. METHODS: This is a quasi-experimental study
      including two groups of test and control. The experimental group received a
      workshop method with a content including (ethical aspect, physiology, assessment 
      tools, and pharmaceutical and non-pharmacological pain management) and was not
      given in the control group. The PNKAS self-efficacy questionnaires was completed 
      by the participants before and one month after the beginning of the study. The
      data were analyzed using descriptive statistics and independent T-test, Fisher
      exact, and Chi-square tests using SPSS version 20 software. RESULTS: The mean
      pre-test scores of knowledge and attitude in the control and experimental groups 
      was 50.79-47.14, and after one month was 47.46-53.09, respectively, showed that, 
      training was significantly effective in the knowledge and attitude of the
      experimental group (P value = 0.01). The mean pre-test score of self-efficacy in 
      the control and experimental groups was (17.01-18.06), and one month later was
      20.36-21.03 respectively. Although the self-efficacy score increased in both
      groups, training significantly increased the self-efficacy of pediatric nurses in
      the experimental group (P value <0.001). CONCLUSION: Pain management training is 
      required due to the poor knowledge of pediatric nurses and the importance of pain
      management in improving the quality of nursing care and the satisfaction of
      patients with the In addition, feeling high self-efficacy without sufficient
      knowledge of pain management can disrupt pediatric pain management.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Parvizy, Soroor
AU  - Parvizy S
AD  - Department of Pediatric Nursing, Faculty of Nursing and Midwifery, Center for
      Educational Research in Medical Sciences, Iran University of Medical Sciences,
      Tehran, Iran.
FAU - Tarvirdinasab, Sakineh
AU  - Tarvirdinasab S
AD  - Department of Community Health Nursing, School of Nursing and Midwifery, Iran
      University of Medical Sciences, Tehran, Iran.
FAU - Raznahan, Rasool
AU  - Raznahan R
AD  - Department of Nursing, School of Nursing and Midwifery, Torbat Heydariyeh
      University of Medical Sciences, Torbat Heydariyeh, Iran.
AD  - Health Sciences Research Center, Torbat Heydariyeh University of Medical
      Sciences, Torbat Heydariyeh, Iran.
FAU - Aliakbari, Mahboobeh
AU  - Aliakbari M
AD  - Department of Pediatric Nursing, Faculty of Nursing and Midwifery, Center for
      Educational Research in Medical Sciences, Iran University of Medical Sciences,
      Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7491795
OTO - NOTNLM
OT  - Pain management
OT  - pediatric nurses
OT  - self-efficacy
COIS- There are no conflicts of interest.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:45
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/09/28 05:45 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_92_20 [doi]
AID - JFMPC-9-2880 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Jun 30;9(6):2880-2884. doi:
      10.4103/jfmpc.jfmpc_92_20. eCollection 2020 Jun.


PMID- 32984141
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun
TI  - Effectiveness of formal training in bioethics of 3(rd) semester undergraduate
      medical students in recognizing bioethical issues and principles in patient care.
PG  - 2871-2876
LID - 10.4103/jfmpc.jfmpc_405_20 [doi]
AB  - INTRODUCTION: Despite well-described code of conduct for physician the recent
      increase in litigation against doctors is an issue of concern which says that
      doctors and health professionals are confronted with many ethical problems
      regularly. The aim of the present study was to see the ability to recognize
      different bioethical issues in relation to patient care among 3(rd) semester
      undergraduate students and also the change in the pattern of recognition of
      bioethical issues after formal training. METHODS: This cross-sectional study was 
      carried out using self-administered questionnaire among the fifty 3(rd) semester 
      undergraduate MBBS students. Each question was designed in a "Likert scale"
      pattern carrying a minimum score of 1 (1 = strongly disagree) and maximum score
      of 5 (5 = strongly agree). After 6 months of training and bedside clinical
      exposure, students were assessed again with same set of questionnaire. The
      statistical analyses were performed using SPSS 17.0. RESULTS: All of the
      respondents in the study group were of the opinion that medical ethics is very
      important but only 24% aware about existence of ethics committee in the
      institute. Changes has been observed after clinical exposure in response like
      disclosure of patient's condition to close relatives (agreed 54% versus 84% pre
      and postexposure, respectively) and discussion of related ethical issues with
      clinical case discussion (agreed 74% versus 94% pre and postexposure,
      respectively). Some of the issues needs further clarification even after clinical
      exposure like doctors must not refuse to do abortion (56% disagreed and 38%
      agreed), consent regarding treatment in children (60% disagreed and 32% agreed), 
      and uses of branded versus generic drugs (76% generic and 26% branded).
      CONCLUSION: There is a need to stress the importance of ethical practice in the
      undergraduate curriculum to make the doctors confident enough to deal the ethical
      dilemma for themselves and better professional efficiency.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Barman, Bhupen
AU  - Barman B
AD  - Department of General Medicine, North Eastern Indira Gandhi Regional Institute of
      Health and Medical Sciences (NEIGRIHMS), Shillong, Meghalaya, India.
FAU - Srivastava, Tripti K
AU  - Srivastava TK
AD  - Department of Physiology, Convener, MCI Nodal Center for Faculty Development,
      JNMC, Sawangi (Meghe), Wardha, Maharashtra, India.
FAU - Sarma, Amitav
AU  - Sarma A
AD  - Department of Anatomy, North Eastern Indira Gandhi Regional Institute of Health
      and Medical Sciences (NEIGRIHMS), Shillong, Meghalaya, India.
FAU - Nath, Chandan K
AU  - Nath CK
AD  - Department of Biochemistry, North Eastern Indira Gandhi Regional Institute of
      Health and Medical Sciences (NEIGRIHMS), Shillong, Meghalaya, India.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7491772
OTO - NOTNLM
OT  - Indian medical graduate
OT  - medical bioethics
OT  - patient care
OT  - undergraduate medical students
COIS- There are no conflicts of interest.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:45
PHST- 2020/03/18 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/09/28 05:45 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_405_20 [doi]
AID - JFMPC-9-2871 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Jun 30;9(6):2871-2876. doi:
      10.4103/jfmpc.jfmpc_405_20. eCollection 2020 Jun.


PMID- 32983898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2214-6350 (Print)
IS  - 2214-6350 (Linking)
VI  - 28
DP  - 2020 Dec
TI  - The impact of Coronavirus (COVID-19) outbreak on faith-based investments: An
      original analysis.
PG  - 100403
LID - 10.1016/j.jbef.2020.100403 [doi]
AB  - This paper examines the rapid spread of Coronavirus (COVID-19) and its short-term
      impact on the Shariah-compliant UK Dow Jones market index to capture the dynamic 
      behavior of stock returns at economy and industry levels. Using daily data over
      the period January 20 to May 20 and ten UK industrial sector groupings, the
      findings suggest a strong and statistically significant relationship between the 
      COVID-19 pandemic and the performance of the conventional stock market index. The
      findings also suggest that the disease interacts negatively but insignificantly
      with the Dow Jones faith-based ethical (Islamic) index compared to its UK
      counterpart. In addition, through an analysis of sector groupings, the paper
      shows that the stock returns of the information technology sector performed
      significantly better than the market, while stock returns of consumer
      discretionary sector, which includes transportation, beverages, tourism and
      leisure, consumer services performed significantly worse than the market during
      the COVID-19 outbreak. Other sector groupings fail to yield significantly
      plausible parameter values.
CI  - (c) 2020 Elsevier B.V. All rights reserved.
FAU - Sherif, Mohamed
AU  - Sherif M
AD  - Edinburgh Business School, Heriot-Watt University, Edinburgh, UK.
AD  - Business School, King Salman University, Ras Sudr, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200919
PL  - Netherlands
TA  - J Behav Exp Finance
JT  - Journal of behavioral and experimental finance
JID - 101668718
PMC - PMC7501051
OTO - NOTNLM
OT  - Behavioral finance
OT  - Coronavirus (COVID-19)
OT  - Faith-based investments
OT  - Stock market indices
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:44
PHST- 2020/06/03 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
PHST- 2020/09/28 05:44 [entrez]
AID - 10.1016/j.jbef.2020.100403 [doi]
AID - S2214-6350(20)30330-0 [pii]
PST - ppublish
SO  - J Behav Exp Finance. 2020 Dec;28:100403. doi: 10.1016/j.jbef.2020.100403. Epub
      2020 Sep 19.


PMID- 32983736
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 26
TI  - Determining the Frequency of Acquired Cystic Kidney Disease in End Stage Renal
      Disease Patients on Hemodialysis at Dialysis Centre of Tertiary Care Hospital.
PG  - e10046
LID - 10.7759/cureus.10046 [doi]
AB  - Objectives To determine the frequency of acquired cystic kidney disease (ACKD)
      among patients of end-stage renal disease. Methods This cross-sectional study was
      conducted at the University of Lahore Teaching Hospital after approval from the
      ethical review committee. About 150 patients with end-stage renal disease
      fulfilling the inclusion criteria and undergoing three hemodialysis sessions per 
      week for six months were approached. The patients underwent ultrasonography by
      the same consultant radiologist and the presence of acquired polycystic kidney
      disease was noted in the proforma. Data was stratified for age, gender and
      duration of hemodialysis and the chi-square test was applied. Results The mean
      age of the study participants was 47.31+/-9.44 years and males were majority in
      number with 92 (61.3%). The acquired cystic kidney disease was noted in 20 (13%) 
      participants. There was significant difference noted in different age groups as
      six (6.5%) patients in the 18-40 age group and 14 (24%) patients in the 40-80 age
      group have acquired kidney disease (p-value=0.002). No important association
      between ACKD, age, and gender were found. None of these patients had evidence of 
      renal cell carcinoma, extrarenal cysts, retroperitoneal or intrarenal hemorrhage.
      Conclusion There was a significant correlation between acquired cystic kidney
      disease and the duration of hemodialysis, and the chances of the development of
      acquired cystic kidney disease rise progressively with increasing time on
      hemodialysis.
CI  - Copyright (c) 2020, Aleem et al.
FAU - Aleem, Muhammad
AU  - Aleem M
AD  - Medicine, Allama Iqbal Medical College/Jinnah Hospital, Lahore, PAK.
FAU - Saleem, Khurram
AU  - Saleem K
AD  - Internal Medicine, University College of Medicine, The University of Lahore
      Teaching Hospital, Lahore, PAK.
FAU - Zafar, Sana
AU  - Zafar S
AD  - Internal Medicine, University College of Medicine, The University of Lahore
      Teaching Hospital, Lahore, PAK.
FAU - Umer, Amina
AU  - Umer A
AD  - Medicine, Allama Iqbal Medical College/Jinnah Hospital, Lahore, PAK.
FAU - Arshad, Rabia
AU  - Arshad R
AD  - Medicine, Allama Iqbal Medical College/Jinnah Hospital, Lahore, PAK.
FAU - Nawaz, Arsalan
AU  - Nawaz A
AD  - Endocrinology, Diabetes and Metabolism, Services Hospital Lahore, Lahore, PAK.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7515804
OTO - NOTNLM
OT  - hemodialysis
OT  - polycystic kidney disease
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:43
PHST- 2020/09/28 05:43 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.7759/cureus.10046 [doi]
PST - epublish
SO  - Cureus. 2020 Aug 26;12(8):e10046. doi: 10.7759/cureus.10046.


PMID- 32983327
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20220417
IS  - 1937-8688 (Electronic)
VI  - 37
DP  - 2020
TI  - A perception survey on the roles of nurses during triage in a selected public
      hospital in Kwazulu-Natal Province, South Africa.
PG  - 9
LID - 10.11604/pamj.2020.37.9.22211 [doi]
AB  - INTRODUCTION: triage is gradually becoming an autonomous nursing role essential
      to patients' safety and the efficient delivery of emergency care. The increased
      need for more holistic and advanced care during triage makes the role of nurses
      during triage highly indispensable. However, several studies have shown that
      nurse-led triage has been so successful over the years in most African countries 
      and in other developing countries. South African Triage Scale (SATS) is an
      example of triage tool that was designed in such a way that the lowest cadre
      nurse can successfully implement. The success recorded by this tool made most
      African countries and some other developing countries adopt the tool. The study
      was designed to explore the roles of nurses during triage in a selected public
      hospital in KwaZulu-Natal province. METHODS: this study utilized a quantitative
      approach, in which a non-experimental survey involving convenience sampling
      technique was chosen as the most suitable sampling technique for the study.
      Recognition-primed decision model formed the framework of the study. Ethical
      clearance was obtained from University of KwaZulu-Natal Ethics Review Board and
      ethics principles were observed during the study. RESULTS: the result of the
      study indicated that majority (100%) of the respondents perceived that nurses
      have lots of roles to perform during triage. They further unveiled that it is
      highly paramount for nurses to manage the waiting room and control overcrowding
      in the unit. CONCLUSION: the study draws on the need for qualified and
      experienced nurses to be in charge of these roles in order to reduce the
      mortality and morbidity rates that usually occur during triage administration.
CI  - Copyright: Olunike Blessing Olofinbiyi et al.
FAU - Olofinbiyi, Olunike Blessing
AU  - Olofinbiyi OB
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, South Africa.
FAU - Dube, Makhosazane
AU  - Dube M
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, South Africa.
FAU - Mhlongo, Euphemia Mbali
AU  - Mhlongo EM
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adult
MH  - Emergency Service, Hospital/organization & administration
MH  - Female
MH  - Hospitals, Public/organization & administration
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nurse's Role
MH  - Nurses/*organization & administration
MH  - Nursing Staff, Hospital/*organization & administration
MH  - South Africa
MH  - Surveys and Questionnaires
MH  - Triage/*organization & administration
MH  - Waiting Lists
MH  - Young Adult
PMC - PMC7501752
OTO - NOTNLM
OT  - Emergency care
OT  - KwaZulu-Natal
OT  - nurses' perceptions
OT  - nursing roles
OT  - public hospital
OT  - triage
COIS- The authors declare no competing interests.
EDAT- 2020/09/29 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/09/28 05:41
PHST- 2020/03/07 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/09/28 05:41 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.11604/pamj.2020.37.9.22211 [doi]
AID - PAMJ-37-9 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Sep 2;37:9. doi: 10.11604/pamj.2020.37.9.22211. eCollection
      2020.


PMID- 32983267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 1765-4629 (Print)
IS  - 1765-4629 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - [Health crisis, ethical crisis].
PG  - 135-136
LID - 10.1016/j.etiqe.2020.08.003 [doi]
FAU - de Broca, A
AU  - de Broca A
AD  - CHU Amiens, neuropediatre, Philosophe, 80054 Amiens cedex 1, France.
LA  - fre
PT  - Editorial
TT  - Crise sanitaire, crises ethiques.
DEP - 20200921
PL  - France
TA  - Ethique Sante
JT  - Ethique & sante
JID - 9885754
PMC - PMC7505593
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:41
PHST- 2020/09/28 05:41 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1016/j.etiqe.2020.08.003 [doi]
AID - S1765-4629(20)30100-8 [pii]
PST - ppublish
SO  - Ethique Sante. 2020 Sep;17(3):135-136. doi: 10.1016/j.etiqe.2020.08.003. Epub
      2020 Sep 21.


PMID- 32983243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1743-7075 (Print)
IS  - 1743-7075 (Linking)
VI  - 17
DP  - 2020
TI  - Uric acid is associated with adiposity factors, especially with fat mass
      reduction during weight loss in obese children and adolescents.
PG  - 79
LID - 10.1186/s12986-020-00500-9 [doi]
AB  - BACKGROUND: Current adult studies suggest that uric acid (UA) is associated with 
      body fat, but the relationship in obese children is unclear. Thus, we aim to
      evaluate the association between uric acid and body composition of obese
      children. METHODS: A total of 79 obese children were included in this study, and 
      52 children (34 boys and 18 girls) underwent a 6-week weight loss camp, including
      34 boys and 18 girls. Six-week weight-loss interventions were performed on all
      participants through aerobic exercise and appropriate dietary control. Laboratory
      tests and body composition were collected before and after the intervention.
      RESULTS: Before the intervention, correlation analysis demonstrated that uric
      acid was positively correlated with height, weight, body mass index (BMI), waist 
      circumference, hip circumference, fat mass (FM), and free fat mass (FFM) with
      adjusting for age and gender (P < 0.05). After 6 weeks of intervention, the
      participants gained 3.12 +/- 0.85 cm in height, body fat percentage decreased by 
      7.23 +/- 1.97%, and lost 10.30 +/- 2.83 kg in weight. Univariate and multivariate
      analysis indicated that uric acid at baseline was associated with FM reduction
      during weight loss (P < 0.05). CONCLUSIONS: This study is the first report that
      uric acid is associated with BMI and FM, and may play an important role in the
      reduction of FM during weight loss in obese children and adolescents. The
      interaction between UA and adiposity factors and its underlying mechanisms need
      to be further explored. TRIAL REGISTRATION: This study was registered in Clinical
      Trials.gov (NCT03490448) and approved by the Ethics Committee of Xinhua Hospital,
      Shanghai Jiao Tong University School of Medicine.
CI  - (c) The Author(s) 2020.
FAU - Niu, Yang
AU  - Niu Y
AD  - Department of Clinical Nutrition, Xinhua Hospital, School of Medicine, Shanghai
      Jiao Tong University, Shanghai, 200092 China.grid.16821.3c0000 0004 0368 8293
FAU - Zhao, Xue-Lin
AU  - Zhao XL
AD  - Department of Clinical Nutrition, Xinhua Hospital, School of Medicine, Shanghai
      Jiao Tong University, Shanghai, 200092 China.grid.16821.3c0000 0004 0368 8293
FAU - Ruan, Hui-Juan
AU  - Ruan HJ
AD  - Department of Clinical Nutrition, Xinhua Hospital, School of Medicine, Shanghai
      Jiao Tong University, Shanghai, 200092 China.grid.16821.3c0000 0004 0368 8293
FAU - Mao, Xiao-Meng
AU  - Mao XM
AD  - Department of Clinical Nutrition, Xinhua Hospital, School of Medicine, Shanghai
      Jiao Tong University, Shanghai, 200092 China.grid.16821.3c0000 0004 0368 8293
FAU - Tang, Qing-Ya
AU  - Tang QY
AD  - Department of Clinical Nutrition, Xinhua Hospital, School of Medicine, Shanghai
      Jiao Tong University, Shanghai, 200092 China.grid.16821.3c0000 0004 0368 8293
AD  - Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai,
      200092 China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03490448
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - Nutr Metab (Lond)
JT  - Nutrition & metabolism
JID - 101231644
PMC - PMC7510267
OTO - NOTNLM
OT  - Body composition
OT  - Children
OT  - Fat mass
OT  - Obese
OT  - Uric acid
COIS- Competing interestsThe all authors declare that they have no competing interests.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:41
PHST- 2020/05/04 00:00 [received]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/28 05:41 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1186/s12986-020-00500-9 [doi]
AID - 500 [pii]
PST - epublish
SO  - Nutr Metab (Lond). 2020 Sep 22;17:79. doi: 10.1186/s12986-020-00500-9.
      eCollection 2020.


PMID- 32982881
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Mitigating the Impact of the Novel Coronavirus Pandemic on Neuroscience and Music
      Research Protocols in Clinical Populations.
PG  - 2160
LID - 10.3389/fpsyg.2020.02160 [doi]
AB  - The COVID-19 disease and the systemic responses to it has impacted lives,
      routines and procedures at an unprecedented level. While medical care and
      emergency response present immediate needs, the implications of this pandemic
      will likely be far-reaching. Most practices that the clinical research within
      neuroscience and music field rely on, take place in hospitals or closely
      connected clinical settings which have been hit hard by the contamination. So too
      have its preventive and treatment measures. This means that clinical research
      protocols may have been altered, postponed or put in complete jeopardy. In this
      context, we would like to present and discuss the problems arising under the
      current crisis. We do so by critically approaching an online discussion
      facilitated by an expert panel in the field of music and neuroscience. This
      effort is hoped to provide an efficient basis to orient ourselves as we begin to 
      map the needs and elements in this field of research as we further propose ideas 
      and solutions on how to overcome, or at least ease the problems and questions we 
      encounter or will encounter, with foresight. Among others, we hope to answer
      questions on technical or social problems that can be expected, possible
      solutions and preparatory steps to take in order to improve or ease research
      implementation, ethical implications and funding considerations. Finally, we
      further hope to facilitate the process of creating new protocols in order to
      minimize the impact of this crisis on essential research which may have the
      potential to relieve health systems.
CI  - Copyright (c) 2020 Papatzikis, Zeba, Sarkamo, Ramirez, Grau-Sanchez, Tervaniemi
      and Loewy.
FAU - Papatzikis, Efthymios
AU  - Papatzikis E
AD  - Department of Psychology, Canadian University Dubai, Dubai, United Arab Emirates.
AD  - Latifa Women and Children Hospital, Dubai, United Arab Emirates.
FAU - Zeba, Fathima
AU  - Zeba F
AD  - Department of Psychology, Canadian University Dubai, Dubai, United Arab Emirates.
FAU - Sarkamo, Teppo
AU  - Sarkamo T
AD  - Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty
      of Medicine, University of Helsinki, Helsinki, Finland.
FAU - Ramirez, Rafael
AU  - Ramirez R
AD  - Music and Machine Learning Lab, Universitat Pompeu Fabra, Barcelona, Spain.
FAU - Grau-Sanchez, Jennifer
AU  - Grau-Sanchez J
AD  - Cognition and Brain Plasticity Unit, Bellvitge Biomedical Research Institute,
      L'Hospitalet de Llobregat, Spain.
AD  - Escola Universitaria d'Infermeria i Terapia Ocupacional de Terrassa, Autonomous
      University of Barcelona, Terrassa, Spain.
FAU - Tervaniemi, Mari
AU  - Tervaniemi M
AD  - Cognitive Brain Research Unit, Department of Psychology and Logopedics, Faculty
      of Medicine, University of Helsinki, Helsinki, Finland.
AD  - Cicero Learning Network, Faculty of Educational Sciences, University of Helsinki,
      Helsinki, Finland.
FAU - Loewy, Joanne
AU  - Loewy J
AD  - The Louis Armstrong Center for Music and Medicine, Mount Sinai Beth Israel, Icahn
      School of Medicine, New York, NY, United States.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7484479
OTO - NOTNLM
OT  - COVID-19
OT  - music and neuroscience
OT  - music and neuroscience research protocols
OT  - music therapy
OT  - research crisis response
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:39
PHST- 2020/05/28 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/09/28 05:39 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.3389/fpsyg.2020.02160 [doi]
PST - epublish
SO  - Front Psychol. 2020 Aug 28;11:2160. doi: 10.3389/fpsyg.2020.02160. eCollection
      2020.

{"error":"error forwarding request","api-key":"2001:1715:9d91:5320:4458:f93:206b:14e6","type":"ip",
"status":"ok"}

PMID- 32982543
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1279-7960 (Print)
IS  - 1279-7960 (Linking)
VI  - 24
IP  - 5
DP  - 2020 Oct
TI  - [Communication with patients' relatives in intensive care].
PG  - 250-258
LID - 10.1016/j.pratan.2020.09.002 [doi]
AB  - The place of relatives of our patients is the deepest change in intensive care
      units in 20 years. Working on collegial discussions and recognizing the voices of
      patients and their loved ones in care projects have become a mandatory part of
      our daily work. This change is also related to the attention and time given to
      ethical decisions in the daily life of resuscitation. We need to recognize the
      need for trust in the health care system as well as with medical providers so
      that the therapeutic relationship can be achieved peacefully. We must therefore
      organize ourselves to improve reception of the families, place of the team
      members, regular formal meetings of information with relatives or the
      representative of our patient. Post-traumatic stress is not only a prerogative of
      our patients, it is also described in accompanying people. If trust is acquired
      few conflicts are challenging, only interfamily conflicts force medical team to
      defend its opinion. The realization that a specific care project after intensive 
      care is more likely to succeed when it is done with the support of the entourage 
      makes possible to understand the importance to take care to the stress of the
      relatives.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Vigue, Bernard
AU  - Vigue B
AD  - Departement d'anesthesie reanimation, CHU de Bicetre, 94275 Le-Kremlin-Bicetre,
      France.
FAU - Radiguer, Francois
AU  - Radiguer F
AD  - Departement d'anesthesie reanimation, CHU de Bicetre, 94275 Le-Kremlin-Bicetre,
      France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Dialogue avec l'entourage des patients en reanimation.
DEP - 20200922
PL  - France
TA  - Prat Anesth Reanim
JT  - Le praticien en anesthesie reanimation
JID - 101141506
PMC - PMC7508493
OTO - NOTNLM
OT  - Care project
OT  - Family conflicts
OT  - Intensive care unit
OT  - Post traumatic stress syndrome
OT  - Relatives
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:38
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
PHST- 2020/09/28 05:38 [entrez]
AID - 10.1016/j.pratan.2020.09.002 [doi]
AID - S1279-7960(20)30119-4 [pii]
PST - ppublish
SO  - Prat Anesth Reanim. 2020 Oct;24(5):250-258. doi: 10.1016/j.pratan.2020.09.002.
      Epub 2020 Sep 22.


PMID- 32982535
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1179-7258 (Print)
IS  - 1179-7258 (Linking)
VI  - 11
DP  - 2020
TI  - Investigating Knowledge, Attitude, and Beliefs Regarding Placebo Interventions in
      Clinical Practice: A Comparative Study of Nursing and Medical University
      Students.
PG  - 619-635
LID - 10.2147/AMEP.S250019 [doi]
AB  - BACKGROUND: Placebo interventions are commonly used in medical practice for
      alleviating symptoms of illnesses. Placebo is considered a pseudo-medication and 
      its use is debatable ethically, professionally, and legally. Despite that there
      is also a lack of evidence on understanding of placebo interventions among health
      profession students. Further, no previous studies have been conducted to
      investigate whether future nurses and physicians differ in their knowledge,
      attitudes, and beliefs regarding placebo intervention. MATERIALS AND METHODS: A
      comparative cross-sectional study was carried out for exploring knowledge,
      attitude, and beliefs about placebo interventions among a convenient sample of
      187 medical and nursing students at King Saud bin Abdulaziz University for Health
      Sciences. Data were collected using a sociodemographic data sheet and a 32-item
      placebo knowledge, beliefs, and attitude scale, which was developed from the
      evidence-based literature. Validity and reliability were ensured through
      utilizing a panel of experts and internal consistency analysis. RESULTS: Overall 
      mean participants' knowledge score was 7.68+/-2.07 (out of 15). Nursing students 
      showed significantly higher knowledge than medical students (P=0.028). More
      nursing than medical students believed in the effectiveness of placebo (P<0.001).
      Medical students had a stronger belief that the placebo effect is mental, while
      nursing students reported that it is both mental and physiologic (P<0.006).
      Concerning placebo attitude, medical students significantly pointed out that it
      should generally be prohibited and should not be permitted unless research
      supports its use (P<0.001). Both groups agreed that impure placebo intervention
      involves deception. CONCLUSION: Participants' overall placebo knowledge was low. 
      Inconsistencies in attitude and beliefs were shown among students. Current study 
      findings offered a unique opportunity to better study misunderstandings for
      placebo, which might open the gate for misuse and place patients at risk of
      deception. Additionally, study findings were imperative as a relevant
      evidence-based recommendation for nursing and medical educators could be
      achieved.
CI  - (c) 2020 Bayoumy et al.
FAU - Bayoumy, Hala Mohamed Mohamed
AU  - Bayoumy HMM
AUID- ORCID: 0000-0002-8178-418X
AD  - Department of Nursing, Cairo University, Gizah, Egypt.
AD  - Department of Nursing, King Saud Bin Abdul Aziz University for Health Sciences,
      Jeddah, Saudi Arabia.
AD  - King Abdullah International Medical Research Center; King Saud Bin Abdul Aziz
      University for Health Sciences, Jeddah, Saudi Arabia.
FAU - Almuwallad, Ghada Eissa
AU  - Almuwallad GE
AUID- ORCID: 0000-0002-0808-2990
AD  - Pediatric Intensive Care Unit, King Faisal Specialist Hospital and Research
      Center, Jeddah, Saudi Arabia.
FAU - Eissa, Ashwag Othman
AU  - Eissa AO
AUID- ORCID: 0000-0002-8977-7857
AD  - Medical-Surgical Intensive Care Unit, King Faisal Specialist Hospital and
      Research Center, Jeddah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - New Zealand
TA  - Adv Med Educ Pract
JT  - Advances in medical education and practice
JID - 101562700
PMC - PMC7498927
OTO - NOTNLM
OT  - attitude
OT  - beliefs
OT  - knowledge
OT  - placebo
COIS- An abstract for the study was presented at the 48th Global Nursing & Healthcare
      Conference, March 4-6, 2019, Barcelona, Spain. The abstract was also published in
      Journal of Nursing & Care, ISSN: 2167-1168. The authors report no conflicts of
      interest in this work.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:38
PHST- 2020/02/16 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/09/28 05:38 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.2147/AMEP.S250019 [doi]
AID - 250019 [pii]
PST - epublish
SO  - Adv Med Educ Pract. 2020 Sep 9;11:619-635. doi: 10.2147/AMEP.S250019. eCollection
      2020.


PMID- 32982269
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Patient Dignity in Iranian Clinical Care Settings as Perceived by Physicians,
      Caregivers, and Patients.
PG  - 923-933
LID - 10.2147/JMDH.S258962 [doi]
AB  - INTRODUCTION: All over the world, healthcare team members are recommended to
      respect patients' human dignity. However, the dignity of hospitalized patients is
      not preserved in many cases. Due to the abstract, complex, and cultural nature of
      the concept of human dignity, further studies are required to precisely determine
      the different aspects of this concept. PURPOSE: The aim of the present study was 
      to explore the experiences and perceptions of physicians, nurses, family
      caregivers, and hospitalized patients with regard to patient dignity in Iranian
      clinical setting. MATERIALS AND METHODS: This is a qualitative, exploratory study
      in which physicians, nurses, family caregivers, and patients were recruited from 
      2 educational hospitals located in an urban area in Iran from April 2016 to
      February 2017 using the purposive sampling method (n = 24). Data were collected
      through individual interviews and subsequently analyzed using conventional
      content analysis in the software MAXQDA 2007, VERBI(O)`. RESULTS: Three major
      themes emerged from analyses of the data obtained from the interviews: a peaceful
      environment, respect, and comprehensive support. CONCLUSION: From the
      participants' point of view, in order for their dignity to be preserved, patients
      need to be hospitalized in a peaceful environment in which they are treated with 
      empathy, they receive comprehensive support, and the care settings are managed
      properly. Furthermore, it is important to respect patient's values and beliefs,
      to provide unbiased care and treatment, and to maintain patient's autonomy in
      order to maintain hospitalized patients' dignity.
CI  - (c) 2020 Tehranineshat et al.
FAU - Tehranineshat, Banafsheh
AU  - Tehranineshat B
AUID- ORCID: 0000-0002-2066-5689
AD  - Community Based Psychiatric Care Research Center, Department of Nursing, School
      of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Rakhshan, Mahnaz
AU  - Rakhshan M
AUID- ORCID: 0000-0003-1687-5154
AD  - Community Based Psychiatric Care Research Center, Department of Nursing, School
      of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Torabizadeh, Camellia
AU  - Torabizadeh C
AUID- ORCID: 0000-0003-2193-5844
AD  - Community Based Psychiatric Care Research Center, Department of Nursing, School
      of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Fararouei, Mohammad
AU  - Fararouei M
AD  - Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7502381
OTO - NOTNLM
OT  - dignity
OT  - family caregiver
OT  - health care ethics
OT  - healthcare providers
OT  - nurse
OT  - patient
OT  - physician
OT  - respect
COIS- The authors declare no potential conflicts of interest regarding the research,
      authorship, this work, or publication of the article.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:37
PHST- 2020/04/20 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.2147/JMDH.S258962 [doi]
AID - 258962 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Sep 16;13:923-933. doi: 10.2147/JMDH.S258962.
      eCollection 2020.


PMID- 32982266
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Perceptions Towards Medical Research Participation: A Study from Jordan.
PG  - 901-907
LID - 10.2147/JMDH.S272696 [doi]
AB  - PURPOSE: Progress and development in medical researches require the participation
      of volunteers in such research, but unfortunately, the participation rate is low.
      This study aimed to assess Jordanian public perceptions towards participation in 
      medical research and to understand motivators and barriers that may affect their 
      participation. PATIENTS AND METHODS: This is a cross-sectional study that was
      conducted from December 2019 to February 2020. Adults from the public were
      invited to participate in this paper-based survey. The survey assessed public
      perception (values, trust and ethics), motivators, and barriers towards
      participation in medical research. RESULTS: During the study period, 2000
      subjects were recruited. Around 82.3% (n = 1643) strongly agreed/agreed that
      medical research is important for the advancement of science. Helping the society
      was found to be the main motivators to participate in medical research (n = 1708,
      85.4%), while time constrains (n = 1400, 70.0%), lack of opportunity (n = 1278,
      63.9%), and the lack of knowledge and awareness about these researches (n = 1152,
      57.6%) were among the top barriers towards the participation in medical research.
      Finally, results showed that previous participation in medical research was
      correlated with lower overall perception of values and ethics of research, and
      higher trust in research (p-value <0.001). CONCLUSION: Jordanians have positive
      perception toward participation in medical research, which could be improved by
      increasing awareness, trust, and training of researchers on responsible conduct
      of research(RCR) in the country.
CI  - (c) 2020 Abu Farha et al.
FAU - Abu Farha, Rana
AU  - Abu Farha R
AUID- ORCID: 0000-0001-8298-4071
AD  - Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied
      Science Private University, Amman 11931, Jordan.
FAU - Alzoubi, Karem
AU  - Alzoubi K
AUID- ORCID: 0000-0002-2808-5099
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of
      Science and Technology, Irbid 22110, Jordan.
FAU - Khabour, Omar
AU  - Khabour O
AUID- ORCID: 0000-0002-3006-3104
AD  - Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences,
      Jordan University of Science and Technology, Irbid 22110, Jordan.
FAU - Mukattash, Tareq
AU  - Mukattash T
AUID- ORCID: 0000-0003-0200-9845
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of
      Science and Technology, Irbid 22110, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7500847
OTO - NOTNLM
OT  - Jordan
OT  - ethics
OT  - medical research
OT  - perception
OT  - trust
OT  - value
COIS- The authors report nopotential conflicts of interest for this work.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:37
PHST- 2020/07/18 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.2147/JMDH.S272696 [doi]
AID - 272696 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Sep 14;13:901-907. doi: 10.2147/JMDH.S272696.
      eCollection 2020.


PMID- 32982197
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220417
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Linking)
VI  - 15
DP  - 2020
TI  - Implementation and Evaluation of a Fall Risk Screening Strategy Among Frail Older
      Adults for the Primary Care Setting: A Study Protocol.
PG  - 1625-1636
LID - 10.2147/CIA.S254864 [doi]
AB  - BACKGROUND: Falls are an increasing problem among older people. There are several
      evidence-based interventions available to prevent falls. However, these are not
      always well implemented in the primary care setting. General practitioners (GPs) 
      are often the first point of contact for health issues, making them the
      designated professionals for providing falls prevention. Because GPs are often
      unaware which patients have a high fall risk and patients themselves do not
      always know they have a high fall risk, this study aims to evaluate the
      implementation of a targeted fall risk screening strategy among independently
      living, frail older people in the primary care setting. MATERIALS AND METHODS:
      The targeted fall risk screening strategy used in this study consists of tools
      for screening high fall risk and for identifying the underlying cause(s) of the
      high fall risk, an accredited training course in falls prevention for
      professionals, and service provision by certified physio- and exercise therapists
      who are able to offer evidence-based falls prevention interventions. This
      targeted fall risk screening strategy will be implemented in the primary care
      setting and evaluated at the level of the GP practice and at the level of the
      patient by using the RE-AIM model of Glasgow et al. In a pre-posttest design,
      data will be collected of the total number of frail older people who are
      screened, referred and enrolled for fall-preventive care. Furthermore, barriers
      and facilitators of the implementation of the fall risk screening strategy will
      be identified by conducting focus groups and interviews with the care providers
      and frail older patients. Additionally, the influence of the falls prevention
      interventions on frail older patients will be evaluated by using a pre-posttest
      design with a 12-month follow-up period during which data are collected regarding
      patients' stability, mobility, strength, balance, self-efficacy, health status,
      and daily activities. STUDY REGISTRATION: This study is approved by the Medical
      Ethics Committee Brabant, the Netherlands (NL61582.028.17/ P1732) and registered 
      at the Netherlands Trial Register, NL7917.
CI  - (c) 2020 Meekes et al.
FAU - Meekes, W M A
AU  - Meekes WMA
AUID- ORCID: 0000-0002-7806-9871
AD  - Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University,
      Tilburg, Noord-Brabant, Netherlands.
FAU - Leemrijse, C J
AU  - Leemrijse CJ
AUID- ORCID: 0000-0001-5678-9037
AD  - NIVEL, Utrecht, Netherlands.
FAU - Korevaar, J C
AU  - Korevaar JC
AUID- ORCID: 0000-0001-9997-040X
AD  - NIVEL, Utrecht, Netherlands.
FAU - Henquet, J M A E
AU  - Henquet JMAE
AUID- ORCID: 0000-0001-5575-9960
AD  - Huisartsenpraktijk de Ypelaer, Hilvarenbeek, Noord-Brabant, Netherlands.
FAU - Nieuwenhuis, M
AU  - Nieuwenhuis M
AD  - Fysiotherapie Nieuwenhuis, Best, Noord-Brabant, Netherlands.
FAU - van de Goor, L A M
AU  - van de Goor LAM
AD  - Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University,
      Tilburg, Noord-Brabant, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
SB  - IM
MH  - Accidental Falls/*prevention & control
MH  - Aged
MH  - Aged, 80 and over
MH  - *Clinical Protocols
MH  - Female
MH  - Frail Elderly/*statistics & numerical data
MH  - General Practitioners/*organization & administration
MH  - Humans
MH  - Male
MH  - Mass Screening/*methods
MH  - Netherlands
MH  - Primary Health Care/*methods
MH  - Program Development
MH  - Referral and Consultation
PMC - PMC7498482
OTO - NOTNLM
OT  - geriatric medicine
OT  - preventive medicine
OT  - primary care
OT  - risk management
COIS- J.C Korevaar reports grants from Ministry of Health, during the conduct of the
      study. The authors report no other potential conflicts of interests in this work.
EDAT- 2020/09/29 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/09/28 05:37
PHST- 2020/03/21 00:00 [received]
PHST- 2020/07/19 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.2147/CIA.S254864 [doi]
AID - 254864 [pii]
PST - epublish
SO  - Clin Interv Aging. 2020 Sep 9;15:1625-1636. doi: 10.2147/CIA.S254864. eCollection
      2020.


PMID- 32982194
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220417
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Linking)
VI  - 15
DP  - 2020
TI  - Medication Reconciliation Associated with Comprehensive Geriatric Assessment in
      Older Patients with Cancer: ChimioAge Study.
PG  - 1587-1598
LID - 10.2147/CIA.S262209 [doi]
AB  - BACKGROUND: Polymorbidity induces polypharmacy in older patients may lead to
      potential drug-drug interactions (DDI) which can modify the tolerance and safety 
      of oncological treatments and alter the intended therapeutic effect. The
      objective of our study was to describe the decision-making process for
      oncological treatment and related outcomes, in a population of older adults
      undergoing a comprehensive geriatric assessment (CGA) associated to a
      comprehensive medication reconciliation (CMR) prior to initiating oncological
      treatment. METHODS: ChimioAge is a prospective observational study conducted
      between 01/2017 and 07/2018 at Marseille University Hospital and approved by the 
      French National Ethics Committee. It comprised all consecutive patients aged 70
      years and over who were referred for a CGA as part of CMR, before initiating
      systemic treatment. RESULTS: One hundred and seventy-one cancer patients were
      included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an
      ECOG performance status zero or one, and two-thirds were independent in daily
      activities. Two-thirds of the patients had polypharmacy and the CMR identified
      potential DDI with systemic treatment in 43.3% of patients. Following the CGA,
      the CMR and the hospital oncologists decision, 30% of the patients received
      adapted systemic treatment with reduced doses at initiation. They presented fewer
      toxicities - irrespective of grade and type - than patients who received standard
      treatment (p<0.001) and had comparable overall survival (Log rank p=0.21).
      CONCLUSION: This is one of the first studies to highlight the value in conducting
      CMR and a CGA simultaneously before initiating systemic treatment in older
      patients with cancer. These two evaluations could give oncologists decisive
      information to personalize cancer treatment of older patients and optimize
      treatment dose to offer the best efficacy and minimize toxicity.
CI  - (c) 2020 Couderc et al.
FAU - Couderc, Anne-Laure
AU  - Couderc AL
AD  - Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille,
      France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille,
      France.
AD  - Aix-Marseille Universite, CNRS, EFS, ADES, Marseille, France.
FAU - Boisseranc, Celia
AU  - Boisseranc C
AD  - Pharmacology Department, AP-HM, Marseille, France.
FAU - Rey, Dominique
AU  - Rey D
AD  - Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille,
      France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille,
      France.
FAU - Nouguerede, Emilie
AU  - Nouguerede E
AD  - Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille,
      France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille,
      France.
FAU - Greillier, Laurent
AU  - Greillier L
AD  - Aix-Marseille University, Marseille, France.
AD  - Multidisciplinary Oncology and Therapeutic Innovations Unit, AP-HM, Marseille,
      France.
FAU - Barlesi, Fabrice
AU  - Barlesi F
AD  - Aix-Marseille University, Marseille, France.
AD  - Multidisciplinary Oncology and Therapeutic Innovations Unit, AP-HM, Marseille,
      France.
FAU - Duffaud, Florence
AU  - Duffaud F
AD  - Aix-Marseille University, Marseille, France.
AD  - Oncology Unit, AP-HM, Marseille, France.
FAU - Deville, Jean-Laurent
AU  - Deville JL
AD  - Oncology Unit, AP-HM, Marseille, France.
FAU - Honore, Stephane
AU  - Honore S
AD  - Pharmacology Department, AP-HM, Marseille, France.
AD  - Aix-Marseille University, Marseille, France.
FAU - Villani, Patrick
AU  - Villani P
AD  - Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille,
      France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille,
      France.
AD  - Aix-Marseille Universite, CNRS, EFS, ADES, Marseille, France.
FAU - Correard, Florian
AU  - Correard F
AD  - Pharmacology Department, AP-HM, Marseille, France.
AD  - Aix-Marseille University, Marseille, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200908
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Clinical Decision-Making/*methods
MH  - Female
MH  - Geriatric Assessment/*methods
MH  - Humans
MH  - Male
MH  - Medical Oncology/methods
MH  - Medication Reconciliation/*methods
MH  - Neoplasms/*therapy
MH  - Patient Care Planning
MH  - *Polypharmacy
MH  - Prospective Studies
PMC - PMC7489933
OTO - NOTNLM
OT  - aged
OT  - antineoplastic protocols
OT  - geriatric assessment
OT  - medication reconciliation
OT  - treatment failure
COIS- Laurent Greillier reports personal fees and non-financial support from ABBVIE,
      ASTRA-ZENECA, BOEHRINGER INGELHEIM, BMS, MSD, and ROCHE and personal fees from
      TAKEDA, outside the submitted work. The authors report no other potential
      conflicts of interest for this work.
EDAT- 2020/09/29 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/09/28 05:37
PHST- 2020/05/14 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.2147/CIA.S262209 [doi]
AID - 262209 [pii]
PST - epublish
SO  - Clin Interv Aging. 2020 Sep 8;15:1587-1598. doi: 10.2147/CIA.S262209. eCollection
      2020.


PMID- 32982188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1177-889X (Print)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - COVID-19 Contact-Tracing Technology: Acceptability and Ethical Issues of Use.
PG  - 1639-1647
LID - 10.2147/PPA.S276183 [doi]
AB  - BACKGROUND: The contact-tracing COVID-19 technology allows for tracing people
      that come in contact to individuals with COVID-19 wherever they are located. The 
      number of tracing COVID-19 infection technology and devices is rapidly
      increasing. This has prompted many researchers to study the acceptability and
      ethical issues related to the implementation of such technology. AIM: The purpose
      of this study was to determine the acceptability of COVID-19 contact-tracing
      technology and ethical issues of use. METHODS: A cross-sectional
      questionnaire-based study was used. The target population was Jordanian adults
      (>18 years). The survey was distributed to a convenience sample of 2000 general
      public in Jordan. RESULTS: The results found that the number of people who accept
      to use COVID-19 contact-tracing technology was 71.6%. However, the percentage of 
      people who were using this technology was 37.8. The main ethical concerns for
      many of participants were privacy, voluntariness, and beneficence of the data.
      Only income and living area were predictors for acceptability and use of tracing 
      technology (p</= 0.01). CONCLUSION: The majority of Jordanians accept the
      implementation of contact-tracing technology for COVID-19 infection. Among
      ethical concerns of the implementation of such technology were privacy,
      beneficence and voluntariness. IMPLICATIONS: The results of this study would help
      in improving the state of science regarding acceptability to use contact-tracing 
      technology for health purposes. Moreover, the present findings provide evidence
      of predictors of acceptance and ethical concerns among Jordanian population about
      COVID-19 contact-tracing technology.
CI  - (c) 2020 Abuhammad et al.
FAU - Abuhammad, Sawsan
AU  - Abuhammad S
AUID- ORCID: 0000-0001-5817-8950
AD  - Department of Maternal and Child Health, Jordan University of Science and
      Technology, Irbid 22110, Jordan.
FAU - Khabour, Omar F
AU  - Khabour OF
AUID- ORCID: 0000-0002-3006-3104
AD  - Department of Medical Laboratory Sciences, Jordan University of Science and
      Technology, Irbid 22110, Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AUID- ORCID: 0000-0002-2808-5099
AD  - Department of Clinical Pharmacy, Jordan University of Science and Technology,
      Irbid 22110, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7509307
OTO - NOTNLM
OT  - Jordan
OT  - ethical issues
OT  - individuals
OT  - research
OT  - tracing COVID-19
COIS- The authors report no conflict of interests for this work.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:37
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.2147/PPA.S276183 [doi]
AID - 276183 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2020 Sep 18;14:1639-1647. doi: 10.2147/PPA.S276183.
      eCollection 2020.


PMID- 32982127
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210101
IS  - 1050-8422 (Print)
IS  - 1050-8422 (Linking)
VI  - 30
IP  - 5
DP  - 2020
TI  - Supporting ethical practice in community-engaged research with 4R: Respond,
      Record, Reflect, and Revise.
PG  - 311-325
LID - 10.1080/10508422.2019.1645665 [doi]
AB  - Efforts towards adaptation, dissemination, and implementation of culturally
      robust, evidence-informed mental healthcare rely on community-engaged research
      (CEnR). Academic-community partnerships help bring science to service for
      vulnerable and historically disenfranchised populations (e.g., communities of
      color and those characterized by poverty). A growing literature supports the
      development of a framework of ethics for CEnR. This article examines ethical
      tensions in the context of the American Psychological Association Ethics Code
      General Principles - Beneficence and Nonmaleficence; Fidelity and Responsibility;
      Integrity; Justice; and Respect for People's Rights and Dignity - and presents
      the 4R action plan to support application of APA guidelines to academic-community
      partnership with youth-serving organizations.
FAU - Chou, Tommy
AU  - Chou T
AD  - Department of Psychology, Florida International University.
FAU - Frazier, Stacy L
AU  - Frazier SL
AD  - Department of Psychology, Florida International University.
LA  - eng
GR  - F31 HD093348/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20190809
PL  - United States
TA  - Ethics Behav
JT  - Ethics & behavior
JID - 9102086
PMC - PMC7518192
MID - NIHMS1535408
OTO - NOTNLM
OT  - academic-community partnership
OT  - community-engaged research
OT  - training
OT  - vulnerable populations
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:36
PHST- 2020/09/28 05:36 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1080/10508422.2019.1645665 [doi]
PST - ppublish
SO  - Ethics Behav. 2020;30(5):311-325. doi: 10.1080/10508422.2019.1645665. Epub 2019
      Aug 9.


PMID- 32982035
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 0735-7028 (Print)
IS  - 0735-7028 (Linking)
VI  - 51
IP  - 2
DP  - 2020 Apr
TI  - Emotional Support Animal Assessments: Toward a Standard and Comprehensive Model
      for Mental Health Professionals.
PG  - 156-162
LID - 10.1037/pro0000260 [doi]
AB  - Growth in the presence of Emotional Support Animals (ESAs) in our society has
      recently garnered a substantial amount of attention, both in the popular media
      and the professional literature. Public media abounds with stories focusing on
      the increasing number of animals claimed as ESAs, the impact of this growth on
      society, the industry claiming to certify ESAs, and the various types of animals 
      described as "certified." The authors propose an assessment model for ESAs
      certification comprising a four-pronged approach for conducting these types of
      assessments: (1) understanding, recognizing, and applying the laws regulating
      ESAs, (2) a thorough valid assessment of the individual requesting an ESA
      certification, (3) an assessment of the animal in question to ensure it actually 
      performs the valid functions of an ESA, and (4) an assessment of the interaction 
      between the animal and the individual to determine whether the animal's presence 
      has a demonstrably beneficial effect on that individual. This model aligns with
      professional ethics, standards of professional practice, and the law and seeks to
      provide clear guidelines for mental health professionals conducting ESA
      evaluations.
FAU - Younggren, Jeffrey N
AU  - Younggren JN
AD  - University of New Mexico.
FAU - Boness, Cassandra L
AU  - Boness CL
AD  - University of Missouri.
FAU - Bryant, Leisl M
AU  - Bryant LM
AD  - Private Practice.
FAU - Koocher, Gerald P
AU  - Koocher GP
AD  - Quincy College.
LA  - eng
GR  - F31 AA026177/AA/NIAAA NIH HHS/United States
PT  - Journal Article
DEP - 20190801
PL  - United States
TA  - Prof Psychol Res Pr
JT  - Professional psychology, research and practice
JID - 8309175
PMC - PMC7517601
MID - NIHMS1039596
OTO - NOTNLM
OT  - ESA
OT  - assessment
OT  - disability
OT  - emotional support animal
OT  - ethics
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:36
PHST- 2020/09/28 05:36 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1037/pro0000260 [doi]
PST - ppublish
SO  - Prof Psychol Res Pr. 2020 Apr;51(2):156-162. doi: 10.1037/pro0000260. Epub 2019
      Aug 1.


PMID- 32982022
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 0313-5926 (Print)
IS  - 0313-5926 (Linking)
VI  - 68
DP  - 2020 Dec
TI  - The human dimension of good economic policymaking.
PG  - 175-178
LID - 10.1016/j.eap.2020.09.009 [doi]
AB  - Good economic policymaking requires the best possible economic advice. To be an
      effective adviser, a policy economist needs to remain credible, even under
      pressure. There is a gap between theory and reality; minding the gap can help
      policy economists determine which theories are more likely to work as a matter of
      practical policymaking. Adding the human dimension makes for better decisions by 
      casting light on how people might respond to otherwise rational policy proposals.
      It is not sufficient for good policy outcomes that economists confer only with
      their professional peers. Citizens must be persuaded that the proposed policy
      reform is in the best interests of the community as a whole. Good economic
      policymaking should not underestimate the power of incentives to override moral
      and ethical restraint. Regulation is a poor substitute for culturally-embedded
      moral restraint. While it is possible to divorce the mechanical side of economics
      from its moral foundations, this is not the route to good economic policymaking.
CI  - (c) 2020 Economic Society of Australia, Queensland. Published by Elsevier B.V.
      All rights reserved.
FAU - Harper Ao, Ian R
AU  - Harper Ao IR
AD  - Melbourne Business School, The University of Melbourne, Victoria 3053, Australia.
FAU - Ramadge, Andrew
AU  - Ramadge A
AD  - Melbourne Business School, The University of Melbourne, Victoria 3053, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - Australia
TA  - Econ Anal Policy
JT  - Economic analysis and policy
JID - 101534797
PMC - PMC7508165
OTO - NOTNLM
OT  - Australian Fair Pay Commission
OT  - Competition Policy Review
OT  - Economic policymaking
OT  - Hayne Royal Commission
OT  - Human dimension
OT  - Metropolitan Hospitals Planning Board
OT  - Moral and ethical restraint
OT  - Practical policymaking
OT  - Reserve Bank of Australia
OT  - Wallis Inquiry
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could appear to have inappropriately influenced the
      work reported in this paper.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:36
PHST- 2020/09/17 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/09/20 00:00 [accepted]
PHST- 2020/09/28 05:36 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1016/j.eap.2020.09.009 [doi]
AID - S0313-5926(20)30420-3 [pii]
PST - ppublish
SO  - Econ Anal Policy. 2020 Dec;68:175-178. doi: 10.1016/j.eap.2020.09.009. Epub 2020 
      Sep 22.


PMID- 32981996
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 0167-4544 (Print)
IS  - 0167-4544 (Linking)
VI  - 166
IP  - 2
DP  - 2020
TI  - Historicizing Modern Slavery: Free-Grown Sugar as an Ethics-Driven Market
      Category in Nineteenth-Century Britain.
PG  - 271-292
LID - 10.1007/s10551-019-04318-1 [doi]
AB  - The modern slavery literature engages with history in an extremely limited
      fashion. Our paper demonstrates to the utility of historical research to modern
      slavery researchers by explaining the rise and fall of the ethics-driven market
      category of "free-grown sugar" in nineteenth-century Britain. In the first
      decades of the century, the market category of "free-grown sugar" enabled
      consumers who were opposed to slavery to pay a premium for a more ethical
      product. After circa 1840, this market category disappeared, even though
      considerable quantities of slave-grown sugar continued to arrive into the UK. We 
      explain the disappearance of the market category. Our paper contributes to the
      on-going debates about slavery in management by historicizing and thus
      problematizing the concept of "slavery". The paper challenges those modern
      slavery scholars who argue that lack of consumer knowledge about product
      provenance is the main barrier to the elimination of slavery from today's
      international supply chains. The historical research presented in this paper
      suggests that consumer indifference, rather than simply ignorance, may be the
      more fundamental problem. The paper challenges the optimistic historical
      metanarrative that pervades much of the research on ethical consumption. It
      highlights the fragility of ethics-driven market categories, offering lessons for
      researchers and practitioners seeking to tackle modern slavery.
CI  - (c) The Author(s) 2019.
FAU - Smith, Andrew
AU  - Smith A
AUID- ORCID: 0000-0002-8589-7608
AD  - University of Liverpool Management School, Chatham St, Liverpool, L69 7ZH
      UK.grid.10025.360000 0004 1936 8470
FAU - Johns, Jennifer
AU  - Johns J
AD  - Department of Management, University of Bristol, 12A Priory Rd, Bristol, BS8 1TU 
      UK.grid.5337.20000 0004 1936 7603
LA  - eng
PT  - Journal Article
DEP - 20191028
PL  - Netherlands
TA  - J Bus Ethics
JT  - Journal of business ethics : JBE
JID - 100972154
PMC - PMC7510010
OTO - NOTNLM
OT  - Consumption ethics
OT  - Market categories
OT  - Slavery
COIS- Conflict of interestAll authors declare that they have no conflict of interest.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
CRDT- 2020/09/28 05:35
PHST- 2018/10/01 00:00 [received]
PHST- 2019/10/15 00:00 [accepted]
PHST- 2020/09/28 05:35 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
AID - 10.1007/s10551-019-04318-1 [doi]
AID - 4318 [pii]
PST - ppublish
SO  - J Bus Ethics. 2020;166(2):271-292. doi: 10.1007/s10551-019-04318-1. Epub 2019 Oct
      28.


PMID- 32981810
OWN - NLM
STAT- Publisher
LR  - 20200928
IS  - 1873-4588 (Electronic)
IS  - 0892-1997 (Linking)
DP  - 2020 Sep 25
TI  - Factor Analysis of the Brazilian Version of the Voice-Related Quality of Life
      (V-RQOL) Questionnaire.
LID - S0892-1997(20)30333-7 [pii]
LID - 10.1016/j.jvoice.2020.08.033 [doi]
AB  - OBJECTIVE: To investigate the psychometric properties of the Voice-Related
      Quality of Life (V-RQOL) questionnaire in Brazilian Portuguese by assessing its
      reliability and conducting exploratory factor analysis (EFA) and confirmatory
      factor analysis (CFA). METHODS: This research was carried out in two stages: (1) 
      a document-based retrospective approach and (2) a field study step. The study
      included 566 dysphonic and vocally healthy individuals. For data collection, the 
      Vocal Screening Protocol and the V-RQOL questionnaire were used, and these
      measures were later statistically analyzed through descriptive analysis,
      reliability tests, CFA, and EFA. Ethical issues were considered. RESULTS: A
      Cronbach's alpha coefficient of 0.916 was observed, indicating good internal
      consistency for the V-RQOL questionnaire. The item-total correlation coefficient 
      indicated that the items had good correlation with each other and with the
      construct, with values higher than 0.30. EFA was performed based on the
      Kaiser-Meyer-Olkin index and Bartlett's test of sphericity, which indicated the
      adequacy of the tested sample. The items presented commonality of >0.30 and
      satisfactory factor loadings, resulting in a single factor. The unifactorial
      structure of the V-RQOL questionnaire was confirmed by CFA. CONCLUSION: EFA and
      CFA indicated that a single factor should be adopted to encompass all the items
      of the V-RQOL questionnaire.
CI  - Copyright (c) 2020 The Voice Foundation. Published by Elsevier Inc. All rights
      reserved.
FAU - Almeida, Larissa Nadjara
AU  - Almeida LN
AD  - Federal University of Paraiba - UFPB, Joao Pessoa, Brazil.
FAU - Behlau, Mara
AU  - Behlau M
AD  - Federal University of Sao Paulo - UNIFESP, Sao Paulo (SP); and Voice Studies
      Center - CEV, Sao Paulo (SP), Brazil.
FAU - Ramos, Noemi Dos Santos
AU  - Ramos NDS
AD  - Federal University of Paraiba - UFPB, Joao Pessoa, Brazil.
FAU - Barbosa, Iandra Kaline
AU  - Barbosa IK
AD  - Federal University of Paraiba - UFPB, Joao Pessoa, Brazil; Universidade Federal
      do Rio Grande do Norte (UFRN), Joao Pessoa, Brazil.
FAU - Almeida, Anna Alice
AU  - Almeida AA
AD  - Federal University of Paraiba - UFPB, Joao Pessoa, Brazil. Electronic address:
      anna_alice@uol.com.br.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - United States
TA  - J Voice
JT  - Journal of voice : official journal of the Voice Foundation
JID - 8712262
SB  - IM
OTO - NOTNLM
OT  - Dysphonia-Factor Analysis-Inventories and Questionnaires-Quality of
      Life-Self-Assessment-Voice
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/09/28 05:34
PHST- 2020/06/19 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/28 05:34 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - S0892-1997(20)30333-7 [pii]
AID - 10.1016/j.jvoice.2020.08.033 [doi]
PST - aheadofprint
SO  - J Voice. 2020 Sep 25. pii: S0892-1997(20)30333-7. doi:
      10.1016/j.jvoice.2020.08.033.


PMID- 32981780
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 45
DP  - 2020 Oct 21
TI  - Integrating public health programs and research after the malaria vaccine
      implementation program (MVIP): Recommendations for next steps.
PG  - 6975-6978
LID - S0264-410X(20)31132-4 [pii]
LID - 10.1016/j.vaccine.2020.08.077 [doi]
AB  - BACKGROUND: In February 2020, international controversy arose about the ethical
      acceptability of the WHO Malaria Vaccine Implementation Program (MVIP). Whereas
      some have argued that this program must be seen as research that is not in line
      with international ethical standards, notably regarding informed consent and
      local ethical review, some WHO representatives consider the MVIP as a public
      health implementation program that need not adhere to these standards. METHODS:
      We performed a case analysis in light of the 2016 CIOMS International Ethical
      Guidelines for Health-related Research involving Humans. FINDINGS: We argue that 
      the MVIP has a substantial research component, and that it is prudent to
      therefore apply ethical norms for research involving humans, such as the CIOMS
      guidelines. Accordingly, we agree that the ethical requirements of informed
      consent and independent ethical review have not been met. In addition, we are
      concerned that the study might not meet CIOMS's social value requirement.
      RECOMMENDATIONS: We urge WHO to release more details about the process that led
      to the MVIP program and make the MVIP protocol publicly available. The full
      protocol should be assessed by the relevant ethics committees, new and already
      enrolled parents should be informed about the uncertainties under investigation
      and given a real opportunity to consent or refuse (continued) participation,
      communities should be engaged, and aspects of MVIP that require alteration in
      light of ethical review should be altered, if possible. Furthermore, in order to 
      improve good ethical practices, it is necessary to engage in international debate
      regarding the integration of research and public health programs. Procedurally,
      vaccine implementation programs that combine both prevention and research should 
      involve the wider international ethics community and ensure participation of the 
      target populations in setting the proper conditions for launching such programs.
CI  - Published by Elsevier Ltd.
FAU - van der Graaf, Rieke
AU  - van der Graaf R
AD  - University Medical Center Utrecht, Julius Center for Health Sciences and Primary 
      Care, PO Box 85500, 3508 GA Utrecht, Netherlands(1). Electronic address:
      r.vandergraaf@umcutrecht.nl.
FAU - Macklin, Ruth
AU  - Macklin R
AD  - Distinguished University Professor Emerita, Albert Einstein College of Medicine, 
      Bronx, NY, USA(2).
FAU - Rid, Annette
AU  - Rid A
AD  - National Institutes of Health, Department of Bioethics, The Clinical Center,
      USA(3).
FAU - Bhan, Anant
AU  - Bhan A
AD  - Yenepoya (deemed to be University), India(4).
FAU - Gefenas, Eugenijus
AU  - Gefenas E
AD  - Centre for Health Ethics, Law and History, Institute of Health Sciences, Medical 
      Faculty of Vilnius University, Lithuania(5).
FAU - Greco, Dirceu
AU  - Greco D
AD  - Professor Emeritus, Infectious Diseases and Bioethics, Federal University of
      Minas Gerais, Brazil(6).
FAU - Haerry, David
AU  - Haerry D
AD  - European AIDS Treatment Group, Brussels, Belgium(7).
FAU - Hurst, Samia
AU  - Hurst S
AD  - Institute for Ethics, History, and the Humanities, Faculty of Medicine,
      University of Geneva, Switzerland(8).
FAU - London, Alex John
AU  - London AJ
AD  - Carnegie Mellon University, Center for Ethics and Policy, Pittsburgh, PA, USA(9).
FAU - Saracci, Rodolfo
AU  - Saracci R
AD  - Former President, International Epidemiological Association, Lyon, France(10).
FAU - Sprumont, Dominique
AU  - Sprumont D
AD  - Deputy Director, Institute of Health Law, University of Neuchatel,
      Switzerland(11).
FAU - van Delden, Johannes J M
AU  - van Delden JJM
AD  - University Medical Center Utrecht, Julius Center for Health Sciences and Primary 
      Care, Netherlands(12).
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20200925
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Malaria Vaccines)
SB  - IM
MH  - *Biomedical Research
MH  - Ethics Committees, Research
MH  - Ethics, Research
MH  - Humans
MH  - Informed Consent
MH  - *Malaria Vaccines
MH  - Public Health
OTO - NOTNLM
OT  - *CIOMS guidelines
OT  - *Cluster-randomized trials
OT  - *Malaria vaccines
OT  - *Research ethics
OT  - *WHO
COIS- Declaration of Competing Interest The authors declare the following financial
      interests/personal relationships which may be considered as potential competing
      interests: RG is a member of the independent Bioethics Advisory Committee to
      Sanofi. The other authors declare no competing interests.
EDAT- 2020/09/29 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/28 05:34
PHST- 2020/04/06 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/28 05:34 [entrez]
AID - S0264-410X(20)31132-4 [pii]
AID - 10.1016/j.vaccine.2020.08.077 [doi]
PST - ppublish
SO  - Vaccine. 2020 Oct 21;38(45):6975-6978. doi: 10.1016/j.vaccine.2020.08.077. Epub
      2020 Sep 25.


PMID- 32981547
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20210902
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
VI  - 36
IP  - 5
DP  - 2020 Oct
TI  - The estimation of health state utility values in rare diseases: overview of
      existing techniques.
PG  - 469-473
LID - 10.1017/S0266462320000665 [doi]
AB  - There are several techniques for estimating health state utility values, each of 
      which presents pros and cons in the context of rare diseases (RDs). Direct
      approaches (e.g. standard gamble and time trade-off) may be too demanding for
      patients with RDs, since most of them affect young children or cause cognitive
      impairment. The alternatives are using "vignettes" that describe hypothetical
      health states for the general public, which may not reflect the heterogeneous
      manifestations of RDs, or multi-attribute utility instruments (i.e. indirect
      techniques), such as EQ-5D, which may be less sensitive in capturing the
      specificities of RDs. The "rule of rescue" approach is a promising alternative in
      RDs, since it prioritizes identifiable patients with life-threatening or
      disabling conditions. However, it raises measurement challenges and ethical
      issues. Furthermore, the literature reports on relevant implications of choosing 
      a technique over others for health technology assessment, which should be
      considered in relation to individual RDs.
FAU - Meregaglia, Michela
AU  - Meregaglia M
AUID- ORCID: https://orcid.org/0000-0003-0092-5970
AD  - Research Centre on Health and Social Care Management (CERGAS), SDA Bocconi School
      of Management, Milan, Italy.
FAU - Nicod, Elena
AU  - Nicod E
AD  - Research Centre on Health and Social Care Management (CERGAS), SDA Bocconi School
      of Management, Milan, Italy.
FAU - Drummond, Michael
AU  - Drummond M
AD  - Centre for Health Economics, University of York, York, UK.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
SB  - IM
MH  - Choice Behavior
MH  - *Health Status
MH  - Humans
MH  - Quality-Adjusted Life Years
MH  - *Rare Diseases
MH  - Surveys and Questionnaires
MH  - Technology Assessment, Biomedical
OTO - NOTNLM
OT  - Direct techniques
OT  - Indirect techniques
OT  - Rare diseases
OT  - Utility
EDAT- 2020/09/29 06:00
MHDA- 2021/09/03 06:00
CRDT- 2020/09/28 05:27
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2020/09/28 05:27 [entrez]
AID - 10.1017/S0266462320000665 [doi]
AID - S0266462320000665 [pii]
PST - ppublish
SO  - Int J Technol Assess Health Care. 2020 Oct;36(5):469-473. doi:
      10.1017/S0266462320000665. Epub 2020 Sep 25.


PMID- 32981538
OWN - NLM
STAT- Publisher
LR  - 20201009
IS  - 1748-5460 (Electronic)
IS  - 0022-2151 (Linking)
DP  - 2020 Sep 28
TI  - Ethical implications of coronavirus disease 2019 for ENT surgeons - a discussion.
PG  - 1-2
LID - 10.1017/S002221512000208X [doi]
AB  - BACKGROUND: Coronavirus disease 2019 has had a dramatic effect on society and
      healthcare. Preparations were based on predictive models of need, and with
      uncertainty regarding risk to patients and healthcare workers. Actions taken had 
      both immediate and ongoing ethical impacts. The most obvious of these was the
      shift in duty of care from individual patients to public health centred ethics
      and decision making. RELEVANCE: In ENT, many procedures are aerosol-generating
      and so our capacity to provide care will remain significantly reduced. This
      reduction in capacity may result in difficult choices for patients when optimal
      care may be replaced by acceptable care. ENT surgeons may also be faced with
      unaccustomed paternalism when capacity prevents them from acting within the
      patients' wishes. CONCLUSION: Despite these challenges, the novel uses of
      technology highlight the desire to preserve and enhance the autonomy of our
      patients.
FAU - Leonard, C G
AU  - Leonard CG
AD  - Department of Otolaryngology - Head and Neck Surgery, Royal Victoria Hospital,
      Belfast, Northern Ireland, UK.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - England
TA  - J Laryngol Otol
JT  - The Journal of laryngology and otology
JID - 8706896
SB  - IM
PMC - PMC7542318
OTO - NOTNLM
OT  - Coronavirus
OT  - Ethics
OT  - Otolaryngology
OT  - Pandemics
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/09/28 05:27
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/09/28 05:27 [entrez]
AID - 10.1017/S002221512000208X [doi]
AID - S002221512000208X [pii]
PST - aheadofprint
SO  - J Laryngol Otol. 2020 Sep 28:1-2. doi: 10.1017/S002221512000208X.


PMID- 32981337
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20211102
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Linking)
VI  - 13
IP  - 11
DP  - 2020 Nov
TI  - Evidence-Based Policy Making for Public Health Interventions in Cardiovascular
      Diseases: Formally Assessing the Feasibility of Clinical Trials.
PG  - e006378
LID - 10.1161/CIRCOUTCOMES.119.006378 [doi]
AB  - Implementation of prevention policies has often been impeded or delayed due to
      the lack of randomized controlled trials (RCTs) with hard clinical outcomes (eg, 
      incident disease, mortality). Despite the prominent role of RCTs in health care, 
      it may not always be feasible to conduct RCTs of public health interventions with
      hard outcomes due to logistical and ethical considerations. RCTs may also lack
      external validity and have limited generalizability. Currently, there is
      insufficient guidance for policymakers charged with establishing evidence-based
      policy to determine whether an RCT with hard outcomes is needed before policy
      recommendations. In this context, the purpose of this article is to assess, in a 
      case study, the feasibility of conducting an RCT of the oft-cited issue of sodium
      reduction on cardiovascular outcomes and then propose a framework for
      decision-making, which includes an assessment of the feasibility of conducting an
      RCT with hard clinical outcomes when such trials are unavailable. We designed and
      assessed the feasibility of potential individual- and cluster-randomized trials
      of sodium reduction on cardiovascular outcomes. Based on our assumptions, a trial
      using any of the designs considered would require tens of thousands of
      participants and cost hundreds of millions of dollars, which is prohibitively
      expensive. Our estimates may be conservative given several key challenges, such
      as the unknown costs of sustaining a long-term difference in sodium intake, the
      effect of differential cotreatment with antihypertensive medications, and long
      lag time to clinical outcomes. Thus, it would be extraordinarily difficult to
      conduct such a trial, and despite the high costs, would still be at substantial
      risk for a spuriously null result. A robust framework, such as the one we
      developed, should be used to guide policymakers when establishing evidence-based 
      public health interventions in the absence of trials with hard clinical outcomes.
FAU - Foti, Kathryn
AU  - Foti K
AD  - Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD
      (K.F., L.J.A.).
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD (K.F., C.A.M.A., L.J.A.).
FAU - Foraker, Randi E
AU  - Foraker RE
AD  - Department of Internal Medicine, Washington University in St. Louis School of
      Medicine, MO (R.E.F.).
FAU - Martyn-Nemeth, Pamela
AU  - Martyn-Nemeth P
AD  - Department of Biobehavioral Nursing Science, University of Illinois at Chicago
      (P.M.-N.).
FAU - Anderson, Cheryl A M
AU  - Anderson CAM
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD (K.F., C.A.M.A., L.J.A.).
AD  - Department of Family Medicine and Public Health, UC San Diego School of Medicine,
      La Jolla, CA (C.A.M.A.).
FAU - Cook, Nancy R
AU  - Cook NR
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical
      School, Boston, MA (N.R.C.).
FAU - Lichtenstein, Alice H
AU  - Lichtenstein AH
AD  - Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research
      Center on Aging, Tufts University, Boston, MA (A.H.L.).
FAU - de Ferranti, Sarah D
AU  - de Ferranti SD
AD  - Department of Cardiology, Boston Children's Hospital, MA (S.D.d.F.).
AD  - Department of Pediatrics, Harvard Medical School, Boston, MA (S.D.d.F.).
FAU - Young, Deborah Rohm
AU  - Young DR
AD  - Division of Behavioral Research, Department of Research and Evaluation, Kaiser
      Permanente Southern California, Pasadena (D.R.Y.).
FAU - Hivert, Marie-France
AU  - Hivert MF
AD  - Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health
      Care Institute, Boston, MA (M.-F.H.).
AD  - Diabetes Unit, Massachusetts General Hospital, Boston (M.-F.H.).
FAU - Ross, Robert
AU  - Ross R
AD  - School of Kinesiology and Health Studies, Queen's University, Kingston, Ontario, 
      Canada (R.R.).
FAU - Deedwania, Prakash
AU  - Deedwania P
AD  - School of Medicine, University of California at San Francisco, Fresno (P.D.).
FAU - Whitsel, Laurie P
AU  - Whitsel LP
AD  - Department of Policy Research and Translation, American Heart Association,
      Washington, DC (L.P.W.).
FAU - Appel, Lawrence J
AU  - Appel LJ
AD  - Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD
      (K.F., L.J.A.).
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD (K.F., C.A.M.A., L.J.A.).
AD  - Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD
      (L.J.A.).
LA  - eng
GR  - P30 DK072488/DK/NIDDK NIH HHS/United States
GR  - T32 HL007024/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200928
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
SB  - IM
MH  - Cardiovascular Diseases/diagnosis/physiopathology/*prevention & control
MH  - *Diet, Sodium-Restricted
MH  - *Evidence-Based Medicine
MH  - Feasibility Studies
MH  - Humans
MH  - *Policy Making
MH  - *Preventive Health Services
MH  - *Public Health
MH  - *Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - *Risk Reduction Behavior
MH  - Treatment Outcome
PMC - PMC7674216
MID - NIHMS1624380
OTO - NOTNLM
OT  - *cardiovascular disease
OT  - *decision-making
OT  - *policy
OT  - *prevention
OT  - *public health
OT  - *randomized controlled trial
EDAT- 2020/09/29 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/28 05:26
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/28 05:26 [entrez]
AID - 10.1161/CIRCOUTCOMES.119.006378 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006378. doi:
      10.1161/CIRCOUTCOMES.119.006378. Epub 2020 Sep 28.


PMID- 32980748
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20210110
IS  - 1873-7897 (Electronic)
IS  - 0887-6185 (Linking)
VI  - 76
DP  - 2020 Dec
TI  - COVID-19 and OCD: Potential impact of exposure and response prevention therapy.
PG  - 102314
LID - S0887-6185(20)30128-6 [pii]
LID - 10.1016/j.janxdis.2020.102314 [doi]
AB  - This brief clinical review critically assesses the use of exposure and response
      prevention therapy (ERP) for patients with obsessive-compulsive disorder (OCD) in
      light of the COVID-19 pandemic. We discuss the ethical and practical
      considerations that clinicians employed in past infectious disease outbreaks, as 
      well as general safety measures routinely practiced in the conduct of exposure
      therapy. During this time, concerns regarding the feasibility of ERP have
      emerged, especially with strict guidelines on social distancing and on following 
      other preventative behaviors. While ERP may have to be modified to follow public 
      health guidelines, this review outlines a) how ERP has been adapted in the
      context of other infectious triggers; b) the potential impacts on OCD patients of
      attenuated ERP, and c) minimizing concerns related to litigation. A case report
      is provided detailing ERP personalized given COVID-19 related considerations. In 
      all, we advise against modifying therapies in ways that may jeopardize the
      efficacy of patient care or progress.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Sheu, Jessica C
AU  - Sheu JC
AD  - Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine,
      United States.
FAU - McKay, Dean
AU  - McKay D
AD  - Department of Psychology, Fordham University, United States.
FAU - Storch, Eric A
AU  - Storch EA
AD  - Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine,
      United States. Electronic address: eric.storch@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200922
PL  - Netherlands
TA  - J Anxiety Disord
JT  - Journal of anxiety disorders
JID - 8710131
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - *Implosive Therapy
MH  - Obsessive-Compulsive Disorder/*epidemiology/*prevention & control/therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Treatment Outcome
PMC - PMC7507975
OTO - NOTNLM
OT  - *Anxiety
OT  - *COVID-19
OT  - *Cognitive behavioral therapy
OT  - *Exposure and response prevention
OT  - *Exposure therapy
OT  - *Obsessive-compulsive disorder
OT  - *Treatment
EDAT- 2020/09/28 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/09/27 20:32
PHST- 2020/07/08 00:00 [received]
PHST- 2020/09/14 00:00 [revised]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/09/28 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/09/27 20:32 [entrez]
AID - S0887-6185(20)30128-6 [pii]
AID - 10.1016/j.janxdis.2020.102314 [doi]
PST - ppublish
SO  - J Anxiety Disord. 2020 Dec;76:102314. doi: 10.1016/j.janxdis.2020.102314. Epub
      2020 Sep 22.


PMID- 32979960
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 151
IP  - 10
DP  - 2020 Oct
TI  - Dental practice reopening: Following the American Dental Association Principles
      of Ethics and Code of Professional Conduct.
PG  - 798-800
LID - S0002-8177(20)30535-3 [pii]
LID - 10.1016/j.adaj.2020.07.020 [doi]
CN  - Ethics Subcommittee of the ADA Council on Ethics, Bylaws and Judicial Affairs
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - IM
MH  - *American Dental Association
MH  - *Codes of Ethics
MH  - Ethics, Dental
MH  - Ethics, Professional
MH  - Humans
MH  - Professional Practice
MH  - United States
EDAT- 2020/09/28 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/27 20:19
PHST- 2020/07/17 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/09/27 20:19 [entrez]
PHST- 2020/09/28 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S0002-8177(20)30535-3 [pii]
AID - 10.1016/j.adaj.2020.07.020 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2020 Oct;151(10):798-800. doi: 10.1016/j.adaj.2020.07.020. Epub 
      2020 Jul 31.


PMID- 32979921
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Sep 26
TI  - Metformin may adversely affect orthostatic blood pressure recovery in patients
      with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and
      Metformin Therapy (CIMT) trial.
PG  - 150
LID - 10.1186/s12933-020-01131-3 [doi]
AB  - BACKGROUND: Metformin has been shown to have both neuroprotective and
      neurodegenerative effects. The aim of this study was to investigate the effect of
      metformin in combination with insulin on cardiovascular autonomic neuropathy
      (CAN) and distal peripheral neuropathy (DPN) in individuals with type 2 diabetes 
      (T2DM). METHODS: The study is a sub-study of the CIMT trial, a randomized
      placebo-controlled trial with a 2 x 3 factorial design, where 412 patients with
      T2DM were randomized to 18 months of metformin or placebo in addition to
      open-labelled insulin. Outcomes were measures of CAN: Changes in heart rate
      response to deep breathing (beat-to-beat), orthostatic blood pressure (OBP) and
      heart rate and vibration detection threshold (VDT) as a marker DPN. Serum levels 
      of vitamin B12 and methyl malonic acid (MMA) were analysed. RESULTS: After 18
      months early drop in OBP (30 s after standing) was increased in the metformin
      group compared to placebo: systolic blood pressure drop increased by 3.4 mmHg
      (95% CI 0.6; 6.2, p = 0.02) and diastolic blood pressure drop increased by 1.3
      mmHg (95% CI 0.3; 2.6, p = 0.045) compared to placebo. Beat-to-beat variation
      decreased in the metformin group by 1.1 beats per minute (95% CI - 2.4; 0.2, p = 
      0.10). Metformin treatment did not affect VDT group difference - 0.33 V (95% CI -
      1.99; 1.33, p = 0.39) or other outcomes. Changes in B12, MMA and HbA1c did not
      confound the associations. CONCLUSIONS: Eighteen months of metformin treatment in
      combination with insulin compared with insulin alone increased early drop in OBP 
      indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA 
      HbA1c. Trial registration The protocol was approved by the Regional Committee on 
      Biomedical Research Ethics (H-D-2007-112), the Danish Medicines Agency and
      registered with ClinicalTrials.gov (NCT00657943).
FAU - Hansen, Christian Stevns
AU  - Hansen CS
AUID- ORCID: 0000-0002-5782-3476
AD  - Steno Diabetes Center Copenhagen, A/S, Niels Steensens Vej 2-4, 2820, Gentofte,
      Denmark. chan0583@regionh.dk.
FAU - Lundby-Christiansen, Louise
AU  - Lundby-Christiansen L
AD  - Steno Diabetes Center Copenhagen, A/S, Niels Steensens Vej 2-4, 2820, Gentofte,
      Denmark.
AD  - Dept of Paediatrics, Nordsjaellands Hospital, Copenhagen University, Copenhagen, 
      Denmark.
FAU - Tarnow, Lise
AU  - Tarnow L
AD  - Department of Clinical Research, Nordsjaellands Hospital, Hillerod, Denmark.
AD  - Health, Aarhus University, Aarhus, Denmark.
FAU - Gluud, Christian
AU  - Gluud C
AD  - Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet,
      Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Hedetoft, Christoffer
AU  - Hedetoft C
AD  - Department of Medicine, University Hospital Koge, Koge, Denmark.
FAU - Thorsteinsson, Birger
AU  - Thorsteinsson B
AD  - Department of Cardiology, Nephrology and Endocrinology, Nordsjaellands University
      Hospital - Hillerod, Hillerod, Denmark.
FAU - Hemmingsen, Bianca
AU  - Hemmingsen B
AD  - Department of Cardiology, Nephrology and Endocrinology, Nordsjaellands University
      Hospital - Hillerod, Hillerod, Denmark.
FAU - Wiinberg, Niels
AU  - Wiinberg N
AD  - Department of Clinical Physiology, Bispebjerg Hospital, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Sneppen, Simone B
AU  - Sneppen SB
AD  - Department of Medicine, Gentofte, Copenhagen University Hospital, Hellerup,
      Denmark.
FAU - Lund, Soren S
AU  - Lund SS
AD  - Steno Diabetes Center Copenhagen, A/S, Niels Steensens Vej 2-4, 2820, Gentofte,
      Denmark.
FAU - Krarup, Thure
AU  - Krarup T
AD  - Department of Endocrinology, Bispebjerg, Copenhagen University Hospital,
      Copenhagen, Denmark.
FAU - Madsbad, Sten
AU  - Madsbad S
AD  - Department of Endocrinology, Hvidovre Hospital, University of Copenhagen,
      Hvidovre, Denmark.
FAU - Almdal, Thomas
AU  - Almdal T
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
AD  - Dept. of Endocrinology PE, Copenhagen University Hospital, Rigshospitalet,
      Denmark.
FAU - Carstensen, Bendix
AU  - Carstensen B
AD  - Steno Diabetes Center Copenhagen, A/S, Niels Steensens Vej 2-4, 2820, Gentofte,
      Denmark.
FAU - Jorgensen, Marit E
AU  - Jorgensen ME
AD  - Steno Diabetes Center Copenhagen, A/S, Niels Steensens Vej 2-4, 2820, Gentofte,
      Denmark.
AD  - National Institute of Public Health, Southern Denmark University, Odense,
      Denmark.
CN  - CIMT study group
LA  - eng
SI  - ClinicalTrials.gov/NCT00657943
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200926
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Aged
MH  - Autonomic Nervous System Diseases/etiology/*physiopathology
MH  - Blood Pressure/*physiology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism/physiopathology
MH  - Diabetic Neuropathies/etiology/*physiopathology
MH  - Female
MH  - Glycated Hemoglobin A/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Hypotension, Orthostatic/*epidemiology
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Peripheral Nervous System Diseases/etiology/*physiopathology
MH  - Risk Factors
MH  - *Standing Position
MH  - Vitamin B 12/metabolism
PMC - PMC7520024
OTO - NOTNLM
OT  - *Autonomic neuropathy
OT  - *Cardiovascular autonomic neuropathy
OT  - *Complications
OT  - *Metformin
OT  - *Orthostatic blood pressure recovery
OT  - *Orthostatic hypotension
OT  - *Peripheral neuropathy
OT  - *Type 2 diabetes
IR  - Almdal T
FIR - Almdal, T
IR  - Boesgaard TW
FIR - Boesgaard, T W
IR  - Breum L
FIR - Breum, L
IR  - Gade-Rasmussen B
FIR - Gade-Rasmussen, B
IR  - Duun E
FIR - Duun, E
IR  - Gluud C
FIR - Gluud, C
IR  - Hedetoft C
FIR - Hedetoft, C
IR  - Hemmingsen B
FIR - Hemmingsen, B
IR  - Jensen T
FIR - Jensen, T
IR  - Krarup T
FIR - Krarup, T
IR  - Lundby-Christensen L
FIR - Lundby-Christensen, L
IR  - Lund S
FIR - Lund, S
IR  - Madsbad S
FIR - Madsbad, S
IR  - Mathiesen ER
FIR - Mathiesen, E R
IR  - Pedersen O
FIR - Pedersen, O
IR  - Perrild H
FIR - Perrild, H
IR  - Roder M
FIR - Roder, M
IR  - Sneppen SB
FIR - Sneppen, S B
IR  - Snorgaard O
FIR - Snorgaard, O
IR  - Tarnow L
FIR - Tarnow, L
IR  - Thorsteinsson B
FIR - Thorsteinsson, B
IR  - Vestergaard H
FIR - Vestergaard, H
IR  - Vaag A
FIR - Vaag, A
IR  - Wiinberg N
FIR - Wiinberg, N
EDAT- 2020/09/28 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/09/27 20:18
PHST- 2020/03/11 00:00 [received]
PHST- 2020/09/18 00:00 [accepted]
PHST- 2020/09/27 20:18 [entrez]
PHST- 2020/09/28 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
AID - 10.1186/s12933-020-01131-3 [doi]
AID - 10.1186/s12933-020-01131-3 [pii]
PST - epublish
SO  - Cardiovasc Diabetol. 2020 Sep 26;19(1):150. doi: 10.1186/s12933-020-01131-3.


PMID- 32979650
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 1872-8243 (Electronic)
IS  - 1386-5056 (Linking)
VI  - 143
DP  - 2020 Nov
TI  - Electronic consenting for conducting research remotely: A review of current
      practice and key recommendations for using e-consenting.
PG  - 104271
LID - S1386-5056(20)31016-9 [pii]
LID - 10.1016/j.ijmedinf.2020.104271 [doi]
AB  - BACKGROUND: Electronic approaches are becoming more widely used to obtain
      informed consent for research participation. Electronic consent (e-consent)
      provides an accessible and versatile approach to the consenting process, which
      can be enhanced with audio-visual and interactive features to improve participant
      engagement and comprehension of study procedures. Best practice guidance
      underpinned by ethical principles is required to ensure effective implementation 
      of e-consent for use in research. AIM: To identify the key considerations for
      successful and ethical implementation of e-consent in the recruitment of
      participants to research projects which are conducted remotely. METHODS:
      Electronic database searches of CINAHL, Medline, Embase, DARE, HTA, PubMed, the
      Cochrane Library, Scopus, Web of Science, NHS Evidence, and hand-searches of
      reference lists were performed. Primary research studies of adult (>/= 18 years
      old) research participants using e-consent, published in English language,
      peer-reviewed journals between 2010-2020 were eligible for inclusion. RESULTS: Of
      the initial 665 identified studies, 18 met the inclusion criteria: 6 cohort
      studies, 5 qualitative studies, 4 randomised control trials, 2 mixed-methods
      studies and one case-control study. Critical appraisal of included studies using 
      Critical Appraisal Skills Program (CASP) tools suggested a low to moderate risk
      of bias in most studies (n = 15). Key practice recommendations for researchers
      using e-consent were identified around five primary themes: 1) accessibility and 
      user-friendliness of e-consent, 2) user engagement and comprehension, 3)
      customisability to participant preferences and demographics, 4) data security and
      5) impact on research teams. CONCLUSION: E-consenting approaches are generally
      well received by participants, with most studies reporting user-friendly
      interfaces and sufficient participant comprehension of consenting documentation. 
      IMPLICATIONS FOR PRACTICE: E-consent may facilitate remotely-conducted research
      by offering a feasible and robust alternative to face-to-face consenting
      approaches, however paper-based options should still be offered, based on
      participant preference. Customising e-consenting platforms may improve
      accessibility for individuals with specific needs, and increase engagement with
      study information. Research teams must offer prospective participants
      opportunities to discuss study information in real-time.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Skelton, Emily
AU  - Skelton E
AD  - Division of Radiography and Midwifery, City, University of London, UK; Department
      of Perinatal Imaging and Health, King's College London, UK. Electronic address:
      emily.skelton@city.ac.uk.
FAU - Drey, Nicholas
AU  - Drey N
AD  - Division of Nursing, City, University of London, UK.
FAU - Rutherford, Mary
AU  - Rutherford M
AD  - Department of Perinatal Imaging and Health, King's College London, UK.
FAU - Ayers, Susan
AU  - Ayers S
AD  - Division of Radiography and Midwifery, City, University of London, UK.
FAU - Malamateniou, Christina
AU  - Malamateniou C
AD  - Division of Radiography and Midwifery, City, University of London, UK; Department
      of Perinatal Imaging and Health, King's College London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200913
PL  - Ireland
TA  - Int J Med Inform
JT  - International journal of medical informatics
JID - 9711057
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - *Comprehension
MH  - Electronics
MH  - Humans
MH  - *Informed Consent
MH  - Prospective Studies
PMC - PMC7487205
OTO - NOTNLM
OT  - *Electronic consenting
OT  - *Informed consent
OT  - *Research ethics
OT  - *User experience
EDAT- 2020/09/27 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/09/26 20:11
PHST- 2020/07/04 00:00 [received]
PHST- 2020/08/20 00:00 [revised]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/09/26 20:11 [entrez]
AID - S1386-5056(20)31016-9 [pii]
AID - 10.1016/j.ijmedinf.2020.104271 [doi]
PST - ppublish
SO  - Int J Med Inform. 2020 Nov;143:104271. doi: 10.1016/j.ijmedinf.2020.104271. Epub 
      2020 Sep 13.


PMID- 32979080
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1433-7347 (Electronic)
IS  - 0942-2056 (Linking)
VI  - 28
IP  - 11
DP  - 2020 Nov
TI  - Meniscal allograft transplantation in The Netherlands: long-term survival,
      patient-reported outcomes, and their association with preoperative complaints and
      interventions.
PG  - 3551-3560
LID - 10.1007/s00167-020-06276-y [doi]
AB  - PURPOSE: Evaluation of survival of meniscal allograft transplantation (MAT) and
      postoperative patient-reported outcome (PRO), and their association with prior
      interventions of the knee. METHODS: A prospective consecutive study of 109
      consecutive patients who had an arthroscopic meniscal allograft transplantation
      (MAT) between 1999 and 2017 by a single surgeon. Patients were assessed with KOOS
      scores, preoperative and after a minimal follow-up of 2 years. Furthermore, two
      anchor questions (whether expectations were met and overall satisfaction, on a
      five-point Likert scale) were asked. Additionally, prior interventions to MAT
      were evaluated. RESULTS: Prior to MAT, patients had undergone an average of 2.8
      (range 1-14) of surgical procedures of the knee. Overall, mean allograft survival
      was 16.1 years (95% CI 14.8-17.5 years). Higher age at surgery was associated
      with lower MAT survival: hazard ratio for MAT failure was 1.19 per year increase 
      (95% CI 1.04 to 1.36, p = 0.009). At 4.5 years (IQR, 2-9) of follow-up, all KOOS 
      score were still improved compared to baseline. Age below 35 years, simultaneous 
      anterior cruciate ligament reconstruction and number of knee surgeries before MAT
      were associated with lower KOOS scores. Overall patient expectations and overall 
      satisfaction after MAT were not associated with preoperative patient
      characteristics nor with the number or kind of preoperative interventions.
      CONCLUSION: Meniscal allograft transplantation has a good overall survival with a
      clinically relevant improvement. Both meniscal allograft survival and PRO were
      associated with age. PRO was lower in patients younger than 35 years at time of
      MAT and meniscal allograft survival was worse in patients older than 50 years.
      PRO was associated with preoperative patient characteristics and number of
      surgical procedures prior to MAT. All patients reported improved postoperative
      satisfaction and met expectations after MAT, both independent of the preoperative
      history of knee interventions. LEVEL OF EVIDENCE: Level III. Trial registration
      Medical ethical review board (METC) number: 17-104 (7 August 2017). Dutch Trial
      Register (NTR) number: NTR6630 (4 July 2017).
FAU - van der Wal, Robert J P
AU  - van der Wal RJP
AD  - Department of Orthopaedics, Leiden University Medical Center, Albinusdreef 2,
      P.O. Box 9600, 2333 ZA, Leiden, The Netherlands. R.J.P.van_der_Wal@lumc.nl.
FAU - Nieuwenhuijse, Marc J
AU  - Nieuwenhuijse MJ
AD  - Department of Orthopaedics, Leiden University Medical Center, Albinusdreef 2,
      P.O. Box 9600, 2333 ZA, Leiden, The Netherlands.
FAU - Spek, Reinier W A
AU  - Spek RWA
AD  - Department of Orthopaedic Surgery and Traumatology, Haaglanden Medical Center,
      The Hague, The Netherlands.
FAU - Thomassen, Bregje J W
AU  - Thomassen BJW
AD  - Department of Orthopaedic Surgery and Traumatology, Haaglanden Medical Center,
      The Hague, The Netherlands.
FAU - van Arkel, Ewoud R A
AU  - van Arkel ERA
AD  - Department of Orthopaedic Surgery and Traumatology, Haaglanden Medical Center,
      The Hague, The Netherlands.
FAU - Nelissen, Rob G H H
AU  - Nelissen RGHH
AD  - Department of Orthopaedics, Leiden University Medical Center, Albinusdreef 2,
      P.O. Box 9600, 2333 ZA, Leiden, The Netherlands.
LA  - eng
SI  - NTR/NTR6630
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200926
PL  - Germany
TA  - Knee Surg Sports Traumatol Arthrosc
JT  - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
JID - 9314730
SB  - IM
MH  - Adult
MH  - Allografts
MH  - Anterior Cruciate Ligament Reconstruction/methods
MH  - Arthroscopy/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - *Graft Survival
MH  - Humans
MH  - Knee Joint/surgery
MH  - Male
MH  - Menisci, Tibial/*transplantation
MH  - Meniscus/surgery
MH  - Middle Aged
MH  - Netherlands
MH  - *Patient Reported Outcome Measures
MH  - Patient Satisfaction
MH  - Prospective Studies
MH  - Tibial Meniscus Injuries/*surgery
MH  - Transplantation, Homologous
PMC - PMC7591451
OTO - NOTNLM
OT  - Meniscal allograft transplantation
OT  - Patient history
OT  - Patient-reported outcome
OT  - Satisfaction
OT  - Survival
EDAT- 2020/09/27 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/09/26 12:04
PHST- 2020/04/02 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/09/26 12:04 [entrez]
AID - 10.1007/s00167-020-06276-y [doi]
AID - 10.1007/s00167-020-06276-y [pii]
PST - ppublish
SO  - Knee Surg Sports Traumatol Arthrosc. 2020 Nov;28(11):3551-3560. doi:
      10.1007/s00167-020-06276-y. Epub 2020 Sep 26.


PMID- 32978920
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20220417
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 68
IP  - 10
DP  - 2020 Oct
TI  - Preliminary Observations and Experiences of Physiotherapy Practice in Acute Care 
      Setup of COVID 19: A Retrospective Observational Study.
PG  - 18-24
AB  - BACKGROUND: The rapid outbreak of coronavirus disease 2019 (COVID-19), a public
      health emergency of grave concern, warranted hospital admissions with almost
      90,000 cases in June 2020 in city of Mumbai. 3-10% of the patients with moderate 
      to severe involvement required intensive care unit (ICU) admission with
      respiratory support. Patients admitted in ICU with an acute COVID event present
      with respiratory dysfunction and are more likely to have critical illness
      myopathy and neuropathy (CIMN). Physiotherapy services being integral part of
      non-pharmacological management of any ICU was implemented for patients with COVID
      19; a novel viral disease. OBJECTIVE: This retrospective study was undertaken to 
      explore the physiotherapy practices that could be implemented in patients
      admitted with COVID 19 in the ICU and its effect on mobility and oxygen
      requirement as an outcome. METHODOLOGY: Following ethical permission of
      institute, the data was extracted from electronic data record sheet in which
      daily parameters for physiotherapy intervention were recorded. Data from a single
      ICU and step down unit (SDU) from 5th June to 5th July 2020 was analysed. Records
      of patients diagnosed with COVID 19 and admitted in ICU or SDU were studied.
      Those in the age group of 18 to 90 years, of either gender were included.
      Demographic characteristics, disease severity, oxygen requirement, mobility
      status, physiotherapy intervention were studied. RESULTS: 278 record sheets (110 
      ICU and 168 SDU) were retrospectively analysed for demographics. 44.55% of
      patients improved with side lying position, 37.27% with prone position and 10.91%
      with quarter prone position. 4.55% of patient maintained oxygenation in propped
      up sitting. 2.73% could not be positioned. Chest physiotherapy techniques applied
      were deep breathing, ACBT, paced breathing and diaphragmatic breathing. Deep
      intercostal pressure on NIV along with vibrations was given to 12.72% of patients
      in the ICU. Group therapy sessions were conducted in SDU where 50.59% patients
      participated. ICU mobility score showed significant improvement on Wilcoxon
      Signed Ranks test status on day 7 in the ICU (z=-5.99, p=0.00) and SDU (z= 7.676,
      p=0.00) compared to day 1. Descriptive analysis showed a definitive reduction in 
      oxygen support requirement. CONCLUSION: Most common form of physiotherapy
      interventions in patients with Covid 19 were therapeutic positioning, early
      mobilization and breathing exercises. Physiotherapy intervention appears
      promising in facilitating early patient ambulation and discharge. This study
      shows that it is safe and feasible to provide early physiotherapy treatment
      techniques in patients with COVID-19 using appropriate measures of infection
      prevention and cross contamination.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Jiandani, Mariya P
AU  - Jiandani MP
AD  - Associate Professor, Department of Physiotherapy, Seth GSMC and KEM Hospital,
      Mumbai, Maharashtra.
FAU - Salagre, Santosh B
AU  - Salagre SB
AD  - Professor and In-charge Covid ICU, Department of Medicine, Seth GSMC and KEM
      Hospital, Mumbai, Maharashtra.
FAU - Kazi, Shabana
AU  - Kazi S
AD  - Junior Physiotherapist, Seth GSMC and KEM Hospital, Mumbai, Maharashtra.
FAU - Iyer, Saraswati
AU  - Iyer S
AD  - Prof. and Head, Department of Physiotherapy, Seth GSMC and KEM Hospital, Mumbai, 
      Maharashtra.
FAU - Patil, Poonam
AU  - Patil P
AD  - Assistant Physiotherapist, Department of Physiotherapy, Seth GSMC and KEM
      Hospital, Mumbai, Maharashtra.
FAU - Khot, Wasim Y
AU  - Khot WY
AD  - Assistant Professor, Department of Medicine, Seth GSMC and KEM Hospital, Mumbai, 
      Maharashtra.
FAU - Patil, Ekta
AU  - Patil E
AD  - Postgraduate Student, Department of Physiotherapy, Seth GSMC and KEM Hospital,
      Mumbai, Maharashtra.
FAU - Sopariwala, Mashira
AU  - Sopariwala M
AD  - Postgraduate Student, Department of Physiotherapy, Seth GSMC and KEM Hospital,
      Mumbai, Maharashtra.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - Intensive Care Units
MH  - Middle Aged
MH  - *Pandemics
MH  - Physical Therapy Modalities
MH  - *Pneumonia, Viral
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Young Adult
EDAT- 2020/09/27 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/09/26 08:11
PHST- 2020/09/26 08:11 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2020 Oct;68(10):18-24.


PMID- 32978542
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20210925
IS  - 1476-5446 (Electronic)
IS  - 1462-0049 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Sep
TI  - Does orthodontic treatment affect caries levels?
PG  - 102-103
LID - 10.1038/s41432-020-0123-5 [doi]
AB  - Design A prospective cohort study.Exposure/sample selection In 2005/2006, the
      authors analysed data from participants in a previous oral epidemiological study 
      conducted in 1988/1989. Children whom were clinically examined in the School
      Dental Clinics in South Australia in 1988/1989 were invited to a follow-up in
      2005/2006. Respondents competed a questionnaire concerning their sociodemographic
      characteristics, dental health behaviours and the receipt of orthodontic
      treatment, and were invited for a clinical examination. Oral health information
      concerning decayed, missing and filled teeth (DMFT) and occlusal status using the
      Dental Aesthetic Index (DAI) were recorded by multiple trained calibrated
      dentists in accordance with the NIDR procedures. The study obtained ethical
      approval from the University of Adelaide and maintained informed consent at each 
      stage of the study.Data analysis Data analysis was performed independently by the
      principle researcher. Analysis involved descriptive statistics, frequency
      distribution and cross tabulation. Explanatory variables for orthodontic
      treatment and dental outcomes were investigated for each DAI category using
      negative binominal regression using the online computer programme 'effect size
      calculator'. The statistical analysis was preformed using IBM SPSS statistics
      version 24. All explanatory variables were introduced into the adjusted negative 
      binominal regression models based on their statistical significance from multiple
      linear regression models, with the p value set at 0.05.Results The response rate 
      for the questionnaire was 34% (n = 632), with 74% (n = 473) of those attending
      for clinical examination. After exclusions, 24% (n = 448) of those originally
      contacted participated. Statistically significant differences in clinical
      outcomes were observed between those who had and had not visited the dentist in
      the last two years. These outcomes included missing teeth (MT), filled teeth (FT)
      and a higher DMFT score. In addition, brushing at least twice daily was
      associated with fewer decayed teeth (DT) and MT (p <0.001). Increased MT was
      observed among individuals who had orthodontic treatment across all DAI
      categories except for participants with very severe malocclusion. In this group, 
      there were significantly more MT among the untreated participants (p <0.001).
      Thirty-five percent (n = 157) of participants reported a history of orthodontic
      treatment by the age of 30. No statistically significant associations were found 
      between orthodontic treatment and all aspects of DMFT using adjusted models for
      participant self-reported sociodemographics, dental health behaviours and
      malocclusion.Conclusions Caries experience does not correlate with previous
      orthodontic treatment. Sociodemographic variables and dental health behaviours
      have a greater impact, and are associated with long-term disease outcomes,
      including numbers of DMFT. Caries experience is also associated with educational 
      attainment and income level, frequency of tooth brushing and dental office
      attendance. In summary, orthodontic treatment does not provide superior long-term
      dental health outcomes in relation to caries. The hypothesis that those with
      previous orthodontic treatment would have lower caries experience was rejected.
FAU - Cave, V
AU  - Cave V
AD  - Oral and Maxillofacial Surgery, Aberdeen Royal Infirmary, Foresterhill Health
      Campus, Foresterhill Road, Aberdeen AB25 2ZN, UK. Victoria.cave1@nhs.net.
FAU - Hutchison, C
AU  - Hutchison C
AD  - Paediatric Dentistry, Glasgow Dental Hospital and School, 378 Sauchiehall Street,
      Glasgow, UK.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Evid Based Dent
JT  - Evidence-based dentistry
JID - 100883603
SB  - IM
CON - Community Dent Oral Epidemiol. 2019 Jun;47(3):210-216. PMID: 30656705
MH  - Australia
MH  - Child
MH  - Cohort Studies
MH  - DMF Index
MH  - *Dental Caries
MH  - Humans
MH  - Prospective Studies
MH  - South Australia
EDAT- 2020/09/27 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/26 05:28
PHST- 2020/09/26 05:28 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1038/s41432-020-0123-5 [doi]
AID - 10.1038/s41432-020-0123-5 [pii]
PST - ppublish
SO  - Evid Based Dent. 2020 Sep;21(3):102-103. doi: 10.1038/s41432-020-0123-5.


PMID- 32978539
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20220531
IS  - 1476-5446 (Electronic)
IS  - 1462-0049 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Sep
TI  - Does personalised text messaging influence patients' caries risk?
PG  - 96-97
LID - 10.1038/s41432-020-0109-3 [doi]
AB  - Design A single-blinded, randomised controlled trial. The experimental group
      received 24 personalised text messages each week, disseminating tailored
      preventive advice using the multifactorial model for individual caries risk
      assessment: Cariogram. The same frequency of text messaging was delivered to the 
      control group; however, these were non-personalised messages and did not factor
      the Cariogram.Sample selection One hundred and ninety-one participants were
      assessed for eligibility by eight calibrated, volunteer dental practitioners in
      County Cork, Ireland. Six different inclusion criteria were detailed, including
      the requirement for medical card holders, serving as an indicator for
      economically underprivileged status. Other criteria included: aged between 19-70 
      years; competent with text messaging services; have a minimum of 20 teeth
      present; not pregnant; and prepared to give consent. Failure to return a baseline
      food diary or possess a mobile phone saw the exclusion of 20 participants.
      Following stratified and blocked randomisation, 85 and 86 participants were
      allocated in the test and control group, respectively. The study received ethical
      approval by the Clinical Research Ethics Committee of the Cork Teaching
      Hospitals.Data analysis One hundred and eleven participants attended the
      follow-up examination, 26 weeks after randomisation, where the 'chance of
      avoiding new cavities' was determined as a numerical index for caries risk. The
      secondary aim was to measure individual changes to seven Cariogram risk factors
      between the baseline assessment and the re-examination. The ANCOVA
      intention-to-threat (ITT) protocol and the per-protocol method were adhered to
      for analyses of outcome measures. Statistical analysis was performed using SAS
      9.4, in adherence to a pre-defined significance level of 5% (two-sided).Results
      Both analytic techniques confirmed no statistically significant difference (p
      >0.05) between the groups regarding the 'chance of avoiding new cavities'. Of the
      risk parameters assessed, only saliva secretion demonstrated a positive effect in
      the intervention group (p = 0.036, OR = 0.3, 95% CI = 0.1, 0.9). Predictive
      modelling techniques were not reliable due to the limited sample size of
      per-protocol analysis.Conclusions The failure to conclude statistical
      significance between the groups validates the null hypothesis. Accordingly, no
      difference can be established between the personalised nor non-personalised
      mobile text messaging intervention on the caries risk of underprivileged adults
      in Ireland. The authors address the value of further studies exploring the
      potential for caries risk reduction through mobile phone communications.
FAU - Patel, Jay
AU  - Patel J
AD  - School of Dentistry, Faculty of Medicine and Health, University of Leeds, Leeds, 
      UK. dn18jyp@leeds.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Evid Based Dent
JT  - Evidence-based dentistry
JID - 100883603
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Cell Phone
MH  - *Dental Caries/prevention & control
MH  - Dentists
MH  - Female
MH  - Humans
MH  - Ireland
MH  - Middle Aged
MH  - Pregnancy
MH  - Professional Role
MH  - Single-Blind Method
MH  - *Text Messaging
MH  - Young Adult
EDAT- 2020/09/27 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/09/26 05:28
PHST- 2020/09/26 05:28 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - 10.1038/s41432-020-0109-3 [doi]
AID - 10.1038/s41432-020-0109-3 [pii]
PST - ppublish
SO  - Evid Based Dent. 2020 Sep;21(3):96-97. doi: 10.1038/s41432-020-0109-3.


PMID- 32978306
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20220323
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Payment in challenge studies: ethics, attitudes and a new payment for risk model.
PG  - 815-826
LID - 10.1136/medethics-2020-106438 [doi]
AB  - Controlled Human Infection Model (CHIM) research involves the infection of
      otherwise healthy participants with disease often for the sake of vaccine
      development. The COVID-19 pandemic has emphasised the urgency of enhancing CHIM
      research capability and the importance of having clear ethical guidance for their
      conduct. The payment of CHIM participants is a controversial issue involving
      stakeholders across ethics, medicine and policymaking with allegations
      circulating suggesting exploitation, coercion and other violations of ethical
      principles. There are multiple approaches to payment: reimbursement, wage payment
      and unlimited payment. We introduce a new Payment for Risk Model, which involves 
      paying for time, pain and inconvenience and for risk associated with
      participation. We give philosophical arguments based on utility, fairness and
      avoidance of exploitation to support this. We also examine a cross-section of the
      UK public and CHIM experts. We found that CHIM participants are currently paid
      variable amounts. A representative sample of the UK public believes CHIM
      participants should be paid approximately triple the UK minimum wage and should
      be paid for the risk they endure throughout participation. CHIM experts believe
      CHIM participants should be paid more than double the UK minimum wage but are
      divided on the payment for risk. The Payment for Risk Model allows risk and pain 
      to be accounted for in payment and could be used to determine ethically
      justifiable payment for CHIM participants.Although many research guidelines warn 
      against paying large amounts or paying for risk, our empirical findings provide
      empirical support to the growing number of ethical arguments challenging this
      status quo. We close by suggesting two ways (value of statistical life or
      consistency with risk in other employment) by which payment for risk could be
      calculated.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Grimwade, Olivia
AU  - Grimwade O
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton,
      Victoria, Australia.
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
      julian.savulescu@philosophy.ox.ac.uk.
AD  - Murdoch Childrens Research Institute, Parkville, Victoria, Australia.
AD  - Melbourne Law School, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Giubilini, Alberto
AU  - Giubilini A
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK.
FAU - Oakley, Justin
AU  - Oakley J
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia.
FAU - Osowicki, Joshua
AU  - Osowicki J
AD  - Tropical Diseases Research Group, Murdoch Childrens Research Institute,
      Parkville, Victoria, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Pollard, Andrew J
AU  - Pollard AJ
AD  - Department of Paediatrics, University of Oxford, Oxford, UK.
FAU - Nussberger, Anne-Marie
AU  - Nussberger AM
AD  - Department of Experimental Psychology, University of Oxford, Oxford, UK.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - MR/R005982/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (COVID-19 Vaccines)
SB  - IM
CIN - J Med Ethics. 2021 Aug;47(8):585-586. PMID: 33046591
CIN - J Med Ethics. 2020 Dec;46(12):827-828. PMID: 33051381
CIN - J Med Ethics. 2020 Dec;46(12):831-832. PMID: 33115857
CIN - J Med Ethics. 2020 Dec;46(12):835-836. PMID: 33154089
CIN - J Med Ethics. 2020 Dec;46(12):829-830. PMID: 33154091
CIN - J Med Ethics. 2020 Dec;46(12):833-834. PMID: 33234545
CIN - J Med Ethics. 2020 Dec;46(12):837-839. PMID: 33234546
MH  - Attitude
MH  - Biomedical Research/ethics/*organization & administration/standards
MH  - COVID-19/*epidemiology/*prevention & control
MH  - COVID-19 Vaccines/*administration & dosage
MH  - Cross-Sectional Studies
MH  - Healthy Volunteers/*psychology
MH  - Humans
MH  - Pandemics
MH  - Public Opinion
MH  - Remuneration
MH  - SARS-CoV-2
PMC - PMC7719900
OTO - NOTNLM
OT  - *coercion
OT  - *research ethics
COIS- Competing interests: AJP and JoO are both Controlled Human Infection Model (CHIM)
      investigators. JoO is an investigator on CHIM studies funded by the Australian
      National Health and Medical Research Council & Medical Research Future Fund. AJP 
      is a CHIM investigator and codirector of the UK MRC Hic-Vac network. AJP is Chair
      of UK DHSC's JCVI and is a member of the WHO's SAGE. AJP is an NIHR Senior
      Investigator.
EDAT- 2020/09/27 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/09/26 05:25
PHST- 2020/05/13 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/09/26 05:25 [entrez]
AID - medethics-2020-106438 [pii]
AID - 10.1136/medethics-2020-106438 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):815-826. doi: 10.1136/medethics-2020-106438. Epub
      2020 Sep 25.


PMID- 32978305
OWN - NLM
STAT- Publisher
LR  - 20201001
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 25
TI  - Balancing health worker well-being and duty to care: an ethical approach to staff
      safety in COVID-19 and beyond.
LID - medethics-2020-106557 [pii]
LID - 10.1136/medethics-2020-106557 [doi]
AB  - The COVID-19 pandemic has highlighted the risks that can be involved in
      healthcare work. In this paper, we explore the issue of staff safety in clinical 
      work using the example of personal protective equipment (PPE) in the COVID-19
      crisis. We articulate some of the specific ethical challenges around PPE
      currently being faced by front-line clinicians, and develop an approach to staff 
      safety that involves balancing duty to care and personal well-being. We describe 
      each of these values, and present a decision-making framework that integrates the
      two. The aim of the framework is to guide the process of balancing these two
      values when staff safety is at stake, by facilitating ethical reflection and/or
      decision-making that is systematic, specific and transparent. It provides a
      structure for individual reflection, collaborative staff discussion, and
      decision-making by those responsible for teams, departments and other groups of
      healthcare staff. Overall the framework guides the decision maker to characterise
      the degree of risk to staff, articulate feasible options for staff protection in 
      that specific setting and identify the option that ensures any decrease in
      patient care is proportionate to the increase in staff well-being. It applies
      specifically to issues of PPE in COVID-19, and also has potential to assist
      decision makers in other situations involving protection of healthcare staff.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - McDougall, Rosalind J
AU  - McDougall RJ
AUID- ORCID: http://orcid.org/0000-0002-3809-2575
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia rmcdo@unimelb.edu.au.
FAU - Gillam, Lynn
AU  - Gillam L
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Children's Bioethics Centre, Royal Children's Hospital, Parkville, Victoria,
      Australia.
FAU - Ko, Danielle
AU  - Ko D
AD  - Department of Palliative Care, Austin Health, Heidelberg, Victoria, Australia.
AD  - Department of Quality and Patient Safety, Austin Health, Heidelberg, Victoria,
      Australia.
FAU - Holmes, Isabella
AU  - Holmes I
AUID- ORCID: http://orcid.org/0000-0002-5822-7561
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Delany, Clare
AU  - Delany C
AD  - Children's Bioethics Centre, Royal Children's Hospital, Parkville, Victoria,
      Australia.
AD  - Department of Medical Education, University of Melbourne, Melbourne, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7520818
OTO - NOTNLM
OT  - clinical ethics
OT  - health personnel
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2020/09/27 06:00
CRDT- 2020/09/26 05:25
PHST- 2020/06/04 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/09/26 05:25 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/09/27 06:00 [medline]
AID - medethics-2020-106557 [pii]
AID - 10.1136/medethics-2020-106557 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 25. pii: medethics-2020-106557. doi:
      10.1136/medethics-2020-106557.


PMID- 32978304
OWN - NLM
STAT- Publisher
LR  - 20211217
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 25
TI  - SARS-CoV-2 challenge studies: ethics and risk minimisation.
LID - medethics-2020-106504 [pii]
LID - 10.1136/medethics-2020-106504 [doi]
AB  - COVID-19 poses an exceptional threat to global public health and well-being.
      Recognition of the need to develop effective vaccines at unprecedented speed has 
      led to calls to accelerate research pathways ethically, including by conducting
      challenge studies (also known as controlled human infection studies (CHIs)) with 
      SARS-CoV-2 (the virus which causes COVID-19). Such research is controversial,
      with concerns being raised about the social, legal, ethical and clinical
      implications of infecting healthy volunteers with SARS-CoV-2 for research
      purposes. Systematic risk evaluations are critical to inform assessments of the
      ethics of any proposed SARS-CoV-2 CHIs. Such evaluations will necessarily take
      place within a rapidly changing and at times contested epidemiological landscape,
      in which differing criteria for the ethical acceptability of research risks have 
      been proposed. This paper critically reviews two such criteria and evaluates
      whether the use of effective treatment should be a necessary condition for the
      ethical acceptability of SARS-CoV-2 CHIs, and whether the choice of study sites
      should be influenced by COVID-19 incidence levels. The paper concludes that
      ethical evaluations of proposed SARS-CoV-2 CHIs should be informed by rigorous,
      consultative and holistic approaches to systematic risk assessment.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Bull, Susan
AU  - Bull S
AUID- ORCID: http://orcid.org/0000-0002-9730-091X
AD  - The Ethox Centre & Wellcome Centre for Ethics and the Humanities, Nuffield
      Department of Population Health, University of Oxford, Oxford, Oxfordshire, UK
      susan.bull@ethox.ox.ac.uk.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AUID- ORCID: http://orcid.org/0000-0001-5940-602X
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia.
FAU - Binik, Ariella
AU  - Binik A
AD  - Department of Philosophy, McMaster University, Hamilton, Ontario, Canada.
FAU - Parker, Michael J
AU  - Parker MJ
AD  - The Ethox Centre, University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7520819
OTO - NOTNLM
OT  - clinical trials
OT  - ethics
OT  - research ethics
OT  - scientific research
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2020/09/27 06:00
CRDT- 2020/09/26 05:25
PHST- 2020/05/25 00:00 [received]
PHST- 2020/08/16 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/09/26 05:25 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/09/27 06:00 [medline]
AID - medethics-2020-106504 [pii]
AID - 10.1136/medethics-2020-106504 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 25. pii: medethics-2020-106504. doi:
      10.1136/medethics-2020-106504.


PMID- 32978206
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Patch validation: an observational study protocol for the evaluation of a
      multisignal wearable sensor in patients during anaesthesia and in the
      postanaesthesia care unit.
PG  - e040453
LID - 10.1136/bmjopen-2020-040453 [doi]
AB  - INTRODUCTION: Except for operating rooms, postanaesthesia care units and
      intensive care units, where the monitoring of vital signs is continuous,
      intermittent care is standard practice. However, at a time when only the patients
      with the most serious conditions are hospitalised and only a fraction of these
      patients are in intensive care units, this type of monitoring is no longer
      sufficient. Wireless monitoring has been proposed, but it requires rigorous
      validation. The aim of this observational study is to compare vital signs
      obtained from a precordial patch sensor to those obtained with conventional
      monitoring. METHODS AND ANALYSIS: This patch validation trial will be an
      observational, prospective, single-centre open study of 115 anaesthetised adult
      patients monitored with both a wireless sensor (myAngel VitalSigns, Devinnova,
      Montpellier, France) and a standard bedside monitor (Carescape Monitor B850, GE
      Healthcare, Chicago, Illinois). Both sensors will be used to record peripheral
      oxygen saturation, respiratory rate, heart rate, body temperature and blood
      pressure (systolic and diastolic). The main objective will be to assess the
      degree of agreement between the two systems during the patients' stay in the
      postanaesthesia care unit, both at the raw signal level and at the clinical
      parameter level. The secondary objectives will be to assess the same performance 
      under anaesthesia, the frequency of missing data or artefacts, the diagnostic
      performance of the systems, the influence of patients' characteristics on
      agreement between the two systems, the adverse events and the acceptability of
      the patch to patients. Bland-Altman plots will be used in the main analysis to
      detect discrepancies and estimate the limits of agreement. ETHICS AND
      DISSEMINATION: Ethics approval was obtained from the Ethical Committee (Toulouse,
      France) on 10 April 2020. We are not yet recruiting subjects for this study. The 
      results will be submitted for publication in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: NCT04344093.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Le Guen, Morgan
AU  - Le Guen M
AD  - Department of Anesthesiology, Hopital Foch, Suresnes, France.
FAU - Squara, Pierre
AU  - Squara P
AUID- ORCID: 0000-0003-1381-6773
AD  - ICU, Clinique Ambroise Pare, Neuilly-sur-Seine, France.
FAU - Ma, Sabrina
AU  - Ma S
AD  - Department of Anesthesiology, Hopital Foch, Suresnes, France.
FAU - Adjavon, Sherifa
AU  - Adjavon S
AD  - Department of Anesthesiology, Hopital Foch, Suresnes, France.
FAU - Trillat, Bernard
AU  - Trillat B
AD  - Department of Information Systems, Hopital Foch, Suresnes, France.
FAU - Merzoug, Messaouda
AU  - Merzoug M
AD  - Research Unit, Clinique Ambroise Pare, Neuilly-sur-Seine, France.
FAU - Aegerter, Philippe
AU  - Aegerter P
AD  - Methodology Unit, GIRCI-IdF, Paris, France.
AD  - U1018 (Center for Epidemiology and Population Health), Paris-Saclay University,
      UVSQ, INSERM, Villejuif, France.
FAU - Fischler, Marc
AU  - Fischler M
AUID- ORCID: 0000-0003-0729-5430
AD  - Department of Anesthesiology, Hopital Foch, Suresnes, France
      m.fischler@orange.fr.
LA  - eng
SI  - ClinicalTrials.gov/NCT04344093
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Anesthesia
MH  - Chicago
MH  - France
MH  - Humans
MH  - Illinois
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - *Wearable Electronic Devices
PMC - PMC7520837
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *adult intensive & critical care
OT  - *surgery
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040453 [pii]
AID - 10.1136/bmjopen-2020-040453 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e040453. doi: 10.1136/bmjopen-2020-040453.


PMID- 32978204
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Effects of a foot-ankle strengthening programme on clinical aspects and gait
      biomechanics in people with knee osteoarthritis: protocol for a randomised
      controlled trial.
PG  - e039279
LID - 10.1136/bmjopen-2020-039279 [doi]
AB  - INTRODUCTION: Studies have indicated that hip and knee muscle strengthening are
      effective in reducing pain, improving self-reported function and increasing lower
      limb strength, without, however, decreasing knee joint overload during gait in
      patients with knee osteoarthritis (KOA). Recent research has shown that
      strengthening the foot-ankle muscles improved function in diabetic patients and
      reduced patellofemoral pain. The aim of this paper is to investigate whether an
      8-week therapeutic foot-ankle exercise programme improves pain, functionality,
      foot strength, foot kinematics and knee joint overload during gait, and decreases
      medication intake in individuals with KOA. METHODS AND ANALYSIS: This two-arm,
      prospectively registered, randomised controlled trial with blinded assessors will
      involve 88 patients with medial tibiofemoral osteoarthritis. Subjects will be
      randomly allocated to a control group that will receive no specific foot
      intervention and will follow treatment recommended by the medical team; or an
      intervention group that will undergo an 8-week physiotherapist-supervised
      strengthening programme for extrinsic and intrinsic foot muscles, three times a
      week. The primary outcome will be the pain domain of the Western Ontario McMaster
      Universities Osteoarthritis Index (WOMAC). The secondary outcomes include WOMAC
      stiffness and function domains, total WOMAC score, physical function, foot muscle
      isometric strength, foot kinematics and knee kinetics during gait, and medication
      intake. Data will be analysed on intention-to-treat principles and a per protocol
      basis. ETHICS AND DISSEMINATION: Investigators and sponsors will communicate
      trial results to participants and healthcare professionals through scientific
      databases and social media. In addition, findings will be reported in peer-review
      publications, and at national and international conference presentations. Ethics 
      approval: Ethics Committee of the Universidade Federal de Sao Carlos, Sao Carlos,
      SP, Brazil (N degrees 3.488.466). TRIAL REGISTRATION NUMBER: NCT04154059.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dantas, Glauko
AU  - Dantas G
AUID- ORCID: 0000-0002-4620-2877
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos (UFSCar), Sao 
      Carlos, Sao Paulo, Brazil.
FAU - Sacco, Isabel C N
AU  - Sacco ICN
AUID- ORCID: 0000-0003-1254-0007
AD  - Department of Physical Therapy, Speech, and Occupational Therapy, USP, Sao Paulo,
      Brazil.
FAU - Dos Santos, Ana F
AU  - Dos Santos AF
AUID- ORCID: 0000-0002-3527-3098
AD  - UNA University Center, Pouso Alegre, Brazil.
FAU - Watari, Ricky
AU  - Watari R
AUID- ORCID: 0000-0003-0788-5414
AD  - Department of Physical Therapy, Speech, and Occupational Therapy, USP, Sao Paulo,
      Brazil.
FAU - Matias, Alessandra B
AU  - Matias AB
AUID- ORCID: 0000-0002-0770-9085
AD  - Department of Physical Therapy, Speech, and Occupational Therapy, USP, Sao Paulo,
      Brazil.
FAU - Serrao, Paula R M S
AU  - Serrao PRMS
AUID- ORCID: 0000-0002-4547-9161
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos (UFSCar), Sao 
      Carlos, Sao Paulo, Brazil.
FAU - Pott-Junior, Henrique
AU  - Pott-Junior H
AUID- ORCID: 0000-0003-3126-2946
AD  - Department of Medicine, Universidade Federal de Sao Carlos (UFSCar), Sao Carlos, 
      Sao Paulo, Brazil.
FAU - Salvini, Tania F
AU  - Salvini TF
AUID- ORCID: 0000-0002-6353-6393
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos (UFSCar), Sao 
      Carlos, Sao Paulo, Brazil tania@ufscar.br.
LA  - eng
SI  - ClinicalTrials.gov/NCT04154059
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ankle
MH  - Biomechanical Phenomena
MH  - Brazil
MH  - Exercise Therapy
MH  - Gait
MH  - Humans
MH  - Knee Joint
MH  - Lower Extremity
MH  - Ontario
MH  - *Osteoarthritis, Knee/therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7520828
OTO - NOTNLM
OT  - *foot & ankle
OT  - *knee
OT  - *rehabilitation medicine
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039279 [pii]
AID - 10.1136/bmjopen-2020-039279 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e039279. doi: 10.1136/bmjopen-2020-039279.


PMID- 32978202
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - PositivMasc: masculinities and violence against women among young people.
      Identifying discourses and developing strategies for change, a mixed-method study
      protocol.
PG  - e038797
LID - 10.1136/bmjopen-2020-038797 [doi]
AB  - INTRODUCTION: Despite public policies and legislative changes aiming to curtail
      men's violence against women (VAW) around the world, women continue to be exposed
      to VAW throughout their life. One in three women in Europe has reported physical 
      or sexual abuse. Men who display unequitable masculinities are more likely to be 
      perpetrators. VAW is increasingly appearing at younger ages. The aims of the
      project are fourfold: (1) to explore and position the discourses that young
      people (men and women, 18-24 years) in Sweden, Spain, Ireland and Israel use in
      their understanding of masculinities, (2) to explore how these discourses
      influence young people's attitudes, behaviours and responses to VAW, (3) to
      explore individual and societal factors supporting and promoting anti-VAW
      masculinities discourses and (4) to develop actions and guidelines to support and
      promote anti-VAW masculinities in these settings. METHODS AND ANALYSIS: A
      participatory explorative mixed-method study will be used. In Phase 1,
      qualitative methods will be used to identify the discourses that young people and
      stakeholders use to conceptualise masculinities, VAW and the actions that are
      needed to support and promote antiviolence masculinities. In Phase 2, concept
      mapping will be used to quantify the coherence, relative importance and perceived
      relationship between the different actions to support and promote anti-VAW
      masculinities. Phase 3 is a knowledge creation and translation phase, based on
      findings from Phases 1 and 2, where actions and guidelines to promote and support
      anti-VAW masculinities will be developed. ETHICS AND DISSEMINATION: Ethical
      clearance has been obtained from ethics review boards in each country. Results
      will be disseminated through peer-reviewed publications, presentations at
      international conferences, policy briefs, social media and through the project
      online hub. With its multicountry approach, our project results seek to inform
      policies and interventions aimed at promoting discourses which challenge
      hegemonic masculinities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Salazar, M
AU  - Salazar M
AUID- ORCID: 0000-0001-6935-9781
AD  - Department of Global Public Health, GloSH research group, Karolinska Institutet, 
      Stockholm, Sweden mariano.salazar@ki.se.
FAU - Daoud, N
AU  - Daoud N
AD  - Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of
      the Negev, Beer-Sheva, Israel.
FAU - Edwards, Claire
AU  - Edwards C
AD  - School of Applied Social Studies, University College Cork, Cork, Ireland.
AD  - Institute for Social Science in the 21st Century (ISS21), University College
      Cork, Cork, Ireland.
FAU - Scanlon, Margaret
AU  - Scanlon M
AD  - Institute for Social Science in the 21st Century (ISS21), University College
      Cork, Cork, Ireland.
FAU - Vives-Cases, C
AU  - Vives-Cases C
AD  - Department of Community Nursing, Preventive Medicine and Public Health and
      History of Science, University of Alicante, Alicante, Spain.
AD  - CIBER of Epidemiology and Public Health, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Europe
MH  - Female
MH  - Humans
MH  - Ireland
MH  - Israel
MH  - Male
MH  - Spain
MH  - Sweden
MH  - *Violence
PMC - PMC7520833
OTO - NOTNLM
OT  - *public health
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038797 [pii]
AID - 10.1136/bmjopen-2020-038797 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e038797. doi: 10.1136/bmjopen-2020-038797.


PMID- 32978201
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Community paramedicine-cost-benefit analysis and safety with paramedical
      emergency services in rural areas: scoping review protocol.
PG  - e038651
LID - 10.1136/bmjopen-2020-038651 [doi]
AB  - INTRODUCTION: Community paramedicine models have been developed around the world 
      in response to demographic changes, healthcare system needs and reforms. The
      traditional role of the paramedic has primarily been to provide emergency medical
      response and transportation of patients to nearby medical facilities. As a
      response to healthcare service gaps in underserved communities and the growing
      professionalisation of the workforce, the role of community paramedicine has
      evolved as a new model of care. A community paramedicine model in one region
      might address other healthcare needs than a model in another region. Various
      terms are also in use for community paramedicine providers, with no consensus on 
      the definition for community paramedics, although the definition used by the
      International Roundtable on Community Paramedicine has been widely accepted. We
      aimed to examine the current knowledge and possibly identify gaps in the
      research/knowledge base for cost-benefit analysis and safety concerning community
      paramedicine in rural areas using a scoping review methodology. METHODS AND
      ANALYSIS: This scoping review will follow the methodology developed by Arksey and
      O'Malley and the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses Extension for Scoping Reviews. In October 2020, we will search
      electronic databases (MEDLINE via PubMed, CINAHL, Cochrane and Embase) and the
      reference lists of key studies to identify studies for inclusion. The selection
      process is in two steps. First, two reviewers will independently screen
      identified articles for title and abstracts and, second, perform a full-text
      review of eligible studies for inclusion. Studies focusing on community
      paramedicine in rural areas, which include cost-benefit analysis or safety
      evaluation, will be included. ETHICS AND DISSEMINATION: The data used are
      available from publicly secondary sources, therefore this study will not require 
      ethical review. The results will be disseminated through peer-reviewed
      publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Elden, Odd Eirik
AU  - Elden OE
AUID- ORCID: 0000-0002-7707-6180
AD  - Department of Pre-Hospital Services, Nord-Trondelag Hospital Trust, Levanger,
      Norway oddeirik.elden@hnt.no.
AD  - Department of Emergency Medicine and Pre-Hospital Services, St Olavs University
      Hospital, Trondheim, Norway.
AD  - Levanger Hospital, Nord-Trondelag Hospital Trust, Levanger, Norway.
FAU - Uleberg, Oddvar
AU  - Uleberg O
AD  - Department of Emergency Medicine and Pre-Hospital Services, St Olavs University
      Hospital, Trondheim, Norway.
AD  - Department of Research and Development, Norwegian Air Ambulance Foundation, Oslo,
      Norway.
FAU - Lysne, Marianne
AU  - Lysne M
AD  - Levanger Hospital, Nord-Trondelag Hospital Trust, Levanger, Norway.
FAU - Haugdahl, Hege Selnes
AU  - Haugdahl HS
AD  - Levanger Hospital, Nord-Trondelag Hospital Trust, Levanger, Norway.
AD  - Department of Public Health and Nursing, Norwegian University of Science and
      Technology, Trondheim, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Allied Health Personnel
MH  - Cost-Benefit Analysis
MH  - Delivery of Health Care
MH  - *Emergency Medical Services
MH  - *Emergency Medical Technicians
MH  - Humans
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7520827
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health & safety
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038651 [pii]
AID - 10.1136/bmjopen-2020-038651 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e038651. doi: 10.1136/bmjopen-2020-038651.


PMID- 32978200
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial
      Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised,
      open-label study.
PG  - e038194
LID - 10.1136/bmjopen-2020-038194 [doi]
AB  - INTRODUCTION: Current international guidelines recommend non-vitamin K oral
      anticoagulants (NOACs) for stroke prevention among patients with non-valvular
      atrial fibrillation (AF) at significant ischaemic stroke risk given the superior 
      safety and comparable efficacy of NOACs over warfarin. Nonetheless, the safety
      and effectiveness of NOACs have not been evaluated in patients with AF with
      underlying moderate or severe mitral stenosis (MS), hence the recommended stroke 
      prevention strategy remains warfarin therapy. METHOD AND ANALYSIS: MS remains
      disproportionately prevalent in Asian countries compared with the developed
      countries. This prospective, randomised, open-label trial with blinded endpoint
      adjudication aims to evaluate the safety and efficacy of dabigatran for stroke
      prevention in AF patients with moderate or severe MS. Patients with AF aged >/=18
      years with moderate or severe MS not planned for valvular intervention in the
      coming 12 months will be randomised in a 1:1 ratio to receive dabigatran 110 mg
      or 150 mg two times per day or warfarin with international normalised ratio 2-3
      in an open-label design. Patients with estimated creatinine clearance <30 mL/min,
      or with a concomitant indication for antiplatelet therapy will be excluded. The
      primary outcome is a composite of stroke and systemic embolism. Secondary
      outcomes are ischaemic stroke, systemic embolism, haemorrhagic stroke,
      intracranial haemorrhage, major bleeding and death. The estimated required sample
      size is approximately 686 participants. ETHICS AND DISSEMINATION: The study
      protocol has been approved by the Institutional Review Board of the University of
      Hong Kong and Hong Kong West Cluster, Hospital Authority, Hong Kong for Fung Yiu 
      King Hospital, Grantham Hospital, Queen Mary Hospital and Tung Wah Hospital in
      Hong Kong. Results will be published in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04045093); pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhou, Mi
AU  - Zhou M
AUID- ORCID: 0000-0002-0864-9512
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Chan, Esther W
AU  - Chan EW
AD  - Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, Hong
      Kong SAR, China.
FAU - Hai, Jo Jo
AU  - Hai JJ
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Wong, Chun Ka
AU  - Wong CK
AUID- ORCID: 0000-0001-5205-9440
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Lau, Yuk Ming
AU  - Lau YM
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Huang, Duo
AU  - Huang D
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Lam, Cheung Chi
AU  - Lam CC
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Tam, Chor Cheung Frankie
AU  - Tam CCF
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Wong, Yiu Tung Anthony
AU  - Wong YTA
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Yung, See Yue Arthur
AU  - Yung SYA
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Chan, Ki Wan Kelvin
AU  - Chan KWK
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Feng, Yingqing
AU  - Feng Y
AD  - Cardiology Division, Guangdong Cardiovascular Institute, Guangzhou, Guangdong,
      China.
FAU - Tan, Ning
AU  - Tan N
AD  - Cardiology Division, Guangdong Cardiovascular Institute, Guangzhou, Guangdong,
      China.
FAU - Chen, Ji-Yan
AU  - Chen JY
AD  - Cardiology Division, Guangdong Cardiovascular Institute, Guangzhou, Guangdong,
      China.
AD  - Cardiology Division, South China University of Technology, Guangzhou, Guangdong, 
      China.
FAU - Yung, Chi Yui
AU  - Yung CY
AD  - Cardiology Division, Department of Medicine and Geriatrics, Ruttonjee and Tang
      Siu Kin Hospital, Hong Kong, Hong Kong SAR, China.
FAU - Lee, Kwok Lun
AU  - Lee KL
AD  - Cardiology Division, Department of Medicine and Geriatrics, Ruttonjee and Tang
      Siu Kin Hospital, Hong Kong, Hong Kong SAR, China.
FAU - Choi, Chun Wai
AU  - Choi CW
AD  - Cardiology Division, Department of Medicine and Geriatrics, Tuen Mun Hospital,
      Hong Kong, Hong Kong SAR, China.
FAU - Lam, Ho
AU  - Lam H
AD  - Cardiology Division, Department of Medicine and Geriatrics, Tuen Mun Hospital,
      Hong Kong, Hong Kong SAR, China.
FAU - Ng, Andrew
AU  - Ng A
AD  - Cardiac Medical Unit, Grantham Hospital, Hong Kong, Hong Kong SAR, China.
FAU - Fan, Katherine
AU  - Fan K
AD  - Cardiac Medical Unit, Grantham Hospital, Hong Kong, Hong Kong SAR, China.
FAU - Jim, Man Hong
AU  - Jim MH
AD  - Cardiac Medical Unit, Grantham Hospital, Hong Kong, Hong Kong SAR, China.
FAU - Yiu, Kai Hang
AU  - Yiu KH
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China.
FAU - Yan, Bryan P
AU  - Yan BP
AD  - Cardiology Division, Department of Medicine & Therapeutics, Chinese University of
      Hong Kong, Hong Kong, Hong Kong SAR, China.
FAU - Siu, Chung Wah
AU  - Siu CW
AD  - Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong, 
      Hong Kong SAR, China cwdsiu@hku.hk.
LA  - eng
SI  - ClinicalTrials.gov/NCT04045093
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
RN  - I0VM4M70GC (Dabigatran)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Anticoagulants/adverse effects
MH  - *Atrial Fibrillation/complications/drug therapy
MH  - *Brain Ischemia/drug therapy
MH  - Dabigatran/adverse effects
MH  - Hong Kong
MH  - Humans
MH  - *Mitral Valve Stenosis/complications
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/drug therapy/etiology/prevention & control
MH  - Treatment Outcome
PMC - PMC7520829
OTO - NOTNLM
OT  - *adult cardiology
OT  - *clinical pharmacology
OT  - *valvular heart disease
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038194 [pii]
AID - 10.1136/bmjopen-2020-038194 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e038194. doi: 10.1136/bmjopen-2020-038194.


PMID- 32978195
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - NEUROlogical Prognosis After Cardiac Arrest in Kids (NEUROPACK) study: protocol
      for a prospective multicentre clinical prediction model derivation and validation
      study in children after cardiac arrest.
PG  - e037517
LID - 10.1136/bmjopen-2020-037517 [doi]
AB  - INTRODUCTION: Currently, we are unable to accurately predict mortality or
      neurological morbidity following resuscitation after paediatric out of hospital
      (OHCA) or in-hospital (IHCA) cardiac arrest. A clinical prediction model may
      improve communication with parents and families and risk stratification of
      patients for appropriate postcardiac arrest care. This study aims to the derive
      and validate a clinical prediction model to predict, within 1 hour of admission
      to the paediatric intensive care unit (PICU), neurodevelopmental outcome at 3
      months after paediatric cardiac arrest. METHODS AND ANALYSIS: A prospective study
      of children (age: >24 hours and <16 years), admitted to 1 of the 24 participating
      PICUs in the UK and Ireland, following an OHCA or IHCA. Patients are included if 
      requiring more than 1 min of cardiopulmonary resuscitation and mechanical
      ventilation at PICU admission Children who had cardiac arrests in PICU or
      neonatal intensive care unit will be excluded. Candidate variables will be
      identified from data submitted to the Paediatric Intensive Care Audit Network
      registry. Primary outcome is neurodevelopmental status, assessed at 3 months by
      telephone interview using the Vineland Adaptive Behavioural Score II
      questionnaire. A clinical prediction model will be derived using logistic
      regression with model performance and accuracy assessment. External validation
      will be performed using the Therapeutic Hypothermia After Paediatric Cardiac
      Arrest trial dataset. We aim to identify 370 patients, with successful consent
      and follow-up of 150 patients. Patient inclusion started 1 January 2018 and
      inclusion will continue over 18 months. ETHICS AND DISSEMINATION: Ethical review 
      of this protocol was completed by 27 September 2017 at the Wales Research Ethics 
      Committee 5, 17/WA/0306. The results of this study will be published in
      peer-reviewed journals and presented in conferences. TRIAL REGISTRATION NUMBER:
      NCT03574025.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Scholefield, Barnaby Robert
AU  - Scholefield BR
AUID- ORCID: 0000-0002-6198-4985
AD  - Birmingham Acute Care Research Group, University of Birmingham College of Medical
      and Dental Sciences, Birmingham, West Midlands, UK b.scholefield@bham.ac.uk.
AD  - Paediatric Intensive Care Unit, Birmingham Women and Children's NHS Foundation
      Trust, Birmingham, West Midlands, UK.
FAU - Martin, James
AU  - Martin J
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Penny-Thomas, Kate
AU  - Penny-Thomas K
AD  - Paediatric Intensive Care Unit, Birmingham Women and Children's NHS Foundation
      Trust, Birmingham, West Midlands, UK.
FAU - Evans, Sarah
AU  - Evans S
AD  - Paediatric Intensive Care Unit, Birmingham Women and Children's NHS Foundation
      Trust, Birmingham, West Midlands, UK.
FAU - Kool, Mirjam
AU  - Kool M
AD  - Birmingham Acute Care Research Group, University of Birmingham College of Medical
      and Dental Sciences, Birmingham, West Midlands, UK.
AD  - Paediatric Intensive Care Unit, Birmingham Women and Children's NHS Foundation
      Trust, Birmingham, West Midlands, UK.
FAU - Parslow, Roger
AU  - Parslow R
AD  - Leeds Institute for Data Analytics, University of Leeds, Leeds, West Yorkshire,
      UK.
FAU - Feltbower, Richard
AU  - Feltbower R
AD  - Leeds Institute for Data Analytics, University of Leeds, Leeds, West Yorkshire,
      UK.
FAU - Draper, Elizabeth S
AU  - Draper ES
AD  - Health Sciences, University of Leicester College of Medicine Biological Sciences 
      and Psychology, Leicester, UK.
FAU - Hiley, Victoria
AU  - Hiley V
AD  - Leeds Institute for Data Analytics, University of Leeds, Leeds, West Yorkshire,
      UK.
FAU - Sitch, Alice J
AU  - Sitch AJ
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, West 
      Midlands, UK.
AD  - NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham,
      UK.
FAU - Kanthimathinathan, Hari Krishnan
AU  - Kanthimathinathan HK
AD  - Birmingham Acute Care Research Group, University of Birmingham College of Medical
      and Dental Sciences, Birmingham, West Midlands, UK.
AD  - Paediatric Intensive Care Unit, Birmingham Women and Children's NHS Foundation
      Trust, Birmingham, West Midlands, UK.
FAU - Morris, Kevin P
AU  - Morris KP
AD  - Paediatric Intensive Care Unit, Birmingham Women and Children's NHS Foundation
      Trust, Birmingham, West Midlands, UK.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, West 
      Midlands, UK.
FAU - Smith, Fang
AU  - Smith F
AD  - Birmingham Acute Care Research Group, University of Birmingham College of Medical
      and Dental Sciences, Birmingham, West Midlands, UK.
CN  - NEUROPACK Investigators for the Paediatric Intensive Care Society-Study Group
      (PICS-SG)
LA  - eng
SI  - ClinicalTrials.gov/NCT03574025
GR  - CS-2015-15-016/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Cardiopulmonary Resuscitation
MH  - Child
MH  - Humans
MH  - Infant, Newborn
MH  - Ireland/epidemiology
MH  - Models, Statistical
MH  - Multicenter Studies as Topic
MH  - *Out-of-Hospital Cardiac Arrest/therapy
MH  - Prognosis
MH  - Prospective Studies
MH  - Wales
PMC - PMC7520830
OTO - NOTNLM
OT  - *paediatric intensive & critical care
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
IR  - Thorburn K
FIR - Thorburn, Kent
IR  - Saxena R
FIR - Saxena, Rohit
IR  - Thiru Y
FIR - Thiru, Yamuna
IR  - Levin R
FIR - Levin, Richard
IR  - Agbecko R
FIR - Agbecko, Rachel
IR  - Thiruchelvam T
FIR - Thiruchelvam, Timothy
IR  - Skellett S
FIR - Skellett, Sophie
IR  - Inwald D
FIR - Inwald, David
IR  - Weitz J
FIR - Weitz, James
IR  - Deep A
FIR - Deep, Akash
IR  - Cooper S
FIR - Cooper, Sian
IR  - Barry P
FIR - Barry, Peter
IR  - Davies P
FIR - Davies, Patrick
IR  - Breatnach C
FIR - Breatnach, Cormac
IR  - Gala-Peralta S
FIR - Gala-Peralta, Sandra
IR  - Lo M
FIR - Lo, Milly
IR  - Barber R
FIR - Barber, Rachael
IR  - Reid S
FIR - Reid, Stewart
IR  - Thomas R
FIR - Thomas, Rum
IR  - Pappachan J
FIR - Pappachan, John
IR  - Dwarakanathan B
FIR - Dwarakanathan, Buvana
IR  - Oruganti S
FIR - Oruganti, Siva
IR  - Sadasivam K
FIR - Sadasivam, Kalai
IR  - Bebbington M
FIR - Bebbington, Mark
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037517 [pii]
AID - 10.1136/bmjopen-2020-037517 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e037517. doi: 10.1136/bmjopen-2020-037517.


PMID- 32978194
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Rehabilitation nursing for motor functional recovery of acute ischaemic stroke:
      study protocol for a randomised controlled trial.
PG  - e037391
LID - 10.1136/bmjopen-2020-037391 [doi]
AB  - INTRODUCTION: Stroke is the second-leading cause of death and disability in the
      world, and patients with stroke often suffer from functional impairments and need
      rehabilitation. Notably, there is much evidence that rehabilitation can lead to
      better mortality and morbidity outcomes. The evidence for the effectiveness of
      rehabilitation nursing, however, is limited. Thus, this study seeks to explore
      whether rehabilitation nursing is not inferior to usual rehabilitation for motor 
      functional recovery in patients with acute ischaemic stroke. METHODS AND
      ANALYSIS: We will conduct an assessor-blinded parallel randomised controlled
      trial of patients who meet the inclusion criteria after stratification by
      weighted corticospinal tract lesion load. The experimental group will receive
      rehabilitation nursing by trained and qualified nurses (seven consecutive days,
      two sessions per day, 30 min each session). The control group will receive usual 
      rehabilitation provided by therapists (seven consecutive days, two sessions per
      day, 30 min each session). The primary outcome measures are the Motor Assessment 
      Scale, the Fugl-Meyer Assessment and the Action Research Arm Test. The secondary 
      outcome measures are the modified Rankin Scale, the modified Barthel Index and
      the National Institute of Health Stroke Scale. Primary and secondary outcome
      assessment will be performed before and after the intervention, and secondary
      outcome be assessed at 4 and 12 weeks follow-up. We will recruit 224 patients
      within a period of 12-18 months from a hospital in southeastern China. ETHICS AND
      DISSEMINATION: The study was approved by the Human Research Ethics Committee from
      the corresponding author's hospital (approval Number is Ethical Review Study No. 
      2018 - 112). Peer-reviewed journals and presentations at national and
      international conferences will be used to disseminate the results. TRIAL
      REGISTRATION NUMBER: NCT03702452.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Jianmiao
AU  - Wang J
AUID- ORCID: 0000-0002-8371-517X
AD  - Nursing Department, The Second Affiliated Hospital of Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang, China.
FAU - Chen, Yuanyuan
AU  - Chen Y
AD  - Neurology Department, The Second Affiliated Hospital of Zhejiang University
      School of Medicine, Hangzhou, Zhejiang, China.
FAU - Zhang, Yuping
AU  - Zhang Y
AD  - Nursing Department, The Second Affiliated Hospital of Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang, China.
FAU - Li, Mei
AU  - Li M
AD  - Nursing Department, The Second Affiliated Hospital of Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang, China.
FAU - Jin, Jingfen
AU  - Jin J
AD  - Nursing Department, The Second Affiliated Hospital of Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang, China zrjzkhl@zju.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03702452
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Brain Ischemia
MH  - China
MH  - Humans
MH  - *Ischemic Stroke
MH  - Randomized Controlled Trials as Topic
MH  - *Rehabilitation Nursing
MH  - *Stroke
MH  - *Stroke Rehabilitation
PMC - PMC7520831
OTO - NOTNLM
OT  - *motor function
OT  - *nursing
OT  - *rehabilitation
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037391 [pii]
AID - 10.1136/bmjopen-2020-037391 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e037391. doi: 10.1136/bmjopen-2020-037391.


PMID- 32978193
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210924
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Cadaveric simulation versus standard training for postgraduate trauma and
      orthopaedic surgical trainees: protocol for the CAD:TRAUMA study multicentre
      randomised controlled educational trial.
PG  - e037319
LID - 10.1136/bmjopen-2020-037319 [doi]
AB  - INTRODUCTION: The quantity and quality of surgical training in the UK has been
      negatively affected by reduced working hours and National Health Service (NHS)
      financial pressures. Traditionally surgical training has occurred by the
      master-apprentice model involving a process of graduated responsibility, but a
      modern alternative is to use simulation for the early stages of training. It is
      not known if simulation training for junior trainees can safeguard patients and
      improve clinical outcomes. This paper details the protocol for a multicentre
      randomised controlled educational trial of a cadaveric simulation training
      intervention versus standard training for junior postgraduate orthopaedic
      surgeons-in-training. This is the first study to assess the effect of cadaveric
      simulation training for open surgery on patient outcome. The feasibility of
      delivering cadaveric training, use of radiographic and clinical outcome measures 
      to assess impact and the challenges of upscaling provision will be explored.
      METHODS AND ANALYSIS: We will recruit postgraduate orthopaedic
      surgeons-in-training in the first 3 years (of 8) of the specialist training
      programme. Participants will be block randomised and allocated to either
      cadaveric simulation or standard 'on-the-job' training, learning three common
      orthopaedic procedures, each of which is a substudy within the trial. The
      procedures are (1) dynamic hip screw, (2) hemiarthroplasty and (3) ankle fracture
      fixation. These procedures have been selected as they are very common procedures 
      which are routinely performed by junior surgeons-in-training. A pragmatic
      approach to sample size is taken in lieu of a formal power calculation as this is
      novel exploratory work with no a priori estimate of effect size to reference. The
      primary outcome measure is the technical success of the surgery performed on
      patients by the participating surgeons-in-training during the follow-up period
      for the three substudy procedures, as measured by the implant position on the
      postoperative radiograph. The secondary outcome measures are procedure time,
      postoperative complication rate and patient health state at 4 months
      postoperation (EQ-5D-substudies 1 and 2 only). ETHICS, REGISTRATION AND
      DISSEMINATION: National research ethics approval was granted for this study by
      the NHS Research Authority South Birmingham Research Ethics Committee
      (15/WM/0464). Confidentiality Advisory Group approval was granted for accessing
      radiographic and outcome data without patient consent on 27 February 2017
      (16/CAG/0125). The results of this trial will be submitted to a peer-reviewed
      journal and will inform educational and clinical practice. TRIAL REGISTRATION
      NUMBER: ISRCTN20431944.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - James, Hannah K
AU  - James HK
AUID- ORCID: 0000-0002-0535-3062
AD  - Clinical Trials Unit, University of Warwick, Warwick Medical School, Coventry, UK
      h.smith.1@warwick.ac.uk.
AD  - Trauma & Orthopaedic Surgery, University Hospitals Coventry and Warwickshire NHS 
      Trust, Coventry, UK.
FAU - Pattison, Giles T R
AU  - Pattison GTR
AD  - Trauma & Orthopaedic Surgery, University Hospitals Coventry and Warwickshire NHS 
      Trust, Coventry, UK.
FAU - Fisher, Joanne D
AU  - Fisher JD
AD  - Clinical Trials Unit, University of Warwick, Warwick Medical School, Coventry,
      UK.
FAU - Griffin, Damian
AU  - Griffin D
AD  - Clinical Trials Unit, University of Warwick, Warwick Medical School, Coventry,
      UK.
AD  - Trauma & Orthopaedic Surgery, University Hospitals Coventry and Warwickshire NHS 
      Trust, Coventry, UK.
LA  - eng
GR  - 20485/VAC_/Versus Arthritis/United Kingdom
GR  - 20845/VAC_/Versus Arthritis/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cadaver
MH  - *Hemiarthroplasty
MH  - *Hip Fractures/surgery
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Orthopedics
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
PMC - PMC7520841
OTO - NOTNLM
OT  - *medical education & training
OT  - *orthopaedic & trauma surgery
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037319 [pii]
AID - 10.1136/bmjopen-2020-037319 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e037319. doi: 10.1136/bmjopen-2020-037319.


PMID- 32978192
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Public health programmes to promote mental health in young people: a systematic
      integrative review protocol.
PG  - e037241
LID - 10.1136/bmjopen-2020-037241 [doi]
AB  - INTRODUCTION: In light of the ever-growing mental health disease burden among
      young people worldwide, we aim to systematically review the global literature to 
      identify the public health programmes targeted at promoting mental health and
      well-being in young people, the reported/anticipated mental health-related
      outcomes of the implemented public health programmes and the reported
      facilitators and barriers in relation to the implementation of those public
      health programmes. METHODS AND ANALYSIS: A comprehensive literature search will
      be carried out in the following electronic bibliographic databases: MEDLINE,
      EMBASE, PsycINFO, Scopus, ASSIA, Web of Science, Global Health, AMED, Health
      Source and The Cochrane Library. Further, a manual search of the reference lists 
      of eligible studies and reviews will be carried out. The search strategy will
      include combinations of three key blocks of terms, namely: 'young people',
      'mental health' and 'public health programme', using database-specific subject
      headings and text words. Two reviewers will independently screen, assess data
      quality and extract data for synthesis. Disagreements at any stage will be
      resolved by consensus with the involvement of a third reviewer. Given the
      anticipated methodological pluralism of the potential eligible studies, we will
      provide a narrative synthesis of the findings on public health programmes aimed
      at promoting the mental health and well-being of young people according to
      identified thematic areas. Furthermore, a narrative synthesis of the reported
      facilitators and barriers in relation to the implementation of public health
      programmes will be provided. ETHICS AND DISSEMINATION: Given that the review
      findings will be focused on understanding the breadth and depth of the global
      research into public health programmes to promote mental health in young people
      with a particular emphasis on the facilitators and barriers of programmatic
      implementation, the findings will be of great value to inform future
      interventions, programmes and approaches to promote mental health and well-being 
      of young people worldwide. PROSPERO REGISTRATION NUMBER: CRD42018099551.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wickramasinghe, Nuwan Darshana
AU  - Wickramasinghe ND
AUID- ORCID: 0000-0001-6025-6022
AD  - Department of Community Medicine, Faculty of Medicine and Allied Sciences,
      Rajarata University of Sri Lanka, Saliyapura, Sri Lanka nuwick74@yahoo.com.
AD  - Cambridge Public Health, University of Cambridge, Cambridge, United Kingdom.
FAU - Samarutilake, Nelum
AU  - Samarutilake N
AD  - Cambridge Public Health, University of Cambridge, Cambridge, United Kingdom.
AD  - Ministry of Health, Nutrition and Indigenous Medicine, Colombo, Sri Lanka.
FAU - Wettasinghe, Mihiri Chami
AU  - Wettasinghe MC
AD  - Department of Radiology, Teaching Hospital Kandy, Kandy, Sri Lanka.
FAU - Feiler, Julie
AU  - Feiler J
AD  - Glasgow Caledonian University London, London, United Kingdom.
FAU - Morgan, Antony
AU  - Morgan A
AD  - Glasgow Caledonian University London, London, United Kingdom.
FAU - Kousoulis, Antonis A
AU  - Kousoulis AA
AD  - Mental Health Foundation, London, United Kingdom.
FAU - Van Bortel, Tine
AU  - Van Bortel T
AUID- ORCID: 0000-0003-0467-6393
AD  - Cambridge Public Health, University of Cambridge, Cambridge, United Kingdom.
AD  - Faculty of Health and Life Sciences, De Montfort University, Leicester, United
      Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Delivery of Health Care
MH  - Global Health
MH  - Humans
MH  - *Mental Disorders/epidemiology
MH  - *Mental Health
MH  - Public Health
MH  - Systematic Reviews as Topic
PMC - PMC7520825
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037241 [pii]
AID - 10.1136/bmjopen-2020-037241 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e037241. doi: 10.1136/bmjopen-2020-037241.


PMID- 32978191
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a
      study protocol for an observational study.
PG  - e037188
LID - 10.1136/bmjopen-2020-037188 [doi]
AB  - INTRODUCTION: Cardiogenic shock is a condition of low cardiac output that
      represents the end stage of a progressive deterioration of cardiac function. The 
      main cause is ischaemic heart disease, but there are several non-ischaemic
      causes, including sepsis. The use of levosimendan in cardiogenic shock during
      sepsis is still under debate. METHODS: We are conducting an observational,
      single-centre, not-for-profit study enrolling patients aged 18-80 years old
      admitted to the intensive care unit with a diagnosis of septic shock. Patients
      will be monitored with the EV1000/VolumeView device (Edwards Lifesciences,
      Irvine, USA). Patients with cardiac index (CI) values <2.5 L/min/m(2) and/or
      stroke volume index (SVI) <30 mL/beat/m(2) are considered eligible for the study.
      Enrolled participants will undergo an echocardiographic examination using the
      Vivid S6 ultrasound machine (General Electric, Northville, Michigan) and a 3.6
      MHz cardiology probe through which the apical projections of chambers 2, 3 and 4 
      will be acquired; this is necessary to calculate the global longitudinal strain
      (GLS) using EchoPAC* Clinical Workstation Software (General Electric). A
      dobutamine infusion will be started in these patients; 24 hours later CI and SVI 
      will be recalculated using EV1000/VolumeView and then a levosimendan infusion
      will begin for 24 hours. Once the infusion cycle of the calcium-sensitising drug 
      has been carried out, the infusion of dobutamine will be reduced until it stops, 
      and the CI, SVI, GLS and arterial elastance (Ea):Ventricular Elastance (Ees) will
      be re-evaluated. The primary endpoint is recovery of GLS >/=15% and the secondary
      endpoint is a relative reduction in mortality of 15%. ETHICS AND DISSEMINATION:
      The investigators declare that the study will be conducted in full compliance
      with international regulations (EU Directive 2016/679/EC) and national
      implementation (DM 15 July 1997; 211/2003; 200/2007) regarding the clinical trial
      and the principles of the Declaration of Helsinki. Study results will be
      disseminated through peer-reviewed journals and conferences. Ethical approval for
      this study has been given by Comitato Etico Regione Toscana - Area Vasta Centro, 
      Florence, Italy (ethical committee number: 13875_oss) on 25 May 2019 (Chairperson
      Professor Marco Marchi). TRIAL REGISTRATION NUMBER: NCT04141410.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cappellini, Iacopo
AU  - Cappellini I
AUID- ORCID: 0000-0001-9596-458X
AD  - Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda
      USL Toscana Centro, Prato, Italy iacopo.cappellini@uslcentro.toscana.it.
FAU - Melai, Alessandra
AU  - Melai A
AD  - Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda
      USL Toscana Centro, Prato, Italy.
FAU - Zamidei, Lucia
AU  - Zamidei L
AD  - Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda
      USL Toscana Centro, Prato, Italy.
FAU - Parise, Maddalena
AU  - Parise M
AD  - Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda
      USL Toscana Centro, Prato, Italy.
FAU - Cipani, Simone
AU  - Cipani S
AD  - Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda
      USL Toscana Centro, Figline Valdarno, Italy.
FAU - Consales, Guglielmo
AU  - Consales G
AD  - Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda
      USL Toscana Centro, Prato, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT04141410
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Humans
MH  - Italy
MH  - Michigan
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - *Sepsis/drug therapy
MH  - *Shock, Septic/drug therapy
MH  - Simendan
MH  - Young Adult
PMC - PMC7520838
OTO - NOTNLM
OT  - *cardiogenic shock
OT  - *levosimendan
OT  - *sepsis
OT  - *septic shock
OT  - *speckle tracking echocardiography
COIS- Competing interests: This trial has been designed independently of any commercial
      organisation and will be independently coordinated, managed and analysed.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037188 [pii]
AID - 10.1136/bmjopen-2020-037188 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e037188. doi: 10.1136/bmjopen-2020-037188.


PMID- 32978188
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Efficacy of acupuncture versus sham acupuncture or waitlist control for patients 
      with chronic plantar fasciitis: study protocol for a two-centre randomised
      controlled trial.
PG  - e036773
LID - 10.1136/bmjopen-2020-036773 [doi]
AB  - INTRODUCTION: Plantar fasciitis (PF) is reported to be the most common cause of
      plantar heel pain. Acupuncture has been used for patients experiencing PF, but
      evidence of the efficacy of acupuncture on PF is limited. The primary objective
      of this trial is to compare combined acupuncture and sham acupuncture (SA) versus
      waitlist control for improving the level of pain experienced by patients
      suffering from chronic PF. METHODS AND ANALYSIS: This will be a two-centre,
      parallel-group, sham and no-treatment controlled, assessor-blinded randomised
      trial. We will randomly allocate 120 participants with chronic PF to acupuncture,
      SA and waitlist control groups at a ratio of 2:1:1. Participants in the
      acupuncture and SA groups will receive a 30 min acupuncture or SA treatment for a
      total of 12 sessions over 4 weeks, with a 12-week follow-up. Participants in the 
      waitlist control group will not undergo treatment for a period of 16 weeks but
      instead will have the option of 4 weeks (12 sessions) of acupuncture free of
      charge at the end of the follow-up period. The primary outcome will be the
      treatment response rate 4 weeks after randomisation, assessed as a minimum of 50%
      improvement in the worst pain intensity during the first steps in the morning
      compared with the baseline. All analyses will be performed with a two-sided p
      value of <0.05 considered significant following the intention-to-treat principle.
      ETHICS AND DISSEMINATION: The study has been approved by the Ethical Committee of
      the Guang'anmen Hospital, China Academy of Chinese Medical Sciences (approval no.
      2019-210-KY). The results will be disseminated through presentation at a
      peer-reviewed medical journal, the relevant conferences and scientific meetings. 
      TRIAL REGISTRATION: NCT04185259.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Weiming
AU  - Wang W
AD  - Acupuncture and Moxibustion Department, China Academy of Traditional Chinese
      Medicine Guang'anmen Hospital, Xicheng District, China.
FAU - Liu, Sixing
AU  - Liu S
AD  - School of Acupuncture-Moxibustion and Tuina, Guizhou University of Traditional
      Chinese Medicine, Guiyang City, Guizhou, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen 
      Hospital, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zang, Zhiwei
AU  - Zang Z
AD  - Department of Acupuncture, Yantai Hospital of Traditional Chinese Medicine,
      Yantai, China.
FAU - Zhang, Weina
AU  - Zhang W
AD  - Acupuncture and Moxibustion Department, China Academy of Traditional Chinese
      Medicine Guang'anmen Hospital, Xicheng District, China.
FAU - Li, Liang
AU  - Li L
AD  - Department of Ultrasound, China Academy of Chinese Medical Sciences Guanganmen
      Hospital, Xicheng District, Beijing, China.
FAU - Liu, Zhishun
AU  - Liu Z
AUID- ORCID: 0000-0001-7570-8917
AD  - Acupuncture and Moxibustion Department, China Academy of Traditional Chinese
      Medicine Guang'anmen Hospital, Xicheng District, China zhishunjournal@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04185259
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - China
MH  - *Fasciitis, Plantar/therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Waiting Lists
PMC - PMC7520861
OTO - NOTNLM
OT  - *clinical trials
OT  - *complementary medicine
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036773 [pii]
AID - 10.1136/bmjopen-2020-036773 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e036773. doi: 10.1136/bmjopen-2020-036773.


PMID- 32978185
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Enhanced Recovery after Intensive Care (ERIC): study protocol for a German
      stepped wedge cluster randomised controlled trial to evaluate the effectiveness
      of a critical care telehealth program on process quality and functional outcomes.
PG  - e036096
LID - 10.1136/bmjopen-2019-036096 [doi]
AB  - INTRODUCTION: Survival after critical illness has noticeably improved over the
      last decades due to advances in critical care medicine. Besides, there is an
      increasing number of elderly patients with chronic diseases being treated in the 
      intensive care unit (ICU). More than half of the survivors of critical illness
      suffer from medium-term or long-term cognitive, psychological and/or physical
      impairments after ICU discharge, which is recognised as post-intensive care
      syndrome (PICS). There are evidence-based and consensus-based quality indicators 
      (QIs) in intensive care medicine, which have a positive influence on patients'
      long-term outcomes if adhered to. METHODS AND ANALYSIS: The protocol of a
      multicentre, pragmatic, stepped wedge cluster randomised controlled, quality
      improvement trial is presented. During 3 predefined steps, 12 academic hospitals 
      in Berlin and Brandenburg, Germany, are randomly selected to move in a one-way
      crossover from the control to the intervention condition. After a multifactorial 
      training programme on QIs and clinical outcomes for site personnel, ICUs will
      receive an adapted, interprofessional protocol for a complex telehealth
      intervention comprising of daily telemedical rounds at ICU. The targeted sample
      size is 1431 patients. The primary objective of this trial is to evaluate the
      effectiveness of the intervention on the adherence to eight QIs daily measured
      during the patient's ICU stay, compared with standard of care. Furthermore, the
      impact on long-term recovery such as PICS-related, patient-centred outcomes
      including health-related quality of life, mental health, clinical assessments of 
      cognition and physical function, all-cause mortality and cost-effectiveness 3 and
      6 months after ICU discharge will be evaluated. ETHICS AND DISSEMINATION: This
      protocol was approved by the ethics committee of the Charite-Universitatsmedizin,
      Berlin, Germany (EA1/006/18). The results will be published in a peer-reviewed
      scientific journal and presented at international conferences. Study findings
      will also be disseminated via the website (www.eric-projekt.net). TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03671447).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Adrion, Christine
AU  - Adrion C
AUID- ORCID: 0000-0003-2408-2533
AD  - Institute for Medical Information Processing, Biometry and Epidemiology,
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Weiss, Bjoern
AU  - Weiss B
AUID- ORCID: 0000-0003-3139-595X
AD  - Department of Anesthesiology and Operative Intensive Care Medicine,
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Paul, Nicolas
AU  - Paul N
AUID- ORCID: 0000-0003-2228-3980
AD  - Department of Anesthesiology and Operative Intensive Care Medicine,
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Berger, Elke
AU  - Berger E
AD  - Department of Health Care Management, Technical University of Berlin, Berlin,
      Germany.
FAU - Busse, Reinhard
AU  - Busse R
AUID- ORCID: 0000-0003-4961-9130
AD  - Department of Health Care Management, Technical University of Berlin, Berlin,
      Germany.
FAU - Marschall, Ursula
AU  - Marschall U
AD  - BARMER, Wuppertal, Germany.
FAU - Caumanns, Jorg
AU  - Caumanns J
AD  - Fraunhofer Institute for Open Communication Systems, Berlin, Germany.
FAU - Rosseau, Simone
AU  - Rosseau S
AD  - Weaning and Ventilation Centre, Ernst von Bergmann Klinikum, Bad Belzig, Germany.
FAU - Mansmann, Ulrich
AU  - Mansmann U
AUID- ORCID: 0000-0002-9955-8906
AD  - Institute for Medical Information Processing, Biometry and Epidemiology,
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Spies, Claudia
AU  - Spies C
AUID- ORCID: 0000-0002-1062-0495
AD  - Department of Anesthesiology and Operative Intensive Care Medicine,
      Charite-Universitatsmedizin Berlin, Berlin, Germany claudia.spies@charite.de.
CN  - ERIC study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03671447
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - postintensive care syndrome
SB  - IM
MH  - Aged
MH  - Berlin
MH  - Critical Care
MH  - Critical Illness
MH  - Germany
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Telemedicine
PMC - PMC7520839
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *clinical trials
OT  - *health economics
OT  - *medical education & training
OT  - *quality in health care
OT  - *telemedicine
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding 
      author) and declare: All authors report grants from the German Innovation Fund of
      the Federal Joint Committee (G-BA), during the conduct of the study. CS reports
      grants from Aridis Pharmaceutical, grants from B. Braun Melsungen AG, grants from
      Dragerwerk AG & Co. KGaA, grants from Grunenthal GmbH, grants from Infectopharm
      GmbH, grants from Sedana Medical, grants from Deutsche
      Forschungsgemeinschaft/German Research Foundation, grants from Deutsches Zentrum 
      fur Luft- und Raumfahrt e. V. (DLR)/German Aerospace Center, grants from Einstein
      Stiftung Berlin/ Einstein Foundation Berlin, grants from European Society of
      Anaesthesiology, grants from Gemeinsamer Bundesausschuss/G-BA, grants from
      Inneruniversitare Forschungsforderung/Inner University Grants, grants from
      Projekttrager im DLR/Project Management Agency, grants from
      Stifterverband/Non-Profit Society Promoting Science and Education, grants from
      WHOCC, grants from Baxter Deutschland GmbH, grants from Biotest AG, grants from
      Cytosorbents Europe GmbH, grants from Edwards Lifesciences Germany GmbH, grants
      from Fresenius Medical Care, grants from Grunenthal GmbH, grants from Masimo
      Europe, grants from Medtronic GmbH, grants from Pfizer Pharma PFE GmbH, personal 
      fees from Georg Thieme Verlag, grants from Dr. F. Kohler Chemie GmbH, grants from
      Sintetica GmbH, grants from European Commission, grants from Stifterverband fur
      die deutsche Wissenschaft e.V. /Philips, grants from Stiftung Charite, outside
      the submitted work. In addition, CS has a patent 10 2014 215 211.9 pending, a
      patent application no. PCT/EP2015/067730 pending to Graft Gesellschaft von
      Architekten mbH, and a patent application no. PCT/EP2015/067731 pending to Graft 
      Gesellschaft von Architekten mbH. BW reports personal fees from Orion Pharma,
      outside the submitted work.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036096 [pii]
AID - 10.1136/bmjopen-2019-036096 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e036096. doi: 10.1136/bmjopen-2019-036096.


PMID- 32978183
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Oral health improvement for nursing home residents through delegated remotivation
      and reinstruction (MundZaRR Study): study protocol of a cluster-randomised
      controlled trial.
PG  - e035999
LID - 10.1136/bmjopen-2019-035999 [doi]
AB  - INTRODUCTION: Oral health and oral health-related quality of life (OHrQL) of
      residents in German long-term residential care (LRC) are poor. We will develop an
      evidence-based catalogue of interventions ('Oral Health Toolbox') and provide
      care-accompanying reinstruction and remotivation of nursing staff by dental
      assistants (DA). We hypothesise that such intervention will significantly improve
      OHrQL, daily oral hygiene/care behaviour and is cost-effective. METHODS AND
      ANALYSIS: A scoping review will be used to identify possible intervention
      components. Mixed methods will be used to identify barriers and enablers of oral 
      hygiene and care in German LRC. The result will be the 'Oral Health Toolbox', a
      two-phased instrument supporting both initial intervention allocation to improve 
      oral health/hygiene and reinstruction/remotivation. A two-arm clustered,
      randomised controlled trial (ratio of 1:1 via block randomisation) will be
      performed in LRC in Rhineland-Palatinate, Germany. Each nursing home represents a
      cluster. Based on a feasibility study, considering clustering and possible
      attrition, we aim at recruiting 618 residents in 18 clusters. In the intervention
      group, dentists will assign one or more intervention component from the box
      (phase 1). During follow-up, nursing staff will be reinstructed and remotivated
      by DA, who use the box to decide how to maintain the intervention (phase 2). In
      the control group residents will receive care as usual. The primary outcome,
      OHrQL, will be measured using the General Oral Health Assessment Index. Secondary
      outcomes include pain condition, general health-related quality of life, caries
      increment, oral/prosthetic hygiene and gingival status, incidence of dental
      emergencies and hospitalisations, and cost-utility/effectiveness. The endpoints
      will be measured at baseline and after 12 months. For our primary outcome, a
      mixed-linear model will be used within an intention-to-treat analysis. A process 
      evaluation using mixed methods will be conducted alongside the trial. ETHICS AND 
      DISSEMINATION: Ethical approval by the University of Kiel was granted (D480/18). 
      TRIAL REGISTRATION NUMBER: NCT04140929.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hertrampf, Katrin
AU  - Hertrampf K
AD  - Clinic of Oral and Maxillofacial Surgery, University Hospital Schleswig-Holstein,
      Kiel, Germany.
FAU - Schlattmann, Peter
AU  - Schlattmann P
AD  - Medical Statistics, Computer and DataSciences, Friedrich-Schiller-Universitat
      Jena, Jena, Germany.
FAU - Meyer, Gabriele
AU  - Meyer G
AD  - Institute for Health Care and Nursing Studies, University Halle, Halle/Saale,
      Germany.
FAU - Gassmann, Georg
AU  - Gassmann G
AD  - praxisHochschule pHfG Tragergesellschaft, praxisHochschule University of Applied 
      Sciences, Cologne, Germany.
FAU - Abraham, Jens
AU  - Abraham J
AD  - Institute for Health Care and Nursing Studies, University Halle, Halle/Saale,
      Germany.
FAU - Hammen, Volker
AU  - Hammen V
AD  - praxisHochschule University of Applied Sciences, praxisHochschule University of
      Applied Sciences, Cologne, Germany.
FAU - Schwendicke, Falk
AU  - Schwendicke F
AUID- ORCID: 0000-0003-1223-1669
AD  - Zahnerhaltung, Charite Universitatsmediz in Berlin Campus Benjamin Franklin,
      Berlin, Germany falk.schwendicke@charite.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT04140929
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Germany
MH  - Humans
MH  - Long-Term Care
MH  - Nursing Homes
MH  - *Oral Health
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7520860
OTO - NOTNLM
OT  - *cluster-randomized clinical trial
OT  - *health services research
OT  - *nursing homes
OT  - *oral hygiene
OT  - *quality of life
OT  - *study protocol
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035999 [pii]
AID - 10.1136/bmjopen-2019-035999 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e035999. doi: 10.1136/bmjopen-2019-035999.


PMID- 32978182
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 25
TI  - Effects of home-based mirror therapy and cognitive therapeutic exercise on the
      improvement of the upper extremity functions in patients with severe hemiparesis 
      after a stroke: a protocol for a pilot randomised clinical trial.
PG  - e035768
LID - 10.1136/bmjopen-2019-035768 [doi]
AB  - INTRODUCTION: Neuroplasticity is defined as the capacity of the brain to
      reorganise new neuronal pathways. Mirror therapy (MT) and cognitive therapeutic
      exercise (CTE) are two neurorehabilitation techniques based on neuroplasticity
      and designed to improve the motor functions of the affected upper extremity in
      patients with severe hemiparesis after a stroke. Home-based interventions are an 
      appropriate alternative to promote independence and autonomy. The objective of
      this study is to evaluate which of these techniques, MT and CTE, combined with
      task-oriented training, is more effective in functional recovery and movement
      patterns of the upper extremities in patients with severe hemiparesis after a
      stroke. METHODS AND ANALYSIS: This is a home-based, single-blind, controlled,
      randomised clinical trial with three parallel arms, including 154 patients who
      had a stroke aged above 18 years. The primary outcome will be the functionality
      of the affected upper extremity measured using the Fugl-Meyer Assessment.
      Secondary variables will include cognitive performance, emotional state, quality 
      of life and activities of daily living. During 6 weeks, one of the intervention
      groups will receive a treatment based on MT and the other one on CTE, both
      combined with task-oriented training. No additional interventions will be
      provided to the control group. To assess the progress of patients who had a
      stroke in the subacute phase, all variables will be evaluated at different
      visits: initial (just before starting treatment and 4 weeks post-stroke),
      post-intervention (6 weeks after initial) and follow-up (6 months). ETHICS AND
      DISSEMINATION: This protocol has been approved by the Institutional Review Board 
      (CEIm-2.134/2.019) and registered at ClinicalTrials.gov (NCT04163666). The
      results will be disseminated through open-access peer-reviewed journals,
      conference presentation, broadcast media and a presentation to stakeholders.
      These study results will provide relevant and novel information on effective
      neurorehabilitation strategies and improve the quality of intervention programmes
      aimed at patients after a stroke. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov
      (NCT04163666).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gonzalez-Santos, Josefa
AU  - Gonzalez-Santos J
AD  - Health Sciences, University of Burgos, Burgos, Spain.
FAU - Soto-Camara, Raul
AU  - Soto-Camara R
AUID- ORCID: 0000-0002-9072-0364
AD  - Health Sciences, University of Burgos, Burgos, Spain rscamara@ubu.es.
FAU - Rodriguez-Fernandez, Paula
AU  - Rodriguez-Fernandez P
AD  - Health Sciences, University of Burgos, Burgos, Spain.
FAU - Jimenez-Barrios, Maria
AU  - Jimenez-Barrios M
AD  - Health Sciences, University of Burgos, Burgos, Spain.
FAU - Gonzalez-Bernal, Jeronimo
AU  - Gonzalez-Bernal J
AD  - Health Sciences, University of Burgos, Burgos, Spain.
FAU - Collazo-Riobo, Carla
AU  - Collazo-Riobo C
AD  - Health Sciences, University of Burgos, Burgos, Spain.
FAU - Jahouh, Maha
AU  - Jahouh M
AD  - Health Sciences, University of Burgos, Burgos, Spain.
FAU - Bravo-Anguiano, Yolanda
AU  - Bravo-Anguiano Y
AD  - Neurology, Burgos University Hospital, Burgos, Spain.
FAU - Trejo-Gabriel-Galan, Jose M
AU  - Trejo-Gabriel-Galan JM
AD  - Neurology, Burgos University Hospital, Burgos, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04163666
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Cognition
MH  - Humans
MH  - Motor Activity
MH  - Paresis/etiology/therapy
MH  - Pilot Projects
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Single-Blind Method
MH  - *Stroke/complications
MH  - *Stroke Rehabilitation
MH  - Treatment Outcome
MH  - Upper Extremity
PMC - PMC7520843
OTO - NOTNLM
OT  - *neurology
OT  - *rehabilitation medicine
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/09/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/26 05:24
PHST- 2020/09/26 05:24 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035768 [pii]
AID - 10.1136/bmjopen-2019-035768 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 25;10(9):e035768. doi: 10.1136/bmjopen-2019-035768.


PMID- 32977846
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Sep 25
TI  - Prevalence, seroconversion and mother-to-child transmission of dual and triplex
      infections of HIV, hepatitis B and C viruses among pregnant women in Nigeria:
      study protocol.
PG  - 144
LID - 10.1186/s12978-020-00995-8 [doi]
AB  - BACKGROUND: Nigeria contributes significantly to the global burden of HIV,
      Hepatitis B and C infections, either singly or in combinations, despite progress 
      in HIV care regionally and globally. Although some limited data on mono infection
      of HIV, Hepatitis B and C virus infections do exists, that of dual and triplex
      infections, including seroconversion and mother-to-child transmission (MTCT)
      rates necessary for planning to address the scourge of infections in pregnancy
      are not available. OBJECTIVES: To determine the seroprevalence, rate of new
      infections, MTCT of dual and triple infections of HIV, Hepatitis B and C viruses 
      and associated factors, among pregnant women in Nigeria. METHOD: A multicenter
      prospective cohort study will be conducted in six tertiary health facilities
      randomly selected from the six geopolitical zones of Nigeria. All eligible
      pregnant women are to be tested at enrollment after informed consent for HIV,
      Hepatitis B and C virus infections. While those positive for at least two of the 
      infections in any combination will be enrolled into the study and followed up to 
      6 weeks post-delivery, those negative for the three infections or positive for
      only one of the infections at enrolment will be retested at delivery using a
      rapid diagnostic test. On enrolment into the study relevant information, will be 
      obtained, and laboratory test of CD4 count, liver function test and full blood
      counts, and prenatal ultrasonography will also be obtained/performed. Management 
      of mother-newborns pairs will be according to appropriate national guidelines.
      All exposed newborns will be tested for HIV, HBV or HCV infection at birth and 6 
      weeks using PCR technique. The study data will be documented on the study case
      record forms. Data will be managed with SPSS for windows version 23. Ethical
      approval was obtained from National Health Research Ethics Committee (NHREC)
      (NHREC/01/01/2007-23/01/2020). CONCLUSION: Pregnant women with multiple of HIV,
      HBV and HCV infections are at increased risk of hepatotoxicity, maternal and
      perinatal morbidity and mortality. Additionally, infected pregnant women transmit
      the virus to their unborn baby even when asymptomatic. Children born with any of 
      the infection have significantly poorer quality of life and lower five-year
      survival rate. Unfortunately, the seroconversion and MTCT rates of dual or
      triplex infections among pregnant women in Nigeria have not been studied making
      planning for prevention and subsequent elimination of the viruses difficult. The 
      study is expected to fill this knowledge gaps. Nigeria joining the rest of the
      world to eliminate the triple infection among children rest on the availability
      of adequate and reliable data generated from appropriately designed, and powered 
      study using representative population sample. The establishment of the
      three-in-one study of prevalence, rate of new infection, rate and risk factor for
      MTCT of dual and triple infection of HIV, Hepatitis B and C viruses among
      pregnant women in Nigeria is urgently needed for policy development and planning 
      for the improvement of the quality of life of mothers and the elimination of
      childhood triplex infection.
FAU - Eleje, George Uchenna
AU  - Eleje GU
AUID- ORCID: https://orcid.org/0000-0002-0390-2152
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University, Awka,
      Nigeria. georgel21@yahoo.com.
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching
      Hospital, PMB 5025, Nnewi, Anambra State, Nigeria. georgel21@yahoo.com.
FAU - Mbachu, Ikechukwu Innocent
AU  - Mbachu II
AUID- ORCID: https://orcid.org/0000-0001-7779-4388
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University, Awka,
      Nigeria.
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching
      Hospital, PMB 5025, Nnewi, Anambra State, Nigeria.
FAU - Ogwaluonye, Uchenna Chukwunonso
AU  - Ogwaluonye UC
AUID- ORCID: https://orcid.org/0000-0001-6108-5165
AD  - Department of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Nigeria.
FAU - Kalu, Stephen Okoroafor
AU  - Kalu SO
AUID- ORCID: https://orcid.org/0000-0002-7354-5971
AD  - HIV Care Laboratory/HIV Care Department, Nnamdi Azikiwe University Teaching
      Hospital, Nnewi, Nigeria.
FAU - Onubogu, Chinyere Ukamaka
AU  - Onubogu CU
AUID- ORCID: https://orcid.org/0000-0002-5277-6914
AD  - Department of Paediatrics, Nnamdi Azikiwe University, Awka, Nigeria.
FAU - Nweje, Sussan Ifeyinwa
AU  - Nweje SI
AUID- ORCID: https://orcid.org/0000-0003-1239-3617
AD  - Department of Nursing, Nnamdi Azikiwe University Teaching Hospital, Nnewi,
      Nigeria.
FAU - Uzochukwu, Chinwe Elizabeth
AU  - Uzochukwu CE
AUID- ORCID: https://orcid.org/0000-0001-9919-798X
AD  - Department of Mass Communication, Nnamdi Azikiwe University, Awka, Nigeria.
FAU - Nwankwo, Chike Henry
AU  - Nwankwo CH
AUID- ORCID: https://orcid.org/0000-0002-0182-4373
AD  - Department of Statistics, Nnamdi Azikiwe University, Awka, Nigeria.
FAU - Fiebai, Preye Owen
AU  - Fiebai PO
AUID- ORCID: https://orcid.org/0000-0002-4136-4690
AD  - Department of Obstetrics and Gynecology, University of Port Harcourt,
      PortHarcourt, Nigeria.
AD  - Department of Obstetrics and Gynecology, University of Port Harcourt Teaching
      Hospital, PortHarcourt, Nigeria.
FAU - Loto, Olabisi Morebise
AU  - Loto OM
AUID- ORCID: https://orcid.org/0000-0001-8905-1442
AD  - Department of Obstetrics and Gynecology, Obafemi Awolowo University, Ile Ife,
      Nigeria.
AD  - Department of Obstetrics and Gynecology, Obafemi Awolowo University Teaching
      Hospital Complex, Ile-Ife, Nigeria.
FAU - Akaba, Godwin Otuodichinma
AU  - Akaba GO
AUID- ORCID: https://orcid.org/0000-0002-8149-5492
AD  - Department of Obstetrics and Gynecology, University of Abuja, Abuja, Nigeria.
AD  - Department of Obstetrics and Gynecology, University of Abuja Teaching Hospital,
      Abuja, Nigeria.
FAU - Usman, Hadiza Abdullahi
AU  - Usman HA
AUID- ORCID: https://orcid.org/0000-0002-0817-5388
AD  - Department of Obstetrics and Gynecology, University of Maiduguri, Maiduguri,
      Nigeria.
AD  - Department of Obstetrics and Gynecology, University of Maiduguri Teaching
      Hospital, Maiduguri, Nigeria.
FAU - Rabiu, Ayyuba
AU  - Rabiu A
AUID- ORCID: https://orcid.org/0000-0003-1398-9121
AD  - Department of Obstetrics and Gynecology, Bayero University, Kano, Nigeria.
AD  - Department of Obstetrics and Gynecology, Aminu Kano Teaching Hospital, Kano,
      Nigeria.
FAU - Egeonu, Richard Obinwanne
AU  - Egeonu RO
AUID- ORCID: https://orcid.org/0000-0003-2680-3955
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching
      Hospital, PMB 5025, Nnewi, Anambra State, Nigeria.
FAU - Igue, Odion Emmanuel
AU  - Igue OE
AUID- ORCID: https://orcid.org/0000-0002-2027-416X
AD  - Department of Physiological Sciences, Obafemi Awolowo University, Ile-Ife,
      Nigeria.
FAU - Adesoji, Bukola Abimbola
AU  - Adesoji BA
AUID- ORCID: https://orcid.org/0000-0001-5624-0159
AD  - Department of Nursing, Obafemi Awolowo University Teaching Hospital Complex,
      Ile-Ife, Nigeria.
FAU - Jibuaku, Chiamaka Henrietta
AU  - Jibuaku CH
AUID- ORCID: https://orcid.org/0000-0002-3241-9338
AD  - Department of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Nigeria.
FAU - Aja, Prince Ogbonnia
AU  - Aja PO
AUID- ORCID: https://orcid.org/0000-0002-6349-906X
AD  - Immunology Unit, Department of Medical Laboratory Science, Nnamdi Azikiwe
      University, Awka, Nigeria.
FAU - Chidozie, Chiamaka Perpetua
AU  - Chidozie CP
AUID- ORCID: https://orcid.org/0000-0002-8858-0390
AD  - Immunology Unit, Department of Medical Laboratory Science, Nnamdi Azikiwe
      University, Awka, Nigeria.
FAU - Ibrahim, Hadiza Sani
AU  - Ibrahim HS
AUID- ORCID: https://orcid.org/0000-0003-2572-9650
AD  - Department of Obstetrics and Gynecology, Aminu Kano Teaching Hospital, Kano,
      Nigeria.
FAU - Aliyu, Fatima Ele
AU  - Aliyu FE
AUID- ORCID: https://orcid.org/0000-0001-7613-0352
AD  - Department of Obstetrics and Gynecology, Aminu Kano Teaching Hospital, Kano,
      Nigeria.
FAU - Numan, Aisha Ismaila
AU  - Numan AI
AUID- ORCID: https://orcid.org/0000-0001-5955-0291
AD  - Department of Obstetrics and Gynecology, University of Maiduguri Teaching
      Hospital, Maiduguri, Nigeria.
FAU - Okoro, Ogbonna Dennis
AU  - Okoro OD
AUID- ORCID: https://orcid.org/0000-0002-3759-0257
AD  - Department of Parasitology & Entomology, Faculty of Veterinary Medicine,
      University of Maiduguri Borno State, Maiduguri, Nigeria.
FAU - Omoruyi, Solace Amechi
AU  - Omoruyi SA
AUID- ORCID: https://orcid.org/0000-0002-1657-4581
AD  - Department of Obstetrics and Gynecology, University of Port Harcourt Teaching
      Hospital, PortHarcourt, Nigeria.
FAU - Oppah, Ijeoma Chioma
AU  - Oppah IC
AUID- ORCID: https://orcid.org/0000-0001-6406-8280
AD  - Department of Obstetrics and Gynecology, University of Port Harcourt Teaching
      Hospital, PortHarcourt, Nigeria.
FAU - Anyang, Ubong Inyang
AU  - Anyang UI
AUID- ORCID: https://orcid.org/0000-0002-4858-9534
AD  - Department of Obstetrics and Gynecology, University of Abuja Teaching Hospital,
      Abuja, Nigeria.
FAU - Ahmed, Aishat
AU  - Ahmed A
AUID- ORCID: https://orcid.org/0000-0003-1568-4735
AD  - Department of Obstetrics and Gynecology, University of Abuja Teaching Hospital,
      Abuja, Nigeria.
FAU - Chukwurah, Shirley Nneka
AU  - Chukwurah SN
AD  - Department of Medicine, Faculty of Medicine, Nnamdi Azikiwe University, Awka,
      Nigeria.
FAU - Umeononihu, Osita Samuel
AU  - Umeononihu OS
AUID- ORCID: https://orcid.org/0000-0003-1636-3845
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University, Awka,
      Nigeria.
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching
      Hospital, PMB 5025, Nnewi, Anambra State, Nigeria.
FAU - Chukwuanukwu, Rebecca Chinyelu
AU  - Chukwuanukwu RC
AUID- ORCID: https://orcid.org/0000-0001-5023-9560
AD  - Immunology Unit, Department of Medical Laboratory Science, Nnamdi Azikiwe
      University, Awka, Nigeria.
FAU - Umeh, Eric Okechukwu
AU  - Umeh EO
AUID- ORCID: https://orcid.org/0000-0002-3217-9581
AD  - Department of Radiology, Faculty of Medicine, Nnamdi Azikiwe University, Awka,
      Nigeria.
FAU - Emeka, Ekene Agatha
AU  - Emeka EA
AUID- ORCID: https://orcid.org/0000-0001-8155-5777
AD  - Department of Family Medicine, Faculty of Medicine, Nnamdi Azikiwe University,
      Awka, Nigeria.
FAU - Ogbuagu, Chukwuanugo Nkemakonam
AU  - Ogbuagu CN
AUID- ORCID: https://orcid.org/0000-0002-6510-4746
AD  - Department of Medical Microbiology and Parasitology, Faculty of Medicine, Nnamdi 
      Azikiwe University, Awka, Nigeria.
FAU - Yakasai, Ibrahim Adamu
AU  - Yakasai IA
AUID- ORCID: https://orcid.org/0000-0003-0102-9764
AD  - Department of Obstetrics and Gynecology, Bayero University, Kano, Nigeria.
AD  - Department of Obstetrics and Gynecology, Aminu Kano Teaching Hospital, Kano,
      Nigeria.
FAU - Ezechi, Oliver Chukwujekwu
AU  - Ezechi OC
AUID- ORCID: https://orcid.org/0000-0003-0688-3898
AD  - Nigerian Institute of Medical Research, Lagos, Nigeria.
FAU - Ikechebelu, Joseph Ifeanyichukwu
AU  - Ikechebelu JI
AUID- ORCID: https://orcid.org/0000-0003-2515-8464
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University, Awka,
      Nigeria.
AD  - Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching
      Hospital, PMB 5025, Nnewi, Anambra State, Nigeria.
CN  - Triplex infection in pregnancy collaboration group
LA  - eng
GR  - TETFund/DR&D/CE/NRF/STI/33./TETFund
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
SB  - IM
MH  - Child
MH  - Coinfection/epidemiology
MH  - Female
MH  - HIV Infections/*complications/epidemiology/transmission
MH  - Hepatitis B/*complications/epidemiology/transmission
MH  - Hepatitis C/*complications/epidemiology/transmission
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/prevention & control/*statistics &
      numerical data
MH  - Multicenter Studies as Topic
MH  - Nigeria/epidemiology
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/epidemiology
MH  - Pregnant Women
MH  - Prevalence
MH  - Prospective Studies
MH  - Quality of Life
MH  - *Seroconversion
MH  - Seroepidemiologic Studies
PMC - PMC7519506
OTO - NOTNLM
OT  - Dual infection
OT  - HBV
OT  - HCV
OT  - HIV
OT  - Multiple infection
OT  - Nigeria
OT  - Seroconversion
OT  - Triplex infection
EDAT- 2020/09/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/26 05:20
PHST- 2020/09/04 00:00 [received]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/09/26 05:20 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s12978-020-00995-8 [doi]
AID - 10.1186/s12978-020-00995-8 [pii]
PST - epublish
SO  - Reprod Health. 2020 Sep 25;17(1):144. doi: 10.1186/s12978-020-00995-8.


PMID- 32977817
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210110
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 25
TI  - Healthcare managers' experiences of technostress and the actions they take to
      handle it - a critical incident analysis.
PG  - 244
LID - 10.1186/s12911-020-01261-4 [doi]
AB  - BACKGROUND: Healthcare managers, in comparison with other healthcare
      professionals, have an increased likelihood of experiencing technostress at work.
      Since knowledge about the causes and severity of technostress and about the
      strategies healthcare managers use to handle it is limited, the aim of this study
      was to describe their experience of technostress and the actions they employ to
      address it. METHODS: An explorative design based on the critical incident
      technique was used. In total, 20 healthcare managers (10 women, 10 men) from four
      hospitals in two county councils in Sweden were purposively selected according to
      professional background, hierarchical management position, control span, time in 
      the management position, and sex. Semi-structured interviews with regard to
      critical incidents and actions taken to handle technostress were conducted.
      RESULTS: Healthcare managers' experiences of technostress (n = 279) were
      categorised related to three main areas. These involved 'negative aspects of
      digital communication' (e.g. high workload, invasion of private life, and
      negative feelings related to digital communication), 'poor user experience of ICT
      systems (such as illogicality of the ICT system, time-consuming ICT system, or
      malfunctioning ICT system) and 'needs to improve organisational resources' (e.g. 
      needs associated with digital literacy, user influence and distribution of work
      and ICT systems). Actions taken to handle technostress (n=196) were described
      relating to three main areas involving 'culture, norms and social support' (such 
      as good email culture, and co-worker support), 'individual resources' (e.g.
      individual strategies and competence) and 'organisational resources' (such as
      IT-related assistance and support). CONCLUSIONS: Healthcare managers described
      negative aspects of digital communication, poor user experience of ICT systems,
      and lack of organisational resources as potential technostress creators. These
      problems were handled by taking action related to culture, norms and social
      support, and individual as well as organisational resources. All these features, 
      along with consideration of healthcare managers' job demands and resources in
      general, should be incorporated into actions monitored by healthcare
      organisations to improve or maintain a sustainable digitalised environment for
      healthcare managers. TRIAL REGISTRATION: Regional Ethics Board in Linkoping
      #2017/597-31. Registered 20 March 2018. URL not available.
FAU - Stadin, Magdalena
AU  - Stadin M
AUID- ORCID: 0000-0002-8196-1289
AD  - School of Health and Welfare, Jonkoping University, P.O. Box 1026, SE-551 11,
      Jonkoping, Sweden. magdalena.stadin@it.uu.se.
AD  - Department of Information Technology, Uppsala University, Uppsala, Sweden.
      magdalena.stadin@it.uu.se.
FAU - Nordin, Maria
AU  - Nordin M
AD  - Department of Psychology, Umea University, Umea, Sweden.
FAU - Fransson, Eleonor I
AU  - Fransson EI
AD  - School of Health and Welfare, Jonkoping University, P.O. Box 1026, SE-551 11,
      Jonkoping, Sweden.
FAU - Brostrom, Anders
AU  - Brostrom A
AD  - School of Health and Welfare, Jonkoping University, P.O. Box 1026, SE-551 11,
      Jonkoping, Sweden.
AD  - Department of Clinical Neurophysiology, Linkoping University Hospital, Linkoping,
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - Administrative Personnel/*psychology
MH  - *Crisis Intervention
MH  - Delivery of Health Care/*organization & administration
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Qualitative Research
MH  - Quality Improvement
MH  - Quality of Health Care/standards
MH  - Sweden
MH  - *Task Performance and Analysis
MH  - *Telemedicine
PMC - PMC7517792
OTO - NOTNLM
OT  - *Digitalisation
OT  - *ICT demands
OT  - *Managers
OT  - *Occupational health
OT  - *Technostress
OT  - *eHealth
EDAT- 2020/09/27 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/09/26 05:19
PHST- 2020/04/08 00:00 [received]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/09/26 05:19 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
AID - 10.1186/s12911-020-01261-4 [doi]
AID - 10.1186/s12911-020-01261-4 [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Sep 25;20(1):244. doi: 10.1186/s12911-020-01261-4.


PMID- 32977796
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 Sep 25
TI  - "Teach for ethics in palliative care": a mixed-method evaluation of a medical
      ethics training programme.
PG  - 149
LID - 10.1186/s12904-020-00653-7 [doi]
AB  - BACKGROUND: Training in medical ethics aims to educate health care professionals 
      in dealing with daily care ethical issues. To guarantee quality of life and
      spiritual and emotional support, palliative care professionals have to develop
      ethical and relational skills. We propose the implementation and evaluation of a 
      specialized training programme in medical ethics dedicated to a hospital-based
      Palliative Care Unit. METHODS: This study is a mixed-method before-after
      evaluation with data triangulation. RESULTS: The results highlight that
      participants developed their ethical knowledge, and a deeper ethical awareness.
      They also felt more confident and motivated to widely apply ethical reflections
      and reasonings in their daily practice. CONCLUSION: The participants appreciated 
      the innovative structure of the training, especially regarding the integration of
      the theoretical-interactive and practical parts. However, they recommended
      increasing the number of concrete occasions for ethical supervision and practical
      application of what they learned during the programme. The training programme
      also has some potential practical implications: the development of advanced
      ethical skills within a hospital-based PC team may improve the quality of life of
      the patients and their families. In addition, health care professionals with
      advanced ethical competencies are able to educate patients and their families
      towards more active participation in the decision-making process.
FAU - De Panfilis, Ludovica
AU  - De Panfilis L
AD  - Unit of Bioethics, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Tanzi, Silvia
AU  - Tanzi S
AD  - Palliative Care Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
AD  - PhD Program in Clinical and Experimental Medicine, University of Modena and
      Reggio Emilia, Modena, Italy.
FAU - Perin, Marta
AU  - Perin M
AUID- ORCID: http://orcid.org/0000-0003-4631-7380
AD  - Unit of Bioethics, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
      marta.perin@ausl.re.it.
AD  - PhD Program in Clinical and Experimental Medicine, University of Modena and
      Reggio Emilia, Modena, Italy. marta.perin@ausl.re.it.
FAU - Turola, Elena
AU  - Turola E
AD  - Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Artioli, Giovanna
AU  - Artioli G
AD  - Palliative Care Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
SB  - IM
MH  - Adult
MH  - Curriculum/standards/trends
MH  - Education, Medical/*methods
MH  - Ethics, Medical
MH  - Female
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Male
MH  - Middle Aged
MH  - Palliative Care/*ethics
MH  - Qualitative Research
PMC - PMC7519533
OTO - NOTNLM
OT  - Education
OT  - Ethical analyses
OT  - Ethics
OT  - Palliative care
OT  - Program evaluation
EDAT- 2020/09/27 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/09/26 05:19
PHST- 2020/06/18 00:00 [received]
PHST- 2020/09/13 00:00 [accepted]
PHST- 2020/09/26 05:19 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.1186/s12904-020-00653-7 [doi]
AID - 10.1186/s12904-020-00653-7 [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 Sep 25;19(1):149. doi: 10.1186/s12904-020-00653-7.


PMID- 32977561
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 10
DP  - 2020 Sep 23
TI  - Grimace Scores: Tools to Support the Identification of Pain in Mammals Used in
      Research.
LID - E1726 [pii]
LID - 10.3390/ani10101726 [doi]
AB  - The 3Rs, Replacement, Reduction and Refinement, is a framework to ensure the
      ethical and justified use of animals in research. The implementation of
      refinements is required to alleviate and minimise the pain and suffering of
      animals in research. Public acceptability of animal use in research is contingent
      on satisfying ethical and legal obligations to provide pain relief along with
      humane endpoints. To fulfil this obligation, staff, researchers, veterinarians,
      and technicians must rapidly, accurately, efficiently and consistently identify, 
      assess and act on signs of pain. This ability is paramount to uphold animal
      welfare, prevent undue suffering and mitigate possible negative impacts on
      research. Identification of pain may be based on indicators such as
      physiological, behavioural, or physical ones. Each has been used to develop
      different pain scoring systems with potential benefits and limitations in
      identifying and assessing pain. Grimace scores are a promising adjunctive
      behavioural technique in some mammalian species to identify and assess pain in
      research animals. The use of this method can be beneficial to animal welfare and 
      research outcomes by identifying animals that may require alleviation of pain or 
      humane intervention. This paper highlights the benefits, caveats, and potential
      applications of grimace scales.
FAU - Cohen, Shari
AU  - Cohen S
AD  - Office of Research, Ethics, and Integrity, University of Melbourne, Melbourne
      3010, Australia.
FAU - Beths, Thierry
AU  - Beths T
AUID- ORCID: 0000-0003-1412-0591
AD  - Anesthesia and Veterinary Clinical Sciences, University of Melbourne, Melbourne
      3010, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200923
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7598254
OTO - NOTNLM
OT  - grimace scores
OT  - laboratory animals
OT  - pain
OT  - pain assessment
EDAT- 2020/09/27 06:00
MHDA- 2020/09/27 06:01
CRDT- 2020/09/26 01:01
PHST- 2020/08/16 00:00 [received]
PHST- 2020/09/15 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/09/26 01:01 [entrez]
PHST- 2020/09/27 06:00 [pubmed]
PHST- 2020/09/27 06:01 [medline]
AID - ani10101726 [pii]
AID - 10.3390/ani10101726 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Sep 23;10(10). pii: ani10101726. doi: 10.3390/ani10101726.


PMID- 32977327
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - After providing end of life care to relatives, what care options do family
      caregivers prefer for themselves?
PG  - e0239423
LID - 10.1371/journal.pone.0239423 [doi]
AB  - OBJECTIVES: We examined how caregivers who had cared for a relative at end of
      life (EoL) wished to be cared for in the event that they experienced advanced
      dementia or physical disability in the future, and what factors influenced their 
      preferences for EoL care. METHODS: In this mixed-methods study, 83 participants, 
      recruited from multiple sources in Israel, were interviewed concerning
      socio-demographic factors, health status, past experience with EoL, preference
      for extension of life vs. quality of life (QoL), willingness to be dependent on
      others, and preferences for EoL care. RESULTS: In case of advanced dementia, 58% 
      preferred euthanasia or suicide; around a third chose those for physical
      disability. Care by family members was the least desired form of care in the
      advanced dementia scenario, although more desirable than institutional care in
      the physical disability scenario. QoL was rated as the highest factor impacting
      preferences for EoL care. Men demonstrated a higher preference than women for
      extension of life over QoL. CONCLUSION: Our study points to the need for society 
      to consider solutions to the request of participants to reject the type of EoL
      experienced by their relatives. Those solutions include investing in improving
      the quality of life at the end of life, and offering alternatives such as
      euthanasia, which a large proportion of our participants found ethically and
      medically appropriate within the current system of care in the event of severe
      physical disability, and more so in the event of advanced dementia.
FAU - Cohen-Mansfield, Jiska
AU  - Cohen-Mansfield J
AUID- ORCID: 0000-0003-0209-7304
AD  - Minerva Center for Interdisciplinary Study of End of Life, Tel-Aviv University,
      Tel Aviv, Israel.
AD  - Department of Health Promotion, School of Public Health, Sackler Faculty of
      Medicine, Tel-Aviv University, Tel Aviv, Israel.
AD  - The Herczeg Institute on Aging, Tel-Aviv University, Tel Aviv, Israel.
FAU - Brill, Shai
AU  - Brill S
AD  - Minerva Center for Interdisciplinary Study of End of Life, Tel-Aviv University,
      Tel Aviv, Israel.
AD  - Beit Rivka Medical Center, Petah Tikva, Israel.
AD  - Tel-Aviv University, Tel-Aviv, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Caregivers/*psychology
MH  - *Family
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Preference/*statistics & numerical data
MH  - Terminal Care/*psychology
PMC - PMC7518928
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/26 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/25 20:20
PHST- 2019/11/05 00:00 [received]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/09/25 20:20 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1371/journal.pone.0239423 [doi]
AID - PONE-D-19-30823 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 25;15(9):e0239423. doi: 10.1371/journal.pone.0239423.
      eCollection 2020.


PMID- 32975826
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20210110
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Recommendations on COVID-19 triage: international comparison and ethical
      analysis.
PG  - 948-959
LID - 10.1111/bioe.12805 [doi]
AB  - On March 11, 2020 the World Health Organization classified COVID-19, caused by
      Sars-CoV-2, as a pandemic. Although not much was known about the new virus, the
      first outbreaks in China and Italy showed that potentially a large number of
      people worldwide could fall critically ill in a short period of time. A shortage 
      of ventilators and intensive care resources was expected in many countries,
      leading to concerns about restrictions of medical care and preventable deaths. In
      order to be prepared for this challenging situation, national triage guidance has
      been developed or adapted from former influenza pandemic guidelines in an
      increasing number of countries over the past few months. In this article, we
      provide a comparative analysis of triage recommendations from selected national
      and international professional societies, including Australia/New Zealand,
      Belgium, Canada, Germany, Great Britain, Italy, Pakistan, South Africa,
      Switzerland, the United States, and the International Society of Critical Care
      Medicine. We describe areas of consensus, including the importance of prognosis, 
      patient will, transparency of the decision-making process, and psychosocial
      support for staff, as well as the role of justice and benefit maximization as
      core principles. We then probe areas of disagreement, such as the role of
      survival versus outcome, long-term versus short-term prognosis, the use of age
      and comorbidities as triage criteria, priority groups and potential tiebreakers
      such as 'lottery' or 'first come, first served'. Having explored a number of
      tensions in current guidance, we conclude with a suggestion for framework
      conditions that are clear, consistent and implementable. This analysis is
      intended to advance the ongoing debate regarding the fair allocation of limited
      resources and may be relevant for future policy-making.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Jobges, Susanne
AU  - Jobges S
AUID- ORCID: 0000-0002-9509-8631
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Switzerland.
FAU - Vinay, Rasita
AU  - Vinay R
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Switzerland.
FAU - Luyckx, Valerie A
AU  - Luyckx VA
AUID- ORCID: 0000-0001-7066-8135
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Switzerland.
FAU - Biller-Andorno, Nikola
AU  - Biller-Andorno N
AUID- ORCID: 0000-0001-7661-1324
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Switzerland.
LA  - eng
GR  - Kathe-Zingg-Schwichtenberg-Fond/Schweizerische Akademie der Medizinischen
      Wissenschaften/International
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200925
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Asia
MH  - Australasia
MH  - COVID-19/*therapy
MH  - Canada
MH  - Critical Care
MH  - Critical Illness
MH  - Decision Making/*ethics
MH  - Ethical Analysis
MH  - Europe
MH  - Health Care Rationing/*ethics
MH  - Health Resources
MH  - Humans
MH  - Pandemics/*ethics
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - *Social Justice
MH  - Societies, Medical
MH  - South Africa
MH  - Triage/*ethics
PMC - PMC7537413
OTO - NOTNLM
OT  - *COVID-19
OT  - *comparison
OT  - *ethics
OT  - *guidelines
OT  - *public health
OT  - *triage
EDAT- 2020/09/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/25 12:17
PHST- 2020/06/18 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/25 12:17 [entrez]
AID - 10.1111/bioe.12805 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):948-959. doi: 10.1111/bioe.12805. Epub 2020 Sep 25.


PMID- 32975817
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Why IRBs should protect bystanders in human research.
PG  - 933-936
LID - 10.1111/bioe.12812 [doi]
AB  - Many types of human research activities present risks and burdens to third
      parties (e.g., bystanders). Few human protection policies directly address the
      protection of research bystanders, though some address it in passing. In what
      follows, I re-iterate reasons why bystanders are entitled to protections. I also 
      argue that Institutional Review Boards (IRBs) are in the best position to signal 
      to researchers and sponsors that bystanders should be protected in research. In
      some cases, IRB review would consist of evaluating bystander protection
      strategies directly; in other cases, this might entail merely certifying that
      another institutions, like a drug regulator, has taken adequate measures to
      protect the welfare of research bystanders.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Kimmelman, Jonathan
AU  - Kimmelman J
AUID- ORCID: 0000-0003-1614-6779
AD  - Studies of Translation, Ethics, and Medicine (STREAM), Department of Biomedical
      Ethics, McGill University, Montreal, Quebec, Canada.
LA  - eng
GR  - 1 R01 AI114617-01A1/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200925
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - *Research Personnel
OTO - NOTNLM
OT  - *IRB
OT  - *bystanders
OT  - *ethics review
OT  - *research ethics
OT  - *risk
EDAT- 2020/09/26 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/09/25 12:17
PHST- 2019/02/06 00:00 [received]
PHST- 2020/02/28 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/09/25 12:17 [entrez]
AID - 10.1111/bioe.12812 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):933-936. doi: 10.1111/bioe.12812. Epub 2020 Sep 25.


PMID- 32975491
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Ethical, Legal, and Social Issues (ELSI) of Responsible Data Sharing Involving
      Children in Genomics: A Systematic Literature Review of Reasons.
PG  - 233-245
LID - 10.1080/23294515.2020.1818875 [doi]
AB  - BACKGROUND: Progress in precision medicine relies on the access to, use of, and
      exchange of genomic and associated clinical data, including from children. The
      ethical, legal, and social issues (ELSI) of such data access, use, and exchange
      may be accentuated in the pediatric context due in part to the highly sensitive
      nature of genomic data, children's consent-related vulnerabilities, and uncertain
      risks of reidentification. Systematic analyses of the ELSI and scientific reasons
      for why and how genomic data may be shared responsibly are, however, limited.
      Methods: We conducted a modified systematic review of reasons according to Sofaer
      and Strech to examine the ELSI and scientific reasons for "responsible" sharing
      of children's genomic and associated clinical data. Empirical articles,
      commentaries, and data-sharing policies indexed in Medline, Scopus, Web of
      Science, and BIOSIS were included in the analysis if they discussed ELSI and were
      published between 2003 and 2017 in English. Results: One hundred and fifty-one
      records met our inclusion criteria. We identified 11 unique reasons and 8
      subreasons for why children's genomic data should or should not be shared.
      Enhancing the prospect of direct and indirect benefits and maximizing the utility
      of children's data were top reasons why data should be shared. Inadequate data
      privacy protection was the leading reason why it should not. We furthermore
      identified 8 reasons and 30 subreasons that support conditional data sharing, in 
      which recontact for the continued use of children's data once they reach the age 
      of majority was the most frequently endorsed condition. Conclusions: The complete
      list of ELSI reasons and responsible conditions provides an evidentiary basis
      upon which institutions can develop data-sharing policies. Institutions should
      encourage the sharing of children's data to advance genomic research, while
      heeding special reconsent and data protection mechanisms that may help mitigate
      uncertain longitudinal risks for children and families.
FAU - Rahimzadeh, Vasiliki
AU  - Rahimzadeh V
AUID- ORCID: 0000-0003-3537-7601
AD  - Center for Biomedical Ethics, Stanford University, Stanford, California, USA.
FAU - Knoppers, Bartha Maria
AU  - Knoppers BM
AUID- ORCID: 0000-0001-7004-2722
AD  - Human Genetics, McGill University, Montreal, Quebec, Canada.
FAU - Bartlett, Gillian
AU  - Bartlett G
AUID- ORCID: 0000-0001-6297-9240
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada.
LA  - eng
GR  - 359258/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200925
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Child
MH  - Computer Security
MH  - Ethics, Research
MH  - Genetic Research/*ethics
MH  - Genomics/*ethics
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - *Informed Consent
MH  - Motivation
MH  - Pediatrics/*ethics
MH  - Policy
MH  - Precision Medicine
MH  - *Privacy
MH  - Social Responsibility
OTO - NOTNLM
OT  - *Genomics
OT  - *data sharing
OT  - *pediatrics
OT  - *policy
OT  - *systematic review of reasons
EDAT- 2020/09/26 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/09/25 12:11
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/09/25 12:11 [entrez]
AID - 10.1080/23294515.2020.1818875 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Oct-Dec;11(4):233-245. doi:
      10.1080/23294515.2020.1818875. Epub 2020 Sep 25.


PMID- 32974999
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1466-769X (Electronic)
IS  - 1466-7681 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Oct
TI  - The theory of caritative caring: Katie Eriksson's theory of caritative caring
      presented from a human science point of view.
PG  - e12321
LID - 10.1111/nup.12321 [doi]
AB  - The Finnish nursing theorist Katie Eriksson's (1943-2019) theory of caritative
      caring represents a non-medical paradigm concerning the phenomena of nursing. The
      aim of this article was to present an oversight of the development of Eriksson's 
      theory of caritative caring from a human science point of view. The historical
      development of the theory is outlined, combined with a brief overview of its
      philosophical connections, its impact on contemporary caring science research and
      its implications for nursing care. Caring science is considered a human science
      in the Nordic tradition, as it is deeply rooted in basic issues of human life and
      existence. The key ideas of Eriksson's theory of caritative caring are linked to 
      the metaparadigm concepts of human being, health and suffering, caring and
      environment. All of these are permeated with the ethos of caritative caring, that
      is, the caritas thought of human love and mercy, and the honouring of the
      absolute dignity of human beings. Epistemologically, Gadamer is the most
      influential philosopher when it comes to the theory of caritative caring.
      Eriksson's theory is used in, for example, intercultural caring, caring for
      patients suffering from addiction, the importance of aesthetic surroundings,
      providing ethically good care for older people and mothers as patients in
      psychiatric care. In these fields of research, Eriksson's ideas of ethics, caring
      and suffering are highlighted in various clinical contexts. Beyond the areas of
      nursing care in which Eriksson's work has been cited and developed, there are at 
      least two areas that have been actively enhanced by her works: the field of
      leadership and education for nursing teachers. According to Eriksson, it is
      momentous to ponder scientific results as not limited to empirically
      strengthened, randomized outcomes. Part of making the results of scientific work 
      evident is up to the individual nurses and their being in the world.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Nasman, Yvonne
AU  - Nasman Y
AUID- ORCID: https://orcid.org/0000-0002-4039-218X
AD  - Department of Caring Science, Faculty of Education and Welfare Studies, Abo
      Akademi University, Vaasa, Finland.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - England
TA  - Nurs Philos
JT  - Nursing philosophy : an international journal for healthcare professionals
JID - 100897394
SB  - IM
MH  - *Empathy
MH  - Female
MH  - Humans
MH  - Nursing Theory
MH  - *Philosophy, Nursing
MH  - Science/*methods/trends
OTO - NOTNLM
OT  - Katie Eriksson
OT  - caritative caring
OT  - philosophy of science
OT  - theory of science
EDAT- 2020/09/26 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/09/25 06:09
PHST- 2019/11/11 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/09/25 06:09 [entrez]
AID - 10.1111/nup.12321 [doi]
PST - ppublish
SO  - Nurs Philos. 2020 Oct;21(4):e12321. doi: 10.1111/nup.12321. Epub 2020 Sep 24.


PMID- 32974891
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Sep 21
TI  - Including adolescents of childbearing potential in clinical trials with possible 
      exposure to teratogenic medication: a challenge for paediatricians and
      researchers.
PG  - w20333
LID - 10.4414/smw.2020.20333 [doi]
LID - Swiss Med Wkly. 2020;150:w20333 [pii]
AB  - The issue of contraception and pregnancy tests among minor adolescent women
      participating in clinical trials, whether healthy or suffering from a disease,
      represents a challenging issue for paediatricians and researchers, given the
      potential harmful effect of various therapeutic procedures being tested. First,
      they need to gauge at what age or developmental stage they need to impose
      pregnancy tests and contraception. Second, if the adolescent denies any sexual
      activity, it may be ethically questionable to impose such procedures. Third,
      these professionals must deal with the issue of confidentiality, taking into
      account the fact that some adolescents engage in penetrative sexual intercourse
      without their parents or caregivers knowing. Fourth, in such cases, they must
      assess the extent to which a minor adolescent can be considered as competent
      (capable of making autonomous decisions) and deserves privacy and
      confidentiality. There is indeed a legal obligation for the provider to check
      that sexual experiences and intercourse take place within a safe relationship.
      Fifth, if the prescription of contraception is warranted, they have to decide who
      should assist the adolescent in choosing the method. Finally, with the occurrence
      of a positive pregnancy test, they may face the rare instance of a competent
      minor adolescent who refuses to inform her parents. This article has been
      developed by a group of experts under the auspices of swissethics, the Swiss
      Association of Research Ethics Committees and SwissPedNet, the umbrella
      organisation that coordinates the paediatric research in Switzerland. The paper
      reviews how to address practical and ethical questions regarding minor
      adolescents of childbearing potential enrolled in a clinical trial that may
      involve teratogenic medication and offers a series of concrete advice and tools
      for dealing with problematic situations. Most paediatric protocols stipulate that
      adolescents included in clinical trials involving potentially teratogenic drugs
      should undergo pregnancy tests and use contraception. The circumstances in which 
      such requirements are undertaken, however, has not been sufficiently addressed.
      The recommendations presented in this article will assist researchers in
      assessing which circumstances apply when considering minor adolescents as
      individuals with childbearing potentials. It also offers concrete suggestions for
      tackling such situations.
FAU - Michaud, Pierre-Andre
AU  - Michaud PA
AD  - University of Lausanne | Retired / honorary professor | Departement of Pediatric 
      | CHUV | Lausanne | 1030 | SWITZERLAND | 41213143769 | 41213143760.
FAU - Diezi, Manuel
AU  - Diezi M
AD  - Associate physician | CHUV, Mother-Child Research Unit, Departement Femme - Mere 
      - Enfant.
FAU - Guihard, Linda
AU  - Guihard L
AD  - Research coordinator | Departement femme mere enfants.
FAU - Jacot-Guillarmod, Martine
AU  - Jacot-Guillarmod M
AD  - Associate physician | Departement femme mere enfants.
FAU - Kleist, Peter
AU  - Kleist P
AD  - Geschaftsfuhrer | Kantonale Ethikkommission.
FAU - Sprumont, Dominique
AU  - Sprumont D
AD  - Universite de Neuchatel | Institute of Health Law.
FAU - Wenger, Pascale
AU  - Wenger P
AD  - Swiss Clinical Trial Organisation | Network Coordination.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200925
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
RN  - 0 (Teratogens)
SB  - IM
MH  - Adolescent
MH  - Confidentiality
MH  - *Contraception
MH  - Female
MH  - Humans
MH  - Pediatricians
MH  - Pregnancy
MH  - Sexual Behavior
MH  - *Teratogens/toxicity
EDAT- 2020/09/26 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/25 06:07
PHST- 2020/09/25 06:07 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.4414/smw.2020.20333 [doi]
AID - Swiss Med Wkly. 2020;150:w20333 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Sep 25;150:w20333. doi: 10.4414/smw.2020.20333. eCollection 
      2020 Sep 21.


PMID- 32974417
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2363-8400 (Electronic)
IS  - 2363-8400 (Linking)
VI  - 18
IP  - 2
DP  - 2020
TI  - The COVID-19 Pandemic and Implications for Gynaecologic Cancer Care.
PG  - 48
LID - 10.1007/s40944-020-00395-7 [doi]
AB  - PURPOSE: The impact of the COVID-19 pandemic on world healthcare system and
      economy is unprecedented. Currently routine surgical procedures are at a halt
      globally, but whether one can delay cancer procedures remains an ethical issue,
      and still there is no clarity on how women with gynaecological cancers should be 
      managed in these critical times. METHODS: Currently available literature on
      impact of COVID-19 on cancer was reviewed with special reference to its
      applicability to the Indian context. RESULTS: Cancer cases are more susceptible
      for COVID-19 infection and rapid deterioration if they get infected. A tumour
      board should plan their management with a "do no harm" approach as the guiding
      principle. Teleconsultation may be used to advise patients for therapy and
      symptom control measures, as well as to advise new patients regarding diagnostic 
      tests. Surgical decision making may be stratified into three categories: patients
      with low (not life threatening) or intermediate (potential for future morbidity
      or mortality) acuity may be delayed; those with high acuity may be taken up for
      planned therapy after explaining the risks. Assessment of the severity of
      disease, comorbid conditions, and logistic challenges, along with COVID census in
      their area are important variables for informed and individualized decision
      making. Safety of healthcare personnel needs to be ensured at the same time.
      CONCLUSION: Currently available evidence is limited by small sample size, and
      full impact of this pandemic on cancer is yet to be seen. However, cancer care
      needs to be individualized taking all variables into consideration.
CI  - (c) Association of Gynecologic Oncologists of India 2020.
FAU - Bhatla, Neerja
AU  - Bhatla N
AD  - Department of Obstetrics and Gynecology, All India Institute of Medical Sciences,
      New Delhi, India.grid.413618.90000 0004 1767 6103
FAU - Singhal, Seema
AU  - Singhal S
AD  - Department of Obstetrics and Gynecology, All India Institute of Medical Sciences,
      New Delhi, India.grid.413618.90000 0004 1767 6103
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200424
PL  - India
TA  - Indian J Gynecol Oncol
JT  - Indian journal of gynecologic oncology
JID - 101689372
PMC - PMC7180676
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus infection and cancer
OT  - Gynaecological cancer care
OT  - Pandemic
COIS- Conflict of interestThe authors declare that there is no conflict of interest.
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:04
PHST- 2020/03/29 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/04/11 00:00 [accepted]
PHST- 2020/09/25 06:04 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.1007/s40944-020-00395-7 [doi]
AID - 395 [pii]
PST - ppublish
SO  - Indian J Gynecol Oncol. 2020;18(2):48. doi: 10.1007/s40944-020-00395-7. Epub 2020
      Apr 24.


PMID- 32974405
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Opinions of Portuguese Veterinarians on Telemedicine-A Policy Delphi Study.
PG  - 549
LID - 10.3389/fvets.2020.00549 [doi]
AB  - Telemedicine has only received limited attention by veterinary professional
      regulatory bodies, particularly in Europe. In Portugal, telemedicine is currently
      outside what is considered acceptable practice by the regulator, the Portuguese
      Veterinary Order (Ordem dos Medicos Veterinarios). As part of a wider research
      aimed at gathering evidence for developing a new veterinary Code of Professional 
      Conduct, this study describes the use of the Policy Delphi technique to gather
      the views and perceptions of a purposeful sample of 41 Portuguese veterinarians
      regarding telemedicine. Four main issues were addressed using mixed research
      methods: teleconsultation, teleconsulting, teleadvice, and the regulator's role. 
      Responses highlight participants' perception of both the relevance of medical
      digital technologies in improving healthcare and their limitations. Overall
      opinion was that, although restrictions to remote veterinary practice should be
      reduced, improved guidance and regulation are warranted. Eighty percent of
      participants considered that limits to the use of veterinary telemedicine should 
      be imposed and two thirds considered that a remote consultation must always be
      preceded by a face-to-face consultation. While most respondents thought that
      vet-to-vet teleconsulting using social media (namely Facebook) should not be
      banned, 83% recognized that it should be regulated by ethical standards.
      Participants' concerns with telemedicine had mostly to do with reputational risk 
      for the veterinary profession, while overlooking privacy or confidentiality
      issues. A consultative group should be established to ensure that telemedicine
      providers comply with professional requirements. It is expected that these
      results will support policy-making by the Portuguese Veterinary Order and by
      veterinary regulators at other jurisdictions.
CI  - Copyright (c) 2020 Magalhaes-Sant'Ana, Peleteiro and Stilwell.
FAU - Magalhaes-Sant'Ana, Manuel
AU  - Magalhaes-Sant'Ana M
AD  - Ordem dos Medicos Veterinarios, Lisbon, Portugal.
AD  - CIISA-Centro de Investigacao Interdisciplinar em Sanidade Animal, Faculdade de
      Medicina Veterinaria, Universidade de Lisboa, Lisbon, Portugal.
FAU - Peleteiro, Maria Conceicao
AU  - Peleteiro MC
AD  - Ordem dos Medicos Veterinarios, Lisbon, Portugal.
AD  - CIISA-Centro de Investigacao Interdisciplinar em Sanidade Animal, Faculdade de
      Medicina Veterinaria, Universidade de Lisboa, Lisbon, Portugal.
FAU - Stilwell, George
AU  - Stilwell G
AD  - Ordem dos Medicos Veterinarios, Lisbon, Portugal.
AD  - CIISA-Centro de Investigacao Interdisciplinar em Sanidade Animal, Faculdade de
      Medicina Veterinaria, Universidade de Lisboa, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200821
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7472629
OTO - NOTNLM
OT  - Policy Delphi
OT  - Portugal
OT  - code of conduct
OT  - teleadvice
OT  - teleconsultation
OT  - teleconsulting
OT  - telehealth
OT  - telemedicine
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:04
PHST- 2020/05/28 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/09/25 06:04 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.3389/fvets.2020.00549 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 Aug 21;7:549. doi: 10.3389/fvets.2020.00549. eCollection
      2020.


PMID- 32974382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-875X (Print)
IS  - 2296-875X (Linking)
VI  - 7
DP  - 2020
TI  - The Role of Machine Learning in Spine Surgery: The Future Is Now.
PG  - 54
LID - 10.3389/fsurg.2020.00054 [doi]
AB  - The recent influx of machine learning centered investigations in the spine
      surgery literature has led to increased enthusiasm as to the prospect of using
      artificial intelligence to create clinical decision support tools, optimize
      postoperative outcomes, and improve technologies used in the operating room.
      However, the methodology underlying machine learning in spine research is often
      overlooked as the subject matter is quite novel and may be foreign to practicing 
      spine surgeons. Improper application of machine learning is a significant
      bioethics challenge, given the potential consequences of over- or underestimating
      the results of such studies for clinical decision-making processes. Proper peer
      review of these publications requires a baseline familiarity of the language
      associated with machine learning, and how it differs from classical statistical
      analyses. This narrative review first introduces the overall field of machine
      learning and its role in artificial intelligence, and defines basic terminology. 
      In addition, common modalities for applying machine learning, including
      classification and regression decision trees, support vector machines, and
      artificial neural networks are examined in the context of examples gathered from 
      the spine literature. Lastly, the ethical challenges associated with adapting
      machine learning for research related to patient care, as well as future
      perspectives on the potential use of machine learning in spine surgery, are
      discussed specifically.
CI  - Copyright (c) 2020 Chang, Canseco, Nicholson, Patel and Vaccaro.
FAU - Chang, Michael
AU  - Chang M
AD  - Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, PA,
      United States.
AD  - Rothman Orthopaedic Institute, Philadelphia, PA, United States.
FAU - Canseco, Jose A
AU  - Canseco JA
AD  - Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, PA,
      United States.
AD  - Rothman Orthopaedic Institute, Philadelphia, PA, United States.
FAU - Nicholson, Kristen J
AU  - Nicholson KJ
AD  - Rothman Orthopaedic Institute, Philadelphia, PA, United States.
FAU - Patel, Neil
AU  - Patel N
AD  - Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, PA,
      United States.
AD  - Rothman Orthopaedic Institute, Philadelphia, PA, United States.
FAU - Vaccaro, Alexander R
AU  - Vaccaro AR
AD  - Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, PA,
      United States.
AD  - Rothman Orthopaedic Institute, Philadelphia, PA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Switzerland
TA  - Front Surg
JT  - Frontiers in surgery
JID - 101645127
PMC - PMC7472375
OTO - NOTNLM
OT  - artificial intelligence
OT  - deep learning
OT  - machine learning
OT  - orthopedic surgery
OT  - spine surgery
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:04
PHST- 2020/04/14 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/09/25 06:04 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.3389/fsurg.2020.00054 [doi]
PST - epublish
SO  - Front Surg. 2020 Aug 21;7:54. doi: 10.3389/fsurg.2020.00054. eCollection 2020.


PMID- 32974054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2056-9920 (Print)
IS  - 2056-9920 (Linking)
VI  - 6
DP  - 2020
TI  - Pedicle internal limiting membrane flap technique for very large macular holes: a
      preliminary report.
PG  - 43
LID - 10.1186/s40942-020-00248-7 [doi]
AB  - BACKGROUND: Conventional vitrectomy technique for macular hole surgery has a good
      outcome in small and medium macular holes, but for very large macular holes
      (minimum linear diameter higher than 700 mum) other techniques were developed
      aiming to achieve greater rates of closure and visual acuity gain. The purpose of
      this article is to report the anatomical and functional outcomes of four very
      large macular hole (MH) cases which have undergone vitrectomy with the pedicle
      internal limiting membrane (ILM) flap technique. METHODS: This is a retrospective
      series of four patients with large MH who were treated with vitrectomy and the
      pedicle ILM flap technique. Comprehensive ophthalmologic evaluation was performed
      before surgery and included ETDRS best-corrected visual acuity (BCVA) and
      spectral domain optical coherence tomography (SD-OCT) for MH measures: height,
      minimum linear diameter (MLD) and external base diameter. The particular detail
      of this technique is related to ILM flap creation. During the peeling, the ILM
      was not removed completely from the retina but was left attached to the edges of 
      the macular hole and subsequently trimmed with the vitrectomy probe using the
      scissors mode. RESULTS: Four patients with very large MH underwent PPV and the
      pedicle ILM flap technique was used to pursue macular closure. Median
      preoperative BCVA was 20/400 (range: 20/320 to 20/400) and median postoperative
      BCVA was 20/200 (range: 20/320 to 20/200). Of the 4 cases reported, 3 obtained
      anatomical closure (75%), and also presented BCVA improvement after surgery,
      considering the last follow-up visit of each case. No additional procedures were 
      performed in either case. One patient demonstrated no anatomic and functional
      improvement. CONCLUSION: The present study describes the first Brazilian case
      series of very large MH treated by the inverted pedicle ILM flap technique. This 
      technique was associated with anatomic and visual improvement in most cases, and 
      represents an alternative therapeutic approach for large macular holes.Trial
      Registration Project registered in Plataforma Brasil with CAAE number
      30163520.0.0000.5440 and approved in ethics committee from Ribeirao Preto Medical
      School Clinics Hospital, University of Sao Paulo-Ribeirao Preto, Sao Paulo,
      Brazil (appreciation number 3.948.426 gave the approval).
CI  - (c) The Author(s) 2020.
FAU - da Silva Tavares Neto, Jose Edisio
AU  - da Silva Tavares Neto JE
AD  - Department of Ophthalmology, Ribeirao Preto Medical School, University of Sao
      Paulo, 3900. Bandeirantes Ave, Ribeirao Preto, SP 14049-900
      Brazil.grid.11899.380000 0004 1937 0722
FAU - Coelho, Igor Neves
AU  - Coelho IN
AD  - Department of Ophthalmology, Ribeirao Preto Medical School, University of Sao
      Paulo, 3900. Bandeirantes Ave, Ribeirao Preto, SP 14049-900
      Brazil.grid.11899.380000 0004 1937 0722
FAU - Jorge, Rodrigo
AU  - Jorge R
AUID- ORCID: 0000-0002-2652-0720
AD  - Department of Ophthalmology, Ribeirao Preto Medical School, University of Sao
      Paulo, 3900. Bandeirantes Ave, Ribeirao Preto, SP 14049-900
      Brazil.grid.11899.380000 0004 1937 0722
FAU - Isaac, David Leonardo Cruvinel
AU  - Isaac DLC
AD  - Department of Ophthalmology, Federal University of Goias, Goiania,
      Brazil.grid.411195.90000 0001 2192 5801
FAU - de Avila, Marcos Pereira
AU  - de Avila MP
AD  - Department of Ophthalmology, Federal University of Goias, Goiania,
      Brazil.grid.411195.90000 0001 2192 5801
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - Int J Retina Vitreous
JT  - International journal of retina and vitreous
JID - 101677897
PMC - PMC7507815
OTO - NOTNLM
OT  - Inner limiting membrane
OT  - Macula lutea
OT  - Macular hole
OT  - Retina
OT  - Vitrectomy
OT  - Vitreous
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:03
PHST- 2020/05/25 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/09/25 06:03 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.1186/s40942-020-00248-7 [doi]
AID - 248 [pii]
PST - epublish
SO  - Int J Retina Vitreous. 2020 Sep 21;6:43. doi: 10.1186/s40942-020-00248-7.
      eCollection 2020.


PMID- 32974044
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
DP  - 2020
TI  - Mood, Activity Participation, and Leisure Engagement Satisfaction (MAPLES): a
      randomised controlled pilot feasibility trial for low mood in acquired brain
      injury.
PG  - 135
LID - 10.1186/s40814-020-00660-8 [doi]
AB  - BACKGROUND: Acquired brain injury (ABI) affects approximately 79.3 million
      individuals annually and is linked with elevated rates of depression and low
      mood. Existing methods for treating depression in ABI have shown mixed efficacy. 
      Behavioural activation (BA) is a potentially promising intervention. Its premise 
      is that individuals with low mood avoid planning and engaging in activities due
      to low expectations of a positive outcome. Consequently, their exposure to
      positive reinforcement is reduced, exacerbating low mood. BA aims to break this
      cycle by encouraging activity planning and engagement. It is unknown whether
      cognitive demands of traditional BA may undermine efficacy in ABI. Here, we
      assess the feasibility and acceptability of two groups designed to increase
      activity engagement. In the activity planning group (traditional BA), the
      importance of meaningful and positive activity will be discussed and participants
      encouraged to plan/engage in activities in everyday life. The activity engagement
      group (experiential BA) instead focuses on engagement in positive experiences
      (crafts, games, discussion) within the group. The primary aims are to evaluate
      the feasibility and acceptability of the two groups in ABI. A secondary aim is to
      explore relative efficacy of the groups compared to an equivalent period of
      waitlist controls. METHOD: This study outlines a parallel-arm pilot feasibility
      trial for individuals with low mood and ABI that compares a traditional vs
      experiential BA group vs waitlist controls. Adults (>/= 18 years) will be
      recruited from local ABI services and randomised to condition. Feasibility and
      acceptability will be assessed via recruitment, retention, attendance and
      participant feedback. Groups will be compared (pre- and post-intervention and 1
      month follow-up) by assessing self-reported activity engagement. Secondary
      outcomes include self-report measures of depression, anxiety, post-traumatic
      distress related to the ABI, motivation, participation and sense of control over 
      one's life. ETHICS AND DISSEMINATION: The trial has been approved by the Health
      Research Authority of the NHS in the UK (East of England-Cambridge Central, REF
      18/EE/0305). Results will inform future research on interventions for mood in ABI
      and be disseminated broadly via peer-reviewed journals, conference presentations 
      and social media. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03874650
      pre-results. Protocol version 2.1, March 5, 2019.
CI  - (c) The Author(s) 2020.
FAU - Kusec, Andrea
AU  - Kusec A
AD  - MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, 
      Cambridge, CB2 7EF UK.grid.5335.00000000121885934
FAU - Murphy, Fionnuala C
AU  - Murphy FC
AD  - MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, 
      Cambridge, CB2 7EF UK.grid.5335.00000000121885934
FAU - Peers, Polly V
AU  - Peers PV
AD  - MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, 
      Cambridge, CB2 7EF UK.grid.5335.00000000121885934
FAU - Lawrence, Cara
AU  - Lawrence C
AD  - Evelyn Community Head Injury Services, Cambridgeshire Community Services, Dynamic
      Health Building, Brookfields Hospital, 351 Mill Road, Cambridge, CB1 3DF
      UK.grid.439658.50000 0004 0447 0720
FAU - Cameron, Emma
AU  - Cameron E
AD  - The National Hospital for Neurology and Neurosurgery, University College London
      Hospitals NHS Trust, Post Box 113, Queen Square, London, WC1N 3BG
      UK.grid.52996.310000 0000 8937 2257
FAU - Morton, Claire
AU  - Morton C
AD  - Evelyn Community Head Injury Services, Cambridgeshire Community Services, Dynamic
      Health Building, Brookfields Hospital, 351 Mill Road, Cambridge, CB1 3DF
      UK.grid.439658.50000 0004 0447 0720
FAU - Bateman, Andrew
AU  - Bateman A
AD  - School of Health and Social Care, University of Essex, Wivenhoe Park, Colchester,
      CO4 3SQ UK.grid.8356.80000 0001 0942 6946
FAU - Watson, Peter
AU  - Watson P
AD  - MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, 
      Cambridge, CB2 7EF UK.grid.5335.00000000121885934
FAU - Manly, Tom
AU  - Manly T
AUID- ORCID: 0000-0003-1137-4457
AD  - MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, 
      Cambridge, CB2 7EF UK.grid.5335.00000000121885934
LA  - eng
SI  - ClinicalTrials.gov/NCT03874650
GR  - MC_U105559837/MRC_/Medical Research Council/United Kingdom
GR  - MC_U105579212/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00005/14/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
PMC - PMC7507282
OTO - NOTNLM
OT  - Acquired brain injury
OT  - Depression
OT  - Executive function
OT  - Neurorehabilitation
OT  - Traumatic brain injury
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:03
PHST- 2020/02/06 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/09/25 06:03 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.1186/s40814-020-00660-8 [doi]
AID - 660 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 Sep 22;6:135. doi: 10.1186/s40814-020-00660-8.
      eCollection 2020.


PMID- 32973921
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1753-2000 (Print)
IS  - 1753-2000 (Linking)
VI  - 14
DP  - 2020
TI  - Children and young people's experiences of completing mental health and wellbeing
      measures for research: learning from two school-based pilot projects.
PG  - 35
LID - 10.1186/s13034-020-00341-7 [doi]
AB  - BACKGROUND: In recent years there has been growing interest in child and
      adolescent mental health and wellbeing, alongside increasing emphasis on schools 
      as a crucial site for research and intervention. This has coincided with an
      increased use of self-report mental health and wellbeing measures in research
      with this population, including in school-based research projects. We set out to 
      explore the way that children and young people perceive and experience completing
      mental health and wellbeing measures, with a specific focus on completion in a
      school context, in order to inform future measure and research design. METHODS:
      We conducted semi-structured interviews and focus groups with 133 participants
      aged 8-16 years following their completion of mental health and wellbeing
      measures as part of school-based research programmes, using thematic analysis to 
      identify patterns of experience. FINDINGS: We identified six themes: Reflecting
      on emotions during completion; the importance of anonymity; understanding what is
      going to happen; ease of responding to items; level of demand; and interacting
      with the measure format. CONCLUSIONS: Our findings offer greater insight into
      children and young people's perceptions and experiences in reporting on their
      mental health and wellbeing. Such understanding can be used to support more
      ethical and robust data collection procedures in child and adolescent mental
      health research, both for data quality and ethical purposes. We offer several
      practical recommendations for researchers, including facilitating this in a
      school context.
CI  - (c) The Author(s) 2020.
FAU - Demkowicz, Ola
AU  - Demkowicz O
AUID- ORCID: 0000-0001-9204-0912
AD  - Manchester Institute of Education, The University of Manchester, Manchester,
      UK.grid.5379.80000000121662407
FAU - Ashworth, Emma
AU  - Ashworth E
AD  - School of Psychology, Liverpool John Moores University, Liverpool,
      UK.grid.4425.70000 0004 0368 0654
FAU - Mansfield, Rosie
AU  - Mansfield R
AD  - Manchester Institute of Education, The University of Manchester, Manchester,
      UK.grid.5379.80000000121662407
FAU - Stapley, Emily
AU  - Stapley E
AD  - Evidence Based Practice Unit (EBPU), University College London and the Anna Freud
      National Centre for Children and Families, London, UK.grid.466510.00000 0004 0423
      5990
FAU - Miles, Helena
AU  - Miles H
AD  - Common Room Consulting, London, UK.
FAU - Hayes, Daniel
AU  - Hayes D
AD  - Evidence Based Practice Unit (EBPU), University College London and the Anna Freud
      National Centre for Children and Families, London, UK.grid.466510.00000 0004 0423
      5990
FAU - Burrell, Kim
AU  - Burrell K
AD  - Evidence Based Practice Unit (EBPU), University College London and the Anna Freud
      National Centre for Children and Families, London, UK.grid.466510.00000 0004 0423
      5990
FAU - Moore, Anna
AU  - Moore A
AD  - Evidence Based Practice Unit (EBPU), University College London and the Anna Freud
      National Centre for Children and Families, London, UK.grid.466510.00000 0004 0423
      5990
FAU - Deighton, Jessica
AU  - Deighton J
AD  - Evidence Based Practice Unit (EBPU), University College London and the Anna Freud
      National Centre for Children and Families, London, UK.grid.466510.00000 0004 0423
      5990
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - England
TA  - Child Adolesc Psychiatry Ment Health
JT  - Child and adolescent psychiatry and mental health
JID - 101297974
PMC - PMC7495852
OTO - NOTNLM
OT  - Child and adolescent mental health
OT  - Measure design
OT  - Measurement
OT  - Mental health outcomes
OT  - Research ethics
OT  - School surveys
OT  - Self report
OT  - Wellbeing
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:02
PHST- 2019/12/20 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/25 06:02 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.1186/s13034-020-00341-7 [doi]
AID - 341 [pii]
PST - epublish
SO  - Child Adolesc Psychiatry Ment Health. 2020 Sep 16;14:35. doi:
      10.1186/s13034-020-00341-7. eCollection 2020.


PMID- 32973639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Contrasting Classical and Machine Learning Approaches in the Estimation of
      Value-Added Scores in Large-Scale Educational Data.
PG  - 2190
LID - 10.3389/fpsyg.2020.02190 [doi]
AB  - There is no consensus on which statistical model estimates school value-added
      (VA) most accurately. To date, the two most common statistical models used for
      the calculation of VA scores are two classical methods: linear regression and
      multilevel models. These models have the advantage of being relatively
      transparent and thus understandable for most researchers and practitioners.
      However, these statistical models are bound to certain assumptions (e.g.,
      linearity) that might limit their prediction accuracy. Machine learning methods, 
      which have yielded spectacular results in numerous fields, may be a valuable
      alternative to these classical models. Although big data is not new in general,
      it is relatively new in the realm of social sciences and education. New types of 
      data require new data analytical approaches. Such techniques have already evolved
      in fields with a long tradition in crunching big data (e.g., gene technology).
      The objective of the present paper is to competently apply these "imported"
      techniques to education data, more precisely VA scores, and assess when and how
      they can extend or replace the classical psychometrics toolbox. The different
      models include linear and non-linear methods and extend classical models with the
      most commonly used machine learning methods (i.e., random forest, neural
      networks, support vector machines, and boosting). We used representative data of 
      3,026 students in 153 schools who took part in the standardized achievement tests
      of the Luxembourg School Monitoring Program in grades 1 and 3. Multilevel models 
      outperformed classical linear and polynomial regressions, as well as different
      machine learning models. However, it could be observed that across all schools,
      school VA scores from different model types correlated highly. Yet, the
      percentage of disagreements as compared to multilevel models was not trivial and 
      real-life implications for individual schools may still be dramatic depending on 
      the model type used. Implications of these results and possible ethical concerns 
      regarding the use of machine learning methods for decision-making in education
      are discussed.
CI  - Copyright (c) 2020 Levy, Mussack, Brunner, Keller, Cardoso-Leite and Fischbach.
FAU - Levy, Jessica
AU  - Levy J
AD  - Luxembourg Centre for Educational Testing, University of Luxembourg,
      Esch-sur-Alzette, Luxembourg.
FAU - Mussack, Dominic
AU  - Mussack D
AD  - Department of Behavioural and Cognitive Sciences, University of Luxembourg,
      Esch-sur-Alzette, Luxembourg.
FAU - Brunner, Martin
AU  - Brunner M
AD  - Department of Education, University of Potsdam, Potsdam, Germany.
FAU - Keller, Ulrich
AU  - Keller U
AD  - Luxembourg Centre for Educational Testing, University of Luxembourg,
      Esch-sur-Alzette, Luxembourg.
FAU - Cardoso-Leite, Pedro
AU  - Cardoso-Leite P
AD  - Department of Behavioural and Cognitive Sciences, University of Luxembourg,
      Esch-sur-Alzette, Luxembourg.
FAU - Fischbach, Antoine
AU  - Fischbach A
AD  - Luxembourg Centre for Educational Testing, University of Luxembourg,
      Esch-sur-Alzette, Luxembourg.
LA  - eng
PT  - Journal Article
DEP - 20200821
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7472739
OTO - NOTNLM
OT  - longitudinal data
OT  - machine learning
OT  - model comparison
OT  - school effectiveness
OT  - value-added modeling
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:01
PHST- 2020/05/12 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/09/25 06:01 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.3389/fpsyg.2020.02190 [doi]
PST - epublish
SO  - Front Psychol. 2020 Aug 21;11:2190. doi: 10.3389/fpsyg.2020.02190. eCollection
      2020.


PMID- 32973457
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220323
IS  - 1662-5102 (Print)
IS  - 1662-5102 (Linking)
VI  - 14
DP  - 2020
TI  - The Use of Induced Pluripotent Stem Cells as a Model for Developmental Eye
      Disorders.
PG  - 265
LID - 10.3389/fncel.2020.00265 [doi]
AB  - Approximately one-third of childhood blindness is attributed to developmental eye
      disorders, of which 80% have a genetic cause. Eye morphogenesis is tightly
      regulated by a highly conserved network of transcription factors when disrupted
      by genetic mutations can result in severe ocular malformation. Human-induced
      pluripotent stem cells (hiPSCs) are an attractive tool to study early eye
      development as they are more physiologically relevant than animal models, can be 
      patient-specific and their use does not elicit the ethical concerns associated
      with human embryonic stem cells. The generation of self-organizing hiPSC-derived 
      optic cups is a major advancement to understanding mechanisms of ocular
      development and disease. Their development in vitro has been found to mirror that
      of the human eye and these early organoids have been used to effectively model
      microphthalmia caused by a VSX2 variant. hiPSC-derived optic cups, retina, and
      cornea organoids are powerful tools for future modeling of disease phenotypes and
      will enable a greater understanding of the pathophysiology of many other
      developmental eye disorders. These models will also provide an effective platform
      for identifying molecular therapeutic targets and for future clinical
      applications.
CI  - Copyright (c) 2020 Eintracht, Toms and Moosajee.
FAU - Eintracht, Jonathan
AU  - Eintracht J
AD  - UCL Institute of Ophthalmology, London, United Kingdom.
FAU - Toms, Maria
AU  - Toms M
AD  - UCL Institute of Ophthalmology, London, United Kingdom.
AD  - The Francis Crick Institute, London, United Kingdom.
FAU - Moosajee, Mariya
AU  - Moosajee M
AD  - UCL Institute of Ophthalmology, London, United Kingdom.
AD  - The Francis Crick Institute, London, United Kingdom.
AD  - Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
AD  - Great Ormond Street Hospital for Children NHS Foundation Trust, London, United
      Kingdom.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - NC/R001766/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction
      of Animals in Research/United Kingdom
PT  - Journal Article
DEP - 20200820
PL  - Switzerland
TA  - Front Cell Neurosci
JT  - Frontiers in cellular neuroscience
JID - 101477935
PMC - PMC7468397
OTO - NOTNLM
OT  - VSX2
OT  - corneal hereditary endothelial dystrophy
OT  - developmental eye disorders
OT  - disease modeling
OT  - eye development
OT  - human induced pluripotent stem cells
OT  - microphthalmia
OT  - ocular maldevelopment
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/09/25 06:00 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - 10.3389/fncel.2020.00265 [doi]
PST - epublish
SO  - Front Cell Neurosci. 2020 Aug 20;14:265. doi: 10.3389/fncel.2020.00265.
      eCollection 2020.


PMID- 32973348
OWN - NLM
STAT- Publisher
LR  - 20210924
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Sep 24
TI  - How helping my international students succeed helped everyone.
LID - 10.1038/d41586-020-02730-6 [doi]
FAU - Long, Michael Scott
AU  - Long MS
LA  - eng
PT  - News
DEP - 20200924
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Careers
OT  - Education
OT  - Ethics
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/25 05:59
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2020/09/25 05:59 [entrez]
AID - 10.1038/d41586-020-02730-6 [doi]
AID - 10.1038/d41586-020-02730-6 [pii]
PST - aheadofprint
SO  - Nature. 2020 Sep 24. pii: 10.1038/d41586-020-02730-6. doi:
      10.1038/d41586-020-02730-6.


PMID- 32973059
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 24
TI  - Mixed methods study protocol to examine perceptions of family medicine among
      long-term patients of a family medicine clinic in Japan.
PG  - e037113
LID - 10.1136/bmjopen-2020-037113 [doi]
AB  - INTRODUCTION: Family physicians or general practitioners play central roles in
      many countries' primary care systems, but family medicine (FM) remains relatively
      unestablished in Japan. Previous studies in Japan have examined the general
      population's understanding of FM as a medical specialty, but none have explored
      this topic using actual FM clinic patients. Here, we describe a protocol to
      explore the perceptions of FM among long-term patients of one of Japan's oldest
      FM clinics. METHODS AND ANALYSIS: The study will be conducted at the Motowanishi 
      Family Clinic in Hokkaido, Japan, using patients who have attended the clinic for
      over 10 years. The analysis will adopt a two-phase explanatory sequential mixed
      methods design. During phase I, quantitative data from participants' medical
      records will be collected and reviewed, and patients' perceptions of FM will be
      assessed through a questionnaire. The correlations between participants'
      knowledge that the clinic specialises in FM and various characteristics will be
      examined. In phase II, qualitative data will be collected through semi-structured
      interviews of approximately 10 participants selected using maximum variation
      sampling based on phase I results. A thematic analysis will be conducted in phase
      II to identify patients' perceptions and changes in perceptions. Finally, each
      theme identified in phase II will be transformed into a quantitative variable to 
      analyse the relationships between the phases. A joint display will be used to
      integrate the phases' findings and examine how phase II results explain phase I
      results. ETHICS AND DISSEMINATION: The institutional review board of the Japan
      Primary Care Association has approved this research (2019-003). The results will 
      be presented at the association's annual academic meeting and submitted for
      publication in relevant journals. The findings will also be provided to the
      patients via the clinic's internal newsletter.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sato, Kotaro
AU  - Sato K
AUID- ORCID: 0000-0002-3764-469X
AD  - Hokkaido Center for Family Medicine, Murroran, Hokkaido, Japan kotaros@hcfm.jp.
FAU - Michinobu, Ryoko
AU  - Michinobu R
AD  - Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo
      Medical University, Sapporo, Hokkaido, Japan.
FAU - Kusaba, Tesshu
AU  - Kusaba T
AD  - Hokkaido Center for Family Medicine, Murroran, Hokkaido, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200924
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Family Practice
MH  - Humans
MH  - Japan
MH  - Perception
MH  - *Physicians, Family
MH  - Surveys and Questionnaires
PMC - PMC7517553
OTO - NOTNLM
OT  - *primary care
OT  - *protocols & guidelines
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/09/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/25 05:54
PHST- 2020/09/25 05:54 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037113 [pii]
AID - 10.1136/bmjopen-2020-037113 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 24;10(9):e037113. doi: 10.1136/bmjopen-2020-037113.


PMID- 32973057
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 24
TI  - Efficacy and safety of left bundle branch area pacing versus biventricular pacing
      in heart failure patients with left bundle branch block: study protocol for a
      randomised controlled trial.
PG  - e036972
LID - 10.1136/bmjopen-2020-036972 [doi]
AB  - INTRODUCTION: Left bundle branch area pacing (LBBaP) has been accepted as a
      physiological pacing method that can yield narrow paced QRS waves. For patients
      with failed biventricular pacing (Bi-V), LBBaP is another feasible option.
      However, no randomised controlled study has evaluated the efficacy and safety of 
      LBBaP in heart failure patients with left bundle branch block (LBBB). Therefore, 
      we aimed to conduct this type of randomised controlled trial. METHODS AND
      ANALYSIS: This study is a single-centre, randomised controlled non-inferiority
      trial. This study will be conducted at the cardiac centre of Beijing Anzhen
      Hospital. From January 2020 to December 2022, 180 heart failure patients with
      reduced left ventricular ejection fraction (LVEF </=35%) and LBBB undergoing Bi-V
      implantation will be consecutively enrolled in this study. Participants will be
      randomised at a 1:1 ratio into an experimental group (LBBaP) and a control group 
      (Bi-V). The primary outcome is LVEF. The secondary outcomes are NT-proBNP,
      duration of the QRS complex, end systolic volume, end diastolic volume, the
      6-minute walking test and quality of life (SF-36 scale), all causes of mortality,
      cardiovascular death, rehospitalisation rate of heart failure, other
      rehospitalisation rates, major complication rates, procedure costs and
      hospitalised dates. ETHICS AND DISSEMINATION: This study has been approved by the
      Beijing Anzhen Hospital Medical Ethics Committee (No. ks201932). The results of
      this study will be presented at domestic and international conferences. We
      hypothesise that LBBaP is non-inferior compared with Bi-V for treating patients
      with heart failure and LBBB. This trial will provide evidence-based
      recommendations for electrophysiologists. TRIAL REGISTRATION NUMBER: Chinese
      Clinical Trial Registry (ChiCTR2000028726).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cheng, Liting
AU  - Cheng L
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China.
FAU - Zhang, Junmeng
AU  - Zhang J
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China.
FAU - Wang, Zefeng
AU  - Wang Z
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China.
FAU - Zhou, Mengge
AU  - Zhou M
AD  - Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, 
      the Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of
      Education, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing,
      China.
FAU - Liang, Zhuo
AU  - Liang Z
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China.
FAU - Zhao, Lin
AU  - Zhao L
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China.
FAU - Chen, Jieruo
AU  - Chen J
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China.
FAU - Wu, Yongquan
AU  - Wu Y
AUID- ORCID: 0000-0001-9156-4669
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China wuyongquan67@163.com.
LA  - eng
SI  - ChiCTR/ChiCTR2000028726
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200924
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bundle-Branch Block/therapy
MH  - *Cardiac Resynchronization Therapy
MH  - Electrocardiography
MH  - *Heart Failure/complications/therapy
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Stroke Volume
MH  - Treatment Outcome
MH  - Ventricular Function, Left
PMC - PMC7517551
OTO - NOTNLM
OT  - *cardiology
OT  - *heart failure
OT  - *pacing & electrophysiology
COIS- Competing interests: None declared.
EDAT- 2020/09/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/25 05:54
PHST- 2020/09/25 05:54 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036972 [pii]
AID - 10.1136/bmjopen-2020-036972 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 24;10(9):e036972. doi: 10.1136/bmjopen-2020-036972.


PMID- 32973050
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 24
TI  - Retrospective analysis of medical malpractice claims in tertiary hospitals of
      China: the view from patient safety.
PG  - e034681
LID - 10.1136/bmjopen-2019-034681 [doi]
AB  - OBJECTIVES: The study analysed medical malpractice claims to assess patient
      safety in hospitals. The information derived from malpractice claims reflects
      potential risks and could help lead to reducing medical errors and improving
      patient safety. DESIGN, SETTING: We analysed 4380 medical malpractice claims from
      351 grade-A tertiary hospitals in China for 2008-2017. We examined the
      characteristics of medical errors and patient safety, including the types of
      medical errors, proportionate liabilities and payments for medical malpractice in
      different clinical specialties. MAIN OUTCOME MEASURES: We assessed claim
      characteristics, payment amounts and liability. RESULTS: Our data analysis
      demonstrated that 72.5% of the claims involved medical errors, with average
      payments of US$31 430. The hospital's errors in medical malpractice resulted in
      41.4% average liability in patient injury payments. Most medical malpractice
      cases occurred in Shanghai (817 claims, 18.7%) and Beijing (468 claims, 10.7%).
      The highest risks for medical error and malpractice claims were related to
      orthopaedics (11.3% of all claims, 72.8% with medical errors) and obstetrics and 
      gynaecology (10.0% of all claims, 76.0% with medical errors). The highest rates
      related to proportionate liabilities were observed in otolaryngology (51.9%) and 
      endocrinology (47.7%). Respiratory medicine had the highest proportion of claims 
      in death rates (77.3%). Medical technology errors accounted for 91.8% of the
      claims and medical ethics errors for 5.8%. The highest average payment was found 
      in cardiovascular surgery (US$41 733) and the lowest in stomatology (US$8822).
      CONCLUSIONS: A previous study found that grade-A tertiary hospitals in China have
      similar medical error rates to general Chinese hospitals. (36)Different
      specialties had different risk characteristics regarding medical errors, payments
      and proportionate liabilities. Orthopaedics had the highest number of
      malpractices claims and higher proportionate liability but lower death rates.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Heng
AU  - Li H
AUID- ORCID: 0000-0003-4854-8537
AD  - School of Public Health, Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
AD  - Center for HTA, China Hospital Development Institute, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Dong, Shengjie
AU  - Dong S
AUID- ORCID: 0000-0002-4573-8792
AD  - School of Public Health, Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
AD  - Center for HTA, China Hospital Development Institute, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Liao, Ziyi
AU  - Liao Z
AD  - School of Public Health, Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Yao, Yao
AU  - Yao Y
AUID- ORCID: 0000-0002-1191-9843
AD  - China Hospital Development Institute, Shanghai Jiao Tong University, Shanghai,
      China.
FAU - Yuan, Suwei
AU  - Yuan S
AD  - China Hospital Development Institute, Shanghai Jiao Tong University, Shanghai,
      China.
FAU - Cui, Yujie
AU  - Cui Y
AD  - China Hospital Development Institute, Shanghai Jiao Tong University, Shanghai,
      China.
FAU - Li, Guohong
AU  - Li G
AUID- ORCID: 0000-0003-0445-5363
AD  - School of Public Health, Shanghai Jiao Tong University School of Medicine,
      Shanghai, China guohongli@sjtu.edu.cn.
AD  - Center for HTA, China Hospital Development Institute, Shanghai Jiao Tong
      University, Shanghai, China.
AD  - China Hospital Development Institute, Shanghai Jiao Tong University, Shanghai,
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200924
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Beijing
MH  - China
MH  - Female
MH  - Humans
MH  - *Malpractice
MH  - Medical Errors
MH  - *Patient Safety
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Tertiary Care Centers
PMC - PMC7517568
OTO - NOTNLM
OT  - *health & safety
OT  - *law (see medical law)
OT  - *medical law
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/09/26 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/25 05:54
PHST- 2020/09/25 05:54 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034681 [pii]
AID - 10.1136/bmjopen-2019-034681 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 24;10(9):e034681. doi: 10.1136/bmjopen-2019-034681.


PMID- 32972663
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1873-2860 (Electronic)
IS  - 0933-3657 (Linking)
VI  - 108
DP  - 2020 Aug
TI  - Canada protocol: An ethical checklist for the use of artificial Intelligence in
      suicide prevention and mental health.
PG  - 101934
LID - S0933-3657(19)31243-6 [pii]
LID - 10.1016/j.artmed.2020.101934 [doi]
FAU - Morch, Carl-Maria
AU  - Morch CM
AD  - Algora Lab, University of Montreal, Canada; International Observatory on the
      Societal Impacts of AI and Digital Technology (OBVIA), Canada; Mila - Quebec
      Artificial Intelligence Institute, Canada; Psychology Department, Universite Du
      Quebec a Montreal, Canada; Centre for Research and Intervention on Suicide,
      Ethical Issues and End of Life Practices (CRISE), Montreal, Canada. Electronic
      address: carl.morch@umontreal.ca.
FAU - Gupta, Abhishek
AU  - Gupta A
AD  - Montreal AI Ethics Institute, Canada; Microsoft, Canada.
FAU - Mishara, Brian L
AU  - Mishara BL
AD  - Psychology Department, Universite Du Quebec a Montreal, Canada; Centre for
      Research and Intervention on Suicide, Ethical Issues and End of Life Practices
      (CRISE), Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200718
PL  - Netherlands
TA  - Artif Intell Med
JT  - Artificial intelligence in medicine
JID - 8915031
SB  - IM
MH  - *Artificial Intelligence
MH  - Big Data
MH  - Checklist
MH  - Humans
MH  - Mental Health
MH  - *Suicide/prevention & control
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Big Data
OT  - *Ethics
OT  - *Machine learning
OT  - *Mental Health
OT  - *Prevention
OT  - *Suicide
EDAT- 2020/09/26 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/25 05:36
PHST- 2019/11/26 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/09/25 05:36 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - S0933-3657(19)31243-6 [pii]
AID - 10.1016/j.artmed.2020.101934 [doi]
PST - ppublish
SO  - Artif Intell Med. 2020 Aug;108:101934. doi: 10.1016/j.artmed.2020.101934. Epub
      2020 Jul 18.


PMID- 32972591
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
VI  - 72
IP  - 4
DP  - 2020 Oct
TI  - Hydration may reverse most symptoms of lower extremity intermittent claudication 
      or rest pain.
PG  - 1459-1463
LID - S0741-5214(20)31457-9 [pii]
LID - 10.1016/j.jvs.2020.05.066 [doi]
AB  - BACKGROUND: Medical treatment of severe intermittent claudication or critical
      limb-threatening ischemia causing rest pain frequently achieves only partial
      relief or is not effective at all. METHODS: Patients with severe intermittent
      claudication or rest pain of the lower extremities who did not improve after
      control of risk factors, supervised exercises, and cilostazol medication were
      included in this study. All patients were treated with hydration. They were asked
      to drink 2500 mL of fluids (water, soup, milk) during a 24-hour period and to
      ingest 0.6 g/kg of albumin a day, as egg white or albumin powder. Total salt
      administered daily was 3.5 g. Symptoms, skin temperature, ankle-brachial index,
      albumin concentration in serum, and time and distance to claudication were
      recorded before treatment, at 6 weeks, and at 6 months. Electrolytes were
      measured monthly. No additional treatment was used during the study. Walking was 
      encouraged but not supervised. The trial has continued indefinitely. For
      statistical analysis, SPSS software (IBM Corp, Armonk, NY) was used. The Ethical 
      Committee approved the protocol, and an informed consent was signed by all
      patients. RESULTS: There were 132 patients (94 male, 38 female) included in the
      study. Median age was 72.5 years (range, 67-77 years); all had severe
      claudication of a mean of 100 meters or rest pain. Symptoms had been present for 
      >5 months in all patients; 22 (16.8%) had rest pain. Proper hydration, determined
      as drinking at least 2000 mL of water during 24 hours for a period of 6 months,
      was achieved in 131 compliant patients. Only one patient failed to drink 2000 mL 
      of water or more. Ankle-brachial index in 131 compliant patients improved from
      0.6 to 0.75 (P < .0001) after 6 months. Skin temperature of the feet increased
      from 29.4 degrees C to 31.7 degrees C (P = .009). Distance to claudication using 
      the treadmill improved from 100 meters to 535 meters (P < .0001) at 6 weeks and
      remained stable at 6 month in 65.83% of the patients; in 34.17% of them, distance
      to claudication increased further by 200 (100-500) meters and time to
      claudication improved from 1.3 to 6.3 minutes (P < .0001) at 6 weeks, but the
      same group of patients (34.17%) that increased the distance to claudication
      further prolonged the time to claudication by 2.49 (1.24-6.23) minutes. All 131
      compliant patients improved their status related to lower extremity ischemia; the
      noncompliant patient did not have any variation of symptoms, skin temperature,
      ankle-brachial index, or time and distance to claudication. All patients survived
      the initial 6 months of treatment; afterward, three patients abandoned the
      treatment and four died of unrelated causes. After the 6-month control, 49% of
      the patients continued to improve the time and distance to claudication as well
      as the ankle-brachial index. The rest of the patients conserved the initial
      improvement. Five patients who had significantly improved the time and distance
      to claudication were asked to decrease water intake for 3 days. No changes in
      time and distance to claudication were detected. Hydration was reinitiated.
      CONCLUSIONS: This study suggests that proper hydration by drinking >/=2000 mL of 
      water daily and albumin complement orally to reach 4 g/dL in serum could be
      included in the armamentarium of physicians treating patients with disabling
      claudication or rest pain caused by peripheral artery disease. Further
      comparative studies to assess the benefit of hydration and increasing the serum
      oncotic pressure are warranted.
CI  - Copyright (c) 2020 Society for Vascular Surgery. Published by Elsevier Inc. All
      rights reserved.
FAU - Parodi, Juan Carlos
AU  - Parodi JC
AD  - Vascular Surgery, Trinidad Hospital, San Isidro, Buenos Aires, Argentina.
      Electronic address: parodijc@yahoo.com.
FAU - Fernandez, Samuel
AU  - Fernandez S
AD  - Vascular Surgery, Malvinas Argentinas Hospital, Buenos Aires, Argentina.
FAU - Moscovich, Fabian
AU  - Moscovich F
AD  - Physical Therapy, Malvinas Argentinas Hospital, Buenos Aires, Argentina.
FAU - Pulmaria, Camilo
AU  - Pulmaria C
AD  - Cardiology, Malvinas Argentinas Hospital, Buenos Aires, Argentina.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
SB  - IM
EIN - J Vasc Surg. 2020 Dec;72(6):2222. PMID: 33222837
MH  - Aged
MH  - Drinking
MH  - Female
MH  - Fluid Therapy/*methods
MH  - Humans
MH  - Intermittent Claudication/diagnosis/etiology/*therapy
MH  - Ischemia/diagnosis/etiology/*therapy
MH  - Lower Extremity/blood supply
MH  - Male
MH  - Pain/etiology
MH  - Pain Management/*methods
MH  - Peripheral Arterial Disease/complications/*therapy
MH  - Prospective Studies
MH  - Rest
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Intermittent claudication
OT  - *Rest pain
OT  - *dehydration
EDAT- 2020/09/26 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/09/25 05:34
PHST- 2020/04/03 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/09/25 05:34 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - S0741-5214(20)31457-9 [pii]
AID - 10.1016/j.jvs.2020.05.066 [doi]
PST - ppublish
SO  - J Vasc Surg. 2020 Oct;72(4):1459-1463. doi: 10.1016/j.jvs.2020.05.066.


PMID- 32972373
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1471-2288 (Electronic)
IS  - 1471-2288 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 24
TI  - Integrating trials into a whole-population cohort of children and parents:
      statement of intent (trials) for the Generation Victoria (GenV) cohort.
PG  - 238
LID - 10.1186/s12874-020-01111-x [doi]
AB  - BACKGROUND: Very large cohorts that span an entire population raise new prospects
      for the conduct of multiple trials that speed up advances in prevention or
      treatment while reducing participant, financial and regulatory burden. However, a
      review of literature reveals no blueprint to guide this systematically in
      practice. This Statement of Intent proposes how diverse trials may be integrated 
      within or alongside Generation Victoria (GenV), a whole-of-state Australian birth
      cohort in planning, and delineates potential processes and opportunities.
      METHODS: Parents of all newborns (estimated 160,000) in the state of Victoria,
      Australia, will be approached for two full years from 2021. The cohort design
      comprises four elements: (1) consent soon after birth to follow the child and
      parent/s until study end or withdrawal; retrospective and prospective (2) linkage
      to clinical and administrative datasets and (3) banking of universal and clinical
      biosamples; and (4) GenV-collected biosamples and data. GenV-collected data will 
      focus on overarching outcome and phenotypic measures using low-burden,
      universal-capable electronic interfaces, with funding-dependent face-to-face
      assessments tailored to universal settings during the early childhood, school
      and/or adult years. RESULTS: For population or registry-type trials within GenV, 
      GenV will provide all outcomes data and consent via traditional, waiver, or
      Trials Within Cohorts models. Trials alongside GenV consent their own
      participants born within the GenV window; GenV may help identify potential
      participants via opt-in or opt-out expression of interest. Data sharing enriches 
      trials with outcomes, prior data, and/or access to linked data contingent on
      custodian's agreements, and supports modeling of causal effects to the population
      and between-trials comparisons of costs, benefits and utility. Data access will
      operate under the Findability, Accessibility, Interoperability, and Reusability
      (FAIR) and Care and Five Safes Principles. We consider governance, ethical and
      shared trial oversight, and expectations that trials will adhere to the best
      practice of the day. CONCLUSIONS: Children and younger adults can access fewer
      trials than older adults. Integrating trials into mega-cohorts should improve
      health and well-being by generating faster, larger-scale evidence on a longer
      and/or broader horizon than previously possible. GenV will explore the limits and
      details of this approach over the coming years.
FAU - Wake, Melissa
AU  - Wake M
AUID- ORCID: 0000-0001-7501-9257
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia. melissa.wake@mcri.edu.au.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052,
      Australia. melissa.wake@mcri.edu.au.
FAU - Hu, Yanhong Jessika
AU  - Hu YJ
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052,
      Australia.
FAU - Warren, Hayley
AU  - Warren H
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
FAU - Danchin, Margie
AU  - Danchin M
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052,
      Australia.
AD  - The Royal Children's Hospital, Parkville, VIC, 3052, Australia.
FAU - Fahey, Michael
AU  - Fahey M
AD  - Department of Paediatrics, Monash University, Clayton, VIC, 3168, Australia.
AD  - Monash Children's Hospital, Clayton, VIC, 3168, Australia.
FAU - Orsini, Francesca
AU  - Orsini F
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
FAU - Pacilli, Maurizio
AU  - Pacilli M
AD  - Department of Paediatrics, Monash University, Clayton, VIC, 3168, Australia.
AD  - Monash Children's Hospital, Clayton, VIC, 3168, Australia.
FAU - Perrett, Kirsten P
AU  - Perrett KP
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052,
      Australia.
AD  - The Royal Children's Hospital, Parkville, VIC, 3052, Australia.
FAU - Saffery, Richard
AU  - Saffery R
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052,
      Australia.
FAU - Davidson, Andrew
AU  - Davidson A
AD  - Murdoch Children's Research Institute, The Royal Children's Hospital, 50
      Flemington Road, Parkville, VIC, 3052, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC, 3052,
      Australia.
AD  - The Royal Children's Hospital, Parkville, VIC, 3052, Australia.
LA  - eng
GR  - Operational Infrastructure Support Program/Victorian Government/International
GR  - 2019-1226/Royal Children's Hospital Foundation/International
GR  - Principal Research Fellowship 1160906/National Health and Medical Research
      Council/International
GR  - David Bickart Clinician Scientist Fellowship/University of
      Melbourne/International
GR  - Clinician Scientist Fellowship/Melbourne Children's/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200924
PL  - England
TA  - BMC Med Res Methodol
JT  - BMC medical research methodology
JID - 100968545
SB  - IM
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - *Family
MH  - Humans
MH  - Infant, Newborn
MH  - *Parents
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Victoria
PMC - PMC7512047
OTO - NOTNLM
OT  - *Children
OT  - *Clinical trial as topic
OT  - *Generation Victoria (GenV)
OT  - *Intervention
OT  - *Multiple baseline randomized trials
OT  - *Population studies
OT  - *Randomization
OT  - *Registry trials
OT  - *Research methodology
OT  - *Trials within cohorts
EDAT- 2020/09/26 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/25 05:32
PHST- 2020/05/21 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/25 05:32 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s12874-020-01111-x [doi]
AID - 10.1186/s12874-020-01111-x [pii]
PST - epublish
SO  - BMC Med Res Methodol. 2020 Sep 24;20(1):238. doi: 10.1186/s12874-020-01111-x.


PMID- 32972185
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 66
IP  - 4
DP  - 2020 Summer
TI  - Witholding dialysis in elderly patients with chronic kidney disease.
PG  - 53-60
AB  - Elderly patients with advanced chronic kidney disease have high symptom burden,
      despite the progress in renal replacement therapy. Dialysis is not a good option 
      especially for frail elderly patients with higher comorbidity rate. Integration
      of palliative and supportive care to conservative management improves quality of 
      life and prolongs survival of these patients. Conservative management of
      symptoms, prognostication, communication of advance care plans and
      shared-decision making should be a part of physicians skills. There are some
      recommended prognostication systems in nephrology, which can help to facilitate
      the physician-patient communication about therapeutic goals of care. Ethical and 
      jural aspects of the process are also very important.
FAU - Kremenova, Zuzana
AU  - Kremenova Z
FAU - Szonowska, Barbora
AU  - Szonowska B
FAU - Vrablova, Barbora
AU  - Vrablova B
LA  - eng
PT  - Journal Article
TT  - Problematika nezahajeni dialyzy u geriatrickych pacient&#367; s pokro&#269;ilym
      chronickym onemocn&#283;nim ledvin.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Kidney Failure, Chronic
MH  - *Nephrology
MH  - Quality of Life
MH  - Renal Dialysis
MH  - *Renal Insufficiency, Chronic/therapy
OTO - NOTNLM
OT  - advanced care plan
OT  - chronic kidney disease
OT  - conservative management
OT  - frailty
OT  - palliative/supportive care
OT  - prognostication
EDAT- 2020/09/26 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/25 05:30
PHST- 2020/09/25 05:30 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 123893 [pii]
PST - ppublish
SO  - Vnitr Lek. 2020 Summer;66(4):53-60.


PMID- 32972111
OWN - NLM
STAT- Publisher
LR  - 20200925
IS  - 1827-1855 (Electronic)
IS  - 0390-5616 (Linking)
DP  - 2020 Sep 24
TI  - Surgical outcomes of traumatic C2 body fractures: a retrospective analysis.
LID - 10.23736/S0390-5616.20.05004-3 [doi]
AB  - BACKGROUND: C2 vertebral body fractures are relatively rare fractures with no
      defined management protocol and outcomes. The aim of the study is to evaluate the
      clinical and radiological outcomes of C2 body fratecures. METHODS: The study was 
      conducted at the Department of Neurosurgery, Nizam's Iinstitute of Medical
      Sciences, Hyderabad, India, following clearance from the Institutional Ethical
      Committee. The data of all patients with traumatic C2 body fracture who were
      managed in our department between Jan'2008 to Jan'2019 was retrieved from the
      database. Functional status of the patients was assessed by Neck disability index
      while pain was assessed by VAS at follow up after at least 6 months. Fusion and
      regional kyphotic angles (O-C2 and C2-C7) were assessed for radiological outcome.
      RESULTS: There were a total of 16 patients with isolated C2 body fractures in the
      defined time period. The male (n=11) : female (n=5) distribution was 2.2:1. Ten
      patients had road traffic accidents while the remaining 6 had history of fall
      from height. Only 3 patients presented with neurological deficits. Benzel Type -3
      fracture pattern distribution was the most common fracture pattern (Type 1 = 1,
      Type 2 = 5, Type 3 = 9). Of these, 10 were operated and 6 were managed
      conservatively. The VAS and NDI values improved significantly in all at follow up
      when compared to values at presentation (p = 0.001). Time to return to work was
      significantly shorter in those treated with surgical intervention (mean = 2.9 +
      0.87) (p = 0.001). Fusion was achieved in all the patients in both groups. Mean
      O-C2 angle at follow up was 21.13 + 10.1. Mean O-C2 angle was significantly
      decreased in non-surgical group at follow up (p = 0.039) but no significant
      reduction was observed in surgical group. CONCLUSIONS: The management of C2 body 
      fractures needs to be individualized, reserving surgical management for fractures
      requiring fragment retrival or restitution of alignment if facets were fractured.
FAU - Pasham, Amarendra
AU  - Pasham A
AD  - Department of Neurosurgery, Nizam's Institute of Medical Sciences, Punjagutta,
      Hyderabad, India.
FAU - Mudumba, Vijaya Saradhi
AU  - Mudumba VS
AD  - Department of Neurosurgery, Nizam's Institute of Medical Sciences, Punjagutta,
      Hyderabad, India - mvijayasaradhi@gmail.com.
FAU - Alugolu, Rajesh
AU  - Alugolu R
AD  - Department of Neurosurgery, Nizam's Institute of Medical Sciences, Punjagutta,
      Hyderabad, India.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - Italy
TA  - J Neurosurg Sci
JT  - Journal of neurosurgical sciences
JID - 0432557
SB  - IM
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/25 03:05
PHST- 2020/09/25 03:05 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - S0390-5616.20.05004-3 [pii]
AID - 10.23736/S0390-5616.20.05004-3 [doi]
PST - aheadofprint
SO  - J Neurosurg Sci. 2020 Sep 24. pii: S0390-5616.20.05004-3. doi:
      10.23736/S0390-5616.20.05004-3.


PMID- 32971910
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - New Frontiers and Old Challenges: How to Manage Incidental Findings When Forensic
      Diagnosis Goes Beyond.
LID - E731 [pii]
LID - 10.3390/diagnostics10090731 [doi]
AB  - Incidental findings (IFs) are well known in medical research and clinical
      practice as unexpected findings having potential health or reproductive
      importance for an individual. IFs are discovered under different contexts but do 
      not fall within the aim of a study, and/or are unanticipated or unintentionally
      revealed, and/or are not the specific focus or target of the particular research 
      or clinical query. Today, in forensic settings, we can consider as incidental
      findings all the information that is neither related to the cause of death nor to
      the dynamic of the event or the scope of the forensic investigation. The question
      whether and how professionals should consider traditional values as guiding
      notions in the reporting of IFs in the context of forensic assessments is the
      focus of this article. We propose a descriptive analysis, which focuses on the
      forensic field, describing forensic situations in which IFs may occur, and
      whether and to whom they may be disclosed. Some considerations will be provided
      regarding forensic experts concerning their moral commitment to warn relatives
      about IFs.
FAU - Caenazzo, Luciana
AU  - Caenazzo L
AUID- ORCID: 0000-0003-3142-2874
AD  - Department of Molecular Medicine, Laboratory of Forensic Genetics, University of 
      Padova, 35121 Padova, Italy.
FAU - Tozzo, Pamela
AU  - Tozzo P
AD  - Department of Molecular Medicine, Laboratory of Forensic Genetics, University of 
      Padova, 35121 Padova, Italy.
FAU - Dierickx, Kris
AU  - Dierickx K
AUID- ORCID: 0000-0002-1016-1145
AD  - Centre for Biomedical Ethics and Law, Faculty of Medicine-KU Leuven,
      Kapucijnenvoer 35 Box 7001, 3000 Leuven, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7555971
OTO - NOTNLM
OT  - confidentiality
OT  - ethical challenges
OT  - forensics
OT  - incidental findings
OT  - information disclosure
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 01:01
PHST- 2020/08/25 00:00 [received]
PHST- 2020/09/18 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/09/25 01:01 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - diagnostics10090731 [pii]
AID - 10.3390/diagnostics10090731 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2020 Sep 22;10(9). pii: diagnostics10090731. doi:
      10.3390/diagnostics10090731.


PMID- 32971754
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201103
IS  - 2306-7381 (Electronic)
IS  - 2306-7381 (Linking)
VI  - 7
IP  - 3
DP  - 2020 Sep 22
TI  - Identifying Sources of Potential Bias When Using Online Survey Data to Explore
      Horse Training, Management, and Behaviour: A Systematic Literature Review.
LID - E140 [pii]
LID - 10.3390/vetsci7030140 [doi]
AB  - Owner-reported behavioural observations form an essential part of the
      veterinarians' diagnosis and treatment plan. The way we train and manage horses
      affects their behaviour and, in turn, their health and welfare. Current horse
      training and management practices are largely driven by traditional techniques
      and longstanding methodologies. These approaches generally lack an evidence base 
      for evaluation purposes. The absence of evidence and evaluation contributes to
      the persistent use of risky practices and this, in turn, increases risk of
      potential harms for both horse and rider, and fuels questioning of the equine
      industry's current social license to operate. Objective evidence is required to
      make training and management decisions based on demonstrable best practice.
      Large-scale experimental or intervention studies using horses are generally not
      practical because of the associated costs and logistics of gaining ethical
      approval. Small studies generally lack statistical power and are subject to the
      effects of many forms of bias that demand caution in the interpretation of any
      observed effects. An alternative to collecting large amounts of empirical data is
      the use of owner-reported observations via online survey. Horse owners are
      ideally placed to report on the domestic equine triad of training, management,
      and behaviour. The current article highlights three sources of potential bias in 
      a systematic review of literature on large-scale online studies of horse owners' 
      observational reports that met the following selection criteria:
      English-language, published, peer-reviewed articles reporting on studies with
      over 1000 respondents and open access to the survey instrument. The online
      surveys were evaluated for three common forms of bias: recall, confirmation, and 
      sampling bias. This review reveals that online surveys are useful for gathering
      data on the triad of horse training, management, and behaviour. However, current 
      use of online surveys to collect data on equitation science (including horse
      training, management, and behaviour) could be improved by using a standardised
      and validated tool. Such a tool would facilitate comparisons among equine and
      equitation science studies, thus advancing our understanding of the impacts of
      training and management on horse behaviour. The authors of the current review
      suggest the use of a standardised behavioural and management assessment tool for 
      horses. Such a tool would help define what constitutes normal behaviour within
      geographically disparate populations of horses, leading to improvements in rider 
      safety and horse welfare.
FAU - Fenner, Kate
AU  - Fenner K
AUID- ORCID: 0000-0002-0649-3278
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney,
      Sydney, NSW 2006, Australia.
FAU - Hyde, Michelle
AU  - Hyde M
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney,
      Sydney, NSW 2006, Australia.
FAU - Crean, Angela
AU  - Crean A
AUID- ORCID: 0000-0003-2605-6435
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney,
      Sydney, NSW 2006, Australia.
FAU - McGreevy, Paul
AU  - McGreevy P
AUID- ORCID: 0000-0001-7220-8378
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney,
      Sydney, NSW 2006, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200922
PL  - Switzerland
TA  - Vet Sci
JT  - Veterinary sciences
JID - 101680127
PMC - PMC7558402
OTO - NOTNLM
OT  - domestic equine triad
OT  - equine veterinary behaviour
OT  - horse behaviour
OT  - owner-reported observations
OT  - social license
OT  - survey bias
EDAT- 2020/09/26 06:00
MHDA- 2020/09/26 06:01
CRDT- 2020/09/25 01:00
PHST- 2020/07/31 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/09/21 00:00 [accepted]
PHST- 2020/09/25 01:00 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2020/09/26 06:01 [medline]
AID - vetsci7030140 [pii]
AID - 10.3390/vetsci7030140 [doi]
PST - epublish
SO  - Vet Sci. 2020 Sep 22;7(3). pii: vetsci7030140. doi: 10.3390/vetsci7030140.


PMID- 32971557
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 145
IP  - 19
DP  - 2020 Sep
TI  - [Out-of-hospital cardiac arrest: current diagnostic and therapeutical concepts].
PG  - 1420-1428
LID - 10.1055/a-1015-1635 [doi]
AB  - Out-of-hospital circulatory arrest represents a challenging situation in
      emergency medicine even until today. Despite optimal emergency care and clinical 
      treatment pathways, we are faced with a mortality rate above 90 %. It is possible
      to improve the survival rate to more than 40 % under ideal clinical and
      preclinical conditions. Thus, more people's life could be saved by standardized
      SOPs and networks in emergency medicine. About 14.000 preclinical resuscitation
      cases are reported in Germany per year. The prognosis out-of-hospital circulatory
      arrest patients is determined by best preclinical treatment including early
      resuscitation by bystanders. However, ethical considerations for not performing
      cardiopulmonary resuscitation include comorbidities, advanced age, and prognostic
      markers of intensive care medicine like lactate level or neuron-specific enolase.
      Since myocardial infarction is the underlying disease in about 3 quarters of
      acute circulatory arrest cases, early angiography and coronary revascularization 
      is of upmost importance. In addition, it is essential to provide hemodynamic
      stabilization for prevention of multiorgan dysfunction syndrome. Neuroprotection 
      by therapeutic hypothermia may further help to improve survival and quality of
      life. Mechanical circulatory support devices may be considered adjunct to
      pharmacological measures for hemodynamic stabilization. Due to lack of evidence, 
      these devices are currently under evaluation and prospectively randomized trials.
      We expect new treatment algorithms for optimal care of these high-risk patients
      in the near future.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Ferrari, Markus W
AU  - Ferrari MW
FAU - Ferrari-Kuhne, Katharina
AU  - Ferrari-Kuhne K
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Diagnostik und Therapie nach praklinischem Kreislaufstillstand.
DEP - 20200924
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
MH  - Comorbidity
MH  - Coronary Angiography
MH  - Emergency Treatment
MH  - Germany
MH  - Humans
MH  - Hypothermia, Induced
MH  - Out-of-Hospital Cardiac Arrest/*diagnosis/physiopathology/*therapy
MH  - Prognosis
COIS- MWF war als Referent und Ausbilder fur die Firma Abiomed tatig. Er ist Mitgrunder
      der Firma Novapump. KFK bestatigt, dass keine Interessenkonflikte bestehen.
EDAT- 2020/09/25 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/09/24 20:20
PHST- 2020/09/24 20:20 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - 10.1055/a-1015-1635 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2020 Sep;145(19):1420-1428. doi: 10.1055/a-1015-1635. Epub 
      2020 Sep 24.


PMID- 32970899
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1467-9566 (Electronic)
IS  - 0141-9889 (Linking)
VI  - 42
IP  - 8
DP  - 2020 Nov
TI  - Giving, receiving ... and forgetting? On the social conditions of receiving an
      anonymous face transplant.
PG  - 1949-1966
LID - 10.1111/1467-9566.13178 [doi]
AB  - In 2004, the French National Consultative Ethics Committee expressed strong
      misgivings about the proposal to include the face among body parts that can be
      removed from deceased donors for organ transplantation. Yet, the first face
      transplant was performed a few months later. How do medical teams and patients
      deal with the singular nature of the face? I argue that what the face represents 
      - from the medium of the donor's personal identity to an interchangeable organ - 
      is not fixed. It emerges through the practices and can evolve through the
      interactions between medical professionals and patients. In the postoperative
      time, I show that patients receive potentially contradictory recommendations
      about how to integrate the organ: to consider it theirs and forget the donor, but
      also to thank the donor for the donation and never forget the origin of the
      graft. Based on the plurality of relationships developed by the patients with
      their donor, I revisit Maussian interpretative analyses of organ reception. The
      effects of giving a face vary both in terms of reciprocity and identity: the
      feeling of debt is variably felt and can be interpreted negatively or positively,
      and the experience is more or less transformative.
CI  - (c) 2020 Foundation for the Sociology of Health & Illness.
FAU - Le Clainche-Piel, Marie
AU  - Le Clainche-Piel M
AUID- ORCID: 0000-0003-1033-8358
AD  - National Centre for Scientific Research, Centre for the Study of Social
      Movements, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200924
PL  - England
TA  - Sociol Health Illn
JT  - Sociology of health & illness
JID - 8205036
SB  - IM
MH  - Emotions
MH  - *Facial Transplantation
MH  - Humans
MH  - *Organ Transplantation
MH  - Social Conditions
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *anonymity
OT  - *brain-dead donor
OT  - *face
OT  - *organ transplantation
OT  - *policy
EDAT- 2020/09/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/24 17:16
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/24 17:16 [entrez]
AID - 10.1111/1467-9566.13178 [doi]
PST - ppublish
SO  - Sociol Health Illn. 2020 Nov;42(8):1949-1966. doi: 10.1111/1467-9566.13178. Epub 
      2020 Sep 24.


PMID- 32970769
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201218
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Knowledge, attitudes, and fear of COVID-19 during the Rapid Rise Period in
      Bangladesh.
PG  - e0239646
LID - 10.1371/journal.pone.0239646 [doi]
AB  - The study aims to determine the level of Knowledge, Attitude, and Practice (KAP) 
      related to COVID-19 preventive health habits and perception of fear towards
      COVID-19 in subjects living in Bangladesh. DESIGN: Prospective, cross-sectional
      survey of (n = 2157) male and female subjects, 13-88 years of age, living in
      Bangladesh. METHODS: Ethical approval and trial registration were obtained before
      the commencement of the study. Subjects who volunteered to participate and signed
      the informed consent were enrolled in the study and completed the structured
      questionnaire on KAP and Fear of COVID-19 scale (FCV-19S). RESULTS: Twenty-eight 
      percent (28.69%) of subjects reported one or more COVID-19 symptoms, and 21.4% of
      subjects reported one or more co-morbidities. Knowledge scores were slightly
      higher in males (8.75+/- 1.58) than females (8.66+/- 1.70). Knowledge was
      significantly correlated with age (p < .005), an education level (p < .001),
      attitude (p < .001), and urban location (p < .001). Knowledge scores showed an
      inverse correlation with fear scores (p < .001). Eighty-three percent (83.7%) of 
      subjects with COVID-19 symptoms reported wearing a mask in public, and 75.4% of
      subjects reported staying away from crowded places. Subjects with one or more
      symptoms reported higher fear compared to subjects without (18.73+/- 4.6;
      18.45+/- 5.1). CONCLUSION: Bangladeshis reported a high prevalence of
      self-isolation, positive preventive health behaviors related to COVID-19, and
      moderate to high fear levels. Higher knowledge and Practice were found in males, 
      higher education levels, older age, and urban location. Fear of COVID-19 was more
      prevalent in female and elderly subjects. A positive attitude was reported for
      the majority of subjects, reflecting the belief that COVID-19 was controllable
      and containable.
FAU - Hossain, Mohammad Anwar
AU  - Hossain MA
AD  - Department of Microbiology, Jashore University of Science & Technology (JUST),
      Jashore, Bangladesh.
FAU - Jahid, Md Iqbal Kabir
AU  - Jahid MIK
AD  - Department of Microbiology, Jashore University of Science & Technology (JUST),
      Jashore, Bangladesh.
FAU - Hossain, K M Amran
AU  - Hossain KMA
AUID- ORCID: 0000-0003-2124-2087
AD  - Department of Physiotherapy, Bangladesh Health Professions Institute (BHPI),
      Dhaka, Bangladesh.
FAU - Walton, Lori Maria
AU  - Walton LM
AUID- ORCID: 0000-0002-3221-7365
AD  - Department of Physical Therapy, School of Health Sciences, University of
      Scranton, Scranton, Pennsylvania, United States of America.
FAU - Uddin, Zakir
AU  - Uddin Z
AD  - School of Physical and Occupational Therapy, Faculty of Medicine, McGill
      University, Montreal, Canada.
FAU - Haque, Md Obaidul
AU  - Haque MO
AD  - Department of Physiotherapy, Bangladesh Health Professions Institute (BHPI),
      Dhaka, Bangladesh.
FAU - Kabir, Md Feroz
AU  - Kabir MF
AUID- ORCID: 0000-0002-5885-4514
AD  - Department of Physiotherapy & Rehabilitation, Jashore University of Science &
      Technology (JUST), Jashore, Bangladesh.
FAU - Arafat, S M Yasir
AU  - Arafat SMY
AUID- ORCID: 0000-0003-0521-5708
AD  - Department of Psychiatry, Enam Medical College Hospital, Dhaka, Bangladesh.
FAU - Sakel, Mohamed
AU  - Sakel M
AD  - East Kent University NHS FT Hospitals, Canterbury, United Kingdom.
FAU - Faruqui, Rafey
AU  - Faruqui R
AD  - Kent & Medway NHS and Social Care Partnership Trust & University of Kent,
      Canterbury, United Kingdom.
FAU - Hossain, Zahid
AU  - Hossain Z
AD  - Department of Physiotherapy, Bangladesh Health Professions Institute (BHPI),
      Dhaka, Bangladesh.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bangladesh/epidemiology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/psychology
MH  - Cross-Sectional Studies
MH  - *Fear
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/psychology
MH  - Prospective Studies
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7514023
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/25 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/24 17:15
PHST- 2020/07/06 00:00 [received]
PHST- 2020/09/11 00:00 [accepted]
PHST- 2020/09/24 17:15 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1371/journal.pone.0239646 [doi]
AID - PONE-D-20-20624 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 24;15(9):e0239646. doi: 10.1371/journal.pone.0239646.
      eCollection 2020.


PMID- 32970544
OWN - NLM
STAT- MEDLINE
DCOM- 20201009
LR  - 20201218
IS  - 1937-190X (Electronic)
IS  - 1937-190X (Linking)
VI  - 35
IP  - 7
DP  - 2020 Sep 1
TI  - Ethics and Racial Equity in Social Welfare Policy: Social Work's Response to the 
      COVID-19 Pandemic.
PG  - 617-632
LID - 10.1080/19371918.2020.1808145 [doi]
AB  - The COVID-19 pandemic has been particularly overwhelming for communities of color
      in the United States. In addition to the higher levels of underlying health
      conditions, circumstances related to a history of oppression and unequal access
      to opportunities and services are apparent. Social service programs will need to 
      be re-developed to accommodate a new reality, both in terms of how people connect
      with services and how social work professionals provide them. Professional social
      work organizations' codes of ethics are analyzed, along with the theoretical
      framework of structural competency. It is an ethical imperative that social
      welfare policy and practice advance as culturally competent, racial equity, and
      empowerment-based programs. Child welfare is portrayed as an example where the
      pandemic could provide an opportunity to learn from the past to construct a more 
      compassionate, competent, and ethical future.
FAU - Wilson, Dana Burdnell
AU  - Wilson DB
AUID- ORCID: 0000-0003-1687-0193
AD  - School of Social Work, Morgan State University , Baltimore, Maryland, USA.
FAU - Solomon, Terry A
AU  - Solomon TA
AD  - Jane Addams College of Social Work, University of Illinois at Chicago , Chicago, 
      Illinois, USA.
AD  - African American Family Research Institute , Chicago, Illinois, USA.
FAU - McLane-Davison, Denise
AU  - McLane-Davison D
AD  - School of Social Work, Morgan State University , Baltimore, Maryland, USA.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
PL  - United States
TA  - Soc Work Public Health
JT  - Social work in public health
JID - 101308228
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Cultural Competency
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - *Public Policy
MH  - Racism/*ethics
MH  - SARS-CoV-2
MH  - Social Welfare/*ethics
MH  - Social Work/*ethics
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *COVID-19 pandemic & social work
OT  - *Ethics
OT  - *racial equity
OT  - *social welfare policy
EDAT- 2020/09/25 06:00
MHDA- 2020/10/10 06:00
CRDT- 2020/09/24 17:13
PHST- 2020/09/24 17:13 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/10/10 06:00 [medline]
AID - 10.1080/19371918.2020.1808145 [doi]
PST - ppublish
SO  - Soc Work Public Health. 2020 Sep 1;35(7):617-632. doi:
      10.1080/19371918.2020.1808145.


PMID- 32969825
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 24
TI  - Reward Responsiveness, Optimism, and Social and Mental Functioning in Children
      Aged 6-7: Protocol of a Cross-Sectional Pilot Study.
PG  - e18902
LID - 10.2196/18902 [doi]
AB  - BACKGROUND: There is evidence that reward responsiveness and optimism are
      associated with mental and social functioning in adolescence and adulthood, but
      it is unknown if this is also the case for young children. Part of the reason for
      this gap in the literature is that the instruments that are used to assess reward
      responsiveness and optimism in adolescents and adults are usually not suitable
      for young children. OBJECTIVE: Two behavioral tasks to assess reward learning, a 
      questionnaire on reward responsiveness, and a questionnaire on optimism/pessimism
      will be tested on their feasibility and reliability in children aged 6-7.
      Depending on their feasibility and reliability, these instruments will also be
      used to investigate if reward responsiveness and optimism are associated with
      mental and social functioning in young children. METHODS: For this
      cross-sectional pilot study, we adapted a number of tasks and questionnaires to
      the needs of 6-7-year-old children, by simplification of items, oral rather than 
      written assessment, and reducing the number of conditions and items. We will
      approach teachers and, with their help, aim to include 70 children aged 6-7 to
      assess the feasibility and reliability of the tasks and questionnaires.
      Feasibility measures that will be reported are the proportion of children
      completing the task/questionnaire, the proportion of children that were able to
      explain the instructions in their own words to the researcher, and the proportion
      of children that correctly answered the control questions. The reliability of the
      scales will be assessed by computing Cronbach alpha and item-total score
      correlations and the reliability of the tasks by correlations between different
      consecutive blocks of trials. Ethics approval was obtained from the Ethics
      Committee of the Department of Pedagogy and Educational Sciences. RESULTS: Data
      collection was originally planned in March and April 2020, but has been postponed
      due to Corona virus regulations. We expect to collect the data in the first half 
      of 2021. The findings will be disseminated in preprints and peer-reviewed
      publications. CONCLUSIONS: The development of feasible and reliable instruments
      for assessing reward responsiveness and optimism in young children is expected to
      benefit future research on underlying mechanisms of mental and social functioning
      in young children. If the instruments assessed in this study are usable with
      young children, it would be particularly interesting to include them in cohort
      studies because this would enable investigating not only concurrent associations,
      but also prospective associations between reward responsiveness and optimism
      early in life and mental and social functioning later in life. If, as we
      hypothesize, reward responsiveness and optimism are not only associated with
      (prospective) mental and social functioning in adults and adolescents but also in
      young children, this could provide a way of identifying vulnerable children
      already at an early stage. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      PRR1-10.2196/18902.
CI  - (c)Charlotte Vrijen, Megane Alice Ackermans, Anna Bosma, Tina Kretschmer.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 24.09.2020.
FAU - Vrijen, Charlotte
AU  - Vrijen C
AUID- ORCID: https://orcid.org/0000-0001-5144-7863
AD  - Faculty of Behavioural and Social Sciences, University of Groningen, Groningen,
      Netherlands.
FAU - Ackermans, Megane Alice
AU  - Ackermans MA
AUID- ORCID: https://orcid.org/0000-0001-7083-3903
AD  - Faculty of Behavioural and Social Sciences, University of Groningen, Groningen,
      Netherlands.
FAU - Bosma, Anna
AU  - Bosma A
AUID- ORCID: https://orcid.org/0000-0001-8540-4597
AD  - Faculty of Behavioural and Social Sciences, University of Groningen, Groningen,
      Netherlands.
FAU - Kretschmer, Tina
AU  - Kretschmer T
AUID- ORCID: https://orcid.org/0000-0001-6936-9285
AD  - Faculty of Behavioural and Social Sciences, University of Groningen, Groningen,
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7545321
OTO - NOTNLM
OT  - children
OT  - mental health
OT  - optimism
OT  - reward responsiveness
OT  - risk-taking
OT  - social relations
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 12:11
PHST- 2020/03/26 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/09/24 12:11 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - v9i9e18902 [pii]
AID - 10.2196/18902 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Sep 24;9(9):e18902. doi: 10.2196/18902.


PMID- 32969411
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20210722
IS  - 2353-1339 (Electronic)
IS  - 0465-5893 (Linking)
VI  - 71
IP  - 5
DP  - 2020 Sep 24
TI  - [Medical error in theory and practice - a review of the most important issues].
PG  - 613-630
LID - 122665 [pii]
LID - 10.13075/mp.5893.00988 [doi]
AB  - In recent years, in Poland, despite the lack of an adverse medical events
      monitoring system, a sharp increase in the number of complaints to various
      medical and legal institutions, as well as court cases with a suspicion of a
      medical error, was found, based on the available reports and statistics, which
      poses a serious medical and legal. The aim of this study was to review the
      theoretical and practical issues of medical errors in the medico-legal context on
      the basis of the current legislation in Poland. This paper presents the
      conceptual scope and the evolution of terminology, starting from "error in the
      medical art/craft" up to the currently defined and used concept of "medical
      error." The problem of medical errors in medico-legal categories, according to
      Polish legal regulations and ethical standards in medicine, was also considered. 
      Different classifications, as well as the causes and consequence of various
      medical errors, were analyzed. Based on current literature, Polish judicial
      decisions were reviewed, and some examples of legal rulings with respect to
      different categories of medical errors were presented. Given the ambiguity, both 
      in conceptual and categorizing terms, with regard to adverse medical events:
      errors, negligence, malpractice and omission, it would be justified to adopt an
      unambiguous definition and classification. Such an arrangement would expand the
      possibilities of research in the field of etiology of medical errors, and more
      importantly, prepare such procedures that would maximally protect the patient,
      and allow the maximum reduction of the number of medical errors and any other
      adverse events. In addition, specifying the medical, legal and economic standards
      in medical units, and determining the scope of personal and institutional
      responsibility for undesirable medical events, would, in turn, improve the
      processing of claims made by patients or their families, as well as the
      activities of medical and legal institutions, including doctors appointed as
      court experts. Med Pr. 2020;71(5):613-30.
CI  - This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL 
      license.
FAU - Puch, Elzbieta Alicja
AU  - Puch EA
AD  - Uniwersytet im. Adama Mickiewicza w Poznaniu / Adam Mickiewicz University in
      Poznan, Poznan, Poland (Wydzial Biologii, Instytut Biologii Czlowieka i Ewolucji 
      / Faculty of Biology, Institute of Human Biology and Evolution).
FAU - Nowak-Jaroszyk, Monika
AU  - Nowak-Jaroszyk M
AD  - Kancelaria Notarialna Monika Nowak-Jaroszyk / Notary Office Monika
      Nowak-Jaroszyk, Poznan, Poland.
FAU - Swora-Cwynar, Ewelina
AU  - Swora-Cwynar E
AD  - Uniwersytet Medyczny im. Karola Marcinkowskiego / Poznan University of Medical
      Science, Poznan, Poland (Wydzial Medyczny, Katedra i Klinika Gastroenterologii,
      Dietetyki i Chorob Wewnetrznych / Faculty of Medical Sciences, Department of
      Gastroenterology, Dietetics and Internal Medicine).
LA  - pol
PT  - Journal Article
PT  - Review
TT  - Blad medyczny w teorii i praktyce - przeglad najwazniejszych zagadnien.
DEP - 20200915
PL  - Poland
TA  - Med Pr
JT  - Medycyna pracy
JID - 0376642
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Malpractice/*classification/*legislation & jurisprudence/*statistics & numerical 
      data
MH  - Medical Errors/*classification/*legislation & jurisprudence/*statistics &
      numerical data
MH  - Middle Aged
MH  - Physicians/*statistics & numerical data
MH  - Poland
MH  - *Terminology as Topic
OTO - NOTNLM
OT  - Polish legislation
OT  - classification
OT  - definition
OT  - jurisprudence
OT  - medical error
OT  - medical malpractice
EDAT- 2020/09/25 06:00
MHDA- 2021/07/23 06:00
CRDT- 2020/09/24 08:48
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
AID - 122665 [pii]
AID - 10.13075/mp.5893.00988 [doi]
PST - ppublish
SO  - Med Pr. 2020 Sep 24;71(5):613-630. doi: 10.13075/mp.5893.00988. Epub 2020 Sep 15.


PMID- 32969410
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220531
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Sep 8
TI  - Working Towards a Framework for Governing Health Research in Nepal.
PG  - 342-344
LID - 10.33314/jnhrc.v18i2.2970 [doi]
AB  - Health research activities have advanced considerably in Nepal over the past
      several years. However, stakeholders' confidence on scientific community is
      shaken as the latter failed occasionally in adhering to ethical principles. Nepal
      Health Research Council has exercised regulatory authority to control and support
      research works. However, much more is needed given the scale at which studies are
      being carried out. It is high time to conduct an analysis of the current
      situation followed by the development of an overarching framework to strengthen
      health research that facilitates a range of actions along the continuum of
      identifying information needs to translation of knowledge into policies and
      practices for ultimately improving people's health. Keywords: Ethics; health
      research systems; knowledge management; research regulation.
FAU - Bhurtyal, Ashok
AU  - Bhurtyal A
AD  - Institute of Medicine, Tribhuvan University, Kathmandu, Nepal.
FAU - Pant, Suman
AU  - Pant S
AD  - Nepal Health Research Council, Ramshahpath, Kathmandu, Nepal.
FAU - Dangal, Ganesh
AU  - Dangal G
AD  - Journal of Nepal Health Research Council, Ramshahpath, Kathmandu, Nepal.
FAU - Gyanwali, Pradip
AU  - Gyanwali P
AD  - Nepal Health Research Council, Ramshahpath, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - *Biomedical Research
MH  - Humans
MH  - Nepal
EDAT- 2020/09/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/24 08:48
PHST- 2020/08/13 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.33314/jnhrc.v18i2.2970 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Sep 8;18(2):342-344. doi:
      10.33314/jnhrc.v18i2.2970.


PMID- 32969396
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201218
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Sep 8
TI  - Knowledge, Attitude and Practice of healthcare workers Towards Coronavirus
      Disease 2019 (COVID-19) Pandemic.
PG  - 293-300
LID - 10.33314/jnhrc.v18i2.2658 [doi]
AB  - BACKGROUND: The emergence of SARS-CoV 2 pandemic is the greatest public health
      concern of the century. Healthcare workers are the front liners of pandemic
      management. Their knowledge, attitudes and practices can influence the outcome of
      pandemic. The study aims to determine the knowledge, attitude and practices among
      healthcare workers. METHODS: Knowledge, attitude and practice related
      questionnaire based online survey through Google forms was conducted from
      Healthcare workers, following ethical approval from NHRC (ERB protocol
      registration number: 297/2020 P). Online forms were disseminated via Facebook,
      Instagram, Whatsapp, Viber and personal messaging. Responses containing
      anonymized data was collected analyzed in using SPSS-version 26, (Year: 2019).
      The results were interpreted in terms of percentage response, knowledge score,
      and practice and discussed on the possible solutions in improving the infection
      prevention and control practice. RESULTS: 473 HCWs responded to the
      questionnaire, out of which 426 responses met inclusion criteria which is 90% of 
      the total responses. The mean score for knowledge was 3.20 + 1.15 out of maximum 
      seven; with 45.7% correct answers. 70.4 % (300) participants felt that Nepal will
      be unable to contain the pandemic, 64 % of the total employed participants felt
      that there was inadequate institutional preparedness to protect HCWs from
      exposure. 91% participants reported practicing hand hygiene after every patient
      encounter; whereas 31.7% (77) and 22.1% (59) participants did not know how to
      check sealing of the N95 masks and use personal protective equipment's
      respectively. CONCLUSIONS: The survey findings showed deficiencies in knowledge
      and appropriate practice among the HCWs, in prevention of SARS-CoV-2
      transmission. Attitudes towards COVID19 were a mix of both positive and negative 
      viewpoints. Even in health care workers with access to internet, there is
      significant gap in universal infection prevention and control practices required 
      for self-protection and limiting untoward transmission.
FAU - Ghimire, Prabina
AU  - Ghimire P
AD  - Star Hospital, Sanepa, Lalitpur, Nepal.
FAU - Dhungel, Samriddh
AU  - Dhungel S
AD  - Star Hospital, Sanepa, Lalitpur, Nepal.
FAU - Pokhrel, Anil
AU  - Pokhrel A
AD  - Star Hospital, Sanepa, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - Adult
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*prevention & control
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - *Health Personnel
MH  - Humans
MH  - Infection Control/standards
MH  - Male
MH  - Nepal/epidemiology
MH  - Pandemics/*prevention & control
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*epidemiology/*prevention & control
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Attitude and practice; COVID-19; healthcare workers; infection prevention and
      control; knowledge Nepal; SARS CoV 2.
EDAT- 2020/09/25 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/24 08:48
PHST- 2020/04/30 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.33314/jnhrc.v18i2.2658 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Sep 8;18(2):293-300. doi:
      10.33314/jnhrc.v18i2.2658.


PMID- 32969395
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Sep 8
TI  - Clinico-demographic Profile of Undifferentiated Inflammatory Arthritis Patients.
PG  - 288-292
LID - 10.33314/jnhrc.v18i2.2739 [doi]
AB  - BACKGROUND: Undifferentiated inflammatory arthritis is a group of inflammatory
      joint diseases that do not fulfil the classification criteria for any other
      rheumatic or connective tissue disorders. This study aims to describe the
      clinical, demographic and serological features of undifferentiated inflammatory
      arthritis cases presenting at a tertiary level rheumatology centre from Nepal.
      METHODS: A descriptive cross-sectional study conducted at National Centre for
      Rheumatic Diseases, Kathmandu, Nepal which represents a midterm analysis of the
      undifferentiated inflammatory arthritis registry maintained at the centre.
      Patients more than 18 years of age, who consented for the study having least one 
      swollen or tender joint were enrolled. Ethical approval was obtained from Nepal
      Health Research Council. RESULTS: A total of 1120 patients were enrolled in the
      study out of which 941 (84%) were females. The mean age at diagnosis was
      46.0+/-12.8 years and most of them were in overweight range (mean BMI:
      27.0+/-5.8) with 818 (73%) patients having BMI more than 24.0. Patients mostly
      had low disease activity at presentation (DAS 28 score of 2.5+/-0.8). Other
      markers of inflammation and patient reported outcome measures (health assessment 
      questionnaire, patient global assessment and visual analogue scale) were also in 
      the moderate range. Seropositivity for anti-citrullinated peptides and
      anti-nuclear antibodies was seen in 5 (0.45%) and 43 (3.8%) patients
      respectively. Majority of patients were non-smokers (77%). Inflammatory arthritis
      on musculoskeletal ultrasonography was seen in 638 (57%). CONCLUSIONS:
      Undifferentiated inflammatory arthritis was more common in overweight females.
      Serological markers and smoking status are not common features in these patients.
FAU - Vaidya, Binit
AU  - Vaidya B
AD  - Department of Rheumatology, National Centre for Rheumatic Diseases, Ratopul,
      Kathmandu, Nepal.
FAU - Bhochhibhoya, Manisha
AU  - Bhochhibhoya M
AD  - Department of Rheumatology, National Centre for Rheumatic Diseases, Ratopul,
      Kathmandu, Nepal.
FAU - Joshi, Rakshya
AU  - Joshi R
AD  - Department of Rheumatology, National Centre for Rheumatic Diseases, Ratopul,
      Kathmandu, Nepal.
FAU - Adhikari, Bhoj Raj
AU  - Adhikari BR
AD  - Department of Internal Medicine, Bharatpur Hospital, Chitwan, Nepal.
FAU - Nakarmi, Shweta
AU  - Nakarmi S
AD  - Department of Rheumatology, National Centre for Rheumatic Diseases, Ratopul,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - Adult
MH  - *Arthritis/epidemiology
MH  - Cross-Sectional Studies
MH  - Demography
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Nepal/epidemiology
OTO - NOTNLM
OT  - Early arthritis; Nepal; undifferentiated arthritis.
EDAT- 2020/09/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/24 08:48
PHST- 2020/05/27 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.33314/jnhrc.v18i2.2739 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Sep 8;18(2):288-292. doi:
      10.33314/jnhrc.v18i2.2739.


PMID- 32969382
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Sep 7
TI  - Variations in the Formation of Hepatic Portal Vein: A Cadaveric Study.
PG  - 224-227
LID - 10.33314/jnhrc.v18i2.2421 [doi]
AB  - BACKGROUND: Portal vein drains blood from the abdominal part of alimentary tract,
      spleen, pancreas and gall bladder to the liver. It is normally formed by the
      union of superior mesenteric and splenic veins behind the neck of pancreas.
      Knowledge of variations regarding the formation of portal vein is very useful for
      surgeons to perform pancreas and duodenum and liver surgeries and for the
      interventional radiologist for catheter-based interventions. The objectives of
      this study are to disclose the variations in formation of hepatic portal vein and
      to measure the length of portal vein in cadavers. METHODS: A descriptive cross
      sectional study was carried out on 40 embalmed cadavers in the Department of
      Human Anatomy, KIST Medical College, Lalitpur Nepal after taking ethical
      approval. The pattern of portal vein formation and its tributaries were
      identified and photographs were taken. The pattern of portal vein formation was
      classified as: Type I: Portal vein formed by the confluence of superior
      mesenteric and splenic vein ; Type II: portal vein formed by the confluence of
      superior mesenteric, splenic and inferior mesenteric vein . Data was analyzed by 
      using SPSS version 20. RESULTS: Type I pattern of portal vein formation was
      observed in 31 cadavers (82.5%) while Type II pattern was observed in 5 cadavers 
      (12.5%). Average length of portal vein was 50.58mm. CONCLUSIONS: Portal vein
      shows variations in the pattern of formation which should be taken into
      consideration during pancreatico-duodenal surgeries and in the interpretation of 
      abdominal angiographs.
FAU - Kadel, Muna
AU  - Kadel M
AD  - Department of Anatomy, Nepalese Army Institute of Healh Seiences, Kathmandu,
      Nepal.
FAU - Pandit, Tinku Kumari
AU  - Pandit TK
AD  - Department of Anatomy, KIST Medical College, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200907
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - Cadaver
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Liver
MH  - Nepal
MH  - *Portal Vein
OTO - NOTNLM
OT  - Length; portal vein; variations.
EDAT- 2020/09/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/24 08:48
PHST- 2019/12/16 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.33314/jnhrc.v18i2.2421 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Sep 7;18(2):224-227. doi:
      10.33314/jnhrc.v18i2.2421.


PMID- 32969378
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Sep 7
TI  - Percutaneous Nephrolithotomy in Paediatric Population: A Single Center
      Experience.
PG  - 205-209
LID - 10.33314/jnhrc.v18i2.2153 [doi]
AB  - BACKGROUND: Management of paediatric stone disease is challenging as they are
      considered high risk group. Percutaneous nephrolithotomy is minimally invasive
      procedure with definite advantages in terms of higher stone clearance in single
      session and no long term effect in renal function. METHODS: Retrospective study
      was done including all patients upto the age of 18 years who underwent
      Percutaneous nephrolithotomy from January 2010 to December 2018 in our center
      after taking approval from ethical committee. Data was collected regarding
      gender, operative side, operative time duration, hospital stay, post-operative
      decrease in hemoglobin, stone size, Guy's stone score and early post-operative
      complications with Clavien-Dindo grade. RESULTS: Percutaneous nephrolithotomy was
      done in 48 renal units in 44 patients. 28 patients were boys and 16 were girls
      with mean age of 10.91 +/- 5.22 years and mean stone size 17.16 +/- 6.43 mm.
      91.6% of cases had Guy's stone score of 1 and 2. Standard percutaneous
      nephrolithotomy was done in 21 renal units, mini percutaneous nephrolithotomy in 
      24 renal units and supermini percutaneous nephrolithotomy was done in three renal
      units with total stone free rate of 93.4%. Three patients required extracorporeal
      shockwave lithotripsy for significant residual stone. Average post-operative
      hemoglobin drop was 1.2 gm%. Overall complications rate was 18.1% with 4.5% of
      complications being grade 1 and 2 whereas 13.6% were Grade 3. CONCLUSIONS:
      Percutaneous nephrolithotomy is safe and feasible in paediatric patients with
      large stone burden, complex anatomy or shock-wave lithotripsy failure with
      acceptable complication and stone free rate.
FAU - Adhikari, Mahesh Bahadur
AU  - Adhikari MB
AD  - Department of Urology, B and B Hospital, Gwarko, Lalitpur, Nepal.
FAU - Karna, Sumeet
AU  - Karna S
AD  - Department of Urology, B and B Hospital, Gwarko, Lalitpur, Nepal.
FAU - Adhikari, Kinju
AU  - Adhikari K
AD  - Department of Urology, B and B Hospital, Gwarko, Lalitpur, Nepal.
FAU - Baidya, Jagdish Lal
AU  - Baidya JL
AD  - Department of Urology, B and B Hospital, Gwarko, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200907
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - *Kidney Calculi/surgery
MH  - Male
MH  - Nepal/epidemiology
MH  - *Nephrolithotomy, Percutaneous/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Endourology; paediatric; percutaneous nephrolithotomy; PNL; urolithiasis.
EDAT- 2020/09/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/24 08:48
PHST- 2019/07/16 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.33314/jnhrc.v18i2.2153 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Sep 7;18(2):205-209. doi:
      10.33314/jnhrc.v18i2.2153.


PMID- 32969374
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1999-6217 (Electronic)
IS  - 1727-5482 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Sep 7
TI  - Maternal and Fetal Outcome in Emergency versus Elective Caesarean Section.
PG  - 186-189
LID - 10.33314/jnhrc.v18i2.2093 [doi]
AB  - BACKGROUND: Caesarean section is one of the most performed surgical procedures
      all over the world. It is associated with high morbidity and mortality as
      compared to vaginal delivery. The present study was carried out to evaluate the
      maternal and neonatal outcome and complications in two groups of pregnant women
      who underwent elective and emergency cesarean section, so that measures can be
      taken to reduce morbidity and mortality in near future. METHODS: It was hospital 
      based descriptive cross-sectional study carried out at Paropakar Maternity and
      Women's Hospital from October to December 2018. There were 340 patients enrolled 
      in the study 170 in elective and 170 in emergency caesareans selected randomly.
      Ethical approval was obtained from the Institutional Review Board and informed
      consent was taken from the patients and patients' guardians. Data were collected 
      daily from the Operation Theater. RESULTS: The rate of caesarean section in the
      hospital was 30.7%. Proportion of emergency caesarean section was 1324 (74.4%)
      and elective caesarean section was 456 (25.6%). Emergency Caesarean section was
      more common in younger age group and in primigravida while elective Caesarean
      section was more common in advanced age group and in multigravida. The most
      common indication for emergency Caesarean section was Fetal Distress and the most
      common indication for elective Caesarean section was previous cesarean with
      refused vaginal delivery after cesarean section. The maternal outcome in terms of
      post-operative wound infection, (post-partum hemorrhage, urinary tract infection 
      need for blood transfusion, fever and need for maternal intensive care unit
      admission was significantly (p- value 0.05) higher in emergency Caesarean section
      than in elective Caesarean section .The fetal outcome in terms of birth asphyxia,
      meconium stained liquor and need for Neonatal ICU admission were significantly (p
      - value 0.05) higher in emergency Caesarean section than in elective Caesarean
      section. CONCLUSIONS: Maternal and fetal complications were significantly higher 
      in the emergency caesarean section as compared to elective caesarean section
      group.
FAU - Darnal, Naveen
AU  - Darnal N
AD  - Department of Obstetrics and Gynecology, Paropakar Maternity and Women's
      Hospital, Thapathali, Kathmandu, Nepal.
FAU - Dangal, Ganesh
AU  - Dangal G
AD  - Department of Obstetrics and Gynecology, Kathmandu Model Hospital, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200907
PL  - Nepal
TA  - J Nepal Health Res Counc
JT  - Journal of Nepal Health Research Council
JID - 101292936
SB  - IM
MH  - *Cesarean Section
MH  - Cross-Sectional Studies
MH  - *Delivery, Obstetric
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Nepal/epidemiology
MH  - Pregnancy
MH  - Prenatal Care
OTO - NOTNLM
OT  - Fetal outcome; emergency cesarean section; elective cesarean section; maternal
      outcome.
EDAT- 2020/09/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/24 08:48
PHST- 2019/06/06 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/24 08:48 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.33314/jnhrc.v18i2.2093 [doi]
PST - epublish
SO  - J Nepal Health Res Counc. 2020 Sep 7;18(2):186-189. doi:
      10.33314/jnhrc.v18i2.2093.


PMID- 32969112
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1600-0722 (Electronic)
IS  - 0909-8836 (Linking)
VI  - 128
IP  - 6
DP  - 2020 Dec
TI  - Advancing racial equity in oral health (research): more of the same is not
      enough.
PG  - 459-466
LID - 10.1111/eos.12737 [doi]
AB  - By critically appraising the literature on the oral health effects of race-based 
      oppression, this focus article makes four recommendations that may both
      facilitate more nuanced research on the topic and mitigate racial/ethnic
      inequities in (oral) health. The first is recognizing that science itself may
      perpetuate racial/ethnic injustice, such that adopting a 'neutral' position must 
      be replaced with actively fostering anti-racist narratives. The second is to not 
      imply that racial oppression is bad because it harms oral health. Rather, studies
      should help build a fairer world, wherein oral health inequities would not
      abound. The third recommendation is encouraging initiatives that understand
      systems of oppression as conjointly operating to shape oral health. The fourth
      and final recommendation is taking race-based oppression as a multi-level system 
      that operates on three inter-related conceptual levels - intra-personal,
      inter-personal, and structural. The extent to which scholars, practitioners, and 
      policymakers are willing to follow these recommendations may determine how
      successful attempts to eradicate (oral) health inequities might be. Learning
      from, and avoiding mistakes made in, previous publications is one ethical pathway
      towards this end.
CI  - (c) 2020 Eur J Oral Sci.
FAU - Bastos, Joao L
AU  - Bastos JL
AUID- ORCID: 0000-0002-1816-0745
AD  - Department of Public Health, Federal University of Santa Catarina, Florianopolis,
      Brazil.
FAU - Constante, Helena M
AU  - Constante HM
AUID- ORCID: 0000-0001-9475-5786
AD  - Department of Public Health, Federal University of Santa Catarina, Florianopolis,
      Brazil.
FAU - Celeste, Roger K
AU  - Celeste RK
AUID- ORCID: 0000-0002-2468-6655
AD  - Department of Preventive and Social Dentistry, Federal University of Rio Grande
      do Sul, Porto Alegre, Brazil.
FAU - Haag, Dandara G
AU  - Haag DG
AD  - Australian Research Centre for Population Oral Health, Adelaide Dental School,
      The University of Adelaide, Adelaide, Australia.
FAU - Jamieson, Lisa M
AU  - Jamieson LM
AD  - Australian Research Centre for Population Oral Health, Adelaide Dental School,
      The University of Adelaide, Adelaide, Australia.
LA  - eng
GR  - 304503/2018-5/Brazilian National Research Council (CNPq)/International
GR  - 311592/2019-8/Brazilian National Research Council (CNPq)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - Eur J Oral Sci
JT  - European journal of oral sciences
JID - 9504563
SB  - IM
MH  - Oral Health
MH  - *Racism
OTO - NOTNLM
OT  - *health policy
OT  - *health status disparities
OT  - *oral health
OT  - *race relations
OT  - *racism
EDAT- 2020/09/25 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/09/24 05:38
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/09/24 05:38 [entrez]
AID - 10.1111/eos.12737 [doi]
PST - ppublish
SO  - Eur J Oral Sci. 2020 Dec;128(6):459-466. doi: 10.1111/eos.12737. Epub 2020 Sep
      23.


PMID- 32968557
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 20
TI  - Telemedicine: Current Impact on the Future.
PG  - e9891
LID - 10.7759/cureus.9891 [doi]
AB  - The current healthcare landscape lends itself to major changes, including
      elevating the prominence of telemedicine. Recent technological advances and
      external pressures have driven telemedicine to the forefront of medical reality. 
      During an emergency declaration made March 17, 2020, the Centers for Medicare &
      Medicaid Services (CMS) stated the need for providers to use telemedicine to
      provide patients care in hospitals, clinics, nursing homes, and other settings
      across the states. Additionally, new policies have been implemented to better
      facilitate patient care, safety, and privacy. The convenience provided by this
      low resource modality facilitates the intercommunication between physicians and
      offers a suitable alternative for patients who are medically or socially unable
      to see providers in person. However, given the nature of the practice, much
      consideration is needed to build patient relationships and comfort. In the
      future, the impact of telemedicine on healthcare environments cannot be
      overstated, especially in hospice and nursing home settings where it stands to
      improve treatment efficacy and monitoring for the elderly. Newer inventions such 
      as the remote patient monitoring system can act as safety nets for clinic
      patients, while improving accessibility of electronic health records (EHRs) will 
      dramatically augment available treatment options. However, the spread of
      telehealth relies on community reimbursement and the ability for physicians to
      consistently offer the same services that are available in person. Additionally, 
      it is imperative that physicians and other healthcare professionals integrate
      these new technologies into their fields while also maintaining the ethics of
      patient security and autonomy.
CI  - Copyright (c) 2020, Jin et al.
FAU - Jin, Michael X
AU  - Jin MX
AD  - Radiology, Stony Brook University Hospital, Stony Brook, USA.
FAU - Kim, Sun Young
AU  - Kim SY
AD  - Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital,
      Northwestern University, Chicago, USA.
FAU - Miller, Lauren J
AU  - Miller LJ
AD  - Internal Medicine, Medical College of Wisconsin, Milwaukee, USA.
FAU - Behari, Gauri
AU  - Behari G
AD  - Department of Medicine, University of Arizona College of Medicine, Phoenix, USA.
FAU - Correa, Ricardo
AU  - Correa R
AD  - Department of Medicine, University of Arizona College of Medicine, Phoenix, USA.
LA  - eng
PT  - Editorial
DEP - 20200820
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7502422
OTO - NOTNLM
OT  - family medecine
OT  - internal medicine (general medicine)
OT  - public health and social work
OT  - tech
OT  - tele health
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:34
PHST- 2020/09/24 05:34 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - 10.7759/cureus.9891 [doi]
PST - epublish
SO  - Cureus. 2020 Aug 20;12(8):e9891. doi: 10.7759/cureus.9891.


PMID- 32968418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 6
DP  - 2020 Sep-Oct
TI  - Telemedicine in the COVID-19 Era: A chance to make a better tomorrow.
PG  - 1405-1407
LID - 10.12669/pjms.36.6.3112 [doi]
AB  - Telemedicine use is increasing globally and in Pakistan. However, Pakistan faces 
      unique challenges related to socioeconomic, geographic and perhaps political
      challenges. This is the time for Pakistan to create policies and protocols for
      ethical and efficient use of telemedicine. The goal of this manuscript is to
      start a discussion, by encouraging questions, and identifying challenges for
      healthcare providers.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Khan, Uzma Zubair
AU  - Khan UZ
AD  - Prof. Uzma Zubair Khan. M.D Department of Medicine University of
      Missouri-Columbia, Cosmopolitan International Diabetes and Endocrinology Center, 
      One Hospital Drive, Columbia, Missouri, 65212, USA.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7501017
OTO - NOTNLM
OT  - COVID-19
OT  - Challenges
OT  - Pakistan
OT  - Telemedicine
COIS- Conflict of Interest: None.
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:34
PHST- 2020/09/24 05:34 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - 10.12669/pjms.36.6.3112 [doi]
AID - PJMS-36-1405 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Sep-Oct;36(6):1405-1407. doi: 10.12669/pjms.36.6.3112.


PMID- 32968391
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 6
DP  - 2020 Sep-Oct
TI  - Comparative response of Desmopressin versus Combination Therapy (Desmopressin +
      Oxybutynin) in Children with Nocturnal Enuresis.
PG  - 1263-1269
LID - 10.12669/pjms.36.6.1957 [doi]
AB  - OBJECTIVE: To assess the safety as well as efficacy of desmopressin monotherapy
      alone and in combination (desmopressin + oxybutynin) in treating nocturnal
      urinary incontinence among children with 7 to 13 years. METHODS: This randomized 
      controlled trial has been carried out in National Institute of Child Health from 
      September 2018 to March 2019 with the utilization of convenient sampling
      technique. Data has been collected after taking ethical approval and informed
      consent of the Parents with complete confidentiality. The sample size was 84 and 
      equal number of patients was divided in two groups. Group-I was given
      desmopressin at monotherapy at a dose of 0.2 mg and Group-II was given
      desmopressin and oxybutynin at the dose of 0.2 mg desmopressin and 5 mg
      oxybutynin patients were diagnosed on the basis of history. Routine lab
      investigation included Urine DR and ultrasound abdomen. RESULTS: In this study
      significant differences between two groups were found with respect to socio
      economic status, lack of education of parents (P Less than 0.05). The frequency, 
      urgency and incontinence of this ailment was significantly controlled by
      combination therapy (desmopressin + oxybutynin) as compared to desmopressin as
      monotherapy (P Less than 0.05) as patient was followed after one, two and three
      monthly basis. CONCLUSION: Desmopressin combination with oxybutynin is more
      effective as compared to monotherapy treatment. The affectivity of the
      combination therapy was very high with least side effects and all the children
      recovered from the condition at third month of treatment. Furthermore, headache
      was observed to be common with monotherapy and loss of appetite was observed with
      combination therapy.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Kazi, Asiya
AU  - Kazi A
AD  - Dr. Asiya Kazi, MBBS, Pharmacology Department, Bahria University Medical & Dental
      College, Sailors Street, Adjacent PNS Shifa, Defence Phase 2, Karachi, Pakistan.
FAU - Moorani, Kemchand N
AU  - Moorani KN
AD  - Prof. Dr. Khemchand N. Moorani, MBBS, MCPS, FCPS. Department of Paediatric
      Nephrology, National Institute of Child Health and Human Development (NICHD),
      Karachi, Pakistan.
FAU - Zehra, Shabih
AU  - Zehra S
AD  - Dr. Shabih Zehra, MBBS, MCPS, FCPS. Department of Radiology, PNS Shifa Hospital
      DHA, Karachi, Pakistan.
FAU - Zaidi, Ijaz Hussain
AU  - Zaidi IH
AD  - Prof. Dr. Ijaz Hussain Zaidi Faisal, MBBS, PhD. Pharmacology Department, Bahria
      University Medical & Dental College, Sailors Street, Adjacent PNS Shifa, Defence 
      Phase 2, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7501033
OTO - NOTNLM
OT  - Desmopressin
OT  - Nocturnal Enuresis
OT  - Oxybutynin
OT  - Recurrence
COIS- Conflict of interest: None.
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:34
PHST- 2020/09/24 05:34 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - 10.12669/pjms.36.6.1957 [doi]
AID - PJMS-36-1263 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Sep-Oct;36(6):1263-1269. doi: 10.12669/pjms.36.6.1957.


PMID- 32968376
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 6
DP  - 2020 Sep-Oct
TI  - Laparoscopic Gastric Resection for Gastric Cancer: Is Intracorporeal Anastomosis 
      Necessary?
PG  - 1177-1182
LID - 10.12669/pjms.36.6.1915 [doi]
AB  - BACKGROUND AND OBJECTIVE: In surgical dissection, laparoscopic approach and open 
      techniques do not differ significantly, but there is still no consensus on how
      anastomosis should be performed in both cardia and distal gastric tumors.
      Anastomosis can be performed by laparoscopy-assisted mini-laparotomy or by
      intracorporeal suture techniques. In this study, we aim to present our four years
      of clinical experience and short-term surgical results from 133 cases in order to
      evaluate the necessity of laparoscopic anastomosis. METHODS: This study was
      approved by Ethics Committee (No: 1-8-19, date: 14/01/2019). Patients who
      underwent curative resection with the diagnosis of gastric adenocarcinoma between
      January 2014 and January 2018 in the Ankara University Surgical Oncology
      Department were included in the study. RESULTS: Of the 133 patients included in
      the study, 108 (81.2) were male and the mean age was 60.51 +/- 12.0 years. The
      time of anastomosis was significantly longer in patients undergoing
      intracorporeal anastomosis (p = 0.021). The incidence of anastomotic leakage was 
      significantly higher in the group undergoing intracorporeal anastomosis (p =
      0.004). CONCLUSIONS: We think that esophagojejunostomy and jejunojejunostomy
      anastomoses in patients undergoing total gastrectomy should be performed with
      intracorporeal techniques in terms of benefit risk assessment. We believe that it
      is more feasible to continue the case with mini laparotomy when anastomosis is
      reached in patients who are planned to have gastrojejunostomy. In addition, in
      terms of intracorporeal anastomoses and advanced laparoscopic techniques,
      intracorporeal anastomoses performed in gastric cancer surgery for a
      laparoscopist who has completed the learning curve do not appear to be very
      different in terms of anastomosis safety.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Ogun, Ersen
AU  - Ogun E
AD  - Ersen Ogun, Ankara University, General Surgery, Surgical Oncology, Ankara,
      Turkey.
FAU - Ekrem, Unal Ali
AU  - Ekrem UA
AD  - Unal Ali Ekrem, Ankara University, General Surgery, Surgical Oncology, Ankara,
      Turkey.
FAU - Yuksel, Cemil
AU  - Yuksel C
AD  - Cemil Yuksel, Ankara University, General Surgery, Surgical Oncology, Ankara,
      Turkey.
FAU - Serdar, Culcu
AU  - Serdar C
AD  - Culcu Serdar Ankara Oncology Hospital, Surgical Oncology, Ankara, Turkey.
FAU - Basceken, Salim Ilksen
AU  - Basceken SI
AD  - Bascseken Ilksen Salim Diyarbakir Oncology Hospital, Surgical Oncology,
      Diyarbakir, Turkey.
FAU - Umit, Mercan
AU  - Umit M
AD  - Mercan Umit, Ankara University, General Surgery, Surgical Oncology, Ankara,
      Turkey.
FAU - Salim, Demirci
AU  - Salim D
AD  - Demirci Salim, Ankara University, General Surgery, Surgical Oncology, Ankara,
      Turkey.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7501006
OTO - NOTNLM
OT  - Gastrectomy
OT  - Laparoscopy
OT  - Stomach Neoplasms
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:33
PHST- 2020/09/24 05:33 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - 10.12669/pjms.36.6.1915 [doi]
AID - PJMS-36-1177 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Sep-Oct;36(6):1177-1182. doi: 10.12669/pjms.36.6.1915.


PMID- 32968374
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 6
DP  - 2020 Sep-Oct
TI  - To be or not to be an Obstetrician / Gynaecologist.
PG  - 1165-1170
LID - 10.12669/pjms.36.6.3080 [doi]
AB  - OBJECTIVES: This qualitative study aimed to explore motivational sources of
      physicians, at the time of selection and while pursuing ObGyn career. Secondary
      aim was to explore challenges and strategies adapted by these physicians to
      overcome these challenges. METHODS: This is qualitative study with constrictive
      worldview. ObGyn residents and consultants of Aga Khan University, Karachi, were 
      interviewed from July 2017 till Jan 2019, after ethical approval, using
      purposeful maximum variation sampling. Analysis were conducted by identifying
      keywords and phrases, these unedited verbatim with no assumptions provided basis 
      for codes, which then clustered as trends. Emerging findings were discussed among
      authors and themes were finalized with consensus. Conclusion was formulated by
      linking these themes. RESULTS: Four themes emerged were, 'grounds for selecting
      ObGyn as career', 'Motivational Factors', 'Demotivating Factors' and 'Strategies 
      to Cope with Challenges'. Results showed that aptitude and passion not only have 
      pivotal role in career selection but also helped in pursuance. Personal
      fulfilment and hands-on experience satisfy emotional needs, while family and
      friends supported participants in maintaining work-life balance and in
      over-coming challenges. CONCLUSIONS: Considering personal preference and aptitude
      at the time of career selection helps in endurance and keep motivations high,
      while challenges in pursuance can be overcome by strong support system.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Ahmed, Iffat
AU  - Ahmed I
AD  - Iffat Ahmed, Assistant Professor, Department Obstetrics Gynaecology, The Aga Khan
      University, Karachi, Pakistan.
FAU - Ashar, Abid
AU  - Ashar A
AD  - Prof. Abid Ashar Principal, College of Dentistry, Professor of Oral &
      Maxillofacial Surgery, Fatima Memorial Hospital, College of Medicine & Dentistry,
      Shadman, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7501043
OTO - NOTNLM
OT  - Career counselling
OT  - Career guidance
OT  - Motivation
OT  - Obstetrics and Gynaecology as a career
OT  - Post-graduate training
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:33
PHST- 2020/09/24 05:33 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - 10.12669/pjms.36.6.3080 [doi]
AID - PJMS-36-1165 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Sep-Oct;36(6):1165-1170. doi: 10.12669/pjms.36.6.3080.


PMID- 32968294
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 228
DP  - 2020 Aug 31
TI  - Prevalence of Dental Anomalies in the Patient with Cleft Lip and Palate Visiting 
      a Tertiary Care Hospital.
PG  - 591-596
LID - 10.31729/jnma.5149 [doi]
AB  - INTRODUCTION: Dental anomaly is one of the major problems in a child born with
      cleft lip and palate. These anomalies have deleterious effects on the dentition
      leading to aesthetic problems, impairment of mastication andimproper phonation.
      The aim of our study was to find out the prevalence of dental anomalies in
      patient with cleft lip and/or palate radiographically. METHODS: A descriptive
      cross-sectional study was conducted from the 208 radiographs, collected by the
      convenience samplingtechnique with cleft lip and/or palate in Department of
      Burns, Plastic and Reconstructive Surgery, Nepal Cleft and Burn Centre, Kirtipur 
      Hospital from January 2017 to July 2019.Ethical clearance for the study was
      obtained from Institutional Review Committee. Demographic data were collected and
      radiographs were evaluated for possible dental anomalies. Data obtained were
      entered and analysed in Statistical Package for Social Sciences version 23.
      RESULTS: Dental anomalies were highly prevalent among cleft lip and palate
      patients with at least one anomaly present in 188 (90.4%) of patients with male
      120 (57.4%) presenting more anomalies than female 88 (42.6%) population. The most
      common anomaly was dental agenesis 161 (77.9%). The prevalence of positional
      anomaly, morphological anomaly and supernumerary teeth were found to be 54 (26%),
      33 (15.9%) and 20 (10%) respectively. Lateral incisor showed the highest
      incidence of agenesis among all other missing teeth 223 (65.2%). CONCLUSIONS: The
      prevalence of dental anomalies among patients with cleft lip and/or palate was
      found to be high. Tooth agenesis was the most common anomaly observed in the
      study with lateral incisor having the highest incidence of agenesis.
FAU - Pradhan, Leeza
AU  - Pradhan L
AD  - Department of Burns, Plastic and Reconstructive Surgery, Nepal Cleft and Burn
      Centre, Kirtipur Hospital, Kathmandu, Nepal.
FAU - Shakya, Pramila
AU  - Shakya P
AD  - Department of Burns, Plastic and Reconstructive Surgery, Nepal Cleft and Burn
      Centre, Kirtipur Hospital, Kathmandu, Nepal.
FAU - Thapa, Swosti
AU  - Thapa S
AD  - Department of Burns, Plastic and Reconstructive Surgery, Nepal Cleft and Burn
      Centre, Kirtipur Hospital, Kathmandu, Nepal.
FAU - Nakarmi, Kiran Kishor
AU  - Nakarmi KK
AD  - Department of Burns, Plastic and Reconstructive Surgery, Nepal Cleft and Burn
      Centre, Kirtipur Hospital, Kathmandu, Nepal.
FAU - Maharjan, Anjana
AU  - Maharjan A
AD  - Department of Dentistry, Patan Academy of Health Sciences, Lalitpur, Nepal.
FAU - Sagtani, Reshu Agrawal
AU  - Sagtani RA
AD  - School of Public Health, Patan Academy of Health Sciences, Lalitpur, Nepal.
FAU - Rai, Shankar Man
AU  - Rai SM
AD  - Department of Burns, Plastic and Reconstructive Surgery, Nepal Cleft and Burn
      Centre, Kirtipur Hospital, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Child
MH  - *Cleft Lip/epidemiology
MH  - *Cleft Palate/epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Pregnancy
MH  - Prevalence
MH  - Tertiary Care Centers
MH  - *Tooth Abnormalities/diagnostic imaging/epidemiology
PMC - PMC7580371
OTO - NOTNLM
OT  - cleft lip and palate; dental anomalies; panoramic radiograph.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/09/24 05:33
PHST- 2020/09/24 05:33 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
AID - 10.31729/jnma.5149 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Aug 31;58(228):591-596. doi: 10.31729/jnma.5149.


PMID- 32968290
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 228
DP  - 2020 Aug 31
TI  - Self-medication Practices among the Peri-urban Households of Two Communities of
      Dharan Sub-metropolitan city of Eastern Nepal: A Descriptive Cross-sectional
      Study.
PG  - 569-573
LID - 10.31729/jnma.5185 [doi]
AB  - INTRODUCTION: Self-medication practice is the use of medication without
      prescription of health care professionals. Drug resistance, drug side effects,
      wastage of resources, and serious health hazards including death are associated
      with self-medication. We conducted this study to find out the prevalence of self-
      medication among the peri-urban population of two randomly selected communities
      of Dharan, Nepal. METHODS: A descriptive cross-sectional study was conducted
      among people residing in two randomly selected wards of peri-urban areas of
      Dharan from November 2017 and April 2018 after obtaining ethical clearance
      (IRC/1030/017). A pretested, structured self-administered questionnaire was used 
      for data collection. Data were collected and entered in Statistical Package for
      the Social Sciences version 11.5; point estimate at 95% Confidence Interval was
      calculated along with frequency and proportion for binary data. RESULTS: Among
      426 respondents, the overall prevalence of self-medication was 312 (73.23%) at
      95% Confidence Interval (67.83-78.63%). It was more common among female 158
      (78.60%). Common symptoms were headache 201 (64.42%), fever 135 (43.26%),
      gastrointestinal 93 (29.8%) and respiratory illness 87 (27.88%). Analgesics and
      antipyretics 275 (88.14%) were the most common drugs self- medicated with.
      Seeking opinion from pharmacist 112 (35.89%) was the commonest method adopted to 
      procure drugs and comfort 127 (40.7%) and time constraints 122 (39.1%) were the
      commonest reasons. CONCLUSIONS: Prevalence of self-medication among the
      peri-urban population was similar to other studies. Headache and fever was the
      common symptoms for which self-medication were adopted. Awareness regarding
      potential dangers of self-medication and different drug side effects are
      recommended at the community level.
FAU - Chapagain, Kumud
AU  - Chapagain K
AD  - Departmentof Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of
      Health Sciences, Dharan, Nepal.
FAU - Rauniyar, Gajendra Prasad
AU  - Rauniyar GP
AD  - Departmentof Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of
      Health Sciences, Dharan, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - *Self Medication
MH  - Surveys and Questionnaires
PMC - PMC7580369
OTO - NOTNLM
OT  - Nepal; prevalence; self-medication.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/09/24 05:33
PHST- 2020/09/24 05:33 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
AID - 10.31729/jnma.5185 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Aug 31;58(228):569-573. doi: 10.31729/jnma.5185.


PMID- 32968288
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 228
DP  - 2020 Aug 31
TI  - Distress Screening among Patients with Hematological Malignancies: A Descriptive 
      Cross-sectional Study.
PG  - 560-563
LID - 10.31729/jnma.5194 [doi]
AB  - INTRODUCTION: Distress is a major concern during diagnosis and treatment of
      hematological malignancies. The Distress Thermometer is a commonly used screening
      tool to detect distress. The objectives of this study was to know the prevalence 
      and identify distress score among patients with hematological malignancies in
      Nepal. METHODS: A descriptive cross sectional study was carried out at the
      Hematology Unit of Civil Service Hospital after obtaining an ethical approval
      from the Institutional Review Committee (reference number 931/076/077). A
      convenient sampling technique was used for this study. Statistical Package for
      the Social Sciences version 20.0 was used. All patients within one week of
      diagnosis and before the start of definitive treatment of hematological
      malignancies were included in the study. National Comprehensive Cancer Network
      Psychosocial Distress Screening Tool was used to measure the seriousness of
      distress. RESULTS: A total of 100 patients were enrolled in the study, among them
      56 (56%) were male and 44 (44%) were female. The mean distress score in our study
      was found to be 5.68+/-1.75. Mean distress score among male and female patients
      were 5.84+/-1.65 and 5.48+/-1.86 respectively. Thirty three percentage (n=33) of 
      patient had mild distress whereas, sixty six percentage (n=67) of patients
      experienced moderate to severe distress. CONCLUSIONS: There was a significant
      level of distress among the patients with hematological malignancies in Nepal.
      Therefore, distress screening should be done to all the patients when initial
      diagnosis is made.
FAU - Paudel, Bishal
AU  - Paudel B
AD  - Department of Clinical Oncology, National Academy of Medical Sciences, Bir
      Hospital, Kathmandu, Nepal.
FAU - Paudel, Bishnu Dutta
AU  - Paudel BD
AD  - Department of Clinical Oncology, National Academy of Medical Sciences, Bir
      Hospital, Kathmandu, Nepal.
FAU - Mishra, Rupesh
AU  - Mishra R
AD  - Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital,
      Minbhawan, Kathmandu, Nepal.
FAU - Karki, Onika
AU  - Karki O
AD  - Department of Gyanecology and Obstetrics, Nepal Medical College, Jorpati,
      Kathmandu, Nepal.
FAU - Shahi, Rukmini
AU  - Shahi R
AD  - Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital,
      Minbhawan, Kathmandu, Nepal.
FAU - Poudyal, Bishesh Sharma
AU  - Poudyal BS
AD  - Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital,
      Minbhawan, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Hematologic Neoplasms/diagnosis/epidemiology
MH  - Humans
MH  - Male
MH  - *Mass Screening
MH  - Nepal/epidemiology
MH  - Prevalence
PMC - PMC7580370
OTO - NOTNLM
OT  - distress; distress thermometer; hematological malignancy.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/19 06:00
CRDT- 2020/09/24 05:33
PHST- 2020/09/24 05:33 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
AID - 10.31729/jnma.5194 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Aug 31;58(228):560-563. doi: 10.31729/jnma.5194.


PMID- 32968286
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20201218
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 228
DP  - 2020 Aug 31
TI  - Prevalence of Psychological Effect of COVID-19 on Medical Professionals in a
      Tertiary Care Center.
PG  - 550-553
LID - 10.31729/jnma.5087 [doi]
AB  - INTRODUCTION: COVID-19 is a pandemic disease first detected in Wuhan, China on
      last December 2019. Many doctors and nurses, were infected and lost their life by
      COVID-19 around the world. Therefore COVID-19 brought unbearable psychological
      pressure on doctors, and nurses. The objective of this study is to find the
      prevalence of anxiety among medical doctors and nurses. METHODS: This is a
      descriptive cross-sectional study of 101 doctors and nurses carried out in a
      tertiary care center. Convenience sampling was done with the study period from
      April to May 2020. Ethical approval was taken from the institutional review board
      of NAMS (IRB reference no. 1076). The collected data stored and analyzed with
      statistical software (SPSS version 26.0). Point estimate at 95% Confidence
      Interval was calculated along with frequency and proportion for binary data.
      RESULTS: Out of 101 participants prevalence of anxiety was found to be 74 (73.3%)
      (64.68-81.33 at 95% Confidence Interval). Among them, 9 (8.9%) of participants
      experienced sever types of generalized anxiety disorder, 23 (22.8%) moderate, and
      42 (41.6%) mild type. Similarly, 18 (17.8%) and 10 (9.9%) of participants felt
      very difficult and extreme difficulty at the workplace and home respectively.
      CONCLUSIONS: The mental health of medical doctors and nurses is significantly
      affected during the COVID-19 pandemic. Hospital administration should conduct
      psychological preparedness training to the medical profession before posting on
      duty to provide quality health services to the patients.
FAU - Shrestha, Surendra Lal
AU  - Shrestha SL
AD  - Department of Medicine, National Academy of Medical Science (NAMS), Bir Hospital,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Anxiety/*epidemiology
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*psychology/therapy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Staff/*psychology
MH  - Mental Health
MH  - Nursing Staff/*psychology
MH  - Occupational Stress/*epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*psychology/therapy
MH  - Prevalence
MH  - SARS-CoV-2
PMC - PMC7580372
OTO - NOTNLM
OT  - COVID-19; doctor; generalized anxiety disorder; nurses.
EDAT- 2020/09/25 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/09/24 05:33
PHST- 2020/09/24 05:33 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - 10.31729/jnma.5087 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Aug 31;58(228):550-553. doi: 10.31729/jnma.5087.


PMID- 32968003
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - COVID-19 and justice.
PG  - 639-640
LID - 10.1136/medethics-2020-106877 [doi]
FAU - McMillan, John
AU  - McMillan J
AD  - Bioethics centre, University of Otago, Dunedin, Otago, New Zealand
      john.r.mcmillan68@gmail.com.
LA  - eng
PT  - Introductory Journal Article
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Social Justice/*ethics
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/24 05:28
PHST- 2020/09/24 05:28 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - medethics-2020-106877 [pii]
AID - 10.1136/medethics-2020-106877 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):639-640. doi: 10.1136/medethics-2020-106877.


PMID- 32967978
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 9
DP  - 2020 Sep
TI  - Engaging culture and context in mhGAP implementation: fostering reflexive
      deliberation in practice.
LID - e002689 [pii]
LID - 10.1136/bmjgh-2020-002689 [doi]
AB  - In 2002, WHO launched the Mental Health Gap Action Programme (mhGAP) as a
      strategy to help member states scale up services to address the growing burden of
      mental, neurological and substance use disorders globally, especially in
      countries with limited resources. Since then, the mhGAP program has been widely
      implemented but also criticised for insufficient attention to cultural and social
      context and ethical issues. To address this issue and help overcome related
      barriers to scale-up, we outline a framework of questions exploring key cultural 
      and ethical dimensions of mhGAP planning, adaptation, training, and
      implementation. This framework is meant to guide mhGAP activity taking place
      around the world. Our approach is informed by recent research on cultural
      formulation and adaptation, and aligned with key components of the WHO
      implementation research guide (Peters, D. H., Tran, N. T., & Adam, T. (2013).
      Implementation research in health: a practical guide. Implementation research in 
      health: a practical guide.). The framework covers three broad domains: (1)
      Concepts of wellness and illness-how to examine cultural norms, knowledge, values
      and attitudes in relation to the "culture of the mhGAP"; (2) Systems of
      care-identifying formal and informal systems of care in the cultural context of
      practice.; and (3) Ethical space: examining issues related to power dynamics,
      communication, and decision-making. Systematic consideration of these issues can 
      guide integration of cultural knowledge, structural competence, and ethics in
      implementation efforts.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gomez-Carrillo, Ana
AU  - Gomez-Carrillo A
AUID- ORCID: 0000-0001-6467-8783
AD  - Division of Social and Transcultural Psychiatry, Culture Mind and Brain Program
      and Global Mental Health Program, McGill University Faculty of Medicine,
      Montreal, Quebec, Canada ana.gomezcarrillo@gmail.com.
FAU - Lencucha, Raphael
AU  - Lencucha R
AUID- ORCID: 0000-0002-9273-2027
AD  - School of Physical and Occupational Therapy, McGill University Faculty of
      Medicine, Montreal, Quebec, Canada.
FAU - Faregh, Neda
AU  - Faregh N
AUID- ORCID: 0000-0002-8968-1484
AD  - Department of Psychology, Carleton University, Ottawa, Ontario, Canada.
FAU - Veissiere, Samuel
AU  - Veissiere S
AUID- ORCID: 0000-0002-1158-2347
AD  - Division of Social and Transcultural Psychiatry, Culture Mind and Brain Program
      and Global Mental Health Program, McGill University Faculty of Medicine,
      Montreal, Quebec, Canada.
FAU - Kirmayer, Laurence J
AU  - Kirmayer LJ
AUID- ORCID: 0000-0002-6228-1739
AD  - Division of Social and Transcultural Psychiatry, Culture Mind and Brain Program
      and Global Mental Health Program, McGill University Faculty of Medicine,
      Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
PMC - PMC7513569
OTO - NOTNLM
OT  - *health services research
OT  - *mental health & psychiatry
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:27
PHST- 2020/04/19 00:00 [received]
PHST- 2020/07/16 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - bmjgh-2020-002689 [pii]
AID - 10.1136/bmjgh-2020-002689 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Sep;5(9). pii: bmjgh-2020-002689. doi:
      10.1136/bmjgh-2020-002689.


PMID- 32967883
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic
      soft tissue sarcomas: STEREOSARC trial protocol.
PG  - e038391
LID - 10.1136/bmjopen-2020-038391 [doi]
AB  - INTRODUCTION: Up to 50% of soft tissue sarcoma (STS) patients develop metastases 
      in the course of their disease. Cytotoxic therapy is a standard treatment in this
      setting but yields average tumour response rates of 25% at first line and </=10% 
      at later lines. In oligometastatic stage, stereotactic body radiation therapy
      (SBRT) allows reaching high control rates at treated sites (>/=80%) and is
      potentially equally effective to surgery in term of overall survival. In order to
      shift the balance towards antitumour immunity by multisite irradiation, radiation
      could be combined with inhibitors of the immunosuppressive pathways. METHODS AND 
      ANALYSIS: STEREOSARC is a prospective, multicentric, randomised phase II,
      designed to evaluate the efficacy of SBRT associated with immunotherapy versus
      SBRT only. Randomisation is performed with a 2:1 ratio within two arms. The
      primary objective is to evaluate the efficacy, in term of progression-free
      survival (PFS) rate at 6 months, of immunomodulated stereotactic multisite
      irradiation in oligometastatic sarcoma patients. The secondary objectives include
      PFS by immune response criteria, overall survival, quality-of-life evaluation and
      developing mathematical models of tumour growth and dissemination predictive of
      oligometastatic versus polymetastatic evolution. Patients will be randomised in
      two groups: SBRT with atezolizumab and SBRT alone. The total number of included
      patients should be 103. TRIAL REGISTRATION: The trial is registered on
      ClinicalTrials.gov (ID: NCT03548428). ETHICS AND DISSEMINATION: This study has
      been approved by Comite de Protection des Personnes du sud-ouest et outre-mer 4
      on 18 October 2019 (Reference CPP2019-09-076-PP) and from National Agency for
      Medical and Health products Safety (Reference:
      MEDAECNAT-2019-08-00004_2017-004239-35) on 18 September 2019.The results will be 
      disseminated to patients upon individual request or through media release from
      scientific meetings. The results will be communicated through scientific meetings
      and publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - le Guevelou, Jennifer
AU  - le Guevelou J
AD  - Radiation oncology department, Centre de Lutte Contre le Cancer, Centre Francois 
      Baclesse, Caen, France.
FAU - Debaigt, Colin
AU  - Debaigt C
AD  - clinical research department, UNICANCER, Paris, Ile-de-France, France.
FAU - Saada-Bouzid, Esma
AU  - Saada-Bouzid E
AD  - Medical oncology department, Centre Antoine Lacassagne, Nice, Provence-Alpes-Cote
      d'Azur, France.
FAU - Viotti, Julien
AU  - Viotti J
AD  - Medical oncology department, Centre Antoine Lacassagne, Nice, Provence-Alpes-Cote
      d'Azur, France.
FAU - Khalladi, Nazim
AU  - Khalladi N
AD  - Biomolecular pathology department, Centre de Lutte Contre le Cancer, Centre
      Francois Baclesse, Caen, France.
FAU - Thibouw, David
AU  - Thibouw D
AD  - Medical oncology department, Georges-Francois Leclerc Centre, Dijon,
      Bourgogne-Franche-Comte, France.
FAU - Penel, Nicolas
AU  - Penel N
AD  - Medical oncology department, Centre Oscar Lambret, lille, France.
FAU - Sunyach, Marie Pierre
AU  - Sunyach MP
AD  - Centre Leon Berard, Lyon, Rhone-Alpes, France.
FAU - Moureau-Zabotto, Laurence
AU  - Moureau-Zabotto L
AD  - Paoli-Calmettes Institute, Marseille, Provence-Alpes-Cote d'Azur, France.
FAU - Benchalal, Mohamed
AU  - Benchalal M
AD  - Eugene Marquis Cancer Institute, Rennes, Bretagne, France.
FAU - Veresezan, Ovidiu
AU  - Veresezan O
AD  - Radiation oncology department, CHU Rouen Biochimie Medicale, Rouen,
      Haute-Normandie, France.
FAU - Ducassou, Anne
AU  - Ducassou A
AD  - Radiation oncology department, IUCT Oncopole, Toulouse,
      Languedoc-Roussillon-Midi, France.
FAU - le Pechoux, Cecile
AU  - le Pechoux C
AD  - Radiation oncology department, Gustave Roussy, Villejuif, France.
FAU - Jolnerovski, Maria
AU  - Jolnerovski M
AD  - clinical research department, UNICANCER, Paris, Ile-de-France, France.
FAU - Bazille, Celine
AU  - Bazille C
AD  - Biomolecular pathology department, CHU Caen, Caen, Basse-Normandie, France.
FAU - Vaur, Dominique
AU  - Vaur D
AD  - Biomolecular pathology department, Centre de Lutte Contre le Cancer, Centre
      Francois Baclesse, Caen, France.
FAU - Escande, Alexandre
AU  - Escande A
AD  - Radiation oncology department, Oscar Lambret Cancer Centre, Lille,
      Hauts-de-France, France.
FAU - Serre, Raphael
AU  - Serre R
AD  - Radiation oncology department, CHU Limoges, Limoges, France.
FAU - Lovera, Christine
AU  - Lovera C
AD  - clinical research department, UNICANCER, Paris, Ile-de-France, France.
FAU - Thariat, Juliette
AU  - Thariat J
AUID- ORCID: 0000-0001-7853-5468
AD  - Radiation oncology department, Centre de Lutte Contre le Cancer, Centre Francois 
      Baclesse, Caen, France jthariat@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03548428
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 52CMI0WC3Y (atezolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - Progression-Free Survival
MH  - Prospective Studies
MH  - *Radiosurgery
MH  - Randomized Controlled Trials as Topic
MH  - *Sarcoma/drug therapy/radiotherapy
PMC - PMC7513631
OTO - NOTNLM
OT  - *SBRT
OT  - *abscopal effect
OT  - *immunotherapy
OT  - *sarcomas
OT  - *tumor mutational burden
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038391 [pii]
AID - 10.1136/bmjopen-2020-038391 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e038391. doi: 10.1136/bmjopen-2020-038391.


PMID- 32967880
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Health impacts and economic costs of residential fires (RESFIRES study): protocol
      for a population-based cohort study using linked administrative data.
PG  - e037709
LID - 10.1136/bmjopen-2020-037709 [doi]
AB  - INTRODUCTION: Residential fires remain a significant global public health
      problem. It is recognised that the reported number of residential fires,
      fire-related injuries and deaths significantly underestimate the true number.
      Australian surveys show that around two-thirds of respondents who experience a
      residential fire are unwilling to call the fire service, and international
      studies highlight that many individuals who access medical treatment for
      fire-related injuries do not have an associated fire incident report. The
      objectives of this study are to quantify the incidence, health impacts, risk
      factors and economic costs of residential fires in New South Wales (NSW),
      Australia. METHODS AND ANALYSIS: The RESFIRE cohort will include all persons
      living at an NSW residential address which experienced a fire over the period
      2005-2014. Nine data sources will be linked to provide a comprehensive picture of
      individual trajectories from fire event to first responder use (fire and
      ambulance services), emergency department presentations, hospital admissions,
      burn out-patient clinic use and death. These data will be used to describe the
      circumstances and characteristics of residential fires, provide a profile of
      fire-related injuries, examine trends over time, and explore the relationship
      between fire circumstance, emergency and health services utilisation, and health 
      outcomes. Regression modelling, including multilevel modelling techniques, will
      be used to explore factors that impact on these relationships. Costing models
      will be constructed. ETHICS AND DISSEMINATION: Ethical approval for this study
      has been obtained from the NSW Population and Health Service Research Ethics
      Committee and Western Sydney University Human Research Ethics Committee. The
      study reference group comprises key stakeholders including Fire and Rescue NSW,
      policy agencies, health service providers and burns clinicians ensuring wide
      dissemination of results and translation of data to inform practice and identify 
      areas for targeted prevention. Summary reports in formats designed for policy
      audiences in parallel with scientific papers will be produced.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Harvey, Lara A
AU  - Harvey LA
AUID- ORCID: 0000-0001-6260-8001
AD  - Falls, Balance and Injury Research Centre, Neuroscience Research Australia,
      Randwick, New South Wales, Australia l.harvey@neura.edu.au.
AD  - School of Public Health and Community Medicine, University of New South Wales,
      Sydney, New South Wales, Australia.
FAU - Ghassempour, Nargess
AU  - Ghassempour N
AD  - School of Business, Western Sydney University, Penrith South, New South Wales,
      Australia.
AD  - Rozetta Insitute, Sydney, New South Wales, Australia.
FAU - Whybro, Mark
AU  - Whybro M
AD  - Community Safety Department, Fire and Rescue New South Wales, Sydney, New South
      Wales, Australia.
FAU - Tannous, W Kathy
AU  - Tannous WK
AUID- ORCID: 0000-0002-3153-5652
AD  - School of Business, Western Sydney University, Penrith South, New South Wales,
      Australia.
AD  - Translational Health Research Institute, Western Sydney University, Penrith
      South, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Cohort Studies
MH  - *Emergency Service, Hospital
MH  - Humans
MH  - New South Wales/epidemiology
MH  - Risk Factors
PMC - PMC7513630
OTO - NOTNLM
OT  - *epidemiology
OT  - *health economics
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037709 [pii]
AID - 10.1136/bmjopen-2020-037709 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e037709. doi: 10.1136/bmjopen-2020-037709.


PMID- 32967877
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab
      alone in childhood-onset steroid-dependent and frequently relapsing nephrotic
      syndrome: protocol for a multicentre randomised controlled trial.
PG  - e037306
LID - 10.1136/bmjopen-2020-037306 [doi]
AB  - INTRODUCTION: Guidelines for the treatment of steroid-dependent nephrotic
      syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS) are lacking.
      Given the substantial impact of SDNS/FRNS on quality of life, strategies aiming
      to provide long-term remission while minimising treatment side effects are
      needed. Several studies confirm that rituximab is effective in preventing early
      relapses in SDNS/FRNS; however, the long-term relapse rate remains high (~70% at 
      2 years). This trial will assess the association of intravenous immunoglobulins
      (IVIgs) to rituximab in patients with SDNS/FRNS and inform clinicians on whether 
      IVIg's immunomodulatory properties can alter the course of the disease and reduce
      the use of immunosuppressive drugs and their side effects. METHODS AND ANALYSIS: 
      We conduct an open-label multicentre, randomised, parallel group in a 1:1 ratio, 
      controlled, superiority trial to assess the safety and efficacy of a single
      infusion of rituximab followed by IVIg compared with rituximab alone in
      childhood-onset FRNS/SDNS. The primary outcome is the occurrence of first relapse
      within 24 months. Patients are allocated to receive either rituximab alone (375
      mg/m(2)) or rituximab followed by IVIg, which includes an initial Ig dose of 2
      g/kg, followed by 1.5 g/kg injections once a month for the following 5 months
      (maximum dose: 100 g). ETHICS AND DISSEMINATION: The study has been approved by
      the ethics committee (Comite de Protection des Personnes) of Ouest I and
      authorised by the French drug regulatory agency (Agence Nationale de Securite du 
      Medicament et des Produits de Sante). Results of the primary study and the
      secondary aims will be disseminated through peer-reviewed publications. TRIAL
      REGISTRATION NUMBER: NCT03560011.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hogan, Julien
AU  - Hogan J
AUID- ORCID: 0000-0003-4838-9417
AD  - Department of Pediatric Nephrology, Robert Debre Hospital, APHP, Paris, France
      julien.hogan@aphp.fr.
AD  - Department of Surgery, Emory University, Atlanta, Georgia, USA.
FAU - Perez, Aubriana
AU  - Perez A
AD  - Department of Surgery, Emory University, Atlanta, Georgia, USA.
FAU - Sellier-Leclerc, Anne-Laure
AU  - Sellier-Leclerc AL
AD  - Department of Pediatric Nephrology, Hopital Femme Mere Enfant, Bron, France.
FAU - Vrillon, Isabelle
AU  - Vrillon I
AD  - Department of Pediatric Nephrology, Hopital Brabois enfants,
      Vandoeuvre-les-Nancy, France.
FAU - Broux, Francoise
AU  - Broux F
AD  - Department of Pediatric Nephrology, University Hospital Centre Rouen, Rouen,
      France.
FAU - Nobili, Francois
AU  - Nobili F
AD  - Department of Pediatric Nephrology, University Hospital Centre Besancon,
      Besancon, France.
FAU - Harambat, Jerome
AU  - Harambat J
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Bordeaux 
      Groupe hospitalier Pellegrin, Bordeaux, France.
FAU - Bessenay, Lucie
AU  - Bessenay L
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de
      Clermont-Ferrand, Clermont-Ferrand, France.
FAU - Audard, V
AU  - Audard V
AD  - Department of Nephrology and Transplantation, Henri Mondor Hospital, APHP,
      Universite Paris-Est, Creteil, France.
FAU - Faudeux, Camille
AU  - Faudeux C
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Nice,
      Nice, France.
FAU - Morin, Denis
AU  - Morin D
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de
      Montpellier, Montpellier, France.
FAU - Pietrement, Christine
AU  - Pietrement C
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Reims
      Hopital d'enfants, Reims, France.
FAU - Tellier, Stephanie
AU  - Tellier S
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Toulouse,
      Toulouse, France.
FAU - Djeddi, Djamal
AU  - Djeddi D
AD  - Department of Paediatrics, Amiens University Hospital and University of Amiens,
      Amiens, France.
FAU - Eckart, Philippe
AU  - Eckart P
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire
      Amiens-Picardie, Amiens, France.
FAU - Lahoche, Annie
AU  - Lahoche A
AD  - Department of Pediatric Nephrology, Centre Hospitalier Regional Universitaire de 
      Lille, Lille, France.
FAU - Roussey-Kesler, G
AU  - Roussey-Kesler G
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Nantes,
      Nantes, France.
FAU - Ulinski, Tim
AU  - Ulinski T
AD  - Department of Pediatric Nephrology, Hopital Trousseau la Roche-Guyon, Paris,
      France.
FAU - Boyer, Olivia
AU  - Boyer O
AD  - Department of Pediatric Nephrology, Hopital Necker-Enfants Malades, Paris,
      France.
FAU - Plaisier, Emmanuelle
AU  - Plaisier E
AD  - Department of Nephrology, Hopital Tenon, Paris, France.
FAU - Cloarec, Sylvie
AU  - Cloarec S
AD  - Department of Pediatric Nephrology, Centre Hospitalier Regional Universitaire de 
      Tours, Tours, France.
FAU - Jolivot, Anne
AU  - Jolivot A
AD  - Department of Nephrology, Groupement Hospitalier Edouard Herriot, Lyon, France.
FAU - Guigonis, Vincent
AU  - Guigonis V
AD  - Department of Pediatric Nephrology, Centre Hospitalier Universitaire de Limoges, 
      Limoges, France.
FAU - Guilmin-Crepon, Sophie
AU  - Guilmin-Crepon S
AD  - Department of Pediatric Nephrology, Robert Debre Hospital, APHP, Paris, France.
FAU - Baudouin, Veronique
AU  - Baudouin V
AD  - Department of Pediatric Nephrology, Robert Debre Hospital, APHP, Paris, France.
FAU - Dossier, Claire
AU  - Dossier C
AD  - Department of Pediatric Nephrology, Robert Debre Hospital, APHP, Paris, France.
FAU - Deschenes, Georges
AU  - Deschenes G
AD  - Department of Pediatric Nephrology, Robert Debre Hospital, APHP, Paris, France.
AD  - Universite Sorbonne Paris Cite, Paris, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03560011
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Humans
MH  - *Immunoglobulins, Intravenous/adverse effects
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local
MH  - *Nephrotic Syndrome/drug therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Rituximab/adverse effects
MH  - Steroids
MH  - Treatment Outcome
PMC - PMC7513594
OTO - NOTNLM
OT  - *glomerulonephritis
OT  - *nephrology
OT  - *paediatric nephrology
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037306 [pii]
AID - 10.1136/bmjopen-2020-037306 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e037306. doi: 10.1136/bmjopen-2020-037306.


PMID- 32967876
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - The AEDUCATE Collaboration. Comprehensive antenatal education birth preparation
      programmes to reduce the rates of caesarean section in nulliparous women.
      Protocol for an individual participant data prospective meta-analysis.
PG  - e037175
LID - 10.1136/bmjopen-2020-037175 [doi]
AB  - INTRODUCTION: Rates of medical interventions in normal labour and birth are
      increasing. This prospective meta-analysis (PMA) proposes to assess whether the
      addition of a comprehensive multicomponent birth preparation programme reduces
      caesarean section (CS) in nulliparous women compared with standard hospital care.
      Additionally, do participant characteristics, intervention components or hospital
      characteristics modify the effectiveness of the programme? METHODS AND ANALYSIS: 
      Population: women with singleton vertex pregnancies, no planned caesarean section
      (CS) or epidural.Intervention: in addition to hospital-based standard care, a
      comprehensive antenatal education programme that includes multiple components for
      birth preparation, addressing the three objectives: preparing women and their
      birth partner/support person for childbirth through education on
      physiological/hormonal birth (knowledge and understanding); building women's
      confidence through psychological preparation (positive mindset) and support their
      ability to birth without pain relief using evidence-based tools (tools and
      techniques). The intervention could occur in a hospital-based or community
      setting.Comparator: standard care alone in hospital-based maternity units.
      OUTCOMES: Primary: CS.Secondary: epidural analgesia, mode of birth, perineal
      trauma, postpartum haemorrhage, newborn resuscitation, psychosocial
      well-being.Subgroup analysis: parity, model of care, maternal risk status,
      maternal education, maternal socio-economic status, intervention components.
      STUDY DESIGN: An individual participant data (IPD) prospective meta-analysis
      (PMA) of randomised controlled trials, including cluster design. Each trial is
      conducted independently but share core protocol elements to contribute data to
      the PMA. Participating trials are deemed eligible for the PMA if their results
      are not yet known outside their Data Monitoring Committees. ETHICS AND
      DISSEMINATION: Participants in the individual trials will consent to
      participation, with respective trials receiving ethical approval by their local
      Human Research Ethics Committees. Individual datasets remain the property of
      trialists, and can be published prior to the publication of final PMA results.
      The overall data for meta-analysis will be held, analysed and published by the
      collaborative group, led by the Cochrane PMA group. TRIAL REGISTRATION NUMBER:
      CRD42020103857.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Levett, Kate M
AU  - Levett KM
AUID- ORCID: 0000-0003-3784-4648
AD  - School of Medicine Sydney, University of Notre Dame Australia, Darlinghurst, New 
      South Wales, Australia kate.levett@nd.edu.au.
AD  - NICM Health Research Institute, University of Western Sydney, Penrith South, New 
      South Wales, Australia.
FAU - Lord, Sarah J
AU  - Lord SJ
AUID- ORCID: 0000-0003-2763-5949
AD  - School of Medicine Sydney, University of Notre Dame Australia, Darlinghurst, New 
      South Wales, Australia.
AD  - NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia.
FAU - Dahlen, Hannah G
AU  - Dahlen HG
AD  - School of Nursing and Midwifery, University of Western Sydney, Parramatta, New
      South Wales, Australia.
FAU - Smith, Caroline A
AU  - Smith CA
AD  - NICM Health Research Institute, University of Western Sydney, Penrith South, New 
      South Wales, Australia.
AD  - Graduate Research School, University of Western Sydney, Kingswood, New South
      Wales, Australia.
FAU - Girosi, Federico
AU  - Girosi F
AUID- ORCID: 0000-0003-3937-2285
AD  - Translational Health Research Institute, Western Sydney University, Penrith, New 
      South Wales, Australia.
AD  - Capital Markets CRC, New South Wales, Australia, Sydney, New South Wales,
      Australia.
FAU - Downe, Soo
AU  - Downe S
AD  - School of Midwifery and Community Health, University of Central Lancashire,
      Preston, Lancashire, UK.
FAU - Finlayson, Kenneth William
AU  - Finlayson KW
AD  - School of Midwifery and Community Health, University of Central Lancashire,
      Preston, Lancashire, UK.
FAU - Fleet, Julie
AU  - Fleet J
AD  - School of Nursing and Midwifery, University of South Australia, Adelaide, South
      Australia, Australia.
FAU - Steen, Mary
AU  - Steen M
AD  - School of Nursing and Midwifery, University of South Australia, Adelaide, South
      Australia, Australia.
FAU - Davey, Mary-Ann
AU  - Davey MA
AD  - Obstetrics & Gynaecology, Monash Health, Monash University Central Clinical
      School, Melbourne, Victoria, Australia.
FAU - Newnham, Elizabeth
AU  - Newnham E
AD  - School of Nursing & Midwifery, Griffith University, Medowbrook, Queensland,
      Australia.
FAU - Werner, Anette
AU  - Werner A
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Arnott, Leslie
AU  - Arnott L
AD  - The B.E.A.R. Program, Lamaze Australia, Melbourne, Victoria, Australia.
FAU - Sutcliffe, Kerry
AU  - Sutcliffe K
AD  - School of Medicine Sydney, University of Notre Dame Australia, Darlinghurst, New 
      South Wales, Australia.
FAU - Seidler, Anna Lene
AU  - Seidler AL
AUID- ORCID: 0000-0002-0027-1623
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South
      Wales, Australia.
FAU - Hunter, Kylie Elizabeth
AU  - Hunter KE
AUID- ORCID: 0000-0002-2796-9220
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South
      Wales, Australia.
FAU - Askie, Lisa
AU  - Askie L
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South
      Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cesarean Section
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Parity
MH  - Parturition
MH  - Pregnancy
MH  - *Prenatal Education
MH  - Prospective Studies
PMC - PMC7513601
OTO - NOTNLM
OT  - *antenatal education
OT  - *complementary medicine
OT  - *maternal medicine
OT  - *obstetrics
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037175 [pii]
AID - 10.1136/bmjopen-2020-037175 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e037175. doi: 10.1136/bmjopen-2020-037175.


PMID- 32967874
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Integrated communication support program for oncologists, caregivers and patients
      with rapidly progressing advanced cancer to promote patient-centered
      communication: J-SUPPORT 1904 study protocol for a randomised controlled trial.
PG  - e036745
LID - 10.1136/bmjopen-2019-036745 [doi]
AB  - INTRODUCTION: Communication is an essential aspect of care for patients with
      progressive serious illnesses. This study aims to evaluate the efficacy of a new,
      integrated communication support program for oncologists, patients with rapidly
      progressing advanced cancer and their caregivers. METHODS AND ANALYSIS: The
      proposed integrated communication support programme is in the randomised control 
      trial stage. It comprises a cluster of oncologists from comprehensive cancer
      centre hospitals in a metropolitan area in Japan. A total of 20 oncologists, 200 
      patients with advanced pancreatic cancer and the patients' caregivers are
      enrolled in this study as of the writing of this protocol report. Oncologists are
      randomly assigned to the intervention group (IG) or control group (CG). Patients 
      and caregivers are allocated to the same group as their oncologists. The IG
      oncologists receive a 2.5-hour individual communication skills training, and
      patients and caregivers receive a half-hour coaching intervention to facilitate
      prioritising and discussing questions and concerns; the CG participants do not
      receive any training. Follow-up data will be collected quarterly for 6 months for
      a year and then annually for up to 3 years. The primary endpoint is the
      intergroup difference between before-intervention and after-intervention
      patient-centred communication behaviours during oncology visits. ETHICS AND
      DISSEMINATION: This study is conducted in accordance with the ethical guidelines 
      for clinical studies published by Japan's Ministry of Education, Cultural,
      Sports, Science and Technology, the Ministry of Health, Labour and Welfare, and
      the ethical principles established for research on humans stipulated in the
      Declaration of Helsinki and further amendments thereto. The protocol was approved
      by the Institutional Review Board of National Cancer Center, Japan on 4 July 2018
      (ID: 2017-474). TRIAL STATUS: This study is currently enrolling participants.
      Enrolment period ends 31 July 2020; estimated follow-up date is 31 March 2023.
      TRIAL REGISTRATION NUMBER: UMIN Clinical Trial Registry (UMIN000033612);
      pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fujimori, Maiko
AU  - Fujimori M
AUID- ORCID: 0000-0003-1639-3390
AD  - Division of Behavioral Science and Division of Health Care Research, Center for
      Public Health Sciences, National Cancer Center, Chuo-ku, Japan
      mfujimor@ncc.go.jp.
AD  - Division of Health Care Research, Center for Public Health Sciences, National
      Cancer Center, Chuo-ku, Japan.
FAU - Sato, Ayako
AU  - Sato A
AD  - Division of Behavioral Science and Division of Health Care Research, Center for
      Public Health Sciences, National Cancer Center, Chuo-ku, Japan.
FAU - Jinno, Sayaka
AU  - Jinno S
AD  - Division of Health Care Research, Center for Public Health Sciences, National
      Cancer Center, Chuo-ku, Japan.
FAU - Okusaka, Takuji
AU  - Okusaka T
AD  - Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 
      Chuo-ku, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Division of Biostatistics, Tohoku University Graduate School of Medicine
      Department of Medical Biochemistry, Sendai, Japan.
FAU - Ikeda, Masafumi
AU  - Ikeda M
AD  - Department of Hepatobiliary Pancreatic Oncology, National Cancer Center-Hospital 
      East, Kashiwa, Japan.
FAU - Ueno, Makoto
AU  - Ueno M
AD  - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology
      Division, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Ozaka, Masato
AU  - Ozaka M
AD  - Department of Hepatobiliary and Pancreatic Medical Oncology, Public Interest
      Incorporated Foundation Cancer Institute Hospital of JFCR, Koto-ku, Japan.
FAU - Takayama, Yukiko
AU  - Takayama Y
AD  - Department of Medicine, Institute of Gastroenterology, Tokyo Women's Medical
      University Hospital, Shinjuku-ku, Japan.
FAU - Miyaji, Tempei
AU  - Miyaji T
AD  - Department of Clinical Trial Data Management, Tokyo University Graduate School of
      Medicine, Bunkyo-ku, Japan.
FAU - Majima, Yoshiyuki
AU  - Majima Y
AD  - President, Pancreatic Cancer Action Network, Tokyo, Japan.
FAU - Uchitomi, Yosuke
AU  - Uchitomi Y
AD  - Division of Behavioral Science and Division of Health Care Research, Center for
      Public Health Sciences, National Cancer Center, Chuo-ku, Japan.
AD  - Innovation Center for Supportive, Palliative and Psychosocial Care, National
      Cancer Center Hospital, Chuo-ku, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000033612
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Caregivers
MH  - Communication
MH  - Humans
MH  - Japan
MH  - *Neoplasms/therapy
MH  - *Oncologists
MH  - Patient-Centered Care
MH  - Randomized Controlled Trials as Topic
PMC - PMC7513597
OTO - NOTNLM
OT  - *adult oncology
OT  - *adult palliative care
OT  - *mental health
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036745 [pii]
AID - 10.1136/bmjopen-2019-036745 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e036745. doi: 10.1136/bmjopen-2019-036745.


PMID- 32967873
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically
      ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre
      double-blind placebo-controlled clinical trial in the Netherlands.
PG  - e036735
LID - 10.1136/bmjopen-2019-036735 [doi]
AB  - INTRODUCTION: Delirium in critically ill adults is associated with prolonged
      hospital stay, increased mortality and greater cognitive and functional decline. 
      Current practice guideline recommendations advocate the use of
      non-pharmacological strategies to reduce delirium. The routine use of scheduled
      haloperidol to treat delirium is not recommended given a lack of evidence
      regarding its ability to resolve delirium nor improve relevant short-term and
      longer-term outcomes. This study aims to evaluate the efficacy and safety of
      haloperidol for the treatment of delirium in adult critically ill patients to
      reduce days spent with coma or delirium. METHODS AND ANALYSIS: EuRIDICE is a
      prospective, multi-centre, randomised, double-blind, placebo-controlled trial.
      Study population consists of adult intensive care unit (ICU) patients without
      acute neurological injury who have delirium based on a positive Intensive Care
      Delirium Screening Checklist (ICDSC) or Confusion Assessment Method for the ICU
      (CAM-ICU) assessment. Intervention is intravenous haloperidol 2.5 mg (or matching
      placebo) every 8 hours, titrated daily based on ICDSC or CAM-ICU positivity to a 
      maximum of 5 mg every 8 hours, until delirium resolution or ICU discharge. Main
      study endpoint is delirium and coma-free days (DCFD) up to 14 days after
      randomisation. Secondary endpoints include (1) 28-day and 1-year mortality, (2)
      cognitive and functional performance at 3 and 12 months, (3) patient and family
      delirium and ICU experience, (4) psychological sequelae during and after ICU
      stay, (4) safety concerns associated with haloperidol use and (5)
      cost-effectiveness. Differences in DCFDs between haloperidol and placebo group
      will be analysed using Poisson regression analysis. Study recruitment started in 
      February 2018 and continues. ETHICS AND DISSEMINATION: The study has been
      approved by the Medical Ethics Committee of the Erasmus University Medical Centre
      Rotterdam (MEC2017-511) and by the Institutional Review Boards of the
      participating sites. Its results will be disseminated via peer-reviewed
      publication and conference presentations. TRIAL REGISTRATION: NCT03628391.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Smit, Lisa
AU  - Smit L
AUID- ORCID: 0000-0001-5199-930X
AD  - Department of Intensive Care Adults, Erasmus MC- University Medical Center,
      Rotterdam, Zuid-Holland, Netherlands.
FAU - Trogrlic, Zoran
AU  - Trogrlic Z
AD  - Department of Intensive Care Adults, Erasmus MC- University Medical Center,
      Rotterdam, Zuid-Holland, Netherlands.
FAU - Devlin, John W
AU  - Devlin JW
AD  - Department of Pharmacy and Health Systems Sciences, Northeastern University Bouve
      College of Health Sciences, Boston, Massachusetts, USA.
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center,
      Boston, Massachusetts, USA.
FAU - Osse, Robert-Jan
AU  - Osse RJ
AD  - Department of Psychiatry, Erasmus MC - University Medical Center, Rotterdam,
      Zuid-Holland, Netherlands.
FAU - Ponssen, Huibert H
AU  - Ponssen HH
AD  - Department of Intensive Care, Albert Schweitzer Hospital Location Dordwijk,
      Dordrecht, Zuid-Holland, Netherlands.
FAU - Slooter, Arjen J C
AU  - Slooter AJC
AD  - Department of Intensive Care Medicine and UMC Utrecht Brain Center, University
      Medical Centre Utrecht Brain Centre, Utrecht, Utrecht, Netherlands.
FAU - Hunfeld, Nicole G M
AU  - Hunfeld NGM
AD  - Department of Pharmacy and Department of Intensive Care Adults, Erasmus MC -
      University Medical Center, Rotterdam, Zuid-Holland, Netherlands.
FAU - Rietdijk, Wim J R
AU  - Rietdijk WJR
AUID- ORCID: 0000-0002-2622-7321
AD  - Department of Intensive Care Adults, Erasmus MC- University Medical Center,
      Rotterdam, Zuid-Holland, Netherlands.
FAU - Gommers, Diederik
AU  - Gommers D
AD  - Department of Intensive Care Adults, Erasmus MC- University Medical Center,
      Rotterdam, Zuid-Holland, Netherlands.
FAU - van der Jagt, Mathieu
AU  - van der Jagt M
AD  - Department of Intensive Care Adults, Erasmus MC- University Medical Center,
      Rotterdam, Zuid-Holland, Netherlands m.vanderjagt@erasmusmc.nl.
CN  - EuRIDICE study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03628391
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Adult
MH  - Critical Illness
MH  - *Delirium/drug therapy/prevention & control
MH  - Double-Blind Method
MH  - *Haloperidol/adverse effects
MH  - Humans
MH  - Intensive Care Units
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7513600
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *adult neurology
OT  - *delirium & cognitive disorders
OT  - *intensive & critical care
OT  - *mental health
OT  - *therapeutics
COIS- Competing interests: None declared.
IR  - van den Boogaard M
FIR - van den Boogaard, M
IR  - Brouwers AJBW
FIR - Brouwers, A J B W
IR  - Lens JA
FIR - Lens, J A
IR  - van der Meer BJM
FIR - van der Meer, B J M
IR  - Ponssen H
FIR - Ponssen, H
IR  - Schoonderbeek FJ
FIR - Schoonderbeek, F J
IR  - Simons KS
FIR - Simons, K S
IR  - Berger E
FIR - Berger, E
IR  - Bouman A
FIR - Bouman, A
IR  - Campo M
FIR - Campo, M
IR  - van Duijn D
FIR - van Duijn, D
IR  - Embden-van Donk H
FIR - Embden-van Donk, H
IR  - van de Graaf D
FIR - van de Graaf, D
IR  - Hoogendoorn E
FIR - Hoogendoorn, E
IR  - Ormskerk P
FIR - Ormskerk, P
IR  - Roovers N
FIR - Roovers, N
IR  - Toscano E
FIR - Toscano, E
IR  - Vileito A
FIR - Vileito, A
IR  - van Zuylen T
FIR - van Zuylen, T
IR  - van den Boogaard M
FIR - van den Boogaard, M
IR  - Brouwers AJBW
FIR - Brouwers, A J B W
IR  - Lens JA
FIR - Lens, J A
IR  - van der Meer BJM
FIR - van der Meer, B J M
IR  - Ponssen H
FIR - Ponssen, H
IR  - Schoonderbeek FJ
FIR - Schoonderbeek, F J
IR  - Simons KS
FIR - Simons, K S
IR  - Berger E
FIR - Berger, E
IR  - Bouman A
FIR - Bouman, A
IR  - Campo M
FIR - Campo, M
IR  - van Duijn D
FIR - van Duijn, D
IR  - Embden-van Donk H
FIR - Embden-van Donk, H
IR  - van de Graaf D
FIR - van de Graaf, D
IR  - Hoogendoorn E
FIR - Hoogendoorn, E
IR  - Ormskerk P
FIR - Ormskerk, P
IR  - Roovers N
FIR - Roovers, N
IR  - Toscano E
FIR - Toscano, E
IR  - Vileito A
FIR - Vileito, A
IR  - van Zuylen T
FIR - van Zuylen, T
IR  - Exler C
FIR - Exler, C
IR  - van den Berg E
FIR - van den Berg, E
IR  - van Meeteren J
FIR - van Meeteren, J
IR  - Koopmanschap M
FIR - Koopmanschap, M
IR  - Nutma I
FIR - Nutma, I
IR  - Kuijper E
FIR - Kuijper, E
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036735 [pii]
AID - 10.1136/bmjopen-2019-036735 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e036735. doi: 10.1136/bmjopen-2019-036735.


PMID- 32967871
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Study protocol of a population-based cohort investigating Physical Activity,
      Sedentarism, lifestyles and Obesity in Spanish youth: the PASOS study.
PG  - e036210
LID - 10.1136/bmjopen-2019-036210 [doi]
AB  - INTRODUCTION: Physical activity (PA) is essential to healthy mental and physical 
      development in early life. However, the prevalence of physical inactivity, which 
      is considered a key modifiable driver of childhood obesity, has reached alarming 
      levels among European youth. There is a need to update the data for Spain, in
      order to establish if current measures are effective or new approaches are
      needed. METHODS AND ANALYSIS: We present the protocol for Physical Activity,
      Sedentarism, lifestyles and Obesity in Spanish youth (PASOS). This observational,
      nationally representative, multicentre study aims to determine the PA levels,
      sedentary behaviours and prevalence of physical inactivity (defined as <60 min of
      moderate to vigorous PA per day) in a representative sample of Spanish children
      and adolescents. The PASOS study has recruited a representative random sample of 
      children and adolescents aged 8-16 years from 242 educational centres in the 17
      'autonomous regions' into which Spain is divided. The aim is to include a total
      of 4508 youth participants and their families. Weight, height and waist
      circumference will be measured by standardised procedures. Adherence to the
      Mediterranean diet, quality of life, sleep duration, PA and sedentary behaviour
      are being measured by validated questionnaires. PA is measured by the Physical
      Activity Unit 7-item Screener. A representative subsample (10% of participants)
      was randomly selected to wear accelerometers for 9 days to obtain objective data 
      on PA. Parents are asked about their educational level, time spent doing PA, diet
      quality, self-perceived stress, smoking habit, weight, height, their child's
      birth weight and if the child was breast fed. ETHICS AND DISSEMINATION: The study
      was approved by the Ethics Committee of the Fundacio Sant Joan de Deu, Barcelona,
      Spain. Main findings of the study will be disseminated to the scientific
      community and to general public by media conferences, social media and a website.
      TRIAL REGISTRATION NUMBER: ISRCTN34251612.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gomez, Santiago Felipe
AU  - Gomez SF
AUID- ORCID: 0000-0003-3352-2510
AD  - Programs, Gasol Foundation, Sant Boi de Llobregat, Barcelona, Spain
      sgomez@gasolfoundation.org.
AD  - GREpS, Health Education Research Group, Nursing and Physiotherapy Department,
      University of Lleida, Lleida, Catalunya, Spain.
FAU - Homs, Clara
AU  - Homs C
AD  - Programs, Gasol Foundation, Sant Boi de Llobregat, Barcelona, Spain.
AD  - Global Research on Wellbeing (GRoW), Blanquerna Ramon Llull University Faculty of
      Health Sciences, Barcelona, Catalunya, Spain.
FAU - Warnberg, Julia
AU  - Warnberg J
AD  - Faculty of Health Sciences, Institute of Biomedical Research of Malaga (IBIMA),
      University of Malaga, Malaga, Andalucia, Spain.
AD  - Centro de Investigacion Biomedica en Red-Fisiopatologia de la Obesidad y la
      Nutricion (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
FAU - Medrano, Maria
AU  - Medrano M
AD  - ELIKOS Group, Institute for Innovation and Sustainable Development in Food Chain 
      (IS-FOOD), Public University of Navarre, Pamplona, Navarra, Spain.
FAU - Gonzalez-Gross, Marcela
AU  - Gonzalez-Gross M
AD  - Centro de Investigacion Biomedica en Red-Fisiopatologia de la Obesidad y la
      Nutricion (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
AD  - ImFINE Research Group, Department of Health and Human Performance, Universidad
      Politecnica de Madrid, Madrid, Comunidad de Madrid, Spain.
FAU - Gusi, Narcis
AU  - Gusi N
AD  - Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport
      Sciences, University of Extremadura, Caceres, Extremadura, Spain.
FAU - Aznar, Susana
AU  - Aznar S
AD  - PAFS Research Group, Faculty of Sports Sciences, University of Castilla-La
      Mancha-Toledo Campus, Toledo, Castilla-La Mancha, Spain.
FAU - Cascales, Elena Marin
AU  - Cascales EM
AD  - Research Center for High Performance Sport, San Antonio Catholic University of
      Murcia, Murcia, Spain.
FAU - Gonzalez-Valeiro, Miguel
AU  - Gonzalez-Valeiro M
AD  - Faculty of Sports Sciences and Physical Education, Universidade da Coruna, A
      Coruna, Galicia, Spain.
FAU - Serra-Majem, Lluis
AU  - Serra-Majem L
AD  - Research Institute of Biomedical and Health Sciences (IUIBS), University of Las
      Palmas de Gran Canaria, Las Palmas, Canary Islands, Spain.
AD  - Preventive Medicine Service, Centro Hospitalario Universitario Insular Materno
      Infantil (CHUIMI), Canarian Health Service, Las Palmas, Spain.
FAU - Terrados, Nicolas
AU  - Terrados N
AD  - Regional Unit of Sports Medicine, Municipal Sports Foundation of Aviles, Aviles, 
      Spain.
FAU - Tur, Josep A
AU  - Tur JA
AD  - Research Group of Community Nutrition and Oxidative Stress, University of the
      Balearic Islands, Palma de Mallorca, Illes Balears, Spain.
FAU - Segu, Marta
AU  - Segu M
AD  - Probitas Foundation, Barcelona, Spain.
FAU - Lassale, Camille
AU  - Lassale C
AUID- ORCID: 0000-0002-9340-2708
AD  - CIBER Epidemiology and Public Health (CIBERESP), Carlos III Health Institute,
      Madrid, Spain.
AD  - Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Institute for 
      Medical Research, Barcelona, Catalunya, Spain.
FAU - Benavente-Marin, Juan Carlos
AU  - Benavente-Marin JC
AD  - Faculty of Health Sciences, Institute of Biomedical Research of Malaga (IBIMA),
      University of Malaga, Malaga, Andalucia, Spain.
FAU - Labayen, Idoia
AU  - Labayen I
AD  - ELIKOS Group, Institute for Innovation and Sustainable Development in Food Chain 
      (IS-FOOD), Public University of Navarre, Pamplona, Navarra, Spain.
FAU - Zapico, Augusto Garcia
AU  - Zapico AG
AD  - ImFINE Research Group, Department of Health and Human Performance, Universidad
      Politecnica de Madrid, Madrid, Comunidad de Madrid, Spain.
AD  - Department of Didactics of Language, Arts and Physical Education, Universidad
      Complutense de Madrid, Madrid, Comunidad de Madrid, Spain.
FAU - Sanchez-Gomez, Jesus
AU  - Sanchez-Gomez J
AD  - Physical Activity and Quality of Life Research Group (AFYCAV), Faculty of Sport
      Sciences, University of Extremadura, Caceres, Extremadura, Spain.
FAU - Jimenez-Zazo, Fabio
AU  - Jimenez-Zazo F
AD  - PAFS Research Group, Faculty of Sports Sciences, University of Castilla-La
      Mancha-Toledo Campus, Toledo, Castilla-La Mancha, Spain.
FAU - Alcaraz, Pedro Emilio
AU  - Alcaraz PE
AD  - Research Center for High Performance Sport, San Antonio Catholic University of
      Murcia, Murcia, Spain.
AD  - Faculty of Sport Sciences, San Antonio Catholic University of Murcia, Murcia,
      Spain.
FAU - Sevilla-Sanchez, Marta
AU  - Sevilla-Sanchez M
AUID- ORCID: 0000-0003-2004-9162
AD  - Faculty of Sports Sciences and Physical Education, Universidade da Coruna, A
      Coruna, Galicia, Spain.
FAU - Herrera-Ramos, Estefania
AU  - Herrera-Ramos E
AD  - Research Institute of Biomedical and Health Sciences (IUIBS), University of Las
      Palmas de Gran Canaria, Las Palmas, Canary Islands, Spain.
FAU - Pulgar, Susana
AU  - Pulgar S
AD  - Regional Unit of Sports Medicine, Municipal Sports Foundation of Aviles, Aviles, 
      Spain.
FAU - Bibiloni, Maria Del Mar
AU  - Bibiloni MDM
AD  - Centro de Investigacion Biomedica en Red-Fisiopatologia de la Obesidad y la
      Nutricion (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
AD  - Research Group of Community Nutrition and Oxidative Stress, University of the
      Balearic Islands, Palma de Mallorca, Illes Balears, Spain.
FAU - Sancho, Olga
AU  - Sancho O
AD  - Probitas Foundation, Barcelona, Spain.
FAU - Schroder, Helmut
AU  - Schroder H
AD  - CIBER Epidemiology and Public Health (CIBERESP), Carlos III Health Institute,
      Madrid, Spain.
AD  - Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Institute for 
      Medical Research, Barcelona, Catalunya, Spain.
LA  - eng
SI  - ISRCTN/ISRCTN34251612
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Exercise
MH  - Humans
MH  - Life Style
MH  - Multicenter Studies as Topic
MH  - *Pediatric Obesity/epidemiology
MH  - *Quality of Life
MH  - Sedentary Behavior
MH  - Spain/epidemiology
PMC - PMC7513598
OTO - NOTNLM
OT  - *community child health
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036210 [pii]
AID - 10.1136/bmjopen-2019-036210 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e036210. doi: 10.1136/bmjopen-2019-036210.


PMID- 32967865
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Study for Improving Maternal Pregnancy And Child ouTcomes (IMPACT): a study
      protocol for a Swedish prospective multicentre cohort study.
PG  - e033851
LID - 10.1136/bmjopen-2019-033851 [doi]
AB  - INTRODUCTION: First-trimester pregnancy risk evaluation facilitates
      individualised antenatal care, as well as application of preventive strategies
      for pre-eclampsia or birth of a small for gestational age infant. A range of
      early intervention strategies in pregnancies identified as high risk at the end
      of the first trimester has been shown to decrease the risk of preterm
      pre-eclampsia (<37 gestational weeks). The aim of this project is to create the
      Improving Maternal Pregnancy And Child ouTcomes (IMPACT) database; a nationwide
      database with individual patient data, including predictors recorded at the end
      of the first trimester and later pregnancy outcomes, to identify women at high
      risk of pre-eclampsia. A second aim is to link the IMPACT database to a biobank
      with first-trimester blood samples. METHODS AND ANALYSIS: This is a Swedish
      prospective multicentre cohort study. Women are included between the 11th and
      14th weeks of pregnancy. At inclusion, pre-identified predictors are retrieved by
      interviews and medical examinations. Blood samples are collected and stored in a 
      biobank. Additional predictors and pregnancy outcomes are retrieved from the
      Swedish Pregnancy Register. Inclusion in the study began in November 2018 with a 
      targeted sample size of 45 000 pregnancies by end of 2021. Creation of a new risk
      prediction model will then be developed, validated and implemented. The database 
      and biobank will enable future research on prediction of various
      pregnancy-related complications. ETHICS AND DISSEMINATION: Confidentiality
      aspects such as data encryption and storage comply with the General Data
      Protection Regulation and with ethical committee requirements. This study has
      been granted national ethical approval by the Swedish Ethical Review Authority
      (Uppsala 2018-231) and national biobank approval at Uppsala Biobank (18237 2 2018
      231). Results from the current as well as future studies using information from
      the IMPACT database will be published in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: NCT03831490.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bergman, Lina
AU  - Bergman L
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
AD  - Department of Obstetrics and Gynecology, University of Gothenburg Sahlgrenska
      Academy, Goteborg, Sweden.
AD  - Department of Obstetrics and Gynecology, Sahlgrenska University Hospital,
      Goteborg, Sweden.
FAU - Sandstrom, Anna
AU  - Sandstrom A
AD  - Department of Women's and Children's Health, Uppsala University Disciplinary
      Domain of Medicine and Pharmacy, Uppsala, Sweden.
AD  - Clinical Epidemiology Division, Department of Medicine, Karolinska Institute,
      Stockholm, Stockholm County, Sweden.
FAU - Jacobsson, Bo
AU  - Jacobsson B
AD  - Department of Obstetrics and Gynecology, University of Gothenburg Sahlgrenska
      Academy, Goteborg, Sweden.
AD  - Department of Obstetrics and Gynecology, Sahlgrenska University Hospital,
      Goteborg, Sweden.
FAU - Hansson, Stefan
AU  - Hansson S
AD  - Department of Clinical Sciences Lund, Obstetrics and Gynecology, Lunds
      Universitet, Lund, Sweden.
AD  - Department of Obstetrics and Gynecology, Skane University Hospital Lund, Lund,
      Skane, Sweden.
FAU - Lindgren, Peter
AU  - Lindgren P
AD  - Center for Fetal Medicine, Karolinska Universitetssjukhuset, Stockholm, Sweden.
AD  - Department of Clinical Science, Intervention and Technology - CLINTEC, Karolinska
      Institutet, Stockholm, Stockholm County, Sweden.
FAU - Larsson, Anders
AU  - Larsson A
AUID- ORCID: 0000-0003-3161-0402
AD  - Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, 
      Sweden.
FAU - Imberg, Henrik
AU  - Imberg H
AD  - Department of Mathematical Sciences, Chalmers University of Technology, Goteborg,
      Sweden.
FAU - Conner, Peter
AU  - Conner P
AD  - Department of Women's and Children's Health, Karolinska Institute, Stockholm,
      Stockholm County, Sweden.
FAU - Kublickas, Marius
AU  - Kublickas M
AUID- ORCID: 0000-0002-1875-0745
AD  - Center for Fetal Medicine, Karolinska Universitetssjukhuset, Stockholm, Sweden.
AD  - Department of Clinical Science, Intervention and Technology - CLINTEC, Karolinska
      Institutet, Stockholm, Stockholm County, Sweden.
FAU - Carlsson, Ylva
AU  - Carlsson Y
AUID- ORCID: 0000-0002-1414-7279
AD  - Department of Obstetrics and Gynecology, University of Gothenburg Sahlgrenska
      Academy, Goteborg, Sweden ylva.carlsson@vgregion.se.
AD  - Department of Obstetrics and Gynecology, Sahlgrenska University Hospital,
      Goteborg, Sweden.
FAU - Wikstrom, Anna-Karin
AU  - Wikstrom AK
AD  - Department of Women's and Children's Health, Uppsala University Disciplinary
      Domain of Medicine and Pharmacy, Uppsala, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03831490
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Language
MH  - Multicenter Studies as Topic
MH  - Pregnancy
MH  - *Pregnancy Outcome/epidemiology
MH  - Prospective Studies
MH  - Sweden/epidemiology
PMC - PMC7513602
OTO - NOTNLM
OT  - *first-trimester screening
OT  - *mean arterial pressure
OT  - *placental growth factor
OT  - *preeclampsia
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-033851 [pii]
AID - 10.1136/bmjopen-2019-033851 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e033851. doi: 10.1136/bmjopen-2019-033851.


PMID- 32967864
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 23
TI  - Prospective study of change in liver function and fat in patients with colorectal
      liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF
      Study.
PG  - e027630
LID - 10.1136/bmjopen-2018-027630 [doi]
AB  - INTRODUCTION: Preoperative chemotherapy in patients undergoing resection for
      colorectal liver metastases (CLM) improves oncological outcomes. However,
      chemotherapy-associated liver injury (occurring in two patterns: vascular and fat
      deposition) is a real clinical concern prior to hepatic resection. After major
      liver resection, regeneration of the residual liver is a prerequisite for
      recovery and avoidance of liver failure, but this regenerative capacity may be
      hindered by chemotherapy. Thus, there is a need to predict for this serious
      complication. Over the past two decades, several tests and derived indices have
      been developed, which have failed to achieve clinical utility, mainly as they
      were indirect measurements of liver function. Here, we will use a novel test of
      liver function (the liver maximum capacity (LiMAx) test), and measure liver fat
      using MRI. METHODS AND ANALYSIS: This prospective study will assess changes in
      liver function longitudinally, measured by the LiMAx test, and liver fat,
      measured by advanced MRI using both MR spectroscopy and the modified Dixon
      method, in up to 35 patients undergoing preoperative chemotherapy for CLM. The
      primary outcomes will be the changes in liver function and fat compared with
      baseline prechemotherapy measurements. Secondary outcome measures include:
      routinely measured liver function blood tests, anthropometric measurements,
      postoperative histology and digital quantification of fat, postoperative
      complications and mortality and quality of life. ETHICS AND DISSEMINATION: The
      study was approved by a National Health Service Research Ethics Committee and
      registered with the Health Research Authority. Dissemination will be via
      international and national conferences and the National Institute for Health
      Research network. Manuscripts will be published. TRIAL REGISTRATION NUMBER: This 
      study is registered online at www.clinicaltrials.gov (registration number
      NCT03562234).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Parmar, Kat L
AU  - Parmar KL
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology,
      Medicine and Health, University of Manchester, Manchester, UK
      kat.parmar@manchester.ac.uk.
AD  - Manchester Cancer Research Centre, Manchester, UK.
FAU - O'Reilly, Derek
AU  - O'Reilly D
AD  - Hepatobiliary Surgery, Central Manchester University Hospitals NHS Foundation
      Trust, Manchester, UK.
FAU - Valle, Juan W
AU  - Valle JW
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology,
      Medicine and Health, University of Manchester, Manchester, UK.
AD  - Oncology, Christie NHS Foundation Trust, Manchester, UK.
FAU - Braun, Michael
AU  - Braun M
AD  - Oncology, Christie NHS Foundation Trust, Manchester, UK.
FAU - Naish, Jo H
AU  - Naish JH
AD  - Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
FAU - Williams, Steve R
AU  - Williams SR
AD  - Centre for Imaging Sciences, University of Manchester, Manchester, UK.
FAU - Lloyd, William K
AU  - Lloyd WK
AD  - Centre for Imaging Sciences, University of Manchester, Manchester, UK.
FAU - Malcomson, Lee
AU  - Malcomson L
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology,
      Medicine and Health, University of Manchester, Manchester, UK.
AD  - Surgery, Christie NHS Foundation Trust, Manchester, UK.
FAU - Cresswell, Katharine
AU  - Cresswell K
AD  - Public Programmes Team, Research and Innovation Division, Manchester University
      NHS Foundation Trust, Manchester, UK.
FAU - Bamford, Colin
AU  - Bamford C
AD  - Cancer Patient and Public Advisory Group, NIHR Manchester Biomedical Research
      Centre, Manchester, UK.
FAU - Renehan, Andrew G
AU  - Renehan AG
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology,
      Medicine and Health, University of Manchester, Manchester, UK.
AD  - Surgery, Christie NHS Foundation Trust, Manchester, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03562234
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Trials as Topic
MH  - *Colorectal Neoplasms/surgery
MH  - Hepatectomy/adverse effects
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/secondary/surgery
MH  - Prospective Studies
MH  - Quality of Life
MH  - State Medicine
MH  - Treatment Outcome
PMC - PMC7513559
OTO - NOTNLM
OT  - *chemotherapy
OT  - *colorectal surgery
OT  - *hepatobiliary surgery
COIS- Competing interests: None declared.
EDAT- 2020/09/25 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/09/24 05:27 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2018-027630 [pii]
AID - 10.1136/bmjopen-2018-027630 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 23;10(9):e027630. doi: 10.1136/bmjopen-2018-027630.


PMID- 32967810
OWN - NLM
STAT- MEDLINE
DCOM- 20211111
LR  - 20211111
IS  - 1472-6491 (Electronic)
IS  - 1472-6483 (Linking)
VI  - 41
IP  - 6
DP  - 2020 Dec
TI  - Follow-up in the field of reproductive medicine: an ethical exploration.
PG  - 1144-1150
LID - S1472-6483(20)30466-1 [pii]
LID - 10.1016/j.rbmo.2020.08.033 [doi]
AB  - RESEARCH QUESTION: What ethical implications, issues and concerns play a role in 
      conducting follow-up studies of children born after assisted reproductive
      technologies (ART)? DESIGN: Literature study and relevant experiences of academic
      medical centres in Brussels, Belgium, and Maastricht, the Netherlands were used
      to identify and analyse the most pertinent ethical implications, issues and
      concerns. RESULTS: According to recommendations from the European Society of
      Human Reproduction and Embryology, follow-up (ideally long term) of children
      conceived through medically assisted reproduction (MAR) should be an integral
      part of introducing new ART. With potentially risky new ART on the horizon, these
      recommendations need to be taken more seriously. Apart from practical barriers,
      such as funding, challenges for follow-up include securing active involvement of 
      families of children conceived through MAR, starting with parents of young
      children, and ideally involving consenting adolescents and adults during a large 
      part of their lives, possibly even into the next generation. CONCLUSIONS: From an
      ethical viewpoint, the most pertinent issues include the proportionality of the
      inevitable burdens and risks for families of children conceived through MAR, and 
      the implications of the principle of respect for autonomy. The proportionality
      requirement is most critical when it concerns incompetent children, who should
      not be included in research with more than minimal burdens and risks if there is 
      no reasonable expectation of benefit for themselves. With respect for autonomy,
      we argue that, when seeking voluntary consent for participating in follow-up
      studies that meet the condition of proportionality, professionals may encourage
      members of families of children conceived through MAR to partake in follow-up
      research.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Jans, Verna
AU  - Jans V
AD  - Department of Health, Ethics and Society Maastricht University, Postbus 616,
      Maastricht 6200 MD, The Netherlands. Electronic address:
      v.jans@maastrichtuniversity.nl.
FAU - Dondorp, Wybo
AU  - Dondorp W
AD  - Department of Health, Ethics and Society Maastricht University, Postbus 616,
      Maastricht 6200 MD, The Netherlands.
FAU - Bonduelle, Maryse
AU  - Bonduelle M
AD  - Center for Medical Genetics, Universitair Ziekenhuis Brussel (UZ Brussel),
      Laarbeeklaan 101, Brussels (Jette) 1090, Belgium.
FAU - de Die, Christine
AU  - de Die C
AD  - Department of Clinical Genetics, Research School GROW for Oncology and
      Developmental Biology, Maastricht University Medical Center, Postbus 5800,
      Maastricht 6202 AZ, the Netherlands.
FAU - Mertes, Heidi
AU  - Mertes H
AD  - Department of Philosophy and Moral Sciences, Faculty of Arts and Philosophy,
      Ghent University, Blandijnberg 2, Ghent B-9000, Belgium.
FAU - Pennings, Guido
AU  - Pennings G
AD  - Department of Philosophy and Moral Sciences, Faculty of Arts and Philosophy,
      Ghent University, Blandijnberg 2, Ghent B-9000, Belgium.
FAU - de Wert, Guido
AU  - de Wert G
AD  - Department of Health, Ethics and Society Maastricht University, Postbus 616,
      Maastricht 6200 MD, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Netherlands
TA  - Reprod Biomed Online
JT  - Reproductive biomedicine online
JID - 101122473
SB  - IM
MH  - Adult
MH  - Belgium
MH  - Biomedical Research/ethics
MH  - Child
MH  - Child Development/*physiology
MH  - Child, Preschool
MH  - Confidentiality/ethics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Informed Consent
MH  - Male
MH  - *Monitoring, Physiologic/ethics
MH  - Netherlands
MH  - Personal Autonomy
MH  - Pregnancy
MH  - Reproductive Medicine/*ethics/methods
MH  - Reproductive Techniques, Assisted/ethics
OTO - NOTNLM
OT  - Ethics
OT  - Follow-up research
OT  - Informed consent
OT  - Proportionality principle
OT  - Reproductive medicine
OT  - Respect for autonomy
EDAT- 2020/09/25 06:00
MHDA- 2021/11/12 06:00
CRDT- 2020/09/24 05:27
PHST- 2020/04/29 00:00 [received]
PHST- 2020/08/18 00:00 [revised]
PHST- 2020/08/23 00:00 [accepted]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/11/12 06:00 [medline]
PHST- 2020/09/24 05:27 [entrez]
AID - S1472-6483(20)30466-1 [pii]
AID - 10.1016/j.rbmo.2020.08.033 [doi]
PST - ppublish
SO  - Reprod Biomed Online. 2020 Dec;41(6):1144-1150. doi: 10.1016/j.rbmo.2020.08.033. 
      Epub 2020 Aug 28.


PMID- 32967692
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 23
TI  - CLASSIE teaching - using virtual reality to incorporate medical ethics into
      clinical decision making.
PG  - 326
LID - 10.1186/s12909-020-02217-y [doi]
AB  - BACKGROUND: Teaching medical ethics (ME) in the clinical environment is often
      difficult, uncalibrated and medical students get variable exposure to skilled
      educators. Explicit discussion of ethical dimensions of patient management is
      often neglected, as clinical teachers may feel inadequately skilled to do this.
      METHODS: We developed a suite of online modules. Each consisted of a clinical
      scenario filmed using virtual reality (VR) technology, linked to an adaptive,
      interactive, online tutorial which explicitly discussed the relevant ethical
      issues and guidelines. These were embedded in clinical placements of students to 
      encourage the transfer of knowledge from these modules to clinical skill
      competency. We conducted a pilot study to evaluate these modules which examined
      student engagement, knowledge gains (self-perceived and measured) and user
      experience. We also reviewed reflections to assess the incorporation of these
      modules and transfer of knowledge into the clinical learning and skill
      development of the students. RESULTS: Engagement and self-perceived knowledge
      gains were extremely high. Students found these modules realistic, interesting
      and helpful. The measured knowledge gains (module exit quiz) were moderate. User 
      experience was positive overall, although students were intolerant of any
      technical glitches. There was mixed feedback on whether the VR aspect of the
      clinical scenarios added value. Student reflections showed high level
      incorporation of these modules into clinical practice of the students and
      evidence of knowledge transfer (level 3 Kirkpatrick model of evaluation) in over 
      (3/4) of students. CONCLUSIONS: This study showed that the use VR clinical
      scenarios combined with interactive online learning modules resulted in
      demonstrable high-level student engagement and learning gains in medical ethics
      and transfer of knowledge to clinical application. It standardised and ensured
      the student experience of high-quality educational deliverables in clinical years
      of medical education. This use of VR and online technology can be adapted for use
      in many areas of the medical curricula where we need to ensure the delivery of
      well calibrated, high quality, educational deliverables at scale for students.
FAU - Torda, Adrienne
AU  - Torda A
AUID- ORCID: http://orcid.org/0000-0003-4154-6459
AD  - Faculty of Medicine, UNSW Sydney, Kensington, NSW, 2052, Australia.
      a.torda@unsw.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Clinical Decision-Making
MH  - Ethics, Medical
MH  - Humans
MH  - Learning
MH  - Pilot Projects
MH  - *Virtual Reality
PMC - PMC7509501
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:25
PHST- 2019/12/08 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/24 05:25 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02217-y [doi]
AID - 10.1186/s12909-020-02217-y [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Sep 23;20(1):326. doi: 10.1186/s12909-020-02217-y.


PMID- 32967659
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 Sep 23
TI  - What do you mean by "palliative sedation"? : Pre-explicative analyses as
      preliminary steps towards better definitions.
PG  - 147
LID - 10.1186/s12904-020-00635-9 [doi]
AB  - BACKGROUND: Sedation in palliative care is frequently but controversially
      discussed. Heterogeneous definitions and conceptual confusion have been cited as 
      contributing to different problems 1) relevant to empirical research, for
      example, inconsistent data about practice, the 'data problem', and 2) relevant
      for an ethically legitimate characterisation of the practice, the 'problem of
      ethical pre-emption'. However, little is known about how exactly definitions
      differ, how they cause confusion and how this can be overcome. METHOD:
      Pre-explicative analyses: (A) systematic literature search for guidelines on
      sedation in palliative care and systematic decomposition of the definitions of
      the practice in these guidelines; (B) logical distinction of different ways
      through which the two problems reported might be caused by definitions; and (C)
      analysis of how content of the definitions contributes to the problems reported
      in these different ways. RESULTS: 29 guidelines from 14 countries were
      identified. Definitions differ significantly in both structure and content. We
      identified three ways in which definitions can cause the 'data problem' - 1)
      different definitions, 2) deviating implicit concepts, 3) disagreement about
      facts. We identified two ways to cause the problem of ethical pre-emption: 1)
      explicit or 2) implicit normativity. Decomposition of definitions linked to the
      distinguished ways of causing the conceptual problems shows how exactly single
      parts of definitions can cause the problems identified. CONCLUSION: Current
      challenges concerning empirical research on sedation in palliative care can be
      remediated partly by improved definitions in the future, if content and structure
      of the used definitions is chosen systematically. In addition, future research
      should bear in mind that there are distinct purposes of definitions. Regarding
      the 'data problem', improving definitions is possible in terms of supplementary
      information, checking for implicit understanding, systematic choice of
      definitional elements. 'Ethical pre-emption', in contrast, is a pseudo problem if
      definitions and the relationship of definitions and norms of good practice are
      understood correctly.
FAU - Kremling, Alexander
AU  - Kremling A
AUID- ORCID: http://orcid.org/0000-0002-2674-2497
AD  - Institute of History and Ethics of Medicine, Interdisciplinary Center for Health 
      Sciences, Madgeburger Strasse 8, Halle (Saale), 06112, Germany.
      alexander.kremling@medizin.uni-halle.de.
FAU - Schildmann, Jan
AU  - Schildmann J
AD  - Institute of History and Ethics of Medicine, Interdisciplinary Center for Health 
      Sciences, Madgeburger Strasse 8, Halle (Saale), 06112, Germany.
LA  - eng
GR  - 01GY1702A-C/Bundesministerium fur Bildung und Forschung
PT  - Journal Article
PT  - Systematic Review
DEP - 20200923
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
RN  - 0 (Hypnotics and Sedatives)
SB  - IM
MH  - Deep Sedation/*classification/methods
MH  - Humans
MH  - Hypnotics and Sedatives/therapeutic use
MH  - Palliative Care/classification/*methods
PMC - PMC7513316
OTO - NOTNLM
OT  - Conceptual analysis
OT  - Empirical research
OT  - End-of-life care
OT  - Palliative care
OT  - Palliative sedation
EDAT- 2020/09/25 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/09/24 05:25
PHST- 2020/06/10 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/24 05:25 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.1186/s12904-020-00635-9 [doi]
AID - 10.1186/s12904-020-00635-9 [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 Sep 23;19(1):147. doi: 10.1186/s12904-020-00635-9.


PMID- 32967650
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 23
TI  - Systemic TNFalpha correlates with residual beta-cell function in children and
      adolescents newly diagnosed with type 1 diabetes.
PG  - 446
LID - 10.1186/s12887-020-02339-8 [doi]
AB  - BACKGROUND: Type 1 diabetes (T1D) is caused by immune-mediated destruction of the
      beta-cells. After initiation of insulin therapy many patients experience a period
      of improved residual beta-cell function leading to partial disease remission.
      Cytokines are important immune-modulatory molecules and contribute to beta-cell
      damage in T1D. The patterns of systemic circulating cytokines during T1D
      remission are not clear but may constitute biomarkers of disease status and
      progression. In this study, we investigated if the plasma levels of various pro- 
      and anti-inflammatory cytokines around time of diagnosis were predictors of
      remission and residual beta-cell function in children with T1D followed for one
      year after disease onset. METHODS: In a cohort of 63 newly diagnosed children
      (33% females) with T1D with a mean age of 11.3 years (3.3-17.7), ten cytokines
      were measured of which eight were detectable in plasma samples by Mesoscale
      Discovery multiplex technology at study start and after 6 and 12 months. Linear
      regression models were used to evaluate association of cytokines with stimulated 
      C-peptide. RESULTS: Systemic levels of tumor necrosis factor (TNF)-alpha,
      interleukin (IL)-2 and IL-6 inversely correlated with stimulated C-peptide levels
      over the entire study (P < 0.05). The concentrations of TNFalpha and IL-10 at
      study start predicted stimulated C-peptide level at 6 months (P = 0.011 and P =
      0.043, respectively, adjusted for sex, age, HbA1c and stage of puberty).
      CONCLUSIONS: In recent-onset T1D, systemic cytokine levels, and in particular
      that of TNFalpha, correlate with residual beta-cell function and may serve as
      prognostic biomarkers of disease remission and progression to optimize treatment 
      strategies. TRIAL REGISTRATION: The study was performed according to the criteria
      of the Helsinki II Declaration and was approved by the Danish Capital Region
      Ethics Committee on Biomedical Research Ethics (journal number H-3-2014-052). The
      parents of all participants gave written consent.
FAU - Overgaard, Anne Julie
AU  - Overgaard AJ
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
      anne.julie.overgaard@regionh.dk.
FAU - Madsen, Jens Otto Broby
AU  - Madsen JOB
AD  - Pediatrics Department E, Herlev Hospital, Herlev, Denmark.
FAU - Pociot, Flemming
AU  - Pociot F
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Johannesen, Jesper
AU  - Johannesen J
AD  - Pediatrics Department E, Herlev Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Storling, Joachim
AU  - Storling J
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (C-Peptide)
RN  - 0 (Cytokines)
RN  - 0 (Insulin)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - C-Peptide
MH  - Child
MH  - Cytokines
MH  - *Diabetes Mellitus, Type 1/diagnosis/drug therapy
MH  - Female
MH  - Humans
MH  - Insulin
MH  - *Insulin-Secreting Cells
MH  - Male
MH  - Tumor Necrosis Factor-alpha
PMC - PMC7510056
OTO - NOTNLM
OT  - *Cytokines
OT  - *Inflammation
OT  - *Remission
OT  - *TNF
OT  - *Type 1 diabetes
OT  - *beta-cell function
EDAT- 2020/09/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/24 05:25
PHST- 2020/05/25 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/24 05:25 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12887-020-02339-8 [doi]
AID - 10.1186/s12887-020-02339-8 [pii]
PST - epublish
SO  - BMC Pediatr. 2020 Sep 23;20(1):446. doi: 10.1186/s12887-020-02339-8.


PMID- 32964135
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210914
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Research protocol for a mixed-methods study to characterise and address the
      socioeconomic impact of accessing TB diagnosis and care in Nepal.
PG  - 19
LID - 10.12688/wellcomeopenres.15677.2 [doi]
AB  - Background: WHO's 2015 End TB Strategy advocates social and economic
      (socioeconomic) support for TB-affected households to improve TB control.
      However, evidence concerning socioeconomic support for TB-affected households
      remains limited, especially in low-income countries. Protocol: This mixed-methods
      study in Nepal will: evaluate the socioeconomic impact of accessing TB diagnosis 
      and care (Project 1); and create a shortlist of feasible, locally-appropriate
      interventions to mitigate this impact (Project 2). The study will be conducted in
      the Chitwan, Mahottari, Makawanpur, and Dhanusha districts of Nepal, which have
      frequent TB and poverty. The study population will include: approximately 200
      people with TB (Cases) starting TB treatment with Nepal's National TB Program and
      100 randomly-selected people without TB (Controls) in the same sites (Project 1);
      and approximately 40 key in-country stakeholders from Nepal including people with
      TB, community leaders, and TB healthcare professionals (Project 2). During
      Project 1, visits will be made to people with TB's households during months 3 and
      6 of TB treatment, and a single visit made to Control households. During visits, 
      participants will be asked about: TB-related costs (if receiving treatment), food
      insecurity, stigma; TB-related knowledge; household poverty level; social
      capital; and quality of life. During Project 2, stakeholders will be invited to
      participate in: a survey and focus group discussion (FGD) to characterise
      socioeconomic impact, barriers and facilitators to accessing and engaging with TB
      care in Nepal; and a one-day workshop to review FGD findings and suggest
      interventions to mitigate the barriers identified. Ethics and dissemination: The 
      study has received ethical approval. Results will be disseminated through
      scientific meetings, open access publications, and a national workshop in Nepal. 
      Conclusions: This research will strengthen understanding of the socioeconomic
      impact of TB in Nepal and generate a shortlist of feasible and
      locally-appropriate socioeconomic interventions for TB-affected households for
      trial evaluation.
CI  - Copyright: (c) 2020 Dixit K et al.
FAU - Dixit, Kritika
AU  - Dixit K
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
AD  - Social medicine, Infectious diseases, and Migration (SIM) Group, Department of
      Public Health Sciences, Karolinska Institute, Solnavagen 1, 171 77 Solna,
      Stockholm, Sweden.
FAU - Rai, Bhola
AU  - Rai B
AUID- ORCID: https://orcid.org/0000-0002-7421-4891
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
FAU - Prasad Aryal, Tara
AU  - Prasad Aryal T
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
FAU - Mishra, Gokul
AU  - Mishra G
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
FAU - Teixeira de Siqueira-Filha, Noemia
AU  - Teixeira de Siqueira-Filha N
AD  - Departments of International Public Health and Clinical Sciences, Liverpool
      School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
FAU - Raj Paudel, Puskar
AU  - Raj Paudel P
AD  - KNCV Tuberculosis Foundation, Postbus 146, 2501 CC Den Haag, The Netherlands.
FAU - Levy, Jens W
AU  - Levy JW
AUID- ORCID: https://orcid.org/0000-0002-5676-2990
AD  - KNCV Tuberculosis Foundation, Postbus 146, 2501 CC Den Haag, The Netherlands.
FAU - van Rest, Job
AU  - van Rest J
AD  - KNCV Tuberculosis Foundation, Postbus 146, 2501 CC Den Haag, The Netherlands.
FAU - Chandra Gurung, Suman
AU  - Chandra Gurung S
AUID- ORCID: https://orcid.org/0000-0002-4012-7562
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
AD  - Departments of International Public Health and Clinical Sciences, Liverpool
      School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
FAU - Dhital, Raghu
AU  - Dhital R
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
FAU - Biermann, Olivia
AU  - Biermann O
AUID- ORCID: https://orcid.org/0000-0002-5978-0211
AD  - Social medicine, Infectious diseases, and Migration (SIM) Group, Department of
      Public Health Sciences, Karolinska Institute, Solnavagen 1, 171 77 Solna,
      Stockholm, Sweden.
FAU - Viney, Kerri
AU  - Viney K
AUID- ORCID: https://orcid.org/0000-0002-0453-4339
AD  - Social medicine, Infectious diseases, and Migration (SIM) Group, Department of
      Public Health Sciences, Karolinska Institute, Solnavagen 1, 171 77 Solna,
      Stockholm, Sweden.
FAU - Lonnroth, Knut
AU  - Lonnroth K
AD  - Social medicine, Infectious diseases, and Migration (SIM) Group, Department of
      Public Health Sciences, Karolinska Institute, Solnavagen 1, 171 77 Solna,
      Stockholm, Sweden.
FAU - Squire, S Bertel
AU  - Squire SB
AUID- ORCID: https://orcid.org/0000-0001-7173-9038
AD  - Departments of International Public Health and Clinical Sciences, Liverpool
      School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
AD  - Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS
      Foundation Trust, Prescot Street, Liverpool, L7 8XP, UK.
FAU - Caws, Maxine
AU  - Caws M
AUID- ORCID: https://orcid.org/0000-0002-9109-350X
AD  - Birat Nepal Medical Trust, Lazimpat Road, Lazimpat, Ward No 2, Box 20564,
      Kathmandu, Nepal.
AD  - Departments of International Public Health and Clinical Sciences, Liverpool
      School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
FAU - Wingfield, Tom
AU  - Wingfield T
AD  - Social medicine, Infectious diseases, and Migration (SIM) Group, Department of
      Public Health Sciences, Karolinska Institute, Solnavagen 1, 171 77 Solna,
      Stockholm, Sweden.
AD  - Departments of International Public Health and Clinical Sciences, Liverpool
      School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
AD  - Tropical and Infectious Disease Unit, Liverpool University Hospitals NHS
      Foundation Trust, Prescot Street, Liverpool, L7 8XP, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7489278
OTO - NOTNLM
OT  - Nepal
OT  - Tuberculosis
OT  - catastrophic costs
OT  - healthcare access
OT  - poverty
OT  - social protection
OT  - socioeconomic support
COIS- No competing interests were disclosed.
EDAT- 2020/09/25 06:00
MHDA- 2020/09/25 06:01
CRDT- 2020/09/24 05:35
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/09/24 05:35 [entrez]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2020/09/25 06:01 [medline]
AID - 10.12688/wellcomeopenres.15677.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Jun 16;5:19. doi: 10.12688/wellcomeopenres.15677.2.
      eCollection 2020.


PMID- 32966696
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20211217
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Dec
TI  - The effectiveness, feasibility, and acceptability of low-sodium salts worldwide: 
      An environmental scan protocol.
PG  - 2258-2265
LID - 10.1111/jch.14054 [doi]
AB  - Excess sodium intake elevates blood pressure and risk for cardiovascular
      diseases. The use of low-sodium salts is a potentially cost-effective strategy to
      counter the rising global burden of cardiovascular diseases. This research aimed 
      to understand the potential scale-up of low-sodium salt interventions by
      examining the availability of low-sodium salts globally, synthesizing evidence
      about the effectiveness of low-sodium salt interventions, and identifying the
      challenges and opportunities associated with implementing low-sodium salt
      interventions. This study consists of three parts. The first part is a systematic
      online search of low-sodium salts. The authors will use the advanced search
      functions of search engines and online shopping sites to execute the search. The 
      second part is a systematic review of academic literature on the use of
      low-sodium salts. A meta-analysis will be performed to quantify the effectiveness
      of low-sodium salt interventions. The third part is key informant interviews to
      understand the challenges of implementing low-sodium salt interventions. Key
      informants will include policymakers, academic researchers, and salt industry
      representatives. The list of key informants will be generated through purposive
      sampling and snowball sampling based on the completed online search and the
      systematic review. The interview guides will be developed based on the RE-AIM
      (Reach, Effective, Adoption, Implementation, and Maintenance) framework. The
      study received ethics approval from the University of New South Wales Human
      Research Ethics Advisory Panel (HC190921). Findings will be disseminated with
      academics and policymakers through a peer-reviewed journal and conference
      presentations.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Yin, Xuejun
AU  - Yin X
AUID- ORCID: 0000-0001-8446-9591
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Liu, Hueiming
AU  - Liu H
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
AD  - Sydney Institute for Women, Children and their Families, Sydney Local Health
      District, Sydney, NSW, Australia.
FAU - Trieu, Kathy
AU  - Trieu K
AUID- ORCID: 0000-0003-1848-2741
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Webster, Jacqui
AU  - Webster J
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Farrand, Clare
AU  - Farrand C
AUID- ORCID: 0000-0002-7660-1414
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Li, Ka-Chun
AU  - Li KC
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Pearson, Sallie
AU  - Pearson S
AD  - Centre for Big Data Research in Health, University of New South Wales, Sydney,
      NSW, Australia.
FAU - Tian, Maoyi
AU  - Tian M
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      NSW, Australia.
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - 0 (Salts)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Diet, Sodium-Restricted
MH  - Feasibility Studies
MH  - Humans
MH  - *Hypertension/epidemiology/prevention & control
MH  - Meta-Analysis as Topic
MH  - Salts
MH  - Sodium
MH  - Systematic Reviews as Topic
PMC - PMC8030108
OTO - NOTNLM
OT  - *environmental scan
OT  - *low-sodium salts
OT  - *salt substitutes
OT  - *study protocol
EDAT- 2020/09/24 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/09/23 17:37
PHST- 2020/08/02 00:00 [received]
PHST- 2020/08/23 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2020/09/23 17:37 [entrez]
AID - 10.1111/jch.14054 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2020 Dec;22(12):2258-2265. doi: 10.1111/jch.14054. 
      Epub 2020 Sep 23.


PMID- 32965447
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20220417
IS  - 1980-220X (Electronic)
IS  - 0080-6234 (Linking)
VI  - 54
DP  - 2020
TI  - Safety of hospitalized older adult patients: an analysis of the risk of falls.
PG  - e03613
LID - S0080-62342020000100461 [pii]
LID - 10.1590/S1980-220X2018054003613 [doi]
AB  - OBJECTIVE: To identify the risk of falls of older adults in a hospital in the
      Trairi region in Rio Grande do Norte, Brazil, and to describe the relationship
      between risk of falls and the sociodemographic characteristics of the
      participants. METHOD: A descriptive, transversal, and quantitative study
      conducted in a regional hospital, respecting the ethical principles in force. The
      Morse Scale was adopted for data collection, which took place in July and August 
      2018, and adapted with sociodemographic questions. A descriptive and inferential 
      statistical analysis was performed. RESULTS: There were 46 participants in the
      study, most of whom were women with low education, and the most frequent reasons 
      for hospitalization were surgical treatment and lung disease. More than half had 
      a high risk of falling (54.35%), followed by moderate (32.61%) and low (13.04%). 
      There was an association between high risk of falls, having lung disease as a
      reason for hospitalization and diabetes as a comorbidity. The high risk of falls 
      was less frequent among older adult patients hospitalized for surgical treatment.
      CONCLUSION: The high risk of falls was found in more than half of the older
      adults, which varied according to the reason for hospitalization and
      comorbidities, being more frequent in those hospitalized for lung disease and in 
      those who had Diabetes.
FAU - Canuto, Carla Patricia de Almeida Santos
AU  - Canuto CPAS
AUID- ORCID: http://orcid.org/0000-0002-0594-4831
AD  - Universidade Federal do Rio Grande do Norte, Faculdade de Ciencias da Saude do
      Trairi, Santa Cruz, RN, Brasil.
FAU - Oliveira, Luciane Paula Batista Araujo de
AU  - Oliveira LPBA
AUID- ORCID: http://orcid.org/0000-0003-1629-8991
AD  - Universidade Federal do Rio Grande do Norte, Faculdade de Ciencias da Saude do
      Trairi, Santa Cruz, RN, Brasil.
FAU - Medeiros, Marilia Rute de Souto
AU  - Medeiros MRS
AUID- ORCID: http://orcid.org/0000-0003-1817-6859
AD  - Universidade Federal do Rio Grande do Norte, Faculdade de Ciencias da Saude do
      Trairi, Santa Cruz, RN, Brasil.
FAU - Barros, Wanessa Cristina Tomaz Dos Santos
AU  - Barros WCTDS
AUID- ORCID: http://orcid.org/0000-0002-1924-3278
AD  - Universidade Federal do Rio Grande do Norte, Faculdade de Ciencias da Saude do
      Trairi, Santa Cruz, RN, Brasil.
LA  - por
LA  - eng
PT  - Journal Article
TT  - Seguranca do paciente idoso hospitalizado: uma analise do risco de quedas.
DEP - 20200918
PL  - Brazil
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
MH  - *Accidental Falls
MH  - Aged
MH  - Brazil
MH  - Comorbidity
MH  - Female
MH  - *Hospitalization
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - *Patient Safety
MH  - Risk Factors
EDAT- 2020/09/24 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/09/23 12:12
PHST- 2018/12/21 00:00 [received]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
AID - S0080-62342020000100461 [pii]
AID - 10.1590/S1980-220X2018054003613 [doi]
PST - epublish
SO  - Rev Esc Enferm USP. 2020 Sep 18;54:e03613. doi: 10.1590/S1980-220X2018054003613. 
      eCollection 2020.


PMID- 32965443
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1980-220X (Electronic)
IS  - 0080-6234 (Linking)
VI  - 54
DP  - 2020 Sep 16
TI  - CAQDAS and Ethics: starting point for something bigger.
PG  - e03598
LID - S0080-62342020000100100 [pii]
LID - 10.1590/S1980-220X2020ed0103598 [doi]
FAU - Costa, Antonio Pedro
AU  - Costa AP
AUID- ORCID: 0000-0002-4644-5879
AD  - Universidade de Aveiro, Centro de Investigacao Didatica e Tecnologia na Formacao 
      de Formadores, Departamento de Educacao e Psicologia, Aveiro, Portugal. e-mail:
      apcosta@ua.pt.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - Brazil
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
MH  - *Data Analysis
MH  - *Ethics
MH  - Humans
EDAT- 2020/09/24 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/09/23 12:12
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
AID - S0080-62342020000100100 [pii]
AID - 10.1590/S1980-220X2020ed0103598 [doi]
PST - epublish
SO  - Rev Esc Enferm USP. 2020 Sep 16;54:e03598. doi: 10.1590/S1980-220X2020ed0103598.


PMID- 32965408
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220417
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73
IP  - suppl 4
DP  - 2020
TI  - Transition of blind women to motherhood from the perspective of Transitions
      Theory.
PG  - e20190234
LID - S0034-71672020001600173 [pii]
LID - 10.1590/0034-7167-2019-0234 [doi]
AB  - OBJECTIVE: to analyze the transition of blind women to motherhood from the
      perspective of Transitions Theory. METHOD: a qualitative, descriptive study,
      which had as participants 11 blind women. An open interview was conducted using
      the narrative method. Analysis occurred in the light of Transitions Theory, with 
      approval from the Research Ethics Committee with Human Beings. RESULTS: the age
      group was 32 to 63 years, mostly Catholic, with social security benefits.
      Transition to motherhood mainly evidenced the experience when becoming a mother
      and feelings related to this new phase of life. FINAL CONSIDERATIONS: the women
      in the study adapted themselves to the maternal role, even with difficulties,
      developed healthy relationships with their children, overcame their disability
      and nurtured dreams and desires. They were aware of their role, achieving with
      mastery a healthy transition. It was evidenced scarcity of nursing therapies.
FAU - Santos, Rosangela da Silva
AU  - Santos RDS
AUID- ORCID: http://orcid.org/0000-0002-2541-5646
AD  - Universidade do Estado do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Ribeiro, Vivian Mara
AU  - Ribeiro VM
AUID- ORCID: http://orcid.org/0000-0002-8860-4428
AD  - Universidade Estadual do Sudoeste da Bahia. Jequie, Bahia, Brazil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20200921
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - Adult
MH  - Child
MH  - *Disabled Persons
MH  - Emotions
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Mothers
MH  - Qualitative Research
EDAT- 2020/09/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/23 12:12
PHST- 2019/03/15 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - S0034-71672020001600173 [pii]
AID - 10.1590/0034-7167-2019-0234 [doi]
PST - epublish
SO  - Rev Bras Enferm. 2020 Sep 21;73(suppl 4):e20190234. doi:
      10.1590/0034-7167-2019-0234. eCollection 2020.


PMID- 32965395
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20220417
IS  - 1982-4335 (Electronic)
IS  - 0103-507X (Linking)
VI  - 32
IP  - 3
DP  - 2020 Jul-Sep
TI  - Rationale and design of the "Tocilizumab in patients with moderate to severe
      COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
PG  - 337-347
LID - S0103-507X2020000300337 [pii]
LID - 10.5935/0103-507X.20200060 [doi]
AB  - INTRODUCTION: Pro-inflammatory markers play a significant role in the disease
      severity of patients with COVID-19. Thus, anti-inflammatory therapies are
      attractive agents for potentially combating the uncontrolled inflammatory cascade
      in these patients. We designed a trial testing tocilizumab versus standard of
      care intending to improve the outcomes by inhibiting interleukin-6, an important 
      inflammatory mediator in COVID-19. METHODS AND ANALYSIS: This open-label
      multicentre randomized controlled trial will compare clinical outcomes of
      tocilizumab plus standard of care versus standard of care alone in patients with 
      moderate to severe COVID-19. Two of the following four criteria are required for 
      protocol enrolment: D-dimer > 1,000ng/mL; C reactive protein > 5mg/dL, ferritin >
      300mg/dL, and lactate dehydrogenase > upper limit of normal. The primary
      objective will be to compare the clinical status on day 15, as measured by a
      7-point ordinal scale applied in COVID-19 trials worldwide. The primary endpoint 
      will be assessed by an ordinal logistic regression assuming proportional odds
      ratios adjusted for stratification variables (age and sex). ETHICS AND
      DISSEMINATION: The TOCIBRAS protocol was approved by local and central (national)
      ethical committees in Brazil following current national and international
      guidelines/directives. Each participating center had the study protocol approved 
      by their institutional review boards before initiating protocol enrolment. The
      data derived from this trial will be published regardless of the results. If
      proven active, this strategy could alleviate the consequences of the inflammatory
      response in COVID-19 patients and improve their clinical outcomes.
FAU - Farias, Danielle Leao Cordeiro de
AU  - Farias DLC
AD  - BP - A Beneficencia Portuguesa de Sao Paulo - Sao Paulo (SP), Brasil.
FAU - Prats, Joao
AU  - Prats J
AD  - BP - A Beneficencia Portuguesa de Sao Paulo - Sao Paulo (SP), Brasil.
FAU - Cavalcanti, Alexandre Biasi
AU  - Cavalcanti AB
AUID- ORCID: http://orcid.org/0000-0003-2798-6263
AD  - Brazilian Research in Intensive Care Network (BRICNet) - Sao Paulo (SP), Brasil.
AD  - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil.
FAU - Rosa, Regis Goulart
AU  - Rosa RG
AUID- ORCID: http://orcid.org/0000-0001-7881-9866
AD  - Brazilian Research in Intensive Care Network (BRICNet) - Sao Paulo (SP), Brasil.
AD  - Hospital Moinhos de Vento - Porto Alegre (RS), Brasil.
FAU - Machado, Flavia Ribeiro
AU  - Machado FR
AUID- ORCID: http://orcid.org/0000-0002-2356-4867
AD  - Brazilian Research in Intensive Care Network (BRICNet) - Sao Paulo (SP), Brasil.
FAU - Berwanger, Otavio
AU  - Berwanger O
AUID- ORCID: http://orcid.org/0000-0002-4972-2958
AD  - Organizacao de Pesquisa Academica, Hospital Israelita Albert Einstein - Sao Paulo
      (SP), Brasil.
FAU - Azevedo, Luciano Cesar Pontes de
AU  - Azevedo LCP
AD  - Brazilian Research in Intensive Care Network (BRICNet) - Sao Paulo (SP), Brasil.
AD  - Hospital Sirio-Libanes - Sao Paulo (SP), Brasil.
FAU - Lopes, Renato Delascio
AU  - Lopes RD
AUID- ORCID: http://orcid.org/0000-0003-2999-4961
AD  - Duke Clinical Research Institute, Duke University Medical Center, Durham, NC,
      Estados Unidos.
AD  - Brazilian Clinical Research Institute - Sao Paulo (SP), Brasil.
FAU - Avezum, Alvaro
AU  - Avezum A
AD  - Centro Internacional de Pesquisa, Hospital Alemao Oswaldo Cruz - Sao Paulo (SP), 
      Brasil.
FAU - Kawano-Dourado, Leticia
AU  - Kawano-Dourado L
AUID- ORCID: http://orcid.org/0000-0003-0784-1331
AD  - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil.
FAU - Damiani, Lucas Petri
AU  - Damiani LP
AD  - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil.
FAU - Rojas, Salomon Soriano Ordinola
AU  - Rojas SSO
AUID- ORCID: http://orcid.org/0000-0001-7304-5654
AD  - BP - A Beneficencia Portuguesa de Sao Paulo - Sao Paulo (SP), Brasil.
FAU - Oliveira, Cleyton Zanardo de
AU  - Oliveira CZ
AD  - BP - A Beneficencia Portuguesa de Sao Paulo - Sao Paulo (SP), Brasil.
FAU - Andrade, Luis Eduardo Coelho
AU  - Andrade LEC
AD  - Fleury Medicina e Laboratorios - Sao Paulo (SP), Brasil.
FAU - Sandes, Alex Freire
AU  - Sandes AF
AD  - Fleury Medicina e Laboratorios - Sao Paulo (SP), Brasil.
FAU - Pintao, Maria Carolina
AU  - Pintao MC
AD  - Fleury Medicina e Laboratorios - Sao Paulo (SP), Brasil.
FAU - Castro Junior, Claudio Galvao de
AU  - Castro Junior CG
AD  - Organizacao de Pesquisa Academica, Hospital Israelita Albert Einstein - Sao Paulo
      (SP), Brasil.
AD  - Santa Casa de Porto Alegre - Porto Alegre (RS), Brasil.
FAU - Scheinberg, Phillip
AU  - Scheinberg P
AUID- ORCID: http://orcid.org/0000-0002-9047-4538
AD  - BP - A Beneficencia Portuguesa de Sao Paulo - Sao Paulo (SP), Brasil.
FAU - Veiga, Viviane Cordeiro
AU  - Veiga VC
AUID- ORCID: http://orcid.org/0000-0002-0287-3601
AD  - BP - A Beneficencia Portuguesa de Sao Paulo - Sao Paulo (SP), Brasil.
AD  - Brazilian Research in Intensive Care Network (BRICNet) - Sao Paulo (SP), Brasil.
LA  - por
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19
      moderado a grave: estudo aberto, multicentrico, randomizado, controlado"
      (TOCIBRAS).
PL  - Brazil
TA  - Rev Bras Ter Intensiva
JT  - Revista Brasileira de terapia intensiva
JID - 9506692
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use
MH  - Brazil
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/physiopathology
MH  - Humans
MH  - Interleukin-6/antagonists & inhibitors
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/physiopathology
MH  - Severity of Illness Index
PMC - PMC7595725
EDAT- 2020/09/24 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/09/23 12:12
PHST- 2020/07/17 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/09/23 12:12 [entrez]
AID - S0103-507X2020005003201 [pii]
AID - 10.5935/0103-507X.20200060 [doi]
PST - ppublish
SO  - Rev Bras Ter Intensiva. 2020 Jul-Sep;32(3):337-347. doi:
      10.5935/0103-507X.20200060.


PMID- 32965367
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201218
IS  - 1806-9282 (Electronic)
IS  - 0104-4230 (Linking)
VI  - 66Suppl 2
IP  - Suppl 2
DP  - 2020
TI  - Ethical dilemmas in COVID-19 times: how to decide who lives and who dies?
PG  - 106-111
LID - S0104-42302020001400106 [pii]
LID - 10.1590/1806-9282.66.S2.106 [doi]
AB  - The respiratory disease caused by the coronavirus SARS-CoV-2 (COVID-19) is a
      pandemic that produces a large number of simultaneous patients with severe
      symptoms and in need of special hospital care, overloading the infrastructure of 
      health services. All of these demands generate the need to ration equipment and
      interventions. Faced with this imbalance, how, when, and who decides, there is
      the impact of the stressful systems of professionals who are at the front line of
      care and, in the background, issues inherent to human subjectivity. Along this
      path, the idea of using artificial intelligence algorithms to replace health
      professionals in the decision-making process also arises. In this context, there 
      is the ethical question of how to manage the demands produced by the pandemic.
      The objective of this work is to reflect, from the point of view of medical
      ethics, on the basic principles of the choices made by the health teams, during
      the COVID-19 pandemic, whose resources are scarce and decisions cause anguish and
      restlessness. The ethical values for the rationing of health resources in an
      epidemic must converge to some proposals based on fundamental values such as
      maximizing the benefits produced by scarce resources, treating people equally,
      promoting and recommending instrumental values, giving priority to critical
      situations. Naturally, different judgments will occur in different circumstances,
      but transparency is essential to ensure public trust. In this way, it is possible
      to develop prioritization guidelines using well-defined values and ethical
      recommendations to achieve fair resource allocation.
FAU - Neves, Nedy M B C
AU  - Neves NMBC
AUID- ORCID: http://orcid.org/0000-0002-6383-3320
AD  - . Universidade Salvador (Unifacs), Salvador, BA, Brasil.
FAU - Bitencourt, Flavia B C S N
AU  - Bitencourt FBCSN
AUID- ORCID: http://orcid.org/0000-0002-1361-6993
AD  - . Fleury Medicina e Saude, Sao Paulo, SP, Brasil.
FAU - Bitencourt, Almir G V
AU  - Bitencourt AGV
AUID- ORCID: http://orcid.org/0000-0003-0192-9885
AD  - . A.C.Camargo Cancer Center, Sao Paulo, SP, Brasil.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
MH  - Artificial Intelligence
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/*epidemiology/therapy
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/therapy
MH  - SARS-CoV-2
MH  - Triage/*ethics
MH  - Ventilators, Mechanical/supply & distribution
EDAT- 2020/09/24 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/23 12:12
PHST- 2020/06/10 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - S0104-42302020001400106 [pii]
AID - 10.1590/1806-9282.66.S2.106 [doi]
PST - epublish
SO  - Rev Assoc Med Bras (1992). 2020 Sep 21;66Suppl 2(Suppl 2):106-111. doi:
      10.1590/1806-9282.66.S2.106. eCollection 2020.


PMID- 32965237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 23
TI  - Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute 
      Coronary Syndrome: Protocol for a Randomized Pilot Trial.
PG  - e19456
LID - 10.2196/19456 [doi]
AB  - BACKGROUND: Inflammation plays a key role in the pathophysiology of coronary
      heart disease (CHD) and its acute manifestation, acute coronary syndrome (ACS).
      Aging is associated with a decline of the immune system, a process known as
      immunosenescence. This is characterized by an increase in highly proinflammatory 
      T cells that are involved in CHD progression, plaque destabilization, and
      myocardial ischemia-reperfusion injury. Telomere dysfunction has been implicated 
      in immunosenescence of T lymphocytes. Telomerase is the enzyme responsible for
      maintaining telomeres during cell divisions. It has a protective effect on cells 
      under oxidative stress and helps regulate flow-mediated dilation in
      microvasculature. OBJECTIVE: The TACTIC (Telomerase ACTivator to reverse
      Immunosenescence in Acute Coronary Syndrome) trial will investigate whether a
      telomerase activator, TA-65MD, can reduce the proportion of senescent T cells in 
      patients with ACS with confirmed CHD. It will also assess the effect of TA-65MD
      on decreasing telomere shortening, reducing oxidative stress, and improving
      endothelial function. METHODS: The study was designed as a single-center,
      randomized, double-blind, parallel-group, placebo-controlled phase II trial.
      Recruitment started in January 2019. A total of 90 patients, aged 65 years or
      older, with treated ACS who have had CHD confirmed by angiography will be
      enrolled. They will be randomized to one of two groups: TA-65MD oral therapy (8
      mg twice daily) or placebo taken for 12 months. The primary outcome is the effect
      on immunosenescence determined by a decrease in the proportion of CD8+ TEMRA (T
      effector memory cells re-expressing CD45RA [CD45 expressing exon A]) cells at 12 
      months. Secondary outcomes include leukocyte telomere length, endothelial
      function, cardiac function as measured by echocardiography and NT-proBNP
      (N-terminal fragment of the prohormone brain-type natriuretic peptide), systemic 
      inflammation, oxidative stress, and telomerase activity. RESULTS: The study
      received National Health Service (NHS) ethics approval on August 9, 2018;
      Medicines and Healthcare products Regulatory Agency approval on October 19, 2018;
      and NHS Health Research Authority approval on October 22, 2018. The trial began
      recruiting participants in January 2019 and completed recruitment in March 2020; 
      the trial is due to report results in 2021. CONCLUSIONS: This pilot trial in
      older patients with CHD will explore outcomes not previously investigated outside
      in vitro or preclinical models. The robust design ensures that bias has been
      minimized. Should the results indicate reduced frequency of immunosenescent CD8+ 
      T cells as well as improvements in telomere length and endothelial function, we
      will plan a larger, multicenter trial in patients to determine if TA-65MD is
      beneficial in the treatment of CHD in elderly patients. TRIAL REGISTRATION:
      ISRCTN Registry ISRCTN16613292; http://www.isrctn.com/ISRCTN16613292 and European
      Union Drug Regulating Authorities Clinical Trials Database (EudraCT), European
      Union Clinical Trials Register 2017-002876-26; https://tinyurl.com/y4m2so8g.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/19456.
CI  - (c)Rebecca Maier, Bilal Bawamia, Karim Bennaceur, Sarah Dunn, Leanne Marsay,
      Roland Amoah, Adetayo Kasim, Andrew Filby, David Austin, Helen Hancock, Ioakim
      Spyridopoulos. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 23.09.2020.
FAU - Maier, Rebecca
AU  - Maier R
AUID- ORCID: https://orcid.org/0000-0002-7350-3288
AD  - Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, United
      Kingdom.
FAU - Bawamia, Bilal
AU  - Bawamia B
AUID- ORCID: https://orcid.org/0000-0003-4460-7544
AD  - James Cook University Hospital, Middlesbrough, United Kingdom.
FAU - Bennaceur, Karim
AU  - Bennaceur K
AUID- ORCID: https://orcid.org/0000-0003-1328-5706
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United 
      Kingdom.
FAU - Dunn, Sarah
AU  - Dunn S
AUID- ORCID: https://orcid.org/0000-0002-1901-3931
AD  - Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, United
      Kingdom.
FAU - Marsay, Leanne
AU  - Marsay L
AUID- ORCID: https://orcid.org/0000-0002-0690-5658
AD  - Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, United
      Kingdom.
FAU - Amoah, Roland
AU  - Amoah R
AUID- ORCID: https://orcid.org/0000-0002-5501-4675
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United 
      Kingdom.
FAU - Kasim, Adetayo
AU  - Kasim A
AUID- ORCID: https://orcid.org/0000-0002-0411-3059
AD  - Wolfson Research Institute for Health and Wellbeing, Durham University, Durham,
      United Kingdom.
FAU - Filby, Andrew
AU  - Filby A
AUID- ORCID: https://orcid.org/0000-0001-9078-4360
AD  - Flow Cytometry Core Facility, Newcastle University, Newcastle Upon Tyne, United
      Kingdom.
FAU - Austin, David
AU  - Austin D
AUID- ORCID: https://orcid.org/0000-0003-4606-1055
AD  - James Cook University Hospital, Middlesbrough, United Kingdom.
FAU - Hancock, Helen
AU  - Hancock H
AUID- ORCID: https://orcid.org/0000-0002-1494-8551
AD  - Newcastle Clinical Trials Unit, Newcastle University, Newcastle Upon Tyne, United
      Kingdom.
FAU - Spyridopoulos, Ioakim
AU  - Spyridopoulos I
AUID- ORCID: https://orcid.org/0000-0002-2750-2444
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United 
      Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7542409
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - coronary heart disease
OT  - immunosenescence
OT  - telomerase activator
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 12:12
PHST- 2020/04/18 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - v9i9e19456 [pii]
AID - 10.2196/19456 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Sep 23;9(9):e19456. doi: 10.2196/19456.


PMID- 32965234
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20220322
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep 23
TI  - Leveraging Interdisciplinary Teams to Develop and Implement Secure Websites for
      Behavioral Research: Applied Tutorial.
PG  - e19217
LID - 10.2196/19217 [doi]
AB  - Behavioral researchers are increasingly using interactive digital platforms,
      either as standalone or supplementary intervention tools, to facilitate positive 
      changes in research participants' health habits. Research-oriented interactive
      websites optimally offer a variety of participatory mediums, such as blogs,
      user-driven content, or health activities. Owing to the multidirectional features
      of interactive websites, and a corresponding need to protect research
      participants' identity and data, it is paramount that researchers design ethical 
      platforms that ensure privacy and minimize loss of anonymity and confidentiality.
      Authentication (ie, digital verification of one's identity) of interactive sites 
      is one viable solution to these concerns. Although previous publications have
      addressed ethical requirements related to authenticated platforms, few applied
      guidelines in the literature facilitate adherence to ethical principles and
      legally compliant study protocols during all phases of research website creation 
      (feasibility, design, implementation, and maintenance). Notably, to remain
      compliant with ethical standards and study protocols, behavioral researchers must
      collaborate with interdisciplinary teams to ensure that the authenticated site
      remains secure and usable in all stages of the project. In this tutorial, we
      present a case study conducted at a large research university. Through iterative 
      and practical recommendations, we detail lessons learned from collaborations with
      the Institutional Review Board, legal experts, and information technology teams. 
      Although the intricacies of our applied tutorial may require adaptations based on
      each institution's technological capacity, we are confident that the core
      takeaways are universal and thus useful to behavioral researchers creating
      ethically responsible and compliant interactive websites.
CI  - (c)Christie L Martin, Eydie N Kramer-Kostecka, Jennifer A Linde, Sarah Friend,
      Vanessa R Zuroski, Jayne A Fulkerson. Originally published in the Journal of
      Medical Internet Research (http://www.jmir.org), 23.09.2020.
FAU - Martin, Christie L
AU  - Martin CL
AUID- ORCID: 0000-0003-1685-0205
AD  - School of Nursing, University of Minnesota, Minneapolis, MN, United States.
FAU - Kramer-Kostecka, Eydie N
AU  - Kramer-Kostecka EN
AUID- ORCID: 0000-0003-4107-6119
AD  - School of Kinesiology, University of Minnesota, Minneapolis, MN, United States.
FAU - Linde, Jennifer A
AU  - Linde JA
AUID- ORCID: 0000-0002-9033-2097
AD  - School of Public Health, University of Minnesota, Minneapolis, MN, United States.
FAU - Friend, Sarah
AU  - Friend S
AUID- ORCID: 0000-0003-3529-8401
AD  - School of Nursing, University of Minnesota, Minneapolis, MN, United States.
FAU - Zuroski, Vanessa R
AU  - Zuroski VR
AUID- ORCID: 0000-0001-8837-5488
AD  - Office of Information Technology, University of Minnesota, Minneapolis, MN,
      United States.
FAU - Fulkerson, Jayne A
AU  - Fulkerson JA
AUID- ORCID: 0000-0002-2110-498X
AD  - School of Nursing, University of Minnesota, Minneapolis, MN, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT02973815
GR  - R01 HL123699/HL/NHLBI NIH HHS/United States
GR  - T32 HL150452/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200923
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Behavioral Research/*methods
MH  - Ethics Committees, Research/*organization & administration
MH  - Humans
MH  - Internet
PMC - PMC7542408
OTO - NOTNLM
OT  - *behavioral research
OT  - *digital interventions
OT  - *research ethics and compliance
OT  - *website authentication
OT  - *website development
OT  - *website security
EDAT- 2020/09/24 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/09/23 12:12
PHST- 2020/04/08 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
AID - v22i9e19217 [pii]
AID - 10.2196/19217 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Sep 23;22(9):e19217. doi: 10.2196/19217.


PMID- 32965226
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 23
TI  - Game-Based Meditation Therapy to Improve Posttraumatic Stress and Neurobiological
      Stress Systems in Traumatized Adolescents: Protocol for a Randomized Controlled
      Trial.
PG  - e19881
LID - 10.2196/19881 [doi]
AB  - BACKGROUND: Many adolescents in residential care have been exposed to prolonged
      traumatic experiences such as violence, neglect, or abuse. Consequently, they
      suffer from posttraumatic stress. This not only negatively affects psychological 
      and behavioral outcomes (eg, increased anxiety, depression, and aggression) but
      also has adverse effects on physiological outcomes, in particular on their
      neurobiological stress systems. Although current evidence-based treatment options
      are effective, they have their limitations. An alternative to traditional trauma 
      treatment is meditation-based treatment that focuses on stress regulation and
      relaxation. Muse is a game-based meditation intervention that makes use of
      adolescents' intrinsic motivation. The neurofeedback element reinforces
      relaxation abilities. OBJECTIVE: This paper describes the protocol for a
      randomized controlled trial in which the goal is to examine the effectiveness of 
      Muse (InteraXon Inc) in reducing posttraumatic stress and normalizing
      neurobiological stress systems in a sample of traumatized adolescents in
      residential care. METHODS: This will be a multicenter, multi-informant, and
      multimethod randomized controlled trial. Participants will be adolescents (N=80),
      aged 10 to 18 years, with clinical levels of posttraumatic symptoms, who are
      randomized to receive either the Muse therapy sessions and treatment as usual
      (intervention) or treatment as usual alone (control). Data will be collected at 3
      measurement instances: pretest (T1), posttest (T2), and at 2-month follow-up.
      Primary outcomes will be posttraumatic symptoms (self-report and mentor report)
      and stress (self-report) at posttest. Secondary outcomes will be neurobiological 
      stress parameters under both resting and acute stress conditions, and anxiety,
      depression, and aggression at posttest. Secondary outcomes also include all
      measures at 2-month follow-up: posttraumatic symptoms, stress, anxiety,
      depression aggression, and neurobiological resting parameters. RESULTS: The
      medical-ethical committee Arnhem-Nijmegen (NL58674.091.16) approved the trial on 
      November 15, 2017. The study was registered on December 2, 2017. Participant
      enrollment started in January 2018, and the results of the study are expected to 
      be published in spring or summer 2021. CONCLUSIONS: Study results will
      demonstrate whether game-based meditation therapy improves posttraumatic stress
      and neurobiological stress systems, and whether it is more effective than
      treatment as usual alone for traumatized adolescents. TRIAL REGISTRATION:
      Netherlands Trial Register NL6689 (NTR6859);
      https://www.trialregister.nl/trial/6689. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): DERR1-10.2196/19881.
CI  - (c)Angela A T Schuurmans, Karin S Nijhof, Ron Scholte, Arne Popma, Roy Otten.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 23.09.2020.
FAU - Schuurmans, Angela A T
AU  - Schuurmans AAT
AUID- ORCID: https://orcid.org/0000-0002-9810-0442
AD  - Behavioural Science Institute, Radboud University, Nijmegen, Netherlands.
AD  - Department of Research and Development, Pluryn, Nijmegen, Netherlands.
FAU - Nijhof, Karin S
AU  - Nijhof KS
AUID- ORCID: https://orcid.org/0000-0002-9010-3112
AD  - Behavioural Science Institute, Radboud University, Nijmegen, Netherlands.
AD  - Department of Research and Development, Pluryn, Nijmegen, Netherlands.
FAU - Scholte, Ron
AU  - Scholte R
AUID- ORCID: https://orcid.org/0000-0001-8258-4190
AD  - Behavioural Science Institute, Radboud University, Nijmegen, Netherlands.
AD  - Praktikon, Nijmegen, Netherlands.
AD  - Tranzo, Tilburg University, Tilburg, Netherlands.
FAU - Popma, Arne
AU  - Popma A
AUID- ORCID: https://orcid.org/0000-0003-2170-3023
AD  - Department of Child and Adolescent Psychiatry, Vrije Universiteit medisch centrum
      De Bascule, Amsterdam, Netherlands.
FAU - Otten, Roy
AU  - Otten R
AUID- ORCID: https://orcid.org/0000-0002-9763-5875
AD  - Behavioural Science Institute, Radboud University, Nijmegen, Netherlands.
AD  - Department of Research and Development, Pluryn, Nijmegen, Netherlands.
AD  - Research and Education Advancing Children's Health Institute, Department of
      Psychology, Arizona State University, Tempe, AZ, United States.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7542410
OTO - NOTNLM
OT  - Adolescents
OT  - Autonomic nervous system
OT  - Cortisol
OT  - Meditation
OT  - Neurofeedback
OT  - Posttraumatic stress
OT  - Randomized controlled trial
OT  - Trauma
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 12:12
PHST- 2020/05/05 00:00 [received]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/07/16 00:00 [revised]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - v9i9e19881 [pii]
AID - 10.2196/19881 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Sep 23;9(9):e19881. doi: 10.2196/19881.


PMID- 32965225
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 2291-9694 (Print)
VI  - 8
IP  - 9
DP  - 2020 Sep 23
TI  - Breast Self-Examination System Using Multifaceted Trustworthiness: Observational 
      Study.
PG  - e21584
LID - 10.2196/21584 [doi]
AB  - BACKGROUND: Breast cancer is the leading cause of mortality among women
      worldwide. However, female patients often feel reluctant and embarrassed about
      meeting physicians in person to discuss their intimate body parts, and prefer to 
      use social media for such interactions. Indeed, the number of patients and
      physicians interacting and seeking information related to breast cancer on social
      media has been growing. However, a physician may behave inappropriately on social
      media by sharing a patient's personal medical data excessively with colleagues or
      the public. Such an act would reduce the physician's trustworthiness from the
      patient's perspective. The multifaceted trust model is currently most commonly
      used for investigating social media interactions, which facilitates its enhanced 
      adoption in the context of breast self-examination. The characteristics of the
      multifaceted trust model go beyond being personalized, context-dependent, and
      transitive. This model is more user-centric, which allows any user to evaluate
      the interaction process. Thus, in this study, we explored and evaluated use of
      the multifaceted trust model for breast self-examination as a more suitable trust
      model for patient-physician social media interactions in breast cancer screening.
      OBJECTIVE: The objectives of this study were: (1) to identify the trustworthiness
      indicators that are suitable for a breast self-examination system, (2) design and
      propose a breast self-examination system, and (3) evaluate the multifaceted
      trustworthiness interaction between patients and physicians. METHODS: We used a
      qualitative study design based on open-ended interviews with 32 participants (16 
      outpatients and 16 physicians). The interview started with an introduction to the
      research objective and an explanation of the steps on how to use the proposed
      breast self-examination system. The breast self-examination system was then
      evaluated by asking the patient to rate their trustworthiness with the physician 
      after the consultation. The evaluation was also based on monitoring the activity 
      in the chat room (interactions between physicians and patients) during daily
      meetings, weekly meetings, and the articles posted by the physician in the forum.
      RESULTS: Based on the interview sessions with 16 physicians and 16 patients on
      using the breast self-examination system, honesty had a strong positive
      correlation (r=0.91) with trustworthiness, followed by credibility (r=0.85),
      confidence (r=0.79), and faith (r=0.79). In addition, belief (r=0.75), competency
      (r=0.73), and reliability (r=0.73) were strongly correlated with trustworthiness,
      with the lowest correlation found for reputation (r=0.72). The correlation among 
      trustworthiness indicators was significant (P<.001). Moreover, the trust level of
      a patient for a particular physician was found to increase after several
      interactions. CONCLUSIONS: Multifaceted trustworthiness has a significant impact 
      on a breast self-examination system. Evaluation of trustworthiness indicators
      helps to ensure a trustworthy system and ethical interaction between a patient
      and physician. A new patient can obtain a consultation by referring to the best
      physician according to preference of other patients. Patients can also trust a
      physician based on another patient's recommendation regarding the physician's
      trust level. The correlation analysis further showed that the most preferred
      trustworthiness indicator is honesty.
CI  - (c)Rajes Khana, Manmeet Mahinderjit Singh, Faten Damanhoori, Norlia Mustaffa.
      Originally published in JMIR Medical Informatics (http://medinform.jmir.org),
      23.09.2020.
FAU - Khana, Rajes
AU  - Khana R
AUID- ORCID: https://orcid.org/0000-0001-6062-6492
AD  - Universiti Sains Malaysia, Penang, Malaysia.
FAU - Mahinderjit Singh, Manmeet
AU  - Mahinderjit Singh M
AUID- ORCID: https://orcid.org/0000-0001-8081-5223
AD  - Universiti Sains Malaysia, Penang, Malaysia.
FAU - Damanhoori, Faten
AU  - Damanhoori F
AUID- ORCID: https://orcid.org/0000-0001-7063-842X
AD  - Universiti Sains Malaysia, Penang, Malaysia.
FAU - Mustaffa, Norlia
AU  - Mustaffa N
AUID- ORCID: https://orcid.org/0000-0003-2290-1478
AD  - Universiti Sains Malaysia, Penang, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200923
PL  - Canada
TA  - JMIR Med Inform
JT  - JMIR medical informatics
JID - 101645109
PMC - PMC7542407
OTO - NOTNLM
OT  - breast cancer
OT  - breast self-examination
OT  - health care system
OT  - multifaceted trust
OT  - social media
OT  - trust
OT  - trustworthiness
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 12:12
PHST- 2020/06/19 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/09/23 12:12 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - v8i9e21584 [pii]
AID - 10.2196/21584 [doi]
PST - epublish
SO  - JMIR Med Inform. 2020 Sep 23;8(9):e21584. doi: 10.2196/21584.


PMID- 32965223
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 23
TI  - The Impact of Previsit Contextual Data Collection on Patient-Provider
      Communication and Patient Activation: Study Protocol for a Randomized Controlled 
      Trial.
PG  - e20309
LID - 10.2196/20309 [doi]
AB  - BACKGROUND: Patient-centered care is respectful of and responsive to individual
      patient preferences, needs, and values. To provide patient-centered care,
      clinicians need to know and incorporate patients' context into their
      communication and care with patients. Patient contextual data (PCD) encompass
      social determinants of health and patients' needs, values, goals, and preferences
      relevant to their care. PCD can be challenging to collect as a routine component 
      of the time-limited primary care visit. OBJECTIVE: This study aims to determine
      if patient-provider communication and patient activation are different for
      patient users and patient nonusers of an electronic health record
      (EHR)-integrated PCD tool and assess if the impact of using PCD on
      patient-provider communication and patient activation differs for Black and White
      patients. METHODS: We describe a randomized controlled trial of a prospective
      cohort of non-Hispanic White and Black patients who receive primary care services
      at a midwestern academic health care system in the United States. We will
      evaluate whether providing PCD through a consumer informatics tool enhances
      patient-provider communication, as measured by the Communication Assessment Tool,
      and we will evaluate patient activation, as measured by the Patient Activation
      Measure for PCD tool users and nonusers. Furthermore, owing to racial disparities
      in care and communication, we seek to determine if the adoption and use of the
      tool might narrow the differences between patient groups. RESULTS: The trial was 
      funded in November 2017 and received local ethics review approval in February
      2019. The study began recruitment in April 2019 and enrollment concluded in
      October 2019 with 301 participants. The analysis was completed in May 2020, and
      trial results are expected to be published in winter 2020. CONCLUSIONS: Recently,
      there has been increased attention to the role of health information technology
      tools to enable patients to collaborate with providers through the sharing of
      PCD. The adoption of such tools may overcome the barriers of current EHRs by
      directly engaging patients to submit their contextual data. Effectively, these
      tools would support the EHR in providing a more holistic understanding of the
      patient. Research further supports that individuals who have robust digital
      engagement using consumer informatics tools have higher participation in
      treatment follow-up and self-care across populations. Therefore, it is critical
      to investigate interventions that elicit and share patients' social risks and
      care preferences with the health care team as a mechanism to improve
      individualized care and reduce the gap in health outcomes. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT03766841; https://clinicaltrials.gov/ct2/show/NCT03766841. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/20309.
CI  - (c)Jeana M Holt, Rachel Cusatis, Aaron Winn, Onur Asan, Charles Spanbauer, Joni S
      Williams, Kathryn E Flynn, Melek Somai, Purushottam Laud, Bradley H Crotty.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 23.09.2020.
FAU - Holt, Jeana M
AU  - Holt JM
AUID- ORCID: https://orcid.org/0000-0003-3392-0164
AD  - College of Nursing, University of Wisconsin-Milwaukee, Milwaukee, WI, United
      States.
AD  - Department of Family & Community Medicine, Medical College of Wisconsin,
      Milwaukee, WI, United States.
FAU - Cusatis, Rachel
AU  - Cusatis R
AUID- ORCID: https://orcid.org/0000-0001-6252-6516
AD  - Hematology and Oncology Department of Medicine, Medical College of Wisconsin,
      Milwaukee, WI, United States.
FAU - Winn, Aaron
AU  - Winn A
AUID- ORCID: https://orcid.org/0000-0003-2906-3913
AD  - School of Pharmacy, Medical College of Wisconsin, Milwaukee, WI, United States.
FAU - Asan, Onur
AU  - Asan O
AUID- ORCID: https://orcid.org/0000-0002-9239-3723
AD  - School of Systems and Enterprises, Stevens Institute of Technology, Hoboken, NJ, 
      United States.
FAU - Spanbauer, Charles
AU  - Spanbauer C
AUID- ORCID: https://orcid.org/0000-0001-5567-0026
AD  - Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI,
      United States.
FAU - Williams, Joni S
AU  - Williams JS
AUID- ORCID: https://orcid.org/0000-0001-8988-3556
AD  - Department of Medicine, Medical College of Wisconsin, Center for Advancing
      Population Science, Milwaukee, WI, United States.
FAU - Flynn, Kathryn E
AU  - Flynn KE
AUID- ORCID: https://orcid.org/0000-0002-4427-3583
AD  - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United
      States.
FAU - Somai, Melek
AU  - Somai M
AUID- ORCID: https://orcid.org/0000-0002-2692-9681
AD  - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United
      States.
FAU - Laud, Purushottam
AU  - Laud P
AUID- ORCID: https://orcid.org/0000-0002-0433-4193
AD  - Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI,
      United States.
FAU - Crotty, Bradley H
AU  - Crotty BH
AUID- ORCID: https://orcid.org/0000-0001-6271-4816
AD  - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United
      States.
LA  - eng
SI  - ClinicalTrials.gov/NCT03766841
PT  - Journal Article
DEP - 20200923
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7542405
OTO - NOTNLM
OT  - consumer health informatics
OT  - mobile phone
OT  - patient participation
OT  - patient-centered care
OT  - physician-patient relations
OT  - randomized controlled trial
OT  - vulnerable populations
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 12:11
PHST- 2020/05/15 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/09/23 12:11 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - v9i9e20309 [pii]
AID - 10.2196/20309 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Sep 23;9(9):e20309. doi: 10.2196/20309.


PMID- 32965057
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 56
IP  - 12
DP  - 2020 Dec
TI  - Protocol for a single patient therapy plan: A randomised, double-blind,
      placebo-controlled N-of-1 trial to assess the efficacy of cannabidiol in patients
      with intractable epilepsy.
PG  - 1918-1923
LID - 10.1111/jpc.15078 [doi]
AB  - AIM: This paper describes the use of the single patient therapy plan (SPTP). The 
      SPTP has been designed to assess the efficacy at an individual level of a
      commercially available cannabinoid product, cannabidiol, in reducing seizure
      frequency in paediatric patients with intractable epilepsy. METHODS: The SPTP is 
      a randomised, double-blind, placebo-controlled N-of-1 trial designed to assess
      the efficacy of treatment in a neurology outpatient setting. The primary
      objective of the SPTP is to assess the efficacy of cannabidiol in reducing
      seizure frequency in each patient with intractable epilepsy, with change in
      seizure frequency being the primary outcome of interest. The analysis adopts a
      Bayesian approach, which provides results in the form of posterior probabilities 
      that various levels of benefit (based on the primary outcome measure, seizure
      frequency) have been achieved under active treatment compared to placebo,
      accompanied by decision rules that provide thresholds for deciding whether
      treatment has been successful in the individual patient. The SPTP arrangement is 
      most accurately considered part of clinical practice rather than research, since 
      it is aimed at making clinical treatment decisions for individual patients and is
      not testing a hypothesis or collecting aggregate data. Therefore, Human Research 
      Ethics Committee approval was considered not to be required, although it is
      recommended that hospital Clinical Ethics Committees provide ethical oversight.
      CONCLUSION: These SPTP resources are made available so that they may inform
      clinical practice in the treatment of severe epilepsy or adapted for use in other
      conditions.
CI  - (c) 2020, Commonwealth of Australia. Journal of Paediatrics and Child Health (c) 
      2020 Paediatrics and Child Health Division (The Royal Australasian College of
      Physicians).
FAU - Ong, Katherine S
AU  - Ong KS
AUID- ORCID: https://orcid.org/0000-0002-0323-0982
AD  - Victoria Department of Health and Human Services, Melbourne, Victoria, Australia.
FAU - Carlin, John B
AU  - Carlin JB
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
AD  - The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Fahey, Michael
AU  - Fahey M
AD  - Monash Children's Hospital, Melbourne, Victoria, Australia.
FAU - Freeman, Jeremy L
AU  - Freeman JL
AD  - Royal Children's Hospital, Melbourne, Victoria, Australia.
FAU - Scheffer, Ingrid E
AU  - Scheffer IE
AD  - The University of Melbourne, Melbourne, Victoria, Australia.
AD  - Austin Hospital, Melbourne, Victoria, Australia.
FAU - Gillam, Lynn
AU  - Gillam L
AD  - The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Anderson, Monique
AU  - Anderson M
AD  - Neuroscience Trials Australia, Melbourne, Victoria, Australia.
FAU - Huque, Md Hamidul
AU  - Huque MH
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
AD  - The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Legge, Donna
AU  - Legge D
AD  - Royal Children's Hospital, Melbourne, Victoria, Australia.
FAU - Dirnbauer, Nicole
AU  - Dirnbauer N
AD  - Monash Children's Hospital, Melbourne, Victoria, Australia.
FAU - Lilley, Brian
AU  - Lilley B
AD  - Royal Children's Hospital, Melbourne, Victoria, Australia.
FAU - Slota-Kan, Simon
AU  - Slota-Kan S
AD  - Victoria Department of Health and Human Services, Melbourne, Victoria, Australia.
FAU - Cranswick, Noel
AU  - Cranswick N
AD  - Royal Children's Hospital, Melbourne, Victoria, Australia.
LA  - eng
GR  - Department of Health and Human Services Victoria, Australia
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200923
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
RN  - 0 (Anticonvulsants)
RN  - 19GBJ60SN5 (Cannabidiol)
SB  - IM
MH  - Anticonvulsants/therapeutic use
MH  - Bayes Theorem
MH  - *Cannabidiol/therapeutic use
MH  - Child
MH  - Double-Blind Method
MH  - *Drug Resistant Epilepsy/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7820972
OTO - NOTNLM
OT  - anticonvulsant/therapeutic use
OT  - cannabidiol
OT  - child
OT  - drug resistant epilepsy
OT  - outcome assessment (health care)
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 09:03
PHST- 2019/11/24 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/23 09:03 [entrez]
AID - 10.1111/jpc.15078 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2020 Dec;56(12):1918-1923. doi: 10.1111/jpc.15078. Epub 
      2020 Sep 23.


PMID- 32964534
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Japan Geriatrics Society "Recommendations for the Promotion of Advance Care
      Planning": End-of-Life Issues Subcommittee consensus statement.
PG  - 1024-1028
LID - 10.1111/ggi.14042 [doi]
AB  - The Japan Geriatrics Society has so far announced "The Japan Geriatrics Society
      Position Statement 2012" and "Guidelines for the Decision-Making Processes in
      Medical and Long-Term Care for the Elderly - Focusing on the Use of Artificial
      Hydration and Nutrition" related to end-of-life care for older adults. In 2018,
      the Ministry of Health, Labor and Welfare revised the "Guidelines for the
      Decision-Making Processes in Medical and Long-Term Care in the End of Life,"
      recommending the practice of advance care planning (ACP). This was the first time
      when the Japanese government publicized its stance on ACP. Immediately after the 
      government's announcement, the Japan Medical Association announced its committee 
      report, "The Super-aged Society and the End-of-life Care," which also recommended
      the practice of ACP. The guidelines were published when the society was
      experiencing substantial changes related to geriatric care in Japan, and required
      timely and ethically appropriate decision-making processes. However, because ACP 
      is a concept imported from English-speaking countries, some Japanese people could
      find it difficult to understand the role and methodology of ACP because of
      differences in culture and the medical/long-term care system. Therefore, the
      Japan Geriatrics Society has decided to publish the "Recommendations for the
      Promotion of Advance Care Planning" for medical and long-term care professionals 
      nationwide with the aim of using the recommendations on a daily basis. The
      society recognizes ACP as indispensable to improve end-of-life care for
      individuals, particularly for older adults. We anticipate that the
      recommendations will provide practical guidance for those strenuously working
      toward this goal. Geriatr Gerontol Int 2020; 20: 1024-1028..
CI  - (c) 2020 Japan Geriatrics Society.
CN  - Japan Geriatrics Society Subcommittee on End-of-Life Issues
FAU - Kuzuya, Masafumi
AU  - Kuzuya M
AUID- ORCID: https://orcid.org/0000-0002-6134-9578
AD  - Department of Community Healthcare & Geriatrics, Nagoya University Graduate
      School of Medicine, Nagoya, Japan.
AD  - Institutes of Innovation for Future Society, Nagoya University, Nagoya, Japan.
FAU - Aita, Kaoruko
AU  - Aita K
AD  - Uehiro Division, Center for Death & Life Studies and Practical Ethics, Graduate
      School of Humanities and Sociology, The University of Tokyo, Tokyo, Japan.
FAU - Katayama, Yoko
AU  - Katayama Y
AD  - Department of Nursing, Kagawa Prefectural University of Health Sciences,
      Takamatsu, Japan.
FAU - Katsuya, Tomohiro
AU  - Katsuya T
AD  - Katsuya Clinic, Amagasaki, Japan.
AD  - Department of Clinical Gene Therapy, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Nishikawa, Mitsunori
AU  - Nishikawa M
AD  - Department of Palliative Care, National Center for Geriatrics and Gerontology,
      Obu, Japan.
FAU - Hirahara, Satoshi
AU  - Hirahara S
AD  - Training/Research Center, Tokyo Fureai Medical & Cooperative Society, Tokyo,
      Japan.
FAU - Miura, Hisayuki
AU  - Miura H
AUID- ORCID: https://orcid.org/0000-0002-4780-9857
AD  - Department of Home Care and Regional Liaison Promotion, National Center for
      Geriatrics and Gerontology, Obu, Japan.
FAU - Rakugi, Hiromi
AU  - Rakugi H
AUID- ORCID: https://orcid.org/0000-0001-6508-4338
AD  - Department of Geriatric and General Medicine, Osaka University Graduate School of
      Medicine, Suita, Japan.
FAU - Akishita, Masahiro
AU  - Akishita M
AD  - Department of Geriatric Medicine, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
DEP - 20200923
PL  - Japan
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
SB  - IM
MH  - *Advance Care Planning
MH  - Decision Making
MH  - Geriatrics/standards
MH  - Humans
MH  - Japan
MH  - Long-Term Care
MH  - Societies, Medical
MH  - Terminal Care
OTO - NOTNLM
OT  - advance care planning
OT  - dialogues
OT  - end-of-life care
OT  - life goals
OT  - shared decision-making
EDAT- 2020/09/24 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/23 06:41
PHST- 2020/07/27 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/09/23 06:41 [entrez]
AID - 10.1111/ggi.14042 [doi]
PST - ppublish
SO  - Geriatr Gerontol Int. 2020 Nov;20(11):1024-1028. doi: 10.1111/ggi.14042. Epub
      2020 Sep 23.


PMID- 32964490
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Gestation as mothering.
PG  - 960-968
LID - 10.1111/bioe.12808 [doi]
AB  - Some commentators maintain that gestational surrogates are not 'mothers' in a way
      capable of grounding a claim to motherhood. These commentators find that the
      practices that constitute motherhood do not extend to gestational surrogates. We 
      argue that gestational surrogates should be construed as mothers of the children 
      they bear, even if they fully intend to surrender those children at birth to the 
      care of others. These women stand in a certain relationship to the expected
      children: they live in changed moral circumstances by reason of their pregnancy, 
      and they engage in the practices said to define motherhood in the post-birth
      context. By contrast, ovum donors and embryo donors are not similarly 'mothers'
      because they do not find themselves involved in these circumstances. Not all
      women involved in three-parent in vitro fertilization qualify as mothers either. 
      Given this analysis of mothering, we note that transmen who gestate children are 
      engaged in mothering activity even if they otherwise function as a father to
      those children. By itself, this defence of the maternity of gestational
      surrogates does not confer moral title to the children they bear; gestation would
      not by itself override the contractual arrangements gestational surrogates have
      made regarding the disposition of their children. This interpretation of
      gestational surrogates as mothers does, however, undercut cultural understandings
      of these women as mere 'vessels', devoid of entitlement to respect as persons and
      parents. We also consider the meaning of mothering for 'brain-dead' women kept
      alive to give birth and for the prospect of extracorporeal gestation.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Murphy, Timothy F
AU  - Murphy TF
AUID- ORCID: 0000-0001-8003-550X
AD  - University of Illinois, College of Medicine, Chicago, Illinois.
FAU - Parks, Jennifer A
AU  - Parks JA
AUID- ORCID: 0000-0002-3673-8264
AD  - Department of Philosophy, Loyola University, Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Child
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - Infant, Newborn
MH  - *Mothers
MH  - Pregnancy
MH  - *Surrogate Mothers
OTO - NOTNLM
OT  - *ethics
OT  - *gestation
OT  - *motherhood
OT  - *mothering
OT  - *surrogacy
EDAT- 2020/09/24 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/09/23 06:40
PHST- 2020/05/02 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/09/23 06:40 [entrez]
AID - 10.1111/bioe.12808 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):960-968. doi: 10.1111/bioe.12808. Epub 2020 Sep 22.


PMID- 32964468
OWN - NLM
STAT- Publisher
LR  - 20210929
IS  - 1471-6712 (Electronic)
IS  - 0283-9318 (Linking)
DP  - 2020 Sep 21
TI  - Feasibility and early effectiveness of the Tell-us Card communication tool to
      increase in-hospital patient participation: a cluster randomised controlled pilot
      study.
LID - 10.1111/scs.12909 [doi]
AB  - BACKGROUND: Patient participation is fundamental to nursing care and has
      beneficial effects on patient outcomes. However, it is not well embedded yet and 
      little is known on how nurses could effectively stimulate patient participation
      in hospital care. The Tell-us Card is a communication tool for inviting patients 
      to talk about their preferences and needs, and to increase patient participation 
      in daily care. OBJECTIVES: To assess feasibility and early effectiveness of the
      Tell-us Card communication tool for enhanced patient participation during
      hospitalisation. DESIGN AND METHOD: A pilot cluster randomised controlled study
      design was used including four nursing wards. Effectiveness was measured with the
      Individualized Care Scale (ICS) and the Quality from the Patients' Perspective
      (QPP) questionnaire. Linear mixed model analysis was used for analysis.
      Feasibility was assessed with an evaluative questionnaire for patients and nurses
      and by reviewing the content of Tell-us Cards using the Fundamentals of Care
      Framework (FOCF) for analysis. Ethical approval was attained. RESULTS: Data of
      265 patients showed a significant increase at one intervention ward on the ICS
      (effect size 0.61, p = 0.02) and most ICS subscales. No effect was visible on the
      QPP. The majority of patients regarded the intervention as beneficial; nurses
      however experienced barriers with incorporating the Tell-us Card into daily care.
      Analysis of the Tell-us Card content showed many elements of the FOCF being
      mentioned, with most patients indicating psychosocial needs like being involved
      and informed. CONCLUSIONS: This pilot study showed a positive early effect of the
      Tell-us Card communication tool on patient participation, although integration in
      daily nursing care appeared to be complex and an optimal fit has not yet been
      reached. Patients were positive about the intervention and wrote meaningful
      issues on the Tell-us Cards. More research is needed on how to incorporate
      patient participation effectively in complex hospital care.
CI  - (c) 2020 The Authors. Scandinavian Journal of Caring Sciences published by John
      Wiley & Sons Ltd on behalf of Nordic College of Caring Science.
FAU - van Belle, Elise
AU  - van Belle E
AUID- ORCID: https://orcid.org/0000-0001-5723-4850
AD  - Radboud Institute for Health Sciences, IQ Healthcare, Radboud University Medical 
      Center, Nijmegen, The Netherlands.
AD  - Department of Cardiology, Radboud University Medical Center, Nijmegen, The
      Netherlands.
FAU - Huisman-De Waal, Getty
AU  - Huisman-De Waal G
AD  - Radboud Institute for Health Sciences, IQ Healthcare, Radboud University Medical 
      Center, Nijmegen, The Netherlands.
FAU - Vermeulen, Hester
AU  - Vermeulen H
AUID- ORCID: https://orcid.org/0000-0002-0743-2979
AD  - Radboud Institute for Health Sciences, IQ Healthcare, Radboud University Medical 
      Center, Nijmegen, The Netherlands.
AD  - Faculty of Health and Social Studies, HAN University of Applied Sciences,
      Nijmegen, The Netherlands.
FAU - Heinen, Maud
AU  - Heinen M
AUID- ORCID: https://orcid.org/0000-0001-7536-1327
AD  - Radboud Institute for Health Sciences, IQ Healthcare, Radboud University Medical 
      Center, Nijmegen, The Netherlands.
LA  - eng
GR  - 520002003/ZonMw
PT  - Journal Article
DEP - 20200921
PL  - Sweden
TA  - Scand J Caring Sci
JT  - Scandinavian journal of caring sciences
JID - 8804206
PMC - PMC8451905
OTO - NOTNLM
OT  - communication
OT  - feasibility studies
OT  - hospitals
OT  - nurse-patient relations
OT  - nursing care
OT  - outcome assessment (health care)
OT  - patient participation
OT  - quality of health care
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/09/23 06:40
PHST- 2020/01/12 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/23 06:40 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - 10.1111/scs.12909 [doi]
PST - aheadofprint
SO  - Scand J Caring Sci. 2020 Sep 21. doi: 10.1111/scs.12909.


PMID- 32964353
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - Why We Never Eat Alone: The Overlooked Role of Microbes and Partners in Obesity
      Debates in Bioethics.
PG  - 435-448
LID - 10.1007/s11673-020-10047-2 [doi]
AB  - Debates about obesity in bioethics tend to unfold in predictable epicycles
      between individual choices and behaviours (e.g., restraint, diet, exercise) and
      the oppressive socio-economic structures constraining them (e.g., food deserts,
      advertising). Here, we argue that recent work from two cutting-edge research
      programmes in microbiology and social psychology can advance this conceptual
      stalemate in the literature. We begin in section 1 by discussing two promising
      lines of obesity research involving the human microbiome and relationship
      partners. Then, in section 2, we show how this research has made viable novel
      strategies for fighting obesity, including microbial therapies and dyad-level
      interventions. Finally, in section 3, we consider objections to our account and
      conclude by arguing that attention to the most immediate features of our
      biological and social environment offers a middle ground solution, while also
      raising important new issues for bioethicists.
FAU - Morar, Nicolae
AU  - Morar N
AD  - University of Oregon, Environmental Studies Program and Department of Philosophy,
      1295 University of Oregon, Eugene, OR, 97403, USA.
FAU - Skorburg, Joshua August
AU  - Skorburg JA
AUID- ORCID: http://orcid.org/0000-0002-3779-5076
AD  - Department of Philosophy, University of Guelph, Guelph, ON, N1G 2W1, Canada.
      g.skorburg@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *Bioethics
MH  - Ethicists
MH  - Humans
MH  - Microbiota
MH  - *Obesity
OTO - NOTNLM
OT  - Food ethics
OT  - Human microbiome
OT  - Obesity in bioethics
OT  - Relationship science
OT  - Social psychology
EDAT- 2020/09/24 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/09/23 06:38
PHST- 2019/08/02 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/09/23 06:38 [entrez]
AID - 10.1007/s11673-020-10047-2 [doi]
AID - 10.1007/s11673-020-10047-2 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Sep;17(3):435-448. doi: 10.1007/s11673-020-10047-2. Epub 2020 
      Sep 22.


PMID- 32964352
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - Balancing Patient and Societal Interests in Decisions About Potentially
      Life-Sustaining Treatment : An Australian Policy Analysis.
PG  - 407-421
LID - 10.1007/s11673-020-09994-7 [doi]
AB  - BACKGROUND: This paper investigates the content of Australian policies that
      address withholding or withdrawing life-sustaining treatment to analyse the
      guidance they provide to doctors about the allocation of resources. METHODS: All 
      publicly available non-institutional policies on withholding and withdrawing
      life-sustaining treatment were identified, including codes of conduct and
      government and professional organization guidelines. The policies that referred
      to resource allocation were isolated and analysed using qualitative thematic
      analysis. Eight Australian policies addressed both withholding and withdrawing
      life-sustaining treatment and resource allocation. RESULTS: Four resource-related
      themes were identified: (1) doctors' ethical duties to consider resource
      allocation; (2) balancing ethical obligations to patient and society; (3) fair
      process and transparent resource allocation; and (4) legal guidance on
      distributive justice as a rationale to limit life-sustaining treatment.
      CONCLUSION: Of the policies that addressed resource allocation, this review found
      broad agreement about the existence of doctors' duties to consider the
      stewardship of scarce resources in decision-making. However, there was disparity 
      in the guidance about how to reconcile competing duties to patient and society.
      There is a need to better address the difficult and confronting issue of the role
      of scarce resources in decisions about life-sustaining treatment.
FAU - Close, Eliana
AU  - Close E
AUID- ORCID: http://orcid.org/0000-0002-7359-3375
AD  - Australian Centre for Health Law Research, Faculty of Law, Queensland University 
      of Technology, 2 George St, Brisbane, Queensland, 4000, Australia.
      eliana.close@qut.edu.au.
FAU - White, Ben P
AU  - White BP
AD  - Australian Centre for Health Law Research, Faculty of Law, Queensland University 
      of Technology, 2 George St, Brisbane, Queensland, 4000, Australia.
FAU - Willmott, Lindy
AU  - Willmott L
AD  - Australian Centre for Health Law Research, Faculty of Law, Queensland University 
      of Technology, 2 George St, Brisbane, Queensland, 4000, Australia.
LA  - eng
GR  - Postgraduate Research Training Program/Department of Education, Australian
      Government (AU)
GR  - Top-Up Scholarship/Centre of Research Excellence in End of Life Care, National
      Health and Medical Research Council
PT  - Journal Article
PT  - Review
DEP - 20200922
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Australia
MH  - Decision Making
MH  - Health Policy
MH  - Humans
MH  - Moral Obligations
MH  - Policy Making
MH  - *Resource Allocation
MH  - *Withholding Treatment
OTO - NOTNLM
OT  - Clinical decision-making
OT  - End-of-life care
OT  - Healthcare rationing
OT  - Medical futility
OT  - Resource allocation
EDAT- 2020/09/24 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/09/23 06:38
PHST- 2019/11/24 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/09/23 06:38 [entrez]
AID - 10.1007/s11673-020-09994-7 [doi]
AID - 10.1007/s11673-020-09994-7 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Sep;17(3):407-421. doi: 10.1007/s11673-020-09994-7. Epub 2020 
      Sep 22.


PMID- 32963790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Management of Outpatient Hemodialysis During the COVID-19 Pandemic:
      Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response
      Team.
PG  - 2054358120938564
LID - 10.1177/2054358120938564 [doi]
AB  - PURPOSE: To collate best practice recommendations on the management of patients
      receiving in-center hemodialysis during the COVID-19 pandemic, based on published
      reports and current public health advice, while considering ethical principles
      and the unique circumstances of Canadian hemodialysis units across the country.
      SOURCES OF INFORMATION: The workgroup members used Internet search engines to
      retrieve documents from provincial and local hemodialysis programs; provincial
      public health agencies; the Centers for Disease Control and Prevention; webinars 
      and slides from other kidney agencies; and nonreviewed preprints. PubMed was used
      to search for peer-reviewed published articles. Informal input was sought from
      knowledge users during a webinar. METHODS: Challenges in the care of hemodialysis
      patients during the COVID-19 pandemic were highlighted within the Canadian Senior
      Renal Leaders Forum discussion group. The Canadian Society of Nephrology (CSN)
      developed the COVID-19 rapid response team (RRT) to address these challenges.
      They identified a pan-Canadian team of clinicians and administrators with
      expertise in hemodialysis to form the workgroup. One lead was chosen who drafted 
      the initial document. Members of the workgroup reviewed and discussed all
      recommendations in detail during 2 virtual meetings on April 7 and April 9.
      Disagreements were resolved by consensus. The document was reviewed by the CSN
      COVID-19 RRT, an ethicist, an infection control expert, a community nephrologist,
      and a patient partner. Content was presented during an interactive webinar on
      April 11, 2020 attended by 269 kidney health professionals, and the webinar and
      first draft of the document were posted online. Final revisions were made based
      on feedback received until April 13, 2020. CJKHD editors reviewed the parallel
      process peer review and edited the manuscript for clarity. KEY FINDINGS:
      Recommendations were made under the following themes: (1) Identification of
      patients with COVID-19 in the dialysis unit, (2) hemodialysis of patients with
      confirmed COVID-19, (3) hemodialysis of patients not yet known to have COVID-19, 
      (4) visitors; (5) testing for COVID-19 in the dialysis unit; (6) resuscitation,
      (6) routine hemodialysis care, (7) hemodialysis care under fixed dialysis
      resources. LIMITATIONS: Because of limitations of time and resources, and the
      large number of questions, formal systematic review was not undertaken. The
      recommendations are based on expert opinion and subject to bias. The parallel
      review process that was created may not be as robust as the standard peer review 
      process. IMPLICATIONS: We hope that these recommendations provide guidance for
      dialysis unit directors, clinicians, and administrators on how to limit risk from
      infection and adverse outcomes, while providing necessary dialysis care in a
      setting of finite resources. We also identify a number of resource allocation
      priorities, which we hope will inform decisions at provincial funding agencies.
CI  - (c) The Author(s) 2020.
FAU - Suri, Rita S
AU  - Suri RS
AUID- ORCID: https://orcid.org/0000-0002-0519-3927
AD  - Division of Nephrology, Department of Medicine/Research Institute, McGill
      University, Montreal, QC, Canada.
AD  - Centre de recherche de l'Universite de Montreal, Montreal, QC, Canada.
FAU - Antonsen, John E
AU  - Antonsen JE
AD  - Hemodialysis Committee, British Columbia Renal Agency, Vancouver, Canada.
FAU - Banks, Cheryl A
AU  - Banks CA
AD  - Prince Edward Island Provincial Renal Program, Summerside, Canada.
FAU - Clark, David A
AU  - Clark DA
AD  - Division of Nephrology, Department of Medicine, Dalhousie University & Nova
      Scotia Health Authority, Halifax, Canada.
FAU - Davison, Sara N
AU  - Davison SN
AUID- ORCID: https://orcid.org/0000-0003-4513-6449
AD  - Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, 
      Canada.
FAU - Frenette, Charles H
AU  - Frenette CH
AD  - Division of Infectious Diseases, Department of Medicine, McGill University,
      Montreal, QC, Canada.
FAU - Kappel, Joanne E
AU  - Kappel JE
AD  - Division of Nephrology, Department of Medicine, University of Saskatchewan,
      Saskatoon, Canada.
FAU - MacRae, Jennifer M
AU  - MacRae JM
AD  - Division of Nephrology, Department of Medicine, University of Calgary/Alberta
      Health Services, Canada.
FAU - Mac-Way, Fabrice
AU  - Mac-Way F
AD  - CHU de Quebec Research Center, L'Hotel-Dieu de Quebec Hospital, Division of
      Nephrology, Department of Medicine, Universite Laval, QC, Canada.
FAU - Mathew, Anna
AU  - Mathew A
AD  - Division of Nephrology, Department of Medicine, McMaster University, Hamilton,
      ON, Canada.
FAU - Moist, Louise M
AU  - Moist LM
AD  - Division of Nephrology, Department of Medicine, Western University, London, ON,
      Canada.
FAU - Qirjazi, Elena
AU  - Qirjazi E
AD  - Division of Nephrology, Department of Medicine, University of Calgary/Alberta
      Health Services, Canada.
FAU - Tennankore, Karthik K
AU  - Tennankore KK
AD  - Division of Nephrology, Department of Medicine, Dalhousie University & Nova
      Scotia Health Authority, Halifax, Canada.
FAU - Vorster, Hans
AU  - Vorster H
AD  - Ontario Renal Network, Toronto, Canada.
CN  - CSN COVID-19 Rapid Response Team
LA  - eng
PT  - Journal Article
DEP - 20200911
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7488889
OTO - NOTNLM
OT  - clinical guidelines
OT  - hemodialysis
OT  - infectious diseases
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
IR  - Antonsen J
FIR - Antonsen, John
IR  - Banks C
FIR - Banks, Cheryl
IR  - Clark D
FIR - Clark, David
IR  - Clark E
FIR - Clark, Edward
IR  - Copland M
FIR - Copland, Michael
IR  - Davison SN
FIR - Davison, Sara N
IR  - Goldberg A
FIR - Goldberg, Aviva
IR  - Hemmett J
FIR - Hemmett, Juliya
IR  - Hiremath S
FIR - Hiremath, Swapnil
IR  - Kappel J
FIR - Kappel, Joanne
IR  - MacRae JM
FIR - MacRae, Jennifer M
IR  - Mac-Way F
FIR - Mac-Way, Fabrice
IR  - Mathew A
FIR - Mathew, Anna
IR  - McCormick B
FIR - McCormick, Brendan
IR  - Moist L
FIR - Moist, Louise
IR  - Moran S
FIR - Moran, Sarah
IR  - Pandeya S
FIR - Pandeya, Sanjay
IR  - Qirjazi E
FIR - Qirjazi, Elena
IR  - Ryz K
FIR - Ryz, Krista
IR  - Singh S
FIR - Singh, Suneet
IR  - Soroka S
FIR - Soroka, Steven
IR  - Suri R
FIR - Suri, Rita
IR  - Tennankore K
FIR - Tennankore, Karthik
IR  - Thanabalasingam S
FIR - Thanabalasingam, Susan
IR  - Wald R
FIR - Wald, Ron
IR  - Weir M
FIR - Weir, Mathew
IR  - White C
FIR - White, Christine
IR  - Zimmerman D
FIR - Zimmerman, Deborah
IR  - Levin A
FIR - Levin, Adeera
IR  - Mustafa RA
FIR - Mustafa, Reem A
IR  - Nesrallah G
FIR - Nesrallah, Gihad
IR  - Soroka S
FIR - Soroka, Steven
IR  - Zimmerman D
FIR - Zimmerman, Deborah
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 06:35
PHST- 2020/04/17 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/09/23 06:35 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - 10.1177/2054358120938564 [doi]
AID - 10.1177_2054358120938564 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Sep 11;7:2054358120938564. doi:
      10.1177/2054358120938564. eCollection 2020.


PMID- 32963672
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201210
IS  - 1937-8688 (Electronic)
VI  - 36
DP  - 2020
TI  - Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues.
PG  - 206
LID - 10.11604/pamj.2020.36.206.23977 [doi]
AB  - The intense global efforts are directed towards development of vaccines to halt
      the COVID-19 virus pandemic. There are 160 candidate vaccines under clinical
      trials across the world using different molecular targets and techniques. This
      race for the vaccine has several challenges and ethical issues like compressed
      timelines, generation and proper management of resources and finances, risks to
      the participating volunteers due to curtailed research trial processes,
      geopolitical contentions, misinformation through social media and parallel race
      with drugs. We feel that the fundamental principles of ethics: autonomy,
      beneficence, non-maleficence and justice should not be violated in this hastened 
      vaccine development process. We recommend constitute a Consortium on a global
      platform to formulate, provide and monitor a comprehensive ethical umbrella to
      the process of vaccine development.
CI  - Copyright: Prathamesh Haridas Kamble et al.
FAU - Kamble, Prathamesh Haridas
AU  - Kamble PH
AD  - Department of Physiology, All India Institute of Medical Sciences, Nagpur, India.
FAU - Dubhashi, Siddharth Pramod
AU  - Dubhashi SP
AD  - Department of General Surgery, All India Institute of Medical Sciences (AIIMS),
      MIHAN, Nagpur, India.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus/*immunology
MH  - Bioethical Issues
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials as Topic/*ethics
MH  - Communication
MH  - Coronavirus Infections/drug therapy/economics/epidemiology/*prevention & control
MH  - Healthy Volunteers
MH  - Humans
MH  - Internationality
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/drug therapy/epidemiology/*prevention & control
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Social Media
MH  - Time Factors
MH  - Viral Vaccines/economics/supply & distribution/*therapeutic use
PMC - PMC7490130
OTO - NOTNLM
OT  - COVID-19
OT  - ethics
OT  - vaccine
COIS- The authors declare no competing interests.
EDAT- 2020/09/24 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/23 06:34
PHST- 2020/06/03 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/09/23 06:34 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.11604/pamj.2020.36.206.23977 [doi]
AID - PAMJ-36-206 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Jul 22;36:206. doi: 10.11604/pamj.2020.36.206.23977.
      eCollection 2020.


PMID- 32963547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1687-966X (Print)
VI  - 2020
DP  - 2020
TI  - 5-Azacytidine-Induced Cardiomyocyte Differentiation of Very Small Embryonic-Like 
      Stem Cells.
PG  - 5162350
LID - 10.1155/2020/5162350 [doi]
AB  - The use of stem cells in generating cell-based pacemaker therapies for
      bradyarrhythmia is currently being considered. Due to the propensity of stem
      cells to form tumors, as well as ethical issues surrounding their use, the seed
      cells used in cardiac biological pacemakers have limitations. Very small
      embryonic-like stem cells (VSELs) are a unique and rare adult stem cell
      population, which have the same structural, genetic, biochemical, and functional 
      characteristics as embryonic stem cells without the ethical controversy. In this 
      study, we investigated the ability of rat bone marrow- (BM-) derived VSELs to
      differentiate in vitro into cardiomyocytes by 5-Azacytidine (5-AzaC) treatment.
      The morphology of VSELs treated with 10 muM 5-AzaC increased in volume and
      gradually changed to cardiomyocyte-like morphology without massive cell death.
      Additionally, mRNA expression of the cardiomyocyte markers cardiac troponin-T
      (cTnT) and alpha-sarcomeric actin (alpha-actin) was significantly upregulated
      after 5-AzaC treatment. Conversely, stem cell markers such as Nanog, Oct-4, and
      Sox2 were continuously downregulated posttreatment. On day 14 post-5-AzaC
      treatment, the positive expression rates of cTnT and alpha-actin were 18.41 +/-
      1.51% and 19.43 +/- 0.51%, respectively. Taken together, our results showed that 
      rat BM-VSELs have the ability to differentiate into cardiomyocytes in vitro.
      These findings suggest that VSELs would be useful as seed cells in exploring the 
      mechanism of biological pacemaker activity.
CI  - Copyright (c) 2020 XiaoLin Sun et al.
FAU - Sun, XiaoLin
AU  - Sun X
AUID- ORCID: https://orcid.org/0000-0002-8486-8776
AD  - Institute of Translational Medicine, Medical College, Yangzhou University,
      Yangzhou 225001, China.
FAU - Li, HongXiao
AU  - Li H
AUID- ORCID: https://orcid.org/0000-0002-7774-5858
AD  - Department of Cardiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu
      225001, China.
FAU - Zhu, Ye
AU  - Zhu Y
AUID- ORCID: https://orcid.org/0000-0003-0865-3260
AD  - Department of Cardiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu
      225001, China.
FAU - Xu, Pei
AU  - Xu P
AUID- ORCID: https://orcid.org/0000-0002-4276-9622
AD  - Taizhou People's Hospital, Taizhou, Jiangsu 225300, China.
FAU - Zuo, QiSheng
AU  - Zuo Q
AUID- ORCID: https://orcid.org/0000-0003-0278-0023
AD  - College of Animal Science and Technology, Yangzhou University, Yangzhou, Jiangsu 
      225001, China.
FAU - Li, BiChun
AU  - Li B
AUID- ORCID: https://orcid.org/0000-0003-0209-0479
AD  - College of Animal Science and Technology, Yangzhou University, Yangzhou, Jiangsu 
      225001, China.
FAU - Gu, Xiang
AU  - Gu X
AUID- ORCID: https://orcid.org/0000-0002-0240-9403
AD  - Institute of Translational Medicine, Medical College, Yangzhou University,
      Yangzhou 225001, China.
AD  - Department of Cardiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu
      225001, China.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC7495233
COIS- The authors declare no potential conflicts of interest.
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 06:34
PHST- 2020/02/17 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/09/23 06:34 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - 10.1155/2020/5162350 [doi]
PST - epublish
SO  - Stem Cells Int. 2020 Sep 8;2020:5162350. doi: 10.1155/2020/5162350. eCollection
      2020.


PMID- 32963466
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1000-9604 (Print)
IS  - 1000-9604 (Linking)
VI  - 32
IP  - 4
DP  - 2020 Aug
TI  - A study protocol of population-based cancer screening cohort study on esophageal,
      stomach and liver cancer in rural China.
PG  - 540-546
LID - 10.21147/j.issn.1000-9604.2020.04.11 [doi]
AB  - OBJECTIVE: National Health Commission of the People's Republic of China
      collaborated with many ministries and commissions government and initiated a
      population-based cancer screening program in high-risk area of rural China,
      targeting three types of cancer that are most prevalent in these areas, including
      esophageal, stomach and liver cancer. This study protocol was reported to show
      the design and evaluate the effectiveness of cancer screening and appropriate
      screening strategies of three cancers in rural China. METHODS AND ANALYSIS: A
      two-step design with cancer risk assessment based on questionnaire interview,
      Hepatitis B surface antigen (HBsAg) test strip and subsequent clinical
      intervention for high-risk populations was adopted free of charge at the local
      hospitals designated in the program. ETHIC AND DISSEMINATION: This study was
      approved by the Institutional Review Board of Cancer Hospital, Chinese Academy of
      Medical Sciences and Peking Union Medical College. The results will evaluate the 
      effectiveness of cancer screening and appropriate screening strategies in rural
      China.
CI  - Copyright (c) 2020 Chinese Journal of Cancer Research. All rights reserved.
FAU - Li, Jiang
AU  - Li J
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Li, He
AU  - Li H
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Zeng, Hongmei
AU  - Zeng H
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Zheng, Rongshou
AU  - Zheng R
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Cao, Maomao
AU  - Cao M
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Sun, Dianqin
AU  - Sun D
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Ren, Jiansong
AU  - Ren J
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - Chen, Wanqing
AU  - Chen W
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
FAU - He, Jie
AU  - He J
AD  - National Cancer Center/National Clinical Research Center for Cancer/Cancer
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
      Beijing 100021, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Cancer Res
JT  - Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
JID - 9315242
PMC - PMC7491543
OTO - NOTNLM
OT  - Esophageal cancer screening
OT  - liver cancer screening
OT  - stomach cancer screening
OT  - study protocol
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 06:33
PHST- 2020/09/23 06:33 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - 10.21147/j.issn.1000-9604.2020.04.11 [doi]
AID - cjcr-32-4-540 [pii]
PST - ppublish
SO  - Chin J Cancer Res. 2020 Aug;32(4):540-546. doi:
      10.21147/j.issn.1000-9604.2020.04.11.


PMID- 32963089
OWN - NLM
STAT- Publisher
LR  - 20200923
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 22
TI  - Psychotherapy is still failing patients: revisiting informed consent-a response
      to Garson Leder.
LID - medethics-2020-106865 [pii]
LID - 10.1136/medethics-2020-106865 [doi]
AB  - Compared with mainstream medicine and complementary and alternative therapies,
      the practice of psychotherapy has enjoyed a relative pass when it comes to
      ethical evaluation. Therefore, contributions to the, although slowly growing,
      body of literature on psychotherapy ethics are to be welcomed. In his paper
      'Psychotherapy, placebos, and informed consent', Garson Leder takes issue with
      what he calls the 'go open' project in psychotherapy ethics-the idea that the
      so-called 'common factors' in therapy should be disclosed to prospective
      patients. Although Leder does not give a detailed list, the common factors
      include therapist characteristics (empathy, positive regard, positive
      expectations that therapy will succeed), patient characteristics (expectations
      about therapy including its plausibility, confidence in the therapist), and the
      working alliance (how well both therapist and patient work well together during
      sessions). He argues that the project advocating disclosure of these factors is
      flawed on two grounds: (1) that information about common factors is not necessary
      for informed consent; and (2) clarity about specific mechanisms of change in
      therapy is consistent with 'many theory-specific forms of psychotherapy'. There
      are multiple serious problems with Leder's critique of the recent literature,
      including how he represents the contours of the debate, which I list, and address
      in this response.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Blease, Charlotte
AU  - Blease C
AD  - General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard 
      Medical School, Boston, MA, USA cblease@bidmc.harvard.edu.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - clinical ethics
OT  - informed consent
OT  - psychiatry
OT  - psychotherapy
COIS- Competing interests: None declared.
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/08/31 00:00 [received]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - medethics-2020-106865 [pii]
AID - 10.1136/medethics-2020-106865 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 22. pii: medethics-2020-106865. doi:
      10.1136/medethics-2020-106865.


PMID- 32963073
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Burden of tinea capitis among children in Africa: protocol for a systematic
      review and meta-analysis of observational studies, 1990-2020.
PG  - e041230
LID - 10.1136/bmjopen-2020-041230 [doi]
AB  - INTRODUCTION: Tinea capitis is the most common form of dermatophytosis among
      children, contributing significantly to the global burden of skin and hair
      infections. However, an accurate account of its burden in Africa, where most
      cases are thought to occur, is lacking. We aim to systematically evaluate the
      burden, aetiology and epidemiological trend of tinea capitis among children over 
      a 30-year period in Africa. METHODS AND ANALYSIS: A systematic review will be
      conducted using Embase, PubMed, African Journals Online, Web of Science and the
      Cochrane Library of Systematic Review. These resources will be used to identify
      studies published between 1990 and December 2020, which report the prevalence,
      aetiology and trend of tinea capitis among children younger than 18 years in
      Africa. Articles in English and French will be considered. Two independent
      reviewers will screen the articles for eligibility, and any discrepancies will be
      resolved by discussion and consensus between the authors. Methodological quality 
      of all studies will be assessed and critically appraised. We will perform a
      metaregression to assess the impact of study characteristics on heterogeneity and
      also to correct the meta-analytical estimates for biases. A qualitative synthesis
      will be performed, and STATA V.16.0 software will be used to estimate the pooled 
      prevalence and aetiology of tinea capitis. The Mann-Kendall trend test will be
      use to evaluate the trend in the prevalence of tinea capitis over the study
      period. ETHICS AND DISSEMINATION: Ethical approval from an institutional review
      board or research ethics committee is not required for this systematic review and
      meta-analysis. The results will be published in a peer-reviewed journal and
      presented in conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bongomin, Felix
AU  - Bongomin F
AUID- ORCID: 0000-0003-4515-8517
AD  - Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu
      University, Gulu, Uganda drbongomin@gmail.com.
FAU - Olum, Ronald
AU  - Olum R
AUID- ORCID: 0000-0003-1289-0111
AD  - School of Medicine, Makerere University College of Health Sciences, Kampala,
      Uganda.
FAU - Nsenga, Lauryn
AU  - Nsenga L
AUID- ORCID: 0000-0001-6155-4718
AD  - School of Medicine, Kabale University, Kabale, Uganda.
FAU - Baluku, Joseph Baruch
AU  - Baluku JB
AUID- ORCID: 0000-0002-5852-9674
AD  - Division of Pulmonology, Mulago National Referral Hospital, Kampala, Uganda.
AD  - Department of Programs, Mildmay Uganda, Wakiso, Uganda.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa/epidemiology
MH  - Child
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Prevalence
MH  - *Research Report
MH  - Systematic Reviews as Topic
MH  - *Tinea Capitis/epidemiology
PMC - PMC7509979
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *tropical medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041230 [pii]
AID - 10.1136/bmjopen-2020-041230 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e041230. doi: 10.1136/bmjopen-2020-041230.


PMID- 32963072
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210920
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Effectiveness of non-pharmacological interventions to decrease fatigue in people 
      living with HIV/AIDS: a protocol of systematic review and meta-analysis.
PG  - e040996
LID - 10.1136/bmjopen-2020-040996 [doi]
AB  - INTRODUCTION: Fatigue is a common symptom among people living with HIV (PLWH). It
      has a substantial adverse impact on functional status and the ability to conduct 
      activities of daily living. Identifying effective strategies to prevent or reduce
      fatigue is significant to promote the quality of life of this vulnerable
      population. The purpose of this review is to synthesise the non-pharmacological
      evidence and assess the effects of interventions on reducing HIV-related fatigue 
      among PLWH. METHODS AND ANALYSIS: We will comprehensively search literature
      available up to 30 June 2020, in the following databases: PubMed, Embase, CINAHL,
      Cochrane Library, Web of Science and PsycINFO. The reference list of selected
      studies and relevant published reviews will also be screened to retrieve
      potential articles. Two reviewers will identify the eligible articles, extract
      data and identify the biases in the selected studies. Any disagreements will be
      referred to a third reviewer. We will qualitatively synthesise the evidence and
      pool data with meta-analysis according to the heterogeneity of different studies.
      ETHICS AND DISSEMINATION: This systematic review will not raise any ethical
      issues since it is a secondary data collection and analysis. The results will
      inform effective strategies to reduce fatigue among PLWH. The final report will
      be published in a peer-reviewed journal and academic conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020153715.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xiao, Xueling
AU  - Xiao X
AUID- ORCID: 0000-0002-8810-9291
AD  - Xiangya Nursing School, Central South University, Changsha, Hunan, China.
AD  - School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Reynolds, Nancy R
AU  - Reynolds NR
AD  - School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Saligan, Leorey
AU  - Saligan L
AD  - National Institute of Nursing Research, National Institutes of Health, Bethesda, 
      Maryland, USA.
FAU - Lei, Yunxiao
AU  - Lei Y
AD  - School of Nursing, Henan University of Science and Technology, Luoyang, Henan,
      China.
FAU - Wang, Min
AU  - Wang M
AD  - HIV/AIDS Department, First Hospital of Changsha, Changsha, Hunan, China
      wangmin2828@163.com.
FAU - Wang, Honghong
AU  - Wang H
AD  - Xiangya Nursing School, Central South University, Changsha, Hunan, China.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Activities of Daily Living
MH  - Fatigue/etiology/prevention & control
MH  - *HIV Infections/complications
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Quality of Life
MH  - Systematic Reviews as Topic
PMC - PMC7509953
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *infectious diseases
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040996 [pii]
AID - 10.1136/bmjopen-2020-040996 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e040996. doi: 10.1136/bmjopen-2020-040996.


PMID- 32963070
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Study protocol: a prospective cohort on non-communicable diseases among primary
      healthcare users living in Kosovo (KOSCO).
PG  - e038889
LID - 10.1136/bmjopen-2020-038889 [doi]
AB  - INTRODUCTION: With the lowest life expectancy in the Balkans, underlying causes
      of morbidity in Kosovo remain unclear due to limited epidemiological evidence.
      The goal of this cohort is to contribute epidemiological evidence for the
      prevention and control of non-communicable diseases such as depression,
      hypertension, diabetes and chronic respiratory disease in Kosovo as the basis for
      policy and decision-making, with a spotlight on the relationships between
      non-experimental primary healthcare (PHC) interventions and lifestyle changes as 
      well as between depression and the course of blood pressure. METHODS AND
      ANALYSIS: PHC users aged 40 years and above were recruited consecutively between 
      March and October 2019 from 12 main family medicine centres across Kosovo. The
      data collected through interviews and health examinations included:
      sociodemographic characteristics, social and environmental factors,
      comorbidities, health system, lifestyle, psychological factors and clinical
      attributes (blood pressure, height, weight, waist/hip/neck circumferences, peak
      expiratory flow and HbA1c measurements). Cohort data were collected annually in
      two phases, approximately 6 months apart, with an expected total follow-up time
      of 5 years. ETHICS AND DISSEMINATION: Ethical approvals were obtained from the
      Ethics Committee Northwest and Central Switzerland (Ref. 2018-00994) and the
      Kosovo Doctors Chamber (Ref. 11/2019). Cohort results will provide novel
      epidemiological evidence on non-communicable diseases in Kosovo, which will be
      published in scientific journals. The study will also examine the health needs of
      the people of Kosovo and provide evidence for health sector decision-makers to
      improve service responsiveness, which will be shared with stakeholders through
      reports and presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Obas, Katrina Ann
AU  - Obas KA
AUID- ORCID: 0000-0001-9110-5331
AD  - Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
      Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Gerold, Jana
AU  - Gerold J
AD  - University of Basel, Basel, Switzerland.
AD  - Swiss Centre for International Health, Swiss Tropical and Public Health
      Institute, Basel, Switzerland.
FAU - Bytyci-Katanolli, Ariana
AU  - Bytyci-Katanolli A
AD  - Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
      Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Jerliu, Naim
AU  - Jerliu N
AD  - National Institute of Public Health, Prishtina, Kosovo.
AD  - University of Prishtina, Prishtina, Kosovo.
FAU - Kwiatkowski, Marek
AU  - Kwiatkowski M
AD  - Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
      Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Ramadani, Qamile
AU  - Ramadani Q
AD  - Accessible Quality Healthcare Project, Prishtina, Kosovo.
FAU - Statovci, Shukrije
AU  - Statovci S
AD  - University Clinical Centre of Kosovo, Prishtina, Kosovo.
FAU - Zahorka, Manfred
AU  - Zahorka M
AD  - University of Basel, Basel, Switzerland.
AD  - Swiss Centre for International Health, Swiss Tropical and Public Health
      Institute, Basel, Switzerland.
FAU - Probst-Hensch, Nicole
AU  - Probst-Hensch N
AD  - Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
      Basel, Switzerland nicole.probst@swisstph.ch.
AD  - University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2021 Jan 20;11(1):1. PMID: 33472795
MH  - Adult
MH  - Humans
MH  - Kosovo
MH  - *Noncommunicable Diseases/epidemiology
MH  - Primary Health Care
MH  - Prospective Studies
MH  - Switzerland
PMC - PMC7509972
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *epidemiology
OT  - *hypertension
OT  - *mental health
OT  - *primary care
COIS- Competing interests: KAO, ABK and QR report personal fees from Swiss Agency for
      Development and Cooperation (SDC) during the conduct of the study. ABK reports
      grants from the Swiss Confederation during the conduct of the study.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038889 [pii]
AID - 10.1136/bmjopen-2020-038889 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e038889. doi: 10.1136/bmjopen-2020-038889.


PMID- 32963069
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Rationale and design of a prospective, observational, multicentre study on the
      safety and efficacy of apixaban for the prevention of thromboembolism in adults
      with congenital heart disease and atrial arrhythmias: the PROTECT-AR study.
PG  - e038012
LID - 10.1136/bmjopen-2020-038012 [doi]
AB  - INTRODUCTION: The risk for stroke in adults with congenital heart disease (ACHD) 
      is increased, especially in the setting of commonly ensuing atrial arrhythmias
      (AA), namely atrial fibrillation, atrial flutter or intra-atrial re-entrant
      tachycardia. Data are limited regarding treatment with non-vitamin K oral
      anticoagulants in long-term studies involving patients with ACHD and AA. METHODS 
      AND ANALYSIS: PReventiOn of ThromboEmbolism in Adults with Congenital HearTau
      disease and Atrial aRrhythmias is a prospective, multicenter, single-arm,
      non-interventional cohort study designed to investigate the safety and efficacy
      of apixaban for the prevention of thromboembolism in ACHD with AA in a
      'real-world' setting. Eligible patients will be evaluated by the means of
      available registries and clinical counter. The study aims to accumulate
      approximately 500 patient-years of exposure to apixaban as part of routine care. 
      Enrolment will take place at four ACHD centres in Greece. The first patient was
      enrolled in July 2019. The primary efficacy endpoint is a composite of stroke,
      systemic or pulmonary embolism and intracardiac thrombosis. The primary safety
      endpoint is major bleeding, according to the International Society on Thrombosis 
      and Haemostasis bleeding criteria. ETHICS AND DISSEMINATION: The study protocol
      has been approved by the institutional review board/independent ethics committee 
      at each site prior to study commencement. All patients will provide written
      informed consent. Results will be disseminated at scientific meetings and
      published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT03854149;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kartas, Anastasios
AU  - Kartas A
AUID- ORCID: 0000-0002-1170-9133
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Doundoulakis, Ioannis
AU  - Doundoulakis I
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Ntiloudi, Despoina
AU  - Ntiloudi D
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Koutsakis, Athanasios
AU  - Koutsakis A
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Kosmidis, Diamantis
AU  - Kosmidis D
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Rampidis, Georgios
AU  - Rampidis G
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Apostolopoulou, Sotiria
AU  - Apostolopoulou S
AD  - Cardiology, Onassis Cardiac Surgery Centre, Athens, Attica, Greece.
FAU - Frogoudaki, Alexandra
AU  - Frogoudaki A
AD  - Cardiology, General University Hospital Attikon, Athens, Attica, Greece.
FAU - Tzifa, Afrodite
AU  - Tzifa A
AD  - Paediatric Cardiology & Adult Congenital Heart Disease, Mitera, Hygeia Group,
      Athens, Attica, Greece.
AD  - Division of Biomedical Engineering and Imaging Sciences, King's College, London, 
      England.
FAU - Avramidis, Dimosthenis
AU  - Avramidis D
AD  - Paediatric Cardiology & Adult Congenital Heart Disease, Mitera, Hygeia Group,
      Athens, Attica, Greece.
FAU - Ntzoyvara, Olga
AU  - Ntzoyvara O
AD  - Cardiology, Onassis Cardiac Surgery Centre, Athens, Attica, Greece.
FAU - Liori, Sotiria
AU  - Liori S
AD  - Cardiology, General University Hospital Attikon, Athens, Attica, Greece.
FAU - Mousiama, Tereza
AU  - Mousiama T
AD  - Paediatric Cardiology & Adult Congenital Heart Disease, Mitera, Hygeia Group,
      Athens, Attica, Greece.
FAU - Mouratoglou, Sophia Anastasia
AU  - Mouratoglou SA
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Karvounis, Haralambos
AU  - Karvounis H
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece.
FAU - Giannakoulas, George
AU  - Giannakoulas G
AD  - Cardiology, University General Hospital of Thessaloniki AHEPA, Thessaloniki,
      Greece ggiannakoulas@auth.gr.
LA  - eng
SI  - ClinicalTrials.gov/NCT03854149
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridones)
RN  - 3Z9Y7UWC1J (apixaban)
SB  - IM
MH  - Adult
MH  - Anticoagulants/adverse effects
MH  - *Atrial Fibrillation/complications/drug therapy
MH  - Cohort Studies
MH  - Greece
MH  - *Heart Defects, Congenital
MH  - Humans
MH  - Prospective Studies
MH  - Pyrazoles
MH  - Pyridones/adverse effects
MH  - *Stroke/prevention & control
MH  - *Thromboembolism/etiology/prevention & control
MH  - Treatment Outcome
PMC - PMC7509965
OTO - NOTNLM
OT  - *anticoagulation
OT  - *congenital heart disease
OT  - *epidemiology
OT  - *protocols & guidelines
OT  - *stroke
OT  - *thromboembolism
COIS- Competing interests: GG and HK have received grants and/or personal fees from
      Pfizer.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038012 [pii]
AID - 10.1136/bmjopen-2020-038012 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e038012. doi: 10.1136/bmjopen-2020-038012.


PMID- 32963067
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Developing and testing community-based tuberculosis (TB) screening intervention
      to increase TB referral, case detection and knowledge among sexual minority
      people in urban Bangladesh: a mixed-method study protocol.
PG  - e037371
LID - 10.1136/bmjopen-2020-037371 [doi]
AB  - INTRODUCTION: Although Bangladesh is a country of generalised tuberculosis (TB)
      epidemic, the HIV prevalence is low among general populations, and 3.9% among key
      populations. Despite the high possibility of HIV-TB coinfection, scientifically
      tested approaches for increasing TB case detection among sexual minority people
      are yet to be developed and implemented in Bangladesh. Such approaches could
      foster service delivery linkages between communities and the government health
      system. Findings of this experimental research are likely to provide new insights
      for programme managers and policy planners for adopting a similar approach in
      order to enhance TB referral, thus ultimately increasing TB case detections and
      reducing the likelihood of TB-related mortalities and morbidities, irrespective
      of HIV status. METHODS AND ANALYSIS: This operational research will follow a
      quasi-experimental design, applying both qualitative and quantitative methods, in
      two drop-in centres in three phases. Phase 1 will encompass baseline data
      collection and development of a community-based TB screening approach. In phase
      2, the newly developed intervention will be implemented, followed by end-line
      data collection in phase 3. Qualitative data collection will be continued
      throughout the first and second phases. The baseline and end-line data will be
      compared both in the intervention and comparison areas to measure the impact of
      the intervention. ETHICS AND DISSEMINATION: Ethical approval was obtained from
      the Institutional Review Board of International Centre for Diarrhoeal Disease
      Research, Bangladesh. The findings will be disseminated through diverse
      scientific forums including peer-reviewed journals, presentation at conferences
      and among the policy-makers for policy implication. The study started in January 
      2019 and will continue until June 2020.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sarwar, Golam
AU  - Sarwar G
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Reza, Masud
AU  - Reza M
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Khan, Mohammad Niaz Morshed
AU  - Khan MNM
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Gourab, Gorkey
AU  - Gourab G
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Rahman, Mahbubur
AU  - Rahman M
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Rana, A K M Masud
AU  - Rana AKMM
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Khan, Shaan Muberra
AU  - Khan SM
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Irfan, Samira Dishti
AU  - Irfan SD
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Ahmed, Shahriar
AU  - Ahmed S
AUID- ORCID: 0000-0002-8833-4130
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Banu, Rupali Sisir
AU  - Banu RS
AD  - National Tuberculosis Control Program, Directorate General of Health Services,
      Govt. Of the People's Republic of Bangladesh, Dhaka, Bangladesh.
FAU - Banu, Sayera
AU  - Banu S
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh.
FAU - Khan, Sharful Islam
AU  - Khan SI
AUID- ORCID: 0000-0002-7319-1333
AD  - Infectious Diseases Division, International Centre for Diarrhoeal Disease
      Research Bangladesh, Dhaka, Bangladesh sharful@icddrb.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bangladesh/epidemiology
MH  - Humans
MH  - Referral and Consultation
MH  - Research Design
MH  - *Sexual and Gender Minorities
MH  - *Tuberculosis/diagnosis/epidemiology
PMC - PMC7509970
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *public health
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037371 [pii]
AID - 10.1136/bmjopen-2020-037371 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e037371. doi: 10.1136/bmjopen-2020-037371.


PMID- 32963066
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Impact of a two-way short message service (SMS) to support maternally
      administered childhood mid-upper arm circumference monitoring and expand
      malnutrition screening in Kenya: the Mama Aweza trial protocol.
PG  - e036660
LID - 10.1136/bmjopen-2019-036660 [doi]
AB  - INTRODUCTION: Over 52 million children under 5 years of age become wasted each
      year, but only 17% of these children receive treatment. Novel methods to identify
      and deliver treatment to malnourished children are necessary to achieve the
      sustainable development goals target for child health. Mobile health (mHealth)
      programmes may provide an opportunity to rapidly identify malnourished children
      in the community and link them to care. METHODS AND ANALYSIS: This randomised
      controlled trial will recruit 1200 children aged 6-12 months at routine vaccine
      appointments in Migori and Homa Bay Counties, Kenya. Caregiver-infant dyads will 
      be randomised to either a maternally administered malnutrition monitoring system 
      (MAMMS) or standard of care (SOC). Study staff will train all caregivers to
      measure their child's mid-upper arm circumference (MUAC). Caregivers in the MAMMS
      arm will be given two colour coded and graduated insertion MUAC tapes and be
      enrolled in a mHealth system that sends weekly short message service (SMS)
      messages prompting caregivers to measure and report their child's MUAC by SMS.
      Caregivers in the SOC arm will receive routine monitoring by community health
      volunteers coupled with a quarterly visit from study staff to ensure adequate
      screening coverage. The primary outcome is identification of childhood
      malnutrition, defined as MUAC <12.5 cm, in the MAMMS arm compared with the SOC
      arm. Secondary outcomes will assess the accuracy of maternal versus health worker
      MUAC measurements and determinants of acute malnutrition among children 6-18
      months of age. Finally, we will explore the acceptability, fidelity and
      feasibility of implementing the MAMMS within existing nutrition programmes.
      ETHICS AND DISSEMINATION: The study was approved by review boards at the
      University of Washington and the Kenya Medical Research Institute. A data and
      safety monitoring board has been convened, and the results of the trial will be
      published in peer-reviewed scientific journals, presented at appropriate
      conferences and to key stakeholders. TRIAL REGISTRATION NUMBER: NCT03967015;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tickell, Kirkby D
AU  - Tickell KD
AUID- ORCID: 0000-0002-4108-1236
AD  - Global Health, University of Washington, Seattle, Washington, USA kirkbt@uw.edu.
AD  - Childhood Acute Illness and Nutrition Network, Nairobi, Kenya.
FAU - Diakhate, Mareme M
AU  - Diakhate MM
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Goodman, Jeanne L
AU  - Goodman JL
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Unger, Jennifer A
AU  - Unger JA
AD  - Global Health, University of Washington, Seattle, Washington, USA.
AD  - Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
FAU - Richardson, Barbra A
AU  - Richardson BA
AD  - Global Health, University of Washington, Seattle, Washington, USA.
AD  - Biostatistics, University of Washington, Seattle, WA, USA.
FAU - Rubin Means, Arianna
AU  - Rubin Means A
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Ronen, Keshet
AU  - Ronen K
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Levin, Carol
AU  - Levin C
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Choo, Esther M
AU  - Choo EM
AD  - Global Health, University of Washington, Seattle, Washington, USA.
FAU - Achieng, Catherine
AU  - Achieng C
AD  - Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
FAU - Masheti, Mary
AU  - Masheti M
AD  - Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
FAU - Singa, Benson O
AU  - Singa BO
AD  - Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
FAU - McGrath, Christine J
AU  - McGrath CJ
AD  - Global Health, University of Washington, Seattle, Washington, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03967015
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arm
MH  - Child
MH  - *Child Nutrition Disorders/diagnosis
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - Kenya
MH  - *Malnutrition
MH  - Randomized Controlled Trials as Topic
MH  - *Text Messaging
PMC - PMC7509951
OTO - NOTNLM
OT  - *community child health
OT  - *nutrition
OT  - *paediatrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036660 [pii]
AID - 10.1136/bmjopen-2019-036660 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e036660. doi: 10.1136/bmjopen-2019-036660.


PMID- 32963065
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Predictors of oral anticoagulant-associated adverse events in seniors
      transitioning from hospital to home: a retrospective cohort study protocol.
PG  - e036537
LID - 10.1136/bmjopen-2019-036537 [doi]
AB  - INTRODUCTION: Oral anticoagulants (OACs) are widely prescribed in older adults.
      High OAC-related adverse event rates in the early period following hospital
      discharge argue for an analysis to identify predictors. Our objective is to
      identify and validate clinical and continuity of care variables among seniors
      discharged from hospital on an OAC, which are independently associated with
      OAC-related adverse events within 30 days. METHODS AND ANALYSIS: We propose a
      population-based retrospective cohort study of all adults aged 66 years or older 
      who were discharged from hospital on an OAC from September 2010 to March 2015 in 
      Ontario, Canada. The primary outcome is a composite of the first hospitalisation 
      or emergency department visit for a haemorrhage or thromboembolic event or
      mortality within 30 days of hospital discharge. A Cox proportional hazards model 
      will be used to determine the association between the composite outcome and a set
      of prespecified covariates. A split sample method will be adopted to validate the
      variables associated with OAC-related adverse events. ETHICS AND DISSEMINATION:
      The use of data in this project was authorised under section 45 of Ontario's
      Personal Health Information Protection Act, which does not require review by a
      research ethics board. Results will be disseminated via peer-reviewed
      publications and presentations at conferences and will determine intervention
      targets to improve OAC management in upcoming randomised trials. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT02777047; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Benipal, Harsukh
AU  - Benipal H
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Holbrook, Anne
AU  - Holbrook A
AUID- ORCID: 0000-0002-3371-4187
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada holbrook@mcmaster.ca.
AD  - Department of Medicine, Division of Clinical Pharmacology & Toxicology, McMaster 
      University, Hamilton, Ontario, Canada.
FAU - Paterson, J Michael
AU  - Paterson JM
AD  - ICES, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Douketis, James
AU  - Douketis J
AD  - Department of Medicine, Division of Hematology and Thromboembolism, McMaster
      University, Hamilton, Ontario, Canada.
AD  - Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
FAU - Foster, Gary
AU  - Foster G
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Biostatistics Unit, Saint Joseph's Healthcare Hamilton, Hamilton, Ontario,
      Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Biostatistics Unit, Saint Joseph's Healthcare Hamilton, Hamilton, Ontario,
      Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT02777047
GR  - 365 834/Canadian Institutes for Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Aged
MH  - *Anticoagulants/adverse effects
MH  - Cohort Studies
MH  - *Hospitals
MH  - Humans
MH  - Ontario/epidemiology
MH  - Retrospective Studies
PMC - PMC7509956
OTO - NOTNLM
OT  - *anticoagulation
OT  - *clinical pharmacology
OT  - *epidemiology
OT  - *protocols & guidelines
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036537 [pii]
AID - 10.1136/bmjopen-2019-036537 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e036537. doi: 10.1136/bmjopen-2019-036537.


PMID- 32963063
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 22
TI  - Increasing the uptake of long-acting reversible contraception in general
      practice: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomised
      controlled trial longitudinal follow-up protocol.
PG  - e035895
LID - 10.1136/bmjopen-2019-035895 [doi]
AB  - INTRODUCTION: Through addressing main barriers to the uptake of long-acting
      reversible contraceptives (LARCs) among Australian women, the Australian
      Contraceptive ChOice pRoject (ACCORd) trialled an educational intervention
      targeting general practitioners (GPs) and provided those in the intervention
      group with a rapid referral service for quick insertion. The cluster randomised
      controlled trial resulted in greater uptake of LARC in the intervention group.
      This protocol paper describes a longitudinal follow-up to the ACCORd Study to
      assess the long-term efficacy and cost-effectiveness of the intervention. METHODS
      AND ANALYSIS: Women participants (patients of ACCORd GPs) completed a baseline,
      6-month and 12-month survey. These participants will be invited to complete an
      additional follow-up survey 3 years post completion of their baseline interview. 
      Based on the original ACCORd Study tools, the online survey will address
      long-term outcomes including contraceptive continuation rates and reproductive
      history, any unintended pregnancies, satisfaction and concerns with their current
      contraceptive method, and an assessment of quality of life. We will analyse data 
      using binary regression models with generalised estimating equations and robust
      standard errors to account for clustering. DISCUSSION: Demonstration of sustained
      use, effectiveness at reducing unwanted pregnancies and cost-effectiveness of
      this strategy among this cohort of Australian primary care patients, will
      strengthen the policy and programme urgency of addressing wider dissemination of 
      these strategies and replicating the study elsewhere. ETHICS AND DISSEMINATION:
      The ACCORd Study received approval from the Monash University Human Research
      Ethics Committee: CF16/188-201000080. Additionally, an amendment to conduct this 
      3-year longitudinal follow-up survey has been approved. The trial follow-up
      outcomes will be disseminated through formal academic pathways, including journal
      articles, national and international conferences and reports as well as using
      more 'mainstream' strategies such as seminars, workshops and media engagement.
      Additionally, outcomes will be communicated through policy briefs to Australian
      state and federal governments. TRAIL REGISTRATION NUMBER: This trial is
      registered with the Australian and New Zealand Trials Registry
      ACTRN12615001346561. Recruitment and data collection have been completed for the 
      baseline, 6-month and 12-month surveys. Data collection for the 3-year survey
      commenced in August 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mazza, Danielle
AU  - Mazza D
AD  - Department of General Practice, Monash University, Melbourne, Victoria, Australia
      Danielle.Mazza@monash.edu.
FAU - Amos, Natalie
AU  - Amos N
AUID- ORCID: 0000-0001-6558-2580
AD  - Department of General Practice, Monash University, Melbourne, Victoria,
      Australia.
FAU - Watson, Cathy J
AU  - Watson CJ
AUID- ORCID: 0000-0002-2816-6956
AD  - Department of General Practice, Monash University, Melbourne, Victoria,
      Australia.
FAU - McGeechan, Kevin
AU  - McGeechan K
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Haas, Marion
AU  - Haas M
AD  - Centre for Health Economics Research & Evaluation, University of Technology
      Sydney, Sydney, New South Wales, Australia.
FAU - Peipert, Jeffrey F
AU  - Peipert JF
AD  - Department of Obstetrics & Gynecology, Indiana University School of Medicine,
      Indianapolis, Indiana, USA.
FAU - Lucke, Jayne
AU  - Lucke J
AD  - School of Psychology and Public Health, La Trobe University, Melbourne, Victoria,
      Australia.
AD  - School of Public Health, University of Queensland, Brisbane, Queensland,
      Australia.
FAU - Taft, Angela
AU  - Taft A
AD  - Judith Lumley Centre, La Trobe University, Melbourne, Victoria, Australia.
FAU - McNamee, Kathleen
AU  - McNamee K
AD  - Family Planning Victoria, Melbourne, Victoria, Australia.
FAU - Black, Kirsten I
AU  - Black KI
AD  - Royal Prince Alfred Hospital, The University of Sydney, Sydney, New South Wales, 
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12615001346561
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Female
MH  - Follow-Up Studies
MH  - *General Practice
MH  - Humans
MH  - *Long-Acting Reversible Contraception
MH  - New Zealand
MH  - Pregnancy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7509957
OTO - NOTNLM
OT  - *preventive medicine
OT  - *primary care
OT  - *public health
OT  - *reproductive medicine
COIS- Competing interests: No competing interests.
EDAT- 2020/09/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/23 06:28
PHST- 2020/09/23 06:28 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035895 [pii]
AID - 10.1136/bmjopen-2019-035895 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 22;10(9):e035895. doi: 10.1136/bmjopen-2019-035895.


PMID- 32962743
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 22
TI  - Neuroplasticity induced by general anaesthesia: study protocol for a randomised
      cross-over clinical trial exploring the effects of sevoflurane and propofol on
      the brain - A 3-T magnetic resonance imaging study of healthy volunteers.
PG  - 805
LID - 10.1186/s13063-020-04468-y [doi]
AB  - BACKGROUND: Although used extensively worldwide, the effects of general
      anaesthesia on the human brain remain largely elusive. Moreover, general
      anaesthesia may contribute to serious conditions or adverse events such as
      postoperative cognitive dysfunction and delirium. To understand the basic
      mechanisms of general anaesthesia, this project aims to study and compare
      possible de novo neuroplastic changes induced by two commonly used types of
      general anaesthesia, i.e. inhalation anaesthesia by sevoflurane and intravenously
      administered anaesthesia by propofol. In addition, we wish to to explore possible
      associations between neuroplastic changes, neuropsychological adverse effects and
      subjective changes in fatigue and well-being. METHODS: This is a randomised,
      participant- and assessor-blinded, cross-over clinical trial. Thirty healthy
      volunteers (male:female ratio 1:1) will be randomised to general anaesthesia by
      either sevoflurane or propofol. Multimodal magnetic resonance imaging (MRI) of
      the brain will be performed before and after general anaesthesia and repeated
      after 1 and 8 days. Each magnetic resonance imaging session will be accompanied
      by cognitive testing and questionnaires on fatigue and well-being. After a
      wash-out period of 4 weeks, the volunteers will receive the other type of
      anaesthetic (sevoflurane or propofol), followed by the same series of tests.
      Primary outcomes: changes in T1-weighted 3D anatomy and diffusion tensor imaging.
      SECONDARY OUTCOMES: changes in resting-state functional magnetic resonance
      imaging, fatigue, well-being, cognitive function, correlations between magnetic
      resonance imaging findings and the clinical outcomes (questionnaires and
      cognitive function). Exploratory outcomes: changes in cerebral perfusion and
      oxygen metabolism, lactate, and response to visual stimuli. DISCUSSION: To the
      best of our knowledge, this is the most extensive and advanced series of studies 
      with head-to-head comparison of two widely used methods for general anaesthesia. 
      Recruitment was initiated in September 2019. TRIAL REGISTRATION: Approved by the 
      Research Ethics Committee in the Capital Region of Denmark, ref. H-18028925 (6
      September 2018). EudraCT and Danish Medicines Agency: 2018-001252-35 (23 March
      2018). www.clinicaltrials.gov , ID: NCT04125121 . Retrospectively registered on
      10 October 2019.
FAU - Madsen, Signe Sloth
AU  - Madsen SS
AUID- ORCID: http://orcid.org/0000-0002-1462-635X
AD  - Department of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet,
      University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
      signe.sloth.madsen@regionh.dk.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark. signe.sloth.madsen@regionh.dk.
AD  - Department of Neuroanaesthesiology, Rigshospitalet Glostrup, University of
      Copenhagen, Valdemar Hansens Vej 15, 2600, Glostrup, Denmark.
      signe.sloth.madsen@regionh.dk.
FAU - Moller, Kirsten
AU  - Moller K
AD  - Department of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet,
      University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Olsen, Karsten Skovgaard
AU  - Olsen KS
AD  - Department of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet,
      University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Vestergaard, Mark Bitsch
AU  - Vestergaard MB
AD  - Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and 
      PET, Rigshospitalet, University of Copenhagen, Valdemar Hansens Vej 1-23,
      entrance 5, 2600, Glostrup, Denmark.
FAU - Lindberg, Ulrich
AU  - Lindberg U
AD  - Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and 
      PET, Rigshospitalet, University of Copenhagen, Valdemar Hansens Vej 1-23,
      entrance 5, 2600, Glostrup, Denmark.
FAU - Larsson, Henrik Bo Wiberg
AU  - Larsson HBW
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
AD  - Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and 
      PET, Rigshospitalet, University of Copenhagen, Valdemar Hansens Vej 1-23,
      entrance 5, 2600, Glostrup, Denmark.
FAU - Martensson, Johan
AU  - Martensson J
AD  - Faculty of Medicine, Department of Clinical Sciences Lund, Logopedics,
      Phoniatrics and Audiology, Lund University, 22100 Lund, Sweden.
FAU - Werner, Mads U
AU  - Werner MU
AD  - Multidisciplinary Pain Center, The Neuroscience Center, Rigshospitalet,
      Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Santos, Sofia Alexandra Gaspar
AU  - Santos SAG
AD  - Department of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet,
      University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
FAU - Asghar, Mohammad Sohail
AU  - Asghar MS
AD  - Department of Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet,
      University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04125121
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Anesthetics, Inhalation)
RN  - 0 (Anesthetics, Intravenous)
RN  - 0 (Methyl Ethers)
RN  - 38LVP0K73A (Sevoflurane)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Anesthesia, General/adverse effects
MH  - *Anesthetics, Inhalation/adverse effects
MH  - Anesthetics, Intravenous/adverse effects
MH  - Brain/diagnostic imaging
MH  - Diffusion Tensor Imaging
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - *Methyl Ethers/adverse effects
MH  - Neuronal Plasticity
MH  - *Propofol/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Sevoflurane/adverse effects
PMC - PMC7506820
OTO - NOTNLM
OT  - Cognitive
OT  - Consciousness
OT  - Fatigue
OT  - General anaesthesia
OT  - Healthy volunteers
OT  - Magnetic resonance imaging
OT  - Neuroplastic changes
OT  - Neuroplasticity
OT  - Propofol
OT  - Sevoflurane
EDAT- 2020/09/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/23 05:56
PHST- 2020/01/06 00:00 [received]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/09/23 05:56 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04468-y [doi]
AID - 10.1186/s13063-020-04468-y [pii]
PST - epublish
SO  - Trials. 2020 Sep 22;21(1):805. doi: 10.1186/s13063-020-04468-y.


PMID- 32962671
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201218
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 22
TI  - Ethical and human rights considerations in public health in low and middle-income
      countries: an assessment using the case of Uganda's responses to COVID-19
      pandemic.
PG  - 91
LID - 10.1186/s12910-020-00523-0 [doi]
AB  - BACKGROUND: In response to COVID-19 pandemic, the Government of Uganda adopted
      public health measures to contain its spread in the country. Some of the initial 
      measures included refusal to repatriate citizens studying in China, mandatory
      institutional quarantine, and social distancing. Despite being a public health
      emergency, the measures adopted deserve critical appraisal using an ethics and
      human rights approach. The goal of this paper is to formulate an ethics and human
      rights criteria for evaluating public health measures and use it to reflect on
      the ethical propriety of those adopted by the government of Uganda to contain the
      spread of COVID-19. MAIN BODY: We begin by illustrating the value of ethics and
      human rights considerations for public health measures including during
      emergencies. We then summarize Uganda's social and economic circumstances and
      some of the measures adopted to contain the spread of COVID-19. After reviewing
      some of the ethics and human rights considerations for public health, we reflect 
      upon the ethical propriety of some of Uganda's responses to COVID-19. We use
      content analysis to identify the measures adopted by the government of Uganda to 
      contain the spread of COVID-19, the ethics and human rights considerations
      commonly recommended for public health responses and their importance. Our study 
      found that some of the measures adopted violate ethics and human rights
      principles. We argue that even though some human rights can sometimes be
      legitimately derogated and limited to meet public health goals during public
      health emergencies, measures that infringe on human rights should satisfy certain
      ethics and human rights criteria. Some of these criteria include being effective,
      strictly necessary, proportionate to the magnitude of the threat, reasonable in
      the circumstances, equitable, and least restrictive. We reflect on Uganda's
      initial measures to combat the spread of COVID-19 and argue that many of them
      fell short of these criteria, and potentially limit their effectiveness.
      CONCLUSION: The ethical legitimacy of public health measures is valuable in
      itself and for enhancing effectiveness of the measures. Such legitimacy depends
      on the extent to which they conform to ethics and human rights principles
      recommended for public health measures.
FAU - Barugahare, John
AU  - Barugahare J
AUID- ORCID: 0000-0001-6420-4756
AD  - Department of Philosophy, College of Humanities and Social Sciences, Makerere
      University, P. O. Box 7062, Kampala, Uganda. jbarugahare@chuss.mak.ac.ug.
FAU - Nakwagala, Fredrick Nelson
AU  - Nakwagala FN
AD  - Department of Internal medicine, Mulago National Referral Hospital, P. O. Box
      7051, Kampala, Uganda.
FAU - Sabakaki, Erisa Mwaka
AU  - Sabakaki EM
AD  - Department of Anatomy, School of Biomedical Sciences, College of Health Sciences,
      Makerere University, P. O. Box 7062, Kampala, Uganda.
FAU - Ochieng, Joseph
AU  - Ochieng J
AD  - Department of Anatomy, School of Biomedical Sciences, College of Health Sciences,
      Makerere University, P. O. Box 7062, Kampala, Uganda.
FAU - K Sewankambo, Nelson
AU  - K Sewankambo N
AD  - Department of Medicine, School of Medicine, Makerere University College of Health
      Sciences, P. O. Box 7062, Kampala, Uganda.
LA  - eng
GR  - R25 TW009730/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200922
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/*organization & administration
MH  - Coronavirus Infections/*epidemiology
MH  - Developing Countries
MH  - *Human Rights
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - Uganda/epidemiology
PMC - PMC7506843
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Human rights
OT  - *Low income countries
OT  - *Public health
OT  - *Public health emergencies
EDAT- 2020/09/24 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/23 05:55
PHST- 2020/04/27 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/23 05:55 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1186/s12910-020-00523-0 [doi]
AID - 10.1186/s12910-020-00523-0 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 22;21(1):91. doi: 10.1186/s12910-020-00523-0.


PMID- 32962541
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201016
IS  - 1471-2954 (Electronic)
IS  - 0962-8452 (Linking)
VI  - 287
IP  - 1935
DP  - 2020 Sep 30
TI  - Navigating cross-cultural research: methodological and ethical considerations.
PG  - 20201245
LID - 10.1098/rspb.2020.1245 [doi]
AB  - The intensifying pace of research based on cross-cultural studies in the social
      sciences necessitates a discussion of the unique challenges of multi-sited
      research. Given an increasing demand for social scientists to expand their data
      collection beyond WEIRD (Western, educated, industrialized, rich and democratic) 
      populations, there is an urgent need for transdisciplinary conversations on the
      logistical, scientific and ethical considerations inherent to this type of
      scholarship. As a group of social scientists engaged in cross-cultural research
      in psychology and anthropology, we hope to guide prospective cross-cultural
      researchers through some of the complex scientific and ethical challenges
      involved in such work: (a) study site selection, (b) community involvement and
      (c) culturally appropriate research methods. We aim to shed light on some of the 
      difficult ethical quandaries of this type of research. Our recommendation
      emphasizes a community-centred approach, in which the desires of the community
      regarding research approach and methodology, community involvement, results
      communication and distribution, and data sharing are held in the highest regard
      by the researchers. We argue that such considerations are central to scientific
      rigour and the foundation of the study of human behaviour.
FAU - Broesch, Tanya
AU  - Broesch T
AD  - Department of Psychology, Simon Fraser University, BC, Canada.
FAU - Crittenden, Alyssa N
AU  - Crittenden AN
AD  - Department of Anthropology, University of Nevada, Las Vegas, NV, USA.
FAU - Beheim, Bret A
AU  - Beheim BA
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Blackwell, Aaron D
AU  - Blackwell AD
AD  - Department of Anthropology, Washington State University, Pullman, WA, USA.
FAU - Bunce, John A
AU  - Bunce JA
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Colleran, Heidi
AU  - Colleran H
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
AD  - BirthRites Independent Max Planck Research Group, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Hagel, Kristin
AU  - Hagel K
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Kline, Michelle
AU  - Kline M
AD  - Centre for Culture and Evolution, Brunel University, London, UK.
FAU - McElreath, Richard
AU  - McElreath R
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Nelson, Robin G
AU  - Nelson RG
AD  - Department of Anthropology, Santa Clara University, CA, USA.
FAU - Pisor, Anne C
AU  - Pisor AC
AD  - Department of Anthropology, Washington State University, Pullman, WA, USA.
FAU - Prall, Sean
AU  - Prall S
AD  - Department of Anthropology, University of Missouri, MO, USA.
FAU - Pretelli, Ilaria
AU  - Pretelli I
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Purzycki, Benjamin
AU  - Purzycki B
AD  - Department of the Study of Religion, Aarhus University, Aarhus, Denmark.
FAU - Quinn, Elizabeth A
AU  - Quinn EA
AD  - Department of Anthropology, Washington University, Saint Louis, MO, USA.
FAU - Ross, Cody
AU  - Ross C
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
FAU - Scelza, Brooke
AU  - Scelza B
AD  - Department of Anthropology, UCLA, Los Angeles, CA, USA.
FAU - Starkweather, Kathrine
AU  - Starkweather K
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
AD  - Department of Anthropology, University of Illinois, Chicago, USA.
FAU - Stieglitz, Jonathan
AU  - Stieglitz J
AD  - Institute for Advanced Study, Toulouse, France.
FAU - Mulder, Monique Borgerhoff
AU  - Mulder MB
AD  - Department of Human Behavior, Ecology and Culture, Max-Planck-Institute for
      Evolutionary Anthropology, Leipzig, Germany.
AD  - Department of Anthropology, University of California, Davis, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200923
PL  - England
TA  - Proc Biol Sci
JT  - Proceedings. Biological sciences
JID - 101245157
SB  - IM
MH  - *Cross-Cultural Comparison
MH  - Data Collection
MH  - Humans
MH  - Morals
MH  - Prospective Studies
PMC - PMC7542829
OTO - NOTNLM
OT  - *cross-cultural research
OT  - *ethics
OT  - *evolutionary anthropology
OT  - *psychology
EDAT- 2020/09/24 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/09/23 05:55
PHST- 2020/09/23 05:55 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1098/rspb.2020.1245 [doi]
PST - ppublish
SO  - Proc Biol Sci. 2020 Sep 30;287(1935):20201245. doi: 10.1098/rspb.2020.1245. Epub 
      2020 Sep 23.


PMID- 32962204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211217
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Linking)
VI  - 7
IP  - 9
DP  - 2020 Sep 20
TI  - Parental Attitudes toward Artificial Intelligence-Driven Precision Medicine
      Technologies in Pediatric Healthcare.
LID - E145 [pii]
LID - 10.3390/children7090145 [doi]
AB  - Precision medicine relies upon artificial intelligence (AI)-driven technologies
      that raise ethical and practical concerns. In this study, we developed and
      validated a measure of parental openness and concerns with AI-driven technologies
      in their child's healthcare. In this cross-sectional survey, we enrolled parents 
      of children <18 years in 2 rounds for exploratory (n = 418) and confirmatory (n =
      386) factor analysis. We developed a 12-item measure of parental openness to
      AI-driven technologies, and a 33-item measure identifying concerns that parents
      found important when considering these technologies. We also evaluated
      associations between openness and attitudes, beliefs, personality traits, and
      demographics. Parents (N = 804) reported mean openness to AI-driven technologies 
      of M = 3.4/5, SD = 0.9. We identified seven concerns that parents considered
      important when evaluating these technologies: quality/accuracy, privacy, shared
      decision making, convenience, cost, human element of care, and social justice. In
      multivariable linear regression, parental openness was positively associated with
      quality (beta = 0.23), convenience (beta = 0.16), and cost (beta = 0.11), as well
      as faith in technology (beta = 0.23) and trust in health information systems
      (beta = 0.12). Parental openness was negatively associated with the perceived
      importance of shared decision making (beta = -0.16) and being female (beta =
      -0.12). Developers might support parental openness by addressing these concerns
      during the development and implementation of novel AI-driven technologies.
FAU - Sisk, Bryan A
AU  - Sisk BA
AUID- ORCID: 0000-0002-2456-2476
AD  - Department of Pediatrics, Division of Hematology/Oncology, Washington University 
      School of Medicine, St. Louis, MO 63110, USA.
FAU - Antes, Alison L
AU  - Antes AL
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO
      63110, USA.
FAU - Burrous, Sara
AU  - Burrous S
AD  - Brown School, Washington University, St. Louis, MO 63130, USA.
FAU - DuBois, James M
AU  - DuBois JM
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO
      63110, USA.
LA  - eng
GR  - K01 HG008990/HG/NHGRI NIH HHS/United States
GR  - UL1 TR002345/TR/NCATS NIH HHS/United States
GR  - K01HG008990/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20200920
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC7552627
OTO - NOTNLM
OT  - artificial intelligence
OT  - biomedical technology
OT  - child health
OT  - ethics
OT  - machine learning
OT  - pediatrics
OT  - personalized medicine
OT  - precision medicine
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 01:03
PHST- 2020/08/14 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/09/23 01:03 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - children7090145 [pii]
AID - 10.3390/children7090145 [doi]
PST - epublish
SO  - Children (Basel). 2020 Sep 20;7(9). pii: children7090145. doi:
      10.3390/children7090145.


PMID- 32961658
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 19
TI  - Ethical and Societal Issues Occasioned by Xenotransplantation.
LID - E1695 [pii]
LID - 10.3390/ani10091695 [doi]
AB  - There are three sorts of issues associated with genetic engineering and, by
      implication, with xenotransplantation. These are dangers associated with the
      technology, animal welfare issues, and the claim that genetic engineering
      represents a technology that humans should not embark upon. Using the hearts of
      pigs for humans in need of transplants has been a major issue in
      xenotransplantation. There are dangers associated with such use, such as
      immunological rejection of the organ, endogenous viruses infecting the
      recipients, and issues of privacy. In addition, the issue of fair distribution of
      organs arises. Animal welfare issues also arise, most notably the living
      conditions of the donor animals, issues notably present in confinement
      agriculture. A major issue emerges from animals' being kept under conditions that
      fail to meet the needs dictated by the animals' biological and psychological
      natures. Xenotransplantation animals will be kept under deprived laboratory
      conditions that similarly fail to meet the animals' natures. This is a
      significant concern for society in general. There are also issues of "bad ethics"
      arising from scientists' disavowal of ethical concerns in science. This in turn, 
      coupled with societal ignorance of science, creates a climate for proliferation
      of religious and other non-rational concerns, such as the claim that
      xenotransplantation violates God's will. These spurious concerns can only be
      ameliorated when public understanding of science improves, and scientific
      understanding of ethics increases.
FAU - Rollin, Bernard E
AU  - Rollin BE
AD  - Department of Philosophy, Colorado State University, Fort Collins, CO 80523, USA.
LA  - eng
PT  - Journal Article
DEP - 20200919
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552641
OTO - NOTNLM
OT  - ethical issues in genetic engineering
OT  - genetic engineering
OT  - societal issues with xenotransplantation
OT  - value-free science
OT  - xenotransplantation
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
CRDT- 2020/09/23 01:01
PHST- 2020/08/28 00:00 [received]
PHST- 2020/09/10 00:00 [revised]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/09/23 01:01 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
AID - ani10091695 [pii]
AID - 10.3390/ani10091695 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Sep 19;10(9). pii: ani10091695. doi: 10.3390/ani10091695.


PMID- 32961462
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1873-491X (Electronic)
IS  - 0020-7489 (Linking)
VI  - 111
DP  - 2020 Nov
TI  - Ethical aspects of self-care: Comment on Riegel et al (2019) Self-care research: 
      Where are we now? Where are we going?
PG  - 103758
LID - S0020-7489(20)30244-3 [pii]
LID - 10.1016/j.ijnurstu.2020.103758 [doi]
FAU - Herber, Oliver Rudolf
AU  - Herber OR
AD  - Institute of General Practice (ifam), Centre for Health and Society (chs),
      Medical Faculty of Heinrich Heine University Dusseldorf, Dusseldorf, Germany.
      Moorenstr. 5, 40225 Dusseldorf, Germany. Electronic address:
      oliver.herber@med.uni-duesseldorf.de.
FAU - Krischel, Matthis
AU  - Krischel M
AD  - Department of the History, Philosophy and Ethics of Medicine, Centre for Health
      and Society (chs), Medical Faculty of Heinrich Heine University Dusseldorf,
      Dusseldorf, Germany. Moorenstr. 5, 40225 Dusseldorf, Germany. Electronic address:
      matthis.krischel@hhu.de.
FAU - Whittal, Amanda
AU  - Whittal A
AD  - Institute of General Practice (ifam), Centre for Health and Society (chs),
      Medical Faculty of Heinrich Heine University Dusseldorf, Dusseldorf, Germany.
      Moorenstr. 5, 40225 Dusseldorf, Germany. Electronic address:
      amandajean.whittal@med.uni-duesseldorf.de.
LA  - eng
PT  - Letter
DEP - 20200826
PL  - England
TA  - Int J Nurs Stud
JT  - International journal of nursing studies
JID - 0400675
SB  - IM
MH  - Humans
MH  - *Personal Autonomy
MH  - Self Care/*ethics
COIS- Declaration of Competing Interest None.
EDAT- 2020/09/23 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/09/22 20:20
PHST- 2020/08/17 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/09/22 20:20 [entrez]
AID - S0020-7489(20)30244-3 [pii]
AID - 10.1016/j.ijnurstu.2020.103758 [doi]
PST - ppublish
SO  - Int J Nurs Stud. 2020 Nov;111:103758. doi: 10.1016/j.ijnurstu.2020.103758. Epub
      2020 Aug 26.


PMID- 32961262
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 216
DP  - 2020 Dec
TI  - The strategies and techniques of drug discovery from natural products.
PG  - 107686
LID - S0163-7258(20)30216-3 [pii]
LID - 10.1016/j.pharmthera.2020.107686 [doi]
AB  - Natural products have been the main sources of new drugs. The different
      strategies have been developed to find the new drugs based on natural products.
      The traditional and ethic medicines have provided information on the therapeutic 
      effects and resulted in some notable drug discovery of natural products. The
      special activities of the medicine plants such as the side effects have inspired 
      scientists to develop the novel small molecular. The microorganisms and the
      endogenous active substances from human or animal also become the important
      approaches to the drug discovery. The tremendous progress in technology led to
      the new strategies in drug discovery from natural products. The bioinformation
      and artificial intelligence have facilitated the research and development of
      natural products. We will provide a scene of strategies and technologies for drug
      discovery from natural products in this review.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Zhang, Li
AU  - Zhang L
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China; General Office, Institute of Materia Medica,
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
      100050, China.
FAU - Song, Junke
AU  - Song J
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China.
FAU - Kong, Linglei
AU  - Kong L
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China.
FAU - Yuan, Tianyi
AU  - Yuan T
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China.
FAU - Li, Wan
AU  - Li W
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China.
FAU - Hou, Biyu
AU  - Hou B
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China.
FAU - Lu, Yang
AU  - Lu Y
AD  - Beijing Key Laboratory of Polymorphic Drug, Institute of Materia Medica, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100050,
      China.
FAU - Du, Guanhua
AU  - Du G
AD  - Beijing Key Laboratory of Drug Target Research and Drug Screening, State Key
      Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute
      of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing 100050, China. Electronic address: dugh@imm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200919
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Biological Products)
RN  - 0 (Plant Extracts)
RN  - 0 (Tissue Extracts)
SB  - IM
MH  - Animals
MH  - Artificial Intelligence
MH  - Bacteria/*chemistry
MH  - Biological Products/isolation & purification/*pharmacology/toxicity
MH  - *Drug Discovery
MH  - High-Throughput Screening Assays
MH  - Humans
MH  - Plant Extracts/isolation & purification/*pharmacology/toxicity
MH  - Tissue Extracts/*chemistry
OTO - NOTNLM
OT  - *Drug discovery
OT  - *Natural product
OT  - *Strategy
OT  - *Technique
COIS- Declaration of Competing Interest The authors declare that there are no conflicts
      of interest.
EDAT- 2020/09/23 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/09/22 20:16
PHST- 2020/08/04 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/09/17 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2020/09/22 20:16 [entrez]
AID - S0163-7258(20)30216-3 [pii]
AID - 10.1016/j.pharmthera.2020.107686 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2020 Dec;216:107686. doi: 10.1016/j.pharmthera.2020.107686. Epub 
      2020 Sep 19.


PMID- 32960811
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Debriefing as a Response to Moral Distress.
PG  - 283-289
LID - 2020313283 [pii]
AB  - There are few evidence-based interventions that have been developed that mitigate
      the negative effects of moral distress. Group debriefing is one approach that
      some clinical ethicists have adopted as a response. However, there is very little
      academic literature or empirical research that identifies best practices and
      approaches to debriefing as a response to moral distress. Our aim at the 2020
      UnConference was to share our different approaches to debriefing with other
      clinical ethicists to identify best practices or guiding principles to enhance
      our respective approaches and meet the needs of healthcare professionals. In this
      article we share an overview of our respective approaches, reflect on our
      discussion with other clinical ethicists and healthcare professionals, and
      propose foundations to move debriefing forward as an intervention to address
      moral distress in the field of clinical ethics.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Morley, Georgina
AU  - Morley G
AD  - Nursing in Ethics Program, Cleveland Clinic Center for Bioethics, Cleveland, Ohio
      USA. morleyg@ccf.org.
FAU - Shashidhara, Shilpa
AU  - Shashidhara S
AD  - Sutter Health Program in Medicine and Human Values, San Francisco, California
      USA. shashis@sutterhealth.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Empirical Research
MH  - *Ethicists
MH  - *Ethics, Clinical
MH  - Humans
MH  - *Morals
MH  - Stress, Psychological
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313283 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):283-289.


PMID- 32960810
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Variation in Clinical Ethics Fellowship Programs: Lessons from the Field.
PG  - 277-282
LID - 2020313277 [pii]
AB  - Given the enduring debate over what constitutes quality, and therefore
      appropriate training, in clinical ethics consultation, it is unsurprising that
      there is variation in the structure and content of clinical ethics fellowship
      programs. However, this variation raises questions about the value of fellowship 
      training when the ethicists that emerge from these programs might be quite
      different. The specifics of fellowship programs are largely internal. As such,
      the extent of variation and whether such variation is problematic remains
      unclear. In this article, we summarize lessons learned from discussions between
      fellows, their mentors and program directors at the 2020 Clinical Ethics
      UnConference, and outline some possible ways to advance the conversation about
      variation in fellowship programs and training. We argue for the more open sharing
      of training specifics in order to help break down the siloed nature of fellowship
      programs. Greater transparency could, firstly, allow for more robust reflection
      on and refinement of training practices and, secondly, allow us to better balance
      professionally appropriate consistency with unavoidable or desirable variation
      based on local norms, culture and leadership.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Moore, Bryanna
AU  - Moore B
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas USA. bryanna.moore@bcm.edu.
FAU - Horner, Claire
AU  - Horner C
AD  - Center for Medical Ethics and Health Policy at Baylor College of Medicine,
      Houston, Texas USA. chorner@bcm.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Ethicists
MH  - *Ethics Consultation
MH  - *Ethics, Clinical/education
MH  - *Fellowships and Scholarships
MH  - Humans
MH  - Surveys and Questionnaires
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313277 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):277-282.


PMID- 32960809
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Demonstrating Value Through Tracking Ethics Program Activities Beyond Ethics
      Consultations.
PG  - 268-276
LID - 2020313268 [pii]
AB  - Demonstrating value is an ongoing process and requirement for institutional
      survival for ethics programs. Although our ethics program has significantly
      increased our ethics consultation volume and maintains a robust database that
      tracks ethics consultation data, these data regarding ethics consultations alone 
      do not accurately represent the program's overall activities and value to the
      institution. The roles and responsibilities of clinical ethicists extend beyond
      clinical ethics consultation, and there are many other ways that clinical
      ethicists contribute and add value to their institutions. This article describes 
      our ethics program's early efforts to systematically track ethics program
      activities outside of ethics consultations as a way to demonstrate additional
      value to the institution that goes beyond ethics consultation. By systematically 
      tracking activities such as internal ethics education sessions, conference
      presentations, publications, grants, committee/policy work, and other activities,
      our ethics program has been able to gather substantial quantitative data that
      highlight our program's numerous activities and outreach, both within and outside
      the institution, that provide additional value to the institution beyond our
      ethical consultation activities.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Lee, Susannah W
AU  - Lee SW
AD  - Ethics Program, Wellstar Health System, Atlanta, Georgia USA.
      Susannah.lee@wellstar.org.
FAU - Potter, Jordan
AU  - Potter J
AD  - Wellstar Fellowship in Clinical Ethics, Wellstar Health System, Atlanta, Georgia 
      USA. jordan.potter@wellstar.org.
FAU - Matsler, Jeff S
AU  - Matsler JS
AD  - Wellstar Health System, Atlanta, Georgia, USA. jeff.matsler@wellstar.org.
FAU - Shields, Steven
AU  - Shields S
AD  - Wellstar Health System, Atlanta, Georgia, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Ethicists
MH  - *Ethics Consultation
MH  - Ethics, Clinical
MH  - Ethics, Medical
MH  - Humans
MH  - Morals
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313268 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):268-276.


PMID- 32960808
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201216
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Building an Organizational Ethics Program on a Clinical Ethics Foundation.
PG  - 259-267
LID - 2020313259 [pii]
AB  - Organizational ethics programs often are created to address tensions in
      organizational values that have been identified through repeated clinical ethics 
      consultation requests. Clinical ethicists possess some core competencies that are
      suitable for the leadership of high-quality organizational ethics programs, but
      they may need to develop new skills to build these programs, such as familiarity 
      with healthcare delivery science, healthcare financing, and quality improvement
      methodology. To this end, we suggest that clinical ethicists build organizational
      ethics programs incrementally and via quality improvement projects undertaken in 
      collaboration with senior clinical leaders. Organizational ethics programs often 
      differ from clinical ethics programs in their membership and processes, and
      likely will require ethicists to forge new partnerships with a wide array of
      organizational leaders. With attention to the ways that organizational ethics
      programs differ from clinical ethics programs, and investment in quality
      improvement methodology and formal institutional needs assessments, clinical
      ethics leaders can position an organizational ethics program to advocate
      effectively for visible and compelling alignment of leadership decision making
      with the values of the organization.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Lahey, Timothy
AU  - Lahey T
AD  - University of Vermont Medical Center, UVM's Larner College of Medicine,
      Burlington, Vermont USA. Timothy.Lahey@UVMhealth.org.
FAU - DeRenzo, Evan G
AU  - DeRenzo EG
AD  - John J. Lynch, MD, Center for Ethics, Medstar Washington Hospital Center,
      Washington, District of Columbia USA. Evan.G.Derenzo@Medstar.net.
FAU - Crites, Joshua
AU  - Crites J
AD  - Staff Ethicist, Center for Bioethics, Cleveland Clinic, Cleveland, Ohio USA.
      critesj@ccf.org.
FAU - Fanning, Joseph
AU  - Fanning J
AD  - Clinical Ethics Consultation Service and Vanderbilt University Medical Center,
      Nashville, Tennessee USA. joe.fanning@vanderbilt.edu.
FAU - Huberman, Barrie J
AU  - Huberman BJ
AD  - Division of Medical Ethics, Weill Cornell Medical College; and Medical Ethics,
      New York Presbyterian Weill Cornell Medicine, New York, New York USA.
      bjh4001@med.cornell.edu.
FAU - Slosar, John Paul
AU  - Slosar JP
AD  - Healthcare Ethics, Ascension Health, St. Louis, Missouri USA.
      jslosar@ascension.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Ethicists
MH  - *Ethics Consultation
MH  - Ethics, Clinical
MH  - *Ethics, Institutional
MH  - Humans
MH  - Leadership
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313259 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):259-267.


PMID- 32960807
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - The Ethics Ambassador Program: A Grassroots Approach.
PG  - 252-258
LID - 2020313252 [pii]
AB  - The Ethics Ambassador program at the University of Colorado Hospital was born
      from a desire to encourage earlier ethics consultation, with the goal of
      providing timely, effective, and patient-centered ethics support. The selected
      Ethics Ambassadors are individuals from multiple roles across the hospital who
      receive regular education to serve as an ethics resource for their respective
      units or specialties. As embedded individuals, they are better able to recognize 
      the unique needs and challenges of their units and provide relevant ethics
      education to staff and faculty. Outcomes of the first year of the program
      illustrated the diverse ethics needs across the hospital and the benefits of
      utilizing embedded individuals, able to straddle both the domains of ethics and
      the needs of their individual units.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Furfari, Kristin
AU  - Furfari K
AD  - Division of Hospital Medicine, University of Colorado School of Medicine, Aurora,
      Colorado USA. Kristin.Furfari@cuanschutz.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Ethics Consultation
MH  - Humans
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313252 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):252-258.


PMID- 32960806
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Clarifying and Expanding the Role of Narrative in Ethics Consultation.
PG  - 241-251
LID - 2020313241 [pii]
AB  - Understanding a patient's story is integral to providing ethically supportable
      and practical recommendations that can improve patient care. Important skills
      include how to elicit an individual's story, how to weave different narrative
      threads together, and how to assist the care team, patients, and caregivers to
      resolve difficult decisions or moral dilemmas. Narrative approaches to ethics
      consultation deepen dialogue and stakeholders' engagement to reveal important
      values, preferences, and beliefs that may prove critical in resolving care
      challenges. Recognizing barriers to narrative inquiry, such as patients who are
      unable or refuse to share their story, is also important. In this article we
      offer specific steps and guidelines that ethicists can follow to systematically
      elicit and construct patients' stories. We provide a case example to illustrate
      how a narrative approach to ethics consultation illuminates salient ethical
      issues that may otherwise go unnoticed. We argue that this approach should be
      part of every consultant's tool kit.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Childress, Andrew
AU  - Childress A
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas USA. andrew.childress@bcm.edu.
FAU - Lee, Susannah W
AU  - Lee SW
AD  - Ethics Program, Wellstar Health System, Atlanta, Georgia USA.
      Susannah.lee@wellstar.org.
FAU - Matsler, Jeff S
AU  - Matsler JS
AD  - Wellstar Health System, Atlanta, Georgia, USA. jeff.matsler@wellstar.org.
FAU - Farroni, Jeffrey S
AU  - Farroni JS
AD  - Institute for the Medical Humanities, University of Texas Medical Branch in
      Galveston, Texas USA. jsfarron@utmb.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Ethicists
MH  - *Ethics Consultation
MH  - Ethics, Clinical
MH  - Humans
MH  - Morals
MH  - Narration
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313241 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):241-251.


PMID- 32960805
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - The Top 10 Questions Facing the Field of Clinical Ethics in 2020: Reflections on 
      the Evolving Clinical Ethics UnConference.
PG  - 233-240
LID - 2020313233 [pii]
AB  - Evolving Clinical Ethics: A Working UnConference, held 5 through 7 February 2020 
      in Houston, Texas, brought together 91 participants from a variety of
      institutions, many of whom are engaged in clinical ethics work. The event
      followed the success of the first Clinical Ethics UnConference hosted by the
      Cleveland Clinic Center for Bioethics in 2018, and offered an opportunity for
      ethicists to share both their challenges and their solutions to clinical ethics
      issues. In this article we explore the emerging themes of the second UnConference
      and identify the top 10 questions currently faced by the field. We address both
      unresolved issues and areas of agreement and highlight new collaborations that
      have been developed to work toward greater standardization in our field.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Malek, Janet
AU  - Malek J
AD  - Baylor College of Medicine Center for Medical Ethics and Health Policy, and the
      Houston Methodist Biomedical Ethics Program, Houston, Texas USA.
      Janet.Malek@bcm.edu.
FAU - Horner, Claire
AU  - Horner C
AD  - Center for Medical Ethics and Health Policy at Baylor College of Medicine,
      Houston, Texas USA. chorner@bcm.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Bioethics
MH  - Ethicists
MH  - *Ethics, Clinical
MH  - Ethics, Medical
MH  - Humans
MH  - Texas
EDAT- 2020/09/23 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/22 17:11
PHST- 2020/09/22 17:11 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 2020313233 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):233-240.


PMID- 32960411
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Surrogates and Artificial Intelligence: Why AI Trumps Family.
PG  - 3217-3227
LID - 10.1007/s11948-020-00266-6 [doi]
AB  - The increasing accuracy of algorithms to predict values and preferences raises
      the possibility that artificial intelligence technology will be able to serve as 
      a surrogate decision-maker for incapacitated patients. Following Camillo Lamanna 
      and Lauren Byrne, we call this technology the autonomy algorithm (AA). Such an
      algorithm would mine medical research, health records, and social media data to
      predict patient treatment preferences. The possibility of developing the AA
      raises the ethical question of whether the AA or a relative ought to serve as
      surrogate decision-maker in cases where the patient has not issued a medical
      power of attorney. We argue that in such cases, and against the standard practice
      of vesting familial surrogates with decision making authority, the AA should have
      sole decision-making authority. This is because the AA will likely be better at
      predicting what treatment option the patient would have chosen. It would also be 
      better at avoiding bias and, therefore, choosing in a more patient-centered
      manner. Furthermore, we argue that these considerations override any moral weight
      of the patient's special relationship with their relatives.
FAU - Hubbard, Ryan
AU  - Hubbard R
AUID- ORCID: http://orcid.org/0000-0003-2881-7138
AD  - Philosophy Department, Gulf Coast State College, Panama City, FL, USA.
      Rhubbard2@gulfcoast.edu.
FAU - Greenblum, Jake
AU  - Greenblum J
AD  - University of Texas Rio Grande Valley, Edinburg, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - *Decision Making
MH  - Humans
MH  - Morals
MH  - Patient Preference
OTO - NOTNLM
OT  - Artificial intelligence (AI)
OT  - Biomedical
OT  - Decision-making
OT  - Ethics
OT  - Surrogate
EDAT- 2020/09/23 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/22 12:13
PHST- 2020/03/15 00:00 [received]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/22 12:13 [entrez]
AID - 10.1007/s11948-020-00266-6 [doi]
AID - 10.1007/s11948-020-00266-6 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3217-3227. doi: 10.1007/s11948-020-00266-6. Epub
      2020 Sep 22.


PMID- 32960103
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1545-5882 (Electronic)
IS  - 0145-9740 (Linking)
VI  - 39
IP  - 7
DP  - 2020 Oct
TI  - "Making Medicine" with Salvia divinorum: Competing Approaches and Their
      Implications.
PG  - 582-596
LID - 10.1080/01459740.2020.1814772 [doi]
AB  - The psychoactive plant Salvia divinorum has long been used medicinally by
      Indigenous people from southern Mexico, the only place where it is endemic, and
      is now studied by pharmaceutical researchers. I analyze competing ways the two
      groups "make medicine" with salvia, attending simultaneously to material/embodied
      and semiotic/linguistic dimensions of those practices. I introduce two concepts -
      stripping and enrobing - to show that differences in how the groups interact with
      salvia have ethical and political consequences. Those repercussions matter
      because salvia is but one of many plants important to marginalized groups whose
      ties to them are threatened by international medical interests.
FAU - Faudree, Paja
AU  - Faudree P
AUID- ORCID: 0000-0002-5802-7391
AD  - Department of Anthropology, Brown University , Providence, RI, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200922
PL  - United States
TA  - Med Anthropol
JT  - Medical anthropology
JID - 7707343
RN  - 0 (Plant Preparations)
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Anthropology, Medical
MH  - Humans
MH  - *Medicine, Traditional
MH  - Mexico/ethnology
MH  - Plant Preparations
MH  - *Plants, Medicinal
MH  - *Psychotropic Drugs
MH  - *Salvia
OTO - NOTNLM
OT  - *Mexico
OT  - *language
OT  - *medicinal practice
OT  - *pharmaceutical research
OT  - *psychoactive plants
OT  - *salvia divinorum
EDAT- 2020/09/23 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/09/22 12:10
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/09/22 12:10 [entrez]
AID - 10.1080/01459740.2020.1814772 [doi]
PST - ppublish
SO  - Med Anthropol. 2020 Oct;39(7):582-596. doi: 10.1080/01459740.2020.1814772. Epub
      2020 Sep 22.


PMID- 32959801
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20210927
IS  - 2384-8553 (Electronic)
IS  - 0021-2571 (Linking)
VI  - 56
IP  - 3
DP  - 2020 Jul-Sep
TI  - Male circumcision: ritual, science and responsibility.
PG  - 351-358
LID - 10.4415/ANN_20_03_13 [doi]
AB  - INTRODUCTION AND OBJECTIVES: In Italy, four minors have died in the last year as 
      a result of male circumcision (MC) procedures performed for cultural and
      religious reasons by unqualified persons in unhygienic conditions. RESULTS AND
      DISCUSSION: After illustrating the historical and ethical outlines of the moral
      admissibility of MC within a comparative perspective, we examine the features of 
      the Italian healthcare system with particular regard both to the heterogeneity of
      services available in the various Regions and to the risks engendered by
      excluding MC from the public health setting. CONCLUSION: In order to adequately
      safeguard public health, particularly that of minors, there is a pressing need
      for thorough discussion of whether the National Health Service should perform MC 
      on minors free of charge or, at least, for a reduced fee. The implementation of
      targeted campaigns may raise awareness of the importance of proper safety
      measures in MC.
FAU - Ventura, Francesco
AU  - Ventura F
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Genova, Genoa,
      Italy.
FAU - Caputo, Fiorella
AU  - Caputo F
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Genova, Genoa,
      Italy.
FAU - Licata, Marta
AU  - Licata M
AD  - Dipartimento di Biotecnologie e Scienze della Vita, Universita degli Studi
      dell'Insubria, Varese, Italy Abstract.
FAU - Bonsignore, Alessandro
AU  - Bonsignore A
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Genova, Genoa,
      Italy.
FAU - Ciliberti, Rosagemma
AU  - Ciliberti R
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Genova, Genoa,
      Italy.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - Italy
TA  - Ann Ist Super Sanita
JT  - Annali dell'Istituto superiore di sanita
JID - 7502520
SB  - IM
MH  - *Ceremonial Behavior
MH  - Child, Preschool
MH  - Circumcision, Male/*adverse effects/ethics/history/legislation & jurisprudence
MH  - Diseases in Twins
MH  - Evidence-Based Medicine
MH  - Health Education
MH  - History, 19th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Italy/epidemiology
MH  - Male
MH  - Motivation
MH  - Parental Consent
MH  - Penile Diseases/prevention & control
MH  - Public Health
MH  - Religion and Medicine
MH  - *Social Responsibility
MH  - Wound Infection/etiology/mortality
EDAT- 2020/09/23 06:00
MHDA- 2021/09/28 06:00
CRDT- 2020/09/22 08:40
PHST- 2020/09/22 08:40 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
AID - 10.4415/ANN_20_03_13 [doi]
PST - ppublish
SO  - Ann Ist Super Sanita. 2020 Jul-Sep;56(3):351-358. doi: 10.4415/ANN_20_03_13.


PMID- 32959789
OWN - NLM
STAT- MEDLINE
DCOM- 20210826
LR  - 20210826
IS  - 2384-8553 (Electronic)
IS  - 0021-2571 (Linking)
VI  - 56
IP  - 3
DP  - 2020 Jul-Sep
TI  - The increasing need for a new Italian legislation to facilitate execution of
      observational studies assuring ethics and the highest standards of scientific and
      methodological quality. Editorial.
PG  - 257-259
LID - 10.4415/ANN_20_03_01 [doi]
FAU - Petrini, Carlo
AU  - Petrini C
AD  - Unita di Bioetica, Istituto Superiore di Sanita, Rome, Italy.
FAU - Fiori, Giovanni
AU  - Fiori G
AD  - Societa Italiana di Medicina Farmaceutica - MediNeos, Modena, Italy.
FAU - Gussoni, Gualberto
AU  - Gussoni G
AD  - FADOI Societa Scientifica di Medicina Interna, Milan, Italy.
FAU - Cazzaniga, Sara
AU  - Cazzaniga S
AD  - Societa Italiana di Medicina Farmaceutica - Janssen Cilag, Cologno Monzese,
      Italy.
FAU - Corrao, Giovannni
AU  - Corrao G
AD  - Centro di Ricerca Interuniversitario Healthcare Research & Pharmacoepidemiology, 
      Universita degli Studi di Milano Bicocca, Milan, Italy.
FAU - Lovato, Valeria
AU  - Lovato V
AD  - Societa Italiana di Medicina Farmaceutica - Roche, Monza, Italy.
FAU - Manfellotto, Dario
AU  - Manfellotto D
AD  - FADOI Societa Scientifica di Medicina Interna - Dipartimento delle Discipline
      Mediche, Ospedale San Giovanni Calibita Fatebenefratelli, Rome, Italy.
FAU - Mastromauro, Francesca
AU  - Mastromauro F
AD  - Societa Italiana di Medicina Farmaceutica - AstraZeneca, Basiglio, Italy.
FAU - Mugelli, Alessandro
AU  - Mugelli A
AD  - Societa Italiana di Farmacologia - Universita degli Studi di Firenze, Florence,
      Italy.
LA  - eng
PT  - Editorial
PL  - Italy
TA  - Ann Ist Super Sanita
JT  - Annali dell'Istituto superiore di sanita
JID - 7502520
SB  - IM
MH  - Humans
MH  - Italy
MH  - Observational Studies as Topic/*ethics/*legislation & jurisprudence/methods
EDAT- 2020/09/23 06:00
MHDA- 2021/08/27 06:00
CRDT- 2020/09/22 08:40
PHST- 2020/09/22 08:40 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/08/27 06:00 [medline]
AID - 10.4415/ANN_20_03_01 [doi]
PST - ppublish
SO  - Ann Ist Super Sanita. 2020 Jul-Sep;56(3):257-259. doi: 10.4415/ANN_20_03_01.


PMID- 32959006
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220220
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - COVID-19 vaccine: vaccinate the young to protect the old?
PG  - lsaa050
LID - 10.1093/jlb/lsaa050 [doi]
AB  - When we have a vaccine against COVID-19, who should be vaccinated first? The
      question is relevant because, initially, vaccine availability will likely be
      limited. After healthcare and some other essential workers, it might seem the
      most obvious candidates are the elderly and other groups that are more vulnerable
      to the virus. However, we argue that this is not necessarily the case. Protecting
      the most vulnerable might require prioritizing vaccinating children in order to
      maximize the benefits of indirect immunity for the elderly and the other
      vulnerable groups. Whether this will be the best strategy from a public health
      perspective will depend on characteristics of the vaccine and of the virus, which
      are currently unknown. Here, we assess this possibility from an ethical point of 
      view, by drawing comparisons and analogies with the case of the flu vaccination
      and with other examples of health policies and practices. We conclude that there 
      are strong ethical reasons to vaccinate the young to protect the old, provided
      that the risks imposed on children are reasonable, even if that implies using
      children as a means to protect the elderly and the vulnerable.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Giubilini, Alberto
AU  - Giubilini A
AUID- ORCID: 0000-0001-5163-3017
AD  - Oxford Uehiro Centre for Practical Ethics and Wellcome Centre for Ethics and
      Humanities, University of Oxford, Oxford, UK.
FAU - Savulescu, Julian
AU  - Savulescu J
AUID- ORCID: 0000-0003-1691-6403
AD  - Oxford Uehiro Centre for Practical Ethics and Wellcome Centre for Ethics and
      Humanities, University of Oxford, Oxford, UK.
AD  - Melbourne Law School, University of Melbourne, Victoria, Australia.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AD  - Oxford Uehiro Centre for Practical Ethics and Wellcome Centre for Ethics and
      Humanities, University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200626
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7337759
OTO - NOTNLM
OT  - COVID-19
OT  - prioritization
OT  - resource allocation
OT  - vaccination
EDAT- 2020/09/23 06:00
MHDA- 2020/09/23 06:01
CRDT- 2020/09/22 05:42
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/09/22 05:42 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/09/23 06:01 [medline]
AID - 10.1093/jlb/lsaa050 [doi]
AID - lsaa050 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 26;7(1):lsaa050. doi: 10.1093/jlb/lsaa050. eCollection
      2020 Jan-Jun.


PMID- 32958945
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 586
IP  - 7827
DP  - 2020 Oct
TI  - The US National Academy of Sciences can now kick out harassers. So why hasn't it?
PG  - 15-16
LID - 10.1038/d41586-020-02640-7 [doi]
FAU - Viglione, Giuliana
AU  - Viglione G
LA  - eng
PT  - News
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - National Academy of Sciences, U.S./*organization & administration
MH  - Research Personnel/*ethics
MH  - Sexual Harassment/*legislation & jurisprudence/*prevention & control
MH  - United States
OTO - NOTNLM
OT  - *Ethics
OT  - *Institutions
OT  - *Policy
OT  - *Scientific community
EDAT- 2020/09/23 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/09/22 05:41
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/09/22 05:41 [entrez]
AID - 10.1038/d41586-020-02640-7 [doi]
AID - 10.1038/d41586-020-02640-7 [pii]
PST - ppublish
SO  - Nature. 2020 Oct;586(7827):15-16. doi: 10.1038/d41586-020-02640-7.


PMID- 32958695
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 21
TI  - A stakeholder meeting exploring the ethical perspectives of immediately
      sequential bilateral cataract surgery.
LID - medethics-2020-106412 [pii]
LID - 10.1136/medethics-2020-106412 [doi]
AB  - PURPOSE: The purported benefits and risks of immediately sequential bilateral
      cataract surgery (ISBCS) have been well described, yet the procedure remains
      controversial among UK ophthalmologists. As many of the controversies of ISBCS
      are underpinned by ethical dilemmas, the aim of this work was to explore the
      ethical perspectives of ISBCS from a variety of stakeholder viewpoints. METHOD: A
      semi-structured independent stakeholder meeting was convened at the Royal College
      of Ophthalmologists London headquarters in June 2018. In total, 29 stakeholders
      attended the meeting. The professional characteristics of stakeholders included
      but were not limited to: ophthalmologists (9), patients (5), religious leaders
      (4), ethicists (2), lawyers (2) and commissioners (1). Thematic qualitative
      analysis using methodology proposed by Braun and Clarke was conducted on the
      resultant transcript of the discussion. RESULTS: Themes identified include: (1)
      beneficence and non-maleficence (patient benefits, patient risks, the
      uncertainties of risk, patient interpretation of the risk-benefit analysis); (2) 
      autonomy (informed consent, the barriers to communication); (3) distributive
      justice (the allocation of resources: the individual vs the collective).
      CONCLUSION: This analysis provides a reference point for the ethical factors
      surrounding ISBCS. The stakeholders concluded that this approach was an ethical
      undertaking provided patient autonomy was appropriately attained. This requires a
      patient's interpretation of the risk-benefit balance, which must include an
      understanding of the low but unquantifiable risk of severe complications. A
      surgeon must aim to minimise risks through the adaption of accepted surgical
      protocols and by performing appropriate patient selection. Currently, cost
      savings to healthcare that may occur following the implementation of ISBCS should
      be considered a secondary benefit of the protocol.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Quinn, Matthew
AU  - Quinn M
AUID- ORCID: http://orcid.org/0000-0002-8877-5024
AD  - Royal United Hospital Bath NHS Trust, Bath and North East Somerset, Bath, UK.
FAU - Gray, Daniel
AU  - Gray D
AD  - School of Social Sciences, Cardiff University, Cardiff, UK.
FAU - Bardan, Ahmed Shalaby
AU  - Bardan AS
AD  - Sussex Eye Hospital, Brighton and Sussex University Hospitals NHS Trust,
      Brighton, East Sussex, UK.
FAU - Zarei-Ghanavati, Mehran
AU  - Zarei-Ghanavati M
AUID- ORCID: http://orcid.org/0000-0002-0679-8055
AD  - Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, The Islamic
      Republic of Iran.
FAU - Sparrow, John
AU  - Sparrow J
AD  - Bristol Eye Hospital, University Hospitals Bristol NHS Trust, Bristol, Somerset, 
      UK.
FAU - Liu, Christopher
AU  - Liu C
AUID- ORCID: http://orcid.org/0000-0002-1045-196X
AD  - Sussex Eye Hospital, Brighton and Sussex University Hospitals NHS Trust,
      Brighton, East Sussex, UK cscliu@aol.com.
AD  - Brighton and Sussex Medical School, Brighton, United Kingdom.
AD  - Tongdean Eye Clinic, Hove, United Kingdom.
LA  - eng
GR  - RP-PG-0611-20013/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639900
OTO - NOTNLM
OT  - autonomy
OT  - ethics
OT  - informed consent
OT  - patient perspective
OT  - surgery
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/09/22 05:37
PHST- 2020/05/07 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
PHST- 2020/09/22 05:37 [entrez]
AID - medethics-2020-106412 [pii]
AID - 10.1136/medethics-2020-106412 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 21. pii: medethics-2020-106412. doi:
      10.1136/medethics-2020-106412.


PMID- 32958694
OWN - NLM
STAT- Publisher
LR  - 20210724
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 21
TI  - Non-maleficence and the ethics of consent to cancer screening.
LID - medethics-2020-106135 [pii]
LID - 10.1136/medethics-2020-106135 [doi]
AB  - Cancer screening programmes cause harm to individuals via overdiagnosis and
      overtreatment, even where they confer population-level benefit. Screening thus
      appears to violate the principle of non-maleficence, since it entails medically
      unnecessary harm to individuals. Can consent to screening programmes negate the
      moral significance of this harm? In therapeutic medical contexts, consent is used
      as a means of rendering medical harm morally permissible. However, in this paper,
      I argue that it is unclear that the model of consent used within therapeutic
      medicine can be applied unproblematically to preventive medicine. Invitation to
      screening changes the pragmatic norms and expectations of the patient-doctor
      encounter such that two key principles of consent may be violated. First, the
      pragmatics of a medical invitation are such that patients may fail to be
      adequately informed, since patients appear to assume medical invitations are made
      with their best interests in mind, even where information to the contrary is
      outlined. Second, screening invitations may place pressure on patients; in the
      context of a medical encounter, to make an invitation to screening may constitute
      an inducement to accept. In order to be sure that a patient's consent to a
      screening invitation is valid, we must make clear to patients that their decision
      to accept screening may be shaped not only by how information about screening is 
      presented, but by the pragmatic form of the invitation itself.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Elton, Lotte
AU  - Elton L
AUID- ORCID: http://orcid.org/0000-0003-4621-9131
AD  - History and Philosophy and Science, University of Cambridge, Cambridge, UK
      lotteelton@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8257550
OTO - NOTNLM
OT  - autonomy
OT  - clinical ethics
OT  - informed consent
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/09/22 05:37
PHST- 2020/02/06 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/22 05:37 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - medethics-2020-106135 [pii]
AID - 10.1136/medethics-2020-106135 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 21. pii: medethics-2020-106135. doi:
      10.1136/medethics-2020-106135.


PMID- 32958693
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220814
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Ethics of sharing medical knowledge with the community: is the physician
      responsible for medical outreach during a pandemic?
PG  - 732-735
LID - 10.1136/medethics-2020-106348 [doi]
AB  - A recent update to the Geneva Declaration's 'Physician Pledge' involves the
      ethical requirement of physicians to share medical knowledge for the benefit of
      patients and healthcare. With the spread of COVID-19, pockets exist in every
      country with different viral expressions. In the Chareidi ('ultra-orthodox')
      religious community, for example, rates of COVID-19 transmission and
      dissemination are above average compared with other communities within the same
      countries. While viral spread in densely populated communities is common during
      pandemics, several reasons have been suggested to explain the blatant flouting of
      public health regulations. It is easy to fault the Chareidi population for their 
      proliferation of COVID-19, partly due to their avoidance of social media and
      internet aversion. However, the question remains: who is to blame for their
      community crisis? The ethical argument suggests that from a public health
      perspective, the physician needs to reach out and share medical knowledge with
      the community. The public's best interests are critical in a pandemic and should 
      supersede any considerations of cultural differences. By all indications,
      therefore, the physician has an ethical obligation to promote population
      healthcare and share medical knowledge based on ethical concepts of beneficence, 
      non-maleficence, utilitarian ethics as well as social, procedural and
      distributive justice. This includes the ethical duty to reduce health disparities
      and convey the message that individual responsibility for health has
      repercussions within the context of broader social accountability. Creative
      channels are clearly demanded for this ethical challenge, including measured
      medical paternalism with appropriate cultural sensitivity in physician community 
      outreach.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Strous, Rael D
AU  - Strous RD
AUID- ORCID: http://orcid.org/0000-0002-2287-1726
AD  - Department of Psychiatry, Mayanei HaYeshua Medical Center, Bnei Brak, Tel Aviv,
      Israel raels@tauex.tau.ac.il.
AD  - Department of Psychiatry, Tel Aviv University Sackler Faculty of Medicine, Tel
      Aviv, Israel.
FAU - Karni, Tami
AU  - Karni T
AD  - Department of Surgery, Yitzhak Shamir Medical Center, Zerifin, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2022 Jul;48(7):495-496. PMID: 34103368
MH  - Access to Information
MH  - Beneficence
MH  - Betacoronavirus
MH  - COVID-19
MH  - Codes of Ethics
MH  - Coronavirus Infections/epidemiology/prevention & control/virology
MH  - Cultural Competency
MH  - Culture
MH  - Ethical Theory
MH  - Health Education/*ethics
MH  - Health Equity
MH  - Health Promotion/ethics
MH  - Humans
MH  - Internet
MH  - *Moral Obligations
MH  - Pandemics/*ethics/prevention & control
MH  - Paternalism
MH  - Physicians/*ethics
MH  - Pneumonia, Viral/epidemiology/prevention & control/virology
MH  - *Professional Role
MH  - Public Health/ethics
MH  - Religion
MH  - SARS-CoV-2
MH  - Social Justice
MH  - *Social Responsibility
PMC - PMC7507248
OTO - NOTNLM
OT  - education
OT  - health promotion
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/22 05:37
PHST- 2020/04/24 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/09/22 05:37 [entrez]
AID - medethics-2020-106348 [pii]
AID - 10.1136/medethics-2020-106348 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):732-735. doi: 10.1136/medethics-2020-106348. Epub
      2020 Sep 21.


PMID- 32958692
OWN - NLM
STAT- Publisher
LR  - 20200922
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 21
TI  - Aligning patient and physician views on educational pelvic examinations under
      anaesthesia: the medical student perspective.
LID - medethics-2020-106473 [pii]
LID - 10.1136/medethics-2020-106473 [doi]
AB  - Recent media articles have stirred controversy over anecdotal reports of medical 
      students practising educational pelvic examinations on women under anaesthesia
      without explicit consent. The understandable public outrage that followed merits 
      a substantive response from the medical community. As medical students, we offer 
      a unique perspective on consent for trainee involvement informed by the
      transitional stage we occupy between patient and physician. We start by
      contextualising the role of educational pelvic examinations under anaesthesia
      (EUAs) within general clinical skill development in medical education. Then we
      analyse two main barriers to achieving explicit consent for educational pelvic
      EUAs: ambiguity within professional guidelines on how to operationalize 'explicit
      consent' and divergent patient and physician perspectives on harm which prevent
      physicians from understanding what a reasonable patient would want to know before
      a procedure. To overcome these barriers, we advocate for more research on patient
      perspectives to empower the reasonable patient standard. Next, we call for
      minimum disclosure standards informed by this research and created in conjunction
      with students, physicians and patients to improve the informed consent process
      and relieve medical student moral injury caused by performing 'unconsented'
      educational pelvic exams.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Salwi, Sanjana
AU  - Salwi S
AD  - Medical Ethics Law and Policy Student Group, Vanderbilt University, Nashville,
      TN, USA sanjana.salwi@vanderbilt.edu.
AD  - School of Medicine, Vanderbilt University School of Medicine, Nashville,
      Tennessee, USA.
FAU - Erath, Alexandra
AU  - Erath A
AD  - Medical Ethics Law and Policy Student Group, Vanderbilt University, Nashville,
      TN, USA.
AD  - School of Medicine, Vanderbilt University School of Medicine, Nashville,
      Tennessee, USA.
FAU - Patel, Pious D
AU  - Patel PD
AD  - School of Medicine, Vanderbilt University School of Medicine, Nashville,
      Tennessee, USA.
FAU - Kaur, Karampreet
AU  - Kaur K
AD  - School of Medicine, Vanderbilt University School of Medicine, Nashville,
      Tennessee, USA.
FAU - Mitchell, Margaret B
AU  - Mitchell MB
AD  - Medical Ethics Law and Policy Student Group, Vanderbilt University, Nashville,
      TN, USA.
AD  - School of Medicine, Vanderbilt University School of Medicine, Nashville,
      Tennessee, USA.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - education for health care professionals
OT  - ethics
OT  - informed consent
OT  - obstetrics and gynaecology
OT  - patient perspective
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/09/22 05:37
PHST- 2020/05/18 00:00 [received]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/08/02 00:00 [accepted]
PHST- 2020/09/22 05:37 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - medethics-2020-106473 [pii]
AID - 10.1136/medethics-2020-106473 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 21. pii: medethics-2020-106473. doi:
      10.1136/medethics-2020-106473.


PMID- 32958496
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Prevalence of non-contrast CT abnormalities in adults with reversible cerebral
      vasoconstriction syndrome: protocol for a systematic review and meta-analysis.
PG  - e041776
LID - 10.1136/bmjopen-2020-041776 [doi]
AB  - INTRODUCTION: Reversible cerebral vasoconstriction syndrome (RCVS) is
      characterised by severe, recurrent thunderclap headaches (TCHs) and
      vasoconstriction of cerebral arteries that resolve within 3 months. Abnormalities
      on non-contrast CT (NCCT) such as ischaemic strokes, intracerebral haemorrhage
      and subarachnoid haemorrhages are frequently observed on brain imaging of
      patients with RCVS though their prevalence varies considerably between studies.
      The aim of this systematic review and meta-analysis is to estimate the prevalence
      of NCCT abnormalities seen on neuroimaging of adult patients with RCVS. METHODS
      AND ANALYSIS: We will search the Medline, Embase and the Cochrane Library
      databases for studies on the prevalence of NCCT abnormalities on neuroimaging of 
      patients with RCVS. Search results will be screened for eligibility by title and 
      abstract. Suitable studies will be fully reviewed and relevant data extracted
      using a data abstraction form. The studies will be assessed for methodological
      quality, risk of bias and heterogeneity. Prevalence estimates across studies will
      be pooled using a random-effects model and subgroup analysis will be performed to
      assess the impact of age, sex, publication year and study design on prevalence of
      vascular lesions. Sensitivity analysis will be used to investigate the robustness
      of the findings. This protocol has been devised using the Preferred Reporting
      Items for Systematic Review and Meta-Analysis Protocols 2015 checklist. ETHICS
      AND DISSEMINATION: Formal ethics is not required as primary data will not be
      collected. The findings of this study will be disseminated through a
      peer-reviewed publication and conference presentations. TRIAL REGISTRATION
      NUMBER: CRD42020190637.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gotesman, Ryan Daniel
AU  - Gotesman RD
AUID- ORCID: 0000-0002-9920-3304
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
      rgote014@uottawa.ca.
FAU - Niznick, Naomi
AU  - Niznick N
AUID- ORCID: 0000-0003-0935-9135
AD  - Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Dewar, Brian
AU  - Dewar B
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Shorr, Risa
AU  - Shorr R
AD  - Learning Services, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Shamy, Michel
AU  - Shamy M
AD  - Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Dowlatshahi, Dar
AU  - Dowlatshahi D
AD  - Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cerebral Hemorrhage
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Prevalence
MH  - *Stroke
MH  - Systematic Reviews as Topic
MH  - Tomography, X-Ray Computed
MH  - *Vasoconstriction
PMC - PMC7507847
OTO - NOTNLM
OT  - *adult neurology
OT  - *computed tomography
OT  - *neurology
OT  - *neuroradiology
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041776 [pii]
AID - 10.1136/bmjopen-2020-041776 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e041776. doi: 10.1136/bmjopen-2020-041776.


PMID- 32958495
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201210
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the 
      safety and efficacy of treatments for COVID-19 in hospitalised adults.
PG  - e041437
LID - 10.1136/bmjopen-2020-041437 [doi]
AB  - INTRODUCTION: To find effective and safe treatments for COVID-19, the WHO
      recommended to systemically evaluate experimental therapeutics in collaborative
      randomised clinical trials. As COVID-19 was spreading in Europe, the French
      national institute for Health and Medical Research (Inserm) established a
      transdisciplinary team to develop a multi-arm randomised controlled trial named
      DisCoVeRy. The objective of the trial is to evaluate the clinical efficacy and
      safety of different investigational re-purposed therapeutics relative to Standard
      of Care (SoC) in patients hospitalised with COVID-19. METHODS AND ANALYSIS:
      DisCoVeRy is a phase III, open-label, adaptive, controlled, multicentre clinical 
      trial in which hospitalised patients with COVID-19 in need of oxygen therapy are 
      randomised between five arms: (1) a control group managed with SoC and four
      therapeutic arms with re-purposed antiviral agents: (2) remdesivir + SoC, (3)
      lopinavir/ritonavir + SoC, (4) lopinavir/ritonavir associated with interferon
      (IFN)-beta-1a + SoC and (5) hydroxychloroquine + SoC. The primary endpoint is the
      clinical status at Day 15 on the 7-point ordinal scale of the WHO Master Protocol
      (V.3.0, 3 March 2020). This trial involves patients hospitalised in conventional 
      departments or intensive care units both from academic or non-academic hospitals 
      throughout Europe. A sample size of 3100 patients (620 patients per arm) is
      targeted. This trial has begun on 22 March 2020. Since 5 April 2020, DisCoVeRy
      has been an add-on trial of the Solidarity consortium of trials conducted by the 
      WHO in Europe and worldwide. On 8 June 2020, 754 patients have been included.
      ETHICS AND DISSEMINATION: Inserm is the sponsor of DisCoVeRy. Ethical approval
      has been obtained from the institutional review board on 13 March 2020
      (20.03.06.51744) and from the French National Agency for Medicines and Health
      Products (ANSM) on 9 March 2020. Results will be submitted for publication in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04315948 Eudra-CT
      2020-000936-23.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ader, Florence
AU  - Ader F
AD  - Infectious and tropical diseases department, Centre Hospitalier Universitaire de 
      Lyon, F-69004 Lyon, and Inserm 1111-Centre International de Recherche en
      Infectiologie (CIRI), Universite Claude Bernard Lyon 1, CNRS, UMR5308, Ecole
      Normale Superieure de Lyon, Univ Lyon, F-69007, Lyon, France
      florence.ader@chu-lyon.fr.
CN  - Discovery French Trial Management Team
LA  - eng
SI  - ClinicalTrials.gov/NCT04315948
SI  - EudraCT/Eudra-CT 2020-000936-23
PT  - Adaptive Clinical Trial
PT  - Clinical Trial Protocol
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (lopinavir-ritonavir drug combination)
RN  - 2494G1JF75 (Lopinavir)
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - O3J8G9O825 (Ritonavir)
RN  - OF5P57N2ZX (Alanine)
RN  - XRO4566Q4R (Interferon beta-1a)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adenosine Monophosphate/*analogs & derivatives/therapeutic use
MH  - Adult
MH  - Alanine/*analogs & derivatives/therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/therapy
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Early Warning Score
MH  - Extracorporeal Membrane Oxygenation
MH  - Hospital Mortality
MH  - Hospitalization
MH  - Humans
MH  - Hydroxychloroquine/*therapeutic use
MH  - Interferon beta-1a/*therapeutic use
MH  - Length of Stay
MH  - Lopinavir/*therapeutic use
MH  - Oxygen Inhalation Therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/therapy
MH  - Respiration, Artificial
MH  - Ritonavir/*therapeutic use
MH  - SARS-CoV-2
MH  - Standard of Care
MH  - Treatment Outcome
PMC - PMC7507250
OTO - NOTNLM
OT  - *clinical trials
OT  - *infectious diseases
OT  - *intensive & critical care
OT  - *public health
OT  - *respiratory infections
COIS- Competing interests: Francois-Xavier Lescure reports fees for development of
      educational presentations from Gilead, outside the submitted work. Dominique
      Costagliola reports personal fees from Merck Switzerland, grants and personal
      fees from MSD France, personal fees from Gilead France, grants and personal fees 
      from Janssen, outside the submitted work. Jean-Francois Timsit reports grants and
      personal fees from Merck, grants and personal fees from Pfizer, grants from
      biomerieux, personal fees from medimune, personal fees from Paratek, personal
      fees from Gilead, outside the submitted work. Benjamin Hamze reports personal
      fees from Sanofi, outside the submitted work. Gilles Peytavin has received travel
      grants, consultancy fees, honoraria, or study grants from various pharmaceutical 
      companies, including Gilead Sciences, Merck, TheraTechnologies and ViiV
      Healthcare. France Mentre reports grants and personal fees from Sanofi, outside
      the submitted work.
IR  - Yazdanpanah Y
FIR - Yazdanpanah, Yazdan
IR  - Mentre F
FIR - Mentre, France
IR  - Peiffer-Smadja N
FIR - Peiffer-Smadja, Nathan
IR  - Lescure FX
FIR - Lescure, Francois-Xavier
IR  - Poissy J
FIR - Poissy, Julien
IR  - Bouadma L
FIR - Bouadma, Lila
IR  - Timsit JF
FIR - Timsit, Jean-Francois
IR  - Lina B
FIR - Lina, Bruno
IR  - Morfin-Sherpa F
FIR - Morfin-Sherpa, Florence
IR  - Bouscambert M
FIR - Bouscambert, Maude
IR  - Gaymard A
FIR - Gaymard, Alexandre
IR  - Peytavin G
FIR - Peytavin, Gilles
IR  - Abel L
FIR - Abel, Laurent
IR  - Guedj J
FIR - Guedj, Jeremie
IR  - Andrejak C
FIR - Andrejak, Claire
IR  - Burdet C
FIR - Burdet, Charles
IR  - Laouenan C
FIR - Laouenan, Cedric
IR  - Belhadi D
FIR - Belhadi, Drifa
IR  - Dupont A
FIR - Dupont, Axelle
IR  - Alfaiate T
FIR - Alfaiate, Toni
IR  - Basli B
FIR - Basli, Basma
IR  - Chair A
FIR - Chair, Anissa
IR  - Laribi S
FIR - Laribi, Samira
IR  - Level J
FIR - Level, Julie
IR  - Schneider M
FIR - Schneider, Marion
IR  - Tellier MC
FIR - Tellier, Marie-Capucine
IR  - Dechanet A
FIR - Dechanet, Aline
IR  - Costagliola D
FIR - Costagliola, Dominique
IR  - Couffin-Cadiergues S
FIR - Couffin-Cadiergues, Sandrine
IR  - Esperou H
FIR - Esperou, Helene
IR  - Delmas C
FIR - Delmas, Christelle
IR  - Saillard J
FIR - Saillard, Juliette
IR  - Fougerou C
FIR - Fougerou, Claire
IR  - Moinot L
FIR - Moinot, LaeTitia
IR  - Wittkop L
FIR - Wittkop, Linda
IR  - Cagnot C
FIR - Cagnot, Carole
IR  - Mestre SL
FIR - Mestre, Soizic Le
IR  - Lebrasseur-Longuet D
FIR - Lebrasseur-Longuet, Delphine
IR  - Petrov-Sanchez V
FIR - Petrov-Sanchez, Ventzislava
IR  - Diallo A
FIR - Diallo, Alpha
IR  - Mercier N
FIR - Mercier, NoeMie
IR  - Icard V
FIR - Icard, Vinca
IR  - Leveau B
FIR - Leveau, Benjamin
IR  - Tubiana S
FIR - Tubiana, Sarah
IR  - Hamze B
FIR - Hamze, Benjamin
IR  - Gelley A
FIR - Gelley, Ambre
IR  - Noret M
FIR - Noret, Marion
IR  - D'Ortenzio E
FIR - D'Ortenzio, Eric
IR  - Puechal O
FIR - Puechal, Oriane
IR  - Semaille C
FIR - Semaille, Caroline
EDAT- 2020/09/23 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - bmjopen-2020-041437 [pii]
AID - 10.1136/bmjopen-2020-041437 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.


PMID- 32958493
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Evaluating level of adherence to nicotine replacement therapy and its impact on
      smoking cessation: a protocol for systematic review and meta-analysis.
PG  - e039775
LID - 10.1136/bmjopen-2020-039775 [doi]
AB  - INTRODUCTION: Nicotine replacement therapy (NRT) has proven effective for smoking
      cessation in clinical trials, however it was found less effective in
      population-based studies, potentially due to inconsistent or incorrect use of
      NRT. The aim of this paper is to describe a systematic review protocol to
      evaluate level of adherence to NRT; the discrepancy of adherence to NRT in
      clinical and population-based studies and degree of association between level of 
      adherence and success of smoking cessation. METHODS AND ANALYSIS: Literature
      search will use five databases (Medline, Scopus, Embase, CINAHL and PsycINFO).
      Studies will be appraised for methodological quality using National Institutes of
      Health Quality Assessment Tool. To reduce heterogeneity, we will analyse clinical
      trials and population-based studies separately; pooled analyses will be done
      among studies that used similar measurements. Heterogeneity of studies will be
      assessed by Higgins' I(2) statistical test. When studies are adequately
      homogeneous, results will be pooled using random-effects model with proportion
      and ORs with 95% CIs and p values for each outcome. We will explain sources of
      heterogeneity by subgroup analysis or sensitivity analysis. Funnel plots and
      Egger's regression asymmetry test with p<0.05 will be used as a cut-off point to 
      affirm presence of statistically significant publication bias. Statistical
      analyses will be carried out using Stata V.16 software. Only studies reporting a 
      valid strategy to control for reverse causality will be included. DISCUSSION:
      This review will provide evidence to support the importance of adherence on rate 
      of smoking cessation and level of adherence to NRT. The findings will be used to 
      inform smoking cessation interventions, researchers and policymakers. ETHICS AND 
      DISSEMINATION: As a systematic literature review, this protocol does not require 
      ethics approval. Research outcomes will be presented at relevant conferences and 
      findings will be published in a relevant peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42020176749.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mersha, Amanual Getnet
AU  - Mersha AG
AUID- ORCID: 0000-0002-1183-8517
AD  - School of Medicine and Public Health, The University of Newcastle, University
      Drive, Callaghan, Newcastle 2308, New South Wales, Australia
      AmanualGetnet.Mersha@uon.edu.au.
FAU - Eftekhari, Parivash
AU  - Eftekhari P
AD  - School of Medicine and Public Health, The University of Newcastle, University
      Drive, Callaghan, Newcastle 2308, New South Wales, Australia.
AD  - Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton
      Heights, Newcastle 2305, NSW, Australia.
FAU - Bovill, Michelle
AU  - Bovill M
AD  - School of Medicine and Public Health, The University of Newcastle, University
      Drive, Callaghan, Newcastle 2308, New South Wales, Australia.
AD  - Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton
      Heights, Newcastle 2305, NSW, Australia.
FAU - Tollosa, Daniel Nigusse
AU  - Tollosa DN
AD  - School of Medicine and Public Health, The University of Newcastle, University
      Drive, Callaghan, Newcastle 2308, New South Wales, Australia.
FAU - Gould, Gillian Sandra
AU  - Gould GS
AUID- ORCID: 0000-0001-8489-2576
AD  - School of Medicine and Public Health, The University of Newcastle, University
      Drive, Callaghan, Newcastle 2308, New South Wales, Australia.
AD  - Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton
      Heights, Newcastle 2305, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Behavior Therapy
MH  - Biological Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - *Smoking Cessation
MH  - Systematic Reviews as Topic
MH  - Tobacco Use Cessation Devices
PMC - PMC7507853
OTO - NOTNLM
OT  - *adult oncology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039775 [pii]
AID - 10.1136/bmjopen-2020-039775 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e039775. doi: 10.1136/bmjopen-2020-039775.


PMID- 32958491
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Implementation of robotic devices in nursing care. Barriers and facilitators: an 
      integrative review.
PG  - e038650
LID - 10.1136/bmjopen-2020-038650 [doi]
AB  - BACKGROUND: Robots in healthcare are gaining increasing attention; however, their
      implementation is challenging due to the complexity of both interventions
      themselves and the contexts in which they are implemented. The objective of this 
      integrative review is to identify barriers to and facilitators of the
      implementation of robotic systems in nursing. METHODS: Articles published from
      2002 to 2019 reporting on projects to implement robotic devices in nursing care
      were searched on Medline (via PubMed), CINAHL and databases on funded research
      projects (Community Research and Development Information Services and Technische 
      Informationsbibliothek) and in journals for robotic research in November 2017 and
      July 2019 for an update. No restrictions regarding study designs were imposed.
      All included articles underwent quality assessments with design-specific critical
      appraisal tools. Barriers to and facilitators of implementation were classified
      using the Context and Implementation of Complex Interventions framework. RESULTS:
      After removing all duplicates, the search revealed 11 204 studies, of which 17
      met the inclusion criteria and were included in the synthesis. The majority of
      the studies dealt with the implementation of robots designed to support
      individuals, either living at home or in nursing homes (n=11). The studies were
      conducted in Europe, the USA and New Zealand and were carried out in nursing
      homes, individual living environments, hospital units and laboratories. The
      quality of reporting and quality of evidence were low in most studies. The most
      frequently reported barriers were in socioeconomic and ethical domains and were
      within the implementation outcomes domain. The most frequently reported
      facilitators were related to the sociocultural context, implementation process
      and implementation strategies. DISCUSSION: This review identified barriers to and
      facilitators of the implementation of robotic devices in nursing within different
      dimensions. The results serve as a basis for the development of suitable
      implementation strategies to reduce potential barriers and promote the
      integration of elements to facilitate implementation. PROSPERO REGISTRATION
      NUMBER: CRD42018073486.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Servaty, Ricarda
AU  - Servaty R
AUID- ORCID: 0000-0002-0534-0296
AD  - Faculty of Applied Health and Social Sciences, Technical University of Applied
      Sciences, Rosenheim, Germany ricarda.servaty@th-rosenheim.de.
AD  - Institute for Medical Information Processing, Biometry, and Epidemiology,
      Ludwig-Maximilians-Universitaet, Muenchen, Germany.
FAU - Kersten, Annalena
AU  - Kersten A
AD  - Protestant University of Applied Sciences, Ludwigsburg, Germany.
FAU - Brukamp, Kirsten
AU  - Brukamp K
AD  - Protestant University of Applied Sciences, Ludwigsburg, Germany.
FAU - Mohler, Ralph
AU  - Mohler R
AD  - School of Public Health, Universitat Bielefeld, Bielefeld, Germany.
FAU - Mueller, Martin
AU  - Mueller M
AD  - Faculty of Applied Health and Social Sciences, Technical University of Applied
      Sciences, Rosenheim, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Europe
MH  - Humans
MH  - New Zealand
MH  - Nursing Homes
MH  - *Robotic Surgical Procedures
PMC - PMC7507851
OTO - NOTNLM
OT  - *biotechnology & bioinformatics
OT  - *geriatric medicine
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038650 [pii]
AID - 10.1136/bmjopen-2020-038650 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e038650. doi: 10.1136/bmjopen-2020-038650.


PMID- 32958490
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Is it necessary for children to receive professional fluoride in addition to
      regular fluoride toothpaste? Protocol for a systematic review.
PG  - e037422
LID - 10.1136/bmjopen-2020-037422 [doi]
AB  - INTRODUCTION: Regular toothbrushing with fluoride toothpaste is a fundamental
      intervention for caries prevention. Professional fluoride application (PFA) is
      widely considered a beneficial supplement to the routine use of fluoride
      toothpaste. However, some recent studies have failed to demonstrate the
      preventive effect of PFA. In addition, an increasing number of studies have
      highlighted the potential adverse effects of fluoride. However, little
      information exists on the effectiveness of additional PFA. The objective of this 
      review is to systematically analyse the efficacy of PFA in addition to regular
      fluoride toothpaste among children under the age of 16. METHOD AND ANALYSIS: We
      will search the PubMed, Embase, Google Scholar and Cochrane Central Register of
      Controlled Trials databases for randomised controlled trials without language or 
      publication date restrictions. Additional studies will be identified by manually 
      searching the reference lists of the included studies and relevant reviews. At
      least two authors will carry out the selection of studies independently and in
      duplicate. The Cochrane Risk of Bias tool will be used to assess the risk of bias
      of the included studies. The random effects model will be used for meta-analyses.
      The data synthesis will be conducted using Review Manager software (RevMan
      V.5.3). The Grading of Recommendation, Assessment, Development and Evaluation
      will be used to assess the quality of supporting evidence for each major
      comparison. ETHICS AND DISSEMINATION: There is no need for ethical approval. The 
      results of this review will be disseminated through peer-reviewed publications
      and social networks. PROSPERO REGISTRATION NUMBER: CRD42020165270.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yu, Lintong
AU  - Yu L
AD  - Department of Paediatric Dentistry, Hubei-MOST KLOS & KLOBM, School & Hospital of
      Stomatology, Wuhan University, Wuhan, China.
FAU - Yu, Xueqian
AU  - Yu X
AD  - Library, Hubei-MOST KLOS & KLOBM, School & Hospital of Stomatology, Wuhan
      University, Wuhan, China.
FAU - Li, Yueyang
AU  - Li Y
AD  - Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji 
      Medical College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Li, Jun
AU  - Li J
AD  - Library, Hubei-MOST KLOS & KLOBM, School & Hospital of Stomatology, Wuhan
      University, Wuhan, China.
FAU - Hua, Fang
AU  - Hua F
AUID- ORCID: 0000-0002-2438-5924
AD  - Centre for Evidence-Based Stomatology, Hubei-MOST KLOS & KLOBM, School & Hospital
      of Stomatology, Wuhan University, Wuhan, China huafang@whu.edu.cn
      gtsong@whu.edu.cn.
AD  - Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine
      and Health, The University of Manchester, Manchester Academic Health Science
      Centre, Manchester, UK.
FAU - Song, Guangtai
AU  - Song G
AUID- ORCID: 0000-0002-5416-1665
AD  - Department of Paediatric Dentistry, Hubei-MOST KLOS & KLOBM, School & Hospital of
      Stomatology, Wuhan University, Wuhan, China huafang@whu.edu.cn gtsong@whu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Toothpastes)
RN  - Q80VPU408O (Fluorides)
SB  - IM
MH  - Child
MH  - Dietary Supplements
MH  - *Fluorides
MH  - Humans
MH  - Review Literature as Topic
MH  - *Toothpastes
PMC - PMC7507841
OTO - NOTNLM
OT  - *child protection
OT  - *oral medicine
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037422 [pii]
AID - 10.1136/bmjopen-2020-037422 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e037422. doi: 10.1136/bmjopen-2020-037422.


PMID- 32958488
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Study protocol for an observational study of cerebrospinal fluid pressure in
      patients with degenerative cervical myelopathy undergoing surgical deCOMPression 
      of the spinal CORD: the COMP-CORD study.
PG  - e037332
LID - 10.1136/bmjopen-2020-037332 [doi]
AB  - INTRODUCTION: Degenerative cervical myelopathy (DCM) is a disabling spinal
      disorder characterised by sensorimotor deficits of upper and lower limbs,
      neurogenic bladder dysfunction and neuropathic pain. When suspected, cervical MRI
      helps to reveal spinal cord compression and rules out alternative diagnoses.
      However, the correlation between radiological findings and symptoms is weak.
      Cerebrospinal fluid pressure (CSFP) analysis may complement the appreciation of
      cord compression and be used for intraoperative and postoperative monitorings in 
      patients undergoing surgical decompression. METHODS AND ANALYSIS: Twenty patients
      diagnosed with DCM undergoing surgical decompression will receive standardised
      lumbar CSFP monitoring immediately before, during and 24 hours after operation.
      Rest (ie, opening pressure, CSF pulsation) and stimulated (ie, Valsalva,
      Queckenstedt's) CSFP-findings in DCM will be compared with 20 controls and
      results from CSFP monitoring will be related to clinical and neurophysiological
      findings. Arterial blood pressure will be recorded perioperatively and
      postoperatively to calculate spinal cord perfusion pressure and spinal vascular
      reactivity index. Furthermore, measures of CSFP will be compared with markers of 
      spinal cord compression by means of MR imaging. ETHICS AND DISSEMINATION: The
      study protocol conformed to the latest revision of the Declaration of Helsinki
      and was approved by the local Ethics Committee of the University Hospital of
      Zurich (KEK-ZH number PB-2016-00623). The main publications from this study will 
      cover the CSFP fluid dynamics and pressure analysis preoperative, perioperative
      and postoperative correlated with imaging, clinical scores and neurophysiology.
      Other publications will deal with preoperative and postoperative spinal
      perfusion. Furthermore, we will disseminate an analysis on waveform morphology
      and the correlation with blood pressure and ECG. Parts of the data will be used
      for computational modelling of cervical stenosis. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT02170155).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zipser, Carl Moritz
AU  - Zipser CM
AUID- ORCID: 0000-0002-4396-4796
AD  - Department of Neurology and Neurophysiology, Balgrist University Hospital,
      Zurich, Switzerland carlmoritz.zipser@balgrist.ch.
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Pfender, Nikolai
AU  - Pfender N
AD  - Department of Neurology and Neurophysiology, Balgrist University Hospital,
      Zurich, Switzerland.
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Spirig, Jose Miguel
AU  - Spirig JM
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Betz, Michael
AU  - Betz M
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Aguirre, Jose
AU  - Aguirre J
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
AD  - Department of Anesthesiology, Balgrist University Hospital, Zurich, Switzerland.
FAU - Hupp, Markus
AU  - Hupp M
AD  - Department of Neurology and Neurophysiology, Balgrist University Hospital,
      Zurich, Switzerland.
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Farshad, Mazda
AU  - Farshad M
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Curt, Armin
AU  - Curt A
AD  - Department of Neurology and Neurophysiology, Balgrist University Hospital,
      Zurich, Switzerland.
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
FAU - Schubert, Martin
AU  - Schubert M
AD  - Department of Neurology and Neurophysiology, Balgrist University Hospital,
      Zurich, Switzerland.
AD  - University Spine Center, Balgrist University Hospital, Zurich, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT02170155
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cerebrospinal Fluid Pressure
MH  - Cervical Vertebrae/diagnostic imaging/surgery
MH  - Decompression, Surgical
MH  - Humans
MH  - Observational Studies as Topic
MH  - Spinal Cord
MH  - *Spinal Cord Compression/diagnostic imaging/surgery
MH  - *Spinal Cord Diseases
PMC - PMC7507854
OTO - NOTNLM
OT  - *adult neurology
OT  - *neurophysiology
OT  - *neurosurgery
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037332 [pii]
AID - 10.1136/bmjopen-2020-037332 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e037332. doi: 10.1136/bmjopen-2020-037332.


PMID- 32958487
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 20
TI  - Nurse-led patient-centred intervention to increase written advance directives for
      outpatients in early-stage palliative care: study protocol for a randomised
      controlled trial with an embedded explanatory qualitative study.
PG  - e037144
LID - 10.1136/bmjopen-2020-037144 [doi]
AB  - INTRODUCTION: Discussing the evolution of life-threatening diseases and
      end-of-life issues remains difficult for patients, relatives and professionals.
      Helping people discuss and formalise their preferences in end-of-life care, as
      planned in the Go Wish intervention, could reduce health-related anxiety in the
      advance care planning (ACP) and advance directive (AD) process. The aims of this 
      study are (1) to test the effectiveness of the Go Wish intervention among
      outpatients in early-stage palliative care and (2) to understand the role of
      defence mechanisms in end-of-life discussions among nurses, patients and
      relatives. METHODS AND ANALYSIS: A mixed-methods study will be performed. A
      cluster randomised controlled trials with three parallel arms will be conducted
      with 45 patients with chronic progressive diseases impacting life expectancy in
      each group: (1) Group A, Go Wish intervention for patients and their relatives;
      (2) Group A, Go Wish intervention for patients alone and (3) Group B, for
      patients (with a waiting list), who will receive the standardised information on 
      ADs (usual care). Randomisation will be at the nurse level as each patient is
      referred to one of the 20 participating nurses (convenience sample of 20 nurses).
      A qualitative study will be conducted to understand the cognitive and emotional
      processes and experiences of nurses, patients and relatives confronted with
      end-of-life discussions. The outcome measurements include the completion of ADs
      (yes/no), anxiety, quality of communication about end-of-life care, empowerment, 
      quality of life and attitudes towards ADs. ETHICS AND DISSEMINATION: The study
      protocol has been approved by the Human Research Ethics Committee of the Canton
      of Geneva, Switzerland (no. 2019-00922). The findings will be disseminated to
      practice (nurses, patients and relatives), to national and international
      scientific conferences, and peer-reviewed journals covering nursing science,
      psychology and medicine. TRIAL REGISTRATION NUMBER: NCT04065685.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Iglesias, Katia
AU  - Iglesias K
AUID- ORCID: 0000-0003-1308-1631
AD  - School of Health Sciences (HEdS-FR), HES-SO University of Applied Sciences and
      Arts Western Switzerland, Friourg, Switzerland katia.iglesias@hefr.ch.
FAU - Busnel, Catherine
AU  - Busnel C
AD  - Geneva Institution for Homecare and Assistance (imad), Geneva, Switzerland.
FAU - Dufour, Florian
AU  - Dufour F
AD  - School of Management and Engineering Vaud (HEIG-VD), HES-SO University of Applied
      Sciences and Arts Western Switzerland, Yverdon, Switzerland.
FAU - Pautex, Sophie
AU  - Pautex S
AD  - Division of Palliative Medicine, Department of rehabilitation and geriatrics,
      University Hospitals Geneva, Geneva, Switzerland.
FAU - Sechaud, Laurence
AU  - Sechaud L
AD  - Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts 
      Western Switzerland, Geneva, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04065685
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200920
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Advance Directives
MH  - Humans
MH  - Nurse's Role
MH  - Outpatients
MH  - *Palliative Care
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Switzerland
PMC - PMC7511622
OTO - NOTNLM
OT  - *adult palliative care
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037144 [pii]
AID - 10.1136/bmjopen-2020-037144 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 20;10(9):e037144. doi: 10.1136/bmjopen-2020-037144.


PMID- 32958486
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Awareness, usage and perceptions of authorship guidelines: an international
      survey of biomedical authors.
PG  - e036899
LID - 10.1136/bmjopen-2020-036899 [doi]
AB  - OBJECTIVES: To investigate authors' awareness and use of authorship guidelines,
      and to assess their perceptions of the fairness of authorship decisions. DESIGN: 
      A cross-sectional online survey. SETTING AND PARTICIPANTS: Corresponding authors 
      of research papers submitted in 2014 to 18 BMJ journals. RESULTS: 3859/12 646
      (31%) researchers responded. They worked in 93 countries and varied in research
      experience. Of these, 1326 (34%) reported their institution had an authorship
      policy providing criteria for authorship; 2871 (74%) were 'very familiar' with
      the International Committee of Medical Journal Editors' authorship criteria and
      3358 (87%) reported that guidelines were beneficial when preparing manuscripts.
      Furthermore, 2609 (68%) reported that their use was 'sometimes' or 'frequently'
      encouraged in their research setting. However, 2859 respondents (74%) reported
      that they had been involved in a study at least once where someone was added as
      an author who had not contributed substantially (honorary authorship), and 1305
      (34%) where someone was not listed as an author but had contributed substantially
      (ghost authorship). Only 740 (19%) reported that they had never experienced
      either honorary or ghost authorship; 1115 (29%) reported that they had
      experienced both at least once. There was no clear pattern in experience of
      authorship misappropriation by continent. For their last coauthored article, 2187
      (57%) reported that explicit authorship criteria had been used to determine
      eligibility, and 3088 (80%) felt that the decision made was fair. When
      institutions frequently encouraged use of authorship guidelines, authorship
      eligibility was more likely to be discussed early (817 of 1410, 58%) and
      perceived as fairer (1273 of 1410, 90%) compared with infrequent encouragement
      (974 of 2449, 40%, and 1891 of 2449, 74%). CONCLUSIONS: Despite a high level of
      awareness of authorship guidelines and criteria, these are not so widely used;
      more explicit encouragement of their use by institutions may result in more
      favourable use of guidelines by authors.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Schroter, Sara
AU  - Schroter S
AUID- ORCID: 0000-0002-8791-8564
AD  - BMJ Publishing Group, London, UK.
FAU - Montagni, Ilaria
AU  - Montagni I
AUID- ORCID: 0000-0003-0076-0010
AD  - Bordeaux Population Health Research Center UMR129, University of Bordeaux-Inserm,
      Bordeaux, France ilaria.montagni@u-bordeaux.fr.
FAU - Loder, Elizabeth
AU  - Loder E
AUID- ORCID: 0000-0003-1501-2947
AD  - BMJ Publishing Group, London, UK.
AD  - Division of Headache, Department of Neurology, Brigham and Women's Hospital,
      Boston, Massachusetts, USA.
FAU - Eikermann, M
AU  - Eikermann M
AUID- ORCID: 0000-0002-7893-0596
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Boston, Massachusetts, USA.
FAU - Schaffner, Elke
AU  - Schaffner E
AUID- ORCID: 0000-0002-7925-4577
AD  - Institute of Public Health, Charite - Universitatsmedizin Berlin, Berlin,
      Germany.
FAU - Kurth, Tobias
AU  - Kurth T
AUID- ORCID: 0000-0001-7169-2620
AD  - Institute of Public Health, Charite - Universitatsmedizin Berlin, Berlin,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Authorship
MH  - *Biomedical Research
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Perception
MH  - Publishing
MH  - Surveys and Questionnaires
PMC - PMC7507845
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *ethics (see medical Ethics)
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: All authors have completed the Unified Competing Interest
      form at www.icmje.org/coi_disclosure.pdf (available on request from the
      corresponding author) and declare that SS is a full-time employee at the BMJ. TK 
      reports having contributed to an advisory board of CoLucid and a research project
      funded by Amgen, for which the Charite - Universitatsmedizin Berlin received an
      unrestricted compensation. TK further reports having received honoraria from
      Lilly, Newsenselab and Total for providing methodological advice, from Novartis
      and Daiichi Sankyo for providing a lecture on neuroepidemiology and research
      methods, and from the BMJ for editorial services. EL receives salary from the BMJ
      for services as head of research, paid to her employer, the Brigham and Women's
      Physician Organisation. IM reports having worked as an independent medical writer
      for Novartis, Sanofi SA and Bristol Myers Squibb. ES has received honoraria from 
      Fresenius Medical Care, Fresenius Kabi and Siemens Healthineers for lectures.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036899 [pii]
AID - 10.1136/bmjopen-2020-036899 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e036899. doi: 10.1136/bmjopen-2020-036899.


PMID- 32958483
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Depression screening using patient-targeted feedback in general practices: study 
      protocol of the German multicentre GET.FEEDBACK.GP randomised controlled trial.
PG  - e035973
LID - 10.1136/bmjopen-2019-035973 [doi]
AB  - INTRODUCTION: Approximately one out of six patients in primary care suffers from 
      depression, which often remains undetected. Evidence regarding the efficacy of
      depression screening in primary care, however, is inconsistent. A previous
      single-centre randomised controlled trial (RCT) in cardiac patients, the
      DEPSCREEN-INFO trial, provided the first evidence that written feedback to
      patients following a positive depression screening reduces depression severity
      and leads to more comprehensive patient engagement in mental healthcare. To
      amplify these effects, the feedback should be tailored according to patients'
      needs and preferences. The GET.FEEDBACK.GP RCT will test the efficacy of this
      patient-targeted feedback intervention in primary care. METHODS AND ANALYSIS: The
      multicentre three-arm GET.FEEDBACK.GP RCT aims to recruit a total of 1074 primary
      care patients from North, East and South Germany. Patients will be screened for
      depression using the Patient Health Questionnaire-9 (PHQ-9). In the case of a
      positive depression screening result (PHQ-9 score >/=10), the participant will be
      randomised into one of three groups to either receive (a) patient-targeted and
      general practitioner (GP)-targeted feedback regarding the depression screening
      results, (b) only GP-targeted feedback or (c) no feedback. Patients will be
      followed over a period of 12 months. The primary outcome is depression severity
      (PHQ-9) 6 months after screening. Secondary outcomes include patient engagement
      in mental healthcare, professional depression care and cost-effectiveness.
      According to a statistical analysis plan, the primary endpoint of all randomised 
      patients will be analysed regarding the intention-to-treat principle. ETHICS AND 
      DISSEMINATION: The Ethics Committee of the Hamburg Medical Association approved
      the study. A clinical trial company will ensure data safety, monitoring and
      supervision. The multicentre GET.FEEDBACK.GP RCT is the first trial in primary
      care that tests the efficacy of a patient-targeted feedback intervention as an
      adjunct to depression screening. Its results have the potential to influence
      future depression guidelines and will be disseminated in scientific as well as
      patient-friendly language. TRIAL REGISTRATION NUMBER: NCT03988985.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kohlmann, Sebastian
AU  - Kohlmann S
AUID- ORCID: 0000-0003-1307-4618
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany s.kohlmann@uke.de.
FAU - Lehmann, Marco
AU  - Lehmann M
AUID- ORCID: 0000-0002-8817-3365
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Eisele, Marion
AU  - Eisele M
AD  - Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Braunschneider, Lea-Elena
AU  - Braunschneider LE
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Marx, Gabriella
AU  - Marx G
AD  - Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Zapf, Antonia
AU  - Zapf A
AD  - Department of Biostatistics and Epidemiology, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Wegscheider, Karl
AU  - Wegscheider K
AUID- ORCID: 0000-0003-2974-3142
AD  - Department of Biostatistics and Epidemiology, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Harter, Martin
AU  - Harter M
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Konig, Hans-Helmut
AU  - Konig HH
AD  - Department of Health Economics and Health Services Research, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Gallinat, Jurgen
AU  - Gallinat J
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Joos, Stefanie
AU  - Joos S
AD  - Department of Primary Care, University Medical Centre Tubingen, Tubingen,
      Germany.
FAU - Resmark, Gaby
AU  - Resmark G
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Schneider, Antonius
AU  - Schneider A
AD  - Department of Primary Care, Technical University of Munich Hospital Rechts der
      Isar, Munchen, Germany.
FAU - Allwang, Christine
AU  - Allwang C
AD  - Department of Psychosomatic Medicine and Psychotherapy, Technical University of
      Munich Hospital Rechts der Isar, Munchen, Germany.
FAU - Szecsenyi, Joachim
AU  - Szecsenyi J
AD  - Department of General Practice and Health Services Research, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Nikendei, Christoph
AU  - Nikendei C
AD  - Department of Psychosomatic Medicine and Psychotherapy for General Internal
      Medicine and Psychosomatics, University Medical Centre of Heidelberg, Heidelberg,
      Germany.
FAU - Schulz, Sven
AU  - Schulz S
AD  - Department of Primary Care, University Medical Centre Jena, Jena, Germany.
FAU - Brenk-Franz, Katja
AU  - Brenk-Franz K
AD  - Department of Psychosocial Medicine and Psychotherapy, University Medical Centre 
      Jena, Jena, Germany.
FAU - Scherer, Martin
AU  - Scherer M
AD  - Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Lowe, Bernd
AU  - Lowe B
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03988985
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Depression/diagnosis
MH  - Feedback
MH  - *General Practitioners
MH  - Germany
MH  - Humans
MH  - Language
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
PMC - PMC7507856
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *depression & mood disorders
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035973 [pii]
AID - 10.1136/bmjopen-2019-035973 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e035973. doi: 10.1136/bmjopen-2019-035973.


PMID- 32958479
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 21
TI  - Protocol for a prospective cohort study: Prevention of Transmissions by Effective
      Colonisation Tracking in Neonates (PROTECT-Neo).
PG  - e034068
LID - 10.1136/bmjopen-2019-034068 [doi]
AB  - INTRODUCTION: Transmissions of opportunistic bacterial pathogens between neonates
      increase the risk of infections with negative repercussions, including higher
      mortality, morbidity and permanent disabilities. The probability of transmissions
      between patients is contingent on a set of intrinsic (patient-related) and
      extrinsic (ward-related) risk factors that are not clearly quantified. It is the 
      dual objective of the Prevention of Transmissions by Effective Colonisation
      Tracking-Neo study to determine the density of transmission events in a level III
      neonatal intensive care unit (NICU) and to identify risk factors that may be
      causally associated with transmission events. METHODS AND ANALYSIS: A full cohort
      of patients treated in a 17-bed level III NICU will be prospectively followed and
      transmission events between two or more patients will be documented. A
      transmission event occurs when isogenic isolates from two different patients can 
      be identified. Isolates will be obtained by routine weekly screening. Isogenicity
      will be determined by whole-genome sequencing. During the study, relevant
      intrinsic and extrinsic risk factors will be recorded. Specimen and data will be 
      collected for 1 year. We postulate that transmission density increases during
      episodes when demand for intensive care cannot be met by existing staff, and that
      threshold dynamics have a bearing on cohorting and hand hygiene performance.
      Poisson logistic regression, proportional hazard and multilevel competing risk
      models will be used to estimate the effect of explanatory variables. ETHICS AND
      DISSEMINATION: This study has been approved by the local ethics committee (study 
      ID 287/18). The results will be published in peer-reviewed medical journals,
      communicated to participants, the general public and all relevant stakeholders.
      TRIAL REGISTRATION NUMBER: The German Clinical Trials Registry (DRKS00017733);
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gotting, Tim
AU  - Gotting T
AUID- ORCID: 0000-0002-7753-3361
AD  - Institute for Infection Prevention and Hospital Epidemiology, Medical
      Center-University of Freiburg, Faculty of Medicine, University of Freiburg,
      Freiburg, Germany tim.goetting@uniklinik-freiburg.de.
FAU - Reuter, Sandra
AU  - Reuter S
AD  - Institute for Infection Prevention and Hospital Epidemiology, Medical
      Center-University of Freiburg, Faculty of Medicine, University of Freiburg,
      Freiburg, Germany.
FAU - Jonas, Daniel
AU  - Jonas D
AD  - Institute for Infection Prevention and Hospital Epidemiology, Medical
      Center-University of Freiburg, Faculty of Medicine, University of Freiburg,
      Freiburg, Germany.
FAU - Hentschel, Roland
AU  - Hentschel R
AD  - Center for Pediatrics and Adolescent Medicine, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Henneke, Philipp
AU  - Henneke P
AD  - Center for Pediatrics and Adolescent Medicine, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
AD  - Institute for Immunodeficiency (CCI), Medical Center-University of Freiburg,
      Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Klotz, Daniel
AU  - Klotz D
AD  - Center for Pediatrics and Adolescent Medicine, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Hock, Simone
AU  - Hock S
AD  - Center for Pediatrics and Adolescent Medicine, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Wolkewitz, Martin
AU  - Wolkewitz M
AD  - Institute of Medical Biometry and Statistics, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Blumel, Benjamin
AU  - Blumel B
AD  - Institute of Medical Microbiology and Hygiene, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Hacker, Georg
AU  - Hacker G
AD  - Institute of Medical Microbiology and Hygiene, Medical Center-University of
      Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Grundmann, Hajo
AU  - Grundmann H
AD  - Institute for Infection Prevention and Hospital Epidemiology, Medical
      Center-University of Freiburg, Faculty of Medicine, University of Freiburg,
      Freiburg, Germany.
FAU - Mutters, Nico
AU  - Mutters N
AUID- ORCID: 0000-0002-0156-9595
AD  - Institute for Infection Prevention and Hospital Epidemiology, Medical
      Center-University of Freiburg, Faculty of Medicine, University of Freiburg,
      Freiburg, Germany.
AD  - Institute for Hygiene and Public Health, University Hospital Bonn, Bonn, Germany.
LA  - eng
SI  - DRKS/DRKS00017733
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Trials as Topic
MH  - *Cross Infection/prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - Infection Control
MH  - Intensive Care Units, Neonatal
MH  - Prospective Studies
PMC - PMC7507848
OTO - NOTNLM
OT  - *infection control
OT  - *multidrug-resistant organisms
OT  - *neonatal intensive & critical care
OT  - *neonatology
OT  - *transmission dynamics
COIS- Competing interests: None declared.
EDAT- 2020/09/23 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/22 05:36
PHST- 2020/09/22 05:36 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034068 [pii]
AID - 10.1136/bmjopen-2019-034068 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 21;10(9):e034068. doi: 10.1136/bmjopen-2019-034068.


PMID- 32958170
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 0072-9752 (Print)
IS  - 0072-9752 (Linking)
VI  - 173
DP  - 2020
TI  - Ethical views and considerations.
PG  - 15-21
LID - B978-0-444-64150-2.00003-4 [pii]
LID - 10.1016/B978-0-444-64150-2.00003-4 [doi]
AB  - Jean Piaget's theory is a central reference point in the study of normal
      development in children. He proposed in the 20th century that distinct stages
      occur in the development of intellectual abilities from the preoperational period
      (intuitive stage: 4-7 years old) to the second stage of conceptual intelligence. 
      One of the most famous Piagetian tasks is number conservation. Failures and
      successes in this task reveal two fundamental stages in children's thinking and
      judgment, shifting at approximately 7 years of age from visuospatial intuition to
      logico-mathematical operation (i.e., number conservation). New emerging
      techniques in the 21st century, such as functional magnetic resonance imaging,
      can support this preeminent theory with an understanding of the cerebral basis of
      the various stages. Since these new technologies are considered to be invasive in
      children, such techniques are subject to ethical views and concerns due to
      pediatric participants. The chapter discusses a brain imaging study on Piaget's
      conservation-of-number task, showing what can be accomplished through careful
      ethical considerations in the context of healthy children with normal cognitive
      development.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Houde, Olivier
AU  - Houde O
AD  - Laboratory for the Psychology of Child Development and Education, University of
      Paris, Paris, France. Electronic address: houde@paris5.sorbonne.fr.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Handb Clin Neurol
JT  - Handbook of clinical neurology
JID - 0166161
SB  - IM
MH  - Child
MH  - *Child Development
MH  - Child, Preschool
MH  - *Cognition
MH  - Comprehension
MH  - Humans
MH  - Judgment
MH  - Morals
OTO - NOTNLM
OT  - Developmental cognitive neurosciences
OT  - Ethical view
OT  - Young children
OT  - fMRI
EDAT- 2020/09/23 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/09/22 05:33
PHST- 2020/09/22 05:33 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
AID - B978-0-444-64150-2.00003-4 [pii]
AID - 10.1016/B978-0-444-64150-2.00003-4 [doi]
PST - ppublish
SO  - Handb Clin Neurol. 2020;173:15-21. doi: 10.1016/B978-0-444-64150-2.00003-4.


PMID- 32958071
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2049-9957 (Electronic)
IS  - 2049-9957 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Sep 21
TI  - Strongyloides stercoralis prevalence and diagnostics in Vientiane, Lao People's
      Democratic Republic.
PG  - 133
LID - 10.1186/s40249-020-00750-y [doi]
AB  - BACKGROUND: Despite the high prevalence of strongyloidiasis in the Laotian
      population, Laotian hospitals still lack diagnostic capacity to appropriately
      diagnose Strongyloides stercoralis infections. This cross-sectional
      hospital-based study was conducted to assess the prevalence of Strongyloides
      stercoralis infection among hospitalized patients treated at Mahosot Hospital,
      the primary reference hospital of Lao People's Democratic Republic (Lao PDR), and
      to validate feasible methods for diagnosing S. stercoralis infection at
      hospital's laboratory. METHODS: Between September and December 2018, stool
      samples of 104 inpatients were investigated for S. stercoralis infection by wet
      smear, Baermann technique, Koga Agar plate culture (KAPC), and real-time
      detection polymerase chain reaction (RTD-PCR) at the Infectious Diseases Ward of 
      the Mahosot Hospital in Vientiane. The sensitivity, the specificity, the negative
      predictive value (NPV) of each diagnostic test, as well as their combination(s)
      was calculated using a composite reference standard (CRS). The correlation of the
      different test methods was assessed by chi-square or Fisher's exact test. Cohen's
      kappa coefficient was used to assess the diagnostic agreement of the different
      test methods. RESULTS: The overall prevalence of S. stercoralis infections among 
      the study population was 33.4%. The cumulative infection prevalence statistically
      significantly increased from the lowest age group of 40 years and below (22.4%), 
      to the medium (40.0%) and to the oldest age group of 61 year and above (72.7%)(P 
      = 0.003). The cumulative infection prevalence of CRS was considerably higher in
      male (40.4%) compared to female patients (28.1%), but not statistically different
      (P = 0.184). The diagnostic sensitivity of Baermann technique, KAPC, RTD-PCR, and
      the combination of Baermann technique and KAPC were 60.0, 60.0, 74.3, and 77.1%, 
      respectively. Only 13 patients (37.1%) of the total 35 S. stercoralis patients
      diagnosed with any technique had a simultaneously positive diagnostic test with
      Baermann, KAPC and RTD-PCR. CONCLUSIONS: We identified Baermann technique and
      KAPC to be currently the most feasible and implementable standard methods for
      diagnosing S. stercoralis at a hospital setting such as Mahosot Hospital and
      provincial and district hospitals in Lao PDR and other low- and middle income
      countries in Southeast Asia. TRIAL REGISTRATION: This study was approved by the
      National Ethics Committee for Health Research in Lao PDR (reference no.
      083/NECHR) and by the Ethics Committee Northwest and Central Switzerland
      (reference no. 2018-00594).
FAU - Chankongsin, Somaphone
AU  - Chankongsin S
AD  - Infectious Diseases Ward, Mahosot Hospital, Vientiane, Lao People's Democratic
      Republic.
AD  - University of Basel, Basel, Switzerland.
FAU - Wampfler, Rahel
AU  - Wampfler R
AD  - University of Basel, Basel, Switzerland.
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
FAU - Ruf, Marie-Therese
AU  - Ruf MT
AD  - University of Basel, Basel, Switzerland.
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
FAU - Odermatt, Peter
AU  - Odermatt P
AD  - University of Basel, Basel, Switzerland.
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
FAU - Marti, Hanspeter
AU  - Marti H
AD  - University of Basel, Basel, Switzerland.
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
FAU - Nickel, Beatrice
AU  - Nickel B
AD  - University of Basel, Basel, Switzerland.
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
FAU - Keoluangkhot, Valy
AU  - Keoluangkhot V
AD  - Infectious Diseases Ward, Mahosot Hospital, Vientiane, Lao People's Democratic
      Republic.
FAU - Neumayr, Andreas
AU  - Neumayr A
AUID- ORCID: http://orcid.org/0000-0001-7358-2791
AD  - University of Basel, Basel, Switzerland. andreas.neumayr@swisstph.ch.
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland. andreas.neumayr@swisstph.ch.
AD  - Public Health and Tropical Medicine, College of Public Health, Medical and
      Veterinary Sciences, James Cook University, Townsville, Australia.
      andreas.neumayr@swisstph.ch.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - England
TA  - Infect Dis Poverty
JT  - Infectious diseases of poverty
JID - 101606645
RN  - 0 (DNA, Helminth)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Cross-Sectional Studies
MH  - DNA, Helminth/*analysis
MH  - Feasibility Studies
MH  - Feces/parasitology
MH  - Female
MH  - Humans
MH  - Inpatients
MH  - Laos/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Reagent Kits, Diagnostic
MH  - Real-Time Polymerase Chain Reaction
MH  - Strongyloides stercoralis/*isolation & purification
MH  - Strongyloidiasis/*diagnosis/*epidemiology
MH  - Young Adult
PMC - PMC7507821
OTO - NOTNLM
OT  - Baermann method
OT  - Koga agar plate culture
OT  - Real time detection PCR
OT  - Strongyloides stercoralis
OT  - Strongyloidiasis
OT  - Wet smear
EDAT- 2020/09/23 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/09/22 05:31
PHST- 2020/03/13 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/22 05:31 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - 10.1186/s40249-020-00750-y [doi]
AID - 10.1186/s40249-020-00750-y [pii]
PST - epublish
SO  - Infect Dis Poverty. 2020 Sep 21;9(1):133. doi: 10.1186/s40249-020-00750-y.


PMID- 32958010
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1748-5908 (Electronic)
IS  - 1748-5908 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Sep 21
TI  - From sensitization to adoption? A qualitative study of the implementation of a
      digitally supported intervention for clinical decision making in polypharmacy.
PG  - 82
LID - 10.1186/s13012-020-01043-6 [doi]
AB  - OBJECTIVE: Formative evaluation of the implementation process for a digitally
      supported intervention in polypharmacy in Germany. Qualitative research was
      conducted within a cluster randomized controlled trial (C-RCT). It focused on
      understanding how the intervention influences behavior-related outcomes in the
      prescription and medication review process. METHODS/SETTING: Twenty-seven general
      practitioners (GPs) were included in the study in the two groups of the C-RCT,
      the intervention, and the wait list control group. Behavior-related outcomes were
      investigated using three-step data analysis (content analytic approach,
      documentary method, and design of a model of implementation pathways). RESULTS:
      Content analysis showed that physicians were more intensely aware of
      polypharmacy-related risks, described positive learning effects of the digital
      technology on their prescribing behavior, and perceived a change in communication
      with patients and pharmacists. Conversely, they felt uncertain about their own
      responsibility when prescribing. Three main dimensions were discovered which
      influenced adoption behavior: (1) the physicians' interpretation of the relevance
      of pharmaceutical knowledge provided by the intervention in changing
      decision-making situations in polypharmacy; (2) their medical code of ethics for 
      clinical decision making in the context of progressing digitalization; and (3)
      their concepts of evidence-based medicine on the basis of professional
      experiences with polypharmacy in primary care settings. In our sample, both
      simple and complex pathways from sensitization to adoption were observed. The
      resulting model on adoption behavior includes a paradigmatic description of
      different pathways and a visualization of different observed levels and applied
      methodological approaches. We assumed that the GP habitus can weaken or
      strengthen interventional effects towards intervention uptake. This formative
      evaluation strategy is beneficial for the identification of behavior-related
      implementation barriers and facilitators. CONCLUSION: Our analyses of the
      adoption behavior of a digitally supported intervention in polypharmacy revealed 
      both simple and complex pathways from awareness to adoption, which may impact the
      implementation of the intervention and therefore, its effectiveness. Future
      consideration of adoption behavior in the planning and evaluation of digitally
      supported interventions may enhance uptake and support the interpretation of
      effects. TRIAL REGISTRATION: NCT03430336 , 12 February 2018.
FAU - Soling, Sara
AU  - Soling S
AUID- ORCID: http://orcid.org/0000-0002-0752-358X
AD  - Institute for Medical Sociology, Health Services Research and Rehabilitation
      Science, Department of Health Services Research, University of Cologne, Cologne, 
      Germany. sara.soeling@uk-koeln.de.
FAU - Koberlein-Neu, Juliane
AU  - Koberlein-Neu J
AD  - Center for Health Economics and Health Services Research, Schumpeter School of
      Business and Economics, University of Wuppertal, Wuppertal, Germany.
FAU - Muller, Beate Sigrid
AU  - Muller BS
AD  - Institute of General Practice, Goethe University, Frankfurt, Germany.
FAU - Dinh, Truc Sophia
AU  - Dinh TS
AD  - Institute of General Practice, Goethe University, Frankfurt, Germany.
FAU - Muth, Christiane
AU  - Muth C
AD  - Institute of General Practice, Goethe University, Frankfurt, Germany.
FAU - Pfaff, Holger
AU  - Pfaff H
AD  - Institute for Medical Sociology, Health Services Research and Rehabilitation
      Science, Department of Health Services Research, University of Cologne, Cologne, 
      Germany.
FAU - Karbach, Ute
AU  - Karbach U
AD  - Department Sociology in Rehabilitation, Faculty of Rehabilitation Sciences,
      Technical University Dortmund, Dortmund, Germany.
CN  - AdAM Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03430336
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - Implement Sci
JT  - Implementation science : IS
JID - 101258411
SB  - IM
MH  - Clinical Decision-Making
MH  - *General Practitioners
MH  - Humans
MH  - *Polypharmacy
MH  - Primary Health Care
MH  - Qualitative Research
PMC - PMC7507604
OTO - NOTNLM
OT  - *Clinical computerized decision support systems
OT  - *Digitalization
OT  - *Evidence-based medicine
OT  - *Implementation
OT  - *Polypharmacy
OT  - *Qualitative study
IR  - Kellermann-Muhlhoff P
FIR - Kellermann-Muhlhoff, Petra
IR  - Duvel L
FIR - Duvel, Lara
IR  - Beckmann T
FIR - Beckmann, Till
IR  - Hammerschmidt R
FIR - Hammerschmidt, Reinhard
IR  - Jachmich J
FIR - Jachmich, Julia
IR  - Leicher E
FIR - Leicher, Eva
IR  - Brandt B
FIR - Brandt, Benjamin
IR  - Richard J
FIR - Richard, Johanna
IR  - Meyer F
FIR - Meyer, Frank
IR  - Flume M
FIR - Flume, Mathias
IR  - Muller T
FIR - Muller, Thomas
IR  - Gerlach FM
FIR - Gerlach, Ferdinand M
IR  - Gonzalez-Gonzalez AI
FIR - Gonzalez-Gonzalez, Ana Isabel
IR  - Chapidi K
FIR - Chapidi, Kiran
IR  - Brunn R
FIR - Brunn, Robin
IR  - Ihle P
FIR - Ihle, Peter
IR  - Meyer I
FIR - Meyer, Ingo
IR  - Timmesfeld N
FIR - Timmesfeld, Nina
IR  - Trampisch HJ
FIR - Trampisch, Hans J
IR  - Klaassen-Mielke R
FIR - Klaassen-Mielke, Renate
IR  - Basten J
FIR - Basten, Jale
IR  - Greiner W
FIR - Greiner, Wolfgang
IR  - Suhrmann B
FIR - Suhrmann, Bastian
IR  - Piotrowski A
FIR - Piotrowski, Alexandra
IR  - Beifuss K
FIR - Beifuss, Karolina
IR  - Meyer S
FIR - Meyer, Sarah
IR  - Grandt D
FIR - Grandt, Daniel
IR  - Grandt S
FIR - Grandt, Simone
EDAT- 2020/09/23 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/09/22 05:30
PHST- 2020/04/29 00:00 [received]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/22 05:30 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.1186/s13012-020-01043-6 [doi]
AID - 10.1186/s13012-020-01043-6 [pii]
PST - epublish
SO  - Implement Sci. 2020 Sep 21;15(1):82. doi: 10.1186/s13012-020-01043-6.


PMID- 32957967
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 21
TI  - Structural coercion in the context of community engagement in global health
      research conducted in a low resource setting in Africa.
PG  - 90
LID - 10.1186/s12910-020-00530-1 [doi]
AB  - BACKGROUND: While community engagement is increasingly promoted in global health 
      research to improve ethical research practice, it can sometimes coerce
      participation and thereby compromise ethical research. This paper seeks to
      discuss some of the ethical issues arising from community engagement in a low
      resource setting. METHODS: A qualitative study design focusing on the engagement 
      activities of three biomedical research projects as ethnographic case studies was
      used to gain in-depth understanding of community engagement as experienced by
      multiple stakeholders in Malawi. Data was collected through participant
      observation, 43 In-depth interviews and 17 focus group discussions with community
      leaders, research staff, community members and research participants. Thematic
      analysis was used to analyse and interpret the findings. RESULTS: The results
      showed that structural coercion arose due to an interplay of factors pertaining
      to social-economic context, study design and power relations among research
      stakeholders. The involvement of community leaders, government stakeholders, and 
      power inequalities among research stakeholders affected some participants'
      ability to make autonomous decisions about research participation. These results 
      have been presented under the themes of perception of research as development,
      research participants' motivation to access individual benefits, the power of
      vernacular translations to influence research participation, and coercive power
      of leaders. CONCLUSION: The study identified ethical issues in community
      engagement practices pertaining to structural coercion. We conclude that
      community engagement alone did not address underlying structural inequalities to 
      ensure adequate protection of communities. These results raise important
      questions on how to balance between engaging communities to improve research
      participation and ensure that informed consent is voluntarily given.
FAU - Nyirenda, Deborah
AU  - Nyirenda D
AUID- ORCID: 0000-0002-5867-4687
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme, PO Box 30096,
      Chichiri, Blantyre 3, Malawi. dnyirenda@mlw.mw.
FAU - Sariola, Salla
AU  - Sariola S
AD  - Department of Social Sciences, University of Helsinki, P.O 18 (Unioninkatu 35),
      00014, Helsinki, Finland.
FAU - Kingori, Patricia
AU  - Kingori P
AD  - The Ethox Centre/ Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
FAU - Squire, Bertie
AU  - Squire B
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme, PO Box 30096,
      Chichiri, Blantyre 3, Malawi.
AD  - Department of Social Sciences, University of Helsinki, P.O 18 (Unioninkatu 35),
      00014, Helsinki, Finland.
FAU - Bandawe, Chiwoza
AU  - Bandawe C
AD  - University of Malawi College of Medicine, Private Bag 360, Chichiri, Blantyre 3, 
      Malawi.
FAU - Parker, Michael
AU  - Parker M
AD  - The Ethox Centre/ Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
FAU - Desmond, Nicola
AU  - Desmond N
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme, PO Box 30096,
      Chichiri, Blantyre 3, Malawi.
AD  - Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
LA  - eng
GR  - 101113/Z/13/Z/WT_/Wellcome Trust/United Kingdom
GR  - 096527/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Coercion
MH  - Community Participation
MH  - *Global Health
MH  - Humans
MH  - Informed Consent
MH  - Malawi
MH  - Qualitative Research
PMC - PMC7504839
OTO - NOTNLM
OT  - *Africa
OT  - *Bioethics
OT  - *Community engagement
OT  - *Global health
OT  - *Health research
OT  - *Research ethics
OT  - *Structural coercion
EDAT- 2020/09/23 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/22 05:30
PHST- 2020/03/25 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/22 05:30 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00530-1 [doi]
AID - 10.1186/s12910-020-00530-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 21;21(1):90. doi: 10.1186/s12910-020-00530-1.


PMID- 32957962
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1748-5908 (Electronic)
IS  - 1748-5908 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Sep 21
TI  - "All about the money?" A qualitative interview study examining organizational-
      and system-level characteristics that promote or hinder shared decision-making in
      cancer care in the United States.
PG  - 81
LID - 10.1186/s13012-020-01042-7 [doi]
AB  - BACKGROUND: Despite decades of ethical, empirical, and policy support, shared
      decision-making (SDM) has failed to become standard practice in US cancer care.
      Organizational and health system characteristics appear to contribute to the
      difficulties in implementing SDM in routine care. However, little is known about 
      the relevance of the different characteristics in specific healthcare settings.
      The aim of the study was to explore how organizational and health system
      characteristics affect SDM implementation in US cancer care. METHODS: We
      conducted semi-structured interviews with diverse cancer care stakeholders in the
      USA. Of the 36 invited, 30 (83%) participants consented to interview. We used
      conventional content analysis to analyze transcript content. RESULTS: The
      dominant theme in the data obtained was that concerns regarding a lack of revenue
      generation, or indeed, the likely loss of revenue, were a major barrier
      preventing implementation of SDM. Many other factors were prominent as well, but 
      the view that SDM might impair organizational or individual profit margins and
      reduce the income of some health professionals was widespread. On the
      organizational level, having leadership support for SDM and multidisciplinary
      teams were viewed as critical to implementation. On the health system level,
      views diverged on whether embedding tools into electronic health records (EHRs), 
      making SDM a criterion for accreditation and certification, and enacting
      legislation could promote SDM implementation. CONCLUSION: Cancer care in the USA 
      has currently limited room for SDM and is prone to paying lip service to the
      idea. Implementation efforts in US cancer care need to go further than
      interventions that target only the clinician-patient level. On a policy level,
      SDM could be included in alternative payment models. However, its implementation 
      would need to be thoroughly assessed in order to prevent further misdirected
      incentivization through box ticking.
FAU - Scholl, Isabelle
AU  - Scholl I
AUID- ORCID: 0000-0002-7639-0880
AD  - Dartmouth College, The Dartmouth Institute for Health Policy & Clinical Practice,
      Level 5, Williamson Translational Research Building, One Medical Center Drive,
      Lebanon, NH, 03756, USA. i.scholl@uke.de.
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Martinistr. 52, W26, 20246, Hamburg, Germany. i.scholl@uke.de.
FAU - Kobrin, Sarah
AU  - Kobrin S
AD  - Healthcare Delivery Research Program, National Cancer Institute, 9609 Medical
      Center Drive, Rockville, MD, 20850, USA.
FAU - Elwyn, Glyn
AU  - Elwyn G
AD  - Dartmouth College, The Dartmouth Institute for Health Policy & Clinical Practice,
      Level 5, Williamson Translational Research Building, One Medical Center Drive,
      Lebanon, NH, 03756, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - Implement Sci
JT  - Implementation science : IS
JID - 101258411
SB  - IM
MH  - Decision Making
MH  - Decision Making, Shared
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - *Neoplasms/therapy
MH  - *Patient Participation
MH  - Qualitative Research
MH  - United States
PMC - PMC7507661
OTO - NOTNLM
OT  - *Cancer care
OT  - *Economic implementation barriers
OT  - *Financial incentives
OT  - *Health system characteristics
OT  - *Implementation
OT  - *Oncology
OT  - *Organizational characteristics
OT  - *Payment models
OT  - *Routine care
OT  - *Shared decision-making
OT  - *United States
EDAT- 2020/09/23 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/09/22 05:30
PHST- 2020/04/30 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/22 05:30 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
AID - 10.1186/s13012-020-01042-7 [doi]
AID - 10.1186/s13012-020-01042-7 [pii]
PST - epublish
SO  - Implement Sci. 2020 Sep 21;15(1):81. doi: 10.1186/s13012-020-01042-7.


PMID- 32957946
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 21
TI  - Are we ready for artificial intelligence health monitoring in elder care?
PG  - 358
LID - 10.1186/s12877-020-01764-9 [doi]
AB  - BACKGROUND: The world is experiencing a dramatic increase in the aging
      population, challenging the sustainability of traditional care models that have
      relied on in-person monitoring. This debate article discusses whether artificial 
      intelligence health monitoring may be suitable enhancement or replacement for
      elder care. MAIN TEXT: Internationally, as life expectancy continues to rise,
      many countries are facing a severe shortage of direct care workers. The health
      workforce is aging, and replacement remains a challenge. Artificial intelligence 
      health monitoring technologies may play a novel and significant role in filling
      the human resource gaps in caring for older adults by complementing current care 
      provision, reducing the burden on family caregivers, and improving the quality of
      care. Nonetheless, opportunities brought on by these emerging technologies raise 
      ethical questions that must be addressed to ensure that these automated systems
      can truly enhance care and health outcomes for older adults. This debate article 
      explores some ethical dimensions of using automated health monitoring
      technologies. It argues that, in order for these health monitoring technologies
      to fulfill the wishes of older adults to age in place and also to empower them
      and improve their quality of life, we need deep knowledge of how stakeholders may
      balance their considerations of relational care, safety, and privacy. CONCLUSION:
      It is only when we design artificial intelligence health monitoring technologies 
      with intersecting clinical and ethical factors in mind that the resulting systems
      will enhance productive relational care, facilitate independent living, promote
      older adults' health outcomes, and minimize waste.
FAU - Ho, Anita
AU  - Ho A
AUID- ORCID: 0000-0002-9797-1326
AD  - Centre for Applied Ethics, University of British Columbia, 227 - 6356
      Agricultural Road, Vancouver, BC, V6T 1Z2, Canada. Anitaho.ethics@gmail.com.
AD  - Bioethics Program, University of California San Francisco, Vancouver, Canada.
      Anitaho.ethics@gmail.com.
AD  - Centre for Health Evaluation & Outcome Sciences, Vancouver, Canada.
      Anitaho.ethics@gmail.com.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Aged
MH  - Aging
MH  - *Artificial Intelligence
MH  - Caregivers
MH  - Humans
MH  - Independent Living
MH  - *Quality of Life
PMC - PMC7504871
OTO - NOTNLM
OT  - *Aging in place
OT  - *Artificial intelligence
OT  - *Ethics
OT  - *Health monitoring
OT  - *Independent living
OT  - *Machine learning
EDAT- 2020/09/23 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/09/22 05:30
PHST- 2019/08/28 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/22 05:30 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12877-020-01764-9 [doi]
AID - 10.1186/s12877-020-01764-9 [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Sep 21;20(1):358. doi: 10.1186/s12877-020-01764-9.


PMID- 32957856
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20211027
IS  - 2043-6289 (Electronic)
IS  - 0266-7681 (Linking)
VI  - 45
IP  - 10
DP  - 2020 Dec
TI  - The use of barbed sutures in the Pulvertaft weave: a biomechanical study.
PG  - 1055-1060
LID - 10.1177/1753193420909452 [doi]
AB  - The use of barbed sutures in tendon repair and reconstruction is advantageous
      because it allows for a knotless suturing technique. In this biomechanical study,
      we compared barbed sutures with conventional sutures in tendon transfers using
      the Pulvertaft weave technique in a human cadaveric model. Thirty human cadaveric
      finger flexor tendons were transected and divided into three groups of ten
      tendons, which were then reconstructed by the Pulvertaft weave technique using
      3-0 Prolene (Ethicon, Inc., Somerville, NJ, USA), 3-0 Ethilon (Ethicon, Inc.,
      Somerville, NJ, USA) or 3-0 V-Loc (Covidien Deutschland GmbH, Neustadt, Germany) 
      sutures. Biomechanical testing showed that repairs in the V-Loc group had
      significantly greater ultimate tensile strength and stiffness than conventional
      sutures. The time taken to complete the weave and the length of sutures used were
      also the least in the V-Loc group. Our study has shown that the barbed suture has
      a better biomechanical performance than conventional suture types when used in
      the Pulvertaft weave technique.
FAU - Xing Fu Hap, Daniel
AU  - Xing Fu Hap D
AD  - Department of Orthopaedic Surgery, Khoo Teck Puat Hospital, Singapore.
FAU - Rung Wong, Yoke
AU  - Rung Wong Y
AD  - Biomechanics Laboratory, Singapore General Hospital, Singapore.
FAU - Rajaratnam, Vaikunthan
AU  - Rajaratnam V
AD  - Department of Orthopaedic Surgery, Khoo Teck Puat Hospital, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20200922
PL  - England
TA  - J Hand Surg Eur Vol
JT  - The Journal of hand surgery, European volume
JID - 101315820
SB  - IM
CIN - J Hand Surg Eur Vol. 2021 Oct;46(8):905-906. PMID: 34544310
MH  - Biomechanical Phenomena
MH  - Germany
MH  - Humans
MH  - Suture Techniques
MH  - *Sutures
MH  - *Tendons/surgery
MH  - Tensile Strength
OTO - NOTNLM
OT  - Barbed sutures
OT  - Pulvertaft weave
OT  - knotless suture
OT  - tendon transfer
EDAT- 2020/09/23 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/22 05:29
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/09/22 05:29 [entrez]
AID - 10.1177/1753193420909452 [doi]
PST - ppublish
SO  - J Hand Surg Eur Vol. 2020 Dec;45(10):1055-1060. doi: 10.1177/1753193420909452.
      Epub 2020 Sep 22.


PMID- 32957420
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Short and medium-term effects of a multicomponent physical exercise program with 
      a Mediterranean diet on bone mineral density, gait, balance, and fall risk for
      patients with Alzheimer disease: Randomized controlled clinical trial study
      protocol.
PG  - e22385
LID - 10.1097/MD.0000000000022385 [doi]
AB  - INTRODUCTION: Reduced bone mineral density and increased risk of falls are
      related with Alzheimer disease, and these increase likelihood of bone
      osteoporotic fractures causing serious complications such as disability, fear of 
      falling, loss autonomy, decreased quality of life, and anticipated mortality in
      elderly patients. Gait and balance disturb are 2 factors to favor falls in
      elderly, and in patients with cognitive impairment, the risk of falls increases
      to double. Exercise and Mediterranean diet produce beneficial effects for aging, 
      cognitive decline, and are widely recommended to reduce the effects of
      osteoporosis, fall risk, and related fragility fractures. The primary objective
      of this study is to evaluate the short and medium-term effects during 6 months,
      of a multicomponent physical exercise program with a Mediterranean diet on bone
      mineral density, fall risk, balance, and gait by a controlled clinical trial in
      patients with Alzheimer disease. METHODS: The study is a 6-month, randomized
      controlled parallel-group, single-blinded clinical trial. Institutionalized
      patients with Alzheimer disease will be included. The intervention group will
      perform a multicomponent physical exercise program in reduced groups, with a
      frequency of 3 sessions per week, associated with a Mediterranean diet. This
      program includes strength, balance, and aerobic resistance exercises, and in the 
      main part of the session, also ludic exercises to improve agility, coordination, 
      and balance. The control group will receive usual care. The outcomes to assess
      are the change of physical functions, such as gait and balance, and the change of
      bone mineral density by calcaneal quantitative ultrasound, during the study
      follow-up at 1, 3, and 6 months. This clinical trial will generate more and new
      evidence on the effects of a multicomponent physical exercise program and
      Mediterranean diet in patients with Alzheimer disease on risk of falls and
      osteoporotic fractures, the relation of these with bone mineral density, gait and
      balance, and the correlations between them. ETHICS AND DISSEMINATION: This study 
      protocol has been approved by the Ethics Committee of the University of
      Salamanca. The results will be published in peer-reviewed journals and
      disseminated in national and international conferences, to the participants and
      their families, and the general public through the associations of people with
      AD. TRIAL REGISTRATION ID: ClinicalTrials.gov ID: NCT04439097.
FAU - Puente-Gonzalez, Ana Silvia
AU  - Puente-Gonzalez AS
AUID- ORCID: 0000-0002-0230-4636
AD  - Department of Nursing and Physical Therapy. University of Salamanca, Salamanca,
      Spain.
AD  - Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
FAU - Sanchez-Gonzalez, Felipe
AU  - Sanchez-Gonzalez F
AD  - Department of Nursing and Physical Therapy. University of Salamanca, Salamanca,
      Spain.
FAU - Hernandez-Xumet, Juan Elicio
AU  - Hernandez-Xumet JE
AUID- ORCID: 0000-0001-7255-967
AD  - Department of Physical Medicine and Pharmacology, University of La Laguna, Santa 
      Cruz de Tenerife, Spain.
FAU - Sanchez-Sanchez, Maria Carmen
AU  - Sanchez-Sanchez MC
AUID- ORCID: 0000-0002-7391-4394
AD  - Department of Nursing and Physical Therapy. University of Salamanca, Salamanca,
      Spain.
AD  - Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
FAU - Barbero-Iglesias, Fausto Jose
AU  - Barbero-Iglesias FJ
AUID- ORCID: 0000-0001-8407-4127
AD  - Department of Nursing and Physical Therapy. University of Salamanca, Salamanca,
      Spain.
AD  - Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
FAU - Mendez-Sanchez, Roberto
AU  - Mendez-Sanchez R
AUID- ORCID: 0000-0002-4486-4076
AD  - Department of Nursing and Physical Therapy. University of Salamanca, Salamanca,
      Spain.
AD  - Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04439097
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Accidental Falls/prevention & control
MH  - Alzheimer Disease/*therapy
MH  - *Bone Density
MH  - *Diet, Mediterranean
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Gait
MH  - Humans
MH  - Male
MH  - Postural Balance
MH  - Randomized Controlled Trials as Topic
PMC - PMC7505369
EDAT- 2020/09/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022385 [doi]
AID - 00005792-202009180-00117 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22385. doi:
      10.1097/MD.0000000000022385.


PMID- 32957406
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Psychological nursing intervention reduces psychological distress in patients
      with thyroid cancer: A randomized clinical trial protocol.
PG  - e22346
LID - 10.1097/MD.0000000000022346 [doi]
AB  - BACKGROUND: Thyroidectomy has been considered an effective method to treat
      thyroid cancer. However, about 20% of patients have psychological distress before
      surgery. Psychological distress is considered common mental illnesses and it has 
      been reported that the patients who suffer psychological distress have poor
      clinical outcomes than the patients without psychosocial disorder. Therefore, we 
      design this randomized controlled study to explore the effect of psychological
      nursing intervention against quality of life and psychological distress of the
      patients with thyroid cancer. METHOD: The trial will be conducted from September 
      2020 to December 2020 at Wuhan Fourth Hospital on the basis of the International 
      Council for Harmonisation's Good Clinical Practice Guidelines and the principles 
      of the Helsinki Declaration. The study was authorized via the Research Ethics
      Committee of the Wuhan Fourth Hospital (Approval number: 20200721-046). This
      study is a single-center, randomized, 2-arm, evaluator-blinded clinical trial. In
      all, 90 patients with thyroid cancer undergoing thyroidectomy will be enrolled in
      this study. The inclusion criteria includes: patients aged between 20 and 60
      years old; ASA I-II classification; normal platelet coagulation and count
      function. The exclusion criteria contains: people with the intellectual and
      cognitive impairment (behavioral-cognitive intervention); BMI above 35 kg/m; the 
      history of renal and hepatic dysfunction; and patients refuse to participate in
      this study. Both the patients in psychological intervention group and control
      group should receive the routine care, while the psychological intervention group
      also needs to receive the additional proper psychological nursing interventions. 
      The emotional disorders are detected with the Chinese version of Profile of Mood 
      States-Brief. And the patients' life quality is evaluated with the European
      Organization for Research and Treatment of Cancer Quality of Life
      Questionnaire-Core Questionnaire (QLQ-C30, version 3.0). All the data are
      collated into Microsoft Excel 2010 and analyzed with SPSS 12.0 (IBM). RESULTS: It
      is assumed that psychological nursing intervention could alleviate the
      psychological distress of patients with thyroid cancer and improve their quality 
      of life. CONCLUSION: This study can provide the reliable evidence regarding the
      influence of psychological nursing intervention against the life quality and
      psychological distress of the patients with thyroid cancer. TRIAL REGISTRATION:
      This study protocol is registered in Research Registry (researchregistry5937).
FAU - Wu, Lingling
AU  - Wu L
AD  - Department of Pain, Wuhan Fourth Hospital, Hubei, China.
FAU - Zou, Yigang
AU  - Zou Y
AUID- ORCID: 0000-0003-2886-0355
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Psychological Distress
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - Thyroid Neoplasms/nursing/*psychology
MH  - Thyroidectomy/nursing/*psychology
MH  - Young Adult
PMC - PMC7505398
EDAT- 2020/09/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022346 [doi]
AID - 00005792-202009180-00103 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22346. doi:
      10.1097/MD.0000000000022346.


PMID- 32957397
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Preoperative nursing visit reduces preoperative anxiety and postoperative
      complications in patients with laparoscopic cholecystectomy: A randomized
      clinical trial protocol.
PG  - e22314
LID - 10.1097/MD.0000000000022314 [doi]
AB  - BACKGROUND: Anxiety is a kind of emotional disorder caused by acute conditions or
      trigger. It is manifested in the components of the autonomic nervous system, for 
      instance, stress, anxiety, nervosity, and discomfort. Most patients with anxiety 
      are more active, nervous, and alert to various stimuli. Inappropriate management 
      of early postoperative anxiety will not only prolong recovery but also increase
      the risk of other complications. We conduct a randomized clinical trial to
      investigate the influences of nursing visits against the preoperative anxiety and
      postoperative complications in patients undergoing laparoscopic cholecystectomy
      (LC). METHODS: This is a single center, placebo-controlled randomized trial,
      which will be performed from August 2020 to December 2020. The trial is performed
      in accordance with the SPIRIT Checklist for randomized studies. It is authorized 
      by the Ethics Committee of Taizhou Hospital of Zhejiang Province (D20211-34). Two
      hundred patients undergoing LC will be included in this study. Patients are
      randomly divided into 2 groups: experiential group (n = 100) or control group (n 
      = 100). The experimental group is given preoperative nursing visit to each
      patient 1 day before the operation, whereas the control group did not receive the
      preoperative nursing intervention. The patients in experience group also received
      education on the surgery team and the environment of operating room, the process 
      of anesthesia, advantages of laparoscopic surgery, and the postoperative care
      from recovery room to discharge. The primary outcomes include State-Trait anxiety
      level and postoperative visual analogue scale. Secondary outcomes include total
      consumption of analgesics and postoperative complications. RESULTS: Figure (a)
      will show the comparison of outcomes between 2 groups. CONCLUSION: The
      preoperative nursing visit may decrease the anxiety and the complications after
      operation in patients receiving LC. TRIAL REGISTRATION: This study protocol is
      registered in Research Registry (researchregistry5924).
FAU - Xu, Ying
AU  - Xu Y
AD  - Department of Vascular surgical hernia and abdominal surgery, Taizhou Hospital of
      Zhejiang Province, Zhejiang, China.
FAU - Wang, Hui
AU  - Wang H
FAU - Yang, Meijuan
AU  - Yang M
AUID- ORCID: 0000-0001-8211-675
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Anxiety/*prevention & control
MH  - Cholecystectomy, Laparoscopic/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Patient Education as Topic
MH  - Postoperative Complications/*prevention & control
MH  - Preoperative Care/*nursing
MH  - Randomized Controlled Trials as Topic
PMC - PMC7505285
EDAT- 2020/09/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022314 [doi]
AID - 00005792-202009180-00094 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22314. doi:
      10.1097/MD.0000000000022314.


PMID- 32957379
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20220417
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - The efficacy and safety of electroacupuncture against urinary incontinence after 
      stroke: A protocol for systematic review and meta analysis.
PG  - e22275
LID - 10.1097/MD.0000000000022275 [doi]
AB  - BACKGROUND: Urinary incontinence (UI) is still a persistent challenge in many
      stroke survivors, affecting the quality of life and emotional being of these
      individuals. Numerous studies have demonstrated the curative effect of
      electroacupuncture on post-stroke incontinence, however they were mired with
      questionable quality and inconsistencies in safety and efficacy. Therefore, the
      main objective of this meta-analysis is to provide a comprehensive evaluation of 
      the efficacy and safety of electroacupuncture against urinary incontinence after 
      stroke, with a view of providing more reliable evidence-based solutions for UI.
      METHODS: A systematic literature search will be conducted using PubMed, EMBASE,
      the Cochrane Central Register of Controlled Trials, Web of Science, and 4 Chinese
      databases from inception to June 2020 to identify randomized control trials that 
      report on electroacupuncture against urinary incontinence after stroke. Two
      reviewers will independently identify eligible studies and extract data. The risk
      of bias of the included randomized control trials will be evaluated according to 
      the Cochrane tool. Risk ratio and 95% confidence intervals will be used to
      estimate the efficacy of treatment,. and the grading of recommendations,
      assessment, development, and evaluation approach to rate the certainty of
      evidence. The statistical heterogeneity will be evaluated by Cochran's Q and the 
      I. Data will be analyzed using Stata software (Version 13.0, Stata Corp, College 
      Station, TX, USA). RESULTS: This study will provide a comprehensive evaluation of
      the efficacy and safety of electroacupuncture against UI after stroke, with a
      view of providing more reliable evidence-based solutions for UI. ETHICS AND
      DISSEMINATION: This work synthesises evidence from previously published studies
      and does not require ethics review or approval. A manuscript describing the
      findings will be submitted for publication in a peer-reviewed scientific journal.
      INPLASY REGISTRATION NUMBER: INPLASY202050073.
FAU - Wang, Peng
AU  - Wang P
AD  - College of Medicine, Zhengzhou University of Industrial Technology.
AD  - Basic Medicine Department, School of Nursing and Health, Zhengzhou University,
      Zhengzhou.
FAU - Shi, Jiyuan
AU  - Shi J
AD  - Evidence-Based Nursing Centre, School of Nursing.
FAU - Zhao, Liang
AU  - Zhao L
AD  - Evidence-Based Nursing Centre, School of Nursing.
FAU - Li, Mengmeng
AU  - Li M
AD  - Basic Medicine Department, School of Nursing and Health, Zhengzhou University,
      Zhengzhou.
FAU - Jiao, Jiawei
AU  - Jiao J
AD  - Basic Medicine Department, School of Nursing and Health, Zhengzhou University,
      Zhengzhou.
FAU - Li, LingYun
AU  - Li L
AD  - Basic Medicine Department, School of Nursing and Health, Zhengzhou University,
      Zhengzhou.
FAU - Tian, Jinhui
AU  - Tian J
AD  - Evidence-Based Nursing Centre, School of Nursing.
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou City, Gansu
      Province.
FAU - Wang, Shiguang
AU  - Wang S
AD  - College of Medicine, Zhengzhou University of Industrial Technology.
FAU - Zhang, Shanfeng
AU  - Zhang S
AD  - Experimental Center for Basic Medicine.
AD  - Biochemistry and Molecular Biology, Zhengzhou University, Zhengzhou, Henan,
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Electroacupuncture/*adverse effects
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Quality of Life
MH  - Stroke/*complications
MH  - *Systematic Reviews as Topic
MH  - Urinary Incontinence/etiology/*therapy
PMC - PMC7505283
EDAT- 2020/09/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022275 [doi]
AID - 00005792-202009180-00076 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22275. doi:
      10.1097/MD.0000000000022275.


PMID- 32957378
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Comparative efficacy of intravitreal pharmacotherapy for macular edema secondary 
      to retinal vein occlusion: A protocol for the systematic review and network
      meta-analysis.
PG  - e22267
LID - 10.1097/MD.0000000000022267 [doi]
AB  - BACKGROUND: Multiple intravitreal pharmacotherapies including different
      anti-vascular endothelial growth factors (VEGF), intravitreal steroids, and
      combined therapy with anti-VEGF and steroids are available for patients with
      macular edema secondary to retinal vein occlusion (RVO). However, the
      recommendation of multiple therapies remains unknown. This study aims to evaluate
      the efficacy and safety of multiple intravitreal pharmacotherapies in patients
      with macular edema secondary to RVO. METHODS: We will systematically search the
      PubMed, Embase, and the Cochrane library for eligible studies. Randomized
      controlled trials (RCTs) with intravitreal pharmacotherapies for patients with
      macular edema secondary to RVO will be included. The Cochrane Collaboration's
      tool will be used to assess the risk of bias in the randomized trial. The primary
      outcome is the mean change in BCVA from baseline. The secondary outcomes are the 
      proportion of patients who gained >/=15 letters in BCVA from baseline, the mean
      change in central retinal thickness from baseline and the number of serious
      adverse events. RESULTS: The result will obtain a comprehensive treatment
      recommendation for macular edema secondary to RVO. CONCLUSION: The results of the
      network meta-analysis will be submitted in a peer-reviewed journal for
      publication. ETHICAL STATEMENT: This article does not contain any studies with
      human or animal subjects performed by any of the authors.
FAU - Zhang, Yun
AU  - Zhang Y
AD  - Department of Ophthalmology.
FAU - Duan, Jianan
AU  - Duan J
AD  - Department of Ophthalmology.
FAU - Chang, Tiancong
AU  - Chang T
AD  - Department of Ophthalmology.
FAU - Li, Xun
AU  - Li X
AD  - Department of Ophthalmology.
FAU - Wang, Miao
AU  - Wang M
AD  - Department of Ophthalmology.
FAU - Zhang, Meixia
AU  - Zhang M
AD  - Department of Ophthalmology.
AD  - National Clinical Research Center for Geriatrics, West China Hospital, Sichuan
      University, Chengdu, Sichuan, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy/etiology
MH  - *Network Meta-Analysis
MH  - Retinal Vein Occlusion/*complications
MH  - *Systematic Reviews as Topic
PMC - PMC7505385
EDAT- 2020/09/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022267 [doi]
AID - 00005792-202009180-00075 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22267. doi:
      10.1097/MD.0000000000022267.


PMID- 32957364
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Heat-sensitive moxibustion self-administration in patients in the community with 
      primary hypertension: A protocol for a multi-center, pragmatic, non-randomized
      trial.
PG  - e22230
LID - 10.1097/MD.0000000000022230 [doi]
AB  - BACKGROUND: Although the efficacy of antihypertensive drugs has been well
      established for primary hypertension, their effectiveness is always limited by
      side effects and poor compliance. Heat-sensitive moxibustion is an innovative
      acupoint stimulation therapy that is promising as a community health care
      intervention for hypertension. AIMS: This study aims to evaluate the pragmatic
      effectiveness and safety of heat-sensitive moxibustion self-administration by
      patients in the community with primary hypertension. METHODS: This study will
      adopt a multi-center, pragmatic, nonrandomized design. Six hundred patients with 
      primary hypertension will be recruited from 4 communities. Each patient will
      choose to either receive heat-sensitive moxibustion self-administration +
      original antihypertensive drugs or maintain their original antihypertensive drugs
      without heat-sensitive moxibustion for 1 year. EXPECTED OUTCOMES: The primary
      outcome will be changes in systolic and diastolic blood pressures and the
      percentage changes in the doses of antihypertensive drugs. The secondary outcomes
      will be changes in quality of life assessed by a validated patient-reported
      outcome scale and the levels of fasting blood glucose, glycated hemoglobin, total
      cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density
      lipoprotein cholesterol, urinary albumin, and serum creatinine. The proportion of
      patients with poor compliance with the heat-sensitive moxibustion regimen will
      also be evaluated as a secondary outcome. The safety of heat-sensitive
      moxibustion will be considered by analyzing the incidence of all and serious
      adverse events and their correlation with heat-sensitive moxibustion. DISCUSSION:
      The findings of this study will provide pragmatic evidence for heat-sensitive
      moxibustion self-administration in patients in the community with primary
      hypertension and may also establish an ethical basis for further randomized
      controlled trials. TRIAL REGISTRATION: The protocol of this trial was registered 
      in ClinicalTrials.gov at May 11, 2020 (No. NCT04381520).
FAU - Zhou, Xu
AU  - Zhou X
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Wu, Qingni
AU  - Wu Q
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Zhang, Gaochuan
AU  - Zhang G
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Wang, Yanping
AU  - Wang Y
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Li, Shuqing
AU  - Li S
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Wang, Baiyang
AU  - Wang B
AD  - Honggutan Branch, Affiliated Hospital of Jiangxi University of Traditional
      Chinese Medicine.
FAU - Chen, Zhihua
AU  - Chen Z
AD  - The Second Affiliated Hospital of Jiangxi University of Traditional Chinese
      Medicine, Jiangxi, China.
FAU - Zhu, Weifeng
AU  - Zhu W
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Wang, Fei
AU  - Wang F
AUID- ORCID: 0000-0003-3630-8819
AD  - Evidence-based Medicine Research Center, Jiangxi University of Traditional
      Chinese Medicine.
FAU - Gan, Chun
AU  - Gan C
AD  - The Second Affiliated Hospital of Jiangxi University of Traditional Chinese
      Medicine, Jiangxi, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04381520
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Pragmatic Clinical Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - *Hot Temperature
MH  - Humans
MH  - Hypertension/blood/drug therapy/*therapy/urine
MH  - Medication Adherence
MH  - Middle Aged
MH  - Moxibustion/adverse effects/*methods
MH  - Patient Reported Outcome Measures
MH  - Quality of Life
MH  - Self Administration
MH  - Young Adult
PMC - PMC7505380
EDAT- 2020/09/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022230 [doi]
AID - 00005792-202009180-00061 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22230. doi:
      10.1097/MD.0000000000022230.


PMID- 32957328
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic
      review and meta-analysis of randomized clinical trials.
PG  - e22066
LID - 10.1097/MD.0000000000022066 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus(T2DM) is a widespread attention of the
      world's major health problems. The international diabetes federation (IDF) has
      released the "global overview of diabetes (ninth edition)". By 2019. It can lead 
      to complications and even death. Among them, the use of Rhizoma Coptidis
      (Huanglian) at large dose has also been proved to be effective in clinical
      practice. However, due to the lack of evidence, there is no specific method or
      suggestion, so it is necessary to carry out systematic evaluation on coptis
      coptis and provide effective evidence for further research. METHODS AND ANALYSIS:
      We will search the following electronic databases from their inception to May
      2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of
      Science, China National Knowledge Infrastructure. Primary outcomes:fasting blood 
      glucose and glycosylated haemoglobin (A1c). SECONDARY OUTCOMES: plasma
      insulin,blood lipid profile,adverse events,and cost associated with the
      intervention and hospital visit. Data will be extracted by 2 researchers
      independently, risk of bias of the meta-analysis will be evaluated based on the
      Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will
      be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. 
      RESULTS: The results of this study will systematically evaluate the effectiveness
      and safety of large dose of Huanglian intervention for people with T2DM.
      CONCLUSION: The systematic review of this study will summarize the current
      published evidence of large dose of Huanglian for the treatment of T2DM, which
      can further guide the promotion and application of it. ETHICS AND DISSEMINATION: 
      This study is a systematic review, the outcomes are based on the published
      evidence, so examination and agreement by the ethics committee are not required
      in this study. We intend to publish the study results in a journal or conference 
      presentations.Open Science Framework(OSF)registration number: July 21, 2020.
      https://osf.io/w7bj6.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Huang, Xiaoying
AU  - Huang X
FAU - Yue, Rensong
AU  - Yue R
AUID- ORCID: 0000-0002-4417-3312
FAU - Yang, Hongjing
AU  - Yang H
FAU - Zhang, Xinyue
AU  - Zhang X
FAU - Tian, Yuan
AU  - Tian Y
FAU - Ding, Ning
AU  - Ding N
FAU - Zhou, Linyue
AU  - Zhou L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (huanglian)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
PMC - PMC7505349
EDAT- 2020/09/23 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1097/MD.0000000000022066 [doi]
AID - 00005792-202009180-00025 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22066. doi:
      10.1097/MD.0000000000022066.


PMID- 32957320
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Large dosage Huangqin (Scutellaria) and Huanglian (Rhizoma Coptidis) for T2DM: A 
      protocol of systematic review and meta-analysis of randomized clinical trials.
PG  - e22032
LID - 10.1097/MD.0000000000022032 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a metabolic disease with
      widespread concern in the world. It has the characteristics of high incidence
      rate and high disability rate, which seriously affects economic and social
      development. large dose herb Rhizoma Coptidis (Huanglian) and Scutellaria
      (Huangqin) or compound prescription contain large dose Huanglian and Huanglian
      for treatment of T2DM has already been confirmed. However, due to the lack of
      evidence, there is no specific method or suggestion, so it is necessary to carry 
      out systematic evaluation on Coptidis and Scutellaria and provide effective
      evidence for further research. METHODS AND ANALYSIS: The following databases will
      be searched from their inception to June 2020: Electronic database includes
      PubMed, Embase, Cochrane Library, Web of Science, Nature, Science online, Chinese
      Biomedical Database WanFang, VIP medicine information, and China National
      Knowledge Infrastructure. Primary outcomes: fasting blood-glucose (FBG), 2 Hours 
      Postprandial Blood Glucose (2hPBG), Glycosylated hemoglobin A1c (HbA1c).
      additional outcomes: Low Density Lipoprotein (LDL), High Density Lipoprotein
      (HDL), triglycerides (TG), total serum cholesterol (TC). Data will be extracted
      by 2 researchers independently, risk of bias of the meta-analysis will be
      evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions.
      All data analysis will be conducted by data statistics software Review Manager
      V.5.3. and Stata V.12.0. RESULTS: The results of this study will systematically
      evaluate the effectiveness and safety of large dose Huanglian and Huangqin
      intervention for people with T2DM. CONCLUSION: The systematic review of this
      study will summarize the current published evidence of large dose Huanglian and
      Huangqin for the treatment of T2DM, which can further guide the promotion and
      application of it. ETHICS AND DISSEMINATION: This study is a systematic review,
      the outcomes are based on the published evidence, so examination and agreement by
      the ethics committee are not required in this study. We intend to publish the
      study results in a journal or conference presentations. OPEN SCIENCE FRAMEWORK
      (OSF) REGISTRATION NUMBER: July 21, 2020. osf.io/b6r3z. (https://osf.io/b6r3z).
FAU - Huang, Xiaoying
AU  - Huang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Yue, Rensong
AU  - Yue R
AUID- ORCID: 0000-0002-4417-3312
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Ding, Ning
AU  - Ding N
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
FAU - Yang, Hongjing
AU  - Yang H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipids)
RN  - 0 (huanglian)
SB  - IM
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin A
MH  - Healthy Lifestyle
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Lipids/blood
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Scutellaria
PMC - PMC7505284
EDAT- 2020/09/23 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1097/MD.0000000000022032 [doi]
AID - 00005792-202009180-00017 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e22032. doi:
      10.1097/MD.0000000000022032.


PMID- 32957317
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - Complementary and alternative therapies for poststroke depression: A protocol for
      systematic review and network meta-analysis.
PG  - e21995
LID - 10.1097/MD.0000000000021995 [doi]
AB  - BACKGROUND: Poststroke depression (PSD) is an important complication of stroke,
      resulting in increased disability and mortality, which is a great threat to
      stroke survivors and public health. Complementary and alternative medicine (CAM) 
      therapies is widely used in the treatment of PSD, However, the selection
      strategies of different CAM approaches in clinical practice is still not clear,
      and the purpose of this protocol is to compare the efficacy and acceptability of 
      different CAM therapies using systematic review and network meta-analysis.
      METHODS: According to the strategy, the authors will retrieve a total of seven
      electronic databases by August 2020, including PubMed, the Cochrane Library,
      EMbase, China National Knowledge Infrastructure, China Biological Medicine,
      Chinese Scientific Journals Database, and Wan-fang databases. The network
      meta-analysis will be performed using Aggregate Data Drug Information System
      1.16.8 and Stata 13.0 software. In addition, the Cochrane Collaboration's tool is
      employed for the methodological quality, and the quality of evidence will be
      evaluated according to the Grading of Recommendations Assessment, Development,
      and Evaluation system. RESULTS: This study will provide a reliable evidence for
      the selection strategy of CAM therapies for PSD. CONCLUSION: The results of this 
      study will provide references for evaluating the effects of different CAM
      therapies on PSD, and provide decision-making references for clinical
      practitioners, patients, and health policy makers. ETHICS AND DISSEMINATION: This
      study does not require ethical approval. the results will be disseminated through
      a peer-reviewed publication. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/TNGH6.
FAU - Song, Kai
AU  - Song K
AD  - College of acupuncture and Tuina.
FAU - Xiong, Fanjie
AU  - Xiong F
AD  - College of acupuncture and Tuina.
FAU - Wang, Yating
AU  - Wang Y
AD  - College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan Province.
FAU - Wang, Haiyan
AU  - Wang H
AD  - College of acupuncture and Tuina.
AD  - Department of Acupuncture and Moxibustion, Affiliated hospital of Gansu
      university of traditional Chinese medicine, Lanzhou, Gansu Province, China.
FAU - Huang, Ailing
AU  - Huang A
AD  - College of acupuncture and Tuina.
FAU - Zhang, Hong
AU  - Zhang H
AUID- ORCID: 0000-0002-6417-8399
AD  - College of acupuncture and Tuina.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Combined Modality Therapy
MH  - Complementary Therapies
MH  - Depression/*etiology/*therapy
MH  - Humans
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Stroke/*complications
PMC - PMC7505372
EDAT- 2020/09/23 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1097/MD.0000000000021995 [doi]
AID - 00005792-202009180-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e21995. doi:
      10.1097/MD.0000000000021995.


PMID- 32957313
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 38
DP  - 2020 Sep 18
TI  - The effect of varicocele repair for sperm DNA fragmentation: A protocol for
      systematic review and meta-analysis.
PG  - e21960
LID - 10.1097/MD.0000000000021960 [doi]
AB  - INTRODUCTION: Sperm DNA integrity has been considered as one of the important
      determinants of normal fertilization and embryonic development in natural and
      assisted pregnancy. It is difficult for men with high levels of sperm DNA
      fragmentation (SDF) in semen to conceive their partners naturally and assist in
      conception. The studies have found that the level of SDF in the semen of patients
      with varicocele (VC) was on the high side. In recent years, the effect of VC
      surgery on DNA fragmentation index has attracted the attention of researchers. In
      this study, we will evaluate the effectiveness of VC repair as a way to alleviate
      SDF and improve male fertility. METHODS AND ANALYSIS: Electronic databases
      including English databases (PubMed, MEDLINE, EMBASE, Web of Science, Cochrane
      Library) and Chinese databases (China National Knowledge Infrastructure, China
      Biology Medicine Database, Wanfang Database, VIP Database) will be searched from 
      their inception to December 2020 to recognize related studies. All the randomized
      controlled trials of microsurgical varicocelectomy for the management of VC
      patients will be included. The potential outcome will include improvement in SDF,
      oxidative stress markers (reactive oxygen species, nitric oxide, and lipid
      peroxidation products), sperm chromatin compaction, other advanced sperm function
      characteristics, follow-up of fertility results. We will conduct this study
      strictly according to the Cochrane Handbook for Systematic Reviews of
      Interventions. RESULTS: The study is a protocol for systematic review and
      meta-analysis without results, and data analysis will be carried out after the
      protocol. We will share our findings on April 5th of 2021. CONCLUSION: This
      systematic review will provide more evidence to assess whether varicocelectomy is
      an effective intervention for patients with SDF. The results will be published in
      a public issue journal and offer the urologists help to make clinical decisions. 
      ETHICS AND DISSEMINATION: Formal ethical approval is not required in this
      protocol. We will collect and analyze data based on published research. Since
      this research does not involve patients, personal privacy will not be affected.
      The results of this review will be distributed to peer-reviewed journals or
      submitted to relevant conferences. PROTOCOL REGISTRATION NUMBER:
      INPLASY202070119.
FAU - Yao, Hangyu
AU  - Yao H
AUID- ORCID: 0000-0003-0481-6165
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Li, Fuhao
AU  - Li F
FAU - Qiu, Xianliang
AU  - Qiu X
FAU - Xu, Yuanjie
AU  - Xu Y
FAU - Xue, Pengfei
AU  - Xue P
FAU - Chang, Degui
AU  - Chang D
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Chromatin)
SB  - IM
MH  - Chromatin/metabolism
MH  - *DNA Fragmentation
MH  - Humans
MH  - Male
MH  - Oxidative Stress/physiology
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Spermatozoa/*pathology
MH  - Varicocele/*surgery
PMC - PMC7505379
EDAT- 2020/09/23 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/09/22 01:02
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1097/MD.0000000000021960 [doi]
AID - 00005792-202009180-00010 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 18;99(38):e21960. doi:
      10.1097/MD.0000000000021960.


PMID- 32957025
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 266
DP  - 2020 Dec
TI  - Parents' decision-making following diagnosis of a severe congenital anomaly in
      pregnancy: Practical, theoretical and ethical tensions.
PG  - 113362
LID - S0277-9536(20)30581-5 [pii]
LID - 10.1016/j.socscimed.2020.113362 [doi]
AB  - Patient involvement, in the form of shared decision-making, is advocated within
      healthcare. This is informed by the principlist account of patient autonomy that 
      prioritises informed understanding, and decision-making free from coercion. This 
      arguably over-simplifies the role of the social, whilst overlooking the role of
      culture and context in medical decision-making. Clinicians encourage patients to 
      demonstrably make decisions in the principlist 'style' that fit with their
      understandings of ethically 'correct' ways to support patient decision-making.
      However, this expected 'style' is often not achieved in practice. In this
      article, we use empirical data from a qualitative study exploring parental
      decision-making following diagnosis or suspicion of a severe congenital anomaly
      in pregnancy. Our study was based in four fetal medicine clinics in England,
      comprising semi-structured interviews with 38 parents whose pregnancy was
      affected by a severe congenital anomaly, 18 interviews with fetal medicine
      clinicians, and audio-recordings of 48 consultations. Examination of the dynamics
      at play within different approaches to decision-making highlights how the
      idealised concepts proposed in theory fail to capture real-life experiences of
      medical decision-making. The influence of the patient-clinician relationship on
      decisions is brought to the fore, highlighting the influence of power dynamics in
      implicitly and explicitly influencing patient decisions, and the need to better
      address this in policy and practice.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Paton, Alexis
AU  - Paton A
AD  - Department of Sociology and Policy, Aston University, Birmingham, B4 7ET, UK.
      Electronic address: a.paton@aston.ac.uk.
FAU - Armstrong, Natalie
AU  - Armstrong N
AD  - SAPPHIRE Group, University of Leicester, Leicester, LE1 7RH, UK.
FAU - Smith, Lucy
AU  - Smith L
AD  - Department of Health Sciences, University of Leicester, Leicester, LE1 7RH, UK.
FAU - Lotto, Robyn
AU  - Lotto R
AD  - School of Nursing and Allied Health, Liverpool John Moores University, Tithebarn 
      Building, 79 Tithebarn Street, Liverpool, L2 2ER, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - *Decision Making
MH  - England
MH  - Female
MH  - Humans
MH  - Morals
MH  - *Parents
MH  - Pregnancy
MH  - Qualitative Research
OTO - NOTNLM
OT  - *Bioethics
OT  - *Congenital anomaly
OT  - *Decision-making
OT  - *Empirical ethics
OT  - *Patient autonomy
OT  - *Qualitative
OT  - *Sociological bioethics
EDAT- 2020/09/22 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/21 20:19
PHST- 2020/09/04 00:00 [revised]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/21 20:19 [entrez]
AID - S0277-9536(20)30581-5 [pii]
AID - 10.1016/j.socscimed.2020.113362 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Dec;266:113362. doi: 10.1016/j.socscimed.2020.113362. Epub 2020
      Sep 13.


PMID- 32956930
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220418
IS  - 1873-491X (Electronic)
IS  - 0020-7489 (Linking)
VI  - 111
DP  - 2020 Nov
TI  - Instruments to assess moral distress among healthcare workers: A systematic
      review of measurement properties.
PG  - 103767
LID - S0020-7489(20)30253-4 [pii]
LID - 10.1016/j.ijnurstu.2020.103767 [doi]
AB  - BACKGROUND: An increasing number of professionals are challenged by the evolution
      of modern healthcare and society, often characterized by more expectations with
      reduced resources. Moral distress is among the psychophysical conditions now most
      under investigation in order to improve the wellbeing of professionals, the
      sustainability of organizations and the quality of care. Over the last decades,
      several instruments have been developed to assess the frequency or intensity of
      moral distress in different studies. Yet, there has not been, so far, a
      systematic assessment of the qualitative properties of the various instruments
      measuring moral distress in healthcare workers based on a universally accepted
      standardized framework. OBJECTIVE: (1) To identify all instruments for the
      measurement of moral distress available in recent literature; (2) to evaluate the
      evidence regarding their measurement properties; (3) to facilitate the selection 
      of the most appropriate instrument to be adopted in practice and research.
      DESIGN: Systematic literature review. DATA SOURCES: PubMed, CINAHL, and PyscINFO.
      REVIEW METHODS: The COnsensus-based Standards for the selection of health
      Measurement INstruments checklist was used to evaluate the methodological quality
      of the identified studies. The quality of measurement properties of each
      instrument was evaluated using Terwee's quality criteria. RESULTS: Among the 1268
      studies found, 88 full-text articles evaluated moral distress adopting different 
      tools. Thirty two of them had a methodological design. The measurement
      instruments assessed in this review are different in terms of targeted population
      and items. The instruments were then divided into two main categories: (1)
      Corley's instruments on moral distress (Moral distress scale and Moral Distress
      Scale - Revised) and (2) instruments not directly derived from Corley's moral
      distress theory (Moral Distress thermometer, Moral Distress Risk Scale, Ethical
      Stress Scale or Moral Distress in Dementia Care Survey). The first set is the
      most frequently studied and used in different clinical settings and healthcare
      populations. A variety of psychometric properties have been evaluated for each
      instrument, revealing different qualities in the methodology used. CONCLUSIONS:
      Several instruments assessing moral distress in healthcare workers have been
      identified and evaluated in this systematic review. Based on the criteria used
      here, Corley's instruments on moral distress seems to be the most useful and most
      appropriate to the clinical setting for practice and research purposes. TWEETABLE
      ABSTRACT: The aim of this systematic review was to identify the instruments
      measuring moral distress now available in the literature, in order to (1) assess 
      the evidence about their measurement properties, (2) support the selection of the
      most appropriate instrument to be used in practice and research.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Giannetta, Noemi
AU  - Giannetta N
AD  - Faculty of Philosophy, Vita-Salute San Raffaele University, Milan, Italy;
      Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome,
      Italy. Electronic address: giannetta.noemi@hsr.it.
FAU - Villa, Giulia
AU  - Villa G
AD  - IRCCS San Raffaele Scientific Institute, Milan, Italy.
FAU - Pennestri, Federico
AU  - Pennestri F
AD  - Faculty of Philosophy, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Sala, Roberta
AU  - Sala R
AD  - Faculty of Philosophy, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Mordacci, Roberto
AU  - Mordacci R
AD  - Faculty of Philosophy, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Manara, Duilio Fiorenzo
AU  - Manara DF
AD  - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan,
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20200902
PL  - England
TA  - Int J Nurs Stud
JT  - International journal of nursing studies
JID - 0400675
SB  - IM
MH  - *Delivery of Health Care
MH  - *Health Personnel
MH  - Humans
MH  - Morals
MH  - Psychometrics
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Ethics
OT  - Health personnel
OT  - Instruments
OT  - Moral distress
OT  - Nursing
OT  - Nursing staff
OT  - Psychological
OT  - Psychometric properties
OT  - Scales
OT  - Stress
COIS- Declaration of Competing Interest None.
EDAT- 2020/09/22 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/21 20:14
PHST- 2020/04/15 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/09/21 20:14 [entrez]
AID - S0020-7489(20)30253-4 [pii]
AID - 10.1016/j.ijnurstu.2020.103767 [doi]
PST - ppublish
SO  - Int J Nurs Stud. 2020 Nov;111:103767. doi: 10.1016/j.ijnurstu.2020.103767. Epub
      2020 Sep 2.


PMID- 32956415
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201028
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Meconium microbiome and its relation to neonatal growth and head circumference
      catch-up in preterm infants.
PG  - e0238632
LID - 10.1371/journal.pone.0238632 [doi]
AB  - The purpose was identify an association between meconium microbiome,
      extra-uterine growth restriction, and head circumference catch-up. MATERIALS AND 
      METHODS: Prospective study with preterm infants born <33 weeks gestational age
      (GA), admitted at Neonatal Unit and attending the Follow-Up Preterm Program of a 
      tertiary hospital. Excluded out born infants; presence of congenital
      malformations or genetic syndromes; congenital infections; HIV-positive mothers; 
      and newborns whose parents or legal guardians did not authorize participation.
      Approved by the institution's ethics committee. Conducted 16S rRNA sequencing
      using PGM Ion Torrent meconium samples for microbiota analysis. RESULTS: Included
      63 newborns, GA 30+/-2.3 weeks, mean weight 1375.80+/-462.6 grams, 68.3% adequate
      weight for GA at birth. Polynucleobacter (p = 0.0163), Gp1 (p = 0.018), and
      Prevotella (p = 0.038) appeared in greater abundance in meconium of preterm
      infants with adequate birth weight for GA. Thirty (47.6%) children reached head
      circumference catch-up before 6 months CA and 33 (52.4%) after 6 months CA.
      Salmonella (p<0.001), Flavobacterium (p = 0.026), and Burkholderia (p = 0.026)
      were found to be more abundant in meconium in the group of newborns who achieved 
      catch-up prior to 6th month CA. CONCLUSION: Meconium microbiome abundance was
      related to adequacy of weight for GA. Meconium microbiome differs between
      children who achieve head circumference catch-up by the 6th month of corrected
      age or after this period.
FAU - Terrazzan Nutricionist, Ana Carolina
AU  - Terrazzan Nutricionist AC
AD  - Postgraduate Program in Child and Adolescent Health-PPGSCA, Federal University of
      Rio Grande do Sul-UFRGS, Porto Alegre, Brazil.
FAU - Procianoy, Renato S
AU  - Procianoy RS
AUID- ORCID: 0000-0001-8297-4164
AD  - Neonatal Intensive Care Unit Hospital de Clinicas de Porto Alegre, RS, Porto
      Alegre, Brazil.
FAU - Roesch, Luiz Fernando Wurdig
AU  - Roesch LFW
AD  - Interdisciplinary Center for Biotechnology Research-CIP-Biotec Federal University
      of Pampa, Sao Gabriel, Rio Grande do Sul, Brazil.
FAU - Corso, Andrea Lucia
AU  - Corso AL
AUID- ORCID: 0000-0003-1186-5133
AD  - Neonatal Intensive Care Unit Hospital de Clinicas de Porto Alegre, RS, Porto
      Alegre, Brazil.
FAU - Dobbler, Priscila Thiago
AU  - Dobbler PT
AUID- ORCID: 0000-0002-7681-5463
AD  - Interdisciplinary Center for Biotechnology Research-CIP-Biotec Federal University
      of Pampa, Sao Gabriel, Rio Grande do Sul, Brazil.
FAU - Silveira, Rita C
AU  - Silveira RC
AUID- ORCID: 0000-0002-2982-2652
AD  - Postgraduate Program in Child and Adolescent Health-PPGSCA, Federal University of
      Rio Grande do Sul-UFRGS, Porto Alegre, Brazil.
AD  - Neonatal Intensive Care Unit Hospital de Clinicas de Porto Alegre, RS, Porto
      Alegre, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200921
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Biodiversity
MH  - *Cephalometry
MH  - Female
MH  - Gastrointestinal Microbiome
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature/*growth & development
MH  - Male
MH  - Meconium/*microbiology
MH  - *Microbiota
MH  - Milk, Human
MH  - Multivariate Analysis
MH  - Phylogeny
PMC - PMC7505439
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/22 06:00
MHDA- 2020/10/29 06:00
CRDT- 2020/09/21 17:14
PHST- 2019/12/11 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/21 17:14 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
AID - 10.1371/journal.pone.0238632 [doi]
AID - PONE-D-19-32916 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 21;15(9):e0238632. doi: 10.1371/journal.pone.0238632.
      eCollection 2020.


PMID- 32956174
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20211204
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 6
DP  - 2020 Dec
TI  - Ethical Centralization of High-risk Surgery Requires Racial and Economic Justice.
PG  - 917-918
LID - 10.1097/SLA.0000000000004460 [doi]
FAU - Binkley, Charles E
AU  - Binkley CE
AD  - Markkula Center for Applied Ethics at Santa Clara University, Santa Clara,
      California.
FAU - Kemp, David S
AU  - Kemp DS
AD  - UC Berkeley School of Law, Berkeley, California.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
MH  - Centralized Hospital Services/*ethics
MH  - Economic Factors
MH  - Health Equity/*ethics
MH  - Humans
MH  - Postoperative Complications/epidemiology/*prevention & control
MH  - *Racial Groups
MH  - Risk Assessment
MH  - Social Justice/*ethics
MH  - Surgical Procedures, Operative/*ethics
MH  - United States
EDAT- 2020/09/22 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/09/21 17:13
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2020/09/21 17:13 [entrez]
AID - 10.1097/SLA.0000000000004460 [doi]
AID - 00000658-202012000-00010 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Dec;272(6):917-918. doi: 10.1097/SLA.0000000000004460.


PMID- 32955812
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201022
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 9
DP  - 2020 Sep
TI  - [RATIONAL DE-PRESCRIBING TO TREAT POLYPHARMACY - COUNTERING THE FIRST IATROGENIC 
      EPIDEMIC].
PG  - 683-688
AB  - INTRODUCTION: Improved medical technology is associated with rapidly growing
      sub-populations suffering from incurable co-morbidities for prolonged periods of 
      time before death. Although there is no evidence based medicine (EBM) proving
      positive benefit/risk ratios for most medications in these sub-populations, it is
      evident that they are attended by an increased number of specialists, each of
      whom add medications based on "their" guidelines. Eventually, more people suffer 
      from inappropriate medication use and polypharmacy (IMUP); IMUP's negative
      medical, economic and social consequences represent the 21st-century iatrogenic
      pandemic. Many barriers interfere with attempts to de-prescribe: The myth
      "drugs=health" is a deep-rooted value; de-prescribing is automatically perceived 
      negatively; physicians are not trained to de-prescribe; and discussing
      de-prescribing with the patient/family is time consuming. In an era of defensive 
      medicine, physicians have fears of lawsuits, of patient/family's reactions, fears
      of not following all guideline recommendations, despite the age-related decrease 
      in their benefit/risk ratio. Like other pandemics, combined international efforts
      are required in order to manage IMUP effectively. The International Group for
      Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP) was established
      and has begun sowing the seeds of global collaboration. Partnership with
      patients/families in decision-making is essential in geriatric-palliative ethical
      approaches, to overcome barriers to de-prescribing. Borrowing the language of
      epidemics, several approaches of "curing the infected" (reducing polypharmacy)
      were suggested; Israeli studies have proven improved functional, mental and
      cognitive status and patient/family satisfaction, following massive
      de-prescribing, compared with those who adhered to standard recommendations.
      "Immunization" (prevention), should concentrate on early education of
      professionals and laymen about IMUP and de-prescribing. Rational de-prescribing
      represents "a triple-win-win game"- improves life quality in the last years of
      life and has huge economic benefits.
FAU - Garfinkel, Doron
AU  - Garfinkel D
AD  - Center for Appropriate Medication Use in Adults.
AD  - Older People, Sheba Medical Center, Israel.
AD  - Homecare Service, Israel Cancer Association.
AD  - IGRIMUP- the International Group for Reducing Inappropriate Medication Use.
AD  - Polypharmacy (Founder).
LA  - heb
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - Aged
MH  - Comorbidity
MH  - Epidemics
MH  - Humans
MH  - *Iatrogenic Disease
MH  - *Inappropriate Prescribing
MH  - *Polypharmacy
EDAT- 2020/09/22 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/09/21 12:15
PHST- 2020/09/21 12:15 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Sep;159(9):683-688.


PMID- 32954017
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Arms sales and child health.
PG  - e000809
LID - 10.1136/bmjpo-2020-000809 [doi]
AB  - The adverse effects of armed conflict on child health are well recognised. The
      relationships among the arms trade, armed conflict and child health are less
      clearly defined. The arms trade is one of the largest industries in the world
      (total expenditure US$1917 billion in 2019), generating colossal profits to
      private companies and individuals at the expense of taxpayers throughout the
      world. The money wasted on weapons designed to kill and maim should be used for
      more socially useful products, such as clean water, food, health and education.
      The sustainable development goals can be funded by diverting money from the arms 
      companies. Health professionals and their organisations have a responsibility to 
      children to try and curb the ever-expanding arms industry.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Feinstein, Andrew
AU  - Feinstein A
AD  - Shadow World Investigations (formerly Corruption Watch UK), London, UK.
FAU - Choonara, Imti
AU  - Choonara I
AUID- ORCID: 0000-0002-3069-6323
AD  - Child Health, University of Nottingham School of Medicine, Derby, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200909
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7482471
OTO - NOTNLM
OT  - epidemiology
OT  - ethics
COIS- Competing interests: IC is Editor in Chief of BMJ Paediatrics Open.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:21
PHST- 2020/07/20 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/21 06:21 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.1136/bmjpo-2020-000809 [doi]
AID - bmjpo-2020-000809 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Sep 9;4(1):e000809. doi: 10.1136/bmjpo-2020-000809.
      eCollection 2020.


PMID- 32953914
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Nurses' professional competences in providing care to the injured in earthquake: 
      A qualitative study.
PG  - 188
LID - 10.4103/jehp.jehp_214_20 [doi]
AB  - BACKGROUND: Iran has experienced an increasing number of earthquake disasters in 
      the past three decades. Due to nurses' unique role as professional and volunteer 
      responders in times of disaster, more information is required regarding the
      capabilities they need to provide more effective care during the crisis. The aim 
      of this study was to identify professional capabilities needed by nurses to
      provide care to the injured of earthquake. MATERIALS AND METHODS: The present
      study was conducted as a qualitative conventional content analysis, and data
      collection was carried out through 16 semi-structured and in-depth interviews
      with the nurses involved in providing care to the injured in the Kermanshah
      earthquake. The data were analyzed following Graneheim and Lundman's approach.
      RESULTS: Data analysis led to the emergence of 427 primary codes, 10
      subcategories, and four categories. The four categories included clinical
      competence (professional knowledge and clinical skills), personal competences
      (communication skills, resiliency, and creativity and innovation in providing
      care), ethical competence (commitment to ethics and professional responsibility),
      and essential skills in caring for the injured (skills in triage, psychological
      care skills, and skills in observation and monitoring). CONCLUSION: The present
      study identified a wide range of professional capabilities required by nurses in 
      disasters. Given that nurses do not acquire some of these specialized and
      technical skills during their education, it is recommended to enhance the
      professional capacity of nurses in disasters. In addition, special training
      programs in this field can be incorporated into the curriculum of nursing
      programs and in-service nursing education.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Rezaei, Soheila Ahangarzadeh
AU  - Rezaei SA
AD  - Department of Nursing, School of Nursing and Midwifery, Urmia University of
      Medical Science, Urmia, Iran.
FAU - Abdi, Alireza
AU  - Abdi A
AD  - Department of Nursing, School of Nursing and Midwifery, Kermanshah University of 
      Medical Science, Kermanshah, Iran.
FAU - Akbari, Farzaneh
AU  - Akbari F
AD  - Department of Midwifery, School of Nursing and Midwifery, Kermanshah University
      of Medical Science, Kermanshah, Iran.
FAU - Moradi, Khalil
AU  - Moradi K
AD  - Department of Nursing, School of Nursing and Midwifery, Urmia University of
      Medical Science, Urmia, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7482699
OTO - NOTNLM
OT  - Earthquake
OT  - nurses
OT  - professional competence
OT  - qualitative study
COIS- There are no conflicts of interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:20
PHST- 2020/03/14 00:00 [received]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/09/21 06:20 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.4103/jehp.jehp_214_20 [doi]
AID - JEHP-9-188 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Jul 28;9:188. doi: 10.4103/jehp.jehp_214_20.
      eCollection 2020.


PMID- 32953908
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - The role of hidden curriculum in the formation of professional ethics in Iranian 
      medical students: A qualitative study.
PG  - 180
LID - 10.4103/jehp.jehp_172_20 [doi]
AB  - INTRODUCTION: Professionalism and medical ethics are a vital quality for doctors,
      which has been taken into account seriously in recent years. Perception of the
      factors affecting professionalism may help develop more efficient approaches to
      promote this quality in medical education. This study was aimed to explain the
      role of hidden curriculum in the formation of professional ethics in Iranian
      medical students. MATERIALS AND METHODS: This qualitative study was performed on 
      15 medical interns of Kermanshah University of Medical Sciences in 2019, using
      grounded theory. Sampling was started by purposive sampling and continued through
      theoretical sampling until complete data saturation. Data collection and analysis
      were done simultaneously. Data were interpreted by a constant comparative method 
      according to Strauss and Corbin's approach. RESULTS: The analysis of the
      participants' interviews and reduction of findings using common themes yielded
      one class and four categories as well as a number of concepts as the role of
      hidden curriculum in the formation of professional ethics in medical students.
      The categories included the role of modeling in the formation of professional
      ethics, role of education in the formation of professional ethics, role of
      environmental factors in the formation of professional ethics, and role of
      personal and inherent attributes in the formation of professional ethics.
      CONCLUSION: Curriculum developers and medical education authorities need to
      proceed in line with the findings of the present study to provide a proper
      learning environment, in which the modeling, learning, and teaching conditions
      and supportive environmental atmosphere are taken into account in accordance with
      the inherent and individual characteristics of the learners in order to guarantee
      the formation of professional ethics in medical students.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Safari, Yahya
AU  - Safari Y
AD  - Research Center for Environmental Determinants of Health, Health Institute,
      Kermanshah University of Medical Sciences, Kermanshah, Iran.
FAU - Khatony, Alireza
AU  - Khatony A
AD  - Social Development and Health Promotion Research Center, Kermanshah University of
      Medical Sciences, Kermanshah, Iran.
FAU - Khodamoradi, Ehsan
AU  - Khodamoradi E
AD  - Department of Radiology and Nuclear Medicine, School of Paramedical Sciences,
      Kermanshah University of Medical Sciences, Kermanshah, Iran.
FAU - Rezaei, Mansour
AU  - Rezaei M
AD  - Department of Biostatistics and Epidemiology, Social Development and Health
      Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah,
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7482700
OTO - NOTNLM
OT  - Curriculum
OT  - medical education
OT  - professional ethics
OT  - professionalism
COIS- There are no conflicts of interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:20
PHST- 2020/02/25 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/09/21 06:20 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.4103/jehp.jehp_172_20 [doi]
AID - JEHP-9-180 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Jul 28;9:180. doi: 10.4103/jehp.jehp_172_20.
      eCollection 2020.


PMID- 32953399
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Sep
TI  - On the BACB's Ethics Requirements: A Response to Rosenberg and Schwartz (2019).
PG  - 714-717
LID - 10.1007/s40617-020-00463-6 [doi]
AB  - Rosenberg and Schwartz (Behavior Analysis in Practice, 12, 473-482, 2019)
      criticize a number of aspects of the Behavior Analyst Certification Board's
      Professional and Ethical Compliance Code for Behavior Analysts and propose, as an
      alternative, a decision-making process for evaluating the ethicality of behavior 
      under a particular set of circumstances. We respond to the authors' main
      criticisms and discuss the broader professional and legal context of any
      profession's ethics code and enforcement activity.
CI  - (c) The Author(s) 2020.
FAU - Sellers, Tyra P
AU  - Sellers TP
AUID- ORCID: 0000-0002-8072-8856
AD  - Behavior Analyst Certification Board, 7950 Shaffer Parkway, Littleton, CO 80127
      USA.
FAU - Carr, James E
AU  - Carr JE
AD  - Behavior Analyst Certification Board, 7950 Shaffer Parkway, Littleton, CO 80127
      USA.
FAU - Nosik, Melissa R
AU  - Nosik MR
AD  - Behavior Analyst Certification Board, 7950 Shaffer Parkway, Littleton, CO 80127
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200612
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7471222
OTO - NOTNLM
OT  - BACB
OT  - Behavior analysts
OT  - Ethics
OT  - Ethics code
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:13
PHST- 2020/09/21 06:13 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.1007/s40617-020-00463-6 [doi]
AID - 463 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Jun 12;13(3):714-717. doi: 10.1007/s40617-020-00463-6.
      eCollection 2020 Sep.


PMID- 32953302
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 16
TI  - A Simple Technique for Intraoperative Scalp Skin Graft Depilation Using
      Dermabond(R).
PG  - e9786
LID - 10.7759/cureus.9786 [doi]
AB  - Skin grafting is an essential aspect of burn and wound reconstruction.
      Split-thickness skin grafts (STSGs) harvested from the scalp are used for wound
      and burn reconstruction. Skin grafts from the scalp bear hair and hair particles.
      Residual hair fragments and pieces of hair in the graft have been associated with
      many complications, including foreign body reaction similar to pseudofolliculitis
      and chronic inflammation that can lead to infections. It is important to remove
      the hair and the hair particles from the scalp graft before its application to
      the donor site. Traditionally, surgeons have employed some techniques including
      saline agitation and mechanical removal of the hair particles with forceps. These
      techniques are time consuming and can subject the graft to mechanical damage.
      There is another technique that has been described using an adhesive tape. This
      technique uses Ioban (3M Healthcare, St. Paul, MN), followed by a saline wash to 
      remove hair from grafts prior to grafting. In this paper, we introduce a novel
      technique for intraoperative hair depilation prior to graft application to
      recipient site. We used Dermabond(R) (Ethicon, Bridgewater, NJ) to remove
      residual hair particles from the STSG donor. Our technique has several
      advantages: it is expeditious, it allows minimal mechanical damage to the graft, 
      and can be used for patients with allergies to Ioban. Intraoperative Dermabond
      depilation of scalp STSGs is safe, easy, and effective.
CI  - Copyright (c) 2020, Opoku-Agyeman et al.
FAU - Opoku-Agyeman, Jude L
AU  - Opoku-Agyeman JL
AD  - Plastic Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, USA.
FAU - Humenansky, Kayla
AU  - Humenansky K
AD  - Plastic and Reconstructive Surgery, Philadelphia College of Osteopathic Medicine,
      Philadelphia, USA.
FAU - Burkey, Brooke
AU  - Burkey B
AD  - Plastic and Reconstructive Surgery, St. Christopher Hospital for Children,
      Philadelphia, USA.
LA  - eng
PT  - Journal Article
DEP - 20200816
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7491690
OTO - NOTNLM
OT  - dermabond
OT  - graft depilation
OT  - scalp graft
OT  - skin graft
OT  - surgical glue
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:12
PHST- 2020/09/21 06:12 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.7759/cureus.9786 [doi]
PST - epublish
SO  - Cureus. 2020 Aug 16;12(8):e9786. doi: 10.7759/cureus.9786.


PMID- 32953242
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2164-2591 (Print)
IS  - 2164-2591 (Linking)
VI  - 9
IP  - 10
DP  - 2020 Sep
TI  - Robotic Retinal Surgery Impacts on Scleral Forces: In Vivo Study.
PG  - 2
LID - 10.1167/tvst.9.10.2 [doi]
AB  - Purpose: This study aims to map force interaction between instrument and sclera
      of in vivo rabbits during retinal procedures, and verify if a robotic active
      force control could prevent unwanted increase of forces on the sclera. Methods:
      Experiments consisted in the performance of intraocular movements of a force
      sensing instrument, adjacent to the retinal surface, in radial directions, from
      the center to the periphery and back, and compared manual manipulations with
      robotic assistance and also robotic assistance with an active force control. This
      protocol was approved by the Animal Use and Ethical Committee and experiments
      were according to ARVO Statement of Animal Use. Results: Mean forces using manual
      manipulations were 115 +/- 51 mN. Using robotic assistance, mean forces were 118 
      +/- 49 mN. Using an active force control method, overall mean forces reduced to
      69 +/- 15, with a statistical difference compared with other methods (P < 0.001).
      Comparing intraocular directions, superior sector required higher forces and the 
      force control method reduced differences in forces between users and retained the
      same force pattern between them. Conclusions: Results validate that the
      introduction of robotic assistance might increase the dynamic interactions
      between instrument and sclera, and the addition of an active force control method
      reduces the forces at levels lower than manual manipulations. Translational
      Relevance: All marketing benefits from extreme accuracy and stability from
      robots, however, redundancy of safety mechanisms during intraocular
      manipulations, especially on force control and surgical awareness, would allow
      all utility of robotic assistance in ophthalmology.
CI  - Copyright 2020 The Authors.
FAU - Urias, Muller G
AU  - Urias MG
AD  - Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD, USA.
AD  - Federal University of Sao Paulo, Sao Paulo, Brazil.
FAU - Patel, Niravkumar
AU  - Patel N
AD  - Laboratory for Computational Sensing and Robotics, Johns Hopkins University,
      Baltimore, MD.
FAU - Ebrahimi, Ali
AU  - Ebrahimi A
AD  - Laboratory for Computational Sensing and Robotics, Johns Hopkins University,
      Baltimore, MD.
FAU - Iordachita, Iulian
AU  - Iordachita I
AD  - Laboratory for Computational Sensing and Robotics, Johns Hopkins University,
      Baltimore, MD.
FAU - Gehlbach, Peter L
AU  - Gehlbach PL
AD  - Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD, USA.
AD  - Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA.
LA  - eng
GR  - R01 EB023943/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200901
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
MH  - Animals
MH  - Microsurgery
MH  - Rabbits
MH  - Retina/surgery
MH  - *Robotic Surgical Procedures/adverse effects
MH  - *Robotics
MH  - Sclera/surgery
PMC - PMC7476674
OTO - NOTNLM
OT  - *microsurgery
OT  - *retina
OT  - *robotic surgical procedures
COIS- Disclosure: M.G. Urias, None; N. Patel, None; A. Ebrahimi, None; I, Iordachita,
      None; P.L. Gehlbach, None
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:11
PHST- 2020/04/03 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/09/21 06:11 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.1167/tvst.9.10.2 [doi]
AID - TVST-20-2482 [pii]
PST - epublish
SO  - Transl Vis Sci Technol. 2020 Sep 1;9(10):2. doi: 10.1167/tvst.9.10.2. eCollection
      2020 Sep.


PMID- 32953110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-9434 (Print)
IS  - 2049-9434 (Linking)
VI  - 13
IP  - 5
DP  - 2020 Nov
TI  - Novel genetic therapeutic approaches for modulating the severity of
      beta-thalassemia (Review).
PG  - 48
LID - 10.3892/br.2020.1355 [doi]
AB  - Thalassemia is a genetic haematological disorder that arises due to defects in
      the alpha and beta-globin genes. Worldwide, 0.3-0.4 million children are born
      with haemoglobinopathies per year. Thalassemic patients, as well as their
      families, face various serious clinical, socio-economic, and psychosocial
      challenges throughout their life. Different therapies are available in clinical
      practice to minimize the suffering of thalassemic patients to some extent and
      potentially cure the disease. Predominantly, patients undergo transfusion therapy
      to maintain their haemoglobin levels. Due to multiple transfusions, the iron
      levels in their bodies are elevated. Iron overload results in damage to body
      organs, resulting in heart failure, liver function failure or endocrine failure, 
      all of which are commonly observed. Certain drugs have been developed to enhance 
      the expression of the gamma-gene, which ultimately results in augmentation of
      fetal haemoglobin (HbF) levels and total haemoglobin levels in the body. However,
      its effectiveness is dependent on the genetic makeup of the individual patient.
      At present, allogeneic haematopoietic Stem Cell Transplantation (HSCT) is the
      only practically available option with a high curative rate. However, the outcome
      of HSCT is strongly influenced by factors such as age at transplantation,
      irregular iron chelation history before transplantation, histocompatibility, and 
      source of stem cells. Gene therapy using the lentiglobin vector is the most
      recent method for cure without any mortality, graft rejection and clonal
      dominance issues. However, delayed platelet engraftment is being reported in some
      patients. Genome editing is a novel approach which may be used to treat patients 
      with thalassemia; it makes use of targeted nucleases to correct the mutations in 
      specific DNA sequences and modify the sequence to the normal wild-type sequence. 
      To edit the genome at the required sites, CRISPR/Cas9 is an efficient and
      accurate tool that is used in various genetic engineering programs. Genome
      editing mediated by CRISPR/Cas9 has the ability to restore the normal beta-globin
      function with minimal side effects. Using CRISPR/Cas9, expression of BCL11A can
      be downregulated along with increased production of HbF. However, these genome
      editing tools are still under in-vitro trials. CRISPR/Cas9 has can be used for
      precise transcriptional regulation, genome modification and epigenetic editing.
      Additional research is required in this regard, as CRISPR/Cas9 may potentially
      exhibit off-target activity and there are legal and ethical considerations
      regarding its use.
CI  - Copyright: (c) Amjad et al.
FAU - Amjad, Fareeha
AU  - Amjad F
AD  - Department of Microbiology and Molecular Genetics, University of The Punjab,
      Lahore, Punjab 54590, Pakistan.
FAU - Fatima, Tamseel
AU  - Fatima T
AD  - Department of Microbiology and Molecular Genetics, University of The Punjab,
      Lahore, Punjab 54590, Pakistan.
FAU - Fayyaz, Tuba
AU  - Fayyaz T
AD  - Department of Microbiology and Molecular Genetics, University of The Punjab,
      Lahore, Punjab 54590, Pakistan.
FAU - Khan, Muhammad Aslam
AU  - Khan MA
AD  - Sundas Molecular Analysis Centre (SUNMAC), Sundas Foundation, Lahore, Punjab
      54000, Pakistan.
FAU - Qadeer, Muhammad Imran
AU  - Qadeer MI
AD  - Department of Microbiology and Molecular Genetics, University of The Punjab,
      Lahore, Punjab 54590, Pakistan.
AD  - Sundas Molecular Analysis Centre (SUNMAC), Sundas Foundation, Lahore, Punjab
      54000, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200902
PL  - England
TA  - Biomed Rep
JT  - Biomedical reports
JID - 101613227
PMC - PMC7484974
OTO - NOTNLM
OT  - CRISPR/Cas9
OT  - base editors
OT  - gene therapy
OT  - genome editing
OT  - haematopoietic stem cell transplant
OT  - thalassemia
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:09
PHST- 2019/12/13 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/09/21 06:09 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.3892/br.2020.1355 [doi]
AID - BR-0-0-01355 [pii]
PST - ppublish
SO  - Biomed Rep. 2020 Nov;13(5):48. doi: 10.3892/br.2020.1355. Epub 2020 Sep 2.


PMID- 32952907
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0019-5413 (Print)
IS  - 0019-5413 (Linking)
VI  - 54
IP  - Suppl 1
DP  - 2020 Sep
TI  - Association of Thrombophilic Factors in Pathogenesis of Osteonecrosis of Femoral 
      Head in Indian Population.
PG  - 33-38
LID - 10.1007/s43465-020-00181-9 [doi]
AB  - PURPOSE: Role of heritable blood clotting disorders, both thrombophilias and
      hypofibrinolysis in causing avascular necrosis (AVN) of femoral head have been
      studied in regions like Europe and U.S.A. This study was done to investigate the 
      role of heritable thrombophilias in ethnic Indian population. MATERIALS AND
      METHODS: A case control study of 150 patients (100 cases and 50 age and sex
      matched controls) of Indian Ethnicity with clinico-radiographically documented
      idiopathic AVN of femoral head was done after ethics committee approval. DNA was 
      extracted from the blood and PCR analysis was used to study heritable
      thrombophilic gene mutation (G1691A Factor V Leiden). Enzyme-linked immunosorbent
      assay (ELISA)-based assays, were utilized to measure antigen levels of protein C,
      antithrombin III levels and protein S. RESULTS: Nine cases out of 100 showed
      deficiency of Protein C (9%) while no control showed deficiency of Protein C (p
      value: 0.028-significant, Odds ratio: 9.791) Ten cases showed deficiency of
      Protein S (10%) in study population as compared to one case (2%) in control
      population (p value: 0.038-significant, Odds ratio: 5.44). ATIII deficiency was
      more prevalent in control group i.e. 22% compared to 11% in study group. Factor V
      mutation was present in 3% cases as compared to one (2%) in control group. (p
      value is 0.393-not significant). CONCLUSION: Difference in thrombophilic
      mutations in various populations indicates possible effect of ethnicity on
      genetic profile in the development of AVN. This risk stratification will enable
      in near future early diagnosis and possible role of antithrombotics in disease
      prevention.
CI  - (c) Indian Orthopaedics Association 2020.
FAU - Rathod, Tushar N
AU  - Rathod TN
AD  - Department of Orthopedics, Seth G. S. Medical College and KEM Hospital, 6th
      Floor, New Multi-Storeyed Building, Parel, Mumbai, 400012 India.grid.414807.e0000
      0004 1766 8840
FAU - Tayade, M B
AU  - Tayade MB
AD  - Department of General Surgery, Sir J.J. Group of Hospitals, Mumbai, India.
FAU - Shetty, Shrimati D
AU  - Shetty SD
AD  - National Institute of Immunohematology (ICMR), 6th Floor, New Multi-Storeyed
      Building, Parel, Mumbai, 400012 India.
FAU - Jadhav, Pratap
AU  - Jadhav P
AD  - Department of Preventive and Social Medicine, Seth G. S. Medical College and KEM 
      Hospital, Parel, Mumbai, 400012 India.grid.414807.e0000 0004 1766 8840
FAU - Sathe, Ashwin Hemant
AU  - Sathe AH
AUID- ORCID: 0000-0002-1196-0694
AD  - Department of Orthopedics, Seth G. S. Medical College and KEM Hospital, 6th
      Floor, New Multi-Storeyed Building, Parel, Mumbai, 400012 India.grid.414807.e0000
      0004 1766 8840
FAU - Mohanty, Shubhranshu S
AU  - Mohanty SS
AD  - Department of Orthopedics, Seth G. S. Medical College and KEM Hospital, 6th
      Floor, New Multi-Storeyed Building, Parel, Mumbai, 400012 India.grid.414807.e0000
      0004 1766 8840
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - Switzerland
TA  - Indian J Orthop
JT  - Indian journal of orthopaedics
JID - 0137736
PMC - PMC7474030
OTO - NOTNLM
OT  - Antithrombin III (AT III)
OT  - Avascular necrosis (AVN)
OT  - Factor V mutation
OT  - Osteonecrosis
OT  - Protein C
OT  - Protein S
COIS- Conflict of interestThe Author(s) declare(s) that there is no conflict of
      interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:07
PHST- 2020/04/02 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/09/21 06:07 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.1007/s43465-020-00181-9 [doi]
AID - 181 [pii]
PST - epublish
SO  - Indian J Orthop. 2020 Jul 2;54(Suppl 1):33-38. doi: 10.1007/s43465-020-00181-9.
      eCollection 2020 Sep.


PMID- 32952857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1948-0210 (Print)
IS  - 1948-0210 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 26
TI  - Human embryonic stem cells as an in vitro model for studying developmental
      origins of type 2 diabetes.
PG  - 761-775
LID - 10.4252/wjsc.v12.i8.761 [doi]
AB  - The developmental origins of health and diseases (DOHaD) is a concept stating
      that adverse intrauterine environments contribute to the health risks of
      offspring. Since the theory emerged more than 30 years ago, many epidemiological 
      and animal studies have confirmed that in utero exposure to environmental
      insults, including hyperglycemia and chemicals, increased the risk of developing 
      noncommunicable diseases (NCDs). These NCDs include metabolic syndrome, type 2
      diabetes, and complications such as diabetic cardiomyopathy. Studying the effects
      of different environmental insults on early embryo development would aid in
      understanding the underlying mechanisms by which these insults promote NCD
      development. Embryonic stem cells (ESCs) have also been utilized by researchers
      to study the DOHaD. ESCs have pluripotent characteristics and can be
      differentiated into almost every cell lineage; therefore, they are excellent in
      vitro models for studying early developmental events. More importantly, human
      ESCs (hESCs) are the best alternative to human embryos for research because of
      ethical concerns. In this review, we will discuss different maternal conditions
      associated with DOHaD, focusing on the complications of maternal diabetes. Next, 
      we will review the differentiation protocols developed to generate different cell
      lineages from hESCs. Additionally, we will review how hESCs are utilized as a
      model for research into the DOHaD. The effects of environmental insults on hESC
      differentiation and the possible involvement of epigenetic regulation will be
      discussed.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Chen, Andy Chun-Hang
AU  - Chen AC
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong,
      China.
FAU - Lee, Kai Fai
AU  - Lee KF
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong,
      China.
FAU - Yeung, William Shu Biu
AU  - Yeung WSB
AD  - Shenzhen Key Laboratory of Fertility Regulation, The University of Hong Kong
      Shenzhen Hospital, Shenzhen 518053, Guangdong Province, China.
FAU - Lee, Yin Lau
AU  - Lee YL
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong,
      China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Stem Cells
JT  - World journal of stem cells
JID - 101535826
PMC - PMC7477660
OTO - NOTNLM
OT  - Development origins of health and diseases
OT  - Environmental insults
OT  - Epigenetics
OT  - Human embryonic stem cells
OT  - Maternal diabetes
OT  - Type 2 diabetes
COIS- Conflict-of-interest statement: The authors declare no conflict of interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:07
PHST- 2020/03/12 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/09/21 06:07 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.4252/wjsc.v12.i8.761 [doi]
PST - ppublish
SO  - World J Stem Cells. 2020 Aug 26;12(8):761-775. doi: 10.4252/wjsc.v12.i8.761.


PMID- 32952709
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 0351-0026 (Print)
IS  - 0351-0026 (Linking)
VI  - 59
IP  - 2
DP  - 2020 Jun
TI  - Physicians' Attitudes Toward Adolescent Confidentiality Services: Scale
      Development and Validation.
PG  - 99-107
LID - 10.2478/sjph-2020-0013 [doi]
AB  - INTRODUCTION: Confidentiality is one of the oldest ethical principles in
      healthcare. However, confidentiality in adolescent healthcare is not a
      universally-accepted doctrine among scholars. The ethical acceptability of
      confidential services in adolescents' healthcare is based on perceptions of
      adolescent maturity and an appreciation of its importance to adolescents' access 
      and utilization of healthcare services. Despite legal policies that promote
      adolescents' rights, physicians' attitudes toward adolescent confidentiality can 
      be a determining factor in their ultimate decision to protect adolescents'
      confidentiality. METHOD: A new Attitude towards Adolescent Confidentiality Scale 
      was developed based on the results of a qualitative interview study. This new
      instrument was administered to a sample of 152 physicians working at school
      pediatric and gynecology departments in 13 primary healthcare institutions in
      Belgrade. Principal component analysis was applied to determine the main
      components of the scale. Reliability was assessed by calculating Cronbach alpha
      and mean inter-item correlations. RESULTS: Psychometric analysis of the final
      19-item version of the scale showed a high level of reliability (Cronbach alpha
      of 0.83). Principal component analysis showed four components, which present
      subscales of the instrument: Confidentiality in clinical situation, Iimportance
      of confidentiality, Adolescent maturity, and Communication with parents.
      CONCLUSIONS: The instrument showed satisfactory levels of reliability and
      validity. The results of the scale dissemination may be a valuable tool for needs
      assessment for future educational interventions and training programs that will
      raise physicians' awareness of the importance of adolescent confidentiality.
CI  - (c) 2020 Vida Jeremic Stojkovic et al., published by Sciendo.
FAU - Jeremic Stojkovic, Vida
AU  - Jeremic Stojkovic V
AD  - University of Belgrade, School of Medicine, Department of Humanities, Pasterova
      2, 11000 Belgrade, Serbia.
FAU - Cvjetkovic, Smiljana
AU  - Cvjetkovic S
AD  - University of Belgrade, Faculty of Medicine, dr Subotica starijeg 8, 11000
      Belgrade, Serbia.
FAU - Matejic, Bojana
AU  - Matejic B
AD  - University of Belgrade, Faculty of Medicine, dr Subotica starijeg 8, 11000
      Belgrade, Serbia.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - Poland
TA  - Zdr Varst
JT  - Zdravstveno varstvo
JID - 9412992
PMC - PMC7478075
OTO - NOTNLM
OT  - adolescent
OT  - attitude of health personnel
OT  - confidentiality
OT  - primary healthcare
OT  - psychometrics
OT  - surveys and questionnaires
COIS- CONFLICTS OF INTEREST The authors declare that there is no conflict of interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:06
PHST- 2019/04/25 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/09/21 06:06 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.2478/sjph-2020-0013 [doi]
AID - sjph-2020-0013 [pii]
PST - epublish
SO  - Zdr Varst. 2020 Apr 6;59(2):99-107. doi: 10.2478/sjph-2020-0013. eCollection 2020
      Jun.


PMID- 32952565
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1687-9589 (Print)
IS  - 1687-9597 (Linking)
VI  - 2020
DP  - 2020
TI  - Obstetric Danger Signs: Knowledge, Attitude, Health-Seeking Action, and
      Associated Factors among Postnatal Mothers in Nekemte Town, Oromia Region,
      Western Ethiopia-A Community-Based Cross-Sectional Study.
PG  - 6573153
LID - 10.1155/2020/6573153 [doi]
AB  - BACKGROUND: Maternal mortality remains unacceptably high due to pregnancy
      complications and remains the major health problems in many developing countries 
      such as Ethiopia. Having poor knowledge of obstetric danger signs contributes to 
      delays in seeking and receiving skilled care which in turn increases maternal
      mortality. However, in Ethiopia, studies are lacking regarding the knowledge
      level of mothers about obstetric danger signs during pregnancy, child birth, and 
      postnatal periods. In Ethiopia, the proportion of those who have full knowledge
      of these obstetric danger signs during pregnancy, child birth, and postnatal
      period is not known. Despite few studies are conducted at health facility level
      focusing on danger signs during pregnancy, the issue of health-seeking action
      after identifying danger signs and attitude of mothers towards obstetric danger
      sign was not addressed. OBJECTIVES: To determine knowledge, attitude,
      health-seeking action towards obstetric danger signs, and associated factors
      among postpartum women. METHODS: A community-based cross-sectional study was
      conducted in Nekemte Town from October 1 to November 30, 2017. Multistage
      sampling technique was employed to select the total sample size of 621. Ethical
      clearance was obtained from Wollega University research and ethical committee. A 
      pretested structured questionnaire was used to collect data from respondents.
      Data were entered to EpiData version 3.1 and exported to SPSS version 20 for
      analysis. To assess the associations between dependent and independent variables,
      binary and multivariate logistic regressions were employed, and the strength of
      association was presented using odds ratios with 95% confidence intervals.
      RESULT: Only 197 (32.3%) of respondents were able to spontaneously mention at
      least five key obstetric danger signs during antepartum, intrapartum, and
      postpartum (in the three phases) with at least one obstetric danger sign in each 
      phase and thus were considered as having good knowledge of key obstetric danger
      signs. Government employee (AOR = 3.28, 95% CI: 1.98-5.42), able to read and
      write (AOR = 4.92, 95% CI: 2.14-11.3), primary school (AOR = 4.90, 95% CI:
      2.11-11.4), ANC follow-up (AOR = 6.2, 95% CI: 1.82-21.21), and ANC visit (AOR =
      4.07, 95% CI: 2.35-7.06) were significantly associated with knowledge of
      obstetric danger sign. From 150 (24.6%) participants who faced obstetric danger
      signs during their last pregnancy, the majority of them, 137 (91.3%), had a good 
      practice which is seeking a health facility for care. Conclusion and
      Recommendation. Despite their low knowledge level and attitude, the practice of
      mothers in response to obstetric danger signs was encouraging. Occupation,
      educational status, ANC follow-up, and number of ANC visits were variables
      significantly associated with knowledge of obstetric danger signs. Health care
      providers should provide health education and counseling to increase awareness,
      and appropriate counseling during antenatal care at each visit is of paramount
      importance.
CI  - Copyright (c) 2020 Misganu Teshoma Regasa et al.
FAU - Teshoma Regasa, Misganu
AU  - Teshoma Regasa M
AUID- ORCID: https://orcid.org/0000-0002-4935-7700
AD  - Department of Midwifery, Institute of Health Sciences, Wollega University,
      Nekemte, Ethiopia.
FAU - Markos, Jote
AU  - Markos J
AD  - Department of Nursing, Institute of Health Sciences, Wollega University, Nekemte,
      Ethiopia.
FAU - Habte, Ashenafi
AU  - Habte A
AD  - Department of Nursing, Institute of Health Sciences, Wollega University, Nekemte,
      Ethiopia.
FAU - Upashe, Shivaleela P
AU  - Upashe SP
AD  - Department of Pediatrics and Neonatal Nursing, Institute of Health Sciences,
      Wollega University, Nekemte, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - Obstet Gynecol Int
JT  - Obstetrics and gynecology international
JID - 101517078
PMC - PMC7481917
COIS- There are no conflicts of interest.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
CRDT- 2020/09/21 06:06
PHST- 2019/12/16 00:00 [received]
PHST- 2020/07/26 00:00 [revised]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/09/21 06:06 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
AID - 10.1155/2020/6573153 [doi]
PST - epublish
SO  - Obstet Gynecol Int. 2020 Sep 1;2020:6573153. doi: 10.1155/2020/6573153.
      eCollection 2020.


PMID- 32952460
OWN - NLM
STAT- Publisher
LR  - 20200928
IS  - 1541-4612 (Print)
IS  - 1541-4612 (Linking)
DP  - 2020 Sep 15
TI  - A Call for Nurse Leader Action: Ethical Nursing Care of Latinx Unauthorized
      Immigrant Children and Families.
LID - 10.1016/j.mnl.2020.08.002 [doi]
AB  - Latinx unauthorized immigrant children and children of unauthorized immigrant
      parents are at risk for care disparities and negative health outcomes.
      Unauthorized immigration from South and Central America to the United States has 
      elevated to crisis level, exposing many children to poor health conditions, human
      rights violations, and risk of death. Unauthorized status greatly influences care
      access and delivery in the hospital setting. Restricted nursing care creates
      ethical dilemmas. Nurse leaders are in key positions to influence and advocate
      care. This article explores issues surrounding nursing care using the Theory of
      Bureaucratic Caring and identifies opportunities for nurse leader action.
CI  - 2020 by Elsevier Inc. All rights reserved.
FAU - Stephen, Jennifer M
AU  - Stephen JM
FAU - Zoucha, Rick
AU  - Zoucha R
LA  - eng
PT  - Journal Article
DEP - 20200915
PL  - United States
TA  - Nurse Lead
JT  - Nurse leader
JID - 101156072
PMC - PMC7492073
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/21 06:05
PHST- 2020/07/25 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/21 06:05 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1016/j.mnl.2020.08.002 [doi]
AID - S1541-4612(20)30212-3 [pii]
PST - aheadofprint
SO  - Nurse Lead. 2020 Sep 15. pii: S1541-4612(20)30212-3. doi:
      10.1016/j.mnl.2020.08.002.


PMID- 32952088
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - An ethics-based approach to global health research part 1: Building partnerships 
      in global health.
PG  - 1574-1579
LID - S1551-7411(20)30165-0 [pii]
LID - 10.1016/j.sapharm.2020.08.022 [doi]
AB  - Global health partnerships (GHPs) can be the cornerstone for advancing research
      and public health. The steps to build a global research partnership focus on
      sharing a common research agenda, identifying key partners in the community, and 
      establishing goals and expectations for partnerships. Moreover, upholding
      important values, such as communication, trust, and transparency is essential for
      building successful partnerships. Ethical dilemmas can propose challenges to
      researchers in global health. These challenges can be overcome by creating a
      shared vision for a research agenda, maintaining communication, and providing
      bidirectional training.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Seo, See-Won
AU  - Seo SW
AD  - Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY,
      12208, USA. Electronic address: See-Won.Seo@acphs.edu.
FAU - Ombengi, David
AU  - Ombengi D
AD  - Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226,
      USA. Electronic address: dombengi@mcw.edu.
FAU - Sultan, Dawood H
AU  - Sultan DH
AD  - Mercer University College of Health Professions, 3001 Mercer University Drive,
      Atlanta, GA, 30341, USA. Electronic address: sultan_dh@mercer.edu.
FAU - Kahaleh, Abby A
AU  - Kahaleh AA
AD  - Roosevelt University College of Pharmacy, 1400 N Roosevelt Blvd, Schaumburg, IL, 
      13 60173, USA. Electronic address: AKahaleh@roosevelt.edu.
FAU - Nonyel, Nkem
AU  - Nonyel N
AD  - University of Maryland, Eastern Shore School of Pharmacy and Health Professions, 
      Hazel Hall, Room 1041, Princess Anne, MD, 21853, USA. Electronic address:
      npnonyel@umes.edu.
FAU - Karwa, Rakhi
AU  - Karwa R
AD  - Purdue University College of Pharmacy, 575 Stadium Mall Drive, West Lafayette,
      IN, 47907, USA. Electronic address: rkarwa@purdue.edu.
FAU - Abrons, Jeanine
AU  - Abrons J
AD  - University of Iowa College of Pharmacy, 180 S Grand Avenue, CP 354, Iowa City,
      IA, 52241, USA. Electronic address: jeanine-abrons@uiowa.edu.
FAU - Lukas, Stephanie
AU  - Lukas S
AD  - St. Louis College of Pharmacy, St. Louis, Missouri, 4588 Parkview Place, St.
      Louis, MO, 63110-1088, USA. Electronic address: Stephanie.Lukas@stlcop.edu.
FAU - Singhal, Mudit
AU  - Singhal M
AD  - D'Youville School of Pharmacy, 320 Porter Avenue, Buffalo, NY, 14201, USA.
      Electronic address: muditm@dyc.edu.
FAU - Miller, Monica
AU  - Miller M
AD  - Purdue University College of Pharmacy, 575 Stadium Mall Drive, West Lafayette,
      IN, 47906, USA. Electronic address: mille355@purdue.edu.
FAU - Truong, Hoai-An
AU  - Truong HA
AD  - University of Maryland Eastern Shore, School of Pharmacy and Health Professions, 
      1 College Backbone Road, Princess Anne, MD, 21853, USA. Electronic address:
      htruong@umes.edu.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
SB  - IM
MH  - Communication
MH  - Ethics
MH  - *Global Health
MH  - Humans
MH  - Public Health
MH  - *Research Personnel
MH  - Trust
OTO - NOTNLM
OT  - Best practice
OT  - Challenges of global health partnerships
OT  - Ethical dilemmas
OT  - Global health research
OT  - Research agenda
OT  - Research collaboration
OT  - Research partnership
EDAT- 2020/09/22 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/09/21 05:37
PHST- 2020/02/18 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/08/30 00:00 [accepted]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/09/21 05:37 [entrez]
AID - S1551-7411(20)30165-0 [pii]
AID - 10.1016/j.sapharm.2020.08.022 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Nov;16(11):1574-1579. doi:
      10.1016/j.sapharm.2020.08.022. Epub 2020 Aug 31.


PMID- 32951666
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20210722
IS  - 1873-5150 (Electronic)
IS  - 0887-8994 (Linking)
VI  - 111
DP  - 2020 Oct
TI  - The American Neurological Association's Book "Eugenical Sterilization: A
      Reorientation of the Problem" Through the Lens of Contemporaneous Book Reviews.
PG  - 73-77
LID - S0887-8994(20)30227-7 [pii]
LID - 10.1016/j.pediatrneurol.2020.06.019 [doi]
AB  - BACKGROUND: In 1936, the American Neurological Association (ANA) published the
      book "Eugenical Sterilization: A Reorientation of the Problem" in response to
      what the first author of the book described as a positive reception to a paper
      presented at the ANA's 1935 annual meeting. The conclusions of the presentation
      were approved by the organization during the same meeting. As evidenced by the
      publication of several book reviews in a variety of medical journals, the book
      garnered some attention. METHODS: Reviews of the ANA's book were sought using
      PubMed, Google Scholar, and Embasa. Also, the book's title was used to search the
      World Wide Web. RESULTS: The search yielded four reviews, all published in 1937. 
      The reviews make evident a positive opinion of the ANA's book's authors'
      recommendations including the option for "selective sterilization" of patients
      with conditions such as Huntington disease, Friedreich ataxia, and epilepsy. In
      addition, reviewers highlighted the book's authors' assessment that "the
      feebleminded [breed] docile, servile, useful people who do the dirty work of the 
      race, [as] servants fulfilling a social function." CONCLUSIONS: Although the
      book's authors did not advocate for all-out eugenical sterilization, they did
      little to counter the popular opinion that patients with certain neurological
      diseases were a drain on society. In addition, they espoused a positive vision of
      the feebleminded's role as servants who can do undesirable work. This message was
      disseminated through book reviews.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Weisleder, Pedro
AU  - Weisleder P
AD  - Division of Neurology, Center for Pediatric Bioethics, Nationwide Children's
      Hospital - The Ohio State University, Columbus, Ohio. Electronic address:
      Weisleder.1@osu.edu.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200703
PL  - United States
TA  - Pediatr Neurol
JT  - Pediatric neurology
JID - 8508183
SB  - IM
CIN - Pediatr Neurol. 2020 Oct;111:87. PMID: 32861581
MH  - *Book Reviews as Topic
MH  - Books/*history
MH  - *Brain Diseases
MH  - Eugenics/*history
MH  - History, 20th Century
MH  - Humans
MH  - Neurology/*history
MH  - Societies, Medical/*history
MH  - Sterilization/*history
OTO - NOTNLM
OT  - *Epilepsy
OT  - *Eugenics
OT  - *Eugenics Record Office
OT  - *Feebleminded
OT  - *Friedreich ataxia
OT  - *Huntington disease
OT  - *Medical ethics
OT  - *Nuremberg Code
EDAT- 2020/09/22 06:00
MHDA- 2021/07/23 06:00
CRDT- 2020/09/21 05:32
PHST- 2020/04/28 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/09/21 05:32 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
AID - S0887-8994(20)30227-7 [pii]
AID - 10.1016/j.pediatrneurol.2020.06.019 [doi]
PST - ppublish
SO  - Pediatr Neurol. 2020 Oct;111:73-77. doi: 10.1016/j.pediatrneurol.2020.06.019.
      Epub 2020 Jul 3.


PMID- 32951656
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20201218
IS  - 1873-5150 (Electronic)
IS  - 0887-8994 (Linking)
VI  - 111
DP  - 2020 Oct
TI  - The Ethic of Care, Disability, and Rehabilitation During the Coronavirus Disease 
      2019 Pandemic.
PG  - 39
LID - S0887-8994(20)30197-1 [pii]
LID - 10.1016/j.pediatrneurol.2020.06.006 [doi]
FAU - Russo, Luigi
AU  - Russo L
AD  - Unit for Severe Disabilities in Developmental Age and Young Adults (Developmental
      Neurology and Neurorehabilitation), Scientific Institute IRCCS "E. Medea",
      Brindisi, Italy.
FAU - Trabacca, Antonio
AU  - Trabacca A
AD  - Unit for Severe Disabilities in Developmental Age and Young Adults (Developmental
      Neurology and Neurorehabilitation), Scientific Institute IRCCS "E. Medea",
      Brindisi, Italy. Electronic address: antonio.trabacca@lanostrafamiglia.it.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200616
PL  - United States
TA  - Pediatr Neurol
JT  - Pediatric neurology
JID - 8508183
SB  - IM
CON - Pediatr Neurol. 2020 Jul;108:3-4. PMID: 32381278
CIN - Pediatr Neurol. 2020 Nov;112:1. PMID: 32823136
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7297163
EDAT- 2020/09/22 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/21 05:32
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/09/21 05:32 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - S0887-8994(20)30197-1 [pii]
AID - 10.1016/j.pediatrneurol.2020.06.006 [doi]
PST - ppublish
SO  - Pediatr Neurol. 2020 Oct;111:39. doi: 10.1016/j.pediatrneurol.2020.06.006. Epub
      2020 Jun 16.


PMID- 32951623
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201218
IS  - 1469-4409 (Electronic)
IS  - 0950-2688 (Linking)
VI  - 148
DP  - 2020 Sep 21
TI  - Public attitude towards quarantine during the COVID-19 outbreak.
PG  - e220
LID - 10.1017/S0950268820002204 [doi]
AB  - Due to the outbreak of the deadly coronavirus disease in 2019 (COVID-19), Wuhan
      was on lockdown for more than 60 days by the state government. This study
      investigated the perceptions and attitudes of the public on quarantine as a
      practical approach to halting the spread of COVID-19. An online survey was
      conducted via WeChat between 10 January 2020 and 10 March 2020 on the general
      population in Hubei province at the height of the COVID-19 outbreak. In total,
      549 respondents participated in the survey. Results revealed that the public
      displayed significantly strong support towards quarantine throughout the outbreak
      period, apart from locking people up and using imprisonment legal sanctions
      against those who failed to comply with the stringent regulations. The support
      exerted by the public stemmed from the execution of authorised officers to
      protect the public interest and provision of psychosocial support for those
      affected. In situations where quarantine could not be imposed, public health
      policy-makers and government officials should implement an extensive system of
      psychosocial support to safeguard, instruct and inform frontline public health
      workers. The public should also be enlisted in an open conversation concerning
      the ethical utility of restrictive values during the COVID-19 outbreak.
FAU - Song, W
AU  - Song W
AUID- ORCID: 0000-0002-7390-2334
AD  - Department of Psychology, Wuhan Sports University, China Resources, Hubei,
      4300079, China.
AD  - Department of Immunology, Wuhan Sports University, Wuhan4300079, China.
FAU - Sawafta, F J
AU  - Sawafta FJ
AD  - Department of Psychology, Wuhan Sports University, China Resources, Hubei,
      4300079, China.
FAU - Ebrahem, B M
AU  - Ebrahem BM
AD  - Department of Psychology, Wuhan Sports University, China Resources, Hubei,
      4300079, China.
FAU - Jebril, M A
AU  - Jebril MA
AD  - Department of Epidemiology and Health, Xian Jiaotong University, Xian710049,
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200921
PL  - England
TA  - Epidemiol Infect
JT  - Epidemiology and infection
JID - 8703737
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Attitude to Health
MH  - Betacoronavirus
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - Disease Outbreaks
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - *Public Opinion
MH  - *Quarantine
MH  - SARS-CoV-2
MH  - State Government
MH  - Young Adult
PMC - PMC7533476
OTO - NOTNLM
OT  - *COVID-19
OT  - *public attitudes
OT  - *quarantine
EDAT- 2020/09/22 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/09/21 05:31
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/09/21 05:31 [entrez]
AID - 10.1017/S0950268820002204 [doi]
AID - S0950268820002204 [pii]
PST - epublish
SO  - Epidemiol Infect. 2020 Sep 21;148:e220. doi: 10.1017/S0950268820002204.


PMID- 32951497
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 1741-2811 (Electronic)
IS  - 1460-4582 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Dec
TI  - Designing virtual communities of practice for informal caregivers of Alzheimer's 
      patients: An integrative review.
PG  - 2976-2991
LID - 10.1177/1460458220950883 [doi]
AB  - The main aim of this study is to review the literature to show how ideas around
      virtual communities of practice (VCoP) offer a model for supporting informal
      caregivers of Alzheimer's patients (caregivers) to learn how to deal with
      caregiving demands. Caregivers are individuals who have a significant personal
      relationship with and provide a broad range of unpaid assistance to an older
      person or an adult with a chronic or disabling condition outside of a
      professional or formal framework. This review will examine the current evidence
      on the needs of caregivers, identify dimensions to be considered in VCoP design
      and suggest further directions of research. The investigation is an integrative
      review that builds a bridge between different areas of work. The outcome is
      eleven dimensions for the design of successful VCoPs for caregivers: Network
      Structure, Technology, Moderator, Scale, Alignment, Community Design, Sense of
      Trust, Knowledge Sharing, Sustainability, Ethics and Evaluation. In addition, we 
      propose a Tree Metaphor to present our research results. Well-designed
      interventions based on VCoP principles have the potential of addressing
      caregivers' needs.
FAU - Romero-Mas, Montse
AU  - Romero-Mas M
AUID- ORCID: 0000-0002-8079-1433
AD  - University of Vic-Central University of Catalonia, Spain.
FAU - Gomez-Zuniga, Beni
AU  - Gomez-Zuniga B
AD  - Universitat Oberta de Catalunya, Spain.
FAU - Cox, Andrew M
AU  - Cox AM
AD  - University of Sheffield, UK.
FAU - Ramon-Aribau, Anna
AU  - Ramon-Aribau A
AD  - University of Vic-Central University of Catalonia, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200919
PL  - England
TA  - Health Informatics J
JT  - Health informatics journal
JID - 100883604
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Alzheimer Disease/therapy
MH  - *Caregivers
MH  - Humans
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *communities of practice
OT  - *informal caregivers
OT  - *online communities
OT  - *virtual communities of practice
EDAT- 2020/09/22 06:00
MHDA- 2021/07/24 06:00
CRDT- 2020/09/21 05:30
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
PHST- 2020/09/21 05:30 [entrez]
AID - 10.1177/1460458220950883 [doi]
PST - ppublish
SO  - Health Informatics J. 2020 Dec;26(4):2976-2991. doi: 10.1177/1460458220950883.
      Epub 2020 Sep 19.


PMID- 32951214
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
VI  - 76
IP  - 11
DP  - 2020 Nov
TI  - An integrative review of nursing staff experiences in high secure forensic mental
      health settings: Implications for recruitment and retention strategies.
PG  - 2897-2908
LID - 10.1111/jan.14521 [doi]
AB  - AIMS: To identify the experiences of nursing in high secure forensic mental
      health settings that may affect staff recruitment and retention. BACKGROUND:
      Recruitment and retention of Registered Nurses is a vital international concern
      in the field of mental health. The high secure forensic setting presents unique
      challenges for the nurse. Studies of nurse's experiences in this setting have not
      previously been reviewed in the context of workforce sustainability pressures.
      DESIGN: An integrative review (Whittemore and Knapfl, 2005). DATA SOURCES: A
      systematic search of data sources: MEDLINE (PubMed), PsycINFO, EMBASE, CINAHL,
      International Bibliography of the Social Sciences, Applied Social Sciences Index 
      and Abstracts (ASSIA), Social Services Abstracts, ProQuest Social Sciences
      Premium collection (IBSS, PAIS, and Sociological Abstracts), and Web of Science
      from inception to December 2019. REVIEW METHODS: Data extraction, quality
      appraisal, and convergent qualitative synthesis. RESULTS: Fifteen papers were
      selected for inclusion in the review, describing 13 studies. Six studies were
      quantitative, all cross-sectional surveys. There were seven qualitative studies, 
      using a variety of methodologies. Four themes were identified: engagement with
      the patient group, the ward social environment, impact on the nurse, and
      implications for practice. CONCLUSION: When policymakers address workforce
      shortages in high secure forensic nursing they must take account of the unique
      features of the setting and patient group. Nurses must be adequately prepared and
      supported to function in an ethically and emotionally challenging environment.
      IMPACT: This study identified factors affecting workforce pressures in the
      speciality of forensic mental health nursing. Findings are of interest to
      national nursing policymakers and workforce leads in mental health service
      provider organizations, seeking to promote forensic nursing as a career option
      and retain nursing staff.
CI  - (c) 2020 The Authors. Journal of Advanced Nursing published by John Wiley & Sons 
      Ltd.
FAU - Oates, Jennifer
AU  - Oates J
AUID- ORCID: https://orcid.org/0000-0001-7745-9539
AD  - Florence Nightingale Faculty of Nursing, King's College London, London, UK.
FAU - Topping, Alice
AU  - Topping A
AD  - Florence Nightingale Faculty of Nursing, King's College London, London, UK.
AD  - West London NHS Trust, London, UK.
FAU - Ezhova, Ivanka
AU  - Ezhova I
AD  - Florence Nightingale Faculty of Nursing, King's College London, London, UK.
FAU - Wadey, Emma
AU  - Wadey E
AD  - NHS England and NHS Improvement, London, UK.
FAU - Marie Rafferty, Anne
AU  - Marie Rafferty A
AD  - Florence Nightingale Faculty of Nursing, King's College London, London, UK.
LA  - eng
GR  - NHS Improvement
PT  - Journal Article
PT  - Review
DEP - 20200919
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Mental Health
MH  - *Nursing Staff
MH  - *Psychiatric Nursing
MH  - Qualitative Research
OTO - NOTNLM
OT  - Nursing
OT  - emotional labour
OT  - forensic
OT  - integrative review
OT  - mental health
OT  - trauma
OT  - workforce
EDAT- 2020/09/21 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/20 20:40
PHST- 2020/03/09 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/20 20:40 [entrez]
AID - 10.1111/jan.14521 [doi]
PST - ppublish
SO  - J Adv Nurs. 2020 Nov;76(11):2897-2908. doi: 10.1111/jan.14521. Epub 2020 Sep 19.


PMID- 32951075
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 1522-9602 (Electronic)
IS  - 0092-8240 (Linking)
VI  - 82
IP  - 10
DP  - 2020 Sep 19
TI  - Changing the Nature of Quantitative Biology Education: Data Science as a Driver.
PG  - 127
LID - 10.1007/s11538-020-00785-0 [doi]
AB  - We live in a data-rich world with rapidly growing databases with zettabytes of
      data. Innovation, computation, and technological advances have now tremendously
      accelerated the pace of discovery, providing driverless cars, robotic devices,
      expert healthcare systems, precision medicine, and automated discovery to mention
      a few. Even though the definition of the term data science continues to evolve,
      the sweeping impact it has already produced on society is undeniable. We are at a
      point when new discoveries through data science have enormous potential to
      advance progress but also to be used maliciously, with harmful ethical and social
      consequences. Perhaps nowhere is this more clearly exemplified than in the
      biological and medical sciences. The confluence of (1) machine learning, (2)
      mathematical modeling, (3) computation/simulation, and (4) big data have moved us
      from the sequencing of genomes to gene editing and individualized medicine; yet, 
      unsettled policies regarding data privacy and ethical norms could potentially
      open doors for serious negative repercussions. The data science revolution has
      amplified the urgent need for a paradigm shift in undergraduate biology
      education. It has reaffirmed that data science education interacts and enhances
      mathematical education in advancing quantitative conceptual and skill development
      for the new generation of biologists. These connections encourage us to strive to
      cultivate a broadly skilled workforce of technologically savvy problem-solvers,
      skilled at handling the unique challenges pertaining to biological data, and
      capable of collaborating across various disciplines in the sciences, the
      humanities, and the social sciences. To accomplish this, we suggest development
      of open curricula that extend beyond the job certification rhetoric and combine
      data acumen with modeling, experimental, and computational methods through
      engaging projects, while also providing awareness and deep exploration of their
      societal implications. This process would benefit from embracing the pedagogy of 
      experiential learning and involve students in open-ended explorations derived
      from authentic inquiries and ongoing research. On this foundation, we encourage
      development of flexible data science initiatives for the education of life
      science undergraduates within and across existing models.
FAU - Robeva, Raina S
AU  - Robeva RS
AD  - Department of Mathematics, Randolph-Macon College, Ashland, VA, 23005, USA.
      RainaRobeva@rmc.edu.
FAU - Jungck, John R
AU  - Jungck JR
AD  - Center for Bioinformatics and Computational Biology, DENIN Delaware Environmental
      Institute, University of Delaware, Newark, DE, 19716, USA.
FAU - Gross, Louis J
AU  - Gross LJ
AD  - Departments of Ecology and Evolutionary Biology and Mathematics, University of
      Tennessee Knoxville, Knoxville, TN, 37996, USA.
AD  - National Institute for Mathematical and Biological Synthesis, University of
      Tennessee Knoxville, Knoxville, TN, 37996, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200919
PL  - United States
TA  - Bull Math Biol
JT  - Bulletin of mathematical biology
JID - 0401404
SB  - IM
MH  - *Computational Biology/education/trends
MH  - Curriculum/trends
MH  - *Data Science
MH  - Humans
OTO - NOTNLM
OT  - *Big data
OT  - *Data science education
OT  - *Education reform
OT  - *Mathematical biology education
EDAT- 2020/09/21 06:00
MHDA- 2020/09/21 06:00
CRDT- 2020/09/20 20:39
PHST- 2020/04/24 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/09/20 20:39 [entrez]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2020/09/21 06:00 [medline]
AID - 10.1007/s11538-020-00785-0 [doi]
AID - 10.1007/s11538-020-00785-0 [pii]
PST - epublish
SO  - Bull Math Biol. 2020 Sep 19;82(10):127. doi: 10.1007/s11538-020-00785-0.


PMID- 32950962
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 19
TI  - Under-reported relationship: a comparative study of pharmaceutical industry and
      patient organisation payment disclosures in the UK (2012-2016).
PG  - e037351
LID - 10.1136/bmjopen-2020-037351 [doi]
AB  - OBJECTIVES: To examine the under-reporting of pharmaceutical company payments to 
      patient organisations by donors and recipients. DESIGN: Comparative descriptive
      analysis of payments disclosed on drug company and charity regulator websites.
      SETTING: UK. PARTICIPANTS: 87 donors (drug companies) and 425 recipients (patient
      organisations) reporting payments in 2012-2016. MAIN OUTCOME MEASURES: Number and
      value of payments reported by donors and recipients; differences in reported
      payments from/to the same donors and recipients; payments reported in either
      dataset but not the other one; agreement between donor-recipient ties established
      by payments; overlap between donor and recipient lists and, respectively,
      industry and patient organisation data. RESULTS: Of 87 donors, 63 (72.4%)
      reported payments but 84 (96.6%) were mentioned by recipients. Although donors
      listed 425 recipients, only 200 (47.1%) reported payments. The number and value
      of payments reported by donors were 259.8% and 163.7% greater than those reported
      by recipients, respectively. The number of donors with matching payment numbers
      and values in both datasets were 3.4% and 0.0%, respectively; for recipients
      these figures were 7.8% and 1.9%. There were 24 and 3 donors missing from
      industry and patient organisation data during the entire study period,
      representing 38.1% and 3.6% of those in the respective datasets. The share of
      donor-recipient ties in which industry and patient organisation data agreed about
      donors and recipients was 38.9% and 68.4% in each dataset, respectively. Of 63
      donors reporting payments, only 3 (4.8%) had their recipient lists fully
      overlapping with patient organisation data. Of 200 recipients reporting industry 
      funding, 102 (51.0%) had their donor lists fully overlapping with industry data. 
      CONCLUSIONS: Both donors and recipients under-reported payments. Existing donor
      and recipient disclosure systems cannot manage potential conflicts of interest
      associated with industry payments. Increased standardisation could limit the
      under-reporting by each side but only an integrated donor-recipient database
      could eliminate it.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ozieranski, Piotr
AU  - Ozieranski P
AUID- ORCID: 0000-0002-2023-3288
AD  - Social and Policy Sciences, University of Bath, Bath, UK p.ozieranski@bath.ac.uk.
FAU - Csanadi, Marcell
AU  - Csanadi M
AD  - Syreon Research Institute, Budapest, Hungary.
FAU - Rickard, Emily
AU  - Rickard E
AD  - Social and Policy Sciences, University of Bath, Bath, UK.
FAU - Mulinari, Shai
AU  - Mulinari S
AD  - Sociology, Lunds Universitet, Lund, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200919
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Conflict of Interest
MH  - *Disclosure
MH  - Drug Industry
MH  - Humans
MH  - Organizations
MH  - United Kingdom
PMC - PMC7511620
OTO - NOTNLM
OT  - *health policy
OT  - *medical ethics
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/09/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/20 20:38
PHST- 2020/09/20 20:38 [entrez]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037351 [pii]
AID - 10.1136/bmjopen-2020-037351 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 19;10(9):e037351. doi: 10.1136/bmjopen-2020-037351.


PMID- 32950833
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1724-191X (Electronic)
IS  - 1120-1797 (Linking)
VI  - 78
DP  - 2020 Oct
TI  - Simple low-cost approaches to semantic segmentation in radiation therapy planning
      for prostate cancer using deep learning with non-contrast planning CT images.
PG  - 93-100
LID - S1120-1797(20)30220-9 [pii]
LID - 10.1016/j.ejmp.2020.09.004 [doi]
AB  - PURPOSE: Deep learning has shown great efficacy for semantic segmentation.
      However, there are difficulties in the collection, labeling and management of
      medical imaging data, because of ethical complications and the limited number of 
      imaging studies available at a single facility. This study aimed to find a simple
      and low-cost method to increase the accuracy of deep learning semantic
      segmentation for radiation therapy of prostate cancer. METHODS: In total, 556
      cases with non-contrast CT images for prostate cancer radiation therapy were
      examined using a two-dimensional U-Net. Initially, all slices were used for the
      input data. Then, we removed slices of the cranial portions, which were beyond
      the margins of the bladder and rectum. Finally, the ground truth labels for the
      bladder and rectum were added as channels to the input for the prostate training 
      dataset. RESULTS: The highest mean dice similarity coefficients (DSCs) for each
      organ in the test dataset of 56 cases were 0.85 +/- 0.05, 0.94 +/- 0.04 and 0.85 
      +/- 0.07 for the prostate, bladder and rectum, respectively. Removal of the
      cranial slices from the original images significantly increased the DSC of the
      rectum from 0.83 +/- 0.09 to 0.85 +/- 0.07 (p < 0.05). Adding bladder and rectum 
      information to prostate training without removing the slices significantly
      increased the DSC of the prostate from 0.79 +/- 0.05 to 0.85 +/- 0.05 (p < 0.05).
      CONCLUSIONS: These cost-free approaches may be useful for new applications, which
      may include updated models and datasets. They may be applicable to other organs
      at risk (OARs) and clinical targets such as elective nodal irradiation.
CI  - Copyright (c) 2020 Associazione Italiana di Fisica Medica. Published by Elsevier 
      Ltd. All rights reserved.
FAU - Nemoto, Takafumi
AU  - Nemoto T
AD  - Department of Radiology, Keio University School of Medicine, Shinanomachi 35,
      Shinjuku-ku, Tokyo 160-8582, Japan; Division of Radiation Oncology, Saiseikai
      Yokohamashi Tobu Hospital, Shimosueyoshi 3-6-1, Tsurumi-ku, Yokohama-shi,
      Kanagawa 230-8765, Japan. Electronic address: takatohoku@gmail.com.
FAU - Futakami, Natsumi
AU  - Futakami N
AD  - Department of Radiation Oncology, Tokai University School of Medicine,
      Shimokasuya 143, Isehara-shi, Kanagawa 259-1143, Japan.
FAU - Yagi, Masamichi
AU  - Yagi M
AD  - HPC&AI Business Dept., Platform Technical Engineer Div., System Platform Solution
      Unit, Fujitsu Limited, World Trade Center Building, 4-1, Hamamatsucho 2-chome,
      Minato-ku, Tokyo 105-6125, Japan.
FAU - Kunieda, Etsuo
AU  - Kunieda E
AD  - Department of Radiation Oncology, Tokai University School of Medicine,
      Shimokasuya 143, Isehara-shi, Kanagawa 259-1143, Japan.
FAU - Akiba, Takeshi
AU  - Akiba T
AD  - Department of Radiation Oncology, Tokai University School of Medicine,
      Shimokasuya 143, Isehara-shi, Kanagawa 259-1143, Japan.
FAU - Takeda, Atsuya
AU  - Takeda A
AD  - Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura-shi 247-0056, Japan.
FAU - Shigematsu, Naoyuki
AU  - Shigematsu N
AD  - Department of Radiology, Keio University School of Medicine, Shinanomachi 35,
      Shinjuku-ku, Tokyo 160-8582, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - Italy
TA  - Phys Med
JT  - Physica medica : PM : an international journal devoted to the applications of
      physics to medicine and biology : official journal of the Italian Association of 
      Biomedical Physics (AIFB)
JID - 9302888
SB  - IM
MH  - *Deep Learning
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Male
MH  - *Prostatic Neoplasms/diagnostic imaging/radiotherapy
MH  - Semantics
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Deep learning
OT  - Prostate cancer
OT  - Semantic segmentation
OT  - U-Net
EDAT- 2020/09/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/20 20:31
PHST- 2020/02/03 00:00 [received]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/09/20 20:31 [entrez]
AID - S1120-1797(20)30220-9 [pii]
AID - 10.1016/j.ejmp.2020.09.004 [doi]
PST - ppublish
SO  - Phys Med. 2020 Oct;78:93-100. doi: 10.1016/j.ejmp.2020.09.004. Epub 2020 Sep 17.


PMID- 32950802
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 72
DP  - 2020 Sep - Oct
TI  - The influence of cognitive distortions on decision-making capacity for physician 
      aid in dying.
PG  - 101627
LID - S0160-2527(20)30086-8 [pii]
LID - 10.1016/j.ijlp.2020.101627 [doi]
AB  - As international laws on physician aid in dying (PAD) evolve, the question of
      permitting PAD in non-terminal illness, and in sole psychiatric illness, is under
      intense debate. In jurisdictions where PAD is permissible, certain safeguards and
      eligibility requirements must be met for all patients making a PAD request, and
      one of these requirements is that the patient have sound decision-making capacity
      with respect to the request. Legal criteria already exist for the determination
      of capacity, and they are quite similar between different jurisdictions. In
      current debates about the question of psychiatric PAD, one concern that has been 
      raised is that cognitive distortions in mental disorders may affect a patient's
      decision-making capacity. At the same time, it has been established that all
      persons, with or without a mental disorder, experience cognitive distortions. If 
      cognitive distortions are ubiquitous, it is likely that the severity and
      frequency of cognitive distortions is dimensional rather than categorical,
      between samples with and without mental illness. Furthermore, currently, there is
      no requirement for a formalized evaluation of cognitive distortions as part of
      capacity assessment for any type of medical decision, including PAD decisions.
      The current paper examines the literature related to cognitive distortions in
      mental disorders and in healthy populations. It proposes that the existence of
      cognitive distortions, alone, cannot be used as an argument for a blanket
      exclusion of psychiatric PAD. It therefore concludes that further research and
      ethical analysis should be undertaken to examine the impact of cognitive
      distortions on decision-making for consequential medical decisions, including
      PAD, in patients with and without mental disorders.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Dembo, Justine
AU  - Dembo J
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
      Electronic address: justine.dembo@mail.utoronto.ca.
FAU - van Veen, Sisco
AU  - van Veen S
AD  - GGZinGeest, Amsterdam University Medical Centres, Vrije Universiteit, Amsterdam, 
      the Netherlands.
FAU - Widdershoven, Guy
AU  - Widdershoven G
AD  - Amsterdam University Medical Centres, Vrije Universiteit, Amsterdam, the
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200917
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - *Cognitive Dysfunction
MH  - *Decision Making
MH  - Humans
MH  - Mental Competency/*psychology
MH  - Mental Disorders/psychology
MH  - Suicide, Assisted/ethics/legislation & jurisprudence/*psychology
OTO - NOTNLM
OT  - *Cognitive distortions
OT  - *Medical aid in dying
OT  - *Medical decision-making capacity
OT  - *Mental disorder
OT  - *Physician aid in dying
COIS- Declaration of Competing Interest JD is a member of the Clinicians' Advisory
      Council for Dying With Dignity Canada. There is no financial reimbursement for
      this role.
EDAT- 2020/09/21 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/09/20 20:30
PHST- 2020/03/23 00:00 [received]
PHST- 2020/08/18 00:00 [revised]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/09/20 20:30 [entrez]
AID - S0160-2527(20)30086-8 [pii]
AID - 10.1016/j.ijlp.2020.101627 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Sep - Oct;72:101627. doi: 10.1016/j.ijlp.2020.101627. 
      Epub 2020 Sep 17.


PMID- 32950387
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1424-3911 (Electronic)
IS  - 1424-3903 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Oct
TI  - Pancreatic resections in patients who refuse blood transfusions. The application 
      of a perioperative protocol for a true bloodless surgery.
PG  - 1550-1557
LID - S1424-3903(20)30669-4 [pii]
LID - 10.1016/j.pan.2020.08.020 [doi]
AB  - BACKGROUND: The refusal of blood transfusions compels surgeons to face ethical
      and clinical issues. A single-institution experience with a dedicated
      perioperative blood management protocol was reviewed to assess feasibility and
      short-term outcomes of true bloodless pancreatic surgery. METHODS: The
      institutional database was reviewed to identify patients who refused transfusion 
      and were scheduled for elective pancreatic surgery from 2010 through 2018. A
      protocol to optimize the hemoglobin values by administration of drugs stimulating
      erythropoiesis was systematically used. RESULTS: Perioperative outcomes of 32
      Jehovah's Witnesses patients were included. Median age was 67 years (range,
      31-77). Nineteen (59.4%) patients were treated with preoperative erythropoietin. 
      Twenty-four (75%) patients underwent pylorus-preserving pancreaticoduodenectomy, 
      4 (12.5%) distal pancreatectomy (DP) with splenectomy, 3 (9.4%) spleen-preserving
      DP, and 1 (3.1%) total pancreatectomy. Median estimated blood loss and surgical
      duration were 400 mL (range, 100-1000) and 470 min (range, 290-595),
      respectively. Median preoperative hemoglobin was 13.9 g/dL (range, 11.7-15.8)
      while median postoperative nadir hemoglobin was 10.5 g/dL (range, 7.1-14.1). The 
      most common histological diagnosis (n = 15, 46.9%) was pancreatic ductal
      adenocarcinoma. Clavien-Dindo grade I-II complications occurred in fourteen
      (43.8%) patients while one (3.1%) patient had a Clavien-Dindo grade IIIa
      complication wich was an abdominal collection that required percutaneous
      drainage. Six (18.8%) patients presented biochemical leak or postoperative
      pancreatic fistula grade B. Median hospital stay was 16 days (range, 8-54) with
      no patient requiring transfusion or re-operation and no 90-day mortality.
      CONCLUSIONS: A multidisciplinary approach and specific perioperative management
      allowed performing pancreatic resections in patients who refused transfusion with
      good short-term outcomes.
CI  - Copyright (c) 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.
FAU - De Bellis, Mario
AU  - De Bellis M
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Girelli, Domenico
AU  - Girelli D
AD  - Department of Medicine, Section of Internal Medicine, University of Verona,
      School of Medicine, Verona, Italy.
FAU - Ruzzenente, Andrea
AU  - Ruzzenente A
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Bagante, Fabio
AU  - Bagante F
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Ziello, Raffaele
AU  - Ziello R
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Campagnaro, Tommaso
AU  - Campagnaro T
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Conci, Simone
AU  - Conci S
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Nifosi, Filippo
AU  - Nifosi F
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Guglielmi, Alfredo
AU  - Guglielmi A
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy.
FAU - Iacono, Calogero
AU  - Iacono C
AD  - Department of Surgery, Division of General and Hepato-Pancreato-Biliary Surgery, 
      University of Verona, School of Medicine, Verona, Italy. Electronic address:
      calogero.iacono@univr.it.
LA  - eng
PT  - Journal Article
DEP - 20200905
PL  - Switzerland
TA  - Pancreatology
JT  - Pancreatology : official journal of the International Association of
      Pancreatology (IAP) ... [et al.]
JID - 100966936
RN  - 0 (Hemoglobins)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Loss, Surgical
MH  - *Blood Transfusion
MH  - *Bloodless Medical and Surgical Procedures
MH  - Carcinoma, Pancreatic Ductal/surgery
MH  - Erythropoietin/therapeutic use
MH  - Feasibility Studies
MH  - Female
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Jehovah's Witnesses
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Pancreatectomy/*methods
MH  - Pancreatic Neoplasms/surgery
MH  - Pancreaticoduodenectomy/*methods
MH  - Perioperative Care/*methods
MH  - Postoperative Complications/epidemiology
MH  - Splenectomy
MH  - Treatment Outcome
MH  - *Treatment Refusal
OTO - NOTNLM
OT  - Bloodless surgery
OT  - Jehovah's Witnesses
OT  - Pancreas surgery
OT  - Patient blood management protocol
OT  - Transfusion
COIS- Declaration of competing interest None to declare.
EDAT- 2020/09/21 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/09/20 20:26
PHST- 2020/03/03 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/09/20 20:26 [entrez]
AID - S1424-3903(20)30669-4 [pii]
AID - 10.1016/j.pan.2020.08.020 [doi]
PST - ppublish
SO  - Pancreatology. 2020 Oct;20(7):1550-1557. doi: 10.1016/j.pan.2020.08.020. Epub
      2020 Sep 5.


PMID- 32949896
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210902
IS  - 1557-8615 (Electronic)
IS  - 0883-9441 (Linking)
VI  - 60
DP  - 2020 Dec
TI  - The wave of very old people in the intensive care unit-A challenge in
      decision-making.
PG  - 290-293
LID - S0883-9441(20)30674-2 [pii]
LID - 10.1016/j.jcrc.2020.08.030 [doi]
AB  - In this paper the authors express the opinion that there is much to be learned
      about the 80+ year old age group as it relates to critical care and end-of-life
      matters. We need to learn how to better predict outcome, we need to learn our
      limitations and deal with uncertainties, we need to better communicate with our
      elderly patients and their caregivers and we need to engage with our colleagues
      in Geriatrics. There is a wave of very old people arriving in the intensive care 
      unit and we have much to do to prepare for it and for the ethical, fair and
      appropriate care of these critically ill, but elderly, patients.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - van Heerden, Peter Vernon
AU  - van Heerden PV
AD  - General Intensive Care Unit, Hadassah-Hebrew University Hospital, Jerusalem,
      Israel. Electronic address: vernon@hadassah.org.il.
FAU - Sviri, Sigal
AU  - Sviri S
AD  - Medical Intensive Care Unit, Hadassah-Hebrew University Hospital, Jerusalem,
      Israel.
FAU - Beil, Michael
AU  - Beil M
AD  - Institute of Health Sciences at PTHV, Pallottistr. 3, 56179 Vallendar, Germany.
FAU - Szczeklik, Wojciech
AU  - Szczeklik W
AD  - Department of Intensive Care and Perioperative Medicine, Jagiellonian University 
      Medical College, Krakow, Poland.
FAU - de Lange, Dylan
AU  - de Lange D
AD  - Department of Intensive Care Medicine, University Medical Center, University
      Utrecht, Utrecht, The Netherlands.
FAU - Jung, Christian
AU  - Jung C
AD  - Department of Cardiology, Pulmonary Diseases, and Vascular Medicine, Medical
      Faculty, Heinrich Heine University of Duesseldorf, Germany.
FAU - Guidet, Bertrand
AU  - Guidet B
AD  - Sorbonne Universite, INSERM, Institut Pierre Louis d'Epidemiomlogie et de Sante
      Publique Hopital Saint-Antoine, Service de Reanimation, Paris, France.
FAU - Leaver, Susannah
AU  - Leaver S
AD  - Department of Adult Critical Care, St George's Healthcare NHS Foundation Trust,
      London, UK.
FAU - Rhodes, Andrew
AU  - Rhodes A
AD  - Department of Adult Critical Care, St George's Healthcare NHS Foundation Trust,
      London, UK.
FAU - Boumendil, Ariane
AU  - Boumendil A
AD  - Hopital Saint Antoine, 75012 Paris, France.
FAU - Flaatten, Hans
AU  - Flaatten H
AD  - Department of Anaesthesia and Intensive Care, Haukeland University Hospital,
      Bergen, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - United States
TA  - J Crit Care
JT  - Journal of critical care
JID - 8610642
SB  - IM
CIN - J Crit Care. 2021 Apr;62:183-184. PMID: 33412480
MH  - Aged, 80 and over
MH  - *Clinical Decision-Making
MH  - *Critical Care
MH  - Critical Illness
MH  - Family/psychology
MH  - Female
MH  - Humans
MH  - *Intensive Care Units
MH  - Male
MH  - Patients
MH  - Professional-Family Relations
MH  - *Quality of Health Care
MH  - *Terminal Care
OTO - NOTNLM
OT  - *Decision-making
OT  - *Intensive care
OT  - *Very old people
COIS- Declaration of Competing Interest All the authors declare that they have no
      conflict of interest issues with this manuscript.
EDAT- 2020/09/20 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/09/19 20:13
PHST- 2020/04/24 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2020/09/19 20:13 [entrez]
AID - S0883-9441(20)30674-2 [pii]
AID - 10.1016/j.jcrc.2020.08.030 [doi]
PST - ppublish
SO  - J Crit Care. 2020 Dec;60:290-293. doi: 10.1016/j.jcrc.2020.08.030. Epub 2020 Sep 
      10.


PMID- 32949507
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210507
IS  - 2215-0374 (Electronic)
IS  - 2215-0366 (Linking)
VI  - 7
IP  - 10
DP  - 2020 Oct
TI  - Psychedelic medicine: safety and ethical concerns.
PG  - 829-830
LID - S2215-0366(20)30146-2 [pii]
LID - 10.1016/S2215-0366(20)30146-2 [doi]
FAU - Anderson, Brian T
AU  - Anderson BT
AD  - Department of Psychiatry, Weill Institute for Neurosciences, University of
      California, San Francisco, CA, USA; Zuckerberg San Francisco General Hospital and
      Trauma Center, San Francisco, CA, USA.
FAU - Danforth, Alicia L
AU  - Danforth AL
AD  - Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA 90509, USA.
FAU - Grob, Charles S
AU  - Grob CS
AD  - Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA 90509, USA;
      Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA 90509, USA.
      Electronic address: cgrob@lundquist.org.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Lancet Psychiatry
JT  - The lancet. Psychiatry
JID - 101638123
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
SB  - IM
CON - JAMA Psychiatry. 2019 Jun 26;:null. PMID: 31241740
MH  - *Hallucinogens
MH  - Lysergic Acid Diethylamide
MH  - Psilocybin
MH  - *Psychopharmacology
EDAT- 2020/09/20 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/19 20:08
PHST- 2020/03/27 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/09/19 20:08 [entrez]
AID - S2215-0366(20)30146-2 [pii]
AID - 10.1016/S2215-0366(20)30146-2 [doi]
PST - ppublish
SO  - Lancet Psychiatry. 2020 Oct;7(10):829-830. doi: 10.1016/S2215-0366(20)30146-2.


PMID- 32949182
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Linking)
VI  - 25
IP  - 12
DP  - 2020 Dec
TI  - Pregnancy in Women with Metastatic Sarcomas.
PG  - e2010-e2012
LID - 10.1002/onco.13529 [doi]
AB  - Successful pregnancy in women with metastatic cancer is rare in the published
      literature. We report here on four women with sarcoma who started and conducted
      their first pregnancies while in metastatic disease. All four pregnancies were
      first pregnancies, and all four women are long-term survivors from 20 to 248
      months after pregnancy. One patient had three pregnancies. All four women stopped
      systemic cancer treatment during their pregnancies, and two had RECIST
      progression during treatment interruption. Three patients still have unresectable
      metastatic disease, whereas one is in complete remission. In selected metastatic 
      sarcomas with indolent courses, successful pregnancies are possible with no or
      minor impact on cancer progression and with prolonged life duration after
      pregnancy. As metastatic cancer becomes more often a chronic disease, this
      possibility opens important practical and ethical questions on how to best to
      advise women of childbearing age with metastatic cancers who are long-term
      survivors.
CI  - (c) 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf
      of AlphaMed Press.
FAU - Yazigi, Alexandre
AU  - Yazigi A
AD  - Centre Leon Berard, Lyon, France.
FAU - Lecointe-Artzner, Estelle
AU  - Lecointe-Artzner E
AD  - Infosarcoma, Rennes, France.
FAU - Cesne, Axel Le
AU  - Cesne AL
AD  - Gustave Roussy, Villejuif, France.
FAU - Ray-Coquard, Isabelle
AU  - Ray-Coquard I
AUID- ORCID: https://orcid.org/0000-0003-2472-8306
AD  - Centre Leon Berard, Lyon, France.
AD  - Universite Claude Bernard, Lyon, France.
AD  - Unicancer, Paris, France.
FAU - Blay, Jean-Yves
AU  - Blay JY
AUID- ORCID: https://orcid.org/0000-0001-7190-120X
AD  - Centre Leon Berard, Lyon, France.
AD  - Universite Claude Bernard, Lyon, France.
AD  - Unicancer, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200928
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
SB  - IM
MH  - Female
MH  - Humans
MH  - *Neoplasms, Second Primary
MH  - Pregnancy
MH  - *Sarcoma/drug therapy
PMC - PMC8108058
EDAT- 2020/09/20 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/19 08:33
PHST- 2020/05/17 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/19 08:33 [entrez]
AID - 10.1002/onco.13529 [doi]
PST - ppublish
SO  - Oncologist. 2020 Dec;25(12):e2010-e2012. doi: 10.1002/onco.13529. Epub 2020 Sep
      28.


PMID- 32948575
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 17
TI  - Impact of hearing loss and vestibular decline on cognition in Alzheimer's
      disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en
      Cognitie, GECkO).
PG  - e039601
LID - 10.1136/bmjopen-2020-039601 [doi]
AB  - INTRODUCTION: Dementia is a prevalent disease affecting a growing number of the
      ageing population. Alzheimer's disease (AD) is the most common cause of dementia.
      Previous research investigated the link between hearing loss and cognition, and
      the effect of vestibular dysfunction on cognition. Hearing loss and, to a lesser 
      extent, vestibular decline both result in a decreasing cognitive function.
      However, their interaction should not be underestimated. The aim of this study is
      to assess the effect of hearing loss, vestibular decline and their interaction on
      cognition in people suffering from mild cognitive impairment (MCI) and dementia
      due to AD (ADD). METHODS AND ANALYSIS: We designed a prospective longitudinal
      study to assess the effect of hearing loss and vestibular decline on cognition. A
      total of 100 cognitively impaired elderly (between 55 and 84 years of age),
      consisting of 60 patients with MCI due to AD and 40 patients with ADD will be
      included. The control group will consist of individuals with preserved cognition 
      group-matched based on age, hearing level and vestibular function. A
      comprehensive assessment is performed at baseline, 12-month and 24-month
      follow-ups. The primary outcome measure is the change in the Repeatable Battery
      for the Assessment of Neuropsychological Status adjusted for Hearing-impaired
      individuals total score, a cognitive test battery assessing different cognitive
      domains. Secondary outcome measures include additional neuropsychological
      assessments, cortical auditory-evoked potentials, and evaluation of general and
      disease-specific health-related quality of life. Variables include cognitive,
      audiological and vestibular evaluation. Variance analyses will assess the effect 
      of hearing loss and vestibular decline on cognition. More precisely, the link
      between hearing loss and non-spatial cognitive functioning, the effect of
      vestibular decline on spatial cognition and the impact of both factors on the
      rate of conversion from MCI due to AD to ADD will be investigated. ETHICS AND
      DISSEMINATION: The study protocol was approved by the ethical committee of the
      Antwerp University Hospital on 4 February 2019 with protocol number
      B300201938949. The findings will be disseminated through peer-reviewed
      publications and conference presentations. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT04385225).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bosmans, Joyce
AU  - Bosmans J
AUID- ORCID: 0000-0002-7665-6810
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium joyce.bosmans@uantwerpen.be.
FAU - Jorissen, Catherine
AU  - Jorissen C
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
AD  - Department of Otorhinolaryngology/Head and Neck Surgery, Antwerp University
      Hospital, Edegem, Antwerp, Belgium.
FAU - Cras, Patrick
AU  - Cras P
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
AD  - Department of Neurology, Antwerp University Hospital, Edegem, Belgium.
FAU - Van Ombergen, Angelique
AU  - Van Ombergen A
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
FAU - Engelborghs, Sebastiaan
AU  - Engelborghs S
AD  - Department of Biomedical Sciences and Institute Born-Bunge, University of
      Antwerp, Antwerp, Belgium.
AD  - Department of Neurology, UZ Brussel and Center for Neurosciences (C4N), VUB,
      Brussels, Belgium.
FAU - Gilles, Annick
AU  - Gilles A
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
AD  - Department of Otorhinolaryngology/Head and Neck Surgery, Antwerp University
      Hospital, Edegem, Antwerp, Belgium.
AD  - Department of Education, Health & Social Work, University College Ghent, Ghent,
      Belgium.
FAU - Princen, Eline
AU  - Princen E
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
FAU - Moyaert, Julie
AU  - Moyaert J
AD  - Department of Otorhinolaryngology/Head and Neck Surgery, Antwerp University
      Hospital, Edegem, Antwerp, Belgium.
FAU - Mertens, Griet
AU  - Mertens G
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
AD  - Department of Otorhinolaryngology/Head and Neck Surgery, Antwerp University
      Hospital, Edegem, Antwerp, Belgium.
FAU - Van Rompaey, Vincent
AU  - Van Rompaey V
AD  - Department of Translational Neurosciences, University of Antwerp, Faculty of
      Medicine and Health Sciences, Wilrijk, Belgium.
AD  - Department of Otorhinolaryngology/Head and Neck Surgery, Antwerp University
      Hospital, Edegem, Antwerp, Belgium.
LA  - eng
SI  - ClinicalTrials.gov/NCT04385225
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Alzheimer Disease
MH  - Animals
MH  - Cognition
MH  - *Cognitive Dysfunction/etiology
MH  - *Hearing Loss
MH  - Humans
MH  - *Lizards
MH  - Longitudinal Studies
MH  - Neuropsychological Tests
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC7500302
OTO - NOTNLM
OT  - *alzheimer's disease
OT  - *bilateral vestibulopathy
OT  - *cognition
OT  - *dementia
OT  - *mild cognitive impairment
OT  - *sensorineural hearing loss
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039601 [pii]
AID - 10.1136/bmjopen-2020-039601 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 17;10(9):e039601. doi: 10.1136/bmjopen-2020-039601.


PMID- 32948573
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 18
TI  - Permeability of the blood-brain barrier through the phases of ischaemic stroke
      and relation with clinical outcome: protocol for a systematic review.
PG  - e039280
LID - 10.1136/bmjopen-2020-039280 [doi]
AB  - INTRODUCTION: Ischaemic stroke is the most prevalent type of stroke and is
      characterised by a myriad of pathological events triggered by a vascular arterial
      occlusion. Disruption of the blood-brain barrier (BBB) is a key pathological
      event that may lead to fatal outcomes. However, it seems to follow a multiphasic 
      pattern that has been associated with distinct biological substrates and possibly
      contrasting outcomes. Addressing the BBB permeability (BBBP) along the different 
      phases of stroke through imaging techniques could lead to a better understanding 
      of the disease, improved patient selection for specific treatments and
      development of new therapeutic modalities and delivery methods. This systematic
      review will aim to comprehensively summarise the existing evidence regarding the 
      evolution of the BBBP values during the different phases of an acute ischaemic
      stroke and correlate this event with the clinical outcome of the patient. METHODS
      AND ANALYSIS: We will conduct a computerised search on Medline, EMBASE, Cochrane 
      Central Register of Controlled Trials, Scopus and Web of Science. In addition,
      grey literature and ClinicalTrials.gov will be scanned. We will include
      randomised controlled trials, cohort, cross-sectional and case-controlled studies
      on humans that quantitatively assess the BBBP in stroke. Retrieved studies will
      be independently reviewed by two authors and any discrepancies will be resolved
      by consensus or with a third reviewer. Reviewers will extract the data and assess
      the risk of bias of the selected studies. If possible, data will be combined in a
      quantitative meta-analysis following the guidelines provided by Cochrane Handbook
      for Systematic Reviews of Interventions. We will assess cumulative evidence using
      the Grading of Recommendations, Assessment, Development and Evaluation approach. 
      ETHICS AND DISSEMINATION: Ethical approval is not needed. All data used for this 
      work are publicly available. The result obtained from this work will be published
      in a peer-reviewed journal and disseminated in relevant conferences. PROSPERO
      REGISTRATION NUMBER: CRD42019147314.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Bernardo-Castro, Sara
AU  - Bernardo-Castro S
AUID- ORCID: 0000-0001-8809-5101
AD  - Stroke Unit, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.
FAU - Donato, Helena
AU  - Donato H
AD  - Documentation Service, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra,
      Portugal.
FAU - Ferreira, Lino
AU  - Ferreira L
AD  - Center for Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra,
      Portugal.
AD  - Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.
FAU - Sargento-Freitas, Joao
AU  - Sargento-Freitas J
AUID- ORCID: 0000-0003-4665-5697
AD  - Stroke Unit, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal 
      jsargentof@hotmail.com.
AD  - Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200918
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Blood-Brain Barrier
MH  - *Brain Ischemia
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Ischemic Stroke
MH  - Meta-Analysis as Topic
MH  - Permeability
MH  - Research Design
MH  - *Stroke
MH  - Systematic Reviews as Topic
PMC - PMC7511624
OTO - NOTNLM
OT  - *computed tomography
OT  - *magnetic resonance imaging
OT  - *neuroradiology
OT  - *stroke
OT  - *vascular medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039280 [pii]
AID - 10.1136/bmjopen-2020-039280 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 18;10(9):e039280. doi: 10.1136/bmjopen-2020-039280.


PMID- 32948571
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 17
TI  - Evaluation of outcome relevance of quality indicators in the emergency department
      (ENQuIRE): study protocol for a prospective multicentre cohort study.
PG  - e038776
LID - 10.1136/bmjopen-2020-038776 [doi]
AB  - INTRODUCTION: Quality of emergency department (ED) care affects patient outcomes 
      substantially. Quality indicators (QIs) for ED care are a major challenge due to 
      the heterogeneity of patient populations, health care structures and processes in
      Germany. Although a number of quality measures are already in use, there is a
      paucity of data on the importance of these QIs on medium-term and long-term
      outcomes. The evaluation of outcome relevance of quality indicators in the
      emergency department study (ENQuIRE) aims to identify and investigate the
      relevance of QIs in the ED on patient outcomes in a 12-month follow-up. METHODS
      AND ANALYSIS: The study is a prospective non-interventional multicentre cohort
      study conducted in 15 EDs throughout Germany. Included are all patients in 2019, 
      who were >/=18 years of age, insured at the Techniker Krankenkasse (statutory
      health insurance (SHI)) and gave their written informed consent to the study.The 
      primary objective of the study is to assess the effect of selected quality
      measures on patient outcome. The data collected for this purpose comprise medical
      records from the ED treatment, discharge (claims) data from hospitalised
      patients, a patient questionnaire to be answered 6-8 weeks after emergency
      admission, and outcome measures in a 12-month follow-up obtained as claims data
      from the SHI.Descriptive and analytical statistics will be applied to provide
      summaries about the characteristics of QIs and associations between quality
      measures and patient outcomes. ETHICS AND DISSEMINATION: Approval of the leading 
      ethics committee at the Medical Faculty of the University of Magdeburg (reference
      number 163/18 from 19 November 2018) has been obtained and adapted by responsible
      local ethics committees.The findings of this work will be disseminated by
      publication of peer-reviewed manuscripts and presentations as conference
      contributions (abstracts, poster or oral presentations).Moreover, results will be
      discussed with clinical experts and medical associations before being proposed
      for implementation into the quality management of EDs. TRIAL REGISTRATION NUMBER:
      German Clinical Trials Registry (DRKS00015203); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Drynda, Susanne
AU  - Drynda S
AUID- ORCID: 0000-0002-5992-7578
AD  - Department of Trauma Surgery, Otto von Guericke University, Magdeburg, Germany
      susanne.drynda@med.ovgu.de.
FAU - Schindler, Wencke
AU  - Schindler W
AD  - Institute of Social Medicine and Health Systems Research, Otto von Guericke
      University, Magdeburg, Germany.
FAU - Slagman, Anna
AU  - Slagman A
AD  - Emergency and Acute Medicine, Charite, Berlin, Germany.
FAU - Pollmanns, Johannes
AU  - Pollmanns J
AD  - Faculty of Health Care, Niederrhein University of Applied Sciences, Krefeld,
      Germany.
FAU - Horenkamp-Sonntag, Dirk
AU  - Horenkamp-Sonntag D
AD  - Techniker Krankenkasse, Hamburg, Germany.
FAU - Schirrmeister, Wiebke
AU  - Schirrmeister W
AD  - Department of Trauma Surgery, Otto von Guericke University, Magdeburg, Germany.
FAU - Otto, Ronny
AU  - Otto R
AD  - Department of Trauma Surgery, Otto von Guericke University, Magdeburg, Germany.
FAU - Bienzeisler, Jonas
AU  - Bienzeisler J
AD  - Institute of Medical Informatics, RWTH Aachen University, Aachen, Germany.
FAU - Greiner, Felix
AU  - Greiner F
AUID- ORCID: 0000-0003-1171-9355
AD  - Department of Trauma Surgery, Otto von Guericke University, Magdeburg, Germany.
FAU - Drosler, Saskia
AU  - Drosler S
AD  - Faculty of Health Care, Niederrhein University of Applied Sciences, Krefeld,
      Germany.
FAU - Lefering, Rolf
AU  - Lefering R
AD  - Institute for Research in Operative Medicine (IFOM), University of
      Witten/Herdecke, Koln, Germany.
FAU - Hitzek, Jennifer
AU  - Hitzek J
AD  - Emergency and Acute Medicine, Charite, Berlin, Germany.
FAU - Mockel, Martin
AU  - Mockel M
AUID- ORCID: 0000-0002-7691-3709
AD  - Emergency and Acute Medicine, Charite, Berlin, Germany.
FAU - Rohrig, Rainer
AU  - Rohrig R
AD  - Institute of Medical Informatics, RWTH Aachen University, Aachen, Germany.
FAU - Swart, Enno
AU  - Swart E
AD  - Institute of Social Medicine and Health Systems Research, Otto von Guericke
      University, Magdeburg, Germany.
FAU - Walcher, Felix
AU  - Walcher F
AD  - Department of Trauma Surgery, Otto von Guericke University, Magdeburg, Germany.
LA  - eng
SI  - DRKS/DRKS00015203
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - *Emergency Service, Hospital
MH  - Germany
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - *Quality Indicators, Health Care
PMC - PMC7500312
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health & safety
OT  - *health services administration & management
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038776 [pii]
AID - 10.1136/bmjopen-2020-038776 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 17;10(9):e038776. doi: 10.1136/bmjopen-2020-038776.


PMID- 32948570
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 18
TI  - Inclusion of diabetic retinopathy screening strategies in national-level diabetes
      care planning in low-income and middle-income settings: protocol for a scoping
      review.
PG  - e038647
LID - 10.1136/bmjopen-2020-038647 [doi]
AB  - INTRODUCTION: The diabetes mellitus (DM) epidemic is a major public health
      concern globally, with the highest-burden in low-income and middle-income
      countries (LMICs). Diabetic retinopathy (DR) is a microvascular complication of
      diabetes, and if left untreated can lead to visual impairment and blindness.
      Epidemiological studies suggest that the incidence of sight-threatening DR is
      decreasing in high-income countries due to improved treatments and management of 
      DM; however, these trends are not replicated in LMICs. In this paper, we outline 
      a scoping review protocol that aims to identify which LMICs have included DR in
      their national DM, non-communicable disease or prevention of blindness plans. The
      scoping review also aims to assess gaps when implementing national DR screening
      programmes in LMICs. METHODS AND ANALYSIS: This scoping review will follow the
      Arksey and O'Malley (2005) methodology and the Preferred Reporting Items for
      Systematic Review and Meta-Analysis extension for Scoping Review guidelines. A
      comprehensive search of peer-reviewed and grey literature will be conducted from 
      October 1989 (St. Vincent Declaration) to February 2020. Studies will be
      identified from electronic databases; Medline, Embase and CENTRAL (Cochrane
      Library). To identify further relevant articles, a hand search will be conducted 
      using the reference lists of included studies. Two reviewers will independently
      screen records for relevant data and disagreements about eligibility will be
      resolved through consensus or arbitration by a third reviewer. A quantitative
      analysis will be performed to highlight key findings and thematic analysis will
      be used to identify emerging themes and subthemes from included studies. The key 
      themes will highlight countries progress in terms of national-level DR service
      planning and screening implementation. ETHICS AND DISSEMINATION: No ethical
      approval is required because the scoping review methodology aims to synthesise
      information from publicly available resources. The results will be disseminated
      through conference presentations and peer-reviewed publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Curran, Katie
AU  - Curran K
AUID- ORCID: 0000-0002-7071-109X
AD  - Centre of Public Health, Queen's University Belfast School of Medicine Dentistry 
      and Biomedical Sciences, Belfast, UK kcurran12@qub.ac.uk.
FAU - Piyasena, Prabhath
AU  - Piyasena P
AUID- ORCID: 0000-0002-0236-0101
AD  - Centre of Public Health, Queen's University Belfast School of Medicine Dentistry 
      and Biomedical Sciences, Belfast, UK.
AD  - Ministry of Health, Directorate of Policy Analysis and Development, Colombo, Sri 
      Lanka.
FAU - Congdon, Nathan
AU  - Congdon N
AD  - Centre of Public Health, Queen's University Belfast School of Medicine Dentistry 
      and Biomedical Sciences, Belfast, UK.
AD  - Ophthalmology and Public Health, Sun Yat-Sen University Zhongshan Ophthalmic
      Center, Guangzhou, China.
FAU - Duke, Lisa
AU  - Duke L
AD  - Policy and Programmes, International Diabetes Federation, Brussels, Belgium.
FAU - Malanda, Belma
AU  - Malanda B
AD  - Policy and Programmes, International Diabetes Federation, Brussels, Belgium.
FAU - Peto, Tunde
AU  - Peto T
AUID- ORCID: 0000-0001-6265-0381
AD  - Centre of Public Health, Queen's University Belfast School of Medicine Dentistry 
      and Biomedical Sciences, Belfast, UK.
AD  - Belfast Health and Social Care Trust, Belfast, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200918
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Developing Countries
MH  - *Diabetes Mellitus
MH  - *Diabetic Retinopathy/diagnosis
MH  - Humans
MH  - Income
MH  - Meta-Analysis as Topic
MH  - Poverty
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7511640
OTO - NOTNLM
OT  - *diabetic retinopathy
OT  - *health policy
OT  - *medical retina
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038647 [pii]
AID - 10.1136/bmjopen-2020-038647 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 18;10(9):e038647. doi: 10.1136/bmjopen-2020-038647.


PMID- 32948564
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 18
TI  - Use and impact of social prescribing: a mixed-methods feasibility study protocol.
PG  - e037681
LID - 10.1136/bmjopen-2020-037681 [doi]
AB  - INTRODUCTION: Social prescribing aims to address social determinants of health,
      which account for 80%-90% of health outcomes, but the evidence base behind it is 
      limited due to a lack of data linkingsocial prescribing activity and outcomes.
      METHODS AND ANALYSIS: The objective of the quantitative component of this
      feasibility studyisto identify the characteristics of individuals who receive
      social prescriptions and describe the use and estimate the impact of social
      prescribing; the latter will be done on a homeless subgroup. We will use the
      Oxford Royal College of General Practitioners (RCGP) Research and Surveillance
      Centre (RSC) primary care sentinel network, whose general practicescover a
      population of over 4 000 000 patients. Social prescribing data will be extracted 
      onall recorded patients for 5 years up to 31 January 2020. The objective for the 
      qualitative component of the study isto explore approaches to understand the
      contextual factors that will have influenced our quantitative findings to
      identify mechanisms to encourage adoption of social prescribing in primary care
      while improving data quality. Itwill comprise up to three 90-120 minute advisory 
      group meetings for six to eight participants. Participants will be recruited
      based on their experience of delivering primary care within Oxfordshire and
      Surrey. The advisory group outputs will be analysed using framework analysis and 
      will be used to create a survey instrument consisting of statements that
      surveyees, who will consist of primary care practitioners within the RCGP RSC,
      can agree or disagree with. ETHICS AND DISSEMINATION: All RCGP RSC data are
      pseudonymised at the point of data extraction. No personally identifiable data
      are required for this investigation. This protocol follows the Good Reporting of 
      a Mixed Methods Study checklist. The study results will be published in a
      peer-reviewed journal and the dataset will be available to other researchers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jani, Anant
AU  - Jani A
AUID- ORCID: 0000-0002-7046-6768
AD  - Oxford Martin School, University of Oxford, Oxford, United Kingdom.
FAU - Liyanage, Harshana
AU  - Liyanage H
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Hoang, Uy
AU  - Hoang U
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Moore, Lucy
AU  - Moore L
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Ferreira, Filipa
AU  - Ferreira F
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Yonova, Ivelina
AU  - Yonova I
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Tzortziou Brown, Victoria
AU  - Tzortziou Brown V
AD  - Royal College of General Practitioners, London, UK.
AD  - Institute of Population Health Sciences, Barts and the London School of Medicine 
      and Dentistry, Queen Mary University of London, London, United Kingdom.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AUID- ORCID: 0000-0002-8553-2641
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK simon.delusignan@phc.ox.ac.uk.
AD  - Royal College of General Practitioners, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200918
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Feasibility Studies
MH  - *General Practitioners
MH  - Humans
MH  - Prescriptions
MH  - *Primary Health Care
MH  - Research Personnel
PMC - PMC7511614
OTO - NOTNLM
OT  - *health informatics
OT  - *primary care
OT  - *social determinants of health
OT  - *social prescribing
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037681 [pii]
AID - 10.1136/bmjopen-2020-037681 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 18;10(9):e037681. doi: 10.1136/bmjopen-2020-037681.


PMID- 32948554
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 18
TI  - Protocol and statistical analysis plan for the PREventing cardiovascular collaPse
      with Administration of fluid REsuscitation during Induction and Intubation
      (PREPARE II) randomised clinical trial.
PG  - e036671
LID - 10.1136/bmjopen-2019-036671 [doi]
AB  - INTRODUCTION: Cardiovascular collapse is a common complication during tracheal
      intubation of critically ill adults. Whether administration of an intravenous
      fluid bolus prevents cardiovascular collapse during tracheal intubation remains
      uncertain. A prior randomised trial found fluid bolus administration to be
      ineffective overall but suggested potential benefit for patients receiving
      positive pressure ventilation during tracheal intubation. METHODS AND ANALYSIS:
      The PREventing cardiovascular collaPse with Administration of fluid REsuscitation
      during Induction and Intubation (PREPARE II) trial is a prospective,
      multi-centre, non-blinded randomised trial being conducted in 13 academic
      intensive care units in the USA. The trial will randomise 1065 critically ill
      adults undergoing tracheal intubation with planned use of positive pressure
      ventilation (non-invasive ventilation or bag-mask ventilation) between induction 
      and laryngoscopy to receive 500 mL of intravenous crystalloid or no intravenous
      fluid bolus. The primary outcome is cardiovascular collapse, defined as any of:
      systolic blood pressure <65 mm Hg, new or increased vasopressor administration
      between induction and 2 min after intubation, or cardiac arrest or death between 
      induction and 1 hour after intubation. The primary analysis will be an
      unadjusted, intention-to-treat comparison of the primary outcome between patients
      randomised to fluid bolus administration and patients randomised to no fluid
      bolus administration using a chi(2) test. The sole secondary outcome is 28-day
      in-hospital mortality. Enrolment began on 1 February 2019 and is expected to
      conclude in June 2020. ETHICS AND DISSEMINATION: The trial was approved by either
      the central institutional review board at Vanderbilt University Medical Center or
      the local institutional review board at each trial site. Results will be
      submitted for publication in a peer-reviewed journal and presented at scientific 
      conferences. TRIAL REGISTRATION NUMBER: NCT03787732.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Russell, Derek W
AU  - Russell DW
AUID- ORCID: 0000-0002-2716-1344
AD  - Department of Medicine, Division of Pulmonary, Allergy, & Critical Care Medicine,
      University of Alabama at Birmingham, Birmingham, Alabama, USA
      dwrussell@uabmc.edu.
AD  - Veterans Integrated Service Network 7, Department of Veterans Affairs,
      Washington, District of Columbia, USA.
FAU - Casey, Jonathan D
AU  - Casey JD
AD  - Department of Medicine, Division of Allergy, Pulmonary and Critical Care
      Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Gibbs, Kevin W
AU  - Gibbs KW
AD  - Department of Medicine, Section of Pulmonary, Critical Care, Allergy and
      Immunologic Disease, Wake Forest School of Medicine, Winston-Salem, North
      Carolina, USA.
FAU - Dargin, James M
AU  - Dargin JM
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey
      Hospital and Medical Center, Burlington, Massachusetts, USA.
FAU - Vonderhaar, Derek J
AU  - Vonderhaar DJ
AD  - Department of Pulmonary and Critical Care Medicine, Ochsner Health System, New
      Orleans, Louisiana, USA.
FAU - Joffe, A M
AU  - Joffe AM
AD  - Department of Anesthesiology and Pain Medicine, University of Washington,
      Seattle, Washington, USA.
FAU - Ghamande, Shekhar
AU  - Ghamande S
AD  - Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine,
      Baylor Scott & White Medical Center, Temple, Texas, USA.
FAU - Khan, Akram
AU  - Khan A
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Oregon 
      Health & Science University School of Medicine, Portland, Oregon, USA.
FAU - Dutta, Simanta
AU  - Dutta S
AD  - Department of Medicine, Section of Pulmonary, Critical Care, Allergy and
      Immunologic Disease, Wake Forest School of Medicine, Winston-Salem, North
      Carolina, USA.
FAU - Landsperger, Janna S
AU  - Landsperger JS
AD  - Department of Medicine, Division of Allergy, Pulmonary and Critical Care
      Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Robison, Sarah W
AU  - Robison SW
AD  - Department of Medicine, Division of Pulmonary, Allergy, & Critical Care Medicine,
      University of Alabama at Birmingham, Birmingham, Alabama, USA.
FAU - Bentov, Itay
AU  - Bentov I
AD  - Department of Anesthesiology and Pain Medicine, University of Washington,
      Seattle, Washington, USA.
FAU - Wozniak, Joanne M
AU  - Wozniak JM
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey
      Hospital and Medical Center, Burlington, Massachusetts, USA.
FAU - Stempek, Susan
AU  - Stempek S
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey
      Hospital and Medical Center, Burlington, Massachusetts, USA.
FAU - White, Heath D
AU  - White HD
AD  - Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine,
      Baylor Scott & White Medical Center, Temple, Texas, USA.
FAU - Krol, Olivia F
AU  - Krol OF
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine, Oregon 
      Health & Science University School of Medicine, Portland, Oregon, USA.
FAU - Prekker, Matthew E
AU  - Prekker ME
AD  - Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis,
      Minnesota, USA.
AD  - Department of Medicine, Division of Pulmonary/Critical Care Medicine, Hennepin
      County Medical Center, Minneapolis, Minnesota, USA.
FAU - Driver, Brian E
AU  - Driver BE
AD  - Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis,
      Minnesota, USA.
FAU - Brewer, Joseph M
AU  - Brewer JM
AD  - Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine,
      University of Mississippi Medical Center, Jackson, Mississippi, USA.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Medicine, Division of Allergy, Pulmonary and Critical Care
      Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Lindsell, Christopher John
AU  - Lindsell CJ
AD  - Department of Medicine, Division of Allergy, Pulmonary and Critical Care
      Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Self, Wesley H
AU  - Self WH
AD  - Department of Emergency Medicine, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Rice, Todd W
AU  - Rice TW
AD  - Department of Medicine, Division of Allergy, Pulmonary and Critical Care
      Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Semler, Matthew W
AU  - Semler MW
AD  - Department of Medicine, Division of Allergy, Pulmonary and Critical Care
      Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Janz, David
AU  - Janz D
AD  - Department of Medicine, Section of Pulmonary/Critical Care Medicine and
      Allergy/Immunology, Louisiana State University School of Medicine in New Orleans,
      New Orleans, Louisiana, USA.
CN  - PREPARE II Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT03787732
GR  - K23 HL143053/HL/NHLBI NIH HHS/United States
GR  - K08 HL148514/HL/NHLBI NIH HHS/United States
GR  - T32 HL087738/HL/NHLBI NIH HHS/United States
GR  - K12 HL133117/HL/NHLBI NIH HHS/United States
GR  - K23 HL153584/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200918
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Critical Illness
MH  - Humans
MH  - Intubation, Intratracheal/adverse effects
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Respiration, Artificial
MH  - *Shock
PMC - PMC7511643
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *clinical trials
OT  - *thoracic medicine
COIS- Competing interests: None declared.
IR  - Gibbs KW
FIR - Gibbs, Kevin W
IR  - Dutta S
FIR - Dutta, Simanta
IR  - Peters SP
FIR - Peters, Stephen P
IR  - Ali M
FIR - Ali, Muhammad
IR  - Bakhru RN
FIR - Bakhru, Rita N
IR  - Bauer S
FIR - Bauer, Scott
IR  - Bellinger CR
FIR - Bellinger, Christina R
IR  - Brown AM
FIR - Brown, Amanda M
IR  - Brown B
FIR - Brown, Blair
IR  - Brown J
FIR - Brown, Jerri
IR  - Bumgarner C
FIR - Bumgarner, Caitlin
IR  - Butcher W
FIR - Butcher, Wendy
IR  - Caudle M
FIR - Caudle, Megan
IR  - Chatterjee AB
FIR - Chatterjee, Arjun B
IR  - Chodos DJ
FIR - Chodos, David J
IR  - Corcino G
FIR - Corcino, Gerardo
IR  - Cutler NS
FIR - Cutler, Nathan S
IR  - Dotson TL
FIR - Dotson, Travis L
IR  - Files DC
FIR - Files, Daniel C
IR  - Forbes JL
FIR - Forbes, Jonathan L
IR  - Gaillard JP
FIR - Gaillard, John P
IR  - Gershner KA
FIR - Gershner, Katherine A
IR  - Ginty S
FIR - Ginty, Shannon
IR  - Hood KR
FIR - Hood, Kiadrick R
IR  - Hazelwood A
FIR - Hazelwood, April
IR  - Hendricks K
FIR - Hendricks, Katherine
IR  - Jacobus K
FIR - Jacobus, Kelly
IR  - Jaffe JT
FIR - Jaffe, Jonathan T
IR  - Kay S
FIR - Kay, Stacy
IR  - Kloefkorn CA
FIR - Kloefkorn, Chad A
IR  - Krall J
FIR - Krall, Jennifer
IR  - Lannan MT
FIR - Lannan, Margo T
IR  - Lane C
FIR - Lane, Cornelia
IR  - Lanning C
FIR - Lanning, Cynthia
IR  - Lyons J
FIR - Lyons, Jessica
IR  - Mariencheck WI
FIR - Mariencheck, William I
IR  - Marion CR
FIR - Marion, Chad R
IR  - Maslonka MA
FIR - Maslonka, Matthew A
IR  - McClintock S
FIR - McClintock, Sara
IR  - Meier NM
FIR - Meier, Nathaniel M
IR  - Miles MC
FIR - Miles, Matthew C
IR  - Miller PJ
FIR - Miller, Peter J
IR  - Mitchell S
FIR - Mitchell, Sophia
IR  - Moore WC
FIR - Moore, Wendy C
IR  - Moss K
FIR - Moss, Katherine
IR  - Namen AM
FIR - Namen, Andrew M
IR  - Norton DL
FIR - Norton, Dustin L
IR  - Ogake SB
FIR - Ogake, Stella B
IR  - Ohar JA
FIR - Ohar, Jill A
IR  - Ortega VE
FIR - Ortega, Victor E
IR  - Palakshappa JA
FIR - Palakshappa, Jessica A
IR  - Pascual RM
FIR - Pascual, Rodolfo M
IR  - Pascual S
FIR - Pascual, Sandi
IR  - Pickens A
FIR - Pickens, Aaron
IR  - Schertz AR
FIR - Schertz, Adam R
IR  - Strong M
FIR - Strong, Matt
IR  - Sy AO
FIR - Sy, Alexander O
IR  - Thyagarajan B
FIR - Thyagarajan, Braghadheeswar
IR  - Townsend A
FIR - Townsend, Amy
IR  - Worthen R
FIR - Worthen, Russell
IR  - Wlodarski M
FIR - Wlodarski, Michael
IR  - Yarbrough C
FIR - Yarbrough, Charles
IR  - York C
FIR - York, Caroline
IR  - Casey JD
FIR - Casey, Jonathan D
IR  - Landsperger JS
FIR - Landsperger, Janna S
IR  - Wang L
FIR - Wang, Li
IR  - Rice TW
FIR - Rice, Todd W
IR  - Semler MW
FIR - Semler, Matthew W
IR  - Self WH
FIR - Self, Wesley H
IR  - Lloyd B
FIR - Lloyd, Bradley
IR  - Dargin J
FIR - Dargin, James
IR  - Wozniak J
FIR - Wozniak, Joanne
IR  - Stempek S
FIR - Stempek, Susan
IR  - Adler C
FIR - Adler, Christopher
IR  - Agameya A
FIR - Agameya, Ahmed
IR  - Colancecco M
FIR - Colancecco, Michael
IR  - Fitelson D
FIR - Fitelson, Daniel
IR  - Giaccotto J
FIR - Giaccotto, Joshua
IR  - Han G
FIR - Han, Gena
IR  - Kane L
FIR - Kane, Louise
IR  - Miller E
FIR - Miller, Ezra
IR  - Noland T
FIR - Noland, Timothy
IR  - Price J
FIR - Price, Jaqueline
IR  - Plourde J
FIR - Plourde, Joseph
IR  - Adams E
FIR - Adams, Emily
IR  - Mackay F
FIR - Mackay, Fraser
IR  - Mahoney L
FIR - Mahoney, Laura
IR  - Patel A
FIR - Patel, Avignat
IR  - Plourde M
FIR - Plourde, Michael
IR  - Saadeh Z
FIR - Saadeh, Zena
IR  - Shadchehr S
FIR - Shadchehr, Sara
IR  - Somalaraju S
FIR - Somalaraju, Sandeep
IR  - Summerhill E
FIR - Summerhill, Eleanor
IR  - Webster R
FIR - Webster, Ryan
IR  - Winnicki J
FIR - Winnicki, Jordan
IR  - Yavarovich E
FIR - Yavarovich, Ekaterina
IR  - Russell DW
FIR - Russell, Derek W
IR  - Robison SW
FIR - Robison, Sarah W
IR  - Gandotra S
FIR - Gandotra, Sheetal
IR  - Gulati S
FIR - Gulati, Swati
IR  - Altz-Stamm A
FIR - Altz-Stamm, Anna
IR  - Bardita C
FIR - Bardita, Cristina
IR  - Boone MC
FIR - Boone, Mary Clay
IR  - Chiles JW
FIR - Chiles, Joe W
IR  - Collins K
FIR - Collins, Kristina
IR  - Drescher A
FIR - Drescher, Abby
IR  - Dsouza KG
FIR - Dsouza, Kevin G
IR  - Dunn J
FIR - Dunn, Janna
IR  - Ejem S
FIR - Ejem, Stacy
IR  - Gautney J
FIR - Gautney, Josh
IR  - Harris N
FIR - Harris, Nicole
IR  - Herder S
FIR - Herder, Savannah
IR  - Hudali T
FIR - Hudali, Tamer
IR  - Chad Wade R
FIR - Chad Wade, R
IR  - Joshi R
FIR - Joshi, Rutwij
IR  - Kelmenson D
FIR - Kelmenson, Daniel
IR  - Mason AM
FIR - Mason, Anne Merrill
IR  - Merriman SR
FIR - Merriman, Scott R
IR  - Mkorombindo T
FIR - Mkorombindo, Takudzwa
IR  - Moore M
FIR - Moore, Megan
IR  - Nowak J
FIR - Nowak, Jada
IR  - O'Connor K
FIR - O'Connor, Kate
IR  - Page DB
FIR - Page, David B
IR  - Sheylan D
FIR - Sheylan, D
IR  - Patel G
FIR - Patel, G
IR  - Pereira B
FIR - Pereira, Bruno
IR  - Sarratt L
FIR - Sarratt, Lisa
IR  - Stewart T
FIR - Stewart, Tabitha
IR  - Stigler WS
FIR - Stigler, William S
IR  - Vijaykumar K
FIR - Vijaykumar, Kadambari
IR  - White G
FIR - White, Gina
IR  - Whitson MR
FIR - Whitson, Micah R
IR  - Vonderhaar DJ
FIR - Vonderhaar, Derek J
IR  - Dischert KM
FIR - Dischert, Kevin M
IR  - Joffe AM
FIR - Joffe, Aaron M
IR  - Bentov I
FIR - Bentov, Itay
IR  - Barnes C
FIR - Barnes, Christopher
IR  - Walters AM
FIR - Walters, Andrew M
IR  - Ghamande S
FIR - Ghamande, Shekhar
IR  - White HD
FIR - White, Heath D
IR  - Arroliga AC
FIR - Arroliga, Alejandro C
IR  - Lat T
FIR - Lat, Tasnim
IR  - Khan A
FIR - Khan, Akram
IR  - Krol OF
FIR - Krol, Olivia F
IR  - Nonas S
FIR - Nonas, Stephanie
IR  - Jouzestani MK
FIR - Jouzestani, Milad K
IR  - Adi R
FIR - Adi, Raya
IR  - Anandkat C
FIR - Anandkat, Chandani
IR  - Benchbani H
FIR - Benchbani, Hanae
IR  - Drake MG
FIR - Drake, Matthew G
IR  - Kamel MN
FIR - Kamel, Makrina N
IR  - Randhawa R
FIR - Randhawa, Ramanpreet
IR  - Tsui JL
FIR - Tsui, Jessica L
IR  - Prekker ME
FIR - Prekker, Matthew E
IR  - Driver BE
FIR - Driver, Brian E
IR  - Brewer JM
FIR - Brewer, Joseph M
IR  - Janz DR
FIR - Janz, David R
IR  - Lindsell CJ
FIR - Lindsell, Christopher J
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036671 [pii]
AID - 10.1136/bmjopen-2019-036671 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 18;10(9):e036671. doi: 10.1136/bmjopen-2019-036671.


PMID- 32948546
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 17
TI  - Bedside hyperspectral imaging for the evaluation of microcirculatory alterations 
      in perioperative intensive care medicine: a study protocol for an observational
      clinical pilot study (HySpI-ICU).
PG  - e035742
LID - 10.1136/bmjopen-2019-035742 [doi]
AB  - INTRODUCTION: Normalisation of macrocirculatory parameters during resuscitation
      therapy does not guarantee the restoration of microcirculatory perfusion in
      critical illness due to haemodynamic incoherence. Persistent microcirculatory
      abnormalities are associated with severity of organ dysfunction and mandate the
      development of bedside microcirculatory monitoring. A novel hyperspectral imaging
      (HSI) system can visualise changes in skin perfusion, oxygenation and water
      content at the bedside. We aim to evaluate the effectiveness of HSI for bedside
      monitoring of skin microcirculation and the association of HSI parameters with
      organ dysfunction in patients with sepsis and major abdominal surgery. METHODS
      AND ANALYSIS: Three independent groups will be assessed and separately analysed
      within a clinical prospective observational study: (1) 25 patients with sepsis or
      septic shock (according to sepsis-3 criteria), (2) 25 patients undergoing
      pancreatic surgery and (3) 25 healthy controls. Patients with sepsis and patients
      undergoing pancreatic surgery will receive standard therapy according to local
      protocols derived from international guidelines. In addition, cardiac output of
      perioperative patients and patients with sepsis will be measured. Healthy
      controls undergo one standardised evaluation. The TIVITA Tissue System is a novel
      HSI system that uses the visible and near-infrared spectral light region to
      determine tissue microcirculatory parameters. HSI analysis (hand/knee) will be
      done in parallel to haemodynamic monitoring within defined intervals during a
      72-hour observation period. HSI data will be correlated with the Sequential Organ
      Failure Assessment score, global haemodynamics, inflammation and glycocalyx
      markers, surgical complications and 30-day outcome. ETHICS AND DISSEMINATION: The
      protocol has been approved by the local ethics committee of the University of
      Heidelberg (S-148/2019). Study results will be submitted to peer-reviewed
      journals and medical conferences. TRIAL REGISTRATION NUMBER: DRKS00017313;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dietrich, Maximilian
AU  - Dietrich M
AD  - Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Marx, Sebastian
AU  - Marx S
AD  - Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Bruckner, Thomas
AU  - Bruckner T
AD  - Institute of Medical Biometry and Informatics, University of Heidelberg,
      Heidelberg, Germany.
FAU - Nickel, Felix
AU  - Nickel F
AD  - Department of General, Visceral and Transplantation Surgery, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Muller-Stich, Beat Peter
AU  - Muller-Stich BP
AD  - Department of General, Visceral and Transplantation Surgery, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Hackert, Thilo
AU  - Hackert T
AD  - Department of General, Visceral and Transplantation Surgery, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Weigand, Markus A
AU  - Weigand MA
AD  - Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Uhle, Florian
AU  - Uhle F
AD  - Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg,
      Germany.
FAU - Brenner, Thorsten
AU  - Brenner T
AD  - Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg,
      Germany.
AD  - Department of Anesthesiology and Intensive Care Medicine, University Hospital
      Essen, University Duisburg-Essen, Essen, North Rhine-Westphalia, Germany.
FAU - Schmidt, Karsten
AU  - Schmidt K
AUID- ORCID: 0000-0001-8373-9406
AD  - Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg,
      Germany karsten.schmidt@uk-essen.de.
AD  - Department of Anesthesiology and Intensive Care Medicine, University Hospital
      Essen, University Duisburg-Essen, Essen, North Rhine-Westphalia, Germany.
LA  - eng
SI  - DRKS/DRKS00017313
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Critical Care
MH  - Humans
MH  - *Hyperspectral Imaging
MH  - Intensive Care Units
MH  - Microcirculation
MH  - Observational Studies as Topic
MH  - Pilot Projects
MH  - *Sepsis/therapy
PMC - PMC7500303
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *adult intensive & critical care
OT  - *anaesthetics
OT  - *intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035742 [pii]
AID - 10.1136/bmjopen-2019-035742 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 17;10(9):e035742. doi: 10.1136/bmjopen-2019-035742.


PMID- 32948544
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 17
TI  - Comparative efficacy and safety of intra-articular analgesics after knee
      arthroscopy: a Bayesian network meta-analysis protocol.
PG  - e035346
LID - 10.1136/bmjopen-2019-035346 [doi]
AB  - INTRODUCTION: Most of the patients who received arthroscopic knee surgery will
      suffer moderate to severe pain, which can delay the rehabilitation process and
      increase the risk of postoperative complications. Therefore, seeking a safe and
      effective postoperative analgesia is necessary for promoting the application of
      arthroscopic surgery. This protocol aims to detail a planned systematic review
      and meta-analysis on the comparative efficacy and safety of single-dose
      intra-articular injection of analgesics for pain relief after knee arthroscopy.
      METHOD AND ANALYSIS: PubMed, Embase, Web of Science and Cochrane Library will be 
      searched from inception to 1 June 2020 to retrieve randomised controlled trials
      (RCTs) that compared the commonly used single-dose intra-articular analgesics
      (ie, morphine; bupivacaine (including levobupivacaine); ropivacaine and magnesium
      alone or in combination) with placebo or between each other for postoperative
      pain relief among patients who had received knee arthroscopy. The primary outcome
      is pain intensity at 2-hour and 24-hour postoperatively; the secondary outcomes
      include side effects (eg, knee effusion, nausea, vomiting and flushing), the
      number of patients requiring supplementary analgesia and the time to first
      analgesic request. The methodological quality of the included RCTs will be
      assessed based on the Cochrane risk of bias table. The Bayesian network
      meta-analysis will be conducted using WinBUGS V.1.4.3. ETHICS AND DISSEMINATION: 
      Since no private or confidential patient data will be contained in the reporting,
      approval from an ethics committee is not required. Our study raises no ethical
      issue, and the results will be published in a peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42019130876.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, Yuchen
AU  - He Y
AD  - Orthopaedics, Xiangya Hospital Central South University, Changsha, China.
FAU - He, Hongyi
AU  - He H
AD  - Orthopaedics, Xiangya Hospital Central South University, Changsha, China.
FAU - Xie, Dong-Xing
AU  - Xie DX
AD  - Orthopaedics, Xiangya Hospital Central South University, Changsha, China.
FAU - Li, Xiaoxiao
AU  - Li X
AD  - Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, Hunan, China.
FAU - Wang, Yilun
AU  - Wang Y
AUID- ORCID: 0000-0002-9468-4110
AD  - Orthopaedics, Xiangya Hospital Central South University, Changsha, China
      yilun_Wang@csu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
RN  - 76I7G6D29C (Morphine)
RN  - Y8335394RO (Bupivacaine)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - Analgesics, Opioid
MH  - *Arthroscopy
MH  - Bupivacaine
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Morphine
MH  - Network Meta-Analysis
MH  - *Pain, Postoperative/drug therapy
PMC - PMC7500288
OTO - NOTNLM
OT  - *anaesthesia in orthopaedics
OT  - *knee
OT  - *orthopaedic & trauma surgery
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035346 [pii]
AID - 10.1136/bmjopen-2019-035346 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 17;10(9):e035346. doi: 10.1136/bmjopen-2019-035346.


PMID- 32948543
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 17
TI  - Psychological interventions for chronic non-specific low back pain: protocol of a
      systematic review with network meta-analysis.
PG  - e034996
LID - 10.1136/bmjopen-2019-034996 [doi]
AB  - INTRODUCTION: Psychological factors such as fear avoidance beliefs, depression,
      anxiety, catastrophic thinking and familial and social stress, have been
      associated with high disability levels in people with chronic low back pain
      (LBP). Guidelines endorse the integration of psychological interventions in the
      management of chronic LBP. However, uncertainty surrounds the comparative
      effectiveness of different psychological approaches. Network meta-analysis (NMA) 
      allows comparison and ranking of numerous competing interventions for a given
      outcome of interest. Therefore, we will perform a systematic review with a NMA to
      determine which type of psychological intervention is most effective for adults
      with chronic non-specific LBP. METHODS AND ANALYSIS: We will search electronic
      databases (MEDLINE, Embase, PsycINFO, Cochrane Central Register of Controlled
      Trials, Web of Science, SCOPUS and CINAHL) from inception until 22 August 2019
      for randomised controlled trials comparing psychological interventions to any
      comparison interventions in adults with chronic non-specific LBP. There will be
      no restriction on language. The primary outcomes will include physical function
      and pain intensity, and secondary outcomes will include health-related quality of
      life, fear avoidance, intervention compliance and safety. Risk of bias will be
      assessed using the Revised Cochrane risk-of-bias tool for randomised trials (RoB 
      2) tool and confidence in the evidence will be assessed using the Confidence in
      NMA (CINeMA) framework. We will conduct a random-effects NMA using a frequentist 
      approach to estimate relative effects for all comparisons between treatments and 
      rank treatments according to the mean rank and surface under the cumulative
      ranking curve values. All analyses will be performed in Stata. ETHICS AND
      DISSEMINATION: No ethical approval is required. The research will be published in
      a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42019138074.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ho, Emma
AU  - Ho E
AUID- ORCID: 0000-0002-2479-0081
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia emma.ho@sydney.edu.au.
FAU - Ferreira, Manuela
AU  - Ferreira M
AD  - Institute of Bone and Joint Research, Faculty of Medicine and Health, University 
      of Sydney, Sydney, New South Wales, Australia.
FAU - Chen, Lingxiao
AU  - Chen L
AUID- ORCID: 0000-0001-7721-0493
AD  - Institute of Bone and Joint Research, Faculty of Medicine and Health, University 
      of Sydney, Sydney, New South Wales, Australia.
FAU - Simic, Milena
AU  - Simic M
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Ashton-James, Claire
AU  - Ashton-James C
AD  - Pain Management Research Institute, Faculty of Medicine and Health, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Comachio, Josielli
AU  - Comachio J
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
AD  - Department of Speech, Physical Therapy and Occupational Therapy, School of
      Medicine, University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
FAU - Hayden, Jill
AU  - Hayden J
AD  - Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Ferreira, Paulo
AU  - Ferreira P
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Low Back Pain/therapy
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Psychosocial Intervention
MH  - Quality of Life
MH  - Systematic Reviews as Topic
PMC - PMC7500308
OTO - NOTNLM
OT  - *back pain
OT  - *musculoskeletal disorders
OT  - *psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:28
PHST- 2020/09/19 05:28 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034996 [pii]
AID - 10.1136/bmjopen-2019-034996 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 17;10(9):e034996. doi: 10.1136/bmjopen-2019-034996.


PMID- 32948242
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Sep 18
TI  - Ficus palmata FORSKaL (BELES ADGI) as a source of milk clotting agent: a
      preliminary research.
PG  - 446
LID - 10.1186/s13104-020-05293-x [doi]
AB  - OBJECTIVE: The demand for cheese, the insufficient supply and high cost of
      rennet, and the ethical issues of harvesting rennet oblige us to search for
      suitable alternatives of finding new proteases from plants. Ficus palmata FORSKaL
      (Moraceae) is one of the plants producing a protease called ficin that coagulates
      fresh milk. This study aims to study the milk coagulating abilities of bark,
      leaf, and stem powders of F. palmata FORSKaL. RESULTS: Stem powder has yielded
      better results. Chemical analyses of the powders have revealed that the
      percentage of crude protein of leaf, bark, and stem powders were 4.17, 7.39, and 
      16.26. This is an indication of the suitability of stem biomass as source of the 
      enzyme of interest. Further research needs to aim at qualitative and quantitative
      analyses of milk-coagulating enzymes of F. palmata FORSKaL stem biomass to get
      new insights into industrial extraction of the enzymes of interest.
FAU - Sbhatu, Desta Berhe
AU  - Sbhatu DB
AUID- ORCID: http://orcid.org/0000-0003-3602-1578
AD  - Department of Biological and Chemical Engineering, Mekelle Institute of
      Technology, Mekelle University, PO Box 1632, Mekelle, Ethiopia.
      desta.sbhatu@mu.edu.et.
FAU - Tekle, Hailekiros Tadesse
AU  - Tekle HT
AD  - Department of Biological and Chemical Engineering, Mekelle Institute of
      Technology, Mekelle University, PO Box 1632, Mekelle, Ethiopia.
FAU - Tesfamariam, Kiros Haddish
AU  - Tesfamariam KH
AD  - Department of Forensic Medicine, School of Medicine, College of Health Sciences, 
      Mekelle University, PO Box 231, Mekelle, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - EC 3.4.- (Endopeptidases)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Animals
MH  - *Cheese
MH  - Endopeptidases
MH  - *Ficus
MH  - Milk
MH  - Peptide Hydrolases
PMC - PMC7501637
OTO - NOTNLM
OT  - Coagulation
OT  - Ficin
OT  - Ficus palmata FORSKaL
OT  - Milk
OT  - Powder
EDAT- 2020/09/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/19 05:23
PHST- 2020/08/27 00:00 [received]
PHST- 2020/09/12 00:00 [accepted]
PHST- 2020/09/19 05:23 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s13104-020-05293-x [doi]
AID - 10.1186/s13104-020-05293-x [pii]
PST - epublish
SO  - BMC Res Notes. 2020 Sep 18;13(1):446. doi: 10.1186/s13104-020-05293-x.


PMID- 32948166
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 18
TI  - A practical approach to the ethical use of memory modulating technologies.
PG  - 89
LID - 10.1186/s12910-020-00532-z [doi]
AB  - BACKGROUND: Recent advancements in neuroscientific techniques have allowed us to 
      make huge progress in our understanding of memories, and in turn has paved the
      way for new memory modification technologies (MMTs) that can modulate memories
      with a degree of precision, which was not previously possible. With advancements 
      in such techniques, new and critical ethical questions have emerged.
      Understanding and framing these ethical questions within the current
      philosophical theories is crucial in order to systematically examine them as we
      translate these techniques to the clinic. MAIN BODY: In this paper, we discuss
      the ethical implications of modern neuroscience techniques that aim to disrupt or
      enhance memories. We attempt to frame the MMTs in the context of existing ethical
      philosophical theories to provide a cohesive analysis of the myriad of ethical
      quagmires that might emerge from such technologies. We argue the application of
      Aristotle's Golden Mean and multiple accounts of authenticity are useful in
      approaching the ethical questions surrounding MMTs. We then propose a framework
      in which ethical considerations can be systematically examined. Lastly, we
      provide caveats and considerations for the use of this framework. Overall, we
      provide a practical approach for the ethical use of MMTs depending on the
      situation. CONCLUSION: While at face value, our model appears to put severe
      limitations on the application of MMTs, we are not completely opposed to their
      use, but rather our framework guides the agent to consider the implications
      before making any decisions. Most importantly, we argue that the use of MMTs does
      not reduce the responsibility of the initial decision, and the agent must accept 
      the post-MMT self as the new "true self" regardless of the outcome. As the
      developmental trajectory of MMTs suggests we are getting closer to practical
      clinical applications, ethical concerns across a wide range of disciplines need
      to be addressed to develop best strategies and policies when dealing with MMTs.
      If this can be achieved, we believe the ethical use of MMTs is not only possible 
      but would also be of tremendous benefit to many people suffering from
      memory-related mental disorders.
FAU - Tan, Shawn Zheng Kai
AU  - Tan SZK
AUID- ORCID: 0000-0001-7258-9596
AD  - School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of
      Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, PR China. shawntanzk@hku.hk.
FAU - Lim, Lee Wei
AU  - Lim LW
AD  - School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of
      Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, PR China. drlimleewei@gmail.com.
LA  - eng
GR  - RGC-ECS 27104616/Hong Kong Research Grant Council/International
GR  - 102009728/The University of Hong Kong URC Supplementary Funding/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200918
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Ethical Theory
MH  - Humans
MH  - *Mental Disorders
MH  - Morals
MH  - *Neurosciences
PMC - PMC7501599
OTO - NOTNLM
OT  - *Authenticity
OT  - *Golden mean
OT  - *Memory
OT  - *Neuroscience
OT  - *Technology
EDAT- 2020/09/20 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/19 05:23
PHST- 2019/10/26 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/19 05:23 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00532-z [doi]
AID - 10.1186/s12910-020-00532-z [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 18;21(1):89. doi: 10.1186/s12910-020-00532-z.


PMID- 32947819
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 16
TI  - Prevalence and Distribution of Lesions in the Nasal Bones and Mandibles of a
      Sample of 144 Riding Horses.
LID - E1661 [pii]
LID - 10.3390/ani10091661 [doi]
AB  - Restrictive nosebands are used in equestrian sports to hold the bit in place and 
      reduce mouth-opening, a response that can attract penalties in some sports and is
      thought to reduce the rider's control of the horse. Sustained pressure from such 
      tightly fitted (restrictive) nosebands denies normal behaviour and thus, causes
      frustration and distress that can jeopardise horse welfare. It also may push the 
      cheek against the molar teeth, compress soft tissues including blood vessels and 
      nerves, and possibly induce chronic changes to underlying bone. This study of
      mature cavalry horses (n = 144) was designed to explore relationships between
      visual and palpable damage to structures that underlie the nosebands of horses
      and any related bony changes in those horses as evidenced by radiography. Working
      independently of each other, two researchers inspected the horses for visual
      changes and palpable changes before the horses were radiographed. The radiographs
      were assessed by a separate pair of veterinary radiologists, again working
      independently of each other. Among the current population of horses, 37.5% had
      one or more radiographic changes to the nasal bones according to both
      radiologists, and 13.8% had one or more radiographic changes to the mandible. For
      nasal bones, the two radiologists reported bone deposition in 6.9% and 8.3% of
      the horses and bone thinning in 33.3% and 56.9% of the horses, respectively. By
      palpation, they found that 82% and 84% of the horses had palpable bone deposition
      of the nasal bones and 32% and 33.4% had palpable bone thinning. For the
      mandibles, the radiologists reported increased bone deposition in 18.8% and 32.6%
      of the horses but no bone thinning. By palpation, the two examiners reported
      30.6% and 32.7% of the horses had palpable bone deposition and 10.4% and 11.1%
      had palpable bone thinning. This is the first report of lesions to the mandible
      at this site and this article presents the first confirmation of bony lesions at 
      the site typically subjected to pressure from restrictive nosebands. These
      results suggest that radiographic bone thinning is more apparent in the nasal
      bones of riding horses than in the mandible and that both palpable and
      radiographic bone deposition are more likely in the mandible than in the nasal
      bones. That said, we note that the current study provides no evidence of a causal
      link between any piece of gear or its putative tightness and the lesions in these
      anatomical locations. Further studies are needed to identify risk factors for
      these clusters of lesions. The inadvertent deformation of bones in the horse's
      head for competitive advantage is difficult to justify on ethical grounds.
FAU - Perez-Manrique, Lucia
AU  - Perez-Manrique L
AD  - Departamento de Etologia, Fauna Silvestre y Animales de Laboratorio, Facultad de 
      Medicina Veterinaria y Zootecnia, Universidad Nacional Autonoma de Mexico, Av.
      Universidad 3000, Circuito Interior, Delegacion Coyoacan, Mexico D.F. 04510,
      Mexico.
FAU - Leon-Perez, Karina
AU  - Leon-Perez K
AD  - Departamento de Etologia, Fauna Silvestre y Animales de Laboratorio, Facultad de 
      Medicina Veterinaria y Zootecnia, Universidad Nacional Autonoma de Mexico, Av.
      Universidad 3000, Circuito Interior, Delegacion Coyoacan, Mexico D.F. 04510,
      Mexico.
FAU - Zamora-Sanchez, Emmanuel
AU  - Zamora-Sanchez E
AD  - Facultad de Medicina Veterinaria y Zootecnia, Universidad Autonoma del Estado de 
      Mexico, El Cerrillo Piedras Blancas, Toluca 50295, Estado de Mexico, Mexico.
FAU - Davies, Sarah
AU  - Davies S
AD  - Veterinary Imaging Associates, 52-56 Atchison St, St Leonards, NSW 2065,
      Australia.
FAU - Ober, Christopher
AU  - Ober C
AUID- ORCID: 0000-0003-1491-6792
AD  - Department of Veterinary Clinical Sciences, College of Veterinary Medicine,
      University of Minnesota, 1365 Gortner Avenue, St. Paul, MN 55108, USA.
FAU - Wilson, Bethany
AU  - Wilson B
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney,
      Sydney, NSW 2006, Australia.
FAU - McGreevy, Paul
AU  - McGreevy P
AUID- ORCID: 0000-0001-7220-8378
AD  - Sydney School of Veterinary Science, Faculty of Science, University of Sydney,
      Sydney, NSW 2006, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552251
OTO - NOTNLM
OT  - equitation science
OT  - lesion
OT  - nosebands
OT  - radiology
OT  - welfare
EDAT- 2020/09/20 06:00
MHDA- 2020/09/20 06:01
CRDT- 2020/09/19 01:02
PHST- 2020/08/10 00:00 [received]
PHST- 2020/09/11 00:00 [revised]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/09/19 01:02 [entrez]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2020/09/20 06:01 [medline]
AID - ani10091661 [pii]
AID - 10.3390/ani10091661 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Sep 16;10(9). pii: ani10091661. doi: 10.3390/ani10091661.


PMID- 32947138
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210110
IS  - 1873-4758 (Electronic)
IS  - 0955-3959 (Linking)
VI  - 85
DP  - 2020 Nov
TI  - Extended lockdown and India's alcohol policy: a qualitative analysis of newspaper
      articles.
PG  - 102940
LID - S0955-3959(20)30279-6 [pii]
LID - 10.1016/j.drugpo.2020.102940 [doi]
AB  - OBJECTIVES: Since 25th March 2020 India went into a complete and extended
      lockdown. Alcohol production, sales, and purchase were barred with this overnight
      prohibition order. We conducted a qualitative analysis of the media reports
      published within the first month of the nationwide lockdown with the objectives
      (a) using the media reports as indications of possible public health impact and
      population response of a sudden alcohol prohibition in India, (b) suggesting
      areas for future research. METHODS: We performed thematic and content analysis of
      350 articles published online in national newspapers between the 26th March, 2020
      and 25th April, 2020. Initial inductive, followed by deductive coding was done in
      this exploratory thematic analysis. RESULTS: The thematic analysis revealed four 
      main themes: the beneficial aspects of the policy, the harmful aspects of the
      policy, non-compliance and attempts to change and / or subvert the policy,
      popularity and level of public buy-in of the policy. We generated relevant
      sub-themes under main themes. Two additional themes, not directly related to the 
      sudden prohibition, were use of stigmatizing language and ethical concerns. The
      content analysis showed the frequency of the appearance of the main themes and
      proportions of sub-themes and codes under those main themes. CONCLUSION: The
      harms, perceived from the media reports, should be balanced against the potential
      benefits. Absence of a national-level alcohol policy was made apparent by the
      reflexive, disconnected, and conflictual measures. Future research could
      systematically examine the potential ramifications of alcohol prohibition on
      public health, social, and economic aspects.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Ghosh, Abhishek
AU  - Ghosh A
AD  - Drug Deaddiction and Treatment Centre & Department of Psychiatry, Postgraduate
      Institute of Medical Education & Research, Chandigarh, 160012 India. Electronic
      address: ghoshabhishek12@gmail.com.
FAU - Choudhury, Shinjini
AU  - Choudhury S
AD  - All India Institute of Medical Sciences, Rishikesh, India.
FAU - Basu, Aniruddha
AU  - Basu A
AD  - All India Institute of Medical Sciences, Rishikesh, India.
FAU - Mahintamani, Tathagata
AU  - Mahintamani T
AD  - Drug Deaddiction and Treatment Centre & Department of Psychiatry, Postgraduate
      Institute of Medical Education & Research, Chandigarh, 160012 India.
FAU - Sharma, Kshitiz
AU  - Sharma K
AD  - Drug Deaddiction and Treatment Centre & Department of Psychiatry, Postgraduate
      Institute of Medical Education & Research, Chandigarh, 160012 India.
FAU - Pillai, Renjith R
AU  - Pillai RR
AD  - Drug Deaddiction and Treatment Centre & Department of Psychiatry, Postgraduate
      Institute of Medical Education & Research, Chandigarh, 160012 India.
FAU - Basu, Debasish
AU  - Basu D
AD  - Drug Deaddiction and Treatment Centre & Department of Psychiatry, Postgraduate
      Institute of Medical Education & Research, Chandigarh, 160012 India.
FAU - Mattoo, S K
AU  - Mattoo SK
AD  - Drug Deaddiction and Treatment Centre & Department of Psychiatry, Postgraduate
      Institute of Medical Education & Research, Chandigarh, 160012 India.
LA  - eng
PT  - Journal Article
DEP - 20200915
PL  - Netherlands
TA  - Int J Drug Policy
JT  - The International journal on drug policy
JID - 9014759
SB  - IM
MH  - Alcohol Drinking/*legislation & jurisprudence
MH  - Alcoholic Beverages
MH  - Alcoholism/epidemiology/therapy
MH  - *COVID-19
MH  - Humans
MH  - India
MH  - Internet
MH  - Legislation, Medical
MH  - *Newspapers as Topic
MH  - *Pandemics
MH  - Patient Acceptance of Health Care
MH  - Public Health
MH  - *Public Policy
MH  - Quarantine/*psychology
MH  - Self-Help Groups
PMC - PMC7490258
OTO - NOTNLM
OT  - *Alcohol
OT  - *India
OT  - *Policy
OT  - *Prohibition
OT  - *Qualitative analysis
OT  - *SARS-CoV-2
EDAT- 2020/09/19 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/09/18 20:16
PHST- 2020/06/30 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/09/18 20:16 [entrez]
AID - S0955-3959(20)30279-6 [pii]
AID - 10.1016/j.drugpo.2020.102940 [doi]
PST - ppublish
SO  - Int J Drug Policy. 2020 Nov;85:102940. doi: 10.1016/j.drugpo.2020.102940. Epub
      2020 Sep 15.


PMID- 32947061
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 83
DP  - 2020 Nov
TI  - Effects of endothelin receptor blockade and COX inhibition on intestinal I/R
      injury in a rat model: Experimental research.
PG  - 89-97
LID - S1743-9191(20)30683-X [pii]
LID - 10.1016/j.ijsu.2020.08.061 [doi]
AB  - BACKGROUND: Intestinal ischemia is a highly morbid and mortal condition with no
      specific treatment. The present study aimed to investigate the effects of
      cyclooxygenase (COX) inhibition synchronized with nitric oxide (NO) release and
      endothelin (ET) receptor blockade on oxidative stress, inflammation,
      vasoconstriction, and bacterial translocation which occur during
      ischemia-reperfusion (I/R) injury in in-vivo rat intestinal I/R model. MATERIALS 
      AND METHODS: 36 male Wistar rats were randomly divided into six groups (n = 6).
      Superior mesenteric artery blood flow (SMABF) was recorded; SMA was occluded for 
      30 min; SMABF was re-recorded at the beginning of the reperfusion phase. Rats
      were sacrificed after the reperfusion period of 60 min. Blood and tissue samples 
      were obtained. Acetylsalicylic acid (ASA), NO-ASA, flurbiprofen (FLUR), and
      Tezosentan (TS) were administered 15 min after ischemia. Histopathological
      examination, bacterial translocation, and biochemical analysis were performed in 
      plasma and tissue samples. RESULTS: SMABF difference, mean Chiu's score and
      bacterial translocation were increased in the I/R group and decreased in the
      treatment groups. Plasma LDH, transaminases, intestinal fatty acid-binding
      protein (I-FABP), TNF-alpha, ICAM-1, interferon-gamma (IFN-) and proinflammatory 
      cytokine panel; tissue lipid peroxidation, MPO, xanthine oxidase (XO), NO, NF-kB 
      levels and the expression of TNF-alpha were significantly elevated in the I/R
      group and markedly decreased in the treatment groups. The tissue antioxidant
      status was decreased in the I/R group and increased in the treatment groups.
      CONCLUSION: It is suggested that NO-ASA, TS, and FLUR can be introduced as
      promising therapeutics to improve intestinal I/R injury. INSTITUTIONAL PROTOCOL
      NO: 2018-29-05 (Animal Experimentations Ethics Committee, Hacettepe University).
CI  - Copyright (c) 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All
      rights reserved.
FAU - Ucar, Bercis Imge
AU  - Ucar BI
AD  - Department of General Surgery, Faculty of Medicine, Kutahya Health Sciences
      University, Kutahya, Turkey. Electronic address: bercis.imge@gmail.com.
FAU - Erikci, Acelya
AU  - Erikci A
AD  - Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Ankara,
      Turkey.
FAU - Kosemehmetoglu, Kemal
AU  - Kosemehmetoglu K
AD  - Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara,
      Turkey.
FAU - Ozkul, Ceren
AU  - Ozkul C
AD  - Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Hacettepe
      University, Ankara, Turkey.
FAU - Iskit, Alper Bektas
AU  - Iskit AB
AD  - Department of Medical Pharmacology, Faculty of Medicine, Hacettepe University,
      Ankara, Turkey.
FAU - Ucar, Gulberk
AU  - Ucar G
AD  - Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Ankara,
      Turkey.
FAU - Zeren, Sezgin
AU  - Zeren S
AD  - Department of General Surgery, Faculty of Medicine, Kutahya Health Sciences
      University, Kutahya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - England
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Cyclooxygenase Inhibitors/*therapeutic use
MH  - Disease Models, Animal
MH  - Endothelin Receptor Antagonists/*therapeutic use
MH  - Intestines/blood supply
MH  - Male
MH  - Mesenteric Artery, Superior/physiopathology
MH  - Mesenteric Ischemia/*drug therapy
MH  - Rats
MH  - Rats, Wistar
MH  - Reperfusion Injury/metabolism/*prevention & control
MH  - Tumor Necrosis Factor-alpha/blood
OTO - NOTNLM
OT  - Cyclooxygenase inhibition
OT  - Endothelin receptor blockers
OT  - Intestinal ischemia reperfusion injury
OT  - Nitric oxide
OT  - Rat
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/09/19 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/09/18 20:13
PHST- 2020/06/22 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/08/30 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
PHST- 2020/09/18 20:13 [entrez]
AID - S1743-9191(20)30683-X [pii]
AID - 10.1016/j.ijsu.2020.08.061 [doi]
PST - ppublish
SO  - Int J Surg. 2020 Nov;83:89-97. doi: 10.1016/j.ijsu.2020.08.061. Epub 2020 Sep 16.


PMID- 32947060
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 83
DP  - 2020 Nov
TI  - Changing the innate consensus about mesh fixation in trans-abdominal
      preperitoneal laparoscopic inguinal hernioplasty in adults: Short and long term
      outcome. Randomized controlled clinical trial.
PG  - 117-124
LID - S1743-9191(20)30685-3 [pii]
LID - 10.1016/j.ijsu.2020.09.013 [doi]
AB  - INTRODUCTION: Inguinal hernioplasty is the standard treatment for inguinal hernia
      in adults. Mesh fixation was used to keep mesh in place for which various mesh
      fixation techniques have been used in laparoscopic inguinal hernia repair in
      adults, but their effectiveness has remained inconclusive. AIM OF THE WORK: to
      evaluate non fixation method of mesh laparoscopic inguinal hernioplasty as safe
      and effective as regard short and long term outcomes. PATIENTS AND METHODS: Over 
      the period from July 2013 to July 2018, 798 patients with oblique inguinal
      hernias undergoing Trans abdominal preperitoneal technique (TAPP) were randomized
      into 3 groups: Group A; mesh non fixation 266 patients. Group B; tacker mesh
      fixation 266 patients Group C: Cyanoacrylic tissue glues (Histoacryl) mesh
      fixation 266 patients. Clinical effects were assessed by the following variables:
      intraoperative data, postoperative outcome as regard recurrence rate,
      postoperative pain [on visual analogue score (VAS)], analgesic consumption,
      operation time, hospital stay, and patient costs. Follow up was 18 months.
      RESULTS: There was no statistical difference between groups (A) and Group (C)
      regarding operative time, postoperative complications, and length of hospital
      stay and risk of chronic groin pain, postoperative pain score. In Group (B): the 
      postoperative pain and complications were higher. There were 5 cases of hernia
      recurrence in all groups, but no significant differences among the three groups. 
      CONCLUSION: Tacker Mesh fixation increased the risk of chronic groin pain. Pain
      score was higher with tacker mesh fixation. Laparoscopic TAPP inguinal hernia
      repair without tacker mesh fixation was safe and feasible with no significant
      increase in recurrence rates. Furthermore, mesh fixation with tacker procedure
      increased the risk of postoperative complications and patient costs. All ethical 
      approval was given by our Faculty of Medicine medical ethical committee.
CI  - Copyright (c) 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All
      rights reserved.
FAU - Habeeb, Tamer A A M
AU  - Habeeb TAAM
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
      Electronic address: tameralnaimy@hotmail.com.
FAU - Mokhtar, Mohammed Mahmoud
AU  - Mokhtar MM
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Sieda, Bassem
AU  - Sieda B
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Osman, Gamal
AU  - Osman G
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Ibrahim, Amr
AU  - Ibrahim A
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Metwalli, Abd-Elrahman M
AU  - Metwalli AM
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Riad, Mohamed
AU  - Riad M
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Khalil, Osama M H
AU  - Khalil OMH
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Mansour, Mohamed Ibrahim
AU  - Mansour MI
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Elshahidy, Tamer Mohamed
AU  - Elshahidy TM
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Abdelhamid, Mohamed I
AU  - Abdelhamid MI
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
FAU - Mohamed, Moustafa B
AU  - Mohamed MB
AD  - Department of General Surgery, Faculty of Medicine, Zagazig University, Egypt.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200915
PL  - England
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
SB  - IM
MH  - Adult
MH  - Chronic Pain/epidemiology
MH  - Consensus
MH  - Female
MH  - Hernia, Inguinal/*surgery
MH  - Herniorrhaphy/adverse effects/*methods
MH  - Humans
MH  - Laparoscopy/*methods
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Pain, Postoperative/epidemiology
MH  - Postoperative Complications/epidemiology
MH  - Recurrence
MH  - *Surgical Mesh/adverse effects
MH  - Young Adult
OTO - NOTNLM
OT  - Fixation
OT  - Hernia
OT  - Mesh
OT  - Migration
OT  - Recurrence
COIS- Declaration of competing interest None.
EDAT- 2020/09/19 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/09/18 20:13
PHST- 2020/06/30 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/09/18 20:13 [entrez]
AID - S1743-9191(20)30685-3 [pii]
AID - 10.1016/j.ijsu.2020.09.013 [doi]
PST - ppublish
SO  - Int J Surg. 2020 Nov;83:117-124. doi: 10.1016/j.ijsu.2020.09.013. Epub 2020 Sep
      15.


PMID- 32946505
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20210528
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - BioPETsurv: Methodology and open source software to evaluate biomarkers for
      prognostic enrichment of time-to-event clinical trials.
PG  - e0239486
LID - 10.1371/journal.pone.0239486 [doi]
AB  - Biomarkers can be used to enrich a clinical trial for patients at higher risk for
      an outcome, a strategy termed "prognostic enrichment." Methodology is needed to
      evaluate biomarkers for prognostic enrichment of trials with time-to-event
      endpoints such as survival. Key considerations when considering prognostic
      enrichment include: clinical trial sample size; the number of patients one must
      screen to enroll the trial; and total patient screening costs and total
      per-patient trial costs. The Biomarker Prognostic Enrichment Tool for Survival
      Outcomes (BioPETsurv) is a suite of methods for estimating these elements to
      evaluate a prognostic enrichment biomarker and/or plan a prognostically enriched 
      clinical trial with a time-to-event primary endpoint. BioPETsurv allows
      investigators to analyze data on a candidate biomarker and potentially censored
      survival times. Alternatively, BioPETsurv can simulate data to match a particular
      clinical setting. BioPETsurv's data simulator enables investigators to explore
      the potential utility of a prognostic enrichment biomarker for their clinical
      setting. Results demonstrate that both modestly prognostic and strongly
      prognostic biomarkers can improve trial metrics such as reducing sample size or
      trial costs. In addition to the quantitative analysis provided by BioPETsurv,
      investigators should consider the generalizability of trial results and evaluate 
      the ethics of trial eligibility criteria. BioPETsurv is freely available as a
      package for the R statistical computing platform, and as a webtool at
      www.prognosticenrichment.com/surv.
FAU - Cheng, Si
AU  - Cheng S
AD  - Department of Biostatistics, University of Washington, Seattle, Washington,
      United States of America.
FAU - Kerr, Kathleen F
AU  - Kerr KF
AUID- ORCID: 0000-0002-6438-9583
AD  - Department of Biostatistics, University of Washington, Seattle, Washington,
      United States of America.
FAU - Thiessen-Philbrook, Heather
AU  - Thiessen-Philbrook H
AUID- ORCID: 0000-0003-2067-0514
AD  - Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, United States of America.
FAU - Coca, Steven G
AU  - Coca SG
AD  - Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount
      Sinai, New York, New York, United States of America.
FAU - Parikh, Chirag R
AU  - Parikh CR
AD  - Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, United States of America.
LA  - eng
GR  - R01 DK115562/DK/NIDDK NIH HHS/United States
GR  - P30 DK079310/DK/NIDDK NIH HHS/United States
GR  - U01 DK082185/DK/NIDDK NIH HHS/United States
GR  - R01 HL085757/HL/NHLBI NIH HHS/United States
GR  - K24 DK090203/DK/NIDDK NIH HHS/United States
GR  - U01 OH011326/OH/NIOSH CDC HHS/United States
GR  - U01 DK106962/DK/NIDDK NIH HHS/United States
GR  - R01 DK112258/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200918
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
SB  - IM
MH  - Area Under Curve
MH  - Biomarkers/*analysis
MH  - Clinical Trials as Topic/*methods/statistics & numerical data
MH  - Computer Simulation
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Patient Selection
MH  - Prognosis
MH  - Sample Size
MH  - *Software
PMC - PMC7500596
COIS- Competing Interests Statement SGC and CRP are members of the advisory board of
      RenalytixAI and own equity in the same. In the past 3 years, SGC has received
      consulting fees from Goldfinch Bio, CHF Solutions, Quark Biopharma, Janssen
      Pharmaceuticals, Takeda Pharmaceuticals, and Relypsa. All remaining authors have 
      nothing to disclose. This does not alter our adherence to PLOS ONE policies on
      sharing data and materials.
EDAT- 2020/09/19 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/09/18 17:12
PHST- 2020/04/28 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/18 17:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.1371/journal.pone.0239486 [doi]
AID - PONE-D-20-12411 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 18;15(9):e0239486. doi: 10.1371/journal.pone.0239486.
      eCollection 2020.


PMID- 32946413
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 10
DP  - 2020 Oct 27
TI  - Artificial Intelligence for COVID-19: Rapid Review.
PG  - e21476
LID - 10.2196/21476 [doi]
AB  - BACKGROUND: COVID-19 was first discovered in December 2019 and has since evolved 
      into a pandemic. OBJECTIVE: To address this global health crisis, artificial
      intelligence (AI) has been deployed at various levels of the health care system. 
      However, AI has both potential benefits and limitations. We therefore conducted a
      review of AI applications for COVID-19. METHODS: We performed an extensive search
      of the PubMed and EMBASE databases for COVID-19-related English-language studies 
      published between December 1, 2019, and March 31, 2020. We supplemented the
      database search with reference list checks. A thematic analysis and narrative
      review of AI applications for COVID-19 was conducted. RESULTS: In total, 11
      papers were included for review. AI was applied to COVID-19 in four areas:
      diagnosis, public health, clinical decision making, and therapeutics. We
      identified several limitations including insufficient data, omission of
      multimodal methods of AI-based assessment, delay in realization of benefits, poor
      internal/external validation, inability to be used by laypersons, inability to be
      used in resource-poor settings, presence of ethical pitfalls, and presence of
      legal barriers. AI could potentially be explored in four other areas:
      surveillance, combination with big data, operation of other core clinical
      services, and management of patients with COVID-19. CONCLUSIONS: In view of the
      continuing increase in the number of cases, and given that multiple waves of
      infections may occur, there is a need for effective methods to help control the
      COVID-19 pandemic. Despite its shortcomings, AI holds the potential to greatly
      augment existing human efforts, which may otherwise be overwhelmed by high
      patient numbers.
CI  - (c)Jiayang Chen, Kay Choong See. Originally published in the Journal of Medical
      Internet Research (http://www.jmir.org), 27.10.2020.
FAU - Chen, Jiayang
AU  - Chen J
AUID- ORCID: 0000-0003-1900-0935
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
FAU - See, Kay Choong
AU  - See KC
AUID- ORCID: 0000-0003-2528-7282
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Respiratory & Critical Care Medicine, Department of Medicine,
      National University Hospital, Singapore, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201027
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Artificial Intelligence
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Clinical Decision-Making
MH  - Coronavirus Infections/*diagnosis/epidemiology/*therapy
MH  - Delivery of Health Care
MH  - Global Health
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/epidemiology/*therapy
MH  - *Public Health
MH  - SARS-CoV-2
PMC - PMC7595751
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS virus
OT  - *artificial intelligence
OT  - *computing
OT  - *coronavirus
OT  - *deep learning
OT  - *machine learning
OT  - *medical informatics
OT  - *review
EDAT- 2020/09/19 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/09/18 17:11
PHST- 2020/06/16 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/09/18 17:11 [entrez]
AID - v22i10e21476 [pii]
AID - 10.2196/21476 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Oct 27;22(10):e21476. doi: 10.2196/21476.


PMID- 32946091
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1306-696X (Print)
VI  - 26
IP  - 5
DP  - 2020 Sep
TI  - Does being a refugee affect prognosis in patients who underwent surgery due to
      peptic ulcer perforation?
PG  - 713-718
LID - 10.14744/tjtes.2020.44902 [doi]
AB  - BACKGROUND: Although Turkey hosts the largest number of Syrian immigrants, the
      interpretation of their health problems seems to be inadequate and understudied. 
      In this study, we aimed to investigate whether being a refugee is a prognostic
      factor or not for peptic ulcer perforation (PUP). METHODS: A retrospective study 
      was designed in Turkish Citizen patients and the refugees to compare the
      prognosis who underwent surgery for PUP. After ethical committee approval, the
      data of 143 patients, constituting 130 males and 13 females, operated for PUP,
      were collected. Patients' files, surgery notes and outpatient policlinic data
      were evaluated. RESULTS: In this study, 105 patients were Turkish Citizen, while 
      the remaining 38 patients were refugees. Eight (7.6%) Turkish and one (2.6%)
      refugee patient died. There was no statistical significance between the two
      groups concerning mortality (p=0.445). Age, perforation diameter and
      localization, need of reoperation, nasogastric tube detention time, CRP,
      hematocrit, albumin, creatinine, BUN levels were found statistically significant 
      for mortality. CONCLUSION: Although being a refugee has been identified as a risk
      in the etiopathogenesis of peptic ulcer disease, we found that being a refugee in
      Turkey is not a negative prognostic factor for PUP.
FAU - Citlak, Gamze
AU  - Citlak G
AD  - University of Health Sciences, Haseki Training and Research Hospital, Department 
      of General Surgery, Istanbul-Turkey.
FAU - Yurtteri, Mustafa Ertugrul
AU  - Yurtteri ME
AD  - University of Health Sciences, Haseki Training and Research Hospital, Department 
      of General Surgery, Istanbul-Turkey.
FAU - Soytas, Yigit
AU  - Soytas Y
AD  - University of Health Sciences, Haseki Training and Research Hospital, Department 
      of General Surgery, Istanbul-Turkey.
FAU - Yuksel, Sercan
AU  - Yuksel S
AD  - University of Health Sciences, Haseki Training and Research Hospital, Department 
      of General Surgery, Istanbul-Turkey.
FAU - Dincer, Mursit
AU  - Dincer M
AD  - Department of General Surgery, Firat University Faculty of Medicine,
      Elazig-Turkey.
FAU - Ferlengez, Ekrem
AU  - Ferlengez E
AD  - University of Health Sciences, Haseki Training and Research Hospital, Department 
      of General Surgery, Istanbul-Turkey.
LA  - eng
PT  - Journal Article
TT  - Peptik ulser perforasyonunun cerrahi tedavisinde multeci olmak prognozu etkiler
      mi? Geriye donuk klinik calisma.
PL  - Turkey
TA  - Ulus Travma Acil Cerrahi Derg
JT  - Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency
      surgery : TJTES
JID - 101274231
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Peptic Ulcer Perforation/diagnosis/epidemiology/surgery
MH  - Prognosis
MH  - Refugees/*statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Turkey
MH  - Young Adult
EDAT- 2020/09/19 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/09/18 12:14
PHST- 2020/09/18 12:14 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.14744/tjtes.2020.44902 [doi]
PST - ppublish
SO  - Ulus Travma Acil Cerrahi Derg. 2020 Sep;26(5):713-718. doi:
      10.14744/tjtes.2020.44902.


PMID- 32946018
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1573-6571 (Electronic)
IS  - 0022-4197 (Linking)
VI  - 59
IP  - 6
DP  - 2020 Dec
TI  - Justifications for Medical Quarantine in Jewish Ethics.
PG  - 2678-2691
LID - 10.1007/s10943-020-01083-8 [doi]
AB  - The current Corona epidemic broke out at the end of 2019 and by early in the year
      2020 was spreading all around the world from China to the USA. Among the moves in
      the fight against the proliferation of the illness, international borders were
      closed to prevent travel among countries. In the next stage in the fight, many
      countries imposed quarantines on carriers of the disease as well as on those
      around them and even on entire civilian populations. Herein, I offer the
      religious justifications in Judaism for preserving the public's health in general
      and particularly in the face of disease, especially during of the course of an
      epidemic. Similarly, I also deal with the religious requirements for preventing
      the spread of an illness, which come at the expense of fulfilling religious
      commandments (mitzvot) and suspending them with a view toward preserving life. My
      conclusion is that ever since the time of the Bible, Judaism has viewed the
      maintenance of health as having social, religious, and medical importance. Rabbis
      over the last centuries have justified separating and isolating the sick and
      extending that isolation to individuals who are in danger of succumbing to the
      illness. They have found religious justifications for issuing instructions to
      suspend religious observances in order to prevent the spread of a disease, as is 
      the case in the epidemic that the world is now experiencing with the Corona
      virus.
FAU - Rashi, Tsuriel
AU  - Rashi T
AUID- ORCID: http://orcid.org/0000-0003-4488-3303
AD  - Ariel University, Ariel, Israel. Tsuriel.rashi@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - United States
TA  - J Relig Health
JT  - Journal of religion and health
JID - 2985199R
SB  - IM
MH  - Bible
MH  - Clergy
MH  - *Ethics, Medical
MH  - Humans
MH  - *Judaism
MH  - *Quarantine
MH  - Social Isolation/*psychology
PMC - PMC7499925
OTO - NOTNLM
OT  - Ethics
OT  - Isolation
OT  - Judaism
OT  - Quarantine
EDAT- 2020/09/19 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/09/18 12:14
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/09/18 12:14 [entrez]
AID - 10.1007/s10943-020-01083-8 [doi]
AID - 10.1007/s10943-020-01083-8 [pii]
PST - ppublish
SO  - J Relig Health. 2020 Dec;59(6):2678-2691. doi: 10.1007/s10943-020-01083-8. Epub
      2020 Sep 18.


PMID- 32945776
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210920
IS  - 2561-326X (Electronic)
IS  - 2561-326X (Linking)
VI  - 4
IP  - 9
DP  - 2020 Sep 18
TI  - Telerehabilitation to Address the Rehabilitation Gap in Anterior Cruciate
      Ligament Care: Survey of Patients.
PG  - e19296
LID - 10.2196/19296 [doi]
AB  - BACKGROUND: Evidence shows that after anterior cruciate ligament (ACL)
      reconstruction, patients may have varied access to physical therapy. In
      particular, physical therapy input may end many months before patients reach full
      recovery. Telerehabilitation may provide an opportunity to address this
      rehabilitation gap and improve access to evidence-based rehabilitation alongside 
      physical therapy at all stages of care. OBJECTIVE: This study aims to understand 
      the opinions of patients who have undergone ACL surgery and rehabilitation on the
      use of telerehabilitation as part of ACL care and define the population and
      explore their experiences and views on the acceptability of telerehabilitation
      after ACL reconstruction. METHODS: This study was a cross-sectional, voluntary,
      web-based survey combining both closed and open questions. Ethical approval was
      obtained from the Yale School of Medicine Institutional Review Board.
      Participants were aged 16 years or older at the time of recruitment and had
      undergone ACL reconstruction within the past 5 years. A 26-item survey was
      developed using the Qualtrics survey platform. No items were mandatory. Responses
      were multiple choice, binary, and qualitative. The CHERRIES (Checklist for
      Reporting Results of Internet E-Surveys) was used to ensure the quality of
      reporting of surveys in the medical literature. Data were analyzed using Stata
      version 15. Qualitative data were analyzed using NVivo 11. The theoretical
      framework for this analysis is based on the Capability, Opportunity, and
      Motivation-Behavior model of behavior change. RESULTS: A total of 100
      participants opened the survey. All completers were unique. The participation and
      completion rates were each 96% (96/100). Patients reported their physical therapy
      care ended at an average of 6.4 months and that they felt fully recovered at an
      average of 13.2 months. Only 26% (25/96) of patients felt fully recovered at the 
      end of physical therapy. Of these 96 patients, 54 (60%) were younger than 30
      years, 71 (74%) were recreational athletes, 24 (24%) were competitive athletes,
      72 (75%) had private insurance, 74 (77%) were not familiar at all with
      telerehabilitation, and 89% (85/96) felt capable. They preferred to use
      telerehabilitation at different stages of care. Reported benefits included
      resource saving, improved access to care, improved learning, and greater
      engagement. Concerns included incorrect performance of exercises or unmanaged
      pain being missed and less access to manual therapy, motivation, and
      opportunities to ask questions. Participants' priorities for a future
      telerehabilitation intervention included its use as an adjunct to physical
      therapy rather than a replacement, with content available for each stage of care,
      especially return to sports. Participants stressed that the intervention should
      be personalized to them and include measures of progress. CONCLUSIONS: These
      findings helped understand and define the ACL reconstruction population.
      Participants found telerehabilitation acceptable in principle and highlighted the
      key user requirements and scope of future interventions.
CI  - (c)Emma Dunphy, Elizabeth C Gardner. Originally published in JMIR Formative
      Research (http://formative.jmir.org), 18.09.2020.
FAU - Dunphy, Emma
AU  - Dunphy E
AUID- ORCID: https://orcid.org/0000-0001-5686-1908
AD  - eHealth Unit, Department of Primary Care and Population Health, University
      College London, Rowland Hill Street, United Kingdom.
FAU - Gardner, Elizabeth C
AU  - Gardner EC
AUID- ORCID: https://orcid.org/0000-0001-6570-1914
AD  - Department of Orthopaedics and Rehabilitation, Yale University School of
      Medicine, 47 College St, New Haven, CT, United States.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200918
PL  - Canada
TA  - JMIR Form Res
JT  - JMIR formative research
JID - 101726394
PMC - PMC7532455
OTO - NOTNLM
OT  - anterior cruciate ligament
OT  - eHealth
OT  - knee
OT  - patient experience
OT  - rehabilitation
OT  - survey
OT  - telehealth
OT  - telerehabilitation
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:01
CRDT- 2020/09/18 12:12
PHST- 2020/04/12 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/07/15 00:00 [revised]
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:01 [medline]
AID - v4i9e19296 [pii]
AID - 10.2196/19296 [doi]
PST - epublish
SO  - JMIR Form Res. 2020 Sep 18;4(9):e19296. doi: 10.2196/19296.


PMID- 32945771
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2368-7959 (Print)
IS  - 2368-7959 (Linking)
VI  - 7
IP  - 9
DP  - 2020 Sep 18
TI  - The VOICES Typology of Curatorial Decisions in Narrative Collections of the Lived
      Experiences of Mental Health Service Use, Recovery, or Madness: Qualitative
      Study.
PG  - e16290
LID - 10.2196/16290 [doi]
AB  - BACKGROUND: Collections of lived experience narratives are increasingly used in
      health research and medical practice. However, there is limited research with
      respect to the decision-making processes involved in curating narrative
      collections and the work that curators do as they build and publish collections. 
      OBJECTIVE: This study aims to develop a typology of curatorial decisions involved
      in curating narrative collections presenting lived experiences of mental health
      service use, recovery, or madness and to document approaches selected by curators
      in relation to identified curatorial decisions. METHODS: A preliminary typology
      was developed by synthesizing the results of a systematic review with insights
      gained through an iterative consultation with an experienced curator of multiple 
      recovery narrative collections. The preliminary typology informed the topic guide
      for semistructured interviews with a maximum variation sample of 30 curators from
      7 different countries. All participants had the experience of curating narrative 
      collections of the lived experiences of mental health service use, recovery, or
      madness. A multidisciplinary team conducted thematic analysis through constant
      comparison. RESULTS: The final typology identified 6 themes, collectively
      referred to as VOICES, which stands for values and motivations, organization,
      inclusion and exclusion, control and collaboration, ethics and legal, and safety 
      and well-being. A total of 26 subthemes related to curation decisions were
      identified. CONCLUSIONS: The VOICES typology identifies the key decisions to
      consider when curating narrative collections about the lived experiences of
      mental health service use, recovery, or madness. It might be used as a
      theoretical basis for a good practice resource to support curators in their
      efforts to balance the challenges and sometimes conflicting imperatives involved 
      in collecting, organizing, and sharing narratives. Future research might seek to 
      document the use of such a tool by curators and hence examine how best to use
      VOICES to support decision making.
CI  - (c)Caroline Yeo, Laurie Hare-Duke, Stefan Rennick-Egglestone, Simon Bradstreet,
      Felicity Callard, Ada Hui, Joy Llewellyn-Beardsley, Eleanor Longden, Tracy
      McDonough, Rose McGranahan, Fiona Ng, Kristian Pollock, James Roe, Mike Slade.
      Originally published in JMIR Mental Health (http://mental.jmir.org), 18.09.2020.
FAU - Yeo, Caroline
AU  - Yeo C
AUID- ORCID: https://orcid.org/0000-0003-3399-4729
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
FAU - Hare-Duke, Laurie
AU  - Hare-Duke L
AUID- ORCID: https://orcid.org/0000-0003-2145-4557
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
FAU - Rennick-Egglestone, Stefan
AU  - Rennick-Egglestone S
AUID- ORCID: https://orcid.org/0000-0003-4187-011X
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
FAU - Bradstreet, Simon
AU  - Bradstreet S
AUID- ORCID: https://orcid.org/0000-0002-0339-1882
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, United
      Kingdom.
FAU - Callard, Felicity
AU  - Callard F
AUID- ORCID: https://orcid.org/0000-0002-5350-1963
AD  - School of Geographical & Earth Sciences, University of Glasgow, Glasgow, United
      Kingdom.
FAU - Hui, Ada
AU  - Hui A
AUID- ORCID: https://orcid.org/0000-0001-7416-046X
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
FAU - Llewellyn-Beardsley, Joy
AU  - Llewellyn-Beardsley J
AUID- ORCID: https://orcid.org/0000-0003-0525-6358
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
FAU - Longden, Eleanor
AU  - Longden E
AUID- ORCID: https://orcid.org/0000-0003-3046-9697
AD  - Greater Manchester Mental Health NHS Foundation Trust, Manchester, United
      Kingdom.
FAU - McDonough, Tracy
AU  - McDonough T
AUID- ORCID: https://orcid.org/0000-0003-4877-7604
AD  - Department of Psychology, Mount St. Joseph University, Cincinnati, OH, United
      States.
FAU - McGranahan, Rose
AU  - McGranahan R
AUID- ORCID: https://orcid.org/0000-0003-2910-0868
AD  - Unit of Social and Community Psychiatry, Queen Mary University of London, London,
      United Kingdom.
FAU - Ng, Fiona
AU  - Ng F
AUID- ORCID: https://orcid.org/0000-0002-8656-8830
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
FAU - Pollock, Kristian
AU  - Pollock K
AUID- ORCID: https://orcid.org/0000-0002-6836-8595
AD  - School of Health Sciences, University of Nottingham, Nottingham, United Kingdom.
FAU - Roe, James
AU  - Roe J
AUID- ORCID: https://orcid.org/0000-0002-9514-5629
AD  - National Institute for Health Research, ARC East Midlands, University of
      Nottingham, Nottingham, United Kingdom.
FAU - Slade, Mike
AU  - Slade M
AUID- ORCID: https://orcid.org/0000-0001-7020-3434
AD  - School of Health Sciences, Institute of Mental Health, University of Nottingham, 
      Nottingham, United Kingdom.
LA  - eng
GR  - RP-PG-0615-20016/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200918
PL  - Canada
TA  - JMIR Ment Health
JT  - JMIR mental health
JID - 101658926
PMC - PMC7532459
OTO - NOTNLM
OT  - decision making
OT  - mental health recovery
OT  - personal narrative
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:01
CRDT- 2020/09/18 12:12
PHST- 2019/09/20 00:00 [received]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/04/02 00:00 [revised]
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:01 [medline]
AID - v7i9e16290 [pii]
AID - 10.2196/16290 [doi]
PST - epublish
SO  - JMIR Ment Health. 2020 Sep 18;7(9):e16290. doi: 10.2196/16290.


PMID- 32945760
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20200923
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - The Fundamental Ethical Concern Is Lack of School Resources to Ensure Student
      Well-Being.
PG  - 65-66
LID - 10.1080/15265161.2020.1806391 [doi]
FAU - Navratil, Judith
AU  - Navratil J
AD  - University of Pittsburgh.
FAU - Chugani, Carla D
AU  - Chugani CD
AD  - University of Pittsburgh.
FAU - Golden, Dawn
AU  - Golden D
AD  - Woodland Hills School District.
FAU - Fuhrman, Barbara
AU  - Fuhrman B
AD  - University of Pittsburgh.
FAU - Ripper, Lisa M
AU  - Ripper LM
AD  - University of Pittsburgh.
FAU - Talis, Janine
AU  - Talis J
AD  - University of Pittsburgh.
FAU - Miller, Elizabeth
AU  - Miller E
AD  - University of Pittsburgh.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):50-60. PMID: 32945754
MH  - Health Surveys
MH  - Humans
MH  - Morals
MH  - Schools
MH  - Students
MH  - *Suicide
EDAT- 2020/09/19 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/09/18 12:12
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - 10.1080/15265161.2020.1806391 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):65-66. doi: 10.1080/15265161.2020.1806391.


PMID- 32945756
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Reassessing the Ethics of Molecular HIV Surveillance in the Era of Cluster
      Detection and Response: Toward HIV Data Justice.
PG  - 10-23
LID - 10.1080/15265161.2020.1806373 [doi]
AB  - In the United States, clinical HIV data reported to surveillance systems operated
      by jurisdictional departments of public health are re-used for epidemiology and
      prevention. In 2018, all jurisdictions began using HIV genetic sequence data from
      clinical drug resistance tests to identify people living with HIV in "clusters"
      of others with genetically similar strains. This is called "molecular HIV
      surveillance" (MHS). In 2019, "cluster detection and response" (CDR) programs
      that re-use MHS data became the "fourth pillar" of the national HIV strategy.
      Public health re-uses of HIV data are done without consent and are a source of
      concern among stakeholders. This article presents three cases that illuminate
      bioethical challenges associated with re-uses of clinical HIV data for public
      health. We focus on evidence-base, risk-benefit ratio, determining directionality
      of HIV transmission, consent, and ethical re-use. The conclusion offers
      strategies for "HIV data justice." The essay contributes to a "bioethics of the
      oppressed."
FAU - Molldrem, Stephen
AU  - Molldrem S
AUID- ORCID: 0000-0002-1907-8081
AD  - University of California Irvine.
FAU - Smith, Anthony K J
AU  - Smith AKJ
AUID- ORCID: 0000-0002-0005-9542
AD  - Centre for Social Research in Health, UNSW Sydney.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Oct;20(10):44-47. PMID: 32945759
CIN - Am J Bioeth. 2020 Oct;20(10):5-6. PMID: 33016820
CIN - Am J Bioeth. 2020 Oct;20(10):42-44. PMID: 33016821
CIN - Am J Bioeth. 2020 Oct;20(10):26-29. PMID: 33016822
CIN - Am J Bioeth. 2020 Oct;20(10):47-49. PMID: 33016824
CIN - Am J Bioeth. 2020 Oct;20(10):36-39. PMID: 33016828
CIN - Am J Bioeth. 2020 Oct;20(10):32-33. PMID: 33016829
CIN - Am J Bioeth. 2020 Oct;20(10):24-26. PMID: 33016830
CIN - Am J Bioeth. 2020 Oct;20(10):29-31. PMID: 33016831
CIN - Am J Bioeth. 2020 Oct;20(10):34-36. PMID: 33016832
CIN - Am J Bioeth. 2020 Oct;20(10):39-41. PMID: 33016834
MH  - *Bioethics
MH  - Confidentiality
MH  - *HIV Infections/diagnosis/epidemiology
MH  - Humans
MH  - Informed Consent
MH  - Public Health
MH  - Social Justice
MH  - United States
OTO - NOTNLM
OT  - *Public health
OT  - *confidentiality & privacy
OT  - *genetic research
OT  - *health policy
OT  - *human subjects research
OT  - *informed consent
EDAT- 2020/09/19 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/09/18 12:12
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1806373 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):10-23. doi: 10.1080/15265161.2020.1806373.


PMID- 32945754
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Duties When an Anonymous Student Health Survey Finds a Hot Spot of Suicidality.
PG  - 50-60
LID - 10.1080/15265161.2020.1806374 [doi]
AB  - Public health agencies regularly survey randomly selected anonymous students to
      track drug use, sexual activities, and other risk behaviors. Students are
      unidentifiable, but a recent project that included school-level analysis
      discovered a school with alarmingly prevalent student suicidality. Given
      confidentiality protocols typical of surveillance, the surveyors were uncertain
      whether and how to intervene. We searched literature for duties to warn at-risk
      groups discovered during public health surveillance, but we found no directly
      applicable guidance or cases. Reasoning by analogy, we conclude that surveyors
      should contact the school's leaders to call attention to its outlier status, but 
      public warning is unwarranted. However, such an ad hoc decision to issue a
      warning, even if only to school leaders, raises significant practical, legal and 
      ethical issues. National public health and education associations should produce 
      guidance that clarifies ethical and legal duties owed to schools and students
      involved in population health-risk surveillance.
FAU - Levinson, Arnold H
AU  - Levinson AH
AUID- ORCID: 0000-0003-3167-0384
AD  - University of Colorado | Anschutz Medical Campus.
AD  - Colorado School of Public Health.
FAU - Crepeau-Hobson, M Franci
AU  - Crepeau-Hobson MF
AD  - University of Colorado Denver.
FAU - Coors, Marilyn E
AU  - Coors ME
AD  - University of Colorado | Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
FAU - Glover, Jacqueline J
AU  - Glover JJ
AD  - University of Colorado | Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
FAU - Goldberg, Daniel S
AU  - Goldberg DS
AD  - University of Colorado | Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
FAU - Wynia, Matthew K
AU  - Wynia MK
AD  - University of Colorado | Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Oct;20(10):W4-W7. PMID: 32945747
CIN - Am J Bioeth. 2020 Oct;20(10):63-65. PMID: 32945755
CIN - Am J Bioeth. 2020 Oct;20(10):77-79. PMID: 32945757
CIN - Am J Bioeth. 2020 Oct;20(10):65-66. PMID: 32945760
CIN - Am J Bioeth. 2020 Oct;20(10):67-69. PMID: 33016823
CIN - Am J Bioeth. 2020 Oct;20(10):70-72. PMID: 33016825
CIN - Am J Bioeth. 2020 Oct;20(10):61-63. PMID: 33016826
CIN - Am J Bioeth. 2020 Oct;20(10):72-74. PMID: 33016827
CIN - Am J Bioeth. 2020 Oct;20(10):79-81. PMID: 33016833
MH  - Humans
MH  - Risk-Taking
MH  - Schools
MH  - Students
MH  - *Suicide
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Student health surveys
OT  - *community protections
OT  - *duty to warn
OT  - *public health surveillance ethics
OT  - *school anonymity
OT  - *suicidality clusters
EDAT- 2020/09/19 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/09/18 12:12
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1806374 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):50-60. doi: 10.1080/15265161.2020.1806374.


PMID- 32945747
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20200923
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Comments Confirm That Student Health Surveillance Needs Ethics Guidelines to Act 
      on Risk-Cluster Findings.
PG  - W4-W7
LID - 10.1080/15265161.2020.1816799 [doi]
FAU - Levinson, Arnold H
AU  - Levinson AH
AUID- ORCID: 0000-0003-3167-0384
AD  - Colorado School of Public Health, Community and Behavioral Health.
AD  - University of Colorado Anschutz Medical Campus.
FAU - Crepeau-Hobson, M Franci
AU  - Crepeau-Hobson MF
AD  - University of Colorado Denver.
FAU - Glover, Jacqueline
AU  - Glover J
AD  - University of Colorado Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
FAU - Coors, Marilyn E
AU  - Coors ME
AD  - University of Colorado Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
FAU - Goldberg, Daniel S
AU  - Goldberg DS
AD  - University of Colorado Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
FAU - Wynia, Matthew K
AU  - Wynia MK
AD  - University of Colorado Anschutz Medical Campus.
AD  - Center for Bioethics and Humanities.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Oct;20(10):50-60. PMID: 32945754
MH  - Health Surveys
MH  - Humans
MH  - Students
MH  - *Suicide
EDAT- 2020/09/19 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/09/18 12:12
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - 10.1080/15265161.2020.1816799 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):W4-W7. doi: 10.1080/15265161.2020.1816799.


PMID- 32945742
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Technology Changes the Ethical Stakes in HIV Surveillance and Prevention:
      Response to Open Peer Commentaries on "Reassessing the Ethics of Molecular HIV
      Surveillance in the Era of Cluster Detection and Response".
PG  - W1-W3
LID - 10.1080/15265161.2020.1815472 [doi]
FAU - Molldrem, Stephen
AU  - Molldrem S
AUID- ORCID: 0000-0002-1907-8081
AD  - University of California Irvine.
FAU - Smith, Anthony K J
AU  - Smith AKJ
AUID- ORCID: 0000-0002-0005-9542
AD  - Centre for Social Research in Health, UNSW Sydney.
LA  - eng
PT  - Letter
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - *Ethics, Research
MH  - *HIV Infections
MH  - Humans
MH  - Technology
EDAT- 2020/09/19 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/09/18 12:12
PHST- 2020/09/18 12:12 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1815472 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Oct;20(10):W1-W3. doi: 10.1080/15265161.2020.1815472.


PMID- 32945616
OWN - NLM
STAT- MEDLINE
DCOM- 20201127
LR  - 20220731
IS  - 1931-2393 (Electronic)
IS  - 1538-6341 (Linking)
VI  - 52
IP  - 3
DP  - 2020 Sep
TI  - Clinician Perspectives on Ethics and COVID-19: Minding the Gap in Sexual and
      Reproductive Health.
PG  - 145-149
LID - 10.1363/psrh.12156 [doi]
FAU - Ott, Mary A
AU  - Ott MA
AD  - Indiana University School of Medicine, Indianapolis.
FAU - Bernard, Caitlin
AU  - Bernard C
AD  - Indiana University School of Medicine, Indianapolis.
FAU - Wilkinson, Tracey A
AU  - Wilkinson TA
AD  - Indiana University School of Medicine, Indianapolis.
FAU - Edmonds, Brownsyne Tucker
AU  - Edmonds BT
AD  - Indiana University School of Medicine, Indianapolis.
LA  - eng
GR  - K23 HD094853/HD/NICHD NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Perspect Sex Reprod Health
JT  - Perspectives on sexual and reproductive health
JID - 101140654
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - Reproductive Health/*ethics
MH  - Reproductive Techniques/*ethics
MH  - Reproductive Techniques, Assisted/ethics
MH  - SARS-CoV-2
MH  - Sexual Health/*ethics
PMC - PMC7537032
EDAT- 2020/09/19 06:00
MHDA- 2020/11/28 06:00
CRDT- 2020/09/18 08:45
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/11/28 06:00 [medline]
PHST- 2020/09/18 08:45 [entrez]
AID - 10.1363/psrh.12156 [doi]
PST - ppublish
SO  - Perspect Sex Reprod Health. 2020 Sep;52(3):145-149. doi: 10.1363/psrh.12156.


PMID- 32945241
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20220109
IS  - 1545-0813 (Electronic)
IS  - 1059-924X (Linking)
VI  - 25
IP  - 4
DP  - 2020 Oct
TI  - Invisible No More: The Impact of COVID-19 on Essential Food Production Workers.
PG  - 378-382
LID - 10.1080/1059924X.2020.1814925 [doi]
AB  - From the farms to the packing plants, essential workers in critical food
      production industries keep food on our tables while risking their and their
      families' health and well-being to bring home a paycheck. They work in essential 
      industries but are often invisible. The disparities illuminated by COVID-19 are
      not new. Instead, they are the result of years of inequities built into
      practices, policies, and systems that reinforce societal power structures. As a
      society, we are now at an antagonizing moment where we can change our collective 
      trajectory to focus forward and promote equity and justice for workers in
      agriculture and food-related industries. To that end, we describe our experience 
      and approach in addressing COVID-19 outbreaks in meat processing facilities,
      which included three pillars of action based on public health ethics and
      international human rights: (1) worksite prevention and control, (2)
      community-based prevention and control, and (3) treatment. Our approach can be
      translated to promote the health, safety, and well-being of the broader
      agricultural workforce.
FAU - Ramos, Athena K
AU  - Ramos AK
AUID- ORCID: 0000-0002-5194-8243
AD  - Assistant Professor, Department of Health Promotion, Center for Reducing Health
      Disparities, College of Public Health, University of Nebraska Medical Center,
      984340 Nebraska Medical Center , Omaha, Nebraska.
FAU - Lowe, Abigail E
AU  - Lowe AE
AD  - Ethics and Public Health Preparedness, Center for Preparedness Education, College
      of Public Health, University of Nebraska Medical Center , Omaha, NE, USA.
FAU - Herstein, Jocelyn J
AU  - Herstein JJ
AD  - Sub-Saharan Africa Region, Global Center for Health Security, College of Public
      Health, University of Nebraska Medical Center , Omaha, NE, USA.
FAU - Schwedhelm, Shelly
AU  - Schwedhelm S
AD  - Emergency Management & Biopreparedness, Nebraska Medicine & Global Center for
      Health Securitu, Nebraska Medical Center , Omaha, Nebraska, USA.
FAU - Dineen, Kelly K
AU  - Dineen KK
AD  - Health Law Program, Creighton University , Omaha, Nebraska, USA.
FAU - Lowe, John J
AU  - Lowe JJ
AUID- ORCID: 0000-0002-2893-1312
AD  - Department of Environmental, Agricultural and Occupational Health, College of
      Public Health and Executive Director, Global Center for Health Security,
      University of Nebraska Medical Center , Omaha, Nebraska, USA.
LA  - eng
GR  - U54 OH010162/OH/NIOSH CDC HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200918
PL  - England
TA  - J Agromedicine
JT  - Journal of agromedicine
JID - 9421530
SB  - IM
MH  - Animals
MH  - COVID-19/epidemiology/*psychology
MH  - Farmers/*psychology/statistics & numerical data
MH  - Food Supply
MH  - Human Rights
MH  - Humans
MH  - Meat-Packing Industry/*statistics & numerical data
MH  - *Occupational Health
MH  - Public Health/statistics & numerical data
OTO - NOTNLM
OT  - *Meatpacking
OT  - *ethics
OT  - *farmworkers
OT  - *human rights
OT  - *processing
EDAT- 2020/09/19 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/09/18 08:42
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/09/18 08:42 [entrez]
AID - 10.1080/1059924X.2020.1814925 [doi]
PST - ppublish
SO  - J Agromedicine. 2020 Oct;25(4):378-382. doi: 10.1080/1059924X.2020.1814925. Epub 
      2020 Sep 18.


PMID- 32944921
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 1090-3941 (Print)
IS  - 1090-3941 (Linking)
VI  - 37
DP  - 2020 Nov 28
TI  - Use and Efficacy of Hemostats in Neurosurgery.
PG  - 414-419
AB  - Hemostasis plays a central role throughout neurosurgery. In microneurosurgery, a 
      bloodless operating field under an operating microscope allows fast and effective
      surgery, thereby reducing the risk of postoperative hemorrhage. Apart from
      mechanical methods, such as positioning of the patient's head and body, bone
      plugging, suction, and metal clips, neurosurgical hemostasis is achieved mainly
      with bipolar coagulation, which permits optimal control of hemorrhage, allows for
      fine coagulation of small vessels and is safe in patients with pacemakers and
      defibrillators. Gelatin sponge is a non-antigenic protein that can absorb 45
      times its weight in blood, and, when wet, is plastered to the irregularities of
      the bleeding surface. It enables the repair of torn veins, such as the superior
      sagittal sinus, without compromising the patency of the vessel. Surgicel(R)
      (Johnson & Johnson, New Brunswick, NJ), the first oxidized cellulose to be
      introduced, is used to control capillary, venous, or smaller arterial bleeding
      because it acts as a matrix for the formation of a clot. Over the past few
      decades, research on the development of hemostatic agents has shifted to the use 
      of fibrin sealants and flowable agents such as Tisseel Fibrin Sealant(R) (Baxter,
      Deerfield, IL), Evicel Fibrin Sealant(R) (Ethicon, Somerville, NJ) and FloSeal(R)
      (Baxter). Very recently, advanced hemostats with sealant properties similar to
      those of fibrin sealants have been introduced, such as Tachosil(R) (Baxter,
      Deerfield, IL) and Hemopatch Sealing Hemostat(R) (Baxter). Due to the different
      properties of these products it is important that we understand the efficacy of
      each hemostatic agent in different neurosurgical settings, such as in the control
      of parenchymal, subdural and epidural bleeding in both cranial and spinal
      surgery. The aim of this work was to review the principal technical aspects of
      hemostatic agents to optimize their use in different neurosurgical procedures.
FAU - Signorelli, Francesco
AU  - Signorelli F
AD  - Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli
      IRCCS, Rome, Italy.
FAU - Montano, Nicola
AU  - Montano N
AD  - Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli
      IRCCS, Rome, Italy, Department of Neuroscience, Neurosurgery Section, Universita 
      Cattolica del Sacro Cuore, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Surg Technol Int
JT  - Surgical technology international
JID - 9604509
RN  - 0 (Fibrin Tissue Adhesive)
RN  - 0 (Hemostatics)
SB  - IM
MH  - Fibrin Tissue Adhesive
MH  - Hemostasis, Surgical
MH  - *Hemostatics/therapeutic use
MH  - Humans
MH  - Neurosurgery
MH  - *Neurosurgical Procedures
MH  - Surgical Instruments
EDAT- 2020/09/19 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/09/18 05:53
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2020/09/18 05:53 [entrez]
AID - sti37/1335 [pii]
PST - ppublish
SO  - Surg Technol Int. 2020 Nov 28;37:414-419.


PMID- 32944754
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210919
IS  - 1460-2237 (Electronic)
IS  - 0268-1080 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Nov 20
TI  - From research to international scale-up: stakeholder engagement essential in
      successful design, evaluation and implementation of paediatric HIV testing
      intervention.
PG  - 1180-1187
LID - 10.1093/heapol/czaa089 [doi]
AB  - Stakeholder engagement between researchers, policymakers and practitioners is
      critical for the successful translation of research into policy and practice. The
      Counseling and Testing for Children at Home (CATCH) study evaluated a paediatric 
      index case testing model, targeting the children of HIV-infected adults in care
      in Kenya. Researchers collaborated with stakeholders in the planning, execution
      and evaluation, and dissemination phases of CATCH. They included a community
      advisory board, the national HIV programme, County health departments,
      institutional ethics review bodies, a paediatric bioethics group, facility heads 
      and frontline healthcare workers . Stakeholder analysis considered the power and 
      interest of each stakeholder in the study. All stakeholders had some power to
      influence the success of the project in the different phases. However, support
      from institutions with higher hierarchical power increased acceptance of the
      study by stakeholders lower in the hierarchy. During the planning, execution and 
      evaluation, and dissemination phases, the study benefitted from deliberate
      stakeholder engagement. Through engagement, changes were made in the approach to 
      recruitment to ensure high external validity, placing recruitment optimally
      within existing clinic flow patterns. Choices in staffing home visits were made
      to include the appropriate cadre of staff. Adaptations were made to the
      consenting process that balanced the child's evolving autonomy and risks of HIV
      disclosure. Dissemination involved delivering site-specific results in each HIV
      clinic, local and international conferences and sharing of study tools, resulting
      in the study approach being scaled up nationally. The deliberate engagement of
      stakeholders early in intervention development optimized study validity and
      accelerated adoption of the CATCH approach in nationwide HIV testing campaigns by
      the Ministry of Health and inclusion of paediatric index-case testing in national
      HIV testing guidelines. Involving policymakers and frontline healthcare workers
      throughout the study cycle builds capacity in the implementing team for quick
      adoption and scale-up of the evidence-based practice.
CI  - (c) The Author(s) 2020. Published by Oxford University Press in association with 
      The London School of Hygiene and Tropical Medicine. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Mugo, Cyrus
AU  - Mugo C
AD  - Department of Research and Programs, Kenyatta National Hospital, PO Box 20723,
      00102, Hospital road, Upperhill, Nairobi, Kenya.
FAU - Njuguna, Irene
AU  - Njuguna I
AD  - Department of Research and Programs, Kenyatta National Hospital, PO Box 20723,
      00102, Hospital road, Upperhill, Nairobi, Kenya.
FAU - Nduati, Margaret
AU  - Nduati M
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - Omondi, Vincent
AU  - Omondi V
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - Otieno, Verlinda
AU  - Otieno V
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - Nyapara, Florence
AU  - Nyapara F
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - Mabele, Elizabeth
AU  - Mabele E
AD  - Department of Pediatrics, Kenyatta National Hospital, PO Box 20723, 00102,
      Hospital road, Upperhill, Nairobi, Kenya.
FAU - Moraa, Hellen
AU  - Moraa H
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - Sherr, Kenneth
AU  - Sherr K
AD  - Department of Global Health, University of Washington, PO Box 357965, 1510 San
      Juan road NE, Seattle, Washington, 98195-7965, USA.
FAU - Inwani, Irene
AU  - Inwani I
AD  - Department of Pediatrics, Kenyatta National Hospital, PO Box 20723, 00102,
      Hospital road, Upperhill, Nairobi, Kenya.
FAU - Maleche-Obimbo, Elizabeth
AU  - Maleche-Obimbo E
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - Wamalwa, Dalton
AU  - Wamalwa D
AD  - Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676,
      00202, Ngong road, Upperhill, Nairobi, Kenya.
FAU - John-Stewart, Grace
AU  - John-Stewart G
AD  - Department of Global Health, University of Washington, PO Box 357965, 1510 San
      Juan road NE, Seattle, Washington, 98195-7965, USA.
AD  - Department of Epidemiology, University of Washington, PO Box 357236, 610 Walnut
      Street NE, Seattle, Washington, 98195, USA.
AD  - Department of Pediatrics, University of Washington, PO Box 356420, 6200 NE 74th
      St, Seattle, Washington, 98115-8160, USA.
AD  - Department of Medicine, University of Washington, PO Box 356420, 1959 NE Pacific 
      St, Seattle, Washington, 98195-6420, USA.
FAU - Slyker, Jennifer
AU  - Slyker J
AD  - Department of Global Health, University of Washington, PO Box 357965, 1510 San
      Juan road NE, Seattle, Washington, 98195-7965, USA.
AD  - Department of Epidemiology, University of Washington, PO Box 357236, 610 Walnut
      Street NE, Seattle, Washington, 98195, USA.
FAU - Wagner, Anjuli D
AU  - Wagner AD
AD  - Department of Global Health, University of Washington, PO Box 357965, 1510 San
      Juan road NE, Seattle, Washington, 98195-7965, USA.
LA  - eng
GR  - K02 TW009207/TW/FIC NIH HHS/United States
GR  - F31 MH099988/MH/NIMH NIH HHS/United States
GR  - K24 HD054314/HD/NICHD NIH HHS/United States
GR  - R01 HD023412/HD/NICHD NIH HHS/United States
GR  - R21 HD079637/HD/NICHD NIH HHS/United States
GR  - P30 AI027757/AI/NIAID NIH HHS/United States
GR  - K01 AI087369/AI/NIAID NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - Health Policy Plan
JT  - Health policy and planning
JID - 8610614
MH  - Child
MH  - Child, Preschool
MH  - Community-Based Participatory Research
MH  - *HIV Testing/methods/statistics & numerical data
MH  - Humans
MH  - Kenya
MH  - *Stakeholder Participation
PMC - PMC7810404
OTO - NOTNLM
OT  - Stakeholder engagement
OT  - community-based participatory research
OT  - index-case testing
OT  - paediatric HIV testing
OT  - stakeholder analysis
EDAT- 2020/09/19 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/09/18 05:52
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2020/09/18 05:52 [entrez]
AID - 5908025 [pii]
AID - 10.1093/heapol/czaa089 [doi]
PST - ppublish
SO  - Health Policy Plan. 2020 Nov 20;35(9):1180-1187. doi: 10.1093/heapol/czaa089.


PMID- 32944510
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2214-9996 (Electronic)
IS  - 2214-9996 (Linking)
VI  - 86
IP  - 1
DP  - 2020 Sep 3
TI  - Integrating Global Health Within Dental Education: Inter-University Collaboration
      for Scaling Up a Pilot Curriculum.
PG  - 113
LID - 10.5334/aogh.3024 [doi]
AB  - Background: New education programs are developing to improve global health
      awareness. Dental students have demonstrated interest in international settings
      but are largely unaware of global health topics. The Timothy A. DeRouen Center
      for Global Oral Health of the University of Washington (UW) and Harvard School of
      Dental Medicine expanded a competency-based global health curriculum (Global
      Health Starter Kit) by integrating it within the UW School of Dentistry (UW SOD) 
      existing elective course "Global Oral Health" to undergraduates, pre-, and
      doctorate students from the UW SOD and Public Health. The study objective was to 
      evaluate the curriculum effectiveness by assessing 1) Knowledge and Attitudes
      (survey), and 2) Didactic coursework (global trends, global goals, primary care, 
      social determinants and risks, and ethics and sustainability). Methods:
      Eligibility included enrolled students with both pre- and post-assessments.
      Descriptive statistics were conducted to present demographic data. Significant
      changes on survey and didactic evaluations were analyzed with paired t-tests (p <
      0.05). Findings: The population (N = 15) represented 88% of the class. All
      Knowledge categories had a significant increase (p < 0.05), except in the topic
      of tropical diseases. At baseline, Attitudes categories had high scores and did
      not significantly increase by the end of the course. Even though all Didactic
      categories improved, only Social Determinants and Risks showed a significant
      increase (p < 0.01). Conclusion: Competency-based global health learning can be
      implemented in the dental curriculum. While the study shows promising results,
      efforts to identify areas for improvement as well as considerations of the
      institution's culture need to be assessed and addressed for each teaching cycle.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Seminario, Ana Lucia
AU  - Seminario AL
AD  - School of Dentistry, University of Washington, US.
AD  - School of Public Health, University of Washington, US.
AD  - Timothy A. DeRouen Center for Global Oral Health, University of Washington, US.
FAU - Chen, Belle
AU  - Chen B
AD  - School of Dentistry, University of Washington, US.
FAU - Liu, Jennifer
AU  - Liu J
AD  - School of Public Health, University of Washington, US.
FAU - Seymour, Brittany
AU  - Seymour B
AD  - Oral Health Policy and Epidemiology, School of Dental Medicine, Harvard
      University, US.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - United States
TA  - Ann Glob Health
JT  - Annals of global health
JID - 101620864
SB  - IM
MH  - Curriculum
MH  - Education, Dental
MH  - *Global Health
MH  - Humans
MH  - Oral Health
MH  - *Universities
PMC - PMC7473179
COIS- The authors have no competing interests to declare.
EDAT- 2020/09/19 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/09/18 05:51
PHST- 2020/09/18 05:51 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.5334/aogh.3024 [doi]
PST - epublish
SO  - Ann Glob Health. 2020 Sep 3;86(1):113. doi: 10.5334/aogh.3024.


PMID- 32944441
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 13
TI  - Association of Pulmonary Hypertension With End-Stage Renal Disease Among the
      Obese Population.
PG  - e9722
LID - 10.7759/cureus.9722 [doi]
AB  - Introduction Pulmonary hypertension (PH) is a known complication that occurs in
      patients of end-stage renal disease (ESRD) that have an arteriovenous fistula
      (AVF) for hemodialysis (HD). It is defined as pulmonary artery pressure (PAP) of 
      greater than 30 mmHg on echocardiography. The presence of PH in ESRD is an
      independent risk factor and decreases the survival likelihood among HD patients. 
      Unexplained PH is frequently seen in ESRD following AVF. Obesity can lead to
      various complications, such as sleep apnea, cardiac complications, pulmonary
      hypertension, and mortality. Data on the prevalence of coexisting PH and obesity 
      are scarce. Obese patients often have increased albumin excretion rates (AER)
      that can lead to early renal impairment and an increase in intraglomerular
      pressure, which may increase the risk of cardiovascular (CV) morbidity and
      mortality. Therefore, the study aimed to evaluate and compare the associated PH
      and obesity separately and collectively among ESRD patients. Methods This
      comparative cross-sectional study was conducted in a tertiary care public sector 
      hospital with the approval of the medical ethics review board committee. The
      study enrolled all consecutive patients with ESRD as defined by having an
      estimated glomerular filtration rate (GFR) of <15 mL/min/1.7 3 m(2) from April
      2017 till March 2019, who presented to our facility. These patients underwent
      dialysis twice or thrice a week, each session lasting three to four hours
      approximately. On initial encounter, trans-thoracic echocardiography (TTE) was
      done by the cardiologist to diagnose pulmonary hypertension. In addition, body
      mass index (BMI) was calculated for all patients, and the patients were
      categorized into underweight, normal, overweight, or obese. All patients
      underwent post-dialysis TTE at one hour or when patients were at the optimal dry 
      weight. Systolic PAP and ejection fraction were measured, and pulmonary
      hypertension was defined as a PAP of 30 mmHg or greater on TTE. ESRD patients
      that were diagnosed with PH prior to hemodialysis or had primary PH were excluded
      from the study. Only ESRD patients developing secondary PH after hemodialysis
      were included in the study. The chi-square test was used to see the correlation
      of gender, ambulation status, smoking status, obesity, pulmonary hypertension,
      body mass index (BMI), and pulmonary hypertension and obesity combined on the
      final outcome. A p-value of 0.05 was considered significant. Odds ratio (OR) and 
      relative risk (RR) were calculated for pulmonary hypertension and obesity
      combined, obesity, and pulmonary hypertension in the final outcome. Results The
      study enrolled 204 patients with a mean age of 46.23 (+/-20.45 SD) having higher 
      female participation of 108 (52.9%), whereas 96 (47.1%) were males. The average
      weight of the cohort was 66.78 kg (+/-22.98 SD) with a mean BMI of 29.91 kg/m(2) 
      (+/-13.29SD), 52 (25.5%) patients were underweight, 40 (19.6%) had a normal BMI, 
      29 (14.2%) were overweight, and 83 (40.7%) patients were obese. Pulmonary
      hypertension and obesity combined were observed in 48 (23.5%) of the cases and
      there was a 4.60 relative risk of death among these individuals, with an odds
      ratio of 13.35 and a p-value of 0.00. Conclusion The study shows a strong
      synergistic effect of pulmonary hypertension and obesity towards the final
      survival outcome in ESRD patients who are on hemodialysis.
CI  - Copyright (c) 2020, Jameel et al.
FAU - Jameel, Farah Anum
AU  - Jameel FA
AD  - Nephrology, Jinnah Postgraduate Medical Center, Karachi, PAK.
FAU - Junejo, Abdul Mannan
AU  - Junejo AM
AD  - Nephrology, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Ejaz, Ayesha
AU  - Ejaz A
AD  - Nephrology, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Khan, Qurat Ul Ain
AU  - Khan QUA
AD  - Nephrology, Jinnah Postgraduate Medical Centre, Karachi, PAK.
FAU - Bhopal, Kamran Faisal
AU  - Bhopal KF
AD  - Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation
      Trust, Cambridge, GBR.
FAU - Faraz, Ahmad
AU  - Faraz A
AD  - Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, GBR.
FAU - Rizvi, Syed Hasan Mustafa
AU  - Rizvi SHM
AD  - Internal Medicine, Peterborough City Hospital, Peterborough, GBR.
FAU - Ahmad, Fatima
AU  - Ahmad F
AD  - Anaesthesia, Punjab Institute of Cardiology, Lahore, PAK.
FAU - Tahir, Muhammad
AU  - Tahir M
AD  - Orthopaedics, Jinnah Postgraduate Medical Center, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7489319
OTO - NOTNLM
OT  - end stage renal disease
OT  - maintenance hemodialysis
OT  - obesity
OT  - pulmonary hypertension
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:01
CRDT- 2020/09/18 05:51
PHST- 2020/09/18 05:51 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:01 [medline]
AID - 10.7759/cureus.9722 [doi]
PST - epublish
SO  - Cureus. 2020 Aug 13;12(8):e9722. doi: 10.7759/cureus.9722.


PMID- 32943853
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1177-889X (Print)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - Development and Psychometric Analysis of the Measure of Perceived Adherence to
      the Principles of Medical Ethics in Clinical Educational Settings: Trainee
      Version (PAMETHIC-CLIN-T).
PG  - 1615-1621
LID - 10.2147/PPA.S258132 [doi]
AB  - OBJECTIVE: This study was conducted to develop and assess psychometric properties
      of the "Measure of Perceived Adherence to the Principles of Medical Ethics in
      Clinical Educational Settings: trainee version (PAMETHIC-CLIN-T)" as a data
      collection tool to enhance research performance rigor in future medical ethics
      studies. PATIENTS AND METHODS: A multi-tiered six stage procedure was applied to 
      develop the PAMETHIC-CLIN-T and assess its psychometric properties in a sample of
      Iranian medical science undergraduate students (n=263). The final constructed
      item pool contained 16 questions with the response options in five Likert-type
      categories. The higher total score indicated better compliance with the ethics
      and professional conduct regulations. Internal consistency reliability was
      examined and exploratory factor analysis (EFA) with direct oblimin rotation and
      principal components analysis (PCA) were carried out to reduce the overall
      constructed items into latent factors based on commonalities within the data set.
      FINDINGS: Factor analysis results revealed a 4-factor solution. All 16 items had 
      factor loading greater than absolute value of 0.3 that accounted for 60.57% of
      the variance. The value of Kaiser Meyer Olkin (KMO) measure of sampling adequacy 
      for factor analysis (0.909) and also Bartlett's test of sphericity (X(2)=1630.63,
      df=120, P-value<0.001) approved interpretability of the EFA output. CONCLUSION:
      Feasibility testing and psychometric analysis of the constructed scale yielded
      research evidence to support a four-factor model to be applied in future studies 
      about the extent of perceived adherence to the principles of medical ethics in
      clinical educational settings.
CI  - (c) 2020 Toupchian et al.
FAU - Toupchian, Arezoo
AU  - Toupchian A
AD  - Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz,
      Iran.
FAU - Sarbakhsh, Parvin
AU  - Sarbakhsh P
AUID- ORCID: 0000-0002-4213-5152
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Tabriz
      University of Medical Sciences, Tabriz, Iran.
FAU - Ghaffari, Reza
AU  - Ghaffari R
AUID- ORCID: 0000-0003-3580-5573
AD  - Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz,
      Iran.
FAU - Kazemi, Abdolhassan
AU  - Kazemi A
AUID- ORCID: 0000-0003-1219-5725
AD  - Medical Philosophy and History Research Center, Tabriz University of Medical
      Sciences, Tabriz, Iran.
FAU - Mahmoodi, Hassan
AU  - Mahmoodi H
AUID- ORCID: 0000-0002-1234-9037
AD  - Social Determinants of Health Research Center, Research Institute for Health
      Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
FAU - Shaghaghi, Abdolreza
AU  - Shaghaghi A
AUID- ORCID: 0000-0002-3884-1847
AD  - Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz,
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20200904
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7481275
OTO - NOTNLM
OT  - ethics
OT  - hidden curriculum
OT  - medical education
COIS- The authors declare no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:01
CRDT- 2020/09/18 05:48
PHST- 2020/04/15 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/09/18 05:48 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:01 [medline]
AID - 10.2147/PPA.S258132 [doi]
AID - 258132 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2020 Sep 4;14:1615-1621. doi: 10.2147/PPA.S258132.
      eCollection 2020.


PMID- 32943477
OWN - NLM
STAT- Publisher
LR  - 20210525
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 17
TI  - Ethical considerations for protecting the options of subjects in primary epidemic
      vaccine trials.
LID - medethics-2020-106851 [pii]
LID - 10.1136/medethics-2020-106851 [doi]
FAU - Caplan, Arthur L
AU  - Caplan AL
AD  - Division of Medical Ethics, NYU Langone Medical Center, New York, New York, USA.
FAU - Abraham, Jerrold L
AU  - Abraham JL
AD  - Department of Pathology, SUNY Upstate Medical University, Syracuse, New York, USA
      abrahamj@upstate.edu.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8108278
OTO - NOTNLM
OT  - ethics
OT  - informed consent
COIS- Competing interests: None declared.
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:00
CRDT- 2020/09/18 05:42
PHST- 2020/08/26 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/18 05:42 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:00 [medline]
AID - medethics-2020-106851 [pii]
AID - 10.1136/medethics-2020-106851 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 17. pii: medethics-2020-106851. doi:
      10.1136/medethics-2020-106851.


PMID- 32943452
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210507
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 369
IP  - 6511
DP  - 2020 Sep 25
TI  - Self-experimentation, ethics, and regulation of vaccines.
PG  - 1570-1572
LID - 10.1126/science.abe1963 [doi]
FAU - Guerrini, Christi J
AU  - Guerrini CJ
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX, USA. guerrini@bcm.edu jsherkow@illinois.edu mmeyer@geisinger.edu
      zettler.25@osu.edu.
FAU - Sherkow, Jacob S
AU  - Sherkow JS
AD  - College of Law, University of Illinois at Urbana-Champaign, Champaign, IL, USA.
      guerrini@bcm.edu jsherkow@illinois.edu mmeyer@geisinger.edu zettler.25@osu.edu.
AD  - Carl R. Woese Institute for Genomic Biology, University of Illinois at
      Urbana-Champaign, Urbana, IL, USA.
AD  - Center for Advanced Studies in Biomedical Innovation Law, University of
      Copenhagen Faculty of Law, Copenhagen, Denmark.
FAU - Meyer, Michelle N
AU  - Meyer MN
AD  - Center for Translational Bioethics and Health Care Policy and Steele Institute
      for Health Innovation, Geisinger Health System, Danville, PA, USA.
      guerrini@bcm.edu jsherkow@illinois.edu mmeyer@geisinger.edu zettler.25@osu.edu.
AD  - Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
FAU - Zettler, Patricia J
AU  - Zettler PJ
AD  - Moritz College of Law, The James Comprehensive Cancer Center and Drug Enforcement
      and Policy Center, Ohio State University, Columbus, OH, USA. guerrini@bcm.edu
      jsherkow@illinois.edu mmeyer@geisinger.edu zettler.25@osu.edu.
LA  - eng
GR  - K01 HG009355/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200917
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Covid-19 aAPC vaccine)
SB  - IM
CIN - Science. 2020 Dec 18;370(6523):1422-1423. PMID: 33335056
MH  - Autoexperimentation/*ethics
MH  - COVID-19 Vaccines/*administration & dosage
MH  - Ethics Committees, Research
MH  - Human Experimentation/*ethics/standards
MH  - Humans
MH  - *Practice Guidelines as Topic
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC8095856
MID - NIHMS1629011
EDAT- 2020/09/19 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/18 05:42
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/18 05:42 [entrez]
AID - science.abe1963 [pii]
AID - 10.1126/science.abe1963 [doi]
PST - ppublish
SO  - Science. 2020 Sep 25;369(6511):1570-1572. doi: 10.1126/science.abe1963. Epub 2020
      Sep 17.


PMID- 32943431
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 9
DP  - 2020 Sep
TI  - Institutionalising global health: a call for ethical reflection.
LID - e003353 [pii]
LID - 10.1136/bmjgh-2020-003353 [doi]
AB  - We describe a global health course and pedagogy that highlights the moral
      ambiguity and many ethical compromises that have emerged as the discipline has
      increasingly become institutionalised. We encourage students to reflect on how
      the oft-declared aspiration for global health equity still remains seriously
      contested as a normative and political matter, especially in settings like the
      USA. We further encourage students to reflect on how authentic concern for social
      justice, health equity and human rights are consistently undermined by
      unconscious and/or intentional fealty to standard operating procedures within
      hierarchical structures and systems. Lastly, we encourage students to openly
      question and critique the dominant socioeconomic and institutional paradigms that
      influence practitioner ways of thinking about global health. Our aim is to
      provide a learning space for students to at least imagine, if not demand, more
      daring modes of engagement. We also encourage our colleagues in the global health
      education community to be forthright that the process of institutionalising
      global health reliably favours our own interests more than those we claim to be
      most concerned about. If the ideal of global health is to build a bridge to human
      solidarity, we see substantial risk that current popularised approaches might
      never yield a structural tipping point.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sayeed, Sadath
AU  - Sayeed S
AUID- ORCID: 0000-0003-3967-8532
AD  - Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts,
      USA Sadath_Sayeed@hms.harvard.edu.
FAU - Taylor, Lauren
AU  - Taylor L
AD  - Population Health, NYU Grossman School of Medicine, New York, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *Global Health
MH  - Health Education
MH  - Human Rights
MH  - Humans
MH  - *Social Justice
PMC - PMC7500186
OTO - NOTNLM
OT  - *health education and promotion
OT  - *health policy
COIS- Competing interests: None declared.
EDAT- 2020/09/19 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/18 05:42
PHST- 2020/07/04 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/09/18 05:42 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-003353 [pii]
AID - 10.1136/bmjgh-2020-003353 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Sep;5(9). pii: bmjgh-2020-003353. doi:
      10.1136/bmjgh-2020-003353.


PMID- 32943297
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20210220
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 31
IP  - 10
DP  - 2020 Oct
TI  - COVID-19 Ethics: What Interventional Radiologists Need to Know.
PG  - 1720-1723
LID - S1051-0443(20)30579-0 [pii]
LID - 10.1016/j.jvir.2020.07.003 [doi]
FAU - Shnayder, Michelle M
AU  - Shnayder MM
AD  - Division of Vascular and Interventional Radiology, Department of Radiology,
      University of Michigan Health System, 1500 E. Medical Center Dr B1D502, Ann
      Arbor, MI 48109-5030. Electronic address: shnayder@med.umich.edu.
FAU - Keller, Eric J
AU  - Keller EJ
AD  - Division of Vascular and Interventional Radiology, Department of Radiology,
      Stanford University Medical Center, Stanford, California.
FAU - Makary, Mina S
AU  - Makary MS
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, The
      Ohio State University Wexner Medical Center, Columbus, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
SB  - IM
MH  - Attitude of Health Personnel
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Medical Futility/ethics
MH  - Moral Obligations
MH  - Occupational Health/ethics
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Radiology, Interventional/*ethics
MH  - SARS-CoV-2
MH  - Social Justice/ethics
PMC - PMC7489880
EDAT- 2020/09/19 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/09/18 05:37
PHST- 2020/06/29 00:00 [received]
PHST- 2020/07/05 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/09/18 05:37 [entrez]
AID - S1051-0443(20)30579-0 [pii]
AID - 10.1016/j.jvir.2020.07.003 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2020 Oct;31(10):1720-1723. doi: 10.1016/j.jvir.2020.07.003.
      Epub 2020 Sep 14.


PMID- 32943137
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1449-8944 (Electronic)
IS  - 0156-5788 (Linking)
VI  - 44
IP  - 5
DP  - 2020 Sep
TI  - Challenges in obtaining research ethics and governance approvals for an
      Australian national intersector, multisite audit study.
PG  - 799-805
LID - 10.1071/AH20022 [doi]
AB  - Objective The aim of this study was to describe timelines and challenges
      encountered in obtaining ethics and governance approvals for an Australian
      multicentre audit study involving 100 public (n=22) and private (n=78) sites from
      three health sectors and all eight Australian states and territories. Methods We 
      determined and compared the processes, documentation and number of business days 
      required to prepare applications and obtain research ethics and governance
      approvals. Results In total, the full ethics and governance process (calculated
      from the date the first application was started to the date the final approval
      was granted) took 203 business days (79% of the study timeline). Standard risk
      ethics applications (n=4) took a median of 17 business days (range 3-35 days) to 
      prepare and 32 business days (range 17-67 days) to be approved; expedited ethics 
      applications (n=4) took a median of 5 business days (range 1-20 days) to prepare 
      and 10 business days (range 1-44 days) to be approved. Governance approvals
      (n=23) took a median of 27 business days (range 4-63 days) to prepare and 20
      business days (range 4-61 days) to be approved. Challenges included the lack of a
      nationwide single-site ethical review process, the extensive time required to
      duplicate content across applications, variability in application requirements
      and submission systems, and contract negotiations. Conclusion Further
      improvements are needed to reduce duplication and increase the efficiency of
      Australian ethics and governance review processes. What is known about the topic?
      The process for obtaining ethics approval for multicentre research has been
      streamlined through the introduction of single-site ethics review. However, the
      process of gaining ethics and governance approvals for national multicentre
      research continues to be time-consuming, resource-intensive and duplicative. What
      does this paper add? This is the first study to examine the challenges of
      obtaining ethics and governance approvals for a non-interventional multicentre
      study involving three health sectors (hospital, aged care, general practice),
      both private and public services and all eight Australian jurisdictions. Previous
      examinations of Australian multicentre studies have considered only one health
      sector, focused on the public system and/or were not national in scope. What are 
      the implications for practitioners? Researchers and funders need to be aware of
      the considerable time, resources and costs involved in gaining research ethics
      and governance approvals for multicentre studies and include this in budgets and 
      study timelines. Policy makers and administrators of ethics and governance review
      processes must address barriers to conducting multicentre research in Australia.
FAU - Buck, Kimberly
AU  - Buck K
AD  - Advance Care Planning Australia, Austin Health, PO Box 5555, Heidelberg, Vic.
      3084, Australia. Email: linda.nolte@austin.org.au; and Corresponding author.
      Email: kim.buck@austin.org.au.
FAU - Nolte, Linda
AU  - Nolte L
AD  - Advance Care Planning Australia, Austin Health, PO Box 5555, Heidelberg, Vic.
      3084, Australia. Email: linda.nolte@austin.org.au.
FAU - Kelly, Helana
AU  - Kelly H
AD  - Advance Care Planning Australia, Austin Health, PO Box 5555, Heidelberg, Vic.
      3084, Australia. Email: linda.nolte@austin.org.au; and Present address: Peter
      MacCallum Cancer Centre, Locked Bag 1, A&#39;Beckett Street, Melbourne, Vic.
      3006, Australia. Email: helana.kelly@petermac.org.
FAU - Detering, Karen
AU  - Detering K
AD  - Advance Care Planning Australia, Austin Health, PO Box 5555, Heidelberg, Vic.
      3084, Australia. Email: linda.nolte@austin.org.au; and Faculty of Medicine,
      Dentistry and Health Sciences, The University of Melbourne, Parkville, Vic. 3010,
      Australia; and Present address: Faculty of Health, Arts and Innovation, Swinburne
      University of Technology, John Street, Hawthorn, Vic. 3121, Australia. Email:
      kdetering@swin.edu.au.
FAU - Sinclair, Craig
AU  - Sinclair C
AD  - Australian Research Council Centre of Excellence in Population Ageing Research,
      UNSW Sydney, 223 Anzac Parade, Kensington, NSW 2033, Australia; and Neuroscience 
      Research Australia (NeuRA), Barker Road, Randwick, NSW 2031, Australia; and
      Present address: School of Psychology, UNSW Sydney, High Street, Kensington, NSW 
      2052, Australia. Email: c.sinclair@unsw.edu.au.
FAU - White, Ben P
AU  - White BP
AD  - Australian Centre for Health Research Law, Faculty of Law, Queensland University 
      of Technology, GPO Box 2434, Brisbane, Qld 4001, Australia. Email:
      bp.white@qut.edu.au.
FAU - Sellars, Marcus
AU  - Sellars M
AD  - Advance Care Planning Australia, Austin Health, PO Box 5555, Heidelberg, Vic.
      3084, Australia. Email: linda.nolte@austin.org.au; and Kolling Institute,
      Northern Clinical School, Faculty of Medicine, The University of Sydney, 10
      Westbourne Street, St Leonards, Sydney, NSW 2064, Australia; and Present address:
      Australian Centre for Health Research Law, Faculty of Law, Queensland University 
      of Technology, GPO Box 2434, Brisbane, Qld 4001, Australia. Email:
      marcus.sellars@qut.edu.au.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Australia
TA  - Aust Health Rev
JT  - Australian health review : a publication of the Australian Hospital Association
JID - 8214381
MH  - Aged
MH  - Australia
MH  - *Ethical Review
MH  - *Ethics, Research
MH  - Hospitals
MH  - Humans
MH  - Research Personnel
EDAT- 2020/09/19 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/18 05:34
PHST- 2020/02/08 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/18 05:34 [entrez]
AID - AH20022 [pii]
AID - 10.1071/AH20022 [doi]
PST - ppublish
SO  - Aust Health Rev. 2020 Sep;44(5):799-805. doi: 10.1071/AH20022.


PMID- 32941859
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20211203
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 110
IP  - 6
DP  - 2020 Dec
TI  - Surgical Ethics: How I Teach It.
PG  - 1805-1808
LID - S0003-4975(20)31472-7 [pii]
LID - 10.1016/j.athoracsur.2020.07.010 [doi]
FAU - Devon, Karen
AU  - Devon K
AD  - Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
FAU - Sade, Robert M
AU  - Sade RM
AD  - Department of Surgery, Medical University of South Carolina, Charleston, South
      Carolina. Electronic address: sader@musc.edu.
LA  - eng
GR  - UL1 TR001450/TR/NCATS NIH HHS/United States
PT  - Editorial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
SB  - IM
MH  - Curriculum
MH  - Ethics, Medical/*education
MH  - General Surgery/*education/*ethics
MH  - Humans
MH  - *Internship and Residency
PMC - PMC7669666
MID - NIHMS1643462
EDAT- 2020/09/18 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/09/17 20:12
PHST- 2020/07/01 00:00 [received]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/09/17 20:12 [entrez]
AID - S0003-4975(20)31472-7 [pii]
AID - 10.1016/j.athoracsur.2020.07.010 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2020 Dec;110(6):1805-1808. doi:
      10.1016/j.athoracsur.2020.07.010. Epub 2020 Sep 14.


PMID- 32941509
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Do bank voles (Myodes glareolus) trapped in live and lethal traps show
      differences in tick burden?
PG  - e0239029
LID - 10.1371/journal.pone.0239029 [doi]
AB  - In studies assessing tick abundance, the use of live traps to capture and
      euthanize rodent hosts is a commonly used method to determine their burden.
      However, captive animals can experience debilitating or fatal capture stress as a
      result prior to collection. An alternative method is the use of lethal traps, but
      this can potentially lead to tick drop-off between the time of capture and
      collection. In this study, in order to determine whether subjecting animals to
      capture stress is inevitable, we tested the difference in sheep tick (Ixodes
      ricinus) larval burdens between bank voles (Myodes glareolus) captured alive and 
      euthanized, and lethally trapped bank voles. During 2017 and 2018, 1318 bank
      voles were captured using live (Ugglan Special no. 2) and lethal (Rapp2
      Mousetrap) traps during two consecutive years over three seasons in two locations
      in Norway. Voles captured alive would remain captive until euthanized, while
      lethally trapped voles were killed instantly upon capture. Log-linear models,
      accounting for overdispersion, were used to determine whether trap type was
      influencing observed tick burden. Bank voles captured in lethal traps carried
      5.7% more larvae compared to euthanized voles captured in live traps, but this
      difference was not significant (p = 0.420). Males were overall captured 2.7 times
      more frequently than females, and the sex ratio was equal in both trap types.
      This study shows that the use of lethal traps to determine tick burden of rodents
      is sufficiently reliable, without having to subject animals to potentially lethal
      stress, hereby reducing some ethical concerns of animal suffering and the results
      thereof, without compromising accuracy. Lethal trapping is also often more
      economical and practical, further favoring this collection method.
FAU - De Pelsmaeker, Nicolas
AU  - De Pelsmaeker N
AUID- ORCID: 0000-0002-5908-040X
AD  - Department of Nature, Health and Environment, University of Southeastern Norway, 
      Bo, Norway.
FAU - Korslund, Lars
AU  - Korslund L
AUID- ORCID: 0000-0001-9825-1294
AD  - Department of Natural Sciences, University of Agder, Kristiansand, Norway.
FAU - Steifetten, Oyvind
AU  - Steifetten O
AD  - Department of Nature, Health and Environment, University of Southeastern Norway, 
      Bo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Arvicolinae/*parasitology
MH  - Epidemiological Monitoring/*veterinary
MH  - Female
MH  - Ixodes/pathogenicity
MH  - Larva
MH  - Male
MH  - Norway
MH  - Tick Infestations/*epidemiology/veterinary
MH  - Ticks/pathogenicity
PMC - PMC7498064
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/18 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/09/17 17:17
PHST- 2020/06/08 00:00 [received]
PHST- 2020/08/30 00:00 [accepted]
PHST- 2020/09/17 17:17 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.1371/journal.pone.0239029 [doi]
AID - PONE-D-20-16817 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 17;15(9):e0239029. doi: 10.1371/journal.pone.0239029.
      eCollection 2020.


PMID- 32941434
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20201027
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 14
IP  - 9
DP  - 2020 Sep
TI  - A case for adoption of continuous albendazole treatment regimen for human
      echinococcal infections.
PG  - e0008566
LID - 10.1371/journal.pntd.0008566 [doi]
AB  - Cystic (CE) and alveolar (AE) echinococcosis are chronic, neglected parasitic
      diseases burdened by high morbidity and, for AE, by high mortality, if left
      untreated. CE and AE have a widespread distribution, including Europe.
      Albendazole (ABZ), a broad-spectrum benzimidazole drug widely used to treat
      parasitic infections, is the drug of choice for the management of CE and AE, and 
      is parasitostatic on echinococcal metacestodes. In Europe, ABZ is licensed for
      interrupted "cyclic" treatment, for a maximum of 3 cycles. However, better
      efficacy with no increased side effects has been shown when the drug is
      administered continuously and for longer periods. Current international
      recommendations, on the basis of clinical, pharmacological, and biological
      studies, recommend continuous administration of ABZ for months to years for the
      treatment of CE and AE, and this schedule has been widely in use for the past 20 
      years. However, in Europe this internationally recommended schedule, with the
      exception of France, is technically "off-label", and, as such, requires an
      informed consent by the patient and, in some countries, even precludes the
      reimbursement of the drug cost. Adding to the very high cost of the drug,
      frequent "out-of-stock" situation, and packaging format impractical for long
      therapies, these conditions put patients with CE and AE regularly at risk of
      treatment discontinuation and disease progression. European regulations envisage 
      variations to marketing authorization, but postauthorization studies should be
      carried out by the holder of the license of the drug, in the form of randomized
      controlled trials. While such studies do not seem feasible and would probably not
      be ethically justified for CE and AE, European regulations envisage other
      possibilities in particular situations, which apply to CE and AE, but there is
      limited interest to invest in this perspective. We urge a coordination between
      stakeholders to find effective and feasible ways to take action to revise the
      benzimidazole dosage regimens for CE and AE and to ensure a fair, regular, and
      easy access to the appropriate treatment to those suffering from these serious
      diseases.
FAU - Tamarozzi, Francesca
AU  - Tamarozzi F
AUID- ORCID: 0000-0003-0478-3914
AD  - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Sacro Cuore Don
      Calabria Hospital, Department of Infectious-Tropical Diseases and Microbiology,
      Negrar, Verona, Italy.
FAU - Horton, John
AU  - Horton J
AUID- ORCID: 0000-0001-7047-5106
AD  - Tropical Projects, Hitchin, United Kingdom.
FAU - Muhtarov, Marin
AU  - Muhtarov M
AUID- ORCID: 0000-0002-9426-1791
AD  - Multi-Profile Hospital for Active Treatment "Kardzhali", Gastroenterology Ward,
      Khardzhali, Bulgaria.
FAU - Ramharter, Michael
AU  - Ramharter M
AUID- ORCID: 0000-0002-9259-1885
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, 
      Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg,
      Germany.
FAU - Siles-Lucas, Mar
AU  - Siles-Lucas M
AD  - Instituto de Recursos Naturales y Agrobiologia de Salamanca (IRNASA), Consejo
      Superior de Investigaciones Cientificas (CSIC), Parasitology Group, Salamanca,
      Spain.
FAU - Gruener, Beate
AU  - Gruener B
AUID- ORCID: 0000-0001-6669-3741
AD  - Division of Infectious Diseases, Department of Internal Medicine III, University 
      Hospital Ulm, Ulm, Germany.
FAU - Vuitton, Dominique A
AU  - Vuitton DA
AUID- ORCID: 0000-0003-0043-3896
AD  - French National Reference Center for Echinococcosis, Besancon University
      Hospital, University Bourgogne Franche-Comte, Besancon, France.
FAU - Bresson-Hadni, Solange
AU  - Bresson-Hadni S
AD  - French National Reference Center for Echinococcosis, Besancon University
      Hospital, University Bourgogne Franche-Comte, Besancon, France.
AD  - Hepato-Gastroenterology and Tropical Medicine Units, University Hospital, Geneva,
      Switzerland.
FAU - Manciulli, Tommaso
AU  - Manciulli T
AUID- ORCID: 0000-0002-6846-8000
AD  - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo Hospital
      Fundation-Unit of Infectious and Tropical Diseases, Pavia, Italy.
AD  - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University
      of Pavia, Pavia, Italy.
FAU - Brunetti, Enrico
AU  - Brunetti E
AD  - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo Hospital
      Fundation-Unit of Infectious and Tropical Diseases, Pavia, Italy.
AD  - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University
      of Pavia, Pavia, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Anthelmintics)
RN  - F4216019LN (Albendazole)
SB  - IM
MH  - Albendazole/*administration & dosage
MH  - Animals
MH  - Anthelmintics/*administration & dosage
MH  - Echinococcosis/*drug therapy
MH  - Echinococcus/drug effects/physiology
MH  - Humans
PMC - PMC7498015
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/18 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/09/17 17:17
PHST- 2020/09/17 17:17 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
AID - 10.1371/journal.pntd.0008566 [doi]
AID - PNTD-D-20-01015 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2020 Sep 17;14(9):e0008566. doi:
      10.1371/journal.pntd.0008566. eCollection 2020 Sep.


PMID- 32940980
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 164
DP  - 2020 Aug 20
TI  - [A nudge in the right direction? Recognition and use of nudging in the medical
      profession].
LID - D4755 [pii]
AB  - 'Nudging' is the subtle stimulation of desirable behaviour based on insights from
      behavioural psychology. 'Nudges' can be used to change patient behaviour; they
      can, however, also be used on medical professionals. We applied a literature
      study to map this form of behavioural influence among medical professionals.
      Different categories can be defined, such as 'reminders' in electronic
      prescription systems and making differences in prescription behaviours between
      doctors visible. Some of these interventions are not labelled 'nudges', which is 
      problematic because there is ongoing debate about whether certain forms of
      behavioural influence are ethically responsible. Nudging has the potential to
      change behaviour, but must be applied with attention to contextual factors such
      as the medical issue in question, the goal of influencing and the type of
      professional. I advise transparency about the use of nudges and checking whether 
      there is support among medical professionals before using them.
FAU - Nagtegaal, R
AU  - Nagtegaal R
AD  - Universiteit Utrecht, Faculteit Recht, Economie, Bestuur en Organisatie, afd.
      Bestuurs- en Organisatiewetenschap (USBO), Utrecht.
AD  - Contact: R. Nagtegaal (r.nagtegaal@uu.nl).
LA  - dut
PT  - Journal Article
TT  - Duwtjes in de goede richting?
DEP - 20200820
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
SB  - IM
MH  - Behavior Control/*methods
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Motivation
MH  - Workplace/*psychology
EDAT- 2020/09/18 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/09/17 12:20
PHST- 2020/09/17 12:20 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - epublish
SO  - Ned Tijdschr Geneeskd. 2020 Aug 20;164.


PMID- 32940567
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20211002
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Perspectives on Precision Medicine in a Tribally Managed Primary Care Setting.
PG  - 246-256
LID - 10.1080/23294515.2020.1817172 [doi]
AB  - BACKGROUND: Precision medicine (PM) research and clinical application is moving
      forward at a rapid pace. To ensure ethical inclusion of all populations in PM,
      in-depth understanding of diverse communities' views of PM research and PM
      implementation is necessary. METHODS: Semi-structured interviews were conducted
      to explore perspectives on PM in a tribally managed healthcare organization.
      Thematic analysis was used to analyze data from 46 interviews. RESULTS:
      Participants described gains in diagnostic efficiency, risk identification for
      preventable disease, and the advancement of population-specific biomedical
      research as key benefits of PM. Concerns expressed related to privacy risks
      associated with data-sharing, overpromising on PM, and managing patient
      expectations related to PM. Stakeholders encouraged PM implementation to be
      preceded by health education activities that leverage a range of communication
      strategies. CONCLUSION: Perspectives described in this study may aid in and
      should be considered prior to implementation of PM in this and other healthcare
      systems, especially those serving diverse populations.
FAU - Beans, Julie A
AU  - Beans JA
AUID- ORCID: 0000-0003-4363-9763
AD  - Southcentral Foundation, Anchorage, Alaska, USA.
FAU - Woodbury, R Brian
AU  - Woodbury RB
AD  - Southcentral Foundation, Anchorage, Alaska, USA.
FAU - Wark, Kyle A
AU  - Wark KA
AD  - Southcentral Foundation, Anchorage, Alaska, USA.
FAU - Hiratsuka, Vanessa Y
AU  - Hiratsuka VY
AD  - Southcentral Foundation, Anchorage, Alaska, USA.
FAU - Spicer, Paul
AU  - Spicer P
AD  - Department of Anthropology, University of Oklahoma, Norman, Oklahoma, USA.
LA  - eng
GR  - R01 HG009500/HG/NHGRI NIH HHS/United States
GR  - RM1 HG009042/HG/NHGRI NIH HHS/United States
GR  - S06 GM123545/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200917
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Adult
MH  - Alaska
MH  - *Attitude
MH  - *Bioethical Issues
MH  - Biomedical Research/ethics
MH  - Communication
MH  - Delivery of Health Care/*ethnology
MH  - Female
MH  - Health Services Accessibility/*ethics
MH  - Health Services, Indigenous
MH  - Humans
MH  - *Indians, North American
MH  - Information Dissemination
MH  - Male
MH  - Precision Medicine/*ethics
MH  - Primary Health Care/*ethics
MH  - Privacy
MH  - Qualitative Research
MH  - Stakeholder Participation
PMC - PMC7606746
MID - NIHMS1638033
OTO - NOTNLM
OT  - *Alaska Native
OT  - *American Indian
OT  - *Precision medicine
OT  - *community views
OT  - *healthcare system
EDAT- 2020/09/18 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/09/17 12:15
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/09/17 12:15 [entrez]
AID - 10.1080/23294515.2020.1817172 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Oct-Dec;11(4):246-256. doi:
      10.1080/23294515.2020.1817172. Epub 2020 Sep 17.


PMID- 32940565
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Ethics Consultations at a Major Academic Medical Center: A Retrospective,
      Longitudinal Analysis.
PG  - 275-286
LID - 10.1080/23294515.2020.1818879 [doi]
AB  - BACKGROUND: Evidence suggests that healthcare professionals feel inadequately
      equipped to manage ethical issues that arise, resulting in ethics-related stress.
      Clinical ethics consultation, and preventive ethics strategies, have been
      described as ways to decrease ethics-related stress, however information is
      limited regarding specific sources of ethical concern. METHODS: The purpose of
      this study was to conduct a retrospective, longitudinal analysis of a
      comprehensive database of ethics consultations, at a major academic medical
      center in the Northeast United States in order to: (1) Discern major sources of
      ethical concern, (2) Evaluate how these have changed over time in their content
      and frequency, (2a) Evaluate trends in nurse versus physician-initiated requests.
      RESULTS: Six major reasons for requesting an ethics consult were identified:
      Conflict Over Goals of Care, Decisional Capacity, Withholding/Withdrawing
      Treatment, Proxy Decision Making, Communication, and Behavior. Themes were
      operationally defined by the study team. An increase in requests related to
      Conflict Over Goals of Care (beta = 0.7, 95% CI = 0.2-1.2, p = 0.008) and
      Discharge Planning (beta = 2.2, 95% CI = 1.4-3.1, p < 0.001), and a trend toward 
      increased number of consults for behavior-related consults from nurses (median
      6.5% versus 2.3%, p = 0.07) were noted. Nurses were significantly more likely
      than physicians to request ethics consultation for Communication (yearly median
      10.4% of cases vs 1.3% of cases, p = 0.01), whereas, physicians were
      significantly more likely to request ethics consultation for Proxy
      Decision-Making than nurses (yearly median 26.0% of cases vs 13.0%, p = 0.005)
      and for Decision-Making Capacity (yearly median 7.5% of cases vs 4.0%, p = 0.04).
      CONCLUSIONS: This study revealed several noteworthy and previously unidentified
      trends in consultation requests, and several important distinctions between the
      sources of ethical concern nurses identify versus those physicians identify.
      These findings can be used to develop future preventive-ethics frameworks.
FAU - Milliken, Aimee
AU  - Milliken A
AUID- ORCID: 0000-0001-9077-1404
AD  - Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Courtwright, Andrew
AU  - Courtwright A
AD  - Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Grace, Pamela
AU  - Grace P
AD  - Boston College, Connell School of Nursing, Chestnut Hill, Massachusetts, USA.
FAU - Eagan-Bengston, Elizabeth
AU  - Eagan-Bengston E
AD  - Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Visser, Monique
AU  - Visser M
AD  - Alberta Health Services, Alberta, Canada.
FAU - Jurchak, Martha
AU  - Jurchak M
AD  - Brigham and Women's Hospital, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200917
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Academic Medical Centers/*ethics
MH  - Databases, Factual
MH  - Ethics Committees, Clinical
MH  - *Ethics Consultation/trends
MH  - Ethics, Medical
MH  - Ethics, Nursing
MH  - Humans
MH  - Longitudinal Studies
MH  - *Motivation
MH  - New England
MH  - *Nurses/trends
MH  - *Occupational Stress
MH  - *Physicians/trends
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *BIOETHICS
OT  - *Ethics consultation
OT  - *clinical ethics
OT  - *ethics committees
OT  - *preventive ethics
EDAT- 2020/09/18 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/09/17 12:15
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/09/17 12:15 [entrez]
AID - 10.1080/23294515.2020.1818879 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Oct-Dec;11(4):275-286. doi:
      10.1080/23294515.2020.1818879. Epub 2020 Sep 17.


PMID- 32940156
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1552-7409 (Electronic)
IS  - 0894-3184 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Oct
TI  - Living the Art of Nursing: Lessons From a Pandemic.
PG  - 297-298
LID - 10.1177/0894318420943135 [doi]
AB  - Living the art of nursing during the challenging times of a pandemic has profound
      implications for the discipline of nursing. Opportunities and limitations coexist
      with persons who shelter in place while others continue to practice amid personal
      risk in institutions where vital healthcare services are provided. This article
      illustrates potential lessons to be learned for future nurse practice and the
      ethos or straight-thinking implications for living quality during a global health
      crisis.
FAU - Milton, Constance L
AU  - Milton CL
AUID- ORCID: 0000-0002-5848-6651
AD  - School of Nursing, Azusa Pacific University, Azusa, CA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurs Sci Q
JT  - Nursing science quarterly
JID - 8805022
MH  - *Humanism
MH  - Humans
MH  - Nursing/*methods/trends
MH  - Pandemics/*prevention & control
OTO - NOTNLM
OT  - *art of nursing
OT  - *ethics
OT  - *humanbecoming
OT  - *pandemic
EDAT- 2020/09/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/09/17 08:45
PHST- 2020/09/17 08:45 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.1177/0894318420943135 [doi]
PST - ppublish
SO  - Nurs Sci Q. 2020 Oct;33(4):297-298. doi: 10.1177/0894318420943135.


PMID- 32940119
OWN - NLM
STAT- Publisher
LR  - 20220422
IS  - 1748-3115 (Electronic)
IS  - 1748-3107 (Linking)
DP  - 2020 Sep 17
TI  - "Re-identifying yourself": a qualitative study of veteran views on implantable
      BCI for mobility and communication in ALS.
PG  - 1-8
LID - 10.1080/17483107.2020.1817991 [doi]
AB  - OBJECTIVES: Brain-computer interface (BCI) technology to assist with mobility and
      communication is an active area of research in amyotrophic lateral sclerosis
      (ALS). Implantable BCI offers promise for individuals with severe disease, such
      as locked-in syndrome, but also raises important ethical issues. We undertook
      in-depth qualitative interviews with ALS patients from a Veterans Administration 
      hospital ALS multi-disciplinary clinic and explored their perspectives on issues 
      of identity, privacy, enhancement, informed consent, and responsibility related
      to implantable BCI. METHODS: Semi-structured interviews were conducted with
      sixteen (n = 16) individuals, and transcripts were analysed using a modified
      grounded theory approach. RESULTS: Emergent themes included: (1) attitudes
      towards BCI were characterised by fear, hope, and hesitation about adoption of
      BCI technology; (2) analogies to other technologies were a useful tool in
      understanding and communicating opinions about ethical issues in BCI; (3)
      concerns about potentially socially stigmatising effects of BCI and the burden of
      adjustment to new therapeutic devices were important considerations to be weighed
      against the potential functional benefit of BCI use; (4) therapeutic
      decision-making in ALS often intimately involves loved ones; and (5) prospective 
      decision-making about BCI was significantly affected by weighing the timing of
      the intervention with the progression of illness. CONCLUSION: The interest in BCI
      and views on ethical issues raised by BCI is moderated by the experience of
      living with ALS. The findings from this study can help guide the development of
      implantable BCI technology for persons with ALS.Implications for
      rehabilitationLoved ones will play crucial roles in helping patients think
      through the possible benefits and burdens of getting a BCI device.Providers
      should consider how the ideal timing for getting an implantable BCI device will
      vary based on the priorities of persons with ALS and their disease stage.Concerns
      about social stigma, burden of adjustment, and the desire to maximise time left
      with loved ones may outweigh the potential functional benefits of BCI devices for
      some persons with ALS.
FAU - Versalovic, Erika
AU  - Versalovic E
AUID- ORCID: https://orcid.org/0000-0002-5354-7777
AD  - Department of Philosophy, University of Washington, Seattle, WA, USA.
FAU - Diamond, Melissa
AU  - Diamond M
AD  - Department of Philosophy, University of Washington, Seattle, WA, USA.
FAU - Klein, Eran
AU  - Klein E
AUID- ORCID: https://orcid.org/0000-0002-0132-5777
AD  - Department of Philosophy, University of Washington, Seattle, WA, USA.
AD  - Department of Neurology, Oregon Health and Science University, Portland, OR, USA.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - England
TA  - Disabil Rehabil Assist Technol
JT  - Disability and rehabilitation. Assistive technology
JID - 101255937
SB  - IM
OTO - NOTNLM
OT  - Amyotrophic lateral sclerosis
OT  - assistive technology
OT  - brain-computer interface
OT  - decision-making
OT  - qualitative study
EDAT- 2020/09/18 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/17 08:44
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/09/17 08:44 [entrez]
AID - 10.1080/17483107.2020.1817991 [doi]
PST - aheadofprint
SO  - Disabil Rehabil Assist Technol. 2020 Sep 17:1-8. doi:
      10.1080/17483107.2020.1817991.


PMID- 32939662
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20210110
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 11
DP  - 2020 Nov
TI  - Navigating assisted reproduction treatment in the time of COVID-19: concerns and 
      considerations.
PG  - 2663-2668
LID - 10.1007/s10815-020-01942-z [doi]
AB  - The COVID-19 pandemic has fueled numerous debates in the field of assisted
      reproductive technology (ART) as the effect of SARS-CoV-2 on pregnancy and
      infancy is still considered uncharted territory. Various theses and
      recommendations on what optimal practice is have emerged, as evidenced by
      surveys, webinars, and recent publications. ART specialists are faced with
      dilemmas in light of the lack of concrete scientific evidence required to pave
      the way towards future safe practice. Meanwhile, infertile couples were similarly
      left in limbo unable to exercise their reproductive autonomy unlike fertile
      couples-where achieving a pregnancy via natural conception is a matter of
      decision. ART treatment being classified as non-essential has only recently
      re-started, facing new challenges while enabling pregnancy at a time of
      uncertainty. This article highlights matters of bioethical nature to be
      considered in the ART world at the time of COVID-19 while presenting an
      all-inclusive critique of the current status. When pursuing pregnancy through IVF
      treatment during the pandemic, distancing and caution have the lead role in an
      effort to defend the health of the intended parents and future children. To
      promote patient autonomy along with our ethical, moral, and legal duty towards
      our patients, emphasis should be given on ascertaining shared decision-making,
      and ensuring that an appropriate all-inclusive informed consent is signed prior
      to initiating any IVF treatment.
FAU - Simopoulou, Mara
AU  - Simopoulou M
AUID- ORCID: http://orcid.org/0000-0002-1000-9100
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Mikras Asias, 11527, Athens, Greece. marasimopoulou@hotmail.com.
AD  - Assisted Conception Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion
      Hospital, Medical School, National and Kapodistrian University of Athens,
      Vasilissis Sofias, 11528, Athens, Greece. marasimopoulou@hotmail.com.
FAU - Sfakianoudis, Konstantinos
AU  - Sfakianoudis K
AD  - Centre for Human Reproduction, Genesis Athens Clinic, Papanikoli, 15232, Athens, 
      Greece.
FAU - Giannelou, Polina
AU  - Giannelou P
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Mikras Asias, 11527, Athens, Greece.
AD  - Centre for Human Reproduction, Genesis Athens Clinic, Papanikoli, 15232, Athens, 
      Greece.
FAU - Rapani, Anna
AU  - Rapani A
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Mikras Asias, 11527, Athens, Greece.
AD  - Assisted Conception Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion
      Hospital, Medical School, National and Kapodistrian University of Athens,
      Vasilissis Sofias, 11528, Athens, Greece.
FAU - Siristatidis, Charalampos
AU  - Siristatidis C
AD  - Assisted Conception Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion
      Hospital, Medical School, National and Kapodistrian University of Athens,
      Vasilissis Sofias, 11528, Athens, Greece.
FAU - Bakas, Panagiotis
AU  - Bakas P
AD  - Assisted Conception Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion
      Hospital, Medical School, National and Kapodistrian University of Athens,
      Vasilissis Sofias, 11528, Athens, Greece.
FAU - Vlahos, Nikolaos
AU  - Vlahos N
AD  - Assisted Conception Unit, 2nd Department of Obstetrics and Gynecology, Aretaieion
      Hospital, Medical School, National and Kapodistrian University of Athens,
      Vasilissis Sofias, 11528, Athens, Greece.
FAU - Pantos, Konstantinos
AU  - Pantos K
AD  - Centre for Human Reproduction, Genesis Athens Clinic, Papanikoli, 15232, Athens, 
      Greece.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Female
MH  - *Health Services Accessibility
MH  - Humans
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - *Reproductive Techniques, Assisted
PMC - PMC7494248
OTO - NOTNLM
OT  - Professional ethics
OT  - Public health
OT  - Reproductive technologies
OT  - Right to health care
EDAT- 2020/09/18 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/09/17 05:46
PHST- 2020/08/03 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/09/17 05:46 [entrez]
AID - 10.1007/s10815-020-01942-z [doi]
AID - 10.1007/s10815-020-01942-z [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Nov;37(11):2663-2668. doi:
      10.1007/s10815-020-01942-z. Epub 2020 Sep 16.


PMID- 32939616
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Corporate Social Responsibility Practices of Colombian Companies as Perceived by 
      Industrial Engineering Students.
PG  - 3183-3215
LID - 10.1007/s11948-020-00264-8 [doi]
AB  - This work describes the perceptions that Industrial Engineering students have
      regarding Colombian firms' corporate social responsibility (CSR) practices. It
      also explores the incidence of gender, academic level, work experience and
      entrepreneurial intention on students' vision. A survey with 70 CSR practices was
      designed based on previous research. Practices were grouped in ten dimensions:
      shareholders, customers, employees, suppliers, stakeholders, ethics, environment,
      legal, human rights and society. A representative sample of 142 students was
      used. Results show that students perceive a higher commitment of Colombian
      companies with the shareholders dimension, while a lower with the society, ethics
      and environmental CSR practices. Work experience and entrepreneurial intention
      are the only variables affecting the identified perceptions. Thus, as they gain
      experience, their perceptions become more favorable. On the other hand, potential
      entrepreneurs have a more critical view on the companies' commitment.
      Additionally, the fact that the academic level does not impact students'
      perceptions constitutes a challenge for the academic program, since it is
      expected that this will affect the vision of future engineers. This is the first 
      study that evaluates perceptions of Industrial Engineering students, who, given
      their object of study, will be responsible for designing and managing production 
      processes in organizations of the future. Results respond to a specific context
      (students at a Colombian public university), therefore further research to
      explore the subject is recommended.
FAU - Morales-Gualdron, Silvia Teresa
AU  - Morales-Gualdron ST
AUID- ORCID: 0000-0003-1784-5176
AD  - Grupo de Investigacion Ingenieria y Sociedad, Departamento de Ingenieria
      Industrial, Facultad de Ingenieria, Universidad de Antioquia, Medellin, Colombia.
      silvia.morales@udea.edu.co.
FAU - La Rotta Forero, Daniel Andres
AU  - La Rotta Forero DA
AUID- ORCID: 0000-0001-7457-5681
AD  - Grupo de Investigacion Ingenieria y Sociedad, Departamento de Ingenieria
      Industrial, Facultad de Ingenieria, Universidad de Antioquia, Medellin, Colombia.
FAU - Arias Vergara, Juliana Andrea
AU  - Arias Vergara JA
AD  - Grupo de Investigacion Ingenieria y Sociedad, Departamento de Ingenieria
      Industrial, Facultad de Ingenieria, Universidad de Antioquia, Medellin, Colombia.
FAU - Montoya Ardila, Juliana
AU  - Montoya Ardila J
AD  - Grupo de Investigacion Ingenieria y Sociedad, Departamento de Ingenieria
      Industrial, Facultad de Ingenieria, Universidad de Antioquia, Medellin, Colombia.
FAU - Herrera Banol, Carolina
AU  - Herrera Banol C
AD  - Grupo de Investigacion Ingenieria y Sociedad, Departamento de Ingenieria
      Industrial, Facultad de Ingenieria, Universidad de Antioquia, Medellin, Colombia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200916
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Colombia
MH  - Engineering
MH  - Humans
MH  - *Organizations
MH  - *Social Responsibility
MH  - Students
OTO - NOTNLM
OT  - *Colombia
OT  - *Corporate social responsibility
OT  - *Entrepreneurial intention
OT  - *Industrial engineering
OT  - *Perceptions
EDAT- 2020/09/18 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/17 05:46
PHST- 2019/11/20 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/17 05:46 [entrez]
AID - 10.1007/s11948-020-00264-8 [doi]
AID - 10.1007/s11948-020-00264-8 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3183-3215. doi: 10.1007/s11948-020-00264-8. Epub
      2020 Sep 16.


PMID- 32939198
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1450-1147 (Print)
IS  - 1450-1147 (Linking)
VI  - 19
IP  - 2
DP  - 2020 Apr-Jun
TI  - Less influence of body mass index on bone mineral density of radius as compared
      to proximal femur: Possible role in the diagnosis of osteoporosis.
PG  - 118-123
LID - 10.4103/wjnm.WJNM_39_19 [doi]
AB  - It has been shown that body mass index (BMI) and obesity may affect the mineral
      density of bones, regionally on weight-bearing bones or systemically through
      hormones and cytokines. The objective of this study was to evaluate the effect of
      BMI on bone mineral density (BMD) of the radius. In this cross-sectional study,
      260 patients, 233 postmenopausal women and 27 men over 50, were included who
      underwent a bone densitometry scanning using dual-energy X-ray absorptiometry
      after obtaining an informed consent. The scanning was performed in three areas
      (i.e., spine, proximal femur, and radius), then densitometric data (BMD, T- and
      Z-score) were extracted. Regression analysis was performed to evaluate the effect
      of independent variables of age, gender, and BMI on the BMD of the above regions.
      By grouping the patients in two categories (BMI <25 as normal or underweight and 
      BMI >25 as overweight and obese), the discordance in the diagnosis following the 
      inclusion of radius into interpretation (diagnosis based on 2 vs. 3 areas), was
      assessed by an agreement test. The study is approved by the ethics committee of
      the university. Of 260 participants in the present study, mean and standard
      deviation for age were 61.48 +/- 8.95 for all patients, 65.81 +/- 10.59 for male 
      and 60.98 +/- 8.62 for women. An increasing effect of BMI was found to be
      statistically significant in weight-bearing areas (total femur and femoral neck) 
      and BMI increase was not associated with increased BMD of radius. An agreement
      test between two diagnoses is used that showed a discordance of 28.5% in
      diagnosis (diagnosis based on 2 vs. 3 areas) with a kappa coefficient of 0.547 (P
      = 0.001). In total, 25.4% was minor discordance and 3.1% was major discordance.
      Based on the results of this study, it is concluded that the BMI is not
      associated with increased BMD in bones that are not weight bearing, such as
      radius. Therefore, it may be preferred to include the densitometric data of
      radius into the diagnosis.
CI  - Copyright: (c) 2020 World Journal of Nuclear Medicine.
FAU - Asli, Isa Neshandar
AU  - Asli IN
AD  - Department of Nuclear Medicine, Taleghani Educational Hospital, School of
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Sheikhnezami, Mahsa
AU  - Sheikhnezami M
AD  - Department of Nuclear Medicine, Taleghani Educational Hospital, School of
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Qutbi, Mohsen
AU  - Qutbi M
AD  - Department of Nuclear Medicine, Taleghani Educational Hospital, School of
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Farsad, Faraneh
AU  - Farsad F
AD  - Department of Rheumatology, Loghman Educational Hospital, School of Medicine,
      Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Asli, Sadaf Neshandar
AU  - Asli SN
AD  - Department of Nuclear Medicine, Taleghani Educational Hospital, School of
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Ranji, Shahla
AU  - Ranji S
AD  - Department of Nuclear Medicine, Taleghani Educational Hospital, School of
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Karami, Maryam
AU  - Karami M
AD  - Department of Nuclear Medicine, Taleghani Educational Hospital, School of
      Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200129
PL  - Germany
TA  - World J Nucl Med
JT  - World journal of nuclear medicine
JID - 101286955
PMC - PMC7478315
OTO - NOTNLM
OT  - Body mass index
OT  - bone mineral density
OT  - obesity
OT  - osteoporosis
OT  - radius
COIS- There are no conflicts of interest.
EDAT- 2020/09/18 06:00
MHDA- 2020/09/18 06:01
CRDT- 2020/09/17 05:44
PHST- 2019/05/22 00:00 [received]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2020/09/17 05:44 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/09/18 06:01 [medline]
AID - 10.4103/wjnm.WJNM_39_19 [doi]
AID - WJNM-19-118 [pii]
PST - epublish
SO  - World J Nucl Med. 2020 Jan 29;19(2):118-123. doi: 10.4103/wjnm.WJNM_39_19.
      eCollection 2020 Apr-Jun.


PMID- 32939074
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210216
IS  - 1471-0064 (Electronic)
IS  - 1471-0056 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Nov
TI  - African ancient DNA research requires robust ethics and permission protocols.
PG  - 645-647
LID - 10.1038/s41576-020-00285-w [doi]
FAU - Gibbon, Victoria E
AU  - Gibbon VE
AUID- ORCID: http://orcid.org/0000-0001-7875-3297
AD  - Division of Clinical Anatomy and Biological Anthropology, Department of Human
      Biology, University of Cape Town, Observatory, Cape Town, South Africa.
      victoria.gibbon@uct.ac.za.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nat Rev Genet
JT  - Nature reviews. Genetics
JID - 100962779
RN  - 0 (DNA, Ancient)
SB  - IM
MH  - Africa
MH  - Archaeology/*ethics
MH  - Body Remains
MH  - *DNA, Ancient
MH  - Genetic Research/*ethics
MH  - Genomics/*ethics
MH  - Humans
MH  - Informed Consent
EDAT- 2020/09/18 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/09/17 05:43
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
PHST- 2020/09/17 05:43 [entrez]
AID - 10.1038/s41576-020-00285-w [doi]
AID - 10.1038/s41576-020-00285-w [pii]
PST - ppublish
SO  - Nat Rev Genet. 2020 Nov;21(11):645-647. doi: 10.1038/s41576-020-00285-w.


PMID- 32938644
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1943-3662 (Electronic)
IS  - 1093-6793 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - Laws and Ethics Related to Emotional Support Animals.
PG  - 509-518
LID - 10.29158/JAAPL.200047-20 [doi]
AB  - The use of animals for therapeutic benefit is well-established. For example, for 
      individuals with a disability such as blindness, trained service dogs can enhance
      the ability to live independently and participate fully in society. An emotional 
      support animal (ESA) is an untrained animal that is used to support a person
      disabled by an emotional or mental disorder. For an animal to qualify as an ESA, 
      a mental health or medical professional needs to write a letter saying that the
      animal is needed for the mental health of the person with the disability. This
      article describes the legal framework for service animals and ESAs, as well as
      the differences between them. We summarize information about the Americans with
      Disabilities Act, the Fair Housing Act, the Air Carrier Access Act, and other
      laws governing an individual's right to be accompanied by a support animal. We
      also summarize the clinical research on ESAs and argue that, although there are
      few studies on the clinical effectiveness of ESAs, a broader body of research
      indicates that animals may have positive clinical effects on medical and mental
      illness. Finally, we suggest there is a need for further research and provider
      education on ESAs.
CI  - (c) 2020 American Academy of Psychiatry and the Law.
FAU - Carroll, Joshua D
AU  - Carroll JD
AD  - Dr. Carroll is Assistant Clinical Professor of Psychiatry, Department of
      Psychiatry, University of California San Francisco, San Francisco, CA. Dr.
      Mohlenhoff is Director of Pharmacotherapy, San Francisco Veterans Affairs Medical
      Center San Francisco, San Francisco, CA. Dr. Kersten is Resident Physician, West 
      Suburban Medical Center, Oak Park, IL. Dr. McNiel is Professor of Clinical
      Psychology, Department of Psychiatry, University of California San Francisco, San
      Francisco, CA. Dr. Binder is Professor of Psychiatry and Director, Psychiatry and
      the Law Program, University of California San Francisco, San Francisco, CA.
      joshuacarroll.md@icloud.com.
FAU - Mohlenhoff, Brian S
AU  - Mohlenhoff BS
AD  - Dr. Carroll is Assistant Clinical Professor of Psychiatry, Department of
      Psychiatry, University of California San Francisco, San Francisco, CA. Dr.
      Mohlenhoff is Director of Pharmacotherapy, San Francisco Veterans Affairs Medical
      Center San Francisco, San Francisco, CA. Dr. Kersten is Resident Physician, West 
      Suburban Medical Center, Oak Park, IL. Dr. McNiel is Professor of Clinical
      Psychology, Department of Psychiatry, University of California San Francisco, San
      Francisco, CA. Dr. Binder is Professor of Psychiatry and Director, Psychiatry and
      the Law Program, University of California San Francisco, San Francisco, CA.
FAU - Kersten, Charlie M
AU  - Kersten CM
AD  - Dr. Carroll is Assistant Clinical Professor of Psychiatry, Department of
      Psychiatry, University of California San Francisco, San Francisco, CA. Dr.
      Mohlenhoff is Director of Pharmacotherapy, San Francisco Veterans Affairs Medical
      Center San Francisco, San Francisco, CA. Dr. Kersten is Resident Physician, West 
      Suburban Medical Center, Oak Park, IL. Dr. McNiel is Professor of Clinical
      Psychology, Department of Psychiatry, University of California San Francisco, San
      Francisco, CA. Dr. Binder is Professor of Psychiatry and Director, Psychiatry and
      the Law Program, University of California San Francisco, San Francisco, CA.
FAU - McNiel, Dale E
AU  - McNiel DE
AD  - Dr. Carroll is Assistant Clinical Professor of Psychiatry, Department of
      Psychiatry, University of California San Francisco, San Francisco, CA. Dr.
      Mohlenhoff is Director of Pharmacotherapy, San Francisco Veterans Affairs Medical
      Center San Francisco, San Francisco, CA. Dr. Kersten is Resident Physician, West 
      Suburban Medical Center, Oak Park, IL. Dr. McNiel is Professor of Clinical
      Psychology, Department of Psychiatry, University of California San Francisco, San
      Francisco, CA. Dr. Binder is Professor of Psychiatry and Director, Psychiatry and
      the Law Program, University of California San Francisco, San Francisco, CA.
FAU - Binder, Renee L
AU  - Binder RL
AD  - Dr. Carroll is Assistant Clinical Professor of Psychiatry, Department of
      Psychiatry, University of California San Francisco, San Francisco, CA. Dr.
      Mohlenhoff is Director of Pharmacotherapy, San Francisco Veterans Affairs Medical
      Center San Francisco, San Francisco, CA. Dr. Kersten is Resident Physician, West 
      Suburban Medical Center, Oak Park, IL. Dr. McNiel is Professor of Clinical
      Psychology, Department of Psychiatry, University of California San Francisco, San
      Francisco, CA. Dr. Binder is Professor of Psychiatry and Director, Psychiatry and
      the Law Program, University of California San Francisco, San Francisco, CA.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - United States
TA  - J Am Acad Psychiatry Law
JT  - The journal of the American Academy of Psychiatry and the Law
JID - 9708963
SB  - IM
MH  - Adult
MH  - Animals
MH  - Certification/standards
MH  - Child
MH  - Disabled Persons/*legislation & jurisprudence
MH  - Humans
MH  - *Legislation as Topic
MH  - *Therapy Animals
OTO - NOTNLM
OT  - Air Carrier Access Act (ACAA)
OT  - Americans with Disabilities Act (ADA)
OT  - Fair Housing Act (FHA)
OT  - emotional support animal(s)
OT  - service animal(s)
OT  - therapy animal(s)
EDAT- 2020/09/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/17 05:37
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/17 05:37 [entrez]
AID - JAAPL.200047-20 [pii]
AID - 10.29158/JAAPL.200047-20 [doi]
PST - ppublish
SO  - J Am Acad Psychiatry Law. 2020 Dec;48(4):509-518. doi: 10.29158/JAAPL.200047-20. 
      Epub 2020 Sep 16.


PMID- 32938603
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 16
TI  - Evaluating underpinning, complexity and implications of ethical situations in
      humanitarian operations: qualitative study through the lens of career
      humanitarian workers.
PG  - e039463
LID - 10.1136/bmjopen-2020-039463 [doi]
AB  - INTRODUCTION: Data regarding underpinning and implications of ethical challenges 
      faced by humanitarian workers and their organisations in humanitarian operations 
      are limited. METHODS: We conducted comprehensive, semistructured interviews with 
      44 experienced humanitarian aid workers, from the field to headquarters, to
      evaluate and describe ethical conditions in humanitarian situations. RESULTS: 61%
      were female; average age was 41.8 years; 500 collective years of humanitarian
      experience (11.8 average) working with diverse major international
      non-governmental organisations. Important themes included; allocation schemes and
      integrity of the humanitarian industry, including resource allocation and fair
      access to and use of services; staff or organisational competencies and aid
      quality; humanitarian process and unintended consequences; corruption, diversion,
      complicity and competing interests, and intentions versus outcomes;
      professionalism and interpersonal and institutional responses; and exposure to
      extreme inequities and emotional and moral distress. Related concepts included
      broader industry context and allocations; decision-making, values, roles and
      sustainability; resource misuse at programme, government and international agency
      levels; aid effectiveness and utility versus futility, and negative consequences.
      Multiple contributing, confounding and contradictory factors were identified,
      including context complexity and multiple decision-making levels; limited input
      from beneficiaries of aid; different or competing social constructs, values or
      sociocultural differences; and shortcomings, impracticality, or competing
      philosophical theories or ethical frameworks. CONCLUSIONS: Ethical situations are
      overarching and often present themselves outside the exclusive scope of moral
      reasoning, philosophical views, professional codes, ethical or legal frameworks, 
      humanitarian principles or social constructivism. This study helped identify a
      common instinct to uphold fairness and justice as an underlying drive to maintain
      humanity through proximity, solidarity, transparency and accountability.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Asgary, Ramin
AU  - Asgary R
AUID- ORCID: 0000-0001-7646-0976
AD  - Global Health, George Washington University Milken Institute of Public Health,
      Washington, District of Columbia, USA ga263@columbia.edu.
AD  - Medicine, Weill Cornell Medical College, New York, New York, USA.
AD  - Medical Department, Medecins Sans Frontieres/Doctors Without Borders, Paris,
      France.
FAU - Lawrence, Katharine
AU  - Lawrence K
AD  - Population Health, New York University School of Medicine, New York, New York,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2021 Apr 5;11(4):1. PMID: 33820794
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - *Morals
MH  - Qualitative Research
MH  - *Social Responsibility
PMC - PMC7497554
OTO - NOTNLM
OT  - *ethics (see medical ethics)
OT  - *health policy
OT  - *international health services
OT  - *rationing
COIS- Competing interests: None declared.
EDAT- 2020/09/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/17 05:37
PHST- 2020/09/17 05:37 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039463 [pii]
AID - 10.1136/bmjopen-2020-039463 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 16;10(9):e039463. doi: 10.1136/bmjopen-2020-039463.


PMID- 32938601
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 16
TI  - Critical appraisal and comparison of recommendations of clinical practice
      guidelines for treatment of schizophrenia in children and adolescents: a
      methodological survey protocol.
PG  - e038646
LID - 10.1136/bmjopen-2020-038646 [doi]
AB  - INTRODUCTION: The number of clinical practice guidelines (CPGs) have increased
      substantially mainly in the paediatric area of mental health. However, little is 
      known about the quality or how recommendations for the treatment of disorders
      such as schizophrenia in children and adolescents have changed over time. The aim
      of this study will be to assess the quality of the development of CPGs for the
      treatment and management of schizophrenia in children and adolescents over time
      using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool 
      and to compare the recommendations and interventions described in these
      documents. METHODS AND ANALYSIS: CPGs will be identified using a prospective
      protocol through a systematic search of multiple databases (Medline, Embase,
      Health Systems Evidence, Epistemonikos, Lilacs, etc) and guideline websites from 
      2004 to December 2020. The quality of the guidelines will be assessed by three
      reviewers, independently using the AGREE II. CPGs will be considered of
      high-quality if they scored >/=60% in four or more domains of the AGREE II
      instrument. Non-parametric tests will be used to test for the change of quality
      over time. We will summarise the different evidence grading systems and compare
      the recommendations. ETHICS AND DISSEMINATION: Ethical approval is not required
      since it is a literature-based study. Future results of the research can be
      submitted for publication in scientific journals of high impact, peer reviewed
      and also published in national and international conferences. The results derived
      from this study will contribute to the improvement of health institutions and
      policies, informing about existing recommendation guidelines and about
      deficiencies and qualities found in those. This study may also identify key areas
      for future research. This study may guide the search and choice for high quality 
      CPGs by health policy makers and health professionals and subsidise future
      adaptations. PROTOCOL REGISTRATION NUMBER: CRD42020164899.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alves, Maira Ramos
AU  - Alves MR
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil.
FAU - Bergamaschi, Cristiane de Cassia
AU  - Bergamaschi CC
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil.
FAU - Sorrilha, Flavia Blaseck
AU  - Sorrilha FB
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil.
FAU - Fulone, Izabela
AU  - Fulone I
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil.
FAU - Barberato-Filho, Silvio
AU  - Barberato-Filho S
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil.
FAU - Mayer, Rejane Coan Ferretti
AU  - Mayer RCF
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil.
FAU - Melo, Daniela Oliveira de
AU  - Melo DO
AD  - Graduate Course of Pharmaceutical Sciences, Universidade Federal de Sao Paulo,
      Sao Paulo, Sao Paulo, Brazil.
FAU - Lopes, Luciane
AU  - Lopes L
AUID- ORCID: 0000-0002-3684-3275
AD  - Graduate Course of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba,
      Sao Paulo, Brazil luslopesbr@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Databases, Factual
MH  - Humans
MH  - Mental Health
MH  - Prospective Studies
MH  - *Schizophrenia/therapy
MH  - Surveys and Questionnaires
PMC - PMC7497528
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *protocols & guidelines
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/09/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/17 05:37
PHST- 2020/09/17 05:37 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038646 [pii]
AID - 10.1136/bmjopen-2020-038646 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 16;10(9):e038646. doi: 10.1136/bmjopen-2020-038646.


PMID- 32938599
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 16
TI  - Augmented reality in patient education and health literacy: a scoping review
      protocol.
PG  - e038416
LID - 10.1136/bmjopen-2020-038416 [doi]
AB  - BACKGROUND: Health literacy enables the patients in understanding the basic
      healthcare information and taking informed health decisions; thus, it is a
      desirable goal of any healthcare system. It increases patients' adherence to
      treatment, improves the quality of care and eases the overall burden on the
      healthcare system. In recent years, technological solutions are being
      increasingly used in educating patients and achieving better health literacy.
      Augmented reality (AR) provides powerful, contextual and situated learning
      experiences and supplements the real world with virtual objects. AR could
      potentially be an effective learning methodology for the patients, thus,
      warranting a comprehensive overview of the current state of AR in patient
      education and health literacy. METHODS: The proposed scoping review will be based
      on the framework developed by Arksey and O'Malley, including the refinements
      suggested by Levac et al. A systematic search for references in the published
      literature will be conducted in nine research databases-Institute of Electrical
      and Electronics Engineers (IEEE), Cumulative Index to Nursing and Allied Health
      Literature (CINAHL), PubMed, PsycInfo, Embase, Web of Science, Scopus,
      Association for Computing Machinery (ACM) and Association for Information Systems
      eLibrary (AISeL). The unpublished studies from ProQuest Dissertations and Theses,
      Conference Proceedings Citation Index and grey literature references obtained
      from a web search will also be included. Databases will be searched from
      inception to 14 January 2020. Two independent reviewers will screen the studies
      from the search results in two successive stages of title/abstract screening
      followed by full-text screening. Data variables will be extracted from the
      selected studies to characterise study design, type of AR technology employed and
      the relational factors affecting patient education. Lastly, key stakeholders will
      be consulted to gather their insights about the study findings. ETHICS AND
      DISSEMINATION: The results will be disseminated through stakeholder meetings and 
      conference presentations. The data used are from publicly available secondary
      sources, so this study does not require ethical review.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Adapa, Karthik
AU  - Adapa K
AUID- ORCID: 0000-0002-3970-588X
AD  - Department of Radiation Oncology and Carolina Health Informatics Program,
      University of North Carolina System, Chapel Hill, North Carolina, USA
      karthikk@live.unc.edu.
FAU - Jain, Saumya
AU  - Jain S
AD  - Department of Radiation Oncology, University of North Carolina System, Chapel
      Hill, North Carolina, USA.
FAU - Kanwar, Richa
AU  - Kanwar R
AD  - Department of Radiation Oncology, University of North Carolina System, Chapel
      Hill, North Carolina, USA.
FAU - Zaman, Tanzila
AU  - Zaman T
AD  - Department of Radiation Oncology and Carolina Health Informatics Program,
      University of North Carolina System, Chapel Hill, North Carolina, USA.
FAU - Taneja, Trusha
AU  - Taneja T
AD  - Department of Radiation Oncology and Carolina Health Informatics Program,
      University of North Carolina System, Chapel Hill, North Carolina, USA.
FAU - Walker, Jennifer
AU  - Walker J
AD  - Health Sciences Library, University of North Carolina System, Chapel Hill, North 
      Carolina, USA.
FAU - Mazur, Lukasz
AU  - Mazur L
AD  - Department of Radiation Oncology and Carolina Health Informatics Program,
      University of North Carolina System, Chapel Hill, North Carolina, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200916
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Augmented Reality
MH  - Delivery of Health Care
MH  - *Health Literacy
MH  - Humans
MH  - Patient Education as Topic
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7497551
OTO - NOTNLM
OT  - *health informatics
OT  - *information management
OT  - *information technology
COIS- Competing interests: None declared.
EDAT- 2020/09/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/17 05:37
PHST- 2020/09/17 05:37 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038416 [pii]
AID - 10.1136/bmjopen-2020-038416 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 16;10(9):e038416. doi: 10.1136/bmjopen-2020-038416.


PMID- 32938595
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 16
TI  - Epidemiology and management of atopic dermatitis in England: an observational
      cohort study protocol.
PG  - e037518
LID - 10.1136/bmjopen-2020-037518 [doi]
AB  - INTRODUCTION: Atopic dermatitis (AD) is one of the most common inflammatory skin 
      conditions in both children and adults. Despite this, contemporary descriptions
      of the incidence, prevalence and current management of the condition in the UK
      are lacking. METHODS AND ANALYSIS: We will perform a series of retrospective
      studies using a large population-based cohort derived from the Royal College of
      General Practitioners (RCGP) Research and Surveillance Centre (RSC) network
      database to explore two key research themes: AD epidemiology and AD management.In
      the epidemiology theme, we will describe the incidence and prevalence of AD in
      children and adults in England from 2009 to 2018 inclusive. We will stratify
      findings by age, national Index of Multiple Deprivation (IMD), ethnicity,
      urban-rural environment and geographic location; and explore independent
      associations of these features with AD in multivariable models.In the management 
      theme, we will explore healthcare utilisation and treatment in people with AD.
      Regarding healthcare utilisation, we will evaluate rates of AD-associated primary
      care visits and specialist dermatology referrals in people with AD. Rates will be
      stratified by age, gender, socioeconomic IMD quintile and ethnicity. We will
      describe contemporary treatment by estimating prescribing rates across medication
      classes used in AD (emollients, topical corticosteroids by potency, topical
      calcineurin inhibitors, topical antimicrobials, antihistamines, oral
      corticosteroids and systemic immunomodulatory therapies) overall, and by age and 
      sociodemographic groupings. We will also examine trends in prescribing over the
      study period. In people first diagnosed with AD during the study period, we will 
      describe differences in treatment escalation by sociodemographic factors using
      time-to-event analysis. ETHICS AND DISSEMINATION: The Health Research Authority
      decision tool classed this a study of 'usual practice', ethics approval was not
      required. Study approval was granted by the RCGP RSC Study Approval Committee.
      Results will be disseminated through peer-reviewed publications. TRIAL
      REGISTRATION NUMBER: NCT03823794.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AUID- ORCID: 0000-0001-5613-6810
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, Oxfordshire, UK.
AD  - Royal College of General Practitioners Research and Surveillance Centre, London, 
      UK.
FAU - Alexander, Helen
AU  - Alexander H
AD  - Unit for Population-Based Dermatology Research, St John's Institute of
      Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London,
      London, UK.
FAU - Broderick, Conor
AU  - Broderick C
AD  - Unit for Population-Based Dermatology Research, St John's Institute of
      Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London,
      London, UK.
FAU - Dennis, John
AU  - Dennis J
AD  - Momentum Data, St Albans, UK.
FAU - McGovern, Andrew
AU  - McGovern A
AD  - Momentum Data, St Albans, UK.
FAU - Feeney, Claire
AU  - Feeney C
AD  - Pfizer, Surrey, UK.
FAU - Flohr, Carsten
AU  - Flohr C
AD  - Unit for Population-Based Dermatology Research, St John's Institute of
      Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London,
      London, UK carsten.flohr@kcl.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT03823794
SI  - ISRCTN/ISRCTN15837754
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200916
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Emollients)
SB  - IM
MH  - Adult
MH  - Child
MH  - Cohort Studies
MH  - *Dermatitis, Atopic/drug therapy/epidemiology
MH  - Emollients/therapeutic use
MH  - England/epidemiology
MH  - Humans
MH  - Observational Studies as Topic
MH  - Retrospective Studies
PMC - PMC7497529
OTO - NOTNLM
OT  - *dermatological epidemiology
OT  - *eczema
OT  - *epidemiology
OT  - *primary care
OT  - *public health
COIS- Competing interests: SdL is director of RCGP RSC, and had received funding for
      projects from Eli Lilly, AstraZeneca, GSK, Seqirus and Takeda-all through his
      universities and none related to this study. JD and AM are employees of Momentum 
      Data who were paid consultants to Pfizer in connection with the development of
      this manuscript. ClF is an employee of Pfizer. CaF is chief investigator of the
      UK National Institute for Health Research-funded TREAT (ISRCTN15837754) and
      SOFTER (ClinicalTrials.gov: NCT03270566) trials as well as the UK-Irish Atopic
      Eczema Systemic Therapy Register (A-STAR; ISRCTN11210918) and a principal
      investigator in the European Union Horizon 2020-funded BIOMAP Consortium
      (http://www.biomap-imi.eu/). His department has also received funding from
      Sanofi-Genzyme.
EDAT- 2020/09/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/17 05:37
PHST- 2020/09/17 05:37 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037518 [pii]
AID - 10.1136/bmjopen-2020-037518 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 16;10(9):e037518. doi: 10.1136/bmjopen-2020-037518.


PMID- 32938589
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 16
TI  - Activities and programmes that support the emotional wellness and well-being of
      refugees, immigrants and other newcomers within settlement agencies: a scoping
      review protocol.
PG  - e033377
LID - 10.1136/bmjopen-2019-033377 [doi]
AB  - INTRODUCTION: Obstacles to successful settlement-social isolation, language
      hardship, issues with employment, housing questions, transportation, barriers to 
      health, education and government service access-all potentially play a role in
      emerging physical and mental health problems. The objective of this scoping
      review is to map the available evidence in order to provide an overview of the
      services and resources offered to refugees, immigrants and other newcomers by
      settlement agencies to support emotional wellness and well-being. METHODS AND
      ANALYSIS: The protocol to be followed for this scoping review is based on the
      Joanna Briggs Institute to provide a map of the current and emergent literature, 
      and examine the extent, range and nature of this literature. The proposed scoping
      review will also identify the gaps in research pertaining to the emotional
      wellness of refugees, immigrants and other newcomers as well as summarise and
      disseminate research findings and provide direction for future reviews. Key
      databases for this scoping review include APA PsycINFO, Medline, Embase,
      Cumulative Index of Nursing and Allied Health Literature Plus, Academic Search
      Complete, and Education Research Complete. The database search start and end
      dates for this scoping review will be from inception to July 2020. The article
      searches will take place between August and October 2020. ETHICS AND
      DISSEMINATION: Ethics is not required as the research will not involve human or
      animal subjects. The research is a scoping review, and thus relies on published
      and grey literature studies and documents. The findings of this proposed scoping 
      review will be disseminated through future publications as well as presentations 
      to relevant stakeholders, including immigrant serving agencies. We anticipate
      that this scoping review will identify gaps in research pertaining to the
      emotional wellness of refugees, immigrants and other newcomers. The results of
      this review will be the first comprehensive recent survey of emotional wellness
      practices employed by settlement agencies.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Goopy, Suzanne
AU  - Goopy S
AD  - Faculty of Nursing, University of Calgary, Calgary, Alberta, Canada
      sgoopy@ucalgary.ca.
FAU - Suva, Cesar
AU  - Suva C
AD  - Faculty of Nursing, University of Calgary, Calgary, Alberta, Canada.
AD  - Research and Program Development, The Immigrant Education Society, Calgary,
      Alberta, Canada.
FAU - Hayden, K Alix
AU  - Hayden KA
AD  - Libraries and Cultural Resources, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Silversides, Halley
AU  - Silversides H
AUID- ORCID: 0000-0002-6846-8078
AD  - Faculty of Nursing, University of Calgary, Calgary, Alberta, Canada.
FAU - Palova, Katerina
AU  - Palova K
AD  - Research and Program Development, The Immigrant Education Society, Calgary,
      Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200916
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Emigrants and Immigrants
MH  - Humans
MH  - Mental Health
MH  - Organizations
MH  - Peer Review
MH  - *Refugees
MH  - Research Design
PMC - PMC7497533
OTO - NOTNLM
OT  - *emotional wellness
OT  - *immigrants
OT  - *scoping review
EDAT- 2020/09/18 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/09/17 05:37
PHST- 2020/09/17 05:37 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2019-033377 [pii]
AID - 10.1136/bmjopen-2019-033377 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 16;10(9):e033377. doi: 10.1136/bmjopen-2019-033377.


PMID- 32938277
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1557-9891 (Electronic)
IS  - 1557-9883 (Linking)
VI  - 14
IP  - 5
DP  - 2020 Sep-Oct
TI  - The SHARED Project: A Novel Approach to Engaging African American Men to Address 
      Lung Cancer Disparities.
PG  - 1557988320958934
LID - 10.1177/1557988320958934 [doi]
AB  - Black men are disproportionately impacted by lung cancer morbidity and mortality.
      Low-dose helical computed tomography (LDCT) lung cancer screening has
      demonstrated benefits for reducing lung cancer deaths by identifying cancers at
      earlier, more treatable stages. Despite the known benefits, LDCT screening is
      underutilized in black men. Studies in racially heterogeneous populations have
      found correlations between screening behaviors and factors such as physician
      trust, physician referral, and a desire to reduce the uncertainty of not knowing 
      if they had lung cancer; yet little is known about the factors that specifically 
      contribute to screening behaviors in black men. Community engagement strategies
      are beneficial for understanding barriers to health-care engagement. One
      community engagement approach is the citizen scientist model. Citizen scientists 
      are lay people who are trained in research methods; they have proven valuable in 
      increasing communities' knowledge of the importance of healthy behaviors such as 
      screening, awareness of research, building trust in research, and improving study
      design and ethics. This paper proposes an intervention, grounded in
      community-based participatory research approaches and social network theory, to
      engage black men as citizen scientists in an effort to increase lung cancer
      screening in black men. This mixed-methods intervention will examine the
      attitudes, behaviors, and beliefs of black men related to uptake of
      evidence-based lung cancer screening.
FAU - Watson, Karriem S
AU  - Watson KS
AUID- ORCID: 0000-0002-5575-7102
AD  - UI Cancer Center, University of Illinois, Chicago, IL, USA.
AD  - Mile Square Health Center, UI Health, Chicago, IL, USA.
AD  - School of Public Health, University of Illinois at Chicago, Chicago, IL, USA.
FAU - Siegel, Leilah D
AU  - Siegel LD
AD  - UI Cancer Center, University of Illinois, Chicago, IL, USA.
AD  - Institute for Health Research and Policy, University of Illinois at Chicago,
      Chicago, IL, USA.
FAU - Henderson, Vida A
AU  - Henderson VA
AD  - UI Cancer Center, University of Illinois, Chicago, IL, USA.
AD  - School of Public Health, University of Illinois at Chicago, Chicago, IL, USA.
FAU - Murray, Marcus
AU  - Murray M
AD  - Project Brotherhood, Chicago, IL, USA.
FAU - Chukwudozie, I Beverly
AU  - Chukwudozie IB
AD  - UI Cancer Center, University of Illinois, Chicago, IL, USA.
FAU - Odell, David
AU  - Odell D
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
FAU - Stinson, James
AU  - Stinson J
AD  - College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
AD  - Department of Urology, John H Stroger Hospital of Cook County, Chicago, IL, USA.
FAU - Ituah, Ose
AU  - Ituah O
AD  - School of Public Health, University of Illinois at Chicago, Chicago, IL, USA.
FAU - Ben Levi, Josef
AU  - Ben Levi J
AD  - College of Education, Northeastern Illinois University, Chicago, IL, USA.
FAU - Fitzgibbon, Marian L
AU  - Fitzgibbon ML
AD  - UI Cancer Center, University of Illinois, Chicago, IL, USA.
AD  - Institute for Health Research and Policy, University of Illinois at Chicago,
      Chicago, IL, USA.
AD  - School of Public Health, University of Illinois at Chicago, Chicago, IL, USA.
AD  - College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
FAU - Kim, Sage
AU  - Kim S
AD  - UI Cancer Center, University of Illinois, Chicago, IL, USA.
AD  - School of Public Health, University of Illinois at Chicago, Chicago, IL, USA.
FAU - Matthews, Phoenix
AU  - Matthews P
AD  - College of Nursing, University of Illinois at Chicago, Chicago, IL, USA.
LA  - eng
GR  - U54 CA202995/CA/NCI NIH HHS/United States
GR  - L30 CA153420/CA/NCI NIH HHS/United States
GR  - U54 CA202997/CA/NCI NIH HHS/United States
GR  - U54 CA203000/CA/NCI NIH HHS/United States
GR  - K07 CA216330/CA/NCI NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Am J Mens Health
JT  - American journal of men's health
JID - 101287723
SB  - IM
MH  - *African Americans
MH  - Chicago
MH  - Early Detection of Cancer/*methods
MH  - Health Behavior
MH  - Health Status Disparities
MH  - Humans
MH  - Lung Neoplasms/*diagnosis
MH  - Male
MH  - Mass Screening/methods
MH  - Men's Health
MH  - *Patient Acceptance of Health Care
MH  - Program Evaluation
PMC - PMC7503018
OTO - NOTNLM
OT  - *black men
OT  - *health behaviors
OT  - *health disparities
OT  - *lung cancer
OT  - *men's health
EDAT- 2020/09/18 06:00
MHDA- 2021/08/12 06:00
CRDT- 2020/09/17 05:30
PHST- 2020/09/17 05:30 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
AID - 10.1177/1557988320958934 [doi]
PST - ppublish
SO  - Am J Mens Health. 2020 Sep-Oct;14(5):1557988320958934. doi:
      10.1177/1557988320958934.


PMID- 32937888
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20211204
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 18
DP  - 2020 Sep 14
TI  - Betel Quid Health Risks of Insulin Resistance Diseases in Poor Young South Asian 
      Native and Immigrant Populations.
LID - E6690 [pii]
LID - 10.3390/ijerph17186690 [doi]
AB  - Betel quid, traditionally prepared with areca nut, betel leaf, and slaked lime,
      has been consumed for thousands of years, mainly in the form of chewing.
      Originally used for cultural, medicinal, and ceremonial purposes mainly in South 
      Asian countries, its use has recently spread across the globe due to its
      psychoactive, euphoric, and aphrodisiac properties. Now it is widely used as a
      social lubricant and source of financial profit. Unfortunately, the profit motive
      has led to high rates of habitual consumption with eventual conversion to
      addiction among young girls and boys. Moreover, the worrisome practice of
      including tobacco in quid preparations has grown, particularly among pregnant
      women. Major health concerns include increased rates of malignancy, oral
      pathology, and cardiovascular, hepatic, fertility, metabolic, and
      neuropsychiatric disorders. Metabolic disorders and insulin resistance disease
      states such as type 2 diabetes, obesity, and metabolic syndrome contribute to
      cognitive decline and neurodegeneration. Mechanistically, the constituents of
      areca nut/betel quid are metabolized to N-nitroso compounds, i.e., nitrosamines, 
      which are carcinogenic at high doses and cause insulin resistance following
      chronic low-level exposures. From an epidemiological perspective, the rising tide
      of insulin resistance diseases including obesity, diabetes, and dementias that
      now disproportionately burden poor countries has been propagated by rapid
      commercialization and enhanced access to betel quid. Public health measures are
      needed to impose socially and ethically responsible barriers to yet another cause
      of global health disparity.
FAU - de la Monte, Suzanne M
AU  - de la Monte SM
AD  - Department of Pathology and Laboratory Medicine, Providence VA Medical Center,
      Providence, RI 02808, USA.
AD  - Women & Infants Hospital of Rhode Island, Providence, RI 02808, USA.
AD  - Alpert Medical School, Brown University, Providence, RI 02808, USA.
AD  - Departments of Medicine, Rhode Island Hospital, Providence, RI 02808, USA.
AD  - Neurology, Neurosurgery and Neuropathology, Rhode Island Hospital, Alpert Medical
      School of Brown University, Providence, RI 02903, USA.
FAU - Moriel, Natalia
AU  - Moriel N
AD  - Department of Molecular Pharmacology and Physiology at Brown University,
      Providence, RI 02912, USA.
FAU - Lin, Amy
AU  - Lin A
AD  - Department of Molecular Pharmacology and Physiology at Brown University,
      Providence, RI 02912, USA.
FAU - Abdullah Tanoukhy, Nada
AU  - Abdullah Tanoukhy N
AD  - Department of Molecular Pharmacology and Physiology at Brown University,
      Providence, RI 02912, USA.
FAU - Homans, Camille
AU  - Homans C
AD  - Department of Neuroscience, Brown University, Providence, RI 02912, USA.
FAU - Gallucci, Gina
AU  - Gallucci G
AD  - Departments of Medicine, Rhode Island Hospital, Providence, RI 02808, USA.
FAU - Tong, Ming
AU  - Tong M
AD  - Departments of Medicine, Rhode Island Hospital, Providence, RI 02808, USA.
FAU - Saito, Ayumi
AU  - Saito A
AD  - Department of Epidemiology in the School of Public Health, Brown University,
      Providence, RI 02912, USA.
LA  - eng
GR  - R37 11431/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200914
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
CIN - Int J Environ Res Public Health. 2021 Aug 19;18(16):. PMID: 34444498
MH  - *Areca/adverse effects
MH  - Asians
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - *Emigrants and Immigrants
MH  - Female
MH  - *Health Status Disparities
MH  - Humans
MH  - *Insulin Resistance
MH  - Male
MH  - Poverty
MH  - Pregnancy
MH  - Young Adult
PMC - PMC7558723
OTO - NOTNLM
OT  - *arecoline
OT  - *betel quid
OT  - *dementia
OT  - *diabetes
OT  - *nitrosamine
OT  - *tobacco
EDAT- 2020/09/18 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/09/17 01:02
PHST- 2020/07/31 00:00 [received]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/17 01:02 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - ijerph17186690 [pii]
AID - 10.3390/ijerph17186690 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Sep 14;17(18). pii: ijerph17186690. doi:
      10.3390/ijerph17186690.


PMID- 32937285
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 266
DP  - 2020 Dec
TI  - Negotiating the practical ethics of 'self-tracking' in intimate relationships:
      Looking for care in healthy living.
PG  - 113301
LID - S0277-9536(20)30520-7 [pii]
LID - 10.1016/j.socscimed.2020.113301 [doi]
AB  - In this paper, we offer insights into practices of tracking as part of healthy
      living through talk about home blood pressure and weight from adults living in
      the UK. Drawing on theoretical resources from feminist ethics of care and Science
      and Technology Studies on care as socio-material practice, we build on interest
      in the relational dimensions of tracking and the potential for intimate
      surveillance and care using monitoring technologies. Our cases offer not only new
      perspectives in a field that has often focused on fitness tracking but also help 
      go beyond a narrow focus on surveillance, showing how surveillance and care may
      be intertwined in the everyday negotiation of health-related tracking and other
      'health practices' in family life. Using the diversity in our relatively large
      sample, and reflecting on the different types of interview completed, we
      highlight the varied ways in which adults engage with tracking blood pressure and
      weight (or body mass index) in the context of established relationships. The
      combination of attentiveness and appeals to responsibility for maintaining health
      as something owed to a partner can make tracking a very ethically sensitive area.
      In this paper we emphasise that reciprocity is one important way in which couples
      make tracking feel more like care. Tracking together or discussing it can take
      couples in this direction even if the actual practice remains somewhat difficult.
      On the other hand, responsiveness to someone else's feelings, including a desire 
      to avoid the topic altogether, or avoid weight as a specific parameter, might all
      help move towards more caring tracking. We therefore develop a more sustained
      account of care in relation to tracking than in previous work, and a novel
      account of tracking as a (potential) care practice between adult partners.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Will, Catherine M
AU  - Will CM
AD  - University of Sussex, United Kingdom. Electronic address: c.will@sussex.ac.uk.
FAU - Henwood, Flis
AU  - Henwood F
AD  - University of Brighton, United Kingdom.
FAU - Weiner, Kate
AU  - Weiner K
AD  - University of Sheffield, United Kingdom.
FAU - Williams, Rosalind
AU  - Williams R
AD  - University of Sheffield, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Adult
MH  - Feminism
MH  - Healthy Lifestyle
MH  - Humans
MH  - Interpersonal Relations
MH  - *Negotiating
MH  - *Sexual Partners
OTO - NOTNLM
OT  - *Care
OT  - *Ethics
OT  - *Health
OT  - *Partner
OT  - *Practice
OT  - *Surveillance
OT  - *Tracking
OT  - *UK
EDAT- 2020/09/17 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/16 20:12
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/16 20:12 [entrez]
AID - S0277-9536(20)30520-7 [pii]
AID - 10.1016/j.socscimed.2020.113301 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Dec;266:113301. doi: 10.1016/j.socscimed.2020.113301. Epub 2020
      Sep 9.


PMID- 32937036
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 5
DP  - 2020 Sep
TI  - Big Data, Biomedical Research, and Ethics Review: New Challenges for IRBs.
PG  - 17-28
LID - 10.1002/eahr.500065 [doi]
AB  - The increased use of big data in the medical field has shifted the way in which
      biomedical research is designed and carried out. The novelty of techniques and
      methods brought by big data research brings new challenges to institutional
      review boards (IRBs). Yet it is unclear if IRBs should be the responsible
      oversight bodies for big data research and, if so, which criteria they should
      use. A large but heterogenous set of ethics guidelines and normative responses
      have emerged to address these issues. In this study, we conducted a scoping
      review of soft-law documents and guidelines with the aim of assessing ongoing
      normative efforts that are proliferating in this domain. We also synthesize a set
      of recurrent guidelines that could work as a baseline to create a harmonized
      process for big data research ethics.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Ferretti, Agata
AU  - Ferretti A
AD  - PhD candidate in Bioethics at the Health Ethics and Policy Lab, Swiss Federal
      Institute of Technology in Zurich.
FAU - Ienca, Marcello
AU  - Ienca M
AD  - Senior researcher at the Health Ethics and Policy Lab, Swiss Federal Institute of
      Technology in Zurich.
FAU - Hurst, Samia
AU  - Hurst S
AD  - Professor of medical ethics and director of the Institute for Ethics, History,
      and the Humanities & Department of Community Health and Medicine, University of
      Geneva, Switzerland.
FAU - Vayena, Effy
AU  - Vayena E
AD  - Professor of bioethics and director of the Health Ethics and Policy Lab, Swiss
      Federal Institute of Technology in Zurich.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
EIN - Ethics Hum Res. 2020 Nov;42(6):20. PMID: 33136334
MH  - *Big Data
MH  - Biomedical Research/*ethics
MH  - *Ethical Review
MH  - *Ethics Committees, Research
MH  - Humans
PMC - PMC7814666
OTO - NOTNLM
OT  - big data
OT  - big data research
OT  - biomedical research
OT  - institutional review board (IRB)
OT  - research ethics
EDAT- 2020/09/17 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/09/16 17:13
PHST- 2020/09/16 17:13 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1002/eahr.500065 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Sep;42(5):17-28. doi: 10.1002/eahr.500065.


PMID- 32937035
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 5
DP  - 2020 Sep
TI  - Ethical and Regulatory Concerns in Pragmatic Clinical Trial Monitoring and
      Oversight.
PG  - 29-37
LID - 10.1002/eahr.500066 [doi]
AB  - The implementation of pragmatic clinical trials (PCTs) can be accompanied by
      unique regulatory challenges. In this paper, we describe the experience and
      management of regulatory noncompliance during a 25-site acute care PCT. During
      the trial, the study team conducted a comprehensive audit of all enrollment forms
      (informed consent and Health Insurance Portability and Accountability Act
      authorization forms) and related study documentation. A review of 997
      participants' enrollment forms identified 138 (13.8%) that required reporting to 
      the institutional review board due to noncompliance. To prevent subsequent
      noncompliance, the study team developed and introduced a revised participant
      tracking system, reviewed all enrollment documentation, and retrained sites
      regarding study procedures. Based on these experiences, we developed a set of
      recommendations for future PCTs to ensure both operational success and regulatory
      compliance.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Roberts, Michelle K
AU  - Roberts MK
AD  - Research coordinator of rehabilitation medicine at the University of Washington
      School of Medicine.
FAU - Fisher, Dylan M
AU  - Fisher DM
AD  - Research study coordinator of psychiatry and behavioral sciences at the
      University of Washington School of Medicine.
FAU - Parker, Lea E
AU  - Parker LE
AD  - Doctoral student in the Department of Psychology at Drexel University.
FAU - Darnell, Doyanne
AU  - Darnell D
AD  - Assistant professor of psychiatry and behavioral sciences at the University of
      Washington School of Medicine.
FAU - Sugarman, Jeremy
AU  - Sugarman J
AD  - Harvey M. Meyerhoff Professor of Bioethics and Medicine at the Berman Institute
      of Bioethics and at the School of Medicine at Johns Hopkins University.
FAU - Carrithers, Judith
AU  - Carrithers J
AD  - Director of regulatory affairs at Advarra.
FAU - Weinfurt, Kevin
AU  - Weinfurt K
AD  - Professor and vice chair of research in the Department of Population Health
      Sciences at the Duke University School of Medicine.
FAU - Jurkovich, Gregory
AU  - Jurkovich G
AD  - Professor and vice chairman and the Lloyd F. & Rosemargaret Donant chair in
      trauma medicine in the Department of Surgery at University of California Davis
      Health.
FAU - Zatzick, Douglas
AU  - Zatzick D
AD  - Professor of psychiatry and behavioral sciences at the University of Washington
      School of Medicine.
LA  - eng
GR  - U54 AT007748/AT/NCCIH NIH HHS/United States
GR  - 1UH2MH106338-01/4UH3MH106338-02/National Institutes of Health (NIH) Common Fund
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Biomedical Research/*ethics
MH  - Documentation
MH  - Ethics Committees, Research/*organization & administration/standards
MH  - *Ethics, Research
MH  - *Government Regulation
MH  - Health Insurance Portability and Accountability Act
MH  - Humans
MH  - Informed Consent/*ethics
MH  - United States
OTO - NOTNLM
OT  - Good Clinical Practice (GCP)
OT  - Health Insurance Portability and Accountability Act (HIPAA)
OT  - informed consent documentation
OT  - institutional review board (IRB)
OT  - noncompliance
OT  - pragmatic clinical trials
EDAT- 2020/09/17 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/09/16 17:13
PHST- 2020/09/16 17:13 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1002/eahr.500066 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Sep;42(5):29-37. doi: 10.1002/eahr.500066.


PMID- 32937033
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 5
DP  - 2020 Sep
TI  - Person-Oriented Research Ethics to Address the Needs of Participants on the
      Autism Spectrum.
PG  - 2-16
LID - 10.1002/eahr.500064 [doi]
AB  - Research ethics scholarship often attends to vulnerability. People with autism
      may be vulnerable in research, but are also vulnerable to unjust exclusion from
      participation. Addressing the needs of participants with autism can facilitate
      inclusion and honor the bioethics principle of respect for persons while
      accounting for risk and vulnerability. Drawing from a review of the literature
      and informed by a moral deliberation process involving a task force of
      stakeholders (including autistic people and parents of autistic people), we use
      the model of person-oriented research ethics to identify several practical
      strategies researchers can use to address these needs and foster inclusion.
      Strategies include using multiple means of communication, addressing the sensory 
      environment, preparing participants in advance, and accounting for social
      context. These practical strategies are not just methodological or design
      choices; they are inherently related to ethical issues. Method and design choices
      fulfill ethical aspirations by facilitating inclusion, reducing discomfort, and
      focusing on individuals.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Cascio, M Ariel
AU  - Cascio MA
AD  - Assistant professor in the art of medicine at Central Michigan University College
      of Medicine and was a postdoctoral fellow at the Pragmatic Health Ethics Research
      Unit at the Institut de recherches cliniques de Montreal when this work was
      conducted.
FAU - Weiss, Jonathan A
AU  - Weiss JA
AD  - Associate professor in the Department of Psychology at York University.
FAU - Racine, Eric
AU  - Racine E
AD  - Full research professor at the Institut de recherches cliniques de Montreal and
      Universite de Montreal as well as the director of Pragmatic Health Ethics.
LA  - eng
GR  - Kids Brain Health Network Core Award
GR  - NeuroEthics Excellence and Societal Innovation Core
GR  - Angelo-Pizzagalli Scholarship of the IRCM Foundation
GR  - Social Sciences and Humanities Research Council of Canada's Banting Postdoctoral 
      Fellowship
GR  - Fonds de recherche du Quebec-Sante
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Autistic Disorder/*psychology
MH  - Communication
MH  - *Ethics, Research
MH  - Humans
MH  - *Patient Selection
MH  - *Research Design
MH  - *Stakeholder Participation
MH  - Vulnerable Populations/psychology
OTO - NOTNLM
OT  - autism spectrum
OT  - human subjects research
OT  - inclusion in research
OT  - person-oriented research ethics
OT  - research design
OT  - vulnerable populations
EDAT- 2020/09/17 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/09/16 17:13
PHST- 2020/09/16 17:13 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1002/eahr.500064 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Sep;42(5):2-16. doi: 10.1002/eahr.500064.


PMID- 32936815
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20201218
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Diabolical dilemmas of COVID-19: An empirical study into Dutch society's
      trade-offs between health impacts and other effects of the lockdown.
PG  - e0238683
LID - 10.1371/journal.pone.0238683 [doi]
AB  - We report and interpret preferences of a sample of the Dutch adult population for
      different strategies to end the so-called 'intelligent lockdown' which their
      government had put in place in response to the COVID-19 pandemic. Using a
      discrete choice experiment, we invited participants to make a series of choices
      between policy scenarios aimed at relaxing the lockdown, which were specified not
      in terms of their nature (e.g. whether or not to allow schools to re-open) but in
      terms of their effects along seven dimensions. These included health-related
      effects, but also impacts on the economy, education, and personal income. From
      the observed choices, we were able to infer the implicit trade-offs made by the
      Dutch between these policy effects. For example, we find that the average
      citizen, in order to avoid one fatality directly or indirectly related to
      COVID-19, is willing to accept a lasting lag in the educational performance of 18
      children, or a lasting (>3 years) and substantial (>15%) reduction in net income 
      of 77 households. We explore heterogeneity across individuals in terms of these
      trade-offs by means of latent class analysis. Our results suggest that most
      citizens are willing to trade-off health-related and other effects of the
      lockdown, implying a consequentialist ethical perspective. Somewhat surprisingly,
      we find that the elderly, known to be at relatively high risk of being affected
      by the virus, are relatively reluctant to sacrifice economic pain and educational
      disadvantages for the younger generation, to avoid fatalities. We also identify a
      so-called taboo trade-off aversion amongst a substantial share of our sample,
      being an aversion to accept morally problematic policies that simultaneously
      imply higher fatality numbers and lower taxes. We explain various ways in which
      our results can be of value to policy makers in the context of the COVID-19 and
      future pandemics.
FAU - Chorus, Caspar
AU  - Chorus C
AUID- ORCID: 0000-0002-6380-4853
AD  - Department of Engineering Systems and Services, Faculty of Technology, Policy and
      Management, Delft University of Technology, Delft, Netherlands.
FAU - Sandorf, Erlend Dancke
AU  - Sandorf ED
AUID- ORCID: 0000-0001-7521-4773
AD  - Economics Division, Stirling Management School, University of Stirling, Stirling,
      Scotland.
FAU - Mouter, Niek
AU  - Mouter N
AD  - Department of Engineering Systems and Services, Faculty of Technology, Policy and
      Management, Delft University of Technology, Delft, Netherlands.
LA  - eng
GR  - ERC_/European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200916
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Altruism
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Choice Behavior
MH  - Communicable Disease Control/legislation & jurisprudence/methods
MH  - Consumer Behavior
MH  - Coronavirus Infections/economics/epidemiology/prevention & control/*psychology
MH  - Cost of Illness
MH  - Empirical Research
MH  - Female
MH  - *Health Policy
MH  - Humans
MH  - Income
MH  - Male
MH  - Middle Aged
MH  - *Models, Econometric
MH  - Netherlands/epidemiology
MH  - *Pandemics/economics/legislation & jurisprudence/prevention & control
MH  - Pneumonia, Viral/economics/epidemiology/prevention & control/*psychology
MH  - Quarantine/economics/legislation & jurisprudence/*psychology/statistics &
      numerical data
MH  - Risk
MH  - SARS-CoV-2
MH  - Schools
MH  - Social Values
MH  - Taxes
MH  - *Value of Life
MH  - Young Adult
PMC - PMC7494093
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/16 17:11
PHST- 2020/06/12 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/09/16 17:11 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - 10.1371/journal.pone.0238683 [doi]
AID - PONE-D-20-17983 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 16;15(9):e0238683. doi: 10.1371/journal.pone.0238683.
      eCollection 2020.


PMID- 32936736
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20210727
IS  - 2374-4650 (Electronic)
IS  - 2374-4642 (Linking)
VI  - 6
DP  - 2020 Sep 15
TI  - Human Organoids for the Study of Retinal Development and Disease.
PG  - 91-114
LID - 10.1146/annurev-vision-121219-081855 [doi]
AB  - Recent advances in stem cell engineering have led to an explosion in the use of
      organoids as model systems for studies in multiple biological disciplines.
      Together with breakthroughs in genome engineering and the various omics, organoid
      technology is making possible studies of human biology that were not previously
      feasible. For vision science, retinal organoids derived from human stem cells
      allow differentiating and mature human retinal cells to be studied in
      unprecedented detail. In this review, we examine the technologies employed to
      generate retinal organoids and how organoids are revolutionizing the fields of
      developmental and cellular biology as they pertain to the retina. Furthermore, we
      explore retinal organoids from a clinical standpoint, offering a new platform
      with which to study retinal diseases and degeneration, test prospective drugs and
      therapeutic strategies, and promote personalized medicine. Finally, we discuss
      the range of possibilities that organoids may bring to future retinal research
      and consider their ethical implications.
FAU - Bell, Claire M
AU  - Bell CM
AD  - Department of Genetic Medicine, Johns Hopkins University School of Medicine,
      Baltimore, Maryland 21287, USA; email: cwenger3@jhmi.edu, dzack@jhmi.edu.
FAU - Zack, Donald J
AU  - Zack DJ
AD  - Department of Genetic Medicine, Johns Hopkins University School of Medicine,
      Baltimore, Maryland 21287, USA; email: cwenger3@jhmi.edu, dzack@jhmi.edu.
AD  - Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University
      School of Medicine, Baltimore, Maryland 21287, USA; email: cdoughe1@jhmi.edu.
AD  - Department of Molecular Biology and Genetics, Johns Hopkins University School of 
      Medicine, Baltimore, Maryland 21287, USA.
AD  - Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of 
      Medicine, Baltimore, Maryland 21287, USA.
FAU - Berlinicke, Cynthia A
AU  - Berlinicke CA
AD  - Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University
      School of Medicine, Baltimore, Maryland 21287, USA; email: cdoughe1@jhmi.edu.
LA  - eng
GR  - T32 GM007814/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Annu Rev Vis Sci
JT  - Annual review of vision science
JID - 101660822
SB  - IM
MH  - Animals
MH  - Cell Culture Techniques/methods
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology
MH  - Mice
MH  - Organoids/*cytology/growth & development
MH  - Rats
MH  - *Research
MH  - Retina/*cytology/metabolism
MH  - Retinal Diseases/genetics/therapy
MH  - Tissue Engineering/methods
OTO - NOTNLM
OT  - *CRISPR/Cas9
OT  - *drug discovery
OT  - *organoid
OT  - *retinal degeneration
OT  - *retinal development
OT  - *screening
EDAT- 2020/09/17 06:00
MHDA- 2021/07/28 06:00
CRDT- 2020/09/16 17:11
PHST- 2020/09/16 17:11 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
AID - 10.1146/annurev-vision-121219-081855 [doi]
PST - ppublish
SO  - Annu Rev Vis Sci. 2020 Sep 15;6:91-114. doi:
      10.1146/annurev-vision-121219-081855.


PMID- 32936676
OWN - NLM
STAT- Publisher
LR  - 20210507
IS  - 2469-4207 (Electronic)
DP  - 2020 Sep 16
TI  - Opt-out Consent in Children's Emergency Medicine Research.
PG  - 1-12
LID - 10.1080/24694193.2020.1812766 [doi]
AB  - There is global acceptance that individuals should be allowed to decide whether
      or not to take part in research studies, and to do so after being informed about 
      the nature of the research and the risk that might attach to participation. The
      process of providing detailed information before seeking consent (formalized by
      signatures) in advance of undertaking research procedures may not be possible in 
      some circumstances, and sometimes an amended approach may be adopted. The use of 
      opt-out consent has been recognized as a valid and ethical means of recruiting
      participants to studies particularly with large samples and where the risk to
      participants is small. However, it is sometimes misunderstood and can be a
      problematic factor in being accepted by research ethics committees and governing 
      authorities. This may be due partly to differing expectations of the amount of
      information and support offered, together with the nature of the process that is 
      adopted to ensure that a decision has been made rather than consent simply being 
      assumed. In accordance with ongoing discussions with young people, and following 
      consultation with parents, an opt-out consent strategy including varied means of 
      providing information was employed in a large study of 44,501 cases of children
      attending emergency or urgent care departments. The study was conducted over more
      than 12 months in dissimilar emergency departments and an urgent care unit, and
      was designed to support better decision-making in pediatric emergency departments
      about whether children need to be admitted to hospital or can be discharged home 
      safely. Robust analysis of the factors that exerted the greatest impact on
      predicting the need to admit or the safety of discharging children led to a
      revised version of an existing tool. In this article, we review approaches to
      consent in research, the nature and impact of opt-out consent, the factors that
      made this an effective strategy for this study, but also more recent concerns
      which may make opt-out consent no longer acceptable.
FAU - Long, Tony
AU  - Long T
AUID- ORCID: https://orcid.org/0000-0003-2726-8798
AD  - School of Health & Society, University of Salford, Salford, UK.
FAU - Rowland, Andrew
AU  - Rowland A
AUID- ORCID: https://orcid.org/0000-0001-9564-0032
AD  - School of Health & Society, University of Salford, Salford, UK.
AD  - Emergency Department, North Manchester General Hospital, The Pennine Acute
      Hospitals NHS Trust, Manchester, UK.
FAU - Cotterill, Sarah
AU  - Cotterill S
AUID- ORCID: https://orcid.org/0000-0001-5136-390X
AD  - Centre for Biostatistics, School of Health Sciences, University of Manchester,
      Manchester, UK.
FAU - Woby, Steve
AU  - Woby S
AUID- ORCID: https://orcid.org/0000-0002-2602-8613
AD  - School of Health & Society, University of Salford, Salford, UK.
AD  - Northern Care Alliance NHS Group, Salford, UK.
FAU - Heal, Calvin
AU  - Heal C
AUID- ORCID: https://orcid.org/0000-0002-6445-1551
AD  - Centre for Biostatistics, School of Health Sciences, University of Manchester,
      Manchester, UK.
FAU - Garratt, Natalie
AU  - Garratt N
AUID- ORCID: https://orcid.org/0000-0003-1987-7657
AD  - Northern Care Alliance NHS Group, Salford, UK.
FAU - Brown, Steve
AU  - Brown S
AUID- ORCID: https://orcid.org/0000-0003-3715-580X
AD  - Children's Emergency Department, Leicester Royal Infirmary, Leicester, UK.
FAU - Roland, Damian
AU  - Roland D
AUID- ORCID: https://orcid.org/0000-0001-9334-5144
AD  - Children's Emergency Department, Leicester Royal Infirmary, Leicester, UK.
AD  - Paediatric Emergency Medicine, SAPPHIRE Group, University of Leicester,
      Leicester, UK.
LA  - eng
GR  - PB-PG-0815-20034/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200916
PL  - England
TA  - Compr Child Adolesc Nurs
JT  - Comprehensive child and adolescent nursing
JID - 101682864
OTO - NOTNLM
OT  - Emergency department
OT  - children
OT  - ethics
OT  - opt-out consent
OT  - research
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/16 17:11
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/09/16 17:11 [entrez]
AID - 10.1080/24694193.2020.1812766 [doi]
PST - aheadofprint
SO  - Compr Child Adolesc Nurs. 2020 Sep 16:1-12. doi: 10.1080/24694193.2020.1812766.


PMID- 32936587
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210914
IS  - 1538-1145 (Electronic)
IS  - 1527-4160 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Sep
TI  - Therapeutic Risk Management for Violence: Augmenting Clinical Risk Assessment
      With Structured Instruments.
PG  - 405-410
LID - 10.1097/PRA.0000000000000495 [doi]
AB  - Violence risk assessment is a requisite component of mental health treatment.
      Adhering to standards of care and ethical and legal requirements necessitates a
      cogent process for conducting, and then documenting, other-directed violence risk
      screening, assessment, and management. In this 5-part series, we describe a model
      for achieving therapeutic risk management of the potentially violent patient,
      with essential elements involving: clinical interview augmented by structured
      screening or assessment tools; risk stratification in terms of temporality and
      severity; chain analysis to intervene on the functions of violent ideation and
      behavior; and a personalized safety plan to mitigate/manage risk. This second
      column in the series describes the advantages of, and offers suggestions for,
      incorporating structured tools into violence risk assessment.
FAU - Wortzel, Hal S
AU  - Wortzel HS
FAU - Borges, Lauren M
AU  - Borges LM
FAU - McGarity, Suzanne
AU  - McGarity S
FAU - Nazem, Sarra
AU  - Nazem S
FAU - Barnes, Sean M
AU  - Barnes SM
FAU - Bahraini, Nazanin H
AU  - Bahraini NH
FAU - Clark, Kaily
AU  - Clark K
FAU - Matarazzo, Bridget B
AU  - Matarazzo BB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Psychiatr Pract
JT  - Journal of psychiatric practice
JID - 100901141
SB  - IM
MH  - Humans
MH  - Mental Disorders/*psychology
MH  - Risk Assessment/*methods
MH  - Violence/*prevention & control/*psychology
EDAT- 2020/09/17 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/09/16 16:44
PHST- 2020/09/16 16:44 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.1097/PRA.0000000000000495 [doi]
AID - 00131746-202009000-00008 [pii]
PST - ppublish
SO  - J Psychiatr Pract. 2020 Sep;26(5):405-410. doi: 10.1097/PRA.0000000000000495.


PMID- 32936113
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2042-8189 (Electronic)
IS  - 1478-2715 (Linking)
VI  - 50
IP  - 3
DP  - 2020 Sep
TI  - Usefulness of a workshop on scientific writing and publication in improving the
      baseline knowledge deficit among postgraduates.
PG  - 316-321
LID - 10.4997/JRCPE.2020.323 [doi]
AB  - BACKGROUND: A well-written manuscript published in a reputable journal is the
      deserved end-point of good research. It is important for postgraduates to be
      trained in scientific writing for their academic progression as well as the
      advancement of science. METHODS: A day-long workshop on scientific writing and
      publication was conducted at Raipur, India in February 2020. The medical
      postgraduate (UK equivalent: Core Medical Trainee) participants were engaged with
      lectures, discussions and a practical session requiring critical appraisal of a
      manuscript. The lectures also discussed publication ethics and the perils of
      falling prey to predatory journals. Pre and post-workshop surveys were given to
      the participants to assess the impact of the workshop on the baseline knowledge
      of scientific writing and publishing. RESULTS: Out of 69 participants, there were
      67 (response rate 97%) and 41 (response rate 59%) respondents to the pre and
      post-workshop surveys respectively. The former identified a lack of baseline
      knowledge ranging from 6% for determining the components of the individual
      sections of the manuscript such as Introduction or Methods, 40% for the use of
      acronyms, and 55% for knowledge of different referencing styles, to 61% for
      knowledge of indexing agencies. The post-workshop survey revealed improvement in 
      participants' knowledge of the contents of various sections of the manuscript and
      their knowledge about referencing styles and indexing agencies. In the
      post-workshop survey, 20% of respondents said that they would be open to engaging
      with predatory journals, which underscored the need to educate them continuously 
      regarding the demerits of such practice. Participants expressed the need for
      longer workshops, preferably spread over two days, with discussion on research
      methodology and statistical analysis, and more 'hands-on' sessions. CONCLUSION:
      This survey underscores the need for structured training in scientific writing.
      Its inclusion in the medical postgraduate curriculum appears desirable.
FAU - Goyal, Mohit
AU  - Goyal M
AD  - CARE Pain < Arthritis Centre, Udaipur 313002, India, Email:
      dr.mohitgoyal@gmail.com.
FAU - Dua, Amit
AU  - Dua A
AD  - Rheumatology < Arthritis Care, Dua's Clinic, Bilaspur, India.
FAU - Kedia, Arun
AU  - Kedia A
AD  - Lifeworth Hospital, Raipur, India.
FAU - Misra, Durga Prasanna
AU  - Misra DP
AD  - Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate
      Institute of Medical Sciences, Lucknow, India.
FAU - Santhanam, Sham
AU  - Santhanam S
AD  - Department of Rheumatology, Gleneagles Global Hospital, Chennai, India.
FAU - Ravindran, Vinod
AU  - Ravindran V
AD  - Centre for Rheumatology, Kozhikode, India.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J R Coll Physicians Edinb
JT  - The journal of the Royal College of Physicians of Edinburgh
JID - 101144324
SB  - IM
MH  - Curriculum
MH  - Humans
MH  - India
MH  - *Publishing
MH  - Surveys and Questionnaires
MH  - *Writing
OTO - NOTNLM
OT  - indexed journals
OT  - journal selection
OT  - manuscript writing
OT  - paper writing
OT  - predatory journals
OT  - publishing
COIS- MG, DPM, SS are Editors of the Indian Journal of Rheumatology (IJR). VR and DPM
      are the Editors of the Journal of the Royal College of Physicians of Edinburgh
      (JRCPE). AK and MG are on the reviewer boards of IJR and JCRPE. This paper has
      undergone peer review in accordance with JRCPE's policies.
EDAT- 2020/09/17 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/16 12:14
PHST- 2020/09/16 12:14 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.4997/JRCPE.2020.323 [doi]
PST - ppublish
SO  - J R Coll Physicians Edinb. 2020 Sep;50(3):316-321. doi: 10.4997/JRCPE.2020.323.


PMID- 32936101
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20201218
IS  - 2042-8189 (Electronic)
IS  - 1478-2715 (Linking)
VI  - 50
IP  - 3
DP  - 2020 Sep
TI  - COVID-19 at the intersections of science, morality and practice - reflections of 
      the physician's soul.
PG  - 274-276
LID - 10.4997/JRCPE.2020.311 [doi]
FAU - Gupta, Latika
AU  - Gupta L
AD  - Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate
      Institute of Medical Sciences, Lucknow, India.
FAU - Goel, Ashish
AU  - Goel A
AD  - Department of Medicine, University College of Medical Sciences, New Delhi, India,
      Email: ashgoe@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J R Coll Physicians Edinb
JT  - The journal of the Royal College of Physicians of Edinburgh
JID - 101144324
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/psychology
MH  - Global Health
MH  - Humans
MH  - *Leadership
MH  - *Pandemics
MH  - *Physician's Role
MH  - Physicians/*psychology
MH  - Pneumonia, Viral/*epidemiology/psychology
MH  - SARS-CoV-2
MH  - Survival Rate/trends
OTO - NOTNLM
OT  - *coronavirus
OT  - *ethics
OT  - *medicine
OT  - *pandemic
OT  - *psychology
COIS- No conflict of interests declared
EDAT- 2020/09/17 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/09/16 12:14
PHST- 2020/09/16 12:14 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - 10.4997/JRCPE.2020.311 [doi]
PST - ppublish
SO  - J R Coll Physicians Edinb. 2020 Sep;50(3):274-276. doi: 10.4997/JRCPE.2020.311.


PMID- 32936082
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep 16
TI  - Ethical Challenges and Opportunities Associated With the Ability to Perform
      Medical Screening From Interactions With Search Engines: Viewpoint.
PG  - e21922
LID - 10.2196/21922 [doi]
AB  - Recent research has shown the efficacy of screening for serious medical
      conditions from data collected while people interact with online services. In
      particular, queries to search engines and the interactions with them were shown
      to be advantageous for screening a range of conditions including diabetes,
      several forms of cancer, eating disorders, and depression. These screening
      abilities offer unique advantages in that they can serve a broad strata of the
      society, including people in underserved populations and in countries with poor
      access to medical services. However, these advantages need to be balanced against
      the potential harm to privacy, autonomy, and nonmaleficence, which are recognized
      as the cornerstones of ethical medical care. Here, we discuss these opportunities
      and challenges, both when collecting data to develop online screening services
      and when deploying them. We offer several solutions that balance the advantages
      of these services with the ethical challenges they pose.
CI  - (c)Elad Yom-Tov, Yuval Cherlow. Originally published in the Journal of Medical
      Internet Research (http://www.jmir.org), 16.09.2020.
FAU - Yom-Tov, Elad
AU  - Yom-Tov E
AUID- ORCID: 0000-0002-2380-4584
AD  - Microsoft Research, Herzeliya, Israel.
AD  - Faculty of Industrial Engineering and Management, Technion, Haifa, Israel.
FAU - Cherlow, Yuval
AU  - Cherlow Y
AUID- ORCID: 0000-0003-1063-4317
AD  - The Tzohar Rabbinical Organization, Lod, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Humans
MH  - Mass Screening/*ethics/standards
MH  - Search Engine/*standards
PMC - PMC7527909
OTO - NOTNLM
OT  - *diagnosis
OT  - *screening
OT  - *search engines
EDAT- 2020/09/17 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/09/16 12:14
PHST- 2020/06/29 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/09/16 12:14 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - v22i9e21922 [pii]
AID - 10.2196/21922 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Sep 16;22(9):e21922. doi: 10.2196/21922.


PMID- 32936058
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20220417
IS  - 1941-0921 (Electronic)
IS  - 1941-0921 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Nov/Dec
TI  - Understanding Cannabis-Based Therapeutics in Sports Medicine.
PG  - 540-546
LID - 10.1177/1941738120956604 [doi]
AB  - CONTEXT: With increased use of cannabis-based products by the public for both
      recreational and medical use, sports medicine clinicians should be informed of
      historical context, current legal considerations, and existing evidence with
      regard to efficacy, safety, and risks in the athletic community. EVIDENCE
      ACQUISITION: A review of ClinicalTrials.gov, MEDLINE, and CINAHL from 2015 to
      present was conducted with emphasis on the most recent literature using search
      terms, cannabis, nabiximols, cannabinoids, pain management, THC, CBD, and
      marijuana. Bibliographies based on original search were utilized to pursue
      further literature search. STUDY DESIGN: Clinical review. LEVEL OF EVIDENCE:
      Level 3. RESULTS: At present, limited high-quality studies exist for use of
      cannabinoids for acute pain, chronic pain, or concussion. None of the trials
      involving cannabinoids included the athletic population. Thus, results from this 
      clinical review are extrapolated to conditions of the sports medicine population.
      For acute pain, 2 small-randomized double-blinded crossover trials concluded no
      immediate effect of cannabinoid therapy. More robust evidence exists for
      treatment of chronic pain conditions through meta-analysis and systemic reviews. 
      Cannabinoid therapy exhibits moderate efficacy as a treatment for some chronic
      pain conditions. Investigations included a broad spectrum of chronic pain
      conditions, including neuropathic, musculoskeletal, inflammatory, and central
      pain conditions, and reveal reduction in pain and improvement of quality of life 
      with limited adverse effects. For concussion, evidence is based on preclinical in
      vitro and animal models revealing possible neuroprotective effects as well as 2
      clinical studies involving the presence of cannabinoids for concussion (some
      sports-related), but there are no high-quality trials evaluating efficacy for
      treatment with cannabinoids at this time. CONCLUSION: Although various
      biochemical explanations exist on the use of cannabinoid therapy through
      modulation of the endocannabinoid system for several medical issues affecting
      athletes, recommendations from clinicians must be extrapolated from a majority of
      research done in the nonathletic population. Lack of strong-quality clinical
      evidence, coupled with inconsistent federal and state law as well as purity
      issues with cannabis-based products, make it difficult for the sports medicine
      clinician to widely recommend cannabinoid therapeutics at present. Future larger,
      higher quality clinical research studies with standardized pure extracts will
      better guide appropriate medical use going forward. At present, evidence for a
      multitude of therapeutic applications is emerging for cannabinoid treatment
      approaches. With emphasis placed on patient-centered clinical decisions,
      cannabinoids hold promise of treatment for athletes with chronic pain conditions.
      Clinicians who treat the athletic community must consider legal and ethical
      issues when discussing and recommending the use of cannabinoids, with
      acknowledgment of inconsistencies in purity of various formulations and concerns 
      of drug testing.
FAU - Maurer, Gretchen E
AU  - Maurer GE
AD  - Lehigh Valley Health Network, Allentown, Pennsylvania.
FAU - Mathews, Neilson M
AU  - Mathews NM
AD  - Lehigh Valley Health Network, Allentown, Pennsylvania.
FAU - Schleich, Kevin T
AU  - Schleich KT
AD  - Carver College of Medicine, University of Iowa, Iowa City, Iowa.
FAU - Slayman, Tyler G
AU  - Slayman TG
AD  - Carver College of Medicine, University of Iowa, Iowa City, Iowa.
FAU - Marcussen, Britt L
AU  - Marcussen BL
AD  - Carver College of Medicine, University of Iowa, Iowa City, Iowa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200916
PL  - United States
TA  - Sports Health
JT  - Sports health
JID - 101518422
RN  - 0 (Cannabinoids)
RN  - 0 (Medical Marijuana)
SB  - IM
MH  - Acute Pain/drug therapy
MH  - Athletic Injuries/*complications/drug therapy
MH  - Brain Concussion/drug therapy
MH  - Cannabinoids/adverse effects/*therapeutic use
MH  - Chronic Pain/drug therapy
MH  - Evidence-Based Medicine/standards
MH  - Humans
MH  - Marijuana Use/legislation & jurisprudence
MH  - Medical Marijuana/adverse effects/*therapeutic use
MH  - Pain Management/*methods
MH  - United States
PMC - PMC7785900
OTO - NOTNLM
OT  - CBD
OT  - THC
OT  - cannabinoids
OT  - cannabis
OT  - endocannabinoid system
OT  - medical marijuana
EDAT- 2020/09/17 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/09/16 12:13
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/09/16 12:13 [entrez]
AID - 10.1177/1941738120956604 [doi]
PST - ppublish
SO  - Sports Health. 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604. Epub
      2020 Sep 16.


PMID- 32935149
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 34
IP  - 11
DP  - 2020 Nov
TI  - Informed consent: a shared decision-making process that creates a new
      professional obligation for care.
PG  - 4713-4716
LID - 10.1007/s00464-020-07970-1 [doi]
AB  - This statement on informed consent, developed by the SAGES Ethics Committee, has 
      been reviewed and approved by the Board of Governors of SAGES. This statement is 
      provided to offer guidance about the purpose and process of obtaining informed
      consent, and it is intended for practicing surgeons as well as patients seeking
      surgical intervention. It is an expression of well-established principles and
      extensive literature. Excluded from this document are discussions of informed
      consent for research and informed consent for introduction of new technology, as 
      that has been addressed in previous publications (Strong in Surg Endosc 28:2272, 
      2014; Stefanidis in Surg Endosc 28:2257, 2014; as reported by Sillin (in: Stain
      (ed) The SAGES Manual Ethics of Surgical Innovation, Springer, Switzerland,
      2016)).
FAU - Rawlings, Arthur
AU  - Rawlings A
AUID- ORCID: 0000-0002-6235-4424
AD  - Adjunct Faculty Center for Health Ethics, University of Missouri, Columbia, MO,
      USA. rawlingsa@health.missouri.edu.
AD  - Department of Surgery, University of Missouri, One Hospital Drive, Columbia, MO, 
      65212, USA. rawlingsa@health.missouri.edu.
FAU - Sillin, Lelan
AU  - Sillin L
AD  - Lahey Hospital & Medical Center, Burlington, MA, USA.
AD  - Tufts University School of Medicine, Boston, MA, USA.
FAU - Shadduck, Phillip
AU  - Shadduck P
AD  - Duke University, Durham, NC, USA.
FAU - McDonald, Marian
AU  - McDonald M
AD  - St Luke's University Health Network, Allentown Campus, Allentown, PA, USA.
AD  - Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
AD  - School of Education, Johns Hopkins University, Baltimore, MD, USA.
FAU - Crookes, Peter
AU  - Crookes P
AD  - Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
AD  - Medical Ethics & History, Queens University Belfast, Belfast, North Ireland, UK.
FAU - MacFadyen, Bruce Jr
AU  - MacFadyen B Jr
AD  - Medical College of Georgia, Augusta, GA, USA.
FAU - Mellinger, John
AU  - Mellinger J
AD  - Department of Surgery, Southern Illinois University School of Medicine,
      Springfield, IL, USA.
CN  - the SAGES Ethics Committee
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200915
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
SB  - IM
MH  - *Decision Making, Shared
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Surgeons/*ethics
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Autonomy
OT  - *Informed Consent
OT  - *Patient-physician relationship
OT  - *Shared decision making
EDAT- 2020/09/17 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/09/16 05:40
PHST- 2020/06/03 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/09/16 05:40 [entrez]
AID - 10.1007/s00464-020-07970-1 [doi]
AID - 10.1007/s00464-020-07970-1 [pii]
PST - ppublish
SO  - Surg Endosc. 2020 Nov;34(11):4713-4716. doi: 10.1007/s00464-020-07970-1. Epub
      2020 Sep 15.


PMID- 32934942
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200917
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - Some ethical concerns related to the coronavirus disease 2019 (COVID-19).
PG  - 53
LID - 10.34171/mjiri.34.53 [doi]
AB  - Although there are many important concerns related to coronavirus disease-19
      (COVID-19), ethical issues should remain the top priority since the humanistic
      dimension of the recent pandemic is of prime importance. This short commentary
      highlights some ethical concerns related to (COVID-19). Political misuse, caring 
      for older adults, and spread of harmful information are the 3 main issues that
      are addressed. It is hoped that those who can influence communities at large
      consider these issues for better public's health.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Montazeri, Ali
AU  - Montazeri A
AUID- ORCID: https://orcid.org/0000-0002-5198-9539
AD  - Population Health Research Group, Health Metrics Research Center, Iranian
      Institute for Health Sciences Research, ACECR, Tehran, Iran.
LA  - eng
PT  - Editorial
DEP - 20200527
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7481854
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Ethics
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:39
PHST- 2020/05/11 00:00 [received]
PHST- 2020/09/16 05:39 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.34171/mjiri.34.53 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 May 27;34:53. doi: 10.34171/mjiri.34.53. eCollection
      2020.


PMID- 32934920
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2223-9170 (Print)
IS  - 2223-9170 (Linking)
VI  - 9
DP  - 2020
TI  - COVID-19, disability and the context of healthcare triage in South Africa: Notes 
      in a time of pandemic.
PG  - 766
LID - 10.4102/ajod.v9i0.766 [doi]
AB  - During disasters, when resources and care are scarce, healthcare workers are
      required to make decisions and prioritise which patients receive life-saving
      resources over others. To assist healthcare workers in standardising resources
      and care, triage policies have been developed. However, the current COVID-19
      triage policies and practices in South Africa may exclude or disadvantage many
      disabled people, especially people with physical and intellectual impairments,
      from gaining intensive care unit (ICU) access and receiving ventilators if
      becoming ill. The exclusion of disabled people goes against the principles
      established in South Africa's Constitution, in which all people are regarded as
      equal, have the right to life and inherent dignity, the right to access
      healthcare, as well as the protection of dignity. In addition, the triage policy 
      contravenes the United Nations Convention on the Rights of Persons with
      Disabilities, which the South African government has signed and ratified. This
      article raises debates about whose lives matter and whose lives are 'worth'
      saving over others, and although the focus is on South Africa, the issues may be 
      relevant to other countries where life-saving resources are being rationed.
CI  - (c) 2020. The Authors.
FAU - McKinney, Emma L
AU  - McKinney EL
AUID- ORCID: https://orcid.org/0000-0001-7483-5463
AD  - Interdisciplinary Centre for Sports Science and Development, Community and Health
      Sciences, University of the Western Cape, Cape Town, South Africa.
FAU - McKinney, Victor
AU  - McKinney V
AUID- ORCID: https://orcid.org/0000-0003-1067-8934
AD  - Department of Health and Rehabilitation Sciences, Faculty of Health Sciences,
      University of Cape Town, Cape Town, South Africa.
FAU - Swartz, Leslie
AU  - Swartz L
AUID- ORCID: https://orcid.org/0000-0003-1741-5897
AD  - Department of Psychology, Faculty of Arts and Social Sciences, Stellenbosch
      University, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - South Africa
TA  - Afr J Disabil
JT  - African journal of disability
JID - 101623460
PMC - PMC7479422
OTO - NOTNLM
OT  - COVID-19
OT  - ICU admission
OT  - South Africa
OT  - accessibility
OT  - disabled people
OT  - ethics of care
OT  - triage policies
OT  - ventilators
COIS- The authors declare that they have no financial or personal relationships that
      may have inappropriately influenced them in writing this article.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:39
PHST- 2020/06/08 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/09/16 05:39 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.4102/ajod.v9i0.766 [doi]
AID - AJOD-9-766 [pii]
PST - epublish
SO  - Afr J Disabil. 2020 Aug 18;9:766. doi: 10.4102/ajod.v9i0.766. eCollection 2020.


PMID- 32934843
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1608-9685 (Print)
IS  - 1608-9685 (Linking)
VI  - 26
DP  - 2020
TI  - Professional quality of life amongst nurses in psychiatric observation units.
PG  - 1553
LID - 10.4102/sajpsychiatry.v26i0.1553 [doi]
AB  - BACKGROUND: Professional quality of life amongst nurses in psychiatric
      observations units may be affected by working conditions such as an overflow of
      mental health care users (MHCUs), a shortage of nurses, lack of specialised staff
      and inadequate infrastructure to accommodate MHCUs amongst others. AIM: The aim
      of the study was to investigate the professional quality of life amongst nurses
      in psychiatric observation units. SETTING: The study was conducted in psychiatric
      observation units in eight hospitals in the Metropole District Health Services in
      the Western Cape. METHOD: A quantitative descriptive survey design using the
      Professional Quality of Life (ProQoL version 5) questionnaire was conducted with 
      an all-inclusive sample of 175 nurses. The ProQoL has two scales, namely, the
      compassion satisfaction and the compassion fatigue. Compassion fatigue includes
      two subscales, burnout and secondary traumatic stress. Ethics to conduct the
      study was obtained from the Research Ethics Committee at the university and the
      Department of Health in the Western Cape. RESULTS: A response rate of 93% (n =
      163) was obtained. Respondents reported moderate compassion satisfaction.
      Psychiatric nurse specialists and registered nurses reported lower compassion
      satisfaction than enrolled nurses and nursing assistants. This came with moderate
      levels of burnout and high levels of secondary traumatic stress, with enrolled
      nurses and enrolled nursing assistants reporting lower levels than the other
      professional groups. CONCLUSION: Psychiatric nurse specialists and registered
      nurses experienced higher burnout and secondary traumatic stress and lower
      compassion satisfaction than the lower categories of nurses.
CI  - (c) 2020. The Authors.
FAU - Maila, Siyavuya
AU  - Maila S
AUID- ORCID: https://orcid.org/0000-0002-2567-2319
AD  - School of Nursing, University of the Western Cape, Cape Town, South Africa.
FAU - Martin, Penelope D
AU  - Martin PD
AUID- ORCID: https://orcid.org/0000-0002-4848-3350
AD  - School of Nursing, University of the Western Cape, Cape Town, South Africa.
FAU - Chipps, Jennifer
AU  - Chipps J
AUID- ORCID: https://orcid.org/0000-0002-7895-4483
AD  - School of Nursing, University of the Western Cape, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - South Africa
TA  - S Afr J Psychiatr
JT  - The South African journal of psychiatry : SAJP : the journal of the Society of
      Psychiatrists of South Africa
JID - 100958626
PMC - PMC7479368
OTO - NOTNLM
OT  - Burnout
OT  - Compassion Fatigue
OT  - Compassion Satisfaction
OT  - Professional Quality of Life
OT  - Secondary Traumatic Stress
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:39
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/09/16 05:39 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.4102/sajpsychiatry.v26i0.1553 [doi]
AID - SAJPsy-26-1553 [pii]
PST - epublish
SO  - S Afr J Psychiatr. 2020 Aug 25;26:1553. doi: 10.4102/sajpsychiatry.v26i0.1553.
      eCollection 2020.


PMID- 32934840
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1608-9685 (Print)
IS  - 1608-9685 (Linking)
VI  - 26
DP  - 2020
TI  - Challenges experienced by South African families caring for state patients on
      leave of absence.
PG  - 1453
LID - 10.4102/sajpsychiatry.v26i0.1453 [doi]
AB  - BACKGROUND: Families of state patients experience challenges related to the
      patient's mental illness and history of criminal behaviour. Family members who
      act as guardians when patients are on leave of absence take responsibility for
      the patient's basic needs, activities of daily living and treatment regimen. They
      need to safeguard the patient from potential self-harm and harming others. Few
      studies have explored the burden these family members experience. AIM: The aim of
      this study was to explore and describe the challenges experienced by families
      caring for mental state patients who are on leave of absence. SETTING: An urban
      area in South Africa. METHODS: A qualitative approach was applied to answer the
      research question, 'what are the challenges experienced by families caring for
      mental state patients on leave of absence?' A purposive sample of nine
      participants who were caring for state patients on leave of absence was selected.
      Individual in-depth interviews were used to collect data. Data were analysed
      using thematic analysis. Ethical considerations and trustworthiness guided the
      study. RESULTS: Three themes illustrate the challenges experienced by family
      members, namely, challenges related to state patient's behaviour, emotional
      challenges and social challenges. A fourth theme focuses on the ways families
      used to cope with these challenges. CONCLUSION: Mental healthcare professionals
      may use the results of this study to design therapeutic interventions for family 
      members of state patients who focus on empathetic understanding and the
      mobilisation of effective coping skills and social support.
CI  - (c) 2020. The Authors.
FAU - Mothwa, Nchaesa G
AU  - Mothwa NG
AUID- ORCID: https://orcid.org/0000-0003-3778-7647
AD  - Department of Nursing Science, Faculty of Health Sciences, University of
      Pretoria, Pretoria, South Africa.
FAU - Moagi, Miriam M
AU  - Moagi MM
AUID- ORCID: https://orcid.org/0000-0001-7291-1418
AD  - Department of Nursing Science, Faculty of Health Sciences, University of
      Pretoria, Pretoria, South Africa.
FAU - van der Wath, Anna E
AU  - van der Wath AE
AUID- ORCID: https://orcid.org/0000-0001-5117-9272
AD  - Department of Nursing Science, Faculty of Health Sciences, University of
      Pretoria, Pretoria, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - South Africa
TA  - S Afr J Psychiatr
JT  - The South African journal of psychiatry : SAJP : the journal of the Society of
      Psychiatrists of South Africa
JID - 100958626
PMC - PMC7479420
OTO - NOTNLM
OT  - burden of care
OT  - family
OT  - forensic patients
OT  - mental health
OT  - psychiatry
OT  - qualitative inquiry
COIS- The authors have declared that no competing interest exists.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:39
PHST- 2019/08/06 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/09/16 05:39 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.4102/sajpsychiatry.v26i0.1453 [doi]
AID - SAJPsy-26-1453 [pii]
PST - epublish
SO  - S Afr J Psychiatr. 2020 Aug 25;26:1453. doi: 10.4102/sajpsychiatry.v26i0.1453.
      eCollection 2020.


PMID- 32934828
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2071-9736 (Electronic)
IS  - 1025-9848 (Linking)
VI  - 25
DP  - 2020
TI  - Here and now: Lived experiences of professional nurses practising caring presence
      in a rural public hospital in the North West Province, South Africa.
PG  - 1405
LID - 10.4102/hsag.v25i0.1405 [doi]
AB  - BACKGROUND: Practising caring presence is recognised as an important nursing
      intervention indispensable to high-quality, patient-centred care. An awareness of
      the real world of professional nurses (PNs) practising caring presence will
      assist in expanding and supporting the existing literature on the same. A clear
      and rich description of what the concept of caring presence entails within the
      unique South African nursing context may guide nurses in the art of this nursing 
      skill, enhance their professionalism and facilitate the formulation of
      recommendations on how to encourage nurses to implement the practice of caring
      presence within nursing. AIM: This study explored and described the lived
      experiences of PNs practising caring presence in a rural public hospital.
      SETTING: The study setting was a 120-bed, level-two district hospital in the
      North West Province of South Africa. METHODS: A descriptive phenomenological
      method, specifically Husserl's approach, informed this study. Semi-structured
      interviews were conducted with a purposive sample of 10 PNs. Data were coded and 
      analysed using Colaizzi's seven-step method. RESULTS: Five themes emerged from
      the data analysis: professional caring presence, ethical caring presence,
      personal caring presence, healing caring presence and what caring presence is
      not. CONCLUSION: Professional nurses experience practising caring presence as
      professionally and personally fulfilling, as an expression of their passion for
      the profession, as a way of portraying ethical care, as a willingness to be
      personally present and as a healing experience that involves commitment and
      taking care of patients holistically. Unprofessional, unethical behaviour and
      depersonalisation of patients were indicated as uncaring behaviour.
CI  - (c) 2020. The Authors.
FAU - Hobbs, Petronella S
AU  - Hobbs PS
AUID- ORCID: https://orcid.org/0000-0002-4083-6174
AD  - NuMIQ Research Focus Area, School of Nursing Science, Faculty of Health Sciences,
      North-West University, Potchefstroom, South Africa.
FAU - du Plessis, Emmerentia
AU  - du Plessis E
AUID- ORCID: https://orcid.org/0000-0002-6469-2021
AD  - NuMIQ Research Focus Area, School of Nursing Science, Faculty of Health Sciences,
      North-West University, Potchefstroom, South Africa.
FAU - Benade, Petronella
AU  - Benade P
AUID- ORCID: 0000-0002-9392-5242
AD  - NuMIQ Research Focus Area, School of Nursing Science, Faculty of Health Sciences,
      North-West University, Potchefstroom, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - South Africa
TA  - Health SA
JT  - Health SA = SA Gesondheid
JID - 101213385
PMC - PMC7479393
OTO - NOTNLM
OT  - caring presence
OT  - descriptive phenomenology
OT  - lived experience
OT  - nursing presence
OT  - rural public hospital
COIS- The authors declare that they have no financial or personal relationships that
      may have inappropriately influenced them in writing this article.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:39
PHST- 2020/01/16 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/09/16 05:39 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.4102/hsag.v25i0.1405 [doi]
AID - HSAG-25-1405 [pii]
PST - epublish
SO  - Health SA. 2020 Aug 5;25:1405. doi: 10.4102/hsag.v25i0.1405. eCollection 2020.


PMID- 32934661
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Chinese Herbal Formula Xuefu Zhuyu for Stable Angina (CheruSA): Study Protocol
      for a Multicenter Randomized Controlled Trial.
PG  - 7612721
LID - 10.1155/2020/7612721 [doi]
AB  - Introduction. Stable angina (SA) in coronary heart disease is a common ischemic
      heart disease endangering the patient's quality of life and longevity. Clinical
      trials have demonstrated that the Chinese herbal formula Xuefu Zhuyu (XFZY) has
      benefits for SA patients. However, there remains a lack of high-quality evidence 
      to support clinical decision-making. Therefore, we designed a randomized
      controlled trial (RCT) to evaluate the efficacy and safety of XFZY for SA.
      Methods and Analysis. This multicenter, double-blinded RCT will be conducted in
      China. 152 eligible participants will be randomly assigned to either an XFZY
      group or a control group at a 1 : 1 ratio. Participants in the XFZY group will
      receive XFZY plus routine care, while those in the control group will receive
      placebo plus routine care. The study period is 26 weeks, including a 2-week
      run-in period, a 12-week treatment period, and a 12-week follow-up. The primary
      outcome is the change in visual analogue scale score for angina pain intensity
      from baseline to 12 weeks. The secondary outcomes are the angina attack frequency
      and duration, the nitroglycerin dosage consumed, the Canadian Cardiovascular
      Society grading of effort angina, the Seattle Angina Questionnaire, the
      EuroQol-5-Dimensions-5-Level, the incidence of major adverse cardiac events,
      health cost evaluation, and overall assessment for study drugs. Ethics and
      Dissemination. The study has been approved by the ethics committee of Guangdong
      Provincial Hospital of Chinese Medicine (approval no. BF2019-175-01). Results
      will be submitted for publication in peer-reviewed journals and disseminated at
      scientific conferences. This trial is registered with ChiCTR1900026899,
      registered on 26 October 2019.
CI  - Copyright (c) 2020 Shaojun Liao et al.
FAU - Liao, Shaojun
AU  - Liao S
AD  - Second Clinical Medical College (Second Affiliated Hospital), Guangzhou
      University of Chinese Medicine, Guangzhou 510405, China.
FAU - Zhang, Zhe
AU  - Zhang Z
AD  - Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China.
FAU - Li, Geng
AU  - Li G
AD  - Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of
      Chinese Medicine, Guangzhou 510120, China.
AD  - Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of
      Chinese Medicine, Guangzhou 510405, China.
FAU - Zhou, Li
AU  - Zhou L
AD  - Second Clinical Medical College (Second Affiliated Hospital), Guangzhou
      University of Chinese Medicine, Guangzhou 510405, China.
AD  - Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of
      Chinese Medicine, Guangzhou 510120, China.
FAU - Jiang, Junwen
AU  - Jiang J
AD  - Cardiovascular Department, Affiliated Hospital of Liaoning University of
      Traditional Chinese Medicine, Shenyang 110032, China.
FAU - Zhang, Ni
AU  - Zhang N
AD  - Cardiovascular Department, Affiliated Hospital of Liaoning University of
      Traditional Chinese Medicine, Shenyang 110032, China.
FAU - Wang, Yang
AU  - Wang Y
AD  - Cardiovascular Department, Affiliated Hospital of Liaoning University of
      Traditional Chinese Medicine, Shenyang 110032, China.
FAU - Du, Yi
AU  - Du Y
AUID- ORCID: https://orcid.org/0000-0002-8705-505X
AD  - Cardiovascular Department, Affiliated Hospital of Liaoning University of
      Traditional Chinese Medicine, Shenyang 110032, China.
FAU - Wen, Zehuai
AU  - Wen Z
AUID- ORCID: https://orcid.org/0000-0002-1797-2047
AD  - Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of
      Chinese Medicine, Guangzhou 510120, China.
AD  - State Key Laboratory of Dampness Syndrome of Chinese Medicine, Second Affiliated 
      Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7479468
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:38
PHST- 2020/05/10 00:00 [received]
PHST- 2020/08/15 00:00 [revised]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/09/16 05:38 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.1155/2020/7612721 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Aug 31;2020:7612721. doi:
      10.1155/2020/7612721. eCollection 2020.


PMID- 32933964
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 15
TI  - Microbiome Understanding in Maternity Study (MUMS), an Australian prospective
      longitudinal cohort study of maternal and infant microbiota: study protocol.
PG  - e040189
LID - 10.1136/bmjopen-2020-040189 [doi]
AB  - INTRODUCTION: Pregnancy induces significant physiological and cardiometabolic
      changes, and is associated with alterations in the maternal microbiota.
      Increasing rates of prepregnancy obesity, metabolic abnormalities and reduced
      physical activity, all impact negatively on the microbiota causing an imbalance
      between the commensal microorganisms (termed dysbiosis), which may drive
      complications, such as gestational diabetes or hypertensive disorders.
      Considerable work is needed to define the inter-relationships between the
      microbiome, nutrition, physical activity and pregnancy outcomes. The role of the 
      microbiota during pregnancy remains unclear. The aim of the study is to define
      microbiota signatures longitudinally throughout pregnancy and the first year post
      birth, and to identify key clinical and environmental variables that shape the
      female microbiota profile during and following pregnancy. METHODS AND ANALYSIS:
      The Microbiome Understanding in Maternity Study (MUMS) is an Australian
      prospective longitudinal cohort study involving 100 mother-infant pairs. Women
      are enrolled in their first trimester and followed longitudinally. Assessment
      occurs at <13+0, 20+0-24+6 and 32+0-36+6 weeks gestation, birth and 6 weeks, 6
      months and 12 months postpartum. At each assessment, self-collected oral, vaginal
      and faecal samples are collected with an additional postpartum skin swab and
      breastmilk sample. Each infant will have oral, faecal and skin swab samples
      collected. Measurements include anthropometrics, body composition, blood
      pressure, serum hormonal and metabolic parameters and vaginal pH. Dietary intake,
      physical activity and psychological state will be assessed using validated
      self-report questionnaires, and pregnancy and infant outcomes recorded.
      Parametric and non-parametric hypothesis tests will be used to test the
      association between high-risk and low-risk pregnancies and their outcomes. ETHICS
      AND DISSEMINATION: The study received the following approval: South Eastern
      Sydney Local Health District Research Ethics Committee (17/293
      (HREC/17/POWH/605). Results will be made available to the participants of MUMS,
      their families and the funding bodies; in the form of a summary document. Results
      for the greater maternity care community and other researchers will be
      disseminated through conferences, local, national and international presentations
      and peer-reviewed publications. TRIAL REGISTRATION NUMBER: ACTRN12618000471280
      (prospectively registered).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Susic, Daniella
AU  - Susic D
AUID- ORCID: 0000-0002-5607-5154
AD  - School of Women's and Children's Health, University of New South Wales Faculty of
      Medicine, Sydney, New South Wales, Australia d.susic@unsw.edu.au.
AD  - Microbiome Research Centre, University of New South Wales Faculty of Medicine,
      Sydney, New South Wales, Australia.
AD  - Department of Women's and Children's Health, St George Hospital, Sydney, New
      South Wales, Australia.
FAU - Davis, Gregory
AU  - Davis G
AUID- ORCID: 0000-0003-1856-3058
AD  - School of Women's and Children's Health, University of New South Wales Faculty of
      Medicine, Sydney, New South Wales, Australia.
AD  - Department of Women's and Children's Health, St George Hospital, Sydney, New
      South Wales, Australia.
FAU - O' Sullivan, Anthony J
AU  - O' Sullivan AJ
AUID- ORCID: 0000-0002-2244-330X
AD  - St George and Sutherland Clinical School, University of New South Wales Faculty
      of Medicine, Sydney, New South Wales, Australia.
FAU - McGovern, Emily
AU  - McGovern E
AUID- ORCID: 0000-0002-1865-7727
AD  - Microbiome Research Centre, University of New South Wales Faculty of Medicine,
      Sydney, New South Wales, Australia.
FAU - Harris, Katie
AU  - Harris K
AUID- ORCID: 0000-0003-2444-2869
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Roberts, Lynne M
AU  - Roberts LM
AUID- ORCID: 0000-0003-2339-3761
AD  - School of Women's and Children's Health, University of New South Wales Faculty of
      Medicine, Sydney, New South Wales, Australia.
AD  - St George and Sutherland Clinical School, University of New South Wales Faculty
      of Medicine, Sydney, New South Wales, Australia.
FAU - Craig, Maria E
AU  - Craig ME
AUID- ORCID: 0000-0001-6004-576X
AD  - School of Women's and Children's Health, University of New South Wales Faculty of
      Medicine, Sydney, New South Wales, Australia.
FAU - Mangos, George
AU  - Mangos G
AUID- ORCID: 0000-0001-5700-5417
AD  - St George and Sutherland Clinical School, University of New South Wales Faculty
      of Medicine, Sydney, New South Wales, Australia.
FAU - Hold, Georgina L
AU  - Hold GL
AUID- ORCID: 0000-0001-7573-3397
AD  - Microbiome Research Centre, University of New South Wales Faculty of Medicine,
      Sydney, New South Wales, Australia.
AD  - St George and Sutherland Clinical School, University of New South Wales Faculty
      of Medicine, Sydney, New South Wales, Australia.
FAU - El-Omar, Emad M
AU  - El-Omar EM
AUID- ORCID: 0000-0002-0011-3924
AD  - Microbiome Research Centre, University of New South Wales Faculty of Medicine,
      Sydney, New South Wales, Australia.
AD  - St George and Sutherland Clinical School, University of New South Wales Faculty
      of Medicine, Sydney, New South Wales, Australia.
FAU - Henry, Amanda
AU  - Henry A
AUID- ORCID: 0000-0002-7351-8922
AD  - School of Women's and Children's Health, University of New South Wales Faculty of
      Medicine, Sydney, New South Wales, Australia.
AD  - Department of Women's and Children's Health, St George Hospital, Sydney, New
      South Wales, Australia.
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618000471280
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Longitudinal Studies
MH  - *Maternal Health Services
MH  - *Microbiota
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7493111
OTO - NOTNLM
OT  - *maternal medicine
OT  - *microbiology
OT  - *obstetrics
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040189 [pii]
AID - 10.1136/bmjopen-2020-040189 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 15;10(9):e040189. doi: 10.1136/bmjopen-2020-040189.


PMID- 32933963
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 15
TI  - Perioperative management for people with chronic kidney disease receiving
      dialysis undergoing major surgery: a protocol for a scoping review.
PG  - e038725
LID - 10.1136/bmjopen-2020-038725 [doi]
AB  - INTRODUCTION: People with chronic kidney disease receiving dialysis (CKD G5D)
      have an increased risk of poor postoperative outcomes and a high incidence of
      major surgery. Despite the high burden of these combined risks, there is a
      paucity of evidence to support tailored perioperative strategies to manage this
      population. A comprehensive evidence synthesis would inform the management of
      these patients in the perioperative period and identify knowledge gaps. We
      describe a protocol for a scoping review of the literature to identify existing
      perioperative strategies, protocols, pathways and interventions for people with
      CKD G5D undergoing major surgery. METHODS AND ANALYSIS: We will conduct a scoping
      review in accordance with the Joanna Briggs Institute methodology and report per 
      the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension 
      for scoping reviews. In February 2020, we will complete our search of MEDLINE,
      EMBASE, CINAHL Plus, Cochrane Database of Systematic Reviews, and Cochrane
      Controlled Trials Registry for published literature from inception to present.
      All study types are eligible for inclusion, without language restriction. Studies
      reporting a perioperative intervention in adult patients with CKD G5D are
      eligible for inclusion. Studies in prevalent kidney transplant patients or
      patients with acute kidney injury, and studies that report on surgical approaches
      without consideration of perioperative management strategies, will be excluded.
      Reviewers will independently assess abstracts for all identified studies in
      duplicate, and again at the full-text stage. Following published literature
      searches, a search of the grey literature will be developed. We will extract and 
      narratively report study, participant and intervention details. This will include
      a summary table outlining the strategies employed, organised into post hoc
      developed perioperative domains. ETHICS AND DISSEMINATION: Ethical considerations
      do not apply to this scoping review. Findings will be disseminated through
      relevant conference presentations and publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Harrison, Tyrone G
AU  - Harrison TG
AUID- ORCID: 0000-0003-1068-8673
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - Hemmelgarn, Brenda R
AU  - Hemmelgarn BR
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Division of Nephrology, Department of Medicine, University of Alberta Faculty of 
      Medicine and Dentistry, Edmonton, Alberta, Canada.
FAU - Farragher, Janine F
AU  - Farragher JF
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - O'Rielly, Connor
AU  - O'Rielly C
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - Donald, Maoliosa
AU  - Donald M
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - James, Matthew
AU  - James M
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
AD  - O'Brien Institute for Public Health, University of Calgary Cumming School of
      Medicine, Calgary, Alberta, Canada.
AD  - Libin Cardiovascular Institute, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
FAU - McCaughey, Deirdre
AU  - McCaughey D
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
AD  - O'Brien Institute for Public Health, University of Calgary Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - Ruzycki, Shannon M
AU  - Ruzycki SM
AUID- ORCID: 0000-0002-8122-2910
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - Zarnke, Kelly B
AU  - Zarnke KB
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
AD  - O'Brien Institute for Public Health, University of Calgary Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - Ronksley, Paul E
AU  - Ronksley PE
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada peronksl@ucalgary.ca.
AD  - O'Brien Institute for Public Health, University of Calgary Cumming School of
      Medicine, Calgary, Alberta, Canada.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Kidney Transplantation
MH  - Renal Dialysis
MH  - *Renal Insufficiency, Chronic/complications/therapy
MH  - Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7493104
OTO - NOTNLM
OT  - *adult nephrology
OT  - *adult surgery
OT  - *dialysis
OT  - *end stage renal failure
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038725 [pii]
AID - 10.1136/bmjopen-2020-038725 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 15;10(9):e038725. doi: 10.1136/bmjopen-2020-038725.


PMID- 32933961
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 15
TI  - Six countries, six individuals: resourceful patients navigating medical records
      in Australia, Canada, Chile, Japan, Sweden and the USA.
PG  - e037016
LID - 10.1136/bmjopen-2020-037016 [doi]
AB  - In the absence of international standards, widely differing attitudes and laws,
      medical and social cultures strongly influence whether and how patients may
      access their medical records in various settings of care. Reviewing records,
      including the notes clinicians write, can help shape how people participate in
      their own care. Aided at times by new technologies, individual patients and care 
      partners are repurposing existing tools and designing innovative, often
      'low-tech' ways to collect, sort and interpret their own health information. To
      illustrate diverse approaches that individuals may take, six individuals from six
      nations offer anecdotes demonstrating how they are learning to collect, assess
      and benefit from their personal health information.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Salmi, Liz
AU  - Salmi L
AUID- ORCID: 0000-0003-3798-7438
AD  - Department of General Medicine, Beth Israel Deaconess Medical Center, Boston,
      Massachusetts, USA lsalmi@bidmc.harvard.edu.
FAU - Brudnicki, Selina
AU  - Brudnicki S
AD  - University Health Network, Toronto, Ontario, Canada.
FAU - Isono, Maho
AU  - Isono M
AD  - International University of Health and Welfare, Otawara, Japan.
FAU - Riggare, Sara
AU  - Riggare S
AD  - Health Informatics Centre, Karolinska Institutet, Stockholm, Sweden.
FAU - Rodriquez, Cecilia
AU  - Rodriquez C
AD  - Fundacion Me Muevo, Santiago, Chile.
FAU - Schaper, Louise K
AU  - Schaper LK
AD  - Health Informatics Society of Australia, Victoria, South Australia, Australia.
FAU - Walker, Jan
AU  - Walker J
AUID- ORCID: 0000-0001-9366-1200
AD  - Department of General Medicine, Beth Israel Deaconess Medical Center, Boston,
      Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Delbanco, Tom
AU  - Delbanco T
AD  - Department of General Medicine, Beth Israel Deaconess Medical Center, Boston,
      Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Canada
MH  - Chile
MH  - *Health Records, Personal
MH  - Humans
MH  - Japan
MH  - *Medical Records
MH  - Sweden
PMC - PMC7493106
OTO - NOTNLM
OT  - *ethics (see medical ethics)
OT  - *general medicine (see internal medicine)
OT  - *health informatics
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037016 [pii]
AID - 10.1136/bmjopen-2020-037016 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 15;10(9):e037016. doi: 10.1136/bmjopen-2020-037016.


PMID- 32933956
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 15
TI  - Role of brain tissue oxygenation (PbtO2) in the management of subarachnoid
      haemorrhage: a scoping review protocol.
PG  - e035521
LID - 10.1136/bmjopen-2019-035521 [doi]
AB  - INTRODUCTION: In patients with subarachnoid haemorrhage (SAH), the initial brain 
      oedema and increased blood volume can cause an increase in intracranial pressure 
      (ICP) leading to impaired cerebral perfusion and tissue hypoxia. However, ICP
      monitoring may not be enough to detect tissue hypoxia, which can also occur in
      the absence of elevated ICP. Moreover, some patients will experience tissue
      hypoxia in a later phase after admission due to the occurrence of delayed
      cerebral ischaemia. Therefore, the measurement of brain oxygenation using
      invasive techniques has become of great interest. This scoping review seeks to
      examine the role of brain tissue oxygenation in the management of patients with
      SAH, mapping the existing literature to identify areas for future research.
      METHODS AND ANALYSIS: This scoping review has been planned following the Joanna
      Briggs Institute recommendations and the Preferred Reporting Items for Systematic
      Reviews and Meta-Analyses guidelines. The literature search will be performed
      using several databases: Medline, EMBASE, the Cochrane Central Register of
      Controlled Trials and Grey literature. The database searches are planned from the
      inception to May 2020. Two reviewers will independently screen titles and
      abstracts, followed by full-text screening of potentially relevant articles with 
      a standardised data extraction. Articles eligible for the inclusion will be
      discussed with a third reviewer. ETHICS AND DISSEMINATION: This paper does not
      require ethics approval. The results of our evaluation will be disseminated on
      author's web sites. Additional dissemination will occur through presentations at 
      conferences, such as courses and science education conferences, regionally and
      nationally, and through articles published in peer-reviewed journals. SCOPING
      REVIEW REGISTRATION: Open Science Framework Registration:
      https://doi.org/10.17605/OSF.IO/ZYJ7R.Trial registration numberClinicalTrials.gov
      Identifier: NCT03754114.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fiore, Marco
AU  - Fiore M
AUID- ORCID: 0000-0001-7263-0229
AD  - Department of Intensive Care, Universite Libre de Bruxelles, Bruxelles,
      Bruxelles, Belgium marco.fiore@unicampania.it.
AD  - Department of Women, Child and General and Specialized Surgery, Universita degli 
      Studi della Campania Luigi Vanvitelli, Napoli, Italy.
FAU - Bogossian, Elisa
AU  - Bogossian E
AD  - Department of Intensive Care, Universite Libre de Bruxelles, Bruxelles,
      Bruxelles, Belgium.
FAU - Creteur, Jacques
AU  - Creteur J
AD  - Department of Intensive Care, Universite Libre de Bruxelles, Bruxelles,
      Bruxelles, Belgium.
FAU - Oddo, Mauro
AU  - Oddo M
AD  - Department of Intensive Care Medicine, University of Lausanne, Lausanne, Vaud,
      Switzerland.
FAU - Taccone, Fabio Silvio
AU  - Taccone FS
AD  - Department of Intensive Care, Universite Libre de Bruxelles, Bruxelles,
      Bruxelles, Belgium.
LA  - eng
SI  - ClinicalTrials.gov/NCT03754114
PT  - Journal Article
DEP - 20200915
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brain
MH  - Humans
MH  - *Intracranial Hypertension
MH  - Intracranial Pressure
MH  - Peer Review
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Subarachnoid Hemorrhage/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7493101
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *neurology
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035521 [pii]
AID - 10.1136/bmjopen-2019-035521 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 15;10(9):e035521. doi: 10.1136/bmjopen-2019-035521.


PMID- 32933955
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 15
TI  - Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination
      with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the
      combination of vaccination and chemoprevention.
PG  - e035433
LID - 10.1136/bmjopen-2019-035433 [doi]
AB  - INTRODUCTION: Seasonal malaria chemoprevention (SMC), with
      sulphadoxine-pyrimethamine plus amodiaquine (SP+AQ) is effective but does not
      provide complete protection against clinical malaria. The RTS,S/AS01E malaria
      vaccine provides a high level of protection shortly after vaccination, but this
      wanes rapidly. Such a vaccine could be an alternative or additive to SMC. This
      trial aims to determine whether seasonal vaccination with RTS,S/AS01E vaccine
      could be an alternative to SMC and whether a combination of the two interventions
      would provide added benefits. METHODS AND ANALYSIS: This is an individually
      randomised, double-blind, placebo-controlled trial. 5920 children aged 5-17
      months were enrolled in April 2017 in Mali and Burkina Faso. Children in group 1 
      received three priming doses of RTS,S/AS01E vaccine before the start of the 2017 
      malaria transmission season and a booster dose at the beginning of two subsequent
      transmission seasons. In addition, they received SMC SP+AQ placebo on four
      occasions each year. Children in group 2 received three doses of rabies vaccine
      in year 1 and hepatitis A vaccine in years 2 and 3 together with four cycles of
      SMC SP+AQ each year. Children in group 3 received RTS,S/AS01E vaccine and four
      courses of SMC SP+AQ. Incidence of clinical malaria is determined by case
      detection at health facilities. Weekly active surveillance for malaria is
      undertaken in a randomly selected subset of children. The prevalence of malaria
      is measured in surveys at the end of each transmission season. The primary
      endpoint is the incidence of clinical malaria confirmed by a positive blood film 
      with a minimum parasite density of 5000 /microL. Primary analysis will be by
      modified intention to treat defined as children who have received the first dose 
      of the malaria or control vaccine. ETHICS AND DISSEMINATION: The protocol was
      approved by the national ethics committees of Mali and Burkina Faso and the
      London School of Hygiene and Tropical Medicine. The results will be presented to 
      all stakeholders and published in open access journals. TRIAL REGISTRATION
      NUMBER: NCT03143218; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chandramohan, Daniel
AU  - Chandramohan D
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, UK Daniel.Chandramohan@lshtm.ac.uk.
FAU - Dicko, Alassane
AU  - Dicko A
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Zongo, Issaka
AU  - Zongo I
AD  - Institut de Recherche en Sciences de la Sante, Bobo-Dioulasso, Burkina Faso.
FAU - Sagara, Issaka
AU  - Sagara I
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Cairns, Matthew
AU  - Cairns M
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Kuepfer, Irene
AU  - Kuepfer I
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, UK.
FAU - Diarra, Modibo
AU  - Diarra M
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Tapily, Amadou
AU  - Tapily A
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Issiaka, Djibrilla
AU  - Issiaka D
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Sanogo, Koualy
AU  - Sanogo K
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Mahamar, Almahamoudou
AU  - Mahamar A
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Sompougdou, Frederic
AU  - Sompougdou F
AD  - Institut de Recherche en Sciences de la Sante, Bobo-Dioulasso, Burkina Faso.
FAU - Yerbanga, Serge
AU  - Yerbanga S
AD  - Institut de Recherche en Sciences de la Sante, Bobo-Dioulasso, Burkina Faso.
FAU - Thera, Ismaila
AU  - Thera I
AD  - Malaria Research and Training Center, Bamako, Mali.
FAU - Milligan, Paul
AU  - Milligan P
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Tinto, Halidou
AU  - Tinto H
AD  - Institut de Recherche en Sciences de la Sante, Bobo-Dioulasso, Burkina Faso.
FAU - Ofori-Anyinam, Opokua
AU  - Ofori-Anyinam O
AD  - GlaxoSmithKline Biologicals SA, Wavre, Belgium.
FAU - Ouedraogo, Jean-Bosco
AU  - Ouedraogo JB
AD  - Institut de Recherche en Sciences de la Sante, Bobo-Dioulasso, Burkina Faso.
FAU - Greenwood, B
AU  - Greenwood B
AD  - Department of Disease Control, London School of Hygiene and Tropical Medicine,
      London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03143218
GR  - MR/P006876/1/MRC_/Medical Research Council/United Kingdom
GR  - Department of Health [UK]/International
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antimalarials)
RN  - 0 (Malaria Vaccines)
SB  - IM
MH  - *Antimalarials/therapeutic use
MH  - Burkina Faso/epidemiology
MH  - Chemoprevention
MH  - Child
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Infant
MH  - London
MH  - *Malaria/drug therapy/epidemiology/prevention & control
MH  - *Malaria Vaccines
MH  - *Malaria, Falciparum/drug therapy/epidemiology/prevention & control
MH  - Mali
MH  - Randomized Controlled Trials as Topic
MH  - Seasons
MH  - Vaccination
PMC - PMC7493088
OTO - NOTNLM
OT  - *epidemiology
OT  - *immunology
OT  - *tropical medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035433 [pii]
AID - 10.1136/bmjopen-2019-035433 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 15;10(9):e035433. doi: 10.1136/bmjopen-2019-035433.


PMID- 32933953
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20220429
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 15
TI  - Protocol for the impact of CBT for insomnia on pain symptoms and central
      sensitisation in fibromyalgia: a randomised controlled trial.
PG  - e033760
LID - 10.1136/bmjopen-2019-033760 [doi]
AB  - INTRODUCTION: Approximately 50% of individuals with fibromyalgia (a chronic
      widespread pain condition) have comorbid insomnia. Treatment for these comorbid
      cases typically target pain, but growing research supports direct interventions
      for insomnia (eg, cognitive behavioural treatment for insomnia (CBT-I)) in these 
      patients. Previous research suggests sustained hyperarousal mediated by a neural 
      central sensitisation mechanism may underlie insomnia and chronic pain symptoms
      in fibromyalgia. We hypothesise CBT-I will improve insomnia symptoms, improve
      clinical pain and reduce central sensitisation. The trial will be the first to
      evaluate the short-term and long-term neural mechanisms underlying insomnia and
      pain improvements in fibromyalgia. Knowledge obtained from this trial might allow
      us to develop new or modify current treatments to better target pain mechanisms, 
      perhaps reversing chronic pain or preventing it. METHODS AND ANALYSIS: Female
      participants (n=130) 18 years of age and older with comorbid fibromyalgia (with
      pain severity of at least 50/100) and insomnia will be recruited from the
      University of Missouri in Columbia, Missouri, and surrounding areas. Participants
      will be randomised to 8 weeks (plus 4 bimonthly booster sessions) of CBT-I or a
      sleep hygiene control group (SH). Participants will be assessed at baseline,
      post-treatment, 6 and 12 months follow-ups. The following assessments will be
      completed: 2 weeks of daily diaries measuring sleep and pain, daily actigraphy,
      insomnia severity index, pain-related disability, single night of polysomnography
      recording, arousal (heart rate variability, cognitive affective arousal),
      structural and functional MRI to examine pain-related neural activity and
      plasticity and mood (depression, anxiety). ETHICS AND DISSEMINATION: Ethics
      approval was obtained in July 2018 from the University of Missouri. All data are 
      expected to be collected by 2022. Full trial results are planned to be published 
      by 2024. Secondary analyses of baseline data will be subsequently published.
      TRIAL REGISTRATION NUMBER: NCT03744156.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McCrae, Christina S
AU  - McCrae CS
AUID- ORCID: 0000-0003-4313-6867
AD  - Department of Psychiatry, University of Missouri System, Columbia, Missouri, USA 
      mccraec@health.missouri.edu.
FAU - Curtis, Ashley F
AU  - Curtis AF
AUID- ORCID: 0000-0002-2311-5674
AD  - Departments of Psychiatry and Psychological Sciences, University of Missouri,
      Columbia, Missouri, USA.
FAU - Craggs, Jason
AU  - Craggs J
AD  - Departments of Physical Therapy and Psychological Sciences, University of
      Missouri, Columbia, Missouri, USA.
FAU - Deroche, Chelsea
AU  - Deroche C
AD  - Department of Health Management and Informatics, University of Missouri,
      Columbia, Missouri, USA.
FAU - Sahota, Pradeep
AU  - Sahota P
AD  - Department of Neurology, University of Missouri, Columbia, Missouri, USA.
FAU - Siva, Chokkalingam
AU  - Siva C
AD  - Division of Immunology and Rheumatology, University of Missouri, Columbia,
      Missouri, USA.
FAU - Staud, Roland
AU  - Staud R
AD  - Department of Rheumatology, University of Florida, Gainesville, Florida, USA.
FAU - Robinson, Michael
AU  - Robinson M
AD  - Department of Clinical and Health Psychology, University of Florida, Gainesville,
      Florida, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03744156
GR  - R01 AR055160/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Central Nervous System Sensitization
MH  - Female
MH  - *Fibromyalgia/complications/therapy
MH  - Humans
MH  - Missouri
MH  - *Sleep Initiation and Maintenance Disorders/therapy
MH  - Treatment Outcome
PMC - PMC7493102
OTO - NOTNLM
OT  - *chronic pain
OT  - *cognitive behavioural therapy for insomnia
OT  - *fibromyalgia
OT  - *functional magnetic resonance imaging
OT  - *insomnia
OT  - *randomised controlled trial protocol
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2019-033760 [pii]
AID - 10.1136/bmjopen-2019-033760 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 15;10(9):e033760. doi: 10.1136/bmjopen-2019-033760.


PMID- 32933927
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Sep
TI  - Effect of a pulmonary rehabilitation programme of 8 weeks compared to 12 weeks
      duration on exercise capacity in people with chronic obstructive pulmonary
      disease (PuRe Duration): protocol for a randomised controlled trial.
LID - e000687 [pii]
LID - 10.1136/bmjresp-2020-000687 [doi]
AB  - INTRODUCTION: Pulmonary rehabilitation (PR) is a key component in the management 
      of chronic obstructive pulmonary disease (COPD). There is no strong evidence on
      the optimal duration of PR programmes. The aim of this study is to determine
      whether an 8-week PR programme is equivalent to a 12-week PR programme in people 
      with COPD. METHODS AND ANALYSIS: This study will be a prospective, multisite,
      randomised controlled, equivalence trial with assessors blinded to group
      allocation and intention-to-treat analysis. 72 participants with COPD will be
      recruited and randomised to either a supervised, twice weekly for 8 weeks or a
      12-week PR programme of exercise training and education. PRIMARY OUTCOME:
      endurance shuttle walk test. SECONDARY OUTCOMES: will include St George's
      Respiratory Questionnaire, 6-min walk distance, COPD assessment test, Hospital
      Anxiety and Depression Scale, physical activity monitoring and hospital
      admissions at 6 months and 12 months. Repeated measures analysis of variance will
      be used to analyse differences between the groups for all outcomes. ETHICS AND
      DISSEMINATION: Ethics approval was gained from all participating sites. Results
      of the trial will be submitted for publication in a peer-reviewed journal. TRIAL 
      REGISTRATION NUMBER: ACTRN12616001586404.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bishop, Joshua
AU  - Bishop J
AD  - Physiotherapy, Balmain Hospital, Balmain, New South Wales, Australia
      joshua.bishop@health.nsw.gov.au.
AD  - Physiotherapy, The University of Sydney Faculty of Medicine and Health, Sydney,
      New South Wales, Australia.
FAU - Spencer, Lissa
AU  - Spencer L
AD  - Physiotherapy, The University of Sydney Faculty of Medicine and Health, Sydney,
      New South Wales, Australia.
AD  - Physiotherapy, Royal Prince Alfred Hospital, Camperdown, New South Wales,
      Australia.
FAU - Alison, Jennifer
AU  - Alison J
AD  - Physiotherapy, The University of Sydney Faculty of Medicine and Health, Sydney,
      New South Wales, Australia.
AD  - Physiotherapy, Royal Prince Alfred Hospital, Camperdown, New South Wales,
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12616001586404
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
SB  - IM
MH  - Equivalence Trials as Topic
MH  - Exercise
MH  - Exercise Therapy/*methods
MH  - *Exercise Tolerance
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Patient Admission/statistics & numerical data
MH  - Patient Education as Topic
MH  - Prospective Studies
MH  - Pulmonary Disease, Chronic Obstructive/*rehabilitation
MH  - Randomized Controlled Trials as Topic
MH  - Surveys and Questionnaires
MH  - *Walk Test
PMC - PMC7493114
OTO - NOTNLM
OT  - *COPD exacerbations
OT  - *exercise
OT  - *pulmonary rehabilitation
COIS- Competing interests: None declared.
EDAT- 2020/09/17 06:00
MHDA- 2021/07/24 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/06/22 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/16 05:32 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
AID - 7/1/e000687 [pii]
AID - 10.1136/bmjresp-2020-000687 [doi]
PST - ppublish
SO  - BMJ Open Respir Res. 2020 Sep;7(1). pii: 7/1/e000687. doi:
      10.1136/bmjresp-2020-000687.


PMID- 32933878
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - An ethics-based approach to global health research part 4: Scholarship and
      publications.
PG  - 1597-1601
LID - S1551-7411(20)30156-X [pii]
LID - 10.1016/j.sapharm.2020.06.015 [doi]
AB  - Disseminating research findings from global health collaborations is essential to
      advancing science. However, there are a number of ethical considerations and
      potential challenges to address to ensure thoughtful and non-exploitative
      reporting. The factors include the benefits and risks to publication, authorship 
      criteria or values, and the accessibility of forums or journals in which to
      pursue publication. This paper provides commentary related to planning for
      writing, communicating intentions to publish, obtaining permissions to publish,
      risks in internationally collaborative work, authorship principles, and journal
      selection. Authors' and editors' knowledge of experienced individuals from both
      pharmacy literature, medical fields, and general publications is incorporated to 
      provide an assessment of risks and benefits of publication of international
      global health research.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Abrons, Jeanine P
AU  - Abrons JP
AD  - University of Iowa, College of Pharmacy, 180 S Grand Avenue, Iowa City, IA,
      52242, USA. Electronic address: jeanine-abrons@uiowa.edu.
FAU - Jonkman, Lauren J
AU  - Jonkman LJ
AD  - University of Pittsburgh, School of Pharmacy, 5607 Baum Blvd., Suite 303,
      Pittsburgh, PA, 15206, USA. Electronic address: ljf1@pitt.edu.
FAU - Nonyel, Nkem P
AU  - Nonyel NP
AD  - University of Maryland Eastern Shore, School of Pharmacy and Health Professions, 
      1 College Backbone Road, Princess Anne, MD, 21853, USA. Electronic address:
      npnonyel@umes.edu.
FAU - Connor, Sharon E
AU  - Connor SE
AD  - University of Pittsburgh, School of Pharmacy, 5607 Baum Blvd., Suite 303,
      Pittsburgh, PA, 15206, USA; University of Pittsburgh, School of Pharmacy,
      Department of Pharmacy and Therapeutics, 5607 Baum Blvd., Suite 303, Pittsburg,
      PA, 15206, USA. Electronic address: sconnor@pitt.edu.
FAU - Ombengi, David N
AU  - Ombengi DN
AD  - Medical College of Wisconsin, School of Pharmacy and Department of Family
      Medicine, Center for Advancing Population Science (CAPS). Milwaukee, Wisconsin,
      8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. Electronic address:
      dombengi@mcw.edu.
FAU - Kahaleh, Abby A
AU  - Kahaleh AA
AD  - Roosevelt University College of Pharmacy, 1400 N Roosevelt Blvd, Schaumburg, IL, 
      60173, USA. Electronic address: akahaleh@roosevelt.edu.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
SB  - IM
MH  - Authorship
MH  - *Biomedical Research
MH  - Fellowships and Scholarships
MH  - *Global Health
MH  - Humans
MH  - Publishing
OTO - NOTNLM
OT  - Authorship
OT  - Ethical dilemmas
OT  - Global health
OT  - Health care ethics
OT  - Low- and middle-income countries
OT  - Pharmacy
OT  - Publication ethics
EDAT- 2020/09/17 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/09/16 05:32
PHST- 2020/02/17 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/09/16 05:32 [entrez]
AID - S1551-7411(20)30156-X [pii]
AID - 10.1016/j.sapharm.2020.06.015 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Nov;16(11):1597-1601. doi:
      10.1016/j.sapharm.2020.06.015. Epub 2020 Sep 2.


PMID- 32932832
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 18
DP  - 2020 Sep 11
TI  - Research Ethics with Gender and Sexually Diverse Persons.
LID - E6615 [pii]
LID - 10.3390/ijerph17186615 [doi]
AB  - Identifying and developing inclusive policy and practice responses to health and 
      social inequities in gender and sexually diverse persons require inclusive
      research ethics and methods in order to develop sound data. This article
      articulates 12 ethical principles for researchers undertaking gender and sexually
      diverse social, health, and related research. We have called these the 'Montreal 
      Ethical Principles for Inclusive Research.' While writing from an international
      social work perspective, our aim is to promote ethical research that benefits
      people being researched by all disciplines. This paper targets four groups of
      interest: 1. Cisgender and heterosexual researchers; 2. Researchers who research 
      'general' populations; 3. and sexually diverse researchers; 4. Human ethics
      committees. This article was stimulated by the 2018 Global Social Work Statement 
      of Ethical Principles, which positions human dignity at its core. It is
      critically important to understand and account for the intersectionality of
      gender and sexuality with discourses of race, ethnicity, colonialism,
      dis/ability, age, etc. Taking this intersectionality into consideration, this
      article draws on scholarship that underpins ethical principles developed for
      other minoritized communities, to ensure that research addresses the autonomy of 
      these participants at every stage. Research that positions inclusive research
      ethics at its foundation can provide a solid basis for policy and practice
      responses to health and social inequities in gender and sexually diverse persons.
FAU - Henrickson, Mark
AU  - Henrickson M
AUID- ORCID: 0000-0003-2769-5132
AD  - School of Social Work, Massey University, Auckland 0745, New Zealand.
FAU - Giwa, Sulaimon
AU  - Giwa S
AUID- ORCID: 0000-0001-8076-0277
AD  - School of Social Work, Memorial University of Newfoundland, St. John's, NL A1C
      5S7, Canada.
FAU - Hafford-Letchfield, Trish
AU  - Hafford-Letchfield T
AUID- ORCID: 0000-0003-0105-0678
AD  - School of Social Work and Social Policy, University of Strathclyde, Glasgow G4
      OLT, UK.
FAU - Cocker, Christine
AU  - Cocker C
AUID- ORCID: 0000-0002-4188-2316
AD  - School of Social Work, University of East Anglia, Norwich NR4 7TJ, UK.
FAU - Mule, Nick J
AU  - Mule NJ
AD  - School of Gender, Sexuality & Women's Studies, York University, Toronto, ON M3J
      1P3, Canada.
FAU - Schaub, Jason
AU  - Schaub J
AUID- ORCID: 0000-0002-6878-2366
AD  - Department of Social Work and Social Care, Birmingham University, Birmingham B15 
      2TT, UK.
FAU - Baril, Alexandre
AU  - Baril A
AD  - Ecole de Service Social/School of Social Work, University of Ottawa, Ottawa, ON
      K1N 6N5, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200911
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Ethics, Research
MH  - *Gender Identity
MH  - Humans
MH  - Research Personnel
MH  - *Sexual Behavior
MH  - Sexuality
PMC - PMC7559910
OTO - NOTNLM
OT  - *bisexual
OT  - *ethical principles
OT  - *gay
OT  - *gender diverse
OT  - *human ethics committees
OT  - *lesbian
OT  - *research ethics
OT  - *transgender
EDAT- 2020/09/17 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/09/16 01:01
PHST- 2020/08/12 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/16 01:01 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - ijerph17186615 [pii]
AID - 10.3390/ijerph17186615 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Sep 11;17(18). pii: ijerph17186615. doi:
      10.3390/ijerph17186615.


PMID- 32923689
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220129
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Half a Century of Wilson & Jungner: Reflections on the Governance of Population
      Screening.
PG  - 158
LID - 10.12688/wellcomeopenres.16057.2 [doi]
AB  - Background: In their landmark report on the "Principles and Practice of Screening
      for Disease" (1968), Wilson and Jungner noted that the practice of screening is
      just as important for securing beneficial outcomes and avoiding harms as the
      formulation of principles. Many jurisdictions have since established various
      kinds of "screening governance organizations" to provide oversight of screening
      practice. Yet to date there has been relatively little reflection on the nature
      and organization of screening governance itself, or on how different governance
      arrangements affect the way screening is implemented and perceived and the
      balance of benefits and harms it delivers. Methods: An international expert
      policy workshop convened by Sturdy, Miller and Hogarth. Results: While effective 
      governance is essential to promote beneficial screening practices and avoid
      attendant harms, screening governance organizations face enduring challenges.
      These challenges are social and ethical as much as technical. Evidence-based
      adjudication of the benefits and harms of population screening must take account 
      of factors that inform the production and interpretation of evidence, including
      the divergent professional, financial and personal commitments of stakeholders.
      Similarly, when planning and overseeing organized screening programs, screening
      governance organizations must persuade or compel multiple stakeholders to work
      together to a common end. Screening governance organizations in different
      jurisdictions vary widely in how they are constituted, how they relate to other
      interested organizations and actors, and what powers and authority they wield.
      Yet we know little about how these differences affect the way screening is
      implemented, and with what consequences. Conclusions: Systematic research into
      how screening governance is organized in different jurisdictions would facilitate
      policy learning to address enduring challenges. Even without such research,
      informal exchange and sharing of experiences between screening governance
      organizations can deliver invaluable insights into the social as well as the
      technical aspects of governance.
CI  - Copyright: (c) 2020 Sturdy S et al.
FAU - Sturdy, Steve
AU  - Sturdy S
AUID- ORCID: https://orcid.org/0000-0002-3273-1727
AD  - Science, Technology and Innovation Studies, University of Edinburgh, Edinburgh,
      EH1 1LZ, UK.
AD  - Centre for Biomedicine, Self and Society, University of Edinburgh, Edinburgh, EH8
      9LN, UK.
FAU - Miller, Fiona
AU  - Miller F
AUID- ORCID: https://orcid.org/0000-0003-4953-6255
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, M5T 3M6, Canada.
FAU - Hogarth, Stuart
AU  - Hogarth S
AD  - Department of Sociology, University of Cambridge, Cambridge, CB2 1SB, UK.
FAU - Armstrong, Natalie
AU  - Armstrong N
AUID- ORCID: https://orcid.org/0000-0003-4046-0119
AD  - University of Leicester, Leicester, UK.
FAU - Chakraborty, Pranesh
AU  - Chakraborty P
AD  - Children's Hospital of Eastern Ontario, Ottawa, Canada.
FAU - Cressman, Celine
AU  - Cressman C
AUID- ORCID: https://orcid.org/0000-0003-3262-0602
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, M5T 3M6, Canada.
FAU - Dobrow, Mark
AU  - Dobrow M
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, M5T 3M6, Canada.
FAU - Flitcroft, Kathy
AU  - Flitcroft K
AD  - Melanoma Institute Australia, Wollstonecraft, Australia.
FAU - Grossman, David
AU  - Grossman D
AD  - Kaiser Permanente Washington Health Research Institute, Seattle, USA.
FAU - Harris, Russell
AU  - Harris R
AD  - University of North Carolina, Chapel Hill, USA.
FAU - Hoebee, Barbara
AU  - Hoebee B
AD  - National Institute of Public Health and the Environment, Bilthoven, The
      Netherlands.
FAU - Holloway, Kelly
AU  - Holloway K
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, M5T 3M6, Canada.
FAU - Kinsinger, Linda
AU  - Kinsinger L
AD  - Independent Scholar, Durham, NC, USA.
FAU - Krag, Marlene
AU  - Krag M
AD  - Danish Health and Medicines Authority, Kobenhavn, Denmark.
FAU - Loblova, Olga
AU  - Loblova O
AD  - Department of Sociology, University of Cambridge, Cambridge, CB2 1SB, UK.
FAU - Lowy, Ilana
AU  - Lowy I
AD  - INSERM, Paris, France.
FAU - Mackie, Anne
AU  - Mackie A
AD  - Public Health England, London, UK.
FAU - Marshall, John
AU  - Marshall J
AD  - UK National Screening Committee, London, UK.
FAU - O'Hallahan, Jane
AU  - O'Hallahan J
AD  - Ministry of Health, Mount Victoria, New Zealand.
FAU - Rabeneck, Linda
AU  - Rabeneck L
AD  - Cancer Care Ontario, Toronto, Canada.
FAU - Raffle, Angela
AU  - Raffle A
AD  - Consultant in Public Health, Bristol, UK.
FAU - Reid, Lynette
AU  - Reid L
AUID- ORCID: https://orcid.org/0000-0002-3709-5061
AD  - Dalhousie University, Halifax, Canada.
FAU - Shortland, Graham
AU  - Shortland G
AD  - University Hospital of Wales, Cardiff, UK.
FAU - Steele, Robert
AU  - Steele R
AD  - University of Dundee, Dundee, UK.
FAU - Tarini, Beth
AU  - Tarini B
AD  - University of Iowa, Iowa City, USA.
FAU - Taylor-Phillips, Sian
AU  - Taylor-Phillips S
AUID- ORCID: https://orcid.org/0000-0002-1841-4346
AD  - University of Warwick, Warwick, UK.
FAU - Towler, Bernie
AU  - Towler B
AD  - Department of Health and Ageing, Canberra, Australia.
FAU - van der Veen, Nynke
AU  - van der Veen N
AD  - National Institute of Public Health and the Environment, Bilthoven, The
      Netherlands.
FAU - Zappa, Marco
AU  - Zappa M
AD  - Instituto per lo Studio e la Prevenzione Oncologica, Firenze, Italy.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - CDF-2016-09-018/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200817
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7468564
OTO - NOTNLM
OT  - governance
OT  - screening
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding 
      author). The following interests were declared: SH and OL reported grants from
      the European Research Council; KH and FM reported grants from the Canadian
      Institutes of Health Research; MK reported being the director responsible for
      national screening program in Denmark in the Danish Health Authority and
      chairperson of the advisory committee on national screening programmes to the
      Danish Health Authority; JM reported being a paid employee of the UK National
      Screening Committee; AR reported personal fees from UK National Screening
      Programmes; SS reported a grant from the Wellcome Trust.
EDAT- 2020/09/17 06:00
MHDA- 2020/09/17 06:01
CRDT- 2020/09/16 05:40
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/09/16 05:40 [entrez]
PHST- 2020/09/17 06:00 [pubmed]
PHST- 2020/09/17 06:01 [medline]
AID - 10.12688/wellcomeopenres.16057.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Aug 17;5:158. doi: 10.12688/wellcomeopenres.16057.2.
      eCollection 2020.


PMID- 32931918
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20211002
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Linking)
VI  - 97
DP  - 2020 Oct
TI  - Early administration of steroids in the ambulance setting: Protocol for a type I 
      hybrid effectiveness-implementation trial with a stepped wedge design.
PG  - 106141
LID - S1551-7144(20)30219-6 [pii]
LID - 10.1016/j.cct.2020.106141 [doi]
AB  - BACKGROUND: Pediatric asthma exacerbations are a frequent reason for emergency
      care. Early administration of oral systemic corticosteroids (OCS) in the
      emergency department (ED) decreases hospitalization rates and ED length-of-stay
      (LOS). However, it is unknown whether even earlier OCS administration by
      emergency medical services (EMS) in the prehospital setting further improves
      outcomes. PURPOSE: To describe the background and methods of a type 1 hybrid
      effectiveness-implementation trial of EMS-administered OCS for pediatric asthma
      patients incorporating a stepped wedge design and the RE-AIM framework. METHODS: 
      The study employs a non-randomized stepped wedge design where multiple EMS
      agencies adopt OCS as a treatment for pediatric asthma exacerbations at varying
      times. This design accommodates ethical considerations of studying pediatric
      subjects in the prehospital setting where informed consent is not feasible. We
      will compare hospitalization rates, ED LOS, and short-term healthcare costs
      between pediatric asthma patients who do and do not receive OCS from EMS. Using
      geographic information systems (GIS), we will measure how differences in outcomes
      scale with increasing EMS transport time. We will use the RE-AIM framework to
      guide a mixed methods analysis of barriers and enablers to EMS administration of 
      OCS for pediatric asthma patients, including quantitative measures of adoption
      and uptake and qualitative EMS provider focus group data. CONCLUSION: This trial 
      will determine if earlier EMS administration of OCS to pediatric asthma patients 
      decreases hospitalizations, ED LOS, and short-term healthcare costs, and if those
      outcomes scale with longer EMS transport times. We will identify barriers and
      enablers to implementing EMS-administered OCS for pediatric asthma patients.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Fishe, Jennifer N
AU  - Fishe JN
AD  - Department of Emergency Medicine, Division of Research, University of Florida
      College of Medicine, Jacksonville. 655 W. 8(th) St., Jacksonville, FL 32209,
      United States of America; Center for Data Solutions, University of Florida
      College of Medicine - Jacksonville, 655 W. 11(th) St., Jacksonville, FL 32209,
      United States of America. Electronic address: Jennifer.Fishe@jax.ufl.edu.
FAU - Hendry, Phyllis
AU  - Hendry P
AD  - Department of Emergency Medicine, Division of Research, University of Florida
      College of Medicine, Jacksonville. 655 W. 8(th) St., Jacksonville, FL 32209,
      United States of America. Electronic address: Phyllis.Hendry@jax.ufl.edu.
FAU - Brailsford, Jennifer
AU  - Brailsford J
AD  - Center for Data Solutions, University of Florida College of Medicine -
      Jacksonville, 655 W. 11(th) St., Jacksonville, FL 32209, United States of
      America. Electronic address: Jennifer.Brailsford@jax.ufl.edu.
FAU - Salloum, Ramzi G
AU  - Salloum RG
AD  - Department of Health Outcomes and Bioinformatics, University of Florida College
      of Medicine, 2004 Mowry Road, Gainesville, FL 32610, United States of America.
      Electronic address: RSalloum@ufl.edu.
FAU - Vogel, Bruce
AU  - Vogel B
AD  - Department of Health Outcomes and Bioinformatics, University of Florida College
      of Medicine, 2004 Mowry Road, Gainesville, FL 32610, United States of America.
      Electronic address: BVogel@ufl.edu.
FAU - Finlay, Erik
AU  - Finlay E
AD  - GeoPlan Center, University of Florida College of Design, Construction, and
      Planning. 1480 Inner Rd, Gainesivlle, FL 32601, United States of America.
      Electronic address: ErikF@geoplan.ufl.edu.
FAU - Palmer, Sam
AU  - Palmer S
AD  - GeoPlan Center, University of Florida College of Design, Construction, and
      Planning. 1480 Inner Rd, Gainesivlle, FL 32601, United States of America.
      Electronic address: Sam@geoplan.ufl.edu.
FAU - Datta, Susmita
AU  - Datta S
AD  - Department of Biostatistics, University of Florida. 2004 Mowry Road, 5(th) Floor 
      CTRB, Gainesville, FL 32611, United States of America. Electronic address:
      Susmita.Datta@ufl.edu.
FAU - Hendeles, Leslie
AU  - Hendeles L
AD  - Department of Pediatrics, Pediatric Pulmonary Division, University of Florida
      College of Medicine, 1600 SW Archer Rd, Ste HD-506, Gainesville, FL 32610, United
      States of America.
FAU - Blake, Kathryn
AU  - Blake K
AD  - Nemours Center for Pharmacogenomics and Translational Research, 807 Children's
      Way, Jacksonville, FL 32207, United States of America. Electronic address:
      Kathryn.Blake@nemours.org.
LA  - eng
GR  - K23 HL149991/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200912
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
RN  - 0 (Steroids)
SB  - IM
MH  - *Ambulances
MH  - Child
MH  - *Emergency Medical Services
MH  - Emergency Service, Hospital
MH  - Hospitalization
MH  - Humans
MH  - *Steroids/therapeutic use
PMC - PMC7686057
MID - NIHMS1639297
OTO - NOTNLM
OT  - *Pediatric asthma emergency medical services systemic corticosteroids hybrid
      implementation-effectiveness trial RE-AIM framework
EDAT- 2020/09/16 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/09/15 20:12
PHST- 2020/05/01 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/09/15 20:12 [entrez]
AID - S1551-7144(20)30219-6 [pii]
AID - 10.1016/j.cct.2020.106141 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2020 Oct;97:106141. doi: 10.1016/j.cct.2020.106141. Epub
      2020 Sep 12.


PMID- 32931728
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1911-6470 (Print)
IS  - 1911-6470 (Linking)
VI  - 14
IP  - 9
DP  - 2020 Sep
TI  - Patients' perspective of telephone visits during the COVID-19 pandemic.
PG  - E402-E406
LID - 10.5489/cuaj.6758 [doi]
AB  - INTRODUCTION: With the cessation of non-urgent clinical office visits due to the 
      coronavirus, there has been a rapid shift to telephone and other virtual visits
      in outpatient practice. We conducted a survey to evaluate patients' perspective
      of telephone visits during the COVID-19 pandemic. METHODS: Patients receiving a
      scheduled telephone call as a virtual visit from urologists at our clinic were
      asked to participate in a three-minute, self-administered, online questionnaire. 
      After verbal permission was obtained, the survey was emailed to each participant.
      The outcomes evaluated were telephone visit satisfaction and preference for type 
      of appointment. Non-parametric tests were used to analyze the results. The study 
      was approved by the Sunnybrook Research Ethics Board. RESULTS: A total of 102
      participants were included; 96% of participants assessed the telephone visit as a
      positive experience in every survey question, while 45% expressed no preference. 
      In those who expressed a preference, this was evenly divided between in-office
      visits and phone visits (p=0.0614). Participants who lived more than 75 km from
      the hospital were less likely to prefer an in-office visit compared to those
      residing locally (U=433, p=0.006; odds ratio 0.29, 95% confidence interval
      0.106-0.779, p=0.0142). CONCLUSIONS: In this survey, most participants assessed
      the telephone visit positively. Almost half had no preference and a similar
      proportion expressed a preference for in-office and telephone visits. Patients
      who resided farther from the hospital were more likely to prefer the telephone
      visit. This is the first study that we know of to assess patients' preferences
      regarding remote encounters in urology.
FAU - Locke, Jennifer
AU  - Locke J
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
FAU - Herschorn, Sender
AU  - Herschorn S
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
FAU - Neu, Sarah
AU  - Neu S
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
FAU - Klotz, Laurence
AU  - Klotz L
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
FAU - Kodama, Ron
AU  - Kodama R
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
FAU - Carr, Lesley
AU  - Carr L
AD  - Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Urol Assoc J
JT  - Canadian Urological Association journal = Journal de l'Association des urologues 
      du Canada
JID - 101312644
PMC - PMC7492037
EDAT- 2020/09/16 06:00
MHDA- 2020/09/16 06:01
CRDT- 2020/09/15 20:11
PHST- 2020/09/15 20:11 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/09/16 06:01 [medline]
AID - cuaj.6758 [pii]
AID - 10.5489/cuaj.6758 [doi]
PST - ppublish
SO  - Can Urol Assoc J. 2020 Sep;14(9):E402-E406. doi: 10.5489/cuaj.6758.


PMID- 32931597
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1440-1630 (Electronic)
IS  - 0045-0766 (Linking)
VI  - 67
IP  - 5
DP  - 2020 Oct
TI  - Ethical and transparent practices of the editorial board.
PG  - 397-398
LID - 10.1111/1440-1630.12701 [doi]
FAU - Gustafsson, Louise
AU  - Gustafsson L
AUID- ORCID: 0000-0001-5232-0987
AD  - Australian Occupational Therapy Journal.
LA  - eng
PT  - Editorial
DEP - 20200915
PL  - Australia
TA  - Aust Occup Ther J
JT  - Australian occupational therapy journal
JID - 15420200R
SB  - IM
MH  - Advisory Committees/ethics/*organization & administration/standards
MH  - Australia
MH  - *Editorial Policies
MH  - Humans
MH  - *Occupational Therapy
MH  - Periodicals as Topic/*ethics/*standards
EDAT- 2020/09/16 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/09/15 17:14
PHST- 2020/08/27 00:00 [received]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/09/15 17:14 [entrez]
AID - 10.1111/1440-1630.12701 [doi]
PST - ppublish
SO  - Aust Occup Ther J. 2020 Oct;67(5):397-398. doi: 10.1111/1440-1630.12701. Epub
      2020 Sep 15.


PMID- 32931509
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20201218
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Evaluating approaches to designing effective Co-Created hand-hygiene
      interventions for children in India, Sierra Leone and the UK.
PG  - e0239234
LID - 10.1371/journal.pone.0239234 [doi]
AB  - Effective and culturally appropriate hand-hygiene education is essential to
      promote health-related practices to control and prevent diseases such as
      Diarrhoea, Ebola and COVID-19. In this paper we outline and evaluate the
      Co-Creation processes underpinning a handwashing intervention for young children 
      (A Germ's Journey) developed and delivered in India, Sierra Leone and the UK, and
      consider the implications surrounding Imperialist/Colonial discourse and the
      White Saviour Complex. The paper focuses both on the ways Co-Creation was
      conceptualised by our collaborators in all three countries and the catalysts and 
      challenges encountered. Qualitative data have been drawn from in-depth interviews
      with five key stakeholders, focus group data from 37 teachers in Sierra Leone and
      responses to open-ended questionnaires completed by teachers in India (N = 66)
      and UK (N = 63). Data were analysed using thematic analysis and three themes,
      each with three constituent subthemes are presented. In the theme
      'Representations of and Unique Approaches to Co-Creation' we explore the ways in 
      which Co-Creation was constructed in relation to teamwork, innovative practice
      and more continuous models of evaluation. In 'Advantages of Co-Creation' we
      consider issues around shared ownership, improved outcomes and more meaningful
      insights alongside the mitigation of risks and short-circuiting of problems. In
      'Challenges of Co-Creation' we discuss issues around timing and organisation,
      attracting and working with appropriate partners and understanding the importance
      of local context with inherent social, economic and structural barriers,
      especially in low-and-middle-income countries. We consider how theoretical
      elements of Co-Creation can inform effective international public health
      interventions; crucial during a global pandemic in which handwashing is the most 
      effective method to control the transmission of COVID-19. Finally we reflect on
      some of the methodological challenges of our own work and in managing the
      potentially conflicting goals of the ethical and participatory values of
      Co-Creation with pragmatic considerations about ensuring an effective final
      'product'.
FAU - Crosby, Sapphire
AU  - Crosby S
AUID- ORCID: 0000-0002-8423-2356
AD  - Institute for Research in Criminology, Community, Education and Social Justice,
      De Montfort University, Leicester, United Kingdom.
FAU - Younie, Sarah
AU  - Younie S
AUID- ORCID: 0000-0001-8981-6476
AD  - Institute for Research in Criminology, Community, Education and Social Justice,
      De Montfort University, Leicester, United Kingdom.
FAU - Williamson, Iain
AU  - Williamson I
AD  - Institute for Psychological Science, De Montfort University, Leicester, United
      Kingdom.
FAU - Laird, Katie
AU  - Laird K
AUID- ORCID: 0000-0001-7187-0415
AD  - Infectious Disease Research Group, Leicester Institute for Pharmaceutical
      Innovation, De Montfort University, Leicester, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Communicable Disease Control/*methods
MH  - Communicable Diseases/pathology/transmission/virology
MH  - Coronavirus Infections/prevention & control/transmission/virology
MH  - Focus Groups
MH  - *Hand Hygiene
MH  - Humans
MH  - India
MH  - Interviews as Topic
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/prevention & control/transmission/virology
MH  - SARS-CoV-2
MH  - School Teachers/psychology
MH  - Sierra Leone
MH  - Surveys and Questionnaires
MH  - United Kingdom
PMC - PMC7491735
COIS- The authors have no competing interests to report.
EDAT- 2020/09/16 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/09/15 17:13
PHST- 2020/05/28 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/15 17:13 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - 10.1371/journal.pone.0239234 [doi]
AID - PONE-D-20-13329 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 15;15(9):e0239234. doi: 10.1371/journal.pone.0239234.
      eCollection 2020.


PMID- 32931482
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20211103
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 130
IP  - 11
DP  - 2020 Nov 2
TI  - Drugs of unproven benefit for COVID-19: a pharma perspective on ethical
      allocation of available therapies.
PG  - 5622-5623
LID - 10.1172/JCI144186 [doi]
LID - 144186 [pii]
FAU - Caplan, Arthur L
AU  - Caplan AL
AD  - Division of Medical Ethics and.
AD  - Department of Population Health, New York University, New York, New York, USA.
FAU - Waldstreicher, Joanne
AU  - Waldstreicher J
AD  - Johnson & Johnson, New Brunswick, New Jersey, USA.
FAU - Childers, Karla
AU  - Childers K
AD  - Johnson & Johnson, New Brunswick, New Jersey, USA.
FAU - Maree, Aran
AU  - Maree A
AD  - Janssen Pharmaceutical Companies of Johnson & Johnson, New Brunswick, New Jersey,
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
SB  - IM
MH  - *Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - *Coronavirus Infections/drug therapy/epidemiology
MH  - Humans
MH  - *Pandemics/ethics
MH  - *Pneumonia, Viral/drug therapy/epidemiology
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
PMC - PMC7598031
EDAT- 2020/09/16 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/09/15 17:13
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/09/15 17:13 [entrez]
AID - 144186 [pii]
AID - 10.1172/JCI144186 [doi]
PST - ppublish
SO  - J Clin Invest. 2020 Nov 2;130(11):5622-5623. doi: 10.1172/JCI144186.


PMID- 32931136
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 127
IP  - 6
DP  - 2020 Dec
TI  - COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY
      trial results.
PG  - 445-447
LID - 10.1111/bcpt.13489 [doi]
FAU - Dal-Re, Rafael
AU  - Dal-Re R
AUID- ORCID: https://orcid.org/0000-0002-0980-2486
AD  - Epidemiology Unit, Health Research Institute-Fundacion Jimenez Diaz University
      Hospital, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Porcher, Raphael
AU  - Porcher R
AD  - Centre of Research in Epidemiology and Statistics, Universite de Paris, Joint
      Research Unit 1153, Institute National de la Sante et de la Recherche Medicale,
      Paris, France.
FAU - Gluud, Christian
AU  - Gluud C
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
SB  - IM
MH  - COVID-19/*drug therapy/*epidemiology
MH  - Clinical Protocols/standards
MH  - Humans
MH  - Pandemics
MH  - Randomized Controlled Trials as Topic/*methods/standards
MH  - Research Design
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - RECOVERY
OT  - ethics
OT  - randomized controlled trials
OT  - results
EDAT- 2020/09/16 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/09/15 12:18
PHST- 2020/07/11 00:00 [received]
PHST- 2020/09/03 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/09/15 12:18 [entrez]
AID - 10.1111/bcpt.13489 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2020 Dec;127(6):445-447. doi: 10.1111/bcpt.13489.
      Epub 2020 Sep 30.


PMID- 32930792
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 1096-0929 (Electronic)
IS  - 1096-0929 (Linking)
VI  - 177
IP  - 2
DP  - 2020 Oct 1
TI  - Assessing Agricultural Toxicity in Brazil: Advances and Opportunities in the 21st
      Century.
PG  - 316-324
LID - 10.1093/toxsci/kfaa120 [doi]
AB  - Agriculture in the 21st century faces multiple challenges to produce food for the
      growing population using ethical/sustainable and efficient methods safely for
      humans and the environment. Brazil today is a world leader in terms of production
      of food of plant origin, both for human consumption and animal feed. Agriculture 
      and livestock raising are critical economic activities in maintaining a positive 
      balance in its economy. As a consequence, the registration and use of pesticides 
      in Brazil have grown at an accelerated rate. This work shows the current
      situation in Brazil in terms of the prevailing laws about the registration of
      pesticides, with a focus on the toxicological aspects related to human health.
      The regulatory aspects of registration of pesticides in Brazil, the mandatory
      testing for evaluating pesticide toxicity, adoption of the Globally Harmonized
      System of Classification and Labeling of Chemicals, and recent progress toward
      nonanimal methods to toxicity evaluation were explored in this work. In this
      field, Brazil has advanced and there are opportunities and challenges. There is
      still much to be done and investments to be made so that Brazil can definitively 
      consolidate its conduct within the context of a Modern Regulatory Toxicology,
      which has entered the 21st century.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society of Toxicology. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - da Silva, Artur Christian Garcia
AU  - da Silva ACG
AD  - Laboratory of Education and Research in In Vitro Toxicology, Tox In, Faculty of
      Pharmacy, Universidade Federal de Goias, Goiania, GO 74605.170, Brazil.
FAU - Sousa, Isabelly Paula
AU  - Sousa IP
AD  - Laboratory of Education and Research in In Vitro Toxicology, Tox In, Faculty of
      Pharmacy, Universidade Federal de Goias, Goiania, GO 74605.170, Brazil.
FAU - Dos Santos, Thais Rosa Marques
AU  - Dos Santos TRM
AD  - Laboratory of Education and Research in In Vitro Toxicology, Tox In, Faculty of
      Pharmacy, Universidade Federal de Goias, Goiania, GO 74605.170, Brazil.
FAU - Valadares, Marize Campos
AU  - Valadares MC
AD  - Laboratory of Education and Research in In Vitro Toxicology, Tox In, Faculty of
      Pharmacy, Universidade Federal de Goias, Goiania, GO 74605.170, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Toxicol Sci
JT  - Toxicological sciences : an official journal of the Society of Toxicology
JID - 9805461
RN  - 0 (Agrochemicals)
RN  - 0 (Pesticides)
SB  - IM
MH  - *Agriculture
MH  - Agrochemicals/*toxicity
MH  - Animals
MH  - Brazil
MH  - Humans
MH  - *Pesticides
OTO - NOTNLM
OT  - *GHS
OT  - *hazard assessment
OT  - *nonanimal testing
OT  - *pesticides
OT  - *regulation
EDAT- 2020/09/16 06:00
MHDA- 2021/07/21 06:00
CRDT- 2020/09/15 12:14
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PHST- 2020/09/15 12:14 [entrez]
AID - 5903752 [pii]
AID - 10.1093/toxsci/kfaa120 [doi]
PST - ppublish
SO  - Toxicol Sci. 2020 Oct 1;177(2):316-324. doi: 10.1093/toxsci/kfaa120.


PMID- 32930445
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1531-8257 (Electronic)
IS  - 0885-3185 (Linking)
VI  - 35
IP  - 11
DP  - 2020 Nov
TI  - Ethical Considerations in Screening for Rapid Eye Movement Sleep Behavior
      Disorder in the General Population.
PG  - 1939-1944
LID - 10.1002/mds.28262 [doi]
AB  - Clinical studies have shown that up to 90% of patients with idiopathic rapid eye 
      movement sleep behavior disorder (RBD) will eventually be diagnosed with a
      clinical alpha-synucleinopathy. Because of this high conversion rate, screening
      for RBD is often performed to identify eligible participants for studies aimed at
      elucidating the prodromal phase of alpha-synucleinopathies. However, screening
      for RBD, especially in the general population, raises many ethical dilemmas. In
      light of the existing ethical literature and our experience in establishing a
      screening approach for RBD in the Rotterdam Study, we discuss ethical dilemmas
      when screening for RBD in population-based studies. We conclude that informing
      study participants about the reason for invitation and the possible trajectory
      that lies ahead when participating is essential. However, participants should not
      be troubled unnecessarily by giving them detailed information about possible
      diagnoses or associated disease risks. (c) 2020 International Parkinson and
      Movement Disorder Society.
CI  - (c) 2020 International Parkinson and Movement Disorder Society.
FAU - Dommershuijsen, Lisanne J
AU  - Dommershuijsen LJ
AUID- ORCID: 0000-0001-6951-6935
AD  - Department of Epidemiology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Darweesh, Sirwan K L
AU  - Darweesh SKL
AUID- ORCID: 0000-0002-4361-4593
AD  - Department of Neurology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Luik, Annemarie I
AU  - Luik AI
AUID- ORCID: 0000-0001-7517-197X
AD  - Department of Epidemiology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Kieboom, Brenda C T
AU  - Kieboom BCT
AD  - Department of Epidemiology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Koudstaal, Peter J
AU  - Koudstaal PJ
AUID- ORCID: 0000-0003-4998-9609
AD  - Department of Neurology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Boon, Agnita J W
AU  - Boon AJW
AD  - Department of Neurology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Ikram, M Arfan
AU  - Ikram MA
AD  - Department of Epidemiology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Ikram, M Kamran
AU  - Ikram MK
AD  - Department of Epidemiology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
AD  - Department of Neurology, Erasmus MC University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Bunnik, Eline M
AU  - Bunnik EM
AUID- ORCID: 0000-0003-1481-6222
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC
      University Medical Center Rotterdam, Rotterdam, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200915
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
SB  - IM
MH  - Humans
MH  - *Parkinson Disease/diagnosis
MH  - *REM Sleep Behavior Disorder/diagnosis
MH  - *Synucleinopathies
OTO - NOTNLM
OT  - *Alpha-synucleinopathy
OT  - *Parkinson's disease
OT  - *REM sleep behavior disorder
OT  - *ethics
OT  - *screening
EDAT- 2020/09/16 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/15 08:54
PHST- 2020/06/30 00:00 [received]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/15 08:54 [entrez]
AID - 10.1002/mds.28262 [doi]
PST - ppublish
SO  - Mov Disord. 2020 Nov;35(11):1939-1944. doi: 10.1002/mds.28262. Epub 2020 Sep 15.


PMID- 32929818
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201218
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 9
DP  - 2020 Sep
TI  - Understanding the ethical implications of the rituals of medicine.
PG  - 1123-1131
LID - 10.1111/imj.14990 [doi]
AB  - Rituals may be understood broadly as stereotyped behaviours carrying symbolic
      meanings, which play a crucial role in defining relationships, legitimating
      authority, giving meaning to certain life events and stabilising social
      structures. Despite intense interest in the subject, and an extensive literature,
      relatively little attention has been given to the nature, role and function of
      ritual in contemporary medicine. Medicine is replete with ritualistic behaviours 
      and imperatives, which play a crucial role in all aspects of clinical practice.
      Rituals play multiple, complex functions in clinical interactions and have an
      important role in shaping interactions, experiences and outcomes. Longstanding
      medical rituals have been disrupted in the wake of coronavirus disease 2019
      (COVID-19). Medical rituals may be evident or invisible, often overlap with or
      operate alongside instrumentalised practices, and play crucial roles in
      establishing, maintaining and guaranteeing the efficacy of clinical practices.
      Rituals can also inhibit progress and change, by enforcing arbitrary authority.
      Physicians should consider when they are undertaking a ritual practice and
      recognise when the exigencies of contemporary practice are affecting that ritual 
      with or without meaning or intention. Physicians should reflect on whether
      aspects of their ritual interactions are undertaken on the basis of sentiment,
      custom or evidence-based outcomes, and whether rituals should be defended,
      continued in a modified fashion or even abandoned in favour of new behaviours
      suitable for and salient with contemporary practice in the interests of patient
      care.
CI  - (c) 2020 Royal Australasian College of Physicians.
FAU - Arnold, Mark H
AU  - Arnold MH
AUID- ORCID: 0000-0003-0546-8924
AD  - Sydney Medical Program, Faculty of Medicine and Health, University of Sydney,
      Camperdown, New South Wales, Australia.
FAU - Komesaroff, Paul
AU  - Komesaroff P
AUID- ORCID: 0000-0002-1360-3375
AD  - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne,
      Victoria, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, School of Public Health, Faculty of Medicine and Health,
      The University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Ceremonial Behavior
MH  - Coronavirus Infections/*epidemiology
MH  - Culture
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Practice Patterns, Physicians'/*ethics/*standards
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *clinical practice
OT  - *context effects
OT  - *ethics
OT  - *patient-doctor relationship
OT  - *rituals
EDAT- 2020/09/16 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/15 05:51
PHST- 2020/05/05 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/09/15 05:51 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1111/imj.14990 [doi]
PST - ppublish
SO  - Intern Med J. 2020 Sep;50(9):1123-1131. doi: 10.1111/imj.14990.


PMID- 32929622
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - Regulating the international surrogacy market:the ethics of commercial surrogacy 
      in the Netherlands and India.
PG  - 621-630
LID - 10.1007/s11019-020-09976-x [doi]
AB  - It is unclear what proper remuneration for surrogacy is, since countries disagree
      and both commercial and altruistic surrogacy have ethical drawbacks. In the
      presence of cross-border surrogacy, these ethical drawbacks are exacerbated. In
      this article, we explore what would be ethical remuneration for surrogacy, and
      suggest regulations for how to ensure this in the international context. A
      normative ethical analysis of commercial surrogacy is conducted. Various
      arguments against commercial surrogacy are explored, such as exploitation and
      commodification of surrogates, reproductive capacities, and the child. We argue
      that, although commodification and exploitation can occur, these problems are not
      specific to surrogacy but should be understood in the broader context of an
      unequal world. Moreover, at least some of these arguments are based on symbolic
      rhetoric or they lack knowledge of real-world experiences. In line with this
      critique we argue that commercial surrogacy can be justified, but how and under
      what circumstances depends on the context. Surrogates should be paid a sufficient
      amount and regulations should be in order. In this article, the Netherlands and
      India (where commercial surrogacy was legal until 2015) are case examples of
      contexts that differ in many respects. In both contexts, surrogacy can be seen as
      a legitimate form of work, which requires the same wage and safety standards as
      other forms of labor. Payments for surrogacy need to be high enough to avoid
      exploitation by underpayment, which can be established by the mechanisms of
      either minimum wage (in high income countries such as the Netherlands), or
      Fair-Trade guidelines (in lower-middle income countries such as India). An
      international treaty governing commercial surrogacy should be in place, and local
      professional bodies to protect the interests of surrogates should be required.
      Commercial surrogacy should be permitted across the globe, which would also
      reduce the need for intended parents to seek surrogacy services abroad.
FAU - Blazier, Jaden
AU  - Blazier J
AD  - Philosophy, Bioethics, and Health, Vrije Universiteit, Amsterdam, The
      Netherlands.
FAU - Janssens, Rien
AU  - Janssens R
AUID- ORCID: http://orcid.org/0000-0001-9503-7575
AD  - Dept. of Medical Humanities, Amsterdam University Medical Center, Location VU
      Medical Center, PO Box 7057, 1007MB, Amsterdam, The Netherlands.
      mjpa.janssens@amsterdamumc.nl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200914
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - *Commodification
MH  - Ethical Analysis
MH  - Guidelines as Topic
MH  - Humans
MH  - India
MH  - Netherlands
MH  - Philosophy, Medical
MH  - *Remuneration
MH  - Social Problems/economics/psychology
MH  - Socioeconomic Factors
MH  - Surrogate Mothers/*legislation & jurisprudence
PMC - PMC7538442
OTO - NOTNLM
OT  - Commodification
OT  - Exploitation
OT  - Market
OT  - Ommercial surrogacy
OT  - Regulation
EDAT- 2020/09/16 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/09/15 05:49
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/09/15 05:49 [entrez]
AID - 10.1007/s11019-020-09976-x [doi]
AID - 10.1007/s11019-020-09976-x [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):621-630. doi: 10.1007/s11019-020-09976-x. 
      Epub 2020 Sep 14.


PMID- 32929465
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 87
IP  - 4
DP  - 2020 Sep 15
TI  - Introduction: Medicine & Law Review Series.
PG  - 613
LID - 10.1093/neuros/nyaa331 [doi]
FAU - Dagi, T Forcht
AU  - Dagi TF
AD  - Queen's University, Befast, Northern Ireland.
AD  - The William J. Clinton Leadership Institute, Belfast, Ireland.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
SB  - IM
OTO - NOTNLM
OT  - *Entrepreneurship
OT  - *Ethics
OT  - *Law
OT  - *Leadership
OT  - *Medicine
OT  - *Neurosurgery
EDAT- 2020/09/16 06:00
MHDA- 2020/09/16 06:01
CRDT- 2020/09/15 05:48
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/06/30 00:00 [received]
PHST- 2020/09/15 05:48 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/09/16 06:01 [medline]
AID - 5904139 [pii]
AID - 10.1093/neuros/nyaa331 [doi]
PST - ppublish
SO  - Neurosurgery. 2020 Sep 15;87(4):613. doi: 10.1093/neuros/nyaa331.


PMID- 32928953
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20210716
IS  - 1558-7118 (Electronic)
IS  - 1557-2625 (Linking)
VI  - 33
IP  - Suppl
DP  - 2020 Sep-Oct
TI  - Medical Professionalism Is Like Pornography: You Know it When You See it.
PG  - S62-S64
LID - 10.3122/jabfm.2020.S1.190408 [doi]
AB  - Addressing professionalism is a key role of Certification Boards, but how best to
      do this is not clear. This article describes a 360 degrees approach to monitoring
      and enhancing professionalism taken by the American Board of Urology (ABU). In
      addition to monitoring full and active medical licenses, ABU has identified
      ethical issues specific to Urology, includes a position article on ethics in
      Urology on its Web site, and requires a completion of modules on ethics. As a
      part of its 10-year cycle, the Board requires peer evaluations from other
      urologists in the community. Finally, and most importantly, ABU uses a portfolio 
      practice log to evaluate the candidates' use of procedures appropriate to their
      stated subspecialty area of expertise, evaluation of potential overuse or
      inappropriate use of procedures and a narrative that details any major
      complications associated with their procedures.
CI  - (c) Copyright 2020 by the American Board of Family Medicine.
FAU - Thrasher, J Brantley
AU  - Thrasher JB
AD  - From the American Board of Urology, Charlottesville, VA. brant@abu.org.
FAU - Hamady, Cynthia R
AU  - Hamady CR
AD  - From the American Board of Urology, Charlottesville, VA.
FAU - Franklin, Lindsay W
AU  - Franklin LW
AD  - From the American Board of Urology, Charlottesville, VA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Board Fam Med
JT  - Journal of the American Board of Family Medicine : JABFM
JID - 101256526
SB  - IM
MH  - *Certification
MH  - Humans
MH  - *Professionalism
MH  - Specialty Boards
MH  - United States
MH  - *Urology/standards
OTO - NOTNLM
OT  - *Certification
OT  - *Licensure
OT  - *Professionalism
OT  - *Urology
COIS- Disclosures: None.
EDAT- 2020/09/16 06:00
MHDA- 2021/07/17 06:00
CRDT- 2020/09/15 05:41
PHST- 2019/11/04 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
AID - 33/Supplement/S62 [pii]
AID - 10.3122/jabfm.2020.S1.190408 [doi]
PST - ppublish
SO  - J Am Board Fam Med. 2020 Sep-Oct;33(Suppl):S62-S64. doi:
      10.3122/jabfm.2020.S1.190408.


PMID- 32928952
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20210716
IS  - 1558-7118 (Electronic)
IS  - 1557-2625 (Linking)
VI  - 33
IP  - Suppl
DP  - 2020 Sep-Oct
TI  - The Built Environment for Professionalism.
PG  - S57-S61
LID - 10.3122/jabfm.2020.S1.190441 [doi]
AB  - The social contract between the public and health professions is fraying,
      challenged by changes in the organization and financing of health care, and by a 
      collective failure to meet some of the expectations of society. It is timely for 
      family medicine to acknowledge the social contract, to accept responsibility for 
      its the role in renegotiating this contract, and to partner with other practice
      communities in doing so. Human behavior is strongly directed by our environment
      and risk aversion rather than rational decision making and it is possible to
      design our practice environment to "nudge" clinician behaviors purposefully
      toward professionalism. Current leveraging of professionalism is a path to
      burnout and the alternative is to create a built environment for good care that
      also supports professionalism rather than taking advantage of it. There are good 
      examples to draw on, and further experimentation, partnerships, policy, and
      facilitation of practice redesign are needed to get there.
CI  - (c) Copyright 2020 by the American Board of Family Medicine.
FAU - Phillips, Robert L Jr
AU  - Phillips RL Jr
AD  - From the Center for Professionalism and Value in Health Care, American Board of
      Family Medicine Foundation, Washington, DC. bphillips@theabfm.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Board Fam Med
JT  - Journal of the American Board of Family Medicine : JABFM
JID - 101256526
SB  - IM
MH  - *Delivery of Health Care/organization & administration
MH  - *Family Practice/organization & administration
MH  - Humans
MH  - *Professionalism
MH  - *Social Responsibility
OTO - NOTNLM
OT  - *Built Environment
OT  - *Contracts
OT  - *Delivery of Health Care
OT  - *Medica Ethics
OT  - *Primary Health Care
OT  - *Professionalism
COIS- Disclosures: None.
EDAT- 2020/09/16 06:00
MHDA- 2021/07/17 06:00
CRDT- 2020/09/15 05:41
PHST- 2019/11/30 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
AID - 33/Supplement/S57 [pii]
AID - 10.3122/jabfm.2020.S1.190441 [doi]
PST - ppublish
SO  - J Am Board Fam Med. 2020 Sep-Oct;33(Suppl):S57-S61. doi:
      10.3122/jabfm.2020.S1.190441.


PMID- 32928943
OWN - NLM
STAT- MEDLINE
DCOM- 20210716
LR  - 20210716
IS  - 1558-7118 (Electronic)
IS  - 1557-2625 (Linking)
VI  - 33
IP  - Suppl
DP  - 2020 Sep-Oct
TI  - Continuing Board Certification: Seeing Our Way Forward.
PG  - S10-S14
LID - 10.3122/jabfm.2020.S1.190439 [doi]
AB  - BACKGROUND: Traditionally the role of certifying boards has been to hold
      physicians accountable for demonstrating standards of competence. In recent
      years, the authority of continuing board certification has been challenged, due
      to multiple factors that have shifted the dynamics. The breadth and depth of new 
      information, combined with the pressures of system barriers and administrative
      burdens, can make it challenging for clinicians stay current and maintain their
      own competency. Absent feedback about their performance, physicians presume
      they're practicing effectively. The resulting gap between confidence and
      competence can also lead physicians to make errors of which they may be unaware. 
      In this environment, assessment and accountability are more important than ever. 
      FOUR KEY AREAS: The authors present four key areas to address to move forward
      with a board certification system that is effective, relevant, and respected.
      First, boards should set and communicate the specific expectations of
      specialists. Second, boards should use technology to create practice-relevant
      assessments. Third, they should collaborate with educators, while maintaining
      their distinct role as assessors. Fourth, boards need to establish and meet
      standards for professionalism and ethics that reflect their position as
      regulatory bodies. CONCLUSION: Boards have a critical role in professional
      self-regulation. They should not compromise on their primary responsibility to
      set and evolve standards for competence and to conduct rigorous assessments of
      physicians. The methods boards use for assessments should evolve to meet the
      changing needs of physicians. Collaboration between educators and assessors
      provides more educational choice, relieves burdens, and supports physicians'
      commitment to lifelong learning. By working together with physicians, educators
      and assessors advance their shared goal of supporting physicians to work at the
      top of their capability and ultimately, optimize patient care.
CI  - (c) Copyright 2020 by the American Board of Family Medicine.
FAU - McMahon, Graham T
AU  - McMahon GT
AD  - From the Accreditation Council for Continuing Medical Education (ACCME), Chicago,
      IL (GTM); American Board of Family Medicine (ABFM), Lexington, KY (WN).
      gmcmahon@accme.org.
FAU - Newton, Warren P
AU  - Newton WP
AD  - From the Accreditation Council for Continuing Medical Education (ACCME), Chicago,
      IL (GTM); American Board of Family Medicine (ABFM), Lexington, KY (WN).
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Board Fam Med
JT  - Journal of the American Board of Family Medicine : JABFM
JID - 101256526
SB  - IM
MH  - *Certification/organization & administration
MH  - *Clinical Competence/standards
MH  - Humans
MH  - *Physicians/standards
MH  - *Specialty Boards
MH  - United States
OTO - NOTNLM
OT  - *Certification
OT  - *Continuing Medical Education
OT  - *Medical Errors
OT  - *Physicians
OT  - *Professional Autonomy
OT  - *Social Responsibility
OT  - *Specialization
COIS- Conflicting and competing interests: Dr. Warren P. Newton is employed by the
      ABFM.
EDAT- 2020/09/16 06:00
MHDA- 2021/07/17 06:00
CRDT- 2020/09/15 05:41
PHST- 2019/11/27 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/07/17 06:00 [medline]
AID - 33/Supplement/S10 [pii]
AID - 10.3122/jabfm.2020.S1.190439 [doi]
PST - ppublish
SO  - J Am Board Fam Med. 2020 Sep-Oct;33(Suppl):S10-S14. doi:
      10.3122/jabfm.2020.S1.190439.


PMID- 32928880
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Responding to unethical research: the importance of transparency.
PG  - 691-692
LID - 10.1136/medethics-2020-106878 [doi]
FAU - Rogers, Wendy A
AU  - Rogers WA
AUID- ORCID: 0000-0001-9186-870X
AD  - Department of Philosophy and Department of Medicine, Macquarie University,
      Sydney, New South Wales, Australia wendy.rogers@mq.edu.au.
FAU - Higgins, Wendy C
AU  - Higgins WC
AUID- ORCID: 0000-0003-1357-8330
AD  - Department of Cognitive Science, Macquarie University, Sydney, New South Wales,
      Australia.
FAU - Ballantyne, Angela
AU  - Ballantyne A
AD  - Centre for Biomedical Ethics, National University of Singapore, Singapore.
AD  - Department of Primary Health Care and General Practice [Wellington], and
      Bioethics Centre [Dunedin], University of Otago, Wellington, New Zealand.
FAU - Lipworth, Wendy
AU  - Lipworth W
AUID- ORCID: 0000-0002-0234-657X
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200914
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Oct;46(10):678-684. PMID: 32611619
CON - J Med Ethics. 2020 Oct;46(10):685-686. PMID: 32792347
CON - J Med Ethics. 2020 Oct;46(10):689-690. PMID: 32817408
CON - J Med Ethics. 2020 Oct;46(10):687-688. PMID: 32895297
MH  - China
MH  - *Ethics, Research
MH  - Humans
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/05 00:00 [received]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/09/15 05:41 [entrez]
AID - medethics-2020-106878 [pii]
AID - 10.1136/medethics-2020-106878 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):691-692. doi: 10.1136/medethics-2020-106878. Epub
      2020 Sep 14.


PMID- 32928866
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Understanding the risks for post-disaster infectious disease outbreaks: a
      systematic review protocol.
PG  - e039608
LID - 10.1136/bmjopen-2020-039608 [doi]
AB  - INTRODUCTION: Disasters have many forms, including those related to natural
      hazards and armed conflict. Human-induced global change, such as climate change, 
      may alter hazard parameters of these disasters. These alterations can have
      serious consequences for vulnerable populations, which often experience
      post-disaster infectious disease outbreaks, leading to morbidity and mortality.
      The risks and drivers for these outbreaks and their ability to form cascades are 
      somewhat contested. Despite evidence for post-disaster outbreaks, reviews
      quantifying them have been on short time scales, specific geographic areas or
      specific hazards. This review aims to fill this gap and gain a greater
      understanding of the risk factors involved in these contextual outbreaks on a
      global level. METHODS AND ANALYSIS: Using the Preferred Reporting Items for
      Systematic Review and Meta-Analysis Protocols 2015 checklist and Khan's
      methodological framework, a systematic search strategy will be created and
      carried out in August 2020. The strategy will search MEDLINE, Embase and
      GlobalHealth electronic databases and reference lists of selected literature will
      also be screened. Eligible studies will include any retrospective
      cross-sectional, case-control or cohort studies investigating an infectious
      disease outbreak in a local disaster affected population. Studies will not be
      excluded based on geographic area or publication date. Excluded papers will
      include non-English studies, reviews, single case studies and research discussing
      general risk factors, international refugee camps, public health, mental health
      and other non-communicable diseases, pathogen genetics or economics. Following
      selection, data will be extracted into a data charting form, that will be
      reviewed by other members of the team. The data will then be analysed both
      numerically and narratively. ETHICS AND DISSEMINATION: Only secondary data will
      be used and there will be no public or patient involvement; therefore, no ethical
      approval is needed. Our findings will aim to be disseminated through a
      peer-reviewed journal. The authors intend to use the results to inform future
      mathematical modelling studies.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Charnley, Gina E C
AU  - Charnley GEC
AUID- ORCID: 0000-0003-2087-7822
AD  - Faculty of Medicine, School of Public Health, Department of Infectious Disease
      Epidemiology, Imperial College London, London, UK g.charnley19@imperial.ac.uk.
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, UK.
FAU - Kelman, Ilan
AU  - Kelman I
AD  - Faculty of Mathematical and Physical Sciences, UCL Institute for Risk and
      Disaster Reduction, University College London, London, UK.
AD  - Faculty of Population Health Sciences, UCL Institute for Global Health,
      University College London, London, UK.
AD  - University of Agder, Kristiansand, Norway.
FAU - Gaythorpe, Katy
AU  - Gaythorpe K
AD  - Faculty of Medicine, School of Public Health, Department of Infectious Disease
      Epidemiology, Imperial College London, London, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, UK.
FAU - Murray, Kris
AU  - Murray K
AD  - Faculty of Medicine, School of Public Health, Department of Infectious Disease
      Epidemiology, Imperial College London, London, UK.
AD  - MRC Centre for Global Infectious Disease Analysis, Imperial College London,
      London, UK.
AD  - MRC Unit The Gambia, London School of Hygiene and Tropical Medicine, Fajara, The 
      Gambia.
LA  - eng
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Disasters
MH  - Disease Outbreaks
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Public Health
MH  - Retrospective Studies
MH  - Review Literature as Topic
PMC - PMC7488804
OTO - NOTNLM
OT  - *epidemiology
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039608 [pii]
AID - 10.1136/bmjopen-2020-039608 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e039608. doi: 10.1136/bmjopen-2020-039608.


PMID- 32928865
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 14
TI  - Understanding perceptions and factors involved in do not resuscitate (DNR)
      decision making in the emergency department of a low-resource country: a
      mixed-methods study protocol.
PG  - e038915
LID - 10.1136/bmjopen-2020-038915 [doi]
AB  - INTRODUCTION: Do not resuscitate (DNR) decision making is an integral component
      of emergency medicine practice. There is a paucity of data, protocols and
      guidelines regarding the perceptions and barriers that are involved in the
      interactions among healthcare professionals, patients and their caregivers
      regarding DNR decision making. The aim of this study is, therefore, to explore
      the perceptions and factors influencing DNR decision making in the emergency
      department and to evaluate the use of a context-based protocol for DNR decision
      making. METHODS AND ANALYSIS: This will be a sequential mixed method study
      beginning with qualitative research involving in-depth interviews (IDIs) with
      patient family members and focus group discussion with healthcare professionals. 
      The consensual qualitative approach will be used to perform a thematic analysis
      to the point of saturation. The expected outcome will be to identify key themes
      that suggest perceptions and factors involved in DNR decision making. After
      piloting, the derived protocol will then be used with a different group of
      individuals (150 healthcare professionals) who meet the eligibility criteria in a
      quantitative cross-sectional study with universal sampling. Data will be analysed
      using NVIVO in the qualitative phase and SPSS V.19 in the quantitative phase. The
      study findings will support the development of a standardised protocol for DNR
      decision making for healthcare professionals in the emergency department. ETHICS 
      AND DISSEMINATION: The proposal was reviewed by the ethics review committee (ERC)
      of the institution (ERC # 2020-1551-7193). The project is an institution SEED
      grant recipient PF139/0719. The results will be disseminated among participants, 
      patient communities and healthcare professionals in the institution through
      seminars, presentations, brochures and emails. The findings will be published in 
      a highly accessed peer-reviewed medical journal and will be presented at
      international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Azizi, Kiran
AU  - Azizi K
AUID- ORCID: 0000-0001-6633-3084
AD  - Emergency Department, Aga Khan University Hospital, Karachi, Sindh, Pakistan
      kiran.nazeem@gmail.com.
FAU - Waheed, Shahan
AU  - Waheed S
AD  - Emergency Department, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
FAU - Barolia, Rubina
AU  - Barolia R
AD  - School of Nursing, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
FAU - Ahmed, Naveed
AU  - Ahmed N
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
FAU - Ismail, Madiha
AU  - Ismail M
AD  - Emergency Medicine, Aga Khan University Hospital, Karachi, Sindh, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Decision Making
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Perception
MH  - *Resuscitation Orders
PMC - PMC7490947
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *adult intensive & critical care
OT  - *internal medicine
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038915 [pii]
AID - 10.1136/bmjopen-2020-038915 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 14;10(9):e038915. doi: 10.1136/bmjopen-2020-038915.


PMID- 32928864
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 14
TI  - Healthcare needs among unaccompanied minor refugees: a study protocol of a
      qualitative study explaining access and utilisation across place and gender.
PG  - e038882
LID - 10.1136/bmjopen-2020-038882 [doi]
AB  - INTRODUCTION: Several studies have identified that unaccompanied minor refugees
      (UMRs) are allegedly 'vulnerable' and belong to a high-risk group in terms of
      psychological distress and post-traumatic stress disorder due to their preflight,
      periflight and postflight experiences. Psychosocial care (PSC) is of high
      importance for UMRs, but little is known about barriers to access and utilisation
      of PSC across place and gender. The aims of this gender-sensitive qualitative
      study will be to build on the existing body of literature and to provide
      qualitative evidence on the contexts and mechanisms of PSC for male and female
      UMRs in Germany by comparing two German regions. METHODS AND ANALYSIS: Following 
      the study preparing realist review, a qualitative study will be undertaken in
      Berlin and Central German cities. Approximately 24 experts from the field of PSC 
      and 12 lay UMRs will participate in face-to-face, semistructured interviews. Data
      will be transcribed and analysed based on the grounded theory research paradigm. 
      ETHICS AND DISSEMINATION: Only participants who have been informed in both German
      and their native tongue and who have signed a declaration of consent will be
      included in the study. The study will comply rigorously with German data
      protection standards. Approval from the Ethical Review Committee at Martin Luther
      University Halle-Wittenberg, Germany has been obtained and granted. The results
      of the study will be presented at several conferences and will be published in
      high-quality, peer-reviewed international journals. The results will display a
      differentiated picture of the PSC of UMRs in Germany. Such knowledge is a
      precondition for a 'science of change' that translates explanations into
      practical recommendations on how to improve healthcare policies. TRIAL
      REGISTRATION NUMBER: DRKS00018080.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ulrich, Hanna-Sophie
AU  - Ulrich HS
AUID- ORCID: 0000-0002-8770-9295
AD  - Institute of Medical Sociology, Martin-Luther-Universitat Halle-Wittenberg,
      Halle, Germany hanna-sophie.ulrich@medizin.uni-halle.de.
FAU - Kohler, Emma
AU  - Kohler E
AD  - Institute of Medical Sociology, Martin-Luther-Universitat Halle-Wittenberg,
      Halle, Germany.
FAU - Fach, Eva-Maria
AU  - Fach EM
AD  - Institute of Medical Sociology, Martin-Luther-Universitat Halle-Wittenberg,
      Halle, Germany.
FAU - Spallek, Jacob
AU  - Spallek J
AD  - Department of Public Health, Brandenburg University of Technology
      Cottbus-Senftenberg, Cottbus, Germany.
FAU - Richter, Matthias
AU  - Richter M
AD  - Institute of Medical Sociology, Martin-Luther-Universitat Halle-Wittenberg,
      Halle, Germany.
FAU - Mlinaric, Martin
AU  - Mlinaric M
AD  - Institute of Medical Sociology, Martin-Luther-Universitat Halle-Wittenberg,
      Halle, Germany.
LA  - eng
SI  - DRKS/DRKS00018080
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Berlin
MH  - Delivery of Health Care
MH  - Female
MH  - Germany
MH  - Humans
MH  - Male
MH  - Qualitative Research
MH  - *Refugees
PMC - PMC7490932
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *child protection
OT  - *mental health
OT  - *organisation of health services
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038882 [pii]
AID - 10.1136/bmjopen-2020-038882 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 14;10(9):e038882. doi: 10.1136/bmjopen-2020-038882.


PMID- 32928863
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Beta-alanine supplementation in patients with COPD receiving non-linear
      periodised exercise training or neuromuscular electrical stimulation: protocol of
      two randomised, double-blind, placebo-controlled trials.
PG  - e038836
LID - 10.1136/bmjopen-2020-038836 [doi]
AB  - INTRODUCTION: Exercise intolerance is common in patients with chronic obstructive
      pulmonary disease (COPD) and, although multifactorial, it is largely caused by
      lower-limb muscle dysfunction. Research has shown that patients with severe to
      very severe COPD have significantly lower levels of muscle carnosine, which acts 
      as a pH buffer and antioxidant. Beta-alanine (BA) supplementation has been shown 
      to consistently elevate muscle carnosine in a variety of populations and may
      therefore improve exercise tolerance and lower-limb muscle function. The primary 
      objective of the current studies is to assess the beneficial effects of BA
      supplementation in enhancing exercise tolerance on top of two types of exercise
      training (non-linear periodised exercise (NLPE) training or neuromuscular
      electrical stimulation (NMES)) in patients with COPD. METHODS AND ANALYSIS: Two
      randomised, double-blind, placebo-controlled trials have been designed. Patients 
      will routinely receive either NLPE (BASE-TRAIN trial) or NMES (BASE-ELECTRIC
      trial) as part of standard exercise-based care during their 8-to-10 week
      pulmonary rehabilitation (PR) programme. A total of 222 patients with COPD (2x77 
      = 154 patients in the BASE-TRAIN trial and 2x34 = 68 patients in the
      BASE-ELECTRIC trial) will be recruited from two specialised PR centres in The
      Netherlands. For study purposes, patients will receive 3.2 g of oral BA
      supplementation or placebo per day. Exercise tolerance is the primary outcome,
      which will be assessed using the endurance shuttle walk test (BASE-TRAIN) or the 
      constant work rate cycle test (BASE-ELECTRIC). Furthermore, quadriceps muscle
      strength and endurance, cognitive function, carnosine levels (in muscle), BA
      levels (in blood and muscle), markers of oxidative stress and inflammation (in
      blood, muscles and lungs), physical activity and quality of life will be
      measured. ETHICS AND DISSEMINATION: Both trials were approved by CMO Regio
      Arnhem-Nijmegen, The Netherlands (NL70781.091.19. and NL68757.091.19). TRIAL
      REGISTRATION NUMBER: NTR8427 (BASE-TRAIN) and NTR8419 (BASE-ELECTRIC).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Meys, Roy
AU  - Meys R
AUID- ORCID: 0000-0002-4855-530X
AD  - Department of Research and Development, CIRO, Horn, The Netherlands
      roymeys@ciro-horn.nl.
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, 
      The Netherlands.
AD  - Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+),
      Maastricht, The Netherlands.
FAU - Stoffels, Anouk A F
AU  - Stoffels AAF
AD  - Department of Research and Development, CIRO, Horn, The Netherlands.
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, 
      The Netherlands.
AD  - Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+),
      Maastricht, The Netherlands.
AD  - Department of Pulmonary Diseases, Radboud UMC Dekkerswald, Nijmegen, The
      Netherlands.
FAU - de Brandt, Jana
AU  - de Brandt J
AUID- ORCID: 0000-0003-3463-1911
AD  - Reval Rehabilitation Research, Biomedical Research Institute, Faculty of
      Rehabilitation Sciences, Hasselt University, DIepenbeek, Belgium.
FAU - van Hees, Hieronymus W H
AU  - van Hees HWH
AD  - Department of Pulmonary Diseases, Radboud UMC Dekkerswald, Nijmegen, The
      Netherlands.
FAU - Franssen, Frits M E
AU  - Franssen FME
AD  - Department of Research and Development, CIRO, Horn, The Netherlands.
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, 
      The Netherlands.
AD  - Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+),
      Maastricht, The Netherlands.
FAU - Sillen, Maurice J H
AU  - Sillen MJH
AD  - Department of Physiotherapy, CIRO, Horn, The Netherlands.
FAU - Wouters, Emiel F M
AU  - Wouters EFM
AD  - Department of Research and Development, CIRO, Horn, The Netherlands.
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, 
      The Netherlands.
AD  - Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+),
      Maastricht, The Netherlands.
FAU - Burtin, Chris
AU  - Burtin C
AD  - Reval Rehabilitation Research, Biomedical Research Institute, Faculty of
      Rehabilitation Sciences, Hasselt University, DIepenbeek, Belgium.
FAU - Klijn, Peter
AU  - Klijn P
AD  - Department of Pulmonology, Merem Pulmonary Rehabilitation Centre, Hilversum, The 
      Netherlands.
AD  - Department of Pulmonary Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
FAU - Bij de Vaate, Eline
AU  - Bij de Vaate E
AD  - Department of Pulmonology, Merem Pulmonary Rehabilitation Centre, Hilversum, The 
      Netherlands.
FAU - van den Borst, Bram
AU  - van den Borst B
AD  - Department of Pulmonary Diseases, Radboud UMC Dekkerswald, Nijmegen, The
      Netherlands.
FAU - Otker, Jacqueline M
AU  - Otker JM
AD  - Patient Advisory Council, Lung Foundation Netherlands, Amersfoort, The
      Netherlands.
AD  - Client Council, CIRO, Horn, The Netherlands.
FAU - Donkers, Jos
AU  - Donkers J
AD  - Client Council, CIRO, Horn, The Netherlands.
FAU - Schleich, Florence N
AU  - Schleich FN
AD  - Department of Respiratory Medicine, CHU Sart-Tilman Liege, GIGA I3, Liege,
      Belgium.
FAU - Hayot, Maurice
AU  - Hayot M
AD  - PhyMedExp, INSERM - CNRS, University of Montpellier - Montpellier CHU,
      Montpellier, France.
FAU - Pomies, Pascal
AU  - Pomies P
AD  - PhyMedExp, INSERM - CNRS, University of Montpellier - Montpellier CHU,
      Montpellier, France.
FAU - Everaert, Inge
AU  - Everaert I
AD  - Department of Movement and Sport Sciences, University Ghent, Ghent, Belgium.
FAU - Derave, Wim
AU  - Derave W
AD  - Department of Movement and Sport Sciences, University Ghent, Ghent, Belgium.
FAU - Spruit, Martijn A
AU  - Spruit MA
AUID- ORCID: 0000-0003-3822-7430
AD  - Department of Research and Development, CIRO, Horn, The Netherlands.
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, 
      The Netherlands.
AD  - Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+),
      Maastricht, The Netherlands.
AD  - Reval Rehabilitation Research, Biomedical Research Institute, Faculty of
      Rehabilitation Sciences, Hasselt University, DIepenbeek, Belgium.
CN  - BASES consortium.
LA  - eng
SI  - NTR/NTR8427
SI  - NTR/NTR8419
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 11P2JDE17B (beta-Alanine)
SB  - IM
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Electric Stimulation
MH  - Exercise
MH  - Exercise Therapy
MH  - Exercise Tolerance
MH  - Humans
MH  - Netherlands
MH  - *Pulmonary Disease, Chronic Obstructive/therapy
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - beta-Alanine
PMC - PMC7488791
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *nutrition & dietetics
OT  - *rehabilitation medicine
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: FMEF reports research grants from AstraZeneca and Novartis, 
      not related to the current projects, and personal fees for consultancies and
      lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline,
      Novartis and TEVA. EBdV reports personal fees for consultancies and lectures from
      Boehringer Ingelheim, Chiesi, Mylan, Novartis, Vivisol and TEVA, not related to
      the current projects. FNS reports speakers fees from AstraZeneca, Chiesi,
      Menarini, Mundipharma and Novartis; reports consultancy fees from GSK; and
      reports service on an advisory board for AstraZeneca, Chiesi, GSK and Novartis,
      all outside the submitted work. MH reports research grants from Bastide Medical, 
      not related to the current project; personal fees from AstraZeneca for
      participation to scientific lectures; financial support for congress
      participation from SOS Oxygene, Eole Sante, Boehringer Ingelheim,
      GlaxoSmithKline, AstraZeneca; and hospitalities during local scientific meetings 
      from ALK-Abello, Actelion Pharmaceuticals France, Vifor Fresenius Medical Care
      Renal Pharma, Sanofi Aventis France, Novartis Pharma, LVL Medical Sud, Chiesi,
      SOS Oxygene Mediterranee. MAS reports a research grant from Netherlands Lung
      Foundation (grant number 5.1.18.232) for the described BASE-TRAIN and
      BASE-ELECTRIC study. Moreover, MAS reports other grants from Netherlands Lung
      Foundation, grants and personal fees from AstraZeneca, grants and personal fees
      from Boehringer Ingelheim, and a grant from Stichting Astma Bestrijding, all
      outside the submitted work.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038836 [pii]
AID - 10.1136/bmjopen-2020-038836 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e038836. doi: 10.1136/bmjopen-2020-038836.


PMID- 32928862
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Non-pharmacological interventions to improve the patient experience of
      colonoscopy under moderate or no sedation: a systematic review protocol.
PG  - e038621
LID - 10.1136/bmjopen-2020-038621 [doi]
AB  - INTRODUCTION: The patient experience is a critical dimension of colonoscopy
      quality. Sedative and analgesic drugs are commonly used to improve the patient
      experience of colonoscopy, with predominant regimens being deep sedation,
      typically achieved with propofol, and moderate sedation, typically achieved with 
      an opioid and a benzodiazepine. However, non-pharmacological interventions exist 
      that may be used to improve patient experience. Furthermore, by identifying
      non-pharmacological interventions to increase the quality of patient experience
      under moderate sedation, jurisdictions facing rising use of deep sedation for
      colonoscopy and its significant associated costs may be better able to encourage 
      patients and clinicians to adopt moderate sedation. Advancing either of these
      aims requires synthesising the evidence and raising awareness around these
      non-pharmacological interventions to improve the patient experience of
      colonoscopy. METHODS AND ANALYSIS: A systematic review will be conducted that
      searches multiple electronic databases from inception until 2020 to identify
      randomised controlled trials evaluating what, if any, non-pharmacological
      interventions are effective compared with placebo or usual care for improving the
      patient experience of routine colonoscopy under moderate or no sedation. Two
      reviewers will independently perform a three-stage screening process and extract 
      all study data using piloted forms. Study quality will be assessed using the
      Cochrane Risk of Bias Tool V.2.0. Where multiple studies evaluate a single
      intervention, evidence will be quantitatively synthesised using pairwise
      meta-analysis, otherwise narrative syntheses will be undertaken. ETHICS AND
      DISSEMINATION: This is a review of existing literature not requiring ethics
      approval. The review findings will be included in future efforts to develop an
      implementation strategy to reduce the use of deep sedation for routine
      colonoscopy. They will also be published in a peer-reviewed journal, presented at
      conferences and contribute to a doctoral thesis. PROSPERO REGISTRATION NUMBER:
      CRD42020173906.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sue-Chue-Lam, Colin
AU  - Sue-Chue-Lam C
AUID- ORCID: 0000-0003-2732-3929
AD  - Department of Surgery, Unity Health Toronto, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Castelo, Matthew
AU  - Castelo M
AD  - Department of Surgery, Unity Health Toronto, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Tinmouth, Jill
AU  - Tinmouth J
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
FAU - Llovet, Diego
AU  - Llovet D
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Cancer Care Ontario, Toronto, Ontario, Canada.
FAU - Kishibe, Teruko
AU  - Kishibe T
AD  - Scotiabank Health Sciences Library, Li Ka Shing Knowledge Institute, Toronto,
      Ontario, Canada.
FAU - Baxter, Nancy N
AU  - Baxter NN
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada BaxterN@smh.ca.
AD  - Melbourne School of Population and Global Health, Melbourne, Victoria, Australia.
LA  - eng
GR  - FDN - 148470/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Hypnotics and Sedatives)
SB  - IM
MH  - *Anesthesia
MH  - Colonoscopy
MH  - Conscious Sedation
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - Meta-Analysis as Topic
MH  - Patient Outcome Assessment
MH  - Systematic Reviews as Topic
PMC - PMC7488806
OTO - NOTNLM
OT  - *adult gastroenterology
OT  - *endoscopy
OT  - *gastroenterology
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038621 [pii]
AID - 10.1136/bmjopen-2020-038621 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e038621. doi: 10.1136/bmjopen-2020-038621.


PMID- 32928860
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 14
TI  - Apical extrusion of debris with different rotary and reciprocating single-file
      endodontic instrumentation systems: a systematic review and meta-analysis
      protocol.
PG  - e038502
LID - 10.1136/bmjopen-2020-038502 [doi]
AB  - INTRODUCTION: Root canal treatment is one of the oldest dental procedures for the
      treatment of endodontic infection. Extrusion of debris beyond the root apex
      during root canal instrumentation and subsequent persistence of pain are common
      complications. A systematic review of the evidence on reciprocating single-file
      instrumentation systems and their comparison with rotary single-file systems,
      with apical extrusion of debris as primary outcome, will be done through this
      study. METHODS AND ANALYSIS: Published ex vivo and in vitro studies with no
      language restriction will be included. We will search MEDLINE (Ovid), EMBASE
      (Ovid), Web of Science, Cochrane and Google Scholar. Strategies will be
      incorporated to search grey literature also. Thorough evaluation of search
      results, completion of data abstraction and assessment of quality will be done by
      two reviewers independent from each other. Assessment of included studies will be
      done by utilising an evidence model developed on the basis of standards of
      quality reported in guidelines to document ex vivo and in vitro studies regarding
      dental materials and pertained for extrusion of debris apically and has been
      already used in quality assessment of studies involving quantification of debris 
      extrusion apically. We will calculate the standardised mean differences for
      apically extruded debris, with congruent 95% CIs. We will measure the statistical
      heterogeneity by applying the Cochrane Q test and quantify using the I(2)
      statistic. Existence of covariates and any potential heterogeneity will be
      explored through prespecified subgroup and sensitivity analyses. ETHICS AND
      DISSEMINATION: Approval from an ethical research committee is not required
      because it will be done using data that have been already published and have no
      concerns related to the privacy of patients. Extensive dissemination of results
      from this review will be done through submission to a peer-reviewed journal for
      publication and conferences. PROSPERO REGISTRATION NUMBER: CRD42019151804.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ahmad, Muhammad Zubair
AU  - Ahmad MZ
AUID- ORCID: 0000-0002-8033-6254
AD  - Department of Restorative Dentistry, College of Dentistry in Ar Rass, Qassim
      University, Ar Rass, Saudi Arabia m.muhammad@qu.edu.sa.
AD  - Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based
      Medicine, University of Oxford, Oxford, UK.
FAU - Sadaf, Durre
AU  - Sadaf D
AUID- ORCID: 0000-0003-4504-6267
AD  - Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based
      Medicine, University of Oxford, Oxford, UK.
AD  - Department of Conservative Sciences, College of Dentistry, Qassim University,
      Buraydha, Saudi Arabia.
FAU - MacBain, Marcy McCall
AU  - MacBain MM
AD  - Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based
      Medicine, University of Oxford, Oxford, UK.
FAU - Mohamed, Ahmed Nabil
AU  - Mohamed AN
AD  - Department of Conservative Sciences, College of Dentistry, Qassim University,
      Buraydha, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Root Canal Preparation
MH  - Systematic Reviews as Topic
MH  - *Tooth Apex
PMC - PMC7490960
OTO - NOTNLM
OT  - *oral & maxillofacial surgery
OT  - *oral medicine
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038502 [pii]
AID - 10.1136/bmjopen-2020-038502 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 14;10(9):e038502. doi: 10.1136/bmjopen-2020-038502.


PMID- 32928859
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Protocol for a systematic review on tertiary prevention interventions for
      patients with stroke in African countries.
PG  - e038459
LID - 10.1136/bmjopen-2020-038459 [doi]
AB  - INTRODUCTION: Stroke is one of the common causes of mortality, morbidity and
      years of life lost worldwide. Baseline research on stroke epidemiology,
      prevention, acute and rehabilitative interventions in Africa is necessary to
      approach specific contexts and regional circumstances. Most studies on stroke
      have been conducted in high-income countries. This protocol describes the
      methodology to summarise the best available evidence on tertiary preventive
      strategies like rehabilitation interventions for patients with stroke in African 
      contexts. METHODS AND ANALYSIS: We will include experimental studies and
      prospective cohort studies conducted in African countries. A protocol has been
      registered in PROSPERO. Systematic search will include eight electronic databases
      (MEDLINE, Embase, the Cochrane Library, CINAHL, Cab-Direct, Physiotherapy
      Evidence Database (PEDro), African Journals Online and African Index Medicus) and
      the International Clinical Trials Register Platform and base on predefined search
      terms. We will search from inception of each database and repeat this strategy 3 
      months prior to review submission. Details of all eligible studies will be
      extracted and risk of bias for outcomes on global disability or dependence in
      daily living will be assessed. Main aim of this systematic review is to provide a
      narrative description of evidence on tertiary prevention strategies (including
      rehabilitation) for stroke. This description will be visualised in structured
      tables to aid interpretation of study characteristics, intervention effects and
      certainty of the evidence. ETHICS AND DISSEMINATION: No ethical approval is
      necessary. Results will be presented in national and international conferences
      and published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020159125.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kroeber, Eric Sven
AU  - Kroeber ES
AUID- ORCID: 0000-0002-7201-6023
AD  - Center of Health Sciences, Institute of General Practice and Family Medicine,
      Martin-Luther-Universitat Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany.
FAU - Adam, Lucas
AU  - Adam L
AD  - Center of Health Sciences, Institute of General Practice and Family Medicine,
      Martin-Luther-Universitat Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany.
FAU - Addissie, Adamu
AU  - Addissie A
AD  - Preventive Medicine, Addis Ababa University School of Public Health, Addis Ababa,
      Oromia, Ethiopia.
FAU - Bauer, Alexander
AU  - Bauer A
AD  - Center of Health Sciences, Institute of General Practice and Family Medicine,
      Martin-Luther-Universitat Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany.
FAU - Frese, Thomas
AU  - Frese T
AD  - Center of Health Sciences, Institute of General Practice and Family Medicine,
      Martin-Luther-Universitat Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany.
FAU - Kantelhardt, Eva Johanna
AU  - Kantelhardt EJ
AUID- ORCID: 0000-0001-7935-719X
AD  - Center of Health Sciences, Institute for Medical Epidemiology, Biostatistics and 
      Informatics, Martin-Luther-Universitat Halle-Wittenberg, Halle, Sachsen-Anhalt,
      Germany.
FAU - Unverzagt, Susanne
AU  - Unverzagt S
AUID- ORCID: 0000-0002-0108-0415
AD  - Center of Health Sciences, Institute of General Practice and Family Medicine,
      Martin-Luther-Universitat Halle-Wittenberg, Halle, Sachsen-Anhalt, Germany
      susanne.unverzagt@uk-halle.de.
AD  - Department of General Practice, Leipzig University, Leipzig, Sachsen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa/epidemiology
MH  - Humans
MH  - Income
MH  - Prospective Studies
MH  - Research Design
MH  - *Stroke/prevention & control
MH  - Systematic Reviews as Topic
MH  - Tertiary Prevention
PMC - PMC7488840
OTO - NOTNLM
OT  - *Africa
OT  - *cerebrovascular diseases
OT  - *protocol
OT  - *rehabilitation
OT  - *stroke
OT  - *systematic review
OT  - *tertiary prevention
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038459 [pii]
AID - 10.1136/bmjopen-2020-038459 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e038459. doi: 10.1136/bmjopen-2020-038459.


PMID- 32928858
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Prevention of mother-to-child transmission of hepatitis B virus: protocol for a
      one-arm, open-label intervention study to estimate the optimal timing of
      tenofovir in pregnancy.
PG  - e038123
LID - 10.1136/bmjopen-2020-038123 [doi]
AB  - INTRODUCTION: Hepatitis B virus (HBV) remains a public health threat and the main
      route of transmission is from mother to child (MTCT). Tenofovir disoproxil
      fumarate (TDF) treatment can reduce MTCT of HBV although the optimal timing to
      attain undetectable HBV DNA concentrations at delivery is unknown. This protocol 
      describes the procedures following early initiation of maternal TDF prior to 20
      weeks gestation to determine efficacy, safety and feasibility of this approach in
      a limited-resource setting. METHODS AND ANALYSES: One hundred and seventy
      pregnant women from the Thailand-Myanmar border between 12 and <20 weeks
      gestational age will be enrolled into a one-arm, open-label, TDF treatment study 
      with cessation of TDF 1 month after delivery. Sampling occurs monthly prenatal,
      at birth and at 1, 2, 4 and 6 months post partum. Measurement of tenofovir
      concentrations in maternal and cord plasma is anticipated in 10-15 women who have
      detectable HBV DNA at delivery and matched to 20-30 women with no detectable HBV 
      DNA. Infant HBsAg status will be determined at 2 months of age and HBV DNA
      confirmed in HBsAg positive cases. Adverse events including risk of flare and
      adherence, based on pill count and questionnaire, will be monitored. Infants will
      receive HBV vaccinations at birth, 2, 4 and 6 months and hepatitis B
      immunoglobulin at birth if the mother is hepatitis B e antigen positive. Infant
      growth and neurodevelopment at 6 months will be compared with established local
      norms. ETHICS AND DISSEMINATION: This study has ethical approval by the Ethics
      Committee of the Faculty of Tropical Medicine, Mahidol University (FTM
      ECF-019-06), Johns Hopkins University (IRB no: 00007432), Chiang Mai University
      (FAM-2559-04227), Oxford Tropical Research Ethics Committee (OxTREC Reference:
      49-16) and by the local Tak Community Advisory Board (TCAB-02/REV/2016). The
      article will be published as an open-access publication. TRIAL REGISTRATION
      NUMBER: NCT02995005, Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Bierhoff, Marieke
AU  - Bierhoff M
AUID- ORCID: 0000-0003-2585-1066
AD  - Department of Maternal and Child health, Shoklo Malaria Research Unit,
      Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Mae Sot, Thailand.
AD  - Amsterdam UMC, Internal Medicine, Department of Infectious Diseases, Centre of
      Tropical Medicine and Travel Medicine, location AMC, University of Amsterdam,
      Amsterdam, The Netherlands.
FAU - Nelson, Kenrad E
AU  - Nelson KE
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Guo, Nan
AU  - Guo N
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Stanford
      University, Stanford, California, USA.
FAU - Jia, Yuanxi
AU  - Jia Y
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Angkurawaranon, Chaisiri
AU  - Angkurawaranon C
AD  - Department of Family Medicine, Chiang Mai University, Suthep, Chiang Mai,
      Thailand.
FAU - Jittamala, Podjanee
AU  - Jittamala P
AD  - Department of Maternal and Child health, Mahidol-Oxford Tropical Medicine
      Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok,
      Thailand.
AD  - Department of Tropical Hygiene, Mahidol University Faculty of Medicine
      Ramathibodi Hospital, Bangkok, Thailand.
FAU - Carrara, Verena
AU  - Carrara V
AD  - Department of Maternal and Child health, Shoklo Malaria Research Unit,
      Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Mae Sot, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Oxford University, Oxford,
      Oxfordshire, UK.
FAU - Watthanaworawit, Wanitda
AU  - Watthanaworawit W
AD  - Department of Microbiology, Shoklo Malaria Research Unit, Mahidol-Oxford Tropical
      Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae
      Sot, Thailand.
FAU - Ling, Clare
AU  - Ling C
AD  - Centre for Tropical Medicine and Global Health, Oxford University, Oxford,
      Oxfordshire, UK.
AD  - Department of Microbiology, Shoklo Malaria Research Unit, Mahidol-Oxford Tropical
      Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae
      Sot, Thailand.
FAU - Tongprasert, Fuanglada
AU  - Tongprasert F
AD  - Department of Obstetrics and Gynecology, Chiang Mai University, Suthep, Chiang
      Mai, Thailand.
FAU - van Vugt, Michele
AU  - van Vugt M
AD  - Amsterdam UMC, Internal Medicine, Department of Infectious Diseases, Centre of
      Tropical Medicine and Travel Medicine, location AMC, University of Amsterdam,
      Amsterdam, The Netherlands.
FAU - Rijken, Marcus
AU  - Rijken M
AD  - Department of Obstetrics and Gynecology, Utrecht University, Utrecht, The
      Netherlands.
FAU - Nosten, Francois
AU  - Nosten F
AUID- ORCID: 0000-0002-7951-0745
AD  - Department of Maternal and Child health, Shoklo Malaria Research Unit,
      Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Mae Sot, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Oxford University, Oxford,
      Oxfordshire, UK.
FAU - McGready, Rose
AU  - McGready R
AD  - Department of Maternal and Child health, Shoklo Malaria Research Unit,
      Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Mae Sot, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Oxford University, Oxford,
      Oxfordshire, UK.
FAU - Ehrhardt, Stephan
AU  - Ehrhardt S
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA
      sehrhar6@jhu.edu.
FAU - Thio, Chloe Lynne
AU  - Thio CL
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02995005
GR  - 106698/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 99YXE507IL (Tenofovir)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Child
MH  - DNA, Viral
MH  - Female
MH  - *Hepatitis B/drug therapy/prevention & control
MH  - Hepatitis B virus/genetics
MH  - *Hepatitis B, Chronic/drug therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/prevention & control
MH  - Myanmar
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/drug therapy/prevention & control
MH  - Tenofovir/therapeutic use
MH  - Thailand
MH  - Viral Load
PMC - PMC7488796
OTO - NOTNLM
OT  - *fetal medicine
OT  - *maternal medicine
OT  - *public health
OT  - *therapeutics
OT  - *tropical medicine
OT  - *virology
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038123 [pii]
AID - 10.1136/bmjopen-2020-038123 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e038123. doi: 10.1136/bmjopen-2020-038123.


PMID- 32928856
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 14
TI  - Prognostic significance of tissue factor in patients with pancreatic cancer: a
      systematic review protocol.
PG  - e037431
LID - 10.1136/bmjopen-2020-037431 [doi]
AB  - INTRODUCTION: Pancreatic cancer is a highly aggressive digestive system tumour
      with poor prognosis. Venous thromboembolism (VTE) is a well-known complication of
      pancreatic cancer, and tissue factor (TF) contributes to the generation of a
      hypercoagulable state and thrombotic disease in pancreatic cancer. Several
      studies showed that an elevated TF level was related to the development of VTE
      and influenced the survival of patients with pancreatic cancer. Thus, we wish to 
      conduct a systematic review of literature to clarify the prognostic significance 
      of TF in pancreatic cancer. METHODS AND ANALYSIS: Studies comparing the
      circulating microparticle-associated TF (MP TF) level between patients who had
      pancreatic cancer with and without VTE will be included to evaluate the roles of 
      TF in VTE development. Studies comparing the survival data between patients with 
      high TF expression and low TF expression will also be included to explore the
      association of TF expression with patient survival. The outcomes are plasma MP TF
      level and survival endpoints (overall and progression-free survival),
      respectively. Primary studies of any type published in English will be included. 
      Two reviewers will search Medline, EMBASE and Cochrane databases from inception
      to June 2020, retrieve relevant studies, and independently select the literatures
      and extract data from the included studies. The quality of each included study
      will be assessed by the Newcastle-Ottawa Scale score. The HR and 95% CI of each
      study will be pooled for survival outcome, and the standardised mean difference
      (SMD) with 95% CIs will be used for continuous outcomes. If meta-analysis is
      inappropriate, the result will only be reported qualitatively. Subgroup and
      sensitivity analyses will be considered to identify sources of heterogeneity. The
      Grades of Recommendation, Assessment, Development and Evaluation method will be
      applied to assess the level of evidence of this systematic review. ETHICS AND
      DISSEMINATION: There are no concerning ethical issues. The results will be
      published. PROSPERO REGISTRATION NUMBER: CRD42019133665.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Haiyuan
AU  - Li H
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Yu, Yang
AU  - Yu Y
AUID- ORCID: 0000-0002-2409-3681
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Shi, Qianling
AU  - Shi Q
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Chen, Xueping
AU  - Chen X
AD  - Sleep Medicine Center, Gansu Provincial Hospital, Lanzhou, China.
FAU - Zheng, Peng
AU  - Zheng P
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Wang, Dengfeng
AU  - Wang D
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Tao, Pengxian
AU  - Tao P
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Gu, Baohong
AU  - Gu B
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Li, Xuemei
AU  - Li X
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Xiang, Lin
AU  - Xiang L
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Xi, Dayong
AU  - Xi D
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Gao, Lei
AU  - Gao L
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Maswikiti Ewetse, Paul
AU  - Maswikiti Ewetse P
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
AD  - The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Chen, Hao
AU  - Chen H
AUID- ORCID: 0000-0001-9741-9403
AD  - Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China
      ery_chenh@lzu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9035-58-9 (Thromboplastin)
SB  - IM
MH  - *Gastrointestinal Neoplasms
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Pancreatic Neoplasms/complications
MH  - Prognosis
MH  - Systematic Reviews as Topic
MH  - Thromboplastin
MH  - *Venous Thromboembolism
PMC - PMC7490930
OTO - NOTNLM
OT  - *gastrointestinal tumours
OT  - *molecular biology
OT  - *pancreatic disease
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037431 [pii]
AID - 10.1136/bmjopen-2020-037431 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 14;10(9):e037431. doi: 10.1136/bmjopen-2020-037431.


PMID- 32928855
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Recurrence of cervical artery dissection: protocol for a systematic review.
PG  - e037124
LID - 10.1136/bmjopen-2020-037124 [doi]
AB  - INTRODUCTION: Cervical artery dissection, including carotid and vertebral artery 
      dissection, is an important cause of stroke in the young. Risk of developing
      cervical artery dissection has been associated with physical activity in various 
      forms and has been presumed to be related to minor trauma and mechanical
      stretching of the cervical arteries. This systematic review will aim to
      synthesise data on the risk of recurrent cervical artery dissection after an
      initial dissection. This information may be applied to further understand the
      natural history of this disease, and potentially to help direct evidence-based
      discussions on safe return to activity after dissection. METHODS AND ANALYSIS: A 
      broad search of multiple electronic databases (Medline, Embase, Cochrane Central 
      Register of Controlled Trials and Web of Science) will be conducted to identify
      studies published as of 13 November 2019, examining all-comers with cervical
      artery dissection observed over time. Studies will be screened by two independent
      reviewers in a two-level process to determine eligibility for inclusion. Data
      will be pooled from eligible articles and the main outcome of recurrent cervical 
      artery dissection at 5 years will be determined using quantitative analysis.
      ETHICS AND DISSEMINATION: Ethics approval is not necessary as no primary data are
      being collected. The information will be disseminated in the form of a systematic
      review article which will be submitted to a peer-reviewed medical journal.
      PROSPERO REGISTRATION NUMBER: CRD42020166105.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lounsbury, Elizabeth
AU  - Lounsbury E
AUID- ORCID: 0000-0002-6238-6047
AD  - Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada elounsbury@toh.ca.
FAU - Dewar, Brian
AU  - Dewar B
AD  - Neuroscience, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Davis, Alexandra
AU  - Davis A
AD  - Library Services, Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AD  - Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Dowlatshahi, Dar
AU  - Dowlatshahi D
AD  - Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Shamy, Michel
AU  - Shamy M
AD  - Neurology, The Ottawa Hospital, Ottawa, Ontario, Canada.
AD  - Neuroscience, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Carotid Arteries
MH  - Dissection
MH  - Humans
MH  - Recurrence
MH  - *Stroke
MH  - Systematic Reviews as Topic
PMC - PMC7488837
OTO - NOTNLM
OT  - *neurology
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037124 [pii]
AID - 10.1136/bmjopen-2020-037124 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e037124. doi: 10.1136/bmjopen-2020-037124.


PMID- 32928853
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Scoping review protocol on non-pharmacological interventions for interpersonal
      and self-directed violence in adults with severe mental illness.
PG  - e037006
LID - 10.1136/bmjopen-2020-037006 [doi]
AB  - INTRODUCTION: Violence committed by people with mental illness has implications
      for mental health policy and clinical practice. Several strategies to reduce the 
      risk of aggressive and violent behaviour have been proposed, and these include
      non-pharmacological interventions. There is, however, a need to identify which of
      these interventions are effective, and as a first step, we will conduct a scoping
      review to identify non-pharmacological interventions for self-directed or
      interpersonal violence in adults with severe mental illness across different
      conditions and settings. METHODS AND ANALYSIS: This is a scoping review protocol.
      The review will include any randomised controlled trials (RCTs) and cluster RCTs 
      that assess the efficacy of interventions on self-directed or interpersonal
      violence with no restrictions on the control treatment in people with severe
      mental illness in any setting. No restrictions will be applied in terms of
      language or date of publication. To identify studies, a search will be performed 
      in the following databases: Embase, MEDLINE (via PubMed), PsycINFO, CINAHL,
      LILACS, SciELO, Cochrane Library, Web of Science, Scopus, ProQuest, Epistemonikos
      and databases of clinical trials. The Preferred Reporting Items for Systematic
      Reviews and Meta-Analysis (PRISMA) statement will be followed for reporting the
      findings, including the use of a PRISMA flow diagram. A standardised form will be
      used to extract data from studies. The findings will be classified using
      conceptual categories that will be specified in detail and a descriptive summary 
      of the main results will be created. Moreover, it will be assessed whether the
      studies identified have been included in systematic reviews or meta-analyses and 
      the results will be used to generate a conceptual map. ETHICS AND DISSEMINATION: 
      No patients or other participants will be involved in this study. We will prepare
      a manuscript for publication in a peer-reviewed journal and the results will be
      presented at mental health conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Moreno-Calvete, Maria Concepcion
AU  - Moreno-Calvete MC
AUID- ORCID: 0000-0001-9712-2319
AD  - Biocruces Bizkaia Health Research Institute, Basque Health Service, Bizkaia
      Mental Health Network, Bilbao, Biscay, Spain
      mariaconcepcion.morenocalvete@osakidetza.eus.
FAU - Ruiz-Ibanez, Ivan
AU  - Ruiz-Ibanez I
AD  - Basque Health Service, Bizkaia Mental Health Network, Assertive Community
      Treatment (ACT) Team, Buenavista Health Centre, Portugalete, Biscay, Spain.
FAU - Uriarte-Uriarte, Jose Juan
AU  - Uriarte-Uriarte JJ
AD  - Biocruces Bizkaia Health Research Institute, Basque Health Service, Bizkaia
      Mental Health Network, Bilbao, Biscay, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Mental Disorders/therapy
MH  - Mental Health
MH  - Meta-Analysis as Topic
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
MH  - Violence/prevention & control
PMC - PMC7488835
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *mental health
OT  - *psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037006 [pii]
AID - 10.1136/bmjopen-2020-037006 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e037006. doi: 10.1136/bmjopen-2020-037006.


PMID- 32928851
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Rhythm and Movement for Self-Regulation (RAMSR) intervention for preschool
      self-regulation development in disadvantaged communities: a clustered randomised 
      controlled trial study protocol.
PG  - e036392
LID - 10.1136/bmjopen-2019-036392 [doi]
AB  - INTRODUCTION: Self-regulation (the ability to regulate emotion, attention,
      cognition and behaviour) is an integral part of early learning competence in the 
      years prior to school. Self-regulation skills are critical to ongoing learning
      behaviours, achievement and well-being. Emerging neurological evidence suggests
      coordinated music and movement participation could support self-regulation
      development for all children. A pilot study in 2016 introduced a coordinated
      music and movement programme designed to boost self-regulation skills in children
      in disadvantaged communities, delivered by visiting specialists, with promising
      findings. The intervention is based on the neuroscience of beat synchronisation, 
      rhythmic entrainment and the cognitive benefits of music therapy and music
      education-and is called Rhythm and Movement for Self-Regulation (RAMSR). This
      study builds on the pilot by training regular teachers to deliver RAMSR in their 
      classrooms (rather than visiting specialists). The study aims to establish the
      effectiveness of RAMSR, which is designed to translate the cognitive benefits
      that accrue from rhythm participation to address self-regulation for children who
      do not typically access high-quality music programmes. METHODS AND ANALYSIS: We
      will recruit 237 children from up to eight kindergartens in low socioeconomic
      areas. INTERVENTION: teachers will be trained to deliver the RAMSR intervention
      during group time in kindergartens, daily for 8 weeks. CONTROL: usual practice
      kindergarten programme. FOLLOW-UP: end of intervention using child assessments
      and teacher report; 12 months postbaseline using school teacher reports following
      school transition. Primary outcomes: executive function and self-regulation.
      SECONDARY OUTCOMES: school readiness; visual-motor integration; teacher-reported 
      behaviour problems, school transition and academic competency; teacher knowledge,
      confidence, practice and attitudes related to self-regulation, rhythm and
      movement; fidelity of intervention implementation. ETHICS AND DISSEMINATION:
      Queensland University of Technology Human Research Ethics Committee, approval
      1900000566. Findings dissemination: in-field workshops to service providers,
      conference presentations, journal and professional publications. TRIAL
      REGISTRATION NUMBER: ACTRN12619001342101; Pre-results (30 September 2019).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Williams, Kate E
AU  - Williams KE
AUID- ORCID: 0000-0001-8983-5503
AD  - School of Early Childhood & Inclusive Education, Faculty of Education, Queensland
      University of Technology, Brisbane, Queensland, Australia
      k15.williams@qut.edu.au.
FAU - Savage, Sally
AU  - Savage S
AD  - School of Early Childhood & Inclusive Education, Faculty of Education, Queensland
      University of Technology, Brisbane, Queensland, Australia.
FAU - Eager, Rebecca
AU  - Eager R
AD  - School of Early Childhood & Inclusive Education, Faculty of Education, Queensland
      University of Technology, Brisbane, Queensland, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001342101
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Pilot Projects
MH  - Queensland
MH  - Randomized Controlled Trials as Topic
MH  - Schools
MH  - *Self-Control
MH  - *Vulnerable Populations
PMC - PMC7488808
OTO - NOTNLM
OT  - *community child health
OT  - *mental health
OT  - *paediatrics
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: KEW reports a grant from Australian Research Council. SS
      reports work as a paid casual relief teacher for the collaborating agency,
      Childcare & Kindergarten Association, for approximately 30 days per year at
      various sites. This agency has no financial interest in the research project,
      they are providing access to research sites only.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036392 [pii]
AID - 10.1136/bmjopen-2019-036392 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e036392. doi: 10.1136/bmjopen-2019-036392.


PMID- 32928848
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Scientific, professional and experiential validation of the model of preventive
      behaviours at work: protocol of a modified Delphi Study.
PG  - e035606
LID - 10.1136/bmjopen-2019-035606 [doi]
AB  - INTRODUCTION: To offer an in-depth understanding of preventive behaviours, those 
      complex behaviours considered as levers to foster work prevention, recent
      theoretical and empirical studies permitted to develop the model of preventive
      behaviours at work. The next step is to validate the model with researchers,
      professionals and workers. This article aims to describe the study protocol that 
      will be used to validate the model of preventive behaviours at work. METHODS AND 
      ANALYSIS: This Delphi Study proposes seven systematic steps to conduct a
      scientifically rigorous validation study based on scientific and professional
      experts' opinion. A focus group to collect workers' opinion about the model has
      also been included in the protocol. Thirty experts (researchers and
      professionals) will be selected regarding their experience (eg, at least 5 years 
      of experience) and expertise (eg, having published at least one article as the
      first author in the last 3 years) towards workers' health or organisational
      behaviours. Workers will be recruited to have a diversity in terms of age, gender
      and working conditions. Quantitative data will be analysed to calculate the
      percentage of experts' agreement on four content validity indicators (ie,
      comprehensiveness, representativeness, relevance and clarity). Qualitative data
      will be examined through a thematic analysis strategy. ETHICS AND DISSEMINATION: 
      Approval of the research ethics board of the Centre integre universitaire de
      sante et de services sociaux de la Capitale Nationale has been obtained. Findings
      will be shared with various stakeholders inclusive of researchers, professionals 
      and workers. Findings will be disseminated in workshops, peer-reviewed journals
      and conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lecours, Alexandra
AU  - Lecours A
AUID- ORCID: 0000-0002-4485-7829
AD  - Department of Rehabilitation, Universite Laval, Quebec, Quebec, Canada
      Alexandra.Lecours@fmed.ulaval.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delphi Technique
MH  - Focus Groups
MH  - Humans
MH  - *Occupational Health
PMC - PMC7488793
OTO - NOTNLM
OT  - *health & safety
OT  - *human resource management
OT  - *occupational & industrial medicine
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035606 [pii]
AID - 10.1136/bmjopen-2019-035606 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e035606. doi: 10.1136/bmjopen-2019-035606.


PMID- 32928844
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 13
TI  - Investigation of predictors of interest in a brief mindfulness-based intervention
      and its effects in patients with psoriasis at a rehabilitation clinic (SkinMind):
      an observational study and randomised controlled trial.
PG  - e033952
LID - 10.1136/bmjopen-2019-033952 [doi]
AB  - INTRODUCTION: Psoriasis (PS) is a chronic inflammatory skin disease accompanied
      by reduced quality of life. Mindfulness is the ability to focus on the present
      moment without evaluation. Findings on the effects of 8-week mindfulness
      trainings in patients with PS reveal positive effects on the severity of the
      disease and quality of life. However, it remained unclear what distinguishes
      patients with PS interested in psychological interventions from those without
      interest and whether also a shorter, namely 2-week mindfulness-based intervention
      is beneficial in this patient group. This will be investigated with this study.
      METHODS AND ANALYSES: Data will be collected at a rehabilitation clinic in
      Germany. The study is divided into two parts: study 1a is an observational study.
      Its aim is to investigate whether sociodemographic, skin-related and
      psychological factors are significant predictors of interest in a brief
      psychological intervention in 127 patients with PS. Study 1b is a randomised
      controlled trial, in which 60 patients (retrieved from study 1a) will be
      randomised to an intervention or control group (treatment as usual). The main
      outcome variables are mindfulness and self-compassion. In addition, mediation
      analyses will be used in an explorative manner to test whether there is a
      relationship between mindfulness/self-compassion and the severity of PS and
      whether it is mediated by itch catastrophising and fear of negative evaluation
      (first model) or perceived stress (second model). ETHICS AND DISSEMINATION: The
      study protocol has been approved by the University of Giessen. Study results will
      be disseminated by publication of the results at (inter) national conferences and
      in scientific journals. TRIAL REGISTRATION NUMBERS: DRKS00017426 and
      DRKS00017429.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Stadtmuller, Laura
AU  - Stadtmuller L
AD  - Institute of Medical Psychology, Justus Liebig Universitat Giessen, Giessen,
      Hessen, Germany.
FAU - Eckardt, Markus
AU  - Eckardt M
AD  - Institute of Medical Psychology, Justus Liebig Universitat Giessen, Giessen,
      Hessen, Germany.
FAU - Zick, Christoph
AU  - Zick C
AD  - Department of Dermatology, Rehabilitation Clinic Borkum Riff, Borkum, Germany,
      Borkum, Germany.
FAU - Kupfer, Joerg
AU  - Kupfer J
AD  - Institute of Medical Psychology, Justus Liebig Universitat Giessen, Giessen,
      Hessen, Germany.
FAU - Schut, Christina
AU  - Schut C
AUID- ORCID: 0000-0001-5366-6285
AD  - Institute of Medical Psychology, Justus Liebig Universitat Giessen, Giessen,
      Hessen, Germany Christina.Schut@mp.med.uni-giessen.de.
AD  - Institute of Psychology, Bergische Universitat Wuppertal, Wuppertal, Germany.
LA  - eng
SI  - DRKS/DRKS00017426
SI  - DRKS/DRKS00017429
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
DEP - 20200913
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Empathy
MH  - Germany
MH  - Humans
MH  - *Mindfulness
MH  - *Psoriasis/therapy
MH  - Quality of Life
PMC - PMC7488799
OTO - NOTNLM
OT  - *RCT
OT  - *itch catastrophizing
OT  - *mindfulness
OT  - *psoriasis
OT  - *rehabilitation clinic
COIS- Competing interests: None declared.
EDAT- 2020/09/16 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/15 05:41
PHST- 2020/09/15 05:41 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-033952 [pii]
AID - 10.1136/bmjopen-2019-033952 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 13;10(9):e033952. doi: 10.1136/bmjopen-2019-033952.


PMID- 32928655
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - The importance of equity, ethics, and rigor in global health research.
PG  - 1509-1512
LID - S1551-7411(20)31058-5 [pii]
LID - 10.1016/j.sapharm.2020.08.024 [doi]
FAU - Drame, Imbi
AU  - Drame I
AD  - Howard University College of Pharmacy, USA. Electronic address:
      imbi.drame@howard.edu.
FAU - Connor, Sharon
AU  - Connor S
AD  - University of Pittsburgh School of Pharmacy, USA. Electronic address:
      sconnor@pitt.edu.
FAU - Abrons, Jeanine
AU  - Abrons J
AD  - University of Iowa, College of Pharmacy, USA. Electronic address:
      jeanine-abrons@uiowa.edu.
FAU - Chen, Aleda M H
AU  - Chen AMH
AD  - Cedarville University School of Pharmacy, 251 N. Main St., Cedarville, OH, 45314,
      USA. Electronic address: amchen@cedarville.edu.
LA  - eng
PT  - Editorial
DEP - 20200905
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
SB  - IM
MH  - *Global Health
MH  - *Health Equity
MH  - Humans
MH  - International Cooperation
EDAT- 2020/09/16 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/09/15 05:40
PHST- 2020/08/30 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/09/15 05:40 [entrez]
AID - S1551-7411(20)31058-5 [pii]
AID - 10.1016/j.sapharm.2020.08.024 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Nov;16(11):1509-1512. doi:
      10.1016/j.sapharm.2020.08.024. Epub 2020 Sep 5.


PMID- 32928517
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 6
DP  - 2020 Dec
TI  - Epidemiology and outcome of patients admitted to intensive care after anaphylaxis
      in France: a retrospective multicentre study.
PG  - 1025-1033
LID - S0007-0912(20)30680-2 [pii]
LID - 10.1016/j.bja.2020.08.024 [doi]
AB  - BACKGROUND: Few data are available on patients who have experienced anaphylaxis
      and were admitted to ICUs. The purpose of this observational study was to
      describe the epidemiology and management of these patients. METHODS: This was a
      multicentre retrospective study carried out in 23 French ICUs between 2012 and
      2017. All patients who suffered anaphylaxis and were transferred to an ICU were
      included. Data were collected using an electronic database after approval by an
      ethics committee. RESULTS: A total of 339 patients were included, and 17 (5%)
      died secondary to anaphylaxis. The main triggers were drugs (77%), contrast media
      (11%), and food (7%). Epinephrine was administered before ICU admission in 88% of
      patients with Grade III anaphylaxis and 100% of patients with Grade IV
      anaphylaxis. Most patients with Grades III and IV anaphylaxes did not receive the
      recommended dose of i.v. fluid of 30 ml kg(-1) within the first 4 h of ICU
      admission. The time to epinephrine administration was not statistically different
      between survivors and non-survivors, but non-survivors received a higher dose of 
      epinephrine (median: 5 [3-10] vs 3 [2-7] mg; P<0.0001), which suggests that some 
      forms of anaphylactic shock may be resistant to epinephrine. In multivariate
      analysis, only lactate concentration at ICU admission was a predictor of death
      (odds ratio: 1.47 [1.15-1.88]; P=0.002). CONCLUSIONS: Lactate concentration at
      ICU admission appeared to be the most reliable criterion for assessing prognosis.
      Epinephrine is widely used during anaphylaxis, but the volume of fluid
      resuscitation was consistently lower than recommended. CLINICAL TRIAL
      REGISTRATION: NCT04290507.
CI  - Copyright (c) 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All
      rights reserved.
FAU - Guerci, Philippe
AU  - Guerci P
AD  - Department of Anaesthesiology and Critical Care Medicine, Institut Lorrain du
      Coeur et des Vaisseaux, University Hospital of Nancy-Brabois,
      Vandoeuvre-les-Nancy, France; INSERM U1116, Groupe Choc, University of Lorraine, 
      Nancy, France. Electronic address: phil.guerci@gmail.com.
FAU - Tacquard, Charles
AU  - Tacquard C
AD  - Service d'Anesthesie-Reanimation Chirurgicale, Nouvel Hopital Civil, Hopitaux
      Universitaires de Strasbourg, Strasbourg, France.
FAU - Chenard, Laura
AU  - Chenard L
AD  - Department of Anaesthesiology and Critical Care Medicine, Institut Lorrain du
      Coeur et des Vaisseaux, University Hospital of Nancy-Brabois,
      Vandoeuvre-les-Nancy, France.
FAU - Millard, David
AU  - Millard D
AD  - Service d'Anesthesie-Reanimation Chirurgicale, Nouvel Hopital Civil, Hopitaux
      Universitaires de Strasbourg, Strasbourg, France.
FAU - Soufir, Lila
AU  - Soufir L
AD  - Service d'Anesthesie-Reanimation, Groupe Hospitalier Paris Saint Joseph, Paris,
      France.
FAU - Malinovsky, Jean-Marc
AU  - Malinovsky JM
AD  - Departement d'Anesthesie-Reanimation, Hopital Maison Blanche, Centre Hospitalier 
      Universitaire de Reims, Reims, France.
FAU - Garot, Matthias
AU  - Garot M
AD  - Departement d'Anesthesie-Reanimation, Hopital Huriez, Centre Hospitalier Regional
      Universitaire de Lille, Lille, France.
FAU - Lalot, Jean-Marc
AU  - Lalot JM
AD  - Reanimation Polyvalente, Centre Hospitalier Emile Durkheim, Epinal, France.
FAU - Besch, Guillaume
AU  - Besch G
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Hospital of
      Besancon, Besancon, France.
FAU - Louis, Guillaume
AU  - Louis G
AD  - Reanimation Polyvalente, Hopital de Mercy, CHR Metz-Thionville, Metz, France.
FAU - Thion, Laurie-Anne
AU  - Thion LA
AD  - Service d'Anesthesie-Reanimation, Fondation Ophtalmologique Adolphe de
      Rothschild, Paris, France.
FAU - Charpentier, Claire
AU  - Charpentier C
AD  - Reanimation Chirurgicale Polyvalente, Hopital Central, Centre Hospitalier
      Universitaire de Nancy, Nancy, France.
FAU - Kimmoun, Antoine
AU  - Kimmoun A
AD  - INSERM U1116, Groupe Choc, University of Lorraine, Nancy, France; Reanimation
      Medicale, Institut Lorrain du Coeur et des Vaisseaux, Centre Hospitalier Regional
      Universitaire Nancy-Brabois, Vandoeuvre-les-Nancy, France.
FAU - Danguy Des Deserts, Marc
AU  - Danguy Des Deserts M
AD  - Reanimation Polyvalente, Hopital d'Instruction des Armees Clermont-Tonnerre,
      Brest, France.
FAU - Carreira, Serge
AU  - Carreira S
AD  - Anesthesie-Reanimation, Hopital Saint Camille, Bry-sur-Marne, France.
FAU - Plantefeve, Gaetan
AU  - Plantefeve G
AD  - Service de Reanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil,
      France.
FAU - Novy, Emmanuel
AU  - Novy E
AD  - Department of Anaesthesiology and Critical Care Medicine, Institut Lorrain du
      Coeur et des Vaisseaux, University Hospital of Nancy-Brabois,
      Vandoeuvre-les-Nancy, France.
FAU - Abraham, Paul
AU  - Abraham P
AD  - Departement d'Anesthesie-Reanimation, Hopital Edouard Heriot, Hospices Civils de 
      Lyon, Lyon, France.
FAU - Mertes, Paul-Michel
AU  - Mertes PM
AD  - Service d'Anesthesie-Reanimation Chirurgicale, Nouvel Hopital Civil, Hopitaux
      Universitaires de Strasbourg, Strasbourg, France.
CN  - Societe Francaise d'Anesthesie et Reanimation (SFAR) Research Network
LA  - eng
SI  - ClinicalTrials.gov/NCT04290507
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200912
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
RN  - 0 (Vasoconstrictor Agents)
RN  - 33X04XA5AT (Lactic Acid)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Aged
MH  - Anaphylaxis/*epidemiology/mortality/*therapy
MH  - Critical Care/*statistics & numerical data
MH  - Epinephrine/therapeutic use
MH  - Female
MH  - France/epidemiology
MH  - Humans
MH  - Intensive Care Units/statistics & numerical data
MH  - Lactic Acid/blood
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survivors
MH  - Treatment Outcome
MH  - Vasoconstrictor Agents/therapeutic use
OTO - NOTNLM
OT  - *anaphylaxis
OT  - *epinephrine
OT  - *fluid resuscitation
OT  - *intensive care unit
OT  - *lactate
OT  - *outcome
OT  - *vasoplegia
EDAT- 2020/09/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/15 05:39
PHST- 2020/05/25 00:00 [received]
PHST- 2020/07/18 00:00 [revised]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/15 05:39 [entrez]
AID - S0007-0912(20)30680-2 [pii]
AID - 10.1016/j.bja.2020.08.024 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Dec;125(6):1025-1033. doi: 10.1016/j.bja.2020.08.024. Epub
      2020 Sep 12.


PMID- 32928341
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210502
IS  - 2769-6677 (Electronic)
IS  - 1559-6109 (Linking)
VI  - 59
IP  - 6
DP  - 2020 Nov 1
TI  - Evaluating IACUCs: Previous Research and Future Directions.
PG  - 656-664
LID - 10.30802/AALAS-JAALAS-20-000077 [doi]
AB  - IACUCs serve a critical role in animal care and use programs, ensuring that
      institutions which use animals in research and teaching do so responsibly and
      humanely. This role is defined in part by federal regulations, policies, and
      guidelines that prescribe the establishment and function of these committees.
      Often, IACUC administrators are expected to evaluate IACUC performance to ensure 
      that committees execute these functions effectively, and in a manner that is
      suitable to the institution. However, methods for IACUC performance evaluation
      have not been well described in the peer-reviewed literature. To address this
      deficit, we conducted a systematic review using MEDLINE to identify methods that 
      have been used to assess IACUCs. The scope of this review was intentionally broad
      to capture evaluation methods used by other institutional committees with similar
      responsibilities in overseeing research conduct, including animal ethics
      committees (AECs), institutional biosafety committees (IBCs), and institutional
      review boards (IRBs). Over 100 publications that included empirical evaluation
      methods were identified, although only 17 evaluated IACUCs in the United States. 
      A substantial number of the studies used qualitative methods, such as surveys or 
      questionnaires, interviews, and observations. The IACUC functions and
      characteristics most often assessed in the 17 publications included components of
      the protocol review processes and committee membership. We compiled this
      information to offer IACUC administrators a source of methodologies that can be
      incorporated into quality improvement and IACUC performance evaluation efforts.
      We also suggest ways in which organizations may evaluate IACUCs using methods
      described in the literature for other types of committees.
FAU - Budda, Madeline L
AU  - Budda ML
AD  - Office of Animal Welfare Assurance, University of Oklahoma Health Sciences
      Center, Oklahoma City, Oklahoma;, Email: madeline-budda@ouhsc.edu.
FAU - Pritt, Stacy L
AU  - Pritt SL
AD  - IACUC Office, University of Texas Southwestern Medical Center, Dallas, Texas.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200914
PL  - United States
TA  - J Am Assoc Lab Anim Sci
JT  - Journal of the American Association for Laboratory Animal Science : JAALAS
JID - 101269489
SB  - IM
MH  - *Animal Care Committees
MH  - Animal Welfare/*standards
MH  - Animals
MH  - Animals, Laboratory
MH  - Guidelines as Topic
MH  - United States
PMC - PMC7604691
EDAT- 2020/09/16 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/09/15 05:35
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/09/15 05:35 [entrez]
AID - 10.30802/AALAS-JAALAS-20-000077 [doi]
PST - ppublish
SO  - J Am Assoc Lab Anim Sci. 2020 Nov 1;59(6):656-664. doi:
      10.30802/AALAS-JAALAS-20-000077. Epub 2020 Sep 14.


PMID- 32928313
OWN - NLM
STAT- MEDLINE
DCOM- 20200922
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 14
TI  - A quadruple blind, randomised controlled trial of gargling agents in reducing
      intraoral viral load among hospitalised COVID-19 patients: A structured summary
      of a study protocol for a randomised controlled trial.
PG  - 785
LID - 10.1186/s13063-020-04634-2 [doi]
AB  - OBJECTIVES: 1- To compare the effectiveness of 1% Hydrogen peroxide, 0.2%
      Povidone-Iodine, 2% hypertonic saline and a novel solution Neem extract
      (Azardirachta indica) in reducing intra-oral viral load in COVID-19 positive
      patients. 2- To determine the salivary cytokine profiles of IL-2, IL-4, IL-6,
      IL-10, TNF-alpha, IFN-gamma and IL- 17 among COVID-19 patients subjected to 1%
      Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline or Neem extract
      (Azardirachta indica) based gargles. TRIAL DESIGN: This will be a parallel group,
      quadruple blind-randomised controlled pilot trial with an add on laboratory based
      study. PARTICIPANTS: A non-probability, purposive sampling technique will be
      followed to identify participants for this study. The clinical trial will be
      carried out at the Aga Khan University Hospital (AKUH), Karachi, Pakistan. The
      viral PCR tests will be done at main AKUH clinical laboratories whereas the
      immunological tests (cytokine analysis) will be done at the Juma research
      laboratory of AKUH. The inclusion criteria are laboratory-confirmed COVID-19
      positive patients, male or female, in the age range of 18-65 years, with mild to 
      moderate disease, already admitted to the AKUH. Subjects with low Glasgow coma
      score, with a history of radiotherapy or chemotherapy, who are more than 7 days
      past the onset of COVID- 19 symptoms, or intubated or edentulous patients will be
      excluded. Patients who are being treated with any form of oral or parenteral
      antiviral therapy will be excluded, as well as patients with known pre-existing
      chronic mucosal lesions such as lichen planus. INTERVENTION AND COMPARATOR: Group
      A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine
      (Betadiene(R) by Aviro Health Inc./ Pyodine(R) by Brooks Pharma Inc.) for 20-30
      seconds, thrice daily for 6 days. Group B (n=10) patients will be subjected to 10
      ml gargle and nasal lavage using 1% Hydrogen peroxide (HP(R) by Karachi Chemicals
      Products Inc./ ActiveOxy(R) by Boumatic Inc.) for 20-30 seconds, thrice daily for
      6 days. Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage
      using Neem extract solution (Azardirachta indica) formulated by Karachi
      University (chemistry department laboratories) for 20-30 seconds, thrice daily
      for 6 days. Group D (n=10) patients will use 2% hypertonic saline (Plabottle(R)
      by Otsuka Inc.) gargle and nasal lavage for a similar time period. Group E (n=10)
      will serve as positive controls. These will be given simple distilled water
      gargles and nasal lavage for 20-30 seconds, thrice daily for six days. For nasal 
      lavage, a special douche syringe will be provided to each participant. Its use
      will be thoroughly explained by the data collection officer. After each use, the 
      patient is asked not to eat, drink, or rinse their mouth for the next 30 minutes.
      MAIN OUTCOMES: The primary outcome is the reduction in the intra-oral viral load 
      confirmed with real time quantitative PCR. RANDOMISATION: The assignment to the
      study group/ allocation will be done using the sealed envelope method under the
      supervision of Clinical Trial Unit (CTU) of Aga Khan University, Karachi,
      Pakistan. The patients will be randomised to their respective study group
      (1:1:1:1:1 allocation ratio) immediately after the eligibility assessment and
      consent administration is done. BLINDING (MASKING): The study will be
      quadruple-blinded. Patients, intervention provider, outcome assessor and the data
      collection officer will be blinded. The groups will be labelled as A, B, C, D or 
      E. The codes of the intervention will be kept in lock & key at the CTU and will
      only be revealed at the end of study or if the study is terminated prematurely.
      NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no prior work on this
      research question, so no assumptions for the sample size calculation could be
      made. The present study will serve as a pilot trial. We intend to study 50
      patients in five study groups with 10 patients in each study group. For details, 
      please refer to Fig. 1 for details. TRIAL STATUS: Protocol version is 7.0,
      approved by the department and institutional ethics committees and clinical trial
      unit of the university hospital. Recruitment is planned to start as soon as the
      funding is sanctioned. The total duration of the study is expected to be 6 months
      i.e. August 2020-January 2021. TRIAL REGISTRATION: This study protocol was
      registered at www.clinicaltrials.gov on 10 April 2020 NCT04341688 . FULL
      PROTOCOL: The full protocol is attached as an additional file, accessible from
      the Trials website (Additional file 1). In the interest in expediting
      dissemination of this material, the familiar formatting has been eliminated; this
      Letter serves as a summary of the key elements of the full protocol. The study
      protocol has been reported in accordance with the Standard Protocol Items:
      Recommendations for Clinical Interventional Trials (SPIRIT) guidelines
      (Additional file 2). Fig. 1 Flow diagram of study-participants' timeline.
FAU - Khan, Farhan Raza
AU  - Khan FR
AUID- ORCID: http://orcid.org/0000-0002-5650-6268
AD  - Department of Surgery, Aga Khan University, Karachi, 74800, Pakistan.
      farhan.raza@aku.edu.
FAU - Kazmi, Syed Murtaza Raza
AU  - Kazmi SMR
AUID- ORCID: https://orcid.org/0000-0002-6934-6945
AD  - Department of Surgery, Aga Khan University, Karachi, 74800, Pakistan.
FAU - Iqbal, Najeeha Talat
AU  - Iqbal NT
AD  - Department of Pediatrics & Child Health, Aga Khan University, Karachi, 74800,
      Pakistan.
FAU - Iqbal, Junaid
AU  - Iqbal J
AD  - Department of Pediatrics & Child Health, Aga Khan University, Karachi, 74800,
      Pakistan.
FAU - Ali, Syed Tariq
AU  - Ali ST
AD  - Department of Chemistry, University of Karachi, Karachi, 75271, Pakistan.
FAU - Abbas, Syed Akbar
AU  - Abbas SA
AUID- ORCID: https://orcid.org/0000-0003-3911-1632
AD  - Department of Surgery, Aga Khan University, Karachi, 74800, Pakistan.
LA  - eng
SI  - ClinicalTrials.gov/NCT04341688
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20200914
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Anti-Infective Agents, Local)
RN  - 0 (Mouthwashes)
RN  - 0 (Plant Extracts)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 85H0HZU99M (Povidone-Iodine)
RN  - BBX060AN9V (Hydrogen Peroxide)
SB  - IM
MH  - Adult
MH  - Anti-Infective Agents, Local/administration & dosage
MH  - *Azadirachta
MH  - *Betacoronavirus/drug effects/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/diagnosis/immunology/therapy
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Hydrogen Peroxide/*administration & dosage
MH  - Male
MH  - Monitoring, Immunologic/methods
MH  - Mouthwashes/administration & dosage
MH  - Nasal Lavage/methods
MH  - *Pandemics
MH  - Plant Extracts/*administration & dosage
MH  - *Pneumonia, Viral/diagnosis/immunology/therapy
MH  - Povidone-Iodine/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Saline Solution, Hypertonic/*administration & dosage
MH  - *Viral Load/drug effects/methods
PMC - PMC7487448
OTO - NOTNLM
OT  - COVID-19
OT  - gargles
OT  - nasal lavage
OT  - protocol
OT  - randomised controlled trial
OT  - viral load
EDAT- 2020/09/16 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/09/15 05:35
PHST- 2020/07/20 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/09/15 05:35 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - 10.1186/s13063-020-04634-2 [doi]
AID - 10.1186/s13063-020-04634-2 [pii]
PST - epublish
SO  - Trials. 2020 Sep 14;21(1):785. doi: 10.1186/s13063-020-04634-2.


PMID- 32928303
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Sep 14
TI  - Motor performance and back pain in children and adolescents: a systematic review 
      and meta-analysis protocol.
PG  - 212
LID - 10.1186/s13643-020-01468-6 [doi]
AB  - BACKGROUND: The relationship between motor performance and back pain in children 
      and adolescents remains unclear. This article describes the protocol for a
      systematic review to summarize the knowledge about the association between motor 
      performance, such as agility, flexibility, balance, strength, muscle endurance,
      and cardiorespiratory fitness, and back pain. Thus, our aim is to identify the
      influence of motor performance on back pain among children and adolescents.
      METHODS: Two independent researchers will search MEDLINE, Scopus, Embase,
      SPORTDiscus, and CINAHL databases, with no period or language restrictions. We
      will include cross-sectional, cohort, case-control, and controlled clinical trial
      studies based on the following criteria: (a) participants from 6 to 19 years of
      age, (b) assessment of motor performance, (c) assessment of back pain, and (d)
      report measures of associations between motor performance and back pain. Study
      quality and risk of bias will be assessed using an adapted version of the Downs
      and Black instrument. Grading of Recommendations, Assessment, Development, and
      Evaluations will be used to assess the strength of the body of evidence.
      Meta-analyses of association measures will be performed for each type of motor
      performance, separately for different study types. The results will be reported
      using forest to show the pooled effect of findings and funnel plots to assess
      precision of the data. If studies are not homogeneous, results from the
      meta-analyses will not be reported. Associations will then be synthesized
      descriptively using a pragmatic approach. DISCUSSION: This systematic review will
      provide critical insights into the association between motor performance and back
      pain among children and adolescents; this information may help support clinical
      practice guidelines as well as public health programs. ETHICS AND DISSEMINATION: 
      Protocol was written according to the Preferred Reporting Items for Systematic
      reviews and Meta-Analyses (PRISMA). SYSTEMATIC REVIEW REGISTRATION: PROSPERO
      CRD42020178496.
FAU - Noll, Matias
AU  - Noll M
AUID- ORCID: 0000-0002-1482-0718
AD  - Instituto Federal Goiano, Ceres, Brazil. matias.noll@ifgoiano.edu.br.
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil. matias.noll@ifgoiano.edu.br.
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Campusvej 55, Odense, Denmark. matias.noll@ifgoiano.edu.br.
FAU - Wedderkopp, Niels
AU  - Wedderkopp N
AUID- ORCID: 0000-0002-9660-6618
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Campusvej 55, Odense, Denmark. nwedderkopp@health.sdu.dk.
AD  - Sports Medicine Clinic, Orthopedic Department, Hospital of Lillebaelt, Odense,
      Denmark. nwedderkopp@health.sdu.dk.
FAU - Mendonca, Carolina Rodrigues
AU  - Mendonca CR
AUID- ORCID: 0000-0002-9902-8227
AD  - Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University 
      of Goias, Goiania, Brazil.
FAU - Kjaer, Per
AU  - Kjaer P
AUID- ORCID: 0000-0001-5340-8649
AD  - Department of Sports Science and Clinical Biomechanics, University of Southern
      Denmark, Campusvej 55, Odense, Denmark. pkjaer@health.sdu.dk.
AD  - Health Sciences Research Centre, UCL University College, Odense, Denmark.
      pkjaer@health.sdu.dk.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - Adolescent
MH  - *Back Pain
MH  - *Cardiorespiratory Fitness
MH  - Case-Control Studies
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7491087
OTO - NOTNLM
OT  - *Back pain
OT  - *Pain
OT  - *Protocol
OT  - *Psychomotor performance
OT  - *Systematic review
OT  - *Teenagers
EDAT- 2020/09/16 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/15 05:35
PHST- 2020/05/06 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/15 05:35 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13643-020-01468-6 [doi]
AID - 10.1186/s13643-020-01468-6 [pii]
PST - epublish
SO  - Syst Rev. 2020 Sep 14;9(1):212. doi: 10.1186/s13643-020-01468-6.


PMID- 32928295
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Sep 14
TI  - Ethics of research on stem cells and regenerative medicine: ethical guidelines in
      the Islamic Republic of Iran.
PG  - 396
LID - 10.1186/s13287-020-01916-z [doi]
AB  - BACKGROUND: Regenerative medicine plays a major role in biomedicine, and given
      the ever-expanding boundaries of this knowledge, numerous ethical considerations 
      have been raised. MAIN TEXT: Rapid advancement of regenerative medicine science
      and technology in Iran, emerged the Iranian National Committee for Ethics in
      Biomedical Research to develop a comprehensive national ethical guideline.
      Therefore, the present ethical guideline which comprises eleven chapters was
      developed in 2019 and approved in early 2020. The titles of these chapters were
      selected based on the ethical considerations of various aspects of the field of
      regenerative medicine: (1) ethical principles of research on stem cells and
      regenerative medicine; (2) ethical considerations for research on stem cells
      (embryonic stem cells, epiblast stem cells, tissue-specific stem cells, stem
      cells derived from transdifferentiation, induced pluripotent stem cells [iPSCs], 
      germline pluripotent stem cells, germline stem cells, and somatic cell nuclear
      transfer [SCNT] stem cells); (3) ethical considerations for research on somatic
      cells in regenerative medicine (adult somatic cells, fetal tissue somatic cells, 
      and somatic cells derived from pregnancy products [other than fetus]); (4)
      ethical considerations for research on gametes in regenerative medicine; (5)
      ethical considerations for research related to genetic manipulation (human and
      animal) in regenerative medicine; (6) ethical considerations for research on
      tissue engineering in regenerative medicine; (7) ethical considerations for
      pre-clinical studies in regenerative medicine; (8) ethical considerations for
      clinical trials in regenerative medicine; (9) ethical considerations for stem
      cells and regenerative medicine bio-banks; (10) ethical considerations for
      privacy and confidentiality; and (11) ethical considerations for obtaining
      informed consent. CONCLUSION: This article discusses the process of developing
      the present ethical guidelines and its practical points. We hope that it can play
      an important worldwide role in advancing ethics of research on stem cells and
      regenerative medicine.
FAU - Afshar, Leila
AU  - Afshar L
AD  - Department of Medical Ethics, Shahid Beheshti University of Medical Sciences,
      Tehran, Iran.
FAU - Aghayan, Hamid-Reza
AU  - Aghayan HR
AD  - Cell therapy and Regenerative Medicine Research Center, Endocrinology and
      Metabolism Molecular Cellular Sciences Institute, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Sadighi, Jila
AU  - Sadighi J
AD  - Department of Health Promotion, Health Metrics Research Center, Institute for
      Health Sciences Research, ACECR, Tehran, Iran.
FAU - Arjmand, Babak
AU  - Arjmand B
AD  - Cell therapy and Regenerative Medicine Research Center, Endocrinology and
      Metabolism Molecular Cellular Sciences Institute, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Hashemi, Seyed-Mahmoud
AU  - Hashemi SM
AD  - Department of Immunology, School of Medicine, Shahid Beheshti University of
      Medical Sciences, Tehran, Iran.
FAU - Basiri, Mohsen
AU  - Basiri M
AD  - Department of Stem Cells and Developmental Biology, Cell Science Research Center,
      Royan Institute for Stem Cell Biology and Technology, ACECR, Banihashem Sq.,
      Banihashem St., Ressalat highway,1665659911, P.O. Box: 16635-148, Tehran, Iran.
FAU - Samani, Reza Omani
AU  - Samani RO
AD  - Department of Medical Ethics and Law, Reproductive Biomedicine Research Center,
      Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
FAU - Ashtiani, Mohammad Kazemi
AU  - Ashtiani MK
AD  - Department of Cell Engineering, Cell Science Research Center, Royan Institute for
      Stem Cell Biology and Technology, ACECR, Tehran, Iran.
FAU - Azin, Seyed-Ali
AU  - Azin SA
AD  - Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR,
      Tehran, Iran.
FAU - Hajizadeh-Saffar, Ensiyeh
AU  - Hajizadeh-Saffar E
AD  - Department of Regenerative Medicine, Cell Science Research Center, Royan
      Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
FAU - Gooshki, Ehsan Shamsi
AU  - Gooshki ES
AD  - Medical Ethics and History of Medicine Research Center, Department of Medical
      Ethics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Hamidieh, Amir-Ali
AU  - Hamidieh AA
AD  - Pediatric cell therapy research center, Tehran University of Medical Sciences,
      Tehran, Iran.
FAU - Rezania Moallem, Mohammad-Reza
AU  - Rezania Moallem MR
AD  - Department of Medical Ethics and Law, Reproductive Biomedicine Research Center,
      Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
FAU - Azin, Seyed-Mohammad
AU  - Azin SM
AD  - Department of Medical Ethics and Law, Reproductive Biomedicine Research Center,
      Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
FAU - Shariatinasab, Sadegh
AU  - Shariatinasab S
AD  - Department of Medical Ethics and Law, Reproductive Biomedicine Research Center,
      Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
FAU - Soleymani-Goloujeh, Mehdi
AU  - Soleymani-Goloujeh M
AD  - Department of Stem Cells and Developmental Biology, Cell Science Research Center,
      Royan Institute for Stem Cell Biology and Technology, ACECR, Banihashem Sq.,
      Banihashem St., Ressalat highway,1665659911, P.O. Box: 16635-148, Tehran, Iran.
FAU - Baharvand, Hossein
AU  - Baharvand H
AUID- ORCID: 0000-0001-6528-3687
AD  - Department of Stem Cells and Developmental Biology, Cell Science Research Center,
      Royan Institute for Stem Cell Biology and Technology, ACECR, Banihashem Sq.,
      Banihashem St., Ressalat highway,1665659911, P.O. Box: 16635-148, Tehran, Iran.
      baharvand@royaninstitute.org.
AD  - Department of Developmental Biology, University of Science and Culture, Tehran,
      Iran. baharvand@royaninstitute.org.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Animals
MH  - Embryonic Stem Cells
MH  - Female
MH  - Humans
MH  - *Induced Pluripotent Stem Cells
MH  - Iran
MH  - *Pluripotent Stem Cells
MH  - Pregnancy
MH  - Regenerative Medicine
PMC - PMC7489032
OTO - NOTNLM
OT  - *Clinical trial
OT  - *Ethics
OT  - *Guideline
OT  - *Regenerative medicine
OT  - *Stem cells
EDAT- 2020/09/16 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/15 05:35
PHST- 2020/02/29 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/09/15 05:35 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-01916-z [doi]
AID - 10.1186/s13287-020-01916-z [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Sep 14;11(1):396. doi: 10.1186/s13287-020-01916-z.


PMID- 32928275
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1747-597X (Electronic)
IS  - 1747-597X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Sep 14
TI  - "Setting people up for success and then failure" - health care and service
      providers' experiences of using prize-based contingency management.
PG  - 71
LID - 10.1186/s13011-020-00316-z [doi]
AB  - BACKGROUND: Over the last 50 years, there has been a growing interest in and use 
      of contingency management (CM) for people who use substances. Yet, despite
      showing some level of efficacy (albeit only short-term) and being praised by
      researchers as beneficial and cost-saving, it continues to be underutilized by
      health care and service providers. Why that is remains unclear. METHODS:
      Recognizing a gap, we conducted a targeted analysis of a larger set of
      qualitative interviews conducted on the experience of health care and service
      providers with incentives (including prize-based CM) (n = 25). RESULTS: Four
      themes were identified during the analysis: 1) The specificities of prize-based
      CM, 2) The role of providers in administering prize-based CM, 3) The positive and
      negative impact on the relationship, and 4) The ethical concerns arising from
      prize-based CM. Overall, our findings are consistent with existing literature and
      suggest that providers are wary of using prize-based CM because they tend to
      value effort over success, support over reward, honesty over deceit, and
      certainty over probability and variability. CONCLUSION: Our analysis offers
      additional insights into the experiences of providers who use prize-based CM and 
      possibly some indications as to why they may not wish to work with this type of
      incentive. The question raised here is not whether there is enough evidence on
      the effectiveness of prize-based CM, but rather if this type of incentive is
      appropriate and ethical when caring for people who use substances.
FAU - Gagnon, Marilou
AU  - Gagnon M
AUID- ORCID: 0000-0003-4214-3088
AD  - Canadian Institute for Substance Use Research, University of Victoria, 2300
      McKenzie Ave, Victoria, BC, V8N 5M8, Canada. marilougagnon@uvic.ca.
FAU - Guta, Adrian
AU  - Guta A
AD  - School of Social Work, University of Windsor, 167 Ferry Street, Windsor, ON, N9A 
      0C5, V6T2B5, Canada.
FAU - Payne, Alayna
AU  - Payne A
AD  - Canadian Institute for Substance Use Research, University of Victoria, 2300
      McKenzie Ave, Victoria, BC, V8N 5M8, Canada.
LA  - eng
GR  - 159826/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - Subst Abuse Treat Prev Policy
JT  - Substance abuse treatment, prevention, and policy
JID - 101258060
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Attitude of Health Personnel
MH  - Behavior Therapy/*methods
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - *Motivation
MH  - Qualitative Research
MH  - *Reinforcement, Psychology
MH  - Socioeconomic Factors
MH  - Substance-Related Disorders/*therapy
PMC - PMC7491156
OTO - NOTNLM
OT  - *Contingency management
OT  - *Drugs
OT  - *HIV
OT  - *Incentives
OT  - *Providers
OT  - *Qualitative
OT  - *Substance use
EDAT- 2020/09/16 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/09/15 05:35
PHST- 2020/06/23 00:00 [received]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/15 05:35 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.1186/s13011-020-00316-z [doi]
AID - 10.1186/s13011-020-00316-z [pii]
PST - epublish
SO  - Subst Abuse Treat Prev Policy. 2020 Sep 14;15(1):71. doi:
      10.1186/s13011-020-00316-z.


PMID- 32928264
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210816
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Sep 14
TI  - Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast
      cancer patients treated with palbociclib and endocrine therapy.
PG  - 98
LID - 10.1186/s13058-020-01334-2 [doi]
AB  - PURPOSE: Previous cohort studies have reported plasma TK1 activity (pTKa) as a
      potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative 
      (HER2-) metastatic breast cancer (MBC). In this prospective study, we report here
      the prognostic impact of pTKa in ER+/HER2- MBC patients treated with endocrine
      therapy and CDK4/6 inhibitor. EXPERIMENTAL DESIGN: Patients were included into
      the prospective, ethics committee-approved ALCINA study (NCT02866149).
      Eligibility criteria were patients with ER+/HER2- MBC treated at Institut Curie
      with endocrine therapy and palbociclib. Plasma samples were obtained at baseline 
      and after 4 weeks of treatment. pTKa was quantified by the DiviTum(R) assay
      (Biovica, Sweden). RESULTS: From May 2016 to August 2018, 103 patients treated
      with endocrine therapy and palbociclib were included. Patients had received a
      median of two prior systemic therapies for MBC (range 0-14). Median follow-up was
      13.8 months (range 6-31), with median PFS and OS of 9.6 months (95%CI [7.0-11.3])
      and 28 months (95%CI [23-not reached]), respectively. Median baseline pTKa was
      292 Du/L (range 20-27,312 Du/L, IQR [89-853]). After adjusting for other
      prognostic factors, baseline pTKa remained an independent prognostic factor for
      both PFS (HR = 1.3 95%CI [1.1-1.4], p = 0.0005) and OS (HR = 1.3 95%CI [1.2-1.6],
      p < 0.0001), and 4-week pTKa was associated with OS (HR = 1.6 95%CI [1.3-2], p < 
      0.0001). That survival prediction was significantly improved by the addition of
      baseline pTKa to clinicopathological characteristics. Adding pTKa changes at 4
      weeks to baseline pTKa did not further increase survival prediction. CONCLUSION: 
      This study demonstrates the clinical validity of pTKa as a new circulating
      prognostic marker in ER+/HER2- MBC patients treated with endocrine therapy and
      palbociclib.
FAU - Cabel, Luc
AU  - Cabel L
AUID- ORCID: 0000-0001-5515-9180
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France. luc.cabel@curie.fr.
AD  - Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.
      luc.cabel@curie.fr.
AD  - UVSQ, Universite Paris-Saclay, Saint-Cloud, Paris, France. luc.cabel@curie.fr.
FAU - Rosenblum, Dan
AU  - Rosenblum D
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Lerebours, Florence
AU  - Lerebours F
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Brain, Etienne
AU  - Brain E
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Loirat, Delphine
AU  - Loirat D
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Bergqvist, Mattias
AU  - Bergqvist M
AD  - Biovica, Uppsala, Sweden.
FAU - Cottu, Paul
AU  - Cottu P
AD  - Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.
FAU - Donnadieu, Anne
AU  - Donnadieu A
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Bethune, Anne
AU  - Bethune A
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Kiavue, Nicolas
AU  - Kiavue N
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Rodrigues, Manuel
AU  - Rodrigues M
AD  - Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.
FAU - Pierga, Jean-Yves
AU  - Pierga JY
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
AD  - Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Tanguy, Marie-Laure
AU  - Tanguy ML
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
FAU - Bidard, Francois-Clement
AU  - Bidard FC
AD  - Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris,
      France.
AD  - Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France.
AD  - UVSQ, Universite Paris-Saclay, Saint-Cloud, Paris, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT02866149
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Piperazines)
RN  - 0 (Pyridines)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 22X328QOC4 (Fulvestrant)
RN  - 7LKK855W8I (Letrozole)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 2.7.1.21 (thymidine kinase 1)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - G9ZF61LE7G (palbociclib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/blood/drug therapy/*pathology
MH  - Estrogen Receptor alpha/metabolism
MH  - Female
MH  - Fulvestrant/administration & dosage
MH  - Humans
MH  - Letrozole/administration & dosage
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Piperazines/administration & dosage
MH  - Prognosis
MH  - Prospective Studies
MH  - Pyridines/administration & dosage
MH  - Receptor, ErbB-2/metabolism
MH  - Survival Rate
MH  - Tamoxifen/administration & dosage
MH  - Thymidine Kinase/*blood
PMC - PMC7489000
OTO - NOTNLM
OT  - *Biomarker
OT  - *CDK4/6 inhibitor
OT  - *Metastatic breast cancer
OT  - *Palbociclib
OT  - *Thymidine kinase 1
EDAT- 2020/09/16 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/09/15 05:35
PHST- 2020/04/07 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/15 05:35 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1186/s13058-020-01334-2 [doi]
AID - 10.1186/s13058-020-01334-2 [pii]
PST - epublish
SO  - Breast Cancer Res. 2020 Sep 14;22(1):98. doi: 10.1186/s13058-020-01334-2.


PMID- 32927991
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1941-2460 (Electronic)
IS  - 0003-0651 (Linking)
VI  - 68
IP  - 4
DP  - 2020 Aug
TI  - The Phenomenology and Dynamics of Wealth Shame: Between Moral Responsibility and 
      Moral Masochism.
PG  - 615-648
LID - 10.1177/0003065120949972 [doi]
AB  - In an age of striking inequality in wealth, a related phenomenon, wealth shame,
      has developed. A multidisciplinary exploration of such shame examines its
      intrapsychic, intersubjective, transgenerational, and sociopolitical roots in the
      U.S., as well as its multiple functions: as an ethical response to economic
      disparity (moral responsibility), as a manifestation of a pervasive shame pattern
      (moral masochism), and as a defense against pleasure, feelings of superiority,
      and the fear of being envied. Several clinical vignettes illustrate these themes 
      and are followed by reflections on their clinical implications. The
      psychoanalytic community's conflicted relationship to social class, money, and
      wealth is also examined. This conflictedness may inform the analyst's
      countertransference to wealth shame and his or her ability to appreciate the
      psychic landscapes of class as they present in the consulting room.
FAU - Sadek, Noha
AU  - Sadek N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Psychoanal Assoc
JT  - Journal of the American Psychoanalytic Association
JID - 7505579
SB  - IM
MH  - Adult
MH  - Countertransference
MH  - *Economic Status
MH  - Humans
MH  - *Morals
MH  - *Professional-Patient Relations
MH  - *Psychoanalytic Therapy
MH  - *Shame
MH  - *Social Class
MH  - Social Mobility
OTO - NOTNLM
OT  - affluence
OT  - class
OT  - ethics
OT  - financial inequity
OT  - money
OT  - moral responsibility
OT  - upward mobility
OT  - wealth inequality
OT  - wealth shame
EDAT- 2020/09/16 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/09/15 05:32
PHST- 2020/09/15 05:32 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
AID - 10.1177/0003065120949972 [doi]
PST - ppublish
SO  - J Am Psychoanal Assoc. 2020 Aug;68(4):615-648. doi: 10.1177/0003065120949972.


PMID- 32927986
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1941-2460 (Electronic)
IS  - 0003-0651 (Linking)
VI  - 68
IP  - 4
DP  - 2020 Aug
TI  - Consenting and Assenting to Psychoanalytic Work.
PG  - 583-613
LID - 10.1177/0003065120954353 [doi]
AB  - The moment is opportune for a renewed look at what we understand about patient
      consent to treatment. Until recently, little reference to informed consent could 
      be found in the literature, as though it has never been a preoccupation for
      psychoanalytic practitioners. Yet several post-Freudian authors offer reasons to 
      suppose the risk of misunderstandings about consent. In fact, the very discovery 
      of transference, replete with unrequited infantile wishes, implies that at some
      level, at some moment, in every psychoanalytic treatment there will be moments
      when "consent" will to some extent vacillate. A distinction, justifiable on
      etymological and intersubjective grounds, is made between patients' consent as a 
      cognitive, somewhat passive, acceptance and patients' assent as an arduous,
      conflicted, partial disagreement with the symbolically limiting details of
      analytic work. It is in the discovery and working through of unexpected
      unconscious responses to aspects of the analytic setting and to the analyst that 
      patients become "informed" of the unique risks to their psychic equilibrium the
      process poses, as well as its benefits. Instead of a static and unitary
      contractual event, informed consent in psychoanalysis is more properly conceived 
      as a multilayered, repetitively posed, and necessarily ambivalent process of
      good-enough assenting over time.
FAU - Furlong, Allannah
AU  - Furlong A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Psychoanal Assoc
JT  - Journal of the American Psychoanalytic Association
JID - 7505579
SB  - IM
MH  - Adult
MH  - Humans
MH  - Informed Consent/*psychology
MH  - Practice Guidelines as Topic
MH  - Psychoanalytic Therapy/*ethics
MH  - *Psychotherapeutic Processes
OTO - NOTNLM
OT  - ethics
OT  - framework
OT  - good-enough assenting
OT  - informed consent
OT  - professional guidelines
EDAT- 2020/09/16 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/09/15 05:32
PHST- 2020/09/15 05:32 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
AID - 10.1177/0003065120954353 [doi]
PST - ppublish
SO  - J Am Psychoanal Assoc. 2020 Aug;68(4):583-613. doi: 10.1177/0003065120954353.


PMID- 32927984
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1941-2460 (Electronic)
IS  - 0003-0651 (Linking)
VI  - 68
IP  - 4
DP  - 2020 Aug
TI  - Impossible Ethics.
PG  - 561-582
LID - 10.1177/0003065120953064 [doi]
AB  - The proper practice of psychoanalysis repudiates a rule-based code of ethical
      conduct. A conflict exists, however, between Freud's rejection of the Biblical
      commandment to love one's neighbor as oneself and his development of
      psychoanalytic techniques that demand something very much of this ilk. Other
      essential conflicts in analytic practice include the impossibility of removing
      the analyst's desire from the analytic relationship, the unruly nature of
      unconscious processes in both analyst and analysand, and the apres-coup nature of
      ethical recognition. A discourse of ethics is recommended in which analysts are
      called on to consider the ethical demands of each clinical moment. Ethical
      demands on the analysand, as well as the analyst, bring to light the way in which
      analysis rests on the foundational ethical situation into which humankind is
      born.
FAU - Ackerman, Sarah
AU  - Ackerman S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Psychoanal Assoc
JT  - Journal of the American Psychoanalytic Association
JID - 7505579
SB  - IM
MH  - *Freudian Theory
MH  - Humans
MH  - *Professional-Patient Relations
MH  - Psychoanalytic Therapy/*ethics
OTO - NOTNLM
OT  - Civilization and Its Discontents
OT  - Freud
OT  - Nebenmensch
OT  - ethics
OT  - psychoanalytic technique
EDAT- 2020/09/16 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/09/15 05:32
PHST- 2020/09/15 05:32 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
AID - 10.1177/0003065120953064 [doi]
PST - ppublish
SO  - J Am Psychoanal Assoc. 2020 Aug;68(4):561-582. doi: 10.1177/0003065120953064.


PMID- 32927777
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Mesenchymal Stem Cells as a Promising Cell Source for Integration in Novel In
      Vitro Models.
LID - E1306 [pii]
LID - 10.3390/biom10091306 [doi]
AB  - The human-relevance of an in vitro model is dependent on two main factors-(i) an 
      appropriate human cell source and (ii) a modeling platform that recapitulates
      human in vivo conditions. Recent years have brought substantial advancements in
      both these aspects. In particular, mesenchymal stem cells (MSCs) have emerged as 
      a promising cell source, as these cells can differentiate into multiple cell
      types, yet do not raise the ethical and practical concerns associated with other 
      types of stem cells. In turn, advanced bioengineered in vitro models such as
      microfluidics, Organs-on-a-Chip, scaffolds, bioprinting and organoids are
      bringing researchers ever closer to mimicking complex in vivo environments,
      thereby overcoming some of the limitations of traditional 2D cell cultures. This 
      review covers each of these advancements separately and discusses how the
      integration of MSCs into novel in vitro platforms may contribute enormously to
      clinical and fundamental research.
FAU - Afflerbach, Ann-Kristin
AU  - Afflerbach AK
AUID- ORCID: 0000-0002-5347-3165
AD  - Department of Biomedical Engineering, Tel Aviv University, Tel Aviv 6997801,
      Israel.
AD  - Faculty of Biosciences, Universitat Heidelberg, 69120 Heidelberg, Germany.
FAU - Kiri, Mark D
AU  - Kiri MD
AUID- ORCID: 0000-0001-7261-5408
AD  - Department of Biomedical Engineering, Tel Aviv University, Tel Aviv 6997801,
      Israel.
FAU - Detinis, Tahir
AU  - Detinis T
AD  - Department of Biomedical Engineering, Tel Aviv University, Tel Aviv 6997801,
      Israel.
FAU - Maoz, Ben M
AU  - Maoz BM
AUID- ORCID: 0000-0002-3823-7682
AD  - Department of Biomedical Engineering, Tel Aviv University, Tel Aviv 6997801,
      Israel.
AD  - Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
AD  - The Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv
      6997801, Israel.
LA  - eng
GR  - ./Azrieli Foundation/International
GR  - 2248/19/Israel Science Foundation/International
GR  - SweetBrain 851765/ERC/International
GR  - ./Slezak Foundation/International
GR  - ./Brainboost/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200910
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
SB  - IM
MH  - Bioartificial Organs
MH  - Biomimetic Materials/therapeutic use
MH  - Bioprinting/methods
MH  - Cell Culture Techniques
MH  - Cell Differentiation
MH  - Cell Lineage/*physiology
MH  - Cell- and Tissue-Based Therapy/*methods
MH  - Humans
MH  - Lab-On-A-Chip Devices
MH  - Mesenchymal Stem Cells/cytology/*physiology
MH  - *Models, Biological
MH  - Organoids/cytology/*physiology
MH  - Tissue Engineering/*methods
MH  - Tissue Scaffolds
PMC - PMC7565384
OTO - NOTNLM
OT  - *in vitro models
OT  - *mesenchymal stem cells
OT  - *microfluidics
OT  - *organoids
OT  - *organs-on-a-chip
OT  - *scaffolds
EDAT- 2020/09/16 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/15 01:03
PHST- 2020/08/21 00:00 [received]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/15 01:03 [entrez]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - biom10091306 [pii]
AID - 10.3390/biom10091306 [doi]
PST - epublish
SO  - Biomolecules. 2020 Sep 10;10(9). pii: biom10091306. doi: 10.3390/biom10091306.


PMID- 32926404
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201218
IS  - 1365-2044 (Electronic)
IS  - 0003-2409 (Linking)
VI  - 75
IP  - 11
DP  - 2020 Nov
TI  - Law, litigation and learning: a legacy from COVID-19.
PG  - 1428-1431
LID - 10.1111/anae.15241 [doi]
FAU - Ferguson, K
AU  - Ferguson K
AD  - Department of Anaesthesia, NHS Grampian, Aberdeen, UK.
FAU - Johnston, P W
AU  - Johnston PW
AD  - Department of Pathology, NHS Grampian, Aberdeen, UK.
AD  - Centre for Healthcare Education Research and Innovation, University of Aberdeen, 
      Aberdeen, UK.
LA  - eng
PT  - Editorial
PT  - Comment
DEP - 20200914
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
SB  - IM
CON - Anaesthesia. 2020 Nov;75(11):1517-1528. PMID: 32445581
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Critical Care
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *education
OT  - *ethics
OT  - *law
OT  - *learning
OT  - *litigation
EDAT- 2020/09/15 06:00
MHDA- 2020/10/29 06:00
CRDT- 2020/09/14 15:48
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
PHST- 2020/09/14 15:48 [entrez]
AID - 10.1111/anae.15241 [doi]
PST - ppublish
SO  - Anaesthesia. 2020 Nov;75(11):1428-1431. doi: 10.1111/anae.15241. Epub 2020 Sep
      14.


PMID- 32925801
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Prevalence of dry eye disease in the elderly: A protocol of systematic review and
      meta-analysis.
PG  - e22234
LID - 10.1097/MD.0000000000022234 [doi]
AB  - INTRODUCTION: Dry eye disease (DED) is one of the most prevalent ocular diseases 
      which remains widely underestimated. New lifestyles driven by information
      technology and the rapid ageing process have brought DED a severe public health
      concern. And DED is highly related to the reduction in vision-related quality of 
      life and interfere with daily activities. Since advanced age has been suggested
      as an important risk factor for DED, the aim of our study was to obtain the
      pooled prevalence of DED in the elderly over 60 years of age. METHODS AND
      ANALYSIS: The following databases will be searched from their inception to August
      2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of
      Science, Nature, Science online, Chinese Biomedical Database WangFang, VIP
      medicine information, and China National Knowledge Infrastructure (CNKI). Primary
      outcomes: the number of participants and DED cases. Data will be extracted by 2
      researchers independently, risk of bias of the meta-analysis will be evaluated
      based on the Cochrane Handbook for Systematic Reviews of Interventions. All data 
      analysis will be conducted by data statistics software Review Manager V.5.3. and 
      Stata V.12.0. RESULTS: The results of this study will systematically evaluate the
      prevalence of DED in the elderly population over 60 years of age. CONCLUSION: The
      systematic review of this study will summarize the current published evidence of 
      epidemiological investigations of DED with advanced age classification. ETHICS
      AND DISSEMINATION: This study is a systematic review, the outcomes are based on
      the published evidence, so examination and agreement by the ethics committee are 
      not required in this study. We intend to publish the study results in a journal
      or conference presentations. OPEN SCIENCE FRA NETWORK (OSF) REGISTRATION NUMBER: 
      August 12, 2020. osf.io/3jyb4. (https://osf.io/3jyb4).
FAU - Zhang, Xinyue
AU  - Zhang X
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Chengdu University of Traditional Chinese Medicine.
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Zheng, Yanlin
AU  - Zheng Y
AUID- ORCID: 0000-0003-2570-1703
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Deng, Lu
AU  - Deng L
AD  - Chengdu University of Traditional Chinese Medicine.
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Huang, Xiaoying
AU  - Huang X
AD  - Chengdu University of Traditional Chinese Medicine.
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Dry Eye Syndromes/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Research Design
MH  - Risk Factors
PMC - PMC7489743
EDAT- 2020/09/15 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022234 [doi]
AID - 00005792-202009110-00093 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22234. doi:
      10.1097/MD.0000000000022234.


PMID- 32925798
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Efficacy and safety of ginkgo preparation in patients with vascular dementia: A
      protocol for systematic review and meta-analysis.
PG  - e22209
LID - 10.1097/MD.0000000000022209 [doi]
AB  - BACKGROUND: Vascular dementia has become the second most common type of dementia 
      after Alzheimer disease. At present, there is no uniform standard for VaD
      treatment guidelines among countries. The efficacy of ginkgo biloba in the
      treatment of vascular dementia is still controversial. The purpose of this study 
      is to evaluate the effectiveness and safety of ginkgo biloba in the treatment of 
      vascular dementia through meta-analysis. METHODS: Six English databases (PubMed, 
      Web of science, Medline, EBASE, Springer Cochrane Library, and WHO International 
      Clinical Trials Registry Platform) and 4 Chinese databases (Wan fang Database,
      Chinese Scientific Journal Database, China National Knowledge Infrastructure
      Database(CNKI) and Chinese Biomedical Literature Database) will be searched
      normatively according to the rule of each database from the inception to August
      1, 2020. Two reviewers will independently conduct article selection, data
      collection, and risk of bias evaluation. Any disagreement will be resolved by
      discussion with the third reviewer. Either the fixed-effects or random-effects
      model will be used for data synthesis based on the heterogeneity test. The change
      in the scores on mini-mental state examination, activity of daily living scale
      and Montreal cognitive assement will be used as the main outcome measure,
      Hamilton depression scale, Hastgawa dementia scale, blessed dementia scale,
      clinical dmentia rating scale as the secondary outcome. Treatment emergent
      symptom scale, general physical examination (temperature, pulse, respiration,
      blood pressure), Routine examination of blood, urine and stool,
      electrocardiogram, liver and kidney function examination as the security indexs. 
      RevMan5.3.5 will be used for meta-analysis. RESULTS: This study will provide
      high-quality evidence to assess the effectiveness and safety of ginkgo
      preparation for vascular dementia. CONCLUSION: This systematic review will
      explore whether ginkgo preparation is an effective and safe intervention for
      vascular dementia. ETHICS AND DISSEMINATION: Ethical approval are not required
      for this study. The systematic review will be published in a peer-reviewed
      journal, presented at conferences, and will be shared on social media platforms. 
      This review will be disseminated in a peer-reviewed journal or conference
      presentation. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42020167851.
FAU - Wang, Miyuan
AU  - Wang M
AUID- ORCID: 0000-0003-2459-9532
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Peng, Hongye
AU  - Peng H
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Peng, Zexu
AU  - Peng Z
AD  - Hubei University of Chinese Medicine, Wuhan Hubei, China.
FAU - Huang, Kailin
AU  - Huang K
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Li, Tingting
AU  - Li T
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Li, Lei
AU  - Li L
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Wu, Xin
AU  - Wu X
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Shi, Heyuan
AU  - Shi H
AD  - Hubei University of Chinese Medicine, Wuhan Hubei, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Plant Extracts)
RN  - 19FUJ2C58T (Ginkgo biloba extract)
SB  - IM
MH  - Activities of Daily Living
MH  - Dementia, Vascular/*drug therapy/epidemiology
MH  - Depression/epidemiology
MH  - Ginkgo biloba
MH  - Health Status
MH  - Humans
MH  - Mental Status and Dementia Tests
MH  - Plant Extracts/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7489658
EDAT- 2020/09/15 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022209 [doi]
AID - 00005792-202009110-00090 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22209. doi:
      10.1097/MD.0000000000022209.


PMID- 32925791
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Traditional Chinese medicine for mild cognitive impairment: A protocol for
      systematic review and network meta-analysis.
PG  - e22187
LID - 10.1097/MD.0000000000022187 [doi]
AB  - BACKGROUND: Mild cognitive impairment (MCI) is an intermediate stage between
      normal aging and Alzheimer disease, which is the most common form of dementia in 
      the world. In clinical practice, traditional Chinese medicine (TCM) interventions
      have been administered for MCI, However, there is still uncertain about what
      strategy of TCM interventions treatment should be preferred in clinical practice.
      This study aims to evaluate the efficacy and acceptability of different TCM
      therapies through systematic review and network meta-analysis. METHODS: According
      to the strategy, the authors will retrieve a total of 7 electronic databases by
      August 2020, including PubMed, the Cochrane Library, EMbase, China National
      Knowledge Infrastructure, China Biological Medicine, Chongqing VIP, and Wan-fang 
      databases. After a series of screening, 2 researchers will use Aggregate Data
      Drug Information System and Stata software to analyze the data extracted from the
      randomized controlled trials of TCM therapies for MCI. The primary outcome of
      this study is the improvement of cognitive function and the secondary outcome is 
      the activities of daily living, clinical efficacy, and adverse events, and the
      quality of the evidence will be evaluated using the Grading of Recommendations
      Assessment, Development and Evaluation instrument. RESULTS: This study will
      provide a reliable evidence for the selection of TCM therapies in the treatment
      of MCI. CONCLUSION: This study will generate evidence for different TCM therapies
      for MCI and provide a decision-making reference for clinical research. ETHICS AND
      DISSEMINATION: This study does not require ethical approval. The results will be 
      disseminated through a peer-reviewed publication. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/JV9KG.
FAU - Wang, Haiyan
AU  - Wang H
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      medicine, Chengdu, Sichuan Province, China.
AD  - Department of Acupuncture and Moxibustion, Affiliated Hospital of Gansu
      University of Traditional Chinese Medicine, Lanzhou, Gansu Province, China.
FAU - Yu, Haiyang
AU  - Yu H
AD  - Department of Traumatic Orthopedics, Affiliated Hospital of Gansu University of
      Traditional Chinese medicine, Lanzhou, Gansu Province, China.
FAU - Song, Kai
AU  - Song K
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      medicine, Chengdu, Sichuan Province, China.
FAU - Xiong, Fanjie
AU  - Xiong F
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      medicine, Chengdu, Sichuan Province, China.
FAU - Zhang, Hong
AU  - Zhang H
AUID- ORCID: 0000-0002-6417-8399
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      medicine, Chengdu, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Activities of Daily Living
MH  - Cognitive Dysfunction/*therapy
MH  - Humans
MH  - Medicine, Chinese Traditional/adverse effects/*methods
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7489630
EDAT- 2020/09/15 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1097/MD.0000000000022187 [doi]
AID - 00005792-202009110-00083 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22187. doi:
      10.1097/MD.0000000000022187.


PMID- 32925789
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Plum-blossom needle for coronavirus disease 2019-related headache: A protocol for
      systematic review and meta-analysis.
PG  - e22179
LID - 10.1097/MD.0000000000022179 [doi]
AB  - BACKGROUND: Assessing the effectiveness and safety of plum-blossom needle for
      (COVID-19) related headache is the main purpose of this systematic review
      protocol. METHODS: We will search the following sources for the identification of
      trials: The Cochrane Library, PubMed, EMBASE, Chinese Biomedical Literature
      Database (CBM), Chinese National Knowledge Infrastructure Database (CNKI),
      Chinese Science and Technique Journals Database (VIP), and the Wanfang Database. 
      The searches were limited to articles published in 2020, but no language
      restrictions were imposed. Only include randomised controlled trials (RCTs), with
      or without blinding, and participant or observer reported outcomes, will be
      included.The primary outcome is the time and rate of appearance of headache
      induced by COVID-19. The secondary outcome is the length of hospital stay. Two
      independent reviewers will conduct the study selection, data extraction and
      assessment. Review Manager Software V.5.3 will be used for the assessment of risk
      of bias and data synthesis. RESULTS: The results will provide a high-quality
      synthesis of current evidence for researchers in this subject area. CONCLUSION:
      The conclusion of our study will provide an evidence to judge whether
      plum-blossom needle is effective and safe for COVID-19-related headache. ETHICS
      AND DISSEMINATION: This protocol will not evaluate individual patient information
      or affect patient rights and therefore does not require ethical approval. Results
      from this review will be disseminated through peer-reviewed journals and
      conference reports. PROSPERO REGISTRATION NUMBER: CRD42020199508.
FAU - Gao, Wei
AU  - Gao W
AD  - Encephalopathy Department, Chengdu Pidu District Hospital of TCM, China.
FAU - Li, Jingfei
AU  - Li J
FAU - Huang, Guoxiang
AU  - Huang G
AUID- ORCID: 0000-0002-8392-5919
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy/instrumentation/methods
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/physiopathology/therapy
MH  - Flowers
MH  - *Headache/etiology/therapy
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - Needles
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/physiopathology/therapy
MH  - *Prunus domestica
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7489690
EDAT- 2020/09/15 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1097/MD.0000000000022179 [doi]
AID - 00005792-202009110-00081 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22179. doi:
      10.1097/MD.0000000000022179.


PMID- 32925756
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Evaluating the efficacy and safety of bromhexine hydrochloride tablets in
      treating pediatric COVID-19: A protocol for meta-analysis and systematic review.
PG  - e22114
LID - 10.1097/MD.0000000000022114 [doi]
AB  - BACKGROUND: Bromhexine hydrochloride tablets may be effective in the treatment of
      Coronavirus disease 2019 (COVID-19) in children. This study will further evaluate
      the efficacy and safety of bromhexine hydrochloride tablets in the treatment of
      COVID-19 in children. METHODS: The following electronic databases will be
      searched, with all relevant randomized controlled trials (RCTs) up to August 2020
      to be included: PubMed, Embase, Web of Science, the Cochrane Library, China
      National Knowledge Infrastructure (CNKI), the Chongqing VIP China Science and
      Technology Database (VIP), Wanfang, the Technology Periodical Database, and the
      Chinese Biomedical Literature Database (CBM). As well as the above, Baidu, the
      International Clinical Trials Registry Platform (ICTRP), Google Scholar, and the 
      Chinese Clinical Trial Registry (ChiCTR) will also be searched to obtain more
      comprehensive data. Besides, the references of the included literature will also 
      be traced to supplement our search results and to obtain all relevant literature.
      RESULTS: This systematic review will evaluate the current status of bromhexine
      hydrochloride in the treatment of COVID-19 in children, to evaluate its efficacy 
      and safety. CONCLUSION: This study will provide the latest evidence for
      evaluating the efficacy and safety of bromhexine hydrochloride in the treatment
      of COVID-19 in children. PROSPERO REGISTRATION NUMBER: CRD42020199805. ETHICS AND
      DISSEMINATION: The private information of individuals will not be published. This
      systematic review will also not involve endangering participant rights. Ethical
      approval is not available. The results may be published in peer-reviewed journals
      or disseminated at relevant conferences.
FAU - Wang, Yuying
AU  - Wang Y
AD  - Department of Pediatric, Baoji Maternal and Child Health Hospital, Baoji.
FAU - Zhang, Yinghua
AU  - Zhang Y
AD  - Department of Pediatric, Taian Maternal and Child Health Hospital, Taian.
FAU - Chen, Xia
AU  - Chen X
AD  - The Fifth Department of Pediatric, Baoji Maternal and Child Health Hospital,
      Baoji.
FAU - Xue, Kun
AU  - Xue K
AD  - The Fifth Department of Pediatric, Baoji Maternal and Child Health Hospital,
      Baoji.
FAU - Zhang, Tianjing
AU  - Zhang T
AD  - Department of Pediatric, Peking Union Medical College Hospital, Beijing, China.
FAU - Ren, Xiaohong
AU  - Ren X
AUID- ORCID: 0000-0001-5904-4989
AD  - The Fifth Department of Pediatric, Baoji Maternal and Child Health Hospital,
      Baoji.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Expectorants)
RN  - Q1J152VB1P (Bromhexine)
SB  - IM
MH  - Betacoronavirus
MH  - Bromhexine/*pharmacology
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/*drug therapy/epidemiology/physiopathology
MH  - Expectorants/pharmacology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/epidemiology/physiopathology
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7489657
EDAT- 2020/09/15 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1097/MD.0000000000022114 [doi]
AID - 00005792-202009110-00048 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22114. doi:
      10.1097/MD.0000000000022114.


PMID- 32925755
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Effect of respiratory rehabilitation training on elderly patients with COVID-19: 
      A protocol for systematic review and meta-analysis.
PG  - e22109
LID - 10.1097/MD.0000000000022109 [doi]
AB  - BACKGROUND: Patients with the Corona Virus Disease 2019 (COVID-19) often see
      their respiratory, physical, and psychological functions impaired to varying
      degrees, especially for the elderly patients. Timely respiratory rehabilitation
      intervention for such patients may improve their prognoses. However, its relative
      effectiveness has not been proved. Therefore, this study is purposed to determine
      the effect of respiratory rehabilitation on elderly patients with COVID-19.
      METHODS: This study will search the following electronic databases: Embase,
      MEDLINE, PubMed, Cochrane Library, China national knowledge infrastructure
      database, Wan Fang database, Chinese Science and Technology Periodical Database, 
      and Chinese Biomedical Literature Database, with the retrieval period running
      from their inception to August 2020. All randomized controlled trials of
      respiratory rehabilitation training on elderly patients with COVID-19 are
      collected, and the data are selected and extracted independently according to the
      pre-designed inclusion/exclusion criteria. Cochrane bias risk assessment tool is 
      used to evaluate the method quality and bias risk. All data analyses will be
      implemented by using Revman5.3 and Stata14 software. RESULTS: This study will
      make a high-quality and comprehensive evaluation of the efficacy of respiratory
      rehabilitation training on elderly patients with COVID-19. CONCLUSION: The
      conclusions of this systematic review will deliver more convincing evidence.
      ETHICS AND DISSEMINATION: The private information collected from individuals will
      not be published. And this systematic review will also not involve impairing the 
      participants' rights. Ethical approval is not required. The results may be
      published in a peer-reviewed journal or disseminated in relevant conferences.
FAU - Yan, Huan
AU  - Yan H
AD  - Department of Acupuncture.
FAU - Ouyang, Yonghong
AU  - Ouyang Y
AUID- ORCID: 0000-0002-6249-7927
AD  - Department of General Medicine, The First Affiliated Hospital of Hunan
      Traditional Chinese Medical College.
FAU - Wang, Lang
AU  - Wang L
AD  - Department of Metabolic Endocrinology, The Affiliated ZhuZhou Hospital XiangYa
      Medical College CSU, Zhuzhou, Hunan 412000.
FAU - Luo, Xiangjun
AU  - Luo X
AD  - Department of Acupuncture.
FAU - Zhan, Qian
AU  - Zhan Q
AD  - Department of Pneumology, West China Hospital, Sichuan University, Chengdu,
      Sichun 610041, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - Betacoronavirus
MH  - *Breathing Exercises
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/psychology/rehabilitation
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/psychology/rehabilitation
MH  - Prognosis
MH  - *Psychosocial Support Systems
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7489687
EDAT- 2020/09/15 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1097/MD.0000000000022109 [doi]
AID - 00005792-202009110-00047 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22109. doi:
      10.1097/MD.0000000000022109.


PMID- 32925744
OWN - NLM
STAT- MEDLINE
DCOM- 20200922
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Effects of a multidisciplinary team-led school-based human papillomavirus
      vaccination health-promotion programme on improving vaccine acceptance and uptake
      among female adolescents: A cluster randomized controlled trial.
PG  - e22072
LID - 10.1097/MD.0000000000022072 [doi]
AB  - INTRODUCTION: Evidence has consistently shown the high efficacy of human
      papillomavirus (HPV) vaccines in preventing cervical cancers. However, the HPV
      vaccine uptake rate in Hong Kong is very low. We will develop and evaluate an
      innovative, theory-based multidisciplinary team-led school-based HPV vaccination 
      health-promotion program (MDL-SHPVP), engaging female adolescents,
      parents/guardians, and secondary school personnel in multicomponent educational
      strategies and interactive discussions. METHODS AND ANALYSIS: A cluster
      randomized controlled trial is proposed. We will recruit 2520 female adolescents 
      and their parents/guardians from 18 secondary day schools. The MDL-SHPVP is
      underpinned by the Health Belief Model and Precaution Adoption Process Model.
      Multicomponent interventions will be offered, including education sessions with
      small group dialogues with a registered nurse and trained healthcare and lay
      volunteers, and educational computer games. A team of volunteers will be
      established to raise HPV, cervical cancer, and HPV vaccine awareness. Outcomes
      include adolescents' uptake of the HPV vaccine, adolescents' intention to receive
      HPV vaccination, vaccine acceptance among parents/guardians, and
      parents'/guardians' and adolescents' HPV knowledge, attitudes, and beliefs. Data 
      will be collected at baseline, 1 month, and 1 year after intervention. The
      generalized estimating equations analysis will be used for comparing the outcomes
      between the 2 groups. ETHICS AND DISSEMINATION: Ethical approval was obtained
      from the Joint Chinese University of Hong Kong-New Territories East Cluster
      Clinical Research Ethics Committee (Ref. no.: 2019.055). We will disseminate the 
      study findings via peer-reviewed publications and presentations at relevant
      events and international and local conferences. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov NCT04438291.
FAU - Chau, Janita Pak Chun
AU  - Chau JPC
AD  - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of 
      Hong Kong.
FAU - Lo, Suzanne Hoi Shan
AU  - Lo SHS
AUID- ORCID: 0000-0002-9970-0642
AD  - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of 
      Hong Kong.
FAU - Choi, Kai Chow
AU  - Choi KC
AD  - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of 
      Hong Kong.
FAU - Lee, Vivian Wing Yan
AU  - Lee VWY
AD  - Centre for Learning Enhancement And Research, The Chinese University of Hong
      Kong.
FAU - Lui, Grace Chung Yan
AU  - Lui GCY
AD  - Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese
      University of Hong Kong.
FAU - Chan, Kam Ming
AU  - Chan KM
AD  - Department of Paediatrics and Adolescent Medicine, United Christian Hospital,
      Hospital Authority, Hong Kong.
FAU - Lau, Alexander Yuk Lun
AU  - Lau AYL
AD  - Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese
      University of Hong Kong.
LA  - eng
SI  - ClinicalTrials.gov/NCT04438291
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - Consumer Health Information/*organization & administration
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Papillomavirus Vaccines
MH  - Parents/psychology
MH  - *Patient Acceptance of Health Care
MH  - School Health Services/*organization & administration
MH  - Socioeconomic Factors
MH  - Students/psychology
MH  - Uterine Cervical Neoplasms/*prevention & control/virology
PMC - PMC7489727
EDAT- 2020/09/15 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/09/14 15:45
PHST- 2020/09/14 15:45 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - 10.1097/MD.0000000000022072 [doi]
AID - 00005792-202009110-00036 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e22072. doi:
      10.1097/MD.0000000000022072.


PMID- 32925717
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 37
DP  - 2020 Sep 11
TI  - Viscossuplementation for the treatment of osteoarthritis of the knee: A protocol 
      for an umbrella review of systematic reviews with meta-analyses of randomized
      controlled trials.
PG  - e21813
LID - 10.1097/MD.0000000000021813 [doi]
AB  - BACKGROUND: Knee osteoarthritis (KOA) is a common chronic disease with worldwide 
      prevalence of 10% to 79%, with costs ranging from $560 to $635 billion for year
      in United States of America. The main guidelines recommend interventions with
      undesirable adverse events (AE) or highly dependent on the patient's persistence.
      Thus, intra-articular (IA) therapies appear to be attractive in patients with
      KOA, as well as a valid therapy by maximizing effects locally in the joint and
      limiting systemic AE. Presently, the main available IA therapies are
      corticosteroids and hyaluronic acid.As several meta-analyses about the efficacy
      of intra-articular hyaluronic acid (IAHA) for treatment of KOA with discordant
      results were published, we decided to conduct an umbrella review to summarize
      this efficacy METHODS:: We will search MEDLINE/PubMed, EMBASE, Cochrane Library, 
      and Virtual Health Library (BVS) from inception to February 2020 for systematic
      reviews with meta-analyses of randomized clinical trials that investigate IAHA
      for therapy of KOA. Grey literature will be searched in Opengray platform,
      Research Gate, and Google Scholar. The reference lists of eligible studies will
      be screened. The search will be performed without language restriction.We will
      include any type of IAHA as experimental intervention and different types of oral
      or intra-articular placebo or medications as controls. The primary outcome will
      be measures of efficacy as the Western Ontario and McMaster Universities
      Osteoarthritis Index.A synthesis of the evidence will be conducted and data will 
      be presented in tables.Two reviewers will independently appraise the quality of
      included meta-analyses using the Assessment of Multiple Systematic Reviews 2
      (AMSTAR 2) tool and will classify the included systematic reviews into high,
      moderate, low, or critically low levels of confidence. RESULTS: The results of
      this study will be published in a peer-reviewed journal. ETHICS AND
      DISSEMINATION: No ethical approval is required since this study data is based on 
      published literature. PROTOCOL REGISTRATION NUMBER: PROSPERO CRD42019120269
      (https://www.crd.york.ac.uk/PROSPERO/#joinuppage).
FAU - Ferreira de, Andrade Carlos Augusto
AU  - Ferreira de ACA
AUID- ORCID: 0000-0002-0098-4957
AD  - Unimed-Rio Institute - Rio de Janeiro.
AD  - Department of Epidemiology and Quantitative Methods in Health, National School of
      Public Health Sergio Arouca (ENSP)/Oswaldo Cruz Foundation (Fiocruz).
AD  - Faculty of Medicine - Vassouras University.
FAU - Genov, Isabel Rugue
AU  - Genov IR
AD  - Nove de Julho University, Sao Paulo.
FAU - Pereira, Sara Regina Neto
AU  - Pereira SRN
AD  - Unimed-Rio Institute - Rio de Janeiro.
AD  - Faculty of Medical Sciences, State University of Rio de Janeiro.
FAU - Barreto, Joao Mauricio
AU  - Barreto JM
AD  - National Institute of Traumatology and Orthopedics Jamil Haddad - Rio de Janeiro.
FAU - Ramos, Max Rogerio Freitas
AU  - Ramos MRF
AD  - Unimed-Rio Institute - Rio de Janeiro.
AD  - Orthopaedic Department, Federal University of Rio de Janeiro - Rio de Janeiro.
FAU - da Silva, Eduardo Costa Freitas
AU  - da Silva ECF
AD  - Unimed-Rio Institute - Rio de Janeiro.
AD  - Department of Internal Medicine.
FAU - de Oliveira, Liszt Palmeira
AU  - de Oliveira LP
AD  - Unimed-Rio Institute - Rio de Janeiro.
AD  - Department of Surgical Specialties, State University of Rio de Janeiro, Rio de
      Janeiro, Brazil.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage
MH  - Meta-Analysis as Topic
MH  - Osteoarthritis, Knee/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Viscosupplementation/methods/*statistics & numerical data
PMC - PMC7489737
EDAT- 2020/09/15 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/14 15:44
PHST- 2020/09/14 15:44 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1097/MD.0000000000021813 [doi]
AID - 00005792-202009110-00009 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 11;99(37):e21813. doi:
      10.1097/MD.0000000000021813.


PMID- 32925697
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210505
IS  - 1535-1815 (Electronic)
IS  - 0749-5161 (Linking)
VI  - 36
IP  - 10
DP  - 2020 Oct
TI  - The 3-Minute Ethical Dilemma: Using Personal Protective Equipment Puts Healthcare
      Providers in the Crossfire of Duty to Care and Staying Healthy.
PG  - 505-507
LID - 10.1097/PEC.0000000000002230 [doi]
FAU - Goldman, Ran
AU  - Goldman R
FAU - Virani, Alice K
AU  - Virani AK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Emerg Care
JT  - Pediatric emergency care
JID - 8507560
SB  - IM
MH  - COVID-19/*prevention & control/transmission
MH  - Delivery of Health Care/ethics
MH  - Health Personnel/*ethics
MH  - Humans
MH  - Personal Protective Equipment/*ethics
MH  - Respiratory Insufficiency/therapy
MH  - SARS-CoV-2
MH  - Time Factors
EDAT- 2020/09/15 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/09/14 15:44
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/09/14 15:44 [entrez]
AID - 10.1097/PEC.0000000000002230 [doi]
AID - 00006565-202010000-00012 [pii]
PST - ppublish
SO  - Pediatr Emerg Care. 2020 Oct;36(10):505-507. doi: 10.1097/PEC.0000000000002230.


PMID- 32925337
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20210126
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 131
IP  - 4
DP  - 2020 Oct
TI  - A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative
      Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery 
      Patients: A Randomized Controlled Trial.
PG  - 1164-1172
LID - 10.1213/ANE.0000000000004730 [doi]
AB  - BACKGROUND: Postoperative nausea and vomiting (PONV) is a common occurrence after
      cardiac surgery. However, in contrast to other surgical populations, routine PONV
      prophylaxis is not a standard of care in cardiac surgery. We hypothesized that
      routine administration of a single prophylactic dose of ondansetron (4 mg) at the
      time of stopping postoperative propofol sedation before extubation in the cardiac
      surgery intensive care unit would decrease the incidence of PONV. METHODS: With
      institutional human ethics board approval and written informed consent, we
      conducted a randomized controlled trial in patients >/=19 years of age with no
      history of PONV undergoing elective or urgent cardiac surgery procedures
      requiring cardiopulmonary bypass. The primary outcome was the incidence of PONV
      in the first 24 hours postextubation, compared by the chi test. Secondary
      outcomes included the incidence and times to first dose of rescue antiemetic
      treatment administration, the incidence of headaches, and the incidence of
      ventricular arrhythmias. RESULTS: PONV within the first 24 hours postextubation
      occurred in 33 of 77 patients (43%) in the ondansetron group versus 50 of 82
      patients (61%) in the placebo group (relative risk, 0.70 [95% confidence interval
      {CI}, 0.51-0.95]; absolute risk difference, -18% [95% CI, -33 to -2]; number
      needed to treat, 5.5 [95% CI, 3.0-58.4]; chi test, P = .022). Kaplan-Meier
      "survival" analysis of the times to first rescue antiemetic treatment
      administration over 24 hours indicated that patients in the ondansetron group
      fared better than those in the placebo group (log-rank [Mantel-Cox] test; P =
      .028). Overall, 32 of 77 patients (42%) in the ondansetron group received rescue 
      antiemetic treatment over the first 24 hours postextubation versus 47 of 82
      patients (57%) in the placebo group (relative risk, 0.73 [95% CI, 0.52-1.00];
      absolute risk difference, -16% [95% CI, -31 to 1]); P = .047. There were no
      significant differences between the groups in the incidence of postoperative
      headache (ondansetron group, 5 of 77 patients [6%] versus placebo group, 4 of 82 
      patients [5%]; Fisher exact test; P = .740) or ventricular arrhythmias
      (ondansetron group, 2 of 77 patients [3%] versus placebo group, 4 of 82 patients 
      [5%]; P = .68). CONCLUSIONS: These findings support the routine administration of
      ondansetron prophylaxis at the time of discontinuation of postoperative propofol 
      sedation before extubation in patients following cardiac surgery. Further
      research is warranted to optimize PONV prophylaxis in cardiac surgery patients.
FAU - Wang, Erica H Z
AU  - Wang EHZ
AD  - From the Pharmacy Department, St Paul's Hospital, Providence Health Care,
      Vancouver, British Columbia, Canada.
AD  - Faculty of Pharmaceutical Sciences.
FAU - Sunderland, Sarah
AU  - Sunderland S
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, The University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Edwards, Nicola Y
AU  - Edwards NY
AD  - Department of Anesthesia, St Paul's Hospital, Providence Health Care, Vancouver, 
      British Columbia, Canada.
FAU - Chima, Navraj S
AU  - Chima NS
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, The University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Yarnold, Cynthia H
AU  - Yarnold CH
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, The University of
      British Columbia, Vancouver, British Columbia, Canada.
AD  - Department of Anesthesia, St Paul's Hospital, Providence Health Care, Vancouver, 
      British Columbia, Canada.
FAU - Schwarz, Stephan K W
AU  - Schwarz SKW
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, The University of
      British Columbia, Vancouver, British Columbia, Canada.
AD  - Department of Anesthesia, St Paul's Hospital, Providence Health Care, Vancouver, 
      British Columbia, Canada.
FAU - Coley, Matthew A
AU  - Coley MA
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, The University of
      British Columbia, Vancouver, British Columbia, Canada.
AD  - Department of Anesthesia, St Paul's Hospital, Providence Health Care, Vancouver, 
      British Columbia, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT02966041
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Antiemetics)
RN  - 4AF302ESOS (Ondansetron)
SB  - IM
MH  - Aged
MH  - Antiemetics/*therapeutic use
MH  - Arrhythmias, Cardiac/epidemiology
MH  - Cardiac Surgical Procedures/*adverse effects
MH  - Cardiopulmonary Bypass
MH  - Double-Blind Method
MH  - Female
MH  - Headache/epidemiology/etiology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Ondansetron/*therapeutic use
MH  - Pain, Postoperative/epidemiology
MH  - Postoperative Nausea and Vomiting/*prevention & control
MH  - Treatment Outcome
EDAT- 2020/09/15 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/09/14 15:43
PHST- 2020/09/14 15:43 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.1213/ANE.0000000000004730 [doi]
AID - 00000539-202010000-00025 [pii]
PST - ppublish
SO  - Anesth Analg. 2020 Oct;131(4):1164-1172. doi: 10.1213/ANE.0000000000004730.


PMID- 32924949
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2292-9495 (Electronic)
IS  - 2292-9495 (Linking)
VI  - 7
IP  - 3
DP  - 2020 Sep 14
TI  - Mobile App for Monitoring 3-Month Postoperative Functional Outcome After Hip
      Fracture: Usability Study.
PG  - e16989
LID - 10.2196/16989 [doi]
AB  - BACKGROUND: As a result of an aging population, there has been an increasing
      incidence of hip fractures worldwide. In the Netherlands, in order to improve the
      quality of care for elderly patients with hip fractures, the multidisciplinary
      Centre for Geriatric Traumatology was established in 2008 at the Department of
      Trauma Surgery at Ziekenhuisgroep Twente hospital (located in Almelo and Hengelo 
      in the Netherlands). OBJECTIVE: Though the Dutch Hip Fracture audit is used to
      monitor the quality of care for patients with fractures of the hip, only 30.7% of
      patients complete registration in the 3-month follow-up period. Mobile apps offer
      an opportunity for improvement in this area. The aim of this study was to
      investigate the usability and acceptance of a mobile app for gathering indicators
      of quality of care in a 3-month follow-up period after postoperative treatment of
      hip fracture. METHODS: From July 2017 to December 2017, patients who underwent
      surgical treatment for hip fracture were recruited. Patients and caregivers, who 
      were collectively considered the participant cohort, were asked to download the
      app and answer a questionnaire. Participants were divided into two groups-those
      who downloaded the app and those who did not download the app. A telephone
      interview that was based upon the Unified Theory of Acceptance and Use of
      Technology was conducted with a subset of participants from each group (1:1
      ratio). This study was designated as not being subject to the Dutch Medical
      Research Involving Human Subjects Act according to the appropriate medical
      research ethics committees. RESULTS: Of the patients and caregivers who
      participated, 26.4% (29/110) downloaded the app, whereas 73.6% (81/110) did not. 
      Telephone interviews with the subset of participants (n=24 per group) revealed
      that 54.0% (13/24) of the group of participants who did not download the app had 
      forgotten the study. Among the group who downloaded the app, 95.8% (23/24) had
      the intention of completing the questionnaire, but only 4.2% (1/24) did so. The
      reasons for not completing the questionnaire included technical problems,
      cognitive disorders, or patient dependency on caregivers. Most participants in
      the group who downloaded the app self-reported a high level of expertise in using
      a smartphone (22/24, 91.7%), and sufficient facilitating conditions for using a
      smartphone were self-reported in both groups (downloaded the app: 23/24, 95.8%;
      did not download the app: 21/24, 87.5%), suggesting that these factors were not
      barriers to completion. CONCLUSIONS: Despite self-reported intention to use the
      app, smartphone expertise, and sufficient facilitating conditions for smartphone 
      use, implementation of the mobile app was infeasible for daily practice. This was
      due to a combination of technical problems, factors related to the implementation
      process, and the population of interest having cognitive disorders or a
      dependency on caregivers for mobile technology.
CI  - (c)Merle A J Geerds, Wieke S Nijmeijer, J H Hegeman, Miriam M R
      Vollenbroek-Hutten. Originally published in JMIR Human Factors
      (http://humanfactors.jmir.org), 14.09.2020.
FAU - Geerds, Merle A J
AU  - Geerds MAJ
AUID- ORCID: https://orcid.org/0000-0001-7808-7810
AD  - Department of Trauma Surgery, Ziekenhuisgroep Twente, Almelo, Netherlands.
FAU - Nijmeijer, Wieke S
AU  - Nijmeijer WS
AUID- ORCID: https://orcid.org/0000-0002-5799-9690
AD  - Department of Trauma Surgery, Ziekenhuisgroep Twente, Almelo, Netherlands.
AD  - Biomedical Signals and Systems, Faculty of Electrical Engineering, Mathematics,
      and Computer Science, University of Twente, Enschede, Netherlands.
FAU - Hegeman, J H
AU  - Hegeman JH
AUID- ORCID: https://orcid.org/0000-0003-2188-2738
AD  - Department of Trauma Surgery, Ziekenhuisgroep Twente, Almelo, Netherlands.
FAU - Vollenbroek-Hutten, Miriam M R
AU  - Vollenbroek-Hutten MMR
AUID- ORCID: https://orcid.org/0000-0001-8730-1487
AD  - Biomedical Signals and Systems, Faculty of Electrical Engineering, Mathematics,
      and Computer Science, University of Twente, Enschede, Netherlands.
AD  - Ziekenhuisgroep Twente Academy, Ziekenhuisgroep Twente, Almelo, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - Canada
TA  - JMIR Hum Factors
JT  - JMIR human factors
JID - 101666561
PMC - PMC7522745
OTO - NOTNLM
OT  - app
OT  - elderly
OT  - hip fracture
OT  - mHealth
OT  - orthogeriatric
OT  - remote monitoring
OT  - telemedicine
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 15:42
PHST- 2019/11/09 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/09/14 15:42 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - v7i3e16989 [pii]
AID - 10.2196/16989 [doi]
PST - epublish
SO  - JMIR Hum Factors. 2020 Sep 14;7(3):e16989. doi: 10.2196/16989.


PMID- 32924863
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 14
DP  - 2020 Dec
TI  - Gratitude in Health Care: A Meta-narrative Review.
PG  - 2303-2315
LID - 10.1177/1049732320951145 [doi]
AB  - Research into gratitude as a significant sociological and psychological
      phenomenon has proliferated in the past two decades. However, there is little
      consensus on how it should be conceptualized or investigated empirically. We
      present a meta-narrative review that focuses on gratitude in health care, with an
      emphasis on research exploring interpersonal experiences in the context of care
      provision. Six meta-narratives from literatures across the humanities, sciences, 
      and medicine are identified, contextualized, and discussed: gratitude as social
      capital; gifts; care ethics; benefits of gratitude; gratitude and staff
      well-being; and gratitude as an indicator of quality of care. Meta-narrative
      review was a valuable framework for making sense of theoretical antecedents and
      findings in this developing area of research. We conclude that greater attention 
      needs to be given to what constitutes "evidence" in gratitude research and call
      for qualitative studies to better understand and shape the role and implications 
      of gratitude in health care.
FAU - Day, Giskin
AU  - Day G
AUID- ORCID: 0000-0002-9901-9267
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, United Kingdom.
AD  - School of Medicine, Imperial College London, London, United Kingdom.
FAU - Robert, Glenn
AU  - Robert G
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, United Kingdom.
FAU - Rafferty, Anne Marie
AU  - Rafferty AM
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, United Kingdom.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 212792/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200913
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - Delivery of Health Care
MH  - *Health Facilities
MH  - Humans
MH  - *Narration
MH  - Qualitative Research
PMC - PMC7649920
OTO - NOTNLM
OT  - *gratitude
OT  - *health care
OT  - *meta-narrative review
OT  - *psychology
OT  - *qualitative
EDAT- 2020/09/15 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/14 15:40
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/09/14 15:40 [entrez]
AID - 10.1177/1049732320951145 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Dec;30(14):2303-2315. doi: 10.1177/1049732320951145. Epub
      2020 Sep 13.


PMID- 32924763
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Linking)
VI  - 11
DP  - 2020 Jan-Dec
TI  - Registered Nurses' Decisions Around Referral of Residents With Urinary Tract
      Infections: A Retrospective Cohort Study.
PG  - 2150132720957441
LID - 10.1177/2150132720957441 [doi]
AB  - BACKGROUND: Referral of residents with urinary tract infections (UTIs) in
      residential aged care facilities (RACFs) to hospital are common. However, there
      is limited information on what influences Registered Nurses' (RN) decision-making
      process. AIM: To investigate resident factors that influence RN's decisions to
      escalate care. DESIGN: A retrospective cohort approach audited electronic
      clinical records of residents with UTIs. METHODS: Data were extracted from the
      electronic database and analyzed using descriptive and regression analysis.
      Approval was obtained from both the RACFs and University Human Research Ethics
      Committee. RESULTS: There was a higher likelihood of being referred to hospital
      if residents were female, had had a past fall, had related comorbidity, or had
      abnormal vital signs. However, being older and having a urinary catheter were
      protective factors for referral by the RN. CONCLUSION: Referral of residents with
      UTIs by RNs to hospital is common in RACFs. Resident characteristics such as
      abnormal vital signs, past falls, and presence of comorbidity influence referrals
      by RNs. Nurse Practitioners dedicated to the RACFs could complement the role of a
      general practitioner. UTI-specific escalation protocols can assist RNs to make
      decisions about referrals. RNs' related risk factors also need to be examined to 
      understand other influencing factors.
FAU - Kosheleva, Ludmila
AU  - Kosheleva L
AUID- ORCID: 0000-0003-4951-2712
AD  - Curtin University, Perth, Western Australia, Australia.
AD  - Bethanie Aged Care Facilities, Perth, Western Australia.
FAU - Ngune, Irene
AU  - Ngune I
AD  - Curtin University, Perth, Western Australia, Australia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
SB  - IM
MH  - Aged
MH  - Female
MH  - *General Practitioners
MH  - Humans
MH  - *Nurses
MH  - Referral and Consultation
MH  - Retrospective Studies
MH  - *Urinary Tract Infections/diagnosis/epidemiology
PMC - PMC7493263
OTO - NOTNLM
OT  - *older people
OT  - *registered nurses
OT  - *residential aged care facilities
OT  - *unplanned hospital admissions
OT  - *urinary tract infection
EDAT- 2020/09/15 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/14 15:39
PHST- 2020/09/14 15:39 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1177/2150132720957441 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2020 Jan-Dec;11:2150132720957441. doi:
      10.1177/2150132720957441.


PMID- 32924148
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20201111
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 7
DP  - 2020 Oct
TI  - Female genital mutilation or cutting: an updated medico-legal analysis.
PG  - 309-311.e1
LID - 10.5694/mja2.50768 [doi]
FAU - Mathews, Ben
AU  - Mathews B
AD  - Queensland University of Technology, Brisbane, QLD.
AD  - Johns Hopkins University, Baltimore, MD, USA.
FAU - Dallaston, Elizabeth
AU  - Dallaston E
AD  - Queensland University of Technology, Brisbane, QLD.
LA  - eng
PT  - Journal Article
DEP - 20200914
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Australia
MH  - Circumcision, Female/ethics/*legislation & jurisprudence
MH  - Female
MH  - Humans
MH  - Reproductive Rights/ethics/*legislation & jurisprudence
MH  - Women's Health/ethics/*legislation & jurisprudence
MH  - Women's Rights/ethics/*legislation & jurisprudence
OTO - NOTNLM
OT  - *Ethics
OT  - *Human rights
OT  - *Jurisprudence
OT  - *Legislation
OT  - *Medicolegal
OT  - *Pediatrics
OT  - *Public health
OT  - *Women's rights
OT  - *medical
OT  - *professional
EDAT- 2020/09/15 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/09/14 05:58
PHST- 2019/12/19 00:00 [received]
PHST- 2020/03/30 00:00 [revised]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
PHST- 2020/09/14 05:58 [entrez]
AID - 10.5694/mja2.50768 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Oct;213(7):309-311.e1. doi: 10.5694/mja2.50768. Epub 2020 Sep
      14.


PMID- 32924131
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201119
IS  - 1003-9406 (Print)
IS  - 1003-9406 (Linking)
VI  - 37
IP  - 10
DP  - 2020 Oct 10
TI  - [Progress of research on induced pluripotent stem cell models for Down syndrome].
PG  - 1183-1185
LID - 10.3760/cma.j.cn511374-20191025-00543 [doi]
AB  - With an incidence of 1/800 - 1/600, Down syndrome (DS) is the most common
      chromosomal disorder in humans. Whilst most DS patients has trisomy 21, a small
      proportion may carry translocations or mosaicisms involving chromosome 21. The
      main characteristics of DS include mental retardation, peculiar facies, growth
      retardation, congenital heart disease, duodenal stenosis, Alzheimer's disease,
      leukemia, and immunodeficiency, which may be due to increased dosage of critical 
      genes. Recent studies also showed that epigenetic changes may also occur in DS.
      For research on patients with DS or other trisomies have been restricted by
      ethical considerations, and commonly used mouse models cannot fully replicate the
      characteristic features of DS, pluripotent stem cells induced from fetal samples 
      or biopsy tissues from DS patients may generate models with the same genetic
      content, which may provide idea materials for studying the pathogenesis of DS and
      customized cell and/or gene therapies.
FAU - Zhang, Tianyuan
AU  - Zhang T
AD  - Center of Prenatal Diagnosis, the First Affiliated Hospital of Zhengzhou
      University, Zhengzhou, Henan 450052, China. kongxd@263.net.
FAU - Kong, Lingrong
AU  - Kong L
FAU - Sun, Gege
AU  - Sun G
FAU - Kong, Xiangdong
AU  - Kong X
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Yi Xue Yi Chuan Xue Za Zhi
JT  - Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese
      journal of medical genetics
JID - 9425197
SB  - IM
MH  - Animals
MH  - Chromosomes, Human, Pair 21
MH  - *Down Syndrome/genetics
MH  - Humans
MH  - *Induced Pluripotent Stem Cells
MH  - Mice
MH  - Models, Biological
MH  - Trisomy
EDAT- 2020/09/15 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/09/14 05:58
PHST- 2020/09/14 05:58 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - 940637249 [pii]
AID - 10.3760/cma.j.cn511374-20191025-00543 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020 Oct 10;37(10):1183-1185. doi:
      10.3760/cma.j.cn511374-20191025-00543.


PMID- 32923695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Cost-effectiveness of neonatal surgery for congenital anomalies in low-income and
      middle-income countries: a systematic review protocol.
PG  - e000755
LID - 10.1136/bmjpo-2020-000755 [doi]
AB  - INTRODUCTION: Congenital anomalies are the fifth leading cause of death in
      children under 5 years old globally (591 000 deaths reported in 2016). Over 95%
      of deaths occur in low-income and middle-income countries (LMICs). It is
      estimated that two-thirds of the congenital anomaly health burden could be
      averted through surgical intervention and that such interventions can be
      cost-effective. This systematic review aims to evaluate current evidence
      regarding the cost-effectiveness of neonatal surgery for congenital anomalies in 
      LMICs. METHODS AND ANALYSIS: A systematic literature review will be conducted in 
      PubMed, MEDLINE, Embase, Cochrane Library, Scielo, Google Scholar, African
      Journals OnLine and Regional WHO's African Index Medicus databases for articles
      on the cost-effectiveness of neonatal surgery for congenital anomalies in LMICs. 
      The following search strings will be used: (1) congenital anomalies; (2) LMICs;
      and (3) cost-effectiveness of surgical interventions. Articles will be uploaded
      to Covidence software, duplicates removed and the remaining articles screened by 
      two independent reviewers. Cost information for interventions or procedures will 
      be extracted by country and condition. Outcome measurements by reported unit and 
      cost-effectiveness ratios will be extracted. Methodological quality of each
      article will be assessed using the Drummond checklist for economic evaluations.
      The Agency for Healthcare Research and Quality's Effective Health Care Program
      guidance will be followed to assess the grade of the studies. ETHICS AND
      DISSEMINATION: No ethical approval is required for conducting the systematic
      review. There will be no direct collection of data from individuals. The
      finalised article will be published in a scientific journal for dissemination.
      The protocol has been registered with PROSPERO (International Prospective
      Register of Systematic Reviews). CONCLUSION: Congenital anomalies form a large
      component of the global health burden that is amenable to surgical intervention. 
      This study will systematically review the current literature on the
      cost-effectiveness of neonatal surgery for congenital anomalies in LMICs.
      PROSPERO REGISTRATION NUMBER: CRD42020172971.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kim, Na Eun
AU  - Kim NE
AUID- ORCID: 0000-0002-7896-9458
AD  - Department of General Surgery, Boston Medical Center, Boston, Massachusetts, USA.
AD  - King's College London, London, UK.
FAU - Vervoot, Dominique
AU  - Vervoot D
AD  - Department of Health Policy and Management, Johns Hopkins Bloomberg School of
      Public Health, Baltimore, Maryland, USA.
FAU - Hammouri, Ahmad
AU  - Hammouri A
AD  - Department of Internal Medicine, Bethlehem Arab Society for Rehabilitation,
      Bethlehem, Palestine, State of.
FAU - Riboni, Cristiana
AU  - Riboni C
AD  - University of Pavia, Pavia, Lombardia, Italy.
FAU - Salem, Hosni
AU  - Salem H
AD  - Cairo University, Giza, Egypt.
FAU - Grimes, Caris
AU  - Grimes C
AD  - King's College London, London, UK.
AD  - Department of Surgery, Medway NHS Foundation Trust, Gillingham, Kent, UK.
FAU - Wright, Naomi Jane
AU  - Wright NJ
AD  - King's Centre for Global Health and Health Partnerships, King's College London,
      London, UK.
LA  - eng
PT  - Systematic Review
DEP - 20200830
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7462241
OTO - NOTNLM
OT  - neonatology
COIS- Competing interests: None declared.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:56
PHST- 2020/06/09 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/09/14 05:56 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1136/bmjpo-2020-000755 [doi]
AID - bmjpo-2020-000755 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Aug 30;4(1):e000755. doi: 10.1136/bmjpo-2020-000755.
      eCollection 2020.


PMID- 32923471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Surgical and Behavioral Relationships With Welfare.
PG  - 519
LID - 10.3389/fvets.2020.00519 [doi]
AB  - Veterinarians perform surgery for a number of reasons, from treating a problem to
      preventing future problems. There is an inextricable link between the physical
      and psychological aspects of an animal's health, and surgery is often a conduit
      to bridge that gap. Some surgical procedures can affect an animal's behavior,
      such as castration, and some pose an ethical dilemma, such as ear cropping and
      declawing. Ameliorating pain, decreasing stressful experiences for the animal,
      and identifying and treating concurrent problem behaviors are hallmarks of
      improving animal welfare. The purpose of this article is to outline some of these
      interrelationships and ethical dilemmas, providing evidence-based verification as
      applicable.
CI  - Copyright (c) 2020 Bain.
FAU - Bain, Melissa
AU  - Bain M
AD  - Clinical Animal Behavior Service, Davis School of Veterinary Medicine, University
      of California, Davis, Davis, CA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200814
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7456887
OTO - NOTNLM
OT  - animal
OT  - behavior
OT  - ethics
OT  - human-animal bond
OT  - medical
OT  - surgery
OT  - welfare
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:55
PHST- 2020/03/15 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/09/14 05:55 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.3389/fvets.2020.00519 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 Aug 14;7:519. doi: 10.3389/fvets.2020.00519. eCollection
      2020.


PMID- 32923311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2200-6133 (Print)
IS  - 2200-6133 (Linking)
VI  - 12
DP  - 2020
TI  - Tuberculosis in migrants - screening, surveillance and ethics.
PG  - 9
LID - 10.1186/s41479-020-00072-5 [doi]
AB  - Tuberculosis (TB) is the leading infectious cause of human mortality and is
      responsible for nearly 2 million deaths every year. It is often regarded as a
      'silent killer' because it predominantly affects the poor and marginalized, and
      disease outbreaks occur in 'slow motion' compared to Ebola or coronavirus 2
      (COVID-19). In low incidence countries, TB is predominantly an imported disease
      and TB control in migrants is pivotal for countries to progress towards TB
      elimination in accordance with the World Health Organisations (WHO's) End TB
      strategy. This review provides a brief overview of the different screening
      approaches and surveillance processes that are in place in low TB incidence
      countries. It also includes a detailed discussion of the ethical issues related
      to TB screening of migrants in these settings and the different interests that
      need to be balanced. Given recognition that a holistic approach that recognizes
      and respects basic human rights is required to end TB, the review considers the
      complexities that require consideration in low-incidence countries that are
      aiming for TB elimination.
CI  - (c) The Author(s) 2020.
FAU - Scandurra, Gabriella
AU  - Scandurra G
AD  - Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of
      Sydney, Sydney, Australia.grid.1013.30000 0004 1936 834X
FAU - Degeling, Chris
AU  - Degeling C
AD  - Australian Centre for Health Engagement Evidence and Values, University of
      Wollongong, Wollongong, Australia.grid.1007.60000 0004 0486 528X
FAU - Douglas, Paul
AU  - Douglas P
AD  - International Organization for Migration (IOM), Geneva,
      Switzerland.grid.435307.60000 0004 0522 5946
FAU - Dobler, Claudia C
AU  - Dobler CC
AD  - Institute for Evidenced-Based Healthcare, Bond University, Gold Coast,
      Australia.grid.1033.10000 0004 0405 3820
FAU - Marais, Ben
AU  - Marais B
AD  - Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of
      Sydney, Sydney, Australia.grid.1013.30000 0004 1936 834X
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200905
PL  - England
TA  - Pneumonia (Nathan)
JT  - Pneumonia (Nathan Qld.)
JID - 101663459
PMC - PMC7473829
OTO - NOTNLM
OT  - Ethics
OT  - Migrants
OT  - Migration
OT  - Pre-screening
OT  - Review
OT  - TB
OT  - Tuberculosis
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:54
PHST- 2020/06/28 00:00 [received]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/09/14 05:54 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1186/s41479-020-00072-5 [doi]
AID - 72 [pii]
PST - epublish
SO  - Pneumonia (Nathan). 2020 Sep 5;12:9. doi: 10.1186/s41479-020-00072-5. eCollection
      2020.


PMID- 32923236
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 9
TI  - Restless Legs Syndrome Among Sudanese Patients With Type 2 Diabetes Mellitus: A
      Case-Control Study.
PG  - e9635
LID - 10.7759/cureus.9635 [doi]
AB  - Background There is increasing awareness about the association of restless legs
      syndrome (RLS) with type 2 diabetes. This study assessed RLS and its associations
      among patients with diabetes. Material and methods This case-control study was
      conducted among 160 subjects (82 patients with diabetes and 78 controls)
      attending a diabetic clinic in Omdurman, Sudan, during the period from June 2018 
      to September 2019. A structured questionnaire was used to collect demographic
      factors, diabetic neuropathy, nephropathy, retinopathy, and macrovascular
      complications. The neck circumference was measured to assess adiposity, and a
      blood sample was taken for the glycated hemoglobin (HbA1c) estimation. The local 
      ethical committee approved the research, and the Statistical Package for Social
      Sciences (SPSS; IBM Corp., Armonk, NY) was used for data analysis. A P-value of
      <0.05 was considered significant. Results There were 82 patients with type 2
      diabetes and 78 controls matched for age and sex. Restless legs syndrome was
      higher among patients with diabetes (31.7% vs. 10.3%%) with a significant
      statistical difference, P-<0.05. A direct positive relationship was found between
      restless legs syndrome and diabetic neuropathy (Wald=5.48, P-value=0.019, 95%CI
      1.70-410.76), no relationship was found between RLS, diabetic retinopathy,
      glycated hemoglobin, sex, and neck circumference, P-values (0.757, 0.804, 0.317, 
      and 0.361 respectively). Conclusion Restless legs syndrome was prevalent among
      patients with type 2 diabetes and was more common among patients with diabetic
      neuropathy, no relationship was found between restless legs syndrome, age, sex,
      neck circumference, HbA1c, and retinopathy.
CI  - Copyright (c) 2020, Mirghani et al.
FAU - Mirghani, Hyder
AU  - Mirghani H
AD  - Internal Medicine, Tabuk University, Tabuk, SAU.
LA  - eng
PT  - Journal Article
DEP - 20200809
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7480782
OTO - NOTNLM
OT  - complications
OT  - glycated hemoglobin
OT  - restless leg syndrome
OT  - sudan
OT  - type 2 diabetes
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:53
PHST- 2020/09/14 05:53 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.7759/cureus.9635 [doi]
PST - epublish
SO  - Cureus. 2020 Aug 9;12(8):e9635. doi: 10.7759/cureus.9635.


PMID- 32922781
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210802
IS  - 2049-4637 (Print)
IS  - 2049-4637 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Aug
TI  - 'You wouldn't do that to an animal, would you?' Ethical issues in managing pain
      in patients with substance dependence.
PG  - 195-205
LID - 10.1177/2049463719888551 [doi]
AB  - In this article, we present a secondary analysis of a descriptive
      phenomenological study that we conducted in the United Kingdom exploring nurses' 
      experiences of working with patients with substance dependence and pain. Our aim 
      was to focus upon the ethical issues that emerged in the empirical data and so we
      used the Four Principles of Biomedical Ethics plus attention to scope to guide
      and inform our analysis. We present six key themes: trust, paternalism, coercion,
      failure to respect autonomy, advocacy and withholding. We discuss how these
      themes intersect with the four principles plus scope to illuminate practice and
      the ethical issues that emerge when managing this patient population's pain. We
      recommend that clinicians adopt a collaborative approach to managing pain for
      patients with substance dependence that they remain aware of the power
      differentials inherent within the clinical setting and ensure that communication 
      and teamwork remain at the forefront of decisions. Clinicians need access to
      ethical guidance to inform their practice decisions and clinical ethics support
      services could provide one solution.
CI  - (c) The British Pain Society 2019.
FAU - Morley, Georgina
AU  - Morley G
AUID- ORCID: https://orcid.org/0000-0002-0099-3597
AD  - Center for Bioethics, Cleveland Clinic, Cleveland, OH, USA.
FAU - Chumbley, Gillian M
AU  - Chumbley GM
AD  - Imperial College Healthcare NHS Trust, London, UK.
FAU - Briggs, Emma V
AU  - Briggs EV
AD  - Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's
      College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20191112
PL  - England
TA  - Br J Pain
JT  - British journal of pain
JID - 101583844
PMC - PMC7453482
OTO - NOTNLM
OT  - Pain
OT  - clinical ethics
OT  - ethical issues
OT  - ethics
OT  - pain management
OT  - substance dependence
COIS- Conflict of interest: The author(s) declared no potential conflicts of interest
      with respect to the research, authorship and/or publication of this article.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:52
PHST- 2020/09/14 05:52 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1177/2049463719888551 [doi]
AID - 10.1177_2049463719888551 [pii]
PST - ppublish
SO  - Br J Pain. 2020 Aug;14(3):195-205. doi: 10.1177/2049463719888551. Epub 2019 Nov
      12.


PMID- 32922777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2049-4637 (Print)
IS  - 2049-4637 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Aug
TI  - Acceptability and usability of smartphone-based brainwave entrainment technology 
      used by individuals with chronic pain in a home setting.
PG  - 161-170
LID - 10.1177/2049463720908798 [doi]
AB  - BACKGROUND: Brainwave entrainment (BWE) using rhythmic visual or auditory
      stimulation has many potential clinical applications, including the management of
      chronic pain, where there is a pressing need for novel, safe and effective
      treatments. The aim of this study was to gain qualitative feedback on the
      acceptability and usability of a novel BWE smartphone application, to ensure it
      meets the needs and wishes of end users. METHODS: Fifteen participants with
      chronic pain used the application at home for 4 weeks. Semi-structured telephone 
      interviews were then carried out. A template analysis approach was used to
      interpret the findings, with an initial coding template structured around the
      constructs of a theoretical framework for assessing acceptability of healthcare
      interventions. Structured data analysis generated a final modified coding
      structure, capturing themes generated across participants' accounts. RESULTS: The
      four main themes were 'approach to trying out the app: affective attitude and
      ethicality', 'perceived effectiveness', 'opportunity costs and burden' and
      'intervention coherence and self-efficacy'. All participants were willing to
      engage with the technology and welcomed it as an alternative approach to
      medications. Participants appreciated the simplicity of design and the ability to
      choose between visual or auditory stimulation. All the participants felt
      confident in using the application. CONCLUSION: The findings demonstrate
      preliminary support for the acceptability and usability of the BWE application.
      This is the first qualitative study of BWE to systematically assess these issues.
CI  - (c) The British Pain Society 2020.
FAU - Locke, Helen N
AU  - Locke HN
AUID- ORCID: https://orcid.org/0000-0001-8747-0432
AD  - Academic Department of Rehabilitation Medicine, Leeds Institute of Rheumatology
      and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
AD  - Leeds Community Healthcare NHS Trust and Leeds Teaching Hospitals NHS Trust,
      Leeds, UK.
FAU - Brooks, Joanna
AU  - Brooks J
AD  - Manchester Centre for Health Psychology, The University of Manchester,
      Manchester, UK.
FAU - Arendsen, Laura J
AU  - Arendsen LJ
AUID- ORCID: https://orcid.org/0000-0002-9160-3282
AD  - Division of Functional and Restorative Neurosurgery, Eberhard Karls University of
      Tubingen, Tubingen, Germany.
FAU - Jacob, Nikhil Kurian
AU  - Jacob NK
AD  - Department of Electrical and Electronic Engineering, The University of
      Manchester, Manchester, UK.
FAU - Casson, Alex
AU  - Casson A
AD  - Department of Electrical and Electronic Engineering, The University of
      Manchester, Manchester, UK.
FAU - Jones, Anthony Kp
AU  - Jones AK
AD  - Human Pain Research Group, Division of Neuroscience and Experimental Psychology, 
      The University of Manchester, Manchester, UK.
FAU - Sivan, Manoj
AU  - Sivan M
AD  - Academic Department of Rehabilitation Medicine, Leeds Institute of Rheumatology
      and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
AD  - Leeds Community Healthcare NHS Trust and Leeds Teaching Hospitals NHS Trust,
      Leeds, UK.
AD  - Human Pain Research Group, Division of Neuroscience and Experimental Psychology, 
      The University of Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200221
PL  - England
TA  - Br J Pain
JT  - British journal of pain
JID - 101583844
PMC - PMC7453483
OTO - NOTNLM
OT  - EEG phase synchronisation
OT  - Mobile applications
OT  - alpha rhythm
OT  - pain management
OT  - pain perception
COIS- Conflict of interest: The author(s) declared no potential conflicts of interest
      with respect to the research, authorship and/or publication of this article.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:52
PHST- 2020/09/14 05:52 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1177/2049463720908798 [doi]
AID - 10.1177_2049463720908798 [pii]
PST - ppublish
SO  - Br J Pain. 2020 Aug;14(3):161-170. doi: 10.1177/2049463720908798. Epub 2020 Feb
      21.


PMID- 32922571
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1885-642X (Print)
IS  - 1885-642X (Linking)
VI  - 18
IP  - 3
DP  - 2020 Jul-Sep
TI  - Pharmacists' practices for non-prescribed antibiotic dispensing in Mozambique.
PG  - 1965
LID - 10.18549/PharmPract.2020.3.1965 [doi]
AB  - BACKGROUND: Antibiotics are the most frequently used medicines worldwide with
      most of the countries defining these as prescription-only medicines. Though,
      dispensing non-prescribed antibiotics represent one of the chief causal factors
      to the irrational use of antibiotics that paves the way to the development of
      antimicrobial resistance. OBJECTIVE: We aimed at describing the practices and the
      enablers for non-prescribed antibiotic dispensing in Maputo city, Mozambique.
      METHODS: A qualitative study was conducted, between October 2018 and March 2019, 
      in nine private pharmacies randomly selected across Maputo city. Eighteen
      pharmacists were contacted and seventeen enrolled through snowball sampling.
      In-depth interviews were conducted, audiotaped, and transcribed verbatim.
      Transcripts were coded and analysed though thematic analysis with guidelines from
      Braun and Clark. The Consolidated Criteria for Reporting Qualitative Studies
      (COREQ) checklist by (Tong, 2007) was performed. RESULTS: Out of seventeen,
      fifteen pharmacists admitted non-prescribed dispensing of antibiotics. Common
      antibiotic dispensing practices included; dispensing without prescription,
      without asking for a brief clinical history of patients, without clear
      explanation of the appropriate way of administering, without advising on the side
      effects. Reasons for non-prescribed antibiotic dispensing are linked to patients'
      behaviour of demanding for non-prescribed antibiotics, to the patients
      expectations and beliefs on the healing power of antibiotics, to the physicians' 
      prescribing practices. Other reasons included the pressure for profits from the
      pharmacy owners, the fragile law enforcement, and absence of accountability
      mechanisms. CONCLUSIONS: The practices of non-prescribed antibiotic dispensing
      characterize the 'daily life' of the pharmacists. On the one hand, the patient's 
      demand for antibiotics without valid prescriptions, and pharmacist's wish to
      assist based on their role in the pharmacy, the pressure for profits and on the
      understanding of the larger forces driving the practices of self-medication with 
      antibiotics - rock. On the other hand, pharmacists are aware of the legal status 
      of antibiotics and the public health consequences of their inappropriate
      dispensing practices and their professional and ethical responsibility for
      upholding the law - hard place. Highlighting the role of pharmacists and their
      skills as health promotion professionals is needed to optimizing antibiotic
      dispensing and better conservancy in Mozambique.
CI  - Copyright: (c) Pharmacy Practice and the Authors.
FAU - Torres, Neusa F
AU  - Torres NF
AUID- ORCID: https://orcid.org/0000-0001-7568-9971
AD  - Higher Institute for Health Sciences (ISCISA). Maputo (Mozambique).
      torresneusa@gmail.com.
FAU - Solomon, Vernon P
AU  - Solomon VP
AUID- ORCID: https://orcid.org/0000-0002-1413-0856
AD  - MSc (Clin Psychol). Discipline of Pharmaceutical Sciences School of Health
      Sciences, University of KwaZulu Natal. Durban (South Africa).
      vernonsolomon@gmail.com.
FAU - Middleton, Lyn E
AU  - Middleton LE
AUID- ORCID: https://orcid.org/0000-0003-4045-5096
AD  - Phd (Nurs & Educ). Discipline of Pharmaceutical Sciences, School of Health
      Sciences, University of KwaZulu Natal. Durban (South Africa).
      lynelizabethmiddleton@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - Spain
TA  - Pharm Pract (Granada)
JT  - Pharmacy practice
JID - 101530029
PMC - PMC7470239
OTO - NOTNLM
OT  - Anti-Bacterial Agents
OT  - Bacterial
OT  - Drug Resistance
OT  - Law Enforcement
OT  - Motivation
OT  - Mozambique
OT  - Pharmacies
OT  - Pharmacists
OT  - Prescriptions
OT  - Professional Practice
OT  - Public Health
OT  - Qualitative Research
OT  - Self Medication
COIS- CONFLICT OF INTEREST The authors declare that they have no competing interests.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:51
PHST- 2020/05/09 00:00 [received]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/09/14 05:51 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.18549/PharmPract.2020.3.1965 [doi]
AID - pharmpract-18-1965 [pii]
PST - ppublish
SO  - Pharm Pract (Granada). 2020 Jul-Sep;18(3):1965. doi:
      10.18549/PharmPract.2020.3.1965. Epub 2020 Aug 18.


PMID- 32922515
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1756-2856 (Print)
IS  - 1756-2856 (Linking)
VI  - 13
DP  - 2020
TI  - Using artificial intelligence for improving stroke diagnosis in emergency
      departments: a practical framework.
PG  - 1756286420938962
LID - 10.1177/1756286420938962 [doi]
AB  - Stroke is the fifth leading cause of death in the United States and a major cause
      of severe disability worldwide. Yet, recognizing the signs of stroke in an acute 
      setting is still challenging and leads to loss of opportunity to intervene, given
      the narrow therapeutic window. A decision support system using artificial
      intelligence (AI) and clinical data from electronic health records combined with 
      patients' presenting symptoms can be designed to support emergency department
      providers in stroke diagnosis and subsequently reduce the treatment delay. In
      this article, we present a practical framework to develop a decision support
      system using AI by reflecting on the various stages, which could eventually
      improve patient care and outcome. We also discuss the technical, operational, and
      ethical challenges of the process.
CI  - (c) The Author(s), 2020.
FAU - Abedi, Vida
AU  - Abedi V
AD  - Department of Molecular and Functional Genomics, Geisinger Health System,
      Danville, PA, USA.
FAU - Khan, Ayesha
AU  - Khan A
AD  - Neuroscience Institute, Geisinger Health System, Danville, PA, USA.
FAU - Chaudhary, Durgesh
AU  - Chaudhary D
AD  - Neuroscience Institute, Geisinger Health System, Danville, PA, USA.
FAU - Misra, Debdipto
AU  - Misra D
AD  - Division of Informatics, Geisinger Health System, Danville, PA, USA.
FAU - Avula, Venkatesh
AU  - Avula V
AD  - Department of Molecular and Functional Genomics, Geisinger Health System,
      Danville, PA, USA.
FAU - Mathrawala, Dhruv
AU  - Mathrawala D
AD  - Division of Informatics, Geisinger Health System, Danville, PA, USA.
FAU - Kraus, Chadd
AU  - Kraus C
AD  - Department of Emergency Medicine, Geisinger Health System, Danville, PA, USA.
FAU - Marshall, Kyle A
AU  - Marshall KA
AD  - Department of Emergency Medicine, Geisinger Health System, Danville, PA, USA.
FAU - Chaudhary, Nayan
AU  - Chaudhary N
AD  - Genentech/Roche inc., South San Francisco, CA, USA.
FAU - Li, Xiao
AU  - Li X
AD  - Genentech/Roche inc., South San Francisco, CA, USA.
FAU - Schirmer, Clemens M
AU  - Schirmer CM
AD  - Neuroscience Institute, Geisinger Health System, Danville, PA, USA.
FAU - Scalzo, Fabien
AU  - Scalzo F
AD  - Department of Neurology, University of California, Los Angeles, CA, USA.
FAU - Li, Jiang
AU  - Li J
AD  - Department of Molecular and Functional Genomics, Geisinger Health System,
      Danville, PA, USA.
FAU - Zand, Ramin
AU  - Zand R
AUID- ORCID: https://orcid.org/0000-0002-9477-0094
AD  - Neuroscience Institute, Geisinger Health System, Stroke Program, Geisinger
      Northeast Region, GRA Stroke Task Force, American Heart Association, Department
      of Neurosciences, 100 N Academy Ave, Danville, PA 17822-2101, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC7453441
OTO - NOTNLM
OT  - acute stroke
OT  - artificial intelligence
OT  - cerebrovascular disease/stroke
OT  - computer aided diagnosis
OT  - ischemic stroke
OT  - machine learning
OT  - stroke diagnosis
OT  - stroke in emergency department
COIS- Conflict of interest statement: The authors declare no competing interests. NC
      and XL are Genentech/Roche paid employees. Genentech/Roche had no role in study
      design, data collection, and interpretation, or the decision to submit the work
      for publication.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:51
PHST- 2020/05/21 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/09/14 05:51 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1177/1756286420938962 [doi]
AID - 10.1177_1756286420938962 [pii]
PST - epublish
SO  - Ther Adv Neurol Disord. 2020 Aug 25;13:1756286420938962. doi:
      10.1177/1756286420938962. eCollection 2020.


PMID- 32922337
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Pregnant Agencies: Movement and Participation in Maternal-Fetal Interactions.
PG  - 1977
LID - 10.3389/fpsyg.2020.01977 [doi]
AB  - Pregnancy presents some interesting challenges for the philosophy of embodied
      cognition. Mother and fetus are generally considered to be passive during
      pregnancy, both individually and in their relation. In this paper, we use the
      enactive operational concepts of autonomy, agency, individuation, and
      participation to examine the relation between mother and fetus in utero. Based on
      biological, physiological, and phenomenological research, we explore the
      emergence of agentive capacities in embryo and fetus, as well as how maternal
      agency changes as pregnancy advances. We show that qualitatively different kinds 
      of agency have their beginnings already in utero, and to what extent fetal and
      maternal movement modulate affectivity and individuation in pregnancy. We thus
      propose that mother and fetus are both agents who participate in pregnancy.
      Pregnancy then emerges as a relational developmental organization that anchors
      and holds its developing participants. We end the paper with reflections on
      ethical implications of this proposal, and suggestions for future research.
CI  - Copyright (c) 2020 Martinez Quintero and De Jaegher.
FAU - Quintero, Alejandra Martinez
AU  - Quintero AM
AD  - IAS-Research Centre for Life, Mind and Society, Department of Philosophy,
      University of the Basque Country, Bilbao, Spain.
FAU - De Jaegher, Hanne
AU  - De Jaegher H
AD  - IAS-Research Centre for Life, Mind and Society, Department of Philosophy,
      University of the Basque Country, Bilbao, Spain.
AD  - ChatLab, School of Psychology, University of Sussex, Brighton, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7456916
OTO - NOTNLM
OT  - embodiment
OT  - enaction
OT  - participation
OT  - phenomenology of pregnancy
OT  - pregnancy
OT  - sensorimotor agency
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:50
PHST- 2019/12/01 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/09/14 05:50 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.3389/fpsyg.2020.01977 [doi]
PST - epublish
SO  - Front Psychol. 2020 Aug 14;11:1977. doi: 10.3389/fpsyg.2020.01977. eCollection
      2020.


PMID- 32922270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1662-5153 (Print)
IS  - 1662-5153 (Linking)
VI  - 14
DP  - 2020
TI  - A New 3-Day Standardized Eyeblink Conditioning Protocol to Assess Extinction
      Learning From Infancy to Adulthood.
PG  - 135
LID - 10.3389/fnbeh.2020.00135 [doi]
AB  - Associative learning can be observed from the neonatal period onward, providing
      opportunities to examine changes in basic learning and memory abilities. One
      method that is suitable to study associative learning is classical eyeblink
      conditioning (EBC) which is dependent on the cerebellum. Extinction learning can 
      be systematically investigated in this paradigm by varying the context during
      learning and extinction. Because of methodological difficulties and ethical
      challenges, no studies have compared extinction learning using EBC across human
      development. Our goal was to test feasibility of a 3-day delay EBC paradigm that 
      can be used from infancy to adulthood. Acceptance/safety was tested especially
      for infancy by investigating attrition rates and parental report on infant
      wellbeing. On a paradigm side, we tested if the paradigm leads to successful
      acquisition and extinction. An air puff served as unconditional stimulus (US) and
      a tone as conditional stimulus (CS). On day 1 during acquisition, participants
      received 36 US-CS pairings in context A. On day 2, participants received 12
      acquisition trials in context A to consolidate association learning, followed by 
      48 extinction trials (tone alone presentations) in context B. Renewal was
      assessed on day 3 and incorporated 12 CS alone trials presented in both the
      acquisition context and the extinction context. Eyeblink responses were
      videotaped and coded offline. The protocol was tested with 12-36-months-old
      infants (N = 72), adolescents (N = 8), and adults (N = 8). Concerning the
      acceptance/safety side, attrition ranged from 21 to 58% in infant samples due to 
      the complex preparation of the children for the paradigm. However, attrition is
      equal to or lower than other infant learning paradigms. Parents of infant samples
      were very interested in the paradigm and reported low levels of infant stress,
      exhaustion, and negative feelings during the sessions. Data quality was very
      high, and no participant had to be excluded because of insufficient data.
      Concerning the paradigm side, participants showed successful acquisition and
      extinction as a group. The procedure is ethically sound, feasible, tolerated by
      many infants, and acceptable among parents. The data show successful acquisition 
      and extinction rates, making the paradigm a valuable tool for investigating
      developmental changes in extinction learning over the lifespan.
CI  - Copyright (c) 2020 Konrad, Adolph, Herbert, Neuhoff, Mohr, Jagusch-Poirier,
      Seehagen, Weigelt and Schneider.
FAU - Konrad, Carolin
AU  - Konrad C
AD  - Faculty of Psychology, Clinical Child and Adolescent Psychology, Mental Health
      Research and Treatment Center, Ruhr University Bochum, Bochum, Germany.
FAU - Adolph, Dirk
AU  - Adolph D
AD  - Faculty of Psychology, Clinical Child and Adolescent Psychology, Mental Health
      Research and Treatment Center, Ruhr University Bochum, Bochum, Germany.
FAU - Herbert, Jane S
AU  - Herbert JS
AD  - Wollongong Infant Learning Lab, School of Psychology and Early Start, University 
      of Wollongong, Wollongong, NSW, Australia.
FAU - Neuhoff, Lina
AU  - Neuhoff L
AD  - Faculty of Psychology, Clinical Child and Adolescent Psychology, Mental Health
      Research and Treatment Center, Ruhr University Bochum, Bochum, Germany.
FAU - Mohr, Cornelia
AU  - Mohr C
AD  - Abteilung fur Kinderschutz, Vestische Kinder- und Jugendklinik Datteln,
      Universitat Witten/Herdecke, Datteln, Germany.
FAU - Jagusch-Poirier, Julie
AU  - Jagusch-Poirier J
AD  - Vision, Visual Impairments & Blindness, Faculty of Rehabilitation Sciences,
      Technical University, Dortmund University, Dortmund, Germany.
FAU - Seehagen, Sabine
AU  - Seehagen S
AD  - Developmental Psychology, Faculty of Psychology, Ruhr University Bochum, Bochum, 
      Germany.
FAU - Weigelt, Sarah
AU  - Weigelt S
AD  - Vision, Visual Impairments & Blindness, Faculty of Rehabilitation Sciences,
      Technical University, Dortmund University, Dortmund, Germany.
FAU - Schneider, Silvia
AU  - Schneider S
AD  - Faculty of Psychology, Clinical Child and Adolescent Psychology, Mental Health
      Research and Treatment Center, Ruhr University Bochum, Bochum, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Switzerland
TA  - Front Behav Neurosci
JT  - Frontiers in behavioral neuroscience
JID - 101477952
PMC - PMC7457038
OTO - NOTNLM
OT  - associative learning
OT  - conditioning
OT  - extinction
OT  - eyeblink conditioning
OT  - infancy
OT  - renewal
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:50
PHST- 2020/05/28 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/09/14 05:50 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.3389/fnbeh.2020.00135 [doi]
PST - epublish
SO  - Front Behav Neurosci. 2020 Aug 14;14:135. doi: 10.3389/fnbeh.2020.00135.
      eCollection 2020.


PMID- 32922135
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1319-0164 (Print)
IS  - 1319-0164 (Linking)
VI  - 28
IP  - 9
DP  - 2020 Sep
TI  - Translation and validation of the Arabic version of the General Medication
      Adherence Scale (GMAS) in Saudi patients with chronic illnesses.
PG  - 1055-1061
LID - 10.1016/j.jsps.2020.07.005 [doi]
AB  - PURPOSE: The study aimed to translate and validate the Arabic version of General 
      Medication Adherence Scale (GMAS) in Saudi patients with chronic diseases.
      METHODS: A multi-center cross sectional study was conducted for a month in
      out-patient wards of hospitals in Khobar, Dammam, Makkah, and Madinah, Saudi
      Arabia. Patients were randomly selected from a registered patient pools at
      hospitals and the item-subject ratio was kept at 1:20. The tool was assessed for 
      factorial, construct, convergent, known group and predictive validities as well
      as, reliability and internal consistency of scale were also evaluated.
      Sensitivity, specificity, and accuracy were also evaluated. Data were analyzed
      using SPSS v24 and MedCalc v19.2. The study was approved by concerned ethics
      committees (IRB-129-25/6/1439) and (IRB-2019-05-002). RESULTS: A total of 282
      responses were received. The values for normed fit index (NFI), comparative fit
      index (CFI), Tucker Lewis index (TLI) and incremental fit index (IFI) were 0.960,
      0.979, 0.954 and 0.980. All values were >0.95. The value for root mean square
      error of approximation (RMSEA) was 0.059, i.e., <0.06. Hence, factorial validity 
      was established. The average factor loading of the scale was 0.725, i.e., >0.7,
      that established convergent validity. Known group validity was established by
      obtaining significant p-value <0.05, for the associations based on hypotheses.
      Cronbach's alpha was 0.865, i.e., >0.7. Predictive validity was established by
      evaluating odds ratios (OR) of demographic factors with adherence score using
      logistic regression. Sensitivity was 78.16%, specificity was 76.85% and, accuracy
      of the tool was 77.66%, i.e., >70%. CONCLUSION: The Arabic version of GMAS
      achieved all required statistical parameters and was validated in Saudi patients 
      with chronic diseases.
CI  - (c) 2020 The Authors.
FAU - Naqvi, Atta Abbas
AU  - Naqvi AA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Mahmoud, Mansour Adam
AU  - Mahmoud MA
AD  - Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah
      University, Al-Madinah Al-Munawarah, Saudi Arabia.
FAU - AlShayban, Dhfer Mahdi
AU  - AlShayban DM
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Alharbi, Fawaz Abdullah
AU  - Alharbi FA
AD  - Drug Information and Poison Center, Alansar Hospital, Al-Madinah Al-Munawarah,
      Saudi Arabia.
FAU - Alolayan, Sultan Othman
AU  - Alolayan SO
AD  - Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah
      University, Al-Madinah Al-Munawarah, Saudi Arabia.
FAU - Althagfan, Sultan
AU  - Althagfan S
AD  - Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah
      University, Al-Madinah Al-Munawarah, Saudi Arabia.
FAU - Iqbal, Muhammad Shahid
AU  - Iqbal MS
AD  - Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz
      University, Alkharj, Saudi Arabia.
FAU - Farooqui, Maryam
AU  - Farooqui M
AD  - Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, 
      Qassim, Saudi Arabia.
FAU - Ishaqui, Azfar Athar
AU  - Ishaqui AA
AD  - Department of Pharmacy, King Abdulaziz Hospital, National Guard Health Authority,
      Alahsa, Saudi Arabia.
FAU - Elrggal, Mahmoud E
AU  - Elrggal ME
AD  - Pharmaceutical Research Center, Deanship of Scientific Research, Umm Al Qura
      University, Makkah, Saudi Arabia.
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Haseeb, Abdul
AU  - Haseeb A
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Hassali, Mohamed Azmi
AU  - Hassali MA
AD  - Discipline of Social and Administrative Pharmacy, School of Pharmaceutical
      Sciences, Universiti Sains Malaysia, Penang, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi
      Pharmaceutical Society
JID - 9705695
PMC - PMC7474165
OTO - NOTNLM
OT  - Chronic illness
OT  - Medication adherence
OT  - Medication persistence
OT  - Patient compliance
OT  - Saudi Arabia
OT  - Validation studies
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper. No funding was obtained for this study.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:49
PHST- 2020/06/06 00:00 [received]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/09/14 05:49 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1016/j.jsps.2020.07.005 [doi]
AID - S1319-0164(20)30155-9 [pii]
PST - ppublish
SO  - Saudi Pharm J. 2020 Sep;28(9):1055-1061. doi: 10.1016/j.jsps.2020.07.005. Epub
      2020 Jul 31.


PMID- 32922014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1176-6328 (Print)
IS  - 1176-6328 (Linking)
VI  - 16
DP  - 2020
TI  - Influence of Parenting Quality and Neuroticism on Perceived Job Stressors and
      Psychological and Physical Stress Response in Adult Workers from the Community.
PG  - 2007-2015
LID - 10.2147/NDT.S260624 [doi]
AB  - BACKGROUND: The complex interaction between parenting styles, job stressors, and 
      the stress response has not been clarified to date. We hypothesized that
      neuroticism acts as a mediator in the effects of parenting quality on perceived
      job stressors and the psychological and physical stress response (PPSR), and
      tested this hypothesis using covariance structure analysis. SUBJECTS AND METHODS:
      We conducted research between April 2017 and April 2018 on 597 adult from the
      community, and 69 subjects were excluded owing to missing data or nonworkers.
      Finally, a total of 528 participants were analyzed using the following
      self-administered questionnaires: the Parental Bonding Instrument, the shortened 
      Eysenck Personality Questionnaire-Revised, and the Brief Job Stress Questionnaire
      (BJSQ). The data were analyzed by single regression analyses and covariance
      structure analyses. Job stress was assessed by the BJSQ and 2 subscales, ie,
      perceived job stressors and the PPSR. This study was approved by the Ethics
      Committee of Tokyo Medical University. RESULTS: On covariance structure analysis,
      high parental overprotection was associated with high neuroticism and high PPSR
      directly, but had no significant effect on perceived job stressors. High parental
      overprotection was associated with high-perceived job stressors and the high PPSR
      indirectly through enhanced neuroticism. High parental overprotection was also
      associated with the high PPSR indirectly through 2 combined paths of neuroticism 
      and perceived job stressors. This model accounted for 40% of the variability of
      the PPSR. On the other hand, parental care had opposite effects to parental
      overprotection, and this model of parental care accounted for 39% of the
      variability of PPSR. The model fits of the 2 models were good. CONCLUSION: Our
      results suggest that the quality of parenting in childhood is associated with
      perceived job stressors and the PPSR indirectly through neuroticism.
CI  - (c) 2020 Seki et al.
FAU - Seki, Tomoteru
AU  - Seki T
AUID- ORCID: 0000-0003-2593-7118
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
AD  - Fuji Psychosomatic Rehabilitation Institute Hospital, Fujinomiya, Shizuoka
      418-0035, Japan.
FAU - Shimura, Akiyoshi
AU  - Shimura A
AUID- ORCID: 0000-0003-0806-4423
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
FAU - Miyama, Hitoshi
AU  - Miyama H
AUID- ORCID: 0000-0002-5361-1919
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
FAU - Furuichi, Wataru
AU  - Furuichi W
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
FAU - Ono, Kotaro
AU  - Ono K
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
FAU - Masuya, Jiro
AU  - Masuya J
AUID- ORCID: 0000-0003-1220-9592
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
FAU - Odagiri, Yuko
AU  - Odagiri Y
AUID- ORCID: 0000-0002-7603-4800
AD  - Department of Preventive Medicine and Public Health, Tokyo Medical University,
      Shinjuku-ku, Tokyo 160-8402, Japan.
FAU - Inoue, Shigeru
AU  - Inoue S
AUID- ORCID: 0000-0003-1931-2613
AD  - Department of Preventive Medicine and Public Health, Tokyo Medical University,
      Shinjuku-ku, Tokyo 160-8402, Japan.
FAU - Inoue, Takeshi
AU  - Inoue T
AUID- ORCID: 0000-0001-5248-1289
AD  - Department of Psychiatry, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC7457739
OTO - NOTNLM
OT  - covariance structure analysis
OT  - job stress
OT  - neuroticism
OT  - parental care
OT  - parental overprotection
OT  - structural equation model
COIS- Akiyoshi Shimura has received fees from Meiji Seika Pharma, Yoshitomi Yakuhin,
      Tanabe Mitsubishi Pharma, and Eisai outside of the submitted work and is a
      stockholder of Children and Future Co., Ltd. Jiro Masuya has received personal
      compensation from Otsuka Pharmaceutical, Eli Lilly, Astellas, and Meiji Yasuda
      Mental Health Foundation, and grants from Pfizer. Takeshi Inoue has received
      personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly,
      Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and 
      Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; and grants
      and personal fees from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma,
      Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma,
      and Meiji Seika Pharma; and is a member of the advisory boards of Pfizer,
      Novartis Pharma, and Mitsubishi Tanabe Pharma. The other authors declare that
      they have no actual or potential conflicts of interest.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/09/14 05:48 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.2147/NDT.S260624 [doi]
AID - 260624 [pii]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2020 Aug 24;16:2007-2015. doi: 10.2147/NDT.S260624.
      eCollection 2020.


PMID- 32921973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210715
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Jun 5
TI  - "Are we getting the biometric bioethics right?" - the use of biometrics within
      the healthcare system in Malawi.
PG  - 67-80
LID - 10.1080/11287462.2020.1773063 [doi]
AB  - Biometrics is the science of establishing the identity of an individual based on 
      their physical attributes. Ethical concerns surrounding the appropriate use of
      biometrics have been raised, especially in resource-poor settings. A qualitative 
      investigation was conducted to explore biometrics clients (n = 14), implementers 
      (n = 12) and policy makers as well as bioethicists (n = 4) perceptions of the
      ethical aspects of implementing biometrics within the healthcare system in
      Malawi. Informed use, privacy and confidentiality as well as perceptions of
      benefits and harms were identified as major issues in the application of
      biometrics. Implementation of biometrics within the healthcare system in Malawi
      poses a range of potential ethical issues and practical challenges that impact on
      equitable uptake. There is a need for more research to explore the benefits and
      harms of biometrics in practice. Improved community engagement and sensitization 
      should be a required component of biometrics introduction in Malawi.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Mwapasa, Mphatso
AU  - Mwapasa M
AUID- ORCID: https://orcid.org/0000-0001-8402-6133
AD  - College of Medicine, University of Malawi, Blantyre, Malawi.
FAU - Gooding, Kate
AU  - Gooding K
AUID- ORCID: https://orcid.org/0000-0003-4926-0287
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), Blantyre,
      Malawi.
FAU - Kumwenda, Moses
AU  - Kumwenda M
AUID- ORCID: https://orcid.org/0000-0003-3091-7330
AD  - College of Medicine, University of Malawi, Blantyre, Malawi.
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), Blantyre,
      Malawi.
FAU - Nliwasa, Marriott
AU  - Nliwasa M
AUID- ORCID: https://orcid.org/0000-0002-3100-5512
AD  - College of Medicine, University of Malawi, Blantyre, Malawi.
FAU - Kaswaswa, Kruger
AU  - Kaswaswa K
AD  - College of Medicine, University of Malawi, Blantyre, Malawi.
FAU - Sambakunsi, Rodrick
AU  - Sambakunsi R
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), Blantyre,
      Malawi.
FAU - Parker, Michael
AU  - Parker M
AUID- ORCID: https://orcid.org/0000-0002-7054-4711
AD  - The Ethox Centre, University of Oxford, Oxford, UK.
FAU - Bull, Susan
AU  - Bull S
AD  - The Ethox Centre, University of Oxford, Oxford, UK.
FAU - Desmond, Nicola
AU  - Desmond N
AUID- ORCID: https://orcid.org/0000-0002-2874-8569
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), Blantyre,
      Malawi.
AD  - Liverpool School of Tropical Medicine, Liverpool, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7448861
OTO - NOTNLM
OT  - Biometrics
OT  - Malawi
OT  - bioethics
OT  - healthcare system
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/09/14 05:48 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1080/11287462.2020.1773063 [doi]
AID - 1773063 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Jun 5;31(1):67-80. doi: 10.1080/11287462.2020.1773063.


PMID- 32921972
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Jun 5
TI  - HIV prevention clinical trials' community engagement guidelines: inequality, and 
      ethical conflicts.
PG  - 47-66
LID - 10.1080/11287462.2020.1773061 [doi]
AB  - In 2004 and 2005, the first clinical trials were launched to investigate the use 
      of tenofovir for HIV prevention in Cambodia,Cameroon, Nigeria and Thailand.
      Controversies erupted over the ethical integrity of the research protocol. We
      reflect on the events that ledto the controversies and identified that scientific
      and ethical concerns raised by members of local communities at each of these
      sites wereerased by trialists, causing crisis that led to premature shut down the
      early PrEP trials. In the aftermath of these trials, the World
      HealthOrganisation, UNAIDS, and AVAC developed ethics guidelines intended to
      recognize the concerns as authentic, and developed guidelines toimprove
      researchers' engagement of communities in biomedical HIV prevention trial design 
      and implementation. Our findings suggest thatthe ethics guidelines are limited in
      its ability to address power inequalities that leads to voice erasures and
      non-recognition of localcompetencies. Rather the ethical documents enabled
      trialists to gain a new sense of authority through the interpretations of ethical
      researchconduct enabling trialists regain power that can further entrench
      inequality and voice erasures. To address concerns with what seems anintractable 
      problem, we suggested models of engagement for off-shored research may be the
      option.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Folayan, Morenike O
AU  - Folayan MO
AUID- ORCID: https://orcid.org/0000-0002-9008-7730
AD  - New HIV Vaccine and Microbicide Advocacy Society, Nigeria.
AD  - Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria.
FAU - Peterson, Kristin
AU  - Peterson K
AD  - Department of Anthropology, University of California, Irvine, USA.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7448920
OTO - NOTNLM
OT  - Cambodia
OT  - Cameroon
OT  - HIV
OT  - HIV prevention
OT  - Malawi
OT  - Nigeria
OT  - PrEP
OT  - clinical trials
OT  - community engagement
OT  - ethics
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/09/14 05:48 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1080/11287462.2020.1773061 [doi]
AID - 1773061 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Jun 5;31(1):47-66. doi: 10.1080/11287462.2020.1773061.


PMID- 32921931
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0959-6526 (Print)
IS  - 0959-6526 (Linking)
VI  - 275
DP  - 2020 Dec 1
TI  - Application of industry 4.0 technologies in SMEs for ethical and sustainable
      operations: Analysis of challenges.
PG  - 124063
LID - 10.1016/j.jclepro.2020.124063 [doi]
AB  - In the era of Industry 4.0 and circular economy, small and medium enterprises
      (SMEs) are under huge pressure to make their manufacturing operations ethical and
      sustainable. Business with ethical and sustainable operations has become the need
      of the day in the present environment of Industry 4.0 and circular economy. It
      has been observed that the application of Industry 4.0 technologies may help in
      achieving the goal of ethical and sustainable operations. Although a lot of
      research has been done in context to larger enterprises, limited research is
      available on the application of Industry 4.0 technologies in SMEs for ethical and
      sustainable operations. The espousal of Industry 4.0 technologies is a
      challenging task for SMEs due to various operational and financial constraints.
      The problem is more acute, specifically in context to developing countries like
      India. Keeping in mind the role of technologies in ethical business and circular 
      economy, we have identified fifteen challenges, impacting the application of
      Industry 4.0 technologies in SMEs. A questionnaire was designed for collecting
      the response from industry and academic experts. On the collected data, the
      DEMATEL approach has been applied to check the degree of influence and
      interrelationship among challenges. It has also helped in the categorization of
      factors as cause and effect. Sensitivity analysis is also performed to validate
      the results obtained from the DEMATEL approach. Authors have observed that lack
      of motivation from partners and customers on the application of I4.0 technologies
      is the leading challenge. Fear of failure of I4.0 technologies is the main effect
      group challenge. The findings of the study will help SMEs in formulating
      strategies for implementing Industry 4.0 technologies for ethical and sustainable
      business processes.
CI  - Crown Copyright (c) 2020 Published by Elsevier Ltd. All rights reserved.
FAU - Kumar, Ravinder
AU  - Kumar R
AD  - Mechanical Engineering Department, Amity University, Noida, India.
FAU - Singh, Rajesh Kr
AU  - Singh RK
AD  - Management Development Institute Gurgaon, India.
FAU - Dwivedi, Yogesh Kr
AU  - Dwivedi YK
AD  - School of Management, Swansea University, Wales, UK.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Netherlands
TA  - J Clean Prod
JT  - Journal of cleaner production
JID - 101538287
PMC - PMC7477609
OTO - NOTNLM
OT  - Challenges
OT  - Circular economy
OT  - DEMATEL
OT  - Ethical and sustainable business
OT  - Industry 4.0
OT  - SMEs
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/03/09 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
PHST- 2020/09/14 05:48 [entrez]
AID - 10.1016/j.jclepro.2020.124063 [doi]
AID - 124063 [pii]
PST - ppublish
SO  - J Clean Prod. 2020 Dec 1;275:124063. doi: 10.1016/j.jclepro.2020.124063. Epub
      2020 Sep 8.


PMID- 32921928
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 0947-8965 (Print)
IS  - 0947-8965 (Linking)
VI  - 26
IP  - 11
DP  - 2020
TI  - [Ethics, communication and interdisciplinary collaboration-by law?!]
PG  - 1010-1018
LID - 10.1007/s00761-020-00831-5 [doi]
AB  - CONTEXT: The coronavirus pandemic of recent months has highlighted the fact that 
      death is still a taboo regardless of the progress that has been made in
      palliative care. The concept of advance care planning is still not adequately
      practiced by individuals yet and we do not know enough about what is important
      for people in the last phase of their lives. CONCLUSIONS: Nurses can play an
      important in discussions about values and the ideas of what is important when
      death is getting closer. In Germany, there is a law ( section sign 132g Abs. 3
      Sozialgesetzbuch V) that makes it possible to receive remuneration for these
      conversations. Hopefully, this is just the first of many steps to further develop
      ethics, communication and interdisciplinary collaboration.
CI  - (c) Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020.
FAU - Gattermann, J
AU  - Gattermann J
AD  - Leitung Fort- und Weiterbildung/IBF, Bildungsakademie Gesundheit Nord gGmbH,
      Standort Klinikum Bremen-Mitte, St.-Jurgen-Str. 1, 28177 Bremen,
      Deutschland.grid.419807.30000 0004 0636 7065
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Ethik, Kommunikation und interdisziplinare Zusammenarbeit - per Gesetz?!
DEP - 20200907
PL  - Germany
TA  - Onkologe (Berl)
JT  - Der Onkologe : Organ der Deutschen Krebsgesellschaft e.V
JID - 9815977
PMC - PMC7476243
OTO - NOTNLM
OT  - Advance care planning
OT  - Attitude to death
OT  - Hospice and palliative care nursing
OT  - Resuscitation orders
OT  - Withholding treatment
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
PHST- 2020/09/14 05:48 [entrez]
AID - 10.1007/s00761-020-00831-5 [doi]
AID - 831 [pii]
PST - ppublish
SO  - Onkologe (Berl). 2020;26(11):1010-1018. doi: 10.1007/s00761-020-00831-5. Epub
      2020 Sep 7.


PMID- 32921895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0360-1315 (Print)
IS  - 0360-1315 (Linking)
VI  - 159
DP  - 2020 Dec
TI  - A systematic review of research on online teaching and learning from 2009 to
      2018.
PG  - 104009
LID - 10.1016/j.compedu.2020.104009 [doi]
AB  - Systematic reviews were conducted in the nineties and early 2000's on online
      learning research. However, there is no review examining the broader aspect of
      research themes in online learning in the last decade. This systematic review
      addresses this gap by examining 619 research articles on online learning
      published in twelve journals in the last decade. These studies were examined for 
      publication trends and patterns, research themes, research methods, and research 
      settings and compared with the research themes from the previous decades. While
      there has been a slight decrease in the number of studies on online learning in
      2015 and 2016, it has then continued to increase in 2017 and 2018. The majority
      of the studies were quantitative in nature and were examined in higher education.
      Online learning research was categorized into twelve themes and a framework
      across learner, course and instructor, and organizational levels was developed.
      Online learner characteristics and online engagement were examined in a high
      number of studies and were consistent with three of the prior systematic reviews.
      However, there is still a need for more research on organization level topics
      such as leadership, policy, and management and access, culture, equity,
      inclusion, and ethics and also on online instructor characteristics.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Martin, Florence
AU  - Martin F
AD  - Educational Leadership, University of North Carolina Charlotte, 9201 University
      City Blvd, Charlotte, NC, 28223, USA.
FAU - Sun, Ting
AU  - Sun T
AD  - Educational Leadership, University of North Carolina Charlotte, 9201 University
      City Blvd, Charlotte, NC, 28223, USA.
FAU - Westine, Carl D
AU  - Westine CD
AD  - Educational Leadership, University of North Carolina Charlotte, 9201 University
      City Blvd, Charlotte, NC, 28223, USA.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - United States
TA  - Comput Educ
JT  - Computers & education
JID - 101511025
PMC - PMC7480742
OTO - NOTNLM
OT  - Distance education
OT  - Online Learning Research
OT  - Research Themes
OT  - Systematic Review
OT  - online teaching and learning
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/04/10 00:00 [received]
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/14 05:48 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1016/j.compedu.2020.104009 [doi]
AID - S0360-1315(20)30207-4 [pii]
AID - 104009 [pii]
PST - ppublish
SO  - Comput Educ. 2020 Dec;159:104009. doi: 10.1016/j.compedu.2020.104009. Epub 2020
      Sep 9.


PMID- 32921851
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201110
IS  - 0160-791X (Print)
IS  - 0160-791X (Linking)
VI  - 63
DP  - 2020 Nov
TI  - The foundations of a policy for the use of social robots in care.
PG  - 101383
LID - 10.1016/j.techsoc.2020.101383 [doi]
AB  - Should we deploy social robots in care settings? This question, asked from a
      policy standpoint, requires that we understand the potential benefits and
      downsides of deploying social robots in care situations. Potential benefits could
      include increased efficiency, increased welfare, physiological and psychological 
      benefits, and experienced satisfaction. There are, however, important objections 
      to the use of social robots in care. These include the possibility that relations
      with robots can potentially displace human contact, that these relations could be
      harmful, that robot care is undignified and disrespectful, and that social robots
      are deceptive. I propose a framework for evaluating all these arguments in terms 
      of three aspects of care: structure, process, and outcome. I then highlight the
      main ethical considerations that have to be made in order to untangle the web of 
      pros and cons of social robots in care as these pros and cons are related the
      trade-offs regarding quantity and quality of care, process and outcome, and
      objective and subjective outcomes.
CI  - (c) 2020 The Author.
FAU - Saetra, Henrik Skaug
AU  - Saetra HS
AD  - Ostfold University College, Remmen, 1757, Halden, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200906
PL  - United States
TA  - Technol Soc
JT  - Technology in society
JID - 100972148
PMC - PMC7474838
OTO - NOTNLM
OT  - Care
OT  - Ethics
OT  - Policy
OT  - Social robots
OT  - Utilitarianism
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:48
PHST- 2020/04/07 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/09/14 05:48 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.1016/j.techsoc.2020.101383 [doi]
AID - S0160-791X(20)30326-2 [pii]
AID - 101383 [pii]
PST - ppublish
SO  - Technol Soc. 2020 Nov;63:101383. doi: 10.1016/j.techsoc.2020.101383. Epub 2020
      Sep 6.


PMID- 32921825
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0034-6233 (Print)
IS  - 0034-6233 (Linking)
VI  - 58
IP  - 4
DP  - 2020
TI  - Subjective sleep disturbances at the time of diagnosis in patients with
      polymyalgia rheumatica and in patients with seronegative elderly-onset rheumatoid
      arthritis. A pilot study.
PG  - 196-201
LID - 10.5114/reum.2020.98430 [doi]
AB  - OBJECTIVES: To investigate subjective sleep disturbances in patients with
      recent-onset polymyalgia rheumatica (PMR) and in patients with recent-onset
      seronegative elderly-onset rheumatoid arthritis (SEORA). MATERIAL AND METHODS:
      The study involved patients consecutively referred to two outpatient clinics from
      January to June 2018, with a diagnosis of PMR according to 2012 European League
      Against Rheumatism and American College of Rheumatology provisional criteria, and
      patients with a diagnosis of SEORA according to 1987 American Rheumatism
      Association criteria + age + absence of rheumatoid factor and anti-citrullinated 
      peptide antibodies. All patients were naive to glucocorticoid (GC) therapy. After
      informed consent, we asked the patients to fill out a questionnaire including the
      Medical Outcomes Study - Sleep Scale (MOS-SS), pain Visual Analogic Scale (VAS), 
      Cumulative Illness Rating Scale (CIRS), Neuropsychiatric Inventory (NPI), and how
      many minutes their morning stiffness (MS) lasted, at baseline and after 1 (T1)
      and 12 (T2) months. Differences between groups were calculated with the t-test;
      all p-values were two-sided and p < 0.05 was used to determine statistical
      significance. The study was approved by the local ethics committee and carried
      out in accordance with the Helsinki Declaration. RESULTS: The MOS-SS scores and
      MS duration were the only variables to show at T0 a significant difference
      between the two groups. In particular, MOS-SS scores were 47.6 +/-8.4 (PMR) and
      28.26 +/-12.4 (SEORA), with p-values = 0.000. The MS duration was 90 +/-9.9
      minutes and 45 +/-5.5 minutes, with p-value = 0.000. At T1 and T2, MOS-SS scores 
      and MS duration decreased in the two groups, and no significant differences were 
      found. CONCLUSIONS: The study suggests that the assessment of subjective sleep
      disturbances can be useful in the differential diagnosis between recent-onset PMR
      and SEORA.
CI  - Copyright (c) 2020 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w
      Warszawie.
FAU - Manzo, Ciro
AU  - Manzo C
AD  - Internal and Geriatric Medicine Department, Azienda Sanitaria Locale Napoli 3
      Sud, Rheumatologic Outpatient Clinic Hospital "Mariano Lauro", Sant'Angello,
      Italy.
FAU - Castagna, Alberto
AU  - Castagna A
AD  - Geriatric Medicine Department Azienda Sanitaria Provinciale Catanzaro, Fragility 
      Outpatient Clinic, Casa della Salute di Chiaravalle Centrale, Catanzaro, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Poland
TA  - Reumatologia
JT  - Reumatologia
JID - 20130190R
PMC - PMC7477470
OTO - NOTNLM
OT  - elderly-onset seronegative rheumatoid arthritis
OT  - polymyalgia rheumatica
OT  - subjective sleep disturbances
COIS- The authors declare no conflict of interest.
EDAT- 2020/09/15 06:00
MHDA- 2020/09/15 06:01
CRDT- 2020/09/14 05:47
PHST- 2020/03/28 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/09/14 05:47 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/15 06:01 [medline]
AID - 10.5114/reum.2020.98430 [doi]
AID - 41648 [pii]
PST - ppublish
SO  - Reumatologia. 2020;58(4):196-201. doi: 10.5114/reum.2020.98430. Epub 2020 Aug 31.


PMID- 32921744
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20201218
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jul 28
TI  - The Telematic solutions in plastic surgery during COVID-19 pandemic.
PG  - ahead of print
LID - 10.23750/abm.v91i3.10291 [doi]
AB  - During the COVID-19 pandemic, surgical elective procedures were stopped in our
      plastic surgery unit. Limitations for consultations and for follow-up of previous
      surgical procedures were imposed in order to minimize the risk of contagion in
      waiting rooms and outpatient clinics. We have identified telemedicine as an
      alternative way to follow patients during the lockdown. Nevertheless, we have
      experienced different difficulties. We have not had the possibility to use a
      secure teleconferencing software. In our unit we had not technological devices.
      Surgeons in our department were not able to use remote video technology for
      patient management. Guidelines for an appropriate selection of patients which
      could be served via telemedicine had to be created. Telemedicine must be
      regulated by healthcare organizations for legal, ethical, medico-legal and risk
      management aspects. Even if we have experienced an important need to use
      telematic solutions during the COVID-19 lockdown, liability and risk management
      issues has greatly limited this possibility in our unit. The need of telemedicine
      in the time of COVID-19 pandemic has encouraged us to implement future virtual
      encounters in order to reduce unnecessary in-person visits by taking into
      consideration all legal, ethical and medico-legal aspects.
FAU - De Santis, Giorgio
AU  - De Santis G
AD  - Division of Plastic Surgery - Modena University Hospital.
      giorgio.desantis@unimore.it.
FAU - Palladino, Teresa
AU  - Palladino T
AD  - Division of Plastic Surgery - Modena University Hospital. tepalladino@gmail.com.
FAU - Leti Acciaro, Andrea
AU  - Leti Acciaro A
AD  - Division of Hand Surgery and Microsurgery - Modena University Hospital.
      andrealetiacciaro@libero.it.
FAU - Starnoni, Marta
AU  - Starnoni M
AD  - Division of Plastic Surgery, Modena University Hospital. martastarn@gmail.com.
LA  - eng
PT  - Letter
DEP - 20200728
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/transmission
MH  - Disease Transmission, Infectious/*prevention & control
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/transmission
MH  - Reconstructive Surgical Procedures/*methods
MH  - Risk Management/*methods
MH  - SARS-CoV-2
MH  - Surgery, Plastic/*organization & administration
MH  - Telemedicine/*methods
PMC - PMC7716977
EDAT- 2020/09/15 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/14 05:47
PHST- 2020/07/20 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/09/14 05:47 [entrez]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.23750/abm.v91i3.10291 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Jul 28;91(3):ahead of print. doi: 10.23750/abm.v91i3.10291.


PMID- 32921623
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210920
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Oct
TI  - [Clinical research in rare diseases: new challenges, opportunities and ethical
      issues].
PG  - 219-221
LID - S1695-4033(20)30261-7 [pii]
LID - 10.1016/j.anpedi.2020.06.029 [doi]
FAU - Alfonso Farnos, Iciar
AU  - Alfonso Farnos I
AD  - Comite de Etica de la Investigacion con medicamentos de Euskadi, Vitoria-Gasteiz,
      Espana. Electronic address: iciar.alfonso@hotmail.com.
FAU - Alcalde Bezhold, Guillermo
AU  - Alcalde Bezhold G
AD  - Comite de Etica de la Investigacion del Hospital Universitario Araba,
      Vitoria-Gasteiz, Espana.
LA  - spa
PT  - Editorial
TT  - Investigacion clinica en enfermedades raras: nuevos retos, oportunidades e
      implicaciones eticas.
DEP - 20200910
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
SB  - IM
CIN - An Pediatr (Engl Ed). 2020 Oct;93(4):219-221. PMID: 34092333
MH  - *Clinical Trials as Topic/ethics/methods/organization & administration
MH  - Humans
MH  - *Rare Diseases/diagnosis/etiology/therapy
MH  - *Research Design
EDAT- 2020/09/15 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/09/14 05:37
PHST- 2020/06/24 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/09/14 05:37 [entrez]
AID - S1695-4033(20)30261-7 [pii]
AID - 10.1016/j.anpedi.2020.06.029 [doi]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Oct;93(4):219-221. doi: 10.1016/j.anpedi.2020.06.029. 
      Epub 2020 Sep 10.


PMID- 32921507
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 45
DP  - 2020 Oct 21
TI  - Brand-specific rates of pertussis disease among Wisconsin children given 1-4
      doses of pertussis Vaccine, 2010-2014.
PG  - 7063-7069
LID - S0264-410X(20)31158-0 [pii]
LID - 10.1016/j.vaccine.2020.09.016 [doi]
AB  - BACKGROUND: Acellular pertussis vaccines were initially licensed based on
      placebo-controlled efficacy trials, but such trials are no longer ethical. The
      effectiveness of current pertussis vaccines among properly vaccinated children <5
      years is so high that a randomized trial is infeasible. Fluctuations in pertussis
      incidence and characteristics of the US vaccine marketplace make selection of
      suitable controls for a case-control study problematic. To satisfy an FDA
      requirement to evaluate rates of pertussis following licensure of Pentacel(R)
      vaccine, we used a case-cohort study design with a novel method for
      characterizing the cohort population. METHODS: This prospective, observational
      study was conducted in Wisconsin from 2010 to 2014 among Wisconsin residents <60 
      months of age who received </=four doses of pertussis vaccine (surveillance
      population). Cases were identified by the Wisconsin Division of Public Health.
      Characteristics and pertussis vaccinations of the surveillance population were
      estimated by ongoing random telephonic survey. The primary objective was to
      determine rates of pertussis disease among those who received only Pentacel
      vaccine (Group 1) vs those who received a single brand of vaccine other than
      Pentacel vaccine (Group 2). RESULTS: 1195 pertussis cases were identified. It was
      estimated that the surveillance population accrued a total of 1,133,403
      person-years (Group 1, 39%; Group 2, 41%; Group 3 [those not in Group 1 or Group 
      2], 20%). Pertussis rates were similar in Group 1 (98.9/100,000) and Group 2
      (96.2/100,000); rate ratios were 1.03 (unadjusted; 90% CI, 0.92-1.15) and 0.99
      (adjusted; 90% CI, 0.89-1.12). Persons with one or more delayed vaccinations had 
      a 66% higher risk of pertussis (90% CI, 39-96%). DISCUSSION: Pertussis protection
      was not found to differ for recipients of the newly licensed vs other available
      pertussis vaccines. Delayed vaccination substantially increased risk of
      pertussis. Sample survey methodology was able to characterize the study cohort
      and enable an otherwise-infeasible study. Clinical Trial Registry number:
      ClinicalTrials.gov, NCT01129362.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Conway, James H
AU  - Conway JH
AD  - Department of Pediatrics, Division of Infectious Diseases, University of
      Wisconsin, School of Medicine and Public Health, Madison, WI, United States.
FAU - Davis, Jeffrey P
AU  - Davis JP
AD  - Formerly State Epidemiologist, Wisconsin Division of Public Health, Madison, WI, 
      United States.
FAU - Eickhoff, Jens C
AU  - Eickhoff JC
AD  - Department of Biostatistics and Medical Informatics, University of Wisconsin,
      School of Medicine and Public Health, Madison, WI, United States.
FAU - Pool, Vitali
AU  - Pool V
AD  - US Medical Affairs, Sanofi Pasteur, Swiftwater, PA, United States.
FAU - Greenberg, David P
AU  - Greenberg DP
AD  - US Medical Affairs, Sanofi Pasteur, Swiftwater, PA, United States.
FAU - Decker, Michael D
AU  - Decker MD
AD  - US Medical Affairs, Sanofi Pasteur, Swiftwater, PA, United States; Department of 
      Health Policy, Vanderbilt University Medical Center, Nashville, TN, United
      States. Electronic address: m5a16@mdd1.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT01129362
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200911
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
RN  - 0 (Pertussis Vaccine)
SB  - IM
MH  - Case-Control Studies
MH  - Child
MH  - Cohort Studies
MH  - Diphtheria-Tetanus-Pertussis Vaccine
MH  - *Diphtheria-Tetanus-acellular Pertussis Vaccines
MH  - Humans
MH  - Infant
MH  - Pertussis Vaccine
MH  - Prospective Studies
MH  - *Whooping Cough/epidemiology/prevention & control
MH  - Wisconsin/epidemiology
OTO - NOTNLM
OT  - *Acellular
OT  - *Case-cohort study
OT  - *Effectiveness
OT  - *Pertussis vaccine
OT  - *Vaccines
COIS- Declaration of Competing Interest The authors declare the following financial
      interests/personal relationships which may be considered as potential competing
      interests: Drs. Decker, Greenberg, and Pool were employees of Sanofi Pasteur at
      the time of the study; Dr. Decker has since retired. Drs Conway and Eickhoff are 
      employees of the University of Wisconsin, which received funding from Sanofi
      Pasteur to conduct this study. Dr. Davis was an employee of the Wisconsin
      Division of Public Health. Drs. Conway, Decker, Greenberg, and Pool participated 
      in the conception, design, oversight, analysis, and reporting of the study; Dr.
      Davis participated in design, oversight, and data collection for the study; Dr.
      Eickhoff participated in design, analysis, and reporting of the study. Apart from
      Dr. Davis, who died in 2018, all authors wrote or revised the manuscript; approve
      of the final manuscript; and attest they meet the ICMJE criteria for authorship.
EDAT- 2020/09/15 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/14 05:35
PHST- 2020/06/27 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/14 05:35 [entrez]
AID - S0264-410X(20)31158-0 [pii]
AID - 10.1016/j.vaccine.2020.09.016 [doi]
PST - ppublish
SO  - Vaccine. 2020 Oct 21;38(45):7063-7069. doi: 10.1016/j.vaccine.2020.09.016. Epub
      2020 Sep 11.


PMID- 32921423
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1545-7206 (Electronic)
IS  - 0033-3182 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Nov - Dec
TI  - The Incapacitated Surrogate: What is the Consultation-Liaison Psychiatrist's
      Role?
PG  - 672-677
LID - S0033-3182(20)30215-2 [pii]
LID - 10.1016/j.psym.2020.07.006 [doi]
AB  - BACKGROUND: When a patient is found to be lacking capacity to make a medical
      decision, the medical team is advised to turn to the patient's most appropriate
      surrogate decision maker (hereafter, surrogate) to make a choice on behalf of the
      patient. The assumption made by the medical team is that the surrogate will have 
      the capacity to make appropriate medical decisions on behalf of the patient. At
      times though, the capacity of the surrogate himself may be called into question, 
      leading to uncertainty in terms of how best to proceed in the care of the
      patient. Consultation-liaison psychiatrists are commonly consulted to assess a
      patient's capacity to make a particular medical decision, but their role
      assisting in cases of incapacitated surrogates is less clear. OBJECTIVE: In this 
      article, we summarize the existing literature and current state laws regarding
      incapacitated surrogates and propose guidelines for the role the
      consultation-liaison psychiatrist can take when the surrogate may be
      incapacitated.
CI  - Copyright (c) 2020 Academy of Consultation-Liaison Psychiatry. Published by
      Elsevier Inc. All rights reserved.
FAU - Allen, Nicole
AU  - Allen N
AD  - Department of Psychiatry, Columbia University Medical Center, New York, NY.
      Electronic address: na2690@cumc.columbia.edu.
FAU - Mishkin, Adrienne
AU  - Mishkin A
AD  - Department of Psychiatry, Columbia University Medical Center, New York, NY;
      Department of Oncology, Columbia University Medical Center, New York, NY.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - Psychosomatics
JT  - Psychosomatics
JID - 0376506
SB  - IM
MH  - Decision Making
MH  - Humans
MH  - *Psychiatry
MH  - *Referral and Consultation
OTO - NOTNLM
OT  - *capacity
OT  - *consultation-liaison psychiatry
OT  - *ethical issues
OT  - *surrogate
EDAT- 2020/09/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/14 05:35
PHST- 2020/06/19 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/09/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/09/14 05:35 [entrez]
AID - S0033-3182(20)30215-2 [pii]
AID - 10.1016/j.psym.2020.07.006 [doi]
PST - ppublish
SO  - Psychosomatics. 2020 Nov - Dec;61(6):672-677. doi: 10.1016/j.psym.2020.07.006.
      Epub 2020 Jul 31.


PMID- 32920459
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 1095-8630 (Electronic)
IS  - 0301-4797 (Linking)
VI  - 276
DP  - 2020 Dec 15
TI  - Preparation and characterization of a decentralized modular yellow water nutrient
      recovery system.
PG  - 111345
LID - S0301-4797(20)31271-8 [pii]
LID - 10.1016/j.jenvman.2020.111345 [doi]
AB  - The peculiarity of human urine as a resource, in terms of ethical and cultural
      considerations, and human perception, demands the development of a highly
      decentralized modular system, to enable the feasibility of the emerging concept
      of nutrient recovery in this regard. Consequently, a modular reactor, with packed
      bed of granular Gastropod shell (GS) was constructed for nutrient recovery from
      yellow water and the operational parameters were derived in simulated and pilot
      studies. Prior to the design of the modular reactor, both the raw and calcined GS
      were screened in a batch reactor for nutrient fraction recovery (i.e. total
      phosphorus (TP) and total nitrogen (TN)). The TP recovery was more favorable than
      the TN, but the TN recovery was the rate determining step. Despite the low TN
      capture efficiency of the reactor, the hydrolysis of the urea fraction that
      promotes nitrogen loss from yellow water was greatly impeded. The system showed
      higher selectivity for the nutrient fraction than the other constituents of the
      human urine, as manifested in the high residual COD and creatinine values in the 
      treated yellow water. The volume of yellow water treated and the nutrient
      recovery capacity of the modular reactor were HRT dependent. A diminution in the 
      nutrient recovery efficiency was observed in the pilot study, when compared with 
      the simulated studies of the same HRT.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Saliu, T D
AU  - Saliu TD
AD  - Hydrochemistry Research Laboratory, Department of Chemical Sciences, Adekunle
      Ajasin University, Akungba Akoko, Nigeria.
FAU - Ali, J
AU  - Ali J
AD  - Fujian Provincial Key Laboratory of Soil Environmental Health and Regulation,
      College of Resources and Environment, Fujian Agriculture and Forestry University,
      Fuzhou, 350002, China.
FAU - Ololade, I A
AU  - Ololade IA
AD  - Department of Chemical Sciences, Adekunle Ajasin University, Akungba Akoko,
      Nigeria.
FAU - Oladoja, N A
AU  - Oladoja NA
AD  - Hydrochemistry Research Laboratory, Department of Chemical Sciences, Adekunle
      Ajasin University, Akungba Akoko, Nigeria. Electronic address:
      bioladoja@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - England
TA  - J Environ Manage
JT  - Journal of environmental management
JID - 0401664
RN  - 059QF0KO0R (Water)
RN  - 27YLU75U4W (Phosphorus)
RN  - N762921K75 (Nitrogen)
SB  - IM
MH  - *Bioreactors
MH  - Humans
MH  - Nitrogen
MH  - Nutrients
MH  - Phosphorus
MH  - Pilot Projects
MH  - *Water
OTO - NOTNLM
OT  - Gastropod shell
OT  - Nitrate
OT  - Nutrient recovery
OT  - Phosphate
OT  - Urine
OT  - Yellow water
EDAT- 2020/09/14 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/13 20:38
PHST- 2020/07/01 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/14 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/09/13 20:38 [entrez]
AID - S0301-4797(20)31271-8 [pii]
AID - 10.1016/j.jenvman.2020.111345 [doi]
PST - ppublish
SO  - J Environ Manage. 2020 Dec 15;276:111345. doi: 10.1016/j.jenvman.2020.111345.
      Epub 2020 Sep 10.


PMID- 32920370
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5223 (Electronic)
IS  - 1471-5953 (Linking)
VI  - 48
DP  - 2020 Oct
TI  - Power and adolescent simulated patients: A qualitative exploration.
PG  - 102871
LID - S1471-5953(19)31006-6 [pii]
LID - 10.1016/j.nepr.2020.102871 [doi]
AB  - Adolescent simulated patients (SPs) work in an environment where complex and
      dynamic power relationships are at play. These relationships differ to those
      encountered in clinical practice. Instead of health professionals exerting their 
      power from a foundation resting on knowledge, to a patient consumed with worry,
      SPs in simulation scenarios often have less worry and more knowledge than the
      learner. Combined with this, their role in judging and assessing learner
      performance adds to their power base. Adolescent SPs also experience power from
      the opposite perspective; where they have power exerted upon them, with limited
      ability to resist. This research aims to explore power relationships from
      adolescent SP's perspectives. Ten adolescent SPs, (10-19 years), participated in 
      semi-structured interviews that were analysed using an interpretive
      phenomenological approach. Four themes resulted from an in-depth analysis of
      interview transcripts: 1) Becoming and being a powerful simulated patient; 2)
      redirection, resistance & responsibility; 3) the power of the role; and 4) a
      complex maze of interactions. These themes reflect the experiences adolescent SPs
      are exposed to and the powerful interactions that can result. Whilst there are
      positive outcomes for adolescent SPs, there is also a risk of harm. Recognizing
      this is an ethical imperative to ensure adolescent safety during the simulation
      process.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Gamble, Andree
AU  - Gamble A
AD  - Faculty of Medicine, Nursing & Health Sciences, Monash University, Victoria,
      Australia. Electronic address: Andree.gamble1@monash.edu.
FAU - Nestel, Debra
AU  - Nestel D
AD  - Simulation Education in Healthcare, Monash Institute for Health and Clinical
      Education, Faculty of Medicine, Nursing & Health Sciences, Monash University,
      Victoria, Australia; Surgical Education, Department of Surgery, University of
      Melbourne, Victoria, Australia. Electronic address: debra.nestel@monash.edu.
FAU - Bearman, Margaret
AU  - Bearman M
AD  - Centre for Research in Assessment and Digital Learning (CRADLE), Deakin
      University, Victoria, Australia. Electronic address:
      margaret.bearman@deakin.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - Scotland
TA  - Nurse Educ Pract
JT  - Nurse education in practice
JID - 101090848
SB  - IM
MH  - Adolescent
MH  - *Health Personnel
MH  - Humans
MH  - *Patient Simulation
MH  - Qualitative Research
OTO - NOTNLM
OT  - Adolescent
OT  - Dynamic interactions
OT  - Ethics
OT  - Health professional education
OT  - Power
OT  - Role-play
OT  - Simulated patient
EDAT- 2020/09/14 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/13 20:35
PHST- 2019/11/20 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/09/14 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/13 20:35 [entrez]
AID - S1471-5953(19)31006-6 [pii]
AID - 10.1016/j.nepr.2020.102871 [doi]
PST - ppublish
SO  - Nurse Educ Pract. 2020 Oct;48:102871. doi: 10.1016/j.nepr.2020.102871. Epub 2020 
      Aug 26.


PMID- 32920219
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20210110
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 131
DP  - 2020 Oct
TI  - COVID-19 associated kidney impairment in adult: Qualitative and quantitative
      analyses with non-enhanced CT on admission.
PG  - 109240
LID - S0720-048X(20)30429-0 [pii]
LID - 10.1016/j.ejrad.2020.109240 [doi]
AB  - PURPOSE: To qualitatively and quantitatively assess kidney imapairment in adults 
      with COVID-19 by analysing imaging features on non-enhanced CT (NECT) and
      possible correlation between renal parenchymal attenuation (RPA) and serum
      creatinine (SCr) levels on admission. METHODS: This study was approved by the
      local institutional ethics committee. A total of 82 patients with COVID-19
      admitted from 10/1/2020 approximately 15/3/2020 were enrolled. RPA and
      perinephric fat stranding (PFS) were evaluated on NECT imaging. According to the 
      presence of PFS, the patients were divided into two groups: Group A, 38 patients 
      with PFS, and Group B, 44 patients without PFS. Clinical data, including age,
      gender, clinical classification, SCr levels, and RPA on NECT were analysed. The
      RPA and SCr of the two groups with COVID-19 were analysed to determine possible
      difference and correlation. Eighty subjects with no kidney diseases were randomly
      selected as control group to determine the RPA of normal kidney performed on the 
      same CT scanner. RESULTS: Mean age, male to female ratio, number of severe and
      critical cases, and SCr of Group A were higher than those of Group B. Both mean
      RPA of Group A and Group B were lower than that of control. Mean RPA of Group A
      was even lower than that of Group B. A significant weak negative linear
      correlation between RPA on NECT and SCr in COVID-19 was indicated. CONCLUSIONS:
      Decrease in RPA on NECT was observed in patients with COVID-19 and a weak linear 
      negative correlation with SCr levels was found. The presence of PFS suggested
      more severe renal impairment in COVID-19. RPA measurements and PFS could be
      useful in quantitative and qualitative evaluation of COVID-19 associated renal
      impairment on admission.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Huang, Qiang
AU  - Huang Q
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Li, Jian
AU  - Li J
AD  - Department of Electrocadiogram, Affiliated Hangzhou First People's Hospital,
      College of Medicine, Zhejiang University, 261 Huansha Road, 310006, Hangzhou,
      Zhejiang, People's Republic of China; Department of Cardiology, The First
      Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, 
      310003, Hangzhou, Zhejiang, People's Republic of China.
FAU - Lyu, Shuangzhi
AU  - Lyu S
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Liang, Wenjie
AU  - Liang W
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Yang, Rong
AU  - Yang R
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Xiao, Wenbo
AU  - Xiao W
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Liu, Jinpeng
AU  - Liu J
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China.
FAU - Yan, Senxiang
AU  - Yan S
AD  - Department of Radiation Oncology, The First Affiliated Hospital, College of
      Medicine, Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang,
      People's Republic of China.
FAU - Zheng, Liangrong
AU  - Zheng L
AD  - Department of Cardiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China. Electronic address: 1191066@zju.edu.cn.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine,
      Zhejiang University, 79 Qingchun Road, 310003, Hangzhou, Zhejiang, People's
      Republic of China. Electronic address: chenfenghz@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications
MH  - Creatinine/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*complications
MH  - Renal Insufficiency/*diagnostic imaging/etiology
MH  - SARS-CoV-2
MH  - Tomography, X-Ray Computed
MH  - Young Adult
PMC - PMC7448815
OTO - NOTNLM
OT  - Attenuation
OT  - COVID-19
OT  - CT
OT  - Coronavirus
OT  - Kidney
OT  - Perinephric
EDAT- 2020/09/14 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/13 20:30
PHST- 2020/06/01 00:00 [received]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/14 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/09/13 20:30 [entrez]
AID - S0720-048X(20)30429-0 [pii]
AID - 10.1016/j.ejrad.2020.109240 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 Oct;131:109240. doi: 10.1016/j.ejrad.2020.109240. Epub 2020
      Aug 26.


PMID- 32919815
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
VI  - 34 Suppl 1
DP  - 2020
TI  - [The trans depathologization perspective: a contribution to public health
      approaches and clinical practices in mental health? SESPAS Report 2020].
PG  - 54-60
LID - S0213-9111(20)30185-0 [pii]
LID - 10.1016/j.gaceta.2020.07.002 [doi]
AB  - Over the last decade, the academic-activist trans depathologization perspective
      has contributed to a change in the conceptualization of gender transition
      processes. Observing an interrelation between psychiatrization and transphobic
      violence, trans depathologization activist groups and allies demand the removal
      of the diagnostic classification of transexuality as a mental disorder.
      Furthermore, they have developed trans health care models and legal gender
      recognition processes based on depathologization and human rights perspectives.
      They propose changing the role of mental health professionals in trans health
      care, substituting the psychiatric assessment role by accompaniment and
      psychological support tasks. The trans depathologization perspective can be
      related to various approaches and topics relevant in public health and mental
      health, among them sociology of diagnosis, human rights based approaches to
      health, human rights protection in mental health, universal health coverage,
      review of diagnostic classifications, intersectionality perspectives, reflections
      on bioethical principles, models of integrated people-centered health services
      and approaches to research ethics. Over the last few years, informed
      decision-making models have been developed for trans health care in several
      countries and world regions. Health professionals, including mental health
      professionals, as well as professionals from the educational and
      judicial-administrative sector, can have an important role in addressing
      situations of discrimination and transphobic violence, contributing to the
      construction of a society that respects, recognizes and celebrates gender
      diversity.
CI  - Copyright (c) 2020 SESPAS. Publicado por Elsevier Espana, S.L.U. All rights
      reserved.
FAU - Suess Schwend, Amets
AU  - Suess Schwend A
AD  - Escuela Andaluza de Salud Publica, Granada, Espana; Grupo de Investigacion Otras.
      Perspectivas Feministas en Investigacion Social (SEJ-430), Universidad de
      Granada, Granada, Espana. Electronic address: suess.amets@gmail.com.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - La perspectiva de despatologizacion trans: inverted question markuna aportacion
      para enfoques de salud publica y practicas clinicas en salud mental? Informe
      SESPAS 2020.
DEP - 20200909
PL  - Spain
TA  - Gac Sanit
JT  - Gaceta sanitaria
JID - 8901623
SB  - IM
MH  - Gender Identity
MH  - Human Rights
MH  - Humans
MH  - *Mental Health
MH  - Public Health
MH  - *Transsexualism
OTO - NOTNLM
OT  - *Derechos humanos
OT  - *Determinantes sociales de la salud
OT  - *Discriminacion social
OT  - *Gender identity
OT  - *Human rights
OT  - *Identidad de genero
OT  - *Mental health services
OT  - *Servicios de salud mental
OT  - *Social determinants of health
OT  - *Social discrimination
EDAT- 2020/09/14 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/09/13 20:27
PHST- 2019/11/10 00:00 [received]
PHST- 2020/07/19 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/09/14 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/09/13 20:27 [entrez]
AID - S0213-9111(20)30185-0 [pii]
AID - 10.1016/j.gaceta.2020.07.002 [doi]
PST - ppublish
SO  - Gac Sanit. 2020;34 Suppl 1:54-60. doi: 10.1016/j.gaceta.2020.07.002. Epub 2020
      Sep 9.


PMID- 32919263
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 131
DP  - 2020 Oct
TI  - Right ventricular strain in repaired Tetralogy of Fallot with regards to
      pulmonary valve replacement.
PG  - 109235
LID - S0720-048X(20)30424-1 [pii]
LID - 10.1016/j.ejrad.2020.109235 [doi]
AB  - PURPOSE: To assess right ventricular (RV) myocardial strain both globally and
      segmentally through feature-tracking cardiac magnetic resonance (CMR) in patients
      with Tetralogy of Fallot (ToF), with regards to pulmonary valve replacement
      (PVR). METHODS: After Ethics Committee approval, we retrospectively included 46
      consecutive ToF patients who had two CMR examinations performed at our
      institution between March 2014 and June 2019. We divided patients into those who 
      had not undergone PVR between the two CMR examinations (Group-0), and those who
      had (Group-1). Ventricular volumes were quantified on cine sequences, and strain 
      was calculated through feature-tracking, using the previously traced
      segmentations. RV longitudinal and radial strain were assessed both globally and 
      separately for the septum and free wall. Variations were normalized for
      intercurrent years, differences were appraised with t-tests or Mann-Whitney U.
      RESULTS: 30 patients belonged to Group-0 and 16 to Group-1. Median age was 22
      years (interquartile range [IQR] 17-29 years) in Group-0, and 21 years (IQR 16-29
      years) in Group-1. No significant differences were reported in RV strain between 
      groups (p>/=0.254) except for RV septal radial strain, significantly higher
      (p=0.010) in Group-0 (24.2 %, IQR 10.1-52.4 %) than in Group-1 (6.0 %, IQR
      -3.3-23.3 %) at the second CMR. Both global and segmental RV strains decreased
      over time in both groups, and yearly variations did not differ significantly
      (p>/=0.081) between groups. CONCLUSIONS: While PVR performed at the appropriate
      timing eases the burden on the RV allowing for a reduction in volumes, RV strain 
      seems to continuously deteriorate as in patients who do not undergo PVR.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Monti, Caterina Beatrice
AU  - Monti CB
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milano, Italy. Electronic address:
      caterina.monti@unimi.it.
FAU - Secchi, Francesco
AU  - Secchi F
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milano, Italy; Unit of Radiology, IRCCS Policlinico San
      Donato, Via Morandi 30, 20097, San Donato Milanese, Italy. Electronic address:
      francesco.secchi@grupposandonato.it.
FAU - Capra, Davide
AU  - Capra D
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milano, Italy. Electronic address:
      davide.capra@unimi.it.
FAU - Guarnieri, Gianluca
AU  - Guarnieri G
AD  - Corso di Laurea in Medicina e Chirurgia, Universita degli Studi di Milano, Via
      Festa del Perdono 7, 20122, Milano, Italy. Electronic address:
      gianlu1993@icloud.com.
FAU - Lastella, Giulia
AU  - Lastella G
AD  - Postgraduation School in Radiodiagnostics, Universita degli Studi di Milano, Via 
      Festa del Perdono 7, 20122, Milano, Italy. Electronic address:
      giulia.lastella@unimi.it.
FAU - Barbaro, Ugo
AU  - Barbaro U
AD  - Department of Radiology, IRCCS Centro Neurolesi "Bonino Pulejo", Viale Europa 45,
      98124, Messina, Italy. Electronic address: ugobarbaro@gmail.com.
FAU - Carminati, Mario
AU  - Carminati M
AD  - Department of Pediatric and Adult Congenital Cardiology and Cardiac Surgery,
      IRCCS Policlinico San Donato, Via Morandi 30, 20097, San Donato Milanese, Italy. 
      Electronic address: mario.carminati@grupposandonato.it.
FAU - Sardanelli, Francesco
AU  - Sardanelli F
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milano, Italy; Unit of Radiology, IRCCS Policlinico San
      Donato, Via Morandi 30, 20097, San Donato Milanese, Italy. Electronic address:
      francesco.sardanelli@unimi.it.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Pulmonary Valve/*physiopathology/*surgery
MH  - Retrospective Studies
MH  - Tetralogy of Fallot/*physiopathology/*surgery
MH  - Treatment Outcome
MH  - Ventricular Function, Right/*physiology
MH  - Young Adult
OTO - NOTNLM
OT  - Congenital heart disease
OT  - Magnetic resonance imaging
OT  - Myocardium
OT  - Pulmonary valve
OT  - Tetralogy of Fallot
EDAT- 2020/09/13 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/09/12 20:15
PHST- 2020/06/20 00:00 [received]
PHST- 2020/08/01 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
PHST- 2020/09/12 20:15 [entrez]
AID - S0720-048X(20)30424-1 [pii]
AID - 10.1016/j.ejrad.2020.109235 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 Oct;131:109235. doi: 10.1016/j.ejrad.2020.109235. Epub 2020
      Aug 28.


PMID- 32918314
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20210604
IS  - 1098-108X (Electronic)
IS  - 0276-3478 (Linking)
VI  - 53
IP  - 12
DP  - 2020 Dec
TI  - Practitioners' perspectives on ethical issues within the treatment of eating
      disorders: Results from a concept mapping study.
PG  - 1941-1951
LID - 10.1002/eat.23381 [doi]
AB  - OBJECTIVE: Treating patients with eating disorders (EDs) is associated with an
      array of ethical concerns, including balancing patients' health and autonomy,
      access to care, and use of harm-reduction versus recovery-oriented treatment
      models. The primary aim of the current study is to gain a better understanding of
      ethical issues faced by ED practitioners by using a concept mapping, or Q-sort,
      approach. METHOD: A total of 12 practitioners completed the brainstorming phase
      and generated statements regarding ethical issues they faced while treating
      patients with EDs. A subsequent 38 practitioners completed a sorting task, where 
      they created and labeled piles, into which they grouped each statement. Of those 
      38 participants, 30 rated both the frequency with which they encountered each
      ethical issue and its impact on patient care. RESULTS: A total of six clusters
      emerged: Insufficient Level of Care, Lack of Evidence-Based Practice, Insurance
      Barriers, Family Involvement, Patient Autonomy, and Limited Access to Expertise. 
      Lack of Evidence-Based Practice, Insurance Barriers, and Insufficient Level of
      Care was the most frequent problem faced by ED practitioners, whereas Insurance
      Barriers and Patient Autonomy had the greatest impact. DISCUSSION: Findings
      outline frequent and impactful areas of ethical concern that arise when treating 
      patients diagnosed with EDs. Practitioners most commonly reported that patient-
      and insurance-driven factors limited patient access to appropriate care.
      Regulations supporting the provision of evidence-based care should be emphasized 
      in public health policy and advocacy efforts, given their impact in limiting the 
      delivery of adequate patient care.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Walker, D Catherine
AU  - Walker DC
AUID- ORCID: 0000-0002-9424-7156
AD  - Department of Psychology, Union College, Schenectady, New York, USA.
FAU - Heiss, Sydney
AU  - Heiss S
AUID- ORCID: 0000-0003-3569-4666
AD  - Department of Psychology, University at Albany, State University of New York,
      Albany, New York, USA.
FAU - Donahue, Joseph M
AU  - Donahue JM
AUID- ORCID: 0000-0002-2843-1457
AD  - Department of Psychiatry, University of California, San Diego, La Jolla,
      California, USA.
FAU - Brooks, Julia M
AU  - Brooks JM
AD  - Department of Psychology, University of Illinois at Chicago, Chicago, Illinois,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200912
PL  - United States
TA  - Int J Eat Disord
JT  - The International journal of eating disorders
JID - 8111226
SB  - IM
MH  - Adult
MH  - Feeding and Eating Disorders/*therapy
MH  - Female
MH  - General Practitioners/*ethics
MH  - Humans
MH  - Male
OTO - NOTNLM
OT  - *Q-sort
OT  - *concept mapping
OT  - *eating disorder treatment
OT  - *eating disorders
OT  - *ethics
EDAT- 2020/09/13 06:00
MHDA- 2021/06/05 06:00
CRDT- 2020/09/12 05:35
PHST- 2020/02/27 00:00 [received]
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/09/12 05:35 [entrez]
AID - 10.1002/eat.23381 [doi]
PST - ppublish
SO  - Int J Eat Disord. 2020 Dec;53(12):1941-1951. doi: 10.1002/eat.23381. Epub 2020
      Sep 12.


PMID- 32917475
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201128
IS  - 1878-4046 (Electronic)
IS  - 1076-6332 (Linking)
VI  - 27
IP  - 12
DP  - 2020 Dec
TI  - Healthcare Improvement Driven by Administrators: Ethical Lessons.
PG  - 1786-1787
LID - S1076-6332(20)30501-8 [pii]
LID - 10.1016/j.acra.2020.08.020 [doi]
FAU - Olivera, Jesus G
AU  - Olivera JG
AD  - Department of Radiology, Indiana University, 702 North Barnhill Drive, Room 1053,
      Indianapolis, IN 46202.
FAU - Gunderman, Richard B
AU  - Gunderman RB
AD  - Department of Radiology, Indiana University, 702 North Barnhill Drive, Room 1053,
      Indianapolis, IN 46202. Electronic address: rbgunder@iupui.edu.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - United States
TA  - Acad Radiol
JT  - Academic radiology
JID - 9440159
SB  - IM
OTO - NOTNLM
OT  - *Administrators
OT  - *Education
OT  - *Ethics
OT  - *Healthcare improvement
EDAT- 2020/09/13 06:00
MHDA- 2020/09/13 06:01
CRDT- 2020/09/12 05:27
PHST- 2020/08/19 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2020/09/13 06:01 [medline]
PHST- 2020/09/12 05:27 [entrez]
AID - S1076-6332(20)30501-8 [pii]
AID - 10.1016/j.acra.2020.08.020 [doi]
PST - ppublish
SO  - Acad Radiol. 2020 Dec;27(12):1786-1787. doi: 10.1016/j.acra.2020.08.020. Epub
      2020 Sep 8.


PMID- 32917398
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1873-1929 (Electronic)
IS  - 0160-9327 (Linking)
VI  - 44
IP  - 3
DP  - 2020 Sep
TI  - Linguists and their work: Epistemic and ethical challenges.
PG  - 100732
LID - S0160-9327(20)30049-1 [pii]
LID - 10.1016/j.endeavour.2020.100732 [doi]
AB  - This paper aims to show how the specific ethics of scientific undertaking tightly
      underlies epistemic reflection upon the nature of linguistic work and its
      outcome. The relationship between linguistics and ethics seems evident at the
      level of the narrative, i.e. the language in which the basic linguistic findings 
      are established. The article is intended as an introduction to an interplay of
      linguistics, epistemology and the ethics of linguistic work. The departure point 
      for the argument is the CONTAINER perception of language by linguists, which
      produces the well-established distinction between internalist and externalist
      positions. The paper, however, invites the reader to reconsider the tension
      between internalists and externalists and instead argues for a more general
      opposition, i.e. between the non-transcendental naturalists (naturalists) and
      transcendental naturalists (extra-naturalists). The polarity is seen as
      underpinning the present-day debates, while concurrently transversing the
      traditionally recognised dichotomies. The distinction promises to be productive
      both at the level of substantive assessment of linguistic research and at the
      level of epistemic qualification of the outcome of a linguistic study. Sharp and 
      uncompromising as the naturalist vs extra-naturalist dichotomy seems to hold, the
      paper offers ways to bridge the gap between the apparently exclusive
      philosophies. The proposed solution, while seemingly only aesthetic, ultimately
      touches an ethical dimension as it centres on the appropriate construction of the
      narrative of linguistic fact-finding, which promotes approximative rather than
      definitive statements in the scholarly discourse. The desired effect is an
      ethical consensus underlying the work of a linguist.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kuzniak, Marek
AU  - Kuzniak M
AD  - University of Wroclaw, Institute of English Studies, Kuznicza 22, 50-138 Wroclaw,
      Poland. Electronic address: marek.kuzniak@uwr.edu.pl.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - Endeavour
JT  - Endeavour
JID - 0375037
SB  - IM
OTO - NOTNLM
OT  - Epistemology
EDAT- 2020/09/13 06:00
MHDA- 2020/09/13 06:01
CRDT- 2020/09/12 05:26
PHST- 2019/03/13 00:00 [received]
PHST- 2019/11/22 00:00 [revised]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2020/09/13 06:01 [medline]
PHST- 2020/09/12 05:26 [entrez]
AID - S0160-9327(20)30049-1 [pii]
AID - 10.1016/j.endeavour.2020.100732 [doi]
PST - ppublish
SO  - Endeavour. 2020 Sep;44(3):100732. doi: 10.1016/j.endeavour.2020.100732. Epub 2020
      Sep 9.


PMID- 32917300
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 2211-9493 (Electronic)
IS  - 2211-9493 (Linking)
VI  - 20
DP  - 2020 Sep
TI  - Fit to Study: Reflections on designing and implementing a large-scale randomized 
      controlled trial in secondary schools.
PG  - 100134
LID - S2211-9493(20)30010-7 [pii]
LID - 10.1016/j.tine.2020.100134 [doi]
AB  - BACKGROUND: The randomised controlled trial (RCT) design is increasingly common
      among studies seeking good-quality evidence to advance educational neuroscience, 
      but conducting RCTs in schools is challenging. Fit to Study, one of six such
      trials funded by the Education Endowment Foundation and Wellcome Trust, tested an
      intervention to increase vigorous physical activity during PE lessons on maths
      attainment among pupils aged 12-13. This review of designing and conducting an
      RCT in 104 schools is intended as a resource on which researchers might draw for 
      future studies. METHOD: We consider intervention design and delivery;
      recruitment, retention, trial management, data collection and analysis including 
      ethical considerations and working with evaluators. RESULTS: Teacher training,
      intervention delivery and data collection during large-scale RCTs require a
      flexible approach appropriate to educational settings, which in turn entails
      planning and resources. CONCLUSION: Simple interventions, with few outcome
      measures and minimal missing data, are preferable to more complex designs.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.
FAU - Wheatley, Catherine
AU  - Wheatley C
AD  - Wellcome Centre for Integrative Neuroimaging, Nuffield Department of Clinical
      Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU.
      Electronic address: catherine.wheatley@ndcn.ox.ac.uk.
FAU - Beale, Nick
AU  - Beale N
AD  - Oxford Institute of Nursing, Midwifery & Allied Health Research, Department of
      Sport & Health Sciences, Oxford Brookes University, Headington Campus, Oxford OX3
      0BP.
FAU - Wassenaar, Thomas
AU  - Wassenaar T
AD  - Wellcome Centre for Integrative Neuroimaging, Nuffield Department of Clinical
      Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU.
FAU - Graham, Mackenzie
AU  - Graham M
AD  - Oxford Uehiro Centre for Practical Ethics, Wellcome Centre for Ethics and
      Humanities, University of Oxford, 6-17 St Ebbes St, Oxford OX1 1PT.
FAU - Eldridge, Emma
AU  - Eldridge E
AD  - Oxford Institute of Nursing, Midwifery & Allied Health Research, Department of
      Sport & Health Sciences, Oxford Brookes University, Headington Campus, Oxford OX3
      0BP.
FAU - Dawes, Helen
AU  - Dawes H
AD  - Oxford Institute of Nursing, Midwifery & Allied Health Research, Department of
      Sport & Health Sciences, Oxford Brookes University, Headington Campus, Oxford OX3
      0BP.
FAU - Johansen-Berg, Heidi
AU  - Johansen-Berg H
AD  - Wellcome Centre for Integrative Neuroimaging, Nuffield Department of Clinical
      Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200624
PL  - Germany
TA  - Trends Neurosci Educ
JT  - Trends in neuroscience and education
JID - 101613233
SB  - IM
MH  - Adolescent
MH  - Brain
MH  - Child
MH  - Cognition
MH  - Exercise/*psychology
MH  - Faculty
MH  - Humans
MH  - Learning
MH  - Physical Education and Training/methods
MH  - Randomized Controlled Trials as Topic
MH  - School Health Services/*trends
MH  - Schools
MH  - Students
PMC - PMC7488648
OTO - NOTNLM
OT  - *EEthics
OT  - *Fit to Study
OT  - *Neuroscience
OT  - *Physical activity
OT  - *Randomized controlled trial
OT  - *Recruitment
OT  - *Trial management
COIS- Declaration of Competing Interest The authors declare no conflict of interest
      other than the funding sources described.
EDAT- 2020/09/13 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/09/12 05:24
PHST- 2020/01/15 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/09/12 05:24 [entrez]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
AID - S2211-9493(20)30010-7 [pii]
AID - 10.1016/j.tine.2020.100134 [doi]
PST - ppublish
SO  - Trends Neurosci Educ. 2020 Sep;20:100134. doi: 10.1016/j.tine.2020.100134. Epub
      2020 Jun 24.


PMID- 32917182
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20211204
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 11
TI  - Study of laboratory staff' knowledge of biobanking in Cote d'Ivoire.
PG  - 88
LID - 10.1186/s12910-020-00533-y [doi]
AB  - BACKGROUND: A biobank is a structure which collects and manages biological
      samples and their associated data. The collected samples will then be made
      available for various uses. The sharing of those samples raised ethical questions
      which have been answered through specific rules. Thus, a Biobank functioning
      under tight ethical rules would be immensely valuable from a scientific and an
      economic view point. In 2009, Cote d'Ivoire established a biobank, which has been
      chosen to house the regional biobank of Economic Community of West African States
      (ECOWAS) countries in 2018. To ensure optimal and efficient use of this biobank, 
      the scientific community must be aware of its existence and its role. It was
      therefore necessary to evaluate the knowledge of laboratories staff on the role
      and activities of a biobank. METHODS: This descriptive study was done by
      questioning staff from laboratories working on human's health, animals or plants.
      The laboratories were located in southern Cote d'Ivoire. RESULTS: A total of 205 
      people completed the questionnaire. Of these 205 people, 34.63% were biologists, 
      7.32% engineers, 48.78% technicians and 9.27% PhD students. The average length of
      work experience was 10.11 +/- 7.83 years. In this study, 43.41% of the
      participants had never heard of biobanking. Only 48.78% of participants had a
      good understanding of the role of a biobank. Technicians and PhD students were
      less educated on the notion of biobank (p < 0.000001). Although biologists were
      more educated on this issue, 21.13% of them had a misconception of biobank. Good 
      knowledge of the role of a biobank was not significantly related to the work
      experience's length (p > 0.88). CONCLUSION: The level of knowledge of laboratory 
      staff about biobanking needs to be improved. Training on the role, activities and
      interests of the biobank is important.
FAU - Kintossou, Ambroise Kouame
AU  - Kintossou AK
AUID- ORCID: 0000-0001-5799-0269
AD  - Biobank, Pasteur Institute of Cote d'Ivoire, 01 BP 490, Abidjan, Cote d'Ivoire.
      kkintossou@gmail.com.
AD  - Training and Research Unit of Biosciences, Felix Houphouet Boigny University,
      Abidjan, Cote d'Ivoire. kkintossou@gmail.com.
FAU - N'dri, Mathias Kouame
AU  - N'dri MK
AD  - Department of Epidemiology and Clinical Research, Pasteur Institute of Cote
      d'Ivoire, Abidjan, Cote d'Ivoire.
FAU - Money, Marcelle
AU  - Money M
AD  - Biobank, Pasteur Institute of Cote d'Ivoire, 01 BP 490, Abidjan, Cote d'Ivoire.
FAU - Cisse, Souleymane
AU  - Cisse S
AD  - Biobank, Pasteur Institute of Cote d'Ivoire, 01 BP 490, Abidjan, Cote d'Ivoire.
FAU - Doumbia, Simini
AU  - Doumbia S
AD  - Biobank, Pasteur Institute of Cote d'Ivoire, 01 BP 490, Abidjan, Cote d'Ivoire.
FAU - Soumahoro, Man-Koumba
AU  - Soumahoro MK
AD  - Department of Epidemiology and Clinical Research, Pasteur Institute of Cote
      d'Ivoire, Abidjan, Cote d'Ivoire.
FAU - Coulibaly, Amadou Founzegue
AU  - Coulibaly AF
AD  - Training and Research Unit of Biosciences, Felix Houphouet Boigny University,
      Abidjan, Cote d'Ivoire.
FAU - Djaman, Joseph Allico
AU  - Djaman JA
AD  - Training and Research Unit of Biosciences, Felix Houphouet Boigny University,
      Abidjan, Cote d'Ivoire.
FAU - Dosso, Mireille
AU  - Dosso M
AD  - Biobank, Pasteur Institute of Cote d'Ivoire, 01 BP 490, Abidjan, Cote d'Ivoire.
AD  - Department of Epidemiology and Clinical Research, Pasteur Institute of Cote
      d'Ivoire, Abidjan, Cote d'Ivoire.
AD  - Training and Research Unit of Medical Sciences, Felix Houphouet Boigny
      University, Abidjan, Cote d'Ivoire.
LA  - eng
PT  - Journal Article
DEP - 20200911
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Biological Specimen Banks
MH  - Cote d'Ivoire
MH  - Ethnicity
MH  - Humans
MH  - *Laboratories
MH  - Students
MH  - Surveys and Questionnaires
PMC - PMC7488401
OTO - NOTNLM
OT  - *Biobank
OT  - *Cote d'Ivoire
OT  - *Knowledge
OT  - *Laboratory staff
EDAT- 2020/09/13 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/12 05:23
PHST- 2020/01/17 00:00 [received]
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/09/12 05:23 [entrez]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00533-y [doi]
AID - 10.1186/s12910-020-00533-y [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 11;21(1):88. doi: 10.1186/s12910-020-00533-y.


PMID- 32917117
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Dec
TI  - An Analysis of Retracted Articles with Authors or Co-authors from the African
      Region: Possible Implications for Training and Awareness Raising.
PG  - 478-493
LID - 10.1177/1556264620955110 [doi]
AB  - Retraction of research articles is increasing but the reasons and characteristics
      of retractions involving authors from Africa have not been studied. Using records
      from the Retraction Watch database, we analyzed information on articles retracted
      between 2014 and 2018 with at least one author or co-author affiliated with an
      institution in the African region to determine the most prevalent types of
      misconduct, subject fields, and the characteristics of researchers or research
      teams associated with retraction. Plagiarism was the most frequent form of
      misconduct, followed by duplication. International collaboration was associated
      with fewer retractions for plagiarism and errors in data, but increased
      retractions due to authorship issues. Teams with at least one senior member were 
      associated with fewer retractions due to plagiarism but more due to duplication
      of articles. We conclude by making recommendations for best practice, further
      research, and highlighting implications for education.
FAU - Rossouw, Theresa M
AU  - Rossouw TM
AUID- ORCID: 0000-0003-4066-922X
AD  - University of Pretoria, Pretoria, South Africa.
FAU - Matsau, Liapeng
AU  - Matsau L
AD  - South African Qualifications Authority, Pretoria, South Africa.
FAU - van Zyl, Christa
AU  - van Zyl C
AD  - Human Sciences Research Council, Pretoria, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200911
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - Authorship
MH  - *Biomedical Research
MH  - Databases, Factual
MH  - Humans
MH  - Plagiarism
MH  - *Scientific Misconduct
OTO - NOTNLM
OT  - *Africa
OT  - *duplication
OT  - *ethics training
OT  - *plagiarism
OT  - *research integrity
OT  - *retractions
EDAT- 2020/09/13 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/09/12 05:22
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/09/12 05:22 [entrez]
AID - 10.1177/1556264620955110 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Dec;15(5):478-493. doi:
      10.1177/1556264620955110. Epub 2020 Sep 11.


PMID- 32917056
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 9
TI  - Didactic Benefits of Surgery on Body Donors during Live Surgery Events in
      Minimally Invasive Surgery.
LID - E2912 [pii]
LID - 10.3390/jcm9092912 [doi]
AB  - BACKGROUND: Live surgery events serve as a valuable tool for surgical education, 
      but also raise ethical concerns about patient safety and professional
      performance. In the present study, we evaluate the technical feasibility and
      didactic benefits of live surgery on body donors compared to real patients.
      METHODS: A live surgery session performed on a body donor's cadaver embalmed in
      ethanol-glycerol-lysoformin was integrated into the live surgery program
      presented at a major gynecological convention of minimally invasive surgery.
      Surgical procedures carried out in real patients were paralleled in the body
      donor, including the dissection and illustration of surgically relevant
      anatomical landmarks. A standardized questionnaire was filled by the participants
      (n = 208) to evaluate the appropriateness, effectiveness, and benefits of this
      novel concept. RESULTS: The live surgery event was appreciated as a useful
      educational tool. With regard to the use of body donors, authenticity was rated
      high (85.5%), and the overall value of body donors for surgical education and
      training was rated very high (95.0%). The didactic benefit of simultaneous
      operations performed on body donors and real patients was considered particularly
      useful (95.5%), whereas complete replacement of real patients by body donors was 
      not favored (14.5%). CONCLUSIONS: The study demonstrated both the technical
      feasibility and didactic benefits of performing minimally invasive surgery in
      body donors as part of live surgery events. This novel concept has the potential 
      to enhance anatomical knowledge, providing insights into complex surgical
      procedures, and may serve to overcome yet unresolved ethical concerns related to 
      live surgery events.
FAU - Ackermann, Johannes
AU  - Ackermann J
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Wedel, Thilo
AU  - Wedel T
AD  - Institute of Anatomy, Christian-Albrechts University Kiel, Otto-Hahn-Platz 8,
      24118 Kiel, Germany.
FAU - Holthaus, Bernd
AU  - Holthaus B
AUID- ORCID: 0000-0001-5455-6002
AD  - Clinic of Obstetrics and Gynecology, St. Elisabeth Hospital, 49401 Damme,
      Germany.
FAU - Bojahr, Bernd
AU  - Bojahr B
AD  - Clinic of Minimally Invasive Surgery, Kurstrasse 11, 14129 Berlin-Zehlendorf,
      Germany.
FAU - Hackethal, Andreas
AU  - Hackethal A
AD  - Frauenklinik an der Elbe, Oberbaumbrucke 1, 20457 Hamburg, Germany.
FAU - Brucker, Sara
AU  - Brucker S
AUID- ORCID: 0000-0001-5162-1542
AD  - Department fur Frauengesundheit, University Hospital Tubingen, Calwer Strasse 7, 
      72076 Tubingen, Germany.
FAU - Biebl, Matthias
AU  - Biebl M
AD  - Department of Surgery, Campus Virchow Klinikum, Charite-Universitatsmedizin
      Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
FAU - Westermann, Martina
AU  - Westermann M
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Gunther, Veronika
AU  - Gunther V
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Kruger, Magret
AU  - Kruger M
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Maass, Nicolai
AU  - Maass N
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Mettler, Liselotte
AU  - Mettler L
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Peters, Gontje
AU  - Peters G
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
FAU - Alkatout, Ibrahim
AU  - Alkatout I
AD  - Department of Obstetrics and Gynecology, Kiel School of Gynaecological Endoscopy,
      University Hospitals Schleswig-Holstein, Campus Kiel, Arnold-Heller Str. 3, House
      C, 24105 Kiel, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7563950
OTO - NOTNLM
OT  - body donors
OT  - clinical anatomy
OT  - laparoscopy
OT  - live surgery events
OT  - minimally invasive surgery
OT  - surgical education
EDAT- 2020/09/13 06:00
MHDA- 2020/09/13 06:01
CRDT- 2020/09/12 01:02
PHST- 2020/08/08 00:00 [received]
PHST- 2020/09/04 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/12 01:02 [entrez]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2020/09/13 06:01 [medline]
AID - jcm9092912 [pii]
AID - 10.3390/jcm9092912 [doi]
PST - epublish
SO  - J Clin Med. 2020 Sep 9;9(9). pii: jcm9092912. doi: 10.3390/jcm9092912.


PMID- 32917047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Dilemmas in the Management of Liminal Rodents-Attitudes of Dutch Pest
      Controllers.
LID - E1614 [pii]
LID - 10.3390/ani10091614 [doi]
AB  - When non-human animals are labeled as 'pests', their moral status and welfare
      seem relatively unimportant. In a multi-stakeholder project, we develop an
      assessment frame for a more responsible rodent management that includes animal
      welfare. An online survey among 129 Dutch pest controllers was carried out in
      order to find out more about pest controllers' attitudes about animal welfare.
      Respondents indicate to consider animal welfare in their job. They see
      differences in the welfare impact of different rodent control methods. A dilemma 
      may occur when methods with a high impact, such as rodenticides, are ofttimes
      used in practice. Respondents also indicate that in different real-life scenarios
      (the hospital kitchen vs. the private backyard), a different weight may be
      attributed to the importance of animal welfare. Almost half of the respondents
      encounter difficulties when weighing animals against human interests. The
      problems are mainly related to clients who are not willing to invest sufficient
      money in preventive methods, where respondents do believe in. Some differences
      were found between respondents depending on membership of a professional
      association for pest controllers. The results of this study are relevant input
      for focus groups with pest controllers and their clients and for the development 
      of the aforementioned assessment frame.
FAU - van Gerwen, Maite A A M
AU  - van Gerwen MAAM
AUID- ORCID: 0000-0003-2704-6036
AD  - Centre for Sustainable Animal Stewardship (CenSAS), Department Population Health 
      Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 2, 3584 CM
      Utrecht, The Netherlands.
FAU - Nieuwland, Joachim
AU  - Nieuwland J
AUID- ORCID: 0000-0003-3282-5173
AD  - Centre for Sustainable Animal Stewardship (CenSAS), Department Population Health 
      Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 2, 3584 CM
      Utrecht, The Netherlands.
FAU - van Lith, Hein A
AU  - van Lith HA
AUID- ORCID: 0000-0002-0898-1793
AD  - Section Laboratory Animal Science/3Rs-Centre, Unit Animals in Science and
      Society, Department Population Health Sciences, Faculty of Veterinary Medicine,
      Utrecht University, Yalelaan 2, 3584 CM Utrecht, The Netherlands.
AD  - Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Universiteitsweg
      100, 3584 CG Utrecht, The Netherlands.
FAU - Meijboom, Franck L B
AU  - Meijboom FLB
AUID- ORCID: 0000-0002-0752-016X
AD  - Centre for Sustainable Animal Stewardship (CenSAS), Department Population Health 
      Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 2, 3584 CM
      Utrecht, The Netherlands.
AD  - Ethics Institute, Faculty of Humanities, Utrecht University, Janskerkhof 13, 3512
      BL Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552245
OTO - NOTNLM
OT  - animal ethics
OT  - animal welfare
OT  - commensal rodents
OT  - liminal rodents
OT  - pest control
OT  - rodent control
OT  - rodent management
EDAT- 2020/09/13 06:00
MHDA- 2020/09/13 06:01
CRDT- 2020/09/12 01:02
PHST- 2020/08/17 00:00 [received]
PHST- 2020/09/04 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/12 01:02 [entrez]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2020/09/13 06:01 [medline]
AID - ani10091614 [pii]
AID - 10.3390/ani10091614 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Sep 9;10(9). pii: ani10091614. doi: 10.3390/ani10091614.


PMID- 32916865
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20211204
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 18
DP  - 2020 Sep 9
TI  - Human Mesenchymal Stromal Cells Unveil an Unexpected Differentiation Potential
      toward the Dopaminergic Neuronal Lineage.
LID - E6589 [pii]
LID - 10.3390/ijms21186589 [doi]
AB  - Degeneration of dopaminergic neurons represents the cause of many
      neurodegenerative diseases, with increasing incidence worldwide. The replacement 
      of dead cells with new healthy ones may represent an appealing therapeutic
      approach to these pathologies, but currently, only pluripotent stem cells can
      generate dopaminergic neurons with high efficiency. However, with the use of
      these cells arises safety and/or ethical issues. Human mesenchymal stromal cells 
      (hFM-MSCs) are perinatal stem cells that can be easily isolated from the
      amniochorionic membrane after delivery. Generally considered multipotent, their
      real differentiative potential is not completely elucidated. The aim of this
      study was to analyze their stemness characteristics and to evaluate whether they 
      may overcome their mesenchymal fate, generating dopaminergic neurons. We
      demonstrated that hFM-MSCs expressed embryonal genes OCT4, NANOG, SOX2, KLF4,
      OVOL1, and ESG1, suggesting they have some features of pluripotency. Moreover,
      hFM-MSCs that underwent a dopaminergic differentiation protocol gradually
      increased the transcription of dopaminergic markers LMX1b, NURR1, PITX3, and DAT.
      We finally obtained a homogeneous population of cells resembling the morphology
      of primary midbrain dopaminergic neurons that expressed the functional
      dopaminergic markers TH, DAT, and Nurr1. In conclusion, our results suggested
      that hFM-MSCs retain the expression of pluripotency genes and are able to
      differentiate not only into mesodermal cells, but also into neuroectodermal
      dopaminergic neuron-like cells.
FAU - Gaggi, Giulia
AU  - Gaggi G
AUID- ORCID: 0000-0002-8761-7390
AD  - Human Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G. D'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Di Credico, Andrea
AU  - Di Credico A
AUID- ORCID: 0000-0002-8388-9305
AD  - Human Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G. D'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Izzicupo, Pascal
AU  - Izzicupo P
AUID- ORCID: 0000-0001-6944-8995
AD  - Human Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G. D'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Alviano, Francesco
AU  - Alviano F
AD  - Department of Experimental Diagnostic and Speciality Medicine, Unit of Histology,
      Embriology and Applied Biology, University of Bologna, 40126 Bologna, Italy.
FAU - Di Mauro, Michele
AU  - Di Mauro M
AD  - Cardio-Thoracic Surgery Unit, Heart and Vascular Centre, Maastricht University
      Medical Centre (MUMC), Cardiovascular Research Institute Maastricht (CARIM), 6202
      Maastricht, The Netherlands.
FAU - Di Baldassarre, Angela
AU  - Di Baldassarre A
AUID- ORCID: 0000-0002-4473-4909
AD  - Human Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G. D'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Ghinassi, Barbara
AU  - Ghinassi B
AUID- ORCID: 0000-0002-3529-2790
AD  - Human Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G. D'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
LA  - eng
GR  - PRIN2017ATZ2YK/Ministero dell'Istruzione, dell'Universita e della Ricerca
PT  - Journal Article
DEP - 20200909
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - *Cell Differentiation
MH  - Cell Lineage
MH  - *Dopaminergic Neurons
MH  - Humans
MH  - Induced Pluripotent Stem Cells
MH  - Kruppel-Like Factor 4
MH  - Mesenchymal Stem Cells/*physiology
PMC - PMC7555006
OTO - NOTNLM
OT  - DAT
OT  - PITX3
OT  - Parkinson's disease
OT  - TH
OT  - dopaminergic neurons
OT  - hFM-MSCs
OT  - human mesenchymal stromal cells
OT  - mesenchymal fate
OT  - perinatal stem cells
OT  - pluripotency
EDAT- 2020/09/13 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/09/12 01:01
PHST- 2020/08/08 00:00 [received]
PHST- 2020/08/29 00:00 [revised]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/12 01:01 [entrez]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
AID - ijms21186589 [pii]
AID - 10.3390/ijms21186589 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Sep 9;21(18). pii: ijms21186589. doi: 10.3390/ijms21186589.


PMID- 32914776
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 9
DP  - 2020 Sep
TI  - [Audit and Feedback approach in the CoViD-19 emergency: adaptation of the
      EASY-NET project in the AOU Citta della Salute e della Scienza of Turin.]
PG  - 487-491
LID - 10.1701/3421.34061 [doi]
AB  - CoViD-19 pandemic heavily impacted most on-going research activities, causing
      delays and need of re-programming. EASY-NET (NET-2016-02364191) is a network
      project, started in April 2019, co-funded by the Italian Ministry of Health and
      the participating regions. Within the general project, centred on the evaluation 
      of Audit and Feedback (A&F) strategies in improving quality and equity in
      different health care contexts, the Piedmont region is responsible of the work
      package 3 (WP3) on specific oncology pathways and procedures. After a thorough
      evaluation of the impact of the CoViD-19 emergency on the WP3 activities, at the 
      beginning of March 2020, the decision was to continue, with some adaptations, the
      audits already started, and to delay those in the early planning phase. The
      provisional availability of part of the time-persons involved in EASY-NET on one 
      side, and the urgency of acquiring data on the management of the large number of 
      CoViD-19 patients admitted to the study coordinator hospital on the other side,
      determined the personnel responsible of the WP3, in accordance with the hospital 
      management, to invest these resources in monitoring the CoViD-19 hospitalized
      patients with both A&F activity and research objectives. Besides periodic
      reports, a web site, with restricted access to the involved health care
      personnel, was developed to allow a direct and timely consultation of graphics
      describing the flow of the patients, their management, and outcomes. This
      experience was made possible thanks to a favourable combination of different
      factors: the presence within the hospital of a group of experienced
      epidemiologists in A&F, the availability of extra resources, the strong support
      and collaboration by the hospital management and the readiness for authorisation 
      by the Ethics Committee. We underline the need to provide a certain degree of
      flexibility in the long-term projects funded by the Ministry of Health, the
      extraordinary adaptability of the A&F approach also to emergency situations and
      the possibility of combining audit activities and research objectives in the same
      project.
FAU - Pagano, Eva
AU  - Pagano E
FAU - Castiglione, Anna
AU  - Castiglione A
AD  - SSD Epidemiologia Clinica e Valutativa, AOU Citta della Salute e della Scienza di
      Torino.
FAU - Scozzari, Gitana
AU  - Scozzari G
AD  - Direzione Sanitaria, Presidio Molinette, AOU Citta della Salute e della Scienza
      di Torino.
FAU - La Valle, Giovanni
AU  - La Valle G
AD  - Direzione Aziendale, AOU Citta della Salute e della Scienza di Torino.
FAU - Angelone, Lorenzo
AU  - Angelone L
AD  - Direzione Aziendale, AOU Citta della Salute e della Scienza di Torino.
FAU - Agabiti, Nera
AU  - Agabiti N
FAU - Scarmozzino, Antonio
AU  - Scarmozzino A
AD  - Direzione Sanitaria, Presidio Molinette, AOU Citta della Salute e della Scienza
      di Torino.
FAU - Ciccone, Giovannino
AU  - Ciccone G
LA  - ita
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Audit e Feedback nell'emergenza CoViD-19: adattamento del progetto EASY-NET
      nell'AOU Citta della Salute e della Scienza di Torino.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - Biomedical Research/organization & administration
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Delivery of Health Care/*organization & administration/standards
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Italy/epidemiology
MH  - Medical Audit/*organization & administration
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Quality of Health Care
EDAT- 2020/09/12 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/11 08:39
PHST- 2020/09/11 08:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1701/3421.34061 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Sep;111(9):487-491. doi: 10.1701/3421.34061.


PMID- 32914118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2665-9271 (Electronic)
IS  - 2665-9271 (Linking)
VI  - 3
DP  - 2020 Nov
TI  - Are mixed meat and vegetable protein products good alternatives for reducing meat
      consumption? A case study with burgers.
PG  - 30-40
LID - 10.1016/j.crfs.2020.02.003 [doi]
AB  - The principal motivations for the worldwide trend towards reducing meat
      consumption are health, the environment and animal welfare. The present study
      investigated the willingness of omnivores to introduce mixed (beef-vegetable
      protein) and 100% vegetable protein products into their diet. The participants (n
      = 251) were young adult omnivores who consumed meat at least once a week. The
      stimuli were images of six different products representing two beef burgers, two 
      mixed-protein burgers (50% beef and 50% seitan or soy) and two 100% vegetable
      protein burgers (seitan and soy). The participants were asked to write down
      spontaneous associations with each product (Word Association technique) and score
      their expected liking and purchase intention for them. In addition, they
      completed a questionnaire (36 statements) to evaluate their attitude towards meat
      reduction, considering six aspects: diet, habits, ethics, hedonism, health, and
      the environment. According to their response to these statements, they were
      classified into three attitude groups: anti- (ANTI, n = 106), intermediate-
      (INTERM, n = 89), and pro- (PRO, n = 56) meat reduction. All the participants
      expected to like the 100% beef burger most, the PRO group expected to like all
      six products to a similar degree and the ANTI group expected to like the mixed
      product significantly more than the 100% vegetable product, indicating that the
      introduction of mixed proteins could be a small first step towards meat reduction
      for those most attached to meat. The associations elicited by the different
      burgers were mostly the same but were mentioned with different frequencies, which
      also depended on the attitude group. These distinctive association patterns
      showed clear connections to the motives underlying each group's attitude towards 
      meat reduction. It may be concluded that mixed products would be a reliable
      although timid option for consumers who are attached to meat to reduce their meat
      intake, while any of the products containing vegetable proteins would be an
      option for consumers who are more favourable towards meat reduction.
CI  - (c) 2020 The Authors.
FAU - Tarrega, Amparo
AU  - Tarrega A
AD  - Instituto de Agroquimica y Tecnologia de Alimentos (IATA-CSIC), Agustin Escardino
      7, Paterna (Valencia), Spain.
FAU - Rizo, Arantxa
AU  - Rizo A
AD  - Instituto de Agroquimica y Tecnologia de Alimentos (IATA-CSIC), Agustin Escardino
      7, Paterna (Valencia), Spain.
FAU - Murciano, Ana
AU  - Murciano A
AD  - Instituto de Agroquimica y Tecnologia de Alimentos (IATA-CSIC), Agustin Escardino
      7, Paterna (Valencia), Spain.
FAU - Laguna, Laura
AU  - Laguna L
AD  - Instituto de Agroquimica y Tecnologia de Alimentos (IATA-CSIC), Agustin Escardino
      7, Paterna (Valencia), Spain.
FAU - Fiszman, Susana
AU  - Fiszman S
AD  - Instituto de Agroquimica y Tecnologia de Alimentos (IATA-CSIC), Agustin Escardino
      7, Paterna (Valencia), Spain.
LA  - eng
PT  - Journal Article
DEP - 20200303
PL  - Netherlands
TA  - Curr Res Food Sci
JT  - Current research in food science
JID - 101771059
PMC - PMC7473368
OTO - NOTNLM
OT  - Attitudes towards meat reduction
OT  - Expected liking
OT  - Meat alternatives
OT  - Purchase intention
OT  - Word association
COIS- None declared.
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 05:46
PHST- 2020/09/11 05:46 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
AID - 10.1016/j.crfs.2020.02.003 [doi]
AID - S2665-9271(20)30006-X [pii]
PST - epublish
SO  - Curr Res Food Sci. 2020 Mar 3;3:30-40. doi: 10.1016/j.crfs.2020.02.003.
      eCollection 2020 Nov.


PMID- 32913894
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2382-1205 (Print)
IS  - 2382-1205 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - From Creation to Evaluation: A Comprehensive Global Health Scholars Program for
      Graduate Medical Education Trainees.
PG  - 2382120520951821
LID - 10.1177/2382120520951821 [doi]
AB  - INTRODUCTION: Recently, participation in clinical global health rotations has
      significantly increased among graduate medical education (GME) trainees. Despite 
      the many benefits these experiences provide, many ethical challenges exist.
      Well-intentioned partnerships and participants often encounter personal and
      professional dilemmas related to safety, social responsibility, and
      accountability. We designed a curriculum to provide trainees of all specialties
      with a comprehensive educational program aimed at delivering culturally mindful
      and ethically responsible clinical care in resource-constrained settings.
      METHODS: The McGaw Global Health Clinical Scholars Program (GHCS) at Northwestern
      University offers a 2-year curriculum for selected GME trainees across
      specialties interested in global health. Each trainee must complete the following
      components: core lectures, peer journal club, specialty-specific lectures, a
      mentorship agreement, ethics and skill-based simulations, a global health field
      experience, a poster presentation, and a mentored scholarly project. RESULTS:
      Since 2014, 84 trainees from 13 specialties have participated in the program with
      50 current trainees and 39 graduates. Twenty-five trainees completed exit
      surveys, of which 95% would recommend this program to other trainees and 84% felt
      more prepared to deliver global health care. In addition, 78% reported career
      plans that included global health and/or work with underserved populations.
      Trainees described "acceptance of differences and respect for those differences" 
      and "understanding sustainability" as learning points from the program.
      DISCUSSION: Providing a comprehensive global health education program across
      specialties can be feasible and effective. GME trainees who participated in this 
      program report feeling both more prepared for clinical experiences and more
      likely to serve the underserved anywhere.
CI  - (c) The Author(s) 2020.
FAU - Morgan, Jennifer
AU  - Morgan J
AD  - Division of Hospital Medicine, Northwestern University Feinberg School of
      Medicine, Chicago, IL, USA.
FAU - Galvin, Shannon
AU  - Galvin S
AD  - Division of Infectious Diseases, Northwestern University Feinberg School of
      Medicine, Chicago, IL; Center for Global Health Education, Northwestern
      University Institute for Global Health, Chicago, IL, USA.
FAU - Goldstein, Joshua
AU  - Goldstein J
AD  - Graduate Medical Education, McGaw Medical Center of Northwestern University,
      Chicago, IL, USA.
FAU - Fant, Colleen
AU  - Fant C
AD  - Department of Pediatrics, Northwestern University Feinberg School of Medicine,
      Chicago, IL, USA; Pediatric Emergency Medicine, Ann and Robert H. Lurie
      Children's Hospital of Chicago, Chicago, IL, USA.
FAU - Murphy, Robert
AU  - Murphy R
AD  - Division of Infectious Diseases, Department of Medicine, Northwestern University 
      Feinberg School of Medicine, Chicago, IL, USA; Northwestern University Institute 
      for Global Health, Chicago, IL, USA.
FAU - Doobay-Persaud, Ashti
AU  - Doobay-Persaud A
AUID- ORCID: https://orcid.org/0000-0001-7063-4429
AD  - Hospital Medicine, Northwestern University Feinberg School of Medicine, Chicago, 
      IL, USA; Center for Global Health Education, Northwestern University Institute
      for Global Health, Chicago, IL, USA.
LA  - eng
GR  - D43 TW009340/TW/FIC NIH HHS/United States
GR  - T32 HD075731/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200821
PL  - United States
TA  - J Med Educ Curric Dev
JT  - Journal of medical education and curricular development
JID - 101690298
PMC - PMC7444107
OTO - NOTNLM
OT  - ethics
OT  - global health
OT  - medical education
COIS- Declaration of conflicting interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 05:45
PHST- 2020/04/10 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/09/11 05:45 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
AID - 10.1177/2382120520951821 [doi]
AID - 10.1177_2382120520951821 [pii]
PST - epublish
SO  - J Med Educ Curric Dev. 2020 Aug 21;7:2382120520951821. doi:
      10.1177/2382120520951821. eCollection 2020 Jan-Dec.


PMID- 32913846
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Linking)
VI  - 8
IP  - 16
DP  - 2020 Aug 26
TI  - Management of cancer patients during COVID-19 pandemic at developing countries.
PG  - 3390-3404
LID - 10.12998/wjcc.v8.i16.3390 [doi]
AB  - Cancer patient care requires a multi-disciplinary approach and multiple medical
      and ethical considerations. Clinical care during a pandemic health crisis
      requires prioritising the use of resources for patients with a greater chance of 
      survival, especially in developing countries. The coronavirus disease 2019 crisis
      has generated new challenges given that cancer patients are normally not
      prioritised for admission in critical care units. Nevertheless, the development
      of new cancer drugs and novel adjuvant/neoadjuvant protocols has dramatically
      improved the prognosis of cancer patients, resulting in a more complex
      decision-making when prioritising intensive care in pandemic times. In this
      context, it is essential to establish an effective and transparent communication 
      between the oncology team, critical care, and emergency units to make the best
      decisions, considering the principles of justice and charity. Concurrently,
      cancer treatment protocols must be adapted to prioritise according to oncologic
      response and prognosis. Communication technologies are powerful tools to optimise
      cancer care during pandemics, and we must adapt quickly to this new scenario of
      clinical care and teaching. In this new challenging pandemic scenario,
      multi-disciplinary work and effective communication between clinics, technology, 
      science, and ethics is the key to optimising clinical care of cancer patients.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Gonzalez-Montero, Jaime
AU  - Gonzalez-Montero J
AD  - Basic and Clinical Oncology Department, Faculty of Medicine, University of Chile,
      Santiago 70058, Chile. jagonzalez@ug.uchile.cl.
FAU - Valenzuela, Guillermo
AU  - Valenzuela G
AD  - Basic and Clinical Oncology Department, Faculty of Medicine, University of Chile,
      Santiago 70058, Chile.
FAU - Ahumada, Monica
AU  - Ahumada M
AD  - Basic and Clinical Oncology Department, Faculty of Medicine, University of Chile,
      Santiago 70058, Chile.
FAU - Barajas, Olga
AU  - Barajas O
AD  - Basic and Clinical Oncology Department, Faculty of Medicine, University of Chile,
      Santiago 70058, Chile.
FAU - Villanueva, Luis
AU  - Villanueva L
AD  - Oncology Department, Hospital Clinico Universidad de Chile and Fundacion Arturo
      Lopez-Perez, Chile.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC7457113
OTO - NOTNLM
OT  - COVID-19
OT  - Cancer
OT  - Oncology
OT  - Pandemic
OT  - SARS-CoV-2
COIS- Conflict-of-interest statement: No potential conflicts of interest.
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 05:45
PHST- 2020/05/12 00:00 [received]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/11 05:45 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
AID - 10.12998/wjcc.v8.i16.3390 [doi]
PST - ppublish
SO  - World J Clin Cases. 2020 Aug 26;8(16):3390-3404. doi: 10.12998/wjcc.v8.i16.3390.


PMID- 32913828
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2239-8031 (Electronic)
IS  - 2239-8031 (Linking)
VI  - 23
IP  - 1
DP  - 2020 May 20
TI  - Values in persons with borderline personality disorder: their relevance for the
      therapeutic interview.
PG  - 449
LID - 10.4081/ripppo.2020.449 [doi]
AB  - This is an explorative study on values of 25 patients affected by borderline
      personality disorder interviewed in a clinical setting (phenomenological-dynamic 
      psychotherapy) and re-classified following Consensual Qualitative Research. We
      identified three main categories of values: recognition (the importance for
      attention, acknowledgment, commendation and acceptance by the other),
      authenticity (the importance of absolute emotional fusion with the other), and
      immediacy (the importance of instantaneous, hic et nunc satisfaction of one's
      needs/desires). Each of these values expresses a kind of 'logic', namely the
      logic of intimacy (the other's closeness as indispensable for defining oneself
      and establish/reinforce one's selfhood and identity), spontaneity (over-reliance 
      on feelings unrestricted by social norms undermining their intensity), and
      instantaneity (glorification of 'now-moments'/execration of procrastination
      draining the vitality of feelings). The borderline person lives an emotional
      normativity constituted by the intensity of feelings under the spell of a
      frustrated normativity since they enter into a collision with the hypocrisy of
      common-sense ethical norms and social rules and conventions, as well as by
      potential conflicts with the feelings of the other. Acknowledging the values
      affirmed by borderline persons may help to better understand their condition -
      that is, to grasp 'what it is like' and make sense of the phenomena that affect
      them - and particularly to find a logic in their otherwise irrational and
      incomprehensible self-defeating behavior.
CI  - (c)Copyright: the Author(s).
FAU - Mancini, Milena
AU  - Mancini M
AD  - Department of Psychological, Health and Territorial Sciences, G. d'Annunzio
      University, Chieti, Italy.
FAU - Stanghellini, Giovanni
AU  - Stanghellini G
AD  - Department of Psychological, Health and Territorial Sciences, G. d'Annunzio
      University, Chieti, Italy.
AD  - D. Portales University, Santiago, Chile.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - Italy
TA  - Res Psychother
JT  - Research in psychotherapy (Milano)
JID - 101684638
PMC - PMC7451322
OTO - NOTNLM
OT  - Authenticity
OT  - borderline personality disorder
OT  - immediacy
OT  - phenomenological-dynamic psychotherapy
OT  - recognition; values
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 05:45
PHST- 2020/01/22 00:00 [received]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/09/11 05:45 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
AID - 10.4081/ripppo.2020.449 [doi]
PST - epublish
SO  - Res Psychother. 2020 May 21;23(1):449. doi: 10.4081/ripppo.2020.449. eCollection 
      2020 May 20.


PMID- 32913648
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-9361 (Print)
IS  - 2049-9361 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Antimicrobial stewardship programs; a two-part narrative review of step-wise
      design and issues of controversy. Part II: Ten questions reflecting knowledge
      gaps and issues of controversy in the field of antimicrobial stewardship.
PG  - 2049936120945083
LID - 10.1177/2049936120945083 [doi]
AB  - Regardless of one's opinion on antimicrobial stewardship programs (ASPs), it is
      hardly possible to work in hospital care and not be exposed to the term or its
      practical effects. Despite the term being relatively new, the number of
      publications in the field is vast, including several excellent reviews of general
      and specific aspects. Work in antimicrobial stewardship is complex, and include
      aspects not only of infectious disease and microbiology, but also of
      epidemiology, genetics, behavioural psychology, systems science, economics and
      ethics, to name but a few. This review aims to take several of these aspects and 
      the scientific evidence from antimicrobial stewardship studies and merge them
      into two questions: How should we design ASPs based on what we know today? and
      Which are the most essential unanswered questions regarding antimicrobial
      stewardship on a broader scale? This narrative review is written in two separate 
      parts aiming to provide answers to the two questions. The first part, published
      separately, is written as a step-wise approach to designing a stewardship
      intervention based on the pillars of unmet need, feasibility, scientific evidence
      and necessary core elements. It is written mainly as a guide to someone new to
      the field. It is sorted into five distinct steps; (a) focusing on designing aims;
      (b) assessing performance and local barriers to rational antimicrobial use; (c)
      deciding on intervention technique; (d) practical, tailored design including core
      element inclusion; and (e) evaluation and sustainability. This second part
      formulates 10 critical questions on controversies in the field of antimicrobial
      stewardship. It is aimed at clinicians and researchers with stewardship
      experience and strives to promote discussion, not to provide answers.
CI  - (c) The Author(s), 2020.
FAU - Resman, Fredrik
AU  - Resman F
AUID- ORCID: https://orcid.org/0000-0002-3433-512X
AD  - Clinical Infection Medicine, Department of Translational Medicine, Lund
      University, Rut Lundskogs gata 3, plan 6, Malmo, 20502, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - England
TA  - Ther Adv Infect Dis
JT  - Therapeutic advances in infectious disease
JID - 101606715
PMC - PMC7443983
OTO - NOTNLM
OT  - Antimicrobial stewardship
OT  - antimicrobial resistance
COIS- Conflict of interest statement: The author declares that there is no conflict of 
      interest.
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 05:44
PHST- 2020/03/13 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/09/11 05:44 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
AID - 10.1177/2049936120945083 [doi]
AID - 10.1177_2049936120945083 [pii]
PST - epublish
SO  - Ther Adv Infect Dis. 2020 Aug 21;7:2049936120945083. doi:
      10.1177/2049936120945083. eCollection 2020 Jan-Dec.


PMID- 32913160
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20220416
IS  - 1119-3077 (Print)
VI  - 23
IP  - 9
DP  - 2020 Sep
TI  - Evaluation of extremity vascular injuries and treatment approaches.
PG  - 1221-1228
LID - 10.4103/njcp.njcp_656_18 [doi]
AB  - BACKGROUND: : Vascular injuries are commonly seen in both emergency services and 
      forensic medicine practise. They are often life-threatening, with high morbidity 
      and mortality rates. AIMS: This study aimed to retrospectively evaluate extremity
      vascular injuries and the associated treatment approaches. METHODS: After
      obtaining approval from the ethics committee of the university, those patients
      admitted to the emergency department of Adiyaman between 1 February 2013 and 31
      August 2018 were included in this study. The patients' data were obtained through
      the electronic records system, and the cases were evaluated according to the age,
      gender and cause of injury, including blunt force trauma injuries (accidents,
      traffic accidents, crush injuries and occupational accidents) and penetrating
      injuries (stabbing, gunshot wounds, suicide attempts and assaults). Additionally,
      the injuries were evaluated based on the extremity, according to the anatomical
      location and whether the injury was life-threatening. RESULTS: This study
      included 76 patients with extremity vascular injuries; 65 were males (85.52%), 11
      were females (14.48%) and their average age was 33.24 +/- 15.85 years. Forty-five
      (59.2%) of the patients had upper extremity vascular injuries, and 31 (40.3%) had
      lower extremity vascular injuries. In addition to arterial injuries, 26 (34.21%) 
      of the patients had venous injuries and 22 (28.94%) had nerve injuries. Nine of
      these patients had neurological deficits due to their nerve injuries. All of the 
      patients were revascularized within 3-5 hours, and none of the patients required 
      amputations. CONCLUSION: The primary goals in extremity vessel injury cases are
      to prevent mortality, especially after major vascular injuries, and save the
      extremity from amputation. With a fast, effective and multi-disciplinary
      approach, an accurate diagnosis and effective surgical intervention can prevent
      morbidity and mortality as well as reduce the rate of undesirable complications.
FAU - Guven, C
AU  - Guven C
AD  - Department of Cardiovascular Surgery, Adiyaman Univesity, Adiyaman, Turkey.
FAU - Kafadar, H
AU  - Kafadar H
AD  - Department of Forensic Medicine, Adiyaman Univesity, Adiyaman, Turkey.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Niger J Clin Pract
JT  - Nigerian journal of clinical practice
JID - 101150032
SB  - IM
MH  - Accidents, Traffic
MH  - Adolescent
MH  - Adult
MH  - Arteries/diagnostic imaging/injuries
MH  - Computed Tomography Angiography
MH  - Extremities
MH  - Female
MH  - Humans
MH  - Lower Extremity/*blood supply/*injuries
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vascular Surgical Procedures/*methods
MH  - Vascular System Injuries/*diagnostic imaging/*surgery
MH  - Wounds, Gunshot/complications/epidemiology/surgery
MH  - Wounds, Nonpenetrating/complications/epidemiology
MH  - Wounds, Penetrating/*diagnostic imaging/epidemiology/surgery
MH  - Young Adult
OTO - NOTNLM
OT  - Forensic medicine
OT  - injury
OT  - revascularization
OT  - vascular injury
COIS- None
EDAT- 2020/09/12 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - NigerJClinPract_2020_23_9_1221_294686 [pii]
AID - 10.4103/njcp.njcp_656_18 [doi]
PST - ppublish
SO  - Niger J Clin Pract. 2020 Sep;23(9):1221-1228. doi: 10.4103/njcp.njcp_656_18.


PMID- 32913115
OWN - NLM
STAT- Publisher
LR  - 20200911
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 10
TI  - Ethics of placebo use in clinical practice: why we need to look beyond
      deontology.
LID - medethics-2020-106253 [pii]
LID - 10.1136/medethics-2020-106253 [doi]
AB  - Beneficent clinical usage of placebos has been a problem for the application of
      Kant's deontology in medical ethics, which, in its strictest form, rejects
      deception universally. Some defenders of deontology have countered this by
      arguing placebos can be used by a physician without necessarily being deceptive. 
      In this paper we argue that such a manipulation of Kant's absolutism is not
      credible, and therefore, that we should look beyond deontology in our
      consideration of placebo usage in clinical practice. We conclude that Kant's
      deontology cannot be made compatible with placebo use in clinical practice due to
      the primacy it affords to the principle of autonomy.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Plowman, Rosanna
AU  - Plowman R
AD  - Medicine, University of London St George's, London, UK.
FAU - Spurr, Sally
AU  - Spurr S
AUID- ORCID: http://orcid.org/0000-0002-3799-6855
AD  - Medicine, University of London St George's, London, UK m1700928@sgul.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - autonomy
OT  - ethics
OT  - philosophical ethics
OT  - truth disclosure
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/03/30 00:00 [received]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - medethics-2020-106253 [pii]
AID - 10.1136/medethics-2020-106253 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 10. pii: medethics-2020-106253. doi:
      10.1136/medethics-2020-106253.


PMID- 32912995
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Home-modification interventions addressing falls and participation in activities 
      of daily living among older adults: a scoping review protocol.
PG  - e039742
LID - 10.1136/bmjopen-2020-039742 [doi]
AB  - INTRODUCTION: Falls are the second leading reason for incidental or unexpected
      deaths worldwide. Many older adults who fall, regardless of whether they are
      injured or not, tend to experience fear of fall and this can lead to decreased
      participation in activities of daily living (ADLs). Subsequent falls lead to
      weakness, a decline in physical functioning, increased chances of falling and a
      negative impact on the instrumental ADLs. Here, we present our scoping review
      protocol to appraise the literature to describe and explain the home-modification
      interventions used by occupational therapists to address falls and participation 
      in ADLs among community-dwelling older adults. We are aiming to review the
      available home-modification intervention protocols, facilitators and barriers to 
      such interventions, and the experiences of occupational therapists and clients
      after receiving these interventions. METHODS AND ANALYSIS: This scoping review
      protocol follows existing guidelines for scoping reviews with a particular
      attention on Arksey and O'Malley (2005) and Colquhoun et al (2014). We will
      include the following databases: Scopus, Web of Science, PubMed, ProQuest,
      Cumulative Index to Nursing and Allied Health Literature and Google Scholar. We
      plan to conduct the literature search from August 16, 2020 to September 15, 2020.
      Two reviewers will independently screen eligible studies for inclusion. We will
      extract the bibliographic data, study design, details of the intervention
      provided, outcomes and experiences of occupational therapists and clients, and
      further organise them for better understanding. ETHICS AND DISSEMINATION: As
      secondary data analysis, this scoping review does not require ethics approval.
      Results will summarise and disseminate the existing literature related to
      home-modification interventions provided by occupational therapists addressing
      falls and participation in ADLs among community-dwelling older adults. We plan to
      disseminate the results through peer-reviewed journals and conferences, targeting
      occupational therapists, other rehabilitation workers, researchers and policy
      makers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Georlee, Gifty M
AU  - Georlee GM
AD  - Former Intern, Department of Occupational Therapy, Manipal College of Health
      Professions, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka,
      India.
FAU - U, Abiram
AU  - U A
AD  - Former Intern, Department of Occupational Therapy, Manipal College of Health
      Professions, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka,
      India.
FAU - Dat, Pham Ngoc
AU  - Dat PN
AD  - Occupational Therapist, Faculty of Nursing and Medical Technology, Ho Chi Minh
      City University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam.
FAU - Tuan, Nguyen Khac
AU  - Tuan NK
AD  - Assistant lecturer, Department of Rehabilitation, Hai Duong Medical Technical
      University, Hai Duong, Viet Nam.
FAU - Mehrotra, Shashank
AU  - Mehrotra S
AUID- ORCID: 0000-0002-6015-8702
AD  - Assistant Professor- Senior Scale, Department of Occupational Therapy, Manipal
      College of Health Professions, Manipal Academy of Higher Education, Manipal,
      Udupi, Karnataka, India shashank.mehrotra@manipal.edu.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Accidental Falls/prevention & control
MH  - *Activities of Daily Living
MH  - Aged
MH  - Delivery of Health Care
MH  - Humans
MH  - Occupational Therapists
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7485230
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039742 [pii]
AID - 10.1136/bmjopen-2020-039742 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e039742. doi: 10.1136/bmjopen-2020-039742.


PMID- 32912994
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol
      monotherapy in cutaneous angiosarcoma-a proof of principle study.
PG  - e039449
LID - 10.1136/bmjopen-2020-039449 [doi]
AB  - INTRODUCTION: Angiosarcoma is a rare and aggressive malignancy with a high
      metastatic potential and recurrence rate. Despite optimal treatment with surgery,
      with or without radiation, the prognosis remains poor and, therefore, new
      treatment strategies are warranted. Recently, propranolol has effectively been
      repurposed for the treatment of infantile haemangioma. Propranolol is a
      beta3-sparing antagonist of the beta-adrenergic receptor. In infantile
      haemangioma, the beta1, beta2 and beta3 receptors are highly expressed.
      Angiosarcoma has several similarities with haemangioma, including its high
      beta-adrenergic receptor expression and the supposedly important role of vascular
      endothelial growth factor in malignant growth. As a result, propranolol has been 
      administered small scale in individual angiosarcoma cases with promising results.
      The precise effect of propranolol, however, is not yet established. METHODS AND
      ANALYSIS: The goal of this neoadjuvant window of opportunity study is to
      prospectively evaluate the activity of propranolol monotherapy in patients with
      cutaneous angiosarcoma. The neoadjuvant setting provides a good opportunity to
      rapidly evaluate both the clinical response and histological response, without a 
      significant delay in standard anticancer treatment. Fourteen patients with
      primary, recurrent or metastatic cutaneous angiosarcoma will be included.
      Propranolol will be administered orally in an escalating dose during 3-6 weeks,
      before the initiation of standard treatment. The primary endpoint is clinical
      response according to Response Evaluation Criteria in Solid Tumours, as measured 
      on consecutive coloured photographs or CT/MRI. The histological response will be 
      determined as secondary endpoint, comparing the difference in proliferation index
      before and after propranolol by measuring the change in immunohistochemistry
      staining of Ki-67. The study will be considered positive when at least three
      patients have a response to propranolol. ETHICS AND DISSEMINATION: Ethical
      approval was obtained from the Medical Ethical Committee of the Netherlands
      Cancer Institute. Independent of the outcome, results of this study will be
      shared and submitted for publication in an international peer-reviewed journal.
      TRIAL REGISTRATION NUMBER: NL8118; registry through the Netherlands Trial
      Register.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Heinhuis, Kimberley M
AU  - Heinhuis KM
AUID- ORCID: 0000-0002-6561-480X
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
AD  - Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam,
      The Netherlands.
FAU - IJzerman, Nikki S
AU  - IJzerman NS
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands n.ijzerman@nki.nl.
AD  - Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam,
      The Netherlands.
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University
      Medical Center, Rotterdam, The Netherlands.
FAU - Koenen, Anne Miek
AU  - Koenen AM
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - van der Graaf, Winette T A
AU  - van der Graaf WTA
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
AD  - Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - Haas, Rick L
AU  - Haas RL
AD  - Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - Beijnen, Jos H
AU  - Beijnen JH
AD  - Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam,
      The Netherlands.
AD  - Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The
      Netherlands.
FAU - Huitema, Alwin D R
AU  - Huitema ADR
AD  - Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam,
      The Netherlands.
AD  - Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht
      University, Utrecht, The Netherlands.
FAU - van Houdt, Winan J
AU  - van Houdt WJ
AD  - Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - Steeghs, Neeltje
AU  - Steeghs N
AD  - Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - *Hemangiosarcoma/drug therapy
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Netherlands
MH  - *Propranolol/therapeutic use
MH  - Vascular Endothelial Growth Factor A
PMC - PMC7485254
OTO - NOTNLM
OT  - *adult oncology
OT  - *oncology
OT  - *sarcoma
OT  - *vascular medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039449 [pii]
AID - 10.1136/bmjopen-2020-039449 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e039449. doi: 10.1136/bmjopen-2020-039449.


PMID- 32912992
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study 
      design.
PG  - e038623
LID - 10.1136/bmjopen-2020-038623 [doi]
AB  - INTRODUCTION: Familial hypercholesterolaemia (FH) is an autosomal-dominant
      inherited genetic disease. It carries an extremely high cardiovascular risk
      associated with significantly elevated low-density lipoprotein (LDL) cholesterol.
      The diagnostic rate of this disease in some European nations is quite high, due
      to the presence of multiple prospective registries. On the other hand, few
      data-and in particular multicentre data-exist regarding this issue among Japanese
      subjects. Therefore, this study intends to assemble a multicentre registry that
      aims to comprehensively assess cardiovascular risk among Japanese FH patients
      while taking into account their genetic backgrounds. METHODS AND ANALYSIS: The
      Hokuriku-plus FH registry is a prospective, observational, multicentre cohort
      study, enrolling consecutive FH patients who fulfil the clinical criteria of FH
      in Japan from 37 participating hospitals mostly in Hokuriku region of Japan from 
      April 2020 to March 2024. A total of 1000 patients will be enrolled into the
      study, and we plan to follow-up participants over 5 years. We will collect
      clinical parameters, including lipids, physical findings, genetic backgrounds and
      clinical events covering atherosclerotic and other important events, such as
      malignancies. The primary endpoint of this study is new atherosclerotic
      cardiovascular disease (ASCVD) events. The secondary endpoints are as follows:
      LDL cholesterol, secondary ASCVD events and the occurrence of other diseases
      including hypertension, diabetes and malignancies. ETHICS AND DISSEMINATION: This
      study is being conducted in compliance with the Declaration of Helsinki, the
      Ethical Guidelines for Medical and Health Research Involving Human Subjects, and 
      all other applicable laws and guidelines in Japan. This study protocol has been
      approved by the Institutional Review Board at Kanazawa University. We will
      disseminate the final results at international conferences and in a peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: UMIN000038210.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tada, Hayato
AU  - Tada H
AUID- ORCID: 0000-0002-3357-1809
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan ht240z@sa3.so-net.ne.jp.
FAU - Okada, Hirofumi
AU  - Okada H
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Yoshida, Shohei
AU  - Yoshida S
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Shimojima, Masaya
AU  - Shimojima M
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Nomura, Akihiro
AU  - Nomura A
AUID- ORCID: 0000-0001-6647-8240
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Tsuda, Toyonobu
AU  - Tsuda T
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Mori, Mika
AU  - Mori M
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Takashima, Shin-Ichiro
AU  - Takashima SI
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Kato, Takeshi
AU  - Kato T
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Usui, Soichiro
AU  - Usui S
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Sakata, Kenji
AU  - Sakata K
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Hayashi, Kenshi
AU  - Hayashi K
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Fujino, Noboru
AU  - Fujino N
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Inazu, Akihiro
AU  - Inazu A
AD  - Department of Laboratory Science, Molecular Biochemistry and Molecular Biology,
      Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
FAU - Takahara, Shizuko
AU  - Takahara S
AD  - Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan.
FAU - Imai, Yasuhito
AU  - Imai Y
AD  - Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan.
FAU - Matsubara, Takao
AU  - Matsubara T
AD  - Department of Cardiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
FAU - Nohara, Atsushi
AU  - Nohara A
AD  - Department of Cardiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
FAU - Miwa, Kenji
AU  - Miwa K
AD  - Department of Cardiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
FAU - Namura, Masanobu
AU  - Namura M
AD  - Department of Cardiology, Kanazawa Cardiovascular Hospital, Kanazawa, Japan.
FAU - Terai, Hidenobu
AU  - Terai H
AD  - Department of Cardiology, Kanazawa Cardiovascular Hospital, Kanazawa, Japan.
FAU - Yoshida, Taiji
AU  - Yoshida T
AD  - Department of Cardiology, Kanazawa Cardiovascular Hospital, Kanazawa, Japan.
FAU - Araki, Tsutomu
AU  - Araki T
AD  - Division of Internal Medicine, Saiseikai Kanazawa Hospital, Kanazawa, Japan.
FAU - Minamoto, Masahiro
AU  - Minamoto M
AD  - Department of Internal Medicine, JCHO Kanazawa Hospital, Kanazawa, Japan.
FAU - Aburao, Toru
AU  - Aburao T
AD  - Department of Internal Medicine, JCHO Kanazawa Hospital, Kanazawa, Japan.
FAU - Ito, Yuji
AU  - Ito Y
AD  - Department of Internal Medicine, KKR Hokuriku Hospital, Kanazawa, Japan.
FAU - Nakanishi, Chiaki
AU  - Nakanishi C
AD  - Department of Internal Medicine, KKR Hokuriku Hospital, Kanazawa, Japan.
FAU - Kawasaki, Suguru
AU  - Kawasaki S
AD  - Department of Internal Medicine, Kanazawa-Nishi Hospital, Kanazawa, Japan.
FAU - Todo, Yasuhiro
AU  - Todo Y
AD  - Department of Internal Medicine, Hokuriku Central Hospital of Japan Mutual Aid
      Association of Public School Teachers, Oyabe, Japan.
FAU - Koizumi, Junji
AU  - Koizumi J
AD  - Department of Internal Medicine, Suzu City General Hospital, Suzu, Japan.
FAU - Kita, Yoshihito
AU  - Kita Y
AD  - Department of Internal Medicine, Wajima City Hospital, Wajima, Japan.
FAU - Matsumoto, Hiroshi
AU  - Matsumoto H
AD  - Department of Internal Medicine, Wajima City Hospital, Wajima, Japan.
FAU - Shintaku, Hiroaki
AU  - Shintaku H
AD  - Department of Internal Medicine, Wajima City Hospital, Wajima, Japan.
FAU - Hodatsu, Akihiko
AU  - Hodatsu A
AD  - Department of Cardiology, Keiju General Hospital, Nanao, Japan.
FAU - Ino, Hidekazu
AU  - Ino H
AD  - Department of Cardiology, Houju Memorial Hospital, Nomi, Japan.
FAU - Higashikata, Toshinori
AU  - Higashikata T
AD  - Department of Internal Medicine, Komatsu Municipal Hospital, Komatsu, Japan.
FAU - Takata, Mutsuko
AU  - Takata M
AD  - Department of Internal Medicine, Komatsu Municipal Hospital, Komatsu, Japan.
FAU - Misawa, Katsushi
AU  - Misawa K
AD  - Department of Internal Medicine, Kaga Medical Center, Kaga, Japan.
FAU - Yamaguchi, Masato
AU  - Yamaguchi M
AD  - Department of Cardiology, Fukui Prefectural Hospital, Fukui, Japan.
FAU - Noji, Yoshihiro
AU  - Noji Y
AD  - Department of Cardiology, Fukui Prefectural Hospital, Fukui, Japan.
FAU - Osato, Kazuo
AU  - Osato K
AD  - Department of Cardiology, Fukui CardioVascular Center, Fukui, Japan.
FAU - Mabuchi, Tomohito
AU  - Mabuchi T
AD  - Department of Cardiology, Fukui CardioVascular Center, Fukui, Japan.
FAU - Ichise, Taro
AU  - Ichise T
AD  - Department of Cardiology, Fukui CardioVascular Center, Fukui, Japan.
FAU - Kaku, Bunji
AU  - Kaku B
AD  - Department of Cardiology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Katsuda, Shoji
AU  - Katsuda S
AD  - Department of Cardiology, Toyama Red Cross Hospital, Toyama, Japan.
FAU - Fujimoto, Manabu
AU  - Fujimoto M
AD  - Department of Cardiology, Koseiren Takaoka Hospital, Takaoka, Japan.
FAU - Uchiyama, Katsuharu
AU  - Uchiyama K
AD  - Department of Cardiology, Koseiren Takaoka Hospital, Takaoka, Japan.
FAU - Fujioka, Kensuke
AU  - Fujioka K
AD  - Department of Cardiology, Koseiren Takaoka Hospital, Takaoka, Japan.
FAU - Nakahashi, Takuya
AU  - Nakahashi T
AD  - Department of Cardiology, Takaoka City Hospital, Takaoka, Japan.
FAU - Nozue, Tsuyoshi
AU  - Nozue T
AD  - Department of Cardiology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan.
FAU - Michishita, Ichiro
AU  - Michishita I
AD  - Department of Cardiology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan.
FAU - Usuda, Kazuo
AU  - Usuda K
AD  - Division of Cardiology, Department of Internal Medicine, Toyama Prefectural
      Central Hospital, Toyama, Japan.
FAU - Otowa, Kanichi
AU  - Otowa K
AD  - Division of Cardiology, Department of Internal Medicine, Toyama Prefectural
      Central Hospital, Toyama, Japan.
FAU - Okeie, Kazuyasu
AU  - Okeie K
AD  - Department of Cardiology, Toyama City Hospital, Toyama, Japan.
FAU - Hirota, Satoshi
AU  - Hirota S
AD  - Department of Cardiology, Kurobe City Hospital, Kurobe, Japan.
FAU - Aburadani, Isao
AU  - Aburadani I
AD  - Department of Cardiology, Kurobe City Hospital, Kurobe, Japan.
FAU - Kurokawa, Keisuke
AU  - Kurokawa K
AD  - Department of Cardiology, Tonami General Hospital, Tonami, Japan.
FAU - Takatori, Osamu
AU  - Takatori O
AD  - Department of Cardiology, Tonami General Hospital, Tonami, Japan.
FAU - Hondo, Shunichiro
AU  - Hondo S
AD  - Department of Cardiology, Public Central Hospital of Matto Ishikawa, Hakusan,
      Japan.
FAU - Oda, Hiroyuki
AU  - Oda H
AD  - Department of Cardiology, Public Central Hospital of Matto Ishikawa, Hakusan,
      Japan.
FAU - Takata, Shigeo
AU  - Takata S
AD  - Department of Cardiology, Kanazawa City Hospital, Kanazawa, Japan.
FAU - Murai, Hisayoshi
AU  - Murai H
AD  - Department of Cardiology, Kanazawa City Hospital, Kanazawa, Japan.
FAU - Kinoshita, Masaki
AU  - Kinoshita M
AD  - Department of Cardiology, Kanazawa Arimatsu Hospital, Kanazawa, Japan.
FAU - Nagai, Hideo
AU  - Nagai H
AD  - Department of Cardiology, Kanazawa Red Cross Hospital, Kanazawa, Japan.
FAU - Sekiguchi, Yoshiteru
AU  - Sekiguchi Y
AD  - Department of Cardiology, Kanazawa Red Cross Hospital, Kanazawa, Japan.
FAU - Sakagami, Satoru
AU  - Sakagami S
AD  - Department of Cardiology, National Hospital Organization Kanazawa Medical Center,
      Kanazawa, Japan.
FAU - Omi, Wataru
AU  - Omi W
AD  - Department of Cardiology, National Hospital Organization Kanazawa Medical Center,
      Kanazawa, Japan.
FAU - Fujita, Chikara
AU  - Fujita C
AD  - Department of Cardiology, Yawata Medical Center, Komatsu, Japan.
FAU - Katsuki, Tatsuo
AU  - Katsuki T
AD  - Department of Cardiology, Yawata Medical Center, Komatsu, Japan.
FAU - Ootsuji, Hiroshi
AU  - Ootsuji H
AD  - Department of Internal Medicine, Hakui Public Hospital, Hakui, Japan.
FAU - Igarashi, Atsushi
AU  - Igarashi A
AD  - Department of Internal Medicine, Hakui Public Hospital, Hakui, Japan.
FAU - Nakano, Manabu
AU  - Nakano M
AD  - Department of Internal Medicine, Noto General Hospital, Nanao, Japan.
FAU - Okura, Seiichiro
AU  - Okura S
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui, Japan.
FAU - Maeno, Koji
AU  - Maeno K
AD  - Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui, Japan.
FAU - Mitamura, Yasuhito
AU  - Mitamura Y
AD  - Department of Cardiology, Municipal Tsuruga Hospital, Tsuruga, Japan.
FAU - Sugimoto, Naoki
AU  - Sugimoto N
AD  - Department of Internal Medicine, Tsurugi Hospital, Hakusan, Japan.
FAU - Yamamoto, Masakazu
AU  - Yamamoto M
AD  - Department of Cardiology, Kouseiren Namerikawa Hospital, Namerikawa, Japan.
FAU - Akao, Hironobu
AU  - Akao H
AD  - Division of Cardiology, Kanazawa Medical University Hospital, Kahoku-gun, Japan.
FAU - Kajinami, Kouji
AU  - Kajinami K
AD  - Division of Cardiology, Kanazawa Medical University Hospital, Kahoku-gun, Japan.
FAU - Takamura, Masayuki
AU  - Takamura M
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
FAU - Kawashiri, Masa-Aki
AU  - Kawashiri MA
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
      Kanazawa University, Kanazawa, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Humans
MH  - *Hyperlipoproteinemia Type II/epidemiology/genetics
MH  - Japan/epidemiology
MH  - Prospective Studies
MH  - Registries
PMC - PMC7485236
OTO - NOTNLM
OT  - *adult cardiology
OT  - *genetics
OT  - *lipid disorders
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038623 [pii]
AID - 10.1136/bmjopen-2020-038623 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e038623. doi: 10.1136/bmjopen-2020-038623.


PMID- 32912991
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Effectiveness of integrated chronic care interventions for older people with
      different frailty levels: a systematic review protocol.
PG  - e038437
LID - 10.1136/bmjopen-2020-038437 [doi]
AB  - INTRODUCTION: Frailty poses a huge burden to individuals, their families and to
      healthcare systems. Several interventions have been evaluated for the improvement
      of outcomes for older people with frailty, including integrated care
      interventions. Reviews synthesising evidence on the effectiveness of integrated
      care for older people with frailty have treated them as a single population,
      without considering the heterogeneity between different frailty levels such as
      non-frail, mild frailty, moderate frailty and severe frailty. Findings from these
      studies have shown inconsistent results on the various outcomes assessed. People 
      with different frailty status have different care needs, which should be
      addressed accordingly. The aim of this study is to synthesise evidence on the
      effectiveness of integrated care interventions on older people with different
      frailty status who are community dwelling or living in retirement housing or
      residential setting but not in care homes or in nursing homes. METHODS AND
      ANALYSIS: This is a protocol for a systematic review assessing the effectiveness 
      of integrated chronic care interventions on older people with different frailty
      status. A literature search will be conducted on the databases Cochrane Central
      Register of Controlled Trials, PubMed, Embase, Web of Science, Cumulative Index
      to Nursing and Allied Health Literature, and clinical trial registers. Two
      authors will independently conduct search and screening for eligible studies.
      Full-text screening will be used to include only studies that fulfil the
      inclusion criteria. Data extraction will be done on a data extraction form and
      methodological quality of studies will be assessed using the Effective Practice
      and Organisation of Care risk of bias tool. The interventions will be described
      following Wagner's Chronic Care Model. ETHICS AND DISSEMINATION: Ethical approval
      for this study was obtained from the Institute for Health Research Ethics
      Committee of the University of Bedfordshire (IHREC934). The results of the review
      will be disseminated through a peer-reviewed journal article, conferences and
      also with local provider and user stakeholders. PROSPERO REGISTRATION NUMBER:
      CRD42020166908.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Khan, Nimra
AU  - Khan N
AUID- ORCID: 0000-0002-6944-4879
AD  - Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire,
      UK.
FAU - Hewson, David
AU  - Hewson D
AUID- ORCID: 0000-0002-7656-4000
AD  - Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire,
      UK.
FAU - Randhawa, Gurch
AU  - Randhawa G
AUID- ORCID: 0000-0002-2289-5859
AD  - Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire,
      UK gurch.randhawa@beds.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Delivery of Health Care
MH  - *Frailty
MH  - Humans
MH  - Independent Living
MH  - Long-Term Care
MH  - Nursing Homes
PMC - PMC7485241
OTO - NOTNLM
OT  - *frailty
OT  - *integrated care service
OT  - *mild frailty
OT  - *moderate frailty
OT  - *severe frailty
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038437 [pii]
AID - 10.1136/bmjopen-2020-038437 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e038437. doi: 10.1136/bmjopen-2020-038437.


PMID- 32912990
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Media content analysis of general practitioners' reactions to care.data expressed
      in the media: what lessons can be learned for future NHS data-sharing
      initiatives?
PG  - e038006
LID - 10.1136/bmjopen-2020-038006 [doi]
AB  - OBJECTIVES: Care.data was a 2013 UK government initiative to extract patient data
      from general practices in England to form a centralised whole-population database
      for service planning and health research. After a public outcry, the scheme was
      postponed and cancelled. Public views of care.data have previously been analysed;
      this study aimed to understand contemporary general practitioners' (GPs) views of
      the scheme, which may have been influential in its downfall. DESIGN: Systematic
      search of media articles, followed by media content analysis. SETTING: UK-based
      mainstream and GP-facing media in 2013 and 2014. PARTICIPANTS: Articles were
      eligible if they focused on care.data, and GPs were quoted, authored the article,
      or if articles were written for a majority GP audience. INTERVENTIONS: N/A.
      PRIMARY AND SECONDARY OUTCOME MEASURES: Themes which explained GPs' reactions to 
      care.data and which could explain support for or opposition to the scheme.
      RESULTS: 162 media articles met inclusion criteria and were drawn from
      newspapers, news websites and GP-facing websites. GPs recognised care.data's
      potential value for research and improving care, but had grave concerns about the
      scheme's implementation. These centred the lack of safeguards and purpose around 
      the scheme which meant patients were not able to make informed decisions about
      opt-out. GPs perceived they were poorly resourced to meet competing demands to
      both share patients' data and protect confidentiality. They distrusted the
      government's likely uses of the data and perceived a risk of patient
      reidentification if the data were sold onto commercial entities. CONCLUSIONS:
      Findings show specific concerns which GPs had about care.data which led to the
      withdrawal of support. Future NHS patient data-sharing schemes should engage with
      GPs and other clinicians as key stakeholders from the earliest moments of
      planning, so that their views and needs are incorporated into the design of such 
      schemes.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ford, Elizabeth
AU  - Ford E
AUID- ORCID: 0000-0001-5613-8509
AD  - Primary Care and Public Health, Brighton & Sussex Medical School, Brighton, UK
      e.m.ford@bsms.ac.uk.
FAU - Kazempour, Yalda
AU  - Kazempour Y
AD  - Primary Care and Public Health, Brighton & Sussex Medical School, Brighton, UK.
FAU - Cooper, Maxwell J F
AU  - Cooper MJF
AD  - Primary Care and Public Health, Brighton & Sussex Medical School, Brighton, UK.
FAU - Katikireddi, Srinivasa Vittal
AU  - Katikireddi SV
AUID- ORCID: 0000-0001-6593-9092
AD  - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow School of
      Life Sciences, Glasgow, UK.
FAU - Boyd, Andy
AU  - Boyd A
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
LA  - eng
GR  - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom
GR  - SCAF/15/02/CSO_/Chief Scientist Office/United Kingdom
GR  - MC_UU_12017/13/MRC_/Medical Research Council/United Kingdom
GR  - SPHSU15/CSO_/Chief Scientist Office/United Kingdom
GR  - MC_UU_12017/15/MRC_/Medical Research Council/United Kingdom
GR  - SPHSU13/CSO_/Chief Scientist Office/United Kingdom
GR  - MC_PC_17210/MRC_/Medical Research Council/United Kingdom
GR  - 102215/2/13/2/WT_/Wellcome Trust/United Kingdom
GR  - SPHSU17/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Attitude of Health Personnel
MH  - England
MH  - *General Practice
MH  - *General Practitioners
MH  - Humans
MH  - Qualitative Research
MH  - State Medicine
PMC - PMC7485233
OTO - NOTNLM
OT  - *epidemiology
OT  - *health informatics
OT  - *medical ethics
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038006 [pii]
AID - 10.1136/bmjopen-2020-038006 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e038006. doi: 10.1136/bmjopen-2020-038006.


PMID- 32912989
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Bariatric surgery and LDL cholesterol (BASALTO) trial study protocol: randomised 
      controlled study evaluating the effect of gastric bypass versus sleeve
      gastrectomy on high LDL cholesterol.
PG  - e037712
LID - 10.1136/bmjopen-2020-037712 [doi]
AB  - INTRODUCTION: Observational studies have shown gastric bypass to be superior to
      sleeve gastrectomy in terms of low-density lipoprotein (LDL) cholesterol
      improvement. If these results are confirmed in randomised controlled trials,
      presurgical LDL cholesterol status could be a relevant factor in surgical
      procedure election. Furthermore, it is also necessary to establish the mechanisms
      by which LDL cholesterol improves after surgery and whether qualitative and
      quantitative changes occur in the different lipoprotein subclasses. The first
      objective is to ascertain whether high LDL cholesterol levels before surgery can 
      be considered an additional factor when selecting the most appropriate surgical
      procedure for each patient (gastric bypass or sleeve gastrectomy). Hence, the
      1-year remission rates of high LDL cholesterol after gastric bypass and sleeve
      gastrectomy in patients with morbid obesity will be compared. Secondary
      objectives were (1) to compare changes in other lipoproteins and LDL composition 
      and (2) to study the pathophysiologic mechanisms related to LDL cholesterol
      remission. METHODS AND ANALYSIS: A randomised clinical trial, with
      intention-to-treat analysis, will be conducted to compare LDL cholesterol
      remission between gastric bypass and sleeve gastrectomy, with a 12-month
      follow-up. Inclusion criteria will be patients between 18 and 60 years of age
      with body mass index >/=40 kg/m(2) or >/=35 kg/m(2) with significant
      obesity-related comorbidity and high LDL cholesterol levels. Patients will be
      evaluated preoperatively and at 3, 6 and 12 months after bariatric surgery.
      Examinations will include routine blood chemistry, anthropometric measurements,
      food intake recall, physical activity questionnaires and serum samples for
      lipidomic and lipoprotein characterisation. ETHICS AND DISSEMINATION: Ethics
      approval has been granted by the Parc de Salut Mar Ethics Committee
      (2019/8471/I). The study and its conclusions regarding the primary and secondary 
      objectives will be presented as manuscripts submitted for peer-reviewed journal
      publication. TRIAL REGISTRATION NUMBER: NCT03975478.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Benaiges, David
AU  - Benaiges D
AUID- ORCID: 0000-0001-5411-364X
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain
      96002@parcdesalutmar.cat.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
AD  - Consorci Sanitari de l'Alt Penedes Garraf, Vilafranca del Penedes, Spain.
FAU - Goday, Albert
AU  - Goday A
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
AD  - CiberOBN. Instituto de Salud Carlos III, Madrid, Spain.
FAU - Flores-Le Roux, Juana A
AU  - Flores-Le Roux JA
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
FAU - Fito, Montserrat
AU  - Fito M
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
AD  - CiberOBN. Instituto de Salud Carlos III, Madrid, Spain.
FAU - Pozo, Oscar
AU  - Pozo O
AD  - Integrative Pharmacology and Systems Neuroscience Research Group, Institut
      Hospital del Mar d'Investigacions Mediques, Barcelona, Spain.
FAU - Rodriguez-Morato, Jose
AU  - Rodriguez-Morato J
AD  - Integrative Pharmacology and Systems Neuroscience Research Group, Institut
      Hospital del Mar d'Investigacions Mediques, Barcelona, Spain.
FAU - Serra, Carme
AU  - Serra C
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
FAU - Pera, Manuel
AU  - Pera M
AD  - Department of General Surgery, Hospital del Mar, Barcelona, Spain.
FAU - Llaurado, Gemma
AU  - Llaurado G
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
AD  - Consorci Sanitari de l'Alt Penedes Garraf, Vilafranca del Penedes, Spain.
FAU - Climent, Elisenda
AU  - Climent E
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
FAU - Castaner, Olga
AU  - Castaner O
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
AD  - CiberOBN. Instituto de Salud Carlos III, Madrid, Spain.
FAU - Ramon, Jose M
AU  - Ramon JM
AD  - Department of General Surgery, Hospital del Mar, Barcelona, Spain.
FAU - Pedro-Botet, Juan
AU  - Pedro-Botet J
AD  - Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03975478
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cholesterol, LDL)
SB  - IM
MH  - *Bariatric Surgery
MH  - Body Mass Index
MH  - Cholesterol, LDL
MH  - Gastrectomy
MH  - *Gastric Bypass
MH  - Humans
MH  - *Obesity, Morbid/surgery
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Weight Loss
PMC - PMC7485237
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *nutrition & dietetics
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037712 [pii]
AID - 10.1136/bmjopen-2020-037712 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037712. doi: 10.1136/bmjopen-2020-037712.


PMID- 32912987
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Predictors of chronic pain and level of physical function in total knee
      arthroplasty: a protocol for a systematic review and meta-analysis.
PG  - e037674
LID - 10.1136/bmjopen-2020-037674 [doi]
AB  - INTRODUCTION: One in five patients undergoing total knee arthroplasty (TKA)
      experience unchanged or worse pain and physical function 1 year after surgery.
      Identifying risk factors for unfavourable outcomes is necessary to develop
      tailored interventions to minimise risk. There is a need to review more current
      literature with updated methodology that addresses the limitations of earlier
      systematic reviews and meta-analyses. We present a Preferred Reporting Items for 
      Systematic Review and Meta-Analysis Protocols compliant protocol for a systematic
      review and meta-analysis of predictors of chronic pain and impaired function
      after TKA. METHODS AND ANALYSIS: This review will include prospective
      longitudinal observational studies, or randomised trials (including cluster and
      crossover designs) that report arm-wise predictors of chronic postsurgical pain
      or impaired physical function at 3 months, 6 months or 12 months. A comprehensive
      literature search of studies published between 2000 and 2019 will be performed in
      Medline, Embase, CINAHL, Cochrane Library and PEDro. Blinded assessment with
      consensus agreement will be applied for inclusion of studies, data extraction and
      assessment of bias risk (Quality in Prognosis Studies tool). The co-primary
      outcomes, pain and impaired function, at 12 months after TKA will be analysed
      separately. Estimates of association between each outcome and any preoperative or
      intraoperative factor that may predict chronic pain or impaired physical function
      will be extracted from the included studies, where possible. For randomised
      studies, results will only be extracted from TKA arms (or the first period of
      crossover trials). Estimates of association from the primary evidence will be
      synthesised narratively, and quantitatively using multivariate meta-analysis to
      provide 'pooled' estimates of association. Subgroup and sensitivity analyses will
      be performed. Certainty of evidence for each predictor will be derived from the
      Grading of Recommendations Assessment, Development and Evaluation framework.
      ETHICS AND DISSEMINATION: No ethical issues are associated with this project. The
      results from this review will be published in peer-reviewed journals and
      presented at international conferences. PROSPERO REGISTRATION NUMBER:
      CRD42018079069.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Olsen, Unni
AU  - Olsen U
AUID- ORCID: 0000-0003-0474-5985
AD  - Department of Nursing Science, Institute of Health and Society, Faculty of
      Medicine, University of Oslo, Oslo, Norway u.s.j.olsen@studmed.uio.no.
AD  - Department of Orthopaedic Surgery, Lovisenberg Diaconal Hospital, Oslo, Norway.
FAU - Lindberg, Maren Falch
AU  - Lindberg MF
AUID- ORCID: 0000-0003-2074-2071
AD  - Department of Nursing Science, Institute of Health and Society, Faculty of
      Medicine, University of Oslo, Oslo, Norway.
AD  - Department of Orthopaedic Surgery, Lovisenberg Diaconal Hospital, Oslo, Norway.
FAU - Denison, Eva Marie-Louise
AU  - Denison EM
AD  - Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway.
FAU - Rose, Christopher James
AU  - Rose CJ
AD  - Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway.
FAU - Gay, Caryl Lynn
AU  - Gay CL
AUID- ORCID: 0000-0002-6865-6335
AD  - Department of Family and Health Care Nursing, University of California, San
      Francisco, California, USA.
AD  - Department of Patient Safety and Research, Lovisenberg Diaconal Hospital, Oslo,
      Norway.
FAU - Aamodt, Arild
AU  - Aamodt A
AD  - Department of Orthopaedic Surgery, Lovisenberg Diaconal Hospital, Oslo, Norway.
FAU - Brox, Jens Ivar
AU  - Brox JI
AUID- ORCID: 0000-0002-2507-1812
AD  - Department of Physical Medicine and Rehabilitation, Oslo University Hospital,
      Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,
      Norway.
FAU - Skare, Oystein
AU  - Skare O
AD  - Department of Orthopaedic Surgery, Lovisenberg Diaconal Hospital, Oslo, Norway.
FAU - Furnes, Ove
AU  - Furnes O
AD  - Norwegian Arthroplasty Register, Haukeland University Hospital, Bergen, Norway.
AD  - Department of Orthopaedic Surgery, University of Bergen, Bergen, Hordaland,
      Norway.
FAU - Lee, Kathryn A
AU  - Lee KA
AD  - Department of Family and Health Care Nursing, University of California, San
      Francisco, California, USA.
FAU - Lerdal, Anners
AU  - Lerdal A
AUID- ORCID: 0000-0002-7144-5096
AD  - Department of Patient Safety and Research, Lovisenberg Diaconal Hospital, Oslo,
      Norway.
AD  - Department of Interdisciplinary Health Sciences, Institute of Health and Society,
      Faculty of Medicine, University of Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Arthroplasty, Replacement, Knee/adverse effects
MH  - Bias
MH  - *Chronic Pain/etiology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pain, Postoperative/etiology
MH  - Prospective Studies
MH  - Review Literature as Topic
PMC - PMC7485240
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *knee
OT  - *orthopaedic & trauma surgery
COIS- Competing interests: CJR reports personal fees from Oncolmmunity AS. He has a
      patent and patent application with no relevance to this study.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037674 [pii]
AID - 10.1136/bmjopen-2020-037674 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037674. doi: 10.1136/bmjopen-2020-037674.


PMID- 32912985
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Validation of the detection of elder abuse through emergency care technicians
      (DETECT) screening tool: a study protocol.
PG  - e037170
LID - 10.1136/bmjopen-2020-037170 [doi]
AB  - INTRODUCTION: Elder mistreatment (EM) is a high prevalence threat to the health
      and well-being of older adults in the USA. Medics are well-positioned to help
      with identification of older adults at risk for EM, however, field robust
      screening tools appropriate for efficient, observation-based screening are
      lacking. Prior work by this team focused on the development and initial pilot
      testing of an observation-based EM screening tool named detection of elder abuse 
      through emergency care technicians (DETECT), designed to be implemented by medics
      during the course of an emergency response (911) call. The objective of the
      present work is to validate and further refine this tool in preparation for
      clinical dissemination. METHODS AND ANALYSIS: Approximately 59 400
      community-dwelling older adults who place 911 calls during the 36-month study
      observation period will be screened by medics responding to the call using the
      DETECT tool. Next, a random subsample of 2520 of the 59 400 older adults screened
      will be selected to participate in a follow-up interview approximately 2 weeks
      following the completion of the screening. Follow-up interviews will consist of a
      medic-led semistructured interview designed to assess the older adult's
      likelihood of abuse exposure, physical/mental health status, cognitive
      functioning, and to systematically evaluate the quality and condition of their
      physical and social living environment. The data from 25% (n=648) of these
      follow-up interviews will be presented to a longitudinal, experts and all data
      panel for a final determination of EM exposure status, representing the closest
      proxy to a 'gold standard' measure available. ETHICS AND DISSEMINATION: This
      study has been reviewed and approved by the Committee for the Protection of Human
      Subjects at the University of Texas School of Public Health. The results will be 
      disseminated through formal presentations at local, national and international
      conferences and through publication in peer-reviewed scientific journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cannell, Brad
AU  - Cannell B
AUID- ORCID: 0000-0002-8711-6772
AD  - Epidemiology, Human Genetics and Environmental Sciences, UTHealth School of
      Public Health, Dallas, Texas, USA Michael.B.Cannell@uth.tmc.edu.
FAU - Weitlauf, Julie
AU  - Weitlauf J
AD  - Psychiatry, Stanford University, Palo Alto, California, USA.
FAU - Livingston, Melvin D
AU  - Livingston MD
AD  - Behavioral Sciences and Health Education, Emory University Woodruff Health
      Sciences Center, Atlanta, Georgia, USA.
FAU - Burnett, Jason
AU  - Burnett J
AD  - Division of Geriatric and Palliative Medicine, UTHealth McGovern Medical School, 
      Houston, Texas, USA.
FAU - Parayil, Megin
AU  - Parayil M
AUID- ORCID: 0000-0003-1739-1629
AD  - Epidemiology, Human Genetics and Environmental Sciences, UTHealth School of
      Public Health, Dallas, Texas, USA.
FAU - Reingle Gonzalez, Jennifer
AU  - Reingle Gonzalez J
AD  - Population Health, Meadows Mental Health Policy Institute, Dallas, Texas, USA.
LA  - eng
GR  - R01 AG059993/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Delivery of Health Care
MH  - *Elder Abuse/diagnosis
MH  - Humans
MH  - Independent Living
MH  - Mass Screening
MH  - Prevalence
PMC - PMC7485249
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *geriatric medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037170 [pii]
AID - 10.1136/bmjopen-2020-037170 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037170. doi: 10.1136/bmjopen-2020-037170.


PMID- 32912984
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Health-related quality of life in patients with non-communicable disease: study
      protocol of a cross-sectional survey.
PG  - e037131
LID - 10.1136/bmjopen-2020-037131 [doi]
AB  - INTRODUCTION: Non-communicable diseases (NCDs) are associated with lower
      health-related quality of life (HRQoL). However, knowledge about those diseases
      and predictors with a greater impact on patients' HRQoL as well as knowledge on
      the complex relationship between HRQoL and comorbidities is lacking. The aim of
      this study is to assess the impact of NCDs on patients' HRQoL, with a focus on
      multimorbidity and socioeconomic status. METHODS AND ANALYSIS: A primary
      care-based cross-sectional study is conducted in Flanders (Belgium). Study
      participants (>/=18 years) are medically diagnosed with at least one of the
      following diseases: cardiometabolic disorders, mental disorders and
      musculoskeletal disorders. A minimum of 50 general practitioners will participate
      to recruit participants (convenient sample) and a total of 531 patients will be
      enrolled (voluntary response sample). Each participant will complete a
      paper-based questionnaire to gather research outcomes. Statistical analyses will 
      be performed using multiple linear regression models with HRQoL as main outcome
      parameter, adjusted for possible confounders. This study will generate new
      evidence on the key predictors of HRQoL in patients with NCDs, and particularly
      provide new insights in multimorbidity to improve the quality of care in primary 
      care, to support patients' self-management and to allocate resources more
      effectively. ETHICS AND DISSEMINATION: The study has been approved by the Ethical
      Committee of Ghent University Hospital, Ghent, Belgium (reference number:
      B670201939629) prior to the beginning of the recruitment. Study results will be
      disseminated through peer-reviewed publications and conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Van Wilder, Lisa
AU  - Van Wilder L
AUID- ORCID: 0000-0003-4394-2623
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium
      lisa.vanwilder@ugent.be.
FAU - Clays, Els
AU  - Clays E
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
FAU - Devleesschauwer, Brecht
AU  - Devleesschauwer B
AD  - Epidemiology and Public Health, Sciensano, Brussels, Belgium.
FAU - Pype, Peter
AU  - Pype P
AUID- ORCID: 0000-0003-2273-0250
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
FAU - Boeckxstaens, Pauline
AU  - Boeckxstaens P
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
FAU - Schrans, Diego
AU  - Schrans D
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
FAU - De Smedt, Delphine
AU  - De Smedt D
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Belgium/epidemiology
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Noncommunicable Diseases/epidemiology
MH  - *Quality of Life
PMC - PMC7485234
OTO - NOTNLM
OT  - *epidemiology
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037131 [pii]
AID - 10.1136/bmjopen-2020-037131 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037131. doi: 10.1136/bmjopen-2020-037131.


PMID- 32912982
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Associations between contextual and compositional characteristics of early
      childcare facilities with health, health behaviours and well-being among young
      children aged 06 years: protocol for a scoping review.
PG  - e037038
LID - 10.1136/bmjopen-2020-037038 [doi]
AB  - INTRODUCTION: Early childhood is an important life stage which is crucial for
      determining health and health inequalities in later life. At the meso-level
      (institutional-level), early childcare facilities (eg, kindergartens, preschools)
      are the most important agent of socialisation next to families in young children 
      aged 06 years. In recent years, an increasing amount of studies has focused on
      contextual and compositional characteristics of early childcare facilities and
      their association with health (eg, self-rated health), health behaviour (eg,
      physical activity) and well-being (eg, emotional well-being) in this age group.
      However, as currently no overview of the available literature on this topic
      exists, we will conduct a scoping review including various study designs (eg,
      cross-sectional studies, prospective studies, qualitative studies). METHODS AND
      ANALYSIS: We will follow the Preferred Reporting Items for Systematic reviews and
      Meta-Analyses extension for Scoping Reviews. A systematic search of the following
      scientific databases will be conducted: PubMed/Medline, PsycInfo, Sociological
      Abstracts, Education Resources Information Center and The Cochrane Library.
      During the selection process, we will follow a two-step process. First, two
      reviewers will independently screen titles/abstracts of all potentially eligible 
      articles by applying a set of previously defined inclusion and exclusion
      criteria. After the completion of the title/abstract screening, full texts of the
      remaining articles will be screened following the same procedure. To determine
      inter-rater agreement between reviewers, we will calculate Cohen's Kappa after
      both steps. Key characteristics (eg, country of origin, sample size, study
      design) of included articles will be extracted. We will map the evidence
      available by providing a summary table on the key characteristics extracted and
      by presenting the associations using various types of illustrations. ETHICS AND
      DISSEMINATION: Since no primary data will be collected for this review, ethical
      approval is not required. Our findings will be published in an international
      peer-reviewed journal and presented at national and international conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hilger-Kolb, Jennifer
AU  - Hilger-Kolb J
AUID- ORCID: 0000-0003-0347-1900
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany
      Jennifer.Hilger-Kolb@medma.uni-heidelberg.de.
FAU - Schneider, Sven
AU  - Schneider S
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Herr, Raphael
AU  - Herr R
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Osenbruegge, Nina
AU  - Osenbruegge N
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Hoffmann, Stephanie
AU  - Hoffmann S
AD  - Department of Public Health, Faculty for Social Work, Health, and Music,
      Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
FAU - Herke, Max
AU  - Herke M
AUID- ORCID: 0000-0001-6425-4366
AD  - Institute of Medical Sociology, Medical Faculty, Martin-Luther-University
      Halle-Wittenberg, Halle (Saale), Germany.
FAU - Pischke, Claudia
AU  - Pischke C
AD  - Institute of Medical Sociology, Centre for Health and Society, Medical Faculty,
      Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
FAU - Sundmacher, Leonie
AU  - Sundmacher L
AD  - Department of Health Economics, Department of Health Science, Technical
      University of Munich, Munich, Germany.
FAU - Diehl, Katharina
AU  - Diehl K
AUID- ORCID: 0000-0002-5408-652X
AD  - Mannheim Institute of Public Health, Social and Preventive Medicine, Medical
      Faculty Mannheim, Heidelberg University, Mannheim, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Health Behavior
MH  - Humans
MH  - *Mental Health
MH  - Prospective Studies
MH  - *Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7485259
OTO - NOTNLM
OT  - *community child health
OT  - *public health
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037038 [pii]
AID - 10.1136/bmjopen-2020-037038 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037038. doi: 10.1136/bmjopen-2020-037038.


PMID- 32912979
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Psychological interventions for depression among informal caregivers of older
      adult populations: protocol of a systematic review and meta-analysis of
      randomised controlled trials.
PG  - e036402
LID - 10.1136/bmjopen-2019-036402 [doi]
AB  - INTRODUCTION: Increased life expectancy has led to an increased demand for family
      members to provide informal care for their older relatives in the home. Many
      studies suggest informal caregivers are at greater risk of experiencing symptoms 
      of depression. However, there is a lack of research examining the effectiveness
      of psychological interventions targeting these symptoms alongside clinical and
      methodological moderators potentially associated with intervention effectiveness.
      This review aims to address this gap and will inform the development of a
      psychological intervention targeting depression among adult-child caregivers of
      older parents, given many studies show that among informal caregivers of older
      adults, adult children experience specific difficulties and needs for
      psychological support. Further, the lack of studies targeting adult children
      specifically necessitates conducting this review targeting caregivers of older
      adults in general. METHODS AND ANALYSIS: Randomised controlled trials of
      psychological interventions targeting symptoms of depression among informal
      caregivers will be identified via a systematic search of electronic databases
      (PubMed, Cumulative Index to Nursing and Allied Health Literature, Excerpta
      Medica DataBase, PsycINFO, Cochrane Library and Web of Science) and supplemented 
      by handsearching of previous systematic reviews, reference and forward citation
      checking, and expert contact. If possible, a meta-analysis will be conducted to
      examine the: (1) effectiveness of psychological interventions for depression
      among informal caregivers of older adults, (2) effectiveness of psychological
      interventions for secondary outcomes such as anxiety, stress, caregiver burden,
      psychological distress, quality of life, well-being and self-efficacy and (3)
      moderating effects of clinical and methodological factors on effectiveness.
      ETHICS AND DISSEMINATION: Ethical approval will not be necessary for this study
      given primary data will not be collected. Results will inform the development of 
      a psychological intervention for adult-child caregivers of older parents and will
      be disseminated through publication in peer-reviewed journals and conference
      presentations. PROSPERO REGISTRATION NUMBER: CRD42020157763.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Martensson, Erika
AU  - Martensson E
AUID- ORCID: 0000-0003-0406-4880
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden erika.martensson@kbh.uu.se.
AD  - Centre for Gender Research, Uppsala University, Uppsala, Sweden.
FAU - Blomberg, Oscar
AU  - Blomberg O
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden.
FAU - Pettman, Danelle
AU  - Pettman D
AUID- ORCID: 0000-0002-5956-4025
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden.
FAU - Sorensdotter, Renita
AU  - Sorensdotter R
AD  - Centre for Gender Research, Uppsala University, Uppsala, Sweden.
FAU - von Essen, Louise
AU  - von Essen L
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden.
FAU - Woodford, Joanne
AU  - Woodford J
AUID- ORCID: 0000-0001-5062-6798
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Anxiety
MH  - *Caregivers
MH  - Child
MH  - *Depression/therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Psychosocial Intervention
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7485246
OTO - NOTNLM
OT  - *clinical trials
OT  - *depression & mood disorders
OT  - *mental health
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036402 [pii]
AID - 10.1136/bmjopen-2019-036402 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e036402. doi: 10.1136/bmjopen-2019-036402.


PMID- 32912977
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Study protocol for a randomised-controlled study on emotion regulation training
      for adolescents with major depression: the KONNI study.
PG  - e036093
LID - 10.1136/bmjopen-2019-036093 [doi]
AB  - INTRODUCTION: Major depression (MD) often has its onset during adolescence and is
      associated with significant morbidity and mortality. One important factor for the
      development and maintenance of adolescent MD are disturbances in emotion
      regulation and the underlying neural processes. Cognitive reappraisal (CR) is a
      particular adaptive emotion regulation strategy. Previously, it has been shown in
      healthy adults that a task-based training in CR is efficient to reduce negative
      affect, and that these effects translate into everyday life.This randomised
      controlled trial examines for the first time whether a task-based training in CR 
      proves effective in MD adolescents. Specifically, we will investigate whether the
      CR training improves the ability to downregulate negative affect in MD
      individuals as assessed by behavioural and neurobiological indices, and whether
      training effects generalise outside the laboratory. METHODS AND ANALYSIS:
      Adolescents with MD will be randomly allocated to a group that either receives a 
      task-based training in CR or a control training. Both involve four training
      sessions over a time period of 2 weeks. In the CR training, participants will be 
      instructed to downregulate negative affective responses to negative pictures via 
      CR, while the control training involves picture viewing. During the training
      sessions, the Late Positive Potential, gaze fixations on negative picture aspects
      and affective responses to pictures will be collected. Before and after the
      training programmes, and at a 2-week follow-up, overall negative and positive
      affect, rumination and perceived stress will be assessed as primary outcomes.
      Analyses of variance will be conducted to test the effectiveness of the CR
      training with regard to both primary outcomes and task-based behavioural and
      neurobiological parameters. ETHICS AND DISSEMINATION: The study was approved by
      the Ethics Committee of the Medical Faculty of the LMU Munich, Germany. The
      results will be published in peer-reviewed journals and disseminated through
      conferences, social media and public events. TRIAL REGISTRATION DETAILS:
      ClinicalTrials.gov NCT03957850, registered 21(st) May 2019; URL:
      https://clinicaltrials.gov/ct2/show/NCT03957850.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Greimel, Ellen
AU  - Greimel E
AUID- ORCID: 0000-0002-9916-9230
AD  - Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, 
      Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
      Ellen.Greimel@med.uni-muenchen.de.
FAU - Feldmann, Lisa
AU  - Feldmann L
AD  - Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, 
      Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
FAU - Piechaczek, Charlotte
AU  - Piechaczek C
AD  - Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, 
      Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
FAU - Oort, Frans
AU  - Oort F
AD  - Research Institute of Child Development and Education, University of Amsterdam,
      Amsterdam, Netherlands.
FAU - Bartling, Jurgen
AU  - Bartling J
AD  - Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, 
      Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
FAU - Schulte-Ruther, Martin
AU  - Schulte-Ruther M
AUID- ORCID: 0000-0002-7198-9923
AD  - Translational Brain Medicine in Psychiatry and Neurology, Department of Child and
      Adolescent Psychiatry, Psychosomatics, and Psychotherapy, RWTH Aachen University,
      Aachen, Germany.
AD  - JARA-Brain, Aachen, Germany.
AD  - Department of Child and Adolescent Psychiatry and Psychotherapy, University
      Medical Center Gottingen, Gottingen, Germany.
FAU - Schulte-Korne, Gerd
AU  - Schulte-Korne G
AD  - Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, 
      Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03957850
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Depression/therapy
MH  - *Depressive Disorder, Major/therapy
MH  - *Emotional Regulation
MH  - Germany
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7485251
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *clinical trials
OT  - *depression & mood disorders
OT  - *neurophysiology
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036093 [pii]
AID - 10.1136/bmjopen-2019-036093 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e036093. doi: 10.1136/bmjopen-2019-036093.


PMID- 32912974
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Protocol for the economic evaluation of metacognitive therapy for cardiac
      rehabilitation participants with symptoms of anxiety and/or depression.
PG  - e035552
LID - 10.1136/bmjopen-2019-035552 [doi]
AB  - INTRODUCTION: Cardiac rehabilitation (CR) is offered to reduce the risk of
      further cardiac events and to improve patients' health and quality of life
      following a cardiac event. Psychological care is a common component of CR as
      symptoms of depression and/or anxiety are more prevalent in this population,
      however evidence for the cost-effectiveness of current interventions is limited. 
      Metacognitive therapy (MCT), is a recent treatment development that is effective 
      in treating anxiety and depression in mental health settings and is being
      evaluated in CR patients. This protocol describes the planned approach to the
      economic evaluation of MCT for CR patients. METHODS AND ANALYSIS: The economic
      evaluation work will consist of a within-trial analysis and an economic model.
      The PATHWAY Group MCT study has been prospectively designed to collect
      comprehensive self-reported resource use and health outcome data, including the
      EQ-5D, within a randomised controlled trial study design (UK Clinical Trials
      Gateway). A within-trial economic evaluation and economic model will compare the 
      cost-effectiveness of MCT plus usual care (UC) to UC, from a health and social
      care perspective in the UK. The within-trial analysis will use intention-to-treat
      and estimate total costs and quality-adjusted life-years (QALYs) for the trial
      follow-up. Single imputation will be used to impute missing baseline variables.
      Multiple imputation will be used to impute values missing at follow-up. Items of 
      resource use will be multiplied by published national healthcare costs.
      Regression analysis will be used to estimate net costs and net QALYs and these
      estimates will be bootstrapped to generate 10 000 net pairs of costs and QALYs to
      inform the probability of cost-effectiveness. A decision analytical economic
      model will be developed to synthesise trial data with the published literature
      over a longer time frame. Sensitivity analysis will explore uncertainty. Guidance
      of the methods for economic models will be followed and dissemination will adhere
      to reporting guidelines. ETHICS AND DISSEMINATION: The economic evaluation
      includes a within-trial analysis. The trial which included the collection of this
      data was reviewed and approved by Ethics. Ethics approval was obtained by the
      Preston Research Ethics Committee (project ID 156862). The modelling analysis is 
      not applicable for Ethics as it will use data from the trial (secondary analysis)
      and the published literature. Results of the main trial and economic evaluation
      will be published in the peer-reviewed National Institute for Health Research
      (NIHR) journals library (Programme Grants for Applied Research), submitted to a
      peer-reviewed journal and presented at appropriate conferences. TRIAL
      REGISTRATION NUMBER: ISRCTN74643496; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Shields, Gemma E
AU  - Shields GE
AUID- ORCID: 0000-0003-4869-7524
AD  - Manchester Centre for Health Economics, The University of Manchester, Manchester,
      UK gemma.shields@manchester.ac.uk.
FAU - Wells, Adrian
AU  - Wells A
AUID- ORCID: 0000-0001-7713-1592
AD  - Faculty of Biology, Medicine and Health, School of Psychological Sciences,
      Manchester Academic Health Science Centre, The University of Manchester,
      Manchester, Manchester, UK.
AD  - Research & Innovation, Greater Manchester Mental Health NHS Foundation Trust,
      Manchester Academic Health Science Centre, Manchester, Manchester, UK.
FAU - Doherty, Patrick
AU  - Doherty P
AUID- ORCID: 0000-0002-1887-0237
AD  - Department of Health Sciences, University of York, York, North Yorkshire, UK.
FAU - Reeves, David
AU  - Reeves D
AUID- ORCID: 0000-0001-6377-6859
AD  - Centre for Primary Care, The University of Manchester, Manchester, Manchester,
      UK.
FAU - Capobianco, Lora
AU  - Capobianco L
AUID- ORCID: 0000-0001-6877-8650
AD  - Research & Innovation, Greater Manchester Mental Health NHS Foundation Trust,
      Manchester Academic Health Science Centre, Manchester, Manchester, UK.
FAU - Heagerty, Anthony
AU  - Heagerty A
AUID- ORCID: 0000-0002-9043-2119
AD  - Institute of Cardiovascular Sciences, The University of Manchester, Manchester,
      Manchester, UK.
FAU - Buck, Deborah
AU  - Buck D
AD  - Manchester Centre for Health Economics, The University of Manchester, Manchester,
      UK.
FAU - Davies, Linda M
AU  - Davies LM
AUID- ORCID: 0000-0001-8801-3559
AD  - Manchester Centre for Health Economics, The University of Manchester, Manchester,
      UK.
LA  - eng
SI  - ISRCTN/ISRCTN74643496
GR  - RP-PG-1211-20011/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anxiety
MH  - *Cardiac Rehabilitation
MH  - Cost-Benefit Analysis
MH  - Depression/therapy
MH  - Humans
MH  - Quality of Life
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
PMC - PMC7485258
OTO - NOTNLM
OT  - *cardiology
OT  - *health economics
OT  - *psychiatry
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035552 [pii]
AID - 10.1136/bmjopen-2019-035552 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e035552. doi: 10.1136/bmjopen-2019-035552.


PMID- 32912973
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Modifiable facilitators and barriers to exercise adherence in older adults with
      MCI/dementia using the Theoretical Domains Framework: a systematic review
      protocol.
PG  - e034500
LID - 10.1136/bmjopen-2019-034500 [doi]
AB  - INTRODUCTION: Exercise has multiple benefits on maintaining or improving
      cognitive function for people with mild cognitive impairment (MCI)/dementia.
      However, many older adults with MCI/dementia are not sufficiently active to
      achieve these benefits. Allowing for the current studies on exercise adherence in
      older adults with MCI/dementia still have some deficiencies. This paper aims: (1)
      to identify the modifiable facilitators and barriers to exercise adherence for
      older adults with MCI/dementia in terms of the perspectives of patients,
      caregivers and healthcare professionals; (2) to organise the identified factors
      of exercise adherence based on the Theoretical Domains Framework (TDF) among
      included studies. METHODS AND ANALYSIS: A systematic computerised literature
      search will be performed in the following online databases: PubMed, Embase,
      Cochrane Library, Web of Science, China National Knowledge Infrastructure and Wan
      Fang Database, which published between January 1990 and June 2020. We will
      identify peer-reviewed publications which examined facilitators and barriers to
      exercise adherence. Searches will have no limitation in language publications
      using search terms related to exercise interventions, adherence and MCI/dementia.
      Two independent reviewers will screen titles, abstracts and full-text articles
      according to the predetermined inclusion and exclusion criteria. We will use the 
      statistical software Nvivo V.12 to manage the information. Basing on the TDF, we 
      will map identified modifiable facilitators and barriers of literature to the
      domains of TDF. ETHICS AND DISSEMINATION: This review will summarise modifiable
      facilitators and barriers to exercise adherence for older adults with
      MCI/dementia for the first time. Ethical approval is not required as no primary
      data are collected. We are going to disseminate our findings to the scientific
      and medical community in peer-reviewed journals. The review findings will
      facilitate adequate and accurate access to care and treatment to help older
      adults with MCI/dementia have a broader adoption to exercise. PROSPERO
      REGISTRATION NUMBER: CRD42019117725.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhen, Xueting
AU  - Zhen X
AUID- ORCID: 0000-0001-8282-3550
AD  - School of Medicine, Huzhou University, Huzhou, Zhejiang, China.
FAU - Wang, Lina
AU  - Wang L
AD  - School of Medicine, Huzhou University, Huzhou Central Hospital, Huzhou, Zhejiang,
      China aring2000@163.com.
FAU - Yan, Hang
AU  - Yan H
AD  - School of Medicine, Huzhou University, Huzhou, Zhejiang, China.
FAU - Tao, Hong
AU  - Tao H
AD  - AdventHealth Whole-Person Research, Orlando, Florida, USA.
FAU - Cai, Yaxiu
AU  - Cai Y
AD  - School of Medicine, Huzhou University, Huzhou, Zhejiang, China.
FAU - Wang, Jie
AU  - Wang J
AD  - School of Medicine, Huzhou University, Huzhou, Zhejiang, China.
FAU - Chen, Haiqin
AU  - Chen H
AD  - Nursing Department, Huzhou Third People's Hospital, Huzhou, Zhejiang, China.
FAU - Ge, Chenxi
AU  - Ge C
AD  - School of Medicine, Huzhou University, Huzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - China
MH  - Cognition
MH  - *Cognitive Dysfunction/therapy
MH  - *Dementia/therapy
MH  - *Exercise
MH  - Humans
PMC - PMC7485229
OTO - NOTNLM
OT  - *adherence
OT  - *dementia
OT  - *exercise
OT  - *factors
OT  - *mild cognitive impairment
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034500 [pii]
AID - 10.1136/bmjopen-2019-034500 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e034500. doi: 10.1136/bmjopen-2019-034500.


PMID- 32912957
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Use of real-world data to study health services utilisation and comorbidities in 
      long-term breast cancer survivors (the SURBCAN study): study protocol for a
      longitudinal population-based cohort study.
PG  - e040253
LID - 10.1136/bmjopen-2020-040253 [doi]
AB  - INTRODUCTION: Breast cancer has become a chronic disease due to survival
      improvement and the need to monitor the side effects of treatment and the disease
      itself. The aim of the SURBCAN study is to describe comorbidity, healthcare
      services use and adherence to preventive recommendations in long-term breast
      cancer survivors and to compare them with those in women without this diagnosis
      in order to improve and adapt the care response to this group of survivors.
      METHODS AND ANALYSIS: Population-based retrospective cohort study using
      real-world data from cancer registries and linked electronic medical records in
      five Spanish regions. Long-term breast cancer survivors diagnosed between 2000
      and 2006 will be identified and matched by age and administrative health area
      with women without this diagnosis. Sociodemographic and clinical variables
      including comorbidities and variables on the use of health services between 2012 
      and 2016 will be obtained from databases in primary and hospital care. Health
      services use will be assessed through the annual number of visits to primary care
      professionals and to specialists and through annual imaging and laboratory tests.
      Factors associated with healthcare utilisation and comorbidities will be analysed
      using multilevel logistic regression models. Recruitment started in December
      2018. ETHICS AND DISSEMINATION: This study was approved by the Ethics Committee
      of Parc de Salut Mar. The results of the study will be published in a
      peer-reviewed journal and will be presented at national and international
      scientific conferences and at patient associations. TRIAL REGISTRATION NUMBER:
      This protocol is registered in Clinical Trials.gov (identifier: NCT03846999).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jansana, Anna
AU  - Jansana A
AUID- ORCID: 0000-0001-8504-1618
AD  - Department of Epidemiology and Evaluation, Hospital del Mar Institute for Medical
      Research, Barcelona, Barcelona, Spain.
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
FAU - Del Cura, Isabel
AU  - Del Cura I
AUID- ORCID: 0000-0002-3931-5304
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Primary Care Research Unit, Madrid Health Service, Madrid, Madrid, Spain.
FAU - Prados-Torres, Alexandra
AU  - Prados-Torres A
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - EpiChron Research Group on Chronic Diseases, IACS, IIS Aragon, Miguel Servet
      University Hospital, Zaragoza, Zaragoza, Spain.
FAU - Sanz Cuesta, Teresa
AU  - Sanz Cuesta T
AUID- ORCID: 0000-0001-8791-8030
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Primary Care Research Unit, Comunidad de Madrid Servicio Madrileno de Salud,
      Madrid, Spain.
FAU - Poblador-Plou, Beatriz
AU  - Poblador-Plou B
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - EpiChron Research Group on Chronic Diseases, IACS, IIS Aragon, Miguel Servet
      University Hospital, Zaragoza, Zaragoza, Spain.
FAU - Gimeno Miguel, A
AU  - Gimeno Miguel A
AUID- ORCID: 0000-0002-5440-1710
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - EpiChron Research Group on Chronic Diseases, IACS, IIS Aragon, Miguel Servet
      University Hospital, Zaragoza, Zaragoza, Spain.
FAU - Lanzuela, Manuela
AU  - Lanzuela M
AD  - Radiotherapy Department, Miguel Servet University Hospital, Zaragoza, Aragon,
      Spain.
FAU - Ibanez, Berta
AU  - Ibanez B
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Unit of Methodology, Navarrabiomed-Fundacion Miguel Servet, Pamplona, Navarra,
      Spain.
FAU - Tamayo, Ibai
AU  - Tamayo I
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Unit of Methodology, Navarrabiomed-Fundacion Miguel Servet, Pamplona, Navarra,
      Spain.
FAU - Moreno-Iribas, Conchi
AU  - Moreno-Iribas C
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Unit of Methodology, Navarrabiomed-Fundacion Miguel Servet, Pamplona, Navarra,
      Spain.
FAU - Padilla-Ruiz, Maria
AU  - Padilla-Ruiz M
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Research Unit - IBIMA, Hospital Costa del Sol, Marbella, Andalucia, Spain.
FAU - Redondo, Maximino
AU  - Redondo M
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
AD  - Research Unit - IBIMA, Hospital Costa del Sol, Marbella, Andalucia, Spain.
FAU - Comas, Merce
AU  - Comas M
AD  - Department of Epidemiology and Evaluation, Hospital del Mar Institute for Medical
      Research, Barcelona, Barcelona, Spain.
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
FAU - Domingo, Laia
AU  - Domingo L
AD  - Department of Epidemiology and Evaluation, Hospital del Mar Institute for Medical
      Research, Barcelona, Barcelona, Spain.
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
FAU - Diaz-Holgado, Antonio
AU  - Diaz-Holgado A
AD  - Information System Unit, Directorate for Public Health, Health Service of Madrid,
      Madrid, Spain.
FAU - Salamanca, Francisco Javier
AU  - Salamanca FJ
AD  - Tumor registry, Hospital Universitario Doce de Octubre, Madrid, Madrid, Spain.
FAU - Castells, Xavier
AU  - Castells X
AD  - Department of Epidemiology and Evaluation, Hospital del Mar Institute for Medical
      Research, Barcelona, Barcelona, Spain.
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
FAU - Sala, Maria
AU  - Sala M
AUID- ORCID: 0000-0002-9955-8746
AD  - Department of Epidemiology and Evaluation, Hospital del Mar Institute for Medical
      Research, Barcelona, Barcelona, Spain Msalaserra@parcdesalutmar.cat.
AD  - Health Services Research on Chronic Patients Network (REDISSEC), Instituto de
      Salud Carlos III, Madrid, Madrid, Spain.
CN  - SURBCAN group
LA  - eng
SI  - ClinicalTrials.gov/NCT03846999
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Breast Neoplasms/epidemiology/therapy
MH  - *Cancer Survivors
MH  - Cohort Studies
MH  - Comorbidity
MH  - Facilities and Services Utilization
MH  - Female
MH  - Humans
MH  - Retrospective Studies
PMC - PMC7482495
OTO - NOTNLM
OT  - *breast tumours
OT  - *epidemiology
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
IR  - Abizanda M
FIR - Abizanda, Merce
IR  - Duarte T
FIR - Duarte, Talita
IR  - Louro J
FIR - Louro, Javier
IR  - Martinez MDC
FIR - Martinez, Maria Del Carmen
IR  - Molina C
FIR - Molina, Cristobal
IR  - Perez G
FIR - Perez, Guillermo
IR  - Munoz AM
FIR - Munoz, Ana Maria
IR  - Toldos O
FIR - Toldos, Oscar
IR  - Baquedano J
FIR - Baquedano, Javier
IR  - Burgui R
FIR - Burgui, Rossana
IR  - Gorricho J
FIR - Gorricho, Javier
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040253 [pii]
AID - 10.1136/bmjopen-2020-040253 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e040253. doi: 10.1136/bmjopen-2020-040253.


PMID- 32912952
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - PERSonalised Incentives for Supporting Tobacco cessation (PERSIST) among
      healthcare employees: a randomised controlled trial protocol.
PG  - e037799
LID - 10.1136/bmjopen-2020-037799 [doi]
AB  - BACKGROUND: Smoking is the primary preventable risk factor for disease and
      premature mortality. It is highly addictive and cessation attempts are often
      unsuccessful. Incentive-based programmes may be an effective method to reach
      sustained abstinence. Individualisation of incentives based on personal
      characteristics yields potential to further increase the effectiveness of
      incentive-based programmes. METHOD: A randomised controlled trial among
      healthcare workers recruited through their employer and signed up for a
      group-based smoking cessation programme. The intervention under study is the
      provision of personalised incentives on validated smoking cessation at several
      time points after the smoking cessation programme. A total of 220 participants
      are required. Participants are randomised 1:1 into intervention (personalised
      incentives) or control (no incentives). All participants join the group-based
      programme. Incentives are provided on validated abstinence directly after the
      smoking cessation programme and after 3, 6 and 12 months.Incentives are provided 
      according to four schemes:(1) Standard: total reward size euro350, pay-out
      scheme: euro50 (t=0), euro50 (t=3 months), euro50 (t=6 months) and euro200 (t=12 
      months), (2) descending: total reward size euro300, pay-out scheme: euro150,
      euro100, euro50 and euro0, (3) ascending: total reward size: euro400, pay-out
      scheme: euro0, euro0, euro50 and euro350 and (4) deposit: total reward size
      euro450, pay-out scheme: euro50, euro50, euro150, euro200; participants pay a
      euro100 deposit, returned conditional on abstinence after 6 months.Advice on
      which incentive scheme suits participants best is based on willingness to provide
      a deposit, readiness to quit, nicotine dependency and long-term or short-term
      reward preference. Participants are free to deviate from this advice. Abstinence 
      is validated at each time point, with 15 months of total follow-up. The primary
      end point is validated abstinence at 12 months. Effectiveness will be determined 
      by intention-to-treat analysis. ETHICS AND DISSEMINATION: The Erasmus MC Medical 
      Ethics Committee decided that according to the Dutch Human Research Law (WMO),
      the protocol required no formal ethical approval. The results will be published
      in a peer-reviewed scientific journal and communicated to the participants. TRIAL
      REGISTRATION NUMBER: Netherlands Trial Register NL7711.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Boderie, Nienke W
AU  - Boderie NW
AUID- ORCID: 0000-0002-1600-380X
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, The Netherlands.
FAU - van Kippersluis, Johannes Lw
AU  - van Kippersluis JL
AD  - Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, The
      Netherlands.
AD  - Tinbergen Institute, Amsterdam, The Netherlands.
FAU - O Ceallaigh, Diarmaid T
AU  - O Ceallaigh DT
AD  - Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, The
      Netherlands.
FAU - Rado, Marta K
AU  - Rado MK
AUID- ORCID: 0000-0002-1676-5951
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, The Netherlands.
AD  - Department of Paediatrics, Division of Neonatology, Erasmus MC - Sophia
      Children's Hospital, University Medical Centre Rotterdam, Rotterdam, The
      Netherlands.
FAU - Burdorf, Alex
AU  - Burdorf A
AUID- ORCID: 0000-0003-3129-2862
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, The Netherlands.
FAU - van Lenthe, Frank J
AU  - van Lenthe FJ
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, The Netherlands.
FAU - Been, Jasper V
AU  - Been JV
AD  - Department of Public Health, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, The Netherlands j.been@erasmusmc.nl.
AD  - Department of Paediatrics, Division of Neonatology, Erasmus MC - Sophia
      Children's Hospital, University Medical Centre Rotterdam, Rotterdam, The
      Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Health Personnel
MH  - Humans
MH  - *Motivation
MH  - Netherlands
MH  - Randomized Controlled Trials as Topic
MH  - *Tobacco Use Cessation
PMC - PMC7482494
OTO - NOTNLM
OT  - *validated
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037799 [pii]
AID - 10.1136/bmjopen-2020-037799 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e037799. doi: 10.1136/bmjopen-2020-037799.


PMID- 32912951
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - East Midlands knee pain multiple randomised controlled trial cohort study: cohort
      establishment and feasibility study protocol.
PG  - e037760
LID - 10.1136/bmjopen-2020-037760 [doi]
AB  - INTRODUCTION: Knee pain due to osteoarthritis (OA) is a common cause of
      disability. The UK National Institute for Health and Care Excellence OA
      guidelines recommend education, exercise and weight loss advice (if overweight)
      as core interventions before pharmacological adjuncts. However, implementation of
      these in primary care is often suboptimal. This study aims to develop a complex
      intervention with non-pharmacological and pharmacological components that can be 
      delivered by nurses. The feasibility and acceptability of the intervention, and
      feasibility of undertaking a future cohort randomised controlled trial (RCT) will
      be explored. METHODS AND ANALYSIS: In phase 1, we will develop a training
      programme for nurses and evaluate the fidelity and acceptability of the
      non-pharmacological element of the intervention. Fidelity checklists completed by
      the nurse will be compared with video analysis of the treatment sessions.
      Patients and nurses will be interviewed to determine the acceptability of the
      intervention and explore challenges to intervention delivery. The
      non-pharmacological component will be modified based on the findings. In phase 2,
      we will assess the feasibility of conducting a cohort RCT comprising both the
      pharmacological and modified non-pharmacological components. We will compare
      three groups: group A will receive the non-pharmacological components delivered
      before pharmacological components; group B will receive pharmacological
      components followed by the non-pharmacological components; and group C (control
      arm) will continue to receive usual care. Study outcomes will be collected at
      three time points: baseline, 13 and 26 weeks after randomisation. Qualitative
      interviews will be conducted with a sample of participants from each of the two
      active intervention arms. ETHICS AND DISSEMINATION: This protocol was approved by
      the East Midlands-Derby Research Ethics Committee (18/EM/0288) and registered at 
      ClinicalTrials.gov (protocol v4.0, 10/02/2020). The study will be reported in
      accordance with the Consolidated Standards of Reporting Trials guidance and
      standards. The results will be submitted for publication in peer-reviewed
      academic journals. TRIAL REGISTRATION NUMBER: NCT03670706.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hall, Michelle
AU  - Hall M
AUID- ORCID: 0000-0003-2231-1507
AD  - School of Health Sciences, University of Nottingham, Nottingham, Nottinghamshire,
      UK michelle.hall@nottingham.ac.uk.
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Fuller, Amy
AU  - Fuller A
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Academic Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Nomikos, Polykarpos Angelos
AU  - Nomikos PA
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Academic Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Millar, Bonnie
AU  - Millar B
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Pain Centre Versus Arthritis, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Ogollah, Reuben
AU  - Ogollah R
AD  - Nottingham Clinical Trials Unit, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Valdes, Ana
AU  - Valdes A
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Pain Centre Versus Arthritis, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Greenhaff, Paul
AU  - Greenhaff P
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - School of Medical and Surgical Sciences, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - das Nair, Roshan
AU  - das Nair R
AD  - Institute of Mental Health, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Division of Psychiatry and Applied Psychology, University of Nottingham,
      Nottingham, Nottinghamshire, UK.
FAU - Doherty, Michael
AU  - Doherty M
AD  - Academic Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, UK.
AD  - Pain Centre Versus Arthritis, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Walsh, David A
AU  - Walsh DA
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Pain Centre Versus Arthritis, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Abhishek, A
AU  - Abhishek A
AD  - NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Academic Rheumatology, University of Nottingham, Nottingham, Nottinghamshire, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03670706
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Exercise
MH  - Feasibility Studies
MH  - Humans
MH  - *Knee Joint
MH  - *Pain
MH  - Randomized Controlled Trials as Topic
PMC - PMC7482502
OTO - NOTNLM
OT  - *knee
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037760 [pii]
AID - 10.1136/bmjopen-2020-037760 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e037760. doi: 10.1136/bmjopen-2020-037760.


PMID- 32912948
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised
      controlled trial to evaluate the effect of adding a personalised smoking
      cessation intervention to a lung cancer screening programme.
PG  - e037086
LID - 10.1136/bmjopen-2020-037086 [doi]
AB  - INTRODUCTION: Integration of smoking cessation (SC) into lung cancer screening is
      essential to optimise clinical and cost effectiveness. The most effective way to 
      use this 'teachable moment' is unclear. The Yorkshire Enhanced Stop Smoking study
      will measure the effectiveness of an SC service integrated within the Yorkshire
      Lung Screening Trial (YLST) and will test the efficacy of a personalised SC
      intervention, incorporating incidental findings detected on the low-dose CT scan 
      performed as part of YLST. METHODS AND ANALYSIS: Unless explicitly declined, all 
      smokers enrolled in YLST will see an SC practitioner at baseline and receive SC
      support over 4 weeks comprising behavioural support, pharmacotherapy and/or a
      commercially available e-cigarette. Eligible smokers will be randomised (1:1 in
      permuted blocks of random size up to size 6) to receive either an enhanced,
      personalised SC support package, including CT scan images, or continued standard 
      best practice. Anticipated recruitment is 1040 smokers (January 2019-December
      2020). The primary objective is to measure 7-day point prevalent carbon monoxide 
      (CO) validated SC after 3 months. Secondary outcomes include CO validated
      cessation at 4 weeks and 12 months, self-reported continuous cessation at 4
      weeks, 3 months and 12 months, attempts to quit smoking and changes in
      psychological variables, including perceived risk of lung cancer, motivation to
      quit smoking tobacco, confidence and efficacy beliefs (self and response) at all 
      follow-up points. A process evaluation will explore under which circumstances and
      on which groups the intervention works best, test intervention fidelity and
      theory test the mechanisms of intervention impact. ETHICS AND DISSEMINATION: This
      study has been approved by the East Midlands-Derby Research Ethics Committee
      (18/EM/0199) and the Health Research Authority/Health and Care Research Wales.
      Results will be disseminated through publication in peer-reviewed scientific
      journals, presentation at conferences and via the YLST website. TRIAL
      REGISTRATION NUMBERS: ISRCTN63825779, NCT03750110.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Murray, Rachael L
AU  - Murray RL
AUID- ORCID: 0000-0001-5477-2557
AD  - Division of Epidemiology & Public Health, Faculty of Medicine, University of
      Nottingham, Nottingham, United Kingdom rachael.murray@nottingham.ac.uk.
AD  - UK Centre for Tobacco and Alcohol Studies, University of Nottingham, Nottingham, 
      United Kingdom.
FAU - Brain, Kate
AU  - Brain K
AD  - Division of Population Medicine, Cardiff University, Cardiff, United Kingdom.
FAU - Britton, John
AU  - Britton J
AD  - Division of Epidemiology & Public Health, Faculty of Medicine, University of
      Nottingham, Nottingham, United Kingdom.
AD  - UK Centre for Tobacco and Alcohol Studies, University of Nottingham, Nottingham, 
      United Kingdom.
FAU - Quinn-Scoggins, Harriet D
AU  - Quinn-Scoggins HD
AD  - Division of Population Medicine, Cardiff University, Cardiff, United Kingdom.
FAU - Lewis, Sarah
AU  - Lewis S
AD  - Division of Epidemiology & Public Health, Faculty of Medicine, University of
      Nottingham, Nottingham, United Kingdom.
AD  - UK Centre for Tobacco and Alcohol Studies, University of Nottingham, Nottingham, 
      United Kingdom.
FAU - McCutchan, Grace M
AU  - McCutchan GM
AUID- ORCID: 0000-0002-8079-2540
AD  - Division of Population Medicine, Cardiff University, Cardiff, United Kingdom.
FAU - Quaife, Samantha L
AU  - Quaife SL
AD  - Research Department of Behavioural Science and Health, University College London,
      London, United Kingdom.
FAU - Wu, Qi
AU  - Wu Q
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Ashurst, Alex
AU  - Ashurst A
AD  - Department of Radiology, Leeds Teaching Hospitals, Leeds, United Kingdom.
FAU - Baldwin, David
AU  - Baldwin D
AUID- ORCID: 0000-0001-8410-7160
AD  - Deaprtment of Respiratory Medicine, Nottingham University Hospitals NHS Trust,
      Nottingham, United Kingdom.
FAU - Crosbie, Philip A J
AU  - Crosbie PAJ
AUID- ORCID: 0000-0001-8941-4813
AD  - Division of Infection, Immunity and Respiratory Medicine, The University of
      Manchester, Wythenshawe, UK.
FAU - Neal, Richard D
AU  - Neal RD
AD  - Institute of Health Science, University of Leeds, Leeds, United Kingdom.
FAU - Parrott, Steve
AU  - Parrott S
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Rogerson, Suzanne
AU  - Rogerson S
AD  - Research and Innivation CSU, Leeds Teaching Hospitals, Leeds, United Kingdom.
FAU - Thorley, Rebecca
AU  - Thorley R
AD  - Division of Epidemiology & Public Health, Faculty of Medicine, University of
      Nottingham, Nottingham, United Kingdom.
AD  - UK Centre for Tobacco and Alcohol Studies, University of Nottingham, Nottingham, 
      United Kingdom.
FAU - Callister, Matthew Ej
AU  - Callister ME
AD  - Department of Respiratory Medicine, Leeds Teaching Hospitals, Leeds, United
      Kingdom.
LA  - eng
SI  - ClinicalTrials.gov/NCT03750110
SI  - ISRCTN/ISRCTN63825779
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Early Detection of Cancer
MH  - *Electronic Nicotine Delivery Systems
MH  - Humans
MH  - *Lung Neoplasms/diagnostic imaging
MH  - Randomized Controlled Trials as Topic
MH  - Smoking
MH  - *Smoking Cessation
MH  - Wales
PMC - PMC7485260
OTO - NOTNLM
OT  - *CT
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: PAJC has received consultation fees and share options from
      Everest Detection.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037086 [pii]
AID - 10.1136/bmjopen-2020-037086 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037086. doi: 10.1136/bmjopen-2020-037086.


PMID- 32912947
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 10
TI  - Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial
      to evaluate invitation to community-based low-dose CT screening for lung cancer
      versus usual care in a targeted population at risk.
PG  - e037075
LID - 10.1136/bmjopen-2020-037075 [doi]
AB  - INTRODUCTION: Lung cancer is the world's leading cause of cancer death. Low-dose 
      computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the 
      US National Lung Screening Trial. Here, we present the Yorkshire Lung Screening
      Trial (YLST), which will address key questions of relevance for screening
      implementation. METHODS AND ANALYSIS: Using a single-consent Zelen's design,
      ever-smokers aged 55-80 years registered with a general practice in Leeds will be
      randomised (1:1) to invitation to a telephone-based risk-assessment for a Lung
      Health Check or to usual care. The anticipated number randomised by household is 
      62 980 individuals. Responders at high risk will be invited for LDCT scanning for
      lung cancer on a mobile van in the community. There will be two rounds of
      screening at an interval of 2 years. Primary objectives are (1) measure
      participation rates, (2) compare the performance of PLCOM2012 (threshold
      >/=1.51%), Liverpool Lung Project (V.2) (threshold >/=5%) and US Preventive
      Services Task Force eligibility criteria for screening population selection and
      (3) assess lung cancer outcomes in the intervention and usual care arms.
      Secondary evaluations include health economics, quality of life, smoking rates
      according to intervention arm, screening programme performance with ancillary
      biomarker and smoking cessation studies. ETHICS AND DISSEMINATION: The study has 
      been approved by the Greater Manchester West research ethics committee
      (18-NW-0012) and the Health Research Authority following review by the
      Confidentiality Advisory Group. The results will be disseminated through
      publication in peer-reviewed scientific journals, presentation at conferences and
      on the YLST website. TRIAL REGISTRATION NUMBERS: ISRCTN42704678 and NCT03750110.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Crosbie, Philip Aj
AU  - Crosbie PA
AUID- ORCID: 0000-0001-8941-4813
AD  - Division of Infection, Immunity and Respiratory Medicine, The University of
      Manchester, Manchester, UK.
FAU - Gabe, Rhian
AU  - Gabe R
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen
      Mary University of London, London, UK.
FAU - Simmonds, Irene
AU  - Simmonds I
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Kennedy, Martyn
AU  - Kennedy M
AD  - Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds,
      UK.
FAU - Rogerson, Suzanne
AU  - Rogerson S
AD  - Department of Research and Innovation, Leeds Teaching Hospitals NHS Trust, Leeds,
      UK.
FAU - Ahmed, Nazia
AU  - Ahmed N
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Baldwin, David R
AU  - Baldwin DR
AUID- ORCID: 0000-0001-8410-7160
AD  - Department of Respiratory Medicine, City Campus, Nottingham University Hospitals,
      Nottingham, UK.
FAU - Booton, Richard
AU  - Booton R
AD  - Lung Cancer and Thoracic Surgery Directorate, Heart and Lung Division, Manchester
      University NHS Foundation Trust, Manchester, UK.
FAU - Cochrane, Ann
AU  - Cochrane A
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Darby, Michael
AU  - Darby M
AD  - Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Franks, Kevin
AU  - Franks K
AD  - Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Hinde, Sebastian
AU  - Hinde S
AUID- ORCID: 0000-0002-7117-4142
AD  - Centre for Health Economics, University of York, York, UK.
FAU - Janes, Sam M
AU  - Janes SM
AD  - Department of Respiratory Medicine, University College London, London, UK.
FAU - Macleod, Una
AU  - Macleod U
AD  - Hull York Medical School, University of Hull, Hull, UK.
FAU - Messenger, Mike
AU  - Messenger M
AD  - Leeds Centre for Personalised Medicine and Health, University of Leeds, Leeds,
      UK.
FAU - Moller, Henrik
AU  - Moller H
AD  - Thames Cancer Registry, Kings College London, London, UK.
FAU - Murray, Rachael L
AU  - Murray RL
AUID- ORCID: 0000-0001-5477-2557
AD  - Division of Epidemiology and Public Health, Faculty of Medicine, University of
      Nottingham, Nottingham, UK.
FAU - Neal, Richard D
AU  - Neal RD
AD  - Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
FAU - Quaife, Samantha L
AU  - Quaife SL
AD  - Research Department of Epidemiology and Public Health, University College London,
      London, UK.
FAU - Sculpher, Mark
AU  - Sculpher M
AD  - Centre for Health Economics, University of York, York, UK.
FAU - Tharmanathan, Puvanendran
AU  - Tharmanathan P
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Torgerson, David
AU  - Torgerson D
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Callister, Matthew Ej
AU  - Callister ME
AD  - Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK
      matthew.callister@nhs.net.
LA  - eng
SI  - ClinicalTrials.gov/NCT03750110
SI  - ISRCTN/ISRCTN42704678
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Early Detection of Cancer
MH  - Humans
MH  - Lung
MH  - *Lung Neoplasms/diagnostic imaging
MH  - Middle Aged
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Tomography, X-Ray Computed
PMC - PMC7485242
OTO - NOTNLM
OT  - *chest imaging
OT  - *respiratory tract tumours
COIS- Competing interests: PAJC has received consultation fees and shares options from 
      Everest Detection. PAJC is supported by the NIHR Manchester Biomedical Research
      Centre.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037075 [pii]
AID - 10.1136/bmjopen-2020-037075 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 10;10(9):e037075. doi: 10.1136/bmjopen-2020-037075.


PMID- 32912944
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Comparative effectiveness of buprenorphine-naloxone versus methadone for
      treatment of opioid use disorder: a population-based observational study protocol
      in British Columbia, Canada.
PG  - e036102
LID - 10.1136/bmjopen-2019-036102 [doi]
AB  - INTRODUCTION: Despite a recent meta-analysis including 31 randomised controlled
      trials comparing methadone and buprenorphine for the treatment of opioid use
      disorder, important knowledge gaps remain regarding the long-term effectiveness
      of different treatment modalities across individuals, including rigorously
      collected data on retention rates and other treatment outcomes. Evidence from
      real-world data represents a valuable opportunity to improve personalised
      treatment and patient-centred guidelines for vulnerable populations and inform
      strategies to reduce opioid-related mortality. Our objective is to determine the 
      comparative effectiveness of methadone versus buprenorphine/naloxone, both
      overall and within key populations, in a setting where both medications are
      simultaneously available in office-based practices and specialised clinics.
      METHODS AND ANALYSIS: We propose a retrospective cohort study of all adults
      living in British Columbia receiving opioid agonist treatment (OAT) with
      methadone or buprenorphine/naloxone between 1 January 2008 and 30 September 2018.
      The study will draw on seven linked population-level administrative databases.
      The primary outcomes include retention in OAT and all-cause mortality. We will
      determine the effectiveness of buprenorphine/naloxone vs methadone using
      intention-to-treat and per-protocol analyses-the former emulating flexible-dose
      trials and the latter focusing on the comparison of the two medication regimens
      offered at the optimal dose. Sensitivity analyses will be used to assess the
      robustness of results to heterogeneity in the patient population and threats to
      internal validity. ETHICS AND DISSEMINATION: The protocol, cohort creation and
      analysis plan have been approved and classified as a quality improvement
      initiative exempt from ethical review (Providence Health Care Research Institute 
      and the Simon Fraser University Office of Research Ethics). Dissemination is
      planned via conferences and publications, and through direct engagement and
      collaboration with entities that issue clinical guidelines, such as professional 
      medical societies and public health organisations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Piske, Micah
AU  - Piske M
AD  - Epidemiology and Population Health Program, BC Centre for Excellence in HIV/AIDS,
      Vancouver, British Columbia, Canada.
FAU - Thomson, Trevor
AU  - Thomson T
AD  - Epidemiology and Population Health Program, BC Centre for Excellence in HIV/AIDS,
      Vancouver, British Columbia, Canada.
FAU - Krebs, Emanuel
AU  - Krebs E
AD  - Epidemiology and Population Health Program, BC Centre for Excellence in HIV/AIDS,
      Vancouver, British Columbia, Canada.
FAU - Hongdilokkul, Natt
AU  - Hongdilokkul N
AD  - Epidemiology and Population Health Program, BC Centre for Excellence in HIV/AIDS,
      Vancouver, British Columbia, Canada.
FAU - Bruneau, Julie
AU  - Bruneau J
AD  - Centre hospitalier de l'Universite de Montreal, CRCHUM, Montreal, Quebec, Canada.
AD  - Departement de medecine de famille et de medecine d'urgence, Universite de
      Montreal, Montreal, Quebec, Canada.
FAU - Greenland, Sander
AU  - Greenland S
AD  - Department of Epidemiology and Department of Statistics, UCLA, Los Angeles,
      California, USA.
FAU - Gustafson, Paul
AU  - Gustafson P
AD  - Department of Statistics, UBC, Vancouver, British Columbia, Canada.
FAU - Karim, M Ehsan
AU  - Karim ME
AD  - School of Population and Public Health, UBC, Vancouver, British Columbia, Canada.
AD  - Providence Health Care Research Institute, Centre for Health Evaluation and
      Outcome Sciences, Vancouver, British Columbia, Canada.
FAU - McCandless, Lawrence C
AU  - McCandless LC
AD  - Department of Statstics and Actuarial Sciences, Simon Fraser University, Burnaby,
      British Columbia, Canada.
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia,
      Canada.
FAU - Maclure, Malcolm
AU  - Maclure M
AD  - Department of Anesthesiology, Pharmacology and Therapeutics, UBC, Vancouver,
      British Columbia, Canada.
FAU - Platt, Robert W
AU  - Platt RW
AD  - Department of Epidemiology, Biostatistics and Occupational Health, McGill
      University, Montreal, Quebec, Canada.
AD  - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research,
      Montreal, Quebec, Canada.
FAU - Siebert, Uwe
AU  - Siebert U
AD  - Department of Health Policy and Management, Harvard University T H Chan School of
      Public Health, Boston, Massachusetts, USA.
AD  - Department of Public Health, Health Services Research and Health Technology
      Assessment, UMIT - University for Health Sciences, Medical Informatics and
      Technology, Tirol, Austria.
AD  - Oncotyrol - Center for Personalized Cancer Medicine, Innsbruck, Austria.
FAU - Socias, M Eugenia
AU  - Socias ME
AD  - BC Centre on Substance Use, Vancouver, British Columbia, Canada.
AD  - Department of Medicine, Faculty of Medicine, UBC, Vancouver, Briitish Columbia,
      Canada.
FAU - Tsui, Judith I
AU  - Tsui JI
AD  - Department of Medicine, Section of General Internal Medicine, University of
      Washington, Seattle, Washington, USA.
FAU - Wood, Evan
AU  - Wood E
AD  - BC Centre on Substance Use, Vancouver, British Columbia, Canada.
AD  - Department of Medicine, Faculty of Medicine, UBC, Vancouver, Briitish Columbia,
      Canada.
FAU - Nosyk, Bohdan
AU  - Nosyk B
AUID- ORCID: 0000-0003-2513-3718
AD  - Epidemiology and Population Health Program, BC Centre for Excellence in HIV/AIDS,
      Vancouver, British Columbia, Canada bnosyk@cfenet.ubc.ca.
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia,
      Canada.
LA  - eng
GR  - P30 AI027757/AI/NIAID NIH HHS/United States
GR  - R25 DA037756/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Buprenorphine, Naloxone Drug Combination)
RN  - 40D3SCR4GZ (Buprenorphine)
RN  - UC6VBE7V1Z (Methadone)
SB  - IM
MH  - Adult
MH  - Analgesics, Opioid/therapeutic use
MH  - British Columbia
MH  - *Buprenorphine/therapeutic use
MH  - Buprenorphine, Naloxone Drug Combination/therapeutic use
MH  - Humans
MH  - Methadone/therapeutic use
MH  - Observational Studies as Topic
MH  - Opiate Substitution Treatment
MH  - *Opioid-Related Disorders/drug therapy
MH  - Retrospective Studies
PMC - PMC7482450
OTO - NOTNLM
OT  - *epidemiology
OT  - *primary care
OT  - *public health
OT  - *statistics & research methods
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036102 [pii]
AID - 10.1136/bmjopen-2019-036102 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e036102. doi: 10.1136/bmjopen-2019-036102.


PMID- 32912942
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Study protocol of a multicentre, randomised, controlled trial evaluating the
      effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing
      desensitisation or tolerance in children with peanut allergy compared with oral
      immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).
PG  - e035871
LID - 10.1136/bmjopen-2019-035871 [doi]
AB  - INTRODUCTION: Peanut allergy is the the most common cause of life-threatening
      food-induced anaphylaxis. There is currently no effective long-term treatment.
      There is a pressing need for definitive treatments that improve the quality of
      life and prevent fatalities. Allergen oral immunotherapy (OIT) is a promising
      approach, which is effective at inducing desensitisation; however, OIT has a
      limited ability to induce sustained unresponsiveness (SU). We have previously
      shown that a novel treatment comprising a combination of the probiotic
      Lactobacillus rhamnosus CGMCC 1.3724 with peanut OIT (Probiotic Peanut Oral
      ImmunoTherapy (PPOIT)) is highly effective at inducing SU, with benefit
      persisting to 4 years after treatment cessation in the majority of initial
      treatment responders. Here we describe the protocol for a Phase IIb multicentre, 
      double-blind, randomised, controlled trial (PPOIT-003) with dual primary
      objectives to evaluate the effectiveness of PPOIT at inducing SU (assessed at 8
      weeks after treatment cessation) compared with placebo treatment and peanut OIT
      alone, in children with peanut allergy. METHODS AND ANALYSIS: 200 children 1 to
      10 years of age with current peanut allergy confirmed by failed double-blind
      placebo-controlled food challenge (DBPCFC) at study screening will be recruited
      from three tertiary paediatric hospitals in Australia. There are three
      intervention arms-PPOIT, peanut OIT alone or placebo. Interventions are
      administered once daily for 18 months. The dual primary outcomes are: (1) the
      proportion of children who attain 8-week SU in the PPOIT group versus placebo
      group and (2) the proportion of children who attain 8-week SU in the PPOIT group 
      versus OIT group. ETHICS AND DISSEMINATION: This study has been approved by the
      Human Research Ethics Committees at the Royal Children's Hospital (HREC 35246)
      and the Child and Adolescent Health Service (RGS 2543). Results will be published
      in peer-reviewed journals and disseminated via presentations at international
      conferences. TRIAL REGISTRATION NUMBER: ACTRN12616000322437.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chebar Lozinsky, Adriana
AU  - Chebar Lozinsky A
AUID- ORCID: 0000-0002-6765-2762
AD  - Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria,
      Australia.
FAU - Loke, Paxton
AU  - Loke P
AD  - Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria,
      Australia.
AD  - Allergy and Immunology, Royal Children's Hospital, Melbourne, Victoria,
      Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Orsini, Francesca
AU  - Orsini F
AD  - Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research
      Institute, Parkville, Victoria, Australia.
AD  - Clinical Epidemiology and Biostatistics Unit, Melbourne Children's Trial Centre, 
      Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
FAU - O'Sullivan, Michael
AU  - O'Sullivan M
AD  - ORIGINS Project, Telethon Kids Institute, Nedlands, Western Australia, Australia.
AD  - Division of Pathology and Laboratory Medicine, School of Medicine, University of 
      Western Australia, Crawley, Western Australia, Australia.
AD  - Allergy, Immunology and Dermatology, Perth Children's Hospital, Nedlands, Western
      Australia, Australia.
FAU - L Prescott, Susan
AU  - L Prescott S
AD  - ORIGINS Project, Telethon Kids Institute, Nedlands, Western Australia, Australia.
AD  - Allergy, Immunology and Dermatology, Perth Children's Hospital, Nedlands, Western
      Australia, Australia.
AD  - Division of Paediatrics, School of Medicine, University of Western Australia,
      Perth, Western Australia, Australia.
FAU - Gold, Michael S
AU  - Gold MS
AD  - Paediatrics, Faculty of Health and Medical Sciences, University of Adelaide,
      Adelaide, South Australia, Australia.
AD  - Allergy and Immunology, Women's and Children's Hospital, North Adelaide, South
      Australia, Australia.
FAU - Quinn, Patrick
AU  - Quinn P
AD  - Paediatrics, Faculty of Health and Medical Sciences, University of Adelaide,
      Adelaide, South Australia, Australia.
AD  - Allergy and Immunology, Women's and Children's Hospital, North Adelaide, South
      Australia, Australia.
FAU - DunnGalvin, Audrey
AU  - DunnGalvin A
AD  - School of Applied Psychology, University College Cork, Cork, Ireland.
AD  - Institute of Child Health, Sechenov First Moscow State Medical University
      (Sechenov University), Moscow, Russia.
FAU - Lk Tang, Mimi
AU  - Lk Tang M
AD  - Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria,
      Australia mimi.tang@rch.org.au.
AD  - Allergy and Immunology, Royal Children's Hospital, Melbourne, Victoria,
      Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
CN  - PPOIT study team
LA  - eng
SI  - ANZCTR/ACTRN12616000322437
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Allergens)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Allergens
MH  - Arachis
MH  - Australia
MH  - Child
MH  - Desensitization, Immunologic
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Peanut Hypersensitivity/therapy
MH  - *Probiotics
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7482477
OTO - NOTNLM
OT  - *allergy
OT  - *clinical trials
OT  - *paediatrics
COIS- Competing interests: MT is a past member of Nestle Nutrition Institute Medical
      Advisory Board Oceania; past member of Nutricia global scientific advisory board;
      speaker fees from Nestle Nutrition Institute and Abbott Nutrition; consultant to 
      Bayer Pharmaceuticals; research funding from Abbott Nutrition, Bayer
      Pharmaceuticals, Prota Therapeutics; employee of Prota Therapeutics and inventor 
      on a patent owned by Murdoch Children's Research Institute 'A method for inducing
      tolerance'.
IR  - Ponsoby AL
FIR - Ponsoby, Anne-Louise
IR  - Su EL
FIR - Su, Ee Lyn
IR  - Robinson M
FIR - Robinson, Marnie
IR  - Tey D
FIR - Tey, Dean
IR  - Hsiao KC
FIR - Hsiao, Kuang-Chih
IR  - O'Sullivan M
FIR - O'Sullivan, Molly
IR  - Axelrad C
FIR - Axelrad, Christine
IR  - Pitkin S
FIR - Pitkin, Sigrid
IR  - Metcalfe J
FIR - Metcalfe, Jessica
IR  - Fahy-Scheer S
FIR - Fahy-Scheer, Susan
IR  - Meera T
FIR - Meera, Thalayasingam
IR  - King J
FIR - King, Jovanka
IR  - Abass F
FIR - Abass, Fuad
IR  - Cheung A
FIR - Cheung, Abigail
IR  - Wallace R
FIR - Wallace, Rachel
IR  - Baldwin S
FIR - Baldwin, Samara
EDAT- 2020/09/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035871 [pii]
AID - 10.1136/bmjopen-2019-035871 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e035871. doi: 10.1136/bmjopen-2019-035871.


PMID- 32912939
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - HEROIC: a 5-year observational cohort study aimed at identifying novel factors
      that drive diabetic kidney disease: rationale and study protocol.
PG  - e033923
LID - 10.1136/bmjopen-2019-033923 [doi]
AB  - INTRODUCTION: Diabetic kidney disease (DKD) is the leading cause of end-stage
      kidney disease worldwide and a major cause of premature mortality in diabetes
      mellitus (DM). While improvements in care have reduced the incidence of kidney
      disease among those with DM, the increasing prevalence of DM means that the
      number of patients worldwide with DKD is increasing. Improved understanding of
      the biology of DKD and identification of novel therapeutic targets may lead to
      new treatments. A major challenge to progress has been the heterogeneity of the
      DKD phenotype and renal progression. To investigate the heterogeneity of DKD we
      have set up The East and North London Diabetes Cohort (HEROIC) Study, a secondary
      care-based, multiethnic observational study of patients with biopsy-proven DKD.
      Our primary objective is to identify histological features of DKD associated with
      kidney endpoints in a cohort of patients diagnosed with type 1 and type 2 DM,
      proteinuria and kidney impairment. METHODS AND ANALYSIS: HEROIC is a longitudinal
      observational study that aims to recruit 500 patients with DKD at high-risk of
      renal and cardiovascular events. Demographic, clinical and laboratory data will
      be collected and assessed annually for 5 years. Renal biopsy tissue will be
      collected and archived at recruitment. Blood and urine samples will be collected 
      at baseline and during annual follow-up visits. Measured glomerular filtration
      rate (GFR), echocardiography, retinal optical coherence tomography angiography
      and kidney and cardiac MRI will be performed at baseline and twice more during
      follow-up. The study is 90% powered to detect an association between key
      histological and imaging parameters and a composite of death, renal replacement
      therapy or a 30% decline in estimated GFR. ETHICS AND DISSEMINATION: Ethical
      approval has been obtained from the Bloomsbury Research Ethics Committee (REC
      18-LO-1921). Any patient identifiable data will be stored on a password-protected
      National Health Services N3 network with full audit trail. Anonymised imaging
      data will be stored in a ISO27001-certificated data warehouse.Results will be
      reported through peer-reviewed manuscripts and conferences and disseminated to
      participants, patients and the public using web-based and social media engagement
      tools as well as through public events.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mccafferty, Kieran
AU  - Mccafferty K
AUID- ORCID: 0000-0002-0762-2270
AD  - Department of Nephrology, Barts Health NHS Trust, London, UK.
FAU - Caplin, Ben
AU  - Caplin B
AUID- ORCID: 0000-0001-9544-164X
AD  - Centre for Nephrology, University College London Medical School, London, UK.
FAU - Knight, Sinead
AU  - Knight S
AD  - Department of Discovery Biology, Discovery Sciences, R&D, AstraZeneca UK Ltd,
      Cambridge, Cambridgeshire, UK.
FAU - Hockings, Paul
AU  - Hockings P
AD  - Antaros Medical, Gothenburg, Sweden.
AD  - MedTech West, Chalmers University of Technology, Goteborg, Sweden.
FAU - Wheeler, David
AU  - Wheeler D
AD  - Centre for Nephrology, University College London Medical School, London, UK.
FAU - Fan, Stanley L
AU  - Fan SL
AD  - Department of Nephrology, Barts Health NHS Trust, London, UK.
FAU - Hulthe, Johannes
AU  - Hulthe J
AD  - Antaros Medical, Gothenburg, Sweden.
FAU - Kleta, Robert
AU  - Kleta R
AD  - Divison of Medicine, University College London, London, UK.
FAU - Ashman, Neil
AU  - Ashman N
AD  - Department of Nephrology, Barts Health NHS Trust, London, UK.
FAU - Papastefanou, Vasilios
AU  - Papastefanou V
AD  - Barts Health NHS Trust, London, UK.
FAU - Mehta, Hemal
AU  - Mehta H
AD  - Royal Free Hampstead NHS Trust, London, London, UK.
FAU - Salama, Alan
AU  - Salama A
AD  - Divison of Medicine, University College London, London, UK.
FAU - Hadzovic, Sinela
AU  - Hadzovic S
AD  - Department of BioPharma Early Biometrics and Statistical Innovation, AstraZeneca,
      Goteborg, Sweden.
FAU - Chowdhury, Tahseen Ahmad
AU  - Chowdhury TA
AD  - Department of Diabetes and Metabolism, Barts Health NHS Trust, London, UK.
FAU - Jarl, Lisa
AU  - Jarl L
AD  - Antaros Medical, Gothenburg, Sweden.
FAU - Unwin, Robert
AU  - Unwin R
AD  - Department of Early Clinical Development, Cardiovascular, Renal and Metabolism,
      BioPharmaceuticals R&D, AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK.
FAU - Challis, Benjamin
AU  - Challis B
AD  - Department of Translational Science & Experimental Medicine, Research and Early
      Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D,
      AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK.
FAU - Sundgren, Anna K
AU  - Sundgren AK
AD  - Department of Late-Stage Development, Cardiovascular, Renal and Metabolism,
      BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
AD  - Data Science & AI | BioPharma Early Biometrics and Statistical Innovation,
      AstraZeneca, Gothenburg, Sweden.
FAU - Yaqoob, Muhammad Magdi
AU  - Yaqoob MM
AD  - Department of Nephrology, Barts Health NHS Trust, London, UK
      m.m.yaqoob@qmul.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 1
MH  - Diabetes Mellitus, Type 2/complications/epidemiology
MH  - *Diabetic Nephropathies/epidemiology
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - London/epidemiology
PMC - PMC7482453
OTO - NOTNLM
OT  - *cohort study
OT  - *diabetic Kidney disease
OT  - *histopathology
OT  - *magnetic resonance imaging
COIS- Competing interests: BCh, RU, SK, SH and AKS are employees of AstraZeneca, and
      authors PH and JH are employees of Antaros Medical.
EDAT- 2020/09/12 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/11 05:39
PHST- 2020/09/11 05:39 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-033923 [pii]
AID - 10.1136/bmjopen-2019-033923 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e033923. doi: 10.1136/bmjopen-2019-033923.


PMID- 32912826
OWN - NLM
STAT- Publisher
LR  - 20201229
IS  - 1873-4758 (Electronic)
IS  - 0955-3959 (Linking)
DP  - 2020 Sep 8
TI  - Towards an ontological politics of drug policy: Intervening through policy,
      evidence and method.
PG  - 102932
LID - S0955-3959(20)30271-1 [pii]
LID - 10.1016/j.drugpo.2020.102932 [doi]
AB  - Increasing attention has been paid to matters of ontology, and its accompanying
      politics, in the drug policy field. In this commentary, we consider what an
      'ontological politics' might mean for how we think about what drug policy is and 
      what it might become, as well as for how we think about (and do) research in drug
      policy. Thinking ontopolitically questions the tacitly accepted status of 'drug
      problems', calls into question the realist presumptions which underpin much drug 
      policy analysis, and provokes thinking about what counts as 'evidence' and the
      'evidence-based policy' paradigm itself. We call attention to the inventive
      possibilities of method when grappling with the challenges thrown forth by the
      ontological turn, with a renewed focus on practice and relations. An ontological 
      politics disrupts consensual claims and draws critical attention to objects that 
      might otherwise appear 'finished' or 'ready-made', not least the things we call
      'drugs' and 'drug policy'. Working with 'drug policy multiples' invites new
      thinking and dialogue to provoke an ethico-political mode of intervention in the 
      field of drug policy and drugs research.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Lancaster, Kari
AU  - Lancaster K
AD  - University of New South Wales, Sydney, Australia. Electronic address:
      k.lancaster@unsw.edu.au.
FAU - Rhodes, Tim
AU  - Rhodes T
AD  - University of New South Wales, Sydney, Australia; London School of Hygiene and
      Tropical Medicine, UK.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Netherlands
TA  - Int J Drug Policy
JT  - The International journal on drug policy
JID - 9014759
SB  - IM
OTO - NOTNLM
OT  - Annemarie Mol
OT  - Carol Bacchi
OT  - Evidence
OT  - John Law
OT  - Method
OT  - Ontological politics
OT  - Performativity
COIS- Declarations of Interests The authors report no conflicts of interest in relation
      to this work.
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/09/11 05:38
PHST- 2020/03/18 00:00 [received]
PHST- 2020/08/30 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/09/11 05:38 [entrez]
AID - S0955-3959(20)30271-1 [pii]
AID - 10.1016/j.drugpo.2020.102932 [doi]
PST - aheadofprint
SO  - Int J Drug Policy. 2020 Sep 8:102932. doi: 10.1016/j.drugpo.2020.102932.


PMID- 32912305
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 10
TI  - A mobile app using therapeutic exercise and education for self-management in
      patients with hand rheumatoid arthritis: a randomized controlled trial protocol.
PG  - 777
LID - 10.1186/s13063-020-04713-4 [doi]
AB  - BACKGROUND: Therapeutic exercise is a safe and cost-effective approach to
      alleviate hand rheumatoid arthritis (RA)-related symptoms. This study aims to
      investigate the differences in self-management between a smartphone app
      (CareHand), using hand exercises and educational advices, compared with a
      standard approach, on hand overall function, pain intensity, stiffness, and grip 
      and pinch strength in patients with hand RA. METHODS: The project is a
      prospective, longitudinal, superiority, randomized controlled trial. Fifty-eight 
      participants with hand RA will be randomly assigned into an experimental group
      (CareHand app) or a control group (conventional treatment). Control intervention 
      involves a paper sheet with exercises and recommendations, and the experimental
      group includes the use of a smartphone app, which provides individualized
      exercise programs, self-management, and educational strategies to promote
      adherence to treatment. Both intervention protocols will last for 3 months. The
      principal investigator will conduct an educational session at baseline for all
      participants. Primary outcome comprises the overall hand function, assessed with 
      the Michigan Hand Outcome Questionnaire (MHQ). Secondary outcomes include
      self-reported functional ability with the Quick DASH questionnaire, self-reported
      pain intensity and morning stiffness using a Visual Analogue Scale (VAS), and
      hand grip and pinch strength (dynamometer). Outcome measures will be collected at
      baseline, and at 1 month and 3-month follow-up. DISCUSSION: This study will
      evaluate the effectiveness of a tele-rehabilitation tool, which uses exercise and
      self-management strategies, compared to a conventional approach, in patients with
      hand RA. The smartphone app will allow to monitor the patient's status and to
      enhance patient-therapist communication. Some limitations may be related to the
      short follow-up duration and the lack of evaluation of psychosocial factors.
      Overall, this new way of promoting long-term effects in patients with a chronic
      rheumatic disease could be feasible and easy to implement in daily life clinical 
      practice and current musculoskeletal care. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT04263974 . Registered on 7 March 2020. Date of last update 15 April 2020.
      Ethics committee code: PI_RH_2018.
FAU - Rodriguez-Sanchez-Laulhe, Pablo
AU  - Rodriguez-Sanchez-Laulhe P
AD  - Andalusian Public Foundation for the Management of Health Research of Seville
      FISEVI, Seville, Spain.
FAU - Luque-Romero, Luis Gabriel
AU  - Luque-Romero LG
AUID- ORCID: http://orcid.org/0000-0002-7818-2380
AD  - Research Unit, Distrito Sanitario Aljarafe-Sevilla Norte, Servicio Andaluz de
      Salud, Seville, Spain. luqueluis2@gmail.com.
AD  - Normal and Pathological Cytology and Histology Department, University of Seville,
      Seville, Spain. luqueluis2@gmail.com.
FAU - Blanquero, Jesus
AU  - Blanquero J
AD  - Physiotherapy Department, Faculty of Nursing, Physiotherapy and Podiatry,
      University of Seville, Seville, Spain.
FAU - Suero-Pineda, Alejandro
AU  - Suero-Pineda A
AD  - Physiotherapy Department, Faculty of Nursing, Physiotherapy and Podiatry,
      University of Seville, Seville, Spain.
FAU - Biscarri-Carbonero, Angela
AU  - Biscarri-Carbonero A
AD  - Research Unit, Distrito Sanitario Aljarafe-Sevilla Norte, Servicio Andaluz de
      Salud, Seville, Spain.
FAU - Barrero-Garcia, Francisco Jose
AU  - Barrero-Garcia FJ
AD  - Research Unit, Distrito Sanitario Aljarafe-Sevilla Norte, Servicio Andaluz de
      Salud, Seville, Spain.
FAU - Heredia-Rizo, Alberto Marcos
AU  - Heredia-Rizo AM
AD  - Physiotherapy Department, Faculty of Nursing, Physiotherapy and Podiatry,
      University of Seville, Seville, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04263974
GR  - AP-0149-2017/Fundacion Publica Andaluza para la Gestion de la Investigacion en
      Salud de Sevilla
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200910
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Arthritis, Rheumatoid/diagnosis/therapy
MH  - Hand Strength
MH  - Humans
MH  - Michigan
MH  - *Mobile Applications
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Management
MH  - Treatment Outcome
PMC - PMC7488084
OTO - NOTNLM
OT  - E-health
OT  - Education
OT  - Exercise therapy
OT  - Mobile applications
OT  - Protocol
OT  - Randomized controlled trial
OT  - Rheumatoid arthritis
OT  - Self-management
OT  - Tele-rehabilitation
EDAT- 2020/09/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/11 05:32
PHST- 2020/05/10 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/11 05:32 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04713-4 [doi]
AID - 10.1186/s13063-020-04713-4 [pii]
PST - epublish
SO  - Trials. 2020 Sep 10;21(1):777. doi: 10.1186/s13063-020-04713-4.


PMID- 32912299
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1475-2891 (Electronic)
IS  - 1475-2891 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Sep 10
TI  - A scoping review of policies promoting and supporting sustainable food systems in
      the university setting.
PG  - 97
LID - 10.1186/s12937-020-00617-w [doi]
AB  - BACKGROUND: Transitioning towards sustainable food systems for the health of the 
      population and planet will require governments and institutions to develop
      effective governance to support the adoption of sustainable food practices. The
      aim of the paper is to describe current governance within Australian and New
      Zealand universities designed to support sustainable food systems. METHODS: A
      systematic search of governance documents to support sustainable food systems
      within Australian and New Zealand universities was conducted. Data were obtained 
      from 1) targeted websites 2) internet search engines and 3) expert consultations.
      Inclusion criteria consisted of university governance documents including
      by-laws, policies, guidelines, frameworks, and procedures that support
      sustainable food systems. RESULTS: Twenty-nine governance documents across
      nineteen Australian and New Zealand universities were included for synthesis,
      including waste management policies (n = 3), fair-trade/procurement policies (n =
      6), catering and or event guidelines (n = 7) and catering policies (n = 2), and
      environmental management plans (n = 11). The main strategies adopted by
      universities were sustainable waste management and prevention (e.g. reducing
      landfill, reducing wasted food, (27%)), ethical procurement practices (i.e.
      fair-trade (27%)) and environmentally sustainable food consumption (e.g. local,
      seasonal, organic, vegetarian food supply (14.5%)). Only 12.5% of universities
      addressed all three of the main strategies identified. CONCLUSIONS: This study
      indicates that while sustainable food systems are considered in some university
      governance documents, efforts are predominantly focused on aspects such as waste 
      management or procurement of fair-trade items which as stand-alone practices are 
      likely to have minimal impact. This review highlights the scope of universities
      to provide strong leadership in promoting and supporting sustainable food systems
      through holistic institutional policies and governance mechanisms.
FAU - Grech, Amanda
AU  - Grech A
AUID- ORCID: 0000-0002-1734-9212
AD  - School of Life and Environmental Sciences, Faculty of Science, The University of 
      Sydney, Sydney, NSW, Australia. agre3682@uni.sydney.edu.au.
AD  - Charles Perkins Centre, The University of Sydney, John Hopkins Drive, Camperdown,
      NSW, 2006, Australia. agre3682@uni.sydney.edu.au.
FAU - Howse, Eloise
AU  - Howse E
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, NSW, Australia.
FAU - Boylan, Sinead
AU  - Boylan S
AD  - School of Life and Environmental Sciences, Faculty of Science, The University of 
      Sydney, Sydney, NSW, Australia.
AD  - Charles Perkins Centre, The University of Sydney, John Hopkins Drive, Camperdown,
      NSW, 2006, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200910
PL  - England
TA  - Nutr J
JT  - Nutrition journal
JID - 101152213
SB  - IM
MH  - Australia
MH  - Food
MH  - Food Supply
MH  - Humans
MH  - *Policy
MH  - *Universities
PMC - PMC7488481
OTO - NOTNLM
OT  - *Environmental policy
OT  - *Fair-trade
OT  - *Food supply
OT  - *Food systems
OT  - *Food waste, university
OT  - *Institutional policy
OT  - *Sustainability
EDAT- 2020/09/12 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/09/11 05:32
PHST- 2020/07/02 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/11 05:32 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.1186/s12937-020-00617-w [doi]
AID - 10.1186/s12937-020-00617-w [pii]
PST - epublish
SO  - Nutr J. 2020 Sep 10;19(1):97. doi: 10.1186/s12937-020-00617-w.


PMID- 32912292
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 10
TI  - Computerised tomography-based planning with conventional total hip arthroplasty
      versus robotic-arm assisted total hip arthroplasty: study protocol for a
      prospective randomised controlled trial.
PG  - 776
LID - 10.1186/s13063-020-04702-7 [doi]
AB  - BACKGROUND: Robotic-arm assisted surgery aims to reduce manual errors and improve
      the accuracy of implant positioning during total hip arthroplasty. The objective 
      of this study is to compare the accuracy of implant positioning, restoration of
      hip biomechanics, patient satisfaction, functional outcomes, implant
      survivorship, cost-effectiveness, and complications in conventional manual total 
      hip arthroplasty (CO THA) versus robotic-arm assisted total hip arthroplasty (RO 
      THA). Preoperative pelvic computerised tomography (CT) scans will be used to
      create patient-specific, virtual, three-dimensional reconstructions for surgical 
      planning in both treatment groups. METHODS AND ANALYSIS: This prospective
      randomised controlled trial will include 60 patients with symptomatic hip
      osteoarthritis undergoing primary THA. Following informed consent, patients will 
      be randomised to CO THA (control group) or RO THA (investigation group) at a
      ratio of 1:1 using an online random number generator. Observers will review
      patients at regular intervals for 2 years after surgery to record predefined
      study outcomes relating to the accuracy of implant positioning, hip biomechanics,
      postoperative rehabilitation, clinical progress, functional outcomes,
      cost-effectiveness, and complications. Primary and secondary objectives will be
      used to quantify and draw inferences on differences in the efficacy of treatment 
      between the two groups. Intention-to-treat and per-protocol population analysis
      will be undertaken. Intention to treat relates to the allocated treatment (CO THA
      or RO THA), and per-protocol refers to the actual treatment received by the
      patient. The following statistical methods will be employed to analyse the data: 
      descriptive statistics, independent t test, paired t test, analysis of variance, 
      Fisher exact test, chi-square test, and graphical displays. Ethical approval was 
      obtained from the London-Bromley Research Ethics Committee, UK. The study is
      sponsored by University College London, UK. DISCUSSION: This study compares a
      comprehensive and robust range of clinical, functional, and radiological outcomes
      in CT-planned CO THA versus CT-planned RO THA. The findings of this study will
      enable an improved understanding of the differences in CO THA versus RO THA with 
      respect to patient satisfaction, functional outcomes, implant survivorship,
      cost-effectiveness, and complications. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT04095845 . Registered on 19 September 2019.
FAU - Kayani, Babar
AU  - Kayani B
AUID- ORCID: http://orcid.org/0000-0001-6611-3989
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK. babar.kayani@gmail.com.
FAU - Konan, Sujith
AU  - Konan S
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Tahmassebi, Jenni
AU  - Tahmassebi J
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Ayuob, Atif
AU  - Ayuob A
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Haddad, Fares S
AU  - Haddad FS
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04095845
GR  - 241382/Stryker
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200910
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Arthroplasty, Replacement, Hip/adverse effects
MH  - Humans
MH  - London
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Robotic Surgical Procedures/adverse effects
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
PMC - PMC7488173
EDAT- 2020/09/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/11 05:32
PHST- 2020/04/22 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/11 05:32 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04702-7 [doi]
AID - 10.1186/s13063-020-04702-7 [pii]
PST - epublish
SO  - Trials. 2020 Sep 10;21(1):776. doi: 10.1186/s13063-020-04702-7.


PMID- 32912247
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220716
IS  - 1478-4505 (Electronic)
IS  - 1478-4505 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Sep 11
TI  - What should community organisations consider when deciding to partner with
      researchers? A critical reflection on the Zilla Budakattu Girijana Abhivrudhhi
      Sangha experience in Karnataka, India.
PG  - 101
LID - 10.1186/s12961-020-00617-6 [doi]
AB  - BACKGROUND: Community organisations and community members are increasingly being 
      involved in health research projects worldwide as part of the engagement
      movement. Achieving deeper forms of community engagement like partnership demands
      that decision-making power be shared with community partners. However, how can
      community partners assess if meaningful engagement and shared decision-making
      will be possible when approached by prospective research partners? In this paper,
      we explore how community organisations decide to join health research projects
      when approached by health researchers. METHODS: Case study research was
      undertaken on a health systems research project in Karnataka, India called
      Participation for Local Action, which was carried out by local researchers in
      partnership with the Zilla Budakattu Girijana Abhivrudhhi Sangha, a community
      development organisation. In-depth interviews were conducted with the
      researchers, Sangha leaders and field investigators from their community.
      RESULTS: Thematic analysis identified two main themes - 'context' and 'deciding
      to engage'. The Sangha's experience offers lessons to other community
      organisations that can help them when deciding to engage with researchers in
      terms of what features to look for in research partners and in proposed research 
      projects, what requests to make of prospective research partners, and what sorts 
      of outcomes or partnership agreements to accept. These lessons may be especially 
      applicable in contexts where relationships of trust already exist between
      partners and where they have the skills to lead data collection and analysis.
      CONCLUSIONS: We hope that this guidance will help empower community organisations
      to select good research partners and promote more equitable partnerships between 
      community partners and academic researchers.
FAU - Pratt, Bridget
AU  - Pratt B
AD  - Centre for Health Equity, School of Population and Global Health, University of
      Melbourne, 207 Bouverie St., Carlton, Victoria, 3053, Australia.
      bridget.pratt@unimelb.edu.au.
FAU - Seshadri, Tanya
AU  - Seshadri T
AD  - Institute of Public Health, 3009, II-A Main, 17th Cross, Krishna Rajendra Rd,
      Banashankari Stage II, Bangalore, Karnataka, 560070, India.
AD  - Vivekananda Girijana Kalyana Kendra, BR hills, Chamarajanagar district,
      Karnataka, 571441, India.
FAU - Srinivas, Prashanth N
AU  - Srinivas PN
AD  - Institute of Public Health, 3009, II-A Main, 17th Cross, Krishna Rajendra Rd,
      Banashankari Stage II, Bangalore, Karnataka, 560070, India.
LA  - eng
GR  - IA/CPHI/16/1/502648/WTDBT_/DBT-Wellcome Trust India Alliance/India
GR  - DE170100414/Australian Research Council
GR  - IA/CPHI/16/1/502648/The Wellcome Trust DBT India Alliance
PT  - Journal Article
DEP - 20200911
PL  - England
TA  - Health Res Policy Syst
JT  - Health research policy and systems
JID - 101170481
SB  - IM
MH  - *Community-Based Participatory Research
MH  - *Cooperative Behavior
MH  - Humans
MH  - India
MH  - Prospective Studies
MH  - Research Personnel
PMC - PMC7488535
OTO - NOTNLM
OT  - collaboration
OT  - community organisation
OT  - engagement
OT  - ethics
OT  - health research
OT  - health systems research
OT  - partnership
OT  - power
EDAT- 2020/09/12 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/11 05:31
PHST- 2020/05/22 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/09/11 05:31 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12961-020-00617-6 [doi]
AID - 10.1186/s12961-020-00617-6 [pii]
PST - epublish
SO  - Health Res Policy Syst. 2020 Sep 11;18(1):101. doi: 10.1186/s12961-020-00617-6.


PMID- 32912214
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1477-3155 (Electronic)
IS  - 1477-3155 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Sep 10
TI  - Multiparametric investigation of non functionalized-AGuIX nanoparticles in 3D
      human airway epithelium models demonstrates preferential targeting of tumor
      cells.
PG  - 129
LID - 10.1186/s12951-020-00683-6 [doi]
AB  - Liquid deposit mimicking surface aerosolization in the airway is a promising
      strategy for targeting bronchopulmonary tumors with reduced doses of nanoparticle
      (NPs). In mimicking and studying such delivery approaches, the use of human in
      vitro 3D culture models can bridge the gap between 2D cell culture and small
      animal investigations. Here, we exposed airway epithelia to liquid-apical
      gadolinium-based AGuIX((R)) NPs in order to determine their safety profile. We
      used a multiparametric methodology to investigate the NP's distribution over time
      in both healthy and tumor-bearing 3D models. AGuIX((R)) NPs were able to target
      tumor cells in the absence of specific surface functionalization, without
      evidence of toxicity. Finally, we validated the therapeutic potential of this
      hybrid theranostic AGuIX((R)) NPs upon radiation exposure in this model. In
      conclusion, 3D cell cultures can efficiently mimic the normal and tumor-bearing
      airway epitheliums, providing an ethical and accessible model for the
      investigation of nebulized NPs.
FAU - Sancey, Lucie
AU  - Sancey L
AUID- ORCID: http://orcid.org/0000-0002-0084-3775
AD  - Institute for Advanced Biosciences, INSERM U1209, CNRS, UMR 5309, Universite
      Grenoble Alpes, 38000, Grenoble, France. lucie.sancey@univ-grenoble-alpes.fr.
FAU - Sabido, Odile
AU  - Sabido O
AD  - INSERM U1059, Laboratoire SAINBIOSE, equipe DVH/PIB, Faculte de Medecine,
      Universite Jean Monnet, Saint-Etienne, France.
AD  - Universite de Lyon, Saint-Etienne, France.
FAU - He, Zhiguo
AU  - He Z
AD  - Universite de Lyon, Saint-Etienne, France.
AD  - , BiiGC EA2521, Saint-Etienne, France.
FAU - Rossetti, Fabien
AU  - Rossetti F
AD  - Institut Lumiere Matiere, CNRS UMR5306, Universite Lyon 1, 69100, Villeurbanne,
      France.
FAU - Guignandon, Alain
AU  - Guignandon A
AD  - Universite de Lyon, Saint-Etienne, France.
AD  - SAINBIOSE, Inserm U1059, LBTO Team, Saint-Etienne, France.
FAU - Bin, Valerie
AU  - Bin V
AD  - INSERM U1059, Laboratoire SAINBIOSE, equipe DVH/PIB, Faculte de Medecine,
      Universite Jean Monnet, Saint-Etienne, France.
AD  - Universite de Lyon, Saint-Etienne, France.
FAU - Coll, Jean-Luc
AU  - Coll JL
AD  - Institute for Advanced Biosciences, INSERM U1209, CNRS, UMR 5309, Universite
      Grenoble Alpes, 38000, Grenoble, France.
FAU - Cottier, Michele
AU  - Cottier M
AD  - INSERM U1059, Laboratoire SAINBIOSE, equipe DVH/PIB, Faculte de Medecine,
      Universite Jean Monnet, Saint-Etienne, France.
AD  - Universite de Lyon, Saint-Etienne, France.
AD  - CHU Saint Etienne, Hopital Nord, UF6725 Cytologie et Histologie Renale,
      St-Etienne, France.
FAU - Lux, Francois
AU  - Lux F
AD  - Institut Lumiere Matiere, CNRS UMR5306, Universite Lyon 1, 69100, Villeurbanne,
      France.
AD  - NH Theraguix, 38240, Meylan, France.
AD  - Institut Universitaire de France (IUF), Paris, France.
FAU - Tillement, Olivier
AU  - Tillement O
AD  - Institut Lumiere Matiere, CNRS UMR5306, Universite Lyon 1, 69100, Villeurbanne,
      France.
AD  - NH Theraguix, 38240, Meylan, France.
FAU - Constant, Samuel
AU  - Constant S
AD  - Epithelix SARL, Geneva, Switzerland.
AD  - OncoTheis SARL, Geneva, Switzerland.
FAU - Mas, Christophe
AU  - Mas C
AD  - OncoTheis SARL, Geneva, Switzerland.
FAU - Boudard, Delphine
AU  - Boudard D
AD  - INSERM U1059, Laboratoire SAINBIOSE, equipe DVH/PIB, Faculte de Medecine,
      Universite Jean Monnet, Saint-Etienne, France.
      delphine.boudard@univ-st-etienne.fr.
AD  - Universite de Lyon, Saint-Etienne, France. delphine.boudard@univ-st-etienne.fr.
AD  - CHU Saint Etienne, Hopital Nord, UF6725 Cytologie et Histologie Renale,
      St-Etienne, France. delphine.boudard@univ-st-etienne.fr.
LA  - eng
GR  - ANR-12-RPIB-0010/Agence Nationale de la Recherche
PT  - Journal Article
DEP - 20200910
PL  - England
TA  - J Nanobiotechnology
JT  - Journal of nanobiotechnology
JID - 101152208
RN  - 0 (AGuIX)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - A549 Cells/pathology
MH  - Animals
MH  - Cell Culture Techniques
MH  - Cell Cycle
MH  - Cell Proliferation
MH  - Drug Delivery Systems/methods
MH  - Epithelium/*drug effects
MH  - Gadolinium/chemistry/*therapeutic use
MH  - Humans
MH  - Lung
MH  - Lung Neoplasms/drug therapy
MH  - Nanoparticles/chemistry/*therapeutic use
MH  - Respiratory System/*drug effects
PMC - PMC7488087
OTO - NOTNLM
OT  - 3D human healthy and tumor airway models
OT  - AGuIX(R) nanoparticles
OT  - Nanoparticle's toxicity
OT  - Nanoparticle's uptake
OT  - Tumor targeting
EDAT- 2020/09/12 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/09/11 05:31
PHST- 2020/05/11 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/11 05:31 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
AID - 10.1186/s12951-020-00683-6 [doi]
AID - 10.1186/s12951-020-00683-6 [pii]
PST - epublish
SO  - J Nanobiotechnology. 2020 Sep 10;18(1):129. doi: 10.1186/s12951-020-00683-6.


PMID- 32912206
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 11
TI  - Human germline editing in the era of CRISPR-Cas: risk and uncertainty,
      inter-generational responsibility, therapeutic legitimacy.
PG  - 87
LID - 10.1186/s12910-020-00487-1 [doi]
AB  - BACKGROUND: Clustered Regularly Interspaced Short Palindromic Repeats-associated 
      (CRISPR-Cas) technology may allow for efficient and highly targeted gene editing 
      in single-cell embryos. This possibility brings human germline editing into the
      focus of ethical and legal debates again. MAIN BODY: Against this background, we 
      explore essential ethical and legal questions of interventions into the human
      germline by means of CRISPR-Cas: How should issues of risk and uncertainty be
      handled? What responsibilities arise regarding future generations? Under which
      conditions can germline editing measures be therapeutically legitimized? For this
      purpose, we refer to a scenario anticipating potential further development in
      CRISPR-Cas technology implying improved accuracy and exclusion of germline
      transmission to future generations. We show that, if certain concepts regarding
      germline editing are clarified, under such conditions a categorical prohibition
      of one-generation germline editing of single-cell embryos appears not to be
      ethically or legally justifiable. CONCLUSION: These findings are important
      prerequisites for the international debate on the ethical and legal justification
      of germline interventions in the human embryo as well as for the harmonization of
      international legal standards.
FAU - Schleidgen, Sebastian
AU  - Schleidgen S
AUID- ORCID: 0000-0002-7564-8675
AD  - Faculty of Humanities and Social Sciences, Institute of Philosophy,
      FernUniversitat in Hagen, Universitatsstrasse 33, 58097, Hagen, Germany.
FAU - Dederer, Hans-Georg
AU  - Dederer HG
AD  - Faculty of Law, University of Passau, Innstrasse 39, 94032, Passau, Germany.
FAU - Sgodda, Susan
AU  - Sgodda S
AD  - Translational Hepatology and Stem Cell Biology, REBIRTH Center for Translational 
      Regenerative Medicine, Department of Gastroenterology, Hepatology, and
      Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover,
      Germany.
FAU - Cravcisin, Stefan
AU  - Cravcisin S
AD  - Faculty of Law, University of Passau, Innstrasse 39, 94032, Passau, Germany.
FAU - Luneburg, Luca
AU  - Luneburg L
AD  - Faculty of Law, University of Passau, Innstrasse 39, 94032, Passau, Germany.
FAU - Cantz, Tobias
AU  - Cantz T
AUID- ORCID: 0000-0002-1382-9577
AD  - Translational Hepatology and Stem Cell Biology, REBIRTH Center for Translational 
      Regenerative Medicine, Department of Gastroenterology, Hepatology, and
      Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hanover,
      Germany.
FAU - Heinemann, Thomas
AU  - Heinemann T
AUID- ORCID: 0000-0002-8316-7054
AD  - Faculty of Nursing Science, University of Philosophy and Theology Vallendar,
      Pallottistrasse 3, 56179, Vallendar, Germany. theinemann@pthv.de.
LA  - eng
GR  - 01GP1616A-C/Bundesministerium fur Bildung und Forschung/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200911
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *CRISPR-Cas Systems/genetics
MH  - *Clustered Regularly Interspaced Short Palindromic Repeats/genetics
MH  - Gene Editing
MH  - Germ Cells
MH  - Humans
MH  - Uncertainty
PMC - PMC7488432
OTO - NOTNLM
OT  - *Germline therapy
OT  - *Human embryos
OT  - *Responsibility for future generations
OT  - *Risks
OT  - *Therapeutic legitimization
EDAT- 2020/09/12 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/11 05:31
PHST- 2020/02/13 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/09/11 05:31 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00487-1 [doi]
AID - 10.1186/s12910-020-00487-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 11;21(1):87. doi: 10.1186/s12910-020-00487-1.


PMID- 32912075
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 2164-6708 (Electronic)
IS  - 1526-9248 (Linking)
VI  - 30
IP  - 4
DP  - 2020 Dec
TI  - The Development and Validation of the Islamic Knowledge of Living Organ Donation 
      Knowledge Scale for Measuring Organ Donation Knowledge Among Muslim Communities.
PG  - 315-321
LID - 10.1177/1526924820958119 [doi]
AB  - INTRODUCTION: Studies around the world demonstrate that Muslim attitudes toward
      organ donation are closely tied to religion, but also that Muslim publics suffer 
      from a lack of detailed knowledge about the Islamic perspectives on organ
      donation. Consequently, organ donation professionals and stakeholders are
      increasingly addressing knowledge gaps in the Muslim community through
      educational interventions. Yet, a measurement of Islamic knowledge of organ
      donation, and thereby the efficacy of such education, is not available. RESEARCH 
      QUESTION: To present the development and psychometric evaluation of the Islamic
      Knowledge of Living Organ Donation scale, designed to measure knowledge of the
      Islamic ethicolegal stances, and their underlying rationale, regarding living
      organ donation. METHODS: Items were developed based on a review of Islamic
      juridical perspectives on organ donation, addressed knowledge gaps pervading
      Muslim communities, and pilot tested. The scale was statistically validated and
      psychometrically analyzed with a sample of 158 mosque-going Muslims in the United
      States. RESULTS: The 9-item Islamic Knowledge of Living Organ Donation scale was 
      found to be reliable (Cronbach alpha: 0.86), unidimensional, independent of
      religiosity, and predictive of social attitudes toward organ donation.
      DISCUSSION: The survey can be used to validly assess Islamic knowledge of living 
      organ donation among Muslim communities in research, educational, and clinical
      settings.
FAU - Padela, Aasim I
AU  - Padela AI
AUID- ORCID: 0000-0003-4834-2889
AD  - Initiative on Islam and Medicine, 2462University of Chicago, Chicago, IL USA.
AD  - Department of Medicine, 2462University of Chicago, Chicago, IL USA.
FAU - Duivenbode, Rosie
AU  - Duivenbode R
AD  - Initiative on Islam and Medicine, 2462University of Chicago, Chicago, IL USA.
FAU - Quinn, Michael
AU  - Quinn M
AD  - Department of Medicine, 2462University of Chicago, Chicago, IL USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200910
PL  - United States
TA  - Prog Transplant
JT  - Progress in transplantation (Aliso Viejo, Calif.)
JID - 100909380
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Islam
MH  - Male
MH  - Middle Aged
MH  - Organ Transplantation/*psychology/*statistics & numerical data
MH  - Program Development
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires/*standards
MH  - Tissue Donors/*psychology/*statistics & numerical data
MH  - Tissue and Organ Procurement/*statistics & numerical data
MH  - United States
OTO - NOTNLM
OT  - *Islamic bioethics
OT  - *organ transplantation
OT  - *psychometrics
OT  - *religion
OT  - *scale development
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/09/11 05:30
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/09/11 05:30 [entrez]
AID - 10.1177/1526924820958119 [doi]
PST - ppublish
SO  - Prog Transplant. 2020 Dec;30(4):315-321. doi: 10.1177/1526924820958119. Epub 2020
      Sep 10.


PMID- 32911994
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1464-5033 (Electronic)
IS  - 0301-4460 (Linking)
VI  - 47
IP  - 7-8
DP  - 2020 Dec
TI  - Evaluation of the genomic diversity and shared ancestry of the Meitei community
      of Manipur (India) with the East Asian populations using autosomal STRs.
PG  - 642-651
LID - 10.1080/03014460.2020.1821772 [doi]
AB  - AIM: To study molecular diversity and genomic heritage of the Meitei community of
      Manipur using 20 autosomal gene loci markers. SUBJECTS AND METHODS: Blood samples
      were collected from 120 unrelated, healthy individuals of the Meitei population
      following ethical standards. DNA was extracted using the Phenol chloroform
      organic extraction method and amplified using the PowerPlex((R)) 21 system.
      Genetic profiles of the individuals were generated using the Genetic Analyser
      3500XL following the recommended protocol. RESULTS: The studied population showed
      Observed Heterozygosity (Hobs) from 0.583 (TH01) to 0.90 (D6S1043) among all the 
      studied loci. The discrimination power and exclusion power for all the studied
      loci were found to be 1 and 0.9999999988, respectively, with the maximum power of
      discrimination being found at Penta E locus. CONCLUSIONS: All the studied loci
      showed a high degree of matching probability and paternity index of 2.83 x
      10(-24) and 7.35 x 10(8), respectively; these are high-level statistical values
      and indicate that these loci might play a very important role in the application 
      of DNA reports in the courts of justice. The studied population showed a
      relatively closer genetic affinity with Newar, Kathmandu, and Han Chinese
      populations compared with the South and West Indian populations. The outcomes of 
      this study will enrich the STR database of the Indian population and this is the 
      first global report on genetic diversity in the Meitei community of Manipur,
      India, at 20 autosomal STR genetic markers.
FAU - Leishangthem, Surendrajit
AU  - Leishangthem S
AD  - Forensic Science Laboratory, Manipur, India.
FAU - Kushwaha, K P S
AU  - Kushwaha KPS
AD  - LNJN National Institute of Criminology and Forensic Science, Delhi, India.
FAU - Chauhan, Tanya
AU  - Chauhan T
AD  - LNJN National Institute of Criminology and Forensic Science, Delhi, India.
FAU - Kumawat, R K
AU  - Kumawat RK
AUID- ORCID: https://orcid.org/0000-0002-7794-9615
AD  - DNA Division, State Forensic Science Laboratory, Jaipur, India.
FAU - Chaubey, Gyaneshwer
AU  - Chaubey G
AD  - Department of Zoology, Cytogenetics Laboratory, Banaras Hindu University,
      Varanasi, India.
FAU - Shrivastava, Pankaj
AU  - Shrivastava P
AUID- ORCID: https://orcid.org/0000-0002-1647-2390
AD  - Department of Home (Police), Govt. of MP, DNA Fingerprinting Unit, State Forensic
      Science Laboratory, Sagar, India.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Hum Biol
JT  - Annals of human biology
JID - 0404024
SB  - IM
MH  - *Genetic Variation
MH  - Genome, Human
MH  - Humans
MH  - India
MH  - *Microsatellite Repeats
OTO - NOTNLM
OT  - Forensic
OT  - India
OT  - Manipur
OT  - Meitei
OT  - PowerPlex(R) 21
OT  - STR
OT  - autosomal
OT  - database
EDAT- 2020/09/12 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/09/11 05:29
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
PHST- 2020/09/11 05:29 [entrez]
AID - 10.1080/03014460.2020.1821772 [doi]
PST - ppublish
SO  - Ann Hum Biol. 2020 Dec;47(7-8):642-651. doi: 10.1080/03014460.2020.1821772.


PMID- 32911961
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1941-2479 (Electronic)
IS  - 1010-5395 (Linking)
VI  - 32
IP  - 8
DP  - 2020 Nov
TI  - COVID-19 and Ethics: A Latin American Perspective.
PG  - 505-506
LID - 10.1177/1010539520957814 [doi]
FAU - Sanchez Diaz, Ignacio
AU  - Sanchez Diaz I
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Lopez Barreda, Rodrigo
AU  - Lopez Barreda R
AUID- ORCID: https://orcid.org/0000-0003-3144-9954
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Valera, Luca
AU  - Valera L
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
LA  - eng
PT  - Journal Article
DEP - 20200910
PL  - China
TA  - Asia Pac J Public Health
JT  - Asia-Pacific journal of public health
JID - 8708538
SB  - IM
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 05:29
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
PHST- 2020/09/11 05:29 [entrez]
AID - 10.1177/1010539520957814 [doi]
PST - ppublish
SO  - Asia Pac J Public Health. 2020 Nov;32(8):505-506. doi: 10.1177/1010539520957814. 
      Epub 2020 Sep 10.


PMID- 32911944
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1211-9059 (Print)
IS  - 1211-9059 (Linking)
VI  - 75
IP  - 6
DP  - 2020 Winter
TI  - Innovative strategies for treating retinal diseases.
PG  - 287-295
LID - 10.31348/2019/6/1 [doi]
AB  - OBJECTIVE: The aim of this comprehensive paper is to acquaint the readers with
      innovative approaches in the treatment of retinal diseases, which could in the
      coming years to get into clinical practice. Retinal prostheses, retinal pigment
      epithelial (RPE) transplantation, gene therapy and optogenetics will be described
      in this paper. METHODOLOGY: Describing the basic characteristics and mechanisms
      of different types of therapy and subsequently literary minireview clarifying the
      current state of knowledge in the area. RESULTS: Retinal prostheses, RPE
      transplantation, gene therapy and optogenetics offer yet unexplored possibilities
      and are considered as the future of treatment of retinal diseases where classical
      pharmacotherapy or surgical treatment are no longer sufficient. However, all
      these methods challenge not only in the innovative technical implementation
      itself, but also for the ethical, administrative and economic demands.
      CONCLUSION: There will be certainly interesting development in the treatment of
      retinal diseases, but it is not possible to fully estimate which modality of
      treatment will be dominant in the future.
FAU - Stranak, Z
AU  - Stranak Z
FAU - Kousal, B
AU  - Kousal B
FAU - Ardan, T
AU  - Ardan T
FAU - Veith, M
AU  - Veith M
LA  - eng
PT  - Journal Article
TT  - Inovativni postupy v le&#269;b&#283; sitnicovych onemocn&#283;ni.
PL  - Czech Republic
TA  - Cesk Slov Oftalmol
JT  - Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a
      Slovenske oftalmologicke spolecnosti
JID - 9600515
SB  - IM
MH  - Genetic Therapy
MH  - Humans
MH  - *Retinal Diseases/therapy
MH  - *Retinal Pigment Epithelium
OTO - NOTNLM
OT  - gene therapy
OT  - induced pluripotent cells
OT  - optogenetics
OT  - retinal prostheses
EDAT- 2020/09/12 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/11 05:29
PHST- 2020/09/11 05:29 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 122573 [pii]
AID - 10.31348/2019/6/1 [doi]
PST - ppublish
SO  - Cesk Slov Oftalmol. 2020 Winter;75(6):287-295. doi: 10.31348/2019/6/1.


PMID- 32911810
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 18
DP  - 2020 Sep 8
TI  - Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic
      Factor Receptors for the Treatment of Neurodegeneration.
LID - E6575 [pii]
LID - 10.3390/ijms21186575 [doi]
AB  - Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) are able
      to promote the survival of multiple neuronal populations in the body and,
      therefore, hold considerable promise for disease-modifying treatments of diseases
      and conditions caused by neurodegeneration. Available data reveal the potential
      of GFLs for the therapy of Parkinson's disease, neuropathic pain and diseases
      caused by retinal degeneration but, also, amyotrophic lateral sclerosis and,
      possibly, Alzheimer's disease. Despite promising data collected in preclinical
      models, clinical translation of GFLs is yet to be conducted. The main reasons for
      the limited success of GFLs clinical development are the poor pharmacological
      characteristics of GFL proteins, such as the inability of GFLs to cross tissue
      barriers, poor diffusion in tissues, biphasic dose-response and activation of
      several receptors in the organism in different cell types, along with ethical
      limitations on patients' selection in clinical trials. The development of small
      molecules selectively targeting particular GFL receptors with improved
      pharmacokinetic properties can overcome many of the difficulties and limitations 
      associated with the clinical use of GFL proteins. The current review lists
      several strategies to target the GFL receptor complex with drug-like molecules,
      discusses their advantages, provides an overview of available chemical scaffolds 
      and peptides able to activate GFL receptors and describes the effects of these
      molecules in cultured cells and animal models.
FAU - Sidorova, Yulia A
AU  - Sidorova YA
AUID- ORCID: 0000-0001-8230-0530
AD  - Laboratory of Molecular Neuroscience, Institute of Biotechnology, HiLIFE,
      University of Helsinki, Viikinkaari 5D, FI-00014 Helsinki, Finland.
FAU - Saarma, Mart
AU  - Saarma M
AD  - Laboratory of Molecular Neuroscience, Institute of Biotechnology, HiLIFE,
      University of Helsinki, Viikinkaari 5D, FI-00014 Helsinki, Finland.
LA  - eng
GR  - 1325555/Academy of Finland
PT  - Journal Article
PT  - Review
DEP - 20200908
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (GDNF protein, human)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor Receptors)
RN  - 0 (Ligands)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Nerve Growth Factor)
RN  - 0 (Small Molecule Libraries)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Drug Delivery Systems/*methods
MH  - Glial Cell Line-Derived Neurotrophic Factor/metabolism
MH  - Glial Cell Line-Derived Neurotrophic Factor Receptors/*drug effects/metabolism
MH  - Humans
MH  - Ligands
MH  - Neuralgia/metabolism
MH  - Neurites/metabolism
MH  - Neurodegenerative Diseases/drug therapy
MH  - Neuroglia/drug effects/metabolism
MH  - Neurons/metabolism
MH  - Peptides/*pharmacology
MH  - Receptors, Nerve Growth Factor/drug effects/metabolism
MH  - Signal Transduction/drug effects
MH  - Small Molecule Libraries/pharmacology
PMC - PMC7554781
OTO - NOTNLM
OT  - GFL mimetic
OT  - Parkinson's disease
OT  - RET agonist
OT  - glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs),
      receptor tyrosine kinase Rearranged in Transfection (RET)
OT  - neurodegeneration
OT  - neuropathic pain
OT  - retinitis pigmentosa
OT  - small molecule
EDAT- 2020/09/12 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/09/11 01:01
PHST- 2020/07/31 00:00 [received]
PHST- 2020/08/31 00:00 [revised]
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/09/11 01:01 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - ijms21186575 [pii]
AID - 10.3390/ijms21186575 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Sep 8;21(18). pii: ijms21186575. doi: 10.3390/ijms21186575.


PMID- 32911732
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 18
DP  - 2020 Sep 8
TI  - A Systematic Review of the Health and Healthcare Inequalities for People with
      Intersex Variance.
LID - E6533 [pii]
LID - 10.3390/ijerph17186533 [doi]
AB  - Extensive research documents the health inequalities LGBTI people experience,
      however far less is known for people with intersex variation. This paper presents
      a review of intersex health and healthcare inequalities by evaluating research
      published from 2012 to 2019. In total 9181 citations were identified with 74
      records screened of which 16 were included. A synthesis of results spans nine
      quantitative, five qualitative and two narrative reviews. Literature was searched
      in Medline, Web of Science, Cochrane, PsychINFO and CINAHL. People with intersex 
      variance experience a higher incidence of anxiety, depression and psychological
      distress compared to the general population linked to stigma and discrimination. 
      Progressive healthcare treatment, including support to question normative
      binaries of sex and gender, aids understand of somatic intersex variance and
      non-binary gender identity, especially when invasive treatment options are
      avoided or delayed until individuals are able to self-identify or provide consent
      to treatment. Findings support rethinking sex and gender to reflect greater
      diversity within a more nuanced sex-gender spectrum, although gaps in research
      remain around the general health profile and the healthcare experiences of people
      with intersex variance. More large-scale research is needed, co-produced with
      peers who have lived experience of intersex variation to ensure policy, education
      and healthcare advances with greater inclusivity and ethical accountability.
FAU - Zeeman, Laetitia
AU  - Zeeman L
AD  - School of Health Sciences, University of Brighton, Brighton BN1 9PH, UK.
AD  - Centre for Transforming Sexuality and Gender, University of Brighton, Brighton
      BN2 0JG, UK.
FAU - Aranda, Kay
AU  - Aranda K
AD  - School of Health Sciences, University of Brighton, Brighton BN1 9PH, UK.
AD  - Centre for Transforming Sexuality and Gender, University of Brighton, Brighton
      BN2 0JG, UK.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200908
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Gender Identity
MH  - Health
MH  - *Healthcare Disparities
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - *Sexual and Gender Minorities
MH  - Young Adult
PMC - PMC7559554
OTO - NOTNLM
OT  - *LGBTI
OT  - *ethical accountability
OT  - *gender
OT  - *health inequalities
OT  - *healthcare
OT  - *intersex
OT  - *sex
COIS- The authors declare that there is no conflict of interest.
EDAT- 2020/09/12 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/09/11 01:01
PHST- 2020/07/21 00:00 [received]
PHST- 2020/08/14 00:00 [revised]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/11 01:01 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - ijerph17186533 [pii]
AID - 10.3390/ijerph17186533 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Sep 8;17(18). pii: ijerph17186533. doi:
      10.3390/ijerph17186533.


PMID- 32911722
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 8
TI  - Establishing Animal Welfare Rules of Conduct for the Portuguese Veterinary
      Profession-Results from a Policy Delphi with Vignettes.
LID - E1596 [pii]
LID - 10.3390/ani10091596 [doi]
AB  - Promoting animal welfare is one of the basic tenets of the veterinary profession 
      and, in doing so, veterinarians are expected to abide to the highest legal and
      professional standards. However, the Portuguese veterinary code of conduct,
      established in 1994, largely overlooks animal welfare and fails to address issues
      such as the euthanasia or humane killing of animals. As part of a wider research 
      aiming to revise the Portuguese veterinary code of conduct, a Policy Delphi study
      was conducted in late 2018, using a pre-validated three-round structure and
      vignette methodology, to explore the range of opinions and the level of agreement
      on end-of-life dilemmas and animal welfare rules of conduct of a purposeful
      sample of forty-one (out of seventy) Portuguese veterinarians. When faced with
      ethical vignettes involving end-of-life dilemmas, veterinarians were shown to
      privilege personal moral agency over legal obligations in order to defend the
      interests of stakeholders, namely of the animals. Most participants agreed that
      the suggested animal welfare rules of conduct reflected their own views on the
      subject (88%), in addition to representing a significant improvement in terms of 
      regulatory standards (93%). We expect that this study will support regulation and
      policy-making by the Portuguese Veterinary Order and by veterinary representative
      bodies elsewhere.
FAU - Magalhaes-Sant'Ana, Manuel
AU  - Magalhaes-Sant'Ana M
AUID- ORCID: 0000-0001-8317-3633
AD  - CIISA-Centre for Interdisciplinary Research in Animal Health, Faculty of
      Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal.
AD  - Ordem dos Medicos Veterinarios, Av. Filipe Folque, 10J, 4 masculine Dto.,
      1050-113 Lisboa, Portugal.
FAU - Peleteiro, Maria Conceicao
AU  - Peleteiro MC
AD  - CIISA-Centre for Interdisciplinary Research in Animal Health, Faculty of
      Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal.
AD  - Ordem dos Medicos Veterinarios, Av. Filipe Folque, 10J, 4 masculine Dto.,
      1050-113 Lisboa, Portugal.
FAU - Stilwell, George
AU  - Stilwell G
AUID- ORCID: 0000-0003-3733-3223
AD  - CIISA-Centre for Interdisciplinary Research in Animal Health, Faculty of
      Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal.
AD  - Ordem dos Medicos Veterinarios, Av. Filipe Folque, 10J, 4 masculine Dto.,
      1050-113 Lisboa, Portugal.
LA  - eng
GR  - SFRH/BPD/117693/2016/Fundacao para a Ciencia e Tecnologia
GR  - Project UID/CVT/00276/2020/Fundacao para a Ciencia e Tecnologia
PT  - Journal Article
DEP - 20200908
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552194
OTO - NOTNLM
OT  - Policy Delphi
OT  - animal law
OT  - animal welfare
OT  - code of conduct
OT  - emergency slaughter
OT  - euthanasia
OT  - fitness for transport
OT  - moral agency
OT  - veterinary ethics
OT  - vignettes
EDAT- 2020/09/12 06:00
MHDA- 2020/09/12 06:01
CRDT- 2020/09/11 01:01
PHST- 2020/07/23 00:00 [received]
PHST- 2020/08/31 00:00 [revised]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/09/11 01:01 [entrez]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2020/09/12 06:01 [medline]
AID - ani10091596 [pii]
AID - 10.3390/ani10091596 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Sep 8;10(9). pii: ani10091596. doi: 10.3390/ani10091596.


PMID- 32911523
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201028
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - The use of embryonic chicken eggs as an alternative model to evaluate the
      virulence of Salmonella enterica serovar Gallinarum.
PG  - e0238630
LID - 10.1371/journal.pone.0238630 [doi]
AB  - Salmonella enterica serovar Gallinarum (S. Gallinarum) can cause fowl typhoid, a 
      severe systemic disease responsible for considerable economic losses. Chicken
      pathogenicity test is the traditional method for assessing the virulence of S.
      Gallinarum. However, this method is limited by several factors, including ethical
      considerations, costs, and the need for specialized facilities. Hence, we
      established a chicken embryo lethality assay (ELA) model to determine the
      virulence of S. Gallinarum. Three virulent and three avirulent representative
      strains, which were confirmed by the chicken pathogenicity test, were used to
      perform the ELA. The most significant difference between the virulent and
      avirulent strains could be observed when 13-day-old embryos were inoculated via
      the AC route and incubated for 5 days. Based on a 50% embryo lethal dose (ELD50),
      isolates considered to be virulent had a Log10ELD50 of </= 4.0, moderately
      virulent strains had a Log10ELD50 of 4.0-6.1, and avirulent isolates had a
      Log10ELD50 of >/= 6.1. Different abilities to invade the liver of embryos were
      found between the virulent and avirulent strains by a growth curve experiment in 
      vitro. The maximum colony-forming units (CFU) of the virulent strain was about
      10,000 times higher than that of the avirulent strain in the liver at 5 days post
      infection. The ELA results of 42 field strains showed that thirty-two strains
      (76.2%) were virulent, nine were moderately virulent (21.4%), and one strain was 
      avirulent (2.4%). In conclusion, these results suggest that the ELA can be used
      as an alternative method to assess the virulence of S. Gallinarum, which will
      contribute to the study of virulence genes, virulence evolution, pathogenic
      mechanisms and vaccine development.
FAU - Zhang, Jun-Feng
AU  - Zhang JF
AD  - Department of Veterinary Infectious Diseases and Avian Diseases, College of
      Veterinary Medicine and Center for Poultry Diseases Control, Jeonbuk National
      University, Iksan, South Korea.
FAU - Wei, Bai
AU  - Wei B
AD  - Department of Veterinary Infectious Diseases and Avian Diseases, College of
      Veterinary Medicine and Center for Poultry Diseases Control, Jeonbuk National
      University, Iksan, South Korea.
FAU - Cha, Se-Yeoun
AU  - Cha SY
AD  - Department of Veterinary Infectious Diseases and Avian Diseases, College of
      Veterinary Medicine and Center for Poultry Diseases Control, Jeonbuk National
      University, Iksan, South Korea.
FAU - Shang, Ke
AU  - Shang K
AD  - Department of Veterinary Infectious Diseases and Avian Diseases, College of
      Veterinary Medicine and Center for Poultry Diseases Control, Jeonbuk National
      University, Iksan, South Korea.
FAU - Jang, Hyung-Kwan
AU  - Jang HK
AD  - Department of Veterinary Infectious Diseases and Avian Diseases, College of
      Veterinary Medicine and Center for Poultry Diseases Control, Jeonbuk National
      University, Iksan, South Korea.
AD  - Bio Disease Control(BIOD) Co., Ltd., Iksan, Republic of Korea.
FAU - Kang, Min
AU  - Kang M
AUID- ORCID: 0000-0001-5650-1144
AD  - Department of Veterinary Infectious Diseases and Avian Diseases, College of
      Veterinary Medicine and Center for Poultry Diseases Control, Jeonbuk National
      University, Iksan, South Korea.
AD  - Bio Disease Control(BIOD) Co., Ltd., Iksan, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200910
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Biological Assay
MH  - Chick Embryo
MH  - *Models, Biological
MH  - Ovum/*microbiology
MH  - Salmonella enterica/growth & development/*pathogenicity
MH  - *Serogroup
MH  - Virulence
PMC - PMC7500061
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/11 06:00
MHDA- 2020/10/29 06:00
CRDT- 2020/09/10 20:22
PHST- 2020/07/09 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/10 20:22 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
AID - 10.1371/journal.pone.0238630 [doi]
AID - PONE-D-20-19850 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 10;15(9):e0238630. doi: 10.1371/journal.pone.0238630.
      eCollection 2020.


PMID- 32910922
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20210520
IS  - 2173-5778 (Electronic)
IS  - 2173-5778 (Linking)
VI  - 111
IP  - 10
DP  - 2020 Dec
TI  - Medicolegal Aspects of Teledermatology.
PG  - 815-821
LID - S0001-7310(20)30313-6 [pii]
LID - 10.1016/j.ad.2020.08.008 [doi]
AB  - Teledermatology has facilitated specialist care during the crisis caused by the
      coronavirus disease 2019 pandemic, eliminating unnecessary office visits and the 
      possible exposure of patients or dermatologists. However, teledermatology brings 
      forward certain ethical and medicolegal questions. A medical consultation in
      which the patient is not physically present is still a medical act, to which all 
      the usual ethical and medicolegal considerations and consequences apply. The
      patient's right to autonomy and privacy, confidentiality, and data protection
      must be guaranteed. The patient must agree to remote consultation by giving
      informed consent, for which a safeguard clause should be included. Well-defined
      practice guidelines and uniform legislation are required to preserve the highest 
      level of safety for transferred data. Adequate training is also needed to prevent
      circumstances involving what might be termed <<telemalpractice>>.
CI  - Copyright (c) 2020 AEDV. Publicado por Elsevier Espana, S.L.U. All rights
      reserved.
FAU - Arimany-Manso, J
AU  - Arimany-Manso J
AD  - Servicio de Responsabilidad Profesional, Area de Praxis, Colegio de Medicos de
      Barcelona, Consejo de Colegios de Medicos de Catalunya, Barcelona, Espana; Unidad
      de Medicina Legal y Forense, Departamento de Salud Publica, Facultad de Medicina,
      Universidad de Barcelona, Barcelona, Espana; Catedra de Responsabilidad
      Profesional Medica y Medicina Legal, Universitat Autonoma de Barcelona (UAB),
      Barcelona, Espana.
FAU - Pujol, R M
AU  - Pujol RM
AD  - Servicio de Dermatologia, Hospital del Mar. Parc de Salut Mar, Institut Mar
      d'Investigacio Medica, Universitat Autonoma de Barcelona, Barcelona, Espana.
FAU - Garcia-Patos, V
AU  - Garcia-Patos V
AD  - Servicio de Dermatologia, Hospital Universitari Vall d'Hebron, Universitat
      Autonoma de Barcelona, Barcelona, Espana.
FAU - Saigi, U
AU  - Saigi U
AD  - Servicio de Responsabilidad Profesional, Area de Praxis, Colegio de Medicos de
      Barcelona, Consejo de Colegios de Medicos de Catalunya, Barcelona, Espana.
FAU - Martin-Fumado, C
AU  - Martin-Fumado C
AD  - Servicio de Responsabilidad Profesional, Area de Praxis, Colegio de Medicos de
      Barcelona, Consejo de Colegios de Medicos de Catalunya, Barcelona, Espana;
      Catedra de Responsabilidad Profesional Medica y Medicina Legal, Universitat
      Autonoma de Barcelona (UAB), Barcelona, Espana; Departamento de Medicina,
      Facultad de Medicina, Universitat Internacional de Catalunya, Barcelona, Espana. 
      Electronic address: carles.martin@comb.cat.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Aspectos medico-legales de la teledermatologia.
DEP - 20200907
PL  - Spain
TA  - Actas Dermosifiliogr (Engl Ed)
JT  - Actas dermo-sifiliograficas
JID - 101777537
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Checklist
MH  - Confidentiality
MH  - Delivery of Health Care/legislation & jurisprudence
MH  - Dermatology/ethics/legislation & jurisprudence/methods
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Informed Consent
MH  - Malpractice
MH  - *Pandemics
MH  - Patient Acceptance of Health Care
MH  - Personal Autonomy
MH  - *SARS-CoV-2
MH  - Spain/epidemiology
MH  - *Telemedicine/ethics/legislation & jurisprudence/methods
PMC - PMC7476561
OTO - NOTNLM
OT  - Clinical safety
OT  - Clausula de salvaguarda
OT  - Consentimiento informado
OT  - Informed consent
OT  - Malpractice
OT  - Malpraxis
OT  - Safeguard clause
OT  - Seguridad clinica
OT  - Teledermatology
OT  - Teledermatologia
OT  - Telemedicina
OT  - Telemedicine
EDAT- 2020/09/11 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/09/10 20:10
PHST- 2020/06/25 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/09/10 20:10 [entrez]
AID - S0001-7310(20)30313-6 [pii]
AID - 10.1016/j.ad.2020.08.008 [doi]
PST - ppublish
SO  - Actas Dermosifiliogr (Engl Ed). 2020 Dec;111(10):815-821. doi:
      10.1016/j.ad.2020.08.008. Epub 2020 Sep 7.


PMID- 32910694
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 2326-5108 (Electronic)
IS  - 2326-5094 (Linking)
VI  - 18
IP  - 6
DP  - 2020 Dec
TI  - The COVID-19 Pandemic in Italy and the World: To Be or Not to Be? That Is the
      Real Problem.
PG  - 499-501
LID - 10.1089/hs.2020.0076 [doi]
FAU - Lorettu, Liliana
AU  - Lorettu L
AD  - Liliana Lorettu, MD, is a Psychiatrist and Chief, Psychiatric Clinic, and
      Professor of Psychiatry; and Alessandra Nivoli, MD, is a Psychiatrist,
      Psychiatric Clinic, and Professor of Psychiatry; both in the Department of
      Medical, Surgical and Experimental Sciences, University of Sassari, Sassari,
      Italy. Antonio Dessanti, MD, is a Professor of Pediatric Surgery, University
      Medical School of Sassari, Sassari, Italy. Saverio Bellizzi, MD, MSc, PhD, is a
      Consulting Medical Epidemiologist, Sassari, Italy.
FAU - Dessanti, Antonio
AU  - Dessanti A
AD  - Liliana Lorettu, MD, is a Psychiatrist and Chief, Psychiatric Clinic, and
      Professor of Psychiatry; and Alessandra Nivoli, MD, is a Psychiatrist,
      Psychiatric Clinic, and Professor of Psychiatry; both in the Department of
      Medical, Surgical and Experimental Sciences, University of Sassari, Sassari,
      Italy. Antonio Dessanti, MD, is a Professor of Pediatric Surgery, University
      Medical School of Sassari, Sassari, Italy. Saverio Bellizzi, MD, MSc, PhD, is a
      Consulting Medical Epidemiologist, Sassari, Italy.
FAU - Nivoli, Alessandra
AU  - Nivoli A
AD  - Liliana Lorettu, MD, is a Psychiatrist and Chief, Psychiatric Clinic, and
      Professor of Psychiatry; and Alessandra Nivoli, MD, is a Psychiatrist,
      Psychiatric Clinic, and Professor of Psychiatry; both in the Department of
      Medical, Surgical and Experimental Sciences, University of Sassari, Sassari,
      Italy. Antonio Dessanti, MD, is a Professor of Pediatric Surgery, University
      Medical School of Sassari, Sassari, Italy. Saverio Bellizzi, MD, MSc, PhD, is a
      Consulting Medical Epidemiologist, Sassari, Italy.
FAU - Bellizzi, Saverio
AU  - Bellizzi S
AD  - Liliana Lorettu, MD, is a Psychiatrist and Chief, Psychiatric Clinic, and
      Professor of Psychiatry; and Alessandra Nivoli, MD, is a Psychiatrist,
      Psychiatric Clinic, and Professor of Psychiatry; both in the Department of
      Medical, Surgical and Experimental Sciences, University of Sassari, Sassari,
      Italy. Antonio Dessanti, MD, is a Professor of Pediatric Surgery, University
      Medical School of Sassari, Sassari, Italy. Saverio Bellizzi, MD, MSc, PhD, is a
      Consulting Medical Epidemiologist, Sassari, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - United States
TA  - Health Secur
JT  - Health security
JID - 101654694
SB  - IM
MH  - *COVID-19
MH  - Delivery of Health Care/*economics
MH  - *Global Health
MH  - *Health Personnel
MH  - Humans
MH  - Italy
MH  - *Politics
OTO - NOTNLM
OT  - Consequence management
OT  - Epidemic management/response
OT  - Ethics
OT  - Leadership
OT  - Public health
OT  - Responsiveness
EDAT- 2020/09/11 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/09/10 17:08
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/09/10 17:08 [entrez]
AID - 10.1089/hs.2020.0076 [doi]
PST - ppublish
SO  - Health Secur. 2020 Dec;18(6):499-501. doi: 10.1089/hs.2020.0076. Epub 2020 Sep 9.


PMID- 32910675
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20201218
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 102
DP  - 2020 May-Aug
TI  - [UNESCO on COVID-19: Ethical Guidelines for a Global Response].
PG  - 269-273
LID - 10.30444/CB.69 [doi]
FAU - Vivanco, Luis
AU  - Vivanco L
AD  - Centro Nacional de Documentacion en Bioetica, Logrono, La Rioja, Espana.
      C/Piqueras 98, 26006, Logrono, La Rioja, Espana. lvivanco@riojasalud.es +34
      941.278.770; +34 941.278.887.
LA  - spa
PT  - Letter
TT  - UNESCO sobre el COVID-19: Directrices Eticas para una Respuesta Global.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/prevention & control
MH  - Emigration and Immigration
MH  - Ethics Committees
MH  - Global Health
MH  - *Health Policy
MH  - Health Resources/ethics/supply & distribution
MH  - Human Rights
MH  - Humans
MH  - Immunity, Herd
MH  - Information Dissemination
MH  - Morals
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/epidemiology/prevention & control
MH  - Population Surveillance
MH  - *Practice Guidelines as Topic
MH  - Resource Allocation/ethics
MH  - SARS-CoV-2
MH  - Travel
MH  - UNESCO
EDAT- 2020/09/11 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/10 17:08
PHST- 2020/09/10 17:08 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - 10.30444/CB.69 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 May-Aug;31(102):269-273. doi: 10.30444/CB.69.


PMID- 32910674
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20201218
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 102
DP  - 2020 May-Aug
TI  - [Ethical reflections on the Measures Taken in Nursing Homes During Pandemic].
PG  - 231-243
LID - 10.30444/CB.64 [doi]
AB  - The crisis in the health system caused by COVID-19 has left some important
      humanitarian deficits on how to care for the sick in their last days of life. The
      humanization of the dying process has been affected in three fundamental aspects,
      each of which constitutes a medical and ethical duty necessary. In this study, I 
      analyze why dying accompanied, with the possibility of saying goodbye and
      receiving spiritual assistance, constitutes a specific triad of care and natural 
      obligations that should not be overlooked - even in times of health crisis - if
      we do not want to see human dignity violated and violated some fundamental rights
      derived from it.
FAU - Gomez Martinez, Carmelo
AU  - Gomez Martinez C
AD  - Catedra de Humanizacion y cuidado a personas mayores. Universidad Catolica de
      Murcia. Facultad de Enfermeria. Universidad Catolica de Murcia. Sociedad Murciana
      de Enfermeria Geriatrica y Gerontologica. Calle Orden de Santiago, Abaran,
      Murcia.+34660742618. gomezmartinezcarmelo@gmail.com.
LA  - spa
PT  - Journal Article
TT  - Reflexiones eticas en torno a las Medidas tomadas en las Residencias durante la
      Pandemia.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/prevention & control
MH  - Ethics Committees
MH  - Health Policy
MH  - Health Resources/ethics/supply & distribution
MH  - Humans
MH  - Information Dissemination
MH  - Nursing Homes/*ethics
MH  - Pandemics/*ethics/prevention & control
MH  - Personhood
MH  - Pneumonia, Viral/prevention & control
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/ethics
MH  - SARS-CoV-2
MH  - Social Justice
MH  - UNESCO
MH  - Vulnerable Populations
EDAT- 2020/09/11 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/10 17:08
PHST- 2020/07/23 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/09/10 17:08 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - 10.30444/CB.64 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 May-Aug;31(102):231-243. doi: 10.30444/CB.64.


PMID- 32910673
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20201218
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 102
DP  - 2020 May-Aug
TI  - [An ethical Response in the Care of Nursing Homes in the COVID-19 Pandemic].
PG  - 223-229
LID - 10.30444/CB.63 [doi]
AB  - With the arrival of the COVID-19 pandemic, the risk of a possible lack of care
      for the elderly in nursing homes became evident. We summarize the experience of a
      multidisciplinary team with volunteer professionals from different specialties
      who carried out support for healthcare professionals in nursing homes. This team 
      was implemented from both Primary and Specialty Care managements. Its work
      paradigm was proposed by our home hospitalization team, which included direct
      care of the most complex patients and general counselling on isolation, hygiene
      and preventive measures within the nursing homes. Thanks to this support, the
      elderly population placed there, with suspected or diagnosed COVID-19, received
      adequate care from an interdisciplinary team, which led part of the pressure to
      be released from their professional workers, and many family members were aware
      that there was no neglect of the elderly. Commitment from various levels of care 
      in a coordinated effort has prevented a vulnerable population from being left
      unattended during the pandemic.
CN  - Equipo COVID Residencias, Area de Salud Valladolid Oeste
AD  - Oncologia Medica Hospital Universitario del Rio Hortega Calle Dulzaina 1, 47013
      Valladolid 983420400 asrubiales@hotmail.com.
LA  - spa
PT  - Journal Article
TT  - Una Respuesta ETica en la AtenciON a Residencias de Ancianos en la Pandemia
      COVID-19.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Continuity of Patient Care
MH  - *Coronavirus Infections/prevention & control
MH  - Cross Infection/prevention & control
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Hygiene
MH  - Infection Control
MH  - Interdisciplinary Communication
MH  - Nursing Homes/*ethics
MH  - Palliative Care/ethics
MH  - *Pandemics/ethics/prevention & control
MH  - Patient Care Team
MH  - Patient Isolation
MH  - Patient Transfer/ethics
MH  - *Pneumonia, Viral/prevention & control
MH  - Professional-Family Relations
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - Symptom Assessment
MH  - Vulnerable Populations
IR  - Arevalo A
FIR - Arevalo, Angela
IR  - Armentia A
FIR - Armentia, Alicia
IR  - Blanco B
FIR - Blanco, Blanca
IR  - Cano M
FIR - Cano, Marta
IR  - Crespo C
FIR - Crespo, Cristina
IR  - Fra J
FIR - Fra, Joaquin
IR  - Galan J
FIR - Galan, Jesus
IR  - Gallego N
FIR - Gallego, Natalia
IR  - Garcia S
FIR - Garcia, Sara
IR  - Lovell E
FIR - Lovell, Edgar
IR  - Navarro C
FIR - Navarro, Claudio
IR  - Ramos D
FIR - Ramos, Daniel
IR  - Sacristan A
FIR - Sacristan, Aurora
IR  - San Segundo D
FIR - San Segundo, Dionisio
IR  - Sanchez C
FIR - Sanchez, Carmen
IR  - Sanz A
FIR - Sanz, Alvaro
IR  - Vacas R
FIR - Vacas, Resurreccion
IR  - Visa J
FIR - Visa, Javier
EDAT- 2020/09/11 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/10 17:08
PHST- 2020/05/10 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/09/10 17:08 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - 10.30444/CB.63 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 May-Aug;31(102):223-229. doi: 10.30444/CB.63.


PMID- 32910672
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20201218
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 102
DP  - 2020 May-Aug
TI  - [Humanize Death in a Time of Sanitary Crisis: Accompanied Die, Farewell and
      Receive Spiritual Care].
PG  - 203-222
LID - 10.30444/CB.62 [doi]
AB  - The crisis in the health system caused by COVID-19 has left some important
      humanitarian deficits on how to care for the sick in their last days of life. The
      humanization of the dying process has been affected in three fundamental aspects,
      each of which constitutes a medical and ethical duty necessary. In this study, I 
      analyze why dying accompanied, with the possibility of saying goodbye and
      receiving spiritual assistance, constitutes a specific triad of care and natural 
      obligations that should not be overlooked - even in times of health crisis - if
      we do not want to see human dignity violated and violated some fundamental rights
      derived from it.
FAU - Garcia Sanchez, Emilio
AU  - Garcia Sanchez E
AD  - Universidad Cardenal Herrera CEU c/ Luis Vives, 1. 46115, Alfara del Patriarca
      (Valencia- Spain) 96 1369000 emilio.garcia@uchceu.es.
LA  - spa
PT  - Journal Article
TT  - Humanizar la Muerte en Tiempos de Crisis Sanitaria: Morir Acompanado, Despedirse 
      y Recibir Atencion Espiritual.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - *Attitude to Death
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Dehumanization
MH  - Emotions
MH  - Humans
MH  - Interpersonal Relations
MH  - Moral Obligations
MH  - Palliative Care
MH  - *Pandemics
MH  - Patient Comfort
MH  - Patient Isolation/ethics
MH  - Patient Rights
MH  - Personhood
MH  - Physician's Role
MH  - *Pneumonia, Viral
MH  - Religion
MH  - SARS-CoV-2
MH  - *Spirituality
MH  - Terminal Care/*ethics/methods/psychology
MH  - Visitors to Patients
EDAT- 2020/09/11 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/09/10 17:08
PHST- 2020/07/08 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/09/10 17:08 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - 10.30444/CB.62 [doi]
PST - ppublish
SO  - Cuad Bioet. 2020 May-Aug;31(102):203-222. doi: 10.30444/CB.62.


PMID- 32910238
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 1432-0738 (Electronic)
IS  - 0340-5761 (Linking)
VI  - 94
IP  - 12
DP  - 2020 Dec
TI  - Use of in vitro bone models to screen for altered bone metabolism, osteopathies, 
      and fracture healing: challenges of complex models.
PG  - 3937-3958
LID - 10.1007/s00204-020-02906-z [doi]
AB  - Approx. every third hospitalized patient in Europe suffers from musculoskeletal
      injuries or diseases. Up to 20% of these patients need costly surgical revisions 
      after delayed or impaired fracture healing. Reasons for this are the severity of 
      the trauma, individual factors, e.g, the patients' age, individual lifestyle,
      chronic diseases, medication, and, over 70 diseases that negatively affect the
      bone quality. To investigate the various disease constellations and/or develop
      new treatment strategies, many in vivo, ex vivo, and in vitro models can be
      applied. Analyzing these various models more closely, it is obvious that many of 
      them have limits and/or restrictions. Undoubtedly, in vivo models most completely
      represent the biological situation. Besides possible species-specific
      differences, ethical concerns may question the use of in vivo models especially
      for large screening approaches. Challenging whether ex vivo or in vitro bone
      models can be used as an adequate replacement for such screenings, we here
      summarize the advantages and challenges of frequently used ex vivo and in vitro
      bone models to study disturbed bone metabolism and fracture healing. Using own
      examples, we discuss the common challenge of cell-specific normalization of data 
      obtained from more complex in vitro models as one example of the analytical
      limits which lower the full potential of these complex model systems.
FAU - Ehnert, Sabrina
AU  - Ehnert S
AUID- ORCID: http://orcid.org/0000-0003-4347-1702
AD  - Siegfried Weller Research Institute at the BG Trauma Center Tubingen, Department 
      of Trauma and Reconstructive Surgery, University of Tubingen, Tubingen, Germany. 
      sabrina.ehnert@med.uni-tuebingen.des.
FAU - Rinderknecht, Helen
AU  - Rinderknecht H
AD  - Siegfried Weller Research Institute at the BG Trauma Center Tubingen, Department 
      of Trauma and Reconstructive Surgery, University of Tubingen, Tubingen, Germany.
FAU - Aspera-Werz, Romina H
AU  - Aspera-Werz RH
AD  - Siegfried Weller Research Institute at the BG Trauma Center Tubingen, Department 
      of Trauma and Reconstructive Surgery, University of Tubingen, Tubingen, Germany.
FAU - Haussling, Victor
AU  - Haussling V
AD  - Siegfried Weller Research Institute at the BG Trauma Center Tubingen, Department 
      of Trauma and Reconstructive Surgery, University of Tubingen, Tubingen, Germany.
FAU - Nussler, Andreas K
AU  - Nussler AK
AUID- ORCID: http://orcid.org/0000-0002-6666-6791
AD  - Siegfried Weller Research Institute at the BG Trauma Center Tubingen, Department 
      of Trauma and Reconstructive Surgery, University of Tubingen, Tubingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200910
PL  - Germany
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
SB  - IM
MH  - Animals
MH  - Bone Diseases/*metabolism/pathology/physiopathology
MH  - *Bone Remodeling
MH  - Bone and Bones/*metabolism/pathology/physiopathology
MH  - Cell Communication
MH  - Cell Culture Techniques
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Endothelial Cells/metabolism/pathology
MH  - *Fracture Healing
MH  - Humans
MH  - Osteoblasts/metabolism/pathology
MH  - Osteoclasts/metabolism/pathology
MH  - Osteocytes/metabolism/pathology
MH  - Tissue Culture Techniques
PMC - PMC7655582
OTO - NOTNLM
OT  - *2D/3D
OT  - *Co-culture
OT  - *Endothelial cells
OT  - *Ex vivo bone cultures
OT  - *Osteoblast/osteocyte
OT  - *Osteoclast
EDAT- 2020/09/11 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/09/10 12:26
PHST- 2020/05/06 00:00 [received]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/09/10 12:26 [entrez]
AID - 10.1007/s00204-020-02906-z [doi]
AID - 10.1007/s00204-020-02906-z [pii]
PST - ppublish
SO  - Arch Toxicol. 2020 Dec;94(12):3937-3958. doi: 10.1007/s00204-020-02906-z. Epub
      2020 Sep 10.


PMID- 32909118
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20211102
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 11
DP  - 2020 Nov
TI  - When pregnancy is a research risk.
PG  - 2687-2690
LID - 10.1007/s10815-020-01938-9 [doi]
AB  - A published study reported by Munne using uterine lavage to retrieve in vivo
      blastocysts for preimplantation genetic testing has been the subject of several
      technical and ethical critiques. None of these critiques has been based on a
      review of the study's IRB-approved informed consent. This commentary seeks to do 
      that, examining the Munne (and related Nadal) consent forms for their conformity 
      to existing requirements for a full and informed consent.
FAU - Green, Ronald M
AU  - Green RM
AUID- ORCID: http://orcid.org/0000-0003-2844-6007
AD  - Department of Religion, Dartmouth College, Hanover, NH, USA.
      Ronald.M.Green@Dartmouth.edu.
LA  - eng
PT  - Editorial
DEP - 20200910
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - Blastocyst/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Informed Consent/ethics
MH  - Pregnancy
MH  - Preimplantation Diagnosis/*ethics
MH  - *Risk Assessment
MH  - Uterus/*metabolism/pathology
PMC - PMC7642000
EDAT- 2020/09/11 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/09/10 05:37
PHST- 2020/07/17 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/09/10 05:37 [entrez]
AID - 10.1007/s10815-020-01938-9 [doi]
AID - 10.1007/s10815-020-01938-9 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Nov;37(11):2687-2690. doi:
      10.1007/s10815-020-01938-9. Epub 2020 Sep 10.


PMID- 32908914
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - The Wooden Skull: An Innovation through the Use of Local Materials and Technology
      to Promote the Teaching and Learning of Human Anatomy.
PG  - 8036737
LID - 10.1155/2020/8036737 [doi]
AB  - Skeleton models are important in facilitating a student's easy retention and
      recollection of information in the future. These may assist students carry out
      hands-on practice in order to acquire and practice new skills that are relevant
      to first aid. The increasing number of medical institutions and medical students 
      attracts the challenge of inadequate facilitation of the teaching and learning
      processes. This warrants a study and/or an exploration of an alternative solution
      such as wooden models in order to solve the problem of scarce and ethically
      restricted human teaching aids. Wooden pieces (50 cm length x 20 cm diameter)
      from a Jacaranda mimosifolia tree were prepared for the carving process, and
      wooden replicas of human skulls were made. Two experimental groups of randomly
      selected medical students (60: active and 60: control) were separately taught
      using wooden and natural skull models, respectively. The two groups were assessed
      and evaluated using the natural skull models to compare their understanding of
      the anatomy of the skull. Additionally, opinion statements were collected from
      participants in the active group during the oral examination. Six (6) wooden
      skull models were produced and used for experimental study. Comparisons of
      academic scores (mean and median) between active (students using the wooden
      skull) and control (students using natural skull) groups showed no statistically 
      significant difference (P >/= 0.05). Concerning the enhancement of learning
      skills, the wooden model was constructed in a way that would be able to enhance
      learning as it would be the natural skull. The wooden skull model, with more
      improvement in structural formation, can adequately facilitate the teaching and
      learning of anatomy of the human skull. This project and the experimental study
      about utilization of the wooden skull model provide a good potential of using the
      wooden models to supplement the use of the natural human skull.
CI  - Copyright (c) 2020 Kintu Mugagga et al.
FAU - Mugagga, Kintu
AU  - Mugagga K
AD  - Department of Human Anatomy, Faculty of Biomedical Sciences, Kampala
      International University, Western Campus, Uganda.
AD  - Department of Anatomy, Faculty of Medicine, Mbarara University of Science and
      Technology, Uganda.
FAU - Mwarisi, Masilili G
AU  - Mwarisi MG
AD  - Department of Human Anatomy, School of Health Sciences, Makerere University,
      Uganda.
FAU - Dare, Samuel S
AU  - Dare SS
AUID- ORCID: https://orcid.org/0000-0002-7022-9818
AD  - Department of Human Anatomy, Faculty of Biomedical Sciences, Kampala
      International University, Western Campus, Uganda.
AD  - Kabale University School of Medicine, Kabale University, Uganda.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Validation Study
DEP - 20200827
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Anatomy/*education
MH  - Bignoniaceae
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Educational Measurement
MH  - Humans
MH  - Learning
MH  - *Models, Anatomic
MH  - Skull/*anatomy & histology
MH  - Students, Medical
MH  - Teaching
MH  - Technology
MH  - Uganda
MH  - *Wood
PMC - PMC7474353
COIS- The authors declare that there is no conflict of interest regarding the
      publication of this paper.
EDAT- 2020/09/11 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/09/10 05:36
PHST- 2020/06/06 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/09/10 05:36 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - 10.1155/2020/8036737 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Aug 27;2020:8036737. doi: 10.1155/2020/8036737. eCollection 
      2020.


PMID- 32908881
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.
PG  - 3038564
LID - 10.1155/2020/3038564 [doi]
AB  - Plant-based products have expanded to include cancer immunotherapy, which has
      made great strides over recent years. Plants are considered inexpensive and
      facile production platforms for recombinant monoclonal antibody (mAb) due to the 
      latest advancements and diversification of transgenic techniques. Current human
      biologics, including those based on mAbs produced by fermentation technologies
      using primarily mammalian cell cultures, have been replaced by plant-produced
      mAbs, which are cost effective, more scalable, speedy, versatile, and safer.
      Moreover, the use of animals for antibody production is always a question of
      ethical unambiguity, and the suitability of animal models for predicting the
      immunogenicity of therapeutic mAbs in humans and transposition of the immunogenic
      potential of therapeutic antibodies in animals to the human situation has no
      scientific rationale. Quite a few plant-based mAbs are approved for the treatment
      of cancer, ranging from tumors to hematological malignancies. This review focuses
      on the cutting-edge approaches for using plant-derived mAbs to suppress or
      prevent cancers. It also discusses the avenues taken to prevent infection by
      oncogenic viruses, solid tumors, lymphomas, and other cancerous conditions using 
      mAbs. The review emphasizes the use of a plant-derived monoclonal antibody as a
      premier platform to combat cancer.
CI  - Copyright (c) 2020 Meher Un Nessa et al.
FAU - Nessa, Meher Un
AU  - Nessa MU
AD  - Environmental Science Discipline, Khulna University, Khulna 9208, Bangladesh.
FAU - Rahman, Md Atiar
AU  - Rahman MA
AUID- ORCID: https://orcid.org/0000-0002-4902-8923
AD  - Department of Biochemistry and Molecular Biology, University of Chittagong,
      Chittagong 4331, Bangladesh.
FAU - Kabir, Yearul
AU  - Kabir Y
AUID- ORCID: https://orcid.org/0000-0002-0242-9199
AD  - Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka
      1000, Bangladesh.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200824
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antineoplastic Agents, Immunological)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/biosynthesis/genetics/*therapeutic use
MH  - Antibodies, Neutralizing/biosynthesis/genetics/therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/*immunology/*therapy
MH  - Plants, Genetically Modified/*genetics/*immunology/metabolism
PMC - PMC7468595
COIS- The authors declare no conflict of interest, financial or otherwise.
EDAT- 2020/09/11 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/09/10 05:36
PHST- 2020/04/25 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/10 05:36 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1155/2020/3038564 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Aug 24;2020:3038564. doi: 10.1155/2020/3038564. eCollection 
      2020.


PMID- 32908805
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2164-7844 (Print)
IS  - 2164-7844 (Linking)
VI  - 9
IP  - 1
DP  - 2020
TI  - Biobanking for Translational Diabetes Research in India.
PG  - 183-189
LID - 10.1089/biores.2019.0052 [doi]
AB  - India is declared as the diabetic capital of the world. Clinically well-annotated
      blood samples will advance diabetes research for better diagnostic and treatment 
      methods. Building a disease-specific biobank with high-quality peripheral blood
      mononuclear cells (PBMCs) and clinical follow-up data system will serve as a good
      platform for clinical research in diabetes. Processing and storage of
      high-quality biospecimen for translational research in diabetes demand the
      implementation of good clinical laboratory practices. "Certification or
      accreditation programs" that improve biorepository processes and frameworks are
      lacking in Indian context. To sustain and translate the research into clinical
      practice, good governance of the biobank and financial resources is required. For
      ethical issues related to health needs of the people and participants in the
      research, issues related to research process, translational research, and
      commercialization, data sharing should be addressed. For India to be an
      innovation and sustainable country Indian government is supporting translational 
      research facilities, including biobanks. India has developed biobanks for various
      diseases; however, diabetes-specific research biorepository is lacking. Given the
      dangers of diabetic burden, India should set up a diabetes disease-specific
      repository learning from the global organizations and customize to the needs of
      Indian context. It is important to have private agencies get involved to develop 
      biobanks and future research as there are commercial goals to translate research 
      into practice. New technologies of specimen storing and preservation, data
      management, and data sharing should be adopted for developing cost-effective
      long-standing disease-specific population biobank in India.
CI  - (c) Charitha Gangadharan et al., 2020; Published by Mary Ann Liebert, Inc.
FAU - Gangadharan, Charitha
AU  - Gangadharan C
AD  - Department of Clinical Research, Narayana Hrudayalaya Foundations, Bommasandra,
      Bangalore, India.
FAU - Wills, Soniya
AU  - Wills S
AD  - Department of Clinical Research, Narayana Hrudayalaya Foundations, Bommasandra,
      Bangalore, India.
FAU - Vangala, Rajani Kanth
AU  - Vangala RK
AD  - Institute for Applied Research and innovation (InARI), Chikkalasandra, Bangalore,
      India.
FAU - Sigamani, Alben
AU  - Sigamani A
AD  - Department of Clinical Research, Narayana Hrudayalaya Foundations, Bommasandra,
      Bangalore, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200819
PL  - United States
TA  - Biores Open Access
JT  - BioResearch open access
JID - 101579333
PMC - PMC7473039
OTO - NOTNLM
OT  - India
OT  - biological specimen bank
OT  - certification
OT  - diabetes
OT  - ethics and legal issue
COIS- No competing financial interests exist.
EDAT- 2020/09/11 06:00
MHDA- 2020/09/11 06:01
CRDT- 2020/09/10 05:36
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/09/10 05:36 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/11 06:01 [medline]
AID - 10.1089/biores.2019.0052 [doi]
AID - 10.1089/biores.2019.0052 [pii]
PST - epublish
SO  - Biores Open Access. 2020 Aug 19;9(1):183-189. doi: 10.1089/biores.2019.0052.
      eCollection 2020.


PMID- 32908700
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2090-1445 (Print)
IS  - 2090-1445 (Linking)
VI  - 2020
DP  - 2020
TI  - Transferability of Simulation-Based Training in Laparoscopic Surgeries: A
      Systematic Review.
PG  - 5879485
LID - 10.1155/2020/5879485 [doi]
AB  - OBJECTIVE: The implementation of simulation-based training in residency programs 
      has been increased, but the transferability of surgical skills in the real
      operating room is not well documented. In our survey, the role of simulation in
      surgical training will be evaluated. Study Design. In this systemic review,
      randomized control trials, which assessed the transferability of acquired skills 
      through simulation in the real operating setting, were included. A systematic
      search strategy was undertaken using a predetermined protocol. RESULTS: Eighteen 
      randomized clinical trials were included in this survey. Two studies investigated
      inguinal hernia repair, six laparoscopic cholecystectomy, five gynecologic
      procedures, two laparoscopic suturing, and two camera navigation during
      laparoscopic procedures. Simulation-trained participants showed superiority in
      surgical performance in comparison with untrained surgeons. The operation time,
      accuracy, incidence of intraoperative errors, and postoperative complications
      were statistically better in the simulation-trained group in comparison with the 
      conventional-trained group. CONCLUSION: Simulation provides a safe, effective,
      and ethical way for residents to acquire surgical skills before entering the
      operating room.
CI  - Copyright (c) 2020 Antonios E. Spiliotis et al.
FAU - Spiliotis, Antonios E
AU  - Spiliotis AE
AUID- ORCID: https://orcid.org/0000-0002-5947-3588
AD  - Department of General, Visceral, Vascular and Pediatric Surgery, Saarland
      University, Saarland University Medical Center, Homburg, Germany.
FAU - Spiliotis, Panagiotis M
AU  - Spiliotis PM
AD  - Department of Surgery, University Hospital Knappschaftskrankenhaus Bochum,
      Ruhr-University Bochum, Bochum, Germany.
FAU - Palios, Ifaistion M
AU  - Palios IM
AD  - Department of Surgery, Laiko General Hospital, National and Kapodistrian
      University of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - United States
TA  - Minim Invasive Surg
JT  - Minimally invasive surgery
JID - 101566870
PMC - PMC7468652
COIS- The authors declare that they have no conflicts of interest or personal
      relationships that could have appeared to influence the work reported in this
      paper.
EDAT- 2020/09/11 06:00
MHDA- 2020/09/11 06:01
CRDT- 2020/09/10 05:35
PHST- 2020/04/16 00:00 [received]
PHST- 2020/08/01 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/09/10 05:35 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/11 06:01 [medline]
AID - 10.1155/2020/5879485 [doi]
PST - epublish
SO  - Minim Invasive Surg. 2020 Aug 25;2020:5879485. doi: 10.1155/2020/5879485.
      eCollection 2020.


PMID- 32908677
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2056-7529 (Electronic)
IS  - 2056-7529 (Linking)
VI  - 6
DP  - 2020
TI  - Informing the development of an E-platform for monitoring wellbeing in schools:
      involving young people in a co-design process.
PG  - 51
LID - 10.1186/s40900-020-00219-0 [doi]
AB  - BACKGROUND: The use of new technologies and methodologies in young people's
      mental health research is needed to allow more frequent and reliable sampling.
      Mobile applications and e-platforms create exciting potential for the collection 
      of large-scale cohort data, however there are various feasibility and ethical
      issues to consider. Consultation with young people is needed to inform the
      research agenda, and ensure these technologies are engaging, useful and safe.
      This article describes the process of Public and Patient Involvement (PPI) with a
      sample of young people in London, with the aim of i) informing the development of
      a mood-monitoring e-platform, and ii) providing feedback and advice for
      researchers developing web-based technologies in the mental health field.
      METHODS: A total of 26 young people were consulted across four advisory group
      co-design sessions. All young people were students enrolled at one of the
      participating London based sixth form colleges, and voluntarily attended a
      workshop session. Audio recordings of the sessions were analysed using a thematic
      analysis framework. RESULTS: We found that young people were engaged in
      discussions around mobile health technologies and valued the opportunity to
      collaborate throughout the early stages of the development process The advisory
      groups identified key considerations for future web-development work to encourage
      engagement and prolonged use, including, the promotion of trust and transparency,
      consideration of accessibility, provision of support, production of engaging and 
      functional design, and acknowledgment of specific contextual influences
      surrounding young people's wellbeing. CONCLUSIONS: Involving young people in the 
      development process of e-health technologies contributes to optimising the
      successful adoption and prolonged usage of new methodologies. The thematic map
      and informant examples can be used to guide researchers interested in developing 
      web-based technologies in the mental health field and will be directly applicable
      to the development of a mood-monitoring e-platform.
CI  - (c) The Author(s) 2020.
FAU - Grant, Claire
AU  - Grant C
AUID- ORCID: 0000-0002-1545-6428
AD  - King's College London, Department of Child & Adolescent Psychiatry, Institute of 
      Psychology, Psychiatry and Neuroscience, London, UK.grid.13097.3c0000 0001 2322
      6764
FAU - Widnall, Emily
AU  - Widnall E
AD  - King's College London, Department of Child & Adolescent Psychiatry, Institute of 
      Psychology, Psychiatry and Neuroscience, London, UK.grid.13097.3c0000 0001 2322
      6764
FAU - Cross, Lauren
AU  - Cross L
AD  - King's College London, Department of Child & Adolescent Psychiatry, Institute of 
      Psychology, Psychiatry and Neuroscience, London, UK.grid.13097.3c0000 0001 2322
      6764
FAU - Simonoff, Emily
AU  - Simonoff E
AD  - King's College London, Department of Child & Adolescent Psychiatry, Institute of 
      Psychology, Psychiatry and Neuroscience, London, UK.grid.13097.3c0000 0001 2322
      6764
AD  - The South London and Maudsley NHS Foundation Trust Biomedical Research Centre
      (SLaM BRC), London, UK.grid.37640.360000 0000 9439 0839
FAU - Downs, Johnny
AU  - Downs J
AD  - King's College London, Department of Child & Adolescent Psychiatry, Institute of 
      Psychology, Psychiatry and Neuroscience, London, UK.grid.13097.3c0000 0001 2322
      6764
AD  - The South London and Maudsley NHS Foundation Trust Biomedical Research Centre
      (SLaM BRC), London, UK.grid.37640.360000 0000 9439 0839
LA  - eng
GR  - CS-2018-18-ST2-014/DH_/Department of Health/United Kingdom
GR  - MC_PC_17214/MRC_/Medical Research Council/United Kingdom
GR  - MR/L017105/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - Res Involv Engagem
JT  - Research involvement and engagement
JID - 101708164
PMC - PMC7470434
OTO - NOTNLM
OT  - Adolescent
OT  - Co-design
OT  - Mental health
OT  - Mobile health
OT  - Mood
OT  - Patient and public involvement
OT  - Smartphones
COIS- Competing interestsThe authors have declared that no competing interests exist.
EDAT- 2020/09/11 06:00
MHDA- 2020/09/11 06:01
CRDT- 2020/09/10 05:35
PHST- 2020/02/13 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/09/10 05:35 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/11 06:01 [medline]
AID - 10.1186/s40900-020-00219-0 [doi]
AID - 219 [pii]
PST - epublish
SO  - Res Involv Engagem. 2020 Sep 3;6:51. doi: 10.1186/s40900-020-00219-0. eCollection
      2020.


PMID- 32908673
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - COVID-19 calls for virtue ethics.
PG  - lsaa056
LID - 10.1093/jlb/lsaa056 [doi]
AB  - The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
      or coronavirus disease 19 (COVID-19) has led to the imposition of severely
      restrictive measures by governments in the Western hemisphere. We feel a contrast
      between these measures and our freedom. This contrast, we argue, is a false
      perception. It only appears to us because we look at the issue through our
      contemporary moral philosophy of utilitarianism and an understanding of freedom
      as absence of constraints. Both these views can be substituted with more
      sophisticated alternatives, namely an ethics of virtue and a notion of freedom of
      the will. These offer a fuller picture of morality and enable us to cooperate
      with the current restrictions by consciously choosing to adhere to them instead
      of perceiving them as draconian and immoral. We ask whether we should collaborate
      with the restrictions and argue that considerations of virtue will lead to an
      affirmative answer. More broadly, virtue ethics permits to deal with the
      practical concerns about how an individual should behave during this pandemic,
      given the current lockdown measures or lack thereof. In section 1, we present how
      utilitarianism and a notion of freedom as negative liberty support the opposition
      to restrictive measures. In section 2, we outline an alternative based on an
      ethics of virtue and a more elaborated notion of free will. In the concluding
      section 3, we argue that considerations of virtue should guide the individual and
      public response to the emergency.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Bellazzi, Francesca
AU  - Bellazzi F
FAU - Boyneburgk, Konrad V
AU  - Boyneburgk KV
AUID- ORCID: 0000-0002-3651-9897
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200707
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7454698
OTO - NOTNLM
OT  - COVID-19
OT  - freedom
OT  - utilitarianism
OT  - virtue ethics
OT  - will
EDAT- 2020/09/11 06:00
MHDA- 2020/09/11 06:01
CRDT- 2020/09/10 05:35
PHST- 2020/04/08 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/09/10 05:35 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/11 06:01 [medline]
AID - 10.1093/jlb/lsaa056 [doi]
AID - lsaa056 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jul 7;7(1):lsaa056. doi: 10.1093/jlb/lsaa056. eCollection 2020
      Jan-Jun.


PMID- 32908509
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1687-8639 (Print)
IS  - 1687-8639 (Linking)
VI  - 2020
DP  - 2020
TI  - Human Papillomavirus Prevalence in Oral and Oropharyngeal Rinse and Gargle
      Specimens of Dental Patients and of an HIV-Positive Cohort from Pretoria, South
      Africa.
PG  - 2395219
LID - 10.1155/2020/2395219 [doi]
AB  - INTRODUCTION: Studies on HPV prevalence in the head and neck region of South
      Africans are sparse. Of the available reports in the literature, there were no
      studies on the association between HPV-DNA presence in the mouth and oropharynx
      in relation to high-risk behaviours such as oral sex practice or tobacco and
      alcohol use. MATERIALS AND METHODS: Following ethical clearance and informed
      consent, patients attending a regional HIV-management clinic and patients
      attending a dental hospital were recruited to this study. The participants
      completed an interview-based questionnaire obtaining demographic information,
      data on HIV serostatus, and behavioural data including sexual practices and
      tobacco and alcohol use, and a rinse-and-gargle specimen was taken. Specimens
      were analysed for HPV DNA on 3 separate PCR/qPCR platforms. Statistical analyses 
      were performed for associations between the study group and categorical
      variables, HPV status, and data from the questionnaires. RESULTS: Of 221
      participants, 149 were from a general population and 72 from the HIV-management
      clinic. Smokers comprised 29.4% of the sample, and 45.2% of participants reported
      to have ever used alcohol. Open mouth kissing during teenage years was confirmed 
      by 64.7% of participants, 40.3% have given oral sex with their mouth, and 44.8%
      confirmed to have received oral sex from their partner's mouth. Seven
      participants (3.2%) had detectable alpha-HPV DNA, and 1 (0.4%) had detectable
      beta-HPV DNA in their rinse-and-gargle specimens. Two participants were from the 
      HIV-management clinic and 6 from the general dental population (overall 3.6%).
      CONCLUSION: Five high-risk HPV, 2 low-risk HPV, and one beta-HPV types were
      detected. The low prevalence of 3.6% compares well to similar studies in
      different cohorts studied in South Africa and falls within the global
      oral/oropharyngeal prevalence spectrum. Only 4 participants, all from the
      HIV-management clinic, had palatine tonsils. No significant relationships were
      found between HPV presence and demographic data or sexual, oral sexual, tobacco
      use, or alcohol use, and no associations were seen with numbers of sexual and
      oral-sex partners.
CI  - Copyright (c) 2020 Neil H. Wood et al.
FAU - Wood, Neil H
AU  - Wood NH
AUID- ORCID: https://orcid.org/0000-0001-8950-7999
AD  - Department of Periodontology and Oral Medicine, School of Oral Health Sciences,
      Sefako Makgatho Health Sciences University, Pretoria, South Africa.
FAU - Makua, Koketso S
AU  - Makua KS
AD  - Department of Virology, Sefako Makgatho Health Sciences University, Pretoria,
      South Africa.
FAU - Lebelo, Ramokone L
AU  - Lebelo RL
AD  - HIV and Hepatitis Research Unit, National Health Laboratory Service, Department
      of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
FAU - Redzic, Nina
AU  - Redzic N
AD  - Faculty of Medicine and Health Sciences, Applied Molecular Biology Research Group
      (AMBIOR), Laboratory of Cell Biology and Histology, University of Antwerp,
      Antwerp, Belgium.
FAU - Benoy, Ina
AU  - Benoy I
AD  - Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
FAU - Vanderveken, Olivier M
AU  - Vanderveken OM
AD  - Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem,
      Belgium.
FAU - Bogers, Johannes
AU  - Bogers J
AD  - Faculty of Medicine and Health Sciences, Applied Molecular Biology Research Group
      (AMBIOR), Laboratory of Cell Biology and Histology, University of Antwerp,
      Antwerp, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - United States
TA  - Adv Virol
JT  - Advances in virology
JID - 101508613
PMC - PMC7471795
COIS- The authors declare that they have no conflicts of interest regarding the
      publication of this paper.
EDAT- 2020/09/11 06:00
MHDA- 2020/09/11 06:01
CRDT- 2020/09/10 05:35
PHST- 2020/02/20 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/09/10 05:35 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/11 06:01 [medline]
AID - 10.1155/2020/2395219 [doi]
PST - epublish
SO  - Adv Virol. 2020 Aug 26;2020:2395219. doi: 10.1155/2020/2395219. eCollection 2020.


PMID- 32908273
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210629
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 26
IP  - 9
DP  - 2020 Sep
TI  - Clinical research underlies ethical integration of healthcare artificial
      intelligence.
PG  - 1325-1326
LID - 10.1038/s41591-020-1035-9 [doi]
FAU - McCradden, Melissa D
AU  - McCradden MD
AUID- ORCID: http://orcid.org/0000-0002-6476-2165
AD  - Department of Bioethics, The Hospital for Sick Children, Toronto, Canada.
      melissa.mccradden@sickkids.ca.
FAU - Stephenson, Elizabeth A
AU  - Stephenson EA
AD  - Department of Paediatrics, University of Toronto, Toronto, Canada.
FAU - Anderson, James A
AU  - Anderson JA
AD  - Department of Bioethics, The Hospital for Sick Children, Toronto, Canada.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Delivery of Health Care/*ethics
MH  - Humans
EDAT- 2020/09/11 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/09/10 05:33
PHST- 2020/09/10 05:33 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
AID - 10.1038/s41591-020-1035-9 [doi]
AID - 10.1038/s41591-020-1035-9 [pii]
PST - ppublish
SO  - Nat Med. 2020 Sep;26(9):1325-1326. doi: 10.1038/s41591-020-1035-9.


PMID- 32908260
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20211204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 585
IP  - 7824
DP  - 2020 Sep
TI  - The controversial company using DNA to sketch the faces of criminals.
PG  - 178-181
LID - 10.1038/d41586-020-02545-5 [doi]
FAU - Arnold, Carrie
AU  - Arnold C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Biometric Identification/ethics/*methods/*standards
MH  - China
MH  - *Criminals
MH  - DNA/*analysis
MH  - Ethnicity/genetics
MH  - Face/*anatomy & histology
MH  - Forensic Genetics/*ethics/*methods
MH  - Genetic Privacy/ethics
MH  - Humans
MH  - Law Enforcement/methods
MH  - Machine Learning
MH  - Male
MH  - Minority Groups
MH  - Pedigree
MH  - *Phenotype
MH  - Polymorphism, Single Nucleotide
MH  - Prejudice
MH  - Reproducibility of Results
MH  - Safety
MH  - United States
OTO - NOTNLM
OT  - *Ethics
OT  - *Genetics
OT  - *Society
EDAT- 2020/09/11 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/10 05:33
PHST- 2020/09/10 05:33 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1038/d41586-020-02545-5 [doi]
AID - 10.1038/d41586-020-02545-5 [pii]
PST - ppublish
SO  - Nature. 2020 Sep;585(7824):178-181. doi: 10.1038/d41586-020-02545-5.


PMID- 32907905
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Risk factors for disruptive behaviours: protocol for a systematic review and
      meta-analysis of quasi-experimental evidence.
PG  - e038258
LID - 10.1136/bmjopen-2020-038258 [doi]
AB  - INTRODUCTION: Disruptive behaviour disorders, including oppositional defiant
      disorder and conduct disorder, are a common set of diagnoses in childhood and
      adolescence, with global estimates of 5.7%, 3.6% and 2.1% for any disruptive
      disorder, oppositional defiant disorder and conduct disorder, respectively. There
      are high economic and social costs associated with disruptive behaviours and the 
      prevalence of these disorders has increased in recent years. As such, disruptive 
      behaviours represent an escalating major public health concern and it is
      important to understand what factors may influence the risk of these behaviours. 
      Such research would inform interventions that aim to prevent the development of
      disruptive behaviours. The current review will identify the most stringent
      evidence of putative risk factors for disruptive behaviour from
      quasi-experimental studies, which enable stronger causal inference. METHODS AND
      ANALYSIS: The review will be carried out according to Preferred Reporting Items
      for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An electronic
      search of references published between 1 January 1980 and 1 March 2020 will be
      conducted using Medline, Embase, PsycINFO and Web of Science. Initial abstract
      and title screening, full-text screening and data extraction will be completed
      independently by two reviewers using Evidence for Policy and Practice Information
      (EPPI)-Reviewer 4 software. Quasi-experimental studies in the English language
      examining the association between any putative risk factor and a clearly defined 
      measure of disruptive behaviour (eg, a validated questionnaire measure) will be
      included. We will conduct meta-analyses if we can pool a minimum of three similar
      studies with the same or similar exposures and outcomes. ETHICS AND
      DISSEMINATION: The proposed review does not require ethical approval. The results
      will help to identify risk factors for which there is strong evidence of causal
      effects on disruptive behaviours and also highlight potential risk factors that
      require further research. The findings will be disseminated via publication in a 
      peer-reviewed scientific journal and through presentations at international
      meetings and conferences. PROSPERO REGISTRATION NUMBER: CRD42020169313.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Karwatowska, Lucy
AU  - Karwatowska L
AUID- ORCID: 0000-0002-6519-5190
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK lucy.karwatowska.18@ucl.ac.uk.
FAU - Russell, Simon
AU  - Russell S
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Solmi, Francesca
AU  - Solmi F
AUID- ORCID: 0000-0003-0219-9503
AD  - Division of Psychiatry, University College London, London, UK.
FAU - De Stavola, Bianca Lucia
AU  - De Stavola BL
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Jaffee, Sara
AU  - Jaffee S
AD  - Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania,
      USA.
FAU - Pingault, Jean-Baptiste
AU  - Pingault JB
AD  - Department of Clinical, Educational and Health Psychology, University College
      London, London, UK.
AD  - Social, Genetic, and Developmental Psychiatry, King's College London, London, UK.
FAU - Viding, Essi
AU  - Viding E
AD  - Department of Clinical, Educational and Health Psychology, University College
      London, London, UK.
LA  - eng
GR  - 209196/Z/17/Z/WT_/Wellcome Trust/United Kingdom
GR  - ES/P000347/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Attention Deficit and Disruptive Behavior Disorders/epidemiology
MH  - *Conduct Disorder
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Problem Behavior
MH  - Public Health
MH  - Review Literature as Topic
MH  - Risk Factors
PMC - PMC7482491
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *epidemiology
OT  - *personality disorders
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/09/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/10 05:29
PHST- 2020/09/10 05:29 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038258 [pii]
AID - 10.1136/bmjopen-2020-038258 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e038258. doi: 10.1136/bmjopen-2020-038258.


PMID- 32907904
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Rationale and design of a randomised, double-blind, placebo-controlled,
      parallel-group, investigator-initiated phase 2a study to investigate the efficacy
      and safety of elobixibat in combination with cholestyramine for non-alcoholic
      fatty liver disease.
PG  - e037961
LID - 10.1136/bmjopen-2020-037961 [doi]
AB  - INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves
      abnormal metabolism of cholesterol and hepatic accumulation of toxic
      free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter.
      EXB and cholestyramine (CTM) facilitate the removal of free cholesterol from the 
      liver by decreasing BA recirculation to the liver, thereby stimulating novel BA
      synthesis from cholesterol. In this randomised, double-blind, placebo-controlled,
      parallel-group, phase IIa study, we aim to provide a proof-of-concept assessment 
      by evaluating the efficacy and safety of EXB in combination with CTM in patients 
      with NAFLD. METHODS AND ANALYSIS: A total of 100 adult patients with NAFLD,
      diagnosed based on low-density lipoprotein cholesterol (LDL-C) level of >120
      mg/dL and liver fat content of >/=8% by MRI-based proton density fat fraction
      (MRI-PDFF), who meet the inclusion/exclusion criteria will be enrolled. The
      patients will be randomly assigned to receive the combination therapy of 10 mg
      EXB and 9 g CTM powder (4 g CTM), 10 mg EXB monotherapy, 9 g CTM powder
      monotherapy or a placebo treatment (n=25 per group). Blood tests and MRIs will be
      performed 16 weeks following treatment initiation. The primary study endpoint
      will be the absolute LDL-C level change at week 16 after treatment initiation.
      The exploratory endpoint will include absolute changes in the liver fat fraction 
      as measured by MRI-PDFF. This proof-of-concept study will determine whether the
      combination therapy of EXB and CTM is effective and safe for patients with NAFLD.
      ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee 
      of Yokohama City University Hospital before participant enrolment. The results of
      this study will be submitted for publication in international peer-reviewed
      journals and the key findings will be presented at international scientific
      conferences. TRIAL REGISTRATION NUMBER: NCT04235205.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kessoku, Takaomi
AU  - Kessoku T
AUID- ORCID: 0000-0002-5587-1386
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
AD  - Department of Palliative Medicine, Yokohama City University Hospital, Yokohama,
      Japan.
FAU - Kobayashi, Takashi
AU  - Kobayashi T
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Ozaki, Anna
AU  - Ozaki A
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Iwaki, Michihiro
AU  - Iwaki M
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Honda, Yasushi
AU  - Honda Y
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
AD  - Department of Palliative Medicine, Yokohama City University Hospital, Yokohama,
      Japan.
FAU - Ogawa, Yuji
AU  - Ogawa Y
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Imajo, Kento
AU  - Imajo K
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Saigusa, Yusuke
AU  - Saigusa Y
AD  - Department of Biostatistics, Yokohama City University Graduate School of
      Medicine, Yokohama, Japan.
FAU - Yamamoto, Koji
AU  - Yamamoto K
AD  - Department of Biostatistics, Yokohama City University Graduate School of
      Medicine, Yokohama, Japan.
FAU - Yamanaka, Takeharu
AU  - Yamanaka T
AD  - Department of Biostatistics, Yokohama City University Graduate School of
      Medicine, Yokohama, Japan.
FAU - Usuda, Haruki
AU  - Usuda H
AD  - Department of Pharmacology, Shimane University Faculty of Medicine Graduate
      School of Medicine, Izumo, Shimane, Japan.
FAU - Wada, Koichiro
AU  - Wada K
AD  - Department of Pharmacology, Shimane University Faculty of Medicine Graduate
      School of Medicine, Izumo, Shimane, Japan.
FAU - Yoneda, Masato
AU  - Yoneda M
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Saito, Satoru
AU  - Saito S
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Nakajima, Atsushi
AU  - Nakajima A
AUID- ORCID: 0000-0002-6263-1436
AD  - Department of Gastroenterology and Hepatology, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan nakajima-tky@umin.ac.jp.
LA  - eng
SI  - ClinicalTrials.gov/NCT04235205
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Dipeptides)
RN  - 0 (Thiazepines)
RN  - 11041-12-6 (Cholestyramine Resin)
RN  - 865UEK4EJC (elobixibat)
SB  - IM
MH  - Adult
MH  - Cholestyramine Resin/therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Dipeptides
MH  - Double-Blind Method
MH  - Humans
MH  - *Non-alcoholic Fatty Liver Disease/diagnostic imaging/drug therapy
MH  - Proof of Concept Study
MH  - Randomized Controlled Trials as Topic
MH  - *Thiazepines
PMC - PMC7482497
OTO - NOTNLM
OT  - *adult gastroenterology
OT  - *clinical trials
OT  - *gastroenterology
OT  - *hepatobiliary disease
COIS- Competing interests: Data will be retained in accordance with the Japanese
      ethical guidelines for clinical research. Participants will be allocated a unique
      identification (ID) number at entry. The master list linking participant personal
      information and ID number will be maintained in a separate locked cabinet and
      password-protected hard drive. Data will be analysed by ID number only. Records
      will be retained for 5 years after study completion, and then destroyed by the
      data center. AN reports grants and research support from Gilead, Mylan EPD, EA
      Pharma, Kowa, Taisho, Biofermin; is a consulting adviser for Gilead, Boehringer
      Ingelheim, BMS, Kowa, Astellas, EA Pharma, Mylan EPD. Other authors declare no
      competing interests.
EDAT- 2020/09/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/10 05:29
PHST- 2020/09/10 05:29 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037961 [pii]
AID - 10.1136/bmjopen-2020-037961 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e037961. doi: 10.1136/bmjopen-2020-037961.


PMID- 32907901
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Microscopic decompressive laminectomy versus percutaneous endoscopic
      decompressive laminectomy in patients with lumbar spinal stenosis: protocol for a
      systematic review and meta-analysis.
PG  - e037096
LID - 10.1136/bmjopen-2020-037096 [doi]
AB  - INTRODUCTION: Lumbar spinal stenosis (LSS) is a common lumbar degenerative
      disease in the elderly, usually requiring surgery if conservative treatment
      fails. Microscopic decompressive laminectomy (MDL) and percutaneous endoscopic
      decompressive laminectomy (PEDL) have been widely used to treat LSS. This study
      aims to provide a protocol for the evaluation and comparison of the efficacy,
      safety and applicability between MDL and PEDL. METHODS AND ANALYSIS: We will
      search for randomised controlled trials (RCTs) comparing MDL and PEDL for
      treating LSS from inception to December 2019 in the following databases: PubMed, 
      The Cochrane Library, Web of Science, Embase and China Biology Medicine. The
      quality of included studies will be assessed using the risk of bias tool
      recommended by the Cochrane Handbook 5.2.0. Subsequently, a meta-analysis will be
      performed using RevMan 5.3 software. ETHICS AND DISSEMINATION: Given the nature
      of this study, no ethical approval will be required. The protocol will be
      disseminated via a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020164765.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Rong
AU  - Wang R
AD  - Department of Spine Surgery, Affiliated Hospital of Gansu University of Chinese
      Medicine, Lanzhou, Gansu, China.
FAU - Li, Xiuxia
AU  - Li X
AD  - Evidence-Based Social Science Research Center, School of Public Health, Lanzhou
      University, Lanzhou, Gansu, China.
AD  - Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu
      Province, Lanzhou, Gansu, China.
FAU - Zhang, Xiaogang
AU  - Zhang X
AD  - Department of Spine Surgery, Affiliated Hospital of Gansu University of Chinese
      Medicine, Lanzhou, Gansu, China.
FAU - Qin, Daping
AU  - Qin D
AD  - Department of Spine Surgery, Affiliated Hospital of Gansu University of Chinese
      Medicine, Lanzhou, Gansu, China.
FAU - Yang, Guodong
AU  - Yang G
AD  - Department of Spine Surgery, Affiliated Hospital of Gansu University of Chinese
      Medicine, Lanzhou, Gansu, China.
FAU - Gao, Guodong
AU  - Gao G
AD  - Department of Spine Surgery, Affiliated Hospital of Gansu University of Chinese
      Medicine, Lanzhou, Gansu, China major1982@163.com goodrunner@126.com.
FAU - Zhang, Hua
AU  - Zhang H
AUID- ORCID: 0000-0001-7688-8462
AD  - Department of Spine Surgery, Affiliated Hospital of Gansu University of Chinese
      Medicine, Lanzhou, Gansu, China major1982@163.com goodrunner@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - China
MH  - Endoscopy
MH  - Humans
MH  - Laminectomy
MH  - Lumbosacral Region
MH  - Meta-Analysis as Topic
MH  - *Spinal Stenosis/surgery
PMC - PMC7482472
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *orthopaedic & trauma surgery
OT  - *spine
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/09/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/10 05:29
PHST- 2020/09/10 05:29 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037096 [pii]
AID - 10.1136/bmjopen-2020-037096 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e037096. doi: 10.1136/bmjopen-2020-037096.


PMID- 32907900
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 9
TI  - Preferences of people with type 2 diabetes for telemedical lifestyle programmes
      in Germany: protocol of a discrete choice experiment.
PG  - e036995
LID - 10.1136/bmjopen-2020-036995 [doi]
AB  - INTRODUCTION: Telemedical lifestyle programmes for people with type 2 diabetes
      mellitus (T2DM) provide an opportunity to develop a healthier lifestyle and
      consequently to improve health outcomes. When implementing new programmes into
      standard care, considering patients' preferences may increase the success of the 
      participants. This study aims to examine the preferences of people with T2DM with
      respect to telemedical lifestyle programmes, to analyse whether these preferences
      predict programme success and to explore the changes that may occur during a
      telemedical lifestyle intervention. METHODS AND ANALYSIS: We outline the protocol
      of the development and assessment of a discrete choice experiment (DCE) to
      examine patient preferences in a telemedical lifestyle programme with regard to
      the functions of the online portal, communication, responsibilities, group
      activities and time requirements. To develop the design of the DCE, we conducted 
      pilot work involving healthcare experts and in particular people with T2DM using 
      cognitive pretesting. The final DCE is being implemented within a randomised
      controlled trial for investigating whether participation in a telemedical
      lifestyle intervention programme sustainably improves the HbA1c values in 850
      members of a large German statutory health insurance with T2DM. Preferences are
      being assessed before and after participants complete the programme. The DCE data
      will be analysed using regression and latent class analyses. ETHICS AND
      DISSEMINATION: The DCE study has been approved by the ethics committee of the
      medical faculty of the Heinrich Heine University Duesseldorf, registration number
      2018-242-ProspDEuA, registered on 6 December 2018. The TeLIPro trial is
      registered at the US National Library of Medicine, registration number
      NCT03675919, registered on 15 September 2018. We aim to disseminate our results
      in peer-reviewed journals, at national and international conferences and among
      interested patient groups and the public.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sommer, Jana
AU  - Sommer J
AUID- ORCID: 0000-0001-7262-5657
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine
      University, Duesseldorf, Germany jana.sommer@uni-duesseldorf.de.
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich Heine University, Duesseldorf,
      Germany.
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
FAU - Dyczmons, Jan
AU  - Dyczmons J
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine
      University, Duesseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich Heine University, Duesseldorf,
      Germany.
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
FAU - Grobosch, Sandra
AU  - Grobosch S
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine
      University, Duesseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich Heine University, Duesseldorf,
      Germany.
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
FAU - Gontscharuk, Veronika
AU  - Gontscharuk V
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine
      University, Duesseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich Heine University, Duesseldorf,
      Germany.
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
FAU - Vomhof, Markus
AU  - Vomhof M
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine
      University, Duesseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich Heine University, Duesseldorf,
      Germany.
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
FAU - Roden, Michael
AU  - Roden M
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
AD  - Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center 
      for Diabetes Research at the Heinrich Heine University, Duesseldorf, Germany.
AD  - Division of Endocrinology and Diabetology, Faculty of Medicine, Heinrich Heine
      University, Duesseldorf, Germany.
FAU - Icks, Andrea
AU  - Icks A
AD  - Institute for Health Services Research and Health Economics, German Diabetes
      Center (DDZ), Leibniz Center for Diabetes Research at the Heinrich Heine
      University, Duesseldorf, Germany.
AD  - Institute for Health Services Research and Health Economics, Centre for Health
      and Society, Faculty of Medicine, Heinrich Heine University, Duesseldorf,
      Germany.
AD  - German Center for Diabetes Research (DZD), Neuherberg, Germany.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200909
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Germany
MH  - Humans
MH  - Life Style
MH  - Patient Preference
MH  - Randomized Controlled Trials as Topic
MH  - *Telemedicine
PMC - PMC7482475
OTO - NOTNLM
OT  - *general diabetes
OT  - *health economics
OT  - *protocols & guidelines
OT  - *qualitative research
OT  - *statistics & research methods
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/09/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/10 05:29
PHST- 2020/09/10 05:29 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036995 [pii]
AID - 10.1136/bmjopen-2020-036995 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 9;10(9):e036995. doi: 10.1136/bmjopen-2020-036995.


PMID- 32907877
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20210110
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 96
IP  - 1140
DP  - 2020 Oct
TI  - Learning from the past in the COVID-19 era: rediscovery of quarantine, previous
      pandemics, origin of hospitals and national healthcare systems, and ethics in
      medicine.
PG  - 633-638
LID - 10.1136/postgradmedj-2020-138370 [doi]
AB  - After the dramatic coronavirus outbreak at the end of 2019 in Wuhan, Hubei
      province, China, on 11 March 2020, a pandemic was declared by the WHO. Most
      countries worldwide imposed a quarantine or lockdown to their citizens, in an
      attempt to prevent uncontrolled infection from spreading. Historically,
      quarantine is the 40-day period of forced isolation to prevent the spread of an
      infectious disease. In this educational paper, a historical overview from the
      sacred temples of ancient Greece-the cradle of medicine-to modern hospitals,
      along with the conceive of healthcare systems, is provided. A few foods for
      thought as to the conflict between ethics in medicine and shortage of personnel
      and financial resources in the coronavirus disease 2019 era are offered as well.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Bassareo, Pier Paolo
AU  - Bassareo PP
AUID- ORCID: http://orcid.org/0000-0002-8374-0260
AD  - Department of Cardiology, University College Dublin, Dublin, Ireland
      piercard@inwind.it.
FAU - Melis, Maria Rosaria
AU  - Melis MR
AD  - Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
FAU - Marras, Silvia
AU  - Marras S
AD  - Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
FAU - Calcaterra, Giuseppe
AU  - Calcaterra G
AD  - Department of Cardiology, University of Palermo, Palermo, Italy.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cholera/epidemiology/history
MH  - Coronavirus Infections/*epidemiology
MH  - Ethics, Medical/*history
MH  - Health Care Rationing/*ethics
MH  - Health Workforce
MH  - Hippocratic Oath
MH  - History, 15th Century
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Hospitals/*history
MH  - Humans
MH  - Leprosy/epidemiology/history
MH  - Pandemics/*history
MH  - Plague/epidemiology/history
MH  - Pneumonia, Viral/*epidemiology
MH  - Quarantine/*history
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - United States/epidemiology
PMC - PMC7439156
OTO - NOTNLM
OT  - Cardiology
OT  - congenital heart disease
OT  - echocardiography
OT  - paediatric cardiology
COIS- Competing interests: None declared.
EDAT- 2020/09/11 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/10 05:29
PHST- 2020/05/30 00:00 [received]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/09/10 05:29 [entrez]
AID - postgradmedj-2020-138370 [pii]
AID - 10.1136/postgradmedj-2020-138370 [doi]
PST - ppublish
SO  - Postgrad Med J. 2020 Oct;96(1140):633-638. doi: 10.1136/postgradmedj-2020-138370.
      Epub 2020 Sep 9.


PMID- 32907831
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20220531
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Immunity passports, fundamental rights and public health hazards: a reply to
      Brown et al.
PG  - 660-661
LID - 10.1136/medethics-2020-106814 [doi]
AB  - In their recent article, Brown et al analyse several ethical aspects around
      immunity passports and put forward some recommendations for implementing them.
      Although they offer a comprehensive perspective, they overlook two essential
      aspects. First, while the authors consider the possibility that immunological
      passports may appear to discriminate against those who do not possess them, the
      opposite viewpoint of immune people is underdeveloped. We argue that if a person 
      has been tested positive for and recovered from COVID-19, becoming immune to it, 
      she cannot be considered a hazard to public health and, therefore, the
      curtailment of her fundamental rights (eg, the right to freedom of movement) is
      not legitimate. Second, they omit that vaccine distribution will create similar
      problems related to immunity-based licenses. Vaccine certificates will de facto
      generate a sort of immunity passport. In the next phases of the pandemic,
      different immunity statuses will be at stake, because the need to identify who
      can spread COVID-19 is unavoidable. If a person does not pose a threat to public 
      health because she cannot spread the infection, then her right to freedom of
      movement should be respected, regardless of how she acquired that immunity.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - de Miguel Beriain, Inigo
AU  - de Miguel Beriain I
AUID- ORCID: 0000-0002-2650-5280
AD  - Derecho Publico, UPV/EHU, Bilbao, Spain.
AD  - Ikerbasque, Bilbao, Spain.
FAU - Rueda, Jon
AU  - Rueda J
AUID- ORCID: 0000-0001-5789-7515
AD  - Department of Philosophy 1, University of Granada, Granada, Spain
      ruetxe@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200909
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Oct;46(10):652-659. PMID: 32817362
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Female
MH  - Humans
MH  - *Immunity
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Public Health
MH  - SARS-CoV-2
PMC - PMC7525775
OTO - NOTNLM
OT  - *ethics
OT  - *law
OT  - *public policy
OT  - *rights
COIS- Competing interests: None declared.
EDAT- 2020/09/11 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/09/10 05:28
PHST- 2020/08/18 00:00 [received]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/09/10 05:28 [entrez]
AID - medethics-2020-106814 [pii]
AID - 10.1136/medethics-2020-106814 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):660-661. doi: 10.1136/medethics-2020-106814. Epub
      2020 Sep 9.


PMID- 32907778
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 253
DP  - 2020 Oct
TI  - Non-invasive prenatal diagnosis and screening for monogenic disorders.
PG  - 320-327
LID - S0301-2115(20)30503-0 [pii]
LID - 10.1016/j.ejogrb.2020.08.001 [doi]
AB  - Cell-free fetal DNA (cffDNA) can be detected in the maternal circulation from 4
      weeks gestation, and is present with cell-free maternal DNA at a level of between
      5 % and 20 %. Cell-free DNA (cfDNA) can be extracted from a maternal blood sample
      and, although it is not possible to separate the fetal from the maternal cfDNA,
      it has enabled non-invasive prenatal diagnosis (NIPD) without the associated
      miscarriage risk that accompanies invasive testing. NIPD for monogenic diseases
      was first reported in 2000 and since then there have been many proof of principle
      studies showing how analysis of cfDNA can provide a definitive diagnosis early in
      pregnancy for a wide range of single gene diseases. Testing for a number of these
      diseases has been available in the UK National Health Service (NHS) since 2012.
      This review highlights the main techniques that are being used for NIPD and
      discusses the technical limitations of the methods, as well as the advances that 
      are being made to overcome some of the issues. NIPD is technologically
      challenging for a number of reasons. Firstly, because it requires the detection
      of low level fetal variants in a high maternal background. For de novo and
      paternally-inherited variants this has been achieved through the use of
      techniques such as next-generation sequencing (NGS) and digital PCR to detect
      variants in the cffDNA that are not present in the maternal cfDNA. However, for
      maternally-inherited variants this is much more challenging and relies on
      dosage-based techniques to detect small differences in the levels of mutant and
      wild-type alleles. Alongside the technical advances that are making NIPD more
      widely available in both the public healthcare and commercial settings, it is
      crucial that we continue to monitor the social and ethical impact to ensure that 
      patients are being offered safe and accurate testing.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Scotchman, E
AU  - Scotchman E
AD  - North Thames Genomic Laboratory Hub, Great Ormond Street, NHS Foundation Trust,
      London, UK.
FAU - Shaw, J
AU  - Shaw J
AD  - North Thames Genomic Laboratory Hub, Great Ormond Street, NHS Foundation Trust,
      London, UK.
FAU - Paternoster, B
AU  - Paternoster B
AD  - North Thames Genomic Laboratory Hub, Great Ormond Street, NHS Foundation Trust,
      London, UK.
FAU - Chandler, N
AU  - Chandler N
AD  - North Thames Genomic Laboratory Hub, Great Ormond Street, NHS Foundation Trust,
      London, UK. Electronic address: natalie.chandler@gosh.nhs.uk.
FAU - Chitty, L S
AU  - Chitty LS
AD  - North Thames Genomic Laboratory Hub, Great Ormond Street, NHS Foundation Trust,
      London, UK; Genetic and Genomic Medicine, UCL Great Ormond Street Institute of
      Child Health, London, UK. Electronic address: l.chitty@ucl.ac.uk.
LA  - eng
GR  - RP-PG-0707-10107/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200807
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
RN  - 0 (Cell-Free Nucleic Acids)
SB  - IM
MH  - *Cell-Free Nucleic Acids
MH  - Female
MH  - Fetus
MH  - Humans
MH  - *Noninvasive Prenatal Testing
MH  - Pregnancy
MH  - Prenatal Diagnosis
MH  - State Medicine
OTO - NOTNLM
OT  - Cell-free fetal DNA
OT  - Monogenic disease
OT  - Non-invasive prenatal diagnosis
COIS- Declaration of Competing Interest LSC has had academic grants from the NIHR,
      Action Medical Research and GOSH Children's Charity for the development of NIPD. 
      The authors have no other relevant affiliations or financial involvement with any
      organization or entity with a financial interest in or financial conflict with
      the subject matter or materials discussed in the manuscript. This includes
      employment, consultancies, honoraria, stock ownership or options, expert
      testimony, or patents received or pending, or royalties.
EDAT- 2020/09/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/10 05:28
PHST- 2020/05/13 00:00 [received]
PHST- 2020/07/20 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/10 05:28 [entrez]
AID - S0301-2115(20)30503-0 [pii]
AID - 10.1016/j.ejogrb.2020.08.001 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2020 Oct;253:320-327. doi:
      10.1016/j.ejogrb.2020.08.001. Epub 2020 Aug 7.


PMID- 32907748
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 114
IP  - 6
DP  - 2020 Dec
TI  - Surgical approaches of drug-free in vitro activation and laparoscopic ovarian
      incision to treat patients with ovarian infertility.
PG  - 1355-1357
LID - S0015-0282(20)30682-8 [pii]
LID - 10.1016/j.fertnstert.2020.07.029 [doi]
AB  - OBJECTIVE: To demonstrate our procedures of drug-free in vitro activation (IVA)
      for treating patients with premature ovarian insufficiency (POI) or diminished
      ovarian reserve (DOR), as well as the laparoscopic ovarian incision (LOI)
      procedure for treating patients with resistant ovary syndrome (ROS). DESIGN:
      Step-by-step video demonstration of the surgical procedures. SETTING: Fertility
      clinic and reproductive medicine department. PATIENTS: Women were diagnosed with 
      POI based on recent amenorrhea before 40 years of age or with DOR according to
      the Bologna criteria, showing growth of a few antral follicles after ovarian
      stimulation. ROS patients were diagnosed based on amenorrhea with
      hypergonadotropic hypoestrogenism but showing age-appropriate number of antral
      follicles under transvaginal ultrasound. INTERVENTIONS: The drug-free IVA
      consists of the following 4 steps: removing a part of the cortex from one or both
      ovaries; cutting ovarian cortical pieces into small cubes in vitro; making
      pockets for ovarian tissue grafting; and grafting ovarian cortical cubes. The LOI
      procedure consisted of only one step: cutting ovarian cortex in situ. Both
      procedures were followed by ovarian hyperstimulation for at least 1 year.
      Informed consent was obtained from patients and approval was granted by the
      Biomedical Ethics Committee of the International University School of Medicine
      and the Rose Ladies Clinic. The present clinical trial was carried out in
      accordance with The Code of Ethics of the World Medical Association (Declaration 
      of Helsinki). MAIN OUTCOME MEASURE: Follicle growth. RESULTS: These procedures
      can be completed within 1 hour under laparoscopic surgery. There were no
      complications. In 13 of 15 patients treated with drug-free IVA, increases in
      antral follicle numbers were found, followed by a higher number of retrieved
      oocytes for in vitro fertilization. In addition to one spontaneous pregnancy,
      embryo transfer allowed four live births and one ongoing pregnancy. Five
      additional patients and one miscarriage patient have cryopreserved embryos for
      future transfer. We also found follicle growth to the preovulatory stage in seven
      of 11 ROS patients who have not responded to any endogenous and exogenous
      follicle-stimulating hormone stimulations for follicle growth prior to LOI
      treatment, allowing the retrieval of mature oocytes for in vitro fertilization.
      Four ROS patients became pregnant, followed by the delivery of three healthy
      infants and one ongoing pregnancy. CONCLUSION: A drug-free IVA approach provided 
      an infertility treatment for recent POI or DOR patients. This procedure promoted 
      growth of residual ovarian follicles following ovarian tissue fragmentation in
      vitro, leading to Hippo signaling disruption. Although ROS patients exhibited
      symptoms of hypergonadotropic hypoestrogenism similar to that of POI patients,
      they still had multiple secondary follicles. Hippo signaling disruption in vivo
      based on cutting ovarian cortex using LOI could promote follicle growth. UMIN
      CLINICAL TRIALS REGISTRATION NUMBER: UMIN000029807.
CI  - Copyright (c) 2020 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Tanaka, Yuka
AU  - Tanaka Y
AD  - Department of Obstetrics and Gynecology, International University School of
      Medicine, Chiba, Japan.
FAU - Hsueh, Aaron J
AU  - Hsueh AJ
AD  - Department of Obstetrics and Gynecology, Stanford University School of Medicine, 
      Stanford, California.
FAU - Kawamura, Kazuhiro
AU  - Kawamura K
AD  - Department of Obstetrics and Gynecology, International University School of
      Medicine, Chiba, Japan; Department of Obstetrics and Gynecology, Stanford
      University School of Medicine, Stanford, California. Electronic address:
      kazuhironanami@gmail.com.
LA  - eng
SI  - UMIN-CTR/UMIN000029807
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
DEP - 20200906
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
CIN - Fertil Steril. 2020 Dec;114(6):1197. PMID: 33280729
MH  - Female
MH  - Humans
MH  - Infertility, Female/diagnosis/physiopathology/*surgery
MH  - *Laparoscopy
MH  - Live Birth
MH  - *Ovarian Reserve
MH  - Ovary/physiopathology/*surgery
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Primary Ovarian Insufficiency/diagnosis/physiopathology/*surgery
MH  - *Reproductive Techniques, Assisted
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Hippo signaling
OT  - *Ovary
OT  - *follicle activation
OT  - *infertility
OT  - *laparoscopic surgery
EDAT- 2020/09/11 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/09/10 05:27
PHST- 2020/02/10 00:00 [received]
PHST- 2020/07/15 00:00 [revised]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/09/10 05:27 [entrez]
AID - S0015-0282(20)30682-8 [pii]
AID - 10.1016/j.fertnstert.2020.07.029 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Dec;114(6):1355-1357. doi: 10.1016/j.fertnstert.2020.07.029. 
      Epub 2020 Sep 6.


PMID- 32907421
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20220416
IS  - 1724-6067 (Electronic)
IS  - 1120-7000 (Linking)
VI  - 30
IP  - 1_suppl
DP  - 2020 Sep
TI  - Survival analysis after hip fracture: higher mortality than the general
      population and delayed surgery increases the risk at any time.
PG  - 54-58
LID - 10.1177/1120700020938029 [doi]
AB  - PURPOSE: To estimate survival curves in patients with hip fracture according to
      gender, age, type of fracture, and waiting time for surgery and to compare them
      with the life expectancy of the general population. The study hypothesis is that 
      survival after hip fractures is significantly lower than in the general
      population, especially in cases that underwent delayed surgery, regardless of age
      and gender. METHODS: A survival analysis study was designed and approved by our
      institutional ethics review board. All patients who were coded with a diagnosis
      of hip fracture from 2002 to 2018 were included in the study. A total of 1176
      patients were included, and the median age was 81 years (18-105 years).
      Kaplan-Meier curves and log-rank tests were performed to compare survival curves 
      between those who underwent surgery on time and those with surgical delays. An
      exponential multivariate regression model was estimated, and a hazard ratio (HR) 
      was reported for age, gender, and wait time for surgery. A significance of 5% was
      used, and a confidence interval level of 95% was reported. RESULTS: The
      Kaplan-Meier curves for delayed surgery (log-rank, p = 0.00) and the age group
      (log-rank, p = 0.00) were significantly different. Exponential regression
      estimated an HR 1.05 (1.05-1.07) for age, HR 1.80 (1.51-2.13) for men, and HR
      1.93 (1.61-2.31) for each day of wait for surgery. CONCLUSIONS: The 2 significant
      findings of this study are that hip fracture patients over 40 years old have a
      higher risk of dying at any time compared to the general population and that the 
      waiting time for surgery (a modifiable factor) decreases survival rates at any
      time.
FAU - Barahona, Maximiliano
AU  - Barahona M
AUID- ORCID: https://orcid.org/0000-0001-7878-8625
AD  - Orthopaedic Department, University of Chile Clinical Hospital, Santiago, Chile.
FAU - Barrientos, Cristian
AU  - Barrientos C
AD  - Orthopaedic Department, University of Chile Clinical Hospital, Santiago, Chile.
FAU - Cavada, Gabriel
AU  - Cavada G
AD  - Epidemiology Department, University of Chile, Santiago, Chile.
FAU - Branes, Julian
AU  - Branes J
AD  - Orthopaedic Department, University of Chile Clinical Hospital, Santiago, Chile.
FAU - Martinez, Alvaro
AU  - Martinez A
AD  - Orthopaedic Department, San Jose Hospital, Santiago, Chile.
FAU - Catalan, Jaime
AU  - Catalan J
AD  - Orthopaedic Department, University of Chile Clinical Hospital, Santiago, Chile.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Hip Int
JT  - Hip international : the journal of clinical and experimental research on hip
      pathology and therapy
JID - 9200413
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chile/epidemiology
MH  - Female
MH  - Fracture Fixation/*statistics & numerical data
MH  - Hip Fractures/*mortality/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Population Surveillance/*methods
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Survival Rate/trends
MH  - Time-to-Treatment
MH  - Young Adult
OTO - NOTNLM
OT  - Epidemiology
OT  - hip fracture
OT  - one-year mortality
OT  - survival Analysis
EDAT- 2020/09/11 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/09/10 05:25
PHST- 2020/09/10 05:25 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - 10.1177/1120700020938029 [doi]
PST - ppublish
SO  - Hip Int. 2020 Sep;30(1_suppl):54-58. doi: 10.1177/1120700020938029.


PMID- 32905735
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20211102
IS  - 1557-7759 (Electronic)
IS  - 1530-3667 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Considerations for Human Blood-Feeding and Arthropod Exposure in Vector Biology
      Research: An Essential Tool for Investigations and Disease Control.
PG  - 807-816
LID - 10.1089/vbz.2020.2620 [doi]
AB  - Eventually there may be a broadly acceptable, even perfected, substitute for the 
      human host requirement for direct feeding experiments by arthropods, most notably
      mosquitoes. However, for now, direct and indirect feeding on human volunteers is 
      an important, if not essential, tool in vector biology research (VBR). This
      article builds on the foundational publication by Achee et al. (2015) covering
      considerations for the use of human participants in VBR pursuits. The authors
      introduced methods involving human participation in VBR, while detailing
      human-landing collections (catches) as a prime example. Benedict et al. (2018)
      continued this theme with an overview of human participation and considerations
      for research that involves release of mosquito vectors into the environment. In
      this study, we discuss another important aspect of human use in VBR activities:
      considerations addressing studies that require an arthropod to feed on a live
      human host. Using mosquito studies as our principal example, in this study, we
      discuss the tremendous importance and value of this approach to support and allow
      study of a wide variety of factors and interactions related to our understanding 
      of vector-borne diseases and their control. This includes establishment of
      laboratory colonies for test populations, characterization of essential nutrients
      that contribute to mosquito fitness, characterization of blood-feeding (biting)
      behavior and pathogen transmission, parameterization for modeling transmission
      dynamics, evaluation of human host attraction and/or agents that repel, and the
      effectiveness of antivector or parasite therapeutic drug studies.
FAU - Harrington, Laura C
AU  - Harrington LC
AD  - Department of Entomology, Cornell University, Ithaca, New York, USA.
FAU - Foy, Brian D
AU  - Foy BD
AD  - Department of Microbiology, Immunology & Pathology, Arthropod-Borne and
      Infectious Diseases Laboratory Fort Collins, Colorado State University, Fort
      Collins, Colorado, USA.
FAU - Bangs, Michael J
AU  - Bangs MJ
AD  - Public Health & Malaria Control, PT Freeport Indonesia/International SOS, Kuala
      Kencana, Indonesia.
AD  - Department of Entomology, Faculty of Agriculture, Kasetsart University, Bangkok, 
      Thailand.
LA  - eng
GR  - R01 AI095491/AI/NIAID NIH HHS/United States
GR  - R21 AI129464/AI/NIAID NIH HHS/United States
GR  - U01 AI138910/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200909
PL  - United States
TA  - Vector Borne Zoonotic Dis
JT  - Vector borne and zoonotic diseases (Larchmont, N.Y.)
JID - 100965525
SB  - IM
MH  - Animals
MH  - Arthropod Vectors/*physiology
MH  - Arthropods/*physiology
MH  - Ethics Committees, Research
MH  - Feeding Behavior/*physiology
MH  - Humans
MH  - Research Personnel
MH  - Vector Borne Diseases/*blood/*transmission
PMC - PMC7698847
OTO - NOTNLM
OT  - *biosafety
OT  - *ethics
OT  - *human host
OT  - *human subjects
OT  - *vector biology research
OT  - *vector-borne diseases
EDAT- 2020/09/10 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/09/09 20:08
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2020/09/09 20:08 [entrez]
AID - 10.1089/vbz.2020.2620 [doi]
PST - ppublish
SO  - Vector Borne Zoonotic Dis. 2020 Nov;20(11):807-816. doi: 10.1089/vbz.2020.2620.
      Epub 2020 Sep 9.


PMID- 32905545
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210903
IS  - 0190-7409 (Print)
IS  - 0190-7409 (Linking)
VI  - 116
DP  - 2020 Sep
TI  - Adolescent perceptions about participating in HIV-related research studies.
LID - 105262 [pii]
LID - 10.1016/j.childyouth.2020.105262 [doi]
AB  - The rising incidence of infection among youth in sub-Saharan Africa makes
      HIV-related research among younger people a top priority. There remains, however,
      a lack of consistent and unambiguous ethical principles and guidance for
      researchers wishing to conduct HIV studies with adolescents. The overarching aim 
      of our research was to better understand youths' experiences with HIV studies.
      The present study explored four questions: (1) What strategies are effective for 
      recruiting youth for HIV studies? (2) What motivates youth to participate in
      these studies? (3) How do study participants perceive HIV testing within the
      context of a research study? (4) What do participants understand about the risks 
      of study participation? These data are essential to inform guidelines for the
      responsible conduct of research with young people. We interviewed 82 adolescents 
      (aged 15-19) in Kenya taking part in a study examining ethical issues pertaining 
      to their involvement in HIV-related research. Pursuant to our research questions,
      we found that direct study recruitment combined with encouragement from female
      relatives was the greatest facilitator to study enrolment among young people.
      Most young participants expressed that they were motivated to join the study in
      order to (1) learn their HIV status (n = 49) and (2) receive HIV-related
      education (n = 26), even though both are already free and widely available.
      Participants largely preferred testing in a place they deemed "private," although
      both the health clinic and home were regarded by adolescents as locations with
      greater privacy. Adolescents largely did not accurately perceive risks of the
      study two months after baseline, although they could remember the benefits with
      great clarity. This work can inform researchers, policymakers, and ethics review 
      committees on approaches to maximize efficiency in recruitment and data
      collection, and to enhance understanding of risks and benefits in HIV-related
      research among adolescents. While further research is needed, these data may be
      used by others conducting HIV research in this region to improve recruitment
      strategies and more effectively engage and appeal to young people.
FAU - Simons-Rudolph, A P
AU  - Simons-Rudolph AP
AD  - Pacific Institute for Research and Evaluation (PIRE), Chapel Hill, USA.
FAU - Iritani, B J
AU  - Iritani BJ
AD  - Pacific Institute for Research and Evaluation (PIRE), Chapel Hill, USA.
FAU - Odongo, F S
AU  - Odongo FS
AD  - Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
FAU - Rennie, S
AU  - Rennie S
AD  - Department of Social Medicine, UNC Center for Bioethics, University of North
      Carolina at Chapel Hill, Chapel Hill, USA.
FAU - Gilbertson, A
AU  - Gilbertson A
AD  - Pacific Institute for Research and Evaluation (PIRE), Chapel Hill, USA.
FAU - Kwaro, D
AU  - Kwaro D
AD  - Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
FAU - Luseno, W K
AU  - Luseno WK
AD  - Pacific Institute for Research and Evaluation (PIRE), Chapel Hill, USA.
LA  - eng
GR  - R01 MH102125/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20200718
PL  - United States
TA  - Child Youth Serv Rev
JT  - Children and youth services review
JID - 8110100
PMC - PMC7472997
MID - NIHMS1616776
OTO - NOTNLM
OT  - Adolescents
OT  - Ethics
OT  - HIV
OT  - Kenya
OT  - Participation
OT  - Recruitment
OT  - Research
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:15
PHST- 2020/09/09 18:15 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1016/j.childyouth.2020.105262 [doi]
PST - ppublish
SO  - Child Youth Serv Rev. 2020 Sep;116. doi: 10.1016/j.childyouth.2020.105262. Epub
      2020 Jul 18.


PMID- 32905295
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2048-8505 (Print)
IS  - 2048-8505 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Aug
TI  - Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it
      time to treat or time to wait?
PG  - 513-521
LID - 10.1093/ckj/sfz187 [doi]
AB  - Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the many
      important complications associated with CKD and may at least partially explain
      the extremely high morbidity and mortality among CKD patients. The 2009 Kidney
      Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline document
      was based on the best information available at that time and was designed not
      only to provide information but also to assist in decision-making. In addition to
      the international KDIGO Work Group, which included worldwide experts, an
      independent Evidence Review Team was assembled to ensure rigorous review and
      grading of the existing evidence. Based on the evidence from new clinical trials,
      an updated Clinical Practice Guideline was published in 2017. In this review, we 
      focus on the conceptual and practical evolution of clinical guidelines (from
      eMinence-based medicine to eVidence-based medicine and 'living' guidelines),
      highlight some of the current important CKD-MBD-related changes, and underline
      the poor or extremely poor level of evidence present in those guidelines (as well
      as in other areas of nephrology). Finally, we emphasize the importance of
      individualization of treatments and shared decision-making (based on important
      ethical considerations and the 'best available evidence'), which may prove useful
      in the face of the uncertainty over the decision whether 'to treat' or 'to wait'.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      ERA-EDTA.
FAU - Bover, Jordi
AU  - Bover J
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Urena-Torres, Pablo
AU  - Urena-Torres P
AD  - Department of Dialysis, AURA Nord Saint Ouen, Saint Ouen and Department of Renal 
      Physiology, Necker Hospital, University of Paris Descartes, Paris, France.
FAU - Mateu, Silvia
AU  - Mateu S
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - DaSilva, Iara
AU  - DaSilva I
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Gracia, Silvia
AU  - Gracia S
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Sanchez-Baya, Maya
AU  - Sanchez-Baya M
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Arana, Carolt
AU  - Arana C
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Fayos, Leonor
AU  - Fayos L
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Guirado, Lluis
AU  - Guirado L
AD  - Fundacio Puigvert, Department of Nephrology, IIB Sant Pau, RedinRen, Barcelona,
      Catalonia, Spain.
FAU - Cozzolino, Mario
AU  - Cozzolino M
AUID- ORCID: 0000-0002-8494-6252
AD  - Renal Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University
      of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200125
PL  - England
TA  - Clin Kidney J
JT  - Clinical kidney journal
JID - 101579321
PMC - PMC7467585
OTO - NOTNLM
OT  - CKD
OT  - CKD-MBD
OT  - EBM
OT  - KDIGO
OT  - evidence-based medicine
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:13
PHST- 2019/09/24 00:00 [received]
PHST- 2019/12/02 00:00 [accepted]
PHST- 2020/09/09 18:13 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1093/ckj/sfz187 [doi]
AID - sfz187 [pii]
PST - epublish
SO  - Clin Kidney J. 2020 Jan 25;13(4):513-521. doi: 10.1093/ckj/sfz187. eCollection
      2020 Aug.


PMID- 32905210
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2056-7529 (Electronic)
IS  - 2056-7529 (Linking)
VI  - 6
DP  - 2020
TI  - Educational content and challenges encountered when training service user
      representatives as peer researchers in a mixed study on patient experience of
      hospital safety.
PG  - 50
LID - 10.1186/s40900-020-00226-1 [doi]
AB  - BACKGROUND AND OBJECTIVES: In France, following the passing of a 2002 law,
      service user representatives (SURs) are part of hospital committees in charge of 
      care quality and safety issues. Ten service user representatives (SURs) were
      recruited and trained as "peer researchers" to participate in all phases of a
      study aimed at outlining how patients experience hospital safety. This article
      aims to describe the study protocol and how peer researchers training was
      designed and implemented to prepare them to drive a qualitative and quantitative 
      research. It also examines the challenges related to collaborative research and
      how these were resolved. METHODS: The way our training was conceived belongs to
      the field of "design-based research", known for its pragmatic and collaborative
      scope, in which viewpoints of all participants are included. Our training was
      therefore based on peer researchers and research sponsors expectations, as well
      as on recommendations of the literature. RESULTS: A 45-h training was held. While
      the program was meant to train peer researchers to respect scientific norms, it
      also aimed to improve their sense of self-legitimacy as they navigated their new 
      role. Peer researchers were particularly eager to understand meaning behind the
      instructions, especially in the field of ethical and scientific norms. Various
      challenges occurred related to project organization, recruitment and peer
      researchers involvement. Some issues were overcome by learning how to share
      control over the research process. CONCLUSION: This experiment highlights the
      importance of a training program's duration and quality to prepare SURs for their
      roles as peer investigators and to create a group dynamic around a research
      project, even with SURs familiar with patient involvement and our research theme 
      (safety issues). Trainers overcame hurdles by being adaptive and by using
      educational approaches. They also learned to include trainees' input, even when
      it forced them to reconsider their own assumptions.
CI  - (c) The Author(s) 2020.
FAU - Gross, O
AU  - Gross O
AUID- ORCID: 0000-0002-1078-2742
AD  - Health Education and Practices Laboratory (LEPS UR3412) University Sorbonne Paris
      Nord, 74 rue Marcel Cachin, 93017 Bobigny, France.grid.462844.80000 0001 2308
      1657
FAU - Garabedian, N
AU  - Garabedian N
AD  - Hopital Necker-Enfants Malades, President of the medical board of Paris
      Universities Hospitals, Paris, France.grid.412134.10000 0004 0593 9113
FAU - Richard, C
AU  - Richard C
AD  - Hopital Bicetre, Member of the medical board of Paris Universities Hospitals, Le 
      Kremlin-Bicetre, France.grid.413784.d0000 0001 2181 7253
FAU - Citrini, M
AU  - Citrini M
AD  - AP-HP service user representative, Association Creteil Respire A Coeur (Society
      of respiratory diseases), 38, rue des Blancs Manteaux, 75004 Paris,
      France.grid.50550.350000 0001 2175 4109
FAU - Sannie, T
AU  - Sannie T
AD  - AP-HP service user representative, Association francaise des hemophiles (French
      Hemophiliacs Society), 6 rue Alexandre Cabanel, 75015 Paris,
      France.grid.50550.350000 0001 2175 4109
FAU - Gagnayre, R
AU  - Gagnayre R
AD  - Health Education and Practices Laboratory (LEPS UR3412) University Sorbonne Paris
      Nord, 74 rue Marcel Cachin, 93017 Bobigny, France.grid.462844.80000 0001 2308
      1657
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - England
TA  - Res Involv Engagem
JT  - Research involvement and engagement
JID - 101708164
PMC - PMC7466417
OTO - NOTNLM
OT  - Hospital safety
OT  - Participative research
OT  - Patient and public involvement
OT  - Peer interviewers
OT  - Training
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:12
PHST- 2019/04/11 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/09/09 18:12 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1186/s40900-020-00226-1 [doi]
AID - 226 [pii]
PST - epublish
SO  - Res Involv Engagem. 2020 Sep 1;6:50. doi: 10.1186/s40900-020-00226-1. eCollection
      2020.


PMID- 32905183
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0970-0218 (Print)
IS  - 0970-0218 (Linking)
VI  - 45
IP  - 2
DP  - 2020 Apr-Jun
TI  - Perspectives about Professionalism among Undergraduate Students in a Medical
      College in India: A Qualitative Study.
PG  - 230-234
LID - 10.4103/ijcm.IJCM_238_19 [doi]
AB  - BACKGROUND: Professionalism has been recognized as an important competency of a
      doctor by various regulatory bodies. OBJECTIVES: The purpose of the study was to 
      explore the perceptions of medical undergraduate students and to assess their
      attitude on professionalism. MATERIALS AND METHODS: It was a qualitative study in
      which four focus group discussions were conducted, one for each year of course.
      RESULTS: A total of seven themes emerged after the qualitative analysis of the
      data, namely qualities of a good doctor, need of teaching professionalism, ways
      of learning professionalism by medical students, ways of teaching
      professionalism, assessment of professionalism, factors promoting
      professionalism, and factors hindering professionalism. The students perceived
      that a good doctor should be committed to excellence, responsive and accountable 
      to patients, profession and community, selfless, healthy, good communicator,
      ethical and law abiding, practice integrity, and social justice. The students
      preferred to learn professionalism by role modeling by faculties and case-based
      scenario discussions. CONCLUSION: Medical undergraduate students should be
      briefed about the need and importance of professionalism through small-group
      discussions involving narratives, case scenarios, and role modeling by faculty.
      Professionalism of both students and faculties should be assessed and appropriate
      action taken.
CI  - Copyright: (c) 2020 Indian Journal of Community Medicine.
FAU - Dhikale, Prasad Tukaram
AU  - Dhikale PT
AD  - Department of Community Medicine, Hinduhridaysamrat Balasaheb Thackrey Medical
      College and Dr. R N Cooper Hospital, Mumbai, Maharashtra, India.
FAU - Shrivastava, Saurabh RamBihariLal
AU  - Shrivastava SR
AD  - Department of Community Medicine, Shri Sathya Sai Medical College and Research
      Institute, Sri Balaji Vidyapeeth - Deemed to be University, Ammapettai,
      Nellikuppam, Chengalpet District, Tamil Nadu, India.
FAU - Srinivasan, Srikanth
AU  - Srinivasan S
AD  - Department of Community Medicine and Family Medicine, AIIMS, Jodhpur, Rajasthan, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - India
TA  - Indian J Community Med
JT  - Indian journal of community medicine : official publication of Indian Association
      of Preventive & Social Medicine
JID - 9315574
PMC - PMC7467191
OTO - NOTNLM
OT  - Medical education
OT  - perspectives
OT  - professional identity development
OT  - professionalism
OT  - role models
OT  - undergraduate medical students
COIS- There are no conflicts of interest.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:11
PHST- 2019/06/05 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/09/09 18:11 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.4103/ijcm.IJCM_238_19 [doi]
AID - IJCM-45-230 [pii]
PST - ppublish
SO  - Indian J Community Med. 2020 Apr-Jun;45(2):230-234. doi:
      10.4103/ijcm.IJCM_238_19. Epub 2020 Jun 2.


PMID- 32905124
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2515-2092 (Electronic)
IS  - 2515-2084 (Linking)
VI  - 3
IP  - 5
DP  - 2020 Oct
TI  - The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with
      Inflammatory Bowel Disease Living in Alberta.
PG  - 234-242
LID - 10.1093/jcag/gwz044 [doi]
AB  - A nonmedical switch policy is currently being considered in Alberta, which would 
      force patients on originator biologics to biosimilar alternatives with the
      hypothetical aim of reducing costs to the health care system. The evidence to
      support the safety of nonmedical switching in patients with inflammatory bowel
      disease (IBD) is of low to very low quality; in fact, existing data suggest a
      potential risk of harm. In a pooled analysis of randomized controlled trials, one
      patient would lose response to infliximab for every 11 patients undergoing
      nonmedical switching. Switching to a biosimilar has important logistical and
      ethical implications including potential forced treatment changes without
      appropriate patient consent and unfairly penalizing patients living in rural
      areas and those without private drug insurance. Even in the best-case scenario,
      assuming perfectly executed switching without logistical delays, we predict
      switching 2,000 patients with Remicade will lead to over 60 avoidable surgeries
      in Alberta. Furthermore, nonmedical switching has not been adequately studied in 
      vulnerable populations such as children, pregnant women, and elderly patients.
      While the crux of the argument for nonmedical switching is cost savings,
      biosimilar switching may not be cost effective: Particularly when originator
      therapies are being offered at the same price as biosimilars. Canadian patients
      with IBD have been surveyed, and their response is clear: They are not in support
      of nonmedical switching. Policies that directly influence patient health need to 
      consider patient perspectives. Solutions to improve cost efficiency in health
      care exist but open, transparent collaboration between all involved stakeholders 
      is required.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Canadian Association of Gastroenterology.
FAU - Kaplan, Gilaad G
AU  - Kaplan GG
AUID- ORCID: 0000-0003-2719-0556
AD  - Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Ma, Christopher
AU  - Ma C
AUID- ORCID: 0000-0002-4698-9948
AD  - Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Seow, Cynthia H
AU  - Seow CH
AUID- ORCID: 0000-0002-1551-9054
AD  - Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Kroeker, Karen I
AU  - Kroeker KI
AD  - Inflammatory Bowel Disease Clinic, Department of Medicine, University of Alberta,
      Edmonton, Alberta, Canada.
FAU - Panaccione, Remo
AU  - Panaccione R
AD  - Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200124
PL  - England
TA  - J Can Assoc Gastroenterol
JT  - Journal of the Canadian Association of Gastroenterology
JID - 101738684
PMC - PMC7465546
OTO - NOTNLM
OT  - Biologic
OT  - Biosimilar
OT  - Inflammatroy bowel disease
OT  - Infliximab
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:11
PHST- 2019/11/30 00:00 [received]
PHST- 2019/12/16 00:00 [accepted]
PHST- 2020/09/09 18:11 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1093/jcag/gwz044 [doi]
AID - gwz044 [pii]
PST - ppublish
SO  - J Can Assoc Gastroenterol. 2020 Oct;3(5):234-242. doi: 10.1093/jcag/gwz044. Epub 
      2020 Jan 24.


PMID- 32905067
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2515-2092 (Electronic)
IS  - 2515-2084 (Linking)
VI  - 3
IP  - 5
DP  - 2020 Oct
TI  - The Law and Ethics of Switching from Biologic to Biosimilar in Canada.
PG  - 228-233
LID - 10.1093/jcag/gwz043 [doi]
AB  - Governments and financial institutions in several jurisdictions are planning or
      implementing nonmedical/'forced' switches by cutting drug coverage for reference 
      biologics and funding only less expensive biosimilars. Switches raise numerous
      ethical and legal challenges, as the drugs are framed as not being identical and,
      despite strong evidence for noninferiority of some biosimilars, there is
      controversy over whether switching can sometimes lead to adverse events. Canadian
      law generally requires physicians to give precedence to their patients' best
      interests over social interests such as cost containment. The primacy of
      patients' interests is also clearly reflected in professional policies and codes 
      of ethics. Moreover, physicians are obligated to disclose everything a reasonable
      person in the patient's position would want to know when obtaining informed
      consent for treatment, including addressing not only scientific information but
      also relevant social controversy about nonmedical switches. Under Canadian law,
      physicians may be obligated to tell patients about the ability to access unfunded
      biologics, even if patients lack the resources to obtain them. In sum, while
      there is no inherent right to funding for reference biologics in Canada,
      physicians in some circumstances may have a legal obligation as fiduciaries to
      advocate on behalf of patients to remain on a reference biologic. At a minimum,
      the controversy surrounding switching will necessitate, as part of the consent
      process, a robust and thorough disclosure of relevant risks, benefits and
      reasonable alternatives.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Canadian Association of Gastroenterology.
FAU - Murdoch, Blake
AU  - Murdoch B
AUID- ORCID: 0000-0003-4654-1980
AD  - Health Law Institute, Faculty of Law, University of Alberta, Edmonton, Alberta,
      Canada.
FAU - Caulfield, Timothy
AU  - Caulfield T
AD  - Health Law Institute, Faculty of Law, University of Alberta, Edmonton, Alberta,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200103
PL  - England
TA  - J Can Assoc Gastroenterol
JT  - Journal of the Canadian Association of Gastroenterology
JID - 101738684
PMC - PMC7465550
OTO - NOTNLM
OT  - Biologics and biosimilars
OT  - Health law
OT  - Physician obligation
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:10
PHST- 2020/09/09 18:10 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1093/jcag/gwz043 [doi]
AID - gwz043 [pii]
PST - ppublish
SO  - J Can Assoc Gastroenterol. 2020 Oct;3(5):228-233. doi: 10.1093/jcag/gwz043. Epub 
      2020 Jan 3.


PMID- 32904882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1472-3891 (Print)
IS  - 1472-3891 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Nov
TI  - The role of university teaching staff members in cognitive awareness and raising 
      the level of health protection, value, and moral of students through the COVID-19
      pandemic.
PG  - e2332
LID - 10.1002/pa.2332 [doi]
AB  - This study aimed to detect the role of teaching staff members in increasing
      university students' awareness, health protection, moral, and value aspects
      through the e-learning, and to reveal the differences in the level of the
      teaching staff members about their roles due to the path of college, academic
      degree, and academic experience. To achieve these aims of the study, the
      descriptive method was applied. The study sample consisted of (101) teaching
      stuff member in health, scientific, and human specializations at Princess Nourah 
      Bint Abdul Rahman University in Saudi Arabia. The researchers designed a
      questionnaire to collect the data that reflects the perceptions of teaching staff
      members about their cognitive, skill, health, and ethical roles toward responding
      to the COVID-19 pandemic through distance education. The results indicated that
      there are high levels of teaching staff members' perception of their skill,
      health, and ethical responsibilities to raise students' awareness about the
      COVID-19 pandemic, while the level of teaching staff members' perception of their
      cognitive responsibilities to raise students' awareness about the COVID-19
      pandemic was average. The findings indicated there are differences in the
      perception of the teaching staff members of their cognitive, skill, health, and
      moral value responsibilities to raise students' awareness about the COVID-19.
CI  - (c) 2020 The Authors. Journal of Public Affairs published by John Wiley & Sons
      Ltd.
FAU - Al-Hosan, Amani M
AU  - Al-Hosan AM
AD  - Faculty of Education Princess Nourah bint Abdulrahman University Riyadh Saudi
      Arabia.
FAU - AlRajeh, Nawal M
AU  - AlRajeh NM
AD  - Faculty of Education Princess Nourah bint Abdulrahman University Riyadh Saudi
      Arabia.
FAU - Arnout, Boshra A
AU  - Arnout BA
AUID- ORCID: https://orcid.org/0000-0003-3418-5667
AD  - Department of Psychology Faculty of Education, King Khalid University Abha Saudi 
      Arabia.
AD  - Department of Psychology Faculty of Arts, Zagazig University Zagazig Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - England
TA  - J Public Aff
JT  - Journal of public affairs
JID - 101668855
PMC - PMC7460939
COIS- The authors of this manuscript declare that they have no conflict of interests.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:08
PHST- 2020/06/25 00:00 [received]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/07/25 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
PHST- 2020/09/09 18:08 [entrez]
AID - 10.1002/pa.2332 [doi]
AID - PA2332 [pii]
PST - ppublish
SO  - J Public Aff. 2020 Nov;20(4):e2332. doi: 10.1002/pa.2332. Epub 2020 Aug 19.


PMID- 32904792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1925-8348 (Print)
IS  - 1925-8348 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Pandemic Dementia Scarce Resource Allocation.
PG  - 216-218
LID - 10.5770/cgj.23.457 [doi]
AB  - Hospitals and intensive care units are straining to provide care for a large
      surge of patients with coronavirus disease 19 (Covid-19). Contingency plans are
      being made for the possibility that resources for lifesaving care, including
      mechanical ventilators, will be in short supply. Covid-19 is more severe and more
      likely to be fatal in older persons. Dementia is one of the commonest severe
      comorbidities of aging. Persons with dementia are vulnerable and often need the
      support of others to make their voices heard. This commentary, created by a task 
      force commissioned by the Alzheimer Society of Canada, provides guidance for
      triaging persons with dementia to scarce medical resources during the Covid-19
      pandemic.
CI  - (c) 2020 Author(s). Published by the Canadian Geriatrics Society.
FAU - Smith, Eric E
AU  - Smith EE
AD  - Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of
      Calgary, Calgary, AB.
FAU - Couillard, Philippe
AU  - Couillard P
AD  - Department of Clinical Neurosciences and Department of Critical Care Medicine,
      Hotchkiss Brain Institute, University of Calgary, Calgary, AB.
FAU - Fisk, John D
AU  - Fisk JD
AD  - Nova Scotia Health Authority, Halifax, and Department of Psychiatry, Dalhousie
      University, Halifax, NS.
FAU - Ismail, Zahinoor
AU  - Ismail Z
AD  - Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary,
      Calgary, AB.
FAU - Montero-Odasso, Manuel
AU  - Montero-Odasso M
AD  - Departments of Medicine (Geriatrics), and Epidemiology and Biostatistics, The
      University of Western Ontario, London; Lawson Health Research Institute, Gait and
      Brain Lab, University of Western Ontario, London, ON.
FAU - Robillard, Julie M
AU  - Robillard JM
AD  - Department of Medicine, University of British Columbia, Vancouver; BC Children's 
      & Women's Hospital, Vancouver, BC.
FAU - Vedel, Isabelle
AU  - Vedel I
AD  - Department of Family Medicine, McGill University, Montreal, QC.
FAU - Sivananthan, Saskia
AU  - Sivananthan S
AD  - Alzheimer Society of Canada, Toronto, ON.
FAU - Gauthier, Serge
AU  - Gauthier S
AD  - Departments of Neurology, Neurosurgery and Psychiatry, McGill University,
      Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - Canada
TA  - Can Geriatr J
JT  - Canadian geriatrics journal : CGJ
JID - 101579189
PMC - PMC7458602
OTO - NOTNLM
OT  - COVID-19
OT  - critical care
OT  - dementia
OT  - ethics
OT  - mechanical ventilation
COIS- CONFLICT OF INTEREST DISCLOSURES The authors declare that no conflicts of
      interest exist.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:07
PHST- 2020/09/09 18:07 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.5770/cgj.23.457 [doi]
AID - cgj-23-216 [pii]
PST - epublish
SO  - Can Geriatr J. 2020 Sep 1;23(3):216-218. doi: 10.5770/cgj.23.457. eCollection
      2020 Sep.


PMID- 32904653
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1179-1594 (Print)
IS  - 1179-1594 (Linking)
VI  - 13
DP  - 2020
TI  - Dental Facilities During the New Corona Outbreak: A SWOT Analysis.
PG  - 1343-1352
LID - 10.2147/RMHP.S265998 [doi]
AB  - Recently, there have been many global outbreaks of diseases. The latest is the
      coronavirus disease of 2019 (COVID-19) pandemic. The virus has spread worldwide
      and is transmitted mainly through droplets or by touching contaminated surfaces. 
      Globally, healthcare systems are challenged due to a lack of workplace safety and
      professional obligations in addition to the rapid spread of the virus. Dental
      facilities are at greater risk due to the nature of dental care. The aim of this 
      review study was to provide a situational analysis within dental facilities
      during the new COVID-19 outbreak. Published papers concerning dental facilities
      and COVID-19 were retrieved from PubMed, search engines, and organizational
      websites. All data were reviewed, arranged into themes, and then categorized
      either as strengths or weaknesses with respect to addressing the COVID-19
      pandemic in dental facilities, and accordingly, threats and possible
      opportunities to the handling of the pandemic were identified. Preparedness of
      dental facilities during the current pandemic is a weakness that needs to be
      addressed promptly. Shortage of dental care providers, cyber security, economic
      losses, and ethical challenges are possible threats due to the current outbreak. 
      Coordination and prompt communication among all healthcare providers during such 
      outbreaks is a strength that needs to be supported. This strengths, weaknesses,
      opportunities, and threats (SWOT) analysis can be a useful tool for guiding
      decision-making as it is crucial during the current pandemic to work on
      weaknesses, avoid threats, and utilize all future opportunities.
CI  - (c) 2020 Gaffar et al.
FAU - Gaffar, Balgis
AU  - Gaffar B
AUID- ORCID: 0000-0001-7593-1887
AD  - Preventive Dental Sciences Department, College of Dentistry, Imam Abdulrahman Bin
      Faisal University, Dammam, Saudi Arabia.
FAU - Alhumaid, Jehan
AU  - Alhumaid J
AD  - Preventive Dental Sciences Department, College of Dentistry, Imam Abdulrahman Bin
      Faisal University, Dammam, Saudi Arabia.
FAU - Alhareky, Muhanad
AU  - Alhareky M
AD  - Preventive Dental Sciences Department, College of Dentistry, Imam Abdulrahman Bin
      Faisal University, Dammam, Saudi Arabia.
FAU - Alonaizan, Faisal
AU  - Alonaizan F
AD  - Restorative Dental Sciences Department, College of Dentistry, Imam Abdulrahman
      Bin Faisal University, Dammam,Saudi Arabia.
FAU - Almas, Khalid
AU  - Almas K
AUID- ORCID: 0000-0002-2552-587X
AD  - Preventive Dental Sciences Department, College of Dentistry, Imam Abdulrahman Bin
      Faisal University, Dammam, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - England
TA  - Risk Manag Healthc Policy
JT  - Risk management and healthcare policy
JID - 101566264
PMC - PMC7457593
OTO - NOTNLM
OT  - COVID-19
OT  - SWOT
OT  - challenges
OT  - dental clinics
OT  - preparedness
COIS- The authors declare no conflicts of interest for this work.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:06
PHST- 2020/06/03 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/09/09 18:06 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.2147/RMHP.S265998 [doi]
AID - 265998 [pii]
PST - epublish
SO  - Risk Manag Healthc Policy. 2020 Aug 25;13:1343-1352. doi: 10.2147/RMHP.S265998.
      eCollection 2020.


PMID- 32904226
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 8
DP  - 2020 Aug
TI  - What we do on social media! Social representations of schoolchildren's activities
      on electronic communication platforms.
PG  - e04584
LID - 10.1016/j.heliyon.2020.e04584 [doi]
AB  - Researchers might be wondering whether the use of social media by students raises
      any ethical issues? It is my opinion that with the astronomical increase in the
      use of social networking websites or platforms by students, ethical issues are
      progressively important. The astronomical increase in the use of social
      networking platforms by minors raises ethical questions in school ecologies. This
      study investigated the ethical issues in social media usage among secondary
      school students in a developing context. A semi-structured questionnaire that
      elicited information on the school children's home background, social media
      operated, and mode of connection to the social media was used to collect data.
      The questionnaire gave the students the opportunity to write their responses to
      the interview questions freely. Mixed methods such as constant comparative
      techniques and descriptive statistical methods were used to analyze data from the
      one hundred and thirty school children that participated in this research. The
      results indicated that Facebook is the most operated social networking website by
      the selected schoolchildren. Most of the schoolchildren operating the popular
      social networking accounts signed up before the age of thirteen with the help of 
      their biological sisters and brothers. Themes such as cyber pornography, sexting,
      cyber stalking, cyber bullying, cyber hacking, and abusive language emanated from
      the individual qualitative interviews. The concluding part of this article
      answers questions on the impact of new communication technologies on
      psycho-social adjustment of school children in developing countries.
CI  - (c) 2020 The Author(s).
FAU - Ige, Olugbenga A
AU  - Ige OA
AD  - University of the Free State, Bloemfontein Campus, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7452393
OTO - NOTNLM
OT  - Abusive language
OT  - Cyber bullying
OT  - Cyber hacking
OT  - Cyber pornography
OT  - Cyber sexting
OT  - Cyber stalking
OT  - Education
OT  - Electronic communication platforms
OT  - Ethical issues
OT  - Facebook
OT  - Information science
OT  - Media education
OT  - Media use
OT  - School children
OT  - Social media
OT  - Sociology
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:02
PHST- 2019/08/27 00:00 [received]
PHST- 2019/09/17 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/09/09 18:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04584 [doi]
AID - S2405-8440(20)31428-6 [pii]
AID - e04584 [pii]
PST - epublish
SO  - Heliyon. 2020 Aug 20;6(8):e04584. doi: 10.1016/j.heliyon.2020.e04584. eCollection
      2020 Aug.


PMID- 32904174
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0974-7052 (Print)
IS  - 0974-7052 (Linking)
VI  - 13
IP  - 3
DP  - 2020 May-Jun
TI  - Emulating Odontolegal Practice: A Paradigm Shift in the Dental Practice Laying
      More Emphasis on Dental Records-A Perspective and Contemporary Study with a
      Reality Check.
PG  - 217-220
LID - 10.5005/jp-journals-10005-1755 [doi]
AB  - AIM: This study was conducted to evaluate the knowledge and the awareness on
      odontolegal practice with more emphasis on significance of maintaining dental
      records by the oral health professionals. MATERIALS AND METHODS: A
      cross-sectional study was carried out among 120 dental practitioners of Jammu and
      Kashmir, Himachal Pradesh, Delhi, Punjab, Gujarat, and Odisha. A questionnaire
      was designed to assess their practice and knowledge regarding the importance of
      maintenance of dental records and the knowledge about dental jurisprudence. Total
      120 questionnaire samples were distributed among dental health professionals, and
      the data obtained were studied and formulated for significance of dental records.
      RESULTS: Feedback obtained was then analyzed. Seventy percentage of the dentists 
      are not maintaining clinical records of their patients and 20% of the dentists
      acknowledged that they are not keeping or maintaining dental records like X-rays 
      and cast models of their patients. Eighty percentage of dentists were not known
      to the ethical importance of dental record, i.e., for how long they have to
      maintain records of their patients and other details. CONCLUSION: This study
      concludes that the oral health professionals lacked the knowledge and awareness
      about odontolegal aspects and the significance of maintaining dental records. It 
      was observed that there was insufficient knowledge about medicolegal systems and 
      there is a need to bring awareness and knowledge of the same in the dental
      fraternity. CLINICAL SIGNIFICANCE: With the increasing use of medical insurance
      and subsequently mediclaims, negligence suits, scientific evaluation, and
      research purposes, and health planning, etc., the "dental records itself have
      evolved as a separate science and therefore needs to be considered in the
      curriculum for dental students as this would introduce the concept for
      application in their future practice, thus avoiding legal complications in the
      future." HOW TO CITE THIS ARTICLE: Kaul B, Gupta S, Vaid V, et al. Emulating
      Odontolegal Practice: A Paradigm Shift in the Dental Practice Laying More
      Emphasis on Dental Records-A Perspective and Contemporary Study with a Reality
      Check. Int J Clin Pediatr Dent 2020;13(3):217-220.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Kaul, Bhavna
AU  - Kaul B
AD  - Department of Pediatric and Preventive Dentistry, Indira Gandhi Government Dental
      College, Jammu, Jammu and Kashmir, India.
FAU - Gupta, Shivam
AU  - Gupta S
AD  - Department of Forensic Odontology, Indian Dental Association, Mumbai,
      Maharashtra, India.
FAU - Vaid, Vasu
AU  - Vaid V
AD  - Department of Forensic Odontology, Gujarat Forensic Sciences University,
      Gandhinagar, Gujarat, India.
FAU - Kaul, Sambhav
AU  - Kaul S
AD  - Department of Dentistry, Govt Hospital Sarwal, Jammu, Jammu and Kashmir, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Int J Clin Pediatr Dent
JT  - International journal of clinical pediatric dentistry
JID - 101585405
PMC - PMC7450200
OTO - NOTNLM
OT  - Consumer Protection Act
OT  - Dental records
OT  - Forensic odontology
OT  - Law
OT  - Medical jurisprudence
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:01
PHST- 2020/09/09 18:01 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.5005/jp-journals-10005-1755 [doi]
PST - ppublish
SO  - Int J Clin Pediatr Dent. 2020 May-Jun;13(3):217-220. doi:
      10.5005/jp-journals-10005-1755.


PMID- 32904094
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0976-5662 (Print)
IS  - 0976-5662 (Linking)
VI  - 11
IP  - 5
DP  - 2020 Sep-Oct
TI  - Animal models of spinal injury for studying back pain and SCI.
PG  - 816-821
LID - 10.1016/j.jcot.2020.07.004 [doi]
AB  - INTRODUCTION: Back pain is a common ailment affecting individuals around the
      globe. Animal models to understand the back pain mechanism, treatment modalities,
      and spinal cord injury are widely researched topics worldwide. Despite the
      presence of several animal models on disc degeneration and Spinal Cord Injury,
      there is a lack of a comprehensive review. MATERIAL AND METHOD: A methodological 
      narrative literature review was carried out for the study. A total of 1273
      publications were found, out of which 763 were related to spine surgery in
      animals. The literature with full-text availability was selected for the review. 
      Scale for the Assessment of Narrative Review Articles (SANRA) guidelines was used
      to assess the studies. Only English language publications were included which
      were listed on PubMed. A total of 113 studies were shortlisted (1976-2019) after 
      internal validation scoring. RESULT: The animal models for spine surgery ranged
      from rodents to primates. These are used to study the mechanisms of back pain as 
      well as spinal cord injuries. The models could either be created surgically or
      through various means like use of electric cautery, chemicals or trauma. Genetic 
      spine models have also been documented in which the injuries are created by
      genetic alterations and knock outs. Though the dorsal approach is the most
      common, the literature also mentions the anterior and lateral approach for spine 
      surgery animal experiments. CONCLUSION: There are no single perfect animal models
      to represent and study human models. The selection is based on the application
      and the methodology. Careful selection is needed to give optimum and appropriate 
      results.
CI  - (c) 2020 Delhi Orthopedic Association. All rights reserved.
FAU - Goel, Shakti A
AU  - Goel SA
AD  - Indian Spinal Injuries Centre, Vasant Kunj, New Delhi, 110070, India.
FAU - Varghese, Vicky
AU  - Varghese V
AD  - TOBB Economics, and Technology University Mechanical Engineering
      Department.Ankara, Turkey.
FAU - Demir, Tyfik
AU  - Demir T
AD  - Department of Neurosurgery, Medical College of Wisconsin, WI, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200708
PL  - India
TA  - J Clin Orthop Trauma
JT  - Journal of clinical orthopaedics and trauma
JID - 101559469
PMC - PMC7452356
OTO - NOTNLM
OT  - Animal ethics
OT  - Animal spine models
OT  - IVD degeneration
OT  - Spinal cord injury
COIS- The authors declare the following financial interests/personal relationships
      which may be considered as potential competing interests: The authors whose names
      are listed immediately below certify that they have NO affiliations with or
      involvement in any organization or entity with any financial interest (such as
      honoraria; educational grants; participation in speakers' bureaus; membership,
      employment, consultancies, stock ownership, or other equity interest; and expert 
      testimony or patent-licensing arrangements), or non-financial interest (such as
      personal or professional relationships, affiliations, knowledge or beliefs) in
      the subject matter or materials discussed in this manuscript. Author names: Dr
      Shakti A Goel, Dr Vicky Varghese, Dr Teyfik Demir.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/09/09 18:00 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1016/j.jcot.2020.07.004 [doi]
AID - S0976-5662(20)30302-7 [pii]
PST - ppublish
SO  - J Clin Orthop Trauma. 2020 Sep-Oct;11(5):816-821. doi:
      10.1016/j.jcot.2020.07.004. Epub 2020 Jul 8.


PMID- 32904024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210924
IS  - 0162-2439 (Print)
IS  - 0162-2439 (Linking)
VI  - 45
IP  - 6
DP  - 2020 Nov
TI  - Changing Infrastructural Practices: Routine and Reproducibility in Automated
      Interdisciplinary Bioscience.
PG  - 1220-1241
LID - 10.1177/0162243919893757 [doi]
AB  - Proponents of engineering and design approaches to biology aim to make
      interdisciplinary bioscience research faster and more reproducible. This paper
      outlines and deploys a practice-based approach to analyses of infrastructure that
      focuses on the routine epistemic activities and charts how two such routines are 
      unsettled and resettled in the background of epistemic culture. This paper
      describes attempts to bring about new research infrastructures in synthetic
      biology using robotics and software-enabled design. A focus on the skills of
      pipetting shows how established manual labor has to be reconfigured to fit with
      novel robotic automations. An analysis of curating frozen materials shows that
      automated design presents new problems for the established activities of storing 
      and retrieving biological materials. These movements, while transient, have
      implications for organizing interdisciplinary collaboration, research
      productivity, and enabling greater reproducibility. This paper explores the idea 
      of infrastructure as practice and shows how this has important implications for
      studies of research infrastructures. This article discusses the main
      contributions of this approach for analysts of infrastructure in terms of
      movements, temporalities, and ethics and offers suggestions for what the research
      implies for synthetic biology.
CI  - (c) The Author(s) 2019.
FAU - Meckin, Robert
AU  - Meckin R
AUID- ORCID: https://orcid.org/0000-0003-1071-9679
AD  - Sociology, University of Manchester.
AD  - The Cathie Marsh Institute, University of Manchester.
AD  - The Morgan Centre for Research into Everyday Lives, University of Manchester.
LA  - eng
GR  - BB/M017702/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
DEP - 20191209
PL  - United States
TA  - Sci Technol Human Values
JT  - Science, technology & human values
JID - 9440757
PMC - PMC7448810
OTO - NOTNLM
OT  - automation
OT  - engineering biology
OT  - infrastructure
OT  - practices
OT  - reproducibility
OT  - synthetic biology
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 18:00
PHST- 2020/09/09 18:00 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1177/0162243919893757 [doi]
AID - 10.1177_0162243919893757 [pii]
PST - ppublish
SO  - Sci Technol Human Values. 2020 Nov;45(6):1220-1241. doi:
      10.1177/0162243919893757. Epub 2019 Dec 9.


PMID- 32903886
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2296-9195 (Print)
IS  - 2296-9160 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Jul
TI  - "Extraction Dermoscopy": Expanding the Utility of Epiluminescence Microscopy.
PG  - 220-223
LID - 10.1159/000508518 [doi]
AB  - INTRODUCTION: Many dermatological conditions require extraction of material from 
      the lesion followed by visualization under a microscope. However, visualization
      of the extracted material can be done using a dermoscope instead. We propose
      "extraction dermoscopy" as an addition to the already existing treasury that
      dermoscopy holds. METHODS: After approval from the institutional ethics
      committee, a cross-sectional study was carried out in a tertiary care hospital.
      Polarized and non-polarized versions of in vivo dermoscopy, as well as extraction
      dermoscopy, were performed on a total of 77 lesions, including 5 eruptive vellus 
      hair cysts, 2 cilia incarnata externum, 10 trichostasis spinulosa, 20 keratosis
      pilaris, 20 molluscum contagiosum, and 20 lesions of milia. Heine Delta 20T and
      Dino-Lite Premier AM4113T were employed for dermoscopic examination. RESULTS: A
      total of 77 lesions were selected, including 5 eruptive vellus hair cysts, 2
      cilia incarnata externum, 10 trichostasis spinulosa, 20 keratosis pilaris, 20
      molluscum contagiosum, and 20 lesions of milia. Extraction dermoscopy of the
      eruptive vellus cysts revealed skin color to brownish colored cysts with a bunch 
      of pigmented hair. Similarly, findings of all other lesions were described and
      recorded post-extraction. CONCLUSION: Extraction dermoscopy helps confirm the
      diagnosis without visualization under a microscope. Its application in recent
      times makes the explanation of the nature of many disorders to patients easier,
      and demonstration of extracted lesions may further improve doctor-patient
      communication.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Daruwalla, Sanober Burzin
AU  - Daruwalla SB
AD  - Department of Dermatology, LTMMC and LTMGH, Sion West, Mumbai, India.
FAU - Dhurat, Rachita S
AU  - Dhurat RS
AD  - Department of Dermatology, LTMMC and LTMGH, Sion West, Mumbai, India.
FAU - Agrawal, Sandip
AU  - Agrawal S
AD  - Department of Dermatology, LTMMC and LTMGH, Sion West, Mumbai, India.
FAU - Mahobia, Shraddha
AU  - Mahobia S
AD  - Department of Dermatology, LTMMC and LTMGH, Sion West, Mumbai, India.
FAU - Naidu Kona, Sradda
AU  - Naidu Kona S
AD  - Department of Dermatology, LTMMC and LTMGH, Sion West, Mumbai, India.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - Switzerland
TA  - Skin Appendage Disord
JT  - Skin appendage disorders
JID - 101670617
PMC - PMC7445566
OTO - NOTNLM
OT  - Cilia incarnata
OT  - Epiluminescence microscopy
OT  - Eruptive vellus hair cyst
OT  - Extraction dermoscopy
OT  - Keratosis pilaris
OT  - Milia
OT  - Molluscum contagiosum
OT  - Trichostasis spinulosa
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 17:58
PHST- 2020/04/21 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/09/09 17:58 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - 10.1159/000508518 [doi]
AID - sad-0006-0220 [pii]
PST - ppublish
SO  - Skin Appendage Disord. 2020 Jul;6(4):220-223. doi: 10.1159/000508518. Epub 2020
      Jun 25.


PMID- 32903198
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210101
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 7
TI  - The Role of Stress and Genital Immunity in Sexual Trauma and HIV Susceptibility
      Among Adolescent Girls and Adult Women (The THRIVE Study): Protocol for a
      Longitudinal Case-Control Study.
PG  - e18190
LID - 10.2196/18190 [doi]
AB  - BACKGROUND: The relationship between sexual violence and HIV risk has been
      extensively documented through social and behavioral research; however, the
      underlying biological mechanisms are poorly understood. OBJECTIVE: The purpose of
      the THRIVE (Trauma and HIV Risk: Investigating Stress and the Immune Disruption
      of the Vaginal Environment) Study is to examine the impact of sexual trauma due
      to sexual violence on HIV susceptibility through dysregulation of soluble
      inflammatory and anti-inflammatory and anti-HIV biomarkers in the female genital 
      tract and dysregulation of the hypothalamic-pituitary-adrenal axis among
      adolescent girls and adult women. METHODS: The THRIVE Study is a longitudinal
      case-control study conducted in San Diego, CA, among a racially diverse sample.
      Cases are adolescent girls (aged 14-19 years) or adult women (aged 20-45 years)
      who have experienced forced vaginal penetration by a phallus perpetrated by a man
      within the past 15 days. Controls are adolescent girls or adult women who have
      engaged in consensual vaginal sex with a man within the past 15 days. At baseline
      and 1- and 3-month follow-up study visits, participants undergo a urine-based
      pregnancy test; venipuncture blood draw for HIV, C-reactive protein,
      adrenocorticotropic hormone, and progesterone testing; a 45-min
      interviewer-administered computer survey; and cervicovaginal lavage to measure
      proinflammatory and anti-inflammatory and anti-HIV soluble immune biomarkers.
      After each study visit, participants self-collect saliva specimens (upon waking, 
      30 min after waking, and 45 min after waking) at home for 3 consecutive days,
      which are later assayed for cortisol and dehydroepiandrosterone sulfate.
      Participants receive compensation at each study visit and for the return of
      saliva specimens, and a list of local medical and support services. Study
      procedures use trauma-informed care methods, given the sensitive nature of the
      study and enrollment of women in the acute phase after sexual trauma. All
      research staff and investigators adhere to ethical principles and guidelines in
      the conduct of research activities. Data will be analyzed for descriptive and
      inferential analyses. RESULTS: The recruitment of participants is ongoing. The
      publication of the first results is expected by late 2021. CONCLUSIONS: The
      THRIVE Study will provide foundational knowledge on how sexual trauma due to
      sexual violence increases susceptibility to HIV acquisition via alterations in
      cervicovaginal immune regulation and the psychobiology of the stress responses.
      These findings will inform future research on mechanistic models of in vitro and 
      in vivo injury and cervicovaginal wound healing processes, which may lead to the 
      development of nonvaccine biomedical HIV prevention products for girls and women.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18190.
CI  - (c)Jamila K Stockman, Katherine M Anderson, Maile Y Karris, Constance A Benson,
      Kiyomi Tsuyuki, Douglas A Granger, Akilah Weber, Mimi Ghosh. Originally published
      in JMIR Research Protocols (http://www.researchprotocols.org), 07.12.2020.
FAU - Stockman, Jamila K
AU  - Stockman JK
AUID- ORCID: https://orcid.org/0000-0003-1909-6965
AD  - Division of Infectious Diseases and Global Public Health, Department of Medicine,
      University of California, San Diego, La Jolla, CA, United States.
FAU - Anderson, Katherine M
AU  - Anderson KM
AUID- ORCID: https://orcid.org/0000-0001-9675-3653
AD  - Division of Infectious Diseases and Global Public Health, Department of Medicine,
      University of California, San Diego, La Jolla, CA, United States.
FAU - Karris, Maile Y
AU  - Karris MY
AUID- ORCID: https://orcid.org/0000-0001-5614-030X
AD  - Division of Infectious Diseases and Global Public Health, Department of Medicine,
      University of California, San Diego, La Jolla, CA, United States.
FAU - Benson, Constance A
AU  - Benson CA
AUID- ORCID: https://orcid.org/0000-0002-3781-1347
AD  - Division of Infectious Diseases and Global Public Health, Department of Medicine,
      University of California, San Diego, La Jolla, CA, United States.
FAU - Tsuyuki, Kiyomi
AU  - Tsuyuki K
AUID- ORCID: https://orcid.org/0000-0002-9141-1395
AD  - Division of Infectious Diseases and Global Public Health, Department of Medicine,
      University of California, San Diego, La Jolla, CA, United States.
FAU - Granger, Douglas A
AU  - Granger DA
AUID- ORCID: https://orcid.org/0000-0002-1355-0218
AD  - Institute for Interdisciplinary Salivary Bioscience Research, University of
      California, Irvine, Irvine, CA, United States.
AD  - School of Nursing, Bloomberg School of Public Health, Johns Hopkins University
      School of Medicine, Baltimore, MD, United States.
FAU - Weber, Akilah
AU  - Weber A
AUID- ORCID: https://orcid.org/0000-0002-1496-7306
AD  - Rady Children's Hospital San Diego, San Diego, CA, United States.
AD  - Department of Obstetrics and Gynecology, University of California San Diego
      Health, San Diego, CA, United States.
FAU - Ghosh, Mimi
AU  - Ghosh M
AUID- ORCID: https://orcid.org/0000-0003-0029-9818
AD  - Department of Epidemiology, Milken Institute School of Public Health, The George 
      Washington University, Washington, DC, United States.
LA  - eng
GR  - K01 AA025009/AA/NIAAA NIH HHS/United States
GR  - L60 MD012089/MD/NIMHD NIH HHS/United States
GR  - P30 AI036214/AI/NIAID NIH HHS/United States
GR  - R01 AI128803/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20201207
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7752525
OTO - NOTNLM
OT  - HIV risk
OT  - United States
OT  - adolescent girls
OT  - adult women
OT  - case-control
OT  - forced sex
OT  - genital immunity
OT  - longitudinal
OT  - sexual trauma
OT  - sexual violence
OT  - stress
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 17:52
PHST- 2020/02/12 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
PHST- 2020/09/09 17:52 [entrez]
AID - v9i12e18190 [pii]
AID - 10.2196/18190 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Dec 7;9(12):e18190. doi: 10.2196/18190.


PMID- 32903194
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1305-3612 (Electronic)
IS  - 1305-3825 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Sep
TI  - Analysis of potential predatory journals in radiology.
PG  - 498-503
LID - 10.5152/dir.2020.20240 [doi]
AB  - PURPOSE: The aim of this study is to determine the presence and evaluate the
      features of potential predatory journals in the radiology field. METHODS: The
      presence of the keywords related to radiology listed in the name of journals was 
      investigated in Beall's list. We have searched and recorded the features and the 
      information of the included journals listed under the following headings: address
      and location, publishing features, editorial board, indexing features,
      submission, and peer-review processes. RESULTS: A total of 66 radiology journals 
      from 27 publishers were identified from the updated version of the original
      Beall's list. Regarding the publishers, 33 journals (50%) reported an address in 
      the United States of America, while others were from United Kingdom, India, Hong 
      Kong, Iran, and Canada. While 44 journals' (67%) website reported a contact
      address, no addresses were declared in the website of 21 journals (32%). The
      median time of publication activity was 3.5 years (interquartile range [IQR], 1-5
      years; range, 0-16 years). Thirty-five journals (53%) indicated their publication
      ethics policy on the website. Forty-seven (71%) journals reported a regular
      editorial board (EB) list. The competency of the EB was considered as
      "inappropriate" in 27 (41%) journals. Only 18% of the total number of EB members 
      had affiliations related to radiology (n=286/1566). Forty journals (61%) did not 
      report any indexing and database coverage. We found 26 journals (39%) which had a
      DOI number in its latest 5 articles. Fifty-nine (89%) journals clearly reported
      article processing change (APC) on the webpage. The median APC value was 641.43
      USD (IQR, 300-918.75 USD; range, 100-2588 USD). Considering the latest 5
      articles, the number of journals with radiologic images in all of the articles
      was 8 (12%). Mean peer-review time was 63.5 days (IQR, 21.75-87.5 days; range,
      1-237 days) for the journals which indicated the submission and acceptance dates 
      clearly. CONCLUSION: We demonstrated the several main characteristics of
      potential predatory journals in the radiology field such as reliability of the
      reported address, APC, publication frequencies, indexing features, features of
      published article and peer-review time which were all found to be similar to the 
      characteristics of potential predatory journals in other biomedical fields.
FAU - Aribal, Serkan
AU  - Aribal S
AD  - Department of Radiology, Okmeydani Research and Trainig Hospital, Istanbul,
      Turkey.
FAU - Ince, Okan
AU  - Ince O
AD  - Department of Radiology, Okmeydani Research and Trainig Hospital, Istanbul,
      Turkey.
FAU - Kaya, Eyup
AU  - Kaya E
AD  - Department of Radiology, Okmeydani Research and Trainig Hospital, Istanbul,
      Turkey.
FAU - Onder, Hakan
AU  - Onder H
AD  - Department of Radiology, Okmeydani Research and Trainig Hospital, Istanbul,
      Turkey.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Diagn Interv Radiol
JT  - Diagnostic and interventional radiology (Ankara, Turkey)
JID - 101241152
SB  - IM
MH  - Humans
MH  - *Periodicals as Topic
MH  - *Radiology
MH  - Reproducibility of Results
PMC - PMC7490022
EDAT- 2020/09/10 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/09/09 17:52
PHST- 2020/09/09 17:52 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - 10.5152/dir.2020.20240 [doi]
PST - ppublish
SO  - Diagn Interv Radiol. 2020 Sep;26(5):498-503. doi: 10.5152/dir.2020.20240.


PMID- 32903047
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210110
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 16
IP  - 34
DP  - 2020 Dec
TI  - Bioethical considerations for cancer patient care during the COVID-19 pandemic.
PG  - 2779-2781
LID - 10.2217/fon-2020-0742 [doi]
FAU - Kourie, Hampig Raphael
AU  - Kourie HR
AD  - Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University
      of Beirut, Riad El Solh, 11-5076, Lebanon.
FAU - Eid, Roland
AU  - Eid R
AUID- ORCID: https://orcid.org/0000-0003-1097-2594
AD  - Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University
      of Beirut, Riad El Solh, 11-5076, Lebanon.
FAU - Gh Haddad, Fady
AU  - Gh Haddad F
AUID- ORCID: https://orcid.org/0000-0002-9702-8485
AD  - Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University
      of Beirut, Riad El Solh, 11-5076, Lebanon.
FAU - Scheuer, Michel
AU  - Scheuer M
AD  - Ethical Committee of Saint Joseph University of Beirut, Riad El Solh, 11-5076,
      Lebanon.
FAU - Tomb, Roland
AU  - Tomb R
AD  - Department of Dermatology, Faculty of Medicine, Saint Joseph University of
      Beirut, Riad El Solh, 11-5076, Lebanon.
LA  - eng
PT  - Editorial
DEP - 20200909
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
SB  - IM
MH  - Beneficence
MH  - *COVID-19
MH  - Health Services Accessibility
MH  - Humans
MH  - Intensive Care Units
MH  - Neoplasms/*therapy
MH  - Patient Care/*ethics
MH  - Personal Autonomy
MH  - Social Justice
PMC - PMC7482404
OTO - NOTNLM
OT  - COVID-19
OT  - bioethical
OT  - bioethics
OT  - medical ethics
OT  - outbreak
OT  - pandemic
OT  - principles
EDAT- 2020/09/10 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/09/09 17:45
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/09/09 17:45 [entrez]
AID - 10.2217/fon-2020-0742 [doi]
PST - ppublish
SO  - Future Oncol. 2020 Dec;16(34):2779-2781. doi: 10.2217/fon-2020-0742. Epub 2020
      Sep 9.


PMID- 32901984
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
VI  - 76
IP  - 11
DP  - 2020 Nov
TI  - Internet-based support program on parenting outcomes for Chinese primiparous
      women: Study protocol for a randomized controlled trial.
PG  - 3155-3163
LID - 10.1111/jan.14517 [doi]
AB  - AIM: To evaluate the effects of internet-based support program for primiparous
      women in terms of improving the levels of maternal self-efficacy, social support,
      and satisfaction; and reducing their postpartum depression symptoms. DESIGN: A
      single-blinded, multicentre, randomized, controlled, parallel-group pre-test and 
      repeated post-test design. METHODS: Based on the self-efficacy theory and the
      social exchange theory, the internet-based support program has five modules: (a) 
      learning forum of parenting knowledge and skills; (b) communication forum; (c)
      ask-the-expert forum; (d) baby home forum; and (e) reminder forum. Primiparous
      women will be recruited in the obstetric wards of two university-affiliated
      hospitals in China. The participants (N = 258) will be randomly allocated to the 
      intervention group that receive routine care and access to the internet-based
      support program and the control group that receive routine care during the 3
      months postpartum. Maternal self-efficacy, social support, and postpartum
      depression symptoms will be measured at baseline, immediately after the
      intervention (post-test 1) and 3 months after the intervention (post-test 2). The
      study was funded in January 2018 and was ethically approved in May 2020.
      DISCUSSION: If the internet-based support program has positive outcomes, it will 
      contribute to the scientific and practical knowledge of nursing interventions to 
      support primiparous women on parenting; and could become the routine health care 
      for health professionals to enhance parenting ability and mental well-being of
      new mothers. IMPACT: As the first RCT study on parenting outcomes using a
      rigorous research design and a theoretical framework in China, this research will
      contribute to evidence on the effectiveness of using internet platform to support
      women after childbirth. The results could help to advance research about the use 
      of internet-based intervention methods to improve women's maternal self-efficacy,
      social support, satisfaction, and to alleviate depression symptoms. Chinese
      Clinical Trial Registry: ChiCTR2000033154.
CI  - (c) 2020 The Authors. Journal of Advanced Nursing published by John Wiley & Sons 
      Ltd.
FAU - Zheng, Xujuan
AU  - Zheng X
AUID- ORCID: https://orcid.org/0000-0002-3942-6960
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Huang, Lingling
AU  - Huang L
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Fang, Qiyu
AU  - Fang Q
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Zhang, Yao
AU  - Zhang Y
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Li, Xilin
AU  - Li X
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Ye, Ziwen
AU  - Ye Z
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
FAU - Wang, Qun
AU  - Wang Q
AD  - Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
MH  - China
MH  - *Depression, Postpartum/prevention & control
MH  - Female
MH  - Humans
MH  - Infant
MH  - Internet
MH  - *Parenting
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Self Efficacy
PMC - PMC7693195
OTO - NOTNLM
OT  - internet-based intervention
OT  - maternal self-efficacy
OT  - nursing
OT  - postpartum depression
OT  - primiparous women
OT  - social support
EDAT- 2020/09/10 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/09 08:48
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/09 08:48 [entrez]
AID - 10.1111/jan.14517 [doi]
PST - ppublish
SO  - J Adv Nurs. 2020 Nov;76(11):3155-3163. doi: 10.1111/jan.14517. Epub 2020 Sep 9.


PMID- 32901964
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1523-1739 (Electronic)
IS  - 0888-8892 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Dec
TI  - Michael Soule (1936-2020) on spirituality, ethics, and conservation biology.
PG  - 1426-1432
LID - 10.1111/cobi.13634 [doi]
AB  - Michael Soule is best known for his scientific contributions and central role in 
      founding the Society for Conservation Biology and its flagship journal. Less well
      known are his childhood experiences, his affinity for Zen Buddhism and Arne
      Naess' deep ecology philosophy, and his contributions as an environmental
      activist to efforts to protect biodiversity and rewild ecosystems. Also less well
      known is the extent to which he was an interdisciplinary environmental studies
      scholar, struggling to understand what promotes and hinders proenvironmental
      behaviors. In this regard, his life and that of many other conservation
      scientists provide important clues, but no easy answers. By attempting to
      integrate the humanities, with its quest for a meaningful and fulfilling human
      existence, with naturalistic nature spirituality and ecocentric values, as well
      as the social and natural sciences, Soule sought to solve the riddle as to why
      human beings seemed unable to understand, slow, and halt negative anthropogenic
      environmental change. He thus modeled what interdisciplinary environmental
      studies is at its best. Those advocating the conservation of biological diversity
      have much to learn from Michael Soule, not only from his scientific findings but 
      also from his way of seeing, the questions he asked, and his love of the living
      world.
CI  - (c) 2020 Society for Conservation Biology.
FAU - Taylor, Bron
AU  - Taylor B
AUID- ORCID: 0000-0002-3328-2687
AD  - University of Florida, 107 Anderson Hall, PO Box 117410, Gainesville, FL,
      32611-7410, U.S.A.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Conserv Biol
JT  - Conservation biology : the journal of the Society for Conservation Biology
JID - 9882301
SB  - IM
MH  - Biodiversity
MH  - Child
MH  - *Conservation of Natural Resources
MH  - Ecology
MH  - *Ecosystem
MH  - Humans
MH  - Spirituality
OTO - NOTNLM
OT  - *Sociedad para la Biologia de la Conservacion
OT  - *Society for Conservation Biology
OT  - *afinidad
OT  - *biodiversidad
OT  - *biodiversity
OT  - *biofilia
OT  - *biophilia
OT  - *deep ecology
OT  - *ecocentrism
OT  - *ecocentrismo
OT  - *ecologia profunda
OT  - *formas de ver el mundo
OT  - *kinship
OT  - *religion
OT  - *religion
OT  - *worldviews
EDAT- 2020/09/10 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/09/09 08:48
PHST- 2020/07/19 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/09/09 08:48 [entrez]
AID - 10.1111/cobi.13634 [doi]
PST - ppublish
SO  - Conserv Biol. 2020 Dec;34(6):1426-1432. doi: 10.1111/cobi.13634.


PMID- 32901790
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201125
IS  - 1972-6007 (Electronic)
IS  - 0009-9074 (Linking)
VI  - 171
IP  - 5
DP  - 2020 Sep-Oct
TI  - Teaching ethics and professionalism in rehabilitation: an empirical research on
      active learning with university rehabilitation students.
PG  - e444-e448
LID - 10.7417/CT.2020.2255 [doi]
AB  - BACKGROUND: Teaching ethics in university courses may benefit from different
      didactic approaches; nonetheless, it still seems unclear whether ethics teaching 
      can be best offered in stand-alone courses or integrated into other courses, or
      perhaps both. OBJECTIVE: We describe the experience derived from a structured
      teaching activity in the field of medical ethics, conducted during a lesson for
      the students of a rehabilitation university second-cycle degree course. METHODS: 
      The participating students were healthcare professionals with different graduate 
      training in rehabilitation. The aim of the lesson was to discuss the essentials
      of the relationship between patients and rehabilitation healthcare providers,
      from an inter-professional viewpoint, focused on the principles of trust, mutual 
      respect, power and personal closeness, which are essential components of the
      therapeutic relationship between patients and physical therapists. RESULT: Shared
      moral norms guiding the professional conduct of healthcare professionals are a
      fundamental characteristic of these professions, promoting the public trust in
      these professions, tearing down barriers to inter-professional collaboration and 
      communication. CONCLUSION: The results are remarkable, and there has been very
      positive feedback from the students concerning the production of the oath and its
      contents, as well as about the proposed teaching method, resulting in great
      interest in clinical ethics.
FAU - Caenazzo, L
AU  - Caenazzo L
AD  - Department of Molecular Medicine, University of Padova, Padova, Italy.
FAU - Tozzo, P
AU  - Tozzo P
AD  - Department of Molecular Medicine, University of Padova, Padova, Italy.
FAU - Borovecki, A
AU  - Borovecki A
AD  - Andrija Stampar, School of Public Health, School of Medicine, University of
      Zagreb, Zagreb, Croatia.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Ter
JT  - La Clinica terapeutica
JID - 0372604
SB  - IM
MH  - Adult
MH  - Empirical Research
MH  - Ethics, Clinical
MH  - Ethics, Medical/*education
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - Morals
MH  - Problem-Based Learning
MH  - Professionalism/*education
MH  - Rehabilitation/*education/ethics
MH  - *Students
MH  - Universities
OTO - NOTNLM
OT  - Active learning
OT  - Ethics education
OT  - Professional oath
OT  - Rehabilitation students
EDAT- 2020/09/10 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/09/09 08:47
PHST- 2020/09/09 08:47 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.7417/CT.2020.2255 [doi]
PST - ppublish
SO  - Clin Ter. 2020 Sep-Oct;171(5):e444-e448. doi: 10.7417/CT.2020.2255.


PMID- 32901783
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201125
IS  - 1972-6007 (Electronic)
IS  - 0009-9074 (Linking)
VI  - 171
IP  - 5
DP  - 2020 Sep-Oct
TI  - Beginning of life ethics at the dawn of a new era of genome editing: are
      bioethical precepts and fast-evolving biotechnologies irreconcilable?
PG  - e407-e411
AB  - The amazing and almost unimaginable advances that have unfolded over the past
      decades in biotechnologies (heritable germline editing in particular) have
      brought bioethical issues to the forefront, sparking public debate and increasing
      attention worldwide. Such mind-blowing progress has already resulted in major
      improvement and enhancements for humans, and holds the potential for even more.
      Technology and bioengineering have begun to take over in the life sciences
      industry. Man's capacity to genetically engineer the biological world is nothing 
      short of mind-boggling in its current magnitude, and may even evolve, in a not
      too distant future, into attempts to fuse man and machine into a cohesive
      bioengineered entity; a "super human being", endowed with enhanced cognitive and 
      physical capabilities and impervious to disease, may be not too far down the
      road. That will not come without caveats, however. In fact, scientific
      advancements at such an accelerated pace have already negatively affected our
      cultural, ethical, and legal values and our ability to harness the opportunities 
      and face the dangers posed by such developments. As a matter of fact, science
      seems to consistently outpace public morals, ethics and policymaking, which calls
      for a high degree of caution and common answers.
FAU - Marinelli, S
AU  - Marinelli S
AD  - Universita Politecnica delle Marche, Ancona.
FAU - Del Rio, A
AU  - Del Rio A
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Ter
JT  - La Clinica terapeutica
JID - 0372604
SB  - IM
MH  - *Beginning of Human Life
MH  - *Bioethical Issues
MH  - Biotechnology/*ethics
MH  - Gene Editing/*ethics
MH  - Genetic Therapy/ethics
MH  - Humans
MH  - Morals
MH  - Policy Making
OTO - NOTNLM
OT  - Bioethics
OT  - CRISPR-Cas9 gene editing
OT  - Genome engineering
OT  - Heritable germline editing
OT  - Human enhancement
EDAT- 2020/09/10 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/09/09 08:47
PHST- 2020/09/09 08:47 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - [doi]
PST - ppublish
SO  - Clin Ter. 2020 Sep-Oct;171(5):e407-e411.


PMID- 32901743
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220416
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73
IP  - 6
DP  - 2020 Sep 7
TI  - Construction of the matrix of individual nursing competences in surgical units.
PG  - e20190584
LID - S0034-71672020000600181 [pii]
LID - 10.1590/0034-7167-2019-0584 [doi]
AB  - OBJECTIVE: to build and to describe an Individual Skills Matrix for nurses
      working in surgical units and their associated behaviors / attitudes. METHOD:
      Exploratory, qualitative study. 43 nurses from five surgical units participated, 
      and data collection was carried out between April and September 2017. The focus
      group technique was used and for data interpretation an inductive thematic
      analysis was performed. The competence matrix was built from the testimonies of
      the participants plus a search in the literature for concepts directed to each
      competence and description of the expected behaviors and / or attitudes. RESULTS:
      For the Matrix, the following individual skills were identified: Planning;
      Communication, Relational Competence, Leadership, Decision Making and Ethics.
      FINAL CONSIDERATIONS: The construction of a Matrix should assist managers in
      recognizing the professional profile and assessing their performance,
      strengthening the achievement of professional and organizational objectives, as
      well as contributing to the quality and effectiveness of the care provided by
      nurses in these places.
FAU - Leal, Laura Andrian
AU  - Leal LA
AUID- ORCID: http://orcid.org/0000-0002-8563-8980
AD  - Universidade de Sao Paulo. Ribeirao Preto, Sao Paulo, Brazil.
FAU - Henriques, Silvia Helena
AU  - Henriques SH
AUID- ORCID: http://orcid.org/0000-0003-2089-3304
AD  - Universidade de Sao Paulo. Ribeirao Preto, Sao Paulo, Brazil.
FAU - Castro, Fabiana Faleiros Santana
AU  - Castro FFS
AUID- ORCID: http://orcid.org/0000-0003-3723-7944
AD  - Universidade de Sao Paulo. Ribeirao Preto, Sao Paulo, Brazil.
FAU - Soares, Mirelle Inacio
AU  - Soares MI
AUID- ORCID: http://orcid.org/0000-0002-5298-8634
AD  - Universidade de Sao Paulo. Ribeirao Preto, Sao Paulo, Brazil.
FAU - Braganca, Cleria
AU  - Braganca C
AUID- ORCID: http://orcid.org/0000-0002-6158-7533
AD  - Universidade de Sao Paulo. Ribeirao Preto, Sao Paulo, Brazil.
FAU - Silva, Beatriz Regina da
AU  - Silva BRD
AUID- ORCID: http://orcid.org/0000-0001-5635-5757
AD  - Universidade de Sao Paulo. Ribeirao Preto, Sao Paulo, Brazil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20200907
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - *Clinical Competence
MH  - Communication
MH  - Focus Groups
MH  - Humans
MH  - *Leadership
MH  - Qualitative Research
EDAT- 2020/09/10 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/09 08:47
PHST- 2019/10/03 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/09/09 08:47 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - S0034-71672020000600181 [pii]
AID - 10.1590/0034-7167-2019-0584 [doi]
PST - epublish
SO  - Rev Bras Enferm. 2020 Sep 7;73(6):e20190584. doi: 10.1590/0034-7167-2019-0584.


PMID- 32901323
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1432-2323 (Electronic)
IS  - 0364-2313 (Linking)
VI  - 44
IP  - 12
DP  - 2020 Dec
TI  - Prospectively Randomized Controlled Trial on Damage Control Surgery for
      Perforated Diverticulitis with Generalized Peritonitis.
PG  - 4098-4105
LID - 10.1007/s00268-020-05762-1 [doi]
AB  - INTRODUCTION: Damage control surgery (DCS) with abdominal negative pressure
      therapy and delayed anastomosis creation in patients with perforated
      diverticulitis and generalized peritonitis was established at our Institution in 
      2006 and has been published. The concept was adopted in other hospitals and
      published as a case series. This is the first prospectively controlled randomized
      study comparing DCS and conventional treatment (Group C) in this setting.
      METHODS: All consecutive patients from 2013 to 2018 with indication for surgery
      were screened and randomized to Group DCS or Group C. The primary outcome was the
      rate of reconstructed bowel at discharge and at 6 month. Informed consent was
      obtained. The trial was approved by the local ethics committee and registered at 
      CinicalTrials.gov: NCT04034407. RESULTS: A total of 56 patients were screened; 41
      patients gave informed consent to participate and ultimately 21 patients (9
      female) with intraoperatively confirmed Hinchey III (n = 14, 67%) or IV (n = 7,
      33%), and a median (range) age of 66 (42-92), Mannheim Peritonitis Index of 25
      (12-37) and Charlson Comorbidity Index of 3 (0-10) were intraoperatively
      randomized and treated as Group DCS (n = 13) or Group C (n = 8). Per protocol
      analysis: A primary anastomosis without ileostomy (PA) was performed in 92%
      (11/12) patients in Group DCS at the second-look operation, one patient died
      before second look, and one underwent a Hartmann procedure (HP). In Group C 63%
      (5/8) patients received a PA and 38% (3/8) patients a HP. Two patients in Group
      C, but none in Group DCS experienced anastomotic leakage (AI). ICU and hospital
      stay was median (range) 2 (1-10) and 17.5 (12-43) in DCS and 2 (1-62) and 22
      (13-65) days in group C. In Group DCS 8% (1/12) patients was discharged with a
      stoma versus 57% (4/7) in Group C (p = 0.038, n.s., alpha = 0.025); one patient
      died before discharge. The odds ratio (95% confidence interval) for discharge
      with a stoma is 0.068 (0.005-0.861). Intent to treat analysis: A PA was performed
      in 90% (9/10) of patients randomized to DCS, one patient died before the second
      look, and one patient received a HP. In group C, 70% (7/10) were treated with PA 
      and 30% (3/10) with HP. 29% (2/7) experienced AI treated with protective
      ileostomy. In group DCS, 9% (1/11) were discharged with a stoma versus 40% (4/10)
      in group C (p = 0.14, n.s.). The odds ratio for discharge with a stoma is 0.139
      (0.012-1.608). CONCLUSION: This is the first prospectively randomized controlled 
      study showing that damage control surgery in perforated diverticulitis Hinchey
      III and IV enhances reconstruction of bowel continuity and can reduce the stoma
      rate at discharge.
FAU - Kafka-Ritsch, Reinhold
AU  - Kafka-Ritsch R
AUID- ORCID: http://orcid.org/0000-0003-1626-3430
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria. reinhold.kafka-ritsch@tirol-kliniken.at.
FAU - Zitt, Matthias
AU  - Zitt M
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
AD  - Department of Surgery, Dornbirn General Hospital, Dornbirn, Austria.
FAU - Perathoner, Alexander
AU  - Perathoner A
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
FAU - Gasser, Elisabeth
AU  - Gasser E
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
FAU - Kaufman, Claudia
AU  - Kaufman C
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
FAU - Czipin, Sasha
AU  - Czipin S
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
FAU - Aigner, Felix
AU  - Aigner F
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
AD  - Department of Surgery, Campus Charite Mitte and Campus Virchow-Klinikum,
      Charite-Universitatsmedizin Berlin, Berlin, Germany.
FAU - Ofner, Dietmar
AU  - Ofner D
AD  - Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative
      Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck,
      Austria.
LA  - eng
SI  - ClinicalTrials.gov/NCT04034407
PT  - Case Reports
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200908
PL  - United States
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anastomosis, Surgical/*adverse effects
MH  - Diverticulitis/complications/*surgery
MH  - Female
MH  - Humans
MH  - Intestinal Perforation/etiology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Negative-Pressure Wound Therapy
MH  - Peritonitis/etiology/*surgery
MH  - Prospective Studies
MH  - Treatment Outcome
PMC - PMC7599157
EDAT- 2020/09/10 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/09 05:31
PHST- 2020/08/16 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/09 05:31 [entrez]
AID - 10.1007/s00268-020-05762-1 [doi]
AID - 10.1007/s00268-020-05762-1 [pii]
PST - ppublish
SO  - World J Surg. 2020 Dec;44(12):4098-4105. doi: 10.1007/s00268-020-05762-1. Epub
      2020 Sep 8.


PMID- 32901198
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1389-0417 (Print)
IS  - 1389-0417 (Linking)
VI  - 64
DP  - 2020 Dec
TI  - Toward ethical cognitive architectures for the development of artificial moral
      agents.
PG  - 117-125
LID - 10.1016/j.cogsys.2020.08.010 [doi]
AB  - New technologies based on artificial agents promise to change the next generation
      of autonomous systems and therefore our interaction with them. Systems based on
      artificial agents such as self-driving cars and social robots are examples of
      this technology that is seeking to improve the quality of people's life.
      Cognitive architectures aim to create some of the most challenging artificial
      agents commonly known as bio-inspired cognitive agents. This type of artificial
      agent seeks to embody human-like intelligence in order to operate and solve
      problems in the real world as humans do. Moreover, some cognitive architectures
      such as Soar, LIDA, ACT-R, and iCub try to be fundamental architectures for the
      Artificial General Intelligence model of human cognition. Therefore, researchers 
      in the machine ethics field face ethical questions related to what mechanisms an 
      artificial agent must have for making moral decisions in order to ensure that
      their actions are always ethically right. This paper aims to identify some
      challenges that researchers need to solve in order to create ethical cognitive
      architectures. These cognitive architectures are characterized by the capacity to
      endow artificial agents with appropriate mechanisms to exhibit explicit ethical
      behavior. Additionally, we offer some reasons to develop ethical cognitive
      architectures. We hope that this study can be useful to guide future research on 
      ethical cognitive architectures.
CI  - (c) 2020 Elsevier B.V. All rights reserved.
FAU - Cervantes, Salvador
AU  - Cervantes S
AD  - Department of Computer Science and Engineering, Universidad de Guadalajara,
      Ameca, P.C. 46600, Mexico.
FAU - Lopez, Sonia
AU  - Lopez S
AD  - Department of Computer Science and Engineering, Universidad de Guadalajara,
      Ameca, P.C. 46600, Mexico.
FAU - Cervantes, Jose-Antonio
AU  - Cervantes JA
AD  - Department of Computer Science and Engineering, Universidad de Guadalajara,
      Ameca, P.C. 46600, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - Netherlands
TA  - Cogn Syst Res
JT  - Cognitive systems research
JID - 100965211
PMC - PMC7470787
OTO - NOTNLM
OT  - Artificial agents
OT  - Artificial moral agents
OT  - Cognitive functions
OT  - Ethical cognitive architectures
OT  - Machine ethics
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 05:30
PHST- 2020/06/15 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
PHST- 2020/09/09 05:30 [entrez]
AID - 10.1016/j.cogsys.2020.08.010 [doi]
AID - S1389-0417(20)30056-5 [pii]
PST - ppublish
SO  - Cogn Syst Res. 2020 Dec;64:117-125. doi: 10.1016/j.cogsys.2020.08.010. Epub 2020 
      Sep 3.


PMID- 32901124
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20211204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 585
IP  - 7824
DP  - 2020 Sep
TI  - Don't ignore genetic data from minority populations.
PG  - 184-186
LID - 10.1038/d41586-020-02547-3 [doi]
FAU - Ben-Eghan, Chief
AU  - Ben-Eghan C
FAU - Sun, Rosie
AU  - Sun R
FAU - Hleap, Jose Sergio
AU  - Hleap JS
FAU - Diaz-Papkovich, Alex
AU  - Diaz-Papkovich A
FAU - Munter, Hans Markus
AU  - Munter HM
FAU - Grant, Audrey V
AU  - Grant AV
FAU - Dupras, Charles
AU  - Dupras C
FAU - Gravel, Simon
AU  - Gravel S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Humans
MH  - Minority Groups/*statistics & numerical data
MH  - Prejudice/*prevention & control
MH  - United Kingdom/ethnology
MH  - Whites/genetics
OTO - NOTNLM
OT  - *Ethics
OT  - *Genomics
OT  - *Society
EDAT- 2020/09/10 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/09 05:29
PHST- 2020/09/09 05:29 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1038/d41586-020-02547-3 [doi]
AID - 10.1038/d41586-020-02547-3 [pii]
PST - ppublish
SO  - Nature. 2020 Sep;585(7824):184-186. doi: 10.1038/d41586-020-02547-3.


PMID- 32900847
OWN - NLM
STAT- Publisher
LR  - 20200909
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 8
TI  - In defence of gestatelings: response to Colgrove.
LID - medethics-2020-106630 [pii]
LID - 10.1136/medethics-2020-106630 [doi]
AB  - Ectogestation-that is, 'artificial' or extramammalian pregnancy-may soon be
      within technological reach. This confronts us with questions about the correct
      moral and legal attitude towards the subjects of this technology, which are
      called 'gestatelings'. Colgrove argues that gestatelings are a kind of newborn,
      and consequently should have the same moral and legal protections as newborns.
      This paper responds that both claims are unsupported by his arguments, which
      equivocate on two understandings of the term 'newborn'. Questions about the
      appropriate moral and legal status of gestatelings are therefore (once again, and
      correctly) left unanswered, but in the course of attempting to answer them, we
      are well advised to continue using the term gestateling.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kingma, Elselijn
AU  - Kingma E
AUID- ORCID: http://orcid.org/0000-0001-9787-3198
AD  - Department of Philosophy, University of Southampton Faculty of Arts and
      Humanities, Southampton, UK e.m.kingma@soton.ac.uk.
AD  - Department of Industrial Engineering and Innovation Sciences, Eindhoven
      University of Technology, Eindhoven, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - abortion
OT  - embryos and fetuses
OT  - ethics
OT  - moral status
OT  - neonatology
COIS- Competing interests: None declared.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/09/09 05:25
PHST- 2020/06/27 00:00 [received]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/09/09 05:25 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - medethics-2020-106630 [pii]
AID - 10.1136/medethics-2020-106630 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 8. pii: medethics-2020-106630. doi:
      10.1136/medethics-2020-106630.


PMID- 32900846
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20220531
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Uncertainty, error and informed consent to challenge trials of COVID-19 vaccines:
      response to Steel et al.
PG  - 813-814
LID - 10.1136/medethics-2020-106793 [doi]
AB  - In a recent article, Steel, Buchak and Eyal (SBE) argue that current levels of
      uncertainty do not present a good reason to bar controlled human infection (CHI) 
      trials of COVID-19 vaccines from proceeding. We argue that their argumentation
      for this conclusion is flawed. SBE are mistaken about the effects which different
      forms of ignorance have on participants' ability to provide valid informed
      consent. Decision-makers considering whether to allow such trials, we argue, must
      ultimately consider the likelihood that consent to participation in such trials
      under current conditions would be valid, and whether this likelihood is high
      enough to permit such trials. This is a question that SBE completely ignore. We
      conclude that there indeed are valid concerns about conducting CHI trials given
      the current state of knowledge about COVID-19, concerns which SBE fail to
      address.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Keren, Arnon
AU  - Keren A
AUID- ORCID: 0000-0002-4899-5495
AD  - Department of Philosophy, University of Haifa, Haifa, Israel
      akeren@research.haifa.ac.il.
FAU - Lev, Ori
AU  - Lev O
AD  - Department of Public Policy and Administration, Sapir Academic College, Hof
      Ashkelon, Israel.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200908
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (COVID-19 Vaccines)
SB  - IM
CON - J Med Ethics. 2020 Dec;46(12):808-812. PMID: 32661074
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Informed Consent
MH  - Pandemics
MH  - SARS-CoV-2
MH  - Uncertainty
PMC - PMC7482142
OTO - NOTNLM
OT  - *autonomy
OT  - *clinical trials
OT  - *informed consent
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/09 05:25
PHST- 2020/08/14 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/09 05:25 [entrez]
AID - medethics-2020-106793 [pii]
AID - 10.1136/medethics-2020-106793 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):813-814. doi: 10.1136/medethics-2020-106793. Epub
      2020 Sep 8.


PMID- 32900845
OWN - NLM
STAT- Publisher
LR  - 20200909
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 8
TI  - Is one narrative enough? Analytical tools should match the problems they address.
LID - medethics-2020-106309 [pii]
LID - 10.1136/medethics-2020-106309 [doi]
AB  - Jeff Nisker describes his personal experience of a diagnosis of advanced prostate
      cancer and the kindnesses he received from friendly doctors. He claims that this 
      narrative account supports the promotion of Prostate Specific Antigen (PSA)
      screening for asymptomatic men and impugns statisticians, mistakenly thinking
      that their opposition to PSA screening derives from concerns about financial
      cost. The account inadvertently demonstrates the danger of over-reliance on a
      single ethical tool for critical analysis. In the first part of this response, we
      describe the statistical evidence. The most reliable Cochrane meta-analyses have 
      not shown that PSA screening saves lives overall. Moreover, the high false
      positive rate of PSA screening leads to overinvestigation which results in
      unnecessary anxiety and increased cases of unnecessary sepsis, urinary
      incontinence and sexual dysfunction. Then we describe how narrative ethics alone 
      is an insufficient tool to make claims about policies, such as PSA screening,
      which have hidden harms. Although Nisker's story-telling is compelling and evokes
      emotions, narrative ethics of this sort have an inherent bias against people who 
      would be harmed by the counterfactual. Particular care must be taken to look for 
      and consider those untellable stories. Ethicists who only consider narratives
      which are readily at hand risk harming those who are voiceless or protected by
      the status quo. PSA screening is the wrong tool to reduce prostate cancer deaths 
      and narrative ethics is the wrong tool to appraise this policy. It is vital that 
      the correct theoretical tools are applied to the medical and ethical questions
      under scrutiny.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hodson, Nathan
AU  - Hodson N
AUID- ORCID: http://orcid.org/0000-0001-6022-2260
AD  - Department of Health Policy and Management, Harvard University T H Chan School of
      Public Health, Boston, Massachusetts, USA n.hodson@doctors.org.uk.
FAU - Bewley, Susan
AU  - Bewley S
AD  - Department of Women and Children's Health, King's College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - philosophical ethics
OT  - primary care
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/09/09 05:25
PHST- 2020/04/15 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/09/09 05:25 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - medethics-2020-106309 [pii]
AID - 10.1136/medethics-2020-106309 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 8. pii: medethics-2020-106309. doi:
      10.1136/medethics-2020-106309.


PMID- 32900844
OWN - NLM
STAT- Publisher
LR  - 20200909
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 8
TI  - Postmortem non-directed sperm donation: quality matters.
LID - medethics-2020-106779 [pii]
LID - 10.1136/medethics-2020-106779 [doi]
AB  - In our paper 'The ethical case for non-directed postmortem sperm donation' we
      argued that it would be ethical for men to donate sperm after death for use by
      strangers. In their thoughtful response Fredrick and Ben Kroon lay out practical 
      concerns regarding our proposal. They raise issues regarding the quality of sperm
      collected postmortem based on empirical studies. Second, they claim that concerns
      about quality would make women unlikely to use sperm collected after death. In
      this response we explore issues of sperm quality in both living and dead donors. 
      We consider whether there might be ways to ensure quality in both. Finally, we
      question whether quality should be a barrier to women choosing to use sperm
      donated after death.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Parker, Joshua
AU  - Parker J
AUID- ORCID: http://orcid.org/0000-0001-5934-8755
AD  - Department of Medicine, Wythenshawe Hospital Education and Research Centre,
      Manchester, UK joshua.parker@doctors.org.uk.
FAU - Hodson, Nathan
AU  - Hodson N
AUID- ORCID: http://orcid.org/0000-0001-6022-2260
AD  - Division of Health Policy and Management, Harvard TH Chan School of Public
      Health, Boston Massachusetts, MA, United States.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - artificial insemination and surrogacy
OT  - cryobanking of sperm
OT  - donation/procurement of organs/tissues
OT  - ova or embryos
OT  - reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/09/09 05:25
PHST- 2020/08/08 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/09 05:25 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - medethics-2020-106779 [pii]
AID - 10.1136/medethics-2020-106779 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 8. pii: medethics-2020-106779. doi:
      10.1136/medethics-2020-106779.


PMID- 32900819
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1943-3662 (Electronic)
IS  - 1093-6793 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Dec
TI  - Ethics in the Time of Injustice.
PG  - 428-430
LID - 10.29158/JAAPL.200067-20 [doi]
FAU - Martinez, Richard
AU  - Martinez R
AD  - Dr. Martinez is Director of Forensic Psychiatry and Fellowship Training, and the 
      Robert D. Miller Professor of Forensic Psychiatry, University of Colorado
      Anschutz Medical Center, Denver, CO. Dr. Candilis is Director of Medical Affairs 
      and co-Director of the Forensic Psychiatry Fellowship, Saint Elizabeths Hospital,
      Washington DC, and Professor of Psychiatry, George Washington University School
      of Medicine and Health Sciences, Washington, DC. richardp.martinez@state.co.us.
FAU - Candilis, Philip
AU  - Candilis P
AD  - Dr. Martinez is Director of Forensic Psychiatry and Fellowship Training, and the 
      Robert D. Miller Professor of Forensic Psychiatry, University of Colorado
      Anschutz Medical Center, Denver, CO. Dr. Candilis is Director of Medical Affairs 
      and co-Director of the Forensic Psychiatry Fellowship, Saint Elizabeths Hospital,
      Washington DC, and Professor of Psychiatry, George Washington University School
      of Medicine and Health Sciences, Washington, DC.
LA  - eng
PT  - Editorial
DEP - 20200908
PL  - United States
TA  - J Am Acad Psychiatry Law
JT  - The journal of the American Academy of Psychiatry and the Law
JID - 9708963
SB  - IM
MH  - Forensic Psychiatry/*ethics
MH  - Humans
MH  - *Prejudice
MH  - Professionalism/*ethics
MH  - *Racism
MH  - Societies, Medical/*ethics
MH  - Vulnerable Populations/*ethnology
OTO - NOTNLM
OT  - *ethics
OT  - *forensic psychiatry
OT  - *justice
OT  - *racism
EDAT- 2020/09/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/09 05:25
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/09 05:25 [entrez]
AID - JAAPL.200067-20 [pii]
AID - 10.29158/JAAPL.200067-20 [doi]
PST - ppublish
SO  - J Am Acad Psychiatry Law. 2020 Dec;48(4):428-430. doi: 10.29158/JAAPL.200067-20. 
      Epub 2020 Sep 8.


PMID- 32900761
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 8
TI  - Cancer Loyalty Card Study (CLOCS): protocol for an observational case-control
      study focusing on the patient interval in ovarian cancer diagnosis.
PG  - e037459
LID - 10.1136/bmjopen-2020-037459 [doi]
AB  - INTRODUCTION: Ovarian cancer is the eighth most common cancer in women worldwide,
      and about 1 in 5 women with ovarian cancer do not receive treatment, because they
      are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are
      non-specific or can be associated with other common conditions, and women
      experiencing these symptoms have been shown to self-manage them using
      over-the-counter medication. Results from a recent proof-of-concept study suggest
      there may be an increase in the purchases of painkillers and indigestion
      medication 10-12 months before ovarian cancer diagnosis. We propose a
      case-control study, as part of a larger project called the Cancer Loyalty Card
      Study (CLOCS), to investigate whether a significant change in medication
      purchases could be an indication for early signs of ovarian cancer, using data
      already collected through store loyalty cards. METHODS AND ANALYSIS: Using a
      retrospective case-control design, we aim to recruit 500 women diagnosed with
      ovarian cancer (cases) and 500 women without ovarian cancer (controls) in the UK 
      who hold a loyalty card with at least one participating high street retailer. We 
      will use pre-existing loyalty card data to compare past purchase patterns of
      cases with those of controls. In order to assess ovarian cancer risk in
      participants and their purchase patterns, we will collect information from
      participants on ovarian cancer risk factors and clinical data including symptoms 
      experienced before diagnosis from recruited women with ovarian cancer. ETHICS AND
      DISSEMINATION: CLOCS was reviewed and approved by the North West-Greater
      Manchester South Research Ethics Committee (19/NW/0427). Study outcomes will be
      disseminated through academic publications, the study website, social media and a
      report to the research sites that support the study once results are published.
      TRIAL REGISTRATION NUMBER: ISRCTN 14897082, CPMS 43323, NCT03994653.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brewer, Hannah R
AU  - Brewer HR
AD  - Surgery and Cancer, Imperial College London, London, UK.
FAU - Hirst, Yasemin
AU  - Hirst Y
AD  - Behavioural Science and Health, University College London, London, UK.
FAU - Sundar, Sudha
AU  - Sundar S
AD  - Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham,
      UK.
AD  - Pan-Birmingham Gynaecological Cancer Centre, City Hospital, Birmingham, UK.
FAU - Chadeau-Hyam, Marc
AU  - Chadeau-Hyam M
AD  - MRC Centre for Environment and Health, Imperial College London, London, UK.
AD  - Epidemiology and Biostatistics, School of Public Health, Imperial College London,
      London, UK.
FAU - Flanagan, James M
AU  - Flanagan JM
AUID- ORCID: 0000-0003-4955-1383
AD  - Surgery and Cancer, Imperial College London, London, UK
      j.flanagan@imperial.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT03994653
SI  - ISRCTN/ISRCTN14897082
GR  - MR/S019669/1/MRC_/Medical Research Council/United Kingdom
GR  - C38463/A26726/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200908
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Carcinoma, Ovarian Epithelial
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Observational Studies as Topic
MH  - *Ovarian Neoplasms/diagnosis
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC7484869
OTO - NOTNLM
OT  - *epidemiology
OT  - *gynaecological oncology
OT  - *oncology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/09 05:25
PHST- 2020/09/09 05:25 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037459 [pii]
AID - 10.1136/bmjopen-2020-037459 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 8;10(9):e037459. doi: 10.1136/bmjopen-2020-037459.


PMID- 32900481
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 532
IP  - 4
DP  - 2020 Nov 19
TI  - Sex hormone-binding globulin regulates the activity of the ERK pathway in the
      placentas of patients with gestational diabetes mellitus.
PG  - 613-619
LID - S0006-291X(20)31700-9 [pii]
LID - 10.1016/j.bbrc.2020.08.100 [doi]
AB  - The sex hormone-binding globulin (SHBG) is involved in the onset and progression 
      of insulin resistance and metabolic syndromes, with its expression downregulated 
      in the placental tissues of patients with gestational diabetes mellitus (GDM).
      However, the underlying mechanisms for these effects remain unclear. In this
      study, we enrolled an equal number (30) of GDM and non-GDM puerperae who
      underwent cesarean section at Shengjing Hospital. After due approval by the
      ethics committee, the expression levels of SHBG and
      extracellular-signal-regulated kinase (ERK) pathway markers in the placental
      tissues of these individuals were measured via reverse transcription-polymerase
      chain reaction (RT-PCR) and Western blot assays. The correlation analysis of
      these genes revealed that the expression of SHBG in placental tissues was
      downregulated and negatively correlated with the expression of ERK pathway
      markers, which were upregulated in placental tissues. Further investigations
      using the HTR-8/SVneo trophoblast cell line revealed that the trophoblasts with
      small interfering RNA (siRNA)-silenced SHBG expression displayed increased mRNA
      and protein expression levels of ERK pathway markers, as well as reduced
      apoptosis and enhanced proliferation. In contrast, trophoblasts with high SHBG
      expression showed a downregulated expression of ERK pathway markers, increased
      apoptosis, reduced proliferation, and a shorter S phase. Therefore, we believe
      that SHBG may participate in the onset of insulin resistance and GDM by
      regulating the activity of the ERK pathway.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical
      University, Shenyang, China.
FAU - Chi, Xinshu
AU  - Chi X
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical
      University, Shenyang, China.
FAU - Feng, Chong
AU  - Feng C
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical
      University, Shenyang, China.
FAU - Zhang, Xuan
AU  - Zhang X
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical
      University, Shenyang, China.
FAU - Jin, Zhen
AU  - Jin Z
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical
      University, Shenyang, China. Electronic address: jinz@sj-hospital.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Sex Hormone-Binding Globulin)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Adult
MH  - Cell Line
MH  - Diabetes, Gestational/enzymology/genetics/*metabolism
MH  - Extracellular Signal-Regulated MAP Kinases/*metabolism
MH  - Female
MH  - Humans
MH  - MAP Kinase Signaling System
MH  - Male
MH  - Placenta/enzymology/*metabolism
MH  - Pregnancy
MH  - Sex Hormone-Binding Globulin/*metabolism
MH  - Trophoblasts/cytology/enzymology/metabolism
OTO - NOTNLM
OT  - *ERK pathway
OT  - *Gestational diabetes mellitus
OT  - *Insulin resistance
OT  - *Introduction
OT  - *Sex hormone-binding globulin
EDAT- 2020/09/10 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/09/09 05:23
PHST- 2020/08/23 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
PHST- 2020/09/09 05:23 [entrez]
AID - S0006-291X(20)31700-9 [pii]
AID - 10.1016/j.bbrc.2020.08.100 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2020 Nov 19;532(4):613-619. doi:
      10.1016/j.bbrc.2020.08.100. Epub 2020 Sep 6.


PMID- 32900388
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20201218
IS  - 1747-5341 (Electronic)
IS  - 1747-5341 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Sep 9
TI  - A Duty to treat? A Right to refrain? Bangladeshi physicians in moral dilemma
      during COVID-19.
PG  - 7
LID - 10.1186/s13010-020-00091-6 [doi]
AB  - BACKGROUND: Normally, physicians understand they have a duty to treat patients,
      and they perform accordingly consistent with codes of medical practice, standards
      of care, and inner moral motivation. In the case of COVID-19 pandemic in a
      developing country such as Bangladesh, however, the fact is that some physicians 
      decline either to report for duty or to treat patients presenting with COVID-19
      symptoms. At issue ethically is whether such medical practitioners are to be
      automatically disciplined for dereliction of duty and gross negligence; or, on
      the contrary, such physicians may legitimately claim a professional right of
      autonomous judgment, on the basis of which professional right they may
      justifiably decline to treat patients. METHODS: This ethical issue is examined
      with a view to providing some guidance and recommendations, insofar as the
      conditions of medical practice in an under-resourced country such as Bangladesh
      are vastly different from medical practice in an industrialized nation such as
      the USA. The concept of moral dilemma as discussed by philosopher Michael Shaw
      Perry and philosopher Immanuel Kant's views on moral appeal to "emergency" are
      considered pertinent to sorting through the moral conundrum of medical care
      during pandemic. RESULTS: Our analysis allows for conditional physician
      discretion in the decision to treat COVID-19 patients, i.e., in the absence of
      personal protective equipment (PPE) combined with claim of duty to family.
      Physicians are nonetheless expected to provide a minimum of initial clinical
      assessment and stabilization of a patient before initiating transfer of a patient
      to a "designated" COVID-19 hospital. The latter is to be done in coordination
      with the national center control room that can assure admission of a patient to a
      referral hospital prior to ambulance transport. CONCLUSIONS: The presence of a
      moral dilemma (i.e., conflict of obligations) in the pandemic situation of
      clinical care requires institutional authorities to exercise tolerance of
      individual physician moral decision about the duty to care. Hospital or
      government authority should respond to such decisions without introducing
      immediate sanction, such as suspension from all clinical duties or termination of
      licensure, and instead arrange for alternative clinical duties consistent with
      routine medical care.
FAU - Swazo, Norman K
AU  - Swazo NK
AD  - Department of History and Philosophy, North South University, Dhaka, Bangladesh. 
      norman.swazo@northsouth.edu.
FAU - Talukder, Md Munir Hossain
AU  - Talukder MMH
AD  - Department of Philosophy, Jahangirnagar University, Savar, Dhaka, 1342,
      Bangladesh.
FAU - Ahsan, Mohammad Kamrul
AU  - Ahsan MK
AD  - Department of Philosophy, Jahangirnagar University, Savar, Dhaka, 1342,
      Bangladesh.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - Philos Ethics Humanit Med
JT  - Philosophy, ethics, and humanities in medicine : PEHM
JID - 101258058
SB  - IM
MH  - Bangladesh
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Moral Obligations
MH  - *Pandemics
MH  - Physicians/*ethics
MH  - *Pneumonia, Viral
MH  - Professional Autonomy
MH  - Refusal to Treat/*ethics
MH  - SARS-CoV-2
PMC - PMC7478915
OTO - NOTNLM
OT  - *Bangladesh
OT  - *COVID-19
OT  - *Duty to treat
OT  - *Medical ethics
OT  - *Pandemic
OT  - *Professional autonomy
EDAT- 2020/09/10 06:00
MHDA- 2020/09/20 06:00
CRDT- 2020/09/09 05:21
PHST- 2020/07/03 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/09 05:21 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
AID - 10.1186/s13010-020-00091-6 [doi]
AID - 10.1186/s13010-020-00091-6 [pii]
PST - epublish
SO  - Philos Ethics Humanit Med. 2020 Sep 9;15(1):7. doi: 10.1186/s13010-020-00091-6.


PMID- 32899937
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Sep 6
TI  - Attitudes and Behavior towards Interprofessional Collaboration among Healthcare
      Professionals in a Large Academic Medical Center.
LID - E323 [pii]
LID - 10.3390/healthcare8030323 [doi]
AB  - The increasing rates of comorbidities among patients and the complexity of care
      have warranted interprofessional collaboration (IPC) as an important component of
      the healthcare structure. An initial step towards assessing the effectiveness of 
      collaboration requires the exploration of the attitudes and experience of
      healthcare professionals towards IPC. This online survey aimed to examine the
      attitudes of healthcare professionals working in a large public academic medical 
      center toward IPC in patient care and the healthcare team, and their behavior and
      experience regarding IPC. The rankings, according to the perceived importance
      among the respondents, of the four Interprofessional Education Collaborative
      (IPEC) core competencies (values/ethics, roles/responsibilities,
      interprofessional communication, teams/teamwork) were assessed. There were strong
      but varying levels of consensus among healthcare professionals (N = 551) that IPC
      facilitates efficient patient care, improves patient problem-solving ability, and
      increases better clinical outcomes for patients. They acknowledged that IPC
      promotes mutual respect within the healthcare team and providers' ability to make
      optimal patient care decisions. However, overall more than 35% of the respondents
      did not attend multidisciplinary education sessions (grand rounds, seminars,
      etc.), and about 23% did not participate in bedside patient care rounds.
      Interprofessional communication was ranked as the most important IPEC core
      competence. Although the attitude towards IPC among healthcare professionals is
      strongly positive, many healthcare professionals face challenges in participating
      in IPC. Institutional policies that facilitate interprofessional learning and
      interactions for this group of healthcare professionals should be formulated.
      Online distance learning and interactions, and simulation-enhanced
      interprofessional education, are options for addressing this barrier. Hospital
      administrators should facilitate conducive work environments that promote IPC,
      based on IPEC core competencies, and promote programs that address the challenges
      of IPC.
FAU - Ansa, Benjamin E
AU  - Ansa BE
AUID- ORCID: 0000-0002-1285-974X
AD  - Applied Health Sciences Program, College of Allied Health Sciences, Augusta
      University, Augusta, GA 30912, USA.
AD  - Institute of Public and Preventive Health, Augusta University, Augusta, GA 30912,
      USA.
FAU - Zechariah, Sunitha
AU  - Zechariah S
AUID- ORCID: 0000-0002-8020-4921
AD  - Applied Health Sciences Program, College of Allied Health Sciences, Augusta
      University, Augusta, GA 30912, USA.
AD  - Morrison Healthcare, Sandy Springs, GA 30350, USA.
FAU - Gates, Amy M
AU  - Gates AM
AD  - Applied Health Sciences Program, College of Allied Health Sciences, Augusta
      University, Augusta, GA 30912, USA.
AD  - Neonatal Intensive Care Unit, Augusta University Health, Augusta, GA 30912, USA.
FAU - Johnson, Stephanie W
AU  - Johnson SW
AD  - Applied Health Sciences Program, College of Allied Health Sciences, Augusta
      University, Augusta, GA 30912, USA.
AD  - Occupational Therapy, College of Allied Health Sciences, Augusta University,
      Augusta, GA 30912, USA.
FAU - Heboyan, Vahe
AU  - Heboyan V
AUID- ORCID: 0000-0002-4949-7703
AD  - Health Economics and Modeling Division, Population Health Sciences Department,
      Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
FAU - De Leo, Gianluca
AU  - De Leo G
AUID- ORCID: 0000-0001-6836-8360
AD  - Department of Interdisciplinary Health Sciences, College of Allied Health
      Sciences, Augusta University, Augusta, GA 30921, USA.
LA  - eng
PT  - Journal Article
DEP - 20200906
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7551229
OTO - NOTNLM
OT  - academic medical center
OT  - attitudes
OT  - behavior
OT  - healthcare professionals
OT  - interprofessional collaboration
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 01:05
PHST- 2020/08/04 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/03 00:00 [accepted]
PHST- 2020/09/09 01:05 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - healthcare8030323 [pii]
AID - 10.3390/healthcare8030323 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Sep 6;8(3). pii: healthcare8030323. doi:
      10.3390/healthcare8030323.


PMID- 32899885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 4
TI  - Laparoscopic Surgery in COVID-19 Era-Safety and Ethical Issues.
LID - E673 [pii]
LID - 10.3390/diagnostics10090673 [doi]
AB  - (1) Background: The paper aims to review the available evidence regarding the
      health risk of the aerosolization induced by laparoscopy induced and impact of
      the COVID-19 pandemic upon minimally invasive surgery. (2) Materials and methods:
      A systematic review of the literature was performed on PubMed, Medline and Scopus
      until 10 July. (3) Results: Chemicals, carcinogens and biologically active
      materials, such as bacteria and viruses, have been isolated in surgical smoke.
      However, the only evidence of viral transmission through surgical smoke to
      medical staff is post-laser ablation of HPV-positive genital warts. The reports
      of SARS-CoV-2 infected patients who underwent laparoscopic surgery revealed the
      presence of the virus, when tested, in digestive wall and stools in 50% of cases 
      but not in bile or peritoneal fluid. All surgeries did not result in
      contamination of the personnel, when protective measures were applied, including 
      personal protective equipment (PPE) and filtration of the pneumoperitoneum. There
      are no comparative studies between classical and laparoscopic surgery. (4)
      Conclusions: Previously published data showed there is a possible infectious and 
      toxic risk related to surgical smoke but not particularly proven for SARS-CoV-2. 
      Implementing standardized filtration systems for smoke evacuation during
      laparoscopy, although increases costs, is necessary to increase the safety and it
      will probably remain a routine also in the future.
FAU - Serban, Dragos
AU  - Serban D
AUID- ORCID: 0000-0002-1380-2112
AD  - Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy
      Bucharest, 030167 Bucharest, Romania.
AD  - IVth Department of Surgery, Emergency University Hospital Bucharest, 050098
      Bucharest, Romania.
FAU - Smarandache, Catalin Gabriel
AU  - Smarandache CG
AD  - Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy
      Bucharest, 030167 Bucharest, Romania.
AD  - IVth Department of Surgery, Emergency University Hospital Bucharest, 050098
      Bucharest, Romania.
FAU - Tudor, Corneliu
AU  - Tudor C
AD  - IVth Department of Surgery, Emergency University Hospital Bucharest, 050098
      Bucharest, Romania.
FAU - Duta, Lucian Nicolae
AU  - Duta LN
AD  - IVth Department of Surgery, Emergency University Hospital Bucharest, 050098
      Bucharest, Romania.
FAU - Dascalu, Ana Maria
AU  - Dascalu AM
AUID- ORCID: 0000-0002-7474-2395
AD  - Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy
      Bucharest, 030167 Bucharest, Romania.
FAU - Alius, Catalin
AU  - Alius C
AD  - IVth Department of Surgery, Emergency University Hospital Bucharest, 050098
      Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200904
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7555582
OTO - NOTNLM
OT  - COVID-19
OT  - aerosolization
OT  - filtration
OT  - laparoscopy
OT  - surgical plume
EDAT- 2020/09/10 06:00
MHDA- 2020/09/10 06:01
CRDT- 2020/09/09 01:05
PHST- 2020/07/24 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/09 01:05 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/10 06:01 [medline]
AID - diagnostics10090673 [pii]
AID - 10.3390/diagnostics10090673 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2020 Sep 4;10(9). pii: diagnostics10090673. doi:
      10.3390/diagnostics10090673.


PMID- 32899861
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 4
TI  - A Humanities-Based Explanation for the Effects of Emotional Eating and Perceived 
      Stress on Food Choice Motives during the COVID-19 Pandemic.
LID - E2712 [pii]
LID - 10.3390/nu12092712 [doi]
AB  - Perceived stress affects emotional eating and food choices. However, the extent
      to which stress associates with food choice motives is not completely understood.
      This study assessed whether emotional eating mediates the associations between
      perceived stress levels and food choice motives (i.e., health, mood, convenience,
      natural content, price, sensory appeal, familiarities, weight control, and
      ethical concerns) during the Coronavirus Disease 2019 pandemic. A total of 800
      respondents were surveyed in the United States in June 2020. Their perceived
      stress, emotional eating, and food choice motives were assessed by the Perceived 
      Stress Scale, Dutch Eating Behavior Questionnaire, and Food Choice Questionnaire,
      respectively. Moderate to high levels of perceived stress were experienced by the
      majority (73.6%) of respondents. Perceived stress was significantly correlated
      with emotional eating (r = 0.26) as well as five out of nine food choice motives:
      mood (r = 0.32), convenience (r = 0.28), natural content (r = -0.14), price (r = 
      0.27), and familiarity (r = 0.15). Emotional eating was significantly correlated 
      with four out of nine food choice motives: mood (r = 0.27), convenience (r =
      0.23), price (r = 0.16), and familiarity (r = 0.16). The mediation analyses
      showed that emotional eating mediates the associations between perceived stress
      and five food choices motives: mood, convenience, sensory appeal, price, and
      familiarity. Findings were interpreted using theories and concepts from the
      humanities, specifically, folklore studies, ritual studies, and symbolic
      anthropology.
FAU - Shen, Wan
AU  - Shen W
AUID- ORCID: 0000-0002-9137-3245
AD  - Food and Nutrition Program, Department of Public and Allied Health, Bowling Green
      State University, Bowling Green, OH 43403, USA.
FAU - Long, Lucy M
AU  - Long LM
AD  - Center for Food and Culture, 550 West Wooster St, Bowling Green, OH 43402, USA.
AD  - Institute for Study of Culture and Society, Bowling Green State University,
      Bowling Green, OH 43403, USA.
FAU - Shih, Chia-Hao
AU  - Shih CH
AD  - Department of Psychiatry, University of Toledo, Toledo, OH 43606, USA.
FAU - Ludy, Mary-Jon
AU  - Ludy MJ
AUID- ORCID: 0000-0002-7887-255X
AD  - Food and Nutrition Program, Department of Public and Allied Health, Bowling Green
      State University, Bowling Green, OH 43403, USA.
LA  - eng
PT  - Journal Article
DEP - 20200904
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
MH  - Adult
MH  - Affect
MH  - Betacoronavirus
MH  - COVID-19
MH  - Choice Behavior
MH  - Coronavirus Infections/prevention & control/*psychology
MH  - Diagnostic Self Evaluation
MH  - Emotions
MH  - Feeding Behavior/*psychology
MH  - Female
MH  - Food Preferences/*psychology
MH  - Humanities
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Motivation
MH  - Pandemics/prevention & control
MH  - Perception
MH  - Pneumonia, Viral/prevention & control/*psychology
MH  - Quarantine/*psychology
MH  - Recognition, Psychology
MH  - SARS-CoV-2
MH  - Stress, Psychological/*psychology
MH  - Surveys and Questionnaires
MH  - United States
PMC - PMC7551550
OTO - NOTNLM
OT  - COVID-19
OT  - emotional eating
OT  - food choice motives
OT  - perceived stress
EDAT- 2020/09/10 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/09 01:05
PHST- 2020/08/12 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/09/09 01:05 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - nu12092712 [pii]
AID - 10.3390/nu12092712 [doi]
PST - epublish
SO  - Nutrients. 2020 Sep 4;12(9). pii: nu12092712. doi: 10.3390/nu12092712.


PMID- 32899411
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 17
DP  - 2020 Sep 3
TI  - Investigating Developmental and Epileptic Encephalopathy Using Drosophila
      melanogaster.
LID - E6442 [pii]
LID - 10.3390/ijms21176442 [doi]
AB  - Developmental and epileptic encephalopathies (DEEs) are the spectrum of severe
      epilepsies characterized by early-onset, refractory seizures occurring in the
      context of developmental regression or plateauing. Early infantile epileptic
      encephalopathy (EIEE) is one of the earliest forms of DEE, manifesting as
      frequent epileptic spasms and characteristic electroencephalogram findings in
      early infancy. In recent years, next-generation sequencing approaches have
      identified a number of monogenic determinants underlying DEE. In the case of
      EIEE, 85 genes have been registered in Online Mendelian Inheritance in Man as
      causative genes. Model organisms are indispensable tools for understanding the in
      vivo roles of the newly identified causative genes. In this review, we first
      present an overview of epilepsy and its genetic etiology, especially focusing on 
      EIEE and then briefly summarize epilepsy research using animal and
      patient-derived induced pluripotent stem cell (iPSC) models. The Drosophila
      model, which is characterized by easy gene manipulation, a short generation time,
      low cost and fewer ethical restrictions when designing experiments, is optimal
      for understanding the genetics of DEE. We therefore highlight studies with
      Drosophila models for EIEE and discuss the future development of their practical 
      use.
FAU - Takai, Akari
AU  - Takai A
AUID- ORCID: 0000-0002-8830-3887
AD  - Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kyoto 602-8566, Japan.
FAU - Yamaguchi, Masamitsu
AU  - Yamaguchi M
AD  - Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki,
      Sakyo-ku, Kyoto 603-8585, Japan.
AD  - Kansai Gakken Laboratory, Kankyo Eisei Yakuhin Co. Ltd., Kyoto 619-0237, Japan.
FAU - Yoshida, Hideki
AU  - Yoshida H
AUID- ORCID: 0000-0001-5911-0659
AD  - Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki,
      Sakyo-ku, Kyoto 603-8585, Japan.
FAU - Chiyonobu, Tomohiro
AU  - Chiyonobu T
AUID- ORCID: 0000-0001-6678-060X
AD  - Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural
      University of Medicine, Kyoto 602-8566, Japan.
LA  - eng
GR  - JP18K07796/Japan Society for the Promotion of Science
PT  - Journal Article
PT  - Review
DEP - 20200903
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - Infantile Epileptic-Dyskinetic Encephalopathy
SB  - IM
MH  - Animals
MH  - Drosophila melanogaster/*genetics/*growth & development
MH  - Phenotype
MH  - Spasms, Infantile/etiology/*pathology
PMC - PMC7503973
OTO - NOTNLM
OT  - Drosophila melanogaster
OT  - bang-sensitivity
OT  - developmental and epileptic encephalopathies
OT  - drug screening
OT  - early infantile epileptic encephalopathy
OT  - genetic screening
EDAT- 2020/09/10 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/09/09 01:03
PHST- 2020/08/15 00:00 [received]
PHST- 2020/08/30 00:00 [revised]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/09/09 01:03 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - ijms21176442 [pii]
AID - 10.3390/ijms21176442 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Sep 3;21(17). pii: ijms21176442. doi: 10.3390/ijms21176442.


PMID- 32899386
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - The Skeleton in the Closet: Faults and Strengths of Public Versus Private Genetic
      Biobanks.
LID - E1273 [pii]
LID - 10.3390/biom10091273 [doi]
AB  - Direct-to-consumer (DTC) genetic testing has been a major ethical controversy
      related to clinical utility, the availability of pre- and post-genetic
      counseling, privacy concerns, and the risk of discrimination and stigmatization. 
      The development of direct-to-consumer genetic testing cannot leave aside some
      considerations on how the samples are managed once the analyses have been
      completed and the customer has received a response. The possibility that these
      samples are maintained by the structure for future research uses, explains the
      definition, which has been proposed in the literature, of these structures such
      as private genetic biobanks. The most relevant aspects that may impact ethical
      aspects, allowing a comparison between the public and private dimensions of
      genetic biobanks, are mainly transparency and participant/donor trust. The
      article aims to analyze the main line of ethical debate related to the mentioned 
      practices and to explore whether market-based and consumer rights regarding DTC
      genetic testing can be counterbalanced by healthcare system developments based on
      policies that encourage the donation of samples in the context of public
      biobanks. A platform for dialogue, both technical-scientific and ethical, is
      indispensable between the public sector, the private sector and citizens to truly
      maximize both transparency and public trust in both contexts.
FAU - Tozzo, Pamela
AU  - Tozzo P
AD  - Department of Molecular Medicine, Laboratory of Forensic Genetics, University of 
      Padova, 35121 Padova, Italy.
FAU - Caenazzo, Luciana
AU  - Caenazzo L
AUID- ORCID: 0000-0003-3142-2874
AD  - Department of Molecular Medicine, Laboratory of Forensic Genetics, University of 
      Padova, 35121 Padova, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
SB  - IM
MH  - Bioethics
MH  - Biological Specimen Banks/*ethics
MH  - Genetic Privacy
MH  - Genetic Research/*ethics
MH  - Genetic Testing/*ethics
MH  - Humans
MH  - Information Dissemination
MH  - Private Sector
MH  - Public Sector
PMC - PMC7564942
OTO - NOTNLM
OT  - *DTC genetic testing
OT  - *genomic data sharing
OT  - *private biobank
OT  - *public biobank
OT  - *public trust
EDAT- 2020/09/10 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/09 01:03
PHST- 2020/07/14 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/09 01:03 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - biom10091273 [pii]
AID - 10.3390/biom10091273 [doi]
PST - epublish
SO  - Biomolecules. 2020 Sep 3;10(9). pii: biom10091273. doi: 10.3390/biom10091273.


PMID- 32899062
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - Efficacy and safety of traditional Chinese herbal formula combined with western
      medicine for uterine fibroid: A protocol for systematic review and meta-analysis.
PG  - e22039
LID - 10.1097/MD.0000000000022039 [doi]
AB  - BACKGROUND: Clinical studies found that the combination of traditional Chinese
      herbal formula, and western medicine therapy are better in shrinking fibroids and
      improve other symptoms. This study aims to systematically evaluate the efficacy
      and safety traditional Chinese herbal formula combined with western medicine in
      the treatment of uterine fibroids. METHODS: Randomized controlled trials of
      traditional Chinese herbal formula combined with western medicine for uterine
      fibroids patients will be searched in PubMed, Medline, Embase, Cochrane Library, 
      China National Knowledge Infrastructure (CNKI), Chongqing VIP Chinese Science and
      Technology Periodical Database, Chinese Biological and Medical database (CMB),
      and Wanfang database from inception to August 2020. Two researchers will perform 
      data extraction and risk of bias assessment independently. Statistical analysis
      will be conducted in RevMan 5.3. RESULTS: This study will summarize the present
      evidence by exploring the efficacy and safety of traditional Chinese herbal
      formula combined with western medicine in the treatment of uterine fibroids
      CONCLUSIONS:: The findings of the study will help to determine potential benefits
      of traditional Chinese herbal formula combined with western medicine in the
      treatment of uterine fibroids. ETHICS AND DISSEMINATION: The private information 
      from individuals will not be published. This systematic review also will not
      involve endangering participant rights. Ethical approval is not required. The
      results may be published in a peer-reviewed journal or disseminated in relevant
      conferences. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/XUA8V.
FAU - Fu, Yu
AU  - Fu Y
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province.
AD  - Ethnic Medicine Research Institute of Southeast of Guizhou province, Kaili,
      Guizhou province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Fan, Wei
AU  - Fan W
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Lv, Yubing
AU  - Lv Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Ai, Siyu
AU  - Ai S
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Yu, Chenghao
AU  - Yu C
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - China/epidemiology
MH  - Combined Modality Therapy
MH  - Drug Prescriptions/standards
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Leiomyoma/*drug therapy
MH  - Medicine, Chinese Traditional/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7478476
EDAT- 2020/09/10 06:00
MHDA- 2020/09/20 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
AID - 10.1097/MD.0000000000022039 [doi]
AID - 00005792-202009040-00074 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e22039. doi: 10.1097/MD.0000000000022039.


PMID- 32899059
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - Coronavirus disease 2019 (COVID-19) related cytopenia: A protocol for systematic 
      review and meta-analysis.
PG  - e22033
LID - 10.1097/MD.0000000000022033 [doi]
AB  - BACKGROUND: In December 2019, the novel coronavirus pneumonia was detected in
      Wuhan and named COVID-19. It is an international outbreak of the respiratory
      illness caused by severe acute respiratory syndrome coronavirus 2. Recent papers 
      pointed out the cytopenia in COVID-19 patients including lymphopenia,
      neutrophilia, thrombocytopenia and lower level of hemoglobin had prognostic
      significance. This systemic review and meta-analysis summaries the latest
      evidence from available data and determine the hematological abnormality caused
      by severe acute respiratory syndrome coronavirus 2 and potential efficacy on the 
      outcomes in patients with COVID-19. METHODS: This protocol for a systematic
      reviews and meta-analysis will be performed according to the preferred reporting 
      items for systematic reviews and meta-analysis protocols 2015 guidelines. The
      database of Cochrane Library, PUBMED, EMBASE, Medline, Web of Science, Google
      Scholar, CNKI, WanFang, as well as gray literatures from the inception to present
      will be comprehensively and systematically searched without limitations of
      regions or language. The main study outcomes will be the mortality of COVID-19
      patients. The meta-analysis was performed by RevMan V.5.3 program and Stata
      V.12.0 software after 2 reviewers independently selected literature, data
      extraction, bias risk evaluation and study quality assessment. Any disagreement
      will be resolved by consensus to the third researcher. RESULTS: This systematic
      review and meta-analysis may help provide clarify on the effect of cytopenia in
      patients with COVID-19. The result will be published at a peer-reviewed journal. 
      CONCLUSIONS: This proposed study will evaluate the existing evidence on the
      effectiveness of cytopenia in COVID-19 patients. ETHIC AND DISSEMINATION: The
      content of this article does not involve moral approval or ethical review because
      no individual data will be collected. PROSPERO REGISTRATION: CRD42020187524.
FAU - Li, Yiwei
AU  - Li Y
AD  - Department of Hematology, Affiliated Hangzhou First People's Hospital, Nanjing
      Medical University.
FAU - Weng, Qianping
AU  - Weng Q
AD  - Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang
      University School of Medicine, Hangzhou, Zhejiang, PR. China.
FAU - Huang, Xilian
AU  - Huang X
AD  - Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang
      University School of Medicine, Hangzhou, Zhejiang, PR. China.
FAU - Xie, Yaping
AU  - Xie Y
AD  - Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang
      University School of Medicine, Hangzhou, Zhejiang, PR. China.
FAU - Chen, Can
AU  - Chen C
AD  - Department of Hematology, Affiliated Hangzhou First People's Hospital, Nanjing
      Medical University.
FAU - Qian, Shenxian
AU  - Qian S
AD  - Department of Hematology, Affiliated Hangzhou First People's Hospital, Nanjing
      Medical University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/physiopathology
MH  - Humans
MH  - Leukocyte Disorders/*etiology/physiopathology
MH  - Pandemics
MH  - Pneumonia, Viral/*complications/physiopathology
MH  - SARS-CoV-2
MH  - Thrombocytopenia/*etiology/physiopathology
PMC - PMC7478643
EDAT- 2020/09/10 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - 10.1097/MD.0000000000022033 [doi]
AID - 00005792-202009040-00071 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e22033. doi: 10.1097/MD.0000000000022033.


PMID- 32899054
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - Tuberculosis infection in children visiting friends and relatives in countries
      with high incidence of tuberculosis: A study protocol.
PG  - e22015
LID - 10.1097/MD.0000000000022015 [doi]
AB  - INTRODUCTION: Tuberculosis (TB) is a global infectious disease. In low-incidence 
      countries, paediatric TB affects mostly immigrant children and children of
      immigrants. We hypothesize that these children are at risk of exposure to
      Mycobacterium tuberculosis when they travel to the country of origin of their
      parents to visit friends and relatives (VFR). In this study, we aim to estimate
      the incidence rate and risk factors associated to latent tuberculosis infection
      (LTBI) and TB in VFR children. METHODS AND ANALYSIS: A prospective study will be 
      carried out in collaboration with 21 primary health care centres (PCC) and 5
      hospitals in Catalonia, Spain. The study participants are children under 15 years
      of age, either immigrant themselves or born to immigrant parents, who travel to
      countries with high incidence of TB (>/= 40 cases/100,000 inhabitants). A sample 
      size of 492 children was calculated. Participants will be recruited before
      traveling, either during a visit to a travel clinic or to their PCC, where a
      questionnaire including sociodemographic, epidemiological and clinical data will 
      be completed, and a tuberculin skin test (TST) will be performed and read after
      48 to 72 hours; patients with a positive TST at baseline will be excluded. A
      visit will be scheduled eight to twelve-weeks after their return to perform a TST
      and a QuantiFERON-TB Gold Plus test. The incidence rate of LTBI will be estimated
      per individual/month and person/year per country visited, and also by age-group. 
      ETHICS AND DISSEMINATION: The study protocol was approved by the Clinical
      Research Ethics Committee of the Hospital Universitari Mutua Terrassa (code
      02/16) and the Clinical Research Ethics Committee of the Fundacio Institut
      Universitari per a la Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina
      (code P16/094). Articles will be published in indexed scientific journals. TRIAL 
      REGISTRATION: Clinical-Trials.gov: NCT04236765.
FAU - Soriano-Arandes, Antoni
AU  - Soriano-Arandes A
AD  - Unitat de Patologia Infecciosa i Immunodeficiencies Pediatriques, Vall d'Hebron
      Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron.
FAU - Cayla, Joan A
AU  - Cayla JA
AD  - Fundacio de la Unitat d'Investigacio en Tuberculosi de Barcelona, Barcelona.
FAU - Goncalves, Alessandra Queiroga
AU  - Goncalves AQ
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, Fundacio Institut Universitari
      per a la Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol).
AD  - Unitat Docent de Medicina de Familia i Comunitaria, Tortosa-Terres de l'Ebre,
      Institut Catala de la Salut, Tortosa, Tarragona.
FAU - Orcau, Angels
AU  - Orcau A
AD  - Servei d'epidemiologia, Agencia de Salut Publica de Barcelona, Barcelona.
AD  - Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica
      (CIBERESP), Madrid.
FAU - Noguera-Julian, Antoni
AU  - Noguera-Julian A
AD  - Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica
      (CIBERESP), Madrid.
AD  - Malalties Infeccioses i Resposta Inflamatoria Sistemica en Pediatria, Unitat
      d'Infeccions, Servei de Pediatria, Institut de Recerca Pediatrica, Hospital Sant 
      Joan de Deu, Barcelona.
AD  - Departament de Pediatria, Universitat de Barcelona, Barcelona.
AD  - Red de Investigacion Translacional en Infectologia Pediatrica (RITIP), Madrid.
FAU - Padilla, Emma
AU  - Padilla E
AD  - Area de Microbiologia de Catlab, Terrassa.
FAU - Sola-Segura, Elisabet
AU  - Sola-Segura E
AD  - Equip d'Atencio Primaria Vic Nord, Institut Catala de la Salut, Vic.
FAU - Gordillo, Neus Rius
AU  - Gordillo NR
AD  - Servei de Pediatria Hospital Universitari Sant Joan de Reus, Reus.
FAU - Espiau, Maria
AU  - Espiau M
AD  - Unitat de Patologia Infecciosa i Immunodeficiencies Pediatriques, Vall d'Hebron
      Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron.
FAU - Garcia-Lerin, Monica G
AU  - Garcia-Lerin MG
AD  - Atencio Primaria, Fundacio Assistencial Mutua Terrassa, Terrassa.
FAU - Rifa-Pujol, Maria Angels
AU  - Rifa-Pujol MA
AD  - Equip d'Atencio Primaria Tona, Institut Catala de la Salut, Tona.
FAU - Jordi Gomez I Prat
AU  - Jordi Gomez I Prat
AD  - Equip de Salut Publica i Comunitaria de la Unitat de Salut Internacional
      Drassanes-Hospital Universitari Vall d'Hebron, Servei de Medicina Preventiva de
      Vall d'Hebron, Barcelona.
FAU - Macia-Rieradevall, Esperanca
AU  - Macia-Rieradevall E
AD  - Equip d'atencio primaria Manlleu, Institut Catala de la Salut, Manlleu.
FAU - Martin-Nalda, Andrea
AU  - Martin-Nalda A
AD  - Unitat de Patologia Infecciosa i Immunodeficiencies Pediatriques, Vall d'Hebron
      Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron.
AD  - Grup de recerca infeccio en el pacient pediatric immunodeprimit, Vall d'Hebron
      Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona.
AD  - Centre de Diagnostic i Investigacio per a Immunodeficiencies Primaries Jeffrey
      Modell, Barcelona.
FAU - Eril-Rius, Maria
AU  - Eril-Rius M
AD  - Equip d'atencio primaria La Vall del Ges, Institut Catala de la Salut, Torello.
FAU - Santos Santiago, Jose
AU  - Santos Santiago J
AD  - Centre de Salut Internacional i Malalties Transmissibles Drassanes/Vall d'Hebron.
      Programa de Salut Internacional de l'ICS (PROSICS), Barcelona.
FAU - Busquets-Poblet, Lidia
AU  - Busquets-Poblet L
AD  - Servei de pediatria, CAP El Remei, L'Equip d'Assistencia Primaria de Vic, Vic.
FAU - Martinez, Raisa Morales
AU  - Martinez RM
AD  - Centre de Salut Internacional i Malalties Transmissibles Drassanes/Vall d'Hebron.
      Programa de Salut Internacional de l'ICS (PROSICS), Barcelona.
FAU - Perez-Porcuna, Tomas Maria
AU  - Perez-Porcuna TM
AD  - Atencio Primaria, Fundacio Assistencial Mutua Terrassa, Terrassa.
AD  - Unitat clinica de Tuberculosi i Salut Internacional, Fundacio de Docencia i
      Recerca Mutua Terrassa, Servei de Pediatria, Hospital Universitari Mutua
      Terrassa, Terrassa, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04236765
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Diagnostic Tests, Routine/methods
MH  - Emigrants and Immigrants
MH  - Family
MH  - Female
MH  - Friends
MH  - Humans
MH  - Incidence
MH  - Interferon-gamma Release Tests/methods
MH  - Latent Tuberculosis/diagnosis/*epidemiology/*transmission
MH  - Male
MH  - Mycobacterium tuberculosis/immunology/*isolation & purification
MH  - Prospective Studies
MH  - Risk Factors
MH  - Spain/epidemiology
MH  - Travel/trends
MH  - Tuberculin Test/methods
PMC - PMC7478479
EDAT- 2020/09/10 06:00
MHDA- 2020/09/20 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
AID - 10.1097/MD.0000000000022015 [doi]
AID - 00005792-202009040-00066 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e22015. doi: 10.1097/MD.0000000000022015.


PMID- 32899051
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - The efficacy and safety of Huangqi Guizhi Wuwu decoction for rheumatoid
      arthritis: A protocol for systematic review and meta-analysis.
PG  - e22011
LID - 10.1097/MD.0000000000022011 [doi]
AB  - BACKGROUND: Rheumatoid arthritis has the characteristics of slow progression,
      long course, and repeated attacks. At present, western medicine commonly used in 
      clinical practice not only reduces pain and improves symptoms, but also has more 
      adverse reactions, affecting the health, and life of patients. In ancient China, 
      Huangqi Guizhi Wuwu decoction was used by doctors to treat rheumatoid arthritis, 
      with remarkable effect. In recent years, many clinical studies have also shown
      that Huangqi Guizhi Wuwu decoction has reliable effect in treating rheumatoid
      arthritis, but there is no evidence of evidence-based medicine. Therefore, this
      study aims to systematically evaluate the clinical efficacy and safety of Huangqi
      Guizhi Wuwu decoction in the treatment of rheumatoid arthritis. METHODS: Using
      computer to retrieve PubMed, The Cochrance Library, Embase, Web of Science, CNKI,
      VIP and Wanfang database, in addition manually retrieve Google academic and Baidu
      academic to collect all randomized controlled trials for Huangqi Guizhi Wuwu
      decoction in the treatment of rheumatoid arthritis, including relevant academic
      journal and conference papers, dissertations, from the establishment of the
      database to July 2020. After 2 evaluators independently screened the literature, 
      extracted the data, and evaluated the risk of bias included in the study,
      RevMan5.3 software was used to analyze the data. RESULTS: This research evaluate 
      the efficacy and safety of Huangqi Guizhi Wuwu decoction in treating Rheumatoid
      arthritis from the aspects of clinical efficacy rate, visual analog scale (VAS), 
      swollen joint count (SJC), morning stiffness time, Rrythrocyte sedimentation rate
      (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and adverse reaction
      incidence. CONCLUSION: This study will provide reliable evidence for the clinical
      application of Huangqi Guizhi Wuwu decoction in the treatment of rheumatoid
      arthritis. ETHICS AND DISSEMINATION: The private information from individuals
      will not publish. This systematic review also will not involve endangering
      participant rights. Ethical approval is not required. The results may be
      published in a peer-reviewed journal or disseminated in relevant conferences. OSF
      REGISTRATION NUMBER: DOI 10.17605/OSF.IO/RZY3V.
FAU - Wang, Lei
AU  - Wang L
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Xin, Ping
AU  - Xin P
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Zhao, Yuetong
AU  - Zhao Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Deng, Huaihan
AU  - Deng H
AD  - Pengzhou Hospital of Traditional Chinese Medicine, Pengzhou, Sichuan Province,
      China.
FAU - Jia, Bo
AU  - Jia B
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (guizhi decoction)
RN  - 0 (huangqi decoction)
SB  - IM
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Phytotherapy
MH  - Systematic Reviews as Topic
PMC - PMC7478548
EDAT- 2020/09/10 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1097/MD.0000000000022011 [doi]
AID - 00005792-202009040-00063 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e22011. doi: 10.1097/MD.0000000000022011.


PMID- 32899050
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - Evidence for acupotomology in the management of cervical radiculopathy: A
      protocol for systematic review and meta-analysis.
PG  - e22007
LID - 10.1097/MD.0000000000022007 [doi]
AB  - BACKGROUND: Cervical radiculopathy (CR) describes compression or stimulation
      secondary to the cervical nerve root, 1 or 2 types of upper limb pain, and/or
      with neck. In clinical practice, both acupotomology and acupuncture are very
      widely and popular for the management of CR. So, we conducted a systematic review
      and meta-analysis to explore the efficacy, safety of acupotomology in the
      treatment of CR. METHODS: We will search the following databases from inception
      to the September 2019 : MEDLINE(PubMed), Web of Science(Thomson Reuters),
      Cochrane Library, Embase (Ovid, Elsevier), SinoMed, Clinical Trials. gov, the
      China National Knowledge Infrastructure, Wanfang database, and VIP database. We
      will apply no language restrictions. We will not use a randomized controlled
      trial filter in EMBASE, as the set of intervention terms will limit the results
      sufficiently. The randomised controlled trials of acupotomology versus
      acupuncture for CR; two independent researchers will use the bias risk tool
      provided by the Cochrane Collaboration to evaluate the quality of the literature 
      using RevMan 5.3 software (Copenhagen, The Nordic Cochrane Centre, The Cochrane
      Collaboration, 2014). RESULTS: This systematic review and meta-analysis will
      provide a synthesis of existing evidence-based medical evidence for
      acupotomology/ acupotomy/needle knife in the treatment of CR. CONCLUSION: The
      conclusions of this systematic review and meta-analysis will provide evidence to 
      evaluate the effectiveness of acupotomology/ acupotomy/needle knife for CR and
      further guide clinical decision-making. ETHICS AND DISSEMINATION: This study is
      based on literature and therefore does not require ethical approval or patient
      consent. The study will be published in a peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42020172274.
FAU - Dai, Wenkang
AU  - Dai W
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Xie, Rui
AU  - Xie R
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Wang, Xiongwei
AU  - Wang X
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhuang, Minghui
AU  - Zhuang M
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Chang, Xiaojuan
AU  - Chang X
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Wei, Xu
AU  - Wei X
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Jin, Zhefeng
AU  - Jin Z
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Wang, Shangquan
AU  - Wang S
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Feng, Minshan
AU  - Feng M
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Yu, Jie
AU  - Yu J
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Zhu, Liguo
AU  - Zhu L
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - *Cervical Vertebrae
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Radiculopathy/*therapy
MH  - Spondylosis/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7478517
EDAT- 2020/09/10 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1097/MD.0000000000022007 [doi]
AID - 00005792-202009040-00062 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e22007. doi: 10.1097/MD.0000000000022007.


PMID- 32899021
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - Efficacy and safety of acupuncture and moxibustion for herpes zoster: A protocol 
      for systematic review and network meta analysis.
PG  - e21905
LID - 10.1097/MD.0000000000021905 [doi]
AB  - INTRODUCTION: Herpes zoster (HZ) is currently treated primarily with antiviral
      drugs, yet this treatment has been debated. Acupuncture is becoming a more
      important treatment in this protocol. For example, pain intensity is lower among 
      HZ patients who receive acupuncture plus moxibustion than among those who receive
      pharmacotherapy. There are many types of acupuncture interventions, including
      electroacupuncture, moxibustion, bloodletting. In this study, a network
      meta-analysis (NMA) is used to rank various interventions of acupuncture. METHODS
      AND ANALYSIS: Electronic searches of abstracts and titles will be performed in
      MEDLINE, EMBASE, CENTRAL, CBM, CNKI, CQVIP, and Wanfang Data databases, from
      inception to December 31, 2019. Published and unpublished controlled trials with 
      different acupuncture interventions will be selected, trials of antiviral drugs
      as the control group. All patients of HZ will be included, except for those
      diagnosed with PHN, immunocompromised patients, or those with complications. The 
      effective therapy rate and the incidence of PHN are primary outcomes. The NMA
      will be analyzed with Stata 13.0 and GeMTC 0.14.3. DISCUSSION: The NMA will be
      established to compare various interventions of acupuncture for the therapy of
      HZ, that could resolve the limitations of previous methodologies with this
      protocol. It will be possible to determine the best acupuncture intervention for 
      more primary outcomes of therapy, including subgroup analysis of patients with
      aged >/=50 years and those of aged <50 years. ETHICS AND DISSEMINATION: The NMA
      does not require ethical approval. The data analyzed is not personal. It is only 
      systematically used to evaluate the effectiveness of acupuncture treatments. The 
      results will be disseminated through international conference reports and
      peer-reviewed manuscripts. STRENGTH AND LIMITATIONS OF THIS STUDY: A
      comprehensive methodology is established to rank various interventions of
      acupuncture by which best evidence-based intervention may be recommended for
      those population groups of aged >/=50 years and aged <50 years. PROSPERO
      REGISTRATION NUMBER: CRD42019118369.
FAU - Zhang, Na
AU  - Zhang N
AD  - Guangzhou University of Chinese Medicine.
FAU - Liu, Kun
AU  - Liu K
AD  - Guangzhou University of Chinese Medicine.
FAU - She, Yalin
AU  - She Y
AD  - Guangzhou University of Chinese Medicine.
FAU - Zhao, Weixuan
AU  - Zhao W
AD  - First Affiliated Hospital of Guangdong Pharmaceutical University.
FAU - Zeng, Jingchun
AU  - Zeng J
AD  - Department of Acupuncture, The First Affiliated Hospital, Guangzhou University of
      Chinese Medicine, Guangzhou, People's Republic of China.
FAU - Lin, Guohua
AU  - Lin G
AD  - Department of Acupuncture, The First Affiliated Hospital, Guangzhou University of
      Chinese Medicine, Guangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Herpes Zoster/*therapy
MH  - Humans
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
PMC - PMC7478486
EDAT- 2020/09/10 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1097/MD.0000000000021905 [doi]
AID - 00005792-202009040-00033 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e21905. doi: 10.1097/MD.0000000000021905.


PMID- 32899017
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - The effect of Tai Chi practice on immunological function in cancer survivors: A
      protocol for systematic review.
PG  - e21869
LID - 10.1097/MD.0000000000021869 [doi]
AB  - BACKGROUND: Tai Chi has been reported to be potentially effective for health and 
      well-being of cancer survivors. It is worth to assess the effectiveness and
      safety of Tai Chi on immunological function in people with cancer. METHODS: All
      relevant randomized controlled trials (RCT) will be reviewed on Tai Chi for
      immunological function in cancer survivors. Literature searching will be
      conducted until March 9, 2019 from major English and Chinese databases: Cochrane 
      Library, Excerpta Medica Database (EMBASE), PubMed, CINAHL, Sprotdicus, American 
      Association for Cancer Research Journals, Sino-Med database, China National
      Knowledge Infrastructure, Chinese Science and Technique Journals Database, and
      Wanfang Data Chinese database. Two authors will conduct data selection and
      extraction independently. Quality assessment will be conducted using the risk of 
      bias tool recommended by the Cochrane Collaboration. We will conduct data
      analysis using Cochrane's RevMan software (V.5.3). Forest plots and summary of
      findings tables will illustrate the results from a meta-analysis if sufficient
      studies with the same outcomes are identified. Funnel plots will be developed to 
      evaluate reporting bias. RESULTS: This review will summarize the evidence on Tai 
      Chi for immunological function in cancer survivors. CONCLUSIONS: We hope that the
      results of this study will provide significant evidence to assess the value Tai
      Chi practice on immunological function in cancer survivors. ETHICS AND
      DISSEMINATION: Ethics approval is not required as this study will not involve
      patients. The results of this study will be submitted to a peer-reviewed journal 
      for publication.
FAU - Wang, Xuejiao
AU  - Wang X
AD  - Beijing University of Chinese Medicine.
FAU - Xu, Lei
AU  - Xu L
AD  - Beijing University of Chinese Medicine.
AD  - Department of Liver Diseases, Guang'anmen Hospital, China Academy of Chinese
      Medical Sciences, Beijing, China.
FAU - Dai, Ning
AU  - Dai N
AD  - Beijing University of Chinese Medicine.
FAU - Yang, Xingzhe
AU  - Yang X
AD  - Beijing University of Chinese Medicine.
FAU - He, Qingyun
AU  - He Q
AD  - Beijing University of Chinese Medicine.
FAU - Tan, Libo
AU  - Tan L
AD  - Beijing University of Chinese Medicine.
FAU - Wang, Ruochong
AU  - Wang R
AD  - Beijing University of Chinese Medicine.
AD  - Department of Liver Diseases, Guang'anmen Hospital, China Academy of Chinese
      Medical Sciences, Beijing, China.
FAU - Li, Feng
AU  - Li F
AD  - Beijing University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Cancer Survivors
MH  - Humans
MH  - Neoplasms/immunology
MH  - Systematic Reviews as Topic
MH  - *Tai Ji
PMC - PMC7478452
EDAT- 2020/09/10 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1097/MD.0000000000021869 [doi]
AID - 00005792-202009040-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e21869. doi: 10.1097/MD.0000000000021869.


PMID- 32898989
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20201001
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 36
DP  - 2020 Sep 4
TI  - 68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate
      cancer: Perspective of radiologist.
PG  - e20755
LID - 10.1097/MD.0000000000020755 [doi]
AB  - Ga-PSMA-11 positron emission computed tomography /computed tomography (PET/CT) is
      more sensitive than magnetic resonance imaging (MRI) in detecting prostate cancer
      (PCa). We evaluated the value of Ga-PSMA-11 PET/CT with MRI in treatment-naive
      PCa.This retrospective study was approved by the hospital ethics committee. The
      MRI and Ga-PSMA-11 PET/CT imaging data of 63 cases of highly suspected PCa were
      enrolled in this study. The SUVmax and apparent diffusion coefficient (ADC), and 
      their ratio, were assessed as diagnostic markers to distinguish PCa from benign
      disease.There were 107 prostate lesions detected in 63 cases. Forty cases with 64
      malignant primary lesions were confirmed PCa, whereas 23 cases had 43 benign
      lesions. PSMA-avid lesions correlated with hypointense signal on ADC maps and
      hyperintense signal on diffusion-weighted imaging. The ADC of PCa was lower than 
      that of benign lesions, and SUVmax and SUVmax/ADC of PCa was higher than that of 
      benign lesions (P < .01). ADC had significant negative correlation with Gleason
      score (GS) and SUVmax, SUVmax, and SUVmax/ADC positively correlated with GS. From
      ROC analysis, we established cutoff values of ADC, SUVmax, and SUVmax/ADC at 1.02
      x 10mm/s, 11.72, and 12.35, respectively, to differentiate PCa from benign
      lesions. The sensitivity, specificity, and AUC were 90.6%, 58.1%, and 0.816 for
      ADC, 67.2%, 97.7%, and 0.905 for SUVmax, and 81.2%, 88.4%, and 0.929 for
      SUVmax/ADC, respectively.Ga-PSMA-11 PET/CT combined with MRI offers higher
      diagnostic efficacy in the detection of PCa than either modality alone.
FAU - Wang, Liwei
AU  - Wang L
AD  - Department of Radiology.
FAU - Yu, Fei
AU  - Yu F
AD  - Department of Nuclear Medicine.
FAU - Yang, Lulu
AU  - Yang L
AD  - Department of Pathology, Nanjing First Hospital, Nanjing Medical University.
FAU - Zang, Shiming
AU  - Zang S
AD  - Department of Nuclear Medicine.
FAU - Xue, Hailin
AU  - Xue H
AD  - Department of Radiology.
FAU - Yin, Xindao
AU  - Yin X
AD  - Department of Radiology.
FAU - Guo, Hongqian
AU  - Guo H
AD  - Department of Urology, Drum Tower Hospital, Medical School of Nanjing University,
      Nanjing University.
FAU - Sun, Hongbin
AU  - Sun H
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nanjing, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Nuclear Medicine.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Humans
MH  - Magnetic Resonance Spectroscopy/*methods
MH  - Male
MH  - Middle Aged
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Prostate-Specific Antigen/*analysis
MH  - Prostatic Neoplasms/diagnostic imaging/*pathology
MH  - Retrospective Studies
PMC - PMC7478544
EDAT- 2020/09/10 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/09 01:02
PHST- 2020/09/09 01:02 [entrez]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1097/MD.0000000000020755 [doi]
AID - 00005792-202009040-00001 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Sep 4;99(36):e20755. doi: 10.1097/MD.0000000000020755.


PMID- 32897669
STAT- Publisher
DA  - 20200909
ISBN- 9780309671132
ISBN- 0309671132
PB  - National Academies Press (US)
CTI - The National Academies Collection: Reports funded by National Institutes of
      Health
DP  - 2020 Sep 3
BTI - Heritable Human Genome Editing
LID - 10.17226/25665 [doi]
AB  - Heritable human genome editing - making changes to the genetic material of eggs, 
      sperm, or any cells that lead to their development, including the cells of early 
      embryos, and establishing a pregnancy - raises not only scientific and medical
      considerations but also a host of ethical, moral, and societal issues. Human
      embryos whose genomes have been edited should not be used to create a pregnancy
      until it is established that precise genomic changes can be made reliably and
      without introducing undesired changes - criteria that have not yet been met, says
      Heritable Human Genome Editing. From an international commission of the U.S.
      National Academy of Medicine, U.S. National Academy of Sciences, and the U.K.'s
      Royal Society, the report considers potential benefits, harms, and uncertainties 
      associated with genome editing technologies and defines a translational pathway
      from rigorous preclinical research to initial clinical uses, should a country
      decide to permit such uses. The report specifies stringent preclinical and
      clinical requirements for establishing safety and efficacy, and for undertaking
      long-term monitoring of outcomes. Extensive national and international dialogue
      is needed before any country decides whether to permit clinical use of this
      technology, according to the report, which identifies essential elements of
      national and international scientific governance and oversight.
CI  - Copyright 2020 by the National Academy of Sciences. All rights reserved.
CN  - The Royal Society; National Academy of Sciences; National Academy of Medicine;
      International Commission on the Clinical Use of Human Germline Genome Editing
LA  - eng
GR  - HHSN263201800029I/NIH HHS/United States
PT  - Review
PT  - Book
PL  - Washington (DC)
EDAT- 2020/09/09 06:01
MHDA- 2020/09/09 06:01
CDAT- 2020/09/09 06:01
AID - NBK561519 [bookaccession]
AID - 10.17226/25665 [doi]


PMID- 32898409
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 26
IP  - 7
DP  - 2020 Jul 15
TI  - The ethical implications of utilizing advertising techniques to increase biologic
      treatment willingness in patients with psoriasis.
LID - 13030/qt5448w3rz [pii]
AB  - Certain techniques used in the advertising and marketing setting may enhance
      patient willingness to initiate and adhere to treatment. Some methods include
      manipulation, nudging, bandwagon effect, testimonial effect, and framing. While
      these tools may improve patient adherence to certain medications, and thus
      overall health-related outcomes, the ethical implications of utilizing
      advertising techniques in the medical setting should be explored. We suggest
      physicians can maintain their ethical duty to act in the patient's best interest,
      while simultaneously maintaining the principles of informed consent and utilizing
      advertising techniques based on human psychology to present treatment options.
FAU - Bray, Jeremy K
AU  - Bray JK
AD  - Center for Dermatology Research, Department of Dermatology, Wake Forest School of
      Medicine, Winston-Salem, NC.
FAU - Feldman, Steven R
AU  - Feldman SR
LA  - eng
PT  - Letter
DEP - 20200715
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Biological Products)
SB  - IM
MH  - Advertising/*ethics
MH  - Biological Products/*therapeutic use
MH  - *Ethics, Medical
MH  - Humans
MH  - Informed Consent
MH  - *Medication Adherence
MH  - Psoriasis/*drug therapy
EDAT- 2020/09/09 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/08 19:38
PHST- 2020/08/20 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/08 19:38 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PST - epublish
SO  - Dermatol Online J. 2020 Jul 15;26(7).


PMID- 32898120
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1554-558X (Electronic)
IS  - 0894-1912 (Linking)
VI  - 40
IP  - 3
DP  - 2020 Summer
TI  - Structuring Mentoring in Medicine and Surgery. A Systematic Scoping Review of
      Mentoring Programs Between 2000 and 2019.
PG  - 158-168
LID - 10.1097/CEH.0000000000000308 [doi]
AB  - INTRODUCTION: Evidence of novice mentoring's successes in having senior
      clinicians support junior doctors and/or medical students in their clinical,
      academic, and research goals has spurred efforts to include mentoring in the core
      medical curriculum. However, lack of effective structuring threatens the
      viability of mentoring programs, precipitating ethical concerns about mentoring. 
      This review aims to answer the question "what is known about mentoring structures
      in novice mentoring among medical students and junior doctors in medicine and
      surgery postings?," which will guide the design of a consistent structure to
      novice mentoring. METHODS: Levac (2010)'s framework was used to guide this
      systematic scoping review of mentoring programs in medicine and surgery published
      between 1 January 2000 and 31 December 2019 in PubMed, ScienceDirect, ERIC,
      Embase, Scopus, Mednar, and OpenGrey. A "split approach" involving concurrent
      independent use of a directed content analysis and thematic approach was used to 
      analyze included articles. RESULTS: Three thousand three hundred ninety-five
      abstracts were identified. There was concordance between the 3 themes and
      categories identified in analyzing the 71 included articles. These were the host 
      organization, mentoring stages, and evaluations. CONCLUSION: The data reveal the 
      need for balance between ensuring consistency and flexibility to meet the
      individual needs of stakeholders throughout the stages of the mentoring process. 
      The Generic Mentoring Framework provides a structured approach to "balancing"
      flexibility and consistency in mentoring processes. The Generic Mentoring
      Framework is reliant upon appropriate, holistic, and longitudinal assessments of 
      the mentoring process to guide adaptations to mentoring processes and ensure
      effective support and oversight of the program.
FAU - Chua, Wen Jie
AU  - Chua WJ
AD  - Mr. Chua: Fourth year medical student, Yong Loo Lin School of Medicine, National 
      University of Singapore, Singapore. Ms. Cheong: Fourth year medical student, Yong
      Loo Lin School of Medicine, National University of Singapore, Singapore, and
      Division of Palliative Medicine, National Cancer Centre Singapore, Singapore. Ms.
      Lee: Fourth year medical student, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore. Dr. Koh: Medical officer, Tan Tock Seng
      Hospital, Singapore. Dr Toh is an Adjunct Lecturer at the Division of Family
      Medicine, Yong Loo Lin School of Medicine, National University of Singapore,
      Singapore. Dr. Toh: National University Hospital Singapore, Family Medicine
      Residency, Singapore. Dr. Mason: Research and Development Lead, Palliative Care
      Institute Liverpool, Academic Palliative & End of Life Care Centre, University of
      Liverpool, Liverpool, United Kingdom. Dr. Krishna: Senior Consultant, Yong Loo
      Lin School of Medicine, National University of Singapore, Singapore, Division of 
      Palliative Medicine, National Cancer Centre Singapore, Singapore, National
      University Hospital Singapore, Family Medicine Residency, Singapore, Palliative
      Care Institute Liverpool, Academic Palliative & End of Life Care Centre,
      University of Liverpool, Liverpool, United Kingdom, Duke-NUS Medical School,
      Singapore, and Centre of Biomedical Ethics, National University of Singapore,
      Singapore.
FAU - Cheong, Clarissa Wei Shuen
AU  - Cheong CWS
FAU - Lee, Fion Qian Hui
AU  - Lee FQH
FAU - Koh, Eugene Yong Hian
AU  - Koh EYH
FAU - Toh, Ying Pin
AU  - Toh YP
FAU - Mason, Stephen
AU  - Mason S
FAU - Krishna, Lalit Kumar Radha
AU  - Krishna LKR
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - J Contin Educ Health Prof
JT  - The Journal of continuing education in the health professions
JID - 8805847
SB  - IM
MH  - General Surgery/*methods/trends
MH  - Humans
MH  - Medicine/*methods/trends
MH  - Mentoring/methods/*standards/trends
MH  - Mentors/education/psychology
MH  - Program Evaluation/*methods
EDAT- 2020/09/09 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/09/08 17:12
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/09/08 17:12 [entrez]
AID - 10.1097/CEH.0000000000000308 [doi]
AID - 00005141-202004030-00003 [pii]
PST - ppublish
SO  - J Contin Educ Health Prof. 2020 Summer;40(3):158-168. doi:
      10.1097/CEH.0000000000000308.


PMID- 32898018
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 27
IP  - 12
DP  - 2020 Dec
TI  - Protocol for development of a core outcome set for menopausal symptoms (COMMA).
PG  - 1371-1375
LID - 10.1097/GME.0000000000001632 [doi]
AB  - OBJECTIVE: Menopause is the natural cessation of menstruation and may be
      accompanied by troublesome symptoms including hot flushes and night sweats
      (vasomotor symptoms) and genitourinary symptoms. Randomized trials evaluating the
      safety and effectiveness of interventions for these symptoms have reported a wide
      range of outcomes and used inconsistent measures. This variation precludes
      comparing and combining data from different trials. To overcome this limitation, 
      we will develop a Core Outcome Set for Menopausal Symptoms. METHODS: We will
      systematically review the literature to identify the outcomes reported in the
      interventional trials for vasomotor and genitourinary symptoms. This list will be
      entered into a two-round modified Delphi survey to be completed by clinicians,
      researchers, and consumers (women who have experienced menopause). Participants
      will score outcomes on a nine-point scale from "not important" to "critically
      important." Representatives from each stakeholder group will then meet to discuss
      the results and finalize the Core Outcome Set. Ethics approval was not required
      as this was considered service evaluation and development. The study is
      registered with the Core Outcome Measures in Effectiveness Trials Initiative
      (http://www.comet-initiative.org/studies/details/917). RESULTS: An agreed upon
      set of minimum outcomes and outcome measures will facilitate combining and
      comparing findings from future trials of treatments for menopausal symptoms.
      CONCLUSIONS: This Core Outcome Set will better enable women and clinicians to
      select effective treatments, improve the quality of trial reporting, reduce
      research wastage, and improve care for women with troublesome menopausal
      symptoms. VIDEO SUMMARY:: http://links.lww.com/MENO/A633.
FAU - Kim, Bobae V
AU  - Kim BV
AD  - The Robinson Institute, University of Adelaide, Adelaide, Australia.
AD  - Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne,
      Parkville, VIC, Australia.
FAU - Iliodromiti, Stamatina
AU  - Iliodromiti S
AD  - Centre for Women's Health, Institute of Population Health Science, Queen Mary
      University, London, United Kingdom.
FAU - Christmas, Monica
AU  - Christmas M
AD  - Department of Obstetrics and Gynaecology, University of Chicago, Chicago, IL.
FAU - Bell, Robin
AU  - Bell R
AD  - Women's Health Research Program, School of Public Health and Preventive Medicine,
      Monash University, Melbourne, Australia.
FAU - Lensen, Sarah
AU  - Lensen S
AD  - Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne,
      Parkville, VIC, Australia.
FAU - Hickey, Martha
AU  - Hickey M
AD  - Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne,
      Parkville, VIC, Australia.
CN  - International COMMA (Core Outcomes in Menopause) Consortium
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
SB  - IM
MH  - Delphi Technique
MH  - Female
MH  - *Hot Flashes/therapy
MH  - Humans
MH  - *Menopause
MH  - Outcome Assessment, Health Care
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7709924
OAB - http://links.lww.com/MENO/A633.
OABL- eng
EDAT- 2020/09/09 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/08 17:12
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/08 17:12 [entrez]
AID - 10.1097/GME.0000000000001632 [doi]
AID - 00042192-202012000-00007 [pii]
PST - ppublish
SO  - Menopause. 2020 Dec;27(12):1371-1375. doi: 10.1097/GME.0000000000001632.


PMID- 32897558
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1468-5922 (Electronic)
IS  - 0021-8774 (Linking)
VI  - 65
IP  - 4
DP  - 2020 Sep
TI  - Psychotherapy as a skilled practice.
PG  - 624-644
LID - 10.1111/1468-5922.12613 [doi]
AB  - While psychotherapy is related to both science and art, it is primarily a craft
      activity requiring the development of skilful practice, epitomized by the
      discipline of the analytic attitude. In terms of the forms of knowledge outlined 
      by Aristotle, this places psychotherapy in the realm of 'techne' (arts and craft)
      rather than episteme (science). In particular, the techne of psychotherapy is
      concerned with the development of phronesis (practical wisdom) in both patient
      and analyst and its ultimate aim is concerned with the promotion of eudaimonia, a
      state of well-being considered by Aristotle to be definitive of 'the good life'. 
      It is therefore fundamentally an ethical endeavour. The nature of
      psychotherapeutic skill is illustrated by analogy with three other forms of
      techne - music, meditation and pottery. Clinical examples illustrate the crafting
      of interpretations and the art of patient holding.
CI  - (c) 2020, The Society of Analytical Psychology.
FAU - Colman, Warren
AU  - Colman W
AD  - St. Albans, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Anal Psychol
JT  - The Journal of analytical psychology
JID - 0376573
SB  - IM
CIN - J Anal Psychol. 2020 Sep;65(4):645-652. PMID: 32897554
MH  - *Art
MH  - Humans
MH  - *Meditation
MH  - *Psychoanalytic Interpretation
MH  - *Psychoanalytic Therapy
OTO - NOTNLM
OT  - *'das gute Leben'
OT  - *'la buona vita'
OT  - *Ethik
OT  - *Gnadenzustande
OT  - *Handwerk
OT  - *actitud analitica
OT  - *analytic attitude
OT  - *analytische Haltung
OT  - *artesania
OT  - *artigianato
OT  - *atteggiamento analitico
OT  - *attitude analytique
OT  - *craftsmanship
OT  - *dexterite
OT  - *disciplina espiritual
OT  - *disciplina spirituale
OT  - *discipline spirituelle
OT  - *episteme
OT  - *estados de gracia
OT  - *ethics
OT  - *etica
OT  - *phronesis
OT  - *spiritual discipline
OT  - *spirituelle Disziplin
OT  - *states of grace
OT  - *stati di grazia
OT  - *techne
OT  - *<< la vie bonne >>
OT  - *<<small ha, Cyrillicsmall o, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall
      sha, Cyrillicsmall a, Cyrillicsmall ya, Cyrillic small zhe, Cyrillicsmall i,
      Cyrillicsmall ze, Cyrillicsmall en, Cyrillicsmall soft sign, Cyrillic>>
OT  - *episteme
OT  - *etats de grace
OT  - *ethique
OT  - *etica
OT  - *small a, Cyrillicsmall en, Cyrillicsmall a, Cyrillicsmall el, Cyrillicsmall i,
      Cyrillicsmall te, Cyrillicsmall i, Cyrillicsmall che, Cyrillicsmall ie,
      Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall o, Cyrillicsmall ie, Cyrillic
      small o, Cyrillicsmall te, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall sha, 
      Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ie, Cyrillic
OT  - *small de, Cyrillicsmall u, Cyrillicsmall ha, Cyrillicsmall o, Cyrillicsmall ve, 
      Cyrillicsmall en, Cyrillicsmall a, Cyrillicsmall ya, Cyrillic small de,
      Cyrillicsmall i, Cyrillicsmall es, Cyrillicsmall tse, Cyrillicsmall i,
      Cyrillicsmall pe, Cyrillicsmall el, Cyrillicsmall i, Cyrillicsmall en,
      Cyrillicsmall a, Cyrillic
OT  - *small em, Cyrillicsmall a, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall ie,
      Cyrillicsmall er, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall ve,
      Cyrillicsmall o, Cyrillic
OT  - *small es, Cyrillicsmall o, Cyrillicsmall es, Cyrillicsmall te, Cyrillicsmall o, 
      Cyrillicsmall ya, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic
      small be, Cyrillicsmall el, Cyrillicsmall a, Cyrillicsmall ghe, Cyrillicsmall o, 
      Cyrillicsmall de, Cyrillicsmall a, Cyrillicsmall te, Cyrillicsmall i, Cyrillic
OT  - *small te, Cyrillicsmall ie, Cyrillicsmall ha, Cyrillicsmall en, Cyrillicsmall
      ie, Cyrillic
OT  - *small ef, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall en, Cyrillicsmall ie,
      Cyrillicsmall ze, Cyrillicsmall i, Cyrillicsmall es, Cyrillic
OT  - *small e, Cyrillicsmall pe, Cyrillicsmall i, Cyrillicsmall es, Cyrillicsmall te, 
      Cyrillicsmall ie, Cyrillicsmall em, Cyrillicsmall ie, Cyrillic
OT  - *small e, Cyrillicsmall te, Cyrillicsmall i, Cyrillicsmall ka, Cyrillicsmall a,
      Cyrillic
OT  - *'la buena vida'
OT  - *'the good life'
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
EDAT- 2020/09/09 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/09/08 12:17
PHST- 2020/09/08 12:17 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
AID - 10.1111/1468-5922.12613 [doi]
PST - ppublish
SO  - J Anal Psychol. 2020 Sep;65(4):624-644. doi: 10.1111/1468-5922.12613.


PMID- 32897437
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1438-8359 (Electronic)
IS  - 0913-8668 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Dec
TI  - Open randomized trial of the effects of 6% hydroxyethyl starch 130/0.4/9 and 5%
      albumin on safety profile, volume efficacy, and glycocalyx degradation in hepatic
      and pancreatic surgery.
PG  - 912-923
LID - 10.1007/s00540-020-02847-y [doi]
AB  - PURPOSE: The aim of this study was to evaluate the effects of hydroxyethyl starch
      (HES) 130/0.4/9 compared to 5% albumin on renal and coagulation safety profiles, 
      volume efficacy and glycocalyx degradation in major abdominal surgery. METHODS:
      The study was approved by the institutional ethics committee as a single center, 
      open-labeled randomized trial. Fifty patients undergoing hepatic or pancreatic
      surgery were randomly assigned to the HES group (n = 25), who received HES
      130/0.4/9, or the Albumin group (n = 25), who received 5% albumin. Ringer's
      acetate solution (3 ml/kg/h) and colloid solution (2 mL/kg/h) were infused and
      goal-directed fluid management was performed to stabilize hemodynamics.
      Perioperative changes and differences in serum creatinine,
      N-acetyl-beta-d-glucosaminidase (NAG), hemodynamics, coagulation parameters and
      glycocalyx biomarkers were compared between the groups. Blood loss and
      requirements for transfusion and vasoactive agents were also examined.
      Statistical analysis was performed by Mann-Whitney U tests, chi-square or Fisher 
      exact test, with P < 0.05 taken to be significant. RESULTS: Serum creatinine
      levels did not differ between the HES and Albumin groups (median: 0.67 vs. 0.75
      mg/dL at anesthesia induction, 0.82 vs. 0.83 mg/dL at ICU admission, 0.67 vs.
      0.73 mg/dL one day after surgery, 0.68 vs. 0.70 mg/dL one month after surgery).
      NAG, coagulation parameters, hemodynamics, glycocalyx biomarkers, intraoperative 
      blood loss, transfusion and use of vasoactive agents did not differ between the
      groups. CONCLUSION: HES 130/0.4/9 can be used as safely and effectively as 5%
      albumin. Glycocalyx degradation did not differ between use of these solutions in 
      major abdominal surgery.
FAU - Suzuki, Toshinari
AU  - Suzuki T
AD  - Department of Anesthesiology, Saitama Medical Center, Saitama Medical University,
      1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. tsuzuki@saitama-med.ac.jp.
FAU - Koyama, Kaoru
AU  - Koyama K
AD  - Department of Anesthesiology, Saitama Medical Center, Saitama Medical University,
      1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN00001347
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200908
PL  - Japan
TA  - J Anesth
JT  - Journal of anesthesia
JID - 8905667
RN  - 0 (Albumins)
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - 0 (Isotonic Solutions)
RN  - 0 (Plasma Substitutes)
SB  - IM
MH  - Albumins
MH  - Fluid Therapy
MH  - *Glycocalyx
MH  - Humans
MH  - Hydroxyethyl Starch Derivatives
MH  - Isotonic Solutions
MH  - *Plasma Substitutes/therapeutic use
OTO - NOTNLM
OT  - *Glycocalyx
OT  - *Hydroxyethyl starch derivatives
OT  - *Volume therapy
EDAT- 2020/09/09 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/09/08 12:15
PHST- 2019/08/14 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/09/08 12:15 [entrez]
AID - 10.1007/s00540-020-02847-y [doi]
AID - 10.1007/s00540-020-02847-y [pii]
PST - ppublish
SO  - J Anesth. 2020 Dec;34(6):912-923. doi: 10.1007/s00540-020-02847-y. Epub 2020 Sep 
      8.


PMID- 32897407
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20210110
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 12
DP  - 2020 Dec
TI  - [Data monitoring committees-state of the art and perspectives for the future].
PG  - 1511-1518
LID - 10.1007/s00103-020-03212-w [doi]
AB  - BACKGROUND: The classic randomized and controlled clinical trial is facing new
      challenges with complex study designs and disease interception concepts. For this
      reason, data monitoring committees (DMCs) can take on a central function if
      professionally integrated into the methodical procedure of clinical trials. On
      this basis, the responsible competent authority and the responsible ethics
      committee have to verify the substantial charter document in the
      implicit/explicit approval procedure reflecting the working process of the
      independent committee. OBJECTIVES: The frequencies and conditions under which
      DMCs are used in clinical trials was investigated. METHODS: The database of the
      Federal Institute for Drugs and Medical Devices (BfArM) was the basis for
      statistical analysis concerning the frequency of implementation of data
      monitoring committees with different criteria over an observation period of more 
      than 15 years. RESULTS: In total, 4152 DMCs have been used in 14,135 clinical
      trials with drugs. The independent expert committee was mostly integrated by
      commercial sponsors in phase III of the clinical development. The ethics
      committees were involved with different absolute frequencies. DISCUSSION:
      Sponsors demonstrate an increasing willingness to integrate DMCs in the
      methodical conduct of clinical trials especially in the case of new study
      designs. DMCs could be an important scientific aid in order to assess the
      implications of coronavirus SARS-CoV2 on clinical trials.
FAU - Fischer, Thomas
AU  - Fischer T
AD  - Fachgebiet Klinische Prufung/Klinik, Bundesinstitut fur Arzneimittel und
      Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Deutschland.
      Thomas.Fischer@bfarm.de.
LA  - ger
PT  - Journal Article
TT  - Das Data Monitoring Committee - State of the Art und Perspektiven fur die
      Zukunft.
DEP - 20200908
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Clinical Trials Data Monitoring Committees
MH  - *Coronavirus Infections
MH  - Germany
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7477738
OTO - NOTNLM
OT  - BfArM databank
OT  - COVID-19
OT  - Data monitoring committees
OT  - New study designs
OT  - Statistical analysis
EDAT- 2020/09/09 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/09/08 12:14
PHST- 2020/05/28 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/09/08 12:14 [entrez]
AID - 10.1007/s00103-020-03212-w [doi]
AID - 10.1007/s00103-020-03212-w [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Dec;63(12):1511-1518. doi: 10.1007/s00103-020-03212-w. Epub 2020 Sep 8.


PMID- 32897240
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 2291-9694 (Print)
VI  - 8
IP  - 9
DP  - 2020 Sep 8
TI  - Including Social and Behavioral Determinants in Predictive Models: Trends,
      Challenges, and Opportunities.
PG  - e18084
LID - 10.2196/18084 [doi]
AB  - In an era of accelerated health information technology capability, health care
      organizations increasingly use digital data to predict outcomes such as emergency
      department use, hospitalizations, and health care costs. This trend occurs
      alongside a growing recognition that social and behavioral determinants of health
      (SBDH) influence health and medical care use. Consequently, health providers and 
      insurers are starting to incorporate new SBDH data sources into a wide range of
      health care prediction models, although existing models that use SBDH variables
      have not been shown to improve health care predictions more than models that use 
      exclusively clinical variables. In this viewpoint, we review the rationale behind
      the push to integrate SBDH data into health care predictive models and explore
      the technical, strategic, and ethical challenges faced as this process unfolds
      across the United States. We also offer several recommendations to overcome these
      challenges to reach the promise of SBDH predictive analytics to improve health
      and reduce health care disparities.
CI  - (c)Marissa Tan, Elham Hatef, Delaram Taghipour, Kinjel Vyas, Hadi Kharrazi, Laura
      Gottlieb, Jonathan Weiner. Originally published in JMIR Medical Informatics
      (http://medinform.jmir.org), 08.09.2020.
FAU - Tan, Marissa
AU  - Tan M
AUID- ORCID: https://orcid.org/0000-0001-7001-8319
AD  - General Preventive Medicine Residency Program, Johns Hopkins Bloomberg School of 
      Public Health, Baltimore, MD, United States.
FAU - Hatef, Elham
AU  - Hatef E
AUID- ORCID: https://orcid.org/0000-0003-2535-8191
AD  - General Preventive Medicine Residency Program, Johns Hopkins Bloomberg School of 
      Public Health, Baltimore, MD, United States.
AD  - Department of Health Policy and Management, Johns Hopkins Bloomberg School of
      Public Health, Center for Population Health Information Technology, Baltimore,
      MD, United States.
AD  - Department of Health Policy and Management, Johns Hopkins Bloomberg School of
      Public Health, Baltimore, MD, United States.
FAU - Taghipour, Delaram
AU  - Taghipour D
AUID- ORCID: https://orcid.org/0000-0002-1714-6175
AD  - General Preventive Medicine Residency Program, Johns Hopkins Bloomberg School of 
      Public Health, Baltimore, MD, United States.
FAU - Vyas, Kinjel
AU  - Vyas K
AUID- ORCID: https://orcid.org/0000-0002-4019-0166
AD  - Division of Health Sciences Informatics, Johns Hopkins School of Medicine,
      Baltimore, MD, United States.
FAU - Kharrazi, Hadi
AU  - Kharrazi H
AUID- ORCID: https://orcid.org/0000-0003-1481-4323
AD  - Department of Health Policy and Management, Johns Hopkins Bloomberg School of
      Public Health, Center for Population Health Information Technology, Baltimore,
      MD, United States.
AD  - Division of Health Sciences Informatics, Johns Hopkins School of Medicine,
      Baltimore, MD, United States.
FAU - Gottlieb, Laura
AU  - Gottlieb L
AUID- ORCID: https://orcid.org/0000-0003-2669-4066
AD  - Social Interventions Research and Evaluation Network, Center for Health &
      Community, University of California, San Francisco, CA, United States.
FAU - Weiner, Jonathan
AU  - Weiner J
AUID- ORCID: https://orcid.org/0000-0002-8299-3995
AD  - Department of Health Policy and Management, Johns Hopkins Bloomberg School of
      Public Health, Center for Population Health Information Technology, Baltimore,
      MD, United States.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Canada
TA  - JMIR Med Inform
JT  - JMIR medical informatics
JID - 101645109
PMC - PMC7509627
OTO - NOTNLM
OT  - health care disparities
OT  - information technology
OT  - population health
OT  - social determinants of health
EDAT- 2020/09/09 06:00
MHDA- 2020/09/09 06:01
CRDT- 2020/09/08 12:13
PHST- 2020/02/02 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/09/08 12:13 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/09/09 06:01 [medline]
AID - v8i9e18084 [pii]
AID - 10.2196/18084 [doi]
PST - epublish
SO  - JMIR Med Inform. 2020 Sep 8;8(9):e18084. doi: 10.2196/18084.


PMID- 32897039
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20210122
IS  - 1549-8425 (Electronic)
IS  - 1549-8417 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Dec
TI  - Returning to Elective Orthopedic Surgery During the COVID-19 Pandemic: A
      Multidisciplinary and Pragmatic Strategy for Initial Patient Selection.
PG  - e292-e298
LID - 10.1097/PTS.0000000000000755 [doi]
AB  - OBJECTIVE: The aim of the study was to design an objective, transparent,
      pragmatic, and flexible workflow to assist with patient selection during the
      initial phase of return to elective orthopedic surgery during the COVID-19
      pandemic with the main purpose of enhancing patient safety. METHODS: A
      multidisciplinary working group was formed consisting of representatives for
      orthopedics, epidemiology, ethics, infectious diseases, cardiovascular diseases, 
      and intensive care medicine. Preparation for upcoming meetings consisted of
      reading up on literature and testing of proposed methodologies on our own waiting
      lists. RESULTS: A workflow based on 3 domains, that is, required resources,
      patient fitness, and time sensitivity of the procedure, was considered most
      useful. All domains function as standalones, in a specific order, and no sum
      score is used. The domain of required resources demands input from the surgical
      team, results in a categorical (yes or no) outcome, and generates a list of
      potential patients who can be scheduled for surgery under these particular
      circumstances. The (weighted) items for the domain of patient fitness are the
      same for every patient, are scored on a numerical scale, but are likely to change
      during the pandemic as more data become available. Time sensitivity of the
      procedure is again scored on a numerical scale and becomes increasingly important
      when returning to elective surgery proves to be acceptably safe. After patient
      selection, an augmented informed consent, screening, and testing according to
      local guidelines will take place. CONCLUSIONS: A workflow is proposed for patient
      selection aiming for the safest possible return to elective orthopedic surgery
      during the COVID-19 pandemic.
FAU - Vles, Georges F
AU  - Vles GF
FAU - Ghijselings, Stijn
AU  - Ghijselings S
FAU - De Ryck, Iris
AU  - De Ryck I
AD  - Department of Safety Evaluation and Risk Management, Epidemiology,
      GlaxoSmithKline Vaccines, Siena, Italy.
FAU - Meyfroidt, Geert
AU  - Meyfroidt G
AD  - Department and Laboratory of Intensive Care Medicine, University Hospitals and KU
      Leuven, Leuven, Belgium.
FAU - Sweeney, Nicola A
AU  - Sweeney NA
AD  - Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust,
      London, United Kingdom.
FAU - Oosterlinck, Wouter
AU  - Oosterlinck W
AD  - Department of Cardiovascular Diseases, Research Unit of Cardiac Surgery,
      University Hospitals and KU Leuven.
FAU - Casteels, Minne
AU  - Casteels M
FAU - Moke, Lieven
AU  - Moke L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Patient Saf
JT  - Journal of patient safety
JID - 101233393
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/*epidemiology/prevention & control
MH  - Elective Surgical Procedures/*methods
MH  - Humans
MH  - Interdisciplinary Communication
MH  - Orthopedic Procedures/*methods
MH  - Pandemics/prevention & control
MH  - *Patient Selection
MH  - Pneumonia, Viral/diagnosis/*epidemiology/prevention & control
MH  - SARS-CoV-2
PMC - PMC7678350
EDAT- 2020/09/09 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/09/08 11:19
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/09/08 11:19 [entrez]
AID - 10.1097/PTS.0000000000000755 [doi]
AID - 01209203-202012000-00032 [pii]
PST - ppublish
SO  - J Patient Saf. 2020 Dec;16(4):e292-e298. doi: 10.1097/PTS.0000000000000755.


PMID- 32896834
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20210206
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 152
IP  - 1 & 2
DP  - 2020 Jul & Aug
TI  - Economics & ethics of the COVID-19 vaccine: How prepared are we?
PG  - 153-155
LID - 10.4103/ijmr.IJMR_3581_20 [doi]
FAU - Gupta, Indrani
AU  - Gupta I
AD  - Health Policy Research Unit, Institute of Economic Growth, University of Delhi
      Enclave, North Campus, Delhi 110 007, India.
FAU - Baru, Rama
AU  - Baru R
AD  - Centre of Social Medicine & Community Health, School of Social Sciences,
      Jawaharlal Nehru University, New Delhi 110 067, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*economics/epidemiology/prevention & control/virology
MH  - Female
MH  - Humans
MH  - Male
MH  - Pandemics/*economics/*ethics
MH  - Pneumonia, Viral/*economics/epidemiology/virology
MH  - Viral Vaccines/*economics
PMC - PMC7853278
EDAT- 2020/09/09 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/09/08 08:55
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PHST- 2020/09/08 08:55 [entrez]
AID - 294519 [pii]
AID - 10.4103/ijmr.IJMR_3581_20 [doi]
PST - ppublish
SO  - Indian J Med Res. 2020 Jul & Aug;152(1 & 2):153-155. doi:
      10.4103/ijmr.IJMR_3581_20.


PMID- 32896173
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 1938-2715 (Electronic)
IS  - 1049-9091 (Linking)
VI  - 37
IP  - 12
DP  - 2020 Dec
TI  - Ethics Roundtable: Distribution of Critical Care Resources in the Setting of a
      COVID-19 Surge.
PG  - 1096-1101
LID - 10.1177/1049909120951084 [doi]
FAU - Baumrucker, Steven J
AU  - Baumrucker SJ
AUID- ORCID: 0000-0002-4902-8579
AD  - Palliative Medicine, 4248Ballad Health System, Kingsport, TN, USA.
FAU - Carter, Gregory
AU  - Carter G
AD  - St. Luke's Rehabilitation Institute, Spokane, WA, USA.
FAU - Adkins, Russel W
AU  - Adkins RW
AD  - Wilson Worley, PC, Kingsport, TN, USA.
FAU - Perkins, Cheryl
AU  - Perkins C
AD  - Case Management, 4248Ballad Health System, Kingsport, TN, USA.
FAU - Stolick, Matt
AU  - Stolick M
AUID- ORCID: 0000-0003-0540-7216
AD  - Department of Religion and Philosophy, 424316University of Findlay, OH, USA.
FAU - VandeKieft, Gregg
AU  - VandeKieft G
AD  - Providence Institute for Human Caring, Providence Hospital and Providence
      Hospice, Olympia, WA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hosp Palliat Care
JT  - The American journal of hospice & palliative care
JID - 9008229
SB  - IM
MH  - Attitude of Health Personnel
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Clinical Decision-Making
MH  - Coronavirus Infections/*therapy
MH  - Critical Care/*ethics
MH  - Ethics, Medical
MH  - Humans
MH  - Intensive Care Units/ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*therapy
MH  - SARS-CoV-2
MH  - Surge Capacity/*ethics
MH  - Ventilators, Mechanical/*ethics
EDAT- 2020/09/09 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/08 08:44
PHST- 2020/09/08 08:44 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1177/1049909120951084 [doi]
PST - ppublish
SO  - Am J Hosp Palliat Care. 2020 Dec;37(12):1096-1101. doi: 10.1177/1049909120951084.


PMID- 32896115
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1988-9518 (Electronic)
IS  - 0214-3429 (Linking)
VI  - 33
IP  - 5
DP  - 2020 Oct
TI  - The situation of infection in the elderly in Spain: a multidisciplinary opinion
      document.
PG  - 327-349
LID - bouza08sep2020 [pii]
LID - 10.37201/req/057.2020 [doi]
AB  - Infection in the elderly is a huge issue whose treatment usually has partial and 
      specific approaches. It is, moreover, one of the areas where intervention can
      have the most success in improving the quality of life of older patients. In an
      attempt to give the widest possible focus to this issue, the Health Sciences
      Foundation has convened experts from different areas to produce this position
      paper on Infection in the Elderly, so as to compare the opinions of expert
      doctors and nurses, pharmacists, journalists, representatives of elderly
      associations and concluding with the ethical aspects raised by the issue. The
      format is that of discussion of a series of pre-formulated questions that were
      discussed by all those present. We begin by discussing the concept of the
      elderly, the reasons for their predisposition to infection, the most frequent
      infections and their causes, and the workload and economic burden they place on
      society. We also considered whether we had the data to estimate the proportion of
      these infections that could be reduced by specific programmes, including
      vaccination programmes. In this context, the limited presence of this issue in
      the media, the position of scientific societies and patient associations on the
      issue and the ethical aspects raised by all this were discussed.
CI  - (c)The Author 2020. Published by Sociedad Espanola de Quimioterapia. This article
      is distributed under the terms of the Creative Commons Attribution-NonCommercial 
      4.0 International (CC BY-NC
      4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
FAU - Bouza, E
AU  - Bouza E
AD  - Emilio Bouza, Instituto de Investigacion Sanitaria Gregorio Maranon. C/ Dr.
      Esquerdo, 46 28007 Madrid, Spain. emilio.bouza@gmail.com.
FAU - Brenes, F J
AU  - Brenes FJ
FAU - Diez Domingo, J
AU  - Diez Domingo J
FAU - Eiros Bouza, J M
AU  - Eiros Bouza JM
FAU - Gonzalez, J
AU  - Gonzalez J
FAU - Gracia, D
AU  - Gracia D
FAU - Juarez Gonzalez, R
AU  - Juarez Gonzalez R
FAU - Munoz, P
AU  - Munoz P
FAU - Petidier Torregrossa, R
AU  - Petidier Torregrossa R
FAU - Ribera Casado, J M
AU  - Ribera Casado JM
FAU - Ramos Cordero, P
AU  - Ramos Cordero P
FAU - Rodriguez Rovira, E
AU  - Rodriguez Rovira E
FAU - Saez Torralba, M E
AU  - Saez Torralba ME
FAU - Serra Rexach, J A
AU  - Serra Rexach JA
FAU - Tovar Garcia, J
AU  - Tovar Garcia J
FAU - Verdejo Bravo, C
AU  - Verdejo Bravo C
FAU - Palomo, E
AU  - Palomo E
AD  - Esteban Palomo, Director. Health Sciences Foundation. C/ Severo Ochoa 2 - 28760
      Tres Cantos. Madrid. Phone +34 91 3530150.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Spain
TA  - Rev Esp Quimioter
JT  - Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola
      de Quimioterapia
JID - 9108821
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Quality of Life
MH  - Spain/epidemiology
MH  - *Vaccination
PMC - PMC7528417
OTO - NOTNLM
OT  - Infection in the elderly
OT  - Urinay tract infection
OT  - aged
OT  - burden of infection
OT  - elderly
OT  - ethics
OT  - nursing homes
OT  - pneumonia
OT  - vaccines
EDAT- 2020/09/09 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/09/08 05:57
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/09/08 05:57 [entrez]
AID - 10.37201/req/057.2020 [doi]
PST - ppublish
SO  - Rev Esp Quimioter. 2020 Oct;33(5):327-349. doi: 10.37201/req/057.2020. Epub 2020 
      Sep 8.


PMID- 32895775
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Dec
TI  - Human cerebral organoids and consciousness: a double-edged sword.
PG  - 105-128
LID - 10.1007/s40592-020-00116-y [doi]
AB  - Human cerebral organoids (HCOs) are three-dimensional in vitro cell cultures that
      mimic the developmental process and organization of the developing human brain.
      In just a few years this technique has produced brain models that are already
      being used to study diseases of the nervous system and to test treatments and
      drugs. Currently, HCOs consist of tens of millions of cells and have a size of a 
      few millimeters. The greatest limitation to further development is due to their
      lack of vascularization. However, recent research has shown that human cerebral
      organoids can manifest the same electrical activity and connections between brain
      neurons and EEG patterns as those recorded in preterm babies. All this suggests
      that, in the future, HCOs may manifest an ability to experience basic sensations 
      such as pain, therefore manifesting sentience, or even rudimentary forms of
      consciousness. This calls for consideration of whether cerebral organoids should 
      be given a moral status and what limitations should be introduced to regulate
      research. In this article I focus particularly on the study of the emergence and 
      mechanisms of human consciousness, i.e. one of the most complex scientific
      problems there are, by means of experiments on HCOs. This type of experiment
      raises relevant ethical issues and, as I will argue, should probably not be
      considered morally acceptable.
FAU - Lavazza, Andrea
AU  - Lavazza A
AD  - Centro Universitario Internazionale, Via Garbasso, 42, 52100, Arezzo, Italy.
      lavazza67@gmail.com.
AD  - University of Pavia, Pavia, Italy. lavazza67@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - *Bioethical Issues
MH  - Biotechnology/*ethics
MH  - *Brain/physiology
MH  - Cell Culture Techniques
MH  - Consciousness/*ethics/physiology
MH  - Dissent and Disputes
MH  - Humans
MH  - *Moral Status
MH  - *Organoids/physiology
PMC - PMC7723930
OTO - NOTNLM
OT  - Chimeras
OT  - Integrated information theory
OT  - Kant's humanity formula
OT  - Moral status
OT  - Personhood
EDAT- 2020/09/09 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/08 05:25
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/08 05:25 [entrez]
AID - 10.1007/s40592-020-00116-y [doi]
AID - 10.1007/s40592-020-00116-y [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(2):105-128. doi: 10.1007/s40592-020-00116-y.


PMID- 32895612
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 58
DP  - 2020 Oct
TI  - An overview of current COVID-19 clinical trials and ethical considerations
      editorial.
PG  - 84-86
LID - 10.1016/j.amsu.2020.08.041 [doi]
AB  - Not applicable.
CI  - (c) 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd.
FAU - Boserup, Brad
AU  - Boserup B
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
FAU - McKenney, Mark
AU  - McKenney M
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
AD  - University of South Florida, Tampa, FL, USA.
FAU - Elkbuli, Adel
AU  - Elkbuli A
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
LA  - eng
PT  - Editorial
DEP - 20200829
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7455793
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - Clinical trials
OT  - Ethical considerations
OT  - Evidence-based medicine
OT  - Patient safety
COIS- Authors declare no competing interests.
EDAT- 2020/09/09 06:00
MHDA- 2020/09/09 06:01
CRDT- 2020/09/08 05:24
PHST- 2020/07/08 00:00 [received]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/08 05:24 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2020/09/09 06:01 [medline]
AID - 10.1016/j.amsu.2020.08.041 [doi]
AID - S2049-0801(20)30289-2 [pii]
PST - ppublish
SO  - Ann Med Surg (Lond). 2020 Oct;58:84-86. doi: 10.1016/j.amsu.2020.08.041. Epub
      2020 Aug 29.


PMID- 32895353
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20210722
IS  - 2184-8777 (Electronic)
IS  - 0303-464X (Linking)
VI  - 45
IP  - 2
DP  - 2020 Apr-Jun
TI  - Intra-articular hyaluronic acid injection vs. atorvastatin; which treatment is
      more effective in controlling symptoms of knee osteoarthritis? A clinical trial.
PG  - 111-115
AB  - BACKGROUND: Knee osteoarthritis is a disease of the elderly population. Two of
      the widely used treatment options for knee osteoarthritis is administration of
      oral atorvastatin and intra articular hyaluronic acid. This study was designed to
      compare the effects of oral atorvastatin and intra articular Hyaluronic acid in
      patients with knee osteoarthritis. METHOD: This study was conducted under the
      approval of Mashhad University of medical sciences ethic committee. Seventy
      patients with knee OA were divided randomly into two groups; thirty five subjects
      were given intra articular Hyaluronic acid injections weekly for three weeks and 
      35 were given atorvastatin 40 milligrams orally daily for 6 months. WOMAC
      questioner was filled for each patient at the beginning of the study and every
      month up to 6 months. Data were analyzed with SPSS version 16. RESULTS: Enrolled 
      subjects were consisted of 28 males (40%) and 42 females (60%), and their mean
      age was 57.9+/-1.1 years. Study groups were similar regarding gender and age
      distribution (P=0.626, P=0.710, respectively) significant difference between
      groups regarding sex (P=0.626). Mean age of patients was 57.9+/-1.1 years. Groups
      mean age did not differ significantly (P=0.710). According to WOMAC
      questionnaire, pain score in the second month after injection was significantly
      lower in the Hyaluronic acid group compared with atorvastatin (P<0.001). Function
      score in the second month after injection was significantly lower in the
      Hyaluronic acid group compared with atorvastatin (P<0.001). These differences
      were absent in the following months. CONCLUSION: Compared to atorvastatin group, 
      significant improvements in pain symptoms and physical function of knee OA
      patients were observed in intra articular Hyaluronic acid treatment group in the 
      second month after treatment. But this improvement did not last through the
      following months.
FAU - Jokar, Mohammad Hasan
AU  - Jokar MH
FAU - Mirfeizi, Zahra
AU  - Mirfeizi Z
FAU - Zarei, Hamzeh
AU  - Zarei H
FAU - Hashemzadeh, Kamila
AU  - Hashemzadeh K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Intra-articular hyaluronic acid injection vs. atorvastatin; which treatment is
      more effective in controlling symptoms of knee osteoarthritis? A clinical trial.
PL  - Portugal
TA  - Acta Reumatol Port
JT  - Acta reumatologica portuguesa
JID - 0431702
RN  - 0 (Viscosupplements)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Arthralgia/*drug therapy/etiology
MH  - Atorvastatin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage
MH  - Injections, Intra-Articular
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/complications/*drug therapy
MH  - Viscosupplements/*administration & dosage
EDAT- 2020/09/09 06:00
MHDA- 2021/07/23 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
AID - AO200040 [pii]
PST - ppublish
SO  - Acta Reumatol Port. 2020 Apr-Jun;45(2):111-115.


PMID- 32895344
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 2093-758X (Electronic)
IS  - 2005-3673 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Aug
TI  - [Opening Status of the Korea Midwifery Birthing Centers and Development of
      Midwifery Practice Guideline].
PG  - 583-598
LID - 10.4040/jkan.20032 [doi]
AB  - PURPOSE: This study was to investigate the operational status of the midwifery
      birthing centers (MBCs) and midwives' job status (Phase 1) and to develop
      midwifery practice guidelines (MPG) (Phase 2) in Korea. METHODS: In the first
      phase, the subjects were 15 midwives who operated 11 of 14 MBCs that were opened 
      as of August 2018. The questionnaire consisted of items to measure the
      operational status of the MBC and midwives' job status. In the second phase, the 
      MPG was developed from literature review, interviews with five midwives opening
      their MBCs, surveys with 74 midwives, and a validity evaluation conducted by
      seven experts. RESULTS: The distribution of operating MBCs was five in
      Gyunggi-do, two each in Seoul and Incheon, one each in Busan, Chungcheongbuk-do, 
      Gyeongsangbuk-do, Gyeongsangnam-do and Jeju-do. The mean age of midwives was 54.3
      and all were female. In 2017, a total of 762 births including 81 homebirths were 
      performed by midwives. The job performance was highest in the order of neonatal
      care 3.81, childbirth care 3.56, and postpartal care 3.53, respectively. The MPG 
      included seven areas of prenatal care, childbirth care, postpartal care, neonatal
      care, primary health care, law/ethics, and administration, with 56 tasks and 166 
      task elements. CONCLUSION: This study provides the valid basic data for the
      operational status of the MBC and the midwives' job status. The MPG describes the
      midwife's job and may be used as basic data for preparing policies for the
      development of midwifery practice in Korea.
CI  - (c) 2020 Korean Society of Nursing Science.
FAU - Song, Ji Young
AU  - Song JY
AUID- ORCID: https://orcid.org/0000-0003-1480-8732
AD  - College of Nursing, Korea University, Seoul, Korea.
FAU - Park, Young Joo
AU  - Park YJ
AUID- ORCID: https://orcid.org/0000-0001-9846-6113
AD  - College of Nursing, Korea University, Seoul, Korea. yjpark@korea.ac.kr.
LA  - kor
PT  - Journal Article
PL  - Korea (South)
TA  - J Korean Acad Nurs
JT  - Journal of Korean Academy of Nursing
JID - 101488689
SB  - IM
MH  - Birthing Centers/organization & administration/*standards
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Middle Aged
MH  - Midwifery/*standards
MH  - Perinatal Care/*standards
MH  - Practice Guidelines as Topic
MH  - Republic of Korea
MH  - Surveys and Questionnaires
MH  - Task Performance and Analysis
OTO - NOTNLM
OT  - Birthing Centers
OT  - Midwifery
OT  - Nurse Midwives
OT  - Practice Guideline
COIS- The authors declared no conflict of interest.
EDAT- 2020/09/09 06:00
MHDA- 2021/07/01 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/02/14 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 50.583 [pii]
AID - 10.4040/jkan.20032 [doi]
PST - ppublish
SO  - J Korean Acad Nurs. 2020 Aug;50(4):583-598. doi: 10.4040/jkan.20032.


PMID- 32895297
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20220531
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - The ethics of the unmentionable.
PG  - 687-688
LID - 10.1136/medethics-2020-106581 [doi]
FAU - Caplan, Arthur L
AU  - Caplan AL
AUID- ORCID: 0000-0002-4061-8011
AD  - Division of Medical Ethics, NYU, New York, New York, USA Arthur.Caplan@nyumc.org.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200907
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Oct;46(10):678-684. PMID: 32611619
CIN - J Med Ethics. 2020 Oct;46(10):691-692. PMID: 32928880
MH  - *China
MH  - *Ethics, Research
MH  - Humans
MH  - *Transplants
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/08/15 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/09/08 05:19 [entrez]
AID - medethics-2020-106581 [pii]
AID - 10.1136/medethics-2020-106581 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):687-688. doi: 10.1136/medethics-2020-106581. Epub
      2020 Sep 7.


PMID- 32895286
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Adaptation of an exercise intervention for pregnant women to community-based
      delivery: a study protocol.
PG  - e038582
LID - 10.1136/bmjopen-2020-038582 [doi]
AB  - INTRODUCTION: Despite well-established guidelines and benefits to exercise, the
      majority of pregnant women in the USA fail to meet recommended activity levels.
      Studies need to determine feasible ways to translate clinical interventions to
      community settings by engaging pregnant women in widely accessible locations to
      ensure benefits to more women. The aim of this study is to adapt and determine
      feasibility, acceptability and fidelity of the research clinic-based Expecting
      intervention (NCT02125149) with pregnant women with obesity in community
      settings. METHODS AND ANALYSIS: We will use the Replicating Effective Programs
      (REP) to guide the adaptation and implementation of the research clinic-based
      intervention into the community. REP provides a four-phase process for
      implementing evidence-based interventions including collection of feedback from
      community stakeholders, iterative piloting of the intervention in the community
      and a process for standardising the intervention across community settings.
      Following adaptation, the updated intervention will be piloted. The pilot study
      will include 60 expecting women. We will randomise half to receive the
      community-adapted Expecting intervention (intervention, N=30) and half to receive
      standard of care (control, N=30). Feasibility and Acceptability of Intervention
      Measures are primary outcomes as key indicators of feasibility. Secondary
      outcomes will include the number of intervention sessions completed, the change
      in the number of minutes of physical activity as measured by accelerometer, as
      well as change in health indicators from enrolment to time of delivery and 6
      months post-delivery (ie, body mass index, blood pressure and total cholesterol).
      ETHICS AND DISSEMINATION: This study has been approved by the Institutional
      Review Board (#260132). Findings will be shared with study participants and
      stakeholder advisors through written summaries and in-person presentations;
      results will also be shared through presentations at scientific conferences and
      publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04298125;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Swindle, Taren
AU  - Swindle T
AUID- ORCID: 0000-0001-7231-6002
AD  - Family and Preventive Medicine, University of Arkansas For Medical Sciences,
      Little Rock, Arkansas, USA tswindle@uams.edu.
FAU - Martinez, Audrey
AU  - Martinez A
AD  - Arkansas Children's Nutrition Center, Little Rock, Arkansas, USA.
FAU - Borsheim, Elisabet
AU  - Borsheim E
AUID- ORCID: 0000-0002-7842-0625
AD  - Arkansas Children's Nutrition Center, Little Rock, Arkansas, USA.
AD  - Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas,
      USA.
FAU - Andres, Aline
AU  - Andres A
AD  - Arkansas Children's Nutrition Center, Little Rock, Arkansas, USA.
AD  - Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas,
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04298125
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Exercise
MH  - Exercise Therapy
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Pilot Projects
MH  - Pregnancy
MH  - *Pregnant Women
MH  - Randomized Controlled Trials as Topic
PMC - PMC7478046
OTO - NOTNLM
OT  - *maternal medicine
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038582 [pii]
AID - 10.1136/bmjopen-2020-038582 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e038582. doi: 10.1136/bmjopen-2020-038582.


PMID- 32895283
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Experiencing the risk of overutilising opioids among patients with chronic
      non-cancer pain in ambulatory care (ERONA): the protocol of an exploratory,
      randomised controlled trial.
PG  - e037642
LID - 10.1136/bmjopen-2020-037642 [doi]
AB  - INTRODUCTION: The US opioid crisis and increasing prescription rates in Europe
      suggest inappropriate risk perceptions and behaviours of people who prescribe,
      take or advise on opioids: physicians, patients and pharmacists. Findings from
      cognitive and decision science in areas other than drug safety suggest that
      people's risk perception and behaviour can differ depending on whether they
      learnt about a risk through personal experience or description. Experiencing the 
      risk of overutilising opioids among patients with chronic non-cancer pain in
      ambulatory care (ERONA) is the first-ever conducted trial that aims at
      investigating the effects of these two modes of learning on individuals' risk
      perception and behaviour in the long-term administration of WHO-III opioids in
      chronic non-cancer pain. METHODS AND ANALYSIS: ERONA-an exploratory, randomised
      controlled online survey intervention trial with two parallel arms-will examine
      the opioid-associated risk perception and behaviour of four groups involved in
      the long-term administration of WHO-III opioids: (1) family physicians, (2)
      physicians specialised in pain therapy, (3) patients with chronic (>/=3 months)
      non-cancer pain and (4) pharmacists who regularly dispense narcotic substances.
      Participants will be randomly assigned to one of two online risk education
      interventions, description based or experiencebased. Both interventions will
      present the best medical evidence available. Participants will be queried at
      baseline and after intervention on their risk perception of opioids' benefit-harm
      ratio, their medical risk literacy and their current/intended risk behaviour (in 
      terms of prescribing, taking or counselling, depending on study group). A
      follow-up will occur after 9 months, when participants will be queried on their
      actual risk behaviour. The study was developed by the authors and will be
      conducted by the market research institution IPSOS Health. ETHICS AND
      DISSEMINATION: The study was approved by the Institutional Review Board of the
      Max Planck Institute for Human Development. Results will be disseminated through 
      peer-reviewed journals, conference presentations and social media. TRIAL
      REGISTRATION NUMBER: DRKS00020358.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wegwarth, Odette
AU  - Wegwarth O
AUID- ORCID: 0000-0003-0885-2673
AD  - Center for Adaptive Rationality, Max-Planck-Institut fur Bildungsforschung,
      Berlin, Germany wegwarth@mpib-berlin.mpg.de.
FAU - Spies, Claudia
AU  - Spies C
AD  - Department of Anesthesiology and Operative Intensive Care Medicine, Charite,
      Universitaetsmedizin Berlin, Berlin, Germany.
FAU - Schulte, Erika
AU  - Schulte E
AD  - Department of Anesthesiology and Operative Intensive Care Medicine, Charite,
      Universitaetsmedizin Berlin, Berlin, Germany.
FAU - Meerpohl, Joerg J
AU  - Meerpohl JJ
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical
      Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Schmucker, Christine
AU  - Schmucker C
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical
      Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Nury, Edris
AU  - Nury E
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical
      Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Brockmann, Dirk
AU  - Brockmann D
AD  - Institute for Theoretical Biology and Integrative Research, Humboldt University
      of Berlin, Berlin, Germany.
AD  - Epidemiological Modelling of Infectious Diseases, Robert Koch Institut, Berlin,
      Germany.
FAU - Donner-Banzhoff, Norbert
AU  - Donner-Banzhoff N
AD  - Department of Primary Care, University of Marburg, Marburg, Germany.
FAU - Wind, Stefan
AU  - Wind S
AD  - Berlin Chamber of Pharmacists, Berlin, Germany.
FAU - Goebel, Eva
AU  - Goebel E
AD  - Berlin Chamber of Pharmacists, Berlin, Germany.
FAU - Ludwig, Wolf-Dieter
AU  - Ludwig WD
AD  - Drug Commission of the German Medical Association, Berlin, Germany.
FAU - Hertwig, Ralph
AU  - Hertwig R
AD  - Center for Adaptive Rationality, Max-Planck-Institut fur Bildungsforschung,
      Berlin, Germany.
LA  - eng
SI  - DRKS/DRKS00020358
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Ambulatory Care
MH  - Analgesics, Opioid/adverse effects
MH  - *Chronic Pain/drug therapy
MH  - Europe
MH  - Humans
MH  - *Physicians
MH  - Randomized Controlled Trials as Topic
PMC - PMC7476567
OTO - NOTNLM
OT  - *health & safety
OT  - *medical education & training
OT  - *pain management
OT  - *public health
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037642 [pii]
AID - 10.1136/bmjopen-2020-037642 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e037642. doi: 10.1136/bmjopen-2020-037642.


PMID- 32895281
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Restrictive transfusion strategy for critically injured patients (RESTRIC) trial:
      a study protocol for a cluster-randomised, crossover non-inferiority trial.
PG  - e037238
LID - 10.1136/bmjopen-2020-037238 [doi]
AB  - INTRODUCTION: Resuscitation using blood products is critical during the acute
      postinjury period. However, the optimal target haemoglobin (Hb) levels have not
      been adequately investigated. With the restrictive transfusion strategy for
      critically injured patients (RESTRIC) trial, we aim to compare the restrictive
      and liberal red blood cell (RBC) transfusion strategies. METHODS AND ANALYSIS:
      This is a cluster-randomised, crossover, non-inferiority trial of patients with
      severe trauma at 22 hospitals that have been randomised in a 1:1 ratio based on
      the use of a restrictive or liberal transfusion strategy with target Hb levels of
      70-90 or 100-120 g/L, respectively, during the first year. Subsequently, after
      1-month washout period, another transfusion strategy will be applied for an
      additional year. RBC transfusion requirements are usually unclear on arrival at
      the emergency department. Therefore, patients with severe bleeding, which could
      lead to haemorrhagic shock, will be included in the trial based on the attending 
      physician's judgement. Each RBC transfusion strategy will be applied until 7 days
      postadmission to the hospital or discharge from the intensive care unit. The
      outcomes measured will include the 28-day survival rate after arrival at the
      emergency department (primary), the cumulative amount of blood transfused,
      event-free days and frequency of transfusion-associated lung injury and organ
      failure (secondary). Demonstration of the non-inferiority of restrictive
      transfusion will emphasise its clinical advantages. ETHICS AND DISSEMINATION: The
      trial will be performed according to the Japanese and International Ethical
      guidelines. It has been approved by the Ethics Committee of each participating
      hospital and The Japanese Association for the Surgery of Trauma (JAST). Written
      informed consent will be obtained from all patients or their representatives. The
      results of the trial will be disseminated to the participating hospitals and
      board-certified educational institutions of JAST, submitted to peer-reviewed
      journals for publication, and presented at congresses. TRIAL REGISTRATION NUMBER:
      UMIN Clinical Trials Registry; UMIN000034405. Registered 8 October 2018.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hayakawa, Mineji
AU  - Hayakawa M
AUID- ORCID: 0000-0001-8341-7626
AD  - Department of Emergency Medicine, Hokkaido University Hospital, Sapporo, Japan
      mineji@dream.com.
FAU - Tagami, Takashi
AU  - Tagami T
AD  - Department of Emergency and Critical Care Medicine, Nippon Medical School
      Musashikosugi Hospital, Kawasaki, Kanagawa, Japan.
AD  - Department of Clinical Epidemiology and Health Economics, School of Public
      Health, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - IIjima, Hiroaki
AU  - IIjima H
AUID- ORCID: 0000-0003-0410-9698
AD  - GBS Japan Biostatistics, R&D, Amgen K.K, Tokyo, Japan.
FAU - Kudo, Daisuke
AU  - Kudo D
AD  - Division of Emergency and Critical Care Medicine, Tohoku University School of
      Medicine, Sendai, Miyagi, Japan.
FAU - Sekine, Kazuhiko
AU  - Sekine K
AD  - Department of Emergency and Critical Care Medicine, Saiseikai Central Hospital,
      Minato-ku, Tokyo, Japan.
FAU - Ogura, Takayuki
AU  - Ogura T
AD  - Department of Emergency Medicine & Critical Care Medicine, Advanced Medical
      Emergency and Critical Care Center, Japan Red Cross Maebashi Hospital, Maebashi, 
      Gunma, Japan.
FAU - Yumoto, Tetsuya
AU  - Yumoto T
AUID- ORCID: 0000-0003-1766-8026
AD  - Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate
      School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan.
FAU - Kondo, Yutaka
AU  - Kondo Y
AUID- ORCID: 0000-0003-1072-7089
AD  - Department of Emergency and Critical Care Medicine, Juntendo University Urayasu
      Hospital, Urayasu, Chiba, Japan.
FAU - Endo, Akira
AU  - Endo A
AD  - Trauma and Acute Critical Care Centre, Medical Hospital of Tokyo Medical and
      Dental University, Bunkyo-ku, Tokyo, Japan.
FAU - Ito, Kaori
AU  - Ito K
AD  - Department of Emergency Medicine, Division of Acute Care Surgery, Teikyo
      University School of Medicine Graduate School of Medicine, Itabashi-ku, Tokyo,
      Japan.
FAU - Matsumura, Yosuke
AU  - Matsumura Y
AD  - Department of Emergency and Critical Care Medicine, Chiba University Graduate
      School of Medicine, Chiba, Chiba, Japan.
FAU - Kushimoto, Shigeki
AU  - Kushimoto S
AD  - Division of Emergency and Critical Care Medicine, Tohoku University School of
      Medicine, Sendai, Miyagi, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000034405
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Hemoglobins)
SB  - IM
MH  - *Blood Transfusion
MH  - Cross-Over Studies
MH  - Equivalence Trials as Topic
MH  - Erythrocyte Transfusion
MH  - *Hemoglobins
MH  - Humans
MH  - Intensive Care Units
MH  - Randomized Controlled Trials as Topic
PMC - PMC7478023
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *blood bank & transfusion medicine
OT  - *haematology
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037238 [pii]
AID - 10.1136/bmjopen-2020-037238 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e037238. doi: 10.1136/bmjopen-2020-037238.


PMID- 32895273
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Estimating the global cost of vision impairment and its major causes: protocol
      for a systematic review.
PG  - e036689
LID - 10.1136/bmjopen-2019-036689 [doi]
AB  - INTRODUCTION: Vision impairment (VI) places a burden on individuals, health
      systems and society in general. In order to support the case for investing in eye
      health services, an updated cost of illness study that measures the global impact
      of VI is necessary. To perform such a study, a systematic review of the
      literature is needed. Here we outline the protocol for a systematic review to
      describe and summarise the costs associated with VI and its major causes. METHODS
      AND ANALYSIS: We will systematically search in Medline (Ovid) and the Centre for 
      Reviews and Dissemination database which includes the National Health Service
      Economics Evaluation Database. No language or geographical restriction will be
      applied. Additional literature will be identified by reviewing the references in 
      the included studies and by contacting field experts. Grey literature will be
      considered. The review will include any study published from 1 January 2000 to
      November 2019 that provides information about costs of illness, burden of disease
      and/or loss of well-being in participants with VI due to an unspecified cause or 
      due to one of the seven leading causes globally.Two reviewers will independently 
      screen studies and extract relevant data from included studies. Methodological
      quality of economic studies will be assessed based on the British Medical Journal
      checklist for economic submissions adapted to costs of illness studies. This
      protocol has been prepared following the Preferred Reporting Items for Systematic
      Reviews and Meta-Analysis protocols and has been published prospectively in Open 
      Science Framework. ETHICS AND DISSEMINATION: Formal ethical approval is not
      required, as primary data will not be collected in this review. The findings of
      this study will be disseminated through peer-reviewed publications, stakeholder
      meetings and inclusion in the ongoing Lancet Global Health Commission on Global
      Eye Health. REGISTRATION DETAILS: https://osf.io/9au3w (DOI
      10.17605/OSF.IO/6F8VM).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Marques, Ana Patricia
AU  - Marques AP
AUID- ORCID: 0000-0001-8242-7021
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK Patricia.Marques@lshtm.ac.uk.
FAU - Ramke, Jacqueline
AU  - Ramke J
AUID- ORCID: 0000-0002-5764-1306
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - School of Optometry and Vision Science, University of Auckland, Auckland, New
      Zealand.
FAU - Cairns, John
AU  - Cairns J
AD  - Department of Health Services Research and Policy, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Butt, Thomas
AU  - Butt T
AD  - UCL Institute of Ophthalmology, University College London, London, UK.
FAU - Zhang, Justine H
AU  - Zhang JH
AUID- ORCID: 0000-0001-8385-2003
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Faal, Hannah B
AU  - Faal HB
AD  - Department of Ophthalmology, University of Calabar, Calabar, Nigeria.
FAU - Taylor, Hugh
AU  - Taylor H
AD  - University of Melbourne School of Population and Global Health, Melbourne,
      Victoria, Australia.
FAU - Jones, Iain
AU  - Jones I
AD  - Sightsavers, Haywards Heath, UK.
FAU - Congdon, Nathan
AU  - Congdon N
AD  - Centre for Public Health, Queen's University, Belfast, UK.
AD  - Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China.
FAU - Bastawrous, Andrew
AU  - Bastawrous A
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Braithwaite, Tasanee
AU  - Braithwaite T
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
FAU - Jovic, Marty
AU  - Jovic M
AD  - PricewaterhouseCoopers, Sydney, New South Wales, Australia.
FAU - Resnikoff, Serge
AU  - Resnikoff S
AUID- ORCID: 0000-0002-5866-4446
AD  - Brien Holden Vision Institute, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - Nandakumar, Allyala
AU  - Nandakumar A
AD  - Brandeis University Heller School for Social Policy and Management, Waltham,
      Massachusetts, USA.
FAU - Khaw, Peng Tee
AU  - Khaw PT
AD  - NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of
      Ophthalmology, London, UK.
FAU - Bourne, Rupert R A
AU  - Bourne RRA
AD  - Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, UK.
FAU - Gordon, Iris
AU  - Gordon I
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Frick, Kevin
AU  - Frick K
AD  - Johns Hopkins University Carey Business School - Baltimore Campus, Baltimore,
      Maryland, USA.
FAU - Burton, Matthew J
AU  - Burton MJ
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
LA  - eng
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Causality
MH  - Cost-Benefit Analysis
MH  - Delivery of Health Care
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Research Design
MH  - Review Literature as Topic
MH  - *State Medicine
PMC - PMC7476478
OTO - NOTNLM
OT  - *health economics
OT  - *ophthalmology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036689 [pii]
AID - 10.1136/bmjopen-2019-036689 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e036689. doi: 10.1136/bmjopen-2019-036689.


PMID- 32895271
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Yoga programme for type-2 diabetes prevention (YOGA-DP) among high risk people in
      India: a multicentre feasibility randomised controlled trial protocol.
PG  - e036277
LID - 10.1136/bmjopen-2019-036277 [doi]
AB  - INTRODUCTION: A huge population in India is at high risk of type-2 diabetes
      (T2DM). Physical activity and a healthy diet (healthy lifestyle) improve blood
      glucose levels in people at high risk of T2DM. However, an unhealthy lifestyle is
      common among Indians. Yoga covers physical activity and a healthy diet and can
      help to prevent T2DM. The research question to be addressed by the main
      randomised controlled trial (RCT) is whether a Yoga programme for T2DM prevention
      (YOGA-DP) is effective in preventing T2DM among high risk people in India as
      compared with enhanced standard care. In this current study, we are determining
      the feasibility of undertaking the main RCT. INTERVENTION: YOGA-DP is a
      structured lifestyle education and exercise programme. The exercise part is based
      on Yoga and includes Shithilikarana Vyayama (loosening exercises), Surya Namaskar
      (sun salutation exercises), Asana (Yogic poses), Pranayama (breathing practices) 
      and Dhyana (meditation) and relaxation practices. METHODS AND ANALYSIS: This is a
      multicentre, two-arm, parallel-group, feasibility RCT with blinded outcome
      assessment and integrated mixed-methods process evaluation. Eligible participants
      should be aged 18-74 years, at high risk of T2DM (fasting plasma glucose level
      5.6-6.9 mmol/L) and safe to participate in physical activities. At least 64
      participants will be randomised to intervention or control group with final
      follow-up at 6 months. Important parameters, needed to design the main RCT, will 
      be estimated, such as SD of the outcome measure (fasting plasma glucose level at 
      6-month follow-up), recruitment, intervention adherence, follow-up, potential
      contamination and time needed to conduct the study. Semistructured qualitative
      interviews will be conducted with up to 20-30 participants, a sample of those
      declining to participate, four YOGA-DP instructors and around eight study staff
      to explore their perceptions and experiences of taking part in the study and of
      the intervention, reasons behind non-participation, experiences of delivering the
      intervention and running the study, respectively. ETHICS AND DISSEMINATION:
      Ethics approval has been obtained from the following Research Ethics Committees: 
      Faculty of Medicine and Health Sciences, University of Nottingham (UK); Centre
      for Chronic Disease Control (CCDC, India); Bapu Nature Cure Hospital and
      Yogashram (BNCHY, India) and Swami Vivekananda Yoga Anusandhana Samsthana
      (S-VYASA, India). The results will be widely disseminated among key stakeholders 
      through various avenues. TRIAL REGISTRATION NUMBER: CTRI/2019/05/018893.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Chattopadhyay, Kaushik
AU  - Chattopadhyay K
AUID- ORCID: 0000-0002-3235-8168
AD  - Division of Epidemiology and Public Health, University of Nottingham, Nottingham,
      UK kaushik.chattopadhyay@nottingham.ac.uk.
FAU - Mishra, Pallavi
AU  - Mishra P
AD  - Centre for Chronic Disease Control, Delhi, India.
FAU - Singh, Kavita
AU  - Singh K
AD  - Centre for Chronic Disease Control, Delhi, India.
FAU - Harris, Tess
AU  - Harris T
AUID- ORCID: 0000-0002-8671-1553
AD  - Population Health Research Institute, St George's University of London, London,
      UK.
FAU - Hamer, Mark
AU  - Hamer M
AUID- ORCID: 0000-0002-8726-7992
AD  - Institute Sport Exercise and Health, Division of Surgery and Interventional
      Science, University College London, London, UK.
FAU - Greenfield, Sheila Margaret
AU  - Greenfield SM
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Lewis, Sarah Anne
AU  - Lewis SA
AD  - Division of Epidemiology and Public Health, University of Nottingham, Nottingham,
      UK.
FAU - Manjunath, Nandi Krishnamurthy
AU  - Manjunath NK
AD  - Swami Vivekananda Yoga Anusandhana Samsthana, Bengaluru, India.
FAU - Nair, Rukamani
AU  - Nair R
AD  - Bapu Nature Cure Hospital and Yogashram, Delhi, India.
FAU - Mukherjee, Somnath
AU  - Mukherjee S
AD  - Bapu Nature Cure Hospital and Yogashram, Delhi, India.
FAU - Harper, David Ross
AU  - Harper DR
AD  - Harper Public Health Consulting Limited, London, UK.
FAU - Tandon, Nikhil
AU  - Tandon N
AD  - All India Institute of Medical Sciences, Delhi, India.
FAU - Kinra, Sanjay
AU  - Kinra S
AD  - London School of Hygiene And Tropical Medicine, London, UK.
FAU - Prabhakaran, Dorairaj
AU  - Prabhakaran D
AD  - Centre for Chronic Disease Control, Delhi, India.
CN  - YOGA-DP Study Team
LA  - eng
GR  - K43 TW011164/TW/FIC NIH HHS/United States
GR  - MR/J000175/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R018278/1/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - Feasibility Studies
MH  - Humans
MH  - India
MH  - *Meditation
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Yoga
MH  - Young Adult
PMC - PMC7477989
OTO - NOTNLM
OT  - *complementary medicine
OT  - *diabetes & endocrinology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036277 [pii]
AID - 10.1136/bmjopen-2019-036277 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e036277. doi: 10.1136/bmjopen-2019-036277.


PMID- 32895267
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - aDolescent and prEconception health peRspectiVe of Adult Non-communicable
      diseases (DERVAN): protocol for rural prospective adolescent girls cohort study
      in Ratnagiri district of Konkan region of India (DERVAN-1).
PG  - e035926
LID - 10.1136/bmjopen-2019-035926 [doi]
AB  - INTRODUCTION: Precise impact of nutritional insufficiencies in adolescence as a
      risk factor for non-communicable diseases (NCD) in later life as adults remains
      largely unknown.We are conducting research into the effects of nutrition on
      adolescent girls of Ratnagiri district by a prospective cohort study (aDolescent 
      and prEconception health peRspectiVe of Adult Non-communicable diseases cohort). 
      Our study focuses on the physical health, nutritional parameters and cognitive
      profiles of adolescent girls, during the prenatal and postnatal period and we aim
      to follow this cohort and their offspring for 20 years. METHODS AND ANALYSIS:
      Cohort recruitment began in June 2019. Our aim is to recruit more than 1500
      adolescent girls, age 16-18 years, over a period of 3 years. The recruit's
      cognition, diet and physical activity will be recorded. The following
      investigations will be performed: body composition by anthropometry and
      bioimpedence, and blood pressure, fasting blood sample to measure glucose,
      insulin, lipids, micronutrients and hormones, abdominal ultrasonography to
      measure liver, pancreas and kidneys.A biorepository has been created for
      long-term storage of blood, urine and saliva samples for future analysis. By this
      longitudinal study, we aim to identify the effects of malnutrition on the
      behavioural and biological measures in adolescent subjects and evaluate if these 
      are associated with the onset of NCDs in adulthood. ETHICS AND DISSEMINATION:
      Institutional Ethic Committee (IEC) of BKL Walawalkar Rural Medical College and
      Hospital has granted the permission to carry out the study. IEC is registered
      with Government of India. Its registration code is EC/755/INST/MH/2015/RR-18. It 
      is not a clinical trial but as required we have also registered the study on
      Clinical Trial Registry of India (CTRI). The registration code is
      CTRI/2019/04/018453.Appropriate written informed consent and assent are obtained 
      from the parents and the adolescent girls, respectively. We plan to publish our
      results in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Patil, Suvarna
AU  - Patil S
AUID- ORCID: 0000-0002-9564-986X
AD  - Department of Medicine, BKL Walawalkar Hospital & Rural Medical College, Sawarde,
      Maharashtra, India dr.suvarnanpatil@gmail.com.
FAU - Patil, Netaji
AU  - Patil N
AD  - Department of Radiology, BKL Walawalkar Hospital & Rural Medical College,
      Sawarde, Maharashtra, India.
FAU - Joglekar, Charudatta
AU  - Joglekar C
AD  - Centre for Adolescent Health and Nutrition, BKL Walawalkar Hospital & Rural
      Medical College, Sawarde, India.
FAU - Yadav, Arvind
AU  - Yadav A
AD  - Department of Biochemistry, BKL Walawalkar Hospital & Rural Medical College,
      Sawarde, Maharashtra, India.
FAU - Nilawar, Anup
AU  - Nilawar A
AD  - Department of Biochemistry, BKL Walawalkar Hospital & Rural Medical College,
      Sawarde, Maharashtra, India.
FAU - Banavali, Ulka
AU  - Banavali U
AD  - Centre for Adolescent Health and Nutrition, BKL Walawalkar Hospital & Rural
      Medical College, Sawarde, India.
FAU - Bhat, Rohit
AU  - Bhat R
AD  - Centre for Adolescent Health and Nutrition, BKL Walawalkar Hospital & Rural
      Medical College, Sawarde, India.
FAU - Dombale, Vijay
AU  - Dombale V
AD  - Department of Pathology, BKL walawalkar Hospital & Rural Medical College,
      Sawarde, Maharashtra, India.
FAU - Warpe, Bhushan
AU  - Warpe B
AD  - Department of Pathology, BKL walawalkar Hospital & Rural Medical College,
      Sawarde, Maharashtra, India.
FAU - Mohite, Rachana
AU  - Mohite R
AD  - Centre for Adolescent Health and Nutrition, BKL Walawalkar Hospital & Rural
      Medical College, Sawarde, India.
FAU - Joshi, Kiran
AU  - Joshi K
AD  - Department of Obstetrics and Gynaecology, BKL walawalkar Hospital & Rural medical
      College, Sawarde, Maharashtra, India.
LA  - eng
SI  - CTRI/CTRI/2019/04/018453
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - India
MH  - Longitudinal Studies
MH  - *Noncommunicable Diseases/prevention & control
MH  - Preconception Care
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7476477
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *epidemiology
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035926 [pii]
AID - 10.1136/bmjopen-2019-035926 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e035926. doi: 10.1136/bmjopen-2019-035926.


PMID- 32895265
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - HPV vaccination and Native Americans: protocol for a systematic review of factors
      associated with HPV vaccine uptake among American Indians and Alaska Natives in
      the USA.
PG  - e035658
LID - 10.1136/bmjopen-2019-035658 [doi]
AB  - INTRODUCTION: The nine-valent human papillomavirus (HPV) vaccine could prevent an
      estimated 92% of the cancers attributable to HPV types targeted by the vaccine.
      However, uptake of the HPV vaccine among American Indian and Alaska Native
      (AI/AN) adolescents has been low. AI/ANs also bear a disproportionate burden of
      cervical and other HPV-associated cancers. Increasing HPV vaccination rates is a 
      national priority, but reviews and national surveys on HPV vaccination factors
      are lacking for the AI/AN population. The objective of this systematic review is 
      to assess factors associated with HPV vaccination among AI/ANs in the USA.
      METHODS AND ANALYSIS: A systematic review is proposed to synthesise the current
      literature on HPV vaccination factors in AI/ANs from 1 July 2006 until 30
      September 2019. As applicable, controlled vocabulary terms, keywords and special 
      features (eg, limits, explode and focus) will be incorporated into database
      searches. To maximise the identification of relevant studies, citation indexes
      and databases that index dissertations, preprints and grey literature are
      included. Studies will be screened and selected independently in two stages. In
      stage 1, titles and abstracts will be screened. In stage 2, full-text articles
      will be screened and selected. A data extraction form and quality assessment tool
      will be piloted, revised and implemented. If available, measures of frequency and
      association will be presented. A narrative synthesis of the included studies will
      also be undertaken and reported. ETHICS AND DISSEMINATION: As our review will use
      publicly available data and publications, an Institutional Review Board review
      will not be required. We will disseminate the findings from this review through
      peer-reviewed publication(s) and conference presentation(s). POTENTIAL
      AMENDMENTS: In the event of amendments to the protocol, we will provide the date,
      rationale, and description of the change for each amendment. PROSPERO
      REGISTRATION NUMBER: CRD42020156865.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gopalani, Sameer Vali
AU  - Gopalani SV
AUID- ORCID: 0000-0003-0611-305X
AD  - Department of Epidemiology and Biostatistics, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA sameer-gopalani@ouhsc.edu.
FAU - Sedani, Ami E
AU  - Sedani AE
AD  - Department of Biostatistics and Epidemiology, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA.
FAU - Janitz, Amanda E
AU  - Janitz AE
AD  - Department of Biostatistics and Epidemiology, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA.
FAU - Clifton, Shari C
AU  - Clifton SC
AD  - Robert M. Bird Health Sciences Library, University of Oklahoma Health Sciences
      Center, Oklahoma City, Oklahoma, USA.
FAU - Stoner, Julie
AU  - Stoner J
AD  - Department of Biostatistics and Epidemiology, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA.
FAU - Peck, Jennifer
AU  - Peck J
AD  - Department of Biostatistics and Epidemiology, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA.
FAU - Comiford, Ashley
AU  - Comiford A
AD  - Community Health Promotion, Cherokee Nation, Tahlequah, Oklahoma, USA.
FAU - Salvatore, Alicia L
AU  - Salvatore AL
AD  - Value Institute, Christiana Care Health Services, Wilmington, Delaware, USA.
FAU - Campbell, Janis
AU  - Campbell J
AD  - Department of Biostatistics and Epidemiology, University of Oklahoma Health
      Sciences Center, Oklahoma City, Oklahoma, USA.
LA  - eng
GR  - P30 CA225520/CA/NCI NIH HHS/United States
GR  - R25 MD011564/MD/NIMHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - *Alaskan Natives
MH  - American Indians or Alaska Natives
MH  - Humans
MH  - *Indians, North American
MH  - *Papillomavirus Infections/prevention & control
MH  - *Papillomavirus Vaccines
MH  - Systematic Reviews as Topic
MH  - United States/epidemiology
MH  - Vaccination
PMC - PMC7478049
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035658 [pii]
AID - 10.1136/bmjopen-2019-035658 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e035658. doi: 10.1136/bmjopen-2019-035658.


PMID- 32895264
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Demographic and motivational factors affecting the whole-body donation programme 
      in Nanjing, China: a cross-sectional survey.
PG  - e035539
LID - 10.1136/bmjopen-2019-035539 [doi]
AB  - OBJECTIVES: To investigate the demographics and motivations of whole-body donors 
      in China, and help suggest a solution to the problem of low body donation
      numbers. DESIGN: A cross-sectional study on body donors in China. Demographic
      analysis of the donating information of deceased donors and in-depth interviews
      of potential body donors. SETTING: Eleven districts in Nanjing, China.
      PARTICIPANTS: Deceased whole-body donors who had donated their bodies to the body
      donation receiving station of Nanjing Medical University between 1 July 2009 and 
      30 June 2019 (n=835), and living registered whole-body donors (n=68). RESULTS:
      Among the whole-body donor population, the numbers of males, people older than 65
      years and those working as teachers, government officials, medical staff and
      farmers were significantly higher than those of the general Nanjing population.
      Donors with an education level of college or above accounted for nearly half of
      the deceased donors, and considered donating their bodies earlier in their lives 
      than others. Cancer and heart disease were the major causes of death among
      donors. Interviews of the 68 living donors revealed the following major
      motivations for the decision to donate: to support medical education; to reduce
      their children's funeral burden; no longer holding traditional Chinese views on
      life and death; influence by role models and annoyance at complex funeral
      ceremonies. CONCLUSIONS: Older people, people with an education level of college 
      or above, labourers, teachers, government officials and farmers are the major
      groups that donate their bodies. Although people's motivations for donation are
      complex, their desire to support medical education is the most prevalent
      motivation. By helping focus on target groups for promotional messaging and
      identifying their prime motivations, this study's findings can provide a
      reference for promoting body donation in China.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jiang, Jiayi
AU  - Jiang J
AD  - School of Pediatrics, Nanjing Medical University, Nanjing, Jiangsu, China.
FAU - Zhang, Mingyi
AU  - Zhang M
AD  - School of Pediatrics, Nanjing Medical University, Nanjing, Jiangsu, China.
FAU - Meng, Haojie
AU  - Meng H
AD  - School of Pediatrics, Nanjing Medical University, Nanjing, Jiangsu, China.
FAU - Cui, Xiang
AU  - Cui X
AD  - School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
FAU - Yang, Yuxin
AU  - Yang Y
AD  - School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu,
      China.
FAU - Yuan, Li
AU  - Yuan L
AD  - School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu,
      China.
FAU - Su, Chuan
AU  - Su C
AD  - School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu,
      China.
FAU - Wang, Jinfan
AU  - Wang J
AD  - Research Center of Doctor-Patient Communication, Nanjing Medical University,
      Nanjing, Jiangsu, China.
FAU - Zhang, Luqing
AU  - Zhang L
AUID- ORCID: 0000-0001-7044-0616
AD  - School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu,
      China luqingzh@njmu.edu.cn.
AD  - Research Center of Doctor-Patient Communication, Nanjing Medical University,
      Nanjing, Jiangsu, China.
AD  - Body Donation Receiving Station, Nanjing Medical University, Nanjing, Jiangsu,
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - China
MH  - Cross-Sectional Studies
MH  - Demography
MH  - Humans
MH  - Living Donors
MH  - Male
MH  - *Motivation
MH  - Surveys and Questionnaires
MH  - *Tissue Donors
PMC - PMC7478054
OTO - NOTNLM
OT  - *anatomy
OT  - *medical education & training
OT  - *medical ethics
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035539 [pii]
AID - 10.1136/bmjopen-2019-035539 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e035539. doi: 10.1136/bmjopen-2019-035539.


PMID- 32895260
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Intra-articular corticosteroids for treatment of temporomandibular joint internal
      disorders: protocol for systematic review and network meta-analysis.
PG  - e034327
LID - 10.1136/bmjopen-2019-034327 [doi]
AB  - INTRODUCTION: Internal temporomandibular joint (TMJ) disorders are present in
      approximately 80% of patients with symptomatic temporomandibular disorders. Among
      the minimally invasive therapies, we find the intra-articular infiltration of
      substances, such as corticosteroids, hyaluronic acid or platelet-rich plasma
      accompanied or not by an arthrocentesis. There are several studies on minimally
      invasive therapy for internal TMJ disorders; however, none compares the
      effectiveness of the different intra-articular corticosteroids to each other.The 
      purpose of this study is to evaluate the effectiveness of the different
      intra-articular corticosteroids for the treatment of internal disorders of the
      TMJ and compare them to each other or to other minimally invasive therapies.
      METHODS AND ANALYSIS: A systematic search will be carried out up to December 2019
      in the electronic databases: Medline, Cochrane Library, EMBASE, SCOPUS and
      LILACS.Randomised clinical trials evaluating patients with internal disorders of 
      the TMJ, with intra-articular corticosteroid therapy and comparing these to each 
      other and/or to other minimally invasive therapy will be included. The main
      outcomes will be pain and range of motion measured through validated scales.Two
      review authors will independently screen search results, extract data from
      included studies and assess the risk of bias in those studies using the Revised
      Cochrane Risk of Bias Tool (RoB 2.0). In the case of any discrepancy and failure 
      to reach consensus, this will be resolved by a third reviewer.A network
      meta-analysis will be conducted based on direct comparisons to generate indirect 
      comparisons of the different treatments. Data will be combined in a meta-analysis
      using a random effects model.The principles of the Grading of Recommendations
      Assessment, Development and Evaluation (GRADE) system will be used to assess the 
      overall quality of the body of evidence associated with the main results. ETHICS 
      AND DISSEMINATION: This protocol will not require ethical approval. The results
      of this review will be disseminated through peer-reviewed publications. TRIAL
      REGISTRATION NUMBER: CRD42019129014.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Torres, Daniela
AU  - Torres D
AD  - Master Program in Dentistry, Faculty of Dentistry, Universidad de La Frontera,
      Temuco, Chile.
AD  - Temporomandibular Disorder and Orofacial Pain Program, Sleep & Pain Research
      Group, Faculty of Dentistry, Universidad de La Frontera, Temuco, Chile.
FAU - Zaror, Carlos
AU  - Zaror C
AUID- ORCID: 0000-0001-6942-6956
AD  - Department of Pediatric Dentistry and Orthodontics, Faculty of Dentistry,
      Universidad de La Frontera, Temuco, Chile carlos.zaror@ufrontera.cl.
AD  - Faculty of Dentistry, Universidad San Sebastian, Puerto Montt, Chile.
FAU - Iturriaga, Veronica
AU  - Iturriaga V
AD  - Department of Integral Adult Care Dentistry, Temporomandibular Disorder and
      Orofacial Pain Program, Sleep & Pain Research Group, Faculty of Dentistry,
      Universidad de La Frontera, Temuco, Chile.
FAU - Tobias, Aurelio
AU  - Tobias A
AD  - Institute of Metabolism and Systems Research, University of Birmingham,
      Birmingham, West Midlands, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Humans
MH  - Injections, Intra-Articular
MH  - Network Meta-Analysis
MH  - Temporomandibular Joint
MH  - *Temporomandibular Joint Disorders/drug therapy
PMC - PMC7476463
OTO - NOTNLM
OT  - *meta-analysis
OT  - *steroids
OT  - *temporomandibular joint
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034327 [pii]
AID - 10.1136/bmjopen-2019-034327 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e034327. doi: 10.1136/bmjopen-2019-034327.


PMID- 32895259
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 6
TI  - Cryoablation for advanced non-small cell lung cancer: a protocol for a systematic
      review.
PG  - e033460
LID - 10.1136/bmjopen-2019-033460 [doi]
AB  - INTRODUCTION: National Comprehensive Cancer Network has recommended cryoablation 
      to replace the resection in the treatment of medically operable non-small cell
      lung cancer (NSCLC). Cryoablation also has been used for the advanced NSCLC in
      randomised controlled trials. However, they have not been systematically
      reviewed. Here, we provide a protocol to evaluate the effectiveness and safety of
      cryoablation in the treatment of advanced NSCLC. METHODS AND ANALYSES: We will
      search PubMed, Embase, the Cochrane Library, Chinese Biomedical Database, China
      National Knowledge Infrastructure, Wanfang Database and Chinese Scientific
      Journal Database without language restrictions from inception until 1 February
      2020. Trial registers (International Clinical Trials Registry platform, the US
      National Institutes of Health Ongoing Trials Register and the ISRCTN registry)
      and reference lists of retrieved articles will also be searched. Two reviewers
      will independently extract data on participants, interventions, comparisons,
      outcomes and assess the methodological quality by the Cochrane risk of bias tool.
      The strength of evidences will be evaluated according to the Grading of
      Recommendations Assessment, Development and Evaluation approach. Review Manager
      V.5.3 software will be used for data analyses. Meta-analyses will be performed if
      the data are sufficiently homogeneous. The primary outcomes will be objective
      response rate and overall survival. The secondary outcomes will be adverse
      effects, health-related quality of life, changes of immune indicators and
      surrogate outcomes (disease control rate, progression-free survival and survival 
      rate). ETHICS AND DISSEMINATION: Ethics approval is not required, as this study
      will not involve patients. The results of this study will be submitted to a
      peer-reviewed journal for publication, to inform both clinical practice and
      further research. PROSPERO REGISTRATION NUMBER: CRD42019138660.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Duan, Hua
AU  - Duan H
AUID- ORCID: 0000-0002-9768-2428
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zheng, Shu-Yue
AU  - Zheng SY
AUID- ORCID: 0000-0002-4805-0483
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Luo, Chufan
AU  - Luo C
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Fang, Xueni
AU  - Fang X
AD  - Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Wang, Dan
AU  - Wang D
AD  - Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Pang, Haoyue
AU  - Pang H
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Wang, Man
AU  - Wang M
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Chen, Yu
AU  - Chen Y
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhou, Tian
AU  - Zhou T
AD  - Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Li, Quanwang
AU  - Li Q
AD  - Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine,
      Beijing, China.
FAU - Hu, Kaiwen
AU  - Hu K
AD  - Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine,
      Beijing, China kaiwenh@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200906
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/surgery
MH  - China
MH  - *Cryosurgery
MH  - Humans
MH  - *Lung Neoplasms/surgery
MH  - Quality of Life
MH  - Systematic Reviews as Topic
PMC - PMC7476476
OTO - NOTNLM
OT  - *advanced
OT  - *carcinoma, non-small-cell lung
OT  - *clinical trial protocol
OT  - *cryosurgery
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/09/09 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/09/08 05:19
PHST- 2020/09/08 05:19 [entrez]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - bmjopen-2019-033460 [pii]
AID - 10.1136/bmjopen-2019-033460 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 6;10(9):e033460. doi: 10.1136/bmjopen-2019-033460.


PMID- 32894872
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20220418
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 82
IP  - 11
DP  - 2020 Nov
TI  - [Ethics University on Regenerative Medicine - As an Instrument for the
      Development of Valid Public Opinions?]
PG  - e124-e137
LID - 10.1055/a-1205-0672 [doi]
AB  - OBJECTIVES: In 2016, we invited interested citizens to participate in the "ethics
      university on regenerative medicine" at Hannover Medical School. The present
      study analyses if and how this discursive and informative event inspired
      participants to form their own opinion on the issues at hand and to develop their
      general ethics literacy. METHODS: The "ethics university" was performed twice in 
      2016; each run consisted of four single consecutive events. Lectures were
      combined with interactive learning stations, and group discussions. Opinions and 
      information level of all participants were surveyed by means of a postal
      questionnaire before and after the course to detect any changes of opinions and
      information levels; additionally, we surveyed participants' self-assessment.
      Participants of the second run were asked to form a waiting list control group to
      compare results from first run-participants. Furthermore, we conducted a content 
      analysis of group discussions during the ethics university. RESULTS: Of 168
      participants of both runs, 101 took part in the pre/post-survey. In addition, 30 
      questionnaires of the waiting list control group were analysed. Participants
      showed a higher level of information after the ethics university (changes between
      0.75 and 1.93 points on a five-point scale). Between 50.5 and 66.0% of
      participants indicated that their opinion on different issues had become either
      more affirmative or more disapprobative as a result of attending the ethics
      university. On average, opinions were more positive after participation (between 
      0.44 and 1.0 points on a 5-point scale). Respondents in the waiting list control 
      group showed no changes in opinion or information level. Participants themselves 
      felt that they formed their opinions mainly on the basis of information they
      received in lectures, conversations with experts, interactive learning sessions, 
      and written information. However, for many participants, interacting with other
      participants in the group discussions, as well as reflecting their own views was 
      an important to forming informed opinions. CONCLUSION: Results of the evaluation 
      show that participants were inspired to form their own opinions by the ethics
      university and to develop their ethics literacy (e. g. ability to reflect on
      normative questions). For future ethics universities, the group of participants
      should be as diverse as possible. In addition, interactive and discursive
      elements should be given a higher priority.
CI  - Thieme. All rights reserved.
FAU - Bossert, Sabine
AU  - Bossert S
AUID- ORCID: 0000-0002-6086-1318
AD  - Institut fur Geschichte, Ethik und Philosophie der Medizin, Medizinische
      Hochschule Hannover, Hannover.
AD  - Forschungszentrum Julich GmbH Stabsstelle Zukunftscampus, Julich.
FAU - Werdecker, Lena
AU  - Werdecker L
AD  - Institut fur Geschichte, Ethik und Philosophie der Medizin, Medizinische
      Hochschule Hannover, Hannover.
AD  - Institut fur Integrative Gesundheitsversorgung und Gesundheitsforderung,
      Universitat Witten/Herdecke, Witten.
FAU - Strech, Daniel
AU  - Strech D
AD  - Institut fur Geschichte, Ethik und Philosophie der Medizin, Medizinische
      Hochschule Hannover, Hannover.
AD  - Berliner Institut fur Gesundheitsforschung, Charite & Max-Delbruck-Centrum,
      Berlin.
FAU - Neitzke, Gerald
AU  - Neitzke G
AD  - Institut fur Geschichte, Ethik und Philosophie der Medizin, Medizinische
      Hochschule Hannover, Hannover.
FAU - Dierks, Marie-Luise
AU  - Dierks ML
AD  - Institut fur Epidemiologie, Sozialmedizin und Gesundheitssystemforschung,
      Medizinische Hochschule Hannover, Hannover.
FAU - Meyer, Antje
AU  - Meyer A
AD  - Institut fur Epidemiologie, Sozialmedizin und Gesundheitssystemforschung,
      Medizinische Hochschule Hannover, Hannover.
FAU - Hirschberg, Irene
AU  - Hirschberg I
AD  - Institut fur Geschichte, Ethik und Philosophie der Medizin, Medizinische
      Hochschule Hannover, Hannover.
LA  - ger
GR  - Ethik-Universitat zur Regenerativen Medizin" wurde gefordert durch das
      Bundesministerium fur Bildung und Forschung (BMBF)/01GP1471
PT  - Journal Article
TT  - Ethik-Universitat zur Regenerativen Medizin - ein Instrument der fundierten
      Meinungsbildung fur Laien?
DEP - 20200907
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes
      (Germany))
JID - 9204210
SB  - IM
MH  - Attitude
MH  - *Ethics, Medical
MH  - Germany
MH  - Humans
MH  - *Public Opinion
MH  - *Regenerative Medicine/ethics
MH  - Universities
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/09/08 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/09/07 20:02
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/09/07 20:02 [entrez]
AID - 10.1055/a-1205-0672 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2020 Nov;82(11):e124-e137. doi: 10.1055/a-1205-0672. Epub 2020 
      Sep 7.


PMID- 32894860
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210318
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 587
IP  - 7834
DP  - 2020 Nov
TI  - LifeTime and improving European healthcare through cell-based interceptive
      medicine.
PG  - 377-386
LID - 10.1038/s41586-020-2715-9 [doi]
AB  - Here we describe the LifeTime Initiative, which aims to track, understand and
      target human cells during the onset and progression of complex diseases, and to
      analyse their response to therapy at single-cell resolution. This mission will be
      implemented through the development, integration and application of single-cell
      multi-omics and imaging, artificial intelligence and patient-derived experimental
      disease models during the progression from health to disease. The analysis of
      large molecular and clinical datasets will identify molecular mechanisms, create 
      predictive computational models of disease progression, and reveal new drug
      targets and therapies. The timely detection and interception of disease embedded 
      in an ethical and patient-centred vision will be achieved through interactions
      across academia, hospitals, patient associations, health data management systems 
      and industry. The application of this strategy to key medical challenges in
      cancer, neurological and neuropsychiatric disorders, and infectious, chronic
      inflammatory and cardiovascular diseases at the single-cell level will usher in
      cell-based interceptive medicine in Europe over the next decade.
FAU - Rajewsky, Nikolaus
AU  - Rajewsky N
AUID- ORCID: 0000-0002-4785-4332
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine in the Helmholtz Association, Berlin, Germany. rajewsky@mdc-berlin.de.
AD  - Charite-Universitatsmedizin, Berlin, Germany. rajewsky@mdc-berlin.de.
AD  - Berlin Institute of Health (BIH), Berlin, Germany. rajewsky@mdc-berlin.de.
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin,
      Germany. rajewsky@mdc-berlin.de.
FAU - Almouzni, Genevieve
AU  - Almouzni G
AUID- ORCID: 0000-0001-5570-0723
AD  - Institut Curie, CNRS, PSL Research University, Sorbonne Universite, Nuclear
      Dynamics Unit, Equipe Labellisee Ligue contre le cancer, Paris, France.
      genevieve.almouzni@curie.fr.
FAU - Gorski, Stanislaw A
AU  - Gorski SA
AUID- ORCID: 0000-0003-0539-3395
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine in the Helmholtz Association, Berlin, Germany.
      stan.gorski@mdc-berlin.de.
FAU - Aerts, Stein
AU  - Aerts S
AUID- ORCID: 0000-0002-8006-0315
AD  - VIB Center for Brain and Disease Research, Leuven, Belgium.
AD  - Department of Human Genetics, KU Leuven, Leuven, Belgium.
FAU - Amit, Ido
AU  - Amit I
AUID- ORCID: 0000-0003-2968-877X
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
FAU - Bertero, Michela G
AU  - Bertero MG
AD  - Centre for Genomic Regulation (CRG), Barcelona Institute of Science and
      Technology, Barcelona, Spain.
FAU - Bock, Christoph
AU  - Bock C
AUID- ORCID: 0000-0001-6091-3088
AD  - CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 
      Vienna, Austria.
AD  - Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
AD  - Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AUID- ORCID: 0000-0002-7542-8963
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary
      Care, University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Cavalli, Giacomo
AU  - Cavalli G
AUID- ORCID: 0000-0003-3709-3469
AD  - Institute of Human Genetics, UMR 9002, CNRS and University of Montpellier,
      Montpellier, France.
FAU - Chiocca, Susanna
AU  - Chiocca S
AUID- ORCID: 0000-0002-9721-0850
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS,
      Milan, Italy.
FAU - Clevers, Hans
AU  - Clevers H
AUID- ORCID: 0000-0002-3077-5582
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW),
      Utrecht, The Netherlands.
AD  - University Medical Center Utrecht, Utrecht, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
AD  - The Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
FAU - De Strooper, Bart
AU  - De Strooper B
AD  - VIB Center for Brain and Disease Research, Leuven, Belgium.
AD  - Department of Neurosciences, KU Leuven, Leuven, Belgium.
AD  - UK Dementia Research Institute at UCL, University College London, London, UK.
FAU - Eggert, Angelika
AU  - Eggert A
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
AD  - Department of Pediatric Oncology/Hematology, Charite-Universitatsmedizin Berlin, 
      Berlin, Germany.
FAU - Ellenberg, Jan
AU  - Ellenberg J
AUID- ORCID: 0000-0001-5909-701X
AD  - Cell Biology and Biophysics Unit, European Molecular Biology Laboratory,
      Heidelberg, Germany.
FAU - Fernandez, Xose M
AU  - Fernandez XM
AUID- ORCID: 0000-0001-7139-6215
AD  - Institut Curie, PSL Research University, Paris, France.
FAU - Figlerowicz, Marek
AU  - Figlerowicz M
AD  - Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
AD  - Institute of Computing Science, Poznan University of Technology, Poznan, Poland.
FAU - Gasser, Susan M
AU  - Gasser SM
AUID- ORCID: 0000-0003-3610-9123
AD  - Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
AD  - Faculty of Natural Sciences, University of Basel, Basel, Switzerland.
FAU - Hubner, Norbert
AU  - Hubner N
AUID- ORCID: 0000-0002-1218-6223
AD  - Charite-Universitatsmedizin, Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
AD  - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin,
      Germany.
AD  - Cardiovascular and Metabolic Sciences, Max Delbruck Center for Molecular Medicine
      in the Helmholtz Association (MDC), Berlin, Germany.
FAU - Kjems, Jorgen
AU  - Kjems J
AD  - Department of Molecular Biology and Genetics (MBG), Aarhus University, Aarhus,
      Denmark.
AD  - Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Aarhus, Denmark.
FAU - Knoblich, Jurgen A
AU  - Knoblich JA
AUID- ORCID: 0000-0002-6751-3404
AD  - Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), 
      Vienna, Austria.
AD  - Medical University of Vienna, Vienna, Austria.
FAU - Krabbe, Grietje
AU  - Krabbe G
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine in the Helmholtz Association, Berlin, Germany.
FAU - Lichter, Peter
AU  - Lichter P
AUID- ORCID: 0000-0002-2960-5279
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg,
      Germany.
FAU - Linnarsson, Sten
AU  - Linnarsson S
AUID- ORCID: 0000-0002-3491-3444
AD  - Division of Molecular Neurobiology, Department of Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
AD  - Science for Life Laboratory, Stockholm, Sweden.
FAU - Marine, Jean-Christophe
AU  - Marine JC
AD  - Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU
      Leuven, Leuven, Belgium.
AD  - Department of Oncology, KU Leuven, Leuven, Belgium.
FAU - Marioni, John C
AU  - Marioni JC
AUID- ORCID: 0000-0001-9092-0852
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute,
      Wellcome Genome Campus, Cambridge, UK.
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
AD  - Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
FAU - Marti-Renom, Marc A
AU  - Marti-Renom MA
AUID- ORCID: 0000-0002-0151-4279
AD  - Centre for Genomic Regulation (CRG), Barcelona Institute of Science and
      Technology, Barcelona, Spain.
AD  - CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and
      Technology, Barcelona, Spain.
AD  - Universitat Pompeu Fabra, Barcelona, Spain.
AD  - ICREA, Barcelona, Spain.
FAU - Netea, Mihai G
AU  - Netea MG
AUID- ORCID: 0000-0003-2421-6052
AD  - Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud 
      University Medical Center, Nijmegen, The Netherlands.
AD  - Radboud Institute for Molecular Life Sciences, Radboud University Medical Center,
      Nijmegen, The Netherlands.
AD  - Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.
FAU - Nickel, Dorthe
AU  - Nickel D
AD  - Institut Curie, PSL Research University, Paris, France.
FAU - Nollmann, Marcelo
AU  - Nollmann M
AUID- ORCID: 0000-0003-3339-2349
AD  - Centre de Biochimie Structurale, CNRS UMR 5048, INSERM U1054, Universite de
      Montpellier, Montpellier, France.
FAU - Novak, Halina R
AU  - Novak HR
AD  - VIB Technology Watch, Ghent, Belgium.
FAU - Parkinson, Helen
AU  - Parkinson H
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute,
      Wellcome Genome Campus, Cambridge, UK.
FAU - Piccolo, Stefano
AU  - Piccolo S
AUID- ORCID: 0000-0002-1600-3092
AD  - Department of Molecular Medicine, University of Padua School of Medicine, Padua, 
      Italy.
AD  - IFOM, The FIRC Institute of Molecular Oncology, Padua, Italy.
FAU - Pinheiro, Ines
AU  - Pinheiro I
AD  - Institut Curie, CNRS, PSL Research University, Sorbonne Universite, Nuclear
      Dynamics Unit, Equipe Labellisee Ligue contre le cancer, Paris, France.
FAU - Pombo, Ana
AU  - Pombo A
AUID- ORCID: 0000-0002-7493-6288
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine in the Helmholtz Association, Berlin, Germany.
AD  - Institute for Biology, Humboldt University of Berlin, Berlin, Germany.
FAU - Popp, Christian
AU  - Popp C
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine in the Helmholtz Association, Berlin, Germany.
FAU - Reik, Wolf
AU  - Reik W
AUID- ORCID: 0000-0003-0216-9881
AD  - Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
AD  - Epigenetics Programme, Babraham Institute, Cambridge, UK.
AD  - Centre for Trophoblast Research, University of Cambridge, Cambridge, UK.
FAU - Roman-Roman, Sergio
AU  - Roman-Roman S
AD  - Department of Translational Research, Institut Curie, PSL Research University,
      Paris, France.
FAU - Rosenstiel, Philip
AU  - Rosenstiel P
AD  - Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
AD  - University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
FAU - Schultze, Joachim L
AU  - Schultze JL
AUID- ORCID: 0000-0003-2812-9853
AD  - Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.
AD  - German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
AD  - PRECISE, Platform for Single Cell Genomics and Epigenomics at the German Center
      for Neurodegenerative Diseases and the University of Bonn, Bonn, Germany.
FAU - Stegle, Oliver
AU  - Stegle O
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute,
      Wellcome Genome Campus, Cambridge, UK.
AD  - Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
AD  - Division of Computational Genomics and Systems Genetics, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
FAU - Tanay, Amos
AU  - Tanay A
AUID- ORCID: 0000-0001-9419-3824
AD  - Department of Computer Science and Applied Mathematics, Weizmann Institute of
      Science, Rehovot, Israel.
FAU - Testa, Giuseppe
AU  - Testa G
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS,
      Milan, Italy.
AD  - Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
AD  - Human Technopole, Milan, Italy.
FAU - Thanos, Dimitris
AU  - Thanos D
AD  - Biomedical Research Foundation, Academy of Athens, Athens, Greece.
FAU - Theis, Fabian J
AU  - Theis FJ
AUID- ORCID: 0000-0002-2419-1943
AD  - Institute of Computational Biology, Helmholtz Zentrum Munchen - German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Department of Mathematics, Technical University of Munich, Munich, Germany.
FAU - Torres-Padilla, Maria-Elena
AU  - Torres-Padilla ME
AUID- ORCID: 0000-0002-1020-2074
AD  - Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum Munchen - German
      Research Center for Environmental Health, Munich, Germany.
AD  - Faculty of Biology, Ludwig-Maximilians Universitat, Munich, Germany.
FAU - Valencia, Alfonso
AU  - Valencia A
AD  - ICREA, Barcelona, Spain.
AD  - Barcelona Supercomputing Center (BSC), Barcelona, Spain.
FAU - Vallot, Celine
AU  - Vallot C
AUID- ORCID: 0000-0003-1601-2359
AD  - Department of Translational Research, Institut Curie, PSL Research University,
      Paris, France.
AD  - CNRS UMR3244, Institut Curie, PSL University, Paris, France.
FAU - van Oudenaarden, Alexander
AU  - van Oudenaarden A
AUID- ORCID: 0000-0002-9442-3551
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW),
      Utrecht, The Netherlands.
AD  - University Medical Center Utrecht, Utrecht, The Netherlands.
AD  - Oncode Institute, Utrecht, The Netherlands.
FAU - Vidal, Marie
AU  - Vidal M
AUID- ORCID: 0000-0003-1186-9994
AD  - Berlin Institute for Medical Systems Biology, Max Delbruck Center for Molecular
      Medicine in the Helmholtz Association, Berlin, Germany.
FAU - Voet, Thierry
AU  - Voet T
AD  - Department of Human Genetics, KU Leuven, Leuven, Belgium.
AD  - Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
CN  - LifeTime Community Working Groups
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200907
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
EIN - Nature. 2021 Apr;592(7852):E8. PMID: 33731935
MH  - Artificial Intelligence
MH  - *Cell- and Tissue-Based Therapy
MH  - Delivery of Health Care/ethics/*methods/standards/*trends
MH  - Early Diagnosis
MH  - Education, Medical
MH  - Europe
MH  - Female
MH  - Health
MH  - Humans
MH  - Legislation, Medical
MH  - Male
MH  - Medicine/*methods/standards/*trends
MH  - *Pathology
MH  - *Single-Cell Analysis
PMC - PMC7656507
IR  - Alberi L
FIR - Alberi, Lavinia
IR  - Alexander S
FIR - Alexander, Stephanie
IR  - Alexandrov T
FIR - Alexandrov, Theodore
IR  - Arenas E
FIR - Arenas, Ernest
IR  - Bagni C
FIR - Bagni, Claudia
IR  - Balderas R
FIR - Balderas, Robert
IR  - Bandelli A
FIR - Bandelli, Andrea
IR  - Becher B
FIR - Becher, Burkhard
IR  - Becker M
FIR - Becker, Matthias
IR  - Beerenwinkel N
FIR - Beerenwinkel, Niko
IR  - Benkirame M
FIR - Benkirame, Monsef
IR  - Beyer M
FIR - Beyer, Marc
IR  - Bickmore W
FIR - Bickmore, Wendy
IR  - Biessen EEAL
FIR - Biessen, Erik E A L
IR  - Blomberg N
FIR - Blomberg, Niklas
IR  - Blumcke I
FIR - Blumcke, Ingmar
IR  - Bodenmiller B
FIR - Bodenmiller, Bernd
IR  - Borroni B
FIR - Borroni, Barbara
IR  - Boumpas DT
FIR - Boumpas, Dimitrios T
IR  - Bourgeron T
FIR - Bourgeron, Thomas
IR  - Bowers S
FIR - Bowers, Sarion
IR  - Braeken D
FIR - Braeken, Dries
IR  - Brooksbank C
FIR - Brooksbank, Catherine
IR  - Brose N
FIR - Brose, Nils
IR  - Bruining H
FIR - Bruining, Hilgo
IR  - Bury J
FIR - Bury, Jo
IR  - Caporale N
FIR - Caporale, Nicolo
IR  - Cattoretti G
FIR - Cattoretti, Giorgio
IR  - Chabane N
FIR - Chabane, Nadia
IR  - Chneiweiss H
FIR - Chneiweiss, Herve
IR  - Cook SA
FIR - Cook, Stuart A
IR  - Curatolo P
FIR - Curatolo, Paolo
IR  - de Jonge MI
FIR - de Jonge, Marien I
IR  - Deplancke B
FIR - Deplancke, Bart
IR  - De Strooper B
FIR - De Strooper, Bart
IR  - de Witte P
FIR - de Witte, Peter
IR  - Dimmeler S
FIR - Dimmeler, Stefanie
IR  - Draganski B
FIR - Draganski, Bogdan
IR  - Drews A
FIR - Drews, Anna
IR  - Dumbrava C
FIR - Dumbrava, Costica
IR  - Engelhardt S
FIR - Engelhardt, Stefan
IR  - Gasser T
FIR - Gasser, Thomas
IR  - Giamarellos-Bourboulis EJ
FIR - Giamarellos-Bourboulis, Evangelos J
IR  - Graff C
FIR - Graff, Caroline
IR  - Grun D
FIR - Grun, Dominic
IR  - Gut I
FIR - Gut, Ivo
IR  - Hansson O
FIR - Hansson, Oskar
IR  - Henshall DC
FIR - Henshall, David C
IR  - Herland A
FIR - Herland, Anna
IR  - Heutink P
FIR - Heutink, Peter
IR  - Heymans SRB
FIR - Heymans, Stephane R B
IR  - Heyn H
FIR - Heyn, Holger
IR  - Huch M
FIR - Huch, Meritxell
IR  - Huitinga I
FIR - Huitinga, Inge
IR  - Jackowiak P
FIR - Jackowiak, Paulina
IR  - Jongsma KR
FIR - Jongsma, Karin R
IR  - Journot L
FIR - Journot, Laurent
IR  - Junker JP
FIR - Junker, Jan Philipp
IR  - Katz S
FIR - Katz, Shauna
IR  - Kehren J
FIR - Kehren, Jeanne
IR  - Kempa S
FIR - Kempa, Stefan
IR  - Kirchhof P
FIR - Kirchhof, Paulus
IR  - Klein C
FIR - Klein, Christine
IR  - Koralewska N
FIR - Koralewska, Natalia
IR  - Korbel JO
FIR - Korbel, Jan O
IR  - Kuhnemund M
FIR - Kuhnemund, Malte
IR  - Lamond AI
FIR - Lamond, Angus I
IR  - Lauwers E
FIR - Lauwers, Elsa
IR  - Le Ber I
FIR - Le Ber, Isabelle
IR  - Leinonen V
FIR - Leinonen, Ville
IR  - Tobon AL
FIR - Tobon, Alejandro Lopez
IR  - Lundberg E
FIR - Lundberg, Emma
IR  - Lunkes A
FIR - Lunkes, Astrid
IR  - Maatz H
FIR - Maatz, Henrike
IR  - Mann M
FIR - Mann, Matthias
IR  - Marelli L
FIR - Marelli, Luca
IR  - Matser V
FIR - Matser, Vera
IR  - Matthews PM
FIR - Matthews, Paul M
IR  - Mechta-Grigoriou F
FIR - Mechta-Grigoriou, Fatima
IR  - Menon R
FIR - Menon, Radhika
IR  - Nielsen AF
FIR - Nielsen, Anne F
IR  - Pagani M
FIR - Pagani, Massimiliano
IR  - Pasterkamp RJ
FIR - Pasterkamp, R Jeroen
IR  - Pitkanen A
FIR - Pitkanen, Asla
IR  - Popescu V
FIR - Popescu, Valentin
IR  - Pottier C
FIR - Pottier, Cyril
IR  - Puisieux A
FIR - Puisieux, Alain
IR  - Rademakers R
FIR - Rademakers, Rosa
IR  - Reiling D
FIR - Reiling, Dory
IR  - Reiner O
FIR - Reiner, Orly
IR  - Remondini D
FIR - Remondini, Daniel
IR  - Ritchie C
FIR - Ritchie, Craig
IR  - Rohrer JD
FIR - Rohrer, Jonathan D
IR  - Saliba AE
FIR - Saliba, Antoine-Emmanuel
IR  - Sanchez-Valle R
FIR - Sanchez-Valle, Raquel
IR  - Santosuosso A
FIR - Santosuosso, Amedeo
IR  - Sauter A
FIR - Sauter, Arnold
IR  - Scheltema RA
FIR - Scheltema, Richard A
IR  - Scheltens P
FIR - Scheltens, Philip
IR  - Schiller HB
FIR - Schiller, Herbert B
IR  - Schneider A
FIR - Schneider, Anja
IR  - Seibler P
FIR - Seibler, Philip
IR  - Sheehan-Rooney K
FIR - Sheehan-Rooney, Kelly
IR  - Shields D
FIR - Shields, David
IR  - Sleegers K
FIR - Sleegers, Kristel
IR  - Smit AB
FIR - Smit, August B
IR  - Smith KGC
FIR - Smith, Kenneth G C
IR  - Smolders I
FIR - Smolders, Ilse
IR  - Synofzik M
FIR - Synofzik, Matthis
IR  - Tam WL
FIR - Tam, Wai Long
IR  - Teichmann S
FIR - Teichmann, Sarah
IR  - Thom M
FIR - Thom, Maria
IR  - Turco MY
FIR - Turco, Margherita Y
IR  - van Beusekom HMM
FIR - van Beusekom, Heleen M M
IR  - Vandenberghe R
FIR - Vandenberghe, Rik
IR  - Van den Hoecke S
FIR - Van den Hoecke, Silvie
IR  - Van de Poel I
FIR - Van de Poel, Ibo
IR  - van der Ven A
FIR - van der Ven, Andre
IR  - van der Zee J
FIR - van der Zee, Julie
IR  - van Lunzen J
FIR - van Lunzen, Jan
IR  - van Minnebruggen G
FIR - van Minnebruggen, Geert
IR  - van Oudenaarden A
FIR - van Oudenaarden, Alexander
IR  - Van Paesschen W
FIR - Van Paesschen, Wim
IR  - van Swieten J
FIR - van Swieten, John
IR  - van Vught R
FIR - van Vught, Remko
IR  - Verhage M
FIR - Verhage, Matthijs
IR  - Verstreken P
FIR - Verstreken, Patrik
IR  - Villa CE
FIR - Villa, Carlo Emanuele
IR  - Vogel J
FIR - Vogel, Jorg
IR  - von Kalle C
FIR - von Kalle, Christof
IR  - Walter J
FIR - Walter, Jorn
IR  - Weckhuysen S
FIR - Weckhuysen, Sarah
IR  - Weichert W
FIR - Weichert, Wilko
IR  - Wood L
FIR - Wood, Louisa
IR  - Ziegler AG
FIR - Ziegler, Anette-Gabriele
IR  - Zipp F
FIR - Zipp, Frauke
EDAT- 2020/09/08 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/09/07 20:02
PHST- 2020/04/29 00:00 [received]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PHST- 2020/09/07 20:02 [entrez]
AID - 10.1038/s41586-020-2715-9 [doi]
AID - 10.1038/s41586-020-2715-9 [pii]
PST - ppublish
SO  - Nature. 2020 Nov;587(7834):377-386. doi: 10.1038/s41586-020-2715-9. Epub 2020 Sep
      7.


PMID- 32894780
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 12
DP  - 2020 Dec
TI  - Health Forums and Twitter for Dementia Research: Opportunities and
      Considerations.
PG  - 2881-2889
LID - 10.1111/jgs.16790 [doi]
AB  - BACKGROUND/OBJECTIVES: Social media platforms are promising sources for large
      quantities of participant-driven research data and circumvent some common
      challenges when conducting dementia research. This study provides a summary of
      key considerations and recommendations about using these platforms as research
      tools for dementia. DESIGN: Mixed methods. SETTING: Alzheimer's Society's online 
      Dementia Talking Point forum from inception to April 17, 2018, and Twitter in
      February and March 2018. PARTICIPANTS: All users of Dementia Talking Point who
      posted in subforums labeled "I have dementia" and "I care for a person with
      dementia," and Twitter users whose posts contained the keywords "dementia,"
      "Alzheimer," or "Alzheimer's." MEASUREMENTS: We quantified the average daily
      number of dementia-related posts on each platform and number of words per post.
      Guided by a codebook, we conducted thematic content analysis of 5% of the 15,513 
      posts collected from Dementia Talking Point, and 10% of the 25,948 comprehensible
      posts from Twitter containing "dementia," "Alzheimer," or "Alzheimer's." We also 
      summarized research-relevant characteristics inherent to platforms and posts.
      RESULTS: On average, Dementia Talking Point provided less than two new daily
      dementia-related posts with 213.5 to 241.5 words, compared with 7,883 new daily
      Twitter posts with 14.5 words. Persons with dementia (PWDs) commonly shared
      dementia-related concerns (75.7%), experiences (68.6%), and requests for, as well
      as offers of, information and support (44.3% and 38.6%, respectively). Caregivers
      commonly shared caregiving experience (67.0%) and requests for information and
      support (52.5%). Most common dementia-related Twitter posts were derogatory use
      of the term dementia (14.5%), advocacy, fundraising, and awareness (11.6%), and
      research dissemination (8.0%). Recommendations about these platforms' unique
      technical and ethical considerations are outlined. CONCLUSIONS: Understanding the
      priorities of PWDs and their caregivers remains important to understand how
      clinicians can best support them. This study will help clinicians and researcher 
      to better leverage online health forums and Twitter for such dementia-related
      information.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Mehta, Nishila
AU  - Mehta N
AD  - Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
FAU - Zhu, Lynn
AU  - Zhu L
AUID- ORCID: 0000-0002-0452-7550
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada.
FAU - Lam, Kenneth
AU  - Lam K
AUID- ORCID: 0000-0002-8148-2421
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Geriatric Medicine, Department of Medicine, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Stall, Nathan M
AU  - Stall NM
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Geriatric Medicine, Department of Medicine, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Savage, Rachel
AU  - Savage R
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Geriatric Medicine, Department of Medicine, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Read, Stephanie H
AU  - Read SH
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
FAU - Wu, Wei
AU  - Wu W
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
FAU - Pop, Paula
AU  - Pop P
AD  - Division of Geriatric Medicine, Department of Medicine, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Faulkner, Colin
AU  - Faulkner C
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
FAU - Bronskill, Susan E
AU  - Bronskill SE
AUID- ORCID: 0000-0002-7341-0655
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - ICES, Toronto, Ontario, Canada.
FAU - Rochon, Paula A
AU  - Rochon PA
AD  - Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Geriatric Medicine, Department of Medicine, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200907
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Caregivers/*psychology
MH  - Dementia/*psychology
MH  - Humans
MH  - *Information Dissemination
MH  - *Research
MH  - Social Media/*statistics & numerical data
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *Twitter
OT  - *caregiving
OT  - *dementia
OT  - *online health forum
OT  - *social media
EDAT- 2020/09/08 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/09/07 17:05
PHST- 2020/04/16 00:00 [received]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2020/09/07 17:05 [entrez]
AID - 10.1111/jgs.16790 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Dec;68(12):2881-2889. doi: 10.1111/jgs.16790. Epub 2020
      Sep 7.


PMID- 32894572
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1460-2075 (Electronic)
IS  - 0261-4189 (Linking)
VI  - 39
IP  - 19
DP  - 2020 Oct 1
TI  - Thinking "ethical" when designing an international, cross-disciplinary biomedical
      research consortium.
PG  - e105725
LID - 10.15252/embj.2020105725 [doi]
AB  - This commentary outlines challenges with identifying and implementing ethical,
      legal and societal considerations when initiating large-scale scientific programs
      and suggests best practices to ensure responsible research.
CI  - (c) 2020 The Authors. Published under the terms of the CC BY 4.0 license.
FAU - Torres-Padilla, Maria-Elena
AU  - Torres-Padilla ME
AUID- ORCID: 0000-0002-1020-2074
AD  - Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum Munchen,
      Munchen, Germany.
AD  - Faculty of Biology, Ludwig-Maximilians Universitat, Munchen, Germany.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AUID- ORCID: 0000-0002-7542-8963
AD  - Department of Medical Humanities, Julius Center, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Jongsma, Karin R
AU  - Jongsma KR
AD  - Department of Medical Humanities, Julius Center, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Lunkes, Astrid
AU  - Lunkes A
AD  - Institute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum Munchen,
      Munchen, Germany.
AD  - Institute of Functional Epigenetics, Helmholtz Zentrum Munchen, Munchen, Germany.
FAU - Marelli, Luca
AU  - Marelli L
AD  - Life Sciences & Society Lab, Centre for Sociological Research, KU Leuven, Leuven,
      Belgium.
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, 
      Milan, Italy.
AD  - Department of Medical Biotechnologies and Translational Medicine, University of
      Milan, Milan, Italy.
FAU - Pinheiro, Ines
AU  - Pinheiro I
AD  - Nuclear Dynamics Unit, Institut Curie, PSL Research University, Paris, France.
FAU - Testa, Giuseppe
AU  - Testa G
AUID- ORCID: 0000-0002-9104-0918
AD  - Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, 
      Milan, Italy.
AD  - Department of Oncology and Hemato-oncology, Universita degli Studi di Milano,
      Milan, Italy.
AD  - Human Technopole, Milan, Italy.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 820431/EC | Horizon 2020 Framework Programme (H2020)
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200907
PL  - England
TA  - EMBO J
JT  - The EMBO journal
JID - 8208664
SB  - IM
MH  - *Bioethical Issues
MH  - Biomedical Research/*ethics
MH  - Humans
PMC - PMC7527923
EDAT- 2020/09/08 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/09/07 12:13
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/09/07 12:13 [entrez]
AID - 10.15252/embj.2020105725 [doi]
PST - ppublish
SO  - EMBO J. 2020 Oct 1;39(19):e105725. doi: 10.15252/embj.2020105725. Epub 2020 Sep
      7.


PMID- 32894373
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2191-219X (Print)
IS  - 2191-219X (Linking)
VI  - 10
IP  - 1
DP  - 2020 Sep 7
TI  - Predictive value of quantitative (18)F-FDG-PET radiomics analysis in patients
      with head and neck squamous cell carcinoma.
PG  - 102
LID - 10.1186/s13550-020-00686-2 [doi]
AB  - BACKGROUND: Radiomics is aimed at image-based tumor phenotyping, enabling
      application within clinical-decision-support-systems to improve diagnostic
      accuracy and allow for personalized treatment. The purpose was to identify
      predictive 18-fluor-fluoro-2-deoxyglucose ((18)F-FDG) positron-emission
      tomography (PET) radiomic features to predict recurrence, distant metastasis, and
      overall survival in patients with head and neck squamous cell carcinoma treated
      with chemoradiotherapy. METHODS: Between 2012 and 2018, 103 retrospectively
      (training cohort) and 71 consecutively included patients (validation cohort)
      underwent (18)F-FDG-PET/CT imaging. The 434 extracted radiomic features were
      subjected, after redundancy filtering, to a projection resulting in
      outcome-independent meta-features (factors). Correlations between clinical,
      first-order (18)F-FDG-PET parameters (e.g., SUVmean), and factors were assessed. 
      Factors were combined with (18)F-FDG-PET and clinical parameters in a
      multivariable survival regression and validated. A clinically applicable
      risk-stratification was constructed for patients' outcome. RESULTS: Based on 124 
      retained radiomic features from 103 patients, 8 factors were constructed.
      Recurrence prediction was significantly most accurate by combining HPV-status,
      SUVmean, SUVpeak, factor 3 (histogram gradient and
      long-run-low-grey-level-emphasis), factor 4 (volume-difference, coarseness, and
      grey-level-non-uniformity), and factor 6 (histogram variation coefficient) (CI = 
      0.645). Distant metastasis prediction was most accurate assessing
      metabolic-active tumor volume (MATV)(CI = 0.627). Overall survival prediction was
      most accurate using HPV-status, SUVmean, SUVmax, factor 1 (least-axis-length,
      non-uniformity, high-dependence-of-high grey-levels), and factor 5 (aspherity,
      major-axis-length, inversed-compactness and, inversed-flatness) (CI = 0.764).
      CONCLUSIONS: Combining HPV-status, first-order (18)F-FDG-PET parameters, and
      complementary radiomic factors was most accurate for time-to-event prediction.
      Predictive phenotype-specific tumor characteristics and interactions might be
      captured and retained using radiomic factors, which allows for personalized risk 
      stratification and optimizing personalized cancer care. TRIAL REGISTRATION: Trial
      NL3946 (NTR4111), local ethics commission reference: Prediction 2013.191 and
      2016.498. Registered 7 August 2013, https://www.trialregister.nl/trial/3946.
FAU - Martens, Roland M
AU  - Martens RM
AUID- ORCID: http://orcid.org/0000-0002-8297-6802
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
      ro.martens@amsterdamumc.nl.
FAU - Koopman, Thomas
AU  - Koopman T
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Noij, Daniel P
AU  - Noij DP
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Pfaehler, Elisabeth
AU  - Pfaehler E
AD  - Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center,
      University of Groningen, University Medical Center Groningen, Groningen, The
      Netherlands.
FAU - Ubelhor, Caroline
AU  - Ubelhor C
AD  - Department of Epidemiology and Biostatistics, Amsterdam University Medical
      Center, De Boelelaan, 1117, Amsterdam, Netherlands.
FAU - Sharma, Sughandi
AU  - Sharma S
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Vergeer, Marije R
AU  - Vergeer MR
AD  - Department of Radiation Oncology, Amsterdam University Medical Center, De
      Boelelaan, 1117, Amsterdam, Netherlands.
FAU - Leemans, C Rene
AU  - Leemans CR
AD  - Department of Otolaryngology-Head and Neck Surgery, Amsterdam University Medical 
      Center, De Boelelaan, 1117, Amsterdam, Netherlands.
FAU - Hoekstra, Otto S
AU  - Hoekstra OS
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Yaqub, Maqsood
AU  - Yaqub M
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Zwezerijnen, Gerben J
AU  - Zwezerijnen GJ
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Heymans, Martijn W
AU  - Heymans MW
AD  - Department of Epidemiology and Biostatistics, Amsterdam University Medical
      Center, De Boelelaan, 1117, Amsterdam, Netherlands.
FAU - Peeters, Carel F W
AU  - Peeters CFW
AD  - Department of Epidemiology and Biostatistics, Amsterdam University Medical
      Center, De Boelelaan, 1117, Amsterdam, Netherlands.
FAU - de Bree, Remco
AU  - de Bree R
AD  - Department of Head and Neck Surgical Oncology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - de Graaf, Pim
AU  - de Graaf P
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Castelijns, Jonas A
AU  - Castelijns JA
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
FAU - Boellaard, Ronald
AU  - Boellaard R
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, De Boelelaan 1117, PO Box 7057, 1007, Amsterdam, MB, Netherlands.
AD  - Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center,
      University of Groningen, University Medical Center Groningen, Groningen, The
      Netherlands.
LA  - eng
GR  - 10-10400-98-14002/ZonMw
PT  - Journal Article
DEP - 20200907
PL  - Germany
TA  - EJNMMI Res
JT  - EJNMMI research
JID - 101560946
PMC - PMC7477048
OTO - NOTNLM
OT  - Head and Neck Neoplasms
OT  - Positron Emission Tomography Computed Tomography
OT  - Prognosis
OT  - Radiomics
EDAT- 2020/09/08 06:00
MHDA- 2020/09/08 06:01
CRDT- 2020/09/07 12:12
PHST- 2020/03/20 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/09/07 12:12 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2020/09/08 06:01 [medline]
AID - 10.1186/s13550-020-00686-2 [doi]
AID - 10.1186/s13550-020-00686-2 [pii]
PST - epublish
SO  - EJNMMI Res. 2020 Sep 7;10(1):102. doi: 10.1186/s13550-020-00686-2.


PMID- 32894282
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1464-360X (Electronic)
IS  - 1101-1262 (Linking)
VI  - 30
IP  - Suppl_4
DP  - 2020 Sep 1
TI  - Health professional mobility in the WHO European Region and the WHO Global Code
      of Practice: data from the joint OECD/EUROSTAT/WHO-Europe questionnaire.
PG  - iv5-iv11
LID - 10.1093/eurpub/ckaa124 [doi]
AB  - WHO Member States adopted the Global Code of Practice on the International
      Recruitment of Health Personnel 10 years ago. This study assesses adherence with 
      the Code's principles and its continuing relevance in the WHO Europe region with 
      regards to international recruitment of health workers. Data from the joint
      OECD/EUROSTAT/WHO-Europe questionnaire from 2010 to 2018 are analyzed to
      determine trends in intra- and inter-regional mobility of foreign-trained doctors
      and nurses working in case study destination countries in Europe. In 2018,
      foreign-trained doctors and nurses comprised over a quarter of the physician
      workforce and 5% of the nursing workforce in five of eight and four of five case 
      study countries, respectively. Since 2010, the proportion of foreign-trained
      nurses and doctors has risen faster than domestically trained professionals, with
      increased mobility driven by rising East-West and South-North intra-European
      migration, especially within the European Union. The number of nurses trained in 
      developing countries but practising in case study countries declined by 26%.
      Although the number of doctors increased by 27%, this was driven by arrivals from
      countries experiencing conflict and volatility, suggesting countries generally
      are increasingly adhering to the Code's principles on ethical recruitment. To
      support ethical recruitment practices and sustainable workforce development in
      the region, data collection and monitoring on health worker mobility should be
      improved.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      European Public Health Association.
FAU - Williams, Gemma A
AU  - Williams GA
AD  - European Observatory on Health Systems and Policies, London, UK.
FAU - Jacob, Gabrielle
AU  - Jacob G
AD  - WHO Regional Office for Europe, Copenhagen, Denmark.
FAU - Rakovac, Ivo
AU  - Rakovac I
AD  - WHO European Office for the Prevention and Control of Noncommunicable Diseases,
      WHO Regional Office for Europe, Moscow, Russian Federation.
FAU - Scotter, Cris
AU  - Scotter C
AD  - WHO Regional Office for Europe, Copenhagen, Denmark.
AD  - Department of Health and Social Care, London, UK.
FAU - Wismar, Matthias
AU  - Wismar M
AD  - European Observatory on Health Systems and Policies, Brussels, Belgium.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PL  - England
TA  - Eur J Public Health
JT  - European journal of public health
JID - 9204966
SB  - IM
MH  - Emigration and Immigration
MH  - European Union
MH  - Foreign Medical Graduates/*statistics & numerical data/supply & distribution
MH  - Foreign Professional Personnel/*supply & distribution
MH  - Health Workforce/*ethics
MH  - Humans
MH  - Organisation for Economic Co-Operation and Development
MH  - Personnel Selection/ethics/*standards
MH  - *Physicians
MH  - Surveys and Questionnaires
MH  - World Health Organization
PMC - PMC7526770
EDAT- 2020/09/08 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/09/07 12:11
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/09/07 12:11 [entrez]
AID - 5902306 [pii]
AID - 10.1093/eurpub/ckaa124 [doi]
PST - ppublish
SO  - Eur J Public Health. 2020 Sep 1;30(Suppl_4):iv5-iv11. doi:
      10.1093/eurpub/ckaa124.


PMID- 32894259
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Sep 7
TI  - [Ethical dimensions of prevention and planning in assisted-living facilities
      during the SARS-CoV-2 pandemic (Covid-19): a public health emergency.]
LID - e202009105 [pii]
AB  - The SARS-CoV-2 pandemic (Covid-19) has had a major impact on residents of
      assisted-living facilities. While it is plausible that the characteristics of
      these patients and their special clinical fragility have contributed to their
      greater vulnerability to infection, other related factors cannot be ruled out,
      such as the quality of management at these centers and the lack of planning for
      actions taken before and during the health crisis. Both aspects pertain to the
      field of public health, where the ethics of the common good conflicts with the
      autonomy of the individual.
FAU - Coronado-Vazquez, Valle
AU  - Coronado-Vazquez V
AD  - Centro de Salud de Illescas. Toledo. Espana.
AD  - Grupo de Bioetica de la Sociedad Madrilena de Medicina de Familia y Comunitaria
      (SoMaMFyC). Madrid. Espana.
FAU - Castro-Martin, Josefa
AU  - Castro-Martin J
AD  - Grupo de Bioetica de la Sociedad Madrilena de Medicina de Familia y Comunitaria
      (SoMaMFyC). Madrid. Espana.
AD  - Centro de Salud Benita de Avila. Madrid. Espana.
FAU - Camara-Escribano, Carmen
AU  - Camara-Escribano C
AD  - Grupo de Bioetica de la Sociedad Madrilena de Medicina de Familia y Comunitaria
      (SoMaMFyC). Madrid. Espana.
AD  - Centro de Salud Dos de Mayo. Madrid. Espana.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Programa de Posgrado de Seguridad y Salud. Universidad Espiritu Santo. Guayaquil.
      Ecuador.
FAU - Martin-Lopez, Cristina
AU  - Martin-Lopez C
AD  - Unidad de Rehabilitacion. Hospital de Rio Tinto. Huelva. Espana.
FAU - Garcia-Iglesias, Juan Jesus
AU  - Garcia-Iglesias JJ
AD  - Departamento de Sociologia, Trabajo Social y Salud Publica. Universidad de
      Huelva. Huelva. Espana.
AD  - Escuela Superior de Salud. Universidade Atlantica. Lisboa. Portugal.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Dimensiones eticas de la prevencion y planificacion en los centros
      sociosanitarios durante la pandemia por SARS-CoV-2 (Covid-19): una emergencia de 
      salud publica.
DEP - 20200907
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Assisted Living Facilities/*ethics
MH  - Betacoronavirus
MH  - COVID-19
MH  - Community Health Planning/*ethics
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health/*ethics
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Spain/epidemiology
OTO - NOTNLM
OT  - Emergency planning
OT  - Ethic
OT  - Public health
OT  - SARS-CoV-2
OT  - Social health centers
OT  - Spain
EDAT- 2020/09/08 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/07 12:11
PHST- 2020/07/10 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/09/07 12:11 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Sep 7;94.


PMID- 32894201
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Sep 7
TI  - Double sperm cloning (DSC) is a promising strategy in mammalian genetic
      engineering and stem cell research.
PG  - 388
LID - 10.1186/s13287-020-01907-0 [doi]
AB  - Embryonic stem cells (ESCs) derived from somatic cell nuclear transfer (SCNT) and
      induced pluripotent stem cells (iPSCs) are promising tools for meeting the
      personalized requirements of regenerative medicine. However, some obstacles need 
      to be overcome before clinical trials can be undertaken. First, donor cells vary,
      and the reprogramming procedures are diverse, so standardization is a great
      obstacle regarding SCNT and iPSCs. Second, somatic cells derived from a patient
      may carry mitochondrial DNA mutations and exhibit telomere instability with aging
      or disease, and SCNT-ESCs and iPSCs retain the epigenetic memory or epigenetic
      modification errors. Third, reprogramming efficiency has remained low. Therefore,
      in addition to improving their success rate, other alternatives for producing
      ESCs should be explored. Producing androgenetic diploid embryos could be an
      outstanding strategy; androgenic diploid embryos are produced through double
      sperm cloning (DSC), in which two capacitated sperms (XY or XX, sorted by flow
      cytometer) are injected into a denucleated oocyte by intracytoplasmic sperm
      injection (ICSI) to reconstruct embryo and derive DSC-ESCs. This process could
      avoid some potential issues, such as mitochondrial interference, telomere
      shortening, and somatic epigenetic memory, all of which accompany somatic donor
      cells. Oocytes are naturally activated by sperm, which is unlike the artificial
      activation that occurs in SCNT. The procedure is simple and practical and can be 
      easily standardized. In addition, DSC-ESCs can overcome ethical concerns and
      resolve immunological response matching with sperm providers. Certainly, some
      challenges must be faced regarding imprinted genes, epigenetics, X chromosome
      inactivation, and dosage compensation. In mice, DSC-ESCs have been produced and
      have shown excellent differentiation ability. Therefore, the many advantages of
      DSC make the study of this process worthwhile for regenerative medicine and
      animal breeding.
FAU - Zhang, Zhi-Ping
AU  - Zhang ZP
AD  - College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450046,
      China.
FAU - Zhang, Jun-Tao
AU  - Zhang JT
AD  - College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450046,
      China.
FAU - Huang, Shu-Cheng
AU  - Huang SC
AUID- ORCID: 0000-0003-3163-8616
AD  - College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450046,
      China.
FAU - He, Xiu-Yuan
AU  - He XY
AD  - College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450046,
      China.
FAU - Deng, Li-Xin
AU  - Deng LX
AD  - College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, 450046,
      China. lx8198@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200907
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Animals
MH  - Cellular Reprogramming
MH  - Cloning, Molecular
MH  - *Cloning, Organism
MH  - Genetic Engineering
MH  - Humans
MH  - Male
MH  - Mice
MH  - Spermatozoa
MH  - *Stem Cell Research
PMC - PMC7487873
OTO - NOTNLM
OT  - *Double sperm cloning
OT  - *Embryonic stem cell
OT  - *Regenerative medicine
OT  - *Reprogramming
EDAT- 2020/09/08 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/07 12:10
PHST- 2020/06/13 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/08/12 00:00 [revised]
PHST- 2020/09/07 12:10 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-01907-0 [doi]
AID - 10.1186/s13287-020-01907-0 [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Sep 7;11(1):388. doi: 10.1186/s13287-020-01907-0.


PMID- 32894190
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 7
TI  - Acupuncture treatment for carotid atherosclerotic plaques: study protocol for a
      pilot randomized, single blinded, controlled clinical trial.
PG  - 768
LID - 10.1186/s13063-020-04709-0 [doi]
AB  - BACKGROUND: Carotid atherosclerosis disease (CAD) is generally associated with
      the occurrence of cardiovascular and cerebrovascular accidents. However, CAD has 
      not been taken seriously enough in the clinic, which, coupled with the single
      treatment and prevention of CAD, has led to a generally low level of patient
      compliance. Therefore, acupuncture is expected to be a safe and effective therapy
      that can be maintained in the long term for patients with CAD. The study
      objective is to evaluate the efficiency and reliability of acupuncture to relieve
      CAD and provide a new therapeutic idea for the clinical treatment of CAD.
      METHODS: This is a three-arm randomized clinical trial in China. Three groups
      (TA, SA, and MC) will be randomly allocated at a 1:1:1 ratio. The study will
      enrol 105 cervical atherosclerosis plaque patients in total on a voluntary basis,
      with 35 patients in each group. The treatment will last for 12 weeks, with two
      treatments per week for twenty-four treatments in total. RESULTS: Two 3D
      ultrasound indicators will be measured as the primary outcomes: the total plaque 
      volume (PV) of the carotid artery on each side and the grey-scale median (GSM).
      The secondary outcomes will include intima-media thickness (IMT), lipid levels,
      apolipoprotein A-IV level, platelet count (PLT), fibrinogen (FIB), and platelet
      aggregation rate (PAR). All the outcomes will be assessed before treatment, after
      treatment, and after a 12-week follow-up period. This study will utilize
      per-protocol (PP) and intention-to-treat (ITT) analysis principles. CONCLUSIONS: 
      This trial is to evaluate the efficacy and reliability of acupuncture in
      relieving carotid atherosclerotic plaques by establishing acupuncture (TA), sham 
      acupuncture (SA), and medication (MC) groups. ETHICS AND DISSEMINATION: This
      study was approved by the Institutional Ethics Committee of Guangdong Provincial 
      Hospital of Traditional Chinese Medicine (no. YF2018-107-01). All data and
      findings will be provided by the principal investigator via email. TRIAL
      REGISTRATION: ChiCTR, ChiCTR1800019259 . Registered on 1 November
      2018-retrospectively registered, http://www.chictr.org.cn/index.aspx.
FAU - Zhou, Junhe
AU  - Zhou J
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,
      Guangzhou, Guangdong Province, China.
FAU - Zhao, Lin
AU  - Zhao L
AUID- ORCID: http://orcid.org/0000-0001-5763-9452
AD  - The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou,
      Guangdong Province, China.
FAU - Meng, Lingcui
AU  - Meng L
AD  - Ultrasonography Department, The Second Affiliated Hospital of Guangzhou
      University of Chinese Medicine, Guangzhou, Guangdong Province, China.
FAU - Liang, Huitao
AU  - Liang H
AD  - The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,
      Guangzhou, Guangdong Province, China.
FAU - Zhou, Ting
AU  - Zhou T
AD  - Ultrasonography Department, The Second Affiliated Hospital of Guangzhou
      University of Chinese Medicine, Guangzhou, Guangdong Province, China.
FAU - Ye, Siting
AU  - Ye S
AD  - Ultrasonography Department, The Second Affiliated Hospital of Guangzhou
      University of Chinese Medicine, Guangzhou, Guangdong Province, China.
FAU - Qi, Zhiqi
AU  - Qi Z
AD  - Acupuncture Department, The Second Affiliated Hospital of Guangzhou University of
      Chinese Medicine, Guangzhou, Guangdong Province, China.
FAU - Huang, Xichang
AU  - Huang X
AD  - Acupuncture Department, The Second Affiliated Hospital of Guangzhou University of
      Chinese Medicine, Guangzhou, Guangdong Province, China.
FAU - Zhou, Peng
AU  - Zhou P
AD  - Shenzhen Bao'an Research Centre for Acupuncture and Moxibustion, Shenzhen, China.
      zpszba@163.com.
FAU - Fu, Wenbin
AU  - Fu W
AD  - The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou,
      Guangdong Province, China. fuwenbin@139.com.
AD  - Acupuncture Department, The Second Affiliated Hospital of Guangzhou University of
      Chinese Medicine, Guangzhou, Guangdong Province, China. fuwenbin@139.com.
LA  - eng
GR  - SZSM201806077/Sanming Project of Medicine in Shenzhen (CN)
GR  - 81774411/National Natural Science Foundation of China
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200907
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Acupuncture Therapy/adverse effects
MH  - Carotid Arteries/diagnostic imaging
MH  - Carotid Intima-Media Thickness
MH  - China
MH  - Humans
MH  - Pilot Projects
MH  - *Plaque, Atherosclerotic
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7487889
OTO - NOTNLM
OT  - Acupuncture
OT  - Carotid atherosclerosis disease
OT  - Cervical atherosclerosis plaque
OT  - Vessel plaque quantification (VPQ)
EDAT- 2020/09/08 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/07 12:10
PHST- 2019/12/22 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/07 12:10 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04709-0 [doi]
AID - 10.1186/s13063-020-04709-0 [pii]
PST - epublish
SO  - Trials. 2020 Sep 7;21(1):768. doi: 10.1186/s13063-020-04709-0.


PMID- 32893962
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - Applying Ethical Principles When Discussing Alcohol Use During Pregnancy.
PG  - 795-801
LID - 10.1111/jmwh.13159 [doi]
AB  - Over the past 2 decades, more women in the United States are engaging in
      excessive alcohol use, including women of reproductive age. Consuming alcohol in 
      amounts greater than recommended limits is associated with an increased risk for 
      adverse health effects, such as breast cancer, hypertension stroke, spontaneous
      abortion, and infertility. No safe time, safe amount, or safe type of alcohol to 
      consume during pregnancy has been identified. Contradictory beliefs about alcohol
      use, fear of stigmatization, and potential legal consequences can provide
      challenges for health care providers who communicate these risks to clients.
      Health care providers can help to prevent alcohol-related health issues,
      including alcohol-exposed pregnancies, by providing their clients with factual
      information about alcohol and health and client-centered options for reducing
      their health risks. Clinicians can use alcohol screening and brief intervention
      as a framework for applying the ethical principles of autonomy, veracity,
      beneficence, and nonmaleficence when talking with women in ways that are
      nonstigmatizing and supportive to help reduce their health risks and prevent
      alcohol-exposed pregnancies.
CI  - (c) 2020 by the American College of Nurse-Midwives.
FAU - Edwards, Alexandra
AU  - Edwards A
AUID- ORCID: 0000-0003-0048-6189
AD  - Center for Behavioral Health Research and Services, University of Alaska
      Anchorage, Anchorage, Alaska.
FAU - Kelsey, Beth
AU  - Kelsey B
AD  - National Association of Nurse Practitioners in Women's Health, Washington, DC.
FAU - Pierce-Bulger, Marilyn
AU  - Pierce-Bulger M
AD  - Alaska Center for Fetal Alcohol Spectrum Disorders, Anchorage, Alaska.
FAU - Rawlins, Susan
AU  - Rawlins S
AD  - National Association of Nurse Practitioners in Women's Health, Washington, DC.
FAU - Ruhl, Catherine
AU  - Ruhl C
AD  - Association of Women's Health, Obstetric, and Neonatal Nurses, Albuquerque, New
      Mexico.
FAU - Ryan, Sharon
AU  - Ryan S
AD  - American College of Nurse-Midwives, Silver Springs, Maryland.
FAU - King, Diane K
AU  - King DK
AD  - Center for Behavioral Health Research and Services, University of Alaska
      Anchorage, Anchorage, Alaska.
LA  - eng
GR  - 84DD000006-01/DD/NCBDD CDC HHS/United States
GR  - 84DD000006-01/DD/NCBDD CDC HHS/United States
PT  - Journal Article
DEP - 20200907
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - *Alcohol Drinking
MH  - Female
MH  - Humans
MH  - *Mass Screening
MH  - Pregnancy
MH  - United States
OTO - NOTNLM
OT  - *alcohol consumption
OT  - *ethics
OT  - *fetal alcohol spectrum disorders
OT  - *patient education
OT  - *preconception care
OT  - *preventive health care
OT  - *substance use disorders
EDAT- 2020/09/08 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/09/07 08:40
PHST- 2020/01/14 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/09/07 08:40 [entrez]
AID - 10.1111/jmwh.13159 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):795-801. doi: 10.1111/jmwh.13159. Epub 
      2020 Sep 7.


PMID- 32893787
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 30
IP  - 8
DP  - 2020 Aug
TI  - Impact of Homozygous C4A Deficiency on Clinical Presentation of Systemic Lupus
      Erythematosus.
PG  - 790-795
LID - 10.29271/jcpsp.2020.08.790 [doi]
AB  - OBJECTIVE: To investigate the association of C4A null allele (C4AQ0) with
      systemic lupus erythematosus (SLE) and determine the clinical presentation of SLE
      in relation to C4A null allele. STUDY DESIGN: Descriptive study. PLACE AND
      DURATION OF STUDY: Armed Forces Institute of Pathology (AFIP), Rawalpindi,
      Immunology Department, from December 2018 to December 2019. METHODOLOGY: Patients
      referred to AFIP, who fulfilled American College of Rheumatology (ACR) criteria
      of 1997 for diagnosis of SLE were included in the study. Approval from the
      Institutional Ethical Review Board was taken. C4A and C4B null alleles were
      determined in 66 SLE patients and 40 age- and gender-matched healthy controls by 
      polymerase chain reaction (PCR) using sequence-specific primers (PCR-SSP).
      Various clinical features and laboratory findings in the SLE patients were
      analysed in relation with C4A null allele. RESULTS: The mean age of the study
      population was 30.56 +/-10.08 years. C4A null allele was detected in 7 (10.6%)
      patients; whereas, C4B null allele was detected in only two (3%) patients. SLE
      patients with C4A null allele had increased incidence of arthritis (100%) and
      renal damage (85.7%); compared to those with normal C4A allele, 57.6% and 32%,
      respectively. Fisher's Exact test revealed strong association of C4A null allele 
      with arthritis and renal damage, (p = 0.039 and 0.01, respectively). CONCLUSION: 
      Homozygous absence of C4A alleles was encountered in 10.6% of Pakistani patients 
      of SLE and is closely related with clinical features of arthritis and renal
      damage. Knowledge of C4A null allele in SLE patients at diagnosis can predict
      disease course. Key Words: SLE, C4A null alleles, C4AQ0, Homozygous C4A
      deficiency.
FAU - Ansari, Ayesha Arooj
AU  - Ansari AA
AD  - Department of Immunology, Armed Forces Institute of Pathology, CMH Rawalpindi,
      Pakistan.
FAU - Tipu, Hamid Nawaz
AU  - Tipu HN
AD  - Department of Immunology, Armed Forces Institute of Pathology, CMH Rawalpindi,
      Pakistan.
FAU - Ahmad, Dawood
AU  - Ahmad D
AD  - Department of Immunology, Armed Forces Institute of Pathology, CMH Rawalpindi,
      Pakistan.
FAU - Farhan, Muhammad
AU  - Farhan M
AD  - Armed Force Bone Marrow Transplant Center, CMH Rawalpindi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
RN  - 80295-49-4 (Complement C4a)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - *Complement C4a/genetics
MH  - Humans
MH  - *Lupus Erythematosus, Systemic/diagnosis/genetics
MH  - Polymerase Chain Reaction
EDAT- 2020/09/08 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/07 08:39
PHST- 2020/04/13 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/09/07 08:39 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 040579197 [pii]
AID - 10.29271/jcpsp.2020.08.790 [doi]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2020 Aug;30(8):790-795. doi:
      10.29271/jcpsp.2020.08.790.


PMID- 32892781
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - Ethical Assessment and Reflection in Research and Development of Non-Conformite
      Europeene Marked Medical Devices.
PG  - 592-606
LID - 10.1017/S0963180120000341 [doi]
AB  - Today there are multiple implantable medical devices on the market. The type of
      implants that interface the body's tissues has been considered to have particular
      strong ethical implications. This article describes a development of a novel
      practice for ethical assessment and reflection within medical device research and
      development of non-CE marked medical devices, taking the perspective of both the 
      ethicist and the researcher. The research case was an EU funded project where the
      aim was to develop and compare the efficiency of invasive and non-invasive
      technological medical devices to create meaningful sensations as a novel therapy 
      for phantom limb pain. An Independent Ethical Advisor (IEA) with a regulatory and
      advisory role was assigned to the project, allowing us to investigate the
      projects deliberate incorporation of ethics. In the article we suggest and
      applied a novel framework based on action research for combining ethical
      assessment with building ethical reflection. The case analyse five different
      activities / elements: 1) the use of informed consent; 2) a survey amongst the
      research partners; 3) a workshop session; 4) observation of consortium meetings; 
      and 5) an interview with a participating patient.
FAU - TellEus, Patrik K
AU  - TellEus PK
FAU - Jensen, Winnie
AU  - Jensen W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - Humans
MH  - *Informed Consent
MH  - *Morals
MH  - Research
OTO - NOTNLM
OT  - *Action research
OT  - *Neuroethics
OT  - *Research ethics
OT  - *biotechnology ethics
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000341 [doi]
AID - S0963180120000341 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):592-606. doi: 10.1017/S0963180120000341.


PMID- 32892778
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - Harm, Consent, and Virtual Selves in Full-Body Ownership Illusions: Real Concerns
      for Immersive Virtual Reality Therapies.
PG  - 585-591
LID - 10.1017/S096318012000033X [doi]
AB  - This paper analyzes in the use of virtual reality when used to induce full-body
      ownership in violent offenders in order to elicit empathetic feelings by allowing
      them to embody the virtual body of a victim of domestic abuse. The authors
      explore potentially harmful effects to individuals participating in this kind of 
      therapy and question whether consent is fully informed. The paper concludes with 
      guidelines for ethical research and rehabilitation using this innovative
      technology.
FAU - Botero, Maria
AU  - Botero M
FAU - Whatley, Elise
AU  - Whatley E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - Humans
MH  - *Illusions
MH  - Informed Consent
MH  - Ownership
MH  - *Virtual Reality
MH  - *Virtual Reality Exposure Therapy
OTO - NOTNLM
OT  - *domestic abuse
OT  - *full-body ownership
OT  - *virtual reality
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S096318012000033X [doi]
AID - S096318012000033X [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):585-591. doi: 10.1017/S096318012000033X.


PMID- 32892777
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211201
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - Pediatric Deep Brain Stimulation for Dystonia: Current State and Ethical
      Considerations.
PG  - 557-573
LID - 10.1017/S0963180120000316 [doi]
AB  - Dystonia is a movement disorder that can have a debilitating impact on motor
      functions and quality of life. There are 250,000 cases in the United States, most
      with childhood onset. Due to the limited effectiveness and side effects of
      available treatments, pediatric deep brain stimulation (pDBS) has emerged as an
      intervention for refractory dystonia. However, there is limited clinical and
      neuroethics research in this area of clinical practice. This paper examines
      whether it is ethically justified to offer pDBS to children with refractory
      dystonia. Given the favorable risk-benefit profile, it is concluded that offering
      pDBS is ethically justified for certain etiologies of dystonia, but it is less
      clear for others. In addition, various ethical and policy concerns are discussed,
      which need to be addressed to optimize the practice of offering pDBS for
      dystonia. Strategies are proposed to help address these concerns as pDBS
      continues to expand.
FAU - MuNoz, Katrina A
AU  - MuNoz KA
FAU - Blumenthal-Barby, Jennifer
AU  - Blumenthal-Barby J
FAU - Storch, Eric A
AU  - Storch EA
FAU - Torgerson, Laura
AU  - Torgerson L
FAU - LAzaro-MuNoz, Gabriel
AU  - LAzaro-MuNoz G
LA  - eng
GR  - RF1 MH121371/MH/NIMH NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - Child
MH  - *Deep Brain Stimulation
MH  - *Dystonia/therapy
MH  - Globus Pallidus
MH  - Humans
MH  - Quality of Life
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *deep brain stimulation
OT  - *dystonia
OT  - *neuroethics
OT  - *pediatric
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000316 [doi]
AID - S0963180120000316 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):557-573. doi: 10.1017/S0963180120000316.


PMID- 32892774
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - Psychiatric Interventions in Virtual Reality: Why We Need an Ethical Framework.
PG  - 574-584
LID - 10.1017/S0963180120000328 [doi]
AB  - Recent improvements in virtual reality (VR) allow for the representation of
      authentic environments and multiple users in a shared complex virtual world in
      real time. These advances have fostered clinical applications including in
      psychiatry. However, although VR is already used in clinical settings to help
      people with mental disorders (e.g., exposure therapy), the related ethical issues
      require greater attention. Based on a thematic literature search the authors
      identified five themes that raise ethical concerns related to the clinical use of
      VR: (1) reality and its representation, (2) autonomy, (3) privacy, (4)
      self-diagnosis and self-treatment, and (5) expectation bias. Reality and its
      representation is a theme that lies at the heart of VR, but is also of specific
      significance in a clinical context when perceptions of reality are concerned, for
      example, during psychosis. Closely associated is the autonomy of VR users.
      Although autonomy is a much-considered topic in biomedical ethics, it has not
      been sufficiently discussed when it comes to applications of VR in psychiatry. In
      this review, the authors address the different themes and recommend the
      development of an ethical framework for the clinical use of VR.
FAU - Marloth, Maria
AU  - Marloth M
FAU - Chandler, Jennifer
AU  - Chandler J
FAU - Vogeley, Kai
AU  - Vogeley K
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - Humans
MH  - *Mental Disorders/therapy
MH  - Morals
MH  - *Psychiatry
MH  - *Virtual Reality
MH  - *Virtual Reality Exposure Therapy
OTO - NOTNLM
OT  - *autonomy
OT  - *human-computer interaction
OT  - *virtual reality
OT  - *virtual reality in clinical context
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000328 [doi]
AID - S0963180120000328 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):574-584. doi: 10.1017/S0963180120000328.


PMID- 32892773
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220531
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - The Impact of Incidental Findings Detected During Brain Imaging on Research
      Participants of the Rotterdam Study: An Interview Study.
PG  - 542-556
LID - 10.1017/S0963180120000304 [doi]
AB  - This interview study investigates the short- and long-term implications of
      incidental findings detected through brain imaging on research participants'
      lives and their surroundings. For this study, nine participants of the Rotterdam 
      Scan Study with an incidental finding were approached and interviewed. When
      examining research participants' narratives on the impact of the disclosure of
      incidental findings, the authors identified five sets of tensions with regard to 
      motivations for and expectations of research participation, preferences regarding
      disclosure, short- and long-term impacts and impacts on self and others. The
      paper shows: (1) that the impact of incidental findings may be greater than
      participants at first let on; (2) incidental findings can have significant
      effects on participants' social environment; and (3) participants may not feel
      prepared for disclosure even if incidental findings have been discussed during
      the informed consent process. The authors call for investigators to be aware of
      research participants' experiences and these short- and long-term impacts when
      designing suitable courses of action for the detection and management of
      incidental findings in research settings.
FAU - Bomhof, Charlotte H C
AU  - Bomhof CHC
FAU - VAN Bodegom, Lisa
AU  - VAN Bodegom L
FAU - Vernooij, Meike W
AU  - Vernooij MW
FAU - Pinxten, Wim
AU  - Pinxten W
FAU - DE Beaufort, Inez D
AU  - DE Beaufort ID
FAU - Bunnik, Eline M
AU  - Bunnik EM
LA  - eng
PT  - Interview
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - *Disclosure
MH  - Emotions
MH  - Humans
MH  - *Incidental Findings
MH  - Informed Consent
MH  - Neuroimaging
PMC - PMC7525112
OTO - NOTNLM
OT  - *imaging studies
OT  - *incidental findings
OT  - *interview study
OT  - *research ethics
OT  - *social impact
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000304 [doi]
AID - S0963180120000304 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):542-556. doi: 10.1017/S0963180120000304.


PMID- 32892772
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - "Who Will I Be?": Relational Identity, Living with Amyotrophic Lateral Sclerosis,
      and Future-Oriented Decisionmaking.
PG  - 617-629
LID - 10.1017/S0963180120000365 [doi]
AB  - Patients with amyotrophic lateral sclerosis (ALS) face many difficult,
      timing-sensitive decisions over the course of their illness, weighing present
      versus future harms and benefits. Supplemented by interviews with people with
      ALS, we argue for a relational approach to understanding these decisions and
      their effects on identity. We highlight two critical aspects of the
      patient-caregiver relationship: (1) the extent to which each may rely on the
      other leaves their wellbeing intimately intertwined and (2) patients often
      require others to help with the imaginative task of considering possible futures 
      for each therapeutic option. We show why family involvement in decisionmaking
      practices can be so critical, and shed light on the ways intimate others help
      preserve and protect people's identities amidst the destabilizing uncertainty
      illness and treatment can bring.
FAU - Versalovic, Erika
AU  - Versalovic E
FAU - Klein, Eran
AU  - Klein E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - *Amyotrophic Lateral Sclerosis
MH  - Caregivers
MH  - Humans
OTO - NOTNLM
OT  - *amyotrophic lateral sclerosis
OT  - *caregiver
OT  - *decisionmaking
OT  - *ethics
OT  - *identity
OT  - *neuroethics
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000365 [doi]
AID - S0963180120000365 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):617-629. doi: 10.1017/S0963180120000365.


PMID- 32892771
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220716
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Oct
TI  - Neuroethics for Fantasyland or for the Clinic? The Limitations of Speculative
      Ethics.
PG  - 630-641
LID - 10.1017/S0963180120000377 [doi]
AB  - What purpose can be served by empirically unsubstantiated speculation in ethics? 
      In answering that question, we need to distinguish between the major branches of 
      ethics. In foundational moral philosophy, the use of speculative examples is
      warranted to the extent that ethical principles and theories are assumed to be
      applicable even under the extreme circumstances referred to in these examples.
      Such an assumption is in need of justification, and it cannot just be taken for
      granted. In applied ethics, the use of unrealistic scenarios is more difficult to
      justify. It can be positively harmful if it diverts our attention from more
      urgent issues. Neuroethics is one of the areas of applied ethics where
      speculative scenarios have taken up much of the attention that could instead have
      been devoted to problems that are relevant for the treatment and care of
      patients. Speculative ethics has often been defended with mere possibility
      arguments that may at first hand seem difficult to refute. It is shown with
      examples how such claims can be defeated with a combination of science and
      argumentation analysis.
FAU - Hansson, Sven Ove
AU  - Hansson SO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - Humans
MH  - Morals
MH  - *Neurosciences
MH  - *Philosophy
PMC - PMC7525104
OTO - NOTNLM
OT  - *applied ethics
OT  - *mere possibility arguments
OT  - *neuroethics
OT  - *speculation
OT  - *speculative examples
OT  - *unrealistic scenarios
EDAT- 2020/09/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/07 05:26 [entrez]
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000377 [doi]
AID - S0963180120000377 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Oct;29(4):630-641. doi: 10.1017/S0963180120000377.


PMID- 32892714
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1347-6947 (Electronic)
IS  - 0916-8451 (Linking)
VI  - 84
IP  - 12
DP  - 2020 Dec
TI  - Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of
      PIPERINE via Bcl2, Bax/Bcl2, and caspase-3 pathways.
PG  - 2533-2544
LID - 10.1080/09168451.2020.1815170 [doi]
AB  - The objective of present investigation was to appraise the effects of piperine on
      STZ-induced diabetic cardiomyopathy in rats. Diabetes was induced in
      Sprague-Dawley rats with intraperitoneal STZ injection, and the rats were
      assigned to seven groups. Electrocardiograph, hemodynamic, various biochemical,
      molecular, and histological parameters were examined. Treatment with piperine
      significantly (p < 0.05) restored altered myocardial functions, inhibited cardiac
      marker, and restored electrocardiogram and hemodynamic alterations. The elevated 
      level of cardiac oxido-nitrosative stress and decreased cardiac Na-K-ATPase
      concentration, after STZ administration, were significantly (p < 0.05) attenuated
      by piperine treatment. Piperine also considerably (p < 0.05) increased myocardial
      mitochondrial enzyme activity. STZ-induced alteration in heart ANP, BNP, cTn-I,
      Bcl2, Bax/Bcl2, and caspase3 mRNA expression was significantly (p < 0.05)
      restored by piperine treatment. Piperine administration reduced histopathological
      aberrations induced by STZ. In conclusion, the present investigation suggests
      that piperine ameliorates STZ-induced diabetic cardiomyopathy via modulation of
      caspase-3, Bcl2, Bax/Bcl2 pathways. Abbreviations: ACE: Angiotensin-Converting
      Enzyme; ANOVA: Analysis of Variance; ANP: Atrial Natriuretic Peptide; APAF:
      Apoptotic Protease-Activating Factor; ARB: Angiotensin Receptor Blockers; ATP:
      Adenosine Triphosphate; Bax: Bcl-2-associated X protein; Bcl2: B-cell lymphoma 2;
      BPM: Beats Per Minute; BNP: brain natriuretic peptide; CAD: Caspase-3-Activated
      DNase; cDNA: Complementary DNA; CK-MB: Creatine Kinase-MB; CPCSEA: Committee for 
      the Purpose of Control And Supervision of Experiments on Animals; cTn-I: cardiac 
      troponin I; DBP: Diastolic Blood Pressure; DCM: Diabetic Cardiomyopathy; DNA:
      Deoxyribonucleic Acid; DPX: DisterenePhthalate Xylene; ECG: Electrocardiogram;
      ETC: Electron Transport Chain; GOD-POD: Glucose Oxidase Peroxidase; GSH:
      Glutathione; IAEC: Institutional Animal Ethics Committee; IL-6: Interleukin-6;
      IL-1b: Interleukin-1b; LDH: Lactate Dehydrogenase; LV: Left Ventricle; LVEDP:
      left ventricular end-diastolic Pressure; MABP: Mean Arterial Blood Pressure; MDA:
      Malondialdehyde; mRNA: Messenger Ribonucleic Acid; MTT: 3-
      (4,5-Dimethylthiazol-2-yl)-2,5-DiphenyltetrazoliumBromide; NADH: Nicotinamide
      Adenine Dinucleotide Phosphate; NADPH: Nicotinamide Adenine Dinucleotide
      Phosphate Hydrogen; NO: nitric oxide; NP: Natriuretic Peptides; OXPHOS: Oxidative
      Phosphorylation; p.o.: per os; PCR: Polymerase Chain Reaction; RT-PCR: Reverse
      Transcriptionpolymerase Chain Reaction; PPAR: Peroxisome Proliferator-Activated
      Receptor Gamma; RAS: Renin-Angiotensin System; RNA: Ribonucleic Acid; ROS:
      Reactive Oxygen Species; SBP: Systolic Blood Pressure; SDH: Succinate
      Dehydrogenase; SEM: Standard Error Means; SOD: superoxide dismutase: STZ:
      Streptozotocin; TNF: Tumor Necrosis Factor Alpha; TnI: Troponin I.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Endocrinology, The Affiliated Hospital of North Sichuan Medical
      College , Nanchong City, Sichuan Province, China.
FAU - Sun, Hui
AU  - Sun H
AD  - Department of Infectious Diseases, The Affiliated Hospital of North Sichuan
      Medical College , Nanchong City, Sichuan Province, China.
FAU - Zhang, Jianwu
AU  - Zhang J
AD  - Department of Pharmacology, School of Pharmacy, North Sichuan Medical College ,
      Nanchong City, Sichuan Province, China.
FAU - Xia, Zhiyang
AU  - Xia Z
AD  - Department of Pathophysiology, School of Basic Medicine, North Sichuan Medical
      College , Nanchong City, Sichuan Province, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Pathophysiology, School of Basic Medicine, North Sichuan Medical
      College , Nanchong City, Sichuan Province, China.
LA  - eng
PT  - Journal Article
DEP - 20200906
PL  - England
TA  - Biosci Biotechnol Biochem
JT  - Bioscience, biotechnology, and biochemistry
JID - 9205717
RN  - 0 (Alkaloids)
RN  - 0 (Benzodioxoles)
RN  - 0 (Piperidines)
RN  - 0 (Polyunsaturated Alkamides)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (RNA, Messenger)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 5W494URQ81 (Streptozocin)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - GAN16C9B8O (Glutathione)
RN  - U71XL721QK (piperine)
SB  - IM
MH  - Alkaloids/*pharmacology/therapeutic use
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Benzodioxoles/*pharmacology/therapeutic use
MH  - Diabetic Cardiomyopathies/*drug therapy/*metabolism/pathology/physiopathology
MH  - Drinking/drug effects
MH  - Eating/drug effects
MH  - Glutathione/metabolism
MH  - Heart/drug effects/physiopathology
MH  - Hemodynamics/drug effects
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Myocardium/pathology
MH  - Nitric Oxide/metabolism
MH  - Organ Size/drug effects
MH  - Piperidines/*pharmacology/therapeutic use
MH  - Polyunsaturated Alkamides/*pharmacology/therapeutic use
MH  - Proto-Oncogene Proteins c-bcl-2/*metabolism
MH  - RNA, Messenger/genetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin/*adverse effects
MH  - Superoxide Dismutase/metabolism
MH  - Urine/chemistry
MH  - bcl-2-Associated X Protein/*metabolism
OTO - NOTNLM
OT  - Bax
OT  - Bcl2
OT  - cTn-I
OT  - diabetic cardiomyopathy
OT  - piperine
EDAT- 2020/09/08 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/09/07 05:26
PHST- 2020/09/08 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/09/07 05:26 [entrez]
AID - 10.1080/09168451.2020.1815170 [doi]
PST - ppublish
SO  - Biosci Biotechnol Biochem. 2020 Dec;84(12):2533-2544. doi:
      10.1080/09168451.2020.1815170. Epub 2020 Sep 6.


PMID- 32892265
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20211102
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 11
DP  - 2020 Nov
TI  - The unknown human trophectoderm: implication for biopsy at the blastocyst stage.
PG  - 2699-2711
LID - 10.1007/s10815-020-01925-0 [doi]
AB  - Trophectoderm biopsy is increasingly performed for pre-implantation genetic
      testing of aneuploidies and considered a safe procedure on short-term clinical
      outcome, without strong assessment of long-term consequences. Poor biological
      information on human trophectoderm is available due to ethical restrictions.
      Therefore, most studies have been conducted in vitro (choriocarcinoma cell lines,
      embryonic and pluripotent stem cells) and on murine models that nevertheless
      poorly reflect the human counterpart. Polarization, compaction, and blastomere
      differentiation (e.g., the basis to ascertain trophectoderm origin) are poorly
      known in humans. In addition, the trophectoderm function is poorly known from a
      biological point of view, although a panoply of questionable and controversial
      microarray studies suggest that important genes overexpressed in trophectoderm
      are involved in pluripotency, metabolism, cell cycle, endocrine function, and
      implantation. The intercellular communication system between the trophectoderm
      cells and the inner cell mass, modulated by cell junctions and filopodia in the
      murine model, is obscure in humans. For the purpose of this paper, data mainly on
      primary cells from human and murine embryos has been reviewed. This review
      suggests that the trophectoderm origin and functions have been insufficiently
      ascertained in humans so far. Therefore, trophectoderm biopsy should be
      considered an experimental procedure to be undertaken only under approved
      rigorous experimental protocols in academic contexts.
FAU - Tocci, Angelo
AU  - Tocci A
AUID- ORCID: http://orcid.org/0000-0002-1156-7251
AD  - Reproductive Medicine Unit, Gruppo Donnamed, Via Giuseppe Silla 12, Rome, Italy. 
      staffdonnamed@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200906
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - Animals
MH  - Biopsy
MH  - Blastocyst/*cytology
MH  - Cell Differentiation/genetics
MH  - Ectoderm/*growth & development/metabolism
MH  - Embryo Implantation/genetics
MH  - Female
MH  - Humans
MH  - Mice
MH  - Pregnancy
MH  - *Preimplantation Diagnosis
MH  - Trophoblasts/cytology/*metabolism
PMC - PMC7642161
OTO - NOTNLM
OT  - Cell junctions
OT  - Compaction
OT  - Human embryo
OT  - Polarization
OT  - Trophectoderm biopsy
EDAT- 2020/09/07 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/09/06 20:36
PHST- 2020/06/05 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/09/06 20:36 [entrez]
AID - 10.1007/s10815-020-01925-0 [doi]
AID - 10.1007/s10815-020-01925-0 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Nov;37(11):2699-2711. doi:
      10.1007/s10815-020-01925-0. Epub 2020 Sep 6.


PMID- 32892060
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210129
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 14
IP  - 6
DP  - 2020 Nov-Dec
TI  - Integrating emerging technologies into COVID-19 contact tracing: Opportunities,
      challenges and pitfalls.
PG  - 1631-1636
LID - S1871-4021(20)30332-5 [pii]
LID - 10.1016/j.dsx.2020.08.029 [doi]
AB  - BACKGROUND AND AIMS: With no approved vaccines for treating COVID-19 as of August
      2020, many health systems and governments rely on contact tracing as one of the
      prevention and containment methods. However, there have been instances when the
      infected person forgets his/her contact-persons and does not have their contact
      details. Therefore, this study aimed at analyzing possible opportunities and
      challenges of integrating emerging technologies into COVID-19 contact tracing.
      METHODS: The study applied literature search from Google Scholar, Science Direct,
      PubMed, Web of Science, IEEE and WHO COVID-19 reports and guidelines analyzed.
      RESULTS: While the integration of technology-based contact tracing applications
      to combat COVID-19 and break transmission chains promise to yield better results,
      these technologies face challenges such as technical limitations, dealing with
      asymptomatic individuals, lack of supporting ICT infrastructure and electronic
      health policy, socio-economic inequalities, deactivation of mobile devices' WIFI,
      GPS services, interoperability and standardization issues, security risks,
      privacy issues, political and structural responses, ethical and legal risks,
      consent and voluntariness, abuse of contact tracing apps, and discrimination.
      CONCLUSION: Integrating emerging technologies into COVID-19 contact tracing is
      seen as a viable option that policymakers, health practitioners and IT
      technocrats need to seriously consider in mitigating the spread of coronavirus.
      Further research is also required on how best to improve efficiency and
      effectiveness in the utilisation of emerging technologies in contact tracing
      while observing the security and privacy of people in fighting the COVID-19
      pandemic.
CI  - Copyright (c) 2020 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
FAU - Mbunge, Elliot
AU  - Mbunge E
AD  - Department of Computer Science, University of Eswatini, Kwaluseni, Kingdom of
      Eswatini. Electronic address: mbungeelliot@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200826
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
MH  - Artificial Intelligence/trends
MH  - Biomedical Technology/methods/*trends
MH  - COVID-19/diagnosis/*epidemiology/*prevention & control
MH  - Contact Tracing/methods/*trends
MH  - Geographic Information Systems/trends
MH  - Humans
PMC - PMC7833487
OTO - NOTNLM
OT  - COVID-19
OT  - Contact tracing
OT  - Emerging technologies
COIS- Declaration of competing interest None.
EDAT- 2020/09/07 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/09/06 20:31
PHST- 2020/08/18 00:00 [received]
PHST- 2020/08/22 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/09/06 20:31 [entrez]
AID - S1871-4021(20)30332-5 [pii]
AID - 10.1016/j.dsx.2020.08.029 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1631-1636. doi:
      10.1016/j.dsx.2020.08.029. Epub 2020 Aug 26.


PMID- 32891616
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1872-7905 (Electronic)
IS  - 0022-1759 (Linking)
VI  - 486
DP  - 2020 Nov
TI  - Potency determination of ricin toxin using a monoclonal antibody-based
      competition assay.
PG  - 112844
LID - S0022-1759(20)30133-2 [pii]
LID - 10.1016/j.jim.2020.112844 [doi]
AB  - Mouse challenge studies with death as an endpoint remain the gold standard in
      assessing the potency of ricin toxin, a Category B biothreat agent derived from
      the castor bean (Ricinus communis). However, animal studies are expensive, time
      consuming and ethically concerning. In an effort to reduce reliance on animals in
      vaccine development, we developed a monoclonal antibody (MAb)-based ricin
      competition ELISA (RiCoE) that indicates conformation integrity of ricin toxin.
      In forced degradation (heat-denaturation) experiments with native ricin
      holotoxin, we demonstrate a correlation between the decline in MAb reactivity in 
      RiCoE and a corresponding loss of toxin potency in Vero cells (IC50) and mice
      (LD50). The RiCoE assay was applied to differentially sourced commercial lots of 
      ricin toxin derived from R. communis blends and compared to toxin potency in
      mice. There was near perfect congruence between RiCoE values with two different
      MAbs (PB10, SyH7) and ricin potency in the mouse model using morbidity as an
      endpoint. In conclusion, we propose that RiCoE can serve as a rapid and sensitive
      substitute to mouse lethal dose challenge studies as a means to determine ricin
      toxin potency and will be valuable at various stages of vaccine development.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Doering, Jennifer
AU  - Doering J
AD  - Division of Infectious Disease, Wadsworth Center, New York State Department of
      Health, Albany, NY 12208, United States of America.
FAU - Czajka, Timothy
AU  - Czajka T
AD  - Department of Biomedical Sciences, University at Albany, Albany, NY 12201, United
      States of America.
FAU - Yates, Jennifer L
AU  - Yates JL
AD  - Division of Infectious Disease, Wadsworth Center, New York State Department of
      Health, Albany, NY 12208, United States of America.
FAU - Donini, Oreola
AU  - Donini O
AD  - Soligenix, Inc., Princeton, NJ 08540, United States of America.
FAU - Mantis, Nicholas J
AU  - Mantis NJ
AD  - Division of Infectious Disease, Wadsworth Center, New York State Department of
      Health, Albany, NY 12208, United States of America; Department of Biomedical
      Sciences, University at Albany, Albany, NY 12201, United States of America.
      Electronic address: nicholas.mantis@health.ny.gov.
LA  - eng
GR  - HHSN272201400039C/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200903
PL  - Netherlands
TA  - J Immunol Methods
JT  - Journal of immunological methods
JID - 1305440
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunodominant Epitopes)
RN  - 9009-86-3 (Ricin)
SB  - IM
MH  - Animal Testing Alternatives
MH  - Animals
MH  - Antibodies, Monoclonal/*immunology
MH  - Antibody Specificity
MH  - Binding, Competitive
MH  - Chlorocebus aethiops
MH  - *Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Immunodominant Epitopes
MH  - Lethal Dose 50
MH  - Mice, Inbred BALB C
MH  - Protein Conformation
MH  - Protein Denaturation
MH  - Ricin/chemistry/immunology/*toxicity
MH  - Structure-Activity Relationship
MH  - Vero Cells
OTO - NOTNLM
OT  - *Biodefense
OT  - *Monoclonal antibodies
OT  - *Toxin
OT  - *Vaccine
COIS- Declaration of Competing Interest JD, TC, JY, and NJM declare no competing
      interests. OD is an employee of Soligenix, Inc., which holds the NIH contract and
      license for RiVax.
EDAT- 2020/09/07 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/09/06 20:24
PHST- 2020/05/13 00:00 [received]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/09/06 20:24 [entrez]
AID - S0022-1759(20)30133-2 [pii]
AID - 10.1016/j.jim.2020.112844 [doi]
PST - ppublish
SO  - J Immunol Methods. 2020 Nov;486:112844. doi: 10.1016/j.jim.2020.112844. Epub 2020
      Sep 3.


PMID- 32891339
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1879-3320 (Electronic)
IS  - 0960-7404 (Linking)
VI  - 34
DP  - 2020 Sep
TI  - Independent risk factors for lymph node metastasis in 2623 patients with
      Non-Small cell lung cancer.
PG  - 256-260
LID - S0960-7404(20)30324-8 [pii]
LID - 10.1016/j.suronc.2020.05.005 [doi]
AB  - PURPOSE: this study attempts to identify the independent risk factors that can
      predict lymph node metastasis for the patients with non-small cell lung cancer
      (NSCLC), and guide doctor adoption of individualized treatment for such patients.
      MATERIALS AND METHODS: This study was approved by the Hospital's Ethics Committee
      and all patients had signed informed consent forms. We retrospectively reviewed
      NSCLC patients who had undergone surgical resection from December 2008 to
      December 2013.The statistical significance of evaluation variables and lymph node
      metastasis was determined with Pearson's Chi-square test. The risk factors of
      lymph node metastasis were determined through univariate and multivariate
      logistic regression analysis. And for the age and tumor diameter factors, optimal
      cutoff points were determined with a receiver operating characteristic analysis. 
      RESULTS: In the present study, a total of 2623 patients were included in the
      study, and 779 patients with lymph node metastasis. Three independent risk
      factors were identified: age, tumor diameter and Ki-67 index. We found that <65
      years of age (Adjusted-OR:1.921), >/=2.85 cm of tumor diameter
      (Adjusted-OR:3.141), and 5%~25% in Ki-67 group (Adjusted-OR:2.137),>/=25%
      (Adjusted-OR:3.341) were significant. Also we found that 307 patients with lymph 
      node metastasis and the lymph node metastasis rate was 51.0%, when the age<65
      years, Ki-67 index>/=25%, and the tumor diameter>/=2.85 cm. On the contrary,
      there were only 2 patients with lymph node metastasis, and the rate of lymph node
      metastasis was 5.1%. CONCLUSION: Identifying three independent risk factors that 
      predict lymph node metastasis in non-small cell patients, Among NSCLC patients in
      whom all three predictors were identified, and over a half of the patients showed
      lymph node metastasis.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Xue, Xinying
AU  - Xue X
AD  - Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital
      Medical University, Beijing, China.
FAU - Zang, Xuelei
AU  - Zang X
AD  - Center of Clinical Laboratory Medicine, the first Medical Centre, Chinese PLA
      General Hospital, Beijing, China.
FAU - Liu, Yuxia
AU  - Liu Y
AD  - Department of Scientific Research, Peking Union Medical College Hospital,
      Beijing, China.
FAU - Lin, Dongliang
AU  - Lin D
AD  - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao
      City, China.
FAU - Jiang, Tianjiao
AU  - Jiang T
AD  - Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao
      City, China.
FAU - Gao, Jie
AU  - Gao J
AD  - Department of Pathology, the first Medical Centre, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Wu, Chongchong
AU  - Wu C
AD  - Department of Radiology, The First Medical Centre, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Ma, Xidong
AU  - Ma X
AD  - Department of Respiratory Medicine, Weifang Medical University, Weifang, China.
FAU - Deng, Hui
AU  - Deng H
AD  - Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital
      Medical University, Beijing, China.
FAU - Yu, Zhaofeng
AU  - Yu Z
AD  - Weifang Medical University, Weifang, China. Electronic address: yzhf@wfmc.edu.cn.
FAU - Pan, Lei
AU  - Pan L
AD  - Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital
      Medical University, Beijing, China. Electronic address: leipan2010@163.com.
FAU - Xue, Zhiqiang
AU  - Xue Z
AD  - Department of Thoracic Surgery, The First Medical Centre, Chinese PLA General
      Hospital, Beijing, China. Electronic address: xuezhiqiang301@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - Netherlands
TA  - Surg Oncol
JT  - Surgical oncology
JID - 9208188
SB  - IM
MH  - Adenocarcinoma of Lung/*secondary/surgery
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*secondary/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/*pathology/surgery
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Ki-67
OT  - Lymph node metastasis
OT  - Non-small cell lung cancer
OT  - Risk factors
EDAT- 2020/09/07 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/09/06 20:21
PHST- 2019/11/17 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/09/06 20:21 [entrez]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
AID - S0960-7404(20)30324-8 [pii]
AID - 10.1016/j.suronc.2020.05.005 [doi]
PST - ppublish
SO  - Surg Oncol. 2020 Sep;34:256-260. doi: 10.1016/j.suronc.2020.05.005. Epub 2020 May
      22.


PMID- 32891286
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1873-6947 (Electronic)
IS  - 1744-3881 (Linking)
VI  - 40
DP  - 2020 Aug
TI  - The effectiveness of cupping therapy on chronic fatigue syndrome: A single-blind 
      randomized controlled trial.
PG  - 101210
LID - S1744-3881(19)30874-6 [pii]
LID - 10.1016/j.ctcp.2020.101210 [doi]
AB  - BACKGROUND: and purpose: We investigated the effectiveness of cupping therapy
      with three different pressures in patients with chronic fatigue syndrome (CFS).
      MATERIALS AND METHODS: The participants were randomly assigned to three groups,
      as follows: cupping pressure of -0.02 mpa (n = 38), -0.03 mpa (n = 38), or -0.05 
      mpa (n = 36). Each group received cupping treatment that consisted of 10 sessions
      over 5 weeks (2 sessions per week). The primary outcomes were Fatigue Scale
      (FS-14) score and Fatigue Assessment Instrument (FAI) score after 5 and 10
      sessions. The secondary outcomes were the Self-Rating Anxiety Scale (SAS) score, 
      the Self-Rating Depression Scale (SDS) score, and the Pittsburgh Sleep Quality
      Index (PSQI) score. RESULTS: There were 91 participants who completed the trial. 
      After five sessions of treatment, the primary outcome of FS-14 score decreased by
      3.20 (2.19, 4.21) in the -0.02 mpa group, by 2.39 (1.51, 3.27) in the -0.03 mpa
      group, and by 3.40 (2.28, 4.52) in the -0.05 mpa group (P = 0.667). After 10
      sessions of treatment, the outcome of FS-14 score decreased by 5.00 (3.79, 6.21) 
      in the -0.02 mpa group, by 4.06 (3.07, 5.05) in the -0.03 mpa group, and by 4.77 
      (3.52, 5.94) in the -0.05 mpa group (P = 0.929). And, the results were
      statistically different between 5 sessions and 10 sessions of treatment (P <
      0.01). However, there were no statistical differences in FAI, SAS, SDS, and PSQI 
      scores between the three groups after 5 sessions and 10 sessions of treatment.
      CONCLUSIONS: In conclusion, cupping therapy has significantly relieved fatigue
      symptoms and improved emotion and sleep condition of CFS patients, and 10
      sessions of treatment had superior results compared with 5 sessions in each
      group. Moreover, in 5 sessions of treatment, cupping with high pressure showed
      better improvement in fatigue syndromes and sleep condition according to
      effective rates. TRIAL REGISTRATION: Chinese clinical trial registry
      (ChiCTR1800017590); Ethical approval number: ChiECRCT-20180085.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Meng, Xiu-Dong
AU  - Meng XD
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: xiudong19@qq.com.
FAU - Guo, Hao-Ran
AU  - Guo HR
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: guohaoran0517@sina.com.
FAU - Zhang, Qing-Ying
AU  - Zhang QY
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: zhangqingying0928@163.com.
FAU - Li, Xin
AU  - Li X
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: 2096599174@qq.com.
FAU - Chen, Yong
AU  - Chen Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: chenyongtcm@163.com.
FAU - Li, Mu-Yang
AU  - Li MY
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: tjutcmlimuyang@163.com.
FAU - Zhuo, Xue-Mao
AU  - Zhuo XM
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: zhuoxm_tjutcm@163.com.
FAU - Wang, Mei-Juan
AU  - Wang MJ
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: 429344246@qq.com.
FAU - Shan, Kai
AU  - Shan K
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: 2646586551@qq.com.
FAU - Gong, Yi-Nan
AU  - Gong YN
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: 1457907206@qq.com.
FAU - Li, Ning-Cen
AU  - Li NC
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: liningcen1009@qq.com.
FAU - Chen, Bo
AU  - Chen B
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: tjutcmchenbo@163.com.
FAU - Chen, Ze-Lin
AU  - Chen ZL
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: chenzelin328@163.com.
FAU - Guo, Yi
AU  - Guo Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
      Electronic address: guoyi_168@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200620
PL  - England
TA  - Complement Ther Clin Pract
JT  - Complementary therapies in clinical practice
JID - 101225531
MH  - Adult
MH  - Cupping Therapy/*methods
MH  - Fatigue Syndrome, Chronic/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Sleep Wake Disorders/therapy
MH  - Young Adult
OTO - NOTNLM
OT  - Chronic fatigue syndrome
OT  - Cupping therapy
OT  - Regularity of effect
EDAT- 2020/09/07 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/06 20:20
PHST- 2019/10/25 00:00 [received]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/09/06 20:20 [entrez]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S1744-3881(19)30874-6 [pii]
AID - 10.1016/j.ctcp.2020.101210 [doi]
PST - ppublish
SO  - Complement Ther Clin Pract. 2020 Aug;40:101210. doi: 10.1016/j.ctcp.2020.101210. 
      Epub 2020 Jun 20.


PMID- 32891235
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20211204
IS  - 1526-3231 (Electronic)
IS  - 0749-8063 (Linking)
VI  - 36
IP  - 9
DP  - 2020 Sep
TI  - Surgical Translational Research May Be Forward or Reverse.
PG  - 2345-2346
LID - S0749-8063(20)30594-6 [pii]
LID - 10.1016/j.arthro.2020.07.001 [doi]
AB  - The classic concept of translational research can be described as a
      bench-to-bedside approach. Reverse translational research, bedside-to-benchtop,
      also may have a place. Under some circumstances, innovative clinicians may
      develop new techniques in advance of basic science research. A recent example of 
      the success of reverse translational research is shoulder superior capsular
      reconstruction. Theoretically, new surgical techniques are ideally first tested
      ex vivo, but this does not guarantee clinical success, and in some cases,
      experienced, specialized surgeon-scientists can modify existing techniques and
      perform novel interventions with little risk to patients. Benefits of reverse
      translational research include a shorter time from innovation to application, and
      real, not theoretical, determination of clinical outcome. If a reverse approach
      is warranted, strict adherence to bioethical principles is required, including
      cooperation with ethics committees, institutional review boards, trial
      registration, and informed consent. Translational research can be bidirectional.
CI  - Copyright (c) 2020 Arthroscopy Association of North America. Published by
      Elsevier Inc. All rights reserved.
FAU - Hohmann, Erik
AU  - Hohmann E
FAU - Rossi, Michael J
AU  - Rossi MJ
FAU - Brand, Jefferson C
AU  - Brand JC
FAU - Lubowitz, James H
AU  - Lubowitz JH
LA  - eng
PT  - Editorial
PL  - United States
TA  - Arthroscopy
JT  - Arthroscopy : the journal of arthroscopic & related surgery : official
      publication of the Arthroscopy Association of North America and the International
      Arthroscopy Association
JID - 8506498
SB  - IM
MH  - Bioethics
MH  - Diffusion of Innovation
MH  - Ethics Committees, Research
MH  - General Surgery/ethics/methods/*trends
MH  - Humans
MH  - Informed Consent
MH  - Translational Research, Biomedical/ethics/methods/*trends
MH  - Treatment Outcome
EDAT- 2020/09/07 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/09/06 20:19
PHST- 2020/07/03 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/09/06 20:19 [entrez]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - S0749-8063(20)30594-6 [pii]
AID - 10.1016/j.arthro.2020.07.001 [doi]
PST - ppublish
SO  - Arthroscopy. 2020 Sep;36(9):2345-2346. doi: 10.1016/j.arthro.2020.07.001.


PMID- 32891139
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 5
TI  - Vitamin D supplementation in obese Sri Lankan children: a randomized controlled
      trial.
PG  - 426
LID - 10.1186/s12887-020-02329-w [doi]
AB  - BACKGROUND: Micronutrient deficiencies are identified among obese individuals.
      Vitamin D deficiency (VDD) is prevalent in obese children, and is hypothesized to
      cause insulin resistance and metabolic abnormalities. This study aimed to
      determine the effect of vitamin D supplementation on obesity and related
      metabolic abnormalities among obese Sri Lankan children with VDD. METHODS: A
      triple-blind randomized controlled trial was conducted among vitamin D deficient 
      (< 20 ng/ml), obese children (n = 96), randomly allocated to three intervention
      arms - treatment arm receiving weekly vitamin D2 50,000 IU; supplementation arm
      receiving 2500 IU weekly and control arm, receiving placebo. Anthropometry,
      percentage fat mass (%FM) and blood pressure were assessed and fasting blood
      glucose, fasting insulin, lipid profile, aspartate transaminase (ALT), alanine
      transaminase (AST), vitamin D, parathyroid hormone (PTH) and hs-CRP and OGTT with
      2-h random blood glucose and insulin was performed at baseline and after 24 weeks
      of treatment. Ethics Review Committee of Faculty of Medicine, University of
      Colombo approved the protocol. RESULTS: Waist circumference Z-score, %FM and
      serum calcium significantly improved across all three arms, ALT significantly
      improved in treatment and supplementation arms while, BMI Z-score, PTH and
      vitamin D significantly improved in the treatment arm. Biceps (p = 0.035) and
      subscapular (0.048) skin fold thickness, vitamin D (p = 0.004) and ALT (p =
      0.012) significantly improved in the treatment arm. CONCLUSIONS: A strict dietary
      and physical activity regimen could improve some of the anthropometric, body
      composition and metabolic profiles, but high dose vitamin D, enhances those
      improvements. Therefore high dose vitamin D seems to potentiate management
      outcomes of obese children with vitamin D deficiency. TRIAL REGISTRATION: The
      study was registered at the Sri Lanka Clinical Trials Registry (SLCTR/2015/017)
      on 12th September 2015 at https://slctr.lk/trials/slctr-2015-017 .
FAU - Samaranayake, D B D L
AU  - Samaranayake DBDL
AD  - Department of Community Medicine, Faculty of Medicine, University of Colombo,
      Colombo, Sri Lanka.
FAU - Adikaram, S G S
AU  - Adikaram SGS
AD  - Colombo South Teaching Hospital, Kalubowila, Sri Lanka.
FAU - Atapattu, N
AU  - Atapattu N
AD  - Lady Ridgeway Hospital, Colombo, Sri Lanka.
FAU - Kendaragama, K M D L D
AU  - Kendaragama KMDLD
AD  - Lady Ridgeway Hospital, Colombo, Sri Lanka.
FAU - Senevirathne, J T N
AU  - Senevirathne JTN
AD  - Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo,
      Sri Lanka.
FAU - Jayasekera, H D
AU  - Jayasekera HD
AD  - Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo,
      Sri Lanka.
FAU - Wickramasinghe, V P
AU  - Wickramasinghe VP
AUID- ORCID: 0000-0002-8355-1283
AD  - Department of Paediatrics, Faculty of Medicine, University of Colombo, Colombo,
      Sri Lanka. pujithaw@yahoo.com.
LA  - eng
SI  - SLCTR/SLCTR/2015/017
GR  - RG/2015/HS/09/National Science Foundation/International
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200905
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (Blood Glucose)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Blood Glucose
MH  - Child
MH  - *Dietary Supplements
MH  - Double-Blind Method
MH  - Humans
MH  - Obesity
MH  - Sri Lanka
MH  - Vitamin D
MH  - *Vitamin D Deficiency/complications/drug therapy
PMC - PMC7487456
OTO - NOTNLM
OT  - *Childhood obesity
OT  - *Insulin resistance
OT  - *Randomized controlled trial
OT  - *Sri Lanka
OT  - *Vitamin D deficiency
EDAT- 2020/09/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/06 20:18
PHST- 2020/04/25 00:00 [received]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/06 20:18 [entrez]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12887-020-02329-w [doi]
AID - 10.1186/s12887-020-02329-w [pii]
PST - epublish
SO  - BMC Pediatr. 2020 Sep 5;20(1):426. doi: 10.1186/s12887-020-02329-w.


PMID- 32891132
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1528-3658 (Electronic)
IS  - 1076-1551 (Linking)
VI  - 26
IP  - 1
DP  - 2020 Sep 5
TI  - Markers of vitality in ovaries of transmen after long-term androgen treatment: a 
      prospective cohort study.
PG  - 83
LID - 10.1186/s10020-020-00214-x [doi]
AB  - BACKGROUND: Gender-affirming hormone therapy has been hypothesized to reduce the 
      patient's reproductive potential in transmen, although the exact long-term
      effects on future fertility are unknown. METHODS: In this prospective cohort
      study we aimed to evaluate ovaries of 20 transmen by using hormone serum levels, 
      histomorphological analysis and fluorescence activated cells sorting (FACS)
      analysis - in order to assess the amount of vital cells. RESULTS: The median
      total number of follicles per field of view was 39 (IQR 12-122). Of all follicles
      (n = 1661), the vast majority was primordial (n = 1505, 90.6%), followed by
      primary (n = 76, 4.6%), abnormal (n = 63, 3.8%) and secondary follicles (n = 17, 
      1.0%). FACS analysis was available for 13 samples (65.0%) and the median
      frequency of vital cells was 87.5% (IQR, 77.7-95.4%). Both a higher age (p =
      0.032) and a lower BMI (p = 0.003) were significantly associated with a higher
      frequency of vital cells. CONCLUSION: The majority of ovarian cells after
      long-term androgen treatment were vital in FACS analysis and histomorphological
      evaluation revealed a normal cortical follicle distribution. These results are
      currently exploratory, but might be promising for issues on fertility
      preservation. TRIAL REGISTRATION: The study was approved by the ethics committee 
      of the Medical University of Vienna (EK 2240/2016) and was retrospectively
      registered in the Current Controlled Trials Register (registration number
      NCT03649087 , date of registration: 28.08.2018).
FAU - Marschalek, Julian
AU  - Marschalek J
AD  - Department of Obstetrics and Gynecology, Clinical Division of Gynecologic
      Endocrinology and Reproductive Medicine, Medical University of Vienna,
      Spitalgasse 23, 1090, Vienna, Austria.
FAU - Pietrowski, Detlef
AU  - Pietrowski D
AD  - Department of Obstetrics and Gynecology, Clinical Division of Gynecologic
      Endocrinology and Reproductive Medicine, Medical University of Vienna,
      Spitalgasse 23, 1090, Vienna, Austria.
FAU - Dekan, Sabine
AU  - Dekan S
AD  - Clinical Institute of Pathology, Medical University of Vienna, Spitalgasse 23,
      1090, Vienna, Austria.
FAU - Marschalek, Marie-Louise
AU  - Marschalek ML
AD  - Department of Obstetrics and Gynecology, Clinical Division of Gynecologic
      Endocrinology and Reproductive Medicine, Medical University of Vienna,
      Spitalgasse 23, 1090, Vienna, Austria.
FAU - Brandstetter, Maximilian
AU  - Brandstetter M
AD  - Department of Obstetrics and Gynecology, Clinical Division of Gynecologic
      Endocrinology and Reproductive Medicine, Medical University of Vienna,
      Spitalgasse 23, 1090, Vienna, Austria.
FAU - Ott, Johannes
AU  - Ott J
AUID- ORCID: 0000-0002-2761-5262
AD  - Department of Obstetrics and Gynecology, Clinical Division of Gynecologic
      Endocrinology and Reproductive Medicine, Medical University of Vienna,
      Spitalgasse 23, 1090, Vienna, Austria. johannes.ott@meduniwien.ac.at.
LA  - eng
SI  - ClinicalTrials.gov/NCT03649087
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200905
PL  - England
TA  - Mol Med
JT  - Molecular medicine (Cambridge, Mass.)
JID - 9501023
RN  - 0 (Androgens)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Androgens/*administration & dosage
MH  - *Biomarkers
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - Ovary/*drug effects/*metabolism
MH  - Reproduction
MH  - *Transgender Persons
MH  - Young Adult
PMC - PMC7487795
OTO - NOTNLM
OT  - *Fertility
OT  - *Fluorescence activated cells sorting (FACS)
OT  - *Histomorphology
OT  - *Transgender
OT  - *Transmen
EDAT- 2020/09/07 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/09/06 20:18
PHST- 2020/04/30 00:00 [received]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/06 20:18 [entrez]
PHST- 2020/09/07 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
AID - 10.1186/s10020-020-00214-x [doi]
AID - 10.1186/s10020-020-00214-x [pii]
PST - epublish
SO  - Mol Med. 2020 Sep 5;26(1):83. doi: 10.1186/s10020-020-00214-x.


PMID- 32890381
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 0353-5053 (Print)
IS  - 0353-5053 (Linking)
VI  - 32
IP  - Suppl 1
DP  - 2020 Sep
TI  - Improving Transition from Child and Adolescent Mental Health Services to Adult
      Mental Health Services for Adolescents in Transition to Young Adulthood: A
      Literature Review.
PG  - 153-157
AB  - BACKGROUND: These last years adolescents in transition to young adulthood (ATYA) 
      have become a new matter of research. This population encounter specific issues
      and challenges regarding their mental health particularly when they have attained
      age boundaries and deal with the issue of transition from child and adolescent
      mental health services (CAMHS) to adult mental health services (AMHS). Many key
      questions regarding how to sustain continuity of mental health care for ATYA
      during transition remain. The aim of this paper is to review recent literature in
      the domain to identify dimensions that should be considered to improve ATYA
      transition from CAMHS to AMHS. SUBJECTS AND METHODS: A qualitative literature
      review was performed in Scopus-Elsevier database using the PRISMA method as
      reporting guidelines. Only papers discussing dimensions involved in the
      transition process from CAMHS to AMHS were considered. We restricted the review
      to researches published between 2010 and 2020. RESULTS: We identified 85
      potential researches, after filtering; only 10 articles were finally included in 
      the qualitative synthesis of the literature. Five main dimensions were
      identified: patient, professional, organization, policy, and ethic related. Those
      dimensions should be considered in order to improve ATYA transition process out
      of CAMHS to AMHS. CONCLUSION: This work contributes to identify principal
      dimensions that should be considered by mental health professionals and
      organizations in order to improve ATYA transition from CAMHS to AMHS.
FAU - Lepiece, Brice
AU  - Lepiece B
AD  - Universite Catholique de Louvain, Institute of Health and Society (IRSS), Clos
      Chapelle-aux-champs, 30 /B1.30.15, B-1200 Brussels, Belgium,
      brice.lepiece@uclouvain.be.
FAU - Patigny, Pierre
AU  - Patigny P
FAU - Dubois, Thomas
AU  - Dubois T
FAU - Jacques, Denis
AU  - Jacques D
FAU - Zdanowicz, Nicolas
AU  - Zdanowicz N
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Croatia
TA  - Psychiatr Danub
JT  - Psychiatria Danubina
JID - 9424753
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health Services
MH  - Adult
MH  - Child
MH  - Humans
MH  - *Mental Disorders
MH  - Mental Health
MH  - *Mental Health Services
MH  - *Transition to Adult Care
MH  - Young Adult
EDAT- 2020/09/06 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/09/05 17:07
PHST- 2020/09/05 17:07 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PST - ppublish
SO  - Psychiatr Danub. 2020 Sep;32(Suppl 1):153-157.


PMID- 32890188
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 2169-981X (Electronic)
IS  - 2169-9798 (Linking)
VI  - 36
IP  - 5
DP  - 2020 Sep/Oct
TI  - Ethics and Interprofessional Learning Environments During a Pandemic:
      Implications for Nursing Professional Development Practitioners.
PG  - 304-306
LID - 10.1097/NND.0000000000000670 [doi]
FAU - Holtschneider, Mary Edel
AU  - Holtschneider ME
AD  - Mary Edel Holtschneider, MEd, MPA, BSN, RN, NPD-BC, NREMT-P, CPTD, is Simulation 
      Education Coordinator and Co-Director, Interprofessional Advanced Fellowship in
      Clinical Simulation, U.S. Department of Veterans Affairs, Durham VA Health Care
      System, and Nursing Program Manager, Duke Area Health Education Center (AHEC),
      Duke University Medical Center, Durham, North Carolina. Chan W. Park, MD, FAAEM, 
      is Director, Simulation Education and Co-Director, Interprofessional Advanced
      Fellowship in Clinical Simulation, U.S. Department of Veterans Affairs, Durham VA
      Health Care System, and Adjunct Assistant Professor, Division of Emergency
      Medicine, DukeUniversity Medical Center, Durham, North Carolina.
FAU - Park, Chan W
AU  - Park CW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nurses Prof Dev
JT  - Journal for nurses in professional development
JID - 101603887
MH  - *COVID-19
MH  - Cooperative Behavior
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Interprofessional Relations
MH  - *Nurse's Role
MH  - Personal Protective Equipment
MH  - *Simulation Training
MH  - *Staff Development
EDAT- 2020/09/06 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/09/05 17:06
PHST- 2020/09/05 17:06 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
AID - 10.1097/NND.0000000000000670 [doi]
AID - 01709760-202009000-00011 [pii]
PST - ppublish
SO  - J Nurses Prof Dev. 2020 Sep/Oct;36(5):304-306. doi: 10.1097/NND.0000000000000670.


PMID- 32890066
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210208
IS  - 1537-1603 (Electronic)
IS  - 0736-0258 (Linking)
VI  - 37
IP  - 5
DP  - 2020 Sep
TI  - Drug Trials in Status Epilepticus: Current Evidence and Future Concepts.
PG  - 434-445
LID - 10.1097/WNP.0000000000000713 [doi]
AB  - Status epilepticus (SE) is a neurologic emergency with high morbidity and
      mortality. After many advances in the field, several unanswered questions remain 
      for optimal treatment after the early stage of SE. This narrative review
      describes some of the important drug trials for SE treatment that have shaped the
      understanding of the treatment of SE. The authors also propose possible clinical 
      trial designs for the later stages of SE that may allow assessment of currently
      available and new treatment options. Status epilepticus can be divided into four 
      stages for treatment purposes: early, established, refractory, and
      superrefractory. Ongoing convulsive seizures for more than 5 minutes or
      nonconvulsive seizure activity for more than 10 to 30 minutes is considered early
      SE. Failure to control the seizure with first-line treatment (usually
      benzodiazepines) is defined as established SE. If SE continues despite treatment 
      with an antiseizure medicine, it is considered refractory SE, which is usually
      treated with additional antiseizure medicines or intravenous anesthetic agents.
      Continued seizures for more than 24 hours despite use of intravenous anesthetic
      agents is termed superrefractory SE. Evidence-based treatment recommendations
      from high-quality clinical trials are available for only the early stages of SE. 
      Among the challenges for designing a treatment trial for the later stages SE is
      the heterogeneity of semiology, etiology, age groups, and EEG correlates. In many
      instances, SE is nonconvulsive in later stages and diagnosis is possible only
      with EEG. EEG patterns can be challenging to interpret and only recently have
      consensus criteria for EEG diagnosis of SE emerged. Despite having these EEG
      criteria, interrater agreement in EEG interpretation can be challenging. Defining
      successful treatment can also be difficult. Finally, the ethics of randomizing
      treatment and possibly using a placebo in critically ill patients must also be
      considered. Despite these challenges, clinical trials can be designed that
      navigate these issues and provide useful answers for how best to treat SE at
      various stages.
FAU - Mandge, Vishal
AU  - Mandge V
AD  - Department of Neurology, Duke University Medical Center, Durham, North Carolina, 
      U.S.A.
FAU - Husain, Aatif M
AU  - Husain AM
AD  - Department of Neurology, Duke University Medical Center, Durham, North Carolina, 
      U.S.A.
AD  - Neuroscience Medicine, Duke Clinical Research Institute, Durham, North Carolina, 
      U.S.A.; and.
AD  - Neurodiagnostic Center, Veterans Affairs Medical Center, Durham, North Carolina, 
      U.S.A.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Neurophysiol
JT  - Journal of clinical neurophysiology : official publication of the American
      Electroencephalographic Society
JID - 8506708
RN  - 0 (Anticonvulsants)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 44YRR34555 (Levetiracetam)
RN  - 5PE9FDE8GB (Clonazepam)
SB  - IM
MH  - Anticonvulsants/*therapeutic use
MH  - Benzodiazepines/therapeutic use
MH  - Clinical Trials as Topic/*methods
MH  - Clonazepam/therapeutic use
MH  - Consensus
MH  - Critical Illness
MH  - Drug Therapy, Combination
MH  - Evidence-Based Medicine/*methods/*trends
MH  - Forecasting
MH  - Humans
MH  - Levetiracetam/therapeutic use
MH  - Seizures/drug therapy
MH  - Status Epilepticus/diagnosis/*drug therapy
EDAT- 2020/09/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/05 17:06
PHST- 2020/09/05 17:06 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/WNP.0000000000000713 [doi]
AID - 00004691-202009000-00011 [pii]
PST - ppublish
SO  - J Clin Neurophysiol. 2020 Sep;37(5):434-445. doi: 10.1097/WNP.0000000000000713.


PMID- 32890035
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 32
IP  - 9
DP  - 2020 Sep
TI  - Academic dishonesty: What impact does it have and what can faculty do?
PG  - 598-601
LID - 10.1097/JXX.0000000000000477 [doi]
AB  - Academic dishonesty occurs among nursing students at multiple levels of
      professional education programs. Studies have shown that students who commit
      dishonest acts in the educational setting may also commit dishonest acts as
      students in the clinical setting and as professionals in their practice setting. 
      This lack of professional integrity may result in poor outcomes for patients as
      well as loss of trust from patients and from colleagues. Although multiple
      studies done among prelicensure nursing students explored academic dishonesty,
      there are few studies of academic integrity among nurse practitioner (NP)
      students. As advanced practice nurses, we need to understand the issues of
      academic dishonesty among NP students through further research. As faculty, we
      must act to prevent academic dishonesty and unethical behavior and to provide
      appropriate consequences when it occurs. It is also important that we consider
      ways to socialize students into ethical behavior to maintain trust in the
      profession. It is important that we respond to both students and colleagues who
      demonstrate a lack of integrity. All NPs must work to create a culture of
      professional integrity among students and members of the profession at every
      level.
FAU - Pittman, Oralea A
AU  - Pittman OA
AD  - Department of Nursing, Ohio State University, Hilliard, Ohio.
FAU - Barker, Elizabeth
AU  - Barker E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
MH  - *Deception
MH  - Faculty, Nursing/*trends
MH  - Humans
MH  - Students, Nursing/*statistics & numerical data
EDAT- 2020/09/06 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/05 17:06
PHST- 2020/09/05 17:06 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.1097/JXX.0000000000000477 [doi]
AID - 01741002-202009000-00002 [pii]
PST - ppublish
SO  - J Am Assoc Nurse Pract. 2020 Sep;32(9):598-601. doi:
      10.1097/JXX.0000000000000477.


PMID- 32889946
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20210112
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 12
DP  - 2020 Dec
TI  - Telemedicine and Medical Education in the Age of COVID-19.
PG  - 1838-1843
LID - 10.1097/ACM.0000000000003711 [doi]
AB  - The COVID-19 pandemic has offered medical schools an opportunity to incorporate
      telemedicine training into the curricula in a timely and practical manner.
      Telemedicine has grown exponentially in the United States, and the shift toward
      remote care to align with social distancing guidelines is fueling this growth.
      Training medical students to deliver high-quality, secure, and personalized
      health care through telemedicine will prepare the next generation of physicians
      to conscientiously use these technologies and meet a growing need for telehealth 
      services. Telemedicine-specific educational goals can be incorporated into
      curricula and integrated with existing clinical experiences to provide students
      with core telemedicine and clinical skills to prepare them for current and future
      pandemics. Medical educators could explore 5 major telemedicine domains: (1)
      access to care, (2) cost, (3) cost-effectiveness, (4) patient experience, and (5)
      clinician experience. Schools could use the following learning vehicles to help
      medical students explore these domains: (1) asynchronous lectures covering
      telehealth history; (2) discussions on applications, ethics, safety, etiquette,
      and patient considerations; (3) faculty-supervised standardized patient
      telehealth encounters; and (4) hands-on diagnostic or therapeutic procedures
      using telehealth equipment. Incorporating telemedicine into the medical school
      curriculum exposes students to the application of telemedicine across specialties
      as well as its limitations.
FAU - Jumreornvong, Oranicha
AU  - Jumreornvong O
AD  - O. Jumreornvong is a third-year student, Icahn School of Medicine at Mount Sinai,
      New York, New York; ORCID: https://orcid.org/0000-0001-7327-9514.
FAU - Yang, Emmy
AU  - Yang E
AD  - E. Yang is a fourth-year student, Icahn School of Medicine at Mount Sinai, New
      York, New York; ORCID: https://orcid.org/0000-0001-8966-9971.
FAU - Race, Jasmine
AU  - Race J
AD  - J. Race is a fourth-year student, Icahn School of Medicine at Mount Sinai, New
      York, New York; ORCID: https://orcid.org/0000-0001-9077-5085.
FAU - Appel, Jacob
AU  - Appel J
AD  - J. Appel is assistant professor, Departments of Psychiatry and Medical Education,
      Icahn School of Medicine at Mount Sinai, New York, New York; ORCID:
      https://orcid.org/0000-0003-3523-9145.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
MH  - *COVID-19
MH  - Clinical Competence
MH  - Curriculum/*trends
MH  - Education, Distance/*methods
MH  - Education, Medical/*methods
MH  - Humans
MH  - SARS-CoV-2
MH  - Students, Medical
MH  - Telemedicine/*trends
MH  - United States
PMC - PMC7489227
EDAT- 2020/09/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/05 17:05
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/05 17:05 [entrez]
AID - 10.1097/ACM.0000000000003711 [doi]
AID - 00001888-202012000-00027 [pii]
PST - ppublish
SO  - Acad Med. 2020 Dec;95(12):1838-1843. doi: 10.1097/ACM.0000000000003711.


PMID- 32889925
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20210505
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 12S Addressing Harmful Bias and Eliminating Discrimination in Health Professions 
      Learning Environments
DP  - 2020 Dec
TI  - Addressing Patient Bias and Discrimination Against Clinicians of Diverse
      Backgrounds.
PG  - S33-S43
LID - 10.1097/ACM.0000000000003682 [doi]
AB  - The duty to care for all patients is central to the health professions, but what 
      happens when clinicians encounter patients who exhibit biased or discriminatory
      behaviors? While significant attention has focused on addressing clinician bias
      toward patients, incidents of patient bias toward clinicians also occur and are
      difficult to navigate.Clinicians anecdotally describe their experiences with
      patient bias, prejudice, and discrimination as profoundly painful and degrading. 
      Though this phenomenon has not been rigorously studied, it is not unreasonable to
      postulate that the moral distress caused by patient bias may ultimately
      contribute to clinician burnout. Because women and minority clinicians are more
      likely to be targets of patient bias, this may worsen existing disparities for
      these groups and increase their risk for burnout. Biased behavior may also affect
      patient outcomes.Although some degree of ignoring derogatory comments is
      necessary to maintain professionalism and workflow, clinicians also have the
      right to a workplace free of mistreatment and abuse. How should clinicians
      reconcile the expectation to always "put patients first" with their basic right
      to be treated with dignity and respect? And how can health care organizations
      develop policies and training to mitigate the effects of these experiences?The
      authors discuss the ethical dilemmas associated with responding to prejudiced
      patients and then present a framework for clinicians to use when directly facing 
      or witnessing biased behavior from patients. Finally, they describe strategies to
      address patient bias at the institutional level.
FAU - Chandrashekar, Pooja
AU  - Chandrashekar P
AD  - P. Chandrashekar is a second-year medical student, Harvard Medical School,
      Boston, Massachusetts.
FAU - Jain, Sachin H
AU  - Jain SH
AD  - S.H. Jain is adjunct professor of medicine, Stanford University School of
      Medicine, Palo Alto, California, and president and chief executive officer, SCAN 
      Group and Health Plan, Long Beach, California.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
MH  - *Bias
MH  - Dissent and Disputes
MH  - Health Personnel/*psychology/trends
MH  - Humans
MH  - Organizational Policy
MH  - Professional-Patient Relations
MH  - Professionalism
MH  - Racism/prevention & control/*psychology
MH  - Workplace/psychology/standards
EDAT- 2020/09/06 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/09/05 17:05
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2020/09/05 17:05 [entrez]
AID - 10.1097/ACM.0000000000003682 [doi]
AID - 00001888-202012001-00007 [pii]
PST - ppublish
SO  - Acad Med. 2020 Dec;95(12S Addressing Harmful Bias and Eliminating Discrimination 
      in Health Professions Learning Environments):S33-S43. doi:
      10.1097/ACM.0000000000003682.


PMID- 32889609
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1534-6285 (Electronic)
IS  - 1527-2737 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Sep 5
TI  - Performing Medical Education Research in Urology: Challenges and Opportunities.
PG  - 45
LID - 10.1007/s11934-020-00997-w [doi]
AB  - PURPOSE OF REVIEW: The Accreditation Council for Graduate Medical Education
      (ACGME) mandates educating resident physicians in evidence-based medicine (EBM)
      as a core program requirement. However, despite the significant emphasis placed
      on EBM, graduate medical education is far from evidence-based, and urology is a
      specialty where medical education research (MER) is particularly sparse. We want 
      to articulate the challenges and opportunities with performing meaningful medical
      education research in urology training programs. RECENT FINDINGS: Some studies
      suggest that the rigor of MER could be much stronger. The nature of GME requires 
      researchers to use alternative study designs. Further, the unique role of
      residents as both learner and study subject and the dual role of faculty as
      researcher and educator pose challenges to carrying out research. There is a
      tremendous opportunity for improvement and innovation in both quality and
      efficiency of urology resident education. Rigorous MER is required to advance
      this opportunity, and the fundamental key is development of mentors and
      collaboration.
FAU - Yong, Courtney
AU  - Yong C
AD  - Department of Urology, University of Iowa, 3 Roy Carver Pavilion, 200 Hawkins
      Drive, Iowa City, IA, 52242-1089, USA.
FAU - Brown, James A
AU  - Brown JA
AD  - Department of Urology, University of Iowa, 3 Roy Carver Pavilion, 200 Hawkins
      Drive, Iowa City, IA, 52242-1089, USA.
FAU - Takacs, Elizabeth B
AU  - Takacs EB
AUID- ORCID: http://orcid.org/0000-0003-2378-7806
AD  - Department of Urology, University of Iowa, 3 Roy Carver Pavilion, 200 Hawkins
      Drive, Iowa City, IA, 52242-1089, USA. elizabeth-takacs@uiowa.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200905
PL  - United States
TA  - Curr Urol Rep
JT  - Current urology reports
JID - 100900943
SB  - IM
MH  - Accreditation/*standards
MH  - Biomedical Research/*organization & administration/standards
MH  - Education, Medical, Graduate/*methods/standards
MH  - Humans
MH  - Internship and Residency/*organization & administration/standards
MH  - Mentors
MH  - Urology/*education
OTO - NOTNLM
OT  - Challenges
OT  - Ethics
OT  - Graduate medical education
OT  - Mentorship
OT  - Opportunities
OT  - Scholarship
EDAT- 2020/09/06 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/09/05 12:32
PHST- 2020/09/05 12:32 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1007/s11934-020-00997-w [doi]
AID - 10.1007/s11934-020-00997-w [pii]
PST - epublish
SO  - Curr Urol Rep. 2020 Sep 5;21(11):45. doi: 10.1007/s11934-020-00997-w.


PMID- 32889504
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 264
DP  - 2020 Nov
TI  - How are frames generated? Insights from the industry lobby against the sugar tax 
      in Ireland.
PG  - 113215
LID - S0277-9536(20)30434-2 [pii]
LID - 10.1016/j.socscimed.2020.113215 [doi]
AB  - There is a causal link between the consumption of ultra-processed foods and a
      range of non-communicable diseases (NCDs) such as obesity, type 2 diabetes and
      cancers. Despite this, no country in the world has reduced its obesity levels
      because the factors that drive obesity continue unchanged (Swinburn et al.,
      2019). One systemic driver is corporate influence on the public policy process.
      The world's largest food and beverage manufacturers engage public relations firms
      to create a narrative which speaks of corporate cooperation with public health
      policy, while simultaneously influencing policy making in ways that are favorable
      to industry. We sought to examine framing as a key strategy in the corporate
      political activity of food industry actors attempting to resist the introduction 
      of a public health policy. Specifically, we analyzed industry submissions for an 
      Irish government consultation for the proposed introduction of a sugar sweetened 
      beverage (SSB) tax in 2018. We describe how a food product like sugar is framed
      positively by corporate actors who rely on it as their principal ingredient.
      Sugar is a good focus from a framing perspective because it is currently
      undergoing recalibration in the public's imagination - from a benign, nourishing 
      treat in its heyday to a dangerous 'substance' that can contribute to premature
      mortality. Framing is already well established as a corporate political activity 
      (CPA) to influence public policy (Shelton et al., 2017; Nixon et al., 2015;
      Darmon et al., 2008). Our research expands this understanding by uncovering four 
      underlying mechanisms used to generate frames - dichotomizing, contesting,
      equating and cropping. Recognizing these mechanisms could help policy makers,
      public health professionals and business ethicists to deconstruct any given frame
      that becomes dominant in corporate discourse, such as 'personal responsibility', 
      'inadequate exercise', 'freedom' and so on. These mechanisms may also apply to
      other industries such as alcohol, fossil fuels and tobacco, where hazards from
      interference in public health strategies are a concern.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Campbell, Norah
AU  - Campbell N
AD  - Trinity Business School, Trinity College, Dublin, 2, Ireland. Electronic address:
      norah.campbell@tcd.ie.
FAU - Mialon, Melissa
AU  - Mialon M
AD  - Faculty of Public Health, University of Sao Paulo, Sao Paulo, Brazil.
FAU - Reilly, Kathryn
AU  - Reilly K
AD  - Irish Heart Foundation, Dublin, 2, Ireland.
FAU - Browne, Sarah
AU  - Browne S
AD  - Trinity Business School, Trinity College, Dublin, 2, Ireland.
FAU - Finucane, Francis M
AU  - Finucane FM
AD  - Bariatric Medicine Service, Centre of Diabetes, Endocrinology and Metabolism,
      Galway University Hospitals and HRB Clinical Research Facility, Galway, Ireland; 
      Department of Medicine, National University of Ireland Galway, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200815
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
RN  - 0 (Sugars)
SB  - IM
MH  - *Diabetes Mellitus, Type 2
MH  - Food Industry
MH  - Humans
MH  - Ireland
MH  - Lobbying
MH  - *Sugars
MH  - Taxes
OTO - NOTNLM
OT  - *Corporate political activity
OT  - *Framing
OT  - *Health related food tax
OT  - *Sugar sweetened beverages
EDAT- 2020/09/06 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/05 12:31
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/05 12:31 [entrez]
AID - S0277-9536(20)30434-2 [pii]
AID - 10.1016/j.socscimed.2020.113215 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Nov;264:113215. doi: 10.1016/j.socscimed.2020.113215. Epub 2020
      Aug 15.


PMID- 32889037
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20210710
IS  - 1873-6513 (Electronic)
IS  - 0885-3924 (Linking)
VI  - 60
IP  - 5
DP  - 2020 Nov
TI  - Will You Hear Me? Have You Heard Me? Do You See Me? Adding Cultural Humility to
      Resource Allocation and Priority Setting Discussions in the Care of African
      American Patients With COVID-19.
PG  - e11-e14
LID - S0885-3924(20)30723-5 [pii]
LID - 10.1016/j.jpainsymman.2020.08.036 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has refocused our attention on
      health care disparities affecting patients of color, with a growing body of
      literature focused on the etiology of these disparities and strategies to
      eliminate their effects. In considering the unique impact COVID-19 is having on
      African American communities, added measure must be given to ensure for
      sensitivity, empathy, and supportive guidance in medical decision making among
      African American patients faced with critical illness secondary to COVID-19. In
      this article, we explore the applications of cultural humility over cultural
      competency in optimizing the care we provide to African American patients faced
      with critical health care decisions during this pandemic. In turn, we charge one 
      another as health care providers to consider how ethical principles and guidance 
      can be applied to honor African American patients' unique stories and
      experiences.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Johnson, Khaliah A
AU  - Johnson KA
AD  - Department of Pediatrics, Emory University, Atlanta, Georgia, USA; Pediatric
      Palliative Care, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
      Electronic address: Khaliah.Johnson@choa.org.
FAU - Quest, Tammie
AU  - Quest T
AD  - Department of Family and Preventative Medicine, Emory University, Atlanta,
      Georgia, USA.
FAU - Curseen, Kimberly
AU  - Curseen K
AD  - Palliative Care, Emory University Hospital, Atlanta, Georgia, USA.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - United States
TA  - J Pain Symptom Manage
JT  - Journal of pain and symptom management
JID - 8605836
SB  - IM
MH  - *African Americans
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - *Cultural Competency
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - *Resource Allocation
PMC - PMC7462785
OTO - NOTNLM
OT  - COVID-19
OT  - communication
OT  - diversity and inclusion
OT  - health disparities
OT  - palliative care
OT  - resource allocation
EDAT- 2020/09/06 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/09/05 12:20
PHST- 2020/05/15 00:00 [received]
PHST- 2020/08/15 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/09/05 12:20 [entrez]
AID - S0885-3924(20)30723-5 [pii]
AID - 10.1016/j.jpainsymman.2020.08.036 [doi]
PST - ppublish
SO  - J Pain Symptom Manage. 2020 Nov;60(5):e11-e14. doi:
      10.1016/j.jpainsymman.2020.08.036. Epub 2020 Sep 2.


PMID- 32888809
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1424-3911 (Electronic)
IS  - 1424-3903 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Oct
TI  - Pancreatic perfusion imaging method that reduces radiation dose and maintains
      image quality by combining volumetric perfusion CT with multiphasic contrast
      enhanced-CT.
PG  - 1406-1412
LID - S1424-3903(20)30659-1 [pii]
LID - 10.1016/j.pan.2020.08.010 [doi]
AB  - OBJECTIVES: The aim of this study is to propose and evaluate a new method of
      volumetric perfusion computed tomography (PCT) incorporated into pancreatic
      multiphasic contrast enhanced (CE)-CT in the clinical setting. METHODS: In this
      ethically approved study, PCT was incorporated into our existing scanning
      protocol in 17 patients and effective doses related to PCT were evaluated. CT
      values and signal-to-noise ratio (SNR) of anatomical structure were compared in
      diagnostic images that were acquired using 320-detector volumetric scan mode and 
      64-detector helical scan mode. In addition, focal lesion depiction was
      qualitatively assessed in the two groups. Perfusion parameters in normal pancreas
      were measured by two radiologists and the interobserver-reliability was assessed.
      RESULTS: The effective dose of PCT was 5.1 +/- 0.3 mSv. The actual effective dose
      (AED) including the dose used in volumetric scans for diagnostic imaging was 22.8
      +/- 5.3 mSv and the putative effective dose (PED) was 21.9 +/- 9.1 mSv on
      average. There was no significant difference between AED and PED (p = 0.404).
      Compared with conventional helical scans, volumetric scans did not decrease CT
      values or SNR, but rather significantly increased those of the aorta in the
      arterial phase. Both groups had acceptable qualitatively assessed image quality
      with no significant difference in the depiction of each structure. There was
      almost perfect interobserver agreement in the measurement of perfusion parameters
      (mean ICCs > 0.9). CONCLUSIONS: Our scanning protocol for pancreatic perfusion CT
      provides high-quality images while requiring lower radiation doses than
      conventional methods.
CI  - Copyright (c) 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.
FAU - Konno, Yoshihiro
AU  - Konno Y
AD  - Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University,
      2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan. Electronic address:
      hiro.konno@med.id.yamagata-u.ac.jp.
FAU - Hiraka, Toshitada
AU  - Hiraka T
AD  - Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University,
      2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan.
FAU - Kanoto, Masafumi
AU  - Kanoto M
AD  - Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University,
      2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan.
FAU - Sato, Toshimitsu
AU  - Sato T
AD  - Department of Radiology, Yamagata University Hospital, Japan.
FAU - Tsunoda, Michihiko
AU  - Tsunoda M
AD  - Department of Gastroenterology, Faculty of Medicine, Yamagata University, Japan.
FAU - Ishizawa, Tetsuya
AU  - Ishizawa T
AD  - Department of Gastroenterology, Faculty of Medicine, Yamagata University, Japan.
FAU - Matsuda, Akiko
AU  - Matsuda A
AD  - Department of Gastroenterology, Faculty of Medicine, Yamagata University, Japan.
FAU - Makino, Naohiko
AU  - Makino N
AD  - Department of Gastroenterology, Faculty of Medicine, Yamagata University, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - Switzerland
TA  - Pancreatology
JT  - Pancreatology : official journal of the International Association of
      Pancreatology (IAP) ... [et al.]
JID - 100966936
RN  - 0 (Contrast Media)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aorta/diagnostic imaging
MH  - *Contrast Media
MH  - Female
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Male
MH  - Middle Aged
MH  - Observer Variation
MH  - Pancreas/*diagnostic imaging
MH  - Pancreatic Neoplasms/diagnostic imaging
MH  - Perfusion Imaging/*methods
MH  - Radiation Dosage
MH  - Radiation Injuries/*prevention & control
MH  - Reproducibility of Results
MH  - Signal-To-Noise Ratio
MH  - Tomography, X-Ray Computed/*methods
OTO - NOTNLM
OT  - Broad clinical use
OT  - Diagnostic imaging
OT  - Pancreatic cancer
OT  - Single examination
EDAT- 2020/09/06 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/09/05 12:19
PHST- 2020/02/16 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/09/05 12:19 [entrez]
AID - S1424-3903(20)30659-1 [pii]
AID - 10.1016/j.pan.2020.08.010 [doi]
PST - ppublish
SO  - Pancreatology. 2020 Oct;20(7):1406-1412. doi: 10.1016/j.pan.2020.08.010. Epub
      2020 Aug 27.


PMID- 32888437
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 1531-6564 (Electronic)
IS  - 0363-5023 (Linking)
VI  - 45
IP  - 9
DP  - 2020 Sep
TI  - Emergency Hand and Reconstructive Microsurgery in the COVID-19-Positive Patient.
PG  - 869-875
LID - S0363-5023(20)30410-X [pii]
LID - 10.1016/j.jhsa.2020.07.013 [doi]
AB  - The case spectrum in hand surgery is one of extremes-purely elective day surgery 
      cases under local anesthesia to mangling limb injuries that require immediate,
      and frequently, lengthy, surgery. Despite the cancellation of most elective
      orthopedic and plastic surgical procedures, hand surgeons around the world
      continue to see a steady stream of limb-threatening cases such as severe trauma
      and infections that require emergent surgical care. With the increase in
      community-spread, an increasing number of COVID-19-infected patients may be
      asymptomatic or have mild, nonspecific or atypical symptoms. Some of them may
      already have an ongoing, severe infection. The time-sensitive nature of some of
      these cases means that hand surgeons may need to operate urgently on patients who
      may be suspected of COVID-19 infections, often before confirmatory test results
      are available. General guidelines for perioperative care of the COVID-19-positive
      patient have been published. However, our practices differ from those of general 
      orthopedic and plastic surgery, primarily because of the focus on trauma. This
      article discusses the perioperative and technical considerations that are
      essential to manage the COVID-19 patient requiring emergency care, without
      compromising clinical outcomes and while ensuring the safety of the attending
      staff.
CI  - Copyright (c) 2020 American Society for Surgery of the Hand. Published by
      Elsevier Inc. All rights reserved.
FAU - Das De, Soumen
AU  - Das De S
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore. Electronic address: soumendasde@gmail.com.
FAU - Liang, Zhen Chang
AU  - Liang ZC
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Cheah, Andre Eu-Jin
AU  - Cheah AE
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Puhaindran, Mark Edward
AU  - Puhaindran ME
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Lee, Ellen Yutan
AU  - Lee EY
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Lim, Aymeric Yu Tang
AU  - Lim AYT
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Chong, Alphonsus Khin Sze
AU  - Chong AKS
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200729
PL  - United States
TA  - J Hand Surg Am
JT  - The Journal of hand surgery
JID - 7609631
SB  - IM
MH  - Adult
MH  - Amputation, Traumatic/*surgery
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Emergency Treatment
MH  - Finger Injuries/*surgery
MH  - Humans
MH  - Male
MH  - Microsurgery/*methods
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Reconstructive Surgical Procedures/*methods
MH  - SARS-CoV-2
PMC - PMC7388858
OTO - NOTNLM
OT  - *COVID-19 pandemic
OT  - *emergency hand and reconstructive microsurgery
OT  - *ethics and decision making
OT  - *perioperative considerations
OT  - *technical modifications
EDAT- 2020/09/06 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/05 12:14
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/25 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/09/05 12:14 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - S0363-5023(20)30410-X [pii]
AID - 10.1016/j.jhsa.2020.07.013 [doi]
PST - ppublish
SO  - J Hand Surg Am. 2020 Sep;45(9):869-875. doi: 10.1016/j.jhsa.2020.07.013. Epub
      2020 Jul 29.


PMID- 32888139
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 184
IP  - 3
DP  - 2020 Dec
TI  - Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided
      biopsy: can we estimate upgrade on surgical pathology?
PG  - 881-890
LID - 10.1007/s10549-020-05893-y [doi]
AB  - PURPOSE: The goal of this study is to evaluate the frequency and imaging features
      of lobular neoplasia (LN) diagnosed on MRI-guided biopsy, determine the upgrade
      rate to malignancy, and assess for any features that may be associated with an
      upgrade on surgical excision. MATERIALS AND METHODS: Research ethical board
      approved the review of consecutive patients with MRI-detected LN between January 
      2009 and December 2018 with differentiation between pure LN and LN with
      associated other high-risk lesions. The final outcome was determined by final
      pathology results from surgical excision or 24 months of follow-up. Appropriate
      statistical tests were used. RESULTS: Out of 1250 MRI-guided biopsies performed, 
      76 lesions (6%) fulfilled the inclusion criteria and formed the study cohort. Of 
      the 76 lesions, 54 (71%) were pure LN while the rest had coexistent high-risk
      lesion. Non-mass enhancement (NME) was the most common lesion type (62, 82%).
      Fifty-nine lesions (78%) were surgically excised, the other 17 had benign
      follow-up. Overall, 8 lesions (11%) were upgraded to malignancy on final
      pathology. Malignant outcome was associated with larger lesion size (5.5 versus
      1.9 cm, P < 0.001) and a clumped NME pattern (75% versus 24%, P = 0.006). Lesion 
      size and clumped NME remained significantly associated with upgrade on
      sub-analysis of the pure LN group. CONCLUSION: Larger lesion size and clumped NME
      are imaging findings associated with upgrade of LN diagnosed by MRI-guided
      biopsy. This may influence patient management in this clinical setting.
      Additional larger studies are needed to consolidate our results and to
      potentially detect additional factors associated with upgrade.
FAU - Amitai, Yoav
AU  - Amitai Y
AD  - Joint Department of Medical Imaging, University Health Network, Sinai Health
      System, Women's College Hospital, University of Toronto, 610 University Avenue,
      Toronto, ON, M5G 2M9, Canada.
FAU - Menes, Tehillah S
AU  - Menes TS
AD  - Department of Surgery, Tel Aviv Sourasky Medical Center, Sackler School of
      Medicine, Tel Aviv University, 6 Weizmann St., 64239, Tel Aviv, Israel.
FAU - Scaranelo, Anabel
AU  - Scaranelo A
AD  - Joint Department of Medical Imaging, University Health Network, Sinai Health
      System, Women's College Hospital, University of Toronto, 610 University Avenue,
      Toronto, ON, M5G 2M9, Canada.
FAU - Fleming, Rachel
AU  - Fleming R
AD  - Joint Department of Medical Imaging, University Health Network, Sinai Health
      System, Women's College Hospital, University of Toronto, 610 University Avenue,
      Toronto, ON, M5G 2M9, Canada.
FAU - Kulkarni, Supriya
AU  - Kulkarni S
AD  - Joint Department of Medical Imaging, University Health Network, Sinai Health
      System, Women's College Hospital, University of Toronto, 610 University Avenue,
      Toronto, ON, M5G 2M9, Canada.
FAU - Ghai, Sandeep
AU  - Ghai S
AD  - Joint Department of Medical Imaging, University Health Network, Sinai Health
      System, Women's College Hospital, University of Toronto, 610 University Avenue,
      Toronto, ON, M5G 2M9, Canada.
FAU - Cil, Tulin
AU  - Cil T
AD  - University Health Network, Department of Surgical Oncology, University of
      Toronto, 3-130, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.
FAU - Done, Susan
AU  - Done S
AD  - Laboratory Medicine Program, University Health Network, Toronto General Hospital 
      Site, University of Toronto, 200 Elizabeth Street, 11th Floor Eaton Wing,
      Toronto, ON, M5G 2C4, Canada.
FAU - Freitas, Vivianne
AU  - Freitas V
AUID- ORCID: http://orcid.org/0000-0003-2563-0861
AD  - Joint Department of Medical Imaging, University Health Network, Sinai Health
      System, Women's College Hospital, University of Toronto, 610 University Avenue,
      Toronto, ON, M5G 2M9, Canada. vivianne.freitas@uhn.ca.
LA  - eng
PT  - Journal Article
DEP - 20200904
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
MH  - Biopsy, Large-Core Needle
MH  - *Breast Neoplasms/diagnostic imaging/epidemiology
MH  - *Carcinoma, Lobular/diagnostic imaging/surgery
MH  - Female
MH  - Humans
MH  - Image-Guided Biopsy
MH  - Magnetic Resonance Imaging
MH  - *Pathology, Surgical
MH  - *Precancerous Conditions
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Breast MRI
OT  - Breast magnetic resonance imaging
OT  - Breast neoplasm
OT  - Invasive ductal carcinoma
OT  - Lobular neoplasia
OT  - Upgrade
EDAT- 2020/09/06 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/09/05 05:20
PHST- 2020/06/26 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/05 05:20 [entrez]
AID - 10.1007/s10549-020-05893-y [doi]
AID - 10.1007/s10549-020-05893-y [pii]
PST - ppublish
SO  - Breast Cancer Res Treat. 2020 Dec;184(3):881-890. doi:
      10.1007/s10549-020-05893-y. Epub 2020 Sep 4.


PMID- 32888112
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220218
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 15
IP  - 8
DP  - 2020 Nov
TI  - Outpatient management or hospitalization of patients with proven or suspected
      SARS-CoV-2 infection: the HOME-CoV rule.
PG  - 1525-1531
LID - 10.1007/s11739-020-02483-0 [doi]
AB  - In the context of the COVID-19 pandemic and overloaded hospitals, a central issue
      is the need to define reliable and consensual criteria for hospitalization or
      outpatient management in mild cases of COVID-19. Our aim was to define an
      easy-to-use clinical rule aiming to help emergency physicians in hospitalization 
      or outpatient management decision-making for patients with suspected or confirmed
      SARS-CoV-2 infection (the HOME-CoV rule). The Delphi method was used to reach a
      consensus of a large panel of 51 experts: emergency physicians, geriatricians,
      infectious disease specialists, and ethical consultants. A preliminary list of
      eligible criteria was compiled based on a literature review. Four rounds of
      anonymized expert consultations were performed. The experts were asked to score
      each item as relevant, possibly relevant and non-relevant, as major or minor, and
      to choose the cut-off. They were also able make suggestions and remarks. Eight
      criteria constituting the HOME-CoV were selected: six correspond to the severity 
      of clinical signs, one to the clinical course (clinically significant worsening
      within the last 24 h), and the last corresponds to the association of a severe
      comorbidity and an inadequate living context. Hospitalization is deemed necessary
      if a patient meets one or more of the criteria. In the end, 94.4% of the experts 
      agreed with the defined rule. Thanks to the Delphi method, an absolute consensus 
      was obtained of a large panel of experts on the HOME-CoV rule, a decision-making 
      support mechanism for clinicians to target patients with suspected or confirmed
      COVID-19 requiring hospitalization.Trial registration: NCT04338841.
FAU - Douillet, Delphine
AU  - Douillet D
AUID- ORCID: http://orcid.org/0000-0002-6458-2965
AD  - Emergency Department, CHU Angers, 4 rue Larrey, 49100, Angers, France.
      Delphine.Douillet@chu-angers.fr.
AD  - UMR (CNRS 6015-INSERM 1083) et Institut MitoVasc, Universite d'Angers, Angers,
      France. Delphine.Douillet@chu-angers.fr.
FAU - Mahieu, Rafael
AU  - Mahieu R
AD  - Department of Infectious Disease, CHU Angers, Universite d'Angers, Angers,
      France.
AD  - CRCINA, Inserm, Universite de Nantes, Nantes, France.
FAU - Boiveau, Violette
AU  - Boiveau V
AD  - Emergency Department, CHU Angers, 4 rue Larrey, 49100, Angers, France.
FAU - Vandamme, Yves-Marie
AU  - Vandamme YM
AD  - Department of Infectious Disease, CHU Angers, Universite d'Angers, Angers,
      France.
FAU - Armand, Aurore
AU  - Armand A
AD  - Emergency Department, CHU Angers, 4 rue Larrey, 49100, Angers, France.
FAU - Morin, Francois
AU  - Morin F
AD  - Emergency Department, CHU Angers, 4 rue Larrey, 49100, Angers, France.
FAU - Savary, Dominique
AU  - Savary D
AD  - Emergency Department, CHU Angers, 4 rue Larrey, 49100, Angers, France.
AD  - EHESP, Irset, Inserm, UMR S1085, CAPTV CDC, Universite Rennes, Rennes, France.
FAU - Dubee, Vincent
AU  - Dubee V
AD  - Department of Infectious Disease, CHU Angers, Universite d'Angers, Angers,
      France.
AD  - CRCINA, Inserm, Universite de Nantes, Nantes, France.
FAU - Annweiler, Cedric
AU  - Annweiler C
AD  - Geriatric Department, CHU Angers, Angers, France.
AD  - Department of Medical Biophysics, Robarts Research Institute, Schulich School of 
      Medicine and Dentistry, the University of Western Ontario, London, ON, Canada.
FAU - Roy, Pierre-Marie
AU  - Roy PM
AD  - Emergency Department, CHU Angers, 4 rue Larrey, 49100, Angers, France.
AD  - UMR (CNRS 6015-INSERM 1083) et Institut MitoVasc, Universite d'Angers, Angers,
      France.
CN  - HOME-CoV expert group
LA  - eng
SI  - ClinicalTrials.gov/NCT04338841
PT  - Journal Article
DEP - 20200904
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
SB  - IM
MH  - Aged
MH  - Ambulatory Care/*methods/trends
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Delphi Technique
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outpatients/statistics & numerical data
MH  - Pandemics/*statistics & numerical data
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Risk Factors
MH  - Surveys and Questionnaires
PMC - PMC7550768
OTO - NOTNLM
OT  - COVID-19
OT  - Delphi method
OT  - Expert consensus
OT  - Hospitalization
OT  - Outpatient
OT  - Rule-based decision-making
IR  - Andrianjafy H
FIR - Andrianjafy, H
IR  - Annweiler C
FIR - Annweiler, C
IR  - Armand A
FIR - Armand, A
IR  - Baudin L
FIR - Baudin, L
IR  - Bekhir L
FIR - Bekhir, L
IR  - Benezit F
FIR - Benezit, F
IR  - Benhammouda K
FIR - Benhammouda, K
IR  - Bissolokele P
FIR - Bissolokele, P
IR  - Blanchi S
FIR - Blanchi, S
IR  - Boiveau V
FIR - Boiveau, V
IR  - Bouiller K
FIR - Bouiller, K
IR  - Bouillon JB
FIR - Bouillon, J-B
IR  - Brice C
FIR - Brice, C
IR  - Brunel AS
FIR - Brunel, A-S
IR  - Cayeux C
FIR - Cayeux, C
IR  - Cazenave B
FIR - Cazenave, B
IR  - Chauvin A
FIR - Chauvin, A
IR  - Claessens YE
FIR - Claessens, Y-E
IR  - Cormier H
FIR - Cormier, H
IR  - Coustilleres F
FIR - Coustilleres, F
IR  - Crochette N
FIR - Crochette, N
IR  - Acqua DD
FIR - Acqua, D Dall
IR  - Douillet D
FIR - Douillet, D
IR  - Dupriez F
FIR - Dupriez, F
IR  - Friou E
FIR - Friou, E
IR  - Gangloff C
FIR - Gangloff, C
IR  - Gennai S
FIR - Gennai, S
IR  - Joly LM
FIR - Joly, L-M
IR  - Karam HH
FIR - Karam, H-H
IR  - Le Bot A
FIR - Le Bot, A
IR  - Lemaignen A
FIR - Lemaignen, A
IR  - Leroy A
FIR - Leroy, A
IR  - Mahieu R
FIR - Mahieu, R
IR  - Marchant N
FIR - Marchant, N
IR  - Marjanovic N
FIR - Marjanovic, N
IR  - Montassier E
FIR - Montassier, E
IR  - Morin F
FIR - Morin, F
IR  - Pasquier J
FIR - Pasquier, J
IR  - Patrat-Delon S
FIR - Patrat-Delon, S
IR  - Penaloza A
FIR - Penaloza, A
IR  - Plantefeve G
FIR - Plantefeve, G
IR  - Roy PM
FIR - Roy, P-M
IR  - Sanderink D
FIR - Sanderink, D
IR  - Savary D
FIR - Savary, D
IR  - Schmidt J
FIR - Schmidt, J
IR  - Schotte T
FIR - Schotte, T
IR  - Soulie C
FIR - Soulie, C
IR  - Tchangai-Kao S
FIR - Tchangai-Kao, S
IR  - Thiebaud PC
FIR - Thiebaud, P-C
IR  - Timsit E
FIR - Timsit, E
IR  - Trabattoni E
FIR - Trabattoni, E
IR  - Turmel JM
FIR - Turmel, J-M
IR  - Vandamme YM
FIR - Vandamme, Y-M
IR  - Violeau M
FIR - Violeau, M
IR  - Yombi JC
FIR - Yombi, J-C
EDAT- 2020/09/06 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/09/05 05:20
PHST- 2020/05/06 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PHST- 2020/09/05 05:20 [entrez]
AID - 10.1007/s11739-020-02483-0 [doi]
AID - 10.1007/s11739-020-02483-0 [pii]
PST - ppublish
SO  - Intern Emerg Med. 2020 Nov;15(8):1525-1531. doi: 10.1007/s11739-020-02483-0. Epub
      2020 Sep 4.


PMID- 32887776
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 95
IP  - 20
DP  - 2020 Nov 17
TI  - Central nervous system involvement in Erdheim-Chester disease: An observational
      cohort study.
PG  - e2746-e2754
LID - 10.1212/WNL.0000000000010748 [doi]
AB  - OBJECTIVE: CNS involvement in Erdheim-Chester disease (ECD) leads to substantial 
      morbidity and mortality. To assess CNS manifestations in a French cohort of 253
      patients with ECD, we determined clinical characteristics and outcomes, including
      those under targeted therapies. METHODS: This was a retrospective longitudinal
      study. CNS manifestations were determined by clinical examination and brain or
      spine MRI. Targeted therapy efficacy was assessed using global assessment from a 
      physician and a radiologist. The study was approved by the ethics committee
      Comite de Protection des Personnes Ile de France III. RESULTS: Ninety-seven of
      253 patients (38%) with ECD had CNS involvement. CNS involvement was
      significantly associated with a younger age at diagnosis (mean 55.5 years) and at
      symptom onset (mean 50.5 years), as well as with the presence of the BRAF (V600E)
      mutation (in 77% of cases), xanthelasma (34%), and diabetes insipidus (36%).
      Median survival among patients with CNS involvement was significantly lower than 
      that of patients with ECD without CNS involvement (124 months vs 146 months, p = 
      0.03). Seventy-four CNS MRIs were centrally reviewed, which showed 3 patterns:
      tumoral in 66%, pseudo-degenerative in 50%, and vascular in 18%. Targeted therapy
      (BRAF or MEK inhibitors) was associated with improved symptoms in 43% of patients
      and MRI improvement in 45%. CONCLUSIONS: CNS manifestations are typically
      associated with poor prognosis in patients with ECD. Three distinct patterns can 
      be recognized: tumoral, pseudodegenerative, and vascular. CLASSIFICATION OF
      EVIDENCE: This study provides Class III evidence that targeted therapy leads to
      clinical or imaging improvement in almost 50% of patients.
CI  - (c) 2020 American Academy of Neurology.
FAU - Cohen Aubart, Fleur
AU  - Cohen Aubart F
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Idbaih, Ahmed
AU  - Idbaih A
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Galanaud, Damien
AU  - Galanaud D
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Law-Ye, Bruno
AU  - Law-Ye B
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Emile, Jean-Francois
AU  - Emile JF
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Charlotte, Frederic
AU  - Charlotte F
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Donadieu, Jean
AU  - Donadieu J
AUID- ORCID: 0000-0002-4485-146X
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Maksud, Philippe
AU  - Maksud P
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Seilhean, Danielle
AU  - Seilhean D
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Amoura, Zahir
AU  - Amoura Z
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Hoang-Xuan, Khe
AU  - Hoang-Xuan K
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France.
FAU - Haroche, Julien
AU  - Haroche J
AD  - From Service de Medecine Interne 2, Centre National de Reference Maladies
      Systemiques Rares et Histiocytoses (F.C.A., Z.A., J.H.), Service de
      Neuroradiologie (D.G., B.L.-Y.), Service d'Anatomopathologie (F.C.), Service de
      Medecine Nucleaire (P.M.), Service de Neuropathologie (D.S.), Hopital
      Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Sorbonne Universite;
      Service de Neurologie 2-Mazarin (A.I., K.H.-Z.), Inserm, CNRS, UMR S 1127,
      Institut du Cerveau et de la Moelle Epiniere, ICM, AP-HP, Hopitaux Universitaires
      La Pitie Salpetriere-Charles Foix, Sorbonne Universite, Paris; Departement de
      Pathologie (J.-F.E.), EA4340, Universite Versailles-Saint Quentin, Assistance
      Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne; and Service
      d'Hematologie Pediatrique, Centre de Reference National Histiocytoses (J.D.),
      Hopital Trousseau, Sorbonne Universite, Paris, France. fleur.cohen@aphp.fr
      julien.haroche@aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200904
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Atrophy/pathology
MH  - Brain Stem/diagnostic imaging/*pathology
MH  - Cerebellum/diagnostic imaging/pathology
MH  - Cerebral Cortex/diagnostic imaging/*pathology
MH  - Diabetes Insipidus/etiology
MH  - Erdheim-Chester Disease/complications/*drug therapy/genetics/*pathology
MH  - Female
MH  - France
MH  - Humans
MH  - Longitudinal Studies
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors/genetics
MH  - Retrospective Studies
MH  - Spinal Cord/diagnostic imaging/*pathology
MH  - Treatment Outcome
EDAT- 2020/09/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/05 05:16
PHST- 2019/11/17 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/05 05:16 [entrez]
AID - WNL.0000000000010748 [pii]
AID - 10.1212/WNL.0000000000010748 [doi]
PST - ppublish
SO  - Neurology. 2020 Nov 17;95(20):e2746-e2754. doi: 10.1212/WNL.0000000000010748.
      Epub 2020 Sep 4.


PMID- 32887493
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 17
DP  - 2020 Sep 2
TI  - Human Cell Modeling for Cardiovascular Diseases.
LID - E6388 [pii]
LID - 10.3390/ijms21176388 [doi]
AB  - The availability of appropriate and reliable in vitro cell models recapitulating 
      human cardiovascular diseases has been the aim of numerous researchers, in order 
      to retrace pathologic phenotypes, elucidate molecular mechanisms, and discover
      therapies using simple and reproducible techniques. In the past years, several
      human cell types have been utilized for these goals, including heterologous
      systems, cardiovascular and non-cardiovascular primary cells, and embryonic stem 
      cells. The introduction of induced pluripotent stem cells and their
      differentiation potential brought new prospects for large-scale cardiovascular
      experiments, bypassing ethical concerns of embryonic stem cells and providing an 
      advanced tool for disease modeling, diagnosis, and therapy. Each model has its
      advantages and disadvantages in terms of accessibility, maintenance, throughput, 
      physiological relevance, recapitulation of the disease. A higher level of
      complexity in diseases modeling has been achieved with multicellular co-cultures.
      Furthermore, the important progresses reached by bioengineering during the last
      years, together with the opportunities given by pluripotent stem cells, have
      allowed the generation of increasingly advanced in vitro three-dimensional
      tissue-like constructs mimicking in vivo physiology. This review provides an
      overview of the main cell models used in cardiovascular research, highlighting
      the pros and cons of each, and describing examples of practical applications in
      disease modeling.
FAU - Lippi, Melania
AU  - Lippi M
AD  - Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino
      IRCCS, 20138 Milan, Italy.
FAU - Stadiotti, Ilaria
AU  - Stadiotti I
AD  - Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino
      IRCCS, 20138 Milan, Italy.
FAU - Pompilio, Giulio
AU  - Pompilio G
AD  - Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino
      IRCCS, 20138 Milan, Italy.
AD  - Department of Clinical Sciences and Community Health, Universita degli Studi di
      Milano, 20122 Milan, Italy.
FAU - Sommariva, Elena
AU  - Sommariva E
AD  - Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino
      IRCCS, 20138 Milan, Italy.
LA  - eng
GR  - GR-2016-02362024/Agenzia Italiana del Farmaco, Ministero della Salute
PT  - Journal Article
PT  - Review
DEP - 20200902
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - Bioengineering
MH  - Cardiovascular Diseases/*pathology/*therapy
MH  - *Cell Differentiation
MH  - Embryonic Stem Cells/*cytology
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology
MH  - *Models, Biological
PMC - PMC7503257
OTO - NOTNLM
OT  - cardiovascular disease
OT  - co-cultures
OT  - disease modeling
OT  - embryonic stem cells
OT  - engineered 3D tissue
OT  - heterologous system
OT  - human cell model
OT  - human induced pluripotent stem cell
OT  - primary cells
EDAT- 2020/09/06 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/09/05 01:04
PHST- 2020/08/13 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/05 01:04 [entrez]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - ijms21176388 [pii]
AID - 10.3390/ijms21176388 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Sep 2;21(17). pii: ijms21176388. doi: 10.3390/ijms21176388.


PMID- 32887184
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220824
IS  - 2191-0278 (Electronic)
IS  - 0334-0139 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Sep 4
TI  - Key components of successful transition for adolescents born with anorectal
      malformations-a Nordic focus group study.
PG  - 211-218
LID - 10.1515/ijamh-2020-0052 [doi]
AB  - OBJECTIVES: Transitional care for adolescents with congenital malformations, such
      as anorectal malformations (ARM), is described sparsely in the literature and
      referred to as being inadequate. In order to organize future successful
      healthcare structures, knowledge of patient-reported important aspects of
      transition is required. The aim of the study was therefore to explore the needs
      and expectations of transitional- and adult healthcare among adolescents and
      adults born with ARM. METHODS: Two tertiary paediatric surgical centres, in
      collaboration with two tertiary pelvic floor centres, in Sweden and Norway,
      conducted a qualitative study, involving adolescents and adults born with ARM in 
      focus group discussions regarding transitional care. Discussions were analyzed by
      qualitative content analysis. Ethical approval was obtained. RESULTS: Sixteen
      participants (10 women) with a median age of 24 (19-47) years, born with mixed
      subtypes of ARM were included in gender-divided focus groups. Participants
      emphasized a need for improved knowledge of ARM, both among patients and adult
      care providers. Participants identified a need for support with coping strategies
      regarding challenging social- and intimate situations due to impaired bowel
      function. Participants pin-pointed well-functioning communication between the
      patient and the paediatric- and adult care providers as a key factor for a
      successful transitional process. Further, participants emphasized the importance 
      of easy access to specialized adult healthcare when needed, suggested to be
      facilitated by appointed patient navigators. CONCLUSION: Adolescents and adults
      born with ARM identify improved knowledge of ARM, well-functioning communication 
      and easy access to specialized adult care as key components of a successful
      transition.
CI  - (c) 2020 Louise Tofft et al., published by De Gruyter, Berlin/Boston.
FAU - Tofft, Louise
AU  - Tofft L
AUID- ORCID: https://orcid.org/0000-0001-5663-035X
AD  - Department of Paediatric Surgery, Skane University Hospital and Department of
      Clinical Sciences, Paediatrics, Lund University, Lund, Sweden.
FAU - Hoel, Anders Telle
AU  - Hoel AT
AD  - Department of Paediatric Surgery, Oslo University Hospital and University of
      Oslo, Oslo, Norway.
FAU - Hakansson, Carita
AU  - Hakansson C
AD  - Division of Occupational and Environmental Medicine, Lund University, Lund,
      Sweden.
FAU - Zawadzki, Antoni
AU  - Zawadzki A
AD  - Department of Surgery, Pelvic Floor Centre Malmo, Skane University Hospital and
      Lund University, Malmo, Sweden.
FAU - Gjone, Helene
AU  - Gjone H
AD  - Division of Paediatric and Adolescent Medicine, Department of Child and
      Adolescent Mental Health in Hospitals, Oslo University Hospital, Oslo, Norway.
FAU - Oresland, Tom
AU  - Oresland T
AD  - Pelvic Floor Centre, Department of GI Surgery, Akershus University Hospital and
      University of Oslo, Oslo, Norway.
FAU - Bjornland, Kristin
AU  - Bjornland K
AD  - Department of Paediatric Surgery, Oslo University Hospital and University of
      Oslo, Oslo, Norway.
FAU - Stenstrom, Pernilla
AU  - Stenstrom P
AD  - Department of Paediatric Surgery, Skane University Hospital and Department of
      Clinical Sciences, Paediatrics, Lund University, Lund, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200904
PL  - Germany
TA  - Int J Adolesc Med Health
JT  - International journal of adolescent medicine and health
JID - 8506960
SB  - IM
OTO - NOTNLM
OT  - anorectal malformations
OT  - focus groups
OT  - health literacy
OT  - patient involvement
OT  - transition
EDAT- 2020/09/06 06:00
MHDA- 2020/09/06 06:01
CRDT- 2020/09/05 01:03
PHST- 2020/03/18 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2020/09/06 06:01 [medline]
PHST- 2020/09/05 01:03 [entrez]
AID - 10.1515/ijamh-2020-0052 [doi]
AID - /j/ijamh.ahead-of-print/ijamh-2020-0052/ijamh-2020-0052.xml [pii]
PST - epublish
SO  - Int J Adolesc Med Health. 2020 Sep 4;34(4):211-218. doi: 10.1515/ijamh-2020-0052.


PMID- 32886659
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201028
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 14
IP  - 9
DP  - 2020 Sep
TI  - Early immune suppression leads to uncontrolled mite proliferation and potent host
      inflammatory responses in a porcine model of crusted versus ordinary scabies.
PG  - e0008601
LID - 10.1371/journal.pntd.0008601 [doi]
AB  - Scabies is a neglected tropical disease of global significance. Our understanding
      of host-parasite interactions has been limited, particularly in crusted scabies
      (CS), a severe clinical manifestation involving hyper-infestation of Sarcoptes
      scabiei mites. Susceptibility to CS may be associated with immunosuppressive
      conditions but CS has also been seen in cases with no identifiable risk factor or
      immune deficit. Due to ethical and logistical difficulties with undertaking
      research on clinical patients with CS, we adopted a porcine model which parallels
      human clinical manifestations. Transcriptomic analysis using microarrays was used
      to explore scabies pathogenesis, and to identify early events differentiating
      pigs with ordinary (OS) and crusted scabies. Pigs with OS (n = 4), CS (n = 4) and
      non-infested controls (n = 4) were compared at pre-infestation, weeks 1, 2, 4 and
      8 post-infestation. In CS relative to OS, there were numerous differentially
      expressed genes including pro-inflammatory cytokines (IL17A, IL8, IL19, IL20 and 
      OSM) and chemokines involved in immune cell activation and recruitment (CCL20,
      CCL27 and CXCL6). The influence of genes associated with immune regulation
      (CD274/PD-L1 and IL27), immune signalling (TLR2, TLR8) and antigen presentation
      (RFX5, HLA-5 and HLA-DOB) were highlighted in the early host response to CS. We
      observed similarities with gene expression profiles associated with psoriasis and
      atopic dermatitis and confirmed previous observations of Th2/17 pronounced
      responses in CS. This is the first comprehensive study describing transcriptional
      changes associated with the development of CS and significantly, the distinction 
      between OS and CS. This provides a basis for clinical follow-up studies,
      potentially identifying new control strategies for this severely debilitating
      disease.
FAU - Bhat, Sajad A
AU  - Bhat SA
AD  - School of Health & Sport Sciences, University of the Sunshine Coast, Sippy Downs,
      Queensland, Australia.
AD  - Animal and Bioscience Research Department, Teagasc, Grange, Ireland.
FAU - Walton, Shelley F
AU  - Walton SF
AUID- ORCID: 0000-0002-5857-6913
AD  - School of Health & Sport Sciences, University of the Sunshine Coast, Sippy Downs,
      Queensland, Australia.
FAU - Ventura, Tomer
AU  - Ventura T
AD  - Genecology Research Centre, University of the Sunshine Coast, Sippy Downs,
      Queensland, Australia.
FAU - Liu, Xiaosong
AU  - Liu X
AD  - School of Health & Sport Sciences, University of the Sunshine Coast, Sippy Downs,
      Queensland, Australia.
AD  - Cancer Research Institute, The First People's Hospital of Foshan, Foshan,
      Guangdong, China.
FAU - McCarthy, James S
AU  - McCarthy JS
AD  - Infectious Diseases Division, QIMR Berghofer Medical Research Institute,
      Brisbane, Queensland, Australia.
FAU - Burgess, Stewart T G
AU  - Burgess STG
AD  - Diagnostics, Moredun Research Institute, Pentlands Science Park, Bush Loan,
      Edinburgh, United Kingdom.
FAU - Mounsey, Kate E
AU  - Mounsey KE
AUID- ORCID: 0000-0003-0579-9424
AD  - School of Health & Sport Sciences, University of the Sunshine Coast, Sippy Downs,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200904
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Cytokines/genetics/immunology
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation/genetics
MH  - Host-Parasite Interactions/*immunology
MH  - Immunomodulation/immunology
MH  - Sarcoptes scabiei/*immunology
MH  - Scabies/immunology/pathology/*veterinary
MH  - Skin/immunology/parasitology/pathology
MH  - Sus scrofa/*immunology/*parasitology
MH  - Swine
MH  - Swine Diseases/immunology/parasitology
MH  - Th17 Cells/immunology
MH  - Th2 Cells/immunology
MH  - Transcriptome/genetics
PMC - PMC7508399
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/05 06:00
MHDA- 2020/10/29 06:00
CRDT- 2020/09/04 17:10
PHST- 2019/08/28 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
PHST- 2020/09/04 17:10 [entrez]
AID - 10.1371/journal.pntd.0008601 [doi]
AID - PNTD-D-19-01488 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2020 Sep 4;14(9):e0008601. doi: 10.1371/journal.pntd.0008601.
      eCollection 2020 Sep.


PMID- 32886069
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20210727
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 3
DP  - 2020 Sep 4
TI  - Practical and Ethical Concerns in Implementing Enhanced Surveillance Methods to
      Improve Continuity of HIV Care: Qualitative Expert Stakeholder Study.
PG  - e19891
LID - 10.2196/19891 [doi]
AB  - BACKGROUND: Retention in HIV care is critical to maintaining viral suppression
      and preventing further transmission, yet less than 50% of people living with HIV 
      in the United States are engaged in care. All US states have a funding mandate to
      implement Data-to-Care (D2C) programs, which use surveillance data (eg,
      laboratory, Medicaid billing) to identify out-of-care HIV-positive persons and
      relink them to treatment. OBJECTIVE: The purpose of this qualitative study was to
      identify and describe practical and ethical considerations that arise in planning
      for and implementing D2C. METHODS: Via purposive sampling, we recruited 43 expert
      stakeholders-including ethicists, privacy experts, researchers, public health
      personnel, HIV medical providers, legal experts, and community advocates-to
      participate in audio-recorded semistructured interviews to share their
      perspectives on D2C. Interview transcripts were analyzed across a priori and
      inductively derived thematic categories. RESULTS: Stakeholders reported practical
      and ethical concerns in seven key domains: permission and consent, government
      assistance versus overreach, privacy and confidentiality, stigma, HIV
      exceptionalism, criminalization, and data integrity and sharing. CONCLUSIONS:
      Participants expressed a great deal of support for D2C, yet also stressed the
      role of public trust and transparency in addressing the practical and ethical
      concerns they identified.
CI  - (c)Mara Buchbinder, Colleen Blue, Stuart Rennie, Eric Juengst, Lauren
      Brinkley-Rubinstein, David L. Rosen. Originally published in JMIR Public Health
      and Surveillance (http://publichealth.jmir.org), 04.09.2020.
FAU - Buchbinder, Mara
AU  - Buchbinder M
AUID- ORCID: 0000-0002-2319-662X
AD  - Department of Social Medicine, Center for Bioethics, University of North Carolina
      at Chapel Hill, Chapel Hill, NC, United States.
FAU - Blue, Colleen
AU  - Blue C
AUID- ORCID: 0000-0002-8844-791X
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill, Chapel Hill, NC, United States.
FAU - Rennie, Stuart
AU  - Rennie S
AUID- ORCID: 0000-0003-3844-972X
AD  - Department of Social Medicine, Center for Bioethics, University of North Carolina
      at Chapel Hill, Chapel Hill, NC, United States.
FAU - Juengst, Eric
AU  - Juengst E
AUID- ORCID: 0000-0002-8374-5774
AD  - Department of Social Medicine, Center for Bioethics, University of North Carolina
      at Chapel Hill, Chapel Hill, NC, United States.
FAU - Brinkley-Rubinstein, Lauren
AU  - Brinkley-Rubinstein L
AUID- ORCID: 0000-0002-2191-6240
AD  - Department of Social Medicine, Center for Health Equity Research, University of
      North Carolina at Chapel Hill, Chapel Hill, NC, United States.
FAU - Rosen, David L
AU  - Rosen DL
AUID- ORCID: 0000-0002-0493-8915
AD  - Division of Infectious Diseases, Department of Medicine, University of North
      Carolina at Chapel Hill, Chapel Hill, NC, United States.
LA  - eng
GR  - R01 AI129731/AI/NIAID NIH HHS/United States
GR  - P30 AI050410/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200904
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - Adult
MH  - Continuity of Patient Care/*standards/statistics & numerical data
MH  - *Expert Testimony
MH  - Female
MH  - HIV Infections/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Population Surveillance/*methods
MH  - Qualitative Research
MH  - Social Stigma
PMC - PMC7501574
OTO - NOTNLM
OT  - *HIV surveillance
OT  - *public health ethics
OT  - *qualitative research
OT  - *retention in HIV care
EDAT- 2020/09/05 06:00
MHDA- 2021/07/28 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
AID - v6i3e19891 [pii]
AID - 10.2196/19891 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 Sep 4;6(3):e19891. doi: 10.2196/19891.


PMID- 32885815
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20220716
IS  - 1613-9860 (Electronic)
IS  - 1613-9860 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct 8
TI  - Adapting to disruption of research during the COVID-19 pandemic while testing
      nonpharmacological approaches to pain management.
PG  - 827-834
LID - 10.1093/tbm/ibaa074 [doi]
AB  - The COVID-19 pandemic has slowed research progress, with particularly disruptive 
      effects on investigations of addressing urgent public health challenges, such as 
      chronic pain. The National Institutes of Health (NIH) Department of Defense (DoD)
      Department of Veterans Affairs (VA) Pain Management Collaboratory (PMC) supports 
      11 large-scale, multisite, embedded pragmatic clinical trials (PCTs) in military 
      and veteran health systems. The PMC rapidly developed and enacted a plan to
      address key issues in response to the COVID-19 pandemic. The PMC tracked and
      collaborated in developing plans for addressing COVID-19 impacts across multiple 
      domains and characterized the impact of COVID-19 on PCT operations, including
      delays in recruitment and revisions of study protocols. A harmonized participant 
      questionnaire will facilitate later meta-analyses and cross-study comparisons of 
      the impact of COVID-19 across all 11 PCTs. The pandemic has affected intervention
      delivery, outcomes, regulatory and ethics issues, participant recruitment, and
      study design. The PMC took concrete steps to ensure scientific rigor while
      encouraging flexibility in the PCTs, while paying close attention to minimizing
      the burden on research participants, investigators, and clinical care teams.
      Sudden changes in the delivery of pain management interventions will probably
      alter treatment effects measured via PMC PCTs. Through the use of harmonized
      instruments and surveys, we are capturing these changes and plan to monitor the
      impact on research practices, as well as on health outcomes. Analyses of
      patient-reported measures over time will inform potential relationships between
      chronic pain, mental health, and various socioeconomic stressors common among
      Americans during the COVID-19 pandemic.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society of Behavioral Medicine.
FAU - Coleman, Brian C
AU  - Coleman BC
AD  - Pain Research, Informatics, Multimorbidities, and Education Center, VA
      Connecticut Healthcare System, West Haven, CT, USA.
AD  - Pain Management Collaboratory Coordinating Center, Yale School of Medicine, New
      Haven, CT, USA.
AD  - Yale Center for Medical Informatics, Yale School of Medicine, New Haven, CT, USA.
FAU - Kean, Jacob
AU  - Kean J
AD  - Pain Management Collaboratory Coordinating Center, Yale School of Medicine, New
      Haven, CT, USA.
AD  - Informatics, Decision Enhancement, and Analytic Sciences (IDEAS 2.0) Center, VA
      Salt Lake City Health Care System, Salt Lake City, UT, USA.
AD  - Department of Population Health Sciences, University of Utah School of Medicine, 
      Salt Lake City, UT, USA.
FAU - Brandt, Cynthia A
AU  - Brandt CA
AD  - Pain Research, Informatics, Multimorbidities, and Education Center, VA
      Connecticut Healthcare System, West Haven, CT, USA.
AD  - Pain Management Collaboratory Coordinating Center, Yale School of Medicine, New
      Haven, CT, USA.
AD  - Yale Center for Medical Informatics, Yale School of Medicine, New Haven, CT, USA.
AD  - Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA.
AD  - Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
FAU - Peduzzi, Peter
AU  - Peduzzi P
AD  - Pain Management Collaboratory Coordinating Center, Yale School of Medicine, New
      Haven, CT, USA.
AD  - Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
FAU - Kerns, Robert D
AU  - Kerns RD
AD  - Pain Management Collaboratory Coordinating Center, Yale School of Medicine, New
      Haven, CT, USA.
AD  - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
LA  - eng
GR  - IU1 HX002607/HX/HSRD VA/United States
GR  - U24 AT009769/AT/NCCIH NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Transl Behav Med
JT  - Translational behavioral medicine
JID - 101554668
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Chronic Pain/epidemiology/psychology/therapy
MH  - Communicable Disease Control/*methods
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - Humans
MH  - Mental Health/*trends
MH  - National Institutes of Health (U.S.)
MH  - *Pain Management/ethics/methods/trends
MH  - *Pandemics/prevention & control
MH  - Patient Selection
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - *Research/organization & administration/trends
MH  - SARS-CoV-2
MH  - Socioeconomic Factors
MH  - United States/epidemiology
MH  - United States Department of Veterans Affairs
PMC - PMC7499692
OTO - NOTNLM
OT  - *COVID-19
OT  - *Disruption of research
OT  - *Interventions
OT  - *Pain management
OT  - *Pragmatic clinical trials
EDAT- 2020/09/05 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/09/05 06:00 [entrez]
AID - 5901420 [pii]
AID - 10.1093/tbm/ibaa074 [doi]
PST - ppublish
SO  - Transl Behav Med. 2020 Oct 8;10(4):827-834. doi: 10.1093/tbm/ibaa074.


PMID- 32885595
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201218
IS  - 1758-8111 (Electronic)
IS  - 1758-8103 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Dec
TI  - "I am terrified of something happening to me" The lived experience of people with
      obesity during the COVID-19 pandemic.
PG  - e12406
LID - 10.1111/cob.12406 [doi]
AB  - Obesity is emerging as a risk factor for COVID-19 disease severity. The impact of
      the pandemic and knowledge of obesity as a risk factor on the lived experience of
      people with obesity is not fully understood. The aim of this study was to
      investigate the impact of the COVID-19 pandemic on people living with severe
      obesity (BMI >/=35 kg/m(2) ), currently engaged in multi-modal treatment. The
      primary objectives were to examine the impact of the pandemic on their lived
      experience from a treatment and psychosocial standpoint and additionally explore 
      their awareness of obesity as a risk factor for COVID-19 disease severity. An
      in-depth qualitative study was adopted employing semi-structured interviews with 
      open-ended questions. Interpretive thematic analysis was adopted to analyse the
      data and identify key themes taking a grounded approach. Themes that emerged from
      the perspective of impact on lived experience were (a) challenge sustaining
      treatment and (b) psychosocial impact. There was an even split regarding
      awareness and lack of awareness of obesity as risk factor which itself
      contributes towards a negative psychosocial impact in most patients. The COVID-19
      pandemic is posing a diverse challenge to people with obesity. This has
      implications for their on-going treatment. From an ethical standpoint, there is a
      need to fully elucidate the link between obesity and COVID-19, disseminate this
      information using people friendly language and imagery in a manner that does not 
      exacerbate a harmful psychosocial response or lead to stigmatization.
CI  - (c) 2020 World Obesity Federation.
FAU - Grannell, Andrew
AU  - Grannell A
AUID- ORCID: https://orcid.org/0000-0001-9529-511X
AD  - Diabetes Complications Research Centre, Conway Institute, University College
      Dublin, Dublin, Ireland.
FAU - le Roux, Carel W
AU  - le Roux CW
AD  - Diabetes Complications Research Centre, Conway Institute, University College
      Dublin, Dublin, Ireland.
FAU - McGillicuddy, Deirdre
AU  - McGillicuddy D
AD  - School of Education, University College Dublin, Dublin, Ireland.
LA  - eng
GR  - 875534/Innovative Medicines Initiative
PT  - Journal Article
DEP - 20200904
PL  - England
TA  - Clin Obes
JT  - Clinical obesity
JID - 101560587
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anxiety
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*psychology
MH  - Diet
MH  - Exercise
MH  - Fear
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Mental Health
MH  - Middle Aged
MH  - Obesity/*psychology
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - Qualitative Research
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Stress, Psychological
OTO - NOTNLM
OT  - COVID-19
OT  - experience
OT  - obesity
OT  - psychosocial
OT  - treatment
EDAT- 2020/09/05 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/06/17 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/09/05 06:00 [entrez]
AID - 10.1111/cob.12406 [doi]
PST - ppublish
SO  - Clin Obes. 2020 Dec;10(6):e12406. doi: 10.1111/cob.12406. Epub 2020 Sep 4.


PMID- 32885548
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 56
IP  - 10
DP  - 2020 Oct
TI  - Parental decision regret in childhood hypospadias surgery: A systematic review.
PG  - 1514-1520
LID - 10.1111/jpc.15075 [doi]
AB  - We conducted a systematic review of the literature to establish the prevalence of
      and predictive factors for parental decision regret in hypospadias surgery. A
      search strategy without language restrictions was developed with expert help, and
      two reviewers undertook independent study selection. Five studies were included
      in this review (four for quantitative analysis) with a total of 783 participants.
      The mean overall prevalence of parental decision regret was 65.2% (moderate to
      severe - 20.3%). Although significant predictors of regret were identified
      (post-operative complications, small size glans, meatal location, decision
      conflict between parents, parental educational level and others), they had
      unexplained discordance between studies. Parental decision regret after proximal 
      hypospadias surgery and refusing surgery was inadequately reported. In
      conclusion, even though the prevalence of parental decision regret after
      consenting for the hypospadias repair appears to be high, risk factors associated
      with it were discordant suggesting imprecision in estimates due to unknown
      confounders.
CI  - (c) 2020 Paediatrics and Child Health Division (The Royal Australasian College of
      Physicians).
FAU - Vavilov, Sergey
AU  - Vavilov S
AUID- ORCID: https://orcid.org/0000-0002-4503-1789
AD  - Faculty of Health and Medicine, University of Newcastle, Newcastle, New South
      Wales, Australia.
AD  - Department of Surgery, John Hunter Hospital, Newcastle, New South Wales,
      Australia.
FAU - Smith, Grahame
AU  - Smith G
AD  - Urology Unit, Department of Surgery, The Children's Hospital at Westmead, Sydney,
      New South Wales, Australia.
FAU - Starkey, Malcolm
AU  - Starkey M
AD  - Department of Immunology and Pathology, Central Clinical School, Monash
      University, Melbourne, Victoria, Australia.
AD  - Priority Research Centre GrowUpWell, Faculty of Health and Medicine, The
      University of Newcastle, Newcastle, New South Wales, Australia.
FAU - Pockney, Peter
AU  - Pockney P
AD  - Faculty of Health and Medicine, University of Newcastle, Newcastle, New South
      Wales, Australia.
AD  - Department of Surgery, John Hunter Hospital, Newcastle, New South Wales,
      Australia.
FAU - Deshpande, Aniruddh V
AU  - Deshpande AV
AD  - Urology Unit, Department of Surgery, The Children's Hospital at Westmead, Sydney,
      New South Wales, Australia.
AD  - Priority Research Centre GrowUpWell, Faculty of Health and Medicine, The
      University of Newcastle, Newcastle, New South Wales, Australia.
AD  - Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New
      South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200903
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
SB  - IM
MH  - Emotions
MH  - Female
MH  - Humans
MH  - *Hypospadias/surgery
MH  - Male
MH  - Parents
MH  - *Reconstructive Surgical Procedures
MH  - Urethra/surgery
OTO - NOTNLM
OT  - ethic
OT  - general paediatrics
OT  - surgery
OT  - urology/gynaecology
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/04/19 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/05 06:00 [entrez]
AID - 10.1111/jpc.15075 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2020 Oct;56(10):1514-1520. doi: 10.1111/jpc.15075. Epub 
      2020 Sep 3.


PMID- 32885060
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 8
DP  - 2020 Aug
TI  - The experiences of foreign doctors in Saudi Arabia: A qualitative study of the
      challenges and retention motives.
PG  - e03901
LID - 10.1016/j.heliyon.2020.e03901 [doi]
AB  - BACKGROUND: The Saudi healthcare system is mainly staffed by foreign doctors who 
      constitute about 73% of the total medical workforce. But, the high rate of
      turnover among these foreigners had deposited an additional unbearable cost and
      threatens the stability of the provided healthcare services in the country.
      OBJECTIVES: This study was conducted to explore the professional and personal
      challenges that were experienced by foreign medical doctors while working in one 
      of the major governmental tertiary-care hospitals in Riyadh city. The study also 
      seeks to explore the factors that could influence or motivate their retention.
      METHODS: A qualitative study based on semi-structured interviews was conducted on
      January 2018. A total of 16 foreign doctors were recruited purposefully using a
      maximum variation sampling strategy. The interviews were recorded, transcribed
      verbatim, and analyzed using thematic analysis technique. RESULTS: Three primary 
      themes have been emerged based on the data analysis: (1) Work-related challenges 
      such as; communication and discrimination challenges. (2) Living-related
      challenges such as; supportive services and restricted movement challenges. (3)
      Factor motivating retention such as providing good children education, offering
      flexible traveling regulations, and providing professional development
      opportunities. CONCLUSIONS: The findings of this study have indicated that there 
      are more important motivators than money for improving the retention of foreign
      doctors in the country. Several policy actions have been recommended to maintain 
      their essential role. For example; implementing an ethical code to protect them
      from receiving deceptive hiring information, developing a specialized pocket
      dictionary to overcome language barriers, embracing "workforce diversity
      management" techniques to minimize discrimination at institutional level, and
      finally it is also recommended to include the foreign doctors' family needs and
      other living related challenges in any future retention strategies.
CI  - (c) 2020 Published by Elsevier Ltd.
FAU - Zawawi, Amal N
AU  - Zawawi AN
AD  - Department of Health Administration, King Saud University, Riyadh, Saudi Arabia.
FAU - Al-Rashed, Abeer M
AU  - Al-Rashed AM
AD  - Department of Health Administration, King Saud University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7453119
OTO - NOTNLM
OT  - Clinical Research
OT  - Doctors' Retention
OT  - Expatriates
OT  - Health Profession
OT  - Health Sciences
OT  - Overseas physician
OT  - Qualitative research
OT  - Riyadh hospitals
OT  - Sociology
OT  - Working experience
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:01
CRDT- 2020/09/05 06:00
PHST- 2019/12/22 00:00 [received]
PHST- 2019/12/29 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e03901 [doi]
AID - S2405-8440(20)30746-5 [pii]
AID - e03901 [pii]
PST - epublish
SO  - Heliyon. 2020 Aug 12;6(8):e03901. doi: 10.1016/j.heliyon.2020.e03901. eCollection
      2020 Aug.


PMID- 32884622
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1941-2789 (Print)
IS  - 1941-2789 (Linking)
VI  - 13
IP  - 6
DP  - 2020 Jun
TI  - iPLEDGE Must Abstain from Abstinence.
PG  - 54-56
AB  - Isotretinoin has unmatched efficacy in the treatment of acne. However, because
      isotretinoin is a teratogen that can cause profound birth defects, the iPLEDGE
      program regulates the drug's distribution in the United States. To minimize fetal
      exposure to isotretinoin, the program requires that female patients capable of
      becoming pregnant use two forms of contraception or commit to abstinence while
      using this therapy. This manuscript argues that iPLEDGE should be revised to
      remove abstinence as an acceptable contraceptive option in the face of evidence
      that disputes its efficacy. All patients, regardless of reported sexual activity,
      should be required to use data-proven contraception. Potential benefits of the
      proposed change (iPLEDGE-R) include reducing the number of isotretinoin
      pregnancies, increasing patient privacy protection, and standardizing patient
      care. Further investigation needs to guide additional strategies to achieve the
      program's public health goal; however, the ethical and pragmatic advantages of
      iPLEDGE-R merit consideration.
CI  - Copyright (c) 2020. Matrix Medical Communications. All rights reserved.
FAU - Lowery, Kami
AU  - Lowery K
AD  - Ms. Lowery is with Baylor College of Medicine in Houston, Texas.
AD  - Dr. Rosen is with the Department of Dermatology at Baylor College of Medicine in 
      Houston, Texas.
AD  - Dr. Malek is with the Center for Medical Ethics and Health Policy at Baylor
      College of Medicine in Houston, Texas.
FAU - Rosen, Theodore
AU  - Rosen T
AD  - Ms. Lowery is with Baylor College of Medicine in Houston, Texas.
AD  - Dr. Rosen is with the Department of Dermatology at Baylor College of Medicine in 
      Houston, Texas.
AD  - Dr. Malek is with the Center for Medical Ethics and Health Policy at Baylor
      College of Medicine in Houston, Texas.
FAU - Malek, Janet
AU  - Malek J
AD  - Ms. Lowery is with Baylor College of Medicine in Houston, Texas.
AD  - Dr. Rosen is with the Department of Dermatology at Baylor College of Medicine in 
      Houston, Texas.
AD  - Dr. Malek is with the Center for Medical Ethics and Health Policy at Baylor
      College of Medicine in Houston, Texas.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - J Clin Aesthet Dermatol
JT  - The Journal of clinical and aesthetic dermatology
JID - 101518173
PMC - PMC7442303
OTO - NOTNLM
OT  - Accutane
OT  - FDA
OT  - Isotretinoin
OT  - REMS
OT  - abstinence
OT  - acne
OT  - birth control
OT  - contraception
OT  - iPLEDGE
OT  - pregnancy
OT  - risk management
OT  - teratogen
COIS- FUNDING:No funding was provided for this study. DISCLOSURES:The authors have no
      conflicts of interest relevant to the content of this article.
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:01
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:01 [medline]
PST - ppublish
SO  - J Clin Aesthet Dermatol. 2020 Jun;13(6):54-56. Epub 2020 Jun 1.


PMID- 32884581
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - The intergenerational impact of war on mental health and psychosocial wellbeing: 
      lessons from the longitudinal study of war-affected youth in Sierra Leone.
PG  - 62
LID - 10.1186/s13031-020-00308-7 [doi]
AB  - BACKGROUND: Globally, one in four children lives in a country affected by armed
      conflict or disaster often accompanied by exposure to a range of adversities
      including violent trauma and loss. Children involved with armed groups (often
      referred to as "child soldiers") typically exhibit high levels of mental health
      needs linked to their experiences. The Longitudinal Study of War-Affected Youth
      (LSWAY) in Sierra Leone is a seventeen-year prospective longitudinal study of the
      long-term effects of children's experiences in the country's eleven-year
      (1991-2002) civil war on their adult mental health and functioning in addition to
      exploring the potential mechanisms by which intergenerational transmission of
      emotional and behavioral disruptions due to war trauma may operate. LSWAY
      illuminates how war-related and post-conflict experiences shape long-term adult
      functioning, family dynamics, and developmental outcomes in offspring.
      DISCUSSION: The LSWAY study utilizes mixed methodologies that incorporate
      qualitative and quantitative data to unpack risk and protective factors involved 
      in social reintegration, psychosocial adjustment, parenting, and interpersonal
      relationships. To date, study findings demonstrate striking levels of persistent 
      mental health problems among former child soldiers as adults with consequences
      for their families, but also risk and protective patterns that involve family-
      and community-level factors. This case study examines the course of LSWAY from
      inception through implementation and dissemination, including building on the
      study results to design and evaluate several intervention models. CONCLUSION: The
      case study offers a unique perspective on challenges and field realities of
      health research in a fragile, post-conflict setting common in the context of
      humanitarian emergencies. LSWAY findings along with lessons learned from the
      field can inform future research as well as intervention research and
      implementation science to address the mental health and development of
      war-affected young people. With four waves of data collection and a planned fifth
      wave, LSWAY also provides rare insights into the intergenerational effects of
      humanitarian crises on children, youth, and families across generations.
CI  - (c) The Author(s) 2020.
FAU - Betancourt, Theresa S
AU  - Betancourt TS
AUID- ORCID: 0000-0002-3683-4440
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA USA.grid.208226.c0000 0004 0444 7053
FAU - Keegan, Katrina
AU  - Keegan K
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA USA.grid.208226.c0000 0004 0444 7053
FAU - Farrar, Jordan
AU  - Farrar J
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA USA.grid.208226.c0000 0004 0444 7053
FAU - Brennan, Robert T
AU  - Brennan RT
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA USA.grid.208226.c0000 0004 0444 7053
AD  - Women's Studies Research Center, Brandeis University, Waltham, MA
      USA.grid.253264.40000 0004 1936 9473
LA  - eng
GR  - R01 HD073349/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200901
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7461150
OTO - NOTNLM
OT  - Child soldiers
OT  - Ebola virus disease
OT  - Ethics
OT  - Global adversity
OT  - Humanitarian crisis
OT  - Implementation science
OT  - Intergenerational trauma
OT  - Longitudinal research
OT  - Post-conflict
OT  - Risk and protective factors
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:01
CRDT- 2020/09/05 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:01 [medline]
AID - 10.1186/s13031-020-00308-7 [doi]
AID - 308 [pii]
PST - epublish
SO  - Confl Health. 2020 Sep 1;14:62. doi: 10.1186/s13031-020-00308-7. eCollection
      2020.


PMID- 32884468
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200905
IS  - 1520-765X (Print)
IS  - 1520-765X (Linking)
VI  - 22
IP  - Suppl H
DP  - 2020 Aug
TI  - May Measurement Month 2018: an analysis of blood pressure screening results from 
      Republic of the Congo.
PG  - H47-H49
LID - 10.1093/eurheartj/suaa026 [doi]
AB  - To determine the proportion with hypertension among opportunistic screenees in
      the Republic of the Congo. This cross-sectional study was conducted in Republic
      of the Congo in May 2018. This screening was done in urban and rural areas that
      included Brazzaville, Pointe-Noire, District of Ngoyo, and District of Nkayi. The
      study protocol was provided by the International Society of Hypertension, and
      local ethical clearance was obtained. The data were processed by the May
      Measurement Month global project team. In total, 6169 people were screened, 2418 
      of which were female (39.2%). Most of the people screened were from 18 to 29
      years old (n = 4184, 67.8%). The proportion of hypertension found was 22.2% (n = 
      1371). Among the hypertensive patients, 40.2% were aware of their hypertension,
      but only 493 (36.0%) were on antihypertensive treatment, and only 16.0% were
      controlled. The frequency of diabetes was 2.2% (n = 135), 2.3% (n = 139) had a
      previous stroke, and overweight and obesity were present in 15.4% (n = 952) and
      7.3% (n = 449), respectively. Hypertension is frequent in the Republic of the
      Congo, and levels of awareness, treatment and control are low. Actions are needed
      to increase access of all to a correct diagnosis and treatment of hypertension to
      achieve universal health coverage.
CI  - Published on behalf of the European Society of Cardiology. (c) The Author(s)
      2020.
FAU - Ellenga Mbolla, Bertrand F
AU  - Ellenga Mbolla BF
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Kouala Landa, Christian M
AU  - Kouala Landa CM
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Bakekolo, Paterne R
AU  - Bakekolo PR
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Makani Bassakouahou, Jospin K
AU  - Makani Bassakouahou JK
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Bouithy, Sabrina N
AU  - Bouithy SN
AD  - Reference Hospital of Talangai, n degrees 35 Avenue des 3 martyrs, Talangai
      District, Brazzaville, Republic of the Congo.
FAU - Eyeni-Sinomono, Tony
AU  - Eyeni-Sinomono T
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Bianza, Jean-R
AU  - Bianza JR
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Ossou-Nguiet, Paul-M
AU  - Ossou-Nguiet PM
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
FAU - Bani, Aloise M
AU  - Bani AM
AD  - General Hospital of Loandjili, Route n degrees 1, BP 8122, Pointe-Noire, Republic
      of the Congo.
FAU - Kimpamboudi, Aubierge
AU  - Kimpamboudi A
AD  - Head of Social and Health District from Pointe-Noire, Pointe-Noire, Republic of
      the Congo.
FAU - Beaney, Thomas
AU  - Beaney T
AD  - Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood
      Lane, London W12 7RH, UK.
AD  - Department of Primary Care and Public Health, Imperial College London, St
      Dunstan's Road, London W6 8RP, UK.
FAU - Ster, Anca Chis
AU  - Ster AC
AD  - Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood
      Lane, London W12 7RH, UK.
FAU - Poulter, Neil R
AU  - Poulter NR
AD  - Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood
      Lane, London W12 7RH, UK.
FAU - Xia, Xin
AU  - Xia X
AD  - Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood
      Lane, London W12 7RH, UK.
FAU - Kimbally Kaky, Suzy-G
AU  - Kimbally Kaky SG
AD  - Faculty of Health Sciences, Marien Ngouabi University of Brazzaville, n degrees 1
      Avenue des 1er Jeux Africains, Brazzaville, Republic of the Congo.
AD  - University Teaching Hospital of Brazzaville, n degrees 13 bd Auxence Ikonga, BP
      32, Brazzaville, Republic of the Congo.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - England
TA  - Eur Heart J Suppl
JT  - European heart journal supplements : journal of the European Society of
      Cardiology
JID - 100886647
PMC - PMC7455256
OTO - NOTNLM
OT  - Black Africans
OT  - Blood pressure
OT  - Hypertension
OT  - Screening
OT  - Sub-Saharan Africa
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:01
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:01 [medline]
AID - 10.1093/eurheartj/suaa026 [doi]
AID - suaa026 [pii]
PST - ppublish
SO  - Eur Heart J Suppl. 2020 Aug;22(Suppl H):H47-H49. doi: 10.1093/eurheartj/suaa026. 
      Epub 2020 Aug 28.


PMID- 32883902
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0970-2113 (Print)
IS  - 0970-2113 (Linking)
VI  - 37
IP  - 5
DP  - 2020 Sep-Oct
TI  - Prevalence and profile of sleep-disordered breathing and obstructive sleep apnea 
      in patients with interstitial lung disease at the pulmonary medicine department
      of a tertiary care hospital in Mumbai.
PG  - 415-420
LID - 10.4103/lungindia.lungindia_6_20 [doi]
AB  - BACKGROUND: Sleep-disordered breathing (SDB), predominantly obstructive sleep
      apnea (OSA), is a frequent phenomenon in interstitial lung disease (ILD) and may 
      be associated with significant morbidity and mortality. METHODOLOGY: A
      prospective, observational, hospital-based study was conducted in a tertiary care
      hospital after ethics committee permission. The study group consisted of 100
      consecutive ILD patients diagnosed by a multidisciplinary diagnosis. They were
      evaluated for the prevalence of SDB with a polysomnography after a comprehensive 
      history, detailed clinical examination, calculation of various pretest
      probability scores, and relevant prerequisite workup. RESULTS: Out of the total
      100 ILD patients, 44 were male (44%) and 56 were female (56%). SDB was present in
      57 (57%) patients. Of these, 29 (29%) were found to have only nocturnal oxygen
      desaturation (NOD), while 28 (28%) had OSA. The 28 cases of OSA were distributed 
      as 15 mild OSA (53.57%), 10 moderate OSA (35.71%), and 3 severe OSA (10.71%). The
      patients were divided into the following four groups: total study Group (A),
      patients with OSA (Group B), patients with NOD without OSA (Group C), and no SDB 
      (Group D). The mean forced vital capacity values predicted in the four groups
      were 53.67%, 50%, 45.56%, and 57.87%, respectively. The mean body mass index in
      the four groups was 24.56, 27, 26.98, and 24.89 kg/m(2), respectively. The mean
      6-min walk distance in the four groups was 280.7, 250, 256.65, and 311.4 m,
      respectively. The mean partial pressure of oxygen in the four groups was 65.65,
      60, 62.10, and 75.66 mmHg, respectively. The mean apnea-hypopnea index in the
      study group was 2.98/h, 8.6/h with mild OSA, 21.69/h with moderate OSA, 48.78/h
      with severe OSA, 3.89/h in patients having NOD without OSA, and 2.54/h in
      patients with no SDB. CONCLUSION: SDB in ILD is associated with a significant
      impact on the cardinal determinants of functional capacity, lung function, and
      quality of life.
FAU - Utpat, Ketaki
AU  - Utpat K
AD  - Department of Pulmonary Medicine, T. N. Medical College, B.Y.L. Nair Hospital,
      Mumbai, Maharashtra, India.
FAU - Gupta, Abhishek
AU  - Gupta A
AD  - Department of Pulmonary Medicine, T. N. Medical College, B.Y.L. Nair Hospital,
      Mumbai, Maharashtra, India.
FAU - Desai, Unnati
AU  - Desai U
AD  - Department of Pulmonary Medicine, T. N. Medical College, B.Y.L. Nair Hospital,
      Mumbai, Maharashtra, India.
FAU - Joshi, Jyotsna M
AU  - Joshi JM
AD  - Department of Pulmonary Medicine, T. N. Medical College, B.Y.L. Nair Hospital,
      Mumbai, Maharashtra, India.
FAU - Bharmal, Ramesh N
AU  - Bharmal RN
AD  - Department of Pulmonary Medicine, T. N. Medical College, B.Y.L. Nair Hospital,
      Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC7857377
OTO - NOTNLM
OT  - Interstitial lung disease
OT  - obstructive sleep apnea
OT  - sleep-disordered breathing
COIS- None
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:01
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:01 [medline]
AID - LungIndia_2020_37_5_415_293990 [pii]
AID - 10.4103/lungindia.lungindia_6_20 [doi]
PST - ppublish
SO  - Lung India. 2020 Sep-Oct;37(5):415-420. doi: 10.4103/lungindia.lungindia_6_20.


PMID- 32883884
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20220215
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 369
IP  - 6509
DP  - 2020 Sep 11
TI  - An ethical framework for global vaccine allocation.
PG  - 1309-1312
LID - 10.1126/science.abe2803 [doi]
FAU - Emanuel, Ezekiel J
AU  - Emanuel EJ
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA, USA. MEHPchair@upenn.edu.
FAU - Persad, Govind
AU  - Persad G
AD  - Sturm College of Law, University of Denver, Denver, CO, USA.
FAU - Kern, Adam
AU  - Kern A
AD  - Department of Politics, Princeton University, Princeton, NJ, USA.
FAU - Buchanan, Allen
AU  - Buchanan A
AD  - Departments of Philosophy, Political Economy and Moral Science, and Freedom
      Center, University of Arizona, Tucson, AZ, USA.
FAU - Fabre, Cecile
AU  - Fabre C
AD  - All Souls College, University of Oxford, Oxford, UK.
FAU - Halliday, Daniel
AU  - Halliday D
AD  - School of Historical and Philosophical Studies, University of Melbourne,
      Melbourne, Australia.
FAU - Heath, Joseph
AU  - Heath J
AD  - Munk School of Global Affairs and Public Policy, University of Toronto, Toronto, 
      Canada.
FAU - Herzog, Lisa
AU  - Herzog L
AD  - Faculty of Philosophy, University of Groningen, Groningen, Netherlands.
FAU - Leland, R J
AU  - Leland RJ
AD  - Department of Philosophy, University of Manitoba, Winnipeg, Canada.
FAU - Lemango, Ephrem T
AU  - Lemango ET
AD  - Jobs Creation Commission, Ethiopia.
FAU - Luna, Florencia
AU  - Luna F
AD  - Bioethics Program, Facultad Latinoamerica de Ciencias Sociales (FLACSO-CONICET), 
      Buenos Aires, Argentina.
FAU - McCoy, Matthew S
AU  - McCoy MS
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA, USA.
FAU - Norheim, Ole F
AU  - Norheim OF
AD  - Bergen Centre for Ethics and Priority Setting, Department of Global Public Health
      and Primary Care, University of Bergen, Bergen, Norway.
FAU - Ottersen, Trygve
AU  - Ottersen T
AD  - Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway.
FAU - Schaefer, G Owen
AU  - Schaefer GO
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Tan, Kok-Chor
AU  - Tan KC
AD  - Department of Philosophy, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Wellman, Christopher Heath
AU  - Wellman CH
AD  - Department of Philosophy, Washington University, St. Louis, MO, USA.
FAU - Wolff, Jonathan
AU  - Wolff J
AD  - Blavatnik School of Government, University of Oxford, Oxford, UK.
FAU - Richardson, Henry S
AU  - Richardson HS
AD  - Department of Philosophy and Kennedy Institute of Ethics, Georgetown University, 
      Washington, DC, USA.
LA  - eng
GR  - R25 TW001605/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200903
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CIN - Anaesth Crit Care Pain Med. 2022 Feb;41(1):100988. PMID: 34864275
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control
MH  - Health Equity/*ethics
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Resource Allocation/*ethics
MH  - Viral Vaccines/*supply & distribution
PMC - PMC8691258
MID - NIHMS1759276
EDAT- 2020/09/05 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/09/05 06:00 [entrez]
AID - science.abe2803 [pii]
AID - 10.1126/science.abe2803 [doi]
PST - ppublish
SO  - Science. 2020 Sep 11;369(6509):1309-1312. doi: 10.1126/science.abe2803. Epub 2020
      Sep 3.


PMID- 32883734
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Readability and understandability of clinical research patient information
      leaflets and consent forms in Ireland and the UK: a retrospective quantitative
      analysis.
PG  - e037994
LID - 10.1136/bmjopen-2020-037994 [doi]
AB  - OBJECTIVES: The first aim of this study was to quantify the difficulty level of
      clinical research Patient Information Leaflets/Informed Consent Forms (PILs/ICFs)
      using validated and widely used readability criteria which provide a broad
      assessment of written communication. The second aim was to compare these findings
      with best practice guidelines. DESIGN: Retrospective, quantitative analysis of
      clinical research PILs/ICFs provided by academic institutions, pharmaceutical
      companies and investigators. SETTING: PILs/ICFs which had received Research
      Ethics Committee approval in the last 5 years were collected from Ireland and the
      UK. INTERVENTION: Not applicable. MAIN OUTCOME MEASURES: PILs/ICFs were evaluated
      against seven validated readability criteria (Flesch Reading Ease, Flesh Kincaid 
      Grade Level, Simplified Measure of Gobbledegook, Gunning Fog, Fry, Raygor and New
      Dale Chall). The documents were also scored according to two health
      literacy-based criteria: the Clear Communication Index (CCI) and the Suitability 
      Assessment of Materials tool. Finally, the documents were assessed for compliance
      with six best practice metrics from literacy agencies. RESULTS: A total of 176
      PILs were collected, of which 154 were evaluable. None of the PILs/ICFs had the
      mean reading age of <12 years recommended by the American Medical Association.
      7.1% of PILs/ICFs were evaluated as 'Plain English', 40.3%: 'Fairly Difficult',
      51.3%: 'Difficult' and 1.3%: 'Very Difficult'. No PILs/ICFs achieved a CCI >90.
      Only two documents complied with all six best practice literacy metrics.
      CONCLUSIONS: When assessed against both traditional readability criteria and
      health literacy-based tools, the PILs/ICFs in this study are inappropriately
      complex. There is also evidence of poor compliance with guidelines produced by
      literacy agencies. These data clearly evidence the need for improved
      documentation to underpin the consent process.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - O'Sullivan, Lydia
AU  - O'Sullivan L
AUID- ORCID: 0000-0002-7131-5048
AD  - School of Medicine & School of Nursing, Midwifery and Health Systems, University 
      College Dublin, Dublin, Ireland lydia.osullivan@ucd.ie.
AD  - Health Research Board - Trials Methodology Research Network, Galway, Ireland.
FAU - Sukumar, Prasanth
AU  - Sukumar P
AUID- ORCID: 0000-0003-3229-2661
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
FAU - Crowley, Rachel
AU  - Crowley R
AUID- ORCID: 0000-0003-1472-4117
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
AD  - Department of Endocrinology, Saint Vincent's University Hospital, Dublin,
      Ireland.
FAU - McAuliffe, Eilish
AU  - McAuliffe E
AUID- ORCID: 0000-0002-9714-5040
AD  - Centre for Interdisciplinary Research, Education, and Innovation in Health
      Systems, School of Nursing, Midwifery and Health Systems, University College
      Dublin, Dublin, Ireland.
FAU - Doran, Peter
AU  - Doran P
AUID- ORCID: 0000-0003-2064-5335
AD  - Health Research Board - Trials Methodology Research Network, Galway, Ireland.
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Comprehension
MH  - *Consent Forms
MH  - *Health Literacy
MH  - Humans
MH  - Internet
MH  - Ireland
MH  - Retrospective Studies
MH  - United Kingdom
PMC - PMC7473620
OTO - NOTNLM
OT  - *clinical trials
OT  - *medical education & training
OT  - *medical ethics
OT  - *medical law
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037994 [pii]
AID - 10.1136/bmjopen-2020-037994 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e037994. doi: 10.1136/bmjopen-2020-037994.


PMID- 32883731
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Realist review protocol for understanding the real-world barriers and enablers to
      practitioners implementing self-management support to people living with and
      beyond cancer.
PG  - e037636
LID - 10.1136/bmjopen-2020-037636 [doi]
AB  - INTRODUCTION: Self-management support can enable and empower people living with
      and beyond cancer to take an active role in managing long-term consequences of
      cancer treatment. Healthcare professionals are key to promoting patients to
      self-manage, however, they do not routinely engage in these discussions. This
      review aims to understand what works for whom and in what circumstances in
      relation to practitioners engaging with supporting people living with and beyond 
      cancer to self-manage long-term consequences of systemic anticancer treatment.
      METHODS AND ANALYSIS: We will follow five steps for undertaking the realist
      review: (1) define the review scope, (2) develop initial programme theories, (3) 
      evidence search, (4) selection and appraisal and (5) data extraction and
      synthesis. We will combine an informal literature search with a theory-based
      approach, using the theoretical domains framework, and stakeholder feedback to
      develop initial programme theories. We will search Medline, EMBASE, CINAHL,
      Scopus, PsycINFO, ERIC and AMED databases to September 2019, and supplement this 
      with citation tracking, grey literature and practitioner surveys. Data selection 
      will be based on relevance and rigour. Data will be extracted and synthesised
      iteratively, and causal links between contexts, mechanism and outcomes
      illuminated in the process. The results will be reported according to the Realist
      And Meta-narrative Evidence Syntheses: Evolving Standards quality and publication
      standards. ETHICS AND DISSEMINATION: We have received ethical approval through
      the Research Ethics Committee, Faculty of Medicine and Health Sciences,
      University of East Anglia (ref 2 01 819-124). We will disseminate to the research
      community through conference presentations and a peer-reviewed journal article.
      We will work with healthcare organisations, cancer charities and patients to
      agree a strategy for disseminating to these groups. PROSPERO REGISTRATION NUMBER:
      CRD42019120910.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kantilal, Kumud
AU  - Kantilal K
AUID- ORCID: 0000-0002-8517-4637
AD  - School of Pharmacy, University of East Anglia, Norwich, Norfolk, UK
      k.kantilal@uea.ac.uk.
FAU - Hardeman, Wendy
AU  - Hardeman W
AD  - School of Health Sciences, University of East Anglia, Norwich, UK.
FAU - Whiteside, Hattie
AU  - Whiteside H
AD  - School of Pharmacy, University of East Anglia, Norwich, Norfolk, UK.
FAU - Karapanagiotou, Eleni
AU  - Karapanagiotou E
AD  - Medical Oncology, Guy's and Saint Thomas' NHS Foundation Trust, London, London,
      UK.
FAU - Small, Matthew
AU  - Small M
AD  - Pharmacy department, Norfolk and Norwich University Hospitals NHS Foundation
      Trust, Norwich, Norfolk, UK.
FAU - Bhattacharya, Debi
AU  - Bhattacharya D
AD  - School of Pharmacy, University of East Anglia, Norwich, Norfolk, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - *Neoplasms/therapy
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Self-Management
PMC - PMC7473657
OTO - NOTNLM
OT  - *adult oncology
OT  - *chemotherapy
OT  - *organisation of health services
OT  - *toxicity
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037636 [pii]
AID - 10.1136/bmjopen-2020-037636 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e037636. doi: 10.1136/bmjopen-2020-037636.


PMID- 32883730
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Models of support to family members during the trajectory of cancer: a scoping
      review protocol.
PG  - e037633
LID - 10.1136/bmjopen-2020-037633 [doi]
AB  - INTRODUCTION: A cancer diagnose, for example, colorectal cancer, not only affects
      the cancer-person stricken, but also the surrounding family. Thus, this scoping
      review intends to identify appropriate models of support that will guide the
      development of a model of support to family members during the trajectory of
      colorectal cancer. METHODS AND ANALYSIS: This scoping review will be guided by
      the methodological framework developed by Arksey and O'Malley, refined by Levac
      et al and Colquhoun et al, and described by the Joanna Briggs Institute. All the 
      stages will be conducted iteratively and reflexively. First, a search strategy
      will be developed with a librarian and applied in the following peer-reviewed
      databases: PubMed, Cumulative Index to Nursing and Allied Health Literature and
      PsycINFO. Additional searches will be performed in Google Scholar and SwePub for 
      identification of grey literature and hand searched in the reference lists.
      Searches will be conducted from December 2019 to February 2020. A draft of the
      preliminary search strategy was performed in PubMed in November 2019.
      Subsequently, three members of the research team will independently screen all
      abstracts for relevance, as well as the full-text articles. Studies meeting the
      inclusion criteria will be critically evaluated using the Joanna Brigg Institute 
      Critical Appraisal Tools. A descriptive summary of study characteristics and of
      the scoping review process will be presented, including a visual flow diagram.
      Lastly, a thematic analysis as presented by Braun and Clarke will be conducted.
      To enhance validity, contact nurses of persons with colorectal cancer will be
      provided an overview of the preliminary results. ETHICS AND DISSEMINATION: Being 
      a secondary analysis, ethical approval is not needed for this study. The findings
      of the analysis will be used to inform the design of a future study aiming to
      develop a model of support and an upcoming scoping review, which will be
      published in a scientific journal and presented at relevant conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Samuelsson, Maria
AU  - Samuelsson M
AUID- ORCID: 0000-0001-8700-4490
AD  - Department of Care Science, Malmo Universitet, Malmo, Skane, Sweden
      maria.samuelsson@mau.se.
FAU - Wennick, Anne
AU  - Wennick A
AD  - Faculty of Health and Society, Care Science, Malmo University, Malmo, Skane,
      Sweden.
FAU - Jakobsson, Jenny
AU  - Jakobsson J
AD  - Department of Care Science, Malmo Universitet, Malmo, Skane, Sweden.
FAU - Bengtsson, Mariette
AU  - Bengtsson M
AD  - Care Science, Malmo University, Malmo, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Delivery of Health Care
MH  - Family
MH  - Humans
MH  - *Neoplasms
MH  - Peer Review
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7473623
OTO - NOTNLM
OT  - *adult oncology
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037633 [pii]
AID - 10.1136/bmjopen-2020-037633 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e037633. doi: 10.1136/bmjopen-2020-037633.


PMID- 32883728
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Comparative CT with stress manoeuvres for diagnosing distal isolated tibiofibular
      syndesmotic injury in acute ankle sprain: a protocol for an accuracy- test
      prospective study.
PG  - e037239
LID - 10.1136/bmjopen-2020-037239 [doi]
AB  - INTRODUCTION: Although several imaging options are available for diagnosing
      syndesmotic injury, a fundamental question that guides treatment remains
      unanswered. Syndesmotic instability is still challenging to diagnose correctly,
      and syndesmotic disruption and true syndesmotic instability should be
      differentiated. Currently, imaging tests quickly diagnose severe syndesmotic
      instability but have difficulty in diagnosing mild and moderate cases. This study
      aims to investigate which strategy among an existing CT index test and two new
      add-on CT index tests with stress manoeuvres more accurately diagnoses
      syndesmotic instability. The secondary objective is to investigate the
      participants' disability outcomes by applying the Foot and Ankle Ability Measure 
      questionnaire. METHODS AND ANALYSES: This study of a diagnostic accuracy test
      will consecutively select individuals older than 18 years with a clinical
      diagnosis of a suspected acute syndesmotic injury. Three strategies of the CT
      index test (one in the neutral position and two with stress) will examine the
      accuracy using MRI as the reference standard. The external rotation and
      dorsiflexion of the ankle will guide the stress manoeuvres. A comparison of
      measurements between the injured syndesmosis and the uninjured contralateral side
      of the same individual will investigate the syndesmotic instability, by
      evaluating the rotational and translational relationships between the fibula and 
      tibia. Sensitivity, specificity, area under the receiver operating characteristic
      curve and likelihood analyses will compare the diagnostic accuracies of the
      strategies. ETHICS AND DISSEMINATION: The Internal Review Board and the Einstein 
      Ethics Committee approved this study (registered number 62100016.5.0000.0071).
      All participants will receive an oral description of the study's aim, and the
      choice to participate will be free and voluntary. Participants will be enrolled
      after they sign the written informed consent form, including the terms of
      confidentiality. The results will be presented at national and international
      conferences and published in peer-reviewed journals and social media. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04095598; preresults).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rodrigues, Joao Carlos
AU  - Rodrigues JC
AUID- ORCID: 0000-0002-7107-2621
AD  - Radiologia, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
      joao.rodrigues@einstein.br.
AD  - Radiologia, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, Brazil.
FAU - Santos, Alexandre Leme Godoy
AU  - Santos ALG
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
AD  - Ortopedia, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, Brazil.
FAU - Prado, Marcelo Pires
AU  - Prado MP
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Alloza, Jose Felipe Marion
AU  - Alloza JFM
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Masagao, Renato Amaral
AU  - Masagao RA
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Rosemberg, Laercio Alberto
AU  - Rosemberg LA
AD  - Radiologia, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
AD  - Radiologia, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, Brazil.
FAU - Barros, Durval do Carmo Santos
AU  - Barros DDCS
AD  - Radiologia, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Castro, Adham do Amaral E
AU  - Castro ADAE
AD  - Radiologia, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Demange, Marco Kawamura
AU  - Demange MK
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
AD  - Ortopedia, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, Brazil.
FAU - Lenza, Mario
AU  - Lenza M
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
FAU - Ferretti, Mario
AU  - Ferretti M
AD  - Programa Locomotor, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
LA  - eng
SI  - ClinicalTrials.gov/NCT04095598
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Ankle Injuries/diagnostic imaging
MH  - Ankle Joint/diagnostic imaging
MH  - Humans
MH  - *Joint Instability/diagnostic imaging
MH  - Prospective Studies
MH  - Tomography, X-Ray Computed
PMC - PMC7473658
OTO - NOTNLM
OT  - *computed tomography
OT  - *diagnostic radiology
OT  - *foot & ankle
OT  - *magnetic resonance imaging
OT  - *musculoskeletal disorders
OT  - *orthopaedic sports trauma
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037239 [pii]
AID - 10.1136/bmjopen-2020-037239 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e037239. doi: 10.1136/bmjopen-2020-037239.


PMID- 32883725
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Immunonutrition for traumatic brain injury in children and adolescents: protocol 
      for a systematic review and meta-analysis.
PG  - e037014
LID - 10.1136/bmjopen-2020-037014 [doi]
AB  - INTRODUCTION: Traumatic brain injury (TBI) is the leading cause of paediatric
      trauma death and disability worldwide. The 'Guidelines for the Management of
      Severe Traumatic Brain Injury (Fourth Edition)' recommend that nutritional goals 
      should be achieved within 5-7 days of injury. Immune-enhancing nutrition or
      immunonutrition, referring to the addition of specialised nutrients, including
      glutamine, alanine, omega-3 fatty acids and nucleotides, to standard nutrition
      formulas, may improve surgical outcomes in the perioperative period. However, the
      role of immune-enhancing nutritional supplements for patients with paediatric TBI
      remains unclear. We will conduct a systematic review to determine the efficacy
      and safety of immunonutrition for patients with paediatric TBI and provide
      evidence for clinical decision-making. METHODS AND ANALYSIS: Studies reporting
      immune-enhancing nutrition treatments for patients with paediatric TBI will be
      included. Outcomes of interest include the length of hospital stay, wound
      infections, all-cause mortality, non-wound infection, including pneumonia,
      urinary tract infection and bacteraemia, and the reports adverse events. Duration
      of follow-up has no restriction. Primary studies consisting of randomised
      controlled trials (RCTs) and non-RCTs will be eligible for this review, and only 
      studies published in English will be included. We will search the Medline, Embase
      and Cochrane Library databases from their inception dates to January 2020. We
      will also search clinicaltrials.gov and the WHO International Clinical Trials
      Registry Platform for additional information. Two reviewers will independently
      select studies and extract data. Risk-of-bias will be assessed with tools based
      on the Cochrane risk-of-bias criteria and Newcastle-Ottawa Quality Assessment
      Scale. A meta-analysis will be used to pool data when there are suf fi cient
      studies with homogeneity. Heterogeneity of the estimates across studies will be
      assessed; if necessary, a subgroup analysis will be performed to explore the
      source of heterogeneity. The Grades of Recommendation, Assessment, Development
      and Evaluation method will be applied to assess the level of evidence obtained
      from this systematic review. ETHICS AND DISSEMINATION: The proposed systematic
      review and meta-analysis will be based on published data, and thus ethical
      approval is not required. The results of this review will be published. PROSPERO 
      REGISTRATION NUMBER: CRD42020154814.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Peng, Rong
AU  - Peng R
AUID- ORCID: 0000-0001-5247-277X
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
AD  - Department of Clinical Nutrition, Affiliated Hospital of Chengdu University,
      Chengdu, Sichuan, China.
FAU - Li, Hailong
AU  - Li H
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
FAU - Yang, Lijun
AU  - Yang L
AD  - Department of General Practice Medicine, Affiliated Hospital of Chengdu
      University, Chengdu, China.
FAU - Chen, Xinwei
AU  - Chen X
AD  - Department of Critical Medicine, Affiliated Hospital of Chengdu University,
      Chengdu, China.
FAU - Zeng, Linan
AU  - Zeng L
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
FAU - Bo, Zhenyan
AU  - Bo Z
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
FAU - Zhang, Lingli
AU  - Zhang L
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan
      University, Chengdu, China zhanglingli@scu.edu.cn.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Brain Injuries, Traumatic/therapy
MH  - Child
MH  - Dietary Supplements
MH  - Humans
MH  - Length of Stay
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
MH  - *Wound Infection
PMC - PMC7473625
OTO - NOTNLM
OT  - *immunology
OT  - *nutrition & dietetics
OT  - *paediatric head & neck surgery
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037014 [pii]
AID - 10.1136/bmjopen-2020-037014 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e037014. doi: 10.1136/bmjopen-2020-037014.


PMID- 32883723
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Online cognitive-behavioural therapy for traumatically bereaved people: study
      protocol for a randomised waitlist-controlled trial.
PG  - e035050
LID - 10.1136/bmjopen-2019-035050 [doi]
AB  - INTRODUCTION: The traumatic death of a loved one, such as death due to a traffic 
      accident, can precipitate persistent complex bereavement disorder (PCBD) and
      comorbid post-traumatic stress disorder (PTSD) and depression.
      Waitlist-controlled trials have shown that grief-specific cognitive-behavioural
      therapy (CBT) is an effective treatment for such mental health problems. This is 
      the first study that will examine the effectiveness of online CBT (vs waitlist
      controls) in a sample exclusively comprised of people bereaved by a traumatic
      death. Our primary hypothesis is that people allocated to the online CBT
      condition will show larger reductions in PCBD, PTSD and depression symptom levels
      at post-treatment than people allocated to a waitlist. We further expect that
      reductions in symptom levels during treatment are associated with reductions of
      negative cognitions and avoidance behaviours and the experience of fewer
      accident-related stressors. Moreover, the effect of the quality of the
      therapeutic alliance on treatment effects and drop-out rates will be explored.
      METHODS AND ANALYSIS: A two-arm (online CBT vs waiting list) open-label parallel 
      randomised controlled trial will be conducted. Participants will complete
      questionnaires at pretreatment and 12 and 20 weeks after study enrolment.
      Eligible for participation are Dutch adults who lost a loved one at least 1 year 
      earlier due to a traffic accident and report clinically relevant levels of PCBD, 
      PTSD and/or depression. Multilevel modelling will be used. ETHICS AND
      DISSEMINATION: Ethics approval has been received by the Medical Ethics Review
      Board of the University Medical Center Groningen (METc UMCG: M20.252121). This
      study will provide new insights in the effectiveness of online CBT for
      traumatically bereaved people. If the treatment is demonstrated to be effective, 
      it will be made publicly accessible. Findings will be disseminated among lay
      people (eg, through newsletters and media performances), our collaborators (eg,
      through presentations at support organisations), and clinicians and researchers
      (eg, through conference presentations and scientific journal articles). TRIAL
      REGISTRATION NUMBER: NL7497.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lenferink, Lonneke
AU  - Lenferink L
AUID- ORCID: 0000-0003-1329-6413
AD  - Clinical Psychology and Experimental Psychopathology, University of Groningen,
      Groningen, The Netherlands l.i.m.lenferink@rug.nl.
AD  - Clinical Psychology, Utrecht University, Utrecht, The Netherlands.
FAU - de Keijser, Jos
AU  - de Keijser J
AD  - Clinical Psychology and Experimental Psychopathology, University of Groningen,
      Groningen, The Netherlands.
FAU - Eisma, Maarten
AU  - Eisma M
AD  - Clinical Psychology and Experimental Psychopathology, University of Groningen,
      Groningen, The Netherlands.
FAU - Smid, Geert
AU  - Smid G
AD  - ARQ Nationaal Psychotrauma Centre, Diemen, The Netherlands.
AD  - Foundation Centrum '45, Diemen, The Netherlands.
AD  - University of Humanistic Studies, Utrecht, The Netherlands.
FAU - Boelen, Paul
AU  - Boelen P
AD  - Clinical Psychology, Utrecht University, Utrecht, The Netherlands.
AD  - ARQ Nationaal Psychotrauma Centre, Diemen, The Netherlands.
AD  - Foundation Centrum '45, Diemen, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Avoidance Learning
MH  - Cognition
MH  - *Cognitive Behavioral Therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Stress Disorders, Post-Traumatic/therapy
MH  - Waiting Lists
PMC - PMC7473627
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *psychiatry
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035050 [pii]
AID - 10.1136/bmjopen-2019-035050 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e035050. doi: 10.1136/bmjopen-2019-035050.


PMID- 32883721
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 3
TI  - Clinical and cost-effectiveness of a guided internet-based Acceptance and
      Commitment Therapy to improve chronic pain-related disability in green
      professions (PACT-A): study protocol of a pragmatic randomised controlled trial.
PG  - e034271
LID - 10.1136/bmjopen-2019-034271 [doi]
AB  - INTRODUCTION: Chronic pain is highly prevalent, associated with substantial
      personal and economic burdens, and increased risk for mental disorders.
      Individuals in green professions (agriculturists, horticulturists, foresters)
      show increased prevalence of chronic pain and other risk factors for mental
      disorders. Available healthcare services in rural areas are limited. Acceptance
      towards face-to-face therapy is low. Internet and mobile-based interventions
      (IMIs) based on Acceptance and Commitment Therapy (ACT) might be a promising
      alternative for this population and may enable effective treatment of chronic
      pain. The present study aims to evaluate the clinical and cost-effectiveness of
      an ACT-based IMI for chronic pain in green professions in comparison with
      enhanced treatment as usual (TAU+). METHODS AND ANALYSIS: A two-armed pragmatic
      randomised controlled trial will be conducted. Two hundred eighty-six
      participants will be randomised and allocated to either an intervention or TAU+
      group. Entrepreneurs in green professions, collaborating spouses, family members 
      and pensioners with chronic pain are eligible for inclusion. The intervention
      group receives an internet-based intervention based on ACT (7 modules, over 7
      weeks) guided by a trained e-coach to support adherence (eg, by positive
      reinforcement). Primary outcome is pain interference (Multidimensional Pain
      Interference scale; MPI) at 9 weeks post-randomisation. Secondary outcomes are
      depression severity (Quick Inventory Depressive Symptomology; QIDS-SR16),
      incidence of major depressive disorder, quality of life (Assessment of Quality of
      Life; AQoL-8D) and possible side effects associated with the treatment (Inventory
      for the Assessment of Negative Effects of Psychotherapy; INEP). Psychological
      flexibility (Chronic Pain Acceptance Questionnaire, Committed Action
      Questionnaire, Cognitive Fusion Questionnaire) will be evaluated as a potential
      mediator of the treatment effect. Furthermore, mediation, moderation and
      health-economic analyses from a societal perspective will be performed. Outcomes 
      will be measured using online self-report questionnaires at baseline, 9-week,
      6-month, 12-month, 24-month and 36-month follow-ups. ETHICS AND DISSEMINATION:
      This study was approved by the Ethics Committee of the University of Ulm, Germany
      (file no. 453/17-FSt/Sta; 22 February 2018). Results will be submitted for
      publication in peer-reviewed journals and presented at conferences. TRIAL
      REGISTRATION NUMBER: German Clinical Trial Registration: DRKS00014619. Registered
      on 16 April 2018.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Terhorst, Yannik
AU  - Terhorst Y
AUID- ORCID: 0000-0003-4091-5048
AD  - Research Methods, Ulm University, Ulm, Baden-Wurttemberg, Germany
      yannik.terhorst@uni-ulm.de.
AD  - Clinical Psychology and Psychotherapy, Ulm University, Ulm, Baden-Wurttemberg,
      Germany.
FAU - Braun, Lina
AU  - Braun L
AUID- ORCID: 0000-0001-6916-0879
AD  - Clinical Psychology and Psychotherapy, Ulm University, Ulm, Baden-Wurttemberg,
      Germany.
FAU - Titzler, Ingrid
AU  - Titzler I
AUID- ORCID: 0000-0002-8963-2324
AD  - Clinical Psychology and Psychotherapy, Friedrich-Alexander University
      Erlangen-Nurnberg, Erlangen, Bayern, Germany.
AD  - GET.ON Institute, Hamburg, Germany.
FAU - Buntrock, Claudia
AU  - Buntrock C
AUID- ORCID: 0000-0002-4974-5455
AD  - Clinical Psychology and Psychotherapy, Friedrich-Alexander University
      Erlangen-Nurnberg, Erlangen, Bayern, Germany.
FAU - Freund, Johanna
AU  - Freund J
AUID- ORCID: 0000-0002-0038-9330
AD  - Clinical Psychology and Psychotherapy, Friedrich-Alexander University
      Erlangen-Nurnberg, Erlangen, Bayern, Germany.
FAU - Thielecke, Janika
AU  - Thielecke J
AD  - Clinical Psychology and Psychotherapy, Friedrich-Alexander University
      Erlangen-Nurnberg, Erlangen, Bayern, Germany.
FAU - Ebert, David
AU  - Ebert D
AD  - GET.ON Institute, Hamburg, Germany.
AD  - Clinical, Neuro- & Developmental Psychology, Vrije Universiteit Amsterdam,
      Amsterdam, The Netherlands.
FAU - Baumeister, Harald
AU  - Baumeister H
AD  - Clinical Psychology and Psychotherapy, Ulm University, Ulm, Baden-Wurttemberg,
      Germany.
LA  - eng
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - *Chronic Pain/therapy
MH  - Cost-Benefit Analysis
MH  - *Depressive Disorder, Major
MH  - Germany
MH  - Humans
MH  - Quality of Life
PMC - PMC7473633
OTO - NOTNLM
OT  - *chronic pain
OT  - *green professions
OT  - *internet- and mobile-based intervention
OT  - *prevention
OT  - *randomised controlled trial
COIS- Competing interests: DE reports to have received consultancy fees and served in
      the scientific advisory board of several companies such as Minddistrict, Lantern,
      Novartis, Sanofi, Schoen Kliniken and German health insurance companies. He is a 
      stakeholder of the Institute for Online Health Training (GET.ON), which aims to
      implement scientific findings related to digital health interventions into
      routine care. HB reports to have received consultancy fees and fees for
      lectures/workshops from chambers of psychotherapists and training institutes for 
      psychotherapists in the e-mental-health context. IT reports to have received fees
      for lectures/workshops in the e-mental-health context from educational
      institutions for psychotherapists. She is implementation lead and project lead
      for the EU-research project ImpleMentAll at the Institute for Online Health
      Training (GET.ON). All other authors reported no competing interests.
EDAT- 2020/09/05 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034271 [pii]
AID - 10.1136/bmjopen-2019-034271 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 3;10(9):e034271. doi: 10.1136/bmjopen-2019-034271.


PMID- 32883709
OWN - NLM
STAT- Publisher
LR  - 20200904
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 3
TI  - More than consent for ethical open-label placebo research.
LID - medethics-2019-105893 [pii]
LID - 10.1136/medethics-2019-105893 [doi]
AB  - Recent studies have explored the effectiveness of open-label placebos (OLPs) for 
      a variety of conditions, including chronic pain, cancer-related fatigue and
      irritable bowel syndrome. OLPs are thought to sidestep traditional ethical
      worries about placebos because they do not involve deception: with an OLP,
      patients or subjects are told outright that they are not given an active
      substance. As deception is framed as the primary hurdle to ethical placebo use,
      the door is ostensibly opened to ethical studies of OLPs. In this article, I
      suggest that even though OLPs seemingly do not involve deception, there are other
      ethical considerations in their clinical investigation and subsequent use.
      Research ethics often focusses on informed consent-of which, deception and
      honesty are a piece-as a means to justify research practices with human subjects.
      Yet, it is but one of the ethical considerations that should be taken into
      account. With research into placebo effects in particular, I argue that the
      history of clinical placebo use grounds special considerations for OLP research
      that go beyond respect for the autonomy of individual patients through informed
      consent and encompass structural concerns about the type of patient for whom a
      placebo has historically been thought appropriate.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Specker Sullivan, Laura
AU  - Specker Sullivan L
AD  - Philosophy, College of Charleston, Charleston, South Carolina, USA
      lspeckersullivan@fordham.edu.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - paternalism
OT  - research ethics
OT  - women
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/09/05 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
AID - medethics-2019-105893 [pii]
AID - 10.1136/medethics-2019-105893 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 3. pii: medethics-2019-105893. doi:
      10.1136/medethics-2019-105893.


PMID- 32883708
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - New way of being a person?
PG  - 755-756
LID - 10.1136/medethics-2020-106584 [doi]
FAU - Wren, Bernadette
AU  - Wren B
AD  - Gender Identity Development Service, Tavistock and Portman NHS Foundation Trust, 
      London, UK bwren@tavi-port.nhs.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200903
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):743-752. PMID: 32709753
CIN - J Med Ethics. 2020 Nov;46(11):761-762. PMID: 33087409
MH  - Adult
MH  - Humans
MH  - Puberty
MH  - *Sexual Behavior
MH  - *Sexuality
OTO - NOTNLM
OT  - *clinical ethics
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/08/01 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/09/05 06:00 [entrez]
AID - medethics-2020-106584 [pii]
AID - 10.1136/medethics-2020-106584 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):755-756. doi: 10.1136/medethics-2020-106584. Epub
      2020 Sep 3.


PMID- 32883707
OWN - NLM
STAT- Publisher
LR  - 20200904
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 3
TI  - Congenitally decorticate children's potential and rights.
LID - medethics-2020-106163 [pii]
LID - 10.1136/medethics-2020-106163 [doi]
AB  - This article is the first indepth ethical analysis of empirical studies that
      support the claim that children born without major parts of their cerebral cortex
      are capable of conscious experiences and have a rudimentary capacity for agency. 
      Congenitally decorticate children have commonly been classified as persistently
      vegetative, with serious consequences for their well-being and opportunities to
      flourish. The paper begins with an explication of the rights-based normative
      framework of the argument, including conceptual analysis of the terms 'agency',
      'potentiality for agency' and 'gradual approach of agency'. It critically
      examines Alan Gewirth's account of the criteria for being a rights bearer and
      principles for settling rights conflicts between agents and potential agents. It 
      then applies the rights-based normative framework to the ethical challenges
      associated with care for congenitally decorticate children. It argues that recent
      empirical studies support the claim that the concepts 'potential for agency' and 
      'capacity for rudimentary agency' apply to children who are born without major
      parts of their cerebral cortex. The article finally discusses important medical
      ethical implications of these results. It specifically focuses on congenitally
      decorticate children's preparatory rights to a stimulating intellectual and
      social environment.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Andersson, Anna-Karin Margareta
AU  - Andersson AM
AD  - Department of Philosophy, Faculty of Humanities, Social Sciences and Education,
      UiT The Arctic University of Norway, Tromso, Troms, Norway
      anna-karin.m.andersson@uit.no.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - capacity
OT  - consciousness
OT  - moral status
OT  - rights
COIS- Competing interests: None declared.
EDAT- 2020/09/05 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/07/11 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
AID - medethics-2020-106163 [pii]
AID - 10.1136/medethics-2020-106163 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 3. pii: medethics-2020-106163. doi:
      10.1136/medethics-2020-106163.


PMID- 32883420
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20201218
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 76
IP  - 10
DP  - 2020 Sep 8
TI  - Ethical Dilemmas Associated With the COVID-19 Pandemic: Dealing With the Unknowns
      and Unanswerables During Training.
PG  - 1266-1269
LID - S0735-1097(20)36100-3 [pii]
LID - 10.1016/j.jacc.2020.07.041 [doi]
FAU - Han, Jason J
AU  - Han JJ
AD  - Division of Cardiovascular Surgery, Department of Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania. Electronic address:
      Jason.Han@Pennmedicine.upenn.edu.
FAU - Luc, Jessica G Y
AU  - Luc JGY
AD  - Division of Cardiovascular Surgery, Department of Surgery, University of British 
      Columbia, Vancouver, British Columbia, Canada.
FAU - Pak, Esther
AU  - Pak E
AD  - Division of Cardiology, Department of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania.
LA  - eng
PT  - Editorial
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
SB  - IM
CIN - J Am Coll Cardiol. 2020 Sep 8;76(10):1269. PMID: 32883421
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Cardiology/education/ethics/trends
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - *Delivery of Health Care/ethics/organization & administration
MH  - *Education/organization & administration/trends
MH  - Ethics, Medical/*education
MH  - Health Care Rationing/*trends
MH  - Humans
MH  - Infection Control/instrumentation/methods
MH  - Medical Staff, Hospital/*education
MH  - Organizational Innovation
MH  - *Pandemics/ethics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Terminal Care/ethics
PMC - PMC7458529
EDAT- 2020/09/05 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - S0735-1097(20)36100-3 [pii]
AID - 10.1016/j.jacc.2020.07.041 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2020 Sep 8;76(10):1266-1269. doi: 10.1016/j.jacc.2020.07.041.


PMID- 32883298
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 3
TI  - South Africa's new standard material transfer agreement: proposals for
      improvement and pointers for implementation.
PG  - 85
LID - 10.1186/s12910-020-00526-x [doi]
AB  - BACKGROUND: Whenever South African (SA) research institutions share human
      biological material and associated data for health research or clinical trials
      they are legally compelled to have a material transfer agreement (MTA) in place
      that uses as framework the standard MTA newly gazetted by the South African
      Minister of Health (SA MTA). MAIN BODY: The article offers a legal analysis of
      the SA MTA and focuses on its substantive fit with the broader legal environment 
      in South Africa, and the clarity and practicality of its terms. The following
      problematic aspects of the SA MTA are highlighted: (a) Where only data and no
      human biological material are transferred, the SA MTA does not apply, leaving a
      lacuna; (b) Health Research Ethics Committees are required to be parties to a MTA
      despite it being outside their legal mandate and undermining their oversight
      function; (c) the SA MTA's consent provisions are not aligned with extant law;
      and, similarly, (d) its provision on donor ownership is misaligned with extant
      law; (e) its creation of fictitious performance can only cause frustration on the
      part of an injured party; (f) its benefit-sharing provision is vague and will
      have little practical effect; (g) its dispute-resolution provisions fail to
      adequately protect South African research institutions and research participants;
      (h) it fails to provide substantive guidance regarding intellectual property as
      its provisions relating to intellectual property may cause practical problems;
      and, finally, (i) its data privacy provision is insufficiently specific, is
      overbroad, and fails to provide terms that in general would facilitate the
      international sharing of human biological material and associated data in terms
      of existing privacy law. CONCLUSIONS: While some of the problematic aspects of
      the SA MTA are intricate and require consultative processes with stakeholders and
      others, to develop comprehensive solutions, most of the problematic aspects can
      be resolved immediately through amendments by the South African Minister of
      Health. The formulation of such amendments is proposed and, where possible,
      interim measures are suggested that may ameliorate the problems presented by the 
      SA MTA.
FAU - Thaldar, Donrich W
AU  - Thaldar DW
AUID- ORCID: https://orcid.org/0000-0002-7346-3490
AD  - School of Law, University of KwaZulu-Natal, Durban, South Africa.
      ThaldarD@ukzn.ac.za.
AD  - African Health Research Flagship, University of KwaZulu-Natal, Durban, South
      Africa. ThaldarD@ukzn.ac.za.
FAU - Botes, Marietjie
AU  - Botes M
AUID- ORCID: https://orcid.org/0000-0002-6613-6977
AD  - School of Law, University of KwaZulu-Natal, Durban, South Africa.
AD  - African Health Research Flagship, University of KwaZulu-Natal, Durban, South
      Africa.
FAU - Nienaber, Annelize
AU  - Nienaber A
AUID- ORCID: https://orcid.org/0000-0002-4518-4312
AD  - Faculty of Law, University of Pretoria, Pretoria, South Africa.
AD  - Centre for Ethics and Philosophy of Health Sciences, Faculty of Health Sciences, 
      University of Pretoria, Pretoria, South Africa.
AD  - Division of Law, Abertay University, Dundee, Scotland, UK.
LA  - eng
GR  - African Health Research Flagship Grant/University of KwaZulu-Natal/International
GR  - 116275/National Research Foundation/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
EIN - BMC Med Ethics. 2020 Nov 20;21(1):120. PMID: 33218333
MH  - Ethics Committees, Research
MH  - Humans
MH  - *Intellectual Property
MH  - Ownership
MH  - South Africa
MH  - *Transfer Agreement
PMC - PMC7469330
OTO - NOTNLM
OT  - *Benefit-sharing
OT  - *Consent
OT  - *Human biological material
OT  - *Intellectual property rights
OT  - *MTA
OT  - *Material transfer agreement
OT  - *Privacy
OT  - *Research ethics
EDAT- 2020/09/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/05 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00526-x [doi]
AID - 10.1186/s12910-020-00526-x [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 3;21(1):85. doi: 10.1186/s12910-020-00526-x.


PMID- 32883258
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 3
TI  - White lie during patient care: a qualitative study of nurses' perspectives.
PG  - 86
LID - 10.1186/s12910-020-00528-9 [doi]
AB  - BACKGROUND: Keeping the patients well and fully informed about diagnosis,
      prognosis, and treatments is one of the patient's rights in any healthcare
      system. Although all healthcare providers have the same viewpoint about rendering
      the truth in treatment process, sometimes the truth is not told to the patients; 
      that is why the healthcare staff tell "white lie" instead. This study aimed to
      explore the nurses' experience of white lies during patient care. METHODS: This
      qualitative study was conducted from June to December 2018. Eighteen hospital
      nurses were recruited with maximum variation from ten state-run educational
      hospitals affiliated to Tehran University of Medical Sciences. Purposeful
      sampling was used and data were collected by semi-structured interviews that were
      continued until data saturation. Data were classified and analyzed by content
      analysis approach. RESULTS: The data analysis in this study resulted in four main
      categories and 11 subcategories. The main categories included hope crisis, bad
      news, cultural diversity, and nurses' limited professional competences.
      CONCLUSION: Results of the present study showed that, white lie told by nurses
      during patient care may be due to a wide range of patient, nurse and/or
      organizational related factors. Communication was the main factor that influenced
      information rendering. Nurses' communication with patients should be based on
      mutual respect, trust and adequate cultural knowledge, and also nurses should
      provide precise information to patients, so that they can make accurate decisions
      regarding their health care.
FAU - Nasrabadi, A Nikbakht
AU  - Nasrabadi AN
AUID- ORCID: 0000-0002-3970-4158
AD  - School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat
      St., Tohid Sq, Tehran, 141973317, Iran.
FAU - Joolaee, S
AU  - Joolaee S
AUID- ORCID: 0000-0003-1487-6110
AD  - School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat
      St., Tohid Sq, Tehran, 141973317, Iran.
AD  - Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
AD  - Center for Evaluation & Outcome Sciences (CHEOS), University of British Columbia,
      Vancouver, Canada.
FAU - Navab, E
AU  - Navab E
AUID- ORCID: 0000-0002-2776-1585
AD  - School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat
      St., Tohid Sq, Tehran, 141973317, Iran.
FAU - Esmaeili, M
AU  - Esmaeili M
AUID- ORCID: 0000-0002-4798-2270
AD  - School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat
      St., Tohid Sq, Tehran, 141973317, Iran.
FAU - Shali, M
AU  - Shali M
AUID- ORCID: 0000-0003-4094-8878
AD  - School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat
      St., Tohid Sq, Tehran, 141973317, Iran. m.shali@ZUMS.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200903
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Communication
MH  - Humans
MH  - Iran
MH  - *Nurses
MH  - Patient Care
MH  - Qualitative Research
PMC - PMC7470607
OTO - NOTNLM
OT  - *Content analysis
OT  - *Ethics
OT  - *Nurse
OT  - *Truth-telling
OT  - *White lie
EDAT- 2020/09/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/05 06:00
PHST- 2019/12/11 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/05 06:00 [entrez]
PHST- 2020/09/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00528-9 [doi]
AID - 10.1186/s12910-020-00528-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 3;21(1):86. doi: 10.1186/s12910-020-00528-9.


PMID- 32882606
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1872-7484 (Electronic)
IS  - 1566-0702 (Linking)
VI  - 228
DP  - 2020 Nov
TI  - Ventromedial medullary pathway mediating cardiac responses evoked from
      periaqueductal gray.
PG  - 102716
LID - S1566-0702(20)30150-8 [pii]
LID - 10.1016/j.autneu.2020.102716 [doi]
AB  - Periaqueductal gray (PAG) is a midbrain region that projects to areas controlling
      behavioral and autonomic outputs and is involved in the behavioral and
      physiological components of defense reactions. Since Raphe Pallidus (RPa) is a
      medial medullary region comprising sympathetic premotor neurons governing heart
      function, it is worth considering the PAG-RPa path. We assessed: i) whether PAG
      projects to RPa; ii) the amplitude of cardiac responses evoked from PAG; iii)
      whether cardiovascular responses evoked from PAG rely on RPa. Experiments
      conducted in Wistar rats (+/-300 g) were approved by Ethics Committee CEUA-UFG
      (092/18). Firstly, (n = 3), monosynaptic retrograde tracer Retrobeads was
      injected into RPa; PAG slices were analyzed. Other two groups (n = 6 each) were
      anesthetized with urethane (1.4 g/kg) and chloralose (120 mg/kg) and underwent
      craniotomy, tracheostomy, catheterization of femoral artery and vein and of
      cardiac left ventricle. In one group, we injected the GABAA receptor antagonist, 
      bicuculline methiodide (BMI - 40 pmol/100 nL) into lateral/dorsolateral PAG.
      Another group was injected (100 nL) with the GABAA receptor agonist muscimol (20 
      mM) into RPa, 20 min before BMI into PAG. The results were: i) retrogradely
      labelled neurons were found in PAG; ii) PAG activation by BMI caused positive
      chronotropism and inotropism, which were accompanied by afterload increases; iii)
      RPa inhibition with Muscimol reduced heart rate, arterial and ventricular
      pressures; iv) the subsequent PAG activation still increased arterial pressure,
      cardiac chronotropy and inotropy, but these responses were significantly
      attenuated. In conclusion, PAG activation increases cardiac chronotropy and
      inotropy, and these responses seem to rely on a direct pathway reaching
      ventromedial medullary RPa neurons.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Moraes, G C A
AU  - Moraes GCA
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil; UNICEUG - Centro
      Universitario de Goiania, Goias, Brazil.
FAU - Mendonca, M M
AU  - Mendonca MM
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Mourao, A A
AU  - Mourao AA
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Graziani, D
AU  - Graziani D
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Pinto, M C X
AU  - Pinto MCX
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Ferreira, P M
AU  - Ferreira PM
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Pedrino, G R
AU  - Pedrino GR
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Fontes, M A P
AU  - Fontes MAP
AD  - Hypertension Laboratory, Institute of Biological Sciences, Federal University of 
      Minas Gerais, Brazil.
FAU - Oliveira-Lima, O C
AU  - Oliveira-Lima OC
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil.
FAU - Xavier, C H
AU  - Xavier CH
AD  - Systems Neurobiology Laboratory, Department of Physiology, Institute of
      Biological Sciences, Federal University of Goias, Brazil. Electronic address:
      carlosxavier@ufg.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200812
PL  - Netherlands
TA  - Auton Neurosci
JT  - Autonomic neuroscience : basic & clinical
JID - 100909359
RN  - 0 (GABA-A Receptor Agonists)
RN  - 0 (GABA-A Receptor Antagonists)
SB  - IM
MH  - Animals
MH  - Blood Pressure/drug effects/*physiology
MH  - GABA-A Receptor Agonists/pharmacology
MH  - GABA-A Receptor Antagonists/pharmacology
MH  - Heart/drug effects/*physiology
MH  - Male
MH  - Neural Pathways/drug effects/physiology
MH  - Nucleus Raphe Pallidus/drug effects/*physiology
MH  - Periaqueductal Gray/drug effects/*physiology
MH  - Rats, Wistar
MH  - Sympathetic Nervous System/drug effects/*physiology
OTO - NOTNLM
OT  - *Blood pressure
OT  - *Cardiac function
OT  - *Defense reaction
OT  - *Periaqueductal gray
OT  - *Raphe pallidus
COIS- Declaration of competing interest No conflicts of interest, financial or
      otherwise, are declared by the authors.
EDAT- 2020/09/04 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - S1566-0702(20)30150-8 [pii]
AID - 10.1016/j.autneu.2020.102716 [doi]
PST - ppublish
SO  - Auton Neurosci. 2020 Nov;228:102716. doi: 10.1016/j.autneu.2020.102716. Epub 2020
      Aug 12.


PMID- 32882512
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 260
DP  - 2020 Nov
TI  - Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical
      therapeutic advancement: Promising development opportunities and translational
      challenges.
PG  - 120163
LID - S0142-9612(20)30409-9 [pii]
LID - 10.1016/j.biomaterials.2020.120163 [doi]
AB  - Nanotechnology and microfabrication approaches are playing instrumental roles in 
      the development of innovative technologies to fight human diseases. Because of
      promising in vitro and preclinical outcomes, micro-/nanorobots (MNRs), are
      increasingly being considered for personalized and precision therapeutic
      diagnoses, sensing, drug delivery, and surgery. Today, designing MNR-based
      devices to improve the safety and efficacy of drugs for targeted cells and
      tissues represents a novel and promising area of therapeutic development.
      Progress has primarily been due to many scientific breakthroughs made in design, 
      fabrication, and operational technologies, which greatly enhanced the
      capabilities of MNRs to meet the requirements of biomedical applications. This
      review focuses on the development and emerging biomedical applications of
      micro-/nanostructures encompassing nanoswimmers, nanoengines, 3D-motion
      nanomachines, and biologically inspired microbots, nanofish, nanorockets, etc.
      Promising applications of these novel devices in various therapeutic areas are
      discussed. We examine the impacts of the rapid progress made in developing these 
      novel devices for drug delivery applications. We also summarize the current
      fabrication, scale-up development and clinical translational challenges and the
      main roadblocks that need to be overcome, particularly those related to patient
      safety and personalized medicine approaches, areas that require the design of
      safe innovative materials. As MNRs are new, scientists should systematically
      investigate their behavior, functionality, biocompatibility, toxicity,
      biodistribution, and efficacy before considering any potential clinical
      evaluations, while also ensuing that they comply with ethical principles.
      Although still an emerging area, MNRs are steadily becoming a realistic prospect 
      as vital future therapeutic tools for a vast array of biomedical applications.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Agrahari, Vibhuti
AU  - Agrahari V
AD  - Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA.
FAU - Agrahari, Vivek
AU  - Agrahari V
AD  - CONRAD, Eastern Virginia Medical School, Arlington, VA, USA. Electronic address: 
      vivekvagrahari@gmail.com.
FAU - Chou, Ming-Li
AU  - Chou ML
AD  - Graduate Institute of Biomedical Materials and Tissue Engineering, College of
      Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
FAU - Chew, Chew Ho
AU  - Chew CH
AD  - Graduate Institute of Biomedical Materials and Tissue Engineering, College of
      Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
FAU - Noll, James
AU  - Noll J
AD  - Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA.
FAU - Burnouf, Thierry
AU  - Burnouf T
AD  - Graduate Institute of Biomedical Materials and Tissue Engineering, College of
      Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International 
      PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei 
      Medical University, Taipei, Taiwan. Electronic address: thburnouf@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200530
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Humans
MH  - Microtechnology
MH  - *Nanostructures
MH  - Nanotechnology
MH  - *Pharmaceutical Preparations
MH  - Tissue Distribution
OTO - NOTNLM
OT  - *Cell delivery
OT  - *Clinical translation
OT  - *Drug delivery
OT  - *Microfabrication
OT  - *Nanomotors
OT  - *Nanorobots
OT  - *Nanotechnology
EDAT- 2020/09/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - S0142-9612(20)30409-9 [pii]
AID - 10.1016/j.biomaterials.2020.120163 [doi]
PST - ppublish
SO  - Biomaterials. 2020 Nov;260:120163. doi: 10.1016/j.biomaterials.2020.120163. Epub 
      2020 May 30.


PMID- 32882359
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1873-6513 (Electronic)
IS  - 0885-3924 (Linking)
VI  - 60
IP  - 6
DP  - 2020 Dec
TI  - Can Orthodox Jewish Patients Undergo Palliative Extubation? A Challenging Ethics 
      Case Study.
PG  - 1260-1265
LID - S0885-3924(20)30713-2 [pii]
LID - 10.1016/j.jpainsymman.2020.08.027 [doi]
AB  - According to Jewish law/ethics, continuous life-sustaining therapy may not be
      withdrawn after its introduction, unless the patient has improved and no longer
      has a medical indication for the treatment. We report the case of an 88-year-old 
      Orthodox Jewish patient, on invasive mechanical ventilation, with severe anoxic
      brain injury after multiple cardiac arrests. Although the patient's son informed 
      the palliative care team that his father did not want to be in pain or to linger 
      in a vegetative state when terminally ill, the mechanical ventilation was keeping
      him alive with a poor neurological prognosis. Additionally, the patient had
      previously stated his wish to observe Orthodox Jewish principles regarding
      end-of-life care. After extensive discussion, the family Rabbi clarified that it 
      would be acceptable to withdraw mechanical ventilation if there were a
      "reasonable expectation" he would breathe on his own for a "reasonable amount of 
      time." Thus, if the patient's death were to occur, it would not be an immediate
      consequence the normal ventilator weaning process. Following intermediation by
      the hospital Rabbi, the definition of what would be a "reasonable expectation"
      and "reasonable amount of time" was established by the family Rabbi as "over 50%"
      and "on the order of hours," respectively. Following pulmonary consultation, the 
      patient underwent palliative extubation and, 12 hours after the procedure, died
      comfortably surrounded by the family. In conclusion, the collaborative and
      interdisciplinary work among the family Rabbi, hospital Rabbi, and the various
      medical teams allowed the development of a plan that met all of the patient's
      personal and religious wishes and beliefs.
CI  - Copyright (c) 2020 American Academy of Hospice and Palliative Medicine. Published
      by Elsevier Inc. All rights reserved.
FAU - Pan, Cynthia X
AU  - Pan CX
AD  - Division of Geriatrics and Palliative Care Medicine, New York-Presbyterian
      Queens, Flushing, New York, USA. Electronic address: cxp9001@nyp.org.
FAU - Costa, Bruno Almeida
AU  - Costa BA
AD  - Department of Internal Medicine, Walter Cantidio University Hospital, Federal
      University of Ceara, Fortaleza, Ceara, Brazil.
FAU - Yushuvayev, Elina K
AU  - Yushuvayev EK
AD  - Division of Geriatrics and Palliative Care Medicine, New York-Presbyterian
      Queens, Flushing, New York, USA.
FAU - Gross, Liam
AU  - Gross L
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine,
      NewYork-Presbyterian Brooklyn Methodist, Brooklyn, New York, USA.
FAU - Kawai, Fernando
AU  - Kawai F
AD  - Division of Geriatrics and Palliative Care Medicine, New York-Presbyterian
      Queens, Flushing, New York, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200831
PL  - United States
TA  - J Pain Symptom Manage
JT  - Journal of pain and symptom management
JID - 8605836
SB  - IM
MH  - Aged, 80 and over
MH  - Airway Extubation
MH  - Humans
MH  - *Jews
MH  - Judaism
MH  - Male
MH  - Palliative Care
MH  - *Terminal Care
OTO - NOTNLM
OT  - *End-of-life care
OT  - *Jewish medical ethics
OT  - *Orthodox Jewish
OT  - *Palliative Extubation
OT  - *Spiritual Competencies
OT  - *Treatment withdrawal
EDAT- 2020/09/04 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - S0885-3924(20)30713-2 [pii]
AID - 10.1016/j.jpainsymman.2020.08.027 [doi]
PST - ppublish
SO  - J Pain Symptom Manage. 2020 Dec;60(6):1260-1265. doi:
      10.1016/j.jpainsymman.2020.08.027. Epub 2020 Aug 31.


PMID- 32882091
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 34
IP  - 11
DP  - 2020 Nov
TI  - Living donor financial assistance programs in liver transplantation: The global
      perspective.
PG  - e14073
LID - 10.1111/ctr.14073 [doi]
AB  - Living donor liver transplantation (LDLT) has increased availability of liver
      transplantation, particularly in countries with limited access to deceased organ 
      donors. It is unclear how individual countries address the financial impact of
      donation for potential living donors. Herein, living liver donor financial
      supports were examined, focusing on countries performing >/=10 LDLT per year in
      the World Health Organization Transplant Observatory. Categories included health 
      insurance coverage, reimbursement of lost wages, employment protection, and other
      incentives designed to promote living liver donation. Overall, 26 countries have 
      some form of asssistance in removing disincentives to ease the financial burden
      of living donation, ranging from childcare, accommodations, meals, and travel
      reimbursement, to coverage of medical complications post-donation. Most countries
      provide donation-related medical coverage. Fourteen provide reimbursement of lost
      wages and/or paid time off. Several unique programs were designed to incentivize 
      living donation, including free entry to museums and observatories, parking and
      airline discounts, and exemptions on mortgages and medical deductibles. This
      study highlights the broad range of programs designed to support living liver
      donation in high-volume LDLT countries. The data collected in this study can
      provide a framework for other nations to propose and implement ethical
      reimbursement and incentivization for living liver donors.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Emamaullee, Juliet
AU  - Emamaullee J
AUID- ORCID: 0000-0003-4238-3057
AD  - Division of Hepatobiliary and Abdominal Organ Transplant Surgery, University of
      Southern California, Los Angeles, California, USA.
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
FAU - Tenorio, Lisa
AU  - Tenorio L
AD  - School of Medicine, St. Louis University, St. Louis, Missouri, USA.
FAU - Khan, Sara
AU  - Khan S
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
FAU - Butler, Chante
AU  - Butler C
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
FAU - Kim, Susan
AU  - Kim S
AD  - University of Southern California Transplant Institute, Los Angeles, California, 
      USA.
FAU - Tucker-Seeley, Reginald
AU  - Tucker-Seeley R
AD  - Davis School of Gerontology, University of Southern California, Los Angeles,
      California, USA.
FAU - Kwon, Yong
AU  - Kwon Y
AD  - Division of Hepatobiliary and Abdominal Organ Transplant Surgery, University of
      Southern California, Los Angeles, California, USA.
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
FAU - Shapiro, James
AU  - Shapiro J
AD  - Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
FAU - Saigal, Sanjiv
AU  - Saigal S
AD  - Medanta The Medicity, Gurgaon, India.
FAU - Sher, Linda
AU  - Sher L
AD  - Division of Hepatobiliary and Abdominal Organ Transplant Surgery, University of
      Southern California, Los Angeles, California, USA.
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
FAU - Genyk, Yuri
AU  - Genyk Y
AD  - Division of Hepatobiliary and Abdominal Organ Transplant Surgery, University of
      Southern California, Los Angeles, California, USA.
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
LA  - eng
PT  - Journal Article
DEP - 20200927
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
SB  - IM
MH  - Humans
MH  - *Liver Transplantation
MH  - Living Donors
MH  - Motivation
MH  - *Tissue and Organ Procurement
MH  - Travel
OTO - NOTNLM
OT  - *comprehensive review
OT  - *living donor incentivization
OT  - *living donor liver transplant
OT  - *living donor reimbursement
EDAT- 2020/09/04 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - 10.1111/ctr.14073 [doi]
PST - ppublish
SO  - Clin Transplant. 2020 Nov;34(11):e14073. doi: 10.1111/ctr.14073. Epub 2020 Sep
      27.


PMID- 32882052
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1938-2367 (Electronic)
IS  - 0147-7447 (Linking)
VI  - 43
IP  - 6
DP  - 2020 Nov 1
TI  - Allergic Contact Dermatitis to Dermabond Prineo After Elective Orthopedic
      Surgery.
PG  - e515-e522
LID - 10.3928/01477447-20200827-01 [doi]
AB  - The Dermabond Prineo skin closure system (Ethicon, Somerville, New Jersey) is a
      wound closure device that combines a 2-octyl cyanoacrylate liquid adhesive and a 
      self-adhesive polyester mesh. Although cyanoacrylates traditionally have been
      associated with low rates of sensitization, allergic contact dermatitis (ACD) to 
      Dermabond products is being increasingly reported after orthopedic surgery. The
      authors describe the first case series of ACD to Dermabond Prineo where patch
      testing confirmed the diagnosis in all patients. Six patients who had suspected
      Dermabond Prineo ACD after lower limb orthopedic surgery were assessed. Of these 
      patients, 5 had itching within 4 days of surgery and rash within 5 days. All 5 of
      these patients reported previous exposure to Dermabond products. All patients had
      removal of the adhesive and mesh earlier than planned and were treated with
      corticosteroids. In addition, 4 patients received systemic antibiotics; however, 
      only 1 had a microbiologically confirmed superficial skin infection. In all
      patients, the dermatitis resolved within 2 weeks of dressing removal, with no
      adverse effect on the orthopedic outcome. Patch testing showed positive reactions
      to Dermabond Prineo glue for all patients. Orthopedic surgeons should be aware of
      the potential for ACD to Dermabond Prineo, especially among patients with
      previous exposure to Dermabond products. The authors discuss the risk factors for
      ACD to Dermabond Prineo in the orthopedic cohort and provide recommendations for 
      prevention and management. [Orthopedics. 2020;43(6):e515-e522.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Ricciardo, Bernadette M
AU  - Ricciardo BM
FAU - Nixon, Rosemary L
AU  - Nixon RL
FAU - Tam, Mei Mui
AU  - Tam MM
FAU - Radic, Ross R
AU  - Radic RR
FAU - Ricciardo, Brendan J
AU  - Ricciardo BJ
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - United States
TA  - Orthopedics
JT  - Orthopedics
JID - 7806107
RN  - 0 (Cyanoacrylates)
RN  - 0 (Tissue Adhesives)
RN  - 6C655P1XVG (octyl 2-cyanoacrylate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cyanoacrylates/*adverse effects
MH  - Dermatitis, Allergic Contact/diagnosis/drug therapy/*etiology
MH  - Elective Surgical Procedures
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Orthopedic Procedures
MH  - Patch Tests
MH  - Surgical Mesh
MH  - Tissue Adhesives/*adverse effects
MH  - Young Adult
EDAT- 2020/09/04 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2019/07/27 00:00 [received]
PHST- 2019/10/08 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - 10.3928/01477447-20200827-01 [doi]
PST - ppublish
SO  - Orthopedics. 2020 Nov 1;43(6):e515-e522. doi: 10.3928/01477447-20200827-01. Epub 
      2020 Sep 3.


PMID- 32881719
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Oct
TI  - Ethical decision-making in simultaneous heart-liver transplantation.
PG  - 519-525
LID - 10.1097/MOT.0000000000000806 [doi]
AB  - PURPOSE OF REVIEW: Simultaneous heart-liver (SHL) transplants are only a small
      proportion of overall heart and liver transplantation, they have been increasing 
      in frequency and thus challenge the equitable allocation of organs. RECENT
      FINDINGS: The incidence of SHL transplants is reviewed along with the outcomes of
      SHL transplants and their impact on the waitlist, particularly in the context of 
      solitary heart and liver transplantation. The ethical implications, most
      importantly the principles of utility and equity, of SHL transplant are
      addressed. In the context of utility, the distinction of a transplant being
      life-saving versus life-enhancing is investigated. The risk of hepatic
      decompensation for those awaiting both solitary and combined organ
      transplantation is an important consideration for the principle of equity.
      Lastly, the lack of standardization of programmatic approaches to SHL transplant 
      candidates, the national approach to allocation, and the criteria by which
      programs are evaluated are reviewed. SUMMARY: As with all multiorgan
      transplantation, SHL transplantation raises ethical issues of utility and equity.
      Given the unique patient population, good outcomes, lack of alternatives, and
      overall small numbers, we feel there is continued ethical justification for SHL, 
      but a more standardized nationwide approach to the evaluation, listing, and
      allocation of organs is warranted.
FAU - Cheng, Xinxing S
AU  - Cheng XS
AD  - Division of Nephrology, Department of Medicine, Stanford University School of
      Medicine, Stanford, California.
FAU - Wall, Anji
AU  - Wall A
AD  - Baylor University Medical Center, Dallas, TX.
FAU - Teuteberg, Jeffrey
AU  - Teuteberg J
AD  - Division of Cardiology, Department of Medicine, Stanford University School of
      Medicine, Stanford, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Decision Making/*ethics
MH  - Heart Transplantation/*ethics/methods
MH  - Humans
MH  - Liver Transplantation/*ethics/methods
EDAT- 2020/09/04 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - 10.1097/MOT.0000000000000806 [doi]
AID - 00075200-202010000-00013 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Oct;25(5):519-525. doi:
      10.1097/MOT.0000000000000806.


PMID- 32881276
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - Finding Strength in Vulnerability: Ethical Approaches when Conducting Research
      with Vulnerable Populations.
PG  - 802-807
LID - 10.1111/jmwh.13151 [doi]
AB  - Researchers who desire to make positive changes for vulnerable populations often 
      conduct problem-focused studies. Although problem-focused research is important, 
      when such studies are not carefully designed, their results can contribute to a
      deficit discourse. A deficit discourse is a narrative that describes the person
      through a myopic lens of negativity characterized only by illness, death,
      depression, failure, or the like. Deficit discourse negatively affects how health
      care providers and society interact with vulnerable people. This article
      discusses deficit discourse in health care and strengths-based research: an
      ethical approach to working with vulnerable individuals in research settings and 
      a strategy to overcome deficit discourse. Strengths-based research approaches
      balance risks with countermeasures that include areas that are positive and
      amenable to growth or intervention. Strengths-based research can be conducted
      using qualitative, quantitative, or mixed-methods methodology. Strengths-based
      research should be culturally relevant and population-specific, often including
      the individuals of study throughout the process. By modifying the research
      approach, critical problems can be identified and addressed while also
      emphasizing positive ways to empower individuals and improve their lives.
      Additionally, these changes better the way researchers and health care providers 
      view and care for people while also challenging deficit discourses in society at 
      large.
CI  - (c) 2020 by the American College of Nurse-Midwives.
FAU - Mollard, Elizabeth
AU  - Mollard E
AUID- ORCID: 0000-0003-0221-3459
AD  - College of Nursing - Lincoln Division, University of Nebraska Medical Center,
      Lincoln, Nebraska.
FAU - Hatton-Bowers, Holly
AU  - Hatton-Bowers H
AUID- ORCID: 0000-0002-4165-791X
AD  - College of Education and Human Sciences, University of Nebraska, Lincoln,
      Nebraska.
FAU - Tippens, Julie
AU  - Tippens J
AUID- ORCID: 0000-0003-0465-3570
AD  - College of Education and Human Sciences, University of Nebraska, Lincoln,
      Nebraska.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - *Delivery of Health Care
MH  - Ethics, Research
MH  - Humans
MH  - *Vulnerable Populations
EDAT- 2020/09/04 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/03/15 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - 10.1111/jmwh.13151 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):802-807. doi: 10.1111/jmwh.13151. Epub 
      2020 Sep 3.


PMID- 32881275
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20210110
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 8
DP  - 2020 Aug
TI  - Advance care planning in Australia during the COVID-19 outbreak: now more
      important than ever.
PG  - 918-923
LID - 10.1111/imj.14937 [doi]
AB  - The novel Coronavirus disease 2019 (COVID-19) outbreak has led to rapid and
      profound changes in healthcare system delivery and society more broadly. Older
      adults, and those living with chronic or life-limiting conditions, are at
      increased risk of experiencing severe or critical symptoms associated with
      COVID-19 infection and are more likely to die. They may also experience
      non-COVID-19 related deterioration in their health status during this period.
      Advance care planning (ACP) is critical for this cohort, yet there is no
      coordinated strategy for increasing the low rates of ACP uptake in these groups, 
      or more broadly. This paper outlines a number of key reasons why ACP is an urgent
      priority, and should form a part of the health system's COVID-19 response
      strategy. These include reducing the need for rationing, planning for surges in
      healthcare demand, respecting human rights, enabling proactive care coordination 
      and leveraging societal change. We conclude with key recommendations for policy
      and practice in the system-wide implementation of ACP, to enable a more ethical, 
      coordinated and person-centred response in the COVID-19 context.
CI  - (c) 2020 The Authors. Internal Medicine Journal published by John Wiley & Sons
      Australia, Ltd on behalf of Royal Australasian College of Physicians.
FAU - Sinclair, Craig
AU  - Sinclair C
AD  - Centre of Excellence in Population Ageing Research, University of New South
      Wales, Sydney, New South Wales, Australia.
AD  - Neuroscience Research Australia (NeuRA), Sydney, New South Wales, Australia.
FAU - Nolte, Linda
AU  - Nolte L
AD  - Advance Care Planning Australia, Austin Health, Melbourne, Victoria, Australia.
FAU - White, Ben P
AU  - White BP
AUID- ORCID: https://orcid.org/0000-0003-3365-939X
AD  - Australian Centre for Health Law Research, Faculty of Law, Queensland University 
      of Technology, Brisbane, Queensland, Australia.
FAU - M Detering, Karen
AU  - M Detering K
AUID- ORCID: https://orcid.org/0000-0002-1884-7272
AD  - Advance Care Planning Australia, Austin Health, Melbourne, Victoria, Australia.
AD  - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Faculty of Health, Arts and Design, Swinburne University of Technology,
      Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
MH  - *Advance Care Planning/ethics/organization & administration
MH  - Age Factors
MH  - Australia/epidemiology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Deterioration
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Critical Illness/therapy
MH  - *Delivery of Health Care/organization & administration/trends
MH  - Health Services Needs and Demand/trends
MH  - Human Rights
MH  - Humans
MH  - Organizational Innovation
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - SARS-CoV-2
PMC - PMC7436410
OTO - NOTNLM
OT  - *COVID-19
OT  - *advance care planning
OT  - *human rights
EDAT- 2020/09/04 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1111/imj.14937 [doi]
PST - ppublish
SO  - Intern Med J. 2020 Aug;50(8):918-923. doi: 10.1111/imj.14937.


PMID- 32880555
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 6
DP  - 2020 Apr 22
TI  - COVID-19 and quarantine orders: A practical approach.
PG  - 469-472
LID - 10.7196/SAMJ.2020v110i6.14794 [doi]
AB  - Quarantine is a very effective method for containing the spread of highly
      infectious diseases in large populations during a pandemic, but it is only
      effective if properly implemented. The co-operation and compliance of people
      entering quarantine are critical to its success. However, owing to the isolating 
      and social distancing nature of quarantine, it often leads to extreme economic
      hardship and shortages in basic needs such as food, medicine, water and
      communication - and to the curtailment of certain universal social norms such as 
      attending a parent's funeral. To escape these hardships, people often refuse to
      enter voluntary quarantine, or breach quarantine rules. In these circumstances,
      health authorities are obliged to act in the best interests of the public and
      obtain court orders to force some people into quarantine. In further extreme
      circumstances, when a national lockdown is ordered, non-compliance with
      quarantine measures may result in arrests and penalties. The scope of this
      article is limited to the period prior to and following such a lockdown, during
      which quarantine may still be vital for the containment of COVID-19. Because a
      quarantine order will deprive an individual of his or her freedom, this must be
      carefully balanced with the public interest. This article explains the legal and 
      ethical considerations of this balancing exercise and provides practical guidance
      for obtaining quarantine orders.
FAU - Botes, W M
AU  - Botes WM
AD  - Health Law and Bioethics, School of Law, University of KwaZulu-Natal, Durban,
      South Africa. botesm@ukzn.ac.za.
FAU - Thaldar, D W
AU  - Thaldar DW
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health/ethics/*legislation & jurisprudence
MH  - Quarantine/ethics/*legislation & jurisprudence
MH  - South Africa/epidemiology
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.7196/SAMJ.2020v110i6.14794 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Apr 22;110(6):469-472. doi: 10.7196/SAMJ.2020v110i6.14794.


PMID- 32880552
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 6
DP  - 2020 Apr 24
TI  - COVID-19 and patient-doctor confidentiality.
PG  - 461-462
AB  - Given the increasing numbers of ethical and legal issues arising from the
      COVID-19 epidemic, particularly in respect of patient-doctor confidentiality,
      doctors must explain to patients how the measures taken to combat the spread of
      the virus impact on their confidentiality. Patients must be reassured that
      doctors are ethically bound to continue to respect such confidentiality, but it
      should be made clear to them that doctors must also comply with the demands of
      the law. While the Constitution, statutory law and the common law all recognise a
      person's right to privacy, during extraordinary times such as the COVID-19
      pandemic, confidentiality must be breached to a degree to halt the spread of the 
      virus.
FAU - McQuoid-Mason, D J
AU  - McQuoid-Mason DJ
AD  - Centre for Socio-Legal Studies, University of KwaZulu-Natal, Durban, South
      Africa. mcquoidm@ukzn.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19
MH  - Confidentiality/ethics/*legislation & jurisprudence
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - *Ethics, Medical
MH  - Humans
MH  - Pandemics/legislation & jurisprudence/prevention & control
MH  - Physician-Patient Relations/*ethics
MH  - Pneumonia, Viral/*epidemiology/prevention & control
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Apr 24;110(6):461-462.


PMID- 32880550
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 6
DP  - 2020 Apr 23
TI  - Isolation and quarantine in South Africa during COVID-19: Draconian measures or
      proportional response?
PG  - 456-457
LID - 10.7196/SAMJ.2020v110i6.14842 [doi]
AB  - In the midst of an unprecedented public health crisis, extraordinary containment 
      measures must be implemented. These include both isolation and quarantine, either
      on a voluntary basis or enforced. In the transition from voluntary to mandatory
      isolation, conflicts arise at the intersection of ethics, human rights and the
      law. The Siracusa Principles adopted by the United Nations Economic and Social
      Council in 1985 and enshrined in international human rights legislation and
      guidelines specify conditions under which civil liberties may be infringed. In
      order for isolation processes in South Africa to claim legitimacy, it is
      important that these principles as well as national laws and constitutional
      rights are embedded in state action.
FAU - Moodley, K
AU  - Moodley K
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Cape Town, South Africa.
      km@sun.ac.za.
FAU - Obasa, A E
AU  - Obasa AE
FAU - London, L
AU  - London L
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Ethics, Medical
MH  - Human Rights/*legislation & jurisprudence
MH  - Humans
MH  - Pandemics/ethics/*prevention & control
MH  - Patient Isolation/*legislation & jurisprudence
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health
MH  - Quarantine/*legislation & jurisprudence
MH  - South Africa/epidemiology
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.7196/SAMJ.2020v110i6.14842 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Apr 23;110(6):456-457. doi: 10.7196/SAMJ.2020v110i6.14842.


PMID- 32880548
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 6
DP  - 2020 May 14
TI  - Pandemics, professionalism and the duty of care: Concerns from the coalface.
PG  - 450-452
AB  - It is likely that the SARS-CoV-2 pandemic will affect a large part of the world's
      population and will last for several years. Many critical ethical issues have
      arisen in the healthcare context. While response from healthcare professionals to
      participating in the care of patients in the era of COVID-19 has generally been
      positive, there have also been disturbing experiences on the ground. The practice
      of medicine is a social contract with humanity. Challenges have arisen because
      the patient is both a victim and a vector of the coronavirus. All humans should
      have a natural instinct to care for those in need. Ethically and legally,
      healthcare professionals cannot be expected to assume a significant and
      unreasonable risk of harm. While fear is understandable, altruism and interest in
      serving the sick exemplify the value of solidarity. Social harms like
      stigmatisation and discrimination can occur. Concerns have been raised regarding 
      protection of privacy and respect for rights of infected individuals. In the era 
      of COVID-19, fear, misinformation and a detachment from one's calling put
      professionalism strongly to the test.
FAU - Dhai, A
AU  - Dhai A
AD  - School of Clinical Medicine, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa. ames.dhai@wits.ac.za.
FAU - Veller, M
AU  - Veller M
FAU - Ballot, D
AU  - Ballot D
FAU - Mokhachane, M
AU  - Mokhachane M
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Altruism
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Delivery of Health Care/ethics/*organization & administration
MH  - Health Personnel/ethics/*organization & administration
MH  - Humans
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Professionalism
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 May 14;110(6):450-452.


PMID- 32880544
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 6
DP  - 2020 May 19
TI  - Building trust during COVID 19: Value-driven and ethical priority-setting.
PG  - 443-444
FAU - Mosam, A
AU  - Mosam A
AD  - PRICELESS SA: SAMRC/Wits Centre for Health Economics and Decision Science, School
      of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
      Johannesburg, South Africa. atiya.sph@gmail.com.
FAU - Goldstein, S
AU  - Goldstein S
FAU - Erzse, A
AU  - Erzse A
FAU - Tugendhaft, A
AU  - Tugendhaft A
FAU - Hofman, K
AU  - Hofman K
LA  - eng
PT  - Editorial
DEP - 20200519
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - *Budgets
MH  - COVID-19
MH  - Coronavirus Infections/economics/*epidemiology
MH  - *Ethics, Medical
MH  - Humans
MH  - Pandemics/economics/ethics
MH  - Pneumonia, Viral/economics/*epidemiology
MH  - South Africa/epidemiology
MH  - Trust
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 May 19;110(6):443-444.


PMID- 32880493
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1745-2422 (Electronic)
IS  - 1743-4440 (Linking)
VI  - 17
IP  - 9
DP  - 2020 Sep
TI  - STUDY PROTOCOL - pulsed radiofrequency in addition to transforaminal epidural
      steroid injection in patients with acute and subacute sciatica due to lumbosacral
      disc herniation: rationale and design of a phase III, multicenter, randomized,
      controlled trial.
PG  - 945-949
LID - 10.1080/17434440.2020.1815529 [doi]
AB  - Lumbosacral disc herniation (LDH) represents the most common cause of sciatica.
      Currently, there is limited evidence about minimally invasive interventional
      therapies for the treatment of this condition. This paper presents the protocol
      for a multicenter, prospective, randomized, controlled, phase III trial
      evaluating if PRF in addition to TFESI leads to better outcomes in patients with 
      sciatica due to LDH, compared to TFESI alone, during the first year after
      treatment (Pulsed Radiofrequency in Addition to TFESI for Sciatica [PRATS]).
      Eligible patients are between 18 and 75 years of age, suffer from sciatica of
      less than 12-week duration with pain intensity >4 on the Visual Analogue Scale
      (VAS) and have unilateral LDH compatible with symptoms at MRI. The Medical Ethics
      Committee of participating hospitals approved the study protocol. Patients will
      be randomized to receive either combined treatment (PRF and TFESI) or TFESI
      alone. The primary outcome will be the assessment of pain intensity with VAS at
      different timepoints from week-1 to 52 after treatment; secondary outcomes will
      include Roland Disability Questionnaire for sciatica and Oswestry Disability
      Index, evaluated at 4, 12 and 52 weeks. The follow-up will last 52 weeks for each
      patient. Statistical analysis will be performed on a per-protocol basis.
FAU - Scipione, Roberto
AU  - Scipione R
AD  - Department of Radiological, Oncological and Pathological Sciences, Policlinico
      Umberto I - Sapienza University of Rome , Rome, Italy.
FAU - Alfieri, Giulia
AU  - Alfieri G
AD  - Department of Radiological, Oncological and Pathological Sciences, Policlinico
      Umberto I - Sapienza University of Rome , Rome, Italy.
FAU - De Maio, Alessandro
AU  - De Maio A
AD  - Department of Radiological, Oncological and Pathological Sciences, Policlinico
      Umberto I - Sapienza University of Rome , Rome, Italy.
FAU - Panella, Emanuela
AU  - Panella E
AD  - Spine Unit, Centro SaNa Servizi Sanitari , Aprilia, Italy.
FAU - Napoli, Simone
AU  - Napoli S
AD  - Spine Unit, Centro SaNa Servizi Sanitari , Aprilia, Italy.
FAU - Bianchi, Luca
AU  - Bianchi L
AD  - Spine Unit, Centro SaNa Servizi Sanitari , Aprilia, Italy.
FAU - Pandaloro, Nunziante
AU  - Pandaloro N
AD  - Spine Unit, Centro SaNa Servizi Sanitari , Aprilia, Italy.
FAU - Bazzocchi, Alberto
AU  - Bazzocchi A
AD  - Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli ,
      Bologna, Italy.
FAU - Facchini, Giancarlo
AU  - Facchini G
AD  - Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli ,
      Bologna, Italy.
FAU - Albisinni, Ugo
AU  - Albisinni U
AD  - Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli ,
      Bologna, Italy.
FAU - Spinnato, Paolo
AU  - Spinnato P
AD  - Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli ,
      Bologna, Italy.
FAU - Catalano, Carlo
AU  - Catalano C
AD  - Department of Radiological, Oncological and Pathological Sciences, Policlinico
      Umberto I - Sapienza University of Rome , Rome, Italy.
FAU - Napoli, Alessandro
AU  - Napoli A
AD  - Department of Radiological, Oncological and Pathological Sciences, Policlinico
      Umberto I - Sapienza University of Rome , Rome, Italy.
AD  - Spine Unit, Centro SaNa Servizi Sanitari , Aprilia, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200903
PL  - England
TA  - Expert Rev Med Devices
JT  - Expert review of medical devices
JID - 101230445
RN  - 0 (Steroids)
SB  - IM
MH  - Acute Disease
MH  - Combined Modality Therapy
MH  - Humans
MH  - Injections, Epidural/adverse effects/methods
MH  - Intervertebral Disc Displacement/complications/drug therapy/*therapy
MH  - Outcome Assessment, Health Care
MH  - Prospective Studies
MH  - *Pulsed Radiofrequency Treatment/adverse effects
MH  - Sciatica/complications/drug therapy/*therapy
MH  - Steroids/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - PRF
OT  - TFESI
OT  - disc herniation
OT  - pain
OT  - sciatica
EDAT- 2020/09/04 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - 10.1080/17434440.2020.1815529 [doi]
PST - ppublish
SO  - Expert Rev Med Devices. 2020 Sep;17(9):945-949. doi:
      10.1080/17434440.2020.1815529. Epub 2020 Sep 3.


PMID- 32880414
OWN - NLM
STAT- MEDLINE
DCOM- 20200904
LR  - 20200904
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 4
DP  - 2020 Aug
TI  - Support Systems for Medical Decision-Making: Considerations for Japan.
PG  - 981-984
AB  - Clinical issues involving ethical dilemmas arise daily and confound physicians as
      they provide medical care. These dilemmas require difficult decisions as
      physicians must respect patients' values, lifestyles, and freedom of choice while
      protecting life and promoting health. This is made more challenging as values and
      lifestyles become more diverse, making third-party support necessary to
      accommodate the wishes of stakeholders, particularly patients. Collaborative work
      is important for addressing clinical ethics issues. Government agencies and
      professional organisations should discuss individual cases as public policy
      concerns and release guidelines based on their deliberations. Medical
      institutions should refer to such guidelines in their own discussions on
      ethically challenging cases. This is not the case today as each organisation
      creates its own guidelines; there is no consensus on how clinical ethics
      committees or consultations should be conducted. Support systems that are public 
      in nature are needed to protect patients' rights and freedoms in medical care.
FAU - Iijima, Yoshihiko
AU  - Iijima Y
AD  - Associate Professor, Department of Medical Research and Clinical Ethics Promotion
      Office, Nagoya University Hospital, Japan.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - *Clinical Decision-Making
MH  - Ethics, Medical
MH  - Freedom
MH  - Humans
MH  - Japan
MH  - Patient Rights
MH  - *Physicians
OTO - NOTNLM
OT  - clinical ethics
OT  - clinical ethics support
OT  - hospital ethics committee
OT  - justice
OT  - medical practice
COIS- None.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Aug;27(4):981-984.


PMID- 32880412
OWN - NLM
STAT- MEDLINE
DCOM- 20200904
LR  - 20200904
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 4
DP  - 2020 Aug
TI  - Doctors and the Voluntary Assisted Dying Act 2017 (Vic): Knowledge and General
      Perspectives.
PG  - 952-966
AB  - The purpose of this article is to report some Victorian doctors' general
      perspectives and knowledge of the new Voluntary Assisted Dying Act 2017 (Vic)
      (VAD Act). Under the VAD Act, doctors are constructed as the only legal providers
      of VAD in Victoria. Doctors who are unwilling to participate in VAD therefore
      constitute a barrier to patient access. This article reports the findings of a
      small empirical study into how some Victorian doctors with no in-principle
      objection towards the legalisation of VAD, are orientating themselves towards the
      law. It also explores participants' understanding of the specific role required
      of doctors under the law. It finds that participants equate their support for the
      Act with biomedical ethical principles and generally hold a level of knowledge of
      the law which is not comprehensive but improves with greater exposure to VAD
      applications. This study serves as a temperature check of this key stakeholder
      group's perspectives on the VAD Act in the first eight months of its operation.
FAU - Rutherford, Jodhi
AU  - Rutherford J
AD  - PhD candidate, Australian Centre for Health Law Research/Sessional Lecturer
      Faculty of Law, Queensland University of Technology.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Attitude of Health Personnel
MH  - Humans
MH  - *Physicians
MH  - *Suicide, Assisted
OTO - NOTNLM
OT  - access barriers
OT  - attitudes
OT  - doctors
OT  - euthanasia
OT  - legislation
OT  - voluntary assisted dying
COIS- None.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Aug;27(4):952-966.


PMID- 32880410
OWN - NLM
STAT- MEDLINE
DCOM- 20200904
LR  - 20200904
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 4
DP  - 2020 Aug
TI  - Regulation of the Abortion Drug RU 486: The Collision of Politics, Ethics and
      Morals in Australia.
PG  - 928-936
AB  - The abortion drug RU 486 is widely available across the developed world, and its 
      benefits and efficacy for women have been well established over the 40 years
      since its development. However, access to RU 486 for women in Australia has been 
      a vexed issue since the mid-1990s. Because of pro-life politics under the Howard 
      Government, importation of the drug into Australia was severely hampered,
      resulting in Australia lagging behind the rest of the developed world in access
      to medical abortions. This article highlights the history of RU 486, the current 
      state of abortion laws in Australia and the issues that the politics of the 1990s
      still cause for Australian women who seek a medical abortion (especially those
      living remotely). Finally, it proposes some options that could alleviate some of 
      the difficulties faced by those who seek access to RU 486.
FAU - Bodor, Nicola
AU  - Bodor N
AD  - LLM Candidate, University of Sydney.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
RN  - 320T6RNW1F (Mifepristone)
SB  - IM
MH  - *Abortion, Induced
MH  - Australia
MH  - Female
MH  - Humans
MH  - *Mifepristone
MH  - Morals
MH  - Politics
MH  - Pregnancy
OTO - NOTNLM
OT  - New South Wales Act
OT  - RU 486
OT  - abortion
OT  - abortion drug
OT  - access to abortion
OT  - medical abortion
OT  - telemedicine
COIS- None.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Aug;27(4):928-936.


PMID- 32880401
OWN - NLM
STAT- MEDLINE
DCOM- 20200904
LR  - 20201218
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 4
DP  - 2020 Aug
TI  - Australian Perspectives on the Ethical and Regulatory Considerations for
      Responsible Data Sharing in Response to the COVID-19 Pandemic.
PG  - 829-838
AB  - As the rush to understand and find solutions to the coronavirus disease 2019
      pandemic continues, it is timely to re-examine the legal, social and ethical
      drivers for sharing health-related data from individuals around the globe.
      International collaboration and data sharing will be essential to the research
      effort. This raises the question of whether the urgent imperative to find
      therapies and vaccines may justify some temporary rebalancing of existing ethical
      and regulatory standards. The Global Alliance for Genomic Health is playing a
      leading role in collecting information about national approaches to these
      challenging questions. In this section, we examine some of the initiatives being 
      taken in Australia against this global backdrop.
FAU - Nicol, Dianne
AU  - Nicol D
AD  - Centre for Law and Genetics, Law Faculty, University of Tasmania.
FAU - Chalmers, Don
AU  - Chalmers D
AD  - Centre for Law and Genetics, Law Faculty, University of Tasmania.
FAU - Critchley, Christine
AU  - Critchley C
AD  - Centre for Law and Genetics, Law Faculty, University of Tasmania; Swinburne
      University of Technology.
FAU - Eckstein, Lisa
AU  - Eckstein L
AD  - Centre for Law and Genetics, Law Faculty, University of Tasmania.
FAU - Nielsen, Jane
AU  - Nielsen J
AD  - Centre for Law and Genetics, Law Faculty, University of Tasmania.
FAU - Otlowski, Margaret
AU  - Otlowski M
AD  - Centre for Law and Genetics, Law Faculty, University of Tasmania.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Australia
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Information Dissemination
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - GA4GH
OT  - genomic data sharing
OT  - intellectual property
OT  - medical devices regulation
OT  - privacy
OT  - research ethics
COIS- None.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Aug;27(4):829-838.


PMID- 32880359
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 1
DP  - 2020 Aug 1
TI  - Ethical Imperatives to Overcome Stigma Against People With Substance Use
      Disorders.
PG  - E702-708
LID - amajethics.2020.702 [pii]
LID - 10.1001/amajethics.2020.702 [doi]
AB  - Responding to the public health crisis in the United States resulting from
      untreated opioid use disorder (OUD) requires expanding delivery of effective
      treatments, including medications, and eliminating stigma against people with OUD
      and people seeking OUD treatment. Stigma discourages people with substance use
      disorders from seeking care and compromises the care they receive when they do
      seek it. Stigma against both medication treatments for OUD and harm-reduction
      approaches like syringe services programs has created additional barriers to
      these strategies' acceptance and use. It is ethically incumbent upon everyone in 
      medicine and health care to recognize addiction not as a moral failing but as a
      treatable disease.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Adams, Jerome M
AU  - Adams JM
AD  - Surgeon general of the United States in Washington, DC.
FAU - Volkow, Nora D
AU  - Volkow ND
AD  - Director of the National Institute on Drug Abuse at the National Institutes of
      Health in North Bethesda, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Health Facilities
MH  - Humans
MH  - Morals
MH  - *Opioid-Related Disorders/therapy
MH  - Public Health
MH  - Social Stigma
MH  - United States
EDAT- 2020/09/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.702 [pii]
AID - 10.1001/amajethics.2020.702 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Aug 1;22(1):E702-708. doi: 10.1001/amajethics.2020.702.


PMID- 32880357
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 1
DP  - 2020 Aug 1
TI  - American College of Preventive Medicine Statement on Prioritizing Prevention in
      Opioid Research.
PG  - E687-694
LID - amajethics.2020.687 [pii]
LID - 10.1001/amajethics.2020.687 [doi]
AB  - Research is the foundation of evidence-based health care that motivates
      innovations in clinical interventions and public health. Prior and current
      research on opioid use has focused mainly on individual patient-physician
      relationships, opioid use disorder and treatment, and overdose responses. This
      article recommends 3 priorities for future research and investigates why, from
      clinical and ethical standpoints, future research should be directed toward
      building the capacity and increasing the effectiveness of population-based
      programs and improving prevention strategies.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Smith, Hunter Jackson
AU  - Smith HJ
AD  - Third-year preventive medicine resident at the Uniformed Services University in
      Bethesda, Maryland.
FAU - Salisbury-Afshar, Elizabeth
AU  - Salisbury-Afshar E
AD  - Director of the Center for Addiction Research and Effective Solutions at the
      American Institutes for Research.
FAU - Carr, Bob
AU  - Carr B
AD  - Chief medical officer for Kumanu.
FAU - Zaza, Stephanie
AU  - Zaza S
AD  - President of the American College of Preventive Medicine.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/adverse effects
MH  - *Drug Overdose
MH  - Humans
MH  - *Opioid-Related Disorders/prevention & control
MH  - Public Health
MH  - United States
EDAT- 2020/09/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.687 [pii]
AID - 10.1001/amajethics.2020.687 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Aug 1;22(1):E687-694. doi: 10.1001/amajethics.2020.687.


PMID- 32880356
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 1
DP  - 2020 Aug 1
TI  - What Clinicians and Health Professions Students Should Learn About How
      Pharmaceutical Marketing Influences Opioid Prescribing and Patient Outcomes.
PG  - E681-686
LID - amajethics.2020.681 [pii]
LID - 10.1001/amajethics.2020.681 [doi]
AB  - Marketing drugs and devices to clinicians affects their prescribing behaviors,
      drives up health care costs, and increases risk of harm to patients. This article
      canvasses what clinicians and health professions students should know about undue
      influence of drug and device marketing on their practices. It also considers
      policy changes that would better protect patients and better situate clinicians
      to care for patients and communities in ways that are ethical, safe, and
      effective.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Erdek, Michael A
AU  - Erdek MA
AD  - Associate professor in the Division of Pain Medicine, Department of
      Anesthesiology and Critical Care Medicine at the Johns Hopkins University School 
      of Medicine in Baltimore, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Analgesics, Opioid
MH  - Drug Industry
MH  - Health Occupations
MH  - Humans
MH  - Marketing
MH  - *Pharmaceutical Preparations
MH  - Practice Patterns, Physicians'
MH  - *Students, Health Occupations
EDAT- 2020/09/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.681 [pii]
AID - 10.1001/amajethics.2020.681 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Aug 1;22(1):E681-686. doi: 10.1001/amajethics.2020.681.


PMID- 32880352
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 1
DP  - 2020 Aug 1
TI  - Should the Location of a Patient's Home Inform Physicians' Opioid Prescription
      Practices?
PG  - E658-663
LID - amajethics.2020.658 [pii]
LID - 10.1001/amajethics.2020.658 [doi]
AB  - This case-and-commentary examines whether and when prescribers should authorize
      prescription opioid refills and questions whether and how a patient's living in
      an area with a high number of overdose deaths should influence that decision.
      Clinical social work perspectives presented in the commentary inform a
      multidisciplinary, team-based approach to this decision that is holistic and
      nondiscriminatory and that prioritizes the ethical value of self-determination.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Byrne, Jennifer D
AU  - Byrne JD
AD  - Licensed clinical social worker and certified alcohol and drug counselor at the
      American Medical Association in Chicago.
FAU - Clancy, Katie S
AU  - Clancy KS
AD  - Consultant with experience in nonprofit education program development and
      management.
FAU - Ciszewski, Isabell
AU  - Ciszewski I
AD  - Licensed clinical social worker and faculty member at the Aurora University
      School of Social Work in Aurora, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/therapeutic use
MH  - *Drug Overdose/prevention & control
MH  - Drug Prescriptions
MH  - Humans
MH  - *Physicians
MH  - Practice Patterns, Physicians'
EDAT- 2020/09/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.658 [pii]
AID - 10.1001/amajethics.2020.658 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Aug 1;22(1):E658-663. doi: 10.1001/amajethics.2020.658.


PMID- 32880350
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 8
DP  - 2020 Aug 1
TI  - Ethics, Public Health, and Addressing the Opioid Crisis.
PG  - E647-650
LID - amajethics.2020.647 [pii]
LID - 10.1001/amajethics.2020.647 [doi]
FAU - Smith, Hunter Jackson
AU  - Smith HJ
AD  - Third-year preventive medicine resident at the Uniformed Services University in
      Bethesda, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/*adverse effects
MH  - Drug Overdose/*mortality
MH  - Humans
MH  - *Opioid Epidemic
MH  - Opioid-Related Disorders/*epidemiology
MH  - Pain Management
MH  - Practice Patterns, Physicians'/*ethics
MH  - Prescription Drug Misuse/*ethics
MH  - Public Health
EDAT- 2020/09/04 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - amajethics.2020.647 [pii]
AID - 10.1001/amajethics.2020.647 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Aug 1;22(8):E647-650. doi: 10.1001/amajethics.2020.647.


PMID- 32880338
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 Jun 5
TI  - Research on COVID-19 in South Africa: Guiding principles for informed consent.
PG  - 635-639
AB  - Research is imperative in addressing the COVID-19 epidemic, both in the short and
      long term. Informed consent is a key pillar of research and should be central to 
      the conduct of COVID-19 research. Yet a range of factors, including physical
      distancing requirements, risk of exposure and infection to research staff, and
      multiple pressures on the healthcare environment, have added layers of challenges
      to the consent process in COVID-19 patients. Internationally, the recognition
      that consent for COVID-19 research may be imperfect has led to a range of
      suggestions to ensure that research remains ethical. Drawing on these guidelines,
      we propose a consent process for COVID-19 research in the South African context
      that combines individual consent with delayed and proxy consent for individuals
      who may be temporarily incapacitated, combined with key principles that should be
      considered in the design of a consent process for COVID-19 research.
FAU - De Vries, J
AU  - De Vries J
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town and
      Groote Schuur Hospital, Cape Town, South Africa. jantina.devries@uct.ac.za.
FAU - Burgess, T
AU  - Burgess T
FAU - Blockman, M
AU  - Blockman M
FAU - Ntusi, N A B
AU  - Ntusi NAB
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19
MH  - Communicable Disease Control/standards
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Databases, Factual/*ethics
MH  - Developing Countries
MH  - Female
MH  - *Guidelines as Topic
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Male
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Research Design
MH  - South Africa
EDAT- 2020/09/04 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Jun 5;110(7):635-639.


PMID- 32880337
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 May 26
TI  - Consent for critical care research after death from COVID-19: Arguments for a
      waiver.
PG  - 629-634
AB  - Pandemics challenge clinicians and scientists in many ways, especially when the
      virus is novel and disease expression becomes variable or unpredictable. Under
      such circumstances, research becomes critical to inform clinical care and protect
      future patients. Given that severely ill patients admitted to intensive care
      units are at high risk of mortality, establishing the cause of death at a
      histopathological level could prove invaluable in contributing to the
      understanding of COVID-19. Postmortem examination including autopsies would be
      optimal. However, in the context of high contagion and limited personal
      protective equipment, full autopsies are not being conducted in South Africa
      (SA). A compromise would require tissue biopsies and samples to be taken
      immediately after death to obtain diagnostic information, which could potentially
      guide care of future patients, or generate hypotheses for finding needed
      solutions. In the absence of an advance written directive (including a will or
      medical record) providing consent for postmortem research, proxy consent is the
      next best option. However, obtaining consent from distraught family members,
      under circumstances of legally mandated lockdown when strict infection control
      measures limit visitors in hospitals, is challenging. Their extreme vulnerability
      and emotional distress make full understanding of the rationale and consent
      process difficult either before or upon death of a family member. While it is
      morally distressing to convey a message of death telephonically, it is inhumane
      to request consent for urgent research in the same conversation. Careful
      balancing of the principles of autonomy, non-maleficence and justice becomes an
      ethical imperative. Under such circumstances, a waiver of consent, preferably
      followed by deferred proxy consent, granted by a research ethics committee in
      keeping with national ethics guidance and legislation, would fulfil the basic
      premise of care and research: first do no harm. This article examines the SA
      research ethics framework, guidance and legislation to justify support for a
      waiver of consent followed by deferred proxy consent, when possible, in urgent
      research after death to inform current and future care to contain the pandemic in
      the public interest.
FAU - Moodley, K
AU  - Moodley K
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Cape Town, South Africa.
      km@sun.ac.za.
FAU - Allwood, B W
AU  - Allwood BW
FAU - Rossouw, T M
AU  - Rossouw TM
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19
MH  - Cause of Death
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Critical Care/*ethics/legislation & jurisprudence
MH  - Critical Illness/mortality/*therapy
MH  - Developing Countries
MH  - Female
MH  - *Hospital Mortality
MH  - Humans
MH  - Infection Control/organization & administration
MH  - Informed Consent/*ethics
MH  - Intensive Care Units/ethics/statistics & numerical data
MH  - Male
MH  - Needs Assessment
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Research Design
MH  - Risk Assessment
MH  - South Africa
MH  - Vulnerable Populations/statistics & numerical data
EDAT- 2020/09/04 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 May 26;110(7):629-634.


PMID- 32880336
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 Jun 17
TI  - Comorbidity in context: Part 2. Ethicolegal considerations around HIV and
      tuberculosis during the COVID-19 pandemic in South Africa.
PG  - 625-628
AB  - The COVID-19 pandemic has brought discussions around the appropriate and fair
      rationing of scare resources to the forefront. This is of special importance in a
      country such as South Africa (SA), where scarce resources interface with high
      levels of need. A large proportion of the SA population has risk factors
      associated with worse COVID-19 outcomes. Many people are also potentially
      medically and socially vulnerable secondary to the high levels of infection with 
      HIV and tuberculosis (TB) in the country. This is the second of two articles. The
      first examined the clinical evidence regarding the inclusion of HIV and TB as
      comorbidities relevant to intensive care unit (ICU) admission triage criteria.
      Given the fact that patients with HIV or TB may potentially be excluded from
      admission to an ICU on the basis of an assumption of lack of clinical suitability
      for critical care, in this article we explore the ethicolegal implications of
      limiting ICU access of persons living with HIV or TB. We argue that all
      allocation and rationing decisions must be in terms of SA law, which prohibits
      unfair discrimination. In addition, ethical decision-making demands accurate and 
      evidence-based strategies for the fair distribution of limited resources.
      Rationing decisions and processes should be fair and based on visible and
      consistent criteria that can be subjected to objective scrutiny, with the
      ultimate aim of ensuring accountability, equity and fairness.
FAU - Rossouw, T M
AU  - Rossouw TM
AD  - 1 Department of Immunology, School of Medicine, Faculty of Health Sciences,
      University of Pretoria, South Africa; University of Pretoria/South African
      Medical Research Council Research Centre for Maternal, Fetal, Newborn and Child
      Health Care Strategies. theresa.rossouw@up.ac.za.
FAU - Nienaber, A G
AU  - Nienaber AG
FAU - Boswell, M T
AU  - Boswell MT
FAU - Moodley, K
AU  - Moodley K
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Coinfection
MH  - *Coronavirus Infections/economics/epidemiology/therapy
MH  - HIV Infections/*epidemiology
MH  - Health Care Rationing/*methods
MH  - Health Services Needs and Demand/organization & administration
MH  - Humans
MH  - *Intensive Care Units/economics/standards
MH  - *Pandemics/economics
MH  - Patient Selection/*ethics
MH  - *Pneumonia, Viral/economics/epidemiology/therapy
MH  - *Resource Allocation/ethics/legislation & jurisprudence
MH  - SARS-CoV-2
MH  - South Africa/epidemiology
MH  - *Triage/economics/ethics/legislation & jurisprudence
MH  - Tuberculosis/*epidemiology
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/17 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Jun 17;110(7):625-628.


PMID- 32880335
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 Jun 17
TI  - Comorbidity in context: Part 1. Medical considerations around HIV and
      tuberculosis during the COVID-19 pandemic in South Africa.
PG  - 621-624
AB  - Infectious diseases pandemics have devastating health, social and economic
      consequences, especially in developing countries such as South Africa. Scarce
      medical resources must often be rationed effectively to contain the disease
      outbreak. In the case of COVID-19, even the best-resourced countries will have
      inadequate intensive care facilities for the large number of patients needing
      admission and ventilation. The scarcity of medical resources creates the need for
      national governments to establish admission criteria that are evidence-based and 
      fair. Questions have been raised whether infection with HIV or tuberculosis (TB) 
      may amplify the risk of adverse COVID-19 outcomes and therefore whether these
      conditions should be factored in when deciding on the rationing of intensive care
      facilities. In light of these questions, clinical evidence regarding inclusion of
      these infections as comorbidities relevant to intensive care unit admission
      triage criteria is investigated in the first of a two-part series of articles.
      There is currently no evidence to indicate that HIV or TB infection on their own 
      predispose to an increased risk of infection with SARS-CoV-2 or worse outcomes
      for COVID-19. It is recommended that, as for other medical conditions, validated 
      scoring systems for poor prognostic factors should be applied. A subsequent
      article examines the ethicolegal implications of limiting intensive care access
      of persons living with HIV or TB.
FAU - Rossouw, T M
AU  - Rossouw TM
AD  - Department of Immunology, School of Medicine, Faculty of Health Sciences,
      University of Pretoria, South Africa; University of Pretoria/South African
      Medical Research Council Research Centre for Maternal, Fetal, Newborn and Child
      Health Care Strategies. theresa.rossouw@up.ac.za.
FAU - Boswell, M T
AU  - Boswell MT
FAU - Nienaber, A G
AU  - Nienaber AG
FAU - Moodley, K
AU  - Moodley K
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Coinfection
MH  - *Coronavirus Infections/economics/epidemiology/therapy
MH  - HIV Infections/*epidemiology
MH  - Health Care Rationing/*methods
MH  - Health Services Needs and Demand/organization & administration
MH  - Humans
MH  - *Intensive Care Units/economics/standards
MH  - *Pandemics/economics
MH  - Patient Selection
MH  - *Pneumonia, Viral/economics/epidemiology/therapy
MH  - Prognosis
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - South Africa/epidemiology
MH  - Triage/*organization & administration
MH  - Tuberculosis/*epidemiology
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/17 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Jun 17;110(7):621-624.


PMID- 32880334
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 Jun 4
TI  - South Africa's COVID-19 Tracing Database: Risks and rewards of which doctors
      should be aware.
PG  - 617-620
AB  - In response to the COVID-19 pandemic, South Africa (SA) has established a Tracing
      Database, collecting both aggregated and individualised mobility and locational
      data on COVID-19 cases and their contacts. There are compelling public health
      reasons for this development, since the database has the potential to assist with
      policy formulation and with contact tracing. While potentially demonstrating the 
      rapid facilitation through technology of an important public service, the Tracing
      Database does, however, infringe immediately upon constitutional rights to
      privacy and heightens the implications of ethical choices facing medical
      professionals. The medical community should be aware of this surveillance
      innovation and the risks and rewards it raises. To deal with some of these risks,
      including the potential for temporary rights- infringing measures to become
      permanent, there are significant safeguards designed into the Tracing Database,
      including a strict duration requirement and reporting to a designated judge.
      African states including SA should monitor this form of contact tracing closely, 
      and also encourage knowledge-sharing among cross-sectoral interventions such as
      the Tracing Database in responding to the COVID-19 pandemic.
FAU - Klaaren, J
AU  - Klaaren J
AD  - School of Law, University of the Witwatersrand, Johannesburg, South Africa; Wits 
      Institute for Social and Economic Research, University of the Witwatersrand,
      Johannesburg, South Africa. jonathan.klaaren@wits.ac.za.
FAU - Breckenridge, K
AU  - Breckenridge K
FAU - Cachalia, F
AU  - Cachalia F
FAU - Fonn, S
AU  - Fonn S
FAU - Veller, M
AU  - Veller M
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - COVID-19
MH  - Communicable Disease Control/*organization & administration
MH  - Confidentiality/*ethics
MH  - Contact Tracing/*ethics/methods
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Databases, Factual/*ethics
MH  - Developing Countries
MH  - Female
MH  - Humans
MH  - Male
MH  - Pandemics/*prevention & control/statistics & numerical data
MH  - Physician's Role
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health
MH  - Risk Assessment
MH  - South Africa
EDAT- 2020/09/04 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/04 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Jun 4;110(7):617-620.


PMID- 32880333
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 May 21
TI  - A policy and decision-making framework for South African doctors during the
      COVID-19 pandemic.
PG  - 613-616
AB  - Faced with a pandemic, doctors around the world are forced to make difficult
      ethical decisions about clinical, economic and politically charged issues in
      medicine and healthcare, with little time or resources for support. A
      decision-making framework is suggested to guide policy and clinical practice to
      support the needs of healthcare workers, help to allocate scarce resources
      equitably and promote communication among stakeholders, while drawing on South
      African doctors' knowledge, culture and experience.
FAU - Jones-Bonofiglio, K
AU  - Jones-Bonofiglio K
AD  - Lakehead University Centre for Health Care Ethics, Thunder Bay, Ontario, Canada; 
      Bioethics Unit, International Network of the UNESCO Chair in Bioethics (Haifa).
      nnortje@mdanderson.org.
FAU - Nortje, N
AU  - Nortje N
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Attitude of Health Personnel
MH  - COVID-19
MH  - Clinical Decision-Making
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Developing Countries
MH  - Female
MH  - Health Policy
MH  - Health Resources
MH  - Humans
MH  - *Interdisciplinary Communication
MH  - Male
MH  - *Outcome Assessment, Health Care
MH  - Pandemics/*prevention & control/statistics & numerical data
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Policy Making
MH  - Practice Patterns, Physicians'/*organization & administration
MH  - South Africa
EDAT- 2020/09/04 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 May 21;110(7):613-616.


PMID- 32880329
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 7
DP  - 2020 Jun 2
TI  - Reintroduction of elective paediatric otolaryngology procedures in South Africa
      during the COVID-19 pandemic.
PG  - 601-604
LID - 10.7196/SAMJ.2020.v110i7.14859 [doi]
AB  - Cancelling elective clinical consultations and surgical procedures was
      instrumental in assisting hospitals prepare for the COVID-19 crisis. Essential
      bed space was made available, and it allowed mobilisation of health workers and
      enforced social distancing. A shift in patient-centred ethics to public health
      ethics was required to provide a utilitarian approach to the crisis. However, at 
      some point, clinicians need to start becoming patient centred again, and this
      needs to happen within the utilitarian framework. Children only account for 1 -
      5% of confirmed COVID-19 cases, and they present with a much milder disease
      spectrum than adults. Consequently, paediatric units may be at the forefront of
      implementing reintroduction of patient-centred elective clinical and surgical
      procedures. The following recommendations provide a framework to do this in a way
      that minimises risk to patients and clinicians. They are the first paediatric
      guidelines in the literature to propose a strategy to reintroduce elective
      surgical procedures.
FAU - McGuire, J K
AU  - McGuire JK
AD  - Division of Otolaryngology, Faculty of Health Sciences, University of Cape Town, 
      South Africa; Division of Otolaryngology, Red Cross War Memorial Children's
      Hospital, Cape Town, South Africa. jkmcguire2@gmail.com.
FAU - Fagan, J J
AU  - Fagan JJ
FAU - Peer, S
AU  - Peer S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200602
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Child
MH  - Child, Preschool
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Developing Countries
MH  - Elective Surgical Procedures/standards/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Infection Control/*methods
MH  - Male
MH  - Organizational Innovation
MH  - Otorhinolaryngologic Surgical Procedures/*standards/statistics & numerical data
MH  - Outcome Assessment, Health Care
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Patient Selection
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - *Practice Guidelines as Topic
MH  - Public Health
MH  - South Africa
EDAT- 2020/09/04 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i7.14859 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Jun 2;110(7):601-604. doi: 10.7196/SAMJ.2020.v110i7.14859.


PMID- 32880314
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 8
DP  - 2020 Jul 29
TI  - The ethicolegal framework relevant to human faecal microbiota transplants in
      South Africa: Part 3. Stool as a 'drug' or medicine.
PG  - 819-821
LID - 10.7196/SAMJ.2020.v110i8.15070 [doi]
AB  - The purpose of this article, the last in a series of three exploring the legal
      framework for the regulation of faecal microbiota transplantation (FMT) in South 
      Africa (SA), is to determine the regulatory framework that applies to
      microbial-based treatments involving a level of manipulation that exceeds that of
      basic stool transplantation, e.g. processed FMT-derived products in capsule form.
      The article highlights the legal requirements for the registration of these
      products as biological medicines in SA law. Although human stool banks are not
      regulated in terms of the National Health Act 61 of 2003 (NHA) and regulations,
      the earlier articles point out that human stool fits the definition of human
      tissue and human biological material as defined by the NHA. For this reason,
      stool banks should be considered tissue banks in terms of the NHA and
      regulations. Healthcare practitioners and researchers involved in FMT banking and
      transplantation should strive to comply with these regulations in the absence of 
      clear legal direction at present.
FAU - Labuschaigne, M
AU  - Labuschaigne M
AD  - Department of Jurisprudence, School of Law, University of South Africa.
      slabbmn@unisa.ac.za.
FAU - Slabbert, M
AU  - Slabbert M
FAU - Budree, S
AU  - Budree S
FAU - Hoosien, E
AU  - Hoosien E
FAU - Brink, A
AU  - Brink A
FAU - Blockman, M
AU  - Blockman M
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Biological Specimen Banks/legislation & jurisprudence
MH  - *Fecal Microbiota Transplantation
MH  - Feces
MH  - Humans
MH  - South Africa
MH  - *Therapeutic Human Experimentation/ethics/legislation & jurisprudence
MH  - Tissue and Organ Procurement/*legislation & jurisprudence
EDAT- 2020/09/04 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i8.15070 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Jul 29;110(8):819-821. doi: 10.7196/SAMJ.2020.v110i8.15070.


PMID- 32880313
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 8
DP  - 2020 Jul 29
TI  - The ethicolegal framework relevant to human faecal microbiota transplants in
      South Africa: Part 2. Human stool as tissue?
PG  - 816-818
LID - 10.7196/SAMJ.2020.v110i8.15069 [doi]
AB  - Faecal microbiota transplantation (FMT) has been shown to be an effective
      treatment for recurrent Clostridioides difficile infection. The purpose of this
      article, the second of a series of three articles, is to explore the legal
      framework governing human FMT in South Africa (SA). FMT involves different modes 
      of administration that require different regulatory considerations. The focus of 
      this article is to explore the legal classification of human stool as tissue in
      terms of the National Health Act 61 of 2003, as well as the regulation of human
      stool banks as tissue banks. The article concludes with specific recommendations 
      aimed at improving the current regulatory vacuum relating to the regulation of
      FMT in SA.
FAU - Labuschaigne, M
AU  - Labuschaigne M
AD  - Department of Jurisprudence, School of Law, University of South Africa.
      slabbmn@unisa.ac.za.
FAU - Slabbert, M
AU  - Slabbert M
FAU - Budree, S
AU  - Budree S
FAU - Hoosien, E
AU  - Hoosien E
FAU - Brink, A
AU  - Brink A
FAU - Blockman, M
AU  - Blockman M
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Biological Specimen Banks/legislation & jurisprudence
MH  - *Fecal Microbiota Transplantation
MH  - Feces
MH  - Humans
MH  - South Africa
MH  - Therapeutic Human Experimentation/ethics/legislation & jurisprudence
MH  - Tissue and Organ Procurement/ethics/*legislation & jurisprudence
EDAT- 2020/09/04 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i8.15069 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Jul 29;110(8):816-818. doi: 10.7196/SAMJ.2020.v110i8.15069.


PMID- 32880312
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 8
DP  - 2020 Jul 29
TI  - The ethicolegal framework relevant to human faecal microbiota transplants in
      South Africa: Part 1. A legal vacuum.
PG  - 812-815
LID - 10.7196/SAMJ.2020.v110i8.14563 [doi]
AB  - The legal regulation of faecal microbiota transplantation (FMT) in South Africa
      (SA) is currently unclear. The purpose of this article, the first of three in a
      series, is to explore the nature, role and clinical application of FMT in SA in
      order to determine, from a legal perspective, the appropriate regulatory pathways
      governing FMT as a procedure that may combine approaches for the treatment of
      drugs, human tissue for transplantation, or clinical treatment as part of the
      practice of medicine. FMT has been shown to be a novel, safe and effective
      treatment for recurrent Clostridioides difficile infection (CDI). Stool banks are
      instrumental in enabling access to FMT for patients and clinicians and help to
      catalyse research in the microbiome. However, the regulatory landscape in SA
      remains unclear. Microbial therapies such as FMT are necessary, especially in a
      time of rising microbiome-associated inflammatory diseases and increasing
      resistance to traditional antibiotics. FMT is now considered as part of the
      standard of care for recurrent CDI overseas, but is currently only being used for
      research purposes in a minority of clinical cases of CDI in SA. This article,
      which lays the foundation for consideration of this question in three parts,
      suggests that the relevant regulatory system would depend on the categorisation
      of human stool as tissue, the exact composition of the FMT, how it is
      administered to patients, and the relevant levels of manipulation of the stool
      for FMT-derived products.
FAU - Labuschaigne, M
AU  - Labuschaigne M
AD  - Department of Jurisprudence, School of Law, University of South Africa.
      slabbmn@unisa.ac.za.
FAU - Slabbert, M
AU  - Slabbert M
FAU - Budree, S
AU  - Budree S
FAU - Hoosien, E
AU  - Hoosien E
FAU - Brink, A
AU  - Brink A
FAU - Blockman, M
AU  - Blockman M
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Biological Specimen Banks/legislation & jurisprudence
MH  - *Fecal Microbiota Transplantation
MH  - Feces
MH  - Gastrointestinal Microbiome
MH  - Humans
MH  - *Legislation, Medical
MH  - South Africa
EDAT- 2020/09/04 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/29 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i8.14563 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Jul 29;110(8):812-815. doi: 10.7196/SAMJ.2020.v110i8.14563.


PMID- 32880283
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 8
DP  - 2020 Jun 5
TI  - The Critical Care Society of Southern Africa guidelines on the allocation of
      scarce critical care resources during the COVID-19 public health emergency in
      South Africa.
PG  - 700-703
AB  - Letter by Gopalan et al. on article by Singh and Moodley (Singh JA, Moodley K.
      Critical care triaging in the shadow of COVID-19: Ethics considerations. S Afr
      Med J 2020;110(5):355-359. https://doi.org/10.7196/SAMJ.2020.v110i5.14778); and
      response by Singh and Moodley.
FAU - Gopalan, P D
AU  - Gopalan PD
AD  - Head: Discipline of Anaesthesiology and Critical Care, School of Clinical
      Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South 
      Africa; President: Critical Care Society of Southern Africa. gopalan@ukzn.ac.za.
FAU - Joubert, I A
AU  - Joubert IA
FAU - Paruk, F
AU  - Paruk F
FAU - Baker, D
AU  - Baker D
FAU - Coetzee, I
AU  - Coetzee I
FAU - De Vasconcellos, K
AU  - De Vasconcellos K
FAU - Dolo, L M
AU  - Dolo LM
FAU - Levy, B L
AU  - Levy BL
FAU - Morrow, B M
AU  - Morrow BM
FAU - Nel, J M
AU  - Nel JM
FAU - Omar, S
AU  - Omar S
FAU - Piercy, J L
AU  - Piercy JL
FAU - Siebert, R S
AU  - Siebert RS
FAU - Veldsman, L
AU  - Veldsman L
FAU - Singh, J A
AU  - Singh JA
FAU - Moodley, K
AU  - Moodley K
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200605
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
CON - S Afr Med J. 2020 Apr 16;110(5):355-359. PMID: 32657716
MH  - Africa, Southern
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Critical Care
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Public Health
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - South Africa
EDAT- 2020/09/04 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Jun 5;110(8):700-703.


PMID- 32880281
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 9
DP  - 2020 Aug 31
TI  - Comparison of adherence measures using claims data in the South African private
      health sector.
PG  - 932-936
LID - 10.7196/SAMJ.2020.v110i9.14189 [doi]
AB  - BACKGROUND: Medication adherence measurement is becoming increasingly important. 
      Biological assays and markers, directly observed therapy, self-reports, pill
      counts and surveys have been successfully used to assess adherence under various 
      circumstances, but may be limited by cost, ethical concerns and self-reported
      bias. Administrative claims data, in addition to offering a solution to these
      limitations, provide access to large study populations under real clinical
      practice situations, and in a timely and effective manner. With the wide range of
      adherence measures determined from claims data available - some of which have
      been found to be mathematically equivalent - researchers are often faced with the
      decision of choosing which is appropriate. An assessment of the various measures 
      is therefore important for better understanding and to facilitate future
      adherence studies using administrative data. OBJECTIVES: To compare different
      adherence measures using data from a medicines claims database in South Africa
      (SA), employing montelukast for the purpose of illustration. METHODS: This
      retrospective, cross-sectional research used data from 1 January 2006 to 31
      December 2015 from a privately owned pharmaceutical benefits management (PBM)
      company in SA. Claims for montelukast were identified and adherence was
      determined using the continuous multiple-interval measure of oversupply (CMOS),
      compliance ratio (CR), modified medication possession ratio (MPRm), refill
      compliance rate (RCR), continuous single-interval measure of medication
      acquisition (CSA) and proportion of days covered (PDC) capped at 1. The measures 
      were compared with the medication possession ratio (MPR) as the reference.
      RESULTS: The MPR, CMOS and CR were equivalent, each yielding an adherence value
      of 86%. The MPRm, RCR and average CSA yielded higher adherence values of 96.9%,
      117.2% and 129.0%, respectively, whereas the PDC produced a lower adherence value
      of 76.0%. The measures that used the entire study period as the denominator
      produced consistent results compared with the measures that used the difference
      between claims dates as denominator. CONCLUSIONS: The MPR is considered the most 
      widely used metric to measure adherence using administrative data, but it may not
      always be applicable owing to the type of data available. Adherence computed
      using the CR, CMOS and PDC capped was found to be comparable to the MPR, and they
      may therefore be used as alternatives.
FAU - Obeng-Kusi, M
AU  - Obeng-Kusi M
AD  - Medicine Usage in South Africa, Faculty of Health Sciences, North-West
      University, Potchefstroom Campus, South Africa. jessamynem25@yahoo.com.
FAU - Lubbe, M S
AU  - Lubbe MS
FAU - Cockeran, M
AU  - Cockeran M
FAU - Burger, J R
AU  - Burger JR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200831
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
RN  - 0 (Acetates)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Cyclopropanes)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/therapeutic use
MH  - *Administrative Claims, Healthcare
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Cross-Sectional Studies
MH  - Cyclopropanes/therapeutic use
MH  - Humans
MH  - *Mathematical Concepts
MH  - Medication Adherence/*statistics & numerical data
MH  - Quinolines/therapeutic use
MH  - Retrospective Studies
MH  - South Africa
MH  - Sulfides/therapeutic use
EDAT- 2020/09/04 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/08/31 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i9.14189 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Aug 31;110(9):932-936. doi: 10.7196/SAMJ.2020.v110i9.14189.


PMID- 32880273
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 9
DP  - 2020 Aug 31
TI  - Financial burden of orthopaedic gunshot-related injury management at a major
      trauma centre.
PG  - 882-886
LID - 10.7196/SAMJ.2020.v110i9.14638 [doi]
AB  - BACKGROUND: Violence and injuries are a significant global public health concern,
      and have a substantial emotional, physical and economic impact on society. In
      South Africa (SA), the Western Cape Injury Mortality Profile shows that homicides
      increased from 38 deaths per 100 000 in 2010 to 52 deaths per 100 000 in 2016.
      This increase is directly related to an increase in firearm-related homicides,
      which doubled from 2010 to 2016. Previous research estimated the average cost per
      gunshot wound (GSW)-related orthopaedic patient at USD2 940. GSW-related patient 
      numbers as well as treatment costs have escalated exponentially over the past few
      years. OBJECTIVES: To calculate the financial costs involved in managing
      gunshot-related orthopaedic injuries both surgically and non-surgically at a
      tertiary centre in SA. METHODS: After ethics approval, a retrospective review of 
      all GSW patients seen in the emergency unit at Tygerberg Hospital in 2017 was
      undertaken. Patient records yielded data on the following parameters: injury site
      and characteristics, imaging modalities, orthopaedic management, hospital
      admission and duration of hospitalisation, theatre episodes, orthopaedic implants
      and blood products administered. Cost analysis was performed using this
      information. RESULTS: A total of 389 patients (360 male and 29 female), average
      age (range, standard deviation) 28 (3 - 69, 9.50) years, were treated during the 
      study period. Patient records identified a total of 449 orthopaedic injuries. A
      total of 187 patients were admitted, with 175 requiring surgical fixation. The
      conservatively calculated cost of managing this patient group was ZAR10 227 503. 
      The average management cost per patient was ZAR26 292, with an average of ZAR46
      670 per case requiring surgical management and ZAR8 810 for non-surgical cases
      (the average USD-ZAR exchange rate in 2017 was USD1-ZAR13.30). CONCLUSIONS: The
      total cost of managing 389 patients with gunshot-related orthopaedic injuries at 
      a tertiary hospital was ZAR10 227 503. Improved understanding of these costs will
      help the healthcare system better prioritise orthopaedic trauma funding and
      training and highlights the urgent need for cost-saving measures, specifically
      primary prevention initiatives.
FAU - Van Heukelum, M
AU  - Van Heukelum M
AD  - Division of Orthopaedic Surgery, Department of Surgical Sciences, Faculty of
      Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
      marcusvanh@gmx.com.
FAU - Le Roux, N
AU  - Le Roux N
FAU - Jakoet, S
AU  - Jakoet S
FAU - Ferreira, N
AU  - Ferreira N
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - Computed Tomography Angiography/economics
MH  - Female
MH  - *Health Care Costs
MH  - Humans
MH  - Length of Stay/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Musculoskeletal System/*injuries
MH  - Orthopedic Procedures/economics/instrumentation
MH  - Patient Admission/statistics & numerical data
MH  - Referral and Consultation/economics
MH  - Retrospective Studies
MH  - Trauma Centers
MH  - Wounds, Gunshot/diagnostic imaging/*economics/surgery
MH  - Young Adult
EDAT- 2020/09/04 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/08/31 00:00 [received]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i9.14638 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Aug 31;110(9):882-886. doi: 10.7196/SAMJ.2020.v110i9.14638.


PMID- 32880268
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20210428
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 9
DP  - 2020 Aug 13
TI  - Comparative strategic approaches to COVID-19 in Africa: Balancing public interest
      with civil liberties.
PG  - 858-863
AB  - As COVID-19 spreads rapidly across Africa, causing havoc to economies and
      disruption to already fragile healthcare systems, it is becoming clear that
      despite standardised global health strategies, national and local government
      responses must be tailored to their individual settings. Some African countries
      have adopted stringent measures such as national lockdown, quarantine or
      isolation, in combination with good hand hygiene, mandatory wearing of masks and 
      physical distancing, to prevent an impending healthcare crisis. The impact of
      stringent measures in low- to middle-income African countries has bought time for
      healthcare facilities to prepare for the onslaught of COVID-19 cases, but some
      measures have been challenging to implement. In some settings, public health
      measures have been associated with serious violations of individual rights owing 
      to abuse of power and gaps in implementation of well-intentioned policy.
      Collateral damage with regard to non-COVID-19 diseases that were suboptimally
      managed in pre-pandemic times may mean that lives lost from other diseases could 
      exceed those saved from COVID-19. While individuals complying with lockdown
      regulations have embraced an acceptance of the concept of the common good, at a
      broad community level many are finding the transition from individualism to
      collective thinking required during a pandemic difficult to navigate. In this
      article, we look at government responses to the pandemic in six African countries
      (Malawi, South Africa, Uganda, Zambia, Zimbabwe and Botswana), and highlight
      ethical concerns arising in these contexts.
FAU - Obasa, A E
AU  - Obasa AE
AD  - Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Cape Town, South Africa.
      obasa@sun.ac.za.
FAU - Singh, S
AU  - Singh S
FAU - Chivunze, E
AU  - Chivunze E
FAU - Burgess, T
AU  - Burgess T
FAU - Masiye, F
AU  - Masiye F
FAU - Mtande, T
AU  - Mtande T
FAU - Ochieng, J
AU  - Ochieng J
FAU - Chalwe, V
AU  - Chalwe V
FAU - Mokgatla, B
AU  - Mokgatla B
FAU - Rennie, S
AU  - Rennie S
FAU - Moodley, K
AU  - Moodley K
LA  - eng
GR  - D43 TW010511/TW/FIC NIH HHS/United States
GR  - U01 HG008222/HG/NHGRI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20200813
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Africa
MH  - Betacoronavirus
MH  - Botswana
MH  - COVID-19
MH  - Civil Rights/*ethics/legislation & jurisprudence
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Freedom
MH  - Humans
MH  - Malawi
MH  - Pandemics/*prevention & control
MH  - *Personal Autonomy
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health/*ethics/legislation & jurisprudence
MH  - SARS-CoV-2
MH  - South Africa
MH  - Uganda
MH  - Zambia
MH  - Zimbabwe
PMC - PMC8066401
MID - NIHMS1689722
EDAT- 2020/09/04 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/08/13 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Aug 13;110(9):858-863.


PMID- 32879963
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1460-2237 (Electronic)
IS  - 0268-1080 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Nov 20
TI  - A public-private partnership for dialysis provision in Ethiopia: a model for
      high-cost care in low-resource settings.
PG  - 1262-1267
LID - 10.1093/heapol/czaa085 [doi]
AB  - Our purpose was to explore whether private-public partnerships (PPPs) can serve
      as a model for access to high-cost care in low-resource settings by examining a
      unique PPP providing haemodialysis services in a remote setting, investigating
      challenges and enablers. The study setting is a 500-bed teaching hospital serving
      a catchment population of 8 million in Northern Ethiopia. Based on local data
      collection, observation and in-depth interviews, we identified the impetus for
      the PPP, described the partnership agreement, reported outcomes after 6 years of 
      activity and examined challenges that have arisen since the programme's
      inception, including funding sustainability. The PPP was established in 2013
      based on a decision by local leadership that treatment of patients with acute
      kidney injury (AKI) is a necessity rather than a luxury. A private partner was
      sought who could ensure service delivery as well as a reliable supply of
      consumables. The hospital contributions included infrastructure, personnel and
      sharing of maintenance costs. The partnership has facilitated uninterrupted
      haemodialysis service to 101 patients with AKI and 202 with chronic kidney
      disease. The former (>50% cured) were mainly supported by charitable donations
      procured by the hospital's leadership, while the latter were self-funded. The
      local university and community contributed to the charity. Utilization has
      increased yearly. Funding and logistical issues remain. In conclusion, this PPP
      enabled access to previously unavailable lifesaving care in Northern Ethiopia and
      could serve as a model for potential scale-up for haemodialysis provision in
      particular, and more broadly, high-cost care in low-resource settings. An ethical
      commitment to provide the service, combined with ongoing administrative and
      community involvement has contributed to its sustained success. Lack of
      affordability for most patients requiring chronic haemodialysis and reliance on
      charitable donations for treatment of patients with AKI pose challenges to
      long-term sustainability.
CI  - (c) The Author(s) 2020. Published by Oxford University Press in association with 
      The London School of Hygiene and Tropical Medicine. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Paltiel, Ora
AU  - Paltiel O
AD  - Braun School of Public Health and Community Medicine, Hadassah-Hebrew University,
      Jerusalem, Israel.
FAU - Berhe, Ephrem
AU  - Berhe E
AD  - Department of Internal Medicine, Nephrology Unit, College of Health Science,
      Ayder Comprehensive Specialized Hospital, Mekelle University, Mekelle, Tigray,
      Ethiopia.
FAU - Aberha, Amanuel Haile
AU  - Aberha AH
AD  - College of Health Science, Ayder Comprehensive Specialized Hospital, Mekelle
      University, Mekelle, Tigray, Ethiopia.
FAU - Tequare, Mengistu Hagazi
AU  - Tequare MH
AD  - College of Health Sciences, School of Public Health, Mekelle University, Mekelle,
      Tigray, Ethiopia.
FAU - Balabanova, Dina
AU  - Balabanova D
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Health Policy Plan
JT  - Health policy and planning
JID - 8610614
MH  - Community Participation
MH  - Costs and Cost Analysis
MH  - Ethiopia
MH  - Humans
MH  - *Public-Private Sector Partnerships
MH  - *Renal Dialysis/economics/statistics & numerical data
OTO - NOTNLM
OT  - Haemodialysis
OT  - high-cost care
OT  - low-income countries
OT  - partnership-public and private
OT  - universal health coverage
EDAT- 2020/09/04 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - 5900838 [pii]
AID - 10.1093/heapol/czaa085 [doi]
PST - ppublish
SO  - Health Policy Plan. 2020 Nov 20;35(9):1262-1267. doi: 10.1093/heapol/czaa085.


PMID- 32879870
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2292-5503 (Print)
IS  - 2292-5503 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Aug
TI  - Resident Behaviours to Prioritize According to Canadian Plastic Surgeons.
PG  - 148-155
LID - 10.1177/2292550320903424 [doi]
AB  - INTRODUCTION: Many articles have been published outlining the resident selection 
      process for plastic surgery training programs. However, which qualities Canadian 
      plastic surgeons value most in their current residents remains unclear. A
      national survey study was conducted to identify which attributes surgeons
      associate with the highest resident performance and which behaviours trainees
      should prioritize during their training. METHODS: A literature review was
      performed to identify studies that documented attributes valued in plastic
      surgery applicants and characteristics of high-performing surgical residents.
      These qualities were extracted to construct a survey consisting of both ranking
      and open-ended questions. After an iterative review process, the survey was
      disseminated nationally to consultants and trainees of Canadian plastic surgery
      training programs. RESULTS: Survey responses were obtained from 120 invitees and 
      a weighted rank was calculated for each evaluated attribute. The terms integrity,
      professional, and work ethic were viewed as the most important attributes prized 
      by surgeons. Dishonesty, lack of dependability, and unprofessionalism were viewed
      as the most concerning behaviours. Additionally, disinterest and arrogance were
      identified by the open-ended questions as behaviours surgeons would like to see
      less frequently in their trainees. When compared to surgeons, trainees
      undervalued the importance of knowledge and the impact of unprofessional
      behaviour. CONCLUSIONS: With the multiple roles that a resident must fulfill,
      understanding which attributes are of the most importance will help focus
      self-directed learning and development within residency programs. Ultimately,
      instilling the importance of integrity and professionalism is most highly valued 
      by members of the Canadian plastic surgery community.
CI  - (c) 2020 The Author(s).
FAU - Mankowski, Peter
AU  - Mankowski P
AUID- ORCID: https://orcid.org/0000-0003-3737-2046
AD  - Division of Plastic & Reconstructive Surgery, Department of Surgery, University
      of British Columbia, Vancouver, British Columbia, Canada.199005
FAU - Demsey, Daniel
AU  - Demsey D
AD  - Division of Plastic & Reconstructive Surgery, Department of Surgery, University
      of British Columbia, Vancouver, British Columbia, Canada.199005
FAU - Brown, Erin
AU  - Brown E
AD  - Division of Plastic & Reconstructive Surgery, Department of Surgery, University
      of British Columbia, Vancouver, British Columbia, Canada.199005
FAU - Knox, Aaron
AU  - Knox A
AD  - Division of Plastic Surgery, University of Calgary, Alberta, Canada.2129
LA  - eng
PT  - Journal Article
DEP - 20200225
PL  - United States
TA  - Plast Surg (Oakv)
JT  - Plastic surgery (Oakville, Ont.)
JID - 101623618
PMC - PMC7436847
OTO - NOTNLM
OT  - clinical competence
OT  - education
OT  - internship and residency
OT  - plastic
OT  - professionalism
OT  - surgery
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:01
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:01 [medline]
AID - 10.1177/2292550320903424 [doi]
AID - 10.1177_2292550320903424 [pii]
PST - ppublish
SO  - Plast Surg (Oakv). 2020 Aug;28(3):148-155. doi: 10.1177/2292550320903424. Epub
      2020 Feb 25.


PMID- 32879733
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Setting priorities fairly in response to Covid-19: identifying overlapping
      consensus and reasonable disagreement.
PG  - lsaa044
LID - 10.1093/jlb/lsaa044 [doi]
AB  - Proposals for allocating scarce lifesaving resources in the face of the Covid-19 
      pandemic have aligned in some ways and conflicted in others. This paper attempts 
      a kind of priority setting in addressing these conflicts. In the first part, we
      identify points on which we do not believe that reasonable people should
      differ-even if they do. These are (i) the inadequacy of traditional clinical
      ethics to address priority-setting in a pandemic; (ii) the relevance of saving
      lives; (iii) the flaws of first-come, first-served allocation; (iv) the relevance
      of post-episode survival; (v) the difference between age and other factors that
      affect life-expectancy; and (vi) the need to avoid quality-of-life judgments. In 
      the second part, we lay out some positions on which reasonable people can and do 
      differ. These include (i) conflicts between maximizing benefits and priority to
      the worst off; (ii) role-based priority; and (iii) whether patients' existing
      lifesaving resources should be subject to redistribution.
CI  - Published by Oxford University Press on behalf of International Society for
      Diseases of the Esophagus 2020.
FAU - Wasserman, David
AU  - Wasserman D
AD  - Clinical Center Department of Bioethics, National Institutes of Health, Bethesda,
      MD 20892, USA.
FAU - Persad, Govind
AU  - Persad G
AD  - Sturm College of Law, University of Denver, Denver, CO 80210, USA.
FAU - Millum, Joseph
AU  - Millum J
AD  - Clinical Center Department of Bioethics, National Institutes of Health, Bethesda,
      MD 20892, USA.
AD  - Fogarty International Center, National Institutes of Health, Bethesda, MD 20894, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7337850
OTO - NOTNLM
OT  - Covid-19
OT  - disability
OT  - ethics
OT  - priority-setting
OT  - triage
OT  - ventilators
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:01
CRDT- 2020/09/04 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:01 [medline]
AID - 10.1093/jlb/lsaa044 [doi]
AID - lsaa044 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 29;7(1):lsaa044. doi: 10.1093/jlb/lsaa044. eCollection
      2020 Jan-Jun.


PMID- 32879631
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2052-9597 (Electronic)
IS  - 1740-3812 (Linking)
VI  - 19
IP  - 3
DP  - 2020
TI  - Responsible Innovation and Climate Engineering. A Step Back to Technology
      Assessment.
PG  - 297-316
LID - 10.1007/s40926-020-00127-z [doi]
AB  - Much in Responsible Research and Innovation (RRI) is part of a participatory turn
      within the Technology Assessment (TA) and Science and Technology Studies (STS)
      community. This has an influence also on the evaluation of Climate Engineering
      (CE) options, as it will be shown by reference to the SPICE project. The SPICE
      example and the call for democratisation of science and innovation raise some
      interesting concerns for the normative evaluation of CE options that will be
      addressed in the paper. It is by far not clear, or so it will be argued, how much
      of the innovation process of CE technologies should be put in the hands of social
      actors and the wider public. This is due not only to special features about CE
      technologies but also to some more principle concerns against some features of
      participatory RRI approaches. Still, this does by no way mean that ethical and
      societal issues in the context of CE technologies should be ignored. Rather, the 
      paper will argue that one can take a step back to expert TA linked to the
      evolution of approaches of ethical impact analysis in this area. This does not
      only lead to reconsider the emphasis on participation and democratisation of
      research and innovation, but also opens up for an alternative evaluative
      framework for CE technologies developed in the last part of the paper.
CI  - (c) The Author(s) 2020.
FAU - Stelzer, Harald
AU  - Stelzer H
AUID- ORCID: 0000-0002-2658-7685
AD  - University of Graz, Heinrichstrasse 26/II, A-8010 Graz,
      Austria.grid.5110.50000000121539003
LA  - eng
PT  - Journal Article
DEP - 20200219
PL  - Switzerland
TA  - Philos Manag
JT  - Philosophy of management
JID - 101770758
PMC - PMC7446290
OTO - NOTNLM
OT  - Climate engineering
OT  - Ethical impact analysis
OT  - Geoengineering
OT  - Participation
OT  - Responsible research and innovation
OT  - Technology assessement
COIS- Conflict of InterestThe author states that there is no conflict of interest.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:01
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:01 [medline]
AID - 10.1007/s40926-020-00127-z [doi]
AID - 127 [pii]
PST - ppublish
SO  - Philos Manag. 2020;19(3):297-316. doi: 10.1007/s40926-020-00127-z. Epub 2020 Feb 
      19.


PMID- 32879517
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 9
DP  - 2020 Sep
TI  - Veterinary Medical Ethics.
PG  - 923-924
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7424929
EDAT- 2020/09/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_09_923 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Sep;61(9):923-924.


PMID- 32878994
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20201218
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Sep
TI  - National registry for patients with inflammatory rheumatic diseases (IRD)
      infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and
      reliable knowledge of the clinical course of SARS-CoV-2 infections in patients
      with IRD.
LID - e001332 [pii]
LID - 10.1136/rmdopen-2020-001332 [doi]
AB  - OBJECTIVES: Patients with inflammatory rheumatic diseases (IRD) infected with
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to
      develop a severe course of COVID-19. The influence of immunomodulating drugs on
      the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2
      infections in patients with IRD, we established a registry shortly after the
      beginning of the pandemic in Germany. METHODS: Using an online questionnaire
      (www.COVID19-rheuma.de), a nationwide database was launched on 30 March 2020,
      with appropriate ethical and data protection approval to collect data of patients
      with IRD infected with SARS-CoV-2. In this registry, key clinical and
      epidemiological parameters-for example, diagnosis of IRD, antirheumatic
      therapies, comorbidities and course of the infection-are documented. RESULTS:
      Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2
      were reported (40 males; 63 females; 1 diverse). Most of them (45%) were
      diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42%
      were treated with biological disease-modifying antirheumatic drugs.
      Hospitalisation was reported in 32% of the patients. Two-thirds of the patients
      already recovered. Unfortunately, 6 patients had a fatal course. CONCLUSIONS: In 
      a short time, a national registry for SARS-CoV2-infected patients with IRD was
      established. Within 4 weeks, 104 cases were documented. The registry enables to
      generate data rapidly in this emerging situation and to gain a better
      understanding of the course of SARS-CoV2-infection in patients with IRD, with a
      distinct focus on their immunomodulatory therapies. This knowledge is valuable
      for timely information of physicians and patients with IRD, and shall also serve 
      for the development of guidance for the management of patients with IRD during
      this pandemic.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hasseli, Rebecca
AU  - Hasseli R
AUID- ORCID: 0000-0002-2982-8253
AD  - Department of Rheumatology and Clinical Immunology, Campus Kerckhoff,
      Justus-Liebig-University Giessen, Giessen, Germany r.hasseli@kerckhoff-klinik.de.
FAU - Mueller-Ladner, Ulf
AU  - Mueller-Ladner U
AD  - Department of Rheumatology and Clinical Immunology, Campus Kerckhoff,
      Justus-Liebig-University Giessen, Giessen, Germany.
FAU - Schmeiser, Tim
AU  - Schmeiser T
AD  - Department of Rheumatology and Immunology, Saint Josef Hospital, Wuppertal,
      Germany.
FAU - Hoyer, Bimba F
AU  - Hoyer BF
AD  - Department of Rheumatology and Clinical Immunology, Clinic for Internal Medicine 
      I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
FAU - Krause, Andreas
AU  - Krause A
AD  - Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital 
      Berlin, Berlin, Germany.
FAU - Lorenz, Hanns-Martin
AU  - Lorenz HM
AD  - Department of Rheumatology, University of Heidelberg, Heidelberg, Germany.
FAU - Regierer, Anne Constanze
AU  - Regierer AC
AUID- ORCID: 0000-0003-2456-4049
AD  - Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
FAU - Richter, Jutta G
AU  - Richter JG
AD  - Department of Rheumatology and Hiller Research Unit, Heinrich-Heine-University,
      Medical Faculty, Duesseldorf, Germany.
FAU - Strangfeld, Anja
AU  - Strangfeld A
AD  - Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
FAU - Voll, Reinhard E
AU  - Voll RE
AD  - Department of Rheumatology and Clinical Immunology, University Medical Center,
      Faculty of Medicine, Albert-Ludwigs University of Freiburg, Freiburg, Germany.
FAU - Pfeil, Alexander
AU  - Pfeil A
AD  - Department of Internal Medicine III, University Hospital Jena, Jena, Germany.
FAU - Schulze-Koops, Hendrik
AU  - Schulze-Koops H
AD  - Division of Rheumatology and Clinical Immunology, Department of Internal Medicine
      IV, University of Munich, Munich, Germany.
FAU - Specker, Christof
AU  - Specker C
AD  - Department of Rheumatology and Clinical Immunology, KEM Kliniken
      Essen-Mitte,Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/complications/drug therapy
MH  - Arthritis, Rheumatoid/complications/drug therapy
MH  - Betacoronavirus
MH  - Biological Products/*therapeutic use
MH  - COVID-19
MH  - Coronavirus Infections/complications/mortality/*physiopathology
MH  - Female
MH  - Germany
MH  - Granulomatosis with Polyangiitis/complications/drug therapy
MH  - Hospitalization
MH  - Humans
MH  - Lupus Erythematosus, Systemic/complications/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/complications/mortality/*physiopathology
MH  - Polymyalgia Rheumatica/complications/drug therapy
MH  - Prognosis
MH  - *Registries
MH  - Rheumatic Diseases/complications/*drug therapy
MH  - SARS-CoV-2
MH  - Scleroderma, Systemic/complications/drug therapy
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/complications/drug therapy
MH  - Young Adult
PMC - PMC7507994
OTO - NOTNLM
OT  - *Antirheumatic Agents
OT  - *Autoimmune Diseases
OT  - *Communicable Diseases
OT  - *Epidemiology
OT  - *Health services research
OT  - *Imported
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - rmdopen-2020-001332 [pii]
AID - 10.1136/rmdopen-2020-001332 [doi]
PST - ppublish
SO  - RMD Open. 2020 Sep;6(2). pii: rmdopen-2020-001332. doi:
      10.1136/rmdopen-2020-001332.


PMID- 32878919
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Commentary on: 'Forever young? The ethics of ongoing puberty suppression for
      non-binary adults'.
PG  - 757-758
LID - 10.1136/medethics-2020-106587 [doi]
FAU - Lemma, Alessandra
AU  - Lemma A
AD  - Queen Anne Street Practice, London, UK alemma@mac.com.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200902
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):743-752. PMID: 32709753
CIN - J Med Ethics. 2020 Nov;46(11):761-762. PMID: 33087409
MH  - Adult
MH  - Humans
MH  - *Puberty
MH  - *Sexuality
OTO - NOTNLM
OT  - *autonomy
OT  - *clinical ethics
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/14 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - medethics-2020-106587 [pii]
AID - 10.1136/medethics-2020-106587 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):757-758. doi: 10.1136/medethics-2020-106587. Epub
      2020 Sep 2.


PMID- 32878918
OWN - NLM
STAT- Publisher
LR  - 20220716
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 2
TI  - Constructing authentic decisions: proxy decision making for research involving
      adults who lack capacity to consent.
LID - medethics-2019-106042 [pii]
LID - 10.1136/medethics-2019-106042 [doi]
AB  - Research involving adults who lack capacity to consent relies on proxy (or
      surrogate) decision making. Proxy decisions about participation are ethically
      complex, with a disparity between normative accounts and empirical evidence.
      Concerns about the accuracy of proxies' decisions arise, in part, from the lack
      of an ethical framework which takes account of the complex and morally
      pluralistic world in which proxy decisions are situated. This qualitative study
      explored the experiences of family members who have acted as a research proxy in 
      order to develop an understanding of the ethical concepts involved, and the
      interactions between those concepts. Proxies described a complex process of
      respecting the wishes and preferences of the person they represented, whist
      integrating preferences with what they viewed as being in the interests of the
      person. They aimed to make a decision that was 'best' for the person and
      protected them from harm; they also aimed to make the 'right' decision, viewed as
      being authentic to the person's values and life. Decisions were underpinned by
      the relationship between the person and their proxy, in which both trust and
      trustworthiness were key. Proxies' decisions, based both on respect for the
      person and the need to protect their interests, arose out of their dual role as
      both proxy and carer. The findings raise questions about accounts which rely on
      existing normative assumptions with a focus on accuracy and discrepancy, and
      which fail to take account of the requirement for proxies to make authentic
      decisions that arise out of their caring obligations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Shepherd, Victoria
AU  - Shepherd V
AUID- ORCID: http://orcid.org/0000-0002-7687-0817
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK
      ShepherdVL1@cardiff.ac.uk.
FAU - Sheehan, Mark
AU  - Sheehan M
AUID- ORCID: http://orcid.org/0000-0002-7191-901X
AD  - Ethox Centre, University of Oxford, Oxford, Oxfordshire, UK.
FAU - Hood, Kerenza
AU  - Hood K
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Griffith, Richard
AU  - Griffith R
AD  - College of Human and Health Sciences, Swansea University, Swansea, UK.
FAU - Wood, Fiona
AU  - Wood F
AD  - Division of Population Medicine, Cardiff University, Cardiff, UK.
LA  - eng
GR  - HCRW_NIHR-FS-2016/HCRW/HCRW_/United Kingdom
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - capacity
OT  - informed consent
OT  - research ethics
OT  - research on special populations
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/09/04 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - medethics-2019-106042 [pii]
AID - 10.1136/medethics-2019-106042 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 2. pii: medethics-2019-106042. doi:
      10.1136/medethics-2019-106042.


PMID- 32878916
OWN - NLM
STAT- Publisher
LR  - 20200903
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Sep 2
TI  - MIP does not save the impairment argument against abortion: a reply to Blackshaw 
      and Hendricks.
LID - medethics-2020-106566 [pii]
LID - 10.1136/medethics-2020-106566 [doi]
AB  - Perry Hendricks' original 'impairment argument' against abortion relied on 'the
      impairment principle' (TIP): 'if it is immoral to impair an organism O to the nth
      degree, then, ceteris paribus, it is immoral to impair O to the n+1 degree.'
      Since death is a bigger impairment than fetal alcohol syndrome (FAS), Hendricks
      reasons that, by TIP, if causing FAS is immoral, then, ceteris paribus, abortion 
      is immoral. Several authors have argued that this conclusion is uninteresting,
      since the ceteris paribus clause is not satisfied in actual cases of abortion:
      women have reasons for wanting abortions which do not apply to drinking during
      pregnancy, so all else is not equal, and the conclusion is irrelevant to the
      morality of actual abortions. In a recent article in this journal, Hendricks and 
      Bruce Blackshaw try to evade this criticism by replacing TIP with the 'modified
      impairment principle' (MIP): 'if it is immoral to impair an organism O to the nth
      degree for reason R, then, provided R continues to hold (or is present), it is
      immoral to impair O to the n+1 degree.' MIP allows us to derive the ultima facie 
      wrongness of abortion (not just its ceteris paribus wrongness) because MIP lacks 
      a ceteris paribus clause. But I argue that this lack also renders MIP false: MIP 
      faces counterexamples and implausibly produces genuine moral dilemmas. Since the 
      moral principle on which it relies is false, the modified impairment argument
      fails. I close by considering what a principle would need to do for the
      impairment argument to succeed.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Crummett, Dustin
AU  - Crummett D
AD  - Chair of Late Antique and Arabic Philosophy, Ludwig-Maximilians-Universitat
      Munchen, Munchen 80539, Germany dustin.crummett@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - abortion
OT  - applied and professional ethics
OT  - ethics
OT  - political philosophy
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/06/10 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - medethics-2020-106566 [pii]
AID - 10.1136/medethics-2020-106566 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Sep 2. pii: medethics-2020-106566. doi:
      10.1136/medethics-2020-106566.


PMID- 32878764
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 2
TI  - Intensive Care Weaning (iCareWean) protocol on weaning from mechanical
      ventilation: a single-blinded multicentre randomised control trial comparing an
      open-loop decision support system and routine care, in the general intensive care
      unit.
PG  - e042145
LID - 10.1136/bmjopen-2020-042145 [doi]
AB  - INTRODUCTION: Automated systems for ventilator management to date have been
      either fully heuristic rule-based systems or based on a combination of simple
      physiological models and rules. These have been shown to reduce the duration of
      mechanical ventilation in simple to wean patients. At present, there are no
      published studies that evaluate the effect of systems that use detailed
      physiological descriptions of the individual patient.The BEACON Caresystem is a
      model-based decision support system that uses mathematical models of patients'
      physiology in combination with models of clinical preferences to provide advice
      on appropriate ventilator settings. An individual physiological description may
      be particularly advantageous in selecting the appropriate therapy for a complex, 
      heterogeneous, intensive care unit (ICU) patient population. METHODS AND
      ANALYSIS: Intenive Care weaning (iCareWean) is a single-blinded, multicentre,
      prospective randomised control trial evaluating management of mechanical
      ventilation as directed by the BEACON Caresystem compared with that of current
      care, in the general intensive care setting. The trial will enrol 274
      participants across multiple London National Health Service ICUs. The trial will 
      use a primary outcome of duration of mechanical ventilation until successful
      extubation. ETHICS AND DISSEMINATION: Safety oversight will be under the
      direction of an independent committee of the study sponsor. Study approval was
      obtained from the regional ethics committee of the Health Research Authority
      (HRA), (Research Ethic Committee (REC) reference: 17/LO/0887. Integrated Research
      Application System (IRAS) reference: 226610. Results will be disseminated through
      international critical care conference/symposium and publication in peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov under NCT03249623. This
      research is registered with the National Institute for Health Research under CPMS
      ID: 34831.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Vizcaychipi, M P
AU  - Vizcaychipi MP
AUID- ORCID: 0000-0001-7894-873X
AD  - APMIC, Imperial College London, London, UK m.vizcaychipi@imperial.ac.uk.
AD  - Magill Department of Anaesthesia and Intensive Care Medicine, Chelsea and
      Westminster Healthcare NHS Trust, London, UK.
FAU - Martins, Laura
AU  - Martins L
AD  - Research Trial Unit, Chelsea and Westminster Hospital NHS Foundation Trust,
      London, London, UK.
FAU - White, James R
AU  - White JR
AD  - Magill Department of Anaesthesia, Chelsea and Westminster Hospital NHS Foundation
      Trust, London, London, UK.
FAU - Karbing, Dan Stleper
AU  - Karbing DS
AD  - Center for Model-based Medical Decision Support, Aalborg Universitet, Aalborg,
      Denmark.
FAU - Gupta, Amandeep
AU  - Gupta A
AD  - Anaesthetic Department, West Middlesex University Hospital NHS Trust, London,
      London, UK.
FAU - Singh, Suveer
AU  - Singh S
AD  - Magill Department of Anaesthesia and Intensive Care Medicine, Chelsea and
      Westminster Healthcare NHS Trust, London, UK.
FAU - Osman, Leyla
AU  - Osman L
AD  - Magill Department of Anaesthesia, Chelsea and Westminster Hospital NHS Foundation
      Trust, London, London, UK.
FAU - Moreno-Cuesta, Jeronimo
AU  - Moreno-Cuesta J
AD  - Anaesthetic Department, North Middlesex University Hospital NHS Trust, London,
      London, UK.
FAU - Rees, Steve
AU  - Rees S
AD  - Department of Health Science and Technology, Aalborg Universitet Institut for
      Medicin og Sundhedsteknologi, Aalborg, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03249623
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200902
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Oct 23;10(10):e042145corr1. PMID: 33099503
MH  - Critical Care
MH  - Humans
MH  - Intensive Care Units
MH  - London
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Respiration, Artificial
MH  - *State Medicine
MH  - Ventilator Weaning
PMC - PMC7470506
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *physiology
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: SR and DSK are minor shareholders of Mermaid Care A/S who
      manufacture the Beacon Caresystem. They have also acted as consultants for
      Mermaid Care A/S. SR is an unpaid board member of Mermaid Care A/S.
EDAT- 2020/09/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-042145 [pii]
AID - 10.1136/bmjopen-2020-042145 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 2;10(9):e042145. doi: 10.1136/bmjopen-2020-042145.


PMID- 32878763
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 2
TI  - Patient education materials for non-specific low back pain and sciatica: a
      protocol for a systematic review and meta-analysis.
PG  - e039530
LID - 10.1136/bmjopen-2020-039530 [doi]
AB  - INTRODUCTION: Low back pain accounts for more disability than any other
      musculoskeletal condition and is associated with severe economic burden. Patients
      commonly present with negative beliefs about low back pain and this can have
      detrimental effects on their health outcomes. Providing evidence-based,
      patient-centred education that meets patient needs could help address these
      negative beliefs and alleviate the substantial low back pain burden. The primary 
      aim of this review is to investigate the effectiveness of patient education
      materials on immediate process, clinical and health system outcomes. METHODS AND 
      ANALYSIS: The search strategy was developed in collaboration with a librarian and
      systematic searches will be performed in MEDLINE, EMBASE, CINAHL, PsycINFO and
      SPORTDiscus. We will also search trial registries and grey literature through the
      OpenGrey database. Study selection will include a title and abstract scan and
      full-text review by two authors. Only randomised controlled trials will be
      included in this review. Trials must include patients with low back pain or
      sciatica and investigate educational interventions with at least one of the
      following contrasts: (1) education alone versus no intervention; (2) education
      alone versus another intervention; (3) education in addition to another
      intervention versus the same intervention with no education. Data extraction,
      risk of bias and grading of the quality of evidence will be performed
      independently by two reviewers. Risk of bias will be assessed using the PEDro
      scale, and the quality of evidence will be assessed with the Grades of
      Recommendation, Assessment, Development and Evaluation approach. A random-effects
      model will be used for each contrast, and results will be pooled if the
      participants, interventions, and outcomes are homogeneous. If heterogeneity is
      high (I(2) >75%), we will evaluate the magnitude and direction of the differences
      in effect sizes across studies to determine if it remains reasonable to pool the 
      results. Analyses of acute and subacute low back pain (less than 12 weeks
      duration) will be performed separately from chronic low back pain (12 weeks or
      greater duration). Likewise, analyses of short-term (less than 6 months) and
      long-term (6 months or greater) follow-up will be performed separately. Subgroup 
      analyses will be performed on non-specific low back pain, sciatica and mixed
      populations. ETHICS AND DISSEMINATION: Ethical approval is not required for this 
      review. This study, along with its results, will be published in a peer-reviewed 
      journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Furlong, Bradley
AU  - Furlong B
AUID- ORCID: 0000-0002-2013-7624
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland, St John's,
      Newfoundland, Canada bradley.furlong@mun.ca.
FAU - Aubrey-Bassler, Kris
AU  - Aubrey-Bassler K
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland, St John's,
      Newfoundland, Canada.
FAU - Etchegary, Holly
AU  - Etchegary H
AD  - Clinical Epidemiology, Memorial University of Newfoundland, St. John's,
      Newfoundland, Canada.
FAU - Pike, Andrea
AU  - Pike A
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland, St John's,
      Newfoundland, Canada.
FAU - Darmonkow, Georgia
AU  - Darmonkow G
AD  - Clinical Epidemiology, Memorial University of Newfoundland, St. John's,
      Newfoundland, Canada.
FAU - Swab, Michelle
AU  - Swab M
AD  - Health Sciences Library, Memorial University of Newfoundland, St. John's,
      Newfoundland, Canada.
FAU - Hall, Amanda
AU  - Hall A
AD  - Primary Healthcare Research Unit, Memorial University of Newfoundland, St John's,
      Newfoundland, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200902
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Disabled Persons
MH  - Humans
MH  - *Low Back Pain/therapy
MH  - Meta-Analysis as Topic
MH  - Patient Education as Topic
MH  - Review Literature as Topic
MH  - *Sciatica/therapy
PMC - PMC7470487
OTO - NOTNLM
OT  - *epidemiology
OT  - *health economics
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039530 [pii]
AID - 10.1136/bmjopen-2020-039530 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 2;10(9):e039530. doi: 10.1136/bmjopen-2020-039530.


PMID- 32878759
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 2
TI  - Understanding the mechanisms of a combined physical and psychological
      intervention for people with neurogenic claudication: protocol for a causal
      mediation analysis of the BOOST trial.
PG  - e037121
LID - 10.1136/bmjopen-2020-037121 [doi]
AB  - INTRODUCTION: Conservative treatments such as exercise are recommended for the
      management of people with neurogenic claudication from spinal stenosis. However, 
      the effectiveness and mechanisms of effect are unknown. This protocol outlines an
      a priori plan for a secondary analysis of a multicentre randomised controlled
      trial of a physiotherapist-delivered, combined physical and psychological
      intervention (Better Outcomes for Older people with Spinal Trouble (BOOST)
      programme). METHODS AND ANALYSES: We will use causal mediation analysis to
      estimate the mechanistic effects of the BOOST programme on the primary outcome of
      disability (measured by the Oswestry Disability Index). The primary mechanism of 
      interest is walking capacity, and secondary mediators include fear-avoidance
      behaviour, walking self-efficacy, physical function, physical activity and/or
      symptom severity. All mediators will be measured at 6 months and the outcome will
      be measured at 12 months from randomisation. Patient characteristics and possible
      confounders of the mediator-outcome effect will be measured at baseline.
      Sensitivity analyses will be conducted to evaluate the robustness of the
      estimated effects to varying levels of residual confounding. ETHICS AND
      DISSEMINATION: Ethical approval was given on 3 March 2016 (National Research
      Ethics Committee number: 16/LO/0349). The results of this analysis will be
      disseminated in peer-reviewed journals and at relevant scientific conferences.
      TRIAL REGISTRATION NUMBER: ISRCTN12698674.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Comer, Christine
AU  - Comer C
AUID- ORCID: 0000-0001-9847-9408
AD  - Musculoskeletal and Rehabilitation Services, Leeds Community Healthcare NHS
      Trust, Leeds, UK c.comer@leeds.ac.uk.
AD  - Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
      Faculty of Medicine and Health, Leeds, UK.
FAU - Lee, Hopin
AU  - Lee H
AD  - School of Medicine and Public Health, University of Newcastle, New South Wales,
      Australia.
AD  - The Centre for Rehabilitation Research, Nuffield Department of Orthopaedics,
      Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford,
      Oxfordshire, UK.
FAU - Williamson, Esther
AU  - Williamson E
AUID- ORCID: 0000-0003-0638-0406
AD  - The Centre for Rehabilitation Research, Nuffield Department of Orthopaedics,
      Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford,
      Oxfordshire, UK.
FAU - Lamb, Sarah
AU  - Lamb S
AD  - The Centre for Rehabilitation Research, Nuffield Department of Orthopaedics,
      Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford,
      Oxfordshire, UK.
AD  - College of Medicine and Health, University of Exeter, Exeter, Devon, UK.
LA  - eng
GR  - ICA-CL-2017-03-015/DH_/Department of Health/United Kingdom
GR  - PTC-RP-PG-0213-20002/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200902
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Back Pain
MH  - *Chronic Pain
MH  - Exercise Therapy
MH  - Humans
MH  - *Mediation Analysis
MH  - Multicenter Studies as Topic
MH  - Psychosocial Intervention
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Walking
PMC - PMC7470505
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *rehabilitation medicine
OT  - *spine
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037121 [pii]
AID - 10.1136/bmjopen-2020-037121 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 2;10(9):e037121. doi: 10.1136/bmjopen-2020-037121.


PMID- 32878758
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 2
TI  - Protocol of a randomised controlled phase II clinical trial investigating
      PREoperative endoscopic injection of BOTulinum toxin into the sphincter of Oddi
      to reduce postoperative pancreatic fistula after distal pancreatectomy: the
      PREBOTPilot trial.
PG  - e036815
LID - 10.1136/bmjopen-2020-036815 [doi]
AB  - INTRODUCTION: Postoperative pancreatic fistula (POPF) is still the most
      frequently occurring and clinically relevant complication after distal
      pancreatectomy (DP). Preoperative endoscopic injection of botulinum toxin (BTX)
      into the sphincter of Oddi represents an innovative approach to prevent POPF. The
      aim of this project (PREBOTPilot) is to generate the first randomised controlled 
      trial data on the safety, feasibility and efficacy of preoperative endoscopic BTX
      injection into the sphincter of Oddi to prevent clinically relevant POPF
      following DP. METHODS AND ANALYSIS: PREBOTPilot is an investigator-initiated,
      single-centre, randomised, controlled, open-label, phase II clinical trial with
      two parallel study groups and an exploratory study design. 60 patients scheduled 
      for DP will be randomised to intervention and control group. In the intervention 
      group, patients will undergo preoperative endoscopic injection of BTX into the
      sphincter of Oddi, whereas in the control group no preoperative endoscopy will be
      performed. The combined primary endpoint is the occurrence of clinically relevant
      POPF and/or death within 30 days after DP. The secondary endpoints comprise
      further postoperative outcome parameters and quality of life up to 3 months after
      DP as well as safety and feasibility of the procedure. Statistical analysis is
      based on the modified intention-to-treat population, excluding patients without
      status post DP. For safety analysis, rates of adverse events (AEs) and serious
      AEs will be calculated with 95% CIs for group comparisons. ETHICS, FUNDING AND
      DISSEMINATION: PREBOTPilot has been approved by the German Federal Institute for 
      Drugs and Medical Devices (reference number 4043654) and the Ethics Committee of 
      Heidelberg University (reference number AFmo-523/2019). This trial is supported
      by the German Federal Ministry of Education and Research (BMBF). The results of
      the trial will be presented at national and international conferences and
      published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: DRKS00020401.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Klaiber, Ulla
AU  - Klaiber U
AUID- ORCID: 0000-0002-9287-1174
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Sauer, Peter
AU  - Sauer P
AD  - Interdisciplinary Centre of Endoscopy, University of Heidelberg, Heidelberg,
      Baden-Wurttemberg, Germany.
FAU - Martin, Eike
AU  - Martin E
AD  - Patient Advocacy, University of Heidelberg, Heidelberg, Baden-Wurttemberg,
      Germany.
FAU - Bruckner, Thomas
AU  - Bruckner T
AD  - Institute of Medical Biometry and Informatics (IMBI), University of Heidelberg,
      Heidelberg, Baden-Wurttemberg, Germany.
FAU - Luntz, Steffen
AU  - Luntz S
AD  - Coordination Centre for Clinical Trials (KKS), University of Heidelberg,
      Heidelberg, Baden-Wurttemberg, Germany.
FAU - Tjaden, Christine
AU  - Tjaden C
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Probst, Pascal
AU  - Probst P
AUID- ORCID: 0000-0002-0895-4015
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Knebel, Phillip
AU  - Knebel P
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Diener, Markus K
AU  - Diener MK
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Hackert, Thilo
AU  - Hackert T
AD  - Department of General, Visceral and Transplantation Surgery, University of
      Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
      thilo_hackert@med.uni-heidelberg.de.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200902
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - EC 3.4.24.69 (Botulinum Toxins)
SB  - IM
MH  - *Botulinum Toxins
MH  - Clinical Trials, Phase II as Topic
MH  - Endoscopy
MH  - Humans
MH  - Pancreatectomy/adverse effects
MH  - Pancreatic Fistula
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Sphincter of Oddi
PMC - PMC7470495
OTO - NOTNLM
OT  - *gastroenterology
OT  - *pancreatic disease
OT  - *pancreatic surgery
COIS- Competing interests: None declared.
EDAT- 2020/09/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036815 [pii]
AID - 10.1136/bmjopen-2020-036815 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 2;10(9):e036815. doi: 10.1136/bmjopen-2020-036815.


PMID- 32878757
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 2
TI  - Efficacy of brief intervention for drug misuse in primary care facilities:
      systematic review and meta-analysis protocol.
PG  - e036633
LID - 10.1136/bmjopen-2019-036633 [doi]
AB  - INTRODUCTION: Drug misuse is associated with significant global morbidity,
      mortality, economic costs and social costs. Many primary care facilities have
      integrated drug misuse screening and brief intervention (BI) into their usual
      care delivery. However, the efficacy of BI for drug misuse in primary care has
      not been substantiated through meta-analysis. The aim of this systematic review
      and meta-analysis is to determine the efficacy of BI for drug misuse in primary
      care settings. METHODS AND ANALYSIS: We will include all randomised controlled
      trials comparing primary care-delivered BI for drug misuse with no intervention
      or minimal screening/assessment and usual care. Primary outcomes are (1) drug use
      frequency scores and (2) severity scores at intermediate follow-up (4-8 months). 
      We will retrieve all studies through searches in CENTRAL, Embase, MEDLINE and
      PsycINFO until 31 May 2020. The reference list will be supplemented with searches
      in trial registries (eg, www.clinicaltrials.gov) and through relevant existing
      study reference lists identified in the literature. We will conduct a
      random-effect pairwise meta-analysis for primary and secondary outcomes. We will 
      assess statistical heterogeneity though visual inspection of a forest plot and
      calculate I (2) statistics. We will assess risk of bias using the Cochrane Risk
      of Bias Tool V.2 and evaluate the certainty of evidence through the Grading of
      Recommendations Assessment, Development and Evaluation (GRADE) approach.
      Sensitivity analyses will account for studies with control group variations and
      studies with a high risk of bias. If heterogeneity is present, subgroup analyses 
      will consider patient variables of age, sex/gender, race/ethnicity, per cent
      insured, baseline severity and primary drug misused. ETHICS AND DISSEMINATION:
      This study will use published aggregate data and will not require ethical
      approval. Findings will be disseminated in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sahker, Ethan
AU  - Sahker E
AUID- ORCID: 0000-0002-4269-4800
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan
      sahker.ethan.2e@kyoto-u.ac.jp.
AD  - Japan Society for the Promotion of Science (JSPS), Overseas Fellowship Division, 
      Kojimachi, Chiyoda-ku, Tokyo, Japan.
FAU - Sakata, Masatsugu
AU  - Sakata M
AUID- ORCID: 0000-0002-5358-5263
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
FAU - Toyomoto, Rie
AU  - Toyomoto R
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
FAU - Hwang, Chiyoung
AU  - Hwang C
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
AD  - Japan Society for the Promotion of Science (JSPS), Research Fellowship Division, 
      Kojimachi, Chiyoda-ku, Tokyo, Japan.
FAU - Yoshida, Kazufumi
AU  - Yoshida K
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
FAU - Luo, Yan
AU  - Luo Y
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
FAU - Watanabe, Norio
AU  - Watanabe N
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
FAU - Furukawa, Toshi A
AU  - Furukawa TA
AD  - Department of Health Promotion and Human Behavior, Graduate School of Medicine,
      School of Public Health, Kyoto University, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200902
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Costs and Cost Analysis
MH  - *Crisis Intervention
MH  - *Drug Misuse
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Primary Health Care
MH  - Systematic Reviews as Topic
PMC - PMC7470504
OTO - NOTNLM
OT  - *mental health
OT  - *primary care
OT  - *substance misuse
COIS- Competing interests: TAF reports personal fees from Mitsubishi-Tanabe, MSD and
      Shionogi, and a grant from Mitsubishi-Tanabe, outside the submitted work; TAF has
      a patent (2018-177688) pending. All the other authors report no competing
      interest.
EDAT- 2020/09/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036633 [pii]
AID - 10.1136/bmjopen-2019-036633 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 2;10(9):e036633. doi: 10.1136/bmjopen-2019-036633.


PMID- 32878735
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210210
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Dec
TI  - Promoting the ethical use of safe and effective cell-based products: the
      Andalusian plan on regenerative medicine.
PG  - 712-717
LID - S1465-3249(20)30794-5 [pii]
LID - 10.1016/j.jcyt.2020.07.007 [doi]
AB  - With regard to regenerative medicine, the expectations generated over the last
      two decades and the time involved in developing this type of therapies, together 
      with the availability of devices that allow point-of-care treatments through the 
      rapid isolation of cellular or plasma products from patients in the operating
      theater, represent the perfect breeding ground for the offering of unproven or
      unregulated therapies on a global scale. A multidisciplinary approach-one based
      on the collaboration of institutions that, from the perspective of their area of 
      competence, can contribute to reversing this worrying situation-to this problem
      is essential. It is a priority for local health authorities to take measures that
      are adapted to the particular situation and regulatory framework of their
      respective territory. In this article, the authors present the regenerative
      medicine action plan promoted by the Andalusian Transplant Coordination (i.e.,
      the action plan for the largest region in Spain), highlighting the aspects the
      authors believe are fundamental to its success. The authors describe, in summary 
      form, the methodology, phases of the plan, actions designed, key collaborators,
      important milestones achieved and main lessons they have drawn from their
      experience so that this can serve as an example for other institutions interested
      in promoting the ethical use of this type of therapy.
CI  - Copyright (c) 2020 International Society for Cell & Gene Therapy. Published by
      Elsevier Inc. All rights reserved.
FAU - Cuende, Natividad
AU  - Cuende N
AD  - Coordinacion Autonomica de Trasplantes de Andalucia, Servicio Andaluz de Salud,
      Sevilla, Spain. Electronic address: natividad.cuende.sspa@juntadeandalucia.es.
FAU - Alvarez-Marquez, Antonia Jose
AU  - Alvarez-Marquez AJ
AD  - Coordinacion Autonomica de Trasplantes de Andalucia, Servicio Andaluz de Salud,
      Sevilla, Spain.
FAU - Diaz-Aunion, Concepcion
AU  - Diaz-Aunion C
AD  - Coordinacion Autonomica de Trasplantes de Andalucia, Servicio Andaluz de Salud,
      Sevilla, Spain.
FAU - Castro, Pablo
AU  - Castro P
AD  - Coordinacion Autonomica de Trasplantes de Andalucia, Servicio Andaluz de Salud,
      Sevilla, Spain.
FAU - Huet, Jesus
AU  - Huet J
AD  - Coordinacion Autonomica de Trasplantes de Andalucia, Servicio Andaluz de Salud,
      Sevilla, Spain.
FAU - Perez-Villares, Jose Miguel
AU  - Perez-Villares JM
AD  - Coordinacion Autonomica de Trasplantes de Andalucia, Servicio Andaluz de Salud,
      Sevilla, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200830
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
SB  - IM
MH  - *Cell- and Tissue-Based Therapy
MH  - Humans
MH  - Regenerative Medicine/*ethics/legislation & jurisprudence
MH  - Social Control, Formal
MH  - Spain
PMC - PMC7456586
OTO - NOTNLM
OT  - *direct-to-consumer marketing
OT  - *platelet-rich plasma
OT  - *point-of-care therapy
OT  - *regenerative medicine
OT  - *unproven stem cell treatments
OT  - *unregulated cell-based interventions
EDAT- 2020/09/04 06:00
MHDA- 2021/02/11 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/22 00:00 [received]
PHST- 2020/07/04 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
PHST- 2020/09/04 06:00 [entrez]
AID - S1465-3249(20)30794-5 [pii]
AID - 10.1016/j.jcyt.2020.07.007 [doi]
PST - ppublish
SO  - Cytotherapy. 2020 Dec;22(12):712-717. doi: 10.1016/j.jcyt.2020.07.007. Epub 2020 
      Aug 30.


PMID- 32878603
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1472-6831 (Electronic)
IS  - 1472-6831 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Sep 2
TI  - Effects of probiotic bacterium Weissella cibaria CMU on periodontal health and
      microbiota: a randomised, double-blind, placebo-controlled trial.
PG  - 243
LID - 10.1186/s12903-020-01231-2 [doi]
AB  - BACKGROUND: Weissella cibaria CMU (oraCMU) has been commercially available in the
      market for several years as oral care probiotics. The present study aimed to
      evaluate the effects of oraCMU-containing tablets on periodontal health and oral 
      microbiota. METHODS: A randomised, double-blind, placebo-controlled trial was
      conducted in 92 adults without periodontitis (20-39 years of age). All subjects
      received dental scaling and root planing, and were randomly assigned to either
      probiotic or placebo groups. The tablets were administered once daily for 8
      weeks. Periodontal clinical parameters included bleeding on probing (BOP),
      probing depth (PD), gingival index (GI), and plaque index (PI). In addition,
      microbiota in the gingival sulcus were analysed. RESULTS: BOP improved more in
      the probiotic group over 8 weeks. There were statistically significant
      differences in BOP of the maxilla buccal and lingual sites between the groups
      during the intervention (P < 0.05). No significant inter-group differences in PD,
      GI, and PI were observed during the intervention. Oral bacteria were observed to 
      be fewer in the probiotic group. There was a significant change in levels of
      Fusobacterium nucleatum at four and 8 weeks between the two groups. Besides,
      there were significant differences at 8 weeks in levels of Staphylococcus aureus.
      CONCLUSIONS: We reported an improvement in BOP and microbial environment and
      demonstrated the antimicrobial activity of oraCMU against F. nucleatum. Thus, its
      supplementation may contribute to overall oral health. TRIAL REGISTRATION:
      Ethical issues approved by the Kangwon National University Institutional Review
      Board with a number of KWNUIRB-2018-05-003-005 and CRIS code Number of KCT0005078
      were retrospectively registered on 06/02/2020. This study was conducted in the
      period of July to November 2018.
FAU - Kang, Mi-Sun
AU  - Kang MS
AD  - R&D Center, OraPharm Inc., Seoul, 04782, South Korea.
FAU - Lee, Dong-Suk
AU  - Lee DS
AD  - School of Nursing, Kangwon National University, Chuncheon, 24341, South Korea.
FAU - Lee, Seung-Ah
AU  - Lee SA
AD  - School of Nursing, Kangwon National University, Chuncheon, 24341, South Korea.
FAU - Kim, Myoung-Suk
AU  - Kim MS
AD  - School of Nursing, Kangwon National University, Chuncheon, 24341, South Korea.
FAU - Nam, Seoul-Hee
AU  - Nam SH
AUID- ORCID: 0000-0001-9529-1282
AD  - Department of Dental Hygiene, College of Health Sciences, Kangwon National
      University, 346 Hwangjo-gil, Dogye-up, Samcheok-si, Gangwon-do, 25949, South
      Korea. nshee@kangwon.ac.kr.
LA  - eng
SI  - CRiS/KCT0005078
GR  - 2017R1D1A1B03030952/Ministry of Education/International
GR  - A study on the programs to support follow-up R&amp;D of corporate R&amp;D centers
      with academia and research institutes/Ministry of Science and ICT of the Korean
      government and the Korea Industrial Technology Association/International
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200902
PL  - England
TA  - BMC Oral Health
JT  - BMC oral health
JID - 101088684
RN  - Weissella cibaria
SB  - IM
MH  - Adult
MH  - Bacteria
MH  - Dental Plaque Index
MH  - Dental Scaling
MH  - Double-Blind Method
MH  - Humans
MH  - *Microbiota
MH  - Periodontal Attachment Loss
MH  - *Probiotics/therapeutic use
MH  - Root Planing
MH  - *Weissella
MH  - Young Adult
PMC - PMC7469353
OTO - NOTNLM
OT  - *Bleeding
OT  - *Clinical study
OT  - *Microbiota
OT  - *Periodontal health
OT  - *Probiotics
OT  - *Weissella cibaria
EDAT- 2020/09/04 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/05/23 00:00 [received]
PHST- 2020/08/23 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 10.1186/s12903-020-01231-2 [doi]
AID - 10.1186/s12903-020-01231-2 [pii]
PST - epublish
SO  - BMC Oral Health. 2020 Sep 2;20(1):243. doi: 10.1186/s12903-020-01231-2.


PMID- 32878275
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 17
DP  - 2020 Aug 31
TI  - Decellularized Extracellular Matrices and Cardiac Differentiation: Study on Human
      Amniotic Fluid-Stem Cells.
LID - E6317 [pii]
LID - 10.3390/ijms21176317 [doi]
AB  - Cell therapy with a variety of stem populations is increasingly being
      investigated as a promising regenerative strategy for cardiovascular (CV)
      diseases. Their combination with adequate scaffolds represents an improved
      therapeutic approach. Recently, several biomaterials were investigated as
      scaffolds for CV tissue repair, with decellularized extracellular matrices
      (dECMs) arousing increasing interest for cardiac tissue engineering applications.
      The aim of this study was to analyze whether dECMs support the cardiac
      differentiation of (Cardiopoietic)AF stem cells. These perinatal stem cells,
      which can be easily isolated without ethical or safety limitations, display a
      high cardiac differentiative potential. Differentiation was previously achieved
      by culturing them on Matrigel, but this 3D scaffold is not transplantable. The
      identification of a new transplantable scaffold able to support (Cardiopoietic)AF
      stem cell cardiac differentiation is pivotal prior to encouraging translation of 
      in vitro studies in animal model preclinical investigations. Our data
      demonstrated that decellularized extracellular matrices already used in cardiac
      surgery (the porcine Cor(TM)PATCH and the equine MatrixPatch(TM)) can efficiently
      support the proliferation and cardiac differentiation of (Cardiopoietic)AF stem
      cells and represent a useful cellular scaffold to be transplanted with stem cells
      in animal hosts.
FAU - Gaggi, Giulia
AU  - Gaggi G
AD  - Haman Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G.d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Di Credico, Andrea
AU  - Di Credico A
AD  - Haman Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G.d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Izzicupo, Pascal
AU  - Izzicupo P
AD  - Haman Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G.d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Sancilio, Silvia
AU  - Sancilio S
AD  - Haman Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G.d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Di Mauro, Michele
AU  - Di Mauro M
AD  - Cardio-Thoracic Surgery Unit, Heart and Vascular Centre, Maastricht University
      Medical Centre (MUMC), Cardiovascular Research Institute Maastricht (CARIM), 6202
      Maastricht, The Netherlands.
FAU - Iannetti, Giovanni
AU  - Iannetti G
AD  - University of Rome La Sapienza, 00185 Rome, Italy.
FAU - Dolci, Susanna
AU  - Dolci S
AD  - Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133
      Rome, Italy.
FAU - Amabile, Giovanni
AU  - Amabile G
AD  - Enthera Srl, 20123 Milan, Italy.
FAU - Di Baldassarre, Angela
AU  - Di Baldassarre A
AD  - Haman Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G.d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Ghinassi, Barbara
AU  - Ghinassi B
AD  - Haman Anatomy and Cell Differentiation Lab, Department of Medicine and Aging
      Sciences, University "G.d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
LA  - eng
GR  - SIR2014-RBSI140GLQ./Ministero dell'Istruzione, dell'Universita e della Ricerca
GR  - PRIN 2017ATZ2YK/Ministero dell'Istruzione, dell'Universita e della Ricerca
PT  - Journal Article
DEP - 20200831
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Drug Combinations)
RN  - 0 (Laminin)
RN  - 0 (Proteoglycans)
RN  - 119978-18-6 (matrigel)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Amniotic Fluid/*cytology/metabolism
MH  - Animals
MH  - Cell Adhesion
MH  - *Cell Differentiation
MH  - Cell Proliferation
MH  - Collagen
MH  - Drug Combinations
MH  - Extracellular Matrix/*chemistry/metabolism
MH  - Female
MH  - Horses
MH  - Humans
MH  - Laminin
MH  - Male
MH  - Myocytes, Cardiac/*cytology/metabolism
MH  - Proteoglycans
MH  - Stem Cells/*cytology/metabolism
MH  - Swine
MH  - *Tissue Engineering
MH  - Tissue Scaffolds/*chemistry
PMC - PMC7504221
OTO - NOTNLM
OT  - CardiopoieticAF cells
OT  - L-type calcium channels
OT  - amniotic fluid stem cells
OT  - biomaterials
OT  - cardiac differentiation
OT  - cardiac tissue engineering
OT  - decellularized extracellular matrix
OT  - induced pluripotent stem cells
OT  - sarcomeric proteins
OT  - scaffolds
COIS- The authors declare no conflict of interest.
EDAT- 2020/09/04 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/30 00:00 [received]
PHST- 2020/08/28 00:00 [revised]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - ijms21176317 [pii]
AID - 10.3390/ijms21176317 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Aug 31;21(17). pii: ijms21176317. doi: 10.3390/ijms21176317.


PMID- 32878205
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Aug 31
TI  - Can Zoos Ever Be Big Enough for Large Wild Animals? A Review Using an Expert
      Panel Assessment of the Psychological Priorities of the Amur Tiger (Panthera
      tigris altaica) as a Model Species.
LID - E1536 [pii]
LID - 10.3390/ani10091536 [doi]
AB  - The ecology of large, wide-ranging carnivores appears to make them vulnerable to 
      conservation challenges in the wild and welfare challenges in captivity. This
      poses an ethical dilemma for the zoo community and supports the case that there
      is a need to reconsider prevailing management paradigms for these species in
      captivity. Whilst the welfare challenges wide ranging carnivores face have been
      attributed to reduced ranging opportunities associated with the decreased size of
      captive habitats, attempts to augment wild carnivore welfare in captivity
      typically focus on behaviours linked to hunting. Thus far, this has yet to result
      in the systematic elimination of signs of compromised welfare amongst captive
      carnivores. Here an assessment is carried out to identify the likely welfare
      priorities for Amur tigers, which, as one of the widest ranging terrestrial
      carnivores, serves as an excellent exemplar for species experiencing extreme
      compression of their ranging opportunities in captivity. These priorities are
      then used to consider novel strategies to address the welfare challenges
      associated with existing management paradigms, and in particular, attempt to
      overcome the issue of restricted space. The insights generated here have wider
      implications for other species experiencing substantive habitat compression in
      captivity. It is proposed here that the impact of habitat compression on captive 
      carnivore welfare may not be a consequence of the reduction in habitat size per
      se, but rather the reduction in cognitive opportunities that likely covary with
      size, and that this should inform strategies to augment welfare.
FAU - Veasey, Jake Stuart
AU  - Veasey JS
AUID- ORCID: 0000-0002-4989-061X
AD  - School of Animal, Rural and Environmental Sciences, Nottingham Trent University, 
      Southwell NG25 0QF, UK.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552275
OTO - NOTNLM
OT  - Amur tiger
OT  - animal welfare
OT  - behavioural need
OT  - psychological priority
OT  - zoo
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:01
CRDT- 2020/09/04 06:00
PHST- 2020/07/20 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:01 [medline]
AID - ani10091536 [pii]
AID - 10.3390/ani10091536 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Aug 31;10(9). pii: ani10091536. doi: 10.3390/ani10091536.


PMID- 32878180
OWN - NLM
STAT- MEDLINE
DCOM- 20200922
LR  - 20201218
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 17
DP  - 2020 Aug 31
TI  - Stigma and Discrimination (SAD) at the Time of the SARS-CoV-2 Pandemic.
LID - E6341 [pii]
LID - 10.3390/ijerph17176341 [doi]
AB  - Infectious disease control is a crucial public health issue. Although it is
      important to urgently perform public health measures in order to reduce the risk 
      of spread, it could end up stigmatizing entire groups of people rather than
      offering control measures based on sound scientific principles. This "us" versus 
      "them" dynamic is common in stigmatization, in general, and indicates a way in
      which disease stigma can be viewed as a proxy for other types of fears,
      especially xenophobia and general fear of outsiders. The pandemic risk associated
      with SARS-CoV-2 infection led us to consider, among other related issues, how
      stigma and discrimination remain serious barriers to care for people suspected of
      being infected, even more if they are assisting professions, such as health
      workers, employed in emergency response. The purpose of this review is to
      evaluate and promote the importance of psychological aspects of the stigma and
      social discrimination (SAD) in pandemic realities and, more specifically,
      nowadays, in the context of SARS-CoV-2/COVID-19. Just as it happened with HIV,
      HCV, tuberculosis, and Zika, stigma and discrimination undermine the social
      fabric compromising the ethics and principles of civilization to which each
      individual in entitled. Recognizing disease stigma history can give us insight
      into how, exactly, stigmatizing attitudes are formed, and how they are disbanded.
      Instead of simply blaming the ignorance of people espousing stigmatizing
      attitudes about certain diseases, we should try to understand precisely how these
      attitudes are formed so that we can intervene in their dissemination. We should
      also look at history to see what sorts of interventions against stigma may have
      worked in the past. Ongoing research into stigma should evaluate what has worked 
      in the past, as above-mentioned, providing us with some clues as to what might
      work in the current pandemic emergency, to reduce devastating discrimination that
      keeps people from getting the care they need. We propose a systematic and
      historical review, in order to create a scientific and solid base for the
      following SAD analysis. The aim is to propose a coping strategy to face stigma
      and discrimination (SAD) related to SARS-CoV-2/COVID-19 pandemic outbreak,
      borrowing coping strategy tools and solutions from other common contagious
      diseases. Furthermore, our study observes how knowledge, education level, and
      socioeconomic status (SES) can influence perception of SARS-CoV-2/ COVID-19 risk 
      in a digital world, based on previous research, best practices, and
      evidence-based research.
FAU - Baldassarre, Antonio
AU  - Baldassarre A
AD  - Doctoral School in Clinical Sciences, University of Florence, 50134 Florence,
      Italy.
AD  - Occupational Medicine Unit, Careggi University Hospital, 50134 Florence, Italy.
FAU - Giorgi, Gabriele
AU  - Giorgi G
AD  - Department of Human Sciences, European University of Rome, 00136 Rome, Italy.
FAU - Alessio, Federico
AU  - Alessio F
AD  - Department of Human Sciences, European University of Rome, 00136 Rome, Italy.
FAU - Lulli, Lucrezia Ginevra
AU  - Lulli LG
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Arcangeli, Giulio
AU  - Arcangeli G
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Mucci, Nicola
AU  - Mucci N
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200831
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*psychology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*psychology
MH  - SARS-CoV-2
MH  - *Social Discrimination
MH  - *Social Stigma
PMC - PMC7503800
OTO - NOTNLM
OT  - *COVID-19
OT  - *Discrimination
OT  - *SARS-CoV-2
OT  - *Stigma
OT  - *avoiding behaviors
OT  - *epidemic outbreak
OT  - *infectious disease
OT  - *pandemic outbreak
COIS- The authors declare no conflict of interest.
EDAT- 2020/09/04 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/09/04 06:00
PHST- 2020/07/14 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - ijerph17176341 [pii]
AID - 10.3390/ijerph17176341 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Aug 31;17(17). pii: ijerph17176341. doi:
      10.3390/ijerph17176341.


PMID- 32877433
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20201027
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 9
DP  - 2020
TI  - Suicide and self-harm content on Instagram: A systematic scoping review.
PG  - e0238603
LID - 10.1371/journal.pone.0238603 [doi]
AB  - Given concerns about suicide or self-harm content on Instagram, we conducted a
      systematic scoping review of peer-reviewed English language primary studies
      published between 2010-2019. Only ten studies had been published. Looking into
      purposive samples of Instagram posts tagged with self-harm related hashtags,
      studies report finding self-harm or suicide content in between 9-66% of their
      studied posts. Studies assessing Instagram's efforts to tackle such content found
      they had not been very effective. Despite heterogeneity in study aims, use of
      terminology, samples, methods of analysis, and study outcomes, we aggregated and 
      distinguished 'content studies' and 'user studies'. Most studies showed concern
      for self-harm risk, but only one examined the relationship between self-harm
      posts and actual self-harm behaviours offline. It found such content had negative
      emotional effects on some users and reported preliminary evidence of potential
      harmful effects in relation to self-harm related behaviours offline, although
      causal effects cannot be claimed. At the same time, some benefits for those who
      engage with self-harm content online have been suggested. More research directly 
      interviewing Instagram users to understand this phenomenon from their perspective
      is required. Finally, some ethical issues are discussed.
FAU - Picardo, Jacobo
AU  - Picardo J
AUID- ORCID: 0000-0001-5607-4891
AD  - Department of Psychological Medicine, Suicide and Mental Health Research Group,
      University of Otago Wellington, Wellington, New Zealand.
FAU - McKenzie, Sarah K
AU  - McKenzie SK
AUID- ORCID: 0000-0002-1811-0211
AD  - Department of Psychological Medicine, Suicide and Mental Health Research Group,
      University of Otago Wellington, Wellington, New Zealand.
FAU - Collings, Sunny
AU  - Collings S
AD  - Victoria University Wellington, Wellington, New Zealand.
FAU - Jenkin, Gabrielle
AU  - Jenkin G
AD  - Department of Psychological Medicine, Suicide and Mental Health Research Group,
      University of Otago Wellington, Wellington, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200902
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Humans
MH  - Self-Injurious Behavior/*psychology
MH  - *Social Media
MH  - Suicide/*psychology
MH  - Young Adult
PMC - PMC7467257
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/03 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
AID - 10.1371/journal.pone.0238603 [doi]
AID - PONE-D-20-08328 [pii]
PST - epublish
SO  - PLoS One. 2020 Sep 2;15(9):e0238603. doi: 10.1371/journal.pone.0238603.
      eCollection 2020.


PMID- 32877312
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20220105
IS  - 1553-3514 (Electronic)
IS  - 1553-3506 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Dec
TI  - Surgical Support for Severe COVID-19 Patients: A Retrospective Cohort Study in a 
      French High-Density COVID-19 Cluster.
PG  - 564-569
LID - 10.1177/1553350620954571 [doi]
AB  - Background. The COVID-19 epidemic has resulted in a massive surge in the need for
      intensive care unit (ICU) care. To avoid being overwhelmed, hospitals had to
      adapt and support the ICU teams in structured ICU care including involving
      surgical teams. This work aims at describing the collaborative efforts between
      the ICU care team and the Surgical Task Force (STF) during a surge of ICU
      activity in a University Hospital in a French high-density COVID-19 cluster.
      Study Design. This retrospective single center study analyzed the STF workflow
      and the ICU population. The study included 55 patients hospitalized in our ICU,
      ICU-converted step-down units, and post-anesthesia care units. The primary
      measure was the global daily STF activity. The secondary measure was the daily
      activity for each of the 5 tasks accomplished by the STF. Results. The STF
      attempted 415 phone calls for 55 patients' families, 237 mobilizations of
      patients requiring prone positions, follow-up of 20 patients requiring medevac,
      and contribution to ethical discussion for 2 patients. The mean (SD) daily number
      of successful phones calls, ethical discussions, mobilizations of patients
      requiring prone positions and medevac follow-up were 18 (7), .1 (.4), 10 (7), and
      2 (3), respectively. No actions for discharge summaries writing were required.
      The maximum number of daily mobilizations for patients requiring prone positions 
      was 25. The maximum number of daily attempted phone calls and successful phone
      calls were 37 and 26, respectively. Conclusion. Surgeons' technical and
      nontechnical skills represented an effective support for ICU teams during the
      COVID-19 pandemic.
FAU - Noll, Eric
AU  - Noll E
AUID- ORCID: https://orcid.org/0000-0001-5655-6866
AD  - Department of Anesthesiology and Intensive Care, Hautepierre Hospital, Strasbourg
      University Hospital, France.
AD  - Institut Hospitalo-Universitaire (Image-Guided Surgery), Strasbourg University,
      Strasbourg, France.
FAU - Muccioli, Christophe
AU  - Muccioli C
AD  - Department of Orthopaedic and Plastic Surgery, University Hospital of Strasbourg,
      FMTS, University of Strasbourg, France.
FAU - Ludes, Pierre-Olivier
AU  - Ludes PO
AD  - Department of Anesthesiology and Intensive Care, Hautepierre Hospital, Strasbourg
      University Hospital, France.
FAU - Pottecher, Julien
AU  - Pottecher J
AD  - Department of Anesthesiology and Intensive Care, Hautepierre Hospital, Strasbourg
      University Hospital, France.
FAU - Diemunsch, Pierre
AU  - Diemunsch P
AD  - Department of Anesthesiology and Intensive Care, Hautepierre Hospital, Strasbourg
      University Hospital, France.
AD  - Institut Hospitalo-Universitaire (Image-Guided Surgery), Strasbourg University,
      Strasbourg, France.
FAU - Diemunsch, Sophie
AU  - Diemunsch S
AD  - Department of Anesthesiology and Intensive Care, Hautepierre Hospital, Strasbourg
      University Hospital, France.
FAU - Tchentcheli, Anaelle
AU  - Tchentcheli A
AD  - Department of Anesthesiology and Intensive Care, Hautepierre Hospital, Strasbourg
      University Hospital, France.
FAU - Clavert, Philippe
AU  - Clavert P
AD  - Department of Orthopaedic and Plastic Surgery, University Hospital of Strasbourg,
      FMTS, University of Strasbourg, France.
FAU - Joshi, Girish P
AU  - Joshi GP
AD  - Department of Anesthesiology and Pain Management, 89063UT Southwestern Medical,
      TX, USA.
FAU - Liverneaux, Philippe A
AU  - Liverneaux PA
AD  - Department of Orthopaedic and Plastic Surgery, University Hospital of Strasbourg,
      FMTS, University of Strasbourg, France.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - United States
TA  - Surg Innov
JT  - Surgical innovation
JID - 101233809
SB  - IM
MH  - Advisory Committees/*organization & administration
MH  - Aged
MH  - COVID-19/epidemiology/*therapy
MH  - Critical Care/*organization & administration
MH  - Feasibility Studies
MH  - Female
MH  - France
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Surgery Department, Hospital/*organization & administration
PMC - PMC8723901
OTO - NOTNLM
OT  - COVID-19
OT  - intensive care unit
OT  - surgical non-technical skills
OT  - surgical technical skills
EDAT- 2020/09/03 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1177/1553350620954571 [doi]
PST - ppublish
SO  - Surg Innov. 2020 Dec;27(6):564-569. doi: 10.1177/1553350620954571. Epub 2020 Sep 
      2.


PMID- 32877147
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Pediatric ethics: 10 key messages].
PG  - 227
FAU - Chevallier, Bertrand
AU  - Chevallier B
AD  - Service de pediatrie-urgences enfants, hopital Ambroise-Pare,
      Boulogne-Billancourt, France.
LA  - fre
PT  - Journal Article
TT  - Ethique en pediatrie : 10 messages Cles.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Child
MH  - *Ethics, Medical
MH  - Humans
MH  - *Internship and Residency
OTO - NOTNLM
OT  - *Ethics
OT  - *Pediatrics
COIS- B. Chevallier declare n'avoir aucun lien d'interets.
EDAT- 2020/09/03 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):227.


PMID- 32877146
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220531
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Disabled child, care and ethical aspects].
PG  - 222-226
AB  - Disabled child, care and ethical aspects. The child's doctor occupies a
      privileged place in the life of a child with a disability. At all times, he must 
      be an adviser, favouring a global approach and support to ensure optimal
      autonomy. Discovery of a neurodevelopmental disorder justifies a systematic
      search for the various causes known to date. Identification and knowledge of a
      precise diagnosis is an essential element in constructing the life plan for a
      disabled child. The announcement of the diagnosis is an integral part of the care
      system, it only makes sense when combined with tailor-made and step by step
      support. This requires that the doctor has a good knowledge of the main childcare
      structures, guidance agencies, and available financial aid. Multidisciplinary
      consultations enable a global approach to support a child with a disability. More
      children with disabilities become adults as medical care progresses. Transition
      from "children" to "adult" consultations represents a major challenge. However,
      some cases could be life-threatening. The decision on whether to continue the
      various therapies have to be considered and discussed with the child and his
      family, with reference to the notion of "unreasonable obstinacy". Drafting an
      individual certificate of "remarkable patient" will best help the implementation 
      of end-of-life support measures.
FAU - Chabrol, Brigitte
AU  - Chabrol B
AD  - Service de neurologie pediatrique, Hopital d'enfants, CHU La Timone, Marseille,
      France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Enfant handicape, prise en charge et aspects ethiques.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Adult
MH  - Child
MH  - *Disabled Children
MH  - *Ethics, Medical
MH  - Family
MH  - Humans
MH  - Male
MH  - Referral and Consultation
OTO - NOTNLM
OT  - Child Care
OT  - Disabled Children
OT  - Ethics
OT  - Pediatrics
COIS- B. Chabrol declare n'avoir aucun lien d'interets.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):222-226.


PMID- 32877145
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Pediatric informed consent in medical care and research].
PG  - 218-221
AB  - Pediatric informed consent in medical care and research. The obligation to obtain
      informed consent from a patient prior to any care does not depend solely on the
      personal ethics of the practitioner. It is defined and framed by law. However,
      innumerable legal difficulties emanate from the simple fact that the subject is a
      child, a vulnerable person who must be protected, and that this protection is
      exercised under the aegis of the parental authority. If in most cases there is an
      alliance with the holders of parental authority, the views sometimes diverge. The
      article lists the most frequently observed cases in clinical practice and the way
      in which the french Public Health Code plans to solve them. Problems specific to 
      research are discussed. Difficulties for consent about off-label prescribing are 
      briefly exposed.
FAU - Cremer, Robin
AU  - Cremer R
AD  - Espace de reflexion ethique regional des Hauts-de-France et reanimation
      pediatrique, CHU de Lille et universite de Lille, Lille, France.
FAU - Din-Dorel, Sylvie
AU  - Din-Dorel S
AD  - Recherche et epidemiologie cliniques, pole de sante publique, Hospices civils de 
      Lyon, Lyon, France.
FAU - Ploin, Dominique
AU  - Ploin D
AD  - Service de reanimation pediatrique et d'accueil des urgences, hopital Femme Mere 
      Enfant, Hospices civils de Lyon, Bron, France.
LA  - fre
PT  - Journal Article
TT  - Consentement eclaire de l'enfant.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Child
MH  - Humans
MH  - *Informed Consent
MH  - *Parents
OTO - NOTNLM
OT  - Child
OT  - Ethics
OT  - Informed Consent By Minors
OT  - Pediatrics
COIS- Les auteurs declarent n'avoir aucun lien d'interets.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):218-221.


PMID- 32877144
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Minor's medical information].
PG  - 215-217
AB  - Minor's medical information. In exercising parental authority, parents make
      medical treatment decisions on children's behalf. However, according to the
      French law, minors must receive clear medical informations and care-givers must
      seek their consent to treatment. In some situations, parental authority may be in
      conflict with child's will. This article examines legislative framework provided 
      by the French law, to respect child's autonomy and situations in which parental
      authority is limited. In practice, the concept of child's 'best interests'
      remains the main key to resolve potential conflicts between parental authority
      and child's autonomy.
FAU - Devictor, Denis
AU  - Devictor D
AD  - Reanimation neonatale et pediatrie neonatologique, hopital Bicetre, Le
      Kremlin-Bicetre, France. Mediateur de l'Assistance publique-Hopitaux de Paris.
      Medecin-conseil de la Direction des affaires juridiques. Docteur en ethique.
LA  - fre
PT  - Journal Article
TT  - Information du patient mineur.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Child
MH  - Humans
MH  - *Minors
MH  - *Parents
OTO - NOTNLM
OT  - Access to Information
OT  - Child
OT  - Ethics
OT  - Pediatrics
COIS- D. Devictor declare n'avoir aucun lien d'interets.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):215-217.


PMID- 32877143
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Announcement of a serious illness to a child].
PG  - 212-214
AB  - Announcement of a serious illness to a child. Critically ill children should be
      directly informed about their illness, in a way that is appropriate to their age,
      family context and alliance with themselves and their parents. The process of the
      announcement of the diagnosis does not correspond to an isolated moment but must 
      be conceived in successive stages, respecting a different rhythm of progression
      in the child and in each of his parents, even if sometimes the clinical
      circumstances require the initiation of treatment fairly quickly. The synthetic
      principle of informing "without violence or betrayal" guides the conditions for
      the announcement of the diagnosis of pediatric serious illness, both to parents
      and to the sick child.
FAU - Doz, Francois
AU  - Doz F
AD  - Centre SIREDO (Soins innovation recherche en oncologie de l'enfant, l'adolescent,
      et l'adulte jeune), institut Curie, Paris, France.
AD  - Universite Paris-Descartes, France.
FAU - Cortina, Maria Rodriguez
AU  - Cortina MR
AD  - Centre SIREDO (Soins innovation recherche en oncologie de l'enfant, l'adolescent,
      et l'adulte jeune), institut Curie, Paris, France.
AD  - Departement interdisciplinaire de soins de supports et de psychooncologie,
      institut Curie, Paris, France.
FAU - Seigneur, Etienne
AU  - Seigneur E
AD  - Centre SIREDO (Soins innovation recherche en oncologie de l'enfant, l'adolescent,
      et l'adulte jeune), institut Curie, Paris, France.
AD  - Departement interdisciplinaire de soins de supports et de psychooncologie,
      institut Curie, Paris, France.
LA  - fre
PT  - Journal Article
TT  - Annonce d'une maladie grave a un enfant.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Child
MH  - *Family
MH  - Humans
MH  - *Parents
MH  - Truth Disclosure
OTO - NOTNLM
OT  - Critical Illness
OT  - Ethics
OT  - Office Visits
OT  - Pediatrics
OT  - Truth Disclosure
COIS- F. Doz declare des liens ponctuels avec Bayer, BMS, Boehringer-Ingelheim, Loxo
      Oncology, Novartis, Roche, Tesaro (essais cliniques et travaux scientifiques),
      Servier (consultant), BMS et Servier (actions de formation, colloque) ; et avoir 
      ete pris en charge lors de congres par Bayer, BMS, Roche. M. Rodriguez Cortina et
      E. Seigneur n'ont pas transmis de declaration d'interets.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):212-214.


PMID- 32877127
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220531
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Early diagnosis of Alzheimer's disease (with the announcement of the
      diagnosis)].
PG  - 158-163
AB  - Early diagnosis of Alzheimer's disease (with the announcement of the diagnosis). 
      The number of patients consulting to find out if they have Alzheimer's disease
      continues to grow. Reasons to consult most often include anxiety about being
      affected by this disease, confidence in medical and therapeutic advances relayed 
      in the media and the desire to plan for the future, taking into account a
      possible deterioration. Advances in the knowledge of the natural history of the
      disease and the technical progress currently allow an early diagnosis, before the
      stage of dementia. Although the clinical use of biomarkers is justified in
      patients who have attended a Memory Clinic, ethical issues remain. The disclosure
      of the diagnosis of Alzheimer's disease to the person who is not yet suffering
      from dementia remains a sensitive subject. In this context, it seems appropriate 
      at this stage to restrict the use of these methods to centers specializing in
      early diagnosis.
FAU - Ivanoiu, Adrian
AU  - Ivanoiu A
AD  - Departement de neurologie, Cliniques universitaires Saint-Luc, Bruxelles,
      Belgique.
AD  - Institute of Neuroscience, Universite catholique de Louvain, Bruxelles, Belgique.
FAU - Engelborghs, Sebastiaan
AU  - Engelborghs S
AD  - Departement de neurologie et Center for Neurosciences, UZ Brussel et Vrije
      Universiteit Brussel (VUB), Bruxelles, Belgique.
AD  - Departement de sciences biomedicales, Institut Born-Bunge, Universiteit
      Antwerpen, Anvers, Belgique.
FAU - Hanseeuw, Bernard
AU  - Hanseeuw B
AD  - Departement de neurologie, Cliniques universitaires Saint-Luc, Bruxelles,
      Belgique.
AD  - Institute of Neuroscience, Universite catholique de Louvain, Bruxelles, Belgique.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Diagnostic precoce de la maladie d'Alzheimer (avec la consultation d'annonce).
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
RN  - 0 (Biomarkers)
SB  - IM
MH  - *Alzheimer Disease
MH  - Biomarkers
MH  - Early Diagnosis
MH  - Humans
OTO - NOTNLM
OT  - Alzheimer Disease
OT  - Diagnosis
OT  - Early Diagnosis
COIS- A. Ivanoiu declare des liens ponctuels (essais cliniques, travaux scientifiques, 
      conferences, prise en charge lors de congres) avec GE Healthcare, Nutricia,
      Schwabe Pharma, AbbVie, Lilly, Roche et MSD. S. Engelborghs declare des liens
      ponctuels (essais cliniques, travaux scientifiques, conferences) avec Janssen
      Pharmaceutica, ADx Neurosciences, Novartis et Nutricia. B. Hanseeuw declare avoir
      ete pris en charge lors de congres par GE Healthcare.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):158-163.


PMID- 32877121
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 2
DP  - 2020 Feb
TI  - [Artifical intelligence in healthcare].
PG  - 135-137
FAU - Parmentier, Florent
AU  - Parmentier F
AD  - Sciences Po, Paris, France. Centre de geopolitique de l'Ecole des hautes etudes
      commerciales (HEC) de Paris, Jouy-en-Josas, France. Co-fondateur de l'initiative 
      citoyenne Ethik-IA et co-auteur de << La Revolution du pilotage des donnees de
      sante. >> Bordeaux : LEH, Enjeux juridiques, ethiques et manageriaux, 2019.
LA  - fre
PT  - Journal Article
TT  - Intelligence artificielle dans le domaine de la sante : quel eclairage
      geopolitique ?
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Intelligence
OTO - NOTNLM
OT  - *Artificial Intelligence
OT  - *Ethics
OT  - *Health Policy
COIS- F. Parmentier declare n'avoir aucun lien d'interets, et avoir ete pris en charge 
      lors de congres par la Federation nationale des medecins radiologues.
EDAT- 2020/09/03 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Feb;70(2):135-137.


PMID- 32877044
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 1
DP  - 2020 Jan
TI  - [Doctor's prescription in Ancient Egypt].
PG  - 112-114
FAU - Ziskind, Bernard
AU  - Ziskind B
AD  - Institut Kheops d'egyptologie Societe internationale d'histoire de la medecine,
      cardiologue, Saint-Gratien, France.
LA  - fre
PT  - Historical Article
PT  - Journal Article
TT  - L'ordonnance du medecin dans l'Egypte ancienne.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Egypt, Ancient
MH  - History, Ancient
MH  - Humans
MH  - *Prescriptions
OTO - NOTNLM
OT  - *Ancient
OT  - *Ethics
OT  - *History
EDAT- 2020/09/03 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Jan;70(1):112-114.


PMID- 32877031
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 2101-017X (Electronic)
IS  - 0035-2640 (Linking)
VI  - 70
IP  - 1
DP  - 2020 Jan
TI  - [Novel insight into suicidal behavior].
PG  - 59-61
AB  - Novel insight into suicidal behavior. This article presents four short examples
      of new insights into suicidal acts and innovative treatments. These include the
      results of cognitive neuroscience studies that have identified hypersensitivity
      to rejection, exclusion, and injustice signals in suicide attempters, as well as 
      persisting trend for risky choices and insufficient cognitive control. These
      processes may be future therapeutic targets. Moreover, several studies showed on 
      early suicidal trajectories, as well as residual epigenetic scars, as a result of
      childhood abuse. The people who were victims of these events may require specific
      intervention. In addition, artificial intelligence is a source of hope to account
      for the etiological and phenotypic complexity of suicidal behavior, and to
      establish more precise algorithms of medical decision-making. Ethical issues are 
      raised at the same time. Finally, ketamine is today an innovative treatment
      (pending authorization) for the rapid reduction of suicidal ideation and a more
      effective crisis management.
FAU - Dardennes, Roland
AU  - Dardennes R
AD  - Universite de Paris (Paris-Descartes), Paris, France. GHU Paris psychiatrie et
      neurosciences, site hopital Sainte-Anne, pole CMME, Paris, France Universite
      McGill, Groupe McGill de recherche sur le suicide, Montreal (Quebec), Canada.
FAU - Jollant, Fabrice
AU  - Jollant F
AD  - Universite de Paris (Paris-Descartes), Paris, France. GHU Paris psychiatrie et
      neurosciences, site hopital Sainte-Anne, pole CMME, Paris, France Universite
      McGill, Groupe McGill de recherche sur le suicide, Montreal (Quebec), Canada.
LA  - fre
PT  - Journal Article
TT  - Nouvelles perspectives sur les conduites suicidaires.
PL  - France
TA  - Rev Prat
JT  - La Revue du praticien
JID - 0404334
SB  - IM
MH  - Artificial Intelligence
MH  - Child
MH  - *Child Abuse
MH  - Humans
MH  - Suicidal Ideation
MH  - *Suicide
MH  - Suicide, Attempted
OTO - NOTNLM
OT  - Comprehension
OT  - Suicide
OT  - Therapeutics
COIS- Les auteurs declarent n'avoir aucun lien d'interets.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Rev Prat. 2020 Jan;70(1):59-61.


PMID- 32876934
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1546-9549 (Electronic)
IS  - 1546-9530 (Linking)
VI  - 17
IP  - 5
DP  - 2020 Oct
TI  - Rethinking the Meaning of Palliation in Heart Failure.
PG  - 309-313
LID - 10.1007/s11897-020-00483-x [doi]
AB  - PURPOSE OF REVIEW: Palliative care follows a philosophy of care that focuses upon
      the quality of life in patients with chronic or life-threatening illness. It also
      focuses upon the needs of their families which is a wider scope of care.
      Cardiovascular disease, and specifically heart failure, affects millions of
      patients and family members who have a symptom burden that exceeds that of many
      cancers and other chronic diseases. RECENTLY FINDINGS: Historically palliative
      care has been viewed as an alternative to curative therapies, but over time, it
      is now recognized that it should be implemented earlier in the course of chronic 
      diseases. Although non-oncologic patients now comprise over half of the patient
      seen by palliative care, patients with cardiovascular disease are still not being
      referred to palliative care. Palliative care goes beyond advance directives and
      end of life planning. There is a need to continue to expand the view of
      palliative care to encompass interventions that help improve the overall health
      of these patients, including their psychosocial well-being and quality of life.
      The collection of papers in this journal provides insight into the breadth of
      palliative care for patients with heart failure and other cardiovascular
      diseases.
FAU - Fedson, Savitri
AU  - Fedson S
AD  - Section of Cardiology, Michael E DeBakey VA Medical Center, Center for Medical
      Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Suite
      310D, Houston, TX, 77030, USA. fedson@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Heart Fail Rep
JT  - Current heart failure reports
JID - 101196487
SB  - IM
MH  - *Decision Making
MH  - Heart Failure/*therapy
MH  - Humans
MH  - Palliative Care/*methods
MH  - *Quality of Life
OTO - NOTNLM
OT  - *Advance directives
OT  - *Ethics
OT  - *Palliative care
OT  - *Quality of life
OT  - *Shared decision-making
EDAT- 2020/09/03 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1007/s11897-020-00483-x [doi]
AID - 10.1007/s11897-020-00483-x [pii]
PST - ppublish
SO  - Curr Heart Fail Rep. 2020 Oct;17(5):309-313. doi: 10.1007/s11897-020-00483-x.


PMID- 32876909
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Should Moral Machines be Banned? A Commentary on van Wynsberghe and Robbins
      "Critiquing the Reasons for Making Artificial Moral Agents".
PG  - 3469-3481
LID - 10.1007/s11948-020-00255-9 [doi]
AB  - In a stimulating recent article for this journal (van Wynsberghe and Robbins in
      Sci Eng Ethics 25(3):719-735. https://doi.org/10.1007/s11948-018-0030-8 , 2019), 
      Aimee van Wynsberghe and Scott Robbins (hereafter, vW&R) mount a serious critique
      of a number of reasons advanced in favor of building artificial moral agents
      (AMAs). In light of their critique, vW&R make two recommendations: they advocate 
      a moratorium on the commercialization of AMAs and suggest that the argumentative 
      burden is now shifted onto the proponents of AMAs to come up with new reasons for
      building them. This commentary aims to explore the implications vW&R draw from
      their critique. In particular, it will raise objections to the moratorium
      argument and propose a presumptive case for commercializing AMAs.
FAU - Chomanski, Bartek
AU  - Chomanski B
AUID- ORCID: http://orcid.org/0000-0001-6533-5918
AD  - Rotman Institute of Philosophy, Western University, 1151 Richmond Street North,
      London, ON, Canada. b.chomanski@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Dissent and Disputes
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - Artificial moral agents
OT  - Autonomy
OT  - Machine ethics
OT  - Robot ethics
EDAT- 2020/09/03 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1007/s11948-020-00255-9 [doi]
AID - 10.1007/s11948-020-00255-9 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3469-3481. doi: 10.1007/s11948-020-00255-9. Epub
      2020 Sep 2.


PMID- 32876406
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 1731-2531 (Electronic)
IS  - 1642-5758 (Linking)
VI  - 52
IP  - 3
DP  - 2020
TI  - Determining airway complications during anaesthesia induction: a prospective,
      observational, cross-sectional clinical study.
PG  - 197-205
LID - 41406 [pii]
LID - 10.5114/ait.2020.97580 [doi]
AB  - BACKGROUND: Although postoperative early airway complications are rarely
      observed, when they do develop, fatal results such as brain damage and cardiac
      arrest may occur. The Royal College of Anaesthetists and Dif fi cult Airway
      Society investigated airway complications developing during anaesthesia over a
      period of 12 months within the context of the Fourth National Audit Project
      (NAP4) study. Inspired by that multicentre research project, this study aims to
      identify early airway complications that can develop in relation to anaesthesia
      induction in our hospital. METHODS: After our proposed study received approval
      from the Ethical Council, adult patients undergoing general anaesthesia at our
      operating theatres within the period of January-July 2018 were included in it.
      Demographic data, ventilation, American Society of Anesthesiologists (ASA) grade,
      Cormack-Lehane scores, tools that are used in airway management, and
      complications were recorded. RESULTS: Out of 909 patients in total, 752 were
      intubated; a laryngeal mask was placed on 157 of these patients. The complication
      rate was 5%, and the 3 most frequently observed complications were desaturation, 
      bronchospasm and pharyngeal injuries. In the group having complications, the body
      mass index value, Cormack-Lehane, Mallampati, and ventilation scores were
      significantly higher than those with no complications. CONCLUSIONS: During
      routine general anaesthesia induction at our clinic, major or minor airway
      complications have developed with a frequency of 5%, and it was determined that
      desaturation was the most frequent reversible cause.
FAU - Yilmaz, Mehmet
AU  - Yilmaz M
AD  - Department of Anesthesiology and Intensive Care, Derince Research and Education
      Hospital, Health Sciences University, Kocaeli, Turkey.
FAU - Turan, Ayse
AU  - Turan A
AD  - Department of Anesthesiology and Intensive Care, Derince Research and Education
      Hospital, Health Sciences University, Kocaeli, Turkey.
FAU - Saracoglu, Ayten
AU  - Saracoglu A
AD  - Department of Anesthesiology and Reanimation, Marmara University Medical School, 
      Istanbul, Turkey.
FAU - Simsek, Tahsin
AU  - Simsek T
AD  - Department of Anesthesiology and Intensive Care, Kartal Dr.Lutfi Kirdar Research 
      and Education Hospital, Health Sciences University, Istanbul, Turkey.
FAU - Saracoglu, Kemal
AU  - Saracoglu K
AD  - Department of Anesthesiology and Intensive Care, Kartal Dr.Lutfi Kirdar Research 
      and Education Hospital, Health Sciences University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Poland
TA  - Anaesthesiol Intensive Ther
JT  - Anaesthesiology intensive therapy
JID - 101472620
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Airway Management/*methods
MH  - Anesthesia, General/adverse effects/*methods
MH  - Body Mass Index
MH  - Bronchial Spasm/chemically induced/epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Hypoxia/epidemiology/etiology
MH  - Male
MH  - Middle Aged
MH  - Oxygen/blood
MH  - Pharynx/injuries
MH  - Prospective Studies
MH  - Pulmonary Ventilation
MH  - Respiratory Tract Diseases/*diagnosis/*etiology
MH  - Young Adult
OTO - NOTNLM
OT  - * airway complications
OT  - * hypoxia
OT  - *general anesthesia
EDAT- 2020/09/03 06:00
MHDA- 2021/08/25 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
AID - 41406 [pii]
AID - 10.5114/ait.2020.97580 [doi]
PST - ppublish
SO  - Anaesthesiol Intensive Ther. 2020;52(3):197-205. doi: 10.5114/ait.2020.97580.


PMID- 32876404
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 1731-2531 (Electronic)
IS  - 1642-5758 (Linking)
VI  - 52
IP  - 3
DP  - 2020
TI  - An observational study comparing the performance of TOF-Cuff with TOF-Scan
      monitoring during anaesthetic induction in clinical routine.
PG  - 181-186
LID - 41573 [pii]
LID - 10.5114/ait.2020.98124 [doi]
AB  - INTRODUCTION: Neuromuscular monitoring by acceleromyography assesses the effects 
      of non-depolarising neuromuscular blocking agents used during anaesthesia
      induction to optimise intubation conditions. A new type of neuromuscular monitor,
      TOF-Cuff, integrates electrode stimulation into a blood pressure monitoring cuff.
      Comparisons of this device with TOF-Scan, considered a clinical standard
      acceleromyography device, have not been published. MATERIAL AND METHODS: This
      prospective, observational study was approved by the Ethics Committee East
      Switzerland (BASEC-nr. 2016-02044), and patients' consent was obtained before
      inclusion. The study's aim was to compare TOF-Cuff with TOF-Scan by measuring the
      duration from the administration of a neuromuscular blocking agent to a
      train-of-four (TOF) ratio of 0%. After anaesthesia induction, atracurium was
      administered (0.5 mg kg-1) and TOF ratios were recorded every 15 seconds using
      the two devices simultaneously. Patients were grouped according to body mass
      index (< or >/= 30 kg m-2). RESULTS: Twenty-five non-obese and twenty-five obese 
      patients were included. In non-obese patients, bias was -3 s (+/- 21.2; limits of
      agreement -44.7 to 38.4; P = 0.702). In obese patients, bias was -20 s (+/- 35.0;
      limits of agreement -88.6 to 48.6; P = 0.0139). Large intra-individual
      differences of up to 60 seconds were detected even in non-obese patients.
      CONCLUSIONS: A significant systematic difference in the time to reach a TOF ratio
      of 0% was found when using the two devices in obese patients. In non-obese and
      obese patients, there were large intra-individual and clinically relevant
      differences. The two devices cannot be used interchangeably.
FAU - Markle, Andrew
AU  - Markle A
AD  - Spital Thurgau AG, Frauenfeld, Switzerland.
FAU - Horn, Katja
AU  - Horn K
AD  - Spital Thurgau AG, Frauenfeld, Switzerland.
FAU - Welter, JoEllen
AU  - Welter J
AD  - Spital Thurgau AG, Frauenfeld, Switzerland.
FAU - Dullenkopf, Alexander
AU  - Dullenkopf A
AD  - Spital Thurgau AG, Frauenfeld, Switzerland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PL  - Poland
TA  - Anaesthesiol Intensive Ther
JT  - Anaesthesiology intensive therapy
JID - 101472620
RN  - 0 (Neuromuscular Blocking Agents)
RN  - 0 (Neuromuscular Nondepolarizing Agents)
RN  - 2GQ1IRY63P (Atracurium)
SB  - IM
MH  - Accelerometry/*methods
MH  - Adult
MH  - Aged
MH  - Anesthesia, General/*methods
MH  - Atracurium
MH  - Blood Pressure Determination
MH  - Body Mass Index
MH  - Electric Stimulation
MH  - Female
MH  - Humans
MH  - Intraoperative Neurophysiological Monitoring/*methods
MH  - Male
MH  - Middle Aged
MH  - Neuromuscular Blocking Agents
MH  - Neuromuscular Monitoring/*methods
MH  - Neuromuscular Nondepolarizing Agents
MH  - Obesity/physiopathology
MH  - Premedication
MH  - Prospective Studies
OTO - NOTNLM
OT  - * neuromuscular monitoring.
OT  - * patient safety
OT  - *general anaesthesia
EDAT- 2020/09/03 06:00
MHDA- 2021/08/25 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
AID - 41573 [pii]
AID - 10.5114/ait.2020.98124 [doi]
PST - ppublish
SO  - Anaesthesiol Intensive Ther. 2020;52(3):181-186. doi: 10.5114/ait.2020.98124.


PMID- 32876398
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1466-769X (Electronic)
IS  - 1466-7681 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Oct
TI  - Ideas of caring in nursing practice.
PG  - e12325
LID - 10.1111/nup.12325 [doi]
AB  - In nursing practice, awareness of ethical inner values and a common understanding
      of nursing and caring are needed. It is therefore important to highlight ideas of
      caring in nursing practice. The aim of this paper was to illuminate nursing,
      caring and ethical inner values in caring and caring in nursing practice. By
      being attentive, open, respectful and treating the patient as a person, nurses
      can enhance both their own and the patient's sense of personal meaning in the
      caring relationship. Nurses can use self-reflection to create an awareness of
      nursing, caring and ethical inner values in caring.
CI  - (c) 2020 The Authors. Nursing Philosophy published by John Wiley & Sons Ltd.
FAU - Karlsson, Margareta
AU  - Karlsson M
AUID- ORCID: https://orcid.org/0000-0003-1981-455X
AD  - Department of Health Sciences, University West, Trollhattan, Sweden.
FAU - Pennbrant, Sandra
AU  - Pennbrant S
AUID- ORCID: https://orcid.org/0000-0002-2793-9937
AD  - Department of Health Sciences, University West, Trollhattan, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - Nurs Philos
JT  - Nursing philosophy : an international journal for healthcare professionals
JID - 100897394
SB  - IM
MH  - *Empathy
MH  - Humanism
MH  - Humans
MH  - Nursing Process/*trends
OTO - NOTNLM
OT  - ethics
OT  - ethics of care
OT  - philosophy of nursing
OT  - qualitative
OT  - theory-practice
EDAT- 2020/09/03 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/03/29 00:00 [received]
PHST- 2020/06/14 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1111/nup.12325 [doi]
PST - ppublish
SO  - Nurs Philos. 2020 Oct;21(4):e12325. doi: 10.1111/nup.12325. Epub 2020 Sep 2.


PMID- 32876289
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Linking)
VI  - 28
DP  - 2020
TI  - The ethical dimension of problems faced in general medicine: relationship with
      moral sensitivity.
PG  - e3309
LID - S0104-11692020000100386 [pii]
LID - 10.1590/1518-8345.4033.3309 [doi]
AB  - OBJECTIVE: to identify the main ethical problems and how these relate to the
      moral sensitivity of nurses working in a general medicine ward. METHOD: this
      qualitative, exploratory, and descriptive study was conducted in a university
      hospital located in the south of Brazil. A total of 18 nurses working in a
      general medicine ward were interviewed. A semi-structured interview script was
      used, and data were analyzed using discursive textual analysis. RESULTS: nurses
      considered the main ethical problems to include conflicts at the institutional
      level, situations involving conflicts with patients and/or family members, and
      conflicts within the staff. The perception of nurses and how they deal with these
      problems relate to moral sensitivity. Two categories emerged: experiencing
      ethical problems, and relationship with moral sensitivity. CONCLUSION: because of
      the multidimensional nature of moral sensitivity, it trains and enables nurses to
      recognize and deal with ethical problems faced in clinical practice so that
      nurses become able to make fair and prudent decisions, improving the quality of
      nursing care.
FAU - Yasin, Janaina Cassana Mello
AU  - Yasin JCM
AD  - Universidade Federal do Rio Grande, Rio Grande, RS, Brazil.
FAU - Barlem, Edison Luiz Devos
AU  - Barlem ELD
AD  - Universidade Federal do Rio Grande, Rio Grande, RS, Brazil.
FAU - Barlem, Jamila Geri Tomaschewski
AU  - Barlem JGT
AD  - Universidade Federal do Rio Grande, Rio Grande, RS, Brazil.
FAU - Silveira, Rosemary Silva da
AU  - Silveira RSD
AD  - Universidade Federal do Rio Grande, Rio Grande, RS, Brazil.
FAU - Dalmolin, Graziele de Lima
AU  - Dalmolin GL
AD  - Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.
FAU - Andrade, Gustavo Baade de
AU  - Andrade GB
AD  - Universidade Federal do Rio Grande, Rio Grande, RS, Brazil.
LA  - por
LA  - spa
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Brazil
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Brazil
MH  - *Ethics, Nursing
MH  - Hospitals, University
MH  - Humans
MH  - Morals
MH  - *Nursing Staff, Hospital
PMC - PMC7458576
EDAT- 2020/09/03 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/03 06:00
PHST- 2019/11/27 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - S0104-11692020000100386 [pii]
AID - 10.1590/1518-8345.4033.3309 [doi]
PST - ppublish
SO  - Rev Lat Am Enfermagem. 2020;28:e3309. doi: 10.1590/1518-8345.4033.3309. Epub 2020
      Aug 31.


PMID- 32876249
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20201210
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 25
IP  - 9
DP  - 2020 Sep
TI  - Off label, compassionate and irrational use of medicines in Covid-19 pandemic,
      health consequences and ethical issues.
PG  - 3413-3419
LID - S1413-81232020000903413 [pii]
LID - 10.1590/1413-81232020259.16792020 [doi]
AB  - When Covid-19 emerged in December last year, there was no vaccine nor was there
      specific effective treatment for this fast-spreading and life-threatening viral
      respiratory infection. Clinical trials were planned and are in progress to
      investigate whether drugs used for influenza, HIV and other viruses, and also
      anthelmintics (ivermectin, nitazoxanide, niclosamide), and antimalarials
      (chloroquine, hydroxychloroquine) showing antiviral activity in in vitro assays, 
      are effective and safe for Covid-19. So far there is no convincing evidence that 
      these antiviral and antiparasitic drugs are of any benefit for Covid-19.
      Notwithsanding the absence of evidence of clinical efficacy, these drugs are
      widely used outside of clinical trials (off label) for prophylaxis and treatment 
      of this viral infection. The rationale behind the prescription of macrolide
      antibiotics (azithromycin) for Covid-19 is obscure as well. The widespread
      prescription and use of drugs of unproven efficacy and safety for Covid-19 is at 
      odds with the rational use of medicines, a cornerstone principle of
      pharmacotherapy advanced by WHO in 1985. This irrational use of drugs is cause
      for concern because some of them are associated with serious heart disorders and 
      deaths.
FAU - Paumgartten, Francisco Jose Roma
AU  - Paumgartten FJR
AD  - Escola Nacional de Saude Publica, Fiocruz, Rio de Janeiro, RJ, Brazil,
      paum@ensp.fiocruz.br.
FAU - Oliveira, Ana Cecilia Amado Xavier de
AU  - Oliveira ACAX
AD  - Escola Nacional de Saude Publica, Fiocruz, Rio de Janeiro, RJ, Brazil,
      paum@ensp.fiocruz.br.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
RN  - 0 (Antiviral Agents)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Antiviral Agents/administration & dosage/adverse effects
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/virology
MH  - Humans
MH  - Inappropriate Prescribing/statistics & numerical data
MH  - *Off-Label Use
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/virology
MH  - Practice Patterns, Physicians'/standards
EDAT- 2020/09/03 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - S1413-81232020000903413 [pii]
AID - 10.1590/1413-81232020259.16792020 [doi]
PST - ppublish
SO  - Cien Saude Colet. 2020 Sep;25(9):3413-3419. doi:
      10.1590/1413-81232020259.16792020. Epub 2020 Aug 28.


PMID- 32876229
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20201210
IS  - 1726-4642 (Electronic)
IS  - 1726-4634 (Linking)
VI  - 37
IP  - 2
DP  - 2020 Apr-Jun
PG  - 356-360
LID - 10.17843/rpmesp.2020.372.5546 [doi]
AB  - COVID-19 represents a global crisis. Rapidly conducting a clinical trial with the
      rigor necessary to obtain reliable results requires the collaboration of various 
      participants involved in the development, evaluation and authorization of
      clinical trials (CT) such as the trial sponsor, researchers, regulatory authority
      and the ethics committee (EC). Carrying out these studies is not only
      scientifically appropriate, but an ethical and moral obligation to guarantee our 
      patients effective treatment. SOLIDARITY is a mega clinical trial that recruited 
      thousands of subjects with moderate to severe disease, who were randomly assigned
      to one of the treatment groups under evaluation, including hydroxychloroquine,
      lopinavir/ritonavir associated or not with interferon; or remdesivir compared to 
      standard therapy. Peru has joined the list of countries where the trial will be
      reproduced, through which it will be possible to quickly identify if any of these
      drugs offers a real benefit to patients.
FAU - Soto, Alonso
AU  - Soto A
AUID- ORCID: http://orcid.org/0000-0001-8648-8032
AD  - Instituto de Investigacion en Ciencias Biomedicas, Universidad Ricardo Palma,
      Lima, Peru.
AD  - Departamento de Medicina, Hospital Nacional Hipolito Unanue, Lima, Peru.
FAU - Quinones-Laveriano, Dante M
AU  - Quinones-Laveriano DM
AUID- ORCID: http://orcid.org/0000-0002-1129-1427
AD  - Instituto de Investigacion en Ciencias Biomedicas, Universidad Ricardo Palma,
      Lima, Peru.
FAU - Garcia, Patricia J
AU  - Garcia PJ
AUID- ORCID: http://orcid.org/0000-0003-3874-2256
AD  - Facultad de Salud Publica y Administracion, Universidad Peruana Cayetano Heredia,
      Lima, Peru.
FAU - Gotuzzo, Eduardo
AU  - Gotuzzo E
AUID- ORCID: http://orcid.org/0000-0003-1747-4352
AD  - Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana
      Cayetano Heredia, Lima, Peru.
FAU - Henao-Restrepo, Ana Maria
AU  - Henao-Restrepo AM
AUID- ORCID: http://orcid.org/0000-0001-9910-7999
AD  - Organizacion Mundial de la Salud, Ginebra, Suiza.
LA  - spa
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Respuestas rapidas a la pandemia de COVID-19 a traves de la ciencia y la
      colaboracion global: el ensayo clinico Solidaridad.
DEP - 20200828
PL  - Peru
TA  - Rev Peru Med Exp Salud Publica
JT  - Revista peruana de medicina experimental y salud publica
JID - 101227566
RN  - 0 (Antiviral Agents)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Antiviral Agents/*administration & dosage
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - International Cooperation
MH  - Pandemics
MH  - Peru
MH  - Pneumonia, Viral/*drug therapy/physiopathology
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2020/09/03 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - 10.17843/rpmesp.2020.372.5546 [doi]
PST - ppublish
SO  - Rev Peru Med Exp Salud Publica. 2020 Apr-Jun;37(2):356-360. doi:
      10.17843/rpmesp.2020.372.5546. Epub 2020 Aug 28.


PMID- 32875752
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20211231
IS  - 2047-9018 (Electronic)
IS  - 0029-6570 (Linking)
VI  - 35
IP  - 11
DP  - 2020 Nov 4
TI  - Artificial hydration at the end of life: balancing benefits and risks in the
      absence of conclusive evidence.
PG  - 61-65
LID - 10.7748/ns.2020.e11595 [doi]
AB  - There is a lack of clear evidence regarding the benefits and harm of artificial
      hydration at the end of life. Trial findings are conflicting and inconclusive,
      offering little basis for recommendations. As a result, the advantages and
      disadvantages of artificial hydration remain largely anecdotal, and decisions
      about its use, withholding or withdrawal are often based on opinion rather than
      evidence. In certain circumstances, some patients who are dying might derive
      benefit from artificial hydration in terms of reducing specific symptoms, such as
      delirium. This article explores the central questions pertaining to artificial
      hydration at the end of life by undertaking a critical exploration of the
      relevant literature.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Beland, Paul
AU  - Beland P
AD  - St Nicholas Hospice, Bury St Edmunds, England.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - Nurs Stand
JT  - Nursing standard (Royal College of Nursing (Great Britain) : 1987)
JID - 9012906
MH  - Death
MH  - Fluid Therapy
MH  - Humans
MH  - Risk Assessment
MH  - *Terminal Care
OTO - NOTNLM
OT  - clinical
OT  - end of life care
OT  - ethical issues
OT  - fluid intake
OT  - fluid management
OT  - hydration
OT  - professional
OT  - terminal care
COIS- None declared
EDAT- 2020/09/03 06:00
MHDA- 2022/01/01 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.7748/ns.2020.e11595 [doi]
AID - e11595 [pii]
PST - ppublish
SO  - Nurs Stand. 2020 Nov 4;35(11):61-65. doi: 10.7748/ns.2020.e11595. Epub 2020 Sep
      2.


PMID- 32875739
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1442-2018 (Electronic)
IS  - 1441-0745 (Linking)
VI  - 22
IP  - 3
DP  - 2020 Sep
TI  - Ethics in quality improvement: Reimagining the clinician role.
PG  - 483-485
LID - 10.1111/nhs.12648 [doi]
FAU - Lockwood, Craig
AU  - Lockwood C
AUID- ORCID: 0000-0003-3722-676X
AD  - The Joanna Briggs Institute, The University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - Sfetcu, Raluca
AU  - Sfetcu R
AD  - Department of Psychology and Educational Sciences, Spiru Haret University,
      Bucharest, Romania.
LA  - eng
PT  - Editorial
PL  - Australia
TA  - Nurs Health Sci
JT  - Nursing & health sciences
JID - 100891857
SB  - IM
MH  - Clinical Nursing Research
MH  - Humans
MH  - Leadership
MH  - *Organizational Innovation
MH  - Quality Improvement/*ethics
EDAT- 2020/09/03 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/09/03 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2019/08/19 00:00 [revised]
PHST- 2019/08/20 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.1111/nhs.12648 [doi]
PST - ppublish
SO  - Nurs Health Sci. 2020 Sep;22(3):483-485. doi: 10.1111/nhs.12648.


PMID- 32875476
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1545-7230 (Electronic)
IS  - 1042-9670 (Linking)
VI  - 44
IP  - 6
DP  - 2020 Dec
TI  - A Survey of Psychiatry Course Offerings for Fourth-Year Medical Students.
PG  - 741-744
LID - 10.1007/s40596-020-01300-2 [doi]
AB  - OBJECTIVE: Fourth-year course offerings seem to vary widely among psychiatry
      departments with some offering a wide selection while others offer little or
      unspecified opportunity. The purpose of this study was to learn the distribution 
      and diversity of fourth-year medical school psychiatry courses and identify
      unique course offerings that may inspire other departments. METHODS: The authors 
      compiled a list of US allopathic medical schools accredited by the Liaison
      Committee on Medical Education (LCME) using the LCME website. They accessed each 
      school's website catalog and recorded all psychiatry electives available to
      fourth-year students listed in the catalog or the Visiting Student Application
      Service(R) (VSAS(R)) database. The authors calculated median published course
      offerings per department and categorized each course according to learning
      opportunity. RESULTS: The authors identified 142 fully accredited allopathic
      medical schools of which n = 126 listed fourth-year medical student courses on
      their website or through VSAS. The median number of fourth-year psychiatry course
      offerings per school was 6 (range, 1-22). The most frequently offered courses
      were inpatient psychiatry (n = 105 schools), child and adolescent psychiatry (n =
      95), and consultation psychiatry (n = 84). The authors also identified unique
      enrichment courses in media, women's health, ethics, research, and cultural
      psychiatry. CONCLUSIONS: The fourth-year curriculum varies widely among
      institutions. Hypotheses to be tested are if prioritizing robust fourth-year
      rotations include improved resident readiness, improved retention of home
      students into the training program, improved recruitment of visiting students,
      increased faculty scholarly activity and career development, and improved
      recruitment into the subspecialties.
FAU - Cenoz-Donati, Aline B
AU  - Cenoz-Donati AB
AUID- ORCID: http://orcid.org/0000-0002-9819-1524
AD  - UT Health San Antonio, San Antonio, TX, USA. acenozdonati@gmail.com.
FAU - McKinley, Jennifer C
AU  - McKinley JC
AD  - South Texas Veterans' Healthcare System, San Antonio, TX, USA.
FAU - Schillerstrom, Jason E
AU  - Schillerstrom JE
AD  - UT Health San Antonio, San Antonio, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - Acad Psychiatry
JT  - Academic psychiatry : the journal of the American Association of Directors of
      Psychiatric Residency Training and the Association for Academic Psychiatry
JID - 8917200
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Curriculum
MH  - *Education, Medical
MH  - *Education, Medical, Undergraduate
MH  - Female
MH  - Humans
MH  - *Psychiatry
MH  - Schools, Medical
MH  - *Students, Medical
OTO - NOTNLM
OT  - Electives
OT  - Medical student education
OT  - Senior medical students
EDAT- 2020/09/03 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1007/s40596-020-01300-2 [doi]
AID - 10.1007/s40596-020-01300-2 [pii]
PST - ppublish
SO  - Acad Psychiatry. 2020 Dec;44(6):741-744. doi: 10.1007/s40596-020-01300-2. Epub
      2020 Sep 1.


PMID- 32875390
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2509-9280 (Electronic)
IS  - 2509-9280 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Sep 2
TI  - 2D perfusion DSA with an open-source, semi-automated, color-coded software for
      the quantification of foot perfusion following infrapopliteal angioplasty: a
      feasibility study.
PG  - 47
LID - 10.1186/s41747-020-00176-z [doi]
AB  - BACKGROUND: Foot perfusion has been recently implemented as a new tool for
      optimizing outcomes of peripheral endovascular procedures. A custom-made,
      two-dimensional perfusion digital subtraction angiography (PDSA) algorithm has
      been implemented to quantify outcomes of endovascular treatment of critical limb 
      ischemia (CLI), assist intra-procedural decision-making, and enhance clinical
      outcomes. METHODS: The study was approved by the Hospital's Ethics Committee.
      This prospective, single-center study included seven consecutive patients
      scheduled to undergo infrapopliteal endovascular treatment of CLI. Perfusion
      blood volume (PBV), mean transit time (MTT), and perfusion blood flow (PBF) maps 
      were extracted by analyzing time-intensity curves and signal intensity on the
      perfused vessel mask. Mean values calculated from user-specified regions of
      interest (ROIs) on perfusion maps were employed to evaluate pre- and
      post-endovascular treatment condition. Measurements were performed immediately
      after final PDSA. RESULTS: In total, five patients (aged 54 +/- 16 years, mean
      +/- standard deviation) were analyzed, as two patients were excluded due to
      significant motion artifacts. Post-procedural MTT presented a mean decrease of
      19.1% for all patients and increased only in 1 of 5 patients, demonstrating in
      4/5 patients an increase in tissue perfusion after revascularization. Overall
      mean PBF and PBV values were also analogously increased following
      revascularization (446% and 69.5% mean, respectively) and in the majority of
      selected ROIs (13/15 and 12/15 ROIs, respectively). CONCLUSIONS: Quantification
      of infrapopliteal angioplasty outcomes using this newly proposed, custom-made,
      intra-procedural PDSA algorithm was performed using PBV, MTT, and PBF maps.
      Further studies are required to determine its role in peripheral endovascular
      procedures ( ClinicalTrials.gov Identifier: NCT04356092).
FAU - Kagadis, George C
AU  - Kagadis GC
AD  - Department of Medical Physics, School of Medicine, University of Patras, GR
      26504, Rion, Greece.
AD  - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, 77030, USA.
FAU - Tsantis, Stavros
AU  - Tsantis S
AD  - Department of Medical Physics, School of Medicine, University of Patras, GR
      26504, Rion, Greece.
FAU - Gatos, Ilias
AU  - Gatos I
AD  - Department of Medical Physics, School of Medicine, University of Patras, GR
      26504, Rion, Greece.
FAU - Spiliopoulos, Stavros
AU  - Spiliopoulos S
AUID- ORCID: 0000-0003-1860-0568
AD  - 2nd Department of Radiology, School of Medicine, "ATTIKON" University Hospital,
      National and Kapodistrian University of Athens, GR 12461, Athens, Greece.
      stavspiliop@med.uoa.gr.
FAU - Katsanos, Konstantinos
AU  - Katsanos K
AD  - Department of Radiology, School of Medicine, University of Patras, GR 26504,
      Rion, Greece.
FAU - Karnabatidis, Dimitris
AU  - Karnabatidis D
AD  - Department of Radiology, School of Medicine, University of Patras, GR 26504,
      Rion, Greece.
LA  - eng
SI  - ClinicalTrials.gov/NCT04356092
PT  - Journal Article
DEP - 20200902
PL  - England
TA  - Eur Radiol Exp
JT  - European radiology experimental
JID - 101721752
SB  - IM
MH  - Algorithms
MH  - *Angiography, Digital Subtraction
MH  - Blood Flow Velocity
MH  - Endovascular Procedures/*methods
MH  - Feasibility Studies
MH  - Female
MH  - Foot/*blood supply
MH  - Humans
MH  - Ischemia/*diagnostic imaging/*surgery
MH  - Male
MH  - Middle Aged
MH  - Peripheral Arterial Disease/*diagnostic imaging/*surgery
MH  - Prospective Studies
MH  - Radiographic Image Interpretation, Computer-Assisted
MH  - *Software
PMC - PMC7462946
OTO - NOTNLM
OT  - *Angiography (digital subtraction)
OT  - *Endovascular procedures
OT  - *Foot
OT  - *Perfusion
OT  - *Peripheral arterial disease
EDAT- 2020/09/03 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1186/s41747-020-00176-z [doi]
AID - 10.1186/s41747-020-00176-z [pii]
PST - epublish
SO  - Eur Radiol Exp. 2020 Sep 2;4(1):47. doi: 10.1186/s41747-020-00176-z.


PMID- 32875096
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Aug 20
TI  - Suicide Assessment and Management Team-Based Learning Module.
PG  - 10952
LID - 10.15766/mep_2374-8265.10952 [doi]
AB  - Introduction: Suicide is a global health problem that health care providers must 
      feel comfortable addressing. Unfortunately, many health care providers are not
      equipped to assess and treat patients at risk for suicide due to lack of training
      and education. Interactive resources are needed to educate health professions
      students about the management of suicidal patients. Methods: The suicide
      assessment and management team-based learning (TBL) module was developed to
      address the gap in suicide education. After completing the module, students were 
      able to identify key elements for a comprehensive assessment of a patient's risk 
      for suicide and to discuss clinical management for a suicidal patient. The
      activity was designed for second-year medical students during a psychopathology
      course, the last organ-system course prior to clerkships. This module could also 
      be used or modified to meet the educational requirements for other health
      professions, including medical residents, nurse practitioner students, and
      physician assistant students. Results: A total of 342 students among 62 teams
      participated in the TBL over a period of 3 consecutive years. The class averages 
      for the individual Readiness Assurance Test ranged from 80% to 88%. The class
      averages for the team Readiness Assurance Test and application questions were
      comparable across all 3 years. Course evaluations showed the TBL helped students 
      think critically and integrate information to prepare them for their future
      careers. Discussion: Overall, this TBL was an effective educational tool that
      stimulated high-quality discussion, in which students remained engaged and asked 
      thought-provoking questions.
CI  - (c) 2020 Lerchenfeldt et al.
FAU - Lerchenfeldt, Sarah
AU  - Lerchenfeldt S
AUID- ORCID: 0000-0002-1383-4456
AD  - Assistant Professor, Department of Foundational Medical Studies, Oakland
      University William Beaumont School of Medicine.
FAU - Kamel-ElSayed, Suzan
AU  - Kamel-ElSayed S
AD  - Associate Professor, Department of Foundational Medical Studies, Oakland
      University William Beaumont School of Medicine.
FAU - Patino, Gustavo
AU  - Patino G
AD  - Assistant Professor, Department of Foundational Medical Studies, Oakland
      University William Beaumont School of Medicine; Assistant Professor, Department
      of Neurology, Oakland University William Beaumont School of Medicine.
FAU - Thomas, David M
AU  - Thomas DM
AD  - Interim Associate Dean for Preclinical Medical Education, Office of Medical
      Education, Oakland University William Beaumont School of Medicine.
FAU - Wagner, Jolyn
AU  - Wagner J
AD  - Assistant Professor, Department of Psychiatry, Oakland University William
      Beaumont School of Medicine.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - Curriculum
MH  - Educational Measurement
MH  - Humans
MH  - Learning
MH  - *Students, Medical
MH  - *Suicide/prevention & control
PMC - PMC7449577
OTO - NOTNLM
OT  - *Clinical Reasoning/Diagnostic Reasoning
OT  - *Communication Skills
OT  - *Ethics
OT  - *Evidence-Based Medicine
OT  - *Patient Safety
OT  - *Suicide
OT  - *Suicide Management
OT  - *Suicide Risk Assessment
OT  - *Suicide Treatment
OT  - *Team-Based Learning
EDAT- 2020/09/03 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10952 [doi]
AID - 10952 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Aug 20;16:10952. doi: 10.15766/mep_2374-8265.10952.


PMID- 32875045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - Hydroxy-chloroquine to treat COVID-19 - infected patients: Some lessons from
      medical anthropology and history of medicine.
PG  - 100587
LID - 10.1016/j.jemep.2020.100587 [doi]
AB  - It is certainly too early to take stock of Professor Raoult's intuitions, and
      moreover, that is not the aim of this short article. Nevertheless, experience has
      shown that in times of unprecedented health crises, prescriptions often turn out 
      to be adventurous, especially when it comes to a new virus. The collective
      imagination around a remedy often takes the place of a guarantee or, on the
      contrary, a safeguard. Here, the authors question the implementation of
      hydroxy-chloroquine treatment in the context of the COVID-19 pandemic. How was
      his prescription discussed in this context of crisis? What lesson can we learn
      from medical anthropology and the history of medicine, by witnessing other
      epidemics and atypical or unconventional substances or behaviors of
      practitioners?
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Charlier, P
AU  - Charlier P
AD  - Department of research and high education, Musee du quai Branly-Jacques-Chirac,
      222, rue de l'Universite, 75007 Paris, France.
AD  - Laboratory anthropology, archaeology, biology (LAAB), Paris-Saclay university
      (UVSQ), 2, avenue de la Source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
FAU - Donell, S
AU  - Donell S
AD  - Norwich medical school, university of East Anglia, NR4 7TJ Norwich, UK.
FAU - Lippi, D
AU  - Lippi D
AD  - Laboratory anthropology, archaeology, biology (LAAB), Paris-Saclay university
      (UVSQ), 2, avenue de la Source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
AD  - Department of experimental and clinical medicine, university of Florence,
      Florence, Italy.
FAU - Nerlich, A
AU  - Nerlich A
AD  - Institute of pathology, Academic clinic Munich-Bogenhausen, Englschalkingerstr,
      77, D-81925 Munich, Germany.
FAU - Asensi, V
AU  - Asensi V
AD  - Laboratory anthropology, archaeology, biology (LAAB), Paris-Saclay university
      (UVSQ), 2, avenue de la Source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
AD  - Infectious diseases unit, hospital universitario central de Asturias, Oviedo
      university medical school, Oviedo, Spain.
AD  - Group of translational research in infectious diseases, Instituto de
      investigacion Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
FAU - Perciaccante, A
AU  - Perciaccante A
AD  - Laboratory anthropology, archaeology, biology (LAAB), Paris-Saclay university
      (UVSQ), 2, avenue de la Source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
AD  - Department of medicine, Azienda Sanitaria universitaria Giuliano Isontina, San
      Giovanni di Dio hospital, Gorizia, Italy.
FAU - Appenzeller, O
AU  - Appenzeller O
AD  - Laboratory anthropology, archaeology, biology (LAAB), Paris-Saclay university
      (UVSQ), 2, avenue de la Source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
AD  - New Mexico health enhancement and marathon clinics research foundation, 361, Big 
      Horn Ridge Dr. NE, Albuquerque, NM, USA.
AD  - New Mexico museum of natural history and science, 1801, Mountain road NW,
      Albuquerque, NM, USA.
FAU - Bianucci, R
AU  - Bianucci R
AD  - Laboratory anthropology, archaeology, biology (LAAB), Paris-Saclay university
      (UVSQ), 2, avenue de la Source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
AD  - Warwick medical school, biomedical sciences, university of Warwick, Coventry, UK.
AD  - Legal medicine section, department of public health and paediatric sciences,
      university of Turin, Turin, Italy.
AD  - Laboratoire d'anthropologie bio-culturelle, droit, ethique et sante (Ades), UMR
      7268, faculte de medecine de Marseille, Marseille, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200827
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7451121
OTO - NOTNLM
OT  - Biomedical ethics
OT  - History of diseases
OT  - History of medicine
OT  - Medical anthropology
OT  - Medical controversy
OT  - Unconventional treatment
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/06/16 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1016/j.jemep.2020.100587 [doi]
AID - 100587 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100587. doi:
      10.1016/j.jemep.2020.100587. Epub 2020 Aug 27.


PMID- 32874934
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 2214-9996 (Electronic)
IS  - 2214-9996 (Linking)
VI  - 86
IP  - 1
DP  - 2020 Aug 19
TI  - Practical and Ethical Solutions for Remote Applied Learning Experiences in Global
      Health.
PG  - 103
LID - 10.5334/aogh.2999 [doi]
AB  - Global health trainees rely on immersive experiences to apply their classroom
      knowledge in real-world settings. However, during the COVID-19 pandemic travel
      has come to a halt and short-term experiences are no longer available in their
      current form. As with didactic material, global health programs have an
      opportunity to innovate the delivery of applied learning, providing trainees with
      robust, mentored experiences that promote the acquisition of core global health
      competencies. We provide a series of practical solutions for remote applied
      learning including case-based learning, pathfinder pedagogy, virtual reality
      simulations, and twinning. We further describe the role of these approaches in
      addressing common criticisms of short-term experiences and their potential for
      creating new win-win dynamics between institutions and trainees.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Kalbarczyk, Anna
AU  - Kalbarczyk A
AD  - Johns Hopkins University, Johns Hopkins Center for Global Health, Baltimore, MD, 
      US.
FAU - Harrison, Meagan
AU  - Harrison M
AD  - Johns Hopkins University, Johns Hopkins Center for Global Health, Baltimore, MD, 
      US.
FAU - Sanguineti, Maria Cecilia Dedios
AU  - Sanguineti MCD
AD  - Universidad de los Andes, School of Government, Bogota, CO.
FAU - Wachira, Juddy
AU  - Wachira J
AD  - Department of Mental Health and Behavioral Sciences, School of Medicine, Moi
      University, Eldoret, KE.
AD  - Department of Media Studies, School of Literature, Language and Media, University
      of Witwatersrand, Johannesburg, ZA.
FAU - Guzman, Carlos A Faerron
AU  - Guzman CAF
AD  - InterAmerican Center for Global Health, CR.
FAU - Hansoti, Bhakti
AU  - Hansoti B
AD  - Johns Hopkins University, Johns Hopkins Center for Global Health, Baltimore, MD, 
      US.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - Ann Glob Health
JT  - Annals of global health
JID - 101620864
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - Education/organization & administration
MH  - *Education, Distance/methods/organization & administration
MH  - Global Health/*education
MH  - Humans
MH  - Organizational Innovation
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - *Problem-Based Learning/methods/organization & administration
MH  - SARS-CoV-2
MH  - Teaching/*trends
PMC - PMC7442166
COIS- The authors have no competing interests to declare.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.5334/aogh.2999 [doi]
PST - epublish
SO  - Ann Glob Health. 2020 Aug 19;86(1):103. doi: 10.5334/aogh.2999.


PMID- 32874841
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2211-5072 (Electronic)
IS  - 2211-5056 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Apr-Jun
TI  - Evaluation of the relation between Lens Opacities Classification System III
      grading and nuclear size by direct measurement.
PG  - 121-126
LID - 10.4103/tjo.tjo_19_19 [doi]
AB  - CONTEXT: Although relation between Lens Opacities Classification System III (LOCS
      III) and nuclear density is established, no data are available about nuclear size
      at different LOCS III grades. AIMS: The aim of this study is to evaluate the
      relation between LOCS III grading of nuclear opacity obtained preoperatively and 
      the size of the nucleus obtained during cataract surgery. SETTINGS AND DESIGN:
      This was a prospective observational study carried out in a hospital attached to 
      medical college. MATERIALS AND METHODS: Patients who underwent manual
      small-incision cataract surgery or extra-large temporal tunnel cataract
      extraction and gave consent were included in this study. Institutional Ethics
      Committee clearance was taken for the study. Preoperative LOCS III grading was
      obtained at slit-lamp biomicroscope. Ocular dimensions were obtained by
      preoperative immersion biometry. The thickness and diameter of the nucleus
      obtained by extraction were measured up to 10 mu accuracy. Data were analyzed for
      the change in nuclear thickness, nuclear diameter, age, lens thickness, and
      anterior chamber depth in relation to the LOCS III grade of the nucleus.
      STATISTICAL ANALYSIS USED: Statistical analysis used in this study was one-way
      ANOVA, mean, and range. RESULTS: There was a significant increase (P < 0.05) in
      nuclear thickness, nuclear diameter, and age with increasing LOCS III grade of
      the nucleus. The change in nuclear size was linear between Grades 1 and 4. The
      nuclear size did not increase between Grades 4 and 5. It increased steeply from
      Grade 5 to Grade 6.9. CONCLUSION: LOCS III grading of the nucleus can be utilized
      for determining the nuclear thickness and diameter preoperatively. These data can
      be helpful in adjusting machine parameters during phacoemulsification.
CI  - Copyright: (c) 2020 Taiwan J Ophthalmol.
FAU - Kulkarni, Chidanand
AU  - Kulkarni C
AD  - Department of Ophthalmology, Kasturba Medical College, Manipal Academy of Higher 
      Education, Manipal, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20190912
PL  - India
TA  - Taiwan J Ophthalmol
JT  - Taiwan journal of ophthalmology
JID - 101582127
PMC - PMC7442107
OTO - NOTNLM
OT  - Cataract/classification
OT  - cataract/diagnosis
OT  - lens nucleus
COIS- The author declares that there are no conflicts of interests of this paper.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2019/02/23 00:00 [received]
PHST- 2019/06/06 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.4103/tjo.tjo_19_19 [doi]
AID - TJO-10-121 [pii]
PST - epublish
SO  - Taiwan J Ophthalmol. 2019 Sep 12;10(2):121-126. doi: 10.4103/tjo.tjo_19_19.
      eCollection 2020 Apr-Jun.


PMID- 32874768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 27
DP  - 2020 Sep
TI  - Levels of PM10 and PM2.5 and Respiratory Health Impacts on School-Going Children 
      in Kenya.
PG  - 200912
LID - 10.5696/2156-9614-10.27.200912 [doi]
AB  - BACKGROUND: The respiratory system of children is vulnerable to exposure to
      particulate matter (PM) with a diameter of less than 2.5 and 10 mum (PM2.5 and
      PM10) or even lower. OBJECTIVE: This study assessed PM10 and PM2.5 levels and
      respiratory health impacts on children in schools located in an industrialized
      suburb in Kenya. METHOD: The PM10 and PM2.5 levels were sampled from five public 
      primary schools in Athi River Township and a control school during the wet and
      dry seasons. Outdoor and classroom samples were collected concurrently on an
      8-hour mean during school hours on two consecutive days in each school and
      analyzed using gravimetric techniques. Five hundred and seventy-eight (n = 578)
      pupils aged 9-14 years from these schools were also evaluated for symptoms of
      respiratory illnesses and lung function using a questionnaire and spirometric
      method, respectively, during the same periods. RESULTS: Indoor median PM10 levels
      (mug/m(3)) ranged from 60.8-269.1 and 52.8-232.3 and PM2.5 values (mug/m(3)) of
      17.7-52.4 and 28.5-75.5 during the dry and wet seasons, respectively. The control
      classrooms had significantly (p <0.05) lower median PM10 levels (mug/m(3)) of 5.2
      and 4.2, and PM2.5 levels (mug/m(3)) of 3.5 and 3.0 during the respective
      seasons. Nearly all the classrooms in Athi River schools had PM2.5 and PM10
      median levels that exceeded the World Health Organization (WHO) recommended
      levels. The indoor-to-outdoor ratios varied from 0.35-1.40 and 0.80-2.40 for PM10
      and 0.30-0.80 and 0.80-1.40 for PM2.5 during the dry and wet seasons,
      respectively, suggesting higher levels in the classrooms during the wet season.
      The relative risk (RR) and odds ratio (OR) presented higher prevalence of
      respiratory diseases following PM exposure in all the Athi River schools than the
      control during the dry and wet seasons. At 95% CI, the RR and OR showed strong
      associations between high PM10 and PM2.5 levels and lung function deficits and
      vice versa. The association was more prevalent during the wet season.
      CONCLUSIONS: The study calls for effective indoor air management programs in
      school environments to reduce PM exposure and respiratory health impacts.
      PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: The research permit and approvals
      were obtained from the University of Nairobi/Kenyatta National Hospital Ethics
      and Research Committee (KNH-UoN ERC Reference: P599/08/2016) and the National
      Commission for Science, Technology and Innovation (Reference:
      NACOSTI/P/18/4268/25724). COMPETING INTERESTS: The authors declare no competing
      financial interests.
CI  - (c) 2020 Pure Earth.
FAU - Were, Faridah Hussein
AU  - Were FH
AUID- ORCID: https://orcid.org/0000-0002-4574-5108
AD  - Department of Chemistry, College of Biological and Physical Sciences, University 
      of Nairobi, Nairobi, Kenya.
FAU - Wafula, Godfrey Angoe
AU  - Wafula GA
AUID- ORCID: https://orcid.org/0000-0002-1734-3259
AD  - Department of Chemistry, College of Biological and Physical Sciences, University 
      of Nairobi, Nairobi, Kenya.
FAU - Lukorito, Cromwel Busolo
AU  - Lukorito CB
AUID- ORCID: https://orcid.org/0000-0001-6963-5213
AD  - Department of Meteorology, College of Biological and Physical Sciences,
      University of Nairobi, Nairobi, Kenya.
FAU - Kamanu, Timothy K K
AU  - Kamanu TKK
AUID- ORCID: https://orcid.org/0000-0002-3842-9502
AD  - School of Mathematics, College of Biological and Physical Sciences, University of
      Nairobi, Nairobi, Kenya.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7453813
OTO - NOTNLM
OT  - Kenya
OT  - indoor air quality
OT  - lung function
OT  - particulate matter
OT  - respiratory diseases
OT  - school children
OT  - school environment
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.5696/2156-9614-10.27.200912 [doi]
PST - epublish
SO  - J Health Pollut. 2020 Aug 19;10(27):200912. doi: 10.5696/2156-9614-10.27.200912. 
      eCollection 2020 Sep.


PMID- 32874765
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 27
DP  - 2020 Sep
TI  - Core Competencies of Truck Drivers Responding to Emergencies during
      Transportation of Hazardous Materials.
PG  - 200909
LID - 10.5696/2156-9614-10.27.200909 [doi]
AB  - BACKGROUND: Hazardous material (HAZMAT) transportation drivers are responsible
      for safe delivery of consignments and face multiple challenges carrying out their
      duties. Drivers are also the first to respond to emergencies and accidents.
      OBJECTIVES: The purpose of the present study was to identify the essential
      competencies needed by HAZMAT transportation drivers to deal with emergencies.
      METHODS: Three rounds of focus groups were conducted using expert panels
      comprised of HAZMAT specialists, health, safety and emergency representatives,
      security experts and transportation advisors from June to July 2019. The panel
      discussed competencies, gathered from a literature review, for emergency
      responders. RESULTS: The panel identified six (6) core and 23 sub-competencies of
      HAZMAT drivers. This is the first study in low- and middle-income countries
      (LMIC) to identify core competencies of HAZMAT truck drivers. CONCLUSIONS: The
      integration of these competencies into a development and training program for
      drivers will better enable drivers to handle emergencies in an efficient and
      effective manner. PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: The Graduate
      Advisory Committee of Comsats University approved study protocols. PARTICIPANT
      CONSENT: Obtained. COMPETING INTERESTS: The authors declare no competing
      financial interests.
CI  - (c) Pure Earth 2020.
FAU - Manzoor, Adnan Fazal
AU  - Manzoor AF
AUID- ORCID: https://orcid.org/0000-0002-0669-3245
AD  - COMSATS University Islamabad, Attock Campus, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7453817
OTO - NOTNLM
OT  - Competencies
OT  - Emergency Response
OT  - HAZMAT Handling
OT  - Risk
OT  - Training
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.5696/2156-9614-10.27.200909 [doi]
PST - epublish
SO  - J Health Pollut. 2020 Aug 25;10(27):200909. doi: 10.5696/2156-9614-10.27.200909. 
      eCollection 2020 Sep.


PMID- 32874762
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 27
DP  - 2020 Sep
TI  - Effect of Air Pollution on Glutathione S-Transferase Activity and Total
      Antioxidant Capacity: Cross Sectional Study in Kuwait.
PG  - 200906
LID - 10.5696/2156-9614-10.27.200906 [doi]
AB  - BACKGROUND: Air pollution poses a significant threat to human health worldwide.
      Investigating potential health impacts is essential to the development of
      regulations and legislation to minimize health risks. OBJECTIVES: The aim of the 
      present study was to investigate the potentially hazardous effect of air
      pollution on the Ali Sabah Al Salem residential area in Kuwait by comparing the
      pollution level to a control area (Al-Qirawan) by assessing two biomarkers:
      erythrocyte glutathione S-transferases (e-GST) and total blood antioxidant, and
      then correlating the activity to pollution-related oxidative stress. METHODS: The
      average concentrations of several airborne gases were measured at Ali Sabah Al
      Salem and Al-Qirawan, including ozone, carbon monoxide, nitrogen dioxide,
      nitrogen oxides, particulate matter less than 10 mum (PM10), sulfur dioxide,
      ammonia, carbon dioxide, hydrogen sulfide, methane, and non-methane hydrocarbon. 
      A total of fifty-eight participants were sampled from two different areas and
      divided into two groups. The study group was composed of 40 residents exposed to 
      polluted ambient air in the Ali Sabah Al Salem residential area. A reference
      group composed of 18 residents in the Al-Qairawan area living far from major
      pollution sources was also tested. RESULTS: All measured gases were higher in
      concentration at Ali Sabah Al Salem compared to the Al-Qirawan area. Furthermore,
      PM10 and sulfur dioxide were higher than World Health Organization (WHO)
      guidelines. The e-GST activity was lower among participants of the Ali Sabah Al
      Salem residential area compared to participants living in the Al-Qairawan area.
      The total antioxidant capacity in whole blood of Ali Sabah Al Salem residents was
      significantly (p<0.0001) higher than in control subjects. CONCLUSIONS: Residents 
      in Ali Sabah Al Salem are exposed to a high level of air pollution that has a
      serious impact on glutathione S-transferases levels. Subsequently, regulations on
      pollution sources are needed to lower current health risks. Furthermore, the
      present study provides evidence that finger-prick blood sampling is a quick,
      non-invasive method suitable for screening e-GST activity and total antioxidants 
      which may be applied for surveillance purposes. PARTICIPANT CONSENT: Obtained.
      ETHICS APPROVAL: The study was approved by the Scientific Research Committee of
      the Public Authority for Applied Education and Training, Kuwait. COMPETING
      INTERESTS: The authors declare no competing financial interests.
CI  - (c) Pure Earth 2020.
FAU - Almutairi, Abeer M
AU  - Almutairi AM
AUID- ORCID: https://orcid.org/0000-0002-9539-5310
AD  - Science Department, College of Basic Education, Public Authority for Applied
      Education and Training, (PAAET), Alardyia, Kuwait.
FAU - Akkam, Yazan
AU  - Akkam Y
AUID- ORCID: https://orcid.org/0000-0003-0699-0060
AD  - Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Yarmouk
      University, Irbid, Jordan.
FAU - Alajmi, Mohammad F
AU  - Alajmi MF
AUID- ORCID: https://orcid.org/0000-0002-1101-7292
AD  - Department of Mathematics and Natural Sciences, College of Arts and Sciences,
      Gulf University for Science and Technology, Mubarak Al-Abdullah, Kuwait.
FAU - Akkam, Nosaibah
AU  - Akkam N
AUID- ORCID: https://orcid.org/0000-0002-0067-203X
AD  - Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Yarmouk
      University, Irbid, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7453819
OTO - NOTNLM
OT  - 1-chloro-2
OT  - 4-dinitrobenzene
OT  - air-pollution
OT  - glutathione S-transferase
OT  - oxidative stress
OT  - total antioxidant
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.5696/2156-9614-10.27.200906 [doi]
PST - epublish
SO  - J Health Pollut. 2020 Aug 25;10(27):200906. doi: 10.5696/2156-9614-10.27.200906. 
      eCollection 2020 Sep.


PMID- 32874759
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 27
DP  - 2020 Sep
TI  - Assessment of Thyroid Function and Oxidative Stress State in Foundry Workers
      Exposed to Lead.
PG  - 200903
LID - 10.5696/2156-9614-10.27.200903 [doi]
AB  - BACKGROUND: Exposure to lead (Pb) has been associated with endocrine,
      hematological, gastrointestinal, renal and neurological problems in humans.
      However, effects on the thyroid gland are controversial. OBJECTIVES: The aim of
      the present study was to assess thyroid function in foundry workers
      occupationally exposed to Pb and the mechanism of oxidative-antioxidant
      imbalance. METHODS: Thyroid function parameters and markers of oxidative stress
      were examined in 59 adult males who had been occupationally exposed to Pb. The
      results were then compared to those of 28 male subjects who had no history of Pb 
      exposure or thyroid abnormalities and served as a control group. RESULTS: Mean
      blood lead levels (16.5+/-1.74 mug/dl) were significantly higher among the
      exposed workers compared to those of the control group (12.8+/-1.16 mug/dl, (p
      <0.001)). The exposed group had significantly increased free triiodothyronine
      (FT3), free thyroxine (FT4) and significantly decreased thyroid stimulating
      hormone (TSH) (1.77+/-0.44 muIU/ml), whereas the control group had a TSH level of
      2.61+/-0.94 muIU/ml (p< 0.0001). A state of oxidative stress was indicated by the
      significant increase in mean levels of malondialdehyde (MDA) and significant
      decrease in glutathione (GSH) (p < 0.0001). There was a significant positive
      correlation (r=0.358, p <0.05) between blood lead levels (BLL) and duration of
      employment, while BLL showed a significant negative correlation with TSH (r
      =-0.486, p <0.001), and GSH (r =-0.336, p <0.05). Of the occupationally exposed
      workers, 32.76% had elevated thyroid hormones. The results showed a significant
      positive relationship between GSH and TSH (beta coefficient=0.274, p < 0.05), MDA
      with FT3 (beta coefficient=0.355, p < 0.05) and FT4 (beta coefficient = 0.491, p 
      < 0.0001) among exposed workers. CONCLUSIONS: Workers exposed to Pb dust proved
      to be at risk for hyperthyroidism, which was found to have a significant role in 
      oxidative-antioxidant imbalance present among workers with increasing duration of
      exposure. PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: This study was approved
      by the Ethical Committee of the National Research Centre in Egypt (NRC) under the
      registration number 15225. COMPETING INTERESTS: The authors declare no competing 
      financial interests.
CI  - (c) Pure Earth 2020.
FAU - Fahim, Yosri A
AU  - Fahim YA
AUID- ORCID: https://orcid.org/0000-0002-1009-7577
AD  - Egyptian Mineral Resources Authority (EMRA), Cairo, Egypt.
AD  - Department of Biochemistry, Faculty of Science, Cairo University, Giza, Egypt.
FAU - Sharaf, Nevin E
AU  - Sharaf NE
AUID- ORCID: https://orcid.org/0000-0003-0485-9536
AD  - Department of Environmental and Occupational Medicine, National Research Centre, 
      Giza, Egypt.
FAU - Hasani, Ibrahim W
AU  - Hasani IW
AUID- ORCID: https://orcid.org/0000-0002-7333-5851
AD  - Department of Biochemistry, Faculty of Science, Idlip University and AL-Shamal
      Private University (SPU), Idlip, Syria.
FAU - Ragab, Eman A
AU  - Ragab EA
AUID- ORCID: https://orcid.org/0000-0002-7977-0221
AD  - Department of Organic Chemistry, Faculty of Science, Cairo University, Giza,
      Egypt.
FAU - Abdelhakim, Heba K
AU  - Abdelhakim HK
AUID- ORCID: https://orcid.org/0000-0001-6994-3283
AD  - Department of Biochemistry, Faculty of Science, Cairo University, Giza, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7453815
OTO - NOTNLM
OT  - antioxidant
OT  - foundry workers
OT  - lead
OT  - oxidative stress
OT  - thyroid hormones
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/06/20 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.5696/2156-9614-10.27.200903 [doi]
PST - epublish
SO  - J Health Pollut. 2020 Aug 19;10(27):200903. doi: 10.5696/2156-9614-10.27.200903. 
      eCollection 2020 Sep.


PMID- 32874757
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 27
DP  - 2020 Sep
TI  - Heavy Metals in Dialysis Fluid and Blood Samples from Hemodialysis Patients in
      Dialysis Centers in Baghdad, Iraq.
PG  - 200901
LID - 10.5696/2156-9614-10.27.200901 [doi]
AB  - BACKGROUND: The kidney is the first target organ of heavy metal toxicity due to
      its capacity to reabsorb and accumulate divalent metals. Hemodialysis therapy is 
      used to purify the blood of individuals with impaired kidney function. OBJECTIVE:
      The aim of the present study was to evaluate the relationship between dialysis
      fluid quality and the health of hemodialysis patients. METHODS: A field sampling 
      program was conducted to collect blood samples from 320 hemodialysis patients
      (56% males and 44% females) in order to examine the concentrations of heavy
      metals that typically occur in municipal water in Baghdad (aluminum (Al), copper 
      (Cu), lead (Pb), and zinc (Zn)), and explore associations with the same metals in
      dialysis fluid collected from four major dialysis centers in Baghdad hospitals
      for a period of one year (2018). RESULTS: The results showed that the dialysis
      fluid quality was not in compliance with international standards. The dialysis
      fluid in 63% of the samples contained high Al concentrations, while Cu and Zn
      concentrations were within international standards. Lead concentrations were
      elevated in dialysis fluid in some hospitals as well. DISCUSSION: The average
      blood levels of biologically important heavy elements were significantly varied
      in hemodialysis patients when compared with local reference values. CONCLUSIONS: 
      Since both deficiency and excess elements are potentially harmful, the hypothesis
      that heavy element status affects the risk of adverse clinical outcomes is a
      worthy investigation. PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: The study
      was approved by the Baghdad Ethics Committee of the Iraqi Ministry of Health and 
      Environment. COMPETING INTERESTS: The authors declare no competing financial
      interests.
CI  - (c) Pure Earth 2020.
FAU - Humudat, Yasamen Raad
AU  - Humudat YR
AUID- ORCID: https://orcid.org/0000-0002-7594-9531
FAU - Al-Naseri, Saadi Kadhim
AU  - Al-Naseri SK
AUID- ORCID: https://orcid.org/0000-0003-0056-3439
AD  - Environment and Water Directorate, Ministry of Science and Technology, Baghdad,
      Iraq.
LA  - eng
PT  - Journal Article
DEP - 20190819
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7453809
OTO - NOTNLM
OT  - chronic kidney disease
OT  - dialysis fluid
OT  - heavy metals
OT  - hemodialysis
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.5696/2156-9614-10.27.200901 [doi]
PST - epublish
SO  - J Health Pollut. 2019 Aug 19;10(27):200901. doi: 10.5696/2156-9614-10.27.200901. 
      eCollection 2020 Sep.


PMID- 32874640
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2054-5703 (Print)
IS  - 2054-5703 (Linking)
VI  - 7
IP  - 7
DP  - 2020 Jul
TI  - An unethical optimization principle.
PG  - 200462
LID - 10.1098/rsos.200462 [doi]
AB  - If an artificial intelligence aims to maximize risk-adjusted return, then under
      mild conditions it is disproportionately likely to pick an unethical strategy
      unless the objective function allows sufficiently for this risk. Even if the
      proportion eta of available unethical strategies is small, the probability p U of
      picking an unethical strategy can become large; indeed, unless returns are
      fat-tailed p U tends to unity as the strategy space becomes large. We define an
      unethical odds ratio, Upsilon (capital upsilon), that allows us to calculate p U 
      from eta, and we derive a simple formula for the limit of Upsilon as the strategy
      space becomes large. We discuss the estimation of Upsilon and p U in finite cases
      and how to deal with infinite strategy spaces. We show how the principle can be
      used to help detect unethical strategies and to estimate eta. Finally we sketch
      some policy implications of this work.
CI  - (c) 2020 The Authors.
FAU - Beale, Nicholas
AU  - Beale N
AUID- ORCID: 0000-0003-0586-0045
AD  - Sciteb Ltd, 23 Berkeley Square, London W1J 6HE, UK.
FAU - Battey, Heather
AU  - Battey H
AUID- ORCID: 0000-0001-9387-4628
AD  - Department of Mathematics, Imperial College London, 180 Queen's Gate, London SW7 
      2AZ, UK.
FAU - Davison, Anthony C
AU  - Davison AC
AUID- ORCID: 0000-0002-8537-6191
AD  - Institute of Mathematics, Ecole Polytechnique Federale de Lausanne, Station 8,
      1015 Lausanne, Switzerland.
FAU - MacKay, Robert S
AU  - MacKay RS
AUID- ORCID: 0000-0003-4771-3692
AD  - Mathematics Institute, University of Warwick, Coventry CV4 7AL, UK.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - R Soc Open Sci
JT  - Royal Society open science
JID - 101647528
PMC - PMC7428226
OTO - NOTNLM
OT  - AI ethics
OT  - artificial intelligence
OT  - economics
OT  - extreme value theory
OT  - financial regulation
COIS- At the time of writing, R.S.M. is an associate editor of Royal Society Open
      Science, but he had no involvement in the review or assessment of the paper.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - 10.1098/rsos.200462 [doi]
AID - rsos200462 [pii]
PST - epublish
SO  - R Soc Open Sci. 2020 Jul 1;7(7):200462. doi: 10.1098/rsos.200462. eCollection
      2020 Jul.


PMID- 32874425
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20220416
IS  - 1937-8688 (Electronic)
VI  - 36
DP  - 2020
TI  - Microalbuminuria in type 1 diabetes mellitus children in University of Port
      Harcourt Teaching Hospital, Nigeria.
PG  - 161
LID - 10.11604/pamj.2020.36.161.23782 [doi]
AB  - INTRODUCTION: glycaemic control is usually best achieved using the basal bolus
      regimen, however, this is not always available in resource-limited settings.
      Long-term complications like renal parenchymal disease are consequences of poor
      glycaemic control. Screening type 1 diabetes patients irrespective of their
      disease duration was used to buttress the need for ethical principles of justice 
      to be incorporated in the care of type 1 diabetes children. METHODS: urine
      albumin creatinine ratio (UAC) was calculated for 20 type 1 diabetes mellitus
      children in the endocrinology clinic after submitting early morning urine over a 
      4-month period. The calculated ratio was compared between duration of disease (< 
      5 years and > 5 years) and between insulin regimen types (mixtard and basal
      bolus). Repeat tests were done for children who had elevated UAC ratio levels
      after 2 months. RESULTS: there were 5 males and 15 females and the mean UAC ratio
      of the cohort was 123mg/g with a range of 5.30 - 906 mg/g. Twelve children (8
      diagnosed less than 5 years) had UAC ratio >/= 30mg/g with a mean of 193.15. The 
      repeat mean UAC ratio for these was 144.35 mg/g. Children who had diabetes for
      more than 5 years and were on mixtard had higher UAC ratio than those with
      diabetes < 5 years and on basal bolus. CONCLUSION: the prevalence of
      microalbuminuria is high in our cohort of type 1 diabetes children and these were
      children on mixtard and had diabetes greater than 5 years.
CI  - Copyright: Iroro Enameguolo Yarhere et al.
FAU - Yarhere, Iroro Enameguolo
AU  - Yarhere IE
AD  - Endocrinology Unit, Paediatrics Department, University of Port Harcourt Teaching 
      Hospital, Port Harcourt, Nigeria.
FAU - Jaja, Tamunopriye
AU  - Jaja T
AD  - Endocrinology Unit, Paediatrics Department, University of Port Harcourt Teaching 
      Hospital, Port Harcourt, Nigeria.
FAU - Anolue, Mirabelle
AU  - Anolue M
AD  - Endocrinology Unit, Paediatrics Department, University of Port Harcourt Teaching 
      Hospital, Port Harcourt, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adolescent
MH  - Albuminuria/diagnosis/*epidemiology/etiology/metabolism
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 1/blood/complications/*epidemiology/urine
MH  - Diabetic Nephropathies/blood/diagnosis/*epidemiology/urine
MH  - Female
MH  - Hospitals, Teaching
MH  - Humans
MH  - Male
MH  - Nigeria/epidemiology
MH  - Prevalence
MH  - Urinalysis
PMC - PMC7436630
OTO - NOTNLM
OT  - Diabetes
OT  - basal bolus
OT  - justice
OT  - microalbuminuria
OT  - mixtard
COIS- The authors declare no competing interests.
EDAT- 2020/09/03 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.11604/pamj.2020.36.161.23782 [doi]
AID - PAMJ-36-161 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Jul 7;36:161. doi: 10.11604/pamj.2020.36.161.23782.
      eCollection 2020.


PMID- 32874417
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20201218
IS  - 1937-8688 (Electronic)
VI  - 36
DP  - 2020
TI  - Oncology practice in the COVID-19 pandemic: a report of a Nigerian expert panel
      discussion (oncology care in Nigeria during the COVID-19 pandemic).
PG  - 153
LID - 10.11604/pamj.2020.36.153.23662 [doi]
AB  - Since the first case of COVID-19 and its progression to a pandemic, healthcare
      systems the world over have experienced severe difficulties coping with patient
      care for both COVID-19 and other diseases most especially non communicable
      diseases like cancer. These difficulties in Low- and middle-income countries
      (LMICs), especially in Sub-Saharan Africa including Nigeria, are myriad. These
      LMICs are already bedeviled weak health systems, ill equipped cancer treatment
      centers, with outdated machines and grossly inadequate numbers of oncologists
      required to treat patients with cancer. As a result of these challenges coupled
      with unclear guidelines on how to manage cancer patients in the wake of the
      COVID-19 pandemic, 11 key Nigerian opinion leaders had a consensus meeting to
      identify challenges and possible workable solutions on continuing cancer care
      during the COVID-19 pandemic. The discussion highlighted ethical issues, barriers
      to continuing cancer care (such as lockdown, fear of contracting disease,
      downscaled health services) and resource constraints such unavailable personal
      protective equipment. Yet, practical solutions were proffered such as necessary
      protective measures, case by case prioritization or de-prioritization,
      telemedicine and other achievable means in the Nigerian setting.
CI  - Copyright: Adeniyi Adedayo Olabumuyi et al.
FAU - Olabumuyi, Adeniyi Adedayo
AU  - Olabumuyi AA
AD  - Radiation Oncology Department, University College Hospital, Ibadan, Nigeria.
FAU - Ali-Gombe, Musa
AU  - Ali-Gombe M
AD  - Department of Radiology, College of Medical Sciences, Gombe State University,
      Nigeria.
FAU - Biyi-Olutunde, Olusegun Abayomi
AU  - Biyi-Olutunde OA
AD  - University of Port-Harcourt Teaching Hospital, Port-Harcourt, Rivers State,
      Nigeria.
FAU - Gbolahan, Olumide
AU  - Gbolahan O
AD  - University of Alabama, Birmingham, USA.
FAU - Iwuji, Chinenye Oluchi
AU  - Iwuji CO
AD  - Oncology Department, Leicester Royal Infirmary, Leicester, UK.
FAU - Joseph, Adedayo Olufemi
AU  - Joseph AO
AD  - NSIA-LUTH Cancer Centre, Lagos University Teaching Hospital, Lagos, Nigeria.
FAU - Lasebikan, Nwamaka Ngozika
AU  - Lasebikan NN
AD  - Department of Radiation Medicine, University of Nigeria Teaching Hospital, Enugu,
      Nigeria.
FAU - Ogunnorin, Babatunde Olutoye
AU  - Ogunnorin BO
AD  - Radiation Oncology Department, University of Ibadan, Ibadan, Nigeria.
FAU - Omikunle, Adebowale Emmanuel
AU  - Omikunle AE
AD  - Breast Cancer Squad, ROCHE Products Nigeria Ltd. Nigeria.
FAU - Salako, Omolola
AU  - Salako O
AD  - College of Medicine, University of Lagos, Lagos, Nigeria.
FAU - Salawu, Abdulazeez
AU  - Salawu A
AD  - Nottingham University Hospitals, NHS Trust, UK.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Delivery of Health Care/*organization & administration
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/*therapy
MH  - Nigeria/epidemiology
MH  - Pandemics/prevention & control
MH  - Personal Protective Equipment/supply & distribution
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Telemedicine/organization & administration
PMC - PMC7436648
OTO - NOTNLM
OT  - COVID-19
OT  - Low- and middle-income countries
OT  - Personal protective equipment
OT  - cancer
OT  - guidelines
COIS- The authors declare no competing interests.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - 10.11604/pamj.2020.36.153.23662 [doi]
AID - PAMJ-36-153 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Jul 6;36:153. doi: 10.11604/pamj.2020.36.153.23662.
      eCollection 2020.


PMID- 32873998
OWN - NLM
STAT- MEDLINE
DCOM- 20210713
LR  - 20210713
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Linking)
VI  - 52
IP  - 3
DP  - 2020 May-Jun
TI  - Understanding the challenges and ethical aspects of compassionate use of drugs in
      emergency situations.
PG  - 163-171
LID - 10.4103/ijp.IJP_665_20 [doi]
FAU - Goyal, Pardeep Kumar
AU  - Goyal PK
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Mathur, Roli
AU  - Mathur R
AD  - ICMR Bioethics Unit, ICMR-National Centre for Disease Informatics and Research,
      Bengaluru, Karnataka, India.
FAU - Medhi, Bikash
AU  - Medhi B
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
LA  - eng
PT  - Editorial
DEP - 20200804
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
SB  - IM
MH  - Clinical Decision-Making
MH  - Compassionate Use Trials/*ethics
MH  - Drug Therapy/*ethics
MH  - *Emergencies
MH  - Humans
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC7446672
EDAT- 2020/09/03 06:00
MHDA- 2021/07/14 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/07/09 00:00 [received]
PHST- 2020/07/18 00:00 [revised]
PHST- 2020/07/18 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/07/14 06:00 [medline]
AID - 10.4103/ijp.IJP_665_20 [doi]
AID - IJPharm-52-163 [pii]
PST - ppublish
SO  - Indian J Pharmacol. 2020 May-Jun;52(3):163-171. doi: 10.4103/ijp.IJP_665_20. Epub
      2020 Aug 4.


PMID- 32873975
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20211204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 585
IP  - 7823
DP  - 2020 Sep
TI  - More testing alone will not get us out of this pandemic.
PG  - 8
LID - 10.1038/d41586-020-02495-y [doi]
FAU - Parthasarathy, Shobita
AU  - Parthasarathy S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Centers for Disease Control and Prevention, U.S./legislation & jurisprudence
MH  - *Clinical Laboratory Techniques
MH  - Contact Tracing
MH  - Coronavirus Infections/*diagnosis/epidemiology/*prevention & control/transmission
MH  - HIV Infections/prevention & control/transmission
MH  - *Healthcare Disparities
MH  - Hispanic or Latino
MH  - Humans
MH  - Oximetry
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*diagnosis/epidemiology/*prevention & control/transmission
MH  - *Problem Solving
MH  - Singapore/epidemiology
MH  - Soccer
MH  - Social Marginalization
MH  - United Kingdom/epidemiology
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *Ethics
OT  - *Infection
OT  - *SARS-CoV-2
OT  - *Society
EDAT- 2020/09/03 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - 10.1038/d41586-020-02495-y [doi]
AID - 10.1038/d41586-020-02495-y [pii]
PST - ppublish
SO  - Nature. 2020 Sep;585(7823):8. doi: 10.1038/d41586-020-02495-y.


PMID- 32873939
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20201020
LR  - 20220416
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 585
IP  - 7825
DP  - 2020 Sep
TI  - Don't be a prig in peer review.
PG  - 472
LID - 10.1038/d41586-020-02512-0 [doi]
FAU - Clements, Jeff C
AU  - Clements JC
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Res Integr Peer Rev. 2020 Jul 24;5:9. PMID: 32760597
OTO - NOTNLM
OT  - *Careers
OT  - *Ethics
OT  - *Publishing
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1038/d41586-020-02512-0 [doi]
AID - 10.1038/d41586-020-02512-0 [pii]
PST - ppublish
SO  - Nature. 2020 Sep;585(7825):472. doi: 10.1038/d41586-020-02512-0.


PMID- 32873686
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Theory-based mobile phone text messaging intervention for blood pressure control 
      (TEXT4BP) among hypertensive patients in Nepal: study protocol for a feasibility 
      randomised controlled trial.
PG  - e040799
LID - 10.1136/bmjopen-2020-040799 [doi]
AB  - INTRODUCTION: Uncontrolled blood pressure is one of the main risk factors for
      cardiovascular disease and death in Low-income and middle-income countries.
      Improvements to medication adherence and lifestyle changes can be assisted by
      using mobile phone text messaging interventions. This study aims to test the
      feasibility and acceptability of a text messaging intervention for blood pressure
      control '(TEXT4BP)', developed based on behavioural change theory to improve
      treatment adherence and lifestyle change among hypertensive patients in Nepal.
      METHODS AND ANALYSIS: The TEXT4BP intervention will be tested using a two-arm
      parallel-group, unblinded, individually randomised controlled trial. This
      feasibility study would recruit 200 clinically diagnosed hypertensive patients
      aged 18-69 years, currently receiving blood pressure-lowering medication for more
      than 3 months, visiting a tertiary healthcare facility in Kathmandu, Nepal. A
      nested qualitative study will assess the acceptability of the short message
      service intervention. The intervention group will receive text messages
      containing information on hypertension, diet, medication and physical activity
      three times a week for 3 months. The control group will receive standard care. At
      baseline and 3 months, measures of medication adherence, salt intake, physical
      activity and blood pressure will be collected. Feasibility measures, such as
      differential rates of recruitment and attrition rates, will be calculated.
      Acceptability of text message interventions will be studied using usability
      measures and in-depth interviews among intervention group participants. This
      pilot study is not funded. ETHICS AND DISSEMINATION: This study has received
      ethics approval from the University of New South Wales Human Research Ethics
      Committee B (HC190357), Nepal Health Research Council (302/2019) and
      Institutional Review Committee of Kathmandu Medical College and Teaching Hospital
      Kathmandu, Nepal (030520192). The findings of the study will be disseminated
      through peer-reviewed publications and conference presentations. TRIAL
      REGISTRATION NUMBER: ACTRN12619001213134.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bhandari, Buna
AU  - Bhandari B
AUID- ORCID: 0000-0002-0102-8844
AD  - School of Public Health and Community Medicine, University of New South Wales,
      Sydney, New South Wales, Australia buna.bhandari@gmail.com.
AD  - Central Department of Public Health, Tribhuvan University Institute of Medicine, 
      Kathmandu, Nepal.
FAU - Narasimhan, Padmanesan
AU  - Narasimhan P
AUID- ORCID: 0000-0002-2020-0865
AD  - School of Public Health and Community Medicine, University of New South Wales,
      Sydney, New South Wales, Australia.
FAU - Vaidya, Abhinav
AU  - Vaidya A
AUID- ORCID: 0000-0001-5523-3459
AD  - Department of Community Medicine, Kathmandu Medical College, Kathmandu, Nepal.
FAU - Jayasuriya, Rohan
AU  - Jayasuriya R
AUID- ORCID: 0000-0003-3108-2304
AD  - School of Public Health and Community Medicine, University of New South Wales,
      Sydney, New South Wales, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Blood Pressure
MH  - *Cell Phone
MH  - Feasibility Studies
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Middle Aged
MH  - Nepal
MH  - Pilot Projects
MH  - Randomized Controlled Trials as Topic
MH  - *Text Messaging
MH  - Young Adult
PMC - PMC7467528
OTO - NOTNLM
OT  - *hypertension
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040799 [pii]
AID - 10.1136/bmjopen-2020-040799 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e040799. doi: 10.1136/bmjopen-2020-040799.


PMID- 32873685
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Impact of COVID-19 and other pandemics and epidemics on people with pre-existing 
      mental disorders: a systematic review protocol and suggestions for clinical care.
PG  - e040229
LID - 10.1136/bmjopen-2020-040229 [doi]
AB  - INTRODUCTION: The current COVID-19 pandemic has resulted in high rates of
      infection and death, as well as widespread social disruption and a reduction in
      access to healthcare services and support. There is growing concern over how the 
      pandemic, as well as measures put in place to curb the pandemic, will impact
      people with mental disorders. We aim to study the effect of pandemics and
      epidemics on mental health outcomes for people with premorbid mental disorders.
      METHODS AND ANALYSIS: With our predefined search strategy, we will search five
      databases for studies reporting on mental health outcomes in people with
      pre-existing mental disorders during pandemic and epidemic settings. Search dates
      are planned as follows: 5 May 2020 and 23 July 2020. The following databases will
      be searched: MEDLINE/PubMed, CINAHL, PsycINFO, MedRxiv and EMBASE. Data will be
      screened and extracted in duplicate by two independent reviewers. Studies
      involving non-clinical populations or patients diagnosed with a mental disorder
      during a pandemic/epidemic will be excluded. We will include data collected from 
      all pandemics and epidemics throughout history, including the present COVID-19
      pandemic. If possible, study findings will be combined in meta-analyses, and
      subgroup analyses will be performed. We hope that this review will shed light on 
      the impact of pandemics and epidemics on those with pre-existing mental
      disorders. Knowledge generated may inform future intervention studies as well as 
      healthcare policies. Given the potential implications of the current pandemic
      measures (ie, disruption of healthcare services) on mental health, we will also
      compile a list of existing mental health resources. ETHICS AND DISSEMINATION: No 
      ethical approval is required for this protocol and proposed systematic review as 
      we will only use data from previously published papers that have themselves
      received ethics clearance and used proper informed consent procedures. SYSTEMATIC
      REVIEW REGISTRATION: PROSPERO registration number: CRD42020179611.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sergeant, Anjali
AU  - Sergeant A
AUID- ORCID: 0000-0002-2076-8901
AD  - Undergraduate Medical Education Program, Michael G. DeGroote School of Medicine, 
      McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
FAU - van Reekum, Emma Alaine
AU  - van Reekum EA
AD  - Department of Psychiatry and Behavioural Neurosciences, McMaster University
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
FAU - Sanger, Nitika
AU  - Sanger N
AUID- ORCID: 0000-0002-5883-1873
AD  - Medical Science Graduate Program, McMaster University, Hamilton, Ontario, Canada.
FAU - Dufort, Alexander
AU  - Dufort A
AD  - Department of Psychiatry and Behavioural Neurosciences, McMaster University
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
FAU - Rosic, Tea
AU  - Rosic T
AUID- ORCID: 0000-0001-7406-4056
AD  - Department of Psychiatry and Behavioural Neurosciences, McMaster University
      Faculty of Health Sciences, Hamilton, Ontario, Canada.
FAU - Sanger, Stephanie
AU  - Sanger S
AD  - Health Sciences Library, McMaster University, Hamilton, Ontario, Canada.
FAU - Lubert, Sandra
AU  - Lubert S
AD  - Community member, Hamilton, Ontario, Canada.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AUID- ORCID: 0000-0001-5855-5461
AD  - Department of Health Research, Evidence and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research, Evidence and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Samaan, Zainab
AU  - Samaan Z
AUID- ORCID: 0000-0002-5974-9361
AD  - Department of Psychiatry and Behavioural Neurosciences, McMaster University
      Faculty of Health Sciences, Hamilton, Ontario, Canada samaanz@mcmaster.ca.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/methods/organization & administration
MH  - *Coronavirus Infections/epidemiology/prevention & control/psychology
MH  - Health Services Accessibility
MH  - Humans
MH  - *Mental Disorders/epidemiology/therapy
MH  - *Mental Health
MH  - Mental Health Services/*supply & distribution
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - *Pneumonia, Viral/epidemiology/prevention & control/psychology
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
PMC - PMC7467512
OTO - NOTNLM
OT  - *COVID-19
OT  - *adult psychiatry
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *psychiatry
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - bmjopen-2020-040229 [pii]
AID - 10.1136/bmjopen-2020-040229 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e040229. doi: 10.1136/bmjopen-2020-040229.


PMID- 32873683
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - The burden of non-specific chronic low back pain among adults in KwaZulu-Natal,
      South Africa: a protocol for a mixed-methods study.
PG  - e039554
LID - 10.1136/bmjopen-2020-039554 [doi]
AB  - INTRODUCTION: Low back pain (LBP) is a major public health concern, affecting
      individuals of all age groups across the world. In about 90% of LBP cases, there 
      is no specific cause identified and is, therefore, referred to as non-specific
      LBP. Due to the non-specific nature of LBP, investigations such as radiological
      and laboratory investigations are unnecessary and results to delayed diagnosis
      and improper treatment culminating in LBP progressing into chronic LBP (CLBP).
      LBP is now the leading cause of disability with a significant socioeconomic
      burden. Despite all these challenges, CLBP is regarded as a trivial condition in 
      low-and-middle-income countries and remains poorly investigated. The distribution
      of CLBP in Africa is unclear. METHODS AND ANALYSIS: The research will be
      conducted in two phases. The initial phase will be an observational,
      cross-sectional hospital-based study that will be recruiting 650 participants, to
      determine the prevalence and risk factors of CLBP. A standardised questionnaire
      will be used to collect baseline data on the socio-demographic characteristics of
      participants and other variables of interest (exercise history, occupational
      posture, level of education and the income status). Disability will be assessed
      using the Oswestry Disability Questionnaire and the psychological risk factors
      will be assessed using the Illness-Behaviour Questionnaire (IBQ) and the
      Fear-Avoidance Belief Questionnaire (FABQ). The second phase will be a
      retrospective, top-down, prevalence-based cost-of-illness study of the 2018-2019 
      health records, to estimate the burden of CLBP from the healthcare system's
      perspective. The SPSS V.25.0 statistical package will be used for data entry and 
      analysis. Statistical analysis will include descriptive statistics by means of
      graphs and cross tabulations, inferential statistics by means of logistic
      regression and chi(2) test. A p value of 0.05 will be deemed statistically
      significant. ETHICS AND DISSEMINATION: This protocol was approved by the
      University of KwaZulu-Natal's Biomedical Research Ethics Committee (Ref. No.:
      BREC/00000205/2019) and the KwaZulu-Natal Department of Health Research Ethics
      (Ref. No.: KZ_201909_002). This will be the first LBP cost-of-illness study in
      the sub-Saharan Africa, and, therefore, it will close these knowledge gaps and
      present important evidence on the estimated burden of CLBP in this context. The
      results of this study will be presented to the Department of Health and to the
      respective stakeholders and decision-makers to discuss the findings and draw
      their attention to the prioritisation of LBP research, its management, prevention
      programmes and implementation of educational programme and for the planning of
      cost-containment policies.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kahere, Morris
AU  - Kahere M
AUID- ORCID: 0000-0003-3669-9768
AD  - Department of Public Health Medicine, College of Health Sciences, University of
      KwaZulu-Natal, Durban, South Africa mrrskhr@gmail.com.
FAU - Ginindza, Themba
AU  - Ginindza T
AD  - Discipline of Public Health, School of Nursing and Public Health, University of
      KwaZulu-Natal, Durban, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Low Back Pain/epidemiology
MH  - Retrospective Studies
MH  - South Africa/epidemiology
MH  - Surveys and Questionnaires
PMC - PMC7467525
OTO - NOTNLM
OT  - *epidemiology
OT  - *health economics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039554 [pii]
AID - 10.1136/bmjopen-2020-039554 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e039554. doi: 10.1136/bmjopen-2020-039554.


PMID- 32873682
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Use of compression therapy to treat lower limb wounds across Europe: a scoping
      review protocol.
PG  - e039008
LID - 10.1136/bmjopen-2020-039008 [doi]
AB  - INTRODUCTION: Poor lower wound care is an avoidable patient harm. Compression
      therapy is an effective way of treating non-ischaemic lower limbs wounds, but it 
      is not always used appropriately. There are many guidelines which set out how
      compression therapy should be used, but there is dearth of evidence about how it 
      is actually used at a population level across Europe. AIM: The aim of this
      scoping review is to map the evidence published in English relating to the use of
      compression therapy to treat lower limb wounds across Europe. METHODS: This
      scoping review will be conducted in line with the Joanna Briggs Institute and
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 
      and Scoping Reviews guidance. A search for relevant publications will be
      conducted on variety of databases and key websites in order to identify a
      comprehensive range of relevant literature. Peer reviewed empirical papers,
      theoretical papers and other publications in English relating to the use of
      compression therapy across Europe will be considered for inclusion. ETHICS AND
      DISSEMINATION: Ethical and research governance for this scoping review is not
      required because we will only gather secondary data. Our results will be
      disseminated to the widest possible audience through an open access paper in a
      peer reviewed international journal, conference presentations and a plain English
      summary. The results of this scoping review will be used by a panel of Key
      Opinion Leaders from across Europe to develop a driver diagram to underpin
      subsequent lower limb wound care improvement efforts.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Samuriwo, Ray
AU  - Samuriwo R
AUID- ORCID: 0000-0001-5954-0501
AD  - School of Healthcare Sciences, Cardiff University College of Biomedical and Life 
      Sciences, Cardiff, UK samuriwor@cardiff.ac.uk.
AD  - Wales Centre for Evidence Based Care, School of Healthcare Sciences, Cardiff
      University, Cardiff, Wales, United Kingdom.
FAU - Christiansen, Natalia
AU  - Christiansen N
AD  - European Wound Management Association, Frederiksberg, Denmark.
FAU - Hopkins, Alison
AU  - Hopkins A
AD  - Accelerate CIC, St Joseph's Hospice, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Europe
MH  - Humans
MH  - Lower Extremity
MH  - *Peer Review
MH  - Publications
MH  - *Research Report
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7467513
OTO - NOTNLM
OT  - *health services administration & management
OT  - *therapeutics
OT  - *wound management
COIS- Competing interests: One of the authors, NC is employed by the European Wound
      Management Association.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039008 [pii]
AID - 10.1136/bmjopen-2020-039008 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e039008. doi: 10.1136/bmjopen-2020-039008.


PMID- 32873681
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210523
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre
      randomised trial comparing (extended) pleurectomy decortication versus no
      (extended) pleurectomy decortication for patients with malignant pleural
      mesothelioma.
PG  - e038892
LID - 10.1136/bmjopen-2020-038892 [doi]
AB  - INTRODUCTION: Mesothelioma remains a lethal cancer. To date, systemic therapy
      with pemetrexed and a platinum drug remains the only licensed standard of care.
      As the median survival for patients with mesothelioma is 12.1 months, surgery is 
      an important consideration to improve survival and/or quality of life. Currently,
      only two surgical trials have been performed which found that neither extensive
      (extra-pleural pneumonectomy) or limited (partial pleurectomy) surgery improved
      survival (although there was some evidence of improved quality of life).
      Therefore, clinicians are now looking to evaluate pleurectomy decortication, the 
      only radical treatment option left. METHODS AND ANALYSIS: The MARS 2 study is a
      UK multicentre open parallel group randomised controlled trial comparing the
      effectiveness and cost-effectiveness of surgery-(extended) pleurectomy
      decortication-versus no surgery for the treatment of pleural mesothelioma. The
      study will test the hypothesis that surgery and chemotherapy is superior to
      chemotherapy alone with respect to overall survival. Secondary outcomes include
      health-related quality of life, progression-free survival, measures of safety
      (adverse events) and resource use to 2 years. The QuinteT Recruitment
      Intervention is integrated into the trial to optimise recruitment. ETHICS AND
      DISSEMINATION: Research ethics approval was granted by London - Camberwell St.
      Giles Research Ethics Committee (reference 13/LO/1481) on 7 November 2013. We
      will submit the results for publication in a peer-reviewed journal. TRIAL
      REGISTRATION NUMBERS: ISRCTN-ISRCTN44351742 and ClinicalTrials.gov-NCT02040272.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lim, Eric
AU  - Lim E
AD  - Academic Division of Thoracic Surgery, Royal Brompton and Harefield NHS Trust,
      London, UK e.lim@rbht.nhs.uk.
FAU - Darlison, Liz
AU  - Darlison L
AD  - The Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester,
      UK.
AD  - Mesothelioma UK, Glenfield Hospital, Leicester, UK.
FAU - Edwards, John
AU  - Edwards J
AD  - Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Elliott, Daisy
AU  - Elliott D
AD  - Population Health Sciences, University of Bristol, Bristol, UK.
FAU - Fennell, D A
AU  - Fennell DA
AD  - Cancer Research UK Centre Leicester, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
FAU - Popat, Sanjay
AU  - Popat S
AD  - Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK.
FAU - Rintoul, Robert C
AU  - Rintoul RC
AD  - Department of Thoracic Oncology, Papworth Hospital NHS Foundation Trust,
      Cambridge, UK.
FAU - Waller, David
AU  - Waller D
AD  - Department of Thoracic Surgery, Barts Health NHS Trust, London, UK.
FAU - Ali, Clinton
AU  - Ali C
AD  - The Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, 
      UK.
FAU - Bille, Andrea
AU  - Bille A
AD  - Thoracic Surgery, Guy's and Saint Thomas' Hospitals NHS Trust, London, UK.
FAU - Fuller, Liz
AU  - Fuller L
AD  - Respiratory Medicine, South Tyneside NHS Foundation Trust, South Shields, UK.
FAU - Ionescu, Andreea
AU  - Ionescu A
AD  - Lung Cancer, Aneurin Bevan University Health Board, Newport, UK.
FAU - Keni, Manjusha
AU  - Keni M
AD  - Oncology, Derby Teaching Hospitals NHS Foundation Trust, Derby, UK.
FAU - Kirk, Alan
AU  - Kirk A
AD  - Department of Thoracic Surgery, Golden Jubilee National Hospital, Clydebank, UK.
FAU - Koh, Pek
AU  - Koh P
AD  - Department of Oncology, New Cross Hospital, Wolverhampton, UK.
FAU - Lau, Kelvin
AU  - Lau K
AD  - Department of Thoracic Surgery, Barts Health NHS Trust, London, UK.
FAU - Mansy, Talal
AU  - Mansy T
AD  - Oncology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.
FAU - Maskell, Nick A
AU  - Maskell NA
AD  - Academic Respiratory Unit, School of Clinical Sciences, University of Bristol,
      Bristol, UK.
AD  - Respiratory Research Unit, North Bristol NHS Trust, Westbury on Trym, UK.
FAU - Milton, Richard
AU  - Milton R
AD  - Thoracic Surgery Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Muthukumar, Dakshinamoorthy
AU  - Muthukumar D
AD  - Oncology, Colchester Hospital University NHS Foundation Trust, Colchester, UK.
FAU - Pope, Tony
AU  - Pope T
AD  - Clatterbridge Cancer Centre, Clatterbridge Cancer Centre NHS Foundation Trust,
      Bebington, UK.
FAU - Roy, Amy
AU  - Roy A
AD  - Plymouth Oncology Centre, University Hospitals Plymouth NHS Trust, Plymouth, UK.
FAU - Shah, Riyaz
AU  - Shah R
AD  - Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
FAU - Shamash, Jonathan
AU  - Shamash J
AD  - Department of Medical Oncology, Barts Health NHS Trust, London, UK.
FAU - Tasigiannopoulos, Zacharias
AU  - Tasigiannopoulos Z
AD  - The Oncology Care Team, Norfolk and Norwich University Hospital NHS Trust,
      Norwich, UK.
FAU - Taylor, Paul
AU  - Taylor P
AD  - Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
FAU - Treece, Sarah
AU  - Treece S
AD  - Heamatology and Oncology Unit, North West Anglia NHS Foundation Trust,
      Peterborough, UK.
FAU - Ashton, Kate
AU  - Ashton K
AD  - Bristol Trials Centre (CTEU), University of Bristol, Bristol, UK.
FAU - Harris, Rosie
AU  - Harris R
AD  - Bristol Trials Centre (CTEU), University of Bristol, Bristol, UK.
FAU - Joyce, Katherine
AU  - Joyce K
AD  - Bristol Trials Centre (CTEU), University of Bristol, Bristol, UK.
FAU - Warnes, Barbara
AU  - Warnes B
AUID- ORCID: 0000-0002-1326-0448
AD  - Bristol Trials Centre (CTEU), University of Bristol, Bristol, UK.
FAU - Mills, Nicola
AU  - Mills N
AD  - Population Health Sciences, University of Bristol, Bristol, UK.
FAU - Stokes, Elizabeth A
AU  - Stokes EA
AUID- ORCID: 0000-0002-4179-1369
AD  - Health Economics Research Centre, Nuffield Department of Population Health,
      University of Oxford, Oxford, UK.
FAU - Rogers, Chris
AU  - Rogers C
AD  - Bristol Trials Centre (CTEU), University of Bristol, Bristol, UK.
CN  - MARS 2 Trialists
LA  - eng
SI  - ClinicalTrials.gov/NCT02040272
SI  - ISRCTN/ISRCTN44351742
GR  - 15/188/31/DH_/Department of Health/United Kingdom
GR  - MR/K025643/1/MRC_/Medical Research Council/United Kingdom
GR  - CRUK_/Cancer Research UK/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - London
MH  - *Lung Neoplasms/surgery
MH  - *Mesothelioma/surgery
MH  - *Mesothelioma, Malignant
MH  - Multicenter Studies as Topic
MH  - *Pleural Neoplasms/surgery
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7467531
OTO - NOTNLM
OT  - *chemotherapy
OT  - *oncology
OT  - *thoracic medicine
OT  - *thoracic surgery
COIS- Competing interests: None declared.
IR  - Gravani A
FIR - Gravani, Athanasia
IR  - McKeon H
FIR - McKeon, Holly
IR  - Underwood W
FIR - Underwood, Wendy
IR  - Brophy R
FIR - Brophy, Rachel
IR  - Farrar N
FIR - Farrar, Nicola
IR  - Hughes V
FIR - Hughes, Victoria
IR  - Elliott J
FIR - Elliott, Jane
IR  - Matthews C
FIR - Matthews, Claire
IR  - Noyes P
FIR - Noyes, Philip
IR  - Nakas A
FIR - Nakas, Apostolos
IR  - Nelson L
FIR - Nelson, Louise
IR  - Tenconi S
FIR - Tenconi, Sara
IR  - Socci L
FIR - Socci, Laura
IR  - Wood H
FIR - Wood, Hilary
IR  - Hanratty H
FIR - Hanratty, Helena
IR  - Stanley H
FIR - Stanley, Helena
IR  - Moore J
FIR - Moore, Judith
IR  - Rintoul R
FIR - Rintoul, Robert
IR  - Miller S
FIR - Miller, Suzanne
IR  - Gladwell A
FIR - Gladwell, Amy
IR  - Castedo J
FIR - Castedo, Jenny
IR  - Stone A
FIR - Stone, Amanda
IR  - Ingle C
FIR - Ingle, Charlotte
IR  - Hewer H
FIR - Hewer, Hayley
IR  - Li L
FIR - Li, Louise
IR  - Aynsley E
FIR - Aynsley, Eleanor
IR  - Watson A
FIR - Watson, Andrea
IR  - Jacobs C
FIR - Jacobs, Charlotte
IR  - Hassall A
FIR - Hassall, Alison
IR  - Begum M
FIR - Begum, Masuma
IR  - Worth C
FIR - Worth, Christopher
IR  - Piggott E
FIR - Piggott, Ellie
IR  - Nadin E
FIR - Nadin, Elizabeth
IR  - Ashford-Turner V
FIR - Ashford-Turner, Victoria
IR  - Callister M
FIR - Callister, Matthew
IR  - Summers Y
FIR - Summers, Yvonne
IR  - Califano R
FIR - Califano, Raffaele
IR  - Cove-Smith L
FIR - Cove-Smith, Laura
IR  - Evison M
FIR - Evison, Matt
IR  - Blinston M
FIR - Blinston, Maria
IR  - Waplington S
FIR - Waplington, Sara
IR  - Ismail A
FIR - Ismail, Amal
IR  - Chant R
FIR - Chant, Rachel
IR  - Desai A
FIR - Desai, Asmita
IR  - Novasio J
FIR - Novasio, Juliette
IR  - Kirwan M
FIR - Kirwan, Marie
IR  - Morgan I
FIR - Morgan, Ian
IR  - Lake V
FIR - Lake, Victoria
IR  - Harris N
FIR - Harris, Nichola
IR  - Hodge S
FIR - Hodge, Simon
IR  - Yousaf N
FIR - Yousaf, Nadia
IR  - Tokaca N
FIR - Tokaca, Nadza
IR  - Januszewski A
FIR - Januszewski, Adam
IR  - Athauda A
FIR - Athauda, Avani
IR  - Ramessur A
FIR - Ramessur, Anisha
IR  - Grist E
FIR - Grist, Emily
IR  - Colman N
FIR - Colman, Niamh
IR  - Flynn M
FIR - Flynn, Michael
IR  - Joyce J
FIR - Joyce, Joan
IR  - Vaughan S
FIR - Vaughan, Sarah
IR  - Piga M
FIR - Piga, Maria
IR  - Sahin D
FIR - Sahin, Derya
IR  - Yongue A
FIR - Yongue, Agnieszka
IR  - Turay E
FIR - Turay, Emma
IR  - O'Brien M
FIR - O'Brien, Mary
IR  - Bhosle J
FIR - Bhosle, Jaishree
IR  - Kumar R
FIR - Kumar, Rajiv
IR  - Milner-Watts C
FIR - Milner-Watts, Charlotte
IR  - Brown J
FIR - Brown, Jessica
IR  - Walder D
FIR - Walder, David
IR  - Georgiou A
FIR - Georgiou, Alexandros
IR  - Wu X
FIR - Wu, Xiaorong
IR  - Kaudeer N
FIR - Kaudeer, Naila
IR  - Joshi K
FIR - Joshi, Kroopa
IR  - Davidson M
FIR - Davidson, Michael
IR  - Khakoo S
FIR - Khakoo, Shelize
IR  - Ayite B
FIR - Ayite, Bee
IR  - Priest K
FIR - Priest, Kathryn
IR  - Dobbyn J
FIR - Dobbyn, James
IR  - Prathapan V
FIR - Prathapan, Vasanthi
IR  - McCrimmon D
FIR - McCrimmon, Deborah
IR  - Ash N
FIR - Ash, Natalie
IR  - Norton A
FIR - Norton, Alison
IR  - Peet B
FIR - Peet, Bianca
IR  - Hennessy L
FIR - Hennessy, Libby
IR  - Johnson R
FIR - Johnson, Rosemary
IR  - White L
FIR - White, Laura
IR  - Armstrong E
FIR - Armstrong, Edward
IR  - Coakley M
FIR - Coakley, Maria
IR  - Shepherd S
FIR - Shepherd, Scott
IR  - Chaabouni N
FIR - Chaabouni, Narda
IR  - Sreter K
FIR - Sreter, Katherina
IR  - Angelis V
FIR - Angelis, Vasileios
IR  - Morishita M
FIR - Morishita, Mariko
IR  - Roca J
FIR - Roca, Jose
IR  - de los Reyes Lauigan MJ
FIR - de los Reyes Lauigan, Mary Jane
IR  - Sainudeen K
FIR - Sainudeen, Katrin
IR  - Morgan H
FIR - Morgan, Helen
IR  - Hollingdale A
FIR - Hollingdale, Abigail
IR  - Eddings C
FIR - Eddings, Chloe
IR  - Warman H
FIR - Warman, Holly
IR  - Steele J
FIR - Steele, Jeremy
IR  - Hargrave J
FIR - Hargrave, Jo
IR  - Jayachandran R
FIR - Jayachandran, Resmi
IR  - Panday P
FIR - Panday, Pratistha
IR  - McInnes A
FIR - McInnes, Austin
IR  - Bilancia R
FIR - Bilancia, Rocco
IR  - Buckley J
FIR - Buckley, Julie
IR  - Boyd E
FIR - Boyd, Elizabeth
IR  - Zahan-Evans N
FIR - Zahan-Evans, Natalie
IR  - Morley A
FIR - Morley, Anna
IR  - Dann A
FIR - Dann, Adela
IR  - Mishra E
FIR - Mishra, Eleanor
IR  - Gkogkou P
FIR - Gkogkou, Pinelopi
IR  - Harvey I
FIR - Harvey, Irene
IR  - Congdon H
FIR - Congdon, Hilary
IR  - Ray A
FIR - Ray, Alison
IR  - Mansi J
FIR - Mansi, Jehan
IR  - Quinn A
FIR - Quinn, Amy
IR  - Rahman NM
FIR - Rahman, Najib M
IR  - Seymour J
FIR - Seymour, Jack
IR  - Ball H
FIR - Ball, Hannah
IR  - Chitnis M
FIR - Chitnis, Meenali
IR  - Petroyannou E
FIR - Petroyannou, Eirini
IR  - Snoad K
FIR - Snoad, Kimberley
IR  - Tavares Barbosa M
FIR - Tavares Barbosa, Monica
IR  - Middleton G
FIR - Middleton, Gary
IR  - Earwaker P
FIR - Earwaker, Philip
IR  - Abbas H
FIR - Abbas, Haider
IR  - Sohal P
FIR - Sohal, Parminder
IR  - Flather M
FIR - Flather, Marcus
IR  - Beckett P
FIR - Beckett, Paul
IR  - Tan C
FIR - Tan, Carol
IR  - Gleeson F
FIR - Gleeson, Fergus
IR  - MacBeth F
FIR - MacBeth, Fergus
IR  - Nye M
FIR - Nye, Mavis
IR  - Pass H
FIR - Pass, Harvey
IR  - Leonard P
FIR - Leonard, Pauline
IR  - Treasure T
FIR - Treasure, Tom
IR  - Sharples L
FIR - Sharples, Linda
IR  - Rusch V
FIR - Rusch, Valerie
IR  - Britton M
FIR - Britton, Mark
IR  - Rudd R
FIR - Rudd, Robin
IR  - Friedberg JS
FIR - Friedberg, Joseph S
IR  - Goldstraw P
FIR - Goldstraw, Peter
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038892 [pii]
AID - 10.1136/bmjopen-2020-038892 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e038892. doi: 10.1136/bmjopen-2020-038892.


PMID- 32873678
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Prospective multicentre randomised trial comparing the efficacy and safety of
      single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) versus
      Roux-en-Y gastric bypass (RYGB): SADISLEEVE study protocol.
PG  - e037576
LID - 10.1136/bmjopen-2020-037576 [doi]
AB  - INTRODUCTION: Despite the non-negligible weight loss failure rate at midterm,
      Roux-en-Y gastric bypass (RYGB) remains the reference procedure in the treatment 
      of morbid obesity with metabolic comorbidities. A recently emerged procedure, the
      single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S), could
      be more effective on weight loss with similar morbidity and lower weight loss
      failure rate than RYGB. We propose the first randomised, open, multicentre
      superiority trial comparing the SADI-S to RYGB (SADISLEEVE). METHODS AND
      ANALYSIS: The main objective is to demonstrate the superiority at 2 years after
      surgery of the SADI-S compared with RYGB in term of excess weight loss
      percentage. The secondary objectives are the evaluation of nutritional status,
      metabolic outcomes, overall complication rates and quality of life, within 2
      years after surgery. Key inclusion criteria are obese patients with body mass
      index (BMI) >/=40 kg/m(2) or >/=35 kg/m(2) with at least one comorbid condition
      and candidate to a first bariatric procedure or after failure of sleeve
      gastrectomy. Patients randomised by minimisation in two arms, based on centre,
      surgery as a revisional procedure, presence of type 2 diabetes and BMI >50
      kg/m(2) will be included over 2 years.A sample size of 166 patients in each group
      will have a power of 90% to detect a probability of 0.603 that excess weight loss
      in the RYGB arm is less than excess weight loss in the SADI-S arm with a 5%
      two-sided significance level. With a drop-out rate of 10%, it will be necessary
      to include 183 patients per group. ETHICS AND DISSEMINATION: The study was
      approved by Institutional Review Board of Centre Hospitalier Universitaire Morvan
      (CPP1089-HPS1). Study was also approved by the French national agency for drug
      safety (2018061500148). Results will be reported in peer-reviewed scientific
      journals. TRIAL REGISTRATION NUMBER: NCT03610256.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Robert, Maud
AU  - Robert M
AD  - Department of Digestive and Bariatric Surgery, Hospices Civils de Lyon, Hopital
      Edouard Herriot, CarMeN Laboratory, INSERM 1060, Universite Claude Bernard Lyon
      1, Lyon, France.
FAU - Poghosyan, Tigran
AU  - Poghosyan T
AUID- ORCID: 0000-0002-7103-1088
AD  - Department of Digestive, Oncologic and Bariatric Surgery; Specialized Center for 
      Obesity Management, Assistance Publique - Hopitaux de Paris, Hopital europeen
      Georges Pompidou, Inserm UMRS 1149, Universite de Paris, Paris, France
      tigran.poghosyan@aphp.fr.
FAU - Delaunay, Dominique
AU  - Delaunay D
AD  - Department of Digestive and Bariatric Surgery, Hospices Civils de Lyon, Hopital
      Edouard Herriot, Lyon, France.
FAU - Pelascini, Elise
AU  - Pelascini E
AD  - Department of Digestive and Bariatric Surgery, Hospices Civils de Lyon, Hopital
      Edouard Herriot, Lyon, France.
FAU - Iceta, Sylvain
AU  - Iceta S
AUID- ORCID: 0000-0002-0054-1865
AD  - Department of Endocrinology, Diabetology and Nutrition, Specialized Center for
      Obesity Management, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France.
FAU - Sterkers, Adrien
AU  - Sterkers A
AD  - Department of Digestive, Hepatobiliary Surgery, Centre Hospitalier Prive
      Saint-Gregoire, Saint-Gregoire, Bretagne, France.
FAU - Barsamian, Charles
AU  - Barsamian C
AD  - Department of Nutrition, Specialized Center for Obesity Management, Assistance
      Publique - Hopitaux de Paris, Hopital europeen Georges Pompidou, Universite de
      Paris, Paris, France.
FAU - Khamphommala, Litavan
AU  - Khamphommala L
AD  - Department of Digestive, Hepatobiliary Surgery, Centre Hospitalier Prive
      Saint-Gregoire, Saint-Gregoire, Bretagne, France.
FAU - Bin Dorel, Sylvie
AU  - Bin Dorel S
AD  - Clinical Research Unit, Hospices Civils de Lyon, Lyon, France.
FAU - Maucort-Boulch, Delphine
AU  - Maucort-Boulch D
AD  - Department of Biostatistics, Hospices Civils de Lyon, Hopital Edouard Herriot,
      Universite Lyon 1, Lyon, France.
FAU - Czernichow, Sebastien
AU  - Czernichow S
AD  - Department of Nutrition, Specialized Center for Obesity Management, Assistance
      Publique - Hopitaux de Paris, Hopital europeen Georges Pompidou, Universite de
      Paris, Paris, France.
AD  - Equipe METHODS, Centre de Recherche Epidemiologie et Statistique Sorbonne Paris
      Cite (CRESS-UMR1153) Inserm, Paris, France.
FAU - Disse, Emmanuel
AU  - Disse E
AD  - Department of Endocrinology, Diabetology and Nutrition, Specialized Center for
      Obesity Management, Hospices Civils de Lyon, Universite Lyon 1, Lyon, France.
AD  - CarMeN Lab, INSERM U1060, Lyon, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03610256
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/surgery
MH  - Gastrectomy/adverse effects
MH  - *Gastric Bypass/adverse effects
MH  - Humans
MH  - *Laparoscopy
MH  - Multicenter Studies as Topic
MH  - *Obesity, Morbid/complications/surgery
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7467507
OTO - NOTNLM
OT  - *clinical trials
OT  - *nutrition & dietetics
OT  - *surgery
COIS- Competing interests: DM-B reports personal fees from Maat Pharma outside of the
      submitted work. MR reports fees as a consultant from Medtronic and fees as an
      expert speaker from Gore outside of the submitted work.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037576 [pii]
AID - 10.1136/bmjopen-2020-037576 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e037576. doi: 10.1136/bmjopen-2020-037576.


PMID- 32873675
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Person-centred eHealth intervention for patients on sick leave due to common
      mental disorders: study protocol of a randomised controlled trial and process
      evaluation (PROMISE).
PG  - e037515
LID - 10.1136/bmjopen-2020-037515 [doi]
AB  - INTRODUCTION: The number of people dealing with common mental disorders (CMDs) is
      a major concern in many countries, including Sweden. Sickness absence resulting
      from CMDs is often long-lasting and advancing return to work is a complex process
      impacted by several factors, among which self-efficacy appears to be an important
      personal resource. Person-centred care (PCC) has previously shown positive
      effects on self-efficacy however this needs to be further investigated in
      relation to patients with CMDs and in an eHealth context. METHODS AND ANALYSIS:
      This study is an open randomised controlled trial comparing a control group
      receiving standard care with an intervention group receiving standard care plus
      PCC by telephone and a digital platform. The primary outcome measure is a
      composite score of changes in sick leave and self-efficacy. Participants will
      include 220 primary care patients on sick leave due to CMDs and data will mainly 
      be collected through questionnaires at baseline and 3, 6, 12 and 24 months from
      the inclusion date. Inclusion is ongoing and expected to be completed during the 
      fall of 2020. A process and health economic evaluation will also be conducted.
      ETHICS AND DISSEMINATION: This study was approved by the Regional Ethical Review 
      Board in Gothenburg, Sweden. Results will be published in peer-reviewed
      scientific journals and presented at national and international scientific
      conferences. This project is part of a broader research programme conducted at
      the Gothenburg Centre for Person-Centred Care (GPCC), where extensive work is
      undertaken to disseminate knowledge on and implementation of PCC. TRIAL
      REGISTRATION NUMBER: NCT03404583.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Cederberg, Matilda
AU  - Cederberg M
AUID- ORCID: 0000-0003-4727-9638
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden matilda.cederberg@gu.se.
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
FAU - Ali, Lilas
AU  - Ali L
AUID- ORCID: 0000-0001-7027-4371
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Psychiatric department, Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Ekman, Inger
AU  - Ekman I
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Department of Internal Medicine and Geriatrics, Sahlgrenska University Hospital
      Ostra, Gothenburg, Sweden.
FAU - Glise, Kristina
AU  - Glise K
AD  - The Institute of Stress Medicine, Region Vastra Gotaland, Gothenburg, Sweden.
FAU - Jonsdottir, Ingibjorg H
AU  - Jonsdottir IH
AD  - The Institute of Stress Medicine, Region Vastra Gotaland, Gothenburg, Sweden.
AD  - School of Public Health and Community Medicine, Institute of Medicine, University
      of Gothenburg, Gothenburg, Sweden.
FAU - Gyllensten, Hanna
AU  - Gyllensten H
AUID- ORCID: 0000-0001-6890-5162
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
FAU - Swedberg, Karl
AU  - Swedberg K
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Fors, Andreas
AU  - Fors A
AUID- ORCID: 0000-0001-8980-0538
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Research and Development, Primary Health Care, Region Vastra Gotaland,
      Gothenburg, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03404583
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Mental Disorders
MH  - Randomized Controlled Trials as Topic
MH  - Sick Leave
MH  - Surveys and Questionnaires
MH  - Sweden
MH  - *Telemedicine
PMC - PMC7467509
OTO - NOTNLM
OT  - *information technology
OT  - *mental health
OT  - *primary care
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037515 [pii]
AID - 10.1136/bmjopen-2020-037515 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e037515. doi: 10.1136/bmjopen-2020-037515.


PMID- 32873673
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Identification and prevalence of frailty in diabetes mellitus and association
      with clinical outcomes: a systematic review protocol.
PG  - e037476
LID - 10.1136/bmjopen-2020-037476 [doi]
AB  - INTRODUCTION: Diabetes mellitus is common and growing in prevalence, and an
      increasing proportion of people with diabetes are living to older age. Frailty
      is, therefore, becoming an important concept in diabetes. Frailty is associated
      with older age and describes a state of increased susceptibility to
      decompensation in response to physiological stress. A range of measures have been
      used to quantify frailty. This systematic review aims to identify measures used
      to quantify frailty in people with diabetes (any type); to summarise the
      prevalence of frailty in diabetes; and to describe the relationship between
      frailty and adverse clinical outcomes in people with diabetes. METHODS AND
      ANALYSIS: Three electronic databases (Medline, Embase and Web of Science) will be
      searched from 2000 to November 2019 and supplemented by citation searching of
      relevant articles and hand searching of reference lists. Two reviewers will
      independently review titles, abstracts and full texts. Inclusion criteria
      include: (1) adults with any type of diabetes mellitus; (2) quantify frailty
      using any validated frailty measure; (3) report the prevalence of frailty and/or 
      the association between frailty and clinical outcomes in people with diabetes;
      (4) studies that assess generic (eg, mortality, hospital admission and falls) or 
      diabetes-specific outcomes (eg, hypoglycaemic episodes, cardiovascular events,
      diabetic nephropathy and diabetic retinopathy); (5) cross-sectional and
      longitudinal observational studies. Study quality will be assessed using the
      Newcastle-Ottawa Scale for observational studies. Clinical and methodological
      heterogeneity will be assessed, and a random effects meta-analysis performed if
      appropriate. Otherwise, a narrative synthesis will be performed. ETHICS AND
      DISSEMINATION: This manuscript describes the protocol for a systematic review of 
      observational studies and does not require ethical approval. PROSPERO
      REGISTRATION NUMBER: CRD42020163109.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Hanlon, Peter
AU  - Hanlon P
AUID- ORCID: 0000-0002-5828-3934
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
      peter.hanlon@glasgow.ac.uk.
FAU - Faure, Isabella
AU  - Faure I
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Corcoran, Neave
AU  - Corcoran N
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Butterly, Elaine
AU  - Butterly E
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Lewsey, Jim
AU  - Lewsey J
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - McAllister, David A
AU  - McAllister DA
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Mair, Frances S
AU  - Mair FS
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
LA  - eng
GR  - MR/S021949/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus/epidemiology
MH  - *Diabetic Retinopathy
MH  - *Frailty/epidemiology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Prevalence
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7467518
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *epidemiology
OT  - *geriatric medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037476 [pii]
AID - 10.1136/bmjopen-2020-037476 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e037476. doi: 10.1136/bmjopen-2020-037476.


PMID- 32873672
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Newborn signal functions in Bangladesh: identification through expert
      consultation and assessment of readiness among public health facilities-study
      protocol using Delphi technique.
PG  - e037418
LID - 10.1136/bmjopen-2020-037418 [doi]
AB  - INTRODUCTION: There is a set of globally accepted and nationally adapted signal
      functions for categorising health facilities for maternal services. Newborn
      resuscitation is the only newborn intervention which is included in the WHO
      recommended list of emergency obstetric care signal functions. This is not enough
      to comprehensively assess the readiness of a health facility for providing
      newborn services. In order to address the major causes of newborn death, the
      Government of Bangladesh has prioritised a set of newborn interventions for
      national scale-up, the majority of which are facility-based. Effective delivery
      of these interventions depends on a core set of functions (skills and services). 
      However, there is no standardised and approved set of newborn signal functions
      (NSFs) based on which the service availability and readiness of a health facility
      can be assessed for providing newborn services. Thus, this study will be the
      first of its kind to identify such NSFs. These NSFs can categorise health
      facilities and assist policymakers and health managers to appropriately plan and 
      adequately monitor the progress and performance of health facilities delivering
      newborn healthcare. METHODS AND ANALYSIS: We will adopt the Delphi technique of
      consensus building for identification of NSFs and 1-2 indicator for each function
      while employing expert consultation from relevant experts in Bangladesh. Based on
      the identified NSFs and signal function indicators, the existing health facility 
      assessment (HFA) tools will be updated, and an HFA survey will be conducted to
      assess service availability and readiness of public health facilities in relation
      to the new NSFs. Descriptive statistics (proportion) with a 95% CI will be used
      to report the level of service availability and readiness of public facilities
      regarding NSFs. ETHICS AND DISSEMINATION: Ethical approval was obtained from
      Research Review and Ethical Review Committee of icddr, b (PR-17089). Results will
      be disseminated through meetings, seminars, conference presentations and
      international peer-review journal articles.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rahman, Ahmed Ehsanur
AU  - Rahman AE
AUID- ORCID: 0000-0001-9216-1079
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease
      Research, Dhaka, Bangladesh ehsanur@icddrb.org.
FAU - Banik, Goutom
AU  - Banik G
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease
      Research, Dhaka, Bangladesh.
FAU - Mhajabin, Shema
AU  - Mhajabin S
AUID- ORCID: 0000-0001-7023-015X
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease
      Research, Dhaka, Bangladesh.
FAU - Tahsina, Tazeen
AU  - Tahsina T
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease
      Research, Dhaka, Bangladesh.
FAU - Islam, Md Jahurul
AU  - Islam MJ
AD  - Directorate General of Health Services, Government of Bangladesh Ministry of
      Health and Family Welfare, Dhaka, Bangladesh.
FAU - Uddin Ahmed, Farid
AU  - Uddin Ahmed F
AD  - Director General of Family planning, Government of Bangladesh Ministry of Health 
      and Family Welfare, Dhaka, Bangladesh.
FAU - Islam, Mushair Ul
AU  - Islam MU
AD  - Directorate General of Health Services, Government of Bangladesh Ministry of
      Health and Family Welfare, Dhaka, Bangladesh.
FAU - Mannan, Md Abdul
AU  - Mannan MA
AD  - Neonatology, BSMMU, Dhaka, Bangladesh.
FAU - Dey, Sanjoy Kumer
AU  - Dey SK
AD  - Neonatology, BSMMU, Dhaka, Bangladesh.
FAU - Sharmin, Shamina
AU  - Sharmin S
AD  - UNICEF Bangladesh, Dhaka, Bangladesh.
FAU - Mehran, Fida
AU  - Mehran F
AD  - USAID Bangladesh, Dhaka, Bangladesh.
FAU - Khan, Mahbuba
AU  - Khan M
AD  - WHO Bangladesh, Dhaka, Bangladesh.
FAU - Ahmed, Anisuddin
AU  - Ahmed A
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease
      Research, Dhaka, Bangladesh.
FAU - Al Sabir, Ahmed
AU  - Al Sabir A
AD  - RTM International, Dhaka, Bangladesh.
FAU - Sultana, Shahin
AU  - Sultana S
AD  - NIPORT, Dhaka, Bangladesh.
FAU - Ahsan, Ziaul
AU  - Ahsan Z
AD  - Ipas, Dhaka, Bangladesh.
FAU - Rubayet, Sayed
AU  - Rubayet S
AD  - Ipas, Dhaka, Bangladesh.
FAU - George, Joby
AU  - George J
AD  - Save the Children Bangladesh, Dhaka, Bangladesh.
FAU - Karim, Afsana
AU  - Karim A
AD  - Save the Children Bangladesh, Dhaka, Bangladesh.
FAU - Shahidullah, Mohammod
AU  - Shahidullah M
AD  - Neonatology, BSMMU, Dhaka, Bangladesh.
FAU - Arifeen, Shams El
AU  - Arifeen SE
AD  - Maternal and Child Health Division, International Centre for Diarrhoeal Disease
      Research, Dhaka, Bangladesh.
CN  - NSF-BD study group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bangladesh
MH  - Delphi Technique
MH  - *Emergency Medical Services
MH  - Female
MH  - *Health Facilities
MH  - Health Services Accessibility
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Referral and Consultation
PMC - PMC7467517
OTO - NOTNLM
OT  - *health policy
OT  - *neonatology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037418 [pii]
AID - 10.1136/bmjopen-2020-037418 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e037418. doi: 10.1136/bmjopen-2020-037418.


PMID- 32873671
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210920
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Protocol for project recovery after cardiac surgery: a single-center cohort study
      leveraging digital platform to characterise longitudinal patient-reported
      postoperative recovery patterns.
PG  - e036959
LID - 10.1136/bmjopen-2020-036959 [doi]
AB  - INTRODUCTION: Improving postoperative patient recovery after cardiac surgery is a
      priority, but our current understanding of individual variations in recovery and 
      factors associated with poor recovery is limited. We are using a
      health-information exchange platform to collect patient-reported outcome measures
      (PROMs) and wearable device data to phenotype recovery patterns in the 30-day
      period after cardiac surgery hospital discharge, to identify factors associated
      with these phenotypes and to investigate phenotype associations with clinical
      outcomes. METHODS AND ANALYSIS: We designed a prospective cohort study to enrol
      200 patients undergoing valve, coronary artery bypass graft or aortic surgery at 
      a tertiary centre in the USA. We are enrolling patients postoperatively after the
      intensive care unit discharge and delivering electronic surveys directly to
      patients every 3 days for 30 days after hospital discharge. We will conduct
      medical record reviews to collect patient demographics, comorbidity, operative
      details and hospital course using the Society of Thoracic Surgeons data
      definitions. We will use phone interview and medical record review data for
      adjudication of survival, readmission and complications. We will apply
      group-based trajectory modelling to the time-series PROM and device data to
      classify patients into distinct categories of recovery trajectories. We will
      evaluate whether certain recovery pattern predicts death or hospital
      readmissions, as well as whether clinical factors predict a patient having poor
      recovery trajectories. We will evaluate whether early recovery patterns predict
      the overall trajectory at the patient-level. ETHICS AND DISSEMINATION: The Yale
      Institutional Review Board approved this study. Following the description of the 
      study procedure, we obtain written informed consent from all study participants. 
      The consent form states that all personal information, survey response and any
      medical records are confidential, will not be shared and are stored in an
      encrypted database. We plan to publish our study findings in peer-reviewed
      journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mori, Makoto
AU  - Mori M
AUID- ORCID: 0000-0002-2367-8354
AD  - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut,
      USA.
AD  - Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, 
      Connecticut, USA.
FAU - Brooks, Cornell
AU  - Brooks C
AD  - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut,
      USA.
FAU - Spatz, Erica
AU  - Spatz E
AUID- ORCID: 0000-0002-1557-7713
AD  - Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, 
      Connecticut, USA.
AD  - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven,
      Connecticut, USA.
FAU - Mortazavi, Bobak J
AU  - Mortazavi BJ
AD  - Department of Computer Science and Engineering, Texas A&M University System,
      College Station, Texas, USA.
FAU - Dhruva, Sanket S
AU  - Dhruva SS
AD  - Department of Medicine, University of California San Francisco, San Francisco,
      California, USA.
FAU - Linderman, George C
AU  - Linderman GC
AD  - Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, 
      Connecticut, USA.
FAU - Grab, Lawrence A
AU  - Grab LA
AD  - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut,
      USA.
FAU - Zhang, Yawei
AU  - Zhang Y
AD  - Department of Environmental Science, Yale School of Public Health, New Haven,
      Connecticut, USA.
FAU - Geirsson, Arnar
AU  - Geirsson A
AD  - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut,
      USA.
FAU - Chaudhry, Sarwat I
AU  - Chaudhry SI
AD  - Section of General Internal Medicine, Department of Internal Medicine, Yale
      School of Medicine, New Haven, Connecticut, USA.
FAU - Krumholz, Harlan M
AU  - Krumholz HM
AUID- ORCID: 0000-0003-2046-127X
AD  - Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, 
      Connecticut, USA harlan.krumholz@yale.edu.
AD  - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven,
      Connecticut, USA.
AD  - Department of Health Policy and Management, Yale School of Public Health, New
      Haven, Connecticut, USA.
LA  - eng
GR  - T32 GM007205/GM/NIGMS NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiac Surgical Procedures
MH  - Cohort Studies
MH  - Humans
MH  - Patient Reported Outcome Measures
MH  - *Postoperative Complications
MH  - Prospective Studies
PMC - PMC7467526
OTO - NOTNLM
OT  - *cardiac surgery
OT  - *quality in health care
OT  - *telemedicine
COIS- Competing interests: SC is a paid reviewer for the CVS Caremark State of CT
      Clinical Pharmacy Program. BJM is supported in part by the Center for Remote
      Health Technologies and Systems and Texas A&M University, as well as awards
      1R01EB028106-01 and 1R21EB028486-01 from the National Institute for Biomedical
      Imaging and Bioengineering (NIBIB) for work employing machine learning on health 
      data. Dr Mortazavi reported having a patent US10201746B1 approved for
      'Near-realistic sports motion analysis and activity monitoring' and a patent to
      US20180315507A1 is pending. HMK works under contract with the Centers for
      Medicare & Medicaid Services to support quality measurement programs; was a
      recipient of a research grant, through Yale, from Medtronic and the U.S. Food and
      Drug Administration to develop methods for post-market surveillance of medical
      devices; was a recipient of a research grant with Medtronic and is the recipient 
      of a research grant from Johnson & Johnson, through Yale University, to support
      clinical trial data sharing; was a recipient of a research agreement, through
      Yale University, from the Shenzhen Center for Health Information for work to
      advance intelligent disease prevention and health promotion; collaborates with
      the National Center for Cardiovascular Diseases in Beijing; receives payment from
      the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel
      litigation, from the Martin/Baughman Law Firm for work related to the Cook Celect
      IVC filter litigation, and from the Siegfried and Jensen Law Firm for work
      related to Vioxx litigation; is a venture partner for F-Prime; chairs a Cardiac
      Scientific Advisory Board for UnitedHealth; was a participant/participant
      representative of the IBM Watson Health Life Sciences Board; is a member of the
      Advisory Board for Element Science, the Advisory Board for Facebook, and the
      Physician Advisory Board for Aetna; and is the co-founder of HugoHealth, a
      personal health information platform, and co-founder of Refactor Health, an
      enterprise healthcare AI-augmented data management company.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036959 [pii]
AID - 10.1136/bmjopen-2020-036959 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e036959. doi: 10.1136/bmjopen-2020-036959.


PMID- 32873669
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Effects of coenzyme Q10 on endothelial and cardiac function in patients
      undergoing haemodialysis: study protocol for a pilot randomised controlled trial.
PG  - e036732
LID - 10.1136/bmjopen-2019-036732 [doi]
AB  - INTRODUCTION: Endothelial and cardiac dysfunction are highly prevalent and are
      associated with cardiovascular morbidity and mortality among patients undergoing 
      dialysis. For patients undergoing dialysis, no study has explored the effect of
      supplementation of coenzyme Q10 (CoQ10) on endothelial function. To our best of
      knowledge, only two small sample studies focused on the efficacy of
      supplementation of CoQ10 on cardiac function. However, the effect of CoQ10
      supplementation on cardiac function remains uncertain in patients who undergo
      haemodialysis. The aim of this study is to explore whether CoQ10 supplementation 
      can improve endothelial and cardiac function in patients undergoing
      haemodialysis. METHODS AND ANALYSIS: This is a pilot randomised controlled study.
      Eligible patients undergoing haemodialysis in our haemodialysis centre will be
      randomly allocated to the CoQ10 and control groups. The follow-up time is 12
      months. The primary outcome is to assess the change of brachial artery
      endothelial-dependent flow-mediated dilation, left ventricular systolic function,
      diastolic function and Myocardial Performance Index at 12 months from baseline.
      Secondary outcomes are death or hospitalisation due to cardiovascular events,
      all-cause mortality, change of CoQ10 concentration, the ratio of ubiquinol to
      ubiquinone, the change of oxidative stress markers (including malondialdehyde and
      8-hydroxy-deoxyguanosine) and Left Ventricular Mass Index. ETHICS AND
      DISSEMINATION: Risks associated with CoQ10 are minor, even at doses as high as
      1800 mg according to previous studies. The trial has received ethics approval
      from the Medical Ethics Committee for Clinical Trials of Drugs, the 306th
      Hospital of Chinese PLA. The results of the study are expected to be published in
      a peer-reviewed journal and presented at academic conferences. TRIAL REGISTRATION
      NUMBER: ChiCTR1900022258.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Yongxing
AU  - Xu Y
AUID- ORCID: 0000-0003-1216-235X
AD  - Department of Nephrology, Chinese PLA Strategic Support Force Characteristic
      Medical Center (The 306th Hospital of Chinese PLA), Beijing, China.
FAU - Li, Xinlou
AU  - Li X
AD  - Department of Medical Research, Chinese PLA Strategic Support Force
      Characteristic Medical Center (The 306th Hospital of Chinese PLA), Beijing,
      China.
FAU - Zuo, Xiaowen
AU  - Zuo X
AD  - Department of Ultrasound in Medicine, Chinese PLA Strategic Support Force
      Characteristic Medical Center (The 306th Hospital of Chinese PLA), Beijing,
      China.
FAU - Jia, Huaping
AU  - Jia H
AD  - Department of Ultrasound in Medicine, Chinese PLA Strategic Support Force
      Characteristic Medical Center (The 306th Hospital of Chinese PLA), Beijing,
      China.
FAU - Han, Enhong
AU  - Han E
AD  - Department of Nephrology, Chinese PLA Strategic Support Force Characteristic
      Medical Center (The 306th Hospital of Chinese PLA), Beijing, China.
FAU - Liang, Fugui
AU  - Liang F
AD  - Department of Nephrology, Chinese PLA Strategic Support Force Characteristic
      Medical Center (The 306th Hospital of Chinese PLA), Beijing, China.
FAU - Xie, Lei
AU  - Xie L
AD  - Department of Nephrology, Chinese PLA Strategic Support Force Characteristic
      Medical Center (The 306th Hospital of Chinese PLA), Beijing, China.
FAU - Gao, Jianjun
AU  - Gao J
AUID- ORCID: 0000-0001-9675-3071
AD  - Department of Nephrology, Chinese PLA Strategic Support Force Characteristic
      Medical Center (The 306th Hospital of Chinese PLA), Beijing, China
      gao306kidney@126.com.
LA  - eng
SI  - ChiCTR/ChiCTR1900022258
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 1339-63-5 (Ubiquinone)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Humans
MH  - Oxidative Stress
MH  - Pilot Projects
MH  - Randomized Controlled Trials as Topic
MH  - *Renal Dialysis/adverse effects
MH  - *Ubiquinone/analogs & derivatives
PMC - PMC7467521
OTO - NOTNLM
OT  - *adult cardiology
OT  - *dialysis
OT  - *end stage renal failure
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036732 [pii]
AID - 10.1136/bmjopen-2019-036732 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e036732. doi: 10.1136/bmjopen-2019-036732.


PMID- 32873668
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Study protocol for the international Systemic Lupus Erythematosus Prospective
      Observational Cohort Study (SPOCS): understanding lupus and the role of type I
      interferon gene signature.
PG  - e036563
LID - 10.1136/bmjopen-2019-036563 [doi]
AB  - INTRODUCTION: The Systemic Lupus Erythematosus (SLE) Prospective Observational
      Cohort Study (SPOCS) aims to describe the disease course of SLE and its
      association with type I interferon gene signature (IFNGS) status. METHODS AND
      ANALYSIS: SPOCS is an international, multicentre, prospective, observational
      cohort study designed to follow patients through biannual study visits during a
      3-year observation period. Patients >/=18 years old with a physician diagnosis
      that meets the American College of Rheumatology or Systemic Lupus International
      Collaborating Clinics SLE classification criteria will be included. SPOCS will
      comprehensively analyse clinical features, disease progression and treatment, SLE
      outcomes, health status assessments and quality of life, and healthcare resource 
      utilisation of patients with moderate to severe SLE. A four-gene test will be
      used to measure IFNGS status; scores will be compared with a pre-established
      cut-off. Patients will be stratified by low or high IFNGS expression levels.
      Enrolment began in June 2017, and study completion is expected in 2022. The total
      number of anticipated patients was initially planned for 1500 patients and was
      amended to 900 patients owing to slow accrual of eligible patients. ETHICS AND
      DISSEMINATION: The ethics committee/institutional review board/independent ethics
      committee at each study site approved the SPOCS protocol prior to study
      initiation (protocol number: D3461R00001, version 3.0, 26 June 2019). Study
      findings will be disseminated through peer-reviewed publications and
      presentations at scientific meetings. TRIAL REGISTRATION NUMBER: NCT03189875.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hammond, Edward R
AU  - Hammond ER
AD  - BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
FAU - Tummala, Raj
AU  - Tummala R
AD  - Inflammation, Autoimmunity and Neuroscience, AstraZeneca, Gaithersburg, Maryland,
      USA raj.tummala@astrazeneca.com.
FAU - Berglind, Anna
AU  - Berglind A
AD  - BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.
FAU - Syed, Farhat
AU  - Syed F
AD  - Precision Medicine, R&D, AstraZeneca, Cambridge, UK.
FAU - Wang, Xia
AU  - Wang X
AD  - Data Science and AI, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
FAU - Desta, Barnabas
AU  - Desta B
AD  - Global Pricing and Market Access, AstraZeneca, Gaithersburg, Maryland, USA.
FAU - Nab, Henk
AU  - Nab H
AD  - Inflammation and Autoimmunity, AstraZeneca, Cambridge, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03189875
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Interferon Type I)
SB  - IM
MH  - Adolescent
MH  - Cohort Studies
MH  - Humans
MH  - *Interferon Type I
MH  - *Lupus Erythematosus, Systemic/genetics
MH  - Multicenter Studies as Topic
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Severity of Illness Index
PMC - PMC7467530
OTO - NOTNLM
OT  - *immunology
OT  - *protocols & guidelines
OT  - *rheumatology
COIS- Competing interests: ERH, RT, AB, BD, FS and XW are AstraZeneca employees. HN was
      an employee at AstraZeneca at the time of the study.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036563 [pii]
AID - 10.1136/bmjopen-2019-036563 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e036563. doi: 10.1136/bmjopen-2019-036563.


PMID- 32873667
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Sep 1
TI  - Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in
      patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study
      protocol.
PG  - e036518
LID - 10.1136/bmjopen-2019-036518 [doi]
AB  - INTRODUCTION: There is emerging evidence for stratified glucose-lowering
      responses to certain oral medications for type 2 diabetes (T2D) by individual
      characteristics. The objective of this study was to test whether glycaemic
      response to representative treatments of dipeptidyl peptidase-4 inhibitors
      (vildagliptin) and thiazolidinediones (pioglitazone) varies according to
      ethnicity, gender, baseline obesity, triglyceride level or genetic variation.
      METHODS: This is a multicentre, two-period, two-treatment, open-label, randomised
      cross-over trial of vildagliptin and pioglitazone as second-line or third-line
      therapy in patients with T2D who have suboptimal glycaemic control on metformin
      and/or sulfonylurea therapy. It is conducted in New Zealand with a target of 300 
      patients (40% with Maori or Pacific ancestry) eligible if aged >/=18 and </=80
      years, with T2D for more than 1 year, on stable doses of metformin and/or
      sulfonylurea for at least 3 months, with HbA1c between 59 and 110 mmol/mol
      inclusive. Participants are assigned to complete 4 months of vildagliptin 50 mg
      per day or pioglitazone 30 mg per day, followed by 4 months of the other
      medications in randomly allocated sequences. Participant characteristics,
      including ethnicity, obesity, lipid profile and candidate genotypes are collected
      at baseline. Primary outcome variable is on treatment HbA1c. Secondary outcomes
      include weight change, frequency of side effects and patient preference. ETHICS
      AND DISSEMINATION: Ethical approval of the trial has been obtained from the New
      Zealand Health and Disability Ethics Committee (18/STH/242). The trial commenced 
      in February 2019 and recruitment is expected to be completed by March 2020.
      Results will be reported in articles submitted to peer-reviewed journals, as well
      as in presentations at national and international meetings. TRIAL REGISTRATION
      NUMBER: ACTRN12618001907235.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yeu, Rui Qian
AU  - Yeu RQ
AD  - Medicine, The University of Auckland Faculty of Medical and Health Sciences,
      Auckland, New Zealand.
AD  - Auckland Diabetes Centre, Auckland City Hospital, Auckland, New Zealand.
FAU - Brandon, Rebecca
AU  - Brandon R
AD  - Medicine, The University of Auckland Faculty of Medical and Health Sciences,
      Auckland, New Zealand.
AD  - Auckland Diabetes Centre, Auckland City Hospital, Auckland, New Zealand.
FAU - Jiang, Yannan
AU  - Jiang Y
AUID- ORCID: 0000-0002-7663-9164
AD  - Department of Statistics, The University of Auckland Faculty of Medical and
      Health Sciences, Auckland, New Zealand.
FAU - Griffiths, Dale
AU  - Griffiths D
AUID- ORCID: 0000-0002-5865-2226
AD  - Zoom Pharmacy, Auckland, New Zealand.
FAU - Smallman, Kate
AU  - Smallman K
AD  - Diabetes Foundation Aotearoa, Auckland, New Zealand.
FAU - Moffitt, Allan
AU  - Moffitt A
AD  - ProCARE Health Limited, Auckland, New Zealand.
FAU - Doherty, Glenn
AU  - Doherty G
AD  - Tongan Health Society, Auckland, New Zealand.
FAU - Paul, Ryan
AU  - Paul R
AD  - University of Waikato, Hamilton, New Zealand.
FAU - Harre Hindmarsh, Jennie
AU  - Harre Hindmarsh J
AD  - Ngati Porou Hauora, Te Puia Springs, Tairawhiti, New Zealand.
FAU - Merriman, Tony R
AU  - Merriman TR
AD  - School of Medical Sciences, University of Otago, Dunedin, New Zealand.
FAU - Macaskill-Smith, Kerry
AU  - Macaskill-Smith K
AD  - Ventures Limited, Hamilton, New Zealand.
FAU - Orr-Walker, Brandon
AU  - Orr-Walker B
AD  - Endocrinology and Diabetes Service, Counties Manukau District Health Board,
      Auckland, New Zealand.
FAU - Murphy, Rinki
AU  - Murphy R
AUID- ORCID: 0000-0002-0043-2423
AD  - Medicine, The University of Auckland Faculty of Medical and Health Sciences,
      Auckland, New Zealand r.murphy@auckland.ac.nz.
AD  - Auckland Diabetes Centre, Auckland City Hospital, Auckland, New Zealand.
LA  - eng
SI  - ANZCTR/ACTRN12618001907235
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aged
MH  - Blood Glucose
MH  - Cross-Over Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Metformin/therapeutic use
MH  - Multicenter Studies as Topic
MH  - New Zealand
MH  - Pioglitazone/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Vildagliptin/therapeutic use
PMC - PMC7467516
OTO - NOTNLM
OT  - *diabetes and endocrinology
OT  - *general diabetes
OT  - *statistics and research methods
COIS- Competing interests: None declared.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036518 [pii]
AID - 10.1136/bmjopen-2019-036518 [doi]
PST - epublish
SO  - BMJ Open. 2020 Sep 1;10(9):e036518. doi: 10.1136/bmjopen-2019-036518.


PMID- 32873486
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1769-6658 (Electronic)
IS  - 1278-3218 (Linking)
VI  - 24
IP  - 6-7
DP  - 2020 Oct
TI  - [Health Data Hub in France, use cases in oncology and radiation oncology].
PG  - 762-767
LID - S1278-3218(20)30188-8 [pii]
LID - 10.1016/j.canrad.2020.07.003 [doi]
AB  - Health data financed by the French national solidarity system constitute a common
      heritage. Such data should be exploited to optimize care while complying with
      ethics and fundamental rights of citizens. The creation of the Health Data Hub
      (HDH) was allowed by the 24 July 2019 Law on the organization and transformation 
      of the French health system. Its objective is to enable authorized innovative
      project leaders to access non-nominative data via a state-of-the-art secure
      technological platform. It appears to be one of the strong points of the French
      Artificial Intelligence strategy. This structure is a public interest group which
      associates 56 stakeholders, mostly from the public authorities. It implements, in
      partnership with the National Health Insurance Fund, the major strategic
      orientations relating to the National Health Data System set by the French State 
      and the Ministry of Solidarity and Health. The Health Data Hub allows
      cross-reference of consolidated databases with SNDS data. Several use cases are
      under construction. The creation of relational databases in radiation oncology is
      also possible through specific strategies to get pseudonymized data from the
      various radiotherapy software programs upstream of the Health Data Hub.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Combes, S
AU  - Combes S
AD  - Health Data Hub, 9, rue Georges-Pitard, 75015 Paris, France. Electronic address: 
      hdh@health-data-hub.fr.
FAU - Bacry, E
AU  - Bacry E
AD  - Health Data Hub, 9, rue Georges-Pitard, 75015 Paris, France.
FAU - Fontbonne, C
AU  - Fontbonne C
AD  - LPC-IN2P3 ENSICAEN/CNRS UMR 6534, 6, boulevard du Marechal-Juin, 14050 Caen
      cedex, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - HealthDataHub ; plateforme des donnees de sante en France, application a
      l'oncologie radiotherapie.
DEP - 20200829
PL  - France
TA  - Cancer Radiother
JT  - Cancer radiotherapie : journal de la Societe francaise de radiotherapie
      oncologique
JID - 9711272
SB  - IM
MH  - *Databases, Factual
MH  - France
MH  - Humans
MH  - *Medical Oncology
MH  - Neoplasms/*radiotherapy
MH  - *Radiation Oncology
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Cancer
OT  - Data
OT  - Donnees
OT  - Health
OT  - Intelligence artificielle
OT  - Oncologie radiotherapie
OT  - Oncology radiation therapy
OT  - Plateforme
OT  - Platform
OT  - Sante
EDAT- 2020/09/03 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/07/06 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - S1278-3218(20)30188-8 [pii]
AID - 10.1016/j.canrad.2020.07.003 [doi]
PST - ppublish
SO  - Cancer Radiother. 2020 Oct;24(6-7):762-767. doi: 10.1016/j.canrad.2020.07.003.
      Epub 2020 Aug 29.


PMID- 32873348
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20210110
IS  - 1710-1107 (Electronic)
IS  - 0714-9808 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Dec
TI  - Covid-19 and Priorities for Research in Aging.
PG  - 500-505
LID - 10.1017/S0714980820000331 [doi]
AB  - This article describes priority areas for research on the impact of the Covid-19 
      pandemic on older adults that have been identified by the CIHR Institute of Aging
      (CIHR-IA). The process used by CIHR-IA consists of several iterative phases and
      thus far has resulted in identification of three key areas for Covid-19 research 
      needs and four cross-cutting thematic areas. The key research priority areas are 
      as follows: response of older adults to disease, vaccination, and therapeutics;
      mental health and isolation; and supportive care environments. The four
      cross-cutting themes are equity, diversity, and inclusion (EDI); ethical/moral
      considerations; evidence-informed practices; and digital health technologies. The
      priorities outlined in this article will inform CIHR-IA's responses to Covid-19
      research needs.
FAU - Rylett, R J
AU  - Rylett RJ
AD  - Robarts Research Institute, University of Western Ontario, London, Ontario.
FAU - Alary, Flamine
AU  - Alary F
AD  - Centre de recherche de l'Institut universitaire de geriatrie de Montreal,
      Universite de Montreal, Quebec.
FAU - Goldberg, Joanne
AU  - Goldberg J
AD  - Centre de recherche de l'Institut universitaire de geriatrie de Montreal,
      Universite de Montreal, Quebec.
FAU - Rogers, Susan
AU  - Rogers S
AD  - Centre de recherche de l'Institut universitaire de geriatrie de Montreal,
      Universite de Montreal, Quebec.
FAU - Versteegh, Patricia
AU  - Versteegh P
AD  - Robarts Research Institute, University of Western Ontario, London, Ontario.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Aging
JT  - Canadian journal on aging = La revue canadienne du vieillissement
JID - 8708560
SB  - IM
MH  - Aging/*psychology
MH  - COVID-19/*psychology
MH  - Canada
MH  - Health Equity
MH  - Humans
MH  - Pandemics
MH  - Research
MH  - Research Support as Topic
MH  - SARS-CoV-2
PMC - PMC7545246
OTO - NOTNLM
OT  - *Canadian Institutes of Health Research
OT  - *Covid-19
OT  - *Institut du vieillissement
OT  - *Institute of Aging
OT  - *Instituts de recherche en sante du Canada
OT  - *adultes plus ages
OT  - *aging
OT  - *older adults
OT  - *priorisation de la recherche
OT  - *research prioritization
OT  - *vieillissement
EDAT- 2020/09/03 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1017/S0714980820000331 [doi]
AID - S0714980820000331 [pii]
PST - ppublish
SO  - Can J Aging. 2020 Dec;39(4):500-505. doi: 10.1017/S0714980820000331.


PMID- 32873312
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 1
TI  - The challenges of ethical behaviors for drug supply in pharmacies in Iran by a
      principle-based approach.
PG  - 84
LID - 10.1186/s12910-020-00531-0 [doi]
AB  - BACKGROUND: Pharmacists as the trustee of pharmacy services must adhere to
      ethical principles and evaluate their professionalism. Pharmacists may sometimes 
      show different unethical behaviors in their interactions, so it is essential to
      understand these behaviors. The present study aimed to determine the challenges
      of ethical behaviors based on a principles-based approach in the area of drug
      supply in pharmacies. METHODS: This qualitative content analysis was conducted in
      Kerman in 2018. A number of key players in the field of medication supply were
      selected using snowball sampling to interview. An effort was made to select
      samples with maximum variation. Exclusion criteria include having less than 3
      years of work experience in pharmacy and supervision, not willing to participate 
      in the interview, and not participating in the interview for 3 times. The
      participants in this study consisted of pharmacy technicians (n = 5), patients (n
      = 6), pharmacists (n = 8), inspectors of insurance companies (n = 4), and
      inspectors of food and drug administration (n = 3). Data were analyzed using
      directed content analysis by Maxqda software version 10 (VERBI Software, Berlin, 
      Germany). The principles of "Beauchamp and Childress Ethics" theory including
      autonomy, beneficence, non-maleficence, and justice were selected as the main
      principles. RESULTS: After data analysis, 8 main categories and 26 subcategories 
      were obtained. The main categories include patient privacy, patient independence,
      communication principles, patient-centered services, drug supplier, patient harm 
      avoidance, supervision, and distributive, procedural, and interactional justice. 
      The subcategories include increasing patient awareness, culturizing prescription,
      and rational drug use, confidentiality and privacy, and pharmacist-patient
      relationship/communication, which were the main ethical challenges in the area of
      drug supply at pharmacies. CONCLUSIONS: According to a principle-based approach, 
      the greatest challenges were related to two principles of autonomy and
      beneficence. The policymakers in the healthcare system should emphasize patient
      independence, patient privacy, and patient-centered services. The results of this
      study can be used as a tool to introduce ethical challenges to policymakers and
      develop educational contents, the chart of professional ethics in pharmacies, and
      accreditation measures of pharmacies.
FAU - Iranmanesh, Mahla
AU  - Iranmanesh M
AD  - Health Services Management Research Center, Institute for Futures Studies in
      Health, Kerman University of Medical Sciences, Haft-Bagh Highway- Kerman
      University of Medical Sciences, Kerman, Iran.
FAU - Yazdi-Feyzabadi, Vahid
AU  - Yazdi-Feyzabadi V
AD  - Social Determinants of Health Research Center, Institute for Futures Studies in
      Health, Kerman University of Medical Sciences, Kerman, Iran.
FAU - Mehrolhassani, Mohammad Hossein
AU  - Mehrolhassani MH
AUID- ORCID: 0000-0002-2412-9277
AD  - Health Services Management Research Center, Institute for Futures Studies in
      Health, Kerman University of Medical Sciences, Haft-Bagh Highway- Kerman
      University of Medical Sciences, Kerman, Iran. mhmhealth@gmail.com.
LA  - eng
GR  - 97001007/Kerman University of Medical Sciences/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Beneficence
MH  - Germany
MH  - Humans
MH  - Iran
MH  - *Pharmaceutical Preparations
MH  - *Pharmacies
PMC - PMC7466816
OTO - NOTNLM
OT  - *Beneficence
OT  - *Deontological approach
OT  - *Dignity and autonomy
OT  - *Drug supply
OT  - *Ethical behaviors
OT  - *Justice
OT  - *Non-maleficence
OT  - *Pharmacy
EDAT- 2020/09/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/08/28 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00531-0 [doi]
AID - 10.1186/s12910-020-00531-0 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 1;21(1):84. doi: 10.1186/s12910-020-00531-0.


PMID- 32873310
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 1
TI  - Implementing clinical ethics committees as a complex intervention: presentation
      of a feasibility study in community care.
PG  - 82
LID - 10.1186/s12910-020-00522-1 [doi]
AB  - BACKGROUND: How should clinical ethics support services such as clinical ethics
      committees (CECs) be implemented and evaluated? We argue that both the CEC itself
      and the implementation of the CEC should be considered as 'complex
      interventions'. MAIN TEXT: We present a research project involving the
      implementation of CECs in community care in four Norwegian municipalities. We
      show that when both the CEC and its implementation are considered as complex
      interventions, important consequences follow - both for implementation and the
      study thereof. Emphasizing four such sets of consequences, we argue, first, that 
      the complexity of the intervention necessitates small-scale testing before
      larger-scale implementation and testing is attempted; second, that it is
      necessary to theorize the intervention in sufficient depth; third, that the
      identification of casual connections charted in so-called logic models allows the
      identification of factors that are vital for the intervention to succeed and
      which must therefore be studied; fourth, that an important part of a feasibility 
      study must be to identify and chart as many as possible of the causally important
      contextual factors. CONCLUSION: The conceptualization of the implementation of a 
      CEC as a complex intervention shapes the intervention and the way evaluation
      research should be performed, in several significant ways. We recommend that
      researchers consider whether a complex intervention approach is called for when
      studying CESS implementation and impact.
FAU - Magelssen, Morten
AU  - Magelssen M
AUID- ORCID: 0000-0002-5994-8029
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Pb. 1130 Blindern, N-0318, Oslo, Norway. magelssen@gmail.com.
FAU - Karlsen, Heidi
AU  - Karlsen H
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Pb. 1130 Blindern, N-0318, Oslo, Norway.
FAU - Pedersen, Reidar
AU  - Pedersen R
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Pb. 1130 Blindern, N-0318, Oslo, Norway.
FAU - Thoresen, Lisbeth
AU  - Thoresen L
AD  - Department of Interdisciplinary Health Sciences, Institute of Health and Society,
      University of Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
EIN - BMC Med Ethics. 2020 Sep 30;21(1):92. PMID: 32998715
MH  - Delivery of Health Care
MH  - Ethics Committees
MH  - *Ethics Committees, Clinical
MH  - *Ethics, Clinical
MH  - Feasibility Studies
MH  - Humans
MH  - Norway
PMC - PMC7466831
OTO - NOTNLM
OT  - *Clinical ethics
OT  - *Clinical ethics committee
OT  - *Clinical ethics support services
OT  - *Complex intervention
OT  - *Ethics in community care
OT  - *Healthcare ethics
EDAT- 2020/09/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00522-1 [doi]
AID - 10.1186/s12910-020-00522-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 1;21(1):82. doi: 10.1186/s12910-020-00522-1.


PMID- 32873120
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1940-5200 (Electronic)
IS  - 1078-3458 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Oct
TI  - Clinician Experiences of Care Provision in the Correctional Setting: A Scoping
      Review.
PG  - 301-314
LID - 10.1177/1078345820953154 [doi]
AB  - Little is known about the experiences of correctional health care providers and
      how their experiences impact the correctional health care system. Following the
      Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols
      guidelines, multiple databases were searched. Each abstract was read by two
      reviewers with a third for consensus as needed. Full-text articles were selected 
      through a second round of review. Of 4,467 citations, 61 were selected for
      full-text evaluation and 23 were ultimately included. Major themes identified
      were the distinctive working environment, burnout, and the presence of ethical
      dilemmas, including the tension between security and clinical considerations.
      This scoping review identified a limited number of articles centered on the
      health care provider experience in the correctional setting.
FAU - Simon, Lisa
AU  - Simon L
AUID- ORCID: 0000-0003-4870-1052
AD  - Harvard School of Dental Medicine, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Beckmann, David
AU  - Beckmann D
AD  - Harvard Medical School, Boston, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
FAU - Stone, Martha
AU  - Stone M
AD  - Massachusetts General Hospital, Boston, MA, USA.
FAU - Williams, Rachael
AU  - Williams R
AD  - Massachusetts General Hospital, Boston, MA, USA.
FAU - Cohen, Marya
AU  - Cohen M
AD  - Harvard Medical School, Boston, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
FAU - Tobey, Matthew
AU  - Tobey M
AD  - Harvard Medical School, Boston, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200902
PL  - United States
TA  - J Correct Health Care
JT  - Journal of correctional health care : the official journal of the National
      Commission on Correctional Health Care
JID - 9503759
SB  - IM
MH  - Burnout, Professional/epidemiology
MH  - Correctional Facilities/*organization & administration
MH  - Environment
MH  - Ethics, Medical
MH  - Health Personnel/*psychology
MH  - Humans
OTO - NOTNLM
OT  - *correctional health
OT  - *health care providers
OT  - *professional burnout
OT  - *scoping review
EDAT- 2020/09/03 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/09/03 06:00 [entrez]
AID - 10.1177/1078345820953154 [doi]
PST - ppublish
SO  - J Correct Health Care. 2020 Oct;26(4):301-314. doi: 10.1177/1078345820953154.
      Epub 2020 Sep 2.


PMID- 32873078
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1545-293X (Electronic)
IS  - 1527-8204 (Linking)
VI  - 21
DP  - 2020 Aug 31
TI  - Credit for and Control of Research Outputs in Genomic Citizen Science.
PG  - 465-489
LID - 10.1146/annurev-genom-083117-021812 [doi]
AB  - Citizen science encompasses activities with scientific objectives in which
      members of the public participate as more than passive research subjects from
      whom personal data or biospecimens are collected and analyzed by others. Citizen 
      science is increasingly common in the biomedical sciences, including the fields
      of genetics and human genomics. Genomic citizen science initiatives are diverse
      and involve citizen scientists in collecting genetic data, solving genetic
      puzzles, and conducting experiments in community laboratories. At the same time
      that genomic citizen science is presenting new opportunities for individuals to
      participate in scientific discovery, it is also challenging norms regarding the
      manner in which scientific research outputs are managed. In this review, we
      present a typology of genomic citizen science initiatives, describe ethical and
      legal foundations for recognizing genomic citizen scientists' claims of credit
      for and control of research outputs, and detail how such claims are or might be
      addressed in practice across a variety of initiatives.
FAU - Guerrini, Christi J
AU  - Guerrini CJ
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas 77030, USA; email: guerrini@bcm.edu.
FAU - Contreras, Jorge L
AU  - Contreras JL
AD  - S.J. Quinney College of Law and School of Medicine, University of Utah, Salt Lake
      City, Utah 84112, USA; email: jorge.contreras@law.utah.edu.
LA  - eng
GR  - K01 HG009355/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Annu Rev Genomics Hum Genet
JT  - Annual review of genomics and human genetics
JID - 100911346
SB  - IM
MH  - Biomedical Research/*ethics
MH  - Citizen Science/*organization & administration
MH  - Community Participation/*methods
MH  - Genomics/*ethics
MH  - Humans
MH  - *Public Opinion
OTO - NOTNLM
OT  - *citizen science
OT  - *copyright
OT  - *crowdsourcing
OT  - *intellectual property
OT  - *participatory research
OT  - *patent
EDAT- 2020/09/03 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1146/annurev-genom-083117-021812 [doi]
PST - ppublish
SO  - Annu Rev Genomics Hum Genet. 2020 Aug 31;21:465-489. doi:
      10.1146/annurev-genom-083117-021812.


PMID- 32872549
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201027
IS  - 2076-0817 (Print)
IS  - 2076-0817 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Aug 29
TI  - Human Mucosal IgA Immune Responses against Enterotoxigenic Escherichia coli.
LID - E714 [pii]
LID - 10.3390/pathogens9090714 [doi]
AB  - Infection with enterotoxigenic Escherichia coli (ETEC) is a major contributor to 
      diarrheal illness in children in low- and middle-income countries and travelers
      to these areas. There is an ongoing effort to develop vaccines against ETEC, and 
      the most reliable immune correlate of protection against ETEC is considered to be
      the small intestinal secretory IgA response that targets ETEC-specific virulence 
      factors. Since isolating IgA from small intestinal mucosa is technically and
      ethically challenging, requiring the use of invasive medical procedures, several 
      other indirect methods are used as a proxy for gauging the small intestinal IgA
      responses. In this review, we summarize the literature reporting on anti-ETEC
      human IgA responses observed in blood, activated lymphocyte assayss, intestinal
      lavage/duodenal aspirates, and saliva from human volunteers being experimentally 
      infected with ETEC. We describe the IgA response kinetics and responder ratios
      against classical and noncanonical ETEC antigens in the different sample types
      and discuss the implications that the results may have on vaccine development and
      testing.
FAU - Riaz, Saman
AU  - Riaz S
AD  - Department of Clinical Science, University of Bergen, Jonas Lies veg 87, N-5021
      Bergen, Norway.
AD  - Centre for International Health, Department of Global Public Health and Primary
      Care, University of Bergen, 5020 Bergen, Norway.
FAU - Steinsland, Hans
AU  - Steinsland H
AD  - Centre for Intervention Science in Maternal and Child Health, Centre for
      International Health, Department of Global Public Health and Primary Care,
      University of Bergen, 5020 Bergen, Norway.
AD  - Department of Biomedicine, University of Bergen, 5020 Bergen, Norway.
FAU - Hanevik, Kurt
AU  - Hanevik K
AUID- ORCID: 0000-0002-1466-2326
AD  - Department of Clinical Science, University of Bergen, Jonas Lies veg 87, N-5021
      Bergen, Norway.
AD  - Norwegian National Advisory Unit on Tropical Infectious Diseases, Department of
      Medicine, Haukeland University Hospital, 5021 Bergen, Norway.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200829
PL  - Switzerland
TA  - Pathogens
JT  - Pathogens (Basel, Switzerland)
JID - 101596317
PMC - PMC7558491
OTO - NOTNLM
OT  - ETEC
OT  - IgA
OT  - SIgA
OT  - experimental infection
OT  - immunity
OT  - mucosal
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/07/16 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - pathogens9090714 [pii]
AID - 10.3390/pathogens9090714 [doi]
PST - epublish
SO  - Pathogens. 2020 Aug 29;9(9). pii: pathogens9090714. doi:
      10.3390/pathogens9090714.


PMID- 32872463
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201027
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Aug 29
TI  - Alternatives to the Use of Mechanical Restraints in the Management of Agitation
      or Aggressions of Psychiatric Patients: A Scoping Review.
LID - E2791 [pii]
LID - 10.3390/jcm9092791 [doi]
AB  - Coercive measures are a highly controversial issue in mental health. Although
      scientific evidence on their impact is limited, they are frequently used.
      Furthermore, they lead to a high number of ethical, legal, and clinical
      repercussions on both patients, and professionals and institutions. This review
      aims to assess the impact of the main alternative measures to prevent or limit
      the use of coercive measures with restraints in the management of agitated
      psychiatric patients. The research was conducted following the guidelines
      recommended by PRISMA (Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses) in Medline, Cochrane Library, CINAHL, Web of Science, PsycInfo,
      LILACS, and Health Database of records between 2015 and 2020. After a critical
      reading, 21 valid articles were included. Both simple interventions and complex
      restraint programs were evaluated. Training in de-escalation techniques, risk
      assessment, and implementation of the "six core strategies" or "Safewards"
      program were the most assessed and effective interventions to reduce aggressive
      behaviors and the use of coercive measures. According to the revised literature, 
      it is possible to reduce the use of restraints and coercive measures and not
      increase the number of incidents and violent behaviors among the patients through
      a non-invasive and non-pharmacological approach. However, further research and
      further randomized clinical trials are needed to compare the different
      alternatives and provide higher quality evidence.
FAU - Fernandez-Costa, Damian
AU  - Fernandez-Costa D
AUID- ORCID: 0000-0001-7317-5870
AD  - Faculty of Nursing, Department of Nursing, University of Huelva, 21071 Huelva,
      Spain.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AUID- ORCID: 0000-0001-9053-7730
AD  - Faculty of Labour Sciences, Department of Sociology, Social Work and Public
      Health, University of Huelva, 21007 Huelva, Spain.
AD  - Safety and Health Postgraduate Programme, Universidad Espiritu Santo, Guayaquil
      091650, Ecuador.
FAU - Fagundo-Rivera, Javier
AU  - Fagundo-Rivera J
AD  - Andalusian Health Service, Primary Care Emergency Service, Health Sciences
      Doctorate School, University of Huelva, 21007 Huelva, Spain.
FAU - Martin-Pereira, Jorge
AU  - Martin-Pereira J
AUID- ORCID: 0000-0002-9544-1532
AD  - Hospital Transport Consortium, Isla Cristina Health Center, Isla Cristina, 21410 
      Huelva, Spain.
FAU - Prieto-Callejero, Blanca
AU  - Prieto-Callejero B
AD  - Hospital Virgen de la Bella, Lepe, 21440 Huelva, Spain.
FAU - Garcia-Iglesias, Juan Jesus
AU  - Garcia-Iglesias JJ
AUID- ORCID: 0000-0003-4074-0399
AD  - Faculty of Labour Sciences, Department of Sociology, Social Work and Public
      Health, University of Huelva, 21007 Huelva, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200829
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7565407
OTO - NOTNLM
OT  - aggressive behaviors
OT  - agitation
OT  - mechanical restraint
OT  - mental disorders
OT  - psychiatry
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/07/30 00:00 [received]
PHST- 2020/08/22 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - jcm9092791 [pii]
AID - 10.3390/jcm9092791 [doi]
PST - epublish
SO  - J Clin Med. 2020 Aug 29;9(9). pii: jcm9092791. doi: 10.3390/jcm9092791.


PMID- 32872227
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Aug 28
TI  - Reply to Wolf et al.: Why Trap-Neuter-Return (TNR) Is Not an Ethical Solution for
      Stray Cat Management.
LID - E1525 [pii]
LID - 10.3390/ani10091525 [doi]
AB  - We critique the recent article by Wolf et al. (2019) that claims scientific merit
      for reducing the number of stray cats in Australia through Trap-Neuter-Return
      (TNR) programs, and then we provide an inventory of biological, welfare, and
      economic reasons why TNR is less successful than adoption and euthanasia for
      managing unowned cats. Like Crawford et al. (2019) and multiple other
      comprehensive and unbiased Australian and international scientific reviews, we
      refute the idea that returning neutered unowned cats to stray populations has any
      valid role in responsible, ethical, affordable, and effective cat management, or 
      in wildlife conservation. The main purported objective of TNR proponents along
      with animal welfare, human health, and wildlife advocacy stakeholders is to
      reduce the number of unhomed cats. We contend that cessation of provisioning
      unowned cats with food is the most effective approach to achieve this objective. 
      We also present evidence from the Brisbane City Council that informed cat
      management policy, advocacy, and laws, backed up by responsible rehoming or
      prompt ethical euthanasia, are together effective at reducing the stray cat
      problem.
FAU - Read, John L
AU  - Read JL
AD  - Earth and Environmental Sciences, University of Adelaide, Adelaide, SA 5000,
      Australia.
FAU - Dickman, Chris R
AU  - Dickman CR
AUID- ORCID: 0000-0002-1067-3730
AD  - School of Life and Environmental Sciences, University of Sydney, Sydney, NSW
      2006, Australia.
FAU - Boardman, Wayne S J
AU  - Boardman WSJ
AUID- ORCID: 0000-0002-1746-0682
AD  - School of Animal and Veterinary Sciences, University of Adelaide, Adelaide, SA
      5000, Australia.
FAU - Lepczyk, Christopher A
AU  - Lepczyk CA
AD  - School of Forestry and Wildlife Sciences, Auburn University, Auburn, AL 36849,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552220
OTO - NOTNLM
OT  - TNR
OT  - animal welfare
OT  - cat
OT  - euthanasia
OT  - infectious disease
OT  - shelters
OT  - trap-neuter-return
OT  - urban stray
OT  - wildlife
EDAT- 2020/09/03 06:00
MHDA- 2020/09/03 06:01
CRDT- 2020/09/03 06:00
PHST- 2020/08/08 00:00 [received]
PHST- 2020/08/20 00:00 [revised]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/03 06:01 [medline]
AID - ani10091525 [pii]
AID - 10.3390/ani10091525 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Aug 28;10(9). pii: ani10091525. doi: 10.3390/ani10091525.


PMID- 32872075
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - A network meta-analysis protocol of conservative interventions for urinary
      incontinence in postpartum women.
PG  - e21772
LID - 10.1097/MD.0000000000021772 [doi]
AB  - BACKGROUND: Postpartum urinary incontinence (PPUI) is a common urological
      condition in women after childbirth. Due to the side effects of surgical and
      pharmacological therapies, the patients and physicians alike express a strong
      preference for conservative approaches on PPUI, such as pelvic floor muscle
      training, biofeedback, electrical stimulation, bladder training, vaginal cones
      and acupuncture. Application of these conservative approaches should be guided by
      high quality evidence, yet their comparative effectiveness has not been well
      documented. Therefore, the network meta-analysis aims to compare, rank and
      summarize all available studies to determine which conservative intervention is
      more effective for PPUI. METHODS: In this present study, qualified English and
      Chinese studies will be searched in PubMed, Scopus, EMBASE, The Cochrane Library,
      Web of Science, VIP Database, Wanfang Database, Chinese Biomedical Literature
      Database and China National Knowledge Infrastructure. All eligible randomized
      controlled trails (RCTs) of conservative interventions for PPUI will be included.
      R software 3.61 (R Foundation for Statistical Computing, Vienna, Austria) will be
      applied to synthesize data and conduct network meta-analysis. I statistic and Z
      test will be used to assess heterogeneity and inconsistency, respectively.
      RESULTS: Ethical approval is not required for this existed literature based
      meta-analysis. The findings of this research will be disseminated through a
      recognized journal. CONCLUSION: The findings of this study will provide ranking
      evidence for clinicians and patients to choose a more appropriate conservative
      therapy on PPUI. TRIAL REGISTRATION NUMBER: PROSPERO CRD42020168042.
FAU - Wang, Yang
AU  - Wang Y
AUID- ORCID: 0000-0002-4920-6515
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
AD  - Department of Rehabilitation, Shuangliu Maternal and Child Health Care Hospital.
FAU - Li, Hui
AU  - Li H
AD  - School of Medicine, Chengdu University.
FAU - Wang, Jun
AU  - Wang J
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Hao, Qinghong
AU  - Hao Q
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Tu, Yang
AU  - Tu Y
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Chen, Yalin
AU  - Chen Y
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Qiu, Mimi
AU  - Qiu M
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Peng, Wei
AU  - Peng W
AD  - School of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Liu, Yunlu
AU  - Liu Y
AD  - Institute of Laboratory Animal Sciences.
AD  - Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial 
      People's Hospital, Chengdu, China.
FAU - Zhu, Tianmin
AU  - Zhu T
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Conservative Treatment
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Puerperal Disorders/*therapy
MH  - Systematic Reviews as Topic
MH  - Urinary Incontinence/*therapy
PMC - PMC7437778
EDAT- 2020/09/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1097/MD.0000000000021772 [doi]
AID - 00005792-202008140-00109 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21772. doi:
      10.1097/MD.0000000000021772.


PMID- 32872065
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - Acupuncture improves postoperative symptoms of pigmented villonodular synovitis: 
      A protocol for systematic review and meta analysis.
PG  - e21748
LID - 10.1097/MD.0000000000021748 [doi]
AB  - BACKGROUND: Pigmented villonodular synovitis (PVNS) is a benign proliferative
      disease of synovial joint, synovial sac and tendon sheath. PVNS is usually
      treated by surgery, but postoperative joint dysfunction and pain will be
      accompanied, which seriously affects the quality of life. The purpose of this
      review is to evaluate the effectiveness and safety of this intervention in
      patients with pain and dysfunction caused by postoperative symptoms of PVNS.
      METHODS: We will search the EMBASE, the Cochrane Library, Ovid MEDLINE, PubMed,
      Web of Science, Chinese Biomedical Literature Database (CBM), Chinese National
      Knowledge Infrastructure (CNKI), Wanfang Database, the Chongqing VIP (VIP), the
      US National Institute of Health, the NIH clinical registry Clinical Trials, the
      ICTRP, and the Australian New Zealand Clinical Trials Registry and the Chinese
      clinical registry, from their inception to 1st July 2020. Randomized controlled
      trials that include patients with postoperative symptoms of pigmented
      villonodular synovitis receiving acupuncture therapy versus a control group will 
      be included. The selection of studies, data extraction and risk of bias
      assessment will be conducted by 2 independent researchers. A third review author 
      resolved disagreements. The dichotomous data will be presented as risk ratios
      with 95% confidence intervals (CIs) and the continuous data will be presented as 
      weighted mean differences or standardized mean differences with 95% CIs. Evidence
      quality will be evaluated using the GRADE system. RESULTS: The results will be
      disseminated through a peer-reviewed journal publication. CONCLUSIONS: This
      systematic review will provide updated evidence of various types of acupuncture
      specifically focuses on its effectiveness and safety for patients' pain and
      dysfunction caused by post-operation of pigmented villonodular synovitis. ETHICS 
      AND DISSEMINATION: Ethical approval is not necessary as this review will not
      require data from individual patients. The results of this will be published
      through peer-reviewed journal articles or conference presentations. REGISTRATION:
      Open Science Framework (OSF). 2020, July 7. 10.17605/OSF.IO/CZW9P.
FAU - Tang, Hongzhi
AU  - Tang H
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
FAU - Fan, Huaying
AU  - Fan H
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine, Chengdu City, Sichuan Province, China.
FAU - Luo, Fei
AU  - Luo F
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
FAU - Huang, Li
AU  - Huang L
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
FAU - Liao, Shichuan
AU  - Liao S
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
FAU - Yu, Wenjing
AU  - Yu W
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
FAU - Chen, Yunbei
AU  - Chen Y
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
FAU - Chen, Jiao
AU  - Chen J
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine, Chengdu City, Sichuan Province, China.
FAU - Qin, Xuefei
AU  - Qin X
AD  - Outpatient Department of Sichuan Orthopedic Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pain, Postoperative/*therapy
MH  - Synovitis, Pigmented Villonodular/*rehabilitation/surgery
MH  - Systematic Reviews as Topic
PMC - PMC7437758
EDAT- 2020/09/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1097/MD.0000000000021748 [doi]
AID - 00005792-202008140-00099 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21748. doi:
      10.1097/MD.0000000000021748.


PMID- 32872063
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - Herbal medicine treatment for Alzheimer disease: A protocol for a systematic
      review and meta-analysis.
PG  - e21745
LID - 10.1097/MD.0000000000021745 [doi]
AB  - BACKGROUND: Alzheimer disease (AD) is a leading progressive neurodegenerative
      disease worldwide, but treating it is challenging in clinical practice. This
      review is aimed at evaluating the efficacy and safety of herbal medicine for
      treating AD. METHODS AND ANALYSIS: We will search for randomized controlled
      trials related to the effect and safety of herbal medicine for AD in the
      following databases: PubMed, Cochrane Central Register of Controlled Trials,
      Excerpta Medica Database, China National Knowledge Infrastructure database,
      Oriental Medicine Advanced Searching Integrated system, Korean Traditional
      Knowledge Portal, and Citation Information by National Institute for Informatics.
      The risk of bias will be evaluated using the Cochrane risk-of-bias assessment
      tool. After screening the studies, a meta-analysis will be performed. The primary
      outcome will be the Mini-Mental State Examination score. Secondary outcomes will 
      consist of other scales for cognitive function and other aspects, such as
      behavioral and psychological symptoms and plasma levels of amyloid-beta. RESULTS:
      This study will provide the current status of evidence for herbal medicine to
      treat AD. CONCLUSION: The results of this review will determine the efficacy and 
      safety of herbal medicine for AD. ETHICS AND DISSEMINATION: Ethical approval is
      not required, as this study is based on a review of published research. This
      review will be published in a peer-reviewed journal and disseminated both
      electronically and in print. TRIAL REGISTRATION NUMBER: Research Registry
      reviewregistry933.
FAU - Lee, JiEun
AU  - Lee J
AD  - Department of Korean Medicine Cardiology and Neurology, Graduate School.
FAU - Jin, Chul
AU  - Jin C
AD  - Department of Korean Medicine Cardiology and Neurology, Graduate School.
FAU - Cho, Seung-Yeon
AU  - Cho SY
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Park, Seong-Uk
AU  - Park SU
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Jung, Woo-Sang
AU  - Jung WS
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Moon, Sang-Kwan
AU  - Moon SK
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Park, Jung-Mi
AU  - Park JM
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Ko, Chang-Nam
AU  - Ko CN
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Cho, Ki-Ho
AU  - Cho KH
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
FAU - Kwon, Seungwon
AU  - Kwon S
AUID- ORCID: 0000-0002-1857-3515
AD  - Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee
      University, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Alzheimer Disease/*drug therapy
MH  - Herbal Medicine
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Phytotherapy
MH  - Plant Extracts/*therapeutic use
MH  - Systematic Reviews as Topic
PMC - PMC7437827
EDAT- 2020/09/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1097/MD.0000000000021745 [doi]
AID - 00005792-202008140-00097 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21745. doi:
      10.1097/MD.0000000000021745.


PMID- 32872033
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - The efficacy and safety of the infiltration of the interspace between the
      popliteal artery and the capsule of the knee block in total knee arthroplasty: A 
      prospective randomized trial protocol.
PG  - e21670
LID - 10.1097/MD.0000000000021670 [doi]
AB  - BACKGROUND: Total knee arthroplasty (TKA) is an established and successful
      surgical procedure which is the major treatment for degenerative knee joint
      diseases. A novel technique to address posterior knee joint pain is the
      infiltration of local anesthetic between the interspace between the popliteal
      artery and capsule of the knee (IPACK). The goal of this randomized clinical
      trial was to assess the efficacy and safety of adding IPACK to adductor canal
      block (ACB) after TKA. METHODS: This was a prospectively randomized trial that
      investigated the effectiveness and safety of the IPACK after TKA. Approval from
      Clinical Studies Ethical Committee in Qilu Hospital of Shandong University was
      obtained. The inclusion criteria were adult patients undergoing primary
      unilateral TKA and American Society of Anesthesiologists grade 1 or 2 with normal
      cognitive function. The patients were randomized to 1 of 2 treatment options:
      ACB-alone group and ACB + IPACK group. The primary outcome was the total morphine
      consumption during postoperative 24 hours. Secondary outcomes included
      postoperative pain score, time to first and total dosage of rescue morphine in
      postoperative 48 hours, early and late postoperative period (from postoperative
      day 0-3 months follow-up) performance-based test (Timed-Up and Go test, and
      quadriceps strength). Postoperative nausea and vomiting, length of hospital stay,
      patient satisfaction, and other adverse events were also evaluated. RESULTS: It
      was hypothesized that when combined with a control group, the IPACK block would
      result in a lower morphine consumption and pain score after TKA. TRIAL
      REGISTRATION: This study protocol was registered in Research Registry
      (researchregistry5765).
FAU - Cong, Zhongxiao
AU  - Cong Z
AUID- ORCID: 0000-0003-2317-7127
AD  - Department of Operating Room, Qilu Hospital of Shandong University, Shandong,
      China.
FAU - Zhang, Lejun
AU  - Zhang L
FAU - Ma, Fengying
AU  - Ma F
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anesthetics, Local)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Analgesics, Opioid/administration & dosage
MH  - Anesthetics, Local/administration & dosage
MH  - Arthroplasty, Replacement, Knee/*methods
MH  - Humans
MH  - Morphine/administration & dosage
MH  - Nerve Block/*methods
MH  - Pain, Postoperative/*prevention & control
MH  - Popliteal Artery
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
PMC - PMC7437726
EDAT- 2020/09/03 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1097/MD.0000000000021670 [doi]
AID - 00005792-202008140-00067 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21670. doi:
      10.1097/MD.0000000000021670.


PMID- 32872012
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - A randomized controlled trial for gualou danshen granules in the treatment of
      unstable angina pectoris patients with phlegm-blood stasis syndrome.
PG  - e21593
LID - 10.1097/MD.0000000000021593 [doi]
AB  - INTRODUCTION: Unstable angina pectoris is an acute exacerbation secondary to
      coronary artery occlusion. In routine clinical treatment, patients with unstable 
      angina pectoris are prone to recurrence or aggravation of symptoms. Based on the 
      traditional Chinese medicine (TCM) theory, phlegm, and blood stasis are one of
      the main pathological factors of unstable angina pectoris. The treatment of
      unstable angina pectoris with phlegm-blood stasis syndrome by Gualou Danshen
      granules (GLDS) has been the focus of many clinical trials. However, there is no 
      evidence to prove the safety or clinical efficacy of GLDS. METHODS AND ANALYSIS: 
      In this study, we will conduct a 4-week randomized, controlled feasibility study,
      with participants recruited from Guang'anmen Hospital, Chinese Academy of
      Traditional Chinese Medicine. Sixty subjects are to be diagnosed as having
      phlegm-blood stasis syndrome and randomly divided into a treatment group (GLDS)
      and placebo group in a 1:1 ratio. Result measurements will include therapeutic
      indicators (Clinical Symptom Rating Scale, Phlegm-Blood Stasis Syndrome Scale,
      and Seattle Angina Questionnaire) and safety indicators (blood routine, urine
      routine, electrocardiogram, liver function, and kidney function). The clinical
      data management system (http://www.tcmcec.net/) will be used to collect and
      manage data. Quality control will be implemented according to good clinical
      practice. DISCUSSION: Previous TCM clinical trials have investigated if adding
      GLDS to standard routine treatment can improve the therapeutic effect in patients
      with unstable angina pectoris. This study focuses on the safety and efficacy of
      GLDS on unstable angina pectoris of phlegm-blood stasis type, in order to obtain 
      relevant clinical evidence. TRIAL REGISTRATION: This study is approved by the
      Ethics Committee of Guang'anmen Hospital of the China Academy of Chinese Medical 
      Sciences (no. 2019-187-KY-02) and is registered with chictr.org (registration
      number ChiCTR2000031780).
FAU - Guo, Jianbo
AU  - Guo J
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Dai, Shuang
AU  - Dai S
AUID- ORCID: 0000-0002-5885-8005
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Ding, Yukun
AU  - Ding Y
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - He, Haoqiang
AU  - He H
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Henan University of Chinese Medicine, Henan 450000, China.
FAU - Dan, Wenchao
AU  - Dan W
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Qin, Kun
AU  - Qin K
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Li, Anqi
AU  - Li A
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Meng, Peipei
AU  - Meng P
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Li, Shangjin
AU  - Li S
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - He, Qingyong
AU  - He Q
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 1693AM5SBN (dan-shen root extract)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angina, Unstable/*drug therapy/therapy
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Medicine, Chinese Traditional/*methods
MH  - Middle Aged
MH  - Salvia miltiorrhiza
PMC - PMC7437832
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.1097/MD.0000000000021593 [doi]
AID - 00005792-202008140-00046 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21593. doi:
      10.1097/MD.0000000000021593.


PMID- 32871993
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - The value of microRNA-21 as a biomarker for the prognosis of lung cancer: A
      protocol for systematic review and meta-analysis.
PG  - e21483
LID - 10.1097/MD.0000000000021483 [doi]
AB  - BACKGROUD: More and more studies are investigating the influence of the
      expression of MicroRNA-21 (miRNA-21) on prognosis and clinical significance in
      patients with lung cancer, but the results are contradictory and uncertain. A
      meta-analysis was conducted with controversial data to accurately assess the
      issue. METHODS: A detailed search of relevant research in Wanfang, Chinese
      Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI),
      the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed,
      Embase, Web of Science and other databases. Two reviewers independently conducted
      data extraction and literature quality evaluation. Odd ratio and its 95%
      confidence intervals were used to evaluate the relationship between miRNA-21 and 
      clinicopathological characteristics of lung cancer patients. Hazard ratios and
      its 95% confidence intervals To assess the prognostic effect of miRNA-21 on
      overall survival and disease-free survival. Meta analysis was performed using
      RevMan 5.3 and Stata 14.0 software. RESULTS: This study will provide a
      high-quality evidence-based medical evidence of the correlations between miRNA-21
      expression and overall survival, disease-free survival and clinicopathological
      features. CONCLUSION: The study will provide updated evidence to evaluate whether
      the expression of miRNA-21 is in association with poor prognosis in patients with
      lung cancer. ETHICS AND DISSEMINATION: The private information from individuals
      will not publish. This systematic review also will not involve endangering
      participant rights. Ethical approval is not available. The results may be
      published in a peer- reviewed journal or disseminated in relevant conferences.
      OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/X3MD6.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan
      Cancer Center/School of Medicine,University of Electronic Science and Technology 
      of China.
FAU - Wei, Lin
AU  - Wei L
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan
      Cancer Center/School of Medicine,University of Electronic Science and Technology 
      of China.
FAU - Luo, Rong
AU  - Luo R
AD  - Department of Medical Oncology, West China fourth hospital of Sichuan University,
      chendu, P. R. China.
FAU - Liu, Hui
AU  - Liu H
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan
      Cancer Center/School of Medicine,University of Electronic Science and Technology 
      of China.
FAU - Chen, Jing
AU  - Chen J
AUID- ORCID: 0000-0001-5668-653
AD  - Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan
      Cancer Center/School of Medicine,University of Electronic Science and Technology 
      of China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Humans
MH  - Lung Neoplasms/*genetics
MH  - Meta-Analysis as Topic
MH  - *MicroRNAs
MH  - Prognosis
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7437733
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021483 [doi]
AID - 00005792-202008140-00027 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21483. doi:
      10.1097/MD.0000000000021483.


PMID- 32871982
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - The prophylactic effects of vitamin K supplementation on coagulopathies
      associated with type 2 diabetes mellitus: A protocol for a systematic review and 
      meta-analysis.
PG  - e21143
LID - 10.1097/MD.0000000000021143 [doi]
AB  - BACKGROUND: The impact of vitamin K in ameliorating diabetes-associated
      complications, especially those linked with platelet activation and coagulation
      remains unclear. The current study aims to systematically explore and discuss the
      available evidence on the impact of vitamin K on the diabetes-cardiovascular
      disease (CVD)-associated complications. METHODS: A systematic review of studies
      published on the MEDLINE (PubMed), EMBASE, and Google Scholar electronic database
      will be conducted. The review will include studies published from inception until
      May 25, 2020, reporting on the effect of vitamin K on CVD-related markers,
      especially coagulation factors and platelet activation in type 2 diabetes
      mellitus. Before the full-text screening, all studies will be screened by title, 
      abstract, and keywords. The Downs and Black checklist will be used to assess the 
      quality of the studies. Additionally, the Cochrane collaboration tool will also
      be used to evaluate the risk of bias across the included studies. Kappa Cohen's
      calculator will be used to assess the level of agreement between the authors.
      DISCUSSIONS: This systematic review will not require ethical approval, and the
      results will be distributed through conference and peer-reviewed publications.
      Our results will assist current and future research scientists on the potential
      use of vitamin K as a protective therapy against CVD-related complications.
      SYSTEMATIC REVIEW REGISTRATION: This protocol is registered on the International 
      Prospective Register of Systematic Reviews (PROSPERO) registration number:
      CRD42020151667.
FAU - Mokgalaboni, Kabelo
AU  - Mokgalaboni K
AUID- ORCID: 0000-0002-3224-7433
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health
      Sciences, University of KwaZulu-Natal, Durban.
FAU - Dludla, Phiwayinkosi V
AU  - Dludla PV
AUID- ORCID: 0000-0001-5965-3610
AD  - Biomedical Research and Innovation Platform, South African Medical Research
      Council, Tygerberg, South Africa.
AD  - Department of Life and Environmental Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
FAU - Nkambule, Bongani B
AU  - Nkambule BB
AUID- ORCID: 0000-0001-8846-1992
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health
      Sciences, University of KwaZulu-Natal, Durban.
LA  - eng
GR  - D43 TW010131/TW/FIC NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 12001-79-5 (Vitamin K)
SB  - IM
MH  - Blood Coagulation Disorders/*etiology/*therapy
MH  - Diabetes Mellitus, Type 2/*complications/therapy
MH  - Dietary Supplements
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Systematic Reviews as Topic
MH  - Vitamin K/*therapeutic use
PMC - PMC7437854
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.1097/MD.0000000000021143 [doi]
AID - 00005792-202008140-00016 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21143. doi:
      10.1097/MD.0000000000021143.


PMID- 32871977
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - Chinese medicine for coronavirus disease 2019 as complementary therapy: A
      protocol for a systematic review and meta-analysis.
PG  - e21034
LID - 10.1097/MD.0000000000021034 [doi]
AB  - BACKGROUND: The aim of this systematic review and meta-analysis is to assess
      effectiveness and safety of Chinese medicine (CM) as complementary therapy in
      treating coronavirus disease 2019 (COVID-19). METHODS: The following databases
      will be searched: PubMed, Cochrane, Embase, China National Knowledge
      Infrastructure, Chinese Science and Technology Periodical Database, and Wanfang
      database from October 1, 2019 to March 1, 2020. Randomized trials and
      quasi-randomized or prospective controlled clinical trials of CM that reported
      data on COVID-19 patients will be included. Study selection, data extraction,
      quality assessment, and assessment of risk bias will be performed by 2 reviewers 
      independently. Odds ratios and correlative 95% confidence intervals will be
      calculated to present the association between the CM and CWM using Review Manager
      version 5.3 when there is sufficient available data. RESULTS: The results will be
      disseminated through a peer-reviewed journal publication. CONCLUSION: This
      systematic review findings will summarize up-to-date evidence for that CM is more
      effective and safe as adjunctive treatment for patients with COVID-19. ETHICS AND
      DISSEMINATION: Ethics approval and patient consent are not required as this study
      is a systematic review based on published articles. PROSPERO REGISTRATION NUMBER:
      CRD42020185382.
FAU - Zhou, Min
AU  - Zhou M
AUID- ORCID: 0000-0001-6739-3919
AD  - College of Clinical Medical, Jiangxi University of Traditional Chinese Medicine.
FAU - Liang, Qijun
AU  - Liang Q
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang.
FAU - Pei, QiuLan
AU  - Pei Q
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang.
FAU - Xu, Fan
AU  - Xu F
AD  - College of Clinical Medical, Jiangxi University of Traditional Chinese Medicine.
FAU - Wen, Hang
AU  - Wen H
AD  - College of Clinical Medical, Shanghai University of Traditional Chinese Medicine,
      Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Complementary Therapies/*methods
MH  - Coronavirus Infections/drug therapy/*therapy/virology
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Medicine, Chinese Traditional/methods
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Odds Ratio
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy/virology
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7437844
EDAT- 2020/09/03 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1097/MD.0000000000021034 [doi]
AID - 00005792-202008140-00011 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e21034. doi:
      10.1097/MD.0000000000021034.


PMID- 32871975
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 33
DP  - 2020 Aug 14
TI  - Vitamin D supplementation in the treatment of type 2 diabetic microangiopathy: A 
      protocol for a systematic review and meta-analysis.
PG  - e20978
LID - 10.1097/MD.0000000000020978 [doi]
AB  - BACKGROUND: The number of people with diabetes is growing exponentially.Human
      studies have shown that vitamin D supplementation is beneficial for type 2
      diabetic microangiopathy. However, owing to the low quality, small sample size,
      and methodological heterogeneity of these studies, this conclusion is not
      convincing. Consequently, in order to determine whether vitamin D supplementation
      is effective and safe in type 2 diabetic microangiopathy, it is necessary to
      conduct a meta-analysis of high-quality clinical trials. METHODS: We will search 
      each database from the built-in until March 2020. The English literature mainly
      searches Cochrane Library, PubMed, EMBASE, and Web of Science, while the Chinese 
      literature comes from CNKI, CBM, VIP, and Wangfang database. Simultaneously we
      will retrieval clinical registration tests and grey literatures. In this study,
      only the clinical randomized controlled trials were selected to evaluate the
      efficacy and safety of vitamin D in the treatment of type 2 diabetic
      microangiopathy. The two researchers independently conducted literature
      selection, data extraction and quality assessment. Statistical heterogeneity
      among studies will be evaluated using the Cochran Q test (x) and the I
      statistical value. We will utilize the Review Manage software V5.3.0 (The Nordic 
      Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) to
      statistically analyze all data. ETHICS AND DISSEMINATION: Ethics and
      dissemination: This study is a systematic review of vitamin D supplementation as 
      a treatment of type 2 diabetic microangiopathy. RESULTS: This study will provide 
      high-quality synthesis of effectiveness and safety of vitamin D supplementation
      for type 2 diabetic microangiopathy. CONCLUSION: This systematic review aims to
      provide new options for vitamin D treatment of type 2 diabetic microangiopathy in
      terms of its efficacy and safety. REGISTRATION NUMBER: LNPLASY202050055.
FAU - Chen, Junmin
AU  - Chen J
AUID- ORCID: 0000-0002-0086-1607
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, P.R. China.
FAU - Gong, Xiayu
AU  - Gong X
FAU - Liu, Jie
AU  - Liu J
FAU - Wang, Tingting
AU  - Wang T
FAU - Shi, Xiaoyan
AU  - Shi X
FAU - Zhang, Xiaoran
AU  - Zhang X
FAU - Chen, Qiu
AU  - Chen Q
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*complications/therapy
MH  - Diabetic Angiopathies/*therapy
MH  - *Dietary Supplements
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Systematic Reviews as Topic
MH  - Vitamin D/adverse effects/*therapeutic use
PMC - PMC7437839
EDAT- 2020/09/03 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.1097/MD.0000000000020978 [doi]
AID - 00005792-202008140-00009 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 14;99(33):e20978. doi:
      10.1097/MD.0000000000020978.


PMID- 32871962
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220809
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Impact of mirna-21 on survival prognosis in patients with pancreatic cancer: A
      protocol for systematic review and meta-analysis.
PG  - e22045
LID - 10.1097/MD.0000000000022045 [doi]
AB  - BACKGROUND: Previous studies have reported that microRNA-21 (mRNA-21) has an
      effect on the prognosis of pancreatic cancer. However, the conclusion is still
      unclear. Therefore, this study will try to explore the effect of high expression 
      of mRNA-21 on the prognosis of pancreatic cancer. METHODS: Retrieved the
      database, including the China National Knowledge Infrastructure (CNKI), Chinese
      Biomedical literature Database (CBM), Chinese Scientific and Journal Database
      (VIP), Wan Fang database, PubMed, and EMBASE. Hazard ratios (HRs) and its 95%
      confidence intervals (CIs) to assess the prognostic effect of miRNA-21 on overall
      survival (OS) and disease-free survival (DFS). RevMan 5.3 and STATA 16.0 software
      were used to perform the meta-analysis. RESULTS: This study will comprehensively 
      review and evaluate the available evidence of high expression of miRNA-21 on the 
      prognosis of patients with pancreatic cancer. CONCLUSION: Our findings will show 
      the effect of high expression of miRNA-21 on the prognosis of patients with
      pancreatic cancer. Such studies may find a new prognostic marker for patients
      with pancreatic cancer and help clinicians and health professionals make clinical
      decisions. ETHICS AND DISSEMINATION: The private information from individuals
      will not publish. This systematic review also will not involve endangering
      participant rights. Ethical approval is not available. The results may be
      published in a peer- reviewed journal or disseminated in relevant conferences.
      OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/2A6KJ.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan
      Cancer Center, Cancer Hospital affiliate to School of Medicine.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan
      Cancer Center, Cancer Hospital affiliate to School of Medicine.
FAU - He, Guoqian
AU  - He G
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education.
AD  - Department of Pediatrics, Sichuan.
FAU - Xu, Wenming
AU  - Xu W
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education.
AD  - Joint Laboratory of Reproductive Medicine.
FAU - He, Guolin
AU  - He G
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University), Ministry of Education.
AD  - Department of Obstetrics and Gynecology, West China Second University Hospital,
      Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - MicroRNAs/*metabolism
MH  - Pancreatic Neoplasms/diagnosis/*metabolism
MH  - Prognosis
MH  - Systematic Reviews as Topic
PMC - PMC7458261
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000022045 [doi]
AID - 00005792-202008280-00105 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e22045. doi:
      10.1097/MD.0000000000022045.


PMID- 32871956
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Traditional Chinese medicine Xiaosheng Powder for dry eye disease: A protocol for
      systematic review and meta analysis.
PG  - e22019
LID - 10.1097/MD.0000000000022019 [doi]
AB  - BACKGROUND: Dry eye disease (DED) has shown a significant increase in recent
      years, which seriously affects people's work and life. Xiaosheng Powder, a
      traditional Chinese medicine decoction, has been widely used in treating DED.
      However, there is no systematic review of the results of the study on this
      therapeutic effect. The purpose of this review is to evaluate the effectiveness
      and safety of Xiaosheng Powder in the treatment of DED. METHODS AND ANALYSIS: The
      electronic databases to be searched will include MEDLINE (PubMed), Cochrane
      Central Register of Controlled Trials in the Cochrane Library, Excerpta Medica
      Database, China National Knowledge Infrastructure, China Scientific Journal
      Database, Wanfang Database and Chinese Biomedical Literature Database. Papers in 
      English or Chinese published from inception to 2020 will be included without any 
      restrictions. Improvement in Ocular Surface Disease Index will be assessed as the
      primary outcomes. Tear break-up time, Schirmer I test, fluorescent, adverse
      events, and the recurrence rate after at least 3 months of the treatment will be 
      evaluated as secondary outcomes. We will conduct a meta-analysis of randomized
      controlled trial if possible. The methodological qualities, including the risk of
      bias, will be evaluated using the Cochrane risk of bias assessment tool, while
      confidence in the cumulative evidence will be evaluated using the Grading of
      Recommendations Assessment, Development, and Evaluation approach. ETHICS AND
      DISSEMINATION: It is not necessary for a formal ethical approval because the data
      is not individualized. The results of this review will offer implications for the
      use of Xiaosheng Powder as a treatment for DED. This knowledge will inform
      recommendations by ophthalmologist and researchers who are interested in the
      treatment of DED. The findings of this systematic review will be disseminated
      through peer-reviewed publications and conference presentations. TRAIL
      REGISTRATION NUMBER: PROSPERO CRD42020147709.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Ophthalmology, Eye Hospital.
AD  - Graduate School.
FAU - Chen, Shuntai
AU  - Chen S
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Hao, Xiaofeng
AU  - Hao X
AD  - Department of Ophthalmology, Eye Hospital.
FAU - Wu, Gaiping
AU  - Wu G
AD  - Department of Ophthalmology, Eye Hospital.
AD  - Graduate School.
FAU - Wang, Shihui
AU  - Wang S
AD  - Department of Ophthalmology, Eye Hospital.
AD  - Graduate School.
FAU - Yuan, Hang
AU  - Yuan H
AD  - Department of Ophthalmology, Eye Hospital.
AD  - Graduate School.
FAU - Jin, Qi
AU  - Jin Q
AD  - Department of Ophthalmology, Eye Hospital.
AD  - Graduate School.
FAU - Sun, Mei
AU  - Sun M
AD  - Department of Ophthalmology, Eye Hospital.
AD  - Graduate School.
FAU - Xie, Like
AU  - Xie L
AD  - Department of Ophthalmology, Eye Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (fructus schizandrae, radix ginseng, radix ophiopogonis drug combination)
RN  - 0 (xiaoyao)
SB  - IM
MH  - Drug Combinations
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Dry Eye Syndromes/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Phytotherapy
MH  - Systematic Reviews as Topic
PMC - PMC7458267
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000022019 [doi]
AID - 00005792-202008280-00099 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e22019. doi:
      10.1097/MD.0000000000022019.


PMID- 32871955
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - The efficacy and safety of Tanreqing injection combined with western medicine for
      severe pneumonia: A protocol for systematic review and meta-analysis.
PG  - e22010
LID - 10.1097/MD.0000000000022010 [doi]
AB  - BACKGROUND: Tanreqing injection, as a kind of traditional Chinese medicine
      injection widely used in clinic, has the effects of clearing heat, reducing
      phlegm and detoxifying, and avoids the problems of slow effect and complicated
      decocting of traditional Chinese medicine. Severe pneumonia is a critical disease
      of the respiratory system, with symptoms such as dyspnea, shortness of breath,
      high fever, and coma. Clinical studies have found that Tanreqing injection
      combined with Western medicine has a good effect in the treatment of severe
      pneumonia. In order to explore the efficacy and safety of Tanreqing injection
      combined with antibiotics in the treatment of severe pneumonia, we plan to
      conduct a systematic evaluation and meta-analysis. METHODS: Randomized controlled
      trials (RCTs) on the treatment of severe pneumonia with Tanreqing injection
      combined with western medicine were collected by searching PubMed, The Cochrane
      Library, Embase, Web of Science, CNKI, Wanfang Database, Weipu Database, and
      China Biomedical Literature Service System (CBM) by computer with the retrieval
      time from establishment of database to July 2020. Two researchers independently
      screened and extracted the literature, and finally evaluated the bias risk of the
      included study, and meta-analysis was conducted using RevMan5.3 software.
      RESULTS: The study evaluated the efficacy and safety of Tanreqing injection
      combined with Western medicine in the treatment of severe pneumonia in terms of
      total response rate, CURB-65 score, white blood cell count (WBC), antipyretic
      time (AT), adverse reaction incidence, etc. CONCLUSIONS:: This study will provide
      a reliable evidence-based basis for the clinical application of Tanreqing
      injection in the treatment of severe pneumonia. ETHICS AND DISSEMINATION: The
      private information from individuals will not be published. This systematic
      review also will not involve endangering participant rights. Ethical approval is 
      not required. The results may be published in a peer-reviewed journal or
      disseminated in relevant conferences. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/SQDMG.
FAU - Wang, Lei
AU  - Wang L
AUID- ORCID: 0000-0002-2524-2562
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan
      Province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin 300193.
FAU - Xu, Jingyu
AU  - Xu J
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
      Tianjin 300193.
FAU - Deng, Huaihan
AU  - Deng H
AD  - Pengzhou Hospital of Traditional Chinese Medicine, Pengzhou 6119301, Sichuan
      Province.
FAU - Geng, Chen
AU  - Geng C
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
FAU - Jia, Bo
AU  - Jia B
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan
      Province.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (tanreqing)
SB  - IM
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Injections
MH  - Meta-Analysis as Topic
MH  - Pneumonia/*drug therapy
MH  - Systematic Reviews as Topic
PMC - PMC7458256
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000022010 [doi]
AID - 00005792-202008280-00098 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e22010. doi:
      10.1097/MD.0000000000022010.


PMID- 32871944
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Does omega-3 lower blood pressure?: A protocol for systematic review and
      meta-analysis.
PG  - e21955
LID - 10.1097/MD.0000000000021955 [doi]
AB  - BACKGROUND: Hypertension is a clinically common cardiovascular disease, resulting
      in many complications. Omega-3 might be beneficial in lowering blood pressure.
      This protocol will be performed to evaluate the effects of omega-3 on blood
      pressure in hypertensive patients. METHODS: We will search both the electronical 
      databases and paper-published journals. Endnote software will be used to complete
      study screening and data extraction by 2 reviewers independently. Review Manager 
      software will be used to synthesize the data. The primary outcomes are systolic
      blood pressure and diastolic blood pressure. Secondary outcome is the adverse
      effects. RESULTS: The results of this study will propose a trustworthy evidence
      to evaluate the effects of omega-3 on blood pressure of hypertensive patients.
      CONCLUSION: The conclusion of our systematic review will reply whether omega-3 is
      an effectual intervention to lower blood pressure of hypertensive patients.
      ETHICS: This review does not require ethical approval because all of the data
      analyzed in this review have been published. REGISTRATION NUMBER:
      INPLASY202070103 (DOI number: 10.37766/inplasy2020.7.0103).
FAU - Tao, Li-Yu
AU  - Tao LY
AD  - Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Wang, Yi-Ru
AU  - Wang YR
AD  - Longhua Hospital Affiliated to Shanghai University of Traditional Chinese
      Medicine, Shanghai, China.
FAU - Zhang, Yi-Fan
AU  - Zhang YF
AD  - Longhua Hospital Affiliated to Shanghai University of Traditional Chinese
      Medicine, Shanghai, China.
FAU - Liu, Ping
AU  - Liu P
AD  - Longhua Hospital Affiliated to Shanghai University of Traditional Chinese
      Medicine, Shanghai, China.
FAU - Chen, Xiao-Hong
AU  - Chen XH
AD  - Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese
      Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Fatty Acids, Omega-3)
SB  - IM
MH  - Blood Pressure/*drug effects
MH  - Fatty Acids, Omega-3/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypertension/*prevention & control
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7458235
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021955 [doi]
AID - 00005792-202008280-00087 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21955. doi:
      10.1097/MD.0000000000021955.


PMID- 32871917
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Comparison adductor canal block combined with local infiltration analgesia and
      adductor canal block alone for pain management after total knee arthroplasty: A
      randomized controlled trial protocol.
PG  - e21881
LID - 10.1097/MD.0000000000021881 [doi]
AB  - BACKGROUND: Pain control after total knee arthroplasty has shown many advances;
      however, the optimal method remains controversial. The purpose of this present
      study is to assess the efficacy and safety of the addition of local infiltration 
      analgesia to adductor canal block for pain control after primary total knee
      arthroplasty. METHODS: This prospective randomized controlled research was
      conducted from January 2018 to June 2019. All the patients and their family
      members signed the informed consent forms, and this work was authorized via the
      ethics committee of Jinxiang Hospital Affiliated to Jining Medical College
      (JXHP0024578). Inclusion criteria were 55 years old or older, who possess the
      physical status I-III of American Society of Anesthesiologists, and the body mass
      index in the range of 18 to 30 kg/m. Exclusion criteria were regional and/or
      neuroaxial anesthesia contraindications, the history of drug allergy involved in 
      the research, neuropathic pain, as well as the chronic pain requiring opioid
      therapy. Seventy-two patients were divided into 2 groups randomly. Study group (n
      = 36) received both adductor canal block and local infiltration analgesia.
      Control group (n = 36) received adductor canal block alone. Primary outcome
      included postoperative pain score (visual analog scale 0 to 10 cm, in which 0
      represents no pain and 10 represents the most severe imaginable pain). The
      measures of secondary outcome included the knee range of motion, opioid
      consumption, the hospital stay length as well as the postoperative complications 
      (for instance, pulmonary embolism, deep vein thrombosis, and the wound
      infection). All the analyses were conducted through utilizing the SPSS for
      Windows Version 20.0. RESULTS: The results will be shown in .(Table is included
      in full-text article.) CONCLUSION:: The study will provide more evidence on the
      combination use of adductor canal block and local infiltration analgesia in the
      treatment of pain after the total knee arthroplasty. TRIAL REGISTRATION: This
      study protocol was registered in Research Registry (researchregistry5832).
FAU - Zhang, Qingchun
AU  - Zhang Q
AD  - Department of Anesthesiology, Jinxiang Hospital Affiliated to Jining Medical
      College, Shandong, China.
FAU - Fan, Limei
AU  - Fan L
AUID- ORCID: 0000-0001-6094-0916
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anesthetics, Local)
RN  - 7IO5LYA57N (Ropivacaine)
RN  - Y8335394RO (Bupivacaine)
SB  - IM
MH  - Analgesics, Opioid/therapeutic use
MH  - Anesthetics, Local/*administration & dosage
MH  - *Arthroplasty, Replacement, Knee
MH  - Bupivacaine/administration & dosage
MH  - Humans
MH  - Injections, Intra-Articular
MH  - Knee Joint
MH  - Length of Stay
MH  - *Nerve Block
MH  - Pain, Postoperative/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Range of Motion, Articular
MH  - Ropivacaine/administration & dosage
MH  - Visual Analog Scale
PMC - PMC7458215
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021881 [doi]
AID - 00005792-202008280-00060 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21881. doi:
      10.1097/MD.0000000000021881.


PMID- 32871914
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Application effect of catgut-embedding therapy combined with minimally invasive
      surgery for slow transit constipation: A protocol for systematic review and
      meta-analysis.
PG  - e21875
LID - 10.1097/MD.0000000000021875 [doi]
AB  - BACKGROUND: Catgut-embedding therapy combined with minimally invasive surgery has
      been used for treating slow transit constipation (STC) widely. However, the
      application effect of catgut-embedding therapy combined with minimally invasive
      surgery for STC are unclear. This study aims to evaluate the application effect
      of catgut-embedding therapy combined with minimally invasive surgery for STC.
      METHODS: Randomized controlled trials of catgut-embedding therapy combined with
      minimally invasive surgery in the treatment of STC will be searched in PubMed,
      EMbase, Cochrane Library, Web of Science, China National Knowledge
      Infrastructure, WanFang, the Chongqing VIP Chinese Science and Technology
      Periodical Database, and China biomedical literature database from inception to
      July, 2020. And Baidu Scholar, Google Scholar, International Clinical Trials
      Registry Platform, and Chinese Clinical Trials Registry will be searched to
      obtain more relevant studies comprehensively. Two researchers will perform data
      extraction and risk of bias assessment independently. Statistical analysis will
      be conducted in RevMan 5.3. RESULTS: This study will summarize the present
      evidence by exploring the application effect of catgut-embedding therapy combined
      with minimally invasive surgery in the treatment of STC. CONCLUSIONS: The
      findings of the study will provide helpful evidence for the application effect of
      catgut-embedding therapy combined with minimally invasive surgery in the
      treatment of STC, facilitating clinical practice and further scientific studies. 
      ETHICS AND DISSEMINATION: The private information from individuals will not
      publish. This systematic review also will not involve endangering participant
      rights. Ethical approval is not required. The results may be published in a
      peer-reviewed journal or disseminated in relevant conferences. OSF REGISTRATION
      NUMBER: DOI 10.17605/OSF.IO/7HVZB.
FAU - Xie, Yanpeng
AU  - Xie Y
AUID- ORCID: 0000-0002-3471-2108
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu610072,
      Sichuan province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
FAU - Fan, Wei
AU  - Fan W
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Yang, Xiangdong
AU  - Yang X
AD  - Chengdu Anorectal Hospital, Chengdu, Sichuan Province, China.
FAU - Xiang, Yanfei
AU  - Xiang Y
AD  - Chengdu Anorectal Hospital, Chengdu, Sichuan Province, China.
FAU - Zhao, Tianyu
AU  - Zhao T
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Catgut
MH  - Combined Modality Therapy
MH  - Constipation/physiopathology/*therapy
MH  - Gastrointestinal Transit/physiology
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - *Minimally Invasive Surgical Procedures
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7458268
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021875 [doi]
AID - 00005792-202008280-00057 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21875. doi:
      10.1097/MD.0000000000021875.


PMID- 32871912
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220426
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Global, national and regional prevalence, and associated factors of ocular
      trauma: A protocol for systematic review and meta-analysis.
PG  - e21870
LID - 10.1097/MD.0000000000021870 [doi]
AB  - BACKGROUND: Ocular trauma is a common eye disease and one of the main causes of
      blindness. There is a dearth of data on a summary and meta-analysis on the global
      epidemiology of the disease. Therefore, this systematic review protocol aims to
      propose the first systematic review and meta-analysis to synthesize existing
      evidence on the global prevalence and associated factors of ocular trauma
      worldwide. METHODS: A systematic search will be performed according to the
      following databases: PubMed, Web of Science, Chinese National Knowledge
      Infrastructure (CNKI), Weipu, and Wanfang. Cross-sectional, case-control, and
      cohort studies reporting on the prevalence and risk factors of ocular trauma will
      be included. The primary outcome will be the prevalence in global, regional, and 
      national ocular trauma. Study searching, data extraction, and quality evaluation 
      will be performed by 2 reviewers, independently. Appropriate meta-analysis will
      then be used to pool studies. STATA software package v 12.0 (Stata Corporation,
      College Station, TX) and R (version 3.4.1; R Foundation for Statistical
      Computing, Vienna, Austria) software will be used for all statistical analyses.
      RESULTS: This study will provide a high-quality synthesis to examine the
      prevalence and associated factors of ocular trauma worldwide. Furthermore,
      current study will project disease estimates in the next 50 years. CONCLUSION:
      This systematic review and meta-analysis will provide first evidence to evaluate 
      the burden of ocular trauma in the general population. ETHICS AND DISSEMINATION: 
      This systematic review and meta-analysis of randomized controlled trials does not
      require ethical recognition, and the results of this paper will be published in
      an open access, internationally influential academic journal. TRIAL REGISTRATION 
      NUMBER: CRD42020189166.
FAU - Bian, Xiaoyan
AU  - Bian X
AD  - Department of Ocular Surface, Baotou Chaoju Eye Hospital, Baotou.
FAU - Xu, Shuang
AU  - Xu S
AD  - Department of Library, China Medical University.
FAU - Song, Yuli
AU  - Song Y
AD  - China Medical University.
FAU - Wang, Yuye
AU  - Wang Y
AD  - China Medical University.
FAU - Zhao, Bin
AU  - Zhao B
AD  - YunCheng Eye Hospital, Yuncheng.
FAU - Zhong, Yifan
AU  - Zhong Y
AD  - Department of Ophthalmology, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
FAU - Liu, Lei
AU  - Liu L
AD  - Department of Ophthalmology, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
FAU - Hu, Yuedong
AU  - Hu Y
AD  - Department of Ophthalmology, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Eye Injuries/*epidemiology
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Prevalence
MH  - Research Design
MH  - *Systematic Reviews as Topic
PMC - PMC7458182
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021870 [doi]
AID - 00005792-202008280-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21870. doi:
      10.1097/MD.0000000000021870.


PMID- 32871911
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Unicondylar knee arthroplasty versus total knee arthroplasty in adults with
      isolated medial osteoarthritis: A matched study protocol.
PG  - e21868
LID - 10.1097/MD.0000000000021868 [doi]
AB  - BACKGROUND: The choice between unicondylar knee arthroplasty (UKA) and total knee
      arthroplasty (TKA) is likely to have long-term implications for patient-reported 
      health outcomes. However, high-quality studies that compare the outcomes of TKA
      and UKA and their effects are still lacking in the literature. Thus, the aim of
      the present study was to compare the UKA and TKA techniques with regard to
      functional outcomes and perioperative complications in patients who had isolated 
      medial osteoarthritis. METHODS: This was a retrospective, single-center,
      matched-controlled study performed with approval of our hospital (Kunshan
      hospital of Traditional Chinese Medicine affiliated to Nanjing University of
      Traditional Chinese Medicine), with the ethics number KZY2020-37. To reduce the
      effect of selection bias and potential confounding in this observational study, a
      1:1 matching algorithm was applied. The groups were split by sex, age to within 6
      years, and body mass index within 5 kg/m. Thus, we retrospectively reviewed the
      records of 240 consecutively enrolled patients who underwent UKA and 240 patients
      who underwent TKA from January 2013 to June 2015 from the database of our
      institution. Written informed consent was obtained from all subjects
      participating in the trial. Clinical outcomes included range of motion, Short
      Form 12 score, new Knee Society Score, Western Ontario and McMaster Universities 
      Arthritis Index, and the complications. The outcome measures were evaluated by a 
      physiotherapist and were assessed preoperatively and postoperatively at 6 months 
      and 2 years. The mean follow-up time was 3 years. CONCLUSION: We hypothesized
      that there was no significant difference between the 2 groups in terms of
      postoperative outcomes. TRIAL REGISTRATION: Our study was registered in Research 
      Registry (researchregistry5828).
FAU - Yin, Zifei
AU  - Yin Z
AD  - Department of joint, Kunshan hospital of Traditional Chinese Medicine affiliated 
      to Nanjing University of Traditional Chinese Medicine, Jiangsu Province, China.
FAU - Qian, Pingkang
AU  - Qian P
FAU - Wu, Xiaofeng
AU  - Wu X
FAU - Gao, Feng
AU  - Gao F
FAU - Xu, Feng
AU  - Xu F
AUID- ORCID: 0000-0001-9028-1675
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Knee/*methods
MH  - China
MH  - Female
MH  - Humans
MH  - Male
MH  - Matched-Pair Analysis
MH  - Middle Aged
MH  - Observational Studies as Topic
MH  - Osteoarthritis, Knee/*surgery
MH  - Patient Reported Outcome Measures
MH  - Range of Motion, Articular
MH  - Research Design
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC7458234
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021868 [doi]
AID - 00005792-202008280-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21868. doi:
      10.1097/MD.0000000000021868.


PMID- 32871889
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Which acupuncture and moxibustion technique is more effective for primary
      dysmenorrhea: A protocol for a network meta-analysis of randomized controlled
      trials.
PG  - e21713
LID - 10.1097/MD.0000000000021713 [doi]
AB  - BACKGROUND: Primary dysmenorrhea (PD), also called functional dysmenorrhea,
      refers to a woman's menstrual period in genital no organic disease, abdominal
      pain, under the belly and other discomfort for the characteristics of disease of 
      department of gynecology. Acupuncture and moxibustion have been accepted as
      treatment options for PD. So far, there are so many therapies for PD and their
      efficacy has been assessed by several systematic reviews. Therefore, this study
      aims at evaluating the effectiveness which acupuncture and moxibustion technique 
      is more effective for primary dysmenorrhea. METHODS AND ANALYSIS: The following
      electronic databases will be searched in this study: the Cochrane Central
      Register of Controlled Trials (CENTRAL);PubMed; EMBASE; China National Knowledge 
      Infrastructure (CNKI); Chinese Biomedical Literature Database (CBM);Chinese
      Scientific Journal Database (VIP database); and Wan-Fang Database(WF). More than 
      two authors independently assessed the quality of the evidence by AMSTAR2,
      PRISMA, PRISMA-A, and GRADE approach. Two of our researchers will use the bias
      risk tool provided by the Cochrane Collaboration to evaluate the quality of the
      literature using WinBUGS 1.4.3 and STATA softwares. The primary outcomes include 
      the extent of pain in the lower abdomen measured by visual analog scale (VAS) and
      relief from symptoms. The quality of life (QoL) and Adverse events will be
      considered as Additional outcome(s). Their reference lists and the citation lists
      of studies meeting the inclusion criteria and relevant systematic reviews will
      also be searched to identify further studies for inclusion. Before this review
      completed, the 2 reviewers will conduct the search once again to ensure the
      latest studies could be included. ETHICS AND DISSEMINATION: This review does not 
      require ethical approval. RESULTS: The results will be published in a
      peer-reviewed journal. CONCLUSION: This study will provide comprehensive evidence
      of acupuncture and moxibustion for patients with PD. INPLASY REGISTRATION NUMBER:
      INPLASY2020500106.
FAU - Wu, Zenan
AU  - Wu Z
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Yang, Yi
AU  - Yang Y
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Xiong, Jun
AU  - Xiong J
AD  - The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang, China.
FAU - Yu, Xinyu
AU  - Yu X
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Zuo, Zhengyun
AU  - Zuo Z
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Xie, Qiongshan
AU  - Xie Q
AD  - Jiangxi University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Dysmenorrhea/*therapy
MH  - Female
MH  - Humans
MH  - Moxibustion/methods
MH  - Network Meta-Analysis
MH  - Pain Measurement
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7458225
EDAT- 2020/09/03 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1097/MD.0000000000021713 [doi]
AID - 00005792-202008280-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21713. doi:
      10.1097/MD.0000000000021713.


PMID- 32871872
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - Acupuncture and moxibustion therapy for scapulohumeral periarthritis: Protocol
      for an overview of systematic reviews and meta-analysis.
PG  - e21567
LID - 10.1097/MD.0000000000021567 [doi]
AB  - BACKGROUND: Scapulohumeral periarthritis (SP) is a very common painful shoulder
      disorder. Several systematic reviews (SRs) and meta-analyses have reported the
      effectiveness of acupuncture for patients with SP. However, the evidence has not 
      been systematically synthesized. This overview aims to map, synthesize, and
      assess the reliability of evidence generated from these SRs and meta-analyses of 
      acupuncture for SP. METHODS: We will electronically search the following
      databases for literature, regardless of publication status and language: the
      Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; China
      National Knowledge Infrastructure (CNKI); Chinese Biomedical Literature Database 
      (CBM); Chinese Scientific Journal Database (VIPdatabase); and Wan-Fang Database. 
      In order to ensure the comprehensiveness and accuracy of the literature
      retrieval, we will combine the Suggestions of evidence-based medicine experts
      with the actual situation in the literature retrieval process to formulate the
      retrieval strategy, and make corresponding records to find the most appropriate
      retrieval strategy. The reference lists and the citation lists of studies meeting
      the inclusion criteria and relevant SRs will also be searched to identify further
      studies for inclusion. Before this review completed, the two reviewers will
      conduct the searching once again to ensure the latest studies could be included. 
      ETHICS AND DISSEMINATION: Ethical approval is not required for overviews. We plan
      to publish results in peer-reviewed journals and present at international and
      national academic, clinical, and patient conferences. RESULTS: The results will
      be published in a peer-reviewed journal. CONCLUSION: This overview will provide
      comprehensive evidence of acupuncture for patients with SP. INPLASY REGISTRATION 
      NUMBER: INPLASY202060020.
FAU - Wu, Zenan
AU  - Wu Z
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Yu, Xinyu
AU  - Yu X
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Xiong, Jun
AU  - Xiong J
AD  - The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang.
FAU - Wu, Guoxin
AU  - Wu G
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zuo, Zhengyun
AU  - Zuo Z
AD  - Jiangxi University of Traditional Chinese Medicine.
FAU - Xie, Qiongshan
AU  - Xie Q
AD  - Jiangxi University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - China/epidemiology
MH  - Female
MH  - Humans
MH  - Joint Capsule/*pathology
MH  - Male
MH  - Moxibustion/*adverse effects/methods
MH  - Periarthritis/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - Shoulder Joint/pathology
PMC - PMC7458254
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021567 [doi]
AID - 00005792-202008280-00015 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21567. doi:
      10.1097/MD.0000000000021567.


PMID- 32871865
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - The efficacy and safety of acupuncture and moxibustion combined with western
      medicine for obsessive-compulsive disorder: A protocol for systematic review and 
      meta-analysis.
PG  - e21395
LID - 10.1097/MD.0000000000021395 [doi]
AB  - BACKGROUND: Obsessive-compulsive disorder is common, chronic mental disorder,
      which is characterized by recurrent, unwanted, or intrusive thoughts and
      repetitive behaviors or mental action. Acupuncture and moxibustion, as a popular 
      form of complementary and alternative therapy, have the advantages of low side
      effects, high safety, and low cost. The research showed that acupuncture and
      moxibustion have a good clinical efficacy on obsessive-compulsive disorder.
      However, there is no literature to systematically evaluate the efficacy and
      safety of acupuncture and moxibustion in treating obsessive-compulsive disorder. 
      Thus, this study is aimed to evaluate the efficacy and safety of acupuncture and 
      moxibustion for obsessive-compulsive disorder patients, providing reliable
      evidence for clinical application. METHODS: Randomized controlled trials of
      acupuncture and moxibustion combined with western medicine for the treatment of
      obsessive-compulsive disorder will be searched in the databases including PubMed,
      EMBASE, the Cochrane library, Web of science, China National Knowledge
      Infrastructure(CNKI), WanFang, the Chongqing VIP Chinese Science and Technology
      Periodical Database, and China biomedical literature database (CBM) from
      inception to June, 2020. In addition, Baidu, Google Scholar, International
      Clinical Trials Registry Platform, and Chinese Clinical Trials Registry will be
      searched to obtain the gray literature and relevant data that have not yet been
      published. Two qualified researchers will extract data and assess the risk of
      bias from included studies dependently. Statistical analysis is performed in
      RevMan 5.3 software. RESULTS: The efficacy and safety of acupuncture and
      moxibustion combined with western medicine for obsessive-compulsive disorder will
      be assessed based on the total effective rate, Hamilton Anxiety Scale score,
      Hamilton Rating Scale for Depression score, Clinical Global Impression score,
      side effects, and so on. CONCLUSIONS: The proposed systematic review and
      meta-analysis of acupuncture and moxibustion combined with western medicine for
      treating obsessive-compulsive disorder is expected to provide reliable evidence
      for clinical application. ETHICS AND DISSEMINATION: The private information from 
      individuals will not publish. This systematic review also will not involve
      endangering participant rights. Ethical approval is not required. The results may
      be published in a peer-reviewed journal or disseminated in relevant conferences. 
      OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/CDGTW.
FAU - Tian, Chunying
AU  - Tian C
AUID- ORCID: 0000-0003-4122-2817
AD  - Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, P. R. China.
FAU - Fan, Yihua
AU  - Fan Y
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, P. R. China.
FAU - Xu, Jingyu
AU  - Xu J
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Huang, Yang
AU  - Huang Y
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Wang, Wen
AU  - Wang W
AD  - Tianjin University of Traditional Chinese Medicine.
FAU - Wang, Shenjun
AU  - Wang S
AD  - Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, P. R. China.
FAU - Song, Ruiwen
AU  - Song R
AD  - Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, P. R. China.
FAU - Li, Xinju
AU  - Li X
AD  - Tianjin University of Traditional Chinese Medicine.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, P. R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/economics/*methods
MH  - China/epidemiology
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Moxibustion/*adverse effects/economics
MH  - Obsessive-Compulsive Disorder/epidemiology/*psychology/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7458263
EDAT- 2020/09/03 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021395 [doi]
AID - 00005792-202008280-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21395. doi:
      10.1097/MD.0000000000021395.


PMID- 32871864
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 35
DP  - 2020 Aug 28
TI  - COVID-19 in hematological malignancy patients: A protocol for a systematic review
      and meta-analysis.
PG  - e21376
LID - 10.1097/MD.0000000000021376 [doi]
AB  - BACKGROUND: COVID-19 is an international outbreak of the respiratory illness
      caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The
      diseases themselves, as well as the intensity of chemotherapy, lead to
      significant immunosuppression, leading hematological malignancy patients
      susceptible to infections. METHODS: This protocol will be performed according to 
      the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and
      reported follow the Cochrane Collaboration Handbook and the Preferred Reporting
      Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic
      databases of PubMed, MEDLINE, Google Scholar, Web of science, Cochrane Library,
      EMBASE, CNKI, CMB, and Wangfang database from the inception to present will be
      comprehensively and systematically searched without limitations of language,
      date, and publication status. Observational, retrospective cohort, prospective
      case-control, cohort studies, cross-sectional studies, or clinical trials will be
      included. All assessment of study selection, data extraction, and study quality
      assessment will be independently performed by 2 reviewers. RevMan V.5.3 program
      and Stata V.12.0 software will be utilized for the methodological quality
      assessment and statistical analysis. RESULTS: The result of this systematic
      review will provide evidence for clinicians on the management of COVID-19
      patients with hematological malignancy. CONCLUSION: This systematic review will
      help raise awareness and guide management of COVID-19 patients with hematological
      malignancy, as well as to improve outcomes in this population. ETHIC AND
      DISSEMINATION: The content of this article does not involve moral approval or
      ethical review because no individual data will be collected. PROSPERO
      REGISTRATION: CRD42020187493.
FAU - Chen, Can
AU  - Chen C
AD  - Department of Hematology.
FAU - Weng, Qianping
AU  - Weng Q
AD  - Department of Hematology.
FAU - Li, Yiwei
AU  - Li Y
AD  - Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital,
      Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.
FAU - Shi, Pengfei
AU  - Shi P
AUID- ORCID: 0000-0002-2165-6944
AD  - Department of Hematology.
FAU - Qian, Shenxian
AU  - Qian S
AD  - Department of Hematology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - *Hematologic Neoplasms/epidemiology/immunology/therapy
MH  - Humans
MH  - *Pandemics
MH  - Patient Care Management/*methods
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
PMC - PMC7458179
EDAT- 2020/09/03 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1097/MD.0000000000021376 [doi]
AID - 00005792-202008280-00007 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 28;99(35):e21376. doi:
      10.1097/MD.0000000000021376.


PMID- 32871704
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 276
DP  - 2020 Nov 1
TI  - Open-Label placebo for the treatment of unipolar depression: Results from a
      randomized controlled trial.
PG  - 707-710
LID - S0165-0327(20)32522-2 [pii]
LID - 10.1016/j.jad.2020.07.077 [doi]
AB  - BACKGROUND: The response to placebo is robust in studies of various
      antidepressant treatments. The strong placebo response, combined with the absence
      of side-effects, has prompted suggestions to use the ethically sound open-label
      placebo (OLP) as a treatment for depression. The aim of the present study was to 
      assess the efficacy of OLP as an adjunct to treatment as usual (TAU) in the
      setting of a randomized controlled trial for the treatment of unipolar
      depression. METHODS: Thirty-eight patients (age: 50 +/- 17.1; 73.7% females) were
      randomized to either eight-week OLP treatment (n = 18) or four weeks of TAU
      followed by four weeks of OLP (n = 20). Clinical and socio-demographic measures
      were assessed at baseline, after four weeks, and at the end of the trial.
      Response to treatment was determined using the QIDS SR-16. RESULTS: There was an 
      overall decrease in depression levels over time, F(2,35) = 3.98, p = .028. A
      significant group x time interaction was found only among non-geriatric patients 
      (<65years) with an early onset of depression (<50years), F(2,22) = 3.89, p =
      .036. Post-hoc tests indicated a significant decrease during the first four
      weeks, but only in the OLP group, t(11) = 2.29, p = .043. LIMITATIONS: Small
      sample size and the use of a self-report questionnaire to assess depressive
      symptoms. CONCLUSIONS: Our findings support the possibility that OLP is an
      effective treatment for the relatively young population of depressed patients.
      Additional studies are warranted to explore the use of OLP in clinical practice.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Nitzan, Uri
AU  - Nitzan U
AD  - Shalvata Mental Health Center, P.O.B 94, Hod-Hasharon, Israel; Sackler School of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address:
      urini@clalit.org.il.
FAU - Carmeli, Gal
AU  - Carmeli G
AD  - Shalvata Mental Health Center, P.O.B 94, Hod-Hasharon, Israel.
FAU - Chalamish, Yossi
AU  - Chalamish Y
AD  - Kibbuzim College, Tel-Aviv, Israel.
FAU - Braw, Yoram
AU  - Braw Y
AD  - Department of Psychology, Ariel University, Israel.
FAU - Kirsch, Irving
AU  - Kirsch I
AD  - Program in Placebo Studies, Beth Israel Deaconess Medical Center and Harvard
      Medical School, Boston, MS, USA.
FAU - Shefet, Daphna
AU  - Shefet D
AD  - Shalvata Mental Health Center, P.O.B 94, Hod-Hasharon, Israel; Sackler School of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Krieger, Israel
AU  - Krieger I
AD  - Shalvata Mental Health Center, P.O.B 94, Hod-Hasharon, Israel; Sackler School of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Mendlovic, Shlomo
AU  - Mendlovic S
AD  - Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Bloch, Yuval
AU  - Bloch Y
AD  - Shalvata Mental Health Center, P.O.B 94, Hod-Hasharon, Israel; Sackler School of 
      Medicine, Tel-Aviv University, Tel-Aviv, Israel.
FAU - Lichtenberg, Pesach
AU  - Lichtenberg P
AD  - Department of Psychiatry, Faculty of Medicine, Hebrew University of Jerusalem,
      Israel.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200721
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Aged
MH  - *Antidepressive Agents/therapeutic use
MH  - Child, Preschool
MH  - Depression/drug therapy
MH  - *Depressive Disorder/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Placebo Effect
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Antidepressants
OT  - *Clinical practice
OT  - *Depression
OT  - *Placebo
EDAT- 2020/09/03 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/09/03 06:00
PHST- 2020/01/25 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - S0165-0327(20)32522-2 [pii]
AID - 10.1016/j.jad.2020.07.077 [doi]
PST - ppublish
SO  - J Affect Disord. 2020 Nov 1;276:707-710. doi: 10.1016/j.jad.2020.07.077. Epub
      2020 Jul 21.


PMID- 35047693
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 2398-8703 (Electronic)
IS  - 2398-8703 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Ethiopian medicinal plants used for their anti-inflammatory, wound healing or
      anti-infective activities: protocol for systematic literature review and
      meta-analysis.
PG  - e100064
LID - 10.1136/bmjos-2020-100064 [doi]
AB  - OBJECTIVES: Medicinal plants are used globally as alternative medicines in the
      management of a range of disease conditions and are widely accepted across
      differing societies. Ethiopia hosts a large number of plant species (>7000 higher
      plant species), of which around 12% are thought to be endemic, making it a rich
      source of plant extracts potentially useful for human health. The aim of this
      review is to evaluate Ethiopian medicinal plants for their anti-inflammatory,
      wound healing, antifungal or antibacterial activities. METHODS AND ANALYSIS: The 
      guidance of the Preferred Reporting Items for Systematic Review and Meta-analysis
      Protocols (PRISMA-P) statement will be used. This review will consider all
      controlled studies of anti-inflammatory and wound healing properties (both in
      vivo and in vitro) and in vitro anti-infective properties of medicinal plants
      found in Ethiopia. Data sources will be EMBASE, PubMed/Medline, Scopus and Google
      Scholar. Guidance documents on good in vitro methods and checklists for reporting
      in vitro studies will be used for quality assessment of in vitro studies. The
      risk of bias tool for animal intervention studies (the SYRCLE RoB tool) will be
      used to assess the validity of studies. The main outcomes will be percent
      inhibition of inflammation, time of epithelisation and tissue tensile strength in
      wounds and microbial growth inhibition. ETHICS AND DISSEMINATION: The findings of
      this systematic review will be disseminated by publishing in a peer-reviewed
      journal and via conference presentations. Ethical clearance was obtained from the
      Brighton and Sussex Medical School, Research Governance & Ethics Committee (RGEC)
      and Addis Ababa University, College of Health Science, Institutional Review
      Board. PROSPERO REGISTRATION NUMBER: This systematic literature review has been
      registered with PROSPERO (registration number CRD42019127471).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Nigussie, Dereje
AU  - Nigussie D
AUID- ORCID: 0000-0002-2145-5990
AD  - Addis Ababa University, College of Health Sciences, Centre for Innovative Drug
      Development and Therapeutic Trials for Africa (CDT-Africa), P.O. Box: 9086, Addis
      Ababa, Ethiopia, Addis Ababa, Ethiopia.
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, University
      of Sussex, Brighton, BN1 9PX, UK, Brighton, UK.
FAU - Legesse, Belete Adefris
AU  - Legesse BA
AD  - Addis Ababa University, College of Health Sciences, Centre for Innovative Drug
      Development and Therapeutic Trials for Africa (CDT-Africa), P.O. Box: 9086, Addis
      Ababa, Ethiopia, Addis Ababa, Ethiopia.
FAU - Davey, Gail
AU  - Davey G
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, University
      of Sussex, Brighton, BN1 9PX, UK, Brighton, UK.
AD  - School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Fekadu, Abebaw
AU  - Fekadu A
AD  - Addis Ababa University, College of Health Sciences, Centre for Innovative Drug
      Development and Therapeutic Trials for Africa (CDT-Africa), P.O. Box: 9086, Addis
      Ababa, Ethiopia, Addis Ababa, Ethiopia.
AD  - Centre for Global Health Research, Brighton and Sussex Medical School, University
      of Sussex, Brighton, BN1 9PX, UK, Brighton, UK.
FAU - Makonnen, Eyasu
AU  - Makonnen E
AD  - Addis Ababa University, College of Health Sciences, Centre for Innovative Drug
      Development and Therapeutic Trials for Africa (CDT-Africa), P.O. Box: 9086, Addis
      Ababa, Ethiopia, Addis Ababa, Ethiopia.
AD  - Department of Pharmacology and Clinical Pharmacy, College of Health Sciences,
      Addis Ababa University, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - England
TA  - BMJ Open Sci
JT  - BMJ open science
JID - 101778290
PMC - PMC8647601
COIS- Competing interests: None declared.
EDAT- 2020/09/03 00:00
MHDA- 2020/09/03 00:01
CRDT- 2022/01/20 06:08
PHST- 2020/02/25 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2022/01/20 06:08 [entrez]
PHST- 2020/09/03 00:00 [pubmed]
PHST- 2020/09/03 00:01 [medline]
AID - 10.1136/bmjos-2020-100064 [doi]
AID - bmjos-2020-100064 [pii]
PST - epublish
SO  - BMJ Open Sci. 2020 Sep 3;4(1):e100064. doi: 10.1136/bmjos-2020-100064.
      eCollection 2020.


PMID- 34977590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2662-4087 (Electronic)
IS  - 2662-4087 (Linking)
VI  - 1
IP  - 4
DP  - 2020
TI  - Trust in Robots: Challenges and Opportunities.
PG  - 297-309
LID - 10.1007/s43154-020-00029-y [doi]
AB  - PURPOSE OF REVIEW: To assess the state-of-the-art in research on trust in robots 
      and to examine if recent methodological advances can aid in the development of
      trustworthy robots. RECENT FINDINGS: While traditional work in trustworthy
      robotics has focused on studying the antecedents and consequences of trust in
      robots, recent work has gravitated towards the development of strategies for
      robots to actively gain, calibrate, and maintain the human user's trust. Among
      these works, there is emphasis on endowing robotic agents with reasoning
      capabilities (e.g., via probabilistic modeling). SUMMARY: The state-of-the-art in
      trust research provides roboticists with a large trove of tools to develop
      trustworthy robots. However, challenges remain when it comes to trust in
      real-world human-robot interaction (HRI) settings: there exist outstanding issues
      in trust measurement, guarantees on robot behavior (e.g., with respect to user
      privacy), and handling rich multidimensional data. We examine how recent advances
      in psychometrics, trustworthy systems, robot-ethics, and deep learning can
      provide resolution to each of these issues. In conclusion, we are of the opinion 
      that these methodological advances could pave the way for the creation of truly
      autonomous, trustworthy social robots.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Kok, Bing Cai
AU  - Kok BC
AD  - Dept. of Computer Science, School of Computing, National University of Singapore,
      13 Computing Drive, Singapore, 119077 Singapore.grid.4280.e0000 0001 2180 6431
FAU - Soh, Harold
AU  - Soh H
AUID- ORCID: 0000-0002-3278-0035
AD  - Dept. of Computer Science, School of Computing, National University of Singapore,
      13 Computing Drive, Singapore, 119077 Singapore.grid.4280.e0000 0001 2180 6431
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200903
PL  - Switzerland
TA  - Curr Robot Rep
JT  - Current robotics reports
JID - 9918317788406676
PMC - PMC7467858
OTO - NOTNLM
OT  - Formal methods
OT  - Human-robot interaction
OT  - Measurement
OT  - Probabilistic models
OT  - Trust
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/09/03 00:00
MHDA- 2020/09/03 00:01
CRDT- 2022/01/03 05:55
PHST- 2020/09/03 00:00 [pubmed]
PHST- 2020/09/03 00:01 [medline]
PHST- 2022/01/03 05:55 [entrez]
AID - 10.1007/s43154-020-00029-y [doi]
AID - 29 [pii]
PST - ppublish
SO  - Curr Robot Rep. 2020;1(4):297-309. doi: 10.1007/s43154-020-00029-y. Epub 2020 Sep
      3.


PMID- 32870622
STAT- Publisher
DA  - 20200902
ISBN- 9780309679596
ISBN- 0309679591
PB  - National Academies Press (US)
CTI - The National Academies Collection: Reports funded by National Institutes of
      Health
DP  - 2020 Aug 28
BTI - The Role of Digital Health Technologies in Drug Development: Proceedings of a
      Workshop
LID - 10.17226/25850 [doi]
AB  - On March 24, 2020, a 1-day public workshop titled The Role of Digital Health
      Technologies in Drug Development was convened by the National Academies of
      Sciences, Engineering, and Medicine. This workshop builds on prior efforts to
      explore how virtual clinical trials facilitated by digital health technologies
      (DHTs) might change the landscape of drug development. To explore the challenges 
      and opportunities in using DHTs for improving the probability of success in drug 
      R&D, enabling better patient care, and improving precision medicine, the workshop
      featured presentations and panel discussions on the integration of DHTs across
      all phases of drug development. Throughout the workshop, participants considered 
      how DHTs could be applied to achieve the greatest impact-and perhaps even change 
      the face of how clinical trials are conducted-in ways that are also ethical,
      equitable, safe, and effective. This publication summarizes the presentations and
      discussions from the workshop.
CI  - Copyright 2020 by the National Academy of Sciences. All rights reserved.
CN  - National Academies of Sciences, Engineering, and Medicine; Health and Medicine
      Division; Board on Health Sciences Policy; Roundtable on Genomics and Precision
      Health; Forum on Drug Discovery, Development, and Translation
FED - Shore, Carolyn
ED  - Shore C
FED - Beachy, Sarah H.
ED  - Beachy SH
FED - Nicholson, Anna
ED  - Nicholson A
FED - Addie, Siobhan
ED  - Addie S
FED - Hackmann, Meredith
ED  - Hackmann M
FED - Khandekar, Eeshan
ED  - Khandekar E
LA  - eng
GR  - HHSN263201800029I/NIH HHS/United States
PT  - Review
PT  - Book
PL  - Washington (DC)
EDAT- 2020/09/02 06:01
MHDA- 2020/09/02 06:01
CDAT- 2020/09/02 06:01
AID - NBK561335 [bookaccession]
AID - 10.17226/25850 [doi]


PMID- 32870328
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 2193-6226 (Electronic)
IS  - 2193-6218 (Linking)
VI  - 115
IP  - 6
DP  - 2020 Sep
TI  - [Clinical leadership competencies in advanced nursing practice : Scoping review].
PG  - 466-476
LID - 10.1007/s00063-020-00716-w [doi]
AB  - BACKGROUND: The competencies of advanced practice nurses (APN) include clinical
      activity in a special field, coaching and consulting, collaboration, leadership, 
      ethical decision-making, and research competence. Clinical leaders initiate and
      implement changes in the healthcare system and respond to the needs of patients
      and healthcare institutions. Clinical leadership based on advanced nursing
      practice can challenge existing management and care structures. OBJECTIVES: The
      aim of the review is to provide an overview of clinical leadership competencies
      based on advanced nursing practice. The investigated question deals with which
      roles and competencies of APN are associated with clinical leadership from a
      national and international perspective. METHODS: A systematic search in
      MEDLINE(R)(US National Center for Biotechnology Information (NCBI))/PubMed,
      CINAHL and the Cochrane Library as well as a hand search in library catalogs and 
      journals (April 2019 to January 2020) produced a total of 235 hits. Eight studies
      were included in the review and analyzed. RESULTS: Clinical leadership
      competencies are increasingly a topic of international studies and can be
      described and recognized in clinical practice on the basis of leadership models, 
      and the role and leadership domains of APNs. Clinical leadership in nursing
      practice is recognized when APNs independently control treatment processes in
      complex nursing situations, exert influence, develop and implement change
      strategies, consult, coach, train, collaborate, and establish a connection to
      other health professionals and management. In order for clinical leadership
      competencies to be effective in nursing care processes, broad support in the
      multiprofessional team, structural support of the organization and legal
      legitimation are required. CONCLUSIONS: There are hardly any studies in the
      German-language literature on the relevance, interpretation, and legitimacy of
      APN clinical leadership. Further research is needed on the interpretation of the 
      roles of APNs, especially clinical leadership competencies, their influence on
      nursing care processes, leadership structures, and their interaction within the
      organizational culture.
FAU - Blanck-Koster, Katrin
AU  - Blanck-Koster K
AD  - Department Pflege & Management, Hochschule fur Angewandte Wissenschaften Hamburg,
      Alexanderstrasse 1, 20099, Hamburg, Deutschland.
      katrin.blanck-koester@haw-hamburg.de.
AD  - Universitat Witten/Herdecke, Witten, Deutschland.
      katrin.blanck-koester@haw-hamburg.de.
FAU - Roes, Martina
AU  - Roes M
AD  - Universitat Witten/Herdecke, Witten, Deutschland.
FAU - Gaidys, Uta
AU  - Gaidys U
AD  - Department Pflege & Management, Hochschule fur Angewandte Wissenschaften Hamburg,
      Alexanderstrasse 1, 20099, Hamburg, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Clinical-Leadership-Kompetenzen auf der Grundlage einer erweiterten und
      vertieften Pflegepraxis (Advanced Nursing Practice) : Ein Scoping-Review.
DEP - 20200901
PL  - Germany
TA  - Med Klin Intensivmed Notfmed
JT  - Medizinische Klinik, Intensivmedizin und Notfallmedizin
JID - 101575086
SB  - IM
MH  - *Advanced Practice Nursing
MH  - Clinical Competence
MH  - Delivery of Health Care
MH  - Humans
MH  - *Leadership
OTO - NOTNLM
OT  - Advanced practice nurse
OT  - Health services research
OT  - Hospitals
OT  - Leadership models
OT  - Multiprofessional team
EDAT- 2020/09/02 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/05/23 00:00 [revised]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/09/02 06:00 [entrez]
AID - 10.1007/s00063-020-00716-w [doi]
AID - 10.1007/s00063-020-00716-w [pii]
PST - ppublish
SO  - Med Klin Intensivmed Notfmed. 2020 Sep;115(6):466-476. doi:
      10.1007/s00063-020-00716-w. Epub 2020 Sep 1.


PMID- 32869946
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - The Ethical Imperative of Self-Care: A Call to Action.
PG  - 733-736
LID - 10.1111/jmwh.13150 [doi]
FAU - Wright, Erin M
AU  - Wright EM
AUID- ORCID: 0000-0003-3116-9071
AD  - Johns Hopkins School of Nursing, Baltimore, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - *Self Care
EDAT- 2020/09/02 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/09/02 06:00 [entrez]
AID - 10.1111/jmwh.13150 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):733-736. doi: 10.1111/jmwh.13150. Epub 
      2020 Sep 1.


PMID- 32868607
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1548-7148 (Electronic)
IS  - 1088-4602 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Jul/Sep
TI  - The Care of the Patients With Alcohol Intoxication in the Emergency Department of
      a Central Hospital: Nurses' Skills, Knowledge, and Attitudes.
PG  - 146-152
LID - 10.1097/JAN.0000000000000345 [doi]
AB  - AIM: The aim of the study was to describe nurses' skills, knowledge of care, and 
      attitudes toward the care of patients with alcohol intoxication in the emergency 
      department. METHOD: The data were collected using theme interviews in 2016. The
      study participants were nurses working in the emergency department (n = 6) that
      has a sobering unit. The data were analyzed using inductive content analysis.
      RESULTS: On the basis of the interviewees' descriptions, five main categories
      were formed: the skills to discuss the use of alcohol on arrival, safety skills, 
      teamwork skills, the skills to organize follow-up care, and nurses' attitudes and
      ethics in patients' care. Asking about the use of alcohol as well as the use of a
      screening tool varied. The interviewees emphasized the skills to anticipate the
      risk of violence as well as ensuring the safety of the working environment.
      Nurses' attitudes were seen as the ability to regulate negative emotions raised
      by the patient. Factors related to nurses' attitudes emerged in patients'
      behavioral disorders and commitment to treatment. Despite some negative feelings 
      toward patients, nurses thought that it is important to ensure ethicality in
      patients' care. CONCLUSIONS: The nurses' skills and knowledge of care and
      attitudes toward patients with alcohol intoxication varied. There is a need for
      additional training on issues relating to the treatment of patients with alcohol 
      intoxication.
FAU - Hakala, Tiina
AU  - Hakala T
AD  - Tiina Hakala, MNSc, RN, Psychiatric Care Division, Satakunta Hospital District,
      Pori, Finland. Jari Kylma, PhD, Faculty of Social Sciences, Health Sciences,
      Nursing Science, University of Tampere, Finland. Eija Paavilainen, PhD, Faculty
      of Social Sciences, Health Sciences, Nursing Science, University of Tampere,
      Etela-Pohjanmaa Hospital District, Finland. Marita Koivunen, PhD, Satakunta
      Hospital District, Pori, and Department of Nursing Science, University of Turku, 
      Finland.
FAU - Kylma, Jari
AU  - Kylma J
FAU - Paavilainen, Eija
AU  - Paavilainen E
FAU - Koivunen, Marita
AU  - Koivunen M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Addict Nurs
JT  - Journal of addictions nursing
JID - 9616159
SB  - IM
MH  - Adult
MH  - Alcoholic Intoxication/*therapy
MH  - *Attitude of Health Personnel
MH  - *Emergency Service, Hospital
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Staff, Hospital/*education
EDAT- 2020/09/02 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
AID - 10.1097/JAN.0000000000000345 [doi]
AID - 00060867-202007000-00005 [pii]
PST - ppublish
SO  - J Addict Nurs. 2020 Jul/Sep;31(3):146-152. doi: 10.1097/JAN.0000000000000345.


PMID- 32868585
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220416
IS  - 1536-0911 (Electronic)
IS  - 1536-0903 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Oct
TI  - The Role of Stigma in the Nursing Care of Families Impacted by Neonatal
      Abstinence Syndrome.
PG  - 354-363
LID - 10.1097/ANC.0000000000000778 [doi]
AB  - BACKGROUND: The current US opioid crisis has resulted in a significant increase
      in opioid use disorder among pregnant and parenting women. Substance use
      disorders, in general, are highly stigmatized conditions. Stigma serves as a
      well-documented global barrier to health-seeking behaviors and engagement in
      healthcare. While extensive research exists on the stigma of mental illness, few 
      studies have explored the stigma experienced by families impacted by neonatal
      abstinence syndrome (NAS). PURPOSE: Therefore, the purpose of this article is to 
      explore the role of stigma in the care of families impacted by NAS. METHODS: In
      this article, we present a discussion about the effects of stigma on this patient
      population and provide exemplars of stigma experiences from our previous research
      and the existing literature. FINDINGS/RESULTS: Mothers of infants with NAS faced 
      the challenges of overcoming stigma as they were often ostracized, excluded, and 
      shamed. Nurses who provide care for these women and their infants have reported
      experiencing ethical distress, moral distress, and compassion fatigue.
      IMPLICATIONS FOR PRACTICE: Greater awareness of the impact of opioid use on the
      maternal-child population has resulted in numerous educational offerings for
      healthcare providers; however, this alone is not adequate to end stigma.
      Fortunately, promising tools and methods have been developed for assisting nurses
      with addressing stigma in a manner that can be both nonconfrontational and highly
      effective. IMPLICATIONS FOR RESEARCH: Future research is needed to explore and
      evaluate the efficacy of various existing strategies for counteracting harmful
      stigma in this patient population.
FAU - Recto, Pamela
AU  - Recto P
AD  - School of Nursing (Drs Recto, McGlothen-Bell, McGrath, Brownell, and Cleveland)
      and Center for Research to Advance Community Health (Dr Recto), The University of
      Texas Health Science Center at San Antonio.
FAU - McGlothen-Bell, Kelly
AU  - McGlothen-Bell K
FAU - McGrath, Jacqueline
AU  - McGrath J
FAU - Brownell, Elizabeth
AU  - Brownell E
FAU - Cleveland, Lisa M
AU  - Cleveland LM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Neonatal Care
JT  - Advances in neonatal care : official journal of the National Association of
      Neonatal Nurses
JID - 101125644
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Family
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Infant, Newborn
MH  - Mothers
MH  - Neonatal Abstinence Syndrome/*psychology
MH  - Nurses/*psychology
MH  - Occupational Stress/psychology
MH  - *Social Stigma
PMC - PMC7467149
EDAT- 2020/09/02 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
AID - 10.1097/ANC.0000000000000778 [doi]
AID - 00149525-202010000-00004 [pii]
PST - ppublish
SO  - Adv Neonatal Care. 2020 Oct;20(5):354-363. doi: 10.1097/ANC.0000000000000778.


PMID- 32868368
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Clinical evolution, management and outcomes of patients with COVID-19 admitted at
      Tygerberg Hospital, Cape Town, South Africa: a research protocol.
PG  - e039455
LID - 10.1136/bmjopen-2020-039455 [doi]
AB  - INTRODUCTION: The outbreak of the SARS-CoV-2 virus causing COVID-19, declared a
      global pandemic by the WHO, is a novel infection with a high rate of morbidity
      and mortality. In South Africa, 55 421 cases have been confirmed as of 10 June
      2020, with most cases in the Western Cape Province. Coronavirus leaves us in a
      position of uncertainty regarding the best clinical approach to successfully
      manage the expected high number of severely ill patients with COVID-19. This
      presents a unique opportunity to gather data to inform best practices in clinical
      approach and public health interventions to control COVID-19 locally.
      Furthermore, this pandemic challenges our resolve due to the high burden of HIV
      and tuberculosis (TB) in our country as data are scarce. This study endeavours to
      determine the clinical presentation, severity and prognosis of patients with
      COVID-19 admitted to our hospital. METHODS AND ANALYSIS: The study will use
      multiple approaches taking into account the evolving nature of the COVID-19
      pandemic. Prospective observational design to describe specific patterns of risk 
      predictors of poor outcomes among patients with severe COVID-19 admitted to
      Tygerberg Hospital. Data will be collected from medical records of patients with 
      severe COVID-19 admitted at Tygerberg Hospital. Using the Cox proportional
      hazards model, we will investigate the association between the survival time of
      patients with COVID-19 in relation to one or more of the predictor variables
      including HIV and TB. ETHICS AND DISSEMINATION: The research team obtained
      ethical approval from the Health Research Ethics Committee of the Faculty of
      Medicine and Health Sciences, Stellenbosch University and Research Committee of
      the Tygerberg Hospital. All procedures for the ethical conduct of scientific
      investigation will be adhered to by the research team. The findings will be
      disseminated in clinical seminars, scientific forums and conferences targeting
      clinical care providers and policy-makers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Allwood, Brian W
AU  - Allwood BW
AD  - Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Koegelenberg, Coenraad Fn
AU  - Koegelenberg CF
AD  - Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Irusen, Elvis
AU  - Irusen E
AD  - Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Lalla, Usha
AU  - Lalla U
AD  - Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Davids, Razeen
AU  - Davids R
AD  - Division of Nephrology, Department of Medicine, Faculty of Medicine & Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Chothia, Yazied
AU  - Chothia Y
AD  - Division of Nephrology, Department of Medicine, Faculty of Medicine & Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Davids, Ryan
AU  - Davids R
AD  - Department of Anesthesia and Critical Care, Faculty of Medicine and Health
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Prozesky, Hans
AU  - Prozesky H
AD  - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and 
      Health Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Taljaard, Jantjie
AU  - Taljaard J
AD  - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and 
      Health Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Parker, Arifa
AU  - Parker A
AUID- ORCID: 0000-0002-2005-698X
AD  - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and 
      Health Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Decloedt, Eric
AU  - Decloedt E
AD  - Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine
      and Health Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Jordan, Portia
AU  - Jordan P
AD  - Department of Nursing, Faculty of Medicine and Health Sciences, Stellenbosch
      University, Cape Town, South Africa.
FAU - Lahri, Sa'ad
AU  - Lahri S
AD  - Department of Emergency Medicine, Faculty of Medicine and Health Sciences,
      Stellenbosch University, Cape Town, South Africa.
FAU - Moosa, Rafique
AU  - Moosa R
AD  - Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch
      University, Cape Town, South Africa.
FAU - Schrueder, Neshaad
AU  - Schrueder N
AD  - Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch
      University, Cape Town, South Africa.
FAU - Du Toit, Riette
AU  - Du Toit R
AD  - Division of Rheumatology, Department of Medicine, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Viljoen, Abraham
AU  - Viljoen A
AD  - Division of Rheumatology, Department of Medicine, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - English, Rene
AU  - English R
AD  - Division of Health Systems and Public Health, Department of Global Health,
      Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,
      South Africa.
FAU - Ayele, Birhanu
AU  - Ayele B
AD  - Division of Epidemiology and Biostatistics, Department of Global Health, Faculty 
      of Medicine and Health Sciences, Stellenbosch University, Cape Town, South
      Africa.
FAU - Nyasulu, Peter
AU  - Nyasulu P
AUID- ORCID: 0000-0003-2757-0663
AD  - Division of Epidemiology and Biostatistics, Department of Global Health, Faculty 
      of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
      pnyasulu@sun.ac.za.
CN  - COVID-19 Research Response Team, Faculty of Medicine and Health Sciences,
      Stellenbosch University
LA  - eng
PT  - Journal Article
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy/virology
MH  - Disease Outbreaks
MH  - Female
MH  - HIV Infections/complications
MH  - *Hospitalization
MH  - *Hospitals
MH  - Humans
MH  - Male
MH  - Medical Records
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy/virology
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Public Health
MH  - Research Design
MH  - SARS-CoV-2
MH  - South Africa/epidemiology
MH  - Survivors
MH  - Tuberculosis/complications
PMC - PMC7462165
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *epidemiology
OT  - *general medicine (see internal medicine)
OT  - *infectious diseases
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - bmjopen-2020-039455 [pii]
AID - 10.1136/bmjopen-2020-039455 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e039455. doi: 10.1136/bmjopen-2020-039455.


PMID- 32868367
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Does obstructive sleep apnoea contribute to obesity, hypertension and kidney
      dysfunction in children? A systematic review protocol.
PG  - e039342
LID - 10.1136/bmjopen-2020-039342 [doi]
AB  - INTRODUCTION: Childhood obstructive sleep apnoea (OSA) is a highly prevalent
      disorder that may directly contribute to the development of obesity, hypertension
      and renal injury. Although those associations seem to be clearer in adults,
      studies in children have revealed conflicting results and updated synthesis of
      the evidence is lacking. The aim of this systematic review is to summarise the
      available evidence on the effect of OSA on obesity, systemic blood pressure and
      kidney function, to help to elucidate whether respiratory interventions to
      correct OSA would have the potential to improve those outcomes. METHODS AND
      ANALYSIS: A systematic literature review search was created by a medical
      librarian and peer-reviewed by a second librarian prior to running. Ovid Medline,
      Ovid Embase, CINAHL via EbscoHOST, Wiley Cochrane Library and ProQuest
      Dissertations and Theses Global were searched on 25 February 2020. Titles and
      abstracts will be screened by two independent reviewers for inclusion, followed
      by full-text screening of relevant articles. Studies in children will be included
      if they report data on OSA and weight, systemic blood pressure or kidney
      parameters. The extracted data will be combined for analysis and the information 
      subcategorised in groups based on outcome. Risk of bias will be determined using 
      tools specific to study methodology and certainty of the evidence using the
      Grading of Recommendations, Assessment, Development and Evaluations approach.
      ETHICS AND DISSEMINATION: This study will provide essential information for
      healthcare professionals to better understand the relationship between childhood 
      OSA and changes in body mass index, systemic blood pressure and kidney function
      indicators. Our findings will be disseminated through conferences and
      publications. The results of this review may guide the initiation of new
      strategies and the development of future research studies. This research did not 
      involve human subjects and therefore did not undergo research ethical review.
      PROSPERO REGISTRATION NUMBER: CRD42020171186.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rodriguez-Lopez, Sara
AU  - Rodriguez-Lopez S
AUID- ORCID: 0000-0003-0543-4855
AD  - Nephrology, Stollery Children's Hospital, Edmonton, Alberta, Canada.
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
FAU - Palkowski, Stefan
AU  - Palkowski S
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Pediatrics, Stollery Children's Hospital, Edmonton, Alberta, Canada.
FAU - Gerdung, Christopher
AU  - Gerdung C
AUID- ORCID: 0000-0003-0096-3993
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Respiratory Medicine, Stollery Children's Hospital, Edmonton, Alberta, Canada.
FAU - Keto-Lambert, Diana
AU  - Keto-Lambert D
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Alberta Strategy for Patient-Oriented Research (SPOR) Knowledge Translation
      Platform, University of Alberta, Edmonton, Alberta, Canada.
FAU - Sebastianski, Meghan
AU  - Sebastianski M
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Alberta Strategy for Patient-Oriented Research (SPOR) Knowledge Translation
      Platform, University of Alberta, Edmonton, Alberta, Canada.
FAU - Castro-Codesal, Maria Luisa
AU  - Castro-Codesal ML
AUID- ORCID: 0000-0002-1079-2502
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada castroco@ualberta.ca.
AD  - Respiratory Medicine, Stollery Children's Hospital, Edmonton, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Hypertension/epidemiology/etiology
MH  - Kidney
MH  - *Obesity/complications/epidemiology
MH  - Retrospective Studies
MH  - *Sleep Apnea, Obstructive/complications/epidemiology
MH  - Systematic Reviews as Topic
PMC - PMC7462153
OTO - NOTNLM
OT  - *paediatric nephrology
OT  - *paediatric thoracic medicine
OT  - *sleep medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-039342 [pii]
AID - 10.1136/bmjopen-2020-039342 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e039342. doi: 10.1136/bmjopen-2020-039342.


PMID- 32868362
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20220319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Eye health and quality of life: an umbrella review protocol.
PG  - e037648
LID - 10.1136/bmjopen-2020-037648 [doi]
AB  - INTRODUCTION: Vision impairment and eye disease are major global health concerns 
      and have been associated with increased morbidity and mortality, and lower
      quality of life. Quality of life, whether generic, vision-specific or
      disease-specific, is an important measure of the impact of eye health on people's
      daily activities, well-being and visual function, and is increasingly used to
      evaluate the impact of ophthalmic interventions and new devices. While many
      studies and reviews have examined the relationship between vision or eye health
      and quality of life across different contexts, there has yet to be a synthesis of
      the impact of vision impairment, eye disease and ophthalmic interventions on
      quality of life globally and across the lifespan. METHODS AND ANALYSIS: An
      umbrella review of systematic reviews will be conducted to address these two
      questions: (1) What is the association of vision impairment and eye disease with 
      quality of life? (2) What is the impact of ophthalmic interventions on quality of
      life? A search of related literature will be performed on the 11 February 2020 in
      Medline Ovid, Embase.com, Cochrane Database of Systematic Reviews, Proquest
      Dissertations and Theses Global, and the grey literature, and repeated at the
      synthesis stage. Title/abstract and full-text screening, methodological quality
      assessment and data extraction will be conducted by reviewers working
      independently and in duplicate. Assessment of methodological quality and data
      extraction will be performed using Joanna Briggs Institute standard forms.
      Findings from the systematic reviews and their methodological quality will be
      summarised qualitatively in the text and using tables. ETHICS AND DISSEMINATION: 
      No ethical approval is required. Results of this umbrella review will be
      published in a peer-reviewed journal and summarised in the Lancet Global Health
      Commission on Global Eye Health. TRIAL REGISTRATION NUMBER: This protocol was
      registered in the Open Science Framework Registries (https://osf.io/qhv9g/).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Assi, Lama
AU  - Assi L
AUID- ORCID: 0000-0001-5855-3896
AD  - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Rosman, Lori
AU  - Rosman L
AD  - Welch Medical Library, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Chamseddine, Fatimah
AU  - Chamseddine F
AD  - Clinical Research Institute, American University of Beirut Faculty of Medicine,
      Beirut, Lebanon.
FAU - Ibrahim, Perla
AU  - Ibrahim P
AD  - Department of Ophthalmology, American University of Beirut Faculty of Medicine,
      Beirut, Lebanon.
FAU - Sabbagh, Hadi
AU  - Sabbagh H
AD  - Department of Ophthalmology, American University of Beirut Faculty of Medicine,
      Beirut, Lebanon.
FAU - Congdon, Nathan
AU  - Congdon N
AD  - Centre for Public Health, Queen's University Belfast School of Medicine Dentistry
      and Biomedical Sciences, Belfast, UK.
AD  - Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.
FAU - Evans, Jennifer
AU  - Evans J
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, UK.
FAU - Ramke, Jacqueline
AU  - Ramke J
AUID- ORCID: 0000-0002-5764-1306
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, UK.
AD  - School of Optometry and Vision Science, The University of Auckland, Auckland, New
      Zealand.
FAU - Kuper, Hannah
AU  - Kuper H
AUID- ORCID: 0000-0002-8952-0023
AD  - International Centre for Evidence in Disability, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Burton, Matthew J
AU  - Burton MJ
AD  - International Centre for Eye Health, London School of Hygiene & Tropical
      Medicine, London, UK.
AD  - Cornea & External Eye Disease, Moorfields Eye Hospital, London, UK.
FAU - Ehrlich, Joshua R
AU  - Ehrlich JR
AUID- ORCID: 0000-0002-0607-3564
AD  - Department of Ophthalmology and Visual Sciences, University of Michigan, Ann
      Arbor, Michigan, USA.
AD  - Institute for Healthcare Policy and Innovation, University of Michigan, Ann
      Arbor, Michigan, USA.
FAU - Swenor, Bonnielin K
AU  - Swenor BK
AD  - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA bswenor@jhmi.edu.
AD  - Department of Epidemiology, Johns Hopkins University Bloomberg School of Public
      Health, Baltimore, Maryland, USA.
LA  - eng
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
GR  - K23 EY027848/EY/NEI NIH HHS/United States
GR  - K01 AG052640/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Blindness
MH  - Child
MH  - *Eye Diseases
MH  - Global Health
MH  - Humans
MH  - *Quality of Life
MH  - Review Literature as Topic
PMC - PMC7462163
OTO - NOTNLM
OT  - *epidemiology
OT  - *ophthalmology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-037648 [pii]
AID - 10.1136/bmjopen-2020-037648 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e037648. doi: 10.1136/bmjopen-2020-037648.


PMID- 32868360
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Protocol for a cluster-randomised non-inferiority trial of one versus two doses
      of ivermectin for the control of scabies using a mass drug administration
      strategy (the RISE study).
PG  - e037305
LID - 10.1136/bmjopen-2020-037305 [doi]
AB  - INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting
      approximately 200 million people at any time. Scabies is endemic in many
      resource-limited tropical settings. Bacterial skin infection (impetigo)
      frequently complicates scabies infestation in these settings. Community-wide
      ivermectin-based mass drug administration (MDA) is an effective control strategy 
      for scabies in island settings, with a single round of MDA reducing population
      prevalence by around 90%. However, current two-dose regimens present a number of 
      barriers to programmatic MDA implementation. We designed the Regimens of
      Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose
      MDA may be as effective as two-dose MDA in controlling scabies in high-prevalence
      settings. METHODS AND ANALYSIS: RISE is a cluster-randomised non-inferiority
      trial. The study will be conducted in 20 isolated villages in Western Province of
      Solomon Islands where population prevalence of scabies is approximately 20%.
      Villages will be randomly allocated to receive either one dose or two doses of
      ivermectin-based MDA in a 1:1 ratio. The primary objective of the study is to
      determine if ivermectin-based MDA with one dose is as effective as MDA with two
      doses in reducing the prevalence of scabies after 12 months. Secondary objectives
      include the effect of ivermectin-based MDA on impetigo prevalence after 12 and 24
      months, the prevalence of scabies at 24 months after the intervention, the impact
      on presentation to health facilities with scabies and impetigo, and the safety of
      one-dose and two-dose MDA. ETHICS AND DISSEMINATION: This trial has been approved
      by the ethics review committees of the Solomon Islands and the Royal Children's
      Hospital, Australia. Results will be disseminated in peer-reviewed publications
      and in meetings with the Solomon Islands Ministry of Health and Medical Services 
      and participating communities. TRIAL REGISTRATION DETAILS: Australian New Zealand
      Clinical Trials Registry: ACTRN12618001086257. Date registered: 28 June 2018.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lake, Susanna J
AU  - Lake SJ
AUID- ORCID: 0000-0002-5508-5430
AD  - Tropical Disease Research Group, Murdoch Childrens Research Institute, Parkville,
      Victoria, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Phelan, Sophie L
AU  - Phelan SL
AD  - The Kirby Institute, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Engelman, Daniel
AU  - Engelman D
AD  - Tropical Disease Research Group, Murdoch Childrens Research Institute, Parkville,
      Victoria, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Sokana, Oliver
AU  - Sokana O
AD  - Ministry of Health and Medical Services, Honiara, Solomon Islands.
FAU - Nasi, Titus
AU  - Nasi T
AD  - Ministry of Health and Medical Services, Honiara, Solomon Islands.
FAU - Boara, Dickson
AU  - Boara D
AD  - Ministry of Health and Medical Services, Honiara, Solomon Islands.
FAU - Gorae, Christina
AU  - Gorae C
AD  - Ministry of Health and Medical Services, Honiara, Solomon Islands.
FAU - Schuster, Tibor
AU  - Schuster T
AD  - Clinical Epidemiology and Biostatistics Unit, McGill University, Montreal,
      Quebec, Canada.
FAU - Grobler, Anneke C
AU  - Grobler AC
AD  - Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research
      Institute, Parkville, Victoria, Australia.
FAU - Osti, Millicent H
AU  - Osti MH
AD  - Tropical Disease Research Group, Murdoch Childrens Research Institute, Parkville,
      Victoria, Australia.
FAU - Andrews, Ross
AU  - Andrews R
AD  - Australian National University, Canberra, Australian Capital Territory,
      Australia.
FAU - Marks, Michael
AU  - Marks M
AUID- ORCID: 0000-0002-7585-4743
AD  - Clinical Research Department, London School of Hygiene and Tropical Medicine,
      London, UK.
AD  - Hospital for Tropical Diseases, London, UK.
FAU - Whitfeld, Margot J
AU  - Whitfeld MJ
AD  - Department of Dermatology, St Vincent's Hospital, Sydney, New South Wales,
      Australia.
FAU - Romani, Lucia
AU  - Romani L
AUID- ORCID: 0000-0001-9038-5300
AD  - The Kirby Institute, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Kaldor, John
AU  - Kaldor J
AD  - The Kirby Institute, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Steer, Andrew
AU  - Steer A
AD  - Tropical Disease Research Group, Murdoch Childrens Research Institute, Parkville,
      Victoria, Australia andrew.steer@rch.org.au.
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Victoria,
      Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiparasitic Agents)
RN  - 70288-86-7 (Ivermectin)
SB  - IM
MH  - *Antiparasitic Agents/therapeutic use
MH  - Australia
MH  - Child
MH  - Humans
MH  - *Ivermectin/therapeutic use
MH  - Mass Drug Administration
MH  - Melanesia/epidemiology
MH  - Randomized Controlled Trials as Topic
MH  - *Scabies/drug therapy/epidemiology/prevention & control
PMC - PMC7462236
OTO - NOTNLM
OT  - *dermatology
OT  - *infectious diseases
OT  - *international health services
OT  - *tropical medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-037305 [pii]
AID - 10.1136/bmjopen-2020-037305 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e037305. doi: 10.1136/bmjopen-2020-037305.


PMID- 32868357
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 31
TI  - Determining the long-term health burden and risk of sequelae for 14 foodborne
      infections in British Columbia, Canada: protocol for a retrospective
      population-based cohort study.
PG  - e036560
LID - 10.1136/bmjopen-2019-036560 [doi]
AB  - INTRODUCTION: Over one in eight Canadians is affected by a foodborne infection
      annually; however, the long-term consequences, including the risks and costs of
      sequelae, are unclear. We aim to estimate the health burden and direct costs of
      14 infections commonly transmitted by food, considering the acute illness and
      subsequent sequelae and mortality, for the population of British Columbia, Canada
      (~4.7 million). METHODS AND ANALYSIS: We will conduct a population-based
      retrospective cohort study of the British Columbia provincial population, over a 
      10-year study period (1 January 2005 to 31 December 2014). Exposure is defined as
      a provincially reported illness caused by Clostridium botulinum, Campylobacter,
      Cryptosporidium, Cyclospora, Giardia, hepatitis A virus, Listeria, non-typhoidal 
      Salmonella spp, Salmonella Typhi, Salmonella Paratyphi, Shiga toxin-producing
      Escherichia coli, Shigella, Vibrio parahaemolyticus or Yersinia (excluding
      pestis). We will link individual-level longitudinal data from eight province-wide
      administrative health and reportable disease databases that include physician
      visits, hospitalisations and day surgeries, deaths, stillbirths, prescription
      medications (except those to treat HIV) and reportable foodborne diseases. Using 
      these linked databases, we will investigate the likelihood of various sequelae
      and death. Hazard models will be used to estimate the risk of outcomes and their 
      association with the type of foodborne infection. Epidemiological analyses will
      be conducted to determine the progression of illness and the fraction of sequelae
      attributable to specific foodborne infections. Economic analyses will assess the 
      consequent direct healthcare costs. ETHICS AND DISSEMINATION: This study has been
      approved by a University of Waterloo Research Ethics Committee (no 30645), the
      University of British Columbia Behavioral Research Ethics Board (no H16-00021)
      and McGill University's Institutional Review Board (no A03-M12-19A). Results will
      be disseminated via presentations to academics, public health practitioners and
      knowledge users, and publication in peer-reviewed journals. Where such
      publications are not open access, manuscripts will also be available via the
      University of Waterloo's Institutional Repository (https://uwspace.uwaterloo.ca).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Majowicz, Shannon E
AU  - Majowicz SE
AUID- ORCID: 0000-0002-0006-8369
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada smajowicz@uwaterloo.ca.
FAU - Panagiotoglou, Dimitra
AU  - Panagiotoglou D
AUID- ORCID: 0000-0002-6175-3634
AD  - Department of Epidemiology, Biostatistics and Occupational Health, McGill
      University, Montreal, Quebec, Canada.
FAU - Taylor, Marsha
AU  - Taylor M
AD  - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
FAU - Gohari, Mahmood R
AU  - Gohari MR
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Kaplan, Gilaad G
AU  - Kaplan GG
AD  - Departments of Medicine and Community Health Sciences, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Chaurasia, Ashok
AU  - Chaurasia A
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Leatherdale, Scott T
AU  - Leatherdale ST
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Cook, Richard J
AU  - Cook RJ
AD  - Department of Statistics and Actuarial Science, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Patrick, David M
AU  - Patrick DM
AD  - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
AD  - School of Population and Public Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Ethelberg, Steen
AU  - Ethelberg S
AD  - Department of Infectious Disease Epidemiology and Prevention, Statens Serum
      Institut, Copenhagen, Denmark.
AD  - Global Health Section, Department of Public Health, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Galanis, Eleni
AU  - Galanis E
AD  - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
AD  - School of Population and Public Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
LA  - eng
GR  - 156385 /CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200831
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Animals
MH  - British Columbia/epidemiology
MH  - Cohort Studies
MH  - *Cryptosporidiosis
MH  - *Cryptosporidium
MH  - *Foodborne Diseases
MH  - Humans
MH  - Retrospective Studies
PMC - PMC7462161
OTO - NOTNLM
OT  - *epidemiology
OT  - *gastrointestinal infections
OT  - *public health
COIS- Competing interests: SEM and EG report funding for this study as per the funding 
      statement. SEM reports other relationships; she is an associate editor at
      Epidemiology and Infection (for which she receives a small honorarium); she has
      served as a paid expert on behalf of the Attorney General of Canada in legal
      proceedings, providing evidence on the public health risks and benefits of
      unpasteurised milk, and she is an expert on the Joint FAO/WHO Expert Meetings on 
      Microbiological Risk Assessment (JEMRA) Roster of Experts. GGK reports honoraria 
      for speaking or consultancy from Abbvie, Janssen, Pfizer and Takeda. He has
      received research support from Ferring, Janssen, Abbvie, GlaxoSmith Kline, Merck 
      and Shire. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, 
      AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent
      WO2019046959A1. PCT/CA2018/051098. 7 September 2018. EG' spouse works for QHR
      Technologies, a Canadian medical records company; these records were not used in 
      this study. All other authors have nothing to disclose.
EDAT- 2020/09/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036560 [pii]
AID - 10.1136/bmjopen-2019-036560 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 31;10(8):e036560. doi: 10.1136/bmjopen-2019-036560.


PMID- 32868356
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Reaching mEthadone users Attending Community pHarmacies with HCV: an
      international cluster randomised controlled trial protocol (REACH HCV).
PG  - e036501
LID - 10.1136/bmjopen-2019-036501 [doi]
AB  - INTRODUCTION: Hepatitis C virus (HCV) is a global public health threat, and novel
      models of care are required to treat those currently or previously at highest
      risk of infection, particularly persons who inject drugs (PWID; ever injected),
      as conventional healthcare models do not have the reach to deliver cure of HCV to
      disadvantaged, disproportionately affected communities. In Western Europe and
      Australasia, it is estimated that HCV affects between 0.4% and 1.0% of the
      regions' populations, accordingly, it affects between 0.4% and 0.7% of the
      populations of countries in this study (Scotland, Wales and Australia). Reaching 
      mEthadone users Attending Community pHarmacies with HCV (REACH HCV) will evaluate
      community pharmacy-based diagnostic outreach and HCV treatment against
      conventional HCV testing and treatment pathways for clients receiving opioid
      substitution therapy (OST) in community pharmacies. METHODS AND ANALYSIS: REACH
      HCV is an international multicentre cluster randomised controlled trial with
      sites in Scotland, Wales and Australia. The sites are community pharmacies which 
      are randomised equally to one of two pathways: the pharmacy intervention pathway 
      or the education-only (control) pathway. Participants are recruited from OST
      clients in these pharmacies.In the pharmacy intervention pathway, participants
      receive a rapid point-of-care HCV PCR test in their pharmacy by a study outreach 
      nurse. If positive, direct-acting antivirals (DAAs) are delivered to participants
      via their pharmacist in line with their OST schedule.In the education-only
      pathway, pharmacists counsel OST clients on HCV and refer them to the nearest
      nurse-led clinic or general practitioner offering HCV testing according to
      standard care protocols. If positive, DAAs are delivered as in the intervention
      pathway.The primary endpoint for both pathways is sustained viral response at 12 
      weeks post-treatment . Secondary outcomes are: cost-efficacy by pathway;
      participants tested by pathway; adherence to therapy by pathway and impact of
      blood test results on treatment decisions.A statistical analysis plan will be
      finalised prior to data lock. Analysis will be by intention to treat (ITT) to
      show superiority. Modified ITT analysis will also be undertaken to explore the
      steps in the pathways. ETHICS AND DISSEMINATION: The trial received ethical
      favourable opinion from the East of Scotland Research Ethics Committee 2
      (19/ES/0025) for UK sites and approval from the Alfred Hospital Ethics Committee 
      (148/19) for Australian sites and complies with principles of Good Clinical
      Practice. Final results will be presented in peer-reviewed journals and at
      relevant conferences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry
      NCT03935906. PROTOCOL VERSION: V.4.0-19 March 2020.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Byrne, Christopher
AU  - Byrne C
AUID- ORCID: 0000-0002-7586-7712
AD  - Department of Molecular and Clinical Medicine, University of Dundee School of
      Medicine, Dundee, UK c.x.byrne@dundee.ac.uk.
AD  - Tayside Clinical Trials Unit, University of Dundee, Dundee, UK.
FAU - Radley, Andrew
AU  - Radley A
AUID- ORCID: 0000-0003-4772-2388
AD  - Department of Molecular and Clinical Medicine, University of Dundee School of
      Medicine, Dundee, UK.
AD  - Directorate of Public Health, National Health Service Tayside, Dundee, UK.
FAU - Inglis, Sarah Karen
AU  - Inglis SK
AD  - Tayside Clinical Trials Unit, University of Dundee, Dundee, UK.
FAU - Beer, Lewis J Z
AU  - Beer LJZ
AD  - Tayside Clinical Trials Unit, University of Dundee, Dundee, UK.
FAU - Palmer, Nicki
AU  - Palmer N
AD  - Public Health Wales Department of Microbiology, University Hospital of Wales,
      Cardiff, UK.
FAU - Pham, Minh Duc
AU  - Pham MD
AUID- ORCID: 0000-0002-5932-3491
AD  - Disease Elimination Programme, Burnet Institute, Melbourne, Victoria, Australia.
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Victoria, Australia.
FAU - Healy, Brendan
AU  - Healy B
AD  - Public Health Wales Department of Microbiology, University Hospital of Wales,
      Cardiff, UK.
FAU - Doyle, Joseph S
AU  - Doyle JS
AD  - Disease Elimination Programme, Burnet Institute, Melbourne, Victoria, Australia.
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Victoria, Australia.
FAU - Donnan, Peter
AU  - Donnan P
AD  - Dundee Epidemiology and Biostatistics Unit, University of Dundee, Dundee, UK.
FAU - Dillon, John F
AU  - Dillon JF
AD  - Department of Molecular and Clinical Medicine, University of Dundee School of
      Medicine, Dundee, UK.
AD  - Department of Gastroenterology, National Health Service Tayside, Dundee, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03935906
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - UC6VBE7V1Z (Methadone)
SB  - IM
MH  - *Antiviral Agents/therapeutic use
MH  - Australasia
MH  - Australia
MH  - *Drug Users
MH  - Europe
MH  - Hepacivirus
MH  - *Hepatitis C/diagnosis/drug therapy/epidemiology
MH  - *Hepatitis C, Chronic/drug therapy
MH  - Humans
MH  - *Methadone/therapeutic use
MH  - *Pharmacies
MH  - Randomized Controlled Trials as Topic
MH  - Scotland
MH  - *Substance Abuse, Intravenous/drug therapy
MH  - Wales
PMC - PMC7462226
OTO - NOTNLM
OT  - *gastroenterology
OT  - *hepatology
OT  - *infectious diseases
COIS- Competing interests: AR has received personal honoraria from AbbVie and Gilead
      and institutional research grants from MSD, AbbVie, Gilead and Roche. BH has
      received unrestricted educational grants, payments for advisory boards and
      payments for presentations from Jannen, Gilead, BMS, Abbvie and Merck in relation
      to HCV products. He has also received funding from Gilead, Merck, Abbvie and BMS 
      for running meetings in relation to HCV in Wales. He has secured unrestricted
      funding from Abbvie, Merck and Gilead for project work related to management of
      HCV. JSD has received investigator initiated research support from AbbVie, Gilead
      Sciences, Merck and Bristol Myers Squibb; and has received honoraria from AbbVie,
      Gilead Sciences, and Merck. JFD has received personal honoraria for lectures and 
      institutional research grants from MSD, AbbVie, Gilead, Roche and Janssen. PD has
      received grants from Gilead, Shire pharmaceuticals. PD is a member of the New
      Drugs Committee of the Scottish Medicines Consortium. AbbVie were involved in a
      collaborative, iterative process to develop the study protocol alongside the
      study Investigators as part of the AbbVie Investigator Initiated Scheme. AbbVie
      provided input to the protocol with regards to safety measures and reporting; the
      participant journey; and HCV medication guidance.
EDAT- 2020/09/02 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036501 [pii]
AID - 10.1136/bmjopen-2019-036501 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e036501. doi: 10.1136/bmjopen-2019-036501.


PMID- 32868354
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211002
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 31
TI  - Point-of-care viral load testing among adolescents and youth living with HIV in
      Haiti: a protocol for a randomised trial to evaluate implementation and effect.
PG  - e036147
LID - 10.1136/bmjopen-2019-036147 [doi]
AB  - INTRODUCTION: Adolescents living with HIV have poor antiretroviral therapy (ART) 
      adherence and viral suppression outcomes. Viral load (VL) monitoring could
      reinforce adherence but standard VL testing requires strong laboratory capacity
      often only available in large central laboratories. Thus, coordinated transport
      of samples and results between the clinic and laboratory is required, presenting 
      opportunities for delayed or misplaced results. Newly available point-of-care
      (POC) VL testing systems return test results the same day and could simplify VL
      monitoring so that adolescents receive test results faster which could strengthen
      adherence counselling and improve ART adherence and viral suppression. METHODS
      AND ANALYSIS: This non-blinded randomised clinical trial is designed to evaluate 
      the implementation and effectiveness of POC VL testing compared with standard
      laboratory-based VL testing among adolescents and youth living with HIV in Haiti.
      A total of 150 participants ages 10-24 who have been on ART for >6 months are
      randomised 1:1 to intervention or standard arms. Intervention arm participants
      receive a POC VL test (Cepheid Xpert HIV-1 Viral Load system) with same-day
      result and immediate ART adherence counselling. Standard care participants
      receive a laboratory-based VL test (Abbott m2000sp/m2000rt) with the result
      available 1 month later, at which time they receive ART adherence counselling. VL
      testing is repeated 6 months later for both arms. The primary objective is to
      describe the implementation of POC VL testing compared with standard
      laboratory-based VL testing. The secondary objective is to evaluate the effect of
      POC VL testing on VL suppression at 6 months and participant comprehension of the
      correlation between VL and ART adherence. ETHICS AND DISSEMINATION: This study is
      approved by GHESKIO, Weill Cornell Medicine and Columbia University ethics
      committees. This trial will provide critical data to understand if and how POC VL
      testing may impact adolescent ART adherence and viral suppression. If effective, 
      POC VL testing could routinely supplement standard laboratory-based VL testing
      among high-risk populations living with HIV. TRIAL REGISTRATION NUMBER:
      NCT03288246.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Reif, Lindsey K
AU  - Reif LK
AUID- ORCID: 0000-0003-3427-4475
AD  - Center for Global Health, Department of Medicine, Weill Cornell Medicine, New
      York, New York, USA lir2020@med.cornell.edu.
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University 
      Irving Medical Center, New York, New York, USA.
FAU - Belizaire, Marie Elmase
AU  - Belizaire ME
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - Seo, Grace
AU  - Seo G
AD  - Center for Global Health, Department of Medicine, Weill Cornell Medicine, New
      York, New York, USA.
FAU - Rouzier, Vanessa
AU  - Rouzier V
AD  - Center for Global Health, Department of Medicine, Weill Cornell Medicine, New
      York, New York, USA.
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - Severe, Patrice
AU  - Severe P
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - Joseph, Joseph Marie
AU  - Joseph JM
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - Joseph, Bernadette
AU  - Joseph B
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - Apollon, Sandra
AU  - Apollon S
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - Abrams, Elaine J
AU  - Abrams EJ
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University 
      Irving Medical Center, New York, New York, USA.
AD  - ICAP at Columbia University, Mailman School of Public Health, Columbia University
      Irving Medical Center, New York, New York, USA.
AD  - Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia
      University Irving Medical Center, New York, New York, USA.
FAU - Arpadi, Stephen M
AU  - Arpadi SM
AD  - ICAP at Columbia University, Mailman School of Public Health, Columbia University
      Irving Medical Center, New York, New York, USA.
AD  - Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia
      University Irving Medical Center, New York, New York, USA.
AD  - Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons,
      Columbia University Irving Medical Center, New York, New York, USA.
FAU - Elul, Batya
AU  - Elul B
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University 
      Irving Medical Center, New York, New York, USA.
FAU - Pape, Jean W
AU  - Pape JW
AD  - Center for Global Health, Department of Medicine, Weill Cornell Medicine, New
      York, New York, USA.
AD  - GHESKIO, Port-au-Prince, Ouest, Haiti.
FAU - McNairy, Margaret L
AU  - McNairy ML
AD  - Division of General Internal Medicine, Department of Medicine, Weill Cornell
      Medicine, New York, New York, USA.
FAU - Fitzgerald, Daniel W
AU  - Fitzgerald DW
AD  - Center for Global Health, Department of Medicine, Weill Cornell Medicine, New
      York, New York, USA.
FAU - Kuhn, Louise
AU  - Kuhn L
AD  - ICAP at Columbia University, Mailman School of Public Health, Columbia University
      Irving Medical Center, New York, New York, USA.
AD  - Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons,
      Columbia University Irving Medical Center, New York, New York, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03288246
GR  - D43 TW011295/TW/FIC NIH HHS/United States
GR  - UM1 AI069421/AI/NIAID NIH HHS/United States
GR  - U01 AI069421/AI/NIAID NIH HHS/United States
GR  - K24 AI098627/AI/NIAID NIH HHS/United States
GR  - D43 TW010062/TW/FIC NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200831
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Child
MH  - *HIV Infections/diagnosis/drug therapy
MH  - Haiti
MH  - Humans
MH  - *Point-of-Care Systems
MH  - Randomized Controlled Trials as Topic
MH  - Viral Load
MH  - Young Adult
PMC - PMC7462242
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *clinical trials
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036147 [pii]
AID - 10.1136/bmjopen-2019-036147 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 31;10(8):e036147. doi: 10.1136/bmjopen-2019-036147.


PMID- 32868352
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Health service use among adults with cerebral palsy: a mixed methods systematic
      review protocol.
PG  - e035892
LID - 10.1136/bmjopen-2019-035892 [doi]
AB  - INTRODUCTION: Cerebral palsy (CP) is a neurodisability that primarily results in 
      motor impairments and activity limitations, but is often associated with epilepsy
      and disturbances of sensation, perception, cognition, behaviour and speech. Most 
      children with CP survive well into adulthood. Adults with CP experience increased
      risk of age-related chronic conditions such as arthritis, stroke,
      cardiorespiratory and mental health conditions in addition to the ongoing
      disabilities experienced from childhood. Therefore, adults with CP often require 
      extensive health services. However, health service use among adults with CP has
      not been well documented. This mixed method review aims to identify, appraise and
      synthesise quantitative and qualitative literature examining health service use
      among adults with CP. METHODS AND ANALYSIS: The mixed method systematic review
      will be conducted in accordance with the Joanna Briggs Institute (JBI)
      methodology. A systematic search of MEDLINE (Ovid), CINAHL, Embase, PsycINFO and 
      Cochrane Library from inception to March 2020 will be conducted. Quantitative
      observational studies, qualitative studies and mixed method studies examining
      health service use among adults with CP (>/=18 years) will be included. Outcomes 
      of interest are the proportion of adults using health services frequency of use
      and experiences of health services from the perspectives of adults with CP,
      caregivers and health service providers. Two reviewers will independently screen 
      titles, abstracts and full-texts, extract data and assess the quality of included
      studies using JBI instruments. Where possible a pooled analysis and aggregation
      of findings will be performed for quantitative and qualitative data,
      respectively, and Grading of Recommendations Assessment, Development and
      Evaluation (GRADE)/GRADE-CERQual (Confidence in Evidence from Reviews of
      Qualitative research) employed. Quantitative and qualitative findings will be
      integrated using a triangulation approach at the synthesis stage. A narrative
      synthesis will be carried out where this is not possible. ETHICS AND
      DISSEMINATION: Ethical approval is not required for this review. The findings
      will be disseminated through a peer-reviewed journal and conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020155 380.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Manikandan, Manjula
AU  - Manikandan M
AUID- ORCID: 0000-0003-2631-8482
AD  - Department of Public Health and Epidemiology, Royal College of Surgeons in
      Ireland, Dublin, Ireland.
FAU - Walsh, Aisling
AU  - Walsh A
AD  - Department of Public Health and Epidemiology, Royal College of Surgeons in
      Ireland, Dublin, Ireland.
FAU - Kerr, Claire
AU  - Kerr C
AD  - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
FAU - Walsh, Michael
AU  - Walsh M
AD  - Office of the Chief Clinical Officer, Health Service Executive, Dublin, Ireland.
FAU - M Ryan, Jennifer
AU  - M Ryan J
AUID- ORCID: 0000-0003-3768-2132
AD  - Department of Public Health and Epidemiology, Royal College of Surgeons in
      Ireland, Dublin, Ireland jennifer.ryan@brunel.ac.uk.
AD  - College of Health, Medicine and Life Sciences, Brunel University London,
      Uxbridge, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cerebral Palsy/psychology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Patient Acceptance of Health Care/*statistics & numerical data
MH  - Young Adult
PMC - PMC7462157
OTO - NOTNLM
OT  - *adult neurology
OT  - *health services administration & management
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035892 [pii]
AID - 10.1136/bmjopen-2019-035892 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e035892. doi: 10.1136/bmjopen-2019-035892.


PMID- 32868348
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 30
TI  - Do insomnia and/or sleep disturbances predict the onset, relapse or worsening of 
      depression in community and clinical samples of children and youth? Protocol for 
      a systematic review and meta-analysis.
PG  - e034606
LID - 10.1136/bmjopen-2019-034606 [doi]
AB  - INTRODUCTION: Disturbed sleep represents a potentially important modifiable risk 
      factor for the development of depression in children and youth. This protocol for
      a systematic review proposes to investigate whether insomnia and/or sleep
      disturbances predict child and youth depression in community and clinical-based
      samples. METHODS AND ANALYSIS: The protocol adheres to the Preferred Reporting
      Items for Systematic Review and Meta-Analysis Protocols guidelines.
      English-written, longitudinal studies that quantitatively estimated the
      prediction of depression by insomnia and/or sleep disturbances in individuals
      5-24 years of age will be included. EMBASE, MEDLINE, PsychINFO, Scopus and Web of
      Science and grey literature will be searched from 1980 to the present. For the
      selection of studies, two reviewers will be involved. Data extraction will be
      conducted by one author and checked independently by a second author. Risk of
      bias will be appraised using the Research Triangle Institute Item Bank tool.
      Heterogeneity will be measured using the I(2) statistics. Meta-analysis will be
      carried out if >/=3 results are available and if outcome measures can be pooled. 
      The choice between a random-effect or fixed-effect model will be based both on
      the I(2) statistics and the participant and study characteristics of the combined
      studies. Results of the meta-analyses will be summarised by a forest plot.
      Analyses will be performed in subgroups stratified by key variables defined
      depending on the amount and type of information retrieved.A narrative synthesis
      will be conducted in place of the meta-analysis should the pooling of data not be
      possible. Quality of evidence will be rated using the Grading of Recommendations 
      Assessment, Development and Evaluation guidelines.As this is a protocol for
      systematic review and meta-analysis of published data, ethics review and approval
      are not required. The findings will be published in a peer-reviewed journal and
      disseminated at scientific conferences and in patient advocacy organisations.
      PROSPERO REGISTRATION NUMBER: CRD42019136729.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Marino, Cecilia
AU  - Marino C
AUID- ORCID: 0000-0001-9308-5610
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada
      cecilia.marino@utoronto.ca.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Andrade, Brendan
AU  - Andrade B
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Aitken, Madison
AU  - Aitken M
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Bonato, Sarah
AU  - Bonato S
AD  - Library Services, Centre for Addiction and Mental Health, Toronto, Ontario,
      Canada.
FAU - Haltigan, John D
AU  - Haltigan JD
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Wang, Wei
AU  - Wang W
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Szatmari, Peter
AU  - Szatmari P
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200830
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Depression/*etiology
MH  - Humans
MH  - Sleep Initiation and Maintenance Disorders/*complications
MH  - Sleep Wake Disorders/*complications
PMC - PMC7462160
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *depression & mood disorders
OT  - *longitudinal studies
OT  - *sleep medicine
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034606 [pii]
AID - 10.1136/bmjopen-2019-034606 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 30;10(8):e034606. doi: 10.1136/bmjopen-2019-034606.


PMID- 32868285
OWN - NLM
STAT- Publisher
LR  - 20200901
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 Aug 31
TI  - Palliative sedation therapy for terminal movement disorders.
LID - bmjspcare-2020-002577 [pii]
LID - 10.1136/bmjspcare-2020-002577 [doi]
AB  - Palliative sedation therapy (PST) can be a challenging area of palliative
      medicine because of the complex ethical considerations involved. PST is a medical
      therapy used for refractory symptoms in terminally ill patients and is often
      considered ethically justified due to the principle of double effect. Even in
      cases where PST is clearly indicated such as refractory cancer pain, there is
      potential for moral distress among clinicians. Here, we present a unique case in 
      which multiple therapeutic options were limited in a patient with overlapping
      diagnoses of catatonia, medication-induced extrapyramidal symptoms, and dementia 
      with Lewy bodies. We review how existing frameworks can be applied to similar
      situations and offer practical strategies to support medical decision-making
      regarding PST and reduce the risk of moral distress among clinicians.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Partain, Daniel Kent
AU  - Partain DK
AUID- ORCID: http://orcid.org/0000-0003-1506-304X
AD  - Center for Palliative Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA 
      partain.daniel@mayo.edu.
FAU - Zehm, April
AU  - Zehm A
AD  - Division of Hematology and Oncology, Palliative Care Program, Medical College of 
      Wisconsin, Milwaukee, Wisconsin, USA.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - delirium
OT  - end of life care
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/07/17 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
AID - bmjspcare-2020-002577 [pii]
AID - 10.1136/bmjspcare-2020-002577 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 Aug 31. pii: bmjspcare-2020-002577. doi:
      10.1136/bmjspcare-2020-002577.


PMID- 32868266
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20210110
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
VI  - 105
IP  - 12
DP  - 2020 Dec
TI  - Young people's views on their role in the COVID-19 pandemic and society's
      recovery from it.
PG  - 1192-1196
LID - 10.1136/archdischild-2020-320040 [doi]
AB  - OBJECTIVE: There has been little formal exploration of how young people see their
      role in the COVID-19 pandemic. DESIGN/SETTING: Focus-group discussion with 15
      Children's Hospital Young People's Forum members (23/5) to explore their
      perspective on the impact of COVID-19 on both their lives and those of their
      community, on school closures, and the role they wished to play in society's
      recovery from the pandemic. Audio recordings were transcribed verbatim using
      NVivo Software and analysed using an inductive thematic analysis approach.
      OUTCOME: Four major themes identified: (1) Awareness of pandemic's impact on
      others: participants showed mature awareness of the effects on broader society,
      especially the elderly, socially disadvantaged and parents. (2) Perceived impact 
      on their own lives: principal concerns were the educational and practical
      repercussions of school closures and social isolation, including effects on
      educational prospects. (3) Views about school reopening: young people understood 
      the broader rationale for school reopening and were generally positive about it, 
      but expressed concerned about their safety and that of others. (4) Communication 
      issues: a need for clear, concise, understandable information readily accessible 
      for young people was expressed. Up to now, they felt passive recipients rather
      than participants. CONCLUSION: Young people were concerned about their future,
      their family and broader society, consistent with a high level of moral
      development. They want to be active participants in social recovery, including
      concepts around return to school but require appropriate information and a means 
      by which their voices can be heard. The alternative suggested roles as pawns or
      pathfinders were discounted.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Larcher, Vic
AU  - Larcher V
AD  - Paediatric Bioethics Centre, Great Ormond Street Hospital For Children NHS Trust,
      London, UK.
FAU - Dittborn, Mariana
AU  - Dittborn M
AD  - Paediatric Bioethics Centre, Great Ormond Street Hospital For Children NHS Trust,
      London, UK.
FAU - Linthicum, James
AU  - Linthicum J
AD  - Paediatric Bioethics Centre, Great Ormond Street Hospital For Children NHS Trust,
      London, UK.
FAU - Sutton, Amy
AU  - Sutton A
AD  - Young people's Forum, Great Ormond Street Hospital Biomedical Research Centre,
      London, United Kingdom.
FAU - Brierley, Joe
AU  - Brierley J
AUID- ORCID: 0000-0003-0919-6882
AD  - Paediatric Bioethics Centre, Great Ormond Street Hospital For Children NHS Trust,
      London, UK joe.brierley@gosh.nhs.uk.
FAU - Payne, Christopher
AU  - Payne C
AD  - Young people's Forum, Great Ormond Street Hospital Biomedical Research Centre,
      London, United Kingdom.
FAU - Hardy, Hannah
AU  - Hardy H
AD  - Young people's Forum, Great Ormond Street Hospital Biomedical Research Centre,
      London, United Kingdom.
CN  - GOSH Young People's Forum
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
SB  - IM
MH  - Adolescent
MH  - Adolescent Development
MH  - *COVID-19/epidemiology/prevention & control/psychology
MH  - Education, Distance
MH  - Female
MH  - Forecasting
MH  - Humans
MH  - Male
MH  - *Moral Development
MH  - Posttraumatic Growth, Psychological/*ethics
MH  - *Psychosocial Functioning
MH  - *Return to School
MH  - SARS-CoV-2
MH  - Social Isolation/psychology
MH  - *Social Perception/ethics/psychology
PMC - PMC7462044
OTO - NOTNLM
OT  - *adolescent health
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/09/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/06/25 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/09/02 06:00 [entrez]
AID - archdischild-2020-320040 [pii]
AID - 10.1136/archdischild-2020-320040 [doi]
PST - ppublish
SO  - Arch Dis Child. 2020 Dec;105(12):1192-1196. doi:
      10.1136/archdischild-2020-320040. Epub 2020 Aug 31.


PMID- 32867940
OWN - NLM
STAT- MEDLINE
DCOM- 20211208
LR  - 20211214
IS  - 1877-1300 (Electronic)
IS  - 1877-1297 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov
TI  - Promoting cultural sensitivity with the ethical and professional use of social
      media during global pharmacy experiences.
PG  - 1383-1386
LID - S1877-1297(20)30205-7 [pii]
LID - 10.1016/j.cptl.2020.05.009 [doi]
AB  - INTRODUCTION: While the use of social media and blogging is an attractive and
      rapidly growing method to disseminate student reflections and information, the
      use of digital online methods of learning also require professional and ethical
      accountability. This commentary describes two approaches to using a checklist to 
      promote the culturally sensitive, professional, and ethical use of social media
      platforms when students are expected to share their global pharmacy experiential 
      experiences. COMMENTARY: Social media sites and online blogs have the potential
      to enhance student experiences and promote intercultural competence of
      participants due to their ease of use and familiarity. If social media
      applications are used by students as a means of gaining self-awareness of
      cultural differences or promotion of cultural knowledge and attitudes, a
      framework for how to approach this process methodically should be employed by
      educators. E-professionalism criteria, such as self-evaluation of implicit
      biases, appropriateness of visual images, and timing of online posting can be
      used to set expectations as part of pre-departure training and to ensure ethical 
      dissemination of online student reflections. IMPLICATIONS: Pharmacy educators can
      assist students during global experiences abroad by improving their cultural
      competence when sharing reflections online. To ensure postings are culturally
      sensitive, ethical, and professional, consideration should be given to the
      deliberate use of a checklist that can assist with ensuring appropriateness of
      content and student reflections as part of a formal educational experience.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Arif, Sally A
AU  - Arif SA
AD  - Midwestern University, Chicago College of Pharmacy, 555 31(st) Street, Downers
      Grove, IL, United States. Electronic address: sarif@midwestern.edu.
FAU - Abrons, Jeanine P
AU  - Abrons JP
AD  - Department of Pharmacy Practice and Science, University of Iowa College of
      Pharmacy, 115 S. Grand Ave., Iowa City, Iowa 52242, United States.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - United States
TA  - Curr Pharm Teach Learn
JT  - Currents in pharmacy teaching & learning
JID - 101560815
SB  - IM
MH  - Cultural Competency
MH  - Humans
MH  - *Pharmaceutical Services
MH  - *Pharmacy
MH  - Professionalism
MH  - *Social Media
OTO - NOTNLM
OT  - *E-professionalism
OT  - *Global pharmacy education
OT  - *Social media
OT  - *Student reflection
EDAT- 2020/09/02 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/09/02 06:00
PHST- 2019/07/29 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - S1877-1297(20)30205-7 [pii]
AID - 10.1016/j.cptl.2020.05.009 [doi]
PST - ppublish
SO  - Curr Pharm Teach Learn. 2020 Nov;12(11):1383-1386. doi:
      10.1016/j.cptl.2020.05.009. Epub 2020 Jun 15.


PMID- 32867758
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 31
TI  - Efficacy of smartphone-based Mobile learning versus lecture-based learning for
      instruction of Cephalometric landmark identification.
PG  - 287
LID - 10.1186/s12909-020-02201-6 [doi]
AB  - BACKGROUND: Considering the increasing popularity of electronic learning,
      particularly smartphone-based mobile learning, and its reportedly optimal
      efficacy for instruction of complicated topics, this study aimed to compare the
      efficacy of smartphone-based mobile learning versus lecture-based learning for
      instruction of cephalometric landmark identification. METHODS: This
      quasi-experimental interventional study evaluated 53 dental students (4th year)
      in two groups of intervention (n = 27; smartphone instruction using an
      application) and control (n = 26, traditional lecture-based instruction). Two
      weeks after the instructions, dental students were asked to identify four
      landmarks namely the posterior nasal spine (PNS), orbitale (Or), articulare (Ar) 
      and gonion (Go) on lateral cephalograms. The mean coordinates of each landmark
      identified by orthodontists served as the reference point, and the mean distance 
      from each identified point to the reference point was reported as the mean
      consistency while the standard deviation of this mean was reported as the
      precision of measurement. Data were analyzed using SPSS version 18 via
      independent sample t-test. RESULTS: No significant difference was noted between
      the two groups in identification of PNS, Ar or Go (P > 0.05). However, the mean
      error rate in identification of Or was significantly lower in smartphone group
      compared with the traditional learning group (P = 0.020). CONCLUSIONS:
      Smartphone-based mobile learning had a comparable, and even slightly superior,
      efficacy to lecture-based learning for instruction of cephalometric landmark
      identification, and may be considered, at least as an adjunct, to enhance the
      instruction of complicated topics. TRIAL REGISTRATION NUMBER: This is not a human
      subject research. https://ethics. RESEARCH:
      ac.ir/ProposalCertificateEn.php?id=33714&Print=true&NoPrintHeader=true&NoPrintFoo
      ter=true&NoPrintPageBorder=true&LetterPrint=true .
FAU - Golshah, Amin
AU  - Golshah A
AD  - Department of Orthodontics, School of Dentistry, Kermanshah University of Medical
      Sciences, Kermanshah, Iran.
FAU - Dehdar, Fatemeh
AU  - Dehdar F
AD  - Faculty of Dentistry, Kermanshah University of Medical Sciences, Kermanshah,
      Iran.
FAU - Imani, Mohammad Moslem
AU  - Imani MM
AUID- ORCID: http://orcid.org/0000-0002-3982-5216
AD  - Department of Orthodontics, School of Dentistry, Kermanshah University of Medical
      Sciences, Kermanshah, Iran. mmoslem.imani@yahoo.com.
FAU - Nikkerdar, Nafiseh
AU  - Nikkerdar N
AD  - Department of Oral and Maxillofacial Radiology, School of Dentistry, Kermanshah
      University of Medical Sciences, Kermanshah, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200831
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Adult
MH  - Cephalometry
MH  - Female
MH  - Humans
MH  - *Learning
MH  - Male
MH  - *Smartphone
PMC - PMC7457473
OTO - NOTNLM
OT  - Lateral cephalometry
OT  - Lecture-based instruction
OT  - Smartphone instruction
EDAT- 2020/09/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02201-6 [doi]
AID - 10.1186/s12909-020-02201-6 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Aug 31;20(1):287. doi: 10.1186/s12909-020-02201-6.


PMID- 32867753
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Sep 1
TI  - Ethics parallel research: an approach for (early) ethical guidance of biomedical 
      innovation.
PG  - 81
LID - 10.1186/s12910-020-00524-z [doi]
AB  - BACKGROUND: Our human societies and certainly also (bio) medicine are more and
      more permeated with technology. There seems to be an increasing awareness among
      bioethicists that an effective and comprehensive approach to ethically guide
      these emerging biomedical innovations into society is needed. Such an approach
      has not been spelled out yet for bioethics, while there are frequent calls for
      ethical guidance of biomedical innovation, also by biomedical researchers
      themselves. New and emerging biotechnologies require anticipation of possible
      effects and implications, meaning the scope is not evaluative after a technology 
      has been fully developed or about hypothetical technologies, but real-time for a 
      real biotechnology. MAIN TEXT: In this paper we aim to substantiate and discuss
      six ingredients that we increasingly see adopted by ethicists and that together
      constitute "ethics parallel research". This approach allows to fulfil two aims:
      guiding the development process of technologies in biomedicine and providing
      input for the normative evaluation of such technologies. The six ingredients of
      ethics parallel research are: (1) disentangling wicked problems, (2) upstream or 
      midstream ethical analysis, (3) ethics from within, (4) inclusion of empirical
      research, (5) public participation and (6) mapping societal impacts, including
      hard and soft impacts. We will draw on gene editing, organoid technology and
      artificial intelligence as examples to illustrate these six ingredients.
      CONCLUSION: Ethics parallel research brings together these ingredients to
      ethically analyse and proactively or parallel guide technological development. It
      widens the roles and judgements from the ethicist to a more anticipatory and
      constructively guiding role. Ethics parallel research is characterised by a
      constructive, rather than a purely critical perspective, it focusses on
      developing best-practices rather than outlining worst practice, and draws on
      insights from social sciences and philosophy of technology.
FAU - Jongsma, Karin R
AU  - Jongsma KR
AUID- ORCID: 0000-0001-8135-6786
AD  - Department of Medical Humanities, University Medical Center Utrecht, Julius
      Center for Health Sciences and Primary Care, University Medical Center Utrecht,
      Utrecht University, Utrecht, The Netherlands. kjongsma@umcutrecht.nl.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AD  - Department of Medical Humanities, University Medical Center Utrecht, Julius
      Center for Health Sciences and Primary Care, University Medical Center Utrecht,
      Utrecht University, Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Artificial Intelligence
MH  - *Bioethics
MH  - Ethical Analysis
MH  - Ethicists
MH  - Humans
MH  - Morals
PMC - PMC7461257
OTO - NOTNLM
OT  - *AI
OT  - *Empirical ethics
OT  - *Gene editing
OT  - *Innovation
OT  - *Medical ethics
OT  - *Organoids
OT  - *Society
OT  - *Technology
EDAT- 2020/09/02 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/08/23 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00524-z [doi]
AID - 10.1186/s12910-020-00524-z [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Sep 1;21(1):81. doi: 10.1186/s12910-020-00524-z.


PMID- 32867676
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1865-1372 (Print)
IS  - 1865-1372 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Aug 31
TI  - Clinical and imaging profiles of pulmonary embolism: a single-institution
      experience.
PG  - 47
LID - 10.1186/s12245-020-00303-y [doi]
AB  - BACKGROUND: Pulmonary embolism (PE) is a common life-threatening condition with
      non-specific clinical presentations. The diagnosis of PE depends highly on
      imaging studies, which may also provide prognostic information. This study aimed 
      to describe the clinical and imaging profiles of patients with PE, emphasizing
      the differences between central and peripheral PE. METHODS: After ethics review
      board approval, this retrospective observational study examined the non-negative 
      results in adult patients who underwent computed tomography pulmonary angiography
      (CT-PA) at our hospital between May 2016 and December 2019. Demographic and
      clinical information and imaging findings were collected from the electronic
      medical records. RESULTS: The study included 85 cases that were identified after 
      re-interpreting the 103 non-negative CT-PA scans. Six cases were excluded for
      incomplete data and 12 cases were false-positive. Central PE was found in 63.5%
      of the cases. Obesity was the most common risk factor seen in 37.6% of the cases.
      Furthermore, 9.4% of the patients had sickle cell disease, which tended to be
      associated with peripheral PE. There was no difference between the peripheral and
      central PE in most clinical and imaging parameters evaluated (P > 0.05). However,
      patients with isolated subsegmental PE were more likely to develop hemoptysis (P 
      = 0.04). CONCLUSION: This study suggests that patients with obesity and sickle
      cell disease constitute an important proportion of all PE cases. Furthermore, the
      clinical and imaging profiles in patients with peripheral PE are similar to those
      in patients with central PE. Future research should focus on the clinical value
      of peripheral PE in patients with sickle cell disease.
FAU - Al Dandan, Omran
AU  - Al Dandan O
AUID- ORCID: https://orcid.org/0000-0002-2472-8261
AD  - Department of Radiology, King Fahd Hospital of the University, Imam Abdulrahman
      Bin Faisal University, Al-Khobar, Saudi Arabia.
FAU - Hassan, Ali
AU  - Hassan A
AUID- ORCID: https://orcid.org/0000-0001-6485-5460
AD  - Department of Radiology, King Fahd Hospital of the University, Imam Abdulrahman
      Bin Faisal University, Al-Khobar, Saudi Arabia. alihy8@gmail.com.
FAU - AbuAlola, Hossain
AU  - AbuAlola H
AUID- ORCID: https://orcid.org/0000-0003-4517-7355
AD  - Department of Radiology, King Fahd Hospital of the University, Imam Abdulrahman
      Bin Faisal University, Al-Khobar, Saudi Arabia.
FAU - Alzaki, Alaa
AU  - Alzaki A
AUID- ORCID: https://orcid.org/0000-0002-7680-8562
AD  - Department of Internal Medicine, King Fahd Hospital of the University, Imam
      Abdulrahman Bin Faisal University, Al-Khobar, Saudi Arabia.
FAU - Alwaheed, Abrar
AU  - Alwaheed A
AUID- ORCID: https://orcid.org/0000-0001-7740-4730
AD  - Department of Internal Medicine, King Fahd Hospital of the University, Imam
      Abdulrahman Bin Faisal University, Al-Khobar, Saudi Arabia.
FAU - Alalwan, Mohannad
AU  - Alalwan M
AD  - Department of Internal Medicine, King Fahd Hospital of the University, Imam
      Abdulrahman Bin Faisal University, Al-Khobar, Saudi Arabia.
FAU - Al Shammari, Malak
AU  - Al Shammari M
AUID- ORCID: https://orcid.org/0000-0002-7434-7432
AD  - Department of Family and Community Medicine, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
FAU - AlShamlan, Nouf
AU  - AlShamlan N
AUID- ORCID: https://orcid.org/0000-0002-8049-237X
AD  - Department of Family and Community Medicine, College of Medicine, Imam
      Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
FAU - Alsaif, Hind S
AU  - Alsaif HS
AUID- ORCID: https://orcid.org/0000-0002-1376-7652
AD  - Department of Radiology, King Fahd Hospital of the University, Imam Abdulrahman
      Bin Faisal University, Al-Khobar, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - England
TA  - Int J Emerg Med
JT  - International journal of emergency medicine
JID - 101469435
PMC - PMC7457516
OTO - NOTNLM
OT  - Computed tomography angiography
OT  - Obesity
OT  - Pulmonary embolism
OT  - Sickle cell disease
EDAT- 2020/09/02 06:00
MHDA- 2020/09/02 06:01
CRDT- 2020/09/02 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2020/09/02 06:01 [medline]
AID - 10.1186/s12245-020-00303-y [doi]
AID - 10.1186/s12245-020-00303-y [pii]
PST - epublish
SO  - Int J Emerg Med. 2020 Aug 31;13(1):47. doi: 10.1186/s12245-020-00303-y.


PMID- 32867510
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1940-9818 (Electronic)
IS  - 0736-6205 (Linking)
VI  - 69
IP  - 5
DP  - 2020 Nov
TI  - Reduced serum methods for contact-based coculture of human dermal fibroblasts and
      epidermal keratinocytes.
PG  - 347-355
LID - 10.2144/btn-2020-0112 [doi]
AB  - Direct contact-based coculture of human dermal fibroblasts and epidermal
      keratinocytes has been a long-standing and challenging issue owing to different
      serum and growth factor requirements of the two cell types. Existing protocols
      employ high serum concentrations (up to 10% fetal bovine serum), complex feeder
      systems and a range of supplemental factors. These approaches are technically
      demanding and labor intensive, and pose scientific and ethical limitations
      associated with the high concentrations of animal serum. On the other hand,
      serum-free conditions often fail to support the proliferation of one or both cell
      types when they are cultured together. We have developed two reduced serum
      approaches (1-2% serum) that support the contact-based coculture of human dermal 
      fibroblasts and immortalized keratinocytes and enable the study of cell migration
      and wound closure.
FAU - Kadam, Snehal
AU  - Kadam S
AUID- ORCID: 0000-0002-6916-9192
AD  - Institute of Bioinformatics & Biotechnology, Savitribai Phule Pune University,
      India.
FAU - Vandana, Madhusoodhanan
AU  - Vandana M
AUID- ORCID: 0000-0001-7534-3145
AD  - Institute of Bioinformatics & Biotechnology, Savitribai Phule Pune University,
      India.
FAU - Kaushik, Karishma S
AU  - Kaushik KS
AUID- ORCID: 0000-0001-5131-1798
AD  - Institute of Bioinformatics & Biotechnology, Savitribai Phule Pune University,
      India.
LA  - eng
GR  - This study was funded by the Ramalingaswami Re-entry Fellowship and Har Gobind
      Khorana-Innovative Young Biotechnologist Award (IYBA), Department of
      Biotechnology, Government of India (to Karishma S Kaushik,
      BT/RLF/Re-entry/11/2015 and BT/12/IYBA/2019/05)
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200901
PL  - England
TA  - Biotechniques
JT  - BioTechniques
JID - 8306785
RN  - 0 (Culture Media)
SB  - IM
MH  - Adult
MH  - Cell Movement
MH  - Cell Shape
MH  - Coculture Techniques/*methods
MH  - Culture Media
MH  - Dermis/*cytology
MH  - Epidermal Cells/*cytology/metabolism
MH  - Fibroblasts/*cytology/metabolism
MH  - HaCaT Cells/cytology
MH  - Humans
MH  - Keratinocytes/*cytology/metabolism
MH  - Serum/*metabolism
MH  - Wound Healing
OTO - NOTNLM
OT  - *coculture
OT  - *fetal bovine serum
OT  - *fibroblasts
OT  - *keratinocytes
OT  - *reduced serum
OT  - *wound bed
EDAT- 2020/09/02 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2020/09/02 06:00 [entrez]
AID - 10.2144/btn-2020-0112 [doi]
PST - ppublish
SO  - Biotechniques. 2020 Nov;69(5):347-355. doi: 10.2144/btn-2020-0112. Epub 2020 Sep 
      1.


PMID- 32867222
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 17
DP  - 2020 Aug 27
TI  - Cell Therapies under Clinical Trials and Polarized Cell Therapies in Pre-Clinical
      Studies to Treat Ischemic Stroke and Neurological Diseases: A Literature Review.
LID - E6194 [pii]
LID - 10.3390/ijms21176194 [doi]
AB  - Stroke remains a major cause of serious disability because the brain has a
      limited capacity to regenerate. In the last two decades, therapies for stroke
      have dramatically changed. However, half of the patients cannot achieve
      functional independence after treatment. Presently, cell-based therapies are
      being investigated to improve functional outcomes. This review aims to describe
      conventional cell therapies under clinical trial and outline the novel concept of
      polarized cell therapies based on protective cell phenotypes, which are currently
      in pre-clinical studies, to facilitate functional recovery after post-reperfusion
      treatment in patients with ischemic stroke. In particular, non-neuronal stem
      cells, such as bone marrow-derived mesenchymal stem/stromal cells and mononuclear
      cells, confer no risk of tumorigenesis and are safe because they do not induce
      rejection and allergy; they also pose no ethical issues. Therefore, recent
      studies have focused on them as a cell source for cell therapies. Some clinical
      trials have shown beneficial therapeutic effects of bone marrow-derived cells in 
      this regard, whereas others have shown no such effects. Therefore, more clinical 
      trials must be performed to reach a conclusion. Polarized microglia or peripheral
      blood mononuclear cells might provide promising therapeutic strategies after
      stroke because they have pleiotropic effects. In traumatic injuries and
      neurodegenerative diseases, astrocytes, neutrophils, and T cells were polarized
      to the protective phenotype in pre-clinical studies. As such, they might be
      useful therapeutic targets. Polarized cell therapies are gaining attention in the
      treatment of stroke and neurological diseases.
FAU - Hatakeyama, Masahiro
AU  - Hatakeyama M
AD  - Department of Neurology, Brain Research Institute, Niigata University, Niigata
      951-8585, Japan.
FAU - Ninomiya, Itaru
AU  - Ninomiya I
AUID- ORCID: 0000-0002-9128-7953
AD  - Department of Neurology, Brain Research Institute, Niigata University, Niigata
      951-8585, Japan.
FAU - Otsu, Yutaka
AU  - Otsu Y
AD  - Department of Neurology, Brain Research Institute, Niigata University, Niigata
      951-8585, Japan.
FAU - Omae, Kaoru
AU  - Omae K
AD  - Translational Research Center for Medical Innovation, Foundation for Biomedical
      Research and Innovation at Kobe, Hougo 650-0047, Japan.
FAU - Kimura, Yasuko
AU  - Kimura Y
AD  - Translational Research Center for Medical Innovation, Foundation for Biomedical
      Research and Innovation at Kobe, Hougo 650-0047, Japan.
FAU - Onodera, Osamu
AU  - Onodera O
AD  - Department of Neurology, Brain Research Institute, Niigata University, Niigata
      951-8585, Japan.
FAU - Fukushima, Masanori
AU  - Fukushima M
AD  - Medical R&D, Fukushima & Partners, Nagoya, Aichi 458-0045, Japan.
FAU - Shimohata, Takayoshi
AU  - Shimohata T
AD  - Department of Neurology, Gifu University Graduate School of Medicine, Gifu
      501-1194, Japan.
FAU - Kanazawa, Masato
AU  - Kanazawa M
AUID- ORCID: 0000-0001-6337-8156
AD  - Department of Neurology, Brain Research Institute, Niigata University, Niigata
      951-8585, Japan.
LA  - eng
GR  - 18K07493/Grant-in-Aid for Scientific Research
GR  - 2019/SENSHIN Medical Research Foundation
GR  - 2020/Takeda Science Foundation
PT  - Journal Article
PT  - Review
DEP - 20200827
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - Cell Polarity
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Humans
MH  - Ischemic Stroke/physiopathology/*therapy
MH  - Leukocytes, Mononuclear/cytology/*transplantation
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Mesenchymal Stem Cells/cytology
MH  - Microglia/cytology/transplantation
MH  - Nervous System Diseases/physiopathology/*therapy
MH  - Recovery of Function
MH  - Treatment Outcome
PMC - PMC7503631
OTO - NOTNLM
OT  - PBMC
OT  - cell therapy
OT  - microglia
OT  - mononuclear cell
OT  - neurological disease
OT  - pleiotropic effects
OT  - polarization
OT  - stem cell
OT  - stroke
EDAT- 2020/09/02 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/07/27 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - ijms21176194 [pii]
AID - 10.3390/ijms21176194 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Aug 27;21(17). pii: ijms21176194. doi: 10.3390/ijms21176194.


PMID- 32865798
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 2168-4804 (Electronic)
IS  - 2168-4790 (Linking)
VI  - 54
IP  - 5
DP  - 2020 Sep
TI  - Technology Considerations for Enabling eSource in Clinical Research: Industry
      Perspective.
PG  - 1166-1174
LID - 10.1007/s43441-020-00132-4 [doi]
AB  - BACKGROUND: The technological complexities and broad operational scope of eSource
      impede coordinated, inter-organizational action on advancing at-scale solutions. 
      METHODS: We introduce an architectural framework for articulating technological
      considerations across organizations. The architecture neither implies nor
      endorses solution implementations; rather, it proposes solution functionality
      based upon principles and good clinical practices. RESULTS: Key technology
      considerations include patterns of anticipated use, implications to the current
      state of clinical trial operations, and the need for new technologies (i.e., IoT,
      Big Data, Predictive Analytics). CONCLUSION: Technology considerations drive
      implications beyond technology-influencing regulatory, process, and ethical
      realms of clinical research.
FAU - Jennings, Donald G
AU  - Jennings DG
AD  - Digital Health, Eli Lilly and Company, MC/525/02, Indianapolis, IN, 46285, USA.
      donald.jennings@lilly.com.
FAU - Nordo, Amy
AU  - Nordo A
AD  - Clinical Trials Solutions Pfizer, Inc., Groton, CT, USA.
FAU - Vattikola, Aruna
AU  - Vattikola A
AD  - Novartis Business Technology Services, East Hanover, NJ, USA.
FAU - Kjaer, Jesper
AU  - Kjaer J
AD  - Novo Nordisk A/S, Bagsvaerd, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200311
PL  - Switzerland
TA  - Ther Innov Regul Sci
JT  - Therapeutic innovation & regulatory science
JID - 101597411
SB  - IM
MH  - Big Data
MH  - *Industry
MH  - *Technology
PMC - PMC7458892
OTO - NOTNLM
OT  - *Analytics
OT  - *Architecture
OT  - *Big data
OT  - *Digital
OT  - *IoT
OT  - *TransCelerate
EDAT- 2020/09/01 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/09/01 06:00
PHST- 2019/08/15 00:00 [received]
PHST- 2020/02/10 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
AID - 10.1007/s43441-020-00132-4 [doi]
AID - 10.1007/s43441-020-00132-4 [pii]
PST - ppublish
SO  - Ther Innov Regul Sci. 2020 Sep;54(5):1166-1174. doi: 10.1007/s43441-020-00132-4. 
      Epub 2020 Mar 11.


PMID- 32865694
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - Embodiment and personal identity in dementia.
PG  - 665-676
LID - 10.1007/s11019-020-09973-0 [doi]
AB  - Theories of personal identity in the tradition of John Locke and Derek Parfit
      emphasize the importance of psychological continuity and the abilities to think, 
      to remember and to make rational choices as a basic criterion for personhood. As 
      a consequence, persons with severe dementia are threatened to lose the status of 
      persons. Such concepts, however, are situated within a dualistic framework, in
      which the body is regarded as a mere vehicle of the person, or a carrier of the
      brain as the organ of mental faculties. Based on the phenomenology of embodiment,
      this paper elaborates a different approach to personal identity in dementia. In
      this perspective, selfhood is primarily constituted by pre-reflective
      self-awareness and the body memory of an individual, which consists in the
      embodiment and enactment of familiar habits, practices and preferences. After
      describing the different types of body memory, the paper develops a phenomenology
      of dementia as a loss of reflexivity and meta-perspective. This is contrasted
      with the preservation of individual forms of body memory even in the later stages
      of the illness. The ethical consequences of an embodied approach to dementia are 
      outlined. A final look is given to narrativistic and constructionist concepts of 
      the self in dementia.
FAU - Fuchs, Thomas
AU  - Fuchs T
AUID- ORCID: http://orcid.org/0000-0001-9466-4956
AD  - Karl-Jaspers-Professor of Philosophical Foundations of Psychiatry, Psychiatrische
      Universitatsklinik, Voss-Str. 4, 69115, Heidelberg, Germany.
      thomas.fuchs@urz.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Dementia/*psychology
MH  - Humans
MH  - Memory
MH  - *Personhood
MH  - Philosophy, Medical
MH  - Self Concept
MH  - Severity of Illness Index
PMC - PMC7538443
OTO - NOTNLM
OT  - Body memory
OT  - Dementia
OT  - Embodiment
OT  - Personal identity
OT  - Pre-reflective self-awareness
OT  - Reflective self-consciousness
EDAT- 2020/09/01 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - 10.1007/s11019-020-09973-0 [doi]
AID - 10.1007/s11019-020-09973-0 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):665-676. doi: 10.1007/s11019-020-09973-0.


PMID- 32865583
OWN - NLM
STAT- MEDLINE
DCOM- 20210630
LR  - 20210630
IS  - 1938-2421 (Electronic)
IS  - 0148-4834 (Linking)
VI  - 59
IP  - 9
DP  - 2020 Sep 1
TI  - Teaching Ethics in Classroom Settings: Nursing Faculty Perceptions in
      Baccalaureate Programs.
PG  - 506-509
LID - 10.3928/01484834-20200817-05 [doi]
AB  - BACKGROUND: The complexity of the current health care system has resulted in
      increasing demands on nurses to act as patient advocates and moral agents.
      Understanding faculty's experiences teaching ethics is instrumental to deliver
      ethically competent care. The purpose of this study was to explore the
      experiences of nursing faculty teaching ethics content in the classroom setting
      to prelicensure baccalaureate nursing students. METHOD: This qualitative,
      descriptive phenomenological design asked 11 nursing faculty with recent
      experience teaching ethics within prelicensure baccalaureate nursing programs to 
      complete qualitative interviews. RESULTS: Participants expressed the importance
      of teaching ethics in undergraduate nursing curricula but experienced significant
      challenges. Three main themes were identified in the data analysis: Lacking Prior
      Preparation, Difficult Content, and No Place Holder for Ethics Content.
      CONCLUSION: Intentional curriculum design incorporating ethics content is
      necessary for the preparation of prelicensure nursing students, along with formal
      and informal opportunities for faculty to explore ethics including philosophical 
      underpinnings. [J Nurs Educ. 2020;59(9):506-509.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Grason, Sharon
AU  - Grason S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nurs Educ
JT  - The Journal of nursing education
JID - 7705432
SB  - IM
MH  - Curriculum
MH  - *Education, Nursing, Baccalaureate/methods
MH  - *Ethics, Nursing/education
MH  - Faculty, Nursing
MH  - Humans
MH  - Perception
MH  - *Students, Nursing
MH  - *Teaching
EDAT- 2020/09/01 06:00
MHDA- 2021/07/01 06:00
CRDT- 2020/09/01 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2021/07/01 06:00 [medline]
AID - 10.3928/01484834-20200817-05 [doi]
PST - ppublish
SO  - J Nurs Educ. 2020 Sep 1;59(9):506-509. doi: 10.3928/01484834-20200817-05.


PMID- 32865502
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201002
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 31
TI  - Type 1 Diabetes Mellitus Virtual Patient Network as a Peer Support Community:
      Protocol for Social Network Analysis and Content Analysis.
PG  - e18714
LID - 10.2196/18714 [doi]
AB  - BACKGROUND: Type 1 Diabetes Mellitus Virtual Patient Network (T1DM-VPN) is a
      private Facebook group for youths with type 1 diabetes mellitus (T1DM) in Canada 
      intended to facilitate peer-to-peer support. It was built on the finding that
      stigma is prevalent among youth with T1DM and impedes self-management. OBJECTIVE:
      We aim to determine if T1DM-VPN provides support as intended and to ascertain
      what type of members provide support. Specifically, we will (1) identify text
      consistent with any one of 5 social support categories, (2) describe the network 
      by visualizing its structure and reporting basic engagement statistics, and (3)
      determine whether being a designated peer leader is related to a member's
      centrality (ie, importance in the network) and how frequently they offer social
      support. METHODS: We will manually extract interaction data from the Facebook
      group (posts, comments, likes/reactions, seen) generated from June 21, 2017
      (addition of first member), to March 1, 2020. Two researchers will independently 
      code posts and comments according to an existing framework of 5 social support
      categories-informational, emotional, esteem, network, and tangible-with an
      additional framework for nonsocial support categories. We will calculate how
      frequently each code is used. We will also report basic engagement statistics
      (eg, number of posts made per person-month) and generate a visualization of the
      network. We will identify stable time intervals in the history of T1DM-VPN by
      modeling monthly membership growth as a Poisson process. Within each interval,
      each member's centrality will be calculated and standardized to that of the most 
      central member. We will use a centrality formula that considers both breadth and 
      depth of connections (centrality = 0.8 x total No. of connections + 0.2 x total
      No. of interactions). Finally, we will construct multivariate linear regression
      models to assess whether peer leader status predicts member centrality and the
      frequency of offering social support. Other variables considered for inclusion in
      the models are gender and age at diagnosis. RESULTS: T1DM-VPN was launched in
      June 2017. As of March 1, 2020, it has 196 patient-members. This research
      protocol received ethics approval from the McGill University Health Centre
      Research Ethics Board on May 20, 2020. Baseline information about each group
      member was collected upon addition into the group, and collection of interaction 
      data is ongoing as of May 2020. CONCLUSIONS: This content analysis and social
      network analysis study of a virtual patient network applies epidemiological
      methods to account for dynamic growth and activity. The results will allow for an
      understanding of the topics of importance to youth with T1DM and how a virtual
      patient network evolves over time. This work is intended to serve as a foundation
      for future action to help youth improve their experience of living with diabetes.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/18714.
CI  - (c)Nancy Wu, Anne-Sophie Brazeau, Meranda Nakhla, Deborah Chan, Deborah Da Costa,
      Geetha Mukerji, Sonia Butalia, Daniele Pacaud, Melanie Henderson, Constadina
      Panagiotopoulos, Elham Rahme, Kaberi Dasgupta. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 31.08.2020.
FAU - Wu, Nancy
AU  - Wu N
AUID- ORCID: https://orcid.org/0000-0001-9397-8937
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, QC, Canada.
FAU - Brazeau, Anne-Sophie
AU  - Brazeau AS
AUID- ORCID: https://orcid.org/0000-0002-2699-2920
AD  - School of Human Nutrition, McGill University, Montreal, QC, Canada.
FAU - Nakhla, Meranda
AU  - Nakhla M
AUID- ORCID: https://orcid.org/0000-0001-5833-5303
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, QC, Canada.
FAU - Chan, Deborah
AU  - Chan D
AUID- ORCID: https://orcid.org/0000-0001-5006-1651
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, QC, Canada.
FAU - Da Costa, Deborah
AU  - Da Costa D
AUID- ORCID: https://orcid.org/0000-0003-4993-4544
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, QC, Canada.
FAU - Mukerji, Geetha
AU  - Mukerji G
AUID- ORCID: https://orcid.org/0000-0002-6477-9848
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, ON, Canada.
FAU - Butalia, Sonia
AU  - Butalia S
AUID- ORCID: https://orcid.org/0000-0001-7865-9161
AD  - Department of Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, AB, Canada.
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, Calgary, AB, Canada.
FAU - Pacaud, Daniele
AU  - Pacaud D
AUID- ORCID: https://orcid.org/0000-0001-6337-7241
AD  - Department of Pediatrics, Alberta Children's Hospital, University of Calgary,
      Calgary, AB, Canada.
FAU - Henderson, Melanie
AU  - Henderson M
AUID- ORCID: https://orcid.org/0000-0002-0102-2389
AD  - Division of Endocrinology and Diabetes, Faculty of Medicine, University of
      Montreal, Montreal, QC, Canada.
FAU - Panagiotopoulos, Constadina
AU  - Panagiotopoulos C
AUID- ORCID: https://orcid.org/0000-0002-1379-7472
AD  - Division of Endocrinology, Faculty of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Rahme, Elham
AU  - Rahme E
AUID- ORCID: https://orcid.org/0000-0002-4168-4993
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, QC, Canada.
FAU - Dasgupta, Kaberi
AU  - Dasgupta K
AUID- ORCID: https://orcid.org/0000-0002-2447-3553
AD  - Centre for Outcomes Research and Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, QC, Canada.
AD  - Department of Medicine, McGill University, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7490683
OTO - NOTNLM
OT  - content analysis
OT  - social media
OT  - social network analysis
OT  - type 1 diabetes
OT  - youth
EDAT- 2020/09/01 06:00
MHDA- 2020/09/01 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2020/09/01 06:01 [medline]
AID - v9i8e18714 [pii]
AID - 10.2196/18714 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 31;9(8):e18714. doi: 10.2196/18714.


PMID- 32865149
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201218
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 14
DP  - 2020 Dec
TI  - Carrying Out Rapid Qualitative Research During a Pandemic: Emerging Lessons From 
      COVID-19.
PG  - 2192-2204
LID - 10.1177/1049732320951526 [doi]
AB  - Social scientists have a robust history of contributing to better understandings 
      of and responses to disease outbreaks. The implementation of qualitative research
      in the context of infectious epidemics, however, continues to lag behind in the
      delivery, credibility, and timeliness of findings when compared with other
      research designs. The purpose of this article is to reflect on our experience of 
      carrying out three research studies (a rapid appraisal, a qualitative study based
      on interviews, and a mixed-methods survey) aimed at exploring health care
      delivery in the context of COVID-19. We highlight the importance of qualitative
      data to inform evidence-based public health responses and provide a way forward
      to global research teams who wish to implement similar rapid qualitative studies.
      We reflect on the challenges of setting up research teams, obtaining ethical
      approval, collecting and analyzing data in real-time and sharing actionable
      findings.
FAU - Vindrola-Padros, Cecilia
AU  - Vindrola-Padros C
AUID- ORCID: 0000-0001-7859-1646
AD  - University College London, London, United Kingdom.
AD  - Royal College of Anaesthetists, London, United Kingdom.
FAU - Chisnall, Georgia
AU  - Chisnall G
AD  - University College London, London, United Kingdom.
FAU - Cooper, Silvie
AU  - Cooper S
AD  - University College London, London, United Kingdom.
FAU - Dowrick, Anna
AU  - Dowrick A
AUID- ORCID: 0000-0002-2937-6728
AD  - Queen Mary University of London, London, United Kingdom.
FAU - Djellouli, Nehla
AU  - Djellouli N
AD  - University College London, London, United Kingdom.
FAU - Symmons, Sophie Mulcahy
AU  - Symmons SM
AD  - University College London, London, United Kingdom.
FAU - Martin, Sam
AU  - Martin S
AD  - University of Oxford, Oxford, United Kingdom.
FAU - Singleton, Georgina
AU  - Singleton G
AD  - University College London, London, United Kingdom.
AD  - Royal College of Anaesthetists, London, United Kingdom.
FAU - Vanderslott, Samantha
AU  - Vanderslott S
AD  - University of Oxford, Oxford, United Kingdom.
FAU - Vera, Norha
AU  - Vera N
AD  - King's College London, London, United Kingdom.
FAU - Johnson, Ginger A
AU  - Johnson GA
AUID- ORCID: 0000-0002-4728-3744
AD  - The Australian National University, Canberra, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Data Accuracy
MH  - Humans
MH  - Newspapers as Topic/statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Public Health
MH  - *Qualitative Research
MH  - *Research Design
MH  - SARS-CoV-2
MH  - Social Media/statistics & numerical data
MH  - Time Factors
PMC - PMC7649912
OTO - NOTNLM
OT  - *United Kingdom
OT  - *anthropology
OT  - *illness and disease
OT  - *infectious
OT  - *interviews
OT  - *medical
OT  - *methodology
OT  - *qualitative
OT  - *research design
EDAT- 2020/09/01 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - 10.1177/1049732320951526 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Dec;30(14):2192-2204. doi: 10.1177/1049732320951526. Epub
      2020 Aug 31.


PMID- 32864989
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1941-2479 (Electronic)
IS  - 1010-5395 (Linking)
VI  - 32
IP  - 8
DP  - 2020 Nov
TI  - Concerns About Research Ethics in COVID-19 Publications.
PG  - 503-504
LID - 10.1177/1010539520956439 [doi]
FAU - Mansourzadeh, Mohammad Javad
AU  - Mansourzadeh MJ
AD  - Tehran University of Medical Sciences, Tehran, Iran.
FAU - Shamsi, Amrollah
AU  - Shamsi A
AUID- ORCID: https://orcid.org/0000-0001-6528-9341
AD  - Bushehr University of Medical Sciences, Bushehr, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200830
PL  - China
TA  - Asia Pac J Public Health
JT  - Asia-Pacific journal of public health
JID - 8708538
SB  - IM
EDAT- 2020/09/01 06:00
MHDA- 2020/09/01 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2020/09/01 06:01 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - 10.1177/1010539520956439 [doi]
PST - ppublish
SO  - Asia Pac J Public Health. 2020 Nov;32(8):503-504. doi: 10.1177/1010539520956439. 
      Epub 2020 Aug 30.


PMID- 35821873
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2332-2136 (Print)
VI  - 6
IP  - 3
DP  - 2020 Sep
TI  - Ethical foundations for graduate students in the psychological sciences.
PG  - 247-256
LID - 10.1037/tps0000269 [doi]
AB  - Preparation to address ethical challenges is an essential component of graduate
      training, and no less so for the psychological sciences. However, in the absence 
      of uniform guidelines, approaches to training vary in form and quality. Classroom
      lectures and online training seem to be the mechanisms of choice, but these fall 
      short. First, such approaches conflict with the scholarship on teaching and
      learning that makes it clear that having a meaningful impact depends on having
      students actively engaged in constructing their own learning. Second, research is
      consistent with intuition that the impact of courses is likely to be far less
      than what happens in a graduate student's research environment. The conclusion is
      that promoting an ethical culture, and for the training of graduate students in
      particular, will be well served by enhancing the role of mentors. Examples of
      options to consider are: (1) recognizing that a primary advisor can be a mentor, 
      but should certainly not be considered the only mentor; (2) emphasizing the
      importance of mentoring for individuals from underrepresented groups (e.g.,
      because of gender or ethnicity); (3) strengthening the APA code of ethics to more
      fully articulate the full range and importance of mentoring; (4) developing and
      implementing mechanisms to evaluate and reward effective mentoring; and (5)
      providing targeted training for faculty advisors to empower them with tools and
      resources to be effective mentors for ethics generally and the responsible
      conduct of research specifically.
FAU - Bravin, Julia
AU  - Bravin J
AD  - SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology.
FAU - Carrasco, Jessica
AU  - Carrasco J
AD  - SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology.
FAU - Kalichman, Michael
AU  - Kalichman M
AD  - Department of Pathology, and Director, Research Ethics Program UC San Diego.
LA  - eng
GR  - UL1 TR001442/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Transl Issues Psychol Sci
JT  - Translational issues in psychological science
JID - 101645472
PMC - PMC9273059
MID - NIHMS1738368
OTO - NOTNLM
OT  - Graduate students
OT  - Mentors
OT  - Research ethics
OT  - Responsible conduct of research
OT  - Teaching and learning
EDAT- 2020/09/01 00:00
MHDA- 2020/09/01 00:01
CRDT- 2022/07/13 02:08
PHST- 2022/07/13 02:08 [entrez]
PHST- 2020/09/01 00:00 [pubmed]
PHST- 2020/09/01 00:01 [medline]
AID - 10.1037/tps0000269 [doi]
PST - ppublish
SO  - Transl Issues Psychol Sci. 2020 Sep;6(3):247-256. doi: 10.1037/tps0000269.


PMID- 35382103
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2543-9251 (Electronic)
IS  - 2543-9251 (Linking)
VI  - 4
IP  - 3
DP  - 2020 Sep 1
TI  - How American Academic Medical/Health Sciences Libraries Responded to the COVID-19
      Health Crisis: An Observational Study.
PG  - 200-208
LID - 10.2478/dim-2020-0013 [doi]
AB  - The novel coronavirus disease (COVID-19) has caused a pandemic and global health 
      crisis. Although normal operation and services in many libraries have been
      greatly disrupted, academic libraries in the United States were reportedly
      responding to challenges by pivoting to new ways to meet the users' needs. This
      observational study was designed to investigate the status, services, and
      resources disclosed via websites of academic medical/health sciences libraries
      (MHSLs) in the United States and document how they adapted and continued to
      provide support to help fight the health crisis and the resulting "infodemic"
      through various means. A complete list of members was obtained from the website
      of the Association of Academic Health Sciences Libraries (AAHSL). The U.S.-based 
      AAHSL member institutions were included in this study. Each American academic
      MHSL website and its associated webpages were browsed; web contents were
      categorized and analyzed based on four research questions proposed by this study.
      A descriptive analysis was conducted to summarize all findings. A total of 157
      AAHSL member institutions were included in the study. These libraries spread all 
      over the United States, and 90% of them announced closures of library buildings
      and facilities. A significant number of MHSLs quickly adapted to the evolving
      situation and transitioned their services and instruction to the online
      environment. The COVID-19 information sources adopted by MHSLs included the
      following ranked by frequency from high to low: The U.S. government agencies such
      as Centers for Disease Control and Prevention and National Library of Medicine,
      the World Health Organization, publishing communities, professional journals,
      organizations, local institutions, government agencies, and news channels. In
      addition, MHSLs undertook a series of actions to support academic communities and
      local healthcare professionals including resource curation, clinical care
      support, education, and outreach to the public. Through library guides, MHSLs
      provided comprehensive and customized search queries to help researchers locate
      the latest and relevant publications to COVID-19, curated multiple data resources
      and data exploration, and visualization tools, and selected the latest biomedical
      and health evidence in a wide range of topics. Other featured resources and
      services were associated with ethical issues (i.e., racism and prejudice),
      educational and entertainment information (e.g., virtual tours of parks), and
      personal experience documentation. This observational study is the most recent
      investigation and documentation on the status, services, and resources of the
      academic MHSLs in the United States during the initial U.S. outbreak of the
      COVID-19 pandemic. Although the current health crisis is taking a heavy toll on
      libraries nationwide, MHSLs are still managing to play a vital role in supporting
      the academic communities, healthcare facilities, and the general public and
      fighting against the pandemic and the resulting information crisis.
CI  - (c) 2020 Fei Yu et al., published by Sciendo.
FAU - Yu, Fei
AU  - Yu F
AD  - Health Sciences Library & School of Information and Library Science, University
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
FAU - Mani, Nandita
AU  - Mani N
AD  - Health Sciences Library, University of North Carolina at Chapel Hill, Chapel
      Hill, North Carolina, USA.
LA  - eng
PT  - Journal Article
DEP - 20220331
PL  - Poland
TA  - Data Inf Manag
JT  - Data and information management
JID - 101736712
PMC - PMC8969554
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - United States
OT  - academic health sciences library
OT  - health crisis
OT  - information curation
OT  - outreach
EDAT- 2020/09/01 00:00
MHDA- 2020/09/01 00:01
CRDT- 2022/04/06 05:11
PHST- 2020/05/07 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2022/04/06 05:11 [entrez]
PHST- 2020/09/01 00:00 [pubmed]
PHST- 2020/09/01 00:01 [medline]
AID - 10.2478/dim-2020-0013 [doi]
AID - S2543-9251(22)00050-X [pii]
PST - ppublish
SO  - Data Inf Manag. 2020 Sep 1;4(3):200-208. doi: 10.2478/dim-2020-0013. Epub 2022
      Mar 31.


PMID- 34761075
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211112
IS  - 2332-2136 (Print)
VI  - 6
IP  - 3
DP  - 2020 Sep
TI  - Examining the Effect of Internalized HIV-Related Stigma on Perceptions of
      Research Participation among HIV-Positive African American Women.
PG  - 223-234
LID - 10.1037/tps0000271 [doi]
AB  - HIV-related stigma may influence ethical concerns in health disparity
      populations, particularly groups with histories of race, gender, and class
      oppression in medical research such as African American women. However, a dearth 
      of research has examined how HIV-related stigma influences perceptions of the
      research process among African American women who participate in health research.
      The goal of the current study was to examine whether HIV-related stigma
      experienced on the micro-level, specifically internalized HIV-related stigma, is 
      associated with reactions to research participation in 5 domains: attitudes
      toward participation, perceptions of research benefits, emotional reactions,
      perceived drawbacks of the research, and global evaluations of the research. We
      also examine whether internalized HIV-related stigma is associated with
      difficulty in answering questions related to sensitive topics. We found that
      women with higher levels of internalized HIV-related stigma reported more
      emotional reactions to research, perceived more drawbacks of the research, and
      expressed more difficulty in answering sensitive questions. Understanding how
      HIV-related stigma influences perceived risks and benefits of research
      participation may play an important role in guiding best practices for ethical
      engagement with HIV-positive African American women who participate in health
      research.
FAU - Overstreet, Nicole M
AU  - Overstreet NM
AD  - Department of Psychology, Clark University.
FAU - Cheeseborough, Thekia
AU  - Cheeseborough T
AD  - Department of Psychology, Clark University.
LA  - eng
GR  - R25 DA031608/DA/NIDA NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Transl Issues Psychol Sci
JT  - Translational issues in psychological science
JID - 101645472
PMC - PMC8577417
MID - NIHMS1738367
OTO - NOTNLM
OT  - African American women
OT  - HIV
OT  - intersectionality
OT  - research ethics
OT  - stigma
COIS- We have no known conflict of interest to disclose.
EDAT- 2020/09/01 00:00
MHDA- 2020/09/01 00:01
CRDT- 2021/11/11 07:02
PHST- 2021/11/11 07:02 [entrez]
PHST- 2020/09/01 00:00 [pubmed]
PHST- 2020/09/01 00:01 [medline]
AID - 10.1037/tps0000271 [doi]
PST - ppublish
SO  - Transl Issues Psychol Sci. 2020 Sep;6(3):223-234. doi: 10.1037/tps0000271.


PMID- 32864643
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2667-677X (Print)
IS  - 2149-276X (Linking)
VI  - 48
IP  - 4
DP  - 2020 Aug
TI  - Incidence of Encephalitis in the Intensive Care Unit, a Tertiary Care Hospital,
      Pakistan: A 5-Year Retrospective Study.
PG  - 288-293
LID - 10.5152/TJAR.2019.62144 [doi]
AB  - OBJECTIVE: Encephalitis is a disease that has a major impact on health systems
      worldwide in terms of mortality, morbidity and costs. Furthermore, it is a
      challenging disease for the treating physician, as the patient presentation
      varies, and not all patients present with typical complaints. In addition, if
      left untreated or if there is a delay in the treatment, the mortality rate due to
      encephalitis can increase. The incidence of encephalitis in Pakistan is scarce in
      the literature because, in most of cases, the specific cause is not evaluated due
      to lack of resources and also because the majority of cases are not reported. The
      aim of this study was to determine the incidence and outcomes of encephalitis in 
      patients admitted to a tertiary care hospital intensive care unit in Pakistan.
      METHODS: This retrospective study was conducted in the intensive care unit of the
      Aziz Fatimah Medical College and Hospital, Faisalabad. After obtaining the
      ethical approval, a total of 75 patients were found in the medical records with a
      confirmed diagnosis of encephalitis out of total 3,921 patients admitted to the
      intensive care unit in the 5-year period from 1(st) January 2013 to 31(st)
      December 2018. RESULTS: The most common clinical presentation were seizures (64%)
      followed by headache (53%), irritability (29.3%) and hemiparesis (26.7%). Among
      all patients, 44 needed invasive ventilation, and 7 required non-invasive
      ventilation. In addition, the outcomes were variable. CONCLUSION: The incidence
      of encephalitis was 1.9% in the 5-year period, and the mortality rate was 37.3%. 
      Also, 6.7% patients improved without any complications.
CI  - (c) Copyright 2020 by Turkish Anaesthesiology and Intensive Care Society.
FAU - Andleeb, Sonia
AU  - Andleeb S
AUID- ORCID: https://orcid.org/0000-0003-3143-9262
AD  - Department of Intensive Care Unit, Aziz Fatimah Medical College and Hospital,
      Faisalabad, Pakistan.
FAU - Yasir Bari, M
AU  - Yasir Bari M
AUID- ORCID: https://orcid.org/0000-0001-9373-9848
AD  - Department of Intensive Care Unit, Aziz Fatimah Medical College and Hospital,
      Faisalabad, Pakistan.
FAU - Gill, Inam
AU  - Gill I
AUID- ORCID: https://orcid.org/0000-0002-6060-3028
AD  - Department of Intensive Care Unit, Aziz Fatimah Medical College and Hospital,
      Faisalabad, Pakistan.
FAU - Urooj, Sana
AU  - Urooj S
AUID- ORCID: https://orcid.org/0000-0002-1381-3612
AD  - Department of Anaethesiology, Dr. Ruth Pfau Civil Hospital, Karachi, Pakistan.
FAU - Nausheen, Sidra
AU  - Nausheen S
AUID- ORCID: https://orcid.org/0000-0002-4120-7193
AD  - Department of Intensive Care Unit, Aziz Fatimah Medical College and Hospital,
      Faisalabad, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20191022
PL  - Turkey
TA  - Turk J Anaesthesiol Reanim
JT  - Turkish journal of anaesthesiology and reanimation
JID - 101680817
PMC - PMC7434350
OTO - NOTNLM
OT  - Encephalitis
OT  - incidence
OT  - outcome
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/07/30 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.5152/TJAR.2019.62144 [doi]
AID - tard-48-4-288 [pii]
PST - ppublish
SO  - Turk J Anaesthesiol Reanim. 2020 Aug;48(4):288-293. doi: 10.5152/TJAR.2019.62144.
      Epub 2019 Oct 22.


PMID- 32864480
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Protocol for a pilot randomised, double-blind, placebo-controlled trial for
      assessing the feasibility and efficacy of faecal microbiota transplantation in
      adolescents with refractory irritable bowel syndrome: FAIS Trial.
PG  - e000689
LID - 10.1136/bmjpo-2020-000689 [doi]
AB  - BACKGROUND: Irritable bowel syndrome (IBS) is a common chronic medical condition,
      in both children and adults. Despite the availability of effective
      (non)pharmacological treatments, symptoms persist in a significant amount of
      patients with IBS. Faecal microbiota transplantation (FMT) may be an effective
      alternative treatment in adolescents with refractory IBS through manipulation of 
      the intestinal microbiota. METHODS AND ANALYSIS: This randomised,
      placebo-controlled single-centre pilot study will assess feasibility and efficacy
      of FMT in 30 adolescents (16-21 years) with refractory IBS. Patients will be
      randomly allocated (1:1) to receive two allogeneic (healthy donor) or two
      autologous (own) faecal infusions at baseline and after 6 weeks. Primary outcomes
      will assess feasibility, including patient and donor recruitment, adherence and
      incidence rates of adverse events. To evaluate clinical efficacy, secondary
      outcomes will include the proportion of patients with at least >50% reduction of 
      their abdominal pain intensity and frequency 12 weeks after the first FMT, and
      after 6-month and 12-month follow-up. Other outcomes comprise changes in faecal
      gut microbiota composition, quality of life, depression and anxiety, school or
      work absenteeism and adequate relief, measured directly after FMTs and after 6
      and 12 months of follow-up. DISCUSSION: This randomised controlled trial will
      investigate the feasibility and effectiveness of repetitive FMTs in adolescents
      with refractory IBS. ETHICS AND DISSEMINATION: The study is approved by the
      Medical Research Ethics Committees AMC (MEC-AMC) in the Netherlands. TRIAL
      REGISTRATION NUMBER: NCT03074227.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Zeevenhooven, Judith
AU  - Zeevenhooven J
AD  - Paediatric Gastroenterology, Emma Childrens Hospital AMC, Amsterdam, North
      Holland, The Netherlands.
AD  - Amsterdam UMC, University of Amsterdam, Gastroenterology and Hepatology,
      Amsterdam Gastroenterology Endocrinology Metabolism Research Institute,
      Amsterdam, the Netherlands.
AD  - Amsterdam University Medical Centers, Location Academic Medical Center/Emma
      Children's Hospital, Amsterdam Reproduction & Development Research Institute,
      Amsterdam, the Netherlands.
FAU - de Bruijn, Clara Marieke Andrea
AU  - de Bruijn CMA
AUID- ORCID: 0000-0001-6259-9918
AD  - Paediatric Gastroenterology, Emma Childrens Hospital AMC, Amsterdam, North
      Holland, The Netherlands.
AD  - Amsterdam UMC, University of Amsterdam, Gastroenterology and Hepatology,
      Amsterdam Gastroenterology Endocrinology Metabolism Research Institute,
      Amsterdam, the Netherlands.
AD  - Amsterdam University Medical Centers, Location Academic Medical Center/Emma
      Children's Hospital, Amsterdam Reproduction & Development Research Institute,
      Amsterdam, the Netherlands.
FAU - Vlieger, Arine
AU  - Vlieger A
AD  - Department of Paediatrics, Sint Antonius Hospital, Nieuwegein, The Netherlands.
FAU - Nieuwdorp, Max
AU  - Nieuwdorp M
AD  - Department of Internal Medicine, Amsterdam UMC-Locatie AMC, Amsterdam, North
      Holland, Netherlands.
FAU - Benninga, Marc Alexander
AU  - Benninga MA
AD  - Paediatric Gastroenterology and Nutrition, Emma Kinderziekenhuis AMC, Amsterdam, 
      North Holland, Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03074227
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7443263
OTO - NOTNLM
OT  - gastroenterology
COIS- Competing interests: MN is in the scientific advisory board of Caelus Health and 
      Kaleido BioSciences; however, none of these are directly related to the current
      manuscript.
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.1136/bmjpo-2020-000689 [doi]
AID - bmjpo-2020-000689 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Aug 20;4(1):e000689. doi: 10.1136/bmjpo-2020-000689.
      eCollection 2020.


PMID- 32864477
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2399-5300 (Electronic)
IS  - 2399-5300 (Linking)
VI  - 4
IP  - 3
DP  - 2020
TI  - The Mental Landscape of Imagining Life Beyond the Current Life Span: Implications
      for Construal and Self-Continuity.
PG  - igaa013
LID - 10.1093/geroni/igaa013 [doi]
AB  - BACKGROUND AND OBJECTIVES: With rapid advancements in medicine, technology, and
      nutrition, the future holds the possibility of longer and healthier lives.
      Despite garnering attention from myriad disciplines, psychological perspectives
      on life extension are scarce. In three studies, we addressed this gap by
      exploring key mental characteristics and psychological variables associated with 
      simulating an expanded life span and thus an extremely distant future self.
      RESEARCH DESIGN AND METHODS: Three studies investigated the construal (i.e.,
      valence, vividness, and visual perspective) of extremely distant future
      simulations and the extent to which participants felt connected to their future
      selves (i.e., self-continuity). Studies 1 and 2 investigated the characteristics 
      of imagery associated with different ages ranging from near the current species
      maximum (e.g., 120, 150) to more highly hypothetical ages (e.g., 201, 501). Study
      3 probed the mental construal of extreme aging among different populations (i.e.,
      life-extension supporters, students, and Mechanical Turk workers). Studies also
      assessed participants' general feelings about the ethicality and likelihood of
      techniques that halt or reverse biological aging to help individuals live beyond 
      the current life expectancy. RESULTS: Participants in all studies reported being 
      able to vividly imagine expanded aging scenarios (increased chronological,
      without biological, and aging), but these simulations were characterized by a
      decreased sense of connection to one's future self (i.e., self-continuity)
      compared to a control condition. Temporal distance did not, however, impact
      ratings of self-continuity when comparing experimental conditions (i.e.,
      imagining one's self 120 vs 150 or 201 vs 501). Curiously, a sense of
      self-continuity (when simulating oneself well beyond the current life expectancy)
      remained intact for individuals who belonged to a community of life-extension
      supporters. The perceived likelihood and ethicality of extended life-span
      scenarios also varied significantly across different populations. DISCUSSION AND 
      IMPLICATIONS: The current work is the first to quantify the disconnect between
      one's current and extremely distant (i.e., beyond the current life expectancy)
      future self. Given the behavioral implications of feeling disconnected from one's
      future self (e.g., failing to save for retirement or care for one's own physical 
      health), these findings inform a critical barrier of extended life spans and
      provide insight into potential remedies (e.g., enhancing the perceived likelihood
      of living longer). Theoretical implications of hypotheticality and temporal
      distance, two key dimensions of Construal Level Theory, and their impact on the
      construal and self-continuity associated with future simulations are also
      discussed.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of The
      Gerontological Society of America.
FAU - Tausen, Brittany M
AU  - Tausen BM
AD  - School of Psychology, Seattle Pacific University, Washington.
FAU - Csordas, Attila
AU  - Csordas A
AD  - Open Lifespan, Cambridge, UK.
FAU - Macrae, C Neil
AU  - Macrae CN
AD  - School of Psychology, University of Aberdeen, UK.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - Innov Aging
JT  - Innovation in aging
JID - 101703706
PMC - PMC7447858
OTO - NOTNLM
OT  - Aging
OT  - Future
OT  - Life extension
OT  - Prospection
OT  - Self-continuity
OT  - Temporal distance
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.1093/geroni/igaa013 [doi]
AID - igaa013 [pii]
PST - epublish
SO  - Innov Aging. 2020 Jun 27;4(3):igaa013. doi: 10.1093/geroni/igaa013. eCollection
      2020.


PMID- 32864469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Ethical challenges in pathogen sequencing: a systematic scoping review.
PG  - 119
LID - 10.12688/wellcomeopenres.15806.1 [doi]
AB  - Background: Going forward, the routine implementation of genomic surveillance
      activities and outbreak investigation is to be expected. We sought to
      systematically identify the emerging ethical challenges; and to systematically
      assess the gaps in ethical frameworks or thinking and identify where further work
      is needed to solve practical challenges. Methods: We systematically searched
      indexed academic literature from PubMed, Google Scholar, and Web of Science from 
      2000 to April 2019 for peer-reviewed articles that substantively engaged in
      discussion of ethical issues in the use of pathogen genome sequencing
      technologies for diagnostic, surveillance and outbreak investigation. Results: 28
      articles were identified; nine United States, five United Kingdom, five The
      Netherlands, three Canada, two Switzerland, one Australia, two South Africa, and 
      one Italy. Eight articles were specifically about the use of sequencing in HIV.
      Eleven were not specific to a particular disease. Results were organized into
      four themes: tensions between public and private interests; difficulties with
      translation from research to clinical and public health practice; the importance 
      of community trust and support; equity and global partnerships; and the
      importance of context. Conclusion: While pathogen sequencing has the potential to
      be transformative for public health, there are a number of key ethical issues
      that must be addressed, particularly around the conditions of use for pathogen
      sequence data. Ethical standards should be informed by public values, and further
      empirical work investigating stakeholders' views are required. Development in the
      field should also be under-pinned by a strong commitment to values of justice, in
      particular global health equity.
CI  - Copyright: (c) 2020 Johnson S and Parker M.
FAU - Johnson, Stephanie
AU  - Johnson S
AUID- ORCID: https://orcid.org/0000-0002-6777-8816
AD  - Wellcome Centre for Ethics and Humanities and Ethox Centre, University of Oxford,
      Oxford, OX3 7LF, UK.
FAU - Parker, Michael
AU  - Parker M
AUID- ORCID: https://orcid.org/0000-0002-7054-4711
AD  - Wellcome Centre for Ethics and Humanities and Ethox Centre, University of Oxford,
      Oxford, OX3 7LF, UK.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7445679
OTO - NOTNLM
OT  - NGS
OT  - ethics
OT  - global health
OT  - infectious disease
OT  - pathogen genomics
COIS- No competing interests were disclosed.
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.12688/wellcomeopenres.15806.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Jun 3;5:119. doi: 10.12688/wellcomeopenres.15806.1.
      eCollection 2020.


PMID- 32864452
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2378-8038 (Print)
IS  - 2378-8038 (Linking)
VI  - 5
IP  - 4
DP  - 2020 Aug
TI  - Contemporary ethical considerations in clinical otolaryngology.
PG  - 778-781
LID - 10.1002/lio2.438 [doi]
AB  - The practice of otolaryngology has been significantly challenged by the
      constraints of the novel virus pandemic, but the specialty has continued to
      provide clinical care for patients in a manner consistent with ethical principles
      and moral leadership. Continued attention to maintaining the ethical foundations 
      for appropriate informed consent, provision of remote health care through
      telemedicine, and strengthening the patient-physician relationship while role
      modeling the highest level of professionalism will continue to be challenging for
      the specialty throughout and beyond the pandemic temporal boundaries. These
      contemporary elements of ethical clinical care, examined in the context of
      disruption of the traditional practice of otolaryngology, are foundational to the
      duties and responsibilities inherent to the profession of medicine. LEVEL OF
      EVIDENCE: 5.
CI  - (c) 2020 The Author. Laryngoscope Investigative Otolaryngology published by Wiley
      Periodicals LLC. on behalf of The Triological Society.
FAU - Holt, G Richard
AU  - Holt GR
AUID- ORCID: https://orcid.org/0000-0003-2698-6122
AD  - Department of Otolaryngology-Head and Neck Surgery The University of Texas Health
      Science Center at San Antonio San Antonio Texas USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200729
PL  - United States
TA  - Laryngoscope Investig Otolaryngol
JT  - Laryngoscope investigative otolaryngology
JID - 101684963
PMC - PMC7444792
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - clinical otolaryngology
OT  - ethics
OT  - informed consent
OT  - patient-physician relationship
OT  - professionalism
OT  - telehealth
COIS- The author declared no potential conflicts of interest.
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/19 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.1002/lio2.438 [doi]
AID - LIO2438 [pii]
PST - epublish
SO  - Laryngoscope Investig Otolaryngol. 2020 Jul 29;5(4):778-781. doi:
      10.1002/lio2.438. eCollection 2020 Aug.


PMID- 32864245
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 7
DP  - 2020 Jul 27
TI  - Effect of Body Mass Index on the Disease Activity of Patients With Rheumatoid
      Arthritis in a Gender-Specific Manner and the Association of Respective Serum
      C-Reactive Protein Levels With the Body's Inflammatory Status.
PG  - e9417
LID - 10.7759/cureus.9417 [doi]
AB  - Background Current literature evaluating the effect of high body mass index (BMI)
      on the disease activity of patients with rheumatoid arthritis (RA) is mixed as
      some studies have shown a positive, linear relationship between BMI and disease
      activity while others have demonstrated an inverse correlation. Through this
      study, we have expanded the effect of BMI on disease activity in patients with
      RA. We have further expanded on whether BMI influences the disease activity
      depending on the gender being studied. Finally, we have studied whether there is 
      a correlation between high BMI values and rising C-reactive protein (CRP) levels.
      Methodology This cross-sectional study was conducted at the Outpatient Clinical
      Department of Buffalo Rheumatology. The study was ethically approved by the
      Catholic Health Institutional Review Board. A total number of 451 patients'
      clinical data was selected based on inclusion/exclusion criteria. The patients
      were divided into different BMI categories based on the guidelines of national
      obesity education initiative of the national heart, lung, and blood Institute.
      The following clinical parameters were studied: BMI, serum CRP level, and disease
      activity through routine assessment of patient index data questionnaire 3
      (RAPID3). The minimum sample size (n = 358) was calculated via the world health
      organization sample size calculator. All data were entered and analyzed through
      Statistical Package for the Social Sciences (SPSS), version 16.0 (IBM Corp.,
      Armonk, NY). Results Our study sample included 98 males and 353 females (22% and 
      78%, respectively). Collective data for both the genders showed significantly
      increased disease activity in RA patients with high BMI values (p = 0.04). When
      the data sets were categorized according to the two genders, it was noted that
      the aforementioned results remain significant for the females only (p = 0.02 for 
      females and p = 0.57 for males). At all BMI values, mean RAPID3 scoring remained 
      significantly higher for females as opposed to their male counterparts (p =
      0.006). Mean serum CRP levels increased linearly with increasing BMI (p < 0.001);
      however, for the underweight patient population, mean CRP levels were the highest
      as compared to normal weight, overweight, moderately obese, and severely obese
      patients. Conclusion We conclude that the association between the BMI and the
      severity of disease remains elusive. High BMI values increase the risk of a
      pro-inflammatory state of the body due to higher serum CRP levels. Estimating the
      clinically significant benefit of this theory would require a large-scale
      clinical trial that would highlight the role of losing weight in improving the
      patients' quality of life, pain control, and mortality.
CI  - Copyright (c) 2020, Iqbal et al.
FAU - Iqbal, Shumaila M
AU  - Iqbal SM
AD  - Internal Medicine, University at Buffalo/Sisters of Charity Hospital, Buffalo,
      USA.
FAU - Burns, Linda
AU  - Burns L
AD  - Rheumatology, Buffalo Rheumatology and Medicine, Buffalo, USA.
FAU - Grisanti, Joseph
AU  - Grisanti J
AD  - Rheumatology, Buffalo Rheumatology and Medicine, Buffalo, USA.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7449617
OTO - NOTNLM
OT  - body mass index
OT  - c-reactive protein
OT  - disease acitivity
OT  - rheumatoid arthritis
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.7759/cureus.9417 [doi]
PST - epublish
SO  - Cureus. 2020 Jul 27;12(7):e9417. doi: 10.7759/cureus.9417.


PMID- 32864151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200902
IS  - 2054-670X (Electronic)
IS  - 0033-2879 (Linking)
VI  - 60
IP  - 1
DP  - 2020 Aug 13
TI  - An Empirical Study on the Relationship between Causes of Teacher Examination
      Anxiety and Dimensions of Coping with Pre-Exam Anxiety: A Structural Equation
      Modelling Approach.
PG  - 255-269
LID - 10.5334/pb.536 [doi]
AB  - In recent years, examination anxiety among teachers assumes a critical sphere in 
      the global academic environment. The causes of teacher examination anxiety in
      education have been reviewed by a few scholars. This shows that teacher
      examination anxiety and its impact on academic development are limited in
      research. Therefore, this study investigated the linear relationship between two 
      self-report instruments - the causes of teacher examination anxiety and
      dimensions of coping with pre-exam anxiety. The study adopted a quantitative
      approach with three-hundred teachers from four secondary schools in Nigeria and
      twenty teachers from two secondary schools in North Cyprus participated in the
      survey. Also, a Structural Equation Modeling (SEM) was utilized for the analysis.
      The results of the study indicate that the two factors (teacher causes of exam
      anxiety and dimensions of coping with pre-exam anxiety) are interconnected. The
      results also indicate teachers' preparation for examinations coupled with various
      dimensions of anxiety is a complex task that demands educational stakeholders to 
      constantly improving on causes of examination anxiety and factors of pre-exam
      anxiety among teachers for better academic and ethical development.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Shimave, Stella
AU  - Shimave S
AD  - Department of Guidance and Psychological Counselling, Near East University, North
      Cyprus, TR.
FAU - Cerkez, Yagmur
AU  - Cerkez Y
AD  - Department of Guidance and Psychological Counselling, Near East University, North
      Cyprus, TR.
FAU - Baysen, Engin
AU  - Baysen E
AD  - Department of Guidance and Psychological Counselling, Near East University, North
      Cyprus, TR.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - Psychol Belg
JT  - Psychologica Belgica
JID - 0067335
PMC - PMC7427682
OTO - NOTNLM
OT  - assessment
OT  - avoidance
OT  - behaviours
OT  - beliefs
OT  - exam anxiety
OT  - preparation
COIS- The authors have no competing interests to declare.
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.5334/pb.536 [doi]
PST - epublish
SO  - Psychol Belg. 2020 Aug 13;60(1):255-269. doi: 10.5334/pb.536.


PMID- 32864104
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20201218
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - School closure in response to epidemic outbreaks: Systems-based logic model of
      downstream impacts.
PG  - 352
LID - 10.12688/f1000research.23631.1 [doi]
AB  - Background: School closures have been a recommended non-pharmaceutical
      intervention in pandemic response owing to the potential to reduce transmission
      of infection between children, school staff and those that they contact. However,
      given the many roles that schools play in society, closure for any extended
      period is likely to have additional impacts. Literature reviews of research
      exploring school closure to date have focused upon epidemiological effects; there
      is an unmet need for research that considers the multiplicity of potential
      impacts of school closures. Methods: We used systematic searching, coding and
      synthesis techniques to develop a systems-based logic model. We included
      literature related to school closure planned in response to epidemics large and
      small, spanning the 1918-19 'flu pandemic through to the emerging literature on
      the 2019 novel coronavirus. We used over 170 research studies and a number of
      policy documents to inform our model. Results: The model organises the concepts
      used by authors into seven higher level domains: children's health and wellbeing,
      children's education, impacts on teachers and other school staff, the school
      organisation, considerations for parents and families, public health
      considerations, and broader economic impacts. The model also collates ideas about
      potential moderating factors and ethical considerations. While dependent upon the
      nature of epidemics experienced to date, we aim for the model to provide a
      starting point for theorising about school closures in general, and as part of a 
      wider system that is influenced by contextual and population factors.
      Conclusions: The model highlights that the impacts of school closures are much
      broader than those related solely to health, and demonstrates that there is a
      need for further concerted work in this area. The publication of this logic model
      should help to frame future research in this area and aid decision-makers when
      considering future school closure policy and possible mitigation strategies.
CI  - Copyright: (c) 2020 Kneale D et al.
FAU - Kneale, Dylan
AU  - Kneale D
AUID- ORCID: 0000-0002-7016-978X
AD  - Department of Social Science, UCL Institute of Education, University College
      London, London, UK.
FAU - O'Mara-Eves, Alison
AU  - O'Mara-Eves A
AUID- ORCID: 0000-0002-0359-6423
AD  - Department of Social Science, UCL Institute of Education, University College
      London, London, UK.
FAU - Rees, Rebecca
AU  - Rees R
AUID- ORCID: 0000-0003-1413-1952
AD  - Department of Social Science, UCL Institute of Education, University College
      London, London, UK.
FAU - Thomas, James
AU  - Thomas J
AUID- ORCID: 0000-0003-4805-4190
AD  - Department of Social Science, UCL Institute of Education, University College
      London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/*methods
MH  - Coronavirus Infections/*prevention & control
MH  - Disease Outbreaks/prevention & control
MH  - Humans
MH  - Influenza, Human/*prevention & control
MH  - Models, Theoretical
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
MH  - *Schools
PMC - PMC7445561
OTO - NOTNLM
OT  - *COVID-19
OT  - *School closure
OT  - *conceptual framework
OT  - *evidence synthesis
OT  - *logic model
OT  - *novel coronavirus
OT  - *pandemic
COIS- No competing interests were disclosed.
EDAT- 2020/08/31 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - 10.12688/f1000research.23631.1 [doi]
PST - epublish
SO  - F1000Res. 2020 May 12;9:352. doi: 10.12688/f1000research.23631.1. eCollection
      2020.


PMID- 32863832
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1735-8949 (Print)
IS  - 1735-9392 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Mar
TI  - Resumption of Elective Surgery Following COVID-19 Outbreak, Guideline for Female 
      Pelvic Medicine and Surgery.
PG  - 1-4
AB  - Division of Female Pelvic Medicine and Surgery, Department of Obstetrics and
      Gynecology, Emam Khomeini Hospital, Tehran University of medical sciences
      proposed a clinically relevant algorithm to guide appropriate decision making
      based on underlying risk stratification and resource utilization in order to
      resume elective surgeries, following COVID-19 pandemic crisis. The consequence of
      standardized decision-making factors and transparency of the principles will
      provide more assurance, consistency, and reliability on both sides, care
      providers and the patient. It also will decrease ethical dilemmas and moral
      criticism for surgeons. Eventually, this approach is applicable in any other
      disaster preparedness as a logical stratification of surgical indications for the
      female pelvic floor surgical procedures.
CI  - Copyright (c) Vali-e-Asr Reproductive Health Research Center, Tehran University
      of Medical Sciences.
FAU - Ghanbari, Zinat
AU  - Ghanbari Z
AD  - Division of Female Pelvic Medicine and Surgery, Department of Obstetrics and
      Gynecology, Imam Khomeini Hospital Complex, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Mostaan, Fatemeh
AU  - Mostaan F
AD  - Division of Female Pelvic Medicine and Surgery, Department of Obstetrics and
      Gynecology, Imam Khomeini Hospital Complex, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Eftekhar, Tahereh
AU  - Eftekhar T
AD  - Division of Female Pelvic Medicine and Surgery, Department of Obstetrics and
      Gynecology, Imam Khomeini Hospital Complex, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Deldar, Maryam
AU  - Deldar M
AD  - Division of Female Pelvic Medicine and Surgery, Department of Obstetrics and
      Gynecology, Imam Khomeini Hospital Complex, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Changiz, Nasrin
AU  - Changiz N
AD  - Maternal, Fetal and Neonatal Research Center, Tehran University of Medical
      Sciences, Tehran, Iran.
AD  - Maternal Health Department, Ministry of Health and Medical Education, Tehran,
      Iran.
FAU - Adabi, Khadijeh
AU  - Adabi K
AD  - Division of Female Pelvic Medicine and Surgery, Department of Obstetrics and
      Gynecology, Imam Khomeini Hospital Complex, Tehran University of Medical
      Sciences, Tehran, Iran.
LA  - eng
PT  - Editorial
PL  - Iran
TA  - J Family Reprod Health
JT  - Journal of family & reproductive health
JID - 101496684
PMC - PMC7428416
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Elective Surgery
OT  - Female Pelvic Medicine
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - JFRH-14-1 [pii]
PST - ppublish
SO  - J Family Reprod Health. 2020 Mar;14(1):1-4.


PMID- 32863631
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 6
DP  - 2020 Jun
TI  - Effects of Delayed Initiation of End-of-life Care in Terminally Ill Intensive
      Care Unit Patients.
PG  - 404-408
LID - 10.5005/jp-journals-10071-23454 [doi]
AB  - INTRODUCTION: Early initiation of end-of-life (EOL) care in terminally ill
      patients can reduce the administration of unnecessary medications, minimize
      laboratory and radiological investigations, and avoid procedures that can provoke
      untoward complications without substantial benefits. This retrospective
      observational study was performed to compare early vs late initiation of EOL care
      in terminally ill ICU patients after the recognition of treatment futility.
      MATERIALS AND METHODS: The medical records of all patients who were considered to
      be terminally ill any time after ICU admission between January 2014 and December 
      2018 were extracted from the ICU database. The patients who were recognized for
      treatment futility were eligible for inclusion. The patients who were already on 
      EOL care prior to the ICU admission or whose diagnosis was unconfirmed were
      excluded from the study. The treatment futility was a subjective decision jointly
      undertaken by the primary physician and the intensivist based upon the disease
      stage and the available therapeutic options. The commencement of EOL care after
      recognition of treatment futility was divided into (a) early group (EG)-within 48
      hours of decision of treatment futility and (b) late group (LG)-after 48 hours of
      recognition of treatment futility. Both the groups were compared for (a) ICU
      mortality, (b) length of ICU stay, (c) number of antibiotic-free days, (d) number
      of ventilator-free days, (e) number of medical and/or surgical interventions
      (insertion of central lines, drains, IABP, etc.), (f) number of blood and
      radiological investigations, and (g) satisfaction level of family members.
      RESULTS: Out of 107 terminally ill patients with diagnosis of treatment futility,
      64 patients (59.8%) underwent early initiation of EOL against delayed initiation 
      in 43 (40.2%) patients (1.3 +/- 0.4 days vs 5.1 +/- 1.6 days; p = 0.01). The
      patients in the late initiation group were younger in age (49 +/- 3.6 years vs 66
      +/- 5.3 years; p = 0.03). The number of antibiotic-free days was higher in the
      early initiation group (12 +/- 5.2 days vs 6 +/- 7.5; p = 0.02). The number of
      medical and surgical interventions was lesser in the early initiation group (3.0 
      +/- 0.7 episodes vs 12 +/- 3.9 episodes; p = 0.007). The late initiation of EOL
      was caused by prognostic dilemma (30.2%), reluctance of the family members
      (44.1%), ambivalence of the primary physician (18.6%), and hesitancy of the
      intensivist (6.9%). The satisfaction level of the family members was similar in
      both the groups. CONCLUSION: We conclude that delayed initiation of EOL care in
      terminally ill ICU patients after recognition of treatment futility can increase 
      the antibiotic usage and medical and/or surgical interventions with no effect on 
      the satisfaction level of the family members. HOW TO CITE THIS ARTICLE: Choudhuri
      AH, Sharma A, Uppal R. Effects of Delayed Initiation of End-of-life Care in
      Terminally Ill Intensive Care Unit Patients. Indian J Crit Care Med
      2020;24(6):404-408.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Choudhuri, Anirban H
AU  - Choudhuri AH
AD  - Department of Anesthesiology and Intensive Care, Govind Ballabh Pant Institute of
      Postgraduate Medical Education and Research, New Delhi, India.
FAU - Sharma, Ankit
AU  - Sharma A
AD  - Department of Anesthesiology and Intensive Care, Govind Ballabh Pant Institute of
      Postgraduate Medical Education and Research, New Delhi, India.
FAU - Uppal, Rajeev
AU  - Uppal R
AD  - Department of Anesthesiology and Intensive Care, Govind Ballabh Pant Institute of
      Postgraduate Medical Education and Research, New Delhi, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7435104
OTO - NOTNLM
OT  - Do not activate cardiopulmonary resuscitation
OT  - End-of-life care
OT  - Ethical issues
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.5005/jp-journals-10071-23454 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Jun;24(6):404-408. doi:
      10.5005/jp-journals-10071-23454.


PMID- 32863628
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0972-5229 (Print)
IS  - 0972-5229 (Linking)
VI  - 24
IP  - 6
DP  - 2020 Jun
TI  - Preparedness of Acute Care Facility and a Hospital for COVID-19 Pandemic: What We
      Did!
PG  - 385-392
LID - 10.5005/jp-journals-10071-23416 [doi]
AB  - BACKGROUND AND AIM: India is facing the pandemic of coronavirus disease
      (COVID-19) just like the whole world. The private sector is the backbone of a
      healthcare facility in India. Presently, only a few major hospitals in the
      country are actively dealing with the COVID-19 patients while others are facing
      troubles due to lack of manpower, management, and required experience to face the
      pandemic. Despite the lockdown, the cases are ever increasing and each and every 
      hospital in the country should be prepared to face this pandemic the world has
      never seen before. As one of the largest multispecialty hospitals and a
      designated COVID center, we have developed and adopted some strategies for better
      preparedness to face the surge of this pandemic. We would like to share our
      experience and hope that the strategies laid down and adopted by us will help
      many other acute care facilities in many parts of India. MATERIALS AND METHODS:
      Different strategies are adopted to deal with the crisis situation of the
      COVID-19 pandemic. Our adopted strategies were directed to mitigate the
      challenges of administration, hospital space organization, management of staff
      and supplies, maintenance of standard of care, and specific COVID care and ethics
      during this pandemic. RESULTS: Based on strategies adopted by us, we feel more
      confident and prepared to deal with COVID-19 pandemic. CONCLUSION: Our approach
      for preparing for the COVID-19 pandemic may not be the best one but we believe
      that the basic managerial principles we adopted will guide many other
      institutions to find their path in tackling the pandemic in the best possible
      way. HOW TO CITE THIS ARTICLE: Jog S, Kelkar D, Bhat M, Patwardhan S, Godavarthy 
      P, Dhundi U, et al. Preparedness of Acute Care Facility and a Hospital for
      COVID-19 Pandemic: What We Did! Indian J Crit Care Med 2020;24(6):385-392.
CI  - Copyright (c) 2020; Jaypee Brothers Medical Publishers (P) Ltd.
FAU - Jog, Sameer
AU  - Jog S
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Kelkar, Dhananjay
AU  - Kelkar D
AD  - Department of Oncosurgery, Deenanath Mangeshkar Hospital, Pune, Maharashtra,
      India.
FAU - Bhat, Madhav
AU  - Bhat M
AD  - Department of Ophthalmology, Deenanath Mangeshkar Hospital, Pune, Maharashtra,
      India.
FAU - Patwardhan, Sampada
AU  - Patwardhan S
AD  - Department of Microbiology, Deenanath Mangeshkar Hospital, Pune, Maharashtra,
      India.
FAU - Godavarthy, Purushotham
AU  - Godavarthy P
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Dhundi, Ujwal
AU  - Dhundi U
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Pawar, Harshwardhan S
AU  - Pawar HS
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Rajhans, Prasad
AU  - Rajhans P
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Pawar, Balasaheb
AU  - Pawar B
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Telbhare, Vishnudas S
AU  - Telbhare VS
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Ranade, Gouri
AU  - Ranade G
AD  - Department of Critical Care and Emergency Medicine, Deenanath Mangeshkar
      Hospital, Pune, Maharashtra, India.
FAU - Upadhye, Vaibhavi
AU  - Upadhye V
AD  - Department of Post Graduate Certification, Deenanath Mangeshkar Hospital, Pune,
      Maharashtra, India.
FAU - Prayag, Parikshit S
AU  - Prayag PS
AD  - Department of Transplant Infectious Diseases, Deenanath Mangeshkar Hospital,
      Pune, Maharashtra, India.
FAU - Purandare, Bharat
AU  - Purandare B
AD  - Department of Infectious Disease, Deenanath Mangeshkar Hospital, Pune,
      Maharashtra, India.
FAU - Purandare, Sukrut
AU  - Purandare S
AD  - Department of Medicine, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India.
FAU - Bhavsar, Rajesh
AU  - Bhavsar R
AD  - Department of Cardiology, Deenanath Mangeshkar Hospital, Pune, Maharashtra,
      India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Crit Care Med
JT  - Indian journal of critical care medicine : peer-reviewed, official publication of
      Indian Society of Critical Care Medicine
JID - 101208863
PMC - PMC7435084
OTO - NOTNLM
OT  - COVID pneumonia
OT  - Intensive care unit
OT  - Pandemic
OT  - Preparedness
COIS- Source of support: Nil Conflict of interest: None
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
AID - 10.5005/jp-journals-10071-23416 [doi]
PST - ppublish
SO  - Indian J Crit Care Med. 2020 Jun;24(6):385-392. doi:
      10.5005/jp-journals-10071-23416.


PMID- 32863413
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20220416
IS  - 2616-163X (Electronic)
IS  - 0016-9560 (Linking)
VI  - 54
IP  - 1
DP  - 2020 Mar
TI  - Prevalence and correlates of prehypertension and hypertension among adults in
      Delta State, Nigeria: a cross-sectional community-based study.
PG  - 48-57
LID - 10.4314/gmj.v54i1.8 [doi]
AB  - BACKGROUND: There are indications that prehypertension precedes hypertension.
      Like hypertension, it is associated with increased cardiovascular risk.
      OBJECTIVE: To determine the prevalence, awareness and correlates of
      prehypertension and hypertension among adults in Delta State, Nigeria. METHODS:
      This was a cross-sectional study. We recruited adults aged >/=18 years from two
      communities in Delta State, Nigeria, using the multi-stage sampling technique.
      The study instrument was a modified WHO-STEPS questionnaire. Prehypertension and 
      hypertension were defined using the JNC-7 criteria. Ethical approval was obtained
      before the recruitment of participants. RESULTS: Of the 852 adults studied, the
      mean (+/-SD) age was 42.64 (+/-16.07) years, females (55.9%) and urban dwellers
      (55.8%). The prevalence of prehypertension and hypertension were 42.5% and 29.3%,
      respectively; both were higher among urban dwellers. The peak age-group for
      prehypertension and hypertension were 25-34 and 35-44 years, respectively.
      Awareness of hypertension was low; 12.0% (102/852). Blood pressure category
      significantly correlated with age, body mass index, place of residence, level of 
      education, employment status and fruit intake. CONCLUSION: The prevalence of
      prehypertension and hypertension in this study were high. Based on the premise
      that prehypertension is a precursor of hypertension and occurred more among
      youths, the higher prevalence of prehypertension gives an inkling to rising
      prevalence of hypertension. FUNDING: Nil.
CI  - Copyright (c) The Author(s).
FAU - Umuerri, Ejiroghene M
AU  - Umuerri EM
AD  - Department of Medicine, Delta State University, PMB 01, Abraka, Nigeria.
AD  - Cardiology Unit, Department of Medicine, Delta State University Teaching
      Hospital, PMB 07, Oghara, Nigeria.
FAU - Aiwuyo, Henry O
AU  - Aiwuyo HO
AD  - Cardiology Unit, Department of Medicine, Delta State University Teaching
      Hospital, PMB 07, Oghara, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Ghana
TA  - Ghana Med J
JT  - Ghana medical journal
JID - 0073210
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Blood Pressure Determination
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - Educational Status
MH  - Employment
MH  - Female
MH  - Fruit
MH  - Humans
MH  - Hypertension/*epidemiology/etiology
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - Prehypertension/*epidemiology/etiology
MH  - Prevalence
MH  - Residence Characteristics
MH  - Risk Factors
MH  - Sex Factors
PMC - PMC7445701
OTO - NOTNLM
OT  - Nigeria
OT  - Prehypertension
OT  - WHO STEPS
OT  - adults
OT  - hypertension
COIS- Conflict of interest: None declared
EDAT- 2020/08/31 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
AID - 10.4314/gmj.v54i1.8 [doi]
AID - jGMJ.v54.i1.pg48 [pii]
PST - ppublish
SO  - Ghana Med J. 2020 Mar;54(1):48-57. doi: 10.4314/gmj.v54i1.8.


PMID- 32862520
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1601-0825 (Electronic)
IS  - 1354-523X (Linking)
VI  - 26 Suppl 1
DP  - 2020 Sep
TI  - The role of patient and public involvement in oral health and HIV/AIDS research, 
      practice and policy.
PG  - 117-122
LID - 10.1111/odi.13584 [doi]
AB  - Patient and public involvement (PPI) is a process whereby patients, caregivers,
      service users and other relevant stakeholders, including the general public, are 
      actively involved and engaged in activities to develop research. The dental
      research agenda has traditionally been driven by clinicians, where patients and
      the public have participated in research as subjects; patient and public
      involvement can contribute to the research agenda including the design and
      conduct of research by providing unique perspectives gained through lived
      experience. This panel of the 8th World Workshop on Oral Health and Diseases in
      AIDS considered the role of people living with HIV (PLHIV) to contribute to oral 
      health and HIV research and policy through a process of involvement and
      empowerment. The panel introduced the concepts of PPI, described the purpose of
      PPI, reflected upon the logistic and ethical considerations thereof and
      considered how PPI had been utilised effectively in HIV research and policy
      change. The audience discussion focused on ways in which PPI could more readily
      and consistently be encouraged within oral health research involving PLHIV.
CI  - (c) 2020 The Authors. Oral Diseases published by John Wiley & Sons Ltd.
FAU - Sharma Mahendra, Vaishali
AU  - Sharma Mahendra V
AD  - Gender, Sexuality and HIV, New Delhi, India.
FAU - Ranauta, Amitha
AU  - Ranauta A
AD  - Institute of Dentistry, Barts and The London School of Medicine and Dentistry,
      Queen Mary University of London, London, UK.
FAU - Yuvraj, Anandi
AU  - Yuvraj A
AD  - HIV, SRHR and Gender, Coimbatore, India.
FAU - Santella, Anthony J
AU  - Santella AJ
AD  - Department of Health Professions, Hofstra University, Hempstead, NY, USA.
FAU - Taslim, Aditia
AU  - Taslim A
AD  - Rumah Cemara, Bali, Indonesia.
FAU - Doughty, Janine
AU  - Doughty J
AD  - University College London, London, UK.
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Oral Dis
JT  - Oral diseases
JID - 9508565
MH  - *Acquired Immunodeficiency Syndrome
MH  - Caregivers
MH  - HIV
MH  - HIV Infections
MH  - Humans
MH  - *Oral Health
MH  - *Patient Participation
OTO - NOTNLM
OT  - HIV
OT  - co-production
OT  - involvement
OT  - oral health
OT  - research methodology
EDAT- 2020/08/31 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/07/22 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/08/31 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1111/odi.13584 [doi]
PST - ppublish
SO  - Oral Dis. 2020 Sep;26 Suppl 1:117-122. doi: 10.1111/odi.13584.


PMID- 32862482
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Ethical issues surrounding controlled human infection challenge studies in
      endemic low-and middle-income countries.
PG  - 797-808
LID - 10.1111/bioe.12802 [doi]
AB  - Controlled human infection challenge studies (CHIs) involve intentionally
      exposing research participants to, and/or thereby infecting them with,
      micro-organisms. There have been increased calls for more CHIs to be conducted in
      low- and middle-income countries (LMICs) where many relevant diseases are
      endemic. This article is based on a research project that identified and analyzed
      ethical and regulatory issues related to endemic LMIC CHIs via (a) a review of
      relevant literature and (b) qualitative interviews involving 45 scientists and
      ethicists with relevant expertise. In this article we argue that though there is 
      an especially strong case for conducting CHIs in endemic (LMIC) settings, certain
      ethical issues related to the design and conduct of such studies (in such
      settings) nonetheless warrant particularly careful attention. We focus on ethical
      implications of endemic LMIC CHIs regarding (a) potential direct benefits for
      participants, (b) risks to participants, (c) third-party risks, (d) informed
      consent, (e) payment of participants, and (f) community engagement. We conclude
      that there is a strong ethical rationale to conduct (well-designed) CHIs in
      endemic LMICs, that certain ethical issues warrant particularly careful
      consideration, and that ethical analyses of endemic LMIC CHIs can inform current 
      debates in research ethics more broadly.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AUID- ORCID: 0000-0001-5940-602X
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia.
AD  - University of Melbourne, Department of Medicine, Royal Melbourne Hospital,
      Melbourne, Victoria, Australia.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AUID- ORCID: 0000-0003-3496-2884
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - Brocher Foundation/International
GR  - 210551/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200830
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Developing Countries
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent
MH  - Poverty
MH  - Research Design
PMC - PMC7984051
OTO - NOTNLM
OT  - *controlled human infection
OT  - *endemic
OT  - *ethics
OT  - *global health
OT  - *human challenge studies
OT  - *research ethics
EDAT- 2020/08/31 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/08/31 06:00
PHST- 2019/07/19 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/08/31 06:00 [entrez]
AID - 10.1111/bioe.12802 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):797-808. doi: 10.1111/bioe.12802. Epub 2020 Aug 30.


PMID- 32862478
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 1440-1843 (Electronic)
IS  - 1323-7799 (Linking)
VI  - 25
IP  - 10
DP  - 2020 Oct
TI  - Ethical challenges posed by COVID-19.
PG  - 1035-1036
LID - 10.1111/resp.13930 [doi]
FAU - Komesaroff, Paul A
AU  - Komesaroff PA
AUID- ORCID: 0000-0002-1360-3375
AD  - School of Public Health, Monash University, Alfred Hospital, Prahran, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200829
PL  - Australia
TA  - Respirology
JT  - Respirology (Carlton, Vic.)
JID - 9616368
SB  - IM
OTO - NOTNLM
OT  - *COVID-19
OT  - *climate change
OT  - *ethics
OT  - *vaccine
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
CRDT- 2020/08/31 06:00
PHST- 2020/08/02 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
PHST- 2020/08/31 06:00 [entrez]
AID - 10.1111/resp.13930 [doi]
PST - ppublish
SO  - Respirology. 2020 Oct;25(10):1035-1036. doi: 10.1111/resp.13930. Epub 2020 Aug
      29.


PMID- 32861921
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1476-5616 (Electronic)
IS  - 0033-3506 (Linking)
VI  - 186
DP  - 2020 Sep
TI  - Ethical guidance for health research in prisons in low- and middle-income
      countries: a scoping review.
PG  - 217-227
LID - S0033-3506(20)30303-6 [pii]
LID - 10.1016/j.puhe.2020.07.008 [doi]
AB  - OBJECTIVES: This study examined the extent, range and nature of the published
      literature, prison policies and technical guidance relating to the ethical
      conduct of health research in prisons in low- and middle-income countries
      (LMICs). STUDY DESIGN: Scoping Review. METHODS: We adhered to the five stages of 
      the scoping review iterative process: identifying the research question,
      identifying relevant studies, study selection, charting the data, and collating, 
      summarizing and content analysis of polices. Disagreements around allocation of
      content were resolved through team discussion. We also appraised the quality of
      the included articles. RESULTS: We included nine records that examined the
      ethical aspects of the conduct of health research in prisons in LMICs; eight of
      these were peer-reviewed publications, and one was a toolkit. Despite the unique 
      vulnerabilities of this group, we could find no comprehensive guidelines on the
      ethical conduct of health research in prisons in LMICs. CONCLUSIONS: The majority
      of the world's imprisoned populations are in LMICs, and they have considerable
      health needs. Research plays an important role in addressing these needs and in
      so doing, will contribute to the achievement of the Sustainable Development
      Goals. With regards to health research, imprisoned people in LMICs are 'left
      behind'; there is a lack of clear, prison-focused guidance and oversight to
      ensure high quality ethical health research so necessary in LMICs. There is an
      urgent need for prison health experts to work with health research ethics experts
      and custodial practitioners for procedural issues in the development of
      prison-specific ethical guidance for health research in LMICs aligned with
      international standards.
CI  - Copyright (c) 2020 The Royal Society for Public Health. Published by Elsevier
      Ltd. All rights reserved.
FAU - Ako, T
AU  - Ako T
AD  - Chief Medical Office, Cameroon Penitentiary Services, Cameroon. Electronic
      address: terrence.ako@yahoo.com.
FAU - Plugge, E
AU  - Plugge E
AD  - UK Collaborating Centre for the WHO (Europe) Health in Prisons Programme, Health 
      and Justice, ADT-J Division, Public Health England, Wellington House, 133-155
      Waterloo Road, London, SE1 8UG, England, United Kingdom. Electronic address:
      emma.plugge@phe.gov.uk.
FAU - Mhlanga-Gunda, R
AU  - Mhlanga-Gunda R
AD  - College of Health Sciences, Centre for Evaluation of Public Health Interventions,
      Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe.
      Electronic address: rosemhlanga3@gmail.com.
FAU - Van Hout, M C
AU  - Van Hout MC
AD  - Public Health Institute, Liverpool John Moore's University, Liverpool, L32ET,
      United Kingdom. Electronic address: m.c.vanhout@ljmu.ac.uk.
LA  - eng
GR  - MC_PC_MR/R024278/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200827
PL  - Netherlands
TA  - Public Health
JT  - Public health
JID - 0376507
SB  - IM
MH  - Biomedical Research/*ethics
MH  - *Developing Countries
MH  - *Guidelines as Topic
MH  - Humans
MH  - *Prisons
PMC - PMC7449980
OTO - NOTNLM
OT  - Ethics
OT  - Health research
OT  - LMICs
OT  - Prison
EDAT- 2020/08/31 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/08/31 06:00 [entrez]
AID - S0033-3506(20)30303-6 [pii]
AID - 10.1016/j.puhe.2020.07.008 [doi]
PST - ppublish
SO  - Public Health. 2020 Sep;186:217-227. doi: 10.1016/j.puhe.2020.07.008. Epub 2020
      Aug 27.


PMID- 32861610
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1769-6658 (Electronic)
IS  - 1278-3218 (Linking)
VI  - 24
IP  - 6-7
DP  - 2020 Oct
TI  - [Health democracy: Patient partnership].
PG  - 736-743
LID - S1278-3218(20)30196-7 [pii]
LID - 10.1016/j.canrad.2020.06.021 [doi]
AB  - In 2019, the scientific committee of the French society of radiation oncology
      (SFRO) created an ethics committee. Its mission is to provide our professional
      community with food for thought on ethical issues, and to identify its
      specificities within the radiation oncology departments. For the 2020 annual
      conference, the commission looked into the evolution of the patient-carer
      relationship, and more particularly to the strong idea of patient partnership.
      Indeed, the writing of the White Book of Cancer gave voice to sick people and
      stressed the need for new devices, such as the Caregiving Time. Patients can no
      longer be considered as objects of care but as people whose dignity and autonomy 
      must be imperatively respected. The acquisition of knowledge allows a bilateral
      exchange, prerequisite of a dynamic collaboration. Patients can be partners in
      their own care, partners in training and research (expert patient), but also
      partners in health institutions and policies. It is this notion of partnership
      and involvement of the person in their path of care in radiation oncology that we
      will analyse here. It will be about defining it, by developing the concept of
      autonomy, and bringing out its complexity and ambivalence through two examples
      from our clinical practice: the shared decision-making process for patients with 
      localized prostate cancer and the patient's involvement in the success of his
      radiotherapy.
CI  - Copyright (c) 2020 Societe francaise de radiotherapie oncologique (SFRO).
      Published by Elsevier Masson SAS. All rights reserved.
FAU - Haaser, T
AU  - Haaser T
AD  - Service de radiotherapie, hopital Haut-Leveque, centre hospitalier universitaire 
      de Bordeaux, Pessac, France. Electronic address: thibaud.haaser@chu-bordeaux.fr.
FAU - Constantinides, Y
AU  - Constantinides Y
AD  - Espace ethique Ile-de-France, Paris Universite Sorbonne Nouvelle, Paris, France.
FAU - Dejean, C
AU  - Dejean C
AD  - Service de radiotherapie, unite de physique medicale, centre Antoine-Lacassagne, 
      Nice, France.
FAU - Escande, A
AU  - Escande A
AD  - Service universitaire de radiotherapie, laboratoire CRIStAL, UMR9189, centre
      Oscar-Lambret, faculte de medecine Henri-Warembourg, universite de Lille, Lille, 
      France.
FAU - Le Tallec, P
AU  - Le Tallec P
AD  - Service de radiotherapie, Quantis Litis EA 4108, centre Henri-Becquerel, Rouen,
      France.
FAU - Lorchel, F
AU  - Lorchel F
AD  - Centre de radiotherapie et oncologie de Macon - Orlam, Macon, France; Service de 
      radiotherapie, centre hospitalier universitaire Lyon-Sud, Lyon, France.
FAU - Marty, S
AU  - Marty S
AD  - Centre de coordination en cancerologie, centre hospitalier universitaire de
      Bordeaux, Pessac, France.
FAU - Thureau, S
AU  - Thureau S
AD  - Service de radiotherapie, Quantis Litis EA 4108, centre Henri-Becquerel, Rouen,
      France.
FAU - Huguet, F
AU  - Huguet F
AD  - Service d'oncologie radiotherapie, centre de recherche Saint-Antoine UMR_S 938,
      Sorbonne universite, hopital Tenon, institut universitaire de cancerologie,
      AP-HP, Paris, France.
FAU - Lagrange, J-L
AU  - Lagrange JL
AD  - Universite Paris-Est Creteil Val-de-Marne, Paris, France.
CN  - pour la Commission ethique de la SFRO
AD  - Service de radiotherapie, hopital Haut-Leveque, centre hospitalier universitaire 
      de Bordeaux, Pessac, France; Espace ethique Ile-de-France, Paris Universite
      Sorbonne Nouvelle, Paris, France; Service de radiotherapie, unite de physique
      medicale, centre Antoine-Lacassagne, Nice, France; Service universitaire de
      radiotherapie, laboratoire CRIStAL, UMR9189, centre Oscar-Lambret, faculte de
      medecine Henri-Warembourg, universite de Lille, Lille, France; Service de
      radiotherapie, Quantis Litis EA 4108, centre Henri-Becquerel, Rouen, France;
      Centre de radiotherapie et oncologie de Macon - Orlam, Macon, France; Service de 
      radiotherapie, centre hospitalier universitaire Lyon-Sud, Lyon, France; Centre de
      coordination en cancerologie, centre hospitalier universitaire de Bordeaux,
      Pessac, France; Service d'oncologie radiotherapie, centre de recherche
      Saint-Antoine UMR_S 938, Sorbonne universite, hopital Tenon, institut
      universitaire de cancerologie, AP-HP, Paris, France; Universite Paris-Est Creteil
      Val-de-Marne, Paris, France.
LA  - fre
PT  - Journal Article
TT  - Democratie sanitaire : le patient partenaire de sa prise en charge.
DEP - 20200827
PL  - France
TA  - Cancer Radiother
JT  - Cancer radiotherapie : journal de la Societe francaise de radiotherapie
      oncologique
JID - 9711272
SB  - IM
MH  - Humans
MH  - Neoplasms/*radiotherapy
MH  - *Patient Participation
MH  - *Physician-Patient Relations
MH  - *Radiation Oncology
OTO - NOTNLM
OT  - Decision partagee
OT  - Ethics
OT  - Oncologie radiotherapie
OT  - Patient partenaire
OT  - Patient partnership
OT  - Radiation oncology
OT  - Security
OT  - Shared decision
OT  - Securite
OT  - Ethique
EDAT- 2020/08/31 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/08/31 06:00 [entrez]
AID - S1278-3218(20)30196-7 [pii]
AID - 10.1016/j.canrad.2020.06.021 [doi]
PST - ppublish
SO  - Cancer Radiother. 2020 Oct;24(6-7):736-743. doi: 10.1016/j.canrad.2020.06.021.
      Epub 2020 Aug 27.


PMID- 32861393
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 2213-3763 (Electronic)
IS  - 0019-4832 (Linking)
VI  - 72
IP  - 4
DP  - 2020 Jul - Aug
TI  - Materiovigilance Programme of India: A scheme to assure cardiovascular devices
      safety surveillance.
PG  - 316-318
LID - S0019-4832(20)30137-1 [pii]
LID - 10.1016/j.ihj.2020.06.009 [doi]
AB  - The Materiovigilance Programme of India (MvPI) has been implemented to ensure the
      safety of medical devices including cardiovascular devices (MD-CVD). This article
      describes the role of MvPI surveillance system that comprehensively collects,
      collates and analyses the adverse events associated with MD-CVD and also its
      supplementing role to the Central Drugs Standard Control Organization for taking 
      regulatory decision to reduce the health burden on account of adverse events due 
      to medical devices to the patients based on the evidence based data. This article
      is expected to stimulate ethical reporting of adverse events due to MD-CVD at
      MvPI.
CI  - Copyright (c) 2020 Cardiological Society of India. Published by Elsevier B.V. All
      rights reserved.
FAU - Kalaiselvan, V
AU  - Kalaiselvan V
AD  - Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government 
      of India, Sector 23, Raj Nagar, Ghaziabad, UP, 201002, India. Electronic address:
      vivekarts@gmail.com.
FAU - Tripathi, Santanu Kumar
AU  - Tripathi SK
AD  - Department of Clinical and Experimental Pharmacology, School of Tropical
      Medicine, Kolkata, 700073, India.
FAU - Prakash, Jai
AU  - Prakash J
AD  - Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government 
      of India, Sector 23, Raj Nagar, Ghaziabad, UP, 201002, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200701
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
SB  - IM
MH  - Cardiovascular Diseases/*therapy
MH  - Device Approval/*standards
MH  - Equipment and Supplies/*standards
MH  - Humans
MH  - India
MH  - *Program Evaluation
MH  - Quality Control
PMC - PMC7474122
OTO - NOTNLM
OT  - Adverse events
OT  - Cardiovascular devices
OT  - Materiovigilance
OT  - Medical devices
COIS- Conflict of interest There is no conflict of interest.
EDAT- 2020/08/31 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/08/31 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - S0019-4832(20)30137-1 [pii]
AID - 10.1016/j.ihj.2020.06.009 [doi]
PST - ppublish
SO  - Indian Heart J. 2020 Jul - Aug;72(4):316-318. doi: 10.1016/j.ihj.2020.06.009.
      Epub 2020 Jul 1.


PMID- 32861338
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20210116
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 95
IP  - 9
DP  - 2020 Sep
TI  - Developing an Ethics Framework for Allocating Remdesivir in the COVID-19
      Pandemic.
PG  - 1946-1954
LID - S0025-6196(20)30620-0 [pii]
LID - 10.1016/j.mayocp.2020.06.016 [doi]
AB  - On May 1, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use
      Authorization (EUA) to allow use of the antiviral drug remdesivir to treat
      patients with severe coronavirus disease-2019 (COVID-19). Remdesivir is an
      investigational drug studied in clinical trials for COVID-19 and is available to 
      children and pregnant women through compassionate-use access but is not yet FDA
      approved. In early May, the US Department of Health and Human Services began to
      distribute remdesivir, donated by Gilead Sciences, Inc., to hospitals and state
      health departments for emergency use; multiple shipments have since been
      distributed. This process has raised questions of how remdesivir should be
      allocated. The Minnesota Department of Health has collaborated with the Minnesota
      COVID Ethics Collaborative and multiple clinical experts to issue an Ethical
      Framework for May 2020 Allocation of Remdesivir in the COVID-19 Pandemic. The
      framework builds on extensive ethical guidance developed for public health
      emergencies in Minnesota before the COVID-19 crisis. The Minnesota remdesivir
      allocation framework specifies an ethical approach to distributing the drug to
      facilities across the state and then among COVID-19 patients within each
      facility. This article describes the process of developing the framework and
      adjustments in the framework over time with emergence of new data, analyzes key
      issues addressed, and suggests next steps. Sharing this framework and the
      development process can encourage transparency and may be useful to other states 
      formulating and refining their approach to remdesivir EUA allocation.
CI  - Copyright (c) 2020 Mayo Foundation for Medical Education and Research. Published 
      by Elsevier Inc. All rights reserved.
FAU - Lim, Sarah
AU  - Lim S
AD  - Minnesota Department of Health, St. Paul, MN.
FAU - DeBruin, Debra A
AU  - DeBruin DA
AD  - University of Minnesota, Minneapolis.
FAU - Leider, Jonathon P
AU  - Leider JP
AD  - University of Minnesota, Minneapolis.
FAU - Sederstrom, Nneka
AU  - Sederstrom N
AD  - Children's Minnesota, Minneapolis, MN.
FAU - Lynfield, Ruth
AU  - Lynfield R
AD  - Minnesota Department of Health, St. Paul, MN.
FAU - Baker, Jason V
AU  - Baker JV
AD  - Hennepin Healthcare, Minneapolis, MN.
FAU - Kline, Susan
AU  - Kline S
AD  - University of Minnesota, Minneapolis.
FAU - Kesler, Sarah
AU  - Kesler S
AD  - University of Minnesota, Minneapolis.
FAU - Rizza, Stacey
AU  - Rizza S
AD  - Mayo Clinic, Rochester, MN.
FAU - Wu, Joel
AU  - Wu J
AD  - University of Minnesota, Minneapolis.
FAU - Sharp, Richard R
AU  - Sharp RR
AD  - Mayo Clinic, Rochester, MN.
FAU - Wolf, Susan M
AU  - Wolf SM
AD  - University of Minnesota, Minneapolis. Electronic address: swolf@umn.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200620
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Antiviral Agents)
RN  - 0 (Drugs, Investigational)
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adenosine Monophosphate/*analogs & derivatives/supply & distribution
MH  - Alanine/*analogs & derivatives/supply & distribution
MH  - Antiviral Agents/*supply & distribution
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy
MH  - Drugs, Investigational/supply & distribution
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Minnesota
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - SARS-CoV-2
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC7305893
EDAT- 2020/08/31 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/31 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - S0025-6196(20)30620-0 [pii]
AID - 10.1016/j.mayocp.2020.06.016 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2020 Sep;95(9):1946-1954. doi: 10.1016/j.mayocp.2020.06.016. Epub
      2020 Jun 20.


PMID- 32860812
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1773-0619 (Electronic)
IS  - 0028-3770 (Linking)
VI  - 66
IP  - 5
DP  - 2020 Nov
TI  - Diffuse infiltrative pontine glioma biopsy in children with neuronavigation,
      frameless procedure: A single center experience of 10 cases.
PG  - 345-348
LID - S0028-3770(20)30391-X [pii]
LID - 10.1016/j.neuchi.2020.05.007 [doi]
AB  - INTRODUCTION: This study presented pediatric DIPG 's biopsy with frameless
      Neuronavigation. PATIENTS AND METHODS: We report our experience about 10 patients
      who had Diffuse Intrinsic Pontine Glioma between 2014 and 2018. All patients were
      biopsied with BrainLab Varioguide Neuronavigation(R). We always used fusion
      between specific CT Scan and MRI to selected target, made planning and biopsies. 
      All patients were included in BIOMEDE after scientific and ethic discussions. We 
      always selected a trans-cerebellar trajectory and made same procedure (lot of
      biopsies at one level). All patients have MRI at J1 to verify site of biopsy and 
      to eliminate complication. RESULTS: The average age was 8.1 years. Symptoms were 
      common with principally headaches and nystagmus. All biopsies were contributive
      for histopathological diagnosis and establish molecular profile for molecular
      study. We have no definitive morbidity and procedure duration was 93minutes in
      average. All MRI didn't showed intracranial complication after procedure and
      showed great precision of biopsy compared with the selected target. DISCUSSION:
      We reviewed the literature and compare our results with series of DIPG biopsies
      using stereotactic frame or robotic assisted frameless. It was a safe, accuracy
      and easiness procedure. We always have histopathological and molecular result to 
      proceed next step of treatment. This modality is an alternative possibility to
      biopsy very young patients with low morbidity.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Joud, A
AU  - Joud A
AD  - Department of Pediatric Neurosurgery, Nancy University Hospital, Hopital
      d'Enfants, University of Lorraine, rue du Morvan, 54511 Vandoeuvre-les-Nancy
      cedex, France. Electronic address: a.joud@chru-nancy.fr.
FAU - Stella, I
AU  - Stella I
AD  - Department of Pediatric Neurosurgery, Nancy University Hospital, Hopital
      d'Enfants, University of Lorraine, rue du Morvan, 54511 Vandoeuvre-les-Nancy
      cedex, France.
FAU - Klein, O
AU  - Klein O
AD  - Department of Pediatric Neurosurgery, Nancy University Hospital, Hopital
      d'Enfants, University of Lorraine, rue du Morvan, 54511 Vandoeuvre-les-Nancy
      cedex, France.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - France
TA  - Neurochirurgie
JT  - Neuro-Chirurgie
JID - 0401057
SB  - IM
MH  - Adolescent
MH  - Biopsy/*methods
MH  - Brain Stem Neoplasms/diagnostic imaging/genetics/*pathology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Glioma/diagnostic imaging/genetics/*pathology
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Neuronavigation/*methods
MH  - Pathology, Molecular
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Biopsy
OT  - Brainstem lesion
OT  - DIPG (Diffuse Infiltrative Pontine Gliomas)
OT  - Neuronavigation
EDAT- 2020/08/30 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
PHST- 2020/08/30 06:00 [entrez]
AID - S0028-3770(20)30391-X [pii]
AID - 10.1016/j.neuchi.2020.05.007 [doi]
PST - ppublish
SO  - Neurochirurgie. 2020 Nov;66(5):345-348. doi: 10.1016/j.neuchi.2020.05.007. Epub
      2020 Aug 27.


PMID- 32859874
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1469-5804 (Electronic)
IS  - 1357-6283 (Linking)
VI  - 33
IP  - 1
DP  - 2020 Jan-Apr
TI  - Is emotional intelligence related to objective parameters of academic performance
      in medical, dental, and nursing students: A systematic review.
PG  - 8-12
LID - 10.4103/efh.EfH_208_17 [doi]
AB  - Background: Current research in medical education is increasingly exploring the
      relevance of emotional intelligence (EI) in the successful performance of
      health-care people. As assessments of core domains are markers of actual
      performance of the student when he or she is not observed, this systematic review
      was aimed to answer the question "what is the influence of EI on objective
      parameters of academic performance in undergraduate medical, dental, and nursing 
      students aged 18-30 years?" Methods: Databases were systematically searched for
      empirical studies which measured EI of medical, nursing, or dental undergraduate 
      students and compared it with academic performance during graduation years from
      January 1, 2000, to August 30, 2016. Quality appraisal and data abstraction was
      done by two independent authors. Results: Six hundred and twenty-three articles
      were retrieved from systematic search. Of these, 25 articles were selected.
      Quality appraisal further led to exclusion of two studies which did not meet
      ethical criterion. Medical undergraduates were included in 12, dental in 4, and
      nursing in 7 studies. Four studies examined the relationship of EI with clinical 
      skills, 8 with communication skills, and 18 with overall academic performance.
      Discussion: The findings of review show that EI has a greater role in academic
      success of clinical year medical and dental students. Although the review has
      addressed different rungs of the health-care profession separately, it preludes
      that better EI skills of health-care team will have a holistic impact on
      health-care improvement.
FAU - Singh, Nikhilesh
AU  - Singh N
AD  - Department of Physiology, Mahatma Gandhi Medical College and Research Institute, 
      Sri Balaji Vidyapeeth, Pondicherry, India.
FAU - Kulkarni, Sweta
AU  - Kulkarni S
AD  - Department of Biochemistry, Mahatma Gandhi Medical College and Research
      Institute, Sri Balaji Vidyapeeth, Pondicherry, India.
FAU - Gupta, Richa
AU  - Gupta R
AD  - Department of Physiology, Mahatma Gandhi Medical College and Research Institute, 
      Sri Balaji Vidyapeeth, Pondicherry, India.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - India
TA  - Educ Health (Abingdon)
JT  - Education for health (Abingdon, England)
JID - 9607101
SB  - IM
MH  - *Academic Performance
MH  - Adult
MH  - Clinical Competence
MH  - Communication
MH  - *Emotional Intelligence
MH  - Female
MH  - Health Occupations/education
MH  - Humans
MH  - Male
MH  - Students, Health Occupations/*psychology
OTO - NOTNLM
OT  - *Dental
OT  - *emotional intelligence
OT  - *interprofessional education
OT  - *medical
OT  - *nursing
OT  - *systematic review
COIS- None
EDAT- 2020/08/30 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - EducHealth_2020_33_1_8_293332 [pii]
AID - 10.4103/efh.EfH_208_17 [doi]
PST - ppublish
SO  - Educ Health (Abingdon). 2020 Jan-Apr;33(1):8-12. doi: 10.4103/efh.EfH_208_17.


PMID- 32859666
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210120
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 27
TI  - Protocol for the process evaluation of the Promoting Activity, Independence and
      Stability in Early Dementia (PrAISED), following changes required by the COVID-19
      pandemic.
PG  - e039305
LID - 10.1136/bmjopen-2020-039305 [doi]
AB  - INTRODUCTION: The Promoting Activity, Independence and Stability in Early
      Dementia (PrAISED) randomised controlled trial (RCT) is evaluating a home-based, 
      face-to-face, individually tailored, activity and exercise programme for people
      living with dementia. Social distancing requirements following the COVID-19
      pandemic necessitated rapid changes to intervention delivery. METHODS AND
      ANALYSIS: A mixed-methods process evaluation will investigate how the changes
      were implemented and the impact that these have on participants' experience. An
      implementation study will investigate how the intervention was delivered during
      the pandemic. A study on the mechanisms of impact and context will investigate
      how these changes were experienced by the PrAISED participants, their carers and 
      the therapists delivering the intervention. The study will commence in May 2020. 
      ETHICS AND DISSEMINATION: The PrAISED RCT and process evaluation have received
      ethical approval number 18/YH/0059. The PrAISED process evaluation will enable us
      to understand how distancing and isolation affected participants, their activity 
      and exercise routines and whether the therapy programme could be continued with
      remote support. This will be valuable both in explaining trial results and also
      contribute to understanding and designing new ways of delivering home-based
      services and rehabilitation interventions for people with dementia and their
      carers. TRIAL REGISTRATION NUMBER: ISRCTN15320670; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Di Lorito, Claudio
AU  - Di Lorito C
AUID- ORCID: 0000-0002-8953-0117
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK claudio.dilorito@nottingham.ac.uk.
FAU - Bosco, Alessandro
AU  - Bosco A
AD  - Division of Psychiatry and Applied Psychology, University of Nottingham,
      Nottingham, UK.
FAU - Goldberg, Sarah E
AU  - Goldberg SE
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK.
FAU - Nair, Roshan
AU  - Nair R
AD  - Division of Psychiatry and Applied Psychology, University of Nottingham,
      Nottingham, UK.
FAU - O'Brien, Rebecca
AU  - O'Brien R
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - Howe, Louise
AU  - Howe L
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - van der Wardt, Veronika
AU  - van der Wardt V
AD  - Philipps-Universitat Marburg, Marburg, Hessen, Germany.
FAU - Pollock, Kristian
AU  - Pollock K
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK.
FAU - Booth, Vicky
AU  - Booth V
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - Logan, Pip
AU  - Logan P
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - Godfrey, Maureen
AU  - Godfrey M
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - Dunlop, Marianne
AU  - Dunlop M
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - Horne, Jane
AU  - Horne J
AD  - Division of Rehabilitation, Ageing and Wellbeing, University of Nottingham,
      Nottingham, UK.
FAU - Harwood, Rowan H
AU  - Harwood RH
AD  - School of Health Sciences, University of Nottingham, Nottingham, UK.
LA  - eng
SI  - ISRCTN/ISRCTN15320670
GR  - RP-PG-0614-20007/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200827
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - Betacoronavirus
MH  - COVID-19
MH  - Caregivers
MH  - Cognitive Dysfunction/*therapy
MH  - *Coronavirus Infections/epidemiology/virology
MH  - Dementia/*therapy
MH  - *Exercise
MH  - Exercise Therapy
MH  - Female
MH  - *Health Promotion
MH  - Home Care Services
MH  - Humans
MH  - *Independent Living
MH  - Male
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/virology
MH  - *Process Assessment, Health Care
MH  - Research Design
MH  - SARS-CoV-2
MH  - Social Isolation
PMC - PMC7453764
OTO - NOTNLM
OT  - *dementia
OT  - *geriatric medicine
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/30 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - bmjopen-2020-039305 [pii]
AID - 10.1136/bmjopen-2020-039305 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 27;10(8):e039305. doi: 10.1136/bmjopen-2020-039305.


PMID- 32859663
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 27
TI  - Adaptive design methods in dialysis clinical trials: a systematic review
      protocol.
PG  - e036755
LID - 10.1136/bmjopen-2019-036755 [doi]
AB  - INTRODUCTION: Adaptive design methods are a potential solution to improve
      efficiency of clinical trials but their uptake in dialysis is unknown. We aim to 
      investigate the use of adaptive design methods in dialysis clinical trials and to
      cultivate further adoption of adaptive design methods by the nephrology
      community. METHODS AND ANALYSIS: We will adhere to the Preferred Reporting Items 
      for Systematic Review and Meta-Analysis Protocols guidelines and the Cochrane
      Collaboration Handbook. We will perform a literature search through MEDLINE
      (PubMed), EMBASE and CENTRAL, a detailed data extraction of trial characteristics
      and a narrative synthesis of the data. There will be no language restrictions. We
      will estimate the percentage of adaptive clinical trials per year in dialysis.
      Subgroup analysis will be performed by dialysis modality, funder and geographical
      location. ETHICS AND DISSEMINATION: Ethical approval will not be required for
      this study as data will be obtained from publicly available clinical trials. We
      will disseminate our results in a peer-reviewed publication. PROSPERO
      REGISTRATION NUMBER.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Judge, Conor
AU  - Judge C
AUID- ORCID: 0000-0001-9473-2920
AD  - HRB-Clinical Research Facility, National University of Ireland, Galway, Co.
      Galway, Ireland conor.judge@nuigalway.ie.
AD  - Translational Medical Device Lab, National University of Ireland Galway, Galway, 
      Co. Galway, Ireland.
AD  - Wellcome Trust - HRB, Irish Clinical Academic Training, National University of
      Ireland Galway, Galway, Ireland.
AD  - Deparrtment of Nephrology, Galway University Hospital, Galway, Ireland.
FAU - Murphy, Robert P
AU  - Murphy RP
AUID- ORCID: 0000-0001-5446-4175
AD  - HRB-Clinical Research Facility, National University of Ireland, Galway, Co.
      Galway, Ireland.
FAU - Cormican, Sarah
AU  - Cormican S
AD  - Wellcome Trust - HRB, Irish Clinical Academic Training, National University of
      Ireland Galway, Galway, Ireland.
AD  - Deparrtment of Nephrology, Galway University Hospital, Galway, Ireland.
FAU - Smyth, Andrew
AU  - Smyth A
AD  - HRB-Clinical Research Facility, National University of Ireland, Galway, Co.
      Galway, Ireland.
AD  - Deparrtment of Nephrology, Galway University Hospital, Galway, Ireland.
FAU - O'Halloran, Martin
AU  - O'Halloran M
AD  - Translational Medical Device Lab, National University of Ireland Galway, Galway, 
      Co. Galway, Ireland.
FAU - O'Donnell, Martin
AU  - O'Donnell M
AD  - HRB-Clinical Research Facility, National University of Ireland, Galway, Co.
      Galway, Ireland.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200827
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Renal Dialysis
MH  - *Research Design
PMC - PMC7454175
OTO - NOTNLM
OT  - *clinical trials
OT  - *dialysis
OT  - *end stage renal failure
COIS- Competing interests: None declared.
EDAT- 2020/08/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036755 [pii]
AID - 10.1136/bmjopen-2019-036755 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 27;10(8):e036755. doi: 10.1136/bmjopen-2019-036755.


PMID- 32859661
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 27
TI  - Feasibility and acceptability of a dietary intervention study to reduce salt
      intake and increase high-nitrate vegetable consumption among middle-aged and
      older Malaysian adults with elevated blood pressure: a study protocol.
PG  - e035453
LID - 10.1136/bmjopen-2019-035453 [doi]
AB  - INTRODUCTION: Global population ageing is one of the key factors linked to the
      projected rise of dementia incidence. Hence, there is a clear need to identify
      strategies to overcome this expected health burden and have a meaningful impact
      on populations' health worldwide. Current evidence supports the role of
      modifiable dietary and lifestyle risk factors in reducing the risk of dementia.
      In South-East Asia, changes in eating and lifestyle patterns under the influence 
      of westernised habits have resulted in significant increases in the prevalence of
      metabolic, cardiovascular and neurodegenerative non-communicable diseases (NCDs).
      Low vegetable consumption and high sodium intake have been identified as key
      contributors to the increased prevalence of NCDs in these countries. Therefore,
      nutritional and lifestyle strategies targeting these dietary risk factors are
      warranted. The overall objective of this randomised feasibility trial is to
      demonstrate the acceptability of a dietary intervention to increase the
      consumption of high-nitrate green leafy vegetables and reduce salt intake over 6 
      months among Malaysian adults with raised blood pressure. METHODS AND ANALYSIS:
      Primary outcomes focus on feasibility measures of recruitment, retention,
      implementation and acceptability of the intervention. Secondary outcomes will
      include blood pressure, cognitive function, body composition and physical
      function (including muscle strength and gait speed). Adherence to the dietary
      intervention will be assessed through collection of biological samples, 24-hour
      recall and Food Frequency Questionnaire. A subgroup of participants will also
      complete postintervention focus groups to further explore the feasibility
      considerations of executing a larger trial, the ability of these individuals to
      make dietary changes and the barriers and facilitators associated with
      implementing these changes. ETHICS AND DISSEMINATION: Ethical approval has been
      obtained from Monash University Human Research Ethics Committee and Medical
      Research and Ethics Committee of Malaysia. Results of the study will be
      disseminated via peer-reviewed publications and presentations at national and
      international conferences.ISRCTN47562685; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - McGrattan, Andrea
AU  - McGrattan A
AUID- ORCID: 0000-0003-1521-213X
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK Andrea.McGrattan@Newcastle.ac.uk.
FAU - Mohan, Devi
AU  - Mohan D
AUID- ORCID: 0000-0002-0898-2729
AD  - Global Public Health. Jeffrey Cheah School of Medicine and Health Sciences,
      Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia.
AD  - South East Asia Community Observatory (SEACO), Monash University Malaysia,
      Segamat, Johor, Malaysia.
FAU - Chua, Pei Wei
AU  - Chua PW
AD  - Global Public Health. Jeffrey Cheah School of Medicine and Health Sciences,
      Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia.
AD  - South East Asia Community Observatory (SEACO), Monash University Malaysia,
      Segamat, Johor, Malaysia.
FAU - Mat Hussin, Azizah
AU  - Mat Hussin A
AD  - Kampus Cawangan Institute of Medical Science Technology, Universiti Kuala Lumpur,
      Kuala Lumpur, Wilayah Persekutuan, Malaysia.
FAU - Soh, Yee Chang
AU  - Soh YC
AD  - Global Public Health. Jeffrey Cheah School of Medicine and Health Sciences,
      Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia.
AD  - South East Asia Community Observatory (SEACO), Monash University Malaysia,
      Segamat, Johor, Malaysia.
FAU - Alawad, Mawada
AU  - Alawad M
AD  - Global Public Health. Jeffrey Cheah School of Medicine and Health Sciences,
      Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia.
AD  - South East Asia Community Observatory (SEACO), Monash University Malaysia,
      Segamat, Johor, Malaysia.
FAU - Bin Kassim, Zaid
AU  - Bin Kassim Z
AD  - District Health Office, Pejabat Kesihatan Daerah (PKD) Segamat, Segamat, Johor,
      Malaysia.
FAU - Bin Mohd Ghazali, Ahmad Nizal
AU  - Bin Mohd Ghazali AN
AD  - District Health Office, Pejabat Kesihatan Daerah (PKD) Segamat, Segamat, Johor,
      Malaysia.
FAU - Stephan, Blossom
AU  - Stephan B
AD  - School of Medicine, University of Nottingham, Nottingham, UK.
FAU - Allotey, Pascale
AU  - Allotey P
AD  - Global Public Health. Jeffrey Cheah School of Medicine and Health Sciences,
      Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia.
FAU - Reidpath, Daniel D
AU  - Reidpath DD
AD  - South East Asia Community Observatory (SEACO), Monash University Malaysia,
      Segamat, Johor, Malaysia.
AD  - International Centre for Diarrhoeal Disease Research, ICDDR,B, Dhaka, Bangladesh.
FAU - Robinson, Louise
AU  - Robinson L
AUID- ORCID: 0000-0003-0209-2503
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Siervo, Mario
AU  - Siervo M
AUID- ORCID: 0000-0001-5515-0944
AD  - School of Life Sciences, University of Nottingham, Nottingham, UK.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200827
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Nitrates)
RN  - 0 (Sodium Chloride, Dietary)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Pressure
MH  - Feasibility Studies
MH  - Humans
MH  - Malaysia/epidemiology
MH  - Middle Aged
MH  - Nitrates
MH  - *Sodium Chloride, Dietary
MH  - *Vegetables
PMC - PMC7454174
OTO - NOTNLM
OT  - *dementia
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: LR reports grants from National Institute of Health Research
      Senior Investigator award during the conduct of the study; no other relationships
      or activities that could appear to have influenced the submitted work.
EDAT- 2020/08/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035453 [pii]
AID - 10.1136/bmjopen-2019-035453 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 27;10(8):e035453. doi: 10.1136/bmjopen-2019-035453.


PMID- 32859245
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 28
TI  - Reporting of key methodological and ethical aspects of cluster trials in
      hemodialysis require improvement: a systematic review.
PG  - 752
LID - 10.1186/s13063-020-04657-9 [doi]
AB  - BACKGROUND: The hemodialysis setting is suitable for trials that use cluster
      randomization, where intact groups of individuals are randomized. However,
      cluster randomized trials (CRTs) are complicated in their design, analysis, and
      reporting and can pose ethical challenges. We reviewed CRTs in the hemodialysis
      setting with respect to reporting of key methodological and ethical issues.
      METHODS: We conducted a systematic review of CRTs in the hemodialysis setting,
      published in English, between 2000 and 2019, and indexed in MEDLINE or Embase.
      Two reviewers extracted data, and study results were summarized using descriptive
      statistics. RESULTS: We identified 26 completed CRTs and five study protocols of 
      CRTs. These studies randomized hemodialysis centers (n = 17, 55%), hemodialysis
      shifts (n = 12, 39%), healthcare providers (n = 1, 3%), and nephrology units (n =
      1, 3%). Trials included a median of 28 clusters with a median cluster size of 20 
      patients. Justification for using a clustered design was provided by 15 trials
      (48%). Methods that accounted for clustering were used during sample size
      calculation in 14 (45%), during analyses in 22 (71%), and during both sample size
      calculation and analyses in 13 trials (42%). Among all CRTs, 26 (84%) reported
      receiving research ethics committee approval; patient consent was reported in 22 
      trials: 10 (32%) reported the method of consent for trial participation and 12
      (39%) reported no details about how consent was obtained or its purpose. Four
      trials (13%) reported receiving waivers of consent, and the remaining 5 (16%)
      provided no or unclear information about the consent process. CONCLUSION: There
      is an opportunity to improve the conduct and reporting of essential
      methodological and ethical issues in future CRTs in hemodialysis. REVIEW
      REGISTRATION: We conducted this systematic review using a pre-specified protocol 
      that was not registered.
FAU - Al-Jaishi, Ahmed A
AU  - Al-Jaishi AA
AUID- ORCID: http://orcid.org/0000-0003-0376-2214
AD  - Lawson Health Research Institute, London, ON, Canada. Ahmed.AlJaishi@lhsc.on.ca.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, ON, Canada. Ahmed.AlJaishi@lhsc.on.ca.
AD  - ICES, Toronto, Canada. Ahmed.AlJaishi@lhsc.on.ca.
FAU - Carroll, Kelly
AU  - Carroll K
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON,
      Canada.
FAU - Goldstein, Cory E
AU  - Goldstein CE
AD  - Department of Philosophy, Western University, London, ON, Canada.
FAU - Dixon, Stephanie N
AU  - Dixon SN
AD  - Lawson Health Research Institute, London, ON, Canada.
AD  - ICES, Toronto, Canada.
AD  - Department Medicine, Epidemiology and Biostatistics, Western University, London, 
      ON, Canada.
AD  - Department of Mathematics and Statistics, University of Guelph, Guelph, ON,
      Canada.
FAU - Garg, Amit X
AU  - Garg AX
AD  - Lawson Health Research Institute, London, ON, Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, ON, Canada.
AD  - ICES, Toronto, Canada.
AD  - Department Medicine, Epidemiology and Biostatistics, Western University, London, 
      ON, Canada.
FAU - Nicholls, Stuart G
AU  - Nicholls SG
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON,
      Canada.
FAU - Grimshaw, Jeremy M
AU  - Grimshaw JM
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON,
      Canada.
AD  - Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
FAU - Weijer, Charles
AU  - Weijer C
AD  - Department of Philosophy, Western University, London, ON, Canada.
AD  - Department Medicine, Epidemiology and Biostatistics, Western University, London, 
      ON, Canada.
FAU - Brehaut, Jamie
AU  - Brehaut J
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON,
      Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, ON, Canada.
FAU - Devereaux, P J
AU  - Devereaux PJ
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, ON, Canada.
FAU - Taljaard, Monica
AU  - Taljaard M
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON,
      Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
LA  - eng
GR  - MYG-151209/CAPMC/ CIHR/Canada
GR  - G-16-00012589/Heart and Stroke Foundation of Canada
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20200828
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - *Abstracting and Indexing
MH  - Cluster Analysis
MH  - Humans
MH  - Informed Consent
MH  - Renal Dialysis/adverse effects
MH  - *Research Design
PMC - PMC7456003
OTO - NOTNLM
OT  - Cluster randomized controlled trial
OT  - Ethics
OT  - Hemodialysis
OT  - Informed consent
OT  - Systematic review
EDAT- 2020/08/30 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/03/28 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13063-020-04657-9 [doi]
AID - 10.1186/s13063-020-04657-9 [pii]
PST - epublish
SO  - Trials. 2020 Aug 28;21(1):752. doi: 10.1186/s13063-020-04657-9.


PMID- 32859235
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Aug 28
TI  - Rifampin combination therapy in staphylococcal prosthetic joint infections: a
      randomized controlled trial.
PG  - 365
LID - 10.1186/s13018-020-01877-2 [doi]
AB  - BACKGROUND: The evidence supporting rifampin combination therapy in prosthetic
      joint infections (PJI) is limited due to the lack of controlled studies. The aim 
      of this study is to evaluate the effect of adding rifampin to conventional
      antimicrobial therapy in early staphylococcal PJIs treated with debridement and
      retention of the implant (DAIR). METHODS: In this multicenter randomized
      controlled trial, 99 patients with PJI after hip and knee arthroplasties were
      enrolled. They were randomly assigned to receive rifampin or not in addition to
      standard antimicrobial treatment with cloxacillin or vancomycin in case of
      methicillin resistance. The primary endpoint was no signs of infection after 2
      years of follow-up. RESULTS: Forty-eight patients were included in the final
      analyses. There were no differences in patient characteristics or comorbidities
      between the two groups. There was no significant difference in remission rate
      between the rifampin combination group (17 of 23 (74%)) and the monotherapy group
      (18 of 25 (72%), relative risk 1.03, 95% confidence interval 0.73 to 1.45, p =
      0.88). CONCLUSION: This trial has not proven a statistically significant
      advantage by adding rifampin to standard antibiotic treatment in acute
      staphylococcal PJIs. TRIAL REGISTRATION: The Regional Ethics Committee and the
      Norwegian Medicines Agency approved the study (EudraCT 2005-005494-29), and the
      study was registered at ClinicalTrials.gov at Jan 18, 2007 ( NCT00423982 ).
FAU - Karlsen, Oystein Espeland
AU  - Karlsen OE
AUID- ORCID: http://orcid.org/0000-0002-9241-5371
AD  - Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
      oekarl00@hotmail.com.
AD  - Department of Orthopaedic Surgery, Betanien Hospital, Skien, Norway.
      oekarl00@hotmail.com.
FAU - Borgen, Pal
AU  - Borgen P
AD  - Department of Orthopaedic Surgery, Martina Hansen Hospital, Baerum, Norway.
FAU - Bragnes, Bjorn
AU  - Bragnes B
AD  - Department of Orthopaedic Surgery, Vestre Viken HF, Drammen, Norway.
FAU - Figved, Wender
AU  - Figved W
AD  - Department of Orthopaedic Surgery, Baerum Hospital, Baerum, Norway.
FAU - Grogaard, Bjarne
AU  - Grogaard B
AD  - Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
FAU - Rydinge, Jonas
AU  - Rydinge J
AD  - Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
FAU - Sandberg, Lars
AU  - Sandberg L
AD  - Department of Orthopaedic Surgery, Sykehuset Innlandet HF, Lillehammer, Norway.
FAU - Snorrason, Finnur
AU  - Snorrason F
AD  - Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
FAU - Wangen, Helge
AU  - Wangen H
AD  - Department of Orthopaedic Surgery, Sykehuset Innlandet HF, Elverum, Norway.
FAU - Witsoe, Eivind
AU  - Witsoe E
AD  - Department of Orthopaedic Surgery, St. Olavs Hospital, Trondheim, Norway.
FAU - Westberg, Marianne
AU  - Westberg M
AD  - Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT00423982
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200828
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
RN  - 0 (Anti-Bacterial Agents)
RN  - 6Q205EH1VU (Vancomycin)
RN  - O6X5QGC2VB (Cloxacillin)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Cloxacillin/administration & dosage
MH  - Debridement
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prosthesis-Related Infections/*drug therapy
MH  - Rifampin/*administration & dosage
MH  - Staphylococcal Infections/*drug therapy
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vancomycin/administration & dosage
PMC - PMC7455995
OTO - NOTNLM
OT  - Prosthetic joint infection
OT  - Rifampin
OT  - Staphylococci
OT  - Surgery
EDAT- 2020/08/30 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.1186/s13018-020-01877-2 [doi]
AID - 10.1186/s13018-020-01877-2 [pii]
PST - epublish
SO  - J Orthop Surg Res. 2020 Aug 28;15(1):365. doi: 10.1186/s13018-020-01877-2.


PMID- 32859179
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 28
TI  - A qualitative investigation of lived experiences of long-term health condition
      management with people who are food insecure.
PG  - 1309
LID - 10.1186/s12889-020-09299-9 [doi]
AB  - BACKGROUND: As more people are living with one or more chronic health conditions,
      supporting patients to become activated, self-managers of their conditions has
      become a key health policy focus both in the UK and internationally. There is
      also growing evidence in the UK that those with long term health conditions have 
      an increased risk of being food insecure. While international evidence indicates 
      that food insecurity adversely affects individual's health condition management
      capability, little is known about how those so affected manage their condition(s)
      in this context. An investigation of lived experience of health condition
      management was undertaken with food insecure people living in north east
      Scotland. The study aimed to explore the challenges facing food insecure people
      in terms of, i. their self-care condition management practices, and ii.
      disclosing and discussing the experience of managing their condition with a
      health care professional, and iii. Notions of the support they might wish to
      receive from them. METHODS: Twenty in-depth interviews were conducted with
      individuals attending a food bank and food pantry in north east Scotland.
      Interview audio recordings were fully transcribed and thematically analysed.
      RESULTS: Individuals reporting multiple physical and mental health conditions,
      took part in the study. Four main themes were identified i.e.: 1. food practices,
      trade-offs and compromises, that relate to economic constraints and lack of
      choice; 2. illness experiences and food as they relate to physical and mental
      ill-health; 3. (in) visibility of participants' economic vulnerability within
      health care consultations; and 4. perceptions and expectations of the health care
      system. CONCLUSIONS: This study, the first of its kind in the UK, indicated that 
      participants' health condition management aspirations were undermined by the
      experience of food insecurity, and that their health care consultations in were, 
      on the whole, devoid of discussions of those challenges. As such, the study
      indicated practical and ethical implications for health care policy, practice and
      research associated with the risk of intervention-generated health inequalities
      that were suggested by this study. Better understanding is needed about the
      impact of household food insecurity on existing ill health, wellbeing and health 
      care use across the UK.
FAU - Douglas, Flora
AU  - Douglas F
AUID- ORCID: http://orcid.org/0000-0002-0333-6605
AD  - School of Nursing and Midwifery, Robert Gordon University, Aberdeen, Scotland.
      f.douglas3@rgu.ac.uk.
FAU - MacIver, Emma
AU  - MacIver E
AD  - School of Nursing and Midwifery, Robert Gordon University, Aberdeen, Scotland.
FAU - Yuill, Chris
AU  - Yuill C
AD  - School of Applied Social Sciences, Robert Gordon University, Aberdeen, Scotland.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chronic Disease/*therapy
MH  - Female
MH  - Food Assistance/statistics & numerical data
MH  - *Food Insecurity
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - Risk Assessment
MH  - Scotland
MH  - Self-Management/*psychology
MH  - Young Adult
PMC - PMC7456079
OTO - NOTNLM
OT  - Chronic health conditions
OT  - Food poverty
OT  - Household food insecurity
OT  - Lived experiences
OT  - Long-term health conditions
OT  - Qualitative research
OT  - Self-care
OT  - Self-management
OT  - Support for self-care
EDAT- 2020/08/30 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/08/30 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.1186/s12889-020-09299-9 [doi]
AID - 10.1186/s12889-020-09299-9 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Aug 28;20(1):1309. doi: 10.1186/s12889-020-09299-9.


PMID- 32858798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Aug 26
TI  - Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa.
      A Critical Review.
LID - E809 [pii]
LID - 10.3390/pharmaceutics12090809 [doi]
AB  - Clinical research in high-income countries is increasingly demonstrating the
      cost- effectiveness of clinical pharmacogenetic (PGx) testing in reducing the
      incidence of adverse drug reactions and improving overall patient care.
      Medications are prescribed based on an individual's genotype (pharmacogenes),
      which underlies a specific phenotypic drug response. The advent of cost-effective
      high-throughput genotyping techniques coupled with the existence of Clinical
      Pharmacogenetics Implementation Consortium (CPIC) dosing guidelines for
      pharmacogenetic "actionable variants" have increased the clinical applicability
      of PGx testing. The implementation of clinical PGx testing in sub-Saharan African
      (SSA) countries can significantly improve health care delivery, considering the
      high incidence of communicable diseases, the increasing incidence of
      non-communicable diseases, and the high degree of genetic diversity in these
      populations. However, the implementation of PGx testing has been sluggish in SSA,
      prompting this review, the aim of which is to document the existing barriers.
      These include under-resourced clinical care logistics, a paucity of
      pharmacogenetics clinical trials, scientific and technical barriers to genotyping
      pharmacogene variants, and socio-cultural as well as ethical issues regarding
      health-care stakeholders, among other barriers. Investing in large-scale SSA PGx 
      research and governance, establishing biobanks/bio-databases coupled with
      clinical electronic health systems, and encouraging the uptake of PGx knowledge
      by health-care stakeholders, will ensure the successful implementation of
      pharmacogenetically guided treatment in SSA.
FAU - B Tata, Emiliene
AU  - B Tata E
AD  - Institute for Cellular and Molecular Medicine, Department of Immunology, and
      South African Medical Research Council Extramural Unit for Stem Cell Research &
      Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South
      Africa.
FAU - A Ambele, Melvin
AU  - A Ambele M
AUID- ORCID: 0000-0002-6636-2026
AD  - Institute for Cellular and Molecular Medicine, Department of Immunology, and
      South African Medical Research Council Extramural Unit for Stem Cell Research &
      Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South
      Africa.
AD  - Department of Oral Pathology and Oral Biology, Faculty of Health Sciences, School
      of Dentistry, University of Pretoria, PO BOX 1266, Pretoria 0001, South Africa.
FAU - S Pepper, Michael
AU  - S Pepper M
AUID- ORCID: 0000-0001-6406-2380
AD  - Institute for Cellular and Molecular Medicine, Department of Immunology, and
      South African Medical Research Council Extramural Unit for Stem Cell Research &
      Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0084, South
      Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200826
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC7560181
OTO - NOTNLM
OT  - Sub-Saharan Africa
OT  - adverse drug reactions
OT  - barriers to pharmacogenetics implementation
OT  - clinical pharmacogenetics
OT  - genotype
OT  - pharmacogene
OT  - pharmacogenetic testing
OT  - phenotype
EDAT- 2020/08/30 06:00
MHDA- 2020/08/30 06:01
CRDT- 2020/08/30 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/22 00:00 [accepted]
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2020/08/30 06:01 [medline]
AID - pharmaceutics12090809 [pii]
AID - 10.3390/pharmaceutics12090809 [doi]
PST - epublish
SO  - Pharmaceutics. 2020 Aug 26;12(9). pii: pharmaceutics12090809. doi:
      10.3390/pharmaceutics12090809.


PMID- 32858703
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210130
IS  - 1538-7488 (Electronic)
IS  - 0002-936X (Linking)
VI  - 120
IP  - 9
DP  - 2020 Sep
TI  - The Moral Distress of Nurses When Patients Forgo Treatment Because of Cost.
PG  - 61-66
LID - 10.1097/01.NAJ.0000697668.09031.71 [doi]
AB  - Nursing must recognize an ethical obligation to respond on behalf of these
      patients.
FAU - Olsen, Douglas P
AU  - Olsen DP
AD  - Douglas P. Olsen and Linda J. Keilman, a gerontological NP, are associate
      professors at the Michigan State University College of Nursing in East Lansing.
      Olsen is a contributing editor of AJN. Contact author: Douglas P. Olsen,
      douglas.olsen@hc.msu.edu. The authors have disclosed no potential conflicts of
      interest, financial or otherwise. A podcast with the authors is available at
      www.ajnonline.com.
FAU - Keilman, Linda J
AU  - Keilman LJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Nurs
JT  - The American journal of nursing
JID - 0372646
SB  - IM
MH  - Burnout, Professional/psychology
MH  - Clinical Decision-Making/*ethics
MH  - Ethics, Nursing
MH  - Humans
MH  - *Morals
MH  - Nursing Diagnosis/*ethics
MH  - Nursing Staff, Hospital/*ethics
MH  - Organizational Culture
MH  - Professional Misconduct/ethics
EDAT- 2020/08/29 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1097/01.NAJ.0000697668.09031.71 [doi]
AID - 00000446-202009000-00033 [pii]
PST - ppublish
SO  - Am J Nurs. 2020 Sep;120(9):61-66. doi: 10.1097/01.NAJ.0000697668.09031.71.


PMID- 32858518
OWN - NLM
STAT- Publisher
LR  - 20200828
IS  - 1547-5646 (Electronic)
IS  - 1547-5646 (Linking)
DP  - 2020 Aug 28
TI  - Surgical management of atlantoaxial dislocation and cervical spinal cord injury
      in craniopagus twins.
PG  - 1-6
LID - 10.3171/2020.5.SPINE20537 [doi]
LID - 2020.5.SPINE20537 [pii]
AB  - A case of cervical spinal cord injury in 12-year-old angular craniopagus twins is
      presented, with a description of the planning and execution of surgical treatment
      along with subsequent clinical outcome. The injury occurred following a fall from
      a standing position, resulting in quadriparesis in one of the twins. Imaging
      revealed severe craniocervical stenosis resulting from a C1-2 dislocation, and
      T2-weighted hyperintensity of the cervical spinal cord. After custom halo
      fixation was obtained, a posterior approach was utilized to decompress and
      instrument the occiput, cervical, and upper thoracic spine with intraoperative
      reduction of the dislocation. Early neurological improvement was noted during the
      acute postoperative phase, and 27 months of follow-up demonstrated intact
      instrumentation with continued neurological improvement to near baseline. The
      complexity of managing such an injury, inclusive of the surgical, anesthetic,
      biomechanical, and ethical considerations, is described in detail.
FAU - Wemhoff, Michael P
AU  - Wemhoff MP
AD  - Departments of1Neurological Surgery and.
FAU - Swong, Kevin
AU  - Swong K
AD  - Departments of1Neurological Surgery and.
FAU - Li, Daphne
AU  - Li D
AD  - Departments of1Neurological Surgery and.
FAU - Mugve, Neal
AU  - Mugve N
AD  - 2Anesthesia, Loyola University Medical Center, Maywood, Illinois.
FAU - Gramlich, Lisa A
AU  - Gramlich LA
AD  - 2Anesthesia, Loyola University Medical Center, Maywood, Illinois.
FAU - Nockels, Russ P
AU  - Nockels RP
AD  - Departments of1Neurological Surgery and.
LA  - eng
PT  - Case Reports
DEP - 20200828
PL  - United States
TA  - J Neurosurg Spine
JT  - Journal of neurosurgery. Spine
JID - 101223545
SB  - IM
OTO - NOTNLM
OT  - AIR = acute inpatient rehabilitation
OT  - C1-2 instability
OT  - LUMC = Loyola University Medical Center
OT  - OR = operating room
OT  - PICU = pediatric intensive care unit
OT  - POD = postoperative day
OT  - SCI = spinal cord injury
OT  - atlantoaxial dislocation
OT  - cervical spinal cord injury
OT  - congenital
OT  - craniocervical deformity
OT  - craniopagus twins
OT  - halo immobilization
OT  - occipitocervicothoracic fusion
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
AID - 10.3171/2020.5.SPINE20537 [doi]
AID - 2020.5.SPINE20537 [pii]
PST - aheadofprint
SO  - J Neurosurg Spine. 2020 Aug 28:1-6. doi: 10.3171/2020.5.SPINE20537.


PMID- 32858104
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1872-8294 (Electronic)
IS  - 0169-409X (Linking)
VI  - 161-162
DP  - 2020
TI  - Microphysiological systems of the placental barrier.
PG  - 161-175
LID - S0169-409X(20)30121-6 [pii]
LID - 10.1016/j.addr.2020.08.010 [doi]
AB  - Methods to evaluate maternal-fetal transport across the placental barrier have
      generally involved clinical observations after-the-fact, ex vivo perfused
      placenta studies, or in vitro Transwell assays. Given the ethical and technical
      limitations in these approaches, and the drive to understand fetal development
      through the lens of transport-induced injury, such as with the examples of
      thalidomide and Zika Virus, efforts to develop novel approaches to study these
      phenomena have expanded in recent years. Notably, within the past 10 years,
      placental barrier models have been developed using hydrogel, bioreactor,
      organ-on-a-chip, and bioprinting approaches. In this review, we discuss the
      biology of the placental barrier and endeavors to recapitulate this barrier in
      vitro using these approaches. We also provide analysis of current limitations to 
      drug discovery in this context, and end with a future outlook.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Arumugasaamy, Navein
AU  - Arumugasaamy N
AD  - Protein, Cellular, and Structural Sciences, GlaxoSmithKline, Collegeville, PA,
      United States of America. Electronic address: navein.x.arumugasaamy@gsk.com.
FAU - Rock, Kylie D
AU  - Rock KD
AD  - Department of Pharmacology, University of Maryland School of Medicine, Baltimore,
      MD, United States of America.
FAU - Kuo, Che-Ying
AU  - Kuo CY
AD  - Materials Engineering, Formlabs, Somerville, MA, United States of America.
FAU - Bale, Tracy L
AU  - Bale TL
AD  - Department of Pharmacology, University of Maryland School of Medicine, Baltimore,
      MD, United States of America.
FAU - Fisher, John P
AU  - Fisher JP
AD  - Center for Engineering Complex Tissues, University of Maryland, College Park, MD,
      United States of America; Fischell Department of Bioengineering, University of
      Maryland, College Park, MD, United States of America. Electronic address:
      jpfisher@umd.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200826
PL  - Netherlands
TA  - Adv Drug Deliv Rev
JT  - Advanced drug delivery reviews
JID - 8710523
RN  - 0 (Hydrogels)
SB  - IM
MH  - Bioprinting/methods
MH  - Bioreactors
MH  - Extracellular Fluid/metabolism
MH  - Female
MH  - Humans
MH  - Hydrogels/chemistry
MH  - Maternal-Fetal Exchange/*physiology
MH  - *Models, Biological
MH  - Placenta/*physiology
MH  - Pregnancy
MH  - Trophoblasts/metabolism
OTO - NOTNLM
OT  - *Bioprinting
OT  - *Bioreactor
OT  - *Hydrogel
OT  - *Metabolism
OT  - *Microphysiological
OT  - *Organ on a chip
OT  - *Placental biology
OT  - *Transport
EDAT- 2020/08/29 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/06/08 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/08/24 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S0169-409X(20)30121-6 [pii]
AID - 10.1016/j.addr.2020.08.010 [doi]
PST - ppublish
SO  - Adv Drug Deliv Rev. 2020;161-162:161-175. doi: 10.1016/j.addr.2020.08.010. Epub
      2020 Aug 26.


PMID- 32858053
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211102
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Linking)
VI  - 102
IP  - 5
DP  - 2020 Nov
TI  - Attitudes and beliefs of obstetricians-gynecologists regarding Medicaid
      postpartum sterilization - A qualitative study.
PG  - 376-382
LID - S0010-7824(20)30332-2 [pii]
LID - 10.1016/j.contraception.2020.08.009 [doi]
AB  - OBJECTIVE: To explore the attitudes and beliefs of obstetrician-gynecologists in 
      the United States (US) regarding the Medicaid postpartum sterilization policy.
      STUDY DESIGN: We recruited obstetrician-gynecologists practicing in ten
      geographically diverse US states for a qualitative study using the American
      College of Obstetricians and Gynecologists directory. We conducted
      semi-structured interviews via telephone, professionally transcribed, and
      analyzed using the constant comparative method and principles of grounded theory.
      RESULTS: We interviewed thirty obstetrician-gynecologists (63.3% women, 76.7%
      non-subspecialized, and 53.3% academic setting). Participants largely described
      the consent form as unnecessary, paternalistic, an administrative hassle, a
      barrier to desired patient care, and associated with worse health outcomes. Views
      on the waiting period's utility and impact were mixed. Many participants felt the
      sterilization policy was discriminatory. However, some participants noted the
      policy's importance in terms of the historical basis, used the form as a
      counseling tool to remind patients of the permanence of sterilization, felt the
      policy prompted them to counsel regarding sterilization, and protected patients
      in contemporary medical practice. CONCLUSION: Many physicians shared concerns
      about the ethics and clinical impact of the Medicaid sterilization policy. Future
      revisions to the Medicaid sterilization policy must balance prevention of
      coercion with reduction in barriers to those desiring sterilization in order to
      maximize reproductive autonomy. IMPLICATIONS: Obstetrician-gynecologists are key 
      stakeholders of the Medicaid sterilization policy. Obstetrician-gynecologists
      largely believe that revision to the Medicaid sterilization policy is warranted
      to balance reduction of external barriers to desired care with a process that
      enforces the need for counseling regarding contraception and reviewing patient
      preference for sterilization throughout pregnancy in order to minimize regret.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Arora, Kavita Shah
AU  - Arora KS
AD  - Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland,
      OH, United States; Department of Bioethics, Case Western Reserve University,
      Cleveland, OH, United States. Electronic address: Kavita.Shah.Arora@gmail.com.
FAU - Ponsaran, Roselle
AU  - Ponsaran R
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, OH, United
      States.
FAU - Morello, Laura
AU  - Morello L
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, OH, United
      States.
FAU - Katabi, Leila
AU  - Katabi L
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, OH, United
      States.
FAU - Behmer Hansen, Rosemary T
AU  - Behmer Hansen RT
AD  - Department of Bioethics, Case Western Reserve University, Cleveland, OH, United
      States.
FAU - Zite, Nikki
AU  - Zite N
AD  - Department of Obstetrics and Gynecology, University of Tennessee, Knoxville, TN, 
      United States.
FAU - White, Kari
AU  - White K
AD  - Steve Hicks School of Social Work and Department of Sociology, University of
      Texas at Austin, Austin, TX, United States.
LA  - eng
GR  - K01 HD079563/HD/NICHD NIH HHS/United States
GR  - KL2 TR002547/TR/NCATS NIH HHS/United States
GR  - UL1 TR002548/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200825
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
SB  - IM
MH  - Attitude of Health Personnel
MH  - Female
MH  - *Gynecology
MH  - Humans
MH  - Male
MH  - Medicaid
MH  - *Obstetrics
MH  - Postpartum Period
MH  - Pregnancy
MH  - Sterilization
MH  - Sterilization, Reproductive
MH  - United States
PMC - PMC7606385
MID - NIHMS1623281
OTO - NOTNLM
OT  - *Disparities
OT  - *Medicaid
OT  - *Obstetrician-gynecologists
OT  - *Postpartum sterilization
OT  - *Reproductive justice
OT  - *Unintended pregnancies
OT  - *Women's health policy
EDAT- 2020/08/29 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/08/13 00:00 [revised]
PHST- 2020/08/14 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S0010-7824(20)30332-2 [pii]
AID - 10.1016/j.contraception.2020.08.009 [doi]
PST - ppublish
SO  - Contraception. 2020 Nov;102(5):376-382. doi: 10.1016/j.contraception.2020.08.009.
      Epub 2020 Aug 25.


PMID- 32857904
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1520-6505 (Electronic)
IS  - 1060-1538 (Linking)
VI  - 29
IP  - 6
DP  - 2020 Nov
TI  - Underestimating Kanzi? Exploring Kanzi-Oldowan comparisons in light of recent
      human stone tool replication.
PG  - 310-316
LID - 10.1002/evan.21858 [doi]
AB  - The knapping experiments with Kanzi, a bonobo, are among the most insightful
      experiments into Oldowan technology ever undertaken. Comparison of his artifacts 
      against archeological material, however, indicated he did not produce Oldowan
      lithic attributes precisely, prompting suggestions that this indicated cognitive 
      or biomechanical impediments. The literature describing the learning environment 
      provided to Kanzi, we suggest, indicates alternative factors. Based on
      consideration of wild chimpanzee learning environments, and experiments with
      modern knappers that have looked at learning environment, we contend that Kanzi's
      performance was impeded by an impoverished learning environment compared to those
      experienced by novice Oldowan knappers. Such issues are precisely those that
      might be tested via a repeat study, but in this case, practical and ethical
      constraints likely impede this possibility. We propose experiments that may be
      relevant to drawing conclusions from Kanzi's experiments that may not need to use
      non-human primates, thus bypassing some of these issues.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Eren, Metin I
AU  - Eren MI
AUID- ORCID: https://orcid.org/0000-0003-3576-6076
AD  - Department of Anthropology, Kent State University, Kent, Ohio, USA.
AD  - Department of Archaeology, Cleveland Museum of Natural History, Cleveland, Ohio, 
      USA.
FAU - Lycett, Stephen J
AU  - Lycett SJ
AD  - Department of Anthropology, University at Buffalo, New York, USA.
FAU - Tomonaga, Masaki
AU  - Tomonaga M
AD  - Primate Research Institute, Kyoto University, Inuyama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - United States
TA  - Evol Anthropol
JT  - Evolutionary anthropology
JID - 9306331
SB  - IM
MH  - Animals
MH  - Anthropology, Physical
MH  - Archaeology
MH  - Hominidae/physiology
MH  - Humans
MH  - Male
MH  - Pan paniscus/*physiology
MH  - *Technology
MH  - *Tool Use Behavior
OTO - NOTNLM
OT  - Kanzi
OT  - Oldowan
OT  - bonobo
OT  - experiments
OT  - learning
OT  - stone tools
EDAT- 2020/08/29 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/08/29 06:00
PHST- 2019/06/05 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - 10.1002/evan.21858 [doi]
PST - ppublish
SO  - Evol Anthropol. 2020 Nov;29(6):310-316. doi: 10.1002/evan.21858. Epub 2020 Aug
      28.


PMID- 32857794
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20201014
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Research data sharing in the Australian national science agency: Understanding
      the relative importance of organisational, disciplinary and domain-specific
      influences.
PG  - e0238071
LID - 10.1371/journal.pone.0238071 [doi]
AB  - This study delineates the relative importance of organisational, research
      discipline and application domain factors in influencing researchers' data
      sharing practices in Australia's national scientific and industrial research
      agency. We surveyed 354 researchers and found that the number of data deposits
      made by researchers were related to the openness of the data culture and the
      contractual inhibitors experienced by researchers. Multi-level modelling revealed
      that organisational unit membership explained 10%, disciplinary membership
      explained 6%, and domain membership explained 4% of the variance in researchers' 
      intentions to share research data. However, only the organisational measure of
      openness to data sharing explained significant unique variance in data sharing.
      Thus, whereas previous research has tended to focus on disciplinary influences on
      data sharing, this study suggests that factors operating within the organisation 
      have the most powerful influence on researchers' data sharing practices. The
      research received approval from the organisation's Human Research Ethics
      Committee (no. 014/18).
FAU - Mason, Claire M
AU  - Mason CM
AUID- ORCID: 0000-0002-4412-5142
AD  - CSIRO, Data61, Fortitude Valley, QLD, Australia.
FAU - Box, Paul J
AU  - Box PJ
AD  - CSIRO, Land & Water, Eveleigh, NSW, Australia.
FAU - Burns, Shanae M
AU  - Burns SM
AUID- ORCID: 0000-0002-4967-8037
AD  - CSIRO, Data61, Fortitude Valley, QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia
MH  - Biomedical Research/organization & administration
MH  - Cooperative Behavior
MH  - Female
MH  - Humans
MH  - *Information Dissemination
MH  - Male
MH  - Middle Aged
MH  - Research Personnel/*psychology
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7454993
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/29 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1371/journal.pone.0238071 [doi]
AID - PONE-D-20-07169 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 28;15(8):e0238071. doi: 10.1371/journal.pone.0238071.
      eCollection 2020.


PMID- 32857359
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20220304
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 80
IP  - 16
DP  - 2020 Nov
TI  - Pharmacological Approaches to Managing Violence and Aggression in Prison
      Populations: Clinical and Ethical Issues.
PG  - 1635-1647
LID - 10.1007/s40265-020-01372-2 [doi]
AB  - Violence and aggression are common problems encountered in prison, which
      frequently require clinical intervention. This increased prevalence is partially 
      attributable to the high morbidity of psychiatric and personality disorders in
      prison inmates. As prisons are non-therapeutic environments, the provision of
      clinical care becomes more complex. This article examines the general principles 
      of management of violence and aggression in prison settings, with a particular
      focus on the clinical and ethical considerations that guide pharmacological
      approaches. Use of psychotropic medication to address these problems is reserved 
      for situations where there is (i) a diagnosable psychiatric disorder, or (ii) a
      significant risk of harm to an individual without urgent intervention. Initial
      focus should be on environmental and behavioural de-escalation strategies. Clear 
      assessment for the presence of major mental illness is crucial, with appropriate 
      pharmacological interventions being targeted and time-limited. Optimising
      management of any underlying psychiatric conditions is an important preventative 
      measure. In the acute setting, rapid tranquilisation should be performed
      according to local guidelines with a focus on oral prior to parenteral
      administration. Clinicians must be mindful of capacity and consent issues amongst
      prisoners to protect patient rights and guide setting of care.
FAU - Weightman, Michael
AU  - Weightman M
AUID- ORCID: http://orcid.org/0000-0001-8451-2529
AD  - Forensic Mental Health Team, Top End Mental Health Service, Tamarind Centre, 12
      Ross Smith Avenue, Parap, Northern Territory, 0820, Australia.
AD  - Flinders University, Darwin, Northern Territory, Australia.
FAU - Kini, Ranjit
AU  - Kini R
AD  - Forensic Mental Health Team, Top End Mental Health Service, Tamarind Centre, 12
      Ross Smith Avenue, Parap, Northern Territory, 0820, Australia.
AD  - University of New South Wales, Sydney, NSW, Australia.
FAU - Parker, Robert
AU  - Parker R
AD  - Forensic Mental Health Team, Top End Mental Health Service, Tamarind Centre, 12
      Ross Smith Avenue, Parap, Northern Territory, 0820, Australia.
AD  - Flinders University, Darwin, Northern Territory, Australia.
AD  - James Cook University, Townsville, Queensland, Australia.
FAU - Das, Mrigendra
AU  - Das M
AUID- ORCID: http://orcid.org/0000-0002-2758-4195
AD  - Forensic Mental Health Team, Top End Mental Health Service, Tamarind Centre, 12
      Ross Smith Avenue, Parap, Northern Territory, 0820, Australia.
      mrigendra.das@nt.gov.au.
AD  - Flinders University, Darwin, Northern Territory, Australia.
      mrigendra.das@nt.gov.au.
AD  - University of New South Wales, Sydney, NSW, Australia. mrigendra.das@nt.gov.au.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Tranquilizing Agents)
SB  - IM
EIN - Drugs. 2022 Mar;82(4):489. PMID: 35218509
MH  - Administration, Oral
MH  - Aggression/*drug effects/psychology
MH  - Human Rights/ethics
MH  - Humans
MH  - Injections
MH  - Mental Disorders/diagnosis/*drug therapy/psychology
MH  - Prevalence
MH  - Prisoners/psychology/statistics & numerical data
MH  - Prisons/*ethics/statistics & numerical data
MH  - Tranquilizing Agents/*administration & dosage
MH  - Treatment Outcome
MH  - Violence/*prevention & control/psychology/statistics & numerical data
PMC - PMC8882096
EDAT- 2020/08/29 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - 10.1007/s40265-020-01372-2 [doi]
AID - 10.1007/s40265-020-01372-2 [pii]
PST - ppublish
SO  - Drugs. 2020 Nov;80(16):1635-1647. doi: 10.1007/s40265-020-01372-2.


PMID- 32857173
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 9
DP  - 2020 Sep
TI  - Population health monitoring: an essential public health field in motion.
PG  - 1134-1142
LID - 10.1007/s00103-020-03205-9 [doi]
AB  - BACKGROUND: Population health monitoring, the regular and institutionalized
      production and dissemination of information and knowledge about the health status
      of a population, is an essential element of public health. Nevertheless, while
      epidemiology and biostatistics, for example, are well-recognized disciplines,
      this does not (yet) apply to population health monitoring. Over the past decade, 
      however, it has matured as a distinct field of expertise. OBJECTIVES: This paper 
      presents a comprehensive model for population health monitoring and describes its
      current status as a field of expertise. It concludes with an overview of the most
      important developments that are likely to shape the health information systems
      and population health monitoring practices of the future. RESULTS AND
      CONCLUSIONS: Combining the information pyramid (an application of the
      data-information-knowledge-wisdom hierarchy), describing outputs, and a so-called
      monitoring chain, describing activities, results in a comprehensive model for
      population health monitoring. The steps of the activity chain can be viewed as a 
      stairway by which the information pyramid is climbed, reaching evidence-informed 
      policymaking at the top. Population health monitoring has several inherent
      strengths, such as its high societal relevance; its integrative, comprehensive,
      and structured approach; and the fact that it makes use of routinely collected
      data. In practice, however, secondary use of routine data is often hampered by
      technical, motivational, economic, political, ethical, and legal barriers.
      Important developments that will shape health information systems and population 
      health monitoring practices of the future include digitalization and data-driven 
      technology, citizen science, and the growing need for intersectoral approaches.
      Population health monitoring practice will need to adapt in order to counteract
      the risks and reap the benefits that these developments hold.
FAU - Verschuuren, Marieke
AU  - Verschuuren M
AD  - Independent public health consultant, Kovelaarstraat 32, 3582GP, Utrecht, The
      Netherlands. info@mariekeverschuuren.nl.
FAU - van Oers, Hans
AU  - van Oers H
AD  - National Institute of Public Health and the Environment, Bilthoven, The
      Netherlands.
AD  - Tilburg University, Tilburg, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Gesundheitsmonitoring auf Bevolkerungsebene: ein wichtiger Bereich der
      offentlichen Gesundheit in Bewegung.
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - Germany
MH  - *Population Health
MH  - *Public Health
OTO - NOTNLM
OT  - Data
OT  - Evidence-informed policymaking
OT  - Health information
OT  - Health information systems
OT  - Health reporting
EDAT- 2020/08/29 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - 10.1007/s00103-020-03205-9 [doi]
AID - 10.1007/s00103-020-03205-9 [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Sep;63(9):1134-1142. doi: 10.1007/s00103-020-03205-9.


PMID- 32857058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 28
TI  - Discriminating Metabolic Health Status in a Cohort of Nursing Students: Protocol 
      for a Cross-Sectional Study.
PG  - e21342
LID - 10.2196/21342 [doi]
AB  - BACKGROUND: Obesity is currently a worldwide health crisis. Nurses are integral
      members of the primary health care team and have an important role in managing
      obesity and administering physical activity (PA) for patients. However, research 
      shows that nurses tend to be overweight or obese, have poor metabolic health, and
      do not meet PA recommendations. This is problematic because PA is linked to both 
      physiological and psychological well-being and may also influence how nurses
      counsel their patients. Nursing students are the next generation of nurses;
      however, there is limited research examining PA (among other lifestyle factors)
      and metabolic health in nursing students. OBJECTIVE: The goal of this research is
      to examine multiple lifestyle factors (including PA, nutrition, sleep, and
      stress) and determine whether these factors are associated with metabolic health 
      in full-time undergraduate nursing students. METHODS: An estimated 320 nursing
      students (18 years of age and older) will be assessed for their metabolic health.
      Metabolic status will be determined by measuring body mass index (BMI),
      waist-to-hip ratio (WHR), body fat percentage [skinfold measures (FitSystems
      Inc)], resting blood pressure [automated oscillatory (Omron Healthcare Inc)], and
      fasting blood glucose (glucometer). Lifestyle factors will also be measured,
      including PA and sleep [the International Physical Activity Questionnaire (IPAQ) 
      and 7-day accelerometry (wGT3X-BT, Actigraph LLC)], nutrition [3-day diet log
      (Nutritionist Pro, Axxya Systems)], and stress [the Depression Anxiety Stress
      Scale, heart rate variability assessments, and salivary cortisol (ELISA, Eagle
      Biosciences)]. The association between metabolic status and PA, sleep quantity
      and quality, nutrition, and stress will be examined by linear regression
      analyses. Differences by year of study in metabolic health status, PA, sleep,
      nutrition, and stress will be examined by 1-way analyses of variance (ANOVAs). To
      determine the ability of PA, sleep, nutrition, and stress to discriminate
      prevalent overweight and obesity or poor metabolic status, logistic regression
      and receiver operating characteristic (ROC) curves will be constructed.
      Statistical analyses will be performed in Stata (version 16.1, StataCorp LLC).
      RESULTS: Based on pilot data, we believe senior nursing students will have worse 
      metabolic health (ie, higher BMI and WHR, increased body fat percentage, higher
      blood pressure, and increased fasting blood glucose) compared to first-year
      students. We hypothesize that poor PA participation, poor sleep quantity and
      quality, increased food intake, poor nutrition, and increased stress will be
      associated with worse metabolic health in full-time nursing students. The study
      received funding in February 2020. Due to the coronavirus disease 2019 (COVID-19)
      pandemic, work on this study has been delayed. We are currently completing our
      application for institutional research ethics approval. Data collection is
      projected to begin in January 2021, with data collection and analyses expected to
      be completed by May 2022. CONCLUSIONS: This study will be the first published
      research to examine the relationship between lifestyle choices and metabolic
      status in nursing students attending a Canadian institution. More importantly,
      the results of this study will support the development of an informed
      intervention that will target the identified lifestyle factors, improving the
      physiological and mental health and well-being of nursing students. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/21342.
CI  - (c)Sarah L West, Holly Bates, Jessica Watson, Ingrid K M Brenner. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      28.08.2020.
FAU - West, Sarah L
AU  - West SL
AUID- ORCID: https://orcid.org/0000-0001-9426-2922
AD  - Department of Biology, Trent University, Peterborough, ON, Canada.
AD  - Trent/Fleming School of Nursing, Trent University, Peterborough, ON, Canada.
FAU - Bates, Holly
AU  - Bates H
AUID- ORCID: https://orcid.org/0000-0002-3310-280X
AD  - Department of Biology, Trent University, Peterborough, ON, Canada.
FAU - Watson, Jessica
AU  - Watson J
AUID- ORCID: https://orcid.org/0000-0002-8124-9515
AD  - Department of Psychology, Trent University, Peterborough, ON, Canada.
FAU - Brenner, Ingrid K M
AU  - Brenner IKM
AUID- ORCID: https://orcid.org/0000-0003-3708-8205
AD  - Department of Biology, Trent University, Peterborough, ON, Canada.
AD  - Trent/Fleming School of Nursing, Trent University, Peterborough, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7486670
OTO - NOTNLM
OT  - metabolic health
OT  - nursing
OT  - nutrition
OT  - physical activity
OT  - sleep
OT  - stress
OT  - students
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
CRDT- 2020/08/29 06:00
PHST- 2020/06/16 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
AID - v9i8e21342 [pii]
AID - 10.2196/21342 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 28;9(8):e21342. doi: 10.2196/21342.


PMID- 32856808
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220531
IS  - 0869-866X (Print)
IS  - 0869-866X (Linking)
VI  - 28
IP  - Special Issue
DP  - 2020 Aug
TI  - [Professional training of nurses for medical organizations in the capital:
      problems and solutions].
PG  - 680-686
LID - 10.32687/0869-866X-2020-28-s1-680-686 [doi]
AB  - The current stage of development of health systems is characterized by an
      increasing role of specialists with secondary medical and higher (nursing)
      education, which imposes additional requirements on their medical, pedagogical,
      psychological and technical knowledge and skills. The article presents the
      results of a study implemented in 2019 on the development of medical personnel in
      the capital's healthcare system. One of the research methods was an expert survey
      in the form of a series of in-depth structured interviews with the leadership of 
      medical colleges, universities and institutions of additional professional
      education (N = 15), the scenario of which included blocks of questions regarding 
      the main determinants of the quality of training of nursing staff and bachelors
      in the direction of "Nursing", as well as ideas for introducing the capital
      standard of a nurse. The analysis of the information obtained made it possible to
      identify a number of problems and directions for their solution: at the college
      level, this is, first of all, poor-quality production practice, which is due to
      the overload of medical staff and, in general, not serious attitude to trainees, 
      as well as insufficient communication training of future nurses; in the case of
      undergraduate studies, the main problems are related to students who have gone to
      university just after school, who have a poor idea of their future profession and
      are poorly motivated to study in condition when courses that dedicated to
      studying nursing medical skills, initially aimed at a more professionally trained
      contingent, have been significantly reduced. Experts, who support the idea of
      expanding the functions of nurses, the main obstacles to its implementation see
      in the stereotypes that the chief physicians and the medical community as a whole
      have about the purely secondary role of the nursing staff, as well as the
      corresponding attitudes of the nurses themselves. Regarding the standard of the
      capital's nurse, experts agree that the main emphasis should be on the
      development of universal competencies, attention to deontological and ethical
      issues.
FAU - Aleksandrova, O A
AU  - Aleksandrova OA
AD  - Research Institute for Healthcare Organization and Medical Management, 115088,
      Moscow, Russia, a762rab@mail.ru.
AD  - Financial University under the Government of the Russian Federation, 125993,
      Moscow, Russia.
FAU - Yarasheva, A V
AU  - Yarasheva AV
AD  - Research Institute for Healthcare Organization and Medical Management, 115088,
      Moscow, Russia.
AD  - Institute of Social and Economic Studies of Population of FCTAS of Russian
      Academy of Sciences, 117218, Moscow, Russia.
FAU - Nenakhova, Yu S
AU  - Nenakhova YS
AD  - Research Institute for Healthcare Organization and Medical Management, 115088,
      Moscow, Russia.
AD  - Institute of Social and Economic Studies of Population of FCTAS of Russian
      Academy of Sciences, 117218, Moscow, Russia.
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med
JT  - Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny
JID - 101270373
SB  - IM
MH  - Attitude of Health Personnel
MH  - *Delivery of Health Care
MH  - *Education, Nursing
MH  - Humans
MH  - *Nursing
MH  - Organizations
OTO - NOTNLM
OT  - expanding the functions of a nurse
OT  - heads of nursing services
OT  - medical education
OT  - nursing staff
EDAT- 2020/08/29 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.32687/0869-866X-2020-28-s1-680-686 [doi]
PST - ppublish
SO  - Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2020 Aug;28(Special
      Issue):680-686. doi: 10.32687/0869-866X-2020-28-s1-680-686.


PMID- 32856718
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20210302
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 107
IP  - 11
DP  - 2020 Oct
TI  - COVID 19 and the race to publish: an ethical issue.
PG  - e504
LID - 10.1002/bjs.11966 [doi]
FAU - Safieddine, Maissa
AU  - Safieddine M
AD  - SAINBIOSE U1059, Universite Jean Monnet, University Lyon, INSERM, F-CRIN INNOVTE 
      Network, F-42023, Saint-Etienne, France.
FAU - Kassir, Radwan
AU  - Kassir R
AUID- ORCID: https://orcid.org/0000-0002-3987-5272
AD  - Department of Obesity Surgery, CHU Felix Guyon, ST Denis de la Reunion, France.
LA  - eng
PT  - Letter
DEP - 20200828
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - IM
CIN - Br J Surg. 2021 Jan 27;108(1):e46. PMID: 33640913
MH  - COVID-19/*epidemiology
MH  - Humans
MH  - Publishing/*statistics & numerical data
MH  - *SARS-CoV-2
PMC - PMC7460919
EDAT- 2020/08/29 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/06/22 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - 10.1002/bjs.11966 [doi]
PST - ppublish
SO  - Br J Surg. 2020 Oct;107(11):e504. doi: 10.1002/bjs.11966. Epub 2020 Aug 28.


PMID- 32856625
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1364-5528 (Electronic)
IS  - 0003-2654 (Linking)
VI  - 145
IP  - 21
DP  - 2020 Oct 26
TI  - Comparison of liver and plasma metabolic profiles in piglets of different ages as
      animal models for paediatric population.
PG  - 6859-6867
LID - 10.1039/d0an00254b [doi]
AB  - Liver plays an important role in drug metabolism, so studying the grade of
      maturation of this organ would help to develop more appropriate dosing regimens
      for paediatric populations. Nevertheless, considering the invasive nature of
      liver analyses there are obvious ethical boundaries, particularly in babies and
      children. In this work, we investigated the suitability of blood plasma as an
      alternative matrix to evaluate the biological age of liver. With this aim, we
      studied the correlation of plasma and liver metabolomic profiles obtained by
      HPLC-TOF-MS for piglets of different ages (newborns, neonates and infants). By
      means of Pearson correlation analysis we observed that 360 and 1784 pairs of
      metabolite features were significantly correlated in positive and negative
      ionization mode, respectively. Procrustes analysis was applied in order to assess
      the similarity of the clustering resulting from the data obtained from the two
      matrices and the two ionisation modes. The Procrustes distances were low for both
      ESI+ (0.3753) and ESI- (0.3673) and, hence, liver and plasma are expected to
      provide similar discriminatory information. Furthermore, we found that Multiblock
      Principal Component Analysis (MB-PCA) readily allowed us to combine the data
      obtained from both matrices and to better understand the clustering according to 
      the three study groups. Considering all these results, we suggest that plasma can
      provide valuable insight into the maturation grade of liver in order to provide
      accurate dosing in paediatric population.
FAU - Alboniga, Oihane E
AU  - Alboniga OE
AD  - Department of Analytical Chemistry, Faculty of Science and Technology, University
      of the Basque Country (UPV/EHU), Barrio Sarriena s/n, 48940, Leioa, Spain.
      oihaneelena.alboniga@ehu.eus.
FAU - Gonzalez, Oskar
AU  - Gonzalez O
FAU - Alonso, Rosa M
AU  - Alonso RM
FAU - Xu, Yun
AU  - Xu Y
FAU - Goodacre, Royston
AU  - Goodacre R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Analyst
JT  - The Analyst
JID - 0372652
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Animals
MH  - Child
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Liver
MH  - *Metabolome
MH  - Models, Animal
MH  - *Pharmaceutical Preparations
MH  - Plasma
MH  - Spectrometry, Mass, Electrospray Ionization
MH  - Swine
EDAT- 2020/08/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - 10.1039/d0an00254b [doi]
PST - ppublish
SO  - Analyst. 2020 Oct 26;145(21):6859-6867. doi: 10.1039/d0an00254b.


PMID- 32855840
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220220
IS  - 2164-2591 (Print)
IS  - 2164-2591 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Jul
TI  - Protecting Data Privacy in the Age of AI-Enabled Ophthalmology.
PG  - 36
LID - 10.1167/tvst.9.2.36 [doi]
FAU - Tom, Elysse
AU  - Tom E
AD  - Department of Ophthalmology, University of Washington, Seattle, WA, USA.
FAU - Keane, Pearse A
AU  - Keane PA
AD  - Medical Retina Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
AD  - Institute of Ophthalmology, University College London, London, UK.
FAU - Blazes, Marian
AU  - Blazes M
AD  - Department of Ophthalmology, University of Washington, Seattle, WA, USA.
FAU - Pasquale, Louis R
AU  - Pasquale LR
AD  - Eye and Vision Research Institute, Icahn School of Medicine at Mount Sinai, New
      York, NY, USA.
FAU - Chiang, Michael F
AU  - Chiang MF
AD  - Departments of Ophthalmology and Medical Informatics & Clinical Epidemiology,
      Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.
FAU - Lee, Aaron Y
AU  - Lee AY
AD  - Department of Ophthalmology, University of Washington, Seattle, WA, USA.
FAU - Lee, Cecilia S
AU  - Lee CS
AD  - Department of Ophthalmology, University of Washington, Seattle, WA, USA.
CN  - AAO Artificial Intelligence Task Force
LA  - eng
GR  - R01 EY019474/EY/NEI NIH HHS/United States
GR  - MR/T019050/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 AG060942/AG/NIA NIH HHS/United States
GR  - K23 EY029246/EY/NEI NIH HHS/United States
GR  - R01 EY015473/EY/NEI NIH HHS/United States
GR  - P30 EY010572/EY/NEI NIH HHS/United States
GR  - MC_PC_19005/MRC_/Medical Research Council/United Kingdom
GR  - K12 EY027720/EY/NEI NIH HHS/United States
GR  - CS-2014-14-023/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
MH  - Artificial Intelligence
MH  - Machine Learning
MH  - *Ophthalmology
MH  - Privacy
PMC - PMC7424948
OTO - NOTNLM
OT  - *Artificial Intelligence
OT  - *Biomedical Ethics
OT  - *Machine Learning
OT  - *Privacy
COIS- Disclosure: E. Tom, None; P.A. Keane, DeepMind Technologies (C), Roche (C),
      Novartis (C), Apellis (C), Bayer (F), Allergan (F), Topcon (F), Heidelberg
      Engineering (F); M. Blazes, None; L.R. Pasquale, Verily (C), Eyenovia (C), Nicox 
      (C), Bausch + Lomb (C), Emerald Bioscience (C); M.F. Chiang, Novartis (C),
      InTeleretina, LLC (I); A.Y. Lee, U.S. Food and Drug Administration (E), Genentech
      (C), Topcon (C), Verana Health (C), Santen (F), Novartis (F), Carl Zeiss Meditec 
      (F); C.S. Lee, None; M.D. Abramoff, IDx (I, F, E, P, S), Alimera (F); J.P.
      Campbell, Genentech (F); R. Singh, Genentech (C), Novartis (C), Apellis (F),
      Bayer (C), Carl Zeiss Meditec (C), Aerie (C), Graybug (F), Regeneron (C); D.
      Ting, EyRIS (I, P), Novartis (C), Ocutrx (I, C), Optomed (C)
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
CRDT- 2020/08/29 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
AID - 10.1167/tvst.9.2.36 [doi]
AID - TVST-20-2460 [pii]
PST - epublish
SO  - Transl Vis Sci Technol. 2020 Jul 6;9(2):36. doi: 10.1167/tvst.9.2.36. eCollection
      2020 Jul.


PMID- 32855774
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2008-126X (Print)
IS  - 2008-126X (Linking)
VI  - 11
IP  - 2
DP  - 2020 Mar-Apr
TI  - COVID-19 and Substance Use Disorder: Study Protocol for the International Society
      of Addiction Medicine Practice and Policy Interest Group Global Survey.
PG  - 155-162
LID - 10.32598/bcn.11.covid19.2545.1 [doi]
AB  - INTRODUCTION: As one of the major health problems in the present century, the
      COVID-19 pandemic affected all parts of the global communities and the health of 
      substance users are potentially at a greater risk of harm. This global study has 
      been designed and conducted by the International Society of Addiction Medicine
      Practice and Policy Interest Group (ISAM-PPIG) to understand better the health
      related issues of people with Substance Use Disorders (SUD) as well as responses 
      of the relevant health care systems during the pandemic. METHODS: This is a
      cross-sectional study using convenient sampling. The data gathering was carried
      out with two follow-up stages each two months apart through an online conducted
      survey prepared using Google platform. The survey started by emergence of
      COVID-19 as a pandemic in March 2020 and respondents were followed till September
      2020 when most of the initial lockdowns by most countries are supposed to be
      reopened. ETHICS AND DISSEMINATION: The study was approved by the ethics
      committee of University of Social Welfare and Rehabilitation Sciences, Tehran,
      Iran. The results will be published in relevant peer reviewing journals and
      communicated with different international stakeholders.
CI  - Copyright(c) 2020 Iranian Neuroscience Society.
FAU - Baldacchino, Alexander
AU  - Baldacchino A
AUID- ORCID: https://orcid.org/0000-0002-5388-7376
AD  - Division of Population and Behavioral Sciences, St Andrews University Medical
      School, University of St Andrews, UK.
FAU - Radfar, Seyed Ramin
AU  - Radfar SR
AUID- ORCID: https://orcid.org/0000-0003-1673-6154
AD  - Integrated Substance Abuse Programs, University of California, Los Angeles, CA,
      USA.
FAU - De Jong, Cornelis
AU  - De Jong C
AUID- ORCID: https://orcid.org/0000-0003-1824-7303
AD  - Behavioral Science Institute, Radboud University, The Netherlands.
FAU - Rafei, Parnian
AU  - Rafei P
AUID- ORCID: https://orcid.org/0000-0002-4770-4801
AD  - Faculty of Psychology and Education, University of Tehran, Tehran, Iran.
FAU - Yunesian, Masud
AU  - Yunesian M
AUID- ORCID: https://orcid.org/0000-0002-2870-7433
AD  - Department of Research Methodology and Data Analysis, Institute for Environmental
      Research, Tehran University of Medical sciences, Tehran, Iran.
FAU - Gerra, Gilberto
AU  - Gerra G
AUID- ORCID: https://orcid.org/0000-0002-4987-6818
AD  - Drug Prevention and Health Branch, Division for Operations, United Nations Office
      on Drugs and Crime, Vienna, Austria.
FAU - Brady, Kathleen
AU  - Brady K
AD  - Department of Psychiatry and Behavioral Sciences, Medical University of South
      Carolina, USA.
FAU - Ebrahimi, Mohsen
AU  - Ebrahimi M
AUID- ORCID: https://orcid.org/0000-0002-9197-3750
AD  - Department of Semiconductors, Materials and Energy Research Center (MERC),
      Tehran, Iran.
FAU - Vahidi, Mehrnoosh
AU  - Vahidi M
AUID- ORCID: https://orcid.org/0000-0001-5824-4970
AD  - Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Khojasteh Zonoozi, Arash
AU  - Khojasteh Zonoozi A
AUID- ORCID: https://orcid.org/0000-0003-4712-8928
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical
      Sciences, Mashhad, Iran.
FAU - Mohaddes Ardabili, Hossein
AU  - Mohaddes Ardabili H
AUID- ORCID: https://orcid.org/0000-0002-6251-0191
AD  - Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Faculty 
      of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Busse, Anja
AU  - Busse A
AD  - Prevention, Treatment and Rehabilitation Section; Drug Prevention and Health
      Branch, Division for Operations, United Nations Office on Drugs and Crime,
      Vienna, Austria.
FAU - Saenz, Elizabeth
AU  - Saenz E
AUID- ORCID: https://orcid.org/0000-0001-7051-1509
AD  - Prevention, Treatment and Rehabilitation Section; Drug Prevention and Health
      Branch, Division for Operations, United Nations Office on Drugs and Crime,
      Vienna, Austria.
FAU - Campello, Giovanna
AU  - Campello G
AD  - Prevention, Treatment and Rehabilitation Section; Drug Prevention and Health
      Branch, Division for Operations, United Nations Office on Drugs and Crime,
      Vienna, Austria.
FAU - Niaz, Kamran
AU  - Niaz K
AUID- ORCID: https://orcid.org/0000-0002-3817-9881
AD  - Research and Trend Analysis Branch, Division for Policy Affairs, United Nations
      Office on Drugs and Crime, Vienna, Austria.
FAU - Ekhtiari, Hamed
AU  - Ekhtiari H
AUID- ORCID: https://orcid.org/0000-0001-6902-8798
AD  - Laureate Institute for Brain Research, Tulsa, Oklahoma, USA.
FAU - Farhoudian, Ali
AU  - Farhoudian A
AUID- ORCID: https://orcid.org/0000-0002-8784-522X
AD  - Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran;
      Substance Abuse and Dependence Research Center, University of Social Welfare and 
      Rehabilitation Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Iran
TA  - Basic Clin Neurosci
JT  - Basic and clinical neuroscience
JID - 101575211
PMC - PMC7368101
OTO - NOTNLM
OT  - COVID-19
OT  - Country response
OT  - Disaster medicine
OT  - Drug addiction
OT  - Health policy
OT  - Health surveys
OT  - Mental health Services
OT  - Opiate substitution treatment
OT  - Pandemics
OT  - Public health
OT  - SARS-CoV-2
OT  - Substance-related disorders
OT  - Telemedicine
COIS- Conflict of interest The authors declare that they have no competing interests.
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
CRDT- 2020/08/29 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
AID - 10.32598/bcn.11.covid19.2545.1 [doi]
AID - BCN-11-155 [pii]
PST - ppublish
SO  - Basic Clin Neurosci. 2020 Mar-Apr;11(2):155-162. doi:
      10.32598/bcn.11.covid19.2545.1. Epub 2020 Apr 15.


PMID- 32855641
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1687-9813 (Electronic)
IS  - 1687-9805 (Linking)
VI  - 2020
DP  - 2020
TI  - Level of Patient Satisfaction with Inpatient Services and Its Determinants: A
      Study of a Specialized Hospital in Ethiopia.
PG  - 2473469
LID - 10.1155/2020/2473469 [doi]
AB  - Background: The health care industry is undergoing a rapid transformation to meet
      the ever-increasing needs and demands of its patient population. Level of
      patients' satisfaction is an important health outcome, which is regarded as a
      determinant measure for quality of care. This study was performed with the aim of
      assessing the level of patient satisfaction with inpatient services and its
      determinants in Black Lion Specialized Hospital, Addis Ababa, Ethiopia. Methods: 
      A facility-based cross-sectional study was conducted from November 25(th) to
      December 20(th), 2015, using 398 randomly selected patients. Ethical clearance
      was obtained from the Jimma University research review board, and verbal consent 
      was also received from the study participants during data collection time. A
      pretested structured interview questionnaire was used to collect data from study 
      participants. The collected data were handled by using SPSS statistical software.
      Before analysis, relevant explanatory variables were identified using factor
      analysis with varimax rotation, and bivariate analysis was carried out using
      linear regression for every independent variable with the outcome variable
      independently. Explanatory variables scoring p value <-0.05 were used for the
      final model after checking the assumption. Study findings are presented by using 
      tables, graphs, and description. Results: A total of 398 patients were
      participated in the study, yielding a response rate of 100%. A total of 46.2%
      (95% CI: 41.2%-51.1%) patients were satisfied by the services they received in
      the hospital. Patient and health care provider interaction and general facility
      amenity-related domains were found to explain 96.4% of the variability in the net
      overall satisfaction score. Good quality services provided by hospital
      physicians, availability of laboratory and radiology services, pain management
      services, and inpatient pharmacy services of the hospital had positive
      influences. Besides toilet cleanliness, availability of rooms for accommodation
      and dietary service had significant relation with level of patient satisfaction. 
      Quality of the inpatient pharmacy service had a great influence on satisfaction; 
      a unit increase in it resulted in 2.3 (95% CI: 2.1-2.5) times increment in
      patient satisfaction level at p </= 0.001. For final predictors, regression
      estimates for level of satisfaction moved from very dissatisfied to very
      satisfied when service improves by a unit. Conclusion: Overall patients'
      satisfaction is lower than other studies in the nation. A great opportunity is
      there to improve patient's satisfaction level if the service quality is improved 
      around the time of patient and health care provider interaction and facility
      amenity services. Besides, improving the health literacy of service providers and
      devising a strategy to routinely assess satisfaction level of patients in the
      facility is critical. On top of this, providing tailored on-the-job training for 
      health care workers in the facility is a crucial step in order to improve their
      knowledge and skills to render patient-centered quality service to improve their 
      patients' satisfaction. Using a checklist during service delivery may improve
      client patient interaction and ensure the standard. Facility design dimension can
      be considered for future research activities.
CI  - Copyright (c) 2020 Nebsu Asamrew et al.
FAU - Asamrew, Nebsu
AU  - Asamrew N
AD  - Health Service Quality Directorate, Addis Ababa Regional Health Bureau, Addis
      Ababa, Ethiopia.
FAU - Endris, Abduilhafiz A
AU  - Endris AA
AUID- ORCID: 0000-0003-4480-7896
AD  - Public Health Emergency Management Center, Ethiopian Public Health Institute,
      P.O. Box: 1242, Addis Ababa, Ethiopia.
FAU - Tadesse, Musse
AU  - Tadesse M
AD  - Public Health Emergency Management Center, Ethiopian Public Health Institute,
      P.O. Box: 1242, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200813
PL  - United States
TA  - J Environ Public Health
JT  - Journal of environmental and public health
JID - 101516361
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Ethiopia
MH  - Female
MH  - Humans
MH  - Inpatients/*statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction/*statistics & numerical data
MH  - Young Adult
PMC - PMC7443030
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2020/08/29 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/08/29 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1155/2020/2473469 [doi]
PST - epublish
SO  - J Environ Public Health. 2020 Aug 13;2020:2473469. doi: 10.1155/2020/2473469.
      eCollection 2020.


PMID- 32855588
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210101
IS  - 1050-8422 (Print)
IS  - 1050-8422 (Linking)
VI  - 30
IP  - 2
DP  - 2020
TI  - Ethical Considerations in Providing Psychological Services to Unaccompanied
      Immigrant Children.
PG  - 83-96
LID - 10.1080/10508422.2019.1623031 [doi]
AB  - Over 50,000 youth, mostly between the ages of 13 and 17 years, migrated to the
      United States (US) without familial accompaniment in fiscal year 2018. The
      tripartite process of pre-flight, flight, and resettlement exposes these
      unaccompanied immigrant children (UIC) to multiple, and often ongoing, traumatic 
      events that can significantly and adversely impact their mental health into
      adulthood. However, the ethical considerations for psychologists working with
      this growing population, with limited exceptions, remain largely unaddressed. As 
      more and more UIC flee their home countries due to violence, abuse, and economic 
      instability only to experience further stressors during the processes of
      detainment, custodial placement, and acculturative adjustment in the US, there is
      an increasing need for psychological services; thus, the importance of
      preparation of mental health providers is increasingly significant. Psychologists
      must have the requisite skills and knowledge of the complex experiences of UIC,
      and of how these intersect with salient cultural, developmental, and systemic
      factors, as a means of providing competent and ethical mental health treatment.
      The present article highlights several ethical issues that arise when providing
      psychological services to UIC, with particular consideration paid to the
      embeddedness of UIC in various organizational entities with which psychologists
      will likely need to interface when working with this population. Implications and
      recommendations for practicing psychologists and training programs are discussed.
FAU - Dash, Genevieve F
AU  - Dash GF
AD  - Department of Psychological Sciences, University of Missouri- Columbia.
LA  - eng
GR  - T32 AA013526/AA/NIAAA NIH HHS/United States
PT  - Journal Article
DEP - 20190618
PL  - United States
TA  - Ethics Behav
JT  - Ethics & behavior
JID - 9102086
PMC - PMC7447159
MID - NIHMS1530327
OTO - NOTNLM
OT  - children
OT  - ethics
OT  - immigration
OT  - psychology
OT  - youth
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
AID - 10.1080/10508422.2019.1623031 [doi]
PST - ppublish
SO  - Ethics Behav. 2020;30(2):83-96. doi: 10.1080/10508422.2019.1623031. Epub 2019 Jun
      18.


PMID- 32855283
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Caster semenya and a level playing field.
PG  - 563-564
LID - 10.1136/medethics-2020-106740 [doi]
FAU - Wall, Jesse
AU  - Wall J
AD  - Faculty of Law, University of Auckland, Auckland, New Zealand
      jesse.wall@auckland.ac.nz.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Sep;46(9):584-590. PMID: 32690761
MH  - Athletes
MH  - Humans
MH  - *Sports
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/08/29 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - medethics-2020-106740 [pii]
AID - 10.1136/medethics-2020-106740 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):563-564. doi: 10.1136/medethics-2020-106740.


PMID- 32855231
OWN - NLM
STAT- Publisher
LR  - 20200828
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 Aug 27
TI  - Ethical issues related to the COVID-19 pandemic in patients with cancer:
      experience and organisations in a French comprehensive cancer centre.
LID - bmjspcare-2020-002504 [pii]
LID - 10.1136/bmjspcare-2020-002504 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has aggressively reached the most vulnerable,
      not only the elderly but also patients with chronic conditions such as cancer. In
      this study, we present the outlines of ethical thinking and the measures
      implemented to try to respect our basic values of care, in the specific
      environment of an oncology hospital. METHODS: Our ethics committee created an
      ethical watch system based on 24/7 shifts to assist practitioners in their daily 
      decisions. We discuss the challenges faced by patients with cancer during the
      pandemic, such as access to critical care and ethical dilemmas in the context of 
      resource scarcity, as well as the issue of isolation of patients. We also debate 
      the restrictions in access to oncology care in a health context strongly
      'prioritised' against COVID-19. RESULTS: In all areas of an ethical dilemma,
      either for sorting out access to critical care or for the dramatic consequences
      of prolonged isolation of patients, our common thread was our attempt to protect,
      whenever possible, the principles of deontological ethics by strictly resisting
      utilitarian pressure. Respecting democratic health decision-making processes is a
      cornerstone of ethically relevant decisions, including in the context of a
      sanitary crisis. CONCLUSION: The role of an ethics committee related to real-life
      situations includes not only a reflexive perspective in respect of fundamental
      principles, but also the help to enlighten and resolve ethical dilemmas in
      complex clinical situations. This ethical watch team assists physicians in
      decision-making, promoting the supportive and palliative dimension of care with a
      holistic approach.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Blot, Francois
AU  - Blot F
AUID- ORCID: http://orcid.org/0000-0003-2613-0957
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France
      francois.blot@gustaveroussy.fr.
FAU - Dumont, Sarah N
AU  - Dumont SN
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Vigouret-Viant, Laurence
AU  - Vigouret-Viant L
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Verotte, Nelly
AU  - Verotte N
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Rossignol, Julien
AU  - Rossignol J
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Rieutord, Andre
AU  - Rieutord A
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Fournier-Bidoz, Nathalie
AU  - Fournier-Bidoz N
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - De Jesus, Anne
AU  - De Jesus A
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Dauchy, Sarah
AU  - Dauchy S
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Chardonnet, Florent
AU  - Chardonnet F
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Baldini, Capucine
AU  - Baldini C
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
FAU - Altea, Anna
AU  - Altea A
AD  - Ethics Committee, Gustave Roussy Institute, Villejuif, France.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - clinical decisions
OT  - cultural issues
OT  - ethics
OT  - supportive care
COIS- Competing interests: None declared.
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/06/24 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
AID - bmjspcare-2020-002504 [pii]
AID - 10.1136/bmjspcare-2020-002504 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 Aug 27. pii: bmjspcare-2020-002504. doi:
      10.1136/bmjspcare-2020-002504.


PMID- 32855113
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 1876-7982 (Electronic)
IS  - 1876-7982 (Linking)
VI  - 51
IP  - 4S
DP  - 2020 Dec
TI  - What Medical Imaging Professionals Talk About When They Talk About Compassion.
PG  - S44-S52
LID - S1939-8654(20)30222-8 [pii]
LID - 10.1016/j.jmir.2020.08.009 [doi]
AB  - BACKGROUND: Compassion is a poorly understood concept in medical Imaging
      research, but an increase in its focus was recommended in the Francis Report
      (2013). Little research has been conducted in this area to date. METHODS: The
      project was conducted from within a constructivist paradigm with appropriate
      ethical approval. As part of a wider doctoral study, data were harvested from a
      Twitter journal club discussion between medical imaging professionals of the
      author's published literature review and one focus group of post-graduate
      radiographers. Data were transcribed and analysed thematically. RESULTS:
      Compassion in DI is conceptualised according to three themes constructed from the
      data: 1) Perceptible elements of the procedure; 2) Underlying qualities, skills
      and abilities of radiographers; 3) Moral and ethical foundations. When medical
      imaging professionals talk about compassion they talk about its importance in
      professional practice, the challenges faced in giving compassionate care and the 
      strategies they employ to cope with the emotional as well as physical demands
      they face. Contradictory organisational values and an over-emphasis on
      individuals' responsibility for providing compassionate care were also
      highlighted. Ethical professional practice need not necessarily include in every 
      interaction expressions of compassion, or feelings in a medical imaging
      professional of caring about their patient. CONCLUSION: The concept of compassion
      has depth, with surface appearances underpinned by moral values and
      behaviour-motivating drivers. These findings offer a clearer understanding of
      compassion that could inform radiographic practice and education.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Bleiker, Jill
AU  - Bleiker J
AD  - Medical Imaging, University of Exeter Medical School. Electronic address:
      j.bleiker@exeter.ac.uk.
FAU - Knapp, Karen
AU  - Knapp K
AD  - Medical Imaging, University of Exeter Medical School.
FAU - Morgan-Trimmer, Sarah
AU  - Morgan-Trimmer S
AD  - University of Exeter Medical School, Institute of Health Research.
FAU - Hopkins, Susan
AU  - Hopkins S
AD  - Medical Imaging, University of Exeter Medical School.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - United States
TA  - J Med Imaging Radiat Sci
JT  - Journal of medical imaging and radiation sciences
JID - 101469694
SB  - IM
MH  - Allied Health Personnel/*psychology
MH  - Attitude of Health Personnel
MH  - *Empathy
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - *Professional-Patient Relations
MH  - *Technology, Radiologic
OTO - NOTNLM
OT  - *Compassion
OT  - *Education
OT  - *Professionalism
OT  - *Qualitative research
OT  - *Radiography
EDAT- 2020/08/29 06:00
MHDA- 2021/08/25 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S1939-8654(20)30222-8 [pii]
AID - 10.1016/j.jmir.2020.08.009 [doi]
PST - ppublish
SO  - J Med Imaging Radiat Sci. 2020 Dec;51(4S):S44-S52. doi:
      10.1016/j.jmir.2020.08.009. Epub 2020 Aug 25.


PMID- 32855075
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 2212-0289 (Electronic)
IS  - 1865-9217 (Linking)
VI  - 156-157
DP  - 2020 Nov
TI  - [Control group formation using propensity score matching: The role of primary and
      secondary data - Results of prevention studies].
PG  - 68-74
LID - S1865-9217(20)30095-7 [pii]
LID - 10.1016/j.zefq.2020.07.004 [doi]
AB  - BACKGROUND: The creation of control groups in the evaluation of statutory health 
      insurances is a key issue. Randomization represents both an ethical and a legal
      problem with legally guaranteed services. Matching procedures are relevant
      alternatives in the construction of control groups. Matchings are mostly based on
      secondary data from statutory health insurances (for example age, gender, cost of
      illness, days of incapacity to work). In this study, we examined whether matching
      based on secondary data alone can cause selection bias. METHODS: We used data
      from three large prevention studies and applied sensitivity analyses to compare
      the results of propensity score matchings used to create control groups on the
      basis of secondary data, with those obtained on the basis of both primary and
      secondary data. Analysis of covariance was used to investigate the impact of
      potential selection bias on cost effects. RESULTS: Matchings based on secondary
      data alone lead to control groups with similar characteristics captured by
      secondary data. However, the control group participants are significantly
      healthier (they have, for example, lower levels of pain, lower levels of
      psychological stress, a higher degree of quality of life) than the patients in
      intervention groups. This selection bias would lead to a systematic
      underestimation of the cost reduction produced by preventive interventions.
      DISCUSSION: Prevention course participants seem to have characteristics that
      differ from the average population (higher health orientation level, preference
      for prevention over medical treatment services, etc.) and cannot be captured by
      secondary data; therefore, matchings based on secondary data alone cause
      selection bias. CONCLUSIONS: Including both primary and secondary data reduces
      the risk of selection bias in matching procedures for prevention studies. The
      E-value can be used to evaluate the robustness of results with regard to
      selection bias.
CI  - Copyright (c) 2020. Published by Elsevier GmbH.
FAU - Muller, Gerhard
AU  - Muller G
AD  - Fachbereich Gesundheitsforderung, AOK Baden-Wurttemberg, Stuttgart, Deutschland. 
      Electronic address: gerhard.mueller@bw.aok.de.
FAU - Giurgiu, Marco
AU  - Giurgiu M
AD  - Institut fur Sport und Sportwissenschaft, Karlsruher Institut fur Technologie,
      Karlsruhe, Deutschland; Institut fur Psychiatrische und Psychosomatische
      Psychotherapie, Zentralinstitut fur Seelische Gesundheit, Universitat Heidelberg,
      Mannheim, Deutschland.
FAU - Heinzel-Gutenbrunner, Monika
AU  - Heinzel-Gutenbrunner M
AD  - MH Statistikberatung, Marburg, Deutschland.
FAU - Bos, Klaus
AU  - Bos K
AD  - Institut fur Sport und Sportwissenschaft, Karlsruher Institut fur Technologie,
      Karlsruhe, Deutschland.
FAU - Kohlmann, Thomas
AU  - Kohlmann T
AD  - Community Medicine, Universitat Greifswald, Greifswald, Deutschland.
FAU - Bombana, Manuela
AU  - Bombana M
AD  - Fachbereich Gesundheitsforderung, AOK Baden-Wurttemberg, Stuttgart, Deutschland; 
      Abteilung Allgemeinmedizin und Versorgungsforschung, Universitatsklinikum
      Heidelberg, Heidelberg, Deutschland.
LA  - ger
PT  - Journal Article
TT  - Kontrollgruppenbildung durch Propensity-Score-Matching: Die Rolle von Primar- und
      Sekundardaten - Ergebnisse aus Praventionsstudien.
DEP - 20200825
PL  - Netherlands
TA  - Z Evid Fortbild Qual Gesundhwes
JT  - Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen
JID - 101477604
SB  - IM
MH  - Control Groups
MH  - Germany
MH  - Humans
MH  - Propensity Score
MH  - *Quality of Life
MH  - Selection Bias
OTO - NOTNLM
OT  - Data linkage
OT  - Datenlinkage
OT  - Matched-Pair-Analysen
OT  - Matched-pair analysis
OT  - Secondary data
OT  - Sekundardaten
OT  - Selection bias
OT  - Selektionsbias
EDAT- 2020/08/29 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/07/03 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S1865-9217(20)30095-7 [pii]
AID - 10.1016/j.zefq.2020.07.004 [doi]
PST - ppublish
SO  - Z Evid Fortbild Qual Gesundhwes. 2020 Nov;156-157:68-74. doi:
      10.1016/j.zefq.2020.07.004. Epub 2020 Aug 25.


PMID- 32854973
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 159
IP  - 2
DP  - 2020 Nov
TI  - Investigation of clinicopathological features of vulvar cancer in 1068 patients: 
      A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study.
PG  - 449-455
LID - S0090-8258(20)33820-8 [pii]
LID - 10.1016/j.ygyno.2020.08.019 [doi]
AB  - OBJECTIVE: Vulvar cancer is a rare malignancy in the aging population, and
      optimizing treatment strategies requires large-scale investigation of the
      clinicopathological features of this disease. In Japan, no such surveys have been
      conducted in the past 30 years. This large-scale retrospective multi-center study
      aimed to examine the clinicopathological features of vulvar cancer in Japan.
      METHODS: Upon obtaining ethical approval by the participating institutions'
      review boards, the medical records of patients with vulvar cancer, who were
      treated between 2001 and 2010 were reviewed. The impact of clinicopathological
      factors on overall survival (OS) was investigated using a multivariate Cox
      regression model. RESULTS: After applying the inclusion and exclusion criteria,
      1068 patients treated in 108 centers were included. The median age was 72 years. 
      The disease was in stage I in 402 patients (37.6%), stage II in 249 patients
      (23.3%), stage III in 252 patients (23.6%), and stage IV in 165 patients (15.4%).
      Squamous cell carcinoma, Paget's disease, adenocarcinoma, and other diseases were
      diagnosed in 773 (72.4%), 154 (14.4%), 59 (5.5%), and 82 (7.7%) patients,
      respectively. Positive inguino-femoral lymph nodes were found in 265 (24.8%)
      patients. The 5-year OS rate for stage I, II, III, and IV vulvar cancer were
      85.6%, 75.1%, 48.8%, and 40.0%, respectively. CONCLUSION: Our study shows that
      advanced age, disease stage, histological diagnosis, tumor diameter, and lymph
      node metastases significantly affect the OS of patients with vulvar cancer in
      Japan.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Nishio, Shin
AU  - Nishio S
AD  - Department of Obstetrics and Gynecology, Kurume University School of Medicine,
      Fukuoka, Japan. Electronic address: shinshin@med.kurume-u.ac.jp.
FAU - Murotani, Kenta
AU  - Murotani K
AD  - Biostatistics Center, Graduate School of Medicine, Kurume University, Fukuoka,
      Japan.
FAU - Nakao, Sari
AU  - Nakao S
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of
      Tsukuba, Ibaragi, Japan.
FAU - Takenaka, Motoki
AU  - Takenaka M
AD  - Department of Obstetrics and Gynecology, Gifu University Graduate School of
      Medicine, Gifu, Japan.
FAU - Suzuki, Shiro
AU  - Suzuki S
AD  - Department of Gynecologic Oncology, Aichi Cancer Center, Aichi, Japan.
FAU - Aoki, Yoichi
AU  - Aoki Y
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, University 
      of the Ryukyus, Okinawa, Japan.
FAU - Todo, Yukiharu
AU  - Todo Y
AD  - Division of Gynecologic Oncology, National Hospital Organization, Hokkaido Cancer
      Center, Hokkaido, Japan.
FAU - Hosaka, Masayoshi
AU  - Hosaka M
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School 
      of Medicine, Hokkaido University, Hokkaido, Japan.
FAU - Nakai, Hidekatsu
AU  - Nakai H
AD  - Department of Obstetrics and Gynecology, Kindai University, Faculty of Medicine, 
      Osaka, Japan.
FAU - Katabuchi, Hidetaka
AU  - Katabuchi H
AD  - Department of Obstetrics and Gynecology, Faculty of Life, Sciences, Kumamoto
      University, Kumamoto, Japan.
FAU - Nishi, Hirotaka
AU  - Nishi H
AD  - Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
FAU - Takekuma, Munetaka
AU  - Takekuma M
AD  - Department of Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
FAU - Mikami, Mikio
AU  - Mikami M
AD  - Department of Obstetrics and Gynecology, Tokai University Hospital, Kanagawa,
      Japan.
FAU - Enomoto, Takayuki
AU  - Enomoto T
AD  - Department of Obstetrics and Gynecology, Niigata University Graduate School of
      Medical and Dental Sciences, Niigata, Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20200825
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
SB  - IM
MH  - Adenocarcinoma/*mortality/pathology/therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*mortality/pathology/therapy
MH  - Chemoradiotherapy/mortality
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Lymph Node Excision/methods
MH  - Lymphatic Metastasis/diagnosis/pathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Vulvar Neoplasms/mortality/*pathology/therapy
MH  - Vulvectomy/mortality
OTO - NOTNLM
OT  - *Clinicopathological factor
OT  - *Japan
OT  - *Survey
OT  - *Survival
OT  - *Treatment
OT  - *Vulvar cancer
COIS- Declaration of Competing Interest The authors have no conflicts of interest to
      declare.
EDAT- 2020/08/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/06/13 00:00 [received]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/08/29 06:00 [entrez]
AID - S0090-8258(20)33820-8 [pii]
AID - 10.1016/j.ygyno.2020.08.019 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2020 Nov;159(2):449-455. doi: 10.1016/j.ygyno.2020.08.019. Epub
      2020 Aug 25.


PMID- 32854772
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 27
TI  - Rivaroxaban compared to no treatment in ER-negative stage I-III early breast
      cancer patients (the TIP Trial): study protocol for a phase II preoperative
      window-of-opportunity study design randomised controlled trial.
PG  - 749
LID - 10.1186/s13063-020-04675-7 [doi]
AB  - BACKGROUND: Breast cancer patients are at a four-fold increased risk of
      developing a venous thromboembolism (VTE), a major cause of death in this group. 
      Conversely, coagulation factors promote tumour growth and metastasis. This has
      been evidenced in preclinical models, with an inhibitory effect of anticoagulants
      on cancer growth through proliferative, angiogenic, apoptotic, cancer stem cell
      and metastatic processes. The extrinsic clotting pathway is also more upregulated
      in patients in the relatively poorer prognosis oestrogen receptor (ER)-negative
      breast cancer subgroup, with increased tumour stromal expression of the
      coagulation factors Tissue Factor and thrombin. Rivaroxaban (Xarelto(R), Bayer
      AG, Leverkusen, Germany) is a direct oral anticoagulant (DOAC). It is a Factor Xa
      inhibitor that is routinely prescribed for the prevention of stroke in
      non-valvular atrial fibrillation and for both VTE prophylaxis and treatment. This
      trial will assess the anti-proliferative and other anti-cancer progression
      mechanisms of Rivaroxaban in ER-negative early breast cancer patients. METHODS:
      This UK-based preoperative window-of-opportunity phase II randomised control
      trial will randomise 88 treatment-naive early breast cancer patients to receive
      20 mg OD Rivaroxaban treatment for 11 to 17 days or no treatment. Treatment will 
      be stopped 24 h (range 18-36 h) prior to surgery or repeat core biopsy. All
      patients will be followed up for 2 weeks following surgery or repeat core biopsy.
      The primary endpoint is change in tumour Ki67. Secondary outcome measures include
      tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway
      activation and systemic markers of metastasis, tumour load and coagulation.
      DISCUSSION: Laboratory evidence supports an anti-cancer role for anticoagulants; 
      however, this has failed to translate into survival benefit when trialled in
      patients with metastatic disease or poor prognosis cancers, such as lung cancer. 
      Subgroup analysis supported a potential survival benefit in better prognosis
      advanced disease patients. This is the first study to investigate the anti-cancer
      effects of anticoagulants in early breast cancer. TRIAL REGISTRATION: UK National
      Research Ethics Service (NRES) approval 15/NW/0406, MHRA Clinical Trials
      Authorisation 48380/0003/001-0001. The sponsor is Manchester University NHS
      Foundation Trust, and the trial is co-ordinated by Cancer Research UK Liverpool
      Cancer Trials Unit (LCTU). EudraCT 2014-004909-33 , registered 27 July 2015.
      ISRCTN14785273 .
FAU - Castle, John
AU  - Castle J
AD  - Manchester Cancer Research Centre, The University of Manchester, Wilmslow Road,
      Manchester, M20 4GJ, UK.
FAU - Blower, Emma
AU  - Blower E
AD  - Manchester Cancer Research Centre, The University of Manchester, Wilmslow Road,
      Manchester, M20 4GJ, UK.
FAU - Bundred, Nigel J
AU  - Bundred NJ
AD  - Manchester Cancer Research Centre, The University of Manchester, Wilmslow Road,
      Manchester, M20 4GJ, UK.
AD  - The Nightingale Centre, Wythenshawe Hospital, Manchester, M23 9LT, UK.
FAU - Harvey, James R
AU  - Harvey JR
AD  - The Nightingale Centre, Wythenshawe Hospital, Manchester, M23 9LT, UK.
FAU - Thachil, Jecko
AU  - Thachil J
AD  - Department of Haematology, Manchester Royal Infirmary, Manchester, M13 9WL, UK.
FAU - Marshall, Andrea
AU  - Marshall A
AD  - Warwick Clinical Trials Unit, University of Warwick, Coventry, CV4 7AL, UK.
FAU - Cox, Karina
AU  - Cox K
AD  - Department of Breast Surgery, Maidstone Hospital, Maidstone, ME16 9QQ, UK.
FAU - Cicconi, Silvia
AU  - Cicconi S
AD  - Cancer Research UK Liverpool Cancer Trials Unit, Liverpool, L69 3GL, UK.
FAU - Holcombe, Chris
AU  - Holcombe C
AD  - Breast Unit, Royal Liverpool and Broadgreen University Hospitals NHS Trust,
      Liverpool, L3 9TA, UK.
FAU - Palmieri, Carlos
AU  - Palmieri C
AD  - Department of Molecular and Clinical Cancer Medicine, Liverpool, L69 3GA, UK.
FAU - Kirwan, Cliona C
AU  - Kirwan CC
AD  - Manchester Cancer Research Centre, The University of Manchester, Wilmslow Road,
      Manchester, M20 4GJ, UK. cliona.kirwan@manchester.ac.uk.
AD  - The Nightingale Centre, Wythenshawe Hospital, Manchester, M23 9LT, UK.
      cliona.kirwan@manchester.ac.uk.
LA  - eng
GR  - NIHR CS-11-014/National Institute for Health Research
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200827
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - *Breast Neoplasms/drug therapy
MH  - Clinical Trials, Phase II as Topic
MH  - Factor Xa Inhibitors/adverse effects/*therapeutic use
MH  - Female
MH  - Germany
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Rivaroxaban/adverse effects/*therapeutic use
MH  - Young Adult
PMC - PMC7534806
OTO - NOTNLM
OT  - Breast cancer
OT  - Clinical trial
OT  - DOAC
OT  - FXa
OT  - Ki67
OT  - NOAC
OT  - Rivaroxaban
OT  - Thrombin
OT  - Tissue Factor
EDAT- 2020/08/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s13063-020-04675-7 [doi]
AID - 10.1186/s13063-020-04675-7 [pii]
PST - epublish
SO  - Trials. 2020 Aug 27;21(1):749. doi: 10.1186/s13063-020-04675-7.


PMID- 32854752
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 27
TI  - The effect of psychoeducational intervention, based on a self-regulation model on
      menstrual distress in adolescents: a protocol of a randomized controlled trial.
PG  - 747
LID - 10.1186/s13063-020-04629-z [doi]
AB  - INTRODUCTION: Menstrual distress caused by primary dysmenorrhea is associated
      with physical and psychological symptoms-before, after, and during menstruation. 
      Leventhal's self-regulation educational model is based on the cognitive and
      emotional experiences of threat responses to symptoms and relates to coping
      responses. This study aims to investigate the effect of the implementation of a
      psychoeducational intervention, based on the self-regulation model of menstrual
      distress in adolescents. METHODS/DESIGN: In this randomized controlled trial, 120
      adolescent girls with moderate to severe menstrual pain (based on visual analog
      scale (VAS) >/= 4) from twelve randomly selected high schools in Qazvin City will
      be enrolled in the study and will be randomly assigned to either a 3-session
      psychoeducational intervention (n = 60) or control (n = 60) groups. The sessions 
      will be between 60 and 90 min apiece, and they will run for three consecutive
      weeks (one session per week). The data collection tools will include
      questionnaire eliciting menstrual information and demographics, the VAS, the Moos
      Menstrual Distress Questionnaire, and the illness perception questionnaire. One
      month prior to the intervention, both groups will participate in an initial
      assessment to assess the severity of their pain and level of menstrual distress. 
      Finally, all questionnaires will be completed for three consecutive months after 
      the intervention is completed. DISCUSSION: It is anticipated that findings of
      this study will provide evidence for the effectiveness of the Leventhal
      self-regulation model. Implications for improved practice, understanding, and
      treatment for menstrual distress may also arise. ETHICAL CONSIDERATIONS: The
      research protocol will be reviewed by the ethics committee, which is affiliated
      with the Qazvin University of Medical Sciences (Decree code:
      IR.QUMS.REC.1398.043). TRIAL REGISTRATION: IRCT20190625044002N1 . Registration
      date: 2019-09-03.
FAU - Asgari, Somayeh
AU  - Asgari S
AD  - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.
FAU - Alimoardi, Zainab
AU  - Alimoardi Z
AD  - Social Determinants of Health Research Center, Research Institute for Prevention 
      of Non-Communicable Diseases, Qazvin University of Medical Sciences, Shahid
      Bahonar Blvd, Qazvin, 3419759811, Iran.
FAU - Soleimani, Mohammad Ali
AU  - Soleimani MA
AD  - Social Determinants of Health Research Center, Research Institute for Prevention 
      of Non-Communicable Diseases, Qazvin University of Medical Sciences, Shahid
      Bahonar Blvd, Qazvin, 3419759811, Iran.
FAU - Allen, Kelly-Ann
AU  - Allen KA
AD  - Educational Psychology and Inclusive Education, Faculty of Education, Monash
      University and The Centre for Positive Psychology, The Melbourne Graduate School 
      of Education, The University of Melbourne, Melbourne, Australia.
FAU - Bahrami, Nasim
AU  - Bahrami N
AUID- ORCID: http://orcid.org/0000-0001-8751-6832
AD  - Social Determinants of Health Research Center, Research Institute for Prevention 
      of Non-Communicable Diseases, Qazvin University of Medical Sciences, Shahid
      Bahonar Blvd, Qazvin, 3419759811, Iran. nbahrami@qums.ac.ir.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200827
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Adolescent
MH  - Dysmenorrhea/diagnosis/*psychology/therapy
MH  - Female
MH  - Humans
MH  - Iran
MH  - *Menstruation
MH  - *Pain Measurement
MH  - Randomized Controlled Trials as Topic
MH  - *Self Care
MH  - Surveys and Questionnaires
MH  - Visual Analog Scale
MH  - Young Adult
PMC - PMC7450926
OTO - NOTNLM
OT  - Dysmenorrhea
OT  - Illness perceptions
OT  - Menstrual distress
OT  - Self-regulation model
EDAT- 2020/08/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/29 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s13063-020-04629-z [doi]
AID - 10.1186/s13063-020-04629-z [pii]
PST - epublish
SO  - Trials. 2020 Aug 27;21(1):747. doi: 10.1186/s13063-020-04629-z.


PMID- 32854696
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1472-6831 (Electronic)
IS  - 1472-6831 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 27
TI  - Does the rate of orthodontic tooth movement change during pregnancy and
      lactation? A systematic review of the evidence from animal studies.
PG  - 237
LID - 10.1186/s12903-020-01223-2 [doi]
AB  - BACKGROUND: The changes in bone homeostasis observed during pregnancy and
      lactation could result in alterations in the rate of orthodontic tooth movement, 
      but research in human subjects presents significant ethical and practical
      limitations. Our aim was to compare the amount of orthodontic tooth movement
      between pregnant/lactating or not animals. METHODS: We searched without
      restrictions 8 databases and performed hand searching until July 2019 (PubMed,
      Central, Cochrane Database of Systematic Reviews, SCOPUS, Web of Science, Arab
      World Research Source, ClinicalTrials.gov , ProQuest Dissertations and Theses
      Global). We searched for studies comparing quantitatively the amount of
      orthodontic tooth movement between pregnant/lactating or not animals. Following
      retrieval and selection of studies, the collection of related data was performed 
      and the risk of bias was assessed using the SYRCLE's Risk of Bias Tool.
      Exploratory synthesis was carried out using the random effects model. RESULTS:
      Four studies were finally identified raising no specific concerns regarding bias.
      One study showed that lactation increased the rate of tooth movement by 50 % [p <
      0.05]. Although an overall increase was noted in the pregnancy group as well, it 
      did not reach statistical significance [3 studies, Weighted Mean Difference:
      0.10; 95% Confidence Interval: - 0.04 - 0.24; p = 0.165]. CONCLUSIONS: The
      metabolic changes occurring during pregnancy and lactation may have an impact on 
      the rate of tooth movement in animals. Although these animal experimental results
      should be approached cautiously, it could be safe practice to consider the impact
      of these physiological changes in the clinical setting. REGISTRATION: PROSPERO
      (CRD42018118003).
FAU - Omar, Moaza
AU  - Omar M
AD  - Dubai Health Authority, Dubai, United Arab Emirates.
FAU - Kaklamanos, Eleftherios G
AU  - Kaklamanos EG
AUID- ORCID: 0000-0002-0513-5110
AD  - Hamdan Bin Mohammed College of Dental Medicine (HBMCDM), Mohammed Bin Rashid
      University of Medicine and Health Sciences (MBRU), Building 34, Dubai Healthcare 
      City, Dubai, United Arab Emirates. eleftherios.kaklamanos@mbru.ac.ae.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200827
PL  - England
TA  - BMC Oral Health
JT  - BMC oral health
JID - 101088684
SB  - IM
MH  - Animals
MH  - Female
MH  - Humans
MH  - *Lactation
MH  - Pregnancy
MH  - *Tooth Movement Techniques
PMC - PMC7450973
OTO - NOTNLM
OT  - *Lactation
OT  - *Orthodontic treatment
OT  - *Pregnancy
OT  - *Rate of tooth movement
EDAT- 2020/08/29 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/08/16 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 10.1186/s12903-020-01223-2 [doi]
AID - 10.1186/s12903-020-01223-2 [pii]
PST - epublish
SO  - BMC Oral Health. 2020 Aug 27;20(1):237. doi: 10.1186/s12903-020-01223-2.


PMID- 32854658
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 27
TI  - Complementary feeding practices among infants and young children in Abu Dhabi,
      United Arab Emirates.
PG  - 1308
LID - 10.1186/s12889-020-09393-y [doi]
AB  - BACKGROUND: Optimal complementary feeding (CF) promotes health and supports
      growth and development in children. While suboptimal feeding practices are
      reported for many countries, very limited information exists about such practices
      in the United Arab Emirates (UAE). The present study describes CF practices in
      Abu Dhabi, UAE, and evaluates them using the United Nations Children's Fund
      (UNICEF) Programming Guide: Infant and Young Child Feeding. METHODS: In this
      cross-sectional study, participating mothers of children below the age of two
      reported on their children's CF introduction and practices via a structured
      questionnaire. The study received ethical approval (ZU17_006_F) from Zayed
      University. RESULTS: Out of 1822 participating mothers, 938 had initiated
      complementary feeding for their children, who had a mean age of 7.1 +/- 5.9
      months. Three quarters of the children (72.2%) were introduced to CF in a timely 
      manner between the ages of 6 and 9 months. A majority (71.4%) consumed >/=4 food 
      groups, i.e. the recommended minimum diet diversity. In total, less than half
      (47.3%) of the children met the requirements for minimum meal frequency, with the
      non-breastfed, 6-23 month old children being the least compliant (21.9%) (p <
      0.001). Many children were fed with sugar-containing snack items. Overall, 36.2% 
      of the children aged >/=6 months had a minimum acceptable diet. CONCLUSION: The
      gap between the suboptimal CF practices and the recommendations may be
      attributable to poor knowledge about feeding practices rather than food
      availability problems. Effective intervention programs can facilitate
      improvements in the feeding practices to better support a healthy upbringing
      among Abu Dhabi infants and toddlers.
FAU - Taha, Zainab
AU  - Taha Z
AUID- ORCID: http://orcid.org/0000-0002-3915-3755
AD  - Department of Health Sciences, CNHS, Zayed University, PO Box 144534, Abu Dhabi, 
      United Arab Emirates. Zainab.Taha@zu.ac.ae.
FAU - Garemo, Malin
AU  - Garemo M
AD  - Department of Health Sciences, CNHS, Zayed University, PO Box 144534, Abu Dhabi, 
      United Arab Emirates.
FAU - Nanda, Joy
AU  - Nanda J
AD  - The John Hopkins Medical Institutions, Baltimore, MD, USA.
LA  - eng
GR  - R17042/Zayed University
PT  - Journal Article
DEP - 20200827
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - *Diet
MH  - Female
MH  - Guidelines as Topic
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Infant
MH  - *Infant Nutritional Physiological Phenomena
MH  - Infant, Newborn
MH  - Male
MH  - Meals
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - United Arab Emirates
MH  - Young Adult
PMC - PMC7453515
OTO - NOTNLM
OT  - Abu Dhabi
OT  - Complementary feeding
OT  - Infant nutrition
OT  - Socio-economics
OT  - Toddler
OT  - United Arab Emirates
EDAT- 2020/08/29 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.1186/s12889-020-09393-y [doi]
AID - 10.1186/s12889-020-09393-y [pii]
PST - epublish
SO  - BMC Public Health. 2020 Aug 27;20(1):1308. doi: 10.1186/s12889-020-09393-y.


PMID- 32854647
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 27
TI  - Neonatal transitional support with intact umbilical cord in assisted vaginal
      deliveries: a quality-improvement cohort study.
PG  - 496
LID - 10.1186/s12884-020-03188-0 [doi]
AB  - BACKGROUND: Deferring cord clamping has proven benefits for both term and preterm
      infants, and recent studies have demonstrated better cardio-respiratory stability
      if clamping is based on the infant's physiology, and whether the infant has
      breathed. Nevertheless, current guidelines for neonatal resuscitation still
      recommend early cord clamping (ECC) for compromised babies, unless equipment and 
      competent personnel to resuscitate the baby are available at the mother's
      bedside. The objective of this quality improvement cohort study was to evaluate
      whether implementing a new delivery room protocol involving mobile resuscitation 
      equipment (LifeStart) reduced the prevalence of ECC in assisted vaginal
      deliveries. METHODS: Data on cord clamping and transitional care were collected 8
      months before and 8 months after implementing the new protocol. The Model for
      Improvement was applied to identify drivers and obstacles to practice change.
      Statistical Process Control analysis was used to demonstrate signals of
      improvement, and whether these changes were sustainable. Multivariate logistic
      regression was used to evaluate the impact of the new protocol on the primary
      outcome, adjusted for possible confounders. RESULTS: Overall prevalence of ECC
      dropped from 13 to 1% (P < 0.01), with a 98% relative risk reduction for infants 
      needing transitional support on a resuscitation table (adjusted OR 0.02, P <
      0.001). Mean cord clamping time increased by 43% (p < 0.001). Although fewer
      infants were placed directly on mothers' chest (n = 43 [42%] vs n = 69 [75.0%], P
      < 0.001), there were no significant differences in needs for immediate
      transitional care or transfers to Neonatal Intensive Care Unit. A pattern of
      improvement was seen already before the intervention, especially after mandatory 
      educational sessions and cross-professional simulation training. CONCLUSIONS: A
      new delivery-room protocol involving mobile resuscitation equipment successfully 
      eliminated early cord clamping in assisted vaginal deliveries of term and
      near-term infants. A systematic approach, like the Model for Improvement, seemed 
      crucial for both achieving and sustaining the desired results. TRIAL
      REGISTRATION: The study was approved as a service evaluation as defined by the
      Regional Committee for Medical and Health Research Ethics ( 2018/1755/REK midt ).
FAU - Saether, Elisabeth
AU  - Saether E
AUID- ORCID: http://orcid.org/0000-0001-8335-7723
AD  - Department of Obstetrics and Gynecology, More and Romsdal Hospital Trust,
      Asehaugen 5, N-6017, Alesund, Norway. elisabeth.sether@helse-mr.no.
FAU - Gulpen, Friedrich Reinhart-Van
AU  - Gulpen FR
AD  - Department of Pediatrics, More and Romsdal Hospital Trust, Alesund Hospital,
      Alesund, Norway.
FAU - Jensen, Christer
AU  - Jensen C
AD  - Department of Medicine and Healthcare, More and Romsdal Hospital Trust, Alesund
      Hospital, Alesund, Norway.
AD  - Department of Health Sciences in Alesund, Faculty of Medicine and Health
      Sciences, Norwegian University of Science and Technology (NTNU), Alesund, Norway.
FAU - Myklebust, Tor Age
AU  - Myklebust TA
AD  - Department of Research and Innovation, Helse More and Romsdal Hospital Trust,
      Alesund, Norway.
FAU - Eriksen, Beate Horsberg
AU  - Eriksen BH
AD  - Department of Pediatrics, More and Romsdal Hospital Trust, Alesund Hospital,
      Alesund, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Clinical Protocols
MH  - Cohort Studies
MH  - Constriction
MH  - Delivery, Obstetric/*methods/*standards
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - *Quality Improvement
MH  - Resuscitation/*standards
MH  - Time Factors
MH  - *Umbilical Cord
PMC - PMC7457264
OTO - NOTNLM
OT  - Assisted vaginal delivery
OT  - Infant
OT  - Resuscitation
OT  - Umbilical cord clamping
EDAT- 2020/08/29 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - 10.1186/s12884-020-03188-0 [doi]
AID - 10.1186/s12884-020-03188-0 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Aug 27;20(1):496. doi: 10.1186/s12884-020-03188-0.


PMID- 32854626
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 27
TI  - Complications of cricothyroidotomy versus tracheostomy in emergency surgical
      airway management: a systematic review.
PG  - 216
LID - 10.1186/s12871-020-01135-2 [doi]
AB  - BACKGROUND: Airway guidelines recommend an emergency surgical airway as a
      potential life-saving treatment in a "Can't Intubate, Can't Oxygenate" (CICO)
      situation. Surgical airways can be achieved either through a cricothyroidotomy or
      tracheostomy. The current literature has limited data regarding complications of 
      cricothyroidotomy and tracheostomy in an emergency situation. The objective of
      this systematic review is to analyze complications following cricothyroidotomy
      and tracheostomy in airway emergencies. METHODS: This synthesis of literature was
      exempt from ethics approval. Eight databases were searched from inception to
      October 2018, using a comprehensive search strategy. Studies were included if
      they were randomized controlled trials or observational studies reporting
      complications following emergency surgical airway. Complications were classified 
      as minor (evolving to spontaneous remission or not requiring intervention or not 
      persisting chronically), major (requiring intervention or persisting
      chronically), early (from the start of the procedure up to 7 days) and late
      (beyond 7 days of the procedure). RESULTS: We retrieved 2659 references from our 
      search criteria. Following the removal of duplicates, title and abstract review, 
      33 articles were selected for full-text reading. Twenty-one articles were finally
      included in the systematic review. We found no differences in minor, major or
      early complications between the two techniques. However, late complications were 
      significantly more frequent in the tracheostomy group [OR (95% CI) 0.21
      (0.20-0.22), p < 0.0001]. CONCLUSIONS: Our results demonstrate that
      cricothyroidotomies performed in emergent situations resulted in fewer late
      complications than tracheostomies. This finding supports the recommendations from
      the latest Difficult Airway Society (DAS) guidelines regarding using
      cricothyroidotomy as the technique of choice for emergency surgical airway.
      However, emergency cricothyroidotomies should be converted to tracheostomies in a
      timely fashion as there is insufficient evidence to suggest that emergency
      cricothyrotomies are long term airways.
FAU - Zasso, Fabricio Batistella
AU  - Zasso FB
AUID- ORCID: 0000-0002-8003-0204
AD  - MD, Department of Anaesthesia, Mount Sinai Hospital, University of Toronto,
      Toronto, Ontario, Canada. Fabricio.Zasso@sinaihealthsystem.ca.
FAU - You-Ten, Kong Eric
AU  - You-Ten KE
AD  - MD, Department of Anaesthesia, Mount Sinai Hospital, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Ryu, Michelle
AU  - Ryu M
AD  - MLIS, Information Specialist, Sidney Liswood Health Science Library, Sinai Health
      System, University of Toronto, Toronto, Ontario, Canada.
FAU - Losyeva, Khrystyna
AU  - Losyeva K
AD  - Summer Research Student, Mount Sinai Hospital, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Tanwani, Jaya
AU  - Tanwani J
AD  - Medical Student, Faculty of Medicine, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Siddiqui, Naveed
AU  - Siddiqui N
AD  - MD, Department of Anaesthesia, Mount Sinai Hospital, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Systematic Review
DEP - 20200827
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
SB  - IM
MH  - Airway Management/*adverse effects/trends
MH  - Cricoid Cartilage/*surgery
MH  - *Emergency Medical Services/trends
MH  - Humans
MH  - Intubation, Intratracheal/adverse effects/trends
MH  - Observational Studies as Topic/methods
MH  - Postoperative Complications/diagnosis/*etiology
MH  - Randomized Controlled Trials as Topic/methods
MH  - Retrospective Studies
MH  - Thyroidectomy/*adverse effects/trends
MH  - Tracheostomy/*adverse effects/trends
PMC - PMC7450579
OTO - NOTNLM
OT  - *Complications
OT  - *Cricothyroidotomy
OT  - *Emergency surgical airway
OT  - *Systematic review
OT  - *Tracheostomy
EDAT- 2020/08/29 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/08/23 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
AID - 10.1186/s12871-020-01135-2 [doi]
AID - 10.1186/s12871-020-01135-2 [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 Aug 27;20(1):216. doi: 10.1186/s12871-020-01135-2.


PMID- 32854390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Aug 25
TI  - Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management.
LID - E2749 [pii]
LID - 10.3390/jcm9092749 [doi]
AB  - One in every four deaths is due to cancer in Europe. In view of its increasing
      incidence, cancer became the leading cause of death and disease burden in
      Denmark, France, the Netherlands, and the UK. Without essential improvements in
      cancer prevention, an additional 775,000 cases of annual incidence have been
      prognosed until 2040. Between 1995 and 2018, the direct costs of cancer doubled
      from EUR 52 billion to EUR 103 billion in Europe, and per capita health spending 
      on cancer increased by 86% from EUR 105 to EUR 195 in general, whereby Austria,
      Germany, Switzerland, Benelux, and France spend the most on cancer care compared 
      to other European countries. In view of the consequent severe socio-economic
      burden on society, the paradigm change from a reactive to a predictive,
      preventive, and personalized medical approach in the overall cancer management is
      essential. Concepts of predictive, preventive, and personalized medicine (3PM)
      demonstrate a great potential to revise the above presented trends and to
      implement cost-effective healthcare that benefits the patient and society as a
      whole. At any stage, application of early and predictive diagnostics, targeted
      prevention, and personalization of medical services are basic pillars making 3PM 
      particularly attractive for the patients as well as ethical and cost-effective
      healthcare. Optimal 3PM approach requires novel instruments such as well-designed
      liquid biopsy application. This review article highlights current achievements
      and details liquid biopsy approaches specifically in cancer management.
      3PM-relevant expert recommendations are provided.
FAU - Liskova, Alena
AU  - Liskova A
AD  - Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius 
      University in Bratislava, 036 01 Martin, Slovakia.
FAU - Samec, Marek
AU  - Samec M
AD  - Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius 
      University in Bratislava, 036 01 Martin, Slovakia.
FAU - Koklesova, Lenka
AU  - Koklesova L
AD  - Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius 
      University in Bratislava, 036 01 Martin, Slovakia.
FAU - Giordano, Frank A
AU  - Giordano FA
AD  - Department of Radiation Oncology, University Hospital Bonn, Rheinische
      Friedrich-Wilhelms-Universitat Bonn, 53127 Bonn, Germany.
FAU - Kubatka, Peter
AU  - Kubatka P
AUID- ORCID: 0000-0003-4312-5076
AD  - Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University
      in Bratislava, 036 01 Martin, Slovakia.
FAU - Golubnitschaja, Olga
AU  - Golubnitschaja O
AD  - Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation
      Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universitat
      Bonn, 53127 Bonn, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7563444
OTO - NOTNLM
OT  - blood
OT  - cancer
OT  - cell-free circulating nucleic acids
OT  - circulating tumor cells (CTC)
OT  - liquid biopsy
OT  - predictive preventive personalized medicine (PPPM/3PM)
OT  - saliva
OT  - tear fluid
OT  - test sensitivity specificity
OT  - urine
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
CRDT- 2020/08/29 06:00
PHST- 2020/07/17 00:00 [received]
PHST- 2020/08/17 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
AID - jcm9092749 [pii]
AID - 10.3390/jcm9092749 [doi]
PST - epublish
SO  - J Clin Med. 2020 Aug 25;9(9). pii: jcm9092749. doi: 10.3390/jcm9092749.


PMID- 32853328
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20210502
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 37
IP  - 3
DP  - 2020 Jun
TI  - [Ethical considerations related to the COVID-19 "passport"].
PG  - 329-330
LID - S0716-10182020000300329 [pii]
LID - 10.4067/s0716-10182020000300329 [doi]
FAU - Salas, Sofia P
AU  - Salas SP
AD  - Centro de Bioetica, Facultad de Medicina, Clinica Alemana Universidad del
      Desarrollo, Santiago, Chile.
LA  - spa
GR  - R25 TW001605/TW/FIC NIH HHS/United States
PT  - Journal Article
TT  - Consideraciones eticas respecto del "pasaporte" COVID-19.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de
      Infectologia
JID - 9305754
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC8084077
MID - NIHMS1692342
EDAT- 2020/08/28 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - S0716-10182020000300329 [pii]
AID - 10.4067/s0716-10182020000300329 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2020 Jun;37(3):329-330. doi:
      10.4067/s0716-10182020000300329.


PMID- 32853252
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201015
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Evaluation of whole-body MRI with diffusion-weighted sequences in the staging of 
      pediatric cancer patients.
PG  - e0238166
LID - 10.1371/journal.pone.0238166 [doi]
AB  - BACKGROUND: The purpose of this study was to determine whether whole-body MRI
      (WBMRI) with diffusion-weighted sequences, which is free of ionizing radiation,
      can perform as well as traditional methods when used alone for staging or
      follow-up of pediatric cancer patients. METHODS: After obtaining approval from
      our institutional research ethics committee and appropriate informed consent, we 
      performed 34 examinations in 32 pediatric patients. The examinations were
      anonymized and analyzed by two radiologists with at least 10 years' experience.
      RESULTS: The sensitivity and specificity findings, respectively, were as follows:
      100% and 100% for primary tumor; 100% and 86% for bone metastasis; 33% and 100%
      for lung metastasis; 85% and 100% for lymph node metastasis; and 100% and 62% for
      global investigation of primary or secondary neoplasias. We observed excellent
      interobserver agreement for WBMRI and excellent agreement with standard staging
      examination results. CONCLUSIONS: Our results suggest that pediatric patients can
      be safely imaged with WBMRI, although not as the only tool but in association
      with low-dose chest CT (for subcentimeter pulmonary nodules). However, additional
      exams with ionizing radiation may be necessary for patients who tested positive
      to correctly quantify and locate the lesions.
FAU - de Oliveira, Alex Dias
AU  - de Oliveira AD
AUID- ORCID: 0000-0001-9169-3153
AD  - Imaging Department, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
FAU - de Souza, Guilherme Heidi Yto
AU  - de Souza GHY
AD  - Imaging Department, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
FAU - Guimaraes, Camila Pinto Brito de Figueiredo
AU  - Guimaraes CPBF
AD  - Imaging Department, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
FAU - Guimaraes, Marcos Duarte
AU  - Guimaraes MD
AD  - Imaging Department, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
FAU - da Costa, Cecilia Maria Lima
AU  - da Costa CML
AD  - Pediatric Department, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
FAU - Porto, Fabio Henrique de Gobbi
AU  - Porto FHG
AD  - Neurology Department, University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Chojniak, Rubens
AU  - Chojniak R
AD  - Imaging Department, A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Diffusion Magnetic Resonance Imaging/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasm Staging/methods
MH  - Neoplasms/*pathology
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Whole Body Imaging/methods
PMC - PMC7451574
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/28 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/28 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1371/journal.pone.0238166 [doi]
AID - PONE-D-19-03567 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 27;15(8):e0238166. doi: 10.1371/journal.pone.0238166.
      eCollection 2020.


PMID- 32853218
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Exploring the ethical issues in research using digital data collection strategies
      with minors: A scoping review.
PG  - e0237875
LID - 10.1371/journal.pone.0237875 [doi]
AB  - While emerging digital health technologies offer researchers new avenues to
      collect real-time data, little is known about current ethical dimensions,
      considerations, and challenges that are associated with conducting digital data
      collection in research with minors. As such, this paper reports the findings of a
      scoping review which explored existing literature to canvass current ethical
      issues that arise when using digital data collection in research with minors.
      Scholarly literature was searched using electronic academic databases for
      articles that provided explicit ethical analysis or presented empirical research 
      that directly addressed ethical issues related to digital data collection used in
      research with minors. After screening 1,156 titles and abstracts, and reviewing
      73 full-text articles, 20 articles were included in this review. Themes which
      emerged across the reviewed literature included: consent, data handling, minors' 
      data rights, observing behaviors that may result in risk of harm to participants 
      or others, private versus public conceptualizations of data generated through
      social media, and gatekeeping. Our findings indicate a degree of uncertainty
      which invariably exists with regards to the ethics of research that involves
      minors and digital technology. The reviewed literature suggests that this
      uncertainty can often lead to the preclusion of minors from otherwise important
      lines of research inquiry. While uncertainty warrants ethical consideration,
      increased ethical scrutiny and restricting the conduct of such research raises
      its own ethical challenges. We conclude by discussing and recommending the
      ethical merits of co-producing ethical practice between researchers and minors as
      a mechanism to proceed with such research while addressing concerns around
      uncertainty.
FAU - Facca, Danica
AU  - Facca D
AUID- ORCID: 0000-0002-3150-4805
AD  - Faculty of Information and Media Studies, Western University, London, ON, Canada.
FAU - Smith, Maxwell J
AU  - Smith MJ
AD  - School of Health Studies, Western University, London, ON, Canada.
FAU - Shelley, Jacob
AU  - Shelley J
AD  - School of Health Studies, Western University, London, ON, Canada.
FAU - Lizotte, Daniel
AU  - Lizotte D
AD  - Department of Computer Science, Western University, London, ON, Canada.
FAU - Donelle, Lorie
AU  - Donelle L
AD  - Arthur Labatt Family School of Nursing, Western University, London, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200827
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Behavior
MH  - *Data Collection
MH  - Data Management
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent/ethics
MH  - *Minors
MH  - Publications
MH  - Risk
MH  - Social Media
PMC - PMC7451523
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/28 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1371/journal.pone.0237875 [doi]
AID - PONE-D-20-09390 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 27;15(8):e0237875. doi: 10.1371/journal.pone.0237875.
      eCollection 2020.


PMID- 32852440
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1550-1841 (Electronic)
IS  - 0741-5206 (Linking)
VI  - 40
IP  - 3
DP  - 2020 Jul/Sep
TI  - Malignant Wounds in Hospitalized Oncology Patients: Prevalence, Characteristics, 
      and Associated Factors.
PG  - 138-144
LID - 10.1097/PSN.0000000000000320 [doi]
AB  - Epidemiological and descriptive research on malignant wounds (MWs) is scarce. The
      objective of this study was to identify the prevalence of MWs and analyze the
      characteristics and associated factors of MWs in hospitalized patients at an
      oncological institution. An epidemiological, cross-sectional, and descriptive
      study, which was derived from a larger study that collected data on the
      prevalence of different types of wounds in 341 adults hospitalized in a large
      oncological hospital, was conducted. The present study comprehensively analyzed
      data related to MWs. Information was obtained through participant interviews,
      physical examination, and medical record review. The study was approved by the
      ethics committee of the institution where the study was conducted. Fourteen MWs
      were identified in 13 patients, who were primarily married (58%) and men (75%),
      with a mean age of 60.5 +/- 15.1 years. Malignant wounds were predominantly
      located in the head and neck region (43%) and classified as 1N (50%) according to
      the Staging of Malignant Cutaneous Wounds instrument. Malignant wounds were
      characterized as painful (83.3%), with significant pain present during dressing
      changes (93%). The presence of MWs was associated with the use of antidepressants
      (odds ratio [OR] = 4.95; p = .012), upper-limb edema (OR = 8.39; p = .003), and
      infection (OR = 12.16; p = .051). The prevalence of MWs in hospitalized patients 
      was 3.8%. Associated clinical variables were related to the degree of disease
      progression. This information provides evidence of the need for research
      identifying and investigating nursing interventions for patients with MW to
      assist with pain control during dressing changes.
FAU - Firmino, Flavia
AU  - Firmino F
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
FAU - Ferreira, Suzana Aparecida da Costa
AU  - Ferreira SADC
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
FAU - Franck, Ednalda Maria
AU  - Franck EM
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
FAU - de Queiroz, Wilka Medeiros Silva
AU  - de Queiroz WMS
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
FAU - Castro, Diana Villela
AU  - Castro DV
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
FAU - Nogueira, Paula Cristina
AU  - Nogueira PC
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
FAU - Santos, Vera Lucia Conceicao Gouveia
AU  - Santos VLCG
AD  - Flavia Firmino, PhD, BSN, RN, ETN, is an oncologist nurse at the Jose Alencar
      Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.
AD  - Suzana Aparecida da Costa Ferreira, EdS, RN, ET, OCN, is a master's student in
      Adult Health Nursing Graduation Program (PROESA), Escola de Enfermagem da
      Universidade de Sao Paulo (USP) (School of Nursing of the University of Sao
      Paulo), Sao Paulo, SP, Brazil.
AD  - Ednalda Maria Franck, RN, ET, is a nurse at the Center for Palliative Care at
      Hospital das Clinicas, Medical School, USP, working in the Interconsulting Group 
      and in the Palliative Care Outpatient Clinic, Hospital das Clinicas, USP Medical 
      School, Nursing Division, Sao Paulo, SP, Brazil.
AD  - Wilka Medeiros Silva de Queiroz, RN, ET, is a public health specialist (Family
      Health Program), and a nurse product specialist at Laboratory B Braun, B Braun
      Laboratories, Sao Paulo, SP, Brazil.
AD  - Diana Villela Castro, PhD, MSc, BSN, RN, is a postdoctoral fellow, Bayer
      Pharmaceuticals, Sao Paulo, SP, Brazil.
AD  - Paula Cristina Nogueira, PhD, MSN, BSN, RN, ETN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
AD  - Vera Lucia Conceicao Gouveia Santos, PhD, MSN, BSN, RN, is a postdoctoral fellow,
      Department of Medical-Surgical Nursing at the School of Nursing of the University
      of Sao Paulo (Universidade de Sao Paulo, Escola de Enfermagem EEUSP), Sao Paulo, 
      SP, Brazil.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Surg Nurs
JT  - Plastic surgical nursing : official journal of the American Society of Plastic
      and Reconstructive Surgical Nurses
JID - 8403490
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*complications/epidemiology/physiopathology
MH  - Prevalence
MH  - Risk Factors
MH  - Wound Healing/drug effects/physiology
MH  - Wounds and Injuries/epidemiology/*etiology/physiopathology
EDAT- 2020/08/28 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
AID - 10.1097/PSN.0000000000000320 [doi]
AID - 00006527-202007000-00009 [pii]
PST - ppublish
SO  - Plast Surg Nurs. 2020 Jul/Sep;40(3):138-144. doi: 10.1097/PSN.0000000000000320.


PMID- 32852276
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200922
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Aug 27
TI  - The Art of Surgery: Balancing Compassionate With Virtual Care.
PG  - e22417
LID - 10.2196/22417 [doi]
AB  - The recent drive to include virtual care in surgical practice has been
      accelerated due to the COVID-19 pandemic. Many physicians feel that communicating
      via telehealth is unlike traditional methods of providing health care, and thus
      guidance on maintaining excellence in communication is necessary, especially as
      academic literature on virtual care in surgery is nonexistent. Challenges faced
      in transitioning to virtual care include the inability to utilize body language, 
      barriers to traditional physical examination, exacerbation of existing
      vulnerabilities and inequities in patient groups, the declining quality of
      medical education, and the fragmentation of the multidisciplinary health care
      team. This paper seeks to resolve these challenges by focusing on the pillars of 
      good communication, including preparation, professionalism, empathy, respect, and
      the virtual physical examination.
CI  - (c)Elisheva Tamar Anne Nemetz, David Robert Urbach, Karen Michelle Devon.
      Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 27.08.2020.
FAU - Nemetz, Elisheva Tamar Anne
AU  - Nemetz ETA
AUID- ORCID: 0000-0003-0158-6392
AD  - Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Urbach, David Robert
AU  - Urbach DR
AUID- ORCID: 0000-0002-6476-7337
AD  - Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON,
      Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, ON, Canada.
AD  - University Health Network, Toronto, ON, Canada.
AD  - Women's College Hospital, Toronto, ON, Canada.
FAU - Devon, Karen Michelle
AU  - Devon KM
AUID- ORCID: 0000-0001-8096-0471
AD  - Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON,
      Canada.
AD  - University Health Network, Toronto, ON, Canada.
AD  - Women's College Hospital, Toronto, ON, Canada.
AD  - Joint Centre for Bioethics, Dalla Lana School of Public Health, University of
      Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Empathy/*physiology
MH  - Humans
MH  - Surgical Procedures, Operative/*psychology
MH  - Telemedicine/*methods
PMC - PMC7484766
OTO - NOTNLM
OT  - *COVID-19 and virtual care
OT  - *bioethics
OT  - *consent
OT  - *medical education
OT  - *medical ethics
OT  - *privacy
OT  - *surgery
OT  - *surgical communication
OT  - *telehealth
OT  - *telehealth in surgery
OT  - *video care in surgery
OT  - *virtual care
OT  - *virtual care in surgery
EDAT- 2020/08/28 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/07/10 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/06 00:00 [revised]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - v22i8e22417 [pii]
AID - 10.2196/22417 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Aug 27;22(8):e22417. doi: 10.2196/22417.


PMID- 32852275
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Aug 27
TI  - The P Value Line Dance: When Does the Music Stop?
PG  - e21345
LID - 10.2196/21345 [doi]
AB  - When should a trial stop? Such a seemingly innocent question evokes concerns of
      type I and II errors among those who believe that certainty can be the product of
      uncertainty and among researchers who have been told that they need to carefully 
      calculate sample sizes, consider multiplicity, and not spend P values on interim 
      analyses. However, the endeavor to dichotomize evidence into significant and
      nonsignificant has led to the basic driving force of science, namely uncertainty,
      to take a back seat. In this viewpoint we discuss that if testing the null
      hypothesis is the ultimate goal of science, then we need not worry about writing 
      protocols, consider ethics, apply for funding, or run any experiments at all-all 
      null hypotheses will be rejected at some point-everything has an effect. The job 
      of science should be to unearth the uncertainties of the effects of treatments,
      not to test their difference from zero. We also show the fickleness of P values, 
      how they may one day point to statistically significant results; and after a few 
      more participants have been recruited, the once statistically significant effect 
      suddenly disappears. We show plots which we hope would intuitively highlight that
      all assessments of evidence will fluctuate over time. Finally, we discuss the
      remedy in the form of Bayesian methods, where uncertainty leads; and which allows
      for continuous decision making to stop or continue recruitment, as new data from 
      a trial is accumulated.
CI  - (c)Marcus Bendtsen. Originally published in the Journal of Medical Internet
      Research (http://www.jmir.org), 27.08.2020.
FAU - Bendtsen, Marcus
AU  - Bendtsen M
AUID- ORCID: 0000-0002-8678-1164
AD  - Department of Health, Medicine and Caring Sciences, Division of Society and
      Health, Linkoping, Sweden.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200827
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Biostatistics
MH  - *Data Interpretation, Statistical
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic/*methods
MH  - *Sample Size
PMC - PMC7484773
OTO - NOTNLM
OT  - *Bayesian analysis
OT  - *P value
OT  - *dichotomization
OT  - *dichotomy
OT  - *error
OT  - *randomized controlled trial
OT  - *sample size
OT  - *uncertainty
EDAT- 2020/08/28 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/06/11 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/07/05 00:00 [revised]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - v22i8e21345 [pii]
AID - 10.2196/21345 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Aug 27;22(8):e21345. doi: 10.2196/21345.


PMID- 32851596
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210110
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Dec
TI  - COVID-19 vaccines: ethical framework concerning human challenge studies.
PG  - 807-812
LID - 10.1007/s40199-020-00371-8 [doi]
AB  - BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues
      to spread worldwide. The most favorable epidemic control scenario, which provides
      long-term protection against COVID-19 outbreak, is the development and
      distribution of an effective and safe vaccine. The need to develop a new COVID-19
      vaccine is pressing; however, it is likely to take a long time, possibly several 
      years. This is due to the time required to demonstrate the safety and efficacy of
      the proposed vaccine. and the time required to manufacture and distribute
      millions of doses. OBJECTIVES: To accelerate this development and associated
      safety testing, the deliberate infection of healthy volunteers has been
      suggested. The purpose of this short communication is to describe the ethical
      aspects of this type of testing, RESULTS: Deliberate infection of volunteers with
      a dangerous virus such as SARS-CoV-2 was initially considered unethical by
      researchers; but the current pandemic is so different from previous ones that
      these studies are considered ethical if certain criteria are met. Participants in
      human challenge studies must be relatively young, in good health and must receive
      the highest quality medical care, with frequent monitoring. Tests should also be 
      performed with great caution and specialized medical supervision. Besides, the
      fact that obtaining vaccines faster through deliberate infection studies of
      healthy people has greater benefits than risks, has been demonstrated by
      obtaining other vaccines in other historical pandemics such as: smallpox,
      influenza, malaria, typhoid fever, Dengue fever and Zika. CONCLUSIONS: One
      possibility to shorten the time required for the development of COVID-19 vaccines
      is to reduce clinical phases II and III by using human challenge studies through 
      eliberate infection of healthy volunteers with SARS-CoV-2 after administration of
      the candidate vaccine. Accelerating the development of a COVID-19 vaccine even
      for a few weeks or months would have a great beneficial impact on public health
      by saving many lives.
FAU - Calina, Daniela
AU  - Calina D
AUID- ORCID: http://orcid.org/0000-0002-1523-9116
AD  - Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 
      200349, Craiova, Romania. calinadaniela@gmail.com.
FAU - Hartung, Thomas
AU  - Hartung T
AD  - CAAT-Europe at the University of Konstanz, 78457, Constance, Germany.
AD  - CAAT, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD,
      21287, USA.
FAU - Docea, Anca Oana
AU  - Docea AO
AD  - Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349,
      Craiova, Romania.
FAU - Spandidos, Demetrios A
AU  - Spandidos DA
AD  - Laboratory of Clinical Virology, Medical School, University of Crete, 71409,
      Heraklion, Greece.
FAU - Egorov, Alex M
AU  - Egorov AM
AD  - FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-
      and Biological Products of Russian Academy of Sciences", 108819, Moscow, Russia.
AD  - Russian Academy of Sciences, Moscow, Russia.
FAU - Shtilman, Michael I
AU  - Shtilman MI
AD  - D.I. Mendeleyev University of Chemical Technology, 125047, Moscow, Russia.
FAU - Carvalho, Felix
AU  - Carvalho F
AD  - UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences,
      Faculty of Pharmacy, University of Porto, 4050-313, Porto, Portugal.
FAU - Tsatsakis, Aristidis
AU  - Tsatsakis A
AD  - Russian Academy of Sciences, Moscow, Russia. tsatsaka@uoc.gr.
AD  - Department of Analytical and Forensic Medical Toxicology, Sechenov University,
      119991, Moscow, Russia. tsatsaka@uoc.gr.
AD  - Department of Forensic Sciences and Toxicology, Faculty of Medicine, University
      of Crete, 71003, Heraklion, Greece. tsatsaka@uoc.gr.
AD  - Laboratory of Toxicology, Medical School, University of Crete, 70013, Heraklion, 
      Greece. tsatsaka@uoc.gr.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Animals
MH  - COVID-19/immunology/*prevention & control/virology
MH  - COVID-19 Vaccines/*administration & dosage/adverse effects/immunology
MH  - Clinical Trials as Topic/ethics
MH  - Human Experimentation/ethics
MH  - Humans
MH  - SARS-CoV-2/*immunology
MH  - Time Factors
PMC - PMC7449865
OTO - NOTNLM
OT  - COVID-19 vaccines
OT  - Human challenge studies
OT  - Randomized clinical trials
OT  - Risk taking
EDAT- 2020/08/28 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/07/08 00:00 [received]
PHST- 2020/08/21 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - 10.1007/s40199-020-00371-8 [doi]
AID - 10.1007/s40199-020-00371-8 [pii]
PST - ppublish
SO  - Daru. 2020 Dec;28(2):807-812. doi: 10.1007/s40199-020-00371-8. Epub 2020 Aug 27.


PMID- 32850915
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Healthcare Transformation in the Post-Coronavirus Pandemic Era.
PG  - 429
LID - 10.3389/fmed.2020.00429 [doi]
FAU - Jazieh, Abdul Rahman
AU  - Jazieh AR
AD  - Department of Oncology, King Abdullah International Medical Research Center, King
      Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
FAU - Kozlakidis, Zisis
AU  - Kozlakidis Z
AD  - Laboratory Services and Biobanking, International Agency for Research on Cancer, 
      World Health Organization, Lyon, France.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7399067
OTO - NOTNLM
OT  - COVID-19
OT  - coronavirus
OT  - ethics
OT  - healthcare transformation
OT  - technological innovation
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/05/09 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fmed.2020.00429 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Jul 28;7:429. doi: 10.3389/fmed.2020.00429.
      eCollection 2020.


PMID- 32850908
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - PrescrAIP: A Pan-European Study on Current Treatment Regimens of Auto-Immune
      Pancreatitis.
PG  - 408
LID - 10.3389/fmed.2020.00408 [doi]
AB  - Introduction: Treatment of autoimmune pancreatitis (AIP) is based solely on
      consensus and has yet to become standardized. Consequently, therapeutic regimens 
      vary greatly between countries and centers, and largely depend on the experience 
      of the physician. At this moment, the optimal regimen for inducing disease
      remission and preventing relapse is unknown. Objectives: The primary objective of
      this study is to describe current treatment regimens used in Europe, and to
      compare their effectiveness in inducing remission and preventing and treating
      relapse. The secondary objectives are: to identify risk factors for relapse; to
      assess the diagnostic accuracy of the Unified-AIP criteria; to assess the
      performance of the M-ANNHEIM score for predicting relapse; and to assess
      long-term outcomes including pancreatic exocrine insufficiency and pancreatic
      cancer. Methods: This is an international, retrospective, observational cohort
      study, performed in over 40 centers from 16 European countries. Eligible are all 
      patients diagnosed with AIP from 2005 onwards, regardless of the used diagnostic 
      criteria. Data on study subjects will be retrieved from the hospital's electronic
      medical records and registered with a standardized, web-based, electronic case
      report form (eCRF). To compare the effectiveness of treatment regimens in
      inducing remission, preventing relapse, and treating relapse, subjects will be
      stratified in groups based on: type of therapy; initial therapy dose; cumulative 
      therapy dose; therapy tapering speed and duration; and having received
      maintenance therapy or not. Ethics and Dissemination: Ethical and/or
      institutional review board approvals are obtained by all participating centers
      according to local regulations. The study complies with the General Data
      Protection Regulation (GDPR). All manuscripts resulting from the study will be
      submitted to peer-reviewed journals. Conclusion: This is the first pan-European
      retrospective registry for AIP. It will produce the first large-scale data on
      treatment of European patients with AIP, providing answers on the use and
      effectiveness of treatment regimens. In the future, this collaboration may
      provide a network for continuation into a prospective European registry.
CI  - Copyright (c) 2020 Lanzillotta, Vinge-Holmquist, Overbeek, Poulsen, Demirci,
      Macinga, Lohr and Rosendahl.
FAU - Lanzillotta, Marco
AU  - Lanzillotta M
AD  - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San
      Raffaele Scientific Institute, Milan, Italy.
FAU - Vinge-Holmquist, Olof
AU  - Vinge-Holmquist O
AD  - Department of Gastroenterological Surgery, Akershus University Hospital,
      Loerenskog, Norway.
FAU - Overbeek, Kasper A
AU  - Overbeek KA
AD  - Department of Gastroenterology & Hepatology, Erasmus University Medical Center,
      Rotterdam, Netherlands.
FAU - Poulsen, Jakob L
AU  - Poulsen JL
AD  - Centre for Pancreatic Diseases, Department of Gastroenterology & Hepatology,
      Aalborg University Hospital, Aalborg, Denmark.
FAU - Demirci, A Fatih
AU  - Demirci AF
AD  - Department of Internal Medicine, Marmara University Research and Education
      Hospital, Istanbul, Turkey.
FAU - Macinga, Peter
AU  - Macinga P
AD  - Department of Gastroenterology and Hepatology, Institute for Clinical and
      Experimental Medicine, Prague, Czechia.
FAU - Lohr, Matthias
AU  - Lohr M
AD  - Gastroenterology and Hepatology, Gastrocentrum, Karolinska University Hospital,
      Karolinska Universitetssjukhuset, Stockholm, Sweden.
FAU - Rosendahl, Jonas
AU  - Rosendahl J
AD  - Department of Internal Medicine I, Martin Luther University, Halle (Saale),
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7419461
OTO - NOTNLM
OT  - IgG4
OT  - IgG4 (autoimmune pancreatitis)
OT  - autoimmune pancreatitis
OT  - cohort studies
OT  - glucococorticoids
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/03/22 00:00 [received]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fmed.2020.00408 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Aug 5;7:408. doi: 10.3389/fmed.2020.00408. eCollection
      2020.


PMID- 32850905
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Online Information of Vaccines: Information Quality, Not Only Privacy, Is an
      Ethical Responsibility of Search Engines.
PG  - 400
LID - 10.3389/fmed.2020.00400 [doi]
AB  - The fact that Internet companies may record our personal data and track our
      online behavior for commercial or political purpose has emphasized aspects
      related to online privacy. This has also led to the development of search engines
      that promise no tracking and privacy. Search engines also have a major role in
      spreading low-quality health information such as that of anti-vaccine websites.
      This study investigates the relationship between search engines' approach to
      privacy and the scientific quality of the information they return. We analyzed
      the first 30 webpages returned searching "vaccines autism" in English, Spanish,
      Italian, and French. The results show that not only "alternative" search engines 
      (Duckduckgo, Ecosia, Qwant, Swisscows, and Mojeek) but also other commercial
      engines (Bing, Yahoo) often return more anti-vaccine pages (10-53%) than
      Google.com (0%). Some localized versions of Google, however, returned more
      anti-vaccine webpages (up to 10%) than Google.com. Health information returned by
      search engines has an impact on public health and, specifically, in the
      acceptance of vaccines. The issue of information quality when seeking information
      for making health-related decisions also impact the ethical aspect represented by
      the right to an informed consent. Our study suggests that designing a search
      engine that is privacy savvy and avoids issues with filter bubbles that can
      result from user-tracking is necessary but insufficient; instead, mechanisms
      should be developed to test search engines from the perspective of information
      quality (particularly for health-related webpages) before they can be deemed
      trustworthy providers of public health information.
CI  - Copyright (c) 2020 Ghezzi, Bannister, Casino, Catalani, Goldman, Morley, Neunez, 
      Prados-Bo, Smeesters, Taddeo, Vanzolini and Floridi.
FAU - Ghezzi, Pietro
AU  - Ghezzi P
AD  - Brighton & Sussex Medical School, Brighton, United Kingdom.
FAU - Bannister, Peter G
AU  - Bannister PG
AD  - Brighton & Sussex Medical School, Brighton, United Kingdom.
FAU - Casino, Gonzalo
AU  - Casino G
AD  - Communication Department, Pompeu Fabra University, Barcelona, Spain.
AD  - Iberoamerican Cochrane Center, Barcelona, Spain.
FAU - Catalani, Alessia
AU  - Catalani A
AD  - Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino,
      Italy.
FAU - Goldman, Michel
AU  - Goldman M
AD  - Institute for Interdisciplinary Innovation in Healthcare (I3h), Universite Libre 
      de Bruxelles, Brussels, Belgium.
FAU - Morley, Jessica
AU  - Morley J
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
FAU - Neunez, Marie
AU  - Neunez M
AD  - Institute for Interdisciplinary Innovation in Healthcare (I3h), Universite Libre 
      de Bruxelles, Brussels, Belgium.
FAU - Prados-Bo, Andreu
AU  - Prados-Bo A
AD  - Communication Department, Pompeu Fabra University, Barcelona, Spain.
AD  - Blanquerna School of Health Sciences, Ramon Llull University, Barcelona, Spain.
FAU - Smeesters, Pierre R
AU  - Smeesters PR
AD  - Molecular Bacteriology Laboratory, Universite Libre de Bruxelles, Brussels,
      Belgium.
AD  - Academic Children Hospital Queen Fabiola, Universite libre de Bruxelles,
      Brussels, Belgium.
FAU - Taddeo, Mariarosaria
AU  - Taddeo M
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
AD  - The Alan Turing Institute, London, United Kingdom.
FAU - Vanzolini, Tania
AU  - Vanzolini T
AD  - Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino,
      Italy.
FAU - Floridi, Luciano
AU  - Floridi L
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
AD  - The Alan Turing Institute, London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200811
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7431660
OTO - NOTNLM
OT  - fake news
OT  - health information
OT  - information quality
OT  - misinformation
OT  - privacy
OT  - search engines
OT  - vaccines
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fmed.2020.00400 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Aug 11;7:400. doi: 10.3389/fmed.2020.00400.
      eCollection 2020.


PMID- 32850568
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Community Benefit: Policies, Practices, and Opportunities at the Half-Century
      Mark.
PG  - 289
LID - 10.3389/fpubh.2020.00289 [doi]
AB  - In the 50 years since the expansion of the legal definition of charity for
      tax-exempt hospitals, there have been periodic regulatory actions at the
      municipal, state, and federal level to quantify charitable contributions and
      justify the deferral of tax revenues. The movement toward risk-based
      reimbursement in the last decade creates an incentive for a shift in hospital
      leadership understanding and approach to community benefit programs and services.
      The historical interpretation of community benefit as an issue of compliance with
      legal obligations is being questioned by forward-thinking hospital leaders, in
      recognition that more strategic resource allocation offers the potential to
      reduce financial risk associated with preventable emergency department and
      inpatient utilization. Recent actions in the policy arena to strengthen community
      benefit practices, as well as policies in related areas such as homelessness and 
      behavioral health, challenge hospitals to strengthen their focus on prevention.
      At the same time, increased availability of data on health care costs, mapping of
      health care utilization patterns, and parallel overlays of hospital location,
      jurisdictional boundaries, and the social determinants of health offer
      significant potential for informed public dialogue at the regional level that
      builds an ethic of shared ownership for health across sectors. Local public
      health agencies can play an important role by establishing baselines, goals, and 
      objectives in communities where health inequities are concentrated within county 
      and municipal jurisdictional boundaries to align and focus the assets of health, 
      community development, and business sector stakeholders.
CI  - Copyright (c) 2020 Barnett.
FAU - Barnett, Kevin
AU  - Barnett K
AD  - Center to Advance Community Health and Equity, Public Health Institute, Oakland, 
      CA, United States.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *Charities
MH  - Community Health Services
MH  - Humans
MH  - Policy
MH  - Public Health
MH  - *Tax Exemption
PMC - PMC7397757
OTO - NOTNLM
OT  - *community benefit
OT  - *municipal property tax
OT  - *risk-based reimbursement
OT  - *social determinants of health
OT  - *state and national policy
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fpubh.2020.00289 [doi]
PST - epublish
SO  - Front Public Health. 2020 Jul 27;8:289. doi: 10.3389/fpubh.2020.00289.
      eCollection 2020.


PMID- 32850537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Turkish Adaptation and Validation of the EMpowerment of PArents in THe Intensive 
      Care (EMPATHIC-30) Questionnaire to Measure Parent Satisfaction in Neonatal
      Intensive Care Units.
PG  - 421
LID - 10.3389/fped.2020.00421 [doi]
AB  - Aim: The aim of this study was to translate and validate the shortened version of
      the "EMpowerment of PArents in THe Intensive Care" (EMPATHIC-30) questionnaire
      into Turkish to measure parent satisfaction in the Neonatal Intensive Care Units 
      (NICU). Method: The study used a cross-sectional design. The data of the study
      were collected from parents with infants staying in the NICU of a training and
      research hospital in Sakarya, Turkey, between July 2018-2019 after obtaining
      ethical approval. Totally, 238 parents (234 mothers, four fathers) agreed to
      participate in the study and completed the questionnaire. Of these, 35 mothers
      were recruited 1 month later for the test-retest reliability analysis. The
      questionnaire was translated using back and forward translation. Reliability and 
      validity test were performed to measure the psychometric properties of the
      Turkish EMPATHIC-30. Results: The mean age of the parents was 28.27 (SD 5.93),
      and 48.3% of them were primary school graduates. The infants: 55.9% were male,
      the mean gestational age was 36.89 (SD 3.25) weeks, and mean length of hospital
      stay was 9.36 (SD 10.17) days. The mean scores of each item with a six-point
      scale of the EMPATHIC-30 questionnaire ranged between 4.01 and 4.87. The
      Cronbach's alpha of the total questionnaire was 0.95. Cronbach's alpha of the
      five domains (Information, Care and Treatment, Organization, Parent
      Participation, and Professional Attitude) ranged between 0.80 and 0.92. Pearson
      correlation coefficient between the domains and total questionnaire was r =
      0.988. The Intraclass correlation coefficient was ICC = 0.998 in the test-retest 
      evaluation. Confirmatory factor analysis was performed for construct validity and
      was moderate; Comparative Fit Index = 0.792, Tucker-Lewis Index = 0.770,
      Standardized Root Mean Square Residual = 0.0811, and Root Mean Square Error of
      Approximation = 0.107. Conclusion: The Turkish version of EMPHATIC-30 has
      adequate psychometric properties. The EMPATHIC-30-Turkish questionnaire is an
      easy and appropriate instrument which can be used to measure satisfaction of
      Turkish parents with infants staying in the NICU.
CI  - Copyright (c) 2020 Tiryaki, Zengin, Cinar, Umaroglu and Latour.
FAU - Tiryaki, Oznur
AU  - Tiryaki O
AD  - Institute of Health Sciences, Sakarya University, Sakarya, Turkey.
FAU - Zengin, Hamide
AU  - Zengin H
AD  - Department of Pediatric Nursing, Faculty of Health Sciences, Bilecik Seyh Edebali
      University, Bilecik, Turkey.
FAU - Cinar, Nursan
AU  - Cinar N
AD  - Department of Pediatric Nursing, Faculty of Health Sciences, Sakarya University, 
      Sakarya, Turkey.
FAU - Umaroglu, Mumtaz Mutlu
AU  - Umaroglu MM
AD  - Faculty of Medicine Basic Medical Sciences, Biostatistics, Sakarya University,
      Sakarya, Turkey.
FAU - Latour, Jos M
AU  - Latour JM
AD  - Faculty of Health: Medicine, Dentistry and Human Sciences, School of Nursing and 
      Midwifery, University of Plymouth, Plymouth, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7403180
OTO - NOTNLM
OT  - EMPATHIC-30
OT  - infants
OT  - neonatal intensive care unit
OT  - parents
OT  - reliability
OT  - satisfaction
OT  - validity
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fped.2020.00421 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Jul 29;8:421. doi: 10.3389/fped.2020.00421. eCollection 2020.


PMID- 32850447
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210527
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future.
PG  - 1387
LID - 10.3389/fonc.2020.01387 [doi]
AB  - A series of recent discoveries harnessing the adaptive immune system of
      prokaryotes to perform targeted genome editing is having a transformative
      influence across the biological sciences. The discovery of Clustered Regularly
      Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas)
      proteins has expanded the applications of genetic research in thousands of
      laboratories across the globe and is redefining our approach to gene therapy.
      Traditional gene therapy has raised some concerns, as its reliance on viral
      vector delivery of therapeutic transgenes can cause both insertional oncogenesis 
      and immunogenic toxicity. While viral vectors remain a key delivery vehicle,
      CRISPR technology provides a relatively simple and efficient alternative for
      site-specific gene editing, obliviating some concerns raised by traditional gene 
      therapy. Although it has apparent advantages, CRISPR/Cas9 brings its own set of
      limitations which must be addressed for safe and efficient clinical translation. 
      This review focuses on the evolution of gene therapy and the role of CRISPR in
      shifting the gene therapy paradigm. We review the emerging data of recent gene
      therapy trials and consider the best strategy to move forward with this powerful 
      but still relatively new technology.
CI  - Copyright (c) 2020 Uddin, Rudin and Sen.
FAU - Uddin, Fathema
AU  - Uddin F
AD  - Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering
      Cancer Center, New York, NY, United States.
FAU - Rudin, Charles M
AU  - Rudin CM
AD  - Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering
      Cancer Center, New York, NY, United States.
AD  - Weill Cornell Medicine, Cornell University, New York, NY, United States.
FAU - Sen, Triparna
AU  - Sen T
AD  - Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering
      Cancer Center, New York, NY, United States.
AD  - Weill Cornell Medicine, Cornell University, New York, NY, United States.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200807
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7427626
OTO - NOTNLM
OT  - CRISPR/Cas9
OT  - clinical trial
OT  - ethics
OT  - gene therapy
OT  - homology-directed repair (HDR)
OT  - non-homologous end joining (NHEJ)
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fonc.2020.01387 [doi]
PST - epublish
SO  - Front Oncol. 2020 Aug 7;10:1387. doi: 10.3389/fonc.2020.01387. eCollection 2020.


PMID- 32850035
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0019-5413 (Print)
IS  - 0019-5413 (Linking)
VI  - 54
IP  - 5
DP  - 2020 Sep
TI  - Ultrasonography in Early Rheumatoid Arthritis of Hand and Wrist Joints:
      Comparison with Magnetic Resonance Imaging.
PG  - 695-703
LID - 10.1007/s43465-020-00178-4 [doi]
AB  - BACKGROUND: The aim of the study was to evaluate the use of ultrasonography (USG)
      including power Doppler in detecting hand and wrist joint changes in early
      rheumatoid arthritis (RA) and to compare USG findings with magnetic resonance
      imaging (MRI). MATERIALS AND METHODS: Thirty-four patients diagnosed as RA by
      2010 ACR/EULAR criteria; with the onset of symptoms within last one year, were
      included in the study after institute ethical clearance and informed consent to
      undergo USG and contrast-enhanced MRI of the dominant affected hand. Second to
      fifth metacarpophalangeal (MCP) joints, second to fifth proximal interphalangeal 
      (PIP) joints and wrist joints (total nine joints) were evaluated for synovitis,
      erosions along with tenosynovitis. USG and MRI features were compared; agreement 
      on the two imaging modalities as well as sensitivity, specificity, positive
      predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy
      of ultrasonography compared to MRI (gold standard) was calculated. RESULTS: One
      hundred thirty-six MCP, 136 PIP and 34 wrist joints (total 306 joints) and 136
      flexor tendons were evaluated. The sensitivity, specificity, PPV, NPV and
      diagnostic accuracy of USG for diagnosing synovitis was 78.6%, 91.1%, 86.1%,
      85.8%, 86.3%; for erosions 67.2%, 97.5%, 84.8%, 90.5%, 91.5%; for tenosynovitis
      86.5%, 100%, 100%, 92.3% and 94.8% respectively. The overall agreement between
      USG and MRI for detection of synovitis was achieved in 83% joints and for
      erosions in 89.5% joints. CONCLUSION: In early RA, USG was nearly as effective in
      diagnosing features of joint and tendon sheath involvement, with relatively
      better performance of USG for tenosynovitis. The performance of USG in diagnosing
      erosions was limited likely due to difficult access of three-dimensional joint
      structure.
CI  - (c) Indian Orthopaedics Association 2020.
FAU - Malla, Sundeep
AU  - Malla S
AD  - Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi,
      110029 India.grid.413618.90000 0004 1767 6103
FAU - Vyas, Surabhi
AU  - Vyas S
AUID- ORCID: 0000-0003-4465-9360
AD  - Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi,
      110029 India.grid.413618.90000 0004 1767 6103
FAU - Bhalla, Ashu Seith
AU  - Bhalla AS
AD  - Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi,
      110029 India.grid.413618.90000 0004 1767 6103
FAU - Kumar, Uma
AU  - Kumar U
AD  - Department of Rheumatology, All India Institute of Medical Sciences, New Delhi,
      India.grid.413618.90000 0004 1767 6103
FAU - Kumar, Sandeep
AU  - Kumar S
AD  - Department of Orthopaedics, Hamdard Institute of Medical Sciences and Research,
      New Delhi, India.grid.411816.b0000 0004 0498 8167
FAU - Gupta, Arun Kumar
AU  - Gupta AK
AD  - Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi,
      110029 India.grid.413618.90000 0004 1767 6103
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - Switzerland
TA  - Indian J Orthop
JT  - Indian journal of orthopaedics
JID - 0137736
PMC - PMC7429602
OTO - NOTNLM
OT  - Early disease
OT  - Erosions
OT  - Magnetic resonance imaging
OT  - Rheumatoid arthritis
OT  - Synovitis
OT  - Tenosynovitis
OT  - Ultrasonography
COIS- Conflict of interestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2019/12/27 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.1007/s43465-020-00178-4 [doi]
AID - 178 [pii]
PST - epublish
SO  - Indian J Orthop. 2020 Jul 2;54(5):695-703. doi: 10.1007/s43465-020-00178-4.
      eCollection 2020 Sep.


PMID- 32849844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Forensic Autosomal Short Tandem Repeats and Their Potential Association With
      Phenotype.
PG  - 884
LID - 10.3389/fgene.2020.00884 [doi]
AB  - Forensic DNA profiling utilizes autosomal short tandem repeat (STR) markers to
      establish identity of missing persons, confirm familial relations, and link
      persons of interest to crime scenes. It is a widely accepted notion that genetic 
      markers used in forensic applications are not predictive of phenotype. At
      present, there has been no demonstration of forensic STR variants directly
      causing or predicting disease. Such a demonstration would have many legal and
      ethical implications. For example, is there a duty to inform a DNA donor if a
      medical condition is discovered during routine analysis of their sample? In this 
      review, we evaluate the possibility that forensic STRs could provide information 
      beyond mere identity. An extensive search of the literature returned 107 articles
      associating a forensic STR with a trait. A total of 57 of these studies met our
      inclusion criteria: a reported link between a STR-inclusive gene and a phenotype 
      and a statistical analysis reporting a p-value less than 0.05. A total of 50
      unique traits were associated with the 24 markers included in the 57 studies.
      TH01 had the greatest number of associations with 27 traits reportedly linked to 
      40 different genotypes. Five of the articles associated TH01 with schizophrenia. 
      None of the associations found were independently causative or predictive of
      disease. Regardless, the likelihood of identifying significant associations is
      increasing as the function of non-coding STRs in gene expression is steadily
      revealed. It is recommended that regular reviews take place in order to remain
      aware of future studies that identify a functional role for any forensic STRs.
CI  - Copyright (c) 2020 Wyner, Barash and McNevin.
FAU - Wyner, Nicole
AU  - Wyner N
AD  - Centre for Forensic Science, School of Mathematical and Physical Sciences,
      Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
FAU - Barash, Mark
AU  - Barash M
AD  - Centre for Forensic Science, School of Mathematical and Physical Sciences,
      Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
AD  - Department of Justice Studies, San Jose State University, San Jose, CA, United
      States.
FAU - McNevin, Dennis
AU  - McNevin D
AD  - Centre for Forensic Science, School of Mathematical and Physical Sciences,
      Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200806
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7425049
OTO - NOTNLM
OT  - DNA profiling
OT  - forensic marker
OT  - junk DNA
OT  - non-coding STRs
OT  - phenotype
OT  - short tandem repeat
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fgene.2020.00884 [doi]
PST - epublish
SO  - Front Genet. 2020 Aug 6;11:884. doi: 10.3389/fgene.2020.00884. eCollection 2020.


PMID- 32849212
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in 
      Multiple Sclerosis: A Study Protocol for a Randomized Clinical Trial.
PG  - 750
LID - 10.3389/fneur.2020.00750 [doi]
AB  - Background: Transcranial Magnetic Stimulation (TMS) is a technique based on the
      principles of electromagnetic induction. It applies pulses of magnetic radiation 
      that penetrate the brain tissue, and it is a non-invasive, painless, and
      practically innocuous procedure. Previous studies advocate the therapeutic
      capacity of TMS in several neurodegenerative and psychiatric processes, both in
      animal models and in human studies. Its uses in Parkinson's disease, Alzheimer's 
      disease and in Huntington's chorea have shown improvement in the symptomatology
      and in the molecular profile, and even in the cellular density of the brain.
      Consequently, the extrapolation of these TMS results in the aforementioned
      neurodegenerative disease to other entities with etiopathogenic and clinical
      analogy would raise the relevance and feasibility of its use in multiple
      sclerosis (MS). The overall objective will be to demonstrate the effectiveness of
      the TMS in terms of safety and clinical improvement, as well as to observe the
      molecular changes in relation to the treatment. Methods and Design: Phase II
      clinical trial, unicentric, controlled, randomized, single blind. A total of 90
      patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who meet
      all the inclusion criteria and do not present any of the exclusion criteria that 
      are established and from which clinically evaluable results can be obtained. The 
      patients included will be assigned under the 1:1:1 randomization formula,
      constituting three groups for the present study: 30 patients treated with
      natalizumab + white (placebo) + 30 patients treated with natalizumab + TMS (1 Hz)
      + 30 patients treated with natalizumab + TMS (5 Hz). Discussion: Results of this 
      study will inform on the efficiency of the TMS for the treatment of MS. The
      expected results are that TMS is a useful therapeutic resource to improve
      clinical status (main parameters) and neurochemical profile (surrogate
      parameters); both types of parameters will be checked. Ethics and Dissemination: 
      The study is approved by the Local Ethics Committee and registered in
      https://clinicaltrials.gov (NCT04062331). Dissemination will include submission
      to a peer-reviewed journal, patients, associations of sick people and family
      members, healthcare magazines and congress presentations. Trial Registration:
      ClinicalTrials.gov ID: NCT04062331 (registration date: 19(th)/ August/2019).
      Version Identifier: EMTr-EMRR, ver-3, 21/11/2017.
CI  - Copyright (c) 2020 Aguera, Caballero-Villarraso, Feijoo, Escribano, Conde,
      Bahamonde, Giraldo, Paz-Rojas and Tunez.
FAU - Aguera, Eduardo
AU  - Aguera E
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Unidad de Gestion Clinica de Neurologia, Hospital Universitario Reina Sofia,
      Cordoba, Spain.
FAU - Caballero-Villarraso, Javier
AU  - Caballero-Villarraso J
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Departmento de Bioquimica y Biologia Molecular, Facultad de Medicina y
      Enfermeria, Universidad de Cordoba, Cordoba, Spain.
AD  - Unidad de Gestion Clinica de Analisis Clinicos, Hospital Universitario Reina
      Sofia, Cordoba, Spain.
FAU - Feijoo, Montserrat
AU  - Feijoo M
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Departmento de Bioquimica y Biologia Molecular, Facultad de Medicina y
      Enfermeria, Universidad de Cordoba, Cordoba, Spain.
FAU - Escribano, Begona M
AU  - Escribano BM
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Departamento de Biologia Celular, Fisiologia e Inmunologia, Universidad de
      Cordoba, Cordoba, Spain.
FAU - Conde, Cristina
AU  - Conde C
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
FAU - Bahamonde, Maria C
AU  - Bahamonde MC
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Unidad de Gestion Clinica de Neurologia, Hospital Universitario Reina Sofia,
      Cordoba, Spain.
FAU - Giraldo, Ana I
AU  - Giraldo AI
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Departmento de Bioquimica y Biologia Molecular, Facultad de Medicina y
      Enfermeria, Universidad de Cordoba, Cordoba, Spain.
FAU - Paz-Rojas, Elier
AU  - Paz-Rojas E
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Canvax Biotech S.L., Cordoba, Spain.
FAU - Tunez, Isaac
AU  - Tunez I
AD  - Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
AD  - Departmento de Bioquimica y Biologia Molecular, Facultad de Medicina y
      Enfermeria, Universidad de Cordoba, Cordoba, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04062331
PT  - Journal Article
DEP - 20200811
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7431867
OTO - NOTNLM
OT  - clinical trial
OT  - multiple sclerosis
OT  - neurochemistry
OT  - neurodegenerative diseases
OT  - neuroplasticity
OT  - transcranial magnetic stimulation
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fneur.2020.00750 [doi]
PST - epublish
SO  - Front Neurol. 2020 Aug 11;11:750. doi: 10.3389/fneur.2020.00750. eCollection
      2020.


PMID- 32849097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The Impact of Self-Efficacy Analysis-Based Psychological Theory and Literary
      Ethics on Chinese American Entrepreneurship Education.
PG  - 1870
LID - 10.3389/fpsyg.2020.01870 [doi]
AB  - In this study, entrepreneurship education was explored from the perspective of
      the combination of psychology and literary ethics, with the purpose of studying
      the entrepreneurial behavior of Chinese American college students and promoting
      the development of entrepreneurship education. Based on the analysis of
      self-efficacy, the correlations among entrepreneurial intention, entrepreneurship
      education, and entrepreneurial efficacy of the research samples were analyzed.
      First, through the questionnaire design, the research samples and the measurement
      scales of each research variable were determined, and the survey results and the 
      reliability of the scale were analyzed and tested. Second, based on the variance 
      analysis and regression analysis methods, a descriptive statistical analysis was 
      performed on the correlations among entrepreneurship education, entrepreneurial
      intentions, and entrepreneurial efficacy among Chinese American college students.
      Finally, the idea of literary ethics was integrated into entrepreneurship
      education, entrepreneurial intentions, and entrepreneurial self-efficacy, and the
      correlation structure model was constructed. The intermediary role of
      entrepreneurial efficacy in entrepreneurship education and entrepreneurial
      intention was tested. In addition, the individual gender and family
      entrepreneurial behaviors were considered. The results show that the valid
      response rate of the questionnaire, is satisfactory at, 96.49%; the reliability
      and validity of the scales of the research variables are satisfactory; the
      Cronbach's Alpha reliability coefficient values are all above 0.80; and the
      fitting results of the confirmatory factors are satisfactory. The regression
      analysis results show significant correlations among entrepreneurship education, 
      entrepreneurial intentions, and entrepreneurial efficacy among Chinese American
      college students. Entrepreneurial efficacy has a partially intermediary role in
      the two dimensions of entrepreneurship education and entrepreneurial intention.
      Individual gender and family entrepreneurial behaviors have moderating effects,
      on the entrepreneurial efficacy levels of college entrepreneurs. From the
      perspectives of psychology and literary ethics, the above results have positive
      effects on the development of entrepreneurship education.
CI  - Copyright (c) 2020 Li, Wang, Zhang, Li and Chen.
FAU - Li, Hang
AU  - Li H
AD  - School of Foreign Languages, Chongqing Jiaotong University, Chongqing, China.
FAU - Wang, Junsheng
AU  - Wang J
AD  - Graduate School of Pan-Pacific International Studies, Kyung Hee University,
      Yongin-si, South Korea.
FAU - Zhang, Yunyu
AU  - Zhang Y
AD  - School of Law, Xiamen University, Xiamen, China.
FAU - Li, Hongmei
AU  - Li H
AD  - School of Education, Jinggangshan University, Ji'an, China.
FAU - Chen, Xialu
AU  - Chen X
AD  - Department of Human Resources, Chongqing Vocational Institute of Engineering,
      Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7417519
OTO - NOTNLM
OT  - entrepreneurial efficacy
OT  - entrepreneurial intention
OT  - entrepreneurship education
OT  - literary ethics
OT  - psychological state
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/04/26 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fpsyg.2020.01870 [doi]
PST - epublish
SO  - Front Psychol. 2020 Aug 4;11:1870. doi: 10.3389/fpsyg.2020.01870. eCollection
      2020.


PMID- 32849075
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Uncoupling Meat From Animal Slaughter and Its Impacts on Human-Animal
      Relationships.
PG  - 1824
LID - 10.3389/fpsyg.2020.01824 [doi]
AB  - Slaughter sets the debate about what is acceptable to do to animals at an
      extremely low bar. Recently, there has been considerable investment in developing
      cell-based meat, an alternative meat production process that does not require the
      raising and slaughtering of animals, instead using muscle cells cultivated in a
      bioreactor. We discuss the animal ethics impacts of cell-based and plant-based
      meat on human-animal interactions from animal welfare and rights perspectives,
      focusing on industrial meat production scenarios. Our hypothesis is that the
      insertion of cell-based meat in the global meat market may alleviate farm animal 
      suffering and potentially restore resources for wild fauna. We employed a
      conservative estimation of the cell-based meat contribution to the global meat
      market in the year 2040 to analyze the consequences for human-animal
      relationships for both wild animals and farmed domesticated animals. We discuss
      possible effects of an animal cell domestication process, previously described as
      the second domestication, on human-animal relationships. We consider its
      potential to reduce the impact of human demographic changes and land use on
      animal life, in particular whether there would be increased biomass availability 
      and free land for wild animals. We anticipate a major reduction in animal
      suffering due to the decrease in the number of individual animals involved in
      food production, which justifies the adoption of cell-based meat from a
      utilitarian perspective. For the conventional animal food production that
      remains, further consideration is needed to understand which systems, either high
      or low welfare, will be retained and the impact of the innovation on the average 
      farm animal welfare. Additionally, it seems likely that there will be less
      acceptance of the necessity of animal suffering in farming systems when meat
      production is uncoupled from animal raising and slaughter, supported by a
      deontological perspective of animal ethics. Consequent to this is anticipated the
      mitigation of relevant barriers to animal protection and to the recognition of
      animals as subjects by legislation. Thus, the development of the alternative
      meats may be related to a significant change in our relationship with non-human
      animals, with greater benefits than the prima facie effects on farm animals.
CI  - Copyright (c) 2020 Heidemann, Molento, Reis and Phillips.
FAU - Heidemann, Marina Sucha
AU  - Heidemann MS
AD  - Animal Welfare Laboratory, Federal University of Parana, Curitiba, Brazil.
FAU - Molento, Carla Forte Maiolino
AU  - Molento CFM
AD  - Animal Welfare Laboratory, Federal University of Parana, Curitiba, Brazil.
FAU - Reis, Germano Glufk
AU  - Reis GG
AD  - School of Business Administration, Federal University of Parana, Curitiba,
      Brazil.
FAU - Phillips, Clive Julian Christie
AU  - Phillips CJC
AD  - Centre for Animal Welfare and Ethics, Faculty of Science, The University of
      Queensland - Gatton Campus, Gatton, QLD, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200804
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7418524
OTO - NOTNLM
OT  - animal protection
OT  - animal suffering
OT  - cell-based meat
OT  - human-animal relationship
OT  - second domestication
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fpsyg.2020.01824 [doi]
PST - epublish
SO  - Front Psychol. 2020 Aug 4;11:1824. doi: 10.3389/fpsyg.2020.01824. eCollection
      2020.


PMID- 32849038
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Being Perceived and Being "Seen": Interpersonal Affordances, Agency, and
      Selfhood.
PG  - 1750
LID - 10.3389/fpsyg.2020.01750 [doi]
AB  - Are interpersonal affordances a distinct type of affordance, and if so, what is
      it that differentiates them from other kinds of affordances? In this paper, I
      show that a hard distinction between interpersonal affordances and other
      affordances is warranted and ethically important. The enactivist theory of
      participatory sense-making demonstrates that there is a difference in coupling
      between agent-environment and agent-agent interactions, and these differences in 
      coupling provide a basis for distinguishing between the perception of
      environmental and interpersonal affordances. Building further on this foundation 
      for understanding interpersonal affordances, I argue that in line with some
      enactivist work on social cognition, interpersonal affordances ought to be
      considered as those that are afforded by agents and are recognized as such. Given
      this distinction, I also make the point that because our social conventions
      establish persons as more than mere agents, the direct perception of
      interpersonal affordances may also involve seeing others as embodied selves.
      Distinguishing between types of affordances thus also matters ethically: there
      can be harms done when an agent is not perceived as an agent, and there can be
      harms done when an agent is not perceived as a self.
CI  - Copyright (c) 2020 Brancazio.
FAU - Brancazio, Nick
AU  - Brancazio N
AD  - School of Humanities and Social Inquiry, Faculty of Arts, Social Sciences, and
      Humanities, University of Wollongong, Wollongong, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7406706
OTO - NOTNLM
OT  - agency
OT  - direct perception
OT  - interpersonal affordances
OT  - selfhood
OT  - social affordances
OT  - social cognition
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fpsyg.2020.01750 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 30;11:1750. doi: 10.3389/fpsyg.2020.01750. eCollection
      2020.


PMID- 32849003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Ecological Psychology and Enactivism: A Normative Way Out From Ontological
      Dilemmas.
PG  - 1637
LID - 10.3389/fpsyg.2020.01637 [doi]
AB  - Two important issues of recent discussion in the philosophy of biology and of the
      cognitive sciences have been the ontological status of living, cognitive agents
      and whether cognition and action have a normative character per se. In this paper
      I will explore the following conditional in relation with both the notion of
      affordance and the idea of the living as self-creation: if we recognize the need 
      to use normative vocabulary to make sense of life in general, we are better off
      avoiding taking sides on the ontological discussion between eliminativists,
      reductionists and emergentists. Looking at life through normative lenses is, at
      the very least, in tension with any kind of realism that aims at prediction and
      control. I will argue that this is so for two separate reasons. On the one hand, 
      understanding the realm of biology in purely factualist, realist terms means to
      dispossess it of its dignity: there is more to life than something that we simply
      aim to manipulate to our own material convenience. On the other hand, a
      descriptivist view that is committed to the existence of biological and mental
      facts that are fully independent of our understanding of nature may be an
      invitation to make our ethical and normative judgments dependent on the discovery
      of such alleged facts, something I diagnose as a form of representationalism.
      This runs counter what I take to be a central democratic ideal: while there are
      experts whose opinion could be considered the last word on purely factual
      matters, where value is concerned, there are no technocratic experts above the
      rest of us. I will rely on the ideas of some central figures of early analytic
      philosophy that, perhaps due to the reductionistic and eliminativist tendencies
      of contemporary philosophy of mind, have not been sufficiently discussed within
      post-cognitivist debates.
CI  - Copyright (c) 2020 de Pinedo Garcia.
FAU - de Pinedo Garcia, Manuel
AU  - de Pinedo Garcia M
AD  - Departamento de Filosofia I, Universidad de Granada, Granada, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200730
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7406712
OTO - NOTNLM
OT  - affordances
OT  - agency
OT  - analytic philosophy
OT  - dispositionalism
OT  - ecological psychology
OT  - enactivism
OT  - normativity
OT  - representationalism
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fpsyg.2020.01637 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 30;11:1637. doi: 10.3389/fpsyg.2020.01637. eCollection
      2020.


PMID- 32848973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Can Ethical Leadership Improve Employees' Well-Being at Work? Another Side of
      Ethical Leadership Based on Organizational Citizenship Anxiety.
PG  - 1478
LID - 10.3389/fpsyg.2020.01478 [doi]
AB  - Most of the previous literature has focused on the positive effects of ethical
      leadership on organizations and employees, but some studies have unexpectedly
      found that ethical leadership is negatively related to employees' well-being at
      work. Based on the theory of workplace anxiety, this research explored whether
      ethical leadership can reduce employees' well-being at work by causing them to
      feel anxious about organizational citizenship behavior and whether organizational
      concern motivation moderates this mechanism. We collected 227 three-stage
      time-crossed data samples from 12 institutions in Hainan China, then tested our
      research hypotheses to confirm that ethical leadership has a negative impact on
      employees' well-being at work under certain conditions. We found that: (1)
      ethical leadership is significantly and positively correlated with the
      organizational citizenship anxiety perceived by employees, (2) organizational
      citizenship anxiety perceived by employees plays a completely mediating role
      between ethical leadership and employee well-being at work, and (3)
      organizational concern motivation not only negatively moderates the negative
      correlation between employees' organizational citizenship anxiety and well-being 
      at work, but also further moderates the indirect negative effect of ethical
      leadership on employee well-being at work through organizational citizenship
      anxiety.
CI  - Copyright (c) 2020 Fu, Long, He and Liu.
FAU - Fu, Jingtao
AU  - Fu J
AD  - School of Management, Hainan University, Haikou, China.
AD  - Institute of Corporation Governance Research of Hainan Province, Haikou, China.
FAU - Long, Yijing
AU  - Long Y
AD  - School of Management, Hainan University, Haikou, China.
FAU - He, Qi
AU  - He Q
AD  - School of Finance & Economics, Jiangsu University, Zhenjiang, China.
FAU - Liu, Yazhen
AU  - Liu Y
AD  - School of Management, Hainan University, Haikou, China.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7401574
OTO - NOTNLM
OT  - another side
OT  - ethical leadership
OT  - organizational citizenship anxiety
OT  - organizational concern motivation
OT  - well-being at work
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/28 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.3389/fpsyg.2020.01478 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 28;11:1478. doi: 10.3389/fpsyg.2020.01478. eCollection
      2020.


PMID- 32848328
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20201218
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 26
IP  - 29
DP  - 2020 Aug 7
TI  - Impact of mobile health and medical applications on clinical practice in
      gastroenterology.
PG  - 4182-4197
LID - 10.3748/wjg.v26.i29.4182 [doi]
AB  - Mobile health apps (MHAs) and medical apps (MAs) are becoming increasingly
      popular as digital interventions in a wide range of health-related applications
      in almost all sectors of healthcare. The surge in demand for digital medical
      solutions has been accelerated by the need for new diagnostic and therapeutic
      methods in the current coronavirus disease 2019 pandemic. This also applies to
      clinical practice in gastroenterology, which has, in many respects, undergone a
      recent digital transformation with numerous consequences that will impact
      patients and health care professionals in the near future. MHAs and MAs are
      considered to have great potential, especially for chronic diseases, as they can 
      support the self-management of patients in many ways. Despite the great potential
      associated with the application of MHAs and MAs in gastroenterology and health
      care in general, there are numerous challenges to be met in the future, including
      both the ethical and legal aspects of applying this technology. The aim of this
      article is to provide an overview of the current status of MHA and MA use in the 
      field of gastroenterology, describe the future perspectives in this field and
      point out some of the challenges that need to be addressed.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Kernebeck, Sven
AU  - Kernebeck S
AD  - Didactics and Educational Research in Health Science, Faculty of Health,
      Witten/Herdecke University, Witten 58455, Germany.
FAU - Busse, Theresa S
AU  - Busse TS
AD  - Didactics and Educational Research in Health Science, Faculty of Health,
      Witten/Herdecke University, Witten 58455, Germany.
FAU - Bottcher, Maximilian D
AU  - Bottcher MD
AD  - Department of GI-, Thoracic- and Vascular Surgery, Dresden Technical University, 
      University Hospital Dresden, Dresden 01307, Germany.
FAU - Weitz, Jurgen
AU  - Weitz J
AD  - Department of GI-, Thoracic- and Vascular Surgery, Dresden Technical University, 
      University Hospital Dresden, Dresden 01307, Germany.
FAU - Ehlers, Jan
AU  - Ehlers J
AD  - Didactics and Educational Research in Health Science, Faculty of Health,
      Witten/Herdecke University, Witten 58455, Germany.
FAU - Bork, Ulrich
AU  - Bork U
AD  - Department of GI-, Thoracic- and Vascular Surgery, Dresden Technical University, 
      University Hospital Dresden, Dresden 01307, Germany.
      ulrich.bork@uniklinikum-dresden.de.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Computer Literacy
MH  - Computer Security
MH  - Coronavirus Infections/epidemiology
MH  - Delivery of Health Care
MH  - Electronic Health Records
MH  - Ethics, Medical
MH  - Gastroenterology/*methods
MH  - Health Behavior
MH  - Humans
MH  - *Mobile Applications
MH  - Pandemics
MH  - Patient Education as Topic
MH  - Physician-Patient Relations
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
MH  - *Self-Management
MH  - Smartphone
MH  - *Telemedicine
MH  - *Wearable Electronic Devices
PMC - PMC7422538
OTO - NOTNLM
OT  - Digital biomarker
OT  - Electronic health records
OT  - Health applications
OT  - Medical applications
OT  - Mobile applications
OT  - Mobile health
OT  - Smartphone
OT  - Technology
OT  - Telemedicine
OT  - eHealth
OT  - mHealth
COIS- Conflict-of-interest statement: All authors declare no conflict-of- interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.3748/wjg.v26.i29.4182 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2020 Aug 7;26(29):4182-4197. doi:
      10.3748/wjg.v26.i29.4182.


PMID- 32848263
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 0026-6620 (Print)
IS  - 0026-6620 (Linking)
VI  - 117
IP  - 4
DP  - 2020 Jul-Aug
TI  - Legality and Ethics of Lien Uses in Medicine.
PG  - 313-318
FAU - Chambers, Ciara
AU  - Chambers C
AD  - Ciara Chambers, JD, and Liz LaFoe, JD, from the Kansas City and Jefferson City
      offices of Husch Blackwell.
FAU - LaFoe, Liz
AU  - LaFoe L
AD  - Ciara Chambers, JD, and Liz LaFoe, JD, from the Kansas City and Jefferson City
      offices of Husch Blackwell.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Mo Med
JT  - Missouri medicine
JID - 0400744
SB  - IM
MH  - Ethics, Medical
MH  - Humans
MH  - *Medicine
PMC - PMC7431059
EDAT- 2020/08/28 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
AID - ms117_p0313 [pii]
PST - ppublish
SO  - Mo Med. 2020 Jul-Aug;117(4):313-318.


PMID- 32847993
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210919
IS  - 2053-3624 (Print)
IS  - 2053-3624 (Linking)
VI  - 7
IP  - 2
DP  - 2020 Aug
TI  - Worksite intervention study to prevent diabetes in Nepal: a randomised trial
      protocol.
LID - e001236 [pii]
LID - 10.1136/openhrt-2019-001236 [doi]
AB  - INTRODUCTION: In Nepal, approximately 31% of adult industrial employees have
      diabetes. While the prevention of type 2 diabetes through behavioural
      intervention has been disseminated, worksite could be an effective platform for
      the translation of this knowledge into action as employed adults spend most of
      their workday waking hours at workplaces. METHODS AND ANALYSIS: We will conduct a
      randomised controlled trial to assess the effectiveness of a behavioural and a
      canteen intervention on diabetes risk reduction among those who are prediabetic
      at two worksites in eastern Nepal. We will recruit 162 adult full-time factory
      workers with haemoglobin A1c (HbA1c) of 5.7%-6.4% at baseline or fasting blood
      sugar of 100-125 mg/dL. The 8-14 months' control period will be followed by the
      behavioural intervention where half of the participants will be randomised to
      receive the behavioural intervention and half will act as a control and will not 
      receive any intervention. Then, all participants will receive the canteen
      intervention. The analysis will be intent-to-treat, comparing the difference in
      the change in HbA1c% between the behavioural intervention group and the control
      group using a two-sample t-test. The within-participant changes in HbA1c after 6 
      or more months on the canteen intervention among those not randomised to the
      behavioural intervention in the previous period will be assessed using the paired
      t-test. ETHICS AND DISSEMINATION: Ethical approval was obtained from the
      Institutional Review Board at Yale School of Public Health, New Havens, USA and
      the Nepal Health Research Council. TRIAL REGISTRATION NUMBER: NCT04161937.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pyakurel, Prajjwal
AU  - Pyakurel P
AUID- ORCID: 0000-0001-5860-9482
AD  - B.P. Koirala Institute of Health Sciences, Dharan, Nepal prazzwal@gmail.com.
FAU - Shrestha, Archana
AU  - Shrestha A
AD  - Kathmandu University School of Medical Sciences, Kathmandu, Nepal.
FAU - Karmacharya, Biraj M
AU  - Karmacharya BM
AD  - Kathmandu University School of Medical Sciences, Kathmandu, Nepal.
FAU - Budhathoki, Shyam S
AU  - Budhathoki SS
AD  - Golden Community Hospital, Lalitpur, Nepal.
FAU - Chaudhari, Rajendra Kumar
AU  - Chaudhari RK
AD  - B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Tamrakar, Dipesh
AU  - Tamrakar D
AD  - Kathmandu University School of Medical Sciences, Kathmandu, Nepal.
FAU - Shrestha, Abha
AU  - Shrestha A
AD  - Kathmandu University School of Medical Sciences, Kathmandu, Nepal.
FAU - Karmacharya, Robin M
AU  - Karmacharya RM
AD  - Kathmandu University School of Medical Sciences, Kathmandu, Nepal.
FAU - Shrestha, Anmol
AU  - Shrestha A
AD  - Kathmandu University School of Medical Sciences, Kathmandu, Nepal.
FAU - Sharma, Sumitra
AU  - Sharma S
AD  - Kathmadnu Medical College Teaching Hospital, Kathmandu, Nepal.
FAU - Sharma, Sanjib Kumar
AU  - Sharma SK
AD  - B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Spiegelman, Donna
AU  - Spiegelman D
AD  - Yale School of Public Health, New Haven, Connecticut, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04161937
GR  - DP1 ES025459/ES/NIEHS NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Open Heart
JT  - Open heart
JID - 101631219
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus/blood/diagnosis/epidemiology/*prevention & control
MH  - Glycated Hemoglobin A/metabolism
MH  - *Health Behavior
MH  - Health Knowledge, Attitudes, Practice
MH  - *Healthy Lifestyle
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Nepal/epidemiology
MH  - *Occupational Health Services
MH  - Patient Education as Topic
MH  - Prediabetic State/blood/diagnosis/epidemiology/*therapy
MH  - *Primary Prevention
MH  - Randomized Controlled Trials as Topic
MH  - *Risk Reduction Behavior
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7451278
OTO - NOTNLM
OT  - *coronary artery disease
OT  - *diabetic heart disease
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/01/01 00:00 [received]
PHST- 2020/07/03 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - openhrt-2019-001236 [pii]
AID - 10.1136/openhrt-2019-001236 [doi]
PST - ppublish
SO  - Open Heart. 2020 Aug;7(2). pii: openhrt-2019-001236. doi:
      10.1136/openhrt-2019-001236.


PMID- 32847944
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Ethical issues for large-scale hearing aid donation programmes to the Pacific
      Islands: a Samoan perspective.
PG  - 710-712
LID - 10.1136/medethics-2020-106560 [doi]
AB  - The Pacific Islands are estimated to have among the highest global burdens of
      hearing loss, however, hearing health services are limited throughout this
      region. The provision of hearing aid is desirable, but should be delivered in
      accordance with WHO recommendations of appropriate and locally sustainable
      services. Large-scale hearing aid donation programmes to the Pacific Islands
      raise ethical questions that challenge these recommendations.The aim of this
      paper is to consider the ethical implications of large-scale hearing aid donation
      programmes to Samoa, a nation of the Pacific Islands. Evaluation of both
      'Western' and 'Pacific Island' perspectives reveals important cross-cultural
      differences regarding attitudes to donation programmes. We attempt to offer
      possible solutions that satisfy both ethical frameworks, and which should enable 
      us to deliver an effective hearing health service for Samoa. These solutions may 
      be translational and benefit other Pacific Island nations in a similar context.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kaspar, Annette
AU  - Kaspar A
AUID- ORCID: 0000-0002-4035-3236
AD  - ENT Clinic, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa
      annette.kaspar@gmail.com.
AD  - Audiology Division, Health and Rehabilitation Sciences, The University of
      Queensland, Saint Lucia, Queensland, Australia.
FAU - Pifeleti, Sione
AU  - Pifeleti S
AD  - ENT Clinic, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa.
FAU - Faumuina, Penaia A
AU  - Faumuina PA
AD  - ENT Clinic, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa.
AD  - ENT Consultant, Wanganui Hospital, Wanganui, New Zealand.
FAU - Newton, Obiga
AU  - Newton O
AD  - ENT Clinic, Tupua Tamasese Meaole Hospital, Apia, Tuamasaga, Samoa.
AD  - ENT Clinic, National Referral Hospital, Honiara, Solomon Islands.
FAU - Driscoll, Carlie
AU  - Driscoll C
AD  - Audiology Division, Health and Rehabilitation Sciences, The University of
      Queensland, Saint Lucia, Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - *Hearing Aids
MH  - Humans
MH  - Pacific Islands
MH  - Samoa
OTO - NOTNLM
OT  - *applied and professional ethics
OT  - *disability
OT  - *quality of health care
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/06/07 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - medethics-2020-106560 [pii]
AID - 10.1136/medethics-2020-106560 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):710-712. doi: 10.1136/medethics-2020-106560. Epub
      2020 Aug 26.


PMID- 32847943
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Lockdown and levelling down: why Savulescu and Cameron are mistaken about
      selective isolation of the elderly.
PG  - 722-723
LID - 10.1136/medethics-2020-106776 [doi]
AB  - In their recent article, 'Why lockdown of the elderly is not ageist and why
      levelling down equality is wrong', Savulescu and Cameron argue for selective
      isolation of the elderly as an alternative to general lockdown. An important part
      of their argument is the claim that the latter amounts to 'levelling down
      equality' and that this is 'unethical' or even 'morally repugnant'. This response
      argues that they fail to justify either part of this claim: the claim that
      levelling down is always morally wrong is subject to challenges that Savulescu
      and Cameron do not consider; and a policy of maintaining general lockdown does
      not constitute levelling down, as it provides absolute benefits to those who
      would be worse off under selective isolation.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hughes, Jonathan A
AU  - Hughes JA
AUID- ORCID: 0000-0002-7219-3249
AD  - School of Law, Keele University, Keele, Staffordshire ST5 5BG, UK
      j.a.hughes@keele.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200826
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):717-721. PMID: 32561661
MH  - Aged
MH  - *Ageism
MH  - Humans
OTO - NOTNLM
OT  - *public health ethics
OT  - *public policy
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/06 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - medethics-2020-106776 [pii]
AID - 10.1136/medethics-2020-106776 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):722-723. doi: 10.1136/medethics-2020-106776. Epub
      2020 Aug 26.


PMID- 32847928
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Development of a computerised neurocognitive battery for children and adolescents
      with HIV in Botswana: study design and protocol for the Ntemoga study.
PG  - e041099
LID - 10.1136/bmjopen-2020-041099 [doi]
AB  - INTRODUCTION: Neurodevelopmental delays and cognitive impairments are common in
      youth living with HIV. Unfortunately, in resource-limited settings, where HIV
      infection impacts millions of children, cognitive and neurodevelopmental
      disorders commonly go undetected because of a lack of appropriate assessment
      instruments and local expertise. Here, we present a protocol to culturally adapt 
      and validate the Penn Computerized Neurocognitive Battery (PennCNB) and examine
      its validity for detecting both advanced and subtle neurodevelopmental problems
      among school-aged children affected by HIV in resource-limited settings. METHODS 
      AND ANALYSIS: This is a prospective, observational cohort study. The venue for
      this study is Gaborone, Botswana, a resource-limited setting with high rates of
      perinatal exposure to HIV and limited neurocognitive assessment tools and
      expertise. We aim to validate the PennCNB in this setting by culturally adapting 
      and then administering the adapted version of the battery to 200 HIV-infected,
      200 HIV-exposed uninfected and 240 HIV-unexposed uninfected children. A series of
      analyses will be conducted to examine the reliability and construct validity of
      the PennCNB in these populations. ETHICS AND DISSEMINATION: This project received
      ethical approval from local and university Institutional Review Boards and
      involved extensive input from local stakeholders. If successful, the proposed
      tools will provide practical screening and streamlined, comprehensive assessments
      that could be implemented in resource-limited settings to identify children with 
      cognitive deficits within programmes focused on the care and treatment of
      children affected by HIV. The utility of such assessments could also extend
      beyond children affected by HIV, increasing general access to paediatric
      cognitive assessments in resource-limited settings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Scott, J Cobb
AU  - Scott JC
AUID- ORCID: 0000-0001-6538-9043
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA scott1@pennmedicine.upenn.edu.
AD  - VISN4 Mental Illness Research, Education, and Clinical Center, Crescenz VA
      Medical Center, Philadelphia, Pennsylvania, USA.
FAU - Van Pelt, Amelia E
AU  - Van Pelt AE
AD  - The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
AD  - Pediatrics and Epidemiology, University of Pennsylvania Perelman School of
      Medicine, Philadelphia, Pennsylvania, USA.
FAU - Port, Allison M
AU  - Port AM
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Njokweni, Lucky
AU  - Njokweni L
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Gur, Ruben C
AU  - Gur RC
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Moore, Tyler M
AU  - Moore TM
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Phoi, Onkemetse
AU  - Phoi O
AD  - Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.
FAU - Tshume, Ontibile
AU  - Tshume O
AD  - Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.
FAU - Matshaba, Mogomotsi
AU  - Matshaba M
AD  - Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana.
AD  - Baylor College of Medicine, Gaborone, Botswana.
FAU - Ruparel, Kosha
AU  - Ruparel K
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Chapman, Jennifer
AU  - Chapman J
AD  - The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
FAU - Lowenthal, Elizabeth D
AU  - Lowenthal ED
AD  - The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
AD  - Pediatrics and Epidemiology, University of Pennsylvania Perelman School of
      Medicine, Philadelphia, Pennsylvania, USA.
LA  - eng
GR  - P30 AI045008/AI/NIAID NIH HHS/United States
GR  - P30 MH097488/MH/NIMH NIH HHS/United States
GR  - R01 HD095278/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Botswana
MH  - Child
MH  - Female
MH  - *HIV Infections/complications/diagnosis
MH  - Humans
MH  - Mass Screening
MH  - Observational Studies as Topic
MH  - Pregnancy
MH  - Prospective Studies
MH  - Reproducibility of Results
PMC - PMC7451956
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *delirium & cognitive disorders
OT  - *infectious disease/HIV
OT  - *paediatric infectious disease & immunisation
OT  - *paediatric neurology
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041099 [pii]
AID - 10.1136/bmjopen-2020-041099 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e041099. doi: 10.1136/bmjopen-2020-041099.


PMID- 32847927
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Study protocol for a pragmatic randomised controlled trial comparing the
      effectiveness and cost-effectiveness of levetiracetam and zonisamide versus
      standard treatments for epilepsy: a comparison of standard and new antiepileptic 
      drugs (SANAD-II).
PG  - e040635
LID - 10.1136/bmjopen-2020-040635 [doi]
AB  - INTRODUCTION: Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment. 
      Over the past 20 years, a number of new drugs have been approved for National
      Health Service (NHS) use on the basis of information from short-term trials that 
      demonstrate efficacy. These trials do not provide information about the longer
      term outcomes, which inform treatment policy. This trial will assess the
      long-term clinical and cost-effectiveness of the newer treatment levetiracetam
      and zonisamide. METHODS AND ANALYSIS: This is a phase IV, multicentre,
      open-label, randomised, controlled clinical trial comparing new and standard
      treatments for patients with newly diagnosed epilepsy. Arm A of the trial
      randomised 990 patients with focal epilepsy to standard AED lamotrigine or new
      AED levetiracetam or zonisamide. Arm B randomised 520 patients with generalised
      epilepsy to standard AED sodium valproate or new AED levetiracetam. Patients are 
      recruited from UK NHS outpatient epilepsy, general neurology and paediatric
      clinics. Included patients are aged 5 years or older with two or more spontaneous
      seizures requiring AED monotherapy, who are not previously treated with AEDs.
      Patients are followed up for a minimum of 2 years. The primary outcome is time to
      12-month remission from seizures. Secondary outcomes include time to treatment
      failure (including due to inadequate seizure control or unacceptable adverse
      reactions); time to first seizure; time to 24-month remission; adverse reactions 
      and quality of life. All primary analyses will be on an intention to treat basis.
      Separate analyses will be undertaken for each arm. Health economic analysis will 
      be conducted from the perspective of the NHS to assess the cost-effectiveness of 
      each AED. ETHICS AND DISSEMINATION: This trial has been approved by the North
      West-Liverpool East REC (Ref. 12/NW/0361). The trial team will disseminate the
      results through scientific meetings, peer-reviewed publications and patient and
      public involvement. TRIAL REGISTRATION NUMBERS: EudraCT 2012-001884-64;
      ISRCTN30294119.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Balabanova, Silviya
AU  - Balabanova S
AUID- ORCID: 0000-0001-6989-8099
AD  - Liverpool Clinical Trials Centre, University of Liverpool, Faculty of Health and 
      Life Sciences, Liverpool, UK.
FAU - Taylor, Claire
AU  - Taylor C
AD  - Liverpool Clinical Trials Centre, University of Liverpool, Faculty of Health and 
      Life Sciences, Liverpool, UK.
FAU - Sills, Graeme
AU  - Sills G
AD  - School of Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Burnside, Girvan
AU  - Burnside G
AD  - Biostatistics, University of Liverpool, Faculty of Health and Life Sciences,
      Liverpool, UK.
FAU - Plumpton, Catrin
AU  - Plumpton C
AD  - Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, 
      UK.
FAU - Smith, Phil E M
AU  - Smith PEM
AUID- ORCID: 0000-0003-4250-2562
AD  - Department of Neurology, University Hospital of Wales, Cardiff, UK.
FAU - Appleton, Richard
AU  - Appleton R
AD  - Paediatric Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
FAU - Leach, John Paul
AU  - Leach JP
AD  - School of Medicine, University of Glasgow, Glasgow, UK.
FAU - Johnson, Michael
AU  - Johnson M
AD  - Department of Brain Sciences, Imperial College London Faculty of Medicine-South
      Kensington Campus, London, UK.
FAU - Baker, Gus
AU  - Baker G
AD  - Molecular and Clinical Pharmacology, University of Liverpool, Faculty of Health
      and Life Sciences, Liverpool, UK.
FAU - Pirmohamed, Munir
AU  - Pirmohamed M
AD  - Department of Pharmacology, University of Liverpool Faculty of Health and Life
      Sciences, Liverpool, UK.
FAU - Hughes, Dyfrig A
AU  - Hughes DA
AD  - Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, 
      UK.
FAU - Williamson, Paula R
AU  - Williamson PR
AD  - Biostatistics, University of Liverpool, Liverpool, UK.
FAU - Tudur-Smith, Catrin
AU  - Tudur-Smith C
AD  - Biostatistics, University of Liverpool, Faculty of Health and Life Sciences,
      Liverpool, UK.
FAU - Marson, Anthony Guy
AU  - Marson AG
AD  - Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
      marjon01@liverpool.ac.uk.
LA  - eng
GR  - PB-PG-0408-15077/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
RN  - 44YRR34555 (Levetiracetam)
RN  - 459384H98V (Zonisamide)
SB  - IM
MH  - *Anticonvulsants/therapeutic use
MH  - Carbamazepine/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Cost-Benefit Analysis
MH  - *Epilepsy/drug therapy
MH  - Humans
MH  - Levetiracetam/therapeutic use
MH  - Multicenter Studies as Topic
MH  - Pragmatic Clinical Trials as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
MH  - Zonisamide/therapeutic use
PMC - PMC7451282
OTO - NOTNLM
OT  - *clinical trials
OT  - *epilepsy
OT  - *health economics
OT  - *health policy
OT  - *paediatric neurology
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040635 [pii]
AID - 10.1136/bmjopen-2020-040635 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e040635. doi: 10.1136/bmjopen-2020-040635.


PMID- 32847926
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Effectiveness of mass testing for control of COVID-19: a systematic review
      protocol.
PG  - e040413
LID - 10.1136/bmjopen-2020-040413 [doi]
AB  - INTRODUCTION: Since March 2020, when the COVID-19 outbreak has been deemed a
      pandemic by the WHO, the SARS-CoV-2 spreading has been the focus of attention of 
      scientists, authorities, public health agencies and communities around the world.
      One of the great concerns and challenges, mainly in low-income and middle-income 
      countries, is the identification and monitoring of COVID-19 cases. The
      large-scale availability of testing is a fundamental aspect of COVID-19 control, 
      but it is currently the biggest challenge faced by many countries around the
      world. We aimed to synthesise and critically evaluate the scientific evidence on 
      the influence of the testing capacity for symptomatic individuals in the control 
      of COVID-19. METHODS AND ANALYSIS: A systematic review will be conducted in eight
      databases, such as Medical Literature Analysis and Retrieval System Online,
      ISI-of-Knowledge, Cochrane Central Register of Controlled Trials, Embase, SCOPUS,
      Latin American and Caribbean Health Sciences Literature, PsycINFO and Chinese
      National Knowledge Infrastructure, from inception to 30 July 2020. No restriction
      regarding the language, publication date or setting will be employed. Primary
      outcomes will include the sensitivity as well as the specificity of the tests for
      COVID-19. Study selection will follow the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses checklist. Methodological assessment of the 
      studies will be evaluated by the Cochrane Risk-of-Bias tool for randomised
      controlled trials, the MINORS for non-randomised studies and the Newcastle-Ottawa
      Scale for cohort or case-control studies. Findings will be structured according
      to the test type and target population characteristics and focused on the primary
      outcomes (sensitivity and specificity). Moreover, if sufficient data are
      available, a meta-analysis will be performed. Pooled standardised mean
      differences and 95% CIs will be calculated. Heterogeneity between the studies
      will be determined by I(2) statistics. Subgroup analyses will also be conducted. 
      Publication bias will be assessed with funnel plots and Egger's test.
      Heterogeneity will be explored by random effects analysis. ETHICS AND
      DISSEMINATION: Ethical approval is not required. The results will be disseminated
      widely via peer-reviewed publication and presentations at conferences related to 
      this field. PROSPERO REGISTRATION NUMBER: CRD42020182724.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lopes-Junior, Luis Carlos
AU  - Lopes-Junior LC
AUID- ORCID: 0000-0002-2424-6510
AD  - Nursing Department, Health Sciences Center, Universidade Federal do Espirito
      Santo (UFES), Vitoria, Brazil lopesjr.lc@gmail.com.
FAU - Bomfim, Emiliana
AU  - Bomfim E
AD  - Department of Medicine, University of Saskatchewan College of Medicine,
      Saskatoon, Saskatchewan, Canada.
FAU - Silveira, Denise Sayuri Calheiros da
AU  - Silveira DSCD
AD  - Department of Biochemistry and Immunology, Ribeirao Preto Medical School at
      University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Pessanha, Raphael Manhaes
AU  - Pessanha RM
AD  - Nursing Department, Health Sciences Center, Universidade Federal do Espirito
      Santo (UFES), Vitoria, Brazil.
FAU - Schuab, Sara Isabel Pimentel Carvalho
AU  - Schuab SIPC
AD  - Nursing Department, Health Sciences Center, Universidade Federal do Espirito
      Santo (UFES), Vitoria, Brazil.
FAU - Lima, Regina Aparecida Garcia
AU  - Lima RAG
AD  - Maternal-Infant and Public Health Nursing Department, University of Sao Paulo at 
      Ribeirao Preto College of Nursing, Ribeirao Preto, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/*methods
MH  - Coronavirus Infections/complications/*diagnosis/prevention & control/virology
MH  - Humans
MH  - *Mass Screening
MH  - *Pandemics/prevention & control
MH  - Pneumonia, Viral/complications/*diagnosis/prevention & control/virology
MH  - Public Health/methods
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
PMC - PMC7451293
OTO - NOTNLM
OT  - *epidemiology
OT  - *health policy
OT  - *health services administration & management
OT  - *infectious diseases
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - bmjopen-2020-040413 [pii]
AID - 10.1136/bmjopen-2020-040413 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e040413. doi: 10.1136/bmjopen-2020-040413.


PMID- 32847925
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Sudden death in individuals with obstructive sleep apnoea: protocol for a
      systematic review and meta-analysis.
PG  - e039774
LID - 10.1136/bmjopen-2020-039774 [doi]
AB  - INTRODUCTION: Obstructive sleep apnoea (OSA) is a form of sleep-disordered
      breathing, characterised by blockage of the airway, snoring, gasping for air
      during sleep, daytime sleepiness and fatigue. OSA is associated with increased
      risk of cardiovascular and cerebrovascular morbidity and mortality, and sudden
      cardiac death (SCD). The magnitude of this risk varies in the literature and
      therefore we aim to systematically assess this risk. This study protocol proposes
      a meta-analysis and systematic review aimed to estimate the magnitude of the
      association between OSA, 'sudden death' and cardiovascular death. METHODS: We
      will conduct a systematic review and meta-analysis of studies published from the 
      inception of each database, which report the risk of 'sudden death' or
      cardiovascular death (including SCD) in individuals diagnosed with OSA versus
      persons without OSA. The primary outcome of interest in this study will be the
      relative risk of 'sudden death' in patients diagnosed with OSA in comparison to
      those without an OSA diagnosis. We will search the following electronic research 
      databases: PubMed (MEDLINE), Cochrane, OVID (Healthstar), OVID (Medline), Scopus 
      and Joana Briggs Institute EBP Database. This protocol was developed in
      accordance with the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses Protocol guidelines. The checklist for this document is included in
      the supplemental material. Two reviewers will screen articles for inclusion
      criteria, extracting appropriate data and evaluating the quality of the included 
      studies. The methodological quality of studies will be appraised using an
      appropriate tool. Funnel plots and the Egger's test will be employed to evaluate 
      potential publication bias. We will fit random-effects model with
      inverse-variance methods for the pooling effect estimates. We will conduct a
      meta-regression analysis, using numerous variables of interest including age,
      gender, race, body mass index, hypertension and diabetes, to explore sources of
      study heterogeneity. PROSPERO REGISTRATION NUMBER: CRD42020164941. ETHICS AND
      DISSEMINATION: No ethics clearance was required for this protocol, for no primary
      data are being collected on research subjects. Only secondary analysis of
      pre-existing data in scientific databases will be evaluated. The findings of this
      meta-analysis will be published in a peer-reviewed journal and presented at
      scientific conferences. These results may assist professionals in the prevention 
      and management of OSA and SCD.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Heilbrunn, Emily
AU  - Heilbrunn E
AD  - Public Health Sciences, Penn State College of Medicine, Hershey, PA, United
      States.
FAU - Ssentongo, Paddy
AU  - Ssentongo P
AUID- ORCID: 0000-0003-1565-5731
AD  - Public Health Sciences, Penn State College of Medicine, Hershey, PA, United
      States.
AD  - Engineering Science and Mechanics, Penn State University, University Park, PA,
      United States.
FAU - Chinchilli, Vernon M
AU  - Chinchilli VM
AD  - Public Health Sciences, Penn State College of Medicine, Hershey, PA, United
      States.
FAU - Ssentongo, Anna E
AU  - Ssentongo AE
AUID- ORCID: 0000-0001-9104-1323
AD  - Public Health Sciences, Penn State College of Medicine, Hershey, PA, United
      States assentongo@pennstatehealth.psu.edu.
AD  - Trauma Surgery, Public Health Sciences, Pennsylvania State University College of 
      Medicine, Hershey, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Body Mass Index
MH  - Death, Sudden/epidemiology/etiology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Sleep
MH  - *Sleep Apnea Syndromes
MH  - *Sleep Apnea, Obstructive
MH  - Systematic Reviews as Topic
PMC - PMC7451469
OTO - NOTNLM
OT  - *cardiology
OT  - *internal medicine
OT  - *public health
OT  - *sleep medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039774 [pii]
AID - 10.1136/bmjopen-2020-039774 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e039774. doi: 10.1136/bmjopen-2020-039774.


PMID- 32847923
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Insulin glucose infusion versus nebulised salbutamol versus combination of
      salbutamol and insulin glucose in acute hyperkalaemia in the emergency room:
      protocol for a randomised, multicentre, controlled study (INSAKA).
PG  - e039277
LID - 10.1136/bmjopen-2020-039277 [doi]
AB  - INTRODUCTION: Hyperkalaemia is a common electrolyte disorder and can be
      life-threatening. In the emergency room (ER), interventions aim to protect
      patients from the immediate dangers of elevated serum potassium by redistributing
      potassium ions from the bloodstream into the cells via intravenous insulin or
      nebulised beta2-agonists. However, to date, evidence for acute management of
      hyperkalaemia is limited. The aim of this randomised controlled trial is
      therefore to compare three strategies, namely insulin/glucose intravenous
      infusion, nebulised salbutamol or a combination of nebulised salbutamol and
      insulin/glucose intravenous infusion to reduce serum potassium concentration at
      60 min as a first-line treatment in patients admitted to the ER with serum
      potassium concentrations superior or equal to 6 mmol/L. METHODS AND ANALYSIS:
      INSAKA is a prospective, multicentre, controlled, open-label, parallel-group,
      randomised in a 1:1:1 ratio clinical trial. Patients will be eligible for
      randomisation if they have serum potassium concentrations superior or equal to 6 
      mmol/L measured in the ER. Patients will receive either: (1) 10 mg of nebulised
      salbutamol, (2) 10 units of short-acting insulin in an intravenous bolus with 500
      mL of 10% glucose or (3) 10 units of short-acting insulin in an intravenous bolus
      with 500 mL of 10% glucose combined with 10 mg of nebulised salbutamol. The
      primary endpoint will be the mean change in the absolute serum potassium level
      from baseline to 60 min measured in mmol/L. We plan to include 525 patients.
      ETHICS AND DISSEMINATION: The INSAKA trial will be conducted in accordance with
      the International Council on Harmonization Good Clinical Practices. All trial
      documents and procedures have been reviewed and approved by the Ethics Committee 
      Sud Mediterranee III (approval ID number: 19.07.16.36428). The results will be
      actively disseminated through peer-reviewed journals, conference presentations,
      social media, broadcast media, print media and the internet. TRIAL REGISTRATION: 
      EudraCT number: 2019-002710-39, Clinicaltrials.gov identifier: NCT04012138.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Montassier, Emmanuel
AU  - Montassier E
AUID- ORCID: 0000-0002-2313-1172
AD  - Department of Emergency Medicine, F-CRIN INI-CRCT (Cardiovascular and Renal
      Clinical Trialists), Nantes University Hospital, 44000-Nantes, France
      emmanuel.montassier@chu-nantes.fr.
FAU - Lemoine, Loic
AU  - Lemoine L
AD  - Department of Emergency Medicine, Nantes University Hospital, 44000-Nantes,
      France.
FAU - Hardouin, Jean Benoit
AU  - Hardouin JB
AD  - SPHERE U1246, Inserm, Universite de Nantes-Universite de Tours, 44000-Nantes,
      France.
FAU - Rossignol, Patrick
AU  - Rossignol P
AD  - Institut Lorrain Du Coeur Et Des Vaisseaux Louis Mathieu, Universite de Lorraine,
      Inserm, Centre d'Investigations Cliniques- Plurithematique 14-33, and Inserm
      U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists),
      Vandoeuvre-les-nancy, France.
FAU - Legrand, Matthieu
AU  - Legrand M
AD  - Department of Anesthesiology & Peri-operative & Critical Care Medicine, F-CRIN
      INI-CRCT (Cardiovascular and Renal Clinical Trialists), University of California,
      San Francisco, California, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04012138
SI  - EudraCT/2019-002710-39
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - *Albuterol
MH  - Emergency Service, Hospital
MH  - Glucose
MH  - Humans
MH  - *Hyperkalemia/drug therapy
MH  - Insulin
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7451466
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *echocardiography
OT  - *nephrology
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039277 [pii]
AID - 10.1136/bmjopen-2020-039277 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e039277. doi: 10.1136/bmjopen-2020-039277.


PMID- 32847922
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Protocol for a scoping review of digital health for older adults with cancer and 
      their families.
PG  - e038876
LID - 10.1136/bmjopen-2020-038876 [doi]
AB  - INTRODUCTION: The potential for digital medicine and healthcare in geriatric
      oncology settings has received much attention. This scoping review will summarise
      the nature and extent of the existing literature that describes and examines
      digital health development, implementation, evaluation, outcome and experience
      for older adults with cancer, their families and their healthcare providers.
      METHODS AND ANALYSIS: Arksey and O'Malley's six stages of scoping review
      methodology framework will be used. Searches will be conducted in Cochrane
      Central Register of Controlled Trials (CENTRAL), PubMed, Embase via OvidSP,
      Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus via EBSCO,
      Scopus and PsycINFO via OvidSP for published articles in peer-reviewed scientific
      journals from year 2000 onwards. In addition, we will screen databases for all
      prospectively registered trials. Research articles using quantitative or
      qualitative study design or reviews will be included if they describe or report
      the design, development or usability of digital health interventions in the
      treatment and care of patients 65 years of age or older with cancer and their
      families before, during and after cancer treatment. Grey literature will not be
      searched and included. Two investigators will independently perform the
      literature search, eligibility assessments and study selection. A Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for the
      scoping reviews (PRISMA-ScR) will be used to delineate the search decision
      process. For included articles, the extracted results will be synthesised both
      quantitatively and qualitatively and reported under key conceptual categories of 
      this scoping review. Research gaps and opportunities will be identified and
      summarised. ETHICS AND DISSEMINATION: Since this review will only include
      published data, ethics approval will not be sought. The results of the review
      will be published in peer-reviewed scientific journals. We will also engage with 
      relevant stakeholders within research team's networks to determine suitable
      approaches for dissemination.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cheng, Karis Kin-Fong
AU  - Cheng KK
AUID- ORCID: 0000-0002-4760-4771
AD  - Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore nurckfk@nus.edu.sg.
FAU - Siah, Rosalind Chiew-Jiat
AU  - Siah RC
AD  - Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Ream, Emma
AU  - Ream E
AD  - School of Health Sciences, Faculty of Health and Medical Sciences, University of 
      Surrey, Guildford, Surrey, UK.
FAU - Kanesvaran, Ravindran
AU  - Kanesvaran R
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Armes, Jo
AU  - Armes J
AD  - School of Health Sciences, Faculty of Health and Medical Sciences, University of 
      Surrey, Guildford, Surrey, UK.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Delivery of Health Care
MH  - Health Personnel
MH  - Humans
MH  - *Neoplasms/therapy
MH  - Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7451461
OTO - NOTNLM
OT  - *adult oncology
OT  - *geriatric medicine
OT  - *oncology
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038876 [pii]
AID - 10.1136/bmjopen-2020-038876 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e038876. doi: 10.1136/bmjopen-2020-038876.


PMID- 32847918
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Economic evaluation protocol for a multicentre randomised controlled trial to
      compare Smartphone Cardiac Rehabilitation, Assisted self-Management (SCRAM)
      versus usual care cardiac rehabilitation among people with coronary heart
      disease.
PG  - e038178
LID - 10.1136/bmjopen-2020-038178 [doi]
AB  - INTRODUCTION: It is important to ascertain the cost-effectiveness of alternative 
      services to traditional cardiac rehabilitation while the economic credentials of 
      the Smartphone Cardiac Rehabilitation, Assisted self-Management (SCRAM) programme
      among people with coronary heart disease (CHD) are unknown. This economic
      protocol outlines the methods for undertaking a trial-based economic evaluation
      of SCRAM in the real-world setting in Australia. METHODS AND ANALYSIS: The
      within-trial economic evaluation will be undertaken alongside a randomised
      controlled trial (RCT) designed to determine the effectiveness of SCRAM in
      comparison with the usual care cardiac rehabilitation (UC) alone in people with
      CHD. Pathway analysis will be performed to identify all the costs related to the 
      delivery of SCRAM and UC. Both a healthcare system and a limited societal
      perspective will be adopted to gauge all costs associated with health resource
      utilisation and productivity loss. Healthcare resource use over the 6-month
      participation period will be extracted from administrative databases (ie,
      Pharmaceutical Benefits Scheme and Medical Benefits Schedule). Productivity loss 
      will be measured by absenteeism from work (valued by human capital approach). The
      primary outcomes for the economic evaluation are maximal oxygen uptake (VO2max,
      mL/kg/min, primary RCT outcome) and quality-adjusted life years estimated from
      health-related quality of life as assessed by the Assessment of Quality of
      Life-8D instrument. The incremental cost-effectiveness ratio will be calculated
      using the differences in costs and benefits (ie, primary and secondary outcomes) 
      between the two randomised groups from both perspectives with no discounting. All
      costs will be valued in Australian dollars for year 2020. ETHICS AND
      DISSEMINATION: The study protocol has been approved under Australia's National
      Mutual Acceptance agreement by the Melbourne Health Human Research Ethics
      Committee (HREC/18/MH/119). It is anticipated that SCRAM is a cost-effective
      cardiac telerehabilitation programme for people with CHD from both a healthcare
      and a limited societal perspective in Australia. The evaluation will provide
      evidence to underpin national scale-up of the programme to a wider population.
      The results of the economic analysis will be submitted for publication in a
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical
      Trials Registry (ACTRN12618001458224).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gao, Lan
AU  - Gao L
AUID- ORCID: 0000-0001-9734-1140
AD  - Deakin Health Economics, Deakin University, Burwood, Victoria, Australia
      lan.gao@deakin.edu.au.
FAU - Maddison, Ralph
AU  - Maddison R
AD  - Institute for Physical Activity and Nutrition, Deakin University, Burwood,
      Victoria, Australia.
FAU - Rawstorn, Jonathan
AU  - Rawstorn J
AD  - Institute for Physical Activity and Nutrition, Deakin University, Burwood,
      Victoria, Australia.
FAU - Ball, Kylie
AU  - Ball K
AD  - Institute for Physical Activity and Nutrition, Deakin University, Burwood,
      Victoria, Australia.
FAU - Oldenburg, Brian
AU  - Oldenburg B
AD  - Nossal Institute for Global Health, University of Melbourne School of Population 
      and Global Health, Melbourne, Victoria, Australia.
FAU - Chow, Clara
AU  - Chow C
AD  - Sydney Medical School, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - McNaughton, Sarah
AU  - McNaughton S
AD  - School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, 
      Australia.
FAU - Lamb, Karen
AU  - Lamb K
AD  - School of Population and Global Health, The University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Amerena, John
AU  - Amerena J
AD  - Cardiac Services, Barwon Health, Geelong, Victoria, Australia.
AD  - Faculty of Health, Deakin University, Burwood, Victoria, Australia.
FAU - Nadurata, Voltaire
AU  - Nadurata V
AD  - Department of Cardiology, Bendigo Health, Bendigo, Victoria, Australia.
FAU - Neil, Christopher
AU  - Neil C
AD  - Western Clinical School, The University of Melbourne, Saint Albans, Victoria,
      Australia.
FAU - Cameron, Stuart
AU  - Cameron S
AD  - Applied Artificial Intelligence Institute, Deakin University, Burwood, Victoria, 
      Australia.
FAU - Moodie, Marj
AU  - Moodie M
AD  - School of Health and Social Development, Deakin University, Burwood, Victoria,
      Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Cardiac Rehabilitation
MH  - *Coronary Disease
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Management
MH  - Smartphone
PMC - PMC7451486
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *health economics
OT  - *myocardial infarction
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038178 [pii]
AID - 10.1136/bmjopen-2020-038178 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e038178. doi: 10.1136/bmjopen-2020-038178.


PMID- 32847917
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Efficacy and safety of high-dose Xueshuantong injection (lyophilised) in reducing
      the incidence of major adverse cardiovascular events in patients with unstable
      angina: a protocol of a randomised, parallel-arm, controlled, double-blind and
      multicentre clinical trial based on dual antiplatelet therapy.
PG  - e038074
LID - 10.1136/bmjopen-2020-038074 [doi]
AB  - INTRODUCTION: Unstable angina (UA), referred to as acute coronary syndrome (ACS),
      causes unexpected chest pain. Xueshuantong injection (lyophilised) (XST) is a
      traditional Chinese herbal injection having the potential to treat ACS. However, 
      no clinical trial has been performed in this field. This clinical trial aims to
      examine the efficacy and safety of XST. METHODS AND ANALYSIS: This is a
      randomised, parallel-arm, controlled, double-blind and multicentre clinical
      trial. A total of 1200 participants with UA will be enrolled in a 1:1 ratio, with
      600 patients included in the XST treatment group and 600 with 1/20th dose in the 
      control group. The efficacy assessment and major adverse cardiovascular events
      will be observed, and the frequency of angina attack, angina pectoris will be
      examined at the start and end of the run-in period. All adverse events will be
      recorded, regardless of the severity, to assess the safety of XST. The baseline
      characteristics of patients will be summarised and compared using the t test or
      non-parametric statistical test. Qualitative data will be analysed using the
      chi(2) or Fisher exact tests, Cochran-Mantel-Hasenszel test and Wilcoxon test.
      ETHICS AND DISSEMINATION: This trial has been approved by the Research Ethics
      Committee of The First Affiliated Hospital of Guangzhou University of Chinese
      Medicine, China (approval number: ZYYEC [2017] 0021). Written informed consent
      will be obtained from all participants. The results of this trial will be
      disseminated to the public through academic conferences and peer-reviewed
      journals. TRIAL REGISTRATION: This study was registered on the Chinese Clinical
      Trial Registry (http://www.chictr.org.cn/) with the ID ChiCTR1800015911.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Long, Wenjie
AU  - Long W
AUID- ORCID: 0000-0002-9849-5077
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
AD  - Lingnan Medical Research Center, Guangzhou University of Chinese Medicine,
      Guangzhou, Guangdong, China.
FAU - Liao, Huili
AU  - Liao H
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
FAU - Huang, Xi
AU  - Huang X
AD  - The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 
      Guangdong, China.
FAU - Liu, Qingqing
AU  - Liu Q
AD  - The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 
      Guangdong, China.
FAU - Tang, Yaqing
AU  - Tang Y
AD  - National Drug Clinical Trial Agency Office, Guangzhou University of Traditional
      Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, China.
FAU - Lu, Liming
AU  - Lu L
AD  - Clinical Research and Data Center, Guangzhou University of Chinese Medicine,
      Guangzhou, Guangdong, China.
FAU - Liu, Jianhong
AU  - Liu J
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
FAU - Yuan, Tianhui
AU  - Yuan T
AD  - National Drug Clinical Trial Agency Office, Guangzhou University of Traditional
      Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, China.
FAU - Ling, Yan
AU  - Ling Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
FAU - Hong, Yu
AU  - Hong Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
FAU - Duan, Jiao
AU  - Duan J
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
FAU - Lin, Weiji
AU  - Lin W
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
FAU - Xian, Shaoxiang
AU  - Xian S
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China.
AD  - Lingnan Medical Research Center, Guangzhou University of Chinese Medicine,
      Guangzhou, Guangdong, China.
FAU - Yang, Zhongqi
AU  - Yang Z
AUID- ORCID: 0000-0003-3582-2672
AD  - Department of Geriatrics, The First Affiliated Hospital of Guangzhou University
      of Chinese Medicine, Guangzhou, Guangdong, China yang_zhongqi@163.com.
AD  - Lingnan Medical Research Center, Guangzhou University of Chinese Medicine,
      Guangzhou, Guangdong, China.
AD  - The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, 
      Guangdong, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Panax notoginseng extract)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - *Angina, Unstable/drug therapy/epidemiology
MH  - China/epidemiology
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal
MH  - Humans
MH  - Incidence
MH  - Multicenter Studies as Topic
MH  - *Platelet Aggregation Inhibitors
MH  - Randomized Controlled Trials as Topic
PMC - PMC7451462
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiology
OT  - *coronary heart disease
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038074 [pii]
AID - 10.1136/bmjopen-2020-038074 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e038074. doi: 10.1136/bmjopen-2020-038074.


PMID- 32847916
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Determining the optimal dose of reactive balance training after stroke: study
      protocol for a pilot randomised controlled trial.
PG  - e038073
LID - 10.1136/bmjopen-2020-038073 [doi]
AB  - INTRODUCTION: Falls risk poststroke is highest soon after discharge from
      rehabilitation. Reactive balance training (RBT) aims to improve control of
      reactions to prevent falling after a loss of balance. In healthy older adults, a 
      single RBT session can lead to lasting improvements in reactive balance control
      and prevent falls in daily life. While increasing the dose of RBT does not appear
      to lead to additional benefit for healthy older adults, stroke survivors, who
      have more severely impaired balance control, may benefit from a higher RBT dose. 
      Our long-term goal is to determine the optimal dose of RBT in people with
      subacute stroke. This assessor-blinded pilot randomised controlled trial aims to 
      inform the design of a larger trial to address this long-term goal. METHODS AND
      ANALYSIS: Participants (n=36) will be attending out-patient stroke
      rehabilitation, and will be randomly allocated to one of three groups: one, three
      or six RBT sessions. RBT will replace a portion of participants' regular
      physiotherapy so that the total physical rehabilitation time will be the same for
      the three groups. Balance and balance confidence will be assessed at: (1) study
      enrolment; (2) out-patient rehabilitation discharge; and (3) 6 months
      postdischarge. Participants will report falls and physical activity for 6 months 
      postdischarge. Pilot data will be used to plan the larger trial (ie, sample size 
      estimate using fall rates, and which groups should be included based on
      between-group trends in pre-to-post training effect sizes for reactive balance
      control measures). Pilot data will also be used to assess the feasibility of the 
      larger trial (ie, based on the accrual rate, outcome completion rate and
      feasibility of prescribing specific training doses). ETHICS AND DISSEMINATION:
      Institutional research ethics approval has been received. Study participants will
      receive a lay summary of results. We will also publish our findings in a
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT04219696; Pre results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mansfield, Avril
AU  - Mansfield A
AUID- ORCID: 0000-0002-0396-5815
AD  - Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario,
      Canada avril.mansfield@uhn.ca.
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
AD  - Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook
      Research Institute, Toronto, Ontario, Canada.
FAU - Inness, Elizabeth L
AU  - Inness EL
AUID- ORCID: 0000-0002-9217-4619
AD  - Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario,
      Canada.
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
FAU - Danells, Cynthia J
AU  - Danells CJ
AD  - Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario,
      Canada.
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
FAU - Jagroop, David
AU  - Jagroop D
AUID- ORCID: 0000-0001-8764-6258
AD  - Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario,
      Canada.
FAU - Bhatt, Tanvi
AU  - Bhatt T
AD  - Department of Physical Therapy, University of Illinois, Chicago, Illinois, USA.
FAU - Huntley, Andrew H
AU  - Huntley AH
AUID- ORCID: 0000-0001-9523-304X
AD  - Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario,
      Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04219696
GR  - MSH-141983/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aftercare
MH  - Aged
MH  - Exercise Therapy
MH  - Humans
MH  - Patient Discharge
MH  - Pilot Projects
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke
MH  - *Stroke Rehabilitation
PMC - PMC7451480
OTO - NOTNLM
OT  - *rehabilitation medicine
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038073 [pii]
AID - 10.1136/bmjopen-2020-038073 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e038073. doi: 10.1136/bmjopen-2020-038073.


PMID- 32847912
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Protocol for a single-centre, parallel-group, randomised, controlled, superiority
      trial on the effects of time-restricted eating on body weight, behaviour and
      metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating 
      Time (RESET) study.
PG  - e037166
LID - 10.1136/bmjopen-2020-037166 [doi]
AB  - INTRODUCTION: The aim of this study is to investigate the effects of
      time-restricted eating (TRE) on change in body weight and describe changes in
      behaviour and metabolism in individuals at high risk of type 2 diabetes. METHODS 
      AND ANALYSIS: The REStricted Eating Time (RESET) study is a randomised controlled
      parallel-group open-label trial. 100 women and men with (1) overweight (body mass
      index (BMI)>/=25 kg/m(2)) and prediabetes (glycated haemoglobin 39-47 mmol/mol); 
      or (2) obesity (BMI>/=30 kg/m(2)) will be randomised to a control group (habitual
      living) or TRE (self-selected 10-hours eating window within the period from 06:00
      to 20:00 in a 1:1 ratio. Testing is scheduled at baseline and after 6 weeks
      (mid-intervention), 3 months (post-intervention) and 6 months (follow-up). The
      primary outcome is change in body weight after 3 months of intervention.
      Secondary outcomes include changes in body composition; measures of glucose
      metabolism including glycaemic variability, hormones and metabolites; subjective 
      and metabolic markers of appetite, food preferences and reward; dietary intake;
      physical activity, sleep, chronotype; gastric emptying, gastrointestinal transit 
      time and motility; respiratory and glycolytic capacities; the plasma proteome and
      metabolome; blood pressure, resting heart rate and heart rate variability; and
      resting energy expenditure and substrate oxidation. Motivation and feasibility
      will be examined based on interviews at baseline and after 3 months. After the
      3-month intervention, a 3-month follow-up period and subsequent testing are
      scheduled to assess maintenance and longer-term effects. ETHICS AND
      DISSEMINATION: The study has been approved by the Ethics Committee of the Capital
      Region of Denmark (H-18059188) and the Danish Data Protection Agency. The study
      will be conducted in accordance with the Declaration of Helsinki. Results from
      the study will address whether TRE is effective and feasible in improving health 
      outcomes in individuals at risk of lifestyle-related diseases and can potentially
      inform the design of feasible health recommendations. TRIAL REGISTRATION NUMBER: 
      NCT03854656.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Quist, Jonas S
AU  - Quist JS
AUID- ORCID: 0000-0001-6036-0962
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark
      jonas.salling.quist@regionh.dk.
FAU - Jensen, Marie M
AU  - Jensen MM
AUID- ORCID: 0000-0003-2660-3240
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Clemmensen, Kim K B
AU  - Clemmensen KKB
AUID- ORCID: 0000-0002-4530-1945
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Pedersen, Hanne
AU  - Pedersen H
AUID- ORCID: 0000-0001-7913-7373
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - iMotions A/S, Frederiksberg, Denmark.
FAU - Bjerre, Natasja
AU  - Bjerre N
AUID- ORCID: 0000-0001-8875-7240
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Storling, Joachim
AU  - Storling J
AUID- ORCID: 0000-0002-7529-4264
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Blond, Martin B
AU  - Blond MB
AUID- ORCID: 0000-0002-2032-1560
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Wewer Albrechtsen, Nicolai J
AU  - Wewer Albrechtsen NJ
AUID- ORCID: 0000-0003-4230-5753
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen,
      Copenhagen, Denmark.
AD  - Novo Nordisk Foundation Center for Protein Research, University of Copenhagen,
      Copenhagen, Denmark.
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, University of
      Copenhagen, Copenhagen, Denmark.
FAU - Holst, Jens J
AU  - Holst JJ
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, University of
      Copenhagen, Copenhagen, Denmark.
FAU - Torekov, Signe S
AU  - Torekov SS
AUID- ORCID: 0000-0001-6779-0252
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, University of
      Copenhagen, Copenhagen, Denmark.
FAU - Vistisen, Dorte
AU  - Vistisen D
AUID- ORCID: 0000-0001-5045-5351
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Jorgensen, Marit E
AU  - Jorgensen ME
AUID- ORCID: 0000-0001-8356-5565
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Denmark.
FAU - Panda, Satchidananda
AU  - Panda S
AD  - Salk Institute for Biological Studies, La Jolla, California, USA.
FAU - Brock, Christina
AU  - Brock C
AUID- ORCID: 0000-0002-3381-1884
AD  - Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
AD  - Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University
      Hospital, Aalborg, Denmark.
FAU - Finlayson, Graham
AU  - Finlayson G
AUID- ORCID: 0000-0002-5620-2256
AD  - School of Psychology, University of Leeds, Leeds, UK.
FAU - Faerch, Kristine
AU  - Faerch K
AUID- ORCID: 0000-0002-6127-0448
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
AD  - Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03854656
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - Female
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Male
MH  - Obesity
MH  - Overweight
MH  - Randomized Controlled Trials as Topic
PMC - PMC7451453
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *nutrition & dietetics
COIS- Competing interests: Steno Diabetes Center Copenhagen is a hospital providing
      health services for the public healthcare system. Steno Diabetes Center
      Copenhagen is partly funded by the Novo Nordisk Foundation through unrestricted
      grants. The Novo Nordisk Foundation has no economic interests in the study. The
      Novo Nordisk Foundation will not have an influence on the study design, data
      collection, analysis, interpretation of data, the writing of the study report or 
      any publication and the decision to submit the paper for publication. The
      investigators employed at Steno Diabetes Center Copenhagen will not benefit
      economically from conducting the study. HP is a coinvestigator on the project
      which is part of her Industrial PhD project in collaboration with iMotions A/S,
      where HP is employed. iMotions A/S is a collaborator on the project and gives
      advice for the use and analysis of biometric methods in the study design phase.
      SP has published a book, The Circadian Code, focusing on the concept of TRE.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037166 [pii]
AID - 10.1136/bmjopen-2020-037166 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e037166. doi: 10.1136/bmjopen-2020-037166.


PMID- 32847910
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Developing and implementing a culturally informed FAmily Motivational Engagement 
      Strategy (FAMES) to increase family engagement in first episode psychosis
      programs: mixed methods pilot study protocol.
PG  - e036907
LID - 10.1136/bmjopen-2020-036907 [doi]
AB  - INTRODUCTION: Despite the proven effectiveness of coordinated specialty care
      (CSC) programmes for first episode psychosis in the USA, CSC programmes often
      have low levels of engagement in family psychoeducation, and engagement of racial
      and ethnic minority family members is even lower than that for non-Latino white
      family members. The goal of this study is to develop and evaluate a culturally
      informed FAmily Motivational Engagement Strategy (FAMES) and implementation
      toolkit for CSC providers. METHODS AND ANALYSIS: This protocol describes a mixed 
      methods, multi-phase study that blends intervention mapping and the Promoting
      Action on Research in Health Services framework to develop, modify and pilot-test
      FAMES and an accompanying implementation toolkit. Phase 1 will convene a
      Stakeholder Advisory Committee to inform modifications based on findings from
      phases 1 and 2. During phase 1, we will also recruit approximately 200 family
      members to complete an online survey to assess barriers and motivation to engage 
      in treatment. Phase 2 we will recruit five family members into a 3-month trial of
      the modified FAMES and implementation toolkit. Results will guide the advisory
      committee in refining the intervention and implementation toolkit. Phase 3 will
      involve a 16-month non-randomised, stepped-wedge trial with 50 family members
      from five CSC programmes in community-based mental health clinics to examine the 
      acceptability, feasibility and initial impact of FAMES and the implementation
      toolkit. ETHICS AND DISSEMINATION: This study received Institutional Review Board
      approval from Washington State University, protocol #17 812-001. Results will be 
      disseminated via peer review publications, presentations at national and
      international conferences, and to local community mental health agencies and
      committees. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT04188366).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oluwoye, Oladunni
AU  - Oluwoye O
AUID- ORCID: 0000-0003-2743-1620
AD  - Elson S. Floyd College of Medicine, Washington State University, Spokane,
      Washington, USA oladunni.oluwoye@wsu.edu.
FAU - Dyck, Dennis
AU  - Dyck D
AD  - Psychology, Washington State University - Spokane, Spokane, Washington, USA.
FAU - McPherson, Sterling M
AU  - McPherson SM
AD  - Elson S. Floyd College of Medicine, Washington State University, Spokane,
      Washington, USA.
FAU - Lewis-Fernandez, Roberto
AU  - Lewis-Fernandez R
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons,
      New York, New York, USA.
FAU - Compton, Michael T
AU  - Compton MT
AD  - Department of Psychiatry, Columbia University College of Physicians and Surgeons,
      New York, New York, USA.
FAU - McDonell, Michael G
AU  - McDonell MG
AD  - Elson S. Floyd College of Medicine, Washington State University, Spokane,
      Washington, USA.
FAU - Cabassa, Leopoldo J
AU  - Cabassa LJ
AD  - George Warren Brown School of Social Work, Washington University in Saint Louis, 
      Saint Louis, Missouri, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04188366
GR  - K01 MH117457/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ethnicity
MH  - Humans
MH  - Minority Groups
MH  - *Motivation
MH  - Pilot Projects
MH  - *Psychotic Disorders/therapy
MH  - Washington
PMC - PMC7451463
OTO - NOTNLM
OT  - *community child health
OT  - *mental health
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036907 [pii]
AID - 10.1136/bmjopen-2020-036907 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e036907. doi: 10.1136/bmjopen-2020-036907.


PMID- 32847906
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Novel approach to estimate tuberculosis transmission in primary care clinics in
      sub-Saharan Africa: protocol of a prospective study.
PG  - e036214
LID - 10.1136/bmjopen-2019-036214 [doi]
AB  - INTRODUCTION: Tuberculosis (TB) transmission is difficult to measure, and its
      drivers are not well understood. The effectiveness of infection control measures 
      at healthcare clinics and the most appropriate intervention strategies to
      interrupt transmission are unclear. We propose a novel approach using clinical,
      environmental and position-tracking data to study the risk of TB transmission at 
      primary care clinics in TB and HIV high burden settings in sub-Saharan Africa.
      METHODS AND ANALYSIS: We describe a novel and rapid study design to assess risk
      factors for airborne TB transmission at primary care clinics in high-burden
      settings. The study protocol combines a range of different measurements. We will 
      collect anonymous data on the number of patients, waiting times and patient
      movements using video sensors. Also, we will collect acoustic sound recordings to
      determine the frequency and intensity of coughing. Environmental data will
      include indoor carbon dioxide levels (CO2 in parts per million) and relative
      humidity. We will also extract routinely collected clinical data from the clinic 
      records. The number of Mycobacterium tuberculosis particles in the air will be
      ascertained from dried filter units using highly sensitive digital droplet PCR.
      We will calculate rebreathed air volume based on people density and CO2 levels
      and develop a mathematical model to estimate the risk of TB transmission. The
      mathematical model can then be used to estimate the effect of possible
      interventions such as separating patient flows or improving ventilation in
      reducing transmission. The feasibility of our approach was recently demonstrated 
      in a pilot study in a primary care clinic in Cape Town, South Africa. ETHICS AND 
      DISSEMINATION: The study was approved by the University of Cape Town (HREC/REF
      no. 228/2019), the City of Cape Town (ID-8139) and the Ethics Committee of the
      Canton Bern (2019-02131), Switzerland. The results will be disseminated in
      international peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Zurcher, Kathrin
AU  - Zurcher K
AUID- ORCID: 0000-0002-7915-3194
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
FAU - Morrow, Carl
AU  - Morrow C
AD  - Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine
      (IDM), University of Cape Town, Cape Town, South Africa.
AD  - Institute of Infectious Disease and Molecular Medicine and the Department of
      Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
FAU - Riou, Julien
AU  - Riou J
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
FAU - Ballif, Marie
AU  - Ballif M
AUID- ORCID: 0000-0003-3133-3011
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
FAU - Koch, Anastasia Sideris
AU  - Koch AS
AUID- ORCID: 0000-0002-5897-4196
AD  - Institute of Infectious Disease and Molecular Medicine and the Department of
      Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
AD  - Molecular Mycobacteriology Research Unit, University of Cape Town, Rondebosch,
      Western Cape, South Africa.
FAU - Bertschinger, Simon
AU  - Bertschinger S
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
AD  - Medical Informatics, Berne University of Applied Sciences, Bern, Switzerland.
FAU - Liu, Xin
AU  - Liu X
AD  - Paul G. Allen School of Computer Science & Engineering, University of Washington,
      Seattle, Washington, USA.
FAU - Sharma, Manuja
AU  - Sharma M
AD  - Paul G. Allen School of Computer Science & Engineering, University of Washington,
      Seattle, Washington, USA.
FAU - Middelkoop, Keren
AU  - Middelkoop K
AUID- ORCID: 0000-0001-9922-4263
AD  - Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine
      (IDM), University of Cape Town, Cape Town, South Africa.
AD  - Institute of Infectious Disease and Molecular Medicine and the Department of
      Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
FAU - Warner, Digby
AU  - Warner D
AD  - Institute of Infectious Disease and Molecular Medicine and the Department of
      Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
AD  - Molecular Mycobacteriology Research Unit, University of Cape Town, Rondebosch,
      Western Cape, South Africa.
FAU - Wood, Robin
AU  - Wood R
AD  - Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine
      (IDM), University of Cape Town, Cape Town, South Africa.
AD  - Institute of Infectious Disease and Molecular Medicine and the Department of
      Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
FAU - Egger, Matthias
AU  - Egger M
AUID- ORCID: 0000-0001-7462-5132
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland.
AD  - Centre for Infectious Disease Epidemiology & Research, School of Public Health & 
      Family Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
AD  - Population Health Sciences, Bristol Medical School, University of Bristol,
      Bristol, UK.
FAU - Fenner, Lukas
AU  - Fenner L
AUID- ORCID: 0000-0003-3309-4835
AD  - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern,
      Switzerland lukas.fenner@ispm.unibe.ch.
LA  - eng
GR  - U01 AI069924/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Pilot Projects
MH  - Primary Health Care
MH  - Prospective Studies
MH  - South Africa
MH  - Switzerland
MH  - *Tuberculosis/diagnosis/epidemiology/prevention & control
PMC - PMC7451471
OTO - NOTNLM
OT  - *infectious diseases
OT  - *primary care
OT  - *public health
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036214 [pii]
AID - 10.1136/bmjopen-2019-036214 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e036214. doi: 10.1136/bmjopen-2019-036214.


PMID- 32847904
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Current provision of myelopathy education in medical schools in the UK: protocol 
      for a national medical student survey.
PG  - e035563
LID - 10.1136/bmjopen-2019-035563 [doi]
AB  - INTRODUCTION: Degenerative cervical myelopathy (DCM) is a common, disabling and
      progressive neurological condition triggered by chronic compression of the
      cervical spinal cord by surrounding degenerative changes. Early diagnosis and
      specialist management are essential to reduce disability, yet time to diagnosis
      is typically prolonged. Lack of sufficient representation of DCM in undergraduate
      and postgraduate medical curricula may contribute to the poor recognition of DCM 
      by non-specialist doctors in clinical practice.In this study, our objective,
      therefore, is to assess DCM teaching provision in medical schools throughout the 
      UK and to assess the impact of teaching on the DCM knowledge of UK medical
      students. METHODS AND ANALYSIS: A 19-item questionnaire capturing data on medical
      student demographics, myelopathy teaching and myelopathy knowledge was designed. 
      Ethical approval was granted by the Psychology Research Ethics Committee,
      University of Cambridge. An online survey was hosted on Myelopathy.org, an
      international myelopathy charity. Students studying at a UK medical school are
      eligible for inclusion. The survey is advertised nationally through university
      social media pages, university email bulletins and the national student network
      of Myelopathy.org. Advertisements are scheduled monthly over a 12-month
      recruitment period. Participation is incentivised by entering consenting
      participants of completed surveys to an Amazon voucher prize draw. Responses are 
      anonymised using participant-chosen unique identifier codes. A participant
      information sheet followed by an explicit survey question captures participant
      informed consent. Regular updates on the progress of the study will be published 
      on Myelopathy.org. ETHICS AND DISSEMINATION: Ethical approval for the study was
      granted by the Psychology Research Ethics Committee, University of Cambridge
      (PRE.2018.099). The findings of the study described in this protocol, and all
      other related work, will be submitted for publication in a peer-reviewed journal 
      and will be presented at scientific conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Mowforth, Oliver
AU  - Mowforth O
AUID- ORCID: 0000-0001-6788-745X
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, University of
      Cambridge, Cambridge, UK.
FAU - Davies, Benjamin
AU  - Davies B
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, University of
      Cambridge, Cambridge, UK.
FAU - Stewart, Max
AU  - Stewart M
AD  - School of Clinical Medicine, University of Cambridge, Cambridge, UK.
FAU - Smith, Sam
AU  - Smith S
AD  - School of Clinical Medicine, University of Cambridge, Cambridge, UK.
FAU - Willison, Alice
AU  - Willison A
AD  - Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
FAU - Ahmed, Shahzaib
AU  - Ahmed S
AD  - School of Clinical Medicine, University of Cambridge, Cambridge, UK.
FAU - Starkey, Michelle
AU  - Starkey M
AD  - Myelopathy.org, Cambridge, UK.
FAU - Sadler, Iwan
AU  - Sadler I
AD  - Myelopathy.org, Cambridge, UK.
FAU - Sarewitz, Ellen
AU  - Sarewitz E
AD  - Myelopathy.org, Cambridge, UK.
FAU - Stacpoole, Sybil
AU  - Stacpoole S
AD  - Neurology Unit, Department of Clinical Neurosciences, University of Cambridge,
      Cambridge, UK.
FAU - Kotter, Mark
AU  - Kotter M
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, University of
      Cambridge, Cambridge, UK mrk25@cam.ac.uk.
AD  - Anne McLaren Laboratory for Regenerative Medicine, Wellcome Trust-Medical
      Research Council Cambridge Stem Cell Institute, University of Cambridge,
      Cambridge, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Humans
MH  - Schools, Medical
MH  - *Spinal Cord Diseases/diagnosis
MH  - *Students, Medical
MH  - United Kingdom
PMC - PMC7451530
OTO - NOTNLM
OT  - *medical education & training
OT  - *neurology
OT  - *neurosurgery
COIS- Competing interests: OM, BD, MS, SSmith, AW, SA, MS, IS, ES and MK have voluntary
      roles at Myelopathy.org, an international DCM charity.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035563 [pii]
AID - 10.1136/bmjopen-2019-035563 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e035563. doi: 10.1136/bmjopen-2019-035563.


PMID- 32847900
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 26
TI  - Effects of preconditioning by nasal splint and mouth breathing on emergence
      delirium after functional endoscopic sinus surgery in Chinese adults: a study
      protocol for a randomised controlled trial.
PG  - e033803
LID - 10.1136/bmjopen-2019-033803 [doi]
AB  - INTRODUCTION: Emergence delirium (ED) is a common adverse manifestation after
      general anaesthesia and may result in undesirable consequences. Its causes and
      mechanisms are diverse and complex, and it is still unavoidable in clinical work.
      There is a high incidence of ED after otorhinolaryngology surgery, which may
      result from the sudden loss of functional senses and discomfort of surgical
      organs. This study aims to test a non-invasive, non-drug treatment modality of
      nose clamping and mouth-breathing training before surgery to reduce ED. METHODS
      AND ANALYSIS: This prospective randomised controlled trial (RCT) will include 200
      patients who undergo functional endoscopic sinus surgery (FESS) at Shanghai
      General Hospital, China. Study participants will be randomly assigned in two
      groups with a 1:1 ratio. The pretreatment group (P-group) will receive an
      intervention by nasal splint and mouth-breathing training before surgery, while
      the control group (C-group) will not receive any intervention; following which
      both groups will undergo FESS under general anaesthesia in accordance with the
      same anaesthesia scheme. After surgery, we will perform a single-blinded
      assessment of ED occurrence with stratification. IBM SPSS Statistics V.20
      statistical software will be used for statistical analyses. A X(2) test will be
      used to compare the two groups, and t-tests will determine the statistical
      significance of continuous variables. ETHICS AND DISSEMINATION: This RCT was
      designed in accordance with the principles of the Declaration of Helsinki and has
      been approved by the Ethics Committee of Shanghai General Hospital, ID:
      2019KY039.We expect to release the original data in February 2022 on the ResMan
      original data sharing platform (IPD sharing platform) of the China clinical trial
      registry, which can be viewed at the following
      website:http://www.medresman.org.cn/pub/cn/proj/projectshow.aspx?proj=6293. TRIAL
      REGISTRATION NUMBER: ChiCTR1900024925.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Hongjiao
AU  - Xu H
AUID- ORCID: 0000-0001-7483-4516
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Li, Xiang
AU  - Li X
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Yang, Bin
AU  - Yang B
AD  - Department of Anaesthesiology, Chongqing University Cancer Hospital, Chongqing,
      China.
FAU - Shen, Zhenyuan
AU  - Shen Z
AD  - Medical department, Mellon community health service center, Shanghai, China.
FAU - Li, Weiwen
AU  - Li W
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Zhou, Yachun
AU  - Zhou Y
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Jiang, Jihong
AU  - Jiang J
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Chen, Xia
AU  - Chen X
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Gu, Yuyu
AU  - Gu Y
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Pei, Zhi
AU  - Pei Z
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China.
FAU - Li, Jinbao
AU  - Li J
AUID- ORCID: 0000-0001-5582-5737
AD  - Department of Anaesthesiology, Shanghai Jiaotong University First People's
      Hospital, Shanghai, China lijinbaoshanghai@163.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Anesthesia, General/adverse effects
MH  - China
MH  - *Emergence Delirium
MH  - Humans
MH  - Mouth Breathing
MH  - Randomized Controlled Trials as Topic
MH  - Splints
PMC - PMC7451479
OTO - NOTNLM
OT  - *ED
OT  - *FESS
OT  - *NRS
OT  - *emergence delirium
OT  - *functional endoscopic sinus surgery
OT  - *numerical rating scale
COIS- Competing interests: None declared.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033803 [pii]
AID - 10.1136/bmjopen-2019-033803 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 26;10(8):e033803. doi: 10.1136/bmjopen-2019-033803.


PMID- 32847640
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1945-1938 (Electronic)
IS  - 1049-023X (Linking)
VI  - 35
IP  - 6
DP  - 2020 Dec
TI  - Mechanical Ventilation with Room Air is Feasible in a Moderate Acute Respiratory 
      Distress Syndrome Pig Model - Implications for Disaster Situations and Low-Income
      Nations.
PG  - 604-611
LID - 10.1017/S1049023X20001016 [doi]
AB  - INTRODUCTION: Patients with respiratory failure are usually mechanically
      ventilated, mostly with fraction of inspired oxygen (FiO2) > 0.21. Minimizing
      FiO2 is increasingly an accepted standard. In underserved nations and disasters, 
      salvageable patients requiring mechanical ventilation may outstrip oxygen
      supplies. STUDY OBJECTIVE: The hypothesis of the present study was that
      mechanical ventilation with FiO2 = 0.21 is feasible. This assumption was tested
      in an Acute Respiratory Distress Syndrome (ARDS) model in pigs. METHODS:
      Seventeen pigs were anesthetized, intubated, and mechanically ventilated with
      FiO2 = 0.4 and Positive End Expiratory Pressure (PEEP) of 5cmH2O. Acute
      Respiratory Distress Syndrome was induced by intravenous (IV) oleic acid (OA)
      infusion, and FiO2 was reduced to 0.21 after 45 minutes of stable moderate ARDS. 
      If peripheral capillary oxygen saturation (SpO2) decreased below 80%, PEEP was
      increased gradually until maximum 20cmH2O, then inspiratory time elevated from
      one second to 1.4 seconds. RESULTS: Animals developed moderate ARDS (mean partial
      pressure of oxygen [PaO2]/FiO2 = 162.8, peak and mean inspiratory pressures
      doubled, and lung compliance decreased). The SpO2 decreased to <80% rapidly after
      FiO2 was decreased to 0.21. In 14/17 animals, increasing PEEP sufficed to
      maintain SpO2 > 80%. Only in 3/17 animals, elevation of FiO2 to 0.25 after PEEP
      reached 20cmH2O was needed to maintain SpO2 > 80%. Animals remained
      hemodynamically stable until euthanasia one hour later. CONCLUSIONS: In a pig
      model of moderate ARDS, mechanical ventilation with room air was feasible in
      14/17 animals by elevating PEEP. These results in animal model support the
      potential feasibility of lowering FiO2 to 0.21 in some ARDS patients. The present
      study was conceived to address the ethical and practical paradigm of mechanical
      ventilation in disasters and underserved areas, which assumes that oxygen is
      mandatory in respiratory failure and is therefore a rate-limiting factor in care 
      capacity allocation. Further studies are needed before paradigm changes are
      considered.
FAU - Halpern, Pinchas
AU  - Halpern P
AD  - Tel Aviv Medical Center and Tel Aviv University Faculty of Medicine, Israel.
FAU - Goldvaser, Michael
AU  - Goldvaser M
AD  - Department of Organic Chemistry, Israel Institute for Biological Research (IIBR),
      Ness-Ziona, Israel.
FAU - Yacov, Guy
AU  - Yacov G
AD  - Department of Pharmacology, Israel Institute for Biological Research (IIBR),
      Ness-Ziona, Israel.
FAU - Rosner, Amir
AU  - Rosner A
AD  - Veterinary Center for Preclinical Research, Israel Institute for Biological
      Research (IIBR), Ness-Ziona, Israel.
FAU - Wenger, Ada
AU  - Wenger A
AD  - Department of Organic Chemistry, Israel Institute for Biological Research (IIBR),
      Ness-Ziona, Israel.
FAU - Bachar, Keren
AU  - Bachar K
AD  - Institute of Pulmonary Medicine, Sheba Medical Center, Tel-Hashomer, Israel.
FAU - Katalan, Shahaf
AU  - Katalan S
AUID- ORCID: https://orcid.org/0000-0001-9477-9307
AD  - Department of Pharmacology, Israel Institute for Biological Research (IIBR),
      Ness-Ziona, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - United States
TA  - Prehosp Disaster Med
JT  - Prehospital and disaster medicine
JID - 8918173
MH  - *Air
MH  - Animals
MH  - Developing Countries
MH  - Disaster Planning
MH  - Disease Models, Animal
MH  - Female
MH  - *Positive-Pressure Respiration
MH  - Respiratory Distress Syndrome/*therapy
MH  - Swine
OTO - NOTNLM
OT  - disaster
OT  - mechanical ventilation
OT  - oleic acid
OT  - oxygen
OT  - respiratory failure
EDAT- 2020/08/28 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - S1049023X20001016 [pii]
AID - 10.1017/S1049023X20001016 [doi]
PST - ppublish
SO  - Prehosp Disaster Med. 2020 Dec;35(6):604-611. doi: 10.1017/S1049023X20001016.
      Epub 2020 Aug 27.


PMID- 32847572
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 26
TI  - Theory and practice of integrative clinical ethics support: a joint experience
      within gender affirmative care.
PG  - 79
LID - 10.1186/s12910-020-00520-3 [doi]
AB  - BACKGROUND: Clinical ethics support (CES) aims to support health care
      professionals in dealing with ethical issues in clinical practice. Although the
      prevalence of CES is increasing, it does meet challenges and pressing questions
      regarding implementation and organization. In this paper we present a specific
      way of organizing CES, which we have called integrative CES, and argue that this 
      approach meets some of the challenges regarding implementation and organization. 
      METHODS: This integrative approach was developed in an iterative process,
      combining actual experiences in a case study in which we offered CES to a team
      that provides transgender health care and reflecting on the theoretical
      underpinnings of our work stemming from pragmatism, hermeneutics and
      organizational and educational sciences. RESULTS: In this paper we describe five 
      key characteristics of an integrative approach to CES; 1. Positioning CES more
      within care practices, 2. Involving new perspectives, 3. Creating co-ownership of
      CES, 4. Paying attention to follow up, and 5. Developing innovative CES
      activities through an emerging design. CONCLUSIONS: In the discussion we compare 
      this approach to the integrated approach to CES developed in the US and the hub
      and spokes strategy developed in Canada. Furthermore, we reflect on how an
      integrative approach to CES can help to handle some of the challenges of current 
      CES.
FAU - Hartman, Laura
AU  - Hartman L
AUID- ORCID: 0000-0001-9206-2708
AD  - Department of Ethics, Law and Humanities, Amsterdam UMC, Vrije Universitieit
      Amsterda, Amsterdam, The Netherlands. la.hartman@amsterdamumc.nl.
FAU - Inguaggiato, Giulia
AU  - Inguaggiato G
AUID- ORCID: 0000-0003-2340-908X
AD  - Department of Ethics, Law and Humanities, Amsterdam UMC, Vrije Universitieit
      Amsterda, Amsterdam, The Netherlands.
FAU - Widdershoven, Guy
AU  - Widdershoven G
AUID- ORCID: 0000-0001-7620-6812
AD  - Department of Ethics, Law and Humanities, Amsterdam UMC, Vrije Universitieit
      Amsterda, Amsterdam, The Netherlands.
FAU - Wensing-Kruger, Annelijn
AU  - Wensing-Kruger A
AD  - Centre of Expertise on Gender Dysphoria, Amsterdam UMC, Vrije Universiteit
      Amsterdam, Amsterdam, The Netherlands.
AD  - Department of Medical Psychology, Amsterdam UMC, Vrije Universiteit Amsterdam,
      Amsterdam, The Netherlands.
FAU - Molewijk, Bert
AU  - Molewijk B
AUID- ORCID: 0000-0003-1944-9759
AD  - Department of Ethics, Law and Humanities, Amsterdam UMC, Vrije Universitieit
      Amsterda, Amsterdam, The Netherlands.
AD  - Centre for Medical Ethics, Institute of Health and Society, Faculty of Medicine, 
      University of Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Canada
MH  - *Ethics, Clinical
MH  - Humans
PMC - PMC7448443
OTO - NOTNLM
OT  - *Clinical ethics support
OT  - *Gender affirmative care
OT  - *Hermeneutics
OT  - *Integrative
OT  - *Pragmatism
OT  - *Responsive evaluation
OT  - *Theory
EDAT- 2020/08/28 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/28 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00520-3 [doi]
AID - 10.1186/s12910-020-00520-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 26;21(1):79. doi: 10.1186/s12910-020-00520-3.


PMID- 32847464
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20201218
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Linking)
VI  - 11
DP  - 2020 Jan-Dec
TI  - Palestinian Health Care Workers' Stress and Stressors During COVID-19 Pandemic: A
      Cross-Sectional Study.
PG  - 2150132720955026
LID - 10.1177/2150132720955026 [doi]
AB  - BACKGROUND: COVID-19 is thought to be the most significant public health threat
      the modern world has encountered. Health care workers (HCWs) face enormous
      pressure due to work overload, negative emotions, exhaustion, lack of contact
      with their families, and risk of catching the infection and death. AIM: This
      study aims to assess the level of stress perceived by HCWs and possible
      associated factors during the COVID-19 outbreak in Palestine. METHODS: A
      cross-sectional sample of 430 frontlines HCWs was conducted using an online
      self-reported questionnaire. HCWs' stress from the COVID-19 outbreak, factors
      that increase stress, and the activities that reduced stress were assessed.
      Chi-square test was used to compare between a categorical variable and the study 
      outcome; associations are presented as odds ratios (OR) and confidence intervals 
      (95% CI) with 0.05 significance level. Al-Najah National University institutional
      review board granted ethics approval. RESULTS: Most respondents (74.0%) reported 
      high-stress levels during the outbreak. Fear of transmitting the virus to family 
      was the most stressful factor (91.6%). HCWs who did not have training on the
      outbreak response were more likely to have high-stress levels (OR = 2.7 [95% CI =
      1.7-4.4], P < .001). Those with high stress reported being disappointed (OR = 2.4
      [95% CI = 1.5-3.6], P < .001), and strongly considered taking sick leave (OR =
      3.9 [95% CI = 1.9-7.9], P < .001). CONCLUSION: HCWs are under tremendous stress, 
      given the ongoing COVID-19 pandemic. Understanding the psychological impact of
      the outbreak on HCWs and the activities that mitigate the stress is crucial to
      guide policies and interventions that can maintain psychological well-being.
FAU - Maraqa, Beesan
AU  - Maraqa B
AD  - An-Najah National University, Nablus, Palestine.
FAU - Nazzal, Zaher
AU  - Nazzal Z
AUID- ORCID: 0000-0002-2655-6109
AD  - Ministry of Health, Hebron, Palestine.
FAU - Zink, Therese
AU  - Zink T
AD  - Brown University, Providence, RI, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Personnel/*psychology/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle East/epidemiology
MH  - Occupational Stress/*epidemiology
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Surveys and Questionnaires
PMC - PMC7457680
OTO - NOTNLM
OT  - *COVID-19
OT  - *Palestine
OT  - *health care workers
OT  - *stress
OT  - *stressors
EDAT- 2020/08/28 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 10.1177/2150132720955026 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2020 Jan-Dec;11:2150132720955026. doi:
      10.1177/2150132720955026.


PMID- 32847442
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 12
DP  - 2020 Dec
TI  - Patients as teachers and arts-based reflection in surgical clerkship: A
      preliminary exploration.
PG  - 1362-1368
LID - 10.1080/0142159X.2020.1807482 [doi]
AB  - BACKGROUND: Involving patients in medical education as teachers is not a novel
      approach, yet it has not been widely adopted by undergraduate surgical curricula 
      in Canada. The Patients as Teachers initiative in surgery (PAT) program, with an 
      arts-based reflection assignment, was developed for surgical clerks with the
      goals of emphasizing patient-centredness in surgical practice, humanistic aspects
      of medicine, and to counterbalance the commonplace emphasis on technical
      competency in surgery. METHODS: Qualitative data was collected exploring the
      question: What was the experience and impact of the PAT program on patient
      teachers and students? Patient teachers (n = 5) were invited to participate in
      one-on-one interviews and students (n = 46) were invited to participate in focus 
      groups at the end of the program. RESULTS: Findings converged around two main
      themes: what students/patient teachers valued about the PAT program and what they
      perceived was learned. While patient teachers felt a sense of emotional healing
      and appreciated a chance to contribute to medical education, students valued
      having protected time to learn in depth from the patient teachers. Students also 
      begrudgingly came to appreciate the arts-based reflection assignment. CONCLUSION:
      By bringing patient voice to the forefront and encouraging reflection, the PAT
      program emphasized to students the compassionate and humanistic side of surgical 
      care. Future studies could examine the mechanisms by which learning occurs and
      long-term impacts.
FAU - Kangasjarvi, Emilia
AU  - Kangasjarvi E
AUID- ORCID: 0000-0003-3123-446X
AD  - Faculty of Medicine, Centre for Faculty Development, University of Toronto at St.
      Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
FAU - Ng, Stella L
AU  - Ng SL
AUID- ORCID: 0000-0003-1433-6851
AD  - Faculty of Medicine, Centre for Faculty Development, University of Toronto at St.
      Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
AD  - Centre for Ambulatory Care Education, Women's College Hospital, Toronto, Ontario,
      Canada.
AD  - Department of Speech-Language Pathology, Faculty of Medicine, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Friesen, Farah
AU  - Friesen F
AD  - Faculty of Medicine, Centre for Faculty Development, University of Toronto at St.
      Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
FAU - Simpson, Jory S
AU  - Simpson JS
AD  - Department of Surgery, Division of General Surgery, Faculty of Medicine, St.
      Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto,
      Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
CIN - Med Teach. 2021 May;43(5):605-606. PMID: 33073651
CIN - Med Teach. 2021 Jun;43(6):727. PMID: 33100117
MH  - Canada
MH  - *Clinical Clerkship
MH  - Curriculum
MH  - *Education, Medical
MH  - *Education, Medical, Undergraduate
MH  - Humanism
MH  - Humans
MH  - *Students, Medical
OTO - NOTNLM
OT  - *Surgery
OT  - *communication skills
OT  - *ethics/attitudes
OT  - *medical education research
OT  - *small group
EDAT- 2020/08/28 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - 10.1080/0142159X.2020.1807482 [doi]
PST - ppublish
SO  - Med Teach. 2020 Dec;42(12):1362-1368. doi: 10.1080/0142159X.2020.1807482. Epub
      2020 Aug 26.


PMID- 32846857
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - Tripterygium and its plant extraction for systemic lupus erythematosus: A
      protocol for systematic review and meta analysis.
PG  - e21909
LID - 10.1097/MD.0000000000021909 [doi]
AB  - BACKGROUND: Systemic Lupus Erythematosus (SLE) is a diffuse connetive tissue
      disease, which is difficult to be conquered. However, the traditional Chinese
      medicine is significant in the treatment. And the Chinese medicine tripterygium
      and its plant extraction can help us to overcome this disease, to some extent.
      METHODS: The deadline should be from inception to February 2020 by computer from 
      the databases: the Cochrane Library, Pubmed, Embase, Web of Science in English
      and the Chinese National Knowledge Infrastructure, Wanfang Database, Chinese
      Biomedical Literature Database and Chinese Science, Chinese Traditional Medicine 
      Database, Chinese Science and Technology Periodical Database in Chinese. Included
      criteria are randomized controlled trials. The primary outcomes are the clinical 
      symptoms, systemic lupus erythematosus disease activity index and quality of life
      questionnaire (the top 10 frequency). We will use RevMan 5.0 statistical software
      for data synthesis, sensitivity analysis, meta regression, subgroup analysis, and
      risk of bias assessment. The publish bias will be assessed by a funnel plot and
      the funnel plot symmetries will be evaluated by Begg and Egger tests. We will use
      the Grading of Recommendations Assessment, Development and Evaluation system to
      assess the quality of evidence. RESULTS: This article will give a protocol for
      meta analysis which can make sure the efficacy and side effect of the
      tripterygium and its plant extraction for SLE. CONCLUSION: The efficacy and side 
      effect of the tripterygium and its plant extraction for SLE will be evaluated.
      ETHICS AND DISSEMINATION: Without personal information involved, ethical approval
      and informed consent form is no need. The review will be submitted to a
      peer-reviewed journal prospectively to spread our findings. PROSPERO REGISTRATION
      NUMBER: PROSPERO CRD42020176444.
FAU - Chen, Fangying
AU  - Chen F
AD  - Continuing Education Division, the First Affiliated Hospital of Guangzhou
      University of Chinese Medicine.
FAU - Liu, Junting
AU  - Liu J
AD  - Continuing Education Division, the First Affiliated Hospital of Guangzhou
      University of Chinese Medicine.
FAU - Zhao, Zhimin
AU  - Zhao Z
AD  - The First Clinical College, Guangzhou University of Chinese Medicine.
FAU - Li, Ziping
AU  - Li Z
AD  - Acupuncture and Moxibustion Department, Guangdong Provincial Hospital of Chinese 
      Medicine, Guangzhou, Guangdong Prov.
FAU - Wu, Kuanyu
AU  - Wu K
AD  - Rheumatism Department, the Second People's Hospital of Fujian Province, Fujian
      Prov., China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*drug therapy/psychology
MH  - Medicine, Chinese Traditional/methods
MH  - Plant Extracts/*therapeutic use
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Tripterygium/adverse effects/*chemistry
PMC - PMC7447359
EDAT- 2020/08/28 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1097/MD.0000000000021909 [doi]
AID - 00005792-202008210-00111 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21909. doi:
      10.1097/MD.0000000000021909.


PMID- 32846841
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - The efficacy of bidirectional barbed sutures for incision closure in total knee
      replacement: A protocol of randomized controlled trial.
PG  - e21867
LID - 10.1097/MD.0000000000021867 [doi]
AB  - BACKGROUND: Barbed suture is a novel type of suture introduced in different
      surgical specialties. Nevertheless, its effect in total knee replacement is still
      unclear in terms of wound complications and cost effectiveness. The purpose of
      the present work is to evaluate the safety and efficacy of bidirectional barbed
      suture in reducing postoperative wound complications in the patients undergoing
      total knee replacement. METHODS: This prospective, randomized, and controlled
      study was performed from January 2017 to December 2018. It was authorized via
      institutional review committee of Yuebei People's Hospital (GDYB1002189). Hundred
      participants were divided randomly into 2 groups, namely, control group (n = 50) 
      and the study group (n = 50), respectively. All operations were performed using
      the Miller-Galante prosthesis (Zimmer; Warsaw, IN). For study groups, the joint
      capsule (Stratafix1-0) and subcutaneous (Stratafix2-0) and intracutaneous
      (Stratafix3-0) tissues were sutured by a bidirectional barbed suture. At the end,
      extra 4 to 5 stitches were made to avoid detachment and incision rupture. For
      control group: the joint capsule was sutured by a traditional absorbable suture
      (Ethicon VICRYL* Plus 1-0), and the subcutaneous tissue was sutured by an
      absorbable suture (Ethicon VICRYL* Plus 2-0). The skin was sutured by staples.
      Incision length, suture time, operation time, postoperative length of hospital
      stay, and incision complications (such as effusion, infection, hematoma, and skin
      necrosis) were recorded. All data analyses are implemented through utilizing SPSS
      for Windows Version 20.0. RESULTS: The results will be shown in Table 1.
      CONCLUSION: This study can reach a reliable evidence for utilizing bidirectional 
      barbed suture in wound closure in total knee replacement. TRIAL REGISTRATION:
      This study protocol was registered in Research Registry (researchregistry5823).
FAU - Ye, Zijian
AU  - Ye Z
AD  - Department of Orthopedics, Yuebei People's Hospital, Shaoguan, Guangdong, China.
FAU - Zhu, Wengang
AU  - Zhu W
FAU - Xi, Xinhua
AU  - Xi X
FAU - Wu, Qiang
AU  - Wu Q
AUID- ORCID: 0000-0002-6952-9856
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Knee/adverse effects/*methods
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Joint Capsule/surgery
MH  - Length of Stay/statistics & numerical data
MH  - Middle Aged
MH  - Operative Time
MH  - Postoperative Complications/pathology/*prevention & control
MH  - Prospective Studies
MH  - Safety
MH  - Subcutaneous Tissue/surgery
MH  - Surgical Stapling/adverse effects
MH  - Suture Techniques/trends
MH  - Sutures/*adverse effects/trends
MH  - Treatment Outcome
MH  - Wound Healing/*physiology
PMC - PMC7447360
EDAT- 2020/08/28 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1097/MD.0000000000021867 [doi]
AID - 00005792-202008210-00095 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21867. doi:
      10.1097/MD.0000000000021867.


PMID- 32846840
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - Selective dorsal neurotomy in the treatment of premature ejaculation: A protocol 
      for systematic review and meta-analysis.
PG  - e21866
LID - 10.1097/MD.0000000000021866 [doi]
AB  - INTRODUCTION: Premature ejaculation (PE) affects 8% to 30% of adult men
      worldwide. Recently, the incidence of PE is on the rise. A series of prior
      studies suggested that the incidence of PE is related to various biological
      factors as low testosterone, low serum vitamin D, diabetes, lower urinary tract
      symptoms, and other psychological factors. At present, the major treatments
      include selective serotonin reuptake inhibitors antidepressants (dapoxetine,
      paroxetine), topical anesthetics, phosphodiesterase-5 inhibitor, circumcision,
      and selective dorsal neurotomy (SDN). The previous study found that SDN is
      effective for PE. METHODS AND ANALYSIS: The electronic databases of MEDLINE,
      PubMed, Web of Science, EMBASE, Cochrane Library, Clinicaltrials. org, China
      National Knowledge Infrastructure Database (CNKI), Wan fang Database, China
      Biology Medicine Database (CBM), VIP Science Technology Periodical Database,
      Chinese Clinical Trial Registry will be retrieved. All the randomized controlled 
      trials of selective dorsal penile neurotomy for patients with PE will be
      included. The outcome includes intravaginal ejaculation latency time and Chinese 
      Index of Sexual Function for Premature Ejaculation-5. We will conduct this study 
      strictly according to the Cochrane Handbook for Systematic Reviews of
      Interventions. RESULTS: The present study is a protocol for systematic review and
      meta-analysis without results, and data analysis will be carried out after the
      protocol. We will share our findings on June 30th of 2021. CONCLUSION: SDN can
      effectively prolong IELT, but its efficacy has not been assessed scientifically
      and systematically. To address this limitation, this study will inspect the
      efficacy and safety of the SDN treatment in patients with PE. ETHICS AND
      DISSEMINATION: Formal ethical approval is not required in this protocol. We will 
      collect and analyze data based on published studies, and since there are no
      patients involved in this study, individual privacy will not be under concerns.
      The results of this review will be disseminated to peer-reviewed journals or
      submit to related conferences. PROTOCOL REGISTRATION NUMBER: INPLASY202070084.
FAU - Li, Guangsen
AU  - Li G
AUID- ORCID: 0000-0003-0999-1413
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Chang, Degui
AU  - Chang D
FAU - Chen, Di'ang
AU  - Chen D
FAU - Zhang, Peihai
AU  - Zhang P
FAU - You, Yaodong
AU  - You Y
FAU - Huang, Xiaopeng
AU  - Huang X
FAU - Cai, Jian
AU  - Cai J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anesthetics, Local)
RN  - 0 (Benzylamines)
RN  - 0 (Naphthalenes)
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 41VRH5220H (Paroxetine)
RN  - GB2433A4M3 (dapoxetine)
SB  - IM
MH  - Adult
MH  - Anesthetics, Local/therapeutic use
MH  - Benzylamines/therapeutic use
MH  - Circumcision, Male/methods
MH  - Ejaculation/physiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Naphthalenes/therapeutic use
MH  - Paroxetine/therapeutic use
MH  - Penis/*innervation/physiopathology
MH  - Phosphodiesterase 5 Inhibitors/therapeutic use
MH  - Premature Ejaculation/epidemiology/physiopathology/*therapy
MH  - Pudendal Nerve/*surgery
MH  - Randomized Controlled Trials as Topic
MH  - Serotonin Uptake Inhibitors/therapeutic use
PMC - PMC7447451
EDAT- 2020/08/28 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1097/MD.0000000000021866 [doi]
AID - 00005792-202008210-00094 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21866. doi:
      10.1097/MD.0000000000021866.


PMID- 32846820
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - Application effect of lattice laser in facial rejuvenation: A protocol for
      systematic review and meta-analysis.
PG  - e21814
LID - 10.1097/MD.0000000000021814 [doi]
AB  - BACKGROUND: Various techniques have been applied in facial rejuvenation and
      lattice laser is the most accepted. However, the application effect of lattice
      laser in facial rejuvenation is unclear. This study aims to evaluate the
      application effect of lattice laser in facial rejuvenation. METHODS: Randomized
      controlled trials of lattice laser in facial rejuvenation will be searched in
      PubMed, EMbase, Web of Science, Cochrane Library, China National Knowledge
      Infrastructure, WanFang, the Chongqing VIP Chinese Science and Technology
      Periodical Database, and China biomedical literature database from inception to
      July 2020. And Baidu Scholar, International Clinical Trials Registry Platform,
      Google Scholar, and Chinese Clinical Trials Registry will be searched to obtain
      more relevant studies comprehensively. Two researchers will perform data
      extraction and risk of bias assessment independently. Statistical analysis will
      be conducted in RevMan 5.3. RESULTS: This study will sum up the present evidence 
      so far by exploring the application effect of lattice laser in facial
      rejuvenation. CONCLUSIONS: The findings of the study will provide helpful
      evidence for the application effect of lattice laser in facial rejuvenation,
      promoting clinical practice, and further scientific research. ETHICS AND
      DISSEMINATION: The private information from individuals will not publish. This
      systematic review also will not involve endangering participant rights. Ethical
      approval is not required. The results may be published in a peer-reviewed journal
      or disseminated in relevant conferences. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/QF6H5.
FAU - Yan, Dan
AU  - Yan D
AUID- ORCID: 0000-0001-7663-6046
AD  - Department of Plastic and Cosmetic Surgery, Chenzhou First People's Hospital,
      Chenzhou, China.
FAU - Huang, Zechun
AU  - Huang Z
FAU - Zhang, Anli
AU  - Zhang A
FAU - Li, Shuaihua
AU  - Li S
FAU - Xiao, Yao
AU  - Xiao Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Face
MH  - Humans
MH  - Laser Therapy/methods
MH  - Lasers, Solid-State/*therapeutic use
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Rejuvenation
MH  - Research Design
MH  - *Skin Aging
MH  - Systematic Reviews as Topic
PMC - PMC7447505
EDAT- 2020/08/28 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1097/MD.0000000000021814 [doi]
AID - 00005792-202008210-00074 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21814. doi:
      10.1097/MD.0000000000021814.


PMID- 32846807
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - Manual therapy for idiopathic scoliosis: A protocol for systematic review and
      meta-analysis.
PG  - e21782
LID - 10.1097/MD.0000000000021782 [doi]
AB  - INTRODUCTION: More patients with idiopathic scoliosis (IS) preferred to choose
      manual therapy as a complementary conservative treatment, but the effects of
      manual therapy for IS remains controversial. The previous reviews could not draw 
      reliable conclusion due to few eligible studies to perform a meta-analysis. In
      the last decade, however, several new studies were published that assessed the
      effects of manual therapy in the management of IS, especially in China.
      Therefore, the present systematic review and meta-analysis will be performed to
      examine whether manual therapy is effective for IS primarily in improving
      patient-centerd symptoms and secondarily in radiographic outcomes. METHODS AND
      ANALYSIS: A computerized literature search will be performed in the following
      electronic databases from their inceptions to June 2020 to identify randomized
      controlled trials of manual therapy in the management of IS: PubMed, EMBASE,
      MEDLINE, Cochrane Central Register of Controlled Clinical Trials, China Knowledge
      Resource Integrated Database, Wanfang Data Information, and Weipu Database for
      Chinese Technical Periodicals. The quality of included studies will be assessed
      independently by 2 reviewers using the Physiotherapy Evidence Database scale. The
      meta-analysis will be performed with the Review Manager Version 5.3 software to
      assess the effects on patient-centred outcomes and radiographic outcomes of
      manual therapy for IS. The heterogeneity will be assessed using I statistic and
      Cochran Q statistic. The subgroup analysis will be conducted based on different
      control interventions and subpopulations. Quality of evidence will be assessed
      using the Grades of Recommendation, Assessment, Development and Evaluation.
      ETHICS AND DISSEMINATION: No ethical statement will be required for the
      performance of this review and meta-analysis. The results of this review will be 
      published in an international peer-reviewed journal.INPLASY registration number: 
      INPLASY202070058.
FAU - Huang, Qian
AU  - Huang Q
AD  - Department of Acupunctue and Tuina, Lianyungang TCM Hospital Affiliated to
      Nanjing University of Chinese Medicine, Lianyungang.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Acupunctue and Tuina, Lianyungang TCM Hospital Affiliated to
      Nanjing University of Chinese Medicine, Lianyungang.
FAU - Li, Zhiwei
AU  - Li Z
AD  - Department of Acupunctue and Tuina, Lianyungang TCM Hospital Affiliated to
      Nanjing University of Chinese Medicine, Lianyungang.
FAU - Kong, Lingjun
AU  - Kong L
AUID- ORCID: 0000-0002-6854-4202
AD  - Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
      University of Traditional Chinese Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Musculoskeletal Manipulations/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Scoliosis/*therapy
PMC - PMC7447396
EDAT- 2020/08/28 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021782 [doi]
AID - 00005792-202008210-00061 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21782. doi:
      10.1097/MD.0000000000021782.


PMID- 32846798
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - The efficacy and safety of intravenous tranexamic acid in anterior cruciate
      ligament reconstruction: A randomized controlled trial protocol.
PG  - e21747
LID - 10.1097/MD.0000000000021747 [doi]
AB  - BACKGROUND: The safety and efficacy of intravenous tranexamic acid (TXA) in the
      anterior cruciate ligament (ACL) reconstruction remains controversial. There is
      an urgent need of studies that efficiently control for confounding, conduct
      comprehensive and consecutive observation of potential risks of the TXA
      administration, and investigate its clinical applicability. The purpose of this
      work is to assess the safety and efficacy of the intravenous TXA in decreasing
      perioperative blood loss in the patients undergoing ACL reconstruction. METHODS: 
      This randomized, controlled, prospective research was carried out between January
      2017 and January 2018. All the patients and their family members signed the
      informed consent forms, and this current work was authorized via the ethics
      committee of Nanjing first hospital (registration No.: NJU1003586). A total of
      100 patients were divided randomly into 2 group: the control group (n = 50) and
      study group (n = 50). The study group receives intravenous TXA administration [1 
      g] before skin incision. The control group receives equivalent normal saline.
      Primary outcome measures including blood loss, hemoglobin decline, transfusion
      rate, C-reactive protein, D-dimer value, fibrinogen, prothrombin time, activated 
      partial thromboplastin time, thrombin time, international normalized ratio and
      erythrocyte sedimentation rate were recorded. The measures of secondary outcomes 
      refer to the clinical data involving the range of motion and postoperative pain
      score. The pain score was quantified by utilizing the 10-cm scale of visual
      analog. The pain strength was in the range of 0-10, where 0 is totally no pain
      and 10 represents the most severe pain. RESULTS: This experiment had strict
      inclusive criteria and exclusive criteria and a well- regulated intervention.
      CONCLUSION: Our results can bring a new perspective on the use of TXA after
      arthroscopically assisted ACL surgery. TRIAL REGISTRATION: This study protocol
      was registered in Research Registry (researchregistry5798).
FAU - Xu, Hongyao
AU  - Xu H
AD  - Department of sports and joint, Nanjing Hospital Affiliated to Nanjing Medical
      University (Nanjing first hospital), Jiangsu, China.
FAU - Xia, Pengcheng
AU  - Xia P
FAU - Zou, Xiangjie
AU  - Zou X
FAU - Huang, He
AU  - Huang H
AUID- ORCID: 0000-0002-8869-6545
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
SB  - IM
MH  - Anterior Cruciate Ligament Reconstruction/*methods
MH  - Antifibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Loss, Surgical/statistics & numerical data
MH  - Blood Transfusion/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Pain, Postoperative
MH  - Prospective Studies
MH  - Range of Motion, Articular
MH  - Research Design
MH  - Tranexamic Acid/administration & dosage/adverse effects/*therapeutic use
PMC - PMC7447492
EDAT- 2020/08/28 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1097/MD.0000000000021747 [doi]
AID - 00005792-202008210-00052 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21747. doi:
      10.1097/MD.0000000000021747.


PMID- 32846777
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 34
DP  - 2020 Aug 21
TI  - Treatment of dysphagia after stroke with acupuncture and related therapies: A
      protocol for systematic review and network meta-analysis.
PG  - e21657
LID - 10.1097/MD.0000000000021657 [doi]
AB  - BACKGROUND: Dysphagia is a common complication after stroke, with high disability
      rate and high fatality rate. Although several clinical studies and evidence-based
      medicine have demonstrated the efficacy of acupuncture in the treatment of
      dysphagia after stroke, there are significant differences in study design and
      intervention methods. The objective of this study is to compare the efficacy and 
      safety of different acupuncture and related therapies in the treatment of
      dysphagia after stroke, so as to provide a superior clinical program. METHODS: We
      will search 7 databases for randomized controlled trials of acupuncture-related
      therapies for dysphagia after stroke, including PubMed, the Cochrane Library,
      EMbase, China National Knowledge Infrastructure, China Biological Medicine,
      Chinese Scientific Journals Database, and wan-fang databases, from the date of
      the establishment of each database to March 31, 2020. The network meta-analysis
      will be implemented through Aggregate Data Drug Information System 1.16.8 and
      Stata 13.0 software. Clinical Efficiency, videofluoroscopic swallowing study
      score and Kubota Drinking Water Test grade will be the primary outcomes,
      Swallowing disorder specific quality of life score, Standardized Assessment and
      Adverse effects will be evaluated as secondary outcomes. Mean differences or odds
      ratios will be used for statistical analysis. We will ensure the reliability of
      the results through node-split model and heterogeneity analysis. In addition,
      methodological quality will be evaluated based on the Cochrane Collaboration's
      tool, and the quality of evidence will be evaluated according to the Grading of
      Recommendations Assessment, Development and Evaluation system. RESULTS: This
      study will provide a reliable evidence for the selection of acupuncture and
      related therapies for dysphagia after stroke. CONCLUSION: The results of this
      study will provide references for evaluating the influence of acupuncture and
      related therapies for dysphagia after stroke, and provide decision-making
      references for clinical research. ETHICS AND DISSEMINATION: This study did not
      require ethical approval. We will disseminate our findings by publishing results 
      in a peer-reviewed journal. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/TAHND.
FAU - Xiong, Fanjie
AU  - Xiong F
AUID- ORCID: 0000-0001-9484-2222
AD  - College of acupuncture and Tuina, Chengdu university of Traditional Chinese
      Medicine, Chengdu, Sichuan, China.
FAU - Song, Kai
AU  - Song K
FAU - Huang, Ailing
AU  - Huang A
FAU - Zhang, Hong
AU  - Zhang H
AUID- ORCID: 0000-0002-6417-8399
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Deglutition Disorders/*etiology/*therapy
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - Stroke/*complications
MH  - *Systematic Reviews as Topic
PMC - PMC7447454
EDAT- 2020/08/28 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1097/MD.0000000000021657 [doi]
AID - 00005792-202008210-00031 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 21;99(34):e21657. doi:
      10.1097/MD.0000000000021657.


PMID- 32845902
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20211006
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Come for the looks, stay for the personality? A mixed methods investigation of
      reacquisition and owner recommendation of Bulldogs, French Bulldogs and Pugs.
PG  - e0237276
LID - 10.1371/journal.pone.0237276 [doi]
AB  - Brachycephalic breeds are proliferating internationally, with dramatic rises in
      popularity juxtaposed with common and severe breed-related health problems.
      Physical appearance is as a dominant factor attracting owners to brachycephalic
      breeds; however, whether these owners will choose their current breed for future 
      ownership and develop 'breed-loyalty' in the face of health problems is not yet
      known. The aims of this study were (1) to quantify levels of, and explore factors
      associated with, brachycephalic dog owners' intentions to: (i) reacquire and/or
      (ii) recommend their current breed to potential first-time dog owners, and (2) to
      use qualitative methods to explore why brachycephalic dog owners would or would
      not recommend their current breed. This large mixed methods study reports on 2168
      owners of brachycephalic breeds (Pugs: n = 789; French Bulldog: n = 741;
      Bulldogs: n = 638). Owners were highly likely to want to own their breed again in
      the future (93.0%) and recommend their breed to other owners (65.5%). Statistical
      modelling identified that first-time ownership and increased strength of the
      dog-owner relationship increased the likelihood of reacquisition and/or
      recommendation. In contrast, an increased number of health problems, positive
      perception of their dog's health compared with the rest of their breed, and dog
      behaviour being worse than expected decreased the likelihood of reacquisition
      and/or recommendation. Thematic analyses constructed three themes describing why 
      owners recommend their breed: positive behavioural attributes for a companion
      dog, breed suited to a sedentary lifestyle with limited space, and suitability
      for households with children. Five themes described why owners recommended
      against their breed: high prevalence of health problems, expense of ownership,
      ethical and welfare issues associated with breeding brachycephalic dogs, negative
      effects upon owner lifestyle and negative behavioural attributes. Understanding
      how breed-loyalty develops, and whether it can be attenuated, will be key to
      controlling the current population boom in brachycephalic breeds in the
      long-term.
FAU - Packer, Rowena M A
AU  - Packer RMA
AUID- ORCID: 0000-0002-9988-9828
AD  - Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire, United
      Kingdom.
FAU - O'Neill, Dan G
AU  - O'Neill DG
AUID- ORCID: 0000-0003-1115-2723
AD  - Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire, United
      Kingdom.
FAU - Fletcher, Francesca
AU  - Fletcher F
AD  - Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter
      Bush Veterinary Centre, Roslin, United Kingdom.
FAU - Farnworth, Mark J
AU  - Farnworth MJ
AUID- ORCID: 0000-0001-6226-0818
AD  - School of Animal, Rural and Environmental Sciences, Nottingham Trent University, 
      Nottingham, United Kingdom.
LA  - eng
GR  - BB/P010881/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Animals
MH  - Breeding
MH  - Dog Diseases/*epidemiology
MH  - *Dogs/physiology
MH  - Female
MH  - Human-Animal Bond
MH  - Humans
MH  - Male
MH  - *Pets/physiology
PMC - PMC7449392
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/28 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1371/journal.pone.0237276 [doi]
AID - PONE-D-20-11809 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 26;15(8):e0237276. doi: 10.1371/journal.pone.0237276.
      eCollection 2020.


PMID- 32845751
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1750-8460 (Print)
IS  - 1750-8460 (Linking)
VI  - 81
IP  - 8
DP  - 2020 Aug 2
TI  - Discussing deactivation of implantable cardiac defibrillators.
PG  - 1-5
LID - 10.12968/hmed.2020.0343 [doi]
AB  - Implantable cardiac defibrillators are a key component in preventing sudden
      cardiac death for patients with life-threatening arrhythmias. Through ageing,
      frailty and the progression of cardiac and non-cardiac morbidity, many will
      develop a 'life-limiting' condition. This raises the challenge of how to approach
      making decisions to deactivate the defibrillator function. This article discusses
      the background to deactivation of implantable cardioverter defibrillators and the
      practical considerations for different circumstances.
FAU - Bahl, Rahul
AU  - Bahl R
AD  - Department of Cardiology, Hillingdon Hospital, Uxbridge, UK.
FAU - Dubrey, Simon
AU  - Dubrey S
AD  - Department of Cardiology, Hillingdon Hospital, Uxbridge, UK.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - England
TA  - Br J Hosp Med (Lond)
JT  - British journal of hospital medicine (London, England : 2005)
JID - 101257109
SB  - IM
MH  - Arrhythmias, Cardiac/therapy
MH  - Communication
MH  - Comorbidity
MH  - *Defibrillators, Implantable
MH  - Humans
MH  - Withholding Treatment/*legislation & jurisprudence
OTO - NOTNLM
OT  - Arrhythmia
OT  - Ethics
OT  - Implantable cardiac defibrillators
OT  - Pacemaker
OT  - Sudden death
EDAT- 2020/08/28 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 10.12968/hmed.2020.0343 [doi]
PST - ppublish
SO  - Br J Hosp Med (Lond). 2020 Aug 2;81(8):1-5. doi: 10.12968/hmed.2020.0343. Epub
      2020 Aug 4.


PMID- 32845462
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Lead Essay-Inside the Pandemic.
PG  - 461-463
LID - 10.1007/s11673-020-10037-4 [doi]
FAU - Komesaroff, Paul A
AU  - Komesaroff PA
AD  - Faculty of Medicine, Monash University Alfred Hospital, Commercial Road, Prahran,
      Victoria, 3181, Australia. paul.komesaroff@monash.edu.
FAU - Chapman, Michael
AU  - Chapman M
AD  - Department of Palliative Care, Canberra Hospital, Canberra, ACT, Australia.
AD  - ANU Medical School, ACT, Canberra, Australia.
AD  - University of Technology Sydney, Sydney, NSW, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, Faculty of Medicine and Health, University of Sydney
      Haematology Department, Royal North Shore Hospital, Sydney, NSW, Australia.
FAU - Upshur, Ross E G
AU  - Upshur REG
AD  - Dalla Lana School of Public Health, University of Toronto, 155 College Street,
      Toronto, Ontario, M5T 3M7, Canada.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *Bioethics
MH  - *COVID-19/epidemiology
MH  - Ethical Analysis
MH  - Humans
MH  - Pandemics/*ethics
MH  - Public Health/*ethics
PMC - PMC7447846
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Pandemic
EDAT- 2020/08/28 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 10.1007/s11673-020-10037-4 [doi]
AID - 10.1007/s11673-020-10037-4 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):461-463. doi: 10.1007/s11673-020-10037-4.


PMID- 32845343
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20210903
IS  - 0098-9134 (Print)
IS  - 0098-9134 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep 1
TI  - Family- and Person-Centered Interdisciplinary Telehealth: Policy and Practice
      Implications Following Onset of the COVID-19 Pandemic.
PG  - 9-13
LID - 10.3928/00989134-20200811-03 [doi]
AB  - With the onset of the COVID-19 pandemic, telehealth was thrust to the forefront, 
      becoming one of the most predominant forms of care almost overnight. Despite
      years of research, practice, and policymaking, tenets for providing telehealth in
      an interdisciplinary, family- and person-centered fashion, and across a wide
      breadth of settings remain underdeveloped. In addition, although telehealth has
      the potential to increase equity in care, it can also further exacerbate
      disparities. The current article discusses the opening created by the pandemic
      and provides recommendations for how to make permanent changes in telehealth
      policy and practice to allow for interdisciplinary, person- and family-centered
      care while also taking care to address issues of equity and ethics and privacy
      issues related to telehealth and remote monitoring. [Journal of Gerontological
      Nursing, 46(9), 9-13.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Brody, Abraham A
AU  - Brody AA
FAU - Sadarangani, Tina
AU  - Sadarangani T
FAU - Jones, Tessa M
AU  - Jones TM
FAU - Convery, Kimberly
AU  - Convery K
FAU - Groom, Lisa
AU  - Groom L
FAU - Bristol, Alycia A
AU  - Bristol AA
FAU - David, Daniel
AU  - David D
LA  - eng
GR  - P20 NR018075/NR/NINR NIH HHS/United States
GR  - R01 AG056610/AG/NIA NIH HHS/United States
GR  - R33 AG061904/AG/NIA NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Gerontol Nurs
JT  - Journal of gerontological nursing
JID - 7510258
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Geriatric Nursing/*organization & administration
MH  - *Health Policy
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Patient-Centered Care/*organization & administration
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Telemedicine/*organization & administration
PMC - PMC7476765
MID - NIHMS1624648
EDAT- 2020/08/28 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - 10.3928/00989134-20200811-03 [doi]
PST - ppublish
SO  - J Gerontol Nurs. 2020 Sep 1;46(9):9-13. doi: 10.3928/00989134-20200811-03.


PMID- 32845303
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20210909
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 9
DP  - 2020 Oct 1
TI  - Human Challenge Studies Are Unlikely to Accelerate Coronavirus Vaccine Licensure 
      Due to Ethical and Practical Issues.
PG  - 1572-1574
LID - 10.1093/infdis/jiaa457 [doi]
FAU - Spinola, Stanley M
AU  - Spinola SM
AD  - Department of Microbiology and Immunology, Indiana University School of Medicine,
      Indiana University, Indianapolis, Indiana, USA.
AD  - Department of Medicine, Indiana University School of Medicine, Indiana
      University, Indianapolis, Indiana, USA.
AD  - Department of Pathology and Laboratory Medicine, Indiana University School of
      Medicine, Indiana University, Indianapolis, Indiana, USA.
FAU - Zimet, Gregory D
AU  - Zimet GD
AD  - Department of Pediatrics, Indiana University School of Medicine, Indiana
      University, Indianapolis, Indiana, USA.
FAU - Ott, Mary A
AU  - Ott MA
AD  - Department of Pediatrics, Indiana University School of Medicine, Indiana
      University, Indianapolis, Indiana, USA.
AD  - Center for Bioethics, Indiana University School of Medicine, Indiana University, 
      Indianapolis, Indiana, USA.
FAU - Katz, Barry P
AU  - Katz BP
AD  - Department of Biostatistics, Indiana University School of Medicine, Indiana
      University, Indianapolis, Indiana, USA.
LA  - eng
GR  - R01 AI137116/AI/NIAID NIH HHS/United States
GR  - UL1 TR002529/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Comment
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CON - J Infect Dis. 2020 May 11;221(11):1752-1756. PMID: 32232474
CIN - J Infect Dis. 2020 Oct 1;222(9):1574-1575. PMID: 32845306
EIN - J Infect Dis. 2021 May 28;223(10):1837. PMID: 33871610
MH  - COVID-19 Vaccines
MH  - *Coronavirus Infections/prevention & control
MH  - Humans
MH  - Licensure
MH  - Vaccination
MH  - *Viral Vaccines
PMC - PMC7499586
EDAT- 2020/08/28 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/06/30 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 5897421 [pii]
AID - 10.1093/infdis/jiaa457 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Oct 1;222(9):1572-1574. doi: 10.1093/infdis/jiaa457.


PMID- 32845247
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 26
TI  - Aftercare of Childhood Cancer Survivors in Switzerland: Protocol for a
      Prospective Multicenter Observational Study.
PG  - e18898
LID - 10.2196/18898 [doi]
AB  - BACKGROUND: Most children and adolescents diagnosed with cancer become long-term 
      survivors. For most of them, regular follow-up examinations to detect and treat
      late effects are necessary, especially in adulthood. The transition from
      pediatric to adult-focused follow-up care is a critical moment for childhood
      cancer survivors (CCSs); a substantial proportion of CCSs are lost to follow-up
      in this transition process and do not attend follow-up care in adulthood. This
      can have serious effects on survivors' health if late effects are not discovered 
      in a timely fashion. OBJECTIVE: In this study, we primarily assess the current
      follow-up situation, related needs, and knowledge of adolescent and young adult
      CCSs who have transitioned from pediatric to adult-focused follow-up care. As
      secondary objectives, we evaluate transition readiness, identify facilitating
      factors of transition and adherence to long-term follow-up (LTFU) care, and
      compare three different transition models. METHODS: The Aftercare of Childhood
      Cancer Survivors (ACCS) Switzerland study is a prospective, multicenter,
      observational study that was approved by the ethics committee in February 2019.
      We are recruiting CCSs from three pediatric oncology centers and using
      questionnaires to answer the study questions. RESULTS: To date, we have recruited
      58 participants. The study is ongoing, and recruitment of participants will
      continue until January 2021. CONCLUSIONS: The ACCS study will provide information
      on CCSs' preferences and expectations for follow-up care and their transition
      into the adult setting. The results will help improve the LTFU care and cancer
      knowledge of CCSs and subsequently enhance adherence to follow-up care and reduce
      loss to follow-up in adulthood. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT04284189; https://clinicaltrials.gov/ct2/show/NCT04284189?id=NCT04284189.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/18898.
CI  - (c)Sibylle Denzler, Maria Otth, Katrin Scheinemann. Originally published in JMIR 
      Research Protocols (http://www.researchprotocols.org), 26.08.2020.
FAU - Denzler, Sibylle
AU  - Denzler S
AUID- ORCID: https://orcid.org/0000-0001-6282-6295
AD  - Division of Oncology-Hematology, Department of Pediatrics, Kantonsspital Aarau,
      Aarau, Switzerland.
FAU - Otth, Maria
AU  - Otth M
AUID- ORCID: https://orcid.org/0000-0002-2839-502X
AD  - Division of Oncology-Hematology, Department of Pediatrics, Kantonsspital Aarau,
      Aarau, Switzerland.
AD  - Institute of Social and Preventive Medicine, University of Bern, Bern,
      Switzerland.
FAU - Scheinemann, Katrin
AU  - Scheinemann K
AUID- ORCID: https://orcid.org/0000-0002-3578-7152
AD  - Division of Oncology-Hematology, Department of Pediatrics, Kantonsspital Aarau,
      Aarau, Switzerland.
AD  - Division of Oncology-Hematology, University Children's Hospital Basel, Basel,
      Switzerland.
AD  - University of Basel, Basel, Switzerland.
AD  - Department of Pediatrics, McMaster Children's Hospital, Hamilton, ON, Canada.
AD  - McMaster University, Hamilton, ON, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04284189
PT  - Journal Article
DEP - 20200826
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7481869
OTO - NOTNLM
OT  - Switzerland
OT  - childhood cancer survivors
OT  - long-term follow-up care
OT  - transition
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/04 00:00 [revised]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - v9i8e18898 [pii]
AID - 10.2196/18898 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 26;9(8):e18898. doi: 10.2196/18898.


PMID- 32844968
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200829
IS  - 2177-6709 (Electronic)
IS  - 2176-9451 (Linking)
VI  - 25
IP  - 3
DP  - 2020 May
TI  - Adult mesenchymal stem cells and their possibilities for Dentistry: what to
      expect?
PG  - 85-92
LID - S2176-94512020000300085 [pii]
LID - 10.1590/2177-6709.25.3.085-092.sar [doi]
AB  - INTRODUCTION: Stem cells obtained from the pulp of human deciduous teeth are
      highly proliferative and plastic multipotent cells, which makes them a relevant
      model of stem cells, applied in several biomedical areas, with different
      purposes. OBJECTIVE: Based on a brief review of the literature, the present work 
      intends to present from conceptual aspects about stem cells, classifications,
      potential (in vitro and in vivo) applications in dental practice, cell culture,
      cryopreservation and its importance, ethical and regulatory aspects, as well as
      the role of the dental surgeon as the endorser responsible for the entire
      clinical stage that involves the process of collecting stem cells obtained from
      dental pulps for cryopreservation, with a view to using them under appropriate
      conditions, in accordance with scientifically proven and justified good
      laboratory and clinical practices.
FAU - Ferreira, Jose Ricardo Muniz
AU  - Ferreira JRM
AD  - Instituto Militar de Engenharia, Rio de Janeiro, RJ, Brazil.
FAU - Greck, Anna Paula
AU  - Greck AP
AD  - University of Paris, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - Brazil
TA  - Dental Press J Orthod
JT  - Dental press journal of orthodontics
JID - 101532240
SB  - IM
MH  - Adult
MH  - Dental Pulp
MH  - Dentistry
MH  - Humans
MH  - *Mesenchymal Stem Cells
MH  - Stem Cells
MH  - Tooth, Deciduous
PMC - PMC7437147
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - S2176-94512020000300085 [pii]
AID - 10.1590/2177-6709.25.3.085-092.sar [doi]
PST - ppublish
SO  - Dental Press J Orthod. 2020 May;25(3):85-92. doi:
      10.1590/2177-6709.25.3.085-092.sar. Epub 2020 Aug 19.


PMID- 32844714
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20211109
IS  - 1744-4144 (Electronic)
IS  - 1385-4046 (Linking)
VI  - 34
IP  - 7-8
DP  - 2020 Oct - Nov
TI  - A survey of international clinical teleneuropsychology service provision prior to
      and in the context of COVID-19.
PG  - 1267-1283
LID - 10.1080/13854046.2020.1810323 [doi]
AB  - Objective: Despite expansion of telecommunication strategies across health
      services and data supporting feasibility of videoconference-based
      neuropsychological assessment, relatively little is known about
      teleneuropsychology (TeleNP) use in practice. The current COVID-19 pandemic
      provides an opportunity for greater use of TeleNP and understanding of
      neuropsychologists' experience with this unique assessment medium.Methods: During
      the course of a no-cost global webinar related to practical/ethical
      considerations of TeleNP practice, attendees were invited to engage in a
      26-question survey about their TeleNP use and related COVID-19 concerns. TeleNP
      practices before the COVID-19 pandemic and early on during the global outbreak
      were queried among survey participants, along with examination of TeleNP
      intentions following COVID-19.Results: Multiple countries were represented across
      five continents, with two-thirds of respondents being from the United States.
      Approximately one-fourth of respondents reported using TeleNP for clinical
      interview, feedback, and intervention prior to the onset of the COVID-19
      pandemic, and approximately one-tenth of individuals used TeleNP for
      testadministration. Increased use of TeleNP for clinical interview, feedback, and
      intervention was reported within the first few weeks of the global COVID-19
      outbreak, though the use of TeleNP for testing remained relatively unchanged.
      Most respondents indicated an intention for future use of TeleNP.Conclusions: Our
      findings suggest the use of TeleNP is increasing, although use of remote TeleNP
      testing is still developing. Findings also illustrate increasing use of TeleNP in
      the context of the COVID-19 pandemic and encourage follow-up investigation in
      future studies to understand the changing practices and rates of TeleNP provision
      over time.
FAU - Hammers, Dustin B
AU  - Hammers DB
AD  - Center for Alzheimer's Care, Imaging, and Research, Department of Neurology,
      University of Utah.
AD  - Center on Aging, University of Utah.
FAU - Stolwyk, Renerus
AU  - Stolwyk R
AD  - Turner Institute for Brain and Mental Health, School of Psychological Sciences,
      Monash University, Melbourne, Australia.
AD  - Monash-Epworth Rehabilitation Research Centre, Monash University, Melbourne,
      Australia.
FAU - Harder, Lana
AU  - Harder L
AD  - Children's Health, Children's Medical Center, Dallas, Texas.
AD  - Department of Psychiatry, University of Texas Southwestern Medical Center,
      Dallas, Texas.
AD  - Department of Neurology and Neurotherapeutics, University of Texas Southwestern
      Medical Center, Dallas, Texas.
FAU - Cullum, C Munro
AU  - Cullum CM
AUID- ORCID: 0000-0001-9706-5465
AD  - Department of Psychiatry, University of Texas Southwestern Medical Center,
      Dallas, Texas.
AD  - Department of Neurology and Neurotherapeutics, University of Texas Southwestern
      Medical Center, Dallas, Texas.
AD  - Department of Neurological Surgery, University of Texas Southwestern Medical
      Center, Dallas, Texas.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - Clin Neuropsychol
JT  - The Clinical neuropsychologist
JID - 8806548
SB  - IM
EIN - Clin Neuropsychol. 2020 Sep 12;:1. PMID: 32921230
MH  - Adult
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/psychology/*therapy
MH  - Delivery of Health Care/methods/trends
MH  - Female
MH  - Humans
MH  - *Internationality
MH  - Male
MH  - Neuropsychological Tests
MH  - Neuropsychology/methods/*trends
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/psychology/*therapy
MH  - SARS-CoV-2
MH  - *Surveys and Questionnaires
MH  - Telemedicine/methods/*trends
OTO - NOTNLM
OT  - *Teleneuropsychology
OT  - *assessment
OT  - *technology
EDAT- 2020/08/28 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 10.1080/13854046.2020.1810323 [doi]
PST - ppublish
SO  - Clin Neuropsychol. 2020 Oct - Nov;34(7-8):1267-1283. doi:
      10.1080/13854046.2020.1810323. Epub 2020 Aug 26.


PMID- 32844460
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Judging the social value of controlled human infection studies.
PG  - 749-763
LID - 10.1111/bioe.12794 [doi]
AB  - In controlled human infection (CHI) studies, investigators deliberately infect
      healthy individuals with pathogens in order to study mechanisms of disease or
      obtain preliminary efficacy data on investigational vaccines and medicines. CHI
      studies offer a fast and cost-effective way of generating new scientific
      insights, prioritizing investigational products for clinical testing, and
      reducing the risk that large numbers of people are exposed to ineffective or
      harmful substances in research or in practice. Yet depending on the pathogen, CHI
      studies can involve significant risks or burdens for participants, pose risks to 
      individuals or communities not involved in the research, and lead to public
      controversy. It is therefore essential to ensure that the risks of CHI studies
      are justified by their social value-that is, their potential to generate benefits
      for society-and that public trust can be maintained. In this paper, we aim to
      clarify how research sponsors, research ethics committees and other reviewers
      should judge the social value of CHI studies. We develop a list of relevant
      considerations for making social value judgments based on the standard view of
      social value. We then use this list to discuss the example of potentially
      conducting dengue virus CHI studies in endemic settings. We argue that dengue
      virus CHI studies in endemic settings would fall on the higher end of the
      spectrum of social value, mostly because of their potential to redirect all
      fields of future dengue research. Drawing on this discussion, we derive several
      general recommendations for how reviewers should judge the social value of CHI
      studies.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Rid, Annette
AU  - Rid A
AUID- ORCID: 0000-0003-1117-1975
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      Bethesda, Maryland.
FAU - Roestenberg, Meta
AU  - Roestenberg M
AUID- ORCID: 0000-0002-5052-2830
AD  - Department of Parasitology & Department of Infectious Diseases, Leiden University
      Medical Center, Leiden, the Netherlands.
LA  - eng
GR  - Clinical Center Department of Bioethics, Intramural Program of the National
      Institutes of Health/International
GR  - A new ethical and regulatory approach for the use of human challenge studies with
      emerging infectious diseases/International
GR  - Greenwall 'Making a Difference in Real-World Bioethics Dilemmas'
      grant/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200825
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Cost-Benefit Analysis
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Research Design
MH  - *Social Values
OTO - NOTNLM
OT  - *acceptable risk
OT  - *controlled human infection studies
OT  - *dengue
OT  - *ethics
OT  - *human challenge trials
OT  - *human infection challenge studies
OT  - *scientific value
OT  - *social value
OT  - *voluntary infection studies
EDAT- 2020/08/28 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/08/27 06:00
PHST- 2019/07/16 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 10.1111/bioe.12794 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):749-763. doi: 10.1111/bioe.12794. Epub 2020 Aug 25.


PMID- 32844270
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1432-5241 (Electronic)
IS  - 0364-216X (Linking)
VI  - 44
IP  - 4
DP  - 2020 Aug
TI  - Aesthetic/Cosmetic Surgery and Ethical Challenges.
PG  - 1364-1374
LID - 10.1007/s00266-020-01821-z [doi]
AB  - Is aesthetic surgery a business guided by market structures aimed primarily at
      material gain and profit or a surgical intervention intended to benefit patients 
      and an integral part of the health-care system? Is it a frivolous subspecialty or
      does it provide a real and much needed service to a wide range of patients? At
      present, cosmetic surgery is passing through an identity crisis as well as an
      acute ethical dilemma. A closer look from an ethical viewpoint makes clear that
      the doctor who offers aesthetic interventions faces many serious ethical problems
      which have to do with the identity of the surgeon as a healer. Aesthetic surgery 
      that works only according to market categories runs the risk of losing the view
      for the real need of patients and will be nothing else than a part of a beauty
      industry which has the only aim to sell something, not to help people. Such an
      aesthetic surgery is losing sight of real values and makes profit from the
      ideology of a society that serves only vanity, youthfulness, and personal
      success. Unfortunately, some colleagues brag that they chose the plastic surgery 
      specialty just to become rich aesthetic surgeons, using marketing tactics to
      promote their practice. This is, at present, the image we project. As rightly
      proposed, going back a little to Hippocrates, to the basics of being a physician,
      is urgently warranted! Being a physician is all that a ''cosmetic'' surgeon
      should be. In the long run, how one skillfully and ethically practices the art of
      plastic surgery will always speak louder than any words.
FAU - Atiyeh, Bishara S
AU  - Atiyeh BS
AD  - Mediterranean Council for Burns and Fire Disasters - MBC, Palermo, Italy.
      aata@terra.net.lb.
AD  - Department of Plastic and Reconstructive Surgery, American University of Beirut
      Medical Center, Beirut, Lebanon. aata@terra.net.lb.
FAU - Rubeiz, Michel T
AU  - Rubeiz MT
AD  - Department of Plastic and Reconstructive Surgery, American University of Beirut
      Medical Center, Beirut, Lebanon.
FAU - Hayek, Shady N
AU  - Hayek SN
AD  - Department of Surgery, University of Iowa Hospital and Clinics, Iowa City, IA,
      52242, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080927
PL  - United States
TA  - Aesthetic Plast Surg
JT  - Aesthetic plastic surgery
JID - 7701756
SB  - IM
MH  - Beauty
MH  - Esthetics
MH  - Ethics, Medical
MH  - Humans
MH  - *Reconstructive Surgical Procedures
MH  - *Surgery, Plastic
OTO - NOTNLM
OT  - *Aesthetic surgery
OT  - *Cosmetic surgery
OT  - *Marketing
OT  - *Medical ethics
EDAT- 2020/08/28 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/08/27 06:00
PHST- 2008/04/24 00:00 [received]
PHST- 2008/06/16 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1007/s00266-020-01821-z [doi]
AID - 10.1007/s00266-020-01821-z [pii]
PST - ppublish
SO  - Aesthetic Plast Surg. 2020 Aug;44(4):1364-1374. doi: 10.1007/s00266-020-01821-z. 
      Epub 2008 Sep 27.


PMID- 32844082
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2198-7866 (Print)
VI  - 6
IP  - 4
DP  - 2020
TI  - Responsible Translational Pathways for Germline Gene Editing?
PG  - 126-133
LID - 10.1007/s40778-020-00179-x [doi]
AB  - PURPOSE OF REVIEW: Continued development of gene editing techniques has raised
      the real possibility of clinical application of germline gene editing. These
      results, as well as reports of an unethical experiment which resulted in the
      birth of at least two children from edited embryos in 2018, have highlighted the 
      urgency and importance of ethical issues about translational pathways for editing
      of human germline cells. Charting responsible translational pathways for germline
      gene editing requires tackling some significant and complex ethical issues.
      RECENT FINDINGS: A literature on development of clinical applications of germline
      gene editing is emerging, and several key ethical issues are coming into focus as
      major challenges for responsible translational pathways. SUMMARY: Potential
      clinical utility, clinical justification, and human subjects research for
      germline gene editing raise outstanding ethical questions. Work on these
      questions will help provide guidance to researchers and clinicians and direct
      translational projects toward justifiable applications.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Cwik, Bryan
AU  - Cwik B
AD  - Philosophy and University Studies, Portland State University, Fourth Ave Building
      Suite 175, 1900 SW 4th Ave, Portland, OR 97201 USA.grid.262075.40000 0001 1087
      1481
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Switzerland
TA  - Curr Stem Cell Rep
JT  - Current stem cell reports
JID - 101650643
PMC - PMC7441015
OTO - NOTNLM
OT  - Clinical utility
OT  - Ethics
OT  - Gene editing
OT  - Germline
OT  - Human subjects research
OT  - Reproductive medicine
COIS- Conflict of InterestDr. Cwik reports grants from the National Human Genome
      Research Institute during the conduct of the study; and the author is a member of
      the external advisory board for the Oregon Health and Science University Center
      for Embryonic Cell and Gene Therapy. Members of this center were involved in
      public research discussed in this paper.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 10.1007/s40778-020-00179-x [doi]
AID - 179 [pii]
PST - ppublish
SO  - Curr Stem Cell Rep. 2020;6(4):126-133. doi: 10.1007/s40778-020-00179-x. Epub 2020
      Aug 21.


PMID- 32843909
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1878-5077 (Print)
IS  - 1878-5077 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Sep
TI  - Prostate cancer management: long-term beliefs, epidemic developments in the early
      twenty-first century and 3PM dimensional solutions.
PG  - 399-418
LID - 10.1007/s13167-020-00214-1 [doi]
AB  - In the early twenty-first century, societies around the world are facing the
      paradoxal epidemic development of PCa as a non-communicable disease. PCa is the
      most frequently diagnosed cancer for men in several countries such as the USA.
      Permanently improving diagnostics and treatments in the PCa management causes an 
      impressive divergence between, on one hand, permanently increasing numbers of
      diagnosed PCa cases and, on the other hand, stable or even slightly decreasing
      mortality rates. Still, aspects listed below are waiting for innovate solutions
      in the context of predictive approaches, targeted prevention and personalisation 
      of medical care (PPPM / 3PM).A.PCa belongs to the cancer types with the highest
      incidence worldwide. Corresponding economic burden is enormous. Moreover, the
      costs of treating PCa are currently increasing more quickly than those of any
      other cancer. Implementing individualised patient profiles and adapted treatment 
      algorithms would make currently too heterogeneous landscape of PCa treatment
      costs more transparent providing clear "road map" for the cost saving.B.PCa is a 
      systemic multi-factorial disease. Consequently, predictive diagnostics by liquid 
      biopsy analysis is instrumental for the disease prediction, targeted prevention
      and curative treatments at early stages.C.The incidence of metastasising PCa is
      rapidly increasing particularly in younger populations. Exemplified by trends
      observed in the USA, prognosis is that the annual burden will increase by over
      40% in 2025. To this end, one of the evident deficits is the reactive character
      of medical services currently provided to populations. Innovative screening
      programmes might be useful to identify persons in suboptimal health conditions
      before the clinical onset of metastasising PCa. Strong predisposition to systemic
      hypoxic conditions and ischemic lesions (e.g. characteristic for individuals with
      Flammer syndrome phenotype) and low-grade inflammation might be indicative for
      specific phenotyping and genotyping in metastasising PCa screening and disease
      management. Predictive liquid biopsy tests for CTC enumeration and their
      molecular characterisation are considered to be useful for secondary prevention
      of metastatic disease in PCa patients.D.Particular rapidly increasing PCa
      incidence rates are characteristic for adolescents and young adults aged 15-40
      years. Patients with early onset prostate cancer pose unique challenges;
      multi-factorial risks for these trends are proposed. Consequently, multi-level
      diagnostics including phenotyping and multi-omics are considered to be the most
      appropriate tool for the risk assessment, prediction and prognosis. Accumulating 
      evidence suggests that early onset prostate cancer is a distinct phenotype from
      both aetiological and clinical perspectives deserving particular attention from
      view point of 3P medical approaches.
CI  - (c) The Author(s) 2020.
FAU - Kucera, Radek
AU  - Kucera R
AD  - Department of Immunochemistry Diagnostics, University Hospital and Faculty of
      Medicine, Pilsen, Czech Republic.grid.412694.c0000 0000 8875 8983
FAU - Pecen, Ladislav
AU  - Pecen L
AD  - Department of Immunochemistry Diagnostics, University Hospital and Faculty of
      Medicine, Pilsen, Czech Republic.grid.412694.c0000 0000 8875 8983
FAU - Topolcan, Ondrej
AU  - Topolcan O
AD  - Department of Immunochemistry Diagnostics, University Hospital and Faculty of
      Medicine, Pilsen, Czech Republic.grid.412694.c0000 0000 8875 8983
FAU - Dahal, Anshu Raj
AU  - Dahal AR
AD  - Center of Molecular Biotechnology, Rheinische Friedrich-Wilhelms-Universitat
      Bonn, Bonn, Germany.grid.10388.320000 0001 2240 3300
FAU - Costigliola, Vincenzo
AU  - Costigliola V
AD  - European Medical Association, Brussels, Belgium.
FAU - Giordano, Frank A
AU  - Giordano FA
AD  - Department of Radiation Oncology, University Hospital Bonn, Rheinische
      Friedrich-Wilhelms-Universitat Bonn, Bonn, Germany.grid.10388.320000 0001 2240
      3300
FAU - Golubnitschaja, Olga
AU  - Golubnitschaja O
AD  - Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation
      Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universitat
      Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.grid.10388.320000 0001 2240 3300
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200626
PL  - Switzerland
TA  - EPMA J
JT  - The EPMA journal
JID - 101517307
PMC - PMC7429585
OTO - NOTNLM
OT  - 3PM)
OT  - Adapted treatment algorithms
OT  - Adolescence
OT  - Aetiology
OT  - Age
OT  - Aggressive metastatic disease
OT  - Alcohol consumption
OT  - Androgen dependent
OT  - Apoptosis resistance
OT  - Biomarker patterns
OT  - Body mass index BMI
OT  - Bone-specific alkaline phosphatase
OT  - C-index
OT  - Castration resistant
OT  - Choline
OT  - Circulating tumour cells (CTC)
OT  - Coffee
OT  - Comorbidities
OT  - Curcumin
OT  - Diet
OT  - Disease manifestation
OT  - Economy
OT  - Elderly
OT  - Ellargic acid
OT  - Ethics
OT  - Ethnicity
OT  - Family history
OT  - Fish
OT  - Folate
OT  - Fruits
OT  - Garlic
OT  - Genetic
OT  - Green tea
OT  - Gut microbiota
OT  - Human development index
OT  - Hybrid imaging
OT  - Incidence
OT  - Indicator
OT  - Individualised patient profile
OT  - Inflammation
OT  - Insulin-like growth factor
OT  - Ischemic lesions
OT  - Lactate dehydrogenase
OT  - Life quality
OT  - Lifestyle
OT  - Liquid biopsy
OT  - Lycopene
OT  - Malignancy
OT  - Meat
OT  - Microcirculation
OT  - Modifiable risk factors
OT  - Mortality
OT  - Multi-factorial systemic disease
OT  - Multi-omics
OT  - Multi-parametric analysis
OT  - Obesity
OT  - Oxidative stress
OT  - PET/MRI
OT  - PSA screening
OT  - Patient stratification
OT  - Personalised nutrition
OT  - Physical activity
OT  - Prebiotics
OT  - Predictive preventive personalised medicine (PPPM
OT  - Probiotics
OT  - Prognosis
OT  - Prostate cancer (PCa)
OT  - Prostate cancer antigen 3
OT  - Quercetin
OT  - Race
OT  - Radical prostatectomy
OT  - Risk assessment
OT  - Roadmap
OT  - Saturated fat
OT  - Selenium/selenite
OT  - Sexually transmitted diseases
OT  - Sleep disorders
OT  - Smoking
OT  - Socio-economic factors
OT  - Stillbenes
OT  - Sulphorapane
OT  - Survival
OT  - Systemic hypoxic condition
OT  - Toxic environment
OT  - Trace elements
OT  - Transrectal ultrasound
OT  - Trends
OT  - Urinary tract infection
OT  - Urology
OT  - Vasectomy
OT  - Vegetables
OT  - Vitamins A, C, D, E, and K
OT  - Young population
OT  - miRNA
COIS- Competing interestThe authors declare that they have no competing interests.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.1007/s13167-020-00214-1 [doi]
AID - 214 [pii]
PST - epublish
SO  - EPMA J. 2020 Jun 26;11(3):399-418. doi: 10.1007/s13167-020-00214-1. eCollection
      2020 Sep.


PMID- 32843816
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0313-5926 (Print)
IS  - 0313-5926 (Linking)
VI  - 68
DP  - 2020 Dec
TI  - Economic, social and political issues raised by the COVID-19 pandemic.
PG  - 17-28
LID - 10.1016/j.eap.2020.08.002 [doi]
AB  - This article contributes to the assessment of public policies to control the
      incidence of COVID-19 in several ways. (1) It contains a brief historical and
      comparative overview of selected pandemics, particularly in relation to the
      COVID-19 pandemic; (2) It provides a simple original model which could be used to
      prioritize the admission of COVID-19 sufferers to hospital (taking into account
      available hospital capacity) and (3) it specifies a second model to evaluate
      desired social choices involving the trade-off between the severity of social
      restrictions (taking into account their impact on the incidence of COVID-19) and 
      the level of economic activity. Bergson-type welfare functions are utilized in
      the second model. It also critically examines the proposition that the isolation 
      (lockdown) of social groups is a desirable method of limiting the incidence of
      COVID-19. This leads onto the consideration of the extent to which personal
      freedom of choice (liberty) ought to be restricted in response to the COVID-19
      pandemic. A brief outline follows illustrating the factors that are likely to
      hinder economic recovery from COVID-19. Particular attention is paid to the moral
      and ethical questions raised by policies to control COVID-19. These appear to
      have received little attention in the relevant economic literature.
CI  - (c) 2020 Economic Society of Australia, Queensland. Published by Elsevier B.V.
      All rights reserved.
FAU - Tisdell, Clement A
AU  - Tisdell CA
AD  - School of Economics, The University of Queensland, Brisbane 4072 QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - Australia
TA  - Econ Anal Policy
JT  - Economic analysis and policy
JID - 101534797
PMC - PMC7440080
OTO - NOTNLM
OT  - Economic activity and COVID-19
OT  - History of pandemics
OT  - Liberty and COVID-19
OT  - Quality of life years (QALYS) and COVID-19
OT  - Social choice and COVID-19
OT  - Triage and COVID-19
OT  - Value of human life and COVID-19
COIS- The author declares that he has no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/07/29 00:00 [received]
PHST- 2020/08/19 00:00 [revised]
PHST- 2020/08/19 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 10.1016/j.eap.2020.08.002 [doi]
AID - S0313-5926(20)30408-2 [pii]
PST - ppublish
SO  - Econ Anal Policy. 2020 Dec;68:17-28. doi: 10.1016/j.eap.2020.08.002. Epub 2020
      Aug 20.


PMID- 32843796
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Jan-Mar
TI  - To Compare the Changes in Hemodynamic Parameters and Blood Loss during
      Percutaneous Nephrolithotomy - General Anesthesia versus Subarachnoid Block.
PG  - 72-74
LID - 10.4103/aer.AER_14_20 [doi]
AB  - BACKGROUND: Percutaneous nephrolithotomy (PCNL) is done under general anesthesia 
      (GA) in most of the centers. However, associated complications and cost are
      higher for GA than for regional anesthesia. AIM: The aim of the study was to
      compare the efficacy of GA versus subarachnoid block (SAB) with regard to
      intraoperative blood loss and postoperative drop in hemoglobin (Hb) in patients
      undergoing PCNL. SETTING AND DESIGN: This prospective, randomized, comparative
      clinical trial was carried out at a tertiary care hospital. After obtaining the
      institute ethical committee clearance (vide no 57/15), patients were randomly
      allocated into two groups using table of randomization (n = 30 each), Group A -
      GA, Group B - SAB. MATERIALS AND METHODS: Intraoperative blood loss was assessed 
      by measuring the Hb of irrigated fluid and postoperative drop in Hb
      concentration. Other parameters such as intraoperative mean arterial pressure and
      heart rate were also compared in these groups. STATISTICAL ANALYSIS: The results 
      are presented in frequencies, percentages, and mean +/- standard deviation. The
      Chi-square test was used to compare the categorical variables between the groups.
      Unpaired t-test was used to compare the continuous variables between the groups. 
      RESULTS: Hemodynamic parameters were similar in both the groups preoperatively.
      The Hb drop was significant in Group A (1.28 +/- 0.35 g.dl(-1)) as compared to
      Group B (1.10 +/- 0.67 g.dl(-1)). On calculating Hb in irrigated fluid-blood
      mixture, it was found to be significantly higher in Group A (1.87 +/- 0.44
      g.L(-1)) as compared to Group B (1.25 +/- 0.25 g.L(-1)). CONCLUSIONS: Both GA and
      SAB are effective and safe in PCNL. However, SAB is associated with less blood
      loss as estimated by intraoperative blood loss and Hb drop.
CI  - Copyright: (c) 2020 Anesthesia: Essays and Researches.
FAU - Ranjan, Ravi
AU  - Ranjan R
AD  - Department of Anesthesiology, Institute of Medical Sciences, Banaras Hindu
      University, Varanasi, Uttar Pradesh, India.
FAU - Malviya, Deepak
AU  - Malviya D
AD  - Department of Anesthesiology and Critical Care Medicine, Dr. Ram Manohar Lohia
      Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
FAU - Misra, Shilpi
AU  - Misra S
AD  - Department of Anesthesiology and Critical Care Medicine, Dr. Ram Manohar Lohia
      Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
FAU - Nath, Soumya Sankar
AU  - Nath SS
AD  - Department of Anesthesiology and Critical Care Medicine, Dr. Ram Manohar Lohia
      Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
FAU - Rastogi, Shivani
AU  - Rastogi S
AD  - Department of Anesthesiology and Critical Care Medicine, Dr. Ram Manohar Lohia
      Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20200325
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC7428097
OTO - NOTNLM
OT  - Blood loss
OT  - general anesthesia
OT  - hemodynamics
OT  - nephrolithiasis
OT  - percutaneous nephrolithotomy
OT  - subarachnoid block
COIS- There are no conflicts of interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.4103/aer.AER_14_20 [doi]
AID - AER-14-72 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jan-Mar;14(1):72-74. doi: 10.4103/aer.AER_14_20. Epub
      2020 Mar 25.


PMID- 32843794
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Jan-Mar
TI  - Etomidate versus Propofol for Motor Seizure Duration during Modified
      Electroconvulsive Therapy.
PG  - 62-67
LID - 10.4103/aer.AER_5_20 [doi]
AB  - BACKGROUND: Certain anesthetic agents on account of their anticonvulsant property
      have a negative impact on motor seizure duration. Etomidate and propofol being
      devoid of the strong anticonvulsant property may be beneficial for use in
      electroconvulsive therapy (ECT). ECT requires sedation with a short-term
      anesthetic agent that does not interfere with seizure activity and has rapid
      onset and recovery to facilitate fast-tracking. AIMS: The primary objective of
      this study was to compare motor seizure duration, and the secondary objective was
      to compare induction time, hemodynamic parameters, recovery time, and adverse
      effects between propofol and etomidate in modified ECT. SETTINGS AND DESIGN: This
      is a prospective, double- blind, randomized, controlled study conducted in the
      Department of Anesthesia and Intensive care in a tertiary care hospital during
      2018-2019. MATERIALS AND METHODS: After ethical clearance from institutional
      ethics committee and written informed consent, a total of 70 patients, aged 18-65
      years were randomly allocated using computer generated random number list into
      two groups - Group A - Propofol (1%) - 1.0 mg.kg(-1) and Group B - Etomidate 0.2 
      mg.kg(-1) as an intravenous induction agent. Intraoperatively, motor seizure
      duration, induction time, and hemodynamic parameters and at the end of procedure 
      recovery parameters were assessed. STATISTICAL ANALYSIS USED: Data were described
      in terms of number (%) and mean +/- standard deviation. Comparison of
      quantitative variables between the study groups was done using Student t-test and
      Mann Whitney U test for parametric and nonparametric variables respectively. For 
      comparing categorical data, Chi -square (chi2) test was performed. RESULTS: Mean 
      motor seizure duration with etomidate (55.17 +/- 19.06 s) was longer as compared 
      to propofol (27.80 +/- 17.33 s), and the difference was highly significant (P <
      0.001). Among hemodynamic parameters, there was a significant increase in heart
      rate (P = 0.016) and significant fall in mean arterial pressure (P = 0.005) after
      induction with propofol as compared to etomidate. CONCLUSION: Etomidate has the
      advantage of longer seizure duration and stable hemodynamics. It can be a useful 
      alternative in patients achieving suboptimal therapeutic responses to ECT or
      where seizure duration is too short.
CI  - Copyright: (c) 2020 Anesthesia: Essays and Researches.
FAU - Jindal, Seema
AU  - Jindal S
AD  - Department of Anaesthesia and Intensive Care, Guru Gobind Singh Medical College
      and Hospital, Faridkot, Punjab, India.
FAU - Sidhu, Gurkaran Kaur
AU  - Sidhu GK
AD  - Department of Anaesthesia and Intensive Care, Guru Gobind Singh Medical College
      and Hospital, Faridkot, Punjab, India.
FAU - Kumari, Samiksha
AU  - Kumari S
AD  - Department of Anaesthesia and Intensive Care, Guru Gobind Singh Medical College
      and Hospital, Faridkot, Punjab, India.
FAU - Kamboj, Preeti
AU  - Kamboj P
AD  - Department of Anaesthesia and Intensive Care, Guru Gobind Singh Medical College
      and Hospital, Faridkot, Punjab, India.
FAU - Chauhan, Rajeev
AU  - Chauhan R
AD  - Department of Anesthesia and Intensive Care, PGIMER, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC7428102
OTO - NOTNLM
OT  - Electroconvulsive therapy
OT  - etomidate
OT  - motor seizure
OT  - propofol
COIS- There are no conflicts of interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/01/30 00:00 [revised]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.4103/aer.AER_5_20 [doi]
AID - AER-14-62 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jan-Mar;14(1):62-67. doi: 10.4103/aer.AER_5_20. Epub 2020
      Jun 22.


PMID- 32843791
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Jan-Mar
TI  - Evaluation of Gastric Emptying by Ultrasonography after Recommended Fasting
      Period and Administration of Prokinetic in End-stage Renal Disease Patients.
PG  - 42-48
LID - 10.4103/aer.AER_18_20 [doi]
AB  - BACKGROUND: Delayed gastric emptying is observed in end-stage renal disease
      (ESRD). AIMS: Evaluation of gastric emptying after recommended fasting period and
      on oral administration of prokinetic in ESRD patients using ultrasonography
      (USG). SETTINGS AND DESIGN: Randomized, double-blind, prospective, controlled
      study. MATERIALS AND METHODS: After institutional ethics committee approval, 200 
      patients were divided randomly into two equal groups. Three sessions of USG
      evaluation of gastric antrum were done in supine and right lateral position for
      assessing gastric emptying, first at 8 am, second after the light meal at 8.30
      am, and third after 6 h of light meal. Group A received placebo (sugar-coated
      pill) and Group B received tablet metoclopramide hydrochloride 10 mg after second
      session of USG. In each session, measurement of anteroposterior and craniocaudal 
      diameters of gastric antrum was done, and then cross-sectional area was
      estimated. Three-point grading system (Perlas) was used to perform qualitative
      evaluation. STATISTICAL ANALYSIS: Comparison of normally distributed continuous
      variables was performed using Student's t-test. Nominal categorical data were
      compared using Chi-squared test. Nonnormal distribution continuous variables were
      compared using Mann-Whitney U-test. RESULTS: 6 h of fasting after light meal
      showed that Group A only had 14% incidence of complete gastric emptying, whereas 
      Group B had 71% as compared by Perlas grading. Gastric antral cross-sectional
      area measured both in supine (480.89 +/- 84.92) and right lateral (575.40 +/-
      92.62) position of Group A was more than Group B supine (394.15 +/- 62.80) and
      right lateral (470.25 +/- 73.63) position (P < 0.05). CONCLUSION: USG of ESRD
      patients preoperatively can evaluate gastric contents to assess risk of pulmonary
      aspiration and guide anesthetic management. Metoclopramide is a good drug to
      enhance gastric emptying in ESRD patients within the recommended fasting period.
CI  - Copyright: (c) 2020 Anesthesia: Essays and Researches.
FAU - Gupta, Richa
AU  - Gupta R
AD  - Department of Anaesthesiology, Himalayan Institute of Medical Sciences, Swami
      Rama Himalayan University, Dehradun, Uttarakhand, India.
FAU - Pokhriyal, Abhimanyu Singh
AU  - Pokhriyal AS
AD  - Department of Anaesthesiology, Himalayan Institute of Medical Sciences, Swami
      Rama Himalayan University, Dehradun, Uttarakhand, India.
FAU - Jindal, Parul
AU  - Jindal P
AD  - Department of Anaesthesiology, Himalayan Institute of Medical Sciences, Swami
      Rama Himalayan University, Dehradun, Uttarakhand, India.
FAU - Sarpal, Rajeev
AU  - Sarpal R
AD  - Department of Urology, Himalayan Institute of Medical Sciences, Swami Rama
      Himalayan University, Dehradun, Uttarakhand, India.
FAU - Goyal, Mamta
AU  - Goyal M
AD  - Department of Radiology, Himalayan Institute of Medical Sciences, Swami Rama
      Himalayan University, Dehradun, Uttarakhand, India.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC7428100
OTO - NOTNLM
OT  - End-stage renal disease
OT  - gastric antrum
OT  - metoclopramide hydrochloride
OT  - stomach
OT  - ultrasound imaging
COIS- There are no conflicts of interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.4103/aer.AER_18_20 [doi]
AID - AER-14-42 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jan-Mar;14(1):42-48. doi: 10.4103/aer.AER_18_20. Epub
      2020 Jun 22.


PMID- 32843787
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Jan-Mar
TI  - Randomized Controlled Trial to Compare Baska(R) Mask versus ProSeal Laryngeal
      Mask Airway for General Anesthesia with Intermittent Positive Pressure
      Ventilation.
PG  - 25-28
LID - 10.4103/aer.AER_23_20 [doi]
AB  - INTRODUCTION: A myriad of supraglottic airway devices (SADs) are developed over
      time to search the device that conforms to the anatomy of the human respiratory
      tract noninvasively, but these devices are associated with the risk of
      aspiration. Baska((R)) mask (BM) is the latest addition to the family of SADs to 
      circumvent the incidence of aspiration. AIMS OF STUDY: The aim of the study was
      to compare the sealing pressure and rapidity of the insertion of BM with ProSeal 
      laryngeal mask (PLM) airway and the incidence of laryngopharyngeal morbidity
      between two devices. MATERIALS AND METHODS: A randomized prospective open-label
      study was done on sixty adult patients of the age group of 18-60 years after
      approval from the institutional ethical committee and registration of trial in
      the Clinical Trials Registry. The patients were randomly divided into two groups:
      Group I (BM) where BM was inserted after the induction of general anesthesia and 
      Group II (PLM) where PLM was inserted after induction. The airway sealing
      pressure in BM was calculated. The mean time of insertion of respective SAD and
      the number of successful attempts were also recorded in both groups. For analysis
      of continuous variables, independent sample Student's t-test was applied, and for
      categorical variables, Chi-square test was used. P < 0.05 was considered
      statistically significant. RESULTS: The rate of successful attempts of insertion 
      was comparable in both the groups. The mean insertion time was 14.25 +/- 3.82 s
      in BM group and 22.01 +/- 2.64 s in PLM group, which was statistically
      significant. The airway sealing pressure was 30.25 +/- 3.34 cmH2O in BM group and
      23.50 +/- 4.05 cmH2O in PLM group, which was also statistically significant.
      CONCLUSION: BM has better ease of insertion with adequate sealing pressure as
      compared to PLM airway, thus reducing the chances of aspiration and offering its 
      potential application in securing airway in emergency situations.
CI  - Copyright: (c) 2020 Anesthesia: Essays and Researches.
FAU - Singh, Balwinderjit
AU  - Singh B
AD  - Department of Anesthesia, PIMS, Jalandhar, Punjab, India.
FAU - Singh, Arwinder Pal
AU  - Singh AP
AD  - Department of Anesthesia, PIMS, Jalandhar, Punjab, India.
FAU - Attri, Joginder Pal
AU  - Attri JP
AD  - Department of Anesthesia, GMC, Amritsar, Punjab, India.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC7428092
OTO - NOTNLM
OT  - Airway sealing pressure
OT  - Baska(R) mask
OT  - ProSeal laryngeal mask
COIS- There are no conflicts of interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.4103/aer.AER_23_20 [doi]
AID - AER-14-25 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jan-Mar;14(1):25-28. doi: 10.4103/aer.AER_23_20. Epub
      2020 Jun 22.


PMID- 32843784
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0259-1162 (Print)
IS  - 2229-7685 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Jan-Mar
TI  - A Randomized Controlled Study to Compare Hemodynamic Effects between Clonidine
      and Pregabalin in Laparoscopic Cholecystectomy.
PG  - 4-15
LID - 10.4103/aer.AER_15_20 [doi]
AB  - BACKGROUND: Laparoscopic cholecystectomy (LC) is associated with pneumoperitoneum
      and hemodynamic disturbances. Pregabalin and Clonidine have been used for
      anesthetic effects, but a better drug for controlling hemodynamic parameters is
      being investigated. AIMS: The study was done to assess and compare the efficacy
      of preoperative single oral dose of pregabalin and clonidine in maintaining the
      hemodynamic parameters in the LC. SETTINGS AND DESIGN: The prospective,
      interventional, randomized, comparative, single-blinded study was conducted in
      the department of anesthesia and surgery from January 2015 to September 2016
      after taking approval from the institutional ethical committee. MATERIALS AND
      METHODS: The study included a total of 90 patients, aged between 18 and 56 years 
      of both sexes scheduled for elective LC. Patients were randomized into three
      groups of 30 each who received oral pregabalin 150 mg, clonidine 200 ug, and
      placebo. The hemodynamic parameters were recorded at various time intervals along
      with any adverse events. STATISTICAL ANALYSIS: Quantitative variables were
      compared using unpaired t-test (when the data sets were not normally distributed)
      between the two groups. Qualitative variables were compared using Chi-square
      test/Fisher's exact test. P < 0.05 was considered statistically significant.
      RESULTS: There was a significant increase in the heart rate (HR) and systolic,
      diastolic, and mean blood pressure during laryngoscopy and pneumoperitoneum in
      the control group as compared to both pregabalin and clonidine. HR was
      significantly lower in clonidine group after extubation and in postoperative
      period than both control group and pregabalin group. There was no major
      difference in the incidence of side effects. CONCLUSION: Both pregabalin (150 mg)
      and clonidine (200 ug) were effective in controlling the hemodynamic parameters
      during LC, with clonidine providing better hemodynamic stability than Pregabalin.
CI  - Copyright: (c) 2020 Anesthesia: Essays and Researches.
FAU - Jain, Mansi
AU  - Jain M
AD  - Department of Anaesthesiology, BJ Medical College, Ahmedabad, Gujarat, India.
FAU - Ramani, Monal
AU  - Ramani M
AD  - Department of Anaesthesiology, BJ Medical College, Ahmedabad, Gujarat, India.
FAU - Gandhi, Seema
AU  - Gandhi S
AD  - Department of Anaesthesiology, BJ Medical College, Ahmedabad, Gujarat, India.
FAU - Jain, Chirag
AU  - Jain C
AD  - Department of Anaesthesiology, BJ Medical College, Ahmedabad, Gujarat, India.
FAU - Sarvanan, V K
AU  - Sarvanan VK
AD  - Department of Anaesthesiology, BJ Medical College, Ahmedabad, Gujarat, India.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - India
TA  - Anesth Essays Res
JT  - Anesthesia, essays and researches
JID - 101578762
PMC - PMC7428121
OTO - NOTNLM
OT  - Clonidine
OT  - hemodynamic parameters
OT  - laparoscopic cholecystectomy
OT  - laryngoscopy
OT  - pneumoperitoneum
OT  - pregabalin
COIS- There are no conflicts of interest.
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
CRDT- 2020/08/27 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/02/23 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
AID - 10.4103/aer.AER_15_20 [doi]
AID - AER-14-4 [pii]
PST - ppublish
SO  - Anesth Essays Res. 2020 Jan-Mar;14(1):4-15. doi: 10.4103/aer.AER_15_20. Epub 2020
      Jun 22.


PMID- 32843517
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 24
TI  - CASNET2: evaluation of an electronic safety netting cancer toolkit for the
      primary care electronic health record: protocol for a pragmatic stepped-wedge
      RCT.
PG  - e038562
LID - 10.1136/bmjopen-2020-038562 [doi]
AB  - INTRODUCTION: Safety-netting in primary care is the best practice in cancer
      diagnosis, ensuring that patients are followed up until symptoms are explained or
      have resolved. Currently, clinicians use haphazard manual solutions. The
      ubiquitous use of electronic health records provides an opportunity to
      standardise safety-netting practices.A new electronic safety-netting toolkit has 
      been introduced to provide systematic ways to track and follow up patients. We
      will evaluate the effectiveness of this toolkit, which is embedded in a major
      primary care clinical system in England:Egerton Medical Information
      System(EMIS)-Web. METHODS AND ANALYSIS: We will conduct a stepped-wedge cluster
      RCT in 60 general practices within the RCGP Research and Surveillance Centre
      (RSC) network. Groups of 10 practices will be randomised into the active phase at
      2-monthly intervals over 12 months. All practices will be activated for at least 
      2 months. The primary outcome is the primary care interval measured as days
      between the first recorded symptom of cancer (within the year prior to diagnosis)
      and the subsequent referral to secondary care. Other outcomes include referrals
      rates and rates of direct access cancer investigation.Analysis of the clustered
      stepped-wedge design will model associations using a fixed effect for
      intervention condition of the cluster at each time step, a fixed effect for time 
      and other covariates, and then include a random effect for practice and for
      patient to account for correlation between observations from the same centre and 
      from the same participant. ETHICS AND DISSEMINATION: Ethical approval has been
      obtained from the North West-Greater Manchester West National Health Service
      Research Ethics Committee (REC Reference 19/NW/0692). Results will be
      disseminated in peer-reviewed journals and conferences, and sent to participating
      practices. They will be published on the University of Oxford Nuffield Department
      of Primary Care and RCGP RSC websites. TRIAL REGISTRATION NUMBER: ISRCTN15913081;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fleming, Susannah
AU  - Fleming S
AUID- ORCID: 0000-0001-7205-2051
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Nicholson, Brian D
AU  - Nicholson BD
AUID- ORCID: 0000-0003-0661-7362
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK brian.nicholson@phc.ox.ac.uk.
FAU - Bhuiya, Afsana
AU  - Bhuiya A
AD  - North Central and East London Cancer Alliance, London, UK.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AUID- ORCID: 0000-0001-5613-6810
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
AD  - Department of Clinical and Experimental Medicine, University of Surrey,
      Guildford, Surrey, UK.
AD  - Research and Surveillance Centre, Royal College of General Practitioners, London,
      London, UK.
FAU - Hirst, Yasemin
AU  - Hirst Y
AD  - Research Department of Behavioural Science and Health, University College,
      London, UK.
FAU - Hobbs, Richard
AU  - Hobbs R
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Perera, Rafael
AU  - Perera R
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Sherlock, Julian
AU  - Sherlock J
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
AD  - Department of Clinical and Experimental Medicine, University of Surrey,
      Guildford, Surrey, UK.
FAU - Yonova, Ivelina
AU  - Yonova I
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
AD  - Department of Clinical and Experimental Medicine, University of Surrey,
      Guildford, Surrey, UK.
AD  - Research and Surveillance Centre, Royal College of General Practitioners, London,
      London, UK.
FAU - Bankhead, Clare
AU  - Bankhead C
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
LA  - eng
SI  - ISRCTN/ISRCTN15913081
GR  - C48270/A27880/CRUK_/Cancer Research UK/United Kingdom
GR  - C38463/A26726/CRUK_/Cancer Research UK/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200824
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Electronic Health Records
MH  - Electronics
MH  - England
MH  - Humans
MH  - *Neoplasms/diagnosis/therapy
MH  - Primary Health Care
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
PMC - PMC7449309
OTO - NOTNLM
OT  - *health informatics
OT  - *oncology
OT  - *primary care
COIS- Competing interests: AB is the innovator of the E-SN toolkit and locally promotes
      the toolkit for the purposes of cancer care along its pathway. SF is a member of 
      the National Body Temperature Measurement Group. SdL is director of the RCGP, as 
      part of his academic work.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038562 [pii]
AID - 10.1136/bmjopen-2020-038562 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 24;10(8):e038562. doi: 10.1136/bmjopen-2020-038562.


PMID- 32843516
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 24
TI  - Design and rationale of DUTCH-AF: a prospective nationwide registry programme and
      observational study on long-term oral antithrombotic treatment in patients with
      atrial fibrillation.
PG  - e036220
LID - 10.1136/bmjopen-2019-036220 [doi]
AB  - INTRODUCTION: Anticoagulation therapy is pivotal in the management of stroke
      prevention in atrial fibrillation (AF). Prospective registries, containing
      longitudinal data are lacking with detailed information on anticoagulant therapy,
      treatment adherence and AF-related adverse events in practice-based patient
      cohorts, in particular for non-vitamin K oral anticoagulants (NOAC). With the
      creation of DUTCH-AF, a nationwide longitudinal AF registry, we aim to provide
      clinical data and answer questions on the (anticoagulant) management over time
      and of the clinical course of patients with newly diagnosed AF in routine
      clinical care. Within DUTCH-AF, our current aim is to assess the effect of
      non-adherence and non-persistence of anticoagulation therapy on clinical adverse 
      events (eg, bleeding and stroke), to determine predictors for such inadequate
      anticoagulant treatment, and to validate and refine bleeding prediction models.
      With DUTCH-AF, we provide the basis for a continuing nationwide AF registry,
      which will facilitate subsequent research, including future registry-based
      clinical trials. METHODS AND ANALYSIS: The DUTCH-AF registry is a nationwide,
      prospective registry of patients with newly diagnosed 'non-valvular' AF. Patients
      will be enrolled from primary, secondary and tertiary care practices across the
      Netherlands. A target of 6000 patients for this initial cohort will be followed
      for at least 2 years. Data on thromboembolic and bleeding events, changes in
      antithrombotic therapy and hospital admissions will be registered.
      Pharmacy-dispensing data will be obtained to calculate parameters of adherence
      and persistence to anticoagulant treatment, which will be linked to AF-related
      outcomes such as ischaemic stroke and major bleeding. In a subset of patients,
      anticoagulation adherence and beliefs about drugs will be assessed by
      questionnaire. ETHICS AND DISSEMINATION: This study protocol was approved as
      exempt for formal review according to Dutch law by the Medical Ethics Committee
      of the Leiden University Medical Centre, Leiden, the Netherlands. Results will be
      disseminated by publications in peer-reviewed journals and presentations at
      scientific congresses. TRIAL REGISTRATION NUMBER: Trial NL7467, NTR7706
      (https://www.trialregister.nl/trial/7464).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chu, Gordon
AU  - Chu G
AUID- ORCID: 0000-0001-5466-3094
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Centre,
      Leiden, The Netherlands k.g.chu@lumc.nl.
FAU - Seelig, Jaap
AU  - Seelig J
AD  - Department of Cardiology, Rijnstate, Arnhem, The Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, Netherlands.
FAU - Trinks-Roerdink, Emmy M
AU  - Trinks-Roerdink EM
AUID- ORCID: 0000-0002-0535-9253
AD  - Department of General Practice, Julius Centre for Health Sciences and Primary
      Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The
      Netherlands.
FAU - van Alem, Anouk P
AU  - van Alem AP
AD  - Department of Cardiology, Haaglanden Medical Centre, The Hague, The Netherlands.
FAU - Alings, Marco
AU  - Alings M
AD  - Department of Cardiology, Amphia Hospital, Breda, The Netherlands.
FAU - van den Bemt, Bart
AU  - van den Bemt B
AD  - Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands.
AD  - Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Boersma, Lucas Va
AU  - Boersma LV
AD  - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
FAU - Brouwer, Marc A
AU  - Brouwer MA
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Cannegieter, Suzanne C
AU  - Cannegieter SC
AD  - Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden,
      The Netherlands.
FAU - Ten Cate, Hugo
AU  - Ten Cate H
AD  - Thrombosis Expert Centre, Maastricht University Medical Centre, Maastricht, The
      Netherlands.
FAU - Kirchhof, Charles Jhj
AU  - Kirchhof CJ
AD  - Department of Cardiology, Alrijne Hospital, Leiderdorp, Netherlands.
FAU - Crijns, Harry Jgm
AU  - Crijns HJ
AUID- ORCID: 0000-0003-1073-5337
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University,
      Maastricht, Netherlands.
FAU - van Dijk, Ewoud J
AU  - van Dijk EJ
AD  - Deparment of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.
FAU - Elvan, Arif
AU  - Elvan A
AD  - Department of Cardiology, Isala Heart Centre, Isala Hospitals, Zwolle,
      Netherlands.
FAU - van Gelder, Isabelle C
AU  - van Gelder IC
AD  - Department of Cardiology, University Medical Centre Groningen, Groningen,
      Netherlands.
FAU - de Groot, Joris R
AU  - de Groot JR
AD  - Department of Cardiology, Heart Centre, Amsterdam University Medical
      Centre/University of Amsterdam, Amsterdam, Netherlands.
FAU - den Hartog, Frank R
AU  - den Hartog FR
AD  - Department of Cardiology, Gelderse Vallei Hospital, Ede, Netherlands.
FAU - de Jong, Jonas Ssg
AU  - de Jong JS
AD  - Department of Cardiology, Heart Centre, OLVG, Amsterdam, Netherlands.
FAU - de Jong, Sylvie
AU  - de Jong S
AD  - Department of Cardiology, Elkerliek Hospital, Helmond, Netherlands.
FAU - Klok, Frederikus A
AU  - Klok FA
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Centre,
      Leiden, The Netherlands.
FAU - Lenderink, Timo
AU  - Lenderink T
AD  - Department of Cardiology, Zuyderland Medical Centre, Heerlen, Netherlands.
FAU - Luermans, Justin G
AU  - Luermans JG
AD  - Department of Cardiology, Maastricht University Medical Centre+, Maastricht,
      Netherlands.
FAU - Meeder, Joan G
AU  - Meeder JG
AD  - Department of Cardiology, VieCuri Medical Centre Noord-Limburg, Venlo,
      Netherlands.
FAU - Pisters, Ron
AU  - Pisters R
AD  - Department of Cardiology, Rijnstate, Arnhem, The Netherlands.
FAU - Polak, Peter
AU  - Polak P
AD  - Department of Cardiology, St. Anna Hospital, Geldrop, Netherlands.
FAU - Rienstra, Michiel
AU  - Rienstra M
AD  - Department of Cardiology, University Medical Centre Groningen, Groningen,
      Netherlands.
FAU - Smeets, Frans
AU  - Smeets F
AD  - Department of Cardiology, Hospital Bernhoven, Uden, Netherlands.
FAU - Tahapary, Giovanni Jm
AU  - Tahapary GJ
AD  - Department of Cardiology, North West Hospital Group, Alkmaar, Netherlands.
FAU - Theunissen, Luc
AU  - Theunissen L
AD  - Department of Cardiology, Maxima Medical Centre, Eindhoven, Netherlands.
FAU - Tieleman, Robert G
AU  - Tieleman RG
AD  - Department of Cardiology, Martini Hospital, Groningen, Netherlands.
FAU - Trines, Serge A
AU  - Trines SA
AUID- ORCID: 0000-0001-7715-9536
AD  - Department of Cardiology, Heart-Lung Centre, Leiden University Medical Centre,
      Leiden, Netherlands.
FAU - van der Voort, Pepijn
AU  - van der Voort P
AD  - Department of Cardiology, Catharina Hospital, Eindhoven, Netherlands.
FAU - Geersing, Geert-Jan
AU  - Geersing GJ
AD  - Department of General Practice, Julius Centre for Health Sciences and Primary
      Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The
      Netherlands.
FAU - Rutten, Frans H
AU  - Rutten FH
AD  - Department of General Practice, Julius Centre for Health Sciences and Primary
      Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The
      Netherlands.
FAU - Hemels, Martin Ew
AU  - Hemels ME
AD  - Department of Cardiology, Rijnstate, Arnhem, The Netherlands.
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Huisman, Menno V
AU  - Huisman MV
AD  - Department of Thrombosis and Hemostasis, Leiden University Medical Centre,
      Leiden, The Netherlands.
LA  - eng
SI  - NTR/NTR7706
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200824
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Anticoagulants/adverse effects
MH  - *Atrial Fibrillation/complications/drug therapy
MH  - *Brain Ischemia/drug therapy
MH  - Fibrinolytic Agents/adverse effects
MH  - Humans
MH  - Netherlands/epidemiology
MH  - Registries
MH  - *Stroke/drug therapy/etiology/prevention & control
PMC - PMC7449286
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiac epidemiology
OT  - *protocols & guidelines
OT  - *thromboembolism
COIS- Competing interests: GC and EMT-R are supported by a research grant of ZonMW
      (project numbers 848050006 and 848050007). JS is supported by a grant from the
      Dutch Federation of Anticoagulation Clinics (FNT), outside the submitted work.
      FAK has received research support from Bayer, Bristol Myers Squibb, Boehringer
      Ingelheim, MSD, Daiichi Sankyo, Actelion, the Dutch Thrombosis Association and
      the Dutch Heart foundation. JRdG reports research grants from Abbott, AtriCure,
      Boston Scientific, Medtronic and Bayer. He received speaker/consultancy honoraria
      from AtriCure, Bayer, Daiichi Sankyo, Johnson & Johnson, Servier and Novartis;
      all outside the scope of this work. JGM received consultancy fees from BMS/Pfizer
      and Daiichi Sankyo. FS received consultancy fees from Daiichi Sankyo and BMS, and
      restricted institutional grants from Daiichi Sankyo. RGT reports grants and
      personal fees from Boehringer Ingelheim, Bayer, Pfizer, Bristol Meyer Squibb and 
      Daiichi Sankyo. FHR and GJG received unrestricted institutional grants from
      Bayer, BMS/Pfizer, Boehringer Ingelheim and Daiichi Sankyo. MEWH received
      consultancy fees from Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo and
      Roche, and received a research grant from Federation of Dutch Thrombosis
      Services. MVH reports unrestricted grants from and personal fees from Boehringer 
      Ingelheim, Pfizer/BMS, Bayer Health Care, Aspen and Daiichi Sankyo, outside the
      submitted work.
EDAT- 2020/08/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036220 [pii]
AID - 10.1136/bmjopen-2019-036220 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 24;10(8):e036220. doi: 10.1136/bmjopen-2019-036220.


PMID- 32843098
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 26
TI  - High dose dexamethasone treatment for Acute Respiratory Distress Syndrome
      secondary to COVID-19: a structured summary of a study protocol for a randomised 
      controlled trial.
PG  - 743
LID - 10.1186/s13063-020-04646-y [doi]
AB  - OBJECTIVES: The aim of this study is to explore the effectiveness and safety of
      high dose dexamethasone treatment for Acute Respiratory Distress Syndrome
      secondary to SARS-Cov-2 pneumonia. TRIAL DESIGN: Multicentre, randomized clinical
      trial, controlled, open label, parallel group, to evaluate the effectiveness and 
      safety of high dose dexamethasone in adult patients with confirmed COVID-19, with
      Acute Respiratory Distress Syndrome. PARTICIPANTS: We will include patients with 
      SARS-Cov-2 pneumonia who develop acute respiratory distress syndrome, in several 
      intensive care units (ICU) in Buenos Aires, Argentina (CEMIC, Clinica Bazterrica,
      Sanatorio Sagrado Corazon) Inclusion criteria: Men and women, age >/= 18 years
      old. Confirmed diagnosis of SARS-CoV-2 infection, by RT-PCR. Diagnosis of Acute
      Respiratory Distress Syndrome (hypoxemic respiratory failure not explained by
      cardiac disease + PaO2/FiO2 ratio < 300 with a Positive End-Expiratory Pressure
      >/= 5 cm H2O + bilateral pulmonary infiltrates) Length of mechanical ventilation 
      of at least 72 hours Informed consent (next of kin / legal guardian) Exclusion
      criteria: Pregnant or breast-feeding women. Terminal disease (advanced cancer;
      under palliative care; cardiovascular, respiratory, or renal disease with a life 
      expectancy less </= 1 year). Therapeutic limitation (advance directives or do not
      resuscitate order) Severe immunosuppression (HIV infection, long-term use of
      immunosuppressive agents, active cancer). Patients under chronic treatment with
      glucocorticoids for other diseases (>/= 8 mg prednisone, or equivalent)
      Participation in another randomized clinical trial. INTERVENTION AND COMPARATOR: 
      Eligible patients will be randomized to receive standard ICU patient care (group 
      1) or standard ICU patient care plus high dose dexamethasone (group 2). Group 1: 
      dexamethasone up to 6 mg/24 hours for up to 10 days + ventilatory, hemodynamic,
      nutritional, and antimicrobial support according to international guidelines.
      Group 2: dexamethasone 16 mg/24 hours for 5 days followed by dexamethasone 8
      mg/24 hours for 5 days + ventilatory, hemodynamic, nutritional, and antimicrobial
      support according to international guidelines. MAIN OUTCOME: The main result is
      ventilator-free days at 28 days (Days without ventilator support in the first 28 
      days following randomization). Secondary outcomes are 28-days and 90-days
      mortality, frequency of nosocomial infections in the first 28 days after
      randomization, Sequential Organ Failure Assessment (SOFA) score variation and
      prone position in the first 10-days, viral shedding 28-days after randomization, 
      and delirium and muscle weakness at ICU discharge. RANDOMISATION: Treatment will 
      be assigned according to site stratified randomization by permuted random blocks 
      sequence 1:1 generated with a table in R language concealed in a randomization
      tool in REDCap (Research Electronic Data CAPture) platform. BLINDING (MASKING):
      This is an open trial, so no masking of treatment assignment will be used.
      NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Assuming a 3 days difference in
      ventilator-free days between treatment groups, with a mean of 9 days, and a
      standard deviation of 9 days; the necessary sample size would be 284 subjects
      (142 per group), with a power of 80% and a two-tailed alpha error of 0.05. TRIAL 
      STATUS: The protocol with code 1264, version 3.0 on date: May 13, 2020 is
      approved by the local Ethics Committee. The trial is in the recruitment phase.
      Recruitment began May 22, 2020 and is anticipated to be complete by the end of
      December 2021. TRIAL REGISTRATION: The trial was registered under the title
      "Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical
      Trial" with ClinicalTrials number NCT04395105,
      https://clinicaltrials.gov/ct2/show/NCT04395105 , registered on 20 May 2020. FULL
      PROTOCOL: The full protocol is attached as an additional file, accessible from
      the Trials website (Additional file 1). In the interest in expediting
      dissemination of this material, the familiar formatting has been eliminated; this
      Letter serves as a summary of the key elements of the full protocol.
FAU - Maskin, Luis Patricio
AU  - Maskin LP
AUID- ORCID: http://orcid.org/0000-0001-7912-7810
AD  - Intensive Care Unit, CEMIC, Buenos Aires, Argentina. pmaskin@cemic.edu.ar.
AD  - Pulmonary Section, Internal Medicine Department, CEMIC, Buenos Aires, Argentina. 
      pmaskin@cemic.edu.ar.
FAU - Olarte, Gabriel Leonardo
AU  - Olarte GL
AD  - Intensive Care Unit, Sanatorio Sagrado Corazon, Buenos Aires, Argentina.
FAU - Palizas, Fernando Jr
AU  - Palizas F Jr
AD  - Intensive Care Unit, Clinica Bazterrica, Buenos Aires, Argentina.
FAU - Velo, Agostina E
AU  - Velo AE
AD  - Intensive Care Unit, CEMIC, Buenos Aires, Argentina.
FAU - Lurbet, Maria Fernanda
AU  - Lurbet MF
AD  - Intensive Care Unit, CEMIC, Buenos Aires, Argentina.
FAU - Bonelli, Ignacio
AU  - Bonelli I
AD  - Intensive Care Unit, CEMIC, Buenos Aires, Argentina.
FAU - Baredes, Natalio D
AU  - Baredes ND
AD  - Intensive Care Unit, Sanatorio Sagrado Corazon, Buenos Aires, Argentina.
FAU - Rodriguez, Pablo Oscar
AU  - Rodriguez PO
AD  - Intensive Care Unit, CEMIC, Buenos Aires, Argentina. prodriguez@cemic.edu.ar.
AD  - Pulmonary Section, Internal Medicine Department, CEMIC, Buenos Aires, Argentina. 
      prodriguez@cemic.edu.ar.
LA  - eng
SI  - ClinicalTrials.gov/NCT04395105
PT  - Clinical Trial Protocol
PT  - Letter
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200826
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Glucocorticoids)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Argentina
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/complications/*drug therapy
MH  - Cross Infection/epidemiology
MH  - Delirium/epidemiology
MH  - Dexamethasone/*administration & dosage
MH  - Glucocorticoids/*administration & dosage
MH  - Humans
MH  - Mortality
MH  - Organ Dysfunction Scores
MH  - Pandemics
MH  - Patient Positioning
MH  - Pneumonia, Viral/complications/*drug therapy
MH  - Prone Position
MH  - Respiration, Artificial/statistics & numerical data
MH  - Respiratory Distress Syndrome/*drug therapy/etiology
MH  - SARS-CoV-2
MH  - Virus Shedding
PMC - PMC7447582
OTO - NOTNLM
OT  - COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised
      controlled trial, protocol, Steroids
EDAT- 2020/08/28 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/07/28 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - 10.1186/s13063-020-04646-y [doi]
AID - 10.1186/s13063-020-04646-y [pii]
PST - epublish
SO  - Trials. 2020 Aug 26;21(1):743. doi: 10.1186/s13063-020-04646-y.


PMID- 32843069
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20201218
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Aug 25
TI  - COVID-19 and ethics in the ICU.
PG  - 519
LID - 10.1186/s13054-020-03250-5 [doi]
FAU - Nelson, Sarah E
AU  - Nelson SE
AD  - Departments of Neurology and Anesthesiology & Critical Care Medicine, Johns
      Hopkins University, 600 N Wolfe Street, Phipps 455, Baltimore, MD, 21287, USA.
      senelson13@gmail.com.
LA  - eng
PT  - Editorial
DEP - 20200825
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - *Ethics, Medical
MH  - Humans
MH  - Intensive Care Units/*ethics
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - United States/epidemiology
PMC - PMC7447086
EDAT- 2020/08/28 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/06 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
AID - 10.1186/s13054-020-03250-5 [doi]
AID - 10.1186/s13054-020-03250-5 [pii]
PST - epublish
SO  - Crit Care. 2020 Aug 25;24(1):519. doi: 10.1186/s13054-020-03250-5.


PMID- 32843062
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210210
IS  - 1757-7241 (Electronic)
IS  - 1757-7241 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Aug 25
TI  - Residents working with Medecins Sans Frontieres: training and pilot evaluation.
PG  - 86
LID - 10.1186/s13049-020-00778-x [doi]
AB  - BACKGROUND: Well-prepared humanitarian workers are now more necessary than ever. 
      Essential to the preparation process are: clearly defined learning objectives,
      curricula tailored to the nuances of humanitarian settings, simulation-based
      training, and evaluation. This manuscript describes a training program designed
      to prepare medical residents for their first field deployment with Medecins Sans 
      Frontieres and presents the results of a pilot assessment of its effectiveness.
      METHODS: The training was jointly developed by the Research Center in Emergency
      and Disaster Medicine- CRIMEDIM of the Universita del Piemonte Orientale, Novara,
      Italy, and the humanitarian aid organization Medecins Sans Frontieres- Italy
      (MSF-Italy); the following topics were covered: disaster medicine, public health,
      safety and security, infectious diseases, psychological support, communication,
      humanitarian law, leadership, and job-specific skills. It used a blended-learning
      approach consisting of a 3-month distance learning module; 1-week instructor-led 
      coaching; and a field placement with MSF. We assessed its effectiveness using the
      first three levels of Kirkpatrick's training evaluation model. RESULTS: Eight
      residents took part in the evaluation. Four were residents in emergency medicine,
      3 in anesthesia, and 1 in pediatrics; 3 of them were female and the median age
      was 31 years. Two residents were deployed in Pakistan, 1 in Afghanistan, 1 in the
      Democratic Republic of Congo, 1 in Iraq, 2 in Haiti and 1 on board of the MSF
      Mediterranean search & rescue ship. Mean deployment time was 3 months. The
      average median score for the overall course was 5 (excellent). There was a
      significant improvement in post-test multiple choice scores (p = 0.001) and in
      residents' overall performance scores (P = 0.000001). CONCLUSION: Residents were 
      highly satisfied with the training program and their knowledge and skills
      improved as a result of participation. TRIAL REGISTRATION: This study was
      approved by the Institutional Ethics Committee (date 24-02-2016, study code
      UPO.2015.4.10).
FAU - Ripoll-Gallardo, Alba
AU  - Ripoll-Gallardo A
AUID- ORCID: http://orcid.org/0000-0003-4719-7333
AD  - CRIMEDIM, Research Center in Emergency and Disaster Medicine, Universita del
      Piemonte Orientale, Via Lanino 1, PC 28100, Novara, Italy.
      alba.ripoll@med.uniupo.it.
FAU - Ragazzoni, Luca
AU  - Ragazzoni L
AD  - CRIMEDIM, Research Center in Emergency and Disaster Medicine, Universita del
      Piemonte Orientale, Via Lanino 1, PC 28100, Novara, Italy.
FAU - Mazzanti, Ettore
AU  - Mazzanti E
AD  - Medecins Sans Frontieres-Italy, Rome, Italy.
FAU - Meneghetti, Grazia
AU  - Meneghetti G
AD  - CRIMEDIM, Research Center in Emergency and Disaster Medicine, Universita del
      Piemonte Orientale, Via Lanino 1, PC 28100, Novara, Italy.
FAU - Franc, Jeffrey Michael
AU  - Franc JM
AD  - CRIMEDIM, Research Center in Emergency and Disaster Medicine, Universita del
      Piemonte Orientale, Via Lanino 1, PC 28100, Novara, Italy.
AD  - Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
FAU - Costa, Alessandro
AU  - Costa A
AD  - CRIMEDIM, Research Center in Emergency and Disaster Medicine, Universita del
      Piemonte Orientale, Via Lanino 1, PC 28100, Novara, Italy.
FAU - Della Corte, Francesco
AU  - Della Corte F
AD  - CRIMEDIM, Research Center in Emergency and Disaster Medicine, Universita del
      Piemonte Orientale, Via Lanino 1, PC 28100, Novara, Italy.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200825
PL  - England
TA  - Scand J Trauma Resusc Emerg Med
JT  - Scandinavian journal of trauma, resuscitation and emergency medicine
JID - 101477511
SB  - IM
MH  - Adult
MH  - Altruism
MH  - Clinical Competence
MH  - Curriculum
MH  - Female
MH  - Health Resources/supply & distribution
MH  - Humans
MH  - *Internship and Residency
MH  - Italy
MH  - Learning
MH  - Male
MH  - *Medical Missions
MH  - Pilot Projects
MH  - Program Evaluation
PMC - PMC7445931
OTO - NOTNLM
OT  - E-learning
OT  - Education
OT  - Evaluation
OT  - Humanitarian aid
OT  - Low-resource environments
OT  - Residents
OT  - Simulation
OT  - Training
EDAT- 2020/08/28 06:00
MHDA- 2021/02/11 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
AID - 10.1186/s13049-020-00778-x [doi]
AID - 10.1186/s13049-020-00778-x [pii]
PST - epublish
SO  - Scand J Trauma Resusc Emerg Med. 2020 Aug 25;28(1):86. doi:
      10.1186/s13049-020-00778-x.


PMID- 32843051
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220416
IS  - 1478-4505 (Electronic)
IS  - 1478-4505 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Aug 26
TI  - Health technology assessment of biosimilars worldwide: a scoping review.
PG  - 95
LID - 10.1186/s12961-020-00611-y [doi]
AB  - BACKGROUND: Health technology assessment (HTA) should provide an assessment of a 
      technology's effects on health and of the related social, economic,
      organisational and ethical issues. HTA reports on biosimilars can specifically
      assess their immunogenicity, their extrapolation to one or more conditions, and
      the risks of interchangeability and substitution. We aimed to complete a scoping 
      review within the context of HTA organisations to synthesise HTA reports on
      biosimilars and to map the extension, scope and methodological practices. MAIN
      BODY: A scoping review methodology was applied. The sources for biosimilars HTA
      reports were database searches and grey literature from HTA organisation websites
      up to June 2019. HTA reports of biosimilars were classified as full HTA, mini-HTA
      or rapid reviews. Data were extracted and recorded on a calibrated predefined
      data form. We identified 70 HTA reports of biosimilars of 16 biologic products
      (65.71% in 2015-2018) produced by 13 HTA organisations from 10 countries; 2 full 
      HTAs, 4 mini-HTAs and 64 rapid reviews met the inclusion criteria. Almost all the
      rapid reviews gave no information regarding any evidence synthesis method and
      approximately half of the rapid reviews did not appraise the risk of bias of
      primary studies or the overall quality of evidence. All full-HTAs and mini-HTAs
      addressed organisational, ethical, social and legal considerations, while these
      factors were assessed in less than half of the rapid reviews. The immunogenicity 
      and extrapolation of one or more conditions were often considered. The majority
      of full-HTAs and mini-HTAs contained an assessment of switching and a discussion 
      of an educational approach about biosimilars. No HTA report rejected the
      adoption/reimbursement of the biosimilar assessed. CONCLUSION: HTA of biosimilars
      are emerging in the context of HTA organisations and those that exist often
      duplicate reports of the same biosimilar. Most HTA reports of biosimilars do not 
      conduct a systematic literature review or consider economic issues. No report has
      rejected the adoption/reimbursement of biosimilars. There is a need to
      standardise the minimum criteria for the development of HTA on biosimilars to
      ensure a better understanding and better decision-making.
FAU - Ascef, Bruna de Oliveira
AU  - Ascef BO
AUID- ORCID: http://orcid.org/0000-0002-2744-3974
AD  - Preventive Medicine Department, Faculty of Medicine, The University of Sao Paulo,
      Av. Dr. Arnaldo, 455, sala 2228, Sao Paulo, SP, CEP: 01246-903, Brazil.
      brunaascef16@gmail.com.
FAU - Lopes, Ana Carolina de Freitas
AU  - Lopes ACF
AD  - Preventive Medicine Department, Faculty of Medicine, The University of Sao Paulo,
      Av. Dr. Arnaldo, 455, sala 2228, Sao Paulo, SP, CEP: 01246-903, Brazil.
FAU - de Soarez, Patricia Coelho
AU  - de Soarez PC
AD  - Preventive Medicine Department, Faculty of Medicine, The University of Sao Paulo,
      Av. Dr. Arnaldo, 455, sala 2228, Sao Paulo, SP, CEP: 01246-903, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20200826
PL  - England
TA  - Health Res Policy Syst
JT  - Health research policy and systems
JID - 101170481
RN  - 0 (Biosimilar Pharmaceuticals)
SB  - IM
MH  - *Biosimilar Pharmaceuticals
MH  - Humans
MH  - Research Design
MH  - *Technology Assessment, Biomedical
PMC - PMC7448328
OTO - NOTNLM
OT  - Biomedical
OT  - Biosimilar pharmaceuticals
OT  - Evidence-based decisions
OT  - Health policy
OT  - Technology assessment
EDAT- 2020/08/28 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12961-020-00611-y [doi]
AID - 10.1186/s12961-020-00611-y [pii]
PST - epublish
SO  - Health Res Policy Syst. 2020 Aug 26;18(1):95. doi: 10.1186/s12961-020-00611-y.


PMID- 32843035
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1747-5341 (Electronic)
IS  - 1747-5341 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Aug 26
TI  - Why 'understanding' of research may not be necessary for ethical emergency
      research.
PG  - 6
LID - 10.1186/s13010-020-00090-7 [doi]
AB  - BACKGROUND: Randomized controlled trials (RCTs) are central to generating
      knowledge about effectiveness of interventions as well as risk, protective and
      prognostic factors related to diseases in emergency newborn care. Whether
      prospective participants understand the purpose of research, and what they
      perceive as the influence of the context on their understanding of the informed
      consent process for RCTs in emergency obstetric and newborn care are not well
      documented. METHODS: Conceptual review. DISCUSSION: Research is necessary to
      identify how the illnesses may be prevented, to explore the causes, and to
      investigate what medications could be used to manage such illness. Voluntary
      informed consent requires that prospective participants understand the disclose
      information about the research, and use this to make autonomous informed decision
      about participation, in line with their preferences and values. Yet the emergency
      context affects how information may be disclosed to prospective research
      participants, how much participants may comprehend, and how participants may
      express their voluntary decision to participate, all of which pose a threat to
      the validity of the informed consent. I challenge the claim that the
      'understanding' of research is always necessary for ethical informed consent for 
      research during emergency care. I argue for reconceptualization of the value of
      understanding, through recognition of other values that may be equally important.
      I then present a reflective perspective that frames moral reflection about
      autonomy, beneficence and justice in research in emergency research. CONCLUSION: 
      While participant 'understanding' of research is important, it is neither
      necessary nor sufficient for a valid informed consent, and may compete with other
      values with which it needs to be considered.
FAU - Kaye, Dan Kabonge
AU  - Kaye DK
AUID- ORCID: 0000-0003-1490-859X
AD  - College of Health Sciences, Department of Obstetrics and Gynecology, Makerere
      University, P.O. Box 7072, Kampala, Uganda. dankkaye@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200826
PL  - England
TA  - Philos Ethics Humanit Med
JT  - Philosophy, ethics, and humanities in medicine : PEHM
JID - 101258058
SB  - IM
MH  - Biomedical Research/*ethics
MH  - *Comprehension
MH  - *Emergency Medical Services
MH  - Informed Consent
PMC - PMC7448305
EDAT- 2020/08/28 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/06/04 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.1186/s13010-020-00090-7 [doi]
AID - 10.1186/s13010-020-00090-7 [pii]
PST - epublish
SO  - Philos Ethics Humanit Med. 2020 Aug 26;15(1):6. doi: 10.1186/s13010-020-00090-7.


PMID- 32842999
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 26
TI  - Biobanking for glomerular diseases: a study design and protocol for KOrea Renal
      biobank NEtwoRk System TOward NExt-generation analysis (KORNERSTONE).
PG  - 367
LID - 10.1186/s12882-020-02016-z [doi]
AB  - BACKGROUNDS: Glomerular diseases, a set of debilitating and complex disease
      entities, are related to mortality and morbidity. To gain insight into
      pathophysiology and novel treatment targets of glomerular disease, various types 
      of biospecimens linked to deep clinical phenotyping including clinical
      information, digital pathology, and well-defined outcomes are required. We
      provide the rationale and design of the KOrea Renal biobank NEtwoRk System TOward
      Next-generation analysis (KORNERSTONE). METHODS: The KORNERSTONE, which has been 
      initiated by Korea Centres for Disease Control and Prevention, is designed as a
      multi-centre, prospective cohort study and biobank for glomerular diseases.
      Clinical data, questionnaires will be collected at the time of kidney biopsy and 
      subsequently every 1 year after kidney biopsy. All of the clinical data will be
      extracted from the electrical health record and automatically uploaded to the
      web-based database. High-quality digital pathologies are obtained and connected
      in the database. Various types of biospecimens are collected at baseline and
      during follow-up: serum, urine, buffy coat, stool, glomerular complementary DNA
      (cDNA), tubulointerstitial cDNA. All data and biospecimens are processed and
      stored in a standardised manner. The primary outcomes are mortality and end-stage
      renal disease. The secondary outcomes will be deterioration renal function,
      remission of proteinuria, cardiovascular events and quality of life. DISCUSSION: 
      Ethical approval has been obtained from the institutional review board of each
      participating centre and ethics oversight committee. The KORNERSTONE is designed 
      to deliver pioneer insights into glomerular diseases. The study design allows
      comprehensive, integrated and high-quality data collection on baseline laboratory
      findings, clinical outcomes including administrative data and digital pathologic 
      images. This may provide various biospecimens and information to many
      researchers, establish the rationale for future more individualised treatment
      strategies for glomerular diseases. TRIAL REGISTRATION: NCT03929887 .
FAU - Kang, Eunjeong
AU  - Kang E
AD  - Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha
      Womans University College of Medicine, Seoul, South Korea.
FAU - Kim, Yaerim
AU  - Kim Y
AD  - Department of Internal Medicine, Keimyung University School of Medicine, Daegu,
      South Korea.
FAU - Kim, Yong Chul
AU  - Kim YC
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Kim, Eunyoung
AU  - Kim E
AD  - Seoul National University Hospital Clinical Trial Centre, Seoul, South Korea.
FAU - Lee, Nankyoung
AU  - Lee N
AD  - Seoul National University Hospital Human Biobank, Seoul, South Korea.
FAU - Kim, Yeonghui
AU  - Kim Y
AD  - Division of Nephrology, Department of Internal Medicine, Keimyung University
      Dongsan Hospital, Daegu, South Korea.
FAU - Lee, Soojin
AU  - Lee S
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Han, Seungyeup
AU  - Han S
AD  - Department of Internal Medicine, Keimyung University School of Medicine, Daegu,
      South Korea.
FAU - Choe, Misun
AU  - Choe M
AD  - Department of Pathology, Keimyung University School of Medicine, Daegu, South
      Korea.
FAU - Hwang, Jin Ho
AU  - Hwang JH
AD  - Department of Internal Medicine, Chung-Ang University Hospital, Seoul, South
      Korea.
FAU - Lee, Sunhwa
AU  - Lee S
AD  - Division of Nephrology, Department of Medicine, Kangwon National University
      Hospital, Kangwon National University School of Medicine, Chuncheon, Gangwon-do, 
      South Korea.
FAU - Park, Ji In
AU  - Park JI
AD  - Division of Nephrology, Department of Medicine, Kangwon National University
      Hospital, Kangwon National University School of Medicine, Chuncheon, Gangwon-do, 
      South Korea.
FAU - Park, Jung Tak
AU  - Park JT
AD  - Department of Internal Medicine, College of Medicine, Institute of Kidney Disease
      Research, Yonsei University, Seoul, South Korea.
FAU - Lim, Beom Jin
AU  - Lim BJ
AD  - Department of Pathology, Yonsei University College of Medicine, Seoul, South
      Korea.
FAU - Lee, Jung Pyo
AU  - Lee JP
AD  - Department of Internal Medicine Seoul National University Boramae Medical Center,
      Seoul National University College of Medicine, Seoul, South Korea.
FAU - An, Jung Nam
AU  - An JN
AD  - Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang,
      South Korea.
FAU - Ryu, Dong-Ryeol
AU  - Ryu DR
AD  - Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha
      Womans University College of Medicine, Seoul, South Korea.
FAU - Kim, Jung-Hyun
AU  - Kim JH
AD  - Department of Home Economics Education, Major of Food and Nutrition, Pai Chai
      University, Daejeon, South Korea.
FAU - Kang, Hee Gyung
AU  - Kang HG
AD  - Department of Paediatrics, Seoul National University Children's Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Lee, Hyun Soon
AU  - Lee HS
AD  - Department of Pathology, Hankook Renal Pathology Lab, Seoul, South Korea.
FAU - Moon, Kyung Chul
AU  - Moon KC
AD  - Department of Pathology, Seoul National University Hospital, Seoul National
      University College of Medicine, Seoul, South Korea.
FAU - Joo, Kwon Wook
AU  - Joo KW
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Oh, Kook-Hwan
AU  - Oh KH
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Han, Seung Seok
AU  - Han SS
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Lee, Hajeong
AU  - Lee H
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea.
FAU - Kim, Dong Ki
AU  - Kim DK
AUID- ORCID: 0000-0002-5195-7852
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul
      National University College of Medicine, Seoul, South Korea. dkkim73@gmail.com.
CN  - KORNERSTONE Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03929887
GR  - #4845-303/Korea Centers for Disease Control and Prevention/International
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
SB  - IM
MH  - *Biological Specimen Banks
MH  - *Databases, Factual
MH  - Glomerulonephritis/genetics/metabolism/*pathology/therapy
MH  - Humans
MH  - Kidney/*pathology
MH  - Kidney Failure, Chronic/metabolism/*pathology/therapy
MH  - Patient Outcome Assessment
MH  - Renal Replacement Therapy
MH  - Republic of Korea
PMC - PMC7448429
OTO - NOTNLM
OT  - *Glomerulonephritis
OT  - *Nephrology
OT  - *Pathology
IR  - Lee JP
FIR - Lee, Jung Pyo
IR  - An JN
FIR - An, Jung Nam
IR  - Lee J
FIR - Lee, Jeonghwan
IR  - Park J
FIR - Park, Jeonghwan
IR  - Kim M
FIR - Kim, Minjung
IR  - Kim T
FIR - Kim, Taekyoung
IR  - Kim J
FIR - Kim, Jinhyuk
IR  - Hwang JH
FIR - Hwang, Jin Ho
IR  - Park EA
FIR - Park, Eun A
IR  - Park E
FIR - Park, Eunji
IR  - In Park J
FIR - In Park, Ji
IR  - Lee SH
FIR - Lee, Sun Hwa
IR  - Park S
FIR - Park, Soyeong
IR  - Koh N
FIR - Koh, Nayoung
IR  - Han S
FIR - Han, Seungyeup
IR  - Kim Y
FIR - Kim, Yaerim
IR  - Choe M
FIR - Choe, Misun
IR  - Kim Y
FIR - Kim, Yeonghui
IR  - Kim DK
FIR - Kim, Dong Ki
IR  - Joo KW
FIR - Joo, Kwon Wook
IR  - Oh KH
FIR - Oh, Kook-Hwan
IR  - Lee H
FIR - Lee, Hajeong
IR  - Han SS
FIR - Han, Seung Seok
IR  - Kim YC
FIR - Kim, Yong Chul
IR  - Kang E
FIR - Kang, Eunjeong
IR  - Lee S
FIR - Lee, Soojin
IR  - Moon KC
FIR - Moon, Kyung Chul
IR  - Kang HG
FIR - Kang, Hee Gyung
IR  - Kim E
FIR - Kim, Eunyoung
IR  - Kim J
FIR - Kim, Junghee
IR  - Park JH
FIR - Park, Ji Hye
IR  - Jeon JW
FIR - Jeon, Ji Won
IR  - Park JT
FIR - Park, Jung Tak
IR  - Lim BJ
FIR - Lim, Beom Jin
IR  - Kim HW
FIR - Kim, Hyung Woo
IR  - Joo YS
FIR - Joo, Young Su
IR  - Kim K
FIR - Kim, Kyungjoon
IR  - Nam BY
FIR - Nam, Bo Young
IR  - Kim E
FIR - Kim, Eunyoung
IR  - Lee N
FIR - Lee, Nankyoung
EDAT- 2020/08/28 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/08/27 06:00
PHST- 2019/12/21 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
AID - 10.1186/s12882-020-02016-z [doi]
AID - 10.1186/s12882-020-02016-z [pii]
PST - epublish
SO  - BMC Nephrol. 2020 Aug 26;21(1):367. doi: 10.1186/s12882-020-02016-z.


PMID- 32842881
OWN - NLM
STAT- Publisher
LR  - 20200925
IS  - 1541-3764 (Electronic)
IS  - 0030-2228 (Linking)
DP  - 2020 Aug 25
TI  - Ethics Trade-Off Between Hazards Prevention and the Safeguard of Death Dignity
      During COVID-19.
PG  - 30222820950890
LID - 10.1177/0030222820950890 [doi]
AB  - Urgent measures established to contain the transmission of COVID-19 and prevent
      biological hazards included very restrictive interventions on public Holy Masses 
      and funerals. Italy banned any burial procedure and the decision particularly
      affected both catholic and islamic communities. The dignity of death and the
      religious competence as cultural competence during COVID-19 epidemic represent
      important aspects of the epidemic preparedness. This article provides relevant
      considerations about the topic from an ethical perspective.
FAU - Logar, Silvia
AU  - Logar S
AUID- ORCID: https://orcid.org/0000-0002-6047-9485
AD  - School of Social Sciences, Humanities & Law, Teesside University, Middlesbrough, 
      UK.
FAU - Leese, Maggie
AU  - Leese M
AD  - School of Social Sciences, Humanities & Law, Teesside University, Middlesbrough, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - United States
TA  - Omega (Westport)
JT  - Omega
JID - 1272106
SB  - IM
OTO - NOTNLM
OT  - COVID-19
OT  - burial
OT  - death
OT  - dignity
OT  - pandemic
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/08/27 06:00 [entrez]
AID - 10.1177/0030222820950890 [doi]
PST - aheadofprint
SO  - Omega (Westport). 2020 Aug 25:30222820950890. doi: 10.1177/0030222820950890.


PMID- 32842847
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2150-5608 (Electronic)
IS  - 2150-5594 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec
TI  - Tobacco Hornworm (Manduca sexta) caterpillars as a novel host model for the study
      of fungal virulence and drug efficacy.
PG  - 1075-1089
LID - 10.1080/21505594.2020.1806665 [doi]
AB  - The two leading yeast pathogens of humans, Candida albicans and Cryptococcus
      neoformans, cause systemic infections in >1.4 million patients worldwide with
      mortality rates approaching 75%. It is thus imperative to study fungal virulence 
      mechanisms, efficacy of antifungal drugs, and host response pathways. While this 
      is commonly done in mammalian models, which are afflicted by ethical and
      practical concerns, invertebrate models, such as wax moth larvae and nematodes
      have been introduced over the last two decades. To complement existing
      invertebrate host models, we developed fifth instar caterpillars of the Tobacco
      Hornworm moth Manduca sexta as a novel host model. These caterpillars can be
      maintained at 37 degrees C, are suitable for injections with defined amounts of
      yeast cells, and are susceptible to the most threatening yeast pathogens,
      including C. albicans, C. neoformans, C. auris, and C. glabrata. Importantly,
      fungal burden can be assessed daily throughout the course of infection in a
      single caterpillar's feces and hemolymph. Infected caterpillars can be rescued by
      treatment with antifungal drugs. Notably, these animals are large enough for
      weight to provide a reliable and reproducible measure of fungal disease and to
      facilitate host tissue-specific expression analyses. M. sexta caterpillars
      combine a suite of parameters that make them suitable for the study of fungal
      virulence.
FAU - Lyons, Naomi
AU  - Lyons N
AD  - School of Molecular Cell Biology and Biotechnology, Tel Aviv University , Tel
      Aviv, Israel.
AD  - Department of Biology & Biochemistry, University of Bath , Bath, UK.
FAU - Softley, Isabel
AU  - Softley I
AD  - Department of Biology & Biochemistry, University of Bath , Bath, UK.
FAU - Balfour, Andrew
AU  - Balfour A
AD  - Department of Biology & Biochemistry, University of Bath , Bath, UK.
FAU - Williamson, Carolyn
AU  - Williamson C
AD  - Department of Biology & Biochemistry, University of Bath , Bath, UK.
FAU - O'Brien, Heath E
AU  - O'Brien HE
AD  - MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological
      Medicine & Clinical Neurosciences, Cardiff University , Cardiff, UK.
FAU - Shetty, Amol C
AU  - Shetty AC
AD  - Institute for Genome Sciences, University of Maryland School of Medicine ,
      Baltimore, MD, USA.
FAU - Bruno, Vincent M
AU  - Bruno VM
AD  - Institute for Genome Sciences, University of Maryland School of Medicine ,
      Baltimore, MD, USA.
FAU - Diezmann, Stephanie
AU  - Diezmann S
AD  - Department of Biology & Biochemistry, University of Bath , Bath, UK.
AD  - School of Cellular and Molecular Medicine, University of Bristol , Bristol, UK.
LA  - eng
GR  - U19 AI110820/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Virulence
JT  - Virulence
JID - 101531386
SB  - IM
MH  - Animals
MH  - *Disease Models, Animal
MH  - Fungi/*pathogenicity
MH  - Gene Expression Profiling
MH  - Larva/microbiology
MH  - *Manduca/genetics/microbiology
MH  - Mycoses/*microbiology
MH  - Virulence
PMC - PMC7549948
OTO - NOTNLM
OT  - * Candida
OT  - * Cryptococcus
OT  - * Manduca sexta
OT  - * Metschnikowia
OT  - * Saccharomyces
OT  - *antifungal drug
OT  - *caterpillar
OT  - *fungal burden
OT  - *fungal virulence
OT  - *host model
EDAT- 2020/08/28 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
AID - 10.1080/21505594.2020.1806665 [doi]
PST - ppublish
SO  - Virulence. 2020 Dec;11(1):1075-1089. doi: 10.1080/21505594.2020.1806665.


PMID- 32842434
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201210
IS  - 1671-0274 (Print)
IS  - 1671-0274 (Linking)
VI  - 23
IP  - 5
DP  - 2020 May 25
TI  - [Indication selection and clinical application strategies of fecal microbiota
      transplantation].
PG  - 509-515
LID - 10.3760/cma.j.cn.441530-20200110-00015 [doi]
AB  - Fecal microbiota transplant (FMT) has become an effective method for the
      treatment of recurrent C. difficile infection. In addition, it has shown certain 
      effects in other diseases inside and outside the intestine. A large number of
      clinical trials have been carried out. However, there is still lack of uniform
      standard for strategies of FMT. In this paper, we discussed the current hot and
      controversial issues of FMT from the aspects of indication, donor screening,
      fecal suspension quality control, methodology, follow-up and efficacy judgment,
      treatment of adverse reaction and ethical supervision based on our team's
      clinical experience.
FAU - Zhang, X Y
AU  - Zhang XY
AD  - Intestinal Microenvironment Treatment Center, the Tenth People's Hospital,
      Institute for Intestinal Diseases, Medical School of Tongji University, Shanghai 
      200072, China.
FAU - Chen, Q Y
AU  - Chen QY
AD  - Intestinal Microenvironment Treatment Center, the Tenth People's Hospital,
      Institute for Intestinal Diseases, Medical School of Tongji University, Shanghai 
      200072, China.
FAU - Li, N
AU  - Li N
AD  - Intestinal Microenvironment Treatment Center, the Tenth People's Hospital,
      Institute for Intestinal Diseases, Medical School of Tongji University, Shanghai 
      200072, China.
FAU - Qin, H L
AU  - Qin HL
AD  - Intestinal Microenvironment Treatment Center, the Tenth People's Hospital,
      Institute for Intestinal Diseases, Medical School of Tongji University, Shanghai 
      200072, China.
LA  - chi
GR  - SHDC12017112, SHDC12019114/Emerging Cutting-Edge Technology Joint Research
      Projects of Shanghai
PT  - Journal Article
PL  - China
TA  - Zhonghua Wei Chang Wai Ke Za Zhi
JT  - Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
JID - 101177990
SB  - IM
MH  - Clostridioides difficile/*isolation & purification
MH  - Clostridium Infections/*therapy
MH  - Donor Selection
MH  - Fecal Microbiota Transplantation/adverse effects/*methods/standards
MH  - Feces/microbiology
MH  - Humans
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Clinical strategy
OT  - Donor screening
OT  - Fecal microbiota transplantation
OT  - Indications
OT  - Quality control
EDAT- 2020/08/28 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/27 06:00
PHST- 2020/08/27 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.3760/cma.j.cn.441530-20200110-00015 [doi]
PST - ppublish
SO  - Zhonghua Wei Chang Wai Ke Za Zhi. 2020 May 25;23(5):509-515. doi:
      10.3760/cma.j.cn.441530-20200110-00015.


PMID- 35296118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220319
IS  - 2673-3080 (Electronic)
IS  - 2673-3080 (Linking)
VI  - 2
DP  - 2020
TI  - Covid-19 Misinformation Alert, or: "Wash Your Hands and Eat Your Veggies!"
PG  - 4
LID - 10.3389/ftox.2020.00004 [doi]
FAU - Fadeel, Bengt
AU  - Fadeel B
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200828
PL  - Switzerland
TA  - Front Toxicol
JT  - Frontiers in toxicology
JID - 101777990
PMC - PMC8915854
OTO - NOTNLM
OT  - COVID-19
OT  - pandemic
OT  - preprints
OT  - research ethics
OT  - retractions
EDAT- 2020/08/28 00:00
MHDA- 2020/08/28 00:01
CRDT- 2022/03/17 05:20
PHST- 2020/07/01 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2022/03/17 05:20 [entrez]
PHST- 2020/08/28 00:00 [pubmed]
PHST- 2020/08/28 00:01 [medline]
AID - 10.3389/ftox.2020.00004 [doi]
PST - epublish
SO  - Front Toxicol. 2020 Aug 28;2:4. doi: 10.3389/ftox.2020.00004. eCollection 2020.


PMID- 32842058
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210208
IS  - 1532-3145 (Electronic)
IS  - 0363-8715 (Linking)
VI  - 44
IP  - 5
DP  - 2020 Sep/Oct
TI  - Computed Tomography Radiomics Can Predict Disease Severity and Outcome in
      Coronavirus Disease 2019 Pneumonia.
PG  - 640-646
LID - 10.1097/RCT.0000000000001094 [doi]
AB  - PURPOSE: This study aimed to assess if computed tomography (CT) radiomics can
      predict the severity and outcome of patients with coronavirus disease 2019
      (COVID-19) pneumonia. METHODS: This institutional ethical board-approved study
      included 92 patients (mean age, 59 +/- 17 years; 57 men, 35 women) with positive 
      reverse transcription polymerase chain reaction assay for COVID-19 infection who 
      underwent noncontrast chest CT. Two radiologists evaluated all chest CT
      examinations and recorded opacity type, distribution, and extent of lobar
      involvement. Information on symptom duration before hospital admission, the
      period of hospital admission, presence of comorbid conditions, laboratory data,
      and outcomes (recovery or death) was obtained from the medical records. The
      entire lung volume was segmented on thin-section Digital Imaging and
      Communication in Medicine images to derive whole-lung radiomics. Data were
      analyzed using multiple logistic regression with receiver operator characteristic
      area under the curve (AUC) as the output. RESULTS: Computed tomography radiomics 
      (AUC, 0.99) outperformed clinical variables (AUC, 0.89) for prediction of the
      extent of pulmonary opacities related to COVID-19 pneumonia. Type of pulmonary
      opacities could be predicted with CT radiomics (AUC, 0.77) but not with clinical 
      or laboratory data (AUC, <0.56; P > 0.05). Prediction of patient outcome with
      radiomics (AUC, 0.85) improved to an AUC of 0.90 with the addition of clinical
      variables (patient age and duration of presenting symptoms before admission).
      Among clinical variables, the combination of peripheral capillary oxygen
      saturation on hospital admission, duration of symptoms, platelet counts, and
      patient age provided an AUC of 0.81 for predicting patient outcomes. CONCLUSIONS:
      Radiomics from noncontrast CT reliably predict disease severity (AUC, 0.99) and
      outcome (AUC, 0.85) in patients with COVID-19 pneumonia.
FAU - Homayounieh, Fatemeh
AU  - Homayounieh F
AD  - From the Department of Radiology, Massachusetts General Hospital and the Harvard 
      Medical School, Boston, MA.
FAU - Babaei, Rosa
AU  - Babaei R
AD  - Department of Radiology, Firoozgar Hospital and Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Karimi Mobin, Hadi
AU  - Karimi Mobin H
AD  - Department of Radiology, Firoozgar Hospital and Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Arru, Chiara D
AU  - Arru CD
AD  - From the Department of Radiology, Massachusetts General Hospital and the Harvard 
      Medical School, Boston, MA.
FAU - Sharifian, Maedeh
AU  - Sharifian M
AD  - Department of Radiology, Firoozgar Hospital and Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Mohseni, Iman
AU  - Mohseni I
AD  - Department of Radiology, Firoozgar Hospital and Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Zhang, Eric
AU  - Zhang E
AD  - From the Department of Radiology, Massachusetts General Hospital and the Harvard 
      Medical School, Boston, MA.
FAU - Digumarthy, Subba R
AU  - Digumarthy SR
AD  - From the Department of Radiology, Massachusetts General Hospital and the Harvard 
      Medical School, Boston, MA.
FAU - Kalra, Mannudeep K
AU  - Kalra MK
AD  - From the Department of Radiology, Massachusetts General Hospital and the Harvard 
      Medical School, Boston, MA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Comput Assist Tomogr
JT  - Journal of computer assisted tomography
JID - 7703942
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*diagnosis
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Lung/*diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Severity of Illness Index
MH  - Tomography, X-Ray Computed/*methods
EDAT- 2020/08/26 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1097/RCT.0000000000001094 [doi]
AID - 00004728-202009000-00003 [pii]
PST - ppublish
SO  - J Comput Assist Tomogr. 2020 Sep/Oct;44(5):640-646. doi:
      10.1097/RCT.0000000000001094.


PMID- 32841903
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 264
DP  - 2020 Nov
TI  - Using an ethics of care lens to understand the place of community health workers 
      in Rwanda's maternal healthcare system.
PG  - 113297
LID - S0277-9536(20)30516-5 [pii]
LID - 10.1016/j.socscimed.2020.113297 [doi]
AB  - This study explores the informal care roles involved in the delivery of maternal 
      health services by Rwanda's elected maternal community health workers. We
      conducted semi-structured interviews with 20 such workers in five Rwandan
      districts to explore their understandings of why they were elected for this
      voluntary position; what motivates them to fulfill their responsibilities; and
      their experiences of providing maternal health services in a resource-limited
      context. Thematically exploring the findings using an ethics of care lens, we
      highlight how responsibility, vulnerability and mutuality inform the place of
      these workers' roles in the maternal care system and their villages. We conclude 
      by acknowledging the significant responsibilities assigned by these works and
      that the burden that may result from taking on such care may negatively affect
      the sustainability of this initiative.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Tuyisenge, Germaine
AU  - Tuyisenge G
AD  - Department of Geography, Simon Fraser University, Burnaby, Canada. Electronic
      address: gtuyisen@sfu.ca.
FAU - Crooks, Valorie A
AU  - Crooks VA
AD  - Department of Geography, Simon Fraser University, Burnaby, Canada. Electronic
      address: valorie_crooks@sfu.ca.
FAU - Berry, Nicole S
AU  - Berry NS
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. Electronic 
      address: nicole_berry@sfu.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200819
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - *Community Health Workers
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - *Maternal Health Services
MH  - Pregnancy
MH  - Rwanda
MH  - Social Behavior
OTO - NOTNLM
OT  - *Community health workers
OT  - *Ethics of care
OT  - *Informal care
OT  - *Maternal care
OT  - *Mutuality
OT  - *Responsibility
OT  - *Rwanda
OT  - *Vulnerability
EDAT- 2020/08/26 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - S0277-9536(20)30516-5 [pii]
AID - 10.1016/j.socscimed.2020.113297 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Nov;264:113297. doi: 10.1016/j.socscimed.2020.113297. Epub 2020
      Aug 19.


PMID- 32841726
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 82
DP  - 2020 Oct
TI  - Neck transection level and postoperative pancreatic fistula after
      pancreaticoduodenectomy: A retrospective cohort study of 195 patients.
PG  - 43-50
LID - S1743-9191(20)30596-3 [pii]
LID - 10.1016/j.ijsu.2020.08.001 [doi]
AB  - BACKGROUND: The aim of this study was to evaluate the impact of the level of neck
      transection on clinically relevant postoperative pancreatic fistula (CR-POPF)
      after standard pancreaticoduodenectomy (PD) with pancreaticojejunostomy. METHOD: 
      A total of 195 patients with an early postoperative CT scan were retrospectively 
      analyzed and divided into 2 groups (CR-POPF and No CR-POPF) in order to seek
      potential risk factors for CR-POPF. We focused our analysis on the relationship
      between CR-POPF and the level of neck transection, defined by measuring the
      distance between the left side of the portal vein and the remnant pancreatic
      stump on the postoperative CT scan. RESULT: CR-POPF occurred in 58 out of 195 PD 
      (29.7%); grade B (17%) and grade C (12.7%). The Clavien-Dindo >/= 3 morbidity
      rate was 33% (65/195) and the mortality rate was 2.5% (5/195). Multivariate
      analysis indicated that a 'right-sided' level of neck transection (P = 0.007), a 
      firm pancreatic texture (P = 0.001), and a PD for non-pancreatic ductal
      adenocarcinoma histology (P = 0.032) were independent risk factors for CR-POPF. A
      full neck resection with systematic transection >/=7 mm at the left side of the
      portal vein seems to prevent CR-POPF harboring a protective effect (OR 0.056; 95%
      CI 0.003 to 0.978; P = 0.039). CONCLUSION: Here we further consolidate the
      concept describing the pancreatic neck as a vascular watershed, showing that a
      long remnant pancreatic neck could be an independent risk factor for CR-POPF
      after PD (NCT03850236). TRIAL REGISTRATION NUMBER AND AGENCY: The present study
      was approved by our local ethics committee and was declared on ClinicalTrials.gov
      (ID: NCT03850236).
CI  - Copyright (c) 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All
      rights reserved.
FAU - Bardol, Thomas
AU  - Bardol T
AD  - Department of Digestive Surgery and Transplantation, University Hospital Center, 
      Montpellier-Nimes University, 641 Avenue Du Doyen Gaston Giraud, 34090,
      Montpellier, France. Electronic address: t-bardol@chu-montpellier.fr.
FAU - Delicque, Julien
AU  - Delicque J
AD  - Department of Radiology, University Hospital Center, Montpellier-Nimes
      University, 641 Avenue Du Doyen Gaston Giraud, 34090, Montpellier, France.
FAU - Hermida, Margaux
AU  - Hermida M
AD  - Department of Radiology, University Hospital Center, Montpellier-Nimes
      University, 641 Avenue Du Doyen Gaston Giraud, 34090, Montpellier, France.
FAU - Herrero, Astrid
AU  - Herrero A
AD  - Department of Digestive Surgery and Transplantation, University Hospital Center, 
      Montpellier-Nimes University, 641 Avenue Du Doyen Gaston Giraud, 34090,
      Montpellier, France.
FAU - Guiu, Boris
AU  - Guiu B
AD  - Department of Radiology, University Hospital Center, Montpellier-Nimes
      University, 641 Avenue Du Doyen Gaston Giraud, 34090, Montpellier, France.
FAU - Fabre, Jean-Michel
AU  - Fabre JM
AD  - Department of Digestive Surgery and Transplantation, University Hospital Center, 
      Montpellier-Nimes University, 641 Avenue Du Doyen Gaston Giraud, 34090,
      Montpellier, France.
FAU - Souche, Regis
AU  - Souche R
AD  - Department of Digestive Surgery and Transplantation, University Hospital Center, 
      Montpellier-Nimes University, 641 Avenue Du Doyen Gaston Giraud, 34090,
      Montpellier, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03850236
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200822
PL  - England
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neck/diagnostic imaging/*surgery
MH  - Pancreas/surgery
MH  - Pancreatectomy/adverse effects
MH  - Pancreatic Fistula/diagnostic imaging/*etiology
MH  - Pancreaticoduodenectomy/*adverse effects
MH  - Pancreaticojejunostomy/*adverse effects
MH  - Postoperative Complications/diagnostic imaging/*etiology
MH  - Postoperative Period
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - Pancreas
OT  - Pancreatic fistula
OT  - Pancreatic neck
OT  - Pancreaticoduodenectomy
OT  - Vascular watershed
EDAT- 2020/08/26 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - S1743-9191(20)30596-3 [pii]
AID - 10.1016/j.ijsu.2020.08.001 [doi]
PST - ppublish
SO  - Int J Surg. 2020 Oct;82:43-50. doi: 10.1016/j.ijsu.2020.08.001. Epub 2020 Aug 22.


PMID- 32841078
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20220416
IS  - 2052-286X (Electronic)
IS  - 1357-6321 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Aug 2
TI  - Palliative and end-of-life care in Egypt: overview and recommendations for
      improvement.
PG  - 284-291
LID - 10.12968/ijpn.2020.26.6.284 [doi]
AB  - BACKGROUND: The literature on the situation of palliative and end-of-life care in
      the Arab and Islamic world, including Egypt, is limited and does not present a
      clear picture of the cultural context. This report aims to portray the palliative
      and end-of-life care situation in Egypt, focusing on the nursing viewpoint.
      First, we describe health- and illness-related cultural, religious, and ethical
      issues. Second, we present an overview of the healthcare and nursing system in
      Egypt. Third, we discuss the situation of palliative and end-of-life care,
      highlighting the shortcomings of existing literature. Finally, we delineate
      country-specific recommendations to improve the palliative and end-of-life care
      situation at the level of policy, education, and research. Countries with similar
      healthcare, cultural, legal, religious, economic, or ethical contexts may benefit
      from the recommendations made in this study.
FAU - Eltaybani, Sameh
AU  - Eltaybani S
AD  - PhD Candidate, Department of Palliative Care Nursing, Graduate School of
      Medicine, University of Tokyo, and Assistant Lecturer, Department of Critical
      Care and Emergency Nursing, Faculty of Nursing, Alexandria University, Egypt.
FAU - Igarashi, Ayumi
AU  - Igarashi A
AD  - Assistant Professor, Department of Gerontological Home Care and Long-Term Care
      Nursing, University of Tokyo, Japan.
FAU - Yamamoto-Mitani, Noriko
AU  - Yamamoto-Mitani N
AD  - Professor, Department of Gerontological Home Care and Long-Term Care Nursing,
      University of Tokyo, Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Palliat Nurs
JT  - International journal of palliative nursing
JID - 9506762
MH  - Attitude to Death/ethnology
MH  - Attitude to Health/ethnology
MH  - Culture
MH  - *Education, Nursing
MH  - Egypt
MH  - *Health Education
MH  - *Health Policy
MH  - *Hospice and Palliative Care Nursing
MH  - Humans
MH  - *Palliative Care
MH  - Quality Improvement
MH  - Research
MH  - *Terminal Care
OTO - NOTNLM
OT  - Arab
OT  - Egypt
OT  - End-of-life
OT  - Islam
OT  - Palliative care
EDAT- 2020/08/26 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
AID - 10.12968/ijpn.2020.26.6.284 [doi]
PST - ppublish
SO  - Int J Palliat Nurs. 2020 Aug 2;26(6):284-291. doi: 10.12968/ijpn.2020.26.6.284.


PMID- 32840858
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Pandemic Surveillance and Racialized Subpopulations: Mitigating Vulnerabilities
      in COVID-19 Apps.
PG  - 829-834
LID - 10.1007/s11673-020-10034-7 [doi]
AB  - Debates about effective responses to the COVID-19 pandemic have emphasized the
      paramount importance of digital tracing technology in suppressing the disease. So
      far, discussions about the ethics of this technology have focused on privacy
      concerns, efficacy, and uptake. However, important issues regarding power
      imbalances and vulnerability also warrant attention. As demonstrated in other
      forms of digital surveillance, vulnerable subpopulations pay a higher price for
      surveillance measures. There is reason to worry that some types of COVID-19
      technology might lead to the employment of disproportionate profiling, policing, 
      and criminalization of marginalized groups. It is, thus, of crucial importance to
      interrogate vulnerability in COVID-19 apps and ensure that the development,
      implementation, and data use of this surveillance technology avoids exacerbating 
      vulnerability and the risk of harm to surveilled subpopulations, while
      maintaining the benefits of data collection across the whole population. This
      paper outlines the major challenges and a set of values that should be taken into
      account when implementing disease surveillance technology in the pandemic
      response.
FAU - Hendl, Tereza
AU  - Hendl T
AD  - Institute of Ethics, History and Theory of Medicine,
      Ludwig-Maximilians-University in Munich, Lessingstr. 2, 80336, Munich, Germany.
      tereza.hendl@med.uni-muenchen.de.
FAU - Chung, Ryoa
AU  - Chung R
AD  - Department of Philosophy, Universite de Montreal, C.P. 6128, succ. Centre-Ville, 
      Montreal, Quebec, H3C 3J7, Canada.
FAU - Wild, Verina
AU  - Wild V
AD  - Institute of Ethics, History and Theory of Medicine,
      Ludwig-Maximilians-University in Munich, Lessingstr. 2, 80336, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
EIN - J Bioeth Inq. 2021 Sep;18(3):535. PMID: 34661848
MH  - COVID-19
MH  - *Digital Technology
MH  - Health Status Disparities
MH  - Humans
MH  - *Pandemics
MH  - *Population Surveillance
MH  - *Racial Groups
MH  - SARS-CoV-2
MH  - Social Marginalization
MH  - Technology
PMC - PMC7445800
OTO - NOTNLM
OT  - COVID-19
OT  - Digital health technologies
OT  - Equity
OT  - Justice
OT  - Pandemic disease surveillance
OT  - Racial inequality
OT  - Racialized subpopulations
OT  - Solidarity COVID-19 apps
OT  - Vulnerability
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10034-7 [doi]
AID - 10.1007/s11673-020-10034-7 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):829-834. doi: 10.1007/s11673-020-10034-7. Epub 2020 
      Aug 25.


PMID- 32840857
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Clever COVID-19, Clever Citizens-98: Critical and Creative Reflections from
      Tehran, Toronto, and Sydney.
PG  - 619-625
LID - 10.1007/s11673-020-10032-9 [doi]
AB  - Our world suffers. Some people suffer more than others. Since the first part of
      2020, ours is justly described as a time of uncertainty, threat, and upheaval. In
      this article, we offer reflections threaded narratively, told from the
      specificity of our societal contexts in Iran, Canada, and Australia. What might
      we learn in the present and anticipated future from people living chronically
      within conditions of uncertainty and immobility and also those experiencing
      uncertainty and immobility for the first time? We argue that reflexive
      comparative analysis bridging social and visual analysis, anchored in embodied
      conditions of such people, offers a way to learn from responses to COVID-19 while
      also being an exercise in ethical research practice. This reflection builds on
      and extends from our scholarly collaborations that have been ongoing since 2015. 
      Our title recognizes this specific virus as stealthy. Importantly, our choice of 
      words identifies resident Iranians-whose experiences were the original impetuses 
      for this paper, and whose lives provide its empirical basis (98 is Iran's country
      code)-as equally steely.
FAU - Bisaillon, Laura
AU  - Bisaillon L
AUID- ORCID: http://orcid.org/0000-0001-5017-0655
AD  - Department of Health and Society, University of Toronto Scarborough, 1265
      Military Trail, Toronto, Ontario, M1C 1A4, Canada. Laura.bisaillon@utoronto.ca.
FAU - Khosravi, Mehdi
AU  - Khosravi M
AD  - Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Jahandoost, Bahareh
AU  - Jahandoost B
AD  - Tehran University of Fine Arts, Tehran, Iran.
FAU - Briskman, Linda
AU  - Briskman L
AD  - Western Sydney University, Penrith, NSW, 2751, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Activities of Daily Living
MH  - COVID-19/*epidemiology/*psychology
MH  - *Cultural Characteristics
MH  - Female
MH  - Humans
MH  - Iran/epidemiology
MH  - Male
MH  - New South Wales/epidemiology
MH  - Ontario/epidemiology
MH  - Physical Distancing
MH  - *Social Control, Formal
MH  - *Uncertainty
PMC - PMC7445823
OTO - NOTNLM
OT  - Australia
OT  - COVID-19
OT  - Canada
OT  - Immobility
OT  - Iran
OT  - Material conditions
OT  - Movement
OT  - Social analysis
OT  - Social suffering
OT  - Visual analysis
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10032-9 [doi]
AID - 10.1007/s11673-020-10032-9 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):619-625. doi: 10.1007/s11673-020-10032-9. Epub 2020 
      Aug 25.


PMID- 32840856
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and
      Risks.
PG  - 709-715
LID - 10.1007/s11673-020-10030-x [doi]
AB  - Human infection challenge studies (HCS) have been proposed as a means to
      accelerate SARS-CoV2 vaccine development and thereby help to mitigate a prolonged
      global public health crisis. A key criterion for the ethical acceptability of
      SARS-CoV2 HCS is that potential benefits outweigh risks. Although the assessment 
      of risks and benefits is meant to be a standard part of research ethics review,
      systematic comparisons are particularly important in the context of SARS-CoV2 HCS
      in light of the significant potential benefits and harms at stake as well as the 
      need to preserve public trust in research and vaccines. In this paper we explore 
      several considerations that should inform systematic assessment of SARS-CoV-2
      HCS. First, we detail key potential benefits of SARS-CoV-2 HCS including, but not
      limited to, those related to the acceleration of vaccine development. Second, we 
      identify where modelling is needed to inform risk-benefit (and thus ethical)
      assessments. Modelling will be particularly useful in (i) comparing potential
      benefits and risks of HCS with those of vaccine field trials under different
      epidemiological conditions and (ii) estimating marginal risks to HCS participants
      in light of the background probabilities of infection in their local community.
      We highlight interactions between public health policy and research priorities,
      including situations in which research ethics assessments may need to strike a
      balance between competing considerations.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AUID- ORCID: http://orcid.org/0000-0001-5940-602X
AD  - Monash Bioethics Centre, Monash University, Melbourne, Australia.
      zeb.jamrozik@monash.edu.
AD  - Royal Melbourne Hospital Department of Medicine, University of Melbourne,
      Melbourne, Australia. zeb.jamrozik@monash.edu.
FAU - Heriot, George S
AU  - Heriot GS
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Australia.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AD  - Monash Bioethics Centre, Monash University, Melbourne, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - *COVID-19/prevention & control
MH  - Drug Development/*ethics/*methods
MH  - Humans
MH  - Pandemics
MH  - Public Health
MH  - Research Design
MH  - Risk Assessment
MH  - SARS-CoV-2/drug effects
MH  - *Viral Vaccines
PMC - PMC7445815
OTO - NOTNLM
OT  - Background risk
OT  - COVID-19
OT  - Controlled human infection model
OT  - Coronavirus
OT  - Human challenge studies
OT  - Infectious disease
OT  - Modelling
OT  - Research Ethics
OT  - Risk
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10030-x [doi]
AID - 10.1007/s11673-020-10030-x [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):709-715. doi: 10.1007/s11673-020-10030-x. Epub 2020 
      Aug 25.


PMID- 32840854
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - COVID-19 Ethics-Looking Down the Muzzle.
PG  - 501-502
LID - 10.1007/s11673-020-10027-6 [doi]
AB  - Public health and pandemic ethics frequently concern themselves with organizing
      principles, utility, and public policy. But the effects of pandemics, and the
      impact of measures to control them, are experienced by individuals and families. 
      This is particularly true for those who are most vulnerable to COVID-19-the
      elderly and "infirm." So while ethics must assist in articulating the policies
      that will determine the allocation of resources during this and future pandemics,
      it must, at the same time, be alert to the intimate narratives of the infection. 
      This is an account from someone looking down the muzzle of COVID-19.
FAU - Gillett, Grant
AU  - Gillett G
AD  - Otago Bioethics Centre, University of Otago, Dunedin, New Zealand.
      grant.gillett@otago.ac.nz.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Aged
MH  - *COVID-19
MH  - Health Care Rationing/*ethics
MH  - *Health Policy
MH  - Humans
MH  - Narration
MH  - Pandemics/*ethics
MH  - Public Health/*ethics
MH  - SARS-CoV-2
PMC - PMC7445817
OTO - NOTNLM
OT  - *Ageism
OT  - *COVID-19
OT  - *Ethics
OT  - *Narrative
OT  - *Vulnerability
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10027-6 [doi]
AID - 10.1007/s11673-020-10027-6 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):501-502. doi: 10.1007/s11673-020-10027-6. Epub 2020 
      Aug 25.


PMID- 32840852
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - The COVID-19 Pandemic and Ethics in Mexico Through a Gender Lens.
PG  - 613-617
LID - 10.1007/s11673-020-10029-4 [doi]
AB  - In Mexico, significant ethical and social issues have been raised by the COVID-19
      pandemic. Some of the most pressing issues are the extent of restrictive
      measures, the reciprocal duties to healthcare workers, the allocation of scarce
      resources, and the need for research. While policy and ethical frameworks are
      being developed to face these problems, the gender perspective has been largely
      overlooked in most of the issues at stake. Domestic violence is the most
      prevalent form of violence against women, which can be exacerbated during a
      pandemic: stress and economic uncertainty are triggers for abuse, and confinement
      limits access to support networks. Confinement also exacerbates the unfair
      distribution of unpaid labor, which is disproportionately assigned to women and
      girls, and highlights inequality in the overall labor market. Lack of security
      measures has resulted in attacks towards health workers, particularly female
      nurses, due to fear of contamination. Finally, resource results in lack of access
      to other health necessities, including sexual and reproductive health services.
      Research across all disciplines to face-and to learn from-this crisis should be
      done through a gender lens, because understanding the realities of women is
      essential to understand the pandemic's true effects in Mexico and the world.
FAU - Manrique De Lara, Amaranta
AU  - Manrique De Lara A
AD  - Bioethics, Health and Biolaw Program, Instituto de Investigaciones Juridicas,
      Universidad Nacional Autonoma de Mexico, Circuito Mario de La Cueva s/n, Ciudad
      Universitaria, 04510, Mexico City, Mexico.
FAU - De Jesus Medina Arellano, Maria
AU  - De Jesus Medina Arellano M
AUID- ORCID: http://orcid.org/0000-0003-4324-4083
AD  - Bioethics, Health and Biolaw Program, Instituto de Investigaciones Juridicas,
      Universidad Nacional Autonoma de Mexico, Circuito Mario de La Cueva s/n, Ciudad
      Universitaria, 04510, Mexico City, Mexico. mariama@unam.mx.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/*epidemiology
MH  - Domestic Violence/statistics & numerical data
MH  - Employment/statistics & numerical data
MH  - Female
MH  - Health Services Accessibility/*ethics
MH  - Humans
MH  - Mexico/epidemiology
MH  - Pandemics
MH  - SARS-CoV-2
MH  - Sex Factors
MH  - Sexism/*ethics
PMC - PMC7445801
OTO - NOTNLM
OT  - Domestic violence
OT  - Equity
OT  - Global health ethics
OT  - Mexico
OT  - Pandemic
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10029-4 [doi]
AID - 10.1007/s11673-020-10029-4 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):613-617. doi: 10.1007/s11673-020-10029-4. Epub 2020 
      Aug 25.


PMID- 32840851
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Accelerating the De-Personalization of Medicine: The Ethical Toxicities of
      COVID-19.
PG  - 815-821
LID - 10.1007/s11673-020-10026-7 [doi]
AB  - The COVID-19 pandemic has, of necessity, demanded the rapid incorporation of
      virtual technologies which, suddenly, have superseded the physical medical
      encounter. These imperatives have been implemented in advance of evaluation, with
      unclear risks to patient care and the nature of medical practice that might be
      justifiable in the context of a pandemic but cannot be extrapolated as a new
      standard of care. Models of care fit for purpose in a pandemic should not be
      generalized to reconfigure medical care as virtual by default, and personal by
      exception at the conclusion of the emergency.
FAU - Arnold, Mark
AU  - Arnold M
AUID- ORCID: http://orcid.org/0000-0003-0546-8924
AD  - School of Rural Health (Dubbo/Orange), Sydney Medical School, Faculty of Medicine
      and Health, University of Sydney, PO BOX 1043, Dubbo, NSW, 2830, Australia.
      mark.arnold@sydney.edu.au.
AD  - Sydney Health Ethics, Faculty of Medicine and Health, University of Sydney,
      Campertown, NSW, 2006, Australia. mark.arnold@sydney.edu.au.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, Faculty of Medicine and Health, Haematology Department,
      Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - Delivery of Health Care/*ethics
MH  - Electronic Health Records
MH  - Humans
MH  - Pandemics
MH  - Patient Isolation
MH  - Quarantine
MH  - SARS-CoV-2
MH  - Telemedicine
PMC - PMC7445805
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical ethics
OT  - Epistemology
OT  - Ontology
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10026-7 [doi]
AID - 10.1007/s11673-020-10026-7 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):815-821. doi: 10.1007/s11673-020-10026-7. Epub 2020 
      Aug 25.


PMID- 32840850
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - In the Shadow of Biological Warfare: Conspiracy Theories on the Origins of
      COVID-19 and Enhancing Global Governance of Biosafety as a Matter of Urgency.
PG  - 567-574
LID - 10.1007/s11673-020-10025-8 [doi]
AB  - Two theories on the origins of COVID-19 have been widely circulating in China and
      the West respectively, one blaming the United States and the other a
      highest-level biocontainment laboratory in Wuhan, the initial epicentre of the
      pandemic. Both theories make claims of biological warfare attempts. According to 
      the available scientific evidence, these claims are groundless. However, like the
      episodes of biological warfare during the mid-twentieth century, the spread of
      these present-day conspiracy theories reflects a series of longstanding and
      damaging trends in the international scene which include deep mistrust,
      animosities, the power of ideologies such as nationalism, and the sacrifice of
      truth in propaganda campaigns. Also, the threats associated with biological
      warfare, bioterrorism, and the accidental leakage of deadly viruses from labs are
      real and growing. Thus, developing a better global governance of biosafety and
      biosecurity than exists at present is an urgent imperative for the international 
      community in the broader context of a looming Cold War II. For such a governance,
      an ethical framework is proposed based upon the triple ethical values of
      transparency, trust, and the common good of humanity.
FAU - Nie, Jing-Bao
AU  - Nie JB
AUID- ORCID: http://orcid.org/0000-0002-1570-2254
AD  - Bioethics Centre, Otago Medical School, University of Otago, 60 Clyde Street,
      Dunedin, 9056, New Zealand. jing-bao.nie@otago.ac.nz.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *Biological Warfare
MH  - Bioterrorism
MH  - COVID-19/epidemiology/etiology/*virology
MH  - China
MH  - *Containment of Biohazards
MH  - *Government
MH  - Guilt
MH  - Humanism
MH  - Humans
MH  - *International Cooperation
MH  - Pandemics
MH  - *SARS-CoV-2
MH  - Trust
MH  - United States
MH  - Viruses
PMC - PMC7445685
OTO - NOTNLM
OT  - Biological warfare
OT  - Biosafety and biosecurity
OT  - China
OT  - Global governance
OT  - Origins of COVID-19
OT  - P4 or BSL-4 lab
OT  - USA
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10025-8 [doi]
AID - 10.1007/s11673-020-10025-8 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):567-574. doi: 10.1007/s11673-020-10025-8. Epub 2020 
      Aug 25.


PMID- 32840848
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Building an Ethics Framework for COVID-19 Resource Allocation: The How and the
      Why.
PG  - 757-760
LID - 10.1007/s11673-020-10022-x [doi]
AB  - This paper expands on "An Ethics Framework for Making Resource Allocation
      Decisions within Clinical Care: Responding to COVID-19," which is also published 
      in this special issue of the Journal of Bioethical Inquiry. I first describe and 
      explain the steps we took to develop this framework, drawing on previous
      experience and literature to explain what frameworks can and cannot do. I
      distinguish frameworks from other kinds of guidance and justify why our framework
      takes the form it does. Our key aim was to help answer practical questions faced 
      by frontline clinicians. I then explain some of the normative issues that shape
      the content of the framework itself. Here, I engage critically with the resource 
      allocation literature and justify the particular positions that we take in the
      framework. Although we undertook this work to address resource allocation
      decisions anticipated during the unfolding COVID-19 pandemic, it will also serve 
      as an example for others who wish to design practical ethics frameworks for other
      bioethical issues that will emerge in the future.
FAU - Dawson, Angus
AU  - Dawson A
AD  - Sydney Health Ethics, Sydney School of Public Health, The University of Sydney,
      Level 1, Medical Foundation Building K25, Sydney, NSW, 2006, Australia.
      angus.dawson@sydney.edu.au.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
CON - J Bioeth Inq. 2020 Dec;17(4):749-755. PMID: 32840833
MH  - *COVID-19
MH  - Decision Making
MH  - Humans
MH  - Pandemics
MH  - Resource Allocation
MH  - SARS-CoV-2
PMC - PMC7445723
OTO - NOTNLM
OT  - *COVID-19
OT  - *Decision-making
OT  - *Ethics
OT  - *Frameworks
OT  - *Resource allocation
EDAT- 2020/08/26 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10022-x [doi]
AID - 10.1007/s11673-020-10022-x [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):757-760. doi: 10.1007/s11673-020-10022-x. Epub 2020 
      Aug 25.


PMID- 32840847
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Learning Lessons from COVID-19 Requires Recognizing Moral Failures.
PG  - 563-566
LID - 10.1007/s11673-020-10019-6 [doi]
AB  - The most powerful lesson learned from the 2013-2016 outbreak of Ebola in West
      Africa was that we do not learn our lessons. A common sentiment at the time was
      that Ebola served as a "wake-up call"-an alarm which signalled that an outbreak
      of that magnitude should never have occurred and that we are ill-prepared
      globally to prevent and respond to them when they do. Pledges were made that we
      must learn from the outbreak before we were faced with another. Nearly five years
      later the world is in the grips of a pandemic of the severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019
      (COVID-19). It is therefore of no surprise that we are now yet again hearing that
      the COVID-19 pandemic serves as the "wake-up call" we need and that there are
      many lessons to be learned to better prepare us for future outbreaks. Will
      anything be different this time around? We argue that nothing will fundamentally 
      change unless we truly understand and appreciate the nature of the lessons we
      should learn from these outbreaks. Our past failures must be understood as moral 
      failures that offer moral lessons. Unless we appreciate that we have a defect in 
      our collective moral attitude toward remediating the conditions that precipitate 
      the emergence of outbreaks, we will never truly learn.
FAU - Smith, Maxwell J
AU  - Smith MJ
AD  - School of Health Studies, Western University, Arthur & Sonia Labatt Health
      Sciences Building, 1151 Richmond Street, London, Ontario, N6A 5B9, Canada.
FAU - Upshur, Ross E G
AU  - Upshur REG
AUID- ORCID: http://orcid.org/0000-0003-1128-0557
AD  - Dalla Lana School of Public Health, University of Toronto, 155 College Street,
      Toronto, Ontario, M5T 3M7, Canada. ross.upshur@utoronto.ca.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19/epidemiology
MH  - *Disaster Planning
MH  - Disease Outbreaks
MH  - *Hemorrhagic Fever, Ebola/epidemiology
MH  - Humans
MH  - *Learning
MH  - *Morals
MH  - *Pandemics
MH  - SARS-CoV-2
PMC - PMC7445711
OTO - NOTNLM
OT  - COVID-19
OT  - Ebola
OT  - Pandemics
OT  - Public health ethics
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/06/11 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10019-6 [doi]
AID - 10.1007/s11673-020-10019-6 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):563-566. doi: 10.1007/s11673-020-10019-6. Epub 2020 
      Aug 25.


PMID- 32840846
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - The Appointment in Samarra: A New Use for Some Old Jokes.
PG  - 473-478
LID - 10.1007/s11673-020-10020-z [doi]
AB  - The coronavirus epidemic is not just a biological phenomenon which affects
      humans: it is also a moment of a profound global and ecological crisis that
      includes many human and nonhuman actors. To confront the crisis, a radical
      philosophical change is needed, which penetrates to natural, economic, and
      cultural processes. The amassing of dictatorial powers of state apparatuses
      evoked by the pandemic highlights their basic impotence and the fact that the
      system as we know it cannot continue in its existing liberal-permissive form.
      While the final outcome is uncertain what is most probable is that a new
      barbarian capitalism will prevail: many old and weak will be sacrificed and let
      to die, workers will have to accept much lower standards of living, digital
      control of our lives will remain a permanent feature, and class distinctions will
      become much more than now a matter of life and death.
FAU - Zizek, Slavoj
AU  - Zizek S
AD  - University of Ljubljana, Ljubljana, Slovenia. slavoj.zizek@guest.arnes.si.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19/economics
MH  - Capitalism
MH  - Disasters
MH  - Global Health
MH  - Humanism
MH  - Humans
MH  - *Pandemics/ethics
MH  - *Political Systems
MH  - *Politics
MH  - Public Health
MH  - SARS-CoV-2
MH  - Social Class
MH  - Social Conditions
MH  - Technology
PMC - PMC7445691
OTO - NOTNLM
OT  - Assemblage
OT  - COVID-19
OT  - Capitalism
OT  - Climate change
OT  - Coronavirus
OT  - Ecological crisis
OT  - Ethics
OT  - Pandemic
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/06/28 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10020-z [doi]
AID - 10.1007/s11673-020-10020-z [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):473-478. doi: 10.1007/s11673-020-10020-z. Epub 2020 
      Aug 25.


PMID- 32840842
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210914
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - COVID-19 and Contact Tracing Apps: Ethical Challenges for a Social Experiment on 
      a Global Scale.
PG  - 835-839
LID - 10.1007/s11673-020-10016-9 [doi]
AB  - Mobile applications are increasingly regarded as important tools for an
      integrated strategy of infection containment in post-lockdown societies around
      the globe. This paper discusses a number of questions that should be addressed
      when assessing the ethical challenges of mobile applications for digital
      contact-tracing of COVID-19: Which safeguards should be designed in the
      technology? Who should access data? What is a legitimate role for "Big Tech"
      companies in the development and implementation of these systems? How should
      cultural and behavioural issues be accounted for in the design of these apps?
      Should use of these apps be compulsory? What does transparency and ethical
      oversight mean in this context? We demonstrate that responses to these questions 
      are complex and contingent and argue that if digital contract-tracing is used,
      then it should be clear that this is on a trial basis and its use should be
      subject to independent monitoring and evaluation.
FAU - Lucivero, Federica
AU  - Lucivero F
AUID- ORCID: http://orcid.org/0000-0002-1308-5846
AD  - Ethox and Wellcome Centre for Ethics and Humanities, Nuffield Department of
      Population Health, University of Oxford, Old Road Campus, Oxford, UK.
      Federica.lucivero@ethox.ox.ac.uk.
FAU - Hallowell, Nina
AU  - Hallowell N
AD  - Ethox and Wellcome Centre for Ethics and Humanities, Nuffield Department of
      Population Health, University of Oxford, Old Road Campus, Oxford, UK.
FAU - Johnson, Stephanie
AU  - Johnson S
AD  - Ethox and Wellcome Centre for Ethics and Humanities, Nuffield Department of
      Population Health, University of Oxford, Old Road Campus, Oxford, UK.
FAU - Prainsack, Barbara
AU  - Prainsack B
AD  - Department of Political Science, University of Vienna, Vienna, Austria.
AD  - Department of Global Health and Social Medicine, King's College London, London,
      UK.
FAU - Samuel, Gabrielle
AU  - Samuel G
AD  - Department of Global Health and Social Medicine, King's College London, London,
      UK.
FAU - Sharon, Tamar
AU  - Sharon T
AD  - Department of Practical Philosophy & Interdisciplinary Hub for Security, Privacy 
      and Data Governance, Radboud University, Nijmegen, The Netherlands.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Access to Information
MH  - *COVID-19
MH  - Contact Tracing/*ethics
MH  - Humans
MH  - Mobile Applications/*ethics
MH  - Privacy
MH  - Public Health
MH  - SARS-CoV-2
PMC - PMC7445718
OTO - NOTNLM
OT  - COVID-19
OT  - Contact tracing apps
OT  - Social experiment
OT  - Transparency
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10016-9 [doi]
AID - 10.1007/s11673-020-10016-9 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):835-839. doi: 10.1007/s11673-020-10016-9. Epub 2020 
      Aug 25.


PMID- 32840841
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Invisible Enemies: Coronavirus and Other Hidden Threats.
PG  - 531-534
LID - 10.1007/s11673-020-10015-w [doi]
AB  - To say that coronavirus is highly visible is a massive understatement in terms of
      its omnipresence in our lives and media coverage concerning it, yet also clearly 
      untrue in terms of the virus itself. COVID-19 is our invisible enemy, changing
      our lives radically without ever revealing itself directly. In this paper I
      explore its invisibility and how it relates to and exposes other invisible
      enemies we are and have been fighting, in many cases without even realizing.
      First, I analyse the virus itself and how its stealthy nature has transformed our
      lives. Second, I describe how the invisible epidemic of social media sharing of
      fake news about the virus worsens the situation further. Third, I explore how the
      virus has revealed to us what really matters in our lives and has forced us to
      re-evaluate our priorities. Fourth, I go on to explore the underlying structural 
      weaknesses and disparities in society that have been exposed by the virus but
      previously remained unconsidered for so long that they too have become
      camouflaged, even if their effects are all too apparent; like the virus,
      neoliberal capitalism is an invisible enemy that has made prisoners of us all. I 
      conclude by suggesting that the coronavirus pandemic represents a hidden
      opportunity to overcome perhaps the biggest invisible enemy of all: the moral
      distance that separates us from others. Only by rendering the rest of humanity
      morally visible to ourselves can we overcome capitalism and stop treating other
      people as invisible enemies.
FAU - Shaw, D M
AU  - Shaw DM
AUID- ORCID: http://orcid.org/0000-0001-8180-6927
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
      David.shaw@unibas.ch.
AD  - Care and Public Health Research Institute, Maastricht University, Maastricht, The
      Netherlands. David.shaw@unibas.ch.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19/virology
MH  - Capitalism
MH  - Coronavirus
MH  - Coronavirus Infections
MH  - Health Equity/*ethics
MH  - *Humanities
MH  - Humans
MH  - Mass Media
MH  - Metaphor
MH  - *Morals
MH  - *Pandemics
MH  - *SARS-CoV-2
MH  - Social Media
MH  - Social Values
PMC - PMC7445728
OTO - NOTNLM
OT  - Capitalism
OT  - Coronavirus
OT  - Ethics
OT  - Inequalities
OT  - Public health
OT  - Social distancing
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10015-w [doi]
AID - 10.1007/s11673-020-10015-w [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):531-534. doi: 10.1007/s11673-020-10015-w. Epub 2020 
      Aug 25.


PMID- 32840840
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Sheltering at Our Common Home.
PG  - 525-529
LID - 10.1007/s11673-020-10014-x [doi]
AB  - The current COVID-19 pandemic has reactivated ancient metaphors (especially
      military ones) but also initiated a new vocabulary: social distancing, lockdown, 
      self-isolation, and sheltering in place. Terminology is not ethically neutral but
      reflects prevailing value systems. I will argue that there are two metaphorical
      vocabularies at work: an authoritarian one and a liberal one. Missing is an
      ecological vocabulary. It has been known for a long time that emerging infectious
      diseases are associated with the destruction of functioning ecosystems and
      biodiversity. Ebola and avian influenza viruses have been significant warnings.
      Obviously, this pandemic will not be the last one. As the planet is our common
      home, the major metaphor to explore is sheltering at this home.
FAU - Ten Have, H A M J
AU  - Ten Have HAMJ
AD  - Center for Healthcare Ethics, Duquesne University, 600 Forbes Avenue, Fisher Hall
      300, Pittsburgh, PA, 15282, USA. tenhaveh@duq.edu.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Animals
MH  - Biodiversity
MH  - Bioethics
MH  - Birds
MH  - *COVID-19/etiology/virology
MH  - Communicable Disease Control
MH  - *Communicable Diseases, Emerging/etiology/virology
MH  - Conservation of Natural Resources
MH  - *Disasters
MH  - Ebolavirus
MH  - *Ecology/ethics
MH  - Ecosystem
MH  - Hemorrhagic Fever, Ebola/virology
MH  - Humans
MH  - Influenza A virus
MH  - Influenza in Birds
MH  - *Metaphor
MH  - *Pandemics
MH  - Physical Distancing
MH  - SARS-CoV-2
PMC - PMC7445689
OTO - NOTNLM
OT  - Bio-invasion
OT  - Bio-preparedness
OT  - Bioethics
OT  - Common home
OT  - Disasters
OT  - Ecology
OT  - Emerging infectious diseases
OT  - Pandemics
OT  - Sheltering at home
OT  - Sheltering in place
OT  - Social distancing
OT  - War metaphor
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10014-x [doi]
AID - 10.1007/s11673-020-10014-x [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):525-529. doi: 10.1007/s11673-020-10014-x. Epub 2020 
      Aug 25.


PMID- 32840839
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20211204
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - COVID-19 Pandemic: The Circus is Over, for the Moment.
PG  - 591-593
LID - 10.1007/s11673-020-10012-z [doi]
AB  - This critical essay responds to the COVID-19 pandemic and subsequent lockdown in 
      Victoria from the perspective of a retired Aboriginal academic and reflects on
      personal responsibility, Indigenous history, and resilience.
FAU - Morrissey, Philip
AU  - Morrissey P
AUID- ORCID: http://orcid.org/0000-0001-7844-518X
AD  - , Box Hill, Australia. philipjohnmorrissey@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Aged
MH  - COVID-19/*epidemiology/*ethnology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medicine in Literature
MH  - Middle Aged
MH  - *Native Hawaiian or Other Pacific Islander
MH  - Pandemics
MH  - *Resilience, Psychological
MH  - SARS-CoV-2
MH  - *Social Responsibility
MH  - Victoria/epidemiology
PMC - PMC7445733
OTO - NOTNLM
OT  - Culture
OT  - Ecology
OT  - Ethics
OT  - Indigenous
OT  - Survival
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/25 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10012-z [doi]
AID - 10.1007/s11673-020-10012-z [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):591-593. doi: 10.1007/s11673-020-10012-z. Epub 2020 
      Aug 25.


PMID- 32840837
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210914
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Advancing Global Health Equity in the COVID-19 Response: Beyond Solidarity.
PG  - 703-707
LID - 10.1007/s11673-020-10008-9 [doi]
AB  - In the coming weeks and months SARS-CoV-2 may ravage countries with weak health
      systems and populations disproportionately affected by HIV, tuberculosis (TB),
      and other infectious diseases. Without safeguards and proper attention to global 
      health equity and justice, the effects of this pandemic are likely to exacerbate 
      existing health and socio-economic inequalities. This paper argues that achieving
      global health equity in the context of COVID-19 will require that notions of
      reciprocity and relational equity are introduced to the response.
FAU - Johnson, Stephanie B
AU  - Johnson SB
AUID- ORCID: http://orcid.org/0000-0002-6777-8816
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK.
      stephanie.johnson@bdi.ox.ac.uk.
AD  - Ethox Centre, University of Oxford, Oxford, UK. stephanie.johnson@bdi.ox.ac.uk.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 096527/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - *Global Health
MH  - *Health Equity
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
MH  - United Nations
PMC - PMC7445720
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Global health justice
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10008-9 [doi]
AID - 10.1007/s11673-020-10008-9 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):703-707. doi: 10.1007/s11673-020-10008-9. Epub 2020 
      Aug 25.


PMID- 32840835
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Family Presence for Patients and Separated Relatives During COVID-19: Physical,
      Virtual, and Surrogate.
PG  - 767-772
LID - 10.1007/s11673-020-10009-8 [doi]
AB  - During an outbreak or pandemic involving a novel disease such as COVID-19,
      infected persons may need to undergo strict medical isolation and be separated
      from their families for public health reasons. Such a practice raises various
      ethical questions, the characteristics of which are heightened by uncertainties
      such as mode of transmission and increasingly scarce healthcare resources. For
      example, under what circumstances should non-infected parents be allowed to stay 
      with their infected children in an isolation facility? This paper will examine
      ethical issues with three modes of "family presence" or "being there or with" a
      separated family member during the current COVID-19 pandemic: physical, virtual, 
      and surrogate. Physical visits, stays, or care by family members in isolation
      facilities are usually prohibited, discouraged, or limited to exceptional
      circumstances. Virtual presence for isolated patients is often recommended and
      used to enable communication. When visits are disallowed, frontline workers
      sometimes act as surrogate family for patients, such as performing bedside vigils
      for dying patients. Drawing on lessons from past outbreaks such as the 2002-2003 
      SARS epidemic and the recent Ebola epidemic in West Africa, we consider the
      ethical management of these modes of family presence and argue for the promotion 
      of physical presence under some conditions.
FAU - Voo, Teck Chuan
AU  - Voo TC
AUID- ORCID: http://orcid.org/0000-0003-4757-7328
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Block MD11, Clinical Research Centre, #02-03, 10 Medical
      Drive, Singapore, 117597, Singapore. medvtc@nus.edu.sg.
FAU - Senguttuvan, Mathavi
AU  - Senguttuvan M
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Block MD11, Clinical Research Centre, #02-03, 10 Medical
      Drive, Singapore, 117597, Singapore.
FAU - Tam, Clarence C
AU  - Tam CC
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Tahir Foundation Building, 12 Science Drive 2,
      #10-01, Singapore, 117549, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - *Family
MH  - Humans
MH  - Organizational Policy
MH  - Pandemics
MH  - Patient Isolation/*ethics
MH  - SARS-CoV-2
MH  - *Visitors to Patients
PMC - PMC7445690
OTO - NOTNLM
OT  - COVID-19
OT  - Communication
OT  - Epidemics
OT  - Family presence
OT  - Family separation
OT  - Medical isolation
OT  - Outbreaks
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/10 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10009-8 [doi]
AID - 10.1007/s11673-020-10009-8 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):767-772. doi: 10.1007/s11673-020-10009-8. Epub 2020 
      Aug 25.


PMID- 32840834
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Not all Bad: Sparks of Hope in a Global Disaster.
PG  - 515-518
LID - 10.1007/s11673-020-10011-0 [doi]
AB  - The focus of discussion about the ethical issues associated with the COVID-19
      pandemic has been on the great suffering to which it has given rise. However,
      there may be some unexpected positive outcomes that also emerge from the global
      disaster. The rupturing of entrenched systems and processes, the challenging of
      certainties that seemed beyond question, and the disruption of the assumed
      consensus of modernity may contribute to a rediscovery of the challenges that
      compose an ethical life. Elements of such a process are evident in the surge of
      community support and mutual caring, of spontaneous acts of joyous solidarity, of
      suspension of past conflicts, and exploration of new forms of reconciliation. The
      experiences are tentative and the outcomes uncertain, but at least for a moment
      the hope of a new way forward has been raised.
FAU - Komesaroff, Paul A
AU  - Komesaroff PA
AUID- ORCID: http://orcid.org/0000-0002-1360-3375
AD  - Faculty of Medicine, Alfred Hospital, Monash University, Commercial Road,
      Prahran, Victoria, 3181, Australia. paul.komesaroff@monash.edu.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - *Disasters
MH  - Hope
MH  - Humans
MH  - Morals
MH  - Optimism
MH  - Pandemics/*ethics
MH  - Residence Characteristics
MH  - SARS-CoV-2
MH  - *Social Change
MH  - Social Values
PMC - PMC7445688
OTO - NOTNLM
OT  - COVID-19
OT  - Community
OT  - Coronavirus
OT  - Epidemic
OT  - Ethics
OT  - Hope
OT  - Microethics
OT  - Music
OT  - Pandemic
OT  - Power
OT  - Reconciliation
OT  - Resistance
OT  - Song
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10011-0 [doi]
AID - 10.1007/s11673-020-10011-0 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):515-518. doi: 10.1007/s11673-020-10011-0. Epub 2020 
      Aug 25.


PMID- 32840833
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210101
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - An Ethics Framework for Making Resource Allocation Decisions Within Clinical
      Care: Responding to COVID-19.
PG  - 749-755
LID - 10.1007/s11673-020-10007-w [doi]
AB  - On March, 24, 2020, 818 cases of COVID-19 had been reported in New South Wales,
      Australia, and new cases were increasing at an exponential rate. In anticipation 
      of resource constraints arising in clinical settings as a result of the COVID-19 
      pandemic, a working party of ten ethicists (seven clinicians and three full-time 
      academics) was convened at the University of Sydney to draft an ethics framework 
      to support resource allocation decisions. The framework guides decision-makers
      using a question-and-answer format, in language that avoids philosophical and
      medical technicality. The working party met five times over the following week
      and then submitted a draft Framework for consideration by two groups of
      intensivists and one group of academic ethicists. It was also presented to a
      panel on a national current affairs programme. The Framework was then revised on 
      the basis of feedback from these sources and made publicly available online on
      April 3, ten days after the initial meeting. The framework is published here in
      full to stimulate ongoing discussion about rapid development of user-friendly
      clinical ethics resources in ongoing and future pandemics.
FAU - Dawson, Angus
AU  - Dawson A
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
FAU - Isaacs, David
AU  - Isaacs D
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
AD  - The Children's Hospital Westmead, Sydney, Australia.
FAU - Jansen, Melanie
AU  - Jansen M
AD  - The Children's Hospital Westmead, Sydney, Australia.
FAU - Jordens, Christopher
AU  - Jordens C
AUID- ORCID: http://orcid.org/0000-0001-9454-1059
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia. chris.jordens@sydney.edu.au.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
AD  - Royal North Shore Hospital, St Leonards, Sydney, Australia.
FAU - Kihlbom, Ulrik
AU  - Kihlbom U
AD  - Centre for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden.
FAU - Kilham, Henry
AU  - Kilham H
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
AD  - The Children's Hospital Westmead, Sydney, Australia.
FAU - Preisz, Anne
AU  - Preisz A
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
AD  - The Sydney Children's Hospitals Network, Sydney, Australia.
FAU - Sheahan, Linda
AU  - Sheahan L
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
AD  - St George Hospital, Sydney, Australia.
AD  - South East Sydney Local Health District, Sydney, Australia.
FAU - Skowronski, George
AU  - Skowronski G
AD  - Sydney Health Ethics, The University of Sydney, Medical Foundation Building
      (K25), Sydney, NSW, 2006, Australia.
AD  - St George Hospital, Sydney, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
CIN - J Bioeth Inq. 2020 Dec;17(4):757-760. PMID: 32840848
MH  - COVID-19
MH  - Decision Making/*ethics
MH  - *Delivery of Health Care
MH  - Humans
MH  - New South Wales
MH  - Pandemics
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
PMC - PMC7445717
OTO - NOTNLM
OT  - Australia
OT  - COVID-19
OT  - Clinical care
OT  - Decision-making
OT  - Ethics framework
OT  - New South Wales
OT  - Pandemic
OT  - Resource allocation
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10007-w [doi]
AID - 10.1007/s11673-020-10007-w [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):749-755. doi: 10.1007/s11673-020-10007-w. Epub 2020 
      Aug 25.


PMID- 32840831
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20211018
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Applying a Precautionary Approach to Mobile Contact Tracing for COVID-19: The
      Value of Reversibility.
PG  - 823-827
LID - 10.1007/s11673-020-10004-z [doi]
AB  - The COVID-19 pandemic presents unprecedented challenges to public health
      decision-making. Specifically, the lack of evidence and the urgency with which a 
      response is called for, raise the ethical challenge of assessing how much (and
      what kind of) evidence is required for the justification of interventions in
      response to the various threats we face. Here we discuss the intervention of
      introducing technology that aims to trace and alert contacts of infected
      persons-contact tracing (CT) technology. Determining whether such an intervention
      is proportional is complicated by complex trade-offs and feedback loops. We
      suggest that the resulting uncertainties necessitate a precautionary approach. On
      the one hand, precautionary reasons support CT technology as a means to
      contribute to the prevention of harms caused by alternative interventions, or
      COVID-19 itself. On the other hand, however, both the extent to which such
      technology itself present risks of serious harm, as well as its effectiveness,
      remain unclear. We therefore argue that a precautionary approach should put
      reversibility of CT technology at the forefront. We outline several practical
      implications.
FAU - Nijsingh, Niels
AU  - Nijsingh N
AUID- ORCID: http://orcid.org/0000-0002-5698-3566
AD  - Institute for Ethics, History and Theory of Medicine, Ludwig Maximilians
      Universitat, Lessingstrasse 2, 80336, Munchen, Germany. nielsnijsingh@posteo.net.
FAU - van Bergen, Anne
AU  - van Bergen A
AD  - Institute for Ethics, History and Theory of Medicine, Ludwig Maximilians
      Universitat, Lessingstrasse 2, 80336, Munchen, Germany.
FAU - Wild, Verina
AU  - Wild V
AD  - Institute for Ethics, History and Theory of Medicine, Ludwig Maximilians
      Universitat, Lessingstrasse 2, 80336, Munchen, Germany.
LA  - eng
GR  - 01GP1791/Bundesministerium fur Bildung und Forschung (DE)
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
EIN - J Bioeth Inq. 2021 Jul;18(2):363. PMID: 33978951
MH  - COVID-19/*transmission
MH  - Contact Tracing/*methods
MH  - Humans
MH  - *Mobile Applications
MH  - Pandemics
MH  - Public Health
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Uncertainty
PMC - PMC7445727
OTO - NOTNLM
OT  - Infectious disease
OT  - Public health ethics
OT  - Risk, Precautionary principle, Pandemic
OT  - Uncertainty
OT  - mHealth
EDAT- 2020/08/26 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/10 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10004-z [doi]
AID - 10.1007/s11673-020-10004-z [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):823-827. doi: 10.1007/s11673-020-10004-z. Epub 2020 
      Aug 25.


PMID- 32840830
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220219
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Understanding Ethical and Legal Obligations in a Pandemic: A Taxonomy of "Duty"
      for Health Practitioners.
PG  - 697-701
LID - 10.1007/s11673-020-10003-0 [doi]
AB  - From the ethics perspective, "duty of care" is a difficult and contested term,
      fraught with misconceptions and apparent misappropriations. However, it is a term
      that clinicians use frequently as they navigate COVID-19, somehow core to their
      understanding of themselves and their obligations, but with uncertainty as to how
      to translate or operationalize this in the context of a pandemic. This paper
      explores the "duty of care" from a legal perspective, distinguishes it from
      broader notions of duty on professional and personal levels, and proposes a
      working taxonomy for practitioners to better understand the concept of "duty" in 
      their response to COVID-19.
FAU - Sheahan, Linda
AU  - Sheahan L
AUID- ORCID: http://orcid.org/0000-0003-4718-9659
AD  - South East Sydney Local Health District, Sydney, Australia.
      Linda.sheahan@health.nsw.gov.au.
AD  - St George Hospital, Gray St, Kogarah, 2217, Australia.
      Linda.sheahan@health.nsw.gov.au.
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
      Linda.sheahan@health.nsw.gov.au.
FAU - Lamont, Scott
AU  - Lamont S
AD  - Mental Health Liaison, Prince of Wales Hospital, High St, Randwick, 2031,
      Australia.
AD  - Casual academic, Southern Cross University, Lismore, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Beneficence
MH  - COVID-19/*epidemiology
MH  - Codes of Ethics
MH  - *Ethics, Professional
MH  - Humans
MH  - *Moral Obligations
MH  - Pandemics/*ethics
MH  - *Professional Role
MH  - Refusal to Treat/ethics/legislation & jurisprudence
MH  - Risk-Taking
MH  - SARS-CoV-2
MH  - Social Responsibility
PMC - PMC7445726
OTO - NOTNLM
OT  - COVID-19
OT  - Clinician
OT  - Duties
OT  - Duty
OT  - Duty of care
OT  - Duty to care
OT  - Ethics
OT  - Health professional
OT  - Pandemic
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/10 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10003-0 [doi]
AID - 10.1007/s11673-020-10003-0 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):697-701. doi: 10.1007/s11673-020-10003-0. Epub 2020 
      Aug 25.


PMID- 32840829
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Gambling with COVID-19 Makes More Sense: Ethical and Practical Challenges in
      COVID-19 Responses in Communalistic Resource-Limited Africa.
PG  - 607-611
LID - 10.1007/s11673-020-10002-1 [doi]
AB  - Informed by evidence from past studies and experiences with epidemics, an
      intervention combining quarantine, lockdowns, curfews, social distancing, and
      washing of hands has been adopted as "international best practice" in COVID-19
      response. With massive total lockdowns complemented by electronic surveillance,
      China successfully controlled the pandemic in country within a few months. But
      would this work for Africa and other communalistic resource-poor settings where
      social togetherness translates to effective sharing of basic needs? What ethical 
      and practical challenges would this pose? How would communalism be translated in 
      special contexts to be useful in contributing to the ultimate common good? This
      paper uses examples from the current situation of COVID-19 in Kenya to address
      these questions.
FAU - Nderitu, David
AU  - Nderitu D
AD  - Egerton University, P.O. Box 536, Egerton, Rift Valley, 20115, Kenya.
FAU - Kamaara, Eunice
AU  - Kamaara E
AUID- ORCID: http://orcid.org/0000-0003-2233-5365
AD  - Moi University, P.O. Box 3900, Eldoret, Rift Valley, 30100, Kenya.
      ekamaara@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Africa/epidemiology
MH  - *Bioethical Issues
MH  - COVID-19/epidemiology/*prevention & control
MH  - Communicable Disease Control/*organization & administration
MH  - Developing Countries
MH  - Humans
MH  - Kenya/epidemiology
MH  - Pandemics
MH  - SARS-CoV-2
MH  - *Social Control, Formal
PMC - PMC7445712
OTO - NOTNLM
OT  - Africa
OT  - COVID-19
OT  - Communalistic resource-poor
OT  - Ethical and practical challenges
OT  - International best practice
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-10002-1 [doi]
AID - 10.1007/s11673-020-10002-1 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):607-611. doi: 10.1007/s11673-020-10002-1. Epub 2020 
      Aug 25.


PMID- 32840825
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20211204
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Fairness, Ethnicity, and COVID-19 Ethics : A Discussion of How the Focus on
      Fairness in Ethical Guidance During the Pandemic Discriminates Against People
      From Ethnic Minority Backgrounds.
PG  - 595-600
LID - 10.1007/s11673-020-09999-2 [doi]
AB  - Recent weeks have seen an increased focus on the ethical response to the COVID-19
      pandemic. Ethics guidance has proliferated across Britain, with ethicists and
      those with a keen interest in ethics in their professions working to produce
      advice and support for the National Health Service. The guiding principles of the
      pandemic have emerged, in one form or another, to favour fairness, especially
      with regard to allocating resources and prioritizing care. However, fairness is
      not equivalent to equity when it comes to healthcare, and the focus on fairness
      means that existing guidance inadvertently discriminates against people from
      ethnic minority backgrounds. Drawing on early criticisms of existing clinical
      guidance (for example, the frailty decision tool) and ethical guidance in
      Britain, this essay will discuss the importance of including sociology,
      specifically the relationship between ethnicity and health, in any ethical and
      clinical guidance for care during the pandemic in the United Kingdom. To do
      otherwise, I will argue, would be actively choosing to allow a proportion of the 
      British population to die for no other reason than their ethnic background.
      Finally, I will end by arguing why sociology must be a key component in any
      guidance, outlining how sociology was incorporated into the cross-college
      guidance produced by the Royal College of Physicians.
FAU - Paton, Alexis
AU  - Paton A
AUID- ORCID: http://orcid.org/0000-0003-4310-6983
AD  - Aston University, Aston St, Birmingham, B4 7ET, UK. a.paton@aston.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - COVID-19/*ethnology
MH  - *Ethics, Medical
MH  - *Ethnicity
MH  - Humans
MH  - Pandemics
MH  - Racism/*ethics/*ethnology
MH  - SARS-CoV-2
MH  - State Medicine/*ethics
MH  - United Kingdom/epidemiology
PMC - PMC7445719
OTO - NOTNLM
OT  - COVID-19
OT  - Ethical guidelines
OT  - Ethnic minorities
OT  - Health inequalities
OT  - Pandemic ethics
OT  - Social sciences and ethics
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-09999-2 [doi]
AID - 10.1007/s11673-020-09999-2 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):595-600. doi: 10.1007/s11673-020-09999-2. Epub 2020 
      Aug 25.


PMID- 32840824
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210512
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Antibodies as Currency: COVID-19's Golden Passport.
PG  - 687-689
LID - 10.1007/s11673-020-09996-5 [doi]
AB  - Due to COVID-19, the fragile economy, travel restrictions, and generalized
      anxieties, the concept of antibodies as a "declaration of immunity" or "passport"
      is sweeping the world. Numerous scientific and ethical issues confound the
      concept of an antibody passport; nonetheless, antibodies can be seen as a
      potential currency to allow movement of people and resuscitation of global
      economics. Just as financial currency can be forged, so too is the potential for 
      fraudulent antibody passports. This paper explores matters of science, ethics,
      and identity theft, as well as the problems of bias and discrimination that could
      promulgate a world of pandemic "golden passports."
FAU - Bramstedt, Katrina A
AU  - Bramstedt KA
AUID- ORCID: http://orcid.org/0000-0001-5446-0123
AD  - Luxembourg Agency for Research Integrity (LARI), 6, avenue des Hauts-Fourneaux,
      L-4362, Esch-sur-Alzette, Luxembourg. txbioethics@yahoo.com.
AD  - Bond University Medical Program, Gold Coast, Queensland, Australia.
      txbioethics@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Antibodies, Viral/*blood
MH  - COVID-19/epidemiology/*immunology
MH  - Emigration and Immigration
MH  - Employment/ethics
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - SARS-CoV-2/*immunology
MH  - Social Class
MH  - Travel/*ethics
PMC - PMC7445692
OTO - NOTNLM
OT  - Antibody
OT  - COVID-19
OT  - Ethics
OT  - Health law
OT  - Identity theft
OT  - Pandemic
OT  - Public health
OT  - Travel medicine
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-09996-5 [doi]
AID - 10.1007/s11673-020-09996-5 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):687-689. doi: 10.1007/s11673-020-09996-5. Epub 2020 
      Aug 25.


PMID- 32840823
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - Humiliating Whistle-Blowers: Li Wenliang, the Response to Covid-19, and the Call 
      for a Decent Society.
PG  - 543-547
LID - 10.1007/s11673-020-09990-x [doi]
AB  - The ethical experience and lessons of China's and the world's response to
      COVID-19 will be debated for many years to come. But one feature of the Chinese
      authoritarian response that should not be overlooked is its practice of silencing
      and humiliating the whistle-blowers who told the truth about the epidemic. In
      this article, we document the humiliation of Dr Li Wenliang (1986-2020), the most
      prominent whistle-blower in the Chinese COVID-19 epidemic. Engaging with the
      thought of Israeli philosopher Avishai Margalit, who argues that humiliation
      constitutes an injury to a person's self-respect, we discuss his contention that 
      a decent society is one that abolishes conditions which constitute a
      justification for its dependents to consider themselves humiliated. We explore
      the ways that institutions humiliate whistle-blowers in Western countries as well
      as in China.
FAU - Nie, Jing-Bao
AU  - Nie JB
AD  - Bioethics Centre, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
FAU - Elliott, Carl
AU  - Elliott C
AD  - Center for Bioethics, University of Minnesota, 410 Church St SE, Minneapolis, MN,
      55455-0346, USA. ellio023@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *COVID-19
MH  - China
MH  - Government
MH  - Humans
MH  - Morals
MH  - *Pandemics
MH  - Philosophy
MH  - Physicians
MH  - Political Systems
MH  - *Public Health/ethics
MH  - Respect
MH  - SARS-CoV-2
MH  - Self Concept
MH  - Social Control, Informal/*methods
MH  - *Whistleblowing/ethics
PMC - PMC7445730
OTO - NOTNLM
OT  - COVID-19
OT  - China
OT  - Decent society
OT  - Public health ethics
OT  - Whistle-blowing
EDAT- 2020/08/26 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s11673-020-09990-x [doi]
AID - 10.1007/s11673-020-09990-x [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Dec;17(4):543-547. doi: 10.1007/s11673-020-09990-x. Epub 2020 
      Aug 25.


PMID- 32840634
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1661-8564 (Electronic)
IS  - 1661-8556 (Linking)
VI  - 65
IP  - 7
DP  - 2020 Sep
TI  - Attitudes and practices of public health academics towards research funding from 
      for-profit organizations: cross-sectional survey.
PG  - 1133-1145
LID - 10.1007/s00038-020-01416-0 [doi]
AB  - OBJECTIVES: The growing trend of for-profit organization (FPO)-funded university 
      research is concerning because resultant potential conflicts of interest might
      lead to biases in methods, results, and interpretation. For public health
      academic programmes, receiving funds from FPOs whose products have negative
      health implications may be particularly problematic. METHODS: A cross-sectional
      survey assessed attitudes and practices of public health academics towards
      accepting funding from FPOs. The sampling frame included universities in five
      world regions offering a graduate degree in public health; 166 academics
      responded. Descriptive, bivariate, and logistic regression analyses were
      conducted. RESULTS: Over half of respondents were in favour of accepting funding 
      from FPOs; attitudes differed by world region and gender but not by rank,
      contract status, % salary offset required, primary identity, or exposure to an
      ethics course. In the last 5 years, almost 20% of respondents had received
      funding from a FPO. Sixty per cent of respondents agreed that there was potential
      for bias in seven aspects of the research process, when funds were from FPOs.
      CONCLUSIONS: Globally, public health academics should increase dialogue around
      the potential harms of research and practice funded by FPOs.
FAU - Nakkash, Rima
AU  - Nakkash R
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Ali, Ahmed
AU  - Ali A
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Alaouie, Hala
AU  - Alaouie H
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Asmar, Khalil
AU  - Asmar K
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Hirschhorn, Norbert
AU  - Hirschhorn N
AD  - Independent Consultant, Minneapolis, MN, USA.
FAU - Mugharbil, Sanaa
AU  - Mugharbil S
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Nuwayhid, Iman
AU  - Nuwayhid I
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - London, Leslie
AU  - London L
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
FAU - Saban, Amina
AU  - Saban A
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
FAU - Rashid, Sabina Faiz
AU  - Rashid SF
AD  - James P. Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
FAU - Ahmed, Md Koushik
AU  - Ahmed MK
AD  - James P. Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
FAU - Knai, Cecile
AU  - Knai C
AD  - London School of Hygiene and Tropical Medicine, London, UK.
FAU - Bigland, Charlotte
AU  - Bigland C
AD  - UK Specialty Registrar, Severn Postgraduate Medical Education School of Public
      Health, Health Education England, London, UK.
FAU - Afifi, Rima A
AU  - Afifi RA
AUID- ORCID: http://orcid.org/0000-0003-3154-3617
AD  - Department of Community and Behavioral Health, College of Public Health,
      University of Iowa, 145 N Riverside Drive, Iowa City, IA, USA.
      rima-afifi@uiowa.edu.
LA  - eng
GR  - 106773-001/IDRC
PT  - Journal Article
DEP - 20200825
PL  - Switzerland
TA  - Int J Public Health
JT  - International journal of public health
JID - 101304551
SB  - IM
MH  - Adult
MH  - Biomedical Research/*economics/statistics & numerical data/*trends
MH  - Conflict of Interest/economics
MH  - Cross-Sectional Studies
MH  - Female
MH  - Financing, Organized/*statistics & numerical data/*trends
MH  - Forecasting
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Public Health/*economics/trends
MH  - Research Personnel/*psychology/statistics & numerical data/trends
MH  - Universities/*economics/trends
PMC - PMC7497330
OTO - NOTNLM
OT  - Commercial determinants of health
OT  - Conflict of interest
OT  - For-profit corporation
OT  - Funding
OT  - Public health
OT  - Unhealthy commodity industries
EDAT- 2020/08/26 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s00038-020-01416-0 [doi]
AID - 10.1007/s00038-020-01416-0 [pii]
PST - ppublish
SO  - Int J Public Health. 2020 Sep;65(7):1133-1145. doi: 10.1007/s00038-020-01416-0.
      Epub 2020 Aug 25.


PMID- 32840631
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1661-8564 (Electronic)
IS  - 1661-8556 (Linking)
VI  - 65
IP  - 7
DP  - 2020 Sep
TI  - Commercial determinants of health: an ethical exploration.
PG  - 1123-1132
LID - 10.1007/s00038-020-01427-x [doi]
AB  - OBJECTIVES: This paper seeks to contribute toward a better understanding of
      commercial determinants of health by proposing a set of ethical principles that
      can be used by researchers and other health actors in understanding and
      addressing Commercial Determinants of Health (CDoH). METHODS: The paper is mainly
      based on a systematic review and qualitative analysis of the existing literature 
      on CDoH and public health ethics frameworks. We conducted searches using selected
      search engines (Google Scholar and Pubmed). For ethical challenges relating to
      CDOH, our searches in Google Scholar yielded 17 papers that discussed ethical
      challenges that affect CDoH. For ethical frameworks relevant for CDOH, our
      searches in Google Scholar and Pubmed yielded 15 papers that clearly described
      bioethical models including relevant ethical principles. Additionally, we
      consulted eight experts working on CDoH. Through these two methods, we were able 
      to identify ethical challenges as well as norms and values related to CDoH that
      we offer as candidates to comprise a foundational ethics framework for CDoH.
      RESULTS: Discussing risk factors associated with CDH frequently brings public
      health into conflict with the interests of industry actors in the food,
      automobile, beverage, alcohol, ammunition, gaming and tobacco industries
      including conflict between profit-making and public health. We propose the
      following candidate ethical principles that can be used in addressing CDoH: moral
      responsibility, nonmaleficence, social justice and equity, consumer sovereignty, 
      evidence-informed actions, responsiveness, accountability, appropriateness,
      transparency, beneficence and holism. CONCLUSIONS: We hope that this set of
      guiding principles will generate wider global debate on CDoH and help inform
      ethical analyses of corporate actions that contribute to ill health and policies 
      aimed at addressing CDoH. These candidate principles can guide researchers and
      health actors including corporations in addressing CDoH.
FAU - Ndebele, Paul
AU  - Ndebele P
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA. pndebele@gwu.edu.
FAU - Shaikh, Hina
AU  - Shaikh H
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA.
FAU - Paichadze, Nino
AU  - Paichadze N
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA.
FAU - Bari, Imran
AU  - Bari I
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA.
FAU - Michaels, David
AU  - Michaels D
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA.
FAU - Santos Burgoa, Carlos
AU  - Santos Burgoa C
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA.
FAU - Hyder, Adnan A
AU  - Hyder AA
AD  - Center for Commercial Determinants of Health, Milken Institute School of Public
      Health, The George Washington University, 950 New Hampshire Ave, Suite 722,
      Washington, DC, 20037, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200825
PL  - Switzerland
TA  - Int J Public Health
JT  - International journal of public health
JID - 101304551
SB  - IM
MH  - Commerce/*ethics/*statistics & numerical data
MH  - Humans
MH  - *Morals
MH  - Population Health/*statistics & numerical data
MH  - Social Determinants of Health/*statistics & numerical data
MH  - Social Justice/*ethics/*psychology/statistics & numerical data
OTO - NOTNLM
OT  - Bioethics
OT  - CDoH
OT  - Commercial determinants of health
OT  - Ethics
OT  - Private sector
OT  - Public health
EDAT- 2020/08/26 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/06/27 00:00 [revised]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s00038-020-01427-x [doi]
AID - 10.1007/s00038-020-01427-x [pii]
PST - ppublish
SO  - Int J Public Health. 2020 Sep;65(7):1123-1132. doi: 10.1007/s00038-020-01427-x.
      Epub 2020 Aug 25.


PMID- 32840630
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1661-8564 (Electronic)
IS  - 1661-8556 (Linking)
VI  - 65
IP  - 7
DP  - 2020 Sep
TI  - Medical labour under neoliberalism: an ethnographic study in Colombia.
PG  - 1011-1017
LID - 10.1007/s00038-020-01420-4 [doi]
AB  - OBJECTIVES: In order to increase the knowledge about the impacts of neoliberal
      market forces on physician's labour, this article's objectives are to analyse how
      and why the labour of physicians is transformed by neoliberalism, and the
      implications of these transformations for patient care. METHODS: Ethnographic
      investigation is carried out through semi-structured interviews with 20 general
      practitioners at public and private facilities in Colombia. The interviews were
      contrasted with national studies of physician's labour since the 1960s. A "mock" 
      job search was also simulated. The analysis was guided by Marxian frameworks. The
      study was approved by a Human Research Ethics Committee, and informed consent was
      obtained from all participants. RESULTS: The overpowering for-profit
      administration of the Colombian healthcare system imposes productivity mechanisms
      on physicians as a result of a deregulated labour market characterized by low
      salaries, reduced and self-funded social security benefits, and job insecurity.
      Overworked physicians with reduced autonomy become frustrated for not being able 
      to provide the care their patients need according to clinical standards.
      CONCLUSIONS: Under neoliberal conditions, medical labour becomes exploitable and 
      directly productive through its formal and real subsumption to Capital. The
      negative consequences of a progressive loss in physician's autonomy unveil the
      incompatibility between neoliberal health systems and people's health.
FAU - Ardila-Sierra, Adriana
AU  - Ardila-Sierra A
AUID- ORCID: http://orcid.org/0000-0002-4070-0365
AD  - Universidad Nacional de Colombia, Bogota, Colombia. amardilas@unal.edu.co.
FAU - Abadia-Barrero, Cesar
AU  - Abadia-Barrero C
AD  - University of Connecticut, Mansfield, CT, USA.
LA  - eng
GR  - 511-2010/Departamento Administrativo de Ciencia, Tecnologia e Innovacion
PT  - Journal Article
DEP - 20200825
PL  - Switzerland
TA  - Int J Public Health
JT  - International journal of public health
JID - 101304551
SB  - IM
MH  - Adult
MH  - Anthropology, Cultural/*economics/statistics & numerical data
MH  - Colombia
MH  - Delivery of Health Care/*economics/statistics & numerical data
MH  - Female
MH  - Health Personnel/*economics/statistics & numerical data
MH  - Humans
MH  - Income/*statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - *Politics
MH  - Salaries and Fringe Benefits/*economics/statistics & numerical data
MH  - Social Security/*economics/statistics & numerical data
OTO - NOTNLM
OT  - Clinical medicine
OT  - Employment
OT  - Exploitation
OT  - Neoliberalism
OT  - Physician-patient relations
OT  - Quality of health care
EDAT- 2020/08/26 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s00038-020-01420-4 [doi]
AID - 10.1007/s00038-020-01420-4 [pii]
PST - ppublish
SO  - Int J Public Health. 2020 Sep;65(7):1011-1017. doi: 10.1007/s00038-020-01420-4.
      Epub 2020 Aug 25.


PMID- 32840461
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20220417
IS  - 1938-9116 (Electronic)
IS  - 1538-5744 (Linking)
VI  - 54
IP  - 8
DP  - 2020 Nov
TI  - Erectile Dysfunction in Peripheral Vascular Disease: Endovascular
      Revascularization as a Potential Therapeutic Target.
PG  - 707-711
LID - 10.1177/1538574420952923 [doi]
AB  - INTRODUCTION: Erectile dysfunction (ED) affects more than 150 million men
      worldwide, with deleterious effects on quality of life. ED is known to be
      associated with ischemic heart disease but the impact of ED in patients with
      peripheral arterial disease (PAD) is unknown. We assessed the prevalence and
      severity of ED in patients with PVD. METHODS: Following ethical approval,
      sequential male patients diagnosed with PAD over a 1-year period following
      diagnosis of intermittent claudication. The patient demographics and
      comorbidities were recorded, with the International Index of Erectile Function
      (IIEF-5) questionnaire used to grade severity of ED. Computed tomographic
      angiography and severity of stenosis in the proximal vessels and internal
      pudendal arteries were correlated using a modified Bollinger Matrix scoring
      system. RESULTS: 60 patients were recruited, most (77.2%) reported erectile
      dysfunction (52.5% severe, 22.5% moderate). Patients with severe ED were more
      likely to have 2 or more comorbidities (P = .009). 86.7% with severe ED had
      bilateral internal pudendal artery stenosis with a mean modified Bollinger score 
      of 17.6. 35.5% of moderate ED patients had bilateral internal pudendal stenosis
      with a mean Bollinger score of 11.75. There was significant difference in overall
      scores between moderate and severe erectile dysfunction (p< 0.05), thus
      indicating a potential link between ED severity and extent of vessel stenosis.
      CONCLUSION: There is a substantial burden of clinically significant ED among
      patients with PAD. This study suggests ED should be discussed with all PAD
      patients and ED may precede a PAD diagnosis. There is scope for endovascular
      revascularization as a treatment option for ED secondary to arterial
      insufficiency.
FAU - Benaragama, Kapila S
AU  - Benaragama KS
AUID- ORCID: https://orcid.org/0000-0002-8131-4153
AD  - 8964University College London Hospitals NHS Foundation Trust, London, UK.
FAU - Singh, Aminder A
AU  - Singh AA
AUID- ORCID: https://orcid.org/0000-0002-9099-4162
AD  - 5983Cambridge Vascular Unit, Cambridge University Hospitals NHS Trust, Cambridge,
      UK.
FAU - Taj, Tahani
AU  - Taj T
AD  - 8964University College London Hospitals NHS Foundation Trust, London, UK.
FAU - Hague, Julian
AU  - Hague J
AD  - 8964University College London Hospitals NHS Foundation Trust, London, UK.
FAU - Boyle, Jonathan R
AU  - Boyle JR
AD  - 5983Cambridge Vascular Unit, Cambridge University Hospitals NHS Trust, Cambridge,
      UK.
FAU - Richards, Toby
AU  - Richards T
AD  - 8964University College London Hospitals NHS Foundation Trust, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200825
PL  - United States
TA  - Vasc Endovascular Surg
JT  - Vascular and endovascular surgery
JID - 101136421
SB  - IM
MH  - Aged
MH  - Computed Tomography Angiography
MH  - Cross-Sectional Studies
MH  - Endovascular Procedures/instrumentation
MH  - England/epidemiology
MH  - Humans
MH  - Impotence, Vasculogenic/diagnostic imaging/*epidemiology/physiopathology/therapy
MH  - Male
MH  - *Penile Erection
MH  - Peripheral Arterial Disease/diagnostic
      imaging/*epidemiology/physiopathology/therapy
MH  - Pilot Projects
MH  - Prevalence
MH  - Prognosis
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Stents
OTO - NOTNLM
OT  - angioplasty
OT  - endovascular
OT  - erectile dysfunction
OT  - peripheral arterial disease
OT  - stenting
EDAT- 2020/08/26 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1177/1538574420952923 [doi]
PST - ppublish
SO  - Vasc Endovascular Surg. 2020 Nov;54(8):707-711. doi: 10.1177/1538574420952923.
      Epub 2020 Aug 25.


PMID- 32840454
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200827
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 9
DP  - 2020 Sep
TI  - Encouraging Vaccination Ethically: How Can Pox Parties for Grannies and
      Vaccine-Preventable Diseases Be Avoided?
PG  - 68-70
LID - 10.1080/15265161.2020.1795545 [doi]
FAU - Vanderslott, Samantha
AU  - Vanderslott S
AUID- ORCID: 0000-0001-8685-7758
AD  - University of Oxford.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Sep;20(9):45-57. PMID: 32840450
CIN - Am J Bioeth. 2020 Dec;20(12):W1-W6. PMID: 33196391
MH  - *Chickenpox
MH  - Humans
MH  - Vaccination
MH  - *Vaccine-Preventable Diseases
EDAT- 2020/08/26 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - 10.1080/15265161.2020.1795545 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Sep;20(9):68-70. doi: 10.1080/15265161.2020.1795545.


PMID- 32840450
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20200928
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 9
DP  - 2020 Sep
TI  - Pox Parties for Grannies? Chickenpox, Exogenous Boosting, and Harmful Injustices.
PG  - 45-57
LID - 10.1080/15265161.2020.1795528 [doi]
AB  - Some societies tolerate or encourage high levels of chickenpox infection among
      children to reduce rates of shingles among older adults. This tradeoff is
      unethical. The varicella zoster virus (VZV) causes both chickenpox and shingles. 
      After people recover from chickenpox, VZV remains in their nerve cells. If their 
      immune systems become unable to suppress the virus, they develop shingles.
      According to the Exogenous Boosting Hypothesis (EBH), a person's ability to keep 
      VZV suppressed can be 'boosted' through exposure to active chickenpox infections.
      We argue that even if this hypothesis were true, immunization policies that
      discourage routine childhood varicella vaccination in order to prevent shingles
      for other people are unethical. Such policies harm children and treat them as
      mere means for the benefit of others, and are inconsistent with how parents
      should treat their children and physicians should treat their patients. These
      policies also seem incompatible with institutional transparency.
FAU - Malm, Heidi
AU  - Malm H
AD  - Loyola University Chicago.
FAU - Navin, Mark Christopher
AU  - Navin MC
AUID- ORCID: 0000-0002-8511-6517
AD  - Loyola University Chicago.
AD  - Oakland University.
AD  - Oakland University William Beaumont School of Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Sep;20(9):76-78. PMID: 32840452
CIN - Am J Bioeth. 2020 Sep;20(9):73-75. PMID: 32840453
CIN - Am J Bioeth. 2020 Sep;20(9):68-70. PMID: 32840454
CIN - Am J Bioeth. 2020 Sep;20(9):58-60. PMID: 32880517
CIN - Am J Bioeth. 2020 Sep;20(9):65-67. PMID: 32880518
CIN - Am J Bioeth. 2020 Sep;20(9):70-72. PMID: 32880519
CIN - Am J Bioeth. 2020 Sep;20(9):62-65. PMID: 32880520
CIN - Am J Bioeth. 2020 Sep;20(9):78-80. PMID: 32880521
CIN - Am J Bioeth. 2020 Sep;20(9):60-62. PMID: 32880522
CIN - Am J Bioeth. 2020 Sep;20(9):81-83. PMID: 32880523
CIN - Am J Bioeth. 2020 Dec;20(12):W1-W6. PMID: 33196391
MH  - Aged
MH  - Chickenpox/*prevention & control/transmission
MH  - Child
MH  - Disease Transmission, Infectious/*ethics
MH  - Herpes Zoster/*prevention & control/transmission
MH  - Herpesvirus 3, Human/*immunology
MH  - Humans
MH  - United States
MH  - Vaccination/*ethics
OTO - NOTNLM
OT  - *Immunization ethics
OT  - *intergenerational justice
OT  - *pediatric ethics
OT  - *public health ethics
OT  - *varicella
EDAT- 2020/08/26 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - 10.1080/15265161.2020.1795528 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Sep;20(9):45-57. doi: 10.1080/15265161.2020.1795528.


PMID- 32840248
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220211
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - Correction to: The Perfect Moral Storm: Diverse Ethical Considerations in the
      COVID-19 Pandemic.
PG  - 85
LID - 10.1007/s41649-020-00131-5 [doi]
AB  - [This corrects the article DOI: 10.1007/s41649-020-00125-3.].
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Xafis, Vicki
AU  - Xafis V
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Schaefer, G Owen
AU  - Schaefer GO
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Labude, Markus K
AU  - Labude MK
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Zhu, Yujia
AU  - Zhu Y
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Hsu, Li Yang
AU  - Hsu LY
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.grid.4280.e0000 0001 2180 6431
AD  - Yong Loo Lin School of Medicine, National University of Singapore,
      Singapore.grid.4280.e0000 0001 2180 6431
LA  - eng
PT  - Published Erratum
DEP - 20200606
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
EFR - Asian Bioeth Rev. 2020 May 28;12(2):65-83. PMID: 32837550
PMC - PMC7275127
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:01
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:01 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1007/s41649-020-00131-5 [doi]
AID - 131 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Jun 6;12(2):85. doi: 10.1007/s41649-020-00131-5.
      eCollection 2020 Jun.


PMID- 32840217
OWN - NLM
STAT- MEDLINE
DCOM- 20210713
LR  - 20210713
IS  - 1105-2333 (Print)
IS  - 1105-2333 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Apr-Jun
TI  - Involuntary psychiatric hospitalization of children and adolescents in Northern
      Greece: Retrospective epidemiological study and related ethical issues.
PG  - 129-139
LID - 10.22365/jpsych.2020.312.129 [doi]
AB  - The aim of the present study was to investigate epidemiological data on
      involuntary hospitalization of underage patients in psychiatric settings and
      illustrate the related ethical issues. The medical records of 131 involuntary
      psychiatric admissions of children and adolescents ordered by public prosecutor
      between 2005 and 2014 were examined carefully. The examined variables involved
      the place of origin, the place of residence of minors after discharge, the length
      of stay in hospitals, the discharge diagnosis, the rate at which the minors were 
      introduced to police and other authorities before their hospitalization, and the 
      results of the neuropsychological assessment (WISC II). Data were analyzed by
      SPSS (Statistical Package for the Social Sciences). The mean age of the minors
      was 14.19 years (Male: Female ratio; 1.6:1). First, a high rate of incidences of 
      compulsory admissions was found [5-year period (2005-2009):(2010-2014) ratio;
      1:1.85] most likely due to organizational factors, which, however, could have
      been avoided in a more patient-oriented healthcare system. It is most likely that
      the criteria used for making decisions in favor of compulsory admissions were
      disproportionately (unduly) broad. In parallel, it was observed that, during
      2010-2014, despite the increase in the rate of the prosecutor's orders, there was
      a decrease in the duration of coercive hospitalization of minors in psychiatric
      departments of hospitals in comparison to the period 2005-2009 [5-year period
      duration of hospitalization (2005-2009):(2010-2014) ratio; 2.33:1]. Furthermore, 
      family was found likely to wield considerable influence on the decision-making
      for compulsory admissions. In addition, the effectiveness of a compulsory
      hospitalization of minors in a child and adolescent psychiatry department was
      found largely dependent on the type of the underlying mental health problem. In
      that respect, low rates of recidivism (7.6%) indicated that the measure of
      involuntary hospitalization was necessary and effective. It was also observed
      that the short-term removal of the minor from the family environment was a
      potentially relieving strategy for both the child and the family apart from the
      need for therapeutic intervention. The paper concludes by highlighting the role
      of a multi-stakeholder decision-making process (which entails shared
      decision-making as an integral component of providing mental healthcare to
      minors) in facilitating a decision about involuntary psychiatric hospitalization 
      that is proportional and respectful to patient autonomy.
FAU - Voultsos, P
AU  - Voultsos P
AD  - Laboratory of Forensic Medicine and Toxicology, Faculty of Medicine, Aristotle
      University, Thessaloniki.
FAU - Tsamadou, E
AU  - Tsamadou E
AD  - Department of Child & Adolescent Psychiatry, Hippokration General Hospital of
      Thessaloniki, Thessaloniki.
FAU - Karakasi, M-V
AU  - Karakasi MV
AD  - Third University Department of Psychiatry, AHEPA University General
      Hospital-Department of Mental Health, Aristotle University-Faculty of Medicine,
      Thessaloniki.
AD  - Laboratory of Forensic Sciences, Democritus University of Thrace, School of
      Medicine, Alexandroupolis, Greece.
FAU - Raikos, N
AU  - Raikos N
AD  - Laboratory of Forensic Medicine and Toxicology, Faculty of Medicine, Aristotle
      University, Thessaloniki.
FAU - Pavlidis, P
AU  - Pavlidis P
AD  - Laboratory of Forensic Sciences, Democritus University of Thrace, School of
      Medicine, Alexandroupolis, Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Psychiatriki
JT  - Psychiatrike = Psychiatriki
JID - 101534363
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child Advocacy/*ethics
MH  - Child Welfare
MH  - Family Health
MH  - Family Relations/*psychology
MH  - Female
MH  - Greece/epidemiology
MH  - Hospitals, Psychiatric/statistics & numerical data
MH  - Humans
MH  - *Involuntary Treatment/ethics/legislation & jurisprudence/methods
MH  - Male
MH  - Medical Records/statistics & numerical data
MH  - *Mental Disorders/epidemiology/psychology/therapy
MH  - Neuropsychological Tests
MH  - Secondary Prevention/statistics & numerical data
MH  - Treatment Outcome
EDAT- 2020/08/26 06:00
MHDA- 2021/07/14 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/07/14 06:00 [medline]
AID - 10.22365/jpsych.2020.312.129 [doi]
PST - ppublish
SO  - Psychiatriki. 2020 Apr-Jun;31(2):129-139. doi: 10.22365/jpsych.2020.312.129.


PMID- 32840069
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 2047-8984 (Electronic)
IS  - 1354-5752 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Nov 11
TI  - Management of cardiac arrest following blunt trauma: a critical evaluation of
      resuscitative thoracotomy.
PG  - 20-24
LID - 10.7748/en.2020.e2029 [doi]
AB  - Survival rates in patients who sustain cardiac arrest following blunt trauma are 
      suboptimal. Although resuscitative thoracotomy is advocated for managing patients
      who present with penetrating trauma, its use in blunt trauma is controversial
      because it has been consistently shown to produce suboptimal outcomes. This
      article examines some of the challenges associated with decision-making regarding
      the management of patients with cardiac arrest following blunt trauma, critically
      evaluates the role of resuscitative thoracotomy and considers some novel
      interventions that may provide clinicians with alternative management options.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Davies, Nicola
AU  - Davies N
AD  - Emergency Department, The Royal London Hospital, London, England.
FAU - English, William
AU  - English W
AD  - Queen's Hospital, London, England.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - England
TA  - Emerg Nurse
JT  - Emergency nurse : the journal of the RCN Accident and Emergency Nursing
      Association
JID - 9208913
MH  - Cardiopulmonary Resuscitation/*methods
MH  - Emergency Service, Hospital
MH  - Heart Arrest/*etiology/*surgery
MH  - Humans
MH  - Thoracotomy/*methods
MH  - Wounds, Nonpenetrating/*complications
OTO - NOTNLM
OT  - cardiorespiratory
OT  - clinical
OT  - decision-making
OT  - emergency care
OT  - ethical issues
OT  - professional
OT  - professional issues
OT  - surgical
OT  - trauma
OT  - urgent care
COIS- None declared
EDAT- 2020/08/26 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.7748/en.2020.e2029 [doi]
AID - e2029 [pii]
PST - ppublish
SO  - Emerg Nurse. 2020 Nov 11;28(6):20-24. doi: 10.7748/en.2020.e2029. Epub 2020 Aug
      25.


PMID- 32839878
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 2195-7819 (Electronic)
IS  - 2195-7819 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Aug 25
TI  - Just data? Solidarity and justice in data-driven medicine.
PG  - 8
LID - 10.1186/s40504-020-00101-7 [doi]
AB  - This paper argues that data-driven medicine gives rise to a particular normative 
      challenge. Against the backdrop of a distinction between the good and the right, 
      harnessing personal health data towards the development and refinement of
      data-driven medicine is to be welcomed from the perspective of the good. Enacting
      solidarity drives progress in research and clinical practice. At the same time,
      such acts of sharing could-especially considering current developments in big
      data and artificial intelligence-compromise the right by leading to injustices
      and affecting concrete modes of individual self-determination. In order to
      address this potential tension, two key elements for ethical reflection on
      data-driven medicine are proposed: the controllability of information flows,
      including technical infrastructures that are conducive towards controllability,
      and a paradigm shift towards output-orientation in governance and policy.
FAU - Hummel, Patrik
AU  - Hummel P
AUID- ORCID: http://orcid.org/0000-0001-9668-0810
AD  - Department of Theology, Friedrich-Alexander University Erlangen-Nurnberg (FAU),
      Kochstrasse 6, 91054, Erlangen, Germany. patrik.hummel@fau.de.
FAU - Braun, Matthias
AU  - Braun M
AUID- ORCID: https://orcid.org/0000-0002-6687-6027
AD  - Department of Theology, Friedrich-Alexander University Erlangen-Nurnberg (FAU),
      Kochstrasse 6, 91054, Erlangen, Germany.
LA  - eng
GR  - 01GP1903A/Bundesministerium fur Bildung und Forschung (DE)
GR  - ZMV/1 - 2517 FSB 013/Bundesministerium fur Gesundheit (DE)
PT  - Journal Article
DEP - 20200825
PL  - England
TA  - Life Sci Soc Policy
JT  - Life sciences, society and policy
JID - 101603561
SB  - IM
MH  - Artificial Intelligence/*standards
MH  - *Big Data
MH  - Biomedical Research/ethics/*organization & administration/standards
MH  - Humans
MH  - Information Dissemination/*methods
MH  - Medicine/*organization & administration
PMC - PMC7445015
OTO - NOTNLM
OT  - Algorithm ethics
OT  - Controllability
OT  - Data ethics
OT  - Data-driven medicine, Precision medicine
OT  - Justice
OT  - Privacy
OT  - Solidarity
EDAT- 2020/08/26 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/08/26 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
AID - 10.1186/s40504-020-00101-7 [doi]
AID - 10.1186/s40504-020-00101-7 [pii]
PST - epublish
SO  - Life Sci Soc Policy. 2020 Aug 25;16(1):8. doi: 10.1186/s40504-020-00101-7.


PMID- 32839695
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2214-6296 (Print)
VI  - 68
DP  - 2020 Oct
TI  - What opportunities could the COVID-19 outbreak offer for sustainability
      transitions research on electricity and mobility?
PG  - 101666
LID - 10.1016/j.erss.2020.101666 [doi]
AB  - The COVID-19 pandemic is a major landscape shock that is having pervasive effects
      across socio-technical systems. Due to its recentness, sustainability scientists 
      and other researchers have only started to investigate the implications of this
      crisis. The COVID-19 outbreak presents a unique opportunity to analyze in real
      time the effects of a protracted landscape-scale perturbation on the trajectories
      of sustainability transitions. In this perspective, we explore the ramifications 
      for sustainability transition research on electricity and mobility, drawing from 
      selected examples in Finland and Sweden. The long-term consequences of the
      COVID-19 pandemic are likely to trigger more permanent changes connected to the
      digitalization of work and other daily activities, thus reducing mobility needs
      and overall fossil-energy consumption. The crisis may encourage governance
      systems to be better prepared for different types of shocks in the future, while 
      it also contains a threat of increasingly populist or undemocratic political
      responses and increased securitization. These developments can guide research by 
      addressing the reproduction of new practices arising from the COVID-19 outbreak
      to accelerate sustainability transitions, enhancing understanding of the role of 
      governance in transitions, and bringing to attention the ethical and political
      implications of landscape shocks.
CI  - (c) 2020 The Authors.
FAU - Kanda, Wisdom
AU  - Kanda W
AD  - Division of Environmental Technology and Management, Linkoping University,
      Sweden.
FAU - Kivimaa, Paula
AU  - Kivimaa P
AD  - Finnish Environment Institute (SYKE), Finland.
AD  - Science Policy Research Unit (SPRU), University of Sussex, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200629
PL  - Netherlands
TA  - Energy Res Soc Sci
JT  - Energy research & social science
JID - 101677741
PMC - PMC7322472
OTO - NOTNLM
OT  - COVID-19
OT  - Landscape shocks
OT  - Sustainability transitions
OT  - Window of opportunity
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:01
CRDT- 2020/08/26 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:01 [medline]
AID - 10.1016/j.erss.2020.101666 [doi]
AID - S2214-6296(20)30241-3 [pii]
AID - 101666 [pii]
PST - ppublish
SO  - Energy Res Soc Sci. 2020 Oct;68:101666. doi: 10.1016/j.erss.2020.101666. Epub
      2020 Jun 29.


PMID- 32839672
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201210
IS  - 2093-7911 (Print)
IS  - 2093-7911 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Dec
TI  - The Need for Developing Technology-Enabled, Safe, and Ethical Workforce for
      Healthcare Delivery.
PG  - 533-536
LID - 10.1016/j.shaw.2020.08.003 [doi]
AB  - Strengthening of the health system is a safety imperative, especially in a crisis
      as caused by the ongoing COVID-19 pandemic. While there is a need for enhancing
      the number and skill sets of the public health professionals, especially the
      frontline workers, it will be prudent to use the digital health technologies,
      including artificial intelligence, in enhancing the capacity of the healthcare
      professional education and delivery. However, it has to be ensured that an
      ethical and safe approach is adopted to develop and use digital health technology
      and, ethically appropriate training is imparted, to enhance the capacity of the
      human resources for health, leading to an overall health system strengthening.
CI  - (c) 2020 The Authors.
FAU - Sarbadhikari, Suptendra N
AU  - Sarbadhikari SN
AD  - Chitkara School of Health Sciences, Chitkara University, Punjab, 140401, India.
FAU - Pradhan, Keerti B
AU  - Pradhan KB
AD  - Chitkara School of Health Sciences, Chitkara University, Punjab, 140401, India.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - Korea (South)
TA  - Saf Health Work
JT  - Safety and health at work
JID - 101542940
PMC - PMC7438991
OTO - NOTNLM
OT  - Ethical capacity building
OT  - Ethical digital health
OT  - Fourth industrial revolution
OT  - Occupational health and safety
OT  - Technology-enabled human resources for health
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:01
CRDT- 2020/08/26 06:00
PHST- 2020/07/03 00:00 [received]
PHST- 2020/08/11 00:00 [revised]
PHST- 2020/08/14 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:01 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1016/j.shaw.2020.08.003 [doi]
AID - S2093-7911(20)30316-4 [pii]
PST - ppublish
SO  - Saf Health Work. 2020 Dec;11(4):533-536. doi: 10.1016/j.shaw.2020.08.003. Epub
      2020 Aug 20.


PMID- 32839671
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - COVID-19 immunity certificates: science, ethics, policy, and law.
PG  - lsaa035
LID - 10.1093/jlb/lsaa035 [doi]
AB  - There is much discussion of adopting COVID-19 immunity certificates to allow
      those proven to have antibodies to the SARS-CoV-2 virus that causes COVID-19 to
      resume normal life and help restart the economy. This article points out issues
      that must be considered before adopting any such program. These issues fall into 
      six categories: the uncertain science of COVID-19 immunity; the questionable
      quality of COVID-19 antibody tests; practical problems with issuing such
      certificates; deciding how the certificates might be used; ethical and social
      issues they would raise, especially fairness and self-infection; and potential
      legal barriers. It does not ultimately take a position on whether some narrow
      COVID-19 immunity plans should be adopted, concluding that the answer depends on 
      too many currently unknown conditions. But its seventh part makes recommendations
      to decision-makers who might consider implementing such programs.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Greely, Henry T
AU  - Greely HT
AUID- ORCID: 0000-0002-1105-6734
AD  - Center for Law and the Biosciences, Stanford University, Stanford, CA 94305, USA.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7313854
OTO - NOTNLM
OT  - Antibodies
OT  - Covid-19
OT  - Ethics
OT  - Immunity Certificates
OT  - Law
OT  - Policy
OT  - SARS-CoV-2
OT  - Testing
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:01
CRDT- 2020/08/26 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:01 [medline]
AID - 10.1093/jlb/lsaa035 [doi]
AID - lsaa035 [pii]
PST - epublish
SO  - J Law Biosci. 2020 May 28;7(1):lsaa035. doi: 10.1093/jlb/lsaa035. eCollection
      2020 Jan-Jun.


PMID- 32839571
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220210
IS  - 1530-0366 (Electronic)
IS  - 1098-3600 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Dec
TI  - Alaska Native genomic research: perspectives from Alaska Native leaders, federal 
      staff, and biomedical researchers.
PG  - 1935-1943
LID - 10.1038/s41436-020-0926-y [doi]
AB  - Meaningful engagement of Alaska Native (AN) tribes and tribal health
      organizations is essential in the conduct of socially responsible and ethical
      research. As genomics becomes increasingly important to advancements in medicine,
      there is a risk that populations not meaningfully included in genomic research
      will not benefit from the outcomes of that research. AN people have historically 
      been underrepresented in biomedical research; AN underrepresentation in genomics 
      research is compounded by mistrust based on past abuses, concerns about privacy
      and data ownership, and cultural considerations specific to this type of
      research. Working together, the National Human Genome Research Institute and two 
      Alaska Native health organizations, Southcentral Foundation and the Alaska Native
      Health Board, cosponsored a workshop in July 2018 to engage key stakeholders in
      discussion, strengthen relationships, and facilitate partnership and
      consideration of participation of AN people in community-driven biomedical and
      genomic research. AN priorities related to translation of genomics research to
      health and health care, return of genomic results, design of research studies,
      and data sharing were discussed. This report summarizes the perspectives that
      emerged from the dialogue and offers considerations for effective and socially
      responsible genomic research partnerships with AN communities.
FAU - Hiratsuka, Vanessa Y
AU  - Hiratsuka VY
AUID- ORCID: http://orcid.org/0000-0002-4234-9441
AD  - Southcentral Foundation, Anchorage, AK, USA. vhiratsuka@scf.cc.
FAU - Hahn, Michael J
AU  - Hahn MJ
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Woodbury, R Brian
AU  - Woodbury RB
AD  - Southcentral Foundation, Anchorage, AK, USA.
FAU - Hull, Sara Chandros
AU  - Hull SC
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Wilson, David R
AU  - Wilson DR
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Bonham, Vence L
AU  - Bonham VL
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Dillard, Denise A
AU  - Dillard DA
AD  - Southcentral Foundation, Anchorage, AK, USA.
CN  - Alaska Native Genomics Research Workshop Group
FAU - Avey, Jaedon P
AU  - Avey JP
AD  - Southcentral Foundation, Anchorage, AK, USA.
FAU - Beckel-Mitchener, Andrea C
AU  - Beckel-Mitchener AC
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Blome, Juliana
AU  - Blome J
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Claw, Katrina
AU  - Claw K
AD  - Department of Medicine-Bioinformatics, University of Colorado Denver, Aurora, CO,
      USA.
FAU - Ferucci, Elizabeth D
AU  - Ferucci ED
AD  - Alaska Native Tribal Health Consortium, Anchorage, AK, USA.
FAU - Gachupin, Francine C
AU  - Gachupin FC
AD  - Department of Family and Community Medicine, University of Arizona, Tucson, AZ,
      USA.
FAU - Ghazarian, Armen
AU  - Ghazarian A
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Hindorff, Lucia
AU  - Hindorff L
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Jooma, Sonya
AU  - Jooma S
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Trinidad, Susan B
AU  - Trinidad SB
AD  - Department of Bioethics, University of Washington, Seattle, WA, USA.
FAU - Troyer, Jennifer
AU  - Troyer J
AD  - National Institutes of Health, Bethesda, MD, USA.
FAU - Walajahi, Hina
AU  - Walajahi H
AD  - National Institutes of Health, Bethesda, MD, USA.
LA  - eng
GR  - R01 HG009500/HG/NHGRI NIH HHS/United States
GR  - RM1 HG009042/HG/NHGRI NIH HHS/United States
GR  - S06 GM123545/GM/NIGMS NIH HHS/United States
GR  - U54 GM115371/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200825
PL  - United States
TA  - Genet Med
JT  - Genetics in medicine : official journal of the American College of Medical
      Genetics
JID - 9815831
SB  - IM
MH  - *Alaskan Natives/genetics
MH  - *Biomedical Research
MH  - Genomics
MH  - Humans
MH  - *Indians, North American
MH  - Information Dissemination
PMC - PMC7708301
MID - NIHMS1624984
OTO - NOTNLM
OT  - *Alaska Natives, North American
OT  - *US National Institutes of Health
OT  - *ethics
OT  - *social responsibility
OT  - *trust
IR  - Avey JP
FIR - Avey, Jaedon P
IR  - Beckel-Mitchener AC
FIR - Beckel-Mitchener, Andrea C
IR  - Blome J
FIR - Blome, Juliana
IR  - Claw K
FIR - Claw, Katrina
IR  - Ferucci ED
FIR - Ferucci, Elizabeth D
IR  - Gachupin FC
FIR - Gachupin, Francine C
IR  - Ghazarian A
FIR - Ghazarian, Armen
IR  - Hindorff L
FIR - Hindorff, Lucia
IR  - Jooma S
FIR - Jooma, Sonya
IR  - Trinidad SB
FIR - Trinidad, Susan B
IR  - Troyer J
FIR - Troyer, Jennifer
IR  - Walajahi H
FIR - Walajahi, Hina
EDAT- 2020/08/26 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - 10.1038/s41436-020-0926-y [doi]
AID - S1098-3600(21)00819-4 [pii]
PST - ppublish
SO  - Genet Med. 2020 Dec;22(12):1935-1943. doi: 10.1038/s41436-020-0926-y. Epub 2020
      Aug 25.


PMID- 32839265
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210903
IS  - 2047-9956 (Print)
IS  - 2047-9956 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Sep
TI  - Guidelines for evidence synthesis reporting: medications.
PG  - 306-309
LID - 10.1136/ejhpharm-2018-001593 [doi]
AB  - In the process of determining if a drug is valuable enough to be included in a
      hospital's pharmacotherapeutic repertoire many factors should be taken into
      account. In order to develop a guide, the methodology of different appraisal
      working groups and similar methodological documents published by Health
      Technology Assessment agencies have been taken into account. We recommend that
      reports are structured with the following headings:
      Medication/Description/Authorised indication; Description of the disease;
      Pathology reference treatment; Evaluation of efficacy and safety (Bibliographic
      search, Quality assessment, Efficacy and safety results); Assessment of ethical, 
      organisational, social and legal aspects; Strengths and limitations of available 
      evidence; Pharmacoeconomic evaluation; and Key points. This guide to evaluate
      technologies may be used as a tool in decision-making scenarios related to health
      innovation. It could be used by hospital pharmacists and by clinicians, health
      system professionals and public services advisors.
CI  - (c) European Association of Hospital Pharmacists 2020. No commercial re-use. See 
      rights and permissions. Published by BMJ.
FAU - Frutos Perez-Surio, Alberto
AU  - Frutos Perez-Surio A
AUID- ORCID: 0000-0001-9962-3387
AD  - Pharmacy Department, University Clinical Hospital 'Lozano Blesa', Zaragoza,
      Aragon, Spain.
AD  - Department of Microbiology, Preventive Medicine and Public Health, University of 
      Zaragoza, Zaragoza, Aragon, Spain.
FAU - Jordan de Luna, Consuelo
AU  - Jordan de Luna C
AD  - Pharmacy Department, Institut Catala d'Oncologia (ICO), L'Hospitalet de
      Llobregat, Cataluna, Spain.
LA  - eng
PT  - Journal Article
DEP - 20181116
PL  - England
TA  - Eur J Hosp Pharm
JT  - European journal of hospital pharmacy : science and practice
JID - 101578294
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Biomedical Technology/methods/*standards
MH  - Evidence-Based Medicine/methods/*standards
MH  - Health Personnel/standards
MH  - Humans
MH  - Pharmaceutical Preparations/administration & dosage/*standards
MH  - Pharmacy Service, Hospital/methods/*standards
MH  - Practice Guidelines as Topic/*standards
PMC - PMC7447240
OTO - NOTNLM
OT  - *evidence-based medicine
OT  - *pharmacy management (personnel)
OT  - *research and teaching
COIS- Competing interests: None declared.
EDAT- 2020/08/26 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/08/26 06:00
PHST- 2018/04/16 00:00 [received]
PHST- 2018/10/23 00:00 [revised]
PHST- 2018/10/25 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
AID - ejhpharm-2018-001593 [pii]
AID - 10.1136/ejhpharm-2018-001593 [doi]
PST - ppublish
SO  - Eur J Hosp Pharm. 2020 Sep;27(5):306-309. doi: 10.1136/ejhpharm-2018-001593. Epub
      2018 Nov 16.


PMID- 32839231
OWN - NLM
STAT- Publisher
LR  - 20200825
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 24
TI  - Against the strengthened impairment argument: never-born fetuses have no FLO to
      deprive.
LID - medethics-2020-106579 [pii]
LID - 10.1136/medethics-2020-106579 [doi]
AB  - In order for the so-called strengthened impairment argument (SIA) to succeed, it 
      must posit some reason R that causing fetal alcohol syndrome (FAS) is immoral,
      one that also holds in cases of abortion. In formulating SIA, Blackshaw and
      Hendricks borrow from Don Marquis to claim that the reason R that causing FAS is 
      immoral lies in the fact that it deprives an organism of a future like ours (an
      FLO). I argue here that SIA fails to show that it is immoral to cause FAS and
      abort fetuses that will not be born because it deprives them of an FLO. This is
      because fetuses that will not be born have no chance of having an FLO in the
      first place, so causing FAS for and aborting them cannot deprive them of one. I
      then consider three responses to my argument. I conclude that each fails. SIA
      does not accomplish its task of showing why it is immoral to impair fetuses that 
      will not be born. Perhaps it can accomplish the task of showing why it is immoral
      to impair fetuses that will be born, but not without sacrificing at least some of
      its alleged significance.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Gillham, Alex R
AU  - Gillham AR
AUID- ORCID: http://orcid.org/0000-0003-2234-6945
AD  - Department of Philosophy, Saint Bonaventure University, Saint Bonaventure, New
      York, USA argillham@icloud.com.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - abortion
OT  - ethics
COIS- Competing interests: None declared.
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/06/11 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - medethics-2020-106579 [pii]
AID - 10.1136/medethics-2020-106579 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 24. pii: medethics-2020-106579. doi:
      10.1136/medethics-2020-106579.


PMID- 32839230
OWN - NLM
STAT- Publisher
LR  - 20200901
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 24
TI  - Instruments of health and harm: how the procurement of healthcare goods
      contributes to global health inequality.
LID - medethics-2020-106286 [pii]
LID - 10.1136/medethics-2020-106286 [doi]
AB  - Many healthcare goods, such as surgical instruments, textiles and gloves, are
      manufactured in unregulated factories and sweatshops where, amongst other labour 
      rights violations, workers are subject to considerable occupational health risks.
      In this paper we undertake an ethical analysis of the supply of
      sweatshop-produced surgical goods to healthcare providers, with a specific focus 
      on the National Health Service of the United Kingdom. We contend that while
      labour abuses and occupational health deficiencies are morally unacceptable in
      the production of any commodity, an additional wrong is incurred when the health 
      of certain populations is secured in ways that endanger the health and well-being
      of people working and living elsewhere. While some measures have been taken to
      better regulate the supply chain to healthcare providers in the UK, further
      action is needed to ensure that surgical goods are sourced from suppliers who
      protect the labour and occupational health rights of their workers.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Trueba, Mei L
AU  - Trueba ML
AUID- ORCID: http://orcid.org/0000-0002-3468-9411
AD  - Global Health and Infection, Brighton and Sussex Medical School, Falmer,
      Brighton, UK m.trueba@bsms.ac.uk.
FAU - Bhutta, Mahmood F
AU  - Bhutta MF
AD  - Department of Ear, Nose and Throat (ENT), Brighton and Sussex University
      Hospitals NHS Trust, Brighton, UK.
FAU - Shahvisi, Arianne
AU  - Shahvisi A
AUID- ORCID: http://orcid.org/0000-0002-9347-7566
AD  - Ethics, Brighton and Sussex Medical School, Falmer, Brighton, UK.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - NHS
OT  - global health inequality
OT  - health care economics
OT  - healthcare supply chains
OT  - occupational health
OT  - occupational health and safety
OT  - public health ethics
OT  - resource allocation
OT  - rights
OT  - surgical equipment
COIS- Competing interests: None declared.
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - medethics-2020-106286 [pii]
AID - 10.1136/medethics-2020-106286 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 24. pii: medethics-2020-106286. doi:
      10.1136/medethics-2020-106286.


PMID- 32839229
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - 'Harm threshold': capacity for decision-making may be reduced by long-term
      pubertal suppression.
PG  - 759-760
LID - 10.1136/medethics-2020-106625 [doi]
FAU - Nahata, Leena
AU  - Nahata L
AD  - Endocrinology and Center for Biobehavioral Health, Nationwide Children's
      Hospital, Columbus, Ohio, USA.
FAU - Quinn, Gwendolyn P
AU  - Quinn GP
AD  - Obstetrics and Gynecology, NYU Langone Health, New York, New York, USA
      gwendolyn.quinn@nyumc.org.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200824
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):743-752. PMID: 32709753
CIN - J Med Ethics. 2020 Nov;46(11):761-762. PMID: 33087409
MH  - Adult
MH  - *Decision Making
MH  - Humans
MH  - *Informed Consent
MH  - Puberty
OTO - NOTNLM
OT  - *capacity
OT  - *decision-making
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/08/26 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/06/22 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - medethics-2020-106625 [pii]
AID - 10.1136/medethics-2020-106625 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):759-760. doi: 10.1136/medethics-2020-106625. Epub
      2020 Aug 24.


PMID- 32839228
OWN - NLM
STAT- Publisher
LR  - 20200825
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 24
TI  - Ethical issues raised by intergenerational monitoring in clinical trials of
      germline gene modification.
LID - medethics-2020-106095 [pii]
LID - 10.1136/medethics-2020-106095 [doi]
AB  - As research involving gene editing continues to advance, we are headed in the
      direction of being able to modify the human germline. Should we reach a point
      where an argument can be made that the benefits of preventing unborn children and
      future generations from inheriting genetic conditions that cause tremendous
      suffering outweigh the risks associated with altering the human germline, the
      next step will be to design clinical trials using this technology in humans.
      These clinical trials will likely require careful follow-up and monitoring of
      future generations born with altered genes. This paper addresses some of the
      ethical issues raised by intergenerational monitoring and sets out to show that
      these issues can be avoided with careful consideration and clinical trial design.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Yeager, Austen
AU  - Yeager A
AUID- ORCID: http://orcid.org/0000-0002-5546-0982
AD  - School of Medicine, Oregon Health & Science University, Portland, Oregon, USA
      yeager@ohsu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical trials
OT  - genethics
OT  - genetic engineering
COIS- Competing interests: None declared.
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - medethics-2020-106095 [pii]
AID - 10.1136/medethics-2020-106095 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 24. pii: medethics-2020-106095. doi:
      10.1136/medethics-2020-106095.


PMID- 32838979
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20210710
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 6
DP  - 2020 Dec
TI  - Bias and ethical considerations in machine learning and the automation of
      perioperative risk assessment.
PG  - 843-846
LID - S0007-0912(20)30631-0 [pii]
LID - 10.1016/j.bja.2020.07.040 [doi]
FAU - O'Reilly-Shah, Vikas N
AU  - O'Reilly-Shah VN
AD  - Department of Anesthesiology and Pain Medicine, University of Washington School
      of Medicine, Seattle, WA, USA; Department of Anesthesiology and Pain Medicine,
      Seattle Children's Hospital, Seattle, WA, USA. Electronic address:
      voreill@uw.edu.
FAU - Gentry, Katherine R
AU  - Gentry KR
AD  - Department of Anesthesiology and Pain Medicine, University of Washington School
      of Medicine, Seattle, WA, USA; Department of Anesthesiology and Pain Medicine,
      Seattle Children's Hospital, Seattle, WA, USA.
FAU - Walters, Andrew M
AU  - Walters AM
AD  - Department of Anesthesiology and Pain Medicine, University of Washington School
      of Medicine, Seattle, WA, USA.
FAU - Zivot, Joel
AU  - Zivot J
AD  - Department of Anesthesiology, Emory University, Atlanta, GA, USA.
FAU - Anderson, Corrie T
AU  - Anderson CT
AD  - Department of Anesthesiology and Pain Medicine, University of Washington School
      of Medicine, Seattle, WA, USA; Department of Anesthesiology and Pain Medicine,
      Seattle Children's Hospital, Seattle, WA, USA.
FAU - Tighe, Patrick J
AU  - Tighe PJ
AD  - Department of Anesthesiology, University of Florida, Gainesville, FL, USA.
LA  - eng
GR  - R01 GM114290/GM/NIGMS NIH HHS/United States
GR  - U24 NS113800/NS/NINDS NIH HHS/United States
PT  - Editorial
PT  - Research Support, N.I.H., Extramural
DEP - 20200821
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
CIN - Br J Anaesth. 2021 Feb;126(2):e59-e61. PMID: 33250182
MH  - Anesthesiology/*methods
MH  - Automation/*methods
MH  - Bias
MH  - Humans
MH  - Machine Learning/*ethics/*statistics & numerical data
MH  - Perioperative Care/*methods
MH  - Risk Assessment
PMC - PMC7442146
OTO - NOTNLM
OT  - *artificial intelligence
OT  - *gender bias
OT  - *healthcare inequality
OT  - *machine learning
OT  - *perioperative medicine
OT  - *racial bias
OT  - *risk prediction
EDAT- 2020/08/26 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/07/17 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - S0007-0912(20)30631-0 [pii]
AID - 10.1016/j.bja.2020.07.040 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Dec;125(6):843-846. doi: 10.1016/j.bja.2020.07.040. Epub 2020 
      Aug 21.


PMID- 32832851
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Ethical Considerations for safeguarding human participants in pandemic research: 
      a rapid review protocol.
PG  - 22
LID - 10.12688/hrbopenres.13053.2 [doi]
AB  - COVID-19 is a respiratory disease caused by a coronavirus, designated SARS-CoV-2,
      which is responsible for a global pandemic in 2020. Public interest in this
      disease has led to the publication of thousands of articles in the medical
      literature in a very short timeframe. It is imperative that medical research into
      COVID-19 is conducted quickly and safely, and that due reference is given to the 
      ethical considerations enshrined in the ICH GCP guidelines, according to the
      Declaration of Helsinki. In order to review the reporting of ethical
      considerations in these papers, we hereby propose a protocol for a systematic
      review of COVID-19 papers up to April 14 (th) 2020. The search criteria proposed 
      for the review are based upon what would be a reasonable search conducted by a
      lay member of the public with access to PubMed.gov. Institutional Research Ethics
      Committees (RECs) face significant challenges in providing thorough and timely
      ethical review during the COVID-19 pandemic. It is proposed to publish the
      findings of this rapid review along with a summary of an institutional REC
      response to the challenges of reviewing and approving clinical research proposals
      in the time of a pandemic.
CI  - Copyright: (c) 2020 O'Sullivan L et al.
FAU - O'Sullivan, Lydia
AU  - O'Sullivan L
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
AD  - HRB Trials Methodology Research Network, Aras Moyola, National University of
      Ireland, Galway, Ireland.
AD  - UCD School of Nursing, Midwifery and Health Systems, University College Dublin,
      Dublin, Dublin 4, Ireland.
FAU - Killeen, Ronan P
AU  - Killeen RP
AD  - Research Ethics Committee, St Vincent's University Hospital, Dublin 4, Ireland.
FAU - Doran, Peter
AU  - Doran P
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
AD  - UCD School of Nursing, Midwifery and Health Systems, University College Dublin,
      Dublin, Dublin 4, Ireland.
FAU - Crowley, Rachel K
AU  - Crowley RK
AUID- ORCID: https://orcid.org/0000-0003-1472-4117
AD  - UCD School of Medicine, University College Dublin, Dublin 4, Ireland.
AD  - Research Ethics Committee, St Vincent's University Hospital, Dublin 4, Ireland.
LA  - eng
SI  - figshare/10.6084/m9.figshare.12249224.v1
PT  - Journal Article
DEP - 20200720
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7424914
OTO - NOTNLM
OT  - COVID-19
OT  - case studies
OT  - clinical trials
OT  - pandemic
OT  - research ethics
COIS- No competing interests were disclosed.
EDAT- 2020/08/26 06:00
MHDA- 2020/08/26 06:01
CRDT- 2020/08/26 06:00
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/26 06:01 [medline]
AID - 10.12688/hrbopenres.13053.2 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Jul 20;3:22. doi: 10.12688/hrbopenres.13053.2. eCollection
      2020.


PMID- 32838375
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220622
IS  - 2688-1152 (Electronic)
IS  - 2688-1152 (Linking)
VI  - 1
IP  - 4
DP  - 2020 Aug
TI  - A proposal for selective resuscitation of adult cardiac arrest patients in a
      pandemic.
PG  - 408-415
LID - 10.1002/emp2.12096 [doi]
AB  - Allocation of limited resources in pandemics begs for ethical guidance. The issue
      of ventilator allocation in pandemics has been reviewed by many medical
      ethicists, but as localities activate crisis standards of care, and health care
      workers are infected from patient exposure, the decision to pursue
      cardiopulmonary resuscitation (CPR) must also be examined to better balance the
      increased risks to healthcare personnel with the very low resuscitation rates of 
      patients infected with coronavirus disease 2019 (COVID-19). A crisis standard of 
      care that is equitable, transparent, and mindful of both human and physical
      resources will lessen the impact on society in this era of COVID-19. This paper
      builds on previous work of ventilator allocation in pandemic crises to propose a 
      literature-based, justice-informed ethical framework for selecting treatment
      options for CPR. The pandemic affects regions differently over time, so these
      suggested guidelines may require adaptation to local practice variations.
CI  - (c) 2020 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of 
      the American College of Emergency Physicians.
FAU - Hsu, Antony
AU  - Hsu A
AD  - Department of Emergency Medicine St. Joseph Mercy Hospital Ann Arbor Michigan
      USA.
FAU - Weber, William
AU  - Weber W
AD  - Section of Emergency Medicine The University of Chicago Chicago Illinois USA.
FAU - Heins, Alan
AU  - Heins A
AD  - Department of Emergency Medicine University of South Alabama Mobile Alabama USA.
FAU - Josephson, Elaine
AU  - Josephson E
AD  - Department of Emergency Medicine Lincoln Medical and Mental Health Center Weill
      Cornell Medical College of Cornell University Bronx New York USA.
FAU - Kornberg, Robert
AU  - Kornberg R
AD  - Division of Cardiology Icahn School of Medicine at Mount Sinai New York New York 
      USA.
FAU - Diaz, Rosemarie
AU  - Diaz R
AD  - Department of Emergency Medicine University of Michigan Ann Arbor Michigan USA.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - United States
TA  - J Am Coll Emerg Physicians Open
JT  - Journal of the American College of Emergency Physicians open
JID - 101764779
PMC - PMC7307030
OTO - NOTNLM
OT  - COVID-19
OT  - CPR
OT  - Ethics
OT  - SOFA
OT  - pandemic
OT  - resource constraints
OT  - resuscitation
OT  - ventilator-allocation
COIS- None.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1002/emp2.12096 [doi]
AID - EMP212096 [pii]
PST - epublish
SO  - J Am Coll Emerg Physicians Open. 2020 Jun 11;1(4):408-415. doi:
      10.1002/emp2.12096. eCollection 2020 Aug.


PMID- 32838181
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2523-8973 (Electronic)
IS  - 2523-8973 (Linking)
VI  - 2
IP  - 9
DP  - 2020
TI  - Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results.
PG  - 1328-1336
LID - 10.1007/s42399-020-00374-1 [doi]
AB  - The aim of this study is to evaluate the effectiveness of rectal ozone (O3) in
      COVID-19 patients with severe pneumonia admitted at Hospital Universitario Santa 
      Cristina, Madrid. In a before-and-after study, four patients admitted with severe
      bilateral pneumonia due to COVID-19 were treated with rectal ozone and confirmed 
      with (+) RT-PCR for SARS-CoV-2 and evaluated afterwards. The analyzed outcome
      variables were as follows: (a) clinical improvement (O2 saturation and O2
      supply); (b) biochemical improvement (fibrinogen, D-dimer, urea, ferritin, LDH,
      IL-6, and CRP); (c) radiological improvement. The treatment protocol consisted of
      5 sessions (1 session/day) of intra-rectal ozone, applied in a volume of 100 mL
      and a concentration of 35 mug/mL. The Protocol was previously approved by the
      Hospital's Health Care Ethics Committee (CEAS) (Report 15/4/2020) for
      compassionate use in the face of this exceptional pandemic situation, and prior
      informed consent was obtained from the patient/legal representative. The patients
      improved oxygen saturation, as observed by the lower number of desaturations and 
      the lower supply of O2. Biomarkers of inflammation decreased (fibrinogen,
      D-dimer, urea, ferritin, LDH, IL-6, and CRP). Finally, the radiological signs of 
      bilateral viral pneumonitis improved between 1 and 2 grades based on Taylor's
      radiological scale. Rectal ozone decreases O2 supply and improves O2 saturation, 
      decreases inflammation biomarkers, and improves Taylor's radiological grade in
      patients with severe COVID-19 pneumonia. Rectal ozone is a safe, effective,
      cheap, and simple alternative capable of acting on the SARS-CoV-2 virus, and it
      is presented as an adjunctive therapeutic option to consider in the management of
      severe bilateral COVID-19 pneumonia.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Fernandez-Cuadros, Marcos Edgar
AU  - Fernandez-Cuadros ME
AUID- ORCID: 0000-0001-6153-9075
AD  - Servicio de Rehabilitacion y Medicina Fisica, Hospital Universitario Santa
      Cristina, Madrid, Spain.grid.411359.b0000 0004 1763 1052
AD  - Servicio de Medicina Fisica y Rehabilitacion, Hospital Universitario Santa
      Cristina, Calle del Maestro Vives 2 y 3, CP28009 Madrid, Spain.grid.411359.b0000 
      0004 1763 1052
FAU - Albaladejo-Florin, Maria Jesus
AU  - Albaladejo-Florin MJ
AD  - Servicio de Rehabilitacion y Medicina Fisica, Hospital Universitario Santa
      Cristina, Madrid, Spain.grid.411359.b0000 0004 1763 1052
FAU - Alava-Rabasa, Sandra
AU  - Alava-Rabasa S
AD  - Servicio de Rehabilitacion y Medicina Fisica, Hospital Universitario Santa
      Cristina, Madrid, Spain.grid.411359.b0000 0004 1763 1052
FAU - Usandizaga-Elio, Isabel
AU  - Usandizaga-Elio I
AD  - Servicio de Medicina Interna, Hospital Universitario Santa Cristina, Madrid,
      Spain.grid.411359.b0000 0004 1763 1052
FAU - Martinez-Quintanilla Jimenez, Dolores
AU  - Martinez-Quintanilla Jimenez D
AD  - Servicio de Reumatologia, Hospital Universitario Santa Cristina, Madrid,
      Spain.grid.411359.b0000 0004 1763 1052
FAU - Pena-Lora, Daiana
AU  - Pena-Lora D
AD  - Unidad de Geriatria, Hospital Universitario Santa Cristina, Madrid,
      Spain.grid.411359.b0000 0004 1763 1052
FAU - Neira-Borrajo, Inmaculada
AU  - Neira-Borrajo I
AD  - Servicio de Traumatologia y Ortopedia, Hospital Universitario Santa Cristina,
      Madrid, Spain.grid.411359.b0000 0004 1763 1052
FAU - Lopez-Munoz, Maria Jesus
AU  - Lopez-Munoz MJ
AD  - Servicio de Farmacia Hospitalaria, Hospital Universitario Santa Cristina, Madrid,
      Spain.grid.411359.b0000 0004 1763 1052
FAU - Rodriguez-de-Cia, Javier
AU  - Rodriguez-de-Cia J
AD  - Servicio de Laboratorio Clinico, Hospital Universitario Santa Cristina, Madrid,
      Spain.grid.411359.b0000 0004 1763 1052
FAU - Perez-Moro, Olga Susana
AU  - Perez-Moro OS
AD  - Servicio de Rehabilitacion y Medicina Fisica, Hospital Universitario Santa
      Cristina, Madrid, Spain.grid.411359.b0000 0004 1763 1052
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - Switzerland
TA  - SN Compr Clin Med
JT  - SN comprehensive clinical medicine
JID - 101740833
PMC - PMC7397966
OTO - NOTNLM
OT  - COVID-19
OT  - Ozone
OT  - Ozone therapy
OT  - Pneumonia
OT  - SARS-CoV-2
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/06/20 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s42399-020-00374-1 [doi]
AID - 374 [pii]
PST - ppublish
SO  - SN Compr Clin Med. 2020;2(9):1328-1336. doi: 10.1007/s42399-020-00374-1. Epub
      2020 Aug 3.


PMID- 32838159
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 2523-8973 (Electronic)
IS  - 2523-8973 (Linking)
VI  - 2
IP  - 8
DP  - 2020
TI  - Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic
      Possibilities According to COVID-19 Evolutionary Stage.
PG  - 1094-1102
LID - 10.1007/s42399-020-00328-7 [doi]
AB  - To date, there is no definitive treatment for the new SARS-CoV-2 pandemic. Three 
      evolutionary stages in SARS-CoV-2 infection are recognized (early infection,
      pulmonary phase, and systemic hyper inflammation), with characteristic clinical
      signs and symptoms. There are 80 international experimental trials underway
      seeking effective treatment for the COVID-19 pandemic. Of these, there are only
      three that consider ozone therapy (major auto hemotherapy) as an alternative
      option. There is no study that evaluates rectal ozone insufflation, despite being
      a safe, cheap, risk-free technique. That technique is a systemic route of ozone
      administration (95-96%) and that could be extrapolated to the use of SARS-CoV-2, 
      given the excellent results observed in the management of Ebola. Ozone has four
      proven biological properties that could allow its use as an alternative therapy
      in the different phases of SARS-CoV-2 infection. Ozone could inactivate the virus
      by direct (O3) or indirect oxidation (ROS and LOPs) and could stimulate the
      cellular and humoral immune systems, being useful in the early COVID-19 infection
      phase (stages 1 and 2a). Ozone improves gas exchange, reduces inflammation, and
      modulates the antioxidant system, so it would be useful in the hyper inflammation
      or "cytokine storm" phase, and in the hypoxemia and/or multi-organ failure phase 
      (stage 2b and stage 3). Given the current pandemic, it is urgent to carry out an 
      experimental study that confirms or rules out the biological properties of ozone 
      and thus allows it to be an alternative or compassionate therapy for the
      effective management of SARS-Cov-2 infection. The Ethical Committee at our
      Hospital has authorized the use of this technique for compassionate management of
      SARS-CoV-2 infection, considering the four biological Ozone properties exposed
      previously.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Fernandez-Cuadros, Marcos Edgar
AU  - Fernandez-Cuadros ME
AUID- ORCID: https://orcid.org/0000-0001-6153-9075
AD  - Calle del Maestro Vives 2 y 3, Servicio de Medicina Fisica y Rehabilitacion,
      Hospital Universitario Santa Cristina, CP28009 Madrid, Spain.grid.411359.b0000
      0004 1763 1052
FAU - Albaladejo-Florin, Maria Jesus
AU  - Albaladejo-Florin MJ
AD  - Calle del Maestro Vives 2 y 3, Servicio de Medicina Fisica y Rehabilitacion,
      Hospital Universitario Santa Cristina, CP28009 Madrid, Spain.grid.411359.b0000
      0004 1763 1052
FAU - Pena-Lora, Daiana
AU  - Pena-Lora D
AD  - Unidad de Geriatria, Hospital Universitario Santa Cristina, Madrid,
      Spain.grid.411359.b0000 0004 1763 1052
FAU - Alava-Rabasa, Sandra
AU  - Alava-Rabasa S
AD  - Calle del Maestro Vives 2 y 3, Servicio de Medicina Fisica y Rehabilitacion,
      Hospital Universitario Santa Cristina, CP28009 Madrid, Spain.grid.411359.b0000
      0004 1763 1052
FAU - Perez-Moro, Olga Susana
AU  - Perez-Moro OS
AD  - Calle del Maestro Vives 2 y 3, Servicio de Medicina Fisica y Rehabilitacion,
      Hospital Universitario Santa Cristina, CP28009 Madrid, Spain.grid.411359.b0000
      0004 1763 1052
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200707
PL  - Switzerland
TA  - SN Compr Clin Med
JT  - SN comprehensive clinical medicine
JID - 101740833
PMC - PMC7340747
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Ozone
OT  - Pandemic
OT  - SARS-CoV-2
COIS- The authors note that there is no commercial relationship giving rise to a
      conflict of interest in conducting this study.Conflict of InterestThe authors
      declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s42399-020-00328-7 [doi]
AID - 328 [pii]
PST - ppublish
SO  - SN Compr Clin Med. 2020;2(8):1094-1102. doi: 10.1007/s42399-020-00328-7. Epub
      2020 Jul 7.


PMID- 32838142
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 2523-8973 (Electronic)
IS  - 2523-8973 (Linking)
VI  - 2
IP  - 7
DP  - 2020
TI  - Anaesthetic Considerations for Rationalizing Drug Use in the Operating Theatre:
      Strategies in a Singapore Hospital During COVID-19.
PG  - 871-873
LID - 10.1007/s42399-020-00345-6 [doi]
AB  - COVID-19 patients in the critical care unit tend to have prolonged hospital stay 
      requiring high doses of sedation and paralysis to treat acute respiratory
      distress syndrome, resulting in a shortage of these drugs. In our hospital, we
      have instituted strategies to rationalise drug and oxygen usage. This includes
      prioritising time-sensitive elective cases, reducing overall elective case load, 
      favouring opioid-reduction strategies and usage of alternative anaesthetic agents
      not commonly used in ICU. Both intensive care physicians and anaesthesiologists
      have to cooperate on drug conservation as similar drugs are used in elective
      operating lists as in the ICU. Patient safety is of utmost importance and we
      should keep in mind some pitfalls and ethical concerns of these alternative
      strategies.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Au Yong, Phui Sze Angie
AU  - Au Yong PSA
AUID- ORCID: 0000-0002-9311-2532
AD  - Division of Anesthesiology and Perioperative Medicine, Singapore General
      Hospital, 1 Hospital Drive, Singapore, 169608 Singapore.grid.163555.10000 0000
      9486 5048
FAU - Kwa, Charlene Wen Xian
AU  - Kwa CWX
AD  - Division of Anesthesiology and Perioperative Medicine, Singapore General
      Hospital, 1 Hospital Drive, Singapore, 169608 Singapore.grid.163555.10000 0000
      9486 5048
FAU - Chan, Xin Hui Diana
AU  - Chan XHD
AD  - Division of Anesthesiology and Perioperative Medicine, Singapore General
      Hospital, 1 Hospital Drive, Singapore, 169608 Singapore.grid.163555.10000 0000
      9486 5048
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - Switzerland
TA  - SN Compr Clin Med
JT  - SN comprehensive clinical medicine
JID - 101740833
PMC - PMC7289710
OTO - NOTNLM
OT  - Anesthesia
OT  - COVID-19
OT  - Conservation
OT  - Drug
OT  - Intensive Care
OT  - Pandemic
OT  - Rational Use
OT  - SARS-CoV-2
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s42399-020-00345-6 [doi]
AID - 345 [pii]
PST - ppublish
SO  - SN Compr Clin Med. 2020;2(7):871-873. doi: 10.1007/s42399-020-00345-6. Epub 2020 
      Jun 12.


PMID- 32838116
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2510-2265 (Print)
IS  - 2510-2265 (Linking)
VI  - 4
IP  - 2
DP  - 2020
TI  - Guidelines of the Indian Society for Sleep Research (ISSR) for Practice of Sleep 
      Medicine during COVID-19.
PG  - 61-72
LID - 10.1007/s41782-020-00097-2 [doi]
AB  - BACKGROUND: Sleep services are assigned a non-essential status during COVID-19.
      The American Academy of Sleep Medicine strongly urges sleep clinicians to
      continue postponing non-urgent care until a later date, if such a recommendation 
      is made by state officials due to local conditions. At the same time, one cannot 
      ignore the fact that sleep is important for people's health and wellbeing.
      Therefore, to protect the health of the population, it is essential to find ways 
      and means to continue the practice of sleep medicine even during the COVID-19
      pandemic. METHOD: Social environment and work ethics in sleep clinics and sleep
      laboratories in Asia, Africa, and Latin America are different from those in the
      US. Under these circumstances, the Indian Society for Sleep Research (ISSR)
      created a task force to develop guidelines for the practice of sleep medicine,
      not only for the Indian environment but also for other countries that are
      affected by the COVID-19 pandemic. The task force examined documents regarding
      practice of sleep medicine and associated specialities during COVID-19 by various
      professional organizations and governmental authorities. The recommendations were
      examined for their applicability. Wherever gaps were identified, consensus was
      reached keeping in view the available evidences. OUTCOME AND RECOMMENDATIONS: The
      emphasis of the guidelines is on avoiding doctor to patient contact during the
      pandemic. Teleconsultation and other modes of audio-visuals can be used as modes 
      for medical practice during the COVID-19 pandemic. However, in addition to the
      patient, the presence of a family member, or a reliable informant is recommended.
      Patients of most sleep disorders can be provided tele-aftercare service. ISSR
      guidelines also give a list of medications allowed to be prescribed during the
      first and the follow-up teleconsultation. Hospitals and clinics are slowly
      opening in India and many other countries. As sleep services resume operations,
      there is a need to find innovative ways to reduce contact with COVID-19 patients,
      follow personal protection guidelines, as well as social distancing. This article
      does discuss strategies for the safe conduct of Level 1 sleep studies. Home sleep
      testing, which had greater acceptance during the last few years, should be given 
      more attention during the COVID-19 period. Once the decision to reopen the sleep 
      laboratory and resume operations is made, the safety of the patients and office
      staff should become the major priority. The ISSR recommendation is to postpone
      and reschedule in-laboratory positive pressure therapy, but it mentions the
      considerations to be followed in emergency situations. At the same time, high
      clinical risk patients may be diagnosed on the basis of clinical findings, and
      without performing polysomnography or home sleep testing. However, at some point,
      there is a need to reinitiate the in-lab testing. In addition, daily assessment
      of the COVID-19 situation in the community, along with a review of the situation 
      with local public health and the state health department is advised.
CI  - (c) Springer Nature Singapore Pte Ltd. 2020.
FAU - Gupta, Ravi
AU  - Gupta R
AD  - Department of Psychiatry, All India Institute of Medical Sciences, Rishikesh,
      249203 India.grid.413618.90000 0004 1767 6103
FAU - Kumar, V Mohan
AU  - Kumar VM
AD  - Department of Physiology, All India Institute of Medical Sciences, New Delhi,
      110029 India.grid.413618.90000 0004 1767 6103
FAU - Tripathi, Manjari
AU  - Tripathi M
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi,
      India.grid.413618.90000 0004 1767 6103
FAU - Datta, Karuna
AU  - Datta K
AD  - Department of Sports Medicine, Armed Forces Medical College, Pune,
      India.grid.413909.60000 0004 1766 9851
FAU - Narayana, Manjunatha
AU  - Narayana M
AD  - Department of Psychiatry, National Institute of Mental Health and Neurosciences, 
      Bengaluru, India.grid.416861.c0000 0001 1516 2246
FAU - Ranjan Sarmah, Kripesh
AU  - Ranjan Sarmah K
AD  - Apollo Hospital, Guwahati, India.
FAU - Bhatia, Manvir
AU  - Bhatia M
AD  - Neurology and Sleep Centre, New Delhi, India.
FAU - Devnani, Preeti
AU  - Devnani P
AD  - Cleveland Clinic, Abu Dhabi, UAE.
FAU - Das, Sourav
AU  - Das S
AD  - Somnos Sleep Clinic, Kolkata, India.
FAU - Shrivastava, Deepak
AU  - Shrivastava D
AD  - Division of Pulmonary, Critical Care and Sleep, Department of Medicine and
      Medical Director, SJGH Sleep Center, UC Davis School of Medicine, Sacramento, CA 
      USA.grid.27860.3b0000 0004 1936 9684
FAU - Gourineni, Rama Devi
AU  - Gourineni RD
AD  - Neurology, Northwestern Feinberg School of Medicine, Chicago,
      USA.grid.16753.360000 0001 2299 3507
AD  - Sleep Department, Amara Hospital, Tirupati, India.
FAU - Singh, Tripat Deep
AU  - Singh TD
AD  - Sleep- Asia-Pacific, Philips Electronics, Singapore, Singapore.
FAU - Jindal, Apar
AU  - Jindal A
AD  - Institute of Heart and Lung Transplant, Gleneagles Global Health City, Cheran
      Nagar, Perumbakkam, Chennai, 600 100 India.grid.418261.80000 0004 1766 0961
FAU - Mallick, Hruda Nanda
AU  - Mallick HN
AD  - Department of Physiology, All India Institute of Medical Sciences, New Delhi,
      110029 India.grid.413618.90000 0004 1767 6103
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200704
PL  - Singapore
TA  - Sleep Vigil
JT  - Sleep and vigilance
JID - 101712170
PMC - PMC7334897
OTO - NOTNLM
OT  - COVID-19
OT  - Home sleep study
OT  - In-lab testing
OT  - Level-1 sleep study
OT  - Pandemic
OT  - Personal protective equipment (PPE)
OT  - Polysomnography
OT  - Positive airway pressure (PAP)
OT  - Sleep medicine
OT  - Teleconsultation
OT  - Titration
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41782-020-00097-2 [doi]
AID - 97 [pii]
PST - ppublish
SO  - Sleep Vigil. 2020;4(2):61-72. doi: 10.1007/s41782-020-00097-2. Epub 2020 Jul 4.


PMID- 32838103
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220622
IS  - 2471-254X (Electronic)
IS  - 2471-254X (Linking)
VI  - 4
IP  - 9
DP  - 2020 Sep
TI  - Liver Transplantation in the Time of COVID19: Barriers and Ethical Considerations
      for Management and Next Steps.
PG  - 1242-1256
LID - 10.1002/hep4.1568 [doi]
AB  - The recent outbreak of the novel virus severe acute respiratory syndrome
      coronavirus-2 (SARS-CoV-2), which causes the corona virus disease of 2019
      (COVID19), has spread globally and affects millions of people. This pandemic has 
      taxed our health care system and disrupted normal operations, even life-saving
      procedures, such as liver transplants. During these unprecedented times,
      providers and patients are imperiled and resources for diagnosis and care may be 
      limited. Continuing to perform resource-intense advanced procedures is
      challenging, as is caring for patients with end-stage liver disease or patients
      with urgent needs for liver tumor control. Liver transplantation, in particular, 
      requires critical resources, like blood products and critical care beds, which
      are fairly limited in the COVID19 pandemic. The potential of COVID19 infections
      in posttransplant recipients on immunosuppression and staff contacts further adds
      to the complexity. Therefore, transplant programs must reevaluate the ethicality,
      feasibility, and safety of performing liver transplants during this pandemic.
      Herein, we discuss the clinical and ethical challenges posed by performing liver 
      transplants and offer guidance for managing patients with end-stage liver disease
      during the COVID19 pandemic.
CI  - (c) 2020 The Authors. Hepatology Communications published by Wiley Periodicals
      LLC on behalf of American Association for the Study of Liver Diseases.
FAU - Jaffe, Ariel
AU  - Jaffe A
AD  - Division of Digestive Diseases, Department of Medicine Yale School of Medicine
      New Haven CT.
FAU - Schilsky, Michael L
AU  - Schilsky ML
AD  - Division of Digestive Diseases, Department of Medicine Yale School of Medicine
      New Haven CT.
AD  - Yale New Haven Transplantation Center Yale School of Medicine New Haven CT.
FAU - Deshpande, Ranjit
AU  - Deshpande R
AD  - Anesthesiology Yale School of Medicine New Haven CT.
FAU - Batra, Ramesh
AU  - Batra R
AD  - Division of Digestive Diseases, Department of Medicine Yale School of Medicine
      New Haven CT.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200724
PL  - United States
TA  - Hepatol Commun
JT  - Hepatology communications
JID - 101695860
SB  - IM
PMC - PMC7361607
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1002/hep4.1568 [doi]
AID - HEP41568 [pii]
PST - epublish
SO  - Hepatol Commun. 2020 Jul 24;4(9):1242-1256. doi: 10.1002/hep4.1568. eCollection
      2020 Sep.


PMID- 32838092
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 24
DP  - 2020
TI  - The B-MaP-C study: Breast cancer management pathways during the COVID-19
      pandemic. Study protocol.
PG  - 1-5
LID - 10.1016/j.isjp.2020.07.003 [doi]
AB  - INTRODUCTION: Approximately 55,000 women in the United Kingdom are diagnosed with
      new breast cancer annually. Since emerging in December 2019, SARS-CoV-2
      (coronavirus disease 2019, COVID-19) has become a global pandemic, affecting
      healthcare delivery worldwide. In response to the pandemic, multiple guidelines
      were issued to assist with rationalising breast cancer care. The primary aim of
      the B-MaP-C study is to audit and describe breast cancer management of patients
      newly diagnosed with breast cancer during the COVID-19 pandemic against
      pre-COVID-19 management practice in the UK. The implications of changes to
      management will be determined and the impact of a COVID-19 diagnosis on the
      patient's breast cancer management will be determined. METHODS AND ANALYSIS: This
      is a multi-centre collaborative audit of consecutive breast cancer patients
      undergoing treatment decisions during the acute and recovery phases of the
      COVID-19 pandemic. All patients with newly diagnosed primary breast cancer, whose
      treatment was decided in a multidisciplinary meeting from the 16th March 2020,
      are eligible for inclusion. ETHICS AND DISSEMINATION: As this is an audit ethical
      approval is not required. Each participating centre is required to register the
      study locally and obtain local governance approvals prior to commencement of data
      collection. Local audit data will be available to individual participating units 
      for governance purposes. The results of the data analysis will be submitted for
      publication, as well as disseminated via the ABS newsletter and a webinar. All
      data will be presented at national and international conferences, circumstances
      permitting. REGISTRATION DETAILS: Each participating centre received local
      governance audit registration.
CI  - (c) 2020 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.
FAU - Courtney, Alona
AU  - Courtney A
AD  - Department of Surgery and Cancer, Imperial College London, UK.
FAU - O'Connell, Rachel
AU  - O'Connell R
AD  - Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, Downs Road,
      Sutton, Surrey SM2 5PT, UK.
FAU - Rattay, Tim
AU  - Rattay T
AD  - Department of Cancer Studies, Clinical Sciences Building, University of
      Leicester, Leicester LE2 2LX, UK.
FAU - Kim, Baek
AU  - Kim B
AD  - Department of Breast Surgery, St. James's University Hospital, Leeds LS9 7TF, UK.
FAU - Cutress, Ramsey I
AU  - Cutress RI
AD  - University of Southampton and University Hospital Southampton, Tremona Road,
      Southampton SO16 6YD UK.
FAU - Kirwan, Cliona C
AU  - Kirwan CC
AD  - The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester M23 9LT,
      UK.
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology,
      Medicine and Health, University of Manchester, Oglesby Cancer Research Building, 
      Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
FAU - Gandhi, Ashu
AU  - Gandhi A
AD  - The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester M23 9LT,
      UK.
AD  - Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology,
      Medicine and Health, University of Manchester, Oglesby Cancer Research Building, 
      Manchester Cancer Research Centre, Wilmslow Road, Manchester M20 4BX, UK.
FAU - Fairbrother, Patricia
AU  - Fairbrother P
AD  - Trustee, Independent Cancer Patients Voice, UK.
FAU - Sharma, Nisha
AU  - Sharma N
AD  - Breast Unit, Level 1 Chancellor Wing, St James's Hospital, Leeds LS9 7TF, UK.
FAU - Cartlidge, Christopher W J
AU  - Cartlidge CWJ
AD  - Queen Margaret Hospital, Dunfermline, Whitefield Rd, Dunfermline KY12 0SU, UK.
FAU - Horgan, Kieran
AU  - Horgan K
AD  - Department of Breast Surgery, St. James's University Hospital, Leeds LS9 7TF, UK.
FAU - McIntosh, Stuart A
AU  - McIntosh SA
AD  - Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 97
      Lisburn Road, Belfast BT9 7AE, UK.
FAU - Leff, Daniel R
AU  - Leff DR
AD  - Department of Surgery and Cancer, Imperial College London, UK.
FAU - Vidya, Raghavan
AU  - Vidya R
AD  - The Royal Wolverhampton NHS Trust, Wolverhampton Road, Wolverhampton WV10 0QP,
      UK.
FAU - Potter, Shelley
AU  - Potter S
AD  - Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical
      School, Canynge Hall, Whatley Road, Bristol BS8 2PS UK.
FAU - Holcombe, Chris
AU  - Holcombe C
AD  - Linda McCartney Centre, Royal Liverpool and Broadgreen University Hospital,
      Prescot Street, Liverpool L7 8XP, UK.
FAU - Copson, Ellen
AU  - Copson E
AD  - University of Southampton and University Hospital Southampton, Tremona Road,
      Southampton SO16 6YD UK.
FAU - Coles, Charlotte E
AU  - Coles CE
AD  - Department of Oncology, University of Cambridge, UK.
FAU - Dave, Rajiv V
AU  - Dave RV
AD  - The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester M23 9LT,
      UK.
LA  - eng
GR  - DRF-2014-07-079/DH_/Department of Health/United Kingdom
GR  - MR/K025643/1/MRC_/Medical Research Council/United Kingdom
GR  - NIHR300024/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7388760
OTO - NOTNLM
OT  - Audit
OT  - Breast cancer
OT  - COVID-19
OT  - Outcomes
OT  - Standard treatment
OT  - Treatment
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/06/21 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.isjp.2020.07.003 [doi]
AID - S2468-3574(20)30024-3 [pii]
PST - ppublish
SO  - Int J Surg Protoc. 2020;24:1-5. doi: 10.1016/j.isjp.2020.07.003. Epub 2020 Jul
      29.


PMID- 32838003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - Dear and Glorious Physician, who are we in COVID-19?
PG  - 100576
LID - 10.1016/j.jemep.2020.100576 [doi]
AB  - We are on the brink of a public health crisis. Science is changing, medicine is
      evolving, politics are adapting as we are attempting to retain our "normal
      lives". The origin of COVID-19 is not exclusively a medical or scientific one.
      Rather, it lingers more towards damaged public policies with a global pandemic
      surfacing as merely a consequence of failed economic and health strategies. In
      this paper we provide a narrative review of the evolution of COVID-19 with
      emphasis on the its origin and the place of physicians in an ethical perspective.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Herrera, B
AU  - Herrera B
AD  - Department of Public Health, Universidad del Rosario, Bogota, Colombia.
FAU - Vinck, E E
AU  - Vinck EE
AD  - Department of Cardiac Surgery, Fundacion Clinica Shaio, Bogota, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7427517
OTO - NOTNLM
OT  - Covid-19
OT  - Ethics
OT  - Public health
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/03 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.jemep.2020.100576 [doi]
AID - 100576 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100576. doi:
      10.1016/j.jemep.2020.100576. Epub 2020 Aug 14.


PMID- 32838001
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - Ethical principles in decision-making during the COVID-19 pandemic.
PG  - 100572
LID - 10.1016/j.jemep.2020.100572 [doi]
FAU - Deps, P
AU  - Deps P
AD  - Department of Social Medicine, Federal University of Espirito Santo, Av. Marechal
      Campos 1468, Maruipe Vitoria, Espirito Santo (ES), Brazil.
FAU - Cassimiro, M
AU  - Cassimiro M
AD  - Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7388753
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/14 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.jemep.2020.100572 [doi]
AID - 100572 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100572. doi:
      10.1016/j.jemep.2020.100572. Epub 2020 Jul 29.


PMID- 32837999
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 2352-5525 (Print)
VI  - 15
DP  - 2020 Oct-Dec
TI  - Choosing which COVID-19 patient to save? The ethical triage and rationing
      dilemma.
PG  - 100570
LID - 10.1016/j.jemep.2020.100570 [doi]
AB  - Killing someone directly is never morally right, but sometimes, choosing someone 
      to save and leaving another to die is. The moral philosophy, law, and medical
      ethics have all wrestled with the problem of distinguishing between saving
      someone and leaving another to die. While this distinction might seem intuitively
      straightforward, it becomes far more complex when applied in treating patients of
      novel Coronavirus Disease pandemic (COVID-19). The World Health Organization
      reports more than eight million and half cases of infection and more than 450,000
      deaths, 26% in USA. However, with the exponential rise in number of COVID-19
      victims and the shortage of life-saving ventilators, the pandemic has imposed to 
      health professionals an ethical medical triage decision-making based on the
      utilitarian theory to maximize total benefits and life expectancy. Moreover, the 
      decision to put restrictions on treatment beneficence is not discretionary, but
      an indispensable response to the overwhelming impacts of COVID-19 pandemic. The
      main concern is not whether to underline priorities, but how to do so
      systematically and ethically, instead of building decisions on individualized
      institutional aspirations or health professionals' intuition. The serious glaring
      disequilibrium, in healthcare market, between supply and demand for scarce
      medical resources in several developed nations (including the USA, UK, France,
      Italy, Spain, etc.) imposes a fundamental question: which COVID-19 patient to
      save when facing scarce resources?
CI  - (c) 2020 Published by Elsevier Masson SAS.
FAU - Jaziri, R
AU  - Jaziri R
AD  - University of Jeddah, College of Business, Department of Healthcare Services and 
      Hospital Administration, Asfan Road 285, Dhahban, P.O. Box: 42801, 21551 Jeddah, 
      Saudi Arabia.
FAU - Alnahdi, S
AU  - Alnahdi S
AD  - University of Jeddah, College of Business, Department of Healthcare Services and 
      Hospital Administration, Asfan Road 285, Dhahban, P.O. Box: 42801, 21551 Jeddah, 
      Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200728
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7386423
OTO - NOTNLM
OT  - COV-19
OT  - Ethics
OT  - Justice
OT  - Moral
OT  - Triage decision-making
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.jemep.2020.100570 [doi]
AID - 100570 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Oct-Dec;15:100570. doi:
      10.1016/j.jemep.2020.100570. Epub 2020 Jul 28.


PMID- 32837992
OWN - NLM
STAT- Publisher
LR  - 20200928
IS  - 2352-5525 (Print)
DP  - 2020 May 21
TI  - [Covid19 and some ethical issues in France].
PG  - 100529
LID - 10.1016/j.jemep.2020.100529 [doi]
FAU - Charlier, Philippe
AU  - Charlier P
AD  - Laboratoire Anthropologie, Archeologie, Biologie (LAAB), Universite Paris-Saclay 
      (UVSQ), 2 avenue de la source de la Bievre, 78180, Montigny-Le-Bretonneux,
      France.
LA  - fre
PT  - Journal Article
TT  - Covid19 et quelques problematiques ethiques en France.
DEP - 20200521
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7241404
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1016/j.jemep.2020.100529 [doi]
AID - S2352-5525(20)30067-0 [pii]
AID - 100529 [pii]
PST - aheadofprint
SO  - Ethics Med Public Health. 2020 May 21:100529. doi: 10.1016/j.jemep.2020.100529.


PMID- 32837984
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2352-3042 (Electronic)
IS  - 2352-3042 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Dec
TI  - Pandemic COVID-19: Current status and challenges of antiviral therapies.
PG  - 502-519
LID - 10.1016/j.gendis.2020.07.001 [doi]
AB  - The pandemic COVID-19, caused by a new coronavirus SARS-CoV-2 infection, has
      infected over 12 million individuals and caused more than 55,200 death worldwide.
      Currently, there is no specific drug to treating this disease. Here we summarized
      the mechanisms of antiviral therapies and the clinic findings from different
      countries. Antiviral chemotherapies have been conducted by in multiple cohorts in
      different counties. Although FDA has fast approved remdesivir for treating
      COVID-19, it only speeds up recovery from COVID-19 with mildly reduced mortality.
      The chloroquine was suggested a potential drug against SARS-CoV-2 infection due
      to its in vitro antiviral effects, it is imperative high-quality data from
      worldwide clinical trials are necessitated for an approved therapy. In terms of
      hydroxychloroquine (HCQ) therapy, although WHO has stopped all the clinic trials 
      due to its strong side-effects in COVID patients, large scale clinical trials
      with a long-term outcome follow-up may warrant HCQ and azithromycin combination
      in combating the virus. Convalescent plasma (CP) therapy suggested its safety use
      in SARS-CoV-2 infection; but both CP immunotherapy and NK cellular therapy must
      be manufactured and utilized according to scrupulous ethical and controlled
      conditions to guarantee a possible role of these products of human origin.
      Further research should be conducted to define the exact mechanism of SARS-CoV-2 
      pathogenesis, suitable animal models or ex vivo human lung tissues aid in
      studying replication, transmission and spread of the novel viruses, thereby
      facilitating highly effective therapies.
CI  - (c) 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.
FAU - Chan, Winglam
AU  - Chan W
AD  - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong,
      China.
FAU - He, Betsy
AU  - He B
AD  - Rensselaer Polytechnic Institute, Troy, NY, USA.
FAU - Wang, Xiong
AU  - Wang X
AD  - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong,
      China.
FAU - He, Ming-Liang
AU  - He ML
AD  - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong,
      China.
AD  - CityU Shenzhen Research Institute, Nanshan, Shenzhen, China.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - China
TA  - Genes Dis
JT  - Genes & diseases
JID - 101635967
PMC - PMC7340039
OTO - NOTNLM
OT  - COVID-19
OT  - Chloroquine
OT  - Convalescent plasma therapy
OT  - Hydroxychloroquine
OT  - Ivermectin
OT  - Natural killer cell therapy
OT  - Remdesivir
OT  - SARS-CoV-2
COIS- All authors declare no conflicts of interests.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/30 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.gendis.2020.07.001 [doi]
AID - S2352-3042(20)30083-0 [pii]
PST - ppublish
SO  - Genes Dis. 2020 Dec;7(4):502-519. doi: 10.1016/j.gendis.2020.07.001. Epub 2020
      Jul 7.


PMID- 32837967
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 2
DP  - 2020 Aug
TI  - National recommendations on pediatric donation.
PG  - 134.e1-134.e9
LID - 10.1016/j.anpede.2020.04.011 [doi]
AB  - Despite being an international reference in donation and transplantation, Spain
      needs to improve pediatric donation, including donation after the circulatory
      determination of death. The present article, a summary of the consensus report
      prepared by the Organizacion Nacional de Trasplantes and the Spanish Pediatrics
      Association, intends the facilitation of donation procedures in newborns and
      children and the analysis of associated ethical dilemma. The ethical basis for
      donation in children, the principles of clinical assessment of possible donors,
      the criteria for the determination of death in children, intensive care
      management of donors, basic concepts of donation after the circulatory
      determination of death and the procedures for donation in newborns with severe
      nervous system's malformation incompatible with life, as well as in children
      receiving palliative care are commented. Systematically considering the donation 
      of organs and tissues when a child dies in conditions consistent with donation is
      an ethical imperative and must become an ethical standard, not only because of
      the need of organs for transplantation, but also to ensure family centered care.
CI  - (c) 2020 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L.U.
FAU - Nunez, Antonio Rodriguez
AU  - Nunez AR
AD  - Seccion de Pediatria Critica, Cuidados Intermedios y Paliativos Pediatricos,
      Hospital Clinico Universitario de Santiago de Compostela, Coruna, Spain.
FAU - Blanco, Alicia Perez
AU  - Blanco AP
AD  - Organizacion Nacional de Trasplantes, Madrid, Spain.
CN  - Grupo de Trabajo de la AEP-ONT
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
PMC - PMC7378478
OTO - NOTNLM
OT  - Brain death
OT  - Children
OT  - Donation after the circulatory determination of death
OT  - Ethics
OT  - Family-centered care
OT  - Newborns
OT  - Organ donation
OT  - Palliative care
OT  - Surrogate consent
OT  - Transplantation
OT  - Withholding and withdrawal of life sustaining measures
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.anpede.2020.04.011 [doi]
AID - S2341-2879(20)30124-1 [pii]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Aug;93(2):134.e1-134.e9. doi:
      10.1016/j.anpede.2020.04.011. Epub 2020 Jul 24.


PMID- 32837877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201208
IS  - 2211-4203 (Electronic)
IS  - 2211-419X (Linking)
VI  - 10
DP  - 2020
TI  - Principles of research ethics: A research primer for low- and middle-income
      countries.
PG  - S125-S129
LID - 10.1016/j.afjem.2020.07.006 [doi]
AB  - Ethical oversight in the form of review boards and research ethics committees
      provide protection for research subjects as well as guidance for safe conduct of 
      studies. As the number of collaborative emergency care research studies carried
      out in low- and middle-income countries increases, it is crucial to have a shared
      understanding of how ethics should inform choice of study topic, study design,
      methods of obtaining consent, data management, and access to treatment after
      closure of the study. This paper describes the basic principles of Western
      research ethics - respect for persons, beneficence, and justice - and how the
      principles may be contextualized in different settings, by researchers of various
      backgrounds with different funding streams. Examples of lapses in ethical
      practice of research are used to highlight best practices.
CI  - (c) 2020 African Federation for Emergency Medicine. Publishing services provided 
      by Elsevier.
FAU - Bitter, Cindy C
AU  - Bitter CC
AD  - Saint Louis University School of Medicine, Division of Emergency Medicine, St.
      Louis MO, USA.
FAU - Ngabirano, Annet Alenyo
AU  - Ngabirano AA
AD  - Aga Khan University, Kampala, Uganda.
AD  - Makerere University College of Health Sciences, Kampala, Uganda.
FAU - Simon, Erin L
AU  - Simon EL
AD  - Cleveland Clinic Akron General, Department of Emergency Medicine, Akron, OH, USA.
AD  - Northeast Ohio Medical University, Rootstown, OH, USA.
FAU - Taylor, David McD
AU  - Taylor DM
AD  - University of Melbourne, Department of Medicine, Parkville, Victoria, Australia.
AD  - Austin Health, Heidelburg, Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - Netherlands
TA  - Afr J Emerg Med
JT  - African journal of emergency medicine : Revue africaine de la medecine d'urgence
JID - 101572277
PMC - PMC7423570
OTO - NOTNLM
OT  - Ethics committees
OT  - autonomy
OT  - beneficence
OT  - consent
OT  - justice
COIS- The authors declared no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.afjem.2020.07.006 [doi]
AID - S2211-419X(20)30073-2 [pii]
PST - ppublish
SO  - Afr J Emerg Med. 2020;10:S125-S129. doi: 10.1016/j.afjem.2020.07.006. Epub 2020
      Aug 13.


PMID- 32837867
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220705
IS  - 2210-5433 (Print)
IS  - 2210-5433 (Linking)
VI  - 33
IP  - 2
DP  - 2020
TI  - Mind the App-Considerations on the Ethical Risks of COVID-19 Apps.
PG  - 167-172
LID - 10.1007/s13347-020-00408-5 [doi]
FAU - Luciano, Floridi
AU  - Luciano F
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS
      UK.grid.4991.50000 0004 1936 8948
AD  - The Alan Turing Institute, 96 Euston Road, London, NW1 2DB UK.grid.499548.d0000
      0004 5903 3632
LA  - eng
PT  - Editorial
DEP - 20200613
PL  - Netherlands
TA  - Philos Technol
JT  - Philosophy & technology
JID - 101583724
PMC - PMC7293165
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s13347-020-00408-5 [doi]
AID - 408 [pii]
PST - ppublish
SO  - Philos Technol. 2020;33(2):167-172. doi: 10.1007/s13347-020-00408-5. Epub 2020
      Jun 13.


PMID- 32837751
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 2095-8099 (Print)
IS  - 2095-8099 (Linking)
VI  - 6
IP  - 10
DP  - 2020 Oct
TI  - Ethical Reflection on the Emergency Engineering Management of COVID-19 Epidemic
      Prevention and Control.
PG  - 1070-1072
LID - 10.1016/j.eng.2020.06.014 [doi]
FAU - Fang, Dongping
AU  - Fang D
AD  - Department of Construction Management, School of Civil Engineering, Tsinghua
      University, Beijing 100084, China.
FAU - Li, Wenqi
AU  - Li W
AD  - Department of Construction Management, School of Civil Engineering, Tsinghua
      University, Beijing 100084, China.
FAU - Zhang, Hengli
AU  - Zhang H
AD  - School of Marxism, Beijing University of Technology, Beijing 100124, China.
FAU - Liu, He
AU  - Liu H
AD  - Research Institute of Petroleum Exploration and Development (RIPED), Beijing
      100083, China.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - China
TA  - Engineering (Beijing)
JT  - Engineering (Beijing, China)
JID - 101673395
PMC - PMC7347490
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.eng.2020.06.014 [doi]
AID - S2095-8099(20)30176-4 [pii]
PST - ppublish
SO  - Engineering (Beijing). 2020 Oct;6(10):1070-1072. doi: 10.1016/j.eng.2020.06.014. 
      Epub 2020 Jul 10.


PMID- 32837709
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220210
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Dec
TI  - Comparison of Telehealth-Related Ethics and Guidelines and a Checklist for
      Ethical Decision Making in the Midst of the COVID-19 Pandemic.
PG  - 736-747
LID - 10.1007/s40617-020-00475-2 [doi]
AB  - Applied behavior analysis (ABA) services have been provided primarily in the
      fields of health care and education across various settings using an in-person
      service delivery model. Due to the COVID-19 pandemic, the necessity of and demand
      for ABA services using telehealth have increased. The purpose of the present
      article was to cross-examine the ethical codes and guidelines of different, but
      related fields of practice and to discuss potential implications for
      telehealth-based ABA service delivery. We reviewed the telehealth-specific
      ethical codes and guidelines of the American Psychological Association, the
      American Academy of Pediatrics, and the National Association of Social Workers,
      along with the related ABA literature. These organizations addressed several
      useful and unique ethical concerns that have not been addressed in ABA
      literature. We also developed a brief checklist for ABA practitioners to evaluate
      their telehealth readiness by meeting the legal, professional, and ethical
      requirements of ABA services.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - Baumes, Andrea
AU  - Baumes A
AUID- ORCID: https://orcid.org/0000-0002-6869-549X
AD  - Positive Behavior Support Corporation, Honolulu, HI USA.
FAU - Colic, Marija
AU  - Colic M
AD  - Special Education Department, University of Hawaii at Manoa, Honolulu, HI
      USA.grid.410445.00000 0001 2188 0957
FAU - Araiba, Sho
AU  - Araiba S
AD  - Positive Behavior Support Corporation, Honolulu, HI USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200817
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7430127
OTO - NOTNLM
OT  - Applied behavior analysis
OT  - COVID-19
OT  - Checklist
OT  - Ethics
OT  - Telehealth
COIS- Conflict of InterestAll three authors declare they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s40617-020-00475-2 [doi]
AID - 475 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Aug 17;13(4):736-747. doi: 10.1007/s40617-020-00475-2.
      eCollection 2020 Dec.


PMID- 32837702
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220705
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Sep
TI  - A University-Based Social Services Parent-Training Model: A Telehealth Adaptation
      During the COVID-19 Pandemic.
PG  - 532-542
LID - 10.1007/s40617-020-00450-x [doi]
AB  - With the COVID-19 pandemic resulting in social-distancing recommendations, many
      service providers find themselves altering the way they must provide medically
      necessary therapy. Even with the advent of more advanced telehealth technologies,
      the implementation of behavioral programming falls mainly on the caregivers of
      the clients that are served. This crisis brings to light ethical dilemmas and
      upends the current ways many programs may have been implemented across the world.
      As a result, a reevaluation of how these services are delivered is in order. This
      article reviews how a university-based, state-funded service delivery program
      (USSDP) provided essential and necessary services during the COVID-19 pandemic.
      Specifically, the purpose of this article is to describe how the USSDP quickly
      adopted a telehealth care model in a program that previously had not delivered
      services in this modality. Ethical, contextual, and competency-based factors are 
      reviewed in the context of this organization, followed by a dialogue on broader
      generalization suggestions utilizing an active support model of care within
      telehealth restrictions.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - Britwum, Kwadwo
AU  - Britwum K
AUID- ORCID: 0000-0001-9250-975X
AD  - Southern Illinois University, Carbondale, IL USA.grid.411026.00000 0001 1090 2313
FAU - Catrone, Rocco
AU  - Catrone R
AD  - Southern Illinois University and the Chicago School of Professional Psychology,
      Chicago, IL USA.grid.35403.310000 0004 1936 9991
FAU - Smith, G David
AU  - Smith GD
AD  - GDS Behavioral Consulting, Carbondale, IL USA.
FAU - Koch, Darwin Shane
AU  - Koch DS
AD  - Southern Illinois University, Carbondale, IL USA.grid.411026.00000 0001 1090 2313
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200702
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7331491
OTO - NOTNLM
OT  - Active support model
OT  - COVID-19
OT  - Ethics
OT  - Parent training
OT  - Telehealth
COIS- Conflict of InterestThe authors declare there are no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s40617-020-00450-x [doi]
AID - 450 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Jul 2;13(3):532-542. doi: 10.1007/s40617-020-00450-x.
      eCollection 2020 Sep.


PMID- 32837697
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220211
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Sep
TI  - The Role of Compassion and Ethics in Decision Making Regarding Access to Applied 
      Behavior Analysis Services During the COVID-19 Crisis: A Response to Cox,
      Plavnick, and Brodhead.
PG  - 604-608
LID - 10.1007/s40617-020-00446-7 [doi]
AB  - Cox, Plavnick, and Brodhead (2020, "A Proposed Process for Risk Mitigation During
      the COVID-19 Pandemic") published a position statement in the emergency section
      of Behavior Analysis in Practice in response to the COVID-19 crisis. They argued 
      against a blanket interpretation that in-person applied behavior analysis
      services for all patients should continue during the pandemic. They strongly
      argued that the risks of continued services are almost always prohibitive and
      that only in rare cases would the continuation of in-person services be
      warranted. Colombo, Wallace, and Taylor (2020, "An Essential Service Decisions
      Model for Applied Behavior Analytic Providers During Crisis") soon thereafter
      published a response to the article pointing out the potential dangers associated
      with the position of the article by Cox et al. They included a detailed decision 
      model to assist providers in making nuanced and informed data-based decisions
      that provide the opportunity to honor the ethical responsibility for not
      abandoning patients. We echo the importance of the Colombo et al. response and
      add points of response centered on balanced ethical decision making informed by
      compassionate family-centered care.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - LeBlanc, Linda A
AU  - LeBlanc LA
AUID- ORCID: 0000-0001-7711-0978
AD  - LeBlanc Behavioral Consulting, Golden, CO USA.
FAU - Lazo-Pearson, Junelyn F
AU  - Lazo-Pearson JF
AD  - Advanced Behavioral Health, Costa Mesa, CA USA.
FAU - Pollard, Joy S
AU  - Pollard JS
AD  - Behavior Change Institute, Stanford University School of Medicine, Stanford, CA
      USA.grid.168010.e0000000419368956
FAU - Unumb, Lorri S
AU  - Unumb LS
AD  - The Council of Autism Service Providers, Wakefield, MA USA.
LA  - eng
PT  - Editorial
DEP - 20200616
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7296895
OTO - NOTNLM
OT  - COVID-19
OT  - Compassion
OT  - Decision making
OT  - Ethics
COIS- Conflict of InterestThe authors do not have a financial interest or any other
      conflicts of interest related to the article.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s40617-020-00446-7 [doi]
AID - 446 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Jun 16;13(3):604-608. doi: 10.1007/s40617-020-00446-7.
      eCollection 2020 Sep.


PMID- 32837675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1938-971X (Print)
IS  - 1938-971X (Linking)
VI  - 13
IP  - 2
DP  - 2020
TI  - Ethical and Professional Considerations in the Forensic Assessment of Complex
      Trauma and Dissociation.
PG  - 124-134
LID - 10.1007/s12207-020-09384-9 [doi]
AB  - Empirical research spanning the past three decades has consistently upheld that
      traumatic experiences are prevalent (Gold, Psychological Trauma Theory Research
      Practice and Policy, S(1), 114-124, 2008; Kilpatrick et al. Journal of Traumatic 
      Stress, 26(5), 537-547, 2013; Resnick, Kilpatrick, Dansky, Saunders, & Best
      Journal of Clinical and Consulting Psychology, 61(6), 984-991, 1993). Therefore, 
      the likelihood of encountering an individual who has experienced significant
      trauma within forensic settings is high (Dalenberg, Straus, & Ardill, 2017).
      Further, forensic psychologists are frequently called upon to assess the impact
      of such traumatic events and to opine about their connection to a specific
      psycho-legal issue such as damages in a civil case or the presence of extreme
      emotional disturbance or mitigating factors in criminal matters. Childhood trauma
      that has occurred repeatedly and cumulatively, particularly within the context of
      family relationships, has been referred to as complex trauma. Complex trauma has 
      been shown to result in significant difficulties in a broad range of capabilities
      such as affect regulation, dissociation, identity development, relational
      capacities, and somatic distress (Courtois and Ford 2009). The author delineates 
      core ethical principles and challenges encountered in forensic assessment both
      generally and more specifically in the forensic assessment of complex trauma and 
      dissociation. She also details practical strategies for responding to those
      challenges. In addition, the author identifies essential skills needed for
      competency in this arena and outlines professional considerations that arise when
      working with this population.
CI  - (c) Springer Science+Business Media, LLC, part of Springer Nature 2020.
FAU - Rocchio, Lisa M
AU  - Rocchio LM
AUID- ORCID: 0000-0002-8579-3892
AD  - Lisa M. Rocchio, Ph.D. & Associates, Inc., 1524 Atwood Avenue, Suite 222,
      Johnston, 02919 RI USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200608
PL  - United States
TA  - Psychol Inj Law
JT  - Psychological injury and law
JID - 101535954
PMC - PMC7278774
OTO - NOTNLM
OT  - Civil litigation
OT  - Complex trauma
OT  - Dissociation
OT  - Ethics
OT  - Forensic
OT  - Personal injury
OT  - Trauma
COIS- Conflict of InterestThe author declares that she has no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s12207-020-09384-9 [doi]
AID - 9384 [pii]
PST - ppublish
SO  - Psychol Inj Law. 2020;13(2):124-134. doi: 10.1007/s12207-020-09384-9. Epub 2020
      Jun 8.


PMID- 32837564
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - COVID-19 Lockdowns: a Public Mental Health Ethics Perspective.
PG  - 503-510
LID - 10.1007/s41649-020-00144-0 [doi]
AB  - States all over the world have reacted to COVID-19 with quarantines of entire
      cities, provinces, and even nations. Previous studies and preliminary evidence
      from current lockdowns suggest that emergency measures protecting the public's
      physical health by dislocating individuals, families, and social networks could
      well be causing a devastating public health crisis of mental ill-health in the
      months and years to come. This article is the first to take a public mental
      health ethics perspective in examining these lockdowns, the lodestar of which is 
      the right to mental health, rooted in the concept of human dignity. Even the
      strictest lockdowns are not necessarily unethical but are prone to damage mental 
      health disproportionately, with vulnerable and disadvantaged populations being at
      particular risk.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Cheung, Daisy
AU  - Cheung D
AUID- ORCID: https://orcid.org/0000-0003-1942-8966
AD  - Faculty of Law, University of Hong Kong, Hong Kong.grid.194645.b0000000121742757
FAU - Ip, Eric C
AU  - Ip EC
AUID- ORCID: https://orcid.org/0000-0001-9832-0288
AD  - Faculty of Law, University of Hong Kong, Hong Kong.grid.194645.b0000000121742757
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7431738
OTO - NOTNLM
OT  - COVID-19
OT  - Lockdowns
OT  - Public health ethics
OT  - Public mental health
OT  - Right to mental health
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/06/24 00:00 [received]
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00144-0 [doi]
AID - 144 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 18;12(4):503-510. doi: 10.1007/s41649-020-00144-0.
      eCollection 2020 Dec.


PMID- 32837563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220707
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - Paediatric Palliative Care during the COVID-19 Pandemic: A Malaysian Perspective.
PG  - 529-537
LID - 10.1007/s41649-020-00142-2 [doi]
AB  - Malaysia had its first four patients with COVID-19 on 25 January 2020. In the
      same week, the World Health Organization declared it as a public health emergency
      of international concern. The pandemic has since challenged the ethics and
      practice of medicine. There is palpable tension from the conflict of interest
      between public health initiatives and individual's rights. Ensuring equitable
      care and distribution of health resources for patients with and without COVID-19 
      is a recurring ethical challenge for clinicians. Palliative care aims to mitigate
      suffering caused by a life-limiting illness, and this crisis has led to the
      awareness and urgency to ensure it reaches all who needs it. We share here the
      palliative care perspectives and ethical challenges during the COVID-19 pandemic 
      in Malaysia.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Chong, Lee Ai
AU  - Chong LA
AUID- ORCID: 0000-0001-7649-1449
AD  - University Malaya Medical Center, Kuala Lumpur, Malaysia.grid.413018.f0000 0000
      8963 3111
FAU - Khoo, Erwin J
AU  - Khoo EJ
AD  - International Medical University, Kuala Lumpur, Malaysia.grid.411729.80000 0000
      8946 5787
FAU - Kamar, Azanna Ahmad
AU  - Kamar AA
AD  - University Malaya Medical Center, Kuala Lumpur, Malaysia.grid.413018.f0000 0000
      8963 3111
FAU - Tan, Hui Siu
AU  - Tan HS
AD  - Hospital Ampang, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7424239
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical ethics
OT  - Malaysia
OT  - Paediatrics
OT  - Palliative care
OT  - Pandemic
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00142-2 [doi]
AID - 142 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 13;12(4):529-537. doi: 10.1007/s41649-020-00142-2.
      eCollection 2020 Dec.


PMID- 32837561
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Sep
TI  - Exclusion of Migrant Workers from National UHC Systems-Perspectives from
      HealthServe, a Non-profit Organisation in Singapore.
PG  - 363-374
LID - 10.1007/s41649-020-00138-y [doi]
AB  - Low-wage migrant workers in Singapore are legally entitled to healthcare provided
      by their employers and supported by private insurance, separate from the national
      UHC (universal health coverage) system. In practice, they face multiple barriers 
      to access. In this article, we describe this policy-practice gap from the
      perspective of HealthServe, a non-profit organisation that assists low-wage
      migrant workers. We outline the healthcare financing system for migrant workers, 
      describe commonly encountered barriers, and comment on their implications for the
      global UHC movement's key ethical concepts of fairness, equity, and solidarity.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Rajaraman, Natarajan
AU  - Rajaraman N
AUID- ORCID: https://orcid.org/0000-0002-0083-2056
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.grid.4280.e0000 0001 2180 6431
FAU - Yip, Teem-Wing
AU  - Yip TW
AD  - Southgate Institute for Health, Society and Equity, Flinders University,
      Adelaide, South Australia Australia.grid.1014.40000 0004 0367 2697
FAU - Kuan, Benjamin Yi Hern
AU  - Kuan BYH
AD  - Medical Services, HealthServe, Singapore.
FAU - Lim, Jeremy Fung Yen
AU  - Lim JFY
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.grid.4280.e0000 0001 2180 6431
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7396727
OTO - NOTNLM
OT  - Health equity
OT  - Health financing
OT  - Healthcare access
OT  - Migrant health
OT  - Migrant workers
OT  - UHC
OT  - Universal health coverage
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/28 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00138-y [doi]
AID - 138 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Aug 3;12(3):363-374. doi: 10.1007/s41649-020-00138-y.
      eCollection 2020 Sep.


PMID- 32837560
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - Epistemic Ignorance, Poverty and the COVID-19 Pandemic.
PG  - 519-527
LID - 10.1007/s41649-020-00140-4 [doi]
AB  - In various responses to the COVID-19 pandemic, we can observe insufficient
      sensitivity towards the needs and circumstances of poorer citizens. Particularly 
      in a context of high inequality, policy makers need to engage with the wider
      public in debates and consultations to gain better insights in the realities of
      the worst-off within their jurisdiction. When consultations involve members of
      traditionally underrepresented groups, these are not only more inclusive, which
      is in itself an ethical aim, but pool ideas and observations from a much more
      diverse array of inhabitants. Inclusivity increases the odds to identify a larger
      range of weak spots for health security and to design health interventions that
      are less burdensome on those worst-off.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Timmermann, Cristian
AU  - Timmermann C
AUID- ORCID: https://orcid.org/0000-0001-7935-2823
AD  - Centro Interdisciplinario de Estudios en Bioetica, Universidad de Chile,
      Santiago, Chile.grid.443909.30000 0004 0385 4466
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7392120
OTO - NOTNLM
OT  - Cognitive diversity
OT  - Epistemic justice
OT  - Pandemic
OT  - Poverty-sensitive
OT  - Public consultations
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00140-4 [doi]
AID - 140 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Jul 30;12(4):519-527. doi: 10.1007/s41649-020-00140-4.
      eCollection 2020 Dec.


PMID- 32837558
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220210
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Sep
TI  - Vietnam's Response to the COVID-19 Outbreak.
PG  - 341-347
LID - 10.1007/s41649-020-00134-2 [doi]
AB  - This article explores Vietnam's response to the COVID-19 pandemic as an example
      of good ethical practice in dealing with the COVID-19 outbreak. Vietnam's
      response to the pandemic is in accordance with the ethics of care which
      emphasizes solidarity and responsibility. Vietnam's approach to the COVID-19
      pandemic is also in accordance with the third generation of human rights that
      promote solidarity and responsibilities towards the community. A full
      implementation of human rights requires more emphasis on responsibilities,
      especially in the time of crisis.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Ivic, Sanja
AU  - Ivic S
AUID- ORCID: 0000-0003-1504-0059
AD  - Department for Management of Science and Technology Development, Ton Duc Thang
      University, Ho Chi Minh City, Vietnam.grid.444812.f0000 0004 5936 4802
AD  - Faculty of Social Sciences and Humanities, Ton Duc Thang University, Ho Chi Minh 
      City, Vietnam.grid.444812.f0000 0004 5936 4802
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7348105
OTO - NOTNLM
OT  - COVID-19
OT  - Care
OT  - Rhetoric
OT  - Solidarity
OT  - Vietnam
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/06/20 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00134-2 [doi]
AID - 134 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Jul 10;12(3):341-347. doi: 10.1007/s41649-020-00134-2.
      eCollection 2020 Sep.


PMID- 32837557
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Dec
TI  - An analysis of the ethics of lockdown in India.
PG  - 481-489
LID - 10.1007/s41649-020-00133-3 [doi]
AB  - Over the past 6 months, coronavirus-induced disease (COVID-19) has spread across 
      212 countries, affecting millions of people. As it has no known cure, social
      distancing is highly recommended for prevention of spread of the disease. Here,
      we have described the impact of the social distancing measures implemented by the
      Government of India on various sections of the society, especially the vulnerable
      sections. Furthermore, we have presented an analysis of these measures, according
      to the World Health Organization s Guidance for Managing Ethical Issues in
      Infectious Disease Outbreaks (2016); we have also applied principles, as
      applicable, from the Indian Council of Medical Research's National Ethical
      Guidelines for Biomedical and Health Research Involving Human Participants
      (2017). Finally, we have presented several measures that should have been adopted
      before and in addition to implementing the lockdown to improve its effectiveness.
CI  - (c) The Author(s) 2020.
FAU - Arunachalam, Meghna Ann
AU  - Arunachalam MA
AD  - YU-FIC Research Ethics Master's Program for India, Yenepoya Deemed to be
      University, Mangalore, India.
FAU - Halwai, Aarti
AU  - Halwai A
AD  - YU-FIC Research Ethics Master's Program for India, Yenepoya Deemed to be
      University, Mangalore, India.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7347396
OTO - NOTNLM
OT  - Community engagement
OT  - India
OT  - Justice
OT  - Lockdown
OT  - Restrictive measures
OT  - Vulnerable
COIS- Conflict of interestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00133-3 [doi]
AID - 133 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Jul 9;12(4):481-489. doi: 10.1007/s41649-020-00133-3.
      eCollection 2020 Dec.


PMID- 32837556
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220210
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Sep
TI  - Sharing Information on COVID-19: the ethical challenges in the Malaysian setting.
PG  - 349-361
LID - 10.1007/s41649-020-00132-4 [doi]
AB  - The COVID-19 pandemic has raised challenges in dealing with information sharing
      by the public and the authorities. There are two categories of information
      sharing on social media that are believed to be potentially problematic and
      unethical: the sharing of personal information of patients and the sharing of
      fake news or false information. We present a discussion on how the response to
      the COVID-19 pandemic in Malaysia can be ethically handled in terms of
      information sharing. It is recommended that the public should cultivate the basic
      skills to evaluate information and determine its validity. On the other hand, the
      authorities should refrain from placing the blame on patients to avoid them from 
      being stigmatized. It is crucial that all parties are aware of their ethical duty
      to ensure only ethical and valid information gets shared on social media.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Yusof, Aimi Nadia Mohd
AU  - Yusof ANM
AUID- ORCID: 0000-0002-6209-7333
AD  - Medical Ethics and Law Unit, Faculty of Medicine, Universiti Teknologi MARA,
      Selangor, Malaysia.grid.412259.90000 0001 2161 1343
FAU - Muuti, Muhamad Zaid
AU  - Muuti MZ
AD  - Medical Ethics and Law Unit, Faculty of Medicine, Universiti Teknologi MARA,
      Selangor, Malaysia.grid.412259.90000 0001 2161 1343
FAU - Ariffin, Lydia Aiseah
AU  - Ariffin LA
AD  - Medical Ethics and Law Unit, Faculty of Medicine, Universiti Teknologi MARA,
      Selangor, Malaysia.grid.412259.90000 0001 2161 1343
FAU - Tan, Mark Kiak Min
AU  - Tan MKM
AD  - Medical Ethics and Law Unit, Faculty of Medicine, Universiti Teknologi MARA,
      Selangor, Malaysia.grid.412259.90000 0001 2161 1343
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7315401
OTO - NOTNLM
OT  - COVID-19
OT  - Confidentiality
OT  - Information sharing
OT  - Pandemic
OT  - Privacy
OT  - Public interest
COIS- Conflict of interestOn behalf of all authors, the corresponding author states
      that there is no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00132-4 [doi]
AID - 132 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 Jun 25;12(3):349-361. doi: 10.1007/s41649-020-00132-4.
      eCollection 2020 Sep.


PMID- 32837551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220210
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - COVID-19 Pandemic: a Litmus Test of Trust in the Health System.
PG  - 213-221
LID - 10.1007/s41649-020-00122-6 [doi]
AB  - The pandemic caused by the SARS-CoV2 novel coronavirus is creating a global
      crisis. There is a global ambience of uncertainty and anxiety. In addition,
      nations have imposed strict and restrictive public health measures including
      lockdowns. In this heightened time of vulnerability, public cooperation to
      preventive measures depends on trust and confidence in the health system. Trust
      is the optimistic acceptance of the vulnerability in the belief that the health
      system has best intentions. On the other hand, confidence is assessed based on
      previous experiences with the health system. Trust and confidence in the health
      system motivate people to accept the public health interventions and cooperate
      with them. Building trust and confidence therefore becomes an ethical imperative.
      This article analyses the COVID-19 pandemic in the south Indian state of Tamil
      Nadu and the state's response to this pandemic. Further, it applies the
      Trust-Confidence-Cooperation framework of risk management to analyse the
      influence of public trust and confidence on the Tamil Nadu health system in the
      context of the preventive strategies adopted by the state. Finally, the article
      proposes a six-pronged strategy to build trust and confidence in health system
      functions to improve cooperation to pandemic containment measures.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Gopichandran, Vijayaprasad
AU  - Gopichandran V
AUID- ORCID: 0000-0003-2635-9583
AD  - Department of Community Medicine, ESIC Medical College and Postgraduate Institute
      of Medical Sciences and Research, Chennai, India.
AD  - NODAL Point, Chennai, India.
FAU - Subramaniam, Sudharshini
AU  - Subramaniam S
AD  - NODAL Point, Chennai, India.
AD  - Institute of Community Medicine, Madras Medical College, Chennai,
      India.grid.416256.20000 0001 0669 1613
FAU - Kalsingh, Maria Jusler
AU  - Kalsingh MJ
AD  - NODAL Point, Chennai, India.
AD  - National Health Mission - Tamil Nadu, Chennai, India.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7259435
OTO - NOTNLM
OT  - COVID-19
OT  - Confidence
OT  - Cooperation
OT  - Pandemic
OT  - Public health
OT  - SARS-CoV2
OT  - Trust
COIS- Conflicts of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00122-6 [doi]
AID - 122 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 29;12(2):213-221. doi: 10.1007/s41649-020-00122-6.
      eCollection 2020 Jun.


PMID- 32837550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220211
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - The Perfect Moral Storm: Diverse Ethical Considerations in the COVID-19 Pandemic.
PG  - 65-83
LID - 10.1007/s41649-020-00125-3 [doi]
AB  - The COVID-19 pandemic has both exposed and created deep rifts in society. It has 
      thrust us into deep ethical thinking to help justify the difficult decisions many
      will be called upon to make and to protect from decisions that lack ethical
      underpinnings. This paper aims to highlight ethical issues in six different areas
      of life highlighting the enormity of the task we are faced with globally. In the 
      context of COVID-19, we consider health inequity, dilemmas in triage and
      allocation of scarce resources, ethical issues associated with research, ethical 
      considerations relating to tracing apps, and exit strategies such as immunity
      passports and COVID-19 vaccines. Finally, we consider environmental issues in
      light of COVID-19. The paper also offers some ethical reflection on these areas
      as many parts of the world contemplate the recovery phase.
CI  - (c) National University of Singapore and Springer Nature Singapore Pte Ltd. 2020.
FAU - Xafis, Vicki
AU  - Xafis V
AUID- ORCID: 0000-0002-5104-9686
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Schaefer, G Owen
AU  - Schaefer GO
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Labude, Markus K
AU  - Labude MK
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Zhu, Yujia
AU  - Zhu Y
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
FAU - Hsu, Li Yan
AU  - Hsu LY
AD  - SHAPES Initiative, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine,
      National University of Singapore, Singapore.grid.4280.e0000 0001 2180 6431
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.grid.4280.e0000 0001 2180 6431
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
EIN - Asian Bioeth Rev. 2020 Jun 6;:1. PMID: 32840248
PMC - PMC7255635
OTO - NOTNLM
OT  - COVID-19
OT  - Health inequity
OT  - Immunity passports
OT  - Resource allocation
OT  - SARS-CoV-2
OT  - Tracing apps
OT  - Triage
OT  - Vaccines
COIS- Conflict of InterestThe authors declare that they have no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00125-3 [doi]
AID - 125 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 28;12(2):65-83. doi: 10.1007/s41649-020-00125-3.
      eCollection 2020 Jun.


PMID- 32837549
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 1793-9453 (Electronic)
IS  - 1793-9453 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - Ethics Education for Successful Infectious Disease Control of COVID-19.
PG  - 243-251
LID - 10.1007/s41649-020-00124-4 [doi]
AB  - The infection rates of COVID-19 have been exponential in some countries despite
      the imposition of infectious disease control measures such as lockdowns and
      physical distancing, which form one of the basic principles of public health and 
      infectious disease control. There have been significant problems with leaders and
      citizenry deliberately ignoring and not complying with such measures and which
      have directly resulted in sudden rises in infection numbers. Here, I show the
      nature and extent of the widespread problem and argue that the problem is in
      large part due to our modern society characterised by liberal individualism. I
      apply the philosophy proposed by philosopher Alasdair MacIntrye to show that one 
      key underlying cause of the non-compliant behaviour of citizenry is due to modern
      liberal individualism that has deprived the modern nation state of the
      opportunities and authority for it to teach or to dictate what is the common good
      of the society as a whole to individuals in its community. This is the first time
      MacIntyre's philosophy has been applied to public health, and this paper
      demonstrates the need for ethics education to counter-balance liberal
      individualism in order to contain and to prevent another pandemic and public
      health crisis in modern society.
CI  - (c) The Author(s) 2020.
FAU - Lim, Hannah YeeFen
AU  - Lim HY
AUID- ORCID: 0000-0002-6472-1830
AD  - Division of Business Law, Nanyang Technological University,
      Singapore.grid.59025.3b0000 0001 2224 0361
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - England
TA  - Asian Bioeth Rev
JT  - Asian bioethics review
JID - 101608807
PMC - PMC7242607
OTO - NOTNLM
OT  - COVID-19
OT  - Law
OT  - Public health
OT  - Social philosophy
OT  - Standard of care
COIS- Conflict of InterestThe author declares that she has no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s41649-020-00124-4 [doi]
AID - 124 [pii]
PST - epublish
SO  - Asian Bioeth Rev. 2020 May 22;12(2):243-251. doi: 10.1007/s41649-020-00124-4.
      eCollection 2020 Jun.


PMID- 32837547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1765-4629 (Print)
IS  - 1765-4629 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Dec
TI  - [What support for vulnerable people during confinement?]
PG  - 220-225
LID - 10.1016/j.etiqe.2020.08.002 [doi]
AB  - What are the ethical issues in connection with the support of the most vulnerable
      people in a context of health crisis, forcing them to be confined? Because the
      concept of vulnerability is broad and complex, the "Espace ethique PACA-Corse"
      (PACA-Corsica Ethical Structure) has taken a particular interest in the care of
      children with disabilities, children entrusted to child welfare services and
      people with psychiatric disorders. Confinement has led to a reorganisation of the
      access to healthcare services and medico-social support, possibly revealing or
      aggravating some situations of vulnerability, or even pushing aside certain
      people. Those most isolated or at risk of abuse may have experienced a double
      confinement. How to identify and respond to the needs of people already in
      vulnerable situations before confinement, who, isolated in the epidemic context, 
      have seen their vulnerabilities increase? While new ways of working have been
      introduced in times of containment, some were interesting, others have shown
      their limits. The challenge was to find the right measure to address the
      specificity of each situation, to activate care networks in an effective and
      supportive manner, despite limited resources and the emergency context. The
      difficulty was to make protocols and care values coexist, acting in a reactive
      and creative way. While revealing vulnerabilities, this period has required both 
      humility toward uncertainty and a duty of responsibility to care for those most
      in need.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Malzac, P
AU  - Malzac P
AD  - UMR 7268 ADES, Espace de reflexion ethique Paca-Corse, Aix-Marseille Universite, 
      Marseille, France.
AD  - Departement de genetique medicale, hopital d'enfants de la Timone, Assistance
      Publique-Hopitaux de Marseille, Marseille, France.
FAU - Mathieu, M
AU  - Mathieu M
AD  - UMR 7268 ADES, Espace de reflexion ethique Paca-Corse, Aix-Marseille Universite, 
      Marseille, France.
AD  - Association Tous Chercheurs, Parc scientifique de Luminy, Marseille, France.
FAU - Einaudi, M A
AU  - Einaudi MA
AD  - UMR 7268 ADES, Espace de reflexion ethique Paca-Corse, Aix-Marseille Universite, 
      Marseille, France.
AD  - Direction de la protection maternelle et infantile et de la sante publique,
      Direction generale adjointe de la solidarite, Conseil departemental des Bouches
      du Rhone, Rhone, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Quel accompagnement pour les personnes vulnerables en contexte de confinement ?
DEP - 20200816
PL  - France
TA  - Ethique Sante
JT  - Ethique & sante
JID - 9885754
PMC - PMC7429073
OTO - NOTNLM
OT  - Confinement
OT  - Health crisis
OT  - Medico-social
OT  - Support
OT  - Vulnerabilities
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.etiqe.2020.08.002 [doi]
AID - S1765-4629(20)30084-2 [pii]
PST - ppublish
SO  - Ethique Sante. 2020 Dec;17(4):220-225. doi: 10.1016/j.etiqe.2020.08.002. Epub
      2020 Aug 16.


PMID- 32837546
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1765-4629 (Print)
IS  - 1765-4629 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - [A ethical approach of funerals in pandemic].
PG  - 168-170
LID - 10.1016/j.etiqe.2020.06.002 [doi]
AB  - The sanitary risk prevention associated with the body overtakes nearly all other 
      considerations. The organisation of funerals isn't actually managed by the
      authorities, and left to the will of funeral officers. How acceptable is this
      during a pandemic with elevated risks and a hightened awareness of death - not
      only of people, but also of a society at fault? An ethical approach is the only
      way to raise to the challenge of organising funerals more responsibly.
CI  - (c) 2020 Published by Elsevier Masson SAS.
FAU - Fery, B
AU  - Fery B
AD  - E.R.E.R Hauts-de-France, espace reflexion ethique regional des Hauts-de-France,
      France.
AD  - Commission nationale du debat public, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Pour une ethique des funerailles en situation de pandemie.
DEP - 20200807
PL  - France
TA  - Ethique Sante
JT  - Ethique & sante
JID - 9885754
PMC - PMC7413651
OTO - NOTNLM
OT  - Ethical
OT  - Funerals
OT  - Pandemic
OT  - Sanitary risk
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.etiqe.2020.06.002 [doi]
AID - S1765-4629(20)30075-1 [pii]
PST - ppublish
SO  - Ethique Sante. 2020 Sep;17(3):168-170. doi: 10.1016/j.etiqe.2020.06.002. Epub
      2020 Aug 7.


PMID- 32837545
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1765-4629 (Print)
IS  - 1765-4629 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - ["Responding to vulnerability": Ethics and CHSLD in the Age of COVID-19].
PG  - 142-146
LID - 10.1016/j.etiqe.2020.07.003 [doi]
AB  - The intrusion of the COVID-19 in Quebec witnesses the failure of seniors'
      residences to adequately protect their residents. The long-standing carelessness 
      of an entire society towards frail elderly people has become clear. The text is
      divided into two parts. The first part shows that as much as the Quebec hospital,
      under the direction of the Ministry of Health, was ready to deal with the
      pandemic, as long-term centres for people with loss of autonomy were not. The
      second part discusses the type of ethics that guided officials in their
      decisions. This type of ethics does not seem to me to be consistent with the
      ethical vision that would be appropriate in long-term care. Ethics should be one 
      that corresponds to the nature of these centres, it should be a response to
      vulnerability. The conclusion calls for citizen dialogue to arrive at an
      appropriate response to the situation of these people.
CI  - (c) 2020 Published by Elsevier Masson SAS.
FAU - Doucet, H
AU  - Doucet H
AD  - Institut d'etudes religieuses, universite de Montreal, Pavillon
      Marguerite-d'Youville, 2375, chemin de la Cote Sainte-Catherine, Montreal, Quebec
      H3T 1A8, Canada.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - << Repondre a la vulnerabilite >> : l'ethique et les CHSLD au temps de la
      COVID-19.
DEP - 20200721
PL  - France
TA  - Ethique Sante
JT  - Ethique & sante
JID - 9885754
PMC - PMC7373036
OTO - NOTNLM
OT  - COVID-19
OT  - Long-term care ethics
OT  - Long-term care homes for the elderly
OT  - Vulnerability
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.etiqe.2020.07.003 [doi]
AID - S1765-4629(20)30082-9 [pii]
PST - ppublish
SO  - Ethique Sante. 2020 Sep;17(3):142-146. doi: 10.1016/j.etiqe.2020.07.003. Epub
      2020 Jul 21.


PMID- 32837544
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1765-4629 (Print)
IS  - 1765-4629 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - [What are the ethical issues raised by the COVID 19 epidemic?]
PG  - 155-159
LID - 10.1016/j.etiqe.2020.06.003 [doi]
AB  - The COVID-19 epidemic has highlighted or revealed real ethical issues, revealing 
      the limits of knowledge, the limits of life, the limits of our health care
      system, the limits of our society. Questioning these limits and therefore these
      ethical issues can be interesting to advance our health system and our society.
      In this article, we have chosen to address a few ethical questions concerning
      more particularly the function of care, the relationship to death, the
      relationship to uncertainty, questions more related to containment measures than 
      to COVID itself and finally a more political questioning on what this epidemic
      reveals about the fragility of our societies and our economies. We arbitrarily
      set aside, given the constrained format of the article, some extremely important 
      issues such as research ethics issues, issues related to the notion of patient
      selection or triage, issues related to the ethics of managing the shortage, and
      finally issues related to the tracing of contacts or patients.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Aubry, R
AU  - Aubry R
AD  - Hopital Jean-Minjoz, boulevard Fleming, 25030 Besancon cedex, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - << Quels enjeux de nature ethique l'epidemie de COVID 19 a-t-elle souleve ? >>.
DEP - 20200625
PL  - France
TA  - Ethique Sante
JT  - Ethique & sante
JID - 9885754
PMC - PMC7315950
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics and politics
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.etiqe.2020.06.003 [doi]
AID - S1765-4629(20)30076-3 [pii]
PST - ppublish
SO  - Ethique Sante. 2020 Sep;17(3):155-159. doi: 10.1016/j.etiqe.2020.06.003. Epub
      2020 Jun 25.


PMID- 32837542
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1765-4629 (Print)
IS  - 1765-4629 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - [What's the covid's name?]
PG  - 137-141
LID - 10.1016/j.etiqe.2020.05.003 [doi]
AB  - The massive irruption of Covid-19 expression in the hospital environment as well 
      as in our lives has brought to light a strange analogy between the expansion of a
      virus and viral dissemination, too, in a way of speaking and naming for action.
      This article proposes to question the impact of the expression Covid-19 on the
      language of caregivers. It proposes to discuss the ethical dimension of a care of
      care words when a way of speaking imposes itself on them. It also questions the
      epistemological and ethical pluralism involving medicine between science,
      clinical and politics.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Pierron, J-P
AU  - Pierron JP
AD  - UMR LIR3S, laboratoire interdisciplinaire de recherches soin sensibilites et
      societes, universite de Bourgogne, boulevard Gabriel, 21000 Dijon, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - De quoi le Covid-19 est-il le nom ? L'impact du langage sur la prise en charge et
      le positionnement ethique par temps de pandemie.
DEP - 20200528
PL  - France
TA  - Ethique Sante
JT  - Ethique & sante
JID - 9885754
PMC - PMC7253988
OTO - NOTNLM
OT  - Acronym
OT  - Covid-19
OT  - Ethics
OT  - Language
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.etiqe.2020.05.003 [doi]
AID - S1765-4629(20)30072-6 [pii]
PST - ppublish
SO  - Ethique Sante. 2020 Sep;17(3):137-141. doi: 10.1016/j.etiqe.2020.05.003. Epub
      2020 May 28.


PMID- 32837540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1758-5880 (Print)
IS  - 1758-5880 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Sep
TI  - Interrogating Technology-led Experiments in Sustainability Governance.
PG  - 523-531
LID - 10.1111/1758-5899.12826 [doi]
AB  - Solutions to global sustainability challenges are increasingly
      technology-intensive. Yet, technologies are neither developed nor applied to
      governance problems in a socio-political vacuum. Despite aspirations to provide
      novel solutions to current sustainability governance challenges, many
      technology-centred projects, pilots and plans remain implicated in
      longer-standing global governance trends shaping the possibilities for success in
      often under-recognized ways. This article identifies three overlapping contexts
      within which technology-led efforts to address sustainability challenges are
      evolving, highlighting the growing roles of: (1) private actors; (2)
      experimentalism; and (3) informality. The confluence of these interconnected
      trends illuminates an important yet often under-recognized paradox: that the use 
      of technology in multi-stakeholder initiatives tends to reduce rather than expand
      the set of actors, enhancing instead of reducing challenges to participation and 
      transparency, and reinforcing rather than transforming existing forms of power
      relations. Without recognizing and attempting to address these limits,
      technology-led multi-stakeholder initiatives will remain less effective in
      addressing the complexity and uncertainty surrounding global sustainability
      governance. We provide pathways for interrogating the ways that novel
      technologies are being harnessed to address long-standing global sustainability
      issues in manners that foreground key ethical, social and political
      considerations and the contexts in which they are evolving.
CI  - (c) 2020 The Authors. Global Policy published by Durham University and John Wiley
      & Sons Ltd.
FAU - Bernards, Nick
AU  - Bernards N
AD  - University of Warwick.
FAU - Campbell-Verduyn, Malcolm
AU  - Campbell-Verduyn M
AD  - University of Groningen.
FAU - Rodima-Taylor, Daivi
AU  - Rodima-Taylor D
AD  - Boston University.
FAU - Duberry, Jerome
AU  - Duberry J
AD  - University of Geneva.
FAU - DuPont, Quinn
AU  - DuPont Q
AD  - University College Dublin.
FAU - Dimmelmeier, Andreas
AU  - Dimmelmeier A
AD  - University of Warwick.
FAU - Huetten, Moritz
AU  - Huetten M
AD  - Darmstadt Business School.
FAU - Mahrenbach, Laura C
AU  - Mahrenbach LC
AD  - Technical University of Munich.
FAU - Porter, Tony
AU  - Porter T
AD  - McMaster University.
FAU - Reinsberg, Bernhard
AU  - Reinsberg B
AD  - University of Glasgow.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - United States
TA  - Glob Policy
JT  - Global policy
JID - 101559259
PMC - PMC7283849
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1111/1758-5899.12826 [doi]
AID - GPOL12826 [pii]
PST - ppublish
SO  - Glob Policy. 2020 Sep;11(4):523-531. doi: 10.1111/1758-5899.12826. Epub 2020 May 
      27.


PMID- 32837517
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220628
IS  - 1682-8631 (Print)
IS  - 1682-1769 (Linking)
VI  - 52
IP  - 5
DP  - 2020
TI  - Sword of Damocles: application of the ethical principles of resource allocation
      to essential cancer surgery patients requiring beds in limited supply during the 
      COVID-19 pandemic.
PG  - 238-239
LID - 10.1007/s10353-020-00655-y [doi]
FAU - Al-Benna, Sammy
AU  - Al-Benna S
AUID- ORCID: 0000-0003-4079-9286
AD  - Division of Plastic and Reconstructive Surgery, Faculty of Medicine and Health
      Sciences, Stellenbosch University and Tygerberg Academic Hospital, Francie van
      Zijl Drive, PO Box 241, 8000 Cape Town, South Africa.grid.11956.3a0000 0001 2214 
      904X
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - Austria
TA  - Eur Surg
JT  - European surgery : ACA : Acta chirurgica Austriaca
JID - 101140655
PMC - PMC7413217
COIS- Conflict of interestS. Al-Benna declares that he has no competing interests.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/06/25 00:00 [received]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10353-020-00655-y [doi]
AID - 655 [pii]
PST - ppublish
SO  - Eur Surg. 2020;52(5):238-239. doi: 10.1007/s10353-020-00655-y. Epub 2020 Aug 7.


PMID- 32837410
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 1556-3316 (Print)
IS  - 1556-3316 (Linking)
VI  - 16
IP  - Suppl 1
DP  - 2020 Nov
TI  - The Ethics of Treating Acute Achilles Tendon Ruptures During the COVID-19
      Pandemic: A Case Report.
PG  - 52-55
LID - 10.1007/s11420-020-09767-3 [doi]
FAU - White, Peter B
AU  - White PB
AUID- ORCID: 0000-0002-3168-6768
AD  - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 
      USA.grid.257060.60000 0001 2284 9943
FAU - Partan, Matthew J
AU  - Partan MJ
AD  - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 
      USA.grid.257060.60000 0001 2284 9943
FAU - Cohn, Randy M
AU  - Cohn RM
AD  - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 
      USA.grid.257060.60000 0001 2284 9943
FAU - Humbyrd, Casey Jo
AU  - Humbyrd CJ
AD  - Department of Orthopaedic Surgery and the Berman Institute of Bioethics, Johns
      Hopkins University School of Medicine, Baltimore, MD USA.grid.21107.350000 0001
      2171 9311
FAU - Katsigiorgis, Gus
AU  - Katsigiorgis G
AD  - Department of Orthopaedic Surgery, Long Island Jewish Valley Stream, Valley
      Stream, NY USA.
FAU - Bitterman, Adam
AU  - Bitterman A
AD  - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 
      USA.grid.257060.60000 0001 2284 9943
LA  - eng
PT  - Journal Article
DEP - 20200723
PL  - United States
TA  - HSS J
JT  - HSS journal : the musculoskeletal journal of Hospital for Special Surgery
JID - 101273938
PMC - PMC7376826
OTO - NOTNLM
OT  - Achilles tendon
OT  - COVID-19
OT  - ethics
OT  - foot and ankle
OT  - surgery
COIS- Conflict of InterestThe authors declare that they have no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s11420-020-09767-3 [doi]
AID - 9767 [pii]
PST - ppublish
SO  - HSS J. 2020 Nov;16(Suppl 1):52-55. doi: 10.1007/s11420-020-09767-3. Epub 2020 Jul
      23.


PMID- 32837402
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1555-4155 (Print)
IS  - 1555-4155 (Linking)
VI  - 16
IP  - 9
DP  - 2020 Oct
TI  - America Needs Nurse Practitioners to Advocate for Social Justice.
PG  - 710-711
LID - 10.1016/j.nurpra.2020.06.024 [doi]
AB  - The era of COVID-19 has highlighted disparities within the health care system.
      The pandemic, in combination with the death of George Floyd, has resulted in
      professional organizations condemning racism as a public health issue. But what
      is the role of individual nurse practitioners in addressing systemic racism
      within the healthcare system? The Code of Ethics for Nurses requires that all
      nurses actively work to reduce disparities. The code states that universal access
      to nursing is a human right and that health must be considered in the frame of
      social determinants. America needs nurse practitioners to reimagine the
      healthcare system and to develop policy and legislation that results in change.
      Nurse practitioners are among the most trusted professionals in America, and we
      can help the country heal from centuries-old injustices.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Russell, Naila
AU  - Russell N
LA  - eng
PT  - Journal Article
DEP - 20200725
PL  - United States
TA  - J Nurse Pract
JT  - The journal for nurse practitioners : JNP
JID - 101264817
PMC - PMC7382568
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.nurpra.2020.06.024 [doi]
AID - S1555-4155(20)30369-X [pii]
PST - ppublish
SO  - J Nurse Pract. 2020 Oct;16(9):710-711. doi: 10.1016/j.nurpra.2020.06.024. Epub
      2020 Jul 25.


PMID- 32837288
OWN - NLM
STAT- Publisher
LR  - 20220218
IS  - 1388-1957 (Print)
IS  - 1388-1957 (Linking)
DP  - 2020 Jul 21
TI  - Corona and value change. The role of social media and emotional contagion.
PG  - 1-10
LID - 10.1007/s10676-020-09545-z [doi]
AB  - People share their emotions on social media and evidence suggests that in times
      of crisis people are especially motivated to post emotional content. The current 
      Coronavirus pandemic is such a crisis. The online sharing of emotional content
      during the Coronavirus crisis may contribute to societal value change. Emotion
      sharing via social media could lead to emotional contagion which in turn could
      facilitate an emotional climate in a society. In turn, the emotional climate of a
      society can influence society's value structure. The emotions that spread in the 
      current Coronavirus crisis are predominantly negative, which could result in a
      negative emotional climate. Based on the dynamic relations of values to each
      other and the way that emotions relate to values, a negative emotional climate
      can contribute to societal value change towards values related to security
      preservation and threat avoidance. As a consequence, a negative emotional climate
      and the shift in values could lead to a change in political attitudes that has
      implications for rights, freedom, privacy and moral progress. Considering the
      impact of social media in terms of emotional contagion and a longer-lasting value
      change is an important perspective in thinking about the ethical long-term impact
      of social media technology.
CI  - (c) The Author(s) 2020.
FAU - Steinert, Steffen
AU  - Steinert S
AUID- ORCID: 0000-0001-8784-7607
AD  - Department of Values, Technology and Innovation, Faculty of Technology, Policy
      and Management, Delft University of Technology, Delft, The
      Netherlands.grid.5292.c0000 0001 2097 4740
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - Netherlands
TA  - Ethics Inf Technol
JT  - Ethics and information technology
JID - 101248311
PMC - PMC7372742
OTO - NOTNLM
OT  - Emotional contagion
OT  - Emotions
OT  - Social media
OT  - Value change
OT  - Values
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1007/s10676-020-09545-z [doi]
AID - 9545 [pii]
PST - aheadofprint
SO  - Ethics Inf Technol. 2020 Jul 21:1-10. doi: 10.1007/s10676-020-09545-z.


PMID- 32837255
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 1386-2820 (Print)
IS  - 1386-2820 (Linking)
VI  - 23
IP  - 3-4
DP  - 2020
TI  - Inducing Fear.
PG  - 501-513
LID - 10.1007/s10677-020-10103-1 [doi]
AB  - This paper offers an ethical consideration of how fear can be a tool of agents,
      used to deliberately shift people away from existing beliefs, commitments, or
      habits, or towards new ones. It contends that properly understanding the ethical 
      dimensions of such uses of fear depends in part on a clear understanding of the
      dynamics of disorientation that can be involved in such uses. Section two begins 
      with a clarification of the connections between fear, orientation, and
      disorientation. It suggests that experiences of fear are in some cases either
      orienting or disorienting, and that the disorienting aspects of fear are in need 
      of more attention. Section three shows how experiences of fear can be tools-they 
      can be cultivated and wielded by agents deliberately for multiple reasons,
      including sometimes in order to disorient or re-orient others. Section four turns
      to a moral evaluation of these uses of fear, attending specifically to why the
      dynamics of disorientation and orientation often involved in experiences of fear 
      are important for understanding the moral status of uses of fear.
CI  - (c) Springer Nature B.V. 2020.
FAU - Harbin, Ami
AU  - Harbin A
AD  - Department of Philosophy, Oakland University, Rochester, MI 48309
      USA.grid.261277.70000 0001 2219 916X
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - Netherlands
TA  - Ethical Theory Moral Pract
JT  - Ethical theory and moral practice : an international forum
JID - 101205290
PMC - PMC7363015
OTO - NOTNLM
OT  - Disorientation
OT  - Fear
OT  - Manipulation
OT  - Paternalism
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10677-020-10103-1 [doi]
AID - 10103 [pii]
PST - ppublish
SO  - Ethical Theory Moral Pract. 2020;23(3-4):501-513. doi:
      10.1007/s10677-020-10103-1. Epub 2020 Jul 15.


PMID- 32837175
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220621
IS  - 1072-0847 (Print)
IS  - 1072-0847 (Linking)
VI  - 35
IP  - 3
DP  - 2020 Jul
TI  - Some actions for behavior analyst licensing bodies to consider in response to the
      COVID-19 pandemic.
PG  - 340-345
LID - 10.1002/bin.1725 [doi]
AB  - The COVID-19 global pandemic has had a significant impact on the practice of
      applied behavior analysis (ABA). Practitioners and caregivers have had to adapt
      quickly as physical distancing, stay-at-home orders, and shelter-in-place
      directives have become commonplace. As the field copes with the changes produced 
      by the COVID-19 outbreak, many behavior analytic practitioners are seeking
      guidance from regulatory bodies to ensure they are practicing legally and
      ethically. This article outlines some actions that the regulatory bodies that
      manage state behavior analyst licensure programs may consider to assist ABA
      practitioners and consumers during this unprecedented time. Additionally,
      suggestions are offered as to how state licensing bodies might prepare to support
      the practice of licensees during future events that present challenges similar to
      the current pandemic.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Fronapfel, Brighid H
AU  - Fronapfel BH
AD  - Department of Special Education, Nevada Center for Excellence in Disabilities
      University of Nevada Reno Nevada USA.
FAU - Dubuque, Erick M
AU  - Dubuque EM
AD  - Department of Special Education, Early Childhood, and Prevention Science
      University of Louisville Louisville Kentucky USA.
FAU - Milyko, Kerri
AU  - Milyko K
AD  - CentralReach Pompano Beach New Jersey USA.
FAU - Fuller, Christine M
AU  - Fuller CM
AD  - Independent Scholar Reno Nevada USA.
FAU - Green, Gina
AU  - Green G
AUID- ORCID: https://orcid.org/0000-0002-1124-9130
AD  - Association of Professional Behavior Analysts San Diego California USA.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - England
TA  - Behav Interv
JT  - Behavioral interventions : theory & practice in residential & community-based
      clinical programs
JID - 9423529
PMC - PMC7361349
OTO - NOTNLM
OT  - COVID-19
OT  - applied behavior analysis
OT  - coronavirus
OT  - licensing
OT  - pandemic
OT  - regulation
COIS- Brighid Fronapfel, Kerri Milyko, Christine Fuller, and Erick Dubuque serve on
      behavior analyst licensing boards in Nevada and Kentucky. Gina Green is employed 
      by the Association of Professional Behavior Analysts. The views and opinions
      expressed in this article are those of the authors and do not represent the
      official policies or positions of their employers or those licensing boards.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1002/bin.1725 [doi]
AID - BIN1725 [pii]
PST - ppublish
SO  - Behav Interv. 2020 Jul;35(3):340-345. doi: 10.1002/bin.1725. Epub 2020 Jul 7.


PMID- 32837015
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 0968-6673 (Print)
IS  - 0968-6673 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Sep
TI  - COVID-19, ethics of care and feminist crisis management.
PG  - 872-883
LID - 10.1111/gwao.12491 [doi]
AB  - The COVID-19 pandemic threatens both lives and livelihoods. To reduce the spread 
      of the virus, governments have introduced crisis management interventions that
      include border closures, quarantines, strict social distancing, marshalling of
      essential workers and enforced homeworking. COVID-19 measures are necessary to
      save the lives of some of the most vulnerable people within society, and yet in
      parallel they create a range of negative everyday effects for already
      marginalized people. Likely unintended consequences of the management of the
      COVID-19 crisis include elevated risk for workers in low-paid, precarious and
      care-based employment, over-representation of minority ethnic groups in case
      numbers and fatalities, and gendered barriers to work. Drawing upon feminist
      ethics of care, I theorize a radical alternative to the normative assumptions of 
      rationalist crisis management. Rationalist approaches to crisis management are
      typified by utilitarian logics, masculine and militaristic language, and the
      belief that crises follow linear processes of signal detection,
      preparation/prevention, containment, recovery and learning. By privileging the
      quantifiable - resources and measurable outcomes - such approaches tend to omit
      considerations of pre-existing structural disadvantage. This article contributes 
      a new theorization of crisis management that is grounded in feminist ethics to
      provide a care-based concern for all crisis affected people.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Branicki, Layla J
AU  - Branicki LJ
AUID- ORCID: https://orcid.org/0000-0002-0952-9504
AD  - Macquarie Business School Macquarie University Australia.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - England
TA  - Gend Work Organ
JT  - Gender, work, and organization
JID - 101544781
PMC - PMC7323200
OTO - NOTNLM
OT  - COVID-19
OT  - crisis management
OT  - ethics of care
OT  - feminism
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1111/gwao.12491 [doi]
AID - GWAO12491 [pii]
PST - ppublish
SO  - Gend Work Organ. 2020 Sep;27(5):872-883. doi: 10.1111/gwao.12491. Epub 2020 Jul
      3.


PMID- 32836869
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220217
IS  - 0924-6495 (Print)
IS  - 0924-6495 (Linking)
VI  - 30
IP  - 2
DP  - 2020
TI  - The Ethical Governance of the Digital During and After the COVID-19 Pandemic.
PG  - 171-176
LID - 10.1007/s11023-020-09528-5 [doi]
FAU - Taddeo, Mariarosaria
AU  - Taddeo M
AD  - Oxford Internet Institute, University of Oxford, Oxford, UK.grid.4991.50000 0004 
      1936 8948
AD  - Alan Turing Institute, London, UK.grid.499548.d0000 0004 5903 3632
LA  - eng
PT  - Editorial
DEP - 20200612
PL  - Netherlands
TA  - Minds Mach (Dordr)
JT  - Minds and machines
JID - 101668779
PMC - PMC7289936
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s11023-020-09528-5 [doi]
AID - 9528 [pii]
PST - ppublish
SO  - Minds Mach (Dordr). 2020;30(2):171-176. doi: 10.1007/s11023-020-09528-5. Epub
      2020 Jun 12.


PMID- 32836868
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 0924-6460 (Print)
IS  - 0924-6460 (Linking)
VI  - 76
IP  - 4
DP  - 2020
TI  - Moral Suasion and the Private Provision of Public Goods: Evidence from the
      COVID-19 Pandemic.
PG  - 1117-1138
LID - 10.1007/s10640-020-00477-2 [doi]
AB  - We study how moral suasion that appeals to two major ethical theories,
      Consequentialism and Deontology, affects individual intentions to contribute to a
      public good. We use the COVID-19 pandemic as an exemplary case where there is a
      large gap between private and social costs and where moral suasion has been
      widely used as a policy instrument. Based on a survey experiment with a
      representative sample of around 3500 Germans at the beginning of the pandemic, we
      study how moral appeals affect contributions with low and high opportunity costs,
      hand washing and social distancing, to reduce the infection externality as well
      as the support for governmental regulation. We find that Deontological moral
      suasion, appealing to individual moral duty, is effective in increasing planned
      social distancing and hand-washing, while a Consequentialist appeal only
      increases planned hand-washing. Both appeals increase support for governmental
      regulation. Exploring heterogeneous treatment effects reveals that younger
      respondents are more susceptible to Deontological appeals. Our results highlight 
      the potential of moral appeals to induce intended private contributions to a
      public good or the reduction of externalities, which can help to overcome
      collective action problems for a range of environmental issues.
CI  - (c) The Author(s) 2020.
FAU - Bos, Bjorn
AU  - Bos B
AD  - Department of Economics, University of Hamburg, Von-Melle-Park 5, 20146 Hamburg, 
      Germany.grid.9026.d0000 0001 2287 2617
FAU - Drupp, Moritz A
AU  - Drupp MA
AUID- ORCID: 0000-0001-8981-0496
AD  - Department of Economics, University of Hamburg, Von-Melle-Park 5, 20146 Hamburg, 
      Germany.grid.9026.d0000 0001 2287 2617
AD  - CESifo, Poschingerstr. 5, 81679 Munich, Germany.grid.469877.30000 0004 0397 0846
FAU - Meya, Jasper N
AU  - Meya JN
AD  - Department of Economics, Leipzig University, Grimmaische Str. 12, 04109 Leipzig, 
      Germany.grid.9647.c0000 0004 7669 9786
AD  - German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig,
      Deutscher Platz 5e, 04103 Leipzig, Germany.grid.421064.50000 0004 7470 3956
FAU - Quaas, Martin F
AU  - Quaas MF
AD  - Department of Economics, Leipzig University, Grimmaische Str. 12, 04109 Leipzig, 
      Germany.grid.9647.c0000 0004 7669 9786
AD  - German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig,
      Deutscher Platz 5e, 04103 Leipzig, Germany.grid.421064.50000 0004 7470 3956
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - Netherlands
TA  - Environ Resour Econ (Dordr)
JT  - Environmental & resource economics
JID - 101620056
PMC - PMC7430132
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Moral appeal
OT  - Moral suasion
OT  - Public good contributions
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10640-020-00477-2 [doi]
AID - 477 [pii]
PST - ppublish
SO  - Environ Resour Econ (Dordr). 2020;76(4):1117-1138. doi:
      10.1007/s10640-020-00477-2. Epub 2020 Aug 17.


PMID- 32836867
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 0924-6460 (Print)
IS  - 0924-6460 (Linking)
VI  - 77
IP  - 2
DP  - 2020
TI  - Tax Exemptions of Ethical Products Revisited.
PG  - 423-447
LID - 10.1007/s10640-020-00502-4 [doi]
AB  - Corporate social responsibility (CSR) activities, being viewed as the corporate's
      provision of a public good, enable tax exemptions in many economies. We examine, 
      in a monopoly setup with heterogeneous consumers, with social image concerns,
      whether these tax exemptions are justified. When private and public investments
      are substitutes, tax exemptions ought to be accorded to CSR activities, and an ad
      valorem subsidy is welfare superior to a specific one, only when both consumers' 
      social consciousness and reputational concerns are sufficiently low and/or when
      the marginal cost on the private good market is sufficiently high. Otherwise, a
      positive ad valorem tax is welfare improving as it redistributes surplus from the
      firm to consumers while increasing total welfare in the process. However, when
      the firm's CSR investment complements the government's provision, tax exemptions 
      appear to be suboptimal relative to a positive tax. Specifically, the relative
      appeal of specific taxes, compared to ad valorem taxes, increases in consumers'
      reputational concerns and the value of the optimal tax decreases in their level
      of altruism.
CI  - (c) Springer Nature B.V. 2020.
FAU - Kassab, Dina
AU  - Kassab D
AUID- ORCID: 0000-0002-7424-2008
AD  - Faculty of Economics and Political Science, Cairo University, Giza,
      Egypt.grid.7776.10000 0004 0639 9286
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Netherlands
TA  - Environ Resour Econ (Dordr)
JT  - Environmental & resource economics
JID - 101620056
PMC - PMC7428202
OTO - NOTNLM
OT  - Ad valorem tax
OT  - Consumption norms
OT  - Corporate social responsibility
OT  - Progressive Tax
OT  - Reputation
OT  - Specific Tax
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10640-020-00502-4 [doi]
AID - 502 [pii]
PST - ppublish
SO  - Environ Resour Econ (Dordr). 2020;77(2):423-447. doi: 10.1007/s10640-020-00502-4.
      Epub 2020 Aug 14.


PMID- 32836866
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 0924-6460 (Print)
IS  - 0924-6460 (Linking)
VI  - 76
IP  - 4
DP  - 2020
TI  - If the Objective is Herd Immunity, on Whom Should it be Built?
PG  - 671-683
LID - 10.1007/s10640-020-00504-2 [doi]
AB  - Assuming that there is no other solution than herd immunity in front of the
      current pandemic, on which groups of citizens should we build this herd immunity?
      Given the fact that young people face a mortality rate which is at least a
      thousand times smaller than people aged 70 years and more, there is a simple
      rational to build it on these younger generations. The transfer of some mortality
      risk from the elderly to younger people raises difficult ethical issues. However,
      none of the familiar moral or operational guidelines (equality of rights, VSL,
      QALY, ...) that have been used in the Western world over the last century weights
      the value of young lives 1000 times or more than the lives of the elders. This
      suggests that Society could offer covid protection to the elders by recommending 
      them to remain confined as long as this herd immunity has not been attained by
      the younger generations. This would be a potent demonstration of
      intergenerational solidarity towards the most vulnerable people in our community.
      The welfare gain of this age-specific deconfinement strategy is huge, as it can
      reduce the global death toll by more than 80% as compared to a strategy of
      non-targeted herd immunity.
CI  - (c) Springer Nature B.V. 2020.
FAU - Gollier, Christian
AU  - Gollier C
AD  - Toulouse School of Economics, University of Toulouse-Capitole, Toulouse,
      France.grid.11417.320000 0001 2353 1689
LA  - eng
PT  - Journal Article
DEP - 20200811
PL  - Netherlands
TA  - Environ Resour Econ (Dordr)
JT  - Environmental & resource economics
JID - 101620056
PMC - PMC7417852
OTO - NOTNLM
OT  - Covid
OT  - Deconfinement
OT  - Herd immunity
OT  - Pandemics
OT  - QALY
OT  - VSL
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10640-020-00504-2 [doi]
AID - 504 [pii]
PST - ppublish
SO  - Environ Resour Econ (Dordr). 2020;76(4):671-683. doi: 10.1007/s10640-020-00504-2.
      Epub 2020 Aug 11.


PMID- 32836795
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 0921-2973 (Print)
IS  - 0921-2973 (Linking)
VI  - 35
IP  - 10
DP  - 2020
TI  - The ethics of isolation, the spread of pandemics, and landscape ecology.
PG  - 2133-2140
LID - 10.1007/s10980-020-01092-8 [doi]
FAU - Azevedo, Joao C
AU  - Azevedo JC
AUID- ORCID: 0000-0002-3061-8261
AD  - Centro de Investigacao de Montanha, Instituto Politecnico de Braganca, Campus de 
      Santa Apolonia, 5300-253 Braganca, Portugal.grid.34822.3f0000 0000 9851 275X
FAU - Luque, Sandra
AU  - Luque S
AD  - TETIS, Univ Montpellier, CNRS, INRAE, 34090 Montpellier, France.grid.121334.60000
      0001 2097 0141
FAU - Dobbs, Cynnamon
AU  - Dobbs C
AD  - Centro de Modelacion y Monitoreo de Ecosistemas, Escuela de Ingenieria Forestal, 
      Universidad Mayor, Jose Toribio Medina 29, Santiago, Chile.grid.412199.60000 0004
      0487 8785
FAU - Sanesi, Giovanni
AU  - Sanesi G
AD  - Department of Agro-Environmental and Territorial Sciences, University of Bari
      Aldo Moro, Via Amendola 165/A, 70126 Bari, Italy.grid.7644.10000 0001 0120 3326
FAU - Sunderland, Terry C H
AU  - Sunderland TCH
AD  - Faculty of Forestry, University of British Columbia, 2424 Main Mall, Vancouver,
      V6T 1Z4 Canada.grid.17091.3e0000 0001 2288 9830
LA  - eng
PT  - Editorial
DEP - 20200811
PL  - Netherlands
TA  - Landsc Ecol
JT  - Landscape ecology
JID - 101534628
PMC - PMC7418287
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/29 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10980-020-01092-8 [doi]
AID - 1092 [pii]
PST - ppublish
SO  - Landsc Ecol. 2020;35(10):2133-2140. doi: 10.1007/s10980-020-01092-8. Epub 2020
      Aug 11.


PMID- 32836765
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220628
IS  - 0889-048X (Print)
IS  - 0889-048X (Linking)
VI  - 37
IP  - 4
DP  - 2020
TI  - 'Workable utopias' for social change through inclusion and empowerment? Community
      supported agriculture (CSA) in Wales as social innovation.
PG  - 1241-1260
LID - 10.1007/s10460-020-10141-6 [doi]
AB  - The focus of this article is community supported agriculture (CSA) as an
      alternative food movement and a bottom-up response to the problems of the
      dominant food systems. By utilizing social innovation approach that explores the 
      relationship between causes for human needs and emergence of socially innovative 
      food initiatives, the article examines how the CSA projects emerge and why, what 
      is their innovative role as part of the social economy and what is their
      transformative potential. Based on qualitative data from four different models of
      CSA case studies in different regions of Wales, UK, and by using concepts from an
      alternative model for social innovation (ALMOLIN) as analytical tool, the article
      demonstrates that the Welsh CSA cases play distinctive roles as part of the
      social economy. They satisfy the needs for ecologically sound and ethically
      produced food, grown within communities of like-minded people and they empower
      individuals and communities at micro level, while at the same time experiment
      with how to be economically sustainable and resilient on a small scale. The paper
      argues that in order to become 'workable utopias', the CSA initiatives need to
      overcome the barriers that prevent them from replicating, participating in
      policies and decision-making at macro level, and scaling up.
CI  - (c) The Author(s) 2021.
FAU - Mert-Cakal, Tezcan
AU  - Mert-Cakal T
AUID- ORCID: 0000-0002-5129-2643
AD  - Cardiff University Alumna, School of Geography and Planning, Glamorgan Building, 
      King Edward VII Avenue, Cardiff, CF10 3WA Wales UK.grid.5600.30000 0001 0807 5670
FAU - Miele, Mara
AU  - Miele M
AD  - School of Geography and Planning, Cardiff University, Glamorgan Building, King
      Edward VII Avenue, Cardiff, CF10 3WA Wales UK.grid.5600.30000 0001 0807 5670
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - United States
TA  - Agric Human Values
JT  - Agriculture and human values
JID - 100973331
PMC - PMC7433275
OTO - NOTNLM
OT  - Alternative food
OT  - CSA
OT  - Community supported agriculture
OT  - Food sustainability
OT  - Grassroots initiatives
OT  - Social innovation
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10460-020-10141-6 [doi]
AID - 10141 [pii]
PST - ppublish
SO  - Agric Human Values. 2020;37(4):1241-1260. doi: 10.1007/s10460-020-10141-6. Epub
      2020 Aug 18.


PMID- 32836724
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 0738-0151 (Print)
IS  - 0738-0151 (Linking)
VI  - 37
IP  - 5
DP  - 2020
TI  - Black Lives Matter, and Yes, You are Racist: The Parallelism of the Twentieth and
      Twenty-First Centuries.
PG  - 463-475
LID - 10.1007/s10560-020-00690-4 [doi]
AB  - The United States of America is at a crossroads, one that we have been at before.
      This is not the first time that we have battled a pandemic while experiencing an 
      economic downturn, state sanctioned violence and racial terror against Blacks,
      the boiling over of racial tensions encouraged by the president of the United
      States, and a movement focused on forcing America to reckon with its endemic
      racism, anti-Blackness, and state-sanctioned violence against Blacks. This
      article provides a brief overview of that history and its striking parallel to
      what is happening today. It pushes White social workers to understand how they
      are beneficiaries of racism. It reminds social workers of their ethical
      obligation to be change agents. Finally, it provides basic suggestions for those 
      who are willing to see their complicity and are still willing to work on
      dismantling the injustice that impacts Black people in America.
CI  - (c) Springer Science+Business Media, LLC, part of Springer Nature 2020.
FAU - McCoy, Henrika
AU  - McCoy H
AUID- ORCID: 0000-0003-0937-8352
AD  - Jane Addams College of Social Work, University of Illinois at Chicago, 1040 W.
      Harrison (M/C 309), Chicago, IL 60607 USA.grid.185648.60000 0001 2175 0319
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - United States
TA  - Child Adolesc Social Work J
JT  - Child & adolescent social work journal : C & A
JID - 8501014
PMC - PMC7429367
OTO - NOTNLM
OT  - Anti-Black
OT  - Black Lives Matter
OT  - Pandemic
OT  - Privilege
OT  - Racism
OT  - State-sanctioned violence
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10560-020-00690-4 [doi]
AID - 690 [pii]
PST - ppublish
SO  - Child Adolesc Social Work J. 2020;37(5):463-475. doi: 10.1007/s10560-020-00690-4.
      Epub 2020 Aug 17.


PMID- 32836582
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 0167-4544 (Print)
IS  - 0167-4544 (Linking)
VI  - 166
IP  - 1
DP  - 2020
TI  - Some Musings About the Future of Business Ethics Scholarship.
PG  - 1-2
LID - 10.1007/s10551-020-04585-3 [doi]
FAU - Werhane, Patricia H
AU  - Werhane PH
AD  - Professor Emerita, University of Virginia, Charlottesville, VA
      USA.grid.27755.320000 0000 9136 933X
AD  - Professor Emerita, DePaul University, Chicago, IL USA.grid.254920.80000 0001 0707
      2013
AD  - Gies College of Business, University of Illinois, Champaign, IL
      USA.grid.35403.310000 0004 1936 9991
LA  - eng
PT  - Editorial
DEP - 20200729
PL  - Netherlands
TA  - J Bus Ethics
JT  - Journal of business ethics : JBE
JID - 100972154
PMC - PMC7387878
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10551-020-04585-3 [doi]
AID - 4585 [pii]
PST - ppublish
SO  - J Bus Ethics. 2020;166(1):1-2. doi: 10.1007/s10551-020-04585-3. Epub 2020 Jul 29.


PMID- 32836570
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201110
IS  - 0160-791X (Print)
IS  - 0160-791X (Linking)
VI  - 63
DP  - 2020 Nov
TI  - Distance education as a response to pandemics: Coronavirus and Arab culture.
PG  - 101317
LID - 10.1016/j.techsoc.2020.101317 [doi]
AB  - Some countries have replaced face-to-face education with distance education in
      response to the coronavirus. This form of distance education differs from
      conventional distance education: being suddenly, unreadily and forcefully
      implemented, invading schooling and constituting a globally discussed phenomenon.
      This article builds a conceptual framework for this education, addressing the
      question: What are the ramifications of implementing distance education amid
      coronavirus? It targets Arab culture, although globalisation and the media may
      have harmonised any substantial cross-cultural variations. Various ramifications 
      have emerged through analysing social-media posts, online classes and interviews.
      Concerning social and cultural ramifications, some may, for ideological
      considerations, tolerate, support, reject or subvert this education through
      campaigning, rumour and humour. Regarding pedagogical and psychological
      ramifications, unreadiness and incompetence may compromise education.
      Additionally, staying home may entail problems (pandemic-related stress, anxiety,
      depression, domestic violence, divorce and pregnancy), preventing students and
      teachers from learning and teaching. Concerning procedural and logistical
      ramifications, some Arab contexts may be digitally readier than non-Arab
      contexts. Additionally, stakeholders may intensify efforts to profit, ethically
      or unethically, from the over-demand for this education. Distance education is
      one of several social distancing initiatives, which Arabs have welcomed despite
      their well-rooted social closeness, bonding to debond, forming unorthodox
      'distanceship'.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Al Lily, Abdulrahman Essa
AU  - Al Lily AE
AD  - King Faisal University, Al Ahsa, Saudi Arabia.
FAU - Ismail, Abdelrahim Fathy
AU  - Ismail AF
AD  - King Faisal University, Al Ahsa, Saudi Arabia.
FAU - Abunasser, Fathi Mohammed
AU  - Abunasser FM
AD  - King Faisal University, Al Ahsa, Saudi Arabia.
FAU - Alhajhoj Alqahtani, Rafdan Hassan
AU  - Alhajhoj Alqahtani RH
AD  - King Faisal University, Al Ahsa, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - United States
TA  - Technol Soc
JT  - Technology in society
JID - 100972148
PMC - PMC7387275
OTO - NOTNLM
OT  - Crisis
OT  - Disaster
OT  - Distance learning
OT  - Emergency
OT  - Social distancing
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.techsoc.2020.101317 [doi]
AID - S0160-791X(20)30300-6 [pii]
AID - 101317 [pii]
PST - ppublish
SO  - Technol Soc. 2020 Nov;63:101317. doi: 10.1016/j.techsoc.2020.101317. Epub 2020
      Jul 29.


PMID- 32836569
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1873-7722 (Electronic)
IS  - 0160-7383 (Linking)
VI  - 84
DP  - 2020 Sep
TI  - Re-thinking sustainability and food in tourism.
PG  - 103005
LID - 10.1016/j.annals.2020.103005 [doi]
AB  - *The sustainability of food tourism is limited and new ways of thinking are
      needed.*Considerations about food tourism in relation to animal ethics and
      sustainability are interconnected.*An extensive use of animal-derived food in
      tourism is in conflict with SDG3 and SDG13.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Bertella, Giovanna
AU  - Bertella G
AD  - UiT-The Arctic University of Norway, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - England
TA  - Ann Tour Res
JT  - Annals of tourism research
JID - 101765681
PMC - PMC7375275
OTO - NOTNLM
OT  - Animal ethics
OT  - Ecofeminism
OT  - Food tourism
OT  - SDGs
OT  - Sustainability
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/09 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.annals.2020.103005 [doi]
AID - S0160-7383(20)30149-3 [pii]
AID - 103005 [pii]
PST - ppublish
SO  - Ann Tour Res. 2020 Sep;84:103005. doi: 10.1016/j.annals.2020.103005. Epub 2020
      Jul 22.


PMID- 32836546
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220630
IS  - 0144-932X (Print)
IS  - 0144-932X (Linking)
VI  - 41
IP  - 2
DP  - 2020
TI  - Reflecting on 25 Years of Teaching Animal Law: Is it Time for an International
      Crime of Animal Ecocide?
PG  - 201-218
LID - 10.1007/s10991-020-09253-0 [doi]
AB  - 2019 marked the 25th anniversary of the introduction of Animal Law to the law
      degree at Liverpool John Moores University. This article examines changes in the 
      legal protection of animals during this time and the impact this will have on
      research and scholarship in the law relating to animals. We examine whether the
      overall international treatment of animals has improved and how far the approach 
      to the Animal Law curriculum should be influenced by the growth in concerns
      around climate change. In this context, we examine the development of the law of 
      ecocide and the extent to which it addresses concerns around animal welfare
      across the globe. We suggest that those involved in the development of Animal
      Law, ethics and policy might usefully engage in a new vision of ecocide, which
      incorporates a clearer notion of 'animal ecocide'. This new approach would
      enhance the international and national focus on animals in their own right, would
      recognise increasing knowledge of animal sentience and would move our
      responsibilities to them beyond anthropocentric approaches to environmental
      protection. We argue that the inclusion of a more specific reference to animal
      ecocide would contribute to the development of Animal Law and would lead to an
      enhanced relationship between Animal Law and attempts to protect the environment.
CI  - (c) The Author(s) 2020.
FAU - Legge, Debbie
AU  - Legge D
AD  - The Open University, Milton Keynes, UK.grid.10837.3d0000000096069301
FAU - Brooman, Simon
AU  - Brooman S
AD  - Liverpool John Moores University, Liverpool, UK.grid.4425.70000 0004 0368 0654
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - Liverp Law Rev
JT  - The Liverpool law review
JID - 100973095
PMC - PMC7351535
OTO - NOTNLM
OT  - Animal ecocide
OT  - Animal law
OT  - Animal welfare
OT  - Ecocide
OT  - Sentience
COIS- Conflict of interestOn behalf of all authors, the corresponding author states
      that there is no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10991-020-09253-0 [doi]
AID - 9253 [pii]
PST - ppublish
SO  - Liverp Law Rev. 2020;41(2):201-218. doi: 10.1007/s10991-020-09253-0. Epub 2020
      Jul 10.


PMID- 32836545
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 0144-932X (Print)
IS  - 0144-932X (Linking)
VI  - 41
IP  - 3
DP  - 2020
TI  - End-of-Life Decisions in Albania: The Call for an Ethical Revision.
PG  - 315-330
LID - 10.1007/s10991-020-09251-2 [doi]
AB  - While in Western European countries, the end-of-life decisions have become a
      matter of public policy, this paper provides a detailed analysis of end-of-life
      decisions in Albania by focusing on instructional medical directives. The
      manuscript investigates the Albanian legal system, the documents published by the
      National Ethics Committee and the National Committee of Health, as the two main
      advisory public bodies on health issues, as well as the national medical
      jurisprudence and the Code of Medical Ethics. After emphasizing the importance of
      instructional medical directives and considering the international literature
      that has underlined the ethical principle of patient autonomy, this paper
      provides some policy suggestions. In the conclusion, this contribution highlights
      the importance of ad hoc rules governing instructional medical directives as well
      as the ethical principles and international literature as an instrument to fill
      the gap in the national system. In addition, particular attention is given to the
      application of ethical principles in end-of-life decisions in the current
      pandemic situation.
CI  - (c) Springer Nature B.V. 2020.
FAU - Veshi, Denard
AU  - Veshi D
AUID- ORCID: 0000-0003-4537-5917
AD  - University of New York Tirana, "Kodra e Diellit", Tirana,
      Albania.grid.444973.90000 0004 0397 2833
FAU - Pupe, Ervin
AU  - Pupe E
AD  - High Court of Albania, Rruga Deshmoret e 4 Shkurtit, Tirana, Albania.
FAU - Venditti, Carlo
AU  - Venditti C
AD  - University of Campania Luigi Vanvitelli, Via Mazzocchi, 68 - Palazzo Melzi, 81055
      Santa Maria Capua Vetere, Caserta Italy.grid.9841.40000 0001 2200 8888
FAU - Kalemaj, Ilir
AU  - Kalemaj I
AD  - University of New York Tirana, "Kodra e Diellit", Tirana,
      Albania.grid.444973.90000 0004 0397 2833
FAU - Koka, Enkelejda
AU  - Koka E
AD  - University of New York Tirana, "Kodra e Diellit", Tirana,
      Albania.grid.444973.90000 0004 0397 2833
FAU - Biring-Pani, Michele
AU  - Biring-Pani M
AD  - University of New York Tirana, "Kodra e Diellit", Tirana,
      Albania.grid.444973.90000 0004 0397 2833
FAU - Ruci, Hektor
AU  - Ruci H
AD  - University of New York Tirana, "Kodra e Diellit", Tirana,
      Albania.grid.444973.90000 0004 0397 2833
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - Liverp Law Rev
JT  - The Liverpool law review
JID - 100973095
PMC - PMC7312106
OTO - NOTNLM
OT  - Albania
OT  - Code of medical ethics
OT  - End-of-life decisions
OT  - Instructional medical directives
OT  - Patient autonomy
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s10991-020-09251-2 [doi]
AID - 9251 [pii]
PST - ppublish
SO  - Liverp Law Rev. 2020;41(3):315-330. doi: 10.1007/s10991-020-09251-2. Epub 2020
      Jun 24.


PMID- 32836451
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220727
IS  - 0033-3352 (Print)
IS  - 0033-3352 (Linking)
VI  - 80
IP  - 4
DP  - 2020 Jul-Aug
TI  - Unprecedented Challenges, Familiar Paradoxes: COVID-19 and Governance in a New
      Normal State of Risks.
PG  - 657-664
LID - 10.1111/puar.13248 [doi]
AB  - This Viewpoint essay understands China's COVID-19 responses through the lens of
      six paradoxes, focusing on normal and non-normal governance, competing values,
      expertise and politics, centralization and decentralization, public and private, 
      and technology and institutions. Preliminary lessons are drawn regarding pandemic
      governance: embedding resilience into all aspects of governance; developing a
      public value framework for pandemic governance and improving individuals' ethical
      capacity; institutionalizing policy capacity on pandemic governance and requiring
      expertise in relevant positions; balancing centralized coordination and
      decentralized responses with a stable and ready-to-work commanding center;
      enabling businesses and nonprofits for pandemic governance but regulating them
      appropriately; and enacting technologies to revolutionize pandemic governance
      with proper institutional safeguards.
CI  - (c) 2020 by The American Society for Public Administration.
FAU - Yang, Kaifeng
AU  - Yang K
AD  - Renmin University of China.
AD  - Florida State University.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - United States
TA  - Public Adm Rev
JT  - Public administration review
JID - 0045715
PMC - PMC7283883
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/05/23 00:00 [revised]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1111/puar.13248 [doi]
AID - PUAR13248 [pii]
PST - ppublish
SO  - Public Adm Rev. 2020 Jul-Aug;80(4):657-664. doi: 10.1111/puar.13248. Epub 2020
      Jun 29.


PMID- 32836418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 0033-1538 (Print)
IS  - 0033-1538 (Linking)
VI  - 49
IP  - 1-2
DP  - 2020
TI  - Pandemics, leadership, and social ethics.
PG  - 73-76
LID - 10.1007/s11125-020-09472-3 [doi]
AB  - This Viewpoint argues that the absence of worldwide social ethics is at the root 
      of our present social, political, and economic crises. More to the point, the
      current COVID-19 pandemic is, in part, a consequence of insufficient scientific
      research, inappropriate education systems, and globally fragile health structures
      and human services.
CI  - (c) UNESCO IBE 2020.
FAU - Escotet, Miguel Angel
AU  - Escotet MA
AD  - Intercontinental Higher Education Institute of Business (IESIDE), Av. de Madrid, 
      60, 36204 Vigo, PO Spain.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - France
TA  - Prospects (Paris)
JT  - Prospects
JID - 101656637
PMC - PMC7265166
OTO - NOTNLM
OT  - Crisis
OT  - Education
OT  - Leadership
OT  - Pandemic
OT  - Social ethics
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s11125-020-09472-3 [doi]
AID - 9472 [pii]
PST - ppublish
SO  - Prospects (Paris). 2020;49(1-2):73-76. doi: 10.1007/s11125-020-09472-3. Epub 2020
      Jun 2.


PMID- 32836233
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201216
IS  - 0001-4079 (Print)
IS  - 0001-4079 (Linking)
VI  - 204
IP  - 9
DP  - 2020 Dec
TI  - COVID-19, epidemiological tracing and medical ethics.
PG  - e66-e67
LID - 10.1016/j.banm.2020.05.066 [doi]
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - Netherlands
TA  - Bull Acad Natl Med
JT  - Bulletin de l'Academie nationale de medecine
JID - 7503383
PMC - PMC7241980
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1016/j.banm.2020.05.066 [doi]
AID - S0001-4079(20)30303-4 [pii]
PST - ppublish
SO  - Bull Acad Natl Med. 2020 Dec;204(9):e66-e67. doi: 10.1016/j.banm.2020.05.066.
      Epub 2020 May 21.


PMID- 32836099
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 1873-4499 (Electronic)
IS  - 0899-7071 (Linking)
VI  - 67
DP  - 2020 Nov
TI  - The highly visible radiologist: Ethics of social media use in radiology.
PG  - 189-190
LID - S0899-7071(20)30304-1 [pii]
LID - 10.1016/j.clinimag.2020.08.002 [doi]
FAU - Schloss, Robert William Jr
AU  - Schloss RW Jr
AD  - Joan & Sanford I. Weill Medical College of Cornell University, 525 East 68th
      Street, New York, NY 10065, United States of America. Electronic address:
      ros9038@med.cornell.edu.
LA  - eng
PT  - Editorial
DEP - 20200814
PL  - United States
TA  - Clin Imaging
JT  - Clinical imaging
JID - 8911831
SB  - IM
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - S0899-7071(20)30304-1 [pii]
AID - 10.1016/j.clinimag.2020.08.002 [doi]
PST - ppublish
SO  - Clin Imaging. 2020 Nov;67:189-190. doi: 10.1016/j.clinimag.2020.08.002. Epub 2020
      Aug 14.


PMID- 32835394
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200827
IS  - 0189-160X (Print)
IS  - 0189-160X (Linking)
VI  - 37
IP  - 4
DP  - 2020 Sep
TI  - Doctors' Knowledge, Comprehension, Attitude to and Application of Ethical
      Principles in Child Healthcare in a Nigerian Teaching Hospital.
PG  - 342-348
AB  - BACKGROUND AND OBJECTIVES: Due to the prevailing socio-cultural and religious
      affiliations, Paediatricians in sub-Saharan Africa face unique ethical dilemmas. 
      An understanding and application of the ethical principles can help prevent and
      resolve these dilemmas, and improve child health indices. The objective is to
      determine the knowledge, attitude and practical applications of non-maleficence
      and beneficence by child-care doctors at a Teaching Hospital. METHODS: This is a 
      questionnaire-based study. Socio-demographics, knowledge and attitude towards the
      ethical principles, and its utilisation by doctors in childcare was sought. Data 
      were analyzed using descriptive statistics. RESULTS: 294 doctors participated.
      The mean percentage knowledge score of nonmaleficence and beneficence was
      31.00+/-21.14, significantly higher among doctors in Paediatrics (39.35+/-23.44, 
      p=0.0001). For every decrease in professional rank, knowledge score decreased by 
      3.8224 (95% CI -5.824 - -1.819; p=0.0001). The doctors had a high mean percentage
      score on attitude towards ethics of 74.79+/-16.34, and for every increase in
      years of practice, attitude towards ethics score would increase by 2.922 (95% CI 
      1.133 to 4.711, p=0.001). There was a low practice score of 34.27+/-20.07.
      Majority (69%) encountered less than one dilemma a month. More than 90% of
      doctors had encountered dilemmas involving the principle of non-maleficence [184 
      (90.6%)], while 154 (75.9%) involved beneficence. CONCLUSION: Most respondents
      have a low level of knowledge and practice of the principles of nonmaleficence
      and beneficence. Their excellent attitude implies their willingness at improving 
      their knowledge and practice.
FAU - West, T P
AU  - West TP
AD  - Department of Paediatrics, Niger Delta University Teaching Hospital, Okolobiri,
      Bayelsa State, Nigeria.
FAU - Tabansi, P N
AU  - Tabansi PN
AD  - University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State,
      Nigeria.
FAU - Yarhere, I
AU  - Yarhere I
AD  - University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State,
      Nigeria.
FAU - Nkanginieme, K E
AU  - Nkanginieme KE
AD  - University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State,
      Nigeria.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - West Afr J Med
JT  - West African journal of medicine
JID - 8301891
SB  - IM
MH  - Attitude of Health Personnel
MH  - Child
MH  - *Comprehension
MH  - *Hospitals, Teaching
MH  - Humans
MH  - Nigeria
MH  - Physicians
EDAT- 2020/08/25 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PST - ppublish
SO  - West Afr J Med. 2020 Sep;37(4):342-348.


PMID- 32835311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2666-3899 (Electronic)
IS  - 2666-3899 (Linking)
VI  - 1
IP  - 4
DP  - 2020 Jul 10
TI  - Do We Need a Coronavirus (Safeguards) Act 2020? Proposed Legal Safeguards for
      Digital Contact Tracing and Other Apps in the COVID-19 Crisis.
PG  - 100072
LID - 10.1016/j.patter.2020.100072 [doi]
AB  - The focus of this Preview is "The Coronavirus (Safeguards) Bill 2020: Proposed
      protections for digital interventions and in relation to immunity certificates," 
      published by Lilian Edwards, professor of law, innovation and society at
      Newcastle Law School and a member of the NHSX Ethical Advisory Board (CV19 App).
CI  - (c) 2020 The Author.
FAU - Darbyshire, Tessa
AU  - Darbyshire T
AD  - Cell Press, 50 Hampshire St, Cambridge, MA, USA.
LA  - eng
PT  - News
PL  - United States
TA  - Patterns (N Y)
JT  - Patterns (New York, N.Y.)
JID - 101767765
PMC - PMC7351072
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.patter.2020.100072 [doi]
AID - S2666-3899(20)30092-1 [pii]
AID - 100072 [pii]
PST - ppublish
SO  - Patterns (N Y). 2020 Jul 10;1(4):100072. doi: 10.1016/j.patter.2020.100072.


PMID- 32835200
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210202
IS  - 2589-7500 (Electronic)
IS  - 2589-7500 (Linking)
VI  - 2
IP  - 8
DP  - 2020 Aug
TI  - Digital tools against COVID-19: taxonomy, ethical challenges, and navigation aid.
PG  - e425-e434
LID - S2589-7500(20)30137-0 [pii]
LID - 10.1016/S2589-7500(20)30137-0 [doi]
AB  - Data collection and processing via digital public health technologies are being
      promoted worldwide by governments and private companies as strategic remedies for
      mitigating the COVID-19 pandemic and loosening lockdown measures. However, the
      ethical and legal boundaries of deploying digital tools for disease surveillance 
      and control purposes are unclear, and a rapidly evolving debate has emerged
      globally around the promises and risks of mobilising digital tools for public
      health. To help scientists and policy makers to navigate technological and
      ethical uncertainty, we present a typology of the primary digital public health
      applications that are in use. These include proximity and contact tracing,
      symptom monitoring, quarantine control, and flow modelling. For each, we discuss 
      context-specific risks, cross-sectional issues, and ethical concerns. Finally,
      recognising the need for practical guidance, we propose a navigation aid for
      policy makers and other decision makers for the ethical development and use of
      digital public health tools.
CI  - (c) 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article
      under the CC BY 4.0 license.
FAU - Gasser, Urs
AU  - Gasser U
AD  - Berkman Klein Center for Internet & Society, Harvard Law School, Harvard
      University, Cambridge, MA, USA.
FAU - Ienca, Marcello
AU  - Ienca M
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland.
FAU - Scheibner, James
AU  - Scheibner J
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland.
FAU - Sleigh, Joanna
AU  - Sleigh J
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland.
FAU - Vayena, Effy
AU  - Vayena E
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland.
      Electronic address: effy.vayena@hest.ethz.ch.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - Lancet Digit Health
JT  - The Lancet. Digital health
JID - 101751302
MH  - *COVID-19
MH  - Contact Tracing/*ethics
MH  - Cross-Sectional Studies
MH  - *Digital Technology
MH  - Humans
MH  - Pandemics
MH  - *Population Surveillance
MH  - SARS-CoV-2
PMC - PMC7324107
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/S2589-7500(20)30137-0 [doi]
AID - S2589-7500(20)30137-0 [pii]
PST - ppublish
SO  - Lancet Digit Health. 2020 Aug;2(8):e425-e434. doi: 10.1016/S2589-7500(20)30137-0.
      Epub 2020 Jun 29.


PMID- 32835148
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 23
DP  - 2020
TI  - CRC COVID: Colorectal cancer services during COVID-19 pandemic. Study protocol
      for service evaluation.
PG  - 15-19
LID - 10.1016/j.isjp.2020.07.005 [doi]
AB  - INTRODUCTION: COVID-19 has had an impact on the provision of colorectal cancer
      care. The aim of the CRC COVID study is to describe the changes in colorectal
      cancer services in the UK and USA in response to the pandemic and to understand
      the long-term impact. METHODS AND ANALYSIS: This study comprises 4 phases. Phase 
      1 is a survey of colorectal units that aims to evaluate adherences and deviations
      from the best practice guidelines during the COVID-19 pandemic. Phase 2 is a
      monthly prospective data collection of service provision that aims to determine
      the impact of the service modifications on the long-term cancer specific outcomes
      compared to the national standards. Phase 3 aims to predict costs attributable to
      the modifications of the CRC services and additional resources required to treat 
      patients whose treatment has been affected by the pandemic. Phase 4 aims to
      compare the impact of COVID-19 on the NHS and USA model of healthcare in terms of
      service provision and cost, and to propose a standardised model of delivering
      colorectal cancer services for future outbreaks. ETHICS AND DISSEMINATION: This
      study is a service evaluation and does not require HRA Approval or Ethical
      Approval in the UK. Local service evaluation registration is required for each
      participating centre. In the USA, Ethical Approval was granted by the Research
      and Development Committee. The results of this study will be disseminated to
      stakeholders, submitted for peer review publications, conference presentations
      and circulated via social media. REGISTRATION DETAILS: Nil.
CI  - (c) 2020 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates 
      Ltd.
FAU - Courtney, Alona
AU  - Courtney A
AD  - Imperial College London, Department of Surgery and Cancer, Chelsea & Westminster 
      Campus, 369 Fulham Rd, Chelsea, London SW10 9NH, United Kingdom.
AD  - Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London SW10 9NH, United
      Kingdom.
FAU - Howell, Ann-Marie
AU  - Howell AM
AD  - Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London SW10 9NH, United
      Kingdom.
FAU - Daulatzai, Najib
AU  - Daulatzai N
AD  - Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London SW10 9NH, United
      Kingdom.
FAU - Savva, Nicos
AU  - Savva N
AD  - London Business School, Regent's Park, London NW1 4SA, United Kingdom.
FAU - Warren, Oliver
AU  - Warren O
AD  - Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London SW10 9NH, United
      Kingdom.
FAU - Mills, Sarah
AU  - Mills S
AD  - Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London SW10 9NH, United
      Kingdom.
FAU - Rasheed, Shahnawaz
AU  - Rasheed S
AD  - Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, United Kingdom.
FAU - Milind, Goel
AU  - Milind G
AD  - London Business School, Regent's Park, London NW1 4SA, United Kingdom.
FAU - Tekkis, Nicholas
AU  - Tekkis N
AD  - University of Cambridge School of Clinical Medicine, Hills Road, Cambridge CB2
      0SP, United Kingdom.
FAU - Gardiner, Matthew
AU  - Gardiner M
AD  - Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive,
      Headington, Oxford OX3 7FY, United Kingdom.
FAU - Dai, Tinglong
AU  - Dai T
AD  - Johns Hopkins University Carey Business School, The Charm'tastic Mile, 100
      International Drive, Baltimore, MD 21202, United States.
FAU - Safar, Bashar
AU  - Safar B
AD  - Johns Hopkins Hospital, 1800 Orleans St, Baltimore, MD 21287, United States.
FAU - Efron, Jonathan E
AU  - Efron JE
AD  - Johns Hopkins Hospital, 1800 Orleans St, Baltimore, MD 21287, United States.
FAU - Darzi, Ara
AU  - Darzi A
AD  - Imperial College London, Department of Surgery and Cancer, Queen Elizabeth the
      Queen Mother Wing (QEQM), St Mary's Campus, Praed St, Paddington, London W2 1NY, 
      United Kingdom.
FAU - Tekkis, Paris
AU  - Tekkis P
AD  - Imperial College London, Department of Surgery and Cancer, Chelsea & Westminster 
      Campus, 369 Fulham Rd, Chelsea, London SW10 9NH, United Kingdom.
AD  - Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, United Kingdom.
FAU - Kontovounisios, Christos
AU  - Kontovounisios C
AD  - Imperial College London, Department of Surgery and Cancer, Chelsea & Westminster 
      Campus, 369 Fulham Rd, Chelsea, London SW10 9NH, United Kingdom.
AD  - Chelsea & Westminster Hospital, 369 Fulham Rd, Chelsea, London SW10 9NH, United
      Kingdom.
AD  - Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200811
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7417919
OTO - NOTNLM
OT  - COVID-19
OT  - Colorectal cancer
OT  - Guidelines
OT  - Service evaluation
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/09 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.isjp.2020.07.005 [doi]
AID - S2468-3574(20)30026-7 [pii]
PST - ppublish
SO  - Int J Surg Protoc. 2020;23:15-19. doi: 10.1016/j.isjp.2020.07.005. Epub 2020 Aug 
      11.


PMID- 32835087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2364-6861 (Electronic)
VI  - 5
IP  - 1
DP  - 2020
TI  - Diets, Diseases, and Discourse: Lessons from COVID-19 for Trade in Wildlife,
      Public Health, and Food Systems Reform.
PG  - 17
LID - 10.1007/s41055-020-00075-4 [doi]
AB  - The COVID-19 pandemic has brought to light significant failures and fragilities
      in our food, health, and market systems. Concomitantly, it has emphasized the
      urgent need for a critical re-evaluation of many of the policies and practices
      that have created the conditions in which viral pathogens can spread. However,
      there are many factors that are complicating this process; among others, the
      uncertain, rapidly evolving, and often poorly reported science surrounding the
      virus' origins has contributed to a politically charged and often rancorous
      public debate, which is concerning insofar as the proliferation of divisive
      discourse may hinder efforts to address complex and collective concerns in a
      mutually cooperative manner. In developing ethical and effective responses to the
      disproportionate risks associated with certain food production and consumption
      practices, we argue that the focus should be on mitigating such risks wherever
      they arise, instead of seeking to ascribe blame to specific countries or
      cultures. To this end, this article is an effort to inject some nuance into
      contemporary conversations about COVID-19 and its broader implications,
      particularly when it comes to trade in wildlife, public health, and food systems 
      reform. If COVID-19 is to represent a turning point towards building a more
      equitable, sustainable, and resilient world for both humans and nonhuman animals 
      alike, the kind of fractioning that is currently being exacerbated by the use of 
      loaded terms such as "wet market" must be eschewed in favour of a greater
      recognition of our fundamental interconnectedness.
CI  - (c) Springer Nature Switzerland AG 2020.
FAU - Lee, Angela
AU  - Lee A
AUID- ORCID: 0000-0002-5945-1725
AD  - Faculty of Law, Ryerson University, Toronto, ON Canada.grid.68312.3e0000 0004
      1936 9422
FAU - Houston, Adam R
AU  - Houston AR
AD  - Faculty of Law, University of Ottawa, Ottawa, ON Canada.grid.28046.380000 0001
      2182 2255
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - Switzerland
TA  - Food Ethics
JT  - Food ethics
JID - 101718388
PMC - PMC7385071
OTO - NOTNLM
OT  - COVID-19
OT  - Discourse
OT  - Food systems
OT  - Pandemic
OT  - Public health
OT  - Wet market
OT  - Wildlife trade
OT  - Zoonotic disease
COIS- Conflict of InterestOn behalf of all authors, the corresponding author states
      that there is no conflict of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1007/s41055-020-00075-4 [doi]
AID - 75 [pii]
PST - ppublish
SO  - Food Ethics. 2020;5(1):17. doi: 10.1007/s41055-020-00075-4. Epub 2020 Jul 28.


PMID- 32835062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - Ethical issues related to the hydroxychloroquine treatment prescription for
      Covid-19.
PG  - 100547
LID - 10.1016/j.jemep.2020.100547 [doi]
AB  - The 2019-20 coronavirus pandemic (COVID-19) has led to severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2). To date, no drugs have demonstrated safety
      and efficacy in randomized controlled trials for patients with COVID-19. Although
      the association between Hydroxychloroquine and Azithromycin efficacy lack of
      solid evidence-base, several governments have adopted it for all virology
      confirmed Covid-19 cases even for those who are asymptomatic. In the following,
      we aim to discuss some of the ethical issues associated with the use of this
      treatment association. We mainly tried to discuss the following controversial
      questions: Is it ethical not to treat a patient while a treatment exists and is
      used for other indications than Covid-19 for which it's not proven yet? If yes,
      is a randomized controlled trial to prove the hydroxychloroquine for the Covid-19
      treatment, necessary, in the context of covid-19 pandemic? If no, is it the
      government's right to decide the hydroxychloroquine treatment for all covid-19
      patients? And what should be the physicians' attitudes? Finally, what are the
      government, physicians, and patient's rights and responsibilities? The paper
      conclude that, since health authorities in some countries recommended this
      off-label use treatment, physicians are challenged by the requirement of veracity
      while providing care to their patients and the implications of such a
      requirement; they are facing the challenge of balancing this guideline and their 
      own conviction. Furthermore, the fundamental principles of beneficence and
      non-maleficence, and respect for persons should underlie any reflection process
      to address this dilemma. In addition, in a pandemic context, the limits between
      the government's, practitioner's and patient's rights and obligations are not
      clear which could significantly endanger the universal ethical principles in
      clinical practice. It could also undermine any attempt to develop serious
      clinical trials to prove the considered off-label drug.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - El Rhazi, K
AU  - El Rhazi K
AD  - Department of Epidemiology and Public Health, Faculty of Medicine of Fez, Sidi
      Mohamed Ben-Abdillah University, Hassan II University hospital Center, 30000 Fez,
      Morocco.
FAU - Adarmouch, L
AU  - Adarmouch L
AD  - Clinical research unit, School of medicine of Marrakech, Cadi-Ayyad University,
      Mohammed VI, Morocco.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200617
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7298480
OTO - NOTNLM
OT  - Covid-19
OT  - Ethical dilemma
OT  - Hydroxychloroquine treatment
OT  - Responsibilities
OT  - Rights
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jemep.2020.100547 [doi]
AID - S2352-5525(20)30085-2 [pii]
AID - 100547 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100547. doi:
      10.1016/j.jemep.2020.100547. Epub 2020 Jun 17.


PMID- 32835057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - [Ethical approach to the issue of confinement of the elderly in the context of
      the COVID-19 pandemic: Prevention of frailty versus risk of vulnerability].
PG  - 100539
LID - 10.1016/j.jemep.2020.100539 [doi]
AB  - COVID-19 pandemic particularly affects older people and exposes them to a higher 
      risk of mortality. Containment, social distancing and isolation measures have
      been implemented to limit viral transmission. While there is a clear rationale
      for reducing the contagiousness of the infection through this means, the adverse 
      consequences of this social isolation, especially for this heterogeneous, aged
      and frail people, are difficult to apprehend. In particular, the disruption of
      the usual support and care ecosystems at home or in institutions may
      paradoxically increase the frailty of these people and lead to adverse events we 
      wanted to avoid. On the other hand, the risk of a decrease in the older person's 
      empowerment regarding his or her own health and social life decisions requires
      particular vigilance to prevent the risk of societal ageism. Regarding this
      population in particular, a possible conflict of values between individual and
      collective protection on one hand and respect for autonomy and independence on
      the other hand could exist. This article proposes an ethical reflection on the
      issue of containment of frail ageing people, based on medical ethics principles, 
      in order to open up positive approaches of vulnerability that guarantee respect
      for the dignity of the person and equity in care access.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Piccoli, M
AU  - Piccoli M
AD  - Departement medico-universitaire de geriatrie, AP-HP, centre universite de Paris,
      site Broca, 54-56, rue Pascal, 75013 Paris, France.
AD  - EA 4468 maladie d'Alzheimer, facteurs de risques, soins et accompagnement des
      patients et familles, universite de Paris, 54-56, rue Pascal, 75013 Paris,
      France.
FAU - Tannou, T
AU  - Tannou T
AD  - service de geriatrie, CHU, 25000 Besancon, France.
AD  - Equipe << ethique et progres medical >>, CIC Inserm 1431, CHU de Besancon, 25000 
      France.
AD  - EA 481 Neurosciences integratives et cliniques, universite Franche Comte, 25000
      Besancon, France.
AD  - Centre de recherche, institut universitaire geriatrique de Montreal, Montreal,
      Quebec, Canada.
FAU - Hernandorena, I
AU  - Hernandorena I
AD  - Departement medico-universitaire de geriatrie, AP-HP, centre universite de Paris,
      site Broca, 54-56, rue Pascal, 75013 Paris, France.
AD  - EA 4468 maladie d'Alzheimer, facteurs de risques, soins et accompagnement des
      patients et familles, universite de Paris, 54-56, rue Pascal, 75013 Paris,
      France.
FAU - Koeberle, S
AU  - Koeberle S
AD  - service de geriatrie, CHU, 25000 Besancon, France.
AD  - Equipe << ethique et progres medical >>, CIC Inserm 1431, CHU de Besancon, 25000 
      France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Une approche ethique de la question du confinement des personnes agees en
      contexte de pandemie COVID-19 : la prevention des fragilites face au risque de
      vulnerabilite.
DEP - 20200527
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7250767
OTO - NOTNLM
OT  - Ageism
OT  - COVID-19
OT  - Frailty
OT  - Geriatrics
OT  - Social isolation
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jemep.2020.100539 [doi]
AID - S2352-5525(20)30077-3 [pii]
AID - 100539 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100539. doi:
      10.1016/j.jemep.2020.100539. Epub 2020 May 27.


PMID- 32835056
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - [From the intimate to the collective, multi-traumas are in process: Let's dare to
      prevent rather than cure, let's dare an ethical policy].
PG  - 100538
LID - 10.1016/j.jemep.2020.100538 [doi]
AB  - The COVID-19 epidemic, its mortality, the uncertainties that persist on its
      origin, its evolution, the period of confinement and its consequences lead to
      situations of anxiety and even anguish to the point of trauma for some people.
      While these are naturally legitimate, this does not mean that they should not be 
      taken seriously, and benefit from appropriate care as soon as they have a
      significant impact on the lives of individuals, knowing that prevention remains
      the best form of care.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Baranes, M
AU  - Baranes M
AD  - Hopital universitaire Pitie-Salpetriere, service d'oncologie radiotherapie, 83,
      boulevard de l'Hopital, 75013 Paris, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - De l'intime au collectif, de multi-traumatismes sont en cours : osons prevenir
      plutot que guerir, osons une politique ethique.
DEP - 20200529
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7256547
OTO - NOTNLM
OT  - COVID-19
OT  - PTSD
OT  - Prevention
OT  - Screening
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jemep.2020.100538 [doi]
AID - S2352-5525(20)30076-1 [pii]
AID - 100538 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100538. doi:
      10.1016/j.jemep.2020.100538. Epub 2020 May 29.


PMID- 32835054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - Ethical dimensions of stigma and discrimination in Nepal during COVID-19
      pandemic.
PG  - 100536
LID - 10.1016/j.jemep.2020.100536 [doi]
AB  - COVID-19 pandemic has ultimately brought down the world in a status of standstill
      as a result of lockdown as one of the measures to combat the situation and to
      prevent cross transmission. On the other hand, it has raised issues like ethical 
      obligation of medical doctors and other staff to attend COVID-19 patients without
      proper PPE and resources increasing the risk to the staff and their family. In
      addition, it has resulted in compromise of the services provided to the people
      like non-availability of medical services to chronic and non-urgent patients.
      Non-COVID-19 patients attending 'Fever Clinic' were harmed due to inappropriate
      management. Medical staff dealing with testing or working in hospitals, isolation
      wards or quarantine centres have been stigmatized as 'possibly infected' and even
      denied food and accommodation.
CI  - (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Aacharya, R P
AU  - Aacharya RP
AD  - Medical Education Commission, 44811 Sanothimi, Bhaktapur, Nepal.
FAU - Shah, A
AU  - Shah A
AD  - Medical Education Commission, 44811 Sanothimi, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7250747
OTO - NOTNLM
OT  - Ethics
OT  - Health care professionals
OT  - Lockdown
OT  - Nepal
OT  - Stigma
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jemep.2020.100536 [doi]
AID - S2352-5525(20)30074-8 [pii]
AID - 100536 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100536. doi:
      10.1016/j.jemep.2020.100536. Epub 2020 May 27.


PMID- 32835052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - [Signatures of the COVID-19 pandemic and the ethical tensions of our modernity].
PG  - 100530
LID - 10.1016/j.jemep.2020.100530 [doi]
FAU - Herve, C
AU  - Herve C
AD  - Hopital Foch, Suresnes, France.
AD  - Universite de Paris, Paris, France.
AD  - Academie internationale d'ethique, medecine et politique publique, universite de 
      Paris, Paris, France.
FAU - Stoekle, H-C
AU  - Stoekle HC
AD  - Hopital Foch, Suresnes, France.
LA  - fre
PT  - Editorial
TT  - Signatures de la pandemie COVID-19 et tensions ethiques de notre modernite.
DEP - 20200526
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7247980
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jemep.2020.100530 [doi]
AID - S2352-5525(20)30068-2 [pii]
AID - 100530 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100530. doi:
      10.1016/j.jemep.2020.100530. Epub 2020 May 26.


PMID- 32835051
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - [Historical setting of a dialogue between two pioneers of ethical reflection
      during the COVID-19 period].
PG  - 100528
LID - 10.1016/j.jemep.2020.100528 [doi]
FAU - Herve, C
AU  - Herve C
AD  - Academie internationale ethique, medecine et politiques publiques (IAMEPH),
      universite de Paris, 45, rue des Saints-Peres, 75006 Paris, France.
LA  - fre
PT  - Journal Article
TT  - Mise en situation historique d'un dialogue entre deux pionniers de la reflexion
      ethique en periode COVID-19.
DEP - 20200521
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7241339
OTO - NOTNLM
OT  - Assisted suicide
OT  - Covid-19
OT  - End of life
OT  - Ethical history
OT  - Religions
OT  - Sober medicine
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jemep.2020.100528 [doi]
AID - S2352-5525(20)30066-9 [pii]
AID - 100528 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100528. doi:
      10.1016/j.jemep.2020.100528. Epub 2020 May 21.


PMID- 32834898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2052-0492 (Print)
IS  - 2052-0492 (Linking)
VI  - 8
DP  - 2020
TI  - Operationalization of critical care triage during a pandemic surge using
      protocolized communication and integrated supportive care.
PG  - 59
LID - 10.1186/s40560-020-00475-y [doi]
AB  - Triage becomes necessary when demand for intensive care unit (ICU) resources
      exceeds supply. Without triage, there is a risk that patients will be admitted to
      the ICU in the sequence that they present, disadvantaging those who either
      present later or have poorer access to healthcare. Moreover, if the patients with
      the best prognosis are not allocated life support, there is the possibility that 
      overall mortality will increase. Before formulating criteria, principles such as 
      maximizing lives saved and fairness ought to have been agreed upon to guide
      decision-making. The triage process is subdivided into three parts, i.e., having 
      explicit inclusion/exclusion criteria for ICU admission, prioritization of
      patients for allocation to available beds, and periodic reassessment of all
      patients already admitted to the ICU. Multi-dimensional criteria offer more
      holistic prognostication than only using age cutoffs. Appointed triage officers
      should also be enabled to make data-driven decisions. However, the process does
      not merely end with an allocation decision being made. Any decision has to be
      sensitively and transparently communicated to the patient and family. With
      infection control measures, there are challenges in managing communication and
      the psychosocial distress of dying alone. Therefore, explicit video call
      protocols and social services expertise will be necessary to mitigate these
      challenges. Besides symptom management and psychosocial management, supportive
      care teams play an integral role in coordination of complex cases. This scoping
      review found support for the three-pronged, triage-communication-supportive care 
      approach to facilitate the smooth operationalization of the triage process in a
      pandemic.
CI  - (c) The Author(s) 2020.
FAU - Anantham, Devanand
AU  - Anantham D
AUID- ORCID: 0000-0002-3375-1164
AD  - Duke-NUS Medical School, Singapore, Singapore.grid.428397.30000 0004 0385 0924
AD  - Department of Respiratory and Critical Care Medicine, Singapore General Hospital,
      Academia Building Level 3, 20 College Road, Singapore, S169856
      Singapore.grid.163555.10000 0000 9486 5048
FAU - Chai-Lim, Crystal
AU  - Chai-Lim C
AD  - Duke-NUS Medical School, Singapore, Singapore.grid.428397.30000 0004 0385 0924
AD  - Medical Social Services Department, Singapore General Hospital, Singapore,
      Singapore.grid.163555.10000 0000 9486 5048
FAU - Zhou, Jamie Xuelian
AU  - Zhou JX
AD  - Duke-NUS Medical School, Singapore, Singapore.grid.428397.30000 0004 0385 0924
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.grid.410724.40000 0004 0620 9745
FAU - Phua, Ghee Chee
AU  - Phua GC
AD  - Duke-NUS Medical School, Singapore, Singapore.grid.428397.30000 0004 0385 0924
AD  - Department of Respiratory and Critical Care Medicine, Singapore General Hospital,
      Academia Building Level 3, 20 College Road, Singapore, S169856
      Singapore.grid.163555.10000 0000 9486 5048
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200806
PL  - England
TA  - J Intensive Care
JT  - Journal of intensive care
JID - 101627304
PMC - PMC7407423
OTO - NOTNLM
OT  - COVID-19
OT  - Communication
OT  - Ethics
OT  - Intensive care unit
OT  - Pandemic surge
OT  - Supportive care
OT  - Triage
COIS- Competing interestsNil
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1186/s40560-020-00475-y [doi]
AID - 475 [pii]
PST - epublish
SO  - J Intensive Care. 2020 Aug 6;8:59. doi: 10.1186/s40560-020-00475-y. eCollection
      2020.


PMID- 32834889
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1878-786X (Print)
IS  - 1878-786X (Linking)
VI  - 157
IP  - 4
DP  - 2020 Aug
TI  - [A crisis of ethics in the ethics of crisis].
PG  - 371
LID - 10.1016/j.jchirv.2020.06.003 [doi]
FAU - Zarzavadjian Le Bian, A
AU  - Zarzavadjian Le Bian A
AD  - Service de chirurgie digestive, bariatrique et endocrinienne, hopital Avicenne,
      hopitaux universitaires Seine Saint-Denis, universite Sorbonne Paris Nord,
      Assistance publique-Hopitaux de Paris, 125, rue de Stalingrad, 93000 Bobigny,
      France.
FAU - Tresallet, C
AU  - Tresallet C
AD  - Service de chirurgie digestive, bariatrique et endocrinienne, hopital Avicenne,
      hopitaux universitaires Seine Saint-Denis, universite Sorbonne Paris Nord,
      Assistance publique-Hopitaux de Paris, 125, rue de Stalingrad, 93000 Bobigny,
      France.
FAU - Martinod, E
AU  - Martinod E
AD  - Service de chirurgie thoracique et vasculaire, hopital Avicenne, hopitaux
      universitaires Seine Saint-Denis, universite Sorbonne Paris Nord, Assistance
      publique-Hopitaux de Paris, 93000 Bobigny, France.
LA  - fre
PT  - Journal Article
TT  - Une crise de l'ethique dans l'ethique de crise.
DEP - 20200729
PL  - France
TA  - J Chir Visc
JT  - Journal de chirurgie viscerale
JID - 101530148
PMC - PMC7388794
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Pandemia
OT  - Surgery
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.jchirv.2020.06.003 [doi]
AID - S1878-786X(20)30312-0 [pii]
PST - ppublish
SO  - J Chir Visc. 2020 Aug;157(4):371. doi: 10.1016/j.jchirv.2020.06.003. Epub 2020
      Jul 29.


PMID- 32834877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1877-0509 (Print)
VI  - 175
DP  - 2020
TI  - Concepts and Solutions of the Digital Teams Platform to Support Mobile Work and
      Virtual Teams.
PG  - 56-63
LID - 10.1016/j.procs.2020.07.011 [doi]
AB  - New work models have been discussed for several years. Especially in the area of 
      knowledge work, mobile and distributed work provides advantages over presence
      time at companies: It offers more freedom and flexibility to the employees,
      reduces travel time, and counteracts a major trend: the exodus from rural areas. 
      However, to provide an optimized digital work environment for distributed teams
      of knowledge workers, many different aspects must be considered, including
      social, physical, legal, and technological aspects. In this article, we focus on 
      the technological aspects. Nowadays, a multitude of tools and technologies exist 
      to support the communication of distributed teams, to allow working concurrently 
      on documents, or to support data and document exchange. However, many existing
      solutions only provide solutions for a specific purpose rather than a
      sophisticated platform that offers all of these services in an integrated manner 
      and additionally takes care of delivering intelligent and data-driven services in
      a trustful and ethical way. In the research project "Digital Teams", we aim at
      developing such a platform as open source. In this article, we provide the basic 
      architecture of our platform and share the main concepts and solutions we are
      currently implementing, such as our dashboard, data exchange concepts, or
      authentication and authorization mechanisms.
CI  - (c) 2020 The Author(s). Published by Elsevier B.V.
FAU - Schweitzer, Stefan
AU  - Schweitzer S
AD  - Fraunhofer IESE, Fraunhofer-Platz 1, 67663 Kaiserslautern, Germany.
FAU - Gerbershagen, Matthias
AU  - Gerbershagen M
AD  - Fraunhofer IESE, Fraunhofer-Platz 1, 67663 Kaiserslautern, Germany.
FAU - Elberzhager, Frank
AU  - Elberzhager F
AD  - Fraunhofer IESE, Fraunhofer-Platz 1, 67663 Kaiserslautern, Germany.
FAU - Braun, Susanne
AU  - Braun S
AD  - Fraunhofer IESE, Fraunhofer-Platz 1, 67663 Kaiserslautern, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - Netherlands
TA  - Procedia Comput Sci
JT  - Procedia computer science
JID - 101537771
PMC - PMC7409829
OTO - NOTNLM
OT  - Digital Ecosystems
OT  - Digitalization
OT  - Distributed Teams
OT  - Knowledge Work
OT  - New Work
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.procs.2020.07.011 [doi]
AID - S1877-0509(20)31690-2 [pii]
PST - ppublish
SO  - Procedia Comput Sci. 2020;175:56-63. doi: 10.1016/j.procs.2020.07.011. Epub 2020 
      Aug 6.


PMID- 32834826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1710-1484 (Print)
IS  - 1710-1484 (Linking)
VI  - 16
DP  - 2020
TI  - Th17/Treg imbalance is associated with reduced indoleamine 2,3 dioxygenase
      activity in childhood allergic asthma.
PG  - 61
LID - 10.1186/s13223-020-00457-7 [doi]
AB  - BACKGROUND: The differentiation of CD4+ lymphocytes Th17/regulatory T cells
      (Treg) and indoleamine 2,3-dioxygenase (IDO) is associated with the pathogenesis 
      of allergic asthma. Basic research has shown that IDO is likely a "switch" of the
      transition from Th17 cells to Tregs under certain conditions. However, no
      relevant clinical studies have been reported on the association between IDO
      activity and Th17/Treg imbalance in children with allergic asthma. The goal of
      this study was to test whether indoleamine 2,3 dioxygenase (IDO) participates in 
      the pathogenesis of pediatric allergic asthma by influencing Th17/regulatory T
      cell (Treg) differentiation and related cytokines. METHODS: Thirty-three children
      with allergic asthma and 33 healthy children were selected. The subjects were
      evaluated via a pulmonary function test, a skin prick test, and an eosinophil
      count. Peripheral blood was collected to measure Th17/Treg percentages and
      related cytokine levels. Blood and induced sputum were obtained to measure the
      IDO level. RESULTS: Compared with the control group, the patient group had an
      obvious Th17/Treg imbalance; their IDO levels were significantly lower, their
      IL-17 and IL-6 levels were markedly higher, and their IL-10 and TGF-beta levels
      were markedly lower than those of the control group. The IDO levels in both blood
      and induced sputum were negatively correlated with the Th17/Treg ratio.
      CONCLUSIONS: A significant correlation was observed between IDO activity and
      Th17/Treg imbalance in children with allergic asthma. IDO may upregulate Treg
      numbers by stimulating IL-10 production and inhibiting IL-6 expression.
      Therefore, IDO may be a molecular switch that leads to the conversion of Th17
      cells to Tregs, thus playing a potentially protective role in the pathogenesis of
      asthma.Trial registration This study was approved by the Chinese Clinical Trial
      Registry with registration number ChiCTR-COC-15006080 and was reviewed and
      approved by the Ethics Committee of Southwest Hospital. The name of registration:
      The effect of indoleamine 2,3 dioxygenase (IDO) on Regulation of Th17/Treg
      Differentiation in Childhood Asthma. Date of registration: 14/03/2015. URL of
      trial registry record: http://www.chictr.org.cn.
CI  - (c) The Author(s) 2020.
FAU - Hu, Ying
AU  - Hu Y
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
FAU - Chen, Zhiqiang
AU  - Chen Z
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
FAU - Zeng, Jing
AU  - Zeng J
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
FAU - Zheng, Shouyan
AU  - Zheng S
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
FAU - Sun, Liujuan
AU  - Sun L
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
FAU - Zhu, Li
AU  - Zhu L
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
FAU - Liao, Wei
AU  - Liao W
AD  - Department of Pediatrics, The First Affiliated Hospital of Army Medical
      University, Chongqing, 400038 China.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC7386249
OTO - NOTNLM
OT  - Childhood allergic asthma
OT  - IDO
OT  - Th17/Treg imbalance
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1186/s13223-020-00457-7 [doi]
AID - 457 [pii]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2020 Jul 7;16:61. doi: 10.1186/s13223-020-00457-7.
      eCollection 2020.


PMID- 32834710
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1081-3004 (Print)
IS  - 1081-3004 (Linking)
VI  - 64
IP  - 1
DP  - 2020 Jul-Aug
TI  - Digital Citizenship During a Global Pandemic: Moving Beyond Digital Literacy.
PG  - 11-17
LID - 10.1002/jaal.1076 [doi]
AB  - In this commentary, the authors move beyond digital literacy and take up the
      question of what digital citizenship means and looks like in the context of the
      COVID-19 pandemic. To engage with questions of ethical practice, the authors
      begin with the International Society for Technology in Education framework for
      digital citizenship. They expand on these standards to argue for an awareness of 
      the ethical questions facing citizens online that are difficult to encompass as a
      set of skills or competencies. The authors then take these considerations into a 
      set of practical steps for teachers to nurture participatory and social
      justice-oriented digital citizenship as part of the curriculum. The authors
      conclude by noting the digital divide and social inequities that have been
      highlighted by the current crisis.
CI  - (c) 2020 International Literacy Association.
FAU - Buchholz, Beth A
AU  - Buchholz BA
FAU - DeHart, Jason
AU  - DeHart J
FAU - Moorman, Gary
AU  - Moorman G
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - United States
TA  - J Adolesc Adult Lit
JT  - Journal of adolescent & adult literacy : a journal from the International Reading
      Association
JID - 101574768
PMC - PMC7405058
OTO - NOTNLM
OT  - 4-Adolescence
OT  - Critical analysis < Digital/media literacies
OT  - Digital/media literacies
OT  - Information literacy < Digital/media literacies
OT  - Informational text < Strategies
OT  - Instructional strategies
OT  - Instructional strategies; methods and materials
OT  - Internet
OT  - New literacies < Digital/media literacies
OT  - Specific media (hypertext
OT  - and materials
OT  - etc.) < Digital/media literacies
OT  - film
OT  - methods
OT  - music
OT  - teaching strategies < Strategies
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1002/jaal.1076 [doi]
AID - JAAL1076 [pii]
PST - ppublish
SO  - J Adolesc Adult Lit. 2020 Jul-Aug;64(1):11-17. doi: 10.1002/jaal.1076. Epub 2020 
      Jul 17.


PMID- 32834442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200824
IS  - 0384-9694 (Print)
IS  - 0384-9694 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - COVID-19 and Religious Ethics.
PG  - 349-387
LID - 10.1111/jore.12328 [doi]
AB  - The editors of the JRE solicited short essays on the COVID-19 pandemic from a
      group of scholars of religious ethics that reflected on how the field might help 
      them make sense of the complex religious, cultural, ethical, and political
      implications of the pandemic, and on how the pandemic might shape the future of
      religious ethics.
CI  - (c) 2020 Journal of Religious Ethics, Inc.
FAU - Alimi, Toni
AU  - Alimi T
FAU - Antus, Elizabeth L
AU  - Antus EL
FAU - Balthrop-Lewis, Alda
AU  - Balthrop-Lewis A
FAU - Childress, James F
AU  - Childress JF
FAU - Dunn, Shannon
AU  - Dunn S
FAU - Green, Ronald M
AU  - Green RM
FAU - Gregory, Eric
AU  - Gregory E
FAU - Herdt, Jennifer A
AU  - Herdt JA
FAU - Jenkins, Willis
AU  - Jenkins W
FAU - Cathleen Kaveny, M
AU  - Cathleen Kaveny M
FAU - Lloyd, Vincent W
AU  - Lloyd VW
FAU - Lo, Ping-Cheung
AU  - Lo PC
FAU - Malesic, Jonathan
AU  - Malesic J
FAU - Newheiser, David
AU  - Newheiser D
FAU - Oh, Irene
AU  - Oh I
FAU - Stalnaker, Aaron
AU  - Stalnaker A
LA  - eng
PT  - Editorial
DEP - 20200811
PL  - United States
TA  - J Relig Ethics
JT  - The Journal of religious ethics
JID - 100972237
PMC - PMC7436539
OTO - NOTNLM
OT  - COVID-19
OT  - Confucian ethics
OT  - environmental ethics
OT  - food ethics
OT  - humanitarianism
OT  - justice
OT  - mental health
OT  - public health
OT  - racism
OT  - refugees
OT  - vulnerability
OT  - work
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1111/jore.12328 [doi]
AID - JORE12328 [pii]
PST - ppublish
SO  - J Relig Ethics. 2020 Sep;48(3):349-387. doi: 10.1111/jore.12328. Epub 2020 Aug
      11.


PMID- 32834385
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210206
IS  - 0305-750X (Print)
IS  - 0305-750X (Linking)
VI  - 136
DP  - 2020 Dec
TI  - Equity as both a means and an end: Lessons for resilient food systems from
      COVID-19.
PG  - 105104
LID - 10.1016/j.worlddev.2020.105104 [doi]
AB  - Food systems are important sites of economic stress, political response and
      adaptation. Access to food is also an important marker of how well a society
      distributes its wealth, reflecting the state of political accountability,
      economic redistribution, and the society's level of commitment to uphold the
      right to food. The COVID-19 pandemic has exposed the interconnected weaknesses of
      our food, social and economic systems and offers lessons for building more just
      and resilient food systems. We focus on three lessons learned anew in the
      pandemic: (1) food insecurity both reflects and reinforces inequity, (2) food
      workers are essential yet treated as sacrificial, and (3) racialized migrant food
      workers face unique forms of inequity. These lessons - chosen for their ethical
      salience, global relevance, and political urgency - show how interconnected
      inequities revealed by the pandemic are undermining resilience. We conclude with 
      specific policy recommendations for redress, both within and beyond food systems.
      This will not be the final global pandemic, nor is it the only shock that regions
      are currently experiencing. COVID-19 is an opening to think about how societies
      might center justice and equity in efforts to build back better. Governments
      should take this opportunity to invest in structural changes to reduce persistent
      inequities in food access due to poverty, health outcomes, decent work and
      overall wellbeing, especially for racialized communities and migrants.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Klassen, Susanna
AU  - Klassen S
AD  - Institute for Resources, Environment and Sustainability, The University of
      British Columbia, Vancouver, Canada.
FAU - Murphy, Sophia
AU  - Murphy S
AD  - Institute for Resources, Environment and Sustainability, The University of
      British Columbia, Vancouver, Canada.
AD  - International Institute for Sustainable Development, Winnipeg, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - England
TA  - World Dev
JT  - World development
JID - 9878856
PMC - PMC7402645
OTO - NOTNLM
OT  - Equity
OT  - Food insecurity
OT  - Food systems
OT  - Labor
OT  - Migration
OT  - Resilience
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.worlddev.2020.105104 [doi]
AID - S0305-750X(20)30231-X [pii]
AID - 105104 [pii]
PST - ppublish
SO  - World Dev. 2020 Dec;136:105104. doi: 10.1016/j.worlddev.2020.105104. Epub 2020
      Aug 4.


PMID- 32834230
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1873-7722 (Electronic)
IS  - 0160-7383 (Linking)
VI  - 84
DP  - 2020 Sep
TI  - The seven sins of hunting tourism.
PG  - 102996
LID - 10.1016/j.annals.2020.102996 [doi]
AB  - In a review of situational pressures on tourists, we identify seven sins or risk 
      zones that induce moral disengagement and allow for behaviour that would be
      considered unethical by the same people when not on holiday. The context of
      hunting tourism reveals the following sins act cumulatively on the hunting
      tourist: "The Pay Effect", "The Tourist Bubble", "Last Chance Tourism", "The
      Bucket List", "When in Rome", "The False Display", and "The Saviour". Identifying
      these sins and the way hunting tourists draw from them to neutralize eco-guilt
      are argued to be a first step on the call to set standards and practices within
      consumptive wildlife tourism consistent with the Precautionary Principle in
      tourism planning.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Tickle, Lara
AU  - Tickle L
AD  - Swedish University of Agricultural Sciences (SLU), Division of Environmental
      Communication, Department of Urban and Rural Development, Sweden.
FAU - von Essen, Erica
AU  - von Essen E
AD  - Norwegian Institute for Nature Research, Sognsveien 68, 0855 Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - Ann Tour Res
JT  - Annals of tourism research
JID - 101765681
PMC - PMC7357523
OTO - NOTNLM
OT  - Eco-guilt
OT  - Ethics
OT  - Hunting
OT  - Precautionary principle
OT  - Trophy
OT  - Wildlife
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.annals.2020.102996 [doi]
AID - S0160-7383(20)30140-7 [pii]
AID - 102996 [pii]
PST - ppublish
SO  - Ann Tour Res. 2020 Sep;84:102996. doi: 10.1016/j.annals.2020.102996. Epub 2020
      Jul 13.


PMID- 32834223
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1873-7722 (Electronic)
IS  - 0160-7383 (Linking)
VI  - 84
DP  - 2020 Sep
TI  - A (Deleuzian) posthumanist paradigm for tourism research.
PG  - 102982
LID - 10.1016/j.annals.2020.102982 [doi]
AB  - Posthumanistic inquiry is young and offers new ways to understand critical and
      ethical relationships, bringing new axiological perspectives to current debates
      around travel, mobilities and (post)modernist conceptualizations of tourism. This
      research note introduces a Deleuzian posthumanism paradigm with ontological,
      epistemological and methodological directions to approach tourism research from a
      non-dualist perspective. French philosopher Gilles Deleuze offers a postdualist, 
      process-oriented ontology of difference that is vital to create radical new
      tourism knowledge, and avoid indefensible 'either-or' binaries in research and
      praxis. The Deleuzian research paradigm we forward eschews anthropocentric
      premises and modernist traditions for a situated, immanent style of encounter and
      relational being with human and non-human others that is vital for a healthy
      planet and justice in the Anthropocene.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Guia, Jaume
AU  - Guia J
AD  - Dept. of Business Administration, Faculty of Tourism, University of Girona,
      Girona, Catalonia, Spain.
AD  - School of Tourism and Hospitality, College of Business and Economics, University 
      of Johannesburg, Johannesburg, South Africa.
FAU - Jamal, Tazim
AU  - Jamal T
AD  - Dept. of Recreation, Park and Tourism, Texas A&M University, College Station, TX,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - England
TA  - Ann Tour Res
JT  - Annals of tourism research
JID - 101765681
PMC - PMC7363618
OTO - NOTNLM
OT  - Axiology
OT  - Gilles Deleuze
OT  - Post-dualism
OT  - Posthumanism
OT  - Relational being
OT  - Research paradigm
OT  - Tourism
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/10/05 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.annals.2020.102982 [doi]
AID - S0160-7383(20)30126-2 [pii]
AID - 102982 [pii]
PST - ppublish
SO  - Ann Tour Res. 2020 Sep;84:102982. doi: 10.1016/j.annals.2020.102982. Epub 2020
      Jul 16.


PMID- 32834134
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200824
IS  - 0040-1625 (Print)
IS  - 0040-1625 (Linking)
VI  - 158
DP  - 2020 Sep
TI  - How Blockchain can impact financial services - The overview, challenges and
      recommendations from expert interviewees.
PG  - 120166
LID - 10.1016/j.techfore.2020.120166 [doi]
AB  - FinTech (Financial Technology) and Blockchain are prevalent topics among
      technology leaders in finance today. This article describes the impact and
      revolution of FinTech and Blockchain in the financial industry and demonstrates
      the main characteristics of such technology. Then, we present three critical
      challenges as well as three ethical issues about using Blockchain technology.
      Next, we discuss the development of Blockchain for the financial sector. In
      addition, we describe the real motivations for banks to explore Blockchain, and
      problems they face. In order to have a good understanding of the industry, a
      qualitative method was adopted, and sixteen experts were interviewed. It was
      identified that knowledge hiding in Blockchain was common and the rationale
      behind was analyzed using the TPB (Theory of Planned Behavior) approach. The
      analysis results suggested that knowledge hiding was due to affective, behavioral
      and cognitive evaluations. The interviewees also provided several recommendations
      and success factors to overcome current issues in Blockchain adoption. Therefore,
      four important propositions have been developed. Finally, this article suggests
      how financial services should respond to this new technology and how to manage
      knowledge sharing in a more structured way. This article contributes to the
      literature related to the current entrepreneurial finance landscape for
      Blockchain.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Chang, Victor
AU  - Chang V
AD  - School of Computing, Engineering and Digital Technologies, Teesside University,
      Middlesbrough, UK.
FAU - Baudier, Patricia
AU  - Baudier P
AD  - EM Normandie Business School, Metis Lab, Paris, France.
FAU - Zhang, Hui
AU  - Zhang H
AD  - IBSS, Xi'an Jiaotong-Liverpool University, Suzhou, China.
FAU - Xu, Qianwen
AU  - Xu Q
AD  - School of Computing, Engineering and Digital Technologies, Teesside University,
      Middlesbrough, UK.
AD  - IBSS, Xi'an Jiaotong-Liverpool University, Suzhou, China.
FAU - Zhang, Jingqi
AU  - Zhang J
AD  - School of Computing, Engineering and Digital Technologies, Teesside University,
      Middlesbrough, UK.
AD  - IBSS, Xi'an Jiaotong-Liverpool University, Suzhou, China.
FAU - Arami, Mitra
AU  - Arami M
AD  - PARDIS Ltd, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200621
PL  - United States
TA  - Technol Forecast Soc Change
JT  - Technological forecasting and social change
JID - 101085131
PMC - PMC7306205
OTO - NOTNLM
OT  - Blockchain
OT  - Blockchain adoption
OT  - Ethical challenges
OT  - Ethics
OT  - Financial industry
OT  - Recommendation for Blockchain adoption
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.techfore.2020.120166 [doi]
AID - S0040-1625(20)30992-6 [pii]
AID - 120166 [pii]
PST - ppublish
SO  - Technol Forecast Soc Change. 2020 Sep;158:120166. doi:
      10.1016/j.techfore.2020.120166. Epub 2020 Jun 21.


PMID- 32834058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0006-3207 (Print)
IS  - 0006-3207 (Linking)
VI  - 248
DP  - 2020 Aug
TI  - The Fox and the Crow. A need to update pest control strategies.
PG  - 108693
LID - 10.1016/j.biocon.2020.108693 [doi]
AB  - The recent discovery that cats and mustelids can be infected by SARS-CoV-2 may
      raise the question of monitoring domestic, feral and wild populations of such
      animals, as an adjunct to the elimination of COVID-19 in humans. Emergency
      solutions might consider large scale control of these animals in the wild.
      However, looking at science recently published on native vertebrate pest control 
      reveals first that usual controls do not succeed in reducing animal numbers and
      associated damages, second that controlling can be counter-productive in
      increasing the infectious risks for humans and livestock. The examples of red fox
      and corvids are detailed in a European context, illustrating the urgent need for 
      an ethical evaluation of ecological and economic costs and benefits of pest
      control strategies. A complete scientific evaluation process must be implemented 
      and up-dated regularly, to be organized in four major steps, once the aim of the 
      control strategy has been defined: (1) evaluating damages/risks caused by the
      animals, to be balanced with the ecosystem services they may provide, also in
      terms of economic costs; (2) unravelling spatial and temporal population dynamics
      of target animals to identify, if any, optimal control scenarios - which could be
      done within an adaptive management framework; (3) estimating the economic costs
      of implementing those optimal control scenarios, to be compared to the economic
      costs of damages/diseases; (4) finally evaluating how the control strategy
      reached its aims. A modern fable of the Fox and the Crow should deliver a timely 
      moral for an ethical, ecological and economical appraisal of pest control
      strategies in Europe.
CI  - (c) 2020 The Author(s).
FAU - Jiguet, Frederic
AU  - Jiguet F
AD  - UMR7204 Centre d'Ecologie et des Sciences de la Conservation, MNHN-CNRS-SU,
      CP135, 43 Rue Buffon, 75005 Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200703
PL  - England
TA  - Biol Conserv
JT  - Biological conservation
JID - 7502018
PMC - PMC7342009
COIS- The author declares that he has no actual or potential conflict of interest
      including any financial, personal or other relationships with other people or
      organizations within three years of beginning the submitted work that could have 
      inappropriately influenced, or be perceived to influence, his work.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/05/25 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1016/j.biocon.2020.108693 [doi]
AID - S0006-3207(20)30751-5 [pii]
AID - 108693 [pii]
PST - ppublish
SO  - Biol Conserv. 2020 Aug;248:108693. doi: 10.1016/j.biocon.2020.108693. Epub 2020
      Jul 3.


PMID- 32834012
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20201014
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - The ethical, social, and cultural dimensions of screening for mental health in
      children and adolescents of the developing world.
PG  - e0237853
LID - 10.1371/journal.pone.0237853 [doi]
AB  - Despite their burden and high prevalence, mental health disorders of children and
      adolescents remain neglected in many parts of the world. In developing countries,
      where half of the population is younger than 18 years old, one of every five
      children and adolescents is estimated to suffer from a mental health disorder. It
      is then essential to detect these conditions through screening in a timely and
      accurate manner. But such screening is fraught with considerable ethical, social,
      and cultural challenges. This study systematically identifies, for the first
      time, these challenges, along with potential solutions to address them. We report
      on the results of an international multi- and inter-disciplinary three-round
      Delphi survey completed by 135 mental health experts from 37 countries. We asked 
      these experts to identify and rank the main ethical, social, and cultural
      challenges of screening for child and adolescent mental health problems in
      developing nations, and to propose solutions for each challenge. Thirty-nine
      significant challenges emerged around eight themes, along with 32 potential
      solutions organized into seven themes. There was a high degree of consensus among
      the experts, but a few interesting disagreements arose between members of the
      panel from high-income countries and those from low- and middle-income nations.
      The panelists overwhelmingly supported mental health screening for children and
      adolescents. They recommended ensuring local acceptance and support for screening
      prior to program initiation, along with careful and comprehensive protection of
      human rights; integrating screening procedures into primary care; designing and
      implementing culturally appropriate screening tools, programs, and follow-up;
      securing long-term funding; expanding capacity building; and task-shifting
      screening to local non-specialists. These recommendations can serve as a guide
      for policy and decision-making, resource allocation, and international
      cooperation. They also offer a novel approach to reduce the burden of these
      disorders by encouraging their timely and context-sensitive prevention and
      management.
FAU - Salamanca-Buentello, Fabio
AU  - Salamanca-Buentello F
AUID- ORCID: 0000-0002-3666-7785
AD  - Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Seeman, Mary V
AU  - Seeman MV
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Daar, Abdallah S
AU  - Daar AS
AD  - Departments of Clinical Public Health and Surgery, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Stellenbosch Institute for Advanced Study, Stellenbosch, Western Cape, South
      Africa.
FAU - Upshur, Ross E G
AU  - Upshur REG
AD  - Division of Clinical Public Health, Dalla Lana School of Public Health,
      University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Family and Community Medicine, University of Toronto, Toronto,
      Ontario, Canada.
AD  - Bridgepoint Collaboratory for Research and Innovation, Lunenfeld - Tanenbaum
      Research Institute, Sinai Health System, Toronto, Ontario, Canada.
LA  - eng
SI  - figshare/10.6084/m9.figshare.c.5086313
PT  - Journal Article
DEP - 20200824
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Culture
MH  - *Developing Countries
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mass Screening
MH  - Mental Disorders/*diagnosis
MH  - Mental Health/*ethics
MH  - *Social Behavior
MH  - Young Adult
PMC - PMC7446846
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/25 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/01/01 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1371/journal.pone.0237853 [doi]
AID - PONE-D-20-00075 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 24;15(8):e0237853. doi: 10.1371/journal.pone.0237853.
      eCollection 2020.


PMID- 32833730
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1537-1611 (Electronic)
IS  - 1522-0443 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Sep
TI  - Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an
      Off-Label Indication.
PG  - 63-64
LID - 10.1097/CND.0000000000000295 [doi]
FAU - Roy, Bhaskar
AU  - Roy B
AD  - Department of Neurology, Yale School of Medicine, New Haven, CT.
FAU - Nowak, Richard J
AU  - Nowak RJ
LA  - eng
PT  - Letter
PL  - United States
TA  - J Clin Neuromuscul Dis
JT  - Journal of clinical neuromuscular disease
JID - 100887391
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Complement Inactivating Agents)
RN  - A3ULP0F556 (eculizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Complement Inactivating Agents/*therapeutic use
MH  - Female
MH  - Guillain-Barre Syndrome/*drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Off-Label Use/*ethics
EDAT- 2020/08/25 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
AID - 10.1097/CND.0000000000000295 [doi]
AID - 00131402-202009000-00012 [pii]
PST - ppublish
SO  - J Clin Neuromuscul Dis. 2020 Sep;22(1):63-64. doi: 10.1097/CND.0000000000000295.


PMID- 32833703
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Oct
TI  - Ethical considerations in xenotransplantation: a review.
PG  - 483-488
LID - 10.1097/MOT.0000000000000796 [doi]
AB  - PURPOSE OF REVIEW: The purpose of this review is to present and analyse recent
      literature on the patterns, trends, and developments of ethical considerations
      concerning xenotransplantation by appraising normative aspects within a coherent 
      framework. RECENT FINDINGS: Developments within xenotransplantation may soon
      allow for pig-to-human xenotransplantation to take place. Ethical analysis of
      xenotransplantation commonly follows an anthropocentric cost-benefit analysis,
      which may imprecisely measure costs. Xenotransplantation should not merely be
      approached from an anthropocentric perspective. Rather, the potential risks
      presented to human and nonhuman donors, recipients, and third parties should all 
      be thoroughly considered. SUMMARY: The range of feasible alternatives to
      xenotransplantation to increase organ supply should be examined before resorting 
      to xenotransplantation because of the moral distinction between imposing certain 
      risks on others before, or after, alternative solutions have been exhausted.
FAU - Cengiz, Nezerith
AU  - Cengiz N
AD  - Steve Biko Centre for Bioethics, University of the Witwatersrand, Johannesburg,
      South Africa.
FAU - Wareham, Christopher Simon
AU  - Wareham CS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Animals
MH  - Humans
MH  - Models, Animal
MH  - Swine
MH  - Transplantation, Heterologous/*ethics
EDAT- 2020/08/25 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1097/MOT.0000000000000796 [doi]
AID - 00075200-202010000-00007 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Oct;25(5):483-488. doi:
      10.1097/MOT.0000000000000796.


PMID- 32833660
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep 2
TI  - Telemonitoring for Patients With COVID-19: Recommendations for Design and
      Implementation.
PG  - e20953
LID - 10.2196/20953 [doi]
AB  - Despite significant efforts, the COVID-19 pandemic has put enormous pressure on
      health care systems around the world, threatening the quality of patient care.
      Telemonitoring offers the opportunity to carefully monitor patients with a
      confirmed or suspected case of COVID-19 from home and allows for the timely
      identification of worsening symptoms. Additionally, it may decrease the number of
      hospital visits and admissions, thereby reducing the use of scarce resources,
      optimizing health care capacity, and minimizing the risk of viral transmission.
      In this paper, we present a COVID-19 telemonitoring care pathway developed at a
      tertiary care hospital in the Netherlands, which combined the monitoring of vital
      parameters with video consultations for adequate clinical assessment.
      Additionally, we report a series of medical, scientific, organizational, and
      ethical recommendations that may be used as a guide for the design and
      implementation of telemonitoring pathways for COVID-19 and other diseases
      worldwide.
CI  - (c)Anna V Silven, Annelieke H J Petrus, Maria Villalobos-Quesada, Ebru Dirikgil, 
      Carlijn R Oerlemans, Cyril P Landstra, Hileen Boosman, Hendrikus J A van Os,
      Marco H Blanker, Roderick W Treskes, Tobias N Bonten, Niels H Chavannes, Douwe E 
      Atsma, Y K Onno Teng. Originally published in the Journal of Medical Internet
      Research (http://www.jmir.org), 02.09.2020.
FAU - Silven, Anna V
AU  - Silven AV
AUID- ORCID: 0000-0002-1521-8956
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Petrus, Annelieke H J
AU  - Petrus AHJ
AUID- ORCID: 0000-0001-5967-805X
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Villalobos-Quesada, Maria
AU  - Villalobos-Quesada M
AUID- ORCID: 0000-0003-4930-1982
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Dirikgil, Ebru
AU  - Dirikgil E
AUID- ORCID: 0000-0002-5619-8138
AD  - Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands.
FAU - Oerlemans, Carlijn R
AU  - Oerlemans CR
AUID- ORCID: 0000-0002-5504-7397
AD  - Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands.
FAU - Landstra, Cyril P
AU  - Landstra CP
AUID- ORCID: 0000-0003-2927-8447
AD  - Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands.
AD  - Department of Endocrinology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Boosman, Hileen
AU  - Boosman H
AUID- ORCID: 0000-0002-4941-8964
AD  - Department of Quality and Patient Safety, Leiden University Medical Center,
      Leiden, Netherlands.
FAU - van Os, Hendrikus J A
AU  - van Os HJA
AUID- ORCID: 0000-0002-8911-8608
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
AD  - Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Blanker, Marco H
AU  - Blanker MH
AUID- ORCID: 0000-0002-1086-8730
AD  - Department of General Practice and Elderly Care Medicine, University Medical
      Center Groningen, Groningen, Netherlands.
FAU - Treskes, Roderick W
AU  - Treskes RW
AUID- ORCID: 0000-0003-3210-6005
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands.
FAU - Bonten, Tobias N
AU  - Bonten TN
AUID- ORCID: 0000-0002-7719-6182
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Chavannes, Niels H
AU  - Chavannes NH
AUID- ORCID: 0000-0002-8607-9199
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Atsma, Douwe E
AU  - Atsma DE
AUID- ORCID: 0000-0002-9664-2985
AD  - National eHealth Living Lab, Leiden University Medical Center, Leiden,
      Netherlands.
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands.
FAU - Teng, Y K Onno
AU  - Teng YKO
AUID- ORCID: 0000-0001-9920-2195
AD  - Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200902
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*diagnosis/prevention & control/*therapy/transmission
MH  - Delivery of Health Care/*methods/organization & administration
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Monitoring, Physiologic/*methods
MH  - Netherlands/epidemiology
MH  - Pandemics/prevention & control
MH  - *Patient Care
MH  - Pneumonia, Viral/*diagnosis/prevention & control/*therapy/transmission
MH  - SARS-CoV-2
MH  - Telemedicine/*methods/organization & administration
MH  - Tertiary Care Centers
MH  - Tertiary Healthcare/*methods/organization & administration
PMC - PMC7473766
OTO - NOTNLM
OT  - *COVID-19
OT  - *digital health
OT  - *eHealth
OT  - *telemedicine
OT  - *telemonitoring
EDAT- 2020/08/25 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/08/15 00:00 [accepted]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - v22i9e20953 [pii]
AID - 10.2196/20953 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Sep 2;22(9):e20953. doi: 10.2196/20953.


PMID- 32833536
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 2573-1602 (Electronic)
IS  - 2573-1599 (Linking)
VI  - 3
IP  - 4
DP  - 2020 Aug
TI  - An Examination of Public Discourse on Human Gene Editing Using Natural Language
      Processing.
PG  - 237-247
LID - 10.1089/crispr.2020.0003 [doi]
AB  - This research aims to explore the different ways in which scientists, ethicists, 
      journalists, and commissions speak to the public about new gene-editing
      technologies. The research collected more than 100,000 sentences from books, news
      articles, and reports written by these four types of authors, examined the
      relative distinctiveness of their speech, and compared the prevalence of key
      terms among the four groups. In addition, the sentiment of each group's speech
      was compared using IBM Watson's sentiment classification functionality. Key
      findings suggest that some topics-such as the issue of "enhancement," the
      parent-child relationship, or the role of China-are covered very
      disproportionately by different groups of authors, and that the current discourse
      regarding gene editing has not demonstrated extensive consideration of the
      perspectives of the disabled, religious adherents, or other relevant interest
      groups. While some group-level differences are highly robust, on many measures,
      the variation within groups is wider than the variation between groups.
FAU - Musser, Micah
AU  - Musser M
AD  - Georgetown University, Washington, DC, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - CRISPR J
JT  - The CRISPR journal
JID - 101738191
SB  - IM
MH  - Ethicists
MH  - *Gene Editing
MH  - Humans
MH  - Judgment
MH  - *Natural Language Processing
MH  - *Public Opinion
MH  - Research Personnel
EDAT- 2020/08/25 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
AID - 10.1089/crispr.2020.0003 [doi]
PST - ppublish
SO  - CRISPR J. 2020 Aug;3(4):237-247. doi: 10.1089/crispr.2020.0003.


PMID- 32833182
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Exploratory Investigation of Personal Influences on Educators' Engagement in
      Engineering Ethics and Societal Impacts Instruction.
PG  - 3143-3165
LID - 10.1007/s11948-020-00261-x [doi]
AB  - Cultivating an understanding of ethical responsibilities and the societal impacts
      of technology is increasingly recognized as an important component in
      undergraduate engineering curricula. There is growing research on how
      ethics-related topics are taught and outcomes are attained, especially in the
      context of accreditation criteria. However, there is a lack of theoretical and
      empirical understanding of the role that educators play in ethics and societal
      impacts (ESI) instruction and the factors that motivate and shape their inclusion
      of this subject in the courses they teach and co-curricular activities they
      mentor. The goal of this research was to explore the role of faculty's personal
      influences on their inclusion of ESI instruction in these settings. Personal
      influences are distinguished from external or environmental drivers such as
      teaching assignments, university policies, and department curriculum decisions.
      This research employed a grounded theory methodology and extracted data from
      interviews with 19 educators who teach ESI to engineering students to develop an 
      emergent conceptualization of personal influences. Four categorie were
      identified: intrapersonal (drawing on self-interests and beliefs), interpersonal 
      (drawing on relationships to engage in the intersectional field of ESI), academic
      (using their experiences as a student), and professional (leveraging non-academic
      work to understand the application of ESI and bring ESI into the classroom). The 
      findings suggested a wide range of entry points (based on varying interests,
      beliefs, interactions, and backgrounds) into ESI instruction for faculty members 
      who do not currently teach ESI and for those looking to expand the inclusion of
      ESI in their courses. Based on these findings, departments and administrators are
      encouraged to foster educators' agency, support access to professional
      development and engagement, facilitate interdisciplinary collaboration, and
      broaden hiring decisions to account for the impact of educators' holistic
      identity on their instruction.
FAU - Polmear, Madeline
AU  - Polmear M
AUID- ORCID: 0000-0002-7774-6834
AD  - Civil and Coastal Engineering, University of Florida, Gainesville, FL, USA.
      mpolmear@ufl.edu.
FAU - Bielefeldt, Angela R
AU  - Bielefeldt AR
AD  - Civil, Environmental, and Architectural Engineering, University of Colorado,
      Boulder, CO, USA.
FAU - Knight, Daniel
AU  - Knight D
AD  - Mechanical Engineering, University of Colorado, Boulder, CO, USA.
FAU - Swan, Chris
AU  - Swan C
AD  - Civil and Environmental Engineering, Tufts University, Medford, MA, USA.
FAU - Canney, Nathan
AU  - Canney N
AD  - CYS Structural Engineers, Sacramento, CA, USA.
LA  - eng
GR  - 1540348/National Science Foundation/International
GR  - 1540341/National Science Foundation/International
GR  - 1540308/National Science Foundation/International
GR  - 1755390/National Science Foundation/International
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200824
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Curriculum
MH  - *Engineering
MH  - Humans
MH  - Morals
MH  - Students
MH  - Teaching
OTO - NOTNLM
OT  - *Engineering ethics
OT  - *Faculty
OT  - *Instruction
OT  - *Qualitative
OT  - *Teaching
EDAT- 2020/08/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/25 06:00
PHST- 2019/09/01 00:00 [received]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1007/s11948-020-00261-x [doi]
AID - 10.1007/s11948-020-00261-x [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3143-3165. doi: 10.1007/s11948-020-00261-x. Epub
      2020 Aug 24.


PMID- 32833094
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20220218
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 37
IP  - 10
DP  - 2020 Aug 24
TI  - Questions asked through two examples of dilemmas of publication ethics in the
      process of COVID-19.
PG  - 86
LID - 10.1007/s12032-020-01411-8 [doi]
AB  - The COVID-19 pandemic is a kind of global disaster caused by the new
      coronavirus-19, the SARS-CoV-2 virus. Since the first eruption of this pandemic, 
      which adversely affected the world in many ways, a large number of publications
      have been presented to the world of science. In this article, possible
      publication ethical dilemmas related to scientific articles increasing in number 
      during the COVID-19 pandemic were tried to be reminded through two examples of
      articles.
FAU - Tanriverdi, Ozgur
AU  - Tanriverdi O
AUID- ORCID: http://orcid.org/0000-0002-0598-7284
AD  - Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman
      University, Mugla Universitesi Egitim Ve Arastirma Hastanesi, Onkoloji
      Poliklinigi, 48000, Mugla, Turkey. dr.ozgur.tanriverdi@gmail.com.
AD  - Department of Molecular Biology and Genetics, Graduate School of Natural and
      Applied Sciences, Mugla Sitki Kocman University, Mugla, Turkey.
      dr.ozgur.tanriverdi@gmail.com.
AD  - Department of Elderly Health, Faculty of Health Science, Mugla Sitki Kocman
      University, Mugla, Turkey. dr.ozgur.tanriverdi@gmail.com.
FAU - Ozcan, Muesser
AU  - Ozcan M
AD  - Department of Elderly Health, Faculty of Health Science, Mugla Sitki Kocman
      University, Mugla, Turkey.
AD  - Deparment of Medicine History and Ethics, Faculty of Medicine, Mugla Sitki Kocman
      University, Mugla, Turkey.
LA  - eng
PT  - Letter
DEP - 20200824
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiovascular Diseases/drug therapy/mortality
MH  - Coronavirus Infections/drug therapy/mortality
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - Pandemics/*ethics
MH  - Periodicals as Topic/*ethics
MH  - Pneumonia, Viral/drug therapy/mortality
MH  - *Publication Bias
MH  - SARS-CoV-2
PMC - PMC7444445
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - Publishing ethics
OT  - SARS-Cov-2
OT  - Scientific articles
EDAT- 2020/08/25 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/07/18 00:00 [received]
PHST- 2020/08/14 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - 10.1007/s12032-020-01411-8 [doi]
AID - 10.1007/s12032-020-01411-8 [pii]
PST - epublish
SO  - Med Oncol. 2020 Aug 24;37(10):86. doi: 10.1007/s12032-020-01411-8.


PMID- 32832926
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2032-0418 (Print)
IS  - 2032-0418 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Aug 5
TI  - Getting back to business: considerations for restarting non-cancer gynaecological
      surgery following the COVID-19 peak.
PG  - 119-127
AB  - As we begin to pass the first peak of the coronavirus pandemic, the backlog of
      routine gynaecological surgical work is becoming more apparent and continues to
      build day by day. The potential for further pandemic surges remain; however it is
      imperative that elective gynaecological surgery is restored safely, ethically and
      in a timely manner. The risks of COVID-19 transmission and potential increased
      surgical morbidity must be weighed up against the patient's ongoing symptoms and 
      quality of life. Universal screening and testing of patients attending for
      routine surgery, as well as staff testing and retesting, will be fundamental to
      reducing the risks to both patients and staff, and avoiding the higher morbidity 
      encountered when operating on asymptomatic infected patients. The aim of this
      paper is to explore pathways to safely reintroduce elective benign gynaecological
      surgery and the challenges that will be encountered including patient counselling
      and informed consent, surgical prioritisation and the screening and testing of
      patients and staff, as well as the logistical and ethical challenges of
      reintroducing benign surgery during COVID-19 times.
CI  - Copyright (c) 2020 Facts, Views & Vision.
FAU - Odejinmi, F
AU  - Odejinmi F
AD  - Whipps Cross Hospital, Barts Health NHS Trust, Whipps Cross Road, Leytonstone,
      London, United Kingdom.
FAU - Clark, T J
AU  - Clark TJ
AD  - Department of Obstetrics and Gynaecology, Birmingham Women's and Children's
      Hospital, Birmingham, United Kingdom.
FAU - Mallick, R
AU  - Mallick R
AD  - Princess Royal Hospital, Brighton and Sussex University Hospitals NHS Trust,
      Lewes Road, Haywards Heath, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - Belgium
TA  - Facts Views Vis Obgyn
JT  - Facts, views & vision in ObGyn
JID - 101578773
PMC - PMC7431199
OTO - NOTNLM
OT  - COVID-19
OT  - coronavirus
OT  - laparoscopy
OT  - surgery
COIS- Conflict of interest: The authors declare no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
PST - epublish
SO  - Facts Views Vis Obgyn. 2020 Aug 5;12(2):119-127.


PMID- 32832732
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2452-2473 (Print)
IS  - 2452-2473 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Jul-Sep
TI  - Critical events during intra-hospital transport of critically ill patients to and
      from intensive care unit.
PG  - 135-141
LID - 10.4103/2452-2473.290067 [doi]
AB  - OBJECTIVES: Intensive care unit (ICU) patients are at an increased risk of many
      catastrophic events during intrahospital transport (IHT) for various procedures. 
      This study was planned to determine the incidence and types of adverse events
      occurring during the transport of critically ill patients in a tertiary care
      hospital. METHODS: This prospective observational study was conducted in the ICU 
      of a tertiary care hospital for 8 months after ethical clearance from the
      institute ethics committee. All patients transported out of the ICU during the
      audit period for diagnostic or therapeutic procedures were included in the study.
      Vitals and several study parameters were recorded before, during, and after
      shifting patients to and from the ICU. Various critical events were noted during 
      transport and classified into major and minor critical events based on the
      presence and absence of potential consequences that lead to a change of therapy
      during transport. RESULTS: One hundred and sixty patients were studied for
      consecutive IHT to and from the ICU. The patients were transported for imaging
      studies (58.1%), minor surgery (31.8%), major surgery (2.5%), and other
      procedures (7.5%). A total of 248 critical events were observed in 104 IHTs (65%;
      95% confidence interval [95% CI]: 57.4%-72.1%). Hence, an average of 2.38
      critical events occurred per IHT. There were 31 major events among the 248
      critical events (12.5%; 95% CI: 8.8%-17.1%). CONCLUSIONS: Standard guidelines
      about the accompanying personnel and monitoring need to be followed during IHT.
      Conduct of minor surgical procedures in the ICU and better bedside diagnostic
      procedures may be considered for the future.
CI  - Copyright: (c) 2020 Turkish Journal of Emergency Medicine.
FAU - Parveez, Mohd Qurram
AU  - Parveez MQ
AUID- ORCID: 0000-0003-4261-5444
AD  - Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Yaddanapudi, Lakshmi Narayana
AU  - Yaddanapudi LN
AUID- ORCID: 0000-0002-9822-0217
AD  - Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Saini, Vikas
AU  - Saini V
AUID- ORCID: 0000-0003-0153-0284
AD  - Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Kajal, Kamal
AU  - Kajal K
AUID- ORCID: 0000-0003-3271-0122
AD  - Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Sharma, Ankur
AU  - Sharma A
AUID- ORCID: 0000-0001-9339-6988
AD  - Department of Trauma and Emergency (Anaesthesiology), All India Institute of
      Medical Sciences, Jodhpur, Rajasthan, India.
LA  - eng
PT  - Journal Article
DEP - 20200718
PL  - India
TA  - Turk J Emerg Med
JT  - Turkish journal of emergency medicine
JID - 101681782
PMC - PMC7416857
OTO - NOTNLM
OT  - Critical events
OT  - intensive care unit
OT  - intrahospital transport
COIS- Conflicts of interest None declared.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.4103/2452-2473.290067 [doi]
AID - TJEM-20-135 [pii]
PST - epublish
SO  - Turk J Emerg Med. 2020 Jul 18;20(3):135-141. doi: 10.4103/2452-2473.290067.
      eCollection 2020 Jul-Sep.


PMID- 32832447
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Jul-Aug
TI  - Role of Histopathology in Predicting type 1 Lepra Reaction in Borderline
      Tuberculoid Leprosy.
PG  - 586-589
LID - 10.4103/idoj.IDOJ_423_19 [doi]
AB  - CONTEXT: Lepra reactions if not managed promptly are an important cause of sudden
      onset nerve palsy and disability due to leprosy. AIM: To evaluate the usefulness 
      of histology in predicting type 1 lepra reaction. SETTING AND DESIGN: After
      obtaining clearance from institutional research and ethics committees, all
      histologically proven borderline tuberculoid patients diagnosed at our center
      from 1.8.2016 to 31.7.2018 were included in this retrospective cross-sectional
      study. METHOD: Clinical details were collected from patient records. The
      pathologist who was blinded to clinical evidence of type 1 lepra reaction at the 
      time of biopsy re-evaluated the histopathology slides for evidence of type 1
      reaction. The data of individual patient was analyzed to identify those who had a
      type 1 reaction at the time of the biopsy or who developed a lepra reaction
      during follow up. STATISTICAL ANALYSIS USED: Association between histological
      evidence of type 1 reaction and clinical manifestation of the same subsequently, 
      was assessed using Pearson's Chi square test. RESULTS: Study group comprised of
      22 females and 18 males. Clinicohistological concordance was noted in 27 patients
      (67.5%). Subclinical type 1 reaction was documented in 11 patients (27.5%) based 
      on histopathology evaluation. Five (45.5%) of these 11 patients subsequently
      developed clinical features of type 1 reaction. This was found to be
      statistically significant (P value 0.02). LIMITATIONS: Main limitation was the
      small sample size. CONCLUSIONS: Histology could serve as a useful tool in
      predicting future type 1 lepra reaction.
CI  - Copyright: (c) 2020 Indian Dermatology Online Journal.
FAU - Sankaran, Dhanya
AU  - Sankaran D
AD  - Department of Dermatology and Venereology, Govt. Medical College, Kozhikode,
      Kerala, India.
FAU - Sasidharanpillai, Sarita
AU  - Sasidharanpillai S
AD  - Department of Dermatology and Venereology, Govt. Medical College, Kozhikode,
      Kerala, India.
FAU - Ajithkumar, Kidangazhiyathmana
AU  - Ajithkumar K
AD  - Department of Dermatology and Venereology, Govt. Medical College, Thrissur,
      Kerala, India.
FAU - Govindan, Aparna
AU  - Govindan A
AD  - Department of Pathology, Govt. Medical College, Kozhikode, Kerala, India.
FAU - Seemi, Ekkila Valappil
AU  - Seemi EV
AD  - Department of Dermatology and Venereology, Govt. Medical College, Kozhikode,
      Kerala, India.
FAU - Sathi, Puthen Parambath
AU  - Sathi PP
AD  - Department of Pathology, Govt. Medical College, Kozhikode, Kerala, India.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC7413463
OTO - NOTNLM
OT  - Histopathology
OT  - leprosy
OT  - type 1 lepra reaction
COIS- There are no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/08/27 00:00 [received]
PHST- 2019/11/06 00:00 [revised]
PHST- 2019/12/02 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.4103/idoj.IDOJ_423_19 [doi]
AID - IDOJ-11-586 [pii]
PST - epublish
SO  - Indian Dermatol Online J. 2020 Jul 13;11(4):586-589. doi:
      10.4103/idoj.IDOJ_423_19. eCollection 2020 Jul-Aug.


PMID- 32832425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201024
IS  - 2231-0770 (Print)
IS  - 2231-0770 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jul-Sep
TI  - Ethical dilemmas in the era of COVID-19.
PG  - 102-105
LID - 10.4103/ajm.ajm_119_20 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic placed an extraordinary demand
      on health systems and healthcare providers all over the world. The pandemic
      presented a number of unprecedented challenging ethical issues. Across the globe,
      hospitals are being challenged by a large number of patients presenting to the
      emergency room for treatment, creating scarcities of critical care resources, and
      uncovering the need for formal crisis standards of care. Difficult life and death
      decisions, which may create severe moral distress to the physicians, have to be
      made in emergency rooms and intensive care units. Other ethical issues, such as
      that related to conducting clinical trials during the pandemic, and the increase 
      in domestic violence during the quarantine period, will be also discussed.
CI  - Copyright: (c) 2020 Avicenna Journal of Medicine.
FAU - Chamsi-Pasha, Hassan
AU  - Chamsi-Pasha H
AD  - Department of Cardiology, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.
FAU - Chamsi-Pasha, Majed
AU  - Chamsi-Pasha M
AD  - Department of Medicine, International Medical Center, Jeddah, Saudi-Arabia.
FAU - Albar, Mohammed A
AU  - Albar MA
AD  - Department of Medical Ethics, International Medical Center, Jeddah, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200703
PL  - Germany
TA  - Avicenna J Med
JT  - Avicenna journal of medicine
JID - 101584155
PMC - PMC7414603
OTO - NOTNLM
OT  - Coronavirus disease 2019
OT  - ethical challenges
OT  - medical ethics
OT  - scarce resources
COIS- There are no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.4103/ajm.ajm_119_20 [doi]
AID - AJM-10-102 [pii]
PST - epublish
SO  - Avicenna J Med. 2020 Jul 3;10(3):102-105. doi: 10.4103/ajm.ajm_119_20.
      eCollection 2020 Jul-Sep.


PMID- 32832209
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211120
IS  - 2164-2591 (Print)
IS  - 2164-2591 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jun
TI  - Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from
      the Second Monaciano Symposium.
PG  - 2
LID - 10.1167/tvst.9.7.2 [doi]
AB  - Major advances in the study of inherited retinal diseases (IRDs) have placed
      efforts to develop treatments for these blinding conditions at the forefront of
      the emerging field of precision medicine. As a result, the growth of clinical
      trials for IRDs has increased rapidly over the past decade and is expected to
      further accelerate as more therapeutic possibilities emerge and qualified
      participants are identified. Although guided by established principles, these
      specialized trials, requiring analysis of novel outcome measures and endpoints in
      small patient populations, present multiple challenges relative to study design
      and ethical considerations. This position paper reviews recent accomplishments
      and existing challenges in clinical trials for IRDs and presents a set of
      recommendations aimed at rapidly advancing future progress. The goal is to
      stimulate discussions among researchers, funding agencies, industry, and policy
      makers that will further the design, conduct, and analysis of clinical trials
      needed to accelerate the approval of effective treatments for IRDs, while
      promoting advocacy and ensuring patient safety.
CI  - Copyright 2020 The Authors.
FAU - Thompson, Debra A
AU  - Thompson DA
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Iannaccone, Alessandro
AU  - Iannaccone A
AD  - Department of Ophthalmology, Duke Eye Center, Duke University Medical Center,
      Durham, NC, USA.
FAU - Ali, Robin R
AU  - Ali RR
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
AD  - Institute of Ophthalmology, University College London, London, UK.
FAU - Arshavsky, Vadim Y
AU  - Arshavsky VY
AD  - Department of Ophthalmology, Duke Eye Center, Duke University Medical Center,
      Durham, NC, USA.
FAU - Audo, Isabelle
AU  - Audo I
AD  - Sorbonne Universite, Institut de la Vision, INSERM, CNRS, Paris, France.
AD  - CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, Paris, France.
FAU - Bainbridge, James W B
AU  - Bainbridge JWB
AD  - Institute of Ophthalmology, University College London, London, UK.
FAU - Besirli, Cagri G
AU  - Besirli CG
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Birch, David G
AU  - Birch DG
AD  - Retina Foundation of the Southwest, Dallas, TX, USA.
FAU - Branham, Kari E
AU  - Branham KE
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Cideciyan, Artur V
AU  - Cideciyan AV
AD  - Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA, USA.
FAU - Daiger, Steven P
AU  - Daiger SP
AD  - Human Genetics Center, School of Public Health, University of Texas Health
      Science Center Houston, Houston, TX, USA.
FAU - Dalkara, Deniz
AU  - Dalkara D
AD  - Sorbonne Universite, Institut de la Vision, INSERM, CNRS, Paris, France.
FAU - Duncan, Jacque L
AU  - Duncan JL
AD  - Department of Ophthalmology, University of California-San Francisco, San
      Francisco, CA, USA.
FAU - Fahim, Abigail T
AU  - Fahim AT
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Flannery, John G
AU  - Flannery JG
AD  - Helen Wills Neuroscience Institute, University of California-Berkeley, Berkeley, 
      CA, USA.
FAU - Gattegna, Roberto
AU  - Gattegna R
AD  - Retina Service, Israelitic Hospital, Roma, Italy.
FAU - Heckenlively, John R
AU  - Heckenlively JR
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Heon, Elise
AU  - Heon E
AD  - Department of Ophthalmology and Vision Sciences, Hospital for Sick Children,
      Toronto, Ontario, Canada.
FAU - Jayasundera, K Thiran
AU  - Jayasundera KT
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Khan, Naheed W
AU  - Khan NW
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Klassen, Henry
AU  - Klassen H
AD  - Gavin Herbert Eye Institute, Stem Cell Research Center, University of
      California-Irvine, Irvine, CA, USA.
FAU - Leroy, Bart P
AU  - Leroy BP
AD  - Department of Ophthalmology and Center Medical Genetics, Ghent University
      Hospital and University, Ghent, Belgium.
AD  - Division of Ophthalmology and Center for Cellular and Molecular Therapeutics,
      Children's Hospital of Philadelphia, Philadelphia, PA, USA.
FAU - Molday, Robert S
AU  - Molday RS
AD  - Department of Biochemistry/Molecular Biology, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Musch, David C
AU  - Musch DC
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Pennesi, Mark E
AU  - Pennesi ME
AD  - Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science
      Center, Portland, OR, USA.
FAU - Petersen-Jones, Simon M
AU  - Petersen-Jones SM
AD  - Small Animal Clinical Sciences, Michigan State University, College of Veterinary 
      Medicine, East Lansing, MI, USA.
FAU - Pierce, Eric A
AU  - Pierce EA
AD  - Ocular Genomics Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical
      School, Boston, MA, USA.
FAU - Rao, Rajesh C
AU  - Rao RC
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Reh, Thomas A
AU  - Reh TA
AD  - Department of Biological Structure, University of Washington, Seattle, WA, USA.
FAU - Sahel, Jose A
AU  - Sahel JA
AD  - Sorbonne Universite, Institut de la Vision, INSERM, CNRS, Paris, France.
AD  - CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, Paris, France.
AD  - Fondation Ophtalmologique Rothschild, Paris, France.
AD  - Department of Ophthalmology, University of Pittsburgh School of Medicine,
      Pittsburgh, PA, USA.
FAU - Sharon, Dror
AU  - Sharon D
AD  - Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The
      Hebrew University of Jerusalem, Jerusalem, Israel.
FAU - Sieving, Paul A
AU  - Sieving PA
AD  - Department of Ophthalmology and Center for Ocular Regenerative Therapy,
      University of California-Davis School of Medicine, Sacramento, CA, USA.
AD  - National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
FAU - Strettoi, Enrica
AU  - Strettoi E
AD  - Institute of Neuroscience, National Research Council (CNR), Pisa, Italy.
FAU - Yang, Paul
AU  - Yang P
AD  - Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science
      Center, Portland, OR, USA.
FAU - Zacks, David N
AU  - Zacks DN
AD  - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University
      of Michigan Medical School, Ann Arbor, MI, USA.
CN  - Monaciano Consortium
LA  - eng
GR  - R01 EY009076/EY/NEI NIH HHS/United States
GR  - MR/T002735/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/M015815/1/MRC_/Medical Research Council/United Kingdom
GR  - K08 EY026650/EY/NEI NIH HHS/United States
GR  - K23 EY026985/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200603
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
MH  - Humans
MH  - Precision Medicine
MH  - Retina
MH  - *Retinal Diseases/drug therapy
PMC - PMC7414644
OTO - NOTNLM
OT  - *clinical trials
OT  - *counseling patients
OT  - *inherited retinal diseases
OT  - *natural history studies
OT  - *outcome measures
COIS- Disclosure: D.A. Thompson, MeiraGTx (F), filed patent on gene therapy (P); A.
      Iannaccone, Editas Medicine (C), Astellas (C), Roivant Pharma (C), IQVIA (C),
      Gyroscope/Orbit Biomedical (C), Rhythm Pharmaceuticals (C), Applied Genetic
      Technologies Corp (F), Allergan (F), Acucela (F), ProQR Therapeutics (F),
      Foundation Fighting Blindness Clinical Research Institute (F), Alia Therapeutics 
      (S); R.R. Ali, MeiraGTx (S), filed patents on gene and cell therapies (P); V.Y.
      Arshavsky, None; I. Audo, None; J.W.B. Bainbridge, MeiraGTx (S), filed patents on
      gene and cell therapies (P); C.G. Besirli, MeiraGTx (F), Spark Therapeutics (F); 
      D.G. Birch, Nightstar Therapeutics/Biogen (C), Applied Genetic Technologies Corp 
      (S), Nacuity Pharmaceuticals (C), Editas Medicine (C), Acucela (S), Foundation
      Fighting Blindness (C), ProQR Therapeutics (C); K.E. Branham, ProQR Therapeutics 
      (C); A.V. Cideciyan, Patents on gene therapies for RPGR, RHO, and
      NPHP5-associated IRDs (P); ProQR Therapeutics (F), IVERIC bio (F); S.P. Daiger,
      Applied Genetic Technologies Corp (S); D. Dalkara, Patent on AAV virions with
      variant capsid and methods of use (P); J.L. Duncan, 4D Therapeutics (C), Applied 
      Genetic Technologies Corp (C), Editas Medicine (C), Gyroscope (C), Horama (C),
      Nightstar Therapeutics/Biogen (C), ProQR Therapeutics (C), SparingVision (S),
      Spark Therapeutics (C), Vedere Bio (C), Acucela (F), Allergan (F), Neurotech (F),
      Second Sight Medical Products (F); A.T. Fahim, None; J.G. Flannery, None; R.
      Gattegna, None; J.R. Heckenlively, None; E. Heon, None; K.T. Jayasundera, Editas 
      Medicine (C); N.W. Khan, None; H. Klassen, jCyte (S, I); B.P. Leroy, Bayer (C),
      Nightstar Therapeutics/Biogen (C), IVERIC bio (C), Novartis Pharma (C), RegenX
      Bio (C), Vedere Bio (C); Novartis (R), Spark Therapeutics (R); GenSight Biologics
      (F), ProQR Therapeutics (F); R.S. Molday, Applied Genetic Technologies Corp (S); 
      D.C. Musch, Belite Bio (S), Mactel Group NTMT-03 trial (S), NEI intramural branch
      clinical trials (S); M.E. Pennesi, Adverum (C), Allergan (C), Astellas (C),
      Pharmaceuticals (C), Biogen (C), IVERIC bio (C), Novartis (C), Regenix Bio (C),
      Spark Therapeutics (C), Wave Biosciences (C), Eyevensys (S), Horama (S), Nayan
      (S), Nacuity Pharmaceuticals (S, I), Ocugen (S, I), Verede (S), ProQR
      Therapeutics (S), Gensight (S), Applied Genetic Technologies Corp (F), Sanofi
      (F), Foundation Fighting Blindness (F), ProQR Therapeutics (F), Allergan (F);
      S.M. Petersen-Jones, None; E.A. Pierce, Astellas (C), Merck (C), Sanofi-Genzyme
      (C), Wave Therapeutics (C); GenSight Biologics (S), Odylia Therapeutics (S),
      Opsis Therapeutics (S), Sana Biotechnology (S); CRISPR Therapeutics (F), Spark
      Therapeutics (F); Editas Medicine (F), MeiraGTx (F), ProQR Therapeutics (F),
      filed patents on gene and genetic therapies (P); R.C. Rao, None; T.A. Reh, Nayan 
      Pharmaceuticals (C, I); J.A. Sahel, Pixium Vision (S, I), GenSight Biologics (S, 
      I), SparingVision (S, I); Prophesee (I), Chronolife (I); D. Sharon, None; P.A.
      Sieving, None; E. Strettoi, None; P. Yang, Astellas (C), Applied Genetic
      Technologies Corp (C); D.N. Zacks, ONL Therapeutics (C, I, P)
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/11/30 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.1167/tvst.9.7.2 [doi]
AID - TVST-19-2146 [pii]
PST - epublish
SO  - Transl Vis Sci Technol. 2020 Jun 3;9(7):2. doi: 10.1167/tvst.9.7.2. eCollection
      2020 Jun.


PMID- 32832125
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1608-9685 (Print)
IS  - 1608-9685 (Linking)
VI  - 26
DP  - 2020
TI  - Prevalence and perception of drug use amongst secondary school students in two
      local government areas of Lagos State, Nigeria.
PG  - 1428
LID - 10.4102/sajpsychiatry.v26i0.1428 [doi]
AB  - BACKGROUND: Drug abuse, an excessive and persistent self-administration of a drug
      without regard to the medically or culturally accepted patterns, has been
      reported amongst teenagers and adolescents in various regions of the world. AIM: 
      This study aimed to measure the prevalence of drug use amongst students of junior
      and senior secondary schools (aged 10-15 years). SETTING: This study was
      conducted at two local government areas in Lagos State. METHODS: The
      cross-sectional study was carried out in Ikotun or Igando local council
      development area (LCDA) and Ikoyi LCDA of Lagos State. Students were sampled
      using stratified random sampling with classes as strata and sampling performed by
      balloting. The modified WHO Model Drug Use Survey Questionnaire was distributed
      to the students for self-reporting. Ethical approval was received from district
      school boards. RESULTS: A total of 1048 students participated in the survey. In
      this study, alcohol had the highest lifetime drug prevalence rate (29.1%),
      followed by pharmaceutical opioids (9%). Gender, educational level, type of
      school management, and geographical economic distribution were found to be
      predictors of prevalence of drug use. This study demonstrated significant
      differences in the prevalence of tobacco and opioids use among students in
      private and public schools; and documented statistically significant differences 
      in the prevalence of cocaine use between low income and high-income areas in two 
      LCDAs in Lagos, Nigeria. CONCLUSION: Prevalence of lifetime, recent use, and
      current use of drugs among secondary school students in two LCDAs located in
      Lagos State, Nigeria were documented with alcohol as the drug with the highest
      prevalence.
CI  - (c) 2020. The Authors.
FAU - Soremekun, Rebecca O
AU  - Soremekun RO
AUID- ORCID: https://orcid.org/0000-0002-2997-666X
AD  - Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University 
      of Lagos, Lagos, Nigeria.
FAU - Folorunso, Bukola O
AU  - Folorunso BO
AUID- ORCID: https://orcid.org/0000-0003-2647-5541
AD  - HealthMaps Pharmacy, Lagos, Nigeria.
FAU - Adeyemi, Oluwatosin C
AU  - Adeyemi OC
AUID- ORCID: https://orcid.org/0000-0003-3358-1430
AD  - Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University 
      of Lagos, Lagos, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - South Africa
TA  - S Afr J Psychiatr
JT  - The South African journal of psychiatry : SAJP : the journal of the Society of
      Psychiatrists of South Africa
JID - 100958626
PMC - PMC7433233
OTO - NOTNLM
OT  - alcohol
OT  - drug abuse
OT  - non-medical drug use
OT  - opioid
OT  - prevalence
OT  - youth
COIS- The authors have declared that no competing interest exists.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2019/07/13 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.4102/sajpsychiatry.v26i0.1428 [doi]
AID - SAJPsy-26-1428 [pii]
PST - epublish
SO  - S Afr J Psychiatr. 2020 Jul 28;26:1428. doi: 10.4102/sajpsychiatry.v26i0.1428.
      eCollection 2020.


PMID- 32831559
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1319-1683 (Print)
IS  - 1319-1683 (Linking)
VI  - 27
IP  - 2
DP  - 2020 May-Aug
TI  - Prevalence of sleep deprivation and its effect on the performance of family
      medicine residents in Riyadh, Saudi Arabia.
PG  - 125-130
LID - 10.4103/jfcm.JFCM_9_20 [doi]
AB  - BACKGROUND: A good night sleep is essential for good health since it supports
      proper brain functions and its ability to make decisions and to learn and
      remember new information. The objectives of this study were to assess the
      prevalence of sleep deprivation (SD) and its effects on the performance of family
      medicine residents in Riyadh. MATERIALS AND METHODS: A cross-sectional study
      design was based on an informative-validated self-assessment questionnaire,
      especially designed by the Medical Council of Canada, to assess the performance
      of family medicine physicians. Ethical approval was obtained from the
      institutional review board. Data was analysed using SPSS; initial analysis
      included computating frequencies and percentages. Odds ratios were calculated for
      association between. RESULTS: Of the total 258 respondents, 32% had low
      performance, and 41.5% of the sample suffered from SD, with a male/female ratio
      of 1:1. There were no significant differences between residency level (R1, R2,
      R3, and R4) and the average number of sleeping hours. However, 45.5% of R1, 47.8%
      of R2, 32.4% of R3, and 41.5% of R4 suffered from SD. The data showed a
      significant difference between the performance and the average number of hours of
      sleep of the respondents on a typical day. SD was associated with the low
      performance of 48.6% of subjects compared to 18.3% in those who slept for 7-9 h
      (aOR=3.96). CONCLUSION: SD negatively affects the performance of family medicine 
      residents. There was no statistically significant difference between males and
      females in performance. The center for residents' training should consider
      adequate sleep as essential for the promotion of health and performance.
CI  - Copyright: (c) 2020 Journal of Family and Community Medicine.
FAU - Alrishan, Mohammed A
AU  - Alrishan MA
AD  - Department of Family and Community Medicine, College of Medicine, King Saud
      University, Riyadh, Saudi Arabia.
FAU - Alshammari, Sulaiman A
AU  - Alshammari SA
AD  - Department of Family and Community Medicine, College of Medicine, King Saud
      University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - India
TA  - J Family Community Med
JT  - Journal of family & community medicine
JID - 100911100
PMC - PMC7415268
OTO - NOTNLM
OT  - Deprivation
OT  - medical
OT  - residents
OT  - sleep
COIS- There are no conflicts of interest.
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - 10.4103/jfcm.JFCM_9_20 [doi]
AID - JFCM-27-125 [pii]
PST - ppublish
SO  - J Family Community Med. 2020 May-Aug;27(2):125-130. doi: 10.4103/jfcm.JFCM_9_20. 
      Epub 2020 Jun 3.


PMID- 32831320
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20211206
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 156
IP  - 4
DP  - 2020
TI  - Mechanical ventilator as a shared resource for the COVID-19 pandemic.
PG  - 306-310
LID - 10.24875/GMM.20000352 [doi]
AB  - COVID-19, the causative agent of which is a new type of coronavirus called
      SARS-CoV-2, has caused the most severe pandemic in the last 100 years. The
      condition is mainly respiratory, and up to 5% of patients develop critical
      illness, a situation that has put enormous pressure on the health systems of
      affected countries. A high demand for care has mainly been observed in intensive 
      care units and critical care resources, which is why the need to redistribute
      resources in critical medicine emerged, with an emphasis on distributive justice,
      which establishes the provision of care to the largest number of people and
      saving the largest number of lives. One principle lies in allocating resources to
      patients with higher life expectancy. Mechanical ventilator has been assumed to
      be an indivisible asset; however, simultaneous mechanical ventilation to more
      than one patient with COVID-19 is technically possible. Ventilator sharing is not
      without risks, but the principles of beneficence, non-maleficence and justice
      prevail. According to distributive justice, being a divisible resource,
      mechanical ventilator can be shared; however, we should ask ourselves if this
      action is ethically correct.
CI  - Copyright: (c) 2020 Permanyer.
FAU - Vazquez-de Anda, Gilberto F
AU  - Vazquez-de Anda GF
AD  - Universidad Autonoma del Estado de Mexico, Estado de Mexico, Mexico.
FAU - Ruiz-de Chavez, Manuel
AU  - Ruiz-de Chavez M
AD  - Academia Nacional de Medicina de Mexico, Ciudad de Mexico, Mexico.
FAU - Perez-Castaneda, Ana I
AU  - Perez-Castaneda AI
AD  - Universidad Autonoma del Estado de Mexico, Facultad de Psicologia, Estado de
      Mexico, Mexico.
FAU - Vazquez-Moreno, Pamela
AU  - Vazquez-Moreno P
AD  - Instituto Tecnologico de Estudios Superiores de Monterrey, Escuela de Ciencias
      Sociales y Gobierno, Nuevo Leon, Mexico.
FAU - Davila-Fernandez, Juan C
AU  - Davila-Fernandez JC
AD  - Instituto Mexicano del Seguro Social, Hospital General de Zona 1, Unidad de
      Cuidados Intensivos, Oaxaca, Mexico.
FAU - Delaye-Aguilar, Ma Guadalupe
AU  - Delaye-Aguilar MG
AD  - Universidad Autonoma del Estado de Mexico, Facultad de Humanidades, Estado de
      Mexico. Mexico.
LA  - eng
PT  - Journal Article
TT  - El ventilador mecanico como recurso divisible ante la pandemia de COVID-19.
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
SB  - IM
CIN - Gac Med Mex. 2020;156(5):477. PMID: 33372935
CIN - Gac Med Mex. 2021;157(2):212. PMID: 34270537
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/physiopathology/*therapy
MH  - Critical Care/*methods
MH  - Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/physiopathology/*therapy
MH  - Respiration, Artificial/*statistics & numerical data
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Bioethics
OT  - Bioetica
OT  - COVID-19
OT  - Mechanical ventilator
OT  - Pandemia
OT  - Pandemic
OT  - SARS-COV-2
OT  - Ventilacion mecanica
EDAT- 2020/08/25 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - j156/4/306 [pii]
AID - 10.24875/GMM.20000352 [doi]
PST - ppublish
SO  - Gac Med Mex. 2020;156(4):306-310. doi: 10.24875/GMM.20000352.


PMID- 32831183
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 24
TI  - Specialized Nutritious Food Combined With Cash Transfers and Social and Behavior 
      Change Communication to Prevent Stunting Among Children Aged 6 to 23 Months in
      Pakistan: Protocol for a Cluster Randomized Controlled Trial.
PG  - e19001
LID - 10.2196/19001 [doi]
AB  - BACKGROUND: In Pakistan, the prevalence of stunting in children younger than 5
      years has remained above global critical levels over the past two decades, with
      the stunting rate being 40.2% in 2018. Children living in rural areas and in the 
      poorest households suffer the most from stunting across the country-43.2% in
      rural areas and 51.4% in the lowest wealth quintile. As a continuing public
      health concern, it is essential that stunting prevention is a national priority
      in order to ensure human capital development, especially among the poorest
      households. OBJECTIVE: The primary objective of this study is to determine the
      effect of a medium quantity of a lipid-based nutrient supplement (LNS) combined
      with unconditional cash transfers and social and behavior change communication
      (SBCC) on reduction of stunting in children aged 6 to 23 months. METHODS: A 5-arm
      cluster randomized controlled trial will be conducted in the district of Rahim
      Yar Khan in Punjab, Pakistan. The intervention packages will be (1) cash only,
      (2) cash with LNS, (3) cash with SBCC, and (4) cash with SBCC and LNS. The
      control arm will receive routine standard of care. We will enroll children at 6
      months of age and follow up on a monthly basis up to 24 months of age. A total of
      2000 children, 400 in each arm, will be enrolled to detect a 20% reduction in the
      prevalence of stunting among children aged 24 months. Length, weight, food
      intake, compliance to interventions, morbidities, and other relevant data will be
      collected at enrollment and on a monthly basis over the period of 18 months. The 
      process evaluation will assess acceptability of the interventions and potential
      barriers to implementation through focus group discussions and in-depth
      interviews with the target population and relevant stakeholders. Furthermore, a
      cost analysis will be conducted to assess the cost-effectiveness of each
      intervention package. RESULTS: The study protocol was approved by the Ethics
      Review Committee of Aga Khan University in Pakistan on January 4, 2017. Data
      collection began in May 2017 and was completed in July 2019. Data analyses are
      yet to be completed. This study will explore the effectiveness of intervention
      packages comprised of cash transfers from Benazir Income Support Programme with
      or without additional LNS and SBCC in preventing childhood stunting. We expect
      the results to be published in peer-reviewed journals by autumn of 2020.
      CONCLUSIONS: The findings of this trial will provide robust evidence as to which 
      intervention packages can have significant effects on linear growth of children
      and design effective intervention packages to prevent stunting in children aged 6
      to 23 months. TRIAL REGISTRATION: ClinicalTrials.gov NCT03299218;
      https://clinicaltrials.gov/ct2/show/NCT03299218. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/19001.
CI  - (c)Gul Nawaz Khan, Sumra Kureishy, Shabina Ariff, Muhammad Atif Habib, Asra Abeer
      Usmani, Areeba Mubarik, Masawar Hussain, Naveed Akbar, Pablo Rodriguez de Castro,
      Alba Cecilia Garzon, Saskia de Pee, Sajid Bashir Soofi. Originally published in
      JMIR Research Protocols (http://www.researchprotocols.org), 24.08.2020.
FAU - Khan, Gul Nawaz
AU  - Khan GN
AUID- ORCID: https://orcid.org/0000-0002-2466-1693
AD  - Department of Paediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Kureishy, Sumra
AU  - Kureishy S
AUID- ORCID: https://orcid.org/0000-0002-8411-1028
AD  - World Food Programme, Islamabad, Pakistan.
FAU - Ariff, Shabina
AU  - Ariff S
AUID- ORCID: https://orcid.org/0000-0002-9627-2662
AD  - Department of Paediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Habib, Muhammad Atif
AU  - Habib MA
AUID- ORCID: https://orcid.org/0000-0002-6575-9195
AD  - Department of Paediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Usmani, Asra Abeer
AU  - Usmani AA
AUID- ORCID: https://orcid.org/0000-0002-5468-0350
AD  - Medical College, Aga Khan University, Karachi, Pakistan.
FAU - Mubarik, Areeba
AU  - Mubarik A
AUID- ORCID: https://orcid.org/0000-0003-0252-4767
AD  - Medical College, Aga Khan University, Karachi, Pakistan.
FAU - Hussain, Masawar
AU  - Hussain M
AUID- ORCID: https://orcid.org/0000-0001-9449-4467
AD  - Department of Paediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Akbar, Naveed
AU  - Akbar N
AUID- ORCID: https://orcid.org/0000-0002-5208-4686
AD  - Benazir Income Support Programme, Government of Pakistan, Islamabad, Pakistan.
FAU - Rodriguez de Castro, Pablo
AU  - Rodriguez de Castro P
AUID- ORCID: https://orcid.org/0000-0002-6320-8680
AD  - World Food Programme, Islamabad, Pakistan.
FAU - Garzon, Alba Cecilia
AU  - Garzon AC
AUID- ORCID: https://orcid.org/0000-0002-3237-5742
AD  - World Food Programme, Islamabad, Pakistan.
FAU - de Pee, Saskia
AU  - de Pee S
AUID- ORCID: https://orcid.org/0000-0002-0138-7118
AD  - World Food Programme, Rome, Italy.
FAU - Soofi, Sajid Bashir
AU  - Soofi SB
AUID- ORCID: https://orcid.org/0000-0003-4192-8406
AD  - Department of Paediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
LA  - eng
SI  - ClinicalTrials.gov/NCT03299218
PT  - Journal Article
DEP - 20200824
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7477667
OTO - NOTNLM
OT  - Pakistan
OT  - cash transfers
OT  - social and behavior change communication
OT  - specialized nutritious food
OT  - stunting
EDAT- 2020/08/25 06:00
MHDA- 2020/08/25 06:01
CRDT- 2020/08/25 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/08/25 06:01 [medline]
AID - v9i8e19001 [pii]
AID - 10.2196/19001 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 24;9(8):e19001. doi: 10.2196/19001.


PMID- 32831076
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 24
TI  - Examination and diagnosis of electronic patient records and their associated
      ethics: a scoping literature review.
PG  - 76
LID - 10.1186/s12910-020-00514-1 [doi]
AB  - BACKGROUND: Electronic patient record (EPR) technology is a key enabler for
      improvements to healthcare service and management. To ensure these improvements
      and the means to achieve them are socially and ethically desirable, careful
      consideration of the ethical implications of EPRs is indicated. The purpose of
      this scoping review was to map the literature related to the ethics of EPR
      technology. The literature review was conducted to catalogue the prevalent
      ethical terms, to describe the associated ethical challenges and opportunities,
      and to identify the actors involved. By doing so, it aimed to support the future 
      development of ethics guidance in the EPR domain. METHODS: To identify journal
      articles debating the ethics of EPRs, Scopus, Web of Science, and PubMed academic
      databases were queried and yielded 123 eligible articles. The following inclusion
      criteria were applied: articles need to be in the English language; present
      normative arguments and not solely empirical research; include an abstract for
      software analysis; and discuss EPR technology. RESULTS: The medical specialty,
      type of information captured and stored in EPRs, their use and functionality
      varied widely across the included articles. Ethical terms extracted were
      categorised into clusters 'privacy', 'autonomy', 'risk/benefit', 'human
      relationships', and 'responsibility'. The literature shows that EPR-related
      ethical concerns can have both positive and negative implications, and that a
      wide variety of actors with rights and/or responsibilities regarding the safe and
      ethical adoption of the technology are involved. CONCLUSIONS: While there is
      considerable consensus in the literature regarding EPR-related ethical
      principles, some of the associated challenges and opportunities remain
      underdiscussed. For example, much of the debate is presented in a manner more in 
      keeping with a traditional model of healthcare and fails to take account of the
      multidimensional ensemble of factors at play in the EPR era and the consequent
      need to redefine/modify ethical norms to align with a digitally-enabled health
      service. Similarly, the academic discussion focuses predominantly on bioethical
      values. However, approaches from digital ethics may also be helpful to identify
      and deliberate about current and emerging EPR-related ethical concerns.
FAU - Jacquemard, Tim
AU  - Jacquemard T
AUID- ORCID: 0000-0002-3614-5020
AD  - FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, 
      123 Stephen's Green, Dublin 2, Ireland. TimJacquemard@RCSI.ie.
FAU - Doherty, Colin P
AU  - Doherty CP
AD  - FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, 
      123 Stephen's Green, Dublin 2, Ireland.
AD  - Department of Neurology, St. James's Hospital, James's Street, Dublin 8, Ireland.
AD  - Trinity College Dublin, College Green, Dublin 2, Ireland.
FAU - Fitzsimons, Mary B
AU  - Fitzsimons MB
AD  - FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, 
      123 Stephen's Green, Dublin 2, Ireland.
LA  - eng
GR  - 16/RC/3948/SFI_/Science Foundation Ireland/Ireland
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200824
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Electronic Health Records
MH  - Humans
MH  - *Privacy
PMC - PMC7446190
OTO - NOTNLM
OT  - *Applied ethics
OT  - *Electronic health records
OT  - *Electronic medical records
OT  - *Electronic patient records
OT  - *Healthcare
OT  - *Review
OT  - *eHealth
EDAT- 2020/08/25 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00514-1 [doi]
AID - 10.1186/s12910-020-00514-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 24;21(1):76. doi: 10.1186/s12910-020-00514-1.


PMID- 32831061
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 24
TI  - Protocol for expanded indications of endoscopic submucosal dissection for early
      gastric cancer in China: a multicenter, ambispective, observational, open-cohort 
      study.
PG  - 801
LID - 10.1186/s12885-020-07312-3 [doi]
AB  - BACKGROUND: The main treatment methods for early gastric cancer (EGC) include
      endoscopic submucosal dissection (ESD) and radical gastrectomy. However,
      appropriate treatment for patients who exceed the absolute indications for ESD
      remains unestablished. In China, evidence-based medicine for the expanding
      indications of ESD and accurate diagnostic staging for EGC patients are lacking. 
      Thus, clinical studies involving Chinese patients with EGC are necessary to
      select appropriate treatment options and promote China's expanded indications for
      ESD and diagnostic staging scheme. METHODS: This is a multicenter, ambispective, 
      observational, open-cohort study that is expected to enroll 554 patients with
      EGC. The study was launched in May 2018 and is scheduled to end in March 2022.
      All enrolled patients should meet the inclusion criteria. Case report forms and
      electronic data capture systems are used to obtain clinical data, which includes 
      demographic information, results of perioperative blood- and auxiliary
      examinations, surgical information, results of postoperative pathology, and the
      outcomes of postoperative recovery and follow-up. Patients are followed up every 
      6 months after surgery for a minimum of 5 years. The primary endpoint is the rate
      of lymph node metastasis (LNM), whereas the secondary endpoints include the
      following: consistency, sensitivity, and specificity of the results of
      preoperative examinations and postoperative pathology; cut-off values for LNM;
      logistic regression model of expanded indications for ESD; and incidence of
      postoperative complications within the 30-day and 5-year relapse-free survival
      rates. DISCUSSION: This study will explore and evaluate expanded indications for 
      ESD that match the characteristics of the Chinese population in patients with EGC
      and will introduce a related staging procedure and examination scheme that is
      appropriate for China. Ethical approval was obtained from all participating
      centers. The findings are expected to be disseminated through publications or
      presentations and will facilitate clinical decision-making in EGC. TRIAL
      REGISTRATION: The name of the registry is ChiCTR. It was registered on May 9,
      2018, with the registration number ( ChiCTR1800016084 ). The clinical trial was
      launched in May 2018 and will end in March 2022, with enrollment to be completed 
      by December 2021. Trial status: Ongoing.
FAU - Zheng, Zhi
AU  - Zheng Z
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
FAU - Yin, Jie
AU  - Yin J
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
FAU - Li, Ziyu
AU  - Li Z
AD  - Department of Gastrointestinal Surgery, Beijing Cancer Hospital, Beijing, China.
FAU - Ye, Yingjiang
AU  - Ye Y
AD  - Department of General Surgery, Peking University People's Hospital, Beijing,
      China.
FAU - Wei, Bo
AU  - Wei B
AD  - Department of General Surgery, Chinese PLA General Hospital, Beijing, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of General Surgery, Peking University First Hospital, Beijing, China.
FAU - Tian, Yantao
AU  - Tian Y
AD  - Department of Pancreatic and Gastric Surgery, Cancer Hospital Chinese Academy of 
      Medical Sciences, Beijing, China.
FAU - Li, Mengyi
AU  - Li M
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Clinical Epidemiology and Evidence-Based Medicine Unit, Beijing Friendship
      Hospital, Capital Medical University, Beijing, China.
FAU - Zeng, Na
AU  - Zeng N
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Clinical Epidemiology and Evidence-Based Medicine Unit, Beijing Friendship
      Hospital, Capital Medical University, Beijing, China.
FAU - Xu, Rui
AU  - Xu R
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Department of Pathology, Beijing Friendship Hospital, Capital Medical University,
      Beijing, China.
FAU - Chen, Guangyong
AU  - Chen G
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Department of General Surgery, Chinese PLA General Hospital, Beijing, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Radiology, Beijing Friendship Hospital, Capital Medical University,
      Beijing, China.
FAU - Li, Peng
AU  - Li P
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
AD  - Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical
      University, Beijing, China.
FAU - Cai, Jun
AU  - Cai J
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
FAU - Yao, Hongwei
AU  - Yao H
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
FAU - Zhang, Jun
AU  - Zhang J
AUID- ORCID: http://orcid.org/0000-0001-5411-1273
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
      zhangjun5986@ccmu.edu.cn.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China. zhangjun5986@ccmu.edu.cn.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
      zhangjun5986@ccmu.edu.cn.
AD  - Beijing Institute of Clinical Medicine, Beijing, China. zhangjun5986@ccmu.edu.cn.
FAU - Zhang, Zhongtao
AU  - Zhang Z
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical
      University, 95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
AD  - Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Beijing,
      China.
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
FAU - Zhang, Shutian
AU  - Zhang S
AD  - National Clinical Research Center for Digestive Diseases, Beijing, China.
AD  - Beijing Institute of Clinical Medicine, Beijing, China.
AD  - Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical
      University, Beijing, China.
LA  - eng
GR  - D171100006517003/Beijing Municipal Science and Technology Commission
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - China/epidemiology
MH  - Clinical Decision-Making/methods
MH  - Disease-Free Survival
MH  - Endoscopic Mucosal Resection/adverse effects/*standards
MH  - Evidence-Based Medicine/methods/standards
MH  - Female
MH  - Follow-Up Studies
MH  - Gastric Mucosa/pathology/surgery
MH  - Gastroscopy/adverse effects/*standards
MH  - Humans
MH  - Incidence
MH  - Lymphatic Metastasis/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local/*epidemiology/prevention & control
MH  - Observational Studies as Topic
MH  - Patient Selection
MH  - Postoperative Complications/*epidemiology/etiology
MH  - Practice Guidelines as Topic
MH  - Stomach Neoplasms/mortality/pathology/*surgery
MH  - Survival Rate
MH  - Young Adult
PMC - PMC7446128
OTO - NOTNLM
OT  - Chinese population
OT  - Early gastric cancer
OT  - Expanded indications for ESD
OT  - Lymph node metastasis
OT  - Staging diagnosis scheme
EDAT- 2020/08/25 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/06/15 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - 10.1186/s12885-020-07312-3 [doi]
AID - 10.1186/s12885-020-07312-3 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Aug 24;20(1):801. doi: 10.1186/s12885-020-07312-3.


PMID- 32831048
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 24
TI  - Monitoring and evaluation of breast cancer screening programmes: selecting
      candidate performance indicators.
PG  - 795
LID - 10.1186/s12885-020-07289-z [doi]
AB  - BACKGROUND: In the scope of the European Commission Initiative on Breast Cancer
      (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify
      breast cancer screening programme (BCSP) performance indicators, including their 
      acceptable and desirable levels, which are associated with breast cancer (BC)
      mortality. This paper documents the methodology used for the indicator selection.
      METHODS: The indicators were identified through a multi-stage process. First, a
      scoping review was conducted to identify existing performance indicators. Second,
      building on existing frameworks for making well-informed health care choices, a
      specific conceptual framework was developed to guide the indicator selection.
      Third, two group exercises including a rating and ranking survey were conducted
      for indicator selection using pre-determined criteria, such as: relevance,
      measurability, accurateness, ethics and understandability. The selected
      indicators were mapped onto a BC screening pathway developed by the M&E subgroup 
      to illustrate the steps of BC screening common to all EU countries. RESULTS: A
      total of 96 indicators were identified from an initial list of 1325 indicators.
      After removing redundant and irrelevant indicators and adding those missing, 39
      candidate indicators underwent the rating and ranking exercise. Based on the
      results, the M&E subgroup selected 13 indicators: screening coverage,
      participation rate, recall rate, breast cancer detection rate, invasive breast
      cancer detection rate, cancers > 20 mm, cancers </=10 mm, lymph node status,
      interval cancer rate, episode sensitivity, time interval between screening and
      first treatment, benign open surgical biopsy rate, and mastectomy rate.
      CONCLUSION: This systematic approach led to the identification of 13 BCSP
      candidate performance indicators to be further evaluated for their association
      with BC mortality.
FAU - Muratov, Sergei
AU  - Muratov S
AD  - Department of Health Research Methods, Evidence, and Impact, Faculty of Health
      Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Canelo-Aybar, Carlos
AU  - Canelo-Aybar C
AD  - Iberoamerican Cochrane Center, Instituto de Investigacion Biomedica Sant Pau (IIB
      Sant Pau-CIBERESP), Barcelona, Spain.
FAU - Tarride, Jean-Eric
AU  - Tarride JE
AD  - Department of Health Research Methods, Evidence, and Impact, Faculty of Health
      Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Alonso-Coello, Pablo
AU  - Alonso-Coello P
AD  - Iberoamerican Cochrane Center, Instituto de Investigacion Biomedica Sant Pau (IIB
      Sant Pau-CIBERESP), Barcelona, Spain.
FAU - Dimitrova, Nadya
AU  - Dimitrova N
AD  - European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, 
      Ispra, VA, Italy. Nadya.Dimitrova@ec.europa.eu.
FAU - Borisch, Bettina
AU  - Borisch B
AD  - Institute of Global Health, University of Geneva, Geneva, Switzerland.
FAU - Castells, Xavier
AU  - Castells X
AD  - IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
FAU - Duffy, Stephen W
AU  - Duffy SW
AD  - Queen Mary University of London, London, UK.
FAU - Fitzpatrick, Patricia
AU  - Fitzpatrick P
AD  - National Screening Service, Dublin, Ireland.
AD  - UCD School of Public Health, Physiotherapy & Sports Science, Dublin, Ireland.
FAU - Follmann, Markus
AU  - Follmann M
AD  - German Cancer Society, Berlin, Germany.
FAU - Giordano, Livia
AU  - Giordano L
AD  - CPO-Piedmont - AOU Citta della Salute e della Scienza, Torino, Italy.
FAU - Hofvind, Solveig
AU  - Hofvind S
AD  - Cancer Registry of Norway, Oslo, Norway.
FAU - Lebeau, Annette
AU  - Lebeau A
AD  - University Medical Center Hamburg-Eppendorf and Private Group Practice for
      Pathology, Hamburg, Germany.
FAU - Quinn, Cecily
AU  - Quinn C
AD  - St. Vincent's University Hospital, Dublin, Ireland.
FAU - Torresin, Alberto
AU  - Torresin A
AD  - ASST Grande Ospedale Metropolitano, Milan, Italy.
FAU - Vialli, Claudia
AU  - Vialli C
AD  - European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, 
      Ispra, VA, Italy.
FAU - Siesling, Sabine
AU  - Siesling S
AD  - Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
AD  - University of Twente, Enschede, Netherlands.
FAU - Ponti, Antonio
AU  - Ponti A
AD  - CPO-Piedmont - AOU Citta della Salute e della Scienza, Torino, Italy.
FAU - Giorgi Rossi, Paolo
AU  - Giorgi Rossi P
AD  - AUSL Reggio Emilia, IRCCS, Reggio Emilia, Italy.
FAU - Schunemann, Holger
AU  - Schunemann H
AD  - Department of Health Research Methods, Evidence, and Impact, Faculty of Health
      Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Nystrom, Lennarth
AU  - Nystrom L
AD  - Department of Epidemiology and Global Health, Umea University, Umea, Sweden.
FAU - Broeders, Mireille
AU  - Broeders M
AUID- ORCID: http://orcid.org/0000-0002-8741-8148
AD  - Radboud Institute of Health Sciences, Radboud University Medical Center,
      Nijmegen, Netherlands. Mireille.Broeders@radboudumc.nl.
CN  - ECIBC contributor group
LA  - eng
GR  - Not applicable/European Commission, Joint Research Centre Ispra, Italy
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Aged
MH  - Biopsy
MH  - Breast/pathology/surgery
MH  - Breast Neoplasms/*diagnosis/mortality/prevention & control/surgery
MH  - Early Detection of Cancer/standards/*statistics & numerical data
MH  - Europe/epidemiology
MH  - Female
MH  - Health Plan Implementation/*standards/statistics & numerical data
MH  - Humans
MH  - Mammography/standards/statistics & numerical data
MH  - Mass Screening/*organization & administration/standards/statistics & numerical
      data
MH  - Mastectomy/statistics & numerical data
MH  - Middle Aged
MH  - Patient Acceptance of Health Care/statistics & numerical data
MH  - Practice Guidelines as Topic
MH  - Program Evaluation
MH  - Quality Indicators, Health Care/*standards/statistics & numerical data
MH  - Time Factors
PMC - PMC7444070
OTO - NOTNLM
OT  - Breast neoplasms/diagnostic imaging*
OT  - Early detection of Cancer*/methods
OT  - Female
OT  - Health care/standards*
OT  - Mass screening/methods
OT  - Programme evaluation
OT  - Quality indicators
IR  - Autelitano M
FIR - Autelitano, Mariangela
IR  - Colzani E
FIR - Colzani, Edoardo
IR  - Danes J
FIR - Danes, Jan
IR  - Grawingholt A
FIR - Grawingholt, Axel
IR  - Ioannidou-Mouzaka L
FIR - Ioannidou-Mouzaka, Lydia
IR  - Knox S
FIR - Knox, Susan
IR  - Langendam M
FIR - Langendam, Miranda
IR  - McGarrigle H
FIR - McGarrigle, Helen
IR  - Perez Gomez E
FIR - Perez Gomez, Elsa
IR  - van Engen R
FIR - van Engen, Ruben
IR  - Warman S
FIR - Warman, Sue
IR  - Young K
FIR - Young, Kenneth
IR  - van Landsveld-Verhoeven C
FIR - van Landsveld-Verhoeven, Cary
IR  - Lerda D
FIR - Lerda, Donata
IR  - Saz-Parkinson Z
FIR - Saz-Parkinson, Zuleika
IR  - Parmelli E
FIR - Parmelli, Elena
IR  - Janusch-Roi A
FIR - Janusch-Roi, Annett
EDAT- 2020/08/25 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - 10.1186/s12885-020-07289-z [doi]
AID - 10.1186/s12885-020-07289-z [pii]
PST - epublish
SO  - BMC Cancer. 2020 Aug 24;20(1):795. doi: 10.1186/s12885-020-07289-z.


PMID- 32830118
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 23
TI  - Does non-invasive ventilation change metabolic markers in children with
      obstructive sleep apnoea? A systematic review and meta-analysis study protocol.
PG  - e039655
LID - 10.1136/bmjopen-2020-039655 [doi]
AB  - INTRODUCTION: Obstructive sleep apnoea (OSA) is not only common within
      paediatrics but is associated with critical childhood metabolic morbidity such as
      obesity, cardiovascular disease and glucose tolerance impairment. Increasing
      evidence suggests an association between childhood OSA and metabolic syndrome
      such as markers of cardiovascular disease, systemic hypertension, glucose
      intoleranceand increased lipid profile. Recent studies have targeted changes in
      metabolic markers in children using non-invasive ventilation (NIV) but no
      systematic reviews are available to summarise this emerging evidence. The purpose
      of this systematic review is to provide systematic synthesis of the evidence on
      the effect of NIV use on metabolic markers in children with OSA. METHODS AND
      ANALYSIS: A systematic search of electronic databases and grey literature will
      include paediatric interventional studies (random controlled trials, cohort
      studies) with and without a comparison group. Two reviewers will independently
      undertake the two step process of title/abstract and full-text screening. Data
      will be extracted and assessed, with aggregate data being reported. When the data
      allow, meta-analysis will be performed. ETHICS AND DISSEMINATION: There are no
      ethical concerns with this systematic review, as data have previously been
      published. This review will inform clinicians taking care of children with OSA
      and obesity/metabolic syndrome about the potential effects of NIV therapies on
      metabolic markers and has the potential to change the approach to childhood OSA
      and obesity. Results of this systematic review will be submitted for
      dissemination in abstract and manuscript form.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gerdung, Christopher
AU  - Gerdung C
AUID- ORCID: 0000-0003-0096-3993
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Stollery Children's Hospital, Edmonton, Alberta, Canada.
FAU - Rodriguez-Lopez, Sara
AU  - Rodriguez-Lopez S
AUID- ORCID: 0000-0003-0543-4855
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Stollery Children's Hospital, Edmonton, Alberta, Canada.
FAU - Palkowski, Stefan
AU  - Palkowski S
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada.
AD  - Stollery Children's Hospital, Edmonton, Alberta, Canada.
FAU - Keto-Lambert, Diana
AU  - Keto-Lambert D
AD  - Alberta Strategy for Patient-Oriented Research (SPOR) Knowledge Translation
      Platform, University of Alberta, Edmonton, Alberta, Canada.
AD  - University of Alberta Faculty of Medicine and Dentistry Department of Pediatrics,
      Edmonton, Alberta, Canada.
FAU - Sebastianski, Meghan
AU  - Sebastianski M
AD  - Alberta Strategy for Patient-Oriented Research (SPOR) Knowledge Translation
      Platform, University of Alberta, Edmonton, Alberta, Canada.
AD  - University of Alberta Faculty of Medicine and Dentistry Department of Pediatrics,
      Edmonton, Alberta, Canada.
FAU - Castro Codesal, Maria Luisa
AU  - Castro Codesal ML
AUID- ORCID: 0000-0002-1079-2502
AD  - Pediatrics, University of Alberta Faculty of Medicine and Dentistry, Edmonton,
      Alberta, Canada castroco@ualberta.ca.
AD  - Stollery Children's Hospital, Edmonton, Alberta, Canada.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200823
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiovascular Diseases
MH  - Child
MH  - Humans
MH  - *Hypertension
MH  - Meta-Analysis as Topic
MH  - *Noninvasive Ventilation
MH  - Obesity
MH  - *Sleep Apnea, Obstructive/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7445331
OTO - NOTNLM
OT  - *other metabolic, e.g. iron, porphyria
OT  - *paediatric cardiology
OT  - *paediatric endocrinology
OT  - *paediatric thoracic medicine
OT  - *sleep medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039655 [pii]
AID - 10.1136/bmjopen-2020-039655 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 23;10(8):e039655. doi: 10.1136/bmjopen-2020-039655.


PMID- 32830115
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 23
TI  - Adolescent mental wellness: a systematic review protocol of instruments measuring
      general mental health and well-being.
PG  - e037237
LID - 10.1136/bmjopen-2020-037237 [doi]
AB  - INTRODUCTION: The promotion of mental health well-being among global adolescent
      populations is of great public health and social significance. This is
      particularly true for adolescents living with chronic illnesses as studies have
      shown that these populations are at higher risk for developing mental health
      problems. There is vast recognition of the need for age and culturally
      appropriate interventions to promote mental well-being and prevent mental health 
      problems. In stark contrast, there is a dearth of relevant measures of mental
      well-being for adolescents. Our proposed systematic review aims to identify
      measures of mental well-being and to assess content, psychometric properties and 
      relevance to adolescent populations. METHODS AND ANALYSIS: The systematic review 
      methodology will be guided by the seven steps proposed by Eggar, Davey and Smith.
      Documents will be sourced from electronic databases (Academic Search Complete,
      Educational Resource Information Center, Medical Literature Analysis Retrieval
      System Online, Cumulative Index of Nursing and Allied Health Literature plus,
      PsyArticles, SocIndex and Sabinet). All documents will be exported to Mendeley
      and two reviewers will independently screen the titles, abstracts and full texts 
      for inclusion. Any discrepancies will be resolved by a third party. We will
      include studies published in all languages from 2000 to 2020, that use an
      instrument(s) that measure mental well-being among adolescent populations.
      Studies reporting on clinically significant mental illnesses or disorders will be
      excluded. A descriptive meta-synthesis approach will be used to identify and
      describe the mental health instruments used among adolescent populations, and to 
      report on the psychometric properties. ETHICS AND DISSEMINATION: Ethical approval
      is not required. The results of this review will be disseminated through a
      peer-reviewed publication as well as conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Orth, Zaida
AU  - Orth Z
AUID- ORCID: 0000-0002-2895-0417
AD  - School of Public Health, University of the Western Cape, Bellville, South Africa 
      zaidaorth@gmail.com.
FAU - van Wyk, Brian
AU  - van Wyk B
AD  - School of Public Health, University of the Western Cape, Bellville, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200823
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Delivery of Health Care
MH  - Humans
MH  - *Mental Disorders
MH  - *Mental Health
MH  - Psychometrics
MH  - Public Health
MH  - Review Literature as Topic
PMC - PMC7445341
OTO - NOTNLM
OT  - *mental health
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/08/25 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037237 [pii]
AID - 10.1136/bmjopen-2020-037237 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 23;10(8):e037237. doi: 10.1136/bmjopen-2020-037237.


PMID- 32829985
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20210110
IS  - 1095-8320 (Electronic)
IS  - 1045-1056 (Linking)
VI  - 67
DP  - 2020 Sep
TI  - SARS-CoV-2 controlled human infection models: Ethics, challenge agent production 
      and regulatory issues.
PG  - 69-74
LID - S1045-1056(20)30096-8 [pii]
LID - 10.1016/j.biologicals.2020.08.006 [doi]
AB  - This second International Alliance for Biological Standardization COVID-19
      webinar brought together a broad range of international stakeholders, including
      academia, regulators, funders and industry, with a considerable participation
      from low- and middle-income countries, to discuss the use of controlled human
      infection models to accelerate development and market authorization assessment of
      a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Baay, Marc
AU  - Baay M
AD  - P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address:
      marc.baay@p-95.com.
FAU - Neels, Pieter
AU  - Neels P
AD  - International Alliance for Biological Standardization - IABS, Geneva,
      Switzerland. Electronic address: Pieter.neels@vaccine-advice.be.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200815
PL  - England
TA  - Biologicals
JT  - Biologicals : journal of the International Association of Biological
      Standardization
JID - 9004494
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control
MH  - Drug Development/*ethics/legislation & jurisprudence
MH  - Human Experimentation/*ethics/legislation & jurisprudence
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Quality Control
MH  - Reference Standards
MH  - SARS-CoV-2
MH  - Viral Vaccines/*therapeutic use
PMC - PMC7428779
OTO - NOTNLM
OT  - CMC
OT  - Controlled human infection models
OT  - Ethics
OT  - SARS-CoV-2
EDAT- 2020/08/25 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/11 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - S1045-1056(20)30096-8 [pii]
AID - 10.1016/j.biologicals.2020.08.006 [doi]
PST - ppublish
SO  - Biologicals. 2020 Sep;67:69-74. doi: 10.1016/j.biologicals.2020.08.006. Epub 2020
      Aug 15.


PMID- 32829740
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 1778-3585 (Electronic)
IS  - 0924-9338 (Linking)
VI  - 63
IP  - 1
DP  - 2020 Aug 24
TI  - Compulsory admissions of patients with mental disorders: State of the art on
      ethical and legislative aspects in 40 European countries.
PG  - e82
LID - 10.1192/j.eurpsy.2020.79 [doi]
AB  - BACKGROUND: Compulsory admission procedures of patients with mental disorders
      vary between countries in Europe. The Ethics Committee of the European
      Psychiatric Association (EPA) launched a survey on involuntary admission
      procedures of patients with mental disorders in 40 countries to gather
      information from all National Psychiatric Associations that are members of the
      EPA to develop recommendations for improving involuntary admission processes and 
      promote voluntary care. METHODS: The survey focused on legislation of involuntary
      admissions and key actors involved in the admission procedure as well as most
      common reasons for involuntary admissions. RESULTS: We analyzed the survey
      categorical data in themes, which highlight that both medical and legal actors
      are involved in involuntary admission procedures. CONCLUSIONS: We conclude that
      legal reasons for compulsory admission should be reworded in order to remove
      stigmatization of the patient, that raising awareness about involuntary admission
      procedures and patient rights with both patients and family advocacy groups is
      paramount, that communication about procedures should be widely available in
      lay-language for the general population, and that training sessions and guidance 
      should be available for legal and medical practitioners. Finally, people working 
      in the field need to be constantly aware about the ethical challenges surrounding
      compulsory admissions.
FAU - Wasserman, D
AU  - Wasserman D
AUID- ORCID: 0000-0002-8436-3989
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - National Centre for Suicide Research and Prevention of Mental-Ill Health,
      Karolinska Institute, Stockholm, Sweden.
FAU - Apter, G
AU  - Apter G
AUID- ORCID: 0000-0001-5185-1479
AD  - French Federation of Psychiatry, Paris, France.
AD  - Groupe Hospitalier du Havre, Universite de Rouen, Rouen, France.
FAU - Baeken, C
AU  - Baeken C
AUID- ORCID: 0000-0001-9885-3041
AD  - Flemish Association of Psychiatry, Kortenberg, Belgium.
AD  - Department of Psychiatry and Medical Psychiatry, Ghent University, Gent, Belgium.
FAU - Bailey, S
AU  - Bailey S
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - University of Central Lancashire, Preston, United Kingdom.
FAU - Balazs, J
AU  - Balazs J
AUID- ORCID: 0000-0001-6397-1419
AD  - Hungarian Psychiatric Association, Budapest, Hungary.
AD  - Department of Developmental and Clinical Child Psychology at the Institute
      Psychology Eotvos Lorand University, Budapest, Hungary.
FAU - Bec, C
AU  - Bec C
AUID- ORCID: 0000-0002-2850-8805
AD  - National Centre for Suicide Research and Prevention of Mental-Ill Health,
      Karolinska Institute, Stockholm, Sweden.
FAU - Bienkowski, P
AU  - Bienkowski P
AUID- ORCID: 0000-0002-7432-3449
AD  - Polish Psychiatric Association, Warsaw, Poland.
AD  - Department of Psychiatry, Warsaw Medical University, Warsaw, Poland.
FAU - Bobes, J
AU  - Bobes J
AUID- ORCID: 0000-0003-2187-4033
AD  - Spanish Society of Psychiatry, Madrid, Spain.
AD  - Department of Psychiatry, School of Medicine, University of Oviedo, Oviedo,
      Spain.
FAU - Ortiz, M F Bravo
AU  - Ortiz MFB
AUID- ORCID: 0000-0001-7969-9245
AD  - Association of Psychiatrists of Spanish Association of Neuropsychiatry, Madrid,
      Spain.
AD  - Department of Psychiatry, Clinical Psychology and Mental Health, La Paz
      University Hospital, Universidad Autonoma de Madrid, Madrid, Spain.
FAU - Brunn, H
AU  - Brunn H
AUID- ORCID: 0000-0003-3955-269X
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - Danish Psychiatric Association, Copenhagen, Denmark.
AD  - Institute of regional Health Research, University of Southern Denmark, Odense,
      Denmark.
FAU - Boke, O
AU  - Boke O
AUID- ORCID: 0000-0003-1556-5226
AD  - Psychiatric Association of Turkey, Ankara, Turkey.
AD  - Ondokuz Mayis Universitesi, Samsun, Turkey.
FAU - Camilleri, N
AU  - Camilleri N
AUID- ORCID: 0000-0002-8946-3575
AD  - Maltese Association of Psychiatry, Attard, Malta.
AD  - University of Malta, Msida, Malta.
FAU - Carpiniello, B
AU  - Carpiniello B
AUID- ORCID: 0000-0002-5385-7871
AD  - European Psychiatric Association Council of National Psychiatric Associations,
      Strasbourg, France.
AD  - Italian Psychiatric Association, Roma, Italy.
AD  - Department of Public Health, Clinical and Molecular Medicine, Universita degli
      studi di Cagliari, Sardinia, Italy.
FAU - Chihai, J
AU  - Chihai J
AUID- ORCID: 0000-0002-7720-5544
AD  - Society of Psychiatrists, Narcologists, Psychotherapists, and Clinical
      Psychologists from the Republic of Moldova, Chisinau, Moldova.
AD  - Department of State Medical and Pharmaceutical University "Nicolae Testemitanu", 
      Chisinau, Republic of Moldova.
FAU - Chkonia, E
AU  - Chkonia E
AUID- ORCID: 0000-0002-8817-9679
AD  - Society of Georgian Psychiatrists, Tbilisi, Georgia.
AD  - Department of Psychiatry, Tbilisi State Medical University, Tbilisi, Georgia.
FAU - Courtet, P
AU  - Courtet P
AUID- ORCID: 0000-0002-6519-8586
AD  - French Congress of Psychiatry, Paris, France.
AD  - University of Montpellier, CHRU Montpellier, Montpellier, France.
AD  - Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital,
      Montpellier, France.
FAU - Cozman, D
AU  - Cozman D
AUID- ORCID: 0000-0001-7102-2432
AD  - Romanian Association of Psychiatry and Psychotherapy, Bucharest, Romania.
AD  - Medical Psychology Department, Iuliu Hatieganu University of Medicine and
      Pharmacy, Cluj-NapocaRomania.
FAU - David, M
AU  - David M
AD  - French Federation of Psychiatry, Paris, France.
AD  - Fondation Bon Sauveur, Begard, France.
FAU - Dom, G
AU  - Dom G
AUID- ORCID: 0000-0001-6492-0429
AD  - Belgium Professional Association of Medical Specialists in Psychiatry, Brussel,
      Belgium.
AD  - Department of Psychiatry, Antwerp University (UA), Antwerpen, Belgium.
FAU - Esanu, A
AU  - Esanu A
AUID- ORCID: 0000-0003-1289-4622
AD  - Society of Psychiatrists, Narcologists, Psychotherapists, and Clinical
      Psychologists from the Republic of Moldova, Chisinau, Moldova.
AD  - Department of Psychiatry, Narcology and Medical Psychology, State University of
      Medicine and Pharmacy, Chisinau, Republic of Moldova.
FAU - Falkai, P
AU  - Falkai P
AUID- ORCID: 0000-0003-2873-8667
AD  - German Association for Psychiatry, Psychotherapy and Psychosomatics, Berlin,
      Germany.
AD  - Clinic for Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich,
      Munich, Germany.
FAU - Flannery, W
AU  - Flannery W
AD  - College of Psychiatrists of Ireland, Dublin, Ireland.
AD  - Department of Adult Psychiatry, Mater Misericordiae University Hospital, Dublin, 
      Ireland.
FAU - Gasparyan, K
AU  - Gasparyan K
AUID- ORCID: 0000-0001-8884-415X
AD  - Armenian Psychiatric Association, Yerevan, Armenia.
AD  - Medical Psychology Department, Yerevan State Mkhitar Herats Medical University,
      Yerevan, Armenia.
FAU - Gerlinger, G
AU  - Gerlinger G
AD  - German Association for Psychiatry, Psychotherapy and Psychosomatics, Berlin,
      Germany.
FAU - Gorwood, P
AU  - Gorwood P
AD  - French Congress of Psychiatry, Paris, France.
AD  - Institute of Psychiatry and Neuroscience of Paris (IPNP), University of
      ParisParis, France.
FAU - Gudmundsson, O
AU  - Gudmundsson O
AUID- ORCID: 0000-0002-4587-7274
AD  - Icelandic Psychiatric Association, Kopavogur, Iceland.
AD  - Psychiatric Department, Landspitali, University Hospital of Iceland, Reykjavik,
      Iceland.
FAU - Hanon, C
AU  - Hanon C
AUID- ORCID: 0000-0002-8414-6319
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - Regional Resource Center of old age Psychiatry, AP-HP Centre - Universite de
      Paris, Corentin-Celton Hospital, Paris, France.
FAU - Heinz, A
AU  - Heinz A
AUID- ORCID: 0000-0001-5405-9065
AD  - German Association for Psychiatry, Psychotherapy and Psychosomatics, Berlin,
      Germany.
AD  - Clinic for Psychiatry and Psychotherapy, Charite - Universitatsmedizin, Berlin,
      Germany.
FAU - Dos Santos, M J Heitor
AU  - Dos Santos MJH
AD  - Portuguese Society of Psychiatry and Mental Health, Lisbon, Portugal.
AD  - Institute of Environmental Health (ISAMB) of the Faculty of Medicine of the
      University of Lisbon (FMUL), Lisbon, Portugal.
FAU - Hedlund, A
AU  - Hedlund A
AD  - Swedish Psychiatry Association, Sundsvall, Sweden.
AD  - North Stockholm Psychiatry, Stockholm County Medical Area (SLSO), Stockholm,
      Sweden.
FAU - Ismayilov, F
AU  - Ismayilov F
AD  - Azerbaijan Psychiatric Association, Baku, Azerbaijan.
AD  - National Mental Health Centre, Baku, Azerbaijan.
FAU - Ismayilov, N
AU  - Ismayilov N
AD  - Azerbaijan Psychiatric Association, Baku, Azerbaijan.
AD  - Department of Psychiatry, Azerbaijan Medical University, Baku, Azerbaijan.
FAU - Isometsa, E T
AU  - Isometsa ET
AD  - Finnish Psychiatric Association, Helsinki, Finland.
AD  - Department of Psychiatry, Faculty of Medicine, University of Helsinki, Helsinki, 
      Finland.
FAU - Izakova, L
AU  - Izakova L
AD  - Slovak Psychiatric Association, Bratislava, Slovakia.
AD  - Department of Psychiatry, Faculty of Medicine Comenius University and University 
      Hospital, Bratislava, Slovakia.
FAU - Kleinberg, A
AU  - Kleinberg A
AD  - Estonian Psychiatric Association, Tartu, Estonia.
AD  - Children Mental Health Centre of Tallinn Children Hospital, Tallinn, Estonia.
FAU - Kurimay, T
AU  - Kurimay T
AD  - European Psychiatric Association Council of National Psychiatric Associations,
      Strasbourg, France.
AD  - Department of Psychiatry and Psychiatric Rehabilitation, Teaching Department of
      Semmelweis University, Budapest, Hungary.
FAU - Reitan, S Klaebo
AU  - Reitan SK
AD  - Department of Psychiatry and Psychiatric Rehabilitation, Teaching Department of
      Semmelweis University, Budapest, Hungary.
AD  - Norwegian Psychiatric Association, Oslo, Norway.
AD  - Department of Mental Health, Faculty of Medicine and Health Sciences, Norweigan
      University of Science and Technology, Trondheim, Norway.
FAU - Lecic-Tosevski, D
AU  - Lecic-Tosevski D
AD  - Serbian Psychiatric Association, Belgrade, Serbia.
AD  - Psychiatric Association of Eastern Europe and the Balkans, Athens, Greece.
AD  - Department of Medical Sciences, Serbian Academy of Sciences and Arts, Belgrade,
      Serbia.
FAU - Lehmets, A
AU  - Lehmets A
AD  - Estonian Psychiatric Association, Tartu, Estonia.
AD  - Psychiatric Centre of the Tallinn West Central Hospital, Tallinn, Estonia.
FAU - Lindberg, N
AU  - Lindberg N
AD  - Finnish Psychiatric Association, Helsinki, Finland.
AD  - Forensic Psychiatry, Helsinki University and Helsinki University Hospital,
      Helsinski, Finland.
FAU - Lundblad, K A
AU  - Lundblad KA
AD  - Swedish Psychiatry Association, Sundsvall, Sweden.
AD  - Adult Psychiatry, Stockholm County Medical Area (SLSO), Stockholm, Sweden.
FAU - Lynch, G
AU  - Lynch G
AD  - Royal College of Psychiatrists, London, United Kingdom.
FAU - Maddock, C
AU  - Maddock C
AD  - Royal College of Psychiatrists, London, United Kingdom.
FAU - Malt, U F
AU  - Malt UF
AD  - Norwegian Psychiatric Association, Oslo, Norway.
AD  - Faculty of Medicine, Psychiatry and Psychosomatic Medicine, Institute of Clinical
      Medicine, University of Oslo, Oslo, Norway.
FAU - Martin, L
AU  - Martin L
AD  - College of Psychiatrists of Ireland, Dublin, Ireland.
AD  - St Loman's Hospital, Mullingar, Ireland.
FAU - Martynikhin, I
AU  - Martynikhin I
AD  - Russian Society of Psychiatrists, Moscow, Russian Federation.
AD  - First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russian
      Federation.
FAU - Maruta, N O
AU  - Maruta NO
AD  - Association of Neurologists, Psychiatrists and Narcologists of Ukraine, Kharkiv, 
      Ukraine.
AD  - Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine State
      Insitution, Kharkiv, Ukraine.
FAU - Matthys, F
AU  - Matthys F
AD  - Flemish Association of Psychiatry, Kortenberg, Belgium.
AD  - Department of Psychiatry, Universitair Ziekenhuis, Brussel, Belgium.
FAU - Mazaliauskiene, R
AU  - Mazaliauskiene R
AD  - Lithuanian Psychiatric Association, Vilnius, Lithuania.
AD  - Lithuanian University of Health Sciences, Psychiatric Clinic, Kaunas, Lithuania.
FAU - Mihajlovic, G
AU  - Mihajlovic G
AD  - Serbian Psychiatric Association, Belgrade, Serbia.
AD  - Clinic for Psychiatry, University of Kragujevac, Kragujevac, Serbia.
FAU - Peles, A Mihaljevic
AU  - Peles AM
AD  - Croatian Psychiatric Association, Zagreb, Croatia.
AD  - Zagreb School of Medicine and Zagreb University Hospital Centre, Zagreb, Croatia.
FAU - Miklavic, V
AU  - Miklavic V
AD  - Slovenian Psychiatric Association, Ljubljana, Slovenia.
AD  - Ljubljana University Medical Centre, Ljubljana, Slovenia.
FAU - Mohr, P
AU  - Mohr P
AD  - Czech Psychiatric Association, Prague, Czech Republic.
AD  - Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
FAU - Ferrandis, M Munarriz
AU  - Ferrandis MM
AD  - Association of Psychiatrists of Spanish Association of Neuropsychiatry, Madrid,
      Spain.
FAU - Musalek, M
AU  - Musalek M
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - Institute for Social Aesthetics and Mental Health, Vienna, Austria.
AD  - Sigmund Freud University, Vienna, Austria.
FAU - Neznanov, N
AU  - Neznanov N
AD  - Russian Society of Psychiatrists, Moscow, Russian Federation.
AD  - St. Petersburg V.M. Bekhterev Psychoneurological Research Institute, St.
      Petersburg, Russian Federation.
FAU - Ostorharics-Horvath, G
AU  - Ostorharics-Horvath G
AD  - Hungarian Psychiatric Association, Budapest, Hungary.
FAU - Pajevic, I
AU  - Pajevic I
AD  - Psychiatric Association of Bosnia-Herzegovina, Tuzla, Bosnia and Herzegovina.
AD  - Department of Psychiatry, University Clinical Center Tuzla, Tuzla, Bosnia and
      Herzegovina.
FAU - Popova, A
AU  - Popova A
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - College Private Psychiatry of Bulgaria, Sofia, Bulgaria.
AD  - Nikola Shipkovenski Mental Health Centre, Sofia, Bulgaria.
FAU - Pregelj, P
AU  - Pregelj P
AD  - Slovenian Psychiatric Association, Ljubljana, Slovenia.
AD  - Department of Psychiatry, University of Ljubljana, Ljubljana, Slovenia.
FAU - Prinsen, E
AU  - Prinsen E
AD  - Netherlands Psychiatric Association, Utrecht, Netherlands.
FAU - Rados, C
AU  - Rados C
AD  - Austrian Society for Psychiatry and Psychotherapy, Vienna, Austria.
AD  - Department of Psychiatry and Psychotherapeutic Medicine, Villach State Hospital, 
      Villach, Austria.
FAU - Roig, A
AU  - Roig A
AD  - Association of Psychiatrists of Spanish Association of Neuropsychiatry, Madrid,
      Spain.
AD  - Mental Health Centre, Horta-Guinardo, Barcelona, Spain.
FAU - Kuzman, M Rojnic
AU  - Kuzman MR
AD  - Croatian Psychiatric Association, Zagreb, Croatia.
AD  - Zagreb School of Medicine and Zagreb University Hospital Centre, Zagreb, Croatia.
FAU - Samochowiec, J
AU  - Samochowiec J
AD  - Polish Psychiatric Association, Warsaw, Poland.
AD  - European Psychiatric Association Council of National Psychiatric Associations,
      Strasbourg, France.
AD  - Department of Psychiatry Pomeranian Medical University, Szczecin, Poland.
FAU - Sartorius, N
AU  - Sartorius N
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - Association for the Improvement of Mental Health Programmes (AMH), Geneva,
      Switzerland.
FAU - Savenko, Y
AU  - Savenko Y
AD  - Independent Psychiatric Association of Russia, Moscow, Russian Federation.
FAU - Skugarevsky, O
AU  - Skugarevsky O
AD  - Belarusian Psychiatric Association, Minsk, Belarus.
AD  - Psychiatry and Medical Psychology Department, Belarusian State Medical
      University, Minsk, Belarus.
FAU - Slodecki, E
AU  - Slodecki E
AD  - Royal College of Psychiatrists, London, United Kingdom.
FAU - Soghoyan, A
AU  - Soghoyan A
AD  - Armenian Psychiatric Association, Yerevan, Armenia.
AD  - Center of Psychosocial Recovery, Yerevan State Medical University, Yerevan,
      Armenia.
FAU - Stone, D S
AU  - Stone DS
AD  - National Centre for Suicide Research and Prevention of Mental-Ill Health,
      Karolinska Institute, Stockholm, Sweden.
FAU - Taylor-East, R
AU  - Taylor-East R
AD  - Maltese Association of Psychiatry, Attard, Malta.
AD  - University of Malta, Msida, Malta.
FAU - Terauds, E
AU  - Terauds E
AD  - Latvian Psychiatric Association, Riga, Latvia.
AD  - Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia.
FAU - Tsopelas, C
AU  - Tsopelas C
AD  - Psychiatric Association of Eastern Europe and the Balkans, Athens, Greece.
AD  - Department of Psychiatry, Psychiatric Hospital of Athens, Athens, Greece.
FAU - Tudose, C
AU  - Tudose C
AD  - Romanian Association of Psychiatry and Psychotherapy, Bucharest, Romania.
AD  - Department of Psychiatry "Carol Davila" University of Medicine and Pharmacy,
      Bucharest, Romania.
FAU - Tyano, S
AU  - Tyano S
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
FAU - Vallon, P
AU  - Vallon P
AD  - Swiss Society of Psychiatry and Psychotherapy, Bern, Switzerland.
FAU - Van der Gaag, R J
AU  - Van der Gaag RJ
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - Psychosomatics and Psychotherapy Stradina Department, University of Riga, Riga,
      Latvia.
FAU - Varandas, P
AU  - Varandas P
AD  - Portuguese Society of Psychiatry and Mental Health, Lisbon, Portugal.
AD  - Casa de Saude da Idanha and San Jose Psychiatric Clinic Instituto das Irmas
      Hospitaleiras do Sagrado Coracao de Jesus, Belas, Portugal.
FAU - Vavrusova, L
AU  - Vavrusova L
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - Slovak Psychiatric Association, Bratislava, Slovakia.
FAU - Voloshyn, P
AU  - Voloshyn P
AD  - Association of Neurologists, Psychiatrists and Narcologists of Ukraine, Kharkiv, 
      Ukraine.
AD  - Department of Neurology and Neurosurgery of Kharkiv Medical Academy of
      Postgraduate Education, Kharkiv, Ukraine.
FAU - Wancata, J
AU  - Wancata J
AD  - Austrian Society for Psychiatry and Psychotherapy, Vienna, Austria.
AD  - Clinical Division of Social Psychiatry, Department of Psychiatry and
      Psychotherapy, Medical University of Vienna, Vienna, Austria.
FAU - Wise, J
AU  - Wise J
AD  - European Psychiatric Association, Committee on Ethical Issues, Strasbourg,
      France.
AD  - CNWL NHS Foundation Trust, London, United Kingdom.
FAU - Zemishlany, Z
AU  - Zemishlany Z
AD  - Israel Psychiatric Association, Ramat Gan, Israel.
FAU - Oncu, F
AU  - Oncu F
AD  - Psychiatric Association of Turkey, Ankara, Turkey.
AD  - Forensic Psychiatry Department, Bakirkoy Research and Training Hospital for
      Psychiatry, Neurology, and Neurosurgery, Istanbul, Turkey.
FAU - Vahip, S
AU  - Vahip S
AD  - European Psychiatric Association Council of National Psychiatric Associations,
      Strasbourg, France.
AD  - Department of Psychiatry, Ege University School of Medicine, Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - Eur Psychiatry
JT  - European psychiatry : the journal of the Association of European Psychiatrists
JID - 9111820
SB  - IM
MH  - *Coercion
MH  - Commitment of Mentally Ill/*ethics/*legislation & jurisprudence
MH  - Europe
MH  - *Hospitalization
MH  - Humans
MH  - *Mental Disorders
MH  - Surveys and Questionnaires
PMC - PMC7576531
OTO - NOTNLM
OT  - *Awareness
OT  - *European Psychiatric Association (EPA)
OT  - *National Psychiatric Associations (NPAs)
OT  - *communication
OT  - *compulsory admission
OT  - *education
OT  - *ethics and human rights
OT  - *involuntary admission
OT  - *legal model
OT  - *medical model
OT  - *psychiatry in Europe
OT  - *stigma
EDAT- 2020/08/25 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/08/25 06:00
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
PHST- 2020/08/25 06:00 [entrez]
AID - 10.1192/j.eurpsy.2020.79 [doi]
AID - S0924933820000796 [pii]
PST - epublish
SO  - Eur Psychiatry. 2020 Aug 24;63(1):e82. doi: 10.1192/j.eurpsy.2020.79.


PMID- 32829712
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210616
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 24
TI  - Introducing enhanced recovery after surgery in a high-volume orthopaedic
      hospital: a health technology assessment.
PG  - 773
LID - 10.1186/s12913-020-05634-3 [doi]
AB  - BACKGROUND: The number of patients undergoing joint arthroplasty is increasing
      worldwide. An Enhanced Recovery After Surgery (ERAS) pathway for hip and knee
      arthroplasty was introduced in an Italian high-volume research hospital in March 
      2018. METHODS: The aim of this mixed methods observational study is to perform a 
      health technology assessment (HTA) of the ERAS pathway, considering 938
      procedures performed after its implementation, by means of a hospital-based
      approach derived from the EUnetHTA (European Network for Health Technology
      Assessment) Core Model. The assessment process is based on dimensions of general 
      relevance, safety, efficacy, effectiveness, economic and financial impact,
      equity, legal aspects, social and ethical impact, and organizational impact. A
      narrative review of the literature helped to identify general relevance, safety
      and efficacy factors, and a set of relevant sub-dimensions submitted to the
      evaluation of the professionals who use the technology through a 7-item Likert
      Scale. The economic and financial impact of the ERAS pathway on the hospital
      budget was supported by quantitative data collected from internal or national
      registries, employing economic modelling strategies to identify the amount of
      resources required to implement it. RESULTS: The relevance of technology under
      assessment is recognized worldwide. A number of studies show accelerated pathways
      to dominate conventional approaches on pain reduction, functional recovery,
      prevention of complications, improvements in tolerability and quality of life,
      including fragile or vulnerable patients. Qualitative surveys on clinical and
      functional outcomes confirm most of these benefits. The ERAS pathway is
      associated with a reduced length of stay in comparison with the Italian
      hospitalization average for the same procedures, despite the poor spread of the
      pathway within the country may generate postcode inequalities. The economic
      analyses show how the resources invested in training activities are largely
      depreciated by benefits once the technology is permanently introduced, which may 
      generate hospital cost savings of up to 2054,123.44 euro per year. CONCLUSIONS:
      Galeazzi Hospital's ERAS pathway for hip and knee arthroplasty results preferable
      to traditional approaches following most of the HTA dimensions, and offers room
      for further improvement. The more comparable practices are shared, the before
      this potential improvement can be identified and addressed.
FAU - Vanni, Francesco
AU  - Vanni F
AD  - IRCCS Orthopedic Institute Galeazzi, Via Riccardo Galeazzi 4, 20161, Milan,
      Italy.
FAU - Foglia, Emanuela
AU  - Foglia E
AD  - Centre for Health Economics, Social and Health Care Management, LIUC Business
      School, LIUC - Universita Cattaneo, Corso Matteotti 22, 21053, Castellanza,
      Varese, Italy.
FAU - Pennestri, Federico
AU  - Pennestri F
AUID- ORCID: http://orcid.org/0000-0001-9969-9955
AD  - IRCCS Orthopedic Institute Galeazzi, Via Riccardo Galeazzi 4, 20161, Milan,
      Italy. federico.pennestri@grupposandonato.it.
FAU - Ferrario, Lucrezia
AU  - Ferrario L
AD  - Centre for Health Economics, Social and Health Care Management, LIUC Business
      School, LIUC - Universita Cattaneo, Corso Matteotti 22, 21053, Castellanza,
      Varese, Italy.
FAU - Banfi, Giuseppe
AU  - Banfi G
AD  - IRCCS Orthopedic Institute Galeazzi, Via Riccardo Galeazzi 4, 20161, Milan,
      Italy.
AD  - Vita-Salute San Raffaele University, Via Olgettina 58, 20132, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200824
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Aged
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - *Enhanced Recovery After Surgery
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Italy
MH  - Male
MH  - Orthopedics
MH  - Technology Assessment, Biomedical
PMC - PMC7444253
OTO - NOTNLM
OT  - Activity-based analysis
OT  - Cost-effectiveness
OT  - EUnetHTA
OT  - Enhanced recovery after surgery
OT  - Health technology assessment
OT  - Joint-arthroplasty
OT  - Value-based healthcare
EDAT- 2020/08/25 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/08/25 06:00
PHST- 2019/09/05 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/25 06:00 [entrez]
PHST- 2020/08/25 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1186/s12913-020-05634-3 [doi]
AID - 10.1186/s12913-020-05634-3 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Aug 24;20(1):773. doi: 10.1186/s12913-020-05634-3.


PMID- 32827936
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1878-013X (Electronic)
IS  - 1878-013X (Linking)
VI  - 52
DP  - 2020 Sep
TI  - The relationship of moral intelligence and social capital with job satisfaction
      among nurses working in the emergency department.
PG  - 100911
LID - S1755-599X(20)30083-5 [pii]
LID - 10.1016/j.ienj.2020.100911 [doi]
AB  - INTRODUCTION: Nurses' job satisfaction has a direct impact on the quality of
      their performance, especially in the emergency department, which is a showcase of
      care in hospitals, since, nurses' moral performance is greatly affected by moral 
      intelligence, Adherence to ethics by nurses, underlies the social capital of the 
      organization. METHODS: The present study was a cross-sectional,
      descriptive-correlational study. 99 nurses working in the emergency department of
      medical educational centers in Semnan, Iran, were selected by simple random
      sampling. Data were collected by questionnaires: demographic information, job
      satisfaction, moral intelligence and social capital of nurses. Data were analyzed
      using descriptive statistics and analytical statistics in SPSS software. All
      P-values <0.05 were considered statistically significant. RESULTS: The mean and
      standard deviation of job satisfaction, moral intelligence, and social capital
      scores were 51.24 +/- 12.03, 148.48 +/- 19.05, and 43.45 +/- 7.28, respectively. 
      Job satisfaction did not have a significant relationship with moral intelligence 
      and its domains, but it had a significant relationship with social capital and
      its domains (P = 0.002). CONCLUSION: Due to the significant relationship between 
      job satisfaction and social capital, Nurses' satisfaction and attitude toward the
      job can be improved by creating a context for progress and self-actualization.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Gholami Motlagh, Farzaneh
AU  - Gholami Motlagh F
AD  - Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
FAU - Nobahar, Monir
AU  - Nobahar M
AD  - Nursing Care Research Center, Semnan University of Medical Sciences, Semnan,
      Iran; Social Determinants of Health Research Center, Semnan University of Medical
      Sciences, Semnan, Iran; Faculty of Nursing and Midwifery, Semnan University of
      Medical Sciences, Semnan, Iran. Electronic address: Nobahar43@semums.ac.ir.
FAU - Raiesdana, Nayyereh
AU  - Raiesdana N
AD  - Nursing Care Research Center, Semnan University of Medical Sciences, Semnan,
      Iran; Faculty of Nursing and Midwifery, Semnan University of Medical Sciences,
      Semnan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - England
TA  - Int Emerg Nurs
JT  - International emergency nursing
JID - 101472191
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Emergency Nursing
MH  - *Emergency Service, Hospital
MH  - Female
MH  - Humans
MH  - Iran
MH  - *Job Satisfaction
MH  - Male
MH  - Middle Aged
MH  - *Morals
MH  - Nursing Staff, Hospital/*psychology
MH  - *Social Capital
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Emergency department
OT  - *Job satisfaction
OT  - *Moral intelligence
OT  - *Nurses
OT  - *Social capital
EDAT- 2020/08/23 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/07/16 00:00 [revised]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - S1755-599X(20)30083-5 [pii]
AID - 10.1016/j.ienj.2020.100911 [doi]
PST - ppublish
SO  - Int Emerg Nurs. 2020 Sep;52:100911. doi: 10.1016/j.ienj.2020.100911. Epub 2020
      Aug 19.


PMID- 32827396
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210506
IS  - 1613-4516 (Electronic)
IS  - 1613-4516 (Linking)
VI  - 17
IP  - 2-3
DP  - 2020 Jul 24
TI  - Towards standardization guidelines for in silico approaches in personalized
      medicine.
LID - 10.1515/jib-2020-0006 [doi]
AB  - Despite the ever-progressing technological advances in producing data in health
      and clinical research, the generation of new knowledge for medical benefits
      through advanced analytics still lags behind its full potential. Reasons for this
      obstacle are the inherent heterogeneity of data sources and the lack of broadly
      accepted standards. Further hurdles are associated with legal and ethical issues 
      surrounding the use of personal/patient data across disciplines and borders.
      Consequently, there is a need for broadly applicable standards compliant with
      legal and ethical regulations that allow interpretation of heterogeneous health
      data through in silico methodologies to advance personalized medicine. To tackle 
      these standardization challenges, the Horizon2020 Coordinating and Support Action
      EU-STANDS4PM initiated an EU-wide mapping process to evaluate strategies for data
      integration and data-driven in silico modelling approaches to develop standards, 
      recommendations and guidelines for personalized medicine. A first step towards
      this goal is a broad stakeholder consultation process initiated by an
      EU-STANDS4PM workshop at the annual COMBINE meeting (COMBINE 2019 workshop report
      in same issue). This forum analysed the status quo of data and model standards
      and reflected on possibilities as well as challenges for cross-domain data
      integration to facilitate in silico modelling approaches for personalized
      medicine.
FAU - Brunak, Soren
AU  - Brunak S
AD  - University of Copenhagen, Copenhagen, Denmark.
FAU - Bjerre Collin, Catherine
AU  - Bjerre Collin C
AD  - University of Copenhagen, Copenhagen, Denmark.
FAU - Eva O Cathaoir, Katharina
AU  - Eva O Cathaoir K
AD  - University of Copenhagen, Copenhagen, Denmark.
FAU - Golebiewski, Martin
AU  - Golebiewski M
AD  - HITS gGmbH, Heidelberg, Germany.
FAU - Kirschner, Marc
AU  - Kirschner M
AD  - University of Copenhagen, Copenhagen, Denmark.
AD  - Forschungszentrum Julich GmbH, Project Management Julich, Julich, Germany.
FAU - Kockum, Ingrid
AU  - Kockum I
AD  - Karolinska Institutet, Solna, Sweden.
FAU - Moser, Heike
AU  - Moser H
AD  - German Institute for Standardization, Berlin, Germany.
FAU - Waltemath, Dagmar
AU  - Waltemath D
AD  - Medical Informatics Laboratory, Institute for Community Medicine, University
      Medicine Greifswald, Greifswald, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - Germany
TA  - J Integr Bioinform
JT  - Journal of integrative bioinformatics
JID - 101503361
SB  - IM
MH  - Computer Simulation
MH  - Humans
MH  - *Precision Medicine
MH  - Reference Standards
PMC - PMC7756614
OTO - NOTNLM
OT  - in silico modelling
OT  - data integration
OT  - personalized medicine
OT  - reproducibility
OT  - standards
EDAT- 2020/08/23 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1515/jib-2020-0006 [doi]
AID - jib-2020-0006 [pii]
PST - epublish
SO  - J Integr Bioinform. 2020 Jul 24;17(2-3). pii: jib-2020-0006. doi:
      10.1515/jib-2020-0006.


PMID- 32827024
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Quackery in Dental Practice in Nepal.
PG  - 543-546
LID - 10.31729/jnma.5036 [doi]
AB  - Quackery and fraud in dental practice, seen in many countries, is also rampant in
      Nepal, and they are unethical practices. There is a growing need for strict
      enforcement of government policy measures to eliminate quackery and fraudulent
      dental practice in Nepal. The government should mobilize all dental workforce
      (dental specialists, dentists, and dental auxiliaries) and aware of their
      responsibilities and limitations. This article presents a brief review showing
      some cases of malpractice in dentistry in Nepal.
FAU - Humagain, Manoj
AU  - Humagain M
AD  - Department of Periodontology, Kathmandu University School of Medical Sciences,
      Dhulikhel, Nepal.
FAU - Bhattarai, Bishwa Prakash
AU  - Bhattarai BP
AD  - Department of Oral and Maxillofacial Surgery, International College of Dentistry 
      Walailak University, Bangkok, Thailand.
FAU - Rokaya, Dinesh
AU  - Rokaya D
AD  - Department of Clinical Dentistry, International College of Dentistry Walailak
      University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Credentialing/ethics/legislation & jurisprudence
MH  - Dental Care/*ethics/legislation & jurisprudence
MH  - Ethics, Dental
MH  - Fraud/ethics/legislation & jurisprudence
MH  - Government Regulation
MH  - Humans
MH  - Malpractice/legislation & jurisprudence
MH  - Nepal
MH  - Practice Patterns, Dentists'/*ethics/legislation & jurisprudence
MH  - *Quackery/ethics/legislation & jurisprudence
PMC - PMC7580404
OTO - NOTNLM
OT  - dental general practice; dentistry; ethics; Nepal; prosthetic dentistry.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5036 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):543-546. doi: 10.31729/jnma.5036.


PMID- 32827009
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20201218
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Knowledge of Health Care Professionals and Medical Students Regarding Covid-19 in
      a Tertiary Care Hospital in Nepal.
PG  - 480-486
LID - 10.31729/jnma.4995 [doi]
AB  - INTRODUCTION: The lack of knowledge among health care professionals leads to
      diagnostic delays, further spread of disease, and poor infection control
      practices. Health care professionals must be updated knowledge regarding
      COVID-19. This study aims to assess the knowledge of health care professionals
      regarding COVID -19 in a medical college in Chitwan. METHODS: A Knowledge,
      Attitude and Practice Study was carried out in a tertiary care hospital in
      Chitwan, Nepal from April 22, 2020, to April 28, 2020. The institutional review
      committee of Chitwan Medical College provided ethical approval for the research. 
      Data were collected with an online questionnaire using Google forms. The
      questionnaire was sent out to 724 potential responders who included health care
      professionals from medical, dental, nursing, and allied health sciences in
      Chitwan Medical College. A convenient sampling method was used for data
      collection. Data were analyzed using Statistical Package of Social Sciences.
      RESULTS: A total of 181 respondents completed the web survey. Overall, a total of
      35 (19.3%) respondents were found to have "Good" knowledge; 105 (58%) respondents
      had "Fair" knowledge and 41 (22.7%) respondents had "Poor" knowledge regarding
      various aspects of COVID-19. There was no significant difference among the
      various health professional groups in their knowledge scores under the four
      knowledge domains. CONCLUSIONS: The study of knowledge of health care
      professionals could act as a reference for the prevention and better management
      of COVID-19. This study shows that there is a need to implement periodic
      educational interventions and training programs on infection control practices
      for COVID-19 across all healthcare professions.
FAU - Neupane, Harish Chandra
AU  - Neupane HC
AD  - Department of Surgery, Chitwan Medical College, Bharatpur, Chitwan, Nepal.
FAU - Shrestha, Niki
AU  - Shrestha N
AD  - Department of Community Medicine, Chitwan Medical College, Bharatpur, Chitwan,
      Nepal.
FAU - Adhikari, Shital
AU  - Adhikari S
AD  - Department of Medicine, Chitwan Medical College, Bharatpur, Chitwan, Nepal.
FAU - Angadi, Siddeshwar
AU  - Angadi S
AD  - School of Nursing, Chitwan Medical College, Bharatpur, Chitwan, Nepal.
FAU - Shrestha, Bishow Kumar
AU  - Shrestha BK
AD  - Department of Medicine, Chitwan Medical College, Bharatpur, Chitwan, Nepal.
FAU - Gauli, Basanta
AU  - Gauli B
AD  - Department of Anaesthesiology & Critical Care Medicine, Chitwan Medical College, 
      Bharatpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - *Allied Health Personnel
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Clinical Competence
MH  - *Coronavirus Infections
MH  - *Dentists
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal
MH  - *Nurses
MH  - *Pandemics
MH  - *Physicians
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Students, Medical
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7580389
OTO - NOTNLM
OT  - COVID -19; health care professionals; knowledge.
EDAT- 2020/08/23 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - 10.31729/jnma.4995 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):480-486. doi: 10.31729/jnma.4995.


PMID- 32827008
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Prevalence of Overweight Among Adult Women of A Metropolitan.
PG  - 474-479
LID - 10.31729/jnma.5190 [doi]
AB  - INTRODUCTION: Globally, Overweight has reached epidemic proportions. It is an
      excessive accumulation of fat that may impair health. Overweight and obesity area
      major contributor to the global burden of non-communicable disease. The
      prevalence of overweight is commonly assessed by using Body Mass Index (BMI),
      where overweight is indicated by BMI greater or equal to 25. Overall, about 13%
      of the world's adult population was obese in 2016, among them women were more
      affected than men. Overall,female population is higher than male in Nepal and
      concentrating on Kaski district female population are significantly more than
      that of male as per population census of 2011. The objective of this study was to
      find out the prevalence of overweight among adult women. METHODS: This was a
      cross-sectional descriptive study, conducted among calculated sample size of 185 
      adult women of Lekhnath Metropolitian of Kaski district, over six months' period.
      Sampling technique was proportionate random sampling. Ethical approval was taken 
      from Institutional Review Board (Ref no. 40/74/75). Anthropometric measurement
      was taken to calculate BMI. Collected data was entered in Epi data, which was
      then exported to SPSS version 20 for further analysis. Descriptive statistics was
      reported for demographic, socio-economic and various overweight related factors
      of the respondents as frequencies and percentage. RESULTS: Out of 185 adult
      women, 69 (37.3%) of them were overweight, 30 (16.2%) of them were obese, and
      central obesity was seen among 97 (52.4%) women at 95% C.I. CONCLUSIONS: The
      finding of this study shows prevalence of overweight and obesity was high.
      Regular Physical exercise and balanced diet should be followed to prevent
      overweight and noncommunicable diseases.
FAU - Nepal, Ashmita
AU  - Nepal A
AD  - Manmohan Memorial Institute of Health Science, Kathmandu, Nepal.
FAU - Karki, Urusha
AU  - Karki U
AD  - Central Department Tribhuwan University, Kathmandu, Nepal.
FAU - Poudel, Lisasha
AU  - Poudel L
AD  - Nepal Institute of Development Studies, Kathmandu, Nepal.
FAU - Rajbhandari, Bibek
AU  - Rajbhandari B
AD  - Nepal Police Hospital, Kathmandu, Nepal.
FAU - Wagle, Shreejana
AU  - Wagle S
AD  - School of Health and Allied sciences, Pokhara University, Kaski, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - *Overweight/epidemiology
MH  - Prevalence
MH  - Risk Factors
MH  - Sex Factors
MH  - Urban Population/statistics & numerical data
MH  - Young Adult
PMC - PMC7580397
OTO - NOTNLM
OT  - adult women; Nepal; overweight; obesity; prevalence.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5190 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):474-479. doi: 10.31729/jnma.5190.


PMID- 32827007
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Acute Poisoning among Patients Presenting to the Emergency Department of a
      Tertiary Care Center: A Descriptive Cross-sectional Study.
PG  - 470-473
LID - 10.31729/jnma.4997 [doi]
AB  - INTRODUCTION: Acute poisoning is a major global public health problem
      contributing to one of the leading causes for a visit to an emergency department.
      This study aims to analyse the demographic and psychosocial characteristics of
      patients with acute poisoning presented to the emergency department. METHODS:
      This was a descriptive cross-sectional study conducted in a tertiary care
      hospital from June to December 2019 after obtaining ethical approval from
      Institutional review board (reference number. 041-075/0760). A convenient
      sampling method was applied. Epidemiological factors, types of poison consumed,
      reason, motive, and place to take poison, time elapse in the presentation to the 
      hospital were studied. Statistical analysis was done using statistical package
      for the social sciences version 20. Point estimate at 95% Confidence Interval was
      calculated along with frequency and proportion for binary data. RESULTS: Out of
      76 cases of acute poisoning, the organophosphorus poisoning was 18 (23.7%)
      followed by unknown 12 (15.8). Of total, 28 (36.8%) had quarrel before taking
      poison and 41 (53.9 %) had intention to commit suicide. Sixty-seven (88.2%) took 
      a poison at home. The average elapsed time to the visit of the emergency
      department was 110+/-80 minutes. CONCLUSIONS: The most common poisoning was
      organophosphorus with a suicide being the most common intention. Quarrel was the 
      most frequent reason to take poison and the home was the most common place to
      take poison.
FAU - Thapa, Sameer
AU  - Thapa S
AD  - Department of Emergency and General Practice, Nepal Medical College and Teaching 
      Hospital, Attarkhel, Kathmandu, Nepal.
FAU - Dawadi, Bishwa Raj
AU  - Dawadi BR
AD  - Department of Emergency and General Practice, Grande International Hospital,
      Dhapasi, Kathmandu, Nepal.
FAU - Upreti, Anup Raj
AU  - Upreti AR
AD  - Clinical Pharmacist, Nepal Medical College and Teaching Hospital, Attarkhel,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Cross-Sectional Studies
MH  - Emergency Service, Hospital/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Organophosphate Poisoning/epidemiology/psychology
MH  - *Poisoning/epidemiology/psychology
MH  - *Suicide, Attempted/psychology/statistics & numerical data
MH  - Tertiary Care Centers/statistics & numerical data
MH  - Young Adult
PMC - PMC7580394
OTO - NOTNLM
OT  - acute; emergency; organophosphates; poisoning; suicide.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.4997 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):470-473. doi: 10.31729/jnma.4997.


PMID- 32827006
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Early experience of Retrograde Intrarenal Surgery for Renal stone: A Descriptive 
      Cross-sectional Study.
PG  - 465-469
LID - 10.31729/jnma.4819 [doi]
AB  - INTRODUCTION: Retrograde intrarenal surgery with improving skill and knowledge
      may be considered one of the first-line treatment options for removal of renal
      stones. The study is done to find the outcome of retrograde intrarenal surgery in
      patients with renal stone. METHODS: This descriptive cross sectional study was
      carried out on patients undergoing retrograde intrarenal surgery for renal stone 
      at a tertiary care hospital December 2019 to March 2020. Ethical approval was
      taken from the institutional review committee (Ref. no.200120202). The Convenient
      sampling method was applied. Data was collected and analyzed in Statistical
      Package for the Social Sciences version 20.0. Point estimate at 95% confidence
      interval was calculated along with frequency and proportion for binary data.
      RESULTS: Out of the 28 patients, the retrograde intrarenal surgery was successful
      in 27 (96.4%) cases. There were 16 (57.15%) females and 12 (42.86%) male patients
      with the mean age of 37.86+/-11.47 years. Most of the stones were in renal pelvis
      18 (64.28%) followed by lower calyx 8 (28.57%). The mean diameter of the stone
      was 11.47 +/-3.33mm whereas most of the stones were on the right side 16
      (57.15%). The mean hardness was 1155.21+/-265.34 Hounsfield units. Perioperative 
      complications like failed access sheath placement in 2 (7.14%) cases, hematuria
      in 6 (21.43%) cases, fever in 6 (21.43%) cases, and septicemia in 4 (14.28%)
      cases. CONCLUSIONS: We found that the success rate of retrograde intrarenal
      surgery for the renal stone was acceptable and similar to other published studies
      . Retrograde intrarenal surgery is feasible for the treatment of kidney stones
      with acceptable complications and success rates.
FAU - Joshi, Robin
AU  - Joshi R
AD  - Department of Urology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Kidney Calculi/surgery
MH  - Kidney Calices/surgery
MH  - Kidney Pelvis/surgery
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Ureteroscopy/*methods
PMC - PMC7580390
OTO - NOTNLM
OT  - nephrolithotomy, percutaneous; nephrolithiasis; renal; retrograde; surgery.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.4819 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):465-469. doi: 10.31729/jnma.4819.


PMID- 32827005
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Clinicodemographic Profile of Kidney Diseases in a Tertiary Hospital of Central
      Nepal, Chitwan: A Descriptive Cross-sectional Study.
PG  - 459-464
LID - 10.31729/jnma.4972 [doi]
AB  - INTRODUCTION: Spectrum of kidney diseases differs significantly in developing and
      developed countries. However, there is no central registry regarding the nature
      of such diseases in Nepal and our center either. The study aims to know the
      clinicodemographic spectrum of kidney disease patients admitted to our hospital. 
      METHODS: This study was a descriptive cross sectional study done in the
      department of Nephrology, College of Medical Sciences Teaching Hospital from May 
      2018 to April 219. Convenient sampling was done and all the consecutive kidney
      disease patients irrespective of their age, sex, and renal diagnosis were
      included in the study. Ethical approval was taken from the Institutional Review
      Committee of the college (reference number. 2016/COMSTH/IRC/049).
      Clinicodemographic profile of kidney diseases were studied using statistical
      package for the social sciences version 20 and were represented as mean, standard
      deviation, number, percentage and ratio. RESULTS: Out of a total of 829 patients,
      the commonest clinical syndrome and the histological patterns were end-stage
      renal disease 248 (29.9%) and IgA nephropathy 18 (20.7%) respectively. The mean
      age was 51.4+/-18.6 years. The commonest reason for hospitalization was sepsis
      372 (44.8%). Males were 486 (58.6%) and females were 343 (41.4%). CONCLUSIONS:
      The commonest clinical presentation and the reason for admissions were end-stage 
      renal disease and sepsis syndrome respectively.
FAU - Ghimire, Madhav
AU  - Ghimire M
AD  - Department of Nephrology, College of Medical Sciences Teaching Hospital,
      Bharatpur, Nepal.
FAU - Vaidya, Shreeju
AU  - Vaidya S
AD  - Department of Nephrology, College of Medical Sciences Teaching Hospital,
      Bharatpur, Nepal.
FAU - Upadhyay, Hari Prasad
AU  - Upadhyay HP
AD  - Department of Community Medicine, College of Medical Sciences Teaching Hospital, 
      Bharatpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Kidney Diseases/*epidemiology/therapy
MH  - Kidney Failure, Chronic/epidemiology/therapy
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - Systemic Inflammatory Response Syndrome/epidemiology/therapy
MH  - Tertiary Care Centers/statistics & numerical data
PMC - PMC7580387
OTO - NOTNLM
OT  - acute kidney injury; chronic kidney disease; end stage renal disease: sepsis.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.4972 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):459-464. doi: 10.31729/jnma.4972.


PMID- 32827004
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Abnormal Fetal Echocardiography in Diabetic Pregnant Women at a Tertiary Care
      Hospital: A Descriptive Cross-sectional Study.
PG  - 456-458
LID - 10.31729/jnma.5178 [doi]
AB  - INTRODUCTION: The sedentary lifestyle of women and change in their food habits
      has a significant role in developing diabetes in pregnancies. This leads to an
      increased chance of fetal cardiac abnormality born by a mother with gestational
      diabetes and pre-existing diabetes. The objective of the study is to find out the
      prevalence of abnormal fetal echocardiography in gestational and pre-existing
      diabetic pregnant women at a tertiary care hospital. METHODS: A descriptive
      cross-sectional study was conducted among 104 diabetic pregnant women in a
      tertiary care hospital from April 15, 2017, to April 14, 2018. Ethical approval
      was obtained from the institutional review committee. The convenient sampling
      method was used. The patients who were diagnosed as gestational diabetes and
      diabetic before pregnancy were included in the study. Fetal echocardiography was 
      mainly done at a gestational age of 22-32 weeks depending upon the time of
      diagnosis of gestational diabetes and for pre-diabetic women, fetal
      echocardiography was done at 24-26 weeks of gestation. Statistical analysis was
      done using the Statistical Package of the Social Sciences version 20. RESULTS:
      Among 104 patients, 16 (15.38%) patients had abnormal fetal echocardiography.
      Eighty-three (79.81%) were gestational diabetics, 21 (20.19%) were pre-existing
      diabetic women. Among 83 gestational diabetes, 7 (8.4%) had abnormal echo finding
      and among 21 pre-existing diabetics, 9 (42.8%) had abnormal echo finding.
      CONCLUSIONS: There was an increased chance of fetal cardiac malformation in
      gestational diabetic and pre-existing diabetics diabetic especially in an
      uncontrolled glycemic state. And, if they were diagnosed prenatally, clinical
      outcomes for both mother and fetus would have been better.
FAU - Sharma, Jyotshna
AU  - Sharma J
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College, Sinamangal, 
      Kathmandu, Nepal.
FAU - Tiwari, Sanjeeb
AU  - Tiwari S
AD  - Department of General Practice and Emergency Medicine, Maharajgunj Medical
      Campus, Institute of Medicine, T.U., Maharajgunj, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus/diagnostic imaging/epidemiology
MH  - *Diabetes, Gestational/diagnostic imaging/epidemiology
MH  - *Echocardiography/methods/statistics & numerical data
MH  - Female
MH  - Fetal Diseases/diagnostic imaging/epidemiology
MH  - Heart Defects, Congenital/*diagnostic imaging/epidemiology
MH  - Humans
MH  - Nepal/epidemiology
MH  - Pregnancy
MH  - *Pregnancy in Diabetics/diagnostic imaging/epidemiology
MH  - Prevalence
MH  - Tertiary Care Centers
MH  - *Ultrasonography, Prenatal/statistics & numerical data
PMC - PMC7580386
OTO - NOTNLM
OT  - diabetes mellitus; echocardiography; gestational diabetes.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5178 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):456-458. doi: 10.31729/jnma.5178.


PMID- 32827003
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 227
DP  - 2020 Jul 31
TI  - Prevalence of Cervical Cancer among Cervical Biopsies in a Tertiary Care Center.
PG  - 453-455
LID - 10.31729/jnma.5060 [doi]
AB  - INTRODUCTION: Cervical cancer is one of the most common cancer among the female
      population in Nepal. The incidence and mortality rate due to cervical cancer is
      higher in developing countries like Nepal due to a lack of proper screening and
      early diagnosis. This study aims to find out the prevalence of cervical cancer
      among cervical biopsies in a tertiary care center. METHODS: A descriptive
      cross-sectional study was conducted among the hospital records of cervical
      biopsies from the department of pathology of Shree Birendra Hospital from 1st May
      2018 to 30th April 2019. Ethical approval was taken from the Institutional Review
      Committee in February 2020. This study was conducted among 146 cervical biopsies 
      by using convenience sampling method. Point estimate at 95% Confidence Interval
      was calculated along with frequency and proportion for binary data. Data were
      analyzed using excel 2016 software. RESULTS: The prevalence of cervical cancer
      among 146 cases included in our study is found to be 6 (4.11%) at 95% Confidence 
      Interval (0.90-7.32). Among those cases of cervical cancer, 4 (66.67%) were
      squamous cell carcinoma, 1 (16.67%) was adenocarcinoma, and 1 (16.67%) was of
      other type. Maximum cases of cervical cancer were prevalent among higher age
      groups. CONCLUSIONS: Cervical cancer-related morbidity and mortality are
      different in different parts of the world. It's burden is primarily seen in
      developing countries where there is a lack of effective screening programs.
FAU - Parajuli, Ganesh
AU  - Parajuli G
AD  - Department of Pathology, Nepalese Army Institute of Health Sciences,
      Sanobharyang, Kathmandu, Nepal.
FAU - Dawadi, Pravakar
AU  - Dawadi P
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
FAU - Khadka, Sabina
AU  - Khadka S
AD  - Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy/statistics & numerical data
MH  - Cervix Uteri/*pathology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - Tertiary Care Centers/statistics & numerical data
MH  - *Uterine Cervical Neoplasms/epidemiology/pathology
PMC - PMC7580393
OTO - NOTNLM
OT  - cervical cancer; mortality; prevalence; screening.
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.31729/jnma.5060 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):453-455. doi: 10.31729/jnma.5060.


PMID- 32826938
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20210821
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Aug 21
TI  - Consistent differences in a virtual world model of ape societies.
PG  - 14075
LID - 10.1038/s41598-020-70955-6 [doi]
AB  - Practical and ethical constraints limit our ability to experimentally test
      socioecological theory in wild primates. We took an alternate approach to model
      this, allowing groups of humans to interact in a virtual world in which they had 
      to find food and interact with both ingroup and outgroup avatars to earn rewards.
      We altered ratios and distributions of high- and low-value foods to test the
      hypothesis that hominoids vary with regards to social cohesion and intergroup
      tolerance due to their feeding ecology. We found larger nesting clusters and
      decreased attacks on outgroup competitors in the Bonobo condition versus the
      Chimpanzee condition, suggesting a significant effect of feeding competition
      alone on social structure. We also demonstrate that virtual worlds are a robust
      mechanism for testing hypotheses that are impossible to study in the wild.
FAU - Wilson, Bart J
AU  - Wilson BJ
AD  - Economic Science Institute & Smith Institute for Political Economy and
      Philosophy, Chapman University, Orange, CA, USA. bartwilson@gmail.com.
FAU - Brosnan, Sarah F
AU  - Brosnan SF
AD  - Departments of Psychology and Philosophy, Neuroscience Institute, Language
      Research Center and Center for Behavioral Neuroscience, Georgia State University,
      Atlanta, GA, USA.
FAU - Lonsdorf, Elizabeth V
AU  - Lonsdorf EV
AD  - Department of Psychology, Biological Foundations of Behavior Program, Franklin
      and Marshall College, Lancaster, PA, USA.
FAU - Sanz, Crickette M
AU  - Sanz CM
AD  - Department of Anthropology, Washington University, Saint Louis, MO, USA.
AD  - Congo Program, Wildlife Conservation Society, Brazzaville, Republic of the Congo.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200821
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Aggression
MH  - Animals
MH  - Competitive Behavior
MH  - Energy Intake
MH  - *Feeding Behavior
MH  - Games, Experimental
MH  - Humans
MH  - *Pan paniscus
MH  - *Pan troglodytes
MH  - *Social Behavior
MH  - *Virtual Reality
PMC - PMC7442632
EDAT- 2020/08/23 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - 10.1038/s41598-020-70955-6 [doi]
AID - 10.1038/s41598-020-70955-6 [pii]
PST - epublish
SO  - Sci Rep. 2020 Aug 21;10(1):14075. doi: 10.1038/s41598-020-70955-6.


PMID- 32826433
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210430
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 48
IP  - 12
DP  - 2020 Dec
TI  - The Triage Stalemate During the Coronavirus Disease 2019 Pandemic: Losing
      Fairness to Ethical Paralysis.
PG  - e1380-e1381
LID - 10.1097/CCM.0000000000004567 [doi]
FAU - Kopar, Piroska K
AU  - Kopar PK
AD  - Department of Surgery, Washington University, St. Louis School of Medicine, St.
      Louis, MO.
FAU - Brown, Douglas E
AU  - Brown DE
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
SB  - IM
CON - Crit Care Med. 2020 Aug;48(8):1196-1202. PMID: 32697491
MH  - Adult
MH  - *COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Humans
MH  - Intensive Care Units
MH  - Pandemics
MH  - Paralysis
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Triage
PMC - PMC7467035
EDAT- 2020/08/23 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - 10.1097/CCM.0000000000004567 [doi]
AID - 00003246-202012000-00100 [pii]
PST - ppublish
SO  - Crit Care Med. 2020 Dec;48(12):e1380-e1381. doi: 10.1097/CCM.0000000000004567.


PMID- 32826303
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - On Loland's conception of fair equality of opportunity in sport.
PG  - 595-596
LID - 10.1136/medethics-2020-106748 [doi]
FAU - Anderson, Lynley C
AU  - Anderson LC
AD  - Bioethics Centre, University of Otago, Dunedin, New Zealand
      lynley.anderson@otago.ac.nz.
FAU - Knox, Taryn Rebecca
AU  - Knox TR
AUID- ORCID: 0000-0002-1595-5454
AD  - Bioethics Centre, University of Otago, Dunedin, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200821
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Sep;46(9):584-590. PMID: 32690761
CIN - J Med Ethics. 2020 Sep;46(9):599-600. PMID: 32826302
MH  - Athletes
MH  - Humans
MH  - *Social Justice
MH  - *Sports
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/08/23 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/07/28 00:00 [received]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - medethics-2020-106748 [pii]
AID - 10.1136/medethics-2020-106748 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):595-596. doi: 10.1136/medethics-2020-106748. Epub
      2020 Aug 21.


PMID- 32826302
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Response to commentaries on 'Caster Semenya, athlete classification, and fair
      equality of opportunity in sport'.
PG  - 599-600
LID - 10.1136/medethics-2020-106755 [doi]
FAU - Loland, Sigmund
AU  - Loland S
AD  - Institute of Sport and Social Sciences, Norwegian School of Sports Sciences,
      Oslo, Norway sigmund.loland@nih.no.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200821
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Sep;46(9):584-590. PMID: 32690761
CON - J Med Ethics. 2020 Sep;46(9):591-592. PMID: 32723761
CON - J Med Ethics. 2020 Sep;46(9):593-594. PMID: 32792348
CON - J Med Ethics. 2020 Sep;46(9):597-598. PMID: 32817411
CON - J Med Ethics. 2020 Sep;46(9):595-596. PMID: 32826303
MH  - Athletes
MH  - Humans
MH  - *Sports
PMC - PMC7476286
OTO - NOTNLM
OT  - *distributive justice
OT  - *ethics
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/08/23 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/07/30 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - medethics-2020-106755 [pii]
AID - 10.1136/medethics-2020-106755 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):599-600. doi: 10.1136/medethics-2020-106755. Epub
      2020 Aug 21.


PMID- 32826185
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - An Ethics-based Approach to Research in Global Health: A Call to Action for
      Pharmacists.
PG  - 1569-1573
LID - S1551-7411(20)30158-3 [pii]
LID - 10.1016/j.sapharm.2020.07.032 [doi]
AB  - As opportunities and interests in international partnerships and research
      continue to grow in pharmacy, so, too, does the likelihood of encountering
      ethical challenges. We posit that the chance of encountering an ethical challenge
      in global health is almost inevitable. This commentary serves as an introduction 
      to a series of four papers highlighting ethical issues in global health research 
      for pharmacists. The authors draw on core ethical principles to guide
      collaborative global research in working to advance the health of people and
      populations worldwide.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Jonkman, Lauren J
AU  - Jonkman LJ
AD  - University of Pittsburgh, School of Pharmacy, 5607 Baum Blvd., Suite 303,
      Pittsburgh, PA, 15206, USA. Electronic address: ljf1@pitt.edu.
FAU - Nonyel, Nkem P
AU  - Nonyel NP
AD  - University of Maryland Eastern Shore, School of Pharmacy and Health Professions, 
      1 College Backbone Road, Princess Anne, MD, 21853, USA. Electronic address:
      npnonyel@umes.edu.
FAU - Law, Miranda G
AU  - Law MG
AD  - Howard University College of Pharmacy, 2300 4th Street NW, Washington, DC, 20059,
      USA. Electronic address: miranda.law@howard.edu.
FAU - Drame, Imbi
AU  - Drame I
AD  - Howard University College of Pharmacy, 2300 4th Street NW, Washington, DC, 20059,
      USA. Electronic address: imbi.drame@howard.edu.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
SB  - IM
MH  - *Global Health
MH  - Humans
MH  - Morals
MH  - Pharmacists
MH  - *Pharmacy
OTO - NOTNLM
OT  - Global health research
OT  - Health care ethics
OT  - Health equity
EDAT- 2020/08/23 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - S1551-7411(20)30158-3 [pii]
AID - 10.1016/j.sapharm.2020.07.032 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Nov;16(11):1569-1573. doi:
      10.1016/j.sapharm.2020.07.032. Epub 2020 Aug 1.


PMID- 32826103
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20210210
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 41
DP  - 2020 Sep 22
TI  - So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine
      development.
PG  - 6381-6387
LID - S0264-410X(20)31048-3 [pii]
LID - 10.1016/j.vaccine.2020.08.017 [doi]
AB  - BACKGROUND: A sense of urgency exists to develop vaccines against SARS CoV-2,
      responsible for numerous global cases and deaths, as well as widespread social
      and economic disruption. Multiple approaches have been proposed to speed up
      vaccine development, including accelerated randomized controlled trials (RCT),
      controlled human challenge trials (CHI), and wide distribution through an
      emergency use authorization after collecting initial data. There is a need to
      examine how best to accelerate vaccine development in the setting of a pandemic, 
      without compromising ethical and scientific norms. METHODS: Trade-offs in
      scientific and social value between generating reliable evidence about safety and
      efficacy while promoting rapid vaccine availability are examined along five
      ethically relevant dimensions: (1) confidence in and generalizability of data,
      (2) feasibility, (3) speed and cost, (4) participant risks, and (5) social risks.
      RESULTS: Accelerated individually randomized RCTs permit expeditious evaluation
      of vaccine candidates using established methods, expertise, and infrastructure.
      RCTs are more likely than other approaches to be feasible, increase speed and
      reduce cost, and generate reliable data about safety and efficacy without
      significantly increasing risks to participants or undermining societal trust.
      CONCLUSION: Ethical analysis suggests that accelerated RCTs are the best approach
      to accelerating vaccine development in a pandemic, and more likely than other
      approaches to enhance social value without compromising ethics or science. RCTs
      can expeditiously collect rigorous data about vaccine safety and efficacy.
      Innovative and flexible designs and implementation strategies to respond to
      shifting incidence and test vaccine candidates in parallel or sequentially would 
      add value, as will coordinated data sharing across vaccine trials. CHI studies
      may be an important complementary strategy when more is known. Widely
      disseminating a vaccine candidate without efficacy data will not serve the public
      health nor achieve the goal of identifying safe and effective SARS Co-V-2
      vaccines.
CI  - Published by Elsevier Ltd.
FAU - Grady, Christine
AU  - Grady C
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      cgrady@nih.gov.
FAU - Shah, Seema
AU  - Shah S
AD  - Lurie Children's Hospital, Northwestern University, Department of Pediatrics, 225
      E. Chicago Ave, Chicago, IL 60611, United States. Electronic address:
      Seshah@lurie.childrens.org.
FAU - Miller, Franklin
AU  - Miller F
AD  - Weill Cornell Medical College, Weill Cornell Medical College, 1300 York Ave, New 
      York, NY 10065, United States. Electronic address: fgm2002@med.cornell.edu.
FAU - Danis, Marion
AU  - Danis M
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      mdanis@nih.gov.
FAU - Nicolini, Marie
AU  - Nicolini M
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      marie.nicolini@nih.gov.
FAU - Ochoa, Jorge
AU  - Ochoa J
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      jorge.ochoa@nih.gov.
FAU - Taylor, Holly
AU  - Taylor H
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      holly.taylor2@nih.gov.
FAU - Wendler, Dave
AU  - Wendler D
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      dwendler@cc.nih.gov.
FAU - Rid, Annette
AU  - Rid A
AD  - Department of Bioethics, National Institutes of Health Clinical Center, Building 
      10/1C118, NIH, Bethesda, MD 20892, United States. Electronic address:
      annette.rid@nih.gov.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200811
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Viral Vaccines)
SB  - IM
CIN - Vaccine. 2021 Feb 12;39(7):1027. PMID: 33546810
MH  - Betacoronavirus/*immunology
MH  - Biomedical Research/*ethics
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Drug Development/*ethics
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
MH  - Vaccination/ethics
MH  - Viral Vaccines/immunology
PMC - PMC7418641
OTO - NOTNLM
OT  - *Clinical trials
OT  - *Ethics
OT  - *SARS Co-V-2
OT  - *Vaccine
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/08/23 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/07/19 00:00 [received]
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - S0264-410X(20)31048-3 [pii]
AID - 10.1016/j.vaccine.2020.08.017 [doi]
PST - ppublish
SO  - Vaccine. 2020 Sep 22;38(41):6381-6387. doi: 10.1016/j.vaccine.2020.08.017. Epub
      2020 Aug 11.


PMID- 32826051
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 114
IP  - 4
DP  - 2020 Oct
TI  - Longitudinal vaginal septum: a proposed classification and surgical management.
PG  - 899-901
LID - S0015-0282(20)30586-0 [pii]
LID - 10.1016/j.fertnstert.2020.06.014 [doi]
AB  - OBJECTIVE: To demonstrate various types of longitudinal vaginal septa (LVS),
      their classification, and the surgical management of typical and unique
      morphologic conditions of LVS. DESIGN: Video presentation of clinical appearance 
      and surgical techniques for treatment of LVS. SETTING: University hospital and
      two private. PATIENT(S): Representative cases from 121 consecutive women treated 
      from 2013 to 2018 with LVS as a part of complex uterovaginal malformations or in 
      isolated forms with [1] typical morphologic configuration of LVS, [2] rarer
      variants, or [3] specific anatomic restrictions. INTERVENTION(S): Resection of
      LVS performed as a main surgical procedure in cases with didelphys and bicornuate
      uterus in symptomatic women and as a part of corrective surgery of complete
      septate uterus. The three main nonsuturing techniques used were speculoscopy and 
      septum excision using three different electrosurgical modalities; speculoscopy
      with laparoscopic devices; and vaginoscopy with hysteroscopic instruments. MAIN
      OUTCOME MEASURE(S): Clinical appearance and suggested classification, feasibility
      of surgery, and perioperative and anatomic results in a short follow-up period (3
      months). RESULT(S): We identified distinct types of longitudinal vaginal septa.
      Considering clinical appearance, we suggest classification of LVS based on four
      main features: [2] completeness of vaginal division: partial and complete type;
      [2] the symmetricity: symmetric and asymmetric position (with dominant left and
      right side); [3] association with the cervix: merged and isolated forms; and [4] 
      concomitant vaginal openings: normal, and narrow openings: vaginal stenosis and
      hymen persistent (Fig. 1). Vaginoscopic techniques by hysteroscope were
      successful in atraumatic treatment of women with substantial anatomic
      restrictions, and all of the presented techniques can be effectively used for
      typical LVS. However, vessel-sealing systems allow for bloodless surgery in
      contrast with other methods. This study was based on previously acquired data
      during large prospective study approved by the local ethics committee, and
      written informed consent to participate in the prospective study and permit
      publishing anonymous data regarding the medical images, videos of procedures, and
      results was obtained from all patients. CONCLUSION(S): A new classification of
      longitudinal vaginal septum allows better characterization compared with the
      currently available classification systems. Different surgical modalities are
      discussed with their respective advantages and disadvantages. Vaginoscopic
      incision using resectoscope is a reasonable alternative for women with an intact 
      hymen and vaginal stenosis. The impact of vaginal septum resection on obstetric, 
      reproductive, and sexual outcomes should be assessed in randomized controlled
      trials and large well-designed studies.
CI  - Copyright (c) 2020 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Ludwin, Artur
AU  - Ludwin A
AD  - Department of Gynecology and Oncology, Jagiellonian University, Krakow, Poland;
      Ludwin & Ludwin Gynecology, Private Medical Center, Krakow, Poland; Centermed
      Private Hospital and Clinic, Krakow, Poland. Electronic address:
      ludwin@cm-uj.krakow.pl.
FAU - Lindheim, Steven R
AU  - Lindheim SR
AD  - Department of Obstetrics and Gynecology, Boonshoft School of Medicine, Wright
      State University, Dayton, Ohio; Shanghai Jiaotong University School of Medicine, 
      Shanghai, People's Republic of China.
FAU - Bhagavath, Bala
AU  - Bhagavath B
AD  - Department of Obstetrics and Gynecology, School of Medicine and Dentistry,
      University of Rochester Medical Center, Rochester, New York.
FAU - Martins, Wellington P
AU  - Martins WP
AD  - Department of Obstetrics and Gynecology, Ribeirao Preto Medical School,
      University of Sao Paulo, Ribeirao Preto, Brazil; SEMEAR Fertilidade, Reproductive
      Medicine, Ribeirao Preto, Brazil.
FAU - Ludwin, Inga
AU  - Ludwin I
AD  - Department of Gynecology and Oncology, Jagiellonian University, Krakow, Poland;
      Ludwin & Ludwin Gynecology, Private Medical Center, Krakow, Poland; Centermed
      Private Hospital and Clinic, Krakow, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
DEP - 20200818
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
CIN - Fertil Steril. 2020 Oct;114(4):768. PMID: 32854932
MH  - Female
MH  - Humans
MH  - Vagina/*abnormalities/*surgery
OTO - NOTNLM
OT  - *Complete septate uterus
OT  - *hysteroscopy
OT  - *mullerian anomalies
OT  - *obstructed hemivagina
OT  - *uterus didelphys
EDAT- 2020/08/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/23 06:00
PHST- 2019/09/08 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - S0015-0282(20)30586-0 [pii]
AID - 10.1016/j.fertnstert.2020.06.014 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Oct;114(4):899-901. doi: 10.1016/j.fertnstert.2020.06.014.
      Epub 2020 Aug 18.


PMID- 32825612
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201027
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Aug 21
TI  - Computer-Aided Diagnosis in Multiparametric MRI of the Prostate: An Open-Access
      Online Tool for Lesion Classification with High Accuracy.
LID - E2366 [pii]
LID - 10.3390/cancers12092366 [doi]
AB  - Computer-aided diagnosis (CADx) approaches could help to objectify reporting on
      prostate mpMRI, but their use in many cases is hampered due to common-built
      algorithms that are not publicly available. The aim of this study was to develop 
      an open-access CADx algorithm with high accuracy for classification of suspicious
      lesions in mpMRI of the prostate. This retrospective study was approved by the
      local ethics commission, with waiver of informed consent. A total of 124 patients
      with 195 reported lesions were included. All patients received mpMRI of the
      prostate between 2014 and 2017, and transrectal ultrasound (TRUS)-guided and
      targeted biopsy within a time period of 30 days. Histopathology of the biopsy
      cores served as a standard of reference. Acquired imaging parameters included the
      size of the lesion, signal intensity (T2w images), diffusion restriction,
      prostate volume, and several dynamic parameters along with the clinical
      parameters patient age and serum PSA level. Inter-reader agreement of the imaging
      parameters was assessed by calculating intraclass correlation coefficients. The
      dataset was stratified into a train set and test set (156 and 39 lesions in 100
      and 24 patients, respectively). Using the above parameters, a CADx based on an
      Extreme Gradient Boosting algorithm was developed on the train set, and tested on
      the test set. Performance optimization was focused on maximizing the area under
      the Receiver Operating Characteristic curve (ROCAUC). The algorithm was made
      publicly available on the internet. The CADx reached an ROCAUC of 0.908 during
      training, and 0.913 during testing (p = 0.93). Additionally, established rule-in 
      and rule-out criteria allowed classifying 35.8% of the malignant and 49.4% of the
      benign lesions with error rates of <2%. All imaging parameters featured excellent
      inter-reader agreement. This study presents an open-access CADx for
      classification of suspicious lesions in mpMRI of the prostate with high accuracy.
      Applying the provided rule-in and rule-out criteria might facilitate to further
      stratify the management of patients at risk.
FAU - Ellmann, Stephan
AU  - Ellmann S
AUID- ORCID: 0000-0003-2737-5526
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Schlicht, Michael
AU  - Schlicht M
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Dietzel, Matthias
AU  - Dietzel M
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Janka, Rolf
AU  - Janka R
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Hammon, Matthias
AU  - Hammon M
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Saake, Marc
AU  - Saake M
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Ganslandt, Thomas
AU  - Ganslandt T
AUID- ORCID: 0000-0001-6864-8936
AD  - Department of Medical Informatics, Friedrich-Alexander-University
      Erlangen-Nuremberg, 91058 Erlangen, Germany.
AD  - Heinrich-Lanz-Center for Digital Health, Department of Biomedical Informatics,
      University Medicine Mannheim, Heidelberg University, 68177 Mannheim, Germany.
FAU - Hartmann, Arndt
AU  - Hartmann A
AD  - Institute of Pathology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Kunath, Frank
AU  - Kunath F
AD  - Department of Urology and Paediatric Urology, University Hospital Erlangen, 91054
      Erlangen, Germany.
FAU - Wullich, Bernd
AU  - Wullich B
AD  - Department of Urology and Paediatric Urology, University Hospital Erlangen, 91054
      Erlangen, Germany.
FAU - Uder, Michael
AU  - Uder M
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
FAU - Bauerle, Tobias
AU  - Bauerle T
AD  - Department of Radiology, University Hospital Erlangen, 91054 Erlangen, Germany.
LA  - eng
GR  - CRC 1181 - project Z02/Deutsche Forschungsgemeinschaft
PT  - Journal Article
DEP - 20200821
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7565879
OTO - NOTNLM
OT  - artificial intelligence
OT  - computer-aided diagnosis
OT  - machine learning
OT  - prostate cancer
OT  - prostate mpMRI
EDAT- 2020/08/23 06:00
MHDA- 2020/08/23 06:01
CRDT- 2020/08/23 06:00
PHST- 2020/07/12 00:00 [received]
PHST- 2020/08/09 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/08/23 06:01 [medline]
AID - cancers12092366 [pii]
AID - 10.3390/cancers12092366 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Aug 21;12(9). pii: cancers12092366. doi:
      10.3390/cancers12092366.


PMID- 32825055
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 9
DP  - 2020 Aug 19
TI  - Optimal Methods of Documenting Analgesic Efficacy in Neonatal Piglets Undergoing 
      Castration.
LID - E1450 [pii]
LID - 10.3390/ani10091450 [doi]
AB  - Analgesic products for piglet castration are critically needed. This requires
      extensive animal experimentation such as to meet regulatory-required proof of
      efficacy. At present, there are no validated methods of assessing pain in
      neonatal piglets. This poses challenges for investigators to optimize trial
      design and to meet ethical obligations to minimize the number of animals needed. 
      Pain in neonatal piglets may be subtle, transient, and/or variably expressed and,
      in the absence of validated methods, investigators must rely on using a range of 
      biochemical, physiological and behavioural variables, many of which appear to
      have very low (or unknown) sensitivity or specificity for documenting pain, or
      pain-relieving effects. A previous systematic review of this subject was hampered
      by the high degree of variability in the literature base both in terms of methods
      used to assess pain and pain mitigation, as well as in outcomes reported. In this
      setting we provide a narrative review to assist in determining the optimal
      methods currently available to detect piglet pain during castration and methods
      to mitigate castration-induced pain. In overview, the optimal outcome variables
      identified are nociceptive motor and vocal response scores during castration and 
      quantitative sensory-threshold response testing and pain-associated behaviour
      scores following castration.
FAU - Sheil, Meredith
AU  - Sheil M
AD  - Animal Ethics Pty. Ltd., Yarra Glen, VIC 3775, Australia.
FAU - Polkinghorne, Adam
AU  - Polkinghorne A
AD  - Department of Microbiology and Infectious Diseases, NSW Health Pathology, Nepean 
      Hospital, Penrith, NSW 2750, Australia.
AD  - Faculty of Medicine and Health, Nepean Clinical School, The University of Sydney 
      Medical School, University of Sydney, Penrith, NSW 2750, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200819
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7552769
OTO - NOTNLM
OT  - anaesthesia
OT  - analgesia
OT  - behaviour
OT  - castration
OT  - neonate
OT  - nociception
OT  - pain
OT  - peri-operative
OT  - piglet
OT  - vocalisation
EDAT- 2020/08/23 06:00
MHDA- 2020/08/23 06:01
CRDT- 2020/08/23 06:00
PHST- 2020/07/27 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/08/13 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/08/23 06:01 [medline]
AID - ani10091450 [pii]
AID - 10.3390/ani10091450 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Aug 19;10(9). pii: ani10091450. doi: 10.3390/ani10091450.


PMID- 32824182
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 16
DP  - 2020 Aug 15
TI  - Counteracting Abuse in Health Care: Evaluating a One-Year Drama Intervention with
      Staff in Sweden.
LID - E5931 [pii]
LID - 10.3390/ijerph17165931 [doi]
AB  - In Northern European countries 13-28% of female patients seeking gynecological
      health care have reported abuse by health care staff (AHC). We conducted
      workshops with health care staff using the improvised role-play method Forum Play
      (FP), based on techniques developed by Boal. The study explores to what extent
      the intervention increased the staff's awareness of AHC and their ability to take
      action against it. A total of 16 half-day FP workshops were conducted with staff 
      from a Swedish women's clinic over one year. Self-reported questionnaires were
      distributed to all staff before, during, and after the intervention. Primary
      outcome measures were the number of reported occasions of AHC and FP
      participants' ability to act in AHC-situations. We found an increase in the
      participants' self-reported ability to act in AHC-related situations. However, no
      change could be observed in the number of reported occasions of AHC between
      baseline and one year after the intervention. Health care staff's participation
      in workshops using improvised role-play can increase staff's perceived ability to
      take action in AHC situations. The voluntary nature of the intervention may have 
      attracted those who were already aware of the topic, and likely explains the
      unchanged awareness of AHC.
FAU - Zbikowski, Anke
AU  - Zbikowski A
AD  - Women's Clinic, Ryhov County Hospital, 55185 Jonkoping, Sweden.
FAU - Bruggemann, A Jelmer
AU  - Bruggemann AJ
AUID- ORCID: 0000-0002-1514-677X
AD  - Department of Thematic Studies-Technology and Social Change, Faculty of Arts and 
      Sciences, Linkoping University, 58183 Linkoping, Sweden.
FAU - Wijma, Barbro
AU  - Wijma B
AD  - Department of Biomedical and Clinical Sciences (BKV), Faculty of Medicine and
      Health Sciences, Division of Children's and Women's Health (BKH), Linkoping
      University, 58183 Linkoping, Sweden.
FAU - Swahnberg, Katarina
AU  - Swahnberg K
AUID- ORCID: 0000-0001-5200-1740
AD  - Department of Health and Caring Sciences, Faculty of Health and Life Sciences,
      Linnaeus University, Hus Vita, 39182 Kalmar, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200815
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Attitude of Health Personnel
MH  - *Crime
MH  - *Delivery of Health Care/standards
MH  - *Drama
MH  - Female
MH  - *Gynecology/standards
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Professional-Patient Relations
MH  - Surveys and Questionnaires
MH  - Sweden
PMC - PMC7459683
OTO - NOTNLM
OT  - *Forum theater
OT  - *abuse in health care
OT  - *communication training
OT  - *ethical learning
OT  - *professional-patient relation
OT  - *role-play
EDAT- 2020/08/23 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/07/16 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - ijerph17165931 [pii]
AID - 10.3390/ijerph17165931 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Aug 15;17(16). pii: ijerph17165931. doi:
      10.3390/ijerph17165931.


PMID- 32823696
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 16
DP  - 2020 Aug 13
TI  - Biomonitoring as an Underused Exposure Assessment Tool in Occupational Safety and
      Health Context-Challenges and Way Forward.
LID - E5884 [pii]
LID - 10.3390/ijerph17165884 [doi]
AB  - Recent advances in analytical chemistry have allowed a greater possibility of
      using quantitative approaches for measuring human exposure to chemicals. One of
      these approaches is biomonitoring (BM), which provides unequivocal evidence that 
      both exposure and uptake of a chemical have taken place. BM has been a
      longstanding practice in occupational health for several reasons. BM integrates
      exposure from all routes. It can help identify unintentional and unexpected
      exposures and assess the effectiveness of existing risk-management measures. BM
      also provides relevant information to support policy development by delivering
      better evidence of workers' exposure to chemical substances, even within the
      framework of the present regulations. Thus, BM can allow for both the evaluation 
      of the impact of regulation and identification of further needs for new or
      improved regulation. However, despite all these well-recognized advantages, BM is
      currently an underused exposure assessment tool. This paper provides an overview 
      of the key aspects to be considered when using BM in the context of occupational 
      health interventions. Additionally, this paper describes the potential of BM as
      an exposure assessment tool, distinguishing the role of BM in exposure assessment
      and health surveillance and clarifies ethical and communication aspects to
      guarantee that general data protection regulations are followed. In addition,
      actions and research needs are identified (particularly with reference to the
      European situation), which aim to encourage the increased use of BM as an
      exposure assessment tool.
FAU - Viegas, Susana
AU  - Viegas S
AUID- ORCID: 0000-0003-1015-8760
AD  - NOVA National School of Public Health, Public Health Research Centre,
      Universidade NOVA de Lisboa, 1600-560 Lisbon, Portugal.
AD  - Comprehensive Health Research Center (CHRC), 1169-056 Lisbon, Portugal.
AD  - H&TRC-Health & Technology Research Center, ESTeSL-Escola Superior de Tecnologia
      da Saude, Instituto Politecnico de Lisboa, 1500-310 Lisboa, Portugal.
FAU - Zare Jeddi, Maryam
AU  - Zare Jeddi M
AUID- ORCID: 0000-0002-9505-812X
AD  - Unit of Biostatistics, Epidemiology and Public Health, Department of
      Cardio-Thoraco-Vascular Sciences and Public Health, 35100 Padova, Italy.
FAU - B Hopf, Nancy
AU  - B Hopf N
AUID- ORCID: 0000-0002-4490-6109
AD  - Center for Primary Care and Public Health (Unisante), University of Lausanne,
      1000 Lausanne, Switzerland.
FAU - Bessems, Jos
AU  - Bessems J
AUID- ORCID: 0000-0001-5718-0733
AD  - VITO-Flemish Institute for Technological Research, BE-2400 Mol, Belgium.
FAU - Palmen, Nicole
AU  - Palmen N
AD  - RIVM-National Institute for Public Health and the Environment, 3721 MA Bilthoven,
      The Netherlands.
FAU - S Galea, Karen
AU  - S Galea K
AD  - Institute of Occupational Medicine (IOM), Edinburgh EH14 4AP, UK.
FAU - Jones, Kate
AU  - Jones K
AUID- ORCID: 0000-0001-8923-2999
AD  - Health and Safety Executive (HSE), Harpur Hill, Buxton SK17 9JN, UK.
FAU - Kujath, Peter
AU  - Kujath P
AD  - BAuA-Federal Institute for Occupational Safety and Health, D-10317 Berlin,
      Germany.
FAU - Duca, Radu-Corneliu
AU  - Duca RC
AUID- ORCID: 0000-0002-9350-3816
AD  - Unit Environmental Hygiene and Human Biological Monitoring, Department of Health 
      Protection, National Health Laboratory, Dudelange, 3555 Luxembourg, Luxembourg.
AD  - Centre Environment and Health, Department of Public Health and Primary Care, KU
      Leuven, 03000 Flanders, Belgium.
FAU - Verhagen, Hans
AU  - Verhagen H
AUID- ORCID: 0000-0001-7952-3530
AD  - European Food Safety Authority (EFSA), 43126 Parma, Italy.
AD  - Nutrition Innovation Center for Food and Health (NICHE), University of Ulster,
      Coleraine BT52 1SA, UK.
FAU - Santonen, Tiina
AU  - Santonen T
AD  - FIOH-Finnish Institute of Occupational Health, P.O. Box 40, FI-00032
      Tyoterveyslaitos, Finland.
FAU - Pasanen-Kase, Robert
AU  - Pasanen-Kase R
AUID- ORCID: 0000-0002-9432-5708
AD  - State Secretariat for Economic Affairs (SECO), Labour Directorate Section
      Chemicals and Work (ABCH), 3003 Berne, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200813
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Biological Monitoring
MH  - Environmental Exposure/analysis
MH  - Environmental Monitoring
MH  - Humans
MH  - *Occupational Exposure/analysis
MH  - *Occupational Health
MH  - Risk Assessment
MH  - Risk Management
PMC - PMC7460384
OTO - NOTNLM
OT  - *biological guidance value
OT  - *biological limit value
OT  - *biological monitoring
OT  - *exposure assessment
OT  - *occupational health
OT  - *risk assessment
EDAT- 2020/08/23 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/07/08 00:00 [received]
PHST- 2020/08/07 00:00 [revised]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - ijerph17165884 [pii]
AID - 10.3390/ijerph17165884 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Aug 13;17(16). pii: ijerph17165884. doi:
      10.3390/ijerph17165884.


PMID- 32823322
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20211129
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - From Patient Engagement to Precision Oncology: Leveraging Informatics to Advance 
      Cancer Care.
PG  - 235-242
LID - 10.1055/s-0040-1701983 [doi]
AB  - OBJECTIVES: Conduct a survey of the literature for advancements in cancer
      informatics over the last three years in three specific areas where there has
      been unprecedented growth: 1) digital health; 2) machine learning; and 3)
      precision oncology. We also highlight the ethical implications and future
      opportunities within each area. METHODS: A search was conducted over a three-year
      period in two electronic databases (PubMed, Google Scholar) to identify
      peer-reviewed articles and conference proceedings. Search terms included
      variations of the following: neoplasms[MeSH], informatics[MeSH], cancer,
      oncology, clinical cancer informatics, medical cancer informatics. The search
      returned too many articles for practical review (23,994 from PubMed and 23,100
      from Google Scholar). Thus, we conducted searches of key PubMed-indexed
      informatics journals and proceedings. We further limited our search to
      manuscripts that demonstrated a clear focus on clinical or translational cancer
      informatics. Manuscripts were then selected based on their methodological rigor, 
      scientific impact, innovation, and contribution towards cancer informatics as a
      field or on their impact on cancer care and research. RESULTS: Key developments
      and opportunities in cancer informatics research in the areas of digital health, 
      machine learning, and precision oncology were summarized. CONCLUSION: While there
      are numerous innovations in the field of cancer informatics to advance prevention
      and clinical care, considerable challenges remain related to data sharing and
      privacy, digital accessibility, and algorithm biases and interpretation. The
      implementation and application of these findings in cancer care necessitates
      further consideration and research.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Griffin, Ashley C
AU  - Griffin AC
AD  - University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
FAU - Topaloglu, Umit
AU  - Topaloglu U
AD  - Wake Forest University School of Medicine, Winston-Salem, NC, USA.
FAU - Davis, Sean
AU  - Davis S
AD  - National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
FAU - Chung, Arlene E
AU  - Chung AE
AD  - University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
AD  - University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 
      USA.
AD  - UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
LA  - eng
GR  - R01 EB025024/EB/NIBIB NIH HHS/United States
GR  - KL2 TR001432/TR/NCATS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - L30 DK099910/DK/NIDDK NIH HHS/United States
GR  - L30 CA200405/CA/NCI NIH HHS/United States
GR  - T15 LM012500/LM/NLM NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Humans
MH  - *Machine Learning
MH  - *Medical Informatics
MH  - *Medical Oncology
MH  - Neoplasms/*therapy
MH  - Patient Participation
MH  - *Precision Medicine
PMC - PMC7442514
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1701983 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):235-242. doi: 10.1055/s-0040-1701983. Epub 2020 
      Aug 21.


PMID- 32823317
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Clinical Research Informatics.
PG  - 203-207
LID - 10.1055/s-0040-1702007 [doi]
AB  - OBJECTIVES: To summarize key contributions to current research in the field of
      Clinical Research Informatics (CRI) and to select best papers published in 2019. 
      METHOD: A bibliographic search using a combination of MeSH descriptors and
      free-text terms on CRI was performed using PubMed, followed by a double-blind
      review in order to select a list of candidate best papers to be then
      peer-reviewed by external reviewers. After peer-review ranking, a consensus
      meeting between the two section editors and the editorial team was organized to
      finally conclude on the selected three best papers. RESULTS: Among the 517
      papers, published in 2019, returned by the search, that were in the scope of the 
      various areas of CRI, the full review process selected three best papers. The
      first best paper describes the use of a homomorphic encryption technique to
      enable federated analysis of real-world data while complying more easily with
      data protection requirements. The authors of the second best paper demonstrate
      the evidence value of federated data networks reporting a large real world data
      study related to the first line treatment for hypertension. The third best paper 
      reports the migration of the US Food and Drug Administration (FDA) adverse event 
      reporting system database to the OMOP common data model. This work opens the
      combined analysis of both spontaneous reporting system and electronic health
      record (EHR) data for pharmacovigilance. CONCLUSIONS: The most significant
      research efforts in the CRI field are currently focusing on real world evidence
      generation and especially the reuse of EHR data. With the progress achieved this 
      year in the areas of phenotyping, data integration, semantic interoperability,
      and data quality assessment, real world data is becoming more accessible and
      reusable. High quality data sets are key assets not only for large scale
      observational studies or for changing the way clinical trials are conducted but
      also for developing or evaluating artificial intelligence algorithms guiding
      clinical decision for more personalized care. And lastly, security and
      confidentiality, ethical and regulatory issues, and more generally speaking data 
      governance are still active research areas this year.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Daniel, Christel
AU  - Daniel C
AD  - Information Technology Department, AP-HP, Paris, France.
AD  - Sorbonne University, University Paris 13, Sorbonne Paris Cite, INSERM UMR_S 1142,
      LIMICS, Paris, France.
FAU - Kalra, Dipak
AU  - Kalra D
AD  - The University of Gent, Gent, Belgium.
CN  - Section Editors for the IMIA Yearbook Section on Clinical Research Informatics
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Adverse Drug Reaction Reporting Systems
MH  - *Biomedical Research
MH  - *Computer Security
MH  - Data Accuracy
MH  - Data Management
MH  - Electronic Health Records
MH  - Humans
MH  - Hypertension/drug therapy
MH  - *Medical Informatics
MH  - Neoplasms/therapy
MH  - Precision Medicine
MH  - Treatment Outcome
PMC - PMC7442510
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1702007 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):203-207. doi: 10.1055/s-0040-1702007. Epub 2020 
      Aug 21.


PMID- 32823313
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Social Media, Research, and Ethics: Does Participant Willingness Matter?
PG  - 176-183
LID - 10.1055/s-0040-1702022 [doi]
AB  - OBJECTIVE: To summarise the state of the art published in 2019 in consumer health
      informatics and education, with a special emphasis on "Ethics and Health
      Informatics". METHODS: We conducted a systematic search of articles published in 
      PubMed using a predefined set of queries, which identified 368 potential articles
      for review. These articles were screened according to topic relevance and 15 were
      selected for consideration of best paper candidates, which were then presented to
      a panel of international experts for full paper review and scoring. The top five 
      papers according to the external reviewers' ranking were discussed in a consensus
      meeting. Finally, the paper that received the highest score from four of the five
      experts was selected as the best paper on social media and ethics for patients
      and consumers of the year 2019. RESULTS: Despite using the terms "ethics" and
      "ethical" in the search query, we retrieved very few articles. The bibliometric
      analysis identified three major clusters centred on "social", "health", and
      "study". Among the top five papers, one was a review where the authors identified
      ethical issues across four areas at the intersection of social media and health: 
      1) the impact of social networking sites on the doctor-patient relationship; 2)
      the development of e-health platforms to deliver care; 3) the use of online data 
      and algorithms to inform health research; and 4) the broader public health
      consequences of widespread social media use. The other papers highlighted ethical
      concerns in using social media to interact with patients at different phases of a
      clinical research protocol, such as recruitment phase, participant engagement,
      data linkage, and detection and monitoring of adverse events. CONCLUSIONS:
      Findings suggest that most users do not think that using social media for patient
      monitoring in clinical research, for example using Twitter for clinical trial
      recruitment, constitutes inappropriate surveillance or a violation of privacy.
      However, further research is needed to identify whether and how views on ethical 
      concerns differed between social media platforms and across populations.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Staccini, Pascal
AU  - Staccini P
AD  - IRIS Department, Lab RETINES, Faculte de Medecine, Universite Cote d'Azur,
      France.
FAU - Lau, Annie Y S
AU  - Lau AYS
AD  - Centre for Health Informatics, Australian Institute of Health Innovation,
      Macquarie University, Australia.
CN  - Section Editors for the IMIA Yearbook Section on Consumer Health Informatics and 
      Education
LA  - eng
PT  - Journal Article
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Consumer Health Informatics/*ethics
MH  - Female
MH  - Humans
MH  - Information Dissemination/ethics
MH  - Male
MH  - Physician-Patient Relations/ethics
MH  - *Privacy
MH  - Social Media/*ethics
PMC - PMC7442513
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1702022 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):176-183. doi: 10.1055/s-0040-1702022. Epub 2020 
      Aug 21.


PMID- 32823312
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Ethics in Surgical Innovations from the Patient Perspective.
PG  - 169-175
LID - 10.1055/s-0040-1701994 [doi]
AB  - OBJECTIVE: Surgical innovation (SI) can place patients at risk. We sought to
      explore what clinical information is readily available to patients who have been 
      offered innovative surgical procedures, using two examples drawn from our recent 
      experience: one a surgical technique, and the other a prosthetic material. We
      wanted to determine from our review the extent to which information available on 
      the Internet might augment the medical literature and help satisfy the ethical
      requirements for patients to be adequately informed before they proceed with
      innovative surgery. METHODS: A scoping review of the medical literature was
      performed to look for studies addressing the review aims; targeted searches on
      Google, YouTube, and patient websites were carried out to find readily available 
      patient information on two chosen innovative surgical procedures. We conducted a 
      content analysis of the selected references to determine the availability,
      relevance, and the utility of the published information to a layperson. RESULTS: 
      Medical database searches identified 614 records, 91 were screened and only six
      were relevant. The Internet searches returned thousands of results; however, we
      limited our screening to the first five pages of results for those sources. From 
      both types of searches, 348 references were excluded because they did not meet
      the inclusion criteria and 51 were included in the analysis. The findings are
      presented in four themes: safety and feasibility of the technique, availability
      and accessibility to a layperson, relevance and utility to a layperson, and
      commercial information. CONCLUSION: The review has shown that lay people seeking 
      to find out more about the two innovations would get very little useful
      information from Google, YouTube, or patient websites. Practitioners offering SI 
      should provide sufficient information to allow their patients to make an
      autonomous decision about whether to proceed. For major SI, we encourage
      innovators to develop a plain language statement that would be made available on 
      the Internet to the mutual advantage of both innovators and patients.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Eyers, Tony
AU  - Eyers T
AD  - Macquarie University, Sydney, Australia.
FAU - Krastev, Yordanka
AU  - Krastev Y
AD  - Macquarie University, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - *Consumer Health Information
MH  - Hernia, Inguinal/surgery
MH  - Humans
MH  - Information Dissemination
MH  - Internet
MH  - Natural Orifice Endoscopic Surgery
MH  - Social Media
MH  - Surgical Mesh
MH  - Surgical Procedures, Operative/*ethics
MH  - Thyroidectomy/methods
PMC - PMC7442521
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1701994 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):169-175. doi: 10.1055/s-0040-1701994. Epub 2020 
      Aug 21.


PMID- 32823305
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Trends in Clinical Information Systems Research in 2019.
PG  - 121-128
LID - 10.1055/s-0040-1702018 [doi]
AB  - OBJECTIVE: To give an overview of recent research and to propose a selection of
      best papers published in 2019 in the field of Clinical Information Systems (CIS).
      METHOD: Each year, we apply a systematic process to retrieve articles for the CIS
      section of the IMIA Yearbook of Medical Informatics. For six years now, we use
      the same query to find relevant publications in the CIS field. Each year we
      retrieve more than 2,000 papers. As CIS section editors, we categorize the
      retrieved articles in a multi-pass review to distill a pre-selection of 15
      candidate best papers. Then, Yearbook editors and external reviewers assess the
      selected candidate best papers. Based on the review results, the IMIA Yearbook
      Editorial Committee chooses the best papers during the selection meeting. We used
      text mining, and term co-occurrence mapping techniques to get an overview of the 
      content of the retrieved articles. RESULTS: We carried out the query in
      mid-January 2020 and retrieved a de-duplicated result set of 2,407 articles from 
      1,023 different journals. This year, we nominated 14 papers as candidate best
      papers, and three of them were finally selected as best papers in the CIS
      section. As in previous years, the content analysis of the articles revealed the 
      broad spectrum of topics covered by CIS research. CONCLUSIONS: We could observe
      ongoing trends, as seen in the last years. Patient benefit research is in the
      focus of many research activities, and trans-institutional aggregation of data
      remains a relevant field of work. Powerful machine-learning-based approaches,
      that use readily available data now often outperform human-based procedures.
      However, the ethical perspective of this development often comes too short in the
      considerations. We thus assume that ethical aspects will and should deliver much 
      food for thought for future CIS research.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Hackl, W O
AU  - Hackl WO
AD  - Institute of Medical Informatics, UMIT - Private University of Health Sciences,
      Medical Informatics and Technology, Hall in Tirol, Austria.
FAU - Hoerbst, A
AU  - Hoerbst A
AD  - Medical Technologies Department, MCI - The Entrepreneurial School, Innsbruck,
      Austria.
CN  - Section Editors for the IMIA Yearbook Section on Clinical Information Systems
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Biomedical Research/*trends
MH  - Computer Security
MH  - Confidentiality
MH  - Electronic Health Records
MH  - Humans
MH  - Information Systems/*trends
MH  - Medical Informatics/*trends
PMC - PMC7442534
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1702018 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):121-128. doi: 10.1055/s-0040-1702018. Epub 2020 
      Aug 21.


PMID- 32823304
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Clinical Information Systems - Seen through the Ethics Lens.
PG  - 104-114
LID - 10.1055/s-0040-1701996 [doi]
AB  - OBJECTIVE: The more people there are who use clinical information systems (CIS)
      beyond their traditional intramural confines, the more promising the benefits
      are, and the more daunting the risks will be. This review thus explores the areas
      of ethical debates prompted by CIS conceptualized as smart systems reaching out
      to patients and citizens. Furthermore, it investigates the ethical competencies
      and education needed to use these systems appropriately. METHODS: A literature
      review covering ethics topics in combination with clinical and health information
      systems, clinical decision support, health information exchange, and various
      mobile devices and media was performed searching the MEDLINE database for
      articles from 2016 to 2019 with a focus on 2018 and 2019. A second search
      combined these keywords with education. RESULTS: By far, most of the discourses
      were dominated by privacy, confidentiality, and informed consent issues.
      Intertwined with confidentiality and clear boundaries, the provider-patient
      relationship has gained much attention. The opacity of algorithms and the lack of
      explicability of the results pose a further challenge. The necessity of
      sociotechnical ethics education was underpinned in many studies including
      advocating education for providers and patients alike. However, only a few
      publications expanded on ethical competencies. In the publications found,
      empirical research designs were employed to capture the stakeholders' attitudes, 
      but not to evaluate specific implementations. CONCLUSION: Despite the broad
      discourses, ethical values have not yet found their firm place in empirically
      rigorous health technology evaluation studies. Similarly, sociotechnical ethics
      competencies obviously need detailed specifications. These two gaps set the stage
      for further research at the junction of clinical information systems and ethics.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Hubner, Ursula H
AU  - Hubner UH
AD  - Health Informatics Research Group, Dept. Business Management and Social Sciences 
      Hochschule Osnabruck, Germany.
AD  - Health Informatics Research Group, Dept. Business Management and Social Sciences 
      Hochschule Osnabruck, Germany.
FAU - Egbert, Nicole
AU  - Egbert N
AD  - Health Informatics Research Group, Dept. Business Management and Social Sciences 
      Hochschule Osnabruck, Germany.
FAU - Schulte, Georg
AU  - Schulte G
AD  - Health Informatics Research Group, Dept. Business Management and Social Sciences 
      Hochschule Osnabruck, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Bioethical Issues
MH  - Electronic Health Records/ethics
MH  - Ethical Analysis
MH  - Health Records, Personal/ethics
MH  - Humans
MH  - Information Systems/*ethics
MH  - Medical Informatics/*ethics
PMC - PMC7442519
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1701996 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):104-114. doi: 10.1055/s-0040-1701996. Epub 2020 
      Aug 21.


PMID- 32823302
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Human-Computer Interaction, Ethics, and Biomedical Informatics.
PG  - 93-98
LID - 10.1055/s-0040-1701990 [doi]
AB  - OBJECTIVES: To provide an overview of recent work at the intersection of
      Biomedical Informatics, Human-Computer Interaction, and Ethics. METHODS: Search
      terms for Human-Computer Interaction, Biomedical Informatics, and Ethics were
      used to identify relevant papers published between 2017 and 2019.Relevant papers 
      were identified through multiple methods, including database searches, manual
      reviews of citations, recent publications, and special collections, as well as
      through peer recommendations. Identified articles were reviewed and organized
      into broad themes. RESULTS: We identified relevant papers at the intersection of 
      Biomedical Informatics, Human-Computer Interactions, and Ethics in over a dozen
      journals. The content of these papers was organized into three broad themes:
      ethical issues associated with systems in use, systems design, and responsible
      conduct of research. CONCLUSIONS: The results of this overview demonstrate an
      active interest in exploring the ethical implications of Human-Computer
      Interaction concerns in Biomedical Informatics. Papers emphasizing ethical
      concerns associated with patient-facing tools, mobile devices, social media,
      privacy, inclusivity, and e-consent reflect the growing prominence of these
      topics in biomedical informatics research. New questions in these areas will
      likely continue to arise with the growth of precision medicine and citizen
      science.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Hochheiser, Harry
AU  - Hochheiser H
AD  - Department of Biomedical Informatics, University of Pittsburgh School of
      Medicine, Pittsburgh, Pennsylvania USA.
FAU - Valdez, Rupa S
AU  - Valdez RS
AD  - Public Health Sciences & Engineering Systems and Environment, University of
      Virginia, Charlottesville, Virginia USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - *Bioethical Issues
MH  - Biomedical Research/ethics
MH  - Computers/ethics
MH  - Health Records, Personal/ethics
MH  - Humans
MH  - Medical Informatics/*ethics
MH  - Mobile Applications/ethics
MH  - *User-Computer Interface
PMC - PMC7442500
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1701990 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):93-98. doi: 10.1055/s-0040-1701990. Epub 2020
      Aug 21.


PMID- 32823299
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Special Section on Ethics in Health Informatics.
PG  - 77-80
LID - 10.1055/s-0040-1702014 [doi]
AB  - OBJECTIVE: To summarize significant research contributions on ethics in medical
      informatics published in 2019. METHODS: An extensive search using PubMed/Medline 
      was conducted to identify the scientific contributions published in 2019 that
      address ethics issues in medical informatics. The selection process comprised
      three steps: 1) 15 candidate best papers were first selected by the two section
      editors; 2) external reviewers from internationally renowned research teams
      reviewed each candidate best paper; and 3) the final selection of three best
      papers was conducted by the editorial committee of the Yearbook. RESULTS: The
      three selected best papers explore timely issues of concern to the community and 
      demonstrate how ethics considerations influence applied informatics. CONCLUSION: 
      With regard to ethics in informatics, data sharing and privacy remain primary
      areas of concern. Ethics issues related to the development and implementation of 
      artificial intelligence is an emerging topic of interest.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Petersen, Carolyn
AU  - Petersen C
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Subbian, Vignesh
AU  - Subbian V
AD  - College of Engineering, The University of Arizona, Tucson, Arizona, USA.
CN  - Section Editors Special Section on Ethics in Health Informatics of the
      International Medical Informatics Association Yearbook
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Biomedical Research/ethics
MH  - Humans
MH  - Information Dissemination/ethics
MH  - Medical Informatics/*ethics
MH  - Privacy
PMC - PMC7442530
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1702014 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):77-80. doi: 10.1055/s-0040-1702014. Epub 2020
      Aug 21.


PMID- 32823296
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Transparency of Health Informatics Processes as the Condition of Healthcare
      Professionals' and Patients' Trust and Adoption: the Rise of Ethical
      Requirements.
PG  - 7-10
LID - 10.1055/s-0040-1702029 [doi]
AB  - OBJECTIVES: To provide an introduction to the 2020 International Medical
      Informatics Association (IMIA) Yearbook by the editors. METHODS: This editorial
      provides an introduction and overview to the 2020 IMIA Yearbook which special
      topic is: "Ethics in Health Informatics". The keynote paper, the survey paper of 
      the Special Topic section, and the paper about Donald Lindberg's ethical
      scientific openness in the History of Medical Informatics chapter of the Yearbook
      are discussed. Changes in the Yearbook Editorial Committee are also described.
      RESULTS: Inspired by medical ethics, ethics in health informatics progresses with
      the advances in biomedical informatics. With the wide use of EHRs, the
      enlargement of the care team perimeter, the need for data sharing for care
      continuity, the reuse of data for the sake of research, and the implementation of
      AI-powered decision support tools, new ethics requirements are necessary to
      address issues such as threats on privacy, confidentiality breaches, poor
      security practices, lack of patient information, tension on data sharing and
      reuse policies, need for more transparency on apps effectiveness, biased
      algorithms with discriminatory outcomes, guarantee on trustworthy AI, concerns on
      the re-identification of de-identified data. CONCLUSIONS: Despite privacy rules
      rooted in the Health Insurance Portability and Accountability Act of 1996 (HIPAA)
      in the USA and even more restrictive new regulations such as the EU General Data 
      Protection Regulation published in May 2018, some people do not believe their
      data will be kept confidential and may not share sensitive information with a
      provider, which may also induce unethical situations. Transparency on healthcare 
      data processes is a condition of healthcare professionals' and patients' trust
      and their adoption of digital tools.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Seroussi, Brigitte
AU  - Seroussi B
AD  - Sorbonne Universite, Universite Sorbonne Paris Nord, INSERM UMR_S1142, LIMICS,
      Paris, France.
AD  - Assistance Publique - Hopitaux de Paris, Hopital Tenon, Paris, France.
FAU - Hollis, Kate Fultz
AU  - Hollis KF
AD  - Oregon Health & Science University Department of Biomedical Informatics and
      Clinical Epidemiology, Portland, Oregon, USA.
FAU - Soualmia, Lina F
AU  - Soualmia LF
AD  - Normandie Universite, Univ Rouen, LITIS EA 4108, Rouen, France.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
DEP - 20200821
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Artificial Intelligence/ethics
MH  - Attitude of Health Personnel
MH  - *Attitude to Health
MH  - Bioethical Issues
MH  - Health Personnel
MH  - Humans
MH  - Medical Informatics/*ethics
MH  - *Trust
PMC - PMC7442515
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/08/22 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1055/s-0040-1702029 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):7-10. doi: 10.1055/s-0040-1702029. Epub 2020 Aug
      21.


PMID- 32823292
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1476-4245 (Electronic)
IS  - 1475-4916 (Linking)
VI  - 109
IP  - 4
DP  - 2020 Nov
TI  - The Effect of Iodium 30c on Experimental Visceral Leishmaniasis.
PG  - 213-223
LID - 10.1055/s-0040-1713361 [doi]
AB  - BACKGROUND: Leishmaniasis is one of several neglected tropical diseases that
      warrant serious attention. A disease of socio-economically poor people, it
      demands safer and cheaper drugs that help to overcome the limitations faced by
      the existing anti-leishmanials. Complementary or traditional medicines might be a
      good option, with an added advantage that resistance may not develop against
      these drugs. Thus, the present investigation was performed to evaluate the
      anti-leishmanial efficacy of an ultra-diluted homeopathic medicine (Iodium 30c)
      in experimental visceral leishmaniasis (VL). METHODS: Compliant with strict
      ethical standards in animal experimentation, the study was performed in-vivo in
      inbred BALB/c mice which were injected intravenously with 1 x 10(7) promastigotes
      of Leishmania donovani before (therapeutic) or after (prophylactic) treatment
      with Iodium 30c for 30 days. In other groups of mice (n = 6 per group),
      amphotericin B served as positive control, infected animals as the disease
      control, while the naive controls included normal animals; animals receiving only
      Iodium 30c or Alcohol 30c served as sham controls. The anti-leishmanial efficacy 
      was assessed by determining the hepatic parasite load and analysing percentages
      of CD4(+) and CD8(+) T cells. Biochemical analysis and histological studies were 
      performed to check any toxicities. RESULTS: Iodium-treated animals showed a
      significantly reduced parasite load (to 1503 +/- 39 Leishman Donovan Units, LDU) 
      as compared with the infected controls (4489 +/- 256 LDU) (p < 0.05): thus, the
      mean therapeutic efficacy of Iodium 30c was 66.5%. In addition, the population of
      CD4(+) and CD8(+) T cells was significantly increased (p < 0.05) after treatment.
      No toxicity was observed, as evidenced from biochemical and histopathological
      studies of the liver and kidneys. Efficacy of Iodium 30c prophylaxis was 58.3%,
      while the therapeutic efficacy of amphotericin B was 85.9%. CONCLUSION: This
      original study has shown that Iodium 30c had significant impact in controlling
      parasite replication in experimental VL, though the effect was less than that
      using standard pharmaceutical treatment.
CI  - Thieme. All rights reserved.
FAU - Joshi, Jyoti
AU  - Joshi J
AD  - Department of Zoology, Panjab University, Chandigarh, India.
FAU - Bandral, Chetna
AU  - Bandral C
AD  - Department of Zoology, Panjab University, Chandigarh, India.
FAU - Manchanda, Raj Kumar
AU  - Manchanda RK
AD  - Central Council for Research in Homeopathy, Ministry of AYUSH, Government of
      India, New Delhi, India.
FAU - Khurana, Anil
AU  - Khurana A
AD  - Central Council for Research in Homeopathy, Ministry of AYUSH, Government of
      India, New Delhi, India.
FAU - Nayak, Debadatta
AU  - Nayak D
AD  - Central Council for Research in Homeopathy, Ministry of AYUSH, Government of
      India, New Delhi, India.
FAU - Kaur, Sukhbir
AU  - Kaur S
AD  - Department of Zoology, Panjab University, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20200821
PL  - Germany
TA  - Homeopathy
JT  - Homeopathy : the journal of the Faculty of Homeopathy
JID - 101140517
RN  - 0 (Iodates)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Homeopathy/*methods
MH  - India
MH  - Iodates/*pharmacology
MH  - Leishmania donovani/drug effects
MH  - Leishmaniasis, Visceral/*drug therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Parasite Load
COIS- None declared.
EDAT- 2020/08/22 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - 10.1055/s-0040-1713361 [doi]
PST - ppublish
SO  - Homeopathy. 2020 Nov;109(4):213-223. doi: 10.1055/s-0040-1713361. Epub 2020 Aug
      21.


PMID- 32822577
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20210203
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - Comparison of molecular testing strategies for COVID-19 control: a mathematical
      modelling study.
PG  - 1381-1389
LID - S1473-3099(20)30630-7 [pii]
LID - 10.1016/S1473-3099(20)30630-7 [doi]
AB  - BACKGROUND: WHO has called for increased testing in response to the COVID-19
      pandemic, but countries have taken different approaches and the effectiveness of 
      alternative strategies is unknown. We aimed to investigate the potential impact
      of different testing and isolation strategies on transmission of severe acute
      respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We developed a
      mathematical model of SARS-CoV-2 transmission based on infectiousness and PCR
      test sensitivity over time since infection. We estimated the reduction in the
      effective reproduction number (R) achieved by testing and isolating symptomatic
      individuals, regular screening of high-risk groups irrespective of symptoms, and 
      quarantine of contacts of laboratory-confirmed cases identified through
      test-and-trace protocols. The expected effectiveness of different testing
      strategies was defined as the percentage reduction in R. We reviewed data on the 
      performance of antibody tests reported by the Foundation for Innovative New
      Diagnostics and examined their implications for the use of so-called immunity
      passports. FINDINGS: If all individuals with symptoms compatible with COVID-19
      self-isolated and self-isolation was 100% effective in reducing onwards
      transmission, self-isolation of symptomatic individuals would result in a
      reduction in R of 47% (95% uncertainty interval [UI] 32-55). PCR testing to
      identify SARS-CoV-2 infection soon after symptom onset could reduce the number of
      individuals needing to self-isolate, but would also reduce the effectiveness of
      self-isolation (around 10% would be false negatives). Weekly screening of
      health-care workers and other high-risk groups irrespective of symptoms by use of
      PCR testing is estimated to reduce their contribution to SARS-CoV-2 transmission 
      by 23% (95% UI 16-40), on top of reductions achieved by self-isolation following 
      symptoms, assuming results are available at 24 h. The effectiveness of test and
      trace depends strongly on coverage and the timeliness of contact tracing,
      potentially reducing R by 26% (95% UI 14-35) on top of reductions achieved by
      self-isolation following symptoms, if 80% of cases and contacts are identified
      and there is immediate testing following symptom onset and quarantine of contacts
      within 24 h. Among currently available antibody tests, performance has been
      highly variable, with specificity around 90% or lower for rapid diagnostic tests 
      and 95-99% for laboratory-based ELISA and chemiluminescent assays.
      INTERPRETATION: Molecular testing can play an important role in prevention of
      SARS-CoV-2 transmission, especially among health-care workers and other high-risk
      groups, but no single strategy will reduce R below 1 at current levels of
      population immunity. Immunity passports based on antibody tests or tests for
      infection face substantial technical, legal, and ethical challenges. FUNDING: UK 
      Medical Research Council.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd. This is an Open
      Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All
      rights reserved.
FAU - Grassly, Nicholas C
AU  - Grassly NC
AD  - MRC Centre for Global Infectious Disease Analysis, Department of Infectious
      Disease Epidemiology, Imperial College London, London, UK. Electronic address:
      n.grassly@imperial.ac.uk.
FAU - Pons-Salort, Margarita
AU  - Pons-Salort M
AD  - MRC Centre for Global Infectious Disease Analysis, Department of Infectious
      Disease Epidemiology, Imperial College London, London, UK.
FAU - Parker, Edward P K
AU  - Parker EPK
AD  - The Vaccine Centre, Department of Clinical Research, Faculty of Infectious and
      Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
FAU - White, Peter J
AU  - White PJ
AD  - MRC Centre for Global Infectious Disease Analysis, Department of Infectious
      Disease Epidemiology, Imperial College London, London, UK.
FAU - Ferguson, Neil M
AU  - Ferguson NM
AD  - MRC Centre for Global Infectious Disease Analysis, Department of Infectious
      Disease Epidemiology, Imperial College London, London, UK.
CN  - Imperial College COVID-19 Response Team
LA  - eng
GR  - MC_PC_19012/MRC_/Medical Research Council/United Kingdom
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200818
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
SB  - IM
MH  - Asymptomatic Infections
MH  - Basic Reproduction Number
MH  - COVID-19/*diagnosis/epidemiology/*prevention & control/transmission
MH  - COVID-19 Testing/*methods
MH  - Contact Tracing
MH  - Health Personnel
MH  - Humans
MH  - Mass Screening/*methods
MH  - Models, Theoretical
MH  - Quarantine
MH  - SARS-CoV-2/genetics/immunology/isolation & purification
MH  - Sensitivity and Specificity
PMC - PMC7434438
IR  - Ainslie K
FIR - Ainslie, Kylie
IR  - Baguelin M
FIR - Baguelin, Marc
IR  - Bhatt S
FIR - Bhatt, Samir
IR  - Boonyasiri A
FIR - Boonyasiri, Adhiratha
IR  - Brazeau N
FIR - Brazeau, Nick
IR  - Cattarino L
FIR - Cattarino, Lorenzo
IR  - Coupland H
FIR - Coupland, Helen
IR  - Cucunuba Z
FIR - Cucunuba, Zulma
IR  - Cuomo-Dannenburg G
FIR - Cuomo-Dannenburg, Gina
IR  - Dighe A
FIR - Dighe, Amy
IR  - Donnelly C
FIR - Donnelly, Christl
IR  - van Elsland SL
FIR - van Elsland, Sabine L
IR  - FitzJohn R
FIR - FitzJohn, Richard
IR  - Flaxman S
FIR - Flaxman, Seth
IR  - Fraser K
FIR - Fraser, Keith
IR  - Gaythorpe K
FIR - Gaythorpe, Katy
IR  - Green W
FIR - Green, Will
IR  - Hamlet A
FIR - Hamlet, Arran
IR  - Hinsley W
FIR - Hinsley, Wes
IR  - Imai N
FIR - Imai, Natsuko
IR  - Knock E
FIR - Knock, Edward
IR  - Laydon D
FIR - Laydon, Daniel
IR  - Mellan T
FIR - Mellan, Thomas
IR  - Mishra S
FIR - Mishra, Swapnil
IR  - Nedjati-Gilani G
FIR - Nedjati-Gilani, Gemma
IR  - Nouvellet P
FIR - Nouvellet, Pierre
IR  - Okell L
FIR - Okell, Lucy
IR  - Ragonnet-Cronin M
FIR - Ragonnet-Cronin, Manon
IR  - Thompson HA
FIR - Thompson, Hayley A
IR  - Unwin HJT
FIR - Unwin, H Juliette T
IR  - Vollmer M
FIR - Vollmer, Michaela
IR  - Volz E
FIR - Volz, Erik
IR  - Walters C
FIR - Walters, Caroline
IR  - Wang Y
FIR - Wang, Yuanrong
IR  - Watson OJ
FIR - Watson, Oliver J
IR  - Whittaker C
FIR - Whittaker, Charles
IR  - Whittles L
FIR - Whittles, Lilith
IR  - Xi X
FIR - Xi, Xiaoyue
EDAT- 2020/08/22 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/07/12 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - S1473-3099(20)30630-7 [pii]
AID - 10.1016/S1473-3099(20)30630-7 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2020 Dec;20(12):1381-1389. doi: 10.1016/S1473-3099(20)30630-7.
      Epub 2020 Aug 18.


PMID- 32822404
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Medical advocacy in the face of Australian immigration practices: A study of
      medical professionals defending the health rights of detained refugees and asylum
      seekers.
PG  - e0237776
LID - 10.1371/journal.pone.0237776 [doi]
AB  - While medical advocacy is mandated as a core professional commitment in a growing
      number of ethical codes and medical training programs, medical advocacy and
      social justice engagement are regularly subordinated to traditional clinical
      responsibilities. This study aims to provide insight into factors that motivate
      clinician engagement and perseverance with medical advocacy, so as to inform
      attempts by policymakers, leaders and educators to promote advocacy practices in 
      medicine. Furthermore, this study aims to provide an analysis of the role of
      medical advocates in systems where patients' rights are perceived to be infringed
      and consider how we might best support and protect these medical advocates as a
      profession, by exploring the experiences and perspectives of Australian
      clinicians defending the health of detained asylum seekers. In this qualitative
      study thirty-two medical and health professionals advocating on asylum seeker
      health in immigration detention were interviewed. Transcripts were coded both
      inductively and deductively from interview question domains and thematically
      analysed. Findings suggested that respondents' motivations for advocacy stemmed
      from deeply intertwined professional and personal ethics. Overall, advocacy
      responses originated from the union of three integral stimuli: personal ethics,
      proximity and readiness. We conclude that each of these three integral factors
      must be addressed in any attempt to foster advocacy within the medical
      profession. In light of current global trends of increasingly protectionist
      immigration practices, promoting effective physician advocacy may become
      essential in ensuring patients' universal right to health.
FAU - Stoddart, Rohanna
AU  - Stoddart R
AUID- ORCID: 0000-0002-5077-304X
AD  - Faculty of Medicine, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Simpson, Paul
AU  - Simpson P
AUID- ORCID: 0000-0002-1947-8923
AD  - The Kirby Institute, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Haire, Bridget
AU  - Haire B
AD  - The Kirby Institute, University of New South Wales, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200821
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Australia
MH  - Female
MH  - *Health Services Accessibility/ethics/legislation & jurisprudence
MH  - Humans
MH  - Male
MH  - *Patient Advocacy/ethics/legislation & jurisprudence
MH  - Patient-Centered Care/ethics/legislation & jurisprudence
MH  - *Refugees/legislation & jurisprudence
PMC - PMC7442262
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/22 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/22 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1371/journal.pone.0237776 [doi]
AID - PONE-D-19-29972 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 21;15(8):e0237776. doi: 10.1371/journal.pone.0237776.
      eCollection 2020.


PMID- 32822387
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201029
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - A qualitative exploration of using financial incentives to improve vaccination
      uptake via consent form return in female adolescents in London.
PG  - e0237805
LID - 10.1371/journal.pone.0237805 [doi]
AB  - OBJECTIVES: Incentivising vaccine consent form return may improve vaccine uptake 
      and be seen as less coercive than incentivising vaccination itself. We assessed
      the acceptability of financial incentives in this context among adolescent
      females and explored potential mechanisms by which incentives might change
      behaviour. DESIGN: Focus groups and analysis of free-text questionnaire
      responses. METHODS: Study 1: 36 female secondary students in London (age 13-14)
      participated in six focus groups exploring the use of incentives in the context
      of vaccination. Data were analysed thematically. Study 2: was conducted to
      triangulate the findings of Study 1, by analysing free-text questionnaire
      responses from 181 female secondary students in London (age 12-13) reporting
      their opinion of incentivising consent form return. Data from Study 1 was also
      used to explore perceived potential mechanisms of action by which incentives
      might encourage consent form return. RESULTS: Focus group participants had
      positive attitudes towards incentives, with 61% of free-text responses also
      expressing this. Most focus group participants thought that incentives would
      encourage consent form return (18% of free-text respondents spontaneously also
      mentioned this). While incentivising consent form return was seen as ethical,
      focus group participants who incorrectly thought that vaccine receipt was being
      incentivised raised concerns about bribery, although only 4% of free text
      respondents reported these concerns. Frequently raised mechanisms of action
      included incentives increasing engagement with, and the perceived value of
      consent form return. CONCLUSIONS: Adolescents had positive views of financially
      incentivising consent form return to promote vaccine uptake, although care must
      be taken to reduce misconceptions regarding what is being incentivised.
      Incentivising vaccination was seen as coercive, but incentivising actions that
      increase the likelihood of vaccination (i.e. consent form return) were not.
      Incentives may encourage adolescents to return consent forms by helping them
      engage with this behaviour or increasing its' perceived value.
FAU - Rockliffe, Lauren
AU  - Rockliffe L
AUID- ORCID: 0000-0001-9546-8690
AD  - Research Department of Behavioural Science and Health, UCL, London, United
      Kingdom.
FAU - Stearns, Selma
AU  - Stearns S
AD  - Research Department of Behavioural Science and Health, UCL, London, United
      Kingdom.
FAU - Forster, Alice S
AU  - Forster AS
AUID- ORCID: 0000-0002-9933-7919
AD  - Research Department of Behavioural Science and Health, UCL, London, United
      Kingdom.
LA  - eng
GR  - C49896/A17429/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200821
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Consent Forms
MH  - Demography
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - London
MH  - Motivation/ethics
MH  - Parents
MH  - *Patient Acceptance of Health Care/statistics & numerical data
MH  - Reward
MH  - Surveys and Questionnaires
MH  - *Vaccination/economics/statistics & numerical data
PMC - PMC7446903
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/22 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - 10.1371/journal.pone.0237805 [doi]
AID - PONE-D-20-13180 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 21;15(8):e0237805. doi: 10.1371/journal.pone.0237805.
      eCollection 2020.


PMID- 32821269
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - Assessing the capacity for conflict and health research in Lebanon: a qualitative
      study.
PG  - 59
LID - 10.1186/s13031-020-00304-x [doi]
AB  - BACKGROUND: Conflicts pose new challenges for health systems, requiring rapid and
      practical approaches to meet emerging needs on the ground. Lebanon has been
      highly influenced by surrounding conflicts in the Middle East and North Africa
      (MENA) region, especially the Syrian crisis. Strengthening research capacity to
      collect evidence on conflict in the MENA region and beyond is crucial to inform
      healthcare policy and practice. For targeted capacity strengthening
      interventions, the main objective of this paper is to present key findings of a
      needs assessment of conflict and health research in Lebanon. This will support
      recent efforts to scale up context-specific policies, interventions to strengthen
      the country's health system, and research capacity. METHODS: The study is based
      on 30 semi-structured interviews with key informants such as specialist
      academics, humanitarian workers and public sector officials. RESULTS: Despite
      being ranked third in the number of publications on biomedical and health
      research per capita in MENA and in hosting reputable universities which are
      considered central academic hubs in the region, lack of nationwide research
      culture, insufficient funding and limited access to data were reported to be
      major challenges for health researchers in Lebanon. Even with the ongoing
      efforts, poor impact of research on policy continues to be a persistent gap.
      Large disparities in research capacities and taught skills were reported between 
      different universities in Lebanon, with a disproportionate emphasis on
      quantitative over qualitative skills. Most medical students are not trained to
      conduct research or to practice in conflict settings. Concerns were also
      expressed regarding the ethics of research conducted, specifically by local
      non-governmental organizations. RECOMMENDATIONS: To conduct contextualized
      trainings on research skills with a stronger focus on qualitative approaches,
      medical practice, and ethical research in conflict. To better involve
      policymakers in designing research agendas by organizing multiple stakeholder
      meetings. CONCLUSION: The study indicates that health research in Lebanon is
      characterized by considerable strengths in terms of human capital and research
      capacities of certain universities. However, the Lebanese research infrastructure
      needs further development in terms of ensuring sustainable funding, providing
      access to data, teaching qualitative research skills, conducting ethical and
      multidisciplinary research, and promoting cross-sectoral knowledge transfer.
CI  - (c) The Author(s) 2020.
FAU - El Achi, Nassim
AU  - El Achi N
AUID- ORCID: 0000-0002-6841-0976
AD  - R4HC-MENA, Conflict Medicine Program, Global Health Institute, American
      University of Beirut, Beirut, 1107 2020 Lebanon.grid.22903.3a0000 0004 1936 9801
FAU - Honein-Abouhaidar, Gladys
AU  - Honein-Abouhaidar G
AD  - Hariri School of Nursing, Global Health Institute, American University of Beirut,
      Beirut, 1107 2020 Lebanon.grid.22903.3a0000 0004 1936 9801
FAU - Rizk, Anthony
AU  - Rizk A
AD  - R4HC-MENA, Conflict Medicine Program, Global Health Institute, American
      University of Beirut, Beirut, 1107 2020 Lebanon.grid.22903.3a0000 0004 1936 9801
FAU - Kobeissi, Elsa
AU  - Kobeissi E
AD  - Conflict Medicine Program, Global Health Institute, American University of
      Beirut, Beirut, 1107 2020 Lebanon.grid.22903.3a0000 0004 1936 9801
FAU - Papamichail, Andreas
AU  - Papamichail A
AD  - School of Politics & International Relations, Queen Mary University of London,
      London, E1 4NS UK.grid.4868.20000 0001 2171 1133
FAU - Meagher, Kristen
AU  - Meagher K
AD  - R4HC-MENA, Conflict and Health Research Group, Department of War Studies, King's 
      College London, London, WC2R 2LS UK.grid.13097.3c0000 0001 2322 6764
FAU - Ekzayez, Abdulkarim
AU  - Ekzayez A
AD  - R4HC-MENA, Conflict and Health Research Group, Department of War Studies, King's 
      College London, London, WC2R 2LS UK.grid.13097.3c0000 0001 2322 6764
FAU - Abu-Sittah, Ghassan S
AU  - Abu-Sittah GS
AD  - R4HC-MENA, Conflict Medicine Program, Global Health Institute, American
      University of Beirut, Beirut, 1107 2020 Lebanon.grid.22903.3a0000 0004 1936 9801
FAU - Patel, Preeti
AU  - Patel P
AD  - R4HC-MENA, Conflict and Health Research Group, Department of War Studies, King's 
      College London, London, WC2R 2LS UK.grid.13097.3c0000 0001 2322 6764
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7432458
OTO - NOTNLM
OT  - Capacity strengthening
OT  - Conflict
OT  - Health
OT  - Lebanon
OT  - MENA
OT  - Needs assessment
OT  - Research
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/08/22 06:00
MHDA- 2020/08/22 06:01
CRDT- 2020/08/22 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2020/08/22 06:01 [medline]
AID - 10.1186/s13031-020-00304-x [doi]
AID - 304 [pii]
PST - epublish
SO  - Confl Health. 2020 Aug 18;14:59. doi: 10.1186/s13031-020-00304-x. eCollection
      2020.


PMID- 32821244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Factors facilitating trained NIMART nurses' adherence to treatment guidelines: a 
      vital matter in the management of TB/HIV treatment in South Africa.
PG  - 77
LID - 10.1186/s12912-020-00470-6 [doi]
AB  - BACKGROUND: Globally, the burden of tuberculosis or human immunodeficiency virus 
      (TB/HIV) is at 24% and this alarming rate compelled the World Health Organization
      (WHO) to declare the African region as a critical workforce shortage area. To
      facilitate adherence to treatment guidelines, WHO recommended a strategy of task 
      shifting for countries with high health workforce shortages. The strategy aimed
      at the redistribution of health care tasks to available workers. The study aimed 
      to determine the factors facilitating nurse-initiated management of
      antiretroviral therapy (NIMART) trained nurses' adherence to TB/HIV treatment
      guidelines. METHODS: The study employed an exploratory-descriptive design. The
      study was conducted in Ugu and Ngaka Modiri Molema Districts of KwaZulu-Natal
      (KZN) and North West (NW) Provinces of South Africa. The population comprised of 
      24 participants who were purposively selected. The in-depth focus group
      discussions were conducted and ATLAS T.I. was used for data analysis following
      the basic steps of notice-collect-think (NCT) analysis. Trustworthiness and
      adherence to ethics were ensured. RESULTS: The singular theme of factors
      facilitating NIMART trained nurses' adherence to treatment guidelines which
      included positive attitudinal needs and positive behavioural change emerged from 
      raw data. CONCLUSION: Continuous training, support supervision, and improved
      relationships with colleagues need to be enhanced to enable NIMART trained nurses
      to adhere to treatment guidelines.
CI  - (c) The Author(s) 2020.
FAU - Makhado, Lufuno
AU  - Makhado L
AUID- ORCID: 0000-0003-1689-9308
AD  - Department of Public Health, School of Health Sciences, University of Venda,
      Thohoyandou, South Africa.grid.412964.c0000 0004 0610 3705
FAU - Davhana-Maselesele, Mashudu
AU  - Davhana-Maselesele M
AD  - Department of Nursing Science, Faculty of Health Sciences, University of
      Pretoria, Tshwane, South Africa.grid.49697.350000 0001 2107 2298
FAU - Lebese, Rachel Tsakani
AU  - Lebese RT
AD  - Research office, School of Health Sciences, University of Venda, Thohoyandou,
      South Africa.grid.412964.c0000 0004 0610 3705
FAU - Maputle, Sonto Maria
AU  - Maputle SM
AD  - Department of Advanced Nursing Science, School of Health Sciences, University of 
      Venda, Thohoyandou, South Africa.grid.412964.c0000 0004 0610 3705
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7429774
OTO - NOTNLM
OT  - Adherence
OT  - NIMART
OT  - NIMART-trained nurses
OT  - TB/HIV
OT  - Treatment guidelines
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/08/22 06:00
MHDA- 2020/08/22 06:01
CRDT- 2020/08/22 06:00
PHST- 2020/02/13 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2020/08/22 06:01 [medline]
AID - 10.1186/s12912-020-00470-6 [doi]
AID - 470 [pii]
PST - epublish
SO  - BMC Nurs. 2020 Aug 17;19:77. doi: 10.1186/s12912-020-00470-6. eCollection 2020.


PMID- 32821021
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Evaluating the Quality of Research Ethics Review and Oversight: A Systematic
      Analysis of Quality Assessment Instruments.
PG  - 208-222
LID - 10.1080/23294515.2020.1798563 [doi]
AB  - BACKGROUND: Research ethics review committees (RERCs) and Human Research
      Protection Programs (HRPPs) are responsible for protecting the rights and welfare
      of research participants while avoiding unnecessary inhibition of valuable
      research. Evaluating RERC/HRPP quality is vital to determining whether they are
      achieving these goals effectively and efficiently, as well as what adjustments
      might be necessary. Various tools, standards, and accreditation mechanisms have
      been developed in the United States and internationally to measure and promote
      RERC/HRPP quality. METHODS: We systematically reviewed 10 quality assessment
      instruments, examining their overall approaches, factors considered relevant to
      quality, how they compare to each other, and what they leave out. For each tool, 
      we counted the number of times each of 34 topics (divided into structure,
      process, and outcome categories) was mentioned. We generated lists of which
      topics are most and least mentioned for each tool, which are most prevalent
      across tools, and which are left unmentioned. We also conducted content analysis 
      for the 10 most common topics. RESULTS: We found wide variability between
      instruments, common emphasis on process and structure with little attention to
      participant outcomes, and failure to identify clear priorities for assessment.
      The most frequently mentioned topics are Review Type, IRB Member Expertise,
      Training and Educational Resources, Protocol Maintenance, Record Keeping, and
      Mission, Approach, and Culture. Participant Outcomes is unmentioned in 8 tools;
      the remaining 2 tools include assessments based on adverse events, failures of
      informed consent, and consideration of participant experiences. CONCLUSIONS: Our 
      analysis confirms that RERC/HRPP quality assessment instruments largely rely on
      surrogate measures of participant protection. To prioritize between these
      measures and preserve limited resources for evaluating the most important
      criteria, we recommend that instruments focus on elements relevant to participant
      outcomes, robust board deliberation, and procedures most likely to address
      participant risks. Validation of these approaches remains an essential next step.
FAU - Lynch, Holly Fernandez
AU  - Lynch HF
AD  - Perelman School of Medicine, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
AD  - Leonard Davis Institute of Health Economics, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Abdirisak, Mohamed
AU  - Abdirisak M
AD  - Leonard Davis Institute of Health Economics, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Bogia, Megan
AU  - Bogia M
AD  - Institutional Review Board, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
FAU - Clapp, Justin
AU  - Clapp J
AD  - Perelman School of Medicine, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
AD  - Leonard Davis Institute of Health Economics, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200821
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Bioethics
MH  - *Ethics Committees, Research
MH  - Ethics, Research
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - *Quality Indicators, Health Care
MH  - Systems Analysis
MH  - United States
OTO - NOTNLM
OT  - *HRPP
OT  - *Human subjects research
OT  - *IRB
OT  - *quality assessment
OT  - *research ethics review
EDAT- 2020/08/22 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - 10.1080/23294515.2020.1798563 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Oct-Dec;11(4):208-222. doi:
      10.1080/23294515.2020.1798563. Epub 2020 Aug 21.


PMID- 32820836
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
VI  - 76
IP  - 11
DP  - 2020 Nov
TI  - Translating dignity principles into practice for continence care for older people
      in care homes: A study protocol.
PG  - 3147-3154
LID - 10.1111/jan.14481 [doi]
AB  - AIM: To develop, implement, evaluate, and disseminate an evidence-based,
      person-centred education program to protect the dignity of care-dependent older
      people with dementia and continence care needs in care homes. DESIGN: A mixed
      method two-phase design underpinned by integrated knowledge translation. METHODS:
      An education program that frames dignity as the main goal of continence care will
      be co-designed with a purposive sample of care home staff who provide or
      supervise continence care for care-dependent older people with dementia in care
      homes and resident relatives. The program will then be implemented and evaluated 
      in a representative sample of care home staff to determine its clinical
      relevance, feasibility, acceptability, and effects on staff ratings of dignity in
      continence care; self-reported continence care practices and the person
      centeredness of the environment. Data analysis will include descriptive
      statistics (survey data) and thematic analysis (focus groups). Funding obtained
      November 2018. Ethics approval obtained May 2019. DISCUSSION: This protocol
      outlines a mixed methods integrated knowledge translation protocol designed to
      translate principles about dignity into practice to improve the care of older
      people who are at risk of violations to their dignity in care homes. The outcome 
      will be a contextually appropriate, evidence-based education program that
      protects the dignity of care-dependent older people who have dementia and
      continence care needs. IMPACT: Based on a sound theoretical model, the education 
      program will be contextually appropriate for use in the care homes setting and
      contribute to improving the overall quality and safety of care in this setting.
      It could also support and inform continence care for other individuals who are
      care dependent. Adopting an integrated knowledge translation approach to the
      design and delivery of the education program and piloting it will ensure the
      program is contextually relevant and sustainable.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Ostaszkiewicz, Joan
AU  - Ostaszkiewicz J
AUID- ORCID: https://orcid.org/0000-0003-4159-4493
AD  - Centre for Quality and Patient Safety Research, Institute for Healthcare
      Transformation, Deakin University, Geelong, Vic., Australia.
AD  - National Ageing Research Institute, Parkville, Vic., Australia.
FAU - Dunning, Trisha
AU  - Dunning T
AD  - Centre for Quality and Patient Safety Research, Institute for Healthcare
      Transformation, Deakin University, Geelong, Vic., Australia.
FAU - Dickson-Swift, Virginia
AU  - Dickson-Swift V
AUID- ORCID: https://orcid.org/0000-0002-7728-2101
AD  - Centre for Quality and Patient Safety Research, Institute for Healthcare
      Transformation, Deakin University, Geelong, Vic., Australia.
LA  - eng
GR  - APP1168041/2018 Medical Research Future Fund Next Generation Clinical Researchers
      Program
PT  - Journal Article
DEP - 20200821
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
MH  - Aged
MH  - Humans
MH  - *Respect
OTO - NOTNLM
OT  - dignity
OT  - dignity in care
OT  - education program
OT  - elder abuse
OT  - incontinence
OT  - integrated knowledge translation
OT  - nurses
OT  - nursing
OT  - older people
OT  - residential aged care
EDAT- 2020/08/22 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - 10.1111/jan.14481 [doi]
PST - ppublish
SO  - J Adv Nurs. 2020 Nov;76(11):3147-3154. doi: 10.1111/jan.14481. Epub 2020 Aug 21.


PMID- 32820623
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2093-2278 (Print)
IS  - 2093-2278 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Aug
TI  - Research ethics ensure the veracity of a study.
PG  - 207-208
LID - 10.5051/jpis.205004edi01 [doi]
FAU - Shin, Seungil
AU  - Shin S
AUID- ORCID: https://orcid.org/0000-0001-8762-6169
AD  - Department of Periodontology, Kyung Hee University School of Dentistry, Seoul,
      Korea. shin.dmd@khu.ac.kr.
LA  - eng
PT  - Editorial
PL  - Korea (South)
TA  - J Periodontal Implant Sci
JT  - Journal of periodontal & implant science
JID - 101526931
PMC - PMC7443388
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/22 06:00
PHST- 2020/07/21 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
AID - 50.207 [pii]
AID - 10.5051/jpis.205004edi01 [doi]
PST - ppublish
SO  - J Periodontal Implant Sci. 2020 Aug;50(4):207-208. doi: 10.5051/jpis.205004edi01.


PMID- 32820019
OWN - NLM
STAT- Publisher
LR  - 20210724
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 20
TI  - Psychotherapy, placebos, and informed consent.
LID - medethics-2020-106453 [pii]
LID - 10.1136/medethics-2020-106453 [doi]
AB  - Several authors have recently argued that psychotherapy, as it is commonly
      practiced, is deceptive and undermines patients' ability to give informed consent
      to treatment. This 'deception' claim is based on the findings that some, and
      possibly most, of the ameliorative effects in psychotherapeutic interventions are
      mediated by therapeutic common factors shared by successful treatments (eg,
      expectancy effects and therapist effects), rather than because of theory-specific
      techniques. These findings have led to claims that psychotherapy is, at least
      partly, likely a placebo, and that practitioners of psychotherapy have a duty to 
      'go open' to patients about the role of common factors in therapy (even if this
      risks negatively affecting the efficacy of treatment); to not 'go open' is
      supposed to unjustly restrict patients' autonomy. This paper makes two related
      arguments against the 'go open' claim. (1) While therapies ought to provide
      patients with sufficient information to make informed treatment decisions,
      informed consent does not require that practitioners 'go open' about therapeutic 
      common factors in psychotherapy, and (2) clarity about the mechanisms of change
      in psychotherapy shows us that the common-factors findings are consistent with,
      rather than undermining of, the truth of many theory-specific forms of
      psychotherapy; psychotherapy, as it is commonly practiced, is not deceptive and
      is not a placebo. The call to 'go open' should be resisted and may have serious
      detrimental effects on patients via the dissemination of a false view about how
      therapy works.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Leder, Garson
AU  - Leder G
AUID- ORCID: http://orcid.org/0000-0003-1350-1579
AD  - Alden March Bioethics Institute, Albany Medical College, Albany, NY 12208, USA
      leder.garson@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8257553
OTO - NOTNLM
OT  - ethics
OT  - informed consent
OT  - paternalism
OT  - psychotherapy
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/05/16 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
AID - medethics-2020-106453 [pii]
AID - 10.1136/medethics-2020-106453 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 20. pii: medethics-2020-106453. doi:
      10.1136/medethics-2020-106453.


PMID- 32820018
OWN - NLM
STAT- Publisher
LR  - 20211217
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 20
TI  - Compulsory medical intervention versus external constraint in pandemic control.
LID - medethics-2020-106435 [pii]
LID - 10.1136/medethics-2020-106435 [doi]
AB  - Would compulsory treatment or vaccination for COVID-19 be justified? In England, 
      there would be significant legal barriers to it. However, we offer a conditional 
      ethical argument in favour of allowing compulsory treatment and vaccination,
      drawing on an ethical comparison with external constraints-such as quarantine,
      isolation and 'lockdown'-that have already been authorised to control the
      pandemic in this jurisdiction. We argue that, if the permissive English approach 
      to external constraints for COVID-19 has been justified, then there is a case for
      a similarly permissive approach to compulsory medical interventions.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Douglas, Thomas
AU  - Douglas T
AUID- ORCID: http://orcid.org/0000-0002-6788-3608
AD  - Oxford Uehiro Centre for Practical Ethics, Oxford University, Oxford,
      Oxfordshire, UK thomas.douglas@philosophy.ox.ac.uk.
AD  - Jesus College, Oxford, Oxfordshire, UK.
AD  - Faculty of Philosophy, University of Oxford, Oxford, Oxfordshire, United Kingdom.
FAU - Forsberg, Lisa
AU  - Forsberg L
AUID- ORCID: http://orcid.org/0000-0002-5239-393X
AD  - Oxford Uehiro Centre for Practical Ethics, Oxford University, Oxford,
      Oxfordshire, UK.
AD  - Faculty of Law, Oxford University, Oxford, Oxfordshire, UK.
AD  - Somerville College, Oxford, Oxfordshire, UK.
FAU - Pugh, Jonathan
AU  - Pugh J
AD  - Oxford Uehiro Centre for Practical Ethics, Oxford University, Oxford,
      Oxfordshire, UK.
AD  - Faculty of Philosophy, University of Oxford, Oxford, Oxfordshire, United Kingdom.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639959
OTO - NOTNLM
OT  - compulsion
OT  - ethics
OT  - isolation
OT  - law
OT  - mental health law
OT  - public health ethics
OT  - public health law
OT  - quarantine
OT  - vaccination
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
AID - medethics-2020-106435 [pii]
AID - 10.1136/medethics-2020-106435 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 20. pii: medethics-2020-106435. doi:
      10.1136/medethics-2020-106435.


PMID- 32820002
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Comparison of strategies for monitoring and treating patients at the early phase 
      of severe traumatic brain injury: the multicentre randomised controlled OXY-TC
      trial study protocol.
PG  - e040550
LID - 10.1136/bmjopen-2020-040550 [doi]
AB  - INTRODUCTION: Intracranial hypertension is considered as an independent risk
      factor of mortality and neurological disabilities after severe traumatic brain
      injury (TBI). However, clinical studies have demonstrated that episodes of brain 
      ischaemia/hypoxia are common despite normalisation of intracranial pressure
      (ICP). This study assesses the impact on neurological outcome of guiding
      therapeutic strategies based on the monitoring of both brain tissue oxygenation
      pressure (PbtO2) and ICP during the first 5 days following severe TBI. METHODS
      AND ANALYSIS: Multicentre, open-labelled, randomised controlled superiority trial
      with two parallel groups in 300 patients with severe TBI. Intracerebral
      monitoring must be in place within the first 16 hours post-trauma. Patients are
      randomly assigned to the ICP group or to the ICP + PbtO2 group. The ICP group is 
      managed according to the international guidelines to maintain ICP</=20 mm Hg. The
      ICP + PbtO2 group is managed to maintain PbtO2 >/=20 mm Hg in addition to the
      conventional optimisation of ICP. The primary outcome measure is the neurological
      status at 6 months as assessed using the extended Glasgow Outcome Scale.
      Secondary outcome measures include quality-of-life assessment, mortality rate,
      therapeutic intensity and incidence of critical events during the first 5 days.
      Analysis will be performed according to the intention-to-treat principle and full
      statistical analysis plan developed prior to database freeze. ETHICS AND
      DISSEMINATION: This study has been approved by the Institutional Review Board of 
      Sud-Est V (14-CHUG-48) and from the National Agency for Medicines and Health
      Products Safety (Agence Nationale de Securite du Medicament et des produits de
      sante) (141 435B-31). Results will be presented at scientific meetings and
      published in peer-reviewed publications.The study was registered with ClinTrials 
      NCT02754063 on 28 April 2016 (pre-results).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Payen, Jean-Francois
AU  - Payen JF
AUID- ORCID: 0000-0001-8400-3839
AD  - Department of Anaesthesia and Intensive Care, Univ. Grenoble Alpes, Centre
      Hospitalier Universitaire Grenoble Alpes, Grenoble Institut des Neurosciences,
      INSERM, U1216, Grenoble, France jfpayen@univ-grenoble-alpes.fr.
FAU - Richard, Marion
AU  - Richard M
AD  - Department of Anaesthesia and Intensive Care, Univ. Grenoble Alpes, Centre
      Hospitalier Universitaire Grenoble Alpes, Grenoble Institut des Neurosciences,
      INSERM, U1216, Grenoble, France.
FAU - Francony, Gilles
AU  - Francony G
AD  - Department of Anaesthesia and Intensive Care, Univ. Grenoble Alpes, Centre
      Hospitalier Universitaire Grenoble Alpes, Grenoble Institut des Neurosciences,
      INSERM, U1216, Grenoble, France.
FAU - Audibert, Gerard
AU  - Audibert G
AD  - Department of Anaesthesia and Intensive Care, Lorraine University, Nancy
      University Hospital, Nancy, France.
FAU - Barbier, Emmanuel L
AU  - Barbier EL
AD  - Department of Anaesthesia and Intensive Care, Univ. Grenoble Alpes, Centre
      Hospitalier Universitaire Grenoble Alpes, Grenoble Institut des Neurosciences,
      INSERM, U1216, Grenoble, France.
FAU - Bruder, Nicolas
AU  - Bruder N
AD  - Department of Anaesthesiology and Intensive Care, Aix-Marseille University,
      Assistance Publique - Hopitaux de Marseille, Marseille, France.
FAU - Dahyot-Fizelier, Claire
AU  - Dahyot-Fizelier C
AD  - Department of Anaesthesia and Intensive Care, Poitiers University Hospital and
      Poitiers Hospital, Pharmacology of antimicrobial agents, INSERM U1070, Poitiers, 
      France.
FAU - Geeraerts, Thomas
AU  - Geeraerts T
AD  - Department of Anaesthesia and Intensive Care, Toulouse University Hospital and
      Toulouse 3-Paul Sabatier University, Toulouse, France.
FAU - Gergele, Laurent
AU  - Gergele L
AD  - Department of Intensive care, Ramsay Sante, Hopital Prive de la Loire,
      Saint-Etienne, France.
FAU - Puybasset, Louis
AU  - Puybasset L
AD  - Department of Anaesthesia and Critical Care, Sorbonne University, GRC 29, AP-HP, 
      DMU DREAM, Pitie-Salpetriere Hospital, Paris, France.
FAU - Vigue, Bernard
AU  - Vigue B
AD  - Department of Anaesthesia and Intensive care, Centre Hospitalier Universitaire de
      Bicetre, Assistance Publique - Hopitaux de Paris, Le Kremlin Bicetre, France.
FAU - Skaare, Kristina
AU  - Skaare K
AD  - Department of Public Health, Univ. Grenoble Alpes, CHU Grenoble Alpes, Grenoble, 
      France.
FAU - Bosson, Jean Luc
AU  - Bosson JL
AD  - TIMC IMAG, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
FAU - Bouzat, Pierre
AU  - Bouzat P
AD  - Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT02754063
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brain
MH  - *Brain Injuries, Traumatic/therapy
MH  - Glasgow Outcome Scale
MH  - Humans
MH  - *Intracranial Hypertension/etiology/therapy
MH  - Intracranial Pressure
MH  - Monitoring, Physiologic
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
PMC - PMC7443301
OTO - NOTNLM
OT  - *Neurosurgery
OT  - *adult intensive & critical care
OT  - *trauma management
COIS- Competing interests: No.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040550 [pii]
AID - 10.1136/bmjopen-2020-040550 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e040550. doi: 10.1136/bmjopen-2020-040550.


PMID- 32820001
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Protocol for the Sri Lankan Cerebral Palsy Register pilot study.
PG  - e039353
LID - 10.1136/bmjopen-2020-039353 [doi]
AB  - INTRODUCTION: Cerebral palsy (CP) describes a heterogeneous group of motor
      disorders resulting from disturbance in the developing brain. CP occurs in
      approximately 2.1 per 1000 live births in high-income countries, but in low- and 
      middle-income countries (LMICs) the prevalence and severity of CP may be greater 
      and aetiological risk factors different. In Sri Lanka, a LMIC, there have been no
      epidemiological studies of CP to date. Systematically collected data are required
      to identify opportunities for primary and secondary prevention, to plan and
      establish services to support children and adults with CP and their families and 
      to act as a sampling frame for new research. Here we describe a pilot study
      protocol for a CP register in Sri Lanka. METHODS AND ANALYSIS: The aim of this
      study is to establish a CP register in Sri Lanka. We will use different
      surveillance methodologies in two provinces of Sri Lanka: hospital and community 
      surveillance in the Western Province and community surveillance in the Eastern
      Province. A common record form will collect demographic, clinical and service
      data for children with CP <18 years living in these two provinces. Data will be
      transferred to a secure online data repository and used to describe the
      epidemiology of CP in these regions. We will describe the strengths and
      challenges of the surveillance mechanisms and estimate the resources required for
      ongoing hospital and community based surveillance in the Western and Eastern
      provinces and to include additional provinces across the country. ETHICS AND
      DISSEMINATION: This study has ethical clearance from The University of Kelaniya, 
      National Health Research Council, the Institutional Ethics Review Committee of
      the Lady Ridgeway Hospital, Colombo South Teaching Hospital and the Director of
      the North Colombo Teaching Hospital. Results from this research will be
      disseminated through local and international conferences and through publications
      in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Heiyanthuduwage, Thilini Madushika
AU  - Heiyanthuduwage TM
AUID- ORCID: 0000-0003-1144-7417
AD  - Department of Disability Studies, Faculty of Medicine, University of Kelaniya,
      Ragama, Western Province, Sri Lanka htmadushika@gmail.com.
FAU - Sumanasena, Samanmali P
AU  - Sumanasena SP
AD  - Department of Disability Studies, Faculty of Medicine, University of Kelaniya,
      Ragama, Western Province, Sri Lanka.
FAU - Kitnasamy, Gopi
AU  - Kitnasamy G
AD  - Cerebral Palsy Lanka Foundation, Colombo, Western Province, Sri Lanka.
FAU - Smithers Sheedy, Hayley
AU  - Smithers Sheedy H
AD  - Cerebral Palsy Alliance, Discipline of Child and Adolescent Health, Sydney
      Medical School, The University of Sydney, Sydney, New South Wales, Australia.
FAU - Khandaker, Gulam
AU  - Khandaker G
AD  - CSF Global, Dhaka, Bangladesh.
AD  - Asian Institute of Disability and Development, University of South Asia, Dhaka,
      Dhaka District, Bangladesh.
AD  - Discipline of Child and Adolescent Health, Sydney Medical School, The University 
      of Sydney, Westmead, New South Wales, Australia.
AD  - Central Queensland Public Health Unit, Central Queensland Hospital and Health
      Services, Rockhampton, Queensland, Australia.
FAU - Fernando, Romaniya
AU  - Fernando R
AD  - Department of Disability Studies, Faculty of Medicine, University of Kelaniya,
      Ragama, Western Province, Sri Lanka.
FAU - Wijesekara, Saraji
AU  - Wijesekara S
AD  - Department of Pediatrics, Faculty of Medical Sciences, University of Sri
      Jayewardenepura, Nugegoda, Western Province, Sri Lanka.
FAU - Jagoda, Jayatri
AU  - Jagoda J
AD  - Lady Ridgeway Children's Hospital, Colombo, Western Province, Sri Lanka.
FAU - Ratnayake, Pyara
AU  - Ratnayake P
AD  - Lady Ridgeway Children's Hospital, Colombo, Western Province, Sri Lanka.
FAU - Wanigasinghe, Jithangi
AU  - Wanigasinghe J
AD  - Department of Pediatrics, Faculty of Medicine, University of Colombo, Colombo,
      Western Province, Sri Lanka.
FAU - Mclntyre, Sarah
AU  - Mclntyre S
AD  - Cerebral Palsy Alliance, Discipline of Child and Adolescent Health, Sydney
      Medical School, The University of Sydney, Sydney, New South Wales, Australia.
FAU - Goldsmith, Shona
AU  - Goldsmith S
AD  - Cerebral Palsy Alliance, Discipline of Child and Adolescent Health, Sydney
      Medical School, The University of Sydney, Sydney, New South Wales, Australia.
FAU - Waight, Emma
AU  - Waight E
AD  - Cerebral Palsy Alliance, Discipline of Child and Adolescent Health, Sydney
      Medical School, The University of Sydney, Sydney, New South Wales, Australia.
FAU - Badawi, Nadia
AU  - Badawi N
AD  - Cerebral Palsy Alliance, Discipline of Child and Adolescent Health, Sydney
      Medical School, The University of Sydney, Sydney, New South Wales, Australia.
AD  - Grace Centre for Newborn Intensive Care, Sydney Children's Hospital Network,
      Westead, New South Wales, Australia.
FAU - Muhit, Mohammad
AU  - Muhit M
AD  - CSF Global, Dhaka, Bangladesh.
AD  - Asian Institute of Disability and Development, University of South Asia, Dhaka,
      Dhaka District, Bangladesh.
FAU - Muttiah, Nimisha
AU  - Muttiah N
AD  - Department of Medicine, University of Kelaniya, Kelaniya, Western Province, Sri
      Lanka.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Cerebral Palsy/epidemiology
MH  - Child
MH  - Humans
MH  - Longitudinal Studies
MH  - Pilot Projects
MH  - Prevalence
MH  - Sri Lanka/epidemiology
PMC - PMC7443274
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *perinatology
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039353 [pii]
AID - 10.1136/bmjopen-2020-039353 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e039353. doi: 10.1136/bmjopen-2020-039353.


PMID- 32820000
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Study protocol for a double-blind, randomised placebo-controlled trial evaluating
      clinical effects of platelet-rich plasma injection for acute grade-2 hamstring
      tear among high performance athletes.
PG  - e039105
LID - 10.1136/bmjopen-2020-039105 [doi]
AB  - INTRODUCTION: Hamstring injury among athletes often results in significant
      morbidity. Currently, there are controversies regarding the clinical use of
      platelet-rich plasma (PRP) for the treatment of acute hamstring injury. METHODS
      AND ANALYSIS: This study is a single-centre double-blind randomised
      placebo-controlled trial. Sixty-eight patients will be randomised to receive
      under ultrasound guidance either a single injection of leucocyte-rich PRP
      (LR-PRP) or normal saline. All patients will undergo a standardised hamstring
      rehabilitation programme under the supervision of a sports physiotherapist.
      Outcome data will be collected before intervention (baseline), and thereafter on 
      a weekly basis. The primary outcome measure is the duration to return-to-play. It
      is defined as the duration (in days) from the date on which the injury occurred
      until the patients were pain-free, able to perform the active knee extension test
      and have regained hamstring muscle strength. Secondary outcome measures include
      assessment of pain intensity and the effect of pain on to day-to-day functions
      using the self-reported Brief Pain Inventory-Short Form questionnaire. Both the
      primary and secondary outcomes were assessed at baseline and thereafter once a
      week until return to play. Also, hamstring injury recurrence within the first 6
      months after recovery will be monitored via telephone. The results of this study 
      will provide insights into the effect of LR-PRP in muscle and may help to
      identify the best PRP application protocol for muscle injuries. ETHICS AND
      DISSEMINATION: Ethics approval were obtained from the Medical Research Ethics
      Committee of the University of Malaya Medical Centre. Results of this trial will 
      be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION
      NUMBER: ISRCTN76844299.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - A Hamid, Mohamad Shariff
AU  - A Hamid MS
AUID- ORCID: 0000-0001-9196-0442
AD  - Sports Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia
      ayip@um.edu.my.
AD  - Division of Sports Medicine, National Sports Institute of Malaysia, Kuala Lumpur,
      Wilayah Persekutuan, Malaysia.
FAU - Hussein, Kamarul Hashimy
AU  - Hussein KH
AD  - Division of Sports Medicine, National Sports Institute of Malaysia, Kuala Lumpur,
      Wilayah Persekutuan, Malaysia.
FAU - Helmi Salim, Ahmad Munawwar
AU  - Helmi Salim AM
AD  - Division of Sports Medicine, National Sports Institute of Malaysia, Kuala Lumpur,
      Wilayah Persekutuan, Malaysia.
FAU - Puji, Arshad
AU  - Puji A
AD  - Department of Orthopaedic and Traumatology, Hospital Kuala Lumpur, Kuala Lumpur, 
      Wilayah Persekutuan, Malaysia.
FAU - Mat Yatim, Rosnah
AU  - Mat Yatim R
AD  - Division of Sports Medicine, National Sports Institute of Malaysia, Kuala Lumpur,
      Wilayah Persekutuan, Malaysia.
FAU - Yong, Chin Chee
AU  - Yong CC
AD  - Division of Sports Medicine, National Sports Institute of Malaysia, Kuala Lumpur,
      Wilayah Persekutuan, Malaysia.
FAU - Sheng, Thomas Wong Yong
AU  - Sheng TWY
AD  - Division of Sports Medicine, National Sports Institute of Malaysia, Kuala Lumpur,
      Wilayah Persekutuan, Malaysia.
LA  - eng
SI  - ISRCTN/ISRCTN76844299
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Athletes
MH  - Double-Blind Method
MH  - *Hamstring Muscles
MH  - Humans
MH  - Neoplasm Recurrence, Local
MH  - *Platelet-Rich Plasma
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7443311
OTO - NOTNLM
OT  - *clinical trials
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039105 [pii]
AID - 10.1136/bmjopen-2020-039105 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e039105. doi: 10.1136/bmjopen-2020-039105.


PMID- 32819999
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Impact of comprehensive molecular testing to reduce antibiotic use in
      community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV
      clinical trial protocol.
PG  - e038957
LID - 10.1136/bmjopen-2020-038957 [doi]
AB  - INTRODUCTION: Community-acquired pneumonia (CAP) continues to be a major health
      problem worldwide and is one of the main reasons for prescribing antibiotics.
      However, the causative agent is often not identified, resulting in antibiotic
      overtreatment, which is a key driver of antimicrobial resistance and adverse
      events. We aim to test the hypothesis that comprehensive molecular testing,
      compared with routine microbiological testing, would be effective in reducing
      antibiotic use in patients with CAP. METHODS AND ANALYSIS: We will perform a
      randomised, controlled, open-label clinical trial with two parallel groups (1:1) 
      at two tertiary hospitals between 2020 and 2022. Non-severely immunosuppressed
      adults hospitalised for CAP will be considered eligible. Patients will be
      randomly assigned to receive either the experimental diagnosis (comprehensive
      molecular testing plus routine microbiological testing) or standard diagnosis
      (only microbiological routine testing). The primary endpoint will be antibiotic
      consumption measured as days of antibiotic therapy per 1000 patient-days.
      Secondary endpoints will be de-escalation to narrower antibiotic treatment, time 
      to switch from intravenous to oral antibiotics, days to reaching an aetiological 
      diagnosis, antibiotic-related side effects, length of stay, days to clinical
      stability, intensive care unit admission, days of mechanical ventilation,
      hospital readmission up to 30 days after randomisation and death from any cause
      by 48 hours and 30 days after randomisation. We will need to include 440 subjects
      to be able to reject the null hypothesis that both groups have equal days of
      antibiotic therapy per 1000 patient-days with a probability >0.8. ETHICS AND
      DISSEMINATION: Ethical approval has been obtained from the Ethics Committee of
      Bellvitge Hospital (AC028/19) and from the Spanish Medicines and Medical Devices 
      Agency, and it is valid for all participating centres under existing Spanish
      legislation. Results will be presented at international meetings and will be made
      available to patients, their caregivers and funders. TRIAL REGISTRATION NUMBER:
      ClinicalTrials: NCT04158492. EudraCT: 2018-004880-29.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Abelenda-Alonso, Gabriela
AU  - Abelenda-Alonso G
AUID- ORCID: 0000-0001-8158-9934
AD  - Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat,
      Barcelona, Spain gabi.abelenda.alonso@gmail.com.
AD  - Bellvitge Institute for Biomedical Research, Barcelona, Spain.
FAU - Rombauts, Alexander
AU  - Rombauts A
AD  - Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat,
      Barcelona, Spain.
AD  - Statistics Advisory Service, Institut d\'Investigacio Biomedica de Bellvitge,
      L'Hospitalet de Llobregat, Spain.
FAU - Gudiol, Carlota
AU  - Gudiol C
AD  - Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat,
      Barcelona, Spain.
AD  - University of Barcelona, Barcelona, Catalunya, Spain.
FAU - Meije, Yolanda
AU  - Meije Y
AD  - Infectious Diseases Unit-Department of Internal Medicine, Hospital de Barcelona, 
      Barcelona, Catalunya, Spain.
FAU - Clemente, Mercedes
AU  - Clemente M
AD  - Infectious Diseases Unit-Department of Internal Medicine, Hospital de Barcelona, 
      Barcelona, Catalunya, Spain.
FAU - Ortega, Lucia
AU  - Ortega L
AD  - Infectious Diseases Unit-Department of Internal Medicine, Hospital de Barcelona, 
      Barcelona, Catalunya, Spain.
FAU - Ardanuy, Carmen
AU  - Ardanuy C
AD  - Department of Clinical Microbiology Unit, Bellvitge University Hospital,
      L'Hospitalet de Llobregat, Barcelona, Spain.
FAU - Niubo, Jordi
AU  - Niubo J
AD  - Department of Clinical Microbiology Unit, Bellvitge University Hospital,
      L'Hospitalet de Llobregat, Barcelona, Spain.
FAU - Padulles, Ariadna
AU  - Padulles A
AD  - Department of Farmacology, Bellvitge University Hospital, L'Hospitalet de
      Llobregat, Barcelona, Spain.
FAU - Videla, Sebastian
AU  - Videla S
AD  - Department of Clinical Farmacology, Bellvitge University Hospital, L'Hospitalet
      de Llobregat, Barcelona, Spain.
FAU - Tebe, Cristian
AU  - Tebe C
AD  - Statistics Advisory Service, Institut d\'Investigacio Biomedica de Bellvitge,
      L'Hospitalet de Llobregat, Spain.
FAU - Carratala, Jordi
AU  - Carratala J
AD  - Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat,
      Barcelona, Spain.
AD  - University of Barcelona, Barcelona, Catalunya, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04158492
SI  - EudraCT/2018-004880-29
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *COVID-19
MH  - Clinical Trials, Phase IV as Topic
MH  - Humans
MH  - Molecular Diagnostic Techniques
MH  - *Pneumonia/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
PMC - PMC7443276
OTO - NOTNLM
OT  - *diagnostic microbiology
OT  - *molecular diagnostics
OT  - *respiratory infections
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038957 [pii]
AID - 10.1136/bmjopen-2020-038957 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e038957. doi: 10.1136/bmjopen-2020-038957.


PMID- 32819997
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - The VRIMM study: Virtual Reality for IMMunisation pain in young children-protocol
      for a randomised controlled trial.
PG  - e038354
LID - 10.1136/bmjopen-2020-038354 [doi]
AB  - INTRODUCTION: Pain caused by routine immunisations is distressing to children,
      their parents and those administering injections. If poorly managed, it can lead 
      to anxiety about future medical procedures, needle phobia and avoidance of future
      vaccinations and other medical treatment. Several strategies, such as
      distraction, are used to manage the distress associated with routine
      immunisations. Virtual reality (VR), a technology which transports users into an 
      immersive 'virtual world', has been used to manage pain and distress in various
      settings such as burns dressing changes and dental treatments. In this study, we 
      aim to compare the effectiveness of VR to standard care in a general practice
      setting as a distraction technique to reduce pain and distress in 4-year-old
      children receiving routine immunisations. METHODS AND ANALYSIS: The study is a
      randomised controlled clinical trial comparing VR with standard care in 100
      children receiving routine 4-year-old vaccination. Children attending a single
      general practice in metropolitan Melbourne, Australia will be allocated using
      blocked randomisation to either VR or standard care. Children in the intervention
      group will receive VR intervention prior to vaccination in addition to standard
      care; the control group will receive standard care. The primary outcome is the
      difference in the child's self-rated pain scores between the VR intervention and 
      control groups measured using The Faces Pain Scale-Revised. Secondary outcomes
      include another measure of self-rated pain (the Poker Chip Tool), parent/guardian
      and healthcare provider ratings of pain (standard 100 mm visual analogue scales) 
      and adverse effects. ETHICS AND DISSEMINATION: Ethics approval has been obtained 
      in Australia from the Royal Australian College of General Practitioners National 
      Research and Evaluation Ethics Committee (NREEC 18-010). Recruitment commenced in
      July 2019. We plan to submit study findings for publication in a peer-reviewed
      journal and presentation at relevant conferences. TRIAL REGISTRATION NUMBER:
      ACTRN12618001363279.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ellerton, Kirrily
AU  - Ellerton K
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - Tharmarajah, Harishan
AU  - Tharmarajah H
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
AD  - Monash University Department of General Practice, Notting Hill, Victoria,
      Australia.
FAU - Medres, Rimma
AU  - Medres R
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
AD  - Monash University Health Service, Clayton, Victoria, Australia.
FAU - Brown, Lona
AU  - Brown L
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - Ringelblum, David
AU  - Ringelblum D
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - Vogel, Kateena
AU  - Vogel K
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - Dolphin, Amanda
AU  - Dolphin A
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - McKellar, Sue
AU  - McKellar S
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - Bridson, Fiona
AU  - Bridson F
AD  - Wellness on Wellington General Practice, Rowville, Victoria, Australia.
FAU - John-White, Marietta
AU  - John-White M
AD  - Emergency Department, Monash Medical Centre Clayton, Clayton, Victoria,
      Australia.
AD  - Department of Paediatrics, Monash University School of Clinical Sciences at
      Monash Health, Clayton, Victoria, Australia.
FAU - Craig, Simon
AU  - Craig S
AUID- ORCID: 0000-0003-2594-1643
AD  - Emergency Department, Monash Medical Centre Clayton, Clayton, Victoria, Australia
      Simon.Craig@monashhealth.org.
AD  - Department of Paediatrics, Monash University School of Clinical Sciences at
      Monash Health, Clayton, Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618001363279
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Child, Preschool
MH  - Humans
MH  - Immunization
MH  - Pain/etiology/prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Vaccination
MH  - *Virtual Reality
PMC - PMC7443262
OTO - NOTNLM
OT  - *paediatric infectious disease & immunisation
OT  - *pain management
OT  - *primary care
COIS- Competing interests: The VR headset was purchased using grant funding.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038354 [pii]
AID - 10.1136/bmjopen-2020-038354 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e038354. doi: 10.1136/bmjopen-2020-038354.


PMID- 32819996
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Efficacy of different surgical approaches on survival outcomes in patients with
      early-stage cervical cancer: protocol for a multicentre longitudinal study in
      China.
PG  - e038020
LID - 10.1136/bmjopen-2020-038020 [doi]
AB  - INTRODUCTION: Recent studies have revealed that the oncological survival outcomes
      of minimally invasive radical hysterectomy (MIRH) are inferior to those of
      abdominal radical hysterectomy (ARH) in early-stage cervical cancer, but the
      potential reasons are unclear. METHODS AND ANALYSIS: Each expert from 28 study
      centres participating in a previously reported randomised controlled trial
      (NCT03739944) will provide successive eligible records of at least 100 patients
      who accepted radical hysterectomy for early-stage cervical cancer between 1
      January 2009 and 31 December 2015. Inclusion criteria consist of a definite
      pathological evaluation of stages IA1 (with positive lymphovascular space
      invasion), IA2 and IB1 according to the International Federation of Gynecology
      and Obstetrics 2009 staging system and a histological subtype of squamous cell
      carcinoma, adenocarcinoma or adenosquamous carcinoma. The primary endpoint is
      5-year disease-free survival between the MIRH and ARH groups. The secondary
      endpoints include the MIRH learning curves of participating surgeons, 5-year
      overall survival between the MIRH and ARH groups, survival outcomes according to 
      surgical chronology, surgical outcomes and sites of recurrence and potential risk
      factors that affect survival outcomes. A subgroup analysis in patients with
      tumour diameter less than 2 cm will follow the similar flow diagram. ETHICS AND
      DISSEMINATION: This study has been approved by the Institutional Review Board of 
      Peking Union Medical College Hospital (registration no. JS-1711), and is also
      filed on record by all other 27 centres. The results will be disseminated through
      community events and peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT03738969.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chao, Xiaopei
AU  - Chao X
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
FAU - Wu, Ming
AU  - Wu M
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
FAU - Ma, Shuiqing
AU  - Ma S
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
FAU - Tan, Xianjie
AU  - Tan X
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
FAU - Zhong, Sen
AU  - Zhong S
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
FAU - Song, Xiaochen
AU  - Song X
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
FAU - Li, Lei
AU  - Li L
AUID- ORCID: 0000-0001-8723-3461
AD  - Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China 
      lileigh@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03738969
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China/epidemiology
MH  - Female
MH  - Humans
MH  - Hysterectomy
MH  - *Laparoscopy
MH  - Longitudinal Studies
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local/pathology
MH  - Neoplasm Staging
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - *Uterine Cervical Neoplasms/pathology/surgery
PMC - PMC7443279
OTO - NOTNLM
OT  - *adult surgery
OT  - *gynaecological oncology
OT  - *minimally invasive surgery
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038020 [pii]
AID - 10.1136/bmjopen-2020-038020 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e038020. doi: 10.1136/bmjopen-2020-038020.


PMID- 32819991
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Interventions promoting physical activity among adults and children in the six
      Gulf Cooperation Council countries: protocol for a systematic review.
PG  - e037122
LID - 10.1136/bmjopen-2020-037122 [doi]
AB  - INTRODUCTION: Prevalence of overweight, obesity and diabetes are high and rising 
      across the Gulf Cooperation Council (GCC) countries (Oman, Bahrain, Kuwait,
      Qatar, Saudi Arabia and the United Arab Emirates). In parallel, physical activity
      (PA) levels are low relative to international standards. PA aids weight control
      and reduces risk of non-communicable diseases including diabetes and
      cardiovascular disease. It is likely interventions developed elsewhere will not
      translate to GCC countries due to unique environmental, social and cultural
      factors. This protocol is for a systematic review assessing the efficacy of
      interventions promoting PA within GCC countries among generally healthy adults
      and children. The primary outcome of interest is change in objectively measured
      or self-reported PA levels, the secondary outcomes of interest are changes in
      anthropometry or chronic disease risk factors (eg, blood pressure). Interventions
      will be compared with no intervention or those of differing PA intensity or
      duration. The relationships between PA change and the following will be assessed:
      intervention intensity or duration, season in which intervention occurs, sex,
      age, nationality and sustainability over time. METHODS AND ANALYSIS: A systematic
      search strategy will identify indexed publications on the efficacy of
      interventions promoting PA. Randomised controlled trials and quasi-experimental
      studies recruiting predominantly healthy children and adults will be included.
      Studies of exercise rehabilitation will be excluded. Medline, Embase, Cinahl,
      Cochrane Library, SportDiscus, Web of Science, Index Medicus for the Eastern
      Mediterranean Region and Qscience will be searched. Clinical trial registries
      including the International Clinical Trials Registry Platform, the Iranian
      Registry of Clinical Trials and ClinicalTrials.gov will be searched for ongoing
      and unpublished studies. Searches will be ran from database inception until 1 May
      2020 and be supplemented by checking references of key articles. Two reviewers
      will independently screen identified citations then full texts using prespecified
      inclusion and exclusion criteria. Piloted data extraction forms will be used in
      duplicate. Inconsistencies in screening or data extraction will be resolved by a 
      third investigator or study author contact. Risk of bias will be independently
      assessed by two reviewers using validated tools. A narrative summary of findings 
      will be produced supplemented with meta-analyses and exploration of heterogeneity
      as appropriate. ETHICS AND DISSEMINATION: The review aims to strengthen the
      findings of the primary studies it incorporates and explore the impact of
      setting. It will synthesise existing published aggregate patient data. If
      publications or data with ethical concerns are identified, they will be excluded 
      from the review. Results of the systematic review will be published in full and
      authors will engage directly with research audiences and key stakeholders to
      share findings. PROSPERO REGISTRATION NUMBER: 131817.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pearson, Fiona
AU  - Pearson F
AUID- ORCID: 0000-0003-1626-0862
AD  - Evidence Synthesis Group, Population Health Research lnstitute, Newcastle
      University, Newcastle Upon Tyne, UK fiona.pearson2@ncl.ac.uk.
FAU - Huangfu, Peijue
AU  - Huangfu P
AD  - Population Health Research Institute, St George's University of London, London,
      UK.
FAU - Abu-Hijleh, Farah M
AU  - Abu-Hijleh FM
AD  - Department of Public Health, College of Health Sciences, Academic Quality Affairs
      Office, QU Health, Qatar University, Doha, Qatar.
FAU - Awad, Susanne F
AU  - Awad SF
AD  - Infectious Disease Epidemiology Group, Weill Cornell Medical College, Qatar,
      Cornell University, Qatar Foundation - Education City, Doha, Qatar.
FAU - Abu-Raddad, Laith J
AU  - Abu-Raddad LJ
AUID- ORCID: 0000-0003-0790-0506
AD  - Infectious Disease Epidemiology Group, Weill Cornell Medical College, Qatar,
      Cornell University, Qatar Foundation - Education City, Doha, Qatar.
AD  - Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell
      University, New York, New York, USA.
FAU - Critchley, Julia A
AU  - Critchley JA
AD  - Population Health Research Institute, St George's University of London, London,
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Bahrain
MH  - Child
MH  - *Exercise
MH  - Humans
MH  - Iran
MH  - Kuwait
MH  - Oman
MH  - Qatar
MH  - Saudi Arabia
MH  - Systematic Reviews as Topic
MH  - United Arab Emirates
PMC - PMC7443261
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *epidemiology
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037122 [pii]
AID - 10.1136/bmjopen-2020-037122 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e037122. doi: 10.1136/bmjopen-2020-037122.


PMID- 32819985
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Effect of subsidies on healthful consumption: a protocol for a systematic review 
      update.
PG  - e036031
LID - 10.1136/bmjopen-2019-036031 [doi]
AB  - INTRODUCTION: The prevalence of diet-related non-communicable diseases (NCDs) are
      rapidly increasing in most parts of the world. In order to ameliorate the related
      public health burden, evidence-informed policies to improve diet need to be
      implemented. Financial subsidies that promote healthful consumption patterns have
      the potential to reduce NCD risk and may also reduce inequality if targeted at
      those of low socio-economic position. This protocol is for an updated systematic 
      review of such evidence. METHODS AND ANALYSIS: A systematic search strategy will 
      be used to identify publications on fiscal intervention studies indexed in
      Embase, CINAHL, Web of Science, EconLit and PubMed in between January 2013 to
      February 2019. Two reviewers will independently sift identified citations using
      prespecified inclusion and exclusion criteria to inform full-text review. The
      outcomes of interest are: consumption patterns (% change in targeted items and in
      overall dietary patterns), purchasing patterns (% change) or body mass index.
      Pretested data capture forms will be used for double data extraction. Any
      inconsistencies in citation sifting or data extraction will be resolved by a
      third investigator and study authors will be contacted if needed. Systematic
      searches will be supplemented by reference checking of key articles. Study
      quality will be assessed and a narrative summary of findings will be produced.
      Meta-analyses and exploration of heterogeneity will be completed if appropriate. 
      ETHICS AND DISSEMINATION: The review aims to strengthen findings of the primary
      studies it incorporates. It will synthesise existing published aggregated patient
      data and only present further aggregate data. Given this, no concerns are held
      relating to confidentiality and informed consent due to re-use of patient data.If
      publications or data with ethical concerns are identified, they will be excluded 
      from the review.Results of the systematic review will be published in full and
      authors will engage directly with research audiences and key stakeholders to
      share findings. PROSPERO REGISTRATION NUMBER: CRD42019125013.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pearson, Fiona
AU  - Pearson F
AUID- ORCID: 0000-0003-1626-0862
AD  - Evidence Synthesis Group, Population Health Sciences Institute, Newcastle
      University, Newcastle upon Tyne, UK fiona.pearson2@ncl.ac.uk.
FAU - Huangfu, Peijue
AU  - Huangfu P
AD  - Population Health Research Institute, St Georges's University of London, London, 
      UK.
FAU - Abu-Hijleh, Farah M
AU  - Abu-Hijleh FM
AD  - Department of Public Health, College of Health Sciences, Academic Quality Affairs
      Office, QU Health, Qatar University, Doha, Qatar.
FAU - Awad, Susanne F
AU  - Awad SF
AD  - Infectious Disease Epidemiology Group, Weill Cornell Medical College - Qatar,
      Cornell University, Qatar Foundation - Education City, Doha, Qatar.
FAU - Abu-Raddad, Laith J
AU  - Abu-Raddad LJ
AUID- ORCID: 0000-0003-0790-0506
AD  - Infectious Disease Epidemiology Group, Weill Cornell Medical College - Qatar,
      Cornell University, Qatar Foundation - Education City, Doha, Qatar.
AD  - Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell
      University, New York City, New York, USA.
FAU - Critchley, Julia A
AU  - Critchley JA
AD  - Population Health Research Institute, St Georges's University of London, London, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Diet
MH  - Humans
MH  - *Noncommunicable Diseases/prevention & control
MH  - Public Health
PMC - PMC7443268
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036031 [pii]
AID - 10.1136/bmjopen-2019-036031 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e036031. doi: 10.1136/bmjopen-2019-036031.


PMID- 32819982
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Measuring shared decision-making and collaborative goal setting in community
      rehabilitation: a focused ethnography using cross-sectional surveys in Canada.
PG  - e034745
LID - 10.1136/bmjopen-2019-034745 [doi]
AB  - OBJECTIVE: To describe and measure the shared decision-making (SDM) experience,
      including goal-setting experiences, from the perspective of patients and
      providers in diverse community-rehabilitation settings. DESIGN: Prospective,
      longitudinal surveys. SETTING: 13 primary level-of-care community-rehabilitation 
      sites in diverse areas varying in geography, patient population and provider
      discipline341 adult, English-speaking patient-participants, and 66
      provider-participants. MEASURES: Alberta Shared decision-maKing Measurement
      Instrument (dyadic tool measuring SDM), WatLX (outpatient rehabilitation
      experience) and demographic questionnaire. Survey packages distributed at two
      timepoints (T0=recruitment; T1=3 months later). RESULTS: We found that among 341 
      patient-provider dyads, 26.4% agreed that the appointment at recruitment involved
      high-quality SDM. Patient perceptions of goal-setting suggested that 19.6% of
      patients did not set a goal for their care, and only 11.4% set goals in
      functional language that tied directly to an activity/role/responsibility that
      was meaningful to their life. Better SDM was clinically associated with higher
      total family income (p=0.045). CONCLUSIONS: These findings provide evidence for
      the importance of SDM and goal setting in community rehabilitation. Among
      patients, lower ratings of SDM corresponded with less recognition of their
      preferences. Actionable strategies include supporting financially vulnerable
      patients in realising SDM through training of providers to make extra space for
      such patients to share their preferences and better preparing patients to
      articulate their preferences. We recommend more research into strategies that
      advance highly functional goal setting with patients, and that lessen survey
      ceiling effects.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Manhas, Kiran Pohar
AU  - Manhas KP
AUID- ORCID: 0000-0002-1486-2387
AD  - Strategic Clinical Networks, Alberta Health Services, Calgary, Alberta, Canada
      kiran.poharmanhas@ahs.ca.
FAU - Olson, Karin
AU  - Olson K
AD  - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
FAU - Churchill, Katie
AU  - Churchill K
AD  - Health Professions, Strategy & Practice, Alberta Health Services, Calgary,
      Alberta, Canada.
FAU - Faris, Peter
AU  - Faris P
AD  - Analytics (DIMR), Health Services Statistical & Analytic Methods, Alberta Health 
      Services, Calgary, Alberta, Canada.
FAU - Vohra, Sunita
AU  - Vohra S
AD  - Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
FAU - Wasylak, Tracy
AU  - Wasylak T
AD  - Strategic Clinical Networks, Alberta Health Services, Calgary, Alberta, Canada.
LA  - eng
GR  - 201705HI7-388576-170744/Canadian Institutes for Health Research /International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Alberta
MH  - *Anthropology, Cultural
MH  - Cross-Sectional Studies
MH  - Decision Making
MH  - *Goals
MH  - Humans
MH  - Patient Participation
MH  - Prospective Studies
PMC - PMC7443299
OTO - NOTNLM
OT  - *ethics (see medical ethics)
OT  - *health services administration & management
OT  - *medical ethics
OT  - *quality in health care
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034745 [pii]
AID - 10.1136/bmjopen-2019-034745 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e034745. doi: 10.1136/bmjopen-2019-034745.


PMID- 32819981
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - mHealth app using machine learning to increase physical activity in diabetes and 
      depression: clinical trial protocol for the DIAMANTE Study.
PG  - e034723
LID - 10.1136/bmjopen-2019-034723 [doi]
AB  - INTRODUCTION: Depression and diabetes are highly disabling diseases with a high
      prevalence and high rate of comorbidity, particularly in low-income ethnic
      minority patients. Though comorbidity increases the risk of adverse outcomes and 
      mortality, most clinical interventions target these diseases separately.
      Increasing physical activity might be effective to simultaneously lower
      depressive symptoms and improve glycaemic control. Self-management apps are a
      cost-effective, scalable and easy access treatment to increase physical activity.
      However, cutting-edge technological applications often do not reach vulnerable
      populations and are not tailored to an individual's behaviour and
      characteristics. Tailoring of interventions using machine learning methods likely
      increases the effectiveness of the intervention. METHODS AND ANALYSIS: In a
      three-arm randomised controlled trial, we will examine the effect of a
      text-messaging smartphone application to encourage physical activity in
      low-income ethnic minority patients with comorbid diabetes and depression. The
      adaptive intervention group receives messages chosen from different messaging
      banks by a reinforcement learning algorithm. The uniform random intervention
      group receives the same messages, but chosen from the messaging banks with equal 
      probabilities. The control group receives a weekly mood message. We aim to
      recruit 276 adults from primary care clinics aged 18-75 years who have been
      diagnosed with current diabetes and show elevated depressive symptoms (Patient
      Health Questionnaire depression scale-8 (PHQ-8) >5). We will compare passively
      collected daily step counts, self-report PHQ-8 and most recent haemoglobin A1c
      from medical records at baseline and at intervention completion at 6-month
      follow-up. ETHICS AND DISSEMINATION: The Institutional Review Board at the
      University of California San Francisco approved this study (IRB: 17-22608). We
      plan to submit manuscripts describing our user-designed methods and testing of
      the adaptive learning algorithm and will submit the results of the trial for
      publication in peer-reviewed journals and presentations at (inter)-national
      scientific meetings. TRIAL REGISTRATION NUMBER: NCT03490253; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aguilera, Adrian
AU  - Aguilera A
AD  - School of Social Welfare, University of California Berkeley, Berkeley,
      California, USA.
AD  - UCSF Center for Vulnerable Populations in the Division of General Internal
      Medicine San Francisco, Zuckerberg San Francisco General Hospital, San Francisco,
      California, USA.
FAU - Figueroa, Caroline A
AU  - Figueroa CA
AUID- ORCID: 0000-0003-0692-2244
AD  - School of Social Welfare, University of California Berkeley, Berkeley,
      California, USA c.a.figueroa@berkeley.edu.
FAU - Hernandez-Ramos, Rosa
AU  - Hernandez-Ramos R
AD  - School of Social Welfare, University of California Berkeley, Berkeley,
      California, USA.
FAU - Sarkar, Urmimala
AU  - Sarkar U
AUID- ORCID: 0000-0003-4213-4405
AD  - UCSF Center for Vulnerable Populations in the Division of General Internal
      Medicine San Francisco, Zuckerberg San Francisco General Hospital, San Francisco,
      California, USA.
FAU - Cemballi, Anupama
AU  - Cemballi A
AD  - UCSF Center for Vulnerable Populations in the Division of General Internal
      Medicine San Francisco, Zuckerberg San Francisco General Hospital, San Francisco,
      California, USA.
FAU - Gomez-Pathak, Laura
AU  - Gomez-Pathak L
AD  - School of Social Welfare, University of California Berkeley, Berkeley,
      California, USA.
FAU - Miramontes, Jose
AU  - Miramontes J
AD  - UCSF Center for Vulnerable Populations in the Division of General Internal
      Medicine San Francisco, Zuckerberg San Francisco General Hospital, San Francisco,
      California, USA.
FAU - Yom-Tov, Elad
AU  - Yom-Tov E
AD  - Microsoft Research, Herzeliya, Israel.
FAU - Chakraborty, Bibhas
AU  - Chakraborty B
AD  - Centre for Quantitative Medicine, Duke-National University of Singapore Medical
      School, Singapore.
AD  - Department of Statistics and Applied Probability, National University of
      Singapore, Singapore.
AD  - Department of Biostatistics and Bioinformatics, Duke University, Durham, North
      Carolina, USA.
FAU - Yan, Xiaoxi
AU  - Yan X
AUID- ORCID: 0000-0003-3291-1637
AD  - Centre for Quantitative Medicine, Duke-National University of Singapore Medical
      School, Singapore.
FAU - Xu, Jing
AU  - Xu J
AD  - Centre for Quantitative Medicine, Duke-National University of Singapore Medical
      School, Singapore.
FAU - Modiri, Arghavan
AU  - Modiri A
AD  - Computer Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Aggarwal, Jai
AU  - Aggarwal J
AD  - Computer Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Jay Williams, Joseph
AU  - Jay Williams J
AD  - Computer Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Lyles, Courtney R
AU  - Lyles CR
AD  - UCSF Center for Vulnerable Populations in the Division of General Internal
      Medicine San Francisco, Zuckerberg San Francisco General Hospital, San Francisco,
      California, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03490253
GR  - R01 HS025429/HS/AHRQ HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Depression/epidemiology
MH  - *Diabetes Mellitus/epidemiology/therapy
MH  - Ethnicity
MH  - Exercise
MH  - Humans
MH  - Machine Learning
MH  - Middle Aged
MH  - Minority Groups
MH  - *Mobile Applications
MH  - Randomized Controlled Trials as Topic
MH  - San Francisco
MH  - *Telemedicine
MH  - Young Adult
PMC - PMC7443305
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *diabetes & endocrinology
OT  - *health informatics
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034723 [pii]
AID - 10.1136/bmjopen-2019-034723 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e034723. doi: 10.1136/bmjopen-2019-034723.


PMID- 32819960
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Supporting self-management of low back pain with an internet intervention in
      primary care: a protocol for a randomised controlled trial of clinical and
      cost-effectiveness (SupportBack 2).
PG  - e040543
LID - 10.1136/bmjopen-2020-040543 [doi]
AB  - INTRODUCTION: Self-management and remaining physically active are first-line
      recommendations for the care of patients with low back pain (LBP). With a
      lifetime prevalence of up to 85%, novel approaches to support behavioural
      self-management are needed. Internet interventions may provide accessible support
      for self-management of LBP in primary care. The aim of this randomised controlled
      trial is to determine the clinical and cost-effectiveness of the 'SupportBack'
      internet intervention, with or without physiotherapist telephone support in
      reducing LBP-related disability in primary care patients. METHODS AND ANALYSIS: A
      three-parallel arm, multicentre randomised controlled trial will compare three
      arms: (1) usual primary care for LBP; (2) usual primary care for LBP and an
      internet intervention; (3) usual primary care for LBP and an internet
      intervention with additional physiotherapist telephone support. Patients with
      current LBP and no indicators of serious spinal pathology are identified and
      invited via general practice list searches and mailouts or opportunistic
      recruitment following LBP consultations. Participants undergo a secondary screen 
      for possible serious spinal pathology and are then asked to complete baseline
      measures online after which they are randomised to an intervention arm.
      Follow-ups occur at 6 weeks, 3, 6 and 12 months. The primary outcome is physical 
      function (using the Roland and Morris Disability Questionnaire) over 12 months
      (repeated measures design). Secondary outcomes include pain intensity,
      troublesome days in pain over the last month, pain self-efficacy,
      catastrophising, kinesophobia, health-related quality of life and cost-related
      measures for a full health economic analysis. A full mixed-methods process
      evaluation will be conducted. ETHICS AND DISSEMINATION: This trial has been
      approved by a National Health Service Research Ethics Committee (REC Ref:
      18/SC/0388). Results will be disseminated through peer-reviewed journals,
      conferences, communication with practices and patient groups. Patient
      representatives will support the implementation of our full dissemination
      strategy. TRIAL REGISTRATION NUMBER: ISRCTN14736486.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Geraghty, Adam W A
AU  - Geraghty AWA
AUID- ORCID: 0000-0001-7984-8351
AD  - Primary Care, Population Sciences and Medical Education, University of
      Southampton, Southampton, Hampshire, UK A.W.Geraghty@soton.ac.uk.
FAU - Roberts, Lisa
AU  - Roberts L
AD  - School of Health Sciences, University of Southampton & University Hospital
      Southampton NHS Foundation Trust, Southampton, Hampshire, UK.
FAU - Hill, Jonathan
AU  - Hill J
AD  - Primary Care Centre Versus Arthritis, School of Primary, Community and Social
      Care, Keele University, Keele, Staffordshire, UK.
FAU - Foster, Nadine E
AU  - Foster NE
AD  - Primary Care Centre Versus Arthritis, School of Primary, Community and Social
      Care, Keele University, Keele, Staffordshire, UK.
FAU - Yardley, Lucy
AU  - Yardley L
AD  - Department of Psychology, University of Southampton, Southampton, Hampshire, UK.
AD  - School of Psychological Science, University of Bristol, Bristol, Bristol, UK.
FAU - Hay, Elaine
AU  - Hay E
AD  - Primary Care Centre Versus Arthritis, School of Primary, Community and Social
      Care, Keele University, Keele, Staffordshire, UK.
FAU - Stuart, Beth
AU  - Stuart B
AD  - Primary Care, Population Sciences and Medical Education, University of
      Southampton, Southampton, Hampshire, UK.
FAU - Turner, David
AU  - Turner D
AD  - Keele Clinical Trials Unit, School of Primary, Community and Social Care, Keele
      University, Keele, Newcastle, UK.
FAU - Griffiths, Gareth
AU  - Griffiths G
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
FAU - Webley, Frances
AU  - Webley F
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
FAU - Durcan, Lorraine
AU  - Durcan L
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
FAU - Morgan, Alannah
AU  - Morgan A
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
FAU - Hughes, Stephanie
AU  - Hughes S
AD  - Primary Care, Population Sciences and Medical Education, University of
      Southampton, Southampton, Hampshire, UK.
FAU - Bathers, Sarah
AU  - Bathers S
AD  - Keele Clinical Trials Unit, Keele University, Keele, Staffordshire, UK.
FAU - Butler-Walley, Stephanie
AU  - Butler-Walley S
AD  - Keele Clinical Trials Unit, Keele University, Keele, Staffordshire, UK.
FAU - Wathall, Simon
AU  - Wathall S
AD  - Keele Clinical Trials Unit, Keele University, Keele, Staffordshire, UK.
FAU - Mansell, Gemma
AU  - Mansell G
AUID- ORCID: 0000-0002-5479-2678
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
FAU - Leigh, Linda
AU  - Leigh L
AD  - Patient and Public Involvement Representative, University of Southampton,
      Southampton, UK.
FAU - Little, Paul
AU  - Little P
AUID- ORCID: 0000-0003-3664-1873
AD  - Primary Care, Population Sciences and Medical Education, University of
      Southampton, Southampton, Hampshire, UK.
LA  - eng
SI  - ISRCTN/ISRCTN14736486
GR  - 16/111/78/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Internet
MH  - *Internet-Based Intervention
MH  - *Low Back Pain/therapy
MH  - Multicenter Studies as Topic
MH  - Primary Health Care
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Management
MH  - State Medicine
PMC - PMC7440707
OTO - NOTNLM
OT  - *back pain
OT  - *primary care
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040543 [pii]
AID - 10.1136/bmjopen-2020-040543 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e040543. doi: 10.1136/bmjopen-2020-040543.


PMID- 32819959
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Clinical prediction models to diagnose neonatal sepsis: a scoping review
      protocol.
PG  - e039712
LID - 10.1136/bmjopen-2020-039712 [doi]
AB  - INTRODUCTION: Neonatal sepsis is responsible for significant morbidity and
      mortality worldwide. Diagnosis is often difficult due to non-specific clinical
      features and the unavailability of laboratory tests in many low-income and
      middle-income countries (LMICs). Clinical prediction models have the potential to
      improve diagnostic accuracy and rationalise antibiotic usage in neonatal units,
      which may result in reduced antimicrobial resistance and improved neonatal
      outcomes. In this paper, we outline our scoping review protocol to map the
      literature concerning clinical prediction models to diagnose neonatal sepsis. We 
      aim to provide an overview of existing models and evidence underlying their use
      and compare prediction models between high-income countries and LMICs. METHODS
      AND ANALYSIS: The protocol was developed with reference to recommendations by the
      Joanna Briggs Institute. Searches will include six electronic databases (Ovid
      MEDLINE, Ovid Embase, Scopus, Web of Science, Global Index Medicus and the
      Cochrane Library) supplemented by hand searching of reference lists and citation 
      analysis on included studies. No time period restrictions will be applied but
      only studies published in English or Spanish will be included. Screening and data
      extraction will be performed independently by two reviewers, with a third
      reviewer used to resolve conflicts. The results will be reported by narrative
      synthesis in line with the Preferred Reporting Items for Systematic reviews and
      Meta-Analyses extension for Scoping Reviews guidelines. ETHICS AND DISSEMINATION:
      The nature of the scoping review methodology means that this study does not
      require ethical approval. Results will be disseminated through peer-reviewed
      publications and conference presentations, as well as through engagement with
      peers and relevant stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Neal, Samuel R
AU  - Neal SR
AUID- ORCID: 0000-0001-6832-9839
AD  - Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child 
      Health, University College London, London, UK.
FAU - Musorowegomo, David
AU  - Musorowegomo D
AD  - Department of Paediatrics and Child Health, University of Zimbabwe College of
      Health Sciences, Harare, Zimbabwe.
FAU - Gannon, Hannah
AU  - Gannon H
AD  - Population, Policy and Practice, UCL Great Ormond Street Institute of Child
      Health, University College London, London, UK.
FAU - Cortina Borja, Mario
AU  - Cortina Borja M
AD  - Population, Policy and Practice, UCL Great Ormond Street Institute of Child
      Health, University College London, London, UK.
FAU - Heys, Michelle
AU  - Heys M
AD  - Population, Policy and Practice, UCL Great Ormond Street Institute of Child
      Health, University College London, London, UK.
AD  - Specialist Children's and Young People's Services, East London NHS Foundation
      Trust, London, UK.
FAU - Chimhini, Gwen
AU  - Chimhini G
AD  - Department of Paediatrics and Child Health, University of Zimbabwe College of
      Health Sciences, Harare, Zimbabwe.
FAU - Fitzgerald, Felicity
AU  - Fitzgerald F
AD  - Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child 
      Health, University College London, London, UK felicity.fitzgerald@ucl.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Infant, Newborn
MH  - Models, Statistical
MH  - *Neonatal Sepsis/diagnosis
MH  - Poverty
MH  - Prognosis
MH  - Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7440696
OTO - NOTNLM
OT  - *infectious diseases
OT  - *neonatal intensive & critical care
OT  - *neonatology
OT  - *paediatrics
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039712 [pii]
AID - 10.1136/bmjopen-2020-039712 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e039712. doi: 10.1136/bmjopen-2020-039712.


PMID- 32819956
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol
      for a systematic review and meta-analysis.
PG  - e039366
LID - 10.1136/bmjopen-2020-039366 [doi]
AB  - INTRODUCTION: Intracerebral haemorrhage (ICH) is a life-threatening condition
      with no effective internal treatment options. However, edaravone is a promising
      therapeutic agent, although its beneficial effects are inconclusive based on
      previous systematic reviews and meta-analyses. While several trials in the last 8
      years have reported the favourable long-term functional outcomes, a few reports
      indicated edaravone to be associated with an increase in adverse events. METHODS 
      AND ANALYSIS: This protocol was performed in accordance with the Preferred
      Reporting Items for Systematic Review and Meta-Analysis Protocols. We will
      perform the comprehensive and manual search for published articles, ongoing
      trials, dissertations and grey literature. The following databases will be
      searched from inception to 23 April 2020: Medline, Embase, the Cochrane Central
      Register of Controlled Trials, China National Knowledge Infrastructure, Chinese
      scientific periodical database of VIP INFORMATION, Wanfang Data and SinoMed, with
      no language restrictions. All randomised controlled trials that (1) compared
      edaravone with placebo or no treatment, and (2) compared edaravone plus routine
      treatment or cointervention with routine treatment or cointervention for treating
      acute ICH will be included. Mortality and long-term dependency will be the
      primary outcomes. The incidence of adverse events will be assessed for safety
      evaluation. Two reviewers in pairs will independently carry out the article
      selection, data extraction and quality assessment. Assessment of the risk of bias
      and data synthesis will be performed using software Review Manager V.5.3.
      Finally, we will use the Grading of Recommendations Assessment, Development and
      Evaluation approach to evaluate the quality of the overall evidence. ETHICS AND
      DISSEMINATION: There are no ethical considerations associated with this updated
      systematic review and meta-analysis. The findings will be disseminated in
      peer-reviewed journals or conference presentations. PROSPERO REGISTRATION NUMBER:
      CRD42019147801.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Feng, Luda
AU  - Feng L
AUID- ORCID: 0000-0002-7259-4421
AD  - Department of Neurology, Beijing University of Chinese Medicine Affiliated
      Dongzhimen Hospital, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing,
      China.
FAU - Liang, Ning
AU  - Liang N
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese
      Medical Sciences, Beijing, China.
FAU - Li, Tingting
AU  - Li T
AD  - Department of Neurology, Beijing University of Chinese Medicine Affiliated
      Dongzhimen Hospital, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Yang, Qinyu
AU  - Yang Q
AD  - Department of Neurology, Beijing University of Chinese Medicine Affiliated
      Dongzhimen Hospital, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Jiang, Ping
AU  - Jiang P
AD  - Department of Neurology, Beijing University of Chinese Medicine Affiliated
      Dongzhimen Hospital, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Guo, Shengnan
AU  - Guo S
AD  - Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical
      Sciences, Beijing, China.
FAU - Zhang, Chi
AU  - Zhang C
AD  - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing,
      China.
FAU - Gao, Ying
AU  - Gao Y
AUID- ORCID: 0000-0001-6972-3846
AD  - Department of Neurology, Beijing University of Chinese Medicine Affiliated
      Dongzhimen Hospital, Beijing, China gaoying973@126.com.
AD  - Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing,
      China.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - S798V6YJRP (Edaravone)
SB  - IM
MH  - *Cerebral Hemorrhage/drug therapy
MH  - China
MH  - *Data Management
MH  - Edaravone
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Treatment Outcome
PMC - PMC7440699
OTO - NOTNLM
OT  - *clinical trials
OT  - *neurology
OT  - *protocols & guidelines
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039366 [pii]
AID - 10.1136/bmjopen-2020-039366 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e039366. doi: 10.1136/bmjopen-2020-039366.


PMID- 32819950
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Study protocol: effects, costs and distributional impact of digital primary care 
      for infectious diseases-an observational, registry-based study in Sweden.
PG  - e038618
LID - 10.1136/bmjopen-2020-038618 [doi]
AB  - INTRODUCTION: The ability to provide primary care with the help of a digital
      platform raises both opportunities and risks. While access to primary care
      improves, overuse of services and medication may occur. The use of digital care
      technologies is likely to continue to increase and evidence of its effects, costs
      and distributional impacts is needed to support policy-making. Since 2016, the
      number of digital primary care consultations for a range of conditions has
      increased rapidly in Sweden. This research project aims to investigate health
      system effects of this development. The overall research question is to what
      extent such care is a cost-effective and equitable alternative to traditional,
      in-office primary care in the context of a publicly funded health system with
      universal access. Three specific areas of investigation are identified: clinical 
      effect; cost and distributional impact. This protocol describes the investigative
      approach of the project in terms of aims, design, materials, methods and expected
      results. METHODS AND ANALYSIS: The research project adopts a retrospective study 
      design and aims to apply statistical analyses of patient-level register data on
      key variables from seven regions of Sweden over the years 2017-2018. In addition 
      to data on three common infectious conditions (upper respiratory tract infection;
      lower urinary tract infection; and skin and soft-tissue infection), information
      on other healthcare use, socioeconomic status and demography will be collected.
      ETHICS AND DISSEMINATION: This registry-based study has received ethical approval
      by the Swedish Ethical Review Authority. Use of data will follow the Swedish
      legislation and practice with regards to consent. The results will be
      disseminated both to the research community, healthcare decision makers and to
      the general public.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wilkens, Jens
AU  - Wilkens J
AUID- ORCID: 0000-0002-5336-8453
AD  - Department of Clinical Sciences, Malmo, Lunds University Faculty of Medicine,
      Lund, Sweden jens.wilkens@med.lu.se.
FAU - Thulesius, Hans
AU  - Thulesius H
AD  - Department of Clinical Sciences, Malmo, Lunds University Faculty of Medicine,
      Lund, Sweden.
AD  - Department of Medicine and Optometry, Linnaeus University Faculty of Health
      Social Work and Behavioural Sciences, Kalmar, Sweden.
FAU - Arvidsson, Eva
AU  - Arvidsson E
AD  - Research and Development unit for Primary Care, Futurum Academy of Health and
      Care, Jonkoping, Sweden.
AD  - Department of Health, Medicine and Caring, Linkoping University, Linkoping,
      Sweden.
FAU - Lindgren, Anna
AU  - Lindgren A
AD  - Centre for Mathematical Sciences, Lund University Faculty of Engineering, Lund,
      Sweden.
FAU - Ekman, Bjorn
AU  - Ekman B
AD  - Department of Clinical Sciences, Malmo, Lunds University Faculty of Medicine,
      Lund, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Communicable Diseases
MH  - Humans
MH  - *Primary Health Care
MH  - Registries
MH  - Retrospective Studies
MH  - Sweden
PMC - PMC7440695
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038618 [pii]
AID - 10.1136/bmjopen-2020-038618 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e038618. doi: 10.1136/bmjopen-2020-038618.


PMID- 32819947
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Recovery-oriented social work practice in mental health and addictions: a scoping
      review protocol.
PG  - e037777
LID - 10.1136/bmjopen-2020-037777 [doi]
AB  - INTRODUCTION: Social work is a key profession in the field of mental health
      worldwide and the profession has values that are aligned with a recovery
      paradigm. However, there are gaps in understanding how social workers are
      applying the recovery paradigm in practice. This study will scope and synthesise 
      the literature related to recovery and social work practice in mental health and 
      addictions. There will also be an exploration of best practices and gaps in
      recovery-oriented social work practice. METHODS AND ANALYSIS: Using a scoping
      review framework developed by Arksey and O'Malley, we will conduct our search in 
      five academic databases: PsycINFO, Medline, CINAHL Plus, Sociological Abstracts
      and Social Services Abstracts. Articles meeting inclusion criteria will be
      charted to extract relevant themes and analysed using a qualitative thematic
      analysis approach. ETHICS AND DISSEMINATION: This review will provide relevant
      information about best practices and gaps in recovery-oriented social work
      practice in mental health and addictions. The study will inform the development
      of mental health curricula in social work programmes and clinical settings.
      Results will be disseminated through a peer-reviewed journal and at conferences
      focusing on mental health, addictions, and social work education. Ethics approval
      is not required for this scoping review.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kourgiantakis, Toula
AU  - Kourgiantakis T
AUID- ORCID: 0000-0002-2491-2595
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada toula.kourgiantakis@utoronto.ca.
FAU - Hussain, Amina
AU  - Hussain A
AUID- ORCID: 0000-0002-8697-0360
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Ashcroft, Rachelle
AU  - Ashcroft R
AUID- ORCID: 0000-0002-5666-1946
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Logan, Judith
AU  - Logan J
AD  - John P. Robarts Library, University of Toronto, Toronto, Ontario, Canada.
FAU - McNeil, Sandra
AU  - McNeil S
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Williams, Charmaine C
AU  - Williams CC
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Behavior, Addictive
MH  - Curriculum
MH  - Humans
MH  - *Mental Health
MH  - Research Design
MH  - Review Literature as Topic
MH  - Social Work
PMC - PMC7440834
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *protocols & guidelines
OT  - *psychiatry
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037777 [pii]
AID - 10.1136/bmjopen-2020-037777 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e037777. doi: 10.1136/bmjopen-2020-037777.


PMID- 32819945
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Treatment of sarcopenia in nursing home residents: a scoping review protocol.
PG  - e037531
LID - 10.1136/bmjopen-2020-037531 [doi]
AB  - INTRODUCTION: Sarcopenia has been recognised as a disease that is consistently
      associated with a range of geriatric syndromes and negative health consequences. 
      The prevalence of sarcopenia is high among nursing home residents. Several
      systematic reviews have assessed the efficacy of a range of treatment strategies 
      against sarcopenia. However, no systematic review discussing specifically the
      treatment options for sarcopenic nursing home residents has been conducted so
      far. The objective of this scoping review, therefore, is to identify and map
      existing studies that assessed the feasibility and effectiveness of interventions
      that were conducted with the aim to treat sarcopenic nursing home residents.
      METHODS AND ANALYSIS: The protocol was developed using an established scoping
      review methodological framework. A systematic search of relevant literature
      databases will be conducted. We will also conduct a search of ClinicalTrials.gov 
      and the WHO International Clinical Trials Registry Platform Search Portal for
      ongoing and recently completed trials, and will search for grey literature. Two
      reviewers will independently screen titles and abstracts for inclusion, followed 
      by screening of the full text of potentially relevant articles to determine final
      inclusion. A data extraction sheet will be developed including key study
      characteristics that will be relevant for collating, summarising and reporting
      the results of the scoping review. ETHICS AND DISSEMINATION: The proposed scoping
      review will undertake a secondary analysis of publicly available data, and
      therefore does not require ethical approval. The results will be disseminated to 
      researchers in the field by submitting the review to a peer-reviewed
      international journal and by presenting our findings at relevant conferences. We 
      expect that the results of the final review will help to guide future research in
      the field of sarcopenia treatment for nursing home residents.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Benzinger, Petra
AU  - Benzinger P
AUID- ORCID: 0000-0003-1121-455X
AD  - Center for Geriatric Medicine, AGAPLESION Bethanien Hospital Heidelberg,
      Heidelberg University Hospital, Heidelberg, Germany
      petra.benzinger@bethanien-heidelberg.de.
AD  - Faculty of Health and Social Sciences, University of Applied Sciences Kempten,
      Kempten, Germany.
FAU - Bauer, Jurgen Martin
AU  - Bauer JM
AD  - Center for Geriatric Medicine, AGAPLESION Bethanien Hospital Heidelberg,
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany.
FAU - Schwenk, Michael
AU  - Schwenk M
AD  - Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany.
FAU - Grund, Stefan
AU  - Grund S
AD  - Center for Geriatric Medicine, AGAPLESION Bethanien Hospital Heidelberg,
      Heidelberg University Hospital, Heidelberg, Germany.
FAU - Goisser, Sabine
AU  - Goisser S
AD  - Center for Geriatric Medicine, AGAPLESION Bethanien Hospital Heidelberg,
      Heidelberg University Hospital, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Humans
MH  - Nursing Homes
MH  - Peer Review
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Sarcopenia/epidemiology/therapy
PMC - PMC7440702
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *nutrition & dietetics
OT  - *rehabilitation medicine
COIS- Competing interests: JMB reported personal fees from Fresenius, personal fees
      from Nestle, personal fees from Novartis, personal fees from Pfizer, personal
      fees from Bayer, grants and personal fees from Nutricia DANONE. He has gained no 
      personal income from these activities and all income received has been
      transferred to his institution.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037531 [pii]
AID - 10.1136/bmjopen-2020-037531 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e037531. doi: 10.1136/bmjopen-2020-037531.


PMID- 32819944
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Protocol of a multicenter, single-blind, randomised, parallel controlled feeding 
      trial evaluating the effect of a Chinese Healthy Heart (CHH) diet in lowering
      blood pressure and other cardiovascular risk factors.
PG  - e036394
LID - 10.1136/bmjopen-2019-036394 [doi]
AB  - INTRODUCTION: Unhealthy diet has been identified as the number one attributor of 
      total mortality in China, accounting for more than 20% of total deaths. Although 
      the Dietary Approach to Stop Hypertension (DASH) and Mediterranean diets have
      been proven beneficial in managing cardiovascular risk factors in Western
      countries, whether healthy diets with similar cardiovascular benefits can be
      developed that are consistent with Chinese food culture remains unknown.
      METHODS/DESIGN: The Diet, ExerCIse and CarDiovascular hEalth (DECIDE)-Diet trial 
      is a multicentre, single-blind, randomised controlled feeding trial to evaluate
      the effect of the Chinese Healthy Heart (CHH) diet, in comparison with the
      Chinese usual diet, in lowering cardiovascular risk factors among community
      residents with the increased cardiovascular risk. A total of 360 adults aged
      between 25 and 75 years old and with systolic blood pressure between 130 and 159 
      mm Hg will be recruited from four centres located in four areas representing four
      major Chinese cuisines: Beijing, Shanghai, Guangzhou and Chengdu. After 1 week of
      run-in period with local usual diet, the compliant participants will be
      randomised to the intervention group with the CHH diet or the control group with 
      the usual local diet, on a 1:1 ratio, for 4 weeks. Body weight of study
      participants will be maintained during the entire study period. The primary
      outcome is the change in SBP from the baseline to the end of the study.
      DECIDE-Diet trial will be the first randomised controlled feeding trial to
      evaluate the effect of a CHH diet in lowering cardiovascular risk factors. This
      trial will provide compelling evidence on the CHH diet in effect of improving
      cardiovascular health among Chinese food consumers all around the world. ETHICS
      AND DISSEMINATION: This trial adheres to the Declaration of Helsinki and
      guidelines of Good Clinical Practice. Signed informed consent will be obtained
      from all participants. The trial has been approved by the Peking University
      Institutional Review Board (approval number: IRB00001052-18094). The results will
      be disseminated through academic conferences and publications in international
      peer-reviewed journals. TRAIL REGISTRATION NUMBER: ClinicalTrials.gov Registry
      (NCT03882645); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xie, Wuxiang
AU  - Xie W
AUID- ORCID: 0000-0001-7527-1022
AD  - Peking University Clinical Research Institute, Peking University First Hospital, 
      Beijing, China.
FAU - Wang, Yanfang
AU  - Wang Y
AD  - Peking University Clinical Research Institute, Peking University Health Science
      Center, Beijing, China pucri_wangyf1225@bjmu.edu.cn.
FAU - Sun, Jianqin
AU  - Sun J
AD  - Clinical Nutrition Center, Huadong Hospital affiliated to Fudan University,
      Shanghai, China.
FAU - Zeng, Guo
AU  - Zeng G
AD  - Department of Nutrition, Food Safety and Toxicology, West China School of Public 
      Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
FAU - Zhu, Huilian
AU  - Zhu H
AD  - Department of Nutrition, School of Public Health, Sun Yat-sen University,
      Guangzhou, China.
FAU - Yang, Zhenquan
AU  - Yang Z
AD  - College of Tourism and Culinary Science, Yangzhou University, Yangzhou, China.
FAU - Gao, Pei
AU  - Gao P
AUID- ORCID: 0000-0001-8649-1290
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University, Beijing, China.
FAU - Yang, Jing
AU  - Yang J
AD  - State Key Laboratory of Infectious Disease Prevention and Control, National
      Institute for Communicable Disease Control and Prevention, China CDC, Beijing,
      China.
FAU - Feng, Lin
AU  - Feng L
AD  - Peking University Clinical Research Institute, Peking University First Hospital, 
      Beijing, China.
FAU - Lin, Pao-Hwa
AU  - Lin PH
AD  - Department of Medicine, Nephrology Division, Duke University Medical Center,
      Durham, North Carolina, USA.
FAU - Li, Ming
AU  - Li M
AD  - Society of Health Risk Assessment & Control, Chinese Preventive Medicine
      Association, Beijing, China.
FAU - Xu, Jianguo
AU  - Xu J
AD  - State Key Laboratory of Infectious Disease Prevention and Control, National
      Institute for Communicable Disease Control and Prevention, China CDC, Beijing,
      China.
FAU - Chen, Junshi
AU  - Chen J
AD  - Key Laboratory of Food Safety Risk Assessment of Ministry of Health, National
      Center for Food Safety Risk Assessment, Beijing, China.
FAU - Wu, Yangfeng
AU  - Wu Y
AD  - Peking University Clinical Research Institute, Peking University First Hospital, 
      Beijing, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University, Beijing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03882645
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Pressure
MH  - *Cardiovascular Diseases/prevention & control
MH  - China
MH  - *Diet, Healthy
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Single-Blind Method
PMC - PMC7440703
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *hypertension
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036394 [pii]
AID - 10.1136/bmjopen-2019-036394 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e036394. doi: 10.1136/bmjopen-2019-036394.


PMID- 32819943
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Effect of music intervention on mental health in patients with diabetes mellitus:
      protocol for a systematic review and meta-analysis of randomizsed controlled
      trials.
PG  - e036268
LID - 10.1136/bmjopen-2019-036268 [doi]
AB  - INTRODUCTION: About 463 million adults aged 20-79 have diabetes globally. Mental 
      disorders often exist in patients with diabetes as comorbidities, which can lead 
      to aggravation of the diseases, increased difficulties in treatment, as well as
      elevated mortality rates. Music intervention has been applied in the treatment of
      comorbidities for 12 years now, but there are still no recommendations due to the
      lack of evidence. Thus, a meta-analysis is necessary to evaluate the effect of
      music intervention in treating mental disorders of patients with diabetes.
      METHODS AND ANALYSIS: We will search the following nine online electronic
      databases from their inception until March 2020: PubMed, Web of Science, Embase, 
      EBSCO, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang
      Database, Chinese Scientific Journal Database (VIP) and Chinese Biomedical and
      Medical Database. We also plan to search other relevant resources, including grey
      literature and the reference lists of relevant publications. Only randomised
      controlled trials of music intervention to treat depression or anxiety in
      patients with diabetes will be involved. The primary outcomes include the
      depression score and anxiety score measured on certain scales, and the secondary 
      outcome is safety. Data extraction will be independently implemented by two
      researchers. The risk of bias will be evaluated through the Cochrane
      Collaboration's Risk of Bias tool. Eventually, all the data will be analysed via 
      the Review Manager V.5.3 software. ETHICS AND DISSEMINATION: This meta-analysis
      will provide information about applying music intervention to treat depression or
      anxiety in patients with diabetes. No ethical approval is required because this
      meta-analysis is based on published data. The results of this systematic review
      will be published in a peer-reviewed journal.PROSPERO registration
      numberCRD42019146439.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhou, Lin-Yue
AU  - Zhou LY
AD  - Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Zhang, Yuan
AU  - Zhang Y
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Tian, Yuan
AU  - Tian Y
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Fu, Xiaoxu
AU  - Fu X
AD  - Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Wang, Li-Zhen
AU  - Wang LZ
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Xie, Chun-Guang
AU  - Xie CG
AUID- ORCID: 0000-0002-0423-5515
AD  - Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China killuya233@stu.cdutcm.edu.cn.
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anxiety
MH  - Bias
MH  - *Diabetes Mellitus/therapy
MH  - Humans
MH  - Mental Health
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - *Music Therapy
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
MH  - Young Adult
PMC - PMC7440704
OTO - NOTNLM
OT  - *complementary medicine
OT  - *diabetes & endocrinology
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036268 [pii]
AID - 10.1136/bmjopen-2019-036268 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e036268. doi: 10.1136/bmjopen-2019-036268.


PMID- 32819940
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - High-resolution spatiotemporal measurement of air and environmental noise
      pollution in Sub-Saharan African cities: Pathways to Equitable Health Cities
      Study protocol for Accra, Ghana.
PG  - e035798
LID - 10.1136/bmjopen-2019-035798 [doi]
AB  - INTRODUCTION: Air and noise pollution are emerging environmental health hazards
      in African cities, with potentially complex spatial and temporal patterns.
      Limited local data are a barrier to the formulation and evaluation of policies to
      reduce air and noise pollution. METHODS AND ANALYSIS: We designed a year-long
      measurement campaign to characterise air and noise pollution and their sources at
      high-resolution within the Greater Accra Metropolitan Area (GAMA), Ghana. Our
      design uses a combination of fixed (year-long, n=10) and rotating (week-long, n
      =~130) sites, selected to represent a range of land uses and source influences
      (eg, background, road traffic, commercial, industrial and residential areas, and 
      various neighbourhood socioeconomic classes). We will collect data on fine
      particulate matter (PM2.5), nitrogen oxides (NOx), weather variables, sound
      (noise level and audio) along with street-level time-lapse images. We deploy
      low-cost, low-power, lightweight monitoring devices that are robust, socially
      unobtrusive, and able to function in Sub-Saharan African (SSA) climate. We will
      use state-of-the-art methods, including spatial statistics, deep/machine
      learning, and processed-based emissions modelling, to capture highly resolved
      temporal and spatial variations in pollution levels across the GAMA and to
      identify their potential sources. This protocol can serve as a prototype for
      other SSA cities. ETHICS AND DISSEMINATION: This environmental study was deemed
      exempt from full ethics review at Imperial College London and the University of
      Massachusetts Amherst; it was approved by the University of Ghana Ethics
      Committee (ECH 149/18-19). This protocol is designed to be implementable in SSA
      cities to map environmental pollution to inform urban planning decisions to
      reduce health harming exposures to air and noise pollution. It will be
      disseminated through local stakeholder engagement (public and private sectors),
      peer-reviewed publications, contribution to policy documents, media, and
      conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Clark, Sierra N
AU  - Clark SN
AUID- ORCID: 0000-0002-8592-3466
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Alli, Abosede S
AU  - Alli AS
AD  - Department of Environmental Health Sciences, University of Massachusetts Amherst,
      Amherst, Massachusetts, USA.
FAU - Brauer, Michael
AU  - Brauer M
AD  - School of Population and Public Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Ezzati, Majid
AU  - Ezzati M
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
AD  - Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial
      College London, London, UK.
AD  - Regional Institute for Population Studies, University of Ghana, Legon, Accra,
      Ghana.
FAU - Baumgartner, Jill
AU  - Baumgartner J
AD  - Institute for Health and Social Policy, McGill University, Montreal, Quebec,
      Canada.
AD  - Department of Epidemiology, Biostatistics, and Occupational Health, McGill
      University, Montreal, Quebec, Canada.
FAU - Toledano, Mireille B
AU  - Toledano MB
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Hughes, Allison F
AU  - Hughes AF
AD  - Department of Physics, University of Ghana, Legon, Accra, Ghana.
FAU - Nimo, James
AU  - Nimo J
AD  - Department of Physics, University of Ghana, Legon, Accra, Ghana.
FAU - Bedford Moses, Josephine
AU  - Bedford Moses J
AD  - Department of Physics, University of Ghana, Legon, Accra, Ghana.
FAU - Terkpertey, Solomon
AU  - Terkpertey S
AD  - Department of Physics, University of Ghana, Legon, Accra, Ghana.
FAU - Vallarino, Jose
AU  - Vallarino J
AD  - Department of Environmental Health, Harvard T.H. Chan School of Public Health,
      Boston, Massachusetts, USA.
FAU - Agyei-Mensah, Samuel
AU  - Agyei-Mensah S
AD  - Department of Geography and Resource Development, University of Ghana, Legon,
      Accra, Ghana.
FAU - Agyemang, Ernest
AU  - Agyemang E
AD  - Department of Geography and Resource Development, University of Ghana, Legon,
      Accra, Ghana.
FAU - Nathvani, Ricky
AU  - Nathvani R
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Muller, Emily
AU  - Muller E
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Bennett, James
AU  - Bennett J
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Wang, Jiayuan
AU  - Wang J
AD  - Department of Environmental Health Sciences, University of Massachusetts Amherst,
      Amherst, Massachusetts, USA.
FAU - Beddows, Andrew
AU  - Beddows A
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Kelly, Frank
AU  - Kelly F
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
AD  - NIHR HPRU in Environmental Exposures and Health, Imperial College London, London,
      UK.
FAU - Barratt, Benjamin
AU  - Barratt B
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
AD  - NIHR HPRU in Environmental Exposures and Health, Imperial College London, London,
      UK.
FAU - Beevers, Sean
AU  - Beevers S
AD  - MRC Center for Environment and Health, Imperial College London, London, UK.
FAU - Arku, Raphael E
AU  - Arku RE
AD  - Department of Environmental Health Sciences, University of Massachusetts Amherst,
      Amherst, Massachusetts, USA rarku@umass.edu.
LA  - eng
GR  - 209376/Z/17/Z/Wellcome Trust/United Kingdom
GR  - MR/S020810/2/MRC_/Medical Research Council/United Kingdom
GR  - MR/L01341X/1/MRC_/Medical Research Council/United Kingdom
GR  - Canadian Institutes for Health Research /International
GR  - Wellcome Trust/United Kingdom
GR  - MR/S019669/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S020810/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Air Pollutants)
RN  - 0 (Particulate Matter)
SB  - IM
MH  - *Air Pollutants/analysis
MH  - *Air Pollution/analysis
MH  - Cities
MH  - Environmental Monitoring
MH  - Ghana
MH  - Humans
MH  - London
MH  - Noise
MH  - Particulate Matter/analysis
PMC - PMC7440835
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035798 [pii]
AID - 10.1136/bmjopen-2019-035798 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e035798. doi: 10.1136/bmjopen-2019-035798.


PMID- 32819938
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Role of endoscopic ultrasonography in the diagnostic work-up of idiopathic acute 
      pancreatitis (PICUS): study protocol for a nationwide prospective cohort study.
PG  - e035504
LID - 10.1136/bmjopen-2019-035504 [doi]
AB  - INTRODUCTION: Idiopathic acute pancreatitis (IAP) remains a dilemma for
      physicians as it is uncertain whether patients with IAP may actually have an
      occult aetiology. It is unclear to what extent additional diagnostic modalities
      such as endoscopic ultrasonography (EUS) are warranted after a first episode of
      IAP in order to uncover this aetiology. Failure to timely determine treatable
      aetiologies delays appropriate treatment and might subsequently cause recurrence 
      of acute pancreatitis. Therefore, the aim of the Pancreatitis of Idiopathic
      origin: Clinical added value of endoscopic UltraSonography (PICUS) Study is to
      determine the value of routine EUS in determining the aetiology of pancreatitis
      in patients with a first episode of IAP. METHODS AND ANALYSIS: PICUS is designed 
      as a multicentre prospective cohort study of 106 patients with a first episode of
      IAP after complete standard diagnostic work-up, in whom a diagnostic EUS will be 
      performed. Standard diagnostic work-up will include a complete personal and
      family history, laboratory tests including serum alanine aminotransferase,
      calcium and triglyceride levels and imaging by transabdominal ultrasound,
      magnetic resonance imaging or magnetic resonance cholangiopancreaticography after
      clinical recovery from the acute pancreatitis episode. The primary outcome
      measure is detection of aetiology by EUS. Secondary outcome measures include
      pancreatitis recurrence rate, severity of recurrent pancreatitis, readmission,
      additional interventions, complications, length of hospital stay, quality of
      life, mortality and costs, during a follow-up period of 12 months. ETHICS AND
      DISSEMINATION: PICUS is conducted according to the Declaration of Helsinki and
      Guideline for Good Clinical Practice. Five medical ethics review committees
      assessed PICUS (Medical Ethics Review Committee of Academic Medical Center,
      University Medical Center Utrecht, Radboud University Medical Center, Erasmus
      Medical Center and Maastricht University Medical Center). The results will be
      submitted for publication in an international peer-reviewed journal. TRIAL
      REGISTRATION NUMBER: Netherlands Trial Registry (NL7066). Prospectively
      registered.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Umans, Devica S
AU  - Umans DS
AUID- ORCID: 0000-0002-4872-8389
AD  - Department of Gastroenterology and Hepatology, Amsterdam University Medical
      Centres, Amsterdam, The Netherlands d.s.umans@amsterdamumc.nl.
AD  - Research and Development, Saint Antonius Hospital, Nieuwegein, Utrecht, The
      Netherlands.
FAU - Timmerhuis, Hester C
AU  - Timmerhuis HC
AD  - Research and Development, Saint Antonius Hospital, Nieuwegein, Utrecht, The
      Netherlands.
AD  - Department of Surgery, Saint Antonius Hospital, Nieuwegein, Utrecht, The
      Netherlands.
FAU - Hallensleben, Nora D
AU  - Hallensleben ND
AD  - Research and Development, Saint Antonius Hospital, Nieuwegein, Utrecht, The
      Netherlands.
AD  - Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Bouwense, Stefan A
AU  - Bouwense SA
AD  - Department of Surgery, Maastricht UMC+, Maastricht, Limburg, The Netherlands.
FAU - Anten, Marie-Paule Gf
AU  - Anten MG
AD  - Department of Gastroenterology and Hepatology, Franciscus Gasthuis en Vlietland, 
      Rotterdam, Zuid-Holland, The Netherlands.
FAU - Bhalla, Abha
AU  - Bhalla A
AD  - Department of Gastroenterology and Hepatology, HagaZiekenhuis, Den Haag,
      Zuid-Holland, The Netherlands.
FAU - Bijlsma, Rina A
AU  - Bijlsma RA
AD  - Department of Gastroenterology and Hepatology, Martini Ziekenhuis, Groningen,
      Groningen, The Netherlands.
FAU - Boermeester, Marja A
AU  - Boermeester MA
AD  - Department of Surgery, Amsterdam University Medical Centres, Amsterdam,
      Noord-Holland, The Netherlands.
FAU - Brink, Menno A
AU  - Brink MA
AD  - Department of Gastroenterology and Hepatology, Meander MC, Amersfoort, Utrecht,
      The Netherlands.
FAU - Hol, Lieke
AU  - Hol L
AD  - Department of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Bruno, Marco J
AU  - Bruno MJ
AD  - Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Curvers, Wouter L
AU  - Curvers WL
AD  - Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven,
      North Brabant, The Netherlands.
FAU - van Dullemen, Hendrik M
AU  - van Dullemen HM
AD  - Department of Gastroenterology and Hepatology, UMCG, Groningen, Groningen, The
      Netherlands.
FAU - van Eijck, Brechje C
AU  - van Eijck BC
AD  - Department of Gastroenterology and Hepatology, Spaarne Gasthuis, Haarlem,
      Noord-Holland, The Netherlands.
FAU - Erkelens, G Willemien
AU  - Erkelens GW
AD  - Department of Gastroenterology and Hepatology, Gelre Ziekenhuizen, Apeldoorn,
      Gelderland, The Netherlands.
FAU - Fockens, Paul
AU  - Fockens P
AD  - Department of Gastroenterology and Hepatology, Amsterdam University Medical
      Centres, Amsterdam, The Netherlands.
FAU - van Geenen, Erwin J M
AU  - van Geenen EJM
AD  - Department of Gastroenterology and Hepatology, Radboud university medical center,
      Nijmegen, the Netherlands.
FAU - Hazen, Wouter L
AU  - Hazen WL
AD  - Department of Gastroenterology and Hepatology, Elisabeth-TweeSteden Ziekenhuis,
      Tilburg, Noord-Brabant, The Netherlands.
FAU - Hoge, Chantal V
AU  - Hoge CV
AD  - Department of Gastroenterology and Hepatology, Maastricht UMC+, Maastricht,
      Limburg, The Netherlands.
FAU - Inderson, Akin
AU  - Inderson A
AD  - Department of Gastroenterology and Hepatology, LUMC, Leiden, Zuid-Holland, The
      Netherlands.
FAU - Kager, Liesbeth M
AU  - Kager LM
AD  - Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep,
      Alkmaar, Noord-Holland, The Netherlands.
FAU - Kuiken, Sjoerd D
AU  - Kuiken SD
AD  - Department of Gastroenterology and Hepatology, OLVG, Amsterdam, Noord-Holland,
      The Netherlands.
FAU - Perk, Lars E
AU  - Perk LE
AD  - Department of Gastroenterology and Hepatology, Medisch Centrum Haaglanden, Den
      Haag, Zuid-Holland, The Netherlands.
FAU - Poley, Jan-Werner
AU  - Poley JW
AD  - Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Quispel, Rutger
AU  - Quispel R
AD  - Department of Gastroenterology and Hepatology, Reinier de Graaf Groep, Delft,
      Zuid-Holland, The Netherlands.
FAU - Romkens, Tessa Eh
AU  - Romkens TE
AD  - Department of Gastroenteroloy and Hepatology, Jeroen Bosch Hospital,
      's-Hertogenbosch, Noord-Brabant, The Netherlands.
FAU - van Santvoort, Hjalmar C
AU  - van Santvoort HC
AD  - Department of Surgery, Saint Antonius Hospital, Nieuwegein, Utrecht, The
      Netherlands.
AD  - Department of Surgery, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Tan, Adriaan Citl
AU  - Tan AC
AD  - Department of Gastroenterology and Hepatology, Canisius Wilhelmina Hospital,
      Nijmegen, Gelderland, The Netherlands.
FAU - Thijssen, Annemieke Y
AU  - Thijssen AY
AD  - Department of Gastroenterology and Hepatology, Albert Schweitzer Ziekenhuis,
      Dordrecht, Zuid-Holland, The Netherlands.
FAU - Venneman, Niels G
AU  - Venneman NG
AD  - Department of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede,
      Overijssel, The Netherlands.
FAU - Vleggaar, Frank P
AU  - Vleggaar FP
AD  - Department of Gastroenterology and Hepatology, University Medical Center Utrecht,
      Utrecht, the Netherlands.
FAU - Voorburg, Annet McJ
AU  - Voorburg AM
AD  - Department of Gastroenterology and Hepatology, Diakonessenhuis Utrecht Zeist
      Doorn, Utrecht, Utrecht, The Netherlands.
FAU - van Wanrooij, Roy Lj
AU  - van Wanrooij RL
AD  - Department of Gastroenterology and Hepatology, Amsterdam University Medical
      Centres, Amsterdam, The Netherlands.
FAU - Witteman, Ben J
AU  - Witteman BJ
AD  - Department of Gastroenterology and Hepatology, Ziekenhuis Gelderse Vallei, Ede,
      Gelderland, The Netherlands.
FAU - Verdonk, Robert C
AU  - Verdonk RC
AD  - Department of Gastroenterology and Hepatology, Saint Antonius Hospital,
      Nieuwegein, Utrecht, The Netherlands.
FAU - Besselink, Marc G
AU  - Besselink MG
AD  - Department of Surgery, Amsterdam University Medical Centres, Amsterdam,
      Noord-Holland, The Netherlands.
FAU - van Hooft, Jeanin E
AU  - van Hooft JE
AD  - AMC, Amsterdam, North Holland, The Netherlands.
CN  - Dutch Pancreatitis Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acute Disease
MH  - *Endosonography
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - *Pancreatitis/diagnostic imaging
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC7440829
OTO - NOTNLM
OT  - *endoscopy
OT  - *hepatobiliary disease
OT  - *pancreatic disease
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035504 [pii]
AID - 10.1136/bmjopen-2019-035504 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e035504. doi: 10.1136/bmjopen-2019-035504.


PMID- 32819937
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - SAFety, Effectiveness of care and Resource use among Australian Hospitals (SAFER 
      Hospitals): a protocol for a population-wide cohort study of outcomes of hospital
      care.
PG  - e035446
LID - 10.1136/bmjopen-2019-035446 [doi]
AB  - INTRODUCTION: Despite global concerns about the safety and quality of health
      care, population-wide studies of hospital outcomes are uncommon. The SAFety,
      Effectiveness of care and Resource use among Australian Hospitals (SAFER
      Hospitals) study seeks to estimate the incidence of serious adverse events,
      mortality, unplanned rehospitalisations and direct costs following hospital
      encounters using nationwide data, and to assess the variation and trends in these
      outcomes. METHODS AND ANALYSIS: SAFER Hospitals is a cohort study with
      retrospective and prospective components. The retrospective component uses data
      from 2012 to 2018 on all hospitalised patients age >/=18 years included in each
      State and Territories' Admitted Patient Collections. These routinely collected
      datasets record every hospital encounter from all public and most private
      hospitals using a standardised set of variables including patient demographics,
      primary and secondary diagnoses, procedures and patient status at discharge. The 
      study outcomes are deaths, adverse events, readmissions and emergency care
      visits. Hospitalisation data will be linked to subsequent hospitalisations and
      each region's Emergency Department Data Collections and Death Registries to
      assess readmissions, emergency care encounters and deaths after discharge. Direct
      hospital costs associated with adverse outcomes will be estimated using data from
      the National Cost Data Collection. Variation in these outcomes among hospitals
      will be assessed adjusting for differences in hospitals' case-mix. The
      prospective component of the study will evaluate the temporal change in outcomes 
      every 4 years from 2019 until 2030. ETHICS AND DISSEMINATION: Human Research
      Ethics Committees of the respective Australian states and territories provided
      ethical approval to conduct this study. A waiver of informed consent was granted 
      for the use of de-identified patient data. Study findings will be disseminated
      via presentations at conferences and publications in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ranasinghe, Isuru
AU  - Ranasinghe I
AUID- ORCID: 0000-0003-0982-1561
AD  - Department of Cardiology, The Prince Charles Hospital, Brisbane, Queensland,
      Australia i.ranasinghe@uq.edu.au.
AD  - School of Clinical Medicine, The University of Queensland, Brisbane, Queensland, 
      Australia.
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
FAU - Hossain, Sadia
AU  - Hossain S
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
FAU - Ali, Anna
AU  - Ali A
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
FAU - Horton, Dennis
AU  - Horton D
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
FAU - Adams, Robert Jt
AU  - Adams RJ
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
AD  - College of Medicine and Public Health, Flinders University, Adelaide, South
      Australia, Australia.
FAU - Aliprandi-Costa, Bernadette
AU  - Aliprandi-Costa B
AD  - Australian Commission on Safety and Quality in Health Care, Sydney, New South
      Wales, Australia.
FAU - Bertilone, Christina
AU  - Bertilone C
AD  - Healthcare Quality Intelligence Unit, Patient Safety and Clinical Quality
      Directorate, Clinical Excellence Division, Department of Health Government of
      Western Australia, Perth, Western Australia, Australia.
FAU - Carneiro, Gustavo
AU  - Carneiro G
AD  - Faculty of Engineering Computer and Mathematical Sciences, The University of
      Adelaide, Adelaide, South Australia, Australia.
FAU - Gallagher, Martin
AU  - Gallagher M
AD  - George Institute for Global Health, Sydney, New South Wales, Australia.
AD  - Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
FAU - Guthridge, Steven
AU  - Guthridge S
AD  - Menzies School of Health Research, Casuarina, Northern Territory, Australia.
FAU - Kaambwa, Billingsley
AU  - Kaambwa B
AD  - Health Economics Unit, Flinders University, Adelaide, South Australia, Australia.
FAU - Kotwal, Sradha
AU  - Kotwal S
AD  - George Institute for Global Health, Sydney, New South Wales, Australia.
AD  - The Prince of Wales Hospital, Sydney, New South Wales, Australia.
FAU - O'Callaghan, Gerry
AU  - O'Callaghan G
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
AD  - Intensive Care Services, Central Adelaide Local Health Network, Adelaide, South
      Australia, Australia.
FAU - Scott, Ian A
AU  - Scott IA
AUID- ORCID: 0000-0002-7596-0837
AD  - School of Clinical Medicine, The University of Queensland, Brisbane, Queensland, 
      Australia.
AD  - Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital,
      Brisbane, Queensland, Australia.
FAU - Visvanathan, Renuka
AU  - Visvanathan R
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
AD  - Adelaide Geriatrics Training and Research with Aged Care (GTRAC) Centre, The
      University of Adelaide, Adelaide, South Australia, Australia.
AD  - Aged & Extended Care Services, The Basil Hetzel Institute, The Queen Elizabeth
      Hospital, Adelaide, South Australia, Australia.
FAU - Woodman, Richard J
AU  - Woodman RJ
AD  - Flinders Centre for Epidemiology and Biostatistics, Flinders University,
      Adelaide, South Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia/epidemiology
MH  - Cohort Studies
MH  - *Hospitals
MH  - Humans
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC7440820
OTO - NOTNLM
OT  - *health & safety
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035446 [pii]
AID - 10.1136/bmjopen-2019-035446 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e035446. doi: 10.1136/bmjopen-2019-035446.


PMID- 32819933
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Fast track rehabilitation after reversed total shoulder arthroplasty: a protocol 
      for an international multicentre prospective cohort study.
PG  - e034934
LID - 10.1136/bmjopen-2019-034934 [doi]
AB  - INTRODUCTION: The use of reversed total shoulder arthroplasty (rTSA) has
      increased because of an increasing number of indications for this procedure and
      by ageing of the population. Usual postoperative care consists of immobilisation 
      of the shoulder for a period of 2-6 weeks to allow healing of the subscapularis
      tendon and protection of the joint. However, new literature proved that
      reattachment of the subscapularis tendon is unnecessary. Therefore we
      hypothesised that immobilisation of the shoulder is not necessary and patients
      can start safely with mobilisation on the first postoperative day. We expect this
      fast track protocol to be safe and result in better short-term and long-term
      functional outcomes. METHODS AND ANALYSIS: In our prospective cohort, we will
      include at least 75 patients aged 50 years and older indicated for rTSA, with
      acute fracture treatment as an exclusion criterion. Patients will be selected and
      operated in three hospitals: two in the Netherlands and one in Curacao.Patients
      will visit the outpatient clinic preoperative, at 6 weeks, 3 months and 1 year
      postoperative. The data that will be collected includes baseline characteristics,
      reason for surgery, complications and adverse events, patient reported outcomes
      (Oxford Shoulder Score, EuroQol-5D and Numeric Rating Scale for pain) and range
      of motion of the shoulder.All patients will be instructed to use a sling only for
      1 day and to follow a progressive physiotherapy schedule for 12 weeks. The
      primary outcome is the occurrence of complications and adverse events. ETHICS AND
      DISSEMINATION: The Medical Ethics Committee from the VUmc and Curacao reviewed
      this study protocol and granted exemption from ethical approval (METC VUmc
      2019.111, METC Curacao 2019-02). Study results will be presented at
      (inter)national conferences and published in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: Netherlands Trial Register (NL7656).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - van Essen, Tom
AU  - van Essen T
AUID- ORCID: 0000-0001-9256-9269
AD  - Orthopaedic Surgery, Dijklander Ziekenhuis, Purmerend, The Netherlands
      tomvanessen11@gmail.com.
FAU - Kornuijt, Anke
AU  - Kornuijt A
AD  - Orthopaedic Surgery, Sint Annaziekenhuis, Geldrop, Noord-Brabant, The
      Netherlands.
FAU - de Vries, Lieke Maria Anna
AU  - de Vries LMA
AD  - Orthopaedic Surgery, Dijklander Ziekenhuis, Hoorn, The Netherlands.
FAU - Stokman, Remco
AU  - Stokman R
AD  - Orthopaedic Surgery, Sint Elisabeth Hospitaal, Willemstad, Curacao.
FAU - van der Weegen, Walter
AU  - van der Weegen W
AD  - Orthopaedic Surgery, Sint Annaziekenhuis, Geldrop, Noord-Brabant, The
      Netherlands.
FAU - Bogie, Rob
AU  - Bogie R
AD  - Orthopaedic Surgery, Sint Annaziekenhuis, Geldrop, Noord-Brabant, The
      Netherlands.
FAU - Hillen, Robert Jan
AU  - Hillen RJ
AD  - Orthopaedic Surgery, Dijklander Ziekenhuis, Purmerend, The Netherlands.
FAU - van Kampen, D A
AU  - van Kampen DA
AD  - Orthopedic Surgery and Traumatologie, Dijklander Ziekenhuis, Hoorn, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Arthroplasty, Replacement, Shoulder
MH  - Cohort Studies
MH  - Humans
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - Prospective Studies
MH  - Range of Motion, Articular
MH  - Treatment Outcome
PMC - PMC7440714
OTO - NOTNLM
OT  - *elbow & shoulder
OT  - *rehabilitation medicine
OT  - *shoulder
COIS- Competing interests: van Kampen and Hillen have a consultancy contract with
      Exactech Company. This study was not sponsored by Exactech. Bogie has a
      consultancy contract with Zimmer Biomet. This study was not sponsored by Zimmer
      Biomet.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034934 [pii]
AID - 10.1136/bmjopen-2019-034934 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e034934. doi: 10.1136/bmjopen-2019-034934.


PMID- 32819932
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Acupuncture for patients with chronic pruritus: protocol of a systematic review
      and meta-analysis.
PG  - e034784
LID - 10.1136/bmjopen-2019-034784 [doi]
AB  - INTRODUCTION: Chronic pruritus (CP) frequently occurs in many skin and systemic
      diseases, and adversely affects quality of life. This systematic review aims to
      evaluate treatment effects of acupuncture on CP. METHODS AND ANALYSIS: An
      electronic and manual search will be conducted for all acupuncture treatments for
      CP, from the inception date of predefined database up to 28 February 2020.
      Databases include PubMed, Embase, Springer, Web of Science, the Cochrane Library,
      the World Health Organization International Clinical Trial Registration Platform,
      the Chinese Medicine Database, the China National Knowledge Infrastructure, the
      Chinese Biomedical Literature Database, the China Science Journal Database and
      the Wanfang Database. Other sources, including existing systematic reviews,
      conference proceedings and reference lists of identified publications will also
      be searched. Additionally, any clinical randomised controlled trials related to
      acupuncture treatment for CP, regardless of the publication status and language
      limitations, will be included. Study selection, data extraction and research
      quality assessments will be conducted independently by two researchers. The
      primary outcome measures include the Visual Analogue Scale, Urdu 5D-Itch Scale or
      other validated scales implemented after at least 2 weeks of treatment. Secondary
      outcomes include the effective rate, Quality of Life Scale (eg, the EQ-5D third
      level, the Dermatology Life Quality Index, etc.), Pittsburgh Sleep Quality Index,
      recurrence rate during the follow-up period and adverse events. If possible,
      meta-analyses will be performed using RevMan V.5.3 statistical software;
      otherwise, a descriptive analysis or subgroup analysis will be conducted. The
      results will be presented as the risk ratio of the binary data and the mean
      difference (MD) or standardised MD of the continuous data. ETHICS AND
      DISSEMINATION: This systematic review protocol does not require formal ethical
      approval because the data are not personalised. It will be published in
      peer-reviewed journals and presented at international academic conferences.
      PROSPERO REGISTRATION NUMBER: CRD42019136727.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Leixiao
AU  - Zhang L
AUID- ORCID: 0000-0002-8117-6213
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Deng, Yanli
AU  - Deng Y
AD  - Sichuan Second Chinese Medicine Hospital, Chengdu, China.
FAU - Yao, Junpeng
AU  - Yao J
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Xiao, Xianjun
AU  - Xiao X
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
AD  - The People's Hospital of Jianyang City, Jianyang, China.
FAU - Yu, Siyi
AU  - Yu S
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Shi, Yunzhou
AU  - Shi Y
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zheng, Hui
AU  - Zheng H
AUID- ORCID: 0000-0002-0494-1217
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zheng, Qianhua
AU  - Zheng Q
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zhou, SiYuan
AU  - Zhou S
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Cao, Wei
AU  - Cao W
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Liu, Ying
AU  - Liu Y
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Hao, Pingsheng
AU  - Hao P
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,
      Chengdu, China liying@cdutcm.edu.cn hpswl@126.com.
FAU - Li, Ying
AU  - Li Y
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China liying@cdutcm.edu.cn hpswl@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - China
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neoplasm Recurrence, Local
MH  - Pruritus/etiology/therapy
MH  - *Quality of Life
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7440697
OTO - NOTNLM
OT  - *allergy
OT  - *complementary medicine
OT  - *immunology
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034784 [pii]
AID - 10.1136/bmjopen-2019-034784 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e034784. doi: 10.1136/bmjopen-2019-034784.


PMID- 32819929
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Multiple-dose tranexamic acid for perioperative blood loss in total knee
      arthroplasty in patients with rheumatoid arthritisa single-blinded, randomised,
      parallel-controlled study protocol in China.
PG  - e034431
LID - 10.1136/bmjopen-2019-034431 [doi]
AB  - INTRODUCTION: This clinical trial is designed to evaluate the effect of
      multiple-dose tranexamic acid (TXA) on perioperative blood loss in patients with 
      rheumatoid arthritis (RA). METHODS AND ANALYSIS: A randomised, single-blinded,
      parallel-controlled study will be designed. Patients with RA (age 50-75 years)
      undergoing unilateral primary end-stage total knee arthroplasty will be randomly 
      divided into group A or group B. Group A will be treated with one dose of TXA (1 
      g; intravenous injection 3 hours postsurgery) and group B with three doses (1 g; 
      intravenous injection at 3, 6 and 12 hours postsurgery) after surgery. The
      primary outcomes will be evaluated with blood loss, maximum haemoglobin drop and 
      transfusion rate. The secondary outcomes will be evaluated with knee function and
      complications. ETHICS AND DISSEMINATION: The Shanghai Guanghua Hospital of
      Integrated Traditional Chinese Medicine and Western Medicine Ethics Committee
      approved in this study in July 2019. Informed consent will be obtained from all
      participants. Results of the trial will be published in the Dryad and repository 
      in a peer-reviewed journal. Additionally, deidentified data collected and
      analysed for this study will be available for review from the corresponding
      author on reasonable request. TRIAL REGISTRATION NUMBER: ChiCTR1900025013.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kang, Bing-Xin
AU  - Kang BX
AUID- ORCID: 0000-0001-8829-3853
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Xu, Hui
AU  - Xu H
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Gao, Chen-Xin
AU  - Gao CX
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Zhong, Sheng
AU  - Zhong S
AUID- ORCID: 0000-0002-2744-6243
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Xie, Jun
AU  - Xie J
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Sun, Song-Tao
AU  - Sun ST
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Ma, Ying-Hui
AU  - Ma YH
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Zhai, Wei-Tao
AU  - Zhai WT
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Xiao, Lian-Bo
AU  - Xiao LB
AD  - Orthopaedics, ShangHai Guanghua Hospital of Integrated Traditional Chinese and
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China 13701888178@163.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
SB  - IM
MH  - Administration, Intravenous
MH  - Aged
MH  - *Antifibrinolytic Agents
MH  - *Arthritis, Rheumatoid/drug therapy/surgery
MH  - *Arthroplasty, Replacement, Knee
MH  - Blood Loss, Surgical/prevention & control
MH  - China
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - *Tranexamic Acid
PMC - PMC7440821
OTO - NOTNLM
OT  - *knee
OT  - *paediatric orthopaedics
OT  - *perioperative blood management
OT  - *total knee arthroplasty
OT  - *tranexamic acid
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034431 [pii]
AID - 10.1136/bmjopen-2019-034431 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e034431. doi: 10.1136/bmjopen-2019-034431.


PMID- 32819928
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - ENACT (ENvironmental enrichment for infants; parenting with Acceptance and
      Commitment Therapy): a randomised controlled trial of an innovative intervention 
      for infants at risk of autism spectrum disorder.
PG  - e034315
LID - 10.1136/bmjopen-2019-034315 [doi]
AB  - INTRODUCTION: Autism spectrum disorder (ASD) is a heterogeneous
      neurodevelopmental condition with impacts on behaviour, cognition, communication,
      social interaction and family mental health. This paper reports the protocol of a
      randomised controlled trial (RCT) of a very early intervention, ENACT
      (ENvironmental enrichment for infants; parenting with Acceptance and Commitment
      Therapy), for families of infants at risk of ASD. METHODS AND ANALYSIS: We aim to
      recruit 66 mothers of infants at risk of ASD (ie, infants with a sibling or
      parent diagnosed with ASD) to this RCT. Families will be randomly assigned to
      care-as-usual or ENACT. ENACT is a very early intervention, leveraging
      parent-child interactions to improve early social reciprocity, while supporting
      parental mental health and the parent-child relationship through Acceptance and
      Commitment Therapy. Intervention content is delivered online (approximately 8
      hours) and supported by more than 7 consultations with a clinician. Parents will 
      perform the social reciprocity intervention with their child (30 min per day).
      Assessments at four time points (baseline, 3 months, 6 months, and 12 months
      corrected age) will assess parent-infant interaction, parental mental health,
      infant development and early ASD markers. Analysis will be by intention to treat 
      using general linear models for RCTs. ETHICS AND DISSEMINATION: This protocol has
      been approved by the Children's Health Queensland Hospital and Health Service
      Human Research Ethics Committee (HREC/19/QCHQ/50131) and the University of
      Queensland Human Research Ethics Committee (2019000558). If efficacy is
      demonstrated, the intervention has the potential for wide and accessible
      dissemination. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials 
      Registry (ACTRN12618002046280).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Whittingham, Koa
AU  - Whittingham K
AUID- ORCID: 0000-0002-5344-9907
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia koawhittingham@uq.edu.au.
FAU - McGlade, Andrea
AU  - McGlade A
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Kulasinghe, Kavindri
AU  - Kulasinghe K
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Mitchell, Amy E
AU  - Mitchell AE
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Heussler, Honey
AU  - Heussler H
AD  - Mater Medical Research Institute, South Brisbane, Queensland, Australia.
FAU - Boyd, Roslyn N
AU  - Boyd RN
AD  - Queensland Cerebral Palsy and Rehabilitation Research Centre, UQ Child Health
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - Australia
MH  - *Autism Spectrum Disorder/therapy
MH  - Child
MH  - Humans
MH  - Infant
MH  - Parenting
MH  - Parents
MH  - Queensland
PMC - PMC7440709
OTO - NOTNLM
OT  - *autism spectrum disorder
OT  - *early intervention
OT  - *infant development
OT  - *maternal mental health
OT  - *parent-infant interaction
COIS- Competing interests: ENACT was developed from PACT, an intervention developed by 
      researchers at The University of Queensland, including KW and RNB. AMG and KW
      developed the very early intervention component of edX. ENACT has been developed 
      using the online platform edX.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034315 [pii]
AID - 10.1136/bmjopen-2019-034315 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e034315. doi: 10.1136/bmjopen-2019-034315.


PMID- 32819924
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Comparative effect of nutraceuticals on lipid profile: a protocol for systematic 
      review and network meta-analysis.
PG  - e032755
LID - 10.1136/bmjopen-2019-032755 [doi]
AB  - INTRODUCTION: According to the common definition, nutraceuticals are components
      found in food that can act as therapeutic substances. Recently, the International
      Lipid Expert Panel published two position papers covering the topic of
      lipid-lowering nutraceuticals and their potential use as a complementary
      treatment in addition to statins or as an alternative treatment in
      statin-intolerant patients. The aim of this study was to compare the effect of
      different nutraceuticals on lipid profiles in a systematic review with pairwise
      and network meta-analyses. METHODS AND ANALYSIS: Three databases, including
      PubMed, Embase and the Cochrane Central Register of Controlled Trials, will be
      searched without time or publication language restrictions. The estimated end
      date for the searches will be 29 March 2020. Each stage of the review, including 
      the study section, data extraction, and risk of bias and quality of evidence
      assessments, will be performed in duplicate. Randomised controlled trials meeting
      the following criteria will be eligible for inclusion: (1) participants aged
      >/=18 years, (2) intervention with a selected nutraceutical (artichoke,
      berberine, bergamot, soluble fibres, green tea, garlic, lupin, plant sterols and 
      stanols, red yeast rice, soybean, spirulina or a combination of the
      aforementioned nutraceuticals), (3) administration of the treatment in the form
      of capsules, pills, powders, solutions, tablets or enriched food items, (4)
      comparison with another nutraceutical or placebo, (5) intervention period >/=3
      weeks and (6) lipid profile (low-density lipoprotein cholesterol, high-density
      lipoprotein cholesterol, total cholesterol, triglycerides) as an outcome.
      Random-effect pairwise and network meta-analyses will be used to summarise the
      relative effect of each nutraceutical in comparison to the effect of every other 
      nutraceutical. Subgroup analyses will be stratified by age, sex, ethnicity,
      sample size, length of trial follow-up, baseline cholesterol level and presence
      of other comorbidities. ETHICS AND DISSEMINATION: This review will summarise
      findings from primary studies, and therefore no ethics approval is required. The 
      results will be presented at conferences as well as published in a peer-reviewed 
      journal. PROSPERO REGISTRATION NUMBER: CRD42019132877.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Morze, Jakub
AU  - Morze J
AUID- ORCID: 0000-0002-7119-0273
AD  - Department of Cardiology and Internal Diseases, University of Warmia and Mazury
      in Olsztyn, Olsztyn, Poland jakub.morze@uwm.edu.pl.
FAU - Osadnik, Tadeusz
AU  - Osadnik T
AD  - Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical
      University of Silesia, Zabrze, Poland.
AD  - 2nd Department of Cardiology and Angiology, Silesian Center for Heart Diseases,
      Zabrze, Poland.
FAU - Osadnik, Kamila
AU  - Osadnik K
AD  - Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical
      University of Silesia, Zabrze, Poland.
FAU - Lejawa, Mateusz
AU  - Lejawa M
AD  - Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical
      University of Silesia, Zabrze, Poland.
FAU - Jakubiak, Grzegorz
AU  - Jakubiak G
AD  - Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical
      University of Silesia, Zabrze, Poland.
FAU - Pawlas, Natalia
AU  - Pawlas N
AUID- ORCID: 0000-0002-7551-9371
AD  - Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical
      University of Silesia, Zabrze, Poland.
FAU - Gasior, Mariusz
AU  - Gasior M
AD  - 3rd Department of Cardiology, School of Medicine with the Division of Dentistry
      in Zabrze, Medical University of Silesia, Zabrze, Poland.
FAU - Schwingshackl, Lukas
AU  - Schwingshackl L
AD  - Institute for Evidence in Medicine, University Medical Center Freiburg, Freiburg,
      Baden-Wurttemberg, Germany.
FAU - Banach, Maciej
AU  - Banach M
AD  - Department of Hypertension, WAM University Hospital in Lodz, Medical University
      of Lodz, Lodz, Poland.
AD  - Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
AD  - Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipids)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cholesterol, LDL
MH  - *Dietary Supplements
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - Lipids
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
PMC - PMC7440701
OTO - NOTNLM
OT  - *lipid profile
OT  - *network meta-analysis
OT  - *nutraceuticals
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-032755 [pii]
AID - 10.1136/bmjopen-2019-032755 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e032755. doi: 10.1136/bmjopen-2019-032755.


PMID- 32819923
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 20
TI  - Pretreatment with transcutaneous electrical acupoint stimulation to prevent
      postoperative ileus in patients undergoing laparoscopic colon surgery: study
      protocol for a randomised controlled trial.
PG  - e030694
LID - 10.1136/bmjopen-2019-030694 [doi]
AB  - INTRODUCTION: Postoperative ileus (POI), a common complication after surgery,
      severely affects postoperative recovery. It is unclear whether pretreatment with 
      transcutaneous electrical acupoint stimulation (TEAS) can improve recovery from
      POI. This trial will evaluate the effects of pretreatment with TEAS on POI.
      METHODS AND ANALYSIS: This will be a prospective, randomised controlled trial.
      American Society of Anesthesiologists (ASA) physical status classification I-III 
      level patients, aged 18-75 years and scheduled for laparoscopic colon surgery,
      will be included in the study. It is planned that 146 subjects will be randomised
      to the TEAS and sham TEAS (STEAS) groups. The groups will undergo two sessions of
      TEAS/STEAS daily for 3 days before surgery, with a final TEAS/STEAS treatment 30 
      min before anaesthesia. The primary endpoint of the study will be time to first
      defaecation. Secondary endpoints will include time to first flatus, time to
      tolerance of oral diet, GI-2 (composite outcome of time to first defaecation and 
      time to tolerance of oral diet), time to independent walking, length of hospital 
      stay, postoperative pain Visual Analogue Scale score on the first 3 days after
      surgery, analgesic requirements, complications and plasma concentrations of
      interferon-beta (IFN-beta), IFN-gamma, interleukin-6 (IL-6) and IL-1beta.
      Multiple linear regression will be used to identify independent predictors of
      outcome measures. ETHICS AND DISSEMINATION: This study has been approved by the
      Chinese Registered Clinical Trial Ethics Review Committee (No.
      ChiECRCT-20170084). The results of the trial will be published in an
      international peer-reviewed journal. TRIAL REGISTRATION NUMBER: This study has
      been registered with the Chinese Clinical Trial Registry (No.
      ChiCTR-INR-17013184). TRIAL STATUS: The study was in the recruitment phase at the
      time of manuscript submission.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Jian
AU  - Wang J
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Li, Dongli
AU  - Li D
AD  - Anesthesiology, Wenzhou Medical University, the sixth Affiliated Hospital,
      Lishui, China.
FAU - Tang, Wei
AU  - Tang W
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Guo, Jun
AU  - Guo J
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Chen, Wenting
AU  - Chen W
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Yong, Yue
AU  - Yong Y
AD  - Research Institute of Acupuncture Anesthesia, Shuguang Hospital Affiliated to
      Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Song, Wei
AU  - Song W
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Yu, Guijie
AU  - Yu G
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Feng, Rui
AU  - Feng R
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Yuan, Lan
AU  - Yuan L
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Fu, Guoqiang
AU  - Fu G
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Song, Jiangang
AU  - Song J
AD  - Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of
      Traditional Chinese Medicine, Shanghai, China.
FAU - Fan, Lihua
AU  - Fan L
AUID- ORCID: 0000-0001-5308-9617
AD  - Anesthesiology, Wenzhou Medical University, the sixth Affiliated Hospital,
      Lishui, China fanlihua_ls@126.com.
LA  - eng
SI  - ChiCTR/ChiCTR-INR-17013184
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200820
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acupuncture Points
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Colon
MH  - Humans
MH  - *Ileus/etiology/prevention & control
MH  - *Laparoscopy
MH  - Middle Aged
MH  - Pain, Postoperative/prevention & control
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Transcutaneous Electric Nerve Stimulation
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7440825
OTO - NOTNLM
OT  - *postoperative ileus (POI)
OT  - *pretreatment
OT  - *transcutaneous electrical acupoint stimulation (TEAS)
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-030694 [pii]
AID - 10.1136/bmjopen-2019-030694 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 20;10(8):e030694. doi: 10.1136/bmjopen-2019-030694.


PMID- 32819690
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1001-0742 (Print)
IS  - 1001-0742 (Linking)
VI  - 96
DP  - 2020 Oct
TI  - Rat cardiomyocyte H9c2(2-1)-based sulforhodamine B assay as a promising in vitro 
      method to assess the biological component of effluent toxicity.
PG  - 163-170
LID - S1001-0742(20)30175-3 [pii]
LID - 10.1016/j.jes.2020.04.029 [doi]
AB  - The treatment of wastewaters is crucial to maintain the ecological status of
      receiving waters, and thereby guarantee the protection of aquatic life and human 
      health. Wastewater quality evaluation is conventionally based on physicochemical 
      parameters, but increasing attention has been paid to integrate physicochemical
      and biological data. Nevertheless, the regulatory use of fish in biological
      testing methods has been subject to various ethical and cost concerns, and in
      vitro cell-based assays have thus become an important topic of interest. Hence,
      the present study intends: (a) to evaluate the efficiency of two different sample
      pre-concentration techniques (lyophilisation and solid phase extraction) to
      assess the toxicity of municipal effluents on rat cardiomyoblast H9c2(2-1) cells,
      and (b) maximizing the use of the effluent sample collected, to estimate the
      environmental condition of the receiving environment. The gathered results
      demonstrate that the H9c2(2-1) sulforhodamine B-based assay is an appropriate in 
      vitro method to assess biological effluent toxicity, and the best results were
      attained by lyophilising the sample as pre-treatment. Due to its response, the
      H9c2(2-1) cell line might be a possible alternative in vitro model for fish
      lethal testing to assess the toxicity of municipal effluents. The physicochemical
      status of the sample suggests a high potential for eutrophication, and iron
      exceeded the permissible level for wastewater discharge, possibly due to the
      addition of ferric chloride for wastewater treatment. In general, the levels of
      carbamazepine and sulfamethoxazole are higher than those reported for other
      countries, and both surpassed the aquatic protective values for long-term
      exposure.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Rodrigues, Elsa T
AU  - Rodrigues ET
AD  - University of Coimbra, Centre for Functional Ecology, Department of Life
      Sciences, Calcada Martim de Freitas, Coimbra 3000-456, Portugal. Electronic
      address: etrodrig@uc.pt.
FAU - Nascimento, Susana F
AU  - Nascimento SF
AD  - University of Coimbra, Coimbra Chemistry Center, Department of Chemistry, Coimbra
      3004-535, Portugal.
FAU - Moreno, Maria Joao
AU  - Moreno MJ
AD  - University of Coimbra, Coimbra Chemistry Center, Department of Chemistry, Coimbra
      3004-535, Portugal.
FAU - Oliveira, Paulo J
AU  - Oliveira PJ
AD  - Centre for Neuroscience and Cell Biology, University of Coimbra, UC Biotech,
      Biocant Park, Cantanhede 3060-197, Portugal.
FAU - Pardal, Miguel A
AU  - Pardal MA
AD  - University of Coimbra, Centre for Functional Ecology, Department of Life
      Sciences, Calcada Martim de Freitas, Coimbra 3000-456, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Netherlands
TA  - J Environ Sci (China)
JT  - Journal of environmental sciences (China)
JID - 100967627
RN  - 0 (Rhodamines)
RN  - 0 (Water Pollutants, Chemical)
RN  - 2609-88-3 (lissamine rhodamine B)
SB  - IM
MH  - Animals
MH  - Biological Assay
MH  - Environmental Monitoring
MH  - Humans
MH  - Myocytes, Cardiac/chemistry
MH  - Rats
MH  - Rhodamines
MH  - Waste Disposal, Fluid
MH  - Water Pollutants, Chemical/*analysis
OTO - NOTNLM
OT  - Cell-based assays
OT  - H9c2(2-1) cell line
OT  - Lyophilisation
OT  - Municipal wastewater treatment plant effluent
OT  - SRB assay
OT  - Solid phase extraction
EDAT- 2020/08/21 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - S1001-0742(20)30175-3 [pii]
AID - 10.1016/j.jes.2020.04.029 [doi]
PST - ppublish
SO  - J Environ Sci (China). 2020 Oct;96:163-170. doi: 10.1016/j.jes.2020.04.029. Epub 
      2020 May 30.


PMID- 32819390
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210715
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 20
TI  - Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer
      (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
PG  - 790
LID - 10.1186/s12885-020-07252-y [doi]
AB  - BACKGROUND: Accurate detection of patients with minimal residual disease (MRD)
      after surgery for stage II colon cancer (CC) remains an urgent unmet clinical
      need to improve selection of patients who might benefit form adjuvant
      chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for
      MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial 
      investigates how many stage II CC patients with detectable ctDNA after surgery
      will accept ACT and whether ACT reduces the risk of recurrence in these patients.
      METHODS/DESIGN: MEDOCC-CrEATE follows the 'trial within cohorts' (TwiCs) design. 
      Patients with colorectal cancer (CRC) are included in the Prospective Dutch
      ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of
      clinical data, tissue and blood samples, and consent for future randomization.
      MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients
      without indication for ACT according to current guidelines, who are randomized
      1:1 into an experimental and a control arm. In the experimental arm, post-surgery
      blood samples and tissue are analyzed for tissue-informed detection of plasma
      ctDNA, using the PGDx elio platform. Patients with detectable ctDNA will be
      offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while
      patients without detectable ctDNA and patients in the control group will standard
      follow-up according to guideline. The primary endpoint is the proportion of
      patients receiving ACT when ctDNA is detectable after resection. The main
      secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR,
      disease free survival, overall survival, time to recurrence, quality of life and 
      cost-effectiveness. Data will be analyzed by intention to treat. DISCUSSION: The 
      MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC
      patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT
      will prevent recurrences in a high-risk population. Use of the TwiCs design
      provides the opportunity to randomize patients before ctDNA measurement, avoiding
      ethical dilemmas of ctDNA status disclosure in the control group. TRIAL
      REGISTRATION: Netherlands Trial Register: NL6281/NTR6455 . Registered 18 May
      2017, https://www.trialregister.nl/trial/6281.
FAU - Schraa, S J
AU  - Schraa SJ
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - van Rooijen, K L
AU  - van Rooijen KL
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - van der Kruijssen, D E W
AU  - van der Kruijssen DEW
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Rubio Alarcon, C
AU  - Rubio Alarcon C
AD  - Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, 
      Amsterdam, The Netherlands.
FAU - Phallen, J
AU  - Phallen J
AD  - The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
      Medicine, Baltimore, MD, 21287, USA.
FAU - Sausen, M
AU  - Sausen M
AD  - Personal Genome Diagnostics, Baltimore, MD, 21224, USA.
FAU - Simmons, J
AU  - Simmons J
AD  - Personal Genome Diagnostics, Baltimore, MD, 21224, USA.
FAU - Coupe, V M H
AU  - Coupe VMH
AD  - Department of Epidemiology and Biostatistics, Amsterdam University Medical
      Centers, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
FAU - van Grevenstein, W M U
AU  - van Grevenstein WMU
AD  - Department of Surgical Oncology, University Medical Center Utrecht, Utrecht
      University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Elias, S
AU  - Elias S
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The
      Netherlands.
FAU - Verkooijen, H M
AU  - Verkooijen HM
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The
      Netherlands.
FAU - Lacle, M M
AU  - Lacle MM
AD  - Department of Pathology, University Medical Center Utrecht, Utrecht University,
      Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Bosch, L J W
AU  - Bosch LJW
AD  - Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, 
      Amsterdam, The Netherlands.
FAU - van den Broek, D
AU  - van den Broek D
AD  - Department of Laboratory Medicine, Netherlands Cancer Institute, Plesmanlaan 121,
      1066 CX, Amsterdam, The Netherlands.
FAU - Meijer, G A
AU  - Meijer GA
AD  - Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, 
      Amsterdam, The Netherlands.
FAU - Velculescu, V E
AU  - Velculescu VE
AD  - The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
      Medicine, Baltimore, MD, 21287, USA.
FAU - Fijneman, R J A
AU  - Fijneman RJA
AD  - Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, 
      Amsterdam, The Netherlands.
FAU - Vink, G R
AU  - Vink GR
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
FAU - Koopman, M
AU  - Koopman M
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
      m.koopman-6@umcutrecht.nl.
CN  - PLCRC-MEDOCC group
LA  - eng
GR  - R01 CA121113/CA/NCI NIH HHS/United States
GR  - 848101011/ZonMW 'Personalised Medicine' program (NL)
GR  - LSHM19027/Healh~Holland(NL)
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Circulating Tumor DNA)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse
      effects/standards
MH  - Biomarkers, Tumor/*blood
MH  - Capecitabine/administration & dosage/adverse effects
MH  - Chemotherapy, Adjuvant/economics/psychology/standards/statistics & numerical data
MH  - Circulating Tumor DNA/*blood
MH  - Colectomy
MH  - Colonic Neoplasms/blood/diagnosis/mortality/*therapy
MH  - Cost-Benefit Analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Liquid Biopsy
MH  - Male
MH  - Neoplasm Recurrence, Local/*epidemiology/prevention & control
MH  - Neoplasm Staging
MH  - Neoplasm, Residual
MH  - Netherlands/epidemiology
MH  - Oxaliplatin/administration & dosage/adverse effects
MH  - Patient Acceptance of Health Care/psychology/statistics & numerical data
MH  - Practice Guidelines as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7441668
OTO - NOTNLM
OT  - Adjuvant chemotherapy
OT  - Circulating tumor DNA
OT  - Colon cancer
OT  - TwiCs
OT  - ctDNA
IR  - Dunker MS
FIR - Dunker, Mich S
IR  - Lutke Holzik MF
FIR - Lutke Holzik, Martijn F
IR  - Hoekstra R
FIR - Hoekstra, Ronald
IR  - Sommeijer DW
FIR - Sommeijer, Dirkje W
IR  - van der Bilt JDW
FIR - van der Bilt, Jarmila D W
IR  - Consten ECJ
FIR - Consten, Esther C J
IR  - Cirkel GA
FIR - Cirkel, Geert A
IR  - Burghgraef TA
FIR - Burghgraef, Thijs A
IR  - van der Schans EM
FIR - van der Schans, Emma M
IR  - Nieboer P
FIR - Nieboer, Peter
IR  - Rietbroek RC
FIR - Rietbroek, Ron C
IR  - Dekker JWT
FIR - Dekker, Jan Willem T
IR  - Verschoor AJ
FIR - Verschoor, Arjan J
IR  - Talsma KAK
FIR - Talsma, Koen A K
IR  - Brosens RPM
FIR - Brosens, Rebecca P M
IR  - Helgason HH
FIR - Helgason, Helgi H
IR  - Marinelli AWKS
FIR - Marinelli, Andreas W K S
IR  - de Hingh IHJT
FIR - de Hingh, Ignace H J T
IR  - Oldenhuis CN
FIR - Oldenhuis, Corina N
IR  - Jansen J
FIR - Jansen, Jan
IR  - van Halteren HK
FIR - van Halteren, Henk K
IR  - Stockmann HBAC
FIR - Stockmann, Hein B A C
IR  - Beeker A
FIR - Beeker, Aart
IR  - Bosscha K
FIR - Bosscha, Koop
IR  - Pruijt HFM
FIR - Pruijt, Hans F M
IR  - Spierings LEAMM
FIR - Spierings, Leontine E A M M
IR  - Valkenburg-Van Iersel LBJ
FIR - Valkenburg-Van Iersel, Liselot B J
IR  - Vles WJ
FIR - Vles, Wouter J
IR  - de Jongh FE
FIR - de Jongh, Felix E
IR  - van Cruijsen H
FIR - van Cruijsen, Hester
IR  - Heikens JT
FIR - Heikens, Joost T
IR  - Zimmerman DDE
FIR - Zimmerman, David D E
IR  - van Alphen RJ
FIR - van Alphen, Robert J
IR  - Schiphorst AHW
FIR - Schiphorst, Anandi H W
IR  - van Leeuwen-Snoeks LL
FIR - van Leeuwen-Snoeks, Lobke L
IR  - Vogelaar JFJ
FIR - Vogelaar, Jeroen F J
IR  - Peters NAJB
FIR - Peters, Natascha A J B
EDAT- 2020/08/21 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/08/22 06:00
PHST- 2020/07/22 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - 10.1186/s12885-020-07252-y [doi]
AID - 10.1186/s12885-020-07252-y [pii]
PST - epublish
SO  - BMC Cancer. 2020 Aug 20;20(1):790. doi: 10.1186/s12885-020-07252-y.


PMID- 32819285
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1471-2288 (Electronic)
IS  - 1471-2288 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 14
TI  - International severe asthma registry (ISAR): protocol for a global registry.
PG  - 212
LID - 10.1186/s12874-020-01065-0 [doi]
AB  - BACKGROUND: Severe asthma exerts a disproportionately heavy burden on patients
      and health care. Due to the heterogeneity of the severe asthma population, many
      patients need to be evaluated to understand the clinical features and outcomes of
      severe asthma in order to facilitate personalised and targeted care. The
      International Severe Asthma Registry (ISAR) is a multi-country registry project
      initiated to aid in this endeavour. METHODS: ISAR is a multi-disciplinary
      initiative benefitting from the combined experience of the ISAR Steering
      Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who
      have a special interest and/or experience in severe asthma management or
      establishment and maintenance of severe asthma registries) in collaboration with 
      scientists and experts in database management and communication. Patients (>/=18 
      years old) receiving treatment according to the 2018 definitions of the Global
      Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will
      be included. Data will be collected on a core set of 95 variables identified
      using the Delphi method. Participating registries will agree to provide access to
      and share standardised anonymous patient-level data with ISAR. ISAR is a
      registered data source on the European Network of Centres for
      Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum 
      Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is 
      overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency
      Committee and the ISAR operational committee, ensuring the conduct of ethical,
      clinically relevant research that brings value to all key stakeholders.
      CONCLUSIONS: ISAR aims to offer a rich source of real-life data for scientific
      research to understand and improve disease burden, treatment patterns and patient
      outcomes in severe asthma. Furthermore, the registry will provide an
      international platform for research collaboration in respiratory medicine, with
      the overarching aim of improving primary and secondary care of adults with severe
      asthma globally.
FAU - FitzGerald, J Mark
AU  - FitzGerald JM
AD  - The Institute for Heart Lung Health, Vancouver, Canada.
FAU - Tran, Trung N
AU  - Tran TN
AD  - AstraZeneca, Gaithersburg, USA.
FAU - Alacqua, Marianna
AU  - Alacqua M
AD  - AstraZeneca, Gaithersburg, USA.
FAU - Altraja, Alan
AU  - Altraja A
AD  - Department of Pulmonary Medicine, University of Tartu and Lung Clinic, Tartu
      University Hospital, Tartu, Estonia.
FAU - Backer, Vibeke
AU  - Backer V
AD  - Center of Physical Activity Research, Rigshospitalet and Copenhagen University,
      Copenhagen, Denmark.
FAU - Bjermer, Leif
AU  - Bjermer L
AD  - Department of Respiratory Medicine & Allergology, Skane University Hospital,
      Lund, Sweden.
FAU - Bjornsdottir, Unnur
AU  - Bjornsdottir U
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
FAU - Bourdin, Arnaud
AU  - Bourdin A
AD  - Department of Respiratory Diseases, Montpellier University Hospitals, Hopital
      Arnaud de Villeneuve and PhyMed Exp (INSERM U 1046, CNRS UMR9214), Universite de 
      Montpellier, Montpellier, France.
FAU - Brusselle, Guy
AU  - Brusselle G
AD  - Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
AD  - Departments of Epidemiology and Respiratory Medicine, Erasmus Medical Center
      Rotterdam, Rotterdam, The Netherlands.
FAU - Bulathsinhala, Lakmini
AU  - Bulathsinhala L
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Busby, John
AU  - Busby J
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Canonica, Giorgio W
AU  - Canonica GW
AD  - Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research
      Hospital, Milan, Italy.
AD  - SANI-Severe Asthma Network Italy, Milan, Italy.
FAU - Carter, Victoria
AU  - Carter V
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Chaudhry, Isha
AU  - Chaudhry I
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Cho, You Sook
AU  - Cho YS
AD  - Division of Allergy, Department of Medicine, Asan Medical Center, College of
      Medicine, University of Ulsan, Seoul, South Korea.
FAU - Christoff, George
AU  - Christoff G
AD  - Faculty of Public Health, Medical University - Sofia, Sofia, Bulgaria.
FAU - Cosio, Borja G
AU  - Cosio BG
AD  - Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.
FAU - Costello, Richard W
AU  - Costello RW
AD  - Clinical Research Centre, Smurfit Building Beaumont Hospital and Department of
      Respiratory Medicine, RCSI, Dublin, Ireland.
FAU - Eleangovan, Neva
AU  - Eleangovan N
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Gibson, Peter G
AU  - Gibson PG
AD  - Australasian Severe Asthma Network, Priority Research Centre for Healthy Lungs,
      University of Newcastle, Newcastle, Australia.
AD  - Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, 
      John Hunter Hospital, New Lambton Heights, Australia.
FAU - Heaney, Liam G
AU  - Heaney LG
AD  - Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.
FAU - Heffler, Enrico
AU  - Heffler E
AD  - Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research
      Hospital, Milan, Italy.
AD  - SANI-Severe Asthma Network Italy, Milan, Italy.
FAU - Hew, Mark
AU  - Hew M
AD  - Alfred Health & Monash University, Melbourne, Australia.
FAU - Hosseini, Naeimeh
AU  - Hosseini N
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Iwanaga, Takashi
AU  - Iwanaga T
AD  - Department of Respiratory Medicine & Allergology, Faculty of Medicine, Kindai
      University Hospital, Osakasayama, Japan.
FAU - Jackson, David J
AU  - Jackson DJ
AD  - Guy's & St Thomas' NHS Trust and King's College London, London, UK.
FAU - Jones, Rupert
AU  - Jones R
AD  - Faculty of Medicine & Dentistry, University of Plymouth, Plymouth, UK.
FAU - Koh, Mariko S
AU  - Koh MS
AD  - Department of Respiratory & Critical Care Medicine, Singapore General Hospital
      and Duke-National University Singapore Medical School, Singapore, Singapore.
FAU - Le, Thao
AU  - Le T
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Lehtimaki, Lauri
AU  - Lehtimaki L
AD  - Allergy Centre, Tampere University Hospital and Tampere University, Tampere,
      Finland.
FAU - Ludviksdottir, Dora
AU  - Ludviksdottir D
AD  - Department of Respiratory Medicine, Faculty of Medicine, Landspitali University
      Hospital and University of Iceland, Reykjavik, Iceland.
FAU - Maitland-van der Zee, Anke H
AU  - Maitland-van der Zee AH
AD  - University of Amsterdam, Amsterdam, The Netherlands.
FAU - Menzies-Gow, Andrew
AU  - Menzies-Gow A
AD  - Royal Brompton & Harefield NHS Foundation Trust, London, UK.
FAU - Murray, Ruth B
AU  - Murray RB
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Papadopoulos, Nikolaos G
AU  - Papadopoulos NG
AD  - University of Athens, Athens, Greece.
AD  - University of Manchester, Manchester, UK.
FAU - Perez-de-Llano, Luis
AU  - Perez-de-Llano L
AD  - Pneumology Service, Hospital Universitario Lucus Augusti, Lugo, Spain.
FAU - Peters, Matthew
AU  - Peters M
AD  - University of Sydney Medical School, Sydney, Australia.
FAU - Pfeffer, Paul E
AU  - Pfeffer PE
AD  - UK Severe Asthma Network, Barts Health NHS Trust and Queen Mary University of
      London, London, UK.
FAU - Popov, Todor A
AU  - Popov TA
AD  - University Hospital "Sv. Ivan Rilski", Sofia, Bulgaria.
FAU - Porsbjerg, Celeste M
AU  - Porsbjerg CM
AD  - Bispebjerg Hospital, Copenhagen University, Copenhagen, Denmark.
FAU - Price, Chris A
AU  - Price CA
AD  - Optimum Patient Care, Cambridge, UK.
FAU - Rhee, Chin K
AU  - Rhee CK
AD  - The Catholic University of Korea, Seoul, South Korea.
FAU - Sadatsafavi, Mohsen
AU  - Sadatsafavi M
AD  - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver,
      Canada.
FAU - Tohda, Yuji
AU  - Tohda Y
AD  - Department of Respiratory Medicine & Allergology, Faculty of Medicine, Kindai
      University Hospital, Osakasayama, Japan.
FAU - Wang, Eileen
AU  - Wang E
AD  - Division of Allergy & Clinical Immunology, Department of Medicine, National
      Jewish Health and Division of Allergy & Clinical Immunology, Department of
      Internal Medicine, University of Colorado Hospital, Denver and Aurora, CO, USA.
FAU - Wechsler, Michael E
AU  - Wechsler ME
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Asthma Program, National
      Jewish Health, Denver, USA.
FAU - Zangrilli, James
AU  - Zangrilli J
AD  - AstraZeneca, Gaithersburg, USA.
FAU - Price, David B
AU  - Price DB
AD  - Optimum Patient Care, Cambridge, UK. dprice@opri.sg.
AD  - Observational and Pragmatic Research Institute, Singapore, Singapore.
      dprice@opri.sg.
AD  - Academic Primary Care, Division of Applied Health Sciences, University of
      Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.
      dprice@opri.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200814
PL  - England
TA  - BMC Med Res Methodol
JT  - BMC medical research methodology
JID - 100968545
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Asthma/diagnosis/drug therapy/epidemiology
MH  - Humans
MH  - Registries
PMC - PMC7439682
OTO - NOTNLM
OT  - *Disease registry
OT  - *Protocol
OT  - *Real-world
OT  - *Severe asthma
EDAT- 2020/08/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/08/22 06:00
PHST- 2019/12/11 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s12874-020-01065-0 [doi]
AID - 10.1186/s12874-020-01065-0 [pii]
PST - epublish
SO  - BMC Med Res Methodol. 2020 Aug 14;20(1):212. doi: 10.1186/s12874-020-01065-0.


PMID- 32818122
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 7
DP  - 2020 Jul 14
TI  - A Concise Review on Current Trends in Imaging and Surgical Management of
      Hepatocellular Carcinoma.
PG  - e9191
LID - 10.7759/cureus.9191 [doi]
AB  - Hepatocellular carcinoma (HCC) is a primary cancer of the liver whose incidence
      has seen an upsurge in the United States within the last 2 decades. Despite
      improvements in detection and management techniques, the prognosis for patients
      with HCC generally remains poor. There are multiple factors that have been
      implicated in the etiology of HCC with cirrhosis occurring as a common final
      pathway. This review presents a concise summary of current trends in imaging and 
      surgical management of HCC. An internet-based (PubMed) search using the search
      terms "hepatocellular carcinoma" and "imaging" and "surgical management" was
      performed. Our search was limited to articles related to human studies published 
      in English during the period of 07/01/2011 to 06/30/2016. A review of all
      relevant articles was conducted, and findings were summarized. Modern imaging
      modalities employed in the diagnosis of HCC include ultrasound scan (USS),
      computed tomography (CT), and magnetic resonance imaging (MRI) scan. The utility 
      of diagnostic imaging is enhanced when interpreted in conjunction with
      appropriate laboratory tests such as alpha-fetoprotein. The definitive treatment 
      for HCC remains challenging; hepatic resection (HR) and liver transplantation
      (LT) are two approaches offering potentially curative options. For patients
      undergoing HR, important considerations include achieving maximum resection while
      maintaining optimal post-resection liver remnant volume (LRV) and functional
      capacity (FC), which can be assessed using 3-dimensional CT and indocyanine green
      clearance. Generally, an LRV of 40-50% is considered an acceptable lower limit
      for individuals with HCC compared to 20-30% among individuals with normal livers.
      With increasing knowledge of disease pathology, appropriate patient selection,
      coupled with advances in anesthesia and surgical technique, overall 5-year
      survival rates have significantly improved. Challenges associated with LT on the 
      other hand include donor-liver shortages with resultant long wait times and
      continued disease progression. The scarcity of cadaveric-donor livers has led to 
      employing living-donor livers. Ethical considerations with respect to subjecting 
      potentially healthy donors to undue morbidity and mortality risk however remain. 
      Additional donor-shortage circumventing strategies include employing marginal,
      domino, and split-organ liver transplants. For patients awaiting transplant,
      employing bridging therapy such as radiofrequency ablation and transhepatic
      artery chemoembolization might occasionally help slow disease progression and
      maintain transplant eligibility. Appropriate patient selection achieved through
      the Milan and UCSF criteria designed to guide allotment of donor livers to
      patients with the best chances of survival could help improve outcomes and 5-year
      survival rates. The main radiological options for diagnosis include USS, CT, and 
      MRI. HR and LT are two distinct surgical options, which in practice can be used
      to complement one another. Appropriate patient selection is necessary to achieve 
      maximum benefits from HCC therapies.
CI  - Copyright (c) 2020, Asemota et al.
FAU - Asemota, Joseph
AU  - Asemota J
AD  - Clinical Anatomy, St. George's University School of Medicine, True Blue, GRD.
AD  - Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, USA.
AD  - Internal Medicine, Howard University Hospital, Washington, USA.
FAU - Saleh, Mohammed
AU  - Saleh M
AD  - Internal Medicine, Howard University Hospital, Washington, USA.
FAU - Igbinovia, Osato
AU  - Igbinovia O
AD  - Cancer Imaging, University of Hull, Hull, GBR.
FAU - Burns, Danny
AU  - Burns D
AD  - Clinical Anatomy, St. George's University School of Medicine, St. George's, GRD.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200714
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7426666
OTO - NOTNLM
OT  - gastroenterology
OT  - hepatic resection
OT  - hepatocellular carcinomas (hcc)
OT  - hepatology
OT  - imaging
OT  - liver cirrhosis
OT  - liver transplant
OT  - management
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
AID - 10.7759/cureus.9191 [doi]
PST - epublish
SO  - Cureus. 2020 Jul 14;12(7):e9191. doi: 10.7759/cureus.9191.


PMID- 32817963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220114
DP  - 2020 Dec 15
TI  - Vaccine optimization for COVID-19: who to vaccinate first?
LID - 2020.08.14.20175257 [pii]
LID - 10.1101/2020.08.14.20175257 [doi]
AB  - A vaccine, when available, will likely become our best tool to control the
      current COVID-19 pandemic. Even in the most optimistic scenarios, vaccine
      shortages will likely occur. Using an age-stratified mathematical model paired
      with optimization algorithms, we determined optimal vaccine allocation for four
      different metrics (deaths, symptomatic infections, and maximum non-ICU and ICU
      hospitalizations) under many scenarios. We find that a vaccine with effectiveness
      >/=50% would be enough to substantially mitigate the ongoing pandemic provided
      that a high percentage of the population is optimally vaccinated. When minimizing
      deaths, we find that for low vaccine effectiveness, irrespective of vaccination
      coverage, it is optimal to allocate vaccine to high-risk (older) age-groups
      first. In contrast, for higher vaccine effectiveness, there is a switch to
      allocate vaccine to high-transmission (younger) age-groups first for high
      vaccination coverage. While there are other societal and ethical considerations, 
      this work can provide an evidence-based rationale for vaccine prioritization.
FAU - Matrajt, Laura
AU  - Matrajt L
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA, USA.
FAU - Eaton, Julia
AU  - Eaton J
AD  - University of Washington, Tacoma, WA, USA.
FAU - Leung, Tiffany
AU  - Leung T
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA, USA.
FAU - Brown, Elizabeth R
AU  - Brown ER
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA, USA.
AD  - Department of Biostatistics, University of Washington, Seattle, WA, USA.
LA  - eng
GR  - S10 OD028685/OD/NIH HHS/United States
GR  - UM1 AI148684/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20201215
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Sci Adv. 2021 Feb 3;7(6):. PMID: 33536223
PMC - PMC7430607
COIS- Declaration of interests We declare no competing interests.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1101/2020.08.14.20175257 [doi]
PST - epublish
SO  - medRxiv. 2020 Dec 15. doi: 10.1101/2020.08.14.20175257.


PMID- 32817857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2352-0132 (Electronic)
IS  - 2352-0132 (Linking)
VI  - 7
IP  - 3
DP  - 2020 Jul 10
TI  - Development and psychometric evaluation of the Hospital Nurse Interpersonal
      Empathy Questionnaire.
PG  - 337-343
LID - 10.1016/j.ijnss.2020.06.012 [doi]
AB  - OBJECTIVE: This study aimed to develop the Hospital Nurse Interpersonal Empathy
      Questionnaire (HNIEQ) and evaluate its psychometric properties. METHODS: The
      primary version of HNIEQ was deductively developed through reviewing the
      literature, and then, its face and content validity were assessed. For construct 
      validity assessment, 250 hospital nurses were randomly selected from hospitals of
      Kashan, Iran. Their data were used for exploratory factor analysis. Internal
      consistency was assessed through Cronbach's alpha coefficient and questionnaire
      stability was assessed through test-retest intraclass correlation coefficient.
      Ceiling and floor effects were also assessed. Data analysis was done via the SPSS
      program (v. 16.0). RESULTS: The final version of HNIEQ contained 45 items.
      Exploratory factor analysis revealed a six-factor structure (empathetic and
      ethical attention, perspective adoption, emotional affectability, altruism,
      emotion identification and responsivity, and reflection forecasting) for the
      questionnaire which explained 52.7% of the total variance of its total score. The
      Cronbach's alpha coefficient and the intraclass correlation coefficient of HNIEQ 
      were 0.953 and 0.972, respectively. CONCLUSION: HNIEQ is a valid and reliable
      instrument for empathy assessment among nurses.
CI  - (c) 2020 The authors. Published by Elsevier B.V. on behalf of the Chinese Nursing
      Association.
FAU - Montazeri, Mina
AU  - Montazeri M
AD  - Trauma Nursing Research Center, Faculty of Nursing and Midwifery, Kashan
      University of Medical Sciences, Kashan, Iran.
FAU - Tagharrobi, Zahra
AU  - Tagharrobi Z
AD  - Trauma Nursing Research Center, Faculty of Nursing and Midwifery, Kashan
      University of Medical Sciences, Kashan, Iran.
FAU - Sooki, Zahra
AU  - Sooki Z
AD  - Trauma Nursing Research Center, Faculty of Nursing and Midwifery, Kashan
      University of Medical Sciences, Kashan, Iran.
FAU - Sharifi, Khadijeh
AU  - Sharifi K
AD  - Trauma Nursing Research Center, Faculty of Nursing and Midwifery, Kashan
      University of Medical Sciences, Kashan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - China
TA  - Int J Nurs Sci
JT  - International journal of nursing sciences
JID - 101660887
PMC - PMC7424150
OTO - NOTNLM
OT  - Empathy
OT  - Instrument development
OT  - Iran
OT  - Nurses
OT  - Psychometric evaluation
COIS- The authors declare no potential conflict of interest with regard to the
      research, authorship, and publication of this study.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2019/08/17 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
AID - 10.1016/j.ijnss.2020.06.012 [doi]
AID - S2352-0132(20)30093-4 [pii]
PST - epublish
SO  - Int J Nurs Sci. 2020 Jun 29;7(3):337-343. doi: 10.1016/j.ijnss.2020.06.012.
      eCollection 2020 Jul 10.


PMID- 32817854
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2352-0132 (Electronic)
IS  - 2352-0132 (Linking)
VI  - 7
IP  - 3
DP  - 2020 Jul 10
TI  - A study of the relationship between professional values and ethical climate and
      nurses' professional quality of life in Iran.
PG  - 313-319
LID - 10.1016/j.ijnss.2020.06.001 [doi]
AB  - OBJECTIVE: To explore the relationship between nursing professional values and
      ethical climate and nurses' professional quality of life. METHODS: The present
      study is a descriptive, cross-sectional work in which 400 nurses from various
      wards of hospitals in the south-east of Iran were studied. Data were collected
      using a questionnaire consisting of four sections: demographics, Nurses'
      Professional Values Scale-Revised (NPVS-R), the Hospital Ethical Climate Survey
      (HECS), and the Professional Quality of Life Scale (ProQOL). RESULTS: The total
      mean scores for professional values were 105.29 +/- 15.60. The total mean score
      for the ethical climate was 100.09 +/- 17.11. The mean scores for the indexes of 
      compassion satisfaction, burnout, and secondary traumatic stress were 45.29 +/-
      8.93, 34.38 +/- 6.84, and 32.15 +/- 7.02 respectively. The relationships between 
      professional values and the indexes of compassion satisfaction (r = 0.56),
      burnout (r = 0.26), and secondary traumatic stress (r = 0.18) were found to be
      positive and significant (P < 0.001). Also, the relationships between ethical
      climate and the items of compassion satisfaction (r = 0.60, P < 0.001), burnout
      (r = 0.15, P = 0.002) were found to be positive and significant. CONCLUSION: An
      understanding of nurses' perception of professional values and improving the
      ethical climate at work can help nursing administrators identify more effective
      strategies toward increasing compassion satisfaction and lessening burnout and
      work-related stress.
CI  - (c) 2020 The authors. Published by Elsevier B.V. on behalf of the Chinese Nursing
      Association.
FAU - Tehranineshat, Banafsheh
AU  - Tehranineshat B
AD  - Department of Nursing and Community Based Psychiatric Care Research Center,
      School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz,
      Iran.
FAU - Torabizadeh, Camellia
AU  - Torabizadeh C
AD  - Department of Nursing and Community Based Psychiatric Care Research Center,
      School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz,
      Iran.
FAU - Bijani, Mostafa
AU  - Bijani M
AD  - Department of Medical Surgical Nursing, Fasa University of Medical Sciences,
      Fasa, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - China
TA  - Int J Nurs Sci
JT  - International journal of nursing sciences
JID - 101660887
PMC - PMC7424154
OTO - NOTNLM
OT  - Hospital nursing staff
OT  - Iran
OT  - Nursing ethics
OT  - Professional quality of life
OT  - Professional role
COIS- There is no conflict of interest.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2019/10/07 00:00 [received]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
AID - 10.1016/j.ijnss.2020.06.001 [doi]
AID - S2352-0132(20)30082-X [pii]
PST - epublish
SO  - Int J Nurs Sci. 2020 Jun 5;7(3):313-319. doi: 10.1016/j.ijnss.2020.06.001.
      eCollection 2020 Jul 10.


PMID- 32817767
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1733-134X (Print)
IS  - 1733-134X (Linking)
VI  - 85
DP  - 2020
TI  - Cone beam computed tomography - extending its arm to explore new possibilities.
PG  - e348-e352
LID - 10.5114/pjr.2020.97656 [doi]
AB  - PURPOSE: To determine whether the greyscale value depicted in cone beam computed 
      tomography (CBCT) differentiates different benign osseous lesions of jaws and to 
      measure the greyscale value of various osseous lesions of jaws and to find the
      correlation (if any) of these greyscale values to that of histopathological
      diagnosis. MATERIAL AND METHODS: This study was conducted in the Department of
      Oral Medicine and Radiology of the Dental Institute after obtaining approval from
      the Ethical Committee. CBCT scans of osseous lesions of jaws confirmed with
      histopathological reports depicting cystic or tumour-like lesions were included
      in the study. Greyscale values depicted in CBCT scans of osseous lesions were
      measured. The greyscale values were grouped as per the histopathological
      diagnosis, and these ranges were then tabulated and statistically evaluated.
      RESULTS: The mean value with standard deviation of greyscale values for cystic
      lesions was 1208.375 +/- 93 and for that of the tumour group was 1603 +/- 425.5. 
      CONCLUSIONS: The greyscale value is a useful tool in differentiating between
      different groups of osseous lesions of jaws.
CI  - Copyright (c) Polish Medical Society of Radiology 2020.
FAU - Chaudhari, Prajakta P
AU  - Chaudhari PP
AD  - Department of Oral Medicine and Radiology, MGV's KBH Dental College and Hospital,
      Nashik, Maharashtra, India.
FAU - Bhadage, Chetan
AU  - Bhadage C
AD  - Department of Oral Medicine and Radiology, MGV's KBH Dental College and Hospital,
      Nashik, Maharashtra, India.
FAU - Bhoosreddy, Ajay
AU  - Bhoosreddy A
AD  - Department of Oral Medicine and Radiology, MGV's KBH Dental College and Hospital,
      Nashik, Maharashtra, India.
FAU - Bramhe, Pragati
AU  - Bramhe P
AD  - Department of Oral Medicine and Radiology, MGV's KBH Dental College and Hospital,
      Nashik, Maharashtra, India.
FAU - Rathod, Prutha
AU  - Rathod P
AD  - Department of Oral Medicine and Radiology, MGV's KBH Dental College and Hospital,
      Nashik, Maharashtra, India.
FAU - Dange, Shreya
AU  - Dange S
AD  - Department of Oral Medicine and Radiology, MGV's KBH Dental College and Hospital,
      Nashik, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - Poland
TA  - Pol J Radiol
JT  - Polish journal of radiology
JID - 101175532
PMC - PMC7425220
OTO - NOTNLM
OT  - cone beam computed tomography
OT  - cyst
OT  - greyscale
OT  - soft and hard tissue lesions
OT  - tumours
COIS- The authors report no conflict of interest.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2019/08/10 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
AID - 10.5114/pjr.2020.97656 [doi]
AID - 41424 [pii]
PST - epublish
SO  - Pol J Radiol. 2020 Jul 10;85:e348-e352. doi: 10.5114/pjr.2020.97656. eCollection 
      2020.


PMID- 32817435
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20210202
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 39
DP  - 2020 Sep 29
TI  - Opportunities and limitations of genetically modified nonhuman primate models for
      neuroscience research.
PG  - 24022-24031
LID - 10.1073/pnas.2006515117 [doi]
AB  - The recently developed new genome-editing technologies, such as the CRISPR/Cas
      system, have opened the door for generating genetically modified nonhuman primate
      (NHP) models for basic neuroscience and brain disorders research. The complex
      circuit formation and experience-dependent refinement of the human brain are very
      difficult to model in vitro, and thus require use of in vivo whole-animal models.
      For many neurodevelopmental and psychiatric disorders, abnormal circuit formation
      and refinement might be at the center of their pathophysiology. Importantly, many
      of the critical circuits and regional cell populations implicated in higher human
      cognitive function and in many psychiatric disorders are not present in lower
      mammalian brains, while these analogous areas are replicated in NHP brains.
      Indeed, neuropsychiatric disorders represent a tremendous health and economic
      burden globally. The emerging field of genetically modified NHP models has the
      potential to transform our study of higher brain function and dramatically
      facilitate the development of effective treatment for human brain disorders. In
      this paper, we discuss the importance of developing such models, the
      infrastructure and training needed to maximize the impact of such models, and
      ethical standards required for using these models.
CI  - Copyright (c) 2020 the Author(s). Published by PNAS.
FAU - Feng, Guoping
AU  - Feng G
AUID- ORCID: 0000-0002-8021-277X
AD  - Department of Brain and Cognitive Sciences, McGovern Institute for Brain
      Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
      fengg@mit.edu frances.jensen@pennmedicine.upenn.edu bnewsome@stanford.edu
      jhmorrison@ucdavis.edu.
AD  - Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,
      Cambridge, MA 02142.
FAU - Jensen, Frances E
AU  - Jensen FE
AD  - Department of Neurology, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, PA 19104; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu
      bnewsome@stanford.edu jhmorrison@ucdavis.edu.
FAU - Greely, Henry T
AU  - Greely HT
AUID- ORCID: 0000-0002-1105-6734
AD  - Center for Law and the Biosciences, Stanford University, Stanford, CA 94305.
FAU - Okano, Hideyuki
AU  - Okano H
AUID- ORCID: 0000-0001-7482-5935
AD  - Department of Physiology, Keio University School of Medicine, Shinjukuku,
      160-8592 Tokyo, Japan.
AD  - Laboratory for Marmoset Neural Architecture, RIKEN Center for Brain Science,
      351-0106 Saitama, Wakoshi, Japan.
FAU - Treue, Stefan
AU  - Treue S
AD  - Cognitive Neuroscience Laboratory, German Primate Center-Leibniz Institute for
      Primate Research, 37077 Goettingen, Germany.
AD  - Faculty of Biology and Psychology, University of Goettingen, 37073 Goettingen,
      Germany.
FAU - Roberts, Angela C
AU  - Roberts AC
AUID- ORCID: 0000-0003-2873-157X
AD  - Department of Physiology, Development, and Neuroscience, University of Cambridge,
      CB2 3DY Cambridge, United Kingdom.
FAU - Fox, James G
AU  - Fox JG
AD  - Division of Comparative Medicine, Massachusetts Institute of Technology,
      Cambridge, MA 02139.
FAU - Caddick, Sarah
AU  - Caddick S
AUID- ORCID: 0000-0001-8823-8838
AD  - The Gatsby Charitable Foundation, SW1V 1AP London, United Kingdom.
FAU - Poo, Mu-Ming
AU  - Poo MM
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Chinese Academy 
      of Sciences Center for Excellence in Brain Science and Intelligence Technology,
      Chinese Academy of Sciences, 200031 Shanghai, China.
FAU - Newsome, William T
AU  - Newsome WT
AUID- ORCID: 0000-0002-4370-5022
AD  - Wu Tsai Neurosciences Institute, Stanford University School of Medicine,
      Stanford, CA 94305; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu
      bnewsome@stanford.edu jhmorrison@ucdavis.edu.
AD  - Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 
      94305.
FAU - Morrison, John H
AU  - Morrison JH
AUID- ORCID: 0000-0002-9584-4411
AD  - California National Primate Research Center, University of California, Davis, CA 
      95616; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu bnewsome@stanford.edu 
      jhmorrison@ucdavis.edu.
AD  - Department of Neurology, School of Medicine, University of California, Davis, CA 
      95616.
LA  - eng
GR  - P50 MH094271/MH/NIMH NIH HHS/United States
GR  - P51 OD011107/OD/NIH HHS/United States
GR  - U24 OD026638/OD/NIH HHS/United States
GR  - R21 NS105437/NS/NINDS NIH HHS/United States
GR  - U01 MH114819/MH/NIMH NIH HHS/United States
GR  - R21 AG064448/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200819
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - Animal Experimentation/*ethics
MH  - Animals
MH  - *Disease Models, Animal
MH  - Mental Disorders/*genetics/physiopathology
MH  - Nervous System Diseases/*genetics/physiopathology
MH  - Neurosciences/ethics/methods
MH  - Primates/*genetics/physiology
PMC - PMC7533691
OTO - NOTNLM
OT  - *CRISPR
OT  - *disease models
OT  - *genetic engineering
OT  - *nonhuman primate
OT  - *primates
COIS- The authors declare no competing interest.
EDAT- 2020/08/21 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 2006515117 [pii]
AID - 10.1073/pnas.2006515117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24022-24031. doi:
      10.1073/pnas.2006515117. Epub 2020 Aug 19.


PMID- 32817411
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - The legacy of Caster Semenya: examining the normative basis for the construction 
      of categories in sport.
PG  - 597-598
LID - 10.1136/medethics-2020-106508 [doi]
FAU - Camporesi, Silvia
AU  - Camporesi S
AUID- ORCID: 0000-0003-4135-1723
AD  - Global Health and Social Medicine, King's College London, London WC2B 4BG, UK
      silvia.camporesi@kcl.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200819
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Sep;46(9):584-590. PMID: 32690761
CIN - J Med Ethics. 2020 Sep;46(9):599-600. PMID: 32826302
MH  - Athletes
MH  - Humans
MH  - *Sports
OTO - NOTNLM
OT  - *ethics
OT  - *philosophy of medicine
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/07/17 00:00 [received]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - medethics-2020-106508 [pii]
AID - 10.1136/medethics-2020-106508 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):597-598. doi: 10.1136/medethics-2020-106508. Epub
      2020 Aug 19.


PMID- 32817410
OWN - NLM
STAT- Publisher
LR  - 20220220
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 19
TI  - In vitro fertilisation with preimplantation genetic testing: the need for
      expanded insurance coverage.
LID - medethics-2019-105879 [pii]
LID - 10.1136/medethics-2019-105879 [doi]
AB  - Technological advances in genetic testing have enabled prospective parents to
      learn about their risk of passing a genetic condition to their future children.
      One option for those who want to ensure that their biological children do not
      inherit a genetic condition is to create embryos through in vitro fertilisation
      (IVF) and use a technique called preimplantation genetic testing (PGT) to screen 
      embryos for genetic abnormalities before implantation. Unfortunately, due to its 
      high cost, IVF-with-PGT is out of reach for the vast majority of Americans. This 
      article addresses an issue that has been underexplored in the medical ethics
      literature: the lack of insurance coverage for IVF-with-PGT.Within the US system,
      a key concept in insurance is that of medically necessary care, which broadly
      consists of diagnostic services and treatment services. In this article, I argue 
      that IVF-with-PGT could be classified as either a diagnostic service or as a
      treatment service. To make this case, I show that IVF-with-PGT is similar to
      other types of services that are often covered by US insurance providers. In
      light of these similarities, I argue that the current system is inconsistent with
      respect to what is-and is not-covered by insurance. To promote consistency and
      fairness in coverage, like cases should be treated alike-starting with greater
      coverage for IVF-with-PGT.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kilbride, Madison K
AU  - Kilbride MK
AUID- ORCID: http://orcid.org/0000-0002-8923-9944
AD  - Medical Ethics and Health Policy, Perelman School of Medicine at the University
      of Pennsylvania, Philadelphia, Pennsylvania, USA madisonk@upenn.edu.
LA  - eng
GR  - T32 HG009496/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20200819
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7892638
MID - NIHMS1657898
OTO - NOTNLM
OT  - ethics
OT  - genethics
OT  - genetic information
OT  - genetic screening/testing
OT  - in vitro fertilisation and embryo transfer
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/08/21 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
AID - medethics-2019-105879 [pii]
AID - 10.1136/medethics-2019-105879 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 19. pii: medethics-2019-105879. doi:
      10.1136/medethics-2019-105879.


PMID- 32817409
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - How to overcome lockdown: selective isolation versus contact tracing.
PG  - 724-725
LID - 10.1136/medethics-2020-106680 [doi]
AB  - At this stage of the COVID-19 pandemic, two policy aims are imperative: avoiding 
      the need for a general lockdown of the population, with all its economic, social 
      and health costs, and preventing the healthcare system from being overwhelmed by 
      the unchecked spread of infection. Achieving these two aims requires the
      consideration of unpalatable measures. Julian Savulescu and James Cameron argue
      that mandatory isolation of the elderly is justified under these circumstances,
      as they are at increased risk of becoming severely ill from COVID-19, and are
      thus likely to put disproportionate strain on limited healthcare resources.
      However, their arguments for this strategy are contingent on the lack of viable
      alternatives. We suggest that there is a possible alternative: a mandatory,
      centralised contact-tracing app. We argue that this strategy is ethically
      preferable to the selective isolation of the elderly, because it does not target 
      members of a certain group, relying instead on the movements of each individual, 
      and because it avoids the extended isolation of certain members of the society.
      Although this type of contact-tracing app has its drawbacks, we contend that this
      measure warrants serious consideration.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - White, Lucie
AU  - White L
AUID- ORCID: 0000-0001-8292-3789
AD  - Institut fur Philosophie, Leibniz Universitat Hannover, Hannover, Niedersachsen, 
      Germany lucie.white@philos.uni-hannover.de.
FAU - van Basshuysen, Philippe
AU  - van Basshuysen P
AD  - Institut fur Philosophie, Leibniz Universitat Hannover, Hannover, Niedersachsen, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200819
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Nov;46(11):717-721. PMID: 32561661
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Contact Tracing
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7662207
OTO - NOTNLM
OT  - *coercion
OT  - *elderly and terminally ill
OT  - *emergency medicine
OT  - *ethics
OT  - *public policy
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/07/06 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - medethics-2020-106680 [pii]
AID - 10.1136/medethics-2020-106680 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):724-725. doi: 10.1136/medethics-2020-106680. Epub
      2020 Aug 19.


PMID- 32817408
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Is it unethical to publish data from Chinese transplant research?
PG  - 689-690
LID - 10.1136/medethics-2020-106719 [doi]
FAU - Goldstein, Cory E
AU  - Goldstein CE
AD  - Rotman Institute for Philosophy, University of Western Ontario, London, ON,
      Canada cgoldst2@uwo.ca.
FAU - Peterson, Andrew
AU  - Peterson A
AD  - Institute for Philosophy and Public Policy, George Mason University, Fairfax, VA,
      United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200819
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Oct;46(10):678-684. PMID: 32611619
CIN - J Med Ethics. 2020 Oct;46(10):691-692. PMID: 32928880
MH  - *Biomedical Research
MH  - China
MH  - Humans
OTO - NOTNLM
OT  - *research ethics
OT  - *transplantation
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/07/20 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - medethics-2020-106719 [pii]
AID - 10.1136/medethics-2020-106719 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):689-690. doi: 10.1136/medethics-2020-106719. Epub
      2020 Aug 19.


PMID- 32817400
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 1938-887X (Electronic)
IS  - 0889-8391 (Linking)
VI  - 34
IP  - 3
DP  - 2020 Aug 1
TI  - Fear Over Facts: When Fellow Clinicians Become a Barrier to Dissemination of
      Exposure and Response Prevention for Obsessive-Compulsive Disorder-A Clinical
      Response to Licensing Board Investigation of Exposure and Response Prevention.
PG  - 179-184
LID - 10.1891/JCPSY-D-20-00005 [doi]
AB  - In 2018, a graduate level student filed a complaint regarding the use of
      exposure-based therapy for persons with obsessive-compulsive disorder (OCD)
      experiencing violent obsessions. In the investigation, the licensing board
      expressed concern about safety of us of exposure and response prevention (ERP)
      with children and in public venues. The licensing board also struggled with
      accurate assessment of a clinician's efficacy in following the gold-standard
      treatment for OCD. Despite extensive research demonstrating ERP is a safe,
      effective treatment for OCD, stigma against exposure based treatments remain
      strong, even among clinicians. This commentary article discusses the specific
      licensing investigation and implications for change throughout the field of
      psychotherapy.
CI  - (c) Copyright 2020 Springer Publishing Company, LLC.
FAU - Lokers, Laura M
AU  - Lokers LM
AUID- ORCID: 0000-0002-3580-2607
AD  - Anxiety and OCD Treatment Center of Ann Arbor, Ann Arbor, MI, USA
      lokers@anxietyannarbor.com.
LA  - eng
PT  - Editorial
DEP - 20200626
PL  - United States
TA  - J Cogn Psychother
JT  - Journal of cognitive psychotherapy
JID - 8806397
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Humans
MH  - Implosive Therapy/*standards
MH  - Licensure/*standards
MH  - Obsessive-Compulsive Disorder/*therapy
MH  - Social Stigma
OTO - NOTNLM
OT  - *ERP
OT  - *OCD
OT  - *clinician anxiety
OT  - *ethics
OT  - *exposure
OT  - *stigma
EDAT- 2020/08/21 06:00
MHDA- 2021/09/22 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
AID - JCPSY-D-20-00005 [pii]
AID - 10.1891/JCPSY-D-20-00005 [doi]
PST - ppublish
SO  - J Cogn Psychother. 2020 Aug 1;34(3):179-184. doi: 10.1891/JCPSY-D-20-00005. Epub 
      2020 Jun 26.


PMID- 32817362
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20220220
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Passport to freedom? Immunity passports for COVID-19.
PG  - 652-659
LID - 10.1136/medethics-2020-106365 [doi]
AB  - The COVID-19 pandemic has led a number of countries to introduce restrictive
      'lockdown' policies on their citizens in order to control infection spread.
      Immunity passports have been proposed as a way of easing the harms of such
      policies, and could be used in conjunction with other strategies for infection
      control. These passports would permit those who test positive for COVID-19
      antibodies to return to some of their normal behaviours, such as travelling more 
      freely and returning to work. The introduction of immunity passports raises a
      number of practical and ethical challenges. In this paper, we seek to review the 
      challenges relating to various practical considerations, fairness issues, the
      risk to social cooperation and the impact on people's civil liberties. We make
      tentative recommendations for the ethical introduction of immunity passports.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brown, Rebecca C H
AU  - Brown RCH
AUID- ORCID: 0000-0001-8023-1092
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
      rebecca.brown@philosophy.ox.ac.uk.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
FAU - Williams, Bridget
AU  - Williams B
AD  - School of Public Health and Preventive Medicine, Monash University, Clayton,
      Victoria, Australia.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: 0000-0003-3958-8633
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200815
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Oct;46(10):660-661. PMID: 32907831
MH  - Asymptomatic Diseases/epidemiology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Certification/*ethics
MH  - Coronavirus Infections/epidemiology/*immunology/*prevention & control
MH  - Health Policy
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*immunology/*prevention & control
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - Travel/*ethics
MH  - United Kingdom
PMC - PMC7525773
OTO - NOTNLM
OT  - *ethics
OT  - *public health ethics
OT  - *public policy
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - medethics-2020-106365 [pii]
AID - 10.1136/medethics-2020-106365 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):652-659. doi: 10.1136/medethics-2020-106365. Epub
      2020 Aug 15.


PMID- 32817280
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 1541-6577 (Print)
IS  - 1541-6577 (Linking)
VI  - 34
IP  - 3
DP  - 2020 Aug 1
TI  - Nurses' Moral Experiences of Ethically Meaningful End-of-Life Care: Distress,
      Resilience, Responsibility, and Care.
PG  - 269-285
LID - 10.1891/RTNP-D-19-00114 [doi]
AB  - BACKGROUND: Moral distress, the phenomenon in which an agent is constrained in
      acting on their ethical choice, is a reoccurring theme in the literature on
      nurses' experiences of end-of-life care (EOLC). Understanding moral engagement
      solely through a lens of moral distress can be limiting-as such, we sought to
      explore the diverse experiences nurses consider ethically meaningful in their
      palliative and EOLC practice. PURPOSE AND METHODS: This article presents an
      exploration and analysis of stories told to us, within an interpretive
      description study, by five nurses practicing in EOLC in diverse settings across
      Canada. Although these stories were told to us in a research context, the purpose
      of this theory article is to explore what these stories demonstrate about the
      moral engagement of nurses caring for dying patients. FINDINGS: Our analysis
      suggests that while moral distress is a feature of nursing stories, so too are
      many other dimensions of moral experience, including resilience, responsibility, 
      and care. IMPLICATIONS FOR PRACTICE: Expanding how we understand nurses' moral
      engagement in the care of dying patients has implications for how we account for 
      the many responsibilities that nurses shoulder in striving to provide "good" care
      to people at the end of life.
CI  - (c) Copyright 2020 Springer Publishing Company, LLC.
FAU - Ma, Kristina
AU  - Ma K
AUID- ORCID: https://orcid.org/0000-0003-0855-254X
AD  - School of Nursing, University of Ottawa, Ottawa, ON kristina.ma@uottawa.ca.
FAU - Wright, David Kenneth
AU  - Wright DK
AUID- ORCID: https://orcid.org/0000-0001-8130-656X
AD  - School of Nursing, University of Ottawa, Ottawa, ON.
FAU - Vanderspank-Wright, Brandi
AU  - Vanderspank-Wright B
AD  - School of Nursing, University of Ottawa, Ottawa, ON.
FAU - Peterson, Wendy E
AU  - Peterson WE
AD  - School of Nursing, University of Ottawa, Ottawa, ON.
FAU - Carnevale, Franco A
AU  - Carnevale FA
AUID- ORCID: https://orcid.org/0000-0001-7255-9979
AD  - Ingram School of Nursing, McGill University, Montreal, QC.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Res Theory Nurs Pract
JT  - Research and theory for nursing practice
JID - 101146940
SB  - IM
MH  - Canada
MH  - Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Narration
MH  - Nursing Staff, Hospital/*psychology
MH  - *Stress, Psychological
MH  - Terminal Care/*ethics
MH  - Young Adult
OTO - NOTNLM
OT  - end-of-life care
OT  - ethics
OT  - moral distress
OT  - moral experience
OT  - palliative care
EDAT- 2020/08/21 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
AID - 34/3/269 [pii]
AID - 10.1891/RTNP-D-19-00114 [doi]
PST - ppublish
SO  - Res Theory Nurs Pract. 2020 Aug 1;34(3):269-285. doi: 10.1891/RTNP-D-19-00114.


PMID- 32817276
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 1541-6577 (Print)
IS  - 1541-6577 (Linking)
VI  - 34
IP  - 3
DP  - 2020 Aug 1
TI  - Designing a Clinical Ethics Education Program for Nurses Based on the ADDIE
      Model.
PG  - 205-222
LID - 10.1891/RTNP-D-19-00135 [doi]
AB  - BACKGROUND AND PURPOSE: The ADDIE (Analysis, Design, Development, Implementation,
      and Evaluation) model enables educators to create programs using a systematic
      approach designed to meet learner's needs. The purpose of this study was to
      develop and evaluate a clinical ethics education program for nurses to improve
      their ethical confidence, ethical competence, and moral sensitivity. METHODS: The
      study was conducted in three steps. In the first step, a seven-session ethics
      program was developed using the ADDIE model. The themes of each session were as
      follows: (a) sharing individual ethical issues in clinical settings; (b)
      understanding a process involved in ethical decision-making; (c) identifying
      ethical issues in end-of-life care; (d) identifying ethical issues in family
      caregiving; (e) learning communication skills; (f) developing ethical leadership 
      skills; and (g) reflecting to build self-awareness of the significance of
      practicing clinical ethics. The second step involved the delivery of the program.
      In the third step, using a mixed methods design, the effects of the program were 
      evaluated through a quantitative survey administered both before and after
      completion of the program and focus group interviews. RESULTS: The seven-session 
      ethics program based on the ADDIE model improved ethical confidence, ethical
      competence, and moral sensitivity in nurses. IMPLICATIONS FOR PRACTICE: The ADDIE
      model can be an effective tool in nursing education, offering an established
      structure for developing educational programs. In order to validate the
      effectiveness of the ethics program, it is necessary to conduct repeated measure 
      studies and further studies at the institutional level.
CI  - (c) Copyright 2020 Springer Publishing Company, LLC.
FAU - Kim, Sanghee
AU  - Kim S
AUID- ORCID: 0000-0002-9806-2757
AD  - Yonsei University College of Nursing & Mo-Im Kim Nursing Research Institute,
      Seoul, South Korea.
FAU - Choi, Soyoung
AU  - Choi S
AUID- ORCID: 0000-0002-0998-3352
AD  - College of Nursing, The Pennsylvania State University, University Park, PA, USA
      sxc940@psu.edu.
FAU - Seo, Minjeong
AU  - Seo M
AD  - College of Nursing, Gyeongsang National University, Kyeonam, South Korea.
FAU - Kim, Doo Ree
AU  - Kim DR
AD  - College of Nursing, Konyang University, Daejeon, South Korea.
FAU - Lee, Kyunghwa
AU  - Lee K
AUID- ORCID: 0000-0003-0210-9176
AD  - College of Nursing, Konyang University, Daejeon, South Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Res Theory Nurs Pract
JT  - Research and theory for nursing practice
JID - 101146940
SB  - IM
MH  - *Clinical Competence
MH  - Curriculum
MH  - *Education, Nursing, Baccalaureate
MH  - Ethics, Clinical/*education
MH  - Focus Groups
MH  - Humans
MH  - Models, Nursing
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *ADDIE model
OT  - *clinical
OT  - *ethics
OT  - *mixed methods
EDAT- 2020/08/21 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
AID - 34/3/205 [pii]
AID - 10.1891/RTNP-D-19-00135 [doi]
PST - ppublish
SO  - Res Theory Nurs Pract. 2020 Aug 1;34(3):205-222. doi: 10.1891/RTNP-D-19-00135.


PMID- 32817267
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 3
DP  - 2020 Sep
TI  - For Victims of Fatal Child Abuse, Who Has the Right to Consent to Organ Donation?
LID - e20200662 [pii]
LID - 10.1542/peds.2020-0662 [doi]
AB  - In rare circumstances, children who have suffered traumatic brain injury from
      child abuse are declared dead by neurologic criteria and are eligible to donate
      organs. When the parents are the suspected abusers, there can be confusion about 
      who has the legal right to authorize organ donation. Furthermore, organ donation 
      may interfere with the collection of forensic evidence that is necessary to
      evaluate the abuse. Under those circumstances, particularly in the context of a
      child homicide investigation, the goals of organ donation and collection and
      preservation of critical forensic evidence may seem mutually exclusive. In this
      Ethics Rounds, we discuss such a case and suggest ways to resolve the apparent
      conflicts between the desire to procure organs for donation and the need to
      thoroughly evaluate the evidence of abuse.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Deutsch, Stephanie Anne
AU  - Deutsch SA
AD  - Divisions of General Pediatrics and stephanie.deutsch@nemours.org.
FAU - Teeple, Erin
AU  - Teeple E
AD  - Division of Pediatric Surgery, Department of Surgery.
FAU - Dickerman, Mindy
AU  - Dickerman M
AD  - Pediatric Critical Care Medicine, Department of Pediatrics.
FAU - Macaulay, Jennifer
AU  - Macaulay J
AD  - Department of Patient and Family Services, Nemours/Alfred I. DuPont Hospital for 
      Children, Wilmington, Delaware.
FAU - Collins, Gary
AU  - Collins G
AD  - Medical Examiner Unit, Division of Forensic Science, and.
LA  - eng
PT  - Case Reports
PT  - Letter
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Autopsy/ethics
MH  - Bioethical Issues
MH  - Child Abuse/*ethics/legislation & jurisprudence
MH  - Child, Preschool
MH  - Family
MH  - Forensic Medicine/*ethics/legislation & jurisprudence
MH  - Homicide/*ethics/legislation & jurisprudence
MH  - Humans
MH  - Male
MH  - Parental Consent/*ethics/legislation & jurisprudence
MH  - Parents
MH  - Shaken Baby Syndrome/etiology
MH  - Tissue Donors/*ethics/legislation & jurisprudence
MH  - Tissue and Organ Procurement/*ethics/legislation & jurisprudence
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/08/21 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - peds.2020-0662 [pii]
AID - 10.1542/peds.2020-0662 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Sep;146(3). pii: peds.2020-0662. doi: 10.1542/peds.2020-0662.


PMID- 32817112
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20210723
IS  - 1600-0617 (Electronic)
IS  - 0905-9180 (Linking)
VI  - 29
IP  - 157
DP  - 2020 Sep 30
TI  - Artificial intelligence in thoracic surgery: past, present, perspective and
      limits.
LID - 200010 [pii]
LID - 10.1183/16000617.0010-2020 [doi]
AB  - Artificial intelligence (AI) technology is becoming prevalent in many areas of
      everyday life. The healthcare industry is concerned by it even though its
      widespread use is still limited. Thoracic surgeons should be aware of the new
      opportunities that could affect their daily practice, by direct use of AI
      technology or indirect use via related medical fields (radiology, pathology and
      respiratory medicine). The objective of this article is to review applications of
      AI related to thoracic surgery and discuss the limits of its application in the
      European Union. Key aspects of AI will be developed through clinical pathways,
      beginning with diagnostics for lung cancer, a prognostic-aided programme for
      decision making, then robotic surgery, and finishing with the limitations of AI, 
      the legal and ethical issues relevant to medicine. It is important for physicians
      and surgeons to have a basic knowledge of AI to understand how it impacts
      healthcare, and to consider ways in which they may interact with this technology.
      Indeed, synergy across related medical specialties and synergistic relationships 
      between machines and surgeons will likely accelerate the capabilities of AI in
      augmenting surgical care.
CI  - Copyright (c)ERS 2020.
FAU - Etienne, Harry
AU  - Etienne H
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France h.etienne@hotmail.fr.
AD  - Sorbonne Universite, INSERM, UMRS1158 Neurophysiologie Respiratoire Experimentale
      et Clinique, Paris, France.
FAU - Hamdi, Sarah
AU  - Hamdi S
AD  - Dept of Thoracic and Vascular Surgery, Le Raincy-Montfermeil Hospital,
      Montfermeil, France.
FAU - Le Roux, Marielle
AU  - Le Roux M
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France.
FAU - Camuset, Juliette
AU  - Camuset J
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France.
FAU - Khalife-Hocquemiller, Theresa
AU  - Khalife-Hocquemiller T
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France.
FAU - Giol, Mihaela
AU  - Giol M
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France.
FAU - Debrosse, Denis
AU  - Debrosse D
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France.
FAU - Assouad, Jalal
AU  - Assouad J
AD  - AP-HP, Dept of Thoracic and Vascular Surgery, Tenon University Hospital, Paris,
      France.
AD  - Sorbonne Universite, INSERM, UMRS1158 Neurophysiologie Respiratoire Experimentale
      et Clinique, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200818
PL  - England
TA  - Eur Respir Rev
JT  - European respiratory review : an official journal of the European Respiratory
      Society
JID - 9111391
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - *Thoracic Surgery
COIS- Conflict of interest: H. Etienne has nothing to disclose. Conflict of interest:
      S. Hamdi has nothing to disclose. Conflict of interest: M. Le Roux has nothing to
      disclose. Conflict of interest: J. Camuset has nothing to disclose. Conflict of
      interest: T. Khalife-Hocquemiller has nothing to disclose. Conflict of interest: 
      M. Giol has nothing to disclose. Conflict of interest: D. Debrosse has nothing to
      disclose. Conflict of interest: J. Assouad has nothing to disclose.
EDAT- 2020/08/21 06:00
MHDA- 2021/07/24 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
AID - 29/157/200010 [pii]
AID - 10.1183/16000617.0010-2020 [doi]
PST - epublish
SO  - Eur Respir Rev. 2020 Aug 18;29(157). pii: 29/157/200010. doi:
      10.1183/16000617.0010-2020. Print 2020 Sep 30.


PMID- 32816830
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 2054-4774 (Print)
IS  - 2054-4774 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Aug
TI  - Does Fibre-fix provided to people with irritable bowel syndrome who are consuming
      a low FODMAP diet improve their gut health, gut microbiome, sleep and mental
      health? A double-blinded, randomised controlled trial.
LID - e000448 [pii]
LID - 10.1136/bmjgast-2020-000448 [doi]
AB  - INTRODUCTION: A diet low in fermentable oligosaccharides, disaccharides,
      monosaccharides and polyols (FODMAP) is an effective way to reduce gut symptoms
      in people with irritable bowel syndrome (IBS). This diet reduces the intake of
      fermentable fibres, leading to changes of the gut microbiota and insufficient
      fermentation in the large bowel, resulting in reduced production of short-chain
      fatty acids (SCFAs), such as butyrate, which has unfavourable implications for
      gut health, sleep and mental health. This study will examine the effect of
      Fibre-fix, a supplement containing a mix of dietary fibres, on the human gut
      microbiome composition, fermentative capacity, sleep, quality of life (QOL) and
      mental health of people with IBS who consume a low FODMAP diet (LFD). METHODS AND
      ANALYSIS: A randomised, double-blind, placebo-controlled, study design is
      proposed to examine whether Fibre-fix added to an existing LFD may help modulate 
      gastrointestinal function, improve markers of sleep, mental health and promote
      QOL in patients with IBS. Participants will provide stool and blood samples,
      daily bowel symptoms diaries and 3-day diet records. Additionally, they will
      complete validated questionnaires relating to FODMAP intake, sleep, mental health
      and QOL before and after a 3-week intervention. Gut health will be assessed via
      faecal microbiome composition, faecal pH and SCFA levels. Alteration of sleep
      will be recorded using an actigraphy device worn by all participants over the
      whole study. Multivariate analysis will be used to examine the gut microbiome and
      repeated measures Analysis of variance (ANOVA) will be used for dependent
      variables from questionnaires related to bowel symptoms, stool type, sleep,
      mental health and QOL to assess the differences between intervention and control 
      groups after adjustment for confounding variables. ETHICS AND DISSEMINATION:
      Ethics approval was obtained from the Human Research Ethics Committee of Edith
      Cowan University (2019-00619-YAN). Results will be disseminated in peer-review
      journal publications, and conference presentations. Participants will be provided
      with a summary of findings once the study is completed. If Fibre-fix is shown to 
      result in favourable changes in gut microbial composition, SCFA production, sleep
      and mental well-being without exacerbating symptoms, this will provide additional
      dietary management options for those with IBS following an LFD. TRIAL
      REGISTRATION NUMBER: ACTRN12620000032954.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yan, Ran
AU  - Yan R
AUID- ORCID: 0000-0003-0011-2259
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia r.yan@ecu.edu.au.
FAU - Murphy, Mandy
AU  - Murphy M
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Genoni, Angela
AU  - Genoni A
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Marlow, Evania
AU  - Marlow E
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Dunican, Ian C
AU  - Dunican IC
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Lo, Johnny
AU  - Lo J
AD  - School of Science, Edith Cowan University, Joondalup, Western Australia,
      Australia.
FAU - Andrew, Lesley
AU  - Andrew L
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Devine, Amanda
AU  - Devine A
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
FAU - Christophersen, Claus T
AU  - Christophersen CT
AUID- ORCID: 0000-0003-1591-5871
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - WA Human Microbiome Collaboration Centre, School of Molecular & Life Sciences,
      Curtin University, Perth, Western Australia, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12620000032954
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Gastroenterol
JT  - BMJ open gastroenterology
JID - 101660690
RN  - 0 (Dietary Fiber)
RN  - 0 (Disaccharides)
RN  - 0 (Fatty Acids, Volatile)
RN  - 0 (Monosaccharides)
RN  - 0 (Oligosaccharides)
RN  - 0 (Polymers)
RN  - 0 (polyol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Dietary Fiber/administration & dosage/*adverse effects/therapeutic use
MH  - Disaccharides/administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Fatty Acids, Volatile
MH  - Feces/microbiology
MH  - Female
MH  - Fermentation/*physiology
MH  - Gastrointestinal Diseases/*diet therapy/microbiology
MH  - Gastrointestinal Microbiome/*immunology/physiology
MH  - Humans
MH  - Irritable Bowel Syndrome/blood/diagnosis/*diet therapy/psychology
MH  - Male
MH  - Mental Health/statistics & numerical data
MH  - Middle Aged
MH  - Monosaccharides/administration & dosage/adverse effects
MH  - Oligosaccharides/administration & dosage/adverse effects
MH  - Outcome Assessment, Health Care
MH  - Polymers/administration & dosage/adverse effects
MH  - Quality of Life
MH  - Sleep/physiology
MH  - Surveys and Questionnaires/statistics & numerical data
PMC - PMC7437697
OTO - NOTNLM
OT  - *clinical trials
OT  - *colonic fermentation
OT  - *dietary fibre
OT  - *irritable bowel syndrome
OT  - *short chain fatty acids
COIS- Competing interests: ICD is the chair of the scientific advisory board for
      Fatigue Science, Canada and receives no monies or incentives related to this
      research project.
EDAT- 2020/08/21 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/07/04 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - bmjgast-2020-000448 [pii]
AID - 10.1136/bmjgast-2020-000448 [doi]
PST - ppublish
SO  - BMJ Open Gastroenterol. 2020 Aug;7(1). pii: bmjgast-2020-000448. doi:
      10.1136/bmjgast-2020-000448.


PMID- 32816705
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201004
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
VI  - 105
IP  - 9
DP  - 2020 Sep
TI  - Towards evidence-based medicine for paediatricians.
PG  - 903
LID - 10.1136/archdischild-2020-320307 [doi]
FAU - Phillips, Bob
AU  - Phillips B
AUID- ORCID: http://orcid.org/0000-0002-4938-9673
AD  - Centre for Reviews and Dissemination, University of York Alcuin College, York, UK
      bob.phillips@doctors.org.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
SB  - IM
OTO - NOTNLM
OT  - ethics
OT  - health services research
COIS- Competing interests: None declared.
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2020/07/22 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
AID - archdischild-2020-320307 [pii]
AID - 10.1136/archdischild-2020-320307 [doi]
PST - ppublish
SO  - Arch Dis Child. 2020 Sep;105(9):903. doi: 10.1136/archdischild-2020-320307.


PMID- 32816585
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210802
IS  - 2326-5108 (Electronic)
IS  - 2326-5094 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Jul/Aug
TI  - The Emerging Neurobioeconomy: Implications for National Security.
PG  - 267-277
LID - 10.1089/hs.2020.0009 [doi]
AB  - Neuroscience and neurotechnology (neuroS/T) are techniques and tools used to
      assess or affect the nervous system. Current and near-future developments are
      enabling an expanding palette of capabilities to understand and influence brain
      functions that can foster wellbeing and economic growth. This "neurobioeconomy"
      is rapidly growing, attributable in large part to the global dissemination of
      knowledge that fosters and contributes to scientific innovation, invention, and
      commercialization. As a result, several countries have initiated programs in
      brain research and innovation. Not all brain sciences engender security concerns,
      but a predominance in global biomedical, bioengineering, wellness/lifestyle, and 
      defense markets enables considerable power. Such power can be leveraged in
      nonkinetic or kinetic domains, and several countries have identified neuroS/T as 
      viable and of growing value for use in warfare, intelligence, and national
      security operations. In addition to the current focus on biotechnology, the
      United States and its allies must acknowledge the significance of brain science
      and its projected impact on the economy, national security, and lifestyles. In
      this article, we examine growth of the neuroS/T market, discuss how the
      neurobioeconomy poses distinct ethical and security issues for the broader
      bioeconomy, provide examples of such issues that arise from specific nation-state
      activity and technological commercialization, and propose a risk assessment and
      mitigation approach that can be engaged by the economic, scientific, and security
      communities.
FAU - DeFranco, Joseph
AU  - DeFranco J
AD  - Joseph DeFranco, MS, is a Graduate Fellow, Program in Biodefense, Schar School of
      Policy and Government, George Mason University, Arlington, VA. Maureen Rhemann,
      PhD, is a Visiting Scholar, O'Neill-Pellegrino Program in Brain Science, Global
      Law and Policy, Georgetown University, Washington, DC. James Giordano, PhD,
      MPhil, is Professor, Departments of Neurology and Biochemistry, and Chief,
      Neuroethics Studies Program, Georgetown University Medical Center, Washington,
      DC; and a Senior Fellow, Project in Biosecurity, Technology, and Ethics, US Naval
      War College, Newport, RI.
FAU - Rhemann, Maureen
AU  - Rhemann M
AD  - Joseph DeFranco, MS, is a Graduate Fellow, Program in Biodefense, Schar School of
      Policy and Government, George Mason University, Arlington, VA. Maureen Rhemann,
      PhD, is a Visiting Scholar, O'Neill-Pellegrino Program in Brain Science, Global
      Law and Policy, Georgetown University, Washington, DC. James Giordano, PhD,
      MPhil, is Professor, Departments of Neurology and Biochemistry, and Chief,
      Neuroethics Studies Program, Georgetown University Medical Center, Washington,
      DC; and a Senior Fellow, Project in Biosecurity, Technology, and Ethics, US Naval
      War College, Newport, RI.
FAU - Giordano, James
AU  - Giordano J
AD  - Joseph DeFranco, MS, is a Graduate Fellow, Program in Biodefense, Schar School of
      Policy and Government, George Mason University, Arlington, VA. Maureen Rhemann,
      PhD, is a Visiting Scholar, O'Neill-Pellegrino Program in Brain Science, Global
      Law and Policy, Georgetown University, Washington, DC. James Giordano, PhD,
      MPhil, is Professor, Departments of Neurology and Biochemistry, and Chief,
      Neuroethics Studies Program, Georgetown University Medical Center, Washington,
      DC; and a Senior Fellow, Project in Biosecurity, Technology, and Ethics, US Naval
      War College, Newport, RI.
LA  - eng
GR  - UL1 TR001409/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Health Secur
JT  - Health security
JID - 101654694
SB  - IM
MH  - Biotechnology/economics/*trends
MH  - Economic Development
MH  - Inventions
MH  - Neurosciences/*trends
MH  - *Security Measures
MH  - United States
PMC - PMC7482132
OTO - NOTNLM
OT  - Bioeconomy
OT  - Bioethics
OT  - Biotechnology
OT  - Dual-use science
OT  - Neuroscience
EDAT- 2020/08/21 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - 10.1089/hs.2020.0009 [doi]
PST - ppublish
SO  - Health Secur. 2020 Jul/Aug;18(4):267-277. doi: 10.1089/hs.2020.0009.


PMID- 32816576
OWN - NLM
STAT- Publisher
LR  - 20210506
IS  - 1744-4160 (Electronic)
IS  - 1381-3455 (Linking)
DP  - 2020 Aug 20
TI  - The protective effect of green tea on diabetes-induced hepato-renal pathological 
      changes: a histological and biochemical study.
PG  - 1-12
LID - 10.1080/13813455.2020.1806885 [doi]
AB  - We investigated the protective effect of green tea on diabetic hepato-renal
      complications. Thirty male Wistar rats were randomly divided into five equal
      groups: normal control, diabetic control, glibenclamide-treated, green
      tea-treated, and combined therapy-treated groups; ethical approval number
      "BERC-014-01-20." After eight weeks, animals were sacrificed by CO2 euthanasia
      method, liver and kidney tissues were processed and stained for pathological
      changes, and blood samples were collected for biochemical analysis. Diabetic rats
      showed multiple hepato-renal morphological and apoptotic changes associated with 
      significantly increased some biochemical parameters, while serum albumin and HDL 
      decreased significantly compared to normal control (p < .05). Monotherapy can
      induce significant improvements in pathological and biochemical changes but has
      not been able to achieve normal patterns. In conclusion, green tea alone has a
      poor hypoglycaemic effect but can reduce diabetic complications, whereas
      glibenclamide cannot prevent diabetic complications. The addition of green tea to
      oral hypoglycaemic therapy has shown a potent synergistic effect.
FAU - Atia, Tarek
AU  - Atia T
AUID- ORCID: https://orcid.org/0000-0001-6659-9173
AD  - Department of Medical Laboratory Sciences, College of Applied Medical Sciences
      Prince, Sattam Bin Abdulaziz University, Al-Kharj, KSA.
AD  - Department of Histology and Cytology, Faculty of Medicine, Al-Azhar University,
      Cairo, Egypt.
FAU - Sakr, Hader I
AU  - Sakr HI
AD  - Department of Medical Physiology, Faculty of Medicine, Cairo University, Cairo,
      Egypt.
AD  - Batterjee Medical College, Jeddah, KSA.
FAU - Damanhory, Ahmed A
AU  - Damanhory AA
AD  - Batterjee Medical College, Jeddah, KSA.
AD  - Department of Biochemistry, Faculty of Medicine, Al-Azhar University, Cairo,
      Egypt.
FAU - Moawad, Karim
AU  - Moawad K
AD  - School of Biological Science, UCI, Irvine, CA, USA.
FAU - Alsawy, Moustfa
AU  - Alsawy M
AD  - Department of Histology and Cytology, Faculty of Medicine, Al-Azhar University,
      Cairo, Egypt.
AD  - Batterjee Medical College, Jeddah, KSA.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - England
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
SB  - IM
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - glibenclamide
OT  - green tea
OT  - hepato-renal changes
OT  - oxidative stress
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1080/13813455.2020.1806885 [doi]
PST - aheadofprint
SO  - Arch Physiol Biochem. 2020 Aug 20:1-12. doi: 10.1080/13813455.2020.1806885.


PMID- 32816541
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20211002
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - 10
DP  - 2020 Oct
TI  - Disability, Ethics, and Health Care in the COVID-19 Pandemic.
PG  - 1523-1527
LID - 10.2105/AJPH.2020.305837 [doi]
AB  - This article considers key ethical, legal, and medical dilemmas arising for
      people with disabilities in the COVID-19 pandemic. We highlight the limited
      application of existing frameworks of emergency planning with and for people with
      disabilities in the COVID-19 pandemic, explore key concerns and issues affecting 
      the health care of people with disabilities (i.e., access to information and
      clinician-patient communication, nondiscrimination and reasonable accommodations,
      and rationing of medical goods), and indicate possible solutions. Finally, we
      suggest clinical and public health policy measures to ensure that people with
      disabilities are included in the planning of future pandemic-related efforts.The 
      devastation evoked by the COVID-19 pandemic raises challenging dilemmas in
      bioethics. It also speaks to social justice issues that have plagued historically
      marginalized communities in the United States.Responses to the pandemic must be
      bound by legal standards, principles of distributive justice, and societal norms 
      of protecting vulnerable populations-core commitments of public health-to ensure 
      that inequities are not exacerbated, and should provide a pathway for
      improvements to ensure equitable access and treatment in the future.
FAU - Sabatello, Maya
AU  - Sabatello M
AD  - Maya Sabatello and Paul S. Appelbaum are with the Center for Law, Ethics, and
      Psychiatry, Department of Psychiatry, Columbia University, New York, NY. Teresa
      Blankmeyer Burke is with the Department of History, Philosophy, Religion, and
      Sociology, Gallaudet University, Washington, DC. Katherine E. McDonald is with
      the Department of Public Health, Falk College, Syracuse University, Syracuse, NY.
FAU - Burke, Teresa Blankmeyer
AU  - Burke TB
AD  - Maya Sabatello and Paul S. Appelbaum are with the Center for Law, Ethics, and
      Psychiatry, Department of Psychiatry, Columbia University, New York, NY. Teresa
      Blankmeyer Burke is with the Department of History, Philosophy, Religion, and
      Sociology, Gallaudet University, Washington, DC. Katherine E. McDonald is with
      the Department of Public Health, Falk College, Syracuse University, Syracuse, NY.
FAU - McDonald, Katherine E
AU  - McDonald KE
AD  - Maya Sabatello and Paul S. Appelbaum are with the Center for Law, Ethics, and
      Psychiatry, Department of Psychiatry, Columbia University, New York, NY. Teresa
      Blankmeyer Burke is with the Department of History, Philosophy, Religion, and
      Sociology, Gallaudet University, Washington, DC. Katherine E. McDonald is with
      the Department of Public Health, Falk College, Syracuse University, Syracuse, NY.
FAU - Appelbaum, Paul S
AU  - Appelbaum PS
AD  - Maya Sabatello and Paul S. Appelbaum are with the Center for Law, Ethics, and
      Psychiatry, Department of Psychiatry, Columbia University, New York, NY. Teresa
      Blankmeyer Burke is with the Department of History, Philosophy, Religion, and
      Sociology, Gallaudet University, Washington, DC. Katherine E. McDonald is with
      the Department of Public Health, Falk College, Syracuse University, Syracuse, NY.
LA  - eng
GR  - K01 HG008653/HG/NHGRI NIH HHS/United States
GR  - RM1 HG007257/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200820
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
CIN - Am J Public Health. 2020 Oct;110(10):1458-1459. PMID: 32903088
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Delivery of Health Care/*ethics
MH  - *Disabled Persons/legislation & jurisprudence
MH  - Emergency Medical Services
MH  - Health Care Rationing
MH  - Health Planning
MH  - *Health Policy
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - United States/epidemiology
MH  - Vulnerable Populations
PMC - PMC7483109
MID - NIHMS1605501
EDAT- 2020/08/21 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.2105/AJPH.2020.305837 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Oct;110(10):1523-1527. doi: 10.2105/AJPH.2020.305837.
      Epub 2020 Aug 20.


PMID- 32816330
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1097-0355 (Electronic)
IS  - 0163-9641 (Linking)
VI  - 41
IP  - 6
DP  - 2020 Nov
TI  - Finding focus in a difficult landscape: Therapists' experiences with challenging 
      video guidance processes for parent-infant dyads.
PG  - 743-756
LID - 10.1002/imhj.21884 [doi]
AB  - Marte Meo video guidance uses filmed interaction of the actual parent-infant dyad
      in the guidance of caregivers. Exploring the challenges that therapists meet in
      the guidance of parent-infant dyads may illuminate important aspects of the
      method itself as well as the therapists' role and requirements. This could lead
      to method development and improved practice, but is hitherto little addressed. In
      this paper, we explore how skilled therapists experience and handle challenging
      or failing guidance processes with parent-infant dyads. We analyzed interviews
      with 13 Marte Meo therapists/supervisors using team-based reflexive thematic
      analysis. Four main themes were identified: promoting relational growth in a
      coercive context, building an alliance that feels safe for the parents, looking
      at positive moments in difficult lives, and handling intense feelings as a
      therapist. Our findings show that therapists experience specific therapeutic and 
      ethical challenges with a vulnerable subgroup of parent-infant dyads where child 
      protective issues arise, where caregivers' insecurities impede the therapeutic
      relationship, and where caregivers have unsolved relational or mental health
      problems. The therapists' role becomes pivotal and demanding with regard to the
      therapeutic alliance, the therapeutic interventions in the guidance process, and 
      their own need for regulation, supervision, and structure. Identification of
      these vulnerable dyads early in the process could facilitate a better adaptation 
      and practice of video guidance. Our findings suggest a need for supporting
      structures, clinical supervision, and training that address these challenges.
CI  - (c) 2020 The Authors. Infant Mental Health Journal published by Wiley
      Periodicals, LLC on behalf of Michigan Association for Infant Mental Health.
FAU - Simhan, Indra
AU  - Simhan I
AUID- ORCID: 0000-0002-4495-4477
AD  - Department of Child and Adolescent Mental Health, Southern Norway Hospital Trust,
      Kristiansand, Norway.
AD  - Department of Clinical Psychology, Faculty of Psychology, University of Bergen,
      Bergen, Norway.
FAU - Veseth, Marius
AU  - Veseth M
AD  - Department of Clinical Psychology, Faculty of Psychology, University of Bergen,
      Bergen, Norway.
FAU - Vik, Kari
AU  - Vik K
AD  - Department of Child and Adolescent Mental Health, Southern Norway Hospital Trust,
      Kristiansand, Norway.
FAU - Hjeltnes, Aslak
AU  - Hjeltnes A
AD  - Department of Clinical Psychology, Faculty of Psychology, University of Bergen,
      Bergen, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200820
PL  - United States
TA  - Infant Ment Health J
JT  - Infant mental health journal
JID - 8007859
SB  - IM
MH  - Adult
MH  - *Emotions
MH  - Humans
MH  - Infant
MH  - Mental Health
MH  - *Parent-Child Relations
MH  - Parents/*psychology
MH  - *Psychotherapists
OTO - NOTNLM
OT  - *Eltern-Kind-Interaktion
OT  - *Marte Meo
OT  - *Marte Meo
OT  - *Video-Beratung Marte Meo
OT  - *analyse thematique de reflexion
OT  - *analisis tematico de reflexion
OT  - *guidance par video
OT  - *guia de video
OT  - *interaccion progenitor-infante
OT  - *interaction parent-bebe
OT  - *parent-infant interaction
OT  - *perspectiva del terapeuta
OT  - *perspective de la ou du therapeute
OT  - *reflexive thematic analysis
OT  - *reflexive thematische Analyse
OT  - *therapeutische Perspektive
OT  - *therapist perspective
OT  - *video guidance
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
EDAT- 2020/08/21 06:00
MHDA- 2021/07/10 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1002/imhj.21884 [doi]
PST - ppublish
SO  - Infant Ment Health J. 2020 Nov;41(6):743-756. doi: 10.1002/imhj.21884. Epub 2020 
      Aug 20.


PMID- 32815830
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1531-2291 (Electronic)
IS  - 0890-5339 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Sep
TI  - Thrombin Hemostatic Matrix Reduces Heterotopic Ossification in Acetabular
      Fractures Fixed Through the Kocher-Langenbeck Approach.
PG  - 451-454
LID - 10.1097/BOT.0000000000001783 [doi]
AB  - OBJECTIVE: To determine whether an injectable thrombin product [thrombin
      hemostatic matrix (THM)] at closure of a Kocher-Langenbeck approach reduces the
      risk of heterotopic ossification (HO) formation after an acetabular fracture.
      DESIGN: Case control. SETTING: Two Level 1 trauma centers. PATIENTS: Patients
      with operatively treated acetabulum fractures fixed through Kocher-Langenbeck
      from 2013 to 2018. INTERVENTION: Records were reviewed for demographics, history 
      of traumatic brain injury, HO medication or radiation prophylaxis, THM (Surgiflo,
      Ethicon, Bridgewater New Jersey) administration, and length of follow-up.
      Radiographs were reviewed for dislocation, fracture, Letournel and Orthopaedic
      Trauma Association classifications, HO, and Brooker grade if applicable. Patients
      receiving HO prophylaxis (eg, nonsteroidal anti-inflammatory drugs and radiation)
      were excluded. Remaining patients were divided into 2 groups: THM administration 
      (intervention) and no THM. Continuous variables were compared using t-tests and
      categorical variables with chi-square or Fisher's exact tests. MAIN OUTCOME
      MEASUREMENTS: Risk ratios for the association between HO occurrence and THM
      administration. RESULTS: Three-hundred and twenty-eight acetabular fractures met 
      inclusion criteria (126 intervention, 202 control) in patients with a mean age of
      38.7 +/- 15.9 years; 62.2% were male, and 42.1% were African American. Traumatic 
      brain injury and posterior dislocation rates were equivalent between groups (P = 
      0.505, 0.754, respectively). HO rate in the control group was 42.6% compared with
      21.4% in the THM group (P < 0.001). Booker grade 3/4 in control group was 17.3%
      versus 3.2% in the THM group (P < 0.001). Patients receiving THM had a 50%
      reduced risk of HO (95% confidence interval 0.35-0.73) compared to those who did 
      not; adjustment for age, gender, ethnicity, and traumatic brain injury did not
      meaningfully change the association (risk ratio 0.46; 95% confidence interval
      0.29-0.73; P < 0.001). CONCLUSION: The use of a surgiflo product at closure of a 
      KO approach may reduce the risk of HO formation by 50% after an acetabular
      fracture. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors 
      for a complete description of levels of evidence.
FAU - Montgomery, Tyler
AU  - Montgomery T
AD  - University of Alabama, Birmingham, AB; and.
FAU - Pearson, Jeffery
AU  - Pearson J
AD  - University of Alabama, Birmingham, AB; and.
FAU - Agarwal, Abhinav
AU  - Agarwal A
AD  - University of Alabama, Birmingham, AB; and.
FAU - Olinger, Catherine
AU  - Olinger C
AD  - Department of Orthopaedic Surgery, Campbell Clinic, Memphis, TN.
FAU - Tobey, Devon
AU  - Tobey D
AD  - Department of Orthopaedic Surgery, Campbell Clinic, Memphis, TN.
FAU - Beebe, Michael
AU  - Beebe M
AD  - Department of Orthopaedic Surgery, Campbell Clinic, Memphis, TN.
FAU - McGwin, Gerald
AU  - McGwin G
AD  - University of Alabama, Birmingham, AB; and.
FAU - Cichos, Kyle
AU  - Cichos K
AD  - University of Alabama, Birmingham, AB; and.
FAU - Ghanem, Ellie
AU  - Ghanem E
AD  - University of Alabama, Birmingham, AB; and.
FAU - Spitler, Clay
AU  - Spitler C
AD  - University of Alabama, Birmingham, AB; and.
FAU - Dubose, Candace
AU  - Dubose C
AD  - University of Alabama, Birmingham, AB; and.
FAU - Quade, Jonathan
AU  - Quade J
AD  - University of Alabama, Birmingham, AB; and.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Orthop Trauma
JT  - Journal of orthopaedic trauma
JID - 8807705
RN  - 0 (Hemostatics)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Acetabulum/surgery
MH  - Adult
MH  - Female
MH  - Fracture Fixation, Internal
MH  - *Fractures, Bone/surgery
MH  - *Hemostatics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Ossification, Heterotopic/etiology/prevention & control
MH  - Retrospective Studies
MH  - *Thrombin
MH  - Young Adult
EDAT- 2020/08/21 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - 10.1097/BOT.0000000000001783 [doi]
AID - 00005131-202009000-00001 [pii]
PST - ppublish
SO  - J Orthop Trauma. 2020 Sep;34(9):451-454. doi: 10.1097/BOT.0000000000001783.


PMID- 32815743
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201214
IS  - 2042-6313 (Electronic)
IS  - 2042-6305 (Linking)
VI  - 9
IP  - 11
DP  - 2020 Aug
TI  - Advancing community-engaged research: increasing trustworthiness within
      community-academic partnerships.
PG  - 751-753
LID - 10.2217/cer-2020-0096 [doi]
FAU - Mullins, C Daniel
AU  - Mullins CD
AUID- ORCID: 0000-0003-4322-2490
AD  - Department of Pharmaceutical Health Services Research, University of Maryland
      Baltimore, Baltimore 21201, MD, USA.
AD  - The PATIENTS Program, University of Maryland Baltimore, USA.
FAU - Tanveer, Sarah
AU  - Tanveer S
AUID- ORCID: 0000-0002-6408-9855
AD  - Department of Pharmaceutical Health Services Research, University of Maryland
      Baltimore, Baltimore 21201, MD, USA.
FAU - Graham, Gail
AU  - Graham G
AUID- ORCID: 0000-0003-2463-6591
AD  - The PATIENTS Program, University of Maryland Baltimore, USA.
FAU - Baquet, Claudia Rose
AU  - Baquet CR
AUID- ORCID: 0000-0002-7914-1871
AD  - Department of Pharmaceutical Health Services Research, University of Maryland
      Baltimore, Baltimore 21201, MD, USA.
LA  - eng
GR  - UL1 TR003098/TR/NCATS NIH HHS/United States
PT  - Editorial
DEP - 20200820
PL  - England
TA  - J Comp Eff Res
JT  - Journal of comparative effectiveness research
JID - 101577308
SB  - IM
OTO - NOTNLM
OT  - *bioethics
OT  - *community-academic partnerships
OT  - *community-based participatory research (CBPR)
OT  - *community-engaged research (CEnR)
OT  - *distrust
OT  - *medical ethics
OT  - *trust
OT  - *trustworthiness
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.2217/cer-2020-0096 [doi]
PST - ppublish
SO  - J Comp Eff Res. 2020 Aug;9(11):751-753. doi: 10.2217/cer-2020-0096. Epub 2020 Aug
      20.


PMID- 32815333
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 0807-7096 (Electronic)
IS  - 0029-2001 (Linking)
VI  - 140
IP  - 11
DP  - 2020 Aug 18
TI  - Medical ethics in the forced return of migrants.
LID - 10.4045/tidsskr.20.0061 [doi]
FAU - Aarseth, Svein
AU  - Aarseth S
FAU - Brelin, Siri Hagen
AU  - Brelin SH
FAU - Horn, Morten Andreas
AU  - Horn MA
FAU - Opsahl, Jan-Henrik
AU  - Opsahl JH
FAU - Haavardsholm, Ida Torgersdotter Oygard
AU  - Haavardsholm ITO
FAU - Ostborg, Tilde
AU  - Ostborg T
LA  - eng
LA  - nor
PT  - Journal Article
TT  - Legeetikk ved tvangsutsendelse av migranter.
DEP - 20200817
PL  - Norway
TA  - Tidsskr Nor Laegeforen
JT  - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny
      raekke
JID - 0413423
SB  - IM
MH  - Emigration and Immigration
MH  - Ethics, Medical
MH  - Humans
MH  - Socioeconomic Factors
MH  - *Transients and Migrants
EDAT- 2020/08/21 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
AID - 20-0061 [pii]
AID - 10.4045/tidsskr.20.0061 [doi]
PST - epublish
SO  - Tidsskr Nor Laegeforen. 2020 Aug 17;140(11). pii: 20-0061. doi:
      10.4045/tidsskr.20.0061. Print 2020 Aug 18.


PMID- 32815061
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211217
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 35
IP  - 12
DP  - 2020 Dec
TI  - Patients' Views About the Disclosure of Collateral Findings in Pragmatic Clinical
      Trials: a Focus Group Study.
PG  - 3436-3442
LID - 10.1007/s11606-020-06113-5 [doi]
AB  - BACKGROUND: Pragmatic clinical trials (PCTs) are increasingly being conducted to 
      efficiently generate evidence to inform healthcare decision-making. Despite their
      growing acceptance, PCTs may involve a variety of ethical issues, including the
      management of pragmatic clinical trial-collateral findings (PCT-CFs), that is,
      information that emerges in PCTs that is unrelated to the primary research
      questions but may have implications for patients, clinicians, and health systems.
      OBJECTIVE: We sought to understand patients' views about PCT-CF disclosure,
      including how, by whom, and the nature and extent of information provided.
      DESIGN: Prospective, qualitative focus group study. PARTICIPANTS: Focus groups
      were conducted in Baltimore, MD; Houston, TX; and Seattle, WA (overall N = 66),
      during July and August 2019. APPROACH: All groups discussed a hypothetical
      scenario involving the detection of a PCT-CF of contraindicated medications.
      Participants were asked about their reactions to the PCT-CF and issues related to
      its disclosure. KEY RESULTS: Reactions to learning about the PCT-CF were mixed,
      ranging from fear of a significant health problem, anger that the contraindicated
      medications had gone unnoticed and/or for being included in research without
      their permission, to gratitude for the information. Preferences for how such
      disclosures are made varied but were driven by several consistent desires, namely
      minimizing patient harm and anxiety and demonstrating trust and respect. Many
      wanted their treating clinician to be informed of the PCT-CF so that they would
      be prepared to answer patients' questions and to discuss treatment options.
      CONCLUSIONS: The detection of PCT-CFs is likely to increase with further
      expansion of PCTs. As such, clinicians will undoubtedly become involved in the
      management of PCT-CFs. Our data illustrate some of the challenges clinicians may 
      face when their patients are informed of a PCT-CF and the need to develop
      guidance for disclosing PCT-CFs in ways that align with patients' preferences and
      values.
FAU - Bollinger, Juli M
AU  - Bollinger JM
AUID- ORCID: http://orcid.org/0000-0001-6850-8562
AD  - Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA.
      jmurph46@jhu.edu.
FAU - Geller, Gail
AU  - Geller G
AD  - Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA.
AD  - Department of Medicine, Johns Hopkins University School of Medicine, , Baltimore,
      MD, USA.
FAU - Weinfurt, Kevin
AU  - Weinfurt K
AD  - Department of Population Health Sciences, Duke University School of Medicine, ,
      Durham, NC, USA.
FAU - May, Elizabeth
AU  - May E
AD  - Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA.
FAU - Morain, Stephanie R
AU  - Morain SR
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, ,
      Houston, TX, USA.
FAU - Mathews, Debra J H
AU  - Mathews DJH
AD  - Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA.
AD  - Department of Pediatrics, Johns Hopkins University School of Medicine, ,
      Baltimore, MD, USA.
FAU - Sugarman, Jeremy
AU  - Sugarman J
AD  - Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA.
AD  - Department of Medicine, Johns Hopkins University School of Medicine, , Baltimore,
      MD, USA.
LA  - eng
GR  - U24 AT009676/AT/NCCIH NIH HHS/United States
GR  - U24AT009676/AT/NCCIH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200819
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
SB  - IM
CIN - J Gen Intern Med. 2020 Dec;35(12):3432-3433. PMID: 32968969
MH  - *Disclosure
MH  - Focus Groups
MH  - Humans
MH  - Prospective Studies
MH  - Qualitative Research
PMC - PMC7728860
OTO - NOTNLM
OT  - *collateral finding
OT  - *patient perspective
OT  - *pragmatic clinical trial
EDAT- 2020/08/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1007/s11606-020-06113-5 [doi]
AID - 10.1007/s11606-020-06113-5 [pii]
PST - ppublish
SO  - J Gen Intern Med. 2020 Dec;35(12):3436-3442. doi: 10.1007/s11606-020-06113-5.
      Epub 2020 Aug 19.


PMID- 32814917
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 584
IP  - 7822
DP  - 2020 Aug
TI  - Author declaration: have you considered equity, diversity and inclusion?
PG  - 525
LID - 10.1038/d41586-020-02429-8 [doi]
FAU - Rossler, Daniela Christina
AU  - Rossler DC
FAU - Lotters, Stefan
AU  - Lotters S
FAU - Da Fonte, Luis Fernando Marin
AU  - Da Fonte LFM
LA  - eng
PT  - Letter
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - *Authorship
MH  - Periodicals as Topic/*standards
MH  - Prejudice/*prevention & control
MH  - Research Personnel/*statistics & numerical data/*supply & distribution
MH  - Sexual and Gender Minorities
MH  - Women
OTO - NOTNLM
OT  - *Authorship
OT  - *Ethics
OT  - *Publishing
EDAT- 2020/08/21 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1038/d41586-020-02429-8 [doi]
AID - 10.1038/d41586-020-02429-8 [pii]
PST - ppublish
SO  - Nature. 2020 Aug;584(7822):525. doi: 10.1038/d41586-020-02429-8.


PMID- 32814914
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20200928
LR  - 20200928
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 584
IP  - 7822
DP  - 2020 Aug
TI  - Myanmar: palaeontologists must stop buying conflict amber.
PG  - 525
LID - 10.1038/d41586-020-02432-z [doi]
FAU - Engel, Michael S
AU  - Engel MS
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Science. 2019 May 24;364(6442):722-729. PMID: 31123120
OTO - NOTNLM
OT  - *Ethics
OT  - *Palaeontology
EDAT- 2020/08/21 06:00
MHDA- 2020/08/21 06:01
CRDT- 2020/08/21 06:00
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/08/21 06:01 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1038/d41586-020-02432-z [doi]
AID - 10.1038/d41586-020-02432-z [pii]
PST - ppublish
SO  - Nature. 2020 Aug;584(7822):525. doi: 10.1038/d41586-020-02432-z.


PMID- 32814249
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1879-3231 (Electronic)
IS  - 0093-691X (Linking)
VI  - 157
DP  - 2020 Nov
TI  - Aging-related mitochondrial alterations in bovine oocytes.
PG  - 218-225
LID - S0093-691X(20)30433-7 [pii]
LID - 10.1016/j.theriogenology.2020.07.036 [doi]
AB  - Advanced maternal age is an emerging health problem which involves many
      functional and structural alterations in oocytes, and its study is relevant to
      design better approaches to improve the reproductive function in women of
      advanced age. A constraint to this type of studies is the limited amount of
      samples and the ethical problems of working with human gametes. This study aims
      to characterize the in vitro-induced age-related modifications in a bovine model,
      as well as to determine if this model is a reliable approach to study human
      aging. For this purpose, we have focused on aging-related alterations related to 
      oocyte mitochondrial dysfunction, a key hallmark in aging. Morphological and
      bioenergetic in vitro-induced alterations in bovine oocytes were compared to an
      in vivo aged group and to the already reported information regarding humans and
      other animal models. Parameters monitored included ooplasmic volume;
      mitochondrial mass, distribution and aggregation, assessed by MitoTracker Green; 
      mitochondrial activity, monitored by JC-1; and the mitochondrial levels of
      hydrogen peroxide (H2O2), quantified using MitoPY. Results show a significant
      decrease in oocyte cytoplasmic volume after both in vitro and in vivo aging (p < 
      0.001). Additionally, the levels of H2O2 increased significantly after in vitro
      and in vivo aging (p < 0.001) and mitochondrial aggregation patterns were
      significantly different after 30 h of in vitro maturation, with MII oocytes
      presenting small aggregates inside the cytoplasm, whereas aged oocytes had a lack
      of granularity (p < 0.001). In contrast, there were no differences between the
      different aging groups in terms of mitochondrial mass, distribution and activity.
      In conclusion, this in vitro approach of inducing aging-related alterations may
      be considered as a reliable approach to study the aging process in human female
      gametes, since it causes the same types of alterations in both species.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Soares, Maria
AU  - Soares M
AD  - CNC - Center for Neuroscience and Cell Biology, CIBB, Azinhaga de Santa Comba,
      Celas, 3004-504, University of Coimbra, Portugal.
FAU - Sousa, Ana Paula
AU  - Sousa AP
AD  - CNC - Center for Neuroscience and Cell Biology, CIBB, Azinhaga de Santa Comba,
      Celas, 3004-504, University of Coimbra, Portugal; Reproductive Medicine Unit,
      Centro Hospitalar e Universitario de Coimbra, Praceta, R. Prof. Mota Pinto,
      3004-561, Coimbra, Portugal.
FAU - Fernandes, Raquel
AU  - Fernandes R
AD  - CNC - Center for Neuroscience and Cell Biology, CIBB, Azinhaga de Santa Comba,
      Celas, 3004-504, University of Coimbra, Portugal.
FAU - Ferreira, Ana Filipa
AU  - Ferreira AF
AD  - Reproductive Medicine Unit, Centro Hospitalar e Universitario de Coimbra,
      Praceta, R. Prof. Mota Pinto, 3004-561, Coimbra, Portugal; University of Coimbra,
      Faculty of Medicine, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
FAU - Almeida-Santos, Teresa
AU  - Almeida-Santos T
AD  - CNC - Center for Neuroscience and Cell Biology, CIBB, Azinhaga de Santa Comba,
      Celas, 3004-504, University of Coimbra, Portugal; Reproductive Medicine Unit,
      Centro Hospitalar e Universitario de Coimbra, Praceta, R. Prof. Mota Pinto,
      3004-561, Coimbra, Portugal; University of Coimbra, Faculty of Medicine, Azinhaga
      de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
FAU - Ramalho-Santos, Joao
AU  - Ramalho-Santos J
AD  - CNC - Center for Neuroscience and Cell Biology, CIBB, Azinhaga de Santa Comba,
      Celas, 3004-504, University of Coimbra, Portugal; University of Coimbra,
      Department of Life Sciences, Calcada Martim de Freitas, 3000-456, Coimbra,
      Portugal. Electronic address: jramalho@uc.pt.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - Theriogenology
JT  - Theriogenology
JID - 0421510
RN  - BBX060AN9V (Hydrogen Peroxide)
SB  - IM
MH  - *Aging
MH  - Animals
MH  - Cattle
MH  - Cytoplasm
MH  - Female
MH  - *Hydrogen Peroxide/metabolism
MH  - *Mitochondria
MH  - *Oocytes/metabolism
OTO - NOTNLM
OT  - Advanced maternal age
OT  - Bovine oocytes
OT  - Mitochondrial dysfunction
OT  - Oocyte aging
COIS- Declaration of competing interest The authors declare that they have no competing
      interests.
EDAT- 2020/08/20 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/08/20 06:00 [entrez]
AID - S0093-691X(20)30433-7 [pii]
AID - 10.1016/j.theriogenology.2020.07.036 [doi]
PST - ppublish
SO  - Theriogenology. 2020 Nov;157:218-225. doi: 10.1016/j.theriogenology.2020.07.036. 
      Epub 2020 Aug 1.


PMID- 32813795
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1678-4464 (Electronic)
IS  - 0102-311X (Linking)
VI  - 36
IP  - 8
DP  - 2020
TI  - [Healthcare experiences of primary care workers with Bengalese immigrants in
      Parana State, Brazil].
PG  - e00087019
LID - S0102-311X2020000805009 [pii]
LID - 10.1590/0102-311x00087019 [doi]
AB  - The aim of this study was to analyze the experiences of primary care workers with
      Bengalese immigrants in Parana State, Brazil. This was a qualitative study in a
      primary care unit with approximately 700 Bengalese immigrants living in its
      coverage area. The study was conducted in a medium-sized city in northern Parana 
      State. Data were obtained through semi-structured interviews with the health
      workers. The data were analyzed adopting proper compliance with all ethical
      aspects. The results showed that the immigrants' physical appearance and language
      affected the way the health workers treated them. It was thus possible to
      identify a series of implications in the actions and services offered to this
      immigrant population: adherence to a protocol, even though it did not take the
      immigrants' specific needs into account; presumption of the immigrant
      population's reasons and needs for seeking the health services; and the omission 
      of some specific health interventions. The Bengalese immigrant population thus
      accesses the primary healthcare services much more through their adaptive skills 
      than by the health workers' capacity to offer care according to the patients'
      needs. It is thus necessary to take a special look at the health workers in this 
      situation and design forms of support that can be offered to healthcare teams
      that deal with immigrant populations on a daily basis.
FAU - Delamuta, Karly Garcia
AU  - Delamuta KG
AD  - Universidade Estadual de Londrina, Londrina, Brazil.
FAU - Mendonca, Fernanda de Freitas
AU  - Mendonca FF
AD  - Universidade Estadual de Londrina, Londrina, Brazil.
FAU - Domingos, Carolina Milena
AU  - Domingos CM
AD  - Universidade Estadual de Londrina, Londrina, Brazil.
FAU - Carvalho, Marselle Nobre de
AU  - Carvalho MN
AD  - Universidade Estadual de Londrina, Londrina, Brazil.
LA  - por
PT  - Journal Article
TT  - Experiencias de atendimento a saude de imigrantes bengaleses entre trabalhadores 
      da atencao primaria a saude no Parana, Brasil.
DEP - 20200817
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
SB  - IM
MH  - Brazil
MH  - *Emigrants and Immigrants
MH  - *Health Services Accessibility
MH  - Humans
MH  - Primary Health Care
MH  - Qualitative Research
EDAT- 2020/08/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/20 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S0102-311X2020000805009 [pii]
AID - 10.1590/0102-311x00087019 [doi]
PST - ppublish
SO  - Cad Saude Publica. 2020;36(8):e00087019. doi: 10.1590/0102-311x00087019. Epub
      2020 Aug 17.


PMID- 32813786
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Linking)
VI  - 28
DP  - 2020
TI  - Validity and reliability study of the Moral Distress Questionnaire in Turkish for
      nurses.
PG  - e3319
LID - S0104-11692020000100379 [pii]
LID - 10.1590/1518-8345.2960.3319 [doi]
AB  - OBJECTIVE: to determine the validity and reliability of the Turkish language
      version of the Moral Distress Questionnaire for nurses. METHOD: methodological
      study whose sample consisted of 200 nurses working in the internal medicine and
      surgery clinics of a university hospital. Data was collected using the personal
      information form and the Moral Distress Questionnaire for nurses. RESULTS: in the
      Main Components Analysis, the items were grouped under three factors. Findings
      regarding confirmatory factor analysis: chi-square goodness: 2.28, goodness of
      fit index: 0.88, comparative fit index: 0.88, non-normed fit index: 0.86, root
      mean square error of approximation: 0.07. The Cronbach's alpha coefficient was
      found to be 0.79 as a result of the analysis conducted in order to test the
      internal consistency of the scale. It was seen that these three factors explained
      44.92% of the total variance. CONCLUSION: in this present study, the Turkish
      version of the Moral Distress Questionnaire was found to be valid and reliable
      for the Turkish society. It is recommended that the Moral Distress Questionnaire 
      for nurses should be used in future studies to be conducted with nurses in order 
      to investigate of issues of ethical dilemma.
FAU - Yucel, Sebnem Cinar
AU  - Yucel SC
AD  - Nursing School, Ege University, Izmir, Turkey.
FAU - Ergin, Eda
AU  - Ergin E
AD  - Faculty of Health Sciences, Izmir Bakircay University, Izmir, Turkey.
FAU - Orgun, Fatma
AU  - Orgun F
AD  - Nursing School, Ege University, Izmir, Turkey.
FAU - Gokcen, Mucahide
AU  - Gokcen M
AD  - Nursing School, Ege University, Izmir, Turkey.
FAU - Eser, Ismet
AU  - Eser I
AD  - Nursing School, Ege University, Izmir, Turkey.
LA  - por
LA  - spa
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - Brazil
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Humans
MH  - *Language
MH  - *Morals
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
MH  - Turkey
PMC - PMC7426139
EDAT- 2020/08/20 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/08/20 06:00
PHST- 2019/02/06 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - S0104-11692020000100379 [pii]
AID - 10.1590/1518-8345.2960.3319 [doi]
PST - ppublish
SO  - Rev Lat Am Enfermagem. 2020;28:e3319. doi: 10.1590/1518-8345.2960.3319. Epub 2020
      Aug 12.


PMID- 32813643
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20210317
IS  - 1715-6580 (Electronic)
IS  - 1715-6572 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Aug
TI  - Informing Canada's Health System Response to COVID-19: Priorities for Health
      Services and Policy Research.
PG  - 112-124
LID - hcpol.2020.26249 [pii]
LID - 10.12927/hcpol.2020.26249 [doi]
AB  - To inform Canada's research response to COVID-19, the Canadian Institutes of
      Health Research's Institute of Health Services and Policy Research (IHSPR)
      conducted a rapid-cycle priority identification process. Seven COVID-19
      priorities for health services and policy research were identified: system
      adaptation and organization of care; resource allocation decision-making and
      ethics; rapid synthesis and comparative policy analysis of the COVID-19 response 
      and outcomes; healthcare workforce; virtual care; long-term consequences of the
      pandemic; and public and patient engagement. Three additional cross-cutting
      themes were identified: supporting the health of Indigenous Peoples and
      vulnerable populations, data and digital infrastructure, and learning health
      systems and knowledge platforms. IHSPR hopes these research priorities will
      contribute to the broader ecosystem for collective research investment and
      action.
CI  - Copyright (c) 2020 Longwoods Publishing.
FAU - McMahon, Meghan
AU  - McMahon M
AD  - Associate Director, CIHR Institute of Health Services and Policy Research,
      Toronto, ON.
FAU - Nadigel, Jessica
AU  - Nadigel J
AD  - Associate Director, CIHR Institute of Health Services and Policy Research,
      Montreal, QC.
FAU - Thompson, Erin
AU  - Thompson E
AD  - Project Officer, CIHR Institute of Health Services and Policy Research, Toronto, 
      ON.
FAU - Glazier, Richard H
AU  - Glazier RH
AD  - Scientific Director, CIHR Institute of Health Services and Policy Research,
      Senior Scientist, ICES (Institute for Clinical Evaluative Sciences), Research
      Scientist, MAP Centre for Urban Health Solutions, St. Michael's Hospital,
      Professor, Family and Community Medicine, University of Toronto, Toronto, ON.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Healthc Policy
JT  - Healthcare policy = Politiques de sante
JID - 101280107
SB  - IM
MH  - COVID-19
MH  - Canada/epidemiology
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Delivery of Health Care/*organization & administration
MH  - Health Policy
MH  - Health Services Research
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - *Research
PMC - PMC7435075
EDAT- 2020/08/20 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - hcpol.2020.26249 [pii]
AID - 10.12927/hcpol.2020.26249 [doi]
PST - ppublish
SO  - Healthc Policy. 2020 Aug;16(1):112-124. doi: 10.12927/hcpol.2020.26249.


PMID- 32813442
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2689-8381 (Electronic)
IS  - 2689-8381 (Linking)
VI  - 18
IP  - 10
DP  - 2020 Oct
TI  - Methodologic approaches in studies using real-world data to measure pediatric
      safety and effectiveness of vaccines administered to pregnant women: a scoping
      review protocol.
PG  - 2164-2170
LID - 10.11124/JBISRIR-D-19-00266 [doi]
AB  - OBJECTIVE: This scoping review aims to map studies using real-world data (RWD) to
      measure pediatric safety and effectiveness of vaccines administered to pregnant
      women. INTRODUCTION: In the United States, two vaccines are recommended for all
      pregnant women to prevent illness in the infant: inactivated influenza vaccine
      (recommended since 2004) and the combined tetanus-diphtheria-acellular pertussis 
      (Tdap) vaccine (recommended since 2013). Because of the ethical constraints in
      conducting randomized clinical trials to measure the effects on the infant, there
      is great interest in using electronic health care data or administrative claims
      data to study the effects of maternal immunization on the infant's health, and it
      is anticipated that such studies may be submitted to support regulatory
      decision-making. This scoping review will map the studies conducted to date that 
      address these questions and provide a context for considering the regulatory
      issues that may arise in the future. INCLUSION CRITERIA: Studies that report on
      pregnant women receiving immunization and the effectiveness or safety outcomes in
      their infants will be included. Study participants may be from any population or 
      country, of any reproductive age, and with any health status. Studies will be
      included if they use real-world data (from electronic health records,
      administrative claims, pharmacy benefit records, or registries). METHODS: An
      electronic search of PubMed and Embase will identify citations for screening. The
      search will be limited to studies published in English during the preceding 10
      years. Two reviewers will screen citations in a two-step process (titles and
      abstracts, then full-text articles), and two reviewers will extract data for
      summary and synthesis.
FAU - Lasky, Tamar
AU  - Lasky T
AD  - US Food and Drug Administration, Center for Biologics Evaluation and Research,
      Silver Spring, MD, USA.
FAU - McMahon, Ann W
AU  - McMahon AW
AD  - US Food and Drug Administration, Office of the Commissioner, Silver Spring, MD,
      USA.
FAU - Hua, Wei
AU  - Hua W
AD  - US Food and Drug Administration, Center for Drugs Evaluation and Research, Silver
      Spring, MD, USA.
FAU - Forshee, Richard
AU  - Forshee R
AD  - US Food and Drug Administration, Center for Biologics Evaluation and Research,
      Silver Spring, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JBI Evid Synth
JT  - JBI evidence synthesis
JID - 101764819
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Child
MH  - *Diphtheria-Tetanus-acellular Pertussis Vaccines
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Influenza Vaccines
MH  - Pregnancy
MH  - Pregnant Women
MH  - Review Literature as Topic
MH  - United States
MH  - Vaccination
MH  - *Whooping Cough
EDAT- 2020/08/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/20 06:00 [entrez]
AID - 10.11124/JBISRIR-D-19-00266 [doi]
AID - 02174543-202010000-00010 [pii]
PST - ppublish
SO  - JBI Evid Synth. 2020 Oct;18(10):2164-2170. doi: 10.11124/JBISRIR-D-19-00266.


PMID- 32813351
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2689-8381 (Electronic)
IS  - 2689-8381 (Linking)
VI  - 18
IP  - 5
DP  - 2020 May
TI  - Curricular and pedagogical aspects of gross anatomy education for undergraduate
      physiotherapy students: a scoping review.
PG  - 893-951
LID - 10.11124/JBISRIR-2017-003903 [doi]
AB  - OBJECTIVE: The objective of this review was to collate and map gross anatomy
      curricular and pedagogical approaches for physiotherapy students. INTRODUCTION:
      Knowledge of anatomy is essential for physiotherapy clinical diagnosis, treatment
      effectiveness and safe practice. The information on this topic is sparse, and
      what does exist is diverse. This scoping review describes anatomy educational
      approaches for physiotherapy students and provides needed insight into this
      topic. INCLUSION CRITERIA: No limits were applied on the date of the database
      search or age of participants. Languages were limited to English, French, German 
      and Spanish. Studies had to include information on gross anatomy curricula or
      pedagogy for physiotherapy students, or information from qualified
      physiotherapists or those teaching gross anatomy to physiotherapy students.
      METHODS: Included studies were mainly sourced from EBSCOhost (CINAHL, ERIC and
      MEDLINE), PubMed and Scopus databases. Perusal of reference lists facilitated
      further retrievals. Studies published from inception up to 21 July 2019 were
      included. Studies were identified and screened, and the process was reported in a
      PRISMA flow diagram. JBI methodology for scoping reviews was followed. Selected
      studies were charted according to a template created and published in a JBI
      scoping review protocol. RESULTS: Fifty-four studies satisfied the inclusion
      criteria. Various studies gave calculable length of intervention in weeks (n=14, 
      26%), hours (n = 7, 13%) or both (n = 21, 39%). The majority of studies (n = 50, 
      93%) were cross-sectional studies; three were randomized controlled trials (6%). 
      Mean sample sizes varied from 55.3 +/- 30.4 (professional behaviors, ethical and 
      humanistic aspects) to 323.2 +/- 219.7 participants (multi-modal and blended
      learning). Overall, 29 studies (54%) included physiotherapy students or personnel
      in physiotherapy anatomy programs exclusively in the sample. Other disciplines
      with physiotherapy students included medical students (n = 12, 22%), and
      occupational therapy students (n = 10, 19%). The interprofessional education
      category (n = 8) determined that interdisciplinary teamwork led to increased
      anatomical learning and awareness of future clinical roles. Computer-assisted
      learning (n = 9) was effective as a stand-alone or adjunct pedagogy, useful for
      self-study and helped anatomical knowledge retention. Team-based learning (n =
      2), peer teaching (n = 6) and clinical input incorporating case-based learning
      and horizontal and vertical integration (n = 4) resulted in anatomical knowledge 
      retention and were associated with mastery of anatomical understanding, an
      increase in examination confidence and higher examination grades. Contradictory
      learning outcomes resulted from the use of online videos in blended and
      multi-model learning studies (n = 7). Increased student participation in
      asynchronous online discussion forums benefitted academic learning outcomes. The 
      category of curriculum, pedagogy and materials (n = 15) identified and compared
      different survey results pertaining to the curricular aspect of the objectives of
      this review. One study investigated the flipped classroom concept. The use of
      anatomy content to encourage professional, ethical and humanistic aspects (n = 3)
      of physiotherapy students' behavior resulted in positive outcomes. CONCLUSIONS:
      This scoping review revealed a multi-faceted topic with many types of
      interventions and outcomes recorded. It identified variations in pedagogies,
      curricular content and learning approaches integral to the subject and their
      impact on gross anatomy education for this population. Beneficial behavioral,
      anatomical learning, knowledge retention and academic outcomes were identified.
FAU - Shead, Dorothy Agnes
AU  - Shead DA
AD  - Department of Physiotherapy, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
AD  - School of Anatomical Sciences, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
FAU - Roos, Ronel
AU  - Roos R
AD  - Department of Physiotherapy, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
AD  - The Wits-JBI Centre for Evidence-Based Practice: A JBI Affiliated Group.
FAU - Olivier, Benita
AU  - Olivier B
AD  - Department of Physiotherapy, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
AD  - The Wits-JBI Centre for Evidence-Based Practice: A JBI Affiliated Group.
FAU - Ihunwo, Amadi O
AU  - Ihunwo AO
AD  - School of Anatomical Sciences, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - JBI Evid Synth
JT  - JBI evidence synthesis
JID - 101764819
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Curriculum
MH  - Educational Status
MH  - Humans
MH  - Physical Therapy Modalities
MH  - *Students
EDAT- 2020/08/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.11124/JBISRIR-2017-003903 [doi]
AID - 02174543-202005000-00005 [pii]
PST - ppublish
SO  - JBI Evid Synth. 2020 May;18(5):893-951. doi: 10.11124/JBISRIR-2017-003903.


PMID- 32813344
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 2689-8381 (Electronic)
IS  - 2689-8381 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Apr
TI  - Approaches for assessing decision-making capacity in older adults: a scoping
      review protocol.
PG  - 832-840
LID - 10.11124/JBISRIR-D-19-00068 [doi]
AB  - OBJECTIVE: This review will identify and map existing evidence on current
      approaches to determining decision-making capacity in older adults. It will
      provide a summary of available evidence and policies and identify gaps in
      research. INTRODUCTION: Assessment of decision-making capacity is emerging as an 
      important issue in society and healthcare. It is considered an ethically
      challenging area of clinical practice, and issues with implementation have been
      identified internationally. With the aging population increasing globally,
      approaches to assess and support decision-making are becoming more pertinent.
      INCLUSION CRITERIA: This scoping review will consider studies on assessment
      approaches and procedures that are used to evaluate the decision-making capacity 
      of older adults, aged 60 years and over. It will include those with age-related
      cognitive impairment, dementia, and neurodegenerative conditions. Quantitative,
      qualitative, and mixed-methods studies along with gray literature, including
      expert opinions, policies reports, and practice guides, will be included.
      METHODS: The JBI scoping review methodological framework will be used. The review
      will also be conducted in accordance with the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR)
      checklist for scoping reviews. The following major healthcare databases will be
      searched: MEDLINE, PsycINFO, Embase, CINAHL, Cochrane Databases, Web of Science, 
      and Scopus. The search will cover studies published in English from January 2000 
      to the present date. Titles and abstracts will be screened against inclusion
      criteria. Data will be extracted using a form developed for this review. A
      stakeholder consultation meeting will be held to provide feedback on the
      findings.
FAU - Usher, Ruth
AU  - Usher R
AD  - Discipline of Occupational Therapy, School of Medicine, Trinity College Dublin,
      Dublin, Ireland.
FAU - Stapleton, Tadhg
AU  - Stapleton T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JBI Evid Synth
JT  - JBI evidence synthesis
JID - 101764819
SB  - IM
MH  - Aged
MH  - *Decision Making
MH  - *Delivery of Health Care
MH  - Female
MH  - Humans
MH  - Male
MH  - *Review Literature as Topic
EDAT- 2020/08/20 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - 10.11124/JBISRIR-D-19-00068 [doi]
AID - 02174543-202004000-00009 [pii]
PST - ppublish
SO  - JBI Evid Synth. 2020 Apr;18(4):832-840. doi: 10.11124/JBISRIR-D-19-00068.


PMID- 32813122
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - The Ethics of Geoengineering: A Literature Review.
PG  - 3069-3119
LID - 10.1007/s11948-020-00258-6 [doi]
AB  - Geoengineering as a technological intervention to avert the dangerous climate
      change has been on the table at least since 2006. The global outreach of the
      technology exercised in a non-encapsulated system, the concerns with
      unprecedented levels and scales of impact and the overarching interdisciplinarity
      of the project make the geoengineering debate ethically quite relevant and
      complex. This paper explores the ethical desirability of geoengineering from an
      overall review of the existing literature on the ethics of geoengineering. It
      identifies the relevant literature on the ethics of geoengineering by employing a
      standard methodology. Based on various framing of the major ethical arguments and
      their subsets, the results section presents the opportunities and challenges at
      stake in geoengineering from an ethical point of view. The discussion section
      takes a keen interest in identifying the evolving dynamics of the debate, the
      grey areas of the debate, with underdeveloped arguments being brought to the
      foreground and in highlighting the arguments that are likely to emerge in the
      future as key contenders. It observes the semantic diversity and ethical
      ambiguity, the academic lop-sidedness of the debate, missing contextual setting, 
      need for interdisciplinary approaches, public engagement, and region-specific
      assessment of ethical issues. Recommendations are made to provide a useful
      platform for the second generation of geoengineering ethicists to help advance
      the debate to more decisive domains with the required clarity and caution.
FAU - Pamplany, Augustine
AU  - Pamplany A
AUID- ORCID: 0000-0002-5142-8774
AD  - Institute of Science and Religion, Little Flower Seminary, Aluva, Kerala, 68301, 
      India. apamplany@gmail.com.
FAU - Gordijn, Bert
AU  - Gordijn B
AD  - Institute of Ethics, Dublin City University, Dublin, Ireland.
FAU - Brereton, Patrick
AU  - Brereton P
AD  - School of Communications, Dublin City University, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200819
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Climate Change
MH  - Ethicists
MH  - Humans
MH  - *Technology
OTO - NOTNLM
OT  - *Carbon dioxide removal
OT  - *Ethics
OT  - *Geoengineering
OT  - *Justice
OT  - *Lesser evil
OT  - *Moral hazard
OT  - *Negative emission
OT  - *Research-ethics
OT  - *Solar radiation management
EDAT- 2020/08/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/20 06:00
PHST- 2019/09/07 00:00 [received]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/20 06:00 [entrez]
AID - 10.1007/s11948-020-00258-6 [doi]
AID - 10.1007/s11948-020-00258-6 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3069-3119. doi: 10.1007/s11948-020-00258-6. Epub
      2020 Aug 19.


PMID- 32813060
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210525
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 34
IP  - 12
DP  - 2020 Dec
TI  - Laparoscopic complete mesocolic excision with true central vascular ligation for 
      right-sided colon cancer.
PG  - 5640-5641
LID - 10.1007/s00464-020-07867-z [doi]
AB  - BACKGROUND: Complete mesocolic excision (CME) is known to be effective for colon 
      cancer. However, in right-sided colon cancer, central vascular ligation (CVL) is 
      not easy to perform. In particular, in patients in whom the superior mesenteric
      vein (SMV) runs on the ventral side of the superior mesenteric artery (SMA) (Type
      V/A), laparoscopic ligation of the artery at its root is extremely difficult
      compared with this procedure in patients in whom the SMA runs on the ventral side
      of the SMV (Type A/V). METHODS: We started performing laparoscopic CME with true 
      CVL for right-sided colon cancer using the SMA as a landmark in 2015, and by
      2019, we had completed it for 60 patients. To start, the mesocolon is opened well
      to the caudal side of the ileocolic vessels. The mesentery is then fully detached
      from the retroperitoneal tissue, after which the ileocolic vessels are ligated at
      their roots. D3 lymph node dissection of the lymph nodes around the SMA and SMV
      on the resection side is also performed using the SMA as a landmark, and
      depending on the location of the tumor, the roots of the right and middle colic
      vessels are ligated and divided. This study was conducted with the approval of
      the Tokyo Medical University Ethics Committee. All patients provided informed
      consent. RESULTS: The tumor was located in the cecum in 21 cases, the ascending
      colon in 33, and the transverse colon in 6. The mean operating time was 229 min
      and the mean volume of hemorrhage was 67 ml. There was one Clavien-Dindo Grade 3 
      or worse postoperative complication (ileus). There were no surgery-related or
      in-hospital deaths. CONCLUSION: This procedure can be performed comparatively
      safely. However, since it requires some skill, we consider that it should only be
      performed in suitable cases by teams with sufficient experience.
FAU - Enomoto, Masanobu
AU  - Enomoto M
AUID- ORCID: http://orcid.org/0000-0002-6935-3619
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
      enomoto@tokyo-med.ac.jp.
FAU - Katsumata, Kenji
AU  - Katsumata K
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Kasahara, Kenta
AU  - Kasahara K
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Tago, Tomoya
AU  - Tago T
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Okazaki, Naoto
AU  - Okazaki N
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Wada, Takahiro
AU  - Wada T
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Kuwabara, Hiroshi
AU  - Kuwabara H
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Mazaki, Junichi
AU  - Mazaki J
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Ishizaki, Tetsuo
AU  - Ishizaki T
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Nagakawa, Yuichi
AU  - Nagakawa Y
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
FAU - Tsuchida, Akihiko
AU  - Tsuchida A
AD  - Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University,
      6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
SB  - IM
MH  - Aged
MH  - Colonic Neoplasms/*surgery
MH  - Female
MH  - Humans
MH  - *Laparoscopy/adverse effects
MH  - *Ligation
MH  - Lymph Nodes/pathology
MH  - Male
MH  - Mesenteric Veins/surgery
MH  - Mesocolon/*surgery
MH  - Middle Aged
MH  - Postoperative Complications/etiology
PMC - PMC7644539
OTO - NOTNLM
OT  - *Colon cancer
OT  - *Complete mesocolic excision
OT  - *D3 lymph node dissection
OT  - *Laparoscopy
OT  - *Right hemicolectomy
EDAT- 2020/08/20 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/05/09 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/08/20 06:00 [entrez]
AID - 10.1007/s00464-020-07867-z [doi]
AID - 10.1007/s00464-020-07867-z [pii]
PST - ppublish
SO  - Surg Endosc. 2020 Dec;34(12):5640-5641. doi: 10.1007/s00464-020-07867-z. Epub
      2020 Aug 19.


PMID- 32812886
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 19
TI  - Promoting Physical Activity With Self-Tracking and Mobile-Based Coaching for
      Cardiac Surgery Patients During the Discharge-Rehabilitation Gap: Protocol for a 
      Randomized Controlled Trial.
PG  - e16737
LID - 10.2196/16737 [doi]
AB  - BACKGROUND: Home-based cardiac rehabilitations (CRs) with digital technologies
      have been researched and implemented to replace, augment, and complement
      traditional center-based CR in recent years with considerable success. One
      problem that technology-enhanced home-based CR can potentially address is the gap
      between cardiac interventions and formal CR programs. In the Netherlands and some
      other countries (eg, Australia), patients after cardiac interventions stay at
      home for 3-4 weeks without much support from their physicians, and often engage
      in very little physical activity (PA). A home-based exercise program enabled by
      digital technologies may help patients to better prepare for the later
      center-based CR programs, potentially increasing the uptake rate of those
      programs. OBJECTIVE: In a randomized controlled trial (RCT), we will evaluate the
      effectiveness of a home-based walking exercise program enhanced by self-tracking 
      and mobile-based coaching (treatment condition), comparing it with a version of
      the same program without these technologies (control condition). The added value 
      of the digital technologies is justified if patients in the treatment group walk 
      more steps on average (primary outcome) and show better physical fitness in a
      bicycle ergometer test and higher self-efficacy toward PA (secondary outcomes).
      METHODS: Based on a power analysis, we will recruit 100 cardiac patients and
      assign them evenly to the 2 parallel groups. Eligible patients are those who are 
      scheduled in the postanesthesia care unit, know the Dutch language, have basic
      literacy of using smartphones, and are without medical conditions that may
      increase risks associated with PA. In a face-to-face meeting with a nurse
      practitioner, all patients are prescribed a 3-week exercise program at home (2
      walking exercises per day with increasing duration), based on national and
      international guidelines and tailored to their physical conditions after cardiac 
      intervention. Their physical activities (daily steps) will be measured by the
      Axivity AX3 accelerometer worn at hip position. Patients in the treatment group
      will also be supported by a Neo Health One self-tracking device and a mobile
      platform called Heart Angel, through which they are monitored and coached by
      their nurses. After the study, all patients will perform a bicycle ergometer test
      and return the devices within 1 week. In addition, 5 questionnaires will be sent 
      to the patients by emails to assess their self-efficacy toward PA and other
      psychological states for exploratory analyses (at discharge, at the end of each
      monitoring week, and 1 week after the study). To minimize bias, the randomization
      procedure will be performed after introducing the exercise program, so the nurse 
      practitioners are blind to the experimental conditions until that point. RESULTS:
      The study protocol has been approved by the Medical Research Ethics Committees
      United on February 26, 2018 (NL 62142.100.17/R17.51). By the end of 2018, we
      completed a small pilot study with 8 patients and the results based on interviews
      and app usage data suggest that a larger clinical trial with the targeted
      population is feasible. We expect to complete the RCT by the end of 2021, and
      statistical analyses will follow. CONCLUSIONS: Results of the RCT will help us to
      test the hypothesized benefits of self-tracking and mobile-based coaching for
      cardiac patients in home-based exercise programs during the
      discharge-rehabilitation gap. If the results are positive, cost-effectiveness
      analysis will be performed based on the insights of the study to inform the
      translation of the technology-enhanced program to clinical practice. We also note
      limitations of the trial in the discussion. TRIAL REGISTRATION: Registered at
      Netherlands Trial Register NL8040; https://www.trialregister.nl/trial/8040.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/16737.
CI  - (c)Chao Zhang, Mohamed Soliman-Hamad, Roxanne Robijns, Niels Verberkmoes, Frank
      Verstappen, Wijnand A IJsselsteijn. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 19.08.2020.
FAU - Zhang, Chao
AU  - Zhang C
AUID- ORCID: https://orcid.org/0000-0001-9811-1881
AD  - Eindhoven University of Technology, Eindhoven, Netherlands.
FAU - Soliman-Hamad, Mohamed
AU  - Soliman-Hamad M
AUID- ORCID: https://orcid.org/0000-0002-2298-7702
AD  - Catharina Ziekenhuis Eindhoven, Eindhoven, Netherlands.
FAU - Robijns, Roxanne
AU  - Robijns R
AUID- ORCID: https://orcid.org/0000-0002-1467-989X
AD  - Scamander, Utrecht, Netherlands.
FAU - Verberkmoes, Niels
AU  - Verberkmoes N
AUID- ORCID: https://orcid.org/0000-0002-1717-7326
AD  - Catharina Ziekenhuis Eindhoven, Eindhoven, Netherlands.
FAU - Verstappen, Frank
AU  - Verstappen F
AUID- ORCID: https://orcid.org/0000-0001-5885-3290
AD  - Catharina Ziekenhuis Eindhoven, Eindhoven, Netherlands.
FAU - IJsselsteijn, Wijnand A
AU  - IJsselsteijn WA
AUID- ORCID: https://orcid.org/0000-0001-6856-9269
AD  - Eindhoven University of Technology, Eindhoven, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7468644
OTO - NOTNLM
OT  - cardiac rehabilitation
OT  - eHealth
OT  - mHealth
OT  - mobile-based coaching
OT  - randomized controlled trial
OT  - self-tracking
EDAT- 2020/08/20 06:00
MHDA- 2020/08/20 06:01
CRDT- 2020/08/20 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/08/20 06:01 [medline]
AID - v9i8e16737 [pii]
AID - 10.2196/16737 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 19;9(8):e16737. doi: 10.2196/16737.


PMID- 32812656
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201022
IS  - 2042-3306 (Electronic)
IS  - 0425-1644 (Linking)
VI  - 52
IP  - 6
DP  - 2020 Nov
TI  - Ethics, genetic technologies and equine sports.
PG  - 893
LID - 10.1111/evj.13308 [doi]
FAU - Campbell, Madeleine
AU  - Campbell M
AUID- ORCID: https://orcid.org/0000-0003-1123-5828
AD  - Pathobiology and Population Sciences, Royal Veterinary College, Hatfield,
      Hertfordshire, UK.
LA  - eng
PT  - Letter
DEP - 20200819
PL  - United States
TA  - Equine Vet J
JT  - Equine veterinary journal
JID - 0173320
SB  - IM
MH  - Animals
MH  - *Doping in Sports
MH  - Horses
MH  - *Sports
EDAT- 2020/08/20 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2020/08/20 06:00 [entrez]
AID - 10.1111/evj.13308 [doi]
PST - ppublish
SO  - Equine Vet J. 2020 Nov;52(6):893. doi: 10.1111/evj.13308. Epub 2020 Aug 19.


PMID- 32811755
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - An Ethics-based Approach to Global Health Research Part 2: Strategies for
      Overcoming Logistic and Implementation Challenges.
PG  - 1580-1587
LID - S1551-7411(20)30161-3 [pii]
LID - 10.1016/j.sapharm.2020.07.010 [doi]
AB  - With the growth of global pharmacy partnerships and collaborative research,
      particularly between high-income countries and low- or middle-income countries,
      it is necessary to establish best practices for fair and ethical collaboration
      and research. There is a gap in the pharmacy literature in this regard. Through
      this commentary, authors will present a pathway for future global health
      researchers including generating ideas based on mutual needs of the partnership
      and the community; exploring the importance of regulations including the need to 
      conduct research and partnership projects within the confines of each
      participant's professional scope of practice, expertise, and licensure;
      describing the need to develop agreements and the components that should be
      included in such an agreement; discussing ethical guidelines for research
      planning, obtaining ethical approval, and planning for adverse events; and
      illustrating ethical considerations for research implementation with
      considerations around consent, data collection, linking patients to care after
      the completion of the study, and dissemination. Global examples, with a
      pharmacy-specific approach where applicable, within each section highlight the
      importance of discussion and action around ethics and equity when pursuing
      collaborative research, recognizing that many of these situations involve
      difficult decisions.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Lukas, Stephanie
AU  - Lukas S
AD  - St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO, 63110, USA.
      Electronic address: stephanie.lukas@stlcop.edu.
FAU - Crowe, Susie J
AU  - Crowe SJ
AD  - Bill Gatton College of Pharmacy, Maple Avenue, Bldg. 7. Mountain Home, TN, USA.
      Electronic address: crowesj@etsu.edu.
FAU - Law, Miranda
AU  - Law M
AD  - Howard University College of Pharmacy, 2300 4th St NW, Washington, DC, 20059,
      USA. Electronic address: miranda.law@howard.edu.
FAU - Kahaleh, Abby
AU  - Kahaleh A
AD  - Roosevelt University College of Pharmacy, 1400 N Roosevelt Blvd Schaumburg, IL,
      60173, USA. Electronic address: akahaleh@roosevelt.edu.
FAU - Addo-Atuah, Joyce
AU  - Addo-Atuah J
AD  - Touro College of Pharmacy, 230 W 125th Street, Room 429, New York, NY, 10027,
      USA. Electronic address: joyce.addo-atuah@touro.edu.
FAU - Nonyel, Nkem P
AU  - Nonyel NP
AD  - University of Maryland Eastern Shore, School of Pharmacy and Health Professions, 
      1 College Backbone Road, Princess Anne, MD, 21853, USA. Electronic address:
      npnonyel@umes.edu.
FAU - Ombengi, David
AU  - Ombengi D
AD  - Medical College of Wisconsin School of Pharmacy and Department of Family
      Medicine, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. Electronic
      address: dombengi@mcw.edu.
FAU - Singhal, Mudit
AU  - Singhal M
AD  - D'Youville School of Pharmacy, 320 Porter Avenue, Buffalo, NY, 14201, USA.
      Electronic address: muditm@dyc.edu.
FAU - Sultan, Dawood
AU  - Sultan D
AD  - Mercer University College of Health Professions, 3001 Mercer University Drive,
      Atlanta, GA, 30341-4155, USA. Electronic address: sultan_dh@mercer.edu.
FAU - Tamukong, Robert
AU  - Tamukong R
AD  - Mbarara University of Science &Technology, P.O.Box 1410, Mbarara, Uganda.
      Electronic address: rtamukong@must.ac.ug.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
SB  - IM
MH  - Data Collection
MH  - *Global Health
MH  - Humans
MH  - *Research Personnel
EDAT- 2020/08/20 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/08/20 06:00 [entrez]
AID - S1551-7411(20)30161-3 [pii]
AID - 10.1016/j.sapharm.2020.07.010 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Nov;16(11):1580-1587. doi:
      10.1016/j.sapharm.2020.07.010. Epub 2020 Jul 24.


PMID- 32811497
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20210616
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 18
TI  - Challenges in health service delivery under public-private partnership in
      Tanzania: stakeholders' views from Dar es Salaam region.
PG  - 765
LID - 10.1186/s12913-020-05638-z [doi]
AB  - BACKGROUND: Public-private partnership in the health sector was introduced to
      improve the delivery of health services in Tanzania. Contrary, the expected
      outcomes have not been fully realised. This study aimed at investigating
      challenges encountered in implementing public-private partnership institutional
      arrangements in health service delivery in Kinondoni Municipality, Dar es Salaam,
      Tanzania. METHODS: A qualitative case study design was employed, where in-depth
      interviews with stakeholders were held and document reviews conducted. Fourteen
      (n = 14) participants engaged in this study. Eight (n = 8) and six (n = 6) of the
      fourteen participants were from the public and private sector respectively. The
      thematic approach was used to analyse data, and ethical principles in the
      research process were upheld. RESULTS: Findings revealed that although
      public-private partnerships are hailed for supplementing the government's efforts
      in the provision of health services, institutional arrangements for the smooth
      provision of these services are lacking. Several challenges encumber smooth
      provision of health services and these include inadequate resources, ineffective 
      monitoring and evaluation, and insufficient consultations between partners.
      CONCLUSION: Inadequate legal and policy framework, or ineffective implementation 
      practices may influence challenges facing institutional arrangements for
      public-private partnerships. Therefore, strengthening of public-private
      partnerships is recommended to improve implementation mechanisms and practices
      such as adherence to partnership agreements and compliance to the policies, laws 
      and regulations.
FAU - Nuhu, Said
AU  - Nuhu S
AUID- ORCID: https://orcid.org/0000-0002-0845-2154
AD  - Institute of Human Settlements Studies, Ardhi University, Dar es Salaam,
      Tanzania. said.nuhu@slu.se.
AD  - Department of Urban and Rural Development, Swedish University of Agricultural
      Sciences, Uppsala, Sweden. said.nuhu@slu.se.
FAU - Mpambije, Chakupewa Joseph
AU  - Mpambije CJ
AD  - Department of Development Studies, History and Political Sciences, Mkwawa
      University College of Education (MUCE), Iringa, Tanzania.
AD  - Institute of Development Studies (IDS), University of Dar es Salaam, Dar es
      Salaam, Tanzania.
FAU - Ngussa, Kinamhala
AU  - Ngussa K
AD  - College of Business Education (CBE), Dar es Salaam, Tanzania.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Delivery of Health Care/*organization & administration
MH  - Health Services Research
MH  - Humans
MH  - Organizational Case Studies
MH  - *Public-Private Sector Partnerships
MH  - Qualitative Research
MH  - Stakeholder Participation/psychology
MH  - Tanzania
PMC - PMC7436953
OTO - NOTNLM
OT  - Health service delivery
OT  - Institutional arrangement
OT  - Public-private partnership
OT  - Stakeholders
OT  - Tanzania
EDAT- 2020/08/20 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
AID - 10.1186/s12913-020-05638-z [doi]
AID - 10.1186/s12913-020-05638-z [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Aug 18;20(1):765. doi: 10.1186/s12913-020-05638-z.


PMID- 32811457
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 18
TI  - Improving clinical management of colon cancer through CONNECTION, a nation-wide
      colon cancer registry and stratification effort (CONNECTION II trial): rationale 
      and protocol of a single arm intervention study.
PG  - 776
LID - 10.1186/s12885-020-07236-y [doi]
AB  - BACKGROUND: It is estimated that around 15-30% of patients with early stage colon
      cancer benefit from adjuvant chemotherapy. We are currently not capable of
      upfront selection of patients who benefit from chemotherapy, which indicates the 
      need for additional predictive markers for response to chemotherapy. It has been 
      shown that the consensus molecular subtypes (CMSs), defined by RNA-profiling,
      have prognostic and/or predictive value. Due to postoperative timing of
      chemotherapy in current guidelines, tumor response to chemotherapy per CMS is not
      known, which makes the differentiation between the prognostic and predictive
      value impossible. Therefore, we propose to assess the tumor response per CMS in
      the neoadjuvant chemotherapy setting. This will provide us with clear data on the
      predictive value for chemotherapy response of the CMSs. METHODS: In this
      prospective, single arm, multicenter intervention study, 262 patients with
      resectable microsatellite stable cT3-4NxM0 colon cancer will be treated with two 
      courses of neoadjuvant and two courses of adjuvant capecitabine and oxaliplatin. 
      The primary endpoint is the pathological tumor response to neoadjuvant
      chemotherapy per CMS. Secondary endpoints are radiological tumor response, the
      prognostic value of these responses for recurrence free survival and overall
      survival and the differences in CMS classification of the same tumor before and
      after neoadjuvant chemotherapy. The study is scheduled to be performed in 8-10
      Dutch hospitals. The first patient was included in February 2020. DISCUSSION:
      Patient selection for adjuvant chemotherapy in early stage colon cancer is far
      from optimal. The CMS classification is a promising new biomarker, but a solid
      chemotherapy response assessment per subtype is lacking. In this study we will
      investigate whether CMS classification can be of added value in clinical decision
      making by analyzing the predictive value for chemotherapy response. This study
      can provide the results necessary to proceed to future studies in which (neo)
      adjuvant chemotherapy may be withhold in patients with a specific CMS subtype,
      who show no benefit from chemotherapy and for whom possible new treatments can be
      investigated. TRIAL REGISTRATION: This study has been registered in the
      Netherlands Trial Register (NL8177) at 11-26-2019,
      https://www.trialregister.nl/trial/8177 . The study has been approved by the
      medical ethics committee Utrecht (MEC18/712).
FAU - van den Berg, I
AU  - van den Berg I
AD  - Department of Surgery, Erasmus MC, University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, the Netherlands.
FAU - van de Weerd, S
AU  - van de Weerd S
AD  - Laboratory for Experimental Oncology and Radiobiology, Center for Experimental
      and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of
      Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
AD  - Department of Pathology, Radboud University Medical Centre, Nijmegen, the
      Netherlands.
AD  - Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The
      Netherlands.
FAU - Roodhart, J M L
AU  - Roodhart JML
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, the Netherlands.
FAU - Vink, G R
AU  - Vink GR
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, the Netherlands.
AD  - Netherlands Comprehensive Cancer Organisation, department of research, Utrecht,
      the Netherlands.
FAU - van den Braak, R R J Coebergh
AU  - van den Braak RRJC
AD  - Department of Surgery, Erasmus MC, University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Jimenez, C R
AU  - Jimenez CR
AD  - Department of Medical Oncology, Amsterdam UMC- location VUmc, Amsterdam, the
      Netherlands.
FAU - Elias, S G
AU  - Elias SG
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
FAU - van Vliet, D
AU  - van Vliet D
AD  - Department of Surgery, Erasmus MC, University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Koelink, M
AU  - Koelink M
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, the Netherlands.
FAU - Hong, E
AU  - Hong E
AD  - Department of radiology, The Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - van Grevenstein, W M U
AU  - van Grevenstein WMU
AD  - Department of Surgery, University Medical Center Utrecht, Utrecht University,
      Utrecht, the Netherlands.
FAU - van Oijen, M G H
AU  - van Oijen MGH
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, the Netherlands.
FAU - Beets-Tan, R G H
AU  - Beets-Tan RGH
AD  - Department of radiology, The Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - van Krieken, J H J M
AU  - van Krieken JHJM
AD  - Department of Pathology, Radboud University Medical Centre, Nijmegen, the
      Netherlands.
FAU - IJzermans, J N M
AU  - IJzermans JNM
AD  - Department of Surgery, Erasmus MC, University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
FAU - Medema, J P
AU  - Medema JP
AUID- ORCID: http://orcid.org/0000-0003-3045-2924
AD  - Laboratory for Experimental Oncology and Radiobiology, Center for Experimental
      and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of
      Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
      j.p.medema@amsterdamumc.nl.
AD  - Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The
      Netherlands. j.p.medema@amsterdamumc.nl.
FAU - Koopman, M
AU  - Koopman M
AD  - Department of Medical Oncology, University Medical Center Utrecht, Utrecht
      University, Utrecht, the Netherlands.
CN  - CONNECTION-study group
LA  - eng
GR  - 6331/KWF Kankerbestrijding
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200818
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/standards/*therapeutic use
MH  - Biomarkers, Tumor/*genetics
MH  - Capecitabine/therapeutic use
MH  - Chemotherapy, Adjuvant/standards
MH  - Clinical Decision-Making/methods
MH  - Colectomy
MH  - Colon/pathology/surgery
MH  - Colonic Neoplasms/diagnosis/genetics/mortality/*therapy
MH  - Disease-Free Survival
MH  - Follow-Up Studies
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Neoadjuvant Therapy/*standards
MH  - Neoplasm Recurrence, Local/*epidemiology/genetics/prevention & control
MH  - Neoplasm Staging
MH  - Netherlands/epidemiology
MH  - Oxaliplatin/therapeutic use
MH  - Patient Selection
MH  - Practice Guidelines as Topic
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Registries/statistics & numerical data
MH  - Risk Assessment/methods
PMC - PMC7433093
OTO - NOTNLM
OT  - Colon cancer
OT  - Consensus molecular subtypes
OT  - Neoadjuvant chemotherapy
OT  - Surgery
EDAT- 2020/08/20 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1186/s12885-020-07236-y [doi]
AID - 10.1186/s12885-020-07236-y [pii]
PST - epublish
SO  - BMC Cancer. 2020 Aug 18;20(1):776. doi: 10.1186/s12885-020-07236-y.


PMID- 32811330
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20201218
IS  - 1012-5302 (Print)
IS  - 1012-5302 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Aug
TI  - COVID-19-Schutzmassnahmen in der stationaren Altenpflege - Ein Mapping Review
      pflegewissenschaftlicher Publikationen.
PG  - 199-206
LID - 10.1024/1012-5302/a000745 [doi]
AB  - Protective measures against COVID-19 in elderly care - A mapping review of
      publications in nursing science Abstract. Background: Protective measures to
      combat the COVID-19 pandemic are associated with isolation among people in need
      of elderly care. Due to the known adverse effects of social isolation on health, 
      discussions have been held about the ethical legitimacy and commensurability of
      these measures. AIM: The article aims to show in which format the discourse in
      scientific publication on protective measures against COVID-19 took place and
      which contents have been addressed. METHODS: A mapping review in PubMed has been 
      conducted. All publication types of scientific papers on nursing care of older
      people were considered. The results were synthesized in form of a quantitative
      content analysis of key aspects. RESULTS: The 38 articles included in the
      synthesis show that only a small part of the scientific publications on the
      COVID-19 pandemic deals with people living in nursing homes. Although critical
      aspects related to the isolation caused by the protective measures against the
      COVID-19 pandemic are named in half of the contributions, specific measures to
      address the negative effects of the isolation are rarely mentioned. CONCLUSIONS: 
      There is a need for further activities in research and nursing practice in order 
      to meet the demand and desiderata of those in need of care and to enable personal
      responsibility and self-determination even in a special situation such as the
      COVID-19 pandemic.
FAU - Fischer, Florian
AU  - Fischer F
AUID- ORCID: 0000-0002-4388-1245
AD  - Institut fur Gerontologische Versorgungs- und Pflegeforschung, Hochschule
      Ravensburg-Weingarten.
FAU - Raiber, Lea
AU  - Raiber L
AD  - Institut fur Gerontologische Versorgungs- und Pflegeforschung, Hochschule
      Ravensburg-Weingarten.
FAU - Boscher, Claudia
AU  - Boscher C
AD  - Institut fur Gerontologische Versorgungs- und Pflegeforschung, Hochschule
      Ravensburg-Weingarten.
FAU - Winter, Maik H-J
AU  - Winter MH
AD  - Institut fur Gerontologische Versorgungs- und Pflegeforschung, Hochschule
      Ravensburg-Weingarten.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Pflege
JT  - Pflege
JID - 8907069
MH  - Aged
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - *Geriatric Nursing
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
OTO - NOTNLM
OT  - *COVID-19
OT  - *Infektionsschutz
OT  - *Pandemie
OT  - *Pflege
OT  - *Versorgung
OT  - *care
OT  - *infection control
OT  - *nursing
OT  - *pandemic
EDAT- 2020/08/20 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1024/1012-5302/a000745 [doi]
PST - ppublish
SO  - Pflege. 2020 Aug;33(4):199-206. doi: 10.1024/1012-5302/a000745.


PMID- 32811326
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20201218
IS  - 1012-5302 (Print)
IS  - 1012-5302 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Aug
TI  - Wahrnehmungen von Pflegenden im Bereich der Intensivpflege wahrend der
      COVID-19-Pandemie.
PG  - 229-236
LID - 10.1024/1012-5302/a000744 [doi]
AB  - Perceptions of intensive care nurses during the COVID-19 pandemic - A qualitative
      survey Abstract. Background: While at the beginning of the COVID-19 pandemic the 
      need for intensive care is increasing, the specific care needs of patients are
      still largely unknown. This is a challenge for the work of intensive care staff. 
      AIM: The aim of the study is to understand how intensive care nurses perceive
      their working conditions and the consequences for patient care. METHODS: The
      study is a qualitative survey. Using a web-based questionnaire, narratives of n =
      902 nurses were collected. This article reports the perceptions of n = 397
      intensive care nurses. The evaluation is based on the qualitative content
      analysis according to 18-2Mayring (2015). RESULTS: The analysis of the data shows
      the following six categories: "The lack of staff is extremely noticeable" to
      "Waiting for something", "struggle for PPE (personal protective equipment)",
      "time to learn", "considerable discrepancy" in patient care, "attempts to
      compensate" and "constantly a bad feeling". The tension between the lack of
      knowledge and information on the one hand and the professional demand to do
      justice to the seriously ill and their relatives on the other hand, brings nurses
      to their professional limits. CONCLUSION: Conditions for ethical decision making 
      have to be developed and concepts for a clear attribution of autonomy and
      responsibility for intensive care nurses must be introduced.
FAU - Begerow, Anke
AU  - Begerow A
AD  - Department Pflege und Management, Hochschule fur Angewandte Wissenschaften,
      Hamburg.
FAU - Michaelis, Ulrike
AU  - Michaelis U
AD  - Department Pflege und Management, Hochschule fur Angewandte Wissenschaften,
      Hamburg.
FAU - Gaidys, Uta
AU  - Gaidys U
AD  - Department Pflege und Management, Hochschule fur Angewandte Wissenschaften,
      Hamburg.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pflege
JT  - Pflege
JID - 8907069
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*nursing
MH  - *Critical Care Nursing
MH  - Humans
MH  - Nursing Staff, Hospital/*psychology
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology/*nursing
MH  - Qualitative Research
OTO - NOTNLM
OT  - Arbeitsbelastung
OT  - COVID-19
OT  - Ethik
OT  - Intensivpflege
OT  - Pflegende
OT  - critical care
OT  - ethics
OT  - nursing staff
OT  - workload
EDAT- 2020/08/20 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/20 06:00
PHST- 2020/08/20 06:00 [entrez]
PHST- 2020/08/20 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1024/1012-5302/a000744 [doi]
PST - ppublish
SO  - Pflege. 2020 Aug;33(4):229-236. doi: 10.1024/1012-5302/a000744.


PMID- 32810723
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20210902
IS  - 1873-281X (Electronic)
IS  - 1472-9792 (Linking)
VI  - 124
DP  - 2020 Sep
TI  - A population approach of rifampicin pharmacogenetics and pharmacokinetics in
      Mexican patients with tuberculosis.
PG  - 101982
LID - S1472-9792(20)30149-9 [pii]
LID - 10.1016/j.tube.2020.101982 [doi]
AB  - The aim of this study was to develop a population pharmacokinetic model of
      rifampicin (RMP) in Mexican patients with tuberculosis (TB) to evaluate the
      influence of anthropometric and clinical covariates, as well as genotypic
      variants associated with MDR1 and OATP1B1 transporters. A prospective study
      approved by Research Ethics Committee was performed at Hospital Central in San
      Luis Potosi, Mexico. TB patients under DOTS scheme and who signed informed
      consent were consecutively included. Anthropometric and clinical information was 
      retrieved from medical records. Single nucleotide polymorphisms in MDR1 (C3435T) 
      and SLCO1B1 (A388G and T521C) genes were evaluated. RMP plasma concentrations and
      time data were assessed with NONMEM software. A total of 71 Mexican TB patients
      from 18 to 72 years old were included for RMP quantification from 0.3 to 12 h
      after dose; 329 and 97 plasma concentrations were available for model development
      and validation, respectively. Sequential process includes a typical lag time of
      0.25 h prior to absorption start with a Ka of 1.24 h(-1) and a zero-order
      absorption of 0.62 h to characterize the gradual increase in RMP plasma
      concentrations. Final model includes total body weight in volume of distribution 
      (0.7 L/kg, CV = 26.8%) and a total clearance of 5.96 L/h (CV = 38.5%).
      Bioavailability was modified according to time under treatment and generic
      formulation administration. In conclusion, a population pharmacokinetic model was
      developed to describe the variability in RMP plasma concentrations in Mexican TB 
      patients. Genetic variants evaluated did not showed significant influence on
      pharmacokinetic parameters. Final model will allow therapeutic drug monitoring at
      early stages.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Medellin-Garibay, Susanna Edith
AU  - Medellin-Garibay SE
AD  - Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, S.L.P,
      Mexico.
FAU - Huerta-Garcia, Ana Patricia
AU  - Huerta-Garcia AP
AD  - Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, S.L.P,
      Mexico.
FAU - Rodriguez-Baez, Ana Socorro
AU  - Rodriguez-Baez AS
AD  - Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, S.L.P,
      Mexico.
FAU - Magana-Aquino, Martin
AU  - Magana-Aquino M
AD  - Hospital Central "Dr. Ignacio Morones Prieto", S.L.P, Mexico.
FAU - Ortiz-Alvarez, Arturo
AU  - Ortiz-Alvarez A
AD  - Hospital Central "Dr. Ignacio Morones Prieto", S.L.P, Mexico.
FAU - Portales-Perez, Diana Patricia
AU  - Portales-Perez DP
AD  - Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, S.L.P,
      Mexico.
FAU - Milan-Segovia, Rosa Del Carmen
AU  - Milan-Segovia RDC
AD  - Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, S.L.P,
      Mexico.
FAU - Romano-Moreno, Silvia
AU  - Romano-Moreno S
AD  - Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, S.L.P,
      Mexico. Electronic address: srm@uaslp.mx.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20200808
PL  - Scotland
TA  - Tuberculosis (Edinb)
JT  - Tuberculosis (Edinburgh, Scotland)
JID - 100971555
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (Antibiotics, Antitubercular)
RN  - 0 (Liver-Specific Organic Anion Transporter 1)
RN  - 0 (SLCO1B1 protein, human)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B/genetics/metabolism
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antitubercular/administration & dosage/*pharmacokinetics
MH  - Bayes Theorem
MH  - Biological Availability
MH  - Drug Administration Schedule
MH  - Drug Dosage Calculations
MH  - Female
MH  - Humans
MH  - Liver-Specific Organic Anion Transporter 1/*genetics/metabolism
MH  - Male
MH  - Mexico/epidemiology
MH  - Middle Aged
MH  - *Models, Biological
MH  - Pharmacogenetics
MH  - *Pharmacogenomic Variants
MH  - *Polymorphism, Single Nucleotide
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Rifampin/administration & dosage/*pharmacokinetics
MH  - Treatment Outcome
MH  - Tuberculosis/diagnosis/*drug therapy/ethnology/microbiology
MH  - Young Adult
OTO - NOTNLM
OT  - *Pharmacogenetics
OT  - *Population pharmacokinetics
OT  - *Rifampicin
OT  - *Therapeutic drug monitoring
OT  - *Tuberculosis
EDAT- 2020/08/19 06:00
MHDA- 2021/09/03 06:00
CRDT- 2020/08/19 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - S1472-9792(20)30149-9 [pii]
AID - 10.1016/j.tube.2020.101982 [doi]
PST - ppublish
SO  - Tuberculosis (Edinb). 2020 Sep;124:101982. doi: 10.1016/j.tube.2020.101982. Epub 
      2020 Aug 8.


PMID- 32810106
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 6
DP  - 2020 Jun
TI  - Review of ethics teaching in undergraduate medical education.
PG  - 1056-1062
LID - 10.5455/JPMA.21013 [doi]
AB  - OBJECTIVE: To provide an overview of existing literature regarding ethics in
      undergraduate medical education around the world, and to identify gaps in
      literature for recommending areas for future research. METHODS: The scoping
      review was conducted in March 2016. PubMed and Web of Science search engines were
      used to identify English language literature on ethics in undergraduate medical
      education published over the preceding 20 years. Google search was used for grey 
      literature. Two reviewers independently screened eligible studies for final study
      selection and review. Descriptive analysis of data was performed with mutual
      consensus. RESULTS: Of the 199 items located, 56(28%) were included; 37(33%) of
      112 studies, and 19(22%) of 87 pieces of grey literature. Papers covered almost
      all regions of the world, including North and South America, Europe, Africa, and 
      different Asian regions like Middle East, central, south-east and far east. The
      analysis identified several curriculum designs and teaching methods used for
      ethics education. CONCLUSIONS: The review identified gaps in evidence that
      required further research. These areas include theoretical underpinning of ethics
      curriculum, role of educators, standardisation and validation of teaching and
      learning strategies, and relevance to cultural context in the development and
      delivery of ethics curriculum, especially in Asian regions.
FAU - Shamim, Muhammad Shahid
AU  - Shamim MS
AD  - Dow University of Health Sciences, Karachi.
FAU - Baig, Lubna
AU  - Baig L
AD  - APPNA Institute of Public Health, Jinnah Sindh Medical University, Karachi,
      Pakistan.
FAU - Zubairi, Nadeem
AU  - Zubairi N
AD  - King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Torda, Adrienne
AU  - Torda A
AD  - Prince of Wales Clinical School, Sydney, Australia University of New South Wales,
      Sydney, Australia.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Curriculum
MH  - Delivery of Health Care
MH  - *Education, Medical, Undergraduate
MH  - Ethics, Medical
MH  - Far East
MH  - Humans
MH  - Teaching
OTO - NOTNLM
OT  - Ethics education, Undergraduate, Medical education, Review.
EDAT- 2020/08/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 9966 [pii]
AID - 10.5455/JPMA.21013 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Jun;70(6):1056-1062. doi: 10.5455/JPMA.21013.


PMID- 32809969
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210403
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 130
IP  - 12
DP  - 2020 Dec 1
TI  - Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
PG  - 6409-6416
LID - 10.1172/JCI141772 [doi]
LID - 141772 [pii]
AB  - BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia
      generally associated with lymphopenia and a severe inflammatory response due to
      uncontrolled cytokine release. These mediators are transcriptionally regulated by
      the JAK/STAT signaling pathways, which can be disabled by small
      molecules.METHODSWe treated a group of patients (n = 20) with baricitinib
      according to an off-label use of the drug. The study was designed as an
      observational, longitudinal trial and approved by the local ethics committee. The
      patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4
      mg per day for the remaining 7 days. Changes in the immune phenotype and
      expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and
      correlated with serum-derived cytokine levels and antibodies against severe acute
      respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated
      patient, we also evaluated the alteration of myeloid cell functional
      activity.RESULTSWe provide evidence that patients treated with baricitinib had a 
      marked reduction in serum levels of IL-6, IL-1beta, and TNF-alpha, a rapid
      recovery of circulating T and B cell frequencies, and increased antibody
      production against the SARS-CoV-2 spike protein, all of which were clinically
      associated with a reduction in the need for oxygen therapy and a progressive
      increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired
      oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the
      progression to a severe, extreme form of the viral disease by modulating the
      patients' immune landscape and that these changes were associated with a safer,
      more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL
      REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the 
      Fondazione Cariverona (ENACT Project) and the Fondazione TIM.
FAU - Bronte, Vincenzo
AU  - Bronte V
AD  - Immunology Section, Department of Medicine.
FAU - Ugel, Stefano
AU  - Ugel S
AD  - Immunology Section, Department of Medicine.
FAU - Tinazzi, Elisa
AU  - Tinazzi E
AD  - Internal Medicine Section B, Department of Medicine.
FAU - Vella, Antonio
AU  - Vella A
AD  - Immunology Section, Department of Medicine.
FAU - De Sanctis, Francesco
AU  - De Sanctis F
AD  - Immunology Section, Department of Medicine.
FAU - Cane, Stefania
AU  - Cane S
AD  - Immunology Section, Department of Medicine.
FAU - Batani, Veronica
AU  - Batani V
AD  - Immunology Section, Department of Medicine.
FAU - Trovato, Rosalinda
AU  - Trovato R
AD  - Immunology Section, Department of Medicine.
FAU - Fiore, Alessandra
AU  - Fiore A
AD  - Immunology Section, Department of Medicine.
FAU - Petrova, Varvara
AU  - Petrova V
AD  - Immunology Section, Department of Medicine.
FAU - Hofer, Francesca
AU  - Hofer F
AD  - Immunology Section, Department of Medicine.
FAU - Barouni, Roza Maria
AU  - Barouni RM
AD  - Immunology Section, Department of Medicine.
FAU - Musiu, Chiara
AU  - Musiu C
AD  - Immunology Section, Department of Medicine.
FAU - Caligola, Simone
AU  - Caligola S
AD  - Immunology Section, Department of Medicine.
FAU - Pinton, Laura
AU  - Pinton L
AD  - Immunology Section, Department of Medicine.
FAU - Torroni, Lorena
AU  - Torroni L
AD  - Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public
      Health, University and Hospital Trust of Verona, Verona, Italy.
FAU - Polati, Enrico
AU  - Polati E
AD  - Intensive Care Unit, Department of Surgery, Dentistry, Maternity and Infant,
      University and Hospital Trust of Verona, Verona, Italy.
FAU - Donadello, Katia
AU  - Donadello K
AD  - Intensive Care Unit, Department of Surgery, Dentistry, Maternity and Infant,
      University and Hospital Trust of Verona, Verona, Italy.
FAU - Friso, Simonetta
AU  - Friso S
AD  - Internal Medicine Section B, Department of Medicine.
FAU - Pizzolo, Francesca
AU  - Pizzolo F
AD  - Internal Medicine Section B, Department of Medicine.
FAU - Iezzi, Manuela
AU  - Iezzi M
AD  - Center for Advanced Studies and Technology (CAST), University of G. D'Annunzio of
      Chieti-Pescara, Chieti, Italy.
FAU - Facciotti, Federica
AU  - Facciotti F
AD  - Department of Experimental Oncology, European Institute of Oncology (IEO),
      Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
FAU - Pelicci, Pier Giuseppe
AU  - Pelicci PG
AD  - Department of Experimental Oncology, European Institute of Oncology (IEO),
      Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
FAU - Righetti, Daniela
AU  - Righetti D
AD  - Pederzoli Hospital, Peschiera sul Garda, Italy.
FAU - Bazzoni, Paolo
AU  - Bazzoni P
AD  - Pederzoli Hospital, Peschiera sul Garda, Italy.
FAU - Rampudda, Mariaelisa
AU  - Rampudda M
AD  - Pederzoli Hospital, Peschiera sul Garda, Italy.
FAU - Comel, Andrea
AU  - Comel A
AD  - Pederzoli Hospital, Peschiera sul Garda, Italy.
FAU - Mosaner, Walter
AU  - Mosaner W
AD  - Pederzoli Hospital, Peschiera sul Garda, Italy.
FAU - Lunardi, Claudio
AU  - Lunardi C
AD  - Internal Medicine Section B, Department of Medicine.
FAU - Olivieri, Oliviero
AU  - Olivieri O
AD  - Internal Medicine Section B, Department of Medicine.
LA  - eng
SI  - ClinicalTrials.gov/NCT04438629
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Azetidines)
RN  - 0 (Cytokines)
RN  - 0 (Purines)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - ISP4442I3Y (baricitinib)
SB  - IM
CIN - J Clin Invest. 2020 Dec 1;130(12):6225-6227. PMID: 32902413
MH  - Aged
MH  - Aged, 80 and over
MH  - Azetidines/*administration & dosage
MH  - B-Lymphocytes/immunology/metabolism/pathology
MH  - *COVID-19/blood/drug therapy/immunology/pathology
MH  - Cytokines/blood/immunology
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - *Off-Label Use
MH  - Purines/*administration & dosage
MH  - Pyrazoles/*administration & dosage
MH  - *SARS-CoV-2/immunology/metabolism
MH  - Severity of Illness Index
MH  - Sulfonamides/*administration & dosage
MH  - T-Lymphocytes/immunology/metabolism/pathology
PMC - PMC8016181
OTO - NOTNLM
OT  - *COVID-19
OT  - *Immunology
OT  - *Innate immunity
EDAT- 2020/08/19 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 141772 [pii]
AID - 10.1172/JCI141772 [doi]
PST - ppublish
SO  - J Clin Invest. 2020 Dec 1;130(12):6409-6416. doi: 10.1172/JCI141772.


PMID- 32808972
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20201218
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 324
IP  - 11
DP  - 2020 Sep 15
TI  - Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities.
PG  - 1031-1032
LID - 10.1001/jama.2020.15589 [doi]
FAU - Wang, Emily A
AU  - Wang EA
AD  - SEICHE Center of Health and Justice, Yale School of Medicine, New Haven,
      Connecticut.
AD  - Section of General Internal Medicine, Department of Internal Medicine, Yale
      School of Medicine, New Haven, Connecticut.
FAU - Zenilman, Jonathan
AU  - Zenilman J
AD  - Division of Infection Diseases, Johns Hopkins University School of Medicine,
      Baltimore, Maryland.
FAU - Brinkley-Rubinstein, Lauren
AU  - Brinkley-Rubinstein L
AD  - Department of Social Medicine, University of North Carolina, Chapel Hill.
AD  - Center for Health Equity Research, University of North Carolina, Chapel Hill.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials, Phase III as Topic/*ethics
MH  - Coronavirus Infections/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - *Prisoners
MH  - SARS-CoV-2
MH  - Therapeutic Human Experimentation/*ethics
MH  - United States
MH  - Vaccination/*ethics
MH  - *Viral Vaccines
EDAT- 2020/08/19 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 2769694 [pii]
AID - 10.1001/jama.2020.15589 [doi]
PST - ppublish
SO  - JAMA. 2020 Sep 15;324(11):1031-1032. doi: 10.1001/jama.2020.15589.


PMID- 32808934
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Aug 18
TI  - The Academic Viewpoint on Patient Data Ownership in the Context of Big Data:
      Scoping Review.
PG  - e22214
LID - 10.2196/22214 [doi]
AB  - BACKGROUND: The ownership of patient information in the context of big data is a 
      relatively new problem, which is not yet fully recognized by the medical academic
      community. The problem is interdisciplinary, incorporating legal, ethical,
      medical, and aspects of information and communication technologies, requiring a
      sophisticated analysis. However, no previous scoping review has mapped existing
      studies on the subject. OBJECTIVE: This study aims to map and assess published
      studies on patient data ownership in the context of big data as viewed by the
      academic community. METHODS: A scoping review was conducted based on the 5-stage 
      framework outlined by Arksey and O'Malley and further developed by Levac,
      Colquhoun, and O'Brien. The organization and reporting of results of the scoping 
      review were conducted according to PRISMA-ScR (Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses and its extensions for Scoping Reviews). A
      systematic and comprehensive search of 4 scientific information databases,
      PubMed, ScienceDirect, Scopus, and Springer, was performed for studies published 
      between January 2000 and October 2019. Two authors independently assessed the
      eligibility of the studies and the extracted data. RESULTS: The review included
      32 eligible articles authored by academicians that correspond to 3 focus areas:
      problem (ownership), area (health care), and context (big data). Five major
      aspects were studied: the scientific area of publications, aspects and
      academicians' perception of ownership in the context of big data, proposed
      solutions, and practical applications for data ownership issues in the context of
      big data. The aspects in which publications consider ownership of medical data
      are not clearly distinguished but can be summarized as ethical, legal, political,
      and managerial. The ownership of patient data is perceived primarily as a
      challenge fundamental to conducting medical research, including data sales and
      sharing, and to a lesser degree as a means of control, problem, threat, and
      opportunity also in view of medical research. Although numerous solutions falling
      into 3 categories, technology, law, and policy, were proposed, only 3 real
      applications were discussed. CONCLUSIONS: The issue of ownership of patient
      information in the context of big data is poorly researched; it is not addressed 
      consistently and in its integrity, and there is no consensus on policy decisions 
      and the necessary legal regulations. Future research should investigate the issue
      of ownership as a core research question and not as a minor fragment among other 
      topics. More research is needed to increase the body of knowledge regarding the
      development of adequate policies and relevant legal frameworks in compliance with
      ethical standards. The combined efforts of multidisciplinary academic teams are
      needed to overcome existing gaps in the perception of ownership, the aspects of
      ownership, and the possible solutions to patient data ownership issues in the
      reality of big data.
CI  - (c)Martin Mirchev, Iskra Mircheva, Albena Kerekovska. Originally published in the
      Journal of Medical Internet Research (http://www.jmir.org), 18.08.2020.
FAU - Mirchev, Martin
AU  - Mirchev M
AUID- ORCID: 0000-0002-7819-2976
AD  - Department of Social Medicine and Healthcare Organization, Faculty of Public
      Health, Medical University of Varna, Varna, Bulgaria.
FAU - Mircheva, Iskra
AU  - Mircheva I
AUID- ORCID: 0000-0001-9844-5590
AD  - Department of Social Medicine and Healthcare Organization, Faculty of Public
      Health, Medical University of Varna, Varna, Bulgaria.
FAU - Kerekovska, Albena
AU  - Kerekovska A
AUID- ORCID: 0000-0002-8948-5053
AD  - Department of Social Medicine and Healthcare Organization, Faculty of Public
      Health, Medical University of Varna, Varna, Bulgaria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200818
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Big Data
MH  - Biomedical Research/*standards
MH  - *Data Analysis
MH  - Female
MH  - Humans
MH  - Male
PMC - PMC7463395
OTO - NOTNLM
OT  - *big data
OT  - *ethics
OT  - *legal aspects
OT  - *ownership
OT  - *patient-generated health data
EDAT- 2020/08/19 06:00
MHDA- 2021/01/23 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/07/06 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - v22i8e22214 [pii]
AID - 10.2196/22214 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Aug 18;22(8):e22214. doi: 10.2196/22214.


PMID- 32808931
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 18
TI  - Mobile Health App (AGRIPPA) to Prevent Relapse After Successful Interdisciplinary
      Treatment for Patients With Chronic Pain: Protocol for a Randomized Controlled
      Trial.
PG  - e18632
LID - 10.2196/18632 [doi]
AB  - BACKGROUND: To facilitate adherence to adaptive pain management behaviors after
      interdisciplinary multimodal pain treatment, we developed a mobile health app
      (AGRIPPA app) that contains two behavior regulation strategies. OBJECTIVE: The
      aims of this project are (1) to test the effectiveness of the AGRIPPA app on pain
      disability; (2) to determine the cost-effectiveness; and (3) to explore the
      levels of engagement and usability of app users. METHODS: We will perform a
      multicenter randomized controlled trial with two parallel groups. Within the
      12-month inclusion period, we plan to recruit 158 adult patients with chronic
      pain during the initial stage of their interdisciplinary treatment program in one
      of the 6 participating centers. Participants will be randomly assigned to the
      standard treatment condition or to the enhanced treatment condition in which they
      will receive the AGRIPPA app. Patients will be monitored from the start of the
      treatment program until 12 months posttreatment. In our primary analysis, we will
      evaluate the difference over time of pain-related disability between the two
      conditions. Other outcome measures will include health-related quality of life,
      illness perceptions, pain self-efficacy, app system usage data, productivity
      loss, and health care expenses. RESULTS: The study was approved by the local
      Medical Research Ethics Committee in October 2019. As of March 20, 2020, we have 
      recruited 88 patients. CONCLUSIONS: This study will be the first step in
      systematically evaluating the effectiveness and efficiency of the AGRIPPA app.
      After 3 years of development and feasibility testing, this formal evaluation will
      help determine to what extent the app will influence the maintenance of treatment
      gains over time. The outcomes of this trial will guide future decisions regarding
      uptake in clinical practice. TRIAL REGISTRATION: Netherlands Trial Register
      NL8076; https://www.trialregister.nl/trial/8076. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/18632.
CI  - (c)Stefan Elbers, Jan Pool, Harriet Wittink, Albere Koke, Else Scheffer, Rob
      Smeets. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 18.08.2020.
FAU - Elbers, Stefan
AU  - Elbers S
AUID- ORCID: https://orcid.org/0000-0002-8928-4307
AD  - Lifestyle and Health Research Group, Healthy and Sustainable Living Research
      Centre, University of Applied Sciences Utrecht, Utrecht, Netherlands.
AD  - Department of Rehabilitation Medicine, Faculty of Health, Life Sciences and
      Medicine, Maastricht University, Maastricht, Netherlands.
FAU - Pool, Jan
AU  - Pool J
AUID- ORCID: https://orcid.org/0000-0002-9240-4488
AD  - Lifestyle and Health Research Group, Healthy and Sustainable Living Research
      Centre, University of Applied Sciences Utrecht, Utrecht, Netherlands.
FAU - Wittink, Harriet
AU  - Wittink H
AUID- ORCID: https://orcid.org/0000-0001-5592-2879
AD  - Lifestyle and Health Research Group, Healthy and Sustainable Living Research
      Centre, University of Applied Sciences Utrecht, Utrecht, Netherlands.
FAU - Koke, Albere
AU  - Koke A
AUID- ORCID: https://orcid.org/0000-0002-4546-4576
AD  - Department of Rehabilitation Medicine, Faculty of Health, Life Sciences and
      Medicine, Maastricht University, Maastricht, Netherlands.
AD  - Adelante Centre of Expertise in Rehabilitation and Audiology, Hoensbroek,
      Netherlands.
AD  - South University of Applied Sciences, Heerlen, Netherlands.
FAU - Scheffer, Else
AU  - Scheffer E
AUID- ORCID: https://orcid.org/0000-0003-4756-5781
AD  - Lifestyle and Health Research Group, Healthy and Sustainable Living Research
      Centre, University of Applied Sciences Utrecht, Utrecht, Netherlands.
FAU - Smeets, Rob
AU  - Smeets R
AUID- ORCID: https://orcid.org/0000-0002-9503-366X
AD  - Department of Rehabilitation Medicine, Faculty of Health, Life Sciences and
      Medicine, Maastricht University, Maastricht, Netherlands.
AD  - CIR Rehabilitation, Eindhoven, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7463414
OTO - NOTNLM
OT  - chronic pain
OT  - clinical trial protocol
OT  - cost-benefit analysis
OT  - mobile apps
OT  - patient care team
OT  - randomized controlled trial
OT  - recurrence
OT  - rehabilitation
OT  - telemedicine
OT  - treatment adherence and compliance
EDAT- 2020/08/19 06:00
MHDA- 2020/08/19 06:01
CRDT- 2020/08/19 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/08/19 06:01 [medline]
AID - v9i8e18632 [pii]
AID - 10.2196/18632 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 18;9(8):e18632. doi: 10.2196/18632.


PMID- 32808910
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20210616
IS  - 1943-281X (Electronic)
IS  - 0033-2747 (Linking)
VI  - 83
IP  - 2
DP  - 2020 Summer
TI  - Psychotherapy and LGBT Identities: Historical, Clinical and Ethical.
PG  - 202-203
LID - 10.1080/00332747.2020.1767993 [doi]
FAU - Lebolt, Jonathan
AU  - Lebolt J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Psychiatry
JT  - Psychiatry
JID - 0376470
SB  - IM
MH  - *Congresses as Topic
MH  - Humans
MH  - *Psychotherapy
MH  - *Sexual and Gender Minorities
EDAT- 2020/08/19 06:00
MHDA- 2021/06/17 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
AID - 10.1080/00332747.2020.1767993 [doi]
PST - ppublish
SO  - Psychiatry. 2020 Summer;83(2):202-203. doi: 10.1080/00332747.2020.1767993.


PMID- 32808880
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct-Dec
TI  - Managing Conflicts and Maximizing Transparency in Industry-Funded Research.
PG  - 223-232
LID - 10.1080/23294515.2020.1798562 [doi]
AB  - BACKGROUND: Industry funding of research comes with important conflicts of
      interest, especially when research findings have financial implications for
      funders. When considering industry funding, academic investigators seek ways to
      mitigate and manage conflict to ensure integrity of research design, analysis,
      interpretation, and to protect researchers' and their institutions' credibility. 
      This qualitative study's purpose was to conduct semi-structured interviews with
      expert stakeholders to gain insight into industry funding of research focused on 
      nutrition and obesity, and determine the feasibility of developing a transparent 
      process using an advisory board to help govern industry funding and manage
      conflict. METHODS: We conducted seven semi-structured interviews with a purposive
      group of expert stakeholders representing varied perspectives. We distributed a
      summary of the advisory board concept to interviewees; developed and used a
      16-question interview guide; and analyzed the interviews using open coding,
      manifest content analysis, axial coding, and code list reviews to identify and
      refine themes. RESULTS: Most interviewees agreed that managing conflicts between 
      industry funders and researchers was possible but difficult. They believed a
      carefully constructed advisory board empowered with specific responsibilities
      could help facilitate this process. They posited that strict guidelines are
      required to protect research quality and reporting, researcher(s)' and research
      institution(s)' reputations, and subsequent policy influenced by the research
      findings. They recommended specific guidelines and a framework for developing and
      administering the advisory board. CONCLUSIONS: A carefully constructed advisory
      board empowered with specific responsibilities could be useful to manage actual
      and perceived conflicts of interest, and increase transparency of research
      processes, funding, and results for industry-funded research. Stricter guidelines
      than those previously proposed in existing frameworks are needed to instill
      confidence in industry-funded nutrition and obesity research. A possible next
      step could include a pilot study of the advisory board concept to determine
      specific requirements for execution and to develop rigorous guidelines.
FAU - Plottel, Gloria Stone
AU  - Plottel GS
AUID- ORCID: 0000-0002-7221-4580
AD  - GSPsquared LLC, Newton, Massachusetts, USA.
FAU - Adler, Rachel
AU  - Adler R
AD  - Wisconsin Surgical Outcomes Program, Univeristy of Wisconsin School of Medicine
      and Public Health, Madison, Wisconsin, USA.
FAU - Jenter, Chelsea
AU  - Jenter C
AD  - Division of Chronic Disease Research Across the Lifecourse, Department of
      Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Division of Chronic Disease Research Across the Lifecourse, Department of
      Population Medicine, Harvard Pilgrim Health Care Institute, Boston,
      Massachusetts, USA.
FAU - Block, Jason P
AU  - Block JP
AUID- ORCID: 0000-0001-7660-9064
AD  - Division of Chronic Disease Research Across the Lifecourse, Department of
      Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Division of Chronic Disease Research Across the Lifecourse, Department of
      Population Medicine, Harvard Pilgrim Health Care Institute, Boston,
      Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200818
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Advisory Committees
MH  - Attitude
MH  - Biomedical Research/economics/*ethics
MH  - *Conflict of Interest
MH  - *Disclosure
MH  - Ethics, Research
MH  - Financial Management
MH  - Food Industry
MH  - Humans
MH  - Industry/*ethics
MH  - Nutritional Sciences
MH  - Obesity
MH  - Qualitative Research
MH  - Research Personnel
MH  - *Research Support as Topic
MH  - Stakeholder Participation
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Health policy
OT  - *conflict of interest
OT  - *decision making
OT  - *empirical research
OT  - *ethics committees
OT  - *research ethics
EDAT- 2020/08/19 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 10.1080/23294515.2020.1798562 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Oct-Dec;11(4):223-232. doi:
      10.1080/23294515.2020.1798562. Epub 2020 Aug 18.


PMID- 32808455
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1369-7625 (Electronic)
IS  - 1369-6513 (Linking)
VI  - 23
IP  - 5
DP  - 2020 Oct
TI  - A national research centre for the evaluation and implementation of
      person-centred care: Content from the first interventional studies.
PG  - 1362-1375
LID - 10.1111/hex.13120 [doi]
AB  - BACKGROUND: Person-centred care (PCC) has been suggested as a potential means to 
      improve the care of patients with chronic and long-term disorders. In this
      regard, a model for PCC was developed by the University of Gothenburg Centre for 
      Person-Centred Care (GPCC). OBJECTIVE: The present study aimed to explore the
      theoretical frameworks, designs, contexts and intervention characteristics in the
      first 27 interventional studies conducted based on the ethics for
      person-centredness provided by the GPCC. DESIGN: Cross-sectional study. SETTING
      AND PARTICIPANTS: A questionnaire to the principal investigators of the 27
      intervention studies financed by the GPCC and conducted between 2010 and 2016.
      MAIN OUTCOME MEASURES: Theoretical frameworks, contexts of studies,
      person-centred ethic, and outcome measures. RESULTS: Most of the interventions
      were based on the same ethical assumptions for person-centredness but theories
      and models in applying the interventions differed. All studies were controlled;
      12 randomized and 15 quasi-experimental. Hospital in- and outpatient and primary 
      care settings were represented and the outcome measures were related to the
      specific theories used. A complexity in designing, introducing and evaluating PCC
      interventions was evident. CONCLUSION: The frameworks, designs and interventions 
      in the studies were in line with the established ethical basis of PCC, whereas
      outcome measures varied widely. Consensus discussions among researchers in the
      field are needed to make comparisons between studies feasible. PATIENT OR PUBLIC 
      CONTRIBUTIONS: Patients or the public made no direct contributions, although most
      of the studied projects included such initiatives.
CI  - (c) 2020 The Authors Health Expectations published by John Wiley & Sons Ltd.
FAU - Gyllensten, Hanna
AU  - Gyllensten H
AUID- ORCID: 0000-0001-6890-5162
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Bjorkman, Ida
AU  - Bjorkman I
AUID- ORCID: 0000-0003-3171-683X
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Jakobsson Ung, Eva
AU  - Jakobsson Ung E
AUID- ORCID: 0000-0002-8955-6552
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Ekman, Inger
AU  - Ekman I
AUID- ORCID: 0000-0002-5559-5203
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Jakobsson, Sofie
AU  - Jakobsson S
AUID- ORCID: 0000-0001-5223-6363
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200818
PL  - England
TA  - Health Expect
JT  - Health expectations : an international journal of public participation in health 
      care and health policy
JID - 9815926
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Patient-Centered Care
MH  - Research
MH  - *Self Care
MH  - Surveys and Questionnaires
PMC - PMC7696144
OTO - NOTNLM
OT  - *clinical trials
OT  - *interdisciplinary research
OT  - *patient-centred care
OT  - *person-centred care
OT  - *surveys and questionnaires
EDAT- 2020/08/19 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 10.1111/hex.13120 [doi]
PST - ppublish
SO  - Health Expect. 2020 Oct;23(5):1362-1375. doi: 10.1111/hex.13120. Epub 2020 Aug
      18.


PMID- 32808300
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 5
DP  - 2020 Sep
TI  - Citation metrics for appraising scientists: misuse, gaming and proper use.
PG  - 237-237.e1
LID - 10.5694/mja2.50738 [doi]
FAU - Teixeira da Silva, Jaime A
AU  - Teixeira da Silva JA
AD  - Miki-cho, Japan.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200818
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
CON - Med J Aust. 2020 Apr;212(6):247-249.e1. PMID: 32017115
MH  - *Benchmarking
MH  - *Video Games
OTO - NOTNLM
OT  - *Cultural competency
OT  - *Education, public health
OT  - *Ethics
OT  - *Ethics, professional
OT  - *Ethics, research
OT  - *History of science
OT  - *Library, medical
OT  - *Medical errors
OT  - *Medical misconduct
OT  - *Medicine in literature
OT  - *Public policy
OT  - *Publishing
EDAT- 2020/08/19 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 10.5694/mja2.50738 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Sep;213(5):237-237.e1. doi: 10.5694/mja2.50738. Epub 2020 Aug
      18.


PMID- 32807529
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210110
IS  - 1528-3968 (Electronic)
IS  - 0029-6554 (Linking)
VI  - 68
IP  - 5
DP  - 2020 Sep - Oct
TI  - Moral outrage: Promise or peril?
PG  - 536-538
LID - S0029-6554(20)30522-4 [pii]
LID - 10.1016/j.outlook.2020.07.006 [doi]
FAU - Rushton, Cynda Hylton
AU  - Rushton CH
AD  - Anne & George Bunting Professor of Clinical Ethics, Johns Hopkins University,
      Berman Institute of Bioethics, School of Nursing, Baltimore, MD. Electronic
      address: crushto1@jhu.edu.
FAU - Thompson, Lindsay
AU  - Thompson L
AD  - Department of Leadership and Social Ethics, Johns Hopkins University, Carey
      Business School, Bloomberg American Health Initiative, Baltimore, MD.
LA  - eng
PT  - Journal Article
DEP - 20200815
PL  - United States
TA  - Nurs Outlook
JT  - Nursing outlook
JID - 0401075
SB  - IM
MH  - *Anger
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/nursing
MH  - Ethics, Clinical
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - *Morals
MH  - Nurse Clinicians/psychology
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/nursing
MH  - Social Justice/ethics/psychology
MH  - United States/epidemiology
PMC - PMC7428747
OTO - NOTNLM
OT  - *COVID-19
OT  - *Clinical ethics
OT  - *Moral outrage
EDAT- 2020/08/19 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/06/29 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - S0029-6554(20)30522-4 [pii]
AID - 10.1016/j.outlook.2020.07.006 [doi]
PST - ppublish
SO  - Nurs Outlook. 2020 Sep - Oct;68(5):536-538. doi: 10.1016/j.outlook.2020.07.006.
      Epub 2020 Aug 15.


PMID- 32807514
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210702
IS  - 0168-9525 (Print)
IS  - 0168-9525 (Linking)
VI  - 36
IP  - 12
DP  - 2020 Dec
TI  - Challenges of Genetic Data Sharing in African Studies.
PG  - 895-896
LID - S0168-9525(20)30187-6 [pii]
LID - 10.1016/j.tig.2020.07.010 [doi]
AB  - Data sharing is a valuable aspect of science and required by most funding bodies 
      and journals. However, the national regulatory guidelines of many African nations
      do not explicitly allow for broad genetic data sharing. Given these restrictions,
      there is a need to reconsider these policies and propose creative solutions.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Stein, Catherine M
AU  - Stein CM
AD  - Department of Population and Quantitative Health Sciences, and Division of
      Infectious Disease and HIV Medicine, Case Western Reserve University, Cleveland, 
      OH 44106, USA. Electronic address: cmj7@case.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200814
PL  - England
TA  - Trends Genet
JT  - Trends in genetics : TIG
JID - 8507085
SB  - IM
MH  - Africa
MH  - Genetic Research/*legislation & jurisprudence
MH  - Genomics/legislation & jurisprudence/*standards
MH  - Humans
MH  - Information Dissemination/*legislation & jurisprudence/methods
OTO - NOTNLM
OT  - *ELSI
OT  - *H3Africa
OT  - *collaboration
OT  - *ethics
OT  - *genomic data sharing policy
OT  - *international research
EDAT- 2020/08/19 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/06/12 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - S0168-9525(20)30187-6 [pii]
AID - 10.1016/j.tig.2020.07.010 [doi]
PST - ppublish
SO  - Trends Genet. 2020 Dec;36(12):895-896. doi: 10.1016/j.tig.2020.07.010. Epub 2020 
      Aug 14.


PMID- 32807492
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20211204
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 531
IP  - 4
DP  - 2020 Oct 22
TI  - ReN VM spheroids in matrix: A neural progenitor three-dimensional in vitro model 
      reveals DYRK1A inhibitors as potential regulators of radio-sensitivity.
PG  - 535-542
LID - S0006-291X(20)31531-X [pii]
LID - 10.1016/j.bbrc.2020.07.130 [doi]
AB  - INTRODUCTION: Pre-clinical testing of small molecules for therapeutic development
      across many pathologies relies on the use of in-vitro and in-vivo models. When
      designed and implemented well, these models serve to predict the clinical outcome
      as well as the toxicity of the evaluated therapies. The two-dimensional (2D)
      reductionist approach where cells are incubated in a mono-layer on hard plastic
      microtiter plates is relatively inexpensive but not physiologically relevant. In 
      contrast, well developed and applied three dimensional (3D) in vitro models could
      be employed to bridge the gap between 2D in vitro primary screening and expensive
      in vivo rodent models by incorporating key features of the tissue
      microenvironment to explore differentiation, cortical development, cancers and
      various neuronal dysfunctions. These features include an extracellular matrix,
      co-culture, tension and perfusion and could replace several hundred rodents in
      the drug screening validation cascade. METHODS: Human neural progenitor cells
      from middle brain (ReN VM, Merck Millipore, UK) were expanded as instructed by
      the supplier (Merck Millipore, UK), and then seeded in 96-well low-attachment
      plates (Corning, UK) to form multicellular spheroids followed by adding a
      Matrigel layer to mimic extracellular matrix around neural stem cell niche. ReN
      VM cells were then differentiated via EGF and bFGF deprivation for 7 days and
      were imaged at day 7. Radiotherapy was mimicked via gamma-radiation at 2Gy in the
      absence and presence of selected DYRK1A inhibitors Harmine, INDY and Leucettine
      41 (L41). Cell viability was measured by AlamarBlue assay. Immunofluorescence
      staining was used to assess cell pluripotency marker SOX2 and differentiation
      marker GFAP. RESULTS: After 7 days of differentiation, neuron early
      differentiation marker (GFAP, red) started to be expressed among the cells
      expressing neural stem cell marker SOX2 (green). Radiation treatment caused
      significant morphology change including the reduced viability of the spheroids.
      These spheroids also revealed sensitizing potential of DYRK1A inhibitors tested
      in this study, including Harmine, INDY and L41. DISCUSSION & CONCLUSIONS:
      Combined with the benefit of greatly reducing the issues associated with in vivo 
      rodent models, including reducing numbers of animals used in a drug screening
      cascade, cost, ethics, and potential animal welfare burden, we feel the
      well-developed and applied 3D neural spheroid model presented in this study will 
      provide a crucial tool to evaluate combinatorial therapies, optimal drug
      concentrations and treatment dosages.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Wan, Xiao
AU  - Wan X
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, OX3 7FZ, Oxford, England, UK.
FAU - Wu, Xiaoning
AU  - Wu X
AD  - Oxford Institute for Radiation Oncology, University of Oxford, OX3 7DQ, Oxford,
      England, UK.
FAU - Hill, Mark A
AU  - Hill MA
AD  - Oxford Institute for Radiation Oncology, University of Oxford, OX3 7DQ, Oxford,
      England, UK.
FAU - Ebner, Daniel V
AU  - Ebner DV
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, OX3 7FZ, Oxford, England, UK. Electronic address:
      daniel.ebner@ndm.ox.ac.uk.
LA  - eng
GR  - MC_U142760473/MRC_/Medical Research Council/United Kingdom
GR  - NC/P002374/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction
      of Animals in Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200814
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0
      (((5Z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4H-imidazol-4-o
      ne))
RN  - 0 (Dioxoles)
RN  - 0 (Drug Combinations)
RN  - 0 (Imidazoles)
RN  - 0 (Laminin)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proteoglycans)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 0 (SOX2 protein, human)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 119978-18-6 (matrigel)
RN  - 4FHH5G48T7 (Harmine)
RN  - 9007-34-5 (Collagen)
RN  - EC 2.7.1.- (Dyrk kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Cell Line
MH  - Collagen
MH  - Dioxoles/pharmacology
MH  - Drug Combinations
MH  - Drug Evaluation, Preclinical/*methods
MH  - Extracellular Matrix
MH  - Gamma Rays
MH  - Harmine/pharmacology
MH  - Humans
MH  - Imidazoles/pharmacology
MH  - Laminin
MH  - Neural Stem Cells/*drug effects/radiation effects
MH  - Neurites/drug effects
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Protein Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Proteoglycans
MH  - Radiation-Sensitizing Agents/pharmacology
MH  - SOXB1 Transcription Factors/metabolism
MH  - Spheroids, Cellular/*drug effects/radiation effects
OTO - NOTNLM
OT  - *Cellular image analysis
OT  - *DYRK1
OT  - *Drug candidates
OT  - *Human midbrain
OT  - *Neural progenitor cells
OT  - *Neurotoxicity
OT  - *Preclinical model
OT  - *Three-dimensional in vitro model
COIS- Declaration of competing interest The authors do not declare any conflict of
      interests.
EDAT- 2020/08/19 06:00
MHDA- 2021/03/20 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/07/09 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - S0006-291X(20)31531-X [pii]
AID - 10.1016/j.bbrc.2020.07.130 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2020 Oct 22;531(4):535-542. doi:
      10.1016/j.bbrc.2020.07.130. Epub 2020 Aug 14.


PMID- 32807219
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 17
TI  - Robotic-arm assisted medial unicondylar knee arthroplasty versus jig-based
      unicompartmental knee arthroplasty with navigation control: study protocol for a 
      prospective randomised controlled trial.
PG  - 721
LID - 10.1186/s13063-020-04631-5 [doi]
AB  - BACKGROUND: There remains a paucity of clinical studies assessing how any
      differences in accuracy of implant positioning between robotic-arm assisted
      unicompartmental knee arthroplasty (RO UKA) and conventional jig-based
      unicompartmental knee arthroplasty (CO UKA) translate to patient satisfaction,
      functional outcomes, and implant survivorship. The objectives of this study are
      to compare accuracy of implant positioning, limb alignment, patient satisfaction,
      functional outcomes, implant survivorship, cost-effectiveness, and complications 
      in CO UKA versus RO UKA. Computer navigation will be used to assess
      intraoperative knee kinematics in all patients undergoing CO UKA. METHODS AND
      ANALYSIS: This prospective randomised controlled trial will include 140 patients 
      with symptomatic medial compartment knee arthritis undergoing primary UKA.
      Following informed consent, patients will be randomised to CO UKA (control group)
      or RO UKA (investigation group) at a ratio of 1:1 using an online random number
      generator. The primary objective of this study is to compare accuracy of implant 
      positioning in CO UKA versus RO UKA. The secondary objectives are to compare the 
      following outcomes between the two treatment groups: limb alignment, surgical
      efficiency, postoperative functional rehabilitation, functional outcomes, quality
      of life, range of motion, resource use, cost effectivness, and complications.
      Observers will review patients at regular intervals for 2 years after surgery to 
      record predefined study outcomes pertaining to these objectives. Ethical approval
      was obtained from the London-Bloomsbury Research Ethics Committee, UK. The study 
      is sponsored by University College London, UK. DISCUSSION: This study compares a 
      comprehensive and robust range of clinical, functional, and radiological outcomes
      in CO UKA versus RO UKA. The findings of this study will provide an improved
      understanding of the differences in CO UKA versus RO UKA with respect to accuracy
      of implant positioning, patient satisfaction, functional outcomes, implant
      survivorship, cost-effectiveness, and complications. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT04095637 . Registered on 19 September 2019.
FAU - Kayani, Babar
AU  - Kayani B
AUID- ORCID: http://orcid.org/0000-0001-6611-3989
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK. babar.kayani@gmail.com.
FAU - Konan, Sujith
AU  - Konan S
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Tahmassebi, Jenni
AU  - Tahmassebi J
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Ayuob, Atif
AU  - Ayuob A
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Moriarty, Peter D
AU  - Moriarty PD
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Haddad, Fares S
AU  - Haddad FS
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04095637
GR  - 25009/Stryker
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200817
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Knee/*methods
MH  - Humans
MH  - Knee Joint/diagnostic imaging/surgery
MH  - London
MH  - Middle Aged
MH  - *Osteoarthritis, Knee/surgery
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Robotic Surgical Procedures
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7430022
EDAT- 2020/08/19 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - 10.1186/s13063-020-04631-5 [doi]
AID - 10.1186/s13063-020-04631-5 [pii]
PST - epublish
SO  - Trials. 2020 Aug 17;21(1):721. doi: 10.1186/s13063-020-04631-5.


PMID- 32807149
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 17
TI  - Home mechanical ventilation: quality of life patterns after six months of
      treatment.
PG  - 221
LID - 10.1186/s12890-020-01262-z [doi]
AB  - BACKGROUND: It has been shown that home mechanical ventilation improves quality
      of life, but it has not been widely studied which particular patient groups
      benefit the most from starting this type of therapy. The purpose of this
      prospective observational study was to evaluate quality of life change patterns 6
      months after initiation of home mechanical ventilation in patients suffering from
      chronic respiratory failure using patient reported outcomes. METHODS: We enrolled
      74 chronic respiratory failure patients starting invasive or noninvasive home
      mechanical ventilation through the Semmelweis University Home Mechanical
      Ventilation Program. Quality of life was evaluated at baseline and at 6 months
      after initiation of home mechanical ventilation using the Severe Respiratory
      Insufficiency Questionnaire. RESULTS: Overall quality of life showed 10.5%
      improvement 6 months after initiation of home mechanical ventilation (p < 0.001).
      The greatest improvement was observed in Respiratory complaint (20.4%, p =
      0.015), Sleep and attendant symptoms (19.3%, p < 0.001), and Anxiety related
      subscales (14.4%, p < 0.001). Interface (invasive versus noninvasive ventilation)
      was not associated with improvement in quality of life (p = 0.660). Severely
      impaired patients showed the greatest improvement (CC = -0.328, p < 0.001).
      Initial diagnosis contributed to the observed change (p = 0.025), with chronic
      obstructive pulmonary disease and obesity hypoventilation syndrome patients
      showing the greatest improvement, while amyotrophic lateral sclerosis patients
      showed no improvement in quality of life. We found that patients who were started
      on long term ventilation in an acute setting, required oxygen supplementation and
      had low baseline quality of life, showed the most improvement during the
      six-month study period. CONCLUSIONS: Our study highlights the profound effect of 
      home mechanical ventilation on quality of life in chronic respiratory failure
      patients that is indifferent of ventilation interface but is dependent on initial
      diagnosis and some baseline characteristics, like acute initiation, oxygen
      supplementation need and baseline quality of life. TRIAL REGISTRATION: This study
      was approved by and registered at the ethics committee of Semmelweis University
      (SE TUKEB 251/2017; 20th of December, 2017).
FAU - Valko, Luca
AU  - Valko L
AUID- ORCID: http://orcid.org/0000-0002-4046-4681
AD  - Department of Anesthesiology and Intensive Therapy, Semmelweis University, Ulloi 
      ut 78/B, Budapest, 1082, Hungary. valko.luca@med.semmelweis-univ.hu.
FAU - Baglyas, Szabolcs
AU  - Baglyas S
AD  - Department of Anesthesiology and Intensive Therapy, Semmelweis University, Ulloi 
      ut 78/B, Budapest, 1082, Hungary.
FAU - Gyarmathy, V Anna
AU  - Gyarmathy VA
AD  - EpiConsult, Dover, DE, USA.
AD  - Johns Hopkins Bloomberg School of Public Health, Karoly Racz School of PhD
      Studies, Semmelweis University, 8 the Green, STE A, Dover, DE, 19904, USA.
FAU - Gal, Janos
AU  - Gal J
AD  - Department of Anesthesiology and Intensive Therapy, Semmelweis University, Ulloi 
      ut 78/B, Budapest, 1082, Hungary.
FAU - Lorx, Andras
AU  - Lorx A
AD  - Department of Anesthesiology and Intensive Therapy, Semmelweis University, Ulloi 
      ut 78/B, Budapest, 1082, Hungary.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200817
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amyotrophic Lateral Sclerosis/physiopathology
MH  - Female
MH  - *Home Care Services, Hospital-Based
MH  - Humans
MH  - Hungary
MH  - Male
MH  - Middle Aged
MH  - Obesity Hypoventilation Syndrome/physiopathology
MH  - Prospective Studies
MH  - Pulmonary Disease, Chronic Obstructive/physiopathology
MH  - Quality of Life/*psychology
MH  - Respiration, Artificial/*methods/psychology
MH  - Respiratory Function Tests
MH  - Respiratory Insufficiency/physiopathology/psychology/*therapy
MH  - Surveys and Questionnaires
PMC - PMC7433042
OTO - NOTNLM
OT  - Chronic respiratory failure
OT  - Domiciliary ventilation
OT  - Home mechanical ventilation
OT  - Long term ventilation
OT  - Quality of life change
EDAT- 2020/08/19 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
AID - 10.1186/s12890-020-01262-z [doi]
AID - 10.1186/s12890-020-01262-z [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Aug 17;20(1):221. doi: 10.1186/s12890-020-01262-z.


PMID- 32806999
OWN - NLM
STAT- MEDLINE
DCOM- 20220411
LR  - 20220411
IS  - 1361-6609 (Electronic)
IS  - 0963-6625 (Linking)
VI  - 29
IP  - 7
DP  - 2020 Oct
TI  - Examining diversity in public willingness to participate in offshore human
      biobanking: An Australian mixed methods study.
PG  - 757-769
LID - 10.1177/0963662520948034 [doi]
AB  - To ensure their sustainability and scientific utility, human biobanks are
      networking internationally. Sharing biospecimens and associated data across
      jurisdictions raise a number of practical, ethical, legal and social challenges
      that could reduce the publics' willingness to donate their much needed tissue for
      research purposes. This research aims to identify the impact of biobank location 
      on willingness to donate through a national quantitative survey (n = 750) and 16 
      in-depth interviews. A latent class analysis in combination with qualitative
      results suggests that a large proportion of Australians are willing to donate
      and/or allow their tissue to be stored offshore to help others, but others are
      reluctant due to uncertainty around foreign ethical and regulatory standards and 
      the loss of potential local benefits. The results highlight for the first time
      the diversity of public views, and provide important guidance for policy makers
      and science communicators eager to tailor strategies for specific publics.
FAU - Critchley, Christine
AU  - Critchley C
AUID- ORCID: 0000-0001-9376-5229
AD  - Swinburne University of Technology, Australia.
AD  - University of Tasmania, Australia.
FAU - Wiersma, Miriam
AU  - Wiersma M
FAU - Lipworth, Wendy
AU  - Lipworth W
FAU - Light, Edwina
AU  - Light E
AUID- ORCID: 0000-0003-2195-7146
FAU - Dive, Lisa
AU  - Dive L
AUID- ORCID: 0000-0001-6655-5138
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - University of Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200817
PL  - England
TA  - Public Underst Sci
JT  - Public understanding of science (Bristol, England)
JID - 9306503
MH  - Australia
MH  - *Biological Specimen Banks
MH  - *Biomedical Research
MH  - Humans
OTO - NOTNLM
OT  - *perceptions
OT  - *public participation
OT  - *science attitudes
EDAT- 2020/08/19 06:00
MHDA- 2022/04/12 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2022/04/12 06:00 [medline]
PHST- 2020/08/19 06:00 [entrez]
AID - 10.1177/0963662520948034 [doi]
PST - ppublish
SO  - Public Underst Sci. 2020 Oct;29(7):757-769. doi: 10.1177/0963662520948034. Epub
      2020 Aug 17.


PMID- 32806372
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 738
DP  - 2020 Oct 10
TI  - In-vitro prediction of the membranotropic action of emerging organic contaminants
      using a liposome-based multidisciplinary approach.
PG  - 140096
LID - S0048-9697(20)33616-0 [pii]
LID - 10.1016/j.scitotenv.2020.140096 [doi]
AB  - According to ISO 17402:2008 more knowledge is needed on processes controlling
      bioavailability of organic species so as to close the still existing gap between 
      chemical measurements and biological effects. The bioavailability concept
      encompasses the investigation of the degree of penetration of target species
      across biological membranes. In addition, REACH (Registration, Evaluation,
      Authorisation and restriction of Chemicals) guidelines promote the use of
      in-vitro methods against conventional ecotoxicological tests because of the
      ethical controversy of in-vivo tests. This work is aimed at filling the gap by
      proposing a multidisciplinary approach based on high-resolution and
      low-resolution empirical techniques, and theoretical quantum mechanics for the
      in-vitro investigation of the bioavailability and membranotropic effects of
      organic emerging contaminants, including bioaccumulation, via passive diffusion
      across lipid bilayers. Phosphatidylcholine (PC) liposomes are selected as
      biomembrane surrogates, and contaminant effects are explored by (i) fluorescence 
      anisotropy and generalized polarization assays using membrane fluorescence probes
      (laurdan and prodan) and UV-Vis spectroscopy, (ii) (1)H NMR measurements to
      ascertain supramolecular interactions with PC and (iii) molecular dynamics
      simulations. In particular, un-regulated model compounds with distinct
      physico-chemical properties that are representative of three different classes of
      emerging contaminants in environmental compartments are chosen for validation of 
      the holistic approach: (i) diclofenac as a model of anti-inflammatory drug; (ii) 
      triclosan as an anti-microbial agent; and (iii) bisphenol A as a plastic-borne
      compound, and compared with chlorpyrifos as a legacy insecticide. Laurdan
      anisotropic measurements are in good agreement with (1)H NMR data and both
      approaches pinpoint that triclosan and chlorpyrifos are highly bioaccumulative in
      membranes. Molecular dynamic studies indicate that the lateral diffusion of the
      lipid bilayer is much lower with the incorporation of either triclosan or
      chlorpyrifos into the bilayer. The theoretical simulations also allowed
      estimating absolute bioavailability data under passive diffusion (<0.1%, 63%, 73%
      and 89% for diclofenac, bisphenol A, triclosan and chlorpyrifos, respectively)
      given as the percentage of time that a given species is located in the region of 
      the fatty acyl chains. Our findings indicate that PC-based liposome assays serve 
      as a fast and cost-effective in-vitro approach, notwithstanding its low
      resolution features, for environmental bioavailability studies of emerging
      contaminants for which insufficient or inconsistent ecotoxicological data are
      identified in the literature.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Oliver, Miquel
AU  - Oliver M
AD  - FI-TRACE Group, Department of Chemistry, University of the Balearic Islands,
      Carretera de Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
FAU - Adrover, Miquel
AU  - Adrover M
AD  - REACMOL Group, Department of Chemistry, University of the Balearic Islands,
      Carretera de Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
FAU - Frontera, Antonio
AU  - Frontera A
AD  - SUPRAMOL Group, Department of Chemistry, University of the Balearic Islands,
      Carretera de Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
FAU - Ortega-Castro, Joaquin
AU  - Ortega-Castro J
AD  - REACMOL Group, Department of Chemistry, University of the Balearic Islands,
      Carretera de Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
FAU - Miro, Manuel
AU  - Miro M
AD  - FI-TRACE Group, Department of Chemistry, University of the Balearic Islands,
      Carretera de Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain. Electronic
      address: manuel.miro@uib.es.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Liposomes)
RN  - 0 (Phosphatidylcholines)
RN  - 4NM5039Y5X (Triclosan)
SB  - IM
MH  - Biological Availability
MH  - Diffusion
MH  - *Liposomes
MH  - Phosphatidylcholines
MH  - *Triclosan
OTO - NOTNLM
OT  - Bioavailability
OT  - Emerging contaminants
OT  - Lipid bilayer
OT  - Liposome
OT  - Membrane
OT  - Permeability
COIS- Declaration of competing interest The authors declare that there is no conflict
      of interest to disclose.
EDAT- 2020/08/19 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/08/19 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - S0048-9697(20)33616-0 [pii]
AID - 10.1016/j.scitotenv.2020.140096 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Oct 10;738:140096. doi: 10.1016/j.scitotenv.2020.140096. 
      Epub 2020 Jun 10.


PMID- 32805703
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep 17
TI  - A New Era of Epidemiology: Digital Epidemiology for Investigating the COVID-19
      Outbreak in China.
PG  - e21685
LID - 10.2196/21685 [doi]
AB  - A novel pneumonia-like coronavirus disease (COVID-19) caused by a novel
      coronavirus named SARS-CoV-2 has swept across China and the world. Public health 
      measures that were effective in previous infection outbreaks (eg, wearing a face 
      mask, quarantining) were implemented in this outbreak. Available multidimensional
      social network data that take advantage of the recent rapid development of
      information and communication technologies allow for an exploration of disease
      spread and control via a modernized epidemiological approach. By using
      spatiotemporal data and real-time information, we can provide more accurate
      estimates of disease spread patterns related to human activities and enable more 
      efficient responses to the outbreak. Two real cases during the COVID-19 outbreak 
      demonstrated the application of emerging technologies and digital data in
      monitoring human movements related to disease spread. Although the ethical issues
      related to using digital epidemiology are still under debate, the cases reported 
      in this article may enable the identification of more effective public health
      measures, as well as future applications of such digitally directed
      epidemiological approaches in controlling infectious disease outbreaks, which
      offer an alternative and modern outlook on addressing the long-standing
      challenges in population health.
CI  - (c)Zonglin He, Casper J P Zhang, Jian Huang, Jingyan Zhai, Shuang Zhou, Joyce
      Wai-Ting Chiu, Jie Sheng, Winghei Tsang, Babatunde O Akinwunmi, Wai-Kit Ming.
      Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 17.09.2020.
FAU - He, Zonglin
AU  - He Z
AUID- ORCID: 0000-0001-7650-1459
AD  - Department of Public Health and Preventive Medicine, School of Medicine, Jinan
      University, Guangzhou, China.
AD  - Faculty of Medicine, International School, Jinan University, Guangzhou, China.
FAU - Zhang, Casper J P
AU  - Zhang CJP
AUID- ORCID: 0000-0003-1047-0287
AD  - School of Public Health, LKS Faculty of Medicine, The University of Hong Kong,
      Hong Kong, China.
FAU - Huang, Jian
AU  - Huang J
AUID- ORCID: 0000-0002-3931-5013
AD  - MRC Centre for Environment and Health, Department of Epidemiology and
      Biostatistics, School of Public Health, St Mary's Campus, Imperial College
      London, London, United Kingdom.
FAU - Zhai, Jingyan
AU  - Zhai J
AUID- ORCID: 0000-0003-1307-1548
AD  - Department of Public Health and Preventive Medicine, School of Medicine, Jinan
      University, Guangzhou, China.
FAU - Zhou, Shuang
AU  - Zhou S
AUID- ORCID: 0000-0002-5086-4670
AD  - Department of Public Health and Preventive Medicine, School of Medicine, Jinan
      University, Guangzhou, China.
FAU - Chiu, Joyce Wai-Ting
AU  - Chiu JW
AUID- ORCID: 0000-0002-0406-9676
AD  - Faculty of Medicine, International School, Jinan University, Guangzhou, China.
FAU - Sheng, Jie
AU  - Sheng J
AUID- ORCID: 0000-0001-5912-8410
AD  - College of Economics, Jinan University, Guangzhou, China.
FAU - Tsang, Winghei
AU  - Tsang W
AUID- ORCID: 0000-0003-4350-3559
AD  - Department of Public Health and Preventive Medicine, School of Medicine, Jinan
      University, Guangzhou, China.
FAU - Akinwunmi, Babatunde O
AU  - Akinwunmi BO
AUID- ORCID: 0000-0001-8316-1552
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Harvard University, 
      Boston, MA, United States.
AD  - Pulmonary & Critical Care Medicine Unit, Asthma Research Center, Brigham and
      Women's Hospital, Harvard Medical School, Boston, MA, United States.
FAU - Ming, Wai-Kit
AU  - Ming WK
AUID- ORCID: 0000-0002-8846-7515
AD  - Department of Public Health and Preventive Medicine, School of Medicine, Jinan
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology/*virology
MH  - Disease Outbreaks/*statistics & numerical data
MH  - *Epidemiologic Methods
MH  - Humans
MH  - Masks
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*virology
MH  - Quarantine/statistics & numerical data
MH  - SARS-CoV-2
PMC - PMC7511225
OTO - NOTNLM
OT  - *COVID-19
OT  - *China
OT  - *case study
OT  - *control
OT  - *digital epidemiology
OT  - *epidemiology
OT  - *outbreak
OT  - *public health
OT  - *risk
EDAT- 2020/08/18 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/06/22 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - v22i9e21685 [pii]
AID - 10.2196/21685 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Sep 17;22(9):e21685. doi: 10.2196/21685.


PMID- 32805638
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220207
IS  - 1872-9614 (Electronic)
IS  - 0969-8051 (Linking)
VI  - 88-89
DP  - 2020 Sep-Oct
TI  - GMP production of [(68)Ga]Ga-BOT5035 for imaging of liver fibrosis in microdosing
      phase 0 study.
PG  - 73-85
LID - S0969-8051(20)30183-9 [pii]
LID - 10.1016/j.nucmedbio.2020.07.009 [doi]
AB  - INTRODUCTION: Early detection of liver fibrosis and monitoring response to
      treatment crucial for the management of patients are currently not feasible in
      clinical practice. Platelet derived growth factor receptor beta (PDGFR-beta)
      expression is regarded as a potential biomarker to determine the stages of
      fibrotic diseases including liver fibrosis. [(68)Ga]Ga-BOT5035 comprising a
      bicyclic peptide was developed for specific targeting of PDGFR-beta overexpressed
      in pathological fibrosis. The realization of microdosing phase 0 study using
      [(68)Ga]Ga-BOT5035 positron emission tomography required automated good
      manufacturing practice (GMP) compliant production of [(68)Ga]Ga-BOT5035 presented
      herein. Moreover, the investigation of radiation dosimetry was conducted to
      ensure possibility of multiple annual examinations for disease monitoring in
      clinical setup. METHODS: The active pharmaceutical ingredient starting material
      BOT5035 (GMP grade) was provided by BiOrion Technologies BV. The (68)Ga-labelling
      process was developed and automated using synthesis platform (Modular-Lab
      PharmTrace, Eckert & Ziegler), disposable cassettes for (68)Ga-labelling, and
      pharmaceutical grade (68)Ge/(68)Ga generator (GalliaPharm(R)) purchased from
      Eckert & Ziegler. Radiolysis sensitive BOT5035 required development and
      systematic optimization of the labelling synthesis parameters such as time,
      temperature, precursor concentration, radical scavenger, buffer concentration and
      pH. The validation process was conducted with regard to the product quality and
      quantity, as well as production reproducibility. Human organ equivalent doses and
      total body effective doses were calculated using Organ Level Internal Dose
      Assessment Code software (OLINDA/EXM 1.1), based on ex vivo organ distribution in
      Sprague-Dawley rats. RESULTS: The GMP compliant automated production of
      [(68)Ga]Ga-BOT5035 with on-line documentation demonstrated high reproducibility. 
      The time for the labelling synthesis and quality control was approximately 60min.
      The non-decay corrected radiochemical yield and radiochemical purity of the
      radiopharmaceutical were 43.7+/-7.6% (n=3, process validation) and 97.7+/-0.4%
      (n=3, process validation), respectively. Predefined acceptance criteria were met 
      for the sterility, endotoxins level, radionuclidic purity and residual solvent
      content. The stability at ambient temperature was controlled for 120min with
      approved results. Ex vivo organ distribution data revealed fast blood clearance
      and washout from most of the organs. The dose-limiting organs were kidney and
      bone marrow. The total effective dose as limiting parameter would allow for up to
      3-4 PET scans per annum. CONCLUSION: The fully automated and GMP compliant
      production of [(68)Ga]Ga-BOT5035 was developed and thoroughly validated. The
      radiopharmaceutical was approved by Swedish Medicinal Products Agency and the
      Ethical Review Authority for the Phase 0 clinical study of the quantitative
      imaging of liver fibrosis. Human dosimetry calculations extrapolated from animal 
      experiment indicated possibility of 3-4 PET examinations per year.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Velikyan, Irina
AU  - Velikyan I
AD  - Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
      Electronic address: irina.velikyan@akademiska.se.
FAU - Doverfjord, Johan G
AU  - Doverfjord JG
AD  - PET Center, Center for Medical Imaging, Uppsala University Hospital, Uppsala,
      Sweden.
FAU - Estrada, Sergio
AU  - Estrada S
AD  - Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
FAU - Steen, Herman
AU  - Steen H
AD  - BiOrion Technologies BV, The Netherlands.
FAU - Van Scharrenburg, Guus
AU  - Van Scharrenburg G
AD  - BiOrion Technologies BV, The Netherlands.
FAU - Antoni, Gunnar
AU  - Antoni G
AD  - Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; PET
      Center, Center for Medical Imaging, Uppsala University Hospital, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - United States
TA  - Nucl Med Biol
JT  - Nuclear medicine and biology
JID - 9304420
RN  - 0 (Gallium Radioisotopes)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Drug Industry/*standards
MH  - Female
MH  - Gallium Radioisotopes/*metabolism
MH  - Humans
MH  - Liver Cirrhosis/diagnostic imaging/metabolism/*pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Peptides, Cyclic/*metabolism
MH  - Positron-Emission Tomography
MH  - Radiopharmaceuticals/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - *Automation
OT  - *GMP
OT  - *Gallium-68
OT  - *Liver fibrosis
OT  - *Plateled derived growth factor receptor beta
OT  - *Radiopharmaceuticals
COIS- Disclosures Herman Steen and Guus van Scharrenburg are an employee of BiOrion
      Technologies BV. Otherwise, the authors have nothing to disclose.
EDAT- 2020/08/18 06:00
MHDA- 2022/02/08 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/06/17 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - S0969-8051(20)30183-9 [pii]
AID - 10.1016/j.nucmedbio.2020.07.009 [doi]
PST - ppublish
SO  - Nucl Med Biol. 2020 Sep-Oct;88-89:73-85. doi: 10.1016/j.nucmedbio.2020.07.009.
      Epub 2020 Jul 31.


PMID- 32805448
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20211204
IS  - 1878-0849 (Electronic)
IS  - 1769-7212 (Linking)
VI  - 63
IP  - 11
DP  - 2020 Nov
TI  - Compassionate use of everolimus for refractory epilepsy in a patient with MTOR
      mosaic mutation.
PG  - 104036
LID - S1769-7212(20)30372-4 [pii]
LID - 10.1016/j.ejmg.2020.104036 [doi]
AB  - The MTOR gene encodes the mechanistic target of rapamycin (mTOR), which is a core
      component of the PI3K-AKT-mTOR signaling pathway. Postzygotic MTOR variants
      result in various mosaic phenotypes, referred to in OMIM as Smith-Kinsgmore
      syndrome or focal cortical dysplasia. We report here the case of a patient, with 
      an MTOR mosaic gain-of-function variant (p.Glu2419Lys) in the DNA of 41% skin
      cells, who received compassionate off-label treatment with everolimus for
      refractory epilepsy. This 12-year-old-girl presented with psychomotor regression,
      intractable seizures, hypopigmentation along Blaschko's lines (hypomelanosis of
      Ito), asymmetric regional body overgrowth, and ocular anomalies, as well as left 
      cerebral hemispheric hypertrophy with some focal underlying migration disorders. 
      In response to the patient's increasingly frequent epileptic seizures, everolimus
      was initiated (after approval from the hospital ethics committee) at 5 mg/day and
      progressively increased to 12.5 mg/day. After 5 months of close monitoring
      (including neuropsychological and electroencephalographic assessment), no
      decrease in seizure frequency was observed. Though the physiopathological
      rationale was good, no significant clinical response was noticed under everolimus
      treatment. A clinical trial would be needed to draw conclusions, but, because the
      phenotype is extremely rare, it would certainly need to be conducted on an
      international scale.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Hadouiri, Nawale
AU  - Hadouiri N
AD  - Centre de Genetique et Centre de Reference Anomalies du Developpement et
      Syndromes Malformatifs de l'Interregion Est, CHU Dijon Bourgogne, 21079, Dijon,
      France.
FAU - Darmency, Veronique
AU  - Darmency V
AD  - Service de Neurophysiologie Clinique, Hopital d'Enfants, CHU Dijon Bourgogne,
      21079, Dijon, France.
FAU - Guibaud, Laurent
AU  - Guibaud L
AD  - Radiologie Pediatrique, Hopital Femme Mere Enfant (HFME), Bron, France.
FAU - Arzimanoglou, Alexis
AU  - Arzimanoglou A
AD  - Service d'epileptologie Clinique, des Troubles du Sommeil et de Neurologie
      Fonctionnelle de l'enfant, Coordinateur du Reseau Europeen pour les epilepsies
      Rares et Complexes, ERN EpiCARE, HCL - GH Est, Hopital Femme Mere Enfant, Bron,
      France.
FAU - Sorlin, Arthur
AU  - Sorlin A
AD  - Centre de Genetique et Centre de Reference Anomalies du Developpement et
      Syndromes Malformatifs de l'Interregion Est, CHU Dijon Bourgogne, 21079, Dijon,
      France; Genetique des Anomalies du Developpement, UMR1231, Universite de
      Bourgogne, 21079, Dijon, France.
FAU - Carmignac, Virginie
AU  - Carmignac V
AD  - Genetique des Anomalies du Developpement, UMR1231, Universite de Bourgogne,
      21079, Dijon, France.
FAU - Riviere, Jean-Baptiste
AU  - Riviere JB
AD  - Genetique des Anomalies du Developpement, UMR1231, Universite de Bourgogne,
      21079, Dijon, France; Federation Hospitalo-Universitaire Medecine
      Translationnelle et Anomalies du Developpement (TRANSLAD), CHU Dijon Bourgogne,
      21079, Dijon, France.
FAU - Huet, Frederic
AU  - Huet F
AD  - Service de Neurophysiologie Clinique, Hopital d'Enfants, CHU Dijon Bourgogne,
      21079, Dijon, France.
FAU - Luu, Maxime
AU  - Luu M
AD  - Centre d'Investigation Clinique Plurithematique, CHU Dijon Bourgogne, 21079,
      Dijon, France.
FAU - Bardou, Marc
AU  - Bardou M
AD  - Centre d'Investigation Clinique Plurithematique, CHU Dijon Bourgogne, 21079,
      Dijon, France.
FAU - Thauvin-Robinet, Christel
AU  - Thauvin-Robinet C
AD  - Genetique des Anomalies du Developpement, UMR1231, Universite de Bourgogne,
      21079, Dijon, France; Federation Hospitalo-Universitaire Medecine
      Translationnelle et Anomalies du Developpement (TRANSLAD), CHU Dijon Bourgogne,
      21079, Dijon, France; Centre de Reference Deficiences Intellectuelles de Causes
      Rares Defi-Bourgogne, CHU Dijon Bourgogne, 21079, Dijon, France.
FAU - Vabres, Pierre
AU  - Vabres P
AD  - Genetique des Anomalies du Developpement, UMR1231, Universite de Bourgogne,
      21079, Dijon, France; Federation Hospitalo-Universitaire Medecine
      Translationnelle et Anomalies du Developpement (TRANSLAD), CHU Dijon Bourgogne,
      21079, Dijon, France; Centre de Reference des Maladies Rares de la Peau et des
      Muqueuses d'origine Genetique (MAGEC), CHU Dijon Bourgogne, 21079, Dijon, France.
FAU - Faivre, Laurence
AU  - Faivre L
AD  - Centre de Genetique et Centre de Reference Anomalies du Developpement et
      Syndromes Malformatifs de l'Interregion Est, CHU Dijon Bourgogne, 21079, Dijon,
      France; Genetique des Anomalies du Developpement, UMR1231, Universite de
      Bourgogne, 21079, Dijon, France; Federation Hospitalo-Universitaire Medecine
      Translationnelle et Anomalies du Developpement (TRANSLAD), CHU Dijon Bourgogne,
      21079, Dijon, France. Electronic address: laurence.faivre@chu-dijon.fr.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200814
PL  - Netherlands
TA  - Eur J Med Genet
JT  - European journal of medical genetics
JID - 101247089
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - Cortical Dysplasia-Focal Epilepsy Syndrome
SB  - IM
MH  - Child
MH  - *Compassionate Use Trials
MH  - Craniofacial Abnormalities/*drug therapy/genetics
MH  - Epilepsies, Partial/*drug therapy/genetics
MH  - Everolimus/administration & dosage/*therapeutic use
MH  - Female
MH  - *Gain of Function Mutation
MH  - Humans
MH  - Malformations of Cortical Development/*drug therapy/genetics
MH  - Mosaicism
MH  - Phenotype
MH  - Protein Kinase Inhibitors/administration & dosage/*therapeutic use
MH  - TOR Serine-Threonine Kinases/*genetics
OTO - NOTNLM
OT  - Everolimus
OT  - Mosaic mTOR mutation
OT  - Seizures
OT  - Therapy in rare diseases
OT  - mTOR
EDAT- 2020/08/18 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - S1769-7212(20)30372-4 [pii]
AID - 10.1016/j.ejmg.2020.104036 [doi]
PST - ppublish
SO  - Eur J Med Genet. 2020 Nov;63(11):104036. doi: 10.1016/j.ejmg.2020.104036. Epub
      2020 Aug 14.


PMID- 32805446
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 1878-0849 (Electronic)
IS  - 1769-7212 (Linking)
VI  - 63
IP  - 11
DP  - 2020 Nov
TI  - Disclosing genetic information to family members without consent: Five Australian
      case studies.
PG  - 104035
LID - S1769-7212(20)30583-8 [pii]
LID - 10.1016/j.ejmg.2020.104035 [doi]
AB  - Genetic risk information is relevant to individual patients and also their blood 
      relatives. Health practitioners (HPs) routinely advise patients of the importance
      of sharing genetic information with family members, especially for clinically
      actionable conditions where prevention is possible. However, some patients refuse
      to share genetic results with at-risk relatives, and HPs must choose whether to
      use or disclose genetic information without consent. This requires an
      understanding of their legal and ethical obligations, which research shows many
      HPs do not have. A recent UK case held that HPs have a duty to a patient's
      relatives where there is a proximate relationship, to conduct a balancing
      exercise of the benefit of disclosure of the genetic risk information to the
      relative against the interest of the patient in maintaining confidentiality. In
      Australia, there is currently no legal duty to disclose genetic information to a 
      patient's at-risk relatives, but there are laws and guidelines governing
      unconsented use/disclosure of genetic information. These laws are inconsistent
      across different Australian states and health contexts, requiring greater
      harmonisation. Here we provide an up-to-date and clinically accessible resource
      summarising the laws applying to HPs across Australia, and outline five
      Australian case studies which have arisen in clinical genetics services,
      regarding the disclosure of genetic results to relatives without consent. The
      issues addressed here are relevant to any Australian HP with access to genetic
      information, as well as HPs and policy-makers in other jurisdictions considering 
      these issues.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Tiller, Jane
AU  - Tiller J
AD  - Public Health Genomics, Monash University, Melbourne, Australia. Electronic
      address: jane.tiller@monash.edu.
FAU - Bilkey, Gemma
AU  - Bilkey G
AD  - Western Australian Department of Health, Perth, Australia.
FAU - Macintosh, Rebecca
AU  - Macintosh R
AD  - Centre for Clinical Genetics, Sydney Children's Hospitals Network, Australia.
FAU - O'Sullivan, Sarah
AU  - O'Sullivan S
AD  - Genetic Services of Western, Australia.
FAU - Groube, Stephanie
AU  - Groube S
AD  - Tasmanian Clinical Genetics Service, Australia.
FAU - Palover, Marili
AU  - Palover M
AD  - Institute of Genomics, University of Tartu, Estonia.
FAU - Pachter, Nicholas
AU  - Pachter N
AD  - Genetic Services of Western, Australia.
FAU - Rothstein, Mark
AU  - Rothstein M
AD  - University of Louisville School of Medicine, USA.
FAU - Lacaze, Paul
AU  - Lacaze P
AD  - Public Health Genomics, Monash University, Melbourne, Australia.
FAU - Otlowski, Margaret
AU  - Otlowski M
AD  - University of Tasmania, Australia.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20200814
PL  - Netherlands
TA  - Eur J Med Genet
JT  - European journal of medical genetics
JID - 101247089
SB  - IM
MH  - Australia
MH  - Duty to Warn/ethics/*legislation & jurisprudence
MH  - *Family
MH  - *Genetic Predisposition to Disease
MH  - Genetic Privacy/ethics/legislation & jurisprudence
MH  - Humans
MH  - Informed Consent/ethics/legislation & jurisprudence
OTO - NOTNLM
OT  - Disclosure
OT  - Duty to warn
OT  - Ethics
OT  - Genetics
OT  - Relatives
EDAT- 2020/08/18 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/06/25 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - S1769-7212(20)30583-8 [pii]
AID - 10.1016/j.ejmg.2020.104035 [doi]
PST - ppublish
SO  - Eur J Med Genet. 2020 Nov;63(11):104035. doi: 10.1016/j.ejmg.2020.104035. Epub
      2020 Aug 14.


PMID- 32805358
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 1879-176X (Electronic)
IS  - 0300-5712 (Linking)
VI  - 102
DP  - 2020 Nov
TI  - Reporting of conflict of interest and sponsorship in dental journals.
PG  - 103452
LID - S0300-5712(20)30198-6 [pii]
LID - 10.1016/j.jdent.2020.103452 [doi]
AB  - OBJECTIVE: Detailed information on potential conflict of interest (COI) and
      sponsorship is pivotal for the adequate understanding and appropriate
      interpretation of the reported study results. The reporting of COI and
      sponsorship and any potential associations with study characteristics in
      publications of all dental journals with impact factor was examined. METHODS: The
      Web of Science database was searched, in March 2019, for articles published from 
      February 28, 2018 to March 1, 2019. A random a sample of 1000 articles in English
      was selected. Two independent authors extracted the following article
      characteristics: type of article, dental field, number of authors,
      country/continent affiliation of the first author, dental journal, journal impact
      factor, number of citations, Altmetric score, type of COI and sponsorship.
      Disagreements during data extraction were resolved by discussion and consensus.
      Descriptive statistics were calculated for the selected variables and multinomial
      logistic regression was implemented to assess the association between COI,
      sponsorship, and the other variables. RESULTS: 3% of dental publications declared
      a COI, whereas in 32.5% of publications the presence of COI was unclear. The most
      prevalent type of COI was financial (n = 26). Non-profit organizations funded
      37.2% of the articles, while the sponsorship for 40.4% articles was unclear.
      Regression analysis showed that publications reporting COI had greater odds of
      receiving sponsorship from for-profit sources. CONCLUSIONS: Sponsorship and COI
      information seem to be underreported in dental journals. Efforts should be made
      by authors, journals, and publishers to provide more comprehensive information to
      allow the reader to understand the potential impact of sponsorship and COI on
      study results. CLINICAL SIGNIFICANCE: The underreporting of COI and sponsorship
      in dental articles hinders the interpretation of findings by readers. The results
      of the present study bring attention to this important topic as well as guide
      further improvements on the reporting of COI and sponsorship in dental articles.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Faggion, Clovis Mariano Jr
AU  - Faggion CM Jr
AD  - Department of Periodontology and Operative Dentistry, Faculty of Dentistry,
      University Hospital Munster, Munster, Germany. Electronic address:
      clovisfaggion@yahoo.com.
FAU - Pandis, Nikolaos
AU  - Pandis N
AD  - Department of Orthodontics and Dentofacial Orthopedics, Dental School/Medical
      Faculty, University of Bern, Switzerland.
FAU - Cardoso, Gabriela C
AU  - Cardoso GC
AD  - Graduate Program in Dentistry, Federal University of Pelotas, Brazil.
FAU - Rodolfo, Bruna
AU  - Rodolfo B
AD  - School of Dentistry, Federal University of Pelotas, Brazil.
FAU - Morel, Laura L
AU  - Morel LL
AD  - School of Dentistry, Federal University of Pelotas, Brazil.
FAU - Moraes, Rafael R
AU  - Moraes RR
AD  - Graduate Program in Dentistry, Federal University of Pelotas, Brazil; School of
      Dentistry, Federal University of Pelotas, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200815
PL  - England
TA  - J Dent
JT  - Journal of dentistry
JID - 0354422
SB  - IM
MH  - *Conflict of Interest
MH  - Journal Impact Factor
MH  - *Periodicals as Topic
OTO - NOTNLM
OT  - *Conflict of interest
OT  - *medical ethics
OT  - *publishing
EDAT- 2020/08/18 06:00
MHDA- 2021/03/11 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - S0300-5712(20)30198-6 [pii]
AID - 10.1016/j.jdent.2020.103452 [doi]
PST - ppublish
SO  - J Dent. 2020 Nov;102:103452. doi: 10.1016/j.jdent.2020.103452. Epub 2020 Aug 15.


PMID- 32805141
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 10
DP  - 2020 Oct
TI  - Education for the Anthropocene: Planetary health, sustainable health care, and
      the health workforce.
PG  - 1091-1096
LID - 10.1080/0142159X.2020.1798914 [doi]
AB  - Over the past few centuries, human activity has wrought dramatic changes in the
      natural systems that support human life. Planetary health is a useful concept for
      health profession education (HPE) teaching and practice because it situates
      health within a broader understanding of the interdependent socio-ecological
      drivers of human and planetary health. It facilitates novel ways of protecting
      both population health and the natural environment on which human health and
      well-being depends. This paper focuses on the climate crisis as an example of the
      relationship between environmental change, healthcare, and education. We analyze 
      how HPE can help decarbonize the healthcare sector to address both climate change
      and inequity in health outcomes. Based on the healthcare practitioner's mandate
      of beneficence, we propose simple learning objectives to equip HPE graduates with
      the knowledge, skills, and values to create a sustainable health system, using
      carbon emission reductions as an example. These learning objectives can be
      integrated into HPE without adding unduly to the curriculum load.
FAU - Barna, Stefi
AU  - Barna S
AUID- ORCID: 0000-0002-9017-4375
AD  - Centre for Sustainable Healthcare, Oxford, UK.
AD  - Centre for Primary Care and Public Health, Queen Mary University, London, UK.
FAU - Maric, Filip
AU  - Maric F
AUID- ORCID: 0000-0002-1265-6205
AD  - Environmental Physiotherapy Association, Oslo, Norway.
FAU - Simons, Julia
AU  - Simons J
AUID- ORCID: 0000-0002-4276-360X
AD  - University of Cambridge School of Clinical Medicine, Cambridge, UK.
AD  - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
FAU - Kumar, Shashank
AU  - Kumar S
AD  - School of Arts and Sciences, Azim Premji University, Bengaluru, India.
AD  - Ontario Institute for Studies in Education, University of Toronto, Toronto,
      Canada.
FAU - Blankestijn, Peter J
AU  - Blankestijn PJ
AUID- ORCID: 0000-0003-4289-632X
AD  - University Medical Center Utrecht, Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - Climate Change
MH  - *Curriculum
MH  - Delivery of Health Care
MH  - *Health Workforce
MH  - Humans
MH  - Learning
OTO - NOTNLM
OT  - *Curriculum
OT  - *education environment
OT  - *ethics/attitudes
OT  - *multiprofessional
OT  - *public health
EDAT- 2020/08/18 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.1080/0142159X.2020.1798914 [doi]
PST - ppublish
SO  - Med Teach. 2020 Oct;42(10):1091-1096. doi: 10.1080/0142159X.2020.1798914. Epub
      2020 Aug 17.


PMID- 32805133
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 9
DP  - 2020 Nov 3
TI  - Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and
      Hypertension : A Randomized Clinical Trial.
PG  - 685-693
LID - 10.7326/M19-3781 [doi]
AB  - BACKGROUND: Midterm effects of bariatric surgery on patients with obesity and
      hypertension remain uncertain. OBJECTIVE: To determine the 3-year effects of
      Roux-en-Y gastric bypass (RYGB) on blood pressure (BP) compared with medical
      therapy (MT) alone. DESIGN: Randomized clinical trial. (ClinicalTrials.gov:
      NCT01784848). SETTING: Investigator-initiated study at Heart Hospital (HCor), Sao
      Paulo, Brazil. PARTICIPANTS: Patients with hypertension receiving at least 2
      medications at maximum doses or more than 2 medications at moderate doses and
      with a body mass index (BMI) between 30.0 and 39.9 kg/m(2) were randomly assigned
      (1:1 ratio). INTERVENTION: RYGB plus MT or MT alone. MEASUREMENTS: The primary
      outcome was at least a 30% reduction in total number of antihypertensive
      medications while maintaining BP less than 140/90 mm Hg. Key secondary outcomes
      were number of antihypertensive medications, hypertension remission, and BP
      control according to current guidelines (<130/80 mm Hg). RESULTS: Among 100
      patients (76% female; mean BMI, 36.9 kg/m(2) [SD, 2.7]), 88% from the RYGB group 
      and 80% from the MT group completed follow-up. At 3 years, the primary outcome
      occurred in 73% of patients from the RYGB group compared with 11% of patients
      from the MT group (relative risk, 6.52 [95% CI, 2.50 to 17.03]; P < 0.001). Of
      the randomly assigned participants, 35% and 31% from the RYGB group and 2% and 0%
      from the MT group achieved BP less than 140/90 mm Hg and less than 130/80 mm Hg
      without medications, respectively. Median (interquartile range) number of
      medications in the RYGB and MT groups at 3 years was 1 (0 to 2) and 3 (2.8 to 4),
      respectively (P < 0.001). Total weight loss was 27.8% and -0.1% in the RYGB and
      MT groups, respectively. In the RYGB group, 13 patients developed hypovitaminosis
      B12 and 2 patients required reoperation. LIMITATION: Single-center, nonblinded
      trial. CONCLUSION: RYGB is an effective strategy for midterm BP control and
      hypertension remission, with fewer medications required in patients with
      hypertension and obesity. PRIMARY FUNDING SOURCE: Ethicon, represented in Brazil 
      by Johnson & Johnson do Brasil.
FAU - Schiavon, Carlos A
AU  - Schiavon CA
AUID- ORCID: 0000-0003-0798-3997
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AUID- ORCID: 0000-0002-1278-6245
AD  - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School,
      Boston, Massachusetts (D.L.B.).
FAU - Ikeoka, Dimas
AU  - Ikeoka D
AUID- ORCID: 0000-0002-8776-9650
AD  - HCor Intensive Unit, Sao Paulo, Brazil (D.I.).
FAU - Santucci, Eliana V
AU  - Santucci EV
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Santos, Renato Nakagawa
AU  - Santos RN
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Damiani, Lucas P
AU  - Damiani LP
AUID- ORCID: 0000-0002-5836-3379
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Oliveira, Juliana D
AU  - Oliveira JD
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Machado, Rachel Helena V
AU  - Machado RHV
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Halpern, Helio
AU  - Halpern H
AD  - HCor Surgical Center, Sao Paulo, Brazil (H.H., F.L.M., P.M.N.).
FAU - Monteiro, Frederico L J
AU  - Monteiro FLJ
AUID- ORCID: 0000-0002-0974-2313
AD  - HCor Surgical Center, Sao Paulo, Brazil (H.H., F.L.M., P.M.N.).
FAU - Noujaim, Patricia M
AU  - Noujaim PM
AD  - HCor Surgical Center, Sao Paulo, Brazil (H.H., F.L.M., P.M.N.).
FAU - Cohen, Ricardo V
AU  - Cohen RV
AD  - Oswaldo Cruz German Hospital, Sao Paulo, Brazil (R.V.C.).
FAU - de Souza, Marcio G
AU  - de Souza MG
AUID- ORCID: 0000-0001-5460-5476
AD  - Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil (M.G.D.).
FAU - Amodeo, Celso
AU  - Amodeo C
AUID- ORCID: 0000-0002-8523-760X
AD  - Federal University of Sao Paulo, Sao Paulo, Brazil (C.A.).
FAU - Bortolotto, Luiz A
AU  - Bortolotto LA
AD  - University of Sao Paulo Medical School, Sao Paulo, Brazil (L.A.B., L.F.D.).
FAU - Berwanger, Otavio
AU  - Berwanger O
AD  - Albert Einstein Hospital, Sao Paulo, Brazil (O.B.).
FAU - Cavalcanti, Alexandre B
AU  - Cavalcanti AB
AUID- ORCID: 0000-0003-2798-6263
AD  - HCor Research Institute, Sao Paulo, Brazil (C.A.S., E.V.S., R.N.S., L.P.D.,
      J.D.O., R.H.M., A.B.C.).
FAU - Drager, Luciano F
AU  - Drager LF
AD  - University of Sao Paulo Medical School, Sao Paulo, Brazil (L.A.B., L.F.D.).
LA  - eng
SI  - ClinicalTrials.gov/NCT01784848
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200818
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Antihypertensive Agents)
SB  - IM
CIN - Ann Intern Med. 2020 Nov 3;173(9):758-759. PMID: 32805129
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anemia/etiology
MH  - Antihypertensive Agents/*therapeutic use
MH  - *Bariatric Surgery/adverse effects
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Counseling
MH  - Female
MH  - Gastric Bypass
MH  - Humans
MH  - Hyperparathyroidism/etiology
MH  - Hypertension/*complications/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Obesity/*complications/physiopathology/*surgery
MH  - Postoperative Complications
MH  - Remission Induction
MH  - Vitamin B 12 Deficiency/etiology
MH  - Weight Loss
MH  - Young Adult
EDAT- 2020/08/18 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.7326/M19-3781 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Nov 3;173(9):685-693. doi: 10.7326/M19-3781. Epub 2020 Aug
      18.


PMID- 32804923
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220416
IS  - 0717-6384 (Electronic)
IS  - 0717-6384 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Aug 3
TI  - Effectiveness of telerehabilitation in physical therapy: A protocol for an
      overview in a time when rapid responses are needed.
PG  - e7970
LID - 10.5867/medwave.2020.07.7970 [doi]
AB  - INTRODUCTION: Rehabilitation and physical therapy have been adapting to the
      telehealth era, increasing accessibility and improving the continuity of
      attention in geographically remote populations with disabilities. Due to the
      spread of infection by SARS-CoV-2, many professionals have had to adapt their
      work to telerehabilitation practices, which require the best evidence at short
      notice and in summarized form. In this context, this protocol has been developed 
      to evaluate the effectiveness of telerehabilitation as a care strategy in
      physical therapy for different conditions, populations, and contexts. METHOD AND 
      ANALYSIS: An overview will be carried out in the format of a rapid review. It
      will include systematic reviews of different conditions, populations, and
      contexts, where the intervention to be evaluated is telerehabilitation by
      physical therapy. The outcomes considered will be clinical effectiveness
      depending on the specific condition, functionality, quality of life,
      satisfaction, adherence, and safety. A search will be carried out of the
      MEDLINE/PubMed, EMBASE, and Cochrane Library databases. Studies will be selected 
      in duplicate with any discrepancies resolved by a third reviewer. Data extraction
      and risk of bias assessment will be carried out by a reviewer with
      non-independent verification by a second reviewer. The findings will be reported 
      qualitatively by tables and figures. ETHICS AND DISSEMINATION: The principles of 
      the value of the research question, the methodological rigor, scientifically
      qualified investigators, an independent evaluation of the protocol, and timely
      and accurate publication of the results will be complied with. The complete
      review will lead to the publication of at least one article, and the results will
      be widely disseminated at various levels of decision-making. REGISTER: This
      protocol has been registered in PROSPERO with the number CRD42020185640.
FAU - Seron, Pamela
AU  - Seron P
AD  - Departamento Medicina Interna y CIGES, Facultad de Medicina, Universidad de La
      Frontera, Temuco, Chile. Adress: Claro Solar 115, Temuco, Chile. Email:
      pamela.seron@ufrontera.cl. ORCID: 0000-0003-0190-8988.
FAU - Oliveros, Maria-Jose
AU  - Oliveros MJ
AD  - Departamento Medicina Interna y CIGES, Facultad de Medicina, Universidad de La
      Frontera, Temuco, Chile. ORCID: 0000-0002-9327-6844.
FAU - Fuentes-Aspe, Rocio
AU  - Fuentes-Aspe R
AD  - Departamento Medicina Interna y CIGES, Facultad de Medicina, Universidad de La
      Frontera, Temuco, Chile. ORCID: 0000-0002-6463-0963.
FAU - Gutierrez-Arias, Ruvistay
AU  - Gutierrez-Arias R
AD  - Unidad de Paciente Critico, Instituto Nacional del Torax, Santiago, Chile;
      Escuela de Kinesiologia, Facultad de Ciencias de la Rehabilitacion, Universidad
      Andres Bello, Santiago, Chile. ORCID: 0000-0003-1881-9316.
LA  - spa
LA  - eng
PT  - Journal Article
TT  - Efectividad de la telerehabilitacion en terapia fisica: protocolo de una revision
      global en tiempos que exigen respuestas rapidas.
DEP - 20200803
PL  - Chile
TA  - Medwave
JT  - Medwave
JID - 101581949
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - *Physical Therapy Modalities
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Quality of Life
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Telerehabilitation/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - remote physical therapy
OT  - tele-medicine
OT  - telerehabilitation
EDAT- 2020/08/18 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - e7970 [pii]
AID - 10.5867/medwave.2020.07.7970 [doi]
PST - epublish
SO  - Medwave. 2020 Aug 3;20(7):e7970. doi: 10.5867/medwave.2020.07.7970.


PMID- 32804874
OWN - NLM
STAT- MEDLINE
DCOM- 20210720
LR  - 20210720
IS  - 1537-1913 (Electronic)
IS  - 0020-5907 (Linking)
VI  - 58
IP  - 4
DP  - 2020 Fall
TI  - Demystifying research in medical education: a novel framework, resources, and
      ethical challenges.
PG  - 46-51
LID - 10.1097/AIA.0000000000000289 [doi]
FAU - Kurup, Viji
AU  - Kurup V
AD  - Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut.
FAU - Sakai, Tetsuro
AU  - Sakai T
AD  - Department of Anesthesiology and Perioperative Medicine, the Clinical &
      Translational Science Institute (CTSI), University of Pittsburgh School of
      Medicine, Pittsburgh, Pennsylvania.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int Anesthesiol Clin
JT  - International anesthesiology clinics
JID - 0370760
SB  - IM
MH  - *Education, Medical
MH  - Humans
EDAT- 2020/08/18 06:00
MHDA- 2021/07/21 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/07/21 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.1097/AIA.0000000000000289 [doi]
AID - 00004311-202005840-00009 [pii]
PST - ppublish
SO  - Int Anesthesiol Clin. 2020 Fall;58(4):46-51. doi: 10.1097/AIA.0000000000000289.


PMID- 32804597
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20220402
IS  - 2472-5560 (Electronic)
IS  - 2472-5552 (Linking)
VI  - 25
IP  - 10
DP  - 2020 Dec
TI  - Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and
      Pathogenesis: Retrospective Analysis of Sinigrin and Prolixin(RX) (Fluphenazine) 
      Provides Off-Label Drug Candidates.
PG  - 1123-1140
LID - 10.1177/2472555220950236 [doi]
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative
      pathogen of pandemic coronavirus disease 2019 (COVID-19). So far, no approved
      therapy has been developed to halt the spread of the pathogen, and unfortunately,
      the strategies for developing a new therapy will require a long time and very
      extensive resources. Therefore, drug repurposing has emerged as an ideal strategy
      toward a smart, versatile, quick way to confine the lethal disease. In this
      endeavor, natural products have been an untapped source for new drugs. This
      review represents the confederated experience of multidisciplinary researchers of
      99 articles using several databases: Google Scholar, Science Direct, MEDLINE, Web
      of Science, Scopus, and PubMed. To establish the hypothesis, a Bayesian
      perspective of a systematic review was used to outline evidence synthesis. Our
      docking documentation of 69 compounds and future research agenda assumptions were
      directed toward finding an effective and economic anti-COVID-19 treatment from
      natural products. Glucosinolate, flavones, and sulfated nitrogenous compounds
      demonstrate direct anti-SARS-CoV-2 activity through inhibition protease enzymes
      and may be considered potential candidates against coronavirus. These findings
      could be a starting point to initiate an integrative study that may encompass
      interested scientists and research institutes to test the hypothesis in vitro, in
      vivo, and in clinics after satisfying all ethical requirements.
FAU - Nazeam, Jilan
AU  - Nazeam J
AD  - Center of Excellence, Natural Products Unit, Pharmacognosy Department, Faculty of
      Pharmacy, October 6 University, Cairo, Egypt.
FAU - Mohammed, Esraa Z
AU  - Mohammed EZ
AD  - Pharmaceutical Chemistry Department, Faculty of Pharmacy, October 6 University,
      Cairo, Egypt.
FAU - Raafat, Mariam
AU  - Raafat M
AD  - Center of Excellence, Natural Products Unit, Pharmacognosy Department, Faculty of
      Pharmacy, October 6 University, Cairo, Egypt.
FAU - Houssein, Mariam
AU  - Houssein M
AD  - Center of Excellence, Natural Products Unit, Pharmacognosy Department, Faculty of
      Pharmacy, October 6 University, Cairo, Egypt.
FAU - Elkafoury, Asmaa
AU  - Elkafoury A
AD  - Center of Excellence, Natural Products Unit, Pharmacognosy Department, Faculty of
      Pharmacy, October 6 University, Cairo, Egypt.
FAU - Hamdy, Dina
AU  - Hamdy D
AD  - Center of Excellence, Natural Products Unit, Pharmacognosy Department, Faculty of
      Pharmacy, October 6 University, Cairo, Egypt.
FAU - Jamil, Lina
AU  - Jamil L
AD  - Microbiology Department, Faculty of Pharmacy, October 6 University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200817
PL  - United States
TA  - SLAS Discov
JT  - SLAS discovery : advancing life sciences R & D
JID - 101697563
RN  - 0 (Antiviral Agents)
RN  - 0 (Biological Products)
RN  - 0 (Glucosinolates)
RN  - 50UM64RMBJ (sinigrin)
RN  - S79426A41Z (Fluphenazine)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Antiviral Agents/chemistry/*pharmacology
MH  - Bayes Theorem
MH  - Biological Products/chemistry/pharmacology
MH  - COVID-19/*drug therapy/*epidemiology/etiology
MH  - Coronavirus/genetics
MH  - Fluphenazine/chemistry/*pharmacology
MH  - Genetic Predisposition to Disease
MH  - Genetic Variation
MH  - Genome, Viral
MH  - Glucosinolates/chemistry/*pharmacology
MH  - Host-Pathogen Interactions
MH  - Humans
MH  - Middle East Respiratory Syndrome Coronavirus/pathogenicity
MH  - Molecular Docking Simulation
MH  - Off-Label Use
MH  - Pneumonia, Viral/etiology
MH  - Retrospective Studies
MH  - SARS-CoV-2/*genetics/pathogenicity
PMC - PMC8960168
OTO - NOTNLM
OT  - *MERS-CoV
OT  - *Prolixin
OT  - *SARS-CoV
OT  - *SARS-CoV-2
OT  - *sinigrin
OT  - *systematic review
EDAT- 2020/08/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.1177/2472555220950236 [doi]
PST - ppublish
SO  - SLAS Discov. 2020 Dec;25(10):1123-1140. doi: 10.1177/2472555220950236. Epub 2020 
      Aug 17.


PMID- 32804206
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1471-8405 (Electronic)
IS  - 0962-7480 (Linking)
VI  - 70
IP  - 7
DP  - 2020 Oct 27
TI  - Peer review audit of non-specialist occupational physician reports.
PG  - 503-506
LID - 10.1093/occmed/kqaa145 [doi]
AB  - BACKGROUND: With declining specialist occupational physician (OP) numbers, there 
      is increasing recognition of the importance of non-specialist physicians in
      occupational health (OH) service delivery, yet to date, this physician group
      remains understudied and their competency requirements poorly understood. AIMS:
      To evaluate the quality of a sample of non-specialist OH reports and compare
      these with specialist reports. METHODS: A retrospective peer review audit of a
      convenience sample of 200 consecutive non-specialist and specialist OH reports
      from an Irish OH service using an assessment form based on the modified Sheffield
      Assessment Instrument for Letters SAIL(OH)1. RESULTS: Of the 200 peer reviewed OH
      reports, 159 (80%) were from non-specialists. For all questions, 87% and above of
      non-specialist reports were 'satisfactory' or 'above expected'. On the overall
      assessment, out of 10, the mean non-specialist report score was 6.8 (standard
      deviation (SD) 3-10) and the specialist score was 7.3 (SD 3-10). Comparatively,
      non-specialist reports highlighted legal/ethical issues marginally more and
      adhered slightly better to contractual/ethical/legal boundaries, while specialist
      reports fared better in addressing manager's questions, in their structure and
      clarity and in covering all significant aspects of the case, particularly if the 
      case was complex. CONCLUSIONS: Our findings demonstrate a high standard of OH
      report quality in this sample of non-specialist OPs that is consistent across all
      key OH report components. Potential development areas are also identified that
      can inform education/training tailored to this physician group and assist in
      competency standard-setting.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society of Occupational Medicine. All rights reserved. For Permissions, please
      email: journals.permissions@oup.com.
FAU - Lalloo, D
AU  - Lalloo D
AD  - Healthy Working Lives Group, Institute of Health and Wellbeing, College of
      Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Gallagher, J
AU  - Gallagher J
AD  - School of Public Health, University College Cork, Cork, Ireland.
FAU - Macdonald, E B
AU  - Macdonald EB
AD  - Healthy Working Lives Group, Institute of Health and Wellbeing, College of
      Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - McDonnell, C
AU  - McDonnell C
AD  - Health Services Executive, Mid-West Region, Limerick, Ireland.
FAU - Vargas-Prada Figueroa, S
AU  - Vargas-Prada Figueroa S
AD  - Healthy Working Lives Group, Institute of Health and Wellbeing, College of
      Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
AD  - Salus Occupational Health & Safety, NHS Lanarkshire, Hamilton, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Occup Med (Lond)
JT  - Occupational medicine (Oxford, England)
JID - 9205857
SB  - IM
CIN - Occup Med (Lond). 2021 Apr 9;71(2):109. PMID: 33836088
CIN - Occup Med (Lond). 2021 Apr 9;71(2):109-110. PMID: 33836089
MH  - Humans
MH  - Ireland
MH  - Medical Audit
MH  - Medical Records/*standards
MH  - Occupational Health Services/standards
MH  - Occupational Medicine/*standards
MH  - Peer Review, Health Care
MH  - *Physicians
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Audit
OT  - competence
OT  - education
OT  - occupational health
OT  - quality assessment
EDAT- 2020/08/18 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 5893352 [pii]
AID - 10.1093/occmed/kqaa145 [doi]
PST - ppublish
SO  - Occup Med (Lond). 2020 Oct 27;70(7):503-506. doi: 10.1093/occmed/kqaa145.


PMID- 32804068
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Surprise Billing in a Hospital Emergency Department - An Ethical, Contractual,
      and Legislative Conundrum.
PG  - 112-114
LID - 10.1080/15265161.2020.1782516 [doi]
FAU - White, Frederick J
AU  - White FJ
AUID- ORCID: 0000-0001-9073-7011
AD  - Willis-Knighton Health System.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):110-111. PMID: 32757923
MH  - *Emergency Service, Hospital
MH  - *Ethicists
MH  - Humans
EDAT- 2020/08/18 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1080/15265161.2020.1782516 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):112-114. doi: 10.1080/15265161.2020.1782516.


PMID- 32804067
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Upstream Ethical Mapping of Germline Genome Editing.
PG  - 1-4
LID - 10.1080/15265161.2020.1792224 [doi]
FAU - Halpern, Jodi
AU  - Halpern J
AD  - School of Public Health, University of California , Berkeley.
AD  - UCB-UCSF Joint Medical Program.
FAU - Paolo, David
AU  - Paolo D
AD  - School of Public Health, University of California , Berkeley.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):7-18. PMID: 32757931
MH  - *CRISPR-Cas Systems
MH  - Clustered Regularly Interspaced Short Palindromic Repeats
MH  - *Gene Editing
MH  - Germ Cells
MH  - Morals
EDAT- 2020/08/18 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1080/15265161.2020.1792224 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):1-4. doi: 10.1080/15265161.2020.1792224.


PMID- 32804065
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Assessing the Ethical Distinctions Between Different Types of Prospective Human
      Germline Genetic Interventions.
PG  - 49-50
LID - 10.1080/15265161.2020.1782522 [doi]
FAU - Chapman, Audrey R
AU  - Chapman AR
AD  - UConn Health.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):7-18. PMID: 32757931
MH  - *Genetic Engineering
MH  - *Germ Cells
MH  - Humans
MH  - Morals
MH  - Prospective Studies
EDAT- 2020/08/18 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1080/15265161.2020.1782522 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):49-50. doi: 10.1080/15265161.2020.1782522.


PMID- 32803748
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20200825
IS  - 1932-149X (Print)
IS  - 1932-149X (Linking)
VI  - 14
IP  - 4
DP  - 2020 Fall
TI  - Planning for the next influenza pandemic: Using the science and art of logistics.
PG  - 287-298
LID - ajdm.2019.0342 [pii]
LID - 10.5055/ajdm.2019.0342 [doi]
AB  - The complexities and challenges for healthcare providers and their efforts to
      provide fundamental basic items to meet the logistical demands of an influenza
      pandemic are discussed in this article. The supply chain, planning, and
      alternatives for inevitable shortages are some of the considerations associated
      with this emergency mass critical care situation. The planning process and
      support for such events are discussed in detail with several recommendations
      obtained from the literature and the experience from recent mass casualty
      incidents (MCIs). The first step in this planning process is the development of
      specific triage requirements during an influenza pandemic. The second step is
      identification of logistical resources required during such a pandemic, which are
      then analyzed within the proposed logistics science and art model for planning
      purposes. Resources highlighted within the model include allocation and use of
      work force, bed space, intensive care unit assets, ventilators, personal
      protective equipment, and oxygen. The third step is using the model to discuss in
      detail possible workarounds, suitable substitutes, and resource allocation. An
      examination is also made of the ethics surrounding palliative care within the
      construction of an MCI and the factors that will inevitably determine rationing
      and prioritizing of these critical assets to palliative care patients.
FAU - Cupp, O Shawn
AU  - Cupp OS
AD  - Associate Professor, Force Management and Maneuver Sustainment, Department of
      Logistics and Resource Operations, US Army Command and General Staff College,
      Fort Leavenworth, Kansas.
FAU - Predmore, Brad G
AU  - Predmore BG
AD  - Assistant Professor, Force Management and Maneuver Sustainment, Department of
      Logistics and Resource Operations, US Army Command and General Staff College,
      Fort Leavenworth, Kansas.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Disaster Med
JT  - American journal of disaster medicine
JID - 101291100
SB  - IM
MH  - Critical Care
MH  - Disaster Planning/*organization & administration
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Influenza, Human/epidemiology/*prevention & control
MH  - Mass Casualty Incidents
MH  - Pandemics/*prevention & control
MH  - Triage/*organization & administration
EDAT- 2020/08/18 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - ajdm.2019.0342 [pii]
AID - 10.5055/ajdm.2019.0342 [doi]
PST - ppublish
SO  - Am J Disaster Med. 2020 Fall;14(4):287-298. doi: 10.5055/ajdm.2019.0342.


PMID- 32803480
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 22
IP  - 10
DP  - 2020 Aug 15
TI  - Sex Doll Ownership: An Agenda for Research.
PG  - 54
LID - 10.1007/s11920-020-01177-w [doi]
AB  - PURPOSE OF REVIEW: The topic of sex doll ownership is becoming an increasingly
      discussed issue from both a social and legal perspective. This review aims to
      examine the veracity of the existing psychological, sexological, and legal
      literature in relation to doll ownership. RECENT FINDINGS: Strong views exist
      across the spectrum of potential socio-legal positions on sex doll ownership.
      However, there is an almost total lack of empirical analyses of the psychological
      characteristics or behavioral implications of doll ownership. As such, existing
      arguments appear to represent the philosophical positions of those scholars
      expressing them, rather than being rooted in any objective evidence base. Despite
      an absence of empirical data on the characteristics and subsequent effects of
      doll ownership, discussions about the ethical and legal status of doll ownership 
      continue. This highlights a real and urgent need for a coherent research agenda
      to be advanced in this area of work.
FAU - Harper, Craig A
AU  - Harper CA
AD  - Department of Psychology, Nottingham Trent University, 50 Shakespeare Street,
      Nottingham, NG1 4FQ, UK. craigaharper19@gmail.com.
FAU - Lievesley, Rebecca
AU  - Lievesley R
AD  - Department of Psychology, Nottingham Trent University, 50 Shakespeare Street,
      Nottingham, NG1 4FQ, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200815
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
SB  - IM
MH  - Humans
MH  - *Ownership
PMC - PMC7429526
OTO - NOTNLM
OT  - *Sex dolls
OT  - *Sex offending
OT  - *Sex robots
OT  - *Sexual abuse prevention
OT  - *Sexuality
EDAT- 2020/08/18 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
AID - 10.1007/s11920-020-01177-w [doi]
AID - 10.1007/s11920-020-01177-w [pii]
PST - epublish
SO  - Curr Psychiatry Rep. 2020 Aug 15;22(10):54. doi: 10.1007/s11920-020-01177-w.


PMID- 32803446
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Dec
TI  - 'It's not worse than eating them': the limits of analogy in bioethics.
PG  - 129-145
LID - 10.1007/s40592-020-00115-z [doi]
AB  - Bioethicists often defend novel practices by drawing analogies with practices
      that we are already familiar with and currently tolerate. If some novel practice 
      is less bad than some widely-accepted practice, then (it is argued) we cannot
      rightly reject it. Using the bioethics literature on xenotransplantation and
      interspecies blastocyst complementation as a case study, I show how this style of
      argument can go awry. The key problem is that our moral intuitions about familiar
      practices can be distorted by their seeming normality. When considering the
      ethics of emerging technologies and novel practices, we should remain open to the
      possibility that our moral views about familiar practices are mistaken.
FAU - Koplin, Julian J
AU  - Koplin JJ
AUID- ORCID: http://orcid.org/0000-0002-2752-7334
AD  - Melbourne Law School, University of Melbourne, Melbourne, Australia.
      koplinj@unimelb.edu.au.
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Melbourne, Australia. koplinj@unimelb.edu.au.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - *Bioethical Issues
MH  - *Bioethics
MH  - Biotechnology/*ethics
MH  - Blastocyst
MH  - Dissent and Disputes
MH  - Ethical Analysis/methods
MH  - Ethicists
MH  - Humans
MH  - Intuition
MH  - Morals
MH  - Transplantation, Heterologous/ethics
OTO - NOTNLM
OT  - Analogical arguments
OT  - Animal ethics
OT  - Human enhancement
OT  - Human-animal chimeras
OT  - Moral status
OT  - Xenotransplantation
EDAT- 2020/08/18 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.1007/s40592-020-00115-z [doi]
AID - 10.1007/s40592-020-00115-z [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(2):129-145. doi: 10.1007/s40592-020-00115-z.


PMID- 32803024
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 23
DP  - 2020
TI  - Adult cardiac surgical cost variation around the world: Protocol for a systematic
      review.
PG  - 11-14
LID - 10.1016/j.isjp.2020.07.004 [doi]
AB  - INTRODUCTION: Globally, over one million cardiac operations occur each year,
      whereas cardiac surgery is expensive and largely inaccessible without insurance
      or philanthropic support. Substantial cost variation has been reported within
      cardiac surgery in the United States and among non-cardiac surgical procedures
      globally, but little is known on the global procedural cost variation for common 
      adult cardiac surgical procedures. OBJECTIVES AND SIGNIFICANCE: This review seeks
      to assess variation in procedural costs of coronary artery bypass grafting
      (CABG), mitral valve repair, mitral valve replacement, aortic valve repair,
      aortic valve replacement, and combined CABG-mitral or CABG-aortic valve
      procedures between and within countries. Results may give insights in the scope
      and drivers of cost variation around the world, posing cost reduction lessons.
      Results may further inform the potential of economies of scale in reducing
      procedural costs, benefiting patients, hospitals, governments, and insurers.
      METHODS AND ANALYSIS: A systematic review will be performed using the EconLit,
      Embase, PubMed/MEDLINE, Web of Science, and WHO Global Index Medicus databases to
      identify articles published between January 1, 2000 and June 1, 2020. Studies
      describing procedural costs for CABG, mitral valve repair, mitral valve
      replacement, aortic valve repair, aortic valve replacement, and combined
      CABG-mitral or CABG-aortic valve procedures will be identified. Articles
      describing other types of cardiac surgery, concomitant aortic surgery, only
      describing costs related to non-surgical care, or with incomplete cost data will 
      be excluded from the analysis. No exclusion will be based solely on article type 
      or language. Identified costs will be converted to 2019 USD to account for local 
      currency unit inflation and exchange fluctuations. ETHICS AND DISSEMINATION: This
      study protocol has been prospectively registered on the International Platform of
      Registered Systematic Review and Meta-analysis Protocols. This review requires no
      institutional review board approval. Results of this study will be summarized and
      disseminated in a peer-review journal.
CI  - (c) 2020 The Author(s).
FAU - Vervoort, Dominique
AU  - Vervoort D
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United
      States.
FAU - Guetter, Camila R
AU  - Guetter CR
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United
      States.
FAU - Trager, Lena
AU  - Trager L
AD  - University of Minnesota Medical School, Minneapolis, Minnesota, United States.
FAU - Shah, Priyansh
AU  - Shah P
AD  - Baroda Medical College, Vadodara, Gujarat, India.
FAU - Diaz-Castrillon, Carlos Eduardo
AU  - Diaz-Castrillon CE
AD  - University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
FAU - Etchill, Eric W
AU  - Etchill EW
AD  - Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, United
      States.
FAU - Salenger, Rawn
AU  - Salenger R
AD  - Division of Cardiac Surgery, Department of Surgery, University of Maryland School
      of Medicine, Baltimore, Maryland, United States.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7417884
OTO - NOTNLM
OT  - Cardiac surgery
OT  - Global health
OT  - Health economics
OT  - Health policy
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/07/03 00:00 [received]
PHST- 2020/07/24 00:00 [revised]
PHST- 2020/07/25 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.1016/j.isjp.2020.07.004 [doi]
AID - S2468-3574(20)30025-5 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Aug 3;23:11-14. doi: 10.1016/j.isjp.2020.07.004.
      eCollection 2020.


PMID- 32803023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 23
DP  - 2020
TI  - Feasibility study of stem-cell enriched autologous lipotransfer to treat
      oro-facial fibrosis in systemic sclerosis (Sys-Stem): Protocol for open-label
      randomised controlled trial.
PG  - 6-10
LID - 10.1016/j.isjp.2020.07.002 [doi]
AB  - INTRODUCTION: Oro-facial fibrosis is a common and disabling manifestation of
      systemic sclerosis (SSc), causing a plethora of functional, aesthetic and social 
      compromise, yet is without effective treatment. Autologous lipotransfer is an
      established minimally invasive surgical procedure that is postulated to exert
      anti-fibrotic effects by adipose-derived stem cells, and presents a novel method 
      in the treatment of fibrotic conditions. This study aims to assess the safety and
      efficacy of autologous lipotransfer for facial involvement in SSc. METHODS AND
      ANALYSIS: This is the first randomised controlled study with an open label design
      to assess autologous lipotransfer for oro-facial involvement in systemic
      sclerosis. The goals of this study are to assess the feasibility of using a range
      of quantitative and qualitative outcome measures to effectively measure disease
      severity and treatment outcome, and to assess patient acceptability for future
      multi-centre trials. A total of 50 participants will be randomised to a treatment
      or control group. The treatment group will receive autologous fat transfer to the
      peri-oral region by a single surgeon. Dermal fibroblasts and adipose-derived stem
      cells will be isolated from tissue samples. All outcome measures will be taken at
      baseline, then at 6 weeks, 3 months and 6 months from the time of intervention in
      the treatment arm, or from baseline in the control arm. ETHICS AND DISSEMINATION:
      The study has ethical approval (REC reference 19/LO/0718). Results will be
      available to patients, patient user groups, clinicians and the public through
      presentations at national and international rheumatology conferences and
      published in peer reviewed journals. TRIAL REGISTRATION: Registered on ISRCTN
      registry (ISRCTN17793055).
CI  - (c) 2020 The Authors.
FAU - Jeon, Faith Hyun Kyung
AU  - Jeon FHK
AD  - Division of Surgery and Interventional Sciences, University College London,
      London, UK.
AD  - Charles Wolfson Centre for Reconstructive Surgery, Royal Free Hospital, London,
      UK.
FAU - Griffin, Michelle
AU  - Griffin M
AD  - Division of Surgery and Interventional Sciences, University College London,
      London, UK.
AD  - Charles Wolfson Centre for Reconstructive Surgery, Royal Free Hospital, London,
      UK.
FAU - Denton, Christopher Paul
AU  - Denton CP
AD  - Centre for Rheumatology and Connective Tissue Diseases, Division of Medicine,
      Royal Free Campus, University College London, London, UK.
FAU - Butler, Peter Edward Michael
AU  - Butler PEM
AD  - Division of Surgery and Interventional Sciences, University College London,
      London, UK.
AD  - Charles Wolfson Centre for Reconstructive Surgery, Royal Free Hospital, London,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200718
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7419663
OTO - NOTNLM
OT  - Autologous fat grafting
OT  - Lipotransfer
OT  - Microstomia
OT  - Scleroderma
OT  - Systemic
COIS- None to declare.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/07/10 00:00 [revised]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.1016/j.isjp.2020.07.002 [doi]
AID - S2468-3574(20)30022-X [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Jul 18;23:6-10. doi: 10.1016/j.isjp.2020.07.002.
      eCollection 2020.


PMID- 32802977
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 8
DP  - 2020 Aug
TI  - The flushing procedure in nursing practices: A cross-sectional study with
      Portuguese and Brazilian nurses.
PG  - e04579
LID - 10.1016/j.heliyon.2020.e04579 [doi]
AB  - BACKGROUND: In patients with peripheral intravenous catheters (PIVCs), performing
      flushing is an essential procedure to maintain catheter patency and prevent
      complications. These PIVC related complications can lead to premature removal and
      therapeutics interruption, which implies the need of a new catheterization thus
      increasing patient discomfort and pain. AIMS: To identify nursing practices
      related to the flushing procedure, namely: moment(s) of the flushing; the syringe
      size used; the flush solution, volume and technique; the knowledge and
      accomplishment of the recommended standards on flushing by nurses. METHODS: A
      cross-sectional study was conducted between July and December 2017, with
      Brazilian and Portuguese nurses. An online questionnaire was developed based on
      the international recommendations on flushing procedure. Descriptive analysis was
      performed. RESULTS: A total of 76 nurses answered the questionnaire. The majority
      of nurses (84.2%) performed flushing: the most common technique used was
      continuous syringe pressure (31.2%), with the push-pause technique being
      performed by 23.4% of the nurses. Despite the majority performs flushing at four 
      distinct moments (after the PIVC insertion, before, between and after drug
      delivery), there are inconsistencies in flush solution, volume, and syringe size.
      The most used volume to perform flushing was 5 mL, filled using normal saline.
      Despite this, they also recognized the omission of this procedure due to time
      constrains, no familiarity with the procedure and unavailable material.
      CONCLUSIONS: This study identified that flushing procedure isn't always performed
      by nurses in their clinical practice. Also, several inconsistencies were observed
      between nurses that performed flushing, reflecting the lack of empirical evidence
      in this area of research.
CI  - (c) 2020 The Author(s).
FAU - Parreira, Pedro
AU  - Parreira P
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Vicente, Ricardo
AU  - Vicente R
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Bernardes, Rafael A
AU  - Bernardes RA
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Sousa, Liliana B
AU  - Sousa LB
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Serambeque, Beatriz
AU  - Serambeque B
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Costa, Paulo
AU  - Costa P
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Braga, Luciene M
AU  - Braga LM
AD  - Department of Medicine and Nursing, Federal University of Vicosa, Vicosa, Minas
      Gerais, Brazil.
FAU - Monico, Lisete
AU  - Monico L
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
FAU - Salgueiro-Oliveira, Anabela
AU  - Salgueiro-Oliveira A
AD  - The Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra
      (ESEnfC), Coimbra, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7417889
OTO - NOTNLM
OT  - Complications
OT  - Flushing
OT  - Health profession
OT  - Health promotion
OT  - Health technology
OT  - Medical ethics
OT  - Nursing
OT  - Occlusion
OT  - Peripherally intravenous catheter
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04579 [doi]
AID - S2405-8440(20)31423-7 [pii]
AID - e04579 [pii]
PST - epublish
SO  - Heliyon. 2020 Aug 8;6(8):e04579. doi: 10.1016/j.heliyon.2020.e04579. eCollection 
      2020 Aug.


PMID- 32802906
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2322-2220 (Print)
IS  - 2322-2220 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Jul
TI  - The systematic approach to faculty development activities for biomedical
      educators.
PG  - 127-133
LID - 10.30476/jamp.2020.84341.1135 [doi]
AB  - INTRODUCTION: The term continuing professional development encompasses
      competencies required to practice the high quality medicine, including medical,
      managerial, ethical, social, and personal skills, whereas continuing medical
      education refers only to expanding the knowledge and skills required by
      physicians. The competencies for basic science faculty identified are management 
      and administration, teaching, assessments, curriculum development, and research. 
      This study aimed to evaluate the outcomes of faculty development initiatives at
      Avalon University School of Medicine and examine the optimal approach to faculty 
      development activities. METHODS: This is a survey-based quantitative study. A
      cross-sectional survey was conducted after implementing the faculty development
      activities. We took thirteen basic science faculty members as a unit and
      recruited them for different faculty development activities from 2015. Faculty
      members were involved in various faculty development courses, workshops, and
      training sessions. A survey was conducted among faculty members using a
      questionnaire on the Likert scale to identify if there are any increased
      knowledge or skills on teaching and assessment methods, educational scholarship, 
      and scholarly activities after implementing faculty development initiatives. The 
      faculty responses were tabulated and quantified in the Excel sheet and analyzed
      by SPSS software. RESULTS: All thirteen faculty members responded to the
      questionnaire (100% response rate). There was an increased self-reported
      knowledge and skills of faculty members. 70% of the faculty agreed that they are 
      able to get involved in designing their course learning objectives. 100% of the
      faculty were aware of different teaching methods, and 93% of them were
      implementing different types of teaching methods, including small group
      discussions, flipped classrooms, standardized patient-based teaching, and
      problem-based learning. 100% of the faculty were aware of different assessment
      methods and implementing them. There were self-reported and observed behavioral
      changes. CONCLUSIONS: Faculty development activities at Avalon University School 
      of Medicine have shown to be effective. At larger institutions, the department
      chair can lead the faculty development activities.
CI  - Copyright: (c) Journal of Advances in Medical Education & Professionalism.
FAU - Arja, Sateesh Babu
AU  - Arja SB
AD  - Medical Education Department, School of Medicine, Avalon University, Curacao.
FAU - Paramban, Simi
AU  - Paramban S
AD  - Medical Education Department, School of Medicine, Avalon University, Curacao.
FAU - Ponnusamy, Kumar
AU  - Ponnusamy K
AD  - Medical Education Department, School of Medicine, Avalon University, Curacao.
FAU - Joseph Nayakanti, Abaraham Ratna
AU  - Joseph Nayakanti AR
AD  - Medical Education Department, School of Medicine, Avalon University, Curacao.
FAU - Fatteh, Reshma
AU  - Fatteh R
AD  - Medical Education Department, School of Medicine, Avalon University, Curacao.
FAU - Bala Arja, Sireesha
AU  - Bala Arja S
AD  - Medical Education Department, School of Medicine, Avalon University, Curacao.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - J Adv Med Educ Prof
JT  - Journal of advances in medical education & professionalism
JID - 101617859
PMC - PMC7395203
OTO - NOTNLM
OT  - Educators
OT  - Faculty
OT  - Medical education
OT  - Biomedical
COIS- Conflict of Interest: None declared.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.30476/jamp.2020.84341.1135 [doi]
AID - JAMP-8-3 [pii]
PST - ppublish
SO  - J Adv Med Educ Prof. 2020 Jul;8(3):127-133. doi: 10.30476/jamp.2020.84341.1135.


PMID- 32802500
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2090-0724 (Print)
IS  - 2090-0724 (Linking)
VI  - 2020
DP  - 2020
TI  - Characteristics of Slovenian Adults in Community-Based Whole-Food Plant-Based
      Lifestyle Program.
PG  - 6950530
LID - 10.1155/2020/6950530 [doi]
AB  - OBJECTIVE: Adopting a plant-based diet (PBD) and lifestyle is healthy,
      sustainable, and increasingly popular, while also demanding. Individuals might
      face challenges to maintain this lifestyle. We aimed to determine the
      anthropometric values and lifestyle factors and motives of adults to adopt a
      whole-food, plant-based (WFPB) lifestyle by joining our ongoing, community-based,
      WFPB lifestyle program 0.5-10 years ago. METHODS: We measured body mass index
      (BMI) and body fat percentage status (BF%) using bioimpedance. Lifestyle status
      was obtained by standardized electronic questionnaires. For evaluating the
      motives for following strict PBD, the participants were asked to rank 8 different
      motives (i.e., 8: the most-, 1: the least important). Setting. A cross-sectional 
      study in Slovenia. Participants. A total of 151 healthy adults with an average
      age of 39.6 years (SD: 12.5 years). RESULTS: The participants had an average BMI 
      of 23.9 kg/m(2) (SD: 3.8 kg/m(2)) and an average BF% of 22.3% (SD: 7.3%), were
      physically very active, with an average Long International Physical Activity
      Questionnaire (L-IPAQ) score of 5541.2 metabolic equivalents (METs) min/week (SD:
      4677.0 METs min/week), having good sleep quality, with an average Pittsburgh
      Sleep Quality Index (PSQI) score of 2.7 (SD: 1.8), perceiving low stress, and
      with an average Perceived Stress Questionnaire (PSQ) score of 0.29 (SD: 0.1). We 
      discovered no significant differences in lifestyle between participants who were 
      involved in our WFPB lifestyle program for short, medium, or long periods of
      time. The motives for WFPB lifestyle included health benefits (score: 7.9/8),
      body mass management (6.3), eating to satiety (4.9), convenience (4.3),
      environmental concerns (4.1), affordability (3.7), animal ethics (3.6), and
      religious reasons (1.1). CONCLUSION: A WFPB lifestyle program for any length of
      time that includes an extensive support system provides favorable, long-term
      lifestyle changes.
CI  - Copyright (c) 2020 Bostjan Jakse et al.
FAU - Jakse, Bostjan
AU  - Jakse B
AD  - Department of Food Science, Biotechnical Faculty, University of Ljubljana,
      Ljubljana, Slovenia.
FAU - Jakse, Barbara
AU  - Jakse B
AD  - Sole Proprietor, 1230 Domzale, Slovenia.
FAU - Pinter, Stanislav
AU  - Pinter S
AD  - Basics of Movements in Sport, Faculty of Sport, University of Ljubljana,
      Ljubljana, Slovenia.
FAU - Pajek, Jernej
AU  - Pajek J
AD  - Department of Nephrology, University Medical Centre Ljubljana, Ljubljana,
      Slovenia.
AD  - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Mis, Natasa Fidler
AU  - Mis NF
AUID- ORCID: https://orcid.org/0000-0003-3199-0484
AD  - Department of Gastroenterology, Hepatology and Nutrition, University Children's
      Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - United States
TA  - J Nutr Metab
JT  - Journal of nutrition and metabolism
JID - 101526296
PMC - PMC7416260
COIS- All authors declare no conflicts of interest. B. J. and S. P. are receiving
      royalty compensation at Herbalife Nutrition.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/02/08 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.1155/2020/6950530 [doi]
PST - epublish
SO  - J Nutr Metab. 2020 Jul 29;2020:6950530. doi: 10.1155/2020/6950530. eCollection
      2020.


PMID- 32801975
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1179-1594 (Print)
IS  - 1179-1594 (Linking)
VI  - 13
DP  - 2020
TI  - Application of the Concepts of Social Responsibility, Sustainability, and Ethics 
      to Healthcare Organizations.
PG  - 1029-1033
LID - 10.2147/RMHP.S258984 [doi]
AB  - Corporate social responsibility (CSR) is a concept that has varied through
      history, with evolving definitions that aim to determine the interconnections
      between corporations and community. Currently, in addition to ethics, this
      concept of social responsibility is increasingly considered in the context of
      healthcare delivery suggesting a new paradigm in hospital management.
      Sustainability is another emerging strategic goal for healthcare systems and
      organizations. In this opinion paper, we briefly discuss the application of
      social responsibility, sustainability and ethics to healthcare organizations.
CI  - (c) 2020 Haddiya et al.
FAU - Haddiya, Intissar
AU  - Haddiya I
AUID- ORCID: 0000-0002-0808-2798
AD  - Department of Nephrology, Faculty of Medicine and Pharmacy of Oujda, University
      Mohamed Premier, Oujda, Morocco.
FAU - Janfi, Taha
AU  - Janfi T
AUID- ORCID: 0000-0002-2676-3319
AD  - Department of Nephrology, Faculty of Medicine and Pharmacy of Oujda, University
      Mohamed Premier, Oujda, Morocco.
FAU - Guedira, Mohamed
AU  - Guedira M
AD  - Education Sciences Faculty, University Mohamed V, Rabat, Morocco.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - England
TA  - Risk Manag Healthc Policy
JT  - Risk management and healthcare policy
JID - 101566264
PMC - PMC7415434
OTO - NOTNLM
OT  - CSR
OT  - ethics
OT  - healthcare
OT  - sustainability
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.2147/RMHP.S258984 [doi]
AID - 258984 [pii]
PST - epublish
SO  - Risk Manag Healthc Policy. 2020 Aug 5;13:1029-1033. doi: 10.2147/RMHP.S258984.
      eCollection 2020.


PMID- 32801935
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1179-1411 (Print)
IS  - 1179-1411 (Linking)
VI  - 12
DP  - 2020
TI  - Mandatory Waiting Periods Before Abortion and Sterilization: Theory and Practice.
PG  - 577-586
LID - 10.2147/IJWH.S257178 [doi]
AB  - Some laws insist on a fixed, compulsory waiting period between the time of
      obtaining consent and when abortions or sterilizations are carried out. Waiting
      periods are designed to allow for reflection on the decision and to minimize
      regret. In fact, the cognitive processing needed for these important decisions
      takes place relatively rapidly. Clinicians are used to handling cases
      individually and tailoring care appropriately, including giving more time for
      decision-making. Psychological considerations in relation to the role of emotion 
      in decision-making, eg, regret, raise the possibility that waiting periods could 
      have a detrimental impact on the emotional wellbeing of those concerned which
      might interfere with decision-making. Having an extended period of time to
      consider how much regret one might feel as a consequence of the decision one is
      faced with may make a person revisit a stable decision. In abortion care, waiting
      periods often result in an extra appointment being needed, delays in securing a
      procedure and personal distress for the applicant. Some women end up being beyond
      the gestational limit for abortion. Those requesting sterilization in a situation
      of active conflict in their relationship will do well to postpone a decision on
      sterilization. Otherwise, applicants for sterilization should not be forced to
      wait. Forced waiting undermines people's agency and autonomous decision-making
      ability. Low-income groups are particularly disadvantaged. It may be
      discriminatory when applied to marginalized groups. Concern about the validity of
      consent is best addressed by protective clinical guidelines rather than through
      rigid legislation. Waiting periods breach reproductive rights. Policymakers and
      politicians in countries that have waiting periods in sexual and reproductive
      health regulation should review relevant laws and policies and bring them into
      line with scientific and ethical evidence and international human rights law.
CI  - (c) 2020 Rowlands and Thomas.
FAU - Rowlands, Sam
AU  - Rowlands S
AUID- ORCID: 0000-0001-5940-9079
AD  - Department of Medical Sciences and Public Health, Faculty of Health and Social
      Sciences, Bournemouth University, Bournemouth, UK.
FAU - Thomas, Kevin
AU  - Thomas K
AD  - Department of Psychology, Faculty of Science and Technology, Bournemouth
      University, Bournemouth, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200731
PL  - New Zealand
TA  - Int J Womens Health
JT  - International journal of women's health
JID - 101531698
PMC - PMC7402852
OTO - NOTNLM
OT  - abortion
OT  - decision-making
OT  - mandatory
OT  - psychology
OT  - sterilization
OT  - waiting period
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.2147/IJWH.S257178 [doi]
AID - 257178 [pii]
PST - epublish
SO  - Int J Womens Health. 2020 Jul 31;12:577-586. doi: 10.2147/IJWH.S257178.
      eCollection 2020.


PMID- 32801932
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1179-1411 (Print)
IS  - 1179-1411 (Linking)
VI  - 12
DP  - 2020
TI  - Determinants of Sub-Optimal Birth Spacing in Gedeo Zone, South Ethiopia: A
      Case-Control Study.
PG  - 549-556
LID - 10.2147/IJWH.S252516 [doi]
AB  - BACKGROUND: Birth spacing is key in ensuring the health of mothers and their
      children as well as determining population growth. Most of the mothers in
      developing nations including Ethiopia have been practicing short inter-birth
      intervals. There is a paucity of studies concerned with suboptimal birth spacing 
      among women in reproductive age in the study area. PURPOSE: This study aims to
      identify the determinants of sub-optimal birth spacing among reproductive-age
      women in Gedeo zone, South Ethiopia. MATERIALS AND METHODS: A community-based
      unmatched case-control study was undertaken among 814 reproductive-age women in
      Gedeo zone, South Ethiopia from October 1 to November 30, 2018. Cases were women 
      practiced suboptimal/short birth intervals (<33 months), whereas controls were
      women practiced inter-birth intervals of 33 months and more. A structured
      interviewer-administered questionnaire was used. A stratified, two-stage cluster 
      sampling technique was used. EpiData version 3.1 and SPSS version 22 were used
      for data entry and analysis, respectively. Bivariate and multivariable logistic
      regression analyses were computed. P-value <0.05 was considered as statistically 
      significant. All ethical procedures were considered. RESULTS: Women's educational
      status, AOR (95% CI) =0.6 (0.43, 0.96), age at first marriage, AOR (95% CI) = 0.9
      (0.85, 0.99), distance from the nearest health facility, AOR (95% CI) = 1.4
      (1.04, 1.94), wealth index, AOR (95% CI) = 4.1 (2.66, 6.19), and postnatal care
      utilization after the previous birth, AOR (95% CI) = 0.4 (0.25, 0.53) were
      statistically significant with suboptimal birth spacing. CONCLUSION: Women's
      educational status age at first marriage, distance from the nearest health
      facility, wealth index and postnatal care utilization after the previous birth
      were the determinants of suboptimal birth spacing.
CI  - (c) 2020 Muluneh et al.
FAU - Muluneh, Abebaw Abeje
AU  - Muluneh AA
AUID- ORCID: 0000-0002-9877-5212
AD  - Department of Midwifery, Hawassa University College of Medicine and Health
      Sciences, Hawassa, Ethiopia.
FAU - Kassa, Zemenu Yohannes
AU  - Kassa ZY
AUID- ORCID: 0000-0002-3496-7493
AD  - Department of Midwifery, Hawassa University College of Medicine and Health
      Sciences, Hawassa, Ethiopia.
FAU - Siyoum, Melese
AU  - Siyoum M
AD  - Department of Midwifery, Hawassa University College of Medicine and Health
      Sciences, Hawassa, Ethiopia.
FAU - Gebretsadik, Achamyelesh
AU  - Gebretsadik A
AD  - School of Public Health, Hawassa University College of Medicine and Health
      Sciences, Hawassa, Ethiopia.
FAU - Woldeyes, Yewlsew
AU  - Woldeyes Y
AUID- ORCID: 0000-0002-5957-8769
AD  - Department of Midwifery, Hawassa University College of Medicine and Health
      Sciences, Hawassa, Ethiopia.
FAU - Tenaw, Zelalem
AU  - Tenaw Z
AUID- ORCID: 0000-0003-1387-7314
AD  - Department of Midwifery, Hawassa University College of Medicine and Health
      Sciences, Hawassa, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - New Zealand
TA  - Int J Womens Health
JT  - International journal of women's health
JID - 101531698
PMC - PMC7399454
OTO - NOTNLM
OT  - Gedeo
OT  - reproductive age women
OT  - suboptimal birth spacing
COIS- The authors report no conflicts of interest in this work. There is no funding
      organization for this work.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.2147/IJWH.S252516 [doi]
AID - 252516 [pii]
PST - epublish
SO  - Int J Womens Health. 2020 Jul 24;12:549-556. doi: 10.2147/IJWH.S252516.
      eCollection 2020.


PMID- 32801734
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Critical Evaluation of Drug Advertisements in a Medical College in Lalitpur,
      Nepal.
PG  - 717-725
LID - 10.2147/JMDH.S259708 [doi]
AB  - PURPOSE: The information provided in drug advertisements (DAs) often do not
      follow the recommended criteria and may promote irrational prescribing behaviors.
      Recently Health Action International (HAI) formulated detailed criteria to
      evaluate DAs which further develop and expand on the World Health Organization
      (WHO) criteria. This study was done to evaluate DAs using both criteria. METHODS:
      The study was carried out from October 2019 to January 2020 in the Department of 
      Pharmacology of KIST Medical College, Lalitpur, Nepal. A structured proforma was 
      used to collect data. RESULTS: Altogether 100 DAs were analyzed. Maximum (85%)
      were having pictorial presentations. Majority (89%) were found to have authentic 
      information and 3% were found to have exaggerated information. All DAs mentioned 
      generic name, brand name, active drug per dosage form and approved therapeutic
      uses. Only 4% of DAs mentioned about the adverse effects that can be caused by
      the use of these medicines. The DAs evaluated as per the HAI criteria for
      pictures and images showed that people portrayed did not seem to be Nepalese.
      Females and males were portrayed differently with females being laypersons and
      males being healthcare professionals. Nineteen DAs contained 33 references to
      scientific literature. Thirty references contained adequate citation information 
      to be identified and were retrievable. Retrieved references were of high
      methodological quality and from peer-reviewed journals. There was only one graph 
      in the DAs and it contained the number needed to treat (NNT) information. The
      graph was not having statistical calculations and was not obscured by other
      visual material. CONCLUSION: Using both HAI and WHO criteria for assessing the
      DAs was the strength of this study. None of the DAs fulfilled all the criteria.
      Additionally, lack of any information on harm in the large majority of DAs, and
      very limited backing of claims with references was also seen.
CI  - (c) 2020 Jha et al.
FAU - Jha, Nisha
AU  - Jha N
AUID- ORCID: 0000-0003-1089-6042
AD  - Department of Pharmacology, KIST Medical College, Gwarko, Lalitpur, Nepal.
FAU - Sapkota, Yunima
AU  - Sapkota Y
AD  - Department of Pharmacy, Central Institute of Science and Technology, Baneshwor,
      Nepal.
FAU - Shankar, Pathiyil Ravi
AU  - Shankar PR
AUID- ORCID: 0000-0001-6105-5636
AD  - Department of Basic Sciences, Oceania University of Medicine, Apia, Samoa.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7406374
OTO - NOTNLM
OT  - Nepal
OT  - drug advertisements
OT  - ethical criteria
OT  - evaluation
OT  - health action international
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.2147/JMDH.S259708 [doi]
AID - 259708 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Jul 29;13:717-725. doi: 10.2147/JMDH.S259708.
      eCollection 2020.


PMID- 32801717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1176-6328 (Print)
IS  - 1176-6328 (Linking)
VI  - 16
DP  - 2020
TI  - Effects of Job Stressors, Stress Response, and Sleep Disturbance on Presenteeism 
      in Office Workers.
PG  - 1827-1833
LID - 10.2147/NDT.S258508 [doi]
AB  - BACKGROUND: Occupational mental health, work environment, sleep health,
      presenteeism, and loss of work productivity caused by health problems are all
      public health concerns. Although sleep affects mental health and presenteeism,
      the associations between sleep disturbance, job stressors, stress responses, and 
      presenteeism have remained unclear. We hypothesized that job stressors affect the
      presenteeism of office workers through sleep disturbance and analyzed the
      association among these factors. SUBJECTS AND METHODS: In 2017, a cross-sectional
      survey of adult office workers was performed. A total of 2899 subjects who
      provided written consent were included in the analysis. The survey collected
      demographic information, as well as the Work Limitation Questionnaire (WLQ),
      Pittsburgh Sleep Quality Index (PSQI), and Brief Job Stress Questionnaire (BJSQ).
      Associations between each of the variables were analyzed by path analysis
      (covariance structure analysis). This study was approved by the Ethics Committee 
      of Tokyo Medical University. RESULTS: The path analysis demonstrated that job
      stressors, psychological and physical stress response (PPSR) in the BJSQ, and
      sleep disturbance in the PSQI had direct effects on presenteeism in the WLQ. Both
      job stressors and social support in the BJSQ indirectly affected presenteeism
      through effects on sleep disturbance and PPSR. Sleep disturbance indirectly
      affected presenteeism via PPSR. This model accounted for the variation of
      presenteeism (R (2) = 0.322). CONCLUSION: In the workplace, job stressors and low
      social support increase presenteeism through psychological and physical stress
      responses, as well as sleep disturbance. Evaluating and resolving work problems
      and sleep disturbance would hence be beneficial from the aspects of public health
      and socioeconomics.
CI  - (c) 2020 Furuichi et al.
FAU - Furuichi, Wataru
AU  - Furuichi W
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
AD  - Department of Psychiatry, Seiwakai Nakayama Hospital, Ichikawa, Chiba, 272-0813, 
      Japan.
FAU - Shimura, Akiyoshi
AU  - Shimura A
AUID- ORCID: 0000-0003-0806-4423
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
FAU - Miyama, Hitoshi
AU  - Miyama H
AUID- ORCID: 0000-0002-5361-1919
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
FAU - Seki, Terutomo
AU  - Seki T
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
FAU - Ono, Kotaro
AU  - Ono K
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
FAU - Masuya, Jiro
AU  - Masuya J
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
FAU - Inoue, Takeshi
AU  - Inoue T
AUID- ORCID: 0000-0001-5248-1289
AD  - Department of Psychiatry, Tokyo Medical University, Tokyo 160-0023, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC7394603
OTO - NOTNLM
OT  - WLQ
OT  - job stress
OT  - occupational stress
OT  - presenteeism
OT  - sleep disturbance
OT  - work limitation questionnaire
COIS- Akiyoshi Shimura reports personal fees from Meiji Seika Pharma, Yoshitomi
      Yakuhin, Tanabe Mitsubishi Pharma, and Eisai, outside the submitted work. Jiro
      Masuya has received personal compensation from Otsuka Pharmaceutical, Eli Lilly, 
      Astellas, and Meiji Yasuda Mental Health Foundation, and grants from Pfizer.
      Takeshi Inoue has received personal fees from Mochida Pharmaceutical, Takeda
      Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama
      Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi,
      Astellas, Tsumura, and Eisai; and grants and personal fees from Otsuka
      Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa
      Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma; and is 
      a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe
      Pharma. The other authors declare that they have no actual or potential conflicts
      of interest associated with this study.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.2147/NDT.S258508 [doi]
AID - 258508 [pii]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2020 Jul 27;16:1827-1833. doi: 10.2147/NDT.S258508.
      eCollection 2020.


PMID- 32801377
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0001-7019 (Print)
IS  - 0001-7019 (Linking)
VI  - 54
IP  - 2
DP  - 2020 Jun
TI  - Motivation to Follow a Career in Dentistry of Students in Three South-East
      European Countries.
PG  - 175-185
LID - 10.15644/asc54/2/8 [doi]
AB  - OBJECTIVE: To investigate and compare the factors that motivated students to
      study dentistry in countries with similar background (Albania, Croatia and the
      Republic of Northern Macedonia) and to assess whether or not their motivation
      changed during time. MATERIAL AND METHODS: In 2014/2015, cross-sectional studies 
      were conducted in state funded dental schools in Tirana (Albania), Zagreb
      (Croatia) and Skopje (Macedonia) to assess student views on their career
      motivation. All dental students from the first, third and final years of study
      were invited to participate. The participation was voluntary and anonymous. A
      five-item questionnaire was translated into languages of the participating
      countries. Ethics approval was granted by the Ethics Committee of the University 
      of Saints Cyril and Methodius, Skopje. The Chi square test was used to test if
      there were statistically significant differences in answers between students in 3
      countries, furthermore between years of the study. RESULTS: The total number of
      respondents was 739 (319 in Tirana, 211 in Zagreb and 208 in Skopje) The
      differences in the answers between the first-year students from all three
      countries were statistically significant (chi(2)=82.65; p<.01). The most striking
      answer was to the question on parents' pressure to study dentistry, which was far
      more frequent in Tirana (up to 27.7%). A "positive image" was the most frequent
      response from students from Zagreb (up to 79.7%), but it declined from the first 
      to the final year in Skopje. There were also significant differences between the 
      schools within the 3(rd)and final years of study. CONCLUSIONS: A positive image
      of dental profession was the main reason for students studying dentistry at all
      three schools; as many as 97% of the students of the final year in Croatia, a
      member of the European Union (EU). In the two non-EU countries (Albania,
      Macedonia) it seemed that dental profession does not have such good status and
      student expectations are not being fulfilled, especially in Skopje (up to 33.9%
      willing to change their vocation and up to 64.5% lost their motivation to study) 
      One of the strategies to improve the situation could be to include more clinical 
      practice and to better organize the study..
FAU - Nikolovska, Julijana
AU  - Nikolovska J
AD  - Faculty of Dental Medicine, University of Sts. Cyril and Methodius, Skopje,
      Republic of Macedonia.
FAU - Eaton, Kenneth A
AU  - Eaton KA
AD  - Centre for Professional Practice, University of Kent, Medway Campus, Chatham
      Maritime, Kent, ME4 4AG, United Kingdom.
FAU - Kenig, Nikolina
AU  - Kenig N
AD  - Faculty of Philosophy, Institute of Psychology, University of Sts. Cyril and
      Methodius, Skopje, Republic of Macedonia.
FAU - Hysi, Dorjan
AU  - Hysi D
AD  - Faculty of Dental Medicine, University of Medicine Tirana, Albania.
FAU - Petricevic, Nikola
AU  - Petricevic N
AD  - School of Dental Medicine, University of Zagreb, Croatia.
LA  - eng
PT  - Journal Article
PL  - Croatia
TA  - Acta Stomatol Croat
JT  - Acta stomatologica Croatica
JID - 0253456
PMC - PMC7362731
OTO - NOTNLM
OT  - Career Choice
OT  - Dental Students
OT  - Motivation
OT  - South-East European Countries
COIS- Competing Interests: The authors report that they have no conflict of interests.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
AID - 10.15644/asc54/2/8 [doi]
AID - ASC_54(2)_175-185 [pii]
PST - ppublish
SO  - Acta Stomatol Croat. 2020 Jun;54(2):175-185. doi: 10.15644/asc54/2/8.


PMID- 32801207
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 16
TI  - Value of lung ultrasound for the diagnosis of COVID-19 pneumonia: a protocol for 
      a systematic review and meta-analysis.
PG  - e039180
LID - 10.1136/bmjopen-2020-039180 [doi]
AB  - INTRODUCTION: In the recent COVID-19 pandemic, cases have exceeded over one
      million, with the number of confirmed cases increasing by 50 000-60 000 per day. 
      The virus has killed nearly 50 000 people all over the world in only 3 months.
      These reforms bring major challenges to the public health and healthcare system. 
      The pulmonary pathological features during the initial phase of COVID-19 are
      alveolar oedema, pneumocyte hyperplasia, gravitational consolidations and
      interstitial thickening. The ability of lung ultrasound (LUS) and its evolving
      applications in the diagnosis of COVID-19 pneumonia are widespread. This study
      aims to evaluate the surveillance value of LUS in the diagnosis of COVID-19
      pneumonia. METHODS AND ANALYSIS: We will perform a systematic search and
      meta-analysis on the use of LUS to diagnose and confirm COVID-19 pneumonia. We
      will search Ovid Medline, Ovid Embase, Web of Science, Cochrane Library, Scopus, 
      Google Scholar, China Biology Medicine disc and WHO Global Health Library for
      studies on diagnostic accuracy from December 2019 to April 2021. Data collection 
      and screening will be individually accomplished by two reviewers. The assessment 
      of risk of bias for each outcome will be conducted using the QUADAS-2 (Quality
      Assessment of Diagnostic Accuracy Studies 2) tool. Data will be synthesised and
      heterogeneity will be evaluated. Meta-analysis will be conducted when strong
      homogeneous data are accessible. Grading of Recommendations Assessment,
      Development and Evaluation(GRADE) will be used to assess quality of evidence.
      ETHICS AND DISSEMINATION: Approval of ethics committee is not needed for this
      review. While results will be disseminated electronically, effective
      dissemination will be done through presentations and peer-reviewed publication.
      PROSPERO REGISTRATION NUMBER: CRD42020177803; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yang, Yujiao
AU  - Yang Y
AUID- ORCID: 0000-0002-5409-6007
AD  - Department of Anesthesiology, Sichuan University West China Hospital, Chengdu,
      China.
AD  - Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical
      College, Nanchong, China.
FAU - Zhang, Donghang
AU  - Zhang D
AD  - Department of Anesthesiology, Sichuan University West China Hospital, Chengdu,
      China.
FAU - Zhou, Cheng
AU  - Zhou C
AD  - Lab of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, 
      Sichuan University West China Hospital, Chengdu, Sichuan, China.
FAU - Huang, Han
AU  - Huang H
AD  - Department of Anesthesiology, Sichuan University West China Second University
      Hospital, Chengdu, Sichuan, China.
FAU - Wang, Rurong
AU  - Wang R
AD  - Department of Anesthesiology, Sichuan University West China Hospital, Chengdu,
      China wangrurong@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*diagnostic imaging/pathology
MH  - Humans
MH  - Lung/*diagnostic imaging/pathology
MH  - *Meta-Analysis as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnostic imaging/pathology
MH  - Research Design
MH  - SARS-CoV-2
MH  - Sensitivity and Specificity
MH  - *Systematic Reviews as Topic
MH  - Ultrasonography
PMC - PMC7430339
OTO - NOTNLM
OT  - *diagnostic radiology
OT  - *infectious diseases & infestations
OT  - *ultrasonography
COIS- Competing interests: None declared.
EDAT- 2020/08/18 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - bmjopen-2020-039180 [pii]
AID - 10.1136/bmjopen-2020-039180 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 16;10(8):e039180. doi: 10.1136/bmjopen-2020-039180.


PMID- 32801202
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 16
TI  - Is untargeted iron supplementation harmful when iron deficiency is not the major 
      cause of anaemia? Study protocol for a double-blind, randomised controlled trial 
      among non-pregnant Cambodian women.
PG  - e037232
LID - 10.1136/bmjopen-2020-037232 [doi]
AB  - INTRODUCTION: The WHO recommends daily oral iron supplementation for 12 weeks in 
      women and adolescents where anaemia prevalence is greater than 40%. However, if
      iron deficiency is not a major cause of anaemia, then, at best, untargeted iron
      supplementation is a waste of resources; at worst, it could cause harm. Further, 
      different forms of iron with varying bioavailability may present greater risks of
      harm. METHODS AND ANALYSIS: A 12-week three-arm, double-blind, randomised
      controlled supplementation trial was conducted in Cambodia to determine if there 
      is potential harm associated with untargeted iron supplementation. We will
      recruit and randomise 480 non-pregnant women (ages 18-45 years) to receive one of
      three interventions: 60 mg elemental iron as ferrous sulfate (the standard,
      commonly used form), 18 mg ferrous bisglycinate (a highly bioavailable iron amino
      acid chelate) or placebo. We will measure ferritin concentrations (to evaluate
      non-inferiority between the two forms of iron), as well as markers of potential
      harm in blood and stool (faecal calprotectin, gut pathogen abundance and DNA
      damage) at baseline and 12 weeks. Mixed-effects generalised linear models will be
      used to assess the effect of iron on ferritin concentration and markers of
      potential harm at 12 weeks. ETHICS AND DISSEMINATION: Ethical approval was
      obtained from the University of British Columbia Clinical Research Ethics Board
      (H18-02610), the Children's and Women's Health Centre of British Columbia
      Research Ethics Board (H18-02610) and the National Ethics Committee for Health
      Research in Cambodia (273-NECHR). Findings will be published in peer-reviewed
      journals, presented to stakeholders and policymakers globally and shared within
      participants' communities. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry
      (NCT04017598).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fischer, Jordie Aj
AU  - Fischer JA
AUID- ORCID: 0000-0003-1268-5564
AD  - Department of Food, Nutrition and Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
AD  - Healthy Starts, British Columbia Children's Hospital Research Institute,
      Vancouver, British Columbia, Canada.
FAU - Pei, Lulu X
AU  - Pei LX
AD  - Department of Food, Nutrition and Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
AD  - Healthy Starts, British Columbia Children's Hospital Research Institute,
      Vancouver, British Columbia, Canada.
FAU - Goldfarb, David M
AU  - Goldfarb DM
AD  - Healthy Starts, British Columbia Children's Hospital Research Institute,
      Vancouver, British Columbia, Canada.
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Albert, Arianne
AU  - Albert A
AD  - Department of Biostatistics, Women's Health Research Institute, Vancouver,
      British Columbia, Canada.
FAU - Elango, Rajavel
AU  - Elango R
AD  - Healthy Starts, British Columbia Children's Hospital Research Institute,
      Vancouver, British Columbia, Canada.
AD  - School of Population and Public Health, The University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Kroeun, Hou
AU  - Kroeun H
AD  - Helen Keller International Cambodia, Phnom Penh, British Columbia, Cambodia.
FAU - Karakochuk, Crystal D
AU  - Karakochuk CD
AD  - Department of Food, Nutrition and Health, The University of British Columbia,
      Vancouver, British Columbia, Canada Crystal.Karakochuk@ubc.ca.
AD  - Healthy Starts, British Columbia Children's Hospital Research Institute,
      Vancouver, British Columbia, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04017598
GR  - ID400771/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - E1UOL152H7 (Iron)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Anemia
MH  - *Anemia, Iron-Deficiency/drug therapy
MH  - Asians
MH  - British Columbia
MH  - Cambodia
MH  - *Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - *Iron/therapeutic use
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Young Adult
PMC - PMC7430471
OTO - NOTNLM
OT  - *Cambodia
OT  - *anaemia
OT  - *gut inflammation
OT  - *haemoglobinopathy
OT  - *iron
OT  - *iron deficiency
OT  - *pathogen growth
OT  - *women
COIS- Competing interests: None declared.
EDAT- 2020/08/18 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-037232 [pii]
AID - 10.1136/bmjopen-2020-037232 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 16;10(8):e037232. doi: 10.1136/bmjopen-2020-037232.


PMID- 32801201
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 16
TI  - Association between plasma exosome neurogranin and brain structure in patients
      with Alzheimer's disease: a protocol study.
PG  - e036990
LID - 10.1136/bmjopen-2020-036990 [doi]
AB  - INTRODUCTION: Neurogranin is known to be significantly elevated in patients with 
      Alzheimer's disease (AD) and may be an effective clinical predictor of cognitive 
      decline and neurodegeneration. Amnestic mild cognitive impairment (aMCI) is an
      intermediate disease state between normal cognitive ageing and dementia, the
      latter of which can easily revert to AD. There remains significant uncertainty
      regarding the conversion of aMCI to AD, and therefore, elucidating such
      progression is paramount to the field of cognitive neuroscience. In this protocol
      study, we therefore aim to investigate the changes in plasma neurogranin in the
      early stage of AD and the mechanism thereof regarding the cognitive progression
      towards AD. METHODS AND ANALYSIS: In this study, patients with aMCI and AD
      patients (n=70 each) will be recruited at the memory clinic of the Department of 
      Neurology of Hongqi Hospital affiliated with the Mudanjiang Medical University of
      China. Healthy older controls (n=70) will also be recruited from the community.
      All subjects will undergo neuroimaging and neuropsychological evaluations in
      addition to blood collection at the first year and the third year. We hope to
      identify a new biomarker of cognitive decline associated with AD and characterise
      its behaviour throughout the progression of aMCI to AD. This work will reveal
      novel targets for the therapeutic prevention, diagnosis and treatment of AD. The 
      primary outcome measures will be (1) neuropsychological evaluation, including
      Mini-Mental State Examination, Montreal Cognitive Assessment, Clinical Dementia
      Rating scale, Shape Trail Test-A&B, Auditory Verbal Learning Test-HuaShan
      version; (2) microstructural alterations and hippocampal features from MRI scans;
      and (3) neurogranin levels in the neuronal-derived exosomes from peripheral blood
      samples. ETHICS AND DISSEMINATION: The ethics committee of the Hongqi Hospital
      affiliated with the Mudanjiang Medical University of China has approved this
      study protocol. The results will be published in peer-reviewed journals and
      presented at national or international scientific conferences. TRIAL REGISTRATION
      NUMBER: ChiCTR2000029055.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, MengFei
AU  - He M
AUID- ORCID: 0000-0002-8191-5231
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Sun, Li
AU  - Sun L
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Cao, Wenhui
AU  - Cao W
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Yin, Changhao
AU  - Yin C
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
AD  - Heilongjiang Key Laboratory of Ischemic Stroke Prevention and Treatment,
      Mudanjiang Medical University, Mudanjiang, China.
FAU - Sun, Wenqiang
AU  - Sun W
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Liu, Ping
AU  - Liu P
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Tan, Lin
AU  - Tan L
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Xu, Zheng
AU  - Xu Z
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China.
FAU - Zhao, Weina
AU  - Zhao W
AD  - Department of Neurology, HongQi Hospital, Mudanjiang Medical University,
      Mudanjiang, China weinzhao@126.com.
AD  - Heilongjiang Key Laboratory of Ischemic Stroke Prevention and Treatment,
      Mudanjiang Medical University, Mudanjiang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 132654-77-4 (Neurogranin)
SB  - IM
MH  - Aged
MH  - *Alzheimer Disease/pathology
MH  - *Brain/diagnostic imaging/pathology
MH  - Case-Control Studies
MH  - *Cognitive Dysfunction
MH  - *Exosomes
MH  - Humans
MH  - *Neurogranin
MH  - Neuropsychological Tests
MH  - Plasma
MH  - Research Design
PMC - PMC7430441
OTO - NOTNLM
OT  - *neurology
OT  - *neuroradiology
OT  - *radiology & imaging
COIS- Competing interests: None declared.
EDAT- 2020/08/18 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-036990 [pii]
AID - 10.1136/bmjopen-2020-036990 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 16;10(8):e036990. doi: 10.1136/bmjopen-2020-036990.


PMID- 32801197
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 16
TI  - Alcohol use and alcohol-related harm in rural and remote communities: protocol
      for a scoping review.
PG  - e036753
LID - 10.1136/bmjopen-2019-036753 [doi]
AB  - INTRODUCTION: Alcohol-related harm is a major public health concern and appears
      to be particularly problematic in rural and remote communities. Evidence from
      several countries has shown that the prevalence of harmful alcohol use and
      alcohol-attributable hospitalisations and emergency department visits are higher 
      in rural and remote communities than in urban centres. The extents of this
      rural-urban disparity in alcohol-related harm as well as the factors that mediate
      it are poorly understood. The objective of this scoping review is to synthesise
      the international research on the factors that influence the prevalence or risk
      of alcohol-related harm in rural and remote communities. This will help to
      clarify the conceptual landscape of rural and remote alcohol research and
      identify the gaps in knowledge that need to be addressed. METHODS AND ANALYSIS:
      This scoping review will access published literature through search strategies
      developed for Medline, PsycINFO, Embase, CINAHL and Sociological Abstracts. There
      will be no date, country or language restrictions placed on the search. Title and
      abstract, followed by full-text screening, will be conducted by two independent
      reviewers to evaluate all identified articles against a set of prespecified
      inclusion and exclusion criteria. Data from selected articles will be extracted
      and compiled into a final manuscript that adheres to the Preferred Reporting
      Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews
      checklist guidelines. ETHICS AND DISSEMINATION: The results of this review will
      be helpful in guiding future research on rural and remote alcohol use and
      alcohol-related harm, which will inform more effective, evidence-based public
      health strategies to reduce alcohol-related harm in rural and remote communities.
      The results will be disseminated via field-specific conference presentations and 
      peer-reviewed publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Friesen, Erik Loewen
AU  - Friesen EL
AUID- ORCID: 0000-0003-4261-2534
AD  - Institute of Health Policy, Management & Evaluation, University of Toronto,
      Toronto, Ontario, Canada erik.friesen@mail.utoronto.ca.
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Kurdyak, Paul
AU  - Kurdyak P
AD  - Institute of Health Policy, Management & Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - ICES, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Alcohol Drinking/adverse effects/epidemiology
MH  - Humans
MH  - *Mass Screening
MH  - Prevalence
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Rural Population
PMC - PMC7430443
OTO - NOTNLM
OT  - *mental health
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/08/18 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036753 [pii]
AID - 10.1136/bmjopen-2019-036753 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 16;10(8):e036753. doi: 10.1136/bmjopen-2019-036753.


PMID- 32801193
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 16
TI  - REFRESH protocol: a non-inferiority randomised clinical trial comparing internet 
      and teleconference to in-person 'Managing Fatigue' interventions on the impact of
      fatigue among persons with multiple sclerosis.
PG  - e035470
LID - 10.1136/bmjopen-2019-035470 [doi]
AB  - INTRODUCTION: Multiple sclerosis (MS) is an immune-mediated disease of the
      central nervous system. It is considered a major cause of non-traumatic
      disability in young adults. One of the most common and disabling symptoms of MS
      is fatigue. MS fatigue can impact all aspects of quality of life, including
      physical, mental and social function. Fortunately, fatigue self-management
      interventions, such as 'Managing Fatigue: A 6 week energy conservation course',
      can decrease the impact of fatigue and improve health-related quality of life.
      The purpose of this study is to compare three modes of delivering the Managing
      Fatigue intervention-two remote delivery formats (teleconference and internet)
      and one in-person format-on perceptions of fatigue and its impact on physical,
      mental and social function. METHODS AND ANALYSIS: A non-inferiority randomised
      clinical trial is being conducted to compare the three delivery formats (1:1:1
      allocation ratio) among 582 participants with MS living in the Midwestern and
      Northeastern United States. The hypothesis is that teleconference and internet
      versions of the intervention are non-inferior to the traditional mode of clinical
      service delivery (ie, one to one, in person) in terms of the primary outcome of
      self-reported fatigue impact (ie, Fatigue Impact Scale) and the secondary outcome
      of health-related quality of life (ie, Multiple Sclerosis Impact Scale). Outcomes
      are being measured at baseline, 2 months, 3 months and 6 months. The primary
      analysis tool will be linear mixed effects model. The prespecified inferiority
      margin for the primary outcome is 10 points. We will also examine whether
      baseline characteristics (eg, sociodemographic) moderate outcomes of the Managing
      Fatigue intervention and whether changes in self-efficacy and fatigue
      self-management behaviours mediate changes in outcomes. ETHICS AND DISSEMINATION:
      The protocol is approved centrally by the institutional review board at Case
      Western Reserve University. Eligible participants give consent before being
      enrolled and randomised into the study. The study results will be disseminated
      through relevant advocacy organisations, newsletters to participants, publication
      in peer-reviewed journals and presentations at scientific conferences. TRIAL
      REGISTRATION NUMBER: NCT03550170; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Plow, Matthew
AU  - Plow M
AUID- ORCID: 0000-0001-5407-4089
AD  - Frances Payne Bolton School of Nursing, Case Western Reserve University,
      Cleveland, Ohio, USA map208@case.edu.
FAU - Packer, Tanya
AU  - Packer T
AUID- ORCID: 0000-0003-4831-7691
AD  - School of Occupational Therapy and School of Health Administration, Dalhousie
      University, Halifax, Nova Scotia, Canada.
FAU - Mathiowetz, Virgil G
AU  - Mathiowetz VG
AD  - Program in Occupational Therapy, University of Minnesota, Minneapolis, Minnesota,
      USA.
FAU - Preissner, Kathy
AU  - Preissner K
AD  - Department of Occupational Therapy, University of Illinois at Chicago, Chicago,
      Illinois, USA.
FAU - Ghahari, Setareh
AU  - Ghahari S
AD  - School of Rehabilitation Therapy, Queen's University, Kingston, Ontario, Canada.
FAU - Sattar, Abdus
AU  - Sattar A
AD  - School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Bethoux, Francois
AU  - Bethoux F
AD  - Department of Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, 
      Ohio, USA.
FAU - Finlayson, Marcia
AU  - Finlayson M
AD  - School of Rehabilitation Therapy, Queen's University, Kingston, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03550170
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Fatigue/etiology/therapy
MH  - Humans
MH  - Internet
MH  - *Multiple Sclerosis/complications
MH  - New England
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Telecommunications
MH  - Young Adult
PMC - PMC7430436
OTO - NOTNLM
OT  - *multiple sclerosis
OT  - *rehabilitation medicine
OT  - *telemedicine
COIS- Competing interests: FB has financial relationships with pharmaceutical and
      devices companies outside the submitted work.
EDAT- 2020/08/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035470 [pii]
AID - 10.1136/bmjopen-2019-035470 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 16;10(8):e035470. doi: 10.1136/bmjopen-2019-035470.


PMID- 32801189
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 16
TI  - Study protocol for a mixed methods prospective cohort study to explore
      experiences of care following a suicidal crisis in the Australian healthcare
      system.
PG  - e033814
LID - 10.1136/bmjopen-2019-033814 [doi]
AB  - INTRODUCTION: For individuals presenting to the emergency department (ED) for a
      suicide attempt, the period after discharge from hospital is marked by heightened
      vulnerability for further suicide attempts. Effective care following a suicidal
      crisis has the potential to significantly decrease this risk. The current study
      aims to examine the impact of the LifeSpan multilevel suicide prevention model on
      experiences of care following a suicidal crisis. Perspectives from healthcare
      consumers (individuals who have presented to the ED following a suicidal crisis),
      carers, and health professionals will be explored. The LifeSpan model is
      currently being evaluated as a high-fidelity trial in four geographically defined
      regions in New South Wales, Australia. METHODS AND ANALYSIS: This study will use 
      a mixed methods prospective cohort design. Quantitative data collection includes 
      a structured survey, administered to healthcare consumers from LifeSpan sites and
      control sites. Two cohorts of healthcare consumers will be recruited 12 months
      apart with baseline assessment occurring within 18 months of the ED presentation,
      and follow-up 12 months after the initial assessment. Survey participants will be
      recruited online and through participating EDs, mental health organisations and
      aftercare services. Qualitative interview data from healthcare consumers, carers 
      who have accompanied a loved one to the ED following a suicidal crisis and health
      professionals who provide care to people at risk of suicide will be collected
      concurrently with the recruitment of the first cohort of survey participants.
      Purposive and convenience sampling techniques will be used for recruitment of
      interview participants. The primary outcome for this study will be healthcare
      consumers' experiences of service provided at the ED. Analysis will be undertaken
      of the change over time within LifeSpan sites, as well as between LifeSpan sites 
      and control sites, using mixed effects repeated measures models as principal
      means of data analysis. ETHICS AND DISSEMINATION: This research has been approved
      by the Hunter New England Human Research Ethics Committee (HREC/17/HNE/144).
      Results will be disseminated via conferences and peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: ACTRN12617000457347.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rosebrock, Hannah
AU  - Rosebrock H
AUID- ORCID: 0000-0003-0650-0711
AD  - Black Dog Institute, Randwick, New South Wales, Australia
      h.rosebrock@blackdog.org.au Fionas@unsw.edu.au.
FAU - Chen, Nicola
AU  - Chen N
AD  - Black Dog Institute, Randwick, New South Wales, Australia.
FAU - Tye, Michelle
AU  - Tye M
AD  - Black Dog Institute, Randwick, New South Wales, Australia.
AD  - Faculty of Medicine, University of New South Wales, Randwick, New South Wales,
      Australia.
FAU - Mackinnon, Andrew
AU  - Mackinnon A
AD  - Black Dog Institute, Randwick, New South Wales, Australia.
FAU - Calear, Alison L
AU  - Calear AL
AD  - Centre for Mental Health Research, Australian National University, Canberra,
      Australian Capital Territory, Australia.
FAU - Batterham, Philip J
AU  - Batterham PJ
AD  - Centre for Mental Health Research, Australian National University, Canberra,
      Australian Capital Territory, Australia.
FAU - Maple, Myfanwy
AU  - Maple M
AD  - School of Health, University of New England, Armidale, New South Wales,
      Australia.
FAU - Rasmussen, Victoria-Mae
AU  - Rasmussen VM
AD  - Black Dog Institute, Randwick, New South Wales, Australia.
FAU - Schroeder, Liz
AU  - Schroeder L
AD  - Health Systems and Populations, Macquarie University, Sydney, New South Wales,
      Australia.
FAU - Cutler, Henry
AU  - Cutler H
AD  - Health Systems and Populations, Macquarie University, Sydney, New South Wales,
      Australia.
FAU - Shand, Fiona
AU  - Shand F
AD  - Black Dog Institute, Randwick, New South Wales, Australia
      h.rosebrock@blackdog.org.au Fionas@unsw.edu.au.
AD  - Faculty of Medicine, University of New South Wales, Randwick, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200816
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Cohort Studies
MH  - *Delivery of Health Care
MH  - Humans
MH  - New England
MH  - New South Wales
MH  - Prospective Studies
MH  - *Suicidal Ideation
PMC - PMC7430469
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *mental health
OT  - *suicide & self-harm
COIS- Competing interests: None declared.
EDAT- 2020/08/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033814 [pii]
AID - 10.1136/bmjopen-2019-033814 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 16;10(8):e033814. doi: 10.1136/bmjopen-2019-033814.


PMID- 32800498
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 13
IP  - 17
DP  - 2020 Sep 14
TI  - Combination of F-ASO and Targeted Medical Therapy in Patients With Secundum ASD
      and Severe PAH.
PG  - 2024-2034
LID - S1936-8798(20)30973-0 [pii]
LID - 10.1016/j.jcin.2020.04.027 [doi]
AB  - OBJECTIVES: This study was conducted to investigate the combined use of
      fenestrated atrial septal occluder (F-ASO) and targeted medical therapy (TMT) in 
      patients with secundum atrial septal defect (ASD) and severe pulmonary arterial
      hypertension (PAH). BACKGROUND: Treatment of patients with ASD and severe PAH is 
      still challenging. METHODS: After ethical approval was obtained, 56 consecutive
      patients with ASD with severe PAH were included (7 men, 49 women; median age 50.5
      years; mean ASD size 26.9 +/- 4.6 mm). After 3 months of TMT, transcatheter
      closure was performed using F-ASO in patients with ratios of pulmonary to
      systemic blood flow >/=1.5. TMT was continued post-operatively together with 6
      months of dual-antiplatelet therapy. The hemodynamic variables during baseline,
      TMT alone, and combined treatment with F-ASO were compared. RESULTS: After only
      TMT, systolic pulmonary arterial pressure (-14.5 mm Hg; p < 0.001), pulmonary
      vascular resistance (-3.9 Wood units; p < 0.001), and exercise capacity (+72.0 m;
      p < 0.001) improved. Ratio of pulmonary to systemic blood flow increased by 0.9
      (p < 0.001), with adverse cardiac remodeling (right ventricular dimension +3.5
      mm; p < 0.001). Closure with F-ASO (median size 34.0 mm) led to further decrease 
      in systolic pulmonary artery pressure (-6.0 mm Hg; p < 0.001). Follow-up (median 
      duration 10 months) revealed further improvement in exercise capacity (+60.5 m; p
      < 0.001), with favorable cardiac remodeling (right ventricular dimension -9.9 mm;
      p < 0.001). In addition, all fenestrations were stable (p = 0.699), with
      negligible shunt (median ratio of pulmonary to systemic blood flow 1.1) and no
      complications. One year later, pulmonary artery pressure was normalized in 8 of
      19 patients, and PAH recurred in 5 patients after discontinuation of TMT.
      CONCLUSIONS: In patients with ASD and severe PAH, combination of F-ASO and TMT
      was a safe and effective procedure. Compared with TMT alone, the combined
      treatment further improved exercise capacity, with favorable cardiac remodeling.
CI  - Copyright (c) 2020 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
FAU - Yan, Chaowu
AU  - Yan C
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China. Electronic address:
      chaowuyan@163.com.
FAU - Pan, Xiangbin
AU  - Pan X
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Wan, Linyuan
AU  - Wan L
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Li, Hua
AU  - Li H
AD  - Department of Cardiology, Beijing TongRen Hospital, Beijing, China.
FAU - Li, Shiguo
AU  - Li S
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Song, Huijun
AU  - Song H
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Liu, Qiong
AU  - Liu Q
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhang, Fengwen
AU  - Zhang F
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Liu, Yao
AU  - Liu Y
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Jiang, Yong
AU  - Jiang Y
AD  - Department of Structural Heart Disease, Cardiovascular Institute and Fuwai
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Nuclear Medicine, Cardiovascular Institute and Fuwai Hospital,
      National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Fang, Wei
AU  - Fang W
AD  - Department of Nuclear Medicine, Cardiovascular Institute and Fuwai Hospital,
      National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
DEP - 20200812
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Antihypertensive Agents)
RN  - Atrial Septal Defect, Secundum Type
SB  - IM
CIN - JACC Cardiovasc Interv. 2020 Sep 14;13(17):2035-2037. PMID: 32800499
CIN - JACC Cardiovasc Interv. 2020 Nov 23;13(22):2708. PMID: 33213753
CIN - JACC Cardiovasc Interv. 2020 Nov 23;13(22):2708-2709. PMID: 33213754
MH  - Adult
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Cardiac Catheterization/adverse effects/*instrumentation
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Heart Septal Defects, Atrial/diagnostic imaging/physiopathology/*therapy
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Arterial Hypertension/diagnosis/*drug therapy/physiopathology
MH  - Recovery of Function
MH  - *Septal Occluder Device
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Remodeling/drug effects
OTO - NOTNLM
OT  - *fenestration
OT  - *pulmonary arterial hypertension
OT  - *secundum atrial septal defect
OT  - *targeted medical therapy
OT  - *transcatheter closure
EDAT- 2020/08/18 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/08/18 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/04/07 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - S1936-8798(20)30973-0 [pii]
AID - 10.1016/j.jcin.2020.04.027 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2020 Sep 14;13(17):2024-2034. doi:
      10.1016/j.jcin.2020.04.027. Epub 2020 Aug 12.


PMID- 32800292
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1558-4488 (Electronic)
IS  - 0270-9295 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Jul
TI  - Bioethical Dilemmas in Conflict Zones: An Ethicist's Perspective Based on Lessons
      Learned from Gaza.
PG  - 421-428
LID - S0270-9295(20)30079-6 [pii]
LID - 10.1016/j.semnephrol.2020.06.009 [doi]
AB  - Health care practitioners practicing in conflict zones, more often than not, face
      ethical conundrums that are more urgent and extreme than those faced by their
      colleagues working in regular medical settings. Indeed, field physicians can
      attest to the fact that, oftentimes, medical ethics in war time is quite
      different, and that indeed they ought to be different. This strain is sensed only
      by those who have witnessed wars and practiced health care in times of conflict. 
      Undeniably, physicians might recourse to what I call contrived medical ethics,
      which allows their medicine as well as moral compass to remain viable and moral. 
      In this article, the challenges and dilemmas surrounding dialysis and renal
      transplants in war zones, particularly in the Middle East using Gaza as a model, 
      are discussed.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Arawi, Thalia
AU  - Arawi T
AD  - Salim El-Hoss Bioethics and Professionalism Program, American University of
      Beirut Faculty of Medicine and Medical Center, Beirut, Lebanon. Electronic
      address: ta16@aub.edu.lb.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Nephrol
JT  - Seminars in nephrology
JID - 8110298
SB  - IM
MH  - *Ethicists
MH  - *Ethics, Medical
MH  - Humans
OTO - NOTNLM
OT  - Conflict zone
OT  - Gaza
OT  - bioethics
OT  - dialysis
OT  - ecology of war
OT  - ethical dilemmas
OT  - renal transplants
EDAT- 2020/08/18 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - S0270-9295(20)30079-6 [pii]
AID - 10.1016/j.semnephrol.2020.06.009 [doi]
PST - ppublish
SO  - Semin Nephrol. 2020 Jul;40(4):421-428. doi: 10.1016/j.semnephrol.2020.06.009.


PMID- 32800288
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1558-4488 (Electronic)
IS  - 0270-9295 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Jul
TI  - Peritoneal Dialysis during Active War.
PG  - 375-385
LID - S0270-9295(20)30075-9 [pii]
LID - 10.1016/j.semnephrol.2020.06.005 [doi]
AB  - Armed conflict jeopardizes patient care through shortages in vital medical
      supplies. When health care resources are both scarce and not secure, ethically
      justified principles of action are required to continue the treatment of
      patients. Although literature exists on the allocation and treatment decisions
      for military health care workers and warfighters, scarce literature exist for the
      use of available resources for civilians living within war zones. Chronic or
      acute kidney disease patients requiring replacement therapies are among the most 
      vulnerable patient population in this regard. In this article, we discuss the use
      of peritoneal dialysis treatment for both acute and chronic kidney disease
      patients during war times.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Gorbatkin, Chad
AU  - Gorbatkin C
AD  - Department of Emergency Medicine, Madigan Army Medical Center, Tacoma, WA.
FAU - Finkelstein, Fredric O
AU  - Finkelstein FO
AD  - Department of Nephrology, Yale University, New Haven, CT.
FAU - Kazancioglu, Rumeyza Turan
AU  - Kazancioglu RT
AD  - Division of Nephrology, Bezmialem Vakif University, Istanbul, Turkey. Electronic 
      address: rkazancioglu@bezmialem.edu.tr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Nephrol
JT  - Seminars in nephrology
JID - 8110298
SB  - IM
MH  - Humans
MH  - *Peritoneal Dialysis
OTO - NOTNLM
OT  - Peritoneal dialysis
OT  - acute kidney injury
OT  - armed conflict
OT  - chronic kidney disease
OT  - disaster
EDAT- 2020/08/18 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - S0270-9295(20)30075-9 [pii]
AID - 10.1016/j.semnephrol.2020.06.005 [doi]
PST - ppublish
SO  - Semin Nephrol. 2020 Jul;40(4):375-385. doi: 10.1016/j.semnephrol.2020.06.005.


PMID- 32800276
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1618-1298 (Electronic)
IS  - 0171-9335 (Linking)
VI  - 99
IP  - 6
DP  - 2020 Aug
TI  - Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising
      frontier.
PG  - 151097
LID - S0171-9335(20)30036-4 [pii]
LID - 10.1016/j.ejcb.2020.151097 [doi]
AB  - Neurodegenerative disorders are a variety of diseases including Alzheimer's (AD),
      Parkinson's (PD), and Huntington's diseases (HD), multiple sclerosis (MS) and
      amyotrophic lateral sclerosis (ALS) along with some other less common diseases
      generally described by the advanced deterioration of central or peripheral
      nervous system, structurally or functionally. In the last two decades,
      mesenchymal stromal cells (MSCs) due to their unique assets encompassing
      self-renewal, multipotency and accessibility in association with low ethical
      concern open new frontiers in the context of neurodegenerative diseases therapy. 
      Interestingly, MSCs can be differentiated into endodermal and ectodermal lineages
      (e.g., neurons, oligodendrocyte, and astrocyte), and thus could be employed to
      advance cell-based therapeutic strategy. Additionally, as inflammation ordinarily
      ensues as a local response provoked by microglia in the neurodegenerative
      diseases, MSCs therapy because of their pronounced immunomodulatory properties is
      noticed as a rational approach for their treatment. Recently, varied types of
      studies have been mostly carried out in vitro and rodent models using MSCs upon
      their procurement from various sources and expansion. The promising results of
      the studies in rodent models have motivated researchers to design and perform
      several clinical trials, with a speedily rising number. In the current review, we
      aim to deliver a brief overview of MSCs sources, expansion strategies, and their 
      immunosuppressive characteristics and discuss credible functional mechanisms
      exerted by MSCs to treat neurodegenerative disorders, covering AD, PD, ALS, MS,
      and HD.
CI  - Copyright (c) 2020. Published by Elsevier GmbH.
FAU - Shariati, Ali
AU  - Shariati A
AD  - Department of Tissue Engineering and Applied Cell Sciences, School of Advanced
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;
      Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran
      University of Medical Sciences, Tehran, Iran. Electronic address:
      alishariati66@gmail.com.
FAU - Nemati, Reza
AU  - Nemati R
AD  - Department of Medical Emergencies, School of Allied Medical Sciences, Bushehr
      University of Medical Sciences, Bushehr, Iran. Electronic address:
      Reza.nemati@outlook.com.
FAU - Sadeghipour, Yasin
AU  - Sadeghipour Y
AD  - Department of Medical Nanotechnology, School of Advanced Medical Sciences and
      Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic
      address: yasin.sadeghipour@yahoo.com.
FAU - Yaghoubi, Yoda
AU  - Yaghoubi Y
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
      Electronic address: Yoda1371@yahoo.com.
FAU - Baghbani, Reza
AU  - Baghbani R
AD  - Department of Medical Emergencies, School of Allied Medical Sciences, Bushehr
      University of Medical Sciences, Bushehr, Iran. Electronic address:
      r.baghbani1216@gmail.com.
FAU - Javidi, Kamran
AU  - Javidi K
AD  - School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
      Electronic address: javidi.kamran@shmu.ac.ir.
FAU - Zamani, Majid
AU  - Zamani M
AD  - Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Gonabad
      University of Medical Sciences, Gonabad, Iran. Electronic address:
      majidzamani12@gmail.com.
FAU - Hassanzadeh, Ali
AU  - Hassanzadeh A
AD  - Department of Tissue Engineering and Applied Cell Sciences, School of Advanced
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran;
      Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran
      University of Medical Sciences, Tehran, Iran; Cell Therapy and Regenerative
      Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
      Electronic address: alihassanzadeh1369@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200626
PL  - Germany
TA  - Eur J Cell Biol
JT  - European journal of cell biology
JID - 7906240
SB  - IM
MH  - Cell- and Tissue-Based Therapy/*methods
MH  - Humans
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Neurodegenerative Diseases/physiopathology/*therapy
OTO - NOTNLM
OT  - Cell therapy
OT  - Expansion
OT  - Immunomodulatory properties
OT  - Mesenchymal stromal cells (MSCs)
OT  - Neurodegenerative diseases
OT  - Source
COIS- Declaration of Competing Interest The authors declare that they have no competing
      interests.
EDAT- 2020/08/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/06/22 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S0171-9335(20)30036-4 [pii]
AID - 10.1016/j.ejcb.2020.151097 [doi]
PST - ppublish
SO  - Eur J Cell Biol. 2020 Aug;99(6):151097. doi: 10.1016/j.ejcb.2020.151097. Epub
      2020 Jun 26.


PMID- 32800066
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20201218
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 67
IP  - 9
DP  - 2020 Aug 6
TI  - Transmission, start of symptom and morbidity among Danish COVID-19 patients
      admitted to hospital.
LID - A05200325 [pii]
AB  - INTRODUCTION: We explored transmission of the coronavirus disease 2019 (COVID-19)
      in severely ill patients and analysed the relationship between co-morbidity and
      mortality or the need for intensive care unit (ICU) care. METHODS: Clinical data,
      treatment and outcome were analysed in this retrospective study of 101
      consecutive patients with COVID-19 admitted to a regional Danish hospital from 2 
      March 2020, based on data from electronic medical records. RESULTS: The mean age 
      was 71.8 years, 33% were never smokers and 82% had one or more predefined chronic
      diseases. In-hospital mortality was 30%, and 20% of the patients were offered ICU
      care. In ICU patients, we found a male preponderance (88% versus 44%, p = 0.006),
      but death (50% versus 25%, p = 0.053) and other pre-defined co-morbidities did
      not differ significantly from non-ICU patients. The source of infection was
      unknown in 74% of patients, related to endemic travel in 10%, hospital acquired
      in 6% and related to close acquaintances in 11%. COVID-19-related symptoms were
      initially observed from February 21 (week 8 and week 9) in the first three
      patients who had no known source of infection. We found that 7% of cases had an
      increased risk of in-hospital transmission, based on a 7-16 days delay in
      coronavirus testing. CONCLUSIONS: The frequency of co-morbidity in
      hospital-admitted COVID-19 patients and the correlation to death and ICU
      attendance were analysed. In all, 74% of the infection cases were of unknown
      source during the first weeks of the epidemic, which points to considerable
      community transmission and possibly pre- or asymptomatic transmission, also
      several weeks before 21 February 2020. FUNDING: none. TRIAL REGISTRATION: not
      relevant after correspondence with the Ethics Committee of Region Zealand.
      Furthermore, permission was granted from The Danish Data Protection Agency,
      Region Zealand (REG-070-2020).
CI  - Articles published in the DMJ are "open access". This means that the articles are
      distributed under the terms of the Creative Commons Attribution Non-commercial
      License, which permits any non-commercial use, distribution, and reproduction in 
      any medium, provided the original author(s) and source are credited.
FAU - Meyer, Christian N
AU  - Meyer CN
AD  - cnm@regionsjaelland.dk.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*transmission
MH  - Denmark/epidemiology
MH  - Female
MH  - Hospital Mortality/trends
MH  - Hospitalization/*trends
MH  - Humans
MH  - Male
MH  - Morbidity/trends
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*transmission
MH  - Retrospective Studies
MH  - SARS-CoV-2
EDAT- 2020/08/18 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - A05200325 [pii]
PST - epublish
SO  - Dan Med J. 2020 Aug 6;67(9). pii: A05200325.


PMID- 32799921
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Aug 16
TI  - Barriers and facilitators to access mental health services among refugee women in
      high-income countries: study protocol for a systematic review.
PG  - 186
LID - 10.1186/s13643-020-01446-y [doi]
AB  - BACKGROUND: According to the United Nation High Commissioner for Refugee Global
      Trends report in 2019, on average, there are 2.7 refugees per 1000 national
      population in high-income countries, where girls and women attributed to 48% of
      the refugee population. Evidence shows high prevalence of mental health disorder 
      among women refugees in comparison to the general population. To our knowledge,
      no systematic reviews have addressed access to mental health services for refugee
      women. The aim of this study will be to examine existing barriers and
      facilitators to accessing mental health services for refugee women in leading
      high-income countries for refugee resettlement. METHODS: We designed and
      registered a study protocol for a systematic review. We will conduct a literature
      search (from inception onwards) in MEDLINE, EMBASE, PsycINFO, and CINAHL.
      Research articles having a qualitative component (i.e., qualitative, mixed, or
      multi-method) will be eligible. Study populations of interest will be refugee
      women at any age that can receive mental health services in leading high-income
      countries for refugee resettlement (e.g., 14 countries from North America,
      Europe, and Oceania). Eligibility will be restricted to studies published in
      English. The primary outcome will be all barriers and facilitators related to
      accessing mental health services. Two reviewers will independently screen all
      citations, full-text articles, and abstract data. Potential conflicts will be
      resolved through discussion. The study methodological quality (or bias) will be
      appraised using appropriate tools. Reporting will follow the Enhancing
      Transparency in Reporting the Synthesis of Qualitative Research (ENTREQ)
      statement. A narrative synthesis will be conducted, and summary of findings
      tables will be produced. As it will be a systematic review, without human
      participants' involvement, there will be no requirement for ethical approval.
      DISCUSSION: The systematic review will present key evidence on barriers and
      facilitators to access mental health services among refugee women in leading
      resettlement countries. The findings will be used to inform program developers,
      policymakers, and other stakeholders to enhance mental health services for
      refugee women. The final manuscript will be disseminated through a peer-reviewed 
      journal and scientific conferences. SYSTEMATIC REVIEW REGISTRATION: PROSPERO
      CRD42020180369.
FAU - DeSa, Sarah
AU  - DeSa S
AD  - Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa,
      Ontario, Canada.
FAU - Gebremeskel, Akalewold T
AU  - Gebremeskel AT
AD  - Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
AD  - School of International Development and Global Studies, University of Ottawa,
      Ottawa, Ontario, Canada.
FAU - Yaya, Sanni
AU  - Yaya S
AUID- ORCID: 0000-0002-4876-6043
AD  - School of International Development and Global Studies, University of Ottawa,
      Ottawa, Ontario, Canada. sanni.yaya@uOttawa.ca.
AD  - The George Institute for Global Health, Imperial College London, London, UK.
      sanni.yaya@uOttawa.ca.
LA  - eng
PT  - Journal Article
DEP - 20200816
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - Developed Countries
MH  - Europe
MH  - Female
MH  - Humans
MH  - *Mental Health Services
MH  - North America
MH  - *Refugees
MH  - Systematic Reviews as Topic
PMC - PMC7429857
EDAT- 2020/08/18 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01446-y [doi]
AID - 10.1186/s13643-020-01446-y [pii]
PST - epublish
SO  - Syst Rev. 2020 Aug 16;9(1):186. doi: 10.1186/s13643-020-01446-y.


PMID- 32799859
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 15
TI  - Public trust and global biobank networks.
PG  - 73
LID - 10.1186/s12910-020-00515-0 [doi]
AB  - BACKGROUND: Biobanks provide an important foundation for genomic and personalised
      medicine. In order to enhance their scientific power and scope, they are
      increasingly becoming part of national or international networks. Public trust is
      essential in fostering public engagement, encouraging donation to, and
      facilitating public funding for biobanks. Globalisation and networking of
      biobanking may challenge this trust. METHODS: We report the results of an
      Australian study examining public attitudes to the networking and globalisation
      of biobanks. The study used quantitative and qualitative methods in conjunction
      with bioethical analysis in order to determine factors that may contribute to,
      and threaten, trust. RESULTS: Our results indicate a generally high level of
      trust in biobanks and in medical research more broadly. Key factors that can
      reduce perceived trustworthiness of biobanks are commercialisation and
      involvement in global networking. CONCLUSIONS: We conclude that robust ethical
      oversight and governance standards can both promote trust in global biobanking
      and ensure that this trust is warranted.
FAU - Dive, Lisa
AU  - Dive L
AUID- ORCID: 0000-0001-6655-5138
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
      lisa.dive@sydney.edu.au.
FAU - Critchley, Christine
AU  - Critchley C
AD  - Department of Psychological Sciences, School of Health Sciences, Swinburne
      University of Technology; and Centre for Law and Genetics, University of
      Tasmania, Hobart, Australia.
FAU - Otlowski, Margaret
AU  - Otlowski M
AD  - Faculty of Law, University of Tasmania, Hobart, Australia.
FAU - Mason, Paul
AU  - Mason P
AD  - Taronga Institute of Science and Learning, Taronga Conservation Society, Mosman, 
      Australia.
FAU - Wiersma, Miriam
AU  - Wiersma M
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
FAU - Light, Edwina
AU  - Light E
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
FAU - Stewart, Cameron
AU  - Stewart C
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
FAU - Lipworth, Wendy
AU  - Lipworth W
AD  - Sydney Health Ethics, University of Sydney, Sydney, Australia.
LA  - eng
GR  - APP1083980/National Health and Medical Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200815
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Australia
MH  - *Biological Specimen Banks
MH  - *Biomedical Research
MH  - Humans
MH  - Public Opinion
MH  - Trust
PMC - PMC7429755
OTO - NOTNLM
OT  - *Biobanks
OT  - *Commercialisation
OT  - *Globalisation
OT  - *Trust
EDAT- 2020/08/18 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/18 06:00
PHST- 2019/08/27 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00515-0 [doi]
AID - 10.1186/s12910-020-00515-0 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 15;21(1):73. doi: 10.1186/s12910-020-00515-0.


PMID- 32799789
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 2146-8427 (Electronic)
IS  - 1304-0855 (Linking)
VI  - 18
IP  - 5
DP  - 2020 Oct
TI  - Effect of Opt-out System for Organ Donation After Brain Death on Ethical
      Legitimacy and Potential Efficacy in a Mathematical Model.
PG  - 626-632
LID - 10.6002/ect.2019.0420 [doi]
AB  - OBJECTIVES: We aimed to compare the possible outcomes of the current (opt-in)
      system and an opt-out system for organ donation in South Korea using a
      mathematical model. MATERIALS AND METHODS: A structured questionnaire was used to
      investigate the decision on organ donation and family consent after brain death
      under the current system and an opt-out system. The survey was conducted in
      August 2018 by means of a voluntary survey of 100 opposite-sex married couples.
      RESULTS: Sixty-three percent of participants wished to self-donate their organs
      after brain death: 69.5% were positive and 30.5% were negative regarding the
      implementation of the opt-out system. Among 200 participants, the total number of
      possible donors increased from 110 (55.0%) in the current system to 139 (69.5%)
      in the opt-out system. Positive autonomy was defined as obtainment of consent
      from the donor and the spouse, and negative autonomy was defined as concordaence 
      of refusal between the donor and the spouse. Comparisons between the systems
      showed that the rate of autonomy increased from 57.0% in the current system to
      61.5% in the opt-out system. Although the achievement of positive autonomy
      increased from 59.5% in the current system to 74.6% in the opt-out system, the
      achievement of negative autonomy decreased from 52.7% in the current system to
      39.2% in the opt-out system. CONCLUSIONS: An opt-out system can increase the
      number of organ donors; however, achievement of negative autonomy can decrease.
FAU - Kim, Sang Woo
AU  - Kim SW
AD  - >From the Department of Surgery, Keimyung University Dongsan Medical Center,
      Daegu, Republic of Korea.
FAU - Lee, Hyun Yong
AU  - Lee HY
FAU - Park, Ui Jun
AU  - Park UJ
FAU - Kim, Hyoung Tae
AU  - Kim HT
FAU - Roh, Young-Nam
AU  - Roh YN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200815
PL  - Turkey
TA  - Exp Clin Transplant
JT  - Experimental and clinical transplantation : official journal of the Middle East
      Society for Organ Transplantation
JID - 101207333
SB  - IM
MH  - Adult
MH  - *Brain Death/legislation & jurisprudence
MH  - Choice Behavior
MH  - Family Relations
MH  - Female
MH  - *Health Policy/legislation & jurisprudence
MH  - Humans
MH  - *Informed Consent/ethics/legislation & jurisprudence
MH  - Male
MH  - Middle Aged
MH  - *Models, Theoretical
MH  - Personal Autonomy
MH  - Policy Making
MH  - *Presumed Consent/ethics/legislation & jurisprudence
MH  - Republic of Korea
MH  - *Spouses/legislation & jurisprudence
MH  - Surveys and Questionnaires
MH  - *Tissue Donors/ethics/legislation & jurisprudence/supply & distribution
MH  - Young Adult
EDAT- 2020/08/18 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.6002/ect.2019.0420 [doi]
PST - ppublish
SO  - Exp Clin Transplant. 2020 Oct;18(5):626-632. doi: 10.6002/ect.2019.0420. Epub
      2020 Aug 15.


PMID- 32799573
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20220417
IS  - 1744-8379 (Electronic)
IS  - 1473-7167 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Oct
TI  - In our war against the opioid epidemic, could 'weed' be a winner?
PG  - 423-429
LID - 10.1080/14737167.2020.1807944 [doi]
AB  - INTRODUCTION: The opioid epidemic has resulted in the deaths of millions of
      Americans and was declared a public health emergency in 2017. In response, many
      states have enacted policies and analyzed various interventions for harm
      reduction and overdose prevention, which have embraced limited success. With more
      states legalizing medical marijuana, another intervention of interest in pain
      management, much research has since focused on the potential for medical
      marijuana laws (MMLs) to curb the opioid epidemic. Nonetheless, marijuana
      legalization and its use for medical purposes has been a polarizing debate from
      ethical, social, and clinical perspectives. AREAS COVERED: We examine evidence on
      the merits of medical marijuana to address its potential as a diversion from
      prescription painkillers. Additionally, we review the impact of MMLs on
      opioid-related outcomes. Furthermore, we provide multi-layered recommendations
      for future directions in the evaluation of medical marijuana and MMLs as
      potential mitigators of the opioid epidemic. EXPERT OPINION: Despite limited and 
      mixed evidence of efficacy, medical marijuana may still play an important role in
      addressing the opioid epidemic in the United States. Furthermore, we believe
      coordinated responses among the federal government, states, researchers, and
      patients are crucial in producing more robust evaluations of medical marijuana
      and MMLs.
FAU - Ding, Delaney D
AU  - Ding DD
AUID- ORCID: https://orcid.org/0000-0002-4658-4553
AD  - Clinical Research Coordinator, Medical Practice Evaluation Center, Massachusetts 
      General Hospital , Boston, MA, USA.
FAU - Balkrishnan, Rajesh
AU  - Balkrishnan R
AUID- ORCID: https://orcid.org/0000-0001-9363-9257
AD  - University of Virginia School of Medicine, Clinical Professor, University of
      Virginia School of Nursing , Charlottesville, VA, USA.
FAU - Diaby, Vakaramoko
AU  - Diaby V
AUID- ORCID: https://orcid.org/0000-0002-6251-0773
AD  - Department of Pharmaceutical Outcomes and Policy (POP), College of Pharmacy,
      University of Florida , Gainesville, FL, USA.
LA  - eng
PT  - Journal Article
DEP - 20200831
PL  - England
TA  - Expert Rev Pharmacoecon Outcomes Res
JT  - Expert review of pharmacoeconomics & outcomes research
JID - 101132257
RN  - 0 (Medical Marijuana)
SB  - IM
MH  - Drug Overdose/prevention & control
MH  - Humans
MH  - Legislation, Drug
MH  - Marijuana Use/*legislation & jurisprudence
MH  - Medical Marijuana/*administration & dosage
MH  - Opioid Epidemic/*prevention & control
MH  - Opioid-Related Disorders/*prevention & control
MH  - Prescription Drug Diversion/prevention & control
MH  - Prescription Drug Misuse/prevention & control
MH  - United States/epidemiology
OTO - NOTNLM
OT  - Health policy
OT  - cannabis as medicine
OT  - medical cannabis
OT  - medical marijuana
OT  - medical marijuana laws
OT  - opioid epidemic
OT  - pain management
OT  - prescription opioids
EDAT- 2020/08/18 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - 10.1080/14737167.2020.1807944 [doi]
PST - ppublish
SO  - Expert Rev Pharmacoecon Outcomes Res. 2020 Oct;20(5):423-429. doi:
      10.1080/14737167.2020.1807944. Epub 2020 Aug 31.


PMID- 32799307
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Aug 10
TI  - Uncertainties about the need for ethics approval in Switzerland: a mixed-methods 
      study.
PG  - w20318
LID - 10.4414/smw.2020.20318 [doi]
LID - Swiss Med Wkly. 2020;150:w20318 [pii]
AB  - BACKGROUND: To ensure ethical oversight, researchers wanting to conduct
      &ldquo;research&rdquo; involving human beings are typically required to obtain
      prior approval from an independent ethics committee. However, it can sometimes be
      unclear if a project needs to be submitted for ethics approval. Swiss researchers
      can contact research ethics committees via a &ldquo;jurisdictional inquiry&rdquo;
      for clarification whether a project needs to be submitted for ethics approval.
      AIMS OF THE STUDY: (1) To examine the characteristics of Swiss jurisdictional
      inquiries, and (2) to identify possible uncertainties regarding the correct
      interpretation of existing legislation in Switzerland. METHODS: All
      jurisdictional inquiries submitted to Swiss research ethics committees between
      July and December 2017 were reviewed using qualitative content analysis. We then 
      conducted an online survey between June 2018 and July 2018 with all researchers
      who had submitted a jurisdictional inquiry including a descriptive quantitative
      analysis. RESULTS: The review included 271 jurisdictional inquiries. Analysis
      identified three groups of jurisdictional inquiries: 80.4% (218/271) sought
      clarification whether the project had to be submitted for ethical approval; 18.5%
      (50/271) requested a &ldquo;declaration of no objection&rdquo;; and 1.1% (3/271) 
      asked for a clarification about which of the two ordinances was applicable to the
      project. Analysis identified eight distinct legal issues that appeared to be the 
      main cause for a number of jurisdictional inquiries, with the two most frequently
      identified issues being whether the project will produce generalisable knowledge,
      and whether the project uses fully anonymised data. Overall, research ethics
      committees decided that 78.6% (213/271) of the jurisdictional inquiries were
      outside their jurisdiction and did not require ethical approval, and that 15.6%
      required submission for ethical approval. The online survey achieved a 56.8%
      response rate. The majority of respondents (94/166; 56.6%) reported that all the 
      questions they were asked during the submission of the jurisdictional inquiry
      were easy to understand. Respondents reported that 88% (147/166) of all projects 
      were started or planned to start. The vast majority (154/166; 93%) of respondents
      also agreed with the decisions made by the research ethics committee.
      CONCLUSIONS: Jurisdictional inquiries are an important means for researchers to
      clarify whether their project requires ethical oversight. However, this
      mixed-methods study has identified some difficulties in the interpretation of
      legal terms, which often reflect persistent structural issues that many other
      countries also face. More detailed guidance may be helpful to reduce the
      researchers&rsquo; uncertainties and ethics committees&rsquo; workloads in
      relation to jurisdictional inquiries.
FAU - Gloy, Viktoria
AU  - Gloy V
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University of Basel and University Hospital Basel, Switzerland.
FAU - McLennan, Stuart
AU  - McLennan S
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University of Basel and University Hospital Basel, Switzerland /
      Institute for Biomedical Ethics, University of Basel, Switzerland / Institute of 
      History and Ethics in Medicine, Technical University of Munich, Germany.
FAU - Rinderknecht, Matthias
AU  - Rinderknecht M
AD  - Swiss Federal Office of Public Health, Division of Biomedicine, Human Research
      Section, Bern, Switzerland.
FAU - Ley, Bettina
AU  - Ley B
AD  - Swiss Federal Office of Public Health, Division of Biomedicine, Human Research
      Section, Bern, Switzerland.
FAU - Meier, Brigitte
AU  - Meier B
AD  - Swiss Federal Office of Public Health, Division of Biomedicine, Human Research
      Section, Bern, Switzerland.
FAU - Driessen, Susanne
AU  - Driessen S
AD  - swissethics, Bern, Switzerland.
FAU - Gervasoni, Pietro
AU  - Gervasoni P
AD  - swissethics, Bern, Switzerland.
FAU - Hirschel, Bernard
AU  - Hirschel B
AD  - Commission cantonale d'ethique de la recherche (CCER), Geneva, Switzerland.
FAU - Benkert, Pascal
AU  - Benkert P
AD  - Department of Clinical Research, Clinical Trial Unit, University of Basel and
      University Hospital Basel, Switzerland.
FAU - Gilles, Ingrid
AU  - Gilles I
AD  - Cellule Enquetes de Satisfaction et d'Opinion des Patient-e-s et des Employe-e-s 
      (ESOPE), Centre for Primary Care and Public Health (Unisante), University of
      Lausanne, Switzerland.
FAU - von Elm, Erik
AU  - von Elm E
AD  - Cochrane Switzerland, Centre for Primary Care and Public Health (Unisante),
      University of Lausanne, Switzerland.
FAU - Briel, Matthias
AU  - Briel M
AD  - Department of Clinical Research, Basel Institute for Clinical Epidemiology and
      Biostatistics, University of Basel and University Hospital Basel, Switzerland /
      Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - *Research Design
MH  - Switzerland
EDAT- 2020/08/18 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.4414/smw.2020.20318 [doi]
AID - Swiss Med Wkly. 2020;150:w20318 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Aug 12;150:w20318. doi: 10.4414/smw.2020.20318. eCollection 
      2020 Aug 10.


PMID- 32799256
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 7
DP  - 2020 Jul
TI  - Ethics of health care in the Corona pandemic.
PG  - 1113-1114
FAU - Zaidi, Shabih H
AU  - Zaidi SH
AD  - Otolaryngologist & Ethicist, National Health Service (NHS), England.
LA  - eng
PT  - Editorial
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - *Influenza, Human/epidemiology
MH  - *Pandemics
EDAT- 2020/08/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10035 [pii]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Jul;70(7):1113-1114.


PMID- 32798573
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 83
IP  - 6
DP  - 2020 Dec
TI  - Ethical issues related to the virtual interviews process faced by applicants and 
      programs.
PG  - 1845-1846
LID - S0190-9622(20)32429-4 [pii]
LID - 10.1016/j.jaad.2020.08.038 [doi]
FAU - Alvarado, Savannah
AU  - Alvarado S
AD  - University of Connecticut School of Medicine, Farmington, Connecticut.
FAU - Grant-Kels, Jane M
AU  - Grant-Kels JM
AD  - Dermatology Department, University of Connecticut School of Medicine, Farmington,
      Connecticut. Electronic address: grant@uchc.edu.
LA  - eng
PT  - Letter
DEP - 20200813
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
SB  - IM
MH  - COVID-19/epidemiology/prevention & control/transmission
MH  - Dermatologists/*ethics
MH  - Dermatology/*ethics/standards
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Personnel Selection/*ethics/methods/standards
MH  - Physical Distancing
MH  - Telecommunications/*ethics
PMC - PMC7424288
EDAT- 2020/08/18 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/18 06:00
PHST- 2020/08/08 00:00 [received]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2020/08/18 06:00 [entrez]
AID - S0190-9622(20)32429-4 [pii]
AID - 10.1016/j.jaad.2020.08.038 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2020 Dec;83(6):1845-1846. doi: 10.1016/j.jaad.2020.08.038.
      Epub 2020 Aug 13.


PMID- 32797639
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20210909
IS  - 1573-2770 (Electronic)
IS  - 0091-0562 (Linking)
VI  - 66
IP  - 3-4
DP  - 2020 Dec
TI  - Implementing Community-Based Participatory Research with Communities Affected by 
      Humanitarian Crises: The Potential to Recalibrate Equity and Power in Vulnerable 
      Contexts.
PG  - 381-391
LID - 10.1002/ajcp.12453 [doi]
AB  - Worldwide, over 70.8 million people are forcibly displaced from their homes as a 
      result of persecution, conflict, violence, or human rights violation. In
      humanitarian crises, protection and the provision of basic needs are often
      prioritized. Research may be seen as opportunistic. However, without documenting 
      and researching humanitarian responses, knowledge is not shared and does not
      accumulate, limiting the application of evidence-based interventions where they
      are most needed. Research in humanitarian crises is complex, both ethically and
      methodologically. Community-engaged research, and specifically community-based
      participatory research (CBPR), can address some of the challenges of research in 
      these settings. Using case studies of research we have conducted with communities
      affected by humanitarian crises, we highlight challenges and opportunities of the
      application of the ten core principles of CBPR in humanitarian settings. Despite 
      some challenges and barriers, CBPR is a highly effective approach to use when
      engaging these populations in research. We argue that the application of CBPR in 
      these settings has the potential to recalibrate the scales of equity and power
      among vulnerable populations.
CI  - (c) 2020 Society for Community Research and Action.
FAU - Afifi, Rima A
AU  - Afifi RA
AD  - Community and Behavioral Health Department, College of Public Health, University 
      of Iowa, Iowa City, IA, USA.
FAU - Abdulrahim, Sawsan
AU  - Abdulrahim S
AD  - Health Promotion and Community Health Department, Faculty of Health Sciences,
      American University of Beirut, Beirut, Lebanon.
FAU - Betancourt, Theresa
AU  - Betancourt T
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA, USA.
FAU - Btedinni, Dima
AU  - Btedinni D
AD  - Health Promotion and Community Health Department, Faculty of Health Sciences,
      American University of Beirut, Beirut, Lebanon.
FAU - Berent, Jenna
AU  - Berent J
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA, USA.
FAU - Dellos, Laura
AU  - Dellos L
AD  - Obstetrics and Gynecology Department, Carver College of Medicine, University of
      Iowa, Iowa City, IA, USA.
FAU - Farrar, Jordan
AU  - Farrar J
AD  - Research Program on Children and Adversity, Boston College School of Social Work,
      Chestnut Hill, MA, USA.
FAU - Nakkash, Rima
AU  - Nakkash R
AD  - Health Promotion and Community Health Department, Faculty of Health Sciences,
      American University of Beirut, Beirut, Lebanon.
FAU - Osman, Rilwan
AU  - Osman R
AD  - Maine Immigrant and Refugee Services, Lewiston, ME, USA.
FAU - Saravanan, Monisa
AU  - Saravanan M
AD  - Community and Behavioral Health Department, College of Public Health, University 
      of Iowa, Iowa City, IA, USA.
FAU - Story, William T
AU  - Story WT
AD  - Community and Behavioral Health Department, College of Public Health, University 
      of Iowa, Iowa City, IA, USA.
FAU - Zombo, Moses
AU  - Zombo M
AD  - Green Africa Sierra Leone, Bo, Sierra Leone.
FAU - Parker, Edith
AU  - Parker E
AD  - Community and Behavioral Health Department, College of Public Health, University 
      of Iowa, Iowa City, IA, USA.
LA  - eng
GR  - P30 ES005605/ES/NIEHS NIH HHS/United States
GR  - R01 MD010613/MD/NIMHD NIH HHS/United States
GR  - 081915/Z/07/Z/WT_/Wellcome Trust/United Kingdom
GR  - R01MD010613/National Center on Minority Health and Health
      Disparities/International
GR  - R01 HD073349/HD/NICHD NIH HHS/United States
GR  - R01HD073349/National Institute of Child Health and Human
      Development/International
GR  - U19MH095705/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200814
PL  - England
TA  - Am J Community Psychol
JT  - American journal of community psychology
JID - 0364535
SB  - IM
MH  - *Altruism
MH  - Community-Based Participatory Research/*methods
MH  - *Community-Institutional Relations
MH  - Humans
MH  - Refugees
MH  - Relief Work
MH  - *Vulnerable Populations
OTO - NOTNLM
OT  - *CBPR
OT  - *Community-engaged research
OT  - *Humanitarian crises
OT  - *POWER
OT  - *Partnership
OT  - *Positionality
EDAT- 2020/08/17 06:00
MHDA- 2021/09/10 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
PHST- 2020/08/16 06:00 [entrez]
AID - 10.1002/ajcp.12453 [doi]
PST - ppublish
SO  - Am J Community Psychol. 2020 Dec;66(3-4):381-391. doi: 10.1002/ajcp.12453. Epub
      2020 Aug 14.


PMID- 32797153
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1464-3677 (Electronic)
IS  - 1353-4505 (Linking)
VI  - 32
IP  - 8
DP  - 2020 Nov 9
TI  - Ethical frameworks for quality improvement activities: an analysis of
      international practice.
PG  - 558-566
LID - 10.1093/intqhc/mzaa092 [doi]
AB  - PURPOSE: To examine international approaches to the ethical oversight and
      regulation of quality improvement and clinical audit in healthcare systems. DATA 
      SOURCES: We searched grey literature including websites of national research and 
      ethics regulatory bodies and health departments of selected countries. STUDY
      SELECTION: National guidance documents were included from six countries: Ireland,
      England, Australia, New Zealand, the United States of America and Canada. DATA
      EXTRACTION: Data were extracted from 19 documents using an a priori framework
      developed from the published literature. RESULTS: We organized data under five
      themes: ethical frameworks; guidance on ethical review; consent, vulnerable
      groups and personal health data. Quality improvement activity tended to be
      outside the scope of the ethics frameworks in most countries. Only New Zealand
      had integrated national ethics standards for both research and quality
      improvement. Across countries, there is consensus that this activity should not
      be automatically exempted from ethical review but requires proportionate review
      or organizational oversight for minimal risk projects. In the majority of
      countries, there is a lack of guidance on participant consent, use of personal
      health information and inclusion of vulnerable groups in routine quality
      improvement. CONCLUSION: Where countries fail to provide specific ethics
      frameworks for quality improvement, guidance is dispersed across several
      organizations which may lack legal certainty. Our review demonstrates a need for 
      appropriate oversight and responsive infrastructure for quality improvement
      underpinned by ethical frameworks that build equivalence with research oversight.
      It outlines aspects of good practice, especially The New Zealand framework that
      integrates research and quality improvement ethics.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      International Society for Quality in Health Care. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Naughton, Corina
AU  - Naughton C
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Meehan, Elaine
AU  - Meehan E
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Lehane, Elaine
AU  - Lehane E
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Landers, Ciara
AU  - Landers C
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Flaherty, Sarah Jane
AU  - Flaherty SJ
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Lane, Aoife
AU  - Lane A
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Landers, Margaret
AU  - Landers M
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Kilty, Caroline
AU  - Kilty C
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Saab, Mohamad
AU  - Saab M
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Goodwin, John
AU  - Goodwin J
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Walshe, Nuala
AU  - Walshe N
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Wills, Teresa
AU  - Wills T
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Mccarthy, Vera
AU  - Mccarthy V
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Murphy, Siobhan
AU  - Murphy S
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Mccarthy, Joan
AU  - Mccarthy J
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Cummins, Helen
AU  - Cummins H
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
FAU - Madden, Deirdre
AU  - Madden D
AD  - School of Law, University College Cork, Aras na Laoi, Cork T12 T656, Ireland.
FAU - Hegarty, Josephine
AU  - Hegarty J
AD  - Catherine McAuley School of Nursing and Midwifery, University College Cork,
      College Road, Cork T12 AK54, Ireland.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Qual Health Care
JT  - International journal for quality in health care : journal of the International
      Society for Quality in Health Care
JID - 9434628
SB  - IM
MH  - Australia
MH  - Canada
MH  - England
MH  - Humans
MH  - Ireland
MH  - New Zealand
MH  - *Quality Improvement
MH  - United States
OTO - NOTNLM
OT  - clinical audit
OT  - consent
OT  - ethics
OT  - personal health data
OT  - quality improvement
EDAT- 2020/08/17 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/16 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/08/16 06:00 [entrez]
AID - 5892739 [pii]
AID - 10.1093/intqhc/mzaa092 [doi]
PST - ppublish
SO  - Int J Qual Health Care. 2020 Nov 9;32(8):558-566. doi: 10.1093/intqhc/mzaa092.


PMID- 32796761
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 11
IP  - 8
DP  - 2020 Aug 11
TI  - CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.
LID - E921 [pii]
LID - 10.3390/genes11080921 [doi]
AB  - Even though chemotherapy and immunotherapy emerged to limit continual and
      unregulated proliferation of cancer cells, currently available therapeutic agents
      are associated with high toxicity levels and low success rates. Additionally,
      ongoing multi-targeted therapies are limited only for few carcinogenesis
      pathways, due to continually emerging and evolving mutations of proto-oncogenes
      and tumor-suppressive genes. CRISPR/Cas9, as a specific gene-editing tool, is
      used to correct causative mutations with minimal toxicity, but is also employed
      as an adjuvant to immunotherapy to achieve a more robust immunological response. 
      Some of the most critical limitations of the CRISPR/Cas9 technology include
      off-target mutations, resulting in nonspecific restrictions of DNA upstream of
      the Protospacer Adjacent Motifs (PAM), ethical agreements, and the lack of a
      scientific consensus aiming at risk evaluation. Currently, CRISPR/Cas9 is tested 
      on animal models to enhance genome editing specificity and induce a stronger
      anti-tumor response. Moreover, ongoing clinical trials use the CRISPR/Cas9 system
      in immune cells to modify genomes in a target-specific manner. Recently,
      error-free in vitro systems have been engineered to overcome limitations of this 
      gene-editing system. The aim of the article is to present the knowledge
      concerning the use of CRISPR Cas9 technique in targeting treatment-resistant
      cancers. Additionally, the use of CRISPR/Cas9 is aided as an emerging
      supplementation of immunotherapy, currently used in experimental oncology.
      Demonstrating further, applications and advances of the CRISPR/Cas9 technique are
      presented in animal models and human clinical trials. Concluding, an overview of 
      the limitations of the gene-editing tool is proffered.
FAU - Khalaf, Khalil
AU  - Khalaf K
AUID- ORCID: 0000-0001-7278-8077
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
FAU - Janowicz, Krzysztof
AU  - Janowicz K
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
FAU - Dyszkiewicz-Konwinska, Marta
AU  - Dyszkiewicz-Konwinska M
AUID- ORCID: 0000-0002-8069-9004
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - Department of Biomaterials and Experimental Dentistry, Poznan University of
      Medical Sciences, 60-812 Poznan, Poland.
FAU - Hutchings, Greg
AU  - Hutchings G
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
FAU - Dompe, Claudia
AU  - Dompe C
AD  - The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
FAU - Moncrieff, Lisa
AU  - Moncrieff L
AD  - The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
FAU - Jankowski, Maurycy
AU  - Jankowski M
AUID- ORCID: 0000-0001-9476-0235
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
FAU - Machnik, Marta
AU  - Machnik M
AUID- ORCID: 0000-0002-2670-5629
AD  - Department of Cancer Immunology, Poznan University of Medical Sciences, 60-408
      Poznan, Poland.
AD  - Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Centre,
      61-866 Poznan, Poland.
FAU - Oleksiewicz, Urszula
AU  - Oleksiewicz U
AUID- ORCID: 0000-0003-0357-9284
AD  - Department of Cancer Immunology, Poznan University of Medical Sciences, 60-408
      Poznan, Poland.
AD  - Department of Cancer Diagnostics and Immunology, Greater Poland Cancer Centre,
      61-866 Poznan, Poland.
FAU - Kocherova, Ievgeniia
AU  - Kocherova I
AUID- ORCID: 0000-0003-2561-9750
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
FAU - Petitte, Jim
AU  - Petitte J
AUID- ORCID: 0000-0003-2764-6007
AD  - Prestage Department of Poultry Science, North Carolina State University, Raleigh,
      NC 27695, USA.
FAU - Mozdziak, Paul
AU  - Mozdziak P
AUID- ORCID: 0000-0002-1575-3123
AD  - Physiology Graduate Program, North Carolina State University, Raleigh, NC 27695, 
      USA.
FAU - Shibli, Jamil A
AU  - Shibli JA
AUID- ORCID: 0000-0003-1971-0195
AD  - Department of Periodontology and Oral Implantology, Dental Research Division,
      University of Guarulhos, Guarulhos 07023-070, Brazil.
FAU - Izycki, Dariusz
AU  - Izycki D
AD  - Department of Cancer Immunology, Poznan University of Medical Sciences, 60-408
      Poznan, Poland.
FAU - Jozkowiak, Malgorzata
AU  - Jozkowiak M
AD  - Department of Toxicology, Poznan University of Medical Sciences, 61-631 Poznan,
      Poland.
FAU - Piotrowska-Kempisty, Hanna
AU  - Piotrowska-Kempisty H
AD  - Department of Toxicology, Poznan University of Medical Sciences, 61-631 Poznan,
      Poland.
FAU - Skowronski, Mariusz T
AU  - Skowronski MT
AUID- ORCID: 0000-0002-9826-2345
AD  - Department of Basic and Preclinical Sciences, Institute of Veterinary Medicine,
      Nicolaus Copernicus University in Torun, 87-100 Torun, Poland.
FAU - Antosik, Pawel
AU  - Antosik P
AD  - Department of Veterinary Surgery, Nicolaus Copernicus University in Torun, 87-100
      Torun, Poland.
FAU - Kempisty, Bartosz
AU  - Kempisty B
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
AD  - Department of Veterinary Surgery, Nicolaus Copernicus University in Torun, 87-100
      Torun, Poland.
AD  - Department of Obstetrics and Gynecology, University Hospital and Masaryk
      University, 601 77 Brno, Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20200811
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
SB  - IM
MH  - Animals
MH  - *CRISPR-Cas Systems
MH  - Clinical Trials as Topic
MH  - Disease
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - *Gene Editing
MH  - *Genetic Therapy
MH  - Humans
MH  - *Immunotherapy
MH  - Immunotherapy, Adoptive
MH  - Neoplasms/etiology/*therapy
MH  - Precision Medicine/methods
PMC - PMC7463827
OTO - NOTNLM
OT  - *animal models
OT  - *cancer
OT  - *experimental oncology
OT  - *genome editing
EDAT- 2020/08/17 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - genes11080921 [pii]
AID - 10.3390/genes11080921 [doi]
PST - epublish
SO  - Genes (Basel). 2020 Aug 11;11(8). pii: genes11080921. doi: 10.3390/genes11080921.


PMID- 32796712
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 11
IP  - 8
DP  - 2020 Aug 11
TI  - Omics Application in Animal Science-A Special Emphasis on Stress Response and
      Damaging Behaviour in Pigs.
LID - E920 [pii]
LID - 10.3390/genes11080920 [doi]
AB  - Increasing stress resilience of livestock is important for ethical and profitable
      meat and dairy production. Susceptibility to stress can entail damaging
      behaviours, a common problem in pig production. Breeding animals with increased
      stress resilience is difficult for various reasons. First, studies on
      neuroendocrine and behavioural stress responses in farm animals are scarce, as it
      is difficult to record adequate phenotypes under field conditions. Second,
      damaging behaviours and stress susceptibility are complex traits, and their
      biology is not yet well understood. Dissecting complex traits into biologically
      better defined, heritable and easily measurable proxy traits and developing
      biomarkers will facilitate recording these traits in large numbers.
      High-throughput molecular technologies ("omics") study the entirety of molecules 
      and their interactions in a single analysis step. They can help to decipher the
      contributions of different physiological systems and identify candidate molecules
      that are representative of different physiological pathways. Here, we provide a
      general overview of different omics approaches and we give examples of how these 
      techniques could be applied to discover biomarkers. We discuss the genetic
      dissection of the stress response by different omics techniques and we provide
      examples and outline potential applications of omics tools to understand and
      prevent outbreaks of damaging behaviours.
FAU - Kasper, Claudia
AU  - Kasper C
AD  - Swine Research Unit, Agroscope, La Tioleyre 4, 1725 Posieux, Switzerland.
FAU - Ribeiro, David
AU  - Ribeiro D
AUID- ORCID: 0000-0002-0990-7739
AD  - Departamento de Ciencias e Engenharia de Biosistemas, Instituto Superior
      d'Agronomia, Universidade de Lisboa, Tapada da Ajuda, 1349-017 Lisboa, Portugal.
FAU - Almeida, Andre M de
AU  - Almeida AM
AD  - Departamento de Ciencias e Engenharia de Biosistemas, Instituto Superior
      d'Agronomia, Universidade de Lisboa, Tapada da Ajuda, 1349-017 Lisboa, Portugal.
FAU - Larzul, Catherine
AU  - Larzul C
AD  - Genetique Physiologie et Systemes d'Elevage (GenPhySE), INRA, 24 chemin de
      Borde-Rouge-Auzeville Tolosane, 31326 Castanet Tolosan, France.
FAU - Liaubet, Laurence
AU  - Liaubet L
AD  - Genetique Physiologie et Systemes d'Elevage (GenPhySE), INRA, 24 chemin de
      Borde-Rouge-Auzeville Tolosane, 31326 Castanet Tolosan, France.
FAU - Murani, Eduard
AU  - Murani E
AUID- ORCID: 0000-0002-3939-6255
AD  - Leibniz Institute for Farm Animal Biology (FBN), Institute of Genome Biology,
      Genomics Unit, Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200811
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (Biomarkers)
SB  - IM
MH  - Animals
MH  - Animals, Domestic
MH  - Behavior, Animal
MH  - Biomarkers
MH  - Breeding
MH  - Genetic Association Studies
MH  - *Genomics/methods
MH  - *Metabolomics/methods
MH  - *Proteomics/methods
MH  - *Stress, Physiological/genetics
MH  - Swine/*genetics/*metabolism
MH  - Systems Biology
PMC - PMC7464449
OTO - NOTNLM
OT  - *animal welfare
OT  - *biomarkers
OT  - *damaging behaviour
OT  - *epigenomics
OT  - *genomics
OT  - *metabolomics
OT  - *proteomics
OT  - *swine
OT  - *transcriptomics
EDAT- 2020/08/17 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/07/22 00:00 [received]
PHST- 2020/08/06 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - genes11080920 [pii]
AID - 10.3390/genes11080920 [doi]
PST - epublish
SO  - Genes (Basel). 2020 Aug 11;11(8). pii: genes11080920. doi: 10.3390/genes11080920.


PMID- 32796614
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Aug 11
TI  - The Influence of Managerial Psychology on Job Satisfaction among Healthcare
      Employees in Ghana.
LID - E262 [pii]
LID - 10.3390/healthcare8030262 [doi]
AB  - Background: Employee job satisfaction has been established to be one of the
      important factors that work towards addressing the subject matter of productivity
      in organizations. Healthcare professionals deserve some level of basic
      psychological need satisfaction in the area of job autonomy. Reasons that lead to
      employees achieving job autonomy and job satisfaction have been researched by
      industrial and organizational psychologists but very few of such studies have
      directed their attention towards the role psychological capital can play.
      Therefore, this study sought to find out how much of an impact positive
      psychology can make on the job autonomy of healthcare employees leading to the
      fulfillment of job satisfaction. Methods: Data were collected from 385 healthcare
      professionals from the public sector. A structural equation model was performed
      to analyze the relationship that exists between the constructs of psychological
      capital and job autonomy leading to job satisfaction on the part of the
      employees. Results: Results showed both a direct and indirect positive
      relationship between hope and job satisfaction and indirect through job autonomy.
      Apart from self-efficacy, that had a very low positive relationship, optimism
      largely influenced job autonomy of healthcare professionals. Results also showed 
      that psychological capital positively related to job autonomy while job autonomy 
      minimally influenced job satisfaction. Conclusions: It is concluded from this
      study that healthcare professionals deserve some level of basic psychological
      need satisfaction in the area of job autonomy and that can stimulate positive
      work ethic.
FAU - Dai, Baozhen
AU  - Dai B
AD  - School of Management, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013,
      China.
FAU - Akey-Torku, Benedicta
AU  - Akey-Torku B
AUID- ORCID: 0000-0003-1079-1291
AD  - School of Management, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013,
      China.
LA  - eng
GR  - 71774069/National Nature Science Foundation of China
PT  - Journal Article
DEP - 20200811
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7551441
OTO - NOTNLM
OT  - healthcare professionals
OT  - job autonomy
OT  - job satisfaction
OT  - psychological capital
EDAT- 2020/08/17 06:00
MHDA- 2020/08/17 06:01
CRDT- 2020/08/16 06:00
PHST- 2020/06/15 00:00 [received]
PHST- 2020/08/07 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2020/08/17 06:01 [medline]
AID - healthcare8030262 [pii]
AID - 10.3390/healthcare8030262 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Aug 11;8(3). pii: healthcare8030262. doi:
      10.3390/healthcare8030262.


PMID- 32796208
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20220517
IS  - 1533-404X (Electronic)
IS  - 0195-7910 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Sep
TI  - Traumatic Decapitation of the Fetus During Birth: Criminalistic and Forensic
      Aspects.
PG  - 234-237
LID - 10.1097/PAF.0000000000000556 [doi]
AB  - Serious intrapartum fetal injuries are unfortunate events that confer severe
      consequences on medical personnel. Most birth traumas are noncritical and resolve
      for a few days. Permanent effects or fatal outcomes occur infrequently. We report
      an unusual case of intrapartum complete fetal decapitation. The labor was
      complicated by shoulder dystocia, with resultant repeated mechanical trauma to
      the fetal neck and, finally, decapitation. The tragic results of biological
      processes in human organisms do not automatically confirm medical malpractice.
      However, there may be grave ethical and forensic outcomes.
FAU - Vojtisek, Tomas
AU  - Vojtisek T
AD  - From the Department of Forensic Medicine, Faculty of Medicine, Masaryk
      University, St. Anne's Faculty Hospital Brno, Brno, Czech Republic.
FAU - Pohlova Kucerova, Stepanka
AU  - Pohlova Kucerova S
AD  - Department of Forensic Medicine, Faculty of Medicine in Hradec Kralove, Charles
      University, University Hospital Hradec Kralove, Czech Republic.
FAU - Duchanova, Svatava
AU  - Duchanova S
AD  - From the Department of Forensic Medicine, Faculty of Medicine, Masaryk
      University, St. Anne's Faculty Hospital Brno, Brno, Czech Republic.
FAU - Krajsa, Jan
AU  - Krajsa J
AD  - From the Department of Forensic Medicine, Faculty of Medicine, Masaryk
      University, St. Anne's Faculty Hospital Brno, Brno, Czech Republic.
FAU - Hejna, Petr
AU  - Hejna P
AD  - Department of Forensic Medicine, Faculty of Medicine in Hradec Kralove, Charles
      University, University Hospital Hradec Kralove, Czech Republic.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Am J Forensic Med Pathol
JT  - The American journal of forensic medicine and pathology
JID - 8108948
SB  - IM
CIN - J Perinat Med. 2021 Dec 15;50(4):503-504. PMID: 34904426
MH  - Adult
MH  - Birth Injuries/*complications
MH  - *Decapitation
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Labor, Induced
MH  - Pregnancy
MH  - *Shoulder Dystocia
MH  - Vacuum Extraction, Obstetrical/*adverse effects
EDAT- 2020/08/17 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.1097/PAF.0000000000000556 [doi]
AID - 00000433-202009000-00019 [pii]
PST - ppublish
SO  - Am J Forensic Med Pathol. 2020 Sep;41(3):234-237. doi:
      10.1097/PAF.0000000000000556.


PMID- 32796181
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20210505
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 48
IP  - 10
DP  - 2020 Oct
TI  - Principles Guiding Nonpandemic Critical Care Research During a Pandemic.
PG  - 1403-1410
LID - 10.1097/CCM.0000000000004538 [doi]
AB  - OBJECTIVES: To describe the importance of critical care clinical research that is
      not pandemic-focused during pandemic times; outline principles to assist in the
      prioritization of nonpandemic research during pandemic times; and propose a
      guiding framework for decisions about whether, when and how to continue
      nonpandemic research while still honoring the moral and scientific imperative to 
      launch research that is pandemic-focused. DESIGN/DATA SOURCES: Using in-person,
      email, and videoconference exchanges, we convened an interprofessional clinical
      research group, conducted a literature review of empirical studies, ethics
      documents and expert commentaries (2010 to present), and viewed traditional and
      social media posts (March 2020 to May 2020). Stakeholder consultation involved
      scientific, ethics, clinical, and administrative leaders. SETTING: Clinical
      research in the ICU. PATIENTS: Patients with and without coronavirus disease
      2019. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: While clinical research
      should be prioritized to advantage patients with coronavirus disease 2019 in
      order to care for affected patients, it ideally would not unduly disadvantage
      patients without coronavirus disease 2019. Thus, timely, rigorous, relevant, and 
      ethical clinical research is needed to improve the care and optimize outcomes for
      both patients with and without coronavirus disease 2019, acknowledging how many
      studies that are not exclusively focused on coronavirus disease 2019 remain
      relevant to patients with coronavirus disease 2019. Considerations to continue
      nonpandemic-focused research include the status of the pandemic, local
      jurisdictional guidance, capacity and safety of bedside and research personnel,
      disposition of patients already enrolled in nonpandemic studies, analyzing
      characteristics of each nonpandemic-focused study, research oversight, and final 
      reporting requirements. CONCLUSIONS: Deliberation about continuing nonpandemic
      research should use objective, transparent criteria considering several aspects
      of the research process such as bedside and research staff safety, infection
      control, the informed consent model, protocol complexity, data collection, and
      implementation integrity. Decisions to pause or pursue nonpandemic research
      should be proportionate, transparent, and revisited as the pandemic abates.
FAU - Cook, Deborah J
AU  - Cook DJ
AD  - Division of Critical Care, Department of Medicine, Faculty of Health Sciences,
      McMaster University; Department of Health Research Methods, Evidence and Impact, 
      Faculty of Health Sciences, McMaster University; and Department of Critical Care,
      St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
FAU - Kho, Michelle E
AU  - Kho ME
AD  - Department of Physiotherapy, School of Rehabilitation Science, Faculty of Health 
      Sciences, McMaster University; and Physiotherapy Department, St. Joseph's
      Healthcare Hamilton, Hamilton, ON, Canada.
FAU - Duan, Eric H
AU  - Duan EH
AD  - Division of Critical Care, Department of Medicine, Faculty of Health Sciences,
      McMaster University; Department of Health Research Methods, Evidence and Impact, 
      Faculty of Health Sciences, McMaster University; and Department of Critical Care,
      St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, Division of Critical
      Care, Niagara Health, St. Catharines, ON, Canada.
FAU - Alhazzani, Waleed
AU  - Alhazzani W
AD  - Division of Critical Care, Department of Medicine, Faculty of Health Sciences,
      McMaster University; Department of Health Research Methods, Evidence and Impact, 
      Faculty of Health Sciences, McMaster University; and, Department of Critical
      Care, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
FAU - Takaoka, Alyson
AU  - Takaoka A
AD  - Department of Health Research Methods, Evidence and Impact, Faculty of Health
      Sciences, McMaster University, Hamilton, ON, Canada.
FAU - Clarke, France J
AU  - Clarke FJ
AD  - Department of Health Research Methods, Evidence and Impact, Faculty of Health
      Sciences, McMaster University, Hamilton, ON, Canada.
FAU - Zytaruk, Nicole
AU  - Zytaruk N
AD  - Department of Health Research Methods, Evidence and Impact, Faculty of Health
      Sciences, McMaster University, Hamilton, ON, Canada.
FAU - Vanstone, Meredith
AU  - Vanstone M
AD  - Department of Family Medicine, Faculty of Health Sciences, McMaster University,
      Hamilton, ON, Canada.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
SB  - IM
MH  - Biomedical Research/*organization & administration
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Critical Care/*standards
MH  - Critical Illness/mortality/therapy
MH  - Female
MH  - Global Health
MH  - Humans
MH  - Infection Control/standards
MH  - Male
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - *Practice Guidelines as Topic
MH  - Research Design
MH  - Safety Management
PMC - PMC7437406
EDAT- 2020/08/17 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/08/16 06:00 [entrez]
AID - 10.1097/CCM.0000000000004538 [doi]
AID - 00003246-202010000-00001 [pii]
PST - ppublish
SO  - Crit Care Med. 2020 Oct;48(10):1403-1410. doi: 10.1097/CCM.0000000000004538.


PMID- 32795326
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 14
TI  - Prevalence and predictors of perceived disrespectful maternity care in postpartum
      Iranian women: a cross-sectional study.
PG  - 463
LID - 10.1186/s12884-020-03124-2 [doi]
AB  - BACKGROUND: Disrespectful maternity care is a key impediment to achieving a good 
      quality care. Identifying predicting factors can be used in mitigating any
      potential risk in for disrespect and abuse in maternity care. The present study
      was conducted to determine prevalence and predictors of perceived disrespectful
      maternity care among Iranian women. METHODS: A cross-sectional study was
      conducted in three public and three private hospitals in the city of Tabriz
      involving 334 postpartum women. Tools included socio-demographic, pregnancy,
      labour and birth characteristics questionnaires, and disrespect and abuse scales.
      Data were collected in 6 to 18 h after birth. Multivariate logistic regression
      was used to determine predictors of disrespectful maternity care. RESULTS: A
      majority of the women (253; 75.7%) reported one or several types of perceived
      disrespectful maternity care. The most frequent types related to not allowing
      women to choose labour positions (142; 44.3%) and not allowing them to move
      during labour (148; 42.5%). Nighttime childbirth (aOR 3.07; 95% CI 1.61 to 5.88) 
      increased the likelihood of perceived disrespectful maternity care. However,
      presence of spouses to accompany their wives in waiting rooms (aOR 0.32; 95% CI
      0.11 to 0.88), the attendance of private physicians (aOR 0.05; 95% CI 0.02 to
      0.12), and midwives (aOR 0.22; 95% CI 0.11 to 0.45) decreased the likelihood of
      perceived disrespectful maternity care. CONCLUSION: The results showed high
      levels of perceived disrespectful maternity care in postpartum women. Therefore, 
      appropriate interventions, such as encouraging spouses' presence, increasing the 
      number of night shift staff, and training obstetric residents and midwives by
      holding ethics classes, with particular emphasis on empathy with patients.
FAU - Hajizadeh, Khadije
AU  - Hajizadeh K
AD  - Midwifery Department, Tabriz University of Medical sciences, Tabriz, Iran.
FAU - Vaezi, Maryam
AU  - Vaezi M
AD  - Department of obstetrics and gynecology, Alzahra teaching hospital, Tabriz
      University of Medical Sciences, Tabriz, Iran.
FAU - Meedya, Shahla
AU  - Meedya S
AD  - School of Nursing, Faculty of Science, Medicine and Health, University of
      Wollongong, Wollongong, Australia.
FAU - Mohammad Alizadeh Charandabi, Sakineh
AU  - Mohammad Alizadeh Charandabi S
AD  - Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Tabriz, Iran.
FAU - Mirghafourvand, Mojgan
AU  - Mirghafourvand M
AUID- ORCID: http://orcid.org/0000-0001-8360-4309
AD  - Social Determinants of Health Research Center, Tabriz University of Medical
      Sciences, Tabriz, Iran. mirghafourvand@gmail.com.
LA  - eng
GR  - IR.TBZMED.REC.1398.202/Tabriz University of Medical Sciences
PT  - Journal Article
DEP - 20200814
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Iran
MH  - Maternal Health Services/*standards
MH  - Patient Preference
MH  - Physical Abuse
MH  - Postpartum Period/*psychology
MH  - Pregnancy
MH  - *Respect
MH  - Young Adult
PMC - PMC7427776
OTO - NOTNLM
OT  - Abuse
OT  - Disrespectful maternity care
OT  - Iran
OT  - Predictor
OT  - Prevalence
EDAT- 2020/08/17 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.1186/s12884-020-03124-2 [doi]
AID - 10.1186/s12884-020-03124-2 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Aug 14;20(1):463. doi: 10.1186/s12884-020-03124-2.


PMID- 32795284
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 14
TI  - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients
      with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer:
      the INCREASE trial.
PG  - 764
LID - 10.1186/s12885-020-07263-9 [doi]
AB  - BACKGROUND: The likelihood of a tumor recurrence in patients with T3-4N0-1
      non-small cell lung cancer following multimodality treatment remains substantial,
      mainly due distant metastases. As pathological complete responses (pCR) in
      resected specimens are seen in only a minority (28-38%) of patients following
      chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number:
      2019-003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates
      could be further improved by adding short course immunotherapy to induction
      chemoradiotherapy. Translational studies will correlate changes in loco-regional 
      and systemic immune status with patterns of recurrence. METHODS/DESIGN: This
      single-arm, prospective phase II trial will enroll 29 patients with either
      resectable, or borderline resectable, T3-4N0-1 NSCLC. The protocol was approved
      by the institutional ethics committee. Study enrollment commenced in February
      2020. On day 1 of guideline-recommended concurrent chemoradiotherapy (CRT),
      ipilimumab (IPI, 1 mg/kg IV) and nivolumab (NIVO, 360 mg flat dose IV) will be
      administered, followed by nivolumab (360 mg flat dose IV) after 3 weeks.
      Radiotherapy consists of once-daily doses of 2 Gy to a total of 50 Gy, and
      chemotherapy will consist of a platinum-doublet. An anatomical pulmonary
      resection is planned 6 weeks after the last day of radiotherapy. The primary
      study objective is to establish the safety of adding IPI/NIVO to pre-operative
      CRT, and its impact on pathological tumor response. Secondary objectives are to
      assess the impact of adding IPI/NIVO to CRT on disease free and overall survival.
      Exploratory objectives are to characterize tumor inflammation and the immune
      contexture in the tumor and tumor-draining lymph nodes (TDLN), and to explore the
      effects of IPI/NIVO and CRT and surgery on distribution and phenotype of
      peripheral blood immune subsets. DISCUSSION: The INCREASE trial will evaluate the
      safety and local efficacy of a combination of 4 modalities in patients with
      resectable, T3-4N0-1 NSCLC. Translational research will investigate the
      mechanisms of action and drug related adverse events. TRIAL REGISTRATION:
      Netherlands Trial Registration (NTR): NL8435 , Registered 03 March 2020.
FAU - Dickhoff, Chris
AU  - Dickhoff C
AUID- ORCID: http://orcid.org/0000-0002-6396-8372
AD  - Department of Surgery and Cardiothoracic Surgery, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands. c.dickhoff@amsterdamumc.nl.
FAU - Senan, Suresh
AU  - Senan S
AD  - Department of Radiation Oncology, Amsterdam University Medical Center, location
      VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Schneiders, Famke L
AU  - Schneiders FL
AD  - Department of Radiation Oncology, Amsterdam University Medical Center, location
      VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Veltman, Joris
AU  - Veltman J
AD  - Department of Pulmonary Diseases, Amsterdam University Medical Center, location
      VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Hashemi, Sayed
AU  - Hashemi S
AD  - Department of Pulmonary Diseases, Amsterdam University Medical Center, location
      VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Daniels, Johannes M A
AU  - Daniels JMA
AD  - Department of Pulmonary Diseases, Amsterdam University Medical Center, location
      VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Fransen, Marieke
AU  - Fransen M
AD  - Department of Pulmonary Diseases, Amsterdam University Medical Center, location
      VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Heineman, David J
AU  - Heineman DJ
AD  - Department of Surgery and Cardiothoracic Surgery, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands.
FAU - Radonic, Teodora
AU  - Radonic T
AD  - Department of Pathology, Amsterdam University Medical Center, location VUmc,
      Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the Netherlands.
FAU - van de Ven, Peter M
AU  - van de Ven PM
AD  - Department of Epidemiology and Biostatistics, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands.
FAU - Bartelink, Imke H
AU  - Bartelink IH
AD  - Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands.
FAU - Meijboom, Lilian J
AU  - Meijboom LJ
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands.
FAU - Garcia-Vallejo, Juan J
AU  - Garcia-Vallejo JJ
AD  - Department of Molecular Cell Biology & Immunology, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands.
FAU - Oprea-Lager, Daniela E
AU  - Oprea-Lager DE
AD  - Department of Radiology and Nuclear Medicine, Amsterdam University Medical
      Center, location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV,
      Amsterdam, the Netherlands.
FAU - de Gruijl, Tanja D
AU  - de Gruijl TD
AD  - Department of Medical Oncology, Amsterdam University Medical Center, location
      VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
FAU - Bahce, Idris
AU  - Bahce I
AD  - Department of Pulmonary Diseases, Amsterdam University Medical Center, location
      VUmcCancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the
      Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200814
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse
      effects
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/immunology/mortality/*therapy
MH  - Chemoradiotherapy, Adjuvant/adverse effects/methods
MH  - Clinical Trials, Phase II as Topic
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immune Checkpoint Inhibitors/administration & dosage/*adverse effects
MH  - Ipilimumab/administration & dosage/*adverse effects
MH  - Lung/diagnostic imaging/pathology/surgery
MH  - Lung Neoplasms/diagnosis/immunology/mortality/*therapy
MH  - Male
MH  - Neoadjuvant Therapy/*adverse effects/methods
MH  - Neoplasm Staging
MH  - Netherlands
MH  - Nivolumab/administration & dosage/adverse effects
MH  - Pneumonectomy
MH  - Prospective Studies
MH  - Tomography, X-Ray Computed
PMC - PMC7427738
OTO - NOTNLM
OT  - Locally advanced
OT  - NSCLC
OT  - Neoadjuvant immunotherapy
OT  - Pathological response
OT  - Thoracic surgery
EDAT- 2020/08/17 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/16 06:00 [entrez]
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - 10.1186/s12885-020-07263-9 [doi]
AID - 10.1186/s12885-020-07263-9 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Aug 14;20(1):764. doi: 10.1186/s12885-020-07263-9.


PMID- 32795119
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
VI  - 18
IP  - 9
DP  - 2020 Nov
TI  - Omeprazole and Spirulina Platensis Ameliorate Steatohepatitis in Experimental
      Nonalcoholic Fatty Liver Disease.
PG  - 426-434
LID - 10.1089/met.2019.0129 [doi]
AB  - Background: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver 
      damage, and it affects about 24% of the population worldwide. This study aimed to
      investigate the effect of omeprazole and Spirulina platensis on hepatic and serum
      biochemical alterations in NAFLD induced by high-fat diet (HFD). Methods: Male
      Wistar rats were divided into four groups; one served as a normal control. The
      other groups received HFD and subdivided into three subgroups; one was left
      untreated and the other two groups were treated orally with either omeprazole (10
      mg/kg) or Spirulina (1000 mg/kg) for 30 consecutive days. Results: Omeprazole
      successfully decreased elevated serum pentraxin-3 (PTX-3) and cytokeratin-18
      (CK-18) levels and hepatic sterol regulatory element binding protein-1c
      (SREBP-1c) expression, while Spirulina had better impact on decreasing liver
      function enzymes, lipid profile, and nuclear factor erythroid 2-related factor 2 
      (Nrf-2) levels compared to omeprazole. Both treatments had similar effects on
      normalizing glucose homeostasis, decreasing insulin resistance, and improving
      adipocytokine levels. Conclusion: Effects of omeprazole and Spirulina on markers 
      of NAFLD appeared to be mediated by regulation of inflammatory, apoptotic, and
      oxidative mediators. Thus, omeprazole and Spirulina may find use as promising
      adjuvant therapy to ameliorate NAFLD. Research ethical committee of the faculty
      of pharmacy, Cairo University approved the research (BC 1479).
FAU - El-Boghdady, Noha A
AU  - El-Boghdady NA
AD  - Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
FAU - Kamel, Maher A
AU  - Kamel MA
AD  - Biochemistry Department, Medical Research Institute, Alexandria University,
      Alexandria, Egypt.
FAU - El-Shamy, Rouaina M
AU  - El-Shamy RM
AD  - Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - United States
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 9005-79-2 (Glycogen)
RN  - KG60484QX9 (Omeprazole)
RN  - Arthrospira platensis
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Apoptosis
MH  - Biomarkers/metabolism
MH  - Diet, High-Fat
MH  - Disease Models, Animal
MH  - Fatty Liver/*drug therapy
MH  - Glycogen/metabolism
MH  - Liver/metabolism
MH  - Male
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism
MH  - Omeprazole/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Spirulina/*metabolism
OTO - NOTNLM
OT  - *Spirulina Platensis
OT  - *hepatocyte apoptosis
OT  - *inflammation
OT  - *metabolic syndrome
OT  - *nonalcoholic fatty liver disease
OT  - *omeprazole
OT  - *oxidative stress
EDAT- 2020/08/17 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/08/16 06:00
PHST- 2020/08/17 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2020/08/16 06:00 [entrez]
AID - 10.1089/met.2019.0129 [doi]
PST - ppublish
SO  - Metab Syndr Relat Disord. 2020 Nov;18(9):426-434. doi: 10.1089/met.2019.0129.
      Epub 2020 Aug 13.


PMID- 34805930
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2590-0293 (Electronic)
IS  - 2590-0293 (Linking)
VI  - 3
IP  - 4
DP  - 2020 Dec
TI  - Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the
      clinical endpoints in patients with intracranial Pipeline flow diverter implant.
PG  - 174-179
LID - 10.1016/j.jimed.2020.08.005 [doi]
AB  - OBJECTIVE: To compare the antiplatelet effect and major adverse cerebrovascular
      events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa
      antagonists (GPI) eptifibatide and tirofiban. METHODS: Retrospective analysis of 
      relevant data of patients using GPIs combined with oral antiplatelet therapy in
      Nanfang Hospital of Southern Medical University from December 2017 to December
      2019. The study was approved by the ethics Committee of Nanfang Hospital of
      Southern Medical University. According to the random use of GPIs drugs, they were
      assigned to the eptifibatide group and tirofiban group. Basic data, platelet
      inhibition rates at baseline, 24h and 72h after administration, short-term major 
      adverse cerebrovascular events, and bleeding complications were compared between 
      the two groups. RESULTS: A total of 47 patients were included in this study,
      including 24 patients in eptifibatide group and 23 patients in tirofiban group.
      There was no significant difference in average age (53.75 vs. 53.91 years) and
      body mass index (BMI) (24.39 vs. 22.73 kg/m2) between eptifibatide group and
      tirofiban group. There was no significant difference in coagulation factor
      function (R), fibrinogen function (K), fibrinolysis function (EPL), comprehensive
      coagulation index (Cl), arachidonic acid pathway inhibition rate (AA%) and
      adenosine diphosphate inhibition rate (ADP%). However, the baseline level of
      residual platelet function MA (ADP) in eptifibatide group was significantly
      higher than that in tirofiban group (50.79 vs. 35.29 mm, P = 0.0026). There was a
      statistical difference in the platelet aggregation function MA (65.38 vs. 62.54
      mm, p = 0.0442), the rate of spontaneous hemorrhagic stroke (4.3% vs. 0%) and the
      rate of asymptomatic minor bleeding (26.08% vs. 4.1%) in the two groups (P <
      0.05). CONCLUSION: Both eptifibatide and tirofiban can effectively inhibit
      platelets, but the effect of etifeptide is better than that of tirofiban in
      preventing intracranial microhemorrhage and asymptomatic cerebral infarction.
CI  - (c) 2020 Shanghai Journal of Interventional Medicine Press. Production and
      hosting by Elsevier B.V. on behalf of KeAi.
FAU - Deng, Qiao
AU  - Deng Q
AD  - Southern Medical University, Department of Neurosurgery, Nanfang Hospital,
      Guangzhou, 510515, China.
FAU - Zhang, Shichao
AU  - Zhang S
AD  - Southern Medical University, Department of Neurosurgery, Nanfang Hospital,
      Guangzhou, 510515, China.
FAU - Li, Mingzhou
AU  - Li M
AD  - Southern Medical University, Department of Neurosurgery, Nanfang Hospital,
      Guangzhou, 510515, China.
FAU - Zhang, Guozhong
AU  - Zhang G
AD  - Southern Medical University, Department of Neurosurgery, Nanfang Hospital,
      Guangzhou, 510515, China.
FAU - Feng, Wenfeng
AU  - Feng W
AD  - Southern Medical University, Department of Neurosurgery, Nanfang Hospital,
      Guangzhou, 510515, China.
LA  - eng
PT  - Journal Article
DEP - 20200816
PL  - China
TA  - J Interv Med
JT  - Journal of interventional medicine
JID - 9918265602006676
PMC - PMC8562166
OTO - NOTNLM
OT  - Cerebral hemorrhage
OT  - Eptifibatide
OT  - Flow guiding device
OT  - Tirofiban
COIS- The authors declare that they have no conflicts of interests to this work. We
      declare that we do not have any commercial or associative interest that
      represents a conflict of interest in connection with the work submitted.
EDAT- 2020/08/16 00:00
MHDA- 2020/08/16 00:01
CRDT- 2021/11/22 07:02
PHST- 2020/04/12 00:00 [received]
PHST- 2020/07/11 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2021/11/22 07:02 [entrez]
PHST- 2020/08/16 00:00 [pubmed]
PHST- 2020/08/16 00:01 [medline]
AID - 10.1016/j.jimed.2020.08.005 [doi]
AID - S2096-3602(20)30053-3 [pii]
PST - epublish
SO  - J Interv Med. 2020 Aug 16;3(4):174-179. doi: 10.1016/j.jimed.2020.08.005.
      eCollection 2020 Dec.


PMID- 32794482
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220416
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 8
DP  - 2020 Aug
TI  - Addition of bismuth to standard triple therapy for Helicobacter pylori
      eradication: a randomised controlled trial.
PG  - 1334-1339
LID - 10.5455/JPMA.55396 [doi]
AB  - OBJECTIVE: To compare the effect of addition of bismuth to the standard triple
      therapy for eradication of Helicobacter pylori (H. pylori) in a randomised
      controlled trial. METHODS: The study was performed from June 2018-May 2019, in
      the two outpatient departments located at two different campuses of Ziauddin
      university hospitals (ZUH) Karachi. Ethical approval was obtained from the Ethics
      Review Committee of ZUH. It was designed as a randomized control trial in a
      parallel fashion. Arm A received triple therapy including amoxicillin,
      clarithromycin, and omeprazole for two weeks and Arm B received quadruple therapy
      adding colloidal bismuth subcitrate to the triple therapy. A stool antigen test
      was done six weeks post treatment to confirm H. pylori eradication. RESULTS: A
      total of 196 participants were included, out of which 102(52%) were males and 94 
      (48%) were females. Among the patients receiving quadruple therapy, 92/98(93.8%) 
      had negative posttreatment stool antigen results, while among triple therapy
      recipients 83/98 (84.6%) had negative stool antigen results, according to
      intention-to-treat analysis (p value=0.038; odds ratio 2.77, 95% CI 1.03-7.47).
      However, p-value changed to 0.082 (odds ratio 2.40, 95% CI 0.87-6.60) in
      per-protocol analysis as stool antigen results were not available in two patients
      in the triple therapy arm. No difference in the side-effect profiles of either
      arm was noted. CONCLUSIONS: Eradication rates of H. pylori may be modestly
      improved by addition of bismuth to the standard triple therapy. CLINICAL TRIAL
      NUMBER: 03968302 (clinicaltrials.gov).
FAU - Asim, Muhammad
AU  - Asim M
AD  - Department of Gastroenterology, Ziauddin University Hospital, Karachi, Pakistan.
FAU - Baqai, Khurram
AU  - Baqai K
AD  - Department of Gastroenterology, Ziauddin University Hospital, Karachi, Pakistan.
FAU - Abbas, Zaigham
AU  - Abbas Z
AD  - Department of Gastroenterology, Ziauddin University Hospital, Karachi, Pakistan.
FAU - Laique, Nasir
AU  - Laique N
AD  - Department of Gastroenterology, Ziauddin University Hospital, Karachi, Pakistan.
FAU - Samejo, Shoukat Ali
AU  - Samejo SA
AD  - Department of Gastroenterology, Ziauddin University Hospital, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
RN  - 0 (Anti-Bacterial Agents)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Bismuth/therapeutic use
MH  - Clarithromycin
MH  - Drug Therapy, Combination
MH  - Female
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Metronidazole/therapeutic use
OTO - NOTNLM
OT  - Helicobacter pylori, Eradication, Amoxicillin, Clarithromycin, Omeprazole,
      Colloidal bismuth subcitrate.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10079 [pii]
AID - 10.5455/JPMA.55396 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Aug;70(8):1334-1339. doi: 10.5455/JPMA.55396.


PMID- 32794190
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 151
IP  - 2
DP  - 2020 Nov
TI  - Bioethics training in reproductive health in Mexico.
PG  - 308-313
LID - 10.1002/ijgo.13344 [doi]
AB  - Bioethical approaches to reproductive health have been of utmost importance for
      the last three decades in Mexico. As Mexican laws regarding abortion, assisted
      reproduction, and conscientious objection have been modified, a number of social 
      actors with an interest in these areas have realized that they have to educate
      the different agents who take part in these procedures in a bioethical approach
      to reproductive health and rights. This strategy was first used in Mexico by the 
      Catholic Church and many Catholic universities. Advocates, scientists, and
      feminist organizations, as well as some public universities, have also realized
      that a grounding in bioethics could help health providers to have an ethical
      frame that supports the provision of abortion services. Bioethics is also a good 
      framework for supporting the legalization of abortion and for more liberal laws
      regarding assisted reproduction. So, for the last few years, one of the
      priorities of these two sides, Catholic and secular groups, has been to train
      healthcare personnel, lawyers, and members of ethics committees and members of
      Congress in the application of their respective bioethical perspectives.
CI  - (c) 2020 International Federation of Gynecology and Obstetrics.
FAU - Ortiz-Millan, Gustavo
AU  - Ortiz-Millan G
AD  - National Autonomous University of Mexico, Mexico City, Mexico.
FAU - Kissling, Frances
AU  - Kissling F
AD  - The Center for Health Ethics and Social Policy, Washington, DC, USA.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the
      International Federation of Gynaecology and Obstetrics
JID - 0210174
SB  - IM
MH  - Abortion, Induced/*ethics
MH  - Bioethics/*education
MH  - Female
MH  - Humans
MH  - Mexico
MH  - Pregnancy
MH  - *Religion
MH  - Reproductive Health/*education
OTO - NOTNLM
OT  - Abortion laws
OT  - Bioethics training
OT  - Mexico
OT  - Reproductive health
EDAT- 2020/08/15 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
AID - 10.1002/ijgo.13344 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2020 Nov;151(2):308-313. doi: 10.1002/ijgo.13344. Epub
      2020 Sep 3.


PMID- 32794073
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1178-1661 (Electronic)
IS  - 1178-1653 (Linking)
VI  - 13
IP  - 5
DP  - 2020 Oct
TI  - Beliefs and Values About Gene Therapy and In-Utero Gene Editing in Patients with 
      Hemophilia and Their Relatives.
PG  - 633-642
LID - 10.1007/s40271-020-00442-7 [doi]
AB  - AIM: Hemophilia is an inherited disease for which current treatment is
      noncurative. While gene therapy and gene editing are being researched, we do not 
      know how the hemophilia community perceives them. Herein, we explore the beliefs 
      and values regarding these new therapies in patients with hemophilia and their
      relatives. METHODS: This qualitative study used phone-based semi-structured
      interviews on 21 adult English-speaking patients with hemophilia A or B and their
      parents across the United States during March to July 2019. The study was
      advertised through different chapters of the Hemophilia Foundation. The interview
      guide included questions about participants' prior experience with hemophilia,
      and included two case scenarios about the use of gene therapy and in utero gene
      editing, after which participants were asked about their opinions, beliefs, and
      values on each scenario. We used a grounded theory approach and identified the
      main themes using an inductive process. RESULTS: We interviewed 21
      participants-12 patients and 9 mothers. Most of them had or were related to a
      patient with severe disease. The main themes discussed were related to efficacy, 
      safety and financial concerns and insurance coverage for both gene therapy and in
      utero gene editing. Patients and their parents had expected outcomes in terms of 
      durability of therapy and impact on emotional health and lifestyle changes in the
      long term. Gene therapy was more accepted among patients with severe and
      uncontrolled disease. In-utero gene editing was not completely accepted because
      of safety and ethical issues. CONCLUSION: Patients with severe hemophilia
      perceive gene therapy as a potential cure, while gene editing was more
      controversial. Patients still have questions that remain to be answered regarding
      safety and efficacy that should be assessed with long-term follow up studies.
FAU - Vasquez-Loarte, Tania C
AU  - Vasquez-Loarte TC
AD  - Public Health Genetics, University of Washington, Seattle, WA, USA.
FAU - Lucas, Tiffany Lin
AU  - Lucas TL
AUID- ORCID: http://orcid.org/0000-0002-0676-2626
AD  - Division of Hematology/Oncology, Department of Pediatrics, University of
      California San Francisco, 550 16th Street Box 0434, San Francisco, CA, USA.
      Tiffany.Lucas@ucsf.edu.
FAU - Harris-Wai, Julie
AU  - Harris-Wai J
AD  - Institute for Health and Aging, University of California San Francisco, San
      Francisco, CA, USA.
FAU - Bowen, Deborah J
AU  - Bowen DJ
AD  - Public Health Genetics, University of Washington, Seattle, WA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Patient
JT  - The patient
JID - 101309314
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Fetus
MH  - *Gene Editing
MH  - *Genetic Therapy
MH  - Health Knowledge, Attitudes, Practice
MH  - *Hemophilia A
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - *Patient Participation
MH  - Pregnancy
MH  - Qualitative Research
MH  - United States
MH  - Young Adult
EDAT- 2020/08/15 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
AID - 10.1007/s40271-020-00442-7 [doi]
AID - 10.1007/s40271-020-00442-7 [pii]
PST - ppublish
SO  - Patient. 2020 Oct;13(5):633-642. doi: 10.1007/s40271-020-00442-7.


PMID- 32794071
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20211002
IS  - 1548-3576 (Electronic)
IS  - 1548-3568 (Linking)
VI  - 17
IP  - 5
DP  - 2020 Oct
TI  - Peer Group Focused eHealth Strategies to Promote HIV Prevention, Testing, and
      Care Engagement.
PG  - 557-576
LID - 10.1007/s11904-020-00527-w [doi]
AB  - PURPOSE OF REVIEW: Electronic communication platforms are increasingly used to
      support all steps of the HIV care cascade (an approach defined as eHealth). Most 
      studies have employed individual-level approaches in which participants are
      connected with information, reminders, or a healthcare worker. Recent growth in
      use of social media platforms, which create digital communities, has created an
      opportunity to leverage virtual peer-to-peer connection to improve HIV prevention
      and care. In this article, we describe the current landscape of peer group
      eHealth interventions in the HIV field, based on a review of published
      literature, an online survey of unpublished ongoing work, and discussions with
      practitioners in the field in an in-person workshop. RECENT FINDINGS: We
      identified 45 published articles and 12 ongoing projects meeting our inclusion
      criteria. Most reports were formative or observational; only three randomized
      evaluations of two interventions were reported. Studies indicated that use of
      peer group eHealth interventions is acceptable and has unique potential to
      influence health behaviors, but participants reported privacy concerns.
      Evaluations of health outcomes of peer group eHealth interventions show promising
      data, but more rigorous evaluations are needed. Development of group eHealth
      interventions presents unique technological, practical, and ethical challenges.
      Intervention design must consider privacy and data sovereignty concerns, and
      respond to rapid changes in platform use. Innovative development of open-source
      tools with high privacy standards is needed.
FAU - Ronen, Keshet
AU  - Ronen K
AUID- ORCID: 0000-0001-5625-4884
AD  - University of Washington, Seattle, WA, USA. keshet@uw.edu.
FAU - Grant, Eli
AU  - Grant E
AD  - Praekelt.org, Cape Town, South Africa.
FAU - Copley, Charles
AU  - Copley C
AD  - Cedar.com, New York, NY, USA.
FAU - Batista, Tara
AU  - Batista T
AD  - Praekelt.org, Cape Town, South Africa.
AD  - Columbia University, New York, NY, USA.
FAU - Guthrie, Brandon L
AU  - Guthrie BL
AD  - University of Washington, Seattle, WA, USA.
LA  - eng
GR  - R34 MH114834/MH/NIMH NIH HHS/United States
GR  - P30 AI027757/AI/NIAID NIH HHS/United States
GR  - TL1 TR002318/TR/NCATS NIH HHS/United States
GR  - UL1 TR002319/TR/NCATS NIH HHS/United States
GR  - KL2 TR002317/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr HIV/AIDS Rep
JT  - Current HIV/AIDS reports
JID - 101235661
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*prevention & control
MH  - Behavior Therapy
MH  - HIV Infections/prevention & control
MH  - Health Behavior
MH  - Humans
MH  - Peer Group
MH  - Primary Prevention/*methods
MH  - *Social Media
MH  - Telemedicine/*methods
MH  - Treatment Outcome
PMC - PMC7492479
MID - NIHMS1620382
OTO - NOTNLM
OT  - *Digital
OT  - *HIV
OT  - *Peer
OT  - *Social media
OT  - *eHealth
OT  - *mHealth
EDAT- 2020/08/15 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
AID - 10.1007/s11904-020-00527-w [doi]
AID - 10.1007/s11904-020-00527-w [pii]
PST - ppublish
SO  - Curr HIV/AIDS Rep. 2020 Oct;17(5):557-576. doi: 10.1007/s11904-020-00527-w.


PMID- 32793569
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Generation of Artificial Gamete and Embryo From Stem Cells in Reproductive
      Medicine.
PG  - 781
LID - 10.3389/fbioe.2020.00781 [doi]
AB  - In addition to the great growing need for assisted reproduction technologies
      (ART), additional solutions for patients without functional gametes are strongly 
      needed. Due to ethical restrictions, limited studies can be performed on human
      gametes and embryos; however, artificial gametes and embryos represent a new hope
      for clinical application and basic research in the field of reproductive
      medicine. Here, we provide a review of the research progress and possible
      application of artificial gametes and embryos from different species, including
      mice, monkeys and humans. Gametes specification from adult stem cells and
      embryonic stem cells (ESCs) as well as propagation of stem cells from the
      reproductive system and from organized embryos, which are similar to blastocysts,
      have been realized in some nonhuman mammals, but not all achievements can be
      replicated in humans. This area of research remains noteworthy and requires
      further study and effort to achieve the reconstitution of the entire cycle of
      gametogenesis and embryo development in vitro.
CI  - Copyright (c) 2020 Zhang, Fan, Tan and Yu.
FAU - Zhang, Pu-Yao
AU  - Zhang PY
AD  - Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing,
      China.
AD  - Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive
      Technology and Key Laboratory of Assisted Reproduction, Ministry of Education,
      Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Fan, Yong
AU  - Fan Y
AD  - Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third
      Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
FAU - Tan, Tao
AU  - Tan T
AD  - Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing,
      China.
AD  - Yunnan Key Laboratory of Primate Biomedical Research, Institute of Primate
      Translational Medicine, Kunming University of Science and Technology, Kunming,
      China.
FAU - Yu, Yang
AU  - Yu Y
AD  - Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing,
      China.
AD  - Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive
      Technology and Key Laboratory of Assisted Reproduction, Ministry of Education,
      Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200722
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7387433
OTO - NOTNLM
OT  - artificial embryogenies
OT  - artificial gametes
OT  - embryo development
OT  - gametogenesis
OT  - reproductive medicine
OT  - stem cell
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.3389/fbioe.2020.00781 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 Jul 22;8:781. doi: 10.3389/fbioe.2020.00781.
      eCollection 2020.


PMID- 32793405
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2190-1678 (Print)
IS  - 2190-1678 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul
TI  - Ethics and practical mitigations for ongoing clinical trials during the COVID-19 
      pandemic.
PG  - 240-241
LID - 10.1007/s13340-020-00449-3 [doi]
FAU - Suzuki, Shota
AU  - Suzuki S
AUID- ORCID: 0000-0003-3199-5883
AD  - Institute for Clinical and Translational Science, Nara Medical University
      Hospital, 840 Shijo-cho, Kashihara, Nara 634-8521 Japan.grid.474851.b0000 0004
      1773 1360
AD  - Department of Health Informatics, Graduate School of Medicine & School of Public 
      Health, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501
      Japan.grid.258799.80000 0004 0372 2033
FAU - Ito, Yukie
AU  - Ito Y
AD  - Bioethics Supervisory Office, Nara Medical University Hospital, 840 Shijo-cho,
      Kashihara, Nara 634-8521 Japan.grid.474851.b0000 0004 1773 1360
FAU - Kasama, Shu
AU  - Kasama S
AD  - Institute for Clinical and Translational Science, Nara Medical University
      Hospital, 840 Shijo-cho, Kashihara, Nara 634-8521 Japan.grid.474851.b0000 0004
      1773 1360
FAU - Murata, Takashi
AU  - Murata T
AD  - Diabetes Center, National Hospital Organization Kyoto Medical Center, 1-1
      Fukakusamukaihata-cho, Fushimi-ku, Kyoto, 612-8555 Japan.grid.410835.b
FAU - Matsuhisa, Munehide
AU  - Matsuhisa M
AD  - Diabetes Therapeutics and Research Center Institute of Advance Medical Sciences, 
      Tokushima University, 3-18-15, Kuramoto-cho, Tokushima, Tokushima 770-8503
      Japan.grid.267335.60000 0001 1092 3579
FAU - Kasahara, Masato
AU  - Kasahara M
AD  - Institute for Clinical and Translational Science, Nara Medical University
      Hospital, 840 Shijo-cho, Kashihara, Nara 634-8521 Japan.grid.474851.b0000 0004
      1773 1360
LA  - eng
PT  - Editorial
DEP - 20200619
PL  - Japan
TA  - Diabetol Int
JT  - Diabetology international
JID - 101553224
PMC - PMC7303272
COIS- Conflict of interestThe author(s) declared no conflicts of interest related to
      the research, authorship, and/or publication of this article.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.1007/s13340-020-00449-3 [doi]
AID - 449 [pii]
PST - epublish
SO  - Diabetol Int. 2020 Jun 19;11(3):240-241. doi: 10.1007/s13340-020-00449-3.
      eCollection 2020 Jul.


PMID- 32793374
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - The use of data from electronic health records in times of a pandemic-a legal and
      ethical assessment.
PG  - lsaa041
LID - 10.1093/jlb/lsaa041 [doi]
AB  - National electronic health record systems controlled (at least in parts) by the
      patient are becoming increasingly common. During a pandemic, data stored in such 
      records could be used by health authorities to identify persons with a particular
      health risk. In this contribution, the authors focus-from the perspective of law 
      and medical ethics-on the question whether such state access to data could, under
      certain circumstances, be disadvantageous to a person's state of health in the
      long run. This may be the case if the data extracted is not only used for the
      purpose of informing persons, but serves as a basis for measures taken against
      the will of the individual concerned. This might be perceived as a "breach of
      trust" and could result in persons opting out of or not opting into an electronic
      health record system. Such unintended consequences raise concerns from an ethical
      and a legal point of view. It follows that, even in times of a pandemic, access
      to personal data stored in patient-controlled health records should be used as a 
      last resort only. While this contribution deals with the legal framework within
      the EU, its considerations are transferable to other national electronic health
      record systems.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Stoeger, Karl
AU  - Stoeger K
AUID- ORCID: 0000-0002-0294-2910
AD  - Institute of Public Law and Political Science, University of Graz,
      Universitaetsstrasse 15/C3, 8010 Graz, Austria.
FAU - Schmidhuber, Martina
AU  - Schmidhuber M
AD  - Chair in Health Care Ethics, Institute of Moral Theology, University of Graz,
      Heinrichstrasse 78/B2, 8010 Graz.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7337813
OTO - NOTNLM
OT  - Covid-19
OT  - data protection
OT  - medical ethics
OT  - pandemic
OT  - personal health records
OT  - trust
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/19 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.1093/jlb/lsaa041 [doi]
AID - lsaa041 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 16;7(1):lsaa041. doi: 10.1093/jlb/lsaa041. eCollection
      2020 Jan-Jun.


PMID- 32793373
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Legal and ethical implications of wastewater monitoring of SARS-CoV-2 for
      COVID-19 surveillance.
PG  - lsaa039
LID - 10.1093/jlb/lsaa039 [doi]
AB  - Scientists have observed that molecular markers for COVID-19 can be detected in
      wastewater of infected communities both during an outbreak and, in some cases,
      before the first case is confirmed. The Centers for Disease Control and
      Prevention and other government entities are considering whether to add community
      surveillance through wastewater monitoring to assist in tracking disease
      prevalence and guiding public health responses to the COVID-19 pandemic. This
      scientific breakthrough may lead to many useful potential applications for
      tracking disease, intensifying testing, initiating social distancing or
      quarantines, and even lifting restrictions once a cessation of infection is
      detected and confirmed. Yet, new technologies developed in response to a public
      health crisis may raise difficult legal and ethical questions about how such
      technologies may impact both the public health and civil liberties of the
      population. This paper describes recent scientific evidence regarding COVID-19
      detection in wastewater, identifying public health benefits that may result from 
      this breakthrough, as well as the limitations of existing data. The paper then
      assesses the legal and ethical implications of implementing policy based on
      positive sewage signals. It concludes that the first step to implementing legal
      and ethical wastewater monitoring is to develop scientific understanding. Even if
      reliability and efficacy are established, limits on sample and data collection,
      use, and sharing must also be considered to prevent undermining privacy and
      autonomy in order to implement these public health strategies consistent with
      legal and ethical considerations.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Gable, Lance
AU  - Gable L
AD  - School of Law, Wayne State University, Detroit, MI 48202, USA.
FAU - Ram, Natalie
AU  - Ram N
AUID- ORCID: 0000-0002-6681-5400
AD  - University of Maryland Francis King Carey School of Law, Baltimore, MD 21201,
      USA.
FAU - Ram, Jeffrey L
AU  - Ram JL
AD  - Department of Physiology, School of Medicine and Director, Belle Isle Aquarium
      Field Research Laboratory, Wayne State University, Detroit, MI 48201, USA.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7337755
OTO - NOTNLM
OT  - monitoring
OT  - privacy
OT  - public health
OT  - quarantine
OT  - sewage
OT  - surveillance
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.1093/jlb/lsaa039 [doi]
AID - lsaa039 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 24;7(1):lsaa039. doi: 10.1093/jlb/lsaa039. eCollection
      2020 Jan-Jun.


PMID- 32793328
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Linking)
VI  - 13
IP  - 7
DP  - 2020 Jul
TI  - The spectrum of primary immunodeficiencies at a tertiary care hospital in
      Pakistan.
PG  - 100133
LID - 10.1016/j.waojou.2020.100133 [doi]
AB  - BACKGROUND: Primary Immunodeficiency Disorders (PIDs) are well-known disorders in
      the West. but the recognition and diagnosis of these disorders is challenging in 
      developing countries. We present the spectrum of PIDs seen at a tertiary care
      center in Pakistan, identified using clinical case definitions and molecular
      methods. METHODS: A retrospective chart review of children suspected to have PID 
      was conducted at the Aga Khan University Hospital (AKUH) Karachi, Pakistan from
      2010 to 2016. Data on demographics, clinical features, family history of
      consanguinity, sibling death, details of laboratory workup done for PID and
      molecular tests targeted panel next generation sequencing (NGS) or whole exome
      sequencing (WES) performed at the Geha laboratory at Boston Children's Hospital, 
      USA was collected. The study was exempted from the Ethical Review Committee of
      AKUH. RESULTS: A total of 43 children visited the hospital with suspected PID
      during the study period. Genetic testing was performed in 31/43 (72.1%) children.
      A confirmed diagnosis of PID was established in 20/43 (46.5%) children. A
      pathogenic gene variant was identified in 17(85%) of the 20 confirmed cases
      (Table 1). Twelve (60%) of the confirmed cases of PID were male. The most common 
      presenting symptom was recurrent diarrhea 11/20 (55%). The mean (+/-S.D) age of
      the cases at the time of diagnosis was 4.2 (+/-4.1) years. Chronic granulomatous 
      disease (CGD) was the most common 6/20 (30%) disorder, followed by severe
      combined immunodeficiency (SCID) 3/20 (15%), leukocyte adhesion deficiency (LAD) 
      3/20 (15%), agammaglobulinemia/hypogammaglobulinemia 3/20 (15%), and
      Hermansky-Pudlak Syndrome (HPS) 2/20 (10%). Wiskott-Aldrich Syndrome,
      Immunodeficiency Centromeric Instability and Facial Anomalies Syndrome (ICF 2),
      Trichohepatoenteric syndrome (TRES), and C3 deficiency were each diagnosed once
      {1/20 (4.3%) each} (Table 1). Of these 20 confirmed cases, almost all 19/20 (95%)
      had a family history of consanguinity. Sibling death was reported in 5/20 (25%)
      of these cases. Five out of the 20 (25%) children died over the 7-year period for
      various reasons. CONCLUSION: PIDs are not uncommon in Pakistan; their diagnosis
      may be missed or delayed due to the overlapping of clinical features of PID with 
      other diseases and a lack of diagnostic facilities. There is a need to build
      capacity for early recognition and diagnosis of PIDs to decrease morbidity and
      mortality.
CI  - (c) 2020 The Authors.
FAU - Qureshi, Sonia
AU  - Qureshi S
AD  - Department of Pediatrics and Child Health, Aga Khan University, Stadium Road,
      Karachi, 74800, Pakistan.
FAU - Mir, Fatima
AU  - Mir F
AD  - Department of Pediatrics and Child Health, Aga Khan University, Stadium Road,
      Karachi, 74800, Pakistan.
FAU - Junejo, Samina
AU  - Junejo S
AD  - Department of Pediatrics, The Indus Hospital, Korangi Road, Karachi, Pakistan.
FAU - Saleem, Khalid
AU  - Saleem K
AD  - Children's Hospital and The Institute of Child Health, Multan, Pakistan.
FAU - Zaidi, Samreen
AU  - Zaidi S
AD  - National Institute of Blood Disease & Bone Marrow Transplantation, P.E.C.H.S,
      Karachi, Pakistan.
FAU - Naveed, Abdullah B
AU  - Naveed AB
AD  - Medical College, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan.
FAU - Ahmad, Khalil
AU  - Ahmad K
AD  - Department of Pediatrics and Child Health, Aga Khan University, Stadium Road,
      Karachi, 74800, Pakistan.
FAU - Qamar, Farah Naz
AU  - Qamar FN
AD  - Department of Pediatrics and Child Health, Aga Khan University, Stadium Road,
      Karachi, 74800, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC7414008
OTO - NOTNLM
OT  - AFIP, Armed Forces Institute of Pathology
OT  - ARDS, Acute Respiratory Distress Syndrome
OT  - BCG, Bacille Calmette-Guerin
OT  - BMT, Bone Marrow Transplant
OT  - CGD, Chronic Granulomatous Disease
OT  - Children
OT  - Chronic granulomatous disease
OT  - Consanguineous marriages
OT  - DHR, Dihydrorhodamine
OT  - HPS, Hermansky-Pudlak Syndrome
OT  - I/V, Intravenous
OT  - ICF-2, Immunodeficiency Centromeric Instability and Facial Anomalies Syndrome
OT  - LAD, Leukocyte Adhesion Deficiency
OT  - LMIC, Low Middle Income Countries
OT  - NBT, Nitrotetrazolium blue test
OT  - NGS, Next-Generation Sequencing
OT  - OPV, Oral Polio Vaccine
OT  - PIDs, Primary Immunodeficiency Disorders
OT  - Primary immunodeficiency disorders
OT  - S/C, Subcutaneous
OT  - SCID, Severe Combined Immunodeficiency Disorder
OT  - TRES, Trichohepatoenteric syndrome
OT  - USA, United States of America
OT  - VDP, Vaccine Derived Poliovirus
OT  - WES, Whole Exome Sequencing
COIS- All the authors declare that they have no conflict of interest, whether financial
      or otherwise.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.1016/j.waojou.2020.100133 [doi]
AID - S1939-4551(20)30036-3 [pii]
AID - 100133 [pii]
PST - epublish
SO  - World Allergy Organ J. 2020 Aug 5;13(7):100133. doi:
      10.1016/j.waojou.2020.100133. eCollection 2020 Jul.


PMID- 32793027
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The Concept of Radical Responsibility for Non-human Animals.
PG  - 1487
LID - 10.3389/fpsyg.2020.01487 [doi]
FAU - Dzwonkowska, Dominika
AU  - Dzwonkowska D
AD  - Institute of Philosophy, Cardinal Stefan Wyszynski University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7393923
OTO - NOTNLM
OT  - animal ethics
OT  - animal usage
OT  - animal use ethics
OT  - human-animal relations
OT  - moral response
OT  - radical responsibility
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.3389/fpsyg.2020.01487 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 24;11:1487. doi: 10.3389/fpsyg.2020.01487. eCollection
      2020.


PMID- 32792739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 7
DP  - 2020 Jul
TI  - A prospective randomised trial to compare three insertion techniques for i-gel
      placement: Standard, reverse, and rotation.
PG  - 618-623
LID - 10.4103/ija.IJA_937_19 [doi]
AB  - BACKGROUND AND AIMS: This prospective randomised study was done to compare
      standard, reverse, and rotation techniques of i-gel placement in terms of
      insertion characteristics and success rate. MATERIAL AND METHODS: After
      institutional ethics committee approval, 135 patients aged 18-50 years, ASA I and
      II undergoing elective surgery under general anesthesia were included. After
      induction of anesthesia, i-gel was inserted by standard, reverse, and rotation
      technique in Groups I, II, and III, respectively. The primary objective was mean 
      time of insertion. Secondary variables included ease of insertion, first attempt 
      success rate, manoeuvres required, fiberoptic view of placement, oropharyngeal
      leak pressure, ease of placement of nasogastric tube, and complications if any.
      RESULTS: Mean time of insertion was 18.04 +/- 5.65 s, 15.00 +/- 5.72 s and 16.12 
      +/- 5.84 s for groups I, II, and III, respectively. Time taken for insertion was 
      shortest and significantly lower (P = 0.048) for group II compared to group I.
      Insertion time was comparable between rest of groups. The overall success rate in
      groups I, II, and III were 91.1%, 95.6%, and 93.3% respectively (P = 0.7). The
      first attempt success rate was 82.2%, 89%, and 84.4% in groups I, II and III,
      respectively (P = 0.07). Manoeuvres were required in five (12.19%) patients in
      group I, four (9.30%) patients in group II, and three (7.14%) patients in group
      III (P = 0.602). Complications occurred in eight, three, and three patients in
      groups I, II, and III, respectively. CONCLUSION: All techniques of i-gel
      insertion are equally good and choice of technique depends upon the experience
      and comfort of the investigator with the particular technique.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Bhardwaj, Mamta
AU  - Bhardwaj M
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Singhal, Suresh K
AU  - Singhal SK
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Rashmi
AU  - Rashmi
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Dahiya, Amit
AU  - Dahiya A
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7413360
OTO - NOTNLM
OT  - Airway management
OT  - fiberoptic
OT  - general anesthesia
OT  - rotation
OT  - supraglottic airway
COIS- There are no conflicts of interest.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2019/12/21 00:00 [received]
PHST- 2020/01/19 00:00 [revised]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.4103/ija.IJA_937_19 [doi]
AID - IJA-64-618 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Jul;64(7):618-623. doi: 10.4103/ija.IJA_937_19. Epub 2020 
      Jul 1.


PMID- 32792716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 6
DP  - 2020 Jun
TI  - Comparison of transversus abdominis plane block and intrathecal morphine for
      laparoscopic donor nephrectomy: Randomised controlled trial.
PG  - 507-512
LID - 10.4103/ija.IJA_868_19 [doi]
AB  - BACKGROUND AND AIMS: Postoperative pain following laparoscopic donor nephrectomy 
      (LDN) is significant and no suitable analgesic technique is described. Opioid
      analgesia in standard doses is often suboptimal and associated with numerous
      adverse effects. Transversus abdominis plane (TAP) block has been evaluated in
      various laparoscopic procedures. Intrathecal morphine (ITM) has been seen to
      provide long-lasting analgesia of superior quality in laparoscopic colorectal
      procedures. METHODS: The present study was undertaken to evaluate the analgesic
      efficacy of single-dose ITM 5 mug/kg for LDN. After ethics approval, 60 adult
      patients scheduled for LDN were randomised to receive intravenous fentanyl,
      ultrasound-guided TAP block or ITM for postoperative analgesia. Postoperative
      24-h patient-controlled analgesia (PCA) fentanyl consumption, visual analogue
      scale (VAS) score and intraoperative fentanyl and muscle relaxant requirements
      were compared. Statistical analysis was performed using appropriate statistical
      tests by using Stata 11.1 software. RESULTS: Haemodynamic stability at
      pneumoperitoneum and in the post anaesthesia care unit was significantly better
      in patients receiving ITM. Intraoperative rescue fentanyl requirement (P = 0.01) 
      and postoperative fentanyl requirement until 24 h (P = 0.000) were significantly 
      lower in the morphine group. Postoperative VAS at rest and on movement was
      significantly lower in the morphine group at all points of assessment (P =
      0.000). CONCLUSION: ITM 5 mug/kg provides better intraoperative and postoperative
      analgesia and reduces postoperative PCA fentanyl requirement in laparoscopic
      donor nephrectomy compared to TAP block or intravenous fentanyl.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Srinivasan, Sathianarayanan
AU  - Srinivasan S
AD  - Department of Anesthesiology, Pain Medicine and Critical Care, New Delhi, India.
FAU - Subramaniam, Rajeshwari
AU  - Subramaniam R
AD  - Department of Anesthesiology, Pain Medicine and Critical Care, New Delhi, India.
FAU - Chhabra, Anjolie
AU  - Chhabra A
AD  - Department of Anesthesiology, Pain Medicine and Critical Care, New Delhi, India.
FAU - Baidya, Dalim K
AU  - Baidya DK
AD  - Department of Anesthesiology, Pain Medicine and Critical Care, New Delhi, India.
FAU - Arora, Mahesh K
AU  - Arora MK
AD  - Department of Anesthesiology, Pain Medicine and Critical Care, New Delhi, India.
FAU - Maitra, Souvik
AU  - Maitra S
AD  - Department of Anesthesiology, Pain Medicine and Critical Care, New Delhi, India.
FAU - Bansal, Virender K
AU  - Bansal VK
AD  - Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India.
FAU - Bhattacharjee, Hemanga K
AU  - Bhattacharjee HK
AD  - Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7398014
OTO - NOTNLM
OT  - Donor nephrectomy
OT  - intrathecal morphine
OT  - laparoscopy
COIS- There are no conflicts of interest.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/01/11 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.4103/ija.IJA_868_19 [doi]
AID - IJA-64-507 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Jun;64(6):507-512. doi: 10.4103/ija.IJA_868_19. Epub 2020 
      Jun 1.


PMID- 32792714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 6
DP  - 2020 Jun
TI  - The effect of anaesthetic exposure in presurgical period on delayed cerebral
      ischaemia and neurological outcome in patients with aneurysmal subarachnoid
      haemorrhage undergoing clipping of aneurysm: A retrospective analysis.
PG  - 495-500
LID - 10.4103/ija.IJA_958_19 [doi]
AB  - BACKGROUND AND AIMS: Delayed cerebral ischaemia is one of the major contributors 
      to morbidity in aneurysmal subarachnoid haemorrhage (aSAH). General anaesthesia
      (GA) in the presurgical period may have a preconditioning effect. The primary aim
      was to assess the effect of preoperative exposure to GA during digital
      subtraction angiography (DSA) on neurological outcome in patients presenting with
      aSAH. METHODS: After Ethical Committee approval, we conducted a retrospective
      analysis of the data of patients with aSAH treated surgically. Patients, admitted
      to neurosurgical ICU (June 2014 and December 2017) with a computed tomography
      (CT) diagnosis of aSAH and underwent DSA, were included. DSA, done with or
      without exposure to a general anaesthetic, was classified to GA group and LA
      group, respectively. Propensity score matching was done on the baseline
      variables. Appropriate statistical methods were applied. RESULTS: Of the 278
      patients, 116 (41.7%) patients had received GA during DSA. Propensity matching
      yielded 114 (57 in each group) matched patients. In a logistic regression model, 
      the odds ratio (OR) for poor outcome at discharge in GA group as compared to LA
      group was 4.4 (CI: 2.7-7.4), P = 0.001, whereas, in the matched data, the OR for 
      poor outcome at discharge in GA group as compared to LA group was 1.2 (CI:
      0.6-2.6), P = 0.57. CONCLUSION: The presurgical exposure to GA did not offer any 
      neuroprotection and the odds of poor outcome were higher compare to non-exposure 
      to GA group.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Mishra, Rajeeb K
AU  - Mishra RK
AD  - Department of Neuroanaesthesia and Neurocritical Care, National Institute of
      Mental Health and Neurosciences, Bengaluru, Karnataka, India.
FAU - Pandia, Mihir P
AU  - Pandia MP
AD  - Department of Neuroanaesthesia and Critical Care, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Kumar, Subodh
AU  - Kumar S
AD  - Department of Anaesthesia and Intensive care, Government Medical College and
      Hospital, Chandigarh, India.
FAU - Singh, Gyaninder P
AU  - Singh GP
AD  - Department of Neuroanaesthesia and Critical Care, All India Institute of Medical 
      Sciences, New Delhi, India.
FAU - Kalaivani, M
AU  - Kalaivani M
AD  - Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7398020
OTO - NOTNLM
OT  - Anaesthesia general
OT  - Glasgow outcome scale
OT  - cerebral infarction
OT  - neuroprotection
OT  - subarachnoid haemorrhage
COIS- There are no conflicts of interest.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.4103/ija.IJA_958_19 [doi]
AID - IJA-64-495 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Jun;64(6):495-500. doi: 10.4103/ija.IJA_958_19. Epub 2020 
      Jun 1.


PMID- 32792711
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 6
DP  - 2020 Jun
TI  - A randomised study comparing the extent of block produced by spinal column height
      and body weight-based formulae for paediatric caudal analgesia.
PG  - 477-482
LID - 10.4103/ija.IJA_824_19 [doi]
AB  - BACKGROUND AND AIMS: Height and weight-based formulae are used for calculation of
      dose of medications for caudal analgesia but these have not been compared. We
      compared spinal column height-based Spiegel and weight-based Takasaki and
      Armitage formulae for achieving maximum height of sensory neuraxial block after
      caudal epidural analgesia in paediatric patients. METHODS: In this double-blind
      randomised study, children aged between 1 and 6 years and planned for
      infra-umbilical surgery were randomly allocated to receive caudal epidural block 
      (targeting T10level block) with 0.25% bupivacaine, using a volume calculated by
      modified Spiegel formula (group I), Takasaki formula (group II), and Armitage
      formula (group III). The Institute ethics committee reviewed and approved the
      study protocol. The primary endpoint of the study was the difference in the
      number of spinal segments blocked as assessed by pinprick method. The secondary
      endpoint was the difference in volume of 0.25% bupivacaine used among the groups.
      The groups were compared using one-way ANOVA. RESULTS: Seventy-five patients (25 
      in each group) completed the study as per protocol. The mean number of spinal
      segments blocked was significantly different among groups (P < 0.001) with
      patients in group I (13.8 +/- 0.83) showing significantly lower number of spinal 
      segments blocked as compared to that in group II (15.8 +/- 1.06; P < 0.001), and 
      group III (16.8 +/- 1.28; P < 0.001). The mean volume of 0.25% bupivacaine used
      in group I was significantly lower (P < 0.001) than that in group II and group
      III. CONCLUSION: Dose calculation in caudal epidural analgesia as per spinal
      column height-based modified Spiegel formula was more precise than
      bodyweight-based Takasaki and Armitage formulae.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Kaushal, Sonali
AU  - Kaushal S
AD  - Department of Anaesthesiology, Indira Gandhi Medical College, Shimla, Himachal
      Pradesh, India.
FAU - Singh, Surinder
AU  - Singh S
AD  - Department of Anaesthesiology, Indira Gandhi Medical College, Shimla, Himachal
      Pradesh, India.
FAU - Sharma, Anupam
AU  - Sharma A
AD  - Department of Anaesthesiology, Indira Gandhi Medical College, Shimla, Himachal
      Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7398024
OTO - NOTNLM
OT  - Bupivacaine
OT  - caudal analgesia
OT  - epidural block
OT  - regional anaesthesia
COIS- There are no conflicts of interest.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2019/12/16 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - 10.4103/ija.IJA_824_19 [doi]
AID - IJA-64-477 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Jun;64(6):477-482. doi: 10.4103/ija.IJA_824_19. Epub 2020 
      Jun 1.


PMID- 32792456
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Evaluating the validity, reliability and clinical utility of the Music therapy
      Sensory Instrument for Cognition, Consciousness and Awareness (MuSICCA): protocol
      of a validation study.
PG  - e039713
LID - 10.1136/bmjopen-2020-039713 [doi]
AB  - INTRODUCTION: A growing number of children and young people are surviving severe 
      acquired brain injuries due to advances in healthcare. However, many fail to
      emerge from coma and continue to live with disorders of consciousness (DOC).
      Diagnostic, clinical and ethical challenges are prominent in this group.
      Misdiagnosis can have severe consequences for children and their families,
      including inadequate care, insufficient access to rehabilitation and stimulation,
      reduced accessibility to services and inappropriately limited opportunities for
      participation. The proposed project will develop and validate a diagnostic
      measure that supports detailed goal-planning-the Music therapy Sensory Instrument
      for Cognition, Consciousness and Awareness (MuSICCA). METHODS AND ANALYSIS: Face 
      validity will be assessed using a short questionnaire and the MuSICCA will be
      amended if face validity is insufficient. Once face validity is sufficient, 80
      participants with suspected DOC will be recruited from multiple sites around the 
      UK, USA and Ireland.Validity will be assessed using external reference standards 
      (Coma Recovery Scale-Revised, Coma Near-Coma Scale and Nociception Coma Scale).
      Intra-rater reliability will be established using repeated ratings of video
      recordings from the assessment sessions. Inter-rater reliability will be assessed
      through video ratings by a second blinded assessor. In addition to these
      analyses, the clinical utility of the MuSICCA will be evaluated using a
      questionnaire to be completed by clinicians and relatives of the participants
      following the completion of the MuSICCA assessment. ETHICS AND DISSEMINATION:
      Ethical approval has been obtained for this study from the Research Ethics
      Committee and Health Research Authority of the National Health Service of the UK 
      (ID: 167534). Results will be presented at national and international
      conferences, published in scientific journals and disseminated to participant
      representatives, clinicians, educators and care providers. TRIAL REGISTRATION
      DETAILS: This study was registered at ClinicalTrials.gov Protocol Registration
      and Results System on 7(th) August 2019 (ID: NCT04050995); Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pool, Jonathan Wain
AU  - Pool JW
AUID- ORCID: 0000-0003-4134-8030
AD  - Cambridge Institute for Music Therapy Research, Anglia Ruskin University,
      Cambridge, UK jonathan.pool1@anglia.ac.uk.
AD  - Research, The Children's Trust, Tadworth, UK.
FAU - Siegert, Richard John
AU  - Siegert RJ
AD  - School of Public Health and Psychosocial Studies and School of Rehabilitation and
      Occupational Studies, Auckland University of Technology, Auckland, New Zealand.
FAU - Taylor, Steven
AU  - Taylor S
AD  - Department of Biostatistics and Epidemiology, Auckland University of Technology, 
      Auckland, New Zealand.
FAU - Dunford, Carolyn
AU  - Dunford C
AD  - Research, The Children's Trust, Tadworth, UK.
AD  - Department of Occupational Therapy, Brunel University College of Health and Life 
      Sciences, Uxbridge, Middlesex, UK.
FAU - Magee, Wendy
AU  - Magee W
AD  - Music Therapy, Temple University, Philadelphia, Pennsylvania, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04050995
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Consciousness
MH  - Humans
MH  - Ireland
MH  - *Music Therapy
MH  - Reproducibility of Results
MH  - State Medicine
MH  - Validation Studies as Topic
PMC - PMC7430455
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *neurological injury
OT  - *paediatric neurology
OT  - *paediatric palliative care
OT  - *rehabilitation medicine
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039713 [pii]
AID - 10.1136/bmjopen-2020-039713 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e039713. doi: 10.1136/bmjopen-2020-039713.


PMID- 32792455
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - E-mental health mindfulness-based and skills-based 'CoPE It' intervention to
      reduce psychological distress in times of COVID-19: study protocol for a bicentre
      longitudinal study.
PG  - e039646
LID - 10.1136/bmjopen-2020-039646 [doi]
AB  - INTRODUCTION: The SARS-CoV-2 (COVID-19) pandemic poses immense challenges for
      national and international healthcare systems. Especially in times of social
      isolation and governmental restrictions, mental health should not be neglected.
      Innovative approaches are required to support psychologically burdened people.
      The e-mental health intervention 'CoPE It' has been developed to offer manualised
      and evidence-based psychotherapeutic support adapted to COVID-19-related issues
      in order to overcome psychological distress. In our study, we aim to assess the
      efficacy of the e-mental health intervention 'CoPE It' in terms of reducing
      distress (primary outcome), depression and anxiety symptoms as well as improving 
      self-efficacy, quality of life and mindfulness (secondary outcomes). Furthermore,
      we want to evaluate the programme's usability, feasibility and participants'
      satisfaction with 'CoPE It' (tertiary outcome). METHODS AND ANALYSIS: The
      e-mental health intervention 'CoPE It' consists of four 30 min modules, conducted
      every other day, involving psychotherapeutic techniques of mindfulness-based
      stress reduction and cognitive-behavioural therapy. The widely applied and
      previously established content has been adapted to the context of the COVID-19
      pandemic by experts in psychosomatic medicine and stress prevention. In our
      longitudinal study, adult participants-with adequate German language and computer
      skills, and who have provided informed consent-will be recruited via emergency
      support hotlines in Germany. Flyers will be distributed, and online channels will
      be used. Participants will complete a baseline assessment (T0), a
      postintervention assessment (T1) and assessments 1 and 3 months later (T2 and T3,
      respectively). We will perform repeated measures analysis of covariance, mixed
      linear models, standard analyses of variance and regression, and correlation
      coefficients. In case of binary outcome variables, either mixed logistic
      regression or chi(2) tests will be used. ETHICS AND DISSEMINATION: The Ethics
      Committees of the University of Duisburg-Essen (20-9243-BO) and University of
      Tubingen (469/2020BO) approved the study. Results will be published in
      peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER:
      DRKS00021301.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bauerle, Alexander
AU  - Bauerle A
AUID- ORCID: 0000-0003-1488-8592
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany
      alexander.baeuerle@uni-due.de.
FAU - Graf, Johanna
AU  - Graf J
AD  - Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tubingen,
      Tubingen, Germany.
FAU - Jansen, Christoph
AU  - Jansen C
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Musche, Venja
AU  - Musche V
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Schweda, Adam
AU  - Schweda A
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Hetkamp, Madeleine
AU  - Hetkamp M
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Weismuller, Benjamin
AU  - Weismuller B
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Dorrie, Nora
AU  - Dorrie N
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Junne, Florian
AU  - Junne F
AD  - Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tubingen,
      Tubingen, Germany.
FAU - Teufel, Martin
AU  - Teufel M
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
FAU - Skoda, Eva-Maria
AU  - Skoda EM
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
LA  - eng
SI  - DRKS/DRKS00021301
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Adaptation, Psychological
MH  - Anxiety/prevention & control/therapy
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cognitive Behavioral Therapy/*methods
MH  - Coronavirus Infections/*psychology
MH  - Depression/prevention & control/therapy
MH  - Distance Counseling/*methods
MH  - Humans
MH  - Mindfulness/*methods
MH  - Pandemics
MH  - Patient Satisfaction
MH  - Pneumonia, Viral/*psychology
MH  - Quality of Life
MH  - SARS-CoV-2
MH  - Self Efficacy
MH  - Stress, Psychological/prevention & control/*therapy
PMC - PMC7430186
OTO - NOTNLM
OT  - *infectious diseases
OT  - *public health
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - bmjopen-2020-039646 [pii]
AID - 10.1136/bmjopen-2020-039646 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e039646. doi: 10.1136/bmjopen-2020-039646.


PMID- 32792454
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - TASCI-transcutaneous tibial nerve stimulation in patients with acute spinal cord 
      injury to prevent neurogenic detrusor overactivity: protocol for a nationwide,
      randomised, sham-controlled, double-blind clinical trial.
PG  - e039164
LID - 10.1136/bmjopen-2020-039164 [doi]
AB  - INTRODUCTION: Neurogenic lower urinary tract dysfunction (NLUTD), including
      neurogenic detrusor overactivity (NDO) and detrusor sphincter dyssynergia, is one
      of the most frequent and devastating sequelae of spinal cord injury (SCI), as it 
      can lead to urinary incontinence and secondary damage such as renal failure.
      Transcutaneous tibial nerve stimulation (TTNS) is a promising, non-invasive
      neuromodulatory intervention that may prevent the emergence of the C-fibre evoked
      bladder reflexes that are thought to cause NDO. This paper presents the protocol 
      for TTNS in acute SCI (TASCI), which will evaluate the efficacy of TTNS in
      preventing NDO. Furthermore, TASCI will provide insight into the mechanisms
      underlying TTNS, and the course of NLUTD development after SCI. METHODS AND
      ANALYSIS: TASCI is a nationwide, randomised, sham-controlled, double-blind
      clinical trial, conducted at all four SCI centres in Switzerland. The
      longitudinal design includes a baseline assessment period 5-39 days after acute
      SCI and follow-up assessments occurring 3, 6 and 12 months after SCI. A planned
      114 participants will be randomised into verum or sham TTNS groups (1:1 ratio),
      stratified on study centre and lower extremity motor score. TTNS is performed for
      30 min/day, 5 days/week, for 6-9 weeks starting within 40 days after SCI. The
      primary outcome is the occurrence of NDO jeopardising the upper urinary tract at 
      1 year after SCI, assessed by urodynamic investigation. Secondary outcome
      measures assess bladder and bowel function and symptoms, sexual function,
      neurological structure and function, functional independence, quality of life, as
      well as changes in biomarkers in the urine, blood, stool and bladder tissue.
      Safety of TTNS is the tertiary outcome. ETHICS AND DISSEMINATION: TASCI is
      approved by the Swiss Ethics Committee for Northwest/Central Switzerland, the
      Swiss Ethics Committee Vaud and the Swiss Ethics Committee Zurich (#2019-00074). 
      Findings will be disseminated through peer-reviewed publications. TRIAL
      REGISTRATION NUMBER: NCT03965299.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Birkhauser, Veronika
AU  - Birkhauser V
AUID- ORCID: 0000-0002-6646-7266
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Liechti, Martina D
AU  - Liechti MD
AUID- ORCID: 0000-0002-3024-0975
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Anderson, Collene E
AU  - Anderson CE
AUID- ORCID: 0000-0002-4350-6816
AD  - Swiss Paraplegic Research, Nottwil, Switzerland.
AD  - Department of Health Sciences and Medicine, University of Lucerne, Lucerne,
      Switzerland.
FAU - Bachmann, Lucas M
AU  - Bachmann LM
AD  - Medignition Inc., Research Consultants, Zurich, Switzerland.
FAU - Baumann, Sarah
AU  - Baumann S
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Baumberger, Michael
AU  - Baumberger M
AD  - Spinal Cord and Rehabilitation Medicine, Swiss Paraplegic Centre, Nottwil,
      Switzerland.
FAU - Birder, Lori A
AU  - Birder LA
AD  - Neuro-Urology, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Botter, Sander M
AU  - Botter SM
AD  - Swiss Center for Musculoskeletal Biobanking, Balgrist Campus AG, Zurich,
      Switzerland.
FAU - Bueler, Silvan
AU  - Bueler S
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Cruz, Celia D
AU  - Cruz CD
AD  - Instituto de Investigacao e Inovacao em Saude, Translational Neuro-urology Group,
      Universidade do Porto, Porto, Portugal.
AD  - Faculdade de Medicina, Departemento de Biomedicina, Unidade de Biologia
      Experimental, Universidade do Porto, Porto, Portugal.
FAU - David, Gergely
AU  - David G
AUID- ORCID: 0000-0002-9379-5193
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Freund, Patrick
AU  - Freund P
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Friedl, Susanne
AU  - Friedl S
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Gross, Oliver
AU  - Gross O
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Hund-Georgiadis, Margret
AU  - Hund-Georgiadis M
AD  - Clinic of Neurorehabilitation and Paraplegiology, REHAB Basel, Basel,
      Switzerland.
FAU - Husmann, Knut
AU  - Husmann K
AD  - Swiss Center for Musculoskeletal Biobanking, Balgrist Campus AG, Zurich,
      Switzerland.
FAU - Jordan, Xavier
AU  - Jordan X
AD  - Spinal Cord Injury Department, Clinique romande de readaptation, Sion,
      Switzerland.
FAU - Koschorke, Miriam
AU  - Koschorke M
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Leitner, Lorenz
AU  - Leitner L
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Luca, Eugenia
AU  - Luca E
AD  - Spinal Cord Injury Department, Clinique romande de readaptation, Sion,
      Switzerland.
FAU - Mehnert, Ulrich
AU  - Mehnert U
AUID- ORCID: 0000-0001-7963-8477
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Mohr, Sandra
AU  - Mohr S
AD  - Clinic of Neurorehabilitation and Paraplegiology, REHAB Basel, Basel,
      Switzerland.
FAU - Mohammadzada, Freschta
AU  - Mohammadzada F
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Monastyrskaya, Katia
AU  - Monastyrskaya K
AD  - Urology Research Laboratory, DBMR, University of Bern, Bern, Switzerland.
FAU - Pfender, Nikolai
AU  - Pfender N
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Pohl, Daniel
AU  - Pohl D
AUID- ORCID: 0000-0002-0855-1152
AD  - Department of Gastroenterology and Hepatology, University Hospital Zurich,
      Zurich, Switzerland.
FAU - Sadri, Helen
AU  - Sadri H
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Sartori, Andrea M
AU  - Sartori AM
AUID- ORCID: 0000-0002-9571-0288
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
AD  - Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland.
FAU - Schubert, Martin
AU  - Schubert M
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Sprengel, Kai
AU  - Sprengel K
AD  - Department of Trauma, University Hospital Zurich, Zurich, Switzerland.
FAU - Stalder, Stephanie A
AU  - Stalder SA
AUID- ORCID: 0000-0002-7914-8264
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Stoyanov, Jivko
AU  - Stoyanov J
AD  - Swiss Paraplegic Research, Nottwil, Switzerland.
AD  - Department of Health Sciences and Medicine, University of Lucerne, Lucerne,
      Switzerland.
FAU - Stress, Cornelia
AU  - Stress C
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Tatu, Aurora
AU  - Tatu A
AD  - Department of Gastroenterology and Hepatology, University Hospital Zurich,
      Zurich, Switzerland.
FAU - Tawadros, Cecile
AU  - Tawadros C
AD  - Spinal Cord Injury Department, Clinique romande de readaptation, Sion,
      Switzerland.
FAU - van der Lely, Stephanie
AU  - van der Lely S
AUID- ORCID: 0000-0002-2688-9042
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland.
FAU - Wollner, Jens
AU  - Wollner J
AD  - Neuro-Urology, Swiss Paraplegic Centre, Nottwil, Switzerland.
FAU - Zubler, Veronika
AU  - Zubler V
AD  - Department of Radiology, Balgrist University Hospital, Zurich, Switzerland.
FAU - Curt, Armin
AU  - Curt A
AD  - Spinal Cord Injury Center, Balgrist University Hospital, University of Zurich,
      Zurich, Switzerland.
FAU - Pannek, Jurgen
AU  - Pannek J
AUID- ORCID: 0000-0002-9910-1295
AD  - Neuro-Urology, Swiss Paraplegic Centre, Nottwil, Switzerland.
AD  - Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland.
FAU - Brinkhof, Martin W G
AU  - Brinkhof MWG
AUID- ORCID: 0000-0002-9319-665X
AD  - Swiss Paraplegic Research, Nottwil, Switzerland.
AD  - Department of Health Sciences and Medicine, University of Lucerne, Lucerne,
      Switzerland.
FAU - Kessler, Thomas M
AU  - Kessler TM
AUID- ORCID: 0000-0002-1991-5919
AD  - Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, 
      Zurich, Switzerland tkessler@gmx.ch.
LA  - eng
SI  - ClinicalTrials.gov/NCT03965299
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Spinal Cord Injuries/complications
MH  - Switzerland
MH  - Tibial Nerve
MH  - Treatment Outcome
MH  - *Urinary Bladder, Neurogenic/etiology/therapy
MH  - *Urinary Bladder, Overactive/etiology/therapy
PMC - PMC7430472
OTO - NOTNLM
OT  - *bladder disorders
OT  - *neuro-urology
OT  - *neurological injury
OT  - *rehabilitation medicine
OT  - *urinary incontinences
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039164 [pii]
AID - 10.1136/bmjopen-2020-039164 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e039164. doi: 10.1136/bmjopen-2020-039164.


PMID- 32792452
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Protocol for systematic review and meta-analysis: impact of statins as
      immune-modulatory agents on inflammatory markers in adults with chronic diseases.
PG  - e039034
LID - 10.1136/bmjopen-2020-039034 [doi]
AB  - INTRODUCTION: Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme-A
      (HMG-CoA) reductase inhibitors, are lipid-lowering agents that are central in
      preventing or reducing the complications of atherosclerotic cardiovascular
      disease. Because statins have anti-inflammatory properties, there is considerable
      interest in their therapeutic potential in other chronic inflammatory conditions.
      We aim to identify the statin with the greatest ability to reduce systemic
      inflammation, independent of the underlying disease entity. METHODS AND ANALYSIS:
      We aim to conduct a comprehensive search of published and peer-reviewed
      randomised controlled clinical trials, with at least one intervention arm of a
      Food & Drug Administration-licensed or European Medicines Agency-licensed statin 
      and a minimum treatment duration of 12 weeks. Our objective is to investigate the
      effect of statins (atorvastatin, fluvastatin, pitavastatin, pravastatin,
      rosuvastatin, simvastatin) on lipid profile, particularly, cholesterol
      low-density lipoprotein and inflammation markers such as high-sensitive C
      reactive protein (hsCRP), CRP, tumour necrosis factor alpha (TNF-alpha),
      interleukin-1beta (IL-1beta), IL-6, IL-8, soluble cluster of differentiation 14
      (sCD14) or sCD16 in adults, published in the last 20 years (between January 1999 
      and December 2019). We aim to identify the most potent statin to reduce systemic 
      inflammation and optimal dosing. The following databases will be searched:
      Medline, Scopus, Web of Science and Cochrane Library of Systematic Reviews. The
      risk of bias of included studies will be assessed by Cochrane Risk of Bias Tool
      and Quality Assessment Tool for Quantitative Studies. The quality of studies will
      be assessed, to show uncertainty, by the Jadad Score. If sufficient evidence is
      identified, a meta-analysis will be conducted with risk ratios or ORs with 95%
      CIs in addition to mean differences. ETHICS AND DISSEMINATION: Ethics approval is
      not required as no primary data will be collected. Results will be presented at
      conferences and published in a peer-reviewed journal. PROSPERO REGISTRATION
      NUMBER: CRD42020169919.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sabeel, Solima
AU  - Sabeel S
AD  - International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town 
      Component, Cape Town, South Africa.
AD  - Institute of Infectious Diseases and Molecular Medicine (IDM), Department of
      Pathology, Division of Immunology, South African Medical Research Council (SAMRC)
      Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape
      Town, Cape Town, South Africa.
FAU - Motaung, Bongani
AU  - Motaung B
AD  - International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town 
      Component, Cape Town, South Africa.
AD  - Institute of Infectious Diseases and Molecular Medicine (IDM), Department of
      Pathology, Division of Immunology, South African Medical Research Council (SAMRC)
      Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape
      Town, Cape Town, South Africa.
FAU - Ozturk, Mumin
AU  - Ozturk M
AD  - International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town 
      Component, Cape Town, South Africa.
AD  - Institute of Infectious Diseases and Molecular Medicine (IDM), Department of
      Pathology, Division of Immunology, South African Medical Research Council (SAMRC)
      Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape
      Town, Cape Town, South Africa.
FAU - Mukasa, Sandra
AU  - Mukasa S
AD  - General Medicine & Global Health, Hatter Institute for Cardiovascular Research in
      Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South
      Africa.
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, South Africa.
FAU - Kengne, Andre Pascal
AU  - Kengne AP
AD  - South African Medical Research Council and University of Cape Town, Cape Town,
      South Africa.
FAU - Blom, Dirk
AU  - Blom D
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, South Africa.
AD  - Hatter Institute for Cardiovascular Research in Africa, Faculty of Health
      Sciences, University of Cape Town, Cape Town, South Africa.
FAU - Sliwa, Karen
AU  - Sliwa K
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, South Africa.
AD  - Hatter Institute for Cardiovascular Research in Africa, Faculty of Health
      Sciences, University of Cape Town, Cape Town, South Africa.
FAU - Nepolo, Emmanuel
AU  - Nepolo E
AD  - University of Namibia School of Medicine, Windhoek, Namibia.
FAU - Gunther, Gunar
AU  - Gunther G
AD  - University of Namibia School of Medicine, Windhoek, Namibia.
AD  - Inselspital Bern, Bern, Switzerland.
FAU - Wilkinson, Robert J
AU  - Wilkinson RJ
AD  - Wellcome Centre for Infectious Diseases Research in Africa, Institute of
      Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences,
      University of Cape Town, Cape Town, South Africa.
AD  - Francis Crick Institute, London NW1 1AT, United Kingdom.
AD  - Department of Infectious Diseases, Imperial College London, London W12 0NN,
      United Kingdom.
FAU - Schacht, Claudia
AU  - Schacht C
AD  - LINQ management GmbH, Berlin, Germany.
FAU - Thienemann, Friedrich
AU  - Thienemann F
AUID- ORCID: 0000-0002-4801-2030
AD  - General Medicine & Global Health, Hatter Institute for Cardiovascular Research in
      Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South
      Africa.
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape
      Town, South Africa.
AD  - Department of Internal Medicine, University Hospital Zurich, University of
      Zurich, Zurich, Switzerland.
FAU - Guler, Reto
AU  - Guler R
AUID- ORCID: 0000-0002-6894-2163
AD  - International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town 
      Component, Cape Town, South Africa reto.guler@uct.ac.za.
AD  - Institute of Infectious Diseases and Molecular Medicine (IDM), Department of
      Pathology, Division of Immunology, South African Medical Research Council (SAMRC)
      Immunology of Infectious Diseases, Faculty of Health Sciences, University of Cape
      Town, Cape Town, South Africa.
AD  - Wellcome Centre for Infectious Diseases Research in Africa, Institute of
      Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences,
      University of Cape Town, Cape Town, South Africa.
LA  - eng
GR  - FC0010218/MRC_/Medical Research Council/United Kingdom
GR  - FC0010218/CRUK_/Cancer Research UK/United Kingdom
GR  - 203135Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - A0JWA85V8F (Atorvastatin)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Adult
MH  - Atorvastatin
MH  - Chronic Disease
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Meta-Analysis as Topic
MH  - Simvastatin
MH  - Systematic Reviews as Topic
PMC - PMC7430409
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *immunology
OT  - *infectious diseases
OT  - *microbiology
OT  - *molecular biology
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039034 [pii]
AID - 10.1136/bmjopen-2020-039034 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e039034. doi: 10.1136/bmjopen-2020-039034.


PMID- 32792451
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Neurosurgeons' experiences of conducting and disseminating clinical research in
      low- and middle-income countries: a qualitative study protocol.
PG  - e038939
LID - 10.1136/bmjopen-2020-038939 [doi]
AB  - INTRODUCTION: Low-income and middle-income countries (LMICs) face the greatest
      burden of neurotrauma. However, most of the research published in scientific
      journals originates from high-income countries, suggesting those in LMICs are
      either not engaging in research or are not publishing it. Evidence originating in
      high-income countries may not be generalisable to LMICs; therefore, it is
      important to nurture research capacity in LMICs so that a relevant evidence base 
      can be developed. However, little is published about specific challenges or
      contextual issues relevant to increasing research activity of neurosurgeons in
      LMICs. Therefore, the aim of this study was to understand neurosurgeons'
      experiences of, aspirations for and ability to conduct and disseminate clinical
      research in LMICs. METHODS AND ANALYSIS: This is a pragmatic qualitative study
      situated within the naturalistic paradigm using focus groups and interviews with 
      a purposive sample of neurosurgeons from LMICs. First, we will conduct
      asynchronous online focus groups with 36 neurosurgeons to broadly explore issues 
      relevant to the study aim. Second, we will select 20 participants for follow-up
      semistructured interviews to explore concepts in more depth and detail than could
      be achieved in the focus group. Interviews will be audio-recorded and transcribed
      verbatim. A thematic analysis will be conducted following Braun and Clarke's six 
      stages and will be supported by NVIVO software. ETHICS AND DISSEMINATION: The
      University of Cambridge Psychology Research Ethics Committee reviewed this study 
      and provided a favourable opinion in January 2020 (REF PRE.2020.006).
      Participants will provide informed consent, be able to withdraw at any time and
      will have their contributions kept confidential. The findings of the study will
      be shared with relevant stakeholders and disseminated in conference presentations
      and journal publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Whiffin, Charlotte J
AU  - Whiffin CJ
AUID- ORCID: 0000-0002-9767-2123
AD  - College of Health and Social Care, University of Derby, Derby, UK
      c.whiffin@derby.ac.uk.
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital and University of Cambridge, Cambridge, UK.
AD  - NIHR Global Health Research Group on Neurotrauma, University of Cambridge,
      Cambridge, UK.
FAU - Smith, Brandon G
AU  - Smith BG
AUID- ORCID: 0000-0001-8471-1368
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital and University of Cambridge, Cambridge, UK.
AD  - NIHR Global Health Research Group on Neurotrauma, University of Cambridge,
      Cambridge, UK.
FAU - Esene, Ignatius N
AU  - Esene IN
AD  - NIHR Global Health Research Group on Neurotrauma, University of Cambridge,
      Cambridge, UK.
AD  - Neurosurgery Division, Faculty of Health Sciences, University of Bamenda,
      Bambili, NW Region, Cameroon.
FAU - Karekezi, Claire
AU  - Karekezi C
AD  - Department of Neurosurgery, Rwanda Military Hospital, Kigali, Kigali City,
      Rwanda.
FAU - Bashford, Tom
AU  - Bashford T
AUID- ORCID: 0000-0003-0228-9779
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital and University of Cambridge, Cambridge, UK.
AD  - NIHR Global Health Research Group on Neurotrauma, University of Cambridge,
      Cambridge, UK.
FAU - Khan, Muhammad Mukhtar
AU  - Khan MM
AD  - Neurosurgery, Northwest School of Medicine and Northwest General Hospital and
      Research Centre, Peshawar, Pakistan.
FAU - Fontoura Solla, Davi J
AU  - Fontoura Solla DJ
AD  - Department of Neurology, Division of Neurosurgery, University of Sao Paulo, Sao
      Paulo, Brazil.
FAU - Hutchinson, Peter J
AU  - Hutchinson PJ
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital and University of Cambridge, Cambridge, UK.
AD  - NIHR Global Health Research Group on Neurotrauma, University of Cambridge,
      Cambridge, UK.
FAU - Kolias, Angelos
AU  - Kolias A
AD  - Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital and University of Cambridge, Cambridge, UK.
AD  - NIHR Global Health Research Group on Neurotrauma, University of Cambridge,
      Cambridge, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Developing Countries
MH  - Ethics Committees, Research
MH  - Humans
MH  - Income
MH  - *Neurosurgeons
MH  - Qualitative Research
PMC - PMC7430326
OTO - NOTNLM
OT  - *neurological injury
OT  - *neurosurgery
OT  - *qualitative research
COIS- Competing interests: AK and PH are supported by the National Institute for Health
      Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Global Health
      Research Group on Neurotrauma. PH is also supported by a NIHR Research
      Professorship and the Royal College of Surgeons of England. The NIHR Global
      Health Research Group on Neurotrauma was commissioned by the United Kingdom NIHR 
      using Official Development Assistance funding (Project No. 16/137/105). The views
      expressed in this manuscript are those of the authors and are not necessarily
      those of the United Kingdom National Health Service, NIHR or the Department of
      Health. Drs Esene, Karekezi, Khan, Solla and Kolias are members of the Young
      Neurosurgeons committee of the World Federation of Neurosurgical Societies. The
      committee is supporting this project.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038939 [pii]
AID - 10.1136/bmjopen-2020-038939 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e038939. doi: 10.1136/bmjopen-2020-038939.


PMID- 32792450
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Hip abductor muscle strength in patients after total or unicompartmental knee
      arthroplasty for knee osteoarthritis or avascular necrosis: a systematic review
      and meta-analysis protocol.
PG  - e038770
LID - 10.1136/bmjopen-2020-038770 [doi]
AB  - INTRODUCTION: Reduced hip abductor strength may indirectly lead to changes in
      knee kinematics and functional impairment and has been reported in patients with 
      patellofemoral pain and knee osteoarthritis (OA). Limited information is
      available regarding hip abductor strength following total or unicompartmental
      knee arthroplasty (TKA/UKA). The aims of this systematic review are to synthesise
      the evidence of hip abductor muscle strength deficits in patients following
      TKA/UKA and to determine influencing factors for these deficits. METHODS AND
      ANALYSIS: Embase, Medline, SportDiscus, the Web of Science Core Collection and
      Scopus will be searched for human-based clinical studies investigating hip
      abductor muscle strength after TKA/UKA for knee OA or avascular necrosis (AVN).
      Articles studying hip abductor strength after knee arthroplasty for
      post-traumatic OA will not be considered. No restriction on study design,
      prosthesis design, surgical approach, patient characteristics or severity of
      OA/AVN will be applied. We will search articles published between 1 January 1990 
      and the date of our last search. Only articles in English or German language will
      be considered for inclusion. Studies reporting manually measured muscle strength 
      or measurements performed at hip abduction angles other than 0 degrees will be
      excluded. References will be screened by two reviewers independently. Where
      necessary, a third author will make the final decision. The assessment of quality
      and risk of bias will be performed with the modified Newcastle-Ottawa scale. Data
      will be extracted and presented in a tabular form. Depending on availability,
      comparable subgroup and meta-analyses will be conducted. Patient characteristics 
      such as age, sex and surgical approach or rehabilitation programme will be
      analysed, if sufficient data are available. ETHICS AND DISSEMINATION: No ethics
      approval is required. The results will be published in a peer-reviewed journal
      and as conference presentation.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kvarda, Peter
AU  - Kvarda P
AUID- ORCID: 0000-0002-1623-4712
AD  - Department of Orthopaedics and Traumatology, University Hospital Basel, Basel,
      Switzerland kvardamed@gmail.com.
AD  - Department of Orthopaedic Surgery and Traumatology, Kantonsspital Baselland,
      Bruderholz, Basel-Landschaft, Switzerland.
FAU - Nuesch, Corina
AU  - Nuesch C
AD  - Department of Orthopaedics and Traumatology, University Hospital Basel, Basel,
      Switzerland.
AD  - Department of Clinical Research, University of Basel, Basel, Switzerland.
AD  - Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
AD  - Department of Spine Surgery, University Hospital of Basel, Basel, Switzerland.
FAU - Egloff, Christian
AU  - Egloff C
AD  - Department of Orthopaedics and Traumatology, University Hospital Basel, Basel,
      Switzerland.
FAU - Appenzeller-Herzog, Christian
AU  - Appenzeller-Herzog C
AD  - University Medical Library, University Library of Basel, Basel, Spiegelgasse,
      Switzerland.
FAU - Mundermann, Annegret
AU  - Mundermann A
AD  - Department of Orthopaedics and Traumatology, University Hospital Basel, Basel,
      Switzerland.
AD  - Department of Clinical Research, University of Basel, Basel, Switzerland.
AD  - Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
AD  - Department of Spine Surgery, University Hospital of Basel, Basel, Switzerland.
FAU - Ismailidis, Petros
AU  - Ismailidis P
AD  - Department of Orthopaedics and Traumatology, University Hospital Basel, Basel,
      Switzerland.
AD  - Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Arthroplasty, Replacement, Knee
MH  - Humans
MH  - Knee Joint
MH  - Meta-Analysis as Topic
MH  - Muscle Strength
MH  - Muscle, Skeletal
MH  - *Osteoarthritis, Knee/surgery
MH  - Systematic Reviews as Topic
PMC - PMC7430403
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *hip
OT  - *knee
OT  - *rehabilitation medicine
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038770 [pii]
AID - 10.1136/bmjopen-2020-038770 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e038770. doi: 10.1136/bmjopen-2020-038770.


PMID- 32792449
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Effectiveness of physical therapy in addition to occlusal splint in myogenic
      temporomandibular disorders: protocol of a randomised controlled trial.
PG  - e038438
LID - 10.1136/bmjopen-2020-038438 [doi]
AB  - INTRODUCTION: Temporomandibular disorders (TMDs) are considered a collection of
      musculoskeletal conditions involving the masticatory muscles, the
      temporomandibular joint and associated structures. The myogenous group appears to
      represent the most frequently diagnosed category. In the context of a multimodal 
      approach, splint therapy and musculoskeletal physiotherapy are often considered
      as a preferred therapy. The purpose of this study will be to investigate the
      effects of musculoskeletal physiotherapy combined with occlusal splint and
      education versus occlusal splint and education alone in the treatment of chronic 
      myogenous TMD on pain and mandibular range of motion. METHODS AND ANALYSIS: All
      consecutive adults complaining of TMDs presented to the Department of Biomedical 
      and Neuromotor Sciences of the University of Bologna will be considered eligible.
      Inclusion criteria shall be based on the presence of myogenous TMDs, as diagnosed
      through clinical examination in reference to the international diagnostic
      criteria of TMDs. Randomisation, concealed allocation, blinded assessment and
      intention-to-treat analysis will be employed. The splint therapy will consist of 
      the use of the splint every night and concurrent delivery of an educational
      programme; the protocol shall have a duration of three consecutive months. The
      combined musculoskeletal physiotherapy, splint therapy and education will
      additionally consist of manual therapy techniques and exercise; such protocol
      shall consist of a duration of three consecutive months, inclusive of 10 sessions
      for the enhanced elements. All outcome measures will be collected at baseline,
      after treatment and at a 6 months follow-up. ETHICS AND DISSEMINATION: Ethical
      approval has been obtained from the Independent Ethic Committee in Clinical
      Research of AUSL Bologna-Italy (47/2018/SPER/AUSLBO). Pursuant to applicable
      rules,we will obtain informed consent from each participant and collect data
      anonymously to maintain privacy. Results will be disseminated to clinicians and
      researchers through peer-reviewed publications and conferences. TRIAL
      REGISTRATION NUMBER: NCT03726060.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Incorvati, Cristina
AU  - Incorvati C
AUID- ORCID: 0000-0002-2759-7930
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Oral and Maxillofacial
      Surgery, Alma Mater Studiorum University of Bologna, Bologna, Emilia-Romagna,
      Italy cristina.incorvati@unibo.it.
FAU - Romeo, Antonio
AU  - Romeo A
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Phisical Therapy, Alma
      Mater Studiorum University of Bologna, Bologna, Emilia-Romagna, Italy.
FAU - Fabrizi, Adele
AU  - Fabrizi A
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Oral and Maxillofacial
      Surgery, Alma Mater Studiorum University of Bologna, Bologna, Emilia-Romagna,
      Italy.
FAU - Defila, Luca
AU  - Defila L
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Oral and Maxillofacial
      Surgery, Alma Mater Studiorum University of Bologna, Bologna, Emilia-Romagna,
      Italy.
FAU - Vanti, Carla
AU  - Vanti C
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Phisical Therapy, Alma
      Mater Studiorum University of Bologna, Bologna, Emilia-Romagna, Italy.
FAU - Gatto, Maria Rosaria Antonella
AU  - Gatto MRA
AD  - Department of Biomedical and Neuromotor Sciences(DIBINEM) Medical Statistics,
      Alma Mater Studiorum University of Bologna, Bologna, Emilia-Romagna, Italy.
FAU - Marchetti, Claudio
AU  - Marchetti C
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Oral and Maxillofacial
      Surgery, Alma Mater Studiorum University of Bologna, Bologna, Emilia-Romagna,
      Italy.
FAU - Pillastrini, Paolo
AU  - Pillastrini P
AD  - Department of Biomedical and Neuromotor Sciences (DIBINEM) Phisical Therapy, Alma
      Mater Studiorum University of Bologna, Bologna, Emilia-Romagna, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT03726060
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Humans
MH  - Italy
MH  - *Occlusal Splints
MH  - Physical Therapy Modalities
MH  - Randomized Controlled Trials as Topic
MH  - *Temporomandibular Joint Disorders/therapy
MH  - Treatment Outcome
PMC - PMC7430414
OTO - NOTNLM
OT  - *Musculoskeletal disorders
OT  - *ORAL MEDICINE
OT  - *Rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038438 [pii]
AID - 10.1136/bmjopen-2020-038438 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e038438. doi: 10.1136/bmjopen-2020-038438.


PMID- 32792447
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Breast feeding after caesarean delivery on maternal request: protocol of a
      systematic review and meta-analysis.
PG  - e038309
LID - 10.1136/bmjopen-2020-038309 [doi]
AB  - INTRODUCTION: Caesarean delivery under maternal request (CDMR) is a major factor 
      contributing to the rising global rates of caesarean section (CS) procedure. The 
      choice of CDMR without medical indications could provide a sense of assured
      safety by avoiding the experiences and complications of vaginal birth, and the
      risks related to an emergency CS. However, it might adversely influence women's
      breast feeding patterns and produce a long-lasting impact on maternal and
      neonatal health. This study aims to systematically review the current evidence
      relating to the effects of intentions of performing CDMR on breast feeding.
      METHODS AND ANALYSIS: A comprehensive literature search will be performed in
      three English-language electronic databases, major clinical study registries and 
      other sources for original studies reporting the breast feeding outcomes after a 
      planned CDMR or vaginal delivery. The three databases Medline, Embase and the
      Cochrane Central Register of Controlled Trials will be searched via Ovid from
      inception to February 2020. Randomised controlled trials (RCTs), pseudo-RCTs,
      cohort studies and case-control studies on this topic will be included.
      Participants in the experimental or case group should meet the Robson criteria of
      classes 2B or 4B and have experienced planned CS undertaken for no maternal or
      foetal indication, whereas participants in the control group have undergone
      scheduled vaginal delivery. All kinds of breast feeding outcomes will be
      included. Meta-analyses will be attempted to provide an estimate of the pooled
      effect and will be stratified by different study designs. A qualitative
      description will be provided if quantitative synthesis proves to be fruitless.
      ETHICS AND DISSEMINATION: This study is a secondary literature review that does
      not need ethical approval. No primary data will be collected from the
      participants. Findings of this study will be presented at scientific conferences 
      and be published in scientific journals. PROSPERO REGISTRATION NUMBER:
      CRD42020160303.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mu, Wei
AU  - Mu W
AUID- ORCID: 0000-0003-2369-7878
AD  - Department of Clinical Pharmacology, Second Affiliated Hospital of Tianjin
      University of Traditional Chinese Medicine, Tianjin, China.
AD  - OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Huang, Yu Hong
AU  - Huang YH
AD  - Department of Clinical Pharmacology, Second Affiliated Hospital of Tianjin
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Chaumont, Andreanne
AU  - Chaumont A
AD  - OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Letourneau, Isabelle
AU  - Letourneau I
AD  - OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
FAU - El-Chaar, Darine
AU  - El-Chaar D
AUID- ORCID: 0000-0002-8266-0242
AD  - OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
AD  - Department of Obstetrics & Gynecology, University of Ottawa Faculty of Medicine, 
      Ottawa, Ontario, Canada.
FAU - Xia, Tian
AU  - Xia T
AD  - Reproductive Center, First Teaching Hospital of Tianjin University of Traditional
      Chinese Medicine, Tianjin, China swwen@ohri.ca xiatian76@163.com.
FAU - Wu Wen, Shi
AU  - Wu Wen S
AD  - OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada 
      swwen@ohri.ca xiatian76@163.com.
AD  - Department of Obstetrics & Gynecology, University of Ottawa Faculty of Medicine, 
      Ottawa, Ontario, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa Faculty of
      Medicine, Ottawa, Ontario, Canada.
LA  - eng
GR  - FND-148438/Canadian Institute of Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Breast Feeding
MH  - *Cesarean Section
MH  - Cohort Studies
MH  - Delivery, Obstetric
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Parturition
MH  - Pregnancy
MH  - Systematic Reviews as Topic
PMC - PMC7430420
OTO - NOTNLM
OT  - *health policy
OT  - *maternal medicine
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038309 [pii]
AID - 10.1136/bmjopen-2020-038309 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e038309. doi: 10.1136/bmjopen-2020-038309.


PMID- 32792446
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - The GALANT trial: study protocol of a randomised placebo-controlled trial in
      patients with a (68) Ga -DOTATATE PET-positive, clinically non-functioning
      pituitary macroadenoma on the effect of lan reotide on t umour size.
PG  - e038250
LID - 10.1136/bmjopen-2020-038250 [doi]
AB  - INTRODUCTION: At present, there is no approved medical treatment option for
      patients with non-functioning pituitary adenoma. A number of open-label studies
      suggest that treatment with somatostatin analogues may prevent tumour
      progression. In vivo somatostatin receptor imaging using (68)Ga-DOTATATE PET
      (PET, positron emission tomography) could help in preselecting patients
      potentially responsive to treatment. Our aim is to investigate the effect of the 
      somatostatin analogue lanreotide as compared with placebo on tumour size in
      patients with a (68)Ga-DOTATATE PET-positive non-functioning pituitary
      macroadenoma (NFMA). METHODS AND ANALYSIS: The GALANT study is a multicentre,
      randomised, double-blind, placebo-controlled trial in adult patients with a
      suprasellar extending NFMA. Included patients undergo a (68)Ga-DOTATATE PET/CT of
      the head and tracer uptake is assessed after coregistration with pituitary MRI.
      Forty-four patients with a (68)Ga-DOTATATE PET-positive NFMA are randomised in a 
      1:1 ratio between lanreotide 120 mg or placebo, both administered as subcutaneous
      injections every 28 days for 72 weeks. The primary outcome is the change in
      cranio-caudal tumour diameter on pituitary MRI after treatment. Secondary
      outcomes are change in tumour volume, time to tumour progression, change in
      quality of life and number of adverse events. Final results are expected in the
      second half of 2021. ETHICS AND DISSEMINATION: The study protocol has been
      approved by the Medical Research Ethics Committee of the Academic Medical Centre 
      (AMC) of the Amsterdam University Medical Centres and by the Dutch competent
      authority. It is an investigator-initiated study with financial support by Ipsen 
      Farmaceutica BV. The AMC, as sponsor, remains owner of all data. Results will be 
      submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: 
      NL5136 (Netherlands Trial Register); pre-recruitment.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Boertien, Tessel M
AU  - Boertien TM
AUID- ORCID: 0000-0002-1285-4834
AD  - Department of Endocrinology and Metabolism, Amsterdam Gastroenterology
      Endocrinology Metabolism, Amsterdam UMC, location AMC, University of Amsterdam,
      Amsterdam, The Netherlands t.m.boertien@amsterdamumc.nl.
FAU - Drent, Madeleine L
AU  - Drent ML
AD  - Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC,
      location VUMC, VU University, Amsterdam, The Netherlands.
FAU - Booij, Jan
AU  - Booij J
AD  - Department of Radiology and Nuclear Medicine, Amsterdam UMC, location AMC,
      University of Amsterdam, Amsterdam, The Netherlands.
FAU - Majoie, Charles B L M
AU  - Majoie CBLM
AD  - Department of Radiology and Nuclear Medicine, Amsterdam UMC, location AMC,
      University of Amsterdam, Amsterdam, The Netherlands.
FAU - Stokkel, Marcel P M
AU  - Stokkel MPM
AD  - Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - Hoogmoed, Jantien
AU  - Hoogmoed J
AD  - Department of Neurosurgery, Neurosurgical Centre Amsterdam, Amsterdam UMC,
      location AMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Pereira, Alberto
AU  - Pereira A
AD  - Department of Medicine, Division of Endocrinology, and Centre for Endocrine
      Tumors Leiden (CETL), Leiden University Medical Centre, Leiden, The Netherlands.
FAU - Biermasz, Nienke R
AU  - Biermasz NR
AD  - Department of Medicine, Division of Endocrinology, and Centre for Endocrine
      Tumors Leiden (CETL), Leiden University Medical Centre, Leiden, The Netherlands.
FAU - Simsek, Suat
AU  - Simsek S
AD  - Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC,
      location VUMC, VU University, Amsterdam, The Netherlands.
AD  - Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
FAU - Groote Veldman, Ronald
AU  - Groote Veldman R
AD  - Department of Internal Medicine, Medical Spectrum Twente, Enschede, The
      Netherlands.
FAU - Tanck, Michael W T
AU  - Tanck MWT
AD  - Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam 
      UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Fliers, Eric
AU  - Fliers E
AD  - Department of Endocrinology and Metabolism, Amsterdam Gastroenterology
      Endocrinology Metabolism, Amsterdam UMC, location AMC, University of Amsterdam,
      Amsterdam, The Netherlands.
FAU - Bisschop, Peter H
AU  - Bisschop PH
AD  - Department of Endocrinology and Metabolism, Amsterdam Gastroenterology
      Endocrinology Metabolism, Amsterdam UMC, location AMC, University of Amsterdam,
      Amsterdam, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Gallium Radioisotopes)
SB  - IM
MH  - Adult
MH  - Gallium Radioisotopes
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - *Pituitary Neoplasms/diagnostic imaging/drug therapy
MH  - Positron Emission Tomography Computed Tomography
MH  - Positron-Emission Tomography
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7430490
OTO - NOTNLM
OT  - *clinical trials
OT  - *endocrine tumours
OT  - *nuclear radiology
OT  - *pituitary disorders
COIS- Competing interests: MLD received a honorarium for chairing a symposium sponsored
      by Ipsen Farmaceutica BV in 2019.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038250 [pii]
AID - 10.1136/bmjopen-2020-038250 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e038250. doi: 10.1136/bmjopen-2020-038250.


PMID- 32792445
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Calgary Normative Study: design of a prospective longitudinal study to
      characterise potential quantitative MR biomarkers of neurodegeneration over the
      adult lifespan.
PG  - e038120
LID - 10.1136/bmjopen-2020-038120 [doi]
AB  - INTRODUCTION: A number of MRI methods have been proposed to be useful,
      quantitative biomarkers of neurodegeneration in ageing. The Calgary Normative
      Study (CNS) is an ongoing single-centre, prospective, longitudinal study that
      seeks to develop, test and assess quantitative magnetic resonance (MR) methods as
      potential biomarkers of neurodegeneration. The CNS has three objectives: first
      and foremost, to evaluate and characterise the dependence of the selected
      quantitative neuroimaging biomarkers on age over the adult lifespan; second, to
      evaluate the precision, variability and repeatability of quantitative
      neuroimaging biomarkers as part of biomarker validation providing
      proof-of-concept and proof-of-principle; and third, provide a shared repository
      of normative data for comparison to various disease cohorts. METHODS AND
      ANALYSIS: Quantitative MR mapping of the brain including longitudinal relaxation 
      time (T1), transverse relaxation time (T2), T2*, magnetic susceptibility (QSM),
      diffusion and perfusion measurements, as well as morphological assessments are
      performed. The Montreal Cognitive Assessment (MoCA) and a brief, self-report
      medical history will be collected. Mixed regression models will be used to
      characterise changes in quantitative MR biomarker measures over the adult
      lifespan. In this report, we describe the study design, strategies to recruit and
      perform changes to the acquisition protocol from inception to 31 December 2018,
      planned statistical approach and data sharing procedures for the study. ETHICS
      AND DISSEMINATION: Participants provide signed informed consent. Changes in
      quantitative MR biomarkers measured over the adult lifespan as well as estimates 
      of measurement variance and repeatability will be disseminated through
      peer-reviewed scientific publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McCreary, Cheryl R
AU  - McCreary CR
AUID- ORCID: 0000-0003-1572-010X
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada crmccrea@ucalgary.ca.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
AD  - Seaman Family MR Research Centre, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Salluzzi, Marina
AU  - Salluzzi M
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
AD  - Calgary Image Analysis and Processing Centre, University of Calgary, Calgary,
      Alberta, Canada.
FAU - Andersen, Linda B
AU  - Andersen LB
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
FAU - Gobbi, David
AU  - Gobbi D
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Calgary Image Analysis and Processing Centre, University of Calgary, Calgary,
      Alberta, Canada.
FAU - Lauzon, Louis
AU  - Lauzon L
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
AD  - Seaman Family MR Research Centre, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Saad, Feryal
AU  - Saad F
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
FAU - Smith, Eric E
AU  - Smith EE
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
AD  - Seaman Family MR Research Centre, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Frayne, Richard
AU  - Frayne R
AD  - Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
AD  - Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
AD  - Seaman Family MR Research Centre, University of Calgary, Calgary, Alberta,
      Canada.
AD  - Calgary Image Analysis and Processing Centre, University of Calgary, Calgary,
      Alberta, Canada.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Biomarkers
MH  - Humans
MH  - *Longevity
MH  - Longitudinal Studies
MH  - *Magnetic Resonance Imaging
MH  - Prospective Studies
PMC - PMC7430487
OTO - NOTNLM
OT  - *dementia
OT  - *magnetic resonance imaging
OT  - *neuroradiology
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038120 [pii]
AID - 10.1136/bmjopen-2020-038120 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e038120. doi: 10.1136/bmjopen-2020-038120.


PMID- 32792444
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Identifying optimal frameworks to implement or evaluate digital health
      interventions: a scoping review protocol.
PG  - e037643
LID - 10.1136/bmjopen-2020-037643 [doi]
AB  - INTRODUCTION: Digital health interventions (DHIs) are defined as health services 
      delivered electronically through formal or informal care. DHIs can range from
      electronic medical records used by providers to mobile health apps used by
      consumers. DHIs involve complex interactions between user, technology and the
      healthcare team, posing challenges for implementation and evaluation. Theoretical
      or interpretive frameworks are crucial in providing researchers guidance and
      clarity on implementation or evaluation approaches; however, there is a lack of
      standardisation on which frameworks to use in which contexts. Our goal is to
      conduct a scoping review to identify frameworks to guide the implementation or
      evaluation of DHIs. METHODS AND ANALYSIS: A scoping review will be conducted
      using methods outlined by the Joanna Briggs Institute reviewers' manual and will 
      conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      Extension for Scoping Reviews. Studies will be included if they report on
      frameworks (ie, theoretical, interpretive, developmental) that are used to guide 
      either implementation or evaluation of DHIs. Electronic databases, including
      MEDLINE, EMBASE, CINAHL and PsychINFO will be searched in addition to grey
      literature and reference lists of included studies. Citations and full text
      articles will be screened independently in Covidence after a reliability check
      among reviewers. We will use qualitative description to summarise findings and
      focus on how research objectives and type of DHIs are aligned with the frameworks
      used. ETHICS AND DISSEMINATION: We engaged an advisory panel of digital health
      knowledge users to provide input at strategic stages of the scoping review to
      enhance the relevance of findings and inform dissemination activities.
      Specifically, they will provide feedback on the eligibility criteria, data
      abstraction elements, interpretation of findings and assist in developing key
      messages for dissemination. This study does not require ethical review. Findings 
      from review will support decision making when selecting appropriate frameworks to
      guide the implementation or evaluation of DHIs.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Soobiah, Charlene
AU  - Soobiah C
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, Ontario, Canada.
FAU - Cooper, Madeline
AU  - Cooper M
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, Ontario, Canada.
FAU - Kishimoto, Vanessa
AU  - Kishimoto V
AUID- ORCID: 0000-0002-4516-1225
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, Ontario, Canada.
FAU - Bhatia, R Sacha
AU  - Bhatia RS
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, Ontario, Canada.
FAU - Scott, Ted
AU  - Scott T
AD  - Hamilton Health Sciences, Hamilton, Ontario, Canada.
AD  - School of Nursing, McMaster University, Hamilton, Ontario, Canada.
FAU - Maloney, Shelagh
AU  - Maloney S
AD  - Canada Health Infoway, Toronto, Ontario, Canada.
FAU - Larsen, Darren
AU  - Larsen D
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, Ontario, Canada.
AD  - OntarioMD, Toronto, Ontario, Canada.
FAU - Wijeysundera, Harindra C
AU  - Wijeysundera HC
AD  - Schulich Heart Center, Sunnybrook Health Sciences Centre, Toronto, Ontario,
      Canada.
FAU - Zelmer, Jennifer
AU  - Zelmer J
AD  - Canadian Foundation for Healthcare Improvement, Ottawa, Ontario, Canada.
FAU - Gray, Carolyn Steele
AU  - Gray CS
AD  - Bridgepoint Collaboratory for Research and Innovation, Lunenfeld-Tanenbaum
      Research Institute, Sinai Health System, Toronto, Ontario, Canada.
AD  - Institute for Health Policy, Management, and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Desveaux, Laura
AU  - Desveaux L
AUID- ORCID: 0000-0003-3429-1865
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, Ontario, Canada laura.desveaux@wchospital.ca.
AD  - Institute for Health Policy, Management, and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Delivery of Health Care
MH  - Diagnostic Tests, Routine
MH  - Publications
MH  - Reproducibility of Results
MH  - *Research Report
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7430416
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *quality in health care
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037643 [pii]
AID - 10.1136/bmjopen-2020-037643 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e037643. doi: 10.1136/bmjopen-2020-037643.


PMID- 32792441
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Protocol for the development of a core outcome set for reporting outcomes of
      management of velopharyngeal dysfunction.
PG  - e036824
LID - 10.1136/bmjopen-2020-036824 [doi]
AB  - INTRODUCTION: Velopharyngeal dysfunction (VPD) is present in up to 40% of
      patients following cleft palate repair. Children with VPD display hypernasal
      speech, nasal air emission and are at a high risk for developing articulation
      disorders. The overall result is decreased intelligibility and acceptability of
      speech, as well as significant functional and social impairments. Although there 
      are several surgical approaches for the management of children with VPD, standard
      treatment protocols have not been well defined. There is a need for a core
      outcome set (COS) to reduce outcome reporting bias and heterogeneity across
      studies of VPD. The COS-VPD Initiative is an international effort to establish a 
      COS for the reporting of studies of the management of VPD. METHODS AND ANALYSIS: 
      The study has been developed according to the Core Outcome Set-STAandards for
      Development standards for the design of a COS study and will be carried out
      according to the guidance of the Core Outcome Measures in Effectiveness Trials
      (COMET) initiative. A long list of clinical and patient-reported outcomes will be
      identified from a systematic review of the literature. A two-stage Delphi
      consensus process will be used to refine this list into a COS. An international
      panel of key stakeholders including patients, parents and multidisciplinary
      clinical and academic experts will be invited to participate in this process.
      Consensus criteria will be specified a priori and the steering group will ratify 
      the final COS. ETHICS AND DISSEMINATION: The study has ethical approval through
      Children's Health Ireland at Crumlin Research and Ethics Committee, Ref:
      GEN/683/18. The study is registered with the COMET Initiative
      (http://www.cometinitiative.org/studies/details/1146?result=true). The COS will
      be disseminated by publication in the peer-reviewed literature, presentation at
      international research meetings and distribution to patient-representative
      organisations. This will facilitate the application of the COS in future studies 
      of the management of VPD.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Blacam, Catherine
AU  - de Blacam C
AUID- ORCID: 0000-0002-3197-4161
AD  - Department of Plastic Surgery, Our Lady's Children's Hospital, Crumlin, Dublin,
      Ireland catherinedeblacam@rcsi.ie.
AD  - Department of Surgical Affairs, Royal College of Surgeons in Ireland, Dublin,
      Ireland.
FAU - Baylis, Adriane L
AU  - Baylis AL
AD  - Department of Plastic and Reconstructive Surgery, Nationwide Children's Hospital,
      Columbus, Ohio, USA.
AD  - Ohio State University College of Medicine, Columbus, Ohio, USA.
FAU - Kirschner, Richard E
AU  - Kirschner RE
AD  - Department of Plastic and Reconstructive Surgery, Nationwide Children's Hospital,
      Columbus, Ohio, USA.
AD  - Ohio State University College of Medicine, Columbus, Ohio, USA.
FAU - Smith, Susan M
AU  - Smith SM
AUID- ORCID: 0000-0001-6027-2727
AD  - Department of General Practice, RCSI, Dublin, Ireland.
FAU - Sell, Debbie
AU  - Sell D
AUID- ORCID: 0000-0002-2488-5881
AD  - Centre for Outcomes and Experience Research in Children's Health, Illness and
      Disability (ORCHID), Great Ormond Street Hospital for Children NHS Foundation
      Trust, London, UK.
FAU - Sie, Kathleen C Y
AU  - Sie KCY
AD  - Division of Pediatric Otolaryngology, Seattle Children's Hospital, Seattle,
      Washington, USA.
FAU - Harris, Helen E
AU  - Harris HE
AUID- ORCID: 0000-0002-0575-9531
AD  - London, UK.
FAU - Orr, David J A
AU  - Orr DJA
AUID- ORCID: 0000-0002-1935-1412
AD  - Department of Plastic Surgery, Our Lady's Children's Hospital, Crumlin, Dublin,
      Ireland.
AD  - School of Medicine, Trinity College Dublin, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Delphi Technique
MH  - Endpoint Determination
MH  - Humans
MH  - Ireland
MH  - *Outcome Assessment, Health Care
MH  - *Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7430341
OTO - NOTNLM
OT  - *paediatric plastic & reconstructive surgery
OT  - *plastic & reconstructive surgery
OT  - *speech pathology
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036824 [pii]
AID - 10.1136/bmjopen-2020-036824 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e036824. doi: 10.1136/bmjopen-2020-036824.


PMID- 32792440
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Children's unscheduled primary and emergency care in Ireland: a multimethod
      approach to understanding decision making, trends, outcomes and parental
      perspectives (CUPID): project protocol.
PG  - e036729
LID - 10.1136/bmjopen-2019-036729 [doi]
AB  - INTRODUCTION: The aim of this project is to determine the patterns,
      decision-making processes and parental preferences associated with unscheduled
      paediatric healthcare utilisation in Ireland. Unscheduled paediatric healthcare
      is outpatient care provided within primary care settings by general practitioners
      (GPs), emergency departments (EDs) located in paediatric and general hospitals,
      and out-of-hours services provided by cooperatives of GPs operating on a regional
      basis. This project will take a multimethod approach to analysing the utilisation
      of unscheduled paediatric healthcare nationally within the context of a
      significant change to the provision of healthcare for young children in
      Ireland-the introduction of free at the point of delivery GP care for all
      children aged under 6. METHODS AND ANALYSIS: A multimethod approach consisting of
      three work packages will be employed. Using patient-level data, work package 1
      will describe patterns of attendance at primary care, out-of-hours medical
      services and at EDs. Applying a difference-in-difference methodology, the impact 
      of the introduction of free GP care for children under 6 on attendance will be
      assessed. Work package 2 will explore geospatial trends of attendance at EDs,
      identifying disparities in ED attendance by local area and demographic
      characteristics. Work package 3 will employ two discrete choice experiments to
      examine parental preferences for unscheduled paediatric healthcare and GP
      decision making when referring a child to the ED. The insights gained by each of 
      the work packages individually and collectively will inform evidence-based health
      policy for the organisation of paediatric care and resource allocation. ETHICS
      AND DISSEMINATION: Ethical approval for this research has been granted by
      University College Dublin, The Irish College of General Practitioners and the
      five participating hospitals. Results will be disseminated via publication in
      peer-reviewed journals, national and international conferences, and to relevant
      stakeholders and interest groups.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McAuliffe, Eilish
AU  - McAuliffe E
AUID- ORCID: 0000-0002-9714-5040
AD  - Centre for Interdisciplinary Research, Education and Innovation in Health Systems
      (IRIS), School of Nursing, Midwifery and Health Systems, University College
      Dublin, Dublin, Ireland.
FAU - Hamza, Moayed
AU  - Hamza M
AD  - School of Nursing, Midwifery and Health Systems, University College Dublin,
      Dublin, Ireland.
FAU - McDonnell, Therese
AU  - McDonnell T
AUID- ORCID: 0000-0002-5890-3689
AD  - Centre for Interdisciplinary Research, Education and Innovation in Health Systems
      (IRIS), School of Nursing, Midwifery and Health Systems, University College
      Dublin, Dublin, Ireland therese.mcdonnell@ucd.ie.
FAU - Nicholson, Emma
AU  - Nicholson E
AUID- ORCID: 0000-0002-6652-2552
AD  - Centre for Interdisciplinary Research, Education and Innovation in Health Systems
      (IRIS), School of Nursing, Midwifery and Health Systems, University College
      Dublin, Dublin, Ireland.
FAU - De Brun, Aoife
AU  - De Brun A
AUID- ORCID: 0000-0003-0124-0893
AD  - Centre for Interdisciplinary Research, Education and Innovation in Health Systems
      (IRIS), School of Nursing, Midwifery and Health Systems, University College
      Dublin, Dublin, Ireland.
FAU - Barrett, Michael
AU  - Barrett M
AUID- ORCID: 0000-0003-1775-8347
AD  - Paediatric Emergency Medicine, Children's Health Ireland at Crumlin, Dublin, Co. 
      Dublin, Ireland.
AD  - Women's and Children's Health, School of Medicine, University College Dublin,
      Dublin, Ireland.
FAU - Brunsdon, Christopher
AU  - Brunsdon C
AUID- ORCID: 0000-0003-4254-1780
AD  - National Centre for Geocomputation, National University of Ireland Maynooth,
      Maynooth, Ireland.
FAU - Bury, Gerard
AU  - Bury G
AUID- ORCID: 0000-0002-4441-6724
AD  - UCD Centre for Emergency Medical Science, School of Medicine, University College 
      Dublin, Dublin, Ireland.
FAU - Collins, Claire
AU  - Collins C
AD  - Research Department, Irish College of General Practitioners, Dublin, Ireland.
FAU - Deasy, Conor
AU  - Deasy C
AD  - Department of Emergency Medicine, Cork University Hospital Group, Cork, Ireland.
FAU - Fitzsimons, John
AU  - Fitzsimons J
AD  - Emergency Department, Children's Health Ireland at Temple St, Dublin, Ireland.
FAU - Galligan, Marie
AU  - Galligan M
AD  - UCD Centre for Clinical Research, University College Dublin, Dublin, Ireland.
FAU - Hensey, Conor
AU  - Hensey C
AD  - Paediatrics, Children's Health Ireland at Temple St, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - Decision Making
MH  - *Emergency Medical Services
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Ireland
MH  - Parents
PMC - PMC7430468
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health policy
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036729 [pii]
AID - 10.1136/bmjopen-2019-036729 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e036729. doi: 10.1136/bmjopen-2019-036729.


PMID- 32792437
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Web-based MINDfulness and Skills-based distress reduction in cancer (MINDS):
      study protocol for a multicentre observational healthcare study.
PG  - e036466
LID - 10.1136/bmjopen-2019-036466 [doi]
AB  - INTRODUCTION: Although a high percentage of patients with cancer experience
      severe psychological distress, few of them receive psycho-oncological care,
      largely due to barriers on the side of patients and healthcare providers that
      pose great challenges to delivering such care. In response, low-threshold,
      self-guided eHealth interventions can enable patients with cancer to deal
      independently and effectively with disease-related challenges and distress.
      Mindfulness and Skills-Based Distress Reduction in Oncology Training, nicknamed
      Make It Training, is one such innovative, self-guided eHealth intervention. In
      our study, we propose to assess different characteristics of such patients in
      order to define target populations for Make It Training, evaluate the
      intervention in terms of its usability, feasibility and sustainability and gather
      longitudinal data concerning the intervention's efficacy. METHODS AND ANALYSIS:
      Self-guided and web-based Make It Training consists of eight 30 min modules
      involving the use of techniques of mindfulness therapy, cognitive-behavioural
      therapy and acceptance and commitment therapy to be completed in a 4-month
      period. In our observational study, adult patients with cancer who possess
      adequate German language skills and provide their informed consent will be
      recruited at Essen, Erlangen and Tubingen University Hospitals at outpatient
      oncological institutions and via online channels. Patients will undergo a
      baseline online assessment (T0), an assessment directly after completing the
      intervention (T1) and assessments 3 and 6 months later (T2 and T3, respectively).
      With the results of those assessments, we will perform descriptive analyses of
      their sociodemographic and medical data, compare means and conduct regression
      analyses. ETHICS AND DISSEMINATION: The Ethics Committees of the University
      Hospitals Essen, Erlangen and Tubingen have approved the study (19-8643-BO, 27_19
      B, 293/2018BO1). Results will be published in peer-reviewed journals and
      conference presentations. TRIAL REGISTRATION NUMBER: DRKS00017119.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bauerle, Alexander
AU  - Bauerle A
AUID- ORCID: 0000-0003-1488-8592
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University-Hospital
      Essen, University of Duisburg-Essen, Essen, Germany
      alexander.baeuerle@uni-due.de.
AD  - Comprehensive Cancer Center Essen, University Hospital Essen, Essen,
      Nordrhein-Westfalen, Germany.
FAU - Teufel, Martin
AU  - Teufel M
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University-Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
AD  - Comprehensive Cancer Center Essen, University Hospital Essen, Essen,
      Nordrhein-Westfalen, Germany.
FAU - Schug, Caterina
AU  - Schug C
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Hospital
      Erlangen, Friedrich-Alexander University Erlangen-Nurnberg, Erlangen, Bayern,
      Germany.
FAU - Skoda, Eva-Maria
AU  - Skoda EM
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University-Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
AD  - Comprehensive Cancer Center Essen, University Hospital Essen, Essen,
      Nordrhein-Westfalen, Germany.
FAU - Beckmann, Mingo
AU  - Beckmann M
AD  - Clinic for Psychosomatic Medicine and Psychotherapy, LVR University-Hospital
      Essen, University of Duisburg-Essen, Essen, Germany.
AD  - Comprehensive Cancer Center Essen, University Hospital Essen, Essen,
      Nordrhein-Westfalen, Germany.
FAU - Schaffeler, Norbert
AU  - Schaffeler N
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Hospital
      Tubingen, Eberhard Karls University Tubingen, Tubingen, Baden-Wurttemberg,
      Germany.
AD  - Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen,
      Tubingen, Germany.
FAU - Junne, Florian
AU  - Junne F
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Hospital
      Tubingen, Eberhard Karls University Tubingen, Tubingen, Baden-Wurttemberg,
      Germany.
AD  - Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen,
      Tubingen, Germany.
FAU - Erim, Yesim
AU  - Erim Y
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Hospital
      Erlangen, Friedrich-Alexander University Erlangen-Nurnberg, Erlangen, Bayern,
      Germany.
FAU - Zipfel, Stephan
AU  - Zipfel S
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Hospital
      Tubingen, Eberhard Karls University Tubingen, Tubingen, Baden-Wurttemberg,
      Germany.
AD  - Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen,
      Tubingen, Germany.
FAU - Graf, Johanna
AU  - Graf J
AD  - Department of Psychosomatic Medicine and Psychotherapy, University Hospital
      Tubingen, Eberhard Karls University Tubingen, Tubingen, Baden-Wurttemberg,
      Germany.
AD  - Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen,
      Tubingen, Germany.
LA  - eng
SI  - DRKS/DRKS00017119
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - Adult
MH  - Humans
MH  - Internet
MH  - *Mindfulness
MH  - Multicenter Studies as Topic
MH  - *Neoplasms/therapy
MH  - Observational Studies as Topic
MH  - Stress, Psychological/therapy
PMC - PMC7430431
OTO - NOTNLM
OT  - *mental health
OT  - *oncology
OT  - *telemedicine
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036466 [pii]
AID - 10.1136/bmjopen-2019-036466 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e036466. doi: 10.1136/bmjopen-2019-036466.


PMID- 32792431
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Impact of incremental versus conventional initiation of haemodialysis on residual
      kidney function: study protocol for a multicentre feasibility randomised
      controlled trial.
PG  - e035919
LID - 10.1136/bmjopen-2019-035919 [doi]
AB  - INTRODUCTION: Preserving residual kidney function (RKF) may be beneficial to
      patients on haemodialysis (HD) and it has been proposed that commencing dialysis 
      incrementally rather than three times a week may preserve RKF. In Incremental HD,
      target dose includes a contribution from RKF, which is added to HD dose, allowing
      individualisation of the HD prescription. We will conduct a feasibility
      randomised controlled trial (RCT) comparing incremental HD and conventional three
      times weekly treatments in incident HD patients. The study is designed also to
      provide pilot data to allow determination of effect size to power a definitive
      study. METHODS AND ANALYSIS: After screening to ensure native renal urea
      clearance >3 mL/min/1.73 m(2), the study will randomise 54 patients within 3
      months of HD initiation to conventional in-centre thrice weekly dialysis or
      incremental in-centre HD commencing 2 days a week. Subjects will be followed up
      for 12 months. The study will be carried out across four UK renal centres.The
      primary outcome is to evaluate the feasibility of conducting a definitive RCT and
      to estimate the difference in rate of decline of RKF between the two groups at 6 
      and 12 months time points. Secondary outcomes will include the impact of dialysis
      intensity on vascular access events, major adverse cardiac events and survival.
      Impact of dialysis intensity on patient-reported outcomes measures, cognition and
      frailty will be assessed using EQ-5D-5L, PHQ-9, Illness Intrusiveness Rating
      Score, Montreal Cognitive assessment and Clinical Frailty Score. Safety outcomes 
      include hospitalisation, fluid overload episodes, hyperkalaemia events and
      vascular access events.This study will inform the design of a definitive study,
      adequately powered to determine whether RKF is better preserved after incremental
      HD initiation compared with conventional initiation. ETHICS AND DISSEMINATION:
      Ethics approval has been granted by Cambridge South Research Ethics Committee,
      United Kingdom(REC17/EE/0311). Results will be disseminated via peer-reviewed
      publication. TRIAL REGISTRATION NUMBER: NCT03418181.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kaja Kamal, Raja Mohammed
AU  - Kaja Kamal RM
AUID- ORCID: 0000-0002-5737-5888
AD  - Renal Unit, East and North Hertfordshire NHS Trust, Stevenage, UK.
AD  - School of Life Sciences, University of Hertfordshire, Hatfield, Hertfordshire,
      UK.
FAU - Farrington, Ken
AU  - Farrington K
AD  - Renal Unit, East and North Hertfordshire NHS Trust, Stevenage, UK.
AD  - School of Life Sciences, University of Hertfordshire, Hatfield, Hertfordshire,
      UK.
FAU - Wellsted, David
AU  - Wellsted D
AD  - School of Life Sciences, University of Hertfordshire, Hatfield, Hertfordshire,
      UK.
FAU - Sridharan, Sivakumar
AU  - Sridharan S
AD  - Renal Unit, East and North Hertfordshire NHS Trust, Stevenage, UK.
AD  - School of Life Sciences, University of Hertfordshire, Hatfield, Hertfordshire,
      UK.
FAU - Alchi, Bassam
AU  - Alchi B
AD  - Renal Unit, Royal Berkshire NHS Foundation Trust, Reading, Berkshire, UK.
FAU - Burton, James
AU  - Burton J
AD  - Renal Unit, University Hospitals of Leicester NHS Trust, Leicester,
      Leicestershire, UK.
FAU - Davenport, Andrew
AU  - Davenport A
AD  - Renal Unit, Royal Free Hospital, London, UK.
FAU - Vilar, Enric
AU  - Vilar E
AD  - Renal Unit, East and North Hertfordshire NHS Trust, Stevenage, UK
      enric.vilar@nhs.net.
AD  - School of Life Sciences, University of Hertfordshire, Hatfield, Hertfordshire,
      UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03418181
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cognition
MH  - Feasibility Studies
MH  - Humans
MH  - Kidney
MH  - *Kidney Failure, Chronic/therapy
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Renal Dialysis
MH  - United Kingdom
PMC - PMC7430462
OTO - NOTNLM
OT  - *adult nephrology
OT  - *dialysis
OT  - *end stage renal failure
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035919 [pii]
AID - 10.1136/bmjopen-2019-035919 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e035919. doi: 10.1136/bmjopen-2019-035919.


PMID- 32792428
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Health programmes and services addressing the prevention and management of
      infectious diseases in persons who inject drugs in Canada: a systematic
      integrative review protocol.
PG  - e035188
LID - 10.1136/bmjopen-2019-035188 [doi]
AB  - INTRODUCTION: Injection drug use (IDU) and intravenous drug use (IVDU) are of
      concern to the people using drugs, their families and health systems. One of the 
      complications of IDU/IVDU is the risk of infection. Clinical experience has shown
      that persons who inject drugs (PWID) are hospitalised and re-hospitalised
      frequently. In Canada there are sparse data about the reasons for which PWID are 
      admitted to hospital and their health trajectories, especially for infectious
      diseases. There are special concerns regarding PWID with infections who leave the
      hospital against medical advice and those who leave with a peripherally inserted 
      central catheter line in place for administration of long-term antibiotics or
      other therapies. Improving our understanding of current programmes and services
      addressing the prevention and management of infectious diseases and their
      complications in PWID could lead to focused interventions to enhance care in this
      population. METHODS AND ANALYSIS: An integrative systematic review allows for
      inclusion of a variety of methodologies to understand a health issue from
      different viewpoints. PubMed, CINAHL, Web of Science Databases and websites of
      the Public Health Agency of Canada, Canadian Institute for Substance Use
      Research, and Canadian Centre on Substance Use and Addiction will be searched
      using terms for infectious diseases, drug use and geography (Canada) and limited 
      to the last 10 years (2009-2019). The Quality Appraisal Tool in Studies with
      Diverse Designs will be used to appraise the quality of identified studies and
      documents. Quantitative, qualitative or mixed methods data synthesis will be used
      as needed. ETHICS AND DISSEMINATION: This study is a secondary analysis of
      publicly available documents; therefore, no ethics approval is required. This
      information will inform a research agenda to further investigate interventions
      that aim to address these issues. PROSPERO REGISTRATION NUMBER: CRD42020142947.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alvarez, Elizabeth
AU  - Alvarez E
AUID- ORCID: 0000-0003-2333-0144
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada alvare@mcmaster.ca.
AD  - Centre for Health Economics and Policy Analysis (CHEPA), McMaster University,
      Hamilton, Ontario, Canada.
FAU - Joshi, Siddharth
AU  - Joshi S
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Lokker, Cynthia
AU  - Lokker C
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Wang, Annie
AU  - Wang A
AD  - Department of Life Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Pavalagantharajah, Sureka
AU  - Pavalagantharajah S
AD  - Department of Undergraduate Medical Education, McMaster University, Hamilton,
      Ontario, Canada.
FAU - Qiu, Yun
AU  - Qiu Y
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - School of Health Sciences, Jiangsu Vocational Institute of Commerce, Nanjing
      City, Jiangsu, China.
FAU - Sidhu, Hargun
AU  - Sidhu H
AD  - Department of Undergraduate Medical Education, McMaster University, Hamilton,
      Ontario, Canada.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AUID- ORCID: 0000-0001-5855-5461
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Qutob, Majdi
AU  - Qutob M
AD  - Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
FAU - Henedi, Alia
AU  - Henedi A
AD  - Eastern Mediterranean University, Cyprus, Turkey.
FAU - Levine, Mitchell
AU  - Levine M
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Centre for Health Economics and Policy Analysis (CHEPA), McMaster University,
      Hamilton, Ontario, Canada.
FAU - Lennox, Robin
AU  - Lennox R
AD  - Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Tarride, Jean-Eric
AU  - Tarride JE
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Centre for Health Economics and Policy Analysis (CHEPA), McMaster University,
      Hamilton, Ontario, Canada.
FAU - Kalina, Dale
AU  - Kalina D
AD  - Infectious Diseases, Joseph Brant Hospital, Burlington, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Canada
MH  - *Communicable Diseases
MH  - *Drug Users
MH  - Humans
MH  - *Pharmaceutical Preparations
MH  - *Substance Abuse, Intravenous/complications
MH  - Systematic Reviews as Topic
PMC - PMC7430337
OTO - NOTNLM
OT  - *infectious diseases
OT  - *organisation of health services
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035188 [pii]
AID - 10.1136/bmjopen-2019-035188 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e035188. doi: 10.1136/bmjopen-2019-035188.


PMID- 32792427
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Microwave ablation versus radiofrequency ablation for the treatment of severe
      complicated monochorionic pregnancies in Chinaprotocol for a pilot randomised
      controlled trial.
PG  - e034995
LID - 10.1136/bmjopen-2019-034995 [doi]
AB  - INTRODUCTION: Complicated monochorionic twin pregnancies are often associated
      with high perinatal morbidity and mortality, some of which are severe enough to
      require a gestational reduction surgery to improve fetal survival and reduce
      disabilities. While radiofrequency ablation is currently the most commonly used
      procedure with higher fetal survival and fewer maternal and fetal complications
      compared with other surgical methods, the therapeutic effect of microwave
      ablation (MWA) is reported to be better, presumably due to the higher thermal
      effect and fewer restrictions. Currently there is limited evidence to prove the
      feasibility of MWA for selective reduction. The aim of this pilot study is to
      explore the feasibility, efficacy and safety of MWA reduction for severe
      complicated monochorionic pregnancies and may provide evidence for using the MWA 
      in intrauterine surgeries extensively. METHODS AND ANALYSIS: This is a study
      protocol for a parallel-design pilot randomised controlled trial. 60 eligible
      patients with severe complicated monochorionic pregnancies will be randomised in 
      a ratio of 1:1 to MWA group and radiofrequency group. Patients will be followed
      up until 6 months of age of the retained fetal. The primary analysis will compare
      the rates of neonatal survival at 28 days to evaluate the effect of MWA. The
      study will also evaluate the safety profile of MWA including the occurrence of
      postoperative adverse events and maternal and fetal complications. Additional
      secondary outcomes to be explored include the condition of neonatal asphyxia and 
      the growth of surviving fetus at 6 months. Outcomes will be analysed by both a
      frequentist and the Bayesian statistical approach. ETHICS AND DISSEMINATION: This
      study was approved by the ethical review committee of the Peking University Third
      Hospital (Beijing, China). The results of this study will be published in
      peer-reviewed scientific journals and presented at relevant academic conferences.
      TRIAL REGISTRATION NUMBER: NCT04014452; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xie, Jialei
AU  - Xie J
AUID- ORCID: 0000-0001-7874-6564
AD  - Department of Maternal and Child Health, School of Public Health, Peking
      University, Beijing, China.
FAU - Cheng, Ziyi
AU  - Cheng Z
AD  - Department of Obstetrics and Gynecology, Peking University Third Hospital,
      Beijing, China.
FAU - Wu, Tianchen
AU  - Wu T
AD  - Department of Maternal and Child Health, School of Public Health, Peking
      University, Beijing, China.
FAU - Wei, Yuan
AU  - Wei Y
AD  - Department of Obstetrics and Gynecology, Peking University Third Hospital,
      Beijing, China xlwang@bjmu.edu.cn weiyuanbysy@163.com.
FAU - Wang, Xiaoli
AU  - Wang X
AD  - Department of Maternal and Child Health, School of Public Health, Peking
      University, Beijing, China xlwang@bjmu.edu.cn weiyuanbysy@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04014452
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bayes Theorem
MH  - China
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - *Microwaves
MH  - Pilot Projects
MH  - Pregnancy
MH  - *Radiofrequency Ablation
MH  - Randomized Controlled Trials as Topic
MH  - Twins, Monozygotic
PMC - PMC7430451
OTO - NOTNLM
OT  - *fetal anomalies
OT  - *microwave ablation
OT  - *monochorionic pregnancy
OT  - *selective fetal reduction
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034995 [pii]
AID - 10.1136/bmjopen-2019-034995 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e034995. doi: 10.1136/bmjopen-2019-034995.


PMID- 32792426
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Ozone exposure and health effects: a protocol for an umbrella review and
      effect-specific systematic maps.
PG  - e034854
LID - 10.1136/bmjopen-2019-034854 [doi]
AB  - INTRODUCTION: Ambient ozone exposure may be adverse to health. Since the reported
      associations between ozone and health effects are heterogeneous and the
      underlying pathways are indistinct, the overall relationship remains unclear.
      Only a few overall syntheses of the evidence regarding ozone and health effects
      are available to date. METHODS AND ANALYSIS: We plan to summarise the current
      evidence on ozone-related health effects systematically. First, to identify the
      possible associations between ambient ozone exposure and health outcomes, we will
      conduct an umbrella review. PubMed, Web of Science and grey literature will be
      searched for systematic reviews on exposure to ambient ozone and any possible
      health endpoints published before 31 May 2019. Data selection and extraction will
      be carried out by one reviewer, and a second reviewer will check the agreement of
      a sample of the studies. The methodological quality of the eligible systematic
      reviews and level of evidence regarding ozone and every specific health effect
      will be evaluated. Second, for each of the identified effects with a high level
      of evidence, comprehensive information retrievals will be conducted, considering 
      both epidemiological and experimental studies. The study selection and data
      mapping will be carried out by one reviewer and checked by the second reviewer.
      We will summarise the information of the filtered epidemiological and
      experimental studies to conduct several systematic maps presenting the currently 
      available evidence for the specific health effect. Because the association
      between ozone exposure and chronic obstructive pulmonary disease (COPD) is
      relatively well investigated, we will at least conduct one systematic map of
      ozone and COPD. ETHICS AND DISSEMINATION: No ethical approval is required for
      this study. The completed umbrella review and systematic maps will be considered 
      for publication and presentation. We will additionally upload the relevant data
      to publicly accessible online databases. PROSPERO REGISTRATION NUMBER:
      CRD42019123064.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhao, Tianyu
AU  - Zhao T
AUID- ORCID: 0000-0002-2696-273X
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine,
      University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
AD  - Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung 
      Research, Munich, Germany.
AD  - Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for
      Environmental Health, Neuherberg, Germany.
AD  - Department of Applied Social Sciences, Munich University of Applied Sciences,
      Munich, Germany.
FAU - Markevych, Iana
AU  - Markevych I
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine,
      University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
AD  - Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung 
      Research, Munich, Germany.
AD  - Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for
      Environmental Health, Neuherberg, Germany.
AD  - Institute of Psychology, Jagiellonian University, Krakow, Poland.
FAU - Janssen, Christian
AU  - Janssen C
AD  - Department of Applied Social Sciences, Munich University of Applied Sciences,
      Munich, Germany.
FAU - Nowak, Dennis
AU  - Nowak D
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine,
      University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
AD  - Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung 
      Research, Munich, Germany.
FAU - Steckling-Muschack, Nadine
AU  - Steckling-Muschack N
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine,
      University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
AD  - Department of Public Health and Health Technology Assessment, University for
      Health Sciences, Medical Computer Science and Technology, Hall in Tirol, Austria.
FAU - Heinrich, Joachim
AU  - Heinrich J
AD  - Institute and Clinic for Occupational, Social and Environmental Medicine,
      University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
      joachim.heinrich@med.uni-muenchen.de.
AD  - Comprehensive Pneumology Center (CPC) Munich, member DZL; German Center for Lung 
      Research, Munich, Germany.
AD  - Institute of Epidemiology, Helmholtz Zentrum Munchen - German Research Center for
      Environmental Health, Neuherberg, Germany.
AD  - Allergy and Lung Health Unit, Melbourne School of Population and Global Health,
      The University of Melbourne, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 66H7ZZK23N (Ozone)
SB  - IM
MH  - Humans
MH  - *Ozone/toxicity
MH  - *Pulmonary Disease, Chronic Obstructive/epidemiology
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7430459
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *thoracic medicine
COIS- Competing interests: No.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034854 [pii]
AID - 10.1136/bmjopen-2019-034854 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e034854. doi: 10.1136/bmjopen-2019-034854.


PMID- 32792425
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - Assessment of the impact of a new sequential approach to antimicrobial use in
      young febrile children in the emergency department (DIAFEVERCHILD): a French
      prospective multicentric controlled, open, cluster-randomised, parallel-group
      study protocol.
PG  - e034828
LID - 10.1136/bmjopen-2019-034828 [doi]
AB  - INTRODUCTION: Fever is one of the most common reasons for consultation in the
      paediatric emergency department (ED). Because of fear of bacterial infection in
      parents and caregivers, clinicians often overprescribe laboratory tests and
      empirical antibiotic treatment. The aims of this study are to demonstrate that
      using a procalcitonin (PCT) rapid test-based prediction rule (1) would not be
      inferior to usual practice in terms of morbidity and mortality (non-inferiority
      objective) and (2) would result in a significant reduction in antibiotic use
      (superiority objective). METHODS AND ANALYSIS: This prospective multicentric
      cluster-randomised study aims to include 7245 febrile children aged 6 days to 3
      years with a diagnosis of fever without source in 26 participating EDs in France 
      and Switzerland during a 24-month period. During first period, all children will 
      receive usual care. In a second period, a point-of-care PCT-based algorithm will 
      be used in half of the clusters. The primary endpoints collected on day 15 after 
      ED consultation will be a composite outcome of death or intensive care unit
      admission for any reason, disease-specific complications, diagnosis of bacterial 
      infection after discharge from the ED for the non-inferiority objective and
      proportion of children with antibiotic treatment administered for the superiority
      objective. The endpoints will be compared between the two groups (experimental
      and control) by using a mixed logistic regression model adjusted on clustering of
      participants within centres and period within centres. DISCUSSION: If the
      algorithm is validated, a new strategy will be discussed with medical societies
      to safely manage fever in young children without the need for invasive procedures
      for microbiological testing or empirical antibiotics. ETHICS AND DISSEMINATION:
      This study was submitted to an independent ethics committee on 17 May 2018 (no.
      2018-A00252-53). Results will be submitted to international peer-reviewed
      journals and presented at international conferences. TRIAL REGISTRATION NUMBER:
      NCT03607162; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hubert, Gaelle
AU  - Hubert G
AUID- ORCID: 0000-0001-9580-3233
AD  - Paediatrics Emergency Department, CHU Nantes, Nantes, France
      gaelle.hubert@chu-nantes.fr.
FAU - Launay, Elise
AU  - Launay E
AD  - General Paediatrics Department, CHU Nantes, Nantes, France.
AD  - Clinical Research Department, Clinical Investigation Center Femme Enfant
      Adolescent-1413 INSERM, CHU Nantes, Nantes, France.
FAU - Feildel Fournial, Cecile
AU  - Feildel Fournial C
AD  - Paediatrics Emergency Department, CHU Nantes, Nantes, France.
FAU - Chauvire-Drouard, Anne
AU  - Chauvire-Drouard A
AD  - Clinical Research Department, Clinical Investigation Center Femme Enfant
      Adolescent-1413 INSERM, CHU Nantes, Nantes, France.
FAU - Lorton, Fleur
AU  - Lorton F
AD  - Paediatrics Emergency Department, CHU Nantes, Nantes, France.
AD  - Clinical Research Department, Clinical Investigation Center Femme Enfant
      Adolescent-1413 INSERM, CHU Nantes, Nantes, France.
FAU - Tavernier, Elsa
AU  - Tavernier E
AD  - Biostatistics Department, Clinical Investigation Center-1415 INSERM, CHU Tours,
      Tours, France.
FAU - Giraudeau, Bruno
AU  - Giraudeau B
AD  - Biostatistics Department, Clinical Investigation Center-1415 INSERM, CHU Tours,
      Tours, France.
FAU - Gras Le Guen, Christele
AU  - Gras Le Guen C
AD  - Paediatrics Emergency Department, CHU Nantes, Nantes, France.
AD  - General Paediatrics Department, CHU Nantes, Nantes, France.
AD  - Clinical Research Department, Clinical Investigation Center Femme Enfant
      Adolescent-1413 INSERM, CHU Nantes, Nantes, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03607162
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Biomarkers)
SB  - IM
MH  - *Anti-Bacterial Agents/therapeutic use
MH  - Biomarkers
MH  - Child
MH  - Child, Preschool
MH  - *Emergency Service, Hospital
MH  - France
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Switzerland
PMC - PMC7430445
OTO - NOTNLM
OT  - *cluster-randomised study
OT  - *fever without source
OT  - *invasive bacterial infection
OT  - *paediatric emergency departements
OT  - *procalcitonin based algorithm
OT  - *procalcitonin rapid test
COIS- Competing interests: The DIAFEVERCHILD study received a French national grant
      from the French Ministry of Health. ThermoFisher will provide instruments and
      tests for the micromethod PCT assay, the B.R.A.H.M.S PCT-direct system.
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034828 [pii]
AID - 10.1136/bmjopen-2019-034828 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e034828. doi: 10.1136/bmjopen-2019-034828.


PMID- 32792424
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 13
TI  - 'Sometimes you are forced to play God...': a qualitative study of healthcare
      worker experiences of using continuous positive airway pressure in newborn care
      in Kenya.
PG  - e034668
LID - 10.1136/bmjopen-2019-034668 [doi]
AB  - OBJECTIVE: To explore the experiences of using continuous positive airway
      pressure (CPAP) in newborn care among healthcare workers in Kenya, and to
      identify factors that would promote successful scale-up. DESIGN AND SETTING: A
      qualitative study using key informant interviews and focus group discussions,
      based at secondary and tertiary level hospitals in Kenya. PARTICIPANTS:
      Healthcare workers in the newborn units providing CPAP. PRIMARY AND SECONDARY
      OUTCOME MEASURE: Facilitators and barriers of CPAP use in newborn care in Kenya. 
      RESULTS: 16 key informant interviews and 15 focus group discussions were
      conducted across 19 hospitals from September 2017 to February 2018. Main barriers
      reported were: (1) inadequate infrastructure to support the effective delivery of
      CPAP, (2) shortage of skilled staff rendering it difficult for the available
      staff to initiate or monitor infants on CPAP and (3) inadequate knowledge and
      training of staff that inhibited the safe care of infants on CPAP. Key
      facilitators reported were positive patient outcomes after CPAP use that
      increased staff confidence and partnership with caregivers in the management of
      newborns on CPAP. Healthcare workers in private/mission hospitals had more
      positive experiences of using CPAP in newborn care as the relevant support and
      infrastructure were available. CONCLUSION: CPAP use in newborn care is valued by 
      healthcare workers in Kenya. However, we identified key challenges that threaten 
      its safe use and sustainability. Further scale-up of CPAP in newborn care should 
      ensure that staff members have ready access to optimal training on CPAP and that 
      there are enough resources and infrastructure to support its use. ETHICS: This
      study was approved through the appropriate ethics committees in Kenya and the UK 
      (see in text) with written informed consent for each participant.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Nabwera, Helen M
AU  - Nabwera HM
AUID- ORCID: 0000-0003-1056-729X
AD  - International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
      Helen.Nabwera@lstmed.ac.uk.
FAU - Wright, Jemma L
AU  - Wright JL
AD  - Paediatrics Department, Betsi Cadwaladr CHC, Wrexham, UK.
FAU - Patil, Manasi
AU  - Patil M
AD  - International Public Health, Liverpool School of Tropical Medicine, Liverpool,
      UK.
FAU - Dickinson, Fiona
AU  - Dickinson F
AD  - International Public Health, Liverpool School of Tropical Medicine, Liverpool,
      UK.
FAU - Godia, Pamela
AU  - Godia P
AD  - International Public Health, Liverpool School of Tropical Medicine, Nairobi,
      Kenya.
FAU - Maua, Judith
AU  - Maua J
AD  - International Public Health, Liverpool School of Tropical Medicine, Nairobi,
      Kenya.
FAU - Sammy, Mercy K
AU  - Sammy MK
AD  - General Paediatrics, Gertrude's Garden Children's Hospital, Nairobi, Kenya.
FAU - Naimoi, Bridget C
AU  - Naimoi BC
AD  - Child Health, AMPATH Kenya, Eldoret, Kenya.
FAU - Warfa, Osman H
AU  - Warfa OH
AD  - Neonatal, Child and Adolescent Health, Kenya Ministry of Health, Nairobi, Kenya.
FAU - Dewez, Juan Emmanuel
AU  - Dewez JE
AUID- ORCID: 0000-0002-5677-8968
AD  - Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
FAU - Murila, Florence
AU  - Murila F
AD  - Paediatrics and Child Health, University of Nairobi School of Medicine, Nairobi, 
      Kenya.
FAU - Manu, Alexander
AU  - Manu A
AD  - International Public Health, Liverpool School of Tropical Medicine, Liverpool,
      UK.
FAU - Smith, Helen
AU  - Smith H
AD  - Maternal and Newborn Health, International Health Consulting Services Ltd,
      Liverpool, UK.
FAU - Mathai, Matthews
AU  - Mathai M
AUID- ORCID: 0000-0002-7352-9330
AD  - International Public Health, Liverpool School of Tropical Medicine, Liverpool,
      UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Continuous Positive Airway Pressure
MH  - Focus Groups
MH  - *Health Personnel
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kenya
MH  - Qualitative Research
PMC - PMC7430418
OTO - NOTNLM
OT  - *neonatology
OT  - *qualitative research
OT  - *respiratory medicine (see thoracic medicine)
EDAT- 2020/08/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034668 [pii]
AID - 10.1136/bmjopen-2019-034668 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 13;10(8):e034668. doi: 10.1136/bmjopen-2019-034668.


PMID- 32792408
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 8
DP  - 2020 Aug
TI  - The impact of country reimbursement programmes on living kidney donations.
LID - e002596 [pii]
LID - 10.1136/bmjgh-2020-002596 [doi]
AB  - INTRODUCTION: Living-donor kidney transplantation is the gold standard treatment 
      for patients with end-stage kidney disease. However, potential donors
      ubiquitously face financial as well as logistical barriers. To remove these
      disincentives from living kidney donations, the governments of 23 countries have 
      implemented reimbursement programmes that shift the burdens of non-medical costs 
      from donors to the governments or private entities. However, scientific evidence 
      for the effectiveness of these programmes is scarce. The present study
      investigates whether these reimbursement programmes designed to ease the
      financial and logistical barriers succeeded in increasing the number of living
      kidney donations at the country level. The study examined within-country
      variations in the timing of such reimbursement programmes. METHOD: The study
      applied the difference-in-difference (two-way panel fixed-effect) technique on
      the Poisson distribution to estimate the effects of these reimbursement
      programmes on a 17 year long (2000-2016) dataset covering 109 countries where
      living donor kidney transplants were performed. RESULTS: The results indicated
      that reimbursement programmes have a statistically significant positive effect.
      Overall, the model predicted that reimbursement programmes increased
      country-level donation numbers by a factor of 1.12-1.16. CONCLUSION:
      Reimbursement programmes may be an effective approach to alleviate the kidney
      shortage worldwide. Further analysis is warranted on the type of reimbursement
      programmes and the ethical dimension of each type of such programmes.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Siddique, Abu Bakkar
AU  - Siddique AB
AUID- ORCID: 0000-0002-9964-7511
AD  - Schar School of Policy and Government, George Mason University-Arlington Campus, 
      Arlington, Virginia, USA anirbanju36@gmail.com.
FAU - Apte, Vandana
AU  - Apte V
AD  - Department of Agricultural, Food and Resource Economics, Rutgers University, New 
      Brunswick, New Jersey, USA.
FAU - Fry-Revere, Sigrid
AU  - Fry-Revere S
AD  - Independent Bioethics Scholar, Washington, District of Columbia, USA.
FAU - Jin, Yanhong
AU  - Jin Y
AD  - Department of Agricultural, Food and Resource Economics, Rutgers University, New 
      Brunswick, New Jersey, USA.
FAU - Koizumi, Naoru
AU  - Koizumi N
AUID- ORCID: 0000-0001-8722-0898
AD  - Schar School of Policy and Government, George Mason University-Arlington Campus, 
      Arlington, Virginia, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Humans
MH  - Kidney
MH  - *Kidney Transplantation
MH  - *Living Donors
PMC - PMC7430320
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *other study design
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-002596 [pii]
AID - 10.1136/bmjgh-2020-002596 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Aug;5(8). pii: bmjgh-2020-002596. doi:
      10.1136/bmjgh-2020-002596.


PMID- 32792348
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Caster Semenya's life and achievements are cause for celebration, respect and
      inclusion; her exclusion is consequential.
PG  - 593-594
LID - 10.1136/medethics-2020-106506 [doi]
FAU - Carpenter, Morgan
AU  - Carpenter M
AUID- ORCID: 0000-0001-6166-7018
AD  - Intersex Human Rights Australia, Altona, Victoria, Australia
      morgan@morgancarpenter.com.
AD  - Sydney Health Ethics, The University of Sydney Faculty of Medicine and Health,
      Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200813
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Sep;46(9):584-590. PMID: 32690761
CIN - J Med Ethics. 2020 Sep;46(9):599-600. PMID: 32826302
MH  - Athletes
MH  - Ethical Theory
MH  - Female
MH  - Humans
MH  - *Respect
MH  - *Sports
OTO - NOTNLM
OT  - *coercion
OT  - *ethics
OT  - *minorities
OT  - *rights
OT  - *women
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/06/13 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
AID - medethics-2020-106506 [pii]
AID - 10.1136/medethics-2020-106506 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):593-594. doi: 10.1136/medethics-2020-106506. Epub
      2020 Aug 13.


PMID- 32792347
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Applying safeguards of research integrity to unethical organ donation and
      transplantation.
PG  - 685-686
LID - 10.1136/medethics-2020-106535 [doi]
FAU - Bramstedt, Katrina A
AU  - Bramstedt KA
AUID- ORCID: 0000-0001-5446-0123
AD  - Luxembourg Agency for Research Integrity, Esch-sur-Alzette, Luxembourg
      txbioethics@yahoo.com.
AD  - Health Advocate & Professional Theme, Bond University School of Medicine, Gold
      Coast, QLD 4226, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200813
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Oct;46(10):678-684. PMID: 32611619
CIN - J Med Ethics. 2020 Oct;46(10):691-692. PMID: 32928880
MH  - China
MH  - Humans
MH  - *Organ Transplantation
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *donation/procurement of organs/tissues
OT  - *publication ethics
OT  - *research ethics
OT  - *transplantation
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
AID - medethics-2020-106535 [pii]
AID - 10.1136/medethics-2020-106535 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):685-686. doi: 10.1136/medethics-2020-106535. Epub
      2020 Aug 13.


PMID- 32792346
OWN - NLM
STAT- Publisher
LR  - 20200814
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 13
TI  - Why unethical papers should be retracted.
LID - medethics-2020-106140 [pii]
LID - 10.1136/medethics-2020-106140 [doi]
AB  - The purpose of retracting published papers is to maintain the integrity of
      academic research. Recent work in research ethics has devoted important attention
      to how to improve the system of paper retraction. In this context, the focus has 
      primarily been on how to handle fraudulent or flawed research papers and how to
      encourage the retraction of papers based on honest mistakes. Less attention has
      been paid to whether papers that report unethical research-for example, research 
      performed without appropriate concern for the moral rights and interests of the
      research participants-should be retracted. The aim of this paper is to examine to
      what extent retraction policies of academic journals and publishers address
      retractions of unethical research and to discuss critically various policy
      options and the reasons for accepting them. The paper starts by reviewing
      retraction policies of academic publishers. The results show that many journals
      do not have explicit policies for how to handle unethical research. Against this 
      background, we then discuss four normative arguments for why unethical research
      should be retracted. In conclusion, we suggest a retraction policy in light of
      our empirical and normative investigations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Bulow, William
AU  - Bulow W
AUID- ORCID: http://orcid.org/0000-0002-5244-6878
AD  - Department of Philosophy, Stockholms Universitet, Stockholm, Sweden
      william.bulow@philosophy.su.se.
FAU - Godskesen, Tove E
AU  - Godskesen TE
AD  - Department of Health Care Sciences, Ersta Skondal Bracke University College,
      Stockholm, Sweden.
AD  - Centre for Research Ethics and Bioethics, Uppsala Universitet, Uppsala, Sweden.
FAU - Helgesson, Gert
AU  - Helgesson G
AUID- ORCID: http://orcid.org/0000-0002-0075-0165
AD  - Stockholm Centre for Healthcare Ethics, Department of Learning, Informatics,
      Management and Ethics, Karolinska Institutet, Stockholm, Sweden.
FAU - Eriksson, Stefan
AU  - Eriksson S
AD  - Centre for Research Ethics and Bioethics, Uppsala Universitet, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - publication ethics
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/02/13 00:00 [received]
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
AID - medethics-2020-106140 [pii]
AID - 10.1136/medethics-2020-106140 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 13. pii: medethics-2020-106140. doi:
      10.1136/medethics-2020-106140.


PMID- 32792345
OWN - NLM
STAT- Publisher
LR  - 20200814
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 13
TI  - Is this person with dementia (currently) competent to request euthanasia? A
      complicated and underexplored question.
LID - medethics-2020-106091 [pii]
LID - 10.1136/medethics-2020-106091 [doi]
AB  - In euthanasia and/or assisted suicide (EAS) of persons with dementia, the
      controversy has mostly focused on decisionally incapable persons with very
      advanced dementia for whom the procedure must be based on a written advance
      euthanasia directive. This focus on advance euthanasia directive-based EAS has
      been accompanied by scant attention to the issue of decision-making capacity
      assessment of persons with dementia who are being evaluated for concurrent
      request EAS. We build on a previous analysis of concurrent request EAS cases from
      the Netherlands, which showed that many such cases involve persons with
      significant cognitive impairment. We use illustrative cases to describe the
      difficulty of determining decisional capacity in persons whose stage of dementia 
      falls between severely impaired and mildly impaired. We show that the Dutch
      practice of capacity assessment in such dementia cases is difficult to reconcile 
      with the widely accepted functional model of capacity-a model explicitly endorsed
      by the Dutch euthanasia review committees. We discuss why such deviations from
      the standard functional model might be occurring, as well as their ethical
      implications for dementia EAS policy and practice.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kim, Scott Yh
AU  - Kim SY
AUID- ORCID: http://orcid.org/0000-0002-9444-4627
AD  - Department of Bioethics, National Institutes of Health, Bethesda, Maryland, USA
      scott.kim@nih.gov.
FAU - Mangino, Dominic
AU  - Mangino D
AD  - Department of Bioethics, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Nicolini, Marie
AU  - Nicolini M
AD  - Department of Bioethics, National Institutes of Health, Bethesda, Maryland, USA.
AD  - Interfaculty Center for Biomedical Ethics and Law, KHLeuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - capacity
OT  - competence/incompetence
OT  - dementia
OT  - euthanasia
OT  - living wills/advance directives
COIS- Competing interests: None declared.
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
AID - medethics-2020-106091 [pii]
AID - 10.1136/medethics-2020-106091 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 13. pii: medethics-2020-106091. doi:
      10.1136/medethics-2020-106091.


PMID- 32792241
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20200911
IS  - 1268-6034 (Print)
IS  - 1268-6034 (Linking)
VI  - 25
IP  - 144
DP  - 2020 Jul - Aug
TI  - [Elderly heart failure patient, quality or quantity of life?]
PG  - 38-42
LID - S1268-6034(20)30107-9 [pii]
LID - 10.1016/j.sger.2020.06.009 [doi]
AB  - Heart failure is a serious and common disease in the elderly. It causes repeated 
      hospitalizations with a progressive overall decline. It is often difficult at an 
      advanced stage of the disease to "choose" between quality and quantity of life
      for both patients and their families and caregivers. A reflection conducted at
      the Centre for Clinical Ethics of the Assistance publique-Hopitaux de Paris can
      help to make progress on these difficult choices.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Goudot, Francois-Xavier
AU  - Goudot FX
AD  - Service de cardiologie, Hopital Avicenne, 125 route de Stalingrad, 93000 Bobigny,
      France. Electronic address: francois-xavier.goudot@aphp.fr.
FAU - Thomas, Sarah
AU  - Thomas S
AD  - Service de court sejour geriatrique, Grand Hopital de l'Est francilien, 2-4 cour 
      de la Gondolier, 77600 Jossigny, France.
FAU - Foureur, Nicolas
AU  - Foureur N
AD  - Centre d'ethique clinique, AP-HP, 1 rue de l'Hopital, 95780 La Roche-Guyon,
      France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Patient age insuffisant cardiaque, qualite ou quantite de vie ?
DEP - 20200610
PL  - France
TA  - Soins Gerontol
JT  - Soins. Gerontologie
JID - 9616322
MH  - Aged
MH  - Caregivers/*psychology
MH  - Choice Behavior
MH  - Heart Failure/*therapy
MH  - Humans
MH  - Quality of Life
OTO - NOTNLM
OT  - clinical ethics
OT  - elderly
OT  - heart failure
OT  - insuffisance cardiaque
OT  - personne agee
OT  - quality of life
OT  - qualite de vie
OT  - ethique clinique
EDAT- 2020/08/15 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - S1268-6034(20)30107-9 [pii]
AID - 10.1016/j.sger.2020.06.009 [doi]
PST - ppublish
SO  - Soins Gerontol. 2020 Jul - Aug;25(144):38-42. doi: 10.1016/j.sger.2020.06.009.
      Epub 2020 Jun 10.


PMID- 32792045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-9172 (Print)
IS  - 2076-9172 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul 31
TI  - Israeli Position Paper: Triage Decisions for Severely Ill Patients During the
      COVID-19 Pandemic. Joint Commission of the Israel National Bioethics Council, the
      Ethics Bureau of the Israel Medical Association and Representatives from the
      Israeli Ministry of Health.
LID - 10.5041/RMMJ.10411 [doi]
AB  - OBJECTIVES: This document provides an English translation of the Israeli Joint
      Commission's national guidelines for triaging severely ill patients during the
      coronavirus disease 2019 (COVID-19) pandemic. METHODS: Four subcommittees of
      medical, legal, ethical-social, and religious experts developed the general
      principles and practical medical criteria for triaging scarce life-saving
      resources. RESULTS: The guidelines provide an overview of general principles as
      well as pragmatic medical criteria and a practical triage protocol to be followed
      should the healthcare system be overwhelmed due to COVID-19. Issues covered
      include triggers for activating the guidelines, guiding ethical, legal, and
      religious principles, equity in access, fair distribution, transparency,
      consistency, palliation, medical policy prioritization, problem-solving
      mechanisms, and public trust. CONCLUSIONS: The Israeli consensus document and
      pragmatic medical triage protocol offer a societal and medical roadmap for
      allocating scarce resources during the COVID-19 pandemic or other disasters.
FAU - Steinberg, Avraham
AU  - Steinberg A
AD  - Medical Ethics Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
AD  - Co-Chairman, Israel National Bioethics Council, Jerusalem, Israel.
FAU - Levy-Lahad, Ephrat
AU  - Levy-Lahad E
AD  - Medical Ethics Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
AD  - Co-Chairman, Israel National Bioethics Council, Jerusalem, Israel.
AD  - Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
AD  - Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
FAU - Karni, Tami
AU  - Karni T
AD  - Head, Breast Care Institute, Assaf Harofe Medical Center, Zerifin, Israel.
AD  - Chairman, Ethics Bureau of the Israel Medical Association, Ramat Gan, Israel.
FAU - Zohar, Noam
AU  - Zohar N
AD  - Head, Advanced Studies in Bioethics, Faculty of Philosophy, Bar-Ilan University, 
      Ramat Gan, Israel.
FAU - Siegal, Gil
AU  - Siegal G
AD  - Director, Center for Health Law & Bioethics, Faculty of Law, Ono Academic
      College, Kiryat Ono, Israel.
FAU - Sprung, Charles L
AU  - Sprung CL
AD  - Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Department of Anesthesiology, Critical Care Medicine and Pain, Hadassah Medical
      Center, Jerusalem, Israel.
CN  - Israel National Bioethics Council, the Ethics Bureau of the Israel Medical
      Association, and Representatives from the Israeli Ministry of Health
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Israel
TA  - Rambam Maimonides Med J
JT  - Rambam Maimonides medical journal
JID - 101538065
PMC - PMC7426554
EDAT- 2020/08/15 06:00
MHDA- 2020/08/15 06:01
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/15 06:01 [medline]
AID - RMMJ.10411 [pii]
AID - 10.5041/RMMJ.10411 [doi]
PST - epublish
SO  - Rambam Maimonides Med J. 2020 Jul 31;11(3). pii: RMMJ.10411. doi:
      10.5041/RMMJ.10411.


PMID- 32792005
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1757-7241 (Electronic)
IS  - 1757-7241 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Aug 13
TI  - Difficulty of the ethical decision-making process in withholding and withdrawing 
      life-sustaining treatments in French EDs during COVID pandemic.
PG  - 78
LID - 10.1186/s13049-020-00772-3 [doi]
FAU - Douplat, Marion
AU  - Douplat M
AUID- ORCID: 0000-0003-1592-4065
AD  - Emergency Department, Lyon Sud Hospital, University Hospital, Hospices Civiles of
      Lyon, 165 chemin du Grand Revoyet, F-69495, Pierre Benite, France.
      marion.douplat@chu-lyon.fr.
AD  - UMR ADeS 7268, Aix-Marseille University/ EFS / CNRS, Espace ethique
      mediterraneen, Timone Adulte's Hospital, Marseille, France.
      marion.douplat@chu-lyon.fr.
FAU - Jacquin, Laurent
AU  - Jacquin L
AD  - Emergency Department, Edouard-Herriot Hospital, Lyon University Hospital,
      Hospices Civiles of Lyon, 5 place d'Arsonval, F-69003, Lyon, France.
FAU - Frugier, Soizic
AU  - Frugier S
AD  - Emergency Department, Lyon Sud Hospital, University Hospital, Hospices Civiles of
      Lyon, 165 chemin du Grand Revoyet, F-69495, Pierre Benite, France.
FAU - Tazarourte, Karim
AU  - Tazarourte K
AD  - Emergency Department, Edouard-Herriot Hospital, Lyon University Hospital,
      Hospices Civiles of Lyon, 5 place d'Arsonval, F-69003, Lyon, France.
FAU - Le Coz, Pierre
AU  - Le Coz P
AD  - UMR ADeS 7268, Aix-Marseille University/ EFS / CNRS, Espace ethique
      mediterraneen, Timone Adulte's Hospital, Marseille, France.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200813
PL  - England
TA  - Scand J Trauma Resusc Emerg Med
JT  - Scandinavian journal of trauma, resuscitation and emergency medicine
JID - 101477511
SB  - IM
CON - N Engl J Med. 2020 May 21;382(21):2049-2055. PMID: 32202722
MH  - *COVID-19
MH  - Humans
MH  - Life Support Care
MH  - *Pandemics
MH  - SARS-CoV-2
MH  - Withholding Treatment
PMC - PMC7424240
EDAT- 2020/08/15 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/07/07 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1186/s13049-020-00772-3 [doi]
AID - 10.1186/s13049-020-00772-3 [pii]
PST - epublish
SO  - Scand J Trauma Resusc Emerg Med. 2020 Aug 13;28(1):78. doi:
      10.1186/s13049-020-00772-3.


PMID- 32791985
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Aug 13
TI  - A monocentric, open-label randomized standard-of-care controlled study of
      XONRID(R), a medical device for the prevention and treatment of radiation-induced
      dermatitis in breast and head and neck cancer patients.
PG  - 193
LID - 10.1186/s13014-020-01633-0 [doi]
AB  - BACKGROUND: This study was an open-label, 2-arms, monocentric, randomized
      clinical trial comparing Xonrid(R), a topical medical device, versus standard of 
      care (SOC) in preventing and treating acute radiation dermatitis (ARD) in Head
      and Neck Cancer (HNC) and Breast Cancer (BC) patients undergoing radiotherapy
      (RT). METHODS: Eligible HNC and BC patients were randomized 1:1 to receive
      Xonrid(R) + SOC or SOC during RT. Patients were instructed to apply Xonrid(R) on 
      the irradiated area three times daily, starting on the first day of RT and until 
      2 weeks after RT completion or until the development of grade >/= 3 skin
      toxicity. The primary endpoint was to evaluate the proportion of patients who
      developed an ARD grade < 2 at the 5th week in both groups. Secondary endpoints
      were median time to grade 2 (G2) skin toxicity onset; changes in skin erythema
      and pigmentation and trans-epidermal water loss (TEWL); patient-reported skin
      symptoms. All patients were evaluated at baseline, weekly during RT and 2 weeks
      after treatment completion. The evaluation included: clinical toxicity
      assessment; reflectance spectrometry (RS) and TEWL examination; measurement of
      patients' quality of life (QoL) through Skindex-16 questionnaire. RESULTS: Eighty
      patients (40 for each cancer site) were enrolled between June 2017 and July 2018.
      Groups were well balanced for population characteristics. All BC patients
      underwent 3-Dimensional Conformal RT (3D-CRT) whereas HNC patients underwent
      Volumetric-Modulated Arc Therapy (VMAT). At week 5 the proportion of BC patients 
      who did not exhibit G2 ARD was higher in Xonrid(R) + SOC group (p = 0.091). In
      the same group the onset time of G2 ARD was significantly longer than in
      SOC-alone group (p < 0.0491). For HNC groups there was a similar trend, but it
      did not reach statistical significance. For both cancer sites, patients' QoL,
      measured by the Skindex-16 score, was always lower in the Xonrid(R) + SOC group. 
      CONCLUSION: Despite the failure to achieve the primary endpoint, this study
      suggests that Xonrid(R) may represent a valid medical device in the prevention
      and treatment of ARD at least in BC patients, delaying time to develop skin
      toxicity and reducing the proportion of patients who experienced G2 ARD during RT
      treatment and 2 weeks later. TRIAL REGISTRATION: The study was approved by the
      Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
      (INT 52/14 - NCT02261181 ). Registered on ClinicalTrial.gov on 21st August 2017.
FAU - Ingargiola, Rossana
AU  - Ingargiola R
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
FAU - De Santis, Maria Carmen
AU  - De Santis MC
AD  - Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
FAU - Iacovelli, Nicola Alessandro
AU  - Iacovelli NA
AUID- ORCID: http://orcid.org/0000-0003-2556-9079
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
      nicolaalessandro.iacovelli@istitutotumori.mi.it.
FAU - Facchinetti, Nadia
AU  - Facchinetti N
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
FAU - Cavallo, Anna
AU  - Cavallo A
AD  - Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
      Milan, Italy.
FAU - Ivaldi, Eliana
AU  - Ivaldi E
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
AD  - Radiotherapy Department, Sassari Hospital, University of Sassari, Sassari, Italy.
FAU - Dispinzieri, Michela
AU  - Dispinzieri M
AD  - Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
FAU - Franceschini, Marzia
AU  - Franceschini M
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
FAU - Giandini, Carlotta
AU  - Giandini C
AD  - Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
FAU - Romanello, Domenico Attilio
AU  - Romanello DA
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
AD  - School of Medicine, University of Milan-Bicocca, Milan, Italy.
FAU - Di Biaso, Simona
AU  - Di Biaso S
AD  - Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
      Milan, Italy.
AD  - Post Graduation School in Medical Physics, University of Milan, Milan, Italy.
FAU - Sabetti, Michela
AU  - Sabetti M
AD  - Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
      Milan, Italy.
AD  - Post Graduation School in Medical Physics, University of Milan, Milan, Italy.
FAU - Locati, Laura
AU  - Locati L
AD  - Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei
      Tumori di Milano, Milan, Italy.
FAU - Alfieri, Salvatore
AU  - Alfieri S
AD  - Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei
      Tumori di Milano, Milan, Italy.
FAU - Bossi, Paolo
AU  - Bossi P
AD  - Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.
FAU - Guglielmo, Mauro
AU  - Guglielmo M
AD  - Oncology-Supportive Care Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
FAU - Macchi, Fabio
AU  - Macchi F
AD  - Helsinn Healthcare SA, Lugano, Switzerland.
FAU - Lozza, Laura
AU  - Lozza L
AD  - Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
FAU - Valdagni, Riccardo
AU  - Valdagni R
AD  - Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
AD  - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
AD  - Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
FAU - Fallai, Carlo
AU  - Fallai C
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
FAU - Pignoli, Emanuele
AU  - Pignoli E
AD  - Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
      Milan, Italy.
FAU - Orlandi, Ester
AU  - Orlandi E
AD  - Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Via Venezian 1, 20133, Milan, Italy.
AD  - Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di
      Milano, Milan, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT02261181
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200813
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
RN  - 0 (Gels)
RN  - 0 (Pharmaceutical Solutions)
SB  - IM
MH  - Administration, Cutaneous
MH  - Adult
MH  - Breast Neoplasms/pathology/*radiotherapy
MH  - Female
MH  - Gels/*administration & dosage
MH  - Head and Neck Neoplasms/pathology/*radiotherapy
MH  - Humans
MH  - Middle Aged
MH  - Pharmaceutical Solutions/*administration & dosage
MH  - Prognosis
MH  - Radiodermatitis/etiology/pathology/*prevention & control
MH  - Radiotherapy/*adverse effects
MH  - *Standard of Care
MH  - Survival Rate
PMC - PMC7427075
OTO - NOTNLM
OT  - Acute radiation dermatitis
OT  - Breast cancer
OT  - Head and neck cancer
OT  - Patient-reported outcome measures
OT  - Quality of life
OT  - Skin toxicity
OT  - Skindex-16
OT  - Xonrid(R)
EDAT- 2020/08/15 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
AID - 10.1186/s13014-020-01633-0 [doi]
AID - 10.1186/s13014-020-01633-0 [pii]
PST - epublish
SO  - Radiat Oncol. 2020 Aug 13;15(1):193. doi: 10.1186/s13014-020-01633-0.


PMID- 32791754
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Efficacy and safety of Lianhua Qingwen combined with conventional antiviral
      Western Medicine in the treatment of coronavirus disease (covid-19) in 2019:
      Protocol for a systematic review and meta-analysis.
PG  - e21404
LID - 10.1097/MD.0000000000021404 [doi]
AB  - BACKGROUND: The novel coronavirus pneumonia (COVID-19) has spread to >200
      countries and regions. There is no effective antiviral drug for COVID-19.
      Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative
      effect in many countries, but its effect is not clear. We aim to assess the
      efficacy and safety of Lianhua Qingwen combined with Conventional antiviral
      Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection.
      METHODS: The following electronic bibliographic databases will be searched to
      identify relevant studies: CNKI, CBM, VIP and Wanfang databases, PubMed, EMBASE, 
      MEDLINE, Cochrane central, and clinical trial registration centers, such as China
      Clinical Trial Registration Center (ChiCTR), Netherlands National Trial
      Registration Center (NTR) and clinical trials.gov. In addition, Manual retrieval 
      of articles, conference papers, ongoing experiments, internal reports, among
      others, to supplement electronic retrieval. Select all eligible studies published
      before May 8, 2020.According to the Cochrane Handbook "bias risk" assessment
      tool, bias risk is independently assessed. The independent Newcastle Ottawa scale
      was used to conduct methodological quality assessment of nonrandomized trials.
      STATA15.1 and RevMan5.3 software were used to analyze meta outcomes of different 
      intervention measures for the treatment of new crown pneumonia and the control
      group (conventional antiviral western medicine treatment) clinical efficacy.
      RESULTS: This study will provide a relatively high-quality synthesis of current
      evidence of Lianhua Qingwen combined with Conventional antiviral Western Medicine
      in the treatment of COVID-19 from several aspects including the Clinical
      effective rate, CT improvement rate, severe conversion rate, antipyretic time,
      disappearance rate of fever symptoms, disappearance rate of cough symptoms,
      disappearance rate of asthenia symptoms, and adverse drug events. CONCLUSION: The
      conclusion of this review will provide evidence to judge whether Lianhua Qingwen 
      combined with Conventional antiviral Western Medicine is an effective and safe
      intervention for COVID-19. ETHICS AND DISSEMINATION: This systemic review will
      evaluate the efficacy and safety of Lianhua Qingwen combined with Conventional
      antiviral Western Medicine in the treatment of COVID-19. Since all the data
      included are published, the systematic review does not need ethical approval.
      INPLASY REGISTRATION NUMBER: INPLASY202060067.
FAU - Zhang, Xiaolin
AU  - Zhang X
AD  - Changchun University of Chinese Medicine.
FAU - Cao, Di
AU  - Cao D
AD  - Changchun Hospital of Chinese Medicine.
FAU - Liu, Junnan
AU  - Liu J
AD  - Changchun University of Chinese Medicine.
AD  - Department of lung diseases, the Third Clinical Hospital of Changchun University 
      of Chinese Medicine, Changchun, Jilin, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Changchun University of Chinese Medicine.
FAU - Liu, Mingjun
AU  - Liu M
AD  - Changchun University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antiviral Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (lianhuaqingwen)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Antiviral Agents/*administration & dosage
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/virology
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/virology
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7387000
EDAT- 2020/08/15 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021404 [doi]
AID - 00005792-202007240-00100 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21404. doi:
      10.1097/MD.0000000000021404.


PMID- 32791725
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Traditional Chinese medicine for symptoms of upper respiratory tract of COVID-19:
      A protocol for systematic review and meta-analysis.
PG  - e21320
LID - 10.1097/MD.0000000000021320 [doi]
AB  - BACKGROUND: Assessing the effectiveness and safety of traditional Chinese
      medicine (TCM) for symptoms of upper respiratory tract of coronavirus disease
      2019 is the main purpose of this systematic review protocol. METHODS: The
      following electronic databases will be searched from inception to Sep 2020: the
      Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, Web of 
      Science, TCM, China National Knowledge Infrastructure, Chinese Biomedical
      Literature Database, Chinese Scientific Journal Database (VIP database), and
      Wan-Fang Database. Search dates: from inception dates to June 2020. Language:
      English. Publication period: from inception dates to June 2020. The primary
      outcome is the time and rate of appearance of main symptoms (including coughing, 
      pharyngalgia, and nasal obstruction). The secondary outcome is the length of
      hospital stay. Two independent reviewers will conduct the study selection, data
      extraction and assessment. RevMan V.5.3 will be used for the assessment of risk
      of bias and data synthesis. RESULTS: The results will provide a high-quality
      synthesis of current evidence for researchers in this subject area. CONCLUSION:
      The conclusion of our study will provide an evidence to judge whether TCM is
      effective and safe for the patients with symptoms of upper respiratory tract of
      coronavirus disease 2019. ETHICS AND DISSEMINATION: This protocol will not
      evaluate individual patient information or affect patient rights and therefore
      does not require ethical approval. Results from this review will be disseminated 
      through peer-reviewed journals and conference reports. PROSPERO REGISTRATION
      NUMBER: CRD42020187422.
FAU - Liang, Fangqi
AU  - Liang F
AD  - Department of Otolaryngology, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Dong, Lei
AU  - Dong L
AD  - Department of Rehabilitation, the people's hospital of Wenjiang.
FAU - Zhou, Li
AU  - Zhou L
AD  - Department of Otolaryngology, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Shi, Yu
AU  - Shi Y
AD  - College of Acupuncture and Moxibustion and Tuina, Chengdu University of
      Traditional Chinese Medicine, China.
FAU - Tian, Li
AU  - Tian L
AD  - Department of Otolaryngology, Hospital of Chengdu University of Traditional
      Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/pathology/*therapy/virology
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Meta-Analysis as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/pathology/*therapy/virology
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Respiratory System/virology
MH  - Respiratory Tract Infections/pathology/*therapy/virology
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7387049
EDAT- 2020/08/15 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021320 [doi]
AID - 00005792-202007240-00071 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21320. doi:
      10.1097/MD.0000000000021320.


PMID- 32791722
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Effectiveness comparisons of catgut implantation at acupoint for obese type 2
      diabetes: A protocol for systematic review and meta analysis.
PG  - e21316
LID - 10.1097/MD.0000000000021316 [doi]
AB  - BACKGROUND: With the change of people's life style, many more people are
      suffering from obese type 2 diabetes mellitus (T2DM). Acupoint catgut embedding
      is one of the acupuncture treatment principles in traditional Chinese medicine,
      which is widely used in the treatment of obese T2DM. However, there is no
      systematic review of the therapeutic effect of acupoint catgut embedding on
      obesity T2DM. Therefore, this article aims at the meta-analysis of acupoint
      catgut embedding in the treatment of obese T2DM, to clarify its curative effect. 
      METHODS: A structured and systemic literature search was conducted in the
      following databases up to December 1, 2019: PubMed, Cochrane Central Register of 
      Controlled Trials (CENTRAL), Web of Science, EMBASE, CNKI, Wanfang Database. We
      will use the Review Manager 5.3 software provided by Cochrane collaborative
      network for statistical analysis. Then we assessed the quality and risk of the
      included studies and observed the outcome measures. RESULTS: This meta-analysis
      will further determine the beneficial efficacy of acupoint catgut embedding on
      obesity T2DM. CONCLUSION: The purpose of this meta-analysis is to explore the
      effect of acupoint catgut embedding intervention on obese T2DM patients, and
      provide more options for clinicians and patients to treat obese T2DM. ETHICS AND 
      DISSEMINATION: This systemic review will evaluate the efficacy and safety of
      acupoint catgut embedding in the treatment of obesity T2DM. Since all the data
      included are published, the systematic review does not need ethical approval.
      REGISTRATION NUMBER: CRD42020160801.
FAU - Piao, Chunli
AU  - Piao C
AD  - Shenzhen Hospital (Futian), Guangzhou University of Chinese Medicine, Shenzhen,
      Guangdong Province.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Changchun University of Chinese Medicine, Changchun, Jilin Province.
FAU - Fu, Huiyan
AU  - Fu H
AD  - The Third Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu
      Province, China.
FAU - Wang, Li
AU  - Wang L
AD  - Shenzhen Hospital (Futian), Guangzhou University of Chinese Medicine, Shenzhen,
      Guangdong Province.
FAU - Tang, Cheng
AU  - Tang C
AD  - Shenzhen Hospital (Futian), Guangzhou University of Chinese Medicine, Shenzhen,
      Guangdong Province.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Points/*classification
MH  - Acupuncture Therapy/*trends
MH  - Catgut/*adverse effects
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/epidemiology/*therapy
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Medicine, Chinese Traditional
MH  - Obesity/complications/*therapy
MH  - Outcome Assessment, Health Care
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7387063
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000021316 [doi]
AID - 00005792-202007240-00068 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21316. doi:
      10.1097/MD.0000000000021316.


PMID- 32791721
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Maternal bacteria to correct abnormal gut microbiota in babies born by C-section.
PG  - e21315
LID - 10.1097/MD.0000000000021315 [doi]
AB  - INTRODUCTION: There is evidence that caesarean section (CS) is associated with
      increased risk of childhood obesity, asthma, and coeliac disease. The gut
      microbiota of CS-born babies differs to those born vaginally, possibly due to
      reduced exposure to maternal vaginal bacteria during birth. Vaginal seeding is a 
      currently unproven practice intended to reduce such differences, so that the gut 
      microbiota of CS-born babies is similar to that of babies born vaginally. Our
      pilot study, which uses oral administration as a novel form of vaginal seeding,
      will assess the degree of maternal strain transfer and overall efficacy of the
      procedure for establishing normal gut microbiota development. METHODS AND
      ANALYSIS: Protocol for a single-blinded, randomized, placebo-controlled pilot
      study of a previously untested method of vaginal seeding (oral administration) in
      30 CS-born babies. A sample of maternal vaginal bacteria is obtained prior to CS,
      and mixed with 5 ml sterile water to obtain a supernatant. Healthy babies are
      randomized at 1:1 to receive active treatment (3 ml supernatant) or placebo (3 ml
      sterile water). A reference group of 15 non-randomized vaginal-born babies are
      also being recruited. Babies' stool samples will undergo whole metagenomic
      shotgun sequencing to identify potential differences in community structure
      between CS babies receiving active treatment compared to those receiving placebo 
      at age 1 month (primary outcome). Secondary outcomes include differences in
      overall gut community between CS groups (24 hours, 3 months); similarity of
      CS-seeded and placebo gut profiles to vaginally-born babies (24 hours, 1 and 3
      months); degree of maternal vaginal strain transfer in CS-born babies (24 hours, 
      1 and 3 months); anthropometry (1 and 3 months) and body composition (3 months). 
      ETHICS AND DISSEMINATION: Ethics approval by the Northern A Health and Disability
      Ethics Committee (18/NTA/49). Results will be published in peer-reviewed journals
      and presented at international conferences. REGISTRATION: Australian New Zealand 
      Clinical Trials Registry (ACTRN12618000339257).
FAU - Butler, Eadaoin M
AU  - Butler EM
AUID- ORCID: 0000-0001-5078-1851
AD  - A Better Start - National Science Challenge.
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Chiavaroli, Valentina
AU  - Chiavaroli V
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - Neonatal Intensive Care Unit, Pescara Public Hospital, Pescara, Italy.
FAU - Derraik, Jose G B
AU  - Derraik JGB
AD  - A Better Start - National Science Challenge.
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
AD  - Endocrinology Department, Children's Hospital of Zhejiang University School of
      Medicine, Hangzhou, China.
FAU - Grigg, Celia P
AU  - Grigg CP
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Wilson, Brooke C
AU  - Wilson BC
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Walker, Nicholas
AU  - Walker N
AD  - Department of Obstetrics and Gynaecology, Auckland City Hospital, Auckland
      District Health Board, New Zealand.
FAU - O'Sullivan, Justin M
AU  - O'Sullivan JM
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Cutfield, Wayne S
AU  - Cutfield WS
AD  - A Better Start - National Science Challenge.
AD  - Liggins Institute, University of Auckland, Auckland, New Zealand.
AD  - Endocrinology Department, Children's Hospital of Zhejiang University School of
      Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Placebos)
SB  - IM
MH  - Adult
MH  - Anthropometry/methods
MH  - Asthma/epidemiology/etiology
MH  - Bacterial Physiological Phenomena
MH  - Body Composition
MH  - Case-Control Studies
MH  - Celiac Disease/epidemiology/etiology
MH  - Cesarean Section/*adverse effects
MH  - Delivery, Obstetric/trends
MH  - Feces
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Metagenomics/methods
MH  - Microbiota/genetics/*physiology
MH  - New Zealand/epidemiology
MH  - Pediatric Obesity/epidemiology/etiology
MH  - Placebos/*administration & dosage
MH  - Pregnancy
MH  - Vagina/*microbiology
PMC - PMC7387037
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000021315 [doi]
AID - 00005792-202007240-00067 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21315. doi:
      10.1097/MD.0000000000021315.


PMID- 32791708
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Risk factors for anxiety and depression among pregnant women during the COVID-19 
      pandemic: A web-based cross-sectional survey.
PG  - e21279
LID - 10.1097/MD.0000000000021279 [doi]
AB  - INTRODUCTION: The article presents a protocol of a cross-sectional study of
      mental health of pregnant women in relation to the coronavirus disease 19
      (COVID-19) pandemic. The primary aim is to compare differences in anxiety and
      depression scores of pregnant women between countries affected by the COVID-19
      pandemic. The secondary aim is to assess demographic, economic, and social
      aspects affecting maternal anxiety and depression scores among pregnant women
      worldwide in the time of the COVID-19 pandemic. Finally, we will be able to
      compare differences in perception of the different aspects of the COVID-19
      pandemic (social distancing, restrictions related to delivery) between countries 
      and according to the epidemic status (number of infected patients, number of
      reported deaths). The comparisons will also be done according to the COVID-19
      status of the participants. METHODS AND ANALYSIS: It is a web-based anonymous
      survey of pregnant women living in countries affected by the COVID-19 pandemic.
      The survey is comprised of 3 sections:Web-based recruitment for health research
      has proven to be cost-effective and efficient. At current times with the COVID-19
      pandemic, limited resources and social distancing restrictions, performing a
      mental health study involving pregnant women on a large international scale
      cannot be safely conducted without involving social-media.The fears of pregnant
      women fall into 3 categories: the medical condition, the economic status and the 
      organization of daily activity.The study has received approval of the medical
      ethics committee and has been registered on Clinicaltrials.gov. Results will be
      published in peer-reviewed journals and made public through all available media.
FAU - Kajdy, Anna
AU  - Kajdy A
AUID- ORCID: 0000-0003-3581-8120
AD  - Department of Reproductive Health, Centre of Postgraduate Medical Education.
FAU - Feduniw, Stepan
AU  - Feduniw S
AD  - St. Sophia's Specialist Hospital.
AD  - Lazarski University, Faculty of Medicine.
FAU - Ajdacka, Urszula
AU  - Ajdacka U
AD  - Clinical Department of Obstetrics and Gynecology, Central Clinical Hospital of
      Ministry of Interior and Administration.
FAU - Modzelewski, Jan
AU  - Modzelewski J
AD  - Department of Reproductive Health, Centre of Postgraduate Medical Education.
FAU - Baranowska, Barbara
AU  - Baranowska B
AD  - Department of Midwifery, Centre of Postgraduate Medical Education, Warsaw.
FAU - Sys, Dorota
AU  - Sys D
AD  - Department of Reproductive Health, Centre of Postgraduate Medical Education.
FAU - Pokropek, Artur
AU  - Pokropek A
AD  - Institute of Philosophy and Sociology, Polish Academy of Sciences.
FAU - Pawlicka, Paulina
AU  - Pawlicka P
AD  - Department of Social Studies, Institute of Psychology, University of Gdansk.
FAU - Kazmierczak, Maria
AU  - Kazmierczak M
AD  - Department of Family Studies and Quality of Life, Institute of Psychology,
      University of Gdansk.
FAU - Rabijewski, Michal
AU  - Rabijewski M
AD  - Department of Reproductive Health, Centre of Postgraduate Medical Education.
FAU - Jasiak, Hanna
AU  - Jasiak H
AD  - Department Obstetrics and Gynecology, Pomeranian Medical University in Szczecin.
FAU - Lewandowska, Roksana
AU  - Lewandowska R
AD  - Department Obstetrics and Gynecology, Pomeranian Medical University in Szczecin.
FAU - Borowski, Dariusz
AU  - Borowski D
AD  - Clinic of Fetal-Maternal, Gynecology and Neonatology, Collegium Medicum, Nicolaus
      Copernicus University in Bydgoszcz, Poland.
FAU - Kwiatkowski, Sebastian
AU  - Kwiatkowski S
AD  - Department Obstetrics and Gynecology, Pomeranian Medical University in Szczecin.
FAU - Poon, Liona C
AU  - Poon LC
AD  - Department of Obstetrics and Gynecology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong SAR.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Anxiety/epidemiology/*psychology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/prevention & control/*psychology
MH  - Cross-Sectional Studies
MH  - Depression/epidemiology/*psychology
MH  - Female
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/prevention & control/*psychology
MH  - Pregnancy
MH  - Pregnancy Complications/epidemiology/*psychology
MH  - Pregnancy Complications, Infectious/prevention & control/*psychology/virology
MH  - Pregnant Women/*psychology
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7387043
EDAT- 2020/08/15 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021279 [doi]
AID - 00005792-202007240-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21279. doi:
      10.1097/MD.0000000000021279.


PMID- 32791699
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - The effectiveness and safety of traditional Chinese medicine for the treatment of
      children with COVID-19.
PG  - e21247
LID - 10.1097/MD.0000000000021247 [doi]
AB  - INTRODUCTION: With the widespread spread of novel coronavirus pneumonia, more and
      more countries have been affected. Some research reports have shown that
      traditional Chinese medicine has a significant effect on COVID-19 infection, and 
      the treatment of traditional Chinese medicine is used in some special people,
      such as children. At present, there is a lack of high-quality systematic reviews 
      on the safety and efficacy of using Chinese medicine to treat children with novel
      coronavirus pneumonia. MATERIALS AND METHODS: We will search Cochran library,
      MEDLINE, EMBASE, China National Knowledge Infrastructure Database (CNKI), China
      Biomedical Database (CBM), VIP Database (VIP), and Wanfang database for research.
      This study includes randomized controlled trials (RCTs) and non-RCTs, and uses
      the Cochrane systematic review to review the safety and efficacy of traditional
      Chinese medicine in preventing and treating children with novel coronavirus
      pneumonia. RCT research tools and quantitative research quality assessment tools 
      for non-randomized studies will be used to assess the risk of bias in studies
      included in the systematic review. We will use Revman 5.3 software for
      meta-analysis, the main result is odds ratio, and then a subgroup analysis will
      be performed based on the age, intervention degree, and disease severity of the
      patients reviewed. ETHICS AND DISSEMINATION: This systematic review protocol is
      designed to provide evidence regarding the effectiveness and safety of
      traditional Chinese medicine for the treatment of children with COVID-19, such
      evidence may be useful and important for clinical treatment decisions. The
      results should be disseminated through publication in a peer-reviewed journal.
      Since the data and results used in the systematic review will be extracted
      exclusively from published studies, approval from an ethics committee will not be
      required. REGISTRATION INFORMATION: PROSPERO CRD42020179150.
FAU - Li, Yanqing
AU  - Li Y
AUID- ORCID: 0000-0003-4696-0069
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Bi, Lin
AU  - Bi L
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Li, Yulin
AU  - Li Y
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Hu, Xiongxin
AU  - Hu X
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Quanxi
AU  - Wang Q
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Liang, Xin
AU  - Liang X
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Yu, Xujun
AU  - Yu X
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Dong, Liang
AU  - Dong L
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine.
FAU - Xie, Quan
AU  - Xie Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      P.R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - COVID-19 drug treatment
SB  - IM
EIN - Medicine (Baltimore). 2020 Aug 14;99(33):e21984. PMID: 32872085
MH  - Adolescent
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Child, Preschool
MH  - Coronavirus Infections/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Medicine, Chinese Traditional/*methods
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7386965
EDAT- 2020/08/15 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021247 [doi]
AID - 00005792-202007240-00045 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21247. doi:
      10.1097/MD.0000000000021247.


PMID- 32791681
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Effect of "Tonifying Kidney and Invigorating Brain" acupuncture in children with 
      spastic cerebral palsy analyzed by multi-modality MRI combined with dynamic
      electroencephalogram.
PG  - e21082
LID - 10.1097/MD.0000000000021082 [doi]
AB  - INTRODUCTION: Cerebral palsy is the most common motor disability of childhood.
      Spastic cerebral palsy accounts for 60% to 70% of cases. Research has shown that 
      acupuncture can improve the quality of life of children with cerebral palsy, but 
      the mechanism of action remains unclear. This study aims to determine the
      effectiveness of acupuncture for treatment of children with spastic cerebral
      palsy and to assess the value of multimodal magnetic resonance imaging (MRI) and 
      ambulatory electroencephalogram (EEG) for evaluation of treatment effect. METHODS
      AND ANALYSIS: This randomized controlled trial will enroll a total of 72 children
      with CP from 2 hospitals-Jiangsu Province Hospital of Chinese Medicine and
      Nanjing State Hospital of Pediatric-with 36 participants from each hospital.
      Patients will be randomly assigned (1:1 ratio) to receive "Tonifying Kidney and
      Invigorating Brain" acupuncture treatment plus standardized physical
      rehabilitation treatment (treatment group) or only standardized physical
      rehabilitation (control group). All participants will receive 3 treatment
      sessions per week for 3 consecutive months; they will then be followed up for
      another 3 months. The primary outcome measures will include multimodal magnetic
      resonance imaging (MRI), ambulatory electroencephalogram (EEG), and Gesell
      Developmental Diagnostic Schedules. The secondary outcome measures will include
      Gross Motor Function Classification System (GMFCS), Gross Motor Function Measure 
      (GMFM), Functional Independence Measure (WeeFIM), and Modified Ashworth Scale
      score. Outcome measures (including primary and secondary outcome measures) were
      collected at the baseline, 3 months and 6 months prior to the intervention.Ethics
      and dissemination PATIENTS CONSENT:: Obtained. ETHICS APPROVAL: The central
      independent ethics committee of Jiangsu Province Hospital of Traditional Chinese 
      Medicine approved the protocol (2017NL-115-02). SAFETY CONSIDERATIONS: Routine
      blood tests and liver and kidney function tests will be conducted to exclude
      patients with severe heart, liver, or kidney diseases. The same examinations will
      be performed again at the end of the study to detect any possible side effects.
      Possible acupuncture-related adverse events (e.g., fainting, needle stick injury,
      local infection, subcutaneous hematoma, and low-grade fever) will be documented. 
      Serious adverse events will be reported to the principal investigator
      immediately. All unexpected and unintended responses, even those not necessarily 
      related to the acupuncture intervention, will be documented as adverse events.
      CASE DROPOUT MANAGEMENT: Participants have a right to withdraw from the study at 
      any time if they feel uncomfortable upon receiving the treatments or being
      diagnosed with serious complications or diseases. They will then be referred to
      the preferred department for further treatment and management. If cases of
      dropout, the researcher need to contact the participant to reason the problem
      out, collect and record all the necessary assessments on the last visit as well
      as the date of last visit. All data available until the date of withdrawal will
      be stored for further statistical analysis. DISCUSSION: This research is being
      conducted to assess the value of acupuncture as an intervention for
      rehabilitation of children with spastic cerebral palsy and also to evaluate the
      usefulness of multimodal MRI and ambulatory EEG for identifying changes in brain 
      function. TRIAL REGISTRATION: This trial is registered with Chinese Clinical
      Trials Register, ChiCTR 1900024546 (registered 15 July 2019; retrospective
      registration, http://www.chictr.org.cn/showproj.aspx?proj=35763).
FAU - Chen, Dong
AU  - Chen D
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Bao, Chao
AU  - Bao C
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Geng, Yan-Xia
AU  - Geng YX
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Yang, Ming
AU  - Yang M
AD  - Childrens Hospital of Nanjing Medical University, Nanjing, China.
FAU - Teo, Elsie Sin May
AU  - Teo ESM
AUID- ORCID: 0000-0002-4537-2989
AD  - Nanjing University of Traditional Chinese Medicine.
FAU - Li, Jan-Bing
AU  - Li JB
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Li, Yan-Cai
AU  - Li YC
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Wang, Nan
AU  - Wang N
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Yuan, Meng-Qian
AU  - Yuan MQ
AD  - Department of Acupuncture, Jiangsu Province Hospital of Traditional Chinese
      Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese
      Medicine.
FAU - Zou, Qin
AU  - Zou Q
AD  - Nanjing University of Traditional Chinese Medicine.
FAU - Tang, Ping-Ping
AU  - Tang PP
AD  - Nanjing University of Traditional Chinese Medicine.
FAU - Zhu, Li-Li
AU  - Zhu LL
AD  - Nanjing University of Traditional Chinese Medicine.
FAU - Xu, Bin
AU  - Xu B
AD  - Nanjing University of Traditional Chinese Medicine.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture
MH  - Brain/diagnostic imaging/physiopathology
MH  - Cerebral Palsy/diagnostic imaging/*physiopathology/rehabilitation/*therapy
MH  - Child
MH  - Child Development
MH  - Electroencephalography
MH  - Humans
MH  - Kidney
MH  - Magnetic Resonance Imaging
MH  - Motor Skills
MH  - Randomized Controlled Trials as Topic
PMC - PMC7386969
EDAT- 2020/08/15 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 10.1097/MD.0000000000021082 [doi]
AID - 00005792-202007240-00027 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21082. doi:
      10.1097/MD.0000000000021082.


PMID- 32791678
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Chinese Herbs Medicine Huatan Huoxue Prescription for obstructive sleep apnea
      hypopnea syndrome as complementary therapy: A protocol for a systematic review
      and meta-analysis.
PG  - e21070
LID - 10.1097/MD.0000000000021070 [doi]
AB  - OBJECTIVE: The aim of this systematic review and meta-analysis is to assess
      effectiveness and safety of Chinese Herbs Medicine Huatan Huoxue Prescription
      (HTHXP) as complementary therapy in treating bronchiectasis. METHODS: The
      following databases will be searched: Embase, Cochrane, PubMed, China National
      Knowledge Infrastructure, Wan Fang, and VIP database from their inception to
      April 1, 2020. We performed and completed meta-analysis and methodologic
      evaluation by Review Manager 5.3.3 and statas 12.0 software. Study selection,
      data extraction, quality assessment, and assessment of risk bias will be
      performed by 2 reviewers independently. Odds ratios and correlative 95%
      confidence intervals will be calculated to present the association between the
      HTHXP and western medicine treatment using Review Manager version 5.3 when there 
      is sufficient available data. RESULTS: The results will be disseminated through a
      peer-reviewed journal publication. CONCLUSION: These systematic review findings
      will summarize up-to-date evidence for that HTHXP is more effective and safe as
      adjunctive treatment for patients with bronchiectasis. ETHICS AND DISSEMINATION: 
      Ethics approval and patient consent are not required as this study is a
      systematic review based on published articles. PROSPERO REGISTRATION NUMBER:
      INPLASY202050079.
FAU - Zhou, Min
AU  - Zhou M
AUID- ORCID: 0000-0001-6739-3919
AD  - College of Clinical Medical, Jiangxi University of Traditional Chinese Medicine.
FAU - Liang, Qijun
AU  - Liang Q
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang.
FAU - Pei, QiuLan
AU  - Pei Q
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,
      Nanchang.
FAU - Xu, Fan
AU  - Xu F
AD  - College of Clinical Medical, Jiangxi University of Traditional Chinese Medicine.
FAU - Wen, Hang
AU  - Wen H
AD  - College of Clinical Medical, Shanghai University of Traditional Chinese Medicine,
      Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (huatan huoxue)
SB  - IM
MH  - Complementary Therapies
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Sleep Apnea, Obstructive/*drug therapy
MH  - Syndrome
MH  - Systematic Reviews as Topic
PMC - PMC7386983
EDAT- 2020/08/15 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 10.1097/MD.0000000000021070 [doi]
AID - 00005792-202007240-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e21070. doi:
      10.1097/MD.0000000000021070.


PMID- 32791669
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Diagnostic value of a spiral breast computed tomography system equipped with
      photon counting detector technology in patients with implants: An observational
      study of our initial experiences.
PG  - e20797
LID - 10.1097/MD.0000000000020797 [doi]
AB  - To evaluate the value of a breast computed tomography (CT) (B-CT) in assessing
      breast density, pathologies and implant integrity in women with breast
      implants.This retrospective study was approved by the local ethics committee.
      B-CT images of 21 women with implants (silicone/saline; 20 bilateral, 1
      unilateral) who underwent opportunistic screening or diagnostic bilateral B-CT
      were included. Breast density, implant integrity, extensive capsular fibrosis,
      soft tissue lesions and micro-/macrocalcifications were rated. In 18 of the 21
      women, an additional ultrasound and in two patients breast magnetic resonance
      imaging was available for comparison. The average dose was calculated for each
      breast using verified Monte Carlo simulations on 3D image data sets.Breast
      density was nearly completely fatty (ACR a) in two patients, scattered
      fibroglandular (ACR b) in five, heterogeneously dense (ACR c) in ten and very
      dense (ACR d) in four women. In three women showed a unilateral positive Linguine
      sign indicative of an inner capsule rupture. Extensive capsular fibrosis was
      found in three women. In three women, soft tissue lesions were depicted, which
      revealed to be cysts (n = 2) and lymph nodes (n = 1) on subsequent sonography.
      Diffuse, non-clustered microcalcifications were found in nine women. Eleven women
      showed cutaneous or intramammary macrocalcifications. Average dose was 6.45 mGy
      (range 5.81-7.28 mGy).In women with implants, B-CT presents a promising modality 
      for evaluating breast density, implant integrity, extensive capsular fibrosis,
      soft tissue lesions and micro-/macrocalcifications without the need of breast
      compression utilizing a lower dose compared to doses reported for conventional
      four-view mammography.
FAU - Ruby, Lisa
AU  - Ruby L
AD  - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich,
      Ramistrasse, Zurich, Switzerland.
FAU - Shim, Sojin
AU  - Shim S
FAU - Berger, Nicole
AU  - Berger N
FAU - Marcon, Magda
AU  - Marcon M
FAU - Frauenfelder, Thomas
AU  - Frauenfelder T
FAU - Boss, Andreas
AU  - Boss A
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast/*diagnostic imaging/pathology
MH  - Breast Diseases/*diagnostic imaging
MH  - *Breast Implants
MH  - Female
MH  - Fibrosis
MH  - Humans
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Tomography, Spiral Computed
PMC - PMC7387031
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000020797 [doi]
AID - 00005792-202007240-00015 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e20797. doi:
      10.1097/MD.0000000000020797.


PMID- 32791668
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - The effect of acupuncture on the quality of life of patients recovering from
      COVID-19: A systematic review protocol.
PG  - e20780
LID - 10.1097/MD.0000000000020780 [doi]
AB  - BACKGROUND: Assessing the effectiveness and safety of acupuncture therapy for
      treating patients with COVID-19 is the main purpose of this systematic review
      protocol. METHODS: The following electronic databases will be searched from
      inception to May 2020: Cochrane Central Register of Controlled Trials, PubMed,
      Web of Science, EMBASE, China National Knowledge Infrastructure, Traditional
      Chinese Medicine, Chinese Biomedical Literature Database, Wan-Fang Database, and 
      Chinese Scientific Journal Database. All published randomized controlled trials
      in English or Chinese related to acupuncture for COVID-19 will be included.
      Primary outcomes are timing of the disappearance of the main symptoms (including 
      fever, asthenia, cough disappearance rate, and temperature recovery time), and
      serum cytokine levels. Secondary outcomes are timing of the disappearance of
      accompanying symptoms (such as myalgia, expectoration, stuffiness, runny nose,
      pharyngalgia, anhelation, chest distress, dyspnea, crackles, headache, nausea,
      vomiting, anorexia, diarrhea), negative COVID-19 results rates on two consecutive
      occasions (not on the same day), CT image improvement, average hospitalization
      time, occurrence rate of common type to severe form, clinical cure rate, and
      mortality. RESULTS: The results will provide a high-quality synthesis of current 
      evidence for researchers in this subject area. CONCLUSION: The conclusion of our 
      study will provide an evidence to judge whether acupuncture is an effective
      intervention for patients suffered from COVID-19. ETHICS AND DISSEMINATION:
      Formal ethical approval is not necessary as the data cannot be individualized.
      The results of this protocol will be disseminated in a peer-reviewed journal or
      presented at relevant conferences. PROSPERO REGISTRATION NUMBER: CRD42020183736.
FAU - Wen, Dengpeng
AU  - Wen D
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Wu, Liu
AU  - Wu L
AD  - Department of Tuina, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan province, P.R. China.
FAU - Dong, Yuting
AU  - Dong Y
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Huang, Ju
AU  - Huang J
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Ren, Kuiyu
AU  - Ren K
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Jiang, Jianzhen
AU  - Jiang J
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Dai, Shunxin
AU  - Dai S
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Zhao, Wei
AU  - Zhao W
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Xu, Xinwei
AU  - Xu X
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Peng, Dezhong
AU  - Peng D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Adolescent
MH  - Adult
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*psychology/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology/*therapy
MH  - *Quality of Life
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7386980
EDAT- 2020/08/15 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000020780 [doi]
AID - 00005792-202007240-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e20780. doi:
      10.1097/MD.0000000000020780.


PMID- 32791666
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20220716
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - The effectiveness of thunder fire moxibustion for treating allergic rhinitis: A
      protocol for systematic review and meta analysis.
PG  - e20711
LID - 10.1097/MD.0000000000020711 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR) is a chronic disease, resulting in severe
      syndromes such as sneezing, itching, nasal blockage, and rhinorrhea. The major
      medications treating AR cause side effects, while thunder fire moxibustion (TFM) 
      is known as a safe and effective treatment for AR. Thus, this systematic review
      and meta analysis aims to systematically evaluate the effectiveness and safety of
      TFM in the treatment of AR. METHODS: Nine databases, including Medline, PubMed,
      Web of Science, Embase, the Cochrane Library, China National Knowledge
      Infrastructure Database (CNKI), WanFang Database (WF), Chinese Scientific Journal
      Database (VIP), and Chinese Biomedical Literature Database (CBM) from inception
      to July 2020 will be searched. In addition, the grey literature and the
      references of all included literature will be retrieved manually. Reviewers will 
      identify studies, extract data and assess the quality independently. The outcomes
      of interest include: total nasal symptom score, total non-nasal symptom score,
      rhinitis quality of life questionnaire, visual analog scale, Laboratory
      indicators: serum immunoglobulin E, immunoglobulin A, or immunoglobulin G level
      and adverse events. Randomized clinical trials will be collected, methodological 
      quality will be evaluated using the Cochrane risk-of-bias assessment tool, and
      the level of evidence will be rated using the Grading of Recommendations,
      Assessment, Development and Evaluation (GRADE) approach. Meta-analysis will be
      performed using RevMan5.3.0 software. RESULTS: Because the review is ongoing, no 
      results can be reported. CONCLUSIONS: The findings from this review will provide 
      reliable evidence for effectiveness and safety of TFM for AR. ETHICS AND
      DISSEMINATION: Ethical approval requirements are not necessary for this review.
      This systematic review and meta analysis will be disseminated online and on paper
      to help guide the clinical practice better. PROSPERO REGISTRATION NUMBER:
      CRD42019141113.
FAU - Xiong, Jun
AU  - Xiong J
AD  - Department of Acupuncture and Moxibustion, The Affiliated Hospital with Jiangxi
      University of TCM.
FAU - Yuan, Ting
AU  - Yuan T
AUID- ORCID: 0000-0002-6630-2816
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine, Nanchang.
FAU - Huang, Qiaotong
AU  - Huang Q
AD  - The First Affiliated Hospital of Guangxi University of Traditional Chinese
      Medicine, Nanning, China.
FAU - Wang, Xue
AU  - Wang X
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine, Nanchang.
FAU - Yang, Jun
AU  - Yang J
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine, Nanchang.
FAU - Jiang, Yunfeng
AU  - Jiang Y
AD  - Department of Acupuncture and Moxibustion, The Affiliated Hospital with Jiangxi
      University of TCM.
FAU - Zhou, Xiaohong
AU  - Zhou X
AD  - Department of Acupuncture and Moxibustion, The Affiliated Hospital with Jiangxi
      University of TCM.
FAU - Liao, Kai
AU  - Liao K
AD  - Department of Acupuncture and Moxibustion, The Affiliated Hospital with Jiangxi
      University of TCM.
FAU - Xu, Lingling
AU  - Xu L
AD  - Department of Acupuncture and Moxibustion, The Affiliated Hospital with Jiangxi
      University of TCM.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Moxibustion
MH  - Rhinitis, Allergic/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7386999
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000020711 [doi]
AID - 00005792-202007240-00012 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e20711. doi:
      10.1097/MD.0000000000020711.


PMID- 32791658
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Early mobilization for children in intensive therapy: A protocol for systematic
      review and meta-analysis.
PG  - e20357
LID - 10.1097/MD.0000000000020357 [doi]
AB  - INTRODUCTION: Intensive care units focus primarily on life support and treatment 
      of critically ill patients, but there are many survivors with complications, such
      as generalized muscle disorders, functional disability and reduced quality of
      life after hospital discharge, resulting from prolonged stays in these units. The
      current evidence suggests that early mobilization-based rehabilitation (exercise 
      initiated immediately after the patient's significant physiological changes have 
      stabilized) in critically ill adults can alleviate these complications from
      immobility and critical illness. However, there are a lack of practice
      guidelines, conflicting perceptions about safety, and knowledge gaps about
      benefits in the critically ill paediatric population. Therefore, we aim to assess
      the effects of early mobilization for children in intensive therapy. METHODS AND 
      ANALYSIS: Systematic searches will be carried out in Medical Literature Analysis 
      and Retrieval System Online, Excerpta Medica database, Cochrane Central Register 
      of Controlled Trials, Latin American and Caribbean Centre on Health Sciences
      Information, Cumulative Index to Nursing & Allied Health Literature and
      physiotherapy evidence database databases at a minimum without date or language
      restrictions for relevant individual parallel, cross-over and cluster randomized 
      controlled trials. In addition, a search will also be carried out in the World
      Health Organization International Clinical Trials Registry Platform, and in the
      clinical trial registries of ClinicalTrials.gov, looking for any on-going
      randomised controlled trials that compare early mobilization with any other type 
      of intervention. Two review authors will independently perform data extraction
      and quality assessments of data from included studies, and any disagreements will
      be resolved by discussion or by arbitration. The primary outcomes will be
      mortality and adverse events. Secondary outcomes will include duration of
      critical care (days), duration of mechanical ventilation support, muscle
      strength, pain and neuropsychomotor development. The Cochrane handbook will be
      used for guidance. If the results are not appropriate for a meta-analysis in
      RevMan 5 software (e.g., if the data have considerable heterogeneity and are
      drawn from different comparisons), a descriptive analysis will be performed.
      ETHICS AND DISSEMINATION: This protocol was prospectively registered at Open
      Science Framework and approved by the Ethics and Research Committee of the
      Federal University of Sao Paulo (8543210519). We intend to update the public
      registry used in this review, report any important protocol amendments and
      publish the results in a widely accessible journal. REGISTRATION:: osf.io/ebju9.
FAU - Gomes, Samantha Guerra Cabo Nunes
AU  - Gomes SGCN
AUID- ORCID: 0000-0001-6440-8011
AD  - Division of Evidence-based Medicine, Department of Medicine, Universidade Federal
      de Sao Paulo, Brazil.
FAU - Nakano, Luis Carlos Uta
AU  - Nakano LCU
AUID- ORCID: 0000-0002-7996-3269
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Brazil.
FAU - Pinto, Ana Carolina Pereira Nunes
AU  - Pinto ACPN
AD  - Division of Evidence-based Medicine, Department of Medicine, Universidade Federal
      de Sao Paulo, Brazil / Department of Physical Therapy, University of Pittsburgh, 
      USA.
FAU - Avila, Rafael Bernardes de
AU  - Avila RB
AUID- ORCID: 0000-0003-2049-8080
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Brazil.
FAU - Santos, Felipe Kenzo Yadoya
AU  - Santos FKY
AUID- ORCID: 0000-0002-2006-7945
AD  - Undergraduate student of medicine, Escola Paulista de Medicina, Universidade
      Federal de Sao Paulo, Brazil.
FAU - Areias, Libnah Leal
AU  - Areias LL
AUID- ORCID: 0000-0001-9563-8047
AD  - Undergraduate student of medicine, Escola Paulista de Medicina, Universidade
      Federal de Sao Paulo, Brazil.
FAU - Trevisani, Virginia Fernandes Mo A
AU  - Trevisani VFMA
AUID- ORCID: 0000-0002-7180-6285
AD  - Division of Evidence-based Medicine, Department of Medicine, Universidade Federal
      de Sao Paulo, Brazil.
FAU - Guedes Neto, Henrique Jorge
AU  - Guedes Neto HJ
AUID- ORCID: 0000-0001-6477-1822
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Brazil.
FAU - Flumignan, Ronald Luiz Gomes
AU  - Flumignan RLG
AUID- ORCID: 0000-0001-6440-8011
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Child
MH  - *Critical Care
MH  - *Early Ambulation
MH  - Humans
MH  - *Intensive Care Units, Pediatric
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7387058
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000020357 [doi]
AID - 00005792-202007240-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e20357. doi:
      10.1097/MD.0000000000020357.


PMID- 32791657
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 30
DP  - 2020 Jul 24
TI  - Peripherally inserted central catheter versus central venous catheter for
      intravenous access: A protocol for systematic review and meta-analysis.
PG  - e20352
LID - 10.1097/MD.0000000000020352 [doi]
AB  - BACKGROUND: Since the first description of the central venous catheter (CVC) in
      1952, it has been used for the rapid administration of drugs, chemotherapy, as a 
      route for nutritional support, blood components, monitoring patients, or
      combinations of these. When CVC is used in the traditional routes (eg,
      subclavian, jugular, and femoral veins), the complication rates range up to 15%
      and are mainly due to mechanical dysfunction, infection, and thrombosis. The
      peripherally inserted central catheter (PICC) is an alternative option for CVC
      access. However, the clinical evidence for PICC compared to CVC is still under
      discussion. In this setting, this systematic review (SR) aims to assess the
      effects of PICC compared to CVC for intravenous access. METHODS: We will perform 
      a comprehensive search for randomised controlled trials (RCTs), which compare
      PICC and traditional CVC for intravenous access. The search strategy will
      consider free text terms and controlled vocabulary (eg, MeSH and Entree) related 
      to "peripherally inserted central venous catheter," "central venous access,"
      "central venous catheter," "catheterisation, peripheral," "vascular access
      devices," "infusions, intravenous," "administration, intravenous," and
      "injections, intravenous." Searches will be carried out in these databases:
      MEDLINE (via PubMed), EMBASE (via Elsevier), Cochrane CENTRAL (via Wiley), IBECS,
      and LILACS (both via Virtual Health Library). We will consider catheter-related
      deep venous thrombosis and overall successful insertion rates as primary outcomes
      and haematoma, venous thromboembolism, reintervention derived from catheter
      dysfunction, catheter-related infections, and quality of life as secondary
      outcomes. Where results are not appropriate for a meta-analysis using RevMan 5
      software (eg, if the data have considerable heterogeneity and are drawn from
      different comparisons), a descriptive analysis will be performed. RESULTS: Our SR
      will be conducted according to the Cochrane Handbook of Systematic Reviews of
      Interventions and the findings will be reported in compliance with PRISMA.
      CONCLUSION: Our study will provide evidence for the effects of PICC versus CVC
      for venous access. ETHICS AND DISSEMINATION: This SR has obtained formal ethical 
      approval and was prospectively registered in Open Science Framework. The findings
      of this SR will be disseminated through peer-reviewed publications or conference 
      presentations. REGISTRATION:: osf.io/xvhzf. ETHICAL APPROVAL:
      69003717.2.0000.5505.
FAU - Santos, Felipe Kenzo Yadoya
AU  - Santos FKY
AUID- ORCID: 0000-0002-2006-7945
AD  - Undergraduate student of medicine.
FAU - Flumignan, Ronald Luiz Gomes
AU  - Flumignan RLG
AUID- ORCID: 0000-0001-6440-8011
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Areias, Libnah Leal
AU  - Areias LL
AUID- ORCID: 0000-0001-9563-8047
AD  - Undergraduate student of medicine.
FAU - Sarpe, Anna Karina Paiva
AU  - Sarpe AKP
AUID- ORCID: 0000-0002-2210-4367
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Amaral, Fabio Cabral Freitas
AU  - Amaral FCF
AUID- ORCID: 0000-0002-1847-4939
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Avila, Rafael Bernardes de
AU  - Avila RB
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Vasconcelos, Vladimir Tonello de
AU  - Vasconcelos VT
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Guedes Neto, Henrique Jorge
AU  - Guedes Neto HJ
AUID- ORCID: 0000-0001-6477-1822
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Amorim, Jorge Eduardo de
AU  - Amorim JE
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
FAU - Nakano, Luis Carlos Uta
AU  - Nakano LCU
AUID- ORCID: 0000-0002-7996-3269
AD  - Division of Vascular and Endovascular Surgery, Department of Surgery, Escola
      Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo-SP, Brazil.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Catheterization, Central Venous
MH  - *Catheterization, Peripheral
MH  - *Central Venous Catheters
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7386962
EDAT- 2020/08/15 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/15 06:00
PHST- 2020/08/15 06:00 [entrez]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000020352 [doi]
AID - 00005792-202007240-00003 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 24;99(30):e20352. doi:
      10.1097/MD.0000000000020352.


PMID- 32791551
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20201218
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 145
IP  - 16
DP  - 2020 Aug
TI  - [Current ethical challenges in intensive care in the face of the corona
      pandemic].
PG  - 1152-1156
LID - 10.1055/a-1068-4183 [doi]
AB  - In view of dramatically increasing patient numbers worldwide in the face of the
      corona pandemic and scarce resources in intensive care medicine in many
      countries, some of which are dramatically undersupplied, concerns and fears have 
      spread among the population in Germany. Healthcare workers didn't know how to
      deal with an overload of the healthcare system. Numerous inquiries from concerned
      physicians as well as ethics committees prompted the German Interdisciplinary
      Association for Intensive Care and Emergency Medicine (DIVI) together with seven 
      other medical associations to work out a clinical-ethical recommendation on
      "Decisions on resource allocation in emergency and intensive care in the context 
      of the COVID-19 pandemic".
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Janssens, Uwe
AU  - Janssens U
AD  - Klinik fur Innere Medizin und Internistische Intensivmedizin,
      St.-Antonius-Hospital, Eschweiler.
LA  - ger
PT  - Journal Article
TT  - Aktuelle ethische Herausforderungen in der Intensivmedizin angesichts der
      Corona-Pandemie.
DEP - 20200813
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
MH  - Advance Care Planning/ethics
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Critical Care/*ethics/statistics & numerical data
MH  - Emergency Medicine/ethics/statistics & numerical data
MH  - Germany/epidemiology
MH  - Health Priorities/ethics
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*therapy
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/08/14 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - 10.1055/a-1068-4183 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2020 Aug;145(16):1152-1156. doi: 10.1055/a-1068-4183. Epub 
      2020 Aug 13.


PMID- 32791033
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20211102
IS  - 1468-2877 (Electronic)
IS  - 0033-3549 (Linking)
VI  - 135
IP  - 6
DP  - 2020 Nov/Dec
TI  - The Role of Law and Ethics in Recent Preparedness and Response for
      Vaccine-Preventable Illness.
PG  - 851-855
LID - 10.1177/0033354920949532 [doi]
FAU - Silverman, Ross D
AU  - Silverman RD
AUID- ORCID: 0000-0003-4492-3096
AD  - 124006 Indiana University Richard M. Fairbanks School of Public Health,
      Indianapolis, IN, USA.
AD  - Indiana University Robert H. McKinney School of Law, Indianapolis, IN, USA.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - United States
TA  - Public Health Rep
JT  - Public health reports (Washington, D.C. : 1974)
JID - 9716844
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/prevention & control
MH  - Disease Outbreaks/*prevention & control
MH  - Humans
MH  - Immunization Programs
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/prevention & control
MH  - Schools
MH  - State Government
MH  - Vaccination/*ethics/*legislation & jurisprudence
MH  - Vaccination Refusal/ethics/legislation & jurisprudence
MH  - Vaccine-Preventable Diseases/*prevention & control
PMC - PMC7649990
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *child health
OT  - *communicable diseases
OT  - *ethics
OT  - *health policy
OT  - *infectious disease
OT  - *law/legal issues
OT  - *parenting
OT  - *public health practice
OT  - *school health
OT  - *vaccines
EDAT- 2020/08/14 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1177/0033354920949532 [doi]
PST - ppublish
SO  - Public Health Rep. 2020 Nov/Dec;135(6):851-855. doi: 10.1177/0033354920949532.
      Epub 2020 Aug 13.


PMID- 32790716
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 14
IP  - 8
DP  - 2020 Aug
TI  - Xenodiagnosis to address key questions in visceral leishmaniasis control and
      elimination.
PG  - e0008363
LID - 10.1371/journal.pntd.0008363 [doi]
AB  - Visceral leishmaniasis (VL) remains an important public health issue worldwide
      causing substantial morbidity and mortality. The Indian subcontinent accounted
      for up to 90% of the global VL burden in the past but made significant progress
      during recent years and is now moving towards elimination. However, to achieve
      and sustain elimination of VL, knowledge gaps on infection reservoirs and
      transmission need to be addressed urgently. Xenodiagnosis is the most direct way 
      for testing the infectiousness of hosts to the vectors and can be used to
      investigate the dynamics and epidemiology of Leishmania donovani transmission.
      There are, however, several logistic and ethical issues with xenodiagnosis that
      need to be addressed before its application on human subjects. In the current
      Review, we discuss the critical knowledge gaps in VL transmission and the role of
      xenodiagnosis in disease transmission dynamics along with its technical
      challenges. Establishment of state of the art xenodiagnosis facilities is
      essential for the generation of much needed evidence in the VL elimination
      initiative.
FAU - Singh, Om Prakash
AU  - Singh OP
AD  - Department of Biochemistry, Institute of Science, Banaras Hindu University,
      Varanasi, India.
AD  - Infectious Diseases Research Laboratory, Department of Medicine, Institute of
      Medical Sciences, Banaras Hindu University, Varanasi, India.
FAU - Hasker, Epco
AU  - Hasker E
AD  - Department of Public Health, Institute of Tropical Medicine Antwerp, Belgium.
FAU - Boelaert, Marleen
AU  - Boelaert M
AD  - Department of Public Health, Institute of Tropical Medicine Antwerp, Belgium.
FAU - Sacks, David
AU  - Sacks D
AD  - Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious
      Diseases, National Institute of Health, Bethesda, Maryland, United States of
      America.
FAU - Sundar, Shyam
AU  - Sundar S
AUID- ORCID: 0000-0001-9988-582X
AD  - Infectious Diseases Research Laboratory, Department of Medicine, Institute of
      Medical Sciences, Banaras Hindu University, Varanasi, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200813
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
SB  - IM
MH  - Animals
MH  - Asia
MH  - Asymptomatic Diseases
MH  - Disease Reservoirs/parasitology
MH  - Humans
MH  - Leishmania donovani/physiology
MH  - Leishmaniasis, Visceral/*diagnosis/*transmission
MH  - Phlebotomus/*parasitology
MH  - *Xenodiagnosis
PMC - PMC7425851
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1371/journal.pntd.0008363 [doi]
AID - PNTD-D-19-00620 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2020 Aug 13;14(8):e0008363. doi:
      10.1371/journal.pntd.0008363. eCollection 2020 Aug.


PMID- 32790699
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Replicating and extending the effects of auditory religious cues on dishonest
      behavior.
PG  - e0237007
LID - 10.1371/journal.pone.0237007 [doi]
AB  - Although scientists agree that replications are critical to the debate on the
      validity of religious priming research, religious priming replications are
      scarce. This paper attempts to replicate and extend previously observed effects
      of religious priming on ethical behavior. We test the effect of religious
      instrumental music on individuals' ethical behavior with university participants 
      (N = 408) in the Czech Republic, Japan, and the US. Participants were randomly
      assigned to listen to one of three musical tracks (religious, secular, or white
      noise) or to no music (control) for the duration of a decision-making game.
      Participants were asked to indicate which side of a vertically-bisected computer 
      screen contained more dots and, in every trial, indicating that the right side of
      the screen had more dots earned participants the most money (irrespective of the 
      number of dots). Therefore, participants were able to report dishonestly to earn 
      more money. In agreement with previous research, we did not observe any main
      effects of condition. However, we were unable to replicate a moderating effect of
      self-reported religiosity on the effects of religious music on ethical behavior. 
      Nevertheless, further analyses revealed moderating effects for ritual
      participation and declared religious affiliation congruent with the musical
      prime. That is, participants affiliated with a religious organization and taking 
      part in rituals cheated significantly less than their peers when listening to
      religious music. We also observed significant differences in cheating behavior
      across samples. On average, US participants cheated the most and Czech
      participants cheated the least. We conclude that normative conduct is, in part,
      learned through active membership in religious communities and our findings
      provide further support for religious music as a subtle, moral cue.
FAU - Nichols, Aaron D
AU  - Nichols AD
AUID- ORCID: 0000-0003-2536-5850
AD  - Questrom School of Business, Boston University, Boston, MA, United States of
      America.
AD  - Social Sciences Research Institute, Duke University, Durham, NC, United States of
      America.
FAU - Lang, Martin
AU  - Lang M
AUID- ORCID: 0000-0002-2231-1059
AD  - LEVYNA Laboratory for the Experimental Research of Religion, Masaryk University, 
      Brno, Czech Republic.
FAU - Kavanagh, Christopher
AU  - Kavanagh C
AD  - Institute of Cognitive & Evolutionary Anthropology, University of Oxford, Oxford,
      United Kingdom.
AD  - Department of Behavioral Science, Hokkaido University, Sapporo, Japan.
FAU - Kundt, Radek
AU  - Kundt R
AD  - LEVYNA Laboratory for the Experimental Research of Religion, Masaryk University, 
      Brno, Czech Republic.
FAU - Yamada, Junko
AU  - Yamada J
AD  - Department of Behavioral Science, Hokkaido University, Sapporo, Japan.
FAU - Ariely, Dan
AU  - Ariely D
AD  - Social Sciences Research Institute, Duke University, Durham, NC, United States of
      America.
FAU - Mitkidis, Panagiotis
AU  - Mitkidis P
AD  - Social Sciences Research Institute, Duke University, Durham, NC, United States of
      America.
AD  - Department of Management, Aarhus University, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Cultural Comparison
MH  - Cues
MH  - Czech Republic
MH  - Decision Making/ethics
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - *Morals
MH  - *Music
MH  - *Religion
MH  - United States
MH  - Video Games/ethics
MH  - Young Adult
PMC - PMC7425871
COIS- NO. The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1371/journal.pone.0237007 [doi]
AID - PONE-D-20-04631 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 13;15(8):e0237007. doi: 10.1371/journal.pone.0237007.
      eCollection 2020.


PMID- 32790668
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20210617
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 14
IP  - 8
DP  - 2020 Aug
TI  - Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia 
      and mild clinical disease in cynomolgus monkeys.
PG  - e0008637
LID - 10.1371/journal.pntd.0008637 [doi]
AB  - BACKGROUND: Development of vaccines and therapies against Crimean-Congo
      hemorrhagic fever virus (CCHFV) have been hindered by the lack of immunocompetent
      animal models. Recently, a lethal nonhuman primate model based on the CCHFV Hoti 
      strain was reported. CCHFV Hoti caused severe disease in cynomolgus monkeys with 
      75% lethality when given by the intravenous (i.v.) route. METHODOLOGY/PRINCIPAL
      FINDINGS: In a series of experiments, eleven cynomologus monkeys were exposed
      i.v. to CCHFV Hoti and four macaques were exposed i.v. to CCHFV Afghanistan.
      Despite transient viremia and changes in clinical pathology such as leukopenia
      and thrombocytopenia developing in all 15 animals, all macaques survived to the
      study endpoint without developing severe disease. CONCLUSIONS/SIGNIFICANCE: We
      were unable to attribute differences in the results of our study versus the
      previous report to differences in the CCHFV Hoti stock, challenge dose, origin,
      or age of the macaques. The observed differences are most likely the result of
      the outbred nature of macaques and low animal numbers often used by necessity and
      for ethical considerations in BSL-4 studies. Nonetheless, while we were unable to
      achieve severe disease or lethality, the CCHFV Hoti and Afghanistan macaque
      models are useful for screening medical countermeasures using biomarkers
      including viremia and clinical pathology to assess efficacy.
FAU - Cross, Robert W
AU  - Cross RW
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Prasad, Abhishek N
AU  - Prasad AN
AUID- ORCID: 0000-0002-4147-2077
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Borisevich, Viktoriya
AU  - Borisevich V
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Geisbert, Joan B
AU  - Geisbert JB
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Agans, Krystle N
AU  - Agans KN
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Deer, Daniel J
AU  - Deer DJ
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Fenton, Karla A
AU  - Fenton KA
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
FAU - Geisbert, Thomas W
AU  - Geisbert TW
AUID- ORCID: 0000-0003-0858-1877
AD  - Galveston National Laboratory, University of Texas Medical Branch, Galveston,
      Texas, United States of America.
AD  - Department of Microbiology & Immunology, University of Texas Medical Branch,
      Galveston, Texas, United States of America.
LA  - eng
GR  - R01 AI132246/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
SB  - IM
MH  - Afghanistan
MH  - Animals
MH  - Chemokines/blood
MH  - Cytokines/blood
MH  - Disease Models, Animal
MH  - Female
MH  - Hemorrhagic Fever Virus, Crimean-Congo/*immunology
MH  - Hemorrhagic Fever, Crimean/pathology/*virology
MH  - Humans
MH  - Macaca fascicularis
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - *Viremia
PMC - PMC7447009
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/12/05 00:00 [received]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1371/journal.pntd.0008637 [doi]
AID - PNTD-D-19-02066 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2020 Aug 13;14(8):e0008637. doi:
      10.1371/journal.pntd.0008637. eCollection 2020 Aug.


PMID- 32790666
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20200929
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Evolution and impact of bias in human and machine learning algorithm interaction.
PG  - e0235502
LID - 10.1371/journal.pone.0235502 [doi]
AB  - Traditionally, machine learning algorithms relied on reliable labels from experts
      to build predictions. More recently however, algorithms have been receiving data 
      from the general population in the form of labeling, annotations, etc. The result
      is that algorithms are subject to bias that is born from ingesting unchecked
      information, such as biased samples and biased labels. Furthermore, people and
      algorithms are increasingly engaged in interactive processes wherein neither the 
      human nor the algorithms receive unbiased data. Algorithms can also make biased
      predictions, leading to what is now known as algorithmic bias. On the other hand,
      human's reaction to the output of machine learning methods with algorithmic bias 
      worsen the situations by making decision based on biased information, which will 
      probably be consumed by algorithms later. Some recent research has focused on the
      ethical and moral implication of machine learning algorithmic bias on society.
      However, most research has so far treated algorithmic bias as a static factor,
      which fails to capture the dynamic and iterative properties of bias. We argue
      that algorithmic bias interacts with humans in an iterative manner, which has a
      long-term effect on algorithms' performance. For this purpose, we present an
      iterated-learning framework that is inspired from human language evolution to
      study the interaction between machine learning algorithms and humans. Our goal is
      to study two sources of bias that interact: the process by which people select
      information to label (human action); and the process by which an algorithm
      selects the subset of information to present to people (iterated algorithmic bias
      mode). We investigate three forms of iterated algorithmic bias (personalization
      filter, active learning, and random) and how they affect the performance of
      machine learning algorithms by formulating research questions about the impact of
      each type of bias. Based on statistical analyses of the results of several
      controlled experiments, we found that the three different iterated bias modes, as
      well as initial training data class imbalance and human action, do affect the
      models learned by machine learning algorithms. We also found that iterated filter
      bias, which is prominent in personalized user interfaces, can lead to more
      inequality in estimated relevance and to a limited human ability to discover
      relevant data. Our findings indicate that the relevance blind spot (items from
      the testing set whose predicted relevance probability is less than 0.5 and who
      thus risk being hidden from humans) amounted to 4% of all relevant items when
      using a content-based filter that predicts relevant items. A similar simulation
      using a real-life rating data set found that the same filter resulted in a blind 
      spot size of 75% of the relevant testing set.
FAU - Sun, Wenlong
AU  - Sun W
AUID- ORCID: 0000-0003-0164-8733
AD  - Department of Computer Engineering and Computer Science, University of
      Louisville, Louisville, Kentucky, United States of America.
FAU - Nasraoui, Olfa
AU  - Nasraoui O
AD  - Department of Computer Engineering and Computer Science, University of
      Louisville, Louisville, Kentucky, United States of America.
FAU - Shafto, Patrick
AU  - Shafto P
AD  - Department of Mathematics and Computer Science, Rutgers University - Newark,
      Newark, New Jersey, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200813
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Bias
MH  - Humans
MH  - *Learning
MH  - Machine Learning/*standards
PMC - PMC7425868
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/12/22 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
AID - 10.1371/journal.pone.0235502 [doi]
AID - PONE-D-19-35469 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 13;15(8):e0235502. doi: 10.1371/journal.pone.0235502.
      eCollection 2020.


PMID- 32790214
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 56
IP  - 9
DP  - 2020 Sep
TI  - Marketing of breast milk substitutes on the internet and television in Mexico.
PG  - 1438-1447
LID - 10.1111/jpc.14968 [doi]
AB  - AIM: We aimed to examine the advertising and marketing of breast milk substitutes
      (BMS) through the internet, social media and television in Mexico. METHODS: We
      recorded the programming of four main TV channels at peak times to identify BMS
      advertisements. In addition, we identified the main BMS products and companies
      present on the internet, as well as related home pages and social networks
      (Facebook, Twitter and YouTube). After that, we examined current BMS' marketing
      practices using the International Code of Marketing of Breast-milk Substitutes
      ('the Code') as a framework for ethical marketing. Qualitative and statistical
      analyses are presented. RESULTS: BMS manufacturers have a presence on television,
      social media and the internet. Violations of the Code, as well as promotional
      practices unforeseen by the Code, were identified in all the studied media. These
      include text and images idealising the use of BMS, as well as mechanisms for
      boosting sales and making contact with consumers. CONCLUSIONS: The Mexican
      population is exposed to BMS advertisements that breach the Code on the internet,
      on social networks and on television. Emerging challenges related to the use of
      electronic means to market BMS may call for new strategies for monitoring and
      enforcing the Code through local regulations.
CI  - (c) 2020 Paediatrics and Child Health Division (The Royal Australasian College of
      Physicians).
FAU - Lozada-Tequeanes, Ana Lilia
AU  - Lozada-Tequeanes AL
AUID- ORCID: https://orcid.org/0000-0002-7371-3525
AD  - Health and Nutrition Research Center, National Institute of Public Health,
      Cuernavaca, Mexico.
FAU - Hernandez-Cordero, Sonia
AU  - Hernandez-Cordero S
AD  - Health Department, Universidad Iberoamericana, Mexico City, Mexico.
FAU - Shamah-Levy, Teresa
AU  - Shamah-Levy T
AD  - Evaluation and Surveys Research Center, National Public Health Institute,
      Cuernavaca, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
SB  - IM
MH  - Female
MH  - Humans
MH  - Internet
MH  - Marketing
MH  - Mexico
MH  - *Milk Substitutes
MH  - Television
OTO - NOTNLM
OT  - advertising
OT  - breast milk substitute
OT  - breastfeeding
OT  - infant formula
OT  - social media
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1111/jpc.14968 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2020 Sep;56(9):1438-1447. doi: 10.1111/jpc.14968. Epub
      2020 Aug 13.


PMID- 32789911
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20201218
IS  - 1520-6629 (Electronic)
IS  - 0090-4392 (Linking)
VI  - 48
IP  - 7
DP  - 2020 Sep
TI  - Community psychology and the crisis of care.
PG  - 2131-2137
LID - 10.1002/jcop.22427 [doi]
AB  - In addition to the twinned crises of ecology and political economy, we face today
      a crisis of care. The crisis of care, I contend, is fundamentally a political and
      an ethical crisis. In this short commentary, I outline the structural (i.e.,
      systemic) and reproductive (i.e., labour) character of this crisis, using the
      COVID-19 pandemic as an example. From here, I argue for the imperative to centre 
      an expansive conception of care in critical community psychology work.
      Specifically, I posit that by working with and alongside activist care workers,
      community psychologists can assist in building socially just modalities of care. 
      After reflecting on my work with collective caring initiatives, I offer five
      (tentative) guiding principles for a community psychology that is committed to
      addressing the crisis of care, namely: (1) commitment to building political
      coalitions; (2) commitment to refuting capitalist conceptions of care; (3)
      commitment to expanding conceptions of care; (4) commitment to embracing the
      psychological consequences of care work; and (5) a politicoethical commitment.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Malherbe, Nick
AU  - Malherbe N
AUID- ORCID: 0000-0002-4968-4058
AD  - Institute for Social and Health Sciences, University of South Africa, Lenasia,
      South Africa.
AD  - Masculinity and Health Research Unit, South African Medical Research
      Council-University of South Africa, Tygerberg, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - United States
TA  - J Community Psychol
JT  - Journal of community psychology
JID - 0367033
SB  - IM
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Delivery of Health Care/*standards
MH  - Health Personnel/*standards
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Politics
MH  - Psychology, Applied/*standards
MH  - *Residence Characteristics
OTO - NOTNLM
OT  - *COVID-19
OT  - *activism
OT  - *care
OT  - *reproductive labour
OT  - *social movements
EDAT- 2020/08/14 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1002/jcop.22427 [doi]
PST - ppublish
SO  - J Community Psychol. 2020 Sep;48(7):2131-2137. doi: 10.1002/jcop.22427. Epub 2020
      Aug 12.


PMID- 32789874
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - A more-than-human approach to bioethics: The example of digital health.
PG  - 969-976
LID - 10.1111/bioe.12798 [doi]
AB  - Digital health technologies are often advocated as a way of helping people
      monitor, promote and manage their health, care for others and reduce the burden
      on healthcare systems. Yet these technologies have also been subject to criticism
      for limiting human flourishing and exacerbating socioeconomic disadvantage.
      Bioethical appraisals of digital health technologies tend to take a conventional 
      risk-benefit approach, positioning the human subject as a rational, autonomous
      agent who is acted on by technologies. In this paper, I present a case for
      adopting an alternative more-than-human perspective on bioethics. A
      more-than-human approach considers human-technological assemblages and agencies
      as distributed, relational, situated and emergent. To illustrate the insights
      that this perspective can offer, I draw on the findings of four empirical
      projects I have conducted on people's use of digital devices and platforms used
      for health-related purposes, including social media groups and online forums,
      mobile apps and wearable devices. I conclude with the argument that a
      more-than-human approach to bioethics can begin to incorporate a new 'zoe ethics'
      that can acknowledge and address the deeper affective, multisensory and
      relational dimensions of humans' encounters with and enactments of material
      things and nonhuman creatures.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Lupton, Deborah
AU  - Lupton D
AUID- ORCID: 0000-0003-2658-4430
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Bioethics
MH  - Biomedical Technology
MH  - Delivery of Health Care
MH  - Humans
MH  - *Mobile Applications
MH  - *Social Media
OTO - NOTNLM
OT  - *bioethics
OT  - *digital health
OT  - *more-than-human theory
OT  - *new materialism
EDAT- 2020/08/14 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/02/29 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1111/bioe.12798 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):969-976. doi: 10.1111/bioe.12798. Epub 2020 Aug 13.


PMID- 32789424
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210803
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 41
IP  - 8
DP  - 2020 Aug
TI  - Increased expressions of cellular ATP-binding cassette transporters may be a
      promising diagnostic marker for colorectal cancer.
PG  - 834-840
LID - 10.15537/smj.2020.8.25187 [doi]
AB  - OBJECTIVES: To measure the blood expression levels of related drug-resistant
      ATP-binding cassette (ABC) transporters in colorectal cancer (CRC) patients and
      to assess these examined transporters for whether they present signi cant
      expression in connection with the tumor appearance of CRC. METHODS: In this
      case-control study, the messenger ribonucleic acids were isolated from the blood 
      of 62 CRC patients who were recruited from King Abdulaziz University Hospital
      Oncology Clinic and 46 controls from King Fahad General Hospital Blood Bank
      (Jeddah, Saudi Arabia) from September 2016 to March 2017. The Biomedical Ethics
      Unit at King Abdulaziz University, Jeddah, Saudi Arabia approved this study. The 
      expressions of ABC transporters were measured using quantitative polymerase chain
      reaction. GraphPad Prism 5 and REST 2009 Software were used to correlate the
      expressions with clinicopathological independent stages and body mass index. A
      p-value of less than 0.05 was considered significant. RESULTS: The results showed
      that the 3 ABC transporters, particularly ABCC1 (p less than 0.0001), were highly
      expressed in the blood of CRC patients compared with controls. However, none of
      the 3 transporters was related to the progression of CRC, age, gender, or body
      mass index. CONCLUSION: The expressions of ABC transporters were found to be
      significantly higher in CRC patients, and they may act as diagnostic markers and 
      should potentially be tested for their contribution to drug sensitivity in CRC
      patients.
FAU - Qutub, Renad M
AU  - Qutub RM
AD  - Biochemistry Department, Faculty of Science, King Fahad Medical Research Centre, 
      King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. E-mail.
      rqutub0001@stu.kau.edu.sa.
FAU - Al-Ghafari, Ayat B
AU  - Al-Ghafari AB
FAU - Al Doghaither, Huda A
AU  - Al Doghaither HA
FAU - Omar, Ulfat M
AU  - Omar UM
FAU - Ghulam, Jihan M
AU  - Ghulam JM
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ABCG2 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily G, Member 2)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - Y49M64GZ4Q (multidrug resistance-associated protein 1)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B/blood/genetics
MH  - ATP Binding Cassette Transporter, Subfamily G, Member 2/blood/genetics
MH  - ATP-Binding Cassette Transporters/*blood/genetics
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/*diagnosis/pathology
MH  - Female
MH  - *Gene Expression
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multidrug Resistance-Associated Proteins/blood/genetics
MH  - Neoplasm Proteins/blood/genetics
MH  - Polymerase Chain Reaction
MH  - Saudi Arabia
PMC - PMC7502964
EDAT- 2020/08/14 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - 10.15537/smj.2020.8.25187 [doi]
PST - ppublish
SO  - Saudi Med J. 2020 Aug;41(8):834-840. doi: 10.15537/smj.2020.8.25187.


PMID- 32789197
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Hitting children is wrong.
PG  - e000675
LID - 10.1136/bmjpo-2020-000675 [doi]
FAU - Waterston, Tony
AU  - Waterston T
AUID- ORCID: 0000-0001-7829-6831
AD  - Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
FAU - Janson, Staffan
AU  - Janson S
AD  - Public Health, Karlstad University, Karlstad, Sweden.
LA  - eng
PT  - Editorial
DEP - 20200727
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7390231
OTO - NOTNLM
OT  - child abuse
OT  - ethics
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2020/08/14 06:01
CRDT- 2020/08/14 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/08/14 06:01 [medline]
AID - 10.1136/bmjpo-2020-000675 [doi]
AID - bmjpo-2020-000675 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Jul 27;4(1):e000675. doi: 10.1136/bmjpo-2020-000675.
      eCollection 2020.


PMID- 32789062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 7
DP  - 2020 Jul 10
TI  - Adequate Knowledge and Low Vaccination Rates of Hepatitis B Virus Infection Among
      Students, Medical, and Paramedical Persons in a Tertiary Care Teaching Hospital.
PG  - e9121
LID - 10.7759/cureus.9121 [doi]
AB  - Introduction Hepatitis B virus (HBV) is probably the only vaccine-preventable
      virus transmitted from one person to the other by blood transfusion, sex, and
      contact with blood and blood products. HBV is highly transmissible, where the
      infection has been noted to transmit among the household contacts. HBV is also
      transmitted from the mother to the child through the transplacental barrier.
      Clinical infection with HBV may be chronic and could remain for a lifetime. Most 
      exposures with HBV are automatically resolved, but a few infected people may
      become carriers and may transmit infections. Although HBV can be treated,
      complete elimination of the virus and the morbidity and mortality associated with
      chronic infection should be considered as a cause of serious concern. Because
      healthcare workers are predisposed to HBV infection, adequate knowledge about the
      virus and the vaccine to prevent the infection is necessary. This study is
      carried out to assess the knowledge of HBV infection and the status of
      vaccination among medical, paramedical students, laboratory technicians, and
      doctors. Methods The study included 256 participants attending a tertiary care
      teaching hospital in Telangana, South India. The participants belonged to three
      groups, the MBBS students (first, second-, and third-year students), the doctors 
      (the postgraduates, medical teachers, and the clinicians), and the paramedical
      personnel. All the participants in the study were included after oral consent,
      and the study was approved by the Institutional Ethics Committee. A questionnaire
      containing 13 points was used for the study. Seven questions were asked to know
      the respondent's knowledge of HBV infection, and the other six were used to know 
      the participant's knowledge and status of HBV vaccination. The study participants
      filled in the responses with their current understanding of the HBV infection and
      the vaccine. All the responses were analyzed using Microsoft Office Excel and
      drawing means and percentages. Results Among the 94 medical students, 79 (84%)
      knew about HBV infection. There was a significant improvement in the knowledge of
      HBV infection among MBBS students, with first-year MBBS (68%) to the final-year
      MBBS (100%). The knowledge of HBV among the doctors (postgraduates, medical
      teachers, and clinicians) was 100%. Among the paramedical participants that
      included the laboratory technicians and the nursing students, all (100%) knew
      about HBV infection. Very few MBBS students (12%), 28% of paramedical persons,
      and 45% of doctors were tested for HBV infection. The knowledge of HBV
      vaccination was best among the doctors (100%) followed by the paramedical
      personnel (89%) and the MBBS students (72%). The teaching faculty including the
      postgraduate students (83%) were vaccinated followed by the paramedical persons
      (66%), and only 24% of MBBS students were vaccinated. Conclusions The study
      participants had a reasonably good knowledge of HBV infection, and low
      vaccination rates were observed among various participants. There is an urgent
      need to understand the significance of HBV infection, especially among healthcare
      workers. Being easily transmissible and because of the availability of an
      effective vaccine, healthcare workers should be adequately vaccinated to prevent 
      the spread of infection.
CI  - Copyright (c) 2020, Kandi et al.
FAU - Kandi, Venkataramana
AU  - Kandi V
AD  - Clinical Microbiology, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Katoch, Abhilasha
AU  - Katoch A
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Miniskar, Harshitha
AU  - Miniskar H
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Jaripiti, Sneha
AU  - Jaripiti S
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Rv, Sai Supreethi
AU  - Rv SS
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Burugu, Hemanth Reddy
AU  - Burugu HR
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Reddy, Akhileshwar V
AU  - Reddy AV
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
FAU - Bhasin, Anurakshat
AU  - Bhasin A
AD  - Medicine, Prathima Institute of Medical Sciences, Karimnagar, IND.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7417095
OTO - NOTNLM
OT  - hbv
OT  - healthcare workers
OT  - hepatitis b virus
OT  - infection
OT  - knowledge
OT  - vaccination
OT  - vaccine-preventable disease
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/08/14 06:01
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/08/14 06:01 [medline]
AID - 10.7759/cureus.9121 [doi]
PST - epublish
SO  - Cureus. 2020 Jul 10;12(7):e9121. doi: 10.7759/cureus.9121.


PMID- 32789031
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 7
DP  - 2020 Jul 8
TI  - Comparison of General Anesthesia (Sevoflurane) and Spinal Anesthesia
      (Levobupivacaine) Methods on QT Dispersion in Inguinal Hernia Operations.
PG  - e9079
LID - 10.7759/cureus.9079 [doi]
AB  - Introduction Arrhythmias are one of the most frequently seen issues during
      surgical operations. In this study, we investigated and compared the effects on
      the QT dispersion of patients when using a method of volatile inhalation mask
      anesthesia with sevoflurane (VIMA: Group I) and when spinal anesthesia was
      performed with levobupivacaine (Group II). Methods The study included 40 patients
      who had American Society of Anesthesiology scores of I-II (ASA I-II), were aged
      from 18 to 65 years, and were scheduled for inguinal hernia operations. Approval 
      of the university ethics committee was obtained before the study began. All
      patients had measurements taken for non-invasive blood pressure, including
      systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean
      arterial pressure (MAP), heart rate (HR), and oxygen saturation (SO2) values. The
      QT intervals were measured using the 12-derivation electrocardiogram (ECG) device
      (Cardiofax V). Our study was performed with randomization using the closed
      envelope method. Results When the percentage differences of the HR values from
      the initial period in both groups were compared, we observed significant
      differences between the groups, with increases in the VIMA group at the second
      period as well as increases in the VIMA group at the fourth, fifth, sixth,
      seventh, and ninth periods but decreases in the spinal anesthesia group for these
      periods. There were statistically significant differences between the two groups 
      at the third and fifth periods when the percentage differences of the QTc values 
      from the initial period were compared. We observed increases in the spinal
      anesthesia group. Conclusion In our study, we suggest that the tendency toward
      arrhythmia may be reduced by choosing general anesthesia with sevoflurane rather 
      than levobupivacaine in patients with cardiac complaints who are undergoing
      regional anesthesia and/or taking medication that affects QT intervals.
CI  - Copyright (c) 2020, Pehlivan et al.
FAU - Pehlivan, Basak
AU  - Pehlivan B
AD  - Anesthesiology, Harran University, Sanliurfa, TUR.
FAU - Akcay, Murat
AU  - Akcay M
AD  - Anesthesiology and Reanimation, Ankara Numune Training and Research Hospital,
      Anesthesiology and Reanimation Clinic, Ankara, TUR.
FAU - Atlas, Ahmet
AU  - Atlas A
AD  - Anesthesiology, Harran University, Sanliurfa, TUR.
FAU - Erol, Mehmet K
AU  - Erol MK
AD  - Anesthesiology, Harran University, Sanliurfa, TUR.
FAU - Duran, Erdogan
AU  - Duran E
AD  - Anesthesiology and Reanimation, Harran University, Sanliurfa, TUR.
FAU - Karahan, Mahmut A
AU  - Karahan MA
AD  - Anesthesiology and Critical Care, Harran University, Sanliurfa, TUR.
FAU - Binici, Orhan
AU  - Binici O
AD  - Anesthesiology and Critical Care, Harran University, Sanliurfa, TUR.
FAU - Buyukfirat, Evren
AU  - Buyukfirat E
AD  - Anesthesiology and Critical Care, Harran University, Sanliurfa, TUR.
FAU - Altay, Nuray
AU  - Altay N
AD  - Anesthesiology and Critical Care, Harran University, Sanliurfa, TUR.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7416987
OTO - NOTNLM
OT  - arrhythmia
OT  - levobupivacaine
OT  - qt interval
OT  - sevoflurane
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/08/14 06:01
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/08/14 06:01 [medline]
AID - 10.7759/cureus.9079 [doi]
PST - epublish
SO  - Cureus. 2020 Jul 8;12(7):e9079. doi: 10.7759/cureus.9079.


PMID- 32788758
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Clinical Profile and Endoscopic Findings in Patients with Upper Gastrointestinal 
      Bleed Attending a Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 409-415
LID - 10.31729/jnma.4967 [doi]
AB  - INTRODUCTION: Upper gastrointestinal bleeding is a common acute medical
      emergency. Endoscopy is the gold standard diagnostic and therapeutic tool in the 
      management of upper gastrointestinal bleed. This study was undertaken to address 
      the clinical profile, endoscopic profile, and outcomes in patients with upper
      gastrointestinal bleed. METHODS: A descriptive cross-sectional study was
      conducted in a tertiary care teaching hospital in Gandaki Province, Nepal from
      January 2018 to December 2019 after obtaining ethical clearance from
      Institutional Review Committee (MEMG/IRC/291/GA) and informed consent from the
      patient or patient relatives. The sample size was calculated. Six hundred and
      sixty patients with upper gastrointestinal bleed were included in the study. Data
      entry was done in Statistical Packages for the Social Sciences version 20.
      RESULTS: Peptic ulcers and ruptured oesophageal varices are the common
      aetiologies of upper gastrointestinal bleed. Inpatient mortality was seen in 98
      (14.8 %) patients. Upper gastrointestinal bleed of variceal etiology presents
      with a higher Rockall score and has more chances of rebleeding and has higher
      mortality than those with non-variceal aetiologies. Bad prognostic factors were
      rebleeding, variceal etiology, and comorbidities including cirrhotic and Rockall 
      score > 6. CONCLUSIONS: Upper gastrointestinal bleeding is a common acute medical
      emergency. Early upper gastrointestinal endoscopy preferably within 24 hours is
      recommended for diagnosis, timely intervention, and management of the patients
      with an upper gastrointestinal bleed that helps in reducing morbidity and
      mortality.
FAU - Bhattarai, Subash
AU  - Bhattarai S
AD  - Unit of Medical Gastroenterology, Department of Medicine, Manipal College of
      Medical Sciences, Pokhara, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - *Endoscopy, Gastrointestinal/methods/statistics & numerical data
MH  - *Esophageal and Gastric Varices/complications/diagnosis/epidemiology
MH  - Female
MH  - *Gastrointestinal Hemorrhage/diagnosis/epidemiology/etiology
MH  - Hospitals, Teaching/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - *Peptic Ulcer/complications/diagnosis/epidemiology
MH  - Retrospective Studies
MH  - Tertiary Care Centers/statistics & numerical data
PMC - PMC7580347
OTO - NOTNLM
OT  - endoscopy; esophageal and gastric varices; peptic ulcer; upper gastrointestinal
      tract.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4967 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):409-415. doi: 10.31729/jnma.4967.


PMID- 32788757
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Prevalence of Hemolysis, Elevated Liver Enzymes, Low Platelet Count Syndrome in
      Pregnant Women in a Tertiary Care Hospital.
PG  - 405-408
LID - 10.31729/jnma.4921 [doi]
AB  - INTRODUCTION: Hemolysis, Elevated Liver Enzymes, Low Platelet count syndrome
      refers to biological syndrome occurring in pre-eclamptic and eclamptic women.
      There is a higher rate of maternal and perinatal morbidity and mortality due to
      the syndrome. So, the objective of the study is to find the prevalence and
      maternal- perinatal outcome in the syndrome. METHODS: A descriptive
      cross-sectional study was done in a tertiary care hospital from 1st April 2017 to
      30th March 2018 after obtaining ethical clearance from the Institutional Review
      Committee. The inclusion criteria were patients giving consent for participation 
      and those who delivered in our hospital. Patient with the syndrome who delivered 
      outside and referred in the postpartum period was excluded because details of the
      neonate may not be available. The Statistical Package for Social Sciences version
      21 was used for the analysis of the data. Point estimate at 95% Confidence
      Interval was calculated along with frequency and proportion for binary data.
      RESULTS: Out of 11974 deliveries, the prevalence of Hemolysis, Elevated Liver
      Enzymes, Low Platelet count syndrome was 83 (0.69%) at 95% Confidence Interval
      (59.06-78.94). Maternal complications were seen in 19 (22.9%) and common
      complications being acute renal failure 9 (47.37%) followed by postpartum
      hemorrhage 4 (21.05%). Nearly 27 (33%) of patients required maternal ICU stay and
      there was one maternal mortality. CONCLUSIONS: Hemolysis, Elevated Liver Enzymes,
      Low Platelet count syndrome is one of the major causes of maternal and perinatal 
      morbidity and mortality. Hence early recognition and prompt management may
      improve maternal and fetal outcomes.
FAU - Sitaula, Sarita
AU  - Sitaula S
AD  - Department of Obstetrics and Gynecology, BP Koirala Institute of Health Sciences,
      Dharan, Nepal.
FAU - Manandhar, Tara
AU  - Manandhar T
AD  - Department of Obstetrics and Gynecology, BP Koirala Institute of Health Sciences,
      Dharan, Nepal.
FAU - Thapa, Baburam Dixit
AU  - Thapa BD
AD  - Department of Obstetrics and Gynecology, BP Koirala Institute of Health Sciences,
      Dharan, Nepal.
FAU - Shrestha, Ramesh
AU  - Shrestha R
AD  - Department of Obstetrics and Gynecology, BP Koirala Institute of Health Sciences,
      Dharan, Nepal.
FAU - Dharel, Dinesh
AU  - Dharel D
AD  - Department of Pediatrics and Department of Community Health and Epidemiology,
      University of Saskatchewan, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - *HELLP Syndrome/epidemiology
MH  - Humans
MH  - Infant, Newborn
MH  - Nepal/epidemiology
MH  - Pregnancy/*statistics & numerical data
MH  - Pregnancy Outcome
MH  - Prevalence
MH  - Tertiary Care Centers/*statistics & numerical data
MH  - Young Adult
PMC - PMC7580356
OTO - NOTNLM
OT  - cesarean section; HELLP syndrome; maternal mortality.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4921 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):405-408. doi: 10.31729/jnma.4921.


PMID- 32788756
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Pain and Oral Health Related Quality of Life among Patients Undergoing Fixed
      Orthodontic Treatment: A Descriptive Cross-sectional Study.
PG  - 400-404
LID - 10.31729/jnma.4817 [doi]
AB  - INTRODUCTION: Fixed orthodontic procedures such as separator placement, archwire 
      placement and activations, application of orthopaedic forces, and debonding of
      brackets produce pain in patients. This study was conducted to assess pain and
      oral health-related quality of life among patients undergoing orthodontic
      treatment. METHODS: This descriptive cross-sectional study was conducted among
      152 orthodontic patients of a teritary care center from January 2019 to October
      2019 after receiving ethical approval from the Institutional Review Committee
      (Ref. no. 2311201813). Convenience sampling method was done to select the
      participants. Oral health-related quality of life using "Oral Health Impact
      Profile-14" and pain experienced during the first month of fixed orthodontic
      treatment were assessed. Data analysis for calculation of frequency and
      proportion was done in Statistical Package of Social Sciences. RESULTS: Mean pain
      score of the study participants was 5.05+/-2.07 and their mean oral health impact
      was 12.71+/-7.27. Most of the study participants 86 (56.58%), had experienced
      moderate pain due to orthodontic treatment. Out of the reported impacts, 134
      (88.2%) had painful aching in mouth and 127 (83.6%) had difficulty during eating.
      Least impact was seen in alteration of taste 35 (23%). CONCLUSIONS: The pain
      intensity experienced by patients was variable. Most participants had moderate
      pain but few patients perceived no pain at all. The participants had at least one
      or other oral health impacts due to fixed orthodontic treatment. Orthodontists
      should counsel the patients regarding possible discomfort so that there is no
      discontinuation of treatment due to pain.
FAU - Poudel, Prakash
AU  - Poudel P
AD  - Department of Orthodontics and Dentofacial Orthopaedics, Kathmandu Medical
      College, Duwakot, Bhaktapur, Nepal.
FAU - Dahal, Sirjana
AU  - Dahal S
AD  - Department of Community and Public Health Dentistry, Kathmandu Medical College,
      Duwakot, Bhaktapur, Nepal.
FAU - Thapa, Vivek Bikram
AU  - Thapa VB
AD  - Department of Orthodontics and Dentofacial Orthopaedics, Kathmandu Medical
      College, Duwakot, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Oral Health
MH  - Orthodontic Appliances, Fixed/*adverse effects
MH  - *Pain/etiology
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7580346
OTO - NOTNLM
OT  - fixed orthodontic treatment; oral health impact profile-14; pain.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4817 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):400-404. doi: 10.31729/jnma.4817.


PMID- 32788755
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Anterior Tooth Width Measurements among Patients in a Tertiary Hospital of Nepal:
      A Descriptive Cross-sectional Study.
PG  - 396-399
LID - 10.31729/jnma.4994 [doi]
AB  - INTRODUCTION: The knowledge of anterior tooth width and their relationships with 
      each other is essential for any esthetic and prosthodontic rehabilitation. The
      objective of this study is to measure the width of the anterior teeth of patients
      coming to a teritary hospital of Nepal. METHODS: This descriptive cross-sectional
      study was conducted at a tertiary care hospital from 30th September 2019 to 30th 
      October 2019 after receiving ethical clearance from the institutional review
      committee (reference number: 2076/77/20). Convenient sampling was done. Point
      estimate at 99% Confidence Interval was calculated along with frequency and
      proportion for binary data. Data analysis was done in Statistical Package for the
      Social Sciences version 21. RESULTS: Out of the 40 participants, the mean width
      of right and left side of anterior teeth of the maxillary central incisors were
      8.62+/-0.62 mm and 8.65+/-0.55 mm; maxillary lateral incisors were 6.97+/-0.74 mm
      and 7.11+/-0.78 mm; maxillary canine were 7.81+/-0.69 mm and 8.15+/-0.72 mm;
      mandibular central incisors were 5.37+/-0.4 mm and 5.43+/-0.37 mm; mandibular
      lateral incisors were 5.88+/-.52 mm and 6.06+/-0.53 mm; mandibular canine were
      6.69+/-0.55 mm and 6.93+/-0.7 mm respectively. The difference between the teeth
      was compared with the central incisors of each side. CONCLUSIONS: Our findings of
      the average values of the anterior teeth and their difference from the central
      incisors on each side showed an agreement with the optimal relationships of
      anterior teeth, with the exception of the maxillary lateral incisors, which were 
      0.5mm larger than the values of the optimal relationship.
FAU - Shrestha, Prabhat
AU  - Shrestha P
AD  - Department of Prosthodontics, KIST Medical College and Teaching Hospital,
      Lalitpur, Nepal.
FAU - Paudel, Sabina
AU  - Paudel S
AD  - Department of Prosthodontics, KIST Medical College and Teaching Hospital,
      Lalitpur, Nepal.
FAU - Neupane, Madhu
AU  - Neupane M
AD  - Department of Prosthodontics, KIST Medical College and Teaching Hospital,
      Lalitpur, Nepal.
FAU - Lamba, Suman
AU  - Lamba S
AD  - Department of Conservative and Endodontics, KIST Medical College and Teaching
      Hospital, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Dental Prosthesis
MH  - Dental Prosthesis Design
MH  - *Esthetics, Dental
MH  - Humans
MH  - Nepal/epidemiology
MH  - *Odontometry
MH  - Tertiary Care Centers
MH  - *Tooth/anatomy & histology
PMC - PMC7580358
OTO - NOTNLM
OT  - aesthetics;dental prosthesis design; dimensional measurement accuracy.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4994 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):396-399. doi: 10.31729/jnma.4994.


PMID- 32788754
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Outcome of Cuffed Tunneled Dialysis Catheters for Hemodialysis Patients at a
      Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 390-395
LID - 10.31729/jnma.4795 [doi]
AB  - INTRODUCTION: Arteriovenous fistula is the most common vascular access for
      patients requiring hemodialysis, but it is not always possible or practical hence
      cuffed tunneled dialysis catheter comes into play. The aim of the study was to
      determine the outcome of cuffed tunneled dialysis catheter used for hemodialysis 
      at a teaching hospital. METHODS: A descriptive cross-sectional study was
      conducted between January 2014 and December 2019 on 103 chronic dialysis patients
      with end-stage renal disease presenting to a tertiary care hospital. Ethical
      approval was received from the institutional review board (2/(6-11) E2/076/77).
      Whole sampling was done. Data entry and analysis were done in Microsoft Excel 10.
      RESULTS: The study included 103 patients with 117 cuffed tunneled dialysis
      catheters placed for hemodialysis. On assessing the outcome of the catheters, the
      primary and secondary patency rates of the catheters were 5.85+/-4.87 and
      1.21+/-3.77 months. Thirty-one (30.1%) patients required one intervention, and 11
      (10.68%) catheters required 3 or more interventions to maintain patency. Eighteen
      (17.48%) patients presented with catheter dysfunction while in 11 (10.68%) cases,
      the catheter was kinked or malpositioned at the notch. In one patient, procedure 
      was abandoned due to severe bleeding and in 2 (1.94%) patients dialysis catheters
      could not be negotiated into the right atrium and left in brachiocephalic
      junction. CONCLUSIONS: Cuffed tunneled dialysis catheter is effective for
      maintenance hemodialysis in patients with the end-stage renal disease if used
      with proper care during dialysis even in our setup. The results and outcomes of
      the procedure are at par with standards.
FAU - Shrestha, Kajan Raj
AU  - Shrestha KR
AD  - Department of Cardiothoracic Vascular Surgery, Manmohan Cardiothoracic Vascular
      and Transplant Center, Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
FAU - Gurung, Dinesh
AU  - Gurung D
AD  - Department of Cardiothoracic Vascular Surgery, Manmohan Cardiothoracic Vascular
      and Transplant Center, Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
FAU - Shrestha, Uttam Krishna
AU  - Shrestha UK
AD  - Department of Cardiothoracic Vascular Surgery, Manmohan Cardiothoracic Vascular
      and Transplant Center, Institute of Medicine, Maharajgunj, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Catheterization, Central Venous/adverse effects
MH  - *Catheters, Indwelling/adverse effects
MH  - *Central Venous Catheters/adverse effects
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Kidney Failure, Chronic/*therapy
MH  - Renal Dialysis/*instrumentation
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - Treatment Outcome
PMC - PMC7580349
OTO - NOTNLM
OT  - catheter; hemodialysis; vascular access.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4795 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):390-395. doi: 10.31729/jnma.4795.


PMID- 32788752
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Micro-Erythrocyte Sedimentation Rate in Neonatal Sepsis of a Tertiary Hospital: A
      Descriptive Cross-sectional Study.
PG  - 377-382
LID - 10.31729/jnma.4984 [doi]
AB  - INTRODUCTION: Neonatal sepsis is the most important cause of morbidity and
      mortality among low birth weight and preterm babies in developing countries. The 
      main objective of this study is to find the level of micro-Erythrocyte
      sedimentation rate in neonatal sepsis. METHODS: This is a descriptive
      cross-sectional study conducted at the neonatal unit over six months period
      (November 2019 to April 2020). All preterm, term and post-term babies with
      neonatal sepsisdelivered at Kathmandu Medical College Teaching Hospital were
      enrolled. Ethical clearance was received from the Institutional Review Committee 
      of Kathmandu Medical College (Ref: 181020191). Convenient sampling method was
      applied and statistical analysis was done with Statistical package for social
      sciences 19 version. RESULTS: Out of 75 babies, confirm sepsis is 13 (17.3%),
      probable sepsis is 40 (53.4%) and suspected sepsis is 22 (29.2%).
      Micro-Erythrocyte sedimentation level is elevated (>/=15mm in 1st hr) in 25
      (33.3%) babies with a mean micro-Erythrocyte sedimentation level 9.32+/-5.4
      (2-18) mm in 1st hr. The elevated micro- Erythrocyte sedimentation level was seen
      in relation to sepsis types and C-reactive protein. CONCLUSIONS: The bedside
      micro-Erythrocyte sedimentation level aids in the diagnosis of neonatal sepsis.
FAU - Manandhar, Sunil Raja
AU  - Manandhar SR
AD  - Neonatal Unit, Department of Paediatrics, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Basnet, Rydam
AU  - Basnet R
AD  - Neonatal Unit, Department of Paediatrics, Kathmandu Medical College and Teaching 
      Hospital, Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Blood Sedimentation
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infant, Newborn/blood
MH  - Infant, Postmature/blood
MH  - Male
MH  - *Neonatal Sepsis/blood/diagnosis/etiology
MH  - Premature Birth/blood
MH  - Term Birth/blood
MH  - Tertiary Care Centers
PMC - PMC7580353
OTO - NOTNLM
OT  - C - reactive protein, micro -ESR level, neonatal sepsis
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4984 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):377-382. doi: 10.31729/jnma.4984.


PMID- 32788751
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Prevalence of Domestic Violence among Infertile Women attending Subfertility
      Clinic of a Tertiary Hospital.
PG  - 372-376
LID - 10.31729/jnma.4886 [doi]
AB  - INTRODUCTION: Millions of couples suffered from Infertility worldwide.
      Infertility can cause intense emotional pain in women resulting in stress,
      anxiety and depression. Domestic violence in infertile women can further results 
      in poor health status and lowers the quality of life. The objective of this study
      is to find out the prevalence of domestic violence among infertile women
      attending subfertility clinic of tertiary hospital. METHODS: This descriptive
      cross-sectional study was conducted among infertile women in a tertiary hospital 
      from July to August 2018 after taking ethical approval. Convenient sampling was
      used. Face to face interview was conducted using a structured interview schedule.
      Data analysis was done in the Statistical Package for Social Sciences.
      Descriptive statistics (frequency, percentage) were used to analyze the data.
      Point estimate at 95% CI was calculated along with frequency and proportion for
      binary data. RESULTS: Domestic violence was found among 62 (55.35%) women at 95% 
      Confidence Interval (46.15-64.55). The emotional violence accounted for 57
      (50.89%), physical violence for 19 (16.96%) and sexual violence for 18 (16.07%). 
      The prevalence of domestic violence was more 22 (61.11%) in women with secondary 
      infertility than in women with primary infertility 40 (52.63%). The main
      perpetrators of domestic violence were family members 28 (45.16%). CONCLUSIONS:
      The study concluded that women experiencing infertility are exposed to various
      forms of domestic violence, emotional one being most common. Routine screening
      for domestic violence in infertility clinics is necessary to give affected women 
      an opportunity to access appropriate health care and support services.
FAU - Silwal, Ajita
AU  - Silwal A
AD  - Bir Hospital Nursing Campus, National Academy of Medical Sciences, Kathmandu,
      Nepal.
FAU - Thapa, Bandana
AU  - Thapa B
AD  - Bir Hospital Nursing Campus, National Academy of Medical Sciences, Kathmandu,
      Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Domestic Violence/statistics & numerical data
MH  - Female
MH  - Humans
MH  - *Infertility, Female/epidemiology
MH  - Nepal/epidemiology
MH  - Outpatient Clinics, Hospital/statistics & numerical data
MH  - Prevalence
MH  - Quality of Life
MH  - Risk Factors
MH  - Tertiary Care Centers/statistics & numerical data
MH  - Young Adult
PMC - PMC7580360
OTO - NOTNLM
OT  - domestic violence; infertility; violence.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.4886 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):372-376. doi: 10.31729/jnma.4886.


PMID- 32788750
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 226
DP  - 2020 Jun 30
TI  - Prevalence of Smoking among Medical Students in a Tertiary Care Teaching
      Hospital.
PG  - 366-371
LID - 10.31729/jnma.5006 [doi]
AB  - INTRODUCTION: Tobacco smoking is one of the most important preventable risk
      factors for noncommunicable diseases. It has been seen that medical students have
      a higher frequency of smoking compared to the general population. This study aims
      to determine the prevalence of smoking among third-year medical students in a
      tertiary care teaching hospital in Nepal. METHODS: This descriptive
      cross-sectional study was conducted among the hospital's third-year undergraduate
      medical students over a four-month period (October 2019 to January 2020). Ethical
      clearance was received from the Institutional Review Committee of Kathmandu
      Medical College and Teaching Hospital. The whole sampling technique was used to
      collect data. The Global Health Professional Students Survey questionnaire was
      used to collect data. Data analysis was done in the statistical package for
      social sciences. RESULTS: The prevalence of current smoking among selected
      medical students of Kathmandu Medical College and Teaching Hospital is 34
      (30.1%), majority male 26 (23%). Fifty-six (49.4%) of them had ever smoked
      cigarettes in their life, and 27 (23.9%) had their first cigarette in late
      adolescence. The number of students who used other forms of tobacco was
      comparatively lower i.e. 6 (5.3%). Many of the students 53 (46.9%) were exposed
      to second-hand smoke both at home and in public, while 18(15.9) exposed only at
      public places, and 6 (5.3%) only at home. CONCLUSIONS: Our study has concluded
      that there is a notable prevalence of smoking among the participants. This points
      to the need for specific training sessions in their clinical years about smoking 
      cessation for themselves and regarding counseling for patients.
FAU - Shrestha, Neharika
AU  - Shrestha N
AD  - Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences,
      Lalitpur, Nepal.
FAU - Shrestha, Nikhil
AU  - Shrestha N
AD  - Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences,
      Lalitpur, Nepal.
FAU - Bhusal, Suzit
AU  - Bhusal S
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Neupane, Asmita
AU  - Neupane A
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Pandey, Rakshya
AU  - Pandey R
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Lohala, Nita
AU  - Lohala N
AD  - Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
FAU - Bhandari, Arpan Pratik
AU  - Bhandari AP
AD  - B & B Hospital, Lalitpur, Nepal.
FAU - Yadav, Mandeep Kumar
AU  - Yadav MK
AD  - Jyoti Hospital, Kathmandu, Nepal.
FAU - Vaidya, Abhinav
AU  - Vaidya A
AD  - Department of Community Medicine, Kathmandu Medical College and Teaching
      Hospital, Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hospitals, Teaching/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - *Students, Medical/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Tertiary Healthcare/*statistics & numerical data
MH  - Tobacco Smoking/*epidemiology
MH  - Tobacco Use Cessation
MH  - Young Adult
PMC - PMC7580352
OTO - NOTNLM
OT  - medical students, prevalence, smoking, tobacco
EDAT- 2020/08/14 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.31729/jnma.5006 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Jun 30;58(226):366-371. doi: 10.31729/jnma.5006.


PMID- 32788296
OWN - NLM
STAT- Publisher
LR  - 20200813
IS  - 1473-0480 (Electronic)
IS  - 0306-3674 (Linking)
DP  - 2020 Aug 11
TI  - Consent, capacity and compliance in concussion management: cave ergo medicus (let
      the doctor beware).
LID - bjsports-2020-102108 [pii]
LID - 10.1136/bjsports-2020-102108 [doi]
AB  - While the acute effects of concussion and mild traumatic brain injury (TBI) are
      well understood, the certainty in the medical literature regarding the long-term 
      outcomes of sports-related concussion is limited. Long-term deficits that may
      result from single, repeated concussions, and possibly subconcussive impacts,
      include cognitive dysfunction, depression and executive dysfunction. Perhaps most
      troublingly, repetitive head impacts have been linked to neurodegenerative
      diseases, including chronic traumatic encephalopathy (CTE), although the precise 
      risk of long-term consequences remains unknown. CTE represents a distinct
      tauopathy with an unknown incidence in athletic populations; however, a cause and
      effect relationship has not yet been demonstrated between CTE and concussions or 
      between CTE and exposure to contact sports, as no prospective longitudinal
      studies have been performed to address that question. Studies of high-school
      sports exposure and long-term outcomes have not demonstrated consistent
      findings.Medical advice regarding return to play and the risk of acute and/or
      long-term consequences is therefore problematic. It is important that the
      individual's right to make their own choices regarding their health is respected.
      Team, coach, parental, peer or financial pressures should not influence this
      decision. The choice to return to play after a concussion or mild TBI injury is
      the athlete's decision once they have (1) recovered from their injury and have
      the legal capacity to make an informed decision; (2) been medically assessed and 
      (3) been informed of any possible long-term risks in a language that they can
      understand.Given the current lack of certainty in relation to long-term outcomes 
      from concussion, is it possible to provide a framework to inform players of
      current evidence, as part of a consent process, even if the information upon
      which the decision to return to sport is based remains uncertain and evolving?
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Turner, Michael
AU  - Turner M
AUID- ORCID: http://orcid.org/0000-0003-2323-2456
AD  - International Concussion and Head Injury Research Foundation, London, UK
      michael@ichirf.org.
FAU - Maddocks, David
AU  - Maddocks D
AD  - Centre for Health Exercise and Sports Medicine, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Hassan, Majid
AU  - Hassan M
AD  - Capsticks LLP, Wimbledon, London, UK.
FAU - Anderson, Adrian
AU  - Anderson A
AD  - Aickin Chambers, Melbourne, Victoria, Australia.
FAU - McCrory, Paul
AU  - McCrory P
AD  - Florey Institute of Neuroscience and Mental Health - Austin Campus, Heidelberg,
      Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200811
PL  - England
TA  - Br J Sports Med
JT  - British journal of sports medicine
JID - 0432520
SB  - IM
OTO - NOTNLM
OT  - assessment
OT  - brain
OT  - concussion
OT  - medical ethics
OT  - trauma
COIS- Competing interests: DM is a coinvestigator in research on long-term follow-up of
      neuropsychological function in former Australian Rules Footballers, funded
      through the Florey Institute of Neuroscience and Mental Health. He has a legal
      practice in medical law and has provided legal advice to professional sporting
      clubs and the Australian Football League (AFL). He is a member of the AFL
      Grievance Tribunal and the AFL Concussion Working Group. PM is a coinvestigator
      on competitive grants relating to mild TBI funded by several governmental and
      other organisations. He is funded under a Fellowship awarded by the National
      Health & Medical Research Council of Australia and is employed at the Florey
      Institute of Neuroscience and Mental Health. He has a clinical consulting
      practice in neurology, including medicolegal work. He has been reimbursed by the 
      government, professional scientific bodies and commercial organisations for
      discussing or presenting research relating to MTBI and sport-related concussion
      at meetings, scientific conferences and symposiums. He acknowledges unrestricted 
      philanthropic support from CogState Inc (2001-2016). He is the chair of the
      scientific committees of the International Concussion and Head Injury Research
      Foundation in London and the Sports Surgery Clinic in Dublin. MT is employed by
      ICHIRF as CEO and Medical Director. He has been reimbursed by universities,
      scientific bodies, and commercial organizations for travel and accommodation
      related to presenting research relating to concussion at meetings, scientific
      conferences, and symposiums.
EDAT- 2020/08/14 06:00
MHDA- 2020/08/14 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
AID - bjsports-2020-102108 [pii]
AID - 10.1136/bjsports-2020-102108 [doi]
PST - aheadofprint
SO  - Br J Sports Med. 2020 Aug 11. pii: bjsports-2020-102108. doi:
      10.1136/bjsports-2020-102108.


PMID- 32788273
OWN - NLM
STAT- Publisher
LR  - 20200813
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 Aug 11
TI  - Medication use in the last year of life: a cross-sectional hospice study.
LID - bmjspcare-2019-002101 [pii]
LID - 10.1136/bmjspcare-2019-002101 [doi]
AB  - OBJECTIVES: The issue of polypharmacy and medication use in people with life
      limiting illness raises important questions from a clinical and ethical
      viewpoint. The objectives of our study were to (1) explore medication use among
      people with life limiting illness receiving hospice care; (2) apply consensus
      criteria to assess medication appropriateness; and (3) determine the overall pill
      burden in this patient population. METHODS: Six hospices in the North East of
      England were included. All deceased adult patients who received hospice care in
      2018 were eligible for study inclusion. Descriptive statistics were used to
      report medication details; while medication appropriateness was assessed
      according to consensus criteria developed by Morin and colleagues. RESULTS: Six
      hundred and ninety patients were included in the study. Patients were using a
      mean number of 8.8 medications per day, while polypharmacy was evident in 80% of 
      patients. In terms of potentially questionable medication, patients were
      prescribed a mean number of 1.3 per day. Common potentially questionable
      medications included vitamin and mineral supplements, antihypertensives,
      antiplatelets, lipid regulating agents and anticoagulants. The pill burden in
      this population was also high with, on average, people using 13.7 oral doses per 
      day. CONCLUSIONS: Polypharmacy is common in patients accessing hospice care, as
      is the use of potentially questionable medication. The pill burden in this
      patient population is also high, which may be an additional treatment burden to
      patients. Holistic deprescribing approaches for this population should be
      developed and implemented.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Scullion, Liam
AU  - Scullion L
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
FAU - Dodds, Hope
AU  - Dodds H
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
FAU - Liu, Qinghao
AU  - Liu Q
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
FAU - Hunt, Mary Elizabeth
AU  - Hunt ME
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
FAU - Gordon, Simon
AU  - Gordon S
AD  - St. Oswald's Hospice, Newcastle upon Tyne, UK.
FAU - Todd, Adam
AU  - Todd A
AUID- ORCID: http://orcid.org/0000-0003-1496-9341
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK
      adam.todd@newcastle.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200811
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - pharmacology
OT  - supportive care
OT  - survivorship
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2020/08/14 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/11/03 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
AID - bmjspcare-2019-002101 [pii]
AID - 10.1136/bmjspcare-2019-002101 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 Aug 11. pii: bmjspcare-2019-002101. doi:
      10.1136/bmjspcare-2019-002101.


PMID- 32788191
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20210324
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - COVID-19 emergency response assessment study: a prospective longitudinal survey
      of frontline doctors in the UK and Ireland: study protocol.
PG  - e039851
LID - 10.1136/bmjopen-2020-039851 [doi]
AB  - INTRODUCTION: The COVID-19 pandemic is putting an unprecedented strain on
      healthcare systems globally. The psychological impact on frontline doctors of
      dealing with the COVID-19 pandemic is currently unknown. This longitudinal
      professional survey aims to understand the evolving and cumulative effects of
      working during the COVID-19 outbreak on the psychological well-being of doctors
      working in emergency departments (ED), intensive care units (ICU) and
      anaesthetics during the pandemic. METHODS AND ANALYSIS: This study is a
      longitudinal questionnaire-based study with three predefined time points spanning
      the acceleration, peak and deceleration phases of the COVID-19 pandemic.The
      primary outcomes are psychological distress and post-trauma stress as measured by
      the General Health Questionnaire-12 (GHQ-12) and Impact of Events Scale-Revised
      (IES-R). Data related to personal and professional characteristics will also be
      collected. Questionnaires will be administered prospectively to all doctors
      working in ED, ICU and anaesthetics in the UK and Ireland via existing research
      networks during the sampling period. Data from the questionnaires will be
      analysed to assess the prevalence and degree of psychological distress and
      trauma, and the nature of the relationship between personal and professional
      characteristics and the primary outcomes. Data will be described, analysed and
      disseminated at each time point; however, the primary endpoint will be
      psychological distress and trauma at the final time point. ETHICS AND
      DISSEMINATION: Ethical approval was obtained from the University of Bath, UK
      (ref: 4421), and Children's Health Ireland at Crumlin, Ethics Committee.
      Regulatory approval from the Health Regulation Authority (UK), Health and Care
      Research Wales (IRAS: 281944).This study is limited by the fact that it focuses
      on doctors only and is survey based without further qualitative interviews of
      participants. It is expected this study will provide clear evidence of the
      psychological impact of COVID-19 on doctors and will allow present and future
      planning to mitigate against any psychological impact. TRIAL REGISTRATION NUMBER:
      ISRCTN10666798.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Roberts, Tom
AU  - Roberts T
AUID- ORCID: 0000-0003-4991-974X
AD  - Trainee Emergency Research Network, The Royal College of Emergency Medicine,
      London, UK tomkieranroberts@gmail.com.
AD  - Emergency Department, Bristol Royal Hospital for Children, Bristol, UK.
FAU - Daniels, Jo
AU  - Daniels J
AD  - Department of Psychology, University of Bath, Bath, Somerset, UK.
FAU - Hulme, William
AU  - Hulme W
AD  - Statistical Consultant, Oxford, UK.
FAU - Horner, Daniel
AU  - Horner D
AD  - Trainee Emergency Research Network, The Royal College of Emergency Medicine,
      London, UK.
AD  - Department of Intensive Care, Salford Royal Hospitals NHS Trust, Salford, UK.
FAU - Lyttle, Mark David
AU  - Lyttle MD
AUID- ORCID: 0000-0002-8634-7210
AD  - Emergency Department, Bristol Royal Hospital for Children, Bristol, UK.
AD  - Faculty of Health and Applied Science, University of the West of England,
      Bristol, UK.
FAU - Samuel, Katie
AU  - Samuel K
AD  - Department of Anaesthesia, North Bristol NHS Trust, Westbury on Trym, Bristol,
      UK.
FAU - Graham, Blair
AU  - Graham B
AD  - Faculty of Health, University of Plymouth, Plymouth, Devon, UK.
AD  - Emergency Department, Plymouth Hospitals NHS Foundation Trust, Plymouth, UK.
FAU - Hirst, Robert
AU  - Hirst R
AD  - Department of Anaesthesia, North Bristol NHS Trust, Westbury on Trym, Bristol,
      UK.
FAU - Reynard, Charles
AU  - Reynard C
AD  - Department of Cardviovascular Sciences, The University of Manchester, Manchester,
      UK.
FAU - Barrett, Michael
AU  - Barrett M
AUID- ORCID: 0000-0003-1775-8347
AD  - School of Medicine, Women's and Children's Health, University College Dublin,
      Dublin, Ireland.
FAU - Carlton, Edward
AU  - Carlton E
AD  - Trainee Emergency Research Network, The Royal College of Emergency Medicine,
      London, UK.
AD  - Emergency Department, North Bristol NHS Trust, Westbury on Trym, UK.
LA  - eng
SI  - ISRCTN/ISRCTN10666798
GR  - NIHR300246/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anesthesia Department, Hospital/organization & administration
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/*therapy/transmission
MH  - Emergency Service, Hospital/organization & administration
MH  - Humans
MH  - Infectious Disease Transmission, Professional-to-Patient/statistics & numerical
      data
MH  - Intensive Care Units/organization & administration
MH  - Ireland/epidemiology
MH  - Longitudinal Studies
MH  - Medical Staff, Hospital/*psychology
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/*therapy/transmission
MH  - Prevalence
MH  - Research Design
MH  - SARS-CoV-2
MH  - Self Report
MH  - Stress, Psychological/*epidemiology
MH  - Surveys and Questionnaires
MH  - United Kingdom/epidemiology
PMC - PMC7422647
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *anaesthetics
OT  - *intensive & critical care
OT  - *psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - bmjopen-2020-039851 [pii]
AID - 10.1136/bmjopen-2020-039851 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e039851. doi: 10.1136/bmjopen-2020-039851.


PMID- 32788190
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study
      protocol: a randomised controlled trial of the efficacy of HPV vaccination in
      preventing transmission of HPV infection in heterosexual couples.
PG  - e039383
LID - 10.1136/bmjopen-2020-039383 [doi]
AB  - INTRODUCTION: Human papillomavirus (HPV) is a causal agent of malignancies
      including cervical, vulvar, vaginal, penile, anal and oropharyngeal cancer, as
      well as benign conditions such as anogenital warts. HPV vaccination protects
      individuals against infections with the target HPV types and their clinical
      outcomes. However, little is known about the protection an immunised individual
      confers to their sexual partner or its impact on HPV transmission dynamics. In
      this context, the Transmission Reduction and Prevention with HPV vaccination
      (TRAP-HPV) study was designed to determine the efficacy of an HPV vaccine in
      reducing transmission of genital and oral HPV infection in sexual partners of
      vaccinated individuals. METHODS AND ANALYSIS: The TRAP-HPV study is an ongoing
      randomised controlled trial among heterosexual couples living in Montreal,
      Canada. Sexually active couples, aged between 18 and 45 years, who have been in a
      relationship no longer than 6 months are considered eligible. Participants are
      independently randomised to receive either the intervention HPV vaccine, Gardasil
      9, or a placebo hepatitis A vaccine, Avaxim, creating four vaccination groups
      among couples: intervention-intervention, intervention-placebo,
      placebo-intervention and the placebo-placebo. Participants provide genital
      (vaginal/penile) and oral samples at baseline and five follow-up visits over a
      1-year duration. Linear Array HPV genotyping is used to detect 36 HPV types. Cox 
      proportional hazard regression models will be used to estimate the effect of
      vaccination on HPV transmission. ETHICS AND DISSEMINATION: The TRAP-HPV study
      received ethical approval by institutional review boards McGill University,
      Concordia University and Centre Hospitalier de l'Universite de Montreal. Before
      enrolment, all participants provide informed written consent. Results will be
      published in peer-reviewed journals and presented at national and international
      conferences. The generated empirical evidence could be used in mathematical
      models of vaccination to inform policymakers in Canada and elsewhere. TRIAL
      REGISTRATION NUMBER: NCT01824537.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - MacCosham, Aaron
AU  - MacCosham A
AD  - Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
FAU - El-Zein, Mariam
AU  - El-Zein M
AD  - Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
FAU - Burchell, Ann N
AU  - Burchell AN
AD  - Department of Family and Community Medicine and Centre for Research on Inner City
      Health, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health
      Toronto, Toronto, Ontario, Canada.
AD  - Department of Family and Community Medicine, University of Toronto Faculty of
      Medicine, Toronto, Ontario, Canada.
FAU - Tellier, Pierre-Paul
AU  - Tellier PP
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada.
FAU - Coutlee, Francois
AU  - Coutlee F
AD  - Service de Microbiologie Medicale et Service d'Infectiologie, Departements de
      Medecine et de Medecine de Laboratoire, Centre Hospitalier de L'Universite de
      Montreal, Montreal, Quebec, Canada.
FAU - Franco, Eduardo L
AU  - Franco EL
AUID- ORCID: 0000-0002-4409-8084
AD  - Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada
      eduardo.franco@mcgill.ca.
LA  - eng
SI  - ClinicalTrials.gov/NCT01824537
GR  - MOP-125949/CAPMC/ CIHR/Canada
GR  - FDN-143347/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
EIN - BMJ Open. 2020 Aug 24;10(8):e039383corr1. PMID: 32839158
MH  - Canada
MH  - Child, Preschool
MH  - Female
MH  - Heterosexuality
MH  - Humans
MH  - Infant
MH  - *Papillomavirus Infections/prevention & control
MH  - *Papillomavirus Vaccines
MH  - Randomized Controlled Trials as Topic
MH  - *Uterine Cervical Neoplasms/prevention & control
MH  - Vaccination
PMC - PMC7422656
OTO - NOTNLM
OT  - *epidemiology
OT  - *infection control
OT  - *public health
COIS- Competing interests: TRAP-HPV study group: Affiliated with the Division of Cancer
      Epidemiology, McGill University, Montreal, Canada: Allita Rodrigues (study
      coordinator); Natalia Morykon and Raphaela Rodrigues (management of subject
      participation and specimen collection); Sheila Bouten and Samantha Shapiro (data 
      management). Affiliated with the Departement de Microbiologie Medicale et
      Infectiologie, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, 
      Canada: Julie Guenoun (HPV testing and genotyping).
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039383 [pii]
AID - 10.1136/bmjopen-2020-039383 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e039383. doi: 10.1136/bmjopen-2020-039383.


PMID- 32788189
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Place4Carers: a mixed-method study protocol for engaging family caregivers in
      meaningful actions for successful ageing in place.
PG  - e037570
LID - 10.1136/bmjopen-2020-037570 [doi]
AB  - INTRODUCTION: Engaging family caregivers could be a critical asset to make the
      'ageing-in-place' imperative a reality. This is particularly evident in rural and
      remote areas, where caregivers can fill the gaps that exist due to the
      fragmentation of the welfare system. However, there is little knowledge about the
      expectations that family caregivers have from healthcare services in rural and
      remote areas.Place4Carers (P4C) project aims to co-produce an innovative
      organisational model of social and healthcare services for family caregivers of
      older citizens living in Vallecamonica (Italy). The project is expected to
      facilitate ageing-in-place for older citizens, thus helping caregivers in their
      daily care activities. METHODS AND ANALYSIS: P4C is a community-based
      participatory research project featuring five work packages (WPs). WP1 consists
      of a survey of unmet needs of caregivers and older people receiving services in
      Vallecamonica. WP2 consists of a scoping literature review to map services that
      provide interventions of support to caregivers living in remote areas and promote
      engagement. WP3 organises co-creation workshops with caregivers to co-design,
      co-manage, and co-assess ideas and proposals for shaping caregiver-oriented
      services and organisational models. WP3 enriches the results of WP1 (survey) and 
      WP2 (scoping literature review), and aims to co-create new ideas for intervention
      support with and for caregivers in relation to the objectives, features and
      characteristics of a new service able to address the caregivers' needs and
      expectations. WP4 tests the service ideas co-created in WP3 through piloting an
      intervention based on ideas co-created with caregivers. Finally, WP5 assesses the
      transferability of the intervention to other similar contexts. ETHICS AND
      DISSEMINATION: The study has been approved by the Ethics Committees of the
      Department of Psychology of Universita Cattolica del Sacro Cuore and Politecnico 
      of Milan. Results will be disseminated through peer-reviewed journals, scientific
      meetings and meetings with the general population.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Graffigna, Guendalina
AU  - Graffigna G
AD  - EngageMinds HUB - Consumer, Food & Health Engagement Research Center, Universita 
      Cattolica del Sacro Cuore, Milan and Cremona, Italy.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Barello, Serena
AU  - Barello S
AUID- ORCID: 0000-0002-8514-2563
AD  - EngageMinds HUB - Consumer, Food & Health Engagement Research Center, Universita 
      Cattolica del Sacro Cuore, Milan and Cremona, Italy serena.barello@unicatt.it.
AD  - Department of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
FAU - Morelli, Niccolo
AU  - Morelli N
AD  - EngageMinds HUB - Consumer, Food & Health Engagement Research Center, Universita 
      Cattolica del Sacro Cuore, Milan and Cremona, Italy.
AD  - Department of Sociology and Business Law, Universita di Bologna, Bologna, Italy.
FAU - Gheduzzi, Eleonora
AU  - Gheduzzi E
AD  - Department of Management Engineering, Politecnico di Milano, Milano, Italy.
FAU - Corbo, Massimo
AU  - Corbo M
AD  - Department of Neurorehabilitation Sciences, Casa Cura Policlinico (CCP), Milano, 
      Italy.
AD  - Fondazione NEED Institute, Milan, Italy.
FAU - Ginex, Valeria
AU  - Ginex V
AD  - Department of Neurorehabilitation Sciences, Casa Cura Policlinico (CCP), Milano, 
      Italy.
AD  - Fondazione NEED Institute, Milan, Italy.
FAU - Ferrari, Roberta
AU  - Ferrari R
AD  - Azienda Territoriale per i Servizi alla Persona Vallecamonica, Breno, Italy.
FAU - Lascioli, Andrea
AU  - Lascioli A
AD  - Azienda Territoriale per i Servizi alla Persona Vallecamonica, Breno, Italy.
FAU - Feriti, Carolina
AU  - Feriti C
AD  - Azienda Territoriale per i Servizi alla Persona Vallecamonica, Breno, Italy.
FAU - Masella, Cristina
AU  - Masella C
AD  - Department of Management Engineering, Politecnico di Milano, Milano, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging
MH  - *Caregivers
MH  - Humans
MH  - *Independent Living
MH  - Italy
MH  - Rural Population
PMC - PMC7422654
OTO - NOTNLM
OT  - *health services administration & management
OT  - *organisation of health services
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037570 [pii]
AID - 10.1136/bmjopen-2020-037570 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e037570. doi: 10.1136/bmjopen-2020-037570.


PMID- 32788188
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Electronic health records (EHR) simulation-based training: a scoping review
      protocol.
PG  - e036884
LID - 10.1136/bmjopen-2020-036884 [doi]
AB  - INTRODUCTION: Effective electronic health record (EHR)-based training
      interventions facilitate improved EHR use for healthcare providers. One such
      training intervention is simulation-based training that emphasises learning
      actual tasks through experimentation in a risk-free environment without negative 
      patient outcomes. EHR-specific simulation-based training can be employed to
      improve EHR use, thereby enhancing healthcare providers' skills and behaviours.
      Despite the potential advantages of this type of training, no study has
      identified and mapped the available evidence. To fill that gap, this scoping
      review will synthesise the current state of literature on EHR simulation-based
      training. METHODS AND ANALYSIS: The Arksey and O'Malley methodological framework 
      will be employed. Three databases (PubMed, Embase and Cumulative Index to Nursing
      and Allied Health Literature) will be searched for published articles. ProQuest
      and Google Scholar will be searched to identify unpublished articles. Databases
      will be searched from inception to 29 January 2020. Only articles written in
      English, randomised control trials, cohort studies, cross-sectional studies and
      case-control studies will be considered for inclusion. Two reviewers will
      independently screen titles and abstracts against inclusion and exclusion
      criteria. Then, they will review full texts to determine articles for final
      inclusion. Citation chaining will be conducted to manually screen references of
      all included studies to identify additional studies not found by the search. A
      data abstraction form with relevant characteristics will be developed to help
      address the research question. Descriptive numerical analysis will be used to
      describe characteristics of included studies. Based on the extracted data,
      research evidence of EHR simulation-based training will be synthesised. ETHICS
      AND DISSEMINATION: Since no primary data will be collected, there will be no
      formal ethical review. Research findings will be disseminated through
      publications, presentations and meetings with relevant stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nuamah, Joseph K
AU  - Nuamah JK
AUID- ORCID: 0000-0001-7172-0716
AD  - Department of Radiation Oncology, UNC-Chapel Hill, Chapel Hill, North Carolina,
      USA jnuamah@okstate.edu.
FAU - Adapa, Karthik
AU  - Adapa K
AUID- ORCID: 0000-0002-3970-588X
AD  - Department of Radiation Oncology, UNC-Chapel Hill, Chapel Hill, North Carolina,
      USA.
AD  - Carolina Health Informatics Program, UNC-Chapel Hill, Chapel Hill, NC, United
      States.
FAU - Mazur, Lukasz
AU  - Mazur L
AD  - Department of Radiation Oncology, UNC-Chapel Hill, Chapel Hill, North Carolina,
      USA.
AD  - Carolina Health Informatics Program, UNC-Chapel Hill, Chapel Hill, NC, United
      States.
LA  - eng
GR  - R18 HS025597/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care
MH  - *Electronic Health Records
MH  - Health Personnel
MH  - Humans
MH  - *Research Design
MH  - Review Literature as Topic
PMC - PMC7422637
OTO - NOTNLM
OT  - *general medicine (see Internal Medicine)
OT  - *health informatics
OT  - *information management
OT  - *information technology
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036884 [pii]
AID - 10.1136/bmjopen-2020-036884 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e036884. doi: 10.1136/bmjopen-2020-036884.


PMID- 32788187
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210924
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Interventions to improve the quality of cataract services: protocol for a global 
      scoping review.
PG  - e036413
LID - 10.1136/bmjopen-2019-036413 [doi]
AB  - INTRODUCTION: Cataract is the leading cause of blindness globally and a major
      cause of vision impairment. Cataract surgery is an efficacious intervention that 
      usually restores vision. Although it is one of the most commonly conducted
      surgical interventions worldwide, good quality services (from being detected with
      operable cataract to undergoing surgery and receiving postoperative care) are not
      universally accessible. Poor quality understandably reduces the willingness of
      people with operable cataract to undergo surgery. Therefore, it is critical to
      improve the quality of care to subsequently reduce vision loss from cataract.
      This scoping review aims to summarise the nature and extent of the published
      literature on interventions to improve the quality of services for primary
      age-related cataract globally. METHODS AND ANALYSIS: We will search MEDLINE,
      Embase and Global Health for peer-reviewed manuscripts published since 1990, with
      no language, geographic or study design restrictions. To define quality, we have 
      used the elements adopted by the WHO-effectiveness, safety, people-centredness,
      timeliness, equity, integration and efficiency-to which we have added the element
      of planetary health. We will exclude studies focused on the technical aspects of 
      the surgical procedure and studies that only involve children (<18 years). Two
      reviewers will screen all titles/abstracts independently, followed by a full-text
      review of potentially relevant articles. For included articles, data regarding
      publication characteristics, study details and quality-related outcomes will be
      extracted by two reviewers independently. Results will be synthesised narratively
      and presented visually using a spider chart. ETHICS AND DISSEMINATION: Ethical
      approval was not sought, as our review will only include published and publicly
      accessible information. We will publish our findings in an open-access
      peer-reviewed journal and develop an accessible summary of the results for
      website posting. A summary of the results will be included in the ongoing Lancet 
      Global Health Commission on Global Eye Health. REGISTRATION DETAILS: Open Science
      Framework (https://osf.io/8gktz).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Yoshizaki, Miho
AU  - Yoshizaki M
AUID- ORCID: 0000-0003-1893-5675
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK miho.yoshizaki@nhs.net.
FAU - Ramke, Jacqueline
AU  - Ramke J
AUID- ORCID: 0000-0002-5764-1306
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - School of Optometry and Vision Science, The University of Auckland, Auckland, New
      Zealand.
FAU - Furtado, Joao M
AU  - Furtado JM
AD  - Division of Ophthalmology, Universidade de Sao Paulo, Faculdade de Medicina de
      Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Burn, Helen
AU  - Burn H
AD  - Department of Ophthalmology, Stoke Mandeville Hospital, Aylesbury,
      Buckinghamshire, UK.
FAU - Gichuhi, Stephen
AU  - Gichuhi S
AD  - Department of Ophthalmology, University of Nairobi, Nairobi, Kenya.
FAU - Gordon, Iris
AU  - Gordon I
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Aghaji, Ada
AU  - Aghaji A
AD  - Department of Ophthalmology, University of Nigeria, Nsukka, Enugu, Nigeria.
FAU - Marques, Ana P
AU  - Marques AP
AUID- ORCID: 0000-0001-8242-7021
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Dean, William H
AU  - Dean WH
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Department of Ophthalmology, University of Cape Town, Rondebosch, Western Cape,
      South Africa.
FAU - Congdon, Nathan
AU  - Congdon N
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
AD  - Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China.
FAU - Buchan, John
AU  - Buchan J
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Burton, Matthew J
AU  - Burton MJ
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
LA  - eng
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cataract/therapy
MH  - *Cataract Extraction
MH  - Child
MH  - Delivery of Health Care
MH  - Global Health
MH  - Humans
MH  - Review Literature as Topic
MH  - Vision, Ocular
PMC - PMC7422650
OTO - NOTNLM
OT  - *cataract and refractive surgery
OT  - *health policy
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036413 [pii]
AID - 10.1136/bmjopen-2019-036413 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e036413. doi: 10.1136/bmjopen-2019-036413.


PMID- 32787950
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 12
TI  - Shared decision making in surgery: a scoping review of patient and surgeon
      preferences.
PG  - 190
LID - 10.1186/s12911-020-01211-0 [doi]
AB  - BACKGROUND: Many suggest that shared decision-making (SDM) is the most effective 
      approach to clinical counseling. It is unclear if this applies to surgical
      decision-making-especially regarding urgent, highly-morbid operations. In this
      scoping review, we identify articles that address patient and surgeon preferences
      toward SDM in surgery. METHODS: We used the Preferred Reporting Items for
      Systematic Reviews and Meta-analyses extension for Scoping Reviews (PRISMA-ScR)
      to develop our protocol. Medline, EMBASE, and Cochrane databases were searched
      from inception through 11.2017. Title/abstract review identified peer-reviewed,
      empirical articles that addressed patient/surgeon preferences toward SDM in
      surgery. Identified articles underwent full review by two independent
      investigators. We addressed the following questions: (1) What is known from
      existing empirical evidence about patients' and/or surgeons' surgical
      decision-making preferences? (2) Why might patients and/or surgeons prefer SDM?
      (3) Does acuity of intervention impact surgical decision-making preferences?
      Outcome measures included study methods, surgical specialty, diagnosis, study
      location/setting, type/number of subjects, acuity of intervention,
      surgeon/patient decision-making preferences, and factors associated with favoring
      SDM. Data was analyzed in Microsoft Excel. RESULTS: 20,359 articles were
      identified with 4988 duplicates, yielding 15,371 articles for title/abstract
      review. 74 articles were included in final analysis. 68% of articles discussed
      oncologic decision-making. 46% of these focused on breast cancer. 92% of articles
      included patients, 22% included surgeons. 75% of articles found surgeons favored 
      SDM, 25% demonstrated surgeons favored surgeon guidance. 54% of articles
      demonstrated patients favored SDM, 35% showed patients favored surgeon guidance, 
      11% showed patients preferred independent decision-making. The most common
      factors for patients favoring SDM included female gender, higher education, and
      younger age. For surgeons, the most common factors for favoring SDM included
      limited evidence for a given treatment plan, multiple treatment options, and
      impact on patient lifestyle. No articles evaluated decision-making preferences in
      an emergent setting. CONCLUSIONS: There has been limited evaluation of patient
      and surgeon preferences toward SDM in surgical decision-making. Generally,
      patients and surgeons expressed preference toward SDM. None of the articles
      evaluated decision-making preferences in an emergent setting, so assessment of
      the impact of acuity on decision-making preferences is limited. Extension of
      research to complex, emergent clinical settings is needed.
FAU - Shinkunas, Laura A
AU  - Shinkunas LA
AD  - Program in Bioethics and Humanities, University of Iowa Carver College of
      Medicine, Iowa City, USA.
FAU - Klipowicz, Caleb J
AU  - Klipowicz CJ
AD  - Department of Anthropology, University of Iowa, Iowa City, USA.
FAU - Carlisle, Erica M
AU  - Carlisle EM
AUID- ORCID: 0000-0002-3884-9793
AD  - Program in Bioethics and Humanities, University of Iowa Carver College of
      Medicine, Iowa City, USA. erica-carlisle@uiowa.edu.
AD  - Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, USA. 
      erica-carlisle@uiowa.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200812
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - Aged
MH  - Decision Making
MH  - *Decision Making, Shared
MH  - Female
MH  - Humans
MH  - Male
MH  - *Patient Participation
MH  - Patient Preference/*psychology
MH  - *Physician-Patient Relations
MH  - *Surgeons
PMC - PMC7424662
OTO - NOTNLM
OT  - *Ethics
OT  - *Shared decision making
OT  - *Surgery
EDAT- 2020/08/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12911-020-01211-0 [doi]
AID - 10.1186/s12911-020-01211-0 [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Aug 12;20(1):190. doi: 10.1186/s12911-020-01211-0.


PMID- 32787817
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1471-2482 (Electronic)
IS  - 1471-2482 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 12
TI  - Robotic assisted treatment of flank hernias: case series.
PG  - 184
LID - 10.1186/s12893-020-00843-3 [doi]
AB  - BACKGROUND: Flank hernias are uncommon, surgical treatment is challenging and the
      minimally-invasive approach not always feasible. The aim of this study was to
      report the safety and feasibility of the robotic-assisted repair. METHODS: The
      study was approved by the local ethic committee (2019-01132 CE3495). A
      retrospective search on a prospectively collected dataset including demographic
      and clinical records on robotic surgery at our institution was performed to
      identify patients treated for a flank hernia. Patients were followed-up 6 months.
      RESULTS: From January 2018 to December 2019, out of 190 patients who underwent
      robotic-assisted hernia surgery, seven with incisional flank hernia were
      included. Median age was 69.0 years (IQR 63.2-78.0), BMI was 27.3 kg/m(2) (IQR
      25.8-32.3) and two patients were male (29%). All patients were referred to
      surgery because of pain, whereas one of them described recurrent episodes of
      small bowel obstruction. The median hernia defect measured 25 mm ((IQR 21-40),
      median mesh diameter was 10 cm (IQR 10-12.5) and median operative time was 137
      min (IQR 133-174). No intraoperative complication occurred. Postoperatively, one 
      patient developed a pneumonia, which required antibiotics. Length of hospital
      stay was 4.0 days (IQR 3.0-7.7). Six months after surgery, neither recurrence nor
      chronic pain were recorded. CONCLUSIONS: Robotics in abdominal wall hernia
      surgery remains a matter of debate, despite a growing interest from the surgical 
      community. In our reported experience with flank hernias, we found the
      robotic-assisted approach to be safe and feasible for the treatment of this
      uncommon clinical entity.
FAU - Di Giuseppe, Matteo
AU  - Di Giuseppe M
AD  - Department of Surgery, Ospedale Regionale di Bellinzona e Valli, via Ospedale 12,
      6500, Bellinzona, Switzerland.
FAU - Mongelli, Francesco
AU  - Mongelli F
AUID- ORCID: http://orcid.org/0000-0002-8824-651X
AD  - Department of Surgery, Ospedale Regionale di Lugano, via Tesserete 46, 6900,
      Lugano, Switzerland. francesco.mongelli@mail.com.
FAU - Marcantonio, Maria
AU  - Marcantonio M
AD  - Department of Surgery, Ospedale Regionale di Bellinzona e Valli, via Ospedale 12,
      6500, Bellinzona, Switzerland.
FAU - La Regina, Davide
AU  - La Regina D
AD  - Department of Surgery, Ospedale Regionale di Bellinzona e Valli, via Ospedale 12,
      6500, Bellinzona, Switzerland.
FAU - Pini, Ramon
AU  - Pini R
AD  - Department of Surgery, Ospedale Regionale di Bellinzona e Valli, via Ospedale 12,
      6500, Bellinzona, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - England
TA  - BMC Surg
JT  - BMC surgery
JID - 100968567
SB  - IM
MH  - *Abdominal Wall/surgery
MH  - Aged
MH  - Feasibility Studies
MH  - Female
MH  - *Hernia, Ventral/etiology/surgery
MH  - Herniorrhaphy/instrumentation/*methods
MH  - Humans
MH  - *Laparoscopy/adverse effects/instrumentation
MH  - Laparotomy/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Robotic Surgical Procedures/*methods
MH  - Surgical Mesh
MH  - Treatment Outcome
PMC - PMC7430830
OTO - NOTNLM
OT  - Abdominal wall
OT  - Flank hernia
OT  - Mesh
OT  - Minimally invasive
OT  - Robotic-assisted
EDAT- 2020/08/14 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1186/s12893-020-00843-3 [doi]
AID - 10.1186/s12893-020-00843-3 [pii]
PST - epublish
SO  - BMC Surg. 2020 Aug 12;20(1):184. doi: 10.1186/s12893-020-00843-3.


PMID- 32787665
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2043-6289 (Electronic)
IS  - 0266-7681 (Linking)
VI  - 45
IP  - 7
DP  - 2020 Sep
TI  - Publication ethics.
PG  - 770-774
LID - 10.1177/1753193420905263 [doi]
FAU - Boeckstyns, Michel E H
AU  - Boeckstyns MEH
AD  - Editor, The Journal of Hand Surgery (European Volume).
FAU - Giddins, Grey
AU  - Giddins G
AD  - Editor-in-Chief, The Journal of Hand Surgery (European Volume [2012--2016]).
FAU - Meals, Roy
AU  - Meals R
AD  - Editor-in-Chief, The Journal of Hand Surgery (American Volume [2011--2015]).
FAU - Tang, Jin Bo
AU  - Tang JB
AD  - Editor-in-Chief, The Journal of Hand Surgery (European Volume).
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Hand Surg Eur Vol
JT  - The Journal of hand surgery, European volume
JID - 101315820
SB  - IM
MH  - *Authorship
MH  - Humans
MH  - *Publishing
EDAT- 2020/08/14 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1177/1753193420905263 [doi]
PST - ppublish
SO  - J Hand Surg Eur Vol. 2020 Sep;45(7):770-774. doi: 10.1177/1753193420905263.


PMID- 32787541
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 2242-3982 (Electronic)
IS  - 1239-9736 (Linking)
VI  - 79
IP  - 1
DP  - 2020 Dec
TI  - Recruitment best practices of a cardiovascular risk reduction randomised control 
      trial in rural Alaska Native communities.
PG  - 1806639
LID - 10.1080/22423982.2020.1806639 [doi]
AB  - Though not native to Alaska, tobacco use is common among Alaska Native people in 
      the Norton Sound region, an area consisting of 16 communities with population
      size 107 to 3,695. We summarise best practices in recruiting Alaska Native adults
      who smoke for a randomised controlled tobacco treatment trial. Participants were 
      Alaska Native, 19 years and older, smoking daily, with hypertension and/or high
      cholesterol, residing in the Norton Sound region of Alaska. Study staff travelled
      to the remote communities to recruit, typically staying 5 days. Screening and
      enrolment success was examined by day, season, and staffing level. From June 2015
      - December 2018, the study team made 122 trips, screening 1089 individuals and
      enrolling 314 participants. In the field, days 2-3 (51%) were best for screening,
      while days 3-4 (53%) had the greatest enrolment. Community size correlated with
      enrolment (r = 0.83, p <.001). Recruitment was optimised in spring and with
      multiple staff in the field. Despite challenges (e.g., harsh weather, poor
      internet connectivity), with active outreach (e.g. tabling in busy areas,
      attending community events, utilising mixed media, collaborating with clinic
      staff), the project reached its recruitment goal. Study findings can inform
      community-based tobacco treatment research trials in remote areas. ABBREVIATIONS:
      CVD: Cardiovascular disease; VTC: Video teleconferencing; ANMC: Alaska Native
      Medical Centre; HEALTHH: Healing and Empowering Alaskan Lives Towards Healthy
      Hearts; NSHC: Norton Sound Health Corporation; RERB: Research Ethics Review
      Board.
FAU - Knox, Mariah
AU  - Knox M
AUID- ORCID: 0000-0002-8163-9097
AD  - Cardiology Department, Alaska Native Tribal Health Consortium , Anchorage, AK,
      USA.
FAU - Skan, Jordan
AU  - Skan J
AD  - Cardiology Department, Alaska Native Tribal Health Consortium , Anchorage, AK,
      USA.
FAU - Benowitz, Neal L
AU  - Benowitz NL
AD  - Department of Medicine, Division of Cardiology, University of California , San
      Francisco, CA, USA.
FAU - Schnellbaecher, Matthew
AU  - Schnellbaecher M
AD  - Cardiology Department, Alaska Native Tribal Health Consortium , Anchorage, AK,
      USA.
FAU - Prochaska, Judith J
AU  - Prochaska JJ
AD  - Stanford Prevention Research Center, Department of Medicine, Stanford University.
LA  - eng
GR  - R01 HL117736/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Int J Circumpolar Health
JT  - International journal of circumpolar health
JID - 9713056
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Alaskan Natives
MH  - Arctic Regions/epidemiology
MH  - Cardiovascular Diseases/*prevention & control
MH  - Female
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Hypercholesterolemia/ethnology
MH  - Hypertension/ethnology
MH  - Male
MH  - Middle Aged
MH  - Personnel Selection/*organization & administration
MH  - Research Design
MH  - *Rural Population
MH  - Seasons
MH  - Tobacco Use/*ethnology
MH  - Transportation
MH  - Young Adult
PMC - PMC7480599
OTO - NOTNLM
OT  - *Alaska Native
OT  - *Recruitment strategies
OT  - *cardiovascular health
OT  - *rural
EDAT- 2020/08/14 06:00
MHDA- 2021/10/06 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
AID - 10.1080/22423982.2020.1806639 [doi]
PST - ppublish
SO  - Int J Circumpolar Health. 2020 Dec;79(1):1806639. doi:
      10.1080/22423982.2020.1806639.


PMID- 32787508
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20211002
IS  - 1744-4144 (Electronic)
IS  - 1385-4046 (Linking)
VI  - 34
IP  - 7-8
DP  - 2020 Oct - Nov
TI  - Pediatric neuropsychological evaluation via telehealth: Novel models of care.
PG  - 1367-1379
LID - 10.1080/13854046.2020.1806359 [doi]
AB  - Objective: As the coronavirus pandemic extends across the globe, the impacts have
      been felt across domains of industry. Neuropsychology services are no exception. 
      Methods for neuropsychological assessments, which typically require an in-person 
      visit, must be modified in order to adhere to social distancing and isolation
      standards enacted in an effort to slow the pandemic. How can providers continue
      to meet the needs of patients referred for neuropsychology evaluations, while
      respecting federal and state guidelines for safety and ethical mandates? We offer
      a novel, tiered model of care, successfully implemented in response to mandated
      social distancing, in a large, pediatric neuropsychology program.Method: We
      describe the considerations and challenges to be addressed in transitioning a
      large neuropsychology department to a new model of care, including triaging
      referrals, developing -or rediscovering - types of services to meet the needs of 
      a virtual patient population, and helping patients, parents, and providers to
      adjust to these new models.Conclusions: Lessons learned as a function of rapid
      changes in care models have implications for the field of neuropsychology as a
      whole as well as for future flexibility in meeting the needs of pediatric
      patients and their families.
FAU - Pritchard, Alison E
AU  - Pritchard AE
AD  - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD, USA.
AD  - Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
FAU - Sweeney, Kristie
AU  - Sweeney K
AD  - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD, USA.
FAU - Salorio, Cynthia F
AU  - Salorio CF
AD  - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD, USA.
AD  - Department of Physical Medicine & Rehabilitation, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
FAU - Jacobson, Lisa A
AU  - Jacobson LA
AUID- ORCID: 0000-0002-6992-029X
AD  - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD, USA.
AD  - Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of
      Medicine, Baltimore, MD, USA.
LA  - eng
GR  - P50 HD103538/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200813
PL  - England
TA  - Clin Neuropsychol
JT  - The Clinical neuropsychologist
JID - 8806548
SB  - IM
MH  - Child
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Humans
MH  - Neurodevelopmental Disorders/epidemiology/psychology/*therapy
MH  - *Neuropsychological Tests
MH  - Neuropsychology/methods/*trends
MH  - Parents/psychology
MH  - Telemedicine/methods/*trends
PMC - PMC8106922
MID - NIHMS1690553
OTO - NOTNLM
OT  - *COVID-19
OT  - *assessment
OT  - *child neuropsychology
OT  - *evaluation
OT  - *telehealth
EDAT- 2020/08/14 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1080/13854046.2020.1806359 [doi]
PST - ppublish
SO  - Clin Neuropsychol. 2020 Oct - Nov;34(7-8):1367-1379. doi:
      10.1080/13854046.2020.1806359. Epub 2020 Aug 13.


PMID- 32787392
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 2078-6204 (Electronic)
IS  - 2078-6190 (Linking)
VI  - 62
IP  - 1
DP  - 2020 Jul 16
TI  - Final-year medical students need to know their future supervisory role of
      clinical associates.
PG  - e1-e4
LID - 10.4102/safp.v62i1.5019 [doi]
AB  - BACKGROUND: A clinical associate (ClinA) is a mid-level health professional who
      may only practise under the supervision of a medical doctor. By extension,
      medical students need to be prepared for this responsibility. This study explored
      whether final-year medical students at one university were aware of this
      supervisory role, felt prepared and were knowledgeable about the ClinAs' scope of
      practice. METHODS: A descriptive, cross-sectional study was conducted. The
      population included all final-year medical students who had completed their
      District Health and Community Obstetrics rotations (March to November 2017).
      After an end-of-rotation session, 151 students were given questionnaires to
      complete. A list of 20 treatments or procedures was extracted from the ClinAs'
      gazetted scope of practice for a 'knowledge test'. Data were analysed with Stata 
      and Microsoft Excel. Ethical permission was granted. RESULTS: The response rate
      was 77.4% (n/N = 117/151). The majority of participants (76.1%, n = 86) had
      worked with a qualified or student ClinA before and had a generally positive
      impression (81.4%; n = 70). Almost half (47.8%; n = 56) thought that the ClinAs' 
      scope of work was similar to registered nurses rather than a doctor's (38.2%; n =
      44). Most were unaware that they would be required to supervise ClinAs once
      qualified (65.8%; n = 77). On average, participants identified 12 out of 20
      treatments or procedures that a ClinA could perform. CONCLUSION: Despite having
      worked with ClinAs, participants appeared largely unaware of their future legal
      obligation of supervision. Adequate clinical supervision is based on the
      knowledge of the scope of practice, which was variable. Formal training on the
      scope of the work of ClinAs is needed to prepare future doctors for their
      supervisory role. Medical schools have an obligation to adequately prepare their 
      students in this regard as part of their transformative education with elements
      of interprofessional education.
FAU - Koortzen, Michiel
AU  - Koortzen M
AD  - School of Medicine, University of Pretoria, Pretoria. michiel.koortzen@gmail.com.
FAU - Biggs, Lourens W
AU  - Biggs LW
FAU - Wolvaardt, Jacqueline
AU  - Wolvaardt J
FAU - Turner, Astrid
AU  - Turner A
FAU - Bac, Martin
AU  - Bac M
FAU - Volpe, Mark
AU  - Volpe M
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - South Africa
TA  - S Afr Fam Pract (2004)
JT  - South African family practice : official journal of the South African Academy of 
      Family Practice/Primary Care
JID - 9701104
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Nursing, Supervisory
MH  - Preceptorship
MH  - Schools, Medical
MH  - *Students, Medical
PMC - PMC8377999
OTO - NOTNLM
OT  - *ClinA
OT  - *Clinical associate
OT  - *bachelor of clinical medical practice
OT  - *clinical supervision
OT  - *doctors
OT  - *medical students
EDAT- 2020/08/14 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.4102/safp.v62i1.5019 [doi]
PST - epublish
SO  - S Afr Fam Pract (2004). 2020 Jul 16;62(1):e1-e4. doi: 10.4102/safp.v62i1.5019.


PMID- 32787385
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 2078-6204 (Electronic)
IS  - 2078-6190 (Linking)
VI  - 62
IP  - 1
DP  - 2020 Jul 23
TI  - Assessing the quality of postnatal care offered to mothers and babies by midwives
      in Lilongwe District.
PG  - e1-e6
LID - 10.4102/safp.v62i1.5026 [doi]
AB  - BACKGROUND: The quality of care received by mothers and newborns in low-resource 
      settings is often poor. This may partly explain the high rates of maternal deaths
      (60%) that occur during the postpartum period in Malawi. However, the quality of 
      care provided to mothers and newborns in the country has not been adequately
      assessed. Therefore, this study aimed at assessing the quality of postnatal care 
      services offered to mothers and babies by midwives in Lilongwe District. METHODS:
      This was a quantitative study that used a sample of 58 midwives to assess the
      quality of postnatal care at three selected health facilities. A structured
      questionnaire, an observation tool and a facility checklist were used to collect 
      data. Descriptive statistics were used to analyse the data. The study received
      ethics approval from the relevant authority. RESULTS: The study found that the
      percentages reported by midwives regarding client monitoring varied and were
      below the 80% threshold. Midwives did not always follow the reproductive health
      standards on client examination so that less than 75% of midwives inspected
      perineal wounds (52.2%), checked vital signs of neonate (66.7%) and mother
      (62.2%), and inspected lochia drainage (30.4%). Most midwives (91.3%) never
      assessed the emotional state of the mother. Midwives covered a range of topics
      during health education and counselling. However, some topics, including
      immunisations (31.1%), were never taught. CONCLUSION: The study has suggested
      that the postnatal care offered by midwives at three health facilities was
      generally substandard and midwives do not always monitor, assess and counsel
      postnatal clients.
FAU - Pindani, Mercy
AU  - Pindani M
AD  - Department of Community Health, Faculty of Community Health Studies, Kamuzu
      College of Nursing, Lilongwe. mercypindani@kcn.unima.mw.
FAU - Phiri, Chrissie
AU  - Phiri C
FAU - Chikazinga, Wanangwa
AU  - Chikazinga W
FAU - Chilinda, Idesi
AU  - Chilinda I
FAU - Botha, Janet
AU  - Botha J
FAU - Chorwe-Sungani, Genesis
AU  - Chorwe-Sungani G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - South Africa
TA  - S Afr Fam Pract (2004)
JT  - South African family practice : official journal of the South African Academy of 
      Family Practice/Primary Care
JID - 9701104
SB  - IM
MH  - Female
MH  - Health Facilities
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Midwifery
MH  - *Mothers
MH  - Postnatal Care
MH  - Postpartum Period
MH  - Pregnancy
PMC - PMC8378184
OTO - NOTNLM
OT  - *babies
OT  - *midwives
OT  - *postnatal care
OT  - *quality
EDAT- 2020/08/14 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/03/14 00:00 [revised]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.4102/safp.v62i1.5026 [doi]
PST - epublish
SO  - S Afr Fam Pract (2004). 2020 Jul 23;62(1):e1-e6. doi: 10.4102/safp.v62i1.5026.


PMID- 32787342
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 2304-3873 (Electronic)
IS  - 2304-3865 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Oct
TI  - BRCA sequencing of tumors: understanding its implications in the oncology
      community.
PG  - 66
LID - 10.21037/cco-19-198 [doi]
AB  - In the current era of personalized medicine, much more information can be gleaned
      through genetic testing and tumor sequencing. Unfortunately, this comes at a
      price of obtaining results that may beget more uncertainties. Sequencing for
      mutations on tumor samples is increasingly performed, more commonly to guide
      treatment for oncology patients, and occasionally as a proxy for germline testing
      when the ideal index patient to initiate genetic testing in a family at risk for 
      hereditary cancer syndrome is no longer alive. Next-generation sequencing (NGS)
      involving tens to hundreds of genes as a testing platform is being used more
      routinely in the clinic now. However, one should keep in mind that the larger
      number of genes included in an NGS panel will yield a correspondingly higher
      probability of finding an incidental germline pathogenic mutation, which will
      have both clinical and ethical implications for patients and their families. The 
      probability of identifying a tumor pathogenic BRCA1/2 variant is about 3-4%, with
      the majority (~80%) being germline in nature; thus, patients should be counselled
      accordingly prior to having their tumor samples sequenced. On the flip side,
      caution should be exercised when tumor sequencing is intended to be a surrogate
      for germline testing. This is because false negative rate is high at ~30%, making
      it an inadequate tool to sufficiently dismiss the presence of a germline BRCA1/2 
      mutation, especially in a setting where there is already a high clinical
      suspicion for a hereditary condition.
FAU - Wong, Rachel Su Jen
AU  - Wong RSJ
AD  - Department of Hematology-Oncology, National University Cancer Institute,
      Singapore (NCIS), Singapore.
FAU - Lee, Soo-Chin
AU  - Lee SC
AD  - Department of Hematology-Oncology, National University Cancer Institute,
      Singapore (NCIS), Singapore; Cancer Science Institute, Singapore.
      csilsc@nus.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200810
PL  - China
TA  - Chin Clin Oncol
JT  - Chinese clinical oncology
JID - 101608375
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
SB  - IM
MH  - BRCA1 Protein/*metabolism
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing/*methods
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Neoplasms/*genetics
OTO - NOTNLM
OT  - BRCA1/2
OT  - germline mutation
OT  - tumor sequencing
EDAT- 2020/08/14 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/09/05 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - cco-19-198 [pii]
AID - 10.21037/cco-19-198 [doi]
PST - ppublish
SO  - Chin Clin Oncol. 2020 Oct;9(5):66. doi: 10.21037/cco-19-198. Epub 2020 Aug 10.


PMID- 32785969
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1098-2361 (Electronic)
IS  - 0733-3188 (Linking)
VI  - 39
IP  - 5
DP  - 2020 Sep
TI  - Individual-level variability among trust criteria relevant to zoos and aquariums.
PG  - 297-303
LID - 10.1002/zoo.21562 [doi]
AB  - Prior research into the conceptual underpinnings of the public's institutional
      trust in zoos and aquariums has suggested a range of ethical dimensions that set 
      these types of cultural institutions apart from others in the museum sector. As
      the recognized holders, care-takers, and nurturers of wild animals, zoos and
      aquariums are sustained at least in part by the public's perception that these
      activities are legitimate pursuits and essential to the long-term conservation of
      the natural world. This paper builds on recent research that identified the
      ethical dimensions of trust in zoos and aquariums and assessed their distribution
      among the U.S. public by analyzing survey responses with respect to the
      importance of trust criteria. We hypothesized that distinct clusters of
      individuals, as defined by their response to trust criteria items, would emerge
      and that these clusters would prioritize different dimensions in their trust of
      zoos and aquariums. Using k-means clustering, we identified four relevant
      clusters of individuals on seven dimensions of institutional trust in zoos and
      aquariums. Based on these clusters, we suggest strategies for addressing what may
      be necessary for zoos and aquariums to claim authority as agents promoting
      conservation behaviors in society.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Dwyer, Joseph de la Torre
AU  - Dwyer JT
AUID- ORCID: https://orcid.org/0000-0002-2717-9077
AD  - Knology, New York, New York.
FAU - Fraser, John
AU  - Fraser J
AUID- ORCID: https://orcid.org/0000-0001-8383-0699
AD  - Knology, New York, New York.
FAU - Voiklis, John
AU  - Voiklis J
AUID- ORCID: https://orcid.org/0000-0002-1590-9028
AD  - Knology, New York, New York.
FAU - Thomas, Uduak Grace
AU  - Thomas UG
AUID- ORCID: https://orcid.org/0000-0002-0038-1398
AD  - Knology, New York, New York.
LA  - eng
GR  - #1612699/National Science Foundation
GR  - #1612729/National Science Foundation
PT  - Journal Article
DEP - 20200812
PL  - United States
TA  - Zoo Biol
JT  - Zoo biology
JID - 8807837
SB  - IM
MH  - Animal Husbandry/*standards
MH  - Animal Welfare/*standards
MH  - Animals
MH  - Animals, Zoo
MH  - *Conservation of Natural Resources
MH  - Education/methods
MH  - Humans
MH  - *Trust
OTO - NOTNLM
OT  - cluster analysis
OT  - ethical integrity
OT  - institutional trust
EDAT- 2020/08/14 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1002/zoo.21562 [doi]
PST - ppublish
SO  - Zoo Biol. 2020 Sep;39(5):297-303. doi: 10.1002/zoo.21562. Epub 2020 Aug 12.


PMID- 32785485
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20201123
IS  - 1807-3107 (Electronic)
IS  - 1806-8324 (Linking)
VI  - 34 Suppl 2
DP  - 2020
TI  - Surrogate endpoints: when to use and when not to use? A critical appraisal of
      current evidences.
PG  - e074
LID - S1806-83242020000300602 [pii]
LID - 10.1590/1807-3107bor-2020.vol34.0074 [doi]
AB  - Clinical research needs to formulate a question, which must be answered by
      obeying ethical precepts with well-defined inclusion/exclusion criteria and
      approval of the study on platforms of ethical appreciation and clinical trial
      records. In comparing the results or clinically relevant outcomes should be
      prioritized in the study of techniques, products, inputs, drugs and therapies.
      However, it is not always possible to use long study drawings, with many
      participants, and with many costs, then look for study designs with surrogate
      outcomes, usually a shorter path, with less sample size and considerably lower
      costs to the research, with shorter intervention time. Considering these outcomes
      as major challenges in clinical research, the premise of this work was to examine
      in relevant research platforms, studies on the feasibility of using surrogate
      endpoints for clinically relevant parameters in dentistry, with a critical
      evaluation of the advantages, disadvantages, and need for validation of
      substitute parameters for clinical studies. After a critical analysis of the
      results, it could be concluded that surrogate endpoints may have an important
      role in the initial process of developing new drugs, faster, with less sampling, 
      and lower risk of side effects for the patient. Careful use of the surrogate
      endpoints is advised because, even if validated, they can provide ambiguous
      evidence and not be extrapolated to other populations, and may lead to bias due
      to the individual interpretation of each researcher. The use of unplanned
      surrogate outcomes that arise during the study requires a lot of caution.
FAU - Pedrazzi, Vinicius
AU  - Pedrazzi V
AD  - Department of Dental Materials and Prosthesis, School of Dentistry of Ribeirao
      Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Figueiredo, Fellipe Augusto Tocchini de
AU  - Figueiredo FAT
AD  - Department of Dental Materials and Prosthesis, School of Dentistry of Ribeirao
      Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Adami, Larisse Eduardo
AU  - Adami LE
AD  - Department of Dental Materials and Prosthesis, School of Dentistry of Ribeirao
      Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Furlaneto, Flavia
AU  - Furlaneto F
AD  - Department of Oral & Maxillofacial Surgery and Periodontology, School of
      Dentistry of Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP,
      Brazil.
FAU - Palioto, Daniela Bazan
AU  - Palioto DB
AD  - Department of Oral & Maxillofacial Surgery and Periodontology, School of
      Dentistry of Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP,
      Brazil.
FAU - Messora, Michel Reis
AU  - Messora MR
AD  - Department of Oral & Maxillofacial Surgery and Periodontology, School of
      Dentistry of Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP,
      Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - Brazil
TA  - Braz Oral Res
JT  - Brazilian oral research
JID - 101307187
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers
MH  - Humans
MH  - *Research Design
EDAT- 2020/08/14 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2019/09/22 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - S1806-83242020000300602 [pii]
AID - 10.1590/1807-3107bor-2020.vol34.0074 [doi]
PST - ppublish
SO  - Braz Oral Res. 2020;34 Suppl 2:e074. doi: 10.1590/1807-3107bor-2020.vol34.0074.
      Epub 2020 Aug 7.


PMID- 32785448
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73 Suppl 5
DP  - 2020
TI  - Evidence of nursing patterns of knowing communicated by the brazilian press
      before Florence Nightingale's model.
PG  - e20190790
LID - S0034-71672020001700153 [pii]
LID - 10.1590/0034-7167-2019-0790 [doi]
AB  - OBJECTIVE: to identify evidence of nursing patterns of knowing disseminated by
      the Brazilian press before the implementation of Florence Nightingale's model in 
      Brazil and categorize topics of journalistic articles according to Carper's and
      White's patterns of knowing. METHODS: categorical content analysis of materials
      related to Florence Nightingale, published in Brazil between 1850 and 1919,
      collected at Hemeroteca Digital. Four analysts identified themes of journalistic 
      article, performing classification in patterns of knowing. RESULTS: there was a
      predominance of evidence of the sociopolitical pattern followed by the empirical 
      pattern. In the analyses per decade, ethical and aesthetic patterns showed
      predominance between 1860 and 1870, respectively. CONCLUSION: White's
      classification by nursing patterns of knowing was useful in understanding
      precursor themes of professional/disciplinary knowledge that spread in Brazil,
      linked to Nightingale's character, in addition to the repercussions of her
      actions and her expanded sociopolitical perspective.
FAU - Brandao, Ana Paula da Costa Lacerda
AU  - Brandao APDCL
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Peres, Maria Angelica de Almeida
AU  - Peres MAA
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Aperibense, Pacita Geovana Gama de Sousa
AU  - Aperibense PGGS
AD  - Universidade Federal do Rio de Janeiro, Macae, Rio de Janeiro, Brazil.
FAU - Lopes, Rafael Oliveira Pitta
AU  - Lopes ROP
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Santos, Jessica de Castro
AU  - Santos JC
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Brandao, Marcos Antonio Gomes
AU  - Brandao MAG
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
LA  - por
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200807
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - Brazil
MH  - *History of Nursing
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - *Knowledge
MH  - Morals
EDAT- 2020/08/14 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - S0034-71672020001700153 [pii]
AID - 10.1590/0034-7167-2019-0790 [doi]
PST - ppublish
SO  - Rev Bras Enferm. 2020;73 Suppl 5:e20190790. doi: 10.1590/0034-7167-2019-0790.
      Epub 2020 Aug 7.


PMID- 32785248
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20201002
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Vaccination discourses among chiropractors, naturopaths and homeopaths: A
      qualitative content analysis of academic literature and Canadian organizational
      webpages.
PG  - e0236691
LID - 10.1371/journal.pone.0236691 [doi]
AB  - Vaccine hesitancy-the reluctance to receive recommended vaccination because of
      concerns and doubts about vaccines-is recognized as a significant threat to the
      success of vaccination programs and has been associated with recent major
      outbreaks of vaccine-preventable diseases. Moreover, the association between
      complementary and alternative medicine (CAM) use and vaccine hesitancy and/or
      refusal has been frequently reported in the literature. To date, significant gaps
      persist in our understanding of contemporary Canadian CAM providers' beliefs
      regarding vaccination and how socio-professional influences may shape their
      vaccine-related attitudes and behaviours. To address the latter gap, the current 
      study aims to explore the content of professional guidelines, recommendations and
      other discourses among CAM providers as they concern vaccination by analyzing
      both academic, peer-reviewed literature and Canadian organizational webpages
      prepared by and/or for practicing chiropractors, naturopaths and homeopaths. In
      the academic literature, we identified a number of complex and diverging views on
      vaccination that spanned topics of effectiveness; safety; theoretical, empirical,
      and ethical soundness; political justifiability; and compatibility with CAM
      philosophy and professional boundaries. However, in its current state the CAM
      literature cannot be described in broad strokes as being either pro- or
      anti-vaccination without considering finer areas of disagreement. Compared to the
      academic literature, which focuses more on the conceptual and evidentiary basis
      of vaccination, a greater proportion of vaccine-related content on Canadian CAM
      organizations' webpages seems to be dedicated to offering specific directives and
      prescriptions to providers. Guidelines and standards of practice address a number
      of issues, including vaccine administration, counsel, education and marketing. As
      CAM organizations further evolve in Canada and elsewhere as part of a broader
      "professionalization" initiative, greater attention will need to be directed at
      their role in shaping providers' beliefs and practices that both support and
      undermine vaccine promotion efforts.
FAU - Filice, Eric
AU  - Filice E
AUID- ORCID: 0000-0001-5743-7279
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Dube, Eve
AU  - Dube E
AD  - Departement Anthropologie, Universite Laval, Quebec City, Quebec, Canada.
AD  - Centre de recherche du CHU de Quebec - Universite Laval, Quebec City, Quebec,
      Canada.
FAU - Graham, Janice E
AU  - Graham JE
AD  - Pediatrics (Infectious Diseases), Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - MacDonald, Noni E
AU  - MacDonald NE
AD  - Pediatrics (Infectious Diseases), Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Bettinger, Julie A
AU  - Bettinger JA
AD  - Vaccine Evaluation Center, BC Children's Hospital and University of British
      Columbia, Vancouver, British Columbia, Canada.
FAU - Greyson, Devon
AU  - Greyson D
AUID- ORCID: 0000-0003-4860-384X
AD  - Department of Communication, University of Massachusetts Amherst, Amherst,
      Massachusetts, United States of America.
FAU - MacDonald, Shannon
AU  - MacDonald S
AD  - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
FAU - Driedger, S Michelle
AU  - Driedger SM
AD  - Department of Community Health Sciences, University of Manitoba, Winnipeg,
      Manitoba, Canada.
FAU - Kawchuk, Greg
AU  - Kawchuk G
AD  - Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta,
      Canada.
FAU - Meyer, Samantha B
AU  - Meyer SB
AUID- ORCID: 0000-0002-2098-2828
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200812
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Vaccines)
SB  - IM
MH  - Canada/epidemiology
MH  - Chiropractic
MH  - *Complementary Therapies
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*psychology
MH  - Homeopathy/psychology
MH  - Humans
MH  - Male
MH  - Naturopathy/psychology
MH  - Vaccination/*psychology
MH  - Vaccination Refusal/*psychology
MH  - Vaccines/adverse effects
PMC - PMC7423113
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
AID - 10.1371/journal.pone.0236691 [doi]
AID - PONE-D-20-05690 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 12;15(8):e0236691. doi: 10.1371/journal.pone.0236691.
      eCollection 2020.


PMID- 32785233
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Changes in biochemical parameters by gender and time: Effect of short-term vegan 
      diet adherence.
PG  - e0237065
LID - 10.1371/journal.pone.0237065 [doi]
AB  - BACKGROUND: Vegetarian diets adapted for various reasons that may include
      religious, ethical, and health considerations have reasonable health benefits
      including weight loss, and favorable metabolic changes. However, studies that
      assessed health benefits associated with vegan diet practices during the
      Ethiopian Orthodox Christian (EOC) Lenten fasting remains limited. This study
      has, therefore, assessed how short-term vegan diet associated with metabolic
      traits, including weight, body mass index (BMI), circumference, blood pressure,
      total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol 
      (HDL-C), and low-density lipoprotein cholesterol (LDL-C), through longitudinal
      cross-sectional study design. METHODS: Seventy-five subjects (34 females and 41
      males) with a mean age of [+SD] 27.3 + 5.8 years (range, 18 and 35) took part in 
      the study. The study followed three assessment sessions: at baseline, during the 
      Lenten (week 7), and 7 weeks after the end of the Lenten (week 14). An automatic 
      chemistry analyzer (Mindray, BE-2000, China) used for lipid profile analysis. We 
      used paired sample t-test in pre and post-performance and repeated measures ANOVA
      with Bonferroni post hoc adjustment between time points. The statistical
      significance was set at p < 0.05. RESULTS: The EOC fasting with vegan diet
      induced significantly lower blood pressure, weight, BMI, TC, HDL-C, LDL-C, and
      TC: HDL-C ratios, during Lenten (that is vegan diet consumption), but a regain
      noted in these parameters 7-weeks after Lenten (that is omnivore diet). On gender
      differences, vegan diet associated with significantly lower blood pressure, TC,
      and LDL-C in females compared with age-matched male counterparts. Some
      methodological limitations of this study are discussed with particular reference 
      to lack of a randomized control group and self-reported data that limit this
      study in establishing a causal relationship through observed associations.
      CONCLUSIONS: Vegan diet consumption even for short period corroborate ideal
      metabolic traits, with more favorable changes noted in women than age-matched men
      counterparts. These findings might help to define vegetarian diets as part of
      religious fasting (beyond its spiritual goals) as a non-pharmacological
      prescription in different populations, and our findings add to growing evidence
      in these subjects.
FAU - Sisay, Tariku
AU  - Sisay T
AUID- ORCID: 0000-0001-7546-3147
AD  - Department of Physiology, School of Medicine, College of Health Sciences, Addis
      Ababa University, Addis Ababa, Ethiopia.
FAU - Tolessa, Tesfaye
AU  - Tolessa T
AD  - Department of Physiology, School of Medicine, College of Health Sciences, Addis
      Ababa University, Addis Ababa, Ethiopia.
FAU - Mekonen, Wondyefraw
AU  - Mekonen W
AD  - Department of Physiology, School of Medicine, College of Health Sciences, Addis
      Ababa University, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200812
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Lipids)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Body Weight/*physiology
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Cross-Sectional Studies
MH  - Diet/methods
MH  - Diet, Vegan/*methods
MH  - Diet, Vegetarian
MH  - Ethiopia
MH  - Fasting/physiology
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Risk Factors
MH  - Sex Factors
MH  - Time Factors
MH  - Triglycerides/blood
MH  - Weight Loss/*physiology
MH  - Young Adult
PMC - PMC7423121
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/14 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/08/14 06:00
PHST- 2019/10/14 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.1371/journal.pone.0237065 [doi]
AID - PONE-D-19-28642 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 12;15(8):e0237065. doi: 10.1371/journal.pone.0237065.
      eCollection 2020.


PMID- 32784263
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - 'Presumptively Initiating Vaccines and Optimizing Talk with Motivational
      Interviewing' (PIVOT with MI) trial: a protocol for a cluster randomised
      controlled trial of a clinician vaccine communication intervention.
PG  - e039299
LID - 10.1136/bmjopen-2020-039299 [doi]
AB  - INTRODUCTION: A key contributor to underimmunisation is parental refusal or delay
      of vaccines due to vaccine concerns. Many clinicians lack confidence in
      communicating with vaccine-hesitant parents (VHP) and perceive that their
      discussions will do little to change parents' minds. Improving clinician
      communication with VHPs is critical to increasing childhood vaccine uptake.
      METHODS AND ANALYSIS: We describe the protocol for a cluster randomised
      controlled trial to test the impact of a novel, multifaceted clinician vaccine
      communication strategy on child immunisation status. The trial will be conducted 
      in 24 primary care practices in two US states (Washington and Colorado). The
      strategy is called Presumptively Initiating Vaccines and Optimizing Talk with
      Motivational Interviewing (PIVOT with MI), and involves clinicians initiating the
      vaccine conversation with all parents of young children using the presumptive
      format, and among those parents who resist vaccines, pivoting to using MI. Our
      primary outcome is the immunisation status of children of VHPs at 19 months, 0
      day of age expressed as the percentage of days underimmunised from birth to 19
      months for 22 doses of eight vaccines recommended during this interval. Secondary
      outcomes include clinician experience communicating with VHPs, parent visit
      experience and clinician adherence to the PIVOT with MI communication strategy.
      ETHICS AND DISSEMINATION: This study is approved by the following institutional
      review boards: Colorado Multiple Institutional Review Board, Washington State
      Institutional Review Board and Swedish Health Services Institutional Review
      Board. Results will be disseminated through peer-reviewed manuscripts and
      conference presentations. TRIAL REGISTRATION NUMBER: NCT03885232.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Opel, Douglas J
AU  - Opel DJ
AUID- ORCID: 0000-0001-7021-191X
AD  - Seattle Children's Research Institute, Seattle, Washington, USA
      douglas.opel@seattlechildrens.org.
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle,
      Washington, USA.
FAU - Robinson, Jeffrey D
AU  - Robinson JD
AD  - Department of Communication, Portland State University, Portland, Oregon, USA.
FAU - Spielvogle, Heather
AU  - Spielvogle H
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
FAU - Spina, Christine
AU  - Spina C
AD  - Children's Hospital Colorado, Aurora, Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Science,
      University of Colorado, Denver, CO, USA.
FAU - Garrett, Kathleen
AU  - Garrett K
AD  - Children's Hospital Colorado, Aurora, Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Science,
      University of Colorado, Denver, CO, USA.
FAU - Dempsey, Amanda F
AU  - Dempsey AF
AD  - Children's Hospital Colorado, Aurora, Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Science,
      University of Colorado, Denver, CO, USA.
AD  - Department of Pediatrics, University of Colorado, Denver, Colorado, USA.
FAU - Perreira, Cathryn
AU  - Perreira C
AD  - Children's Hospital Colorado, Aurora, Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Science,
      University of Colorado, Denver, CO, USA.
FAU - Dickinson, Miriam
AU  - Dickinson M
AD  - Children's Hospital Colorado, Aurora, Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Science,
      University of Colorado, Denver, CO, USA.
FAU - Zhou, Chuan
AU  - Zhou C
AD  - Seattle Children's Research Institute, Seattle, Washington, USA.
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle,
      Washington, USA.
FAU - Pahud, Barbara
AU  - Pahud B
AD  - Department of Pediatrics, University of Missouri-Kansas City, Kansas City,
      Missouri, USA.
FAU - Taylor, James A
AU  - Taylor JA
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle,
      Washington, USA.
FAU - O'Leary, Sean T
AU  - O'Leary ST
AD  - Children's Hospital Colorado, Aurora, Colorado, USA.
AD  - Adult and Child Consortium for Health Outcomes Research and Delivery Science,
      University of Colorado, Denver, CO, USA.
AD  - Department of Pediatrics, University of Colorado, Denver, Colorado, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03885232
GR  - R01 HD093628/HD/NICHD NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vaccines)
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Colorado
MH  - Communication
MH  - Humans
MH  - Infant
MH  - *Motivational Interviewing
MH  - Parents
MH  - Randomized Controlled Trials as Topic
MH  - Vaccination
MH  - *Vaccines
MH  - Washington
PMC - PMC7418671
OTO - NOTNLM
OT  - *community child health
OT  - *paediatrics
OT  - *public health
COIS- Competing interests: AD and BP serve on advisory boards for Merck, Pfizer and
      Sanofi Pasteur, and have provided consulting services to Pfizer. BP's institution
      receives research funding from GSK and Pfizer.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039299 [pii]
AID - 10.1136/bmjopen-2020-039299 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e039299. doi: 10.1136/bmjopen-2020-039299.


PMID- 32784260
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Effect of regulating gut microbiota using probiotics on functional changes in the
      brain: protocol for a systematic review.
PG  - e037582
LID - 10.1136/bmjopen-2020-037582 [doi]
AB  - INTRODUCTION: There is a growing number of randomised controlled trials (RCTs)
      that focus on functional changes in the brain detected by functional MRI (fMRI)
      and gut microbiota composition changes after using probiotics.However, the effect
      of probiotics on functional changes in the brain through gut microbiota remains
      controversial in existing RCTs. Furthermore, to our knowledge, there is no
      systematic review to evaluate the effect of probiotics on functional changes in
      the brain through gut microbiota. Therefore, we aim to summarise literatures
      evaluating the potential association between probiotics, gut microbiota and
      functional changes in the brain to elucidate whether probiotics influence gut
      microbiota and affect functional changes in the brain through gut microbiota.
      METHODS AND ANALYSIS: China National Knowledge Infrastructure, Wanfang Data, VIP 
      Databases (the Chongqing VIP Chinese Science and Technology Periodical Database),
      SinoMed, PubMed, Web of Science, MEDLINE (The National Library of Medicine),
      EMBASE (Excerpt Medica Database), Scopus, the Cochrane Central Register of
      Controlled Trials and ClinicalTrials.gov will be searched until July 2019. The
      Grey Literature in Europe (OpenSIGLE) database and Google search engine will also
      be used. The reference lists of each included study will be reviewed to determine
      whether there are any further relevant studies. RCTs using probiotics compared
      with a placebo/control will be included. We will use risk of bias assessment and 
      the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
      system to assess the quality of evidence. The results of the systematic review
      will be synthesised narratively in the domains of the three primary outcome
      measures: (1) Increased/decreased activity in brain regions or altered functional
      connectivity (FC) of brain detected by fMRI and their association with changes in
      behaviour, gastrointestinal/emotional symptoms after using probiotics. (2)
      Changes in composition and diversity of the gut microbiota and their association 
      with changes in behaviour, gastrointestinal/emotional symptoms after using
      probiotics. (3) Increased/decreased activity in brain regions or altered FC of
      brain detected by fMRI and the changes in composition or diversity of the gut
      microbiota after administration of probiotics. ETHICS AND DISSEMINATION: The
      results will be disseminated through a peer-reviewed publication. As no private
      and confidential patient data will be included in the reporting, there are no
      ethical considerations associated with this protocol. PROSPERO REGISTRATION
      NUMBER: CRD42019145114.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liu, Lu
AU  - Liu L
AUID- ORCID: 0000-0003-2196-7627
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Ni, Xixiu
AU  - Ni X
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Tian, Tian
AU  - Tian T
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Li, Xiao
AU  - Li X
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Li, Fengmei
AU  - Li F
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Sun, Mingsheng
AU  - Sun M
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Chen, Jiao
AU  - Chen J
AUID- ORCID: 0000-0003-0830-6242
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zhou, SiYuan
AU  - Zhou S
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China zhaoling@cdutcm.edu.cn zsy@cdutcm.edu.cn.
AD  - Acupuncture & Chronobiology Key Laboratory of Sichuan Province, Chengdu, China.
FAU - Zhao, Ling
AU  - Zhao L
AUID- ORCID: 0000-0002-3955-0072
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China zhaoling@cdutcm.edu.cn zsy@cdutcm.edu.cn.
AD  - Acupuncture & Chronobiology Key Laboratory of Sichuan Province, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brain/diagnostic imaging
MH  - China
MH  - Europe
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - *Probiotics/therapeutic use
PMC - PMC7418664
OTO - NOTNLM
OT  - *head & neck imaging
OT  - *magnetic resonance imaging
OT  - *microbiology
OT  - *neurobiology
OT  - *neuropathology
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037582 [pii]
AID - 10.1136/bmjopen-2020-037582 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e037582. doi: 10.1136/bmjopen-2020-037582.


PMID- 32784259
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Protocol of an interdisciplinary consensus project aiming to develop an AGREE II 
      extension for guidelines in surgery.
PG  - e037107
LID - 10.1136/bmjopen-2020-037107 [doi]
AB  - INTRODUCTION: Appraisal of Guidelines for Research and Evaluation (AGREE II) is
      an instrument that informs development, reporting and assessment of clinical
      practice guidelines. Previous research has demonstrated the need for improvement 
      in methodological and reporting quality of clinical practice guidelines
      specifically in surgery. We aimed to develop an AGREE II extension document for
      application in surgical guidelines. METHODS AND ANALYSIS: We have performed a
      structured literature review and assessment of guidelines in surgery using the
      AGREE II instrument. In exploratory analyses, we have identified factors
      associated with guideline quality. We have performed reliability and factor
      analyses to inform the development of an extension document. We will summarise
      this information and present it to a Delphi panel of stakeholders. We will
      perform iterative Delphi rounds and we will summarise the final results to
      develop the extension instrument in a dedicated consensus conference. ETHICS AND 
      DISSEMINATION: Funding bodies will not be involved in the development of the
      instrument. Research ethics committee and Health Research Authority approval was 
      waived, since this is a professional staff study only and no duty of care lies
      with the National Health Service to any of the participants. Conflicts of
      interest, if any, will be addressed by reassigning functions or replacing
      participants with relevant conflicts. The results will be disseminated through
      publication in peer reviewed journals, the funders' websites, social media and
      direct contact with guideline development organisations and peer-reviewed
      journals that publish guidelines.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Antoniou, George A
AU  - Antoniou GA
AUID- ORCID: 0000-0001-8209-0406
AD  - Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital,
      Pennine Acute Hospitals NHS Trust, Northern Care Alliance NHS Group, Manchester, 
      UK antoniou.ga@hotmail.com.
AD  - Division of Cardiovascular Sciences, School of Medical Sciences, University of
      Manchester, Manchester, UK.
FAU - Mavridis, Dimitris
AU  - Mavridis D
AD  - Department of Primary Education, School of Education, University of Ioannina,
      Ioannina, Greece.
AD  - Faculte de Medecine, Universite Paris Descartes, Paris, France.
FAU - Tsokani, Sofia
AU  - Tsokani S
AD  - Department of Primary Education, School of Education, University of Ioannina,
      Ioannina, Greece.
FAU - Lopez-Cano, Manuel
AU  - Lopez-Cano M
AD  - Abdominal Wall Surgery Unit, Department of General Surgery, Hospital Universitari
      Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Florez, Ivan D
AU  - Florez ID
AD  - Department of Health Research Methods Evidence and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Department of Pediatrics, Universidad de Antioquia, Medellin, Colombia.
FAU - Brouwers, Melissa
AU  - Brouwers M
AD  - Department of Health Research Methods Evidence and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Markar, Sheraz R
AU  - Markar SR
AD  - Department of Surgery and Cancer, Imperial College London, London, UK.
FAU - Silecchia, Gianfranco
AU  - Silecchia G
AD  - Department of Surgery, University Hospital "La Sapienza", Rome, Italy.
FAU - Francis, Nader K
AU  - Francis NK
AD  - Department of General Surgery, Yeovil District Hospital NHS Foundation Trust,
      Yeovil, UK.
FAU - Antoniou, Stavros A
AU  - Antoniou SA
AD  - Medical School, European University Cyprus, Nicosia, Cyprus.
AD  - Department of Surgery, Mediterranean Hospital of Cyprus, Limassol, Cyprus.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Consensus
MH  - Humans
MH  - *Interdisciplinary Studies
MH  - Peer Review
MH  - Reproducibility of Results
MH  - *State Medicine
PMC - PMC7418673
OTO - NOTNLM
OT  - *health policy
OT  - *protocols & guidelines
OT  - *quality in health care
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037107 [pii]
AID - 10.1136/bmjopen-2020-037107 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e037107. doi: 10.1136/bmjopen-2020-037107.


PMID- 32784257
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Study protocol for the use of photobiomodulation with red or infrared LED on
      waist circumference reduction: a randomised, double-blind clinical trial.
PG  - e036684
LID - 10.1136/bmjopen-2019-036684 [doi]
AB  - INTRODUCTION: The search for non-invasive procedures to reduce localised
      adiposity in aesthetics clinics has recently been increasing. In this context,
      procedures, such as cryolipolysis, ultracavitation, photobiomodulation (PBM) and 
      other techniques have been proposed. Some studies have shown that PBM can be used
      in body contouring. However, there is no standardisation of the protocol. More
      than that, as in other techniques for reducing adipose tissue, the availability
      of triacylglycerol may affect the lipid profile in the blood, bringing
      consequences to the general health of an individual. This work will aim to
      compare the light wavelengths when using PBM as a technique for reducing the
      abdominal waist circumference, while also evaluating the efficacy of the method. 
      Changes in the lipid profile in the blood, with a long-term follow-up, will also 
      be appraised. METHODS AND ANALYSIS: This will be a controlled, randomised,
      double-blind, single-centred clinical trial. 174 patients will be recruited at
      the Nove de Julho University, Brazil, and then divided into three groups: Group
      A-RED PBM; Group B-INFRARED PBM; Group C-PLACEBO (Sham) treatment. The treatments
      will consist of eight sessions, two times a week, for 4 weeks. At each session,
      the participants will receive 30 minutes PBM (using a radiant exposure of 127
      J/cm(2)), with an abdominal strap containing 4 LED clusters, with 72 devices
      each, following the indication of randomisation. All of the groups will receive
      30 min of Aussie Current, at 4 kHz, modulated at 10 Hz, 40-60 mA. The main
      outcome of this study will be waist circumference reduction. The secondary
      variables will be anthropometric data, lipid profile, liver function and adipose 
      tissue thickness, changes in the local microcirculation, and the quality of life 
      and self-esteem. The analyses will be performed at four stages of the research,
      D0, end of the eighth session (D30), 15 days after the last session (FU15), 90
      days after the last session (FU90) and 180 days after the last session (FU180).
      ETHICS AND DISSEMINATION: The Ethics Committee of the Nove de Julho University,
      Brazil, approved the modified version of this project under No. 3414146 on 26
      June 2019. This study is not yet recruiting. The results obtained will be
      published in a peer-reviewed journal in the related field. TRIAL REGISTRATION
      NUMBER: Brazilian Registry of Clinical Trials-ReBec (RBR-9bwxcx).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Marreira, Marcelo
AU  - Marreira M
AD  - Biophotonics Applied to Health Sciences, Universidade Nove de Julho, Sao Paulo,
      Brazil.
FAU - Rocha Mota, Lidiane
AU  - Rocha Mota L
AD  - Biophotonics Applied to Health Sciences, Universidade Nove de Julho, Sao Paulo,
      Brazil.
FAU - Silva, Daniela Fatima Teixeira
AU  - Silva DFT
AUID- ORCID: 0000-0002-7228-6146
AD  - Biophotonics Applied to Health Sciences, Universidade Nove de Julho, Sao Paulo,
      Brazil.
FAU - Pavani, Christiane
AU  - Pavani C
AUID- ORCID: 0000-0001-8275-7370
AD  - Biophotonics Applied to Health Sciences, Universidade Nove de Julho, Sao Paulo,
      Brazil chrispavani@gmail.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brazil
MH  - Double-Blind Method
MH  - Humans
MH  - *Low-Level Light Therapy
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Waist Circumference
PMC - PMC7418772
OTO - NOTNLM
OT  - *biophysics
OT  - *laser therapy
OT  - *lipid disorders
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036684 [pii]
AID - 10.1136/bmjopen-2019-036684 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e036684. doi: 10.1136/bmjopen-2019-036684.


PMID- 32784256
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Long-term economic outcomes for interventions in early childhood: protocol for a 
      systematic review.
PG  - e036647
LID - 10.1136/bmjopen-2019-036647 [doi]
AB  - INTRODUCTION: Investment in early childhood produces positive returns: for the
      child, the family and the community. Benefits have been shown to be significant
      within certain parameters, but a systematic review of the economic evidence
      across multiple sectors including health, education and social welfare will have 
      the capacity to inform policy relative to the full range of social determinants. 
      This review will take a broad approach, encompassing a range of costs and
      benefits to enable the identification of the most beneficial investments in early
      childhood and to highlight gaps in current research. METHODS AND ANALYSIS:
      Economic evaluations incorporating both costs and long-term outcomes of early
      childhood interventions and programmes will be included. Outcomes may be valued
      in monetary units or quantified non-monetary units (eg, quality-adjusted life
      years (QALY), disability-adjusted life years (DALY)). Results will be expressed
      as a ratio according to the outcome; with monetary outcomes expressed as
      cost-benefit ratios or return on investment, and non-monetary outcomes expressed 
      as cost per QALY or DALY. The target population is children aged 0-5
      years.Extensive database searches across sectors will be undertaken. The review
      will involve five phases: defining the research question, identifying relevant
      studies, selecting studies, extracting and collating data, and summarising and
      reporting results. The search commenced in 2019 and the expected end date is
      December 2020. ETHICS AND DISSEMINATION: The findings of this review will inform 
      policymakers and practitioners in public health, education, social welfare and
      primary care settings. The publication plan includes a series of academic
      publications, and policy papers prepared and disseminated through Telethon Kids
      Institute networks. Exemption from ethics approval was granted by the University 
      of Western Australia Human Ethics Office (RA/4/20/5677). PROSPERO REGISTRATION
      NUMBER: CRD42020145901.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Geelhoed, Elizabeth
AU  - Geelhoed E
AUID- ORCID: 0000-0001-6718-9264
AD  - Collaboration for Kids (CoLab), Telethon Kids Institute, Nedlands, Western
      Australia, Australia liz.geelhoed@telethonkids.org.au.
FAU - Mandzufas, Joelie
AU  - Mandzufas J
AUID- ORCID: 0000-0003-4236-1384
AD  - Collaboration for Kids (CoLab), Telethon Kids Institute, Nedlands, Western
      Australia, Australia.
FAU - George, Phoebe
AU  - George P
AD  - Collaboration for Kids (CoLab), Telethon Kids Institute, Nedlands, Western
      Australia, Australia.
FAU - Strahan, Ken
AU  - Strahan K
AD  - Collaboration for Kids (CoLab), Telethon Kids Institute, Nedlands, Western
      Australia, Australia.
FAU - Duffield, Alison
AU  - Duffield A
AD  - Collaboration for Kids (CoLab), Telethon Kids Institute, Nedlands, Western
      Australia, Australia.
FAU - Li, Ian
AU  - Li I
AUID- ORCID: 0000-0002-1438-8830
AD  - School of Population and Global Health, University of Western Australia, Crawley,
      Western Australia, Australia.
FAU - Cross, Donna
AU  - Cross D
AUID- ORCID: 0000-0001-6217-5058
AD  - Collaboration for Kids (CoLab), Telethon Kids Institute, Nedlands, Western
      Australia, Australia.
AD  - School of Population and Global Health, University of Western Australia, Crawley,
      Western Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Child
MH  - Child, Preschool
MH  - Cost-Benefit Analysis
MH  - *Health Care Costs
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Primary Health Care
MH  - Quality-Adjusted Life Years
MH  - Systematic Reviews as Topic
PMC - PMC7418662
OTO - NOTNLM
OT  - *community child health
OT  - *health economics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036647 [pii]
AID - 10.1136/bmjopen-2019-036647 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e036647. doi: 10.1136/bmjopen-2019-036647.


PMID- 32784255
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Youth participatory research evidence to inform health policy: a systematic
      review protocol.
PG  - e036522
LID - 10.1136/bmjopen-2019-036522 [doi]
AB  - INTRODUCTION: Young people's participation in health research produces knowledge 
      that is indispensable for creating appropriate and effective policies. However,
      how best to disseminate youth participatory research evidence to impact health
      policy is not known. Therefore, the objectives of this systematic review are to
      describe the evidence produced through youth participatory research, including
      the strategies used to disseminate youth participatory research evidence to
      health policymakers. These are necessary to improve policymakers' use of youth
      participatory research evidence and, thereby, make programmes more impactful for 
      young people. METHODS AND ANALYSIS: The meta-narrative methodology will guide the
      systematic review to highlight the contrasting and complementary evidence on the 
      use of engaging youth in research to affect health policymaking. Relevant studies
      will be identified by searching electronic databases, including but not limited
      to EBSCO, PROQUEST, OVID Medline, Sociological Abstracts and Google Scholar from 
      inception to December 2020. The methodological quality of included quantitative, 
      qualitative and mixed-methods research studies will be assessed using valid
      appraisal tools. The meta-narrative approach to analysis will include identifying
      meta-narratives of how youth participation informed the health research findings.
      ETHICS AND DISSEMINATION: An advisory group of young people will advise on the
      study and dissemination of the findings. As part of our plan for active
      dissemination, we will produce a policy brief that builds the rationale for using
      research with and by youth as part of an evidence base necessary for achieving
      youth health outcomes.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Njelesani, Janet
AU  - Njelesani J
AUID- ORCID: 0000-0002-6134-3950
AD  - Occupational Therapy, New York University, New York, New York, USA.
AD  - International Centre for Disability and Rehabilitation, University of Toronto,
      Toronto, Canada.
FAU - Hunleth, Jean
AU  - Hunleth J
AD  - Division of Public Health Sciences, Washington University in Saint Louis, Saint
      Louis, Missouri, USA jean.hunleth@wustl.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Community-Based Participatory Research
MH  - *Health Policy
MH  - Humans
MH  - Knowledge
MH  - Narration
MH  - Policy Making
MH  - Systematic Reviews as Topic
PMC - PMC7418675
OTO - NOTNLM
OT  - *health policy
OT  - *paediatrics
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036522 [pii]
AID - 10.1136/bmjopen-2019-036522 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e036522. doi: 10.1136/bmjopen-2019-036522.


PMID- 32784254
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 11
TI  - Mapping evidence of food safety at transport stations in Africa: a scoping review
      protocol.
PG  - e035879
LID - 10.1136/bmjopen-2019-035879 [doi]
AB  - INTRODUCTION: In Africa, travels, urbanisation and changing consumer habits are
      increasing the number of people buying and eating food prepared/sold at public
      spaces including transport stations, particularly in the urban and periurban
      areas. Although food trading in such public spaces serves as a source of
      livelihood for many people, unsafe food can have a negative impact on health. We,
      therefore, aim to systematically explore and examine the literature, and describe
      the evidence on food safety (food handling, storage, preparation and sale,
      packaging of food when sold, hygiene of sale venue and quality (nutrition) of
      food sold/purchased/eaten) at transport stations to inform policy, as well as
      identify research gaps for future studies in Africa. METHODS AND ANALYSIS: We
      will employ the Arksey & O'Malley framework, Levac et al recommendations and the 
      Joanna Briggs Institute guidelines to guide this study. We will conduct a
      comprehensive search in PubMed, SCOPUS, Web of Science, Google Scholar and
      EBSCOhost (Academic search complete, CINAHL with Full-text and Health Source)
      from inception to December 2019 for relevant peer-review articles using a
      combination of keywords/search terms with no limitations. We will also search for
      relevant literature from the reference list of all included articles. Two
      investigators will independently screen the articles in parallel at the abstract 
      and full-text phases using the eligibility criteria as a guide. Data extraction
      will be done using a piloted data extraction form designed in a Microsoft Word
      tabular format. Afterward, the extracted data will be collated into themes and
      subthemes, summarised, and the results reported using a narrative approach. We
      will the Preferred Reporting Items for Systematic Reviews and Meta-analyses:
      Extension for scoping reviews checklist to report this study results. ETHICS AND 
      DISSEMINATION: Ethics approval is not required. All sources of data will be
      adequately cited and added to the reference list. We will present the final
      scoping review results at the appropriate workshops, meetings, conferences, as
      well as submit for peer-review and publication in a scientific journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ncama, Busisiwe Purity
AU  - Ncama BP
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, Durban, South Africa.
FAU - Kuupiel, Desmond
AU  - Kuupiel D
AUID- ORCID: 0000-0001-7780-1955
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, Durban, South Africa desmondkuupiel98@hotmail.com.
AD  - Research for Sustainable Development Consult, Sunyani, Ghana.
FAU - Duma, Sinegugu E
AU  - Duma SE
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, Durban, South Africa.
FAU - Mchunu, Gugu
AU  - Mchunu G
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, Durban, South Africa.
FAU - Guga, Phindile
AU  - Guga P
AD  - School of Nursing and Public Health, College of Health Sciences, University of
      KwaZulu-Natal, Durban, South Africa.
FAU - Slotow, Rob
AU  - Slotow R
AD  - School of Life Sciences, College of Agriculture, Engineering and Science,
      University of Kwazulu-Natal, Pietermaritzburg, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa
MH  - Delivery of Health Care
MH  - *Food Safety
MH  - Humans
MH  - *Peer Review
MH  - Policy
MH  - Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7418661
OTO - NOTNLM
OT  - *health & safety
OT  - *health policy
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/08/14 06:00 [entrez]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035879 [pii]
AID - 10.1136/bmjopen-2019-035879 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 11;10(8):e035879. doi: 10.1136/bmjopen-2019-035879.


PMID- 32782505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Sep
TI  - Clinical observation of apatinib-related hypothyroidism in patients with advanced
      malignancies.
PG  - 1961-1966
LID - 10.3892/etm.2020.8937 [doi]
AB  - Thyroid dysfunction has been previously reported during treatment with certain
      small-molecule multi-tyrosine kinase inhibitors, including sunitinib and
      sorafenib. Apatinib, which has a similar mechanism of action to these inhibitors,
      has reportedly induced hypothyroidism during treatment. Fully elucidating
      drug-associated adverse events could aid in patient monitoring and
      recommendations of suitable management strategies. The current 2-year
      observational study monitored patients with solid tumors who were prescribed
      apatinib. A total of 149 patients treated with apatinib from February 2015 to
      January 2016 were included. Their thyroid function and thyroid ultrastructure was
      evaluated for at least 24 months or until death. The primary objective of the
      current study was evaluating accepted thyroid replacement treatment. Secondary
      objective was ultrastructural changes in the thyroid gland. The current study was
      approved by the Medical Ethics Committee of Qianfoshan Hospital, affiliated with 
      Shandong University and written informed consent was obtained from all patients
      prior to commencing the clinical trial. A total of 53 (35.57%) patients developed
      hypothyroidism, which varied from subclinical (12 cases; 8.05%) to clinical (41
      cases; 27.52%). Thyroid nodules were noted in 15 cases (10.07%). Furthermore, 3
      cases (2.01%) had thyroid imaging reporting and data system scores of 4a/4b/4c
      and 12 cases (8.05%) had scores of 1, 2 and 3. A total of 25 patients (16.78%)
      experienced 1-2 grade fatigue and 2 patients (1.34%) reported 3-4 grade fatigue. 
      There was no reported association between disease control rate and
      hypothyroidism. Apatinib significantly increased the risk of clinically relevant 
      hypothyroidism and altered thyroid gland structure.
CI  - Copyright: (c) Xiao et al.
FAU - Xiao, Junjuan
AU  - Xiao J
AD  - Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong
      University, Jinan, Shandong 250014, P.R. China.
FAU - Liang, Jing
AU  - Liang J
AD  - Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong
      University, Jinan, Shandong 250014, P.R. China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Ultrasonography, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, Shandong 250014, P.R. China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong
      University, Jinan, Shandong 250014, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7401193
OTO - NOTNLM
OT  - adverse reaction
OT  - apatinib
OT  - hypothyroidism
EDAT- 2020/08/13 06:00
MHDA- 2020/08/13 06:01
CRDT- 2020/08/13 06:00
PHST- 2019/08/12 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/08/13 06:00 [entrez]
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/08/13 06:01 [medline]
AID - 10.3892/etm.2020.8937 [doi]
AID - ETM-0-0-8937 [pii]
PST - ppublish
SO  - Exp Ther Med. 2020 Sep;20(3):1961-1966. doi: 10.3892/etm.2020.8937. Epub 2020 Jun
      25.


PMID- 32782340
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210217
IS  - 1471-0080 (Electronic)
IS  - 1471-0072 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Nov
TI  - Applications and ethics of computer-designed organisms.
PG  - 655-656
LID - 10.1038/s41580-020-00284-z [doi]
FAU - Levin, M
AU  - Levin M
AUID- ORCID: http://orcid.org/0000-0001-7292-8084
AD  - Allen Discovery Center at Tufts University, Medford, MA, USA.
      michael.levin@tufts.edu.
AD  - Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston,
      MA, USA. michael.levin@tufts.edu.
FAU - Bongard, J
AU  - Bongard J
AD  - Department of Computer Science, University of Vermont, Burlington, VT, USA.
FAU - Lunshof, J E
AU  - Lunshof JE
AUID- ORCID: http://orcid.org/0000-0002-5630-7947
AD  - Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston,
      MA, USA.
AD  - Department of Global Health and Social Medicine, Harvard Center for Bioethics,
      Harvard Medical School, Boston, MA, USA.
AD  - Department of Genetics, University Medical Center Groningen, University of
      Groningen, Groningen, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Nat Rev Mol Cell Biol
JT  - Nature reviews. Molecular cell biology
JID - 100962782
SB  - IM
MH  - Animals
MH  - Biomedical Engineering/ethics
MH  - Computer-Assisted Instruction/*ethics
MH  - Computers/ethics
MH  - Developmental Biology/ethics
MH  - Humans
MH  - Machine Learning/ethics
EDAT- 2020/08/13 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/13 06:00
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/13 06:00 [entrez]
AID - 10.1038/s41580-020-00284-z [doi]
AID - 10.1038/s41580-020-00284-z [pii]
PST - ppublish
SO  - Nat Rev Mol Cell Biol. 2020 Nov;21(11):655-656. doi: 10.1038/s41580-020-00284-z.


PMID- 32782048
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210110
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jun
TI  - Public Health Lessons Learned From Biases in Coronavirus Mortality
      Overestimation.
PG  - 364-371
LID - 10.1017/dmp.2020.298 [doi]
AB  - In testimony before US Congress on March 11, 2020, members of the House Oversight
      and Reform Committee were informed that estimated mortality for the novel
      coronavirus was 10-times higher than for seasonal influenza. Additional evidence,
      however, suggests the validity of this estimation could benefit from vetting for 
      biases and miscalculations. The main objective of this article is to critically
      appraise the coronavirus mortality estimation presented to Congress.
      Informational texts from the World Health Organization and the Centers for
      Disease Control and Prevention are compared with coronavirus mortality
      calculations in Congressional testimony. Results of this critical appraisal
      reveal information bias and selection bias in coronavirus mortality
      overestimation, most likely caused by misclassifying an influenza infection
      fatality rate as a case fatality rate. Public health lessons learned for future
      infectious disease pandemics include: safeguarding against research biases that
      may underestimate or overestimate an associated risk of disease and mortality;
      reassessing the ethics of fear-based public health campaigns; and providing full 
      public disclosure of adverse effects from severe mitigation measures to contain
      viral transmission.
FAU - Brown, Ronald B
AU  - Brown RB
AUID- ORCID: 0000-0002-9473-2274
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200812
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
MH  - *Bias
MH  - COVID-19
MH  - Congresses as Topic/legislation & jurisprudence
MH  - Coronavirus Infections/epidemiology/*mortality
MH  - Humans
MH  - Mortality/*trends
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*mortality
MH  - Public Health/methods/trends
MH  - Statistics as Topic/methods/*standards/trends
PMC - PMC7511835
OTO - NOTNLM
OT  - *COVID-19
OT  - *case fatality rate
OT  - *coronavirus mortality overestimation
OT  - *infection fatality rate
OT  - *sampling bias
EDAT- 2020/08/13 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/08/13 06:00
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/08/13 06:00 [entrez]
AID - S1935789320002980 [pii]
AID - 10.1017/dmp.2020.298 [doi]
PST - ppublish
SO  - Disaster Med Public Health Prep. 2020 Jun;14(3):364-371. doi:
      10.1017/dmp.2020.298. Epub 2020 Aug 12.


PMID- 32782010
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20220531
IS  - 1475-2891 (Electronic)
IS  - 1475-2891 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Aug 11
TI  - The effects of spinach-derived thylakoid supplementation in combination with
      calorie restriction on anthropometric parameters and metabolic profiles in obese 
      women with polycystic ovary syndrome: a randomized, double-blind,
      placebo-controlled clinical trial.
PG  - 82
LID - 10.1186/s12937-020-00601-4 [doi]
AB  - BACKGROUND: There is a promising outlook regarding the potential effect of
      spinach-derived thylakoids in the management of obesity and its associated
      metabolic disturbances. This research aimed to evaluate the effects of
      spinach-derived thylakoids supplementation combined with a calorie-restricted
      diet on anthropometric and metabolic profiles in obese women with the polycystic 
      ovary syndrome (PCOS). METHODS: In a 12-week double-blind placebo-controlled
      randomized clinical trial, 48 females with obesity and PCOS were randomly
      allocated into either intervention (5 g/day thylakoid) or placebo (5 g/day
      cornstarch) groups along with calorie-restricted diets. Anthropometric measures, 
      physical activity levels, dietary intakes, insulin resistance markers, as well as
      serum levels of insulin, fasting blood glucose (FBG), non-esterified fatty acids 
      (NEFA), and sex hormones including dehydroepiandrosterone sulfate (DHEAS),
      follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormone-binding
      globulin (SHBG), and free androgen index (FAI) were evaluated pre-and
      post-intervention. RESULTS: After the 12-week intervention, there were
      significant decreases in weight (- 6.97 +/- 0.52 vs. -3.19 +/- 0.72 kg; P <
      0.001), waist circumference (- 7.78 +/- 2.50 vs. -3.73 +/- 1.40 cm; P < 0.001),
      fat mass (- 5.19 +/- 0.53 vs. -1.36 +/- 0.39 kg; P < 0.001), and insulin levels
      (- 5.40 +/- 1.86 vs. -1.19 +/- 0.85 muU/mL; P < 0.001) in the spinach-derived
      thylakoid group compared to the placebo group. Furthermore, insulin resistance
      markers and serum levels of testosterone decreased significantly in the thylakoid
      group compared to the placebo group (P < 0.05). The changes in other parameters
      did not show significant differences between the two groups. CONCLUSIONS:
      Spinach-derived thylakoid supplementation resulted in more favorable improvements
      in anthropometric indices and insulin sensitivity compared to the calorie
      restriction alone. TRIAL REGISTRATION: The study was approved by the Ethics
      Committee of Research Vice-chancellor of Tabriz University of Medical Sciences,
      Tabriz, Iran, and was registered in the Iranian Registry of Clinical Trials
      (registration ID: IRCT20140907019082N9 ).
FAU - Tabrizi, Fatemeh Pourteymour Fard
AU  - Tabrizi FPF
AD  - Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Farhangi, Mahdieh Abbasalizad
AU  - Farhangi MA
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences,
      Attar-neishabouri Ave, Golgasht St, Tabriz, 5165665931, Iran.
      abbasalizad_m@yahoo.com.
FAU - Vaezi, Maryam
AU  - Vaezi M
AD  - Women's Reproductive Health Research Center, Tabriz University of Medical
      Sciences, Tabriz, Iran.
AD  - Department. of Obstetrics and Gynecology, Alzahra Teaching Hospital, Tabriz
      University of Medical Sciences, Tabriz, Iran.
FAU - Hemmati, Salar
AU  - Hemmati S
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz,
      Iran.
LA  - eng
SI  - IRCT/IRCT20140907019082N9
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - Nutr J
JT  - Nutrition journal
JID - 101152213
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Blood Glucose
MH  - Caloric Restriction
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Insulin
MH  - *Insulin Resistance
MH  - Iran
MH  - Metabolome
MH  - Obesity
MH  - *Polycystic Ovary Syndrome
MH  - Spinacia oleracea
MH  - Testosterone
MH  - Thylakoids
PMC - PMC7422584
OTO - NOTNLM
OT  - *Obesity
OT  - *Polycystic ovary syndrome
OT  - *Spinach-derived thylakoid
OT  - *Thylakoid
EDAT- 2020/08/13 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/08/13 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/08/06 00:00 [accepted]
PHST- 2020/08/13 06:00 [entrez]
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
AID - 10.1186/s12937-020-00601-4 [doi]
AID - 10.1186/s12937-020-00601-4 [pii]
PST - epublish
SO  - Nutr J. 2020 Aug 11;19(1):82. doi: 10.1186/s12937-020-00601-4.


PMID- 32781912
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201218
IS  - 1937-190X (Electronic)
IS  - 1937-190X (Linking)
VI  - 35
IP  - 7
DP  - 2020 Sep 1
TI  - Contact Tracing: An Opportunity for Social Work to Lead.
PG  - 533-545
LID - 10.1080/19371918.2020.1806170 [doi]
AB  - Since the novel coronavirus disease (COVID-19) first emerged in December 2019,
      there have been unprecedented efforts worldwide to contain and mitigate the rapid
      spread of the virus through evidence-based public health measures. As a component
      of pandemic response in the United States, efforts to develop, launch, and
      scale-up contact tracing initiatives are rapidly expanding, yet the presence of
      social work is noticeably absent. In this paper, we identify the specialized
      skill set necessary for high quality contact tracing in the COVID-19 era and
      explore its alignment with social work competencies and skills. Described are
      current examples of contact tracing efforts, and an argument for greater social
      work leadership, based on the profession's ethics, competencies and
      person-in-environment orientation is offered. In light of the dire need for
      widespread high-quality contact tracing, social work is well-positioned to
      participate in interprofessional efforts to design, oversee and manage highly
      effective front-line contact tracing efforts.
FAU - Ross, Abigail M
AU  - Ross AM
AUID- ORCID: 0000-0003-3706-4166
AD  - Graduate School of Social Service, Fordham University , New York, New York, USA.
FAU - Zerden, Lisa De Saxe
AU  - Zerden LS
AD  - School of Social Work-Chapel Hill, University of North Carolina , Chapel Hill,
      North Carolina, USA.
FAU - Ruth, Betty J
AU  - Ruth BJ
AD  - School of Social Work, Boston University , Boston, Massachusetts, USA.
FAU - Zelnick, Jennifer
AU  - Zelnick J
AD  - Graduate School of Social Work, Touro College , New York, New York, USA.
FAU - Cederbaum, Julie
AU  - Cederbaum J
AD  - Suzanne Dworak-Peck School of Social Work, University of Southern California ,
      Los Angeles, California, USA.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20200812
PL  - United States
TA  - Soc Work Public Health
JT  - Social work in public health
JID - 101308228
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Contact Tracing
MH  - Coronavirus Infections/epidemiology/*prevention & control/*transmission
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control/*transmission
MH  - SARS-CoV-2
MH  - Social Work/*standards
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *COVID-19
OT  - *Social work
OT  - *contact tracing
OT  - *public health
EDAT- 2020/08/13 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/08/13 06:00
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/08/13 06:00 [entrez]
AID - 10.1080/19371918.2020.1806170 [doi]
PST - ppublish
SO  - Soc Work Public Health. 2020 Sep 1;35(7):533-545. doi:
      10.1080/19371918.2020.1806170. Epub 2020 Aug 12.


PMID- 32781639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Aug 6
TI  - End-of-Life Care in Acute Hospitals: Practice Change Reported by Health
      Professionals Following Online Education.
LID - E254 [pii]
LID - 10.3390/healthcare8030254 [doi]
AB  - Providing quality care for those dying in hospital is challenging for health
      professionals who receive little training in this. "End of Life Essentials"
      (EOLE) was developed to address gaps in health professionals' knowledge, skills
      and confidence in end-of-life care via the provision of online learning modules
      and practice resources. This study aimed to determine whether respondents could
      describe clinical practice change as a result of module completion. Deidentified 
      data were collected between October and November 2018 from learners registered
      for the online learning modules. Both quantitative and qualitative data were
      extracted and analysed. The survey design and conduct were reviewed, and ethical 
      approval was obtained. Although the response rate was very low, results from n = 
      122 learners show improvements in knowledge, skills, awareness and confidence as 
      a result of the undertaking of the learning modules. Two thirds self-reported
      practice changes (71%, n = 59) following the education, with "communication"
      cited most commonly (n = 19). The findings suggest that the EOLE education
      modules can help to improve end-of-life care by increasing health professionals' 
      awareness of good practice as well as their knowledge, skills and confidence.
      Online learning has also been reinforced as an appropriate forum for end-of-life 
      education. Following education, implementing what has been learned occurs more
      easily at a personal level rather than at a team and organisational level.
      Barriers to and enablers of clinical practice change in hospital are described,
      including the fact that the organisation may not be responsive to changes or have
      the relevant resources to support change.
FAU - Rawlings, Deb
AU  - Rawlings D
AUID- ORCID: 0000-0002-8998-9403
AD  - Palliative and Supportive Services, Flinders University, Adelaide, SA 5001,
      Australia.
FAU - Yin, Huahua
AU  - Yin H
AD  - Palliative and Supportive Services, Flinders University, Adelaide, SA 5001,
      Australia.
FAU - Devery, Kim
AU  - Devery K
AD  - Palliative and Supportive Services, Flinders University, Adelaide, SA 5001,
      Australia.
FAU - Morgan, Deidre
AU  - Morgan D
AUID- ORCID: 0000-0001-8725-9477
AD  - Palliative and Supportive Services, Flinders University, Adelaide, SA 5001,
      Australia.
FAU - Tieman, Jennifer
AU  - Tieman J
AUID- ORCID: 0000-0002-2611-1900
AD  - Palliative and Supportive Services, Flinders University, Adelaide, SA 5001,
      Australia.
LA  - eng
GR  - 123456/Department of Health, Australian Government
PT  - Journal Article
DEP - 20200806
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7551093
OTO - NOTNLM
OT  - e-learning
OT  - education
OT  - end of life
OT  - healthcare professionals
OT  - hospital
OT  - practice change
EDAT- 2020/08/13 06:00
MHDA- 2020/08/13 06:01
CRDT- 2020/08/13 06:00
PHST- 2020/06/11 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/08/13 06:00 [entrez]
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/08/13 06:01 [medline]
AID - healthcare8030254 [pii]
AID - 10.3390/healthcare8030254 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Aug 6;8(3). pii: healthcare8030254. doi:
      10.3390/healthcare8030254.


PMID- 32781429
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1878-0326 (Electronic)
IS  - 1872-4973 (Linking)
VI  - 48
DP  - 2020 Sep
TI  - The impact of investigative genetic genealogy: perceptions of UK professional and
      public stakeholders.
PG  - 102366
LID - S1872-4973(20)30138-1 [pii]
LID - 10.1016/j.fsigen.2020.102366 [doi]
AB  - Law enforcement authorities in the United States have been increasingly employing
      genealogists to search genetic genealogy databases with unknown origin DNA from
      unidentified human remains, or from a serious crime scene, to identify the victim
      or a potential suspected perpetrator. There are benefits to this form of
      searching in terms of public safety and bringing justice to victims of crime, and
      such searches are legally permissible. However, ethical questions arise regarding
      whether database users have a reasonable expectation that their DNA information
      will be searched by law enforcement in this way, and so, in turn, questions about
      consent and privacy have emerged. While initial surveys suggest generally
      positive support for using genetic genealogy methods, less work has explored the 
      underlying reasons behind this support. We were interested in exploring the
      perceptions of key stakeholders in the UK with relation to this, specifically for
      the purposes of solving serious crimes. Through a series of 45 predominantly UK
      public and stakeholder interviews, we show a general support for the technology, 
      though interviewees were also able to articulate a range of social and ethical
      concerns. Support was associated with the extent interviewees perceived the
      technology as impacting the current use of genetic genealogy databases in terms
      of individual genealogy database users, the genealogy community, and/or genetic
      genealogy and law enforcement practices. We present our findings and discuss
      their implications.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Samuel, G
AU  - Samuel G
AD  - Department of Global Health and Social Medicine, King's College London, Bush
      House, Strand, United Kingdom. Electronic address: gabbysamuel@gmail.com.
FAU - Kennett, D
AU  - Kennett D
AD  - Research Department of Genetics, Evolution and Environment, University College
      London, Gower Street, London WC1E 6BT, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200802
PL  - Netherlands
TA  - Forensic Sci Int Genet
JT  - Forensic science international. Genetics
JID - 101317016
SB  - IM
MH  - Adult
MH  - *DNA Fingerprinting
MH  - Databases, Genetic
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Law Enforcement
MH  - Male
MH  - Middle Aged
MH  - *Pedigree
MH  - United Kingdom
OTO - NOTNLM
OT  - *DNA testing
OT  - *Investigative genetic genealogy
OT  - *ancestry
OT  - *ethics
OT  - *forensic genetic genealogy
OT  - *forensics
OT  - *genetic genealogy
OT  - *genetic testing
EDAT- 2020/08/12 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/07/10 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - S1872-4973(20)30138-1 [pii]
AID - 10.1016/j.fsigen.2020.102366 [doi]
PST - ppublish
SO  - Forensic Sci Int Genet. 2020 Sep;48:102366. doi: 10.1016/j.fsigen.2020.102366.
      Epub 2020 Aug 2.


PMID- 32780985
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1449-8944 (Electronic)
IS  - 0156-5788 (Linking)
VI  - 44
IP  - 5
DP  - 2020 Sep
TI  - Engaging consumers in health research: a narrative review.
PG  - 806-813
LID - 10.1071/AH19202 [doi]
AB  - Objective Consumer and community engagement (CCE) in research is increasingly
      valued in a contemporary healthcare environment that seeks to genuinely partner
      with consumers and the wider community. Although there is widespread agreement at
      research governance levels as to the benefits of CCE in research, there is little
      available research-based guidance as to how best to proceed with CCE
      organisationally and how to manage and overcome barriers. The aim of this
      narrative review was to draw together the available research, review findings and
      relevant governance-related material and to discuss these in light of a case
      series among research-engaged consumers in order to chart a practical way
      forward. Methods A narrative literature review about CCE in research was
      conducted. Following this, a case series among seven consumers who had been
      engaged as partners in health research was conducted. Finally, the lived
      experience of these consumers was explored against the findings of the narrative 
      review. Results In all, 121 papers were identified and reviewed, 37 of which were
      used to inform the content of this paper. The most important benefits of CCE to
      both consumers and healthcare researchers were related to improvements in trust
      between consumer and researchers, and the increased relevance and ethics of
      research agendas ultimately pursued. Barriers to CCE were found to be pragmatic, 
      attitudinal and organisational. Enabling factors that capitalise on the benefits 
      and help address the barriers to meaningful CCE are outlined and discussed in
      light of a case series conducted among research-engaged consumers in Australia
      and internationally. Conclusion Best practice standards, organisational
      commitments and resources are needed to improve the status quo in Australia and
      to provide health research end-users with research outcomes that better align
      with their priorities and needs. What is known about the topic? Consumer and
      community engagement (CCE) in research is increasing in prevalence and is likely 
      to be beneficial to both consumers and healthcare providers and researchers. What
      does this paper add? Following review of the available research findings and
      governance statements about CCE, enabling strategies are presented in light of a 
      case series among Sydney-based research-engaged consumers. What are the
      implications for practitioners? Barriers to consumer and community engagement can
      be overcome if well understood and tackled organisationally. The potential
      benefits of shifting to a fully consumer- or community-engaged healthcare
      research environment are multifactorial and represent a paradigm shift in favour 
      of evidence-based patient and family-centred care.
FAU - Anderst, Ania
AU  - Anderst A
AD  - The George Institute for Global Health, Level 5, 1 King Street, Newtown, NSW
      2042, Australia. Email: kconroy@georgeinstitute.org.au; and Corresponding author.
      Email: aanderst@georgeinstitute.org.au.
FAU - Conroy, Karena
AU  - Conroy K
AD  - The George Institute for Global Health, Level 5, 1 King Street, Newtown, NSW
      2042, Australia. Email: kconroy@georgeinstitute.org.au; and Sydney Local Health
      District, Level 11, King George V Building, Missenden Road, Camperdown, NSW 2050,
      Australia. Email: Greg.Fairbrother@health.nsw.gov.au;
      Laila.Hallam@health.nsw.gov.au; alan.mcphail@gmail.com;
      vicki.taylor@health.nsw.gov.au.
FAU - Fairbrother, Greg
AU  - Fairbrother G
AD  - Sydney Local Health District, Level 11, King George V Building, Missenden Road,
      Camperdown, NSW 2050, Australia. Email: Greg.Fairbrother@health.nsw.gov.au;
      Laila.Hallam@health.nsw.gov.au; alan.mcphail@gmail.com;
      vicki.taylor@health.nsw.gov.au; and University of Sydney, Faculty of Medicine and
      Health, Level 11, King George V Building, Royal Prince Alfred Hospital,
      Camperdown, NSW 2050, Australia.
FAU - Hallam, Laila
AU  - Hallam L
AD  - Sydney Local Health District, Level 11, King George V Building, Missenden Road,
      Camperdown, NSW 2050, Australia. Email: Greg.Fairbrother@health.nsw.gov.au;
      Laila.Hallam@health.nsw.gov.au; alan.mcphail@gmail.com;
      vicki.taylor@health.nsw.gov.au; and The University of Sydney, Centre for
      Disability Research and Policy (CDRP), 92-94 Parramatta Road, Camperdown, NSW
      2050, Australia.
FAU - McPhail, Alan
AU  - McPhail A
AD  - Sydney Local Health District, Level 11, King George V Building, Missenden Road,
      Camperdown, NSW 2050, Australia. Email: Greg.Fairbrother@health.nsw.gov.au;
      Laila.Hallam@health.nsw.gov.au; alan.mcphail@gmail.com;
      vicki.taylor@health.nsw.gov.au.
FAU - Taylor, Vicki
AU  - Taylor V
AD  - Sydney Local Health District, Level 11, King George V Building, Missenden Road,
      Camperdown, NSW 2050, Australia. Email: Greg.Fairbrother@health.nsw.gov.au;
      Laila.Hallam@health.nsw.gov.au; alan.mcphail@gmail.com;
      vicki.taylor@health.nsw.gov.au; and University of Sydney, Faculty of Medicine and
      Health, Level 11, King George V Building, Royal Prince Alfred Hospital,
      Camperdown, NSW 2050, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Aust Health Rev
JT  - Australian health review : a publication of the Australian Hospital Association
JID - 8214381
MH  - Australia
MH  - *Delivery of Health Care
MH  - *Health Personnel
MH  - Humans
EDAT- 2020/08/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/12 06:00
PHST- 2019/09/09 00:00 [received]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - AH19202 [pii]
AID - 10.1071/AH19202 [doi]
PST - ppublish
SO  - Aust Health Rev. 2020 Sep;44(5):806-813. doi: 10.1071/AH19202.


PMID- 32780317
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20211002
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 10
DP  - 2020 Oct
TI  - Ethical issues involving fertility preservation for transgender youth.
PG  - 2453-2462
LID - 10.1007/s10815-020-01873-9 [doi]
AB  - PURPOSE: To investigate ethical issues associated with fertility preservation
      (FP) in transgender youth based on reports of patients and their parents.
      METHODS: Our qualitative study involved in-person interviews with 54 subjects (35
      patients and 19 parents). Interviews were audio recorded, transcribed, and
      verified. Each subject completed a demographic questionnaire, and each patient's 
      medical chart was reviewed for additional information. We analyzed the data using
      inductive thematic content analysis. RESULTS: Themes that emerged included a
      range of desires and ambivalence about having genetically related children,
      variability in understanding the potentially irreversible impact of gender
      affirming hormones (GAHs) on fertility, use of adoption, and the impact of age on
      decision-making. Subjects (patients and parents) noted barriers to FP, such as
      cost and insurance coverage. Several parents expressed concern that their
      transgender children may have future regret about not attempting FP. Both
      transgender youth and their parents felt FP was an important precaution.
      CONCLUSIONS: Our study took advantage of the richness of personal narratives to
      identify ongoing ethical issues associated with fertility preservation in
      transgender youth. Transgender youth and their parents did not fully understand
      the process of FP, especially regarding the effects of GAHs, had fears that FP
      could reactivate gender dysphoria, and noted barriers to FP, such as cost,
      highlighting economic disparity and lack of justice. These findings highlight
      ethical issues involving the adequacy of informed consent and economic injustice 
      in access to FP despite expressed interest in the topic.
FAU - Harris, Rebecca M
AU  - Harris RM
AUID- ORCID: http://orcid.org/0000-0002-2170-9487
AD  - Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
      rebecca.harris@childrens.harvard.edu.
FAU - Kolaitis, Irini N
AU  - Kolaitis IN
AD  - Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago,
      Chicago, IL, USA.
FAU - Frader, Joel E
AU  - Frader JE
AD  - Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago,
      Chicago, IL, USA.
LA  - eng
GR  - R01 HD082554/HD/NICHD NIH HHS/United States
GR  - R01-HD082554-01A1/National Institutes of Health (US)
PT  - Journal Article
DEP - 20200811
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Decision Making
MH  - Female
MH  - Fertility/*ethics
MH  - Fertility Preservation/*ethics
MH  - Gender Dysphoria/*epidemiology/psychology
MH  - Humans
MH  - Male
MH  - Transgender Persons/*psychology
PMC - PMC7550448
OTO - NOTNLM
OT  - Ethics
OT  - Fertility preservation
OT  - Justice
OT  - Pediatrics
OT  - Transgender
OT  - Transgender youth
EDAT- 2020/08/12 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1007/s10815-020-01873-9 [doi]
AID - 10.1007/s10815-020-01873-9 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Oct;37(10):2453-2462. doi:
      10.1007/s10815-020-01873-9. Epub 2020 Aug 11.


PMID- 32779331
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Ovarian cryopreservation for children aged 3 years or younger: A report of three 
      cases.
PG  - 2164-2168
LID - 10.1111/jog.14415 [doi]
AB  - Ovarian tissue cryopreservation has recently been performed as an option for
      fertility preservation in prepubertal girls with cancer. In this study, ovarian
      tissue was cryopreserved from 3 girls of 3 years of age or younger during a
      3-year period at our institution. Case 1 was a 1-year-old girl, who was diagnosed
      with a yolk sac tumor in the sacral region. Case 2 was a 2-year-old girl, who was
      diagnosed with retroperitoneal neuroblastoma. Case 3 was a 3-year-old girl, who
      was diagnosed with cerebellar medulloblastoma. All patients had planned to
      undergo chemotherapy that would affect the ovarian reserve. Because these
      patients were toddlers, consideration of ethics, the surgical procedure and
      postoperative management, and optimal method for freezing ovarian tissue was
      necessary, although gynecologists rarely experience these challenges in daily
      clinical practice. We herein present the clinical course of these three cases and
      discuss the peculiarities and countermeasures of ovarian cryopreservation in
      children.
CI  - (c) 2020 Japan Society of Obstetrics and Gynecology.
FAU - Kasei, Ryo
AU  - Kasei R
AD  - Department of Obstetrics and Gynecology, Shiga University of Medical Science,
      Otsu, Japan.
FAU - Morimune, Aina
AU  - Morimune A
AD  - Department of Obstetrics and Gynecology, Shiga University of Medical Science,
      Otsu, Japan.
FAU - Kimura, Fuminori
AU  - Kimura F
AUID- ORCID: https://orcid.org/0000-0002-9840-4227
AD  - Department of Obstetrics and Gynecology, Shiga University of Medical Science,
      Otsu, Japan.
FAU - Kitazawa, Jun
AU  - Kitazawa J
AD  - Department of Obstetrics and Gynecology, Shiga University of Medical Science,
      Otsu, Japan.
FAU - Hanada, Tetsuro
AU  - Hanada T
AD  - Department of Obstetrics and Gynecology, Shiga University of Medical Science,
      Otsu, Japan.
FAU - Murakami, Takashi
AU  - Murakami T
AD  - Department of Obstetrics and Gynecology, Shiga University of Medical Science,
      Otsu, Japan.
LA  - eng
PT  - Case Reports
DEP - 20200810
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
SB  - IM
MH  - Child, Preschool
MH  - Cryopreservation
MH  - Female
MH  - *Fertility Preservation
MH  - Humans
MH  - Infant
MH  - *Neoplasms
MH  - Ovary
OTO - NOTNLM
OT  - cancer
OT  - ethics
OT  - fertility preservation
OT  - infant
OT  - ovarian tissue cryopreservation
EDAT- 2020/08/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1111/jog.14415 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2020 Oct;46(10):2164-2168. doi: 10.1111/jog.14415. Epub
      2020 Aug 10.


PMID- 32779237
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20211204
IS  - 1540-5834 (Electronic)
IS  - 0037-976X (Linking)
VI  - 85
IP  - 3
DP  - 2020 Sep
TI  - The Development of Respect in Children and Adolescents.
PG  - 7-99
LID - 10.1111/mono.12417 [doi]
AB  - Respect is an integral part of everyday life. It is a virtue central to the aim
      of living an ethically good life. Despite its importance, little is known about
      its emergence, development, correlates, and consequences. In this monograph, we
      aim to fill this gap by presenting empirical work on children's and adolescents' 
      thinking and feelings about respect. Specifically, we examined the development of
      respect in ethnically diverse samples of children between the ages of 5 and 15
      years (N = 476). Using a narrative and semi-structured interview, as well as
      self-, caregiver- and teacher-reports, and peer-nominations, we collected
      information on children's respect conceptions and reasoning, as well as on the
      social-emotional correlates and prosocial and aggressive behavioral outcomes of
      respect. We begin with a review of theoretical accounts on respect. This includes
      a selective overview of the history of respect in philosophy and psychology in
      Chapter I. Here, we discuss early writings and conceptualizations of respect
      across the seminal works of Kant and others. We then provide an account of the
      various ways in which respect is conceptualized across the psychological
      literature. In Chapter II, we review extant developmental theory and research on 
      respect and its development, correlates, and behavioral consequences. In this
      chapter, as part of our developmental framework, we discuss how respect is
      related and distinct from other emotions such as sympathy and admiration. Next,
      we describe our methodology (Chapter III). This includes a summary of our
      research aims, samples, and measures used for exploring this novel area of
      research. Our primary goals were to examine how children and adolescents
      conceptualize respect, how their conceptualizations differ by age, whether and to
      what degree children feel respect toward others' "good" behavior (i.e., respect
      evaluations for behavior rooted in ethical norms of kindness, fairness, and
      personal achievement goals), and how children's respect is related to other
      ethical emotions and behaviors. The next three chapters provide a summary of our 
      empirical findings. Chapter IV showcases our prominent results on the development
      of children's conceptions of respect. Results revealed that children, across age,
      considered prosociality to be the most important component involved in
      conceptualizations of respect. We also found age-related increases in children's 
      beliefs about fairness as a core component of respect. Children and adolescents
      also reported feeling higher levels of respect for behavior in the ethical domain
      (e.g., sharing fairly and inclusion) than behavior in the personal domain (i.e., 
      achieving high grades in school). Chapter V investigates how sympathy and
      feelings of sadness over wrongdoing relate to respect conceptions and respect for
      behavior. Our findings show that sadness over wrongdoing was positively
      associated with adolescents' fairness conceptions of respect. Sympathy was
      positively related to children's feelings of respect toward others' ethical
      behavior. In Chapter VI, we present links between respect and social behavior.
      Our findings provide some evidence that children's feelings of respect are
      positively linked with prosocial behavior and children's conceptions of respect
      (particularly those reflecting themes of fairness and equality) are negatively
      related to physical aggression. In the last two chapters, we discuss the
      empirical findings and their implications for practice and policy. In Chapter
      VII, we draw upon recent work in the field of social-emotional development to
      interpret our results and provide insight into how our findings extend previous
      seminal work on the development of respect from early childhood to adolescence.
      Finally, in Chapter VIII, we conclude by discussing implications for educational 
      and clinical practice with children and adolescents, as well as social policies
      aimed at reducing discrimination and nurturing children's well-being and positive
      peer relationships.
CI  - (c) 2020 The Society for Research in Child Development.
FAU - Malti, Tina
AU  - Malti T
AD  - Department of Psychology, University of Toronto.
AD  - Centre for Child Development, Mental Health, and Policy, University of Toronto
      Mississauga.
FAU - Peplak, Joanna
AU  - Peplak J
AD  - Department of Psychology, University of Toronto.
AD  - Centre for Child Development, Mental Health, and Policy, University of Toronto
      Mississauga.
FAU - Zhang, Linlin
AU  - Zhang L
AD  - School of Psychology, Capital Normal University Beijing.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Monogr Soc Res Child Dev
JT  - Monographs of the Society for Research in Child Development
JID - 7508397
SB  - IM
MH  - Adolescent
MH  - *Adolescent Development
MH  - Child
MH  - *Child Development
MH  - Child, Preschool
MH  - Concept Formation
MH  - Emotions
MH  - Empirical Research
MH  - Ethnicity
MH  - Female
MH  - Humans
MH  - *Interpersonal Relations
MH  - Interviews as Topic
MH  - Male
MH  - Philosophy
MH  - Psychological Theory
MH  - Social Behavior
EDAT- 2020/08/12 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [entrez]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
AID - 10.1111/mono.12417 [doi]
PST - ppublish
SO  - Monogr Soc Res Child Dev. 2020 Sep;85(3):7-99. doi: 10.1111/mono.12417.


PMID- 32779233
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Informed consent for controlled human infection studies in low- and middle-income
      countries: Ethical challenges and proposed solutions.
PG  - 809-818
LID - 10.1111/bioe.12795 [doi]
AB  - In controlled human infection studies (CHIs), participants are deliberately
      exposed to infectious agents in order to better understand the mechanism of
      infection or disease and test therapies or vaccines. While most CHIs have been
      conducted in high-income countries, CHIs have recently been expanding into low-
      and middle-income countries (LMICs). One potential ethical concern about this
      expansion is the challenge of obtaining the voluntary informed consent of
      participants, especially those who may not be literate or have limited education.
      In some CHIs in LMICs, researchers have attempted to address this potential
      concern by limiting access to literate or educated populations. In this paper, we
      argue that this practice is unjustified, as it does not increase the chances of
      obtaining valid informed consent and therefore unfairly excludes illiterate
      populations and populations with lower education. Instead, we recommend that
      investigators improve the informed consent process by drawing on existing data on
      obtaining informed consent in these populations and interventions aimed at
      improving their understanding. Based on a literature review, we provide concrete 
      suggestions for how to follow this recommendation and ensure that populations
      with lower literacy or education are given a fair opportunity to protect their
      rights and interests in the informed consent process.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Vaswani, Vina
AU  - Vaswani V
AUID- ORCID: 0000-0001-8914-0795
AD  - Centre for Ethics, Yenepoya University, Managlore, India.
FAU - Saxena, Abha
AU  - Saxena A
AD  - The INCLEN Trust International, New Delhi, India.
AD  - Institut Ethique Histoire Humanites, University of Geneva, Geneva, Switzerland.
FAU - Shah, Seema K
AU  - Shah SK
AUID- ORCID: 0000-0001-7726-1186
AD  - Division of Academic General Pediatrics, Lurie Children's Hospital, Chicago, IL, 
      USA.
AD  - Department of Pediatrics, Northwestern University Feinberg School of Medicine,
      Chicago, IL, USA.
FAU - Palacios, Ricardo
AU  - Palacios R
AUID- ORCID: 0000-0002-1410-8579
AD  - Clinical Trials and Pharmacovigilance Center, Instituto Butantan, Sao Paulo,
      Brazil.
FAU - Rid, Annette
AU  - Rid A
AUID- ORCID: 0000-0003-1117-1975
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      Betherda, USA.
LA  - eng
GR  - Greenwall Foundation/International
GR  - Brocher Foundation/International
GR  - NIH Clinical Center/International
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200810
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Developing Countries
MH  - Humans
MH  - Income
MH  - *Informed Consent
MH  - Poverty
MH  - Research Design
OTO - NOTNLM
OT  - *LMIC
OT  - *challenge
OT  - *consent
OT  - *human
OT  - *informed
OT  - *trial
EDAT- 2020/08/12 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/08/12 06:00
PHST- 2019/04/30 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1111/bioe.12795 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):809-818. doi: 10.1111/bioe.12795. Epub 2020 Aug 10.


PMID- 32779143
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211217
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 35
IP  - 12
DP  - 2020 Dec
TI  - A Multicenter VA Study of the Format and Content of Internal Medicine Morning
      Report.
PG  - 3591-3596
LID - 10.1007/s11606-020-06069-6 [doi]
AB  - BACKGROUND: There are more than five hundred internal medicine residency programs
      in the USA, involving 27,000 residents. Morning report is a central educational
      activity in resident education, but no recent studies describe its format or
      content. OBJECTIVE: To describe the format and content of internal medicine
      morning reports. DESIGN AND PARTICIPANTS: Prospective observational study of
      morning reports occurring between September 1, 2018, and April 30, 2019, in ten
      different VA academic medical centers in the USA. MAIN MEASURES: Report format,
      number and type of learner, number and background of attending, frequency of
      learner participation, and the type of media used. Content areas including
      quality and safety, high-value care, social determinants of health,
      evidence-based medicine, ethics, and bedside teaching. For case-based reports,
      the duration of different aspects of the case was recorded, the ultimate
      diagnosis when known, and if the case was scripted or unscripted. RESULTS: A
      total of 225 morning reports were observed. Reports were predominantly
      case-based, moderated by a chief resident, utilized digital presentation slides, 
      and involved a range of learners including medicine residents, medical students, 
      and non-physician learners. The most common attending physician present was a
      hospitalist. Reports typically involved a single case, which the chief resident
      reviewed prior to report and prepared a teaching presentation using digital
      presentation slides. One-half of cases were categorized as either rare or
      life-threatening. The most common category of diagnosis was medication side
      effects. Quality and safety, high-value care, social determinants of health, and 
      evidence-based medicine were commonly discussed. Medical ethics was rarely
      addressed. CONCLUSIONS: Although a wide range of formats and content were
      described, internal medicine morning report most commonly involves a single case 
      that is prepared ahead of time by the chief resident, uses digital presentation
      slides, and emphasizes history, differential diagnosis, didactics, and rare or
      life-threatening diseases.
FAU - Heppe, Daniel B
AU  - Heppe DB
AUID- ORCID: http://orcid.org/0000-0003-3716-0174
AD  - Department of Medicine, University of Colorado School of Medicine, Aurora, CO,
      USA. Daniel.Heppe@Cuanschutz.edu.
AD  - VA Eastern Colorado Health Care System, Aurora, CO, USA.
      Daniel.Heppe@Cuanschutz.edu.
FAU - Beard, Albertine S
AU  - Beard AS
AD  - Department of Medicine, University of Minnesota School of Medicine, Minneapolis, 
      MN, USA.
AD  - Minneapolis VA Health Care System, Minneapolis, MN, USA.
FAU - Cornia, Paul B
AU  - Cornia PB
AD  - University of Washington School of Medicine, Seattle, WA, USA.
AD  - VA Puget Sound Health Care System, Seattle, WA, USA.
FAU - Albert, Tyler J
AU  - Albert TJ
AD  - University of Washington School of Medicine, Seattle, WA, USA.
AD  - VA Puget Sound Health Care System, Seattle, WA, USA.
FAU - Lankarani-Fard, Azadeh
AU  - Lankarani-Fard A
AD  - David Geffen School of Medicine, Los Angeles, CA, USA.
AD  - VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
FAU - Bradley, Joel M
AU  - Bradley JM
AD  - Geisel School of Medicine, Hanover, NH, USA.
AD  - White River Junction VA Medical Center, Hartford, VT, USA.
FAU - Guidry, Michelle M
AU  - Guidry MM
AD  - Tulane University School of Medicine, New Orleans, LA, USA.
AD  - Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.
FAU - Kwan, Brian
AU  - Kwan B
AD  - University of California San Diego School of Medicine, San Diego, CA, USA.
AD  - VA San Diego Healthcare System, San Diego, CA, USA.
FAU - Jagannath, Anand
AU  - Jagannath A
AD  - University of California San Diego School of Medicine, San Diego, CA, USA.
AD  - VA San Diego Healthcare System, San Diego, CA, USA.
FAU - Tuck, Matthew
AU  - Tuck M
AD  - George Washington University School of Medicine, Washington, DC, USA.
AD  - Washington DC VA Medical Center, Washington, DC, USA.
FAU - Fletcher, Kathlyn E
AU  - Fletcher KE
AD  - Medical College of Wisconsin, Wauwatosa, WI, USA.
AD  - Milwaukee VA Medical Center, Milwaukee, WI, USA.
FAU - Gromisch, Elizabeth S
AU  - Gromisch ES
AD  - Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital,
      Trinity Health of New England, Hartford, CT, USA.
AD  - Department of Neurology, University of Connecticut School of Medicine,
      Farmington, CT, USA.
AD  - Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD
      School of Medicine at Quinnipiac University, Hamden, CT, USA.
FAU - Gunderson, Craig G
AU  - Gunderson CG
AD  - Yale University School of Medicine, New Haven, CT, USA.
AD  - VA Connecticut Healthcare System, West Haven, CT, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200810
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
SB  - IM
MH  - Academic Medical Centers
MH  - Humans
MH  - Internal Medicine/education
MH  - *Internship and Residency
MH  - Medical Staff, Hospital
MH  - *Teaching Rounds
PMC - PMC7728907
OTO - NOTNLM
OT  - *education
OT  - *internal medicine residency
OT  - *morning report
EDAT- 2020/08/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1007/s11606-020-06069-6 [doi]
AID - 10.1007/s11606-020-06069-6 [pii]
PST - ppublish
SO  - J Gen Intern Med. 2020 Dec;35(12):3591-3596. doi: 10.1007/s11606-020-06069-6.
      Epub 2020 Aug 10.


PMID- 32779114
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Institutional Approaches to Research Integrity in Ghana.
PG  - 3037-3052
LID - 10.1007/s11948-020-00257-7 [doi]
AB  - Research misconduct (RM) remains an important problem in health research despite 
      decades of local, national, regional, and international efforts to eliminate it. 
      The ultimate goal of every health research project, irrespective of setting, is
      to produce trustworthy findings to address local as well as global health issues.
      To be able to lead or participate meaningfully in international research
      collaborations, individual and institutional capacities for research integrity
      (RI) are paramount. Accordingly, this paper concerns itself not only with
      individuals' research skills but also with institutional and national policies
      and governance. Such policies and governance provide an ethical scaffold for the 
      production of knowledge and structure incentives. This paper's operational
      definition of research therefore draws from Institute of Medicine's articulation 
      of health research as an inquiry that aims to produce knowledge about the
      structure, processes, or effects of personal health services; and from an
      existing health systems framework. The paper reviews the research regulatory
      environment and the ethics apparatus in Ghana, and describes a project jointly
      undertaken by Ghanaian researchers in collaboration with New York University to
      assess the perceived adequacy of current institutional practices, opportunities, 
      and incentives for promoting RI.
FAU - Laar, Amos K
AU  - Laar AK
AUID- ORCID: 0000-0001-5557-0164
AD  - Department of Population, Family and Reproductive Health, School of Public
      Health, University of Ghana, Box LG 13, Legon, Accra, Ghana. alaar@ug.edu.gh.
FAU - Redman, Barbara K
AU  - Redman BK
AUID- ORCID: 0000-0001-5119-9898
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, NY, USA.
FAU - Ferguson, Kyle
AU  - Ferguson K
AUID- ORCID: 0000-0001-9285-4975
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, NY, USA.
FAU - Caplan, Arthur
AU  - Caplan A
AUID- ORCID: 0000-0002-4061-8011
AD  - Division of Medical Ethics, New York University Grossman School of Medicine, New 
      York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20200810
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Academies and Institutes
MH  - Ghana
MH  - Humans
MH  - Policy
MH  - Research Personnel
MH  - *Scientific Misconduct
OTO - NOTNLM
OT  - *Ethics apparatus
OT  - *Ghana
OT  - *Health research
OT  - *Research climate
OT  - *Research integrity
EDAT- 2020/08/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/12 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1007/s11948-020-00257-7 [doi]
AID - 10.1007/s11948-020-00257-7 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):3037-3052. doi: 10.1007/s11948-020-00257-7. Epub
      2020 Aug 10.


PMID- 32779019
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201118
IS  - 1935-973X (Print)
IS  - 1935-9748 (Linking)
VI  - 13
IP  - 6
DP  - 2020 Dec
TI  - Virtual Reality and Augmented Reality-Translating Surgical Training into Surgical
      Technique.
PG  - 663-674
LID - 10.1007/s12178-020-09667-3 [doi]
AB  - PURPOSE OF REVIEW: As immersive learning outside of the operating room is
      increasingly recognized as a valuable method of surgical training, virtual
      reality (VR) and augmented reality (AR) are increasingly utilized in orthopedic
      surgical training. This article reviews the evolving nature of these training
      tools and provides examples of their use and efficacy. The practical and ethical 
      implications of incorporating this technology and its impact on both orthopedic
      surgeons and their patients are also discussed. RECENT FINDINGS: Head-mounted
      displays (HMDs) represent a possible adjunct to surgical accuracy and education. 
      While the hardware is advanced, there is still much work to be done in developing
      software that allows for seamless, reliable, useful integration into clinical
      practice and training. Surgical training is changing: AR and VR will become
      mainstays of future training efforts. More evidence is needed to determine which 
      training technology translates to improved clinical performance. Volatility
      within the HMD industry will likely delay advances in surgical training.
FAU - McKnight, R Randall
AU  - McKnight RR
AUID- ORCID: https://orcid.org/0000-0001-5701-0603
AD  - Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute, 1001 
      Blythe Blvd, Charlotte, NC, 28203, USA. randall.mcknight@gmail.com.
FAU - Pean, Christian A
AU  - Pean CA
AUID- ORCID: https://orcid.org/0000-0001-7445-1152
AD  - Department of Orthopedic Surgery, NYU Langone Health, New York, NY, USA.
FAU - Buck, J Stewart
AU  - Buck JS
AD  - Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute, 1001 
      Blythe Blvd, Charlotte, NC, 28203, USA.
FAU - Hwang, John S
AU  - Hwang JS
AD  - Department of Orthopedic Surgery, Mount Carmel, Columbus, OH, USA.
AD  - Department of Orthopedic Surgery, Orthopedic ONE, Columbus, OH, USA.
FAU - Hsu, Joseph R
AU  - Hsu JR
AD  - Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute, 1001 
      Blythe Blvd, Charlotte, NC, 28203, USA.
FAU - Pierrie, Sarah N
AU  - Pierrie SN
AD  - Department of Orthopaedics and Center for the Intrepid, San Antonio Military
      Medical Center, Fort Sam Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rev Musculoskelet Med
JT  - Current reviews in musculoskeletal medicine
JID - 101317803
PMC - PMC7661680
OTO - NOTNLM
OT  - Augmented reality
OT  - Medical education
OT  - Orthopedic surgery
OT  - Surgical simulation
OT  - Virtual reality
EDAT- 2020/08/12 06:00
MHDA- 2020/08/12 06:01
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2020/08/12 06:01 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1007/s12178-020-09667-3 [doi]
AID - 10.1007/s12178-020-09667-3 [pii]
PST - ppublish
SO  - Curr Rev Musculoskelet Med. 2020 Dec;13(6):663-674. doi:
      10.1007/s12178-020-09667-3.


PMID- 32778580
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201210
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 34
DP  - 2020 Aug 25
TI  - Virtuous violence from the war room to death row.
PG  - 20474-20482
LID - 10.1073/pnas.2001583117 [doi]
AB  - How likely is it that someone would approve of using a nuclear weapon to kill
      millions of enemy civilians in the hope of ending a ground war that threatens
      thousands of American troops? Ask them how they feel about prosecuting
      immigrants, banning abortion, supporting the death penalty, and protecting gun
      rights and you will know. This is the finding from two national surveys of
      Democrats and Republicans that measured support for punitive regulations and
      policies across these four seemingly unrelated issues, and a fifth, using nuclear
      weapons against enemy civilians (in survey 1) or approving of disproportionate
      killing with conventional weapons (in survey 2). Those who support these various 
      policies that threaten harm to many people tend to believe that the victims are
      blameworthy and it is ethical to take actions or policies that might harm them.
      This lends support to the provocative notion of "virtuous violence" put forth by 
      Fiske and Rai [A. P. Fiske, T. S. Rai, Virtuous Violence: Hurting and Killing to 
      Create, Sustain, End, and Honor Social Relationships (2014)], who assert that
      people commit violence because they believe it is the morally right thing to do. 
      The common thread of punitiveness underlying and connecting these issues needs to
      be recognized, understood, and confronted by any society that professes to value 
      fundamental human rights and wishes to prevent important decisions from being
      affected by irrelevant and harmful sociocultural and political biases.
CI  - Copyright (c) 2020 the Author(s). Published by PNAS.
FAU - Slovic, Paul
AU  - Slovic P
AUID- ORCID: 0000-0002-7473-6403
AD  - Decision Research, Eugene, OR 97401; pslovic@uoregon.edu.
AD  - Department of Psychology, College of Arts and Sciences, University of Oregon,
      Eugene, OR 97403.
FAU - Mertz, C K
AU  - Mertz CK
AD  - Decision Research, Eugene, OR 97401.
FAU - Markowitz, David M
AU  - Markowitz DM
AUID- ORCID: 0000-0002-7159-7014
AD  - School of Journalism and Communication, University of Oregon, Eugene, OR 97403.
FAU - Quist, Andrew
AU  - Quist A
AUID- ORCID: 0000-0001-5807-5361
AD  - Decision Research, Eugene, OR 97401.
FAU - Vastfjall, Daniel
AU  - Vastfjall D
AD  - Decision Research, Eugene, OR 97401.
AD  - Division of Psychology, Department of Behavioural Sciences and Learning,
      Linkoping University, 581 83 Linkoping, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Capital Punishment
MH  - Dehumanization
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nuclear Warfare/*psychology
MH  - Nuclear Weapons
MH  - *Politics
MH  - Psychological Distance
MH  - Punishment/*psychology
MH  - Violence/*psychology
MH  - Young Adult
PMC - PMC7456115
OTO - NOTNLM
OT  - *dehumanization
OT  - *nuclear weapons
OT  - *virtuous violence
COIS- The authors declare no competing interest.
EDAT- 2020/08/12 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 2001583117 [pii]
AID - 10.1073/pnas.2001583117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20474-20482. doi:
      10.1073/pnas.2001583117. Epub 2020 Aug 10.


PMID- 32778172
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 10
TI  - The impact of a hands-on arthrocentesis workshop in undergraduate medical
      education.
PG  - 260
LID - 10.1186/s12909-020-02174-6 [doi]
AB  - BACKGROUND: To evaluate the impact of a training programme for arthrocentesis on 
      procedural skills enhancement and self-confidence in medical students. METHODS:
      Participants were provided a structured workshop on injection models. A
      self-confidence questionnaire and medical knowledge assessment were performed.
      Retention of knowledge and skills were assessed at a later time point during a
      formal OSCE examination and compared to participants who had not attended a
      lecture and clinical attachments only. P-values, 95% confidence intervals about
      the mean, standard error of the mean, and standard deviations of the differences 
      were calculated. RESULTS: All participants gained self-confidence, and
      improvement of their skills was significant. The mean self-confidence with
      performing an arthrocentesis procedure increased from 1.3 pre- to 5.9 points
      post-workshop (10-point Likert scale). The knee was the joint students felt most 
      confident with (1.3 to 6.5 points). Knowledge on the selection of corticosteroid 
      preparations (1.2 to 5.8 points) gained substantially, as well as confidence in
      providing post-injection advice (1.9 to 6.6 points). Upon the OSCE examination,
      attendance to the workshop resulted in a significant higher total score (16.2 vs 
      14.8 points, p < 0.05). CONCLUSIONS: A workshop for arthrocentesis procedures, in
      conjunction with other learning activities, is well suited to increasing skills
      and self-confidence in fourth year medical students and allows for developing
      important baseline knowledge and practicing invasive techniques without risk to a
      patient. TRIAL REGISTRATION: This trial has been approved by the human research
      ethics committee of the University of Adelaide (Ethics approval No H-2019-134).
FAU - Ladurner, Andreas
AU  - Ladurner A
AUID- ORCID: http://orcid.org/0000-0003-0580-7455
AD  - Department of Orthopaedics and Trauma, Royal Adelaide Hospital, Port Road,
      Adelaide, SA, 5000, Australia. andreas.ladurner@kssg.ch.
FAU - Nijman, Thomas
AU  - Nijman T
AD  - Department of Orthopaedics and Trauma, Royal Adelaide Hospital, Port Road,
      Adelaide, SA, 5000, Australia.
FAU - Gill, Tiffany K
AU  - Gill TK
AD  - Adelaide Medical School, Adelaide, SA, Australia.
FAU - Smitham, Peter J
AU  - Smitham PJ
AD  - Department of Orthopaedics and Trauma, Royal Adelaide Hospital, Port Road,
      Adelaide, SA, 5000, Australia.
AD  - Centre for Orthopaedic and Trauma Research, The University of Adelaide, Adelaide,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Arthrocentesis
MH  - Clinical Competence
MH  - *Education, Medical, Undergraduate
MH  - Humans
MH  - Learning
MH  - *Students, Medical
PMC - PMC7419181
OTO - NOTNLM
OT  - Arthrocentesis workshop
OT  - Medical student's education
OT  - Skills enhancement
OT  - Synthetic joint model
EDAT- 2020/08/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/12 06:00 [entrez]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02174-6 [doi]
AID - 10.1186/s12909-020-02174-6 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Aug 10;20(1):260. doi: 10.1186/s12909-020-02174-6.


PMID- 32778047
OWN - NLM
STAT- MEDLINE
DCOM- 20210928
LR  - 20210928
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 10
TI  - Perioperative non-invasive versus semi-invasive cardiac index monitoring in
      patients with bariatric surgery - a prospective observational study.
PG  - 196
LID - 10.1186/s12871-020-01110-x [doi]
AB  - BACKGROUND: In morbidly obese patients undergoing laparoscopic bariatric surgery,
      the combination of obesity-related comorbidities, pneumoperitoneum and extreme
      posture changes constitutes a high risk of perioperative hemodynamic
      complications. Thus, an advanced hemodynamic monitoring including continuous
      cardiac index (CI) assessment is desirable. While invasive catheterization may
      bear technical difficulties, transesophageal echocardiography is contraindicated 
      due to the surgical procedure. Evidence on the clinical reliability of
      alternative semi- or non-invasive cardiac monitoring devices is limited. The aim 
      was to compare the non-invasive vascular unloading to a semi-invasive pulse
      contour analysis reference technique for continuous CI measurements in bariatric 
      surgical patients. METHODS: This prospective observational study included adult
      patients scheduled for elective, laparoscopic bariatric surgery after obtained
      institutional ethics approval and written informed consent. CI measurements were 
      performed using the vascular unloading technique (Nexfin(R)) and semi-invasive
      reference method (FloTrac). At 10 defined measurement time points, the influence 
      of clinically indicated body posture changes, passive leg raising, fluid bolus
      administration and pneumoperitoneum was evaluated pre- and intraoperatively.
      Correlation, Bland-Altman and concordance analyses were performed. RESULTS: Sixty
      patients (mean BMI 49.2 kg/m(2)) were enrolled into the study and data from 54
      patients could be entered in the final analysis. Baseline CI was 3.2 +/- 0.9 and 
      3.3 +/- 0.8 l/min/m(2), respectively. Pooled absolute CI values showed a positive
      correlation (rs = 0.76, P < 0.001) and mean bias of of - 0.16 l/min/m(2) (limits 
      of agreement: - 1.48 to 1.15 l/min/m(2)) between the two methods. Pooled
      percentage error was 56.51%, missing the criteria of interchangeability (< 30%). 
      Preoperatively, bias ranged from - 0.33 to 0.08 l/min/m(2) with wide limits of
      agreement. Correlation of CI was best (rs = 0.82, P < 0.001) and percentage error
      lowest (46.34%) during anesthesia and after fluid bolus administration.
      Intraoperatively, bias ranged from - 0.34 to - 0.03 l/min/m(2) with wide limits
      of agreement. CI measurements correlated best during pneumoperitoneum and after
      fluid bolus administration (rs = 0.77, P < 0.001; percentage error 35.95%).
      Trending ability for all 10 measurement points showed a concordance rate of
      85.12%, not reaching the predefined Critchley criterion (> 92%). CONCLUSION:
      Non-invasive as compared to semi-invasive CI measurements did not reach criteria 
      of interchangeability for monitoring absolute and trending values of CI in
      morbidly obese patients undergoing bariatric surgery. TRIAL REGISTRATION: The
      study was registered retrospectively on June 12, 2017 with the registration
      number NCT03184272 .
FAU - Lorenzen, Ulf
AU  - Lorenzen U
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Medical
      Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105,
      Kiel, Germany.
FAU - Pohlmann, Markus
AU  - Pohlmann M
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Medical
      Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105,
      Kiel, Germany.
FAU - Hansen, Jonathan
AU  - Hansen J
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Medical
      Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105,
      Kiel, Germany.
FAU - Klose, Phil
AU  - Klose P
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Medical
      Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105,
      Kiel, Germany.
FAU - Gruenewald, Matthias
AU  - Gruenewald M
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Medical
      Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105,
      Kiel, Germany.
FAU - Renner, Jochen
AU  - Renner J
AD  - Department of Anesthesiology, Helios Kliniken Schwerin, 19055, Schwerin, Germany.
FAU - Elke, Gunnar
AU  - Elke G
AUID- ORCID: 0000-0002-4948-1605
AD  - Department of Anaesthesiology and Intensive Care Medicine, University Medical
      Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105,
      Kiel, Germany. gunnar.elke@uksh.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT03184272
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20200810
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
SB  - IM
MH  - Adult
MH  - Bariatric Surgery/adverse effects/*methods
MH  - Blood Pressure/physiology
MH  - Cardiac Output/*physiology
MH  - Cohort Studies
MH  - Female
MH  - Heart Rate/physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Intraoperative/*methods
MH  - Obesity, Morbid/diagnosis/*physiopathology/*surgery
MH  - Patient Positioning/methods
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC7419223
OTO - NOTNLM
OT  - *Bariatric surgery
OT  - *Cardiac output
OT  - *Finger-cuff
OT  - *Hemodynamic monitoring
OT  - *Non-invasive monitoring
OT  - *Obesity
OT  - *Vascular unloading technique
EDAT- 2020/08/12 06:00
MHDA- 2021/09/29 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/05/28 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/12 06:00 [entrez]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/09/29 06:00 [medline]
AID - 10.1186/s12871-020-01110-x [doi]
AID - 10.1186/s12871-020-01110-x [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 Aug 10;20(1):196. doi: 10.1186/s12871-020-01110-x.


PMID- 32777956
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1872-969X (Electronic)
IS  - 0146-6453 (Linking)
VI  - 49
IP  - 1_suppl
DP  - 2020 Dec
TI  - Ethical aspects in the use of radiation in medicine: update from ICRP Task Group 
      109.
PG  - 143-153
LID - 10.1177/0146645320929630 [doi]
AB  - Whereas scientific evidence is the basis for recommendations and guidance on
      radiological protection, professional ethics is critically important and should
      always guide professional behaviour. The International Commission on Radiological
      Protection (ICRP) established Task Group 109 to advise medical professionals,
      patients, families, carers, the public, and authorities about the ethical aspects
      of radiological protection of patients in the diagnostic and therapeutic use of
      radiation in medicine. Occupational exposures and research-related exposures are 
      not within the scope of this task group. Task Group 109 will produce a report
      that will be available to the different interested parties for consultation
      before publication. Presently, the report is at the stage of a working document
      that has benefitted from an international workshop organised on the topic by the 
      World Health Organization. It presents the history of ethics in medicine in ICRP,
      and explains why this subject is important, and the benefits it can bring to the 
      standard biomedical ethics. As risk is an essential part in decision-making and
      communication, a summary is included on what is known about the dose-effect
      relationship, with emphasis on the associated uncertainties. Once this
      theoretical framework has been presented, the report becomes resolutely more
      practical. First, it proposes an evaluation method to analyse specific situations
      from an ethical point of view. This method allows stakeholders to review a set of
      six ethical values and provides hints on how they could be balanced. Next,
      various situations (e.g. pregnancy, elderly, paediatric, end of life) are
      considered in two steps: first within a realistic, ethically challenging scenario
      on which the evaluation method is applied; and second within a more general
      context. Scenarios are presented and discussed with attention to specific patient
      circumstances, and on how and which reflections on ethical values can be of help 
      in the decision-making process. Finally, two important related aspects are
      considered: how should we communicate with patients, family, and other
      stakeholders; and how should we incorporate ethics into the education and
      training of medical professionals?
FAU - Bochud, F
AU  - Bochud F
AD  - IRA Lausanne University Hospital, Rue du Grand-Pre 1, CH-1007 Lausanne,
      Switzerland; e-mail: francois.bochud@chuv.ch.
FAU - Cantone, M C
AU  - Cantone MC
AD  - University of Milan, Italy.
FAU - Applegate, K
AU  - Applegate K
AD  - University of Kentucky, USA.
FAU - Coffey, M
AU  - Coffey M
AD  - Trinity College Dublin, Ireland.
FAU - Damilakis, J
AU  - Damilakis J
AD  - University of Crete, Greece.
FAU - Del Rosario Perez, M
AU  - Del Rosario Perez M
AD  - World Health Organization, Switzerland.
FAU - Fahey, F
AU  - Fahey F
AD  - Boston Children's Hospital, USA.
FAU - Jesudasan, M
AU  - Jesudasan M
AD  - WHO Global Network of Patients for Patient Safety, Malaysia.
FAU - Kurihara-Saio, C
AU  - Kurihara-Saio C
AD  - National Institute for Quantum and Radiological Sciences and Technology, Japan.
FAU - Le Guen, B
AU  - Le Guen B
AD  - International Radiation Protection Association, France.
FAU - Malone, J
AU  - Malone J
AD  - University of Kentucky, USA.
FAU - Murphy, M
AU  - Murphy M
AD  - WHO Global Network of Patients for Patient Safety, Ireland.
FAU - Reid, L
AU  - Reid L
AD  - Dalhousie University, Canada.
FAU - Zolzer, F
AU  - Zolzer F
AD  - University of South Bohemia, Czech Republic.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
DEP - 20200811
PL  - England
TA  - Ann ICRP
JT  - Annals of the ICRP
JID - 7708044
SB  - IM
MH  - *Guidelines as Topic
MH  - Humans
MH  - International Agencies
MH  - Nuclear Medicine/*ethics
MH  - Radiation Exposure/*prevention & control
MH  - Radiation Protection/*standards
OTO - NOTNLM
OT  - Ethics; Radiological protection; Medicine; ICRP publication
EDAT- 2020/08/12 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1177/0146645320929630 [doi]
PST - ppublish
SO  - Ann ICRP. 2020 Dec;49(1_suppl):143-153. doi: 10.1177/0146645320929630. Epub 2020 
      Aug 11.


PMID- 32777937
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 0261-1929 (Print)
IS  - 0261-1929 (Linking)
VI  - 48
IP  - 3
DP  - 2020 May
TI  - Some Reasons Why Preclinical Studies of Psychiatric Disorders Fail to Translate: 
      What Can Be Rescued from the Misunderstanding and Misuse of Animal 'Models'?
PG  - 106-115
LID - 10.1177/0261192920939876 [doi]
AB  - The repeated failure of animal models to yield findings that translate into
      humans is a serious threat to the credibility of preclinical biomedical research.
      The use of animals in research that lacks translational validity is unacceptable 
      in any ethical environment, and so this problem needs urgent attention. To
      reproduce any human illness in animals is a serious challenge, but this is
      especially the case for psychiatric disorders. Yet, many authors do not hesitate 
      to describe their findings as a 'model' of such a disorder. More cautious
      scientists describe the behavioural phenotype as 'disorder-like', without
      specifying the way(s) in which the abnormal behaviour could be regarded as being 
      analogous to any of the diagnostic features of the disorder in question. By way
      of discussing these problems, this article focuses on common, but flawed,
      assumptions that pervade preclinical research of depression and antidepressants. 
      Particular attention is given to the difference between putative 'models' of this
      illness and predictive screens for candidate drug treatments, which is evidently 
      widely misunderstood. However, the problems highlighted in this article are
      generic and afflict research of all psychiatric disorders. This dire situation
      will be resolved only when funders and journal editors take action to ensure that
      researchers interpret their findings in a less ambitious, but more realistic,
      evidence-based way that would parallel changes in research of the cause(s),
      diagnosis and treatment of psychiatric problems in humans.
FAU - Stanford, S Clare
AU  - Stanford SC
AD  - Department of Neuroscience, Physiology and Pharmacology, 4919University College
      London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - England
TA  - Altern Lab Anim
JT  - Alternatives to laboratory animals : ATLA
JID - 8110074
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Humans
MH  - *Mental Disorders/drug therapy
MH  - Research
OTO - NOTNLM
OT  - Forced Swim Test
OT  - animal model
OT  - depression and antidepressants
OT  - endophenotype
OT  - predictive drug screen
OT  - psychiatry
OT  - psychopharmacology
OT  - translation
OT  - validity
EDAT- 2020/08/12 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1177/0261192920939876 [doi]
PST - ppublish
SO  - Altern Lab Anim. 2020 May;48(3):106-115. doi: 10.1177/0261192920939876. Epub 2020
      Aug 10.


PMID- 32777930
OWN - NLM
STAT- MEDLINE
DCOM- 20201009
LR  - 20211002
IS  - 1478-7083 (Electronic)
IS  - 0035-8843 (Linking)
VI  - 102
IP  - 8
DP  - 2020 Oct
TI  - Artificial Intelligence in plastic surgery: What is it? Where are we now? What is
      on the horizon?
PG  - 577-580
LID - 10.1308/rcsann.2020.0158 [doi]
AB  - INTRODUCTION: An increasing quantity of data is required to guide precision
      medicine and advance future healthcare practices, but current analytical methods 
      often become overwhelmed. Artificial intelligence (AI) provides a promising
      solution. Plastic surgery is an innovative surgical specialty expected to
      implement AI into current and future practices. It is important for all plastic
      surgeons to understand how AI may affect current and future practice, and to
      recognise its potential limitations. METHODS: Peer-reviewed published literature 
      and online content were comprehensively reviewed. We report current applications 
      of AI in plastic surgery and possible future applications based on published
      literature and continuing scientific studies, and detail its potential
      limitations and ethical considerations. FINDINGS: Current machine learning models
      using convolutional neural networks can evaluate breast mammography and
      differentiate benign and malignant tumours as accurately as specialist doctors,
      and motion sensor surgical instruments can collate real-time data to advise
      intraoperative technical adjustments. Centralised big data portals are expected
      to collate large datasets to accelerate understanding of disease pathogeneses and
      best practices. Information obtained using computer vision could guide
      intraoperative surgical decisions in unprecedented detail and semi-autonomous
      surgical systems guided by AI algorithms may enable improved surgical outcomes in
      low- and middle-income countries. Surgeons must collaborate with computer
      scientists to ensure that AI algorithms inform clinically relevant health
      objectives and are interpretable. Ethical concerns such as systematic biases
      causing non-representative conclusions for under-represented patient groups,
      patient confidentiality and the limitations of AI based on the quality of data
      input suggests that AI will accompany the plastic surgeon, rather than replace
      them.
FAU - Murphy, D C
AU  - Murphy DC
AD  - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
AD  - Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK.
AD  - Northumbria Healthcare NHS Foundation Trust, Tyne and Wear, UK.
FAU - Saleh, D B
AU  - Saleh DB
AD  - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
AD  - PA Southside Clinical School, University of Queensland, Brisbane, Queensland,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200811
PL  - England
TA  - Ann R Coll Surg Engl
JT  - Annals of the Royal College of Surgeons of England
JID - 7506860
SB  - IM
MH  - *Artificial Intelligence
MH  - Big Data
MH  - Breast/diagnostic imaging/surgery
MH  - Breast Neoplasms/diagnostic imaging/surgery
MH  - Female
MH  - Humans
MH  - *Image Interpretation, Computer-Assisted
MH  - Mammography
MH  - *Reconstructive Surgical Procedures
PMC - PMC7538735
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Big data
OT  - Machine learning
OT  - Plastic surgery
OT  - Technology
EDAT- 2020/08/12 06:00
MHDA- 2020/10/10 06:00
CRDT- 2020/08/12 06:00
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2020/10/10 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
AID - 10.1308/rcsann.2020.0158 [doi]
PST - ppublish
SO  - Ann R Coll Surg Engl. 2020 Oct;102(8):577-580. doi: 10.1308/rcsann.2020.0158.
      Epub 2020 Aug 11.


PMID- 32777737
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20220418
IS  - 2590-0412 (Electronic)
IS  - 2590-0412 (Linking)
VI  - 78
DP  - 2020 Nov
TI  - Evaluation of efficacy and safety of rituximab in combination with mycophenolate 
      mofetil in patients with nonspecific interstitial pneumonia non-responding to a
      first-line immunosuppressive treatment (EVER-ILD): A double-blind
      placebo-controlled randomized trial.
PG  - 100770
LID - S2590-0412(20)30025-8 [pii]
LID - 10.1016/j.resmer.2020.100770 [doi]
AB  - INTRODUCTION: Nonspecific interstitial pneumonia (NSIP) are rare but severe
      diseases, with high mortality and morbidity, with no effective pharmacological
      treatment allowing for long-term remission, and therefore no clear therapeutic
      recommendations. Classic immunosuppressants are used as first-line treatment,
      with only one third of patients being responders and no clear recommendations
      exist for the choice of the second-line therapy. The EvER-ILD study is the first 
      one to prospectively evaluate the efficacy and safety of rituximab and
      mycophenolate mofetil (MMF) versus placebo and MMF in a broad range of NSIP
      patients that did not respond to a first-line therapy. A
      pharmacokinetic-pharmacodynamic analysis based on rituximab serum concentrations 
      will allow identification of potential factors associated with therapeutic
      response and/or adverse effects. METHODS: EvER-ILD study is a French multicenter,
      prospective, randomized, double blind, placebo-controlled, superiority trial.
      Patients with severe and progressive NSIP non-responding to a first line
      immunosuppressive treatment will be randomized in 2 groups of treatment: one
      course of rituximab plus 6 months MMF (RTX-MMF group) and one course of placebo
      plus 6 months MMF (Placebo-MMF group). The primary outcome is the change in
      Forced Vital Capacity (FVC, % of predicted) from baseline to 6 months. Several
      clinical, biological, and quality of life secondary outcomes will be measured at 
      3, 6 and 12 months. A sample size of 122 patients (61 patients per group) would
      allow to show a point difference between groups in the change of FVC at 6 months,
      based on a common standard deviation for FVC change of 8% with a power of 90%,
      alpha 5% two-sided, and anticipating an extreme 10% drop-out rate. ETHICS AND
      DISSEMINATION: The protocol was approved by the French Research Ethics Committee 
      (CPP Tours Ouest 1 2016-R28) on November 10, 2016, and by the French competent
      authority (ANSM, reference 160771A-22) on December 1st, 2016. This article refers
      to protocol V2, dated November 18, 2016. An independent data safety monitoring
      board will review safety and tolerability data for the duration of the trial.
      Results will be disseminated via peer reviewed publication and presentation at
      international conferences. TRIAL REGISTRATION NUMBER: NCT02990286
      (clinicaltrials.gov), EudraCT 2016-003026-16 (European Medicines agency).
CI  - Copyright (c) 2020 SPLF and Elsevier Masson SAS. All rights reserved.
FAU - Bejan-Angoulvant, T
AU  - Bejan-Angoulvant T
AD  - Service de Pharmacologie medicale, CHRU de Tours, Hopital Bretonneau, Universite 
      de Tours, Tours, France.
FAU - Naccache, J-Marc
AU  - Naccache JM
AD  - AP-HP, Hopital Tenon, service de pneumologie, Site constitutif du centre de
      reference pour les maladies pulmonaires rares OrphaLung, and Sorbonne Universite,
      Paris, France.
FAU - Caille, A
AU  - Caille A
AD  - Inserm CIC1415, CHRU Tours, Universite de Tours, Universite de Nantes, SPHERE,
      U1246, Tours, France.
FAU - Borie, R
AU  - Borie R
AD  - AP-HP, service de pneumologie, centre de competences pour les maladies
      pulmonaires rares, Hopital Bichat, Paris, France.
FAU - Nunes, H
AU  - Nunes H
AD  - Service de pneumologie, centre constitutif pour les maladies pulmonaires rares,
      hopital Avicenne, CHU Paris Seine-Saint-Denis, Bobigny, France.
FAU - Ferreira, M
AU  - Ferreira M
AD  - Service de Pneumologie, CHRU de Tours, Centre de competences des maladies
      pulmonaires rares de la region Centre, Hopital Bretonneau, Tours, France;
      Universite de Tours, CEPR Inserm U1100, Tours, France.
FAU - Cadranel, J
AU  - Cadranel J
AD  - AP-HP, Hopital Tenon, service de pneumologie, Site constitutif du centre de
      reference pour les maladies pulmonaires rares OrphaLung, and Sorbonne Universite,
      Paris, France.
FAU - Crestani, B
AU  - Crestani B
AD  - AP-HP, service de pneumologie, centre de competences pour les maladies
      pulmonaires rares, Hopital Bichat, Paris, France.
FAU - Cottin, V
AU  - Cottin V
AD  - Service de Pneumologie, Centre national coordonnateur de reference des maladies
      pulmonaires rares, Hopital Louis Pradel, Hospices civils de Lyon, UMR 754,
      Universite Claude Bernard Lyon 1, Lyon, France.
FAU - Marchand-Adam, S
AU  - Marchand-Adam S
AD  - Service de Pneumologie, CHRU de Tours, Centre de competences des maladies
      pulmonaires rares de la region Centre, Hopital Bretonneau, Tours, France;
      Universite de Tours, CEPR Inserm U1100, Tours, France. Electronic address:
      s.marchandadam@univ-tours.fr.
CN  - OrphaLung
LA  - eng
SI  - ClinicalTrials.gov/NCT02990286
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200523
PL  - France
TA  - Respir Med Res
JT  - Respiratory medicine and research
JID - 101746324
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Double-Blind Method
MH  - Drug Resistance/drug effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - France
MH  - Humans
MH  - Idiopathic Interstitial Pneumonias/*drug therapy
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mycophenolic Acid/*administration & dosage/adverse effects
MH  - Rituximab/*administration & dosage/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Interstitial lung desease
OT  - Mycophenolate mofetil
OT  - Nonspecific interstitial pneumonia
OT  - Pulmonary fibrosis
OT  - Rituximab
EDAT- 2020/08/11 06:00
MHDA- 2021/09/28 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - S2590-0412(20)30025-8 [pii]
AID - 10.1016/j.resmer.2020.100770 [doi]
PST - ppublish
SO  - Respir Med Res. 2020 Nov;78:100770. doi: 10.1016/j.resmer.2020.100770. Epub 2020 
      May 23.


PMID- 32776776
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1559-713X (Electronic)
IS  - 1559-2332 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Aug
TI  - Guidelines for the Responsible Use of Deception in Simulation: Ethical and
      Educational Considerations.
PG  - 282-288
LID - 10.1097/SIH.0000000000000440 [doi]
AB  - STATEMENT: Many techniques and modifications commonly used by the simulation
      community have been identified as deceptive. Deception is an important issue
      addressed by both the newly adopted Healthcare Simulationist Code of Ethics and
      the American Psychological Association Code of Conduct. Some view these
      approaches as essential whereas others question their necessity as well as their 
      untoward psychological effects. In an attempt to offer guidance to
      simulation-based healthcare educators, we explore educational practices commonly 
      identified as deceptive along with their potential benefits and detriments. We
      then address important decision points and high-risk situations that should be
      avoided to uphold ethical boundaries and psychological safety among learners.
      These are subsequently analyzed in light of the Code of Ethics and used to
      formulate guidelines for educators that are intended to ensure that deception,
      when necessary, is implemented in as psychologically safe a manner as possible.
FAU - Calhoun, Aaron W
AU  - Calhoun AW
AD  - From the Department of Pediatrics (A.C.), University of Louisville School of
      Medicine, Louisville, KY; Department of Anesthesia (M.P.-S.), Harvard Medical
      School, Boston, MA; Department of Anesthesia (A.S., A.L., S.D., A.G.), Icahn
      School of Medicine at Mount Sinai, New York, NY; Department of Anesthesia (D.G.),
      Stanford University School of Medicine, Stanford, CA; and Department of
      Psychiatry and Center for Bioethics (E.M.), Harvard Medical School, Boston, MA.
FAU - Pian-Smith, May
AU  - Pian-Smith M
FAU - Shah, Anjan
AU  - Shah A
FAU - Levine, Adam
AU  - Levine A
FAU - Gaba, David
AU  - Gaba D
FAU - DeMaria, Samuel
AU  - DeMaria S
FAU - Goldberg, Andrew
AU  - Goldberg A
FAU - Meyer, Elaine C
AU  - Meyer EC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Simul Healthc
JT  - Simulation in healthcare : journal of the Society for Simulation in Healthcare
JID - 101264408
SB  - IM
MH  - Codes of Ethics
MH  - *Deception
MH  - Education, Medical/*ethics/organization & administration
MH  - Humans
MH  - Simulation Training/*ethics/organization & administration
EDAT- 2020/08/11 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.1097/SIH.0000000000000440 [doi]
AID - 01266021-202008000-00009 [pii]
PST - ppublish
SO  - Simul Healthc. 2020 Aug;15(4):282-288. doi: 10.1097/SIH.0000000000000440.


PMID- 32776571
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1753-6405 (Electronic)
IS  - 1326-0200 (Linking)
VI  - 44
IP  - 5
DP  - 2020 Oct
TI  - A qualitative study of the role of Samoan Church ministers in health literacy
      messages and health promotion in Auckland, New Zealand.
PG  - 404-409
LID - 10.1111/1753-6405.13027 [doi]
AB  - OBJECTIVE: Health promotion and health literacy activities within church
      congregations are not a new concept; however, this has not yet been widely
      researched in New Zealand. This paper explores the views of Samoan Methodist
      Church ministers about health-related issues and their role in health promotion
      and health literacy in their churches. METHODS: This was a qualitative research
      study with Samoan Methodist Church ministers from Auckland, New Zealand. Ten
      participants were interviewed face-to-face using a semi-structured approach. A
      general inductive approach for analysis of qualitative data was utilised. Ethics 
      approval was granted by the University of Auckland Human Participants Ethics
      Committee. RESULTS: All of the church ministers described a holistic view of
      health and had a sense of responsibility for the holistic wellbeing of their
      members. Culture was seen as the main barrier to good health. Most of the
      ministers identified their role in health promotion as being associated with an
      external health provider. CONCLUSION: Church ministers are well-respected leaders
      in the Samoan Church, which helps them play an important role in communicating
      health-promoting messages and encouraging healthy behaviours. The elders and
      chiefs are recognised as the cultural leaders in the church; without their
      support, the cultural barriers to health will be difficult to overcome.
      Implications for public health: Church ministers are important in health literacy
      messages and health promotion.
CI  - (c) 2020 The Authors.
FAU - Hopoi, Natalie
AU  - Hopoi N
AD  - Pacific Health, School of Population Health, The University of Auckland, New
      Zealand.
FAU - Nosa, Vili
AU  - Nosa V
AD  - Pacific Health, School of Population Health, The University of Auckland, New
      Zealand.
LA  - eng
GR  - New Zealand College of Public Health Medicine
PT  - Journal Article
DEP - 20200810
PL  - Australia
TA  - Aust N Z J Public Health
JT  - Australian and New Zealand journal of public health
JID - 9611095
SB  - IM
MH  - Adult
MH  - *Christianity
MH  - Clergy/*psychology
MH  - Cultural Characteristics
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - *Health Literacy
MH  - *Health Promotion
MH  - Health Status
MH  - Humans
MH  - Interviews as Topic
MH  - *Leadership
MH  - Male
MH  - New Zealand
MH  - Qualitative Research
MH  - Religion and Medicine
MH  - Samoa
MH  - Young Adult
OTO - NOTNLM
OT  - church ministers
OT  - cultural barriers
OT  - health literacy
OT  - health promotion
OT  - leaders
EDAT- 2020/08/11 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/08/11 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1111/1753-6405.13027 [doi]
PST - ppublish
SO  - Aust N Z J Public Health. 2020 Oct;44(5):404-409. doi: 10.1111/1753-6405.13027.
      Epub 2020 Aug 10.


PMID- 32776516
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1097-0290 (Electronic)
IS  - 0006-3592 (Linking)
VI  - 117
IP  - 12
DP  - 2020 Dec
TI  - Anatomical templates for tissue (re)generation and beyond.
PG  - 3938-3951
LID - 10.1002/bit.27533 [doi]
AB  - Induced pluripotent stem cells (iPSCs) represent a valuable alternative to stem
      cells in regenerative medicine overcoming their ethical limitations, like embryo 
      disruption. Takahashi and Yamanaka in 2006 reprogrammed, for the first time,
      mouse fibroblasts into iPSCs through the retroviral delivery of four
      reprogramming factors: Oct3/4, Sox2, c-Myc, and Klf4. Since then, several studies
      started reporting the derivation of iPSC lines from animals other than rodents
      for translational and veterinary medicine. Here, we review the potential of using
      these cells for further intriguing applications, such as "cellular agriculture." 
      iPSCs, indeed, can be a source of in vitro, skeletal muscle tissue, namely
      "cultured meat," a product that improves animal welfare and encourages the
      consumption of healthier meat along with environmental preservation. Also, we
      report the potential of using iPSCs, obtained from endangered species, for
      therapeutic treatments for captive animals and for assisted reproductive
      technologies as well. This review offers a unique opportunity to explore the
      whole spectrum of iPSC applications from regenerative translational and
      veterinary medicine to the production of artificial meat and the preservation of 
      currently endangered species.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Mavaro, Isabella
AU  - Mavaro I
AD  - Department of Veterinary Medicine and Animal Productions, University of Naples
      Federico II, Naples, Italy.
AD  - Interdepartmental Center for Research in Biomaterials (CRIB), University of
      Naples Federico II, Naples, Italy.
FAU - De Felice, Elena
AU  - De Felice E
AD  - School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, 
      Italy.
FAU - Palladino, Antonio
AU  - Palladino A
AD  - Department of Veterinary Medicine and Animal Productions, University of Naples
      Federico II, Naples, Italy.
FAU - D'Angelo, Livia
AU  - D'Angelo L
AD  - Department of Veterinary Medicine and Animal Productions, University of Naples
      Federico II, Naples, Italy.
AD  - Department of Biology and Evolution of Marine Organisms, Stazione Zoologica Anton
      Dohrn, Naples, Italy.
FAU - de Girolamo, Paolo
AU  - de Girolamo P
AD  - Department of Veterinary Medicine and Animal Productions, University of Naples
      Federico II, Naples, Italy.
FAU - Attanasio, Chiara
AU  - Attanasio C
AUID- ORCID: 0000-0001-5817-4087
AD  - Department of Veterinary Medicine and Animal Productions, University of Naples
      Federico II, Naples, Italy.
AD  - Interdepartmental Center for Research in Biomaterials (CRIB), University of
      Naples Federico II, Naples, Italy.
AD  - Center for Advanced Biomaterials for Healthcare, Istituto Italiano di Tecnologia,
      Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200820
PL  - United States
TA  - Biotechnol Bioeng
JT  - Biotechnology and bioengineering
JID - 7502021
SB  - IM
MH  - Animals
MH  - *Cell Differentiation
MH  - *Cellular Reprogramming
MH  - Humans
MH  - *Induced Pluripotent Stem Cells/metabolism/transplantation
MH  - Mice
MH  - *Regenerative Medicine
OTO - NOTNLM
OT  - *cell reprogramming
OT  - *clinical applications
OT  - *meat culture
OT  - *species preservation
OT  - *veterinary science
EDAT- 2020/08/11 06:00
MHDA- 2022/03/04 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1002/bit.27533 [doi]
PST - ppublish
SO  - Biotechnol Bioeng. 2020 Dec;117(12):3938-3951. doi: 10.1002/bit.27533. Epub 2020 
      Aug 20.


PMID- 32776279
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1724-6059 (Electronic)
IS  - 1121-8428 (Linking)
VI  - 33
IP  - 6
DP  - 2020 Dec
TI  - Legislative proposal in Italy to facilitate contacts between deceased organ donor
      families and transplant recipients.
PG  - 1333-1342
LID - 10.1007/s40620-020-00824-y [doi]
AB  - Contacts between organ donors and recipients might be possible in the near future
      in Italy. As suggested by The Italian Committee of Bioethics "anonymity is
      requested by the Italian National Transplant Centre" before transplantation
      anonymity shall be strict in order to grant privacy, gratuity, justice,
      solidarity and benefits and avoids organ trafficking. Following a period that is 
      ethically correct and justifiable, organ donor families and recipients can meet
      after signing a valid declaration of consent, expressed on a template valid for
      the whole country. A third party within the body of the National Health Systems
      shall control the validity of the consent. The opinion stresses that contacts are
      not a right but a possibility justifiable on ethical grounds if the procedure is 
      followed appropriately. A legislative proposal has been presented before the
      Chamber of deputies incorporating all suggestions made by the National Committee 
      of Bioethics. The agreement between parties might be signed a year after
      transplantation. This is a long enough period of time for the recipients to fully
      appreciate the benefits of the procedure and for the donor families to see the
      effects of their decision (the opinion and the Law proposal hit the Zeitgeist,
      and keep Italy in the regulation of European Union).
FAU - De Santo, Natale Gaspare
AU  - De Santo NG
AD  - Emeritus Professor, University of Campania Luigi Vanvitelli, Pansini 5,
      Policlinico Pad 17, 80131, Naples, Italy. NataleGaspare.Desanto@unicampania.it.
FAU - Cirillo, Massimo
AU  - Cirillo M
AD  - Department of Nephrology, University Federico II, Naples, Italy.
FAU - De Santo, Luca S
AU  - De Santo LS
AD  - Division of Heart Surgery, Department of Translational Medical Sciences,
      University of Campania Luigi Vanvitelli, Naples, Italy.
FAU - Abbas, Mohamed Hamed
AU  - Abbas MH
AD  - Department of Dialysis and Transplantation, The Urology and Nephrology Center,
      Mansoura University, Mansoura, Egypt.
FAU - De Rosa, Giusy
AU  - De Rosa G
AD  - Istituto Comprensivo A. Ruggiero, Caserta, Italy.
FAU - Resic, Halima
AU  - Resic H
AD  - Department of Medicine, Clinical Center University of Sarajevo, Sarajevo, Bosnia 
      and Herzegovina.
FAU - Perna, Alessandra F
AU  - Perna AF
AD  - Department of Translational Medical Sciences, Chair of Nephrology, University of 
      Campania Luigi Vanvitelli, Naples, Italy.
FAU - Spasovski, Goce
AU  - Spasovski G
AD  - University Department of Nephrology, Medical Faculty, University of Skopje,
      Skopje, 1000, North Macedonia.
FAU - Citterio, Franco
AU  - Citterio F
AD  - Department of Surgery, University Sacro Cuore, Rome, Italy.
FAU - Venditti, Guglielmo
AU  - Venditti G
AD  - Division of Nephrology Veneziale Hospital, Isernia, Italy.
FAU - Balat, Ayse
AU  - Balat A
AD  - Division of Pediatric Nephrology and Rheumatology, Aydin University, Istanbul,
      Turkey.
FAU - Santini, Luigi
AU  - Santini L
AD  - Chair of General Surgery, University Luigi Vanvitelli, Naples, Italy.
FAU - Masullo, Aldo
AU  - Masullo A
AD  - Emeritus Professor of Moral Philosophy, University Federico II, Naples, Italy.
FAU - Casavola, Francesco Paolo
AU  - Casavola FP
AD  - Emeritus President of the Constitutional Court, Naples, Italy.
FAU - Zecchino, Ortensio
AU  - Zecchino O
AD  - Presidency Biogem, Ariano Irpino, Italy.
FAU - Di Iorio, Biagio
AU  - Di Iorio B
AD  - Division of Nephrology, Moscati Hospital, Avellino, Italy.
FAU - Capasso, Giovambattista
AU  - Capasso G
AD  - Department of Translational Medical Sciences, University of Campania L.
      Vanvitelli, Naples, and Biogem Scarl, Ariano Irpino, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - Italy
TA  - J Nephrol
JT  - Journal of nephrology
JID - 9012268
SB  - IM
MH  - Humans
MH  - Italy
MH  - *Tissue Donors
MH  - *Transplant Recipients
OTO - NOTNLM
OT  - Anonymity
OT  - Donor families
OT  - Organ donation
OT  - Recipients
EDAT- 2020/08/11 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/05/02 00:00 [received]
PHST- 2020/08/01 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1007/s40620-020-00824-y [doi]
AID - 10.1007/s40620-020-00824-y [pii]
PST - ppublish
SO  - J Nephrol. 2020 Dec;33(6):1333-1342. doi: 10.1007/s40620-020-00824-y. Epub 2020
      Aug 10.


PMID- 32775942
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2473-1242 (Electronic)
IS  - 2473-1242 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Implicit Bias in Counseling for Permanent Contraception: Historical Context and
      Recommendations for Counseling.
PG  - 326-329
LID - 10.1089/heq.2020.0025 [doi]
AB  - We provide an overview of the causes, manifestations, and potential mitigating
      steps regarding implicit bias in counseling for permanent contraception. The
      historical context of sterilization abuses and the implications of these on
      society's notions of fitness for parenthood are reviewed. We present contemporary
      examples of contraceptive coercion and discuss the impact of implicit bias from
      health care providers. Finally, we outline steps for ensuring a patient-centered 
      shared decision-making ethical approach to permanent contraceptive counseling.
CI  - (c) Cosette A. Kathawa and Kavita Shah Arora, 2020; Published by Mary Ann
      Liebert, Inc.
FAU - Kathawa, Cosette A
AU  - Kathawa CA
AD  - School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Arora, Kavita Shah
AU  - Arora KS
AD  - Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland,
      Ohio, USA.
LA  - eng
GR  - R01 HD098127/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200717
PL  - United States
TA  - Health Equity
JT  - Health equity
JID - 101708316
PMC - PMC7410277
OTO - NOTNLM
OT  - contraception
OT  - contraceptive counseling
OT  - ethics
OT  - implicit bias
OT  - permanent contraception
OT  - sterilization
COIS- No competing financial interests exist.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.1089/heq.2020.0025 [doi]
AID - 10.1089/heq.2020.0025 [pii]
PST - epublish
SO  - Health Equity. 2020 Jul 17;4(1):326-329. doi: 10.1089/heq.2020.0025. eCollection 
      2020.


PMID- 32775777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2452-1094 (Print)
IS  - 2452-1094 (Linking)
VI  - 5
IP  - 4
DP  - 2020 Jul-Aug
TI  - Ethical Issues in Radiation Oncology During a Pandemic.
PG  - 656-658
LID - 10.1016/j.adro.2020.04.037 [doi]
AB  - Medicine in the United States has generally followed ethical principles espoused 
      by Immanuel Kant where the individual patient takes priority in decision-making. 
      With the advent of coronavirus disease 2019 as a major health event, radiation
      oncologists in some situations need to alter the manner in which they act with
      individual patients. The well-being of health care workers and society as a whole
      needs to be considered in management decisions. During the time of a pandemic,
      ethics principles may be based more on a utilitarian approach that emphasizes the
      common good. Thus, at times treatment decisions might result in delays in
      initiating therapy, modifying the radiation treatment course (such as to a short 
      course rather than a long course of therapy), and the sequence of therapies, all 
      to minimize viral exposure. It is important that altered therapy is based as much
      as possible on institutional or departmental decisions and, to the extent
      possible, not on a case-by-case basis. However, in all situations, we need to
      still respect the individual's autonomy and fully inform patients of our
      decisions and the reasons for those decisions.
CI  - (c) 2020 The Author(s).
FAU - Tepper, Joel E
AU  - Tepper JE
AD  - Department of Radiation Oncology, UNC/Lineberger Comprehensive Cancer Center, UNC
      School of Medicine, Chapel Hill, North Carolina.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - United States
TA  - Adv Radiat Oncol
JT  - Advances in radiation oncology
JID - 101677247
PMC - PMC7242180
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.1016/j.adro.2020.04.037 [doi]
AID - S2452-1094(20)30136-6 [pii]
PST - epublish
SO  - Adv Radiat Oncol. 2020 May 22;5(4):656-658. doi: 10.1016/j.adro.2020.04.037.
      eCollection 2020 Jul-Aug.


PMID- 32775762
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Study protocol for assessing the user acceptance, safety and efficacy of a
      tablet-based workflow and decision support system with incorporated basal insulin
      algorithm for glycaemic management in participants with type 2 diabetes receiving
      home health care: A single-centre, open-label, uncontrolled proof-of-concept
      study.
PG  - 100620
LID - 10.1016/j.conctc.2020.100620 [doi]
AB  - INTRODUCTION: Diabetes management can be especially complex for older adults who 
      receive health care at home. Thus, international guidelines recommend
      basal-insulin regimens due to simpler handling and low hypoglycaemia risk. A
      basal-insulin algorithm (including basal-plus) was developed to also include
      participant's health status and subsequently implemented into a tablet-based
      workflow and decision support system, GlucoTab@MobileCare. This study protocol
      describes a proof-of-concept study to investigate user acceptance, safety and
      efficacy of the GlucoTab@MobileCare system in participants receiving home health 
      care. METHODS: The open-label, single-centre, uncontrolled study will recruit a
      maximum of ten participants with insulin treated type-2-diabetes (age >/=18
      years) who receive home health care. During a three month study period
      participants will receive basal- or basal-plus-insulin therapy once daily as
      suggested by the GlucoTab@MobileCare system. Statistical analysis will be
      conducted on an intention-to-treat basis. The primary endpoint is the percentage 
      of tasks (BG measurements, insulin dose calculations, insulin injections) that
      were performed according to GlucoTab@MobileCare suggestions relative to the total
      of suggested tasks. Secondary endpoints include user acceptance, safety and
      efficacy parameters. The study was approved by the ethics committee and
      regulatory authorities. Before obtaining written informed consent, all
      participants will receive oral and written information about all aspects of the
      study. Results will be published in a peer-reviewed journal and at diabetes and
      geriatric conferences. DISCUSSION: Potential implications may be improved quality
      and safety of basal-insulin therapy in older adults as well as support for
      health-care-providers in daily routine including evidence-based knowledge. TRIAL 
      REGISTRATION: German Clinical Trials Register (DRKS00015059).
CI  - (c) 2020 The Authors.
FAU - Libiseller, Angela
AU  - Libiseller A
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
FAU - Kopanz, Julia
AU  - Kopanz J
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
FAU - Lichtenegger, Katharina M
AU  - Lichtenegger KM
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
FAU - Mader, Julia K
AU  - Mader JK
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
FAU - Truskaller, Thomas
AU  - Truskaller T
AD  - JOANNEUM RESEARCH Forschungsgesellschaft mbH, HEALTH, Institute for Biomedicine
      and Health Sciences, Graz, Austria.
FAU - Lackner, Bettina
AU  - Lackner B
AD  - JOANNEUM RESEARCH Forschungsgesellschaft mbH, HEALTH, Institute for Biomedicine
      and Health Sciences, Graz, Austria.
FAU - Aberer, Felix
AU  - Aberer F
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
FAU - Pandis, Marlene
AU  - Pandis M
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
FAU - Reinisch-Gratzer, Johanna
AU  - Reinisch-Gratzer J
AD  - AUSTRIAN RED CROSS, Landesverband Steiermark, Graz, Austria.
FAU - Ambrosch, Gisela C
AU  - Ambrosch GC
AD  - AUSTRIAN RED CROSS, Landesverband Steiermark, Graz, Austria.
FAU - Sinner, Frank
AU  - Sinner F
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
AD  - JOANNEUM RESEARCH Forschungsgesellschaft mbH, HEALTH, Institute for Biomedicine
      and Health Sciences, Graz, Austria.
FAU - Pieber, Thomas R
AU  - Pieber TR
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Austria.
AD  - JOANNEUM RESEARCH Forschungsgesellschaft mbH, HEALTH, Institute for Biomedicine
      and Health Sciences, Graz, Austria.
FAU - Donsa, Klaus
AU  - Donsa K
AD  - JOANNEUM RESEARCH Forschungsgesellschaft mbH, HEALTH, Institute for Biomedicine
      and Health Sciences, Graz, Austria.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7399114
OTO - NOTNLM
OT  - Clinical trials
OT  - Devices
OT  - Diabetes
OT  - Elderly
OT  - Insulin therapy
COIS- JM, FS, TP and KD are founders of the decide Clinical Software Ltd. JM is a
      member in the advisory board of Boehringer Ingelheim, Eli Lilly, Medtronic,
      Prediktor A/S, Roche Diabetes Care, Sanofi-Aventis and received speaker honoraria
      from Abbott Diabetes Care, Astra Zeneca, Dexcom, Eli Lilly, NovoNordisk A/S,
      Roche Diabetes Care, Servier and Takeda. FA received speaker honoraria from Astra
      Zeneca, Boehringer Ingelheim, Eli Lilly and MSD. TP is a member in the advisory
      board of Arecor, Novo Nordisk, Sanofi, Astra-Zeneca, Adocia and received speaker 
      honoraria from Novo Nordisk. The remaining authors have no relevant competing
      interests to disclose.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/06/22 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.1016/j.conctc.2020.100620 [doi]
AID - S2451-8654(20)30104-6 [pii]
AID - 100620 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Jul 17;19:100620. doi:
      10.1016/j.conctc.2020.100620. eCollection 2020 Sep.


PMID- 32775316
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Information, Sharing, and Self-Determination: Understanding the Current
      Challenges for the Improvement of Pediatric Care Pathways.
PG  - 371
LID - 10.3389/fped.2020.00371 [doi]
AB  - Despite the considerable progress of medical science over the years, pediatric
      patients can still be affected by serious illnesses that, regardless of age, lead
      to experiencing all the clinical, psychological, ethical and spiritual problems
      related to incurable diseases and death. The interaction between the
      peculiarities of individuals, and the clinical conditions presented define a
      changing and complex profile of health needs, which requires organized, dynamic
      and multidimensional responses. The approach to the pediatric patient must
      consider its biological, psychological, relational and clinical characteristics. 
      Such aspects in fact determine and modulate the type and quantity of the needs
      presented, conditioning the actions to be taken and the organizational models to 
      be implemented. In accordance with some international regulations, it is
      essential that healthcare professionals provide adequate information to the
      patient's understanding in order to enhance participation in the decision-making 
      process regardless of the possibility of expressing consent or dissent to the
      treatment. Frequently, the sharing of decisions on the care path not only fails
      to involve children, but often lacks rigorously designed interventions for
      parental involvement. Therefore, the development of care models that focus on the
      needs of the pediatric population is crucial. The present paper aims to analyze
      the problems of information quality and sharing in pediatric care pathways in
      order to promote shared decision-making and improve the knowledge of the
      professionals involved. As a secondary objective, the study will provide useful
      insights for the prevention of decision-making conflicts frequently at the basis 
      of the dispute in the pediatric field.
CI  - Copyright (c) 2020 Scopetti, Santurro, Gatto, Padovano, Manetti, D'Errico and
      Fineschi.
FAU - Scopetti, Matteo
AU  - Scopetti M
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
FAU - Santurro, Alessandro
AU  - Santurro A
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
FAU - Gatto, Vittorio
AU  - Gatto V
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
FAU - Padovano, Martina
AU  - Padovano M
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
FAU - Manetti, Federico
AU  - Manetti F
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
FAU - D'Errico, Stefano
AU  - D'Errico S
AD  - Department of Medicine, Surgery and Health Sciences, University of Trieste,
      Trieste, Italy.
FAU - Fineschi, Vittorio
AU  - Fineschi V
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7381337
OTO - NOTNLM
OT  - care planning
OT  - end of life
OT  - ethics
OT  - healthcare quality
OT  - pediatrics
OT  - shared decision-making
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.3389/fped.2020.00371 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Jul 8;8:371. doi: 10.3389/fped.2020.00371. eCollection 2020.


PMID- 32774987
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210903
IS  - 2522-8552 (Electronic)
IS  - 2096-5524 (Linking)
VI  - 3
IP  - 3
DP  - 2020 Sep
TI  - Bioengineering models of female reproduction.
PG  - 237-251
LID - 10.1007/s42242-020-00082-8 [doi]
AB  - The female reproductive system consists of the ovaries, the female gonads, and
      the reproductive track organs of the fallopian tubes, uterus, cervix, and vagina.
      It functions to provide hormonal support and anatomical structure for the
      production of new offspring. A number of endogenous and exogenous factors can
      impact female reproductive health and fertility, including genetic vulnerability,
      medications, environmental exposures, age, nutrition, and diseases, etc. To date,
      due to the ethical concerns of using human subjects in biomedical research, the
      majority of studies use in vivo animal models and 2D cell/tissue culture models
      to study female reproduction. However, the complexity and species difference of
      the female reproductive system in humans makes it difficult to compare to those
      of animals. Moreover, the monolayered cells cultured on flat plastics or glass
      lose their 3D architecture as well as the physical and/or biochemical contacts
      with other cells in vivo. Further, all reproductive organs do not work alone but 
      interconnect with each other and also with non-reproductive organs to support
      female reproductive, endocrine, and systemic health. These facts suggest that
      there is an urgent and unmet need to develop representative, effective, and
      efficient in vitro models for studying human female reproduction. The prodigious 
      advancements of bioengineering (e.g. biomaterials, 3D printing, and
      organ-on-a-chip) allow us to study female reproduction in an entirely new way.
      Here, we review recent advances that use bioengineering methods to study female
      reproduction, including the bioengineering models of the ovary, fallopian tube,
      uterus, embryo implantation, placenta, and reproductive disease.
FAU - Zubizarreta, Maria E
AU  - Zubizarreta ME
AD  - Department of Environmental Health Sciences, Arnold School of Public Health,
      University of South Carolina, Columbia, SC 29208, USA.
FAU - Xiao, Shuo
AU  - Xiao S
AD  - Department of Environmental Health Sciences, Arnold School of Public Health,
      University of South Carolina, Columbia, SC 29208, USA.
AD  - Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy,
      Environmental Health Sciences Institute, Rutgers University, Piscataway, NJ,
      08854, USA.
LA  - eng
GR  - K01 ES030014/ES/NIEHS NIH HHS/United States
GR  - P01 ES028942/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20200616
PL  - Singapore
TA  - Biodes Manuf
JT  - Bio-design and manufacturing
JID - 101732987
PMC - PMC7413245
MID - NIHMS1605067
OTO - NOTNLM
OT  - 3D printing
OT  - bioengineering
OT  - biomaterials
OT  - female reproduction
OT  - microfluidics
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.1007/s42242-020-00082-8 [doi]
PST - ppublish
SO  - Biodes Manuf. 2020 Sep;3(3):237-251. doi: 10.1007/s42242-020-00082-8. Epub 2020
      Jun 16.


PMID- 32774905
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-004X (Print)
IS  - 2090-004X (Linking)
VI  - 2020
DP  - 2020
TI  - Effect of the Duration of Intraretinal or Subretinal Fluid on the Response to
      Treatment in Undertreated Age-Related Macular Degeneration.
PG  - 5308597
LID - 10.1155/2020/5308597 [doi]
AB  - We investigated the association between the duration of intraretinal fluid (IRF) 
      or subretinal fluid (SRF) and the response to antivascular endothelial growth
      factor injection in patients with undertreated age-related macular degeneration
      (ARMD). The Ethics Committee of Toho University Sakura Medical Center approved
      this study (no. S18030). Eighty eyes of ARMD patients with VA </=20/100 were
      retrospectively assessed. Each injection's efficacy was classified, and the fluid
      accumulation prior to each injection was evaluated. The effect changes following 
      to accumulated IRF, SRF, the longest persistent IRF period (>/=10 months), and
      their determining factors were evaluated. Throughout observation, acquired
      refractoriness was rarely associated with increased accumulation of IRF or SRF.
      The injection span had a tendency to be short, and the polypoidal choroidal
      vasculopathy and occult choroidal neovasculopathy (CNV) proportions had a
      tendency to be higher among patients with diminished effects than among those
      with maintained effects. VA differed significantly with continuous IRF duration, 
      but not with accumulated fluid. The diminishing effect of injections during
      long-standing IRF was rarely associated with undertreatment. The mechanism
      underlying acquired refractoriness remains unknown; the effect change
      demonstrated various patterns, including diminished and improved responses. The
      longest continuous IRF duration was associated with VA decline. Shortening the
      duration of continuous IRF may be necessary.
CI  - Copyright (c) 2020 Izumi Yoshida et al.
FAU - Yoshida, Izumi
AU  - Yoshida I
AUID- ORCID: https://orcid.org/0000-0001-8921-052X
AD  - Sakura Medical Center, Toho University, Sakura-shi, Chiba, Japan.
FAU - Sakamoto, Masashi
AU  - Sakamoto M
AUID- ORCID: https://orcid.org/0000-0002-5599-6576
AD  - Sakura Medical Center, Toho University, Sakura-shi, Chiba, Japan.
FAU - Sakai, Asao
AU  - Sakai A
AD  - Sakura Medical Center, Toho University, Sakura-shi, Chiba, Japan.
FAU - Maeno, Takatoshi
AU  - Maeno T
AUID- ORCID: https://orcid.org/0000-0001-6235-0784
AD  - Sakura Medical Center, Toho University, Sakura-shi, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200726
PL  - United States
TA  - J Ophthalmol
JT  - Journal of ophthalmology
JID - 101524199
PMC - PMC7399753
COIS- The authors declare no conflicts of interest.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.1155/2020/5308597 [doi]
PST - epublish
SO  - J Ophthalmol. 2020 Jul 26;2020:5308597. doi: 10.1155/2020/5308597. eCollection
      2020.


PMID- 32774604
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20220416
IS  - 1937-8688 (Electronic)
VI  - 36
DP  - 2020
TI  - Landscape analysis of healthcare policy: the instrumental role of governance in
      HIV/AIDS services integration framework.
PG  - 27
LID - 10.11604/pamj.2020.36.27.22795 [doi]
AB  - INTRODUCTION: Low and middle-income countries HIV/AIDS interventions are yet to
      achieve the desired levels of health outcome due to lack of effectiveness and
      efficiency in programming, a challenge associated with resource limitations,
      fragmented services, complexities in population and disease characteristics
      including political landscape. The objective of this study was to establish the
      instrumental role of governance in the implementation of HIV/AIDS services
      integration policy framework, with focus on organization structure, participation
      in decision making, collaboration, stakeholder engagement, political commitment
      as study variables. METHODS: Using a mixed method design, a total number of 30
      health workers, 5 county AIDS services coordinators (CASCOs), 8 sub-CASCOs and 3 
      representatives of inter coordinating committee were interviewed in compliance
      with ethical protocols. Multi-stage sampling techniques was used to select
      counties in Kenya, health institutions and respondents. Quantitative and
      qualitative data was generated by administering semi structured questionnaire and
      key informant interview guide. RESULTS: Generated from excel sheet and NVivo
      software indicate that organization structures existed and clarity and ease of
      work varied across the different levels of care. Collaboration efforts, however
      varied, created synergy in policy framework implementation and political
      commitment complemented the various leadership actions for successful
      implementation of integration policy framework. CONCLUSION: Governance role is
      indispensable in the implementation of health policy framework. Policy makers
      need accurate epidemiological and demographic information to implement
      contextualized policy framework necessary for sustained improvement in health
      outcomes.
CI  - (c) Maureen Atieno Adoyo et al.
FAU - Adoyo, Maureen Atieno
AU  - Adoyo MA
AD  - Faculty of Health Sciences, Rongo University, Migori, Kenya.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*therapy
MH  - Administrative Personnel
MH  - Delivery of Health Care/legislation & jurisprudence/*organization &
      administration
MH  - Developing Countries
MH  - HIV Infections/*therapy
MH  - Health Personnel/statistics & numerical data
MH  - *Health Policy
MH  - Humans
MH  - Interviews as Topic
MH  - Kenya
MH  - Leadership
PMC - PMC7388594
OTO - NOTNLM
OT  - Governance
OT  - Kenya
OT  - framework
OT  - healthcare
OT  - integration
OT  - policy
COIS- The author declares no competing interests.
EDAT- 2020/08/11 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/04/18 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.11604/pamj.2020.36.27.22795 [doi]
AID - PAMJ-36-27 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 May 21;36:27. doi: 10.11604/pamj.2020.36.27.22795.
      eCollection 2020.


PMID- 32774396
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1719-8429 (Print)
IS  - 1719-8429 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Aug
TI  - The Ethically Questionable Lack of Research Evaluation of What We Deliver in the 
      Child and Youth Mental Health Service System.
PG  - 130-131
FAU - McLennan, John D
AU  - McLennan JD
AD  - Editor.
LA  - eng
PT  - Editorial
DEP - 20200801
PL  - Canada
TA  - J Can Acad Child Adolesc Psychiatry
JT  - Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de
      l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
JID - 101280868
PMC - PMC7391872
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - ccap29_p0130 [pii]
PST - ppublish
SO  - J Can Acad Child Adolesc Psychiatry. 2020 Aug;29(3):130-131. Epub 2020 Aug 1.


PMID- 32774309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Use of Prazosin for Pediatric Post-Traumatic Stress Disorder With Nightmares
      and/or Sleep Disorder: Case Series of 18 Patients Prospectively Assessed.
PG  - 724
LID - 10.3389/fpsyt.2020.00724 [doi]
AB  - OBJECTIVES: Few studies have investigated pharmacologic treatment for pediatric
      post-traumatic stress disorder (PTSD). Prazosin, an alpha-1 adrenergic receptor
      antagonist, has been studied and demonstrated to be efficacious in an adult
      population for PTSD related sleep disturbances; however, in the pediatric
      population, data is limited to case reports and retrospective case series. This
      study prospectively assessed the safety and effects of Prazosin on PTSD symptoms 
      in a pediatric sample. METHODS: Since 2016, 18 patients with PSTD under the age
      of 15 admitted in a child and adolescent psychiatric unit were challenged with
      prazosin as part of a treatment protocol. PTSD symptoms and adverse effects were 
      collected weekly and prospectively assessed each month with validated clinical
      scales. All data were retrospectively analyzed. This treatment protocol and the
      evaluation of clinical data were approved by our Ethical committee for research
      on preexisting data at the University Teaching Hospital of Rouen. RESULTS: Among 
      the 18 patients (10 girls and 8 boys), 13 (72%) had experienced sexual abuse and 
      5 (28%) family violence. After 1 month of treatment with a mean prazosin dose of 
      2.16 ( +/- 0.6) mg/day, the CGI-S score significantly decreased from 5.3 ( +/-
      0.9) to 2.9 ( +/- 0.7) (improvement of 43%). The mean total UCLA-PTSD-RI score
      significantly decreased 11.4 points ( +/- 5.4) during the first week and 37.9 (
      +/- 16) during the first month, leading to an improvement of 20% and 67%,
      respectively. The improvement was significant irrespective of trauma exposure or 
      sex. No adverse effects were reported except for one patient (hypotension).
      CONCLUSION: Consistent with prior case reports and retrospective reviews, our
      retrospective analysis of data prospectively and systematically assessed among 18
      patients suggests that prazosin is well-tolerated and associated with improvement
      in symptoms for pediatric PTSD.
CI  - Copyright (c) 2020 Ferrafiat, Soleimani, Chaumette, Martinez, Guile, Keeshin and 
      Gerardin.
FAU - Ferrafiat, Vladimir
AU  - Ferrafiat V
AD  - Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Rouen,
      France.
AD  - Child and Adolescent Psychiatric Department, CHU Charles Nicolle, Rouen, France.
FAU - Soleimani, Maryam
AU  - Soleimani M
AD  - Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Rouen,
      France.
AD  - Child and Adolescent Psychiatric Department, CHU Charles Nicolle, Rouen, France.
FAU - Chaumette, Boris
AU  - Chaumette B
AD  - Department of Neurology and Neurosurgery, Montreal Neurological Institute and
      Hospital, McGill University, Montreal, QC, Canada.
FAU - Martinez, Audrey
AU  - Martinez A
AD  - Child and Adolescent Psychiatric Department, CHU Charles Nicolle, Rouen, France.
FAU - Guile, Jean-Marc
AU  - Guile JM
AD  - Child and Adolescent Psychiatry Services, Amiens University Hospital, Picardie
      Jules Verne University, Amiens, France.
AD  - Department of Psychiatry, McGill University, Montreal, QC, Canada.
AD  - INSERM U1105 Research Group for Analysis of the Multimodal Cerebral Function,
      University of Picardie-Jules Verne (UPJV), Amiens, France.
FAU - Keeshin, Brooks
AU  - Keeshin B
AD  - Department of Pediatrics, University of Utah, Salt Lake City, UT, United States.
FAU - Gerardin, Priscille
AU  - Gerardin P
AD  - Child and Adolescent Psychiatric Unit, URHEA, CHSR Sotteville les Rouen, Rouen,
      France.
AD  - Child and Adolescent Psychiatric Department, CHU Charles Nicolle, Rouen, France.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7388897
OTO - NOTNLM
OT  - nightmares
OT  - post-traumatic stress disorder
OT  - prazosin
OT  - sleep disorder
OT  - youth
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.3389/fpsyt.2020.00724 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Jul 22;11:724. doi: 10.3389/fpsyt.2020.00724. eCollection 
      2020.


PMID- 32774153
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Self-assessed competence and need for further training among registered nurses in
      somatic hospital wards in Sweden: a cross-sectional survey.
PG  - 74
LID - 10.1186/s12912-020-00466-2 [doi]
AB  - BACKGROUND: Professional competence and continuous professional development is
      essential for ensuring high quality and safe nursing care, and it might be
      important for motivating nurses to stay in the profession. Thus, there is a need 
      to identify the developmental process of nursing competency. Assessment of
      competence and need for further training helps to identify areas for quality
      improvement, and to design interventions in order to facilitate continuous
      competence development in different work contexts. The current study aimed to 1) 
      describe registered nurses' self-assessment of clinical competence as well as the
      need for further training, and 2) explore possible differences between registered
      nurses with varying lengths of professional experience as a nurse (</= 0,5 year, 
      > 0,5-5 years, and >/= 6 years). METHODS: A cross-sectional survey design was
      applied, using the Professional Nurse Self-Assessment Scale of clinical core
      competencies II. Registered nurses (n = 266) working in medical and surgical
      contexts in hospitals in Sweden responded (response rate 51%). Independent
      student t-test and analysis of variance were carried out. RESULTS: Registered
      nurses assessed their competence highest in statements related to cooperation
      with other health professionals; taking full responsibility for own activities;
      and acting ethically when caring for patients. They assessed their need for
      further training most for statements related to assessing patients' health needs 
      by telephone; giving health promotion advice and recommendations to patients by
      telephone; as well as improving a creative learning environment for staff at the 
      workplace. For self-assessed competence and need for further training,
      differences between the groups for 35 and 46 items respectively, out of 50 were
      statistically significant. CONCLUSIONS: Although the registered nurses assessed
      their competence high for important competence components expected of
      professionals such as cooperation with other healthcare professionals, it is
      problematic that knowledge of interactions and side-effects of different types of
      medication were reported as having the highest need of training. Longitudinal
      follow up of newly graduated nurses regarding their continuous development of
      competence as well as further training is needed.
CI  - (c) The Author(s) 2020.
FAU - Allvin, Renee
AU  - Allvin R
AUID- ORCID: 0000-0003-2470-4902
AD  - Clinical Skills Center, Orebro University Hospital, S-701 85 Orebro,
      Sweden.grid.412367.50000 0001 0123 6208
AD  - Faculty of Medicine and Health, School of Health Sciences, Orebro University,
      S-702 81 Orebro, Sweden.grid.15895.300000 0001 0738 8966
FAU - Bisholt, Birgitta
AU  - Bisholt B
AD  - Department of Health Science, Faculty of Health, Science and Technology, Karlstad
      University, S-651 88 Karlstad, Sweden.grid.20258.3d0000 0001 0721 1351
AD  - Department of Health care Sciences, Ersta Skondal Bracke University College,
      S-100 61 Stockholm, Sweden.grid.412175.40000 0000 9487 9343
FAU - Blomberg, Karin
AU  - Blomberg K
AD  - Faculty of Medicine and Health, School of Health Sciences, Orebro University,
      S-702 81 Orebro, Sweden.grid.15895.300000 0001 0738 8966
FAU - Baath, Carina
AU  - Baath C
AD  - Department of Health Science, Faculty of Health, Science and Technology, Karlstad
      University, S-651 88 Karlstad, Sweden.grid.20258.3d0000 0001 0721 1351
AD  - Faculty of Health and Welfare, Ostfold University College Fredrikstad, N-1757
      Halden, Norway.grid.446040.20000 0001 1940 9648
FAU - Wangensteen, Sigrid
AU  - Wangensteen S
AD  - Department of Health Sciences in Gjovik, NTNU, Norwegian University of Science
      and Technology, Trondheim, Norway.grid.5947.f0000 0001 1516 2393
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7397675
OTO - NOTNLM
OT  - Clinical competence
OT  - Nurse competence
OT  - Registered nurses
OT  - Self-assessment
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.1186/s12912-020-00466-2 [doi]
AID - 466 [pii]
PST - epublish
SO  - BMC Nurs. 2020 Aug 3;19:74. doi: 10.1186/s12912-020-00466-2. eCollection 2020.


PMID- 32773996
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220819
IS  - 0974-777X (Print)
IS  - 0974-777X (Linking)
VI  - 12
IP  - 2
DP  - 2020 Apr-Jun
TI  - The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2)
      Pandemic: A Joint American College of Academic International Medicine-World
      Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group
      Consensus Paper.
PG  - 47-93
LID - 10.4103/jgid.jgid_86_20 [doi]
AB  - What started as a cluster of patients with a mysterious respiratory illness in
      Wuhan, China, in December 2019, was later determined to be coronavirus disease
      2019 (COVID-19). The pathogen severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2), a novel Betacoronavirus, was subsequently isolated as the causative
      agent. SARS-CoV-2 is transmitted by respiratory droplets and fomites and presents
      clinically with fever, fatigue, myalgias, conjunctivitis, anosmia, dysgeusia,
      sore throat, nasal congestion, cough, dyspnea, nausea, vomiting, and/or diarrhea.
      In most critical cases, symptoms can escalate into acute respiratory distress
      syndrome accompanied by a runaway inflammatory cytokine response and multiorgan
      failure. As of this article's publication date, COVID-19 has spread to
      approximately 200 countries and territories, with over 4.3 million infections and
      more than 290,000 deaths as it has escalated into a global pandemic. Public
      health concerns mount as the situation evolves with an increasing number of
      infection hotspots around the globe. New information about the virus is emerging 
      just as rapidly. This has led to the prompt development of clinical patient risk 
      stratification tools to aid in determining the need for testing, isolation,
      monitoring, ventilator support, and disposition. COVID-19 spread is rapid,
      including imported cases in travelers, cases among close contacts of known
      infected individuals, and community-acquired cases without a readily identifiable
      source of infection. Critical shortages of personal protective equipment and
      ventilators are compounding the stress on overburdened healthcare systems. The
      continued challenges of social distancing, containment, isolation, and surge
      capacity in already stressed hospitals, clinics, and emergency departments have
      led to a swell in technologically-assisted care delivery strategies, such as
      telemedicine and web-based triage. As the race to develop an effective vaccine
      intensifies, several clinical trials of antivirals and immune modulators are
      underway, though no reliable COVID-19-specific therapeutics (inclusive of some
      potentially effective single and multi-drug regimens) have been identified as of 
      yet. With many nations and regions declaring a state of emergency, unprecedented 
      quarantine, social distancing, and border closing efforts are underway.
      Implementation of social and physical isolation measures has caused sudden and
      profound economic hardship, with marked decreases in global trade and local small
      business activity alike, and full ramifications likely yet to be felt. Current
      state-of-science, mitigation strategies, possible therapies, ethical
      considerations for healthcare workers and policymakers, as well as lessons
      learned for this evolving global threat and the eventual return to a "new normal"
      are discussed in this article.
CI  - Copyright: (c) 2020 Journal of Global Infectious Diseases.
FAU - Stawicki, Stanislaw P
AU  - Stawicki SP
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Jeanmonod, Rebecca
AU  - Jeanmonod R
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Miller, Andrew C
AU  - Miller AC
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Paladino, Lorenzo
AU  - Paladino L
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Gaieski, David F
AU  - Gaieski DF
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Yaffee, Anna Q
AU  - Yaffee AQ
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - De Wulf, Annelies
AU  - De Wulf A
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Grover, Joydeep
AU  - Grover J
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Papadimos, Thomas J
AU  - Papadimos TJ
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Bloem, Christina
AU  - Bloem C
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Galwankar, Sagar C
AU  - Galwankar SC
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Chauhan, Vivek
AU  - Chauhan V
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Firstenberg, Michael S
AU  - Firstenberg MS
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Di Somma, Salvatore
AU  - Di Somma S
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Jeanmonod, Donald
AU  - Jeanmonod D
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Garg, Sona M
AU  - Garg SM
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Tucci, Veronica
AU  - Tucci V
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Anderson, Harry L
AU  - Anderson HL
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Fatimah, Lateef
AU  - Fatimah L
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Worlton, Tamara J
AU  - Worlton TJ
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Dubhashi, Siddharth P
AU  - Dubhashi SP
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Glaze, Krystal S
AU  - Glaze KS
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Sinha, Sagar
AU  - Sinha S
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Opara, Ijeoma Nnodim
AU  - Opara IN
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Yellapu, Vikas
AU  - Yellapu V
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Kelkar, Dhanashree
AU  - Kelkar D
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - El-Menyar, Ayman
AU  - El-Menyar A
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Krishnan, Vimal
AU  - Krishnan V
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Venkataramanaiah, S
AU  - Venkataramanaiah S
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Leyfman, Yan
AU  - Leyfman Y
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Saoud Al Thani, Hassan Ali
AU  - Saoud Al Thani HA
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Wb Nanayakkara, Prabath
AU  - Wb Nanayakkara P
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Nanda, Sudip
AU  - Nanda S
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Cioe-Pena, Eric
AU  - Cioe-Pena E
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Sardesai, Indrani
AU  - Sardesai I
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Chandra, Shruti
AU  - Chandra S
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Munasinghe, Aruna
AU  - Munasinghe A
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Dutta, Vibha
AU  - Dutta V
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Dal Ponte, Silvana Teixeira
AU  - Dal Ponte ST
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Izurieta, Ricardo
AU  - Izurieta R
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
FAU - Asensio, Juan A
AU  - Asensio JA
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
FAU - Garg, Manish
AU  - Garg M
AD  - Working Group on International Health Security, The American College of Academic 
      International Academic Medicine, USA.
AD  - COVID-19 Pandemic Taskforce, World Academic Council of Emergency Medicine, USA.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - India
TA  - J Glob Infect Dis
JT  - Journal of global infectious diseases
JID - 101521436
PMC - PMC7384689
OTO - NOTNLM
OT  - 2019-nCoV
OT  - COVID-19
OT  - International Health Security
OT  - coronavirus
OT  - global impact
OT  - pandemic
OT  - severe acute respiratory syndrome coronavirus 2
COIS- There are no conflicts of interest.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - 10.4103/jgid.jgid_86_20 [doi]
AID - JGID-12-47 [pii]
PST - epublish
SO  - J Glob Infect Dis. 2020 May 22;12(2):47-93. doi: 10.4103/jgid.jgid_86_20.
      eCollection 2020 Apr-Jun.


PMID- 32773405
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - The COVID-19 Crisis and Clinical Ethics in New York City.
PG  - 228-232
LID - 2020313228 [pii]
AB  - The COVID-19 pandemic that struck New York City in the spring of 2020 was a
      natural experiment for the clinical ethics services of NewYork-Presbyterian
      (NYP). Two distinct teams at NYP's flagship academic medical centers-at
      NYP/Columbia University Medical Center (Columbia) and NYP/Weill Cornell Medical
      Center (Weill Cornell)-were faced with the same pandemic and operated under the
      same institutional rules. Each campus used time as an heuristic to analyze our
      collective response. The Columbia team compares consults during the pandemic with
      the same period during the year prior. The Weill Cornell service describes the
      phases of the pandemic to depict its temporal evolution and subsequent ethical
      challenges. Both sites report that the predominant ethical challenges centered
      around end-of-life decision making, setting goals of care, and medical futility, 
      all complicated by resource allocation questions and the ambiguity of state law
      under crisis standards of care. The Columbia campus saw a statistically
      significant increase in ethics consultations provided to Hispanic patients,
      perhaps reflective of the disproportionate burden of COVID-19 suffered by this
      demographic. While Weill Cornell and Columbia saw a surge in clinical ethics
      consultations, the two services assumed a more expansive role than one normally
      played in institutional life. Serving as intermediaries between frontline
      clinicians and senior hospital administrators, consultants provided critical
      intelligence to hospital leadership about the evolution of the pandemic,
      disseminated information to clinicians, and attended to the moral distress of
      colleagues who were asked to provide care under truly extraordinary
      circumstances. The COVID-19 surge in New York City revealed latent capabilities
      in ethics consultation that may prove useful to the broader clinical ethics
      community as it responds to the current pandemic and reconceptualizes its
      potential for future service.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Fins, Joseph J
AU  - Fins JJ
AD  - William E. Davis, Jr., MD Professor of Medical Ethics, Professor of Medicine, and
      Chief of the Division of Medical Ethics at Weill Cornell Medical College; and is 
      Director of Medical Ethics and an Attending Physician at New York Presbyterian
      Weil Cornell Medicine in New York, New York USA. jjfins@med.cornell. edu.
FAU - Prager, Kenneth M
AU  - Prager KM
AD  - Professor of Medicine, Director of Clinical Ethics, and Chair of the Ethics
      Committee at Columbia University Medical Center in New York, New York USA.
      kmp1@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Academic Medical Centers
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - *Ethics, Clinical
MH  - Humans
MH  - New York City/epidemiology
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
EDAT- 2020/08/11 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 2020313228 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):228-232.


PMID- 32773404
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Phases of a Pandemic Surge: The Experience of an Ethics Service in New York City 
      during COVID-19.
PG  - 219-227
LID - 2020313219 [pii]
AB  - When the COVID-19 surge hit New York City hospitals, the Division of Medical
      Ethics at Weill Cornell Medical College, and our affiliated ethics consultation
      services, faced waves of ethical issues sweeping forward with intensity and
      urgency. In this article, we describe our experience over an eight-week period
      (16 March through 10 May 2020), and describe three types of services: clinical
      ethics consultation (CEC); service practice communications/interventions (SPCI); 
      and organizational ethics advisement (OEA). We tell this narrative through the
      prism of time, describing the evolution of ethical issues and trends as the
      pandemic unfolded. We delineate three phases: anticipation and preparation,
      crisis management, and reflection and adjustment. The first phase focused
      predominantly on ways to address impending resource shortages and to plan for
      remote ethics consultation, and CECs focused on code status discussions with
      surrogates. The second phase was characterized by the dramatic convergence of a
      rapid increase in the number of critically ill patients, a growing scarcity of
      resources, and the reassignment/redeployment of staff outside their specialty
      areas. The third phase was characterized by the recognition that while the worst 
      of the crisis was waning, its medium- and long-term consequences continued to
      pose immense challenges. We note that there were times during the crisis that
      serving in the role of clinical ethics consultant created a sense of dis-ease as 
      novel as the coronavirus itself. In retrospect we learned that our activities far
      exceeded the familiar terrain of clinical ethics consultation and extended into
      other spheres of organizational life in novel ways that were unanticipated before
      this pandemic. To that end, we defined and categorized a middle level of ethics
      consultation, which we have termed service practice communication intervention
      (SPCI). This is an underappreciated dimension of the work that ethics consult
      services are capable of in times of crisis. We believe that the pandemic has
      revealed the many enduring ways that ethics consultation services can more
      robustly contribute to the ethical life of their institutions moving forward.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Huberman, Barrie J
AU  - Huberman BJ
AD  - Interim Assistant Professor of Medical Ethics in Clinical Medicine and Clinical
      Director of the Division of Medical Ethics at Weill Cornell Medical College; and 
      Clinical Director of Medical Ethics and Senior Clinical Ethicist at New York
      Presbyterian Weill Cornell Medicine in New York, New York USA.
      bjh4001@med.cornell.edu.
FAU - Mukherjee, Debjani
AU  - Mukherjee D
AD  - Interim Assistant Professor of Medical Ethics in Clinical Medicine and in
      Clinical Rehabilitation Medicine at Weill Cornell Medical College; and Associate 
      Clinical Ethicist at New York Presbyterian Weill Cornell Medicine in New York,
      New York USA. dem9199@med.cornell.edu.
FAU - Gabbay, Ezra
AU  - Gabbay E
AD  - Assistant Professor of Medicine in the Divisions of General Internal Medicine
      (Hospital Medicine Section) and Medical Ethics in Medicine at Weill Cornell
      Medical College; and Associate Clinical Ethicist at New York Presbyterian Weill
      Cornell Medicine in New York, New York USA. ezg9002@med.cornell.edu.
FAU - Knowlton, Samantha F
AU  - Knowlton SF
AD  - Clinical Assistant Professor of Medical Ethics in Medicine in the Division of
      Medical Ethics at Weill Cornell Medical College; and Associate Clinical Ethicist 
      at New York Presbyterian Weill Cornell Medicine in New York, New York USA.
      sfk2002@med.cornell.edu.
FAU - Green, Douglas S T
AU  - Green DST
AD  - Clinical Assistant Professor of Anesthesiology at Weill Cornell Medical College; 
      and an Attending Anesthesiologist in the Department of Anesthesiology, Critical
      Care, and Pain Management at Hospital for Special Surgery in New York, New York
      USA. greendo@HSS.edu.
FAU - Pandya, Nekee
AU  - Pandya N
AD  - Assistant Professor of Medicine and Clinical Ethics Fellow at Weill Cornell
      Medical College; and Attending Physician in the Division of General Internal
      Medicine (Hospital Medicine Section) at New York-Presbyterian Weill Cornell
      Medicine in New York, New York USA. nep9024@med.cornell.edu.
FAU - Meredith, Nicole
AU  - Meredith N
AD  - PGY-4 General Surgery Resident at New York Presbyterian Weill Cornell Medicine
      and recently completed her Clinical Ethics Fellowship at Weill Cornell Medical
      College in New York, New York USA. nam9121@nyp.org.
FAU - Walker, Joan M
AU  - Walker JM
AD  - Lecturer of Medical Ethics in Medicine and Administrative Director, Division of
      Medical Ethics, Weill Cornell Medical College; and an Associate Clinical Ethicist
      at New York Presbyterian Weill Cornell Medicine in New York, New York USA.
      jow9033@ med.cornell.edu.
FAU - Shapiro, Zachary E
AU  - Shapiro ZE
AD  - Postdoctoral Fellow in the Division of Medical Ethics at Weill Cornell Medical
      College in New York, New York USA. Zas4001@med.cornell.edu.
FAU - Hersh, Jennifer E
AU  - Hersh JE
AD  - Research Coordinator for the Division of Medical Ethics at Weill Cornell Medical 
      College in New York, New York USA. jeh2015@med.cornell.edu.
FAU - Chisholm, Mary F
AU  - Chisholm MF
AD  - Clinical Assistant Professor of Anesthesiology and Clinical Assistant Professor
      of Medical Ethics in Medicine at Weill Cornell Medical College; an Associate
      Clinical Ethicist at New York Presbyterian Weill Cornell Medicine; and Assistant 
      Attending Anesthesiologist, Department of Anesthesiology, Critical Care and Pain 
      Management at Hospital for Special Surgery in New York, New York USA.
      mac2085@med.cornell.edu.
FAU - Waldman, Seth A
AU  - Waldman SA
AD  - Director of the Division of Pain Management, the C.V. Starr Endowed Chair in Pain
      Management, and Attending Physician in the Department of Anesthesiology, Critical
      Care, and Pain Management at Hospital for Special Surgery; Clinical Assistant
      Professor of Anesthesiology and Pain Management at Weill Cornell Medical College;
      and Assistant Medical Ethicist at New York Presbyterian Weill Cornell Medicine in
      New York, New York USA. waldmans@hss.edu.
FAU - MacKenzie, C Ronald
AU  - MacKenzie CR
AD  - C Ronald MacKenzie Chair in Ethics and Medicine and Attending Physician at
      Hospital for Special Surgery; Professor of Clinical Medicine at Weill Cornell
      Medical College; and Attending Physician at New York Presbyterian Weill Cornell
      Medicine in New York, New York USA. mackenzier@hss.edu.
FAU - de Melo-Martin, Inmaculada
AU  - de Melo-Martin I
AD  - Professor of Medical Ethics in Medicine, Professor of Medical Ethics in
      Reproductive Health, and Professor of Healthcare Policy and Research at Weill
      Cornell Medical College in New York, New York USA. imd2001@med.cornell.edu.
FAU - Fins, Joseph J
AU  - Fins JJ
AD  - William E. Davis, Jr., MD Professor of Medical Ethics, Professor of Medicine, and
      Chief of the Division of Medical Ethics at Weill Cornell Medical College; and is 
      Director of Medical Ethics and an Attending Physician at New York Presbyterian
      Weil Cornell Medicine in New York, New York USA. jjfins@med.cornell. edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Academic Medical Centers
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - Ethics Consultation/*organization & administration
MH  - Humans
MH  - New York City/epidemiology
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
EDAT- 2020/08/11 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 2020313219 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):219-227.


PMID- 32773403
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Clinical Ethics Consultations during the COVID-19 Pandemic Surge at a New York
      City Medical Center.
PG  - 212-218
LID - 2020313212 [pii]
AB  - The COVID-19 pandemic swept through New York City swiftly and with devastating
      effect. The crisis put enormous pressure on all hospital services, including the 
      clinical ethics consultation team. This report describes the recent experience of
      the ethics consultants and Columbia University Irving Medical Center during the
      COVID-19 surge and compares the case load and characteristics to the
      corresponding period in 2019. By reporting this experience, we hope to supplement
      the growing body of COVID-19 scientific literature and provide details of the
      human toll the virus took on our hospitals and communities. We also aim to
      highlight the role of the clinical ethics consultant as well as areas of policy
      and law that may need to be addressed in order to be better prepared for a future
      public health crisis.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Fischkoff, Katherine
AU  - Fischkoff K
AD  - Assistant Professor of Surgery and Critical Care at Columbia University Irving
      Medical Center in New York, New York USA. kf2403@cumc.columbia.edu.
FAU - Neuberg, Gerald
AU  - Neuberg G
AD  - Professor of Medicine at Columbia University Irving Medical Center in New York,
      New York USA. gwn1@cumc.columbia.edu.
FAU - Dastidar, Joyeeta
AU  - Dastidar J
AD  - Assistant Professor of Medicine at Columbia University Irving Medical Center in
      New York, New York USA. jgd2133@cumc.columbia.edu.
FAU - Williams, Erin P
AU  - Williams EP
AD  - Medical Student at Columbia University Irving Medical Center in New York, New
      York USA. epw2114@cumc.columbia.edu.
FAU - Prager, Kenneth M
AU  - Prager KM
AD  - Professor of Medicine, Director of Clinical Ethics, and Chair of the Ethics
      Committee at Columbia University Medical Center in New York, New York USA.
      kmp1@cumc.columbia.edu.
FAU - Dugdale, Lydia
AU  - Dugdale L
AD  - Associate Professor of Medicine at Columbia University Irving Medical Centerin
      New York, New York USA. lsd2134@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Academic Medical Centers
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - *Ethics Consultation
MH  - Humans
MH  - New York City/epidemiology
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
EDAT- 2020/08/11 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 2020313212 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):212-218.


PMID- 32773402
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Fall
TI  - Meeting the Challenge of COVID-19: The Response of Two Ethics Consultation
      Services in New York City.
PG  - 209-211
LID - 2020313209 [pii]
AB  - From mid-March through May 2020, New York City was the world's epicenter of the
      COVID-19 pandemic, and its hospitals faced an unparalleled surge of patients who 
      were critically ill with the virus. In addition to putting an enormous strain on 
      medical resources, the pandemic presented many ethical issues to emotionally and 
      physically stressed clinicians and hospital administrators. Analyses of the
      challenges faced by the ethics consultation services of the two campuses of New
      York Presbyterian Hospital, and how they assisted their clinician and
      administrative colleagues, is the subject of the following four articles.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Prager, Kenneth M
AU  - Prager KM
AD  - Professor of Medicine, Director of Clinical Ethics, and Chair of the Ethics
      Committee at Columbia University Medical Center in New York, New York USA.
      kmp1@cumc.columbia.edu.
FAU - Fins, Joseph J
AU  - Fins JJ
AD  - William E. Davis, Jr., MD Professor of Medical Ethics, Professor of Medicine, and
      Chief of the Division of Medical Ethics at Weill Cornell Medical College; and is 
      Director of Medical Ethics and an Attending Physician at New York Presbyterian
      Weil Cornell Medicine in New York, New York USA. jjfins@med.cornell. edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - *Ethics Consultation
MH  - Humans
MH  - New York City/epidemiology
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
EDAT- 2020/08/11 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 2020313209 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(3):209-211.


PMID- 32773379
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 10
TI  - Binocular Vision, Visual Function, and Pupil Dynamics in People Living With
      Dementia and Their Relation to the Rate of Cognitive Decline and Structural
      Changes Within the Brain: Protocol for an Observational Study.
PG  - e16089
LID - 10.2196/16089 [doi]
AB  - BACKGROUND: Visual impairment is a common comorbidity in people living with
      dementia. Addressing sources of visual difficulties can have a significant impact
      on the quality of life for people living with dementia and their caregivers.
      Depth perception problems are purportedly common in dementia and also contribute 
      to falls, visuomotor task difficulties, and poorer psychosocial well-being.
      However, depth perception and binocular vision are rarely assessed in dementia
      research. Sleep fragmentation is also common for people living with dementia, and
      binocular cooperation for depth perception can be affected by fatigue. Pupillary 
      responses under cognitive load also have the potential to be a risk marker for
      cognitive decline in people living with dementia and can be combined with the
      above measures for a comprehensive evaluation of clinical visual changes in
      people living with dementia and their relation to changes in cognitive status,
      sleep quality, and cortical structure or function. OBJECTIVE: This study aims to 
      characterize the nature of clinical visual changes and altered task-evoked
      pupillary responses that may occur in people living with dementia and evaluate
      whether these responses relate to changes in cognitive status (standardized Mini 
      Mental State Examination [MMSE] score), Pittsburgh sleep quality index, and
      cortical structure or function. METHODS: This proposed exploratory observational 
      study will enroll </=210 people with recently diagnosed dementia (within the last
      24 months). The following parameters will be assessed on 3 occasions, 4 months
      apart (plus or minus 2 weeks): visual function (visual acuity and contrast
      sensitivity), binocular function (motor fusion and stereopsis), task-evoked
      pupillary responses (minimum and maximum pupil size, time to maximum dilation,
      and dilation velocity), cognitive status (MMSE score), and sleep quality
      (Pittsburgh Sleep Quality Index). A subset of patients (n=30) with Alzheimer
      disease will undergo structural and functional magnetic resonance imaging at
      first and third visits, completing a 10-day consensus sleep diary to monitor
      sleep quality, verified by sleep actimetry. RESULTS: This research was funded in 
      February 2018 and received National Health Service Research Ethics Committee
      approval in September 2018. The data collection period was from October 1, 2018, 
      to November 30, 2019. A total of 24 participants were recruited for the study.
      The data analysis is complete, with results expected to be published before the
      end of 2020. CONCLUSIONS: Findings will demonstrate how often people with
      dementia experience binocular vision problems. If frequent, diagnosing and
      treating them could improve quality of life by reducing the risk of falls and
      fine visuomotor task impairment and by relieving psychosocial anxiety. This
      research will also demonstrate whether changes in depth perception, pupillary
      responses, and quality of vision relate to changes in memory or sleep quality and
      brain structure or function. If related, these quick and noninvasive eye tests
      help monitor dementia. This would help justify whether binocular vision and
      pupillary response testing should be included in dementia-friendly eye-testing
      guidelines. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      RR1-10.2196/16089.
CI  - (c)Marianne Piano, Ramin Nilforooshan, Simon Evans. Originally published in JMIR 
      Research Protocols (http://www.researchprotocols.org), 10.08.2020.
FAU - Piano, Marianne
AU  - Piano M
AUID- ORCID: https://orcid.org/0000-0003-0714-6339
AD  - School of Health Sciences, Faculty of Health and Medical Sciences, University of 
      Surrey, Guildford, United Kingdom.
AD  - Department of Optometry and Vision Sciences, University of Melbourne, Melbourne, 
      Australia.
AD  - National Vision Research Institute, Australian College of Optometry, Melbourne,
      Australia.
FAU - Nilforooshan, Ramin
AU  - Nilforooshan R
AUID- ORCID: https://orcid.org/0000-0001-9801-183X
AD  - Surrey and Borders Partnership NHS Trust, Chertsey, United Kingdom.
FAU - Evans, Simon
AU  - Evans S
AUID- ORCID: https://orcid.org/0000-0001-7875-9445
AD  - School of Psychology, Faculty of Health and Medical Sciences, University of
      Surrey, Guildford, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7445601
OTO - NOTNLM
OT  - binocular vision
OT  - dementia
OT  - magnetic resonance imaging
OT  - pupil
OT  - sleep
OT  - stereopsis
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - v9i8e16089 [pii]
AID - 10.2196/16089 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 10;9(8):e16089. doi: 10.2196/16089.


PMID- 32773373
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 10
TI  - A Combined Digital and Biomarker Diagnostic Aid for Mood Disorders (the Delta
      Trial): Protocol for an Observational Study.
PG  - e18453
LID - 10.2196/18453 [doi]
AB  - BACKGROUND: Mood disorders affect hundreds of millions of people worldwide,
      imposing a substantial medical and economic burden. Existing diagnostic methods
      for mood disorders often result in a delay until accurate diagnosis, exacerbating
      the challenges of these disorders. Advances in digital tools for psychiatry and
      understanding the biological basis of mood disorders offer the potential for
      novel diagnostic methods that facilitate early and accurate diagnosis of
      patients. OBJECTIVE: The Delta Trial was launched to develop an algorithm-based
      diagnostic aid combining symptom data and proteomic biomarkers to reduce the
      misdiagnosis of bipolar disorder (BD) as a major depressive disorder (MDD) and
      achieve more accurate and earlier MDD diagnosis. METHODS: Participants for this
      ethically approved trial were recruited through the internet, mainly through
      Facebook advertising. Participants were then screened for eligibility, consented 
      to participate, and completed an adaptive digital questionnaire that was designed
      and created for the trial on a purpose-built digital platform. A subset of these 
      participants was selected to provide dried blood spot (DBS) samples and undertake
      a World Health Organization World Mental Health Composite International
      Diagnostic Interview (CIDI). Inclusion and exclusion criteria were chosen to
      maximize the safety of a trial population that was both relevant to the trial
      objectives and generalizable. To provide statistical power and validation sets
      for the primary and secondary objectives, 840 participants were required to
      complete the digital questionnaire, submit DBS samples, and undertake a CIDI.
      RESULTS: The Delta Trial is now complete. More than 3200 participants completed
      the digital questionnaire, 924 of whom also submitted DBS samples and a CIDI,
      whereas a total of 1780 participants completed a 6-month follow-up questionnaire 
      and 1542 completed a 12-month follow-up questionnaire. The analysis of the trial 
      data is now underway. CONCLUSIONS: If a diagnostic aid is able to improve the
      diagnosis of BD and MDD, it may enable earlier treatment for patients with mood
      disorders. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/18453.
CI  - (c)Tony Olmert, Jason D Cooper, Sung Yeon Sarah Han, Giles Barton-Owen, Lynn
      Farrag, Emily Bell, Lauren V Friend, Sureyya Ozcan, Nitin Rustogi, Rhian L
      Preece, Pawel Eljasz, Jakub Tomasik, Daniel Cowell, Sabine Bahn. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      10.08.2020.
FAU - Olmert, Tony
AU  - Olmert T
AUID- ORCID: https://orcid.org/0000-0003-4641-6442
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Cooper, Jason D
AU  - Cooper JD
AUID- ORCID: https://orcid.org/0000-0002-2459-5286
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Han, Sung Yeon Sarah
AU  - Han SYS
AUID- ORCID: https://orcid.org/0000-0002-1459-2516
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Barton-Owen, Giles
AU  - Barton-Owen G
AUID- ORCID: https://orcid.org/0000-0002-7552-1295
AD  - Psyomics Ltd, Cambridge, United Kingdom.
FAU - Farrag, Lynn
AU  - Farrag L
AUID- ORCID: https://orcid.org/0000-0002-5045-5308
AD  - Psyomics Ltd, Cambridge, United Kingdom.
FAU - Bell, Emily
AU  - Bell E
AUID- ORCID: https://orcid.org/0000-0003-2037-3093
AD  - Psyomics Ltd, Cambridge, United Kingdom.
FAU - Friend, Lauren V
AU  - Friend LV
AUID- ORCID: https://orcid.org/0000-0003-4340-7401
AD  - Psyomics Ltd, Cambridge, United Kingdom.
FAU - Ozcan, Sureyya
AU  - Ozcan S
AUID- ORCID: https://orcid.org/0000-0002-9371-3696
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Rustogi, Nitin
AU  - Rustogi N
AUID- ORCID: https://orcid.org/0000-0002-4381-1271
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Preece, Rhian L
AU  - Preece RL
AUID- ORCID: https://orcid.org/0000-0001-8022-0182
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Eljasz, Pawel
AU  - Eljasz P
AUID- ORCID: https://orcid.org/0000-0002-0592-3934
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Tomasik, Jakub
AU  - Tomasik J
AUID- ORCID: https://orcid.org/0000-0002-2127-4487
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Cowell, Daniel
AU  - Cowell D
AUID- ORCID: https://orcid.org/0000-0001-6061-3544
AD  - Psyomics Ltd, Cambridge, United Kingdom.
FAU - Bahn, Sabine
AU  - Bahn S
AUID- ORCID: https://orcid.org/0000-0003-4690-6302
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7445599
OTO - NOTNLM
OT  - bipolar disorder
OT  - early diagnosis
OT  - major depressive disorders
OT  - mood disorders
OT  - proteomics
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
CRDT- 2020/08/11 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
AID - v9i8e18453 [pii]
AID - 10.2196/18453 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 10;9(8):e18453. doi: 10.2196/18453.


PMID- 32773372
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Aug 10
TI  - Personal Health Information Inference Using Machine Learning on RNA Expression
      Data from Patients With Cancer: Algorithm Validation Study.
PG  - e18387
LID - 10.2196/18387 [doi]
AB  - BACKGROUND: As the need for sharing genomic data grows, privacy issues and
      concerns, such as the ethics surrounding data sharing and disclosure of personal 
      information, are raised. OBJECTIVE: The main purpose of this study was to verify 
      whether genomic data is sufficient to predict a patient's personal information.
      METHODS: RNA expression data and matched patient personal information were
      collected from 9538 patients in The Cancer Genome Atlas program. Five personal
      information variables (age, gender, race, cancer type, and cancer stage) were
      recorded for each patient. Four different machine learning algorithms (support
      vector machine, decision tree, random forest, and artificial neural network) were
      used to determine whether a patient's personal information could be accurately
      predicted from RNA expression data. Performance measurement of the prediction
      models was based on the accuracy and area under the receiver operating
      characteristic curve. We selected five cancer types (breast carcinoma, kidney
      renal clear cell carcinoma, head and neck squamous cell carcinoma, low-grade
      glioma, and lung adenocarcinoma) with large samples sizes to verify whether
      predictive accuracy would differ between them. We also validated the efficacy of 
      our four machine learning models in analyzing normal samples from 593 cancer
      patients. RESULTS: In most samples, personal information with high genetic
      relevance, such as gender and cancer type, could be predicted from RNA expression
      data alone. The prediction accuracies for gender and cancer type, which were the 
      best models, were 0.93-0.99 and 0.78-0.94, respectively. Other aspects of
      personal information, such as age, race, and cancer stage, were difficult to
      predict from RNA expression data, with accuracies ranging from 0.0026-0.29,
      0.76-0.96, and 0.45-0.79, respectively. Among the tested machine learning
      methods, the highest predictive accuracy was obtained using the support vector
      machine algorithm (mean accuracy 0.77), while the lowest accuracy was obtained
      using the random forest method (mean accuracy 0.65). Gender and race were
      predicted more accurately than other variables in the samples. On average, the
      accuracy of cancer stage prediction ranged between 0.71-0.67, while the age
      prediction accuracy ranged between 0.18-0.23 for the five cancer types.
      CONCLUSIONS: We attempted to predict patient information using RNA expression
      data. We found that some identifiers could be predicted, but most others could
      not. This study showed that personal information available from RNA expression
      data is limited and this information cannot be used to identify specific
      patients.
CI  - (c)Solbi Kweon, Jeong Hoon Lee, Younghee Lee, Yu Rang Park. Originally published 
      in the Journal of Medical Internet Research (http://www.jmir.org), 10.08.2020.
FAU - Kweon, Solbi
AU  - Kweon S
AUID- ORCID: 0000-0002-8021-9605
AD  - Department of Biomedical System Informatics, Yonsei University College of
      Medicine, Seoul, Republic of Korea.
AD  - Department of Medical Engineering, Asan Medical Institute of Convergence Science 
      and Technology, Asan Medical Center, University of Ulsan College of Medicine,
      Seoul, Republic of Korea.
FAU - Lee, Jeong Hoon
AU  - Lee JH
AUID- ORCID: 0000-0002-1789-8270
AD  - Department of Biomedical System Informatics, Yonsei University College of
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Younghee
AU  - Lee Y
AUID- ORCID: 0000-0002-6850-0082
AD  - Department of Biomedical Informatics, University of Utah School of Medicine, Salt
      Lake City, UT, United States.
FAU - Park, Yu Rang
AU  - Park YR
AUID- ORCID: 0000-0002-4210-2094
AD  - Department of Biomedical System Informatics, Yonsei University College of
      Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20200810
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - Child
MH  - Female
MH  - Health Records, Personal/*psychology
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - Machine Learning/*standards
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*epidemiology
MH  - Neural Networks, Computer
MH  - RNA/*metabolism
MH  - *Support Vector Machine
MH  - Young Adult
PMC - PMC7445622
OTO - NOTNLM
OT  - *RNA sequencing
OT  - *cancer
OT  - *machine learning
OT  - *personal information
OT  - *prediction
OT  - *privacy issue
EDAT- 2020/08/11 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - v22i8e18387 [pii]
AID - 10.2196/18387 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Aug 10;22(8):e18387. doi: 10.2196/18387.


PMID- 32773180
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1558-3481 (Electronic)
IS  - 0899-5885 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Sep
TI  - Moral Resilience for Critical Care Nurses.
PG  - 383-393
LID - S0899-5885(20)30041-1 [pii]
LID - 10.1016/j.cnc.2020.05.002 [doi]
AB  - Ethically challenging situations are an increasing phenomenon in the nurse's
      environment, and literature on the subject is growing. Morally challenging
      experiences common in the critical care environment include end-of-life
      situations, barriers to providing the best care possible, and lack of
      organizational resources. These experiences can lead to moral distress and
      subsequent negative impacts on the clinician. Emerging in the literature are
      strategies to address the impact of moral distress through the development of
      moral resilience. Moral resilience is gained through personal commitment and
      organizational support.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Stutzer, Karen
AU  - Stutzer K
AD  - Nursing, The College of Saint Elizabeth, Morristown, NJ, USA; Thomas Edison State
      University, Trenton, NJ, USA. Electronic address: kstrn1@gmail.com.
FAU - Rodriguez, Anna M
AU  - Rodriguez AM
AD  - Endoscopy, University of Utah Health, 50 N Medical Drive, Salt Lake City, 84132, 
      USA. Electronic address: https://twitter.com/theburnoutbook.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Care Nurs Clin North Am
JT  - Critical care nursing clinics of North America
JID - 8912620
MH  - *Critical Care
MH  - *Critical Care Nursing
MH  - Humans
MH  - *Morals
MH  - Organizational Case Studies
MH  - *Resilience, Psychological
MH  - Workplace/psychology
OTO - NOTNLM
OT  - Ethical work environment
OT  - Healthy work environment
OT  - Moral courage
OT  - Moral distress
OT  - Moral resilience
OT  - Nursing ethics
COIS- Disclosure The authors have nothing to disclose.
EDAT- 2020/08/11 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - S0899-5885(20)30041-1 [pii]
AID - 10.1016/j.cnc.2020.05.002 [doi]
PST - ppublish
SO  - Crit Care Nurs Clin North Am. 2020 Sep;32(3):383-393. doi:
      10.1016/j.cnc.2020.05.002.


PMID- 32773179
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210523
IS  - 1558-3481 (Electronic)
IS  - 0899-5885 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Sep
TI  - Replenish at Work: An Integrative Program to Decrease Stress and Promote a
      Culture of Wellness in the Intensive Care Unit.
PG  - 369-381
LID - S0899-5885(20)30040-X [pii]
LID - 10.1016/j.cnc.2020.05.001 [doi]
AB  - Intensive care unit (ICU) nurses report some of the highest levels of stress and 
      burnout because they are exposed to excessive workloads, end-of-life concerns,
      prolonged care, and ethical dilemmas. Supporting ICU staff through self-care and 
      mindfulness programs is successful in improving stress and burnout and in
      promoting resilience. Addressing barriers to engaging in self-care practices and 
      identifying unit-specific needs are important to consider when implementing
      wellness programs. Micro-restorative practices can alleviate immediate stress
      generated from patient care and provide a moment of peace in busy ICUs.
      Leadership and organizational support are vital in identifying the need for and
      promoting wellness programs.
CI  - Published by Elsevier Inc.
FAU - Alvarez, Catherine
AU  - Alvarez C
AD  - Yale New Haven Hospital, New Haven, CT, USA. Electronic address:
      catherine.alvarez@ynhh.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Care Nurs Clin North Am
JT  - Critical care nursing clinics of North America
JID - 8912620
EIN - Crit Care Nurs Clin North Am. 2021 Jun;33(2):ix. PMID: 34023089
MH  - Burnout, Professional/prevention & control
MH  - Critical Care
MH  - *Health Promotion
MH  - Humans
MH  - *Intensive Care Units
MH  - *Mindfulness
MH  - Nurses/*psychology
MH  - Program Development
MH  - Stress, Psychological/*prevention & control
OTO - NOTNLM
OT  - Burnout
OT  - Critical care
OT  - Mindfulness
OT  - Self-care
OT  - Wellness program
COIS- Disclosure The author has nothing to disclose.
EDAT- 2020/08/11 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - S0899-5885(20)30040-X [pii]
AID - 10.1016/j.cnc.2020.05.001 [doi]
PST - ppublish
SO  - Crit Care Nurs Clin North Am. 2020 Sep;32(3):369-381. doi:
      10.1016/j.cnc.2020.05.001.


PMID- 32773054
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1557-9859 (Electronic)
IS  - 0025-7125 (Linking)
VI  - 104
IP  - 5
DP  - 2020 Sep
TI  - Challenges Related to Safety and Independence.
PG  - 909-917
LID - S0025-7125(20)30058-4 [pii]
LID - 10.1016/j.mcna.2020.06.006 [doi]
AB  - Advancing age is associated with increasing risk of activities important for
      independence, such as driving and living alone. Cognitive impairment is more
      common with older age; financial resources and social support may dwindle. Risk, 
      cognitive impairment, and decisional capacity each change over time. Transparent 
      decision making and harm reduction help balance risk and safety. When a patient
      lacks decisional capacity, an option that considers the patient's preferences and
      shows respect for the person is favored. Vulnerable patients making choices that 
      are high risk, and patients for whom others are making such choices, may require 
      state intervention.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ward, Hannah
AU  - Ward H
AD  - Department of Internal Medicine, Johns Hopkins Bayview Medical Center, 4940
      Eastern Avenue, 3rd Floor, Baltimore, MD 21224, USA.
FAU - Finucane, Thomas E
AU  - Finucane TE
AD  - Harvard Medical School, Massachusetts General Hospital, 165 Cambridge Street.,
      Senior Health, 5th Floor, Boston, MA 02114, USA.
FAU - Schuchman, Mattan
AU  - Schuchman M
AD  - Division of Geriatric Medicine and Gerontology, Johns Hopkins University School
      of Medicine, Mason F. Lord Building - Suite 2200, 5200 Eastern Avenue, Baltimore,
      MD 21224, USA. Electronic address: mattan@jhmi.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200715
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
SB  - IM
MH  - Aged
MH  - *Automobile Driving/legislation & jurisprudence/psychology
MH  - *Cognitive Dysfunction/physiopathology/psychology
MH  - Executive Function
MH  - Humans
MH  - *Independent Living/ethics/psychology
MH  - Risk
MH  - *Safety
MH  - *Vulnerable Populations/legislation & jurisprudence/psychology
OTO - NOTNLM
OT  - Autonomy
OT  - Ethics
OT  - Geriatrics
OT  - Independence
OT  - Older adults
OT  - Risk
OT  - Safety
COIS- Disclosure The authors have nothing to disclose.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - S0025-7125(20)30058-4 [pii]
AID - 10.1016/j.mcna.2020.06.006 [doi]
PST - ppublish
SO  - Med Clin North Am. 2020 Sep;104(5):909-917. doi: 10.1016/j.mcna.2020.06.006. Epub
      2020 Jul 15.


PMID- 32773044
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20210903
IS  - 1557-9859 (Electronic)
IS  - 0025-7125 (Linking)
VI  - 104
IP  - 5
DP  - 2020 Sep
TI  - Identifying Goals of Care.
PG  - 767-775
LID - S0025-7125(20)30054-7 [pii]
LID - 10.1016/j.mcna.2020.06.002 [doi]
AB  - Goals of care conversations are important but complex for clinicians caring for
      older adults. Although clinicians tend to focus on specific medical
      interventions, these conversations are more successful if they begin with gaining
      a shared understanding of the medical conditions and possible outcomes, followed 
      by discussion of values and goals. Although training in the medical setting is
      incomplete, there are many published and online resources that can help
      clinicians gain these valuable skills.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Comer, Amber
AU  - Comer A
AD  - School of Health and Human Sciences, Indiana University, 1050 Wishard Boulevard, 
      RG 3034, Indianapolis, IN 46202, USA.
FAU - Fettig, Lyle
AU  - Fettig L
AD  - Division of General Medicine and Geriatrics, Palliative Care, Indiana University 
      School of Medicine, Eskenazi Health, 640 Eskenazi Avenue, Indianapolis, IN 46202,
      USA.
FAU - Torke, Alexia M
AU  - Torke AM
AD  - Division of General Medicine and Geriatrics, Indiana University School of
      Medicine, Indiana University Center for Aging Research, Regenstrief Institute,
      Incorporated, 1101 West 10th Street, Indianapolis, IN 46202, USA. Electronic
      address: atorke@iu.edu.
LA  - eng
GR  - K24 AG053794/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
SB  - IM
MH  - Aged
MH  - Clinical Competence
MH  - *Decision Making, Shared
MH  - Humans
MH  - *Palliative Care/ethics/methods/psychology
MH  - *Patient Care Planning/ethics/standards
MH  - Physician-Patient Relations
PMC - PMC7458156
MID - NIHMS1612031
OTO - NOTNLM
OT  - Ethics
OT  - Geriatrics
OT  - Goals of care
OT  - Palliative care
COIS- Disclosure Dr. Torke was supported by a Patient Midcareer Investigator Award in
      Patient Oriented Research (K24AG053794) from the National Institute on Aging.
EDAT- 2020/08/11 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - S0025-7125(20)30054-7 [pii]
AID - 10.1016/j.mcna.2020.06.002 [doi]
PST - ppublish
SO  - Med Clin North Am. 2020 Sep;104(5):767-775. doi: 10.1016/j.mcna.2020.06.002.


PMID- 32772429
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1432-2277 (Electronic)
IS  - 0934-0874 (Linking)
VI  - 33
IP  - 10
DP  - 2020 Oct
TI  - Kidney exchange strategies: new aspects and applications with a focus on deceased
      donor-initiated chains.
PG  - 1177-1184
LID - 10.1111/tri.13712 [doi]
AB  - Kidney paired donation (KPD) is a valuable way to overcome immunological
      incompatibility in the context of living donation, and several strategies have
      been implemented to boost its development. In this article, we reviewed the
      current state of the art in this field, with a particular focus on advanced KPD
      strategies, including the most recent idea of initiating living donor (LD)
      transplantation chains with a deceased donor (DD) kidney, first applied
      successfully in 2018. Since then, Italy has been running a national programme in 
      which a chain-initiating kidney is selected from a DD pool and allocated to a
      recipient with an incompatible LD, and the LD's kidney is transplanted into a
      patient on the waiting list (WL). At this stage, since the ethical and logistic
      issues have been managed appropriately, KPD starting with a DD has proved to be a
      feasible strategy. It enables transplants in recipients of incompatible pairs
      without the need for desensitizing and also benefits patients on the WL who are
      allocated chain-ending kidneys from LDs (prioritizing sensitized patients and
      those on the WL for longer).
CI  - (c) 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
FAU - Furian, Lucrezia
AU  - Furian L
AUID- ORCID: 0000-0002-2264-7986
AD  - Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and
      Gastroenterological Sciences, University of Padova, Padova, Italy.
FAU - Nicolo, Antonio
AU  - Nicolo A
AD  - Department of Economics and Management, University of Padova, Padova, Italy.
FAU - Di Bella, Caterina
AU  - Di Bella C
AD  - Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and
      Gastroenterological Sciences, University of Padova, Padova, Italy.
FAU - Cardillo, Massimo
AU  - Cardillo M
AD  - National Transplant Center, Rome, Italy.
FAU - Cozzi, Emanuele
AU  - Cozzi E
AD  - Transplant Immunology Unit, Department of Cardio-Thoracic, Vascular Sciences, and
      Public Health, University of Padova, Padova, Italy.
FAU - Rigotti, Paolo
AU  - Rigotti P
AD  - Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and
      Gastroenterological Sciences, University of Padova, Padova, Italy.
LA  - eng
GR  - by Progetti Strategici di Ateneo - bando 2011, University of Padova: "Kidney -
      Incorporating patients' preferences in kidney transplant decision protocols"
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200904
PL  - Switzerland
TA  - Transpl Int
JT  - Transplant international : official journal of the European Society for Organ
      Transplantation
JID - 8908516
SB  - IM
MH  - Humans
MH  - Italy
MH  - Kidney
MH  - *Kidney Transplantation
MH  - Living Donors
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *advanced kidney paired donation
OT  - *deceased donor-initiated domino chains
OT  - *domino-paired chains
OT  - *incompatible pairs
OT  - *living kidney donor
EDAT- 2020/08/11 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1111/tri.13712 [doi]
PST - ppublish
SO  - Transpl Int. 2020 Oct;33(10):1177-1184. doi: 10.1111/tri.13712. Epub 2020 Sep 4.


PMID- 32772171
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20201006
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 146
IP  - 11
DP  - 2020 Nov
TI  - Increased expression of IGF-1Ec with increasing colonic polyp dysplasia and
      colorectal cancer.
PG  - 2861-2870
LID - 10.1007/s00432-020-03345-0 [doi]
AB  - PURPOSE: IGF-1Ec is an isoform of Insulin-like growth factor 1 (IGF-1) and has
      recently been identified to be overexpressed in cancers including prostate and
      neuroendocrine tumours. The aim of this paper is to investigate the expression of
      IGF-1Ec in colorectal cancer and polyps compared to normal colon tissues and its 
      association with recurrent disease using semi-quantitative immunohistochemistry. 
      METHODS: Immunohistochemistry for IGF-1Ec expression was performed for colorectal
      cancer, colorectal polyps and normal colonic tissues. The quantification of
      IGF-1Ec expression was performed with the use of Image J software and the IHC
      profiler plugin. Following ethics approval from the National Research Ethics
      Service (Reference 11/LO/1521), clinical information including recurrent disease 
      on follow-up was collected for patients with colorectal cancer. RESULTS:
      Immunohistochemistry was performed in 16 patients with colorectal cancer and 11
      patients with colonic polyps and compared to normal colon tissues and prostate
      adenocarcinoma (positive control) tissues. Significantly increased expression of 
      IGF-1Ec was demonstrated in colorectal cancer (p < 0.001) and colorectal polyps
      (p < 0.05) compared to normal colonic tissues. Colonic adenomas with high-grade
      dysplasia had significantly higher expression of IGF-1Ec compared to low-grade
      dysplastic adenomas (p < 0.001). Colorectal cancers without lymph node metastases
      at the time of presentation had significantly higher IGF-1Ec expression compared 
      to lymph node-positive disease (p < 0.05). No correlation with recurrent disease 
      was identified with IGF-1Ec expression. CONCLUSION: IGF-1Ec is significantly
      overexpressed in colorectal cancer and polyps compared to normal colon tissues
      offering a potential target to improve colonoscopic identification of colorectal 
      polyps and cancer and intraoperative identification of colorectal tumours.
FAU - Alagaratnam, Swethan
AU  - Alagaratnam S
AUID- ORCID: http://orcid.org/0000-0002-4903-6886
AD  - Research Department of Surgical Biotechnology, Division of Surgery and
      Interventional Science, Royal Free Campus, UCL, London, UK.
      swethan@doctors.org.uk.
AD  - Higher Surgical Trainee, North East Thames Deanery, London, UK.
      swethan@doctors.org.uk.
FAU - Loizidou, Marilena
AU  - Loizidou M
AD  - Research Department of Surgical Biotechnology, Division of Surgery and
      Interventional Science, Royal Free Campus, UCL, London, UK.
FAU - Yang, Shi- Yu
AU  - Yang SY
AD  - Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology,
      London, UK.
FAU - Fuller, Barry
AU  - Fuller B
AD  - Research Department of Surgical Biotechnology, Division of Surgery and
      Interventional Science, Royal Free Campus, UCL, London, UK.
FAU - Ramesh, Bala
AU  - Ramesh B
AD  - Research Department of Surgical Biotechnology, Division of Surgery and
      Interventional Science, Royal Free Campus, UCL, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IGF1 protein, human)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Adenomatous Polyps/*diagnosis/metabolism/pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis
MH  - Colonic Polyps/*diagnosis/metabolism/pathology
MH  - Colorectal Neoplasms/*diagnosis/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Insulin-Like Growth Factor I/analysis/*metabolism
MH  - Male
OTO - NOTNLM
OT  - Colorectal cancer
OT  - IGF-1
OT  - IGF-1Ec
OT  - MGF
EDAT- 2020/08/11 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/06/28 00:00 [received]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1007/s00432-020-03345-0 [doi]
AID - 10.1007/s00432-020-03345-0 [pii]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2020 Nov;146(11):2861-2870. doi:
      10.1007/s00432-020-03345-0. Epub 2020 Aug 8.


PMID- 32772101
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 10
DP  - 2020 Oct 1
TI  - The ethics of embryo donation: what are the moral similarities and differences of
      surplus embryo donation and double gamete donation?
PG  - 2171-2178
LID - 10.1093/humrep/deaa166 [doi]
AB  - Over the years, the demand for ART with donated embryos has increased. Treatment 
      can be performed using donated 'surplus embryos' from IVF treatment or with
      embryos intentionally created through so-called 'double gamete donation'. Embryo 
      donation is particularly sensitive because treatment results in the absence of a 
      genetic link between the parent(s) and the child, creating complex family
      structures, including full genetic siblings living in another family in the case 
      of surplus embryo donation. In this paper, we explore the ethical acceptability
      of embryo donation in light of the similarities and differences between surplus
      embryo donation and double gamete donation. We will argue that no overriding
      objections to either form of embryo donation exist. First of all, ART with
      donated embryos respects patients' reproductive autonomy by allowing them to
      experience gestational parenthood. It also respects IVF patients' reproductive
      autonomy by providing an additional option to discarding or donating surplus
      embryos to research. Second, an extensive body of empirical research has shown
      that a genetic link between parent and child is not a condition for a loving
      caring relationship between parent(s) and child. Third, the low moral status of a
      pre-implantation embryo signifies no moral duty for clinics to first use
      available surplus embryos or to prevent the development of (more) surplus embryos
      through double gamete donation. Fourth, there is no reason to assume that
      knowledge of having (full or half) genetically related persons living elsewhere
      provides an unacceptable impact on the welfare of donor-conceived offspring,
      existing children of the donors, and their respective families. Thus, patients
      and clinicians should discuss which form of ART would be suitable in their
      specific situation. To guarantee ethically sound ART with donated embryos certain
      conditions have to be met. Counselling of IVF patients should involve a
      discussion on the destination of potential surplus embryos. When counselling
      donors and recipient(s) a discussion of the significance of early disclosure of
      the child's mode of conception, the implications of having children raised in
      families with whom they share no genetic ties, expectations around
      information-exchange and contact between donor and recipient families or
      genetically related siblings is warranted. Importantly, conclusions are mainly
      drawn from results of empirical studies on single gamete donation families. To
      evaluate the welfare of families created through surplus embryo donation or
      double gamete donation additional empirical research on these particular families
      is warranted.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Huele, E H
AU  - Huele EH
AD  - Department of Reproductive Medicine and Gynecology, University Medical Centre,
      3508 GA Utrecht, The Netherlands.
FAU - Kool, E M
AU  - Kool EM
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, 3508 GA Utrecht, The Netherlands.
FAU - Bos, A M E
AU  - Bos AME
AD  - Department of Reproductive Medicine and Gynecology, University Medical Centre,
      3508 GA Utrecht, The Netherlands.
FAU - Fauser, B C J M
AU  - Fauser BCJM
AD  - Department of Reproductive Medicine and Gynecology, University Medical Centre,
      3508 GA Utrecht, The Netherlands.
FAU - Bredenoord, A L
AU  - Bredenoord AL
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, 3508 GA Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Child
MH  - Disclosure
MH  - *Embryo Disposition
MH  - Germ Cells
MH  - Humans
MH  - Morals
MH  - Oocyte Donation
MH  - *Tissue Donors
OTO - NOTNLM
OT  - *double gamete donation
OT  - *ethics
OT  - *genetic link
OT  - *surplus embryo donation
OT  - *welfare of the child
EDAT- 2020/08/11 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/08/11 06:00
PHST- 2019/07/12 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 5890122 [pii]
AID - 10.1093/humrep/deaa166 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Oct 1;35(10):2171-2178. doi: 10.1093/humrep/deaa166.


PMID- 32772051
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210512
IS  - 1476-5543 (Electronic)
IS  - 0743-8346 (Linking)
VI  - 40
IP  - 10
DP  - 2020 Oct
TI  - Visitation restrictions: is it right and how do we support families in the NICU
      during COVID-19?
PG  - 1576-1581
LID - 10.1038/s41372-020-00781-1 [doi]
AB  - Although the COVID-19 pandemic has largely not clinically affected infants in
      neonatal intensive care units around the globe, it has affected how care is
      provided. Most hospitals, including their NICUs, have significantly reduced
      parental and family visitation privileges. From an ethical perspective, this
      restriction of parental visitation in settings where infectious risk is difficult
      to understand. No matter what the right thing to do is, NICUs are currently
      having to support families of their patients via different mechanisms. In this
      perspective, we discuss ways NICUs can support parents and families when they are
      home and when they are in the NICU as well as provide infants the support needed 
      when family members are not able to visit.
FAU - Murray, Peter D
AU  - Murray PD
AD  - Department of Pediatrics, Division of Neonatology, University of Virginia
      Children's Hospital, Charlottesville, VA, USA.
FAU - Swanson, Jonathan R
AU  - Swanson JR
AUID- ORCID: http://orcid.org/0000-0002-9446-9306
AD  - Department of Pediatrics, Division of Neonatology, University of Virginia
      Children's Hospital, Charlottesville, VA, USA. jswanson@virginia.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200808
PL  - United States
TA  - J Perinatol
JT  - Journal of perinatology : official journal of the California Perinatal
      Association
JID - 8501884
SB  - IM
CIN - J Perinatol. 2021 May;41(5):1187-1188. PMID: 33589731
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/prevention & control/transmission
MH  - Family/psychology
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Infection Control/*methods
MH  - Intensive Care Units, Neonatal/*organization & administration
MH  - *Intensive Care, Neonatal/organization & administration/psychology
MH  - Organizational Innovation
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control/transmission
MH  - *Psychosocial Support Systems
MH  - SARS-CoV-2
PMC - PMC7414900
EDAT- 2020/08/11 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/08/03 00:00 [accepted]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - 10.1038/s41372-020-00781-1 [doi]
AID - 10.1038/s41372-020-00781-1 [pii]
PST - ppublish
SO  - J Perinatol. 2020 Oct;40(10):1576-1581. doi: 10.1038/s41372-020-00781-1. Epub
      2020 Aug 8.


PMID- 32771989
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 7
TI  - Role of probiotics in patients with colorectal cancer: a systematic review
      protocol of randomised controlled trial studies.
PG  - e038128
LID - 10.1136/bmjopen-2020-038128 [doi]
AB  - INTRODUCTION: Colorectal cancer is one of the leading causes of cancer-related
      morbidity worldwide and it has been reported to be associated with poor lifestyle
      habits which include excess tobacco and alcohol intake as well as genetics and
      age factors. Probiotics such as the lactic acid bacteria and Bifidobacterium as
      well as probiotic containing foods (kombucha, kefir, miso etc) have received lots
      of attention as anticancer agents for prevention and treatment. The effects of
      the administration of probiotics to patients with colorectal cancer is the
      primary goal of this systematic review. The overall aim is to assess how the use 
      of probiotics in patients with colorectal cancer helps in the management of
      colorectal cancer and its effect on the diversity of gut microbiota. The final
      systematic review will provide a comprehensive evidence base for the use and
      efficacy of probiotics in patient with colorectal cancer care. METHODS AND
      ANALYSIS: The systematic review, will be conducted by extensively searching
      different databases such as PubMed, Web of Science, Scopus, Wiley and ProQuest to
      identify randomised controlled trials (with no time frame) which relate to the
      administration of probiotics to patients with colorectal cancer. The search
      strategy will include words like colorectal cancer, probiotics, Bifidobacterium, 
      clinical trials etc. A systematic search of databases was performed between 17
      and 20 January 2020. Two reviewers will independently review the studies and also
      search the reference lists of the eligible studies to obtain more references.
      Data will be extracted from the eligible studies using standardised data
      extraction form. After assessing the risk of bias, qualitative analysis will be
      used to synthesise the systematic review. ETHICS AND DISSEMINATION: This is a
      protocol for a systematic review; therefore, it doesn't require any ethics
      approval. We intend to disseminate the protocol in a peer reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dikeocha, Ifeoma Julieth
AU  - Dikeocha IJ
AUID- ORCID: 0000-0003-1700-828X
AD  - Faculty of Medicine, University of Cyberjaya, Persiaran Bestari, Cyberjaya,
      Selangor, Malaysia.
FAU - Al-Kabsi, Abdelkodose Mohammed
AU  - Al-Kabsi AM
AD  - Faculty of Medicine, University of Cyberjaya, Persiaran Bestari, Cyberjaya,
      Selangor, Malaysia.
FAU - Hussin, Salasawati
AU  - Hussin S
AD  - Faculty of Medicine, University of Cyberjaya, Persiaran Bestari, Cyberjaya,
      Selangor, Malaysia.
FAU - Alshawsh, Mohammed Abdullah
AU  - Alshawsh MA
AUID- ORCID: 0000-0001-8342-5183
AD  - Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala
      Lumpur, Malaysia alshaweshmam@um.edu.my.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200807
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Colonic Neoplasms
MH  - *Colorectal Neoplasms/drug therapy
MH  - Databases, Factual
MH  - Humans
MH  - Motivation
MH  - *Probiotics/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7418674
OTO - NOTNLM
OT  - *clinical trials
OT  - *gastrointestinal tumours
OT  - *microbiology
COIS- Competing interests: None declared.
EDAT- 2020/08/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038128 [pii]
AID - 10.1136/bmjopen-2020-038128 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 7;10(8):e038128. doi: 10.1136/bmjopen-2020-038128.


PMID- 32771485
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20210110
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 510
DP  - 2020 Nov
TI  - Ethical and organizational considerations for mandatory COVID-19 vaccination of
      health care workers: A clinical laboratorian's perspective.
PG  - 421-422
LID - S0009-8981(20)30385-5 [pii]
LID - 10.1016/j.cca.2020.08.003 [doi]
FAU - Bowen, Raffick A R
AU  - Bowen RAR
AD  - Department of Pathology, Stanford Health Care, Rm. H1507B, 300 Pasteur Drive,
      Stanford, CA 94305-5627, United States. Electronic address:
      Rbowen@stanfordmed.org.
LA  - eng
PT  - Letter
DEP - 20200807
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/prevention & control/psychology
MH  - Health Personnel/*ethics/organization & administration/psychology
MH  - Humans
MH  - Mandatory Programs/*ethics/organization & administration
MH  - Medical Laboratory Personnel/*ethics/organization & administration/psychology
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/prevention & control/psychology
MH  - SARS-CoV-2
MH  - Vaccination/*ethics/psychology
PMC - PMC7410812
EDAT- 2020/08/11 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/08/11 06:00
PHST- 2020/07/14 00:00 [received]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/08/11 06:00 [entrez]
AID - S0009-8981(20)30385-5 [pii]
AID - 10.1016/j.cca.2020.08.003 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2020 Nov;510:421-422. doi: 10.1016/j.cca.2020.08.003. Epub 2020
      Aug 7.


PMID- 32770839
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 5
DP  - 2020 Sep
TI  - Sexual relationships between health practitioners and former patients: when is it
      misconduct?
PG  - 212-215.e1
LID - 10.5694/mja2.50717 [doi]
FAU - Millbank, Jenni
AU  - Millbank J
AUID- ORCID: 0000-0002-8934-7945
AD  - University of Technology Sydney, Sydney, NSW.
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Australia
MH  - Humans
MH  - Physician-Patient Relations/*ethics
MH  - *Professional Misconduct
MH  - Sexual Behavior/*ethics
MH  - Time Factors
OTO - NOTNLM
OT  - *Ethics, professional
OT  - *Legislation, medical
OT  - *Medical misconduct
EDAT- 2020/08/10 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 10.5694/mja2.50717 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Sep;213(5):212-215.e1. doi: 10.5694/mja2.50717. Epub 2020 Aug 8.


PMID- 32770449
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2110-5820 (Print)
IS  - 2110-5820 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Aug 8
TI  - Symptoms of burnout in intensive care unit specialists facing the COVID-19
      outbreak.
PG  - 110
LID - 10.1186/s13613-020-00722-3 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has resulted in an unprecedented healthcare
      crisis with a high prevalence of psychological distress in healthcare providers. 
      We sought to document the prevalence of burnout syndrome amongst intensivists
      facing the COVID-19 outbreak. METHODS: Cross-sectional survey among intensivists 
      part of the European Society of Intensive Care Medicine. Symptoms of severe
      burnout, anxiety and depression were collected. Factors independently associated 
      with severe burnout were assessed using Cox model. RESULTS: Response rate was 20%
      (1001 completed questionnaires were returned, 45 years [39-53], 34% women, from
      85 countries, 12 regions, 50% university-affiliated hospitals). The prevalence of
      symptoms of anxiety and depression or severe burnout was 46.5%, 30.2%, and 51%,
      respectively, and varied significantly across regions. Rating of the relationship
      between intensivists and other ICU stakeholders differed significantly according 
      to the presence of anxiety, depression, or burnout. Similar figures were reported
      for their rating of the ethical climate or the quality of the decision-making.
      Factors independently associated with anxiety were female gender (HR 1.85
      [1.33-2.55]), working in a university-affiliated hospital (HR 0.58 [0.42-0.80]), 
      living in a city of > 1 million inhabitants (HR 1.40 [1.01-1.94]), and
      clinician's rating of the ethical climate (HR 0.83 [0.77-0.90]). Independent
      determinants of depression included female gender (HR 1.63 [1.15-2.31]) and
      clinician's rating of the ethical climate (HR 0.84 [0.78-0.92]). Factors
      independently associated with symptoms of severe burnout included age (HR
      0.98/year [0.97-0.99]) and clinician's rating of the ethical climate (HR 0.76
      [0.69-0.82]). CONCLUSIONS: The COVID-19 pandemic has had an overwhelming
      psychological impact on intensivists. Follow-up, and management are warranted to 
      assess long-term psychological outcomes and alleviate the psychological burden of
      the pandemic on frontline personnel.
FAU - Azoulay, Elie
AU  - Azoulay E
AUID- ORCID: http://orcid.org/0000-0002-8162-1508
AD  - Medecine Intensive et Reanimation, PHP, Hopital Saint-Louis, Paris University,
      Paris, France. elie.azoulay@aphp.fr.
FAU - De Waele, Jan
AU  - De Waele J
AD  - Department of Critical Care Medicine, Ghent University Hospital, 9000, Gent, The 
      Netherlands.
FAU - Ferrer, Ricard
AU  - Ferrer R
AD  - Shock, Organ Dysfunction, and Resuscitation Research Group (SODIR), Instituto de 
      Investigacion de Vall d'Hebron, Barcelona, Spain.
AD  - Departmento de Medicina Intensiva, Hospital Universitario de Vall dHebron, Centro
      de Investigacion Biomedica en Red (CIBER) de Enfermedades Respiratorias,
      Barcelona, Spain.
FAU - Staudinger, Thomas
AU  - Staudinger T
AD  - Department of Medicine I, Intensive Care Unit, Medical University of Vienna,
      Vienna General Hospital, Vienna, Austria.
FAU - Borkowska, Marta
AU  - Borkowska M
AD  - Department of Critical Care Medicine, Ghent University Hospital, 9000, Gent, The 
      Netherlands.
FAU - Povoa, Pedro
AU  - Povoa P
AD  - NOVA Medical School, CHRC, New University of Lisbon, Lisbon, Portugal.
AD  - Unidade de Cuidados Intensivos Polivalente, Hospital de Sao Francisco Xavier,
      CHLO, Estrada Do Forte Do Alto Do Duque, 1449-005, Lisbon, Portugal.
FAU - Iliopoulou, Katerina
AU  - Iliopoulou K
AD  - Hellenic Army, ICU Nurse Manager General Military Hospital, Athens, Greece.
FAU - Artigas, Antonio
AU  - Artigas A
AD  - Critical Care Center, Sabadell Hospital, University Institute Parc Tauli,
      Autonomous University of Barcelona, Ciberes, Barcelona, Spain.
FAU - Schaller, Stefan J
AU  - Schaller SJ
AD  - Department of Anesthesiology and Intensive Care, School of Medicine, Klinikum
      rechts der Isar, Technical University of Munich, Munich, Germany.
FAU - Hari, Manu Shankar
AU  - Hari MS
AD  - School of Immunology and Microbial Science, Kings College London, London, UK.
AD  - Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, St Thomas'
      Hospital, London, UK.
FAU - Pellegrini, Mariangela
AU  - Pellegrini M
AD  - Department of Surgical Sciences and Central Intensive Care Unit, Department of
      Anesthesia, Operation, and Intensive Care and Department of Anesthesiology and
      Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy,
      University of Gothenburg, Gothenburg, Sweden.
FAU - Darmon, Michael
AU  - Darmon M
AD  - Medecine Intensive et Reanimation, PHP, Hopital Saint-Louis, Paris University,
      Paris, France.
FAU - Kesecioglu, Jozef
AU  - Kesecioglu J
AD  - Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care
      and Emergency Medicine, University Medical Center Utrecht, Utrecht University,
      Utrecht, The Netherlands.
FAU - Cecconi, Maurizio
AU  - Cecconi M
AD  - Humanitas Clinical and Research Center, Humanitas University, Milan, Italy.
CN  - ESICM
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - Germany
TA  - Ann Intensive Care
JT  - Annals of intensive care
JID - 101562873
PMC - PMC7414284
OTO - NOTNLM
OT  - Acute respiratory distress syndrome
OT  - Coronavirus
OT  - Depersonalization
OT  - Exhaustion
OT  - Pneumonia
OT  - Well-being
EDAT- 2020/08/10 06:00
MHDA- 2020/08/10 06:01
CRDT- 2020/08/10 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/25 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/10 06:01 [medline]
AID - 10.1186/s13613-020-00722-3 [doi]
AID - 10.1186/s13613-020-00722-3 [pii]
PST - epublish
SO  - Ann Intensive Care. 2020 Aug 8;10(1):110. doi: 10.1186/s13613-020-00722-3.


PMID- 32770309
OWN - NLM
STAT- MEDLINE
DCOM- 20211008
LR  - 20211204
IS  - 2196-8837 (Electronic)
IS  - 2196-8837 (Linking)
VI  - 7
IP  - 6
DP  - 2020 Dec
TI  - The Face of Medicine Is Not My Face...But, It Should Be.
PG  - 1035-1038
LID - 10.1007/s40615-020-00834-3 [doi]
AB  - The "face of medicine" is a term commonly used to describe the leaders and
      decision-makers of medicine. Medical ethics often discuss past historical
      atrocities committed by the "face of medicine," such as the American eugenics
      movement and medical experimentation. However, a great irony persists: the "faces
      of medicine" do not resemble the faces of the oppressed populations.
      Nevertheless, the discussion of white supremacy and systemic racism, structures
      which fueled historical medical atrocities, is often omitted. This reflection
      discusses the need for education, conversation, and action surrounding these
      topics to adequately combat racial and ethnic health disparities. We also argue
      that the decision-makers of medicine should be a diverse group of stakeholders,
      thereby representative of and personally invested in a diverse group of
      populations.
FAU - Calhoun, Amanda
AU  - Calhoun A
AD  - Yale Child Study Center/Yale University School of Medicine, 230 S Frontage Rd,
      New Haven, CT, 06519, USA. amanda.calhoun@yale.edu.
FAU - Parker, Carmen Black
AU  - Parker CB
AD  - Yale University School of Medicine, Connecticut Mental Health Center, 34 Park St,
      New Haven, CT, 06519, USA.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - Switzerland
TA  - J Racial Ethn Health Disparities
JT  - Journal of racial and ethnic health disparities
JID - 101628476
SB  - IM
MH  - *Cultural Diversity
MH  - Ethnicity
MH  - Humans
MH  - *Leadership
MH  - *Medicine
MH  - United States
OTO - NOTNLM
OT  - *Diversity
OT  - *Ethics
OT  - *Exploitation
OT  - *Leadership
OT  - *Psychiatry
OT  - *Racism
EDAT- 2020/08/10 06:00
MHDA- 2021/10/09 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/10/09 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 10.1007/s40615-020-00834-3 [doi]
AID - 10.1007/s40615-020-00834-3 [pii]
PST - ppublish
SO  - J Racial Ethn Health Disparities. 2020 Dec;7(6):1035-1038. doi:
      10.1007/s40615-020-00834-3. Epub 2020 Aug 7.


PMID- 32770180
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20210910
IS  - 1465-735X (Electronic)
IS  - 0146-8693 (Linking)
VI  - 45
IP  - 8
DP  - 2020 Sep 1
TI  - Commentary: Reflections on the COVID-19 Pandemic and Health Disparities in
      Pediatric Psychology.
PG  - 839-841
LID - 10.1093/jpepsy/jsaa063 [doi]
AB  - The COVID-19 (2019 novel coronavirus) pandemic has had a significant economic,
      social, emotional, and public health impact in the United States. A disturbing
      trend is that Black, Indigenous, and/or People of Color (BIPOC) are
      disproportionately contracting coronavirus, as well as dying from COVID-19.
      Objective/Methods The pandemic has the potential to entrench and magnify existing
      health disparities and families marginalized across multiple demographic
      intersections such as race/ethnicity, class, immigration status, are especially
      vulnerable. These inequities have been further underscored by the recent murders 
      of Black Americans by police and a resulting spotlight on racial injustice in the
      United States. Results Efforts to lessen the spread of the virus, have resulted
      in changes in pediatric primary and subspecialty service delivery which may
      affect access for BIPOC communities. BIPOC trainees including those with debt or 
      caregiving responsibilities may be faced with new barriers resulting in delays in
      completion of their training. Further, clinical, community-based, and
      translational research has been disrupted by heightened safety precautions and
      social distancing which may affect BIPOC representation in research downstream.
      Conclusion In our roles as clinicians, supervisors, trainees, and researchers in 
      primary and subspecialty care as well as in academia, pediatric psychologists
      have an ethical responsibility to address the disproportionate burden of this
      pandemic on vulnerable communities and to allocate our time and resources to
      ensuring health equity now and in the aftermath of COVID-19.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society of Pediatric Psychology. All rights reserved. For permissions, please
      e-mail: journals.permissions@oup.com.
FAU - Valenzuela, Jessica
AU  - Valenzuela J
AD  - College of Psychology, Nova Southeastern University.
FAU - Crosby, Lori E
AU  - Crosby LE
AD  - Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's
      Hospital Medical Center.
AD  - College of Medicine, University of Cincinnati.
FAU - Harrison, Roger R
AU  - Harrison RR
AD  - Nemours/Alfred I. duPont Hospital for Children.
AD  - Sydney Kimmel Medical College at Thomas Jefferson University.
LA  - eng
GR  - UL1 TR001425/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Pediatr Psychol
JT  - Journal of pediatric psychology
JID - 7801773
SB  - IM
MH  - COVID-19
MH  - Child
MH  - *Coronavirus Infections
MH  - *Health Status Disparities
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Psychology, Child
MH  - *Racism
MH  - United States
PMC - PMC7438958
OTO - NOTNLM
OT  - *clinical
OT  - *economic disadvantage
OT  - *race/ethnicity
OT  - *research
OT  - *training
EDAT- 2020/08/10 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 5885276 [pii]
AID - 10.1093/jpepsy/jsaa063 [doi]
PST - ppublish
SO  - J Pediatr Psychol. 2020 Sep 1;45(8):839-841. doi: 10.1093/jpepsy/jsaa063.


PMID- 32770165
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210130
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 26
IP  - 8
DP  - 2020 Aug
TI  - Digital technologies in the public-health response to COVID-19.
PG  - 1183-1192
LID - 10.1038/s41591-020-1011-4 [doi]
AB  - Digital technologies are being harnessed to support the public-health response to
      COVID-19 worldwide, including population surveillance, case identification,
      contact tracing and evaluation of interventions on the basis of mobility data and
      communication with the public. These rapid responses leverage billions of mobile 
      phones, large online datasets, connected devices, relatively low-cost computing
      resources and advances in machine learning and natural language processing. This 
      Review aims to capture the breadth of digital innovations for the public-health
      response to COVID-19 worldwide and their limitations, and barriers to their
      implementation, including legal, ethical and privacy barriers, as well as
      organizational and workforce barriers. The future of public health is likely to
      become increasingly digital, and we review the need for the alignment of
      international strategies for the regulation, evaluation and use of digital
      technologies to strengthen pandemic management, and future preparedness for
      COVID-19 and other infectious diseases.
FAU - Budd, Jobie
AU  - Budd J
AUID- ORCID: http://orcid.org/0000-0003-3337-6859
AD  - London Centre for Nanotechnology, University College London, London, UK.
AD  - Division of Medicine, University College London, London, UK.
FAU - Miller, Benjamin S
AU  - Miller BS
AUID- ORCID: http://orcid.org/0000-0003-3032-018X
AD  - London Centre for Nanotechnology, University College London, London, UK.
FAU - Manning, Erin M
AU  - Manning EM
AD  - London Centre for Nanotechnology, University College London, London, UK.
FAU - Lampos, Vasileios
AU  - Lampos V
AUID- ORCID: http://orcid.org/0000-0001-8555-2063
AD  - Department of Computer Science, University College London, London, UK.
FAU - Zhuang, Mengdie
AU  - Zhuang M
AD  - The Centre for Advanced Spatial Analysis, University College London, London, UK.
FAU - Edelstein, Michael
AU  - Edelstein M
AD  - Centre on Global Security, Chatham House, London, UK.
FAU - Rees, Geraint
AU  - Rees G
AUID- ORCID: http://orcid.org/0000-0002-9623-7007
AD  - Faculty of Life Sciences, University College London, London, UK.
FAU - Emery, Vincent C
AU  - Emery VC
AUID- ORCID: http://orcid.org/0000-0001-5893-9756
AD  - Department of Microbial Sciences, University of Surrey, Guildford, UK.
FAU - Stevens, Molly M
AU  - Stevens MM
AUID- ORCID: http://orcid.org/0000-0002-7335-266X
AD  - Department of Materials and Department of Bioengineering, Imperial College
      London, London, UK.
FAU - Keegan, Neil
AU  - Keegan N
AD  - Translational and Clinical Research Institute, Newcastle University, Newcastle,
      UK.
FAU - Short, Michael J
AU  - Short MJ
AD  - Department for International Trade, University College London, London, UK.
FAU - Pillay, Deenan
AU  - Pillay D
AD  - Division of Infection and Immunity, University College London, London, UK.
FAU - Manley, Ed
AU  - Manley E
AD  - School of Geography, University of Leeds, Leeds, UK.
FAU - Cox, Ingemar J
AU  - Cox IJ
AD  - Department of Computer Science, University College London, London, UK.
AD  - Department of Computer Science, University of Copenhagen, Copenhagen, Denmark.
FAU - Heymann, David
AU  - Heymann D
AD  - London School of Hygiene and Tropical Medicine, London, UK.
FAU - Johnson, Anne M
AU  - Johnson AM
AD  - Institute of Global Health, University College London, London, UK.
FAU - McKendry, Rachel A
AU  - McKendry RA
AD  - London Centre for Nanotechnology, University College London, London, UK.
      r.a.mckendry@ucl.ac.uk.
AD  - Division of Medicine, University College London, London, UK.
      r.a.mckendry@ucl.ac.uk.
LA  - eng
GR  - EP/R00529X/1/RCUK | Engineering and Physical Sciences Research Council
      (EPSRC)/International
GR  - EP/R018391/1/RCUK | Engineering and Physical Sciences Research Council
      (EPSRC)/International
GR  - MC_PC_19070/RCUK | MRC | Medical Research Foundation/International
GR  - MC_PC_19070/RCUK | Medical Research Council (MRC)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200807
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
MH  - Betacoronavirus/pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control/virology
MH  - Humans
MH  - Machine Learning
MH  - Natural Language Processing
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Pneumonia, Viral/epidemiology/*prevention & control/virology
MH  - *Population Surveillance
MH  - Privacy
MH  - Public Health/*statistics & numerical data
MH  - SARS-CoV-2
EDAT- 2020/08/10 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 10.1038/s41591-020-1011-4 [doi]
AID - 10.1038/s41591-020-1011-4 [pii]
PST - ppublish
SO  - Nat Med. 2020 Aug;26(8):1183-1192. doi: 10.1038/s41591-020-1011-4. Epub 2020 Aug 
      7.


PMID- 32769932
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - The efficacy and safety of Chinese herbal compound in pediatric patients with
      allergic rhinitis: A protocol for systematic review and meta-analysis.
PG  - e21643
LID - 10.1097/MD.0000000000021643 [doi]
AB  - BACKGROUND: We design this study to assess the efficacy and safety of Chinese
      herbal compound for allergic rhinitis in children. METHODS: PubMed, EMbase,
      Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI),
      WanFang, the Chongqing VIP Chinese Science and Technology Periodical Database,
      and China biomedical literature database (CBM) will be searched from the
      establishment of each database to July 2020. Randomized controlled trials of
      Chinese herbal compound for the treatment of allergic rhinitis in children will
      be included. Two researchers will screen the literature, extract data, and assess
      the risk of bias independently. Statistical analysis will be performed in RevMan 
      5.3. RESULTS: This study will summarize high quality evidence of randomized
      controlled trials on exploring the efficacy and safety of Chinese herbal compound
      for allergic rhinitis in children. CONCLUSIONS: The findings of study will
      provide scientific evidence of the efficacy and safety of Chinese herbal compound
      for allergic rhinitis in children for clinician and further studies. ETHICS AND
      DISSEMINATION: The private information from individuals will not be published.
      This systematic review also will not involve endangering participant rights.
      Ethical approval is not required. The results may be published in a peer-reviewed
      journal or disseminated in relevant conferences. OSF REGISTRATION NUMBER: DOI
      10.17605/OSF.IO/Q5TRZ.
FAU - Zhang, Mengni
AU  - Zhang M
AUID- ORCID: 0000-0001-7437-5209
AD  - Chengdu University of Traditional Chinese Medicine.
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Tian, Chunying
AU  - Tian C
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Xie, Yue
AU  - Xie Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Huang, Yao
AU  - Huang Y
AD  - Chengdu University of Traditional Chinese Medicine.
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      province.
FAU - Yang, Shasha
AU  - Yang S
AD  - First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou province.
FAU - Zhang, Qinxiu
AU  - Zhang Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      province.
AD  - School of Medical and Life Sciences/Reproductive & Women-Children Hospital,
      Chengdu University of Traditional Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - *Clinical Protocols
MH  - Drugs, Chinese Herbal/*standards/therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pediatrics/instrumentation/methods/standards
MH  - Rhinitis, Allergic/*drug therapy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7592995
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021643 [doi]
AID - 00005792-202008070-00073 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21643. doi: 10.1097/MD.0000000000021643.


PMID- 32769925
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - The efficacy and safety of acupoint application combined with western medicine
      for allergic rhinitis: A protocol for systematic review and meta-analysis.
PG  - e21627
LID - 10.1097/MD.0000000000021627 [doi]
AB  - BACKGROUND: Acupoint application combined with western medicine has been used for
      treating allergic rhinitis widely. However, the efficacy and safety of acupoint
      application combined with western medicine for allergic rhinitis are unclear.
      This study aims to evaluate the efficacy and safety of acupoint application
      combined with western medicine for allergic rhinitis. METHODS: Randomized
      controlled trials of acupoint application combined with western medicine for
      allergic rhinitis will be searched in PubMed, EMbase, Cochrane Library, Web of
      Science, China National Knowledge Infrastructure, WanFang, the Chongqing VIP
      Chinese Science and Technology Periodical Database, and China biomedical
      literature database from inception to July, 2020. And Baidu Scholar, Google
      Scholar, International Clinical Trials Registry Platform, and Chinese Clinical
      Trials Registry will be searched to obtain more relevant studies comprehensively.
      Two researchers will perform data extraction and risk of bias assessment
      independently. Statistical analysis will be conducted in RevMan 5.3. RESULTS:
      This study will summarize the present evidence by exploring the efficacy and
      safety of acupoint application combined with western medicine for the treatment
      of allergic rhinitis. CONCLUSIONS: The findings of the study will provide helpful
      evidence for the efficacy and safety of acupoint application combined with
      western medicine in the treatment of allergic rhinitis, facilitating clinical
      practice and further scientific studies. ETHICS AND DISSEMINATION: The private
      information from individuals will not publish. This systematic review also will
      not involve endangering participant rights. Ethical approval is not required. The
      results may be published in a peer-reviewed journal or disseminated in relevant
      conferences. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/NSGJH.
FAU - Huang, Yao
AU  - Huang Y
AUID- ORCID: 0000-0002-7754-9902
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province.
FAU - Fan, Yihua
AU  - Fan Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Tian, Chunying
AU  - Tian C
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Zhang, Mengni
AU  - Zhang M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province.
FAU - Yang, Shasha
AU  - Yang S
AD  - First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou province.
FAU - Ji, Yue
AU  - Ji Y
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin.
FAU - Zhang, Qinxiu
AU  - Zhang Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - School of Medical and Life Sciences/Reproductive & Women-Children Hospital,
      Chengdu University of Traditional Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Points
MH  - Acupuncture Therapy/methods
MH  - *Clinical Protocols
MH  - Drug Therapy, Combination/adverse effects/*standards
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Patient Safety/*standards
MH  - Rhinitis, Allergic/*therapy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7593031
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021627 [doi]
AID - 00005792-202008070-00066 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21627. doi: 10.1097/MD.0000000000021627.


PMID- 32769920
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Adverse cardiac events in the treatment of non-small cell lung cancer with
      programmed death-1and programmed death-ligand 1 inhibitors: A protocol for
      systematic review and meta-analysis.
PG  - e21613
LID - 10.1097/MD.0000000000021613 [doi]
AB  - BACKGROUND: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1)
      inhibitors are immune therapies that have shown great promise in the treatment of
      multiple cancers. However, immune-related adverse events of PD-1 and PD-L1
      inhibitors may limit their use in non-small cell lung cancer (NSCLC). Given the
      rising number of clinical trials in recent years, it is essential to perform a
      meta-analysis to provide assess the cardiotoxicity of PD-1/ PD-L1 inhibitors in
      NSCLC therapy. METHOD AND ANALYSIS: The ClinicalTrials.gov, Embase, PubMed, and
      Cochrane Central Register of Controlled Trials repositories will be searched from
      their inception to December 2019. The bibliography of the searching process will 
      be imported into Endnote X9 software. Two reviewers independently will screen the
      literature, extract data, and conduct the risk of bias for every added study. The
      data analysis will be analyzed using Stata15.0 software. Specific adverse cardiac
      events will be identified, with particular attention on atrial fibrillation,
      cardiac arrest, cardiac failure, and pericarditis. This review will be performed 
      as per the Preferred Reporting Item for Systematic Review and meta-analysis
      statement recommendations. ETHICS AND DISSEMINATION: This study will provide
      support for the cardiotoxicity linked to the treatment of NSCLC using PD-1/PD-L1 
      inhibitors. The data in the meta-analysis will be retrieved from completed and
      published clinical trials; therefore, ethical review and patient informed consent
      will not be required. PROSPERO NUMBER: CRD42020156397.
FAU - Li, Honglin
AU  - Li H
AD  - First Clinical College.
FAU - Han, Deting
AU  - Han D
AD  - First Clinical College.
FAU - Feng, Xiaoteng
AU  - Feng X
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Yu, Wenjun
AU  - Yu W
AD  - First Clinical College.
FAU - Xu, Tongtong
AU  - Xu T
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Ma, Tao
AU  - Ma T
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine.
FAU - Song, Lucheng
AU  - Song L
AD  - The First Affiliated Hospital of Shandong First Medicial University (Shandong
      Provincial Qianfoshan Hosipital, Shandong University), Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antineoplastic Agents, Immunological/adverse effects/therapeutic use
MH  - Apoptosis/drug effects
MH  - Carcinoma, Non-Small-Cell Lung/complications/*drug therapy
MH  - Cardiotoxicity/*etiology/physiopathology
MH  - *Clinical Protocols
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors/*therapeutic use
MH  - Systematic Reviews as Topic
PMC - PMC7593004
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021613 [doi]
AID - 00005792-202008070-00061 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21613. doi: 10.1097/MD.0000000000021613.


PMID- 32769911
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - The effect of nebivolol on erectile function in the cases with coronary artery
      bypass surgery: A protocol for a systematic review and meta-analysis of
      randomized controlled trials.
PG  - e21588
LID - 10.1097/MD.0000000000021588 [doi]
AB  - BACKGROUND: Erectile dysfunction is a common disease. It affects the quality of
      life of both husband and wife and its prevalence is higher in patients with overt
      cardiovascular disease or cardiovascular risk factors. In recent years, multiple 
      studies confirm that nebivolol exerts protective effects on erectile function
      against the disruptive effects of cardiopulmonary bypass in patients undergoing
      coronary artery bypass grafting, but its quality and efficacy have not been
      systematically evaluated. Therefore, it is necessary to carry out a systematic
      review and meta-analysis to fully evaluate the efficacy and safety of nebivolol
      on erectile function in the cases with coronary artery bypass grafting. METHODS
      AND ANALYSIS: Chinese and English literature of nebivolol on erectile function in
      the cases with coronary artery bypass surgery published before August 31, 2020
      will be comprehensive searched in PubMed, Cochrane Library, EMBASE, WANFANG,
      China National Knowledge Infrastructure, VIP Chinese Science and Technology
      Journal Database, Chinese biomedical document service system, and
      Clinicaltrials.gov. Only randomized controlled trials that meet the eligibility
      criteria will be included. Two researchers will independently complete literature
      screening, data extraction and assess the risk of bias, and the third
      investigator will handle disagreements. Our main evaluation includes 2 outcome
      indicators including the international index of erectile function 5 score and
      adverse events. RevMan 5.3 and Stata 14.0 will be used to conduct this systematic
      review. The preferred reporting items for systematic reviews and meta-analysis
      protocols (PRISMA-P) statement is followed in this protocol and the PRISMA
      statement will be followed in the completed systematic review. CONCLUSION AND
      DISSEMINATION: The efficacy and safety of nebivolol on erectile function in the
      cases with coronary artery bypass grafting will be evaluated. We will publish the
      results of this systematic review in peer-reviewed journals to provide new
      evidence to clinicians. ETHICS AND DISSEMINATION: Ethical approval is not
      required as the review is a secondary study based on published literature. The
      results will be published in a public issue journal to provide evidence-based
      medical evidence for urologists and andrologists to make better clinical
      decisions. REGISTRATION INFORMATION: INPLASY202060110.
FAU - Yang, Yali
AU  - Yang Y
AUID- ORCID: 0000-0002-6304-4313
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Yong, Shanshan
AU  - Yong S
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Li, Fuhao
AU  - Li F
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Dong, Liang
AU  - Dong L
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
FAU - Chang, Degui
AU  - Chang D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 030Y90569U (Nebivolol)
SB  - IM
MH  - *Clinical Protocols
MH  - Coronary Artery Bypass/*adverse effects/methods
MH  - Erectile Dysfunction/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Nebivolol/standards/*therapeutic use
MH  - Systematic Reviews as Topic
PMC - PMC7593072
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021588 [doi]
AID - 00005792-202008070-00052 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21588. doi: 10.1097/MD.0000000000021588.


PMID- 32769910
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Acupotomy combined with massage for cervical spondylotic radiculopathy: A
      protocol for systematic review and meta-analysis.
PG  - e21587
LID - 10.1097/MD.0000000000021587 [doi]
AB  - BACKGROUND: Cervical spondylotic radiculopathy (CSR) is a clinical syndrome of
      radial neck and shoulder pain. Both Massage and Acupotomy have been widely used
      in the treatment of CSR, in China and achieved satisfied efficacy. Therefore, the
      aim of this study is to systematically evaluate the clinical efficacy of
      acupotomy combined with massage in the treatment of CSR. METHODS: The following
      electronic databases will be searched: PubMed, Web of Science, the Cochrane
      Central Register of Controlled Trials (CENTRAL), the Cochrane Library, Embase,
      SinoMed, Clinical Trials. gov, the China National Knowledge Infrastructure
      (CNKI), Wanfang database, and VIP database. Two review authors independently
      search databases from their respective inception dates to September 2019 to
      identify potentially eligible studies. Cochrane Handbook 5.1 risk of bias
      assessment tool will be used to evaluate the methodological quality of the
      included studies. The Review Manager 5.3 will be used for all statistical
      analysis of the final included study. RESULTS: The results of this systematic
      review and meta-analysis will provide a synthesis of existing evidences for the
      treatment of acupotomy combined with massage on CSR, especially in improving
      visual analog scale and symptom score. CONCLUSION: This study will summarize the 
      current evidence of acupotomy combined with massage for the treatment of CSR.
      This study can further guide the promotion and clinical decisions. ETHICS AND
      DISSEMINATION: Ethical approval and patient consent are not required because this
      study is a literature-based study. This systematic review and meta-analysis will 
      be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020171825.
FAU - Dai, Wenkang
AU  - Dai W
AUID- ORCID: 0000-0001-9787-4414
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Wang, Xiongwei
AU  - Wang X
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
AD  - Beijing University of Chinese Medicine, Chaoyang District, Beijing, China.
FAU - Xie, Rui
AU  - Xie R
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Zhuang, Minghui
AU  - Zhuang M
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Chang, Xiaojuan
AU  - Chang X
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Jin, Zhefeng
AU  - Jin Z
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Yin, He
AU  - Yin H
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Feng, Minshan
AU  - Feng M
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Wei, Xu
AU  - Wei X
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Yu, Jie
AU  - Yu J
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
FAU - Zhu, Liguo
AU  - Zhu L
AD  - Wangjing Hospital of China Academy of Chinese Medical Sciences.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/methods/*standards
MH  - *Clinical Protocols
MH  - Humans
MH  - Massage/methods/*standards
MH  - Meta-Analysis as Topic
MH  - Radiculopathy/physiopathology/*therapy
MH  - Spondylosis/*complications/physiopathology/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7593079
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021587 [doi]
AID - 00005792-202008070-00051 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21587. doi: 10.1097/MD.0000000000021587.


PMID- 32769889
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Chinese herbal medicine si-miao-san decoction for acute gouty arthritis: A
      protocol for systematic review and meta-analysis of randomized controlled trials.
PG  - e21510
LID - 10.1097/MD.0000000000021510 [doi]
AB  - BACKGROUND: The prevalence of gout is increasing worldwide, and the symptoms of
      acute arthritis appearing in gout patients seriously affect the quality of life. 
      The pain and functional limitation caused by acute gouty arthritis (AGA) bring
      great pain to patients. At present, mainstream drugs have problems such as poor
      efficacy and side effects. Traditional Chinese medicine has extensive clinical
      experience in the prevention and treatment of gout, and it also shows clear
      advantages in the treatment of AGA. Clinical studies have confirmed that
      si-miao-san decoction (SMSD), a traditional Chinese medicine decoction, can
      improve the clinical symptoms and signs of AGA patients. Therefore, we will
      conduct a systematic review to clarify the effectiveness and safety of SMSD for
      AGA. METHODS: We will search different database from the built-in to October
      2020. The electronic database includes PubMed, Embase, Cochrane Library, Web of
      Science, CNKI, WanFang, VIP, and CBM. At the same time, we will also search for
      clinical registration tests and gray literatures. This study only screened
      clinical randomized controlled trials (RCT) for SMSD for AGA. The 2 researchers
      independently conducted literature selection, data extraction, and quality
      assessment. Dichotomous data are represented by relative risk (RR), continuous
      data are represented by mean difference (MD) or standard mean deviation (SMD),
      and the final data are fixed effect model (FEM) or random effect model (REM),
      depending on whether it exists heterogeneity. The main outcomes are clinical
      efficacy, including pain score, joint function, and degree of swelling. The
      secondary outcomes include: blood uric acid (BUA), C-reactive protein (CRP), and 
      erythrocyte sedimentation rate (ESR). Finally, a meta-analysis was conducted
      through Review Manager software version 5.3. RESULTS: This study will conduct a
      comprehensive analysis based on the currently released Si-Miao-San data for the
      treatment of AGA and provide high-quality evidence of clinical efficacy and
      safety. CONCLUSION: This systematic review aims to provide new options for SMSD
      treatment of AGA in terms of its efficacy and safety. ETHICS AND DISSEMINATION:
      The review is based solely on a secondary study of published literatures and does
      not require ethics committee approval. Its conclusion will be disseminated in
      conference papers, magazines, or peer-reviewed journals. INPLASY REGISTRATION
      NUMBER: INPLASY202040163.
FAU - Wang, Heting
AU  - Wang H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Duan, Hua
AU  - Duan H
AD  - Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,
      Chengdu, Sichuan Province, P.R. China.
FAU - Chen, Shiyin
AU  - Chen S
AD  - Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,
      Chengdu, Sichuan Province, P.R. China.
FAU - Luo, Yong
AU  - Luo Y
AD  - Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,
      Chengdu, Sichuan Province, P.R. China.
FAU - Zhang, Yuan
AU  - Zhang Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Liu, Qingsong
AU  - Liu Q
AD  - Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,
      Chengdu, Sichuan Province, P.R. China.
FAU - Zhang, Xiyu
AU  - Zhang X
AUID- ORCID: 0000-0003-3244-3554
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (jiawei simiaosan)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arthritis, Gouty/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7593063
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021510 [doi]
AID - 00005792-202008070-00030 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21510. doi: 10.1097/MD.0000000000021510.


PMID- 32769888
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Computer-navigated versus conventional total knee arthroplasty: A randomized
      controlled trial protocol in China.
PG  - e21508
LID - 10.1097/MD.0000000000021508 [doi]
AB  - BACKGROUND: The literature lacks studies that confirm whether the improved
      radiographic alignment that can be achieved with computer-navigated total knee
      arthroplasty (TKA) improves patients' activities of daily living or the
      durability of total knee prostheses. Thus, in this protocol, we designed a
      randomized controlled trial to compare implant alignment, functional scores, and 
      survival of the implant using computer-assisted surgery versus a conventional
      surgical technique. METHODS: This prospective, blinded randomized controlled
      trial was conducted at our single hospital. This study was approved by the ethics
      committee of Jiaxing Second Hospital. The patient inclusion criteria were age 20 
      to 80 years' old, a body mass index of </=35 kg/m, and consented for primary knee
      arthroplasty performed through a medial parapatellar approach by the senior
      author. We randomized consented study participants on a 1:1 ratio to 1 of 2 study
      groups using a computer-generated list of random numbers in varying block sizes. 
      The primary outcome in this study was the Knee Injury and Osteoarthritis Outcome 
      Score. Secondary outcomes were the Knee Society Score, Western Ontario and
      McMaster Universities Osteoarthritis Index, complications, and range of motion
      together with alignment and rotational positioning of the implant. Statistical
      significance was defined as a P value of </=0.05. CONCLUSIONS: Authors
      hypothesized that computer-assisted surgery in primary TKA improves implant
      alignment, functional scores, and survival of the implant compared to the
      conventional technique.
FAU - Yu, Yefeng
AU  - Yu Y
AD  - Department of orthopedics, Jiaxing Second Hospital, Zhejiang Province, China.
FAU - Sheng, Jianming
AU  - Sheng J
FAU - Zhou, Xiao
AU  - Zhou X
AUID- ORCID: 0000-0002-8730-5434
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Knee/adverse effects/*methods
MH  - China
MH  - Female
MH  - Humans
MH  - Knee Prosthesis/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/*surgery
MH  - Postoperative Complications/etiology
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Range of Motion, Articular
MH  - Recovery of Function
MH  - Single-Blind Method
MH  - Surgery, Computer-Assisted/adverse effects/*methods
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7593008
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021508 [doi]
AID - 00005792-202008070-00029 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21508. doi: 10.1097/MD.0000000000021508.


PMID- 32769874
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Tai Chi for coronavirus disease 2019 in recovery period: A protocol for
      systematic review and meta analysis.
PG  - e21459
LID - 10.1097/MD.0000000000021459 [doi]
AB  - BACKGROUND: Assessing the effectiveness and safety of Tai Chi for coronavirus
      disease 2019 (COVID-19) in recovery period is the main purpose of this systematic
      review protocol. METHODS: The following electronic databases will be searched
      from inception to April 2020: MEDLINE, Ovid, EMBASE, the Cochrane Library, the
      Allied and Complementary Medicine Database, Chinese National Knowledge
      Infrastructure, Chinese Biomedical Literature Database, VIP Database and Wanfang 
      Database. In addition, Clinical trial registries, like the Chinese Clinical Trial
      Registry, the Netherlands National Trial Register and ClinicalTrials.gov, will be
      searched for ongoing trials with unpublished data. No language restrictions will 
      be applied. The primary outcome will be the time of disappearance of main
      symptoms (including fever, asthenia, cough disappearance rate, and temperature
      recovery time), and serum cytokine levels. The secondary outcome will be the
      accompanying symptoms (such as myalgia, expectoration, stuffiness, runny nose,
      pharyngalgia, anhelation, chest distress, dyspnea, crackles, headache, nausea,
      vomiting, anorexia, diarrhea) disappear rate, negative COVID-19 results rate on 2
      consecutive occasions (not on the same day), CT image improvement, average
      hospitalization time, occurrence rate of common type to severe form, clinical
      cure rate, and mortality. Two independent reviewers will conduct the study
      selection, data extraction and assessment. Review manager software V.5.3 will be 
      used for the assessment of risk of bias and data synthesis. RESULTS: The results 
      will provide a high-quality synthesis of current evidence for researchers in this
      subject area. CONCLUSION: The conclusion of the study will provide an evidence to
      judge whether Tai Chi is effective and safe for COVID-19 in recovery period.
      ETHICS AND DISSEMINATION: This protocol will not evaluate individual patient
      information or infringe patient rights and therefore does not require ethical
      approval. Results from this review will be disseminated through peer-reviewed
      journals and conference reports.PROSPERO registration number CRD42020181456.
FAU - Shi, Yu
AU  - Shi Y
AD  - College of Acupuncture and Moxibustion and Tuina, Chengdu University of
      Traditional Chinese Medicine.
FAU - Wen, Dengpeng
AU  - Wen D
AD  - College of Acupuncture and Moxibustion and Tuina, Chengdu University of
      Traditional Chinese Medicine.
FAU - Wang, Hui
AU  - Wang H
AD  - Beibei District Traditional Chinese Medicine Hospital of Chongqing.
FAU - Zhang, Puyue
AU  - Zhang P
AD  - College of Acupuncture and Moxibustion and Tuina, Chengdu University of
      Traditional Chinese Medicine.
FAU - Zhong, Yanmei
AU  - Zhong Y
AD  - School of Medical Information Engineering, Chengdu University of Traditional
      Chinese Medicine.
FAU - Liu, Donghao
AU  - Liu D
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese
      Medicine.
FAU - Zhou, Deqi
AU  - Zhou D
AUID- ORCID: 0000-0002-1384-7425
AD  - Beibei District Traditional Chinese Medicine Hospital of Chongqing.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - COVID-19
MH  - China
MH  - Coronavirus Infections/*epidemiology/*rehabilitation
MH  - Female
MH  - Humans
MH  - Male
MH  - Pandemics/*statistics & numerical data
MH  - Pneumonia, Viral/*epidemiology/*rehabilitation
MH  - Recovery of Function
MH  - Tai Ji/*methods
PMC - PMC7592991
EDAT- 2020/08/10 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
AID - 10.1097/MD.0000000000021459 [doi]
AID - 00005792-202008070-00015 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21459. doi: 10.1097/MD.0000000000021459.


PMID- 32769861
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Combination of traditional Chinese medicine and epidermal growth factor receptor 
      tyrosine kinase inhibitors in the treatment of non-small cell lung cancer: A
      systematic review and meta-analysis.
PG  - e20683
LID - 10.1097/MD.0000000000020683 [doi]
AB  - BACKGROUND: In China, traditional Chinese medicine (TCM) is an increasingly
      important part of the treatment of non-small cell lung cancer (NSCLC), which
      usually includes a combination of prescription and syndrome differentiation.
      Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been
      proven to be the first-line drugs for the treatment of advanced EGFR
      mutation-positive NSCLC. In China, EGFR-TKIs are used in combination with
      traditional Chinese medicines to reduce side effects and/or enhance
      effectiveness. Nevertheless, the relationship between TCMs and EGFR-TKIs remain
      unclear. This meta-review aimed to explore the clinical evidence of TCMs combined
      with EGFR-TKIs in the treatment of NSCLC. METHODS: Related studies were found by 
      searching the databases of EMBASE, PubMed, Web of Science, MEDLINE, Cochrane
      library database, China Academic Journals (CNKI), Wanfang and Weipu. This study
      included 57 randomized controlled trials, all of these were processed by Stata
      software (version 12.0). In the study, all the materials are published articles, 
      patient anonymity and informed consent and ethics Approval/Institutional review
      board are not necessary. RESULTS: This study demonstrated that the objective
      response rate was higher in the group of TCMs plus EGFR-TKIs than in the group of
      EGFR-TKIs alone (risk ratios 1.39, 95% confidence intervals [1.29, 1.50]).
      Further research of specific herbal medicines showed that Huangqi, Baishu,
      Fuling, Gancao, Maidong, Baihuashecao, Shashen, Dangshen and Renshen, had
      significant higher contributions to results. CONCLUSION: TCMs may improve the
      efficacy of EGFR-TKIs in the treatment of NSCLC.
FAU - Sui, Xinbing
AU  - Sui X
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
AD  - Zhejiang Key Laboratory of Elemene Anticancer Traditional Chinese Medicine,
      Hangzhou Normal University, Zhejiang Provincial Engineering Laboratory of
      Traditional Chinese Medicine Development and Application, Hangzhou, Zhejiang.
FAU - Zhang, Mingming
AU  - Zhang M
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
AD  - Zhejiang Key Laboratory of Elemene Anticancer Traditional Chinese Medicine,
      Hangzhou Normal University, Zhejiang Provincial Engineering Laboratory of
      Traditional Chinese Medicine Development and Application, Hangzhou, Zhejiang.
FAU - Han, Xuemeng
AU  - Han X
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
AD  - Zhejiang Key Laboratory of Elemene Anticancer Traditional Chinese Medicine,
      Hangzhou Normal University, Zhejiang Provincial Engineering Laboratory of
      Traditional Chinese Medicine Development and Application, Hangzhou, Zhejiang.
FAU - Zhang, Ruonan
AU  - Zhang R
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
AD  - Zhejiang Key Laboratory of Elemene Anticancer Traditional Chinese Medicine,
      Hangzhou Normal University, Zhejiang Provincial Engineering Laboratory of
      Traditional Chinese Medicine Development and Application, Hangzhou, Zhejiang.
FAU - Chen, Liuxi
AU  - Chen L
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
FAU - Liu, Ying
AU  - Liu Y
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University,
      Hangzhou, China.
FAU - Xiang, Yu
AU  - Xiang Y
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
AD  - Zhejiang Key Laboratory of Elemene Anticancer Traditional Chinese Medicine,
      Hangzhou Normal University, Zhejiang Provincial Engineering Laboratory of
      Traditional Chinese Medicine Development and Application, Hangzhou, Zhejiang.
FAU - Xie, Tian
AU  - Xie T
AD  - Holistic Integrative Pharmacy Institutes and Department of Medical Oncology, the 
      Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou 
      Normal University.
AD  - Zhejiang Key Laboratory of Elemene Anticancer Traditional Chinese Medicine,
      Hangzhou Normal University, Zhejiang Provincial Engineering Laboratory of
      Traditional Chinese Medicine Development and Application, Hangzhou, Zhejiang.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*therapy
MH  - Combined Modality Therapy
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Humans
MH  - Lung Neoplasms/*therapy
MH  - *Medicine, Chinese Traditional
MH  - Protein Kinase Inhibitors/*therapeutic use
PMC - PMC7593038
EDAT- 2020/08/10 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/MD.0000000000020683 [doi]
AID - 00005792-202008070-00002 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e20683. doi: 10.1097/MD.0000000000020683.


PMID- 32769696
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20210205
IS  - 1531-7021 (Electronic)
IS  - 1040-8738 (Linking)
VI  - 31
IP  - 5
DP  - 2020 Sep
TI  - Controversies in artificial intelligence.
PG  - 324-328
LID - 10.1097/ICU.0000000000000694 [doi]
AB  - PURPOSE OF REVIEW: To review four recent controversial topics arising from deep
      learning applications in ophthalmology. RECENT FINDINGS: The controversies of
      four recent topics surrounding deep learning applications in ophthalmology are
      discussed, including the following: lack of explainability, limited
      generalizability, potential biases and protection of patient confidentiality in
      large-scale data transfer. SUMMARY: These controversial issues spanning the
      domains of clinical medicine, public health, computer science, ethics and legal
      issues, are complex and likely will benefit from an interdisciplinary approach if
      artificial intelligence in ophthalmology is to succeed over the next decade.
FAU - Liu, T Y Alvin
AU  - Liu TYA
AD  - Retina Division, Wilmer Eye Institute, Johns Hopkins University School of
      Medicine, Baltimore, Maryland, USA.
FAU - Bressler, Neil M
AU  - Bressler NM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Ophthalmol
JT  - Current opinion in ophthalmology
JID - 9011108
SB  - IM
MH  - *Artificial Intelligence
MH  - Big Data
MH  - Eye Diseases/*diagnosis
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/*methods
MH  - *Ophthalmology
EDAT- 2020/08/10 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1097/ICU.0000000000000694 [doi]
AID - 00055735-202009000-00005 [pii]
PST - ppublish
SO  - Curr Opin Ophthalmol. 2020 Sep;31(5):324-328. doi: 10.1097/ICU.0000000000000694.


PMID- 32769655
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20210903
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 136
IP  - 3
DP  - 2020 Sep
TI  - Care for Incarcerated Pregnant People With Opioid Use Disorder: Equity and
      Justice Implications.
PG  - 576-581
LID - 10.1097/AOG.0000000000004002 [doi]
AB  - With the simultaneous rise in maternal opioid use disorder (OUD) and the
      incarceration of pregnant people in the United States, we must ensure that
      prisons and jails adequately address the health and well-being of incarcerated
      pregnant people with OUD. Despite long-established, clear, and evidence-based
      recommendations regarding the treatment of OUD during pregnancy, incarcerated
      pregnant people with OUD do not consistently receive medication treatment and are
      instead forced into opioid withdrawal. This inadequate care raises multiple
      concerns, including issues of justice and equity, considerations regarding the
      legal and ethical obligations of the provision of health care, and violations of 
      the medical and legal rights of incarcerated people. We offer recommendations for
      improving care for this often-ignored group.
FAU - Ahlbach, Chris
AU  - Ahlbach C
AD  - University of California San Francisco School of Medicine, San Francisco,
      California; the Department of Gynecology and Obstetrics, Johns Hopkins School of 
      Medicine, and the Department of Health, Behavior & Society, Johns Hopkins
      Bloomberg School of Public Health, Baltimore, Maryland; and the Division of
      General Pediatrics and Adolescent Health, Department of Pediatrics, University of
      Minnesota, Minneapolis, Minnesota.
FAU - Sufrin, Carolyn
AU  - Sufrin C
FAU - Shlafer, Rebecca
AU  - Shlafer R
LA  - eng
GR  - K23 DA045934/DA/NIDA NIH HHS/United States
GR  - TL1 TR001871/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - IM
MH  - Female
MH  - *Health Equity
MH  - Humans
MH  - Opioid-Related Disorders/*therapy
MH  - Practice Guidelines as Topic
MH  - Pregnancy
MH  - Pregnancy Complications/*therapy
MH  - *Prisoners
MH  - *Social Justice
MH  - United States
PMC - PMC7483637
MID - NIHMS1596913
EDAT- 2020/08/10 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 10.1097/AOG.0000000000004002 [doi]
AID - 00006250-202009000-00018 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2020 Sep;136(3):576-581. doi: 10.1097/AOG.0000000000004002.


PMID- 32769228
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20210213
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 48
IP  - 9
DP  - 2020 Nov 26
TI  - Professionally responsible advocacy for women and children first during the
      COVID-19 pandemic: guidance from World Association of Perinatal Medicine and
      International Academy of Perinatal Medicine.
PG  - 867-873
LID - 10.1515/jpm-2020-0329 [doi]
AB  - The goal of perinatal medicine is to provide professionally responsible clinical 
      management of the conditions and diagnoses of pregnant, fetal, and neonatal
      patients. The New York Declaration of the International Academy of Perinatal
      Medicine, "Women and children First - or Last?" was directed toward the ethical
      challenges of perinatal medicine in middle-income and low-income countries. The
      global COVID-19 pandemic presents common ethical challenges in all countries,
      independent of their national wealth. In this paper the World Association of
      Perinatal Medicine provides ethics-based guidance for professionally responsible 
      advocacy for women and children first during the COVID-19 pandemic. We first
      present an ethical framework that explains ethical reasoning, clinically relevant
      ethical principles and professional virtues, and decision making with pregnant
      patients and parents. We then apply this ethical framework to evidence-based
      treatment and its improvement, planned home birth, ring-fencing obstetric
      services, attendance of spouse or partner at birth, and the responsible
      management of organizational resources. Perinatal physicians should focus on the 
      mission of perinatal medicine to put women and children first and frame-shifting 
      when necessary to put the lives and health of the population of patients served
      by a hospital first.
FAU - Chervenak, Frank A
AU  - Chervenak FA
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - McCullough, Laurence B
AU  - McCullough LB
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Grunebaum, Amos
AU  - Grunebaum A
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Bornstein, Eran
AU  - Bornstein E
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Sen, Cihat
AU  - Sen C
AD  - Department of Perinatology, Cerrahpasa Medical School, University of Istanbul,
      Istanbul, Turkey.
FAU - Stanojevic, Milan
AU  - Stanojevic M
AD  - Department of Neonatology, University Hospital "Sveti Duh", Zagreb, Croatia.
FAU - Degtyareva, Marina
AU  - Degtyareva M
AUID- ORCID: https://orcid.org/0000-0002-1769-5430
AD  - Department of Neonatology, Pirogov Russian National Research Medical University, 
      Moscow, Russia.
FAU - Kurjak, Asim
AU  - Kurjak A
AD  - Department of Obstetrics and Gynecology, University of Zagreb, Zagreb, Croatia.
AD  - University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/ethics
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Care/ethics
MH  - Ethics, Medical
MH  - Female
MH  - Fetus
MH  - Hospitalization
MH  - Humans
MH  - Infant, Newborn
MH  - Obstetrics/ethics
MH  - *Pandemics
MH  - Patient Advocacy/*ethics
MH  - Pediatrics/ethics
MH  - Perinatal Care/*ethics/methods
MH  - Pneumonia, Viral/*epidemiology
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Triage
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - frame-shifting
OT  - professional ethics in perinatal medicine
OT  - ring-fencing
OT  - triage
EDAT- 2020/08/10 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/07/13 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 10.1515/jpm-2020-0329 [doi]
AID - jpm-2020-0329 [pii]
PST - ppublish
SO  - J Perinat Med. 2020 Nov 26;48(9):867-873. doi: 10.1515/jpm-2020-0329.


PMID- 32769095
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Tragic choices in intensive care during the COVID-19 pandemic: on fairness,
      consistency and community.
PG  - 646-651
LID - 10.1136/medethics-2020-106487 [doi]
AB  - Tragic choices arise during the COVID-19 pandemic when the limited resources made
      available in acute medical settings cannot be accessed by all patients who need
      them. In these circumstances, healthcare rationing is unavoidable. It is
      important in any healthcare rationing process that the interests of the community
      are recognised, and that decision-making upholds these interests through a fair
      and consistent process of decision-making. Responding to recent calls (1) to
      safeguard individuals' legal rights in decision-making in intensive care, and (2)
      for new authoritative national guidance for decision-making, this paper seeks to 
      clarify what consistency and fairness demand in healthcare rationing during the
      COVID-19 pandemic, from both a legal and ethical standpoint. The paper begins
      with a brief review of UK law concerning healthcare resource allocation,
      considering how community interests and individual rights have been marshalled in
      judicial deliberation about the use of limited health resources within the
      National Health Service (NHS). It is then argued that an important distinction
      needs to be drawn between procedural and outcome consistency, and that a
      procedurally consistent decision-making process ought to be favoured. Congruent
      with the position that UK courts have adopted for resource allocation
      decision-making in the NHS more generally, specific requirements for a procedural
      framework and substantive triage criteria to be applied within that framework
      during the COVID-19 pandemic are considered in detail.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Newdick, Chris
AU  - Newdick C
AUID- ORCID: 0000-0002-3511-5137
AD  - School of Law, University of Reading, Reading, Berkshire, UK
      c.newdick@reading.ac.uk.
FAU - Sheehan, Mark
AU  - Sheehan M
AUID- ORCID: 0000-0002-7191-901X
AD  - Ethox Centre, University of Oxford, Oxford, UK.
AD  - Wellcome Centre for Ethics and the Humanities, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Dunn, Michael
AU  - Dunn M
AUID- ORCID: 0000-0002-5603-6200
AD  - Ethox Centre, University of Oxford, Oxford, UK.
AD  - Wellcome Centre for Ethics and the Humanities, University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200807
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Critical Care/*ethics/legislation & jurisprudence
MH  - Decision Making/*ethics
MH  - Health Care Rationing/*ethics/legislation & jurisprudence
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - SARS-CoV-2
MH  - State Medicine
MH  - United Kingdom
PMC - PMC7415071
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *clinical ethics
OT  - *decision-making
OT  - *law
COIS- Competing interests: CN and MS are members of the Thames Valley Priorities
      Committee. MD and MS are members of clinical ethics advisory groups that have
      developed policies and procedures on the allocation of intensive care resources
      during the COVID-19 pandemic.
EDAT- 2020/08/10 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/05/22 00:00 [received]
PHST- 2020/07/23 00:00 [revised]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - medethics-2020-106487 [pii]
AID - 10.1136/medethics-2020-106487 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):646-651. doi: 10.1136/medethics-2020-106487. Epub
      2020 Aug 7.


PMID- 32769094
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Ethical framework for adult social care in COVID-19.
PG  - 662-667
LID - 10.1136/medethics-2020-106513 [doi]
AB  - In March 2020, the Government produced a document entitled "Responding to
      COVID-19: The Ethical Framework for Adult Social Care" ('The Ethical Framework').
      In this article, we summarise the key features of the proposed ethical framework 
      and subject it to critical analysis. We highlight three primary issues. First,
      the emphasis placed on autonomy as the primary ethical principle. We argue if
      ever there was a context in which autonomy should dominate the ethical analysis, 
      this is not it. Second, we examine the interface between ethics and law which is 
      largely overlooked in the document. Finally, we explore the surprising lack of
      attention paid to the concept of responsibility and communal obligations within
      the framework.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Elves, Charlotte Bryony
AU  - Elves CB
AUID- ORCID: 0000-0002-5023-7650
AD  - Exeter College, University of Oxford, Oxford, UK charlotte.elves@law.ox.ac.uk.
FAU - Herring, Jonathan
AU  - Herring J
AD  - Exeter College, University of Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Adult
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Decision Making/*ethics
MH  - *Ethical Analysis
MH  - Ethical Theory
MH  - *Ethics, Medical
MH  - Humans
MH  - Legislation, Medical/*ethics
MH  - Pandemics
MH  - *Personal Autonomy
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - SARS-CoV-2
MH  - *Social Responsibility
MH  - State Medicine/ethics/legislation & jurisprudence
MH  - United Kingdom
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *autonomy
OT  - *law
OT  - *philosophical ethics
OT  - *regulation
COIS- Competing interests: None declared.
EDAT- 2020/08/10 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - medethics-2020-106513 [pii]
AID - 10.1136/medethics-2020-106513 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):662-667. doi: 10.1136/medethics-2020-106513. Epub
      2020 Aug 7.


PMID- 32768654
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1878-1632 (Electronic)
IS  - 1529-9430 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - Influences of functional structures on the kinematic behavior of the cervical
      spine.
PG  - 2014-2024
LID - S1529-9430(20)31006-8 [pii]
LID - 10.1016/j.spinee.2020.07.017 [doi]
AB  - BACKGROUND CONTEXT: A few studies have already investigated the influences of
      functional structures of the cervical spine on its biomechanical behavior. In
      most studies, this has been done by measuring the range of motion. However, this 
      parameter lacks of qualitative information about the overall kinematic behavior, 
      such as coupled motions or translations. These data are essential for future
      development of cervical implants and surgical techniques. PURPOSE: An
      investigation of the influences of cervical structures on the kinematic behavior 
      of the cervical spine under in vivo conditions is almost impossible due to
      ethical reasons. Therefore, an in vitro study was conducted which allowed the
      analysis of these influences using three-dimensional helical axes. STUDY
      DESIGN/SETTING: An in vitro test applying pure moments on mono-segmental
      specimens was designed in order to investigate the influences of a series of
      structures on the kinematic behavior of the cervical spine using
      three-dimensional helical axes. METHODS: In this study we extracted motion
      segments C2-C3, C4-C5, and C6-C7 from 6 human cadaveric specimens with an average
      age of 48 years. The specimens were carefully selected using X-ray images. For
      the in vitro experiments, seven states were defined. The first state represented 
      the intact state of each specimen. The remaining six states correspond with the
      subsequent resection of the following structures in the given order: interspinous
      ligament, ligamentum flavum, facet capsule, vertebral arch, posterior
      longitudinal ligament, and anterior longitudinal ligament. Each state was tested 
      using a well-established spine tester. Each test sequence included 3.5
      quasi-static motion cycles in all three bending directions using pure moments of 
      1 Nm. All motions were recorded using a motion tracking device and six reflective
      markers which were attached to the specimens. The recordings were then used to
      calculate the 3D helical axes, which were matched with the X-ray images. Due to
      the small number of specimens, qualitative results, such as the helical axes,
      were analyzed using descriptive statistics. RESULTS: In general, the overall
      range of motion was increased in all loading directions due to the resection
      steps. The least change in the kinematic behavior of the cervical spine was
      observed during flexion/extension. For lateral bending and axial rotation the
      greatest change in the pattern of the helical axes was observed during the
      resection of the vertebral arch. For some specimens, however, typical patterns
      regarding the orientation of the helical axes remained until the last state. For 
      lateral bending, it could be observed that the deviation in the axes' orientation
      increased whereas for axial rotation it decreased. CONCLUSION: Resection of the
      cervical ligaments are much less crucial than the removal of guiding structures
      such as the facet joint. Furthermore, coupled motions not only result from the
      orientations of the articular surfaces of the facet joints but also from the
      overall shape of the cervical vertebrae including the uncinate processes.
      CLINICAL SIGNIFICANCE: It is well-known that coupled motions play a substantial
      role in cervical kinematics. However, the influences of cervical structures on
      the overall kinematic behavior of the cervical spine are not yet fully
      understood. Knowledge of these influences could help to reduce or even prevent
      iatrogenic degeneration after surgical intervention. Furthermore, the data
      provided by this study can be helpful for future developments of cervical
      implants as well as finite element models for more advanced numerical
      investigations.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Jonas, Rene
AU  - Jonas R
AD  - Institute of Orthopaedic Research and Biomechanics, Helmholtzstrasse 14, 89081
      Ulm, Germany.
FAU - Demmelmaier, Robert
AU  - Demmelmaier R
AD  - Institute of Orthopaedic Research and Biomechanics, Helmholtzstrasse 14, 89081
      Ulm, Germany.
FAU - Wilke, Hans-Joachim
AU  - Wilke HJ
AD  - Institute of Orthopaedic Research and Biomechanics, Helmholtzstrasse 14, 89081
      Ulm, Germany. Electronic address: hans-joachim.wilke@uni-ulm.de.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - United States
TA  - Spine J
JT  - The spine journal : official journal of the North American Spine Society
JID - 101130732
SB  - IM
MH  - Biomechanical Phenomena
MH  - *Cervical Vertebrae/diagnostic imaging/surgery
MH  - Humans
MH  - Middle Aged
MH  - Range of Motion, Articular
MH  - Rotation
MH  - *Zygapophyseal Joint
OTO - NOTNLM
OT  - *Biomechanics
OT  - *Cervical spine
OT  - *Helical axes
OT  - *In vitro
OT  - *Injury
OT  - *Kinematics
EDAT- 2020/08/10 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/08/10 06:00
PHST- 2019/12/11 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - S1529-9430(20)31006-8 [pii]
AID - 10.1016/j.spinee.2020.07.017 [doi]
PST - ppublish
SO  - Spine J. 2020 Dec;20(12):2014-2024. doi: 10.1016/j.spinee.2020.07.017. Epub 2020 
      Aug 5.


PMID- 32768390
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20211129
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - STROBE-metagenomics: a STROBE extension statement to guide the reporting of
      metagenomics studies.
PG  - e251-e260
LID - S1473-3099(20)30199-7 [pii]
LID - 10.1016/S1473-3099(20)30199-7 [doi]
AB  - The term metagenomics refers to the use of sequencing methods to simultaneously
      identify genomic material from all organisms present in a sample, with the
      advantage of greater taxonomic resolution than culture or other methods.
      Applications include pathogen detection and discovery, species characterisation, 
      antimicrobial resistance detection, virulence profiling, and study of the
      microbiome and microecological factors affecting health. However, metagenomics
      involves complex and multistep processes and there are important technical and
      methodological challenges that require careful consideration to support valid
      inference. We co-ordinated a multidisciplinary, international expert group to
      establish reporting guidelines that address specimen processing, nucleic acid
      extraction, sequencing platforms, bioinformatics considerations, quality
      assurance, limits of detection, power and sample size, confirmatory testing,
      causality criteria, cost, and ethical issues. The guidance recognises that
      metagenomics research requires pragmatism and caution in interpretation, and that
      this field is rapidly evolving.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Bharucha, Tehmina
AU  - Bharucha T
AD  - Department of Biochemistry, University of Oxford, Oxford, UK; Lao-Oxford-Mahosot 
      Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital,
      Vientiane, Laos. Electronic address: t.bharucha@doctors.org.uk.
FAU - Oeser, Clarissa
AU  - Oeser C
AD  - Centre for Molecular Epidemiology and Translational Research, University College 
      London, London, UK.
FAU - Balloux, Francois
AU  - Balloux F
AD  - UCL Genetics Institute, University College London, London, UK.
FAU - Brown, Julianne R
AU  - Brown JR
AD  - Microbiology, Virology and Infection Prevention and Control, Great Ormond Street 
      Hospital for Children, London, UK.
FAU - Carbo, Ellen C
AU  - Carbo EC
AD  - Department of Medical Microbiology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Charlett, Andre
AU  - Charlett A
AD  - Statistics, Modelling and Economics Department, Public Health England, London,
      UK.
FAU - Chiu, Charles Y
AU  - Chiu CY
AD  - Department of Laboratory Medicine, University of California San Francisco, San
      Francisco, CA, USA.
FAU - Claas, Eric C J
AU  - Claas ECJ
AD  - Department of Medical Microbiology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - de Goffau, Marcus C
AU  - de Goffau MC
AD  - Wellcome Sanger Institute, Hinxton, UK; Department of Veterinary Medicine,
      University of Cambridge, Cambridge, UK.
FAU - de Vries, Jutte J C
AU  - de Vries JJC
AD  - Department of Medical Microbiology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Eloit, Marc
AU  - Eloit M
AD  - Pathogen Discovery Laboratory, Institut Pasteur, Paris, France.
FAU - Hopkins, Susan
AU  - Hopkins S
AD  - Healthcare-Associated Infection and Antimicrobial Resistance, Public Health
      England, London, UK; Infectious Diseases Unit, Royal Free Hospital, London, UK.
FAU - Huggett, Jim F
AU  - Huggett JF
AD  - National Measurement Laboratory, LGC, Teddington, UK; School of Biosciences &
      Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, 
      UK.
FAU - MacCannell, Duncan
AU  - MacCannell D
AD  - Office of Advanced Molecular Detection, Centers for Disease Control and
      Prevention, Atlanta, GA, USA.
FAU - Morfopoulou, Sofia
AU  - Morfopoulou S
AD  - Division of Infection and Immunity, University College London, London, UK.
FAU - Nath, Avindra
AU  - Nath A
AD  - Section of Infections of the Nervous System, National Institutes of Health,
      Bethesda, MD, USA.
FAU - O'Sullivan, Denise M
AU  - O'Sullivan DM
AD  - National Measurement Laboratory, LGC, Teddington, UK.
FAU - Reoma, Lauren B
AU  - Reoma LB
AD  - Section of Infections of the Nervous System, National Institutes of Health,
      Bethesda, MD, USA.
FAU - Shaw, Liam P
AU  - Shaw LP
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Sidorov, Igor
AU  - Sidorov I
AD  - Department of Medical Microbiology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Simner, Patricia J
AU  - Simner PJ
AD  - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA.
FAU - Van Tan, Le
AU  - Van Tan L
AD  - Emerging Infections Group, Oxford University Clinical Research Unit, Ho Chi Minh 
      city, Vietnam.
FAU - Thomson, Emma C
AU  - Thomson EC
AD  - MRC-University of Glasgow Centre for Virus Research, University of Glasgow,
      Glasgow, UK.
FAU - van Dorp, Lucy
AU  - van Dorp L
AD  - UCL Genetics Institute, University College London, London, UK.
FAU - Wilson, Michael R
AU  - Wilson MR
AD  - Weill Institute for Neurosciences and Department of Neurology, University of
      California, San Francisco, CA, USA.
FAU - Breuer, Judith
AU  - Breuer J
AD  - Division of Infection and Immunity, University College London, London, UK; Great 
      Ormond Street Hospital for Children, London, UK.
FAU - Field, Nigel
AU  - Field N
AD  - Centre for Molecular Epidemiology and Translational Research, University College 
      London, London, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - K08 NS096117/NS/NINDS NIH HHS/United States
GR  - 204904/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - NS003130/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200805
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
SB  - IM
EIN - Lancet Infect Dis. 2020 Dec;20(12):e298. PMID: 33120055
MH  - Computational Biology
MH  - Humans
MH  - Metagenomics/*methods/*statistics & numerical data
MH  - Molecular Epidemiology
MH  - Research Design/standards
PMC - PMC7406238
EDAT- 2020/08/10 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/10 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - S1473-3099(20)30199-7 [pii]
AID - 10.1016/S1473-3099(20)30199-7 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2020 Oct;20(10):e251-e260. doi: 10.1016/S1473-3099(20)30199-7.
      Epub 2020 Aug 5.


PMID- 32768113
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210110
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 71
DP  - 2020 Jul - Aug
TI  - COVID-19 and forced alcohol abstinence in India: The dilemmas around ethics and
      rights.
PG  - 101579
LID - S0160-2527(20)30038-8 [pii]
LID - 10.1016/j.ijlp.2020.101579 [doi]
AB  - In response to the COVID-19 pandemic, as with other countries across the world,
      the Central and State Governments of India initiated several measures to slow
      down the spread of the virus and to 'flatten the curve'. One such measure was a
      'total lockdown' for several weeks across the country. A complex and unexpected
      outcome of the lockdown which has medical, ethical, economic, and social
      dimensions is related to alcohol consumption. The lockdown and consequent acute
      non-availability of alcohol resulted in people with alcohol dependence going into
      withdrawals, black marketing of alcohol, and in extreme cases suicide resulting
      from the alleged frustration of not having access to alcohol. The health dilemmas
      around this situation are biological (e.g. pushing people into risky
      situations-potentially fatal alcohol withdrawal, consumption of illicit or other 
      non-consumable alcohol) and psychosocial (e.g. isolation increasing the risk of
      relapses, loss of control over the decision to abstain which can be detrimental
      to recovery, restriction of access to services for alcohol problems). The legal
      and rights-related dilemmas are centred around whether States have the right to
      impinge on individual autonomy on the grounds of public health, the capacity of
      the health systems to provide appropriate services to cope with those who will
      struggle with the unavailability of alcohol, the constitutionality of the Central
      government's impinging on jurisdiction of states under the guise of a health
      emergency caused by the pandemic, and the ability of the State to make unbiased
      decisions about this issue when it is highly dependent on the revenue from the
      sale of alcohol and associated industries. The way forward could be a pragmatic
      and utilitarian approach involving continued access to alcohol, while observing
      all physical distancing norms necessary during the pandemic, for those who want
      to continue drinking; and implementing innovative measures such as
      tele-counselling for those who wish not to return back to drinking.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Nadkarni, Abhijit
AU  - Nadkarni A
AD  - Centre for Global Mental Health, Department of Population Health, London School
      of Hygiene and Tropical Medicine, United Kingdom; Addictions Research Group,
      Sangath, India. Electronic address: abhijit.nadkarni@lshtm.ac.uk.
FAU - Kapoor, Arjun
AU  - Kapoor A
AD  - Centre for Mental Health Law and Policy, Indian Law Society, India.
FAU - Pathare, Soumitra
AU  - Pathare S
AD  - Centre for Mental Health Law and Policy, Indian Law Society, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200520
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Alcohol Abstinence/*ethics/*psychology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Federal Government
MH  - Harm Reduction
MH  - *Human Rights
MH  - Humans
MH  - India/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - *Public Health
MH  - Quarantine
MH  - SARS-CoV-2
MH  - State Government
MH  - Substance Withdrawal Syndrome/epidemiology
PMC - PMC7237931
OTO - NOTNLM
OT  - *Alcohol
OT  - *Autonomy
OT  - *COVID-19
OT  - *Harm minimisation
OT  - *India
OT  - *Prohibition
EDAT- 2020/08/10 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/05/09 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - S0160-2527(20)30038-8 [pii]
AID - 10.1016/j.ijlp.2020.101579 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Jul - Aug;71:101579. doi: 10.1016/j.ijlp.2020.101579. 
      Epub 2020 May 20.


PMID- 32768110
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210110
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 71
DP  - 2020 Jul - Aug
TI  - Isolation of patients in psychiatric hospitals in the context of the COVID-19
      pandemic: An ethical, legal, and practical challenge.
PG  - 101572
LID - S0160-2527(20)30031-5 [pii]
LID - 10.1016/j.ijlp.2020.101572 [doi]
AB  - Psychiatric inpatients are particularly vulnerable to the transmission and
      effects of COVID-19. As such, healthcare providers should implement measures to
      prevent its spread within mental health units, including adequate testing,
      cohorting, and in some cases, the isolation of patients. Respiratory isolation
      imposes a significant limitation on an individual's right to liberty, and should 
      be accompanied by appropriate legal safeguards. This paper explores the
      implications of respiratory isolation in English law, considering the
      applicability of the common law doctrine of necessity, the Mental Capacity Act
      2005, the Mental Health Act 1983, and public health legislation. We then
      interrogate the practicality of currently available approaches by applying them
      to a series of hypothetical cases. There are currently no 'neat' or practicable
      solutions to the problem of lawfully isolating patients on mental health units,
      and we discuss the myriad issues with both mental health and public health law
      approaches to the problem. We conclude by making some suggestions to
      policymakers.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Brown, Christian
AU  - Brown C
AD  - South West London and St. George's Mental Health NHS Trust, 61 Glenburnie Road,
      London SW17 7DJ, UK. Electronic address: cp.brown@nhs.net.
FAU - Ruck Keene, Alex
AU  - Ruck Keene A
AD  - 39 Essex Chambers, London, UK; King's College London, UK.
FAU - Hooper, Carwyn Rhys
AU  - Hooper CR
AD  - St George's University of London, UK.
FAU - O'Brien, Aileen
AU  - O'Brien A
AD  - St George's University of London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - England/epidemiology
MH  - Hospitals, Psychiatric/*ethics/*legislation & jurisprudence
MH  - Humans
MH  - Infection Control/*legislation & jurisprudence
MH  - Mental Competency/*legislation & jurisprudence
MH  - Pandemics/*prevention & control
MH  - Patient Isolation/*ethics/*legislation & jurisprudence
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - SARS-CoV-2
MH  - Wales/epidemiology
PMC - PMC7205628
OTO - NOTNLM
OT  - *COVID-19
OT  - *Isolation
OT  - *Mental Health Act
OT  - *Public health law
OT  - *Seclusion
COIS- Declaration of Competing Interest ARK was a legal adviser to the Independent
      Review of the Mental Health Act 1983 (reported December 2018).
EDAT- 2020/08/10 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - S0160-2527(20)30031-5 [pii]
AID - 10.1016/j.ijlp.2020.101572 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Jul - Aug;71:101572. doi: 10.1016/j.ijlp.2020.101572. 
      Epub 2020 May 8.


PMID- 32768108
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 71
DP  - 2020 Jul - Aug
TI  - Homicide and dementia: An investigation of legal, ethical, and clinical factors
      of Australian legal cases.
PG  - 101578
LID - S0160-2527(20)30037-6 [pii]
LID - 10.1016/j.ijlp.2020.101578 [doi]
FAU - Baird, Amee
AU  - Baird A
AD  - Department of Psychology, Macquarie University, Australia.
FAU - Kennett, Jeanette
AU  - Kennett J
AD  - Department of Philosopy, Macquarie University, Australia. Electronic address:
      jeanette.kennett@mq.edu.au.
FAU - Schier, Elizabeth
AU  - Schier E
AD  - Department of Philosopy, Macquarie University, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia
MH  - Criminal Law/*ethics/*legislation & jurisprudence
MH  - Dementia/*diagnosis
MH  - Female
MH  - Homicide/*psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morals
MH  - Neuroimaging
MH  - Punishment
EDAT- 2020/08/10 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/08/10 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/05/10 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
AID - S0160-2527(20)30037-6 [pii]
AID - 10.1016/j.ijlp.2020.101578 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Jul - Aug;71:101578. doi: 10.1016/j.ijlp.2020.101578. 
      Epub 2020 Jun 29.


PMID- 32768103
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20201218
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 71
DP  - 2020 Jul - Aug
TI  - Scottish mental health and capacity law: The normal, pandemic and 'new normal'.
PG  - 101593
LID - S0160-2527(20)30052-2 [pii]
LID - 10.1016/j.ijlp.2020.101593 [doi]
AB  - A state's real commitment to its international human rights obligations is never 
      more challenged than when it faces emergency situations. Addressing actual and
      potential resourcing pressures arising from the COVID-19 pandemic has resulted
      in, amongst other things, modifications to Scottish mental health and capacity
      law and the issuing of new guidance relating to associated practice. Whether
      these emergency or ordinary measures are invoked during the crisis there are
      potential implications for the rights of persons with mental illness, learning
      disability and dementia notably those relating to individual autonomy and
      dignity. This article will consider areas of particular concern but how strict
      adherence to the legal, ethical and human rights framework in Scotland will help 
      to reduce the risk of adverse consequences.
CI  - Crown Copyright (c) 2020. Published by Elsevier Ltd. All rights reserved.
FAU - Stavert, Jill
AU  - Stavert J
AD  - Centre for Mental Health and Capacity Law, Edinburgh Napier University, Scotland,
      UK. Electronic address: j.stavert@napier.ac.uk.
FAU - McKay, Colin
AU  - McKay C
AD  - Centre for Mental Health and Capacity Law, Edinburgh Napier University, Scotland,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Human Rights/*legislation & jurisprudence
MH  - Humans
MH  - Mental Competency/*legislation & jurisprudence
MH  - Mental Health/*legislation & jurisprudence
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Scotland/epidemiology
PMC - PMC7305488
OTO - NOTNLM
OT  - *COVID-19
OT  - *Emergency measures
OT  - *Human rights
OT  - *Mental health and capacity law
OT  - *Scotland
EDAT- 2020/08/10 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - S0160-2527(20)30052-2 [pii]
AID - 10.1016/j.ijlp.2020.101593 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Jul - Aug;71:101593. doi: 10.1016/j.ijlp.2020.101593. 
      Epub 2020 Jun 20.


PMID- 32767988
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 7
TI  - A single-center, randomized, non-inferiority study evaluating seroma formation
      after mastectomy combined with flap fixation with or without suction drainage:
      protocol for the Seroma reduction and drAin fRee mAstectomy (SARA) trial.
PG  - 735
LID - 10.1186/s12885-020-07242-0 [doi]
AB  - BACKGROUND: Seroma formation is a common complication after breast cancer surgery
      and can lead to delayed wound healing, infection, patient discomfort and repeated
      visits to the outpatient clinic. Mastectomy combined with flap fixation is
      becoming standard practice and is currently combined with closed-suction
      drainage. There is evidence showing that closed-suction drainage may be
      insufficient in preventing seroma formation. There is reasonable doubt whether
      there is still place for closed-suction drainage after mastectomy when flap
      fixation is performed. We hypothesize that mastectomy combined with flap fixation
      and closed suction drainage does not cause a significant lower incidence of
      seroma aspirations, when compared to mastectomy and flap fixation alone.
      Furthermore, we expect that patients without drainage will experience
      significantly less discomfort and comparable rates of surgical site infections.
      METHODS: This is a randomized controlled trial in female breast cancer patients
      undergoing mastectomy and flap fixation using sutures with or without sentinel
      lymph node biopsy (SLNB). Patients will be eligible for inclusion if they are
      older than 18 years, have an indication for mastectomy with or without sentinel
      procedure. Exclusion criteria are modified radical mastectomy, direct breast
      reconstruction, previous history of radiation therapy of the unilateral breast,
      breast conserving therapy and inability to give informed consent. A total of 250 
      patients will be randomly allocated to one of two groups: mastectomy combined
      with flap fixation and closed-suction drainage or mastectomy combined with flap
      fixation without drainage. Follow-up will be conducted up to six months
      postoperatively. The primary outcome is the proportion of patients undergoing one
      or more seroma aspirations. Secondary outcome measures consist of the number of
      invasive interventions, surgical site infection, quality of life measured using
      the SF-12 Health Survey, cosmesis, pain and number of additional outpatient
      department visits. DISCUSSION: To our knowledge, no randomized controlled trial
      has been conducted comparing flap fixation with and without closed-suction
      drainage with seroma aspiration as the primary outcome. This study could result
      in finding evidence that supports performing mastectomy without closed-suction
      drainage. TRIAL REGISTRATION: This trial was approved by the medical ethical
      committee of Zuyderland Medical Center METC-Z on 20 March 2019 (METCZ20190023).
      The SARA Trial was registered at ClinicalTrials.gov as per July 2019, Identifier:
      NCT04035590 .
FAU - de Rooij, Lisa
AU  - de Rooij L
AUID- ORCID: http://orcid.org/0000-0002-7859-5986
AD  - Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB,
      Sittard, the Netherlands. l.derooij@zuyderland.nl.
FAU - van Kuijk, Sander M J
AU  - van Kuijk SMJ
AD  - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht
      University Medical Center, Maastricht, the Netherlands.
FAU - van Haaren, Els R M
AU  - van Haaren ERM
AD  - Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB,
      Sittard, the Netherlands.
FAU - Janssen, Alfred
AU  - Janssen A
AD  - Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB,
      Sittard, the Netherlands.
FAU - Vissers, Yvonne L J
AU  - Vissers YLJ
AD  - Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB,
      Sittard, the Netherlands.
FAU - Beets, Geerard L
AU  - Beets GL
AD  - Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
AD  - GROW School for Oncology and Developmental Biology, University of Maastricht,
      Maastricht, the Netherlands.
FAU - van Bastelaar, James
AU  - van Bastelaar J
AD  - Department of Surgery, Zuyderland Medical Center, Postbus 5500, 6130, MB,
      Sittard, the Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT04035590
PT  - Clinical Trial Protocol
PT  - Equivalence Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200807
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Mastectomy/adverse effects/*methods
MH  - Netherlands
MH  - Outcome Assessment, Health Care
MH  - Postoperative Complications/etiology/*therapy
MH  - Sample Size
MH  - Sentinel Lymph Node Biopsy
MH  - Seroma/etiology/*therapy
MH  - Suction
MH  - Surgical Flaps/*transplantation
MH  - Suture Techniques
PMC - PMC7412663
OTO - NOTNLM
OT  - Drain free
OT  - Flap fixation
OT  - Mastectomy
OT  - Seroma
EDAT- 2020/08/10 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 10.1186/s12885-020-07242-0 [doi]
AID - 10.1186/s12885-020-07242-0 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Aug 7;20(1):735. doi: 10.1186/s12885-020-07242-0.


PMID- 32767971
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 7
TI  - Intraoperative cell salvage for obstetrics: a prospective randomized controlled
      clinical trial.
PG  - 452
LID - 10.1186/s12884-020-03138-w [doi]
AB  - BACKGROUND: The latest basic studies and clinical evidence have confirmed the
      safety and efficacy of intraoperative autologous blood cell transfusion in
      cardiac surgery and orthopaedics. However, in caesarean section, there are still 
      concerns about the contamination of amniotic fluid and foetal components, and
      consequently the application of intraoperative autologous blood cell transfusion 
      is not universal. Therefore, this study aimed to evaluate the clinical value of
      intraoperative autologous blood cell transfusion in obstetric surgery. METHODS: A
      prospective, randomized, controlled, feasibility study was performed in women
      undergoing caesarean section. One hundred sixteen participants were randomly
      assigned at a 1:1 ratio into either the intraoperative cell salvage group or the 
      control group. Allogeneic blood cells were transfused into patients with
      haemoglobin concentrations < 80 g/dL in both the intraoperative cell salvage
      group and the control group. RESULTS: No significant differences were found
      between the two groups in age, weight, maternal parity, history of previous
      caesarean section, gestational weeks of delivery, etc. However, compared with the
      control group, patients in the intraoperative cell salvage group had a
      significantly lower amount of allogeneic blood cell transfusion, lower incidence 
      of postoperative incision infection, delayed wound healing, perioperative
      allergy, adverse cardiovascular events, hypoproteinaemia and shorter hospital
      stay. CONCLUSION: The results of this study suggest that the use of autologous
      blood cell transfusion is safe and effective for patients with obstetric
      haemorrhage. TRIAL REGISTRATION: All procedures performed in studies involving
      human participants were in accordance with the ethical standards of the
      Institutional and/or National Research Committee of Beijing Obstetrics and
      Gynecology Hospital, Capital Medical University (2016-XJS-003-01) as well as the 
      1964 Helsinki Declaration and its later amendments or other comparable ethical
      standards. The clinical trials were registered (ChiCTR-ICC-15,007,096) on
      September 28, 2015.
FAU - Liu, Ye
AU  - Liu Y
AD  - Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital,
      Capital Medical University, 100026, Beijing, China.
FAU - Li, Xiaoguang
AU  - Li X
AD  - Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital,
      Capital Medical University, 100026, Beijing, China.
FAU - Che, Xiangming
AU  - Che X
AD  - Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital,
      Capital Medical University, 100026, Beijing, China.
FAU - Zhao, Guosheng
AU  - Zhao G
AD  - Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital,
      Capital Medical University, 100026, Beijing, China.
FAU - Xu, Mingjun
AU  - Xu M
AD  - Department of Anaesthesiology, Beijing Obstetrics and Gynecology Hospital,
      Capital Medical University, 100026, Beijing, China. snake650222@126.com.
LA  - eng
GR  - FCYY201904/Beijing Obstetrics and Gynecology Hospital
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200807
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adult
MH  - Blood Cells
MH  - *Blood Transfusion, Autologous
MH  - *Cesarean Section
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - *Operative Blood Salvage
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7412832
OTO - NOTNLM
OT  - Adverse events
OT  - Allogeneic blood transfusion
OT  - Caesarean section
OT  - Intraoperative cell salvage
OT  - Postpartum haemorrhage
EDAT- 2020/08/10 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
AID - 10.1186/s12884-020-03138-w [doi]
AID - 10.1186/s12884-020-03138-w [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Aug 7;20(1):452. doi: 10.1186/s12884-020-03138-w.


PMID- 32767661
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec
TI  - Coculture techniques for modeling retinal development and disease, and enabling
      regenerative medicine.
PG  - 1531-1548
LID - 10.1002/sctm.20-0201 [doi]
AB  - Stem cell-derived retinal organoids offer the opportunity to cure retinal
      degeneration of wide-ranging etiology either through the study of in vitro models
      or the generation of tissue for transplantation. However, despite much work in
      animals and several human pilot studies, satisfactory therapies have not been
      developed. Two major challenges for retinal regenerative medicine are (a)
      physical cell-cell interactions, which are critical to graft function, are not
      formed and (b) the host environment does not provide suitable queues for
      development. Several strategies offer to improve the delivery, integration,
      maturation, and functionality of cell transplantation. These include minimally
      invasive delivery, biocompatible material vehicles, retinal cell sheets, and
      optogenetics. Optimizing several variables in animal models is practically
      difficult, limited by anatomical and disease pathology which is often different
      to humans, and faces regulatory and ethical challenges. High-throughput methods
      are needed to experimentally optimize these variables. Retinal organoids will be 
      important to the success of these models. In their current state, they do not
      incorporate a representative retinal pigment epithelium (RPE)-photoreceptor
      interface nor vascular elements, which influence the neural retina phenotype
      directly and are known to be dysfunctional in common retinal diseases such as
      age-related macular degeneration. Advanced coculture techniques, which emulate
      the RPE-photoreceptor and RPE-Bruch's-choriocapillaris interactions, can
      incorporate disease-specific, human retinal organoids and overcome these
      drawbacks. Herein, we review retinal coculture models of the neural retina, RPE, 
      and choriocapillaris. We delineate the scientific need for such systems in the
      study of retinal organogenesis, disease modeling, and the optimization of
      regenerative cell therapies for retinal degeneration.
CI  - (c) 2020 The Authors. STEM CELLS Translational Medicine published by Wiley
      Periodicals LLC on behalf of AlphaMed Press.
FAU - Ghareeb, Ali E
AU  - Ghareeb AE
AUID- ORCID: 0000-0002-8552-3139
AD  - Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust,
      Sunderland, UK.
AD  - Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK.
FAU - Lako, Majlinda
AU  - Lako M
AD  - Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK.
FAU - Steel, David H
AU  - Steel DH
AD  - Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust,
      Sunderland, UK.
AD  - Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK.
LA  - eng
GR  - MC_PC_15030/MRC_/Medical Research Council/United Kingdom
GR  - MR/T017503/1/MRC_/Medical Research Council/United Kingdom
GR  - NC/C016106/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction
      of Animals in Research/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200807
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
SB  - IM
MH  - Coculture Techniques/*methods
MH  - Humans
MH  - Regenerative Medicine/*methods
MH  - Retina/*pathology
MH  - Retinal Degeneration/*therapy
PMC - PMC7695644
OTO - NOTNLM
OT  - *biocompatible materials
OT  - *cell transplantation
OT  - *coculture techniques
OT  - *microphysiological systems
OT  - *organ culture techniques
OT  - *organ-on-a-chip
OT  - *organoids
OT  - *retina
OT  - *retinal degeneration
OT  - *tissue transplantation
EDAT- 2020/08/09 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/06/22 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - 10.1002/sctm.20-0201 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2020 Dec;9(12):1531-1548. doi: 10.1002/sctm.20-0201. Epub 
      2020 Aug 7.


PMID- 32767598
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
VI  - 76
IP  - 10
DP  - 2020 Oct
TI  - Conflict in nursing studies: A bibliometric analysis of the top 100 cited papers.
PG  - 2531-2546
LID - 10.1111/jan.14463 [doi]
AB  - AIM: This study aimed to identify and investigate the main characteristics of the
      top 100 most cited studies on conflict in published in nursing category in the
      Web of Science database using bibliometric and social network analysis methods.
      DESIGN: A retrospective bibliometric analysis was used. METHODS: The study data
      were obtained from the Web of Science (WoS) database. The top 100 studies with
      the highest number of citations were included in the study. The study data were
      analysed with Excel and SPSS and they were visualized with VOSviewer. RESULTS: It
      was concluded that the studies in the research were published in 38 different
      journals between 1974-2019 and they were conducted by 245 different authors from 
      24 different countries. It was further reported that the Journal of Advanced
      Nursing was the most productive journal and the USA was the most productive
      country. The most commonly used keywords were "nurse," "conflict," "nursing,"
      "job satisfaction," "work-family conflict" and "ethical conflict." CONCLUSION:
      The issue of conflict is a growing field of scientific study for nursing
      researchers. The quality of researches will be certainly enhanced in future with 
      the studies published in journals with high impact factors. IMPACT: The research 
      of the top 100 most cited paper is a new and innovative bibliometric approach to 
      understand nursing literature. There is very little information about the
      development, structure and characteristics of the existing mass of knowledge on
      conflict in nursing studies. The study findings establish a basis of information 
      for planning further studies and providing guidance. In addition, this study
      provides researchers, scientific journals, institutions and countries with an
      opportunity to assess and compare their own performance in conflict literature in
      nursing studies. However, the fact that the most cited studies in the field of
      conflict in nursing is in demand by journals with high impact factor is a source 
      of motivation for researchers studying in this field.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Kantek, Filiz
AU  - Kantek F
AUID- ORCID: https://orcid.org/0000-0002-1524-9824
AD  - Department of Nursing Management, Faculty of Nursing, Akdeniz University,
      Antalya, Turkey.
FAU - Yesilbas, Hande
AU  - Yesilbas H
AUID- ORCID: https://orcid.org/0000-0003-1388-221X
AD  - Department of Nursing Management, Faculty of Nursing, Akdeniz University,
      Antalya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
MH  - *Bibliometrics
MH  - Humans
MH  - *Publications
MH  - Research Design
MH  - Research Report
MH  - Retrospective Studies
OTO - NOTNLM
OT  - bibliometric analysis
OT  - bibliometry
OT  - conflict
OT  - nurse
OT  - nursing
OT  - social network analysis
EDAT- 2020/08/09 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/09 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - 10.1111/jan.14463 [doi]
PST - ppublish
SO  - J Adv Nurs. 2020 Oct;76(10):2531-2546. doi: 10.1111/jan.14463. Epub 2020 Aug 7.


PMID- 32767423
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 60
IP  - 9
DP  - 2020 Sep
TI  - Discarded plasma obtained after cord blood volume reduction as an alternative for
      fetal calf serum in mesenchymal stromal cells cultures.
PG  - 1910-1917
LID - 10.1111/trf.15920 [doi]
AB  - BACKGROUND: Utilization of the fetal calf serum (FCS) carries a potential health 
      risk and raises growing economic and ethical problems. Umbilical cord blood
      volume reduction, required for banking, provides clinical-grade umbilical cord
      blood plasma (UCBP) discarded as a waste. The aim of this study was to test
      whether serum derived from UCBP could replace FCS for the amplification of
      mesenchymal stromal cells (MSCs). STUDY DESIGN AND METHODS: To this end, the
      amplification of the MSCs and mesenchymal progenitors was estimated in the
      presence of serum derived from UCBP and its cytokine content was determined by
      cytometric bead array and enzyme-linked immunosorbent assay techniques. As a
      comparison, other sources of clinical-grade human serum were tested in parallel: 
      serum derived from solvent/detergent-treated fresh-frozen plasma (S/D-FFP) and
      from platelet (PLT)-rich and PLT-poor umbilical plasma. RESULTS: Serum derived
      from UCBP-supplemented culture sustains identical amplification of MSCs and their
      progenitors as in the case of FCS addition. Furthermore, the assays reveal the
      presence in the serum derived from UCBP of cytokines influencing the properties
      of MSCs (basic fibroblast growth factor, transforming growth factor-beta,
      vascular endothelial growth factor, and interleukin-8) or involved in the
      development of the myeloid lineage (thrombopoietin, erythropoietin,
      granulocyte-colony-stimulating factor, and
      granulocyte-macrophage-colony-stimulating factor). Also, our study indicates
      important differences between neonatal and adult-derived serum. Poor cytokine
      content in the S/D-FFP makes a less efficient replacement of FCS comparing to
      other human blood-derived supplements. CONCLUSION: Our work shows that the
      discarded human cord blood plasma from volume reduction is an easily obtainable
      and greatly available, xeno-free source of serum that is a highly efficient
      replacement of FCS in sustaining MSC growth.
CI  - (c) 2020 AABB.
FAU - Vlaski-Lafarge, Marija
AU  - Vlaski-Lafarge M
AD  - Etablissement Francais du Sang Nouvelle-Aquitaine, Bordeaux, France.
AD  - INSERM U1035 University of Bordeaux, Bordeaux, France.
FAU - Chevaleyre, Jean
AU  - Chevaleyre J
AD  - Etablissement Francais du Sang Nouvelle-Aquitaine, Bordeaux, France.
FAU - Cohen, Julie
AU  - Cohen J
AD  - Etablissement Francais du Sang Nouvelle-Aquitaine, Bordeaux, France.
FAU - Ivanovic, Zoran
AU  - Ivanovic Z
AD  - Etablissement Francais du Sang Nouvelle-Aquitaine, Bordeaux, France.
AD  - INSERM U1035 University of Bordeaux, Bordeaux, France.
FAU - Lafarge, Xavier
AU  - Lafarge X
AUID- ORCID: 0000-0002-1190-5601
AD  - Etablissement Francais du Sang Nouvelle-Aquitaine, Bordeaux, France.
AD  - INSERM U1035 University of Bordeaux, Bordeaux, France.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Culture Media)
RN  - 27432CM55Q (Serum Albumin, Bovine)
SB  - IM
MH  - *Cell Culture Techniques
MH  - Culture Media/*chemistry
MH  - Fetal Blood/*chemistry
MH  - Humans
MH  - *Mesenchymal Stem Cells/cytology/metabolism
MH  - Plasma/*chemistry
MH  - Serum Albumin, Bovine
EDAT- 2020/08/09 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/08/09 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - 10.1111/trf.15920 [doi]
PST - ppublish
SO  - Transfusion. 2020 Sep;60(9):1910-1917. doi: 10.1111/trf.15920. Epub 2020 Aug 6.


PMID- 32767419
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1744-6198 (Electronic)
IS  - 0029-6473 (Linking)
VI  - 55
IP  - 4
DP  - 2020 Nov
TI  - Promoting civility in nursing practice using systems thinking: Evidence-based
      teaching strategies for nurse educators.
PG  - 754-762
LID - 10.1111/nuf.12493 [doi]
AB  - There is a critical need for nurse educators to promote civility in nursing
      practice using systems thinking to promote quality and safety and improve patient
      outcomes by preventing undue patient harm. In this article, evidence is
      synthesized in order that readers can recognize, respond and manage workplace
      incivility. Systems thinking is introduced as a best practice solution for
      advancing a civil workplace culture. The author-created Systems Awareness Model, 
      adapted for civility awareness, guides nurse educators with evidence-based
      strategies for teaching nurses the essential skills to promoting a civility
      culture within health systems. The strategies can be used by nurse educators in
      practice to interface workplace application. Proposed examples of evaluation
      methods are aligned with the teaching strategies. The purpose of this article is 
      to provide nurse educators in practice with evidence-based teaching strategies
      and evaluation methods to address incivility in health care using a systems
      thinking perspective.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Stalter, Ann M
AU  - Stalter AM
AUID- ORCID: https://orcid.org/0000-0001-8975-2695
AD  - Wright State University College of Nursing and Health, Dayton, Ohio.
FAU - Phillips, Janet M
AU  - Phillips JM
AUID- ORCID: http://orcid.org/0000-0001-8718-1585
AD  - Indiana University School of Nursing, Indianapolis, Indiana.
FAU - Goldschmidt, Karen A
AU  - Goldschmidt KA
AUID- ORCID: https://orcid.org/0000-0003-0380-8024
AD  - College of Nursing and Health Professions, Drexel University, Philadelphia,
      Pennsylvania.
FAU - Brodhead, Josette
AU  - Brodhead J
AUID- ORCID: https://orcid.org/0000-0001-7610-6205
AD  - Department of Nursing, Daemen College, Amherst, New York.
FAU - Ruggiero, Jeanne S
AU  - Ruggiero JS
AUID- ORCID: https://orcid.org/0000-0002-4540-5568
AD  - Nursing Department, New Jersey City University, Scotch Plains, New Jersey.
FAU - Scardaville, Debra L
AU  - Scardaville DL
AD  - New Jersey City University, Jersey City, New Jersey.
FAU - McKay, Mary
AU  - McKay M
AUID- ORCID: https://orcid.org/0000-0002-0252-4620
AD  - University of Miami School of Nursing and Health Studies, Coral Gables, Florida.
FAU - Bonnett, Pamela L
AU  - Bonnett PL
AD  - University of Akron, Akron, Ohio.
FAU - Merriam, Deborah
AU  - Merriam D
AUID- ORCID: https://orcid.org/0000-0002-8928-8009
AD  - Department of Nursing, Daemen College, Amherst, New York.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - United States
TA  - Nurs Forum
JT  - Nursing forum
JID - 0401006
MH  - Education, Nursing, Baccalaureate/methods/standards/trends
MH  - Evidence-Based Practice/methods
MH  - Faculty, Nursing/*education/psychology/standards
MH  - Humans
MH  - Incivility/*prevention & control
MH  - Nursing/methods/*standards/trends
MH  - *Systems Analysis
OTO - NOTNLM
OT  - abuse/bullying/harassment/incivility
OT  - education
OT  - educator
OT  - ethics/moral courage
OT  - leadership
EDAT- 2020/08/09 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - 10.1111/nuf.12493 [doi]
PST - ppublish
SO  - Nurs Forum. 2020 Nov;55(4):754-762. doi: 10.1111/nuf.12493. Epub 2020 Aug 6.


PMID- 32767271
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20201218
IS  - 1920-7476 (Electronic)
IS  - 0008-4263 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Aug
TI  - Ethics of COVID-19-related school closures.
PG  - 462-465
LID - 10.17269/s41997-020-00396-1 [doi]
AB  - COVID-19 mitigation strategies have led to widespread school closures around the 
      world. Initially, these were undertaken based on data from influenza outbreaks in
      which children were highly susceptible and important in community-wide
      transmission. An argument was made that school closures were necessary to prevent
      harm to vulnerable adults, especially the elderly. Although data are still
      accumulating, the recently described complication, pediatric multisystem
      inflammatory syndrome, is extremely rare and children remain remarkably
      unaffected by COVID-19. We also do not have evidence that children are
      epidemiologically important in community-wide viral spread. Previous studies have
      shown long-term educational, social, and medical harms from school exclusion,
      with very young children and those from marginalized groups such as immigrants
      and racialized minorities most affected. The policy and ethical implications of
      ongoing mandatory school closures, in order to protect others, need urgent
      reassessment in light of the very limited data of public health benefit.
FAU - Silverman, Michael
AU  - Silverman M
AUID- ORCID: 0000-0002-0389-7656
AD  - Division of Infectious Diseases, Western University, London, Ontario, Canada.
      Michael.Silverman@sjhc.london.on.ca.
AD  - Department of Epidemiology and Biostatistics, Western University, London,
      Ontario, Canada. Michael.Silverman@sjhc.london.on.ca.
FAU - Sibbald, Robert
AU  - Sibbald R
AD  - Division of Medical Bioethics, Department of Family Practice, London Health
      Sciences Centre, London, Ontario, Canada.
FAU - Stranges, Saverio
AU  - Stranges S
AD  - Department of Epidemiology and Biostatistics, Western University, London,
      Ontario, Canada.
AD  - Department of Family Medicine, Western University, London, Ontario, Canada.
AD  - Department of Population Health, Luxembourg Institute of Health, Strassen,
      Luxembourg.
LA  - eng
PT  - Journal Article
DEP - 20200807
PL  - Switzerland
TA  - Can J Public Health
JT  - Canadian journal of public health = Revue canadienne de sante publique
JID - 0372714
SB  - IM
MH  - COVID-19
MH  - Canada/epidemiology
MH  - Child
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - *Health Policy
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health Practice/*ethics
MH  - Schools/*organization & administration
PMC - PMC7412780
OTO - NOTNLM
OT  - *COVID-19
OT  - *Child
OT  - *Ethics
OT  - *School closure
EDAT- 2020/08/09 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/06/18 00:00 [received]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - 10.17269/s41997-020-00396-1 [doi]
AID - 10.17269/s41997-020-00396-1 [pii]
PST - ppublish
SO  - Can J Public Health. 2020 Aug;111(4):462-465. doi: 10.17269/s41997-020-00396-1.
      Epub 2020 Aug 7.


PMID- 32766894
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1432-5241 (Electronic)
IS  - 0364-216X (Linking)
VI  - 44
IP  - 4
DP  - 2020 Aug
TI  - Aesthetic/Cosmetic Surgery and Ethical Challenges: The Social Media Era.
PG  - 1375-1377
LID - 10.1007/s00266-020-01765-4 [doi]
FAU - Atiyeh, B
AU  - Atiyeh B
AD  - , Beirut, Lebanon. bechara.atieh@gmail.com.
FAU - Ibrahim, A
AU  - Ibrahim A
AD  - , Beirut, Lebanon.
LA  - eng
PT  - Editorial
PL  - United States
TA  - Aesthetic Plast Surg
JT  - Aesthetic plastic surgery
JID - 7701756
SB  - IM
MH  - *Cosmetic Techniques
MH  - Esthetics
MH  - Humans
MH  - *Social Media
MH  - *Surgery, Plastic
EDAT- 2020/08/09 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - 10.1007/s00266-020-01765-4 [doi]
AID - 10.1007/s00266-020-01765-4 [pii]
PST - ppublish
SO  - Aesthetic Plast Surg. 2020 Aug;44(4):1375-1377. doi: 10.1007/s00266-020-01765-4.


PMID- 32766329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Opportunities and challenges of social media for health knowledge management: A
      narrative review.
PG  - 144
LID - 10.4103/jehp.jehp_754_19 [doi]
AB  - INTRODUCTION: Social media is becoming a new tool for developing health knowledge
      management. However, despite the rapid growth of research in this area, few
      attempts have been made to review previous research. This study tried to
      summarize the opportunities and challenges of using social media to managing
      health knowledge. METHODOLOGY: This article used a narrative approach to collect 
      and review studies. In this review, published documents during 2010-2019 were
      retrieved by search in the following three electronic scientific databases: Web
      of Knowledge, PubMed, and Google Scholar search engine using keywords including
      social media, public health, health knowledge, knowledge management, and health
      promotion. RESULTS: Social media by overcoming geographical barriers, developing 
      health promotion, facilitating decision-making, and providing public health
      education has been able to enhancing health awareness and improving health
      behavior. Doctors' unwillingness to interact with the public, lack of compliance 
      with the principles of medical ethics, users' privacy concerns, and difficulty of
      managing negative comments are the four challenges to health knowledge management
      in social media. CONCLUSION: Social media can be a suitable tool for developing
      health knowledge management processes if medical professional ethics and users'
      privacy managed properly.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Ghalavand, Hossein
AU  - Ghalavand H
AD  - Department of Medical Library and Information Science, School of Health
      Management and Information Sciences, Iran University of Medical Sciences, Abadan,
      Iran.
AD  - Department of Medical Library and Information Science, Abadan Faculty of Medical 
      Sciences, Abadan.
FAU - Panahi, Sirous
AU  - Panahi S
AD  - Department of Medical Library and Information Science, School of Health
      Management and Information Sciences, Iran University of Medical Sciences, Abadan,
      Iran.
AD  - Department of Medical Library and Information Science, Health Management and
      Economics Research Center, School of Health Management and Information Sciences, 
      Iran University of Medical Sciences, Tehran, Iran.
FAU - Sedghi, Shahram
AU  - Sedghi S
AD  - Department of Medical Library and Information Science, School of Health
      Management and Information Sciences, Iran University of Medical Sciences, Abadan,
      Iran.
AD  - Department of Medical Library and Information Science, Health Management and
      Economics Research Center, School of Health Management and Information Sciences, 
      Iran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7377150
OTO - NOTNLM
OT  - Health communication
OT  - health knowledge
OT  - health promotion
OT  - knowledge management
OT  - public health
OT  - social media
OT  - technology
COIS- There are no conflicts of interest.
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2019/12/28 00:00 [received]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.4103/jehp.jehp_754_19 [doi]
AID - JEHP-9-144 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Jun 30;9:144. doi: 10.4103/jehp.jehp_754_19.
      eCollection 2020.


PMID- 32766204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-2646 (Print)
IS  - 2296-2646 (Linking)
VI  - 8
DP  - 2020
TI  - How to Study the Metabolism of New Psychoactive Substances for the Purpose of
      Toxicological Screenings-A Follow-Up Study Comparing Pooled Human Liver S9,
      HepaRG Cells, and Zebrafish Larvae.
PG  - 539
LID - 10.3389/fchem.2020.00539 [doi]
AB  - The new psychoactive substances (NPS) market continues to be very dynamic. A
      large number of compounds belonging to diverse chemical groups continue to
      emerge. This makes their detection in biological samples challenging for clinical
      and forensic toxicologists. Knowledge of the metabolic fate of NPS is crucial for
      developing comprehensive screening procedures. As human studies are not feasible 
      due to ethical concerns, the current study aimed to compare the NPS' metabolic
      pattern in incubations with pooled human liver S9 fraction (pHLS9), human liver
      HepaRG cells, and zebrafish larvae. The latter model was recently shown to be a
      promising preclinical surrogate for human hepatic metabolism of a synthetic
      cannabinoid. However, studies concerning other NPS classes are still missing and 
      therefore an amphetamine-based N-methoxybenzyl (NBOMe) compound, a synthetic
      cathinone, a pyrrolidinophenone analog, a lysergamide, as well as another
      synthetic cannabinoid were included in the current study. Liquid chromatography
      coupled to Orbitrap-based high-resolution tandem mass spectrometry was used to
      analyze metabolic data. Zebrafish larvae were found to produce the highest number
      of phase I but also phase II metabolites (79 metabolites in total), followed by
      HepaRG cells (66 metabolites). Incubations with pHLS9 produced the least
      metabolites (57 metabolites). Furthermore, the involvement of monooxygenases and 
      esterases in the metabolic phase I transformations of 4F-MDMB-BINACA was
      elucidated using single-enzyme incubations. Several cytochrome P450 (CYP)
      isozymes were shown to contribute, and CYP3A5 was involved in all CYP-catalyzed
      reactions, while amide and ester hydrolysis were catalyzed by the human
      carboxylesterase (hCES) isoforms hCES1b and/or hCES1c. Finally, metabolites were 
      compared to those present in human biosamples if data were available. Overall,
      the metabolic patterns in HepaRG cells provided the worst overlap with that in
      human biosamples. Zebrafish larvae experiments agreed best with data found in
      human plasma and urine analysis. The current study underlines the potential of
      zebrafish larvae as a tool for elucidating the toxicokinetics of NPS in the
      future.
CI  - Copyright (c) 2020 Wagmann, Frankenfeld, Park, Herrmann, Fischmann, Westphal,
      Muller, Flockerzi and Meyer.
FAU - Wagmann, Lea
AU  - Wagmann L
AD  - Department of Experimental and Clinical Toxicology, Institute of Experimental and
      Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS),
      Saarland University, Homburg, Germany.
FAU - Frankenfeld, Fabian
AU  - Frankenfeld F
AD  - Department of Experimental and Clinical Toxicology, Institute of Experimental and
      Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS),
      Saarland University, Homburg, Germany.
FAU - Park, Yu Mi
AU  - Park YM
AD  - Department of Microbial Natural Products (MINS), Helmholtz Institute for
      Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrucken,
      Germany.
AD  - Environmental Safety Group, Korea Institute of Science and Technology (KIST)
      Europe, Saarbrucken, Germany.
FAU - Herrmann, Jennifer
AU  - Herrmann J
AD  - Department of Microbial Natural Products (MINS), Helmholtz Institute for
      Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrucken,
      Germany.
AD  - German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 
      Saarbrucken, Germany.
FAU - Fischmann, Svenja
AU  - Fischmann S
AD  - State Bureau of Criminal Investigation Schleswig-Holstein, Kiel, Germany.
FAU - Westphal, Folker
AU  - Westphal F
AD  - State Bureau of Criminal Investigation Schleswig-Holstein, Kiel, Germany.
FAU - Muller, Rolf
AU  - Muller R
AD  - Department of Microbial Natural Products (MINS), Helmholtz Institute for
      Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrucken,
      Germany.
AD  - German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 
      Saarbrucken, Germany.
FAU - Flockerzi, Veit
AU  - Flockerzi V
AD  - Department of Experimental and Clinical Pharmacology, Institute of Experimental
      and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), 
      Saarland University, Homburg, Germany.
FAU - Meyer, Markus R
AU  - Meyer MR
AD  - Department of Experimental and Clinical Toxicology, Institute of Experimental and
      Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS),
      Saarland University, Homburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Switzerland
TA  - Front Chem
JT  - Frontiers in chemistry
JID - 101627988
PMC - PMC7380166
OTO - NOTNLM
OT  - LC-HRMS/MS
OT  - drugs of abuse
OT  - isozyme mapping
OT  - metabolism study
OT  - toxicological screening
OT  - zebrafish
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3389/fchem.2020.00539 [doi]
PST - epublish
SO  - Front Chem. 2020 Jul 17;8:539. doi: 10.3389/fchem.2020.00539. eCollection 2020.


PMID- 32766195
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Editorial: Patient Safety: Delivering Cost-Contained, High Quality,
      Person-Centered, and Safe Healthcare.
PG  - 288
LID - 10.3389/fpubh.2020.00288 [doi]
FAU - Buttigieg, Sandra C
AU  - Buttigieg SC
AD  - Department of Health Services Management, Faculty of Health Sciences, University 
      of Malta, Msida, Malta.
FAU - Tomaselli, Gianpaolo
AU  - Tomaselli G
AD  - Department of Health Services Management, Faculty of Health Sciences, University 
      of Malta, Msida, Malta.
FAU - von Eiff, Wilfried
AU  - von Eiff W
AD  - Center for Hospital Management, University of Muunster, Muunster, Germany.
FAU - Byers, Vivienne
AU  - Byers V
AD  - Department of General Practice, HRB Centre for Primary Care Research, Royal
      College of Surgeons in Ireland, Dublin, Ireland.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
DEP - 20200714
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Delivery of Health Care
MH  - Health Facilities
MH  - Humans
MH  - *Patient-Centered Care
MH  - *Self Care
PMC - PMC7381138
OTO - NOTNLM
OT  - *decision-making
OT  - *economic efficiency
OT  - *ethics
OT  - *innovation
OT  - *patient safety
OT  - *person-centered care (PCC)
OT  - *technology
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3389/fpubh.2020.00288 [doi]
PST - epublish
SO  - Front Public Health. 2020 Jul 14;8:288. doi: 10.3389/fpubh.2020.00288.
      eCollection 2020.


PMID- 32765846
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 57
DP  - 2020 Sep
TI  - Surgical consent during the COVID19 pandemic: Saving lives while in crisis
      editorial.
PG  - 163-165
LID - 10.1016/j.amsu.2020.07.039 [doi]
AB  - *Compares obtaining informed consent from a non-COVID-19 patient versus a
      COVID-19 person under investigation or confirmed positive in order to maintain
      healthcare workers safety and minimize PPE use.*Explains the use of technology in
      the form of video chat to aid in informed consent from healthcare surrogates of
      patients who are unable to provide their own informed consent.*Discusses
      alternative solutions to obtaining informed consent from a COVID-19 person under 
      investigation or confirmed positive.
CI  - (c) 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd.
FAU - Meneses, Evander
AU  - Meneses E
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
FAU - McKenney, Mark
AU  - McKenney M
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
AD  - University of South Florida, Tampa, FL, USA.
FAU - Boneva, Dessy
AU  - Boneva D
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
AD  - University of South Florida, Tampa, FL, USA.
FAU - Elkbuli, Adel
AU  - Elkbuli A
AD  - Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall
      Regional Medical Center, Miami, FL, USA.
LA  - eng
PT  - Editorial
DEP - 20200726
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7382928
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - Emergency surgery
OT  - Medical ethics
OT  - Surgical consent
OT  - Trauma surgery
COIS- Authors declare no competing interests.
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/06/28 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/07/18 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.1016/j.amsu.2020.07.039 [doi]
AID - S2049-0801(20)30221-1 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Jul 26;57:163-165. doi: 10.1016/j.amsu.2020.07.039.
      eCollection 2020 Sep.


PMID- 32765770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Sep
TI  - Bone marrow stromal cells-derived exosomes target DAB2IP to induce microglial
      cell autophagy, a new strategy for neural stem cell transplantation in brain
      injury.
PG  - 2752-2764
LID - 10.3892/etm.2020.9008 [doi]
AB  - Bone marrow stromal cells (MSCs) are a useful source of stem cells for the
      treatment of various brain injury diseases due to their abundant supply and fewer
      ethical problems compared with transplant treatment. However, the clinical
      application of MSCs is limited due to allograft rejection and immunosuppression
      in the process of MSCs transplantation. According to previous studies, microglial
      cell autophagy occurs following co-culture with MSCs. In the present study,
      exosomes were obtained from MSCs and subsequently characterized using
      transmission electron microscopy, atomic force microscopy and dynamic light
      scattering particle size analysis. The type of microRNAs (miRs) found in the
      exosomes was then analyzed via gene chip. The results demonstrated that
      microglial cell autophagy could be induced by exosomes. This mechanism was
      therefore investigated further via reverse transcription-quantitative PCR,
      western blotting and luciferase assays. These results demonstrated that exosomes 
      from MSCs could induce microglial cell autophagy through the miR-32-mediated
      regulation of disabled homolog 2-interacting protein, thus providing a
      theoretical basis for the clinical application of miRs in MSCs.
CI  - Copyright: (c) Yuan et al.
FAU - Yuan, Feng-Ying
AU  - Yuan FY
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital, Jinan
      University, Guangzhou, Guangdong 510632, P.R. China.
AD  - Department of Rehabilitation Medicine The First Affiliated Hospital, Guangdong
      Pharmaceutical University, Guangzhou, Guangdong 510600, P.R. China.
FAU - Zhang, Ming-Xing
AU  - Zhang MX
AD  - Department of Rehabilitation Medicine The First Affiliated Hospital, Guangdong
      Pharmaceutical University, Guangzhou, Guangdong 510600, P.R. China.
FAU - Shi, Yi-Hua
AU  - Shi YH
AD  - Department of Rehabilitation Medicine The First Affiliated Hospital, Guangdong
      Pharmaceutical University, Guangzhou, Guangdong 510600, P.R. China.
FAU - Li, Mei-Hui
AU  - Li MH
AD  - Department of Rehabilitation Medicine, Guangdong Provincial People's Hospital,
      Guangzhou, Guangdong 510120, P.R. China.
FAU - Ou, Jia-Yuan
AU  - Ou JY
AD  - Department of Rehabilitation Medicine, Guangdong Provincial People's Hospital,
      Guangzhou, Guangdong 510120, P.R. China.
FAU - Bai, Wen-Fang
AU  - Bai WF
AD  - Department of Rehabilitation Medicine, Guangdong Provincial People's Hospital,
      Guangzhou, Guangdong 510120, P.R. China.
AD  - Academy of Medical Sciences, Guangdong Provincial Institute of Geriatrics,
      Guangzhou, Guangdong 510080, P.R. China.
FAU - Zhang, Ming-Sheng
AU  - Zhang MS
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital, Jinan
      University, Guangzhou, Guangdong 510632, P.R. China.
AD  - Department of Rehabilitation Medicine, Guangdong Provincial People's Hospital,
      Guangzhou, Guangdong 510120, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7401953
OTO - NOTNLM
OT  - autophagy
OT  - bone marrow-derived neural progenitor cell
OT  - disabled homolog 2-interacting protein
OT  - exosomes
OT  - microRNAR-32-3p
OT  - microglial cell
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3892/etm.2020.9008 [doi]
AID - ETM-0-0-9008 [pii]
PST - ppublish
SO  - Exp Ther Med. 2020 Sep;20(3):2752-2764. doi: 10.3892/etm.2020.9008. Epub 2020 Jul
      13.


PMID- 32765742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Sep
TI  - Distress in neurocognitive disorders due to Alzheimer's disease and stroke.
PG  - 2501-2509
LID - 10.3892/etm.2020.8806 [doi]
AB  - Patients with neurocognitive disorders experience subjectively the concept of
      quality of life; this is the reason why researchers avoid approaching this
      concept and prefer to focus attention on the emotional profile of the caregivers.
      Many studies highlight the efforts both emotional and financial made by
      caregivers in case of patients diagnosed with neurocognitive disorders. The
      present study shows the differences between the patients diagnosed with
      neurocognitive disorder due to Alzheimer's disease and patients diagnosed with
      stroke, as well as the Romanian norms for the short form of Geriatric Depression 
      Scale. The study group consisted of the clinical population (N=45), selected
      according to the inclusion/exclusion criteria, following the principles of
      Helsinki Declaration for Ethical Medical Research. The study was conducted at the
      Neuropsychiatry section of the Municipal Clinical Hospital, Dr Gavril Curteanu,
      Oradea, Romania. The results showed significant differences between the two types
      of patients in terms of quality of life, t(43)=-7.99, P=0.001, affective
      distress, t(43)=5.10, P=0.001 and perceived stress, t(43)=3.81, P=0.001. The
      internal consistency of the scale is high, the coefficient KR-20 being 0.86.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Dindelegan, Camelia Maria
AU  - Dindelegan CM
AD  - Psychology Department, Faculty of Social Humanistic Science, University of
      Oradea, 410087 Oradea, Romania.
FAU - Faur, Darian
AU  - Faur D
AD  - Psychology Department, Faculty of Social Humanistic Science, University of
      Oradea, 410087 Oradea, Romania.
FAU - Purza, Lavinia
AU  - Purza L
AD  - Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea,
      410028 Oradea, Romania.
FAU - Bumbu, Adrian
AU  - Bumbu A
AD  - Department of Psycho-Neurosciences and Rehabilitation, Faculty of Medicine and
      Pharmacy, University of Oradea, 410068 Oradea, Romania.
FAU - Sabau, Monica
AU  - Sabau M
AD  - Department of Psycho-Neurosciences and Rehabilitation, Faculty of Medicine and
      Pharmacy, University of Oradea, 410068 Oradea, Romania.
AD  - Clinical Department of Neurology, Emergency Clinical County Hospital, 410169
      Oradea, Romania.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7401825
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Geriatric Depression Scale
OT  - cognitive impairment
OT  - distress
OT  - neurocognitive disorders
OT  - stroke
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3892/etm.2020.8806 [doi]
AID - ETM-0-0-8806 [pii]
PST - ppublish
SO  - Exp Ther Med. 2020 Sep;20(3):2501-2509. doi: 10.3892/etm.2020.8806. Epub 2020 May
      28.


PMID- 32765647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210612
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Apr
TI  - Scraping the Web for Public Health Gains: Ethical Considerations from a 'Big
      Data' Research Project on HIV and Incarceration.
PG  - 111-121
LID - 10.1093/phe/phaa006 [doi]
AB  - Web scraping involves using computer programs for automated extraction and
      organization of data from the Web for the purpose of further data analysis and
      use. It is frequently used by commercial companies, but also has become a
      valuable tool in epidemiological research and public health planning. In this
      paper, we explore ethical issues in a project that "scrapes" public websites of
      U.S. county jails as part of an effort to develop a comprehensive database
      (including individual-level jail incarcerations, court records and confidential
      HIV records) to enhance HIV surveillance and improve continuity of care for
      incarcerated populations. We argue that the well-known framework of Emanuel et
      al. (2000) provides only partial ethical guidance for the activities we describe,
      which lie at a complex intersection of public health research and public health
      practice. We suggest some ethical considerations from the ethics of public health
      practice to help fill gaps in this relatively unexplored area.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. Available online at
      www.phe.oxfordjournals.org.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - UNC Bioethics Center, Department of Social Medicine, University of North Carolina
      at Chapel Hill.
FAU - Buchbinder, Mara
AU  - Buchbinder M
AD  - UNC Bioethics Center, Department of Social Medicine, University of North Carolina
      at Chapel Hill.
FAU - Juengst, Eric
AU  - Juengst E
AD  - UNC Bioethics Center, Department of Social Medicine, University of North Carolina
      at Chapel Hill.
FAU - Brinkley-Rubinstein, Lauren
AU  - Brinkley-Rubinstein L
AD  - Center for Health Equity, Department of Social Medicine, University of North
      Carolina at Chapel Hill.
FAU - Blue, Colleen
AU  - Blue C
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill.
FAU - Rosen, David L
AU  - Rosen DL
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill.
LA  - eng
GR  - P30 AI050410/AI/NIAID NIH HHS/United States
GR  - R01 AI129731/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20200311
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
EIN - Public Health Ethics. 2020 May 04;13(3):314. PMID: 33391393
PMC - PMC7392638
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.1093/phe/phaa006 [doi]
AID - phaa006 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Mar 11;13(1):111-121. doi: 10.1093/phe/phaa006.
      eCollection 2020 Apr.


PMID- 32765577
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Stem Cell Statute in Jordan: Leading the Way.
PG  - 657
LID - 10.3389/fgene.2020.00657 [doi]
AB  - The use of stem cells in research has caused much controversy and ethical
      dilemma. The primary source of stem cells is human embryos, a source which has
      been confronted with objections based on ethical, moral, and religious positions.
      Jordan has passed the first of its-kind Statute in the region, aiming at
      regulating the use of stem cells both for therapeutic and research purposes. The 
      Statute adopted a regulatory approach between the restrictive and intermediate.
      The Statute, however, pays more attention to stem cell banking in many of its
      articles. Many critical aspects in regulating stem cell research activities are
      overlooked. This is including but not limited to the process of informed consent,
      protecting privacy, maintaining confidentiality, the need for a national entity
      responsible for regulating embryonic stem cell (ESC) research, and requirements
      of monitoring activity. The authors recommend further review of the current
      Statute in light of the deficiencies discussed so as to develop a more
      comprehensive and coherent Statute.
CI  - Copyright (c) 2020 Al-Tabba', Dajani and Al-Hussaini.
FAU - Al-Tabba', Amal
AU  - Al-Tabba' A
AD  - Office of Human Research Protection Program, King Hussein Cancer Center, Amman,
      Jordan.
FAU - Dajani, Rana
AU  - Dajani R
AD  - Department of Biology and Biotechnology, Hashemite University, Zarqa, Jordan.
AD  - Jepson School of Leadership, University of Richmond, Richmond, VA, United States.
FAU - Al-Hussaini, Maysa
AU  - Al-Hussaini M
AD  - Office of Human Research Protection Program, King Hussein Cancer Center, Amman,
      Jordan.
AD  - Department of Pathology and Laboratory Medicine, King Hussein Cancer Center,
      Amman, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7379862
OTO - NOTNLM
OT  - Islam
OT  - Jordan
OT  - research
OT  - statute
OT  - stem cell
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3389/fgene.2020.00657 [doi]
PST - epublish
SO  - Front Genet. 2020 Jul 17;11:657. doi: 10.3389/fgene.2020.00657. eCollection 2020.


PMID- 32765345
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - The Contribution of Rat Studies to Current Knowledge of Major Depressive
      Disorder: Results From Citation Analysis.
PG  - 1486
LID - 10.3389/fpsyg.2020.01486 [doi]
AB  - Major depressive disorder (MDD) is the most severe depression type and one of the
      leading causes of morbidity worldwide. Animal models are widely used to
      understand MDD etiology, pathogenesis, and treatment, but the efficacy of this
      research for patients has barely been systematically evaluated. Such evaluation
      is important given the resource consumption and ethical concerns incurred by
      animal use. We used the citation tracking facilities within Web of Science and
      Scopus to locate citations of original research papers on rats related to MDD
      published prior to 2013-to allow adequate time for citations-identified in PubMed
      and Scopus by relevant search terms. Resulting citations were thematically coded 
      in eight categories, and descriptive statistics were calculated. 178 publications
      describing relevant rat studies were identified. They were cited 8,712 times.
      More than half (4,633) of their citations were by other animal studies. 794 (less
      than 10%) were by human medical papers. Citation analysis indicates that rat
      model research has contributed very little to the contemporary clinical
      understanding of MDD. This suggests a misuse of limited funding hence supporting 
      a change in allocation of research and development funds targeting this disorder 
      to maximise benefits for patients.
CI  - Copyright (c) 2020 Carvalho, Peste, Marques, Knight and Vicente.
FAU - Carvalho, Constanca
AU  - Carvalho C
AD  - Centro de Filosofia das Ciencias da Universidade de Lisboa (CFCUL), Faculdade de 
      Ciencias da Universidade de Lisboa, Lisbon, Portugal.
FAU - Peste, Filipa
AU  - Peste F
AD  - Centre for Environmental and Marine Studies, Departamento de Biologia,
      Universidade de Aveiro, Aveiro, Portugal.
FAU - Marques, Tiago A
AU  - Marques TA
AD  - Centre for Research into Ecological and Environmental Modelling, Departamento de 
      Biologia Animal, Centro de Estatistica e Aplicacoes, Faculdade de Ciencias,
      Universidade de Lisboa, Lisbon, Portugal.
FAU - Knight, Andrew
AU  - Knight A
AD  - Centre for Animal Welfare, University of Winchester, Winchester, United Kingdom.
FAU - Vicente, Luis M
AU  - Vicente LM
AD  - Centro de Filosofia das Ciencias da Universidade de Lisboa (CFCUL), Faculdade de 
      Ciencias da Universidade de Lisboa, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7381216
OTO - NOTNLM
OT  - animal models
OT  - animal use alternatives
OT  - citation analysis
OT  - major depressive disorder
OT  - rat
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3389/fpsyg.2020.01486 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 14;11:1486. doi: 10.3389/fpsyg.2020.01486. eCollection
      2020.


PMID- 32765264
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Validation of the General Medication Adherence Scale in Pakistani Patients With
      Rheumatoid Arthritis.
PG  - 1039
LID - 10.3389/fphar.2020.01039 [doi]
AB  - OBJECTIVE: The aim was to validate the Urdu version of General Medication
      Adherence Scale (GMAS) in patients with rheumatoid arthritis disease. METHODS: A 
      2-month (March-April 2019) cross-sectional study was conducted in randomly
      selected out-patients with rheumatoid arthritis. The sample size was calculated
      using item-subject ratio of 1:20. The scale was evaluated for factorial,
      concrete, concurrent, and known group validities. Concrete validity was
      established by correlating scores of EQ-5D quality of life scale and GMAS
      adherence score. Concurrent validity was established by correlating the GMAS
      adherence score with pill count. Analyses for sensitivity were also conducted.
      Cut-off value was determined through receiver operator curve (ROC), and
      test-retest method was used to analyze internal consistency and reliability. Data
      were analyzed through IBM SPSS, IBM AMOS, and MedCalc software. The Urdu version 
      of EQ-5D quality of life questionnaire was used with permission from developers
      (#ID20884). The study was approved by an ethics committee (#NOV:15). RESULTS: A
      total of 351 responses were analyzed. The response rate was 98%. Reliability was 
      in acceptable range, i.e., Cronbach alpha = 0.797. Factorial validity was
      established by calculation of satisfactory fit indices. Correlation coefficients 
      for concrete and concurrent validities were rho = 0.687, p < 0.01 and rho =
      0.779, p < 0.01, respectively. Known group validity was established as
      significant association of adherence score with insurance and illness duration (p
      < 0.05) that were reported. Sensitivity of the scale was 94%. Most patients had
      high adherence (N = 159, 45.3%). CONCLUSION: The Urdu version of GMAS
      demonstrated adequate internal consistency and was validated. These results
      indicate that it is an appropriate tool to measure medication adherence in
      Pakistani patients with rheumatoid arthritis.
CI  - Copyright (c) 2020 Naqvi, Hassali, Rizvi, Zehra, Nisa, Islam, Iqbal, Farooqui,
      Imam, Hossain, Khan, Iqbal, Ali and Haseeb.
FAU - Naqvi, Atta Abbas
AU  - Naqvi AA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Hassali, Mohamed Azmi
AU  - Hassali MA
AD  - Discipline of Social and Administrative Pharmacy, School of Pharmaceutical
      Sciences, Universiti Sains Malaysia, Penang, Malaysia.
FAU - Rizvi, Mehwish
AU  - Rizvi M
AD  - Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Zehra, Ale
AU  - Zehra A
AD  - Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Nisa, Zeb-Un-
AU  - Nisa ZU
AD  - Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan.
FAU - Islam, Md Ashraful
AU  - Islam MA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Iqbal, Muhammad Shahid
AU  - Iqbal MS
AD  - Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz
      University, Alkharj, Saudi Arabia.
FAU - Farooqui, Maryam
AU  - Farooqui M
AD  - Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, 
      Qassim, Saudi Arabia.
FAU - Imam, Mohammad Tarique
AU  - Imam MT
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Hossain, Mohammad Akbar
AU  - Hossain MA
AD  - Department of Pharmacology and Toxicology, College of Medicine, Umm Al-Qura
      University, Makkah, Saudi Arabia.
FAU - Khan, Irfanullah
AU  - Khan I
AD  - Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti
      Sains Malaysia, Penang, Malaysia.
FAU - Iqbal, Muhammad Zahid
AU  - Iqbal MZ
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, AIMST
      University, Bedong, Malaysia.
FAU - Ali, Majid
AU  - Ali M
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Haseeb, Abdul
AU  - Haseeb A
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7379482
OTO - NOTNLM
OT  - Pakistan
OT  - arthritis
OT  - medication adherence
OT  - medication persistence
OT  - patient compliance
OT  - rheumatoid
OT  - validation studies
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.3389/fphar.2020.01039 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jul 17;11:1039. doi: 10.3389/fphar.2020.01039. eCollection 
      2020.


PMID- 32764952
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Perceptions of Non-Communicable Disease and War Injury Management in the
      Palestinian Health System: A Qualitative Study of Healthcare Providers
      Perspectives.
PG  - 593-605
LID - 10.2147/JMDH.S253080 [doi]
AB  - BACKGROUND: Palestine, like other low-income countries, is confronting an
      increasing epidemic of non-communicable disease (NCD) and trend of war injury.
      The management of health problems often presents a critical challenge to the
      Palestinian health system (PHS). Understanding the perceptions of healthcare
      providers is essential in exploring the gaps in the health system to develop an
      effective healthcare intervention. Unfortunately, health research on management
      of NCD and war injury has largely been neglected and received little attention.
      Therefore, the study aimed to explore the perspectives of healthcare providers
      regarding NCD and war injury management in the PHS in the Gaza Strip. METHODS: A 
      qualitative study approach was used, based on four focus group discussions (FGDs)
      involving a purposive sampling strategy of 30 healthcare providers from three
      main public hospitals in Gaza Strip. A semi-structured topic guide was used, and 
      the focus group interviews data were analyzed using manifest content analysis.
      The study was approved by the Palestinian Health Research Council (PHRC) for
      ethics approval. RESULTS: From the healthcare providers perspective, four main
      themes and several sub-themes have emerged from the descriptive manifest content 
      analysis: functioning of healthcare system; system-related challenges;
      patients-related challenges; strategies and actions to navigating the challenges 
      and improving care. Informants frequently discussed that despite some positive
      aspects in the system, fundamental changes and significant improvements are
      needed. Some expressed serious concerns that the healthcare system needs complete
      rebuilding to facilitate the management of NCD and war-related injury. They
      perceived important barriers to effective management of NCD and war injury such
      as poor hospital infrastructure and logistics, shortage of micro and
      sub-specialities and essential resources. Participants also expressed a dilemma
      and troubles in communication and interactions, especially during emergencies or 
      crises. The informants stressed the unused of updated clinical management
      guidelines. There was a consensus regarding poor shared-care/task sharing,
      partnership, and cooperation among healthcare facilities. CONCLUSION: Our
      findings suggest that fundamental changes and significant reforms are needed in
      the health system to make healthcare services more effective, timely, and
      efficient. The study disclosed the non-use of clinical guidelines as well as
      suboptimal sectorial task-sharing among different stakeholders and healthcare
      providers. A clear and comprehensive healthcare policy considering the gaps in
      the system must be adopted for the improvement and development of care in the
      PHS.
CI  - (c) 2020 Mosleh et al.
FAU - Mosleh, Marwan
AU  - Mosleh M
AD  - Department of Health Sciences (HLV), Public Health Science, Mid Sweden
      University, Sundsvall, Sweden.
AD  - Ministry of Health, Gaza, Palestine.
FAU - Aljeesh, Yousef
AU  - Aljeesh Y
AD  - International Public Health Medicine, Islamic University, Gaza, Palestine.
FAU - Dalal, Koustuv
AU  - Dalal K
AUID- ORCID: 0000-0001-7393-796X
AD  - Department of Health Sciences (HLV), Public Health Science, Mid Sweden
      University, Sundsvall, Sweden.
AD  - Department of Epidemiology, Biostatistics, and EBM; Faculty of Medicine and
      Health Care, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
FAU - Eriksson, Charli
AU  - Eriksson C
AD  - Department of Public Health, Stockholm University, Stockholm, Sweden.
FAU - Carlerby, Heidi
AU  - Carlerby H
AUID- ORCID: 0000-0001-5134-4338
AD  - Department of Health Sciences (HLV), Public Health Science, Mid Sweden
      University, Sundsvall, Sweden.
FAU - Viitasara, Eija
AU  - Viitasara E
AD  - Department of Health Sciences (HLV), Public Health Science, Mid Sweden
      University, Sundsvall, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7363484
OTO - NOTNLM
OT  - NCD
OT  - Palestinian health system
OT  - management
OT  - perception
OT  - war injury
COIS- The authors declare no conflicts of interest.
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.2147/JMDH.S253080 [doi]
AID - 253080 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Jul 9;13:593-605. doi: 10.2147/JMDH.S253080.
      eCollection 2020.


PMID- 32764900
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20220215
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Linking)
VI  - 15
DP  - 2020
TI  - Home-Based Cognitively Assistive Robots: Maximizing Cognitive Functioning and
      Maintaining Independence in Older Adults Without Dementia.
PG  - 1129-1139
LID - 10.2147/CIA.S253236 [doi]
AB  - Promoting health and prolonging independence in the home is a priority for older 
      adults, caregivers, clinicians, and society at large. Rapidly developing robotics
      technology provides a platform for interventions, with the fields of physically
      and socially assistive robots expanding in recent years. However, less attention 
      has been paid to using robots to enhance the cognitive health of older adults.
      The goal of this review is to synthesize the current literature on home-based
      cognitively assistive robots (CAR) in older adults without dementia and to
      provide suggestions to improve the quality of the scientific evidence in this
      subfield. First, we set the stage for CAR by: a) introducing the field of
      robotics to improve health, b) summarizing evidence emphasizing the importance of
      home-based interventions for older adults, c) reviewing literature on robot
      acceptability in older adults, d) highlighting important ethical issues in
      healthcare robotics, and e) reviewing current findings on socially assistive
      robots, with a focus on translating findings to the CAR context. With this
      foundation in place, we then review the literature on CAR, identifying gaps and
      limitations of current evidence, and proposing future directions for research. We
      conclude that CAR is promising and feasible and that there is a need for more
      methodologically rigorous evaluations of CAR to promote prolonged home-based
      independence in older adults.
CI  - (c) 2020 Van Patten et al.
FAU - Van Patten, Ryan
AU  - Van Patten R
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA 92093,
      USA.
AD  - Research Service, VA San Diego Healthcare System, San Diego, CA 92161, USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA 92063, USA.
FAU - Keller, Amber V
AU  - Keller AV
AUID- ORCID: 0000-0002-2972-784X
AD  - Research Service, VA San Diego Healthcare System, San Diego, CA 92161, USA.
FAU - Maye, Jacqueline E
AU  - Maye JE
AUID- ORCID: 0000-0002-9073-2445
AD  - Center of Excellence for Stress and Mental Health, VA San Diego Healthcare
      System, San Diego, CA 92161, USA.
FAU - Jeste, Dilip V
AU  - Jeste DV
AUID- ORCID: 0000-0002-1161-7351
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA 92093,
      USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA 92063, USA.
AD  - Department of Neurosciences, University of California San Diego, La Jolla, CA
      92063, USA.
FAU - Depp, Colin
AU  - Depp C
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA 92093,
      USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA 92063, USA.
FAU - Riek, Laurel D
AU  - Riek LD
AD  - Computer Science and Engineering, University of California San Diego, La Jolla,
      CA 92063, USA.
AD  - Department of Emergency Medicine, University of California San Diego, La Jolla,
      CA 92063, USA.
AD  - Contextual Robotics Institute, University of California San Diego, La Jolla, CA
      92063, USA.
FAU - Twamley, Elizabeth W
AU  - Twamley EW
AUID- ORCID: 0000-0002-8693-8782
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA 92093,
      USA.
AD  - Research Service, VA San Diego Healthcare System, San Diego, CA 92161, USA.
AD  - Center of Excellence for Stress and Mental Health, VA San Diego Healthcare
      System, San Diego, CA 92161, USA.
LA  - eng
GR  - T32 MH019934/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200713
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
SB  - IM
MH  - *Activities of Daily Living
MH  - Aged
MH  - Caregivers
MH  - Cognition
MH  - Cognitive Dysfunction/*therapy
MH  - Humans
MH  - *Independent Living
MH  - Robotics/*statistics & numerical data
MH  - Self-Help Devices/*statistics & numerical data
MH  - User-Computer Interface
PMC - PMC7371917
OTO - NOTNLM
OT  - aging
OT  - autonomy
OT  - cognitive status
OT  - healthy aging
OT  - successful aging
OT  - technology
COIS- No conflicts of interest were declared. The authors disclosed receipt of the
      following financial support for the authorship and/or publication of this
      article: Funding for this study was provided, in part, by the National Institutes
      of Health (grant R01MH094151-01 to D.V.J. [PI]), by the National Institute of
      Mental Health T32 Geriatric Mental Health Program (grant MH019934 to D.V.J. and
      E.W.T. [PIs]), the Stein Institute for Research on Aging at the University of
      California, San Diego.
EDAT- 2020/08/09 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 10.2147/CIA.S253236 [doi]
AID - 253236 [pii]
PST - epublish
SO  - Clin Interv Aging. 2020 Jul 13;15:1129-1139. doi: 10.2147/CIA.S253236.
      eCollection 2020.


PMID- 32764853
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210802
IS  - 0971-9202 (Print)
IS  - 0975-6434 (Linking)
VI  - 70
IP  - 4
DP  - 2020 Aug
TI  - Pregnancy in a Persistent Vegetative State: A Management Dilemma. Case Report,
      Literature Review and Ethical Concerns.
PG  - 310-313
LID - 10.1007/s13224-019-01274-8 [doi]
FAU - Siwatch, Sujata
AU  - Siwatch S
AUID- ORCID: 0000-0001-5076-6686
AD  - Department of Obstetrics & Gynecology, PGIMER, Sector-12, Chandigarh,
      India.grid.415131.30000 0004 1767 2903
FAU - Rohilla, Minakshi
AU  - Rohilla M
AD  - Department of Obstetrics & Gynecology, PGIMER, Sector-12, Chandigarh,
      India.grid.415131.30000 0004 1767 2903
FAU - Singh, Apinderpreet
AU  - Singh A
AD  - Department of Neurosurgery, PGIMER, Chandigarh, India.grid.415131.30000 0004 1767
      2903
FAU - Ahuja, Chirag
AU  - Ahuja C
AD  - Department of Radiology, PGIMER, Chandigarh, India.grid.415131.30000 0004 1767
      2903
FAU - Jain, Kajal
AU  - Jain K
AD  - Department of Anaesthesia and Intensive Care, PGIMER, Chandigarh,
      India.grid.415131.30000 0004 1767 2903
FAU - Jain, Vanita
AU  - Jain V
AD  - Department of Obstetrics & Gynecology, PGIMER, Sector-12, Chandigarh,
      India.grid.415131.30000 0004 1767 2903
LA  - eng
PT  - Case Reports
DEP - 20190920
PL  - India
TA  - J Obstet Gynaecol India
JT  - Journal of obstetrics and gynaecology of India
JID - 0374763
PMC - PMC7381523
OTO - NOTNLM
OT  - Coma
OT  - Ethical issues
OT  - Persistent vegetative state
OT  - Pregnancy
COIS- Conflicts of interestThere are no conflicts of interest.
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2019/09/03 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - 10.1007/s13224-019-01274-8 [doi]
AID - 1274 [pii]
PST - ppublish
SO  - J Obstet Gynaecol India. 2020 Aug;70(4):310-313. doi: 10.1007/s13224-019-01274-8.
      Epub 2019 Sep 20.


PMID- 32764129
OWN - NLM
STAT- MEDLINE
DCOM- 20200820
LR  - 20201218
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 8
DP  - 2020 Aug
TI  - Patient-centric research in the time of COVID-19: conducting ethical COVID-19
      research in Africa.
LID - e003035 [pii]
LID - 10.1136/bmjgh-2020-003035 [doi]
FAU - Nembaware, Victoria
AU  - Nembaware V
AD  - Human Genetics Division, University of Cape Town, Cape Town, South Africa.
FAU - Munung, Nchangwi Syntia
AU  - Munung NS
AD  - Human Genetics Division, University of Cape Town, Cape Town, South Africa.
FAU - Matimba, Alice
AU  - Matimba A
AD  - Advanced Courses and Scientific Conferences, Wellcome Genome Campus, Cambridge,
      UK.
FAU - Tiffin, Nicki
AU  - Tiffin N
AUID- ORCID: 0000-0001-5083-2735
AD  - Wellcome Centre for Infectious Disease Research in Africa, University of Cape
      Town, Cape Town, South Africa nicki.tiffin@uct.ac.za.
AD  - Computational Biology Division, University of Cape Town, Cape Town, South Africa.
LA  - eng
GR  - U24 HG006941/HG/NHGRI NIH HHS/United States
GR  - R01 HD080465/HD/NICHD NIH HHS/United States
GR  - U24 HL135600/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Africa
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics/methods
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - Informed Consent
MH  - *Pandemics
MH  - Personal Autonomy
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7411326
OTO - NOTNLM
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/09 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
AID - bmjgh-2020-003035 [pii]
AID - 10.1136/bmjgh-2020-003035 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Aug;5(8). pii: bmjgh-2020-003035. doi:
      10.1136/bmjgh-2020-003035.


PMID- 32764090
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 6
TI  - Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet
      therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical
      trial.
PG  - e038936
LID - 10.1136/bmjopen-2020-038936 [doi]
AB  - INTRODUCTION: Minority populations in the USA are disproportionately affected by 
      cardiovascular conditions. Reduced responsiveness to clopidogrel among carriers
      of CYP2C19 variants has been reported in patients with either coronary artery
      disease (CAD) or acute coronary syndrome (ACS) after the percutaneous coronary
      intervention (PCI). Previous studies have evaluated CYP2C19 genotyping-guided
      antiplatelet therapy in selected populations; however, this has yet to be tested 
      among Hispanics. Given the paucity of clinical research on CYP2C19 and
      antiplatelet clinical outcomes in Hispanics, our study will test the safety and
      efficacy of a genetic-driven treatment algorithm to guide dual antiplatelet
      therapy (DAPT) in Caribbean Hispanics. METHODS AND ANALYSIS: This is a
      multicentre, prospective, non-randomised clinical trial that proposes an
      assessment of pharmacogenomic-guided DAPT in post-PCI Caribbean Hispanic patients
      with ACS or CAD. We will recruit 250 patients to be compared with a matched
      non-concurrent cohort of 250 clopidogrel-treated patients (standard-of-care).
      Major adverse cardiovascular events (MACEs) such as all-cause death, myocardial
      infarction (MI), stroke, coronary revascularisation, stent thrombosis and
      bleedings over 6 months will be the study endpoints. Among the recruited,
      high-risk patients will be escalated to ticagrelor and low-risk patients will
      remain on clopidogrel. The primary objective is to determine whether
      genetic-guided therapy is superior to standard of care. The secondary objective
      will determine if clopidogrel treatment in low-risk patients is not associated
      with a higher rate of MACEs compared with escalated antiplatelet therapy in
      high-risk patients. Patients will be enrolled up to the group's completion.
      ETHICS AND DISSEMINATION: Approval was obtained from the Institutional Review
      Board of the University of Puerto Rico Medical Sciences Campus (protocol #
      A4070417). The study will be carried out in compliance with the Declaration of
      Helsinki and International Conference on Harmonization Good Clinical Practice
      Guidelines. Findings will be published in a peer-reviewed journal and controlled 
      access to experimental data will be available. TRIAL REGISTRATION NUMBER:
      NCT03419325; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hernandez-Suarez, Dagmar F
AU  - Hernandez-Suarez DF
AUID- ORCID: 0000-0003-1850-9078
AD  - Division of Cardiovascular Medicine, University of Puerto Rico School of
      Medicine, Medical Sciences Campus, San Juan, Puerto Rico, USA.
FAU - Melin, Kyle
AU  - Melin K
AUID- ORCID: 0000-0002-4698-8021
AD  - Department of Pharmacy Practice, University of Puerto Rico School of Pharmacy,
      Medical Sciences Campus, San Juan, Puerto Rico, USA.
FAU - Marin-Maldonado, Frances
AU  - Marin-Maldonado F
AD  - RCMI Program, Academic Affairs Deanship, University of Puerto Rico, Medical
      Sciences Campus, San Juan, Puerto Rico, USA.
FAU - Nunez, Hector J
AU  - Nunez HJ
AD  - Division of Cardiovascular Medicine, University of Puerto Rico School of
      Medicine, Medical Sciences Campus, San Juan, Puerto Rico, USA.
FAU - Gonzalez, Ariel F
AU  - Gonzalez AF
AD  - Division of Cardiovascular Medicine, University of Puerto Rico School of
      Medicine, Medical Sciences Campus, San Juan, Puerto Rico, USA.
FAU - Gonzalez-Sepulveda, Lorena
AU  - Gonzalez-Sepulveda L
AD  - Research Design and Biostatistics Core, Puerto Rico Clinical and Translational
      Research Consortium (PRCTRC), Medical Sciences Campus, San Juan, Puerto Rico,
      USA.
FAU - Rivas-Tumanyan, Sona
AU  - Rivas-Tumanyan S
AD  - Research Design and Biostatistics Core, Puerto Rico Clinical and Translational
      Research Consortium (PRCTRC), Medical Sciences Campus, San Juan, Puerto Rico,
      USA.
FAU - Naik, Hetanshi
AU  - Naik H
AD  - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
      Sinai, New York City, New York, USA.
FAU - Ruano, Gualberto
AU  - Ruano G
AD  - Hartford Hospital Institute of Living, Hartford, Connecticut, USA.
FAU - Scott, Stuart A
AU  - Scott SA
AD  - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount
      Sinai, New York City, New York, USA.
FAU - Duconge, Jorge
AU  - Duconge J
AUID- ORCID: 0000-0002-5955-3449
AD  - Department of Pharmaceutical Sciences, University of Puerto Rico School of
      Pharmacy, Medical Sciences Campus, San Juan, Puerto Rico, USA
      jorge.duconge@upr.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT03419325
GR  - U54 GM133807/GM/NIGMS NIH HHS/United States
GR  - U54 MD007587/MD/NIMHD NIH HHS/United States
GR  - U54 MD007600/MD/NIMHD NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20200806
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Dinucleoside Phosphates)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 19192-40-6 (2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
SB  - IM
MH  - *Acute Coronary Syndrome/drug therapy
MH  - Algorithms
MH  - Caribbean Region
MH  - Dinucleoside Phosphates
MH  - Hispanic or Latino
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Pharmacogenetics
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prasugrel Hydrochloride
MH  - Prospective Studies
MH  - Treatment Outcome
PMC - PMC7412606
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *coronary heart disease
OT  - *coronary intervention
OT  - *genetics
COIS- Competing interests: None declared.
EDAT- 2020/08/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038936 [pii]
AID - 10.1136/bmjopen-2020-038936 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 6;10(8):e038936. doi: 10.1136/bmjopen-2020-038936.


PMID- 32764089
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 6
TI  - Study protocol for a cluster randomised controlled trial testing the
      effectiveness of the 'High schools High on life' intervention on reducing
      excessive drinking in Danish high schools.
PG  - e038857
LID - 10.1136/bmjopen-2020-038857 [doi]
AB  - INTRODUCTION: This paper describes the evaluation design of the 'High schools
      High on life' intervention; a school-based intervention to reduce excessive
      drinking among high school students in Denmark. The intervention includes a
      school environmental component to limit access to alcohol at school, a
      school-educational component to change social norms around alcohol among first
      year students and a parental component addressing parents' knowledge and
      attitudes towards alcohol. METHODS AND DESIGN: The study will employ a cluster
      randomised controlled study design and will include a random sample of 16 high
      schools randomly allocated 1:1 to either intervention or control group. Target
      group: first year high school students. Timeline: baseline survey: January to
      March 2019, collected as part of the Danish National Youth Study 2019. Delivery
      of intervention: April 2019 to March 2020. Follow-up survey: April to May 2020.
      PRIMARY OUTCOME MEASURE: 30% reduction in mean number of binge-drinking episodes 
      (five or more alcoholic drinks on one occasion) within the last 30 days.
      SECONDARY OUTCOME MEASURES: proportion of students who drink alcohol, mean weekly
      alcohol consumption, alcohol intake at last school party, alcohol intake at the
      school during last school party, proportion of students who agree to be able to
      have fun at a party without drinking and the proportion of students who think
      alcohol plays a too dominant part at the school. Implementation will be monitored
      through process evaluation. ETHICS AND DISSEMINATION: The Scientific Ethics
      Committees for the Capital Region of Denmark has declared that the trial is not
      subject to notification (jnr. 19021957). The study is registered at the Research 
      an Innovation Office at University of Southern Denmark (ref: 10.314) allowing
      collection of personal data. Results will be published in peer-reviewed journals.
      TRIAL REGISTRATION NUMBER: NCT03906500.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pisinger, Veronica Sofie Clara
AU  - Pisinger VSC
AUID- ORCID: 0000-0002-5605-138X
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark vepi@sdu.dk.
FAU - Hoffmann, Sofie
AU  - Hoffmann S
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
FAU - Rosing, Johanne Aviaja
AU  - Rosing JA
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
FAU - Gronbaek, Morten
AU  - Gronbaek M
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
FAU - Tolstrup, Janne Schurmann
AU  - Tolstrup JS
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
FAU - Thygesen, Lau
AU  - Thygesen L
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
FAU - Krolner, Rikke
AU  - Krolner R
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Syddanmark, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03906500
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200806
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Alcohol Drinking/prevention & control
MH  - Alcoholic Beverages
MH  - Denmark
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - School Health Services
MH  - *Schools
MH  - *Students
PMC - PMC7412607
OTO - NOTNLM
OT  - *epidemiology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: The Danish Cancer Society developed intervention materials
      based on an ongoing campaign. The Danish Cancer Society had no influence on the
      study design, data analysis or interpretation of data.
EDAT- 2020/08/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038857 [pii]
AID - 10.1136/bmjopen-2020-038857 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 6;10(8):e038857. doi: 10.1136/bmjopen-2020-038857.


PMID- 32763878
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220129
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 7
TI  - Notifications to Improve Engagement With an Alcohol Reduction App: Protocol for a
      Micro-Randomized Trial.
PG  - e18690
LID - 10.2196/18690 [doi]
AB  - BACKGROUND: Drink Less is a behavior change app that aims to help users in the
      general adult population reduce hazardous and harmful alcohol consumption. The
      app includes a daily push notification, delivered at 11 am, asking users to
      "Please complete your mood and drinking diaries." Previous analysis of Drink Less
      engagement data suggests the current notification strongly influences how users
      engage with the app in the subsequent hour. To exploit a potential increase of
      vulnerability of excess drinking and opportunity to engage with the app in the
      evenings, we changed the delivery time from 11 am to 8 pm. We now aim to further 
      optimise the content and sequence of notifications, testing 30 new
      evidence-informed notifications targeting the user's perceived usefulness of the 
      app. OBJECTIVE: The primary objective is to assess whether sending a notification
      at 8 pm increases behavioral engagement (opening the app) in the subsequent hour.
      Secondary objectives include comparing the effect of the new bank of messages
      with the standard message and effect moderation over time. We also aim to more
      generally understand the role notifications have on the overall duration, depth, 
      and frequency of engagement with Drink Less over the first 30 days after
      download. METHODS: This is a protocol for a micro-randomized trial with two
      additional parallel arms. Inclusion criteria are Drink Less users who (1) consent
      to participate in the trial; (2) self-report a baseline Alcohol Use Disorders
      Identification Test score of 8 or above; (3) reside in the United Kingdom; (4)
      age >/=18 years and; (5) report interest in drinking less alcohol. In the
      micro-randomized trial, participants will be randomized daily at 8 pm to receive 
      no notification, a notification with text from the new message bank, or the
      standard message. The primary outcome is the time-varying, binary outcome of "Did
      the user open the app in the hour from 8 pm to 9 pm?". The primary analysis will 
      estimate the marginal relative risk for the notifications using an estimator
      developed for micro-randomized trials with binary outcomes. Participants
      randomized to the parallel arms will receive no notifications (Secondary Arm A), 
      or the standard notification delivered daily at 11 am (Secondary Arm B) over 30
      days, allowing the comparison of overall engagement between different
      notification delivery strategies. RESULTS: Approval was granted by the University
      College of London's Departmental Research Ethics Committee (CEHP/2016/556) on
      October 11, 2019, and The London School of Hygiene and Tropical Medicine
      Interventions Research Ethics Committee (17929) on November 27, 2019. Recruitment
      began on January 2, 2020, and is ongoing. CONCLUSIONS: Understanding how push
      notifications may impact engagement with a behavior change app can lead to
      further improvements in engagement, and ultimately help users reduce their
      alcohol consumption. This understanding may also be generalizable to other apps
      that target a variety of behavior changes. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): DERR1-10.2196/18690.
CI  - (c)Lauren Bell, Claire Garnett, Tianchen Qian, Olga Perski, Henry W W Potts,
      Elizabeth Williamson. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 07.08.2020.
FAU - Bell, Lauren
AU  - Bell L
AUID- ORCID: https://orcid.org/0000-0002-5408-8525
AD  - Department of Medical Statistics, London School of Hygiene and Tropical Medicine,
      London, United Kingdom.
FAU - Garnett, Claire
AU  - Garnett C
AUID- ORCID: https://orcid.org/0000-0002-6589-299X
AD  - Research Department of Behavioural Science and Health, University College London,
      London, United Kingdom.
FAU - Qian, Tianchen
AU  - Qian T
AUID- ORCID: https://orcid.org/0000-0003-4282-7826
AD  - Department of Statistics, Harvard University, Cambridge, MA, United States.
FAU - Perski, Olga
AU  - Perski O
AUID- ORCID: https://orcid.org/0000-0003-3285-3174
AD  - Research Department of Behavioural Science and Health, University College London,
      London, United Kingdom.
FAU - Potts, Henry W W
AU  - Potts HWW
AUID- ORCID: https://orcid.org/0000-0002-6200-8804
AD  - Institute of Health Informatics, University College London, London, United
      Kingdom.
AD  - Health Data Research UK, London, United Kingdom.
FAU - Williamson, Elizabeth
AU  - Williamson E
AUID- ORCID: https://orcid.org/0000-0001-6905-876X
AD  - Department of Medical Statistics, London School of Hygiene and Tropical Medicine,
      London, United Kingdom.
AD  - Health Data Research UK, London, United Kingdom.
LA  - eng
GR  - U54 EB020404/EB/NIBIB NIH HHS/United States
GR  - R01 AA023187/AA/NIAAA NIH HHS/United States
GR  - U01 CA229437/CA/NCI NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
GR  - MR/L004933/2/MRC_/Medical Research Council/United Kingdom
GR  - P50 DA039838/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20200807
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7442945
OTO - NOTNLM
OT  - alcohol
OT  - digital behavior change
OT  - engagement
OT  - excessive alcohol consumption
OT  - mHealth
OT  - micro-randomized trial
OT  - mobile health
OT  - push notifications
OT  - smartphone app
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - v9i8e18690 [pii]
AID - 10.2196/18690 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 7;9(8):e18690. doi: 10.2196/18690.


PMID- 32763874
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 7
TI  - Lung Function Variability in Children and Adolescents With and Without Asthma
      (LUV Study): Protocol for a Prospective, Nonrandomized, Clinical Trial.
PG  - e20350
LID - 10.2196/20350 [doi]
AB  - BACKGROUND: Variability analysis of peak expiratory flow (PEF) and forced
      expiratory volume at 1 second (FEV1) has been used in research to predict
      exacerbations in adults with asthma. However, there is a paucity of data
      regarding PEF and FEV1 variability in healthy children and adolescents and those 
      with asthma. OBJECTIVE: The objective of this study is the assessment of PEF and 
      FEV1 variability in (1) healthy children and adolescents, to define the normal
      daily fluctuation of PEF and FEV1 and the parameters that may influence it, and
      (2) children and adolescents with asthma, to explore the differences from healthy
      subjects and reveal any specific variability changes prior to exacerbation.
      METHODS: The study will include 100 healthy children and adolescents aged 6-18
      years (assessment of normal PEF and FEV1 variability) and 100 children and
      adolescents of the same age with diagnosed asthma (assessment of PEF and FEV1
      variability in subjects with asthma). PEF and FEV1 measurements will be performed
      using an ultraportable spirometer (Spirobank Smart; MIR Medical International
      Research) capable of smartphone connection. Measurements will be performed twice 
      a day between 7 AM and 9 AM and between 7 PM and 9 PM and will be dispatched via 
      email to a central database for a period of 3 months. PEF and FEV1 variability
      will be assessed by detrended fluctuation and sample entropy analysis, aiming to 
      define the normal pattern (healthy controls) and to detect and quantify any
      deviations among individuals with asthma. The anticipated duration of the study
      is 24 months. RESULTS: The study is funded by the "C. Caratheodory" Programme of 
      the University of Patras, Greece (PN 47014/24.9.2018). It was approved by the
      Ethics Committee (decision 218/19-03-2019) and the Scientific Board (decision
      329/02-04-2019) of the University Hospital of Patras, Greece. Patient recruitment
      started in January 2020, and as of June 2020, 100 healthy children have been
      enrolled (74 of them have completed the measurements). The anticipated duration
      of the study is 24 months. The first part of the study (assessment of lung
      function variability in healthy children and adolescents) will be completed in
      August 2020, and the results will be available for publication by October 2020.
      CONCLUSIONS: Healthy children and adolescents may present normal short- and
      long-term fluctuations in lung function; the pattern of this variability may be
      influenced by age, sex, and environmental conditions. Significant lung function
      variability may also be present in children and adolescents with asthma, but the 
      patterns may differ from those observed in healthy children and adolescents. Such
      data would improve our understanding regarding the chronobiology of asthma and
      permit the development of integrated tools for assessing the level of control and
      risk of future exacerbations. TRIAL REGISTRATION: ClinicalTrials.gov NCT04163146;
      https://clinicaltrials.gov/ct2/show/NCT04163146. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/20350.
CI  - (c)Eirini-Sofia Frima, Ilias Theodorakopoulos, Dimos Gidaris, Nikolaos
      Karantaglis, Grigorios Chatziparasidis, Panagiotis Plotas, Michael
      Anthracopoulos, Sotirios Fouzas. Originally published in JMIR Research Protocols 
      (http://www.researchprotocols.org), 07.08.2020.
FAU - Frima, Eirini-Sofia
AU  - Frima ES
AUID- ORCID: https://orcid.org/0000-0002-4647-3909
AD  - Pediatric Respiratory Unit, University Hospital of Patras, Patras, Greece.
AD  - Pediatric Respiratory Research Group, University of Patras, Patras, Greece.
FAU - Theodorakopoulos, Ilias
AU  - Theodorakopoulos I
AUID- ORCID: https://orcid.org/0000-0002-9392-8902
AD  - Pediatric Respiratory Research Group, University of Patras, Patras, Greece.
AD  - Electronics Laboratory, Department of Physics, University of Patras, Patras,
      Greece.
FAU - Gidaris, Dimos
AU  - Gidaris D
AUID- ORCID: https://orcid.org/0000-0001-7945-3595
AD  - University of Nicosia, Nicosia, Cyprus.
FAU - Karantaglis, Nikolaos
AU  - Karantaglis N
AUID- ORCID: https://orcid.org/0000-0002-7539-8426
AD  - Pediatric Pulmonology Unit, 3rd Pediatric Department, Aristotle University of
      Thessaloniki, Thessaloniki, Greece.
FAU - Chatziparasidis, Grigorios
AU  - Chatziparasidis G
AUID- ORCID: https://orcid.org/0000-0003-4308-4710
AD  - Department of Primary Ciliary Dyskinesia, School of Medicine, University of
      Thessaly, Larissa, Greece.
FAU - Plotas, Panagiotis
AU  - Plotas P
AUID- ORCID: https://orcid.org/0000-0001-5514-7083
AD  - Department of Public Health, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Anthracopoulos, Michael
AU  - Anthracopoulos M
AUID- ORCID: https://orcid.org/0000-0002-1487-824X
AD  - Pediatric Respiratory Unit, University Hospital of Patras, Patras, Greece.
AD  - Pediatric Respiratory Research Group, University of Patras, Patras, Greece.
FAU - Fouzas, Sotirios
AU  - Fouzas S
AUID- ORCID: https://orcid.org/0000-0001-7617-9076
AD  - Pediatric Respiratory Unit, University Hospital of Patras, Patras, Greece.
AD  - Pediatric Respiratory Research Group, University of Patras, Patras, Greece.
LA  - eng
SI  - ClinicalTrials.gov/NCT04163146
PT  - Journal Article
DEP - 20200807
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7442949
OTO - NOTNLM
OT  - adolescents
OT  - asthma
OT  - children
OT  - fluctuation analysis
OT  - lung function variability
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
CRDT- 2020/08/09 06:00
PHST- 2020/05/17 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
AID - v9i8e20350 [pii]
AID - 10.2196/20350 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 7;9(8):e20350. doi: 10.2196/20350.


PMID- 32763523
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20210110
IS  - 1876-2026 (Electronic)
IS  - 1876-2018 (Linking)
VI  - 54
DP  - 2020 Dec
TI  - Ethical issues when planning mental health services after the COVID-19 outbreak.
PG  - 102285
LID - S1876-2018(20)30397-X [pii]
LID - 10.1016/j.ajp.2020.102285 [doi]
FAU - Maldonado-Castellanos, Isaac
AU  - Maldonado-Castellanos I
AD  - Universidad Nacional Autonoma de Mexico, Unidad de Posgrado, Cto. de los
      Posgrados S/N, C.U., Coyoacan, 04510, Ciudad de Mexico, Mexico. Electronic
      address: imaldonadoc1500@comunidad.unam.mx.
LA  - eng
PT  - Letter
DEP - 20200713
PL  - Netherlands
TA  - Asian J Psychiatr
JT  - Asian journal of psychiatry
JID - 101517820
SB  - IM
MH  - Adult
MH  - *COVID-19/prevention & control
MH  - *Guidelines as Topic
MH  - Health Planning/*ethics
MH  - Humans
MH  - Mental Health Services/*ethics
MH  - *Physical Distancing
MH  - Societies, Scientific
PMC - PMC7357509
OTO - NOTNLM
OT  - COVID-19
OT  - Mental health ethical issues
OT  - Mental health services
EDAT- 2020/08/09 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/05/17 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - S1876-2018(20)30397-X [pii]
AID - 10.1016/j.ajp.2020.102285 [doi]
PST - ppublish
SO  - Asian J Psychiatr. 2020 Dec;54:102285. doi: 10.1016/j.ajp.2020.102285. Epub 2020 
      Jul 13.


PMID- 32763291
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 258
DP  - 2020 Oct 1
TI  - Cell therapy in female infertility-related diseases: Emphasis on recurrent
      miscarriage and repeated implantation failure.
PG  - 118181
LID - S0024-3205(20)30933-4 [pii]
LID - 10.1016/j.lfs.2020.118181 [doi]
AB  - About 17% of couples suffer from infertility conditions, worldwide. The most
      common reasons for female infertility are ovulation disorders, fallopian-related 
      disorders, RM, RIF, endometriosis, and unexplained infertility. Despite advances 
      in Assisted Reproductive Technologies, infertility has remained a serious
      problem. In recent years, a considerable progress in cell therapy as an emerging 
      approach for the treatment infertility has been made. Cell therapy involves
      utilizing lymphocytes, platelet -rich plasma, PBMCs and different types of stem
      cells as therapeutic agents. Stem cells are usually multipotent cells existed in 
      embryos, fetuses, and adults that proliferate and differentiate into different
      cell types under certain circumstances. The main types of stem cells are
      embryonic stem cells, decidual stromal cells, MSCs, human amniotic epithelial
      cells, and induced pluripotent-stem cells each functioning in a different way.
      The advantages of using stem cells as therapeutic agents are convenient sampling,
      abundant sources, and avoidable ethical issues. Lymphocyte immunotherapy, a
      simple and cost effective method, can be safe and useful approach if performed
      with proper dose of fresh lymphocytes intradermally before and during pregnancy. 
      Overall, cell therapy mechanism of actions are inducing the production of
      cytokines, blocking antibodies and growth factors, proliferation of B10 cells,
      reducing the activity of NK cells, increasingTh2 and Treg cells and decreasing
      Th1 and Th17 cells. Cell therapy can be an effective strategy as it provides an
      interactive, dynamic, specific and individualized treatment. Although cell
      therapy is a promising approach, it still needs more investigation in order to
      improve and make it safer.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Pourakbari, Ramin
AU  - Pourakbari R
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Ahmadi, Hamid
AU  - Ahmadi H
AD  - Department of Medical Biology and Central Electron Microscope Laboratory, Medical
      School, Pecs University, Pecs, Hungary.
FAU - Yousefi, Mehdi
AU  - Yousefi M
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;
      Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Aghebati-Maleki, Leili
AU  - Aghebati-Maleki L
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 
      Department of Immunology, School of Medicine, Tabriz University of Medical
      Sciences, Tabriz, Iran. Electronic address: aghebatil@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200805
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
SB  - IM
MH  - Abortion, Habitual/*therapy
MH  - *Cell- and Tissue-Based Therapy
MH  - *Embryo Implantation
MH  - Female
MH  - Humans
MH  - Infertility, Female/*therapy
MH  - Reproduction
OTO - NOTNLM
OT  - Cell therapy
OT  - Infertility
OT  - Recurrent Implantation Failure (RIF)
OT  - Recurrent Miscarriage (RM)
COIS- Declaration of competing interest The authors declare that the research was
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2020/08/09 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/07/19 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/08/09 06:00 [entrez]
AID - S0024-3205(20)30933-4 [pii]
AID - 10.1016/j.lfs.2020.118181 [doi]
PST - ppublish
SO  - Life Sci. 2020 Oct 1;258:118181. doi: 10.1016/j.lfs.2020.118181. Epub 2020 Aug 5.


PMID- 32763189
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210206
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 107
IP  - 2
DP  - 2020 Aug 6
TI  - Fostering Responsible Research on Ancient DNA.
PG  - 183-195
LID - S0002-9297(20)30205-6 [pii]
LID - 10.1016/j.ajhg.2020.06.017 [doi]
AB  - Anticipating and addressing the social implications of scientific work is a
      fundamental responsibility of all scientists. However, expectations for ethically
      sound practices can evolve over time as the implications of science come to be
      better understood. Contemporary researchers who work with ancient human remains, 
      including those who conduct ancient DNA research, face precisely this challenge
      as it becomes clear that practices such as community engagement are needed to
      address the important social implications of this work. To foster and promote
      ethical engagement between researchers and communities, we offer five practical
      recommendations for ancient DNA researchers: (1) formally consult with
      communities; (2) address cultural and ethical considerations; (3) engage
      communities and support capacity building; (4) develop plans to report results
      and manage data; and (5) develop plans for long-term responsibility and
      stewardship. Ultimately, every member of a research team has an important role in
      fostering ethical research on ancient DNA.
CI  - Copyright (c) 2020 American Society of Human Genetics. Published by Elsevier Inc.
      All rights reserved.
FAU - Wagner, Jennifer K
AU  - Wagner JK
AD  - Professional Practice and Social Implications Committee (formerly the Social
      Issues Committee), American Society of Human Genetics, Bethesda, MD 20814, USA;
      Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Center for Translational Bioethics and Health 
      Care Policy, Geisinger, Danville, PA 17822, USA. Electronic address:
      jwagner1@geisinger.edu.
FAU - Colwell, Chip
AU  - Colwell C
AD  - Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Department of Anthropology, Denver Museum of
      Nature and Science, Denver, CO 80205, USA.
FAU - Claw, Katrina G
AU  - Claw KG
AD  - Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Division of Biomedical Informatics and
      Personalized Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
      80045, USA.
FAU - Stone, Anne C
AU  - Stone AC
AD  - Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; School of Human Evolution and Social Change,
      Arizona State University, Tempe, AZ 85287, USA.
FAU - Bolnick, Deborah A
AU  - Bolnick DA
AD  - Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Department of Anthropology, University of
      Connecticut, Storrs, CT 06269, USA; Institute for Systems Genomics, University of
      Connecticut, Storrs, CT 06269, USA.
FAU - Hawks, John
AU  - Hawks J
AD  - Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Department of Anthropology, University of
      Wisconsin-Madison, Madison, WI 53706, USA.
FAU - Brothers, Kyle B
AU  - Brothers KB
AD  - Professional Practice and Social Implications Committee (formerly the Social
      Issues Committee), American Society of Human Genetics, Bethesda, MD 20814, USA;
      Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Department of Pediatrics, University of
      Louisville, Louisville, KY 40202, USA.
FAU - Garrison, Nanibaa' A
AU  - Garrison NA
AD  - Professional Practice and Social Implications Committee (formerly the Social
      Issues Committee), American Society of Human Genetics, Bethesda, MD 20814, USA;
      Responsible Ancient DNA Research Working Group, American Society of Human
      Genetics, Bethesda, MD 20814, USA; Institute for Society and Genetics, University
      of California, Los Angeles, Los Angeles, CA 90095, USA; Institute for Precision
      Health, David Geffen School of Medicine, University of California, Los Angeles,
      Los Angeles, CA 90095, USA; Division of General Internal Medicine and Health
      Services Research, David Geffen School of Medicine, University of California, Los
      Angeles, Los Angeles, CA 90095, USA.
LA  - eng
GR  - K01 HG008818/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (DNA, Ancient)
SB  - IM
MH  - Animals
MH  - DNA, Ancient/*analysis
MH  - Foster Home Care
MH  - Humans
PMC - PMC7413888
EDAT- 2020/08/09 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S0002-9297(20)30205-6 [pii]
AID - 10.1016/j.ajhg.2020.06.017 [doi]
PST - ppublish
SO  - Am J Hum Genet. 2020 Aug 6;107(2):183-195. doi: 10.1016/j.ajhg.2020.06.017.


PMID- 32762973
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1556-4088 (Electronic)
IS  - 1556-407X (Linking)
VI  - 15
IP  - 3
DP  - 2020 Sep
TI  - Regulatory, Legal, and Ethical Considerations of Telemedicine.
PG  - 409-416
LID - S1556-407X(20)30049-7 [pii]
LID - 10.1016/j.jsmc.2020.06.004 [doi]
AB  - Sleep telemedicine practitioners must ensure their practice complies with all
      applicable institutional, state, and federal regulations. Providers must be
      licensed in any state in which they provide care, have undergone credentialing
      and privileging procedures at outside facilities, and avoid real or perceived
      conflicts of interest while providing that care. Internet-based prescribing
      remains limited to certain circumstances. Whether or not a malpractice insurance 
      policy covers telemedicine depends on the insurer, especially if interstate care 
      is provided. All telemedicine programs must protect patient health information.
      Similarly, bioethical principles of autonomy, beneficence, nonmaleficence, and
      justice apply to both in-person and telemedicine-based care.
CI  - Published by Elsevier Inc.
FAU - Fields, Barry G
AU  - Fields BG
AD  - Department of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory
      University School of Medicine, Atlanta VA Health Care System, Atlanta, GA, USA.
      Electronic address: barry.fields@emory.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200707
PL  - United States
TA  - Sleep Med Clin
JT  - Sleep medicine clinics
JID - 101271531
SB  - IM
MH  - Credentialing
MH  - Electronic Prescribing
MH  - Humans
MH  - Informed Consent
MH  - Internet/legislation & jurisprudence
MH  - Telemedicine/*ethics/*legislation & jurisprudence
PMC - PMC7340020
OTO - NOTNLM
OT  - Informed consent
OT  - Interstate licensure compact
OT  - Protected health information
OT  - Ryan Haight act
OT  - Stark law
OT  - Telemedicine
COIS- Disclosure The author has nothing to disclose.
EDAT- 2020/08/09 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S1556-407X(20)30049-7 [pii]
AID - 10.1016/j.jsmc.2020.06.004 [doi]
PST - ppublish
SO  - Sleep Med Clin. 2020 Sep;15(3):409-416. doi: 10.1016/j.jsmc.2020.06.004. Epub
      2020 Jul 7.


PMID- 32762851
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1558-1357 (Electronic)
IS  - 0029-6465 (Linking)
VI  - 55
IP  - 3
DP  - 2020 Sep
TI  - The Stigma of Sexually Transmitted Infections.
PG  - 295-305
LID - S0029-6465(20)30030-X [pii]
LID - 10.1016/j.cnur.2020.05.002 [doi]
AB  - Evidence-based guidelines have improved diagnosis and treatment of sexually
      transmitted infections (STI). Social stigma remains a barrier to STI testing and 
      is associated with underutilization of prevention services. Alternatives for STI 
      testing (eg, in-home testing) are convenient. However, some individuals decline
      follow-up treatment in fear of unintentional disclosure of their diagnosis. This 
      article reviews STI treatment guidelines and examines the impact of stigma and
      ethical issues on testing, adherence, partner notification, and transmission
      rates. An understanding of STI-associated ethical issues and controversies is an 
      important step toward eliminating stigma and reducing STI prevalence and
      morbidity.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Lee, Amy S D
AU  - Lee ASD
AD  - Capstone College of Nursing, The University of Alabama, 650 University Boulevard 
      East, Tuscaloosa, AL 35401, USA. Electronic address: adlee5@ua.edu.
FAU - Cody, Shameka L
AU  - Cody SL
AD  - Capstone College of Nursing, The University of Alabama, 650 University Boulevard 
      East, Tuscaloosa, AL 35401, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200715
PL  - United States
TA  - Nurs Clin North Am
JT  - The Nursing clinics of North America
JID - 0042033
SB  - IM
MH  - Centers for Disease Control and Prevention, U.S./standards
MH  - Guidelines as Topic/*standards
MH  - HIV Infections/therapy/transmission
MH  - Humans
MH  - *Patient Acceptance of Health Care
MH  - *Sexually Transmitted Diseases/classification/therapy
MH  - *Social Stigma
MH  - United States
OTO - NOTNLM
OT  - *Delayed care
OT  - *Partner treatment
OT  - *Provider-patient relationship
OT  - *Sexually transmitted infections
OT  - *Stigma
COIS- Disclosure The authors have nothing to disclose.
EDAT- 2020/08/09 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - S0029-6465(20)30030-X [pii]
AID - 10.1016/j.cnur.2020.05.002 [doi]
PST - ppublish
SO  - Nurs Clin North Am. 2020 Sep;55(3):295-305. doi: 10.1016/j.cnur.2020.05.002. Epub
      2020 Jul 15.


PMID- 32762757
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Aug 6
TI  - Transformation of the Taiwan Biobank 3.0: vertical and horizontal integration.
PG  - 304
LID - 10.1186/s12967-020-02451-4 [doi]
AB  - Researchers expect a high quality of biospecimens/data and value-added services
      from biobanks. Therefore, the concept of "biobank 3.0" was introduced so that
      biobanks could better meet the needs of stakeholders and maintain sustainable
      operations. Theoretically, the Taiwan Biobank (TWB) has already gone through the 
      concepts of biobank 1.0 and 2.0. However, three challenges still need to be
      addressed before it can be transformed into a new generation of the TWB (namely, 
      the TWB 3.0): (1) the difficulty of integrating other biobanks' resources, (2)
      the efficiency and effectiveness of the release and use of biospecimens/data, and
      (3) the development of income and revenue models of sustainability. To address
      these issues, this paper proposes a framework for the TWB 3.0 transformation
      based on a dual-pillar approach composed of a "physically" vertical integration
      driven by the TWB and a "virtually" horizontal network led by the National Health
      Research Institutes (NHRI) of Taiwan. Using prominent biobanks such as the
      Biobanking and BioMolecular Resources Research Infrastructure-European Research
      Infrastructure Consortium (BBMRI-ERIC), the UK Biobank, and the National
      Institutes of Health (NIH)'s All of Us Research Program as models, the TWB can
      strengthen its on-going TWB 2.0 operations in regional and/or international
      collaboration, increase the value of data collected and develop closer
      relationships with biobank participants and users. To these ends, the authors
      highlight key issues that include, but are not limited to, the harmonization of
      relevant ELSI standards for various biobanks' integrations; the value-added
      services and the efficiency of Big Data Era related research and/or precision
      medicine development, and financial concerns related to biobank sustainability.
      This paper concludes by discussing how greater participant engagement and the
      uptake of Information Technology (IT) and Artificial Intelligence (AI)
      applications can be used in partnership with vertical and horizontal integration 
      as part of a four-pronged approach to promote biobank sustainability, and
      facilitate the TWB 3.0 transformation.
FAU - Lin, Jui-Chu
AU  - Lin JC
AD  - College of Liberal Arts and Social Sciences, National Taiwan University of
      Science and Technology, Taipei, Taiwan, ROC.
AD  - Graduate Institute of Applied Science and Technology, National Taiwan University 
      of Science and Technology, Taipei, Taiwan, ROC.
AD  - Law & Technology Innovation Center, National Taiwan University of Science and
      Technology, Taipei, Taiwan, ROC.
AD  - Ethical, Legal and Social Implications (ELSI) Working Task of the Taiwan Biobank,
      Taipei, Taiwan, ROC.
FAU - Hsiao, Wesley Wei-Wen
AU  - Hsiao WW
AD  - Graduate Institute of Applied Science and Technology, National Taiwan University 
      of Science and Technology, Taipei, Taiwan, ROC.
AD  - Department of Chemical Engineering, National Taiwan University of Science and
      Technology, Taipei, Taiwan, ROC.
FAU - Fan, Chien-Te
AU  - Fan CT
AUID- ORCID: 0000-0002-6482-8320
AD  - Institute of Law for Science and Technology, National Tsing Hua University,
      Hsin-Chu, Taiwan, ROC. ctfan@gapp.nthu.edu.tw.
LA  - eng
PT  - Letter
DEP - 20200806
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
SB  - IM
MH  - Artificial Intelligence
MH  - *Biological Specimen Banks
MH  - Humans
MH  - *Population Health
MH  - Research Personnel
MH  - Taiwan
PMC - PMC7406956
OTO - NOTNLM
OT  - *Artificial intelligence (AI)
OT  - *Big Data
OT  - *Biobank 3.0
OT  - *Ethical, Legal and Social Implications (ELSI)
OT  - *Horizontal integration
OT  - *Vertical integration
EDAT- 2020/08/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12967-020-02451-4 [doi]
AID - 10.1186/s12967-020-02451-4 [pii]
PST - epublish
SO  - J Transl Med. 2020 Aug 6;18(1):304. doi: 10.1186/s12967-020-02451-4.


PMID- 32762729
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 2041-1480 (Electronic)
VI  - 11
IP  - 1
DP  - 2020 Aug 6
TI  - CAS: corpus of clinical cases in French.
PG  - 7
LID - 10.1186/s13326-020-00225-x [doi]
AB  - BACKGROUND: Textual corpora are extremely important for various NLP applications 
      as they provide information necessary for creating, setting and testing those
      applications and the corresponding tools. They are also crucial for designing
      reliable methods and reproducible results. Yet, in some areas, such as the
      medical area, due to confidentiality or to ethical reasons, it is complicated or 
      even impossible to access representative textual data. We propose the CAS corpus 
      built with clinical cases, such as they are reported in the published scientific 
      literature in French. RESULTS: Currently, the corpus contains 4,900 clinical
      cases in French, totaling nearly 1.7M word occurrences. Some clinical cases are
      associated with discussions. A subset of the whole set of cases is enriched with 
      morpho-syntactic (PoS-tagging, lemmatization) and semantic (the UMLS concepts,
      negation, uncertainty) annotations. The corpus is being continuously enriched
      with new clinical cases and annotations. The CAS corpus has been compared with
      similar clinical narratives. When computed on tokenized and lowercase words, the 
      Jaccard index indicates that the similarity between clinical cases and narratives
      reaches up to 0.9727. CONCLUSION: We assume that the CAS corpus can be
      effectively exploited for the development and testing of NLP tools and methods.
      Besides, the corpus will be used in NLP challenges and distributed to the
      research community.
FAU - Grabar, Natalia
AU  - Grabar N
AD  - CNRS, UMR 8163, Lille, F-59000, France. natalia.grabar@univ-lille.fr.
AD  - Univ. Lille, UMR 8163 - STL - Savoirs Textes Langage, Lille, F-59000, France.
      natalia.grabar@univ-lille.fr.
FAU - Dalloux, Clement
AU  - Dalloux C
AD  - Univ Rennes, Inria, CNRS, IRISA, Rennes, F-35000, France.
FAU - Claveau, Vincent
AU  - Claveau V
AD  - Univ Rennes, Inria, CNRS, IRISA, Rennes, F-35000, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200806
PL  - England
TA  - J Biomed Semantics
JT  - Journal of biomedical semantics
JID - 101531992
SB  - IM
MH  - Electronic Health Records
MH  - Information Storage and Retrieval
MH  - *Natural Language Processing
MH  - Semantics
PMC - PMC7410149
OTO - NOTNLM
OT  - *Corpus with clinical cases
OT  - *Medical area
OT  - *Morpho-syntactic and semantic annotation
OT  - *Natural language processing
OT  - *Reproducibility
OT  - *Sustainability
EDAT- 2020/08/09 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/08/09 06:00
PHST- 2019/06/06 00:00 [received]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
AID - 10.1186/s13326-020-00225-x [doi]
AID - 10.1186/s13326-020-00225-x [pii]
PST - epublish
SO  - J Biomed Semantics. 2020 Aug 6;11(1):7. doi: 10.1186/s13326-020-00225-x.


PMID- 32762679
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 6
TI  - Conscientious objection to abortion: why it should be a specified legal right for
      doctors in South Korea.
PG  - 70
LID - 10.1186/s12910-020-00512-3 [doi]
AB  - BACKGROUND: In 2019, the Constitutional Court of South Korea ruled that the
      anti-abortion provisions in the Criminal Act, which criminalize abortion, do not 
      conform to the Constitution. This decision will lead to a total reversal of
      doctors' legal duty from the obligation to refuse abortion services to their
      requirement to provide them, given the Medical Service Act that states that a
      doctor may not refuse a request for treatment or assistance in childbirth. I
      argue, confined to abortion services in Korea that will take place in the near
      future, that doctors should be granted the legal right to exercise conscientious 
      objection to abortion. MAIN TEXT: Considering that doctors in Korea have been
      ethically and legally obligated to refrain from abortions for many years,
      imposing a universal legal duty to provide abortions that does not allow
      exception may endanger the moral integrity of individual doctors who chose a
      career when abortion was illegal. The universal imposition of such a duty may
      result in repudiation of doctors as moral agents and damage trust in doctors that
      forms the basis of medical professionalism. Even if conscientious objection to
      abortion is granted as a legal right, most patients would experience no
      impediment to receiving abortion services because the healthcare environment of
      Korea provides options in which patients can choose their doctors based on prior 
      information, there are many doctors who would be willing to provide an abortion, 
      and Korea is a relatively small country. Finally, the responsibility to
      effectively balance and guarantee the respective rights of the two agents
      involved in abortion, the doctor and the patient, should be imposed on the
      government rather than individual doctors. This assertion is based on the
      government's past behaviours, the nature of its relationship with doctors, and
      the capacity it has to satisfy both doctors' right to conscientious objection and
      patients' right to legal medical services. CONCLUSION: With regard to abortion
      services that will be sought in the near future, doctors should be granted the
      legal right to exercise conscientious objection based on the importance of
      doctor's moral integrity, lack of impediment to patients, and government
      responsibility.
FAU - Kim, Claire Junga
AU  - Kim CJ
AUID- ORCID: 0000-0001-6889-5478
AD  - Department of Medical Education, Ewha Womans University College of Medicine, 52
      Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea.
      clairejungakim@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Abortion, Induced
MH  - Civil Rights
MH  - *Conscience
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Refusal to Treat
MH  - Republic of Korea
PMC - PMC7407431
OTO - NOTNLM
OT  - *Abortion
OT  - *Conscientious objections
OT  - *Decriminalization of abortion
OT  - *Moral integrity
OT  - *No-impediment condition
EDAT- 2020/08/09 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00512-3 [doi]
AID - 10.1186/s12910-020-00512-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 6;21(1):70. doi: 10.1186/s12910-020-00512-3.


PMID- 32762629
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20200812
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Host as a Unique Ethical Dimension of Germline Interventions.
PG  - 51-53
LID - 10.1080/15265161.2020.1782517 [doi]
FAU - Brenna, Connor T A
AU  - Brenna CTA
AUID- ORCID: 0000-0002-6126-3897
AD  - University of Toronto.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):7-18. PMID: 32757931
MH  - *Germ Cells
MH  - *Morals
EDAT- 2020/08/09 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 10.1080/15265161.2020.1782517 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):51-53. doi: 10.1080/15265161.2020.1782517.


PMID- 32762627
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20200812
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Ethical Framework for Next-Generation Genome and Epigenome Editing.
PG  - 32-36
LID - 10.1080/15265161.2020.1782524 [doi]
FAU - Akatsuka, Kyoko
AU  - Akatsuka K
AUID- ORCID: 0000-0003-0254-0943
AD  - Kyoto University.
FAU - Sasaki-Honda, Mitsuru
AU  - Sasaki-Honda M
AUID- ORCID: 0000-0003-1288-1346
AD  - Kyoto University.
FAU - Sawai, Tsutomu
AU  - Sawai T
AUID- ORCID: 0000-0002-3806-0573
AD  - Kyoto University.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):7-18. PMID: 32757931
MH  - CRISPR-Cas Systems
MH  - *Epigenome
MH  - *Gene Editing
EDAT- 2020/08/09 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 10.1080/15265161.2020.1782524 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):32-36. doi: 10.1080/15265161.2020.1782524.


PMID- 32762626
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20200812
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Technical Categories and Ethical Justifications: Why Cwik's Approach is the Wrong
      Way Around for Categorizing Germ-Line Gene Editing.
PG  - 27-29
LID - 10.1080/15265161.2020.1782525 [doi]
FAU - Wrigley, Anthony
AU  - Wrigley A
AUID- ORCID: 0000-0001-8582-9915
AD  - Keele University.
FAU - Newson, Ainsley J
AU  - Newson AJ
AUID- ORCID: 0000-0002-3460-772X
AD  - University of Sydney.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):7-18. PMID: 32757931
MH  - *Gene Editing
MH  - Germ Cells
MH  - *Morals
EDAT- 2020/08/09 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/08/09 06:00
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
AID - 10.1080/15265161.2020.1782525 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):27-29. doi: 10.1080/15265161.2020.1782525.


PMID- 32762186
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 0869-2084 (Print)
IS  - 0869-2084 (Linking)
VI  - 65
IP  - 7
DP  - 2020 Jun 4
TI  - [Ethical boundaries of the legal regulation of genome sequencing in Russia and
      abroad.]
PG  - 458-463
LID - 10.18821/0869-2084-2020-65-7-458-463 [doi]
AB  - The relevance of the chosen topic is due to the need to resolve ethical problems 
      that arise in the framework of legal regulation of genome-wide sequencing in
      Russia and foreign countries. The purpose of this research is to form ethical
      principles that should become a reference point for law - making in this area. In
      order to achieve this goal, we have solved the tasks of studying the normative
      legal acts of Russia and a number of foreign countries from an ethical point of
      view. General scientific, private scientific and special methods of scientific
      knowledge (system-structural, formal-legal) are used. In order to comply with the
      ethical boundaries of legal regulation, to store access and protect full-genome
      sequencing data in Russia and foreign countries, it is proposed to develop a set 
      of restrictions that prevent possible discrimination on genetic grounds, to
      create the necessary conditions for the inadmissibility of disclosure of
      personalized data, disclosure of information about a genetic disease to the
      subject and his relatives, as well as the boundaries of editing the genome of a
      human embryo. For the first time, the authors substantiate the need to establish 
      clear ethical boundaries in the implementation of genome-wide sequencing in
      Russia based on foreign experience.
FAU - Suranova, T G
AU  - Suranova TG
AUID- ORCID: 0000-0003-0768-8365
AD  - Federal Research and Clinical Center of the Federal Medical-Biological Agency,
      125371, Moscow, Russia.
FAU - Suvorov, G N
AU  - Suvorov GN
AUID- ORCID: 0000-0001-8452-5522
AD  - Federal Research and Clinical Center of the Federal Medical-Biological Agency,
      125371, Moscow, Russia.
FAU - Zenin, S S
AU  - Zenin SS
AUID- ORCID: 0000-0002-4520-757X
AD  - Kutafin Moscow State Law University (MSAL), 125993, Moscow, Russia.
LA  - rus
GR  - 18-29-14037/The Russian Foundation for Basic Research
PT  - Journal Article
TT  - capital E, Cyrillicsmall te, Cyrillicsmall i, Cyrillicsmall che, Cyrillicsmall
      ie, Cyrillicsmall es, Cyrillicsmall ka, Cyrillicsmall i, Cyrillicsmall ie,
      Cyrillic small ghe, Cyrillicsmall er, Cyrillicsmall a, Cyrillicsmall en,
      Cyrillicsmall i, Cyrillicsmall tse, Cyrillicsmall yeru, Cyrillic small pe,
      Cyrillicsmall er, Cyrillicsmall a, Cyrillicsmall ve, Cyrillicsmall o,
      Cyrillicsmall ve, Cyrillicsmall o, Cyrillicsmall ghe, Cyrillicsmall o, Cyrillic
      small er, Cyrillicsmall ie, Cyrillicsmall ghe, Cyrillicsmall u, Cyrillicsmall el,
      Cyrillicsmall i, Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ve,
      Cyrillicsmall a, Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic
      small pe, Cyrillicsmall o, Cyrillicsmall el, Cyrillicsmall en, Cyrillicsmall o,
      Cyrillicsmall ghe, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall o,
      Cyrillicsmall em, Cyrillicsmall en, Cyrillicsmall o, Cyrillicsmall ghe,
      Cyrillicsmall o, Cyrillic small es, Cyrillicsmall ie, Cyrillicsmall ka,
      Cyrillicsmall ve, Cyrillicsmall ie, Cyrillicsmall en, Cyrillicsmall i,
      Cyrillicsmall er, Cyrillicsmall o, Cyrillicsmall ve, Cyrillicsmall a,
      Cyrillicsmall en, Cyrillicsmall i, Cyrillicsmall ya, Cyrillic small ve, Cyrillic 
      capital ER, Cyrillicsmall o, Cyrillicsmall es, Cyrillicsmall es, Cyrillicsmall i,
      Cyrillicsmall i, Cyrillic small i, Cyrillic small ze, Cyrillicsmall a, Cyrillic
      small er, Cyrillicsmall u, Cyrillicsmall be, Cyrillicsmall ie, Cyrillicsmall zhe,
      Cyrillicsmall o, Cyrillicsmall em, Cyrillic.
PL  - Russia (Federation)
TA  - Klin Lab Diagn
JT  - Klinicheskaia laboratornaia diagnostika
JID - 9432021
SB  - IM
MH  - Humans
MH  - *Internationality
MH  - Russia
MH  - *Whole Genome Sequencing/ethics
OTO - NOTNLM
OT  - bioethics
OT  - discrimination
OT  - ethical issues
OT  - genome-wide sequencing
OT  - legal regulation
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/08 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.18821/0869-2084-2020-65-7-458-463 [doi]
PST - ppublish
SO  - Klin Lab Diagn. 2020 Jun 4;65(7):458-463. doi:
      10.18821/0869-2084-2020-65-7-458-463.


PMID- 32762024
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 67
IP  - 10
DP  - 2020 Oct
TI  - Comment on: An ethical imperative: Safety and specialization as nursing
      priorities of WHO global initiative for childhood cancer: Advocating for the
      baseline nursing standards.
PG  - e28642
LID - 10.1002/pbc.28642 [doi]
FAU - Abramovitz, Linda
AU  - Abramovitz L
AUID- ORCID: 0000-0002-7216-590X
AD  - School of Nursing and Global Cancer Program, University of California, San
      Francisco, California.
FAU - Afungchwi, Glenn
AU  - Afungchwi G
AUID- ORCID: 0000-0002-5512-9624
AD  - Paediatric Oncology, Mbingo Baptist Hospital and Banso Baptist Hospital, Mbingo, 
      Cameroon.
FAU - Punjwani, Rehana
AU  - Punjwani R
AD  - Nursing Department, The Indus Hospital, Karachi, Pakistan.
FAU - Sullivan, Courtney
AU  - Sullivan C
AD  - Department of Global Pediatric Medicine, St Jude Children's Research Hospital,
      Memphis, Tennessee.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200806
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
SB  - IM
CON - Pediatr Blood Cancer. 2020 Apr;67(4):e28143. PMID: 31886610
MH  - Child
MH  - Humans
MH  - *Neoplasms
MH  - Reference Standards
MH  - Specialization
MH  - World Health Organization
EDAT- 2020/08/08 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/07/19 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1002/pbc.28642 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2020 Oct;67(10):e28642. doi: 10.1002/pbc.28642. Epub 2020
      Aug 6.


PMID- 32762002
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov
TI  - A Public Health Ethics Analysis of the Criminalization of Direct Entry Midwifery.
PG  - 789-794
LID - 10.1111/jmwh.13144 [doi]
AB  - Multiple types of midwives practice in the United States, but regulation of
      midwifery practice varies by state. In some states, direct entry midwifery
      practice is unregulated or criminalized. Because regulations are the most
      burdensome of the public health interventions, they require the most stringent
      ethical critique. This article uses the most recent Public Health Code of Ethics 
      to analyze the ethics of regulations that criminalize direct entry midwifery
      practice. The Code establishes 8 criteria for ethical actions: (1)
      permissibility, (2) respect, (3) reciprocity, (4) effectiveness, (5) responsible 
      use of scarce resources, (6) proportionality, (7) accountability and
      transparency, and (8) public participation. Laws that criminalize direct entry
      midwifery practice violate all of these criteria and therefore cannot be
      considered an ethical approach to the state's duty to safeguard public health.
      The remedy for this problem is for all states to license and regulate all types
      of midwives that meet international standards of education and training.
CI  - (c) 2020 by the American College of Nurse-Midwives.
FAU - DeJoy, Sharon Bernecki
AU  - DeJoy SB
AUID- ORCID: 0000-0003-4273-4531
AD  - Department of Health, College of Health Sciences, West Chester University, West
      Chester, Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - United States
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
SB  - IM
MH  - *Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Licensure
MH  - *Midwifery
MH  - *Nurse Midwives
MH  - Pregnancy
MH  - Public Health
MH  - Social Responsibility
MH  - United States
OTO - NOTNLM
OT  - *codes of ethics
OT  - *home birth
OT  - *licensure
OT  - *midwifery
OT  - *pregnancy
OT  - *public health
EDAT- 2020/08/08 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1111/jmwh.13144 [doi]
PST - ppublish
SO  - J Midwifery Womens Health. 2020 Nov;65(6):789-794. doi: 10.1111/jmwh.13144. Epub 
      2020 Aug 6.


PMID- 32761691
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20220727
IS  - 1440-1843 (Electronic)
IS  - 1323-7799 (Linking)
VI  - 25
IP  - 10
DP  - 2020 Oct
TI  - Medical ethics in the era of COVID-19: Now and the future.
PG  - 1033-1034
LID - 10.1111/resp.13927 [doi]
FAU - Chew, Christopher
AU  - Chew C
AUID- ORCID: 0000-0002-4784-2526
AD  - Department of Respiratory and Sleep Medicine, Western Health, Melbourne, VIC,
      Australia.
FAU - Ko, Danielle
AU  - Ko D
AD  - Department of Pallative Care, Austin Health, Melbourne, VIC, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200805
PL  - Australia
TA  - Respirology
JT  - Respirology (Carlton, Vic.)
JID - 9616368
SB  - IM
CON - Crit Care. 2020 Apr 22;24(1):165. PMID: 32321562
MH  - *COVID-19
MH  - Critical Care
MH  - Ethics, Clinical
MH  - Ethics, Medical
MH  - Humans
MH  - Italy
MH  - Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - Resource Allocation
MH  - SARS-CoV-2
PMC - PMC7436603
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *pandemic
EDAT- 2020/08/08 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/07/15 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1111/resp.13927 [doi]
PST - ppublish
SO  - Respirology. 2020 Oct;25(10):1033-1034. doi: 10.1111/resp.13927. Epub 2020 Aug 5.


PMID- 32761554
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1678-8052 (Electronic)
IS  - 1519-566X (Linking)
VI  - 49
IP  - 4
DP  - 2020 Aug
TI  - Why the views of Latin American Scientists on Citizen Science as a Tool for
      Pollinator Monitoring and Conservation Matter?
PG  - 604-613
LID - 10.1007/s13744-020-00793-8 [doi]
AB  - Pollinators are threatened all over the planet; scientific data about the status 
      of them is essential for planning conservation and impact mitigation. Appropriate
      methods and costs for monitoring are being discussed and non-scientist
      participation in data collection in citizen science (CS) projects is a very
      promising option. However, there is criticism regarding the quality of data
      gathered by non-scientists and their real contribution to scientific research,
      which makes the engagement of scientists in these projects crucial for data
      verification and validation and training volunteers. CS is still poorly spread in
      Latin America, so in order to propose strategies to engage scientists, it is
      necessary to understand the attitude of these professionals towards CS and their 
      interests in engaging in it. To this end, we conducted a survey with 96
      biodiversity scientists based in five Latin American countries. In general, the
      respondents have a very favorable attitude towards CS, although only a small
      percentage of them are engaged in CS projects. Obtaining data for scientific
      research is the scientists' main interest in CS, although some of them have also 
      expressed more altruistic reasons for engaging in CS related to ethical and
      social values. Our paper also suggests five interrelated strategies that can be
      taken to engage scientists in CS, covering the following: (a) create funding
      lines to support projects, (b) include extension and outreach activities in the
      system of scientists' evaluation, (c) promote an inter and transdisciplinary
      infrastructure, (d) promote scientists' building capacities in CS, and (e)
      encourage scientists to do science communication.
FAU - Viana, B F
AU  - Viana BF
AUID- ORCID: https://orcid.org/0000-0002-4924-1257
AD  - Biology Institute, Federal Univ of Bahia, Ondina, Salvador, Bahia, CEP:
      40170-115, Brazil. blande.viana@gmail.com.
AD  - National Institute of Science and Technology in Inter and Transdisciplinary
      Studies in Ecology and Evolution - INCT IN-TREE, Salvador, Bahia, 40170-115,
      Brazil. blande.viana@gmail.com.
FAU - Souza, C Q
AU  - Souza CQ
AD  - Biology Institute, Federal Univ of Bahia, Ondina, Salvador, Bahia, CEP:
      40170-115, Brazil.
AD  - National Institute of Science and Technology in Inter and Transdisciplinary
      Studies in Ecology and Evolution - INCT IN-TREE, Salvador, Bahia, 40170-115,
      Brazil.
FAU - Moreira, E F
AU  - Moreira EF
AD  - Biology Institute, Federal Univ of Bahia, Ondina, Salvador, Bahia, CEP:
      40170-115, Brazil.
AD  - National Institute of Science and Technology in Inter and Transdisciplinary
      Studies in Ecology and Evolution - INCT IN-TREE, Salvador, Bahia, 40170-115,
      Brazil.
LA  - eng
GR  - codes: INCT-IN-TREE (465767/2014-1/Instituto Nacional de Ciencia e Tecnologia
GR  - code: 305470/2013-2/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
GR  - Processo: Programa de Professor Visitante no Exterior -
      88881.172329/2018-01/CAPES
PT  - Journal Article
DEP - 20200806
PL  - Netherlands
TA  - Neotrop Entomol
JT  - Neotropical entomology
JID - 101189728
SB  - IM
MH  - *Attitude
MH  - *Biodiversity
MH  - *Citizen Science
MH  - Female
MH  - Humans
MH  - Latin America
MH  - Male
MH  - *Pollination
MH  - *Research Personnel
MH  - Surveys and Questionnaires
MH  - Volunteers
OTO - NOTNLM
OT  - Engagement strategies
OT  - perception
OT  - pollination service
OT  - public engagement with science
OT  - public policies
EDAT- 2020/08/08 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/08/08 06:00
PHST- 2019/09/11 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1007/s13744-020-00793-8 [doi]
AID - 10.1007/s13744-020-00793-8 [pii]
PST - ppublish
SO  - Neotrop Entomol. 2020 Aug;49(4):604-613. doi: 10.1007/s13744-020-00793-8. Epub
      2020 Aug 6.


PMID- 32761351
OWN - NLM
STAT- MEDLINE
DCOM- 20201016
LR  - 20210110
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - COVID-19 and the ethics of quarantine: a lesson from the Eyam plague.
PG  - 603-609
LID - 10.1007/s11019-020-09971-2 [doi]
AB  - The recent outbreak of the SARS-CoV-2 coronavirus is posing many different
      challenges to local communities, directly affected by the pandemic, and to the
      global community, trying to find how to respond to this threat in a larger scale.
      The history of the Eyam Plague, read in light of Ross Upshur's Four Principles
      for the Justification of Public Health Intervention, and of the Siracusa
      Principles on the Limitation and Derogation Provisions in the International
      Covenant on Civil and Political Rights, could provide useful guidance in
      navigating the complex ethical issues that arise when quarantine measures need to
      be put in place.
FAU - Spitale, Giovanni
AU  - Spitale G
AUID- ORCID: http://orcid.org/0000-0002-6812-0979
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland. giovanni.spitale@ibme.uzh.ch.
LA  - eng
GR  - 31CA30_195905/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen 
      Forschung
PT  - Historical Article
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - England/epidemiology
MH  - History, 17th Century
MH  - Humans
MH  - Infection Control/methods
MH  - London/epidemiology
MH  - Pandemics/*prevention & control
MH  - Plague/*history/prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Public Health/ethics
MH  - Quarantine/ethics/*history
PMC - PMC7405927
OTO - NOTNLM
OT  - COVID-19
OT  - Eyam
OT  - History of epidemiology
OT  - History of medicine
OT  - Plague
OT  - Public health ethics
OT  - SARS-CoV-2
EDAT- 2020/08/08 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1007/s11019-020-09971-2 [doi]
AID - 10.1007/s11019-020-09971-2 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):603-609. doi: 10.1007/s11019-020-09971-2.


PMID- 32761302
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 2195-7819 (Electronic)
IS  - 2195-7819 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Aug 6
TI  - How should researchers cope with the ethical demands of discovering research
      misconduct? Going beyond reporting and whistleblowing.
PG  - 6
LID - 10.1186/s40504-020-00102-6 [doi]
AB  - In this paper, I will argue that making it mandatory to report research
      misconduct is too demanding, as this kind of intervention can at times be
      self-destructive for the researcher reporting the misconduct. I will also argue
      that posing the question as a binary dilemma masks important ethical aspects of
      such situations. In situations that are too demanding for individual researchers 
      to rectify through reporting, there can be other forms of social control
      available. I will argue that researchers should explore these. Finally, framing
      the issue as a question about the responsibilities of individual researchers
      masks the responsibilities of research institutions. Until institutions introduce
      measures that make this safe and effective, we should not consider reporting
      research misconduct mandatory. I will discuss this in light of both quantitative 
      and qualitative data gathered as part of a survey in the PRINTEGER-project.
FAU - Vie, Knut Jorgen
AU  - Vie KJ
AUID- ORCID: http://orcid.org/0000-0002-8228-6078
AD  - Work Research Institute - Oslo Metropolitan University, Stensberggt. 26, Oslo,
      Norway. vikj@oslomet.no.
LA  - eng
GR  - 665926/Horizon 2020
PT  - Journal Article
DEP - 20200806
PL  - England
TA  - Life Sci Soc Policy
JT  - Life sciences, society and policy
JID - 101603561
SB  - IM
MH  - Adaptation, Psychological
MH  - Humans
MH  - Qualitative Research
MH  - Research Personnel/*ethics/*psychology
MH  - Scientific Misconduct/*ethics
MH  - Whistleblowing/*ethics/*psychology
PMC - PMC7409624
EDAT- 2020/08/08 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/08/08 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
AID - 10.1186/s40504-020-00102-6 [doi]
AID - 10.1186/s40504-020-00102-6 [pii]
PST - epublish
SO  - Life Sci Soc Policy. 2020 Aug 6;16(1):6. doi: 10.1186/s40504-020-00102-6.


PMID- 32761149
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20210127
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Linking)
VI  - 6
IP  - 9
DP  - 2020 Sep 1
TI  - Applying Lessons Learned From Low-Resource Settings to Prioritize Cancer Care in 
      a Pandemic.
PG  - 1429-1433
LID - 10.1001/jamaoncol.2020.2976 [doi]
AB  - Importance: The coronavirus disease 2019 (COVID-19) pandemic has forced oncology 
      clinicians and administrators in the United States to set priorities for cancer
      care owing to resource constraints. As oncology practices adapt to a contracted
      health care system, expertise gained from partnerships in low-resource settings
      can be used for guidance. This article provides a primer on priority setting in
      oncology and ethical guidance based on lessons learned from experience with
      cancer care priority setting in low-resource settings. Observations: Lessons
      learned from real-world experiences are myriad. First, in the setting of limited 
      resources, a utilitarian approach to maximizing survival benefit should guide
      decision-making. Second, conflicting principles will often arise among
      stakeholders and decision makers. Third, fair decision-making procedures should
      be established to ensure moral legitimacy and accountability. Fourth, proactive
      safeguards must be implemented to protect vulnerable individuals, or disparities 
      in cancer treatment and outcomes will only widen further. Fifth, communication
      with patients and families about priority setting decisions should be intentional
      and standardized. Sixth, moral distress among clinicians must be addressed to
      avoid burnout during a time when resilience is critical. Conclusions and
      Relevance: Although the need to triage cancer care may be new to those who
      underwent training and now practice oncology in high-resource settings, it is
      familiar for those who practice in low- and middle-income countries. Oncologists 
      in the United States facing unprecedented decisions about prioritization can draw
      on ethical frameworks and lessons learned from real-world cancer care priority
      setting in resource-constrained environments.
FAU - DeBoer, Rebecca J
AU  - DeBoer RJ
AD  - Division of Hematology/Oncology, University of California, San Francisco.
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
FAU - Fadelu, Temidayo A
AU  - Fadelu TA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Shulman, Lawrence N
AU  - Shulman LN
AD  - Abramson Cancer Center, University of Pennsylvania, Philadelphia.
FAU - Van Loon, Katherine
AU  - Van Loon K
AD  - Division of Hematology/Oncology, University of California, San Francisco.
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
LA  - eng
GR  - D43 TW009343/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
SB  - IM
EIN - JAMA Oncol. 2020 Sep 1;6(9):1473. PMID: 32910157
MH  - Betacoronavirus/pathogenicity
MH  - COVID-19
MH  - Communication
MH  - Coronavirus Infections/complications/*epidemiology/virology
MH  - Decision Making
MH  - Health Resources
MH  - Humans
MH  - Neoplasms/complications/*epidemiology/virology
MH  - *Oncology Service, Hospital
MH  - *Pandemics
MH  - Pneumonia, Viral/complications/*epidemiology/virology
MH  - SARS-CoV-2
MH  - United States/epidemiology
EDAT- 2020/08/08 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 2769128 [pii]
AID - 10.1001/jamaoncol.2020.2976 [doi]
PST - ppublish
SO  - JAMA Oncol. 2020 Sep 1;6(9):1429-1433. doi: 10.1001/jamaoncol.2020.2976.


PMID- 32761078
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20211204
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 50
IP  - 9
DP  - 2020 Sep 5
TI  - Advance care planning in Asian culture.
PG  - 976-989
LID - 10.1093/jjco/hyaa131 [doi]
AB  - Ageing has been recognized as one of the most critically important health-care
      issues worldwide. It is relevant to Asia, where the increasing number of older
      populations has drawn attention to the paramount need for health-care investment,
      particularly in end-of-life care. The advocacy of advance care planning is a mean
      to honor patient autonomy. Since most East Asian countries are influenced by
      Confucianism and the concept of 'filial piety,' patient autonomy is consequently 
      subordinate to family values and physician authority. The dominance from family
      members and physicians during a patient's end-of-life decision-making is
      recognized as a cultural feature in Asia. Physicians often disclose the patient's
      poor prognosis and corresponding treatment options to the male, family member
      rather to the patient him/herself. In order to address this ethical and practical
      dilemma, the concept of 'relational autonomy' and the collectivism paradigm might
      be ideally used to assist Asian people, especially older adults, to share their
      preferences on future care and decision-making on certain clinical situations
      with their families and important others. In this review article, we invited
      experts in end-of-life care from Hong Kong, Indonesia, Japan, South Korea,
      Singapore and Taiwan to briefly report the current status of advance care
      planning in each country from policy, legal and clinical perspectives. According 
      to the Asian experiences, we have seen different models of advance care planning 
      implementation. The Asian Delphi Taskforce for advance care planning is currently
      undertaken by six Asian countries and a more detailed, culturally sensitive
      whitepaper will be published in the near future.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights
      reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Cheng, Shao-Yi
AU  - Cheng SY
AD  - Department of Family Medicine, College of Medicine and Hospital, National Taiwan 
      University, Taipei, Taiwan.
FAU - Lin, Cheng-Pei
AU  - Lin CP
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's
      College London, London, UK.
FAU - Chan, Helen Yue-Lai
AU  - Chan HY
AD  - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of 
      Hong Kong, Central Ave, Hong Kong.
FAU - Martina, Diah
AU  - Martina D
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical
      Center Rotterdam, Rotterdam, the Netherlands.
AD  - Department of Public Health, Erasmus MC, University Medical Center Rotterdam,
      Rotterdam, the Netherlands.
AD  - Division of Psychosomatic and Palliative Medicine, Department of Internal
      Medicine Universitas Indonesia, Jakarta Pusat, Indonesia.
FAU - Mori, Masanori
AU  - Mori M
AD  - Palliative Care Team, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
FAU - Kim, Sun-Hyun
AU  - Kim SH
AD  - Department of Family Medicine, International St. Mary's Hospital, College of
      Medicine, Catholic Kwandong University, Incheon, Republic of Korea.
FAU - Ng, Raymond
AU  - Ng R
AD  - Department of Palliative Medicine, Tan Tock Seng Hospital, Jln Tan Tock Seng,
      Singapore.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
SB  - IM
MH  - Advance Care Planning/*standards
MH  - Aged
MH  - Aging
MH  - Asians
MH  - Female
MH  - Humans
MH  - Male
MH  - Terminal Care/*standards
OTO - NOTNLM
OT  - advance care planning
OT  - autonomy
OT  - palliative care
EDAT- 2020/08/08 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/08/08 06:00
PHST- 2019/11/28 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 5881673 [pii]
AID - 10.1093/jjco/hyaa131 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2020 Sep 5;50(9):976-989. doi: 10.1093/jjco/hyaa131.


PMID- 32760838
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 7
DP  - 2020 Jul
TI  - Improper disposal practice of unused and expired pharmaceutical products in
      Indonesian households.
PG  - e04551
LID - 10.1016/j.heliyon.2020.e04551 [doi]
AB  - BACKGROUND: Improperly disposed medicines could adversely affect the environment 
      and increase the risk of drug misuse or accidental poisoning. OBJECTIVE: To
      evaluate the disposal practices of unused and expired medicines among the general
      population in Bandung, Indonesia. METHOD: This was a descriptive cross-sectional 
      survey conducted among 497 respondents in Bandung, Indonesia. Data were collected
      through interviews using a prevalidated structured questionnaire. Descriptive
      statistics were calculated using the Statistical Package for Social Science
      (SPSS) version 23. Ethics approval was obtained. MAIN OUTCOME MEASURE: General
      public knowledge and attitude regarding unused and expired medication disposal
      practice. RESULTS: Approximately 95% of the respondents had unused medicines
      stored in their homes, with nonsteroidal anti-inflammatory drugs (NSAIDs),
      vitamins/nutritional supplements, and antibiotics were the most common types of
      medicines left unused. The majority of the respondents checked the expiration
      date of the drugs before purchasing (72.8%). The most common disposal method of
      unwanted medicines was throwing away in household garbage (82.1%). A significant 
      percentage of them never received information about proper medication disposal
      practice (79.5%). Furthermore, more than half of the respondents were unaware
      that unsafe medication disposal practices could harm the environment and
      population health (53.1%). CONCLUSION: Disposal of unwanted pharmaceutical
      products through environmentally unsafe route was prevalent among the
      respondents. There is also a lack of awareness of the impact of improperly
      disposed of medicines for the ecosystem. These findings call upon the strategies 
      to strengthen the pharmaceutical waste management program.
CI  - (c) 2020 The Author(s).
FAU - Insani, Widya N
AU  - Insani WN
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Qonita, Nabilla A
AU  - Qonita NA
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Jannah, Siti S
AU  - Jannah SS
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Nuraliyah, Nisa M
AU  - Nuraliyah NM
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Supadmi, Woro
AU  - Supadmi W
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Gatera, Vesara A
AU  - Gatera VA
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Alfian, Sofa D
AU  - Alfian SD
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
FAU - Abdulah, Rizky
AU  - Abdulah R
AD  - Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran,
      Indonesia.
AD  - Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
      Universitas Padjadjaran, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7393449
OTO - NOTNLM
OT  - Environmental hazard
OT  - Environmental health
OT  - Expired
OT  - Medication disposal
OT  - Pharmaceuticals
OT  - Public health
OT  - Unused
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04551 [doi]
AID - S2405-8440(20)31395-5 [pii]
AID - e04551 [pii]
PST - epublish
SO  - Heliyon. 2020 Jul 29;6(7):e04551. doi: 10.1016/j.heliyon.2020.e04551. eCollection
      2020 Jul.


PMID- 32760646
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2212-4268 (Print)
IS  - 2212-4268 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Influence of platelet-rich fibrin on wound healing and bone regeneration after
      tooth extraction: A clinical and radiographic study.
PG  - 385-390
LID - 10.1016/j.jobcr.2020.06.012 [doi]
AB  - AIM: The aim of the study was to evaluate the influence of autologous
      platelet-rich fibrin (PRF) on soft tissue healing and bone regeneration following
      tooth extraction clinically and radio-graphically. MATERIALS AND METHODS: 30
      Patients between the age group of 18-40 years requiring extraction of bilateral
      mandibular molars except third molars were selected to conduct a split-mouth
      study after ethical approval. Teeth extraction was done on both sides in the same
      appointment. Autologous PRF was placed into the socket on one side randomly, and 
      the socket on the other side was taken as control side. Parameters evaluated were
      soft tissue healing and bone regeneration. Soft tissue healing was evaluated on
      post-extraction day-3, day-7 and day-14 using healing index by Landry et al. Bone
      regeneration was assessed immediately and 4 months post-extraction by observation
      of change in radiopacity through digital panoramic-radiograph. Data obtained was 
      statistically analysed and comparison of outcome variables was done using
      Mann-Whitney U-test, p < 0.05 was considered statistically significant. RESULTS: 
      Case group had better soft tissue healing when compared to the control group with
      the p-value of 0.025 at 3rd day 0.039 at 7th day and 0.00 at 14th day. The rise
      in radiopacity at the end of 16th week for PRF group was higher as compared to
      control group but did not differ significantly. CONCLUSION: PRF is significantly 
      better in promoting soft tissue healing and also hastens bone formation in
      extraction socket. PRF may be recommended as a valuable material for encouraging 
      soft tissue healing and bone regeneration.
CI  - (c) 2020 Craniofacial Research Foundation. Published by Elsevier B.V. All rights 
      reserved.
FAU - Sharma, Ankit
AU  - Sharma A
AD  - Department of Oral and Maxillofacial Surgery, R R Dental College & Hospital,
      Udaipur, Rajasthan, 313015, India.
FAU - Ingole, Snehal
AU  - Ingole S
AD  - Department of Oral and Maxillofacial Surgery, Nair Hospital Dental College,
      Mumbai Central, Mumbai, Maharashtra, 400008, India.
FAU - Deshpande, Mohan
AU  - Deshpande M
AD  - Department of Oral and Maxillofacial Surgery, Nair Hospital Dental College,
      Mumbai Central, Mumbai, Maharashtra, 400008, India.
FAU - Ranadive, Pallavi
AU  - Ranadive P
AD  - Department of Oral and Maxillofacial Surgery, Nair Hospital Dental College,
      Mumbai Central, Mumbai, Maharashtra, 400008, India.
FAU - Sharma, Sneha
AU  - Sharma S
AD  - Department of Oral Medicine and Radiology, Nair Hospital Dental College, Mumbai
      Central, Mumbai, 400008, Maharashtra, India.
FAU - Kazi, Noaman
AU  - Kazi N
AD  - Department of Oral and Maxillofacial Surgery, Nair Hospital Dental College,
      Mumbai Central, Mumbai, Maharashtra, 400008, India.
FAU - Rajurkar, Suday
AU  - Rajurkar S
AD  - Department of Oral and Maxillofacial Surgery, Nair Hospital Dental College,
      Mumbai Central, Mumbai, Maharashtra, 400008, India.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - Netherlands
TA  - J Oral Biol Craniofac Res
JT  - Journal of oral biology and craniofacial research
JID - 101619156
PMC - PMC7393389
OTO - NOTNLM
OT  - Bone regeneration
OT  - Platelet rich fibrin
OT  - Post extraction socket
OT  - Wound healing
COIS- The authors declare no conflict of interest regarding the publication of this
      article.
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.1016/j.jobcr.2020.06.012 [doi]
AID - S2212-4268(20)30080-4 [pii]
PST - ppublish
SO  - J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):385-390. doi:
      10.1016/j.jobcr.2020.06.012. Epub 2020 Jul 1.


PMID- 32760589
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2052-1847 (Print)
IS  - 2052-1847 (Linking)
VI  - 12
DP  - 2020
TI  - Comparative study of physiologic characteristics between the newly compiled Bafa 
      Wubu of tai chi and 24 form simplified tai chi.
PG  - 43
LID - 10.1186/s13102-020-00192-x [doi]
AB  - BACKGROUND: The newly compiled Bafa Wubu of Tai Chi (Eight Methods and Five
      Footworks) is a fitness routine that has been developed in accordance with the
      appeal of the General Administration of Sport of China and promoted both in China
      and abroad. This paper aims to compare the differences in energy consumption and 
      related parameters between the two types of Tai Chi. METHODS: A total of 60
      healthy participants were recruited; 37 males (aged 37.4 +/- 10.4 years) and 23
      females (aged 31.9 +/- 12.8 years). The maximal exercise capacity of participants
      was measured at baseline. Then, they received Tai Chi training for 12-week and
      their energy metabolism was measured dynamically. RESULTS: A set of the Bafa Wubu
      of Tai Chi requires approximately 3 min, while a set of 24 form simplified Tai
      Chi approximately 5 min and 40 s. The average oxygen uptake/kg (VO2/kg, 10.8 +/- 
      2.52 ml/kg/min vs. 12.9 +/- 2.59 ml/kg/min, P = 0.000), the highest VO2/kg (19.3 
      +/- 6.03 ml/kg/min vs. 24.1 +/- 7.50 ml/kg/min, p = 0.000, the average metabolic 
      equivalent (METs,2.3 +/- 0.16 METs vs. 3.2 +/- 0.14 METs, p = 0.000), the highest
      oxygen pulse (VO2/HR, 11.1 +/- 0.99 ml vs. 13.9 +/- 0.93 ml, p = 0.000) and rate 
      of perceived exertion (RPE, 10.7 +/- 0.70 vs. 1.3 +/- 0.62, p = 0.000) gained
      immediately after Bafa Wubu of Tai Chi exercise were significantly lower than
      those in 24 form simplified Tai Chi; heart rate recovery (HRR,1.5 +/- 0.41 vs.
      1.3 +/- 0.45, p = 0.008) at 1 min after the practice was significantly higher
      than after the 24 form simplified Tai Chi. Meanwhile, the average heart rate (HR,
      104.1 +/- 11.41 bpm vs. 105.7 +/- 9.68 bpm, p = 0.696) and the highest
      respiratory quotient (RQ, 1.0 +/- 0.06 vs. 0.9 +/- 0.09, p = 0.643) were not
      significantly different. The intensity of Tai Chi was described as the highest
      oxygen uptake of the participants when they performed the Tai Chi divided by
      their individual maximal oxygen uptake. Tai Chi intensity during Bafa Wubu of Tai
      Chi (50% +/- 11.7% vs. 64% +/- 12.5%) was significantly lower than during 24 form
      simplified Tai Chi. CONCLUSION: The newly compiled Bafa Wubu of Tai Chi is
      characterized by lower energy consumption than 24 form simplified Tai Chi. TRIAL 
      REGISTRATION: Ethics Committee of Sports Science Experiment, Beijing Sport
      University- 2018010H. Registered 19 June 2018.
CI  - (c) The Author(s) 2020.
FAU - Lyu, Shaojun
AU  - Lyu S
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      100875 China.grid.20513.350000 0004 1789 9964
FAU - Zhang, Jianwei
AU  - Zhang J
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      100875 China.grid.20513.350000 0004 1789 9964
FAU - Nie, Jianquan
AU  - Nie J
AD  - Party Office, The Central Institute of Ethnic Administrators, Beijing, 100094
      China.
FAU - Li, Cuihan
AU  - Li C
AD  - College of Wushu, Beijing Sport University, Beijing, 100084
      China.grid.411614.70000 0001 2223 5394
FAU - Gao, Tianming
AU  - Gao T
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      100875 China.grid.20513.350000 0004 1789 9964
FAU - Yuan, Wen
AU  - Yuan W
AD  - College of Wushu, Beijing Sport University, Beijing, 100084
      China.grid.411614.70000 0001 2223 5394
FAU - Chen, Zaihao
AU  - Chen Z
AD  - College of Wushu, Beijing Sport University, Beijing, 100084
      China.grid.411614.70000 0001 2223 5394
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Cardiology, First Medical Center of Chinese People's Libration Army
      General Hospital, Beijing, 100853 China.grid.414252.40000 0004 1761 8894
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - BMC Sports Sci Med Rehabil
JT  - BMC sports science, medicine & rehabilitation
JID - 101605016
PMC - PMC7391605
OTO - NOTNLM
OT  - 24 form simplified tai chi
OT  - Bafa Wubu of tai chi
OT  - Energy metabolism
OT  - Exercise intensity
OT  - Oxygen uptake
COIS- Competing interestsThe authors declare that they have no competing interest.
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2019/10/12 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.1186/s13102-020-00192-x [doi]
AID - 192 [pii]
PST - epublish
SO  - BMC Sports Sci Med Rehabil. 2020 Jul 29;12:43. doi: 10.1186/s13102-020-00192-x.
      eCollection 2020.


PMID- 32760584
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 57
DP  - 2020 Sep
TI  - Stroke care and outcomes in the Department of Neurology in Parakou, Benin:
      Retrospective cohort study.
PG  - 148-152
LID - 10.1016/j.amsu.2020.07.041 [doi]
AB  - INTRODUCTION: Stroke is one of the most common causes of high mortality rates in 
      Africa with many unknown aspects around its prognosis. In this study we aim to
      describe stroke characteristics and in-hospital mortality of stroke in Parakou.
      METHODS: This is a retrospective cohort study including all stroke patients
      admitted to the Department of Neurology at Parakou Teaching Hospital from January
      1, 2013 through to December 31, 2019. Clinical data, vascular risk factors,
      stroke subtype and outcome data were recorded. The in-hospital case-fatality and 
      its associated factors were determined. The study was approved by the Local
      Ethics Committee of Biomedical research and has been registered under the unique 
      indentifying number researchregistry5687 and is available at
      https://www.researchregistry.com/browse-the-registry#home/. RESULTS: Stroke cases
      represented 51.5% of all patients. There were 372 patients included in the study 
      with a mean age of 58.2 +/- 14.2 years. The sex ratio was 1:3. Ischemic stroke
      accounted for 40.3%, intracerebral hemorrhage 30.4%, and unknown 29.3%. The main 
      vascular risk factors were hypertension (69.1%), alcoholism (23.9%) and diabetes 
      mellitus (16.9%). The mean NIHSS at admission was 9.4 +/- 5.7 and the length of
      hospital stay was 9.0 +/- 7.3. The most common complications recorded during the 
      acute phase were swallowing disorders (10.2%), pneumonia (9.1%) and urinary tract
      infections (8.3%). The in-hospital case fatality was 6.2% and was associated with
      loss of consciousness (p = 0.0001), high NIHSS on admission (p = 0.001), fever (p
      = 0.0001), swallowing disorders (p = 0.001) and leukocytosis (p = 0.021). On
      discharge, 27.6% were independent and 97.8% were on antihypertensive drugs.
      CONCLUSION: The in-hospital stroke mortality was close to that reported by other 
      studies in Africa.
CI  - (c) 2020 The Author(s).
FAU - Adoukonou, Thierry
AU  - Adoukonou T
AD  - Department of Neurology, University of Parakou, 03BP 10, Parakou, Benin.
AD  - Clinic of Neurology, University Teaching Hospital of Parakou, Benin.
AD  - U-1094 INSERM, University of Limoges, CHU Limoges, U-1094, Tropical
      Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,
      87000, Limoges, France.
AD  - Department of Neurology, CHU Limoges Dupuytren, 87000, Limoges, France.
FAU - Agbetou, Mendinatou
AU  - Agbetou M
AD  - Department of Neurology, University of Parakou, 03BP 10, Parakou, Benin.
AD  - Clinic of Neurology, University Teaching Hospital of Parakou, Benin.
FAU - Sowanou, Arlos
AU  - Sowanou A
AD  - Clinic of Neurology, University Teaching Hospital of Parakou, Benin.
FAU - Kossi, Oyene
AU  - Kossi O
AD  - Clinic of Neurology, University Teaching Hospital of Parakou, Benin.
FAU - Fotso, Pervenche
AU  - Fotso P
AD  - Clinic of Neurology, University Teaching Hospital of Parakou, Benin.
FAU - Houehanou, Corine
AU  - Houehanou C
AD  - Clinic of Neurology, University Teaching Hospital of Parakou, Benin.
AD  - U-1094 INSERM, University of Limoges, CHU Limoges, U-1094, Tropical
      Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,
      87000, Limoges, France.
FAU - Vallat, Jean-Michel
AU  - Vallat JM
AD  - Department of Neurology, CHU Limoges Dupuytren, 87000, Limoges, France.
FAU - Houinato, Dismand
AU  - Houinato D
AD  - U-1094 INSERM, University of Limoges, CHU Limoges, U-1094, Tropical
      Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,
      87000, Limoges, France.
AD  - Department of Neurology, University of Abomey-Calavi, BP 188, Cotonou, Benin.
FAU - Preux, Pierre-Marie
AU  - Preux PM
AD  - U-1094 INSERM, University of Limoges, CHU Limoges, U-1094, Tropical
      Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,
      87000, Limoges, France.
FAU - Lacroix, Philippe
AU  - Lacroix P
AD  - U-1094 INSERM, University of Limoges, CHU Limoges, U-1094, Tropical
      Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST,
      87000, Limoges, France.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7393444
OTO - NOTNLM
OT  - Benin
OT  - Mortality
OT  - Stroke
COIS- No conflict of interest.
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.1016/j.amsu.2020.07.041 [doi]
AID - S2049-0801(20)30223-5 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Jul 28;57:148-152. doi: 10.1016/j.amsu.2020.07.041.
      eCollection 2020 Sep.


PMID- 32760449
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1754-9973 (Print)
IS  - 1754-9973 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Apr
TI  - The Future of Phage: Ethical Challenges of Using Phage Therapy to Treat Bacterial
      Infections.
PG  - 82-88
LID - 10.1093/phe/phaa003 [doi]
AB  - For over a century, scientists have run experiments using phage viruses to treat 
      bacterial infections. Until recently, the results were inconclusive because the
      mechanisms viruses use to attack bacteria were poorly understood. With the
      development of molecular biology, scientists now have a better sense of how phage
      work, and how they can be used to target infections. As resistance to traditional
      antibiotics continues to spread around the world, there is a moral imperative to 
      facilitate research into phage therapy as an alternative treatment. This essay
      reviews ethical questions raised by phage therapy, and discusses regulatory
      challenges associated with phage research, and phage treatments.
CI  - (c) The Author(s) 2020. Published by Oxford University Press.
FAU - Anomaly, Jonathan
AU  - Anomaly J
AUID- ORCID: 0000-0001-5485-0121
AD  - University of Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20200220
PL  - England
TA  - Public Health Ethics
JT  - Public health ethics
JID - 101463048
PMC - PMC7392637
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.1093/phe/phaa003 [doi]
AID - phaa003 [pii]
PST - epublish
SO  - Public Health Ethics. 2020 Feb 20;13(1):82-88. doi: 10.1093/phe/phaa003.
      eCollection 2020 Apr.


PMID- 32760299
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - The Ethical Use of Telepsychiatry in the Covid-19 Pandemic.
PG  - 665
LID - 10.3389/fpsyt.2020.00665 [doi]
FAU - Stoll, Julia
AU  - Stoll J
AD  - Faculty of Medicine, Institute of Biomedical Ethics and History of Medicine,
      University of Zurich, Zurich, Switzerland.
FAU - Sadler, John Z
AU  - Sadler JZ
AD  - Department of Psychiatry, The University of Texas Southwestern Medical Center,
      Dallas, TX, United States.
FAU - Trachsel, Manuel
AU  - Trachsel M
AD  - Faculty of Medicine, Institute of Biomedical Ethics and History of Medicine,
      University of Zurich, Zurich, Switzerland.
AD  - Clinical Ethics Unit, University Hospital Basel and University Psychiatric
      Clinics Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7371958
OTO - NOTNLM
OT  - COVID 19
OT  - ethics
OT  - mental health
OT  - social justice
OT  - telepsychiatry
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.3389/fpsyt.2020.00665 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Jul 14;11:665. doi: 10.3389/fpsyt.2020.00665. eCollection 
      2020.


PMID- 32759534
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210218
IS  - 1881-7122 (Electronic)
IS  - 0007-5124 (Linking)
VI  - 69
IP  - Supplement
DP  - 2020
TI  - Management, Facilities, Ethics and Welfare.
PG  - S58-S67
LID - 10.1538/expanim.69suppl-P-1 [doi]
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Exp Anim
JT  - Experimental animals
JID - 9604830
SB  - IM
PMC - PMC7405541
EDAT- 2020/08/08 06:00
MHDA- 2020/08/08 06:01
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/08 06:01 [medline]
AID - 10.1538/expanim.69suppl-P-1 [doi]
PST - ppublish
SO  - Exp Anim. 2020;69(Supplement):S58-S67. doi: 10.1538/expanim.69suppl-P-1.


PMID- 32759454
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20200811
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 73
IP  - 7
DP  - 2020
TI  - International legal instruments in the field of bioethics and their impact on
      protection of human rights.
PG  - 1554-1560
AB  - OBJECTIVE: Introduction: A rapid development of biomedicine, genetics,
      pharmacology, transplantation and biotechnology has posed a number of problems to
      humanity, in particular, with regard to human rights protection in healthcare.
      These problems solution requires considering the achievements and propositions of
      biology, medicine, ethics and law. International legal standards in the field of 
      bioethics are of significance in development of national states regulations on
      bioethics and biotic legislation. Aim: To investigate the impact of international
      legal instruments in the field of bioethics on protection of human rights.
      PATIENTS AND METHODS: Materials and methods: In the research the international
      legal instruments and documents in the field of healthcare and bioethics were
      used. Civilizational, axiological, dialectical, systemic and comparative legal
      methods as well as systematization, analysis and synthesis were decisive in the
      research process. CONCLUSION: Conclusions: Legal instruments in the field of
      biomedical technologies (directives and regulations) are mainly advisory by
      nature. In many cases, the problems arising in biotechnology are resolved through
      establishment and involvement of national supervision bodies: councils
      (commissions, committees) in bioethics as well as courts. An important role in
      protection of human rights in the field of biotechnology is played by the ECHR
      the decisions of which are dynamic, based on the Convention and consideration of 
      national legislations. At the same time, a number of problems remain unresolved
      because of constant development of biomedical technologies, necessity to take
      into account the latest achievements and discoveries as well as all types and
      methods of applying of genetic engineering to humans. In general, insufficient
      attention is paid to the problems of medical biotechnologies application both at 
      the international and national levels.
FAU - Horodovenko, Viktor V
AU  - Horodovenko VV
AD  - Zaporizhzhia National University, Zaporizhzhia, Ukraine.
FAU - Pashkov, Vitalii M
AU  - Pashkov VM
AD  - Poltava Law Institute Of Yaroslav Mudriy National Law University, Poltava,
      Ukraine.
FAU - Udovyka, Larysa G
AU  - Udovyka LG
AD  - Zaporizhzhia National University, Zaporizhzhia, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
SB  - IM
MH  - *Bioethics
MH  - Delivery of Health Care
MH  - Human Rights
MH  - Humans
OTO - NOTNLM
OT  - bioethics
OT  - biolaw
OT  - biomedicine
OT  - international medical law
OT  - medical law
OT  - international document
EDAT- 2020/08/08 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PST - ppublish
SO  - Wiad Lek. 2020;73(7):1554-1560.


PMID- 32759251
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's
      disease: protocol for a two-centre, randomised, double-blind, placebo-controlled 
      trial, The 'UP' study.
PG  - e038911
LID - 10.1136/bmjopen-2020-038911 [doi]
AB  - INTRODUCTION: There are no disease-modifying treatments for Parkinson's disease
      (PD). We undertook the first drug screen in PD patient tissue and idntified
      ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims
      of this trial are to determine safety and tolerability of UDCA in PD at 30 mg/kg,
      confirm the target engagement of UDCA, apply a novel motion sensor-based approach
      to quantify disease progression objectively, and estimate the mean effect size
      and its variance on the change in motor severity. METHODS AND ANALYSIS: This is a
      phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA 
      at a dose of 30 mg/kg in 30 participants with early PD. Treatment duration is 48 
      weeks, followed by an 8-week washout phase. Randomisation is 2:1, drug to
      placebo. Assessments are performed at baseline, week 12, 24, 36, 48 and 56. The
      primary outcome is safety and tolerability. Secondary outcomes will compare the
      change between baseline and week 48 using the following three approaches: the
      Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 in the
      practically defined 'OFF' medication state; confirmation of target engagement,
      applying (31)Phosphorus MR Spectroscopy to assess the levels of ATP and relevant 
      metabolites in the brain; and objective quantification of motor impairment, using
      a validated, motion sensor-based approach. The primary outcome will be reported
      using descriptive statistics and comparisons between treatment groups. For each
      secondary outcome, the change from baseline will be summarised within treatment
      groups using summary statistics and appropriate statistical tests assessing for
      significant differences. All outcomes will use an intention-to-treat analysis
      population. ETHICS AND DISSEMINATION: This trial has been approved by the East of
      England - Cambridgeshire and Hertfordshire Research Ethics committee. Results
      will be disseminated in peer-reviewed journals, presentations at scientific
      meetings and to patients in a lay-summary format. TRIAL REGISTRATION NUMBER:
      NCT03840005.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Payne, Thomas
AU  - Payne T
AUID- ORCID: 0000-0001-6753-7847
AD  - Sheffield Institute for Translational Neuroscience, The University of Sheffield, 
      Sheffield, UK.
AD  - NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield,
      UK.
FAU - Sassani, Matilde
AU  - Sassani M
AD  - Sheffield Institute for Translational Neuroscience, The University of Sheffield, 
      Sheffield, UK.
FAU - Buckley, Ellen
AU  - Buckley E
AUID- ORCID: 0000-0002-0968-6286
AD  - NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield,
      UK.
AD  - Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK.
FAU - Moll, Sarah
AU  - Moll S
AD  - NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield,
      UK.
FAU - Anton, Adriana
AU  - Anton A
AD  - NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield,
      UK.
AD  - Academic Unit of Radiology, The University of Sheffield, Sheffield, UK.
FAU - Appleby, Matthew
AU  - Appleby M
AD  - Department of Clinical and Movement Neurosciences, University College London
      Institute of Neurology, London, UK.
FAU - Maru, Seema
AU  - Maru S
AD  - Department of Clinical and Movement Neurosciences, University College London
      Institute of Neurology, London, UK.
FAU - Taylor, Rosie
AU  - Taylor R
AD  - Statistical Services Unit, The University of Sheffield, Sheffield, UK.
FAU - McNeill, Alisdair
AU  - McNeill A
AD  - Sheffield Institute for Translational Neuroscience, The University of Sheffield, 
      Sheffield, UK.
FAU - Hoggard, N
AU  - Hoggard N
AD  - Academic Unit of Radiology, The University of Sheffield, Sheffield, UK.
FAU - Mazza, Claudia
AU  - Mazza C
AD  - Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK.
FAU - Wilkinson, Iain D
AU  - Wilkinson ID
AD  - Academic Unit of Radiology, The University of Sheffield, Sheffield, UK.
FAU - Jenkins, Thomas
AU  - Jenkins T
AD  - Sheffield Institute for Translational Neuroscience, The University of Sheffield, 
      Sheffield, UK.
FAU - Foltynie, Thomas
AU  - Foltynie T
AD  - Department of Clinical and Movement Neurosciences, University College London
      Institute of Neurology, London, UK.
FAU - Bandmann, O
AU  - Bandmann O
AUID- ORCID: 0000-0003-3149-0252
AD  - Sheffield Institute for Translational Neuroscience, The University of Sheffield, 
      Sheffield, UK o.bandmann@sheffield.ac.uk.
AD  - NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield,
      UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03840005
GR  - G-1202/PUK_/Parkinson's UK/United Kingdom
GR  - MR/R011354/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 724L30Y2QR (Ursodeoxycholic Acid)
SB  - IM
MH  - Disease Progression
MH  - Double-Blind Method
MH  - England
MH  - Humans
MH  - *Parkinson Disease/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - *Ursodeoxycholic Acid/therapeutic use
PMC - PMC7409998
OTO - NOTNLM
OT  - *adult neurology
OT  - *clinical trials
OT  - *magnetic resonance imaging
OT  - *neurology
OT  - *neuroradiology
OT  - *parkinson's disease
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038911 [pii]
AID - 10.1136/bmjopen-2020-038911 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e038911. doi: 10.1136/bmjopen-2020-038911.


PMID- 32759250
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Frailty in major trauma study (FRAIL-T): a study protocol to determine the
      feasibility of nurse-led frailty assessment in elderly trauma and the impact on
      outcome in patients with major trauma.
PG  - e038082
LID - 10.1136/bmjopen-2020-038082 [doi]
AB  - INTRODUCTION: The burden of frailty on older people is easily recognisable by
      increasing mortality and morbidity, longer hospital stays and adverse discharge
      locations. In the UK, frailty screening has recently become part of the best
      practice commissioning tariff within National Health Service England, yet there
      is no evidence or consensus as to who should carry out this assessment or within 
      which time frame. As major trauma is an increasing burden for older people, there
      is a need to focus clinician's attention on early identification of frailty in
      the emergency department (ED) in patients with major trauma as a way to underpin 
      frailty specific major trauma pathways, to optimise recovery and improve patient 
      experience. Throughout the patient with major trauma pathway, nurses are perhaps 
      best placed to conduct timely clinical assessments working with the patient,
      family and multidisciplinary team to influence ongoing care. This study aims to
      determine the feasibility of nurse-led assessment of frailty in patients aged 65 
      years or more admitted to major trauma centres (MTCs). METHODS AND ANALYSIS: This
      is a prospective observational study conducted across five UK MTCs, enrolling 370
      participants over 9 months. The primary aim is to determine the feasibility of
      nurse-led frailty assessment in MTC EDs in patients aged 65 years or more
      following traumatic injury. The prevalence of frailty and the best assessment
      tool for use in the ED will be determined. Other outcome measures include quality
      of life and frailty assessment 6 months after injury, mortality and discharge
      outcomes. ETHICS AND DISSEMINATION: The study was given ethical approval by the
      Social Care Research Ethics Committee (REC no 19/IEC08/0006). Findings will be
      published in scientific journals and presented to national and international
      conferences. TRIAL REGISTRATION NUMBER: ISRCTN10671514.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jarman, Heather
AU  - Jarman H
AUID- ORCID: 0000-0002-4820-3291
AD  - Emergency Department Clinical Research Unit, St George's University Hospitals NHS
      Foundation Trust, London, UK heather.jarman@stgeorges.nhs.uk.
FAU - Crouch, Robert
AU  - Crouch R
AD  - Emergency Department, University Hospital Southampton NHS Foundation Trust,
      Southampton, UK.
FAU - Baxter, Mark
AU  - Baxter M
AD  - Geriatric Medicine, University Hospital Southampton NHS Foundation Trust,
      Southampton, UK.
FAU - Cole, Elaine
AU  - Cole E
AD  - Blizard Institute, Queen Mary University of London, London, UK.
FAU - Dillane, Bebhinn
AU  - Dillane B
AD  - Emergency Department Clinical Research Unit, St George's University Hospitals NHS
      Foundation Trust, London, UK.
FAU - Wang, Chao
AU  - Wang C
AD  - Kingston University Faculty of Health Social Care and Education, London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN10671514
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - England/epidemiology
MH  - Feasibility Studies
MH  - Frail Elderly
MH  - *Frailty/diagnosis
MH  - Geriatric Assessment
MH  - Humans
MH  - Nurse's Role
MH  - Observational Studies as Topic
MH  - Quality of Life
MH  - State Medicine
PMC - PMC7409962
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *geriatric medicine
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038082 [pii]
AID - 10.1136/bmjopen-2020-038082 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e038082. doi: 10.1136/bmjopen-2020-038082.


PMID- 32759249
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic
      stroke: protocol for multicentre observational study.
PG  - e038031
LID - 10.1136/bmjopen-2020-038031 [doi]
AB  - INTRODUCTION: Clopidogrel is an antiplatelet agent that is widely used for the
      secondary prevention of cardiovascular and cerebrovascular events. The genotype
      of cytochrome P450 2C19 (CYP2C19) differentially affects the liver's metabolism
      of clopidogrel, which may influence the drug's response and efficacy for
      cardiovascular event prevention. In contrast to prior studies of patients with
      coronary artery diseases, little is known about whether the CYP2C19 genotype
      influences the preventive efficacy of clopidogrel in patients who had a stroke.
      We hypothesise that, among patients who had an acute ischaemic stroke who are
      prescribed clopidogrel, the patients with a loss-of-function CYP2C19 genotype
      (poor and intermediate metabolisers) may be at a higher risk of composite
      cardiovascular events than those who are non-carriers (extensive metabolisers).
      METHODS AND ANALYSIS: This prospective observational multicentre study was
      designed to determine whether composite cardiovascular events would differ among 
      patients who had an ischaemic stroke prescribed clopidogrel according to CYP2C19 
      genotype (poor or intermediate vs extensive metabolisers). Inclusion criteria
      were patients who had an acute ischaemic stroke who underwent CYP2C19 genotype
      evaluation and received clopidogrel within 72 hours of stroke onset. The primary 
      outcome is composite cardiovascular events (stroke, myocardial infarction, or
      cardiovascular death) within 6 months after acute ischaemic stroke between
      patients categorised as poor or intermediate metabolisers and those categorised
      as extensive metabolisers according to their CYP2C19 genotype. ETHICS AND
      DISSEMINATION: The Institutional Review Board of Severance Hospital, Yonsei
      University College of Medicine approved this study (3-2019-0195). We received
      study approval from the institutional review board of each participating
      hospital. We plan to disseminate our findings at relevant conferences and
      meetings and through peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT04072705.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Song, Tae-Jin
AU  - Song TJ
AUID- ORCID: 0000-0002-9937-762X
AD  - Department of Neurology, Seoul Hospital, College of Medicine, Ewha Womans
      University, Seoul, South Korea.
FAU - Kim, Jinkwon
AU  - Kim J
AD  - Department of Neurology, Yongin Severance Hospital, Yonsei University College of 
      Medicine, Seoul, South Korea.
FAU - Han, Sang Won
AU  - Han SW
AD  - Department of Neurology, Inje University Sanggye Paik Hospital, Seoul, South
      Korea.
FAU - Kim, Young Dae
AU  - Kim YD
AD  - Department of Neurology, Severance Hospital, Yonsei University College of
      Medicine, Seoul, South Korea.
FAU - Lee, Jong Yun
AU  - Lee JY
AD  - Department of Neurology, National Medical Center, Seoul, South Korea.
FAU - Ahn, Seong Hwan
AU  - Ahn SH
AD  - Department of Neurology, Chosun University Hospital, Gwangju, South Korea.
FAU - Lee, Hye Sun
AU  - Lee HS
AD  - Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul,
      South Korea.
FAU - Jung, Yo Han
AU  - Jung YH
AD  - Department of Neurology, Gangnam Severance Hospital, Yonsei University Collegel
      of Medicine, Seoul, South Korea.
FAU - Lee, Kyung-Yul
AU  - Lee KY
AUID- ORCID: 0000-0001-5585-7739
AD  - Department of Neurology, Gangnam Severance Hospital, Yonsei University Collegel
      of Medicine, Seoul, South Korea kylee@yuhs.ac.
LA  - eng
SI  - ClinicalTrials.gov/NCT04072705
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - *Brain Ischemia/drug therapy/genetics/prevention & control
MH  - Clopidogrel/therapeutic use
MH  - Cytochrome P-450 CYP2C19/genetics
MH  - Genotype
MH  - Humans
MH  - *Ischemic Stroke
MH  - Multicenter Studies as Topic
MH  - Observational Studies as Topic
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - *Stroke/genetics/prevention & control
MH  - Ticlopidine/therapeutic use
MH  - Treatment Outcome
PMC - PMC7409960
OTO - NOTNLM
OT  - *neurogenetics
OT  - *neurology
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038031 [pii]
AID - 10.1136/bmjopen-2020-038031 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e038031. doi: 10.1136/bmjopen-2020-038031.


PMID- 32759248
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Amyotrophic lateral sclerosis and the innate immune system: protocol for
      establishing a biobank and statistical analysis plan.
PG  - e037753
LID - 10.1136/bmjopen-2020-037753 [doi]
AB  - INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a devastating, progressive
      disease that causes degeneration of the motor neurons leading to paresis of the
      bulbar and the skeletal musculature. The pathogenesis of ALS remains unknown. We 
      will test the hypothesis that the complement system is involved in the
      pathophysiology of ALS. This protocol article describes our efforts to establish 
      a national Danish ALS biobank. The primary aim is to obtain biological material
      from patients with ALS for the current study as well as for future studies.
      METHODS AND ANALYSIS: We intend to establish an observational ALS biobank; some
      of the material from this biobank will be used for a prospective, observational
      case-control study. The participants are patients with ALS, neurologically
      healthy controls and non-ALS neurological controls. Each participant consents to 
      be interviewed and to donate blood and cerebrospinal fluid to the biobank.
      Analysis of the complement system will be carried out on the three groups of
      patients and compared. ETHICS AND DISSEMINATION: The project has been approved by
      the Committees on Health Research Ethics in the Capital Region of Denmark
      (Approval number H-16017145) and the Danish Data Protection Agency (file number
      2012-58-0004). All results will be published in peer-reviewed, medical journals
      and presented at scientific conferences. TRIAL REGISTRATION NUMBER: NCT02869048.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kjaeldgaard, Anne-Lene
AU  - Kjaeldgaard AL
AUID- ORCID: 0000-0002-7197-8298
AD  - Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen,
      Denmark akja0044@regionh.dk.
AD  - Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631,
      Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.
FAU - Pilely, Katrine
AU  - Pilely K
AD  - Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631,
      Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.
FAU - Olsen, Karsten Skovgaard
AU  - Olsen KS
AD  - Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen,
      Denmark.
FAU - Lauritsen, Anne Oberg
AU  - Lauritsen AO
AD  - Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen,
      Denmark.
FAU - Pedersen, Stephen Worlich
AU  - Pedersen SW
AD  - Neurology, The Neuroscience Centre, Rigshospitalet, Glostrup, Denmark.
FAU - Moller, Kirsten
AU  - Moller K
AD  - Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen,
      Denmark.
AD  - Institute of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Garred, Peter
AU  - Garred P
AD  - Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631,
      Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.
AD  - Institute of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT02869048
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Amyotrophic Lateral Sclerosis
MH  - Biological Specimen Banks
MH  - Case-Control Studies
MH  - Humans
MH  - Immune System
MH  - Prospective Studies
PMC - PMC7409992
OTO - NOTNLM
OT  - *adult neurology
OT  - *immunology
OT  - *motor neurone disease
OT  - *neuropathology
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037753 [pii]
AID - 10.1136/bmjopen-2020-037753 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e037753. doi: 10.1136/bmjopen-2020-037753.


PMID- 32759244
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Comparative efficacy of different exercise interventions in chronic non-specific 
      low back pain: protocol of a systematic review and network meta-analysis.
PG  - e036050
LID - 10.1136/bmjopen-2019-036050 [doi]
AB  - INTRODUCTION: Chronic non-specific low back pain is a major public health
      problem. Evidence supports the effectiveness of exercise as an intervention. Due 
      to a paucity of direct comparisons of different exercise categories, medical
      guidelines were unable to make specific recommendations regarding the type of
      exercise working best in improving chronic low back pain. This network
      meta-analysis (NMA) of randomised controlled trials aims to investigate the
      comparative efficacy of different exercise interventions in patients with chronic
      non-specific low back pain. METHODS AND ANALYSIS: MEDLINE, Scopus, Cochrane
      Central Register of Controlled Trials, Physiotherapy Evidence Database,
      SPORTDiscus, Clinicaltrials.gov and the WHO International Clinical Trials
      Registry Platform search portal were searched on November 2019 and without
      language restrictions. The search will be updated after data analysis. Studies on
      adults with non-specific low back pain of at least 12 weeks duration comparing
      exercise to either no specific intervention (ie, no treatment, wait-list or usual
      care at the treating physician's discretion) and/or functionally inert
      interventions (ie, sham or attention control interventions) will be eligible.
      Pain intensity and back-specific disability are defined as primary outcomes.
      Secondary outcomes will include health-related physical and mental quality of
      life, work disability, frequency of analgesic use and adverse events. All
      outcomes will be analysed short-term, intermediate-term and long-term. Data will 
      be extracted independently by two review authors. Risk of bias will be assessed
      using the recommendations by the Cochrane Back and Neck Group and be based on an 
      adaptation of the Cochrane Risk of Bias tool. ETHICS AND DISSEMINATION: This NMA 
      will be reported in accordance with the Preferred Reporting Items for Systematic 
      Reviews and Meta-Analyses_NMA checklist. The results will be presented in
      peer-reviewed journals, implemented in existing national and international
      guidelines and will be presented to health care providers and decision makers.
      The planned completion date of the study is 1 July 2021. PROSPERO REGISTRATION
      NUMBER: CRD42020151472.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Anheyer, Dennis
AU  - Anheyer D
AD  - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University
      of Duisburg-Essen, Faculty of Medicine, Essen, Germany.
FAU - Klose, Petra
AU  - Klose P
AD  - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University
      of Duisburg-Essen, Faculty of Medicine, Essen, Germany.
FAU - Koch, Anna Katharina
AU  - Koch AK
AUID- ORCID: 0000-0002-2565-8744
AD  - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University
      of Duisburg-Essen, Faculty of Medicine, Essen, Germany a.koch@kem-med.com.
FAU - Haller, Heidemarie
AU  - Haller H
AUID- ORCID: 0000-0001-7973-4071
AD  - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University
      of Duisburg-Essen, Faculty of Medicine, Essen, Germany.
FAU - Dobos, Gustav
AU  - Dobos G
AD  - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University
      of Duisburg-Essen, Faculty of Medicine, Essen, Germany.
FAU - Cramer, Holger
AU  - Cramer H
AD  - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University
      of Duisburg-Essen, Faculty of Medicine, Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Chronic Pain/therapy
MH  - Exercise Therapy
MH  - Humans
MH  - *Low Back Pain/therapy
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Physical Therapy Modalities
MH  - Quality of Life
MH  - Systematic Reviews as Topic
PMC - PMC7409959
OTO - NOTNLM
OT  - *back pain
OT  - *complementary medicine
OT  - *pain management
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036050 [pii]
AID - 10.1136/bmjopen-2019-036050 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e036050. doi: 10.1136/bmjopen-2019-036050.


PMID- 32759241
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210709
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Ethnographic investigation of patient-provider communication among African
      American men newly diagnosed with prostate cancer: a study protocol.
PG  - e035032
LID - 10.1136/bmjopen-2019-035032 [doi]
AB  - INTRODUCTION: In the USA, African American men bear a disproportionate burden of 
      prostate cancer (PCa) compared with all other groups, having a higher incidence
      and mortality, poorer quality of life and higher dissatisfaction with care. They 
      are also less likely to receive guideline-concordant treatment (eg,
      undertreatment of aggressive disease). Inadequate patient-provider communication 
      contributes to suboptimal care, which can be exacerbated by patients' limited
      health literacy, providers' lack of communication skills and time constraints in 
      low-resource, safety net settings. This study is designed to examine the
      communication experiences of African American patients with PCa as they undertake
      treatment decision-making. METHODS AND ANALYSIS: Using an ethnographic approach, 
      we will follow 25 African American men newly diagnosed with PCa at two public
      hospitals, from diagnosis through treatment decision. Data sources include: (1)
      audio-recorded clinic observations during urology, radiation oncology, medical
      oncology and primary care visits, (2) field notes from clinic observations, (3)
      patient surveys after clinic visits, (4) two in-depth patient interviews, (5) a
      provider survey, and (6) in-depth interviews with providers. We will explore
      patients' understanding of their diagnoses and treatment options, sources of
      support in decision-making, patient-provider communication and treatment
      decision-making processes. Audio-recorded observations and interviews will be
      transcribed verbatim. An iterative process of coding and team discussions will be
      used to thematically analyse patients' experiences and providers' perspectives,
      and to refine codes and identify key themes. Descriptive statistics will
      summarise survey data. ETHICS AND DISSEMINATION: To our knowledge, this is the
      first study to examine in-depth patient-provider communication among African
      American patients with PCa. For a population as marginalised as African American 
      men, an ethnographic approach allows for explication of complex sociocultural and
      contextual influences on healthcare processes and outcomes. Study findings will
      inform the development of interventions and initiatives that promote
      patient-centred communication, shared decision-making and guideline-concordant
      care. This study was approved by the University of California San Francisco and
      the Alameda Health System Institutional Review Boards.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Palmer, Nynikka R
AU  - Palmer NR
AUID- ORCID: 0000-0002-5311-447X
AD  - Division of General Internal Medicine at San Francisco General Hospital,
      Department of Medicine, University of California San Francisco, San Francisco,
      California, USA nynikka.palmer@ucsf.edu.
AD  - Center for Vulnerable Populations, San Francisco General Hospital, University of 
      California San Francisco, San Francisco, California, USA.
AD  - Helen Diller Family Comprehensive Cancer Center, University of California San
      Francisco, San Francisco, California, USA.
FAU - Shim, Janet K
AU  - Shim JK
AD  - Department of Social and Behavioral Sciences, School of Nursing, University of
      California San Francisco, San Francisco, California, USA.
FAU - Kaplan, Celia P
AU  - Kaplan CP
AD  - Helen Diller Family Comprehensive Cancer Center, University of California San
      Francisco, San Francisco, California, USA.
AD  - Division of General Internal Medicine, Department of Medicine, University of
      California San Francisco, San Francisco, California, USA.
FAU - Schillinger, Dean
AU  - Schillinger D
AD  - Division of General Internal Medicine at San Francisco General Hospital,
      Department of Medicine, University of California San Francisco, San Francisco,
      California, USA.
AD  - Center for Vulnerable Populations, San Francisco General Hospital, University of 
      California San Francisco, San Francisco, California, USA.
FAU - Blaschko, Sarah D
AU  - Blaschko SD
AD  - Division of Urology, Highland Hospital, Oakland, California, USA.
FAU - Breyer, Benjamin N
AU  - Breyer BN
AD  - Department of Urology, University of California San Francisco, San Francisco,
      California, USA.
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco, San Francisco, California, USA.
FAU - Pasick, Rena J
AU  - Pasick RJ
AD  - Helen Diller Family Comprehensive Cancer Center, University of California San
      Francisco, San Francisco, California, USA.
AD  - Division of General Internal Medicine, Department of Medicine, University of
      California San Francisco, San Francisco, California, USA.
LA  - eng
GR  - K01 CA211965/CA/NCI NIH HHS/United States
GR  - P30 AG015272/AG/NIA NIH HHS/United States
GR  - P30 DK092924/DK/NIDDK NIH HHS/United States
GR  - KL2 TR001870/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *African Americans
MH  - Communication
MH  - Humans
MH  - Male
MH  - *Prostatic Neoplasms/therapy
MH  - Quality of Life
MH  - San Francisco
PMC - PMC7409964
OTO - NOTNLM
OT  - *oncology
OT  - *protocols & guidelines
OT  - *public health
OT  - *qualitative research
OT  - *quality in health care
OT  - *urological tumours
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035032 [pii]
AID - 10.1136/bmjopen-2019-035032 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e035032. doi: 10.1136/bmjopen-2019-035032.


PMID- 32759239
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 5
TI  - Efficacy of biofeedback, repetitive transcranial magnetic stimulation and pelvic 
      floor muscle training for female neurogenic bladder dysfunction after spinal cord
      injury: a study protocol for a randomised controlled trial.
PG  - e034582
LID - 10.1136/bmjopen-2019-034582 [doi]
AB  - INTRODUCTION: Neurogenic bladder dysfunction is prevalent in female patients with
      spinal cord injury (SCI), and previous guidelines have recommended pelvic floor
      muscle training (PFMT) for first-line conservative treatment. However, the actual
      regimen of PFMT varies widely and the single treatment does not satisfy the need 
      of some patients. Therefore, this study aims to provide a detailed rationale and 
      methodology for comparing the effectiveness of PFMT, biofeedback and repetitive
      transcranial magnetic stimulation (rTMS) as adjunct treatments for neurogenic
      bladder dysfunction. METHODS AND ANALYSIS: This trial is a single-centre
      randomised controlled trial for female patients with urinary incontinence (UI) in
      phase of chronic SCI. Eligible participants will be randomised to one of four
      arms: (1) PFMT, (2) PFMT with biofeedback, (3) PFMT and rTMS and (4) PFMT with
      biofeedback and rTMS. There will be 44 participants in each arm and all the
      subjects will undergo 20 treatment sessions, five times a week for 4 weeks. The
      outcomes will be evaluated at 4 weeks, 3 months and 6 months after randomisation.
      The primary outcome is the International Consultation on Incontinence
      Questionnaire-Urinary Incontinence Short Form, and the secondary outcomes include
      bladder diary, pelvic floor muscle function and the International Spinal Cord
      Injury Quality of Life Basic Data Set. ETHICS AND DISSEMINATION: The Clinical
      Research and Biomedical Ethics Committee of the West China Hospital, Sichuan
      University has approved this trial and the approval number is 2019-885. All
      participants will be provided written informed consent after verification of the 
      eligibility criteria. The results of this study will be accessible in
      peer-reviewed publications and be presented at academic conferences. TRIAL
      REGISTRATION NUMBER: Chinese Clinical Trial Registry (ChiCTR1900026126).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Lin
AU  - Xu L
AUID- ORCID: 0000-0001-7139-6725
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - Fu, Chenying
AU  - Fu C
AD  - State Key Laboratory of Biotherapy, West China Hospital, Sichuan University,
      Chengdu, Sichuan, PR China.
FAU - Zhang, Qing
AU  - Zhang Q
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - Xiong, Feng
AU  - Xiong F
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - Peng, Lihong
AU  - Peng L
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - Liang, Zejun
AU  - Liang Z
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - Chen, Li
AU  - Chen L
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - He, Chengqi
AU  - He C
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
FAU - Wei, Quan
AU  - Wei Q
AD  - Department of Rehabilitation Medicine Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, PR China weiquan@scu.edu.cn.
AD  - Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, 
      PR China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Biofeedback, Psychology
MH  - China
MH  - Exercise Therapy
MH  - Female
MH  - Humans
MH  - Pelvic Floor
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Spinal Cord Injuries/complications
MH  - Transcranial Magnetic Stimulation
MH  - Treatment Outcome
MH  - *Urinary Bladder, Neurogenic/etiology/therapy
MH  - *Urinary Incontinence, Stress
PMC - PMC7409967
OTO - NOTNLM
OT  - *rehabilitation
OT  - *urinary bladder, neurogenic
OT  - *urinary incontinence
COIS- Competing interests: None declared.
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034582 [pii]
AID - 10.1136/bmjopen-2019-034582 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 5;10(8):e034582. doi: 10.1136/bmjopen-2019-034582.


PMID- 32758962
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 739
DP  - 2020 Oct 15
TI  - In vitro methods for predicting the bioconcentration of xenobiotics in aquatic
      organisms.
PG  - 140261
LID - S0048-9697(20)33782-7 [pii]
LID - 10.1016/j.scitotenv.2020.140261 [doi]
AB  - The accumulation of anthropogenic chemical substances in aquatic organisms is an 
      immensely important issue from the point of view of environmental protection. In 
      the context of the increasing number and variety of compounds that may
      potentially enter the environment, there is a need for efficient and reliable
      solutions to assess the risks. However, the classic approach of testing with fish
      or other animals is not sufficient. Due to very high costs, significant time and 
      labour intensity, as well as ethical concerns, in vivo methods need to be
      replaced by new laboratory-based tools. So far, many models have been developed
      to estimate the bioconcentration potential of chemicals. However, most of them
      are not sufficiently reliable and their predictions are based on limited input
      data, often obtained with doubtful quality. The octanol-water partition
      coefficient is still often used as the main laboratory tool for estimating
      bioconcentration. However, according to current knowledge, this method can lead
      to very unreliable results, both for neutral species and, above all, for ionic
      compounds. It is therefore essential to start using new, more advanced and
      credible solutions on a large scale. Over the last years, many in vitro methods
      have been newly developed or improved, allowing for a much more adequate
      estimation of the bioconcentration potential. Therefore, the aim of this work was
      to review the most recent laboratory methods for assessing the bioconcentration
      potential and to evaluate their applicability in further research.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Maculewicz, Jakub
AU  - Maculewicz J
AD  - Department of Environmental Analysis, Faculty of Chemistry, University of Gdansk,
      Wita Stwosza 63, 80-308 Gdansk, Poland. Electronic address:
      jakub.maculewicz@phdstud.ug.edu.pl.
FAU - Swiacka, Klaudia
AU  - Swiacka K
AD  - Department of Experimental Ecology of Marine Organisms, Institute of
      Oceanography, University of Gdansk, Av. Pilsudskiego 46, 81-378 Gdynia, Poland.
FAU - Kowalska, Dorota
AU  - Kowalska D
AD  - Department of Environmental Analysis, Faculty of Chemistry, University of Gdansk,
      Wita Stwosza 63, 80-308 Gdansk, Poland.
FAU - Stepnowski, Piotr
AU  - Stepnowski P
AD  - Department of Environmental Analysis, Faculty of Chemistry, University of Gdansk,
      Wita Stwosza 63, 80-308 Gdansk, Poland.
FAU - Stolte, Stefan
AU  - Stolte S
AD  - Faculty of Environmental Sciences, Department of Hydrosciences, Institute of
      Water Chemistry, Technische Universitat Dresden, Bergstrasse 66, 01069 Dresden,
      Germany.
FAU - Dolzonek, Joanna
AU  - Dolzonek J
AD  - Department of Environmental Analysis, Faculty of Chemistry, University of Gdansk,
      Wita Stwosza 63, 80-308 Gdansk, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200618
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
RN  - 0 (Water Pollutants, Chemical)
RN  - 0 (Xenobiotics)
SB  - IM
MH  - Animals
MH  - *Aquatic Organisms
MH  - Bioaccumulation
MH  - Fishes
MH  - Water Pollutants, Chemical/*analysis
MH  - Xenobiotics
OTO - NOTNLM
OT  - Bioaccumulation
OT  - Bioconcentration
OT  - Membrane partitioning
OT  - Protein binding
OT  - Sorption
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/08/08 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - S0048-9697(20)33782-7 [pii]
AID - 10.1016/j.scitotenv.2020.140261 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Oct 15;739:140261. doi: 10.1016/j.scitotenv.2020.140261. 
      Epub 2020 Jun 18.


PMID- 32758521
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1096-0295 (Electronic)
IS  - 0273-2300 (Linking)
VI  - 116
DP  - 2020 Oct
TI  - Advances in selecting appropriate non-rodent species for regulatory toxicology
      research: Policy, ethical, and experimental considerations.
PG  - 104757
LID - S0273-2300(20)30183-5 [pii]
LID - 10.1016/j.yrtph.2020.104757 [doi]
AB  - In vivo animal studies are required by regulatory agencies to investigate drug
      safety before clinical trials. In this review, we summarize the process of
      selecting a relevant non-rodent species for preclinical studies. The dog is the
      primary, default non-rodent used in toxicology studies with multiple scientific
      advantages, including adequate background data and availability. Rabbit has many 
      regulatory advantages as the first non-rodent for the evaluation of reproductive 
      and developmental as well as local toxicity. Recently, minipigs have increasingly
      replaced dogs and rabbits in toxicology studies due to ethical and scientific
      advantages including similarity to humans and breeding habits. When these species
      are not relevant, nonhuman primates (NHPs) can be used as the available animal
      models, especially in toxicology studies investigating biotherapeutics.
      Particularly, based on the phylogenetic relationships, the use of New-World
      marmosets can be considered before Old-World monkeys, especially cynomolgus with 
      robust historical data. Importantly, the use of NHPs should be justified in terms
      of scientific benefits considering target affinity, expression pattern, and
      pharmacological cross-reactivity. Strict standards are required for the use of
      animals. Therefore, this review is helpful for the selection of appropriate
      non-rodent in regulatory toxicology studies by providing sufficient regulatory,
      ethical, and scientific data for each species.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Son, Yong-Wook
AU  - Son YW
AD  - Department of Biotechnology, The Catholic University of Korea, Bucheon, 14662,
      South Korea.
FAU - Choi, Ha-Ni
AU  - Choi HN
AD  - Department of Biotechnology, The Catholic University of Korea, Bucheon, 14662,
      South Korea.
FAU - Che, Jeong-Hwan
AU  - Che JH
AD  - Biomedical Center for Animal Resource and Development, Seoul National University 
      College of Medicine, Seoul, 03080, South Korea.
FAU - Kang, Byeong-Cheol
AU  - Kang BC
AD  - Graduate School of Translational Medicine, Seoul National University College of
      Medicine, Seoul, 03080, South Korea.
FAU - Yun, Jun-Won
AU  - Yun JW
AD  - Department of Biotechnology, The Catholic University of Korea, Bucheon, 14662,
      South Korea. Electronic address: jwyun@catholic.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200803
PL  - Netherlands
TA  - Regul Toxicol Pharmacol
JT  - Regulatory toxicology and pharmacology : RTP
JID - 8214983
SB  - IM
MH  - Animals
MH  - *Models, Animal
MH  - Research Design
MH  - Toxicology/ethics/*methods
OTO - NOTNLM
OT  - Experimental animal
OT  - Non-human primate
OT  - Non-rodent
OT  - Regulatory toxicology
OT  - Safety assessment
EDAT- 2020/08/08 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/07/31 00:00 [accepted]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - S0273-2300(20)30183-5 [pii]
AID - 10.1016/j.yrtph.2020.104757 [doi]
PST - ppublish
SO  - Regul Toxicol Pharmacol. 2020 Oct;116:104757. doi: 10.1016/j.yrtph.2020.104757.
      Epub 2020 Aug 3.


PMID- 32758241
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210702
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 5
TI  - Analysis of serum polyunsaturated fatty acid metabolites in allergic
      bronchopulmonary aspergillosis.
PG  - 205
LID - 10.1186/s12931-020-01471-4 [doi]
AB  - BACKGROUND: The importance of lipid mediators in allergic diseases has been long 
      recognized, whereas little is known about their role in allergic bronchopulmonary
      aspergillosis (ABPA). We investigated whether lipid mediators are associated with
      ABPA. METHODS: We recruited 12 ABPA patients, 23 asthma patients and 12 healthy
      control in our study. Serum of 11 ABPA patients were collected before and
      following treatment. 36 polyunsaturated fatty acid metabolites were measured in
      serum samples by using liquid chromatography-mass spectrometry. This study was
      approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou
      Medical University, with ethics number GYFYY-2016-73. RESULTS: Levels of
      arachidonic acid (AA), 15(S)-hydroxyeicosatetraenoic acid (HETE), 12(S)-HETE,
      8(S)-HETE, 5(S)-HETE, LTB4, PGB2, 12(S)-hydroxyeicosapentaenoic acid (HEPE),
      12-hydro-xyheptadecatrienoic acid (HHTrE) were significantly higher in ABPA
      patients than that in HC groups. Compared with asthma group, ABPA group expressed
      lower levels of 15(S)-hy-droperoxyeicosatetraenoic acid (HPETE), 5(S)-HPETE,
      13(S)-hydroperoxyoctadecadienoic acid (HPODE) and 9(S)-HPODE. In APBA patients,
      AA level was positively correlated with serumtotal IgE (tIgE). The levels of
      12(S)-HPETE, 15(S)-HEPE and 12(S)-HEPE correlated with Asp-ergillus fumigatus
      specific IgE(A. fumigatus sIgE) positively. Peripheral blood eosinophilia
      correlated with high levels of 12(S)-HETE and 15(S)-HETE. In addition, the serum 
      levels of15(S)-HETE and 12(S)-HETE in ABPA subjects both declined with the
      decrease of tIgE, A. fumigatus sIgE and sIgG concentrations after treatment.
      CONCLUSIONS: We present data regarding the role of polyunsaturated fatty acid
      metabolites in APBA for the first time. Most of the tested metabolites increased 
      in ABPA when co-mpared with healthy controls and 15(S)-HETE and 12(S)-HETE may
      play a role in the pat-hogenesis of ABPA. These findings can provide new ideas
      for diagnosis, therapy and mon-itor of ABPA.
FAU - Li, Lu
AU  - Li L
AD  - Department of Allergy and Clinical Immunology, State Key Laboratory of
      Respiratory Disease, National Clinical Research Center of Respiratory Disease,
      Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou
      Medical University, Guangzhou, Guangdong, China.
AD  - Sino-French Hoffmann Institute of Immunology, Guangzhou Medical University,
      Guangzhou, Guangdong, China.
FAU - Wu, Jianlin
AU  - Wu J
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for
      Applied Research in Medicine and Health, Macau University of Science and
      Technology, Taipa, Macao, China.
FAU - Bian, Xiqing
AU  - Bian X
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for
      Applied Research in Medicine and Health, Macau University of Science and
      Technology, Taipa, Macao, China.
FAU - Wu, Ge
AU  - Wu G
AD  - Department of Allergy and Clinical Immunology, State Key Laboratory of
      Respiratory Disease, National Clinical Research Center of Respiratory Disease,
      Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou
      Medical University, Guangzhou, Guangdong, China.
FAU - Zheng, Peiyan
AU  - Zheng P
AD  - Department of Allergy and Clinical Immunology, State Key Laboratory of
      Respiratory Disease, National Clinical Research Center of Respiratory Disease,
      Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou
      Medical University, Guangzhou, Guangdong, China.
FAU - Xue, Mingshan
AU  - Xue M
AD  - Department of Allergy and Clinical Immunology, State Key Laboratory of
      Respiratory Disease, National Clinical Research Center of Respiratory Disease,
      Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou
      Medical University, Guangzhou, Guangdong, China.
FAU - Sun, Baoqing
AU  - Sun B
AUID- ORCID: http://orcid.org/0000-0002-1671-0723
AD  - Department of Allergy and Clinical Immunology, State Key Laboratory of
      Respiratory Disease, National Clinical Research Center of Respiratory Disease,
      Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou
      Medical University, Guangzhou, Guangdong, China. sunbaoqing@vip.163.com.
LA  - eng
GR  - 81871736/National Natural Science Foundation of China
GR  - 81601394/National Natural Science Foundation of China
GR  - 81572063/National Natural Science Foundation of China
GR  - 20192048/Key Laboratory of Chemical Biology andTraditional Chinese Medicine
      Research, Ministry of Education (CN)
GR  - 201831802/Key Projects of Guangzhou Education Bureau
GR  - FDCT 009/2017/A1/the Science and Technology Development Fund, Macau SAR
PT  - Journal Article
DEP - 20200805
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - 0 (Biomarkers)
RN  - 0 (Fatty Acids, Unsaturated)
SB  - IM
MH  - Adult
MH  - Aspergillosis, Allergic Bronchopulmonary/*blood/*diagnosis
MH  - Aspergillus fumigatus/isolation & purification/*metabolism
MH  - Biomarkers/blood
MH  - Fatty Acids, Unsaturated/*blood/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Retrospective Studies
MH  - Sputum/metabolism
MH  - Young Adult
PMC - PMC7409426
OTO - NOTNLM
OT  - ABPA
OT  - HETEs
OT  - Lipid mediators
OT  - Polyunsaturated fatty acid
EDAT- 2020/08/08 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
AID - 10.1186/s12931-020-01471-4 [doi]
AID - 10.1186/s12931-020-01471-4 [pii]
PST - epublish
SO  - Respir Res. 2020 Aug 5;21(1):205. doi: 10.1186/s12931-020-01471-4.


PMID- 32758219
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 5
TI  - Medical ethics: knowledge, attitude and practice among doctors in three teaching 
      hospitals in Sri Lanka.
PG  - 69
LID - 10.1186/s12910-020-00511-4 [doi]
AB  - BACKGROUND: Medical ethics deals with the ethical obligations of doctors to their
      patients, colleagues and society. The annual reports of Sri Lanka Medical Council
      indicate that the number of complaints against doctors has increased over the
      years. We aimed to assess the level of knowledge, attitude and practice regarding
      medical ethics among doctors in three teaching hospitals in Sri Lanka. METHODS: A
      hospital-based cross-sectional study was conducted among doctors (n = 313) using 
      a pre-tested self-administered, anonymous questionnaire. Chi Squared test, and
      ANOVA test were used to identify the significance of association between level of
      knowledge and selected factors. RESULTS: Most doctors (81.2%) had a poor level of
      knowledge on medical ethics, with postgraduate trainees showing significantly (p 
      = 0.023, Chi square) higher level of knowledge. The average knowledge on medical 
      ethics among doctors was significantly different between the three hospitals (p =
      0.008, ANOVA). Over 95% had a favourable attitude towards gaining knowledge and
      advocated the need for training. The majority (69.3%) indicated awareness of
      unethical practices. 24.6% of respondents stated that they get a chaperone
      'sometimes' during patient examination while 3.5% never do. The majority (54%)
      responded that they never accept gifts from pharmaceutical companies in
      recognition of their prescribing pattern. 12-41% of doctors participated in the
      study acknowledged that they 'sometime' engaged in unethical practices related to
      prescribing drugs, accepting gifts from pharmaceutical companies and when
      obtaining leave. CONCLUSION: Most doctors had a poor level of knowledge of
      medical ethics. Postgraduate trainees had a higher level of knowledge than other 
      doctors. The majority showed a favourable attitude towards gaining knowledge and 
      the need of training. Regular in-service training on medical ethics for doctors
      would help to improve their knowledge on medical ethics, as well as attitudes and
      ethical conduct.
FAU - Ranasinghe, A W I P
AU  - Ranasinghe AWIP
AD  - Postgraduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka.
      prabhathaya@yahoo.com.
FAU - Fernando, Buddhika
AU  - Fernando B
AD  - Research Institute for Primary Care and Health Sciences, School of Medicine,
      Keele University, Keele, UK.
FAU - Sumathipala, Athula
AU  - Sumathipala A
AD  - Research Institute for Primary Care and Health Sciences, School of Medicine,
      Keele University, Keele, UK.
FAU - Gunathunga, Wasantha
AU  - Gunathunga W
AD  - Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - *Health Knowledge, Attitudes, Practice
MH  - Hospitals, Teaching
MH  - Humans
MH  - Sri Lanka
MH  - Surveys and Questionnaires
PMC - PMC7405426
OTO - NOTNLM
OT  - *Attitudes
OT  - *Doctors
OT  - *Knowledge
OT  - *Medical ethics
OT  - *Practice
OT  - *Sri Lanka
EDAT- 2020/08/08 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/08 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00511-4 [doi]
AID - 10.1186/s12910-020-00511-4 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 5;21(1):69. doi: 10.1186/s12910-020-00511-4.


PMID- 32758152
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 5
TI  - A randomized crossover trial to assess therapeutic efficacy and cost reduction of
      acid ursodeoxycholic manufactured by the university hospital for the treatment of
      primary biliary cholangitis.
PG  - 253
LID - 10.1186/s12876-020-01399-5 [doi]
AB  - BACKGROUND: Health care costs are growing faster than the rest of the global
      economy, according to the World Health Organization (WHO). Countries' health
      expenditures include paying for general medicine, diagnostic procedures,
      hospitalizations and surgeries, as well as medications and prescribed treatment. 
      Primary biliary cholangitis (PBC) is a rare autoimmune liver disease and the
      first line available treatment is ursodeoxycholic acid (UDCA), however, direct
      and indirect treatment costs are expensive. Main aim of this trial was to assess 
      if the therapeutic efficacy of UDCA manufactured by the university hospital is
      equivalent to that of standard UDCA and treatment cost reduction in patients with
      PBC. METHODS: It is a prospective, interventional, randomized, and crossover
      study in patients diagnosed with PBC. UDCA 300 mg tablets and capsules were
      developed and manufactured by the university hospital. Thirty patients under
      treatment with standard UDCA, in stable doses were randomized in sequence A and
      B, 15 patients in each arm. The groups were treated for 12 weeks and after, the
      UDCA formulation was changed, following for another 12 weeks of continuous
      therapy (tablets and capsules / capsules and tablets). Laboratory tests were
      performed at time T0 (beginning of treatment), T1 (at the 12 week-therapy, before
      the crossing-over) and T2 (end of treatment). The evaluation was done by
      comparing the hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also
      considering the adverse events. The comparison of costs was based on price of the
      manufactured UDCA and standard UDCA price of the hospital. RESULTS: Hospital
      reduced 66.1% the PBC treatment costs using manufactured UDCA. There were no
      differences in the biochemical parameters between sequence (A and B) and tablets 
      or capsules of UDCA formulations applied in the treatment of PBC. CONCLUSIONS:
      The study showed that there was no significant difference between manufactured
      UDCA (capsule and tablet) and standard UDCA. Hospital reduced the PBC treatment
      costs using the manufactured UDCA by the university hospital. TRIAL REGISTRATION:
      ClinicalTrials.gov: NCT03489889 retrospectively registered on January 12th, 2018;
      Ethics Committee approved the study (ID: 1.790.088) on October 25th, 2016.
FAU - Nakano, Larissa Akeme
AU  - Nakano LA
AD  - Department of Gastroenterology, Division of Clinical Gastroenterology and
      Hepatology, Hospital das Clinicas, University of Sao Paulo School of Medicine,
      Av. Dr. Eneas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, Sao Paulo,
      SP 05403-000, Brazil.
FAU - Cancado, Eduardo Luiz Rachid
AU  - Cancado ELR
AD  - Department of Gastroenterology, Division of Clinical Gastroenterology and
      Hepatology, Hospital das Clinicas, University of Sao Paulo School of Medicine,
      Av. Dr. Eneas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, Sao Paulo,
      SP 05403-000, Brazil.
AD  - Laboratory of Medical Investigation LIM 06, Institute of Tropical Medicine,
      University of Sao Paulo, Sao Paulo, Brazil.
FAU - Chaves, Cleuber Esteves
AU  - Chaves CE
AD  - Division of Pharmacy of Hospital das Clinicas, University of Sao Paulo School of 
      Medicine, Sao Paulo, Brazil.
FAU - Madeira, Maria Cristina Vaz
AU  - Madeira MCV
AD  - Division of Pharmacy of Hospital das Clinicas, University of Sao Paulo School of 
      Medicine, Sao Paulo, Brazil.
FAU - Katayose, Jessica Toshie
AU  - Katayose JT
AD  - Division of Pharmacy of Hospital das Clinicas, University of Sao Paulo School of 
      Medicine, Sao Paulo, Brazil.
FAU - Nabeshima, Mariana Akemi
AU  - Nabeshima MA
AD  - Department of Gastroenterology, Division of Clinical Gastroenterology and
      Hepatology, Hospital das Clinicas, University of Sao Paulo School of Medicine,
      Av. Dr. Eneas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, Sao Paulo,
      SP 05403-000, Brazil.
FAU - Fossaluza, Victor
AU  - Fossaluza V
AD  - Institute of Mathematics and Statistics, University of Sao Paulo, Sao Paulo,
      Brazil.
FAU - Uhrigshardt, Gabriela Guimaraes
AU  - Uhrigshardt GG
AD  - Institute of Mathematics and Statistics, University of Sao Paulo, Sao Paulo,
      Brazil.
FAU - Liting, Zheng
AU  - Liting Z
AD  - Institute of Mathematics and Statistics, University of Sao Paulo, Sao Paulo,
      Brazil.
FAU - Pinto, Vanusa Barbosa
AU  - Pinto VB
AD  - Division of Pharmacy of Hospital das Clinicas, University of Sao Paulo School of 
      Medicine, Sao Paulo, Brazil.
FAU - Carrilho, Flair Jose
AU  - Carrilho FJ
AD  - Department of Gastroenterology, Division of Clinical Gastroenterology and
      Hepatology, Hospital das Clinicas, University of Sao Paulo School of Medicine,
      Av. Dr. Eneas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, Sao Paulo,
      SP 05403-000, Brazil.
FAU - Ono, Suzane Kioko
AU  - Ono SK
AUID- ORCID: http://orcid.org/0000-0002-6963-0911
AD  - Department of Gastroenterology, Division of Clinical Gastroenterology and
      Hepatology, Hospital das Clinicas, University of Sao Paulo School of Medicine,
      Av. Dr. Eneas Carvalho de Aguiar, 255, ICHC, 9th Floor, office 9159, Sao Paulo,
      SP 05403-000, Brazil. suzane.ono@fm.usp.br.
LA  - eng
SI  - ClinicalTrials.gov/NCT03489889
GR  - 1734244/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
GR  - 308609/2018-2/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200805
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Cholagogues and Choleretics)
RN  - 724L30Y2QR (Ursodeoxycholic Acid)
SB  - IM
MH  - Cholagogues and Choleretics/therapeutic use
MH  - Cross-Over Studies
MH  - Hospitals
MH  - Humans
MH  - *Liver Cirrhosis, Biliary/drug therapy
MH  - Prospective Studies
MH  - Ursodeoxycholic Acid/therapeutic use
PMC - PMC7406387
OTO - NOTNLM
OT  - Capsules
OT  - Health care costs
OT  - Hospital
OT  - Primary biliary cholangitis
OT  - Tablets
OT  - Ursodeoxycholic acid
EDAT- 2020/08/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/08 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12876-020-01399-5 [doi]
AID - 10.1186/s12876-020-01399-5 [pii]
PST - epublish
SO  - BMC Gastroenterol. 2020 Aug 5;20(1):253. doi: 10.1186/s12876-020-01399-5.


PMID- 32758118
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 2146-8427 (Electronic)
IS  - 1304-0855 (Linking)
VI  - 18
IP  - Suppl 2
DP  - 2020 Jul
TI  - Deceased-Donor Organ Transplantation in India: Current Status, Challenges, and
      Solutions.
PG  - 31-42
LID - 10.6002/ect.rlgnsymp2020.L6 [doi]
AB  - Tamil Nadu, Gujarat, Telangana, Maharashtra, Kerala, Chandigarh, Karnataka,
      National Capital Territory of Delhi, and Rajasthan are states and union
      territories having active deceased-donor organ transplant programs in India.
      Transplant data (2013-2018) have been collected by the National Organ and Tissue 
      Transplant Organization from all states and union territories of India and
      submitted to the Global Observatory on Donation and Transplantation. From 2013 to
      2018, 49155 transplants were reported in India, including 39000 living-donor
      organ recipients and 10 155 deceased-donor organ recipients. These transplants
      were for kidney (living donor = 32584, deceased donor = 5748), liver (living
      donor = 6416, deceased donor = 2967), heart (deceased donor = 895), lung
      (deceased donor = 459), pancreas (deceased donor = 78), and small bowel (deceased
      donor = 8). According to 2018 data, India was the second largest transplanting
      country in the world in terms of the absolute number of transplants. Here, we
      discuss the status, progress, challenges, and solutions for deceaseddonor organ
      transplantation. The plan to increase rates of organ donation in India include
      the following points: teamwork and focus by intensive care unit doctors; public
      education on organ donation using social media; professional education and family
      donation conversation programs for brain death declaration and donor management; 
      organ procurement organizations; international collaboration and regular meetings
      and updates for organizations working in the field of organ transplantation;
      grief counseling and reporting of potential donation for families of recently
      deceased people; nonfinancial incentivization to families of potential organ
      donors; expert committees and standard operating protocols for use of marginal
      donor organs, donation after circulatory death programs, and machine perfusion;
      maintenance of transparency and ethics in organ donation, allocation, and
      transplantation as directed by governmental, nongovernmental, and
      intergovernmental entities; and regular audit of progress and registry data.
FAU - Kute, Vivek
AU  - Kute V
AD  - From the Department of Nephrology and Transplantation Medicine, Smt. G. R. Doshi 
      and Smt. K. M. Mehta Institute of Kidney Diseases and Research Centre and Dr. H. 
      L. Trivedi Institute of Transplantation Sciences; the Indian Society of Organ
      Transplantation, Ahmedabad, India.
FAU - Ramesh, Vasanthi
AU  - Ramesh V
FAU - Shroff, Sunil
AU  - Shroff S
FAU - Guleria, Sandeep
AU  - Guleria S
FAU - Prakash, Jai
AU  - Prakash J
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Exp Clin Transplant
JT  - Experimental and clinical transplantation : official journal of the Middle East
      Society for Organ Transplantation
JID - 101207333
SB  - IM
MH  - Attitude to Death
MH  - *Brain Death
MH  - COVID-19
MH  - Health Education
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Services Needs and Demand
MH  - Humans
MH  - India
MH  - *Organ Transplantation
MH  - Religion and Medicine
MH  - Time Factors
MH  - Tissue Donors/*supply & distribution
MH  - *Tissue and Organ Procurement
EDAT- 2020/08/08 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.6002/ect.rlgnsymp2020.L6 [doi]
PST - ppublish
SO  - Exp Clin Transplant. 2020 Jul;18(Suppl 2):31-42. doi:
      10.6002/ect.rlgnsymp2020.L6.


PMID- 32757931
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210802
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Revising, Correcting, and Transferring Genes.
PG  - 7-18
LID - 10.1080/15265161.2020.1783024 [doi]
AB  - The distinction between germline and somatic gene editing is fundamental to the
      ethics of human gene editing. Multiple conferences of scientists, ethicists, and 
      policymakers, and multiple professional bodies, have called for moratoria on
      germline gene editing, and editing of human germline cells is considered to be an
      ethical "red line" that either never should be crossed, or should only be crossed
      with great caution and care. However, as research on germline gene editing has
      progressed, it has become clear that not all germline interventions are alike,
      and that these differences make a significant moral difference, when it comes to 
      ethical questions about research, regulation, clinical application, and medical
      justification. In this paper, I argue that, rather than lumping all germline
      interventions together, we should distinguish between revising, correcting, and
      transferring genes, and I assess the consequences of this move for the ethics of 
      gene editing.
FAU - Cwik, Bryan
AU  - Cwik B
AUID- ORCID: 0000-0002-5570-3403
AD  - Portland State University.
LA  - eng
GR  - R03 HG010417/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Aug;20(8):19-21. PMID: 32757933
CIN - Am J Bioeth. 2020 Aug;20(8):41-43. PMID: 32757935
CIN - Am J Bioeth. 2020 Aug;20(8):44-46. PMID: 32757937
CIN - Am J Bioeth. 2020 Aug;20(8):25-27. PMID: 32757938
CIN - Am J Bioeth. 2020 Aug;20(8):27-29. PMID: 32762626
CIN - Am J Bioeth. 2020 Aug;20(8):32-36. PMID: 32762627
CIN - Am J Bioeth. 2020 Aug;20(8):36-38. PMID: 32762628
CIN - Am J Bioeth. 2020 Aug;20(8):51-53. PMID: 32762629
CIN - Am J Bioeth. 2020 Aug;20(8):46-49. PMID: 32804058
CIN - Am J Bioeth. 2020 Aug;20(8):30-32. PMID: 32804061
CIN - Am J Bioeth. 2020 Aug;20(8):23-25. PMID: 32804062
CIN - Am J Bioeth. 2020 Aug;20(8):38-40. PMID: 32804063
CIN - Am J Bioeth. 2020 Aug;20(8):21-23. PMID: 32804064
CIN - Am J Bioeth. 2020 Aug;20(8):49-50. PMID: 32804065
CIN - Am J Bioeth. 2020 Aug;20(8):W1-W3. PMID: 32804066
CIN - Am J Bioeth. 2020 Aug;20(8):1-4. PMID: 32804067
MH  - Ethics, Clinical
MH  - Ethics, Research
MH  - Gene Editing/*ethics
MH  - Genetic Therapy/*ethics
MH  - *Germ Cells
MH  - Humans
MH  - Morals
MH  - Policy
PMC - PMC7473466
MID - NIHMS1621224
OTO - NOTNLM
OT  - *Gene editing
OT  - *germline intervention
OT  - *mitochondrial replacement therapy
OT  - *somatic/germline distinction
EDAT- 2020/08/08 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1080/15265161.2020.1783024 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):7-18. doi: 10.1080/15265161.2020.1783024.


PMID- 32757930
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20200810
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - The Nexus of Medical Professional Ethics and Business Ethics.
PG  - 117-118
LID - 10.1080/15265161.2020.1782512 [doi]
FAU - Solomon, Robert Charles
AU  - Solomon RC
AD  - Ellwood City Medical Center.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):110-111. PMID: 32757923
MH  - Emergency Service, Hospital
MH  - *Ethicists
MH  - *Ethics, Business
MH  - Ethics, Medical
MH  - Ethics, Professional
MH  - Humans
EDAT- 2020/08/08 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1080/15265161.2020.1782512 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):117-118. doi: 10.1080/15265161.2020.1782512.


PMID- 32757924
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20200810
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Surprise Billing as a Source of Vulnerability-An Ethics Question Indeed.
PG  - 114-116
LID - 10.1080/15265161.2020.1782515 [doi]
FAU - Kuhnel, Leslie
AU  - Kuhnel L
AD  - CHI Health.
AD  - Creighton University.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Aug;20(8):110-111. PMID: 32757923
MH  - Emergency Service, Hospital
MH  - *Ethicists
MH  - Humans
MH  - *Palliative Care
EDAT- 2020/08/08 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1080/15265161.2020.1782515 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):114-116. doi: 10.1080/15265161.2020.1782515.


PMID- 32757923
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Surprise Billing in the Emergency Department: What's a Clinical Ethics Consultant
      to Do?
PG  - 110-111
LID - 10.1080/15265161.2020.1782119 [doi]
FAU - Tarzian, Anita
AU  - Tarzian A
AD  - University of Maryland.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Aug;20(8):114-116. PMID: 32757924
CIN - Am J Bioeth. 2020 Aug;20(8):117-118. PMID: 32757930
CIN - Am J Bioeth. 2020 Aug;20(8):112-114. PMID: 32804068
MH  - Consultants
MH  - Disclosure/*ethics
MH  - *Emergency Service, Hospital
MH  - Ethical Analysis
MH  - Ethicists
MH  - Fees and Charges/*ethics
MH  - Hospitals
MH  - Humans
MH  - *Insurance Coverage
MH  - Morals
MH  - Physicians/*ethics
EDAT- 2020/08/08 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1080/15265161.2020.1782119 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):110-111. doi: 10.1080/15265161.2020.1782119.


PMID- 32757913
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210802
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Ethically Problematic Medical Device Representation.
PG  - 5-6
LID - 10.1080/15265161.2020.1782643 [doi]
FAU - Illes, Judy
AU  - Illes J
AD  - University of British Columbia.
FAU - McDonald, Patrick J
AU  - McDonald PJ
AD  - University of British Columbia.
FAU - Lau, Chloe
AU  - Lau C
AD  - University of British Columbia.
FAU - Hrincu, Viorica M
AU  - Hrincu VM
AD  - University of British Columbia.
FAU - Connolly, Mary B
AU  - Connolly MB
AD  - University of British Columbia.
LA  - eng
GR  - RF1 MH117805/MH/NIMH NIH HHS/United States
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - Commerce
MH  - *Equipment and Supplies
MH  - *Ethics, Business
MH  - Health Care Sector/*ethics
MH  - Humans
MH  - Marketing/*ethics/methods
PMC - PMC7703377
MID - NIHMS1648279
EDAT- 2020/08/08 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [entrez]
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1080/15265161.2020.1782643 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Aug;20(8):5-6. doi: 10.1080/15265161.2020.1782643.


PMID- 32757288
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1348-0421 (Electronic)
IS  - 0385-5600 (Linking)
VI  - 64
IP  - 9
DP  - 2020 Sep
TI  - Animal infection models using non-mammals.
PG  - 585-592
LID - 10.1111/1348-0421.12834 [doi]
AB  - The use of non-human animal models for infection experiments is important for
      investigating the infectious processes of human pathogenic bacteria at the
      molecular level. Mammals, such as mice and rabbits, are also utilized as animal
      infection models, but large numbers of animals are needed for these experiments, 
      which is costly, and fraught with ethical issues. Various non-mammalian animal
      infection models have been used to investigate the molecular mechanisms of
      various human pathogenic bacteria, including Staphylococcus aureus, Streptococcus
      pyogenes, and Pseudomonas aeruginosa. This review discusses the desirable
      characteristics of non-mammalian infection models and describes recent
      non-mammalian infection models that utilize Caenorhabditis elegans, silkworm,
      fruit fly, zebrafish, two-spotted cricket, hornworm, and waxworm.
CI  - (c) 2020 The Authors. Microbiology and Immunology published by The Societies and 
      John Wiley & Sons Australia, Ltd.
FAU - Kaito, Chikara
AU  - Kaito C
AUID- ORCID: http://orcid.org/0000-0002-2895-3386
AD  - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama
      University, Okayama, Japan.
FAU - Murakami, Kanade
AU  - Murakami K
AD  - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama
      University, Okayama, Japan.
FAU - Imai, Lina
AU  - Imai L
AD  - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama
      University, Okayama, Japan.
FAU - Furuta, Kazuyuki
AU  - Furuta K
AD  - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama
      University, Okayama, Japan.
LA  - eng
GR  - 19H03466/JSPS Grants-in-Aid for Scientific Research
GR  - 19K22523/JSPS Grants-in-Aid for Scientific Research
GR  - Ichiro Kanehara Foundation
GR  - Takeda Science Foundation
PT  - Journal Article
PT  - Review
DEP - 20200822
PL  - Australia
TA  - Microbiol Immunol
JT  - Microbiology and immunology
JID - 7703966
SB  - IM
MH  - Animals
MH  - Bacteria/pathogenicity
MH  - Bacterial Infections/*microbiology
MH  - Bombyx/microbiology
MH  - Caenorhabditis elegans/*microbiology
MH  - *Disease Models, Animal
MH  - Drosophila melanogaster/*microbiology
MH  - Gryllidae/*microbiology
MH  - Humans
MH  - Larva/microbiology
MH  - Manduca/microbiology
MH  - Moths/microbiology
MH  - Zebrafish/*microbiology
PMC - PMC7590188
OTO - NOTNLM
OT  - infection model
OT  - non-mammals
OT  - pathogenic bacteria
EDAT- 2020/08/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/06/18 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.1111/1348-0421.12834 [doi]
PST - ppublish
SO  - Microbiol Immunol. 2020 Sep;64(9):585-592. doi: 10.1111/1348-0421.12834. Epub
      2020 Aug 22.


PMID- 32757281
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1467-9566 (Electronic)
IS  - 0141-9889 (Linking)
VI  - 42 Suppl 1
DP  - 2020 Aug
TI  - Understanding and managing uncertainty in health care: revisiting and advancing
      sociological contributions.
PG  - 1-20
LID - 10.1111/1467-9566.13160 [doi]
AB  - In this collection we revisit the enduring phenomenon of uncertainty in health
      care, and demonstrate how it still offers coherence and significance as an
      analytic concept. Through empirical studies of contemporary examples of health
      care related uncertainties and their management, our collection explores the
      different ways in which uncertainty may be articulated, enacted and experienced. 
      The papers address a diverse range of healthcare contexts - Alzheimer's disease, 
      neonatal surgery, cardiovascular disease prevention, cancer, addiction (use of
      alcohol and other drugs during pregnancy), mental health/disorders and medical
      education - and many tackle issues of contemporary relevance, such as an ageing
      population, and novel medical interventions and their sequelae. These empirical
      papers are complemented by a further theoretical contribution, which considers
      the role of 'implicit normativity' in masking and containing potential ethical
      uncertainty. By mapping themes across the collection, in this introduction we
      present a number of core analytical strands: (1) conceptualising uncertainty; (2)
      intersections of uncertainty with aspects of care; (3) managing uncertainty; and 
      (4) structural constraints, economic austerity and uncertainty work. We reflect
      on the methodological and theoretical stances used to think sociologically about 
      uncertainty in health care, and the strengths, silences and gaps we observe in
      the collection. We conclude by considering the implications of the insights
      gained for 'synthesising certainty' in practice and for future research in this
      area.
CI  - (c) 2020 The Authors. Sociology of Health & Illness published by John Wiley &
      Sons Ltd on behalf of Foundation for SHIL (SHIL).
FAU - Mackintosh, Nicola
AU  - Mackintosh N
AD  - Social Science Applied to Healthcare Improvement Research (SAPPHIRE) Group,
      Department of Health Sciences, University of Leicester, Leicester, UK.
FAU - Armstrong, Natalie
AU  - Armstrong N
AD  - Social Science Applied to Healthcare Improvement Research (SAPPHIRE) Group,
      Department of Health Sciences, University of Leicester, Leicester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - England
TA  - Sociol Health Illn
JT  - Sociology of health & illness
JID - 8205036
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
MH  - Infant, Newborn
MH  - *Sociology
MH  - Uncertainty
EDAT- 2020/08/07 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.1111/1467-9566.13160 [doi]
PST - ppublish
SO  - Sociol Health Illn. 2020 Aug;42 Suppl 1:1-20. doi: 10.1111/1467-9566.13160. Epub 
      2020 Aug 5.


PMID- 32756603
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - RandoMice, a novel, user-friendly randomization tool in animal research.
PG  - e0237096
LID - 10.1371/journal.pone.0237096 [doi]
AB  - Careful design of experiments using living organisms (e.g. mice) is of critical
      importance from both an ethical and a scientific standpoint. Randomization
      should, whenever possible, be an integral part of such experimental design to
      reduce bias thereby increasing its reliability and reproducibility. To keep the
      sample size as low as possible, one might take randomization one step further by 
      controlling for baseline variations in the dependent variable(s) and/or certain
      known covariates. To give an example, in animal experiments aimed to study
      atherosclerosis development, one would want to control for baseline
      characteristics such as plasma triglyceride and total cholesterol levels and body
      weight. This can be done by first defining blocks to create balance among groups 
      in terms of group size and baseline characteristics, followed by random
      assignment of the blocks to the various control and intervention groups. In the
      current study we developed a novel, user-friendly tool that allows users to
      easily randomize animals into blocks and identify random block divisions that are
      well-balanced based on given baseline characteristics, making randomization
      time-efficient and easy-to-use. Here, we present the resulting software tool that
      we have named RandoMice.
FAU - van Eenige, Robin
AU  - van Eenige R
AUID- ORCID: 0000-0003-2637-3801
AD  - Department of Medicine, Division of Endocrinology, Leiden University Medical
      Center, Leiden, the Netherlands.
AD  - Einthoven Laboratory for Experimental Vascular Medicine, Leiden University
      Medical Center, Leiden, The Netherlands.
FAU - Verhave, Peternella S
AU  - Verhave PS
AD  - Animal Welfare Body, Leiden University Medical Center, Leiden, The Netherlands.
FAU - Koemans, Peter J
AU  - Koemans PJ
AD  - Independent Consultant, Gouda, The Netherlands.
FAU - Tiebosch, Ivo A C W
AU  - Tiebosch IACW
AD  - Animal Welfare Body Utrecht, Utrecht, The Netherlands.
FAU - Rensen, Patrick C N
AU  - Rensen PCN
AD  - Department of Medicine, Division of Endocrinology, Leiden University Medical
      Center, Leiden, the Netherlands.
AD  - Einthoven Laboratory for Experimental Vascular Medicine, Leiden University
      Medical Center, Leiden, The Netherlands.
FAU - Kooijman, Sander
AU  - Kooijman S
AD  - Department of Medicine, Division of Endocrinology, Leiden University Medical
      Center, Leiden, the Netherlands.
AD  - Einthoven Laboratory for Experimental Vascular Medicine, Leiden University
      Medical Center, Leiden, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Animal Experimentation
MH  - Animals
MH  - Biostatistics/*methods
MH  - Control Groups
MH  - Mice
MH  - Random Allocation
MH  - *Software
PMC - PMC7406044
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/07 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1371/journal.pone.0237096 [doi]
AID - PONE-D-20-11684 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 5;15(8):e0237096. doi: 10.1371/journal.pone.0237096.
      eCollection 2020.


PMID- 32756563
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20200929
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Points of contention: Qualitative research identifying where researchers and
      research ethics committees disagree about consent waivers for secondary research 
      with tissue and data.
PG  - e0235618
LID - 10.1371/journal.pone.0235618 [doi]
AB  - BACKGROUND: This is a multi-method, in-depth, three part qualitative study
      exploring the regulation and practice of secondary research with tissue and data 
      in a high-income country. We explore and compare the perspectives of researchers,
      research ethics committees (RECs) and other relevant professionals (e.g.
      pathologists and clinicians). We focus on points of contention because they
      demonstrate misalignment between the expectations, values and assumptions of
      these stakeholders. METHODS: This is a multi-method study using observational
      research, focus groups and interviews with 42 participants (conducted 2016-2017) 
      and analyzed using thematic analysis. RESULTS: Results are arranged under the
      following themes: consent; balancing the social value of the research with
      consent requirements; and harm. Our findings demonstrate different perspectives
      on the review process, styles of ethical reasoning and issues of concern. First, 
      researchers and RECs disagreed about whether the cost of re-consenting patients
      satisfied the criterion of impracticability for consent waivers. Second, most
      researchers were skeptical that secondary research with already collected tissue 
      and data could harm patients. Researchers often pointed to the harm arising from 
      a failure to use existing material for research. RECs were concerned about the
      potential for secondary research to stigmatize communities. Third, researchers
      adopted a more consequentialist approach to decision-making, including some
      willingness to trade off the benefit of the research against the cost of getting 
      consent; whereas RECs were more deontological and typically considered research
      benefit only after it had been established that re-consent was impractical.
      CONCLUSION: This research highlights ways in which RECs and researchers may be
      talking past each other, resulting in confusion and frustration. These finding
      provide a platform for realignment of the expectations of RECs and researchers,
      which could contribute to making research ethics review more effective.
FAU - Ballantyne, Angela
AU  - Ballantyne A
AUID- ORCID: 0000-0003-2666-9557
AD  - Department of Primary Health Care and General Practice and the Bioethics Centre, 
      University of Otago, Wellington, New Zealand.
FAU - Moore, Andrew
AU  - Moore A
AD  - Philosophy, University of Otago, Dunedin, New Zealand.
FAU - Bartholomew, Karen
AU  - Bartholomew K
AD  - Waitemata and Auckland District Health Boards, Auckland, New Zealand.
FAU - Aagaard, Nic
AU  - Aagaard N
AD  - Ethics, Health System Improvement and Innovation, Ministry of Health, Wellington,
      New Zealand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200805
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Ethics Committees, Research/ethics
MH  - Ethics, Research
MH  - Focus Groups
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Qualitative Research
MH  - Research Design
MH  - Research Personnel/ethics
MH  - Tissue Banks/ethics
PMC - PMC7406047
COIS- The authors have read the journal's policy and the authors of this manuscript
      have the following competing interests: Andrew Moore was a lead author of the
      current National Ethics Advisory Committee Guidelines for research ethics. Angela
      Ballantyne was a member of a Health and Disability Ethics Committee from
      2010-2018; Karen Bartholomew is a current member of a Health and Disability
      Ethics Committee. Nic Aagaard and Karen Bartholomew have been involved with
      drafting the revised New Zealand research ethics guidelines (released Dec 2019). 
      This does not alter our adherence to PLOS ONE policies on sharing data and
      materials.
EDAT- 2020/08/07 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
AID - 10.1371/journal.pone.0235618 [doi]
AID - PONE-D-20-03585 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 5;15(8):e0235618. doi: 10.1371/journal.pone.0235618.
      eCollection 2020.


PMID- 32756492
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 3
TI  - Review of the Online One Welfare Portal: Shared Curriculum Resources for
      Veterinary Undergraduate Learning and Teaching in Animal Welfare and Ethics.
LID - E1341 [pii]
LID - 10.3390/ani10081341 [doi]
AB  - This article introduces the online One Welfare learning and teaching portal (OWP)
      and describes its development, use, importance and relevance to animal welfare
      and ethics (AWE) stakeholders. As animal welfare issues increase in importance,
      veterinarians must be trained to lead the science that underpins AWE discourses. 
      The OWP is a collection of resources designed to engage and challenge veterinary 
      science students as they become advocates for animals. It was developed
      collaboratively by all eight veterinary schools in Australia and New Zealand, and
      funded by the Australian Government Office for Learning and Teaching. Surveys to 
      investigate the attitudes of students and educators to AWE issues in six
      context-specific themes based on the Australian Animal Welfare Strategy (AAWS)
      (companion animals; animals used in research and teaching; livestock/production
      animals; animals used for sport, recreation or display; animals in the wild and
      aquatic animals) were administered through all participating schools. Students
      assigned more importance to Day One competence in knowledge of welfare concepts
      than did educators for the following groups: production animals, companion
      animals, animals in the wild, aquatic animals, animals used in research and
      teaching, and animals used for sport, recreation or display (all p < 0.01).
      Agreement between educators and students was closer regarding the importance of
      Day One competence for euthanasia for all six context-specific themes (p < 0.01 -
      0.03). Students assigned more importance than educators to social, economic and
      cultural drivers of welfare outcomes in production animals (p < 0.01); slaughter 
      and preslaughter inspections in production animals (p < 0.01); animal abuse and
      hoarding in companion animals (p < 0.01); shelter medicine in companion animals
      (p < 0.01); disaster preparedness in wildlife animals (p < 0.01); pain and
      distress caused by fishing in aquatic animals (p < 0.01); conscientious objection
      related to animals held for research and teaching (p < 0.01); behaviour,
      selection and training of animals used for sport, recreation and display (p =
      0.046) and educating the public around sporting animal welfare (p < 0.01).
      Agreement between educators and students was closer for strategies to address
      painful husbandry procedures in production animals (p = 0.03); behaviour and
      training of companion animals (p = 0.03); veterinarians' duties to wild animals
      in wildlife (p = 0.02); the 3Rs in animals held for research and teaching (p =
      0.03) and ownership responsibility in sporting animals (p = 0.01). This report
      discusses the reasons for differences among students and educators as they
      approach these issues. The portal is expected to gather more content as
      veterinary schools in other countries use its resources and users submit
      scenarios and discussion topics that reflect local needs.
FAU - D McGreevy, Paul
AU  - D McGreevy P
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
FAU - Fawcett, Anne
AU  - Fawcett A
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
FAU - Johnson, Jane
AU  - Johnson J
AD  - Department of Philosophy, Hearing Hub, Macquarie University, North Ryde, NSW
      2109, Australia.
FAU - Freire, Rafael
AU  - Freire R
AD  - School of Animal and Veterinary Science, Institute for Land, Water and Society,
      Charles Sturt University, Wagga Wagga, NSW 2650, Australia.
FAU - Collins, Teresa
AU  - Collins T
AD  - School of Veterinary Medicine, College of Science, Health, Engineering and
      Education, Murdoch University, Murdoch, WA 6150, Australia.
FAU - Degeling, Chris
AU  - Degeling C
AD  - Australian Centre for Health Engagement, Evidence and Values, University of
      Wollongong, Wollongong, NSW 2522, Australia.
FAU - Fisher, Andrew D
AU  - Fisher AD
AD  - Faculty of Veterinary Science, University of Melbourne, Parkville, VIC 3100,
      Australia.
FAU - Hazel, Susan J
AU  - Hazel SJ
AD  - School of Animal and Veterinary Sciences, University of Adelaide, Roseworthy, SA 
      5005, Australia.
FAU - Hood, Jennifer
AU  - Hood J
AD  - School of Veterinary Medicine, College of Science, Health, Engineering and
      Education, Murdoch University, Murdoch, WA 6150, Australia.
FAU - Lloyd, Janice K F
AU  - Lloyd JKF
AD  - College of Public Health, Medical and Veterinary Sciences, James Cook University,
      Townsville, QLD 4811, Australia.
FAU - Phillips, Clive J C
AU  - Phillips CJC
AD  - School of Veterinary Science, University of Queensland, Gatton, QLD 4343,
      Australia.
FAU - Stafford, Kevin
AU  - Stafford K
AD  - Institute of Veterinary, Animal and Biomedical Sciences, Massey University,
      Palmerston North 4442, New Zealand.
FAU - Hyde, Michelle L
AU  - Hyde ML
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
FAU - Wilson, Bethany
AU  - Wilson B
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
FAU - Tzioumis, Vicky
AU  - Tzioumis V
AD  - Sydney School of Veterinary Science, University of Sydney, Sydney, NSW 2006,
      Australia.
LA  - eng
GR  - ID13-2833/Australian Government Office for Learning and Teaching
PT  - Journal Article
PT  - Review
DEP - 20200803
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7460400
OTO - NOTNLM
OT  - One Welfare
OT  - animal ethics
OT  - animal welfare
OT  - learning and teaching
OT  - online curriculum resources
OT  - veterinary medicine
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/07 06:00
MHDA- 2020/08/07 06:01
CRDT- 2020/08/07 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/27 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/07 06:01 [medline]
AID - ani10081341 [pii]
AID - 10.3390/ani10081341 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Aug 3;10(8). pii: ani10081341. doi: 10.3390/ani10081341.


PMID- 32756214
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Acupuncture for treating chronic stable angina pectoris-associated anxiety and
      depression: A protocol for systematic review and meta-analysis.
PG  - e21583
LID - 10.1097/MD.0000000000021583 [doi]
AB  - BACKGROUND: There are numerous studies worldwide on the use of acupuncture as
      complementary therapy for chronic stable angina pectoris (CSAP). However, the
      high morbidity of CSAP-associated anxiety and depression is often overlooked.
      This protocol of systematic review and meta-analysis aims to assess whether
      acupuncture is effective as a complementary therapy for anxiety and depression in
      patients with CSAP. METHODS: The following 8 databases will be searched from
      inception to February 2020 with no language restrictions: PubMed, Excerpt Medical
      Database, Web of Science, the Cochrane Library, Chinese Biomedical Database,
      China National Knowledge Infrastructure, VIP Database and Wanfang Database.
      Eligible randomized controlled trials and controlled clinical trials will be
      included. Study selection, data extraction, and risk of bias assessment will be
      performed independently by 2 reviewers, differences will be resolved by the third
      reviewer. The primary outcomes include the level of anxiety or depression
      measured by qualified scales, angina attack frequency, and angina pain intensity.
      Revman 5.3 software will be used to perform the assessment of the risk of bias
      and data synthesis. The review will grade the quality of the evidence based on
      the Grading of Recommendation, Assessment, Development, and Evaluation system.
      RESULTS: This systematic review and meta-analysis will provide reliable evidence 
      about the effect and safety of acupuncture as a complementary therapy for
      CSAP-associated anxiety and depression. CONCLUSION: The conclusion of this study 
      will be published in a peer-reviewed journal. ETHICS AND DISSEMINATION: This
      review will not involve private information of participants, so the ethical
      approval will not be required. The results will be disseminated in a
      peer-reviewed journal or conference presentation. Important protocol
      modifications will be updated on PROSPERO. PROSPERO REGISTRATION NUMBER:
      CRD42020165492.
FAU - Tu, Mingqi
AU  - Tu M
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province.
FAU - Jiang, Yongliang
AU  - Jiang Y
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province.
FAU - Yu, Jie
AU  - Yu J
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province.
AD  - Department of Acupuncture and Massage, Affiliated Hangzhou First People's
      Hospital, Zhejiang University School of Medicine, Hangzhou, China.
FAU - Liao, Binjun
AU  - Liao B
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - Department of Neurobiology and Acupuncture Research, the Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Angina, Stable/*complications
MH  - Anxiety/*etiology/*therapy
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Depression/*etiology/*therapy
MH  - Humans
MH  - Quality of Life
MH  - Research Design
PMC - PMC7402712
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021583 [doi]
AID - 00005792-202007310-00144 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21583. doi:
      10.1097/MD.0000000000021583.


PMID- 32756206
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Efficacy and safety of cinobufacini injection combined with vinorelbine and
      cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer: A
      protocol for systematic review and meta-analysis of randomized controlled trials.
PG  - e21539
LID - 10.1097/MD.0000000000021539 [doi]
AB  - BACKGROUND: The main component of cinobufacini injection is dry toad skin, which 
      is used as adjuvant therapy for stage III/IV non-small cell lung cancer patients 
      in long-term combination with vinorelbine and cisplatin. However, the efficacy
      and safety of this combination therapy remain unclear. METHODS: A systematic
      review and meta-analysis will be conducted following the preferred reported items
      for systematic review and meta-analysis guidelines. Two independent reviewers
      (LRL and ZLN) will carry out a comprehensive search of the PubMed, Web of
      Science, Cochrane Library, EMBASE, the Chinese Science and Technology Periodical 
      Database, China National Knowledge Infrastructure, Wanfang Databases, China
      Biology Medicine. The last search date will be July 30, 2020. Reference list of
      all selected articles will independently screened to identify additional studies 
      left out in the initial search. The Cochrane Risk of Bias Tool will be used to
      evaluate the risk of bias of the randomized controlled trials. Outcome index: The
      main efficacy indicators were based on the objective efficacy evaluation criteria
      of the World Health Organization antineoplastic drugs or the objective efficacy
      evaluation criteria of solid tumors established by RECIST. Secondary criteria
      Karnofsky performance scale (KPS) score, pain efficacy criteria, side effects of 
      chemotherapy such as myelosuppression and gastrointestinal symptoms. Assessment
      of risk of bias and data synthesis will be conducted using Review Manager V5.3
      software. RESULTS: This study will systematically evaluate the efficacy and
      safety of cinobufacini combined with vinorelbine and cisplatin in the treatment
      of stage III/IV non-small cell lung cancer. The results of this systematic review
      will be published in peer-reviewed scientific journals. ETHICS: The ethical
      approval is not required since systematic review is based on published studies.
      INPLASY REGISTRATION NUMBER: INPLASY202060091.
FAU - Li, Qian
AU  - Li Q
AUID- ORCID: 0000-0003-3124-3139
AD  - School of Health Preservation and Rehabilitation.
FAU - Liang, Ren-Long
AU  - Liang RL
AD  - School of Health Preservation and Rehabilitation.
FAU - Yu, Qian-Ru
AU  - Yu QR
AD  - School of Health Preservation and Rehabilitation.
FAU - Tian, De-Qing
AU  - Tian DQ
AD  - School of Health Preservation and Rehabilitation.
FAU - Zhao, Li-Na
AU  - Zhao LN
AD  - School of Health Preservation and Rehabilitation.
FAU - Wang, Wen-Wen
AU  - Wang WW
AD  - School of Health Preservation and Rehabilitation.
FAU - Xiao, Hua
AU  - Xiao H
AD  - School of Health Preservation and Rehabilitation.
FAU - Yong, Xiao-Jia
AU  - Yong XJ
AD  - Basic Medical School, Chengdu University of Traditional Chinese Medicine.
FAU - Peng, Xiao-Dong
AU  - Peng XD
AD  - Department of Oncology, The Second People's Hospital of Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Bufanolides)
RN  - 0 (Drugs, Chinese Herbal)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q6C979R91Y (Vinorelbine)
RN  - T9PSN4R8IR (cinobufagin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse
      effects/*therapeutic use
MH  - Bufanolides/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cisplatin/therapeutic use
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Neoplasm Staging
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Vinorelbine/therapeutic use
PMC - PMC7402891
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021539 [doi]
AID - 00005792-202007310-00136 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21539. doi:
      10.1097/MD.0000000000021539.


PMID- 32756205
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - A comparison of the efficacy and safety of complementary and alternative
      therapies for premature ovarian insufficiency: A protocol for network
      meta-analysis.
PG  - e21538
LID - 10.1097/MD.0000000000021538 [doi]
AB  - BACKGROUND: With the increase in the incidence of premature ovarian insufficiency
      (POI) over the years, the ovarian function has become one of the integral aspects
      of research in reproductive medicine today. POI seriously affects the physical
      and mental health of women, especially reproductive health. Studies show both
      complementary and alternative therapies to be effective in treating POIs.
      However, consistency in conclusions is still far-fetched. In light of this, we
      will carry out a study to evaluate the effectiveness and safety of complementary 
      and alternative therapies for POIs. We therefore develop a study protocol for a
      proposed network meta-analysis (NMA) and systematic review on POI. METHODS: The
      following electronic bibliographic database will be searched: VIP database,
      Wanfang database, Chinese National Knowledge Infrastructure (CNKI), The Cochrane 
      Library, PubMed, EMBASE and Web of Science from inception till 31 December 2019. 
      A search at the World Health Organization (WHO) International Clinical Trials
      Registry Platform will also be done. Subsequently, the searched data will undergo
      independent screening, retrieving, and risk of bias assessment by 2 reviewers.
      Analysis will be performed on included studies using the NMA technique. Next, the
      primary outcomes will be compared using ADDIS 1.16.5 and Stata 15.0. RESULTS: The
      safety and effectiveness of alternative and complementary therapies used in the
      treatment of POI will be compared and evaluated. CONCLUSION: This work will
      provide high-quality evidence for clinicians in the field to build on for best
      practices in effective interventions (complementary and alternative therapies)
      for POI. ETHICS AND DISSEMINATION: This NMA is a secondary research which based
      on some previously published data. Therefore, the ethical approval was not
      necessary. PROSPERO REGISTRATION NUMBER: CRD42020163873.
FAU - Zhang, Lei
AU  - Zhang L
AUID- ORCID: 0000-0003-1279-7822
AD  - The First Clinical College, Shandong University of Traditional Chinese Medicine.
FAU - Li, Honglin
AU  - Li H
AD  - The First Clinical College, Shandong University of Traditional Chinese Medicine.
FAU - Zhang, Jianwei
AU  - Zhang J
AD  - Hospital Affiliated to Shandong University of Traditional Chinese Medicine.
FAU - Kong, Xinliang
AU  - Kong X
AD  - The College of Traditional Chinese Medicine, Shandong University of Traditional
      Chinese Medicine, Jinan.
FAU - Wu, Zhijuan
AU  - Wu Z
AD  - The First Clinical College, Shandong University of Traditional Chinese Medicine.
AD  - Hospital Affiliated to Shandong University of Traditional Chinese Medicine.
FAU - Dong, Shuangqian
AU  - Dong S
AD  - The First Clinical College, Shandong University of Traditional Chinese Medicine.
FAU - Qin, Xiuyun
AU  - Qin X
AD  - Rizhao Maternal and Child Health Care Hospital, Rizhao, Shandong Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Estrogens)
RN  - 80497-65-0 (Anti-Mullerian Hormone)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - 9002-68-0 (Follicle Stimulating Hormone)
SB  - IM
MH  - Adult
MH  - Anti-Mullerian Hormone/blood
MH  - Complementary Therapies/adverse effects/*methods
MH  - Estrogens/blood
MH  - Female
MH  - Follicle Stimulating Hormone/blood
MH  - Humans
MH  - Luteinizing Hormone/blood
MH  - Network Meta-Analysis
MH  - Primary Ovarian Insufficiency/*therapy
MH  - Research Design
MH  - Young Adult
PMC - PMC7402872
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021538 [doi]
AID - 00005792-202007310-00135 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21538. doi:
      10.1097/MD.0000000000021538.


PMID- 32756183
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Non-pharmacological interventions for postpartum depression: A protocol for
      systematic review and network meta-analysis.
PG  - e21496
LID - 10.1097/MD.0000000000021496 [doi]
AB  - BACKGROUND: Postpartum depression (PPD) is one of the most common mental
      disorders in women following childbirth with heightened prevalence across the
      globe. Both pharmacotherapy and non-pharmacological interventions are effective
      for PPD. However, due to the concerns about the side effect on the mother and
      child of pharmacological treatments, most of women with PPD choose
      non-pharmacological therapies as their first line option. Prescription of these
      non-drug approaches should be guided by high quality evidence. Therefore, this
      network meta-analysis aims to compare, rank and interpret existed
      non-pharmacological evidence for the effective treatment of women with PPD.
      METHODS: Electronic bibliographic databases including EMBASE, PubMed, Scopus, The
      Cochrane Library, Web of Science, China National Knowledge Infrastructure
      (CNKI),VIP Database, Wanfang Database and Chinese Biomedical Literature Database 
      will be searched for relevant randomized controlled trials (RCTs) of
      non-pharmacological interventions for PPD. Heterogeneity and inconsistencies will
      be analyzed by I statistic and Z test, respectively. We will assess the quality
      of evidence by the Grading of Recommendations Assessment, Development and
      Evaluation (GRADE) and evaluate the risk of bias according to Cochrane risk of
      bias tool. R software 3.6.1 (R Foundation for Statistical Computing, Vienna,
      Austria) will be used to conduct a network meta-analysis. RESULTS: Formal ethical
      approval is not required, because the present study is a meta-analysis based on
      existed studies. The findings of this research will be reported in a recognized
      journal. CONCLUSION: The review results will ascertain the hierarchy of
      effectiveness of different non-pharmacological approaches for PPD, and
      systematically provide suggests for physicians and patients. TRIAL REGISTRATION
      NUMBER: PROSPERO CRD42020166801.
FAU - Wang, Yang
AU  - Wang Y
AUID- ORCID: 0000-0002-4920-6515
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
AD  - Department of Rehabilitation, Shuangliu Maternal and Child Health Care Hospital.
FAU - Li, Hui
AU  - Li H
AD  - School of Medicine, Chengdu University.
FAU - Peng, Wei
AU  - Peng W
AD  - School of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Chen, Yalin
AU  - Chen Y
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Qiu, Mimi
AU  - Qiu M
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Wang, Jun
AU  - Wang J
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Hao, Qinghong
AU  - Hao Q
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Tu, Yang
AU  - Tu Y
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
FAU - Liu, Yunlu
AU  - Liu Y
AD  - Institute of Laboratory Animal Sciences, Sichuan Academy of Medical Sciences &
      Sichuan Provincial People's Hospital.
AD  - Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial 
      People's Hospital, Chengdu, China.
FAU - Zhu, Tianmin
AU  - Zhu T
AD  - School of Rehabilitation and Health Preservation, Chengdu University of
      Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Complementary Therapies/*methods
MH  - Depression, Postpartum/*therapy
MH  - Female
MH  - Humans
MH  - Network Meta-Analysis
MH  - Pregnancy
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7402874
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021496 [doi]
AID - 00005792-202007310-00113 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21496. doi:
      10.1097/MD.0000000000021496.


PMID- 32756161
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Efficacy and safety of acupuncture combined with western medicine for anxiety: A 
      systematic review protocol.
PG  - e21445
LID - 10.1097/MD.0000000000021445 [doi]
AB  - BACKGROUND: As a common clinical mental disorder, the prevalence rate of anxiety 
      disorder increased yearly, devastating both physical health and social-economic
      prospect. The most common treatment relied on the use of western medications
      which is yet to fulfill ideal performance. While acupuncture is adopted as a
      treatment for anxiety disorders, the combination treatment of acupuncture and
      western medicines becomes more acknowledged. Albeit a spike in related
      literatures, the curative effect and safety of the treatment are still in lack of
      evidence. Therefore, this systematic review and meta-analysis protocol is planned
      to evaluate the efficacy and safety of the combination treatment of acupuncture
      and western medications. METHODS: Six English databases (PubMed, Web of science, 
      Medline, EBASE, Springer Cochrane Library and WHO International Clinical Trials
      Registry Platform) and four Chinese databases (Wan fang Database, Chinese
      Scientific Journal Database, China National Knowledge Infrastructure Database
      (CNKI) and Chinese Biomedical Literature Database) will be searched normatively
      according to the rule of each database from the inception to June 1, 2020. Two
      reviewers will independently conduct article selection, data collection, and risk
      of bias evaluation. Any disagreement will be resolved by discussion with the
      third reviewer. Either the fixed-effects or random-effects model will be used for
      data synthesis based on the heterogeneity test. The change in the scores on the
      Hamilton Anxiety Scale (HANA) and the self-rating anxiety scale (SAS) will be
      used as the main outcome measure, quality of life scale (SF-36), changes of
      symptoms in TCM, hormone levels and clinical global impression (CGI) as the
      secondary outcome. treatment emergent symptom scale (TESS), general physical
      examination(temperature, pulse, respiration, blood pressure), Routine examination
      of blood, urine and stool, Electrocardiogram, Liver and kidney function
      examination as the security indexes. RevMan 5.3.5 will be used for meta-analysis.
      RESULTS: This study will provide high-quality evidence to assess the
      effectiveness and safety of acupuncture combined with western medicine for
      anxiety. CONCLUSION: This systematic review will explore whether acupuncture
      combined with western medicine is an effective and safe intervention for anxiety.
      ETHICS AND DISSEMINATION: Ethical approval is not required for this study. The
      systematic review will be published in a peer-reviewed journal, presented at
      conferences, and will be shared on social media platforms. This review will be
      disseminated in a peer-reviewed journal or conference presentation. PROSPERO
      REGISTRATION NUMBER: PROSPERO CRD42020149746.
FAU - Tan, Aihua
AU  - Tan A
AUID- ORCID: 0000-0002-5099-3720
AD  - Hubei University of Chinese Medicine, Wuhan, Hubei.
FAU - Wang, Miyuan
AU  - Wang M
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Liu, Jia
AU  - Liu J
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Huang, Kailin
AU  - Huang K
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Dai, Disha
AU  - Dai D
AD  - People's Hospital of Wuhan University, Wuhan, Hubei, China.
FAU - Li, Lei
AU  - Li L
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Shi, Heyuan
AU  - Shi H
AD  - Hubei University of Chinese Medicine, Wuhan, Hubei.
FAU - Wang, Ping
AU  - Wang P
AD  - Hubei University of Chinese Medicine, Wuhan, Hubei.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Anxiety/psychology/*therapy
MH  - Anxiety Disorders/epidemiology
MH  - Combined Modality Therapy/*methods
MH  - Drug Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Outcome Assessment, Health Care
MH  - Prevalence
MH  - Quality of Life
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7402772
EDAT- 2020/08/07 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
AID - 10.1097/MD.0000000000021445 [doi]
AID - 00005792-202007310-00091 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21445. doi:
      10.1097/MD.0000000000021445.


PMID- 32756159
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Comparison of outcome of transcatheter aortic valve implantation in patients with
      advanced age: A systematic review and meta-analysis.
PG  - e21443
LID - 10.1097/MD.0000000000021443 [doi]
AB  - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an effective
      treatment to aortic stenosis in patients with advanced age. However, age is
      recognized as one of the most important risk factors. The aim of our study is to 
      compare the outcome of TAVI between octogenarian patients and young patients.
      METHODS: Randomized controlled trials, cohort studies and propensity score
      matching studies will be included in our systematic review and meta-analysis to
      evaluate clinical outcome in octogenarian patients who undergo TAVI. PubMed,
      EMBASE, MEDLINE, Cochrane Library and Web of Science will be searched using a
      comprehensive strategy. The related conference proceedings and reference lists of
      the included studies will also be checked to identify additional studies.
      Retrieved records, extract information and assess the risk of bias will be
      screened by two reviewers independently. STATA software will be used to conduct
      data synthesis. There is no requirement of ethical approval and informed consent.
      RESULTS: This study will eventually be published in a peer reviewed journal in
      the form of a scientific paper. CONCLUSION: This study will provide a
      comprehensive review of the available evidence for the treatment of aortic
      stenosis in octogenarian patients underwent TAVI. We hope it will provide a
      relatively comprehensive reference for clinical practice and future relevant
      clinical trials. PROSPERO REGISTRATION NUMBER: CRD42020155189. STUDY PROTOCOL
      REGISTRY: The protocol has been registered in PROSPERO, which is an International
      Prospective Register of Systematic Reviews. The registration number is
      CRD42020155189. ETHICS AND DISSEMINATION: Ethics approval and patient consent are
      not required as this study is a systematic review and meta-analysis.
FAU - Zhu, Shengde
AU  - Zhu S
AD  - First Clinical Medical College, Lanzhou University.
FAU - Li, Han
AU  - Li H
AD  - First Clinical Medical College, Lanzhou University.
FAU - Zhang, Guoliang
AU  - Zhang G
AD  - First Clinical Medical College, Lanzhou University.
FAU - Liu, Shidong
AU  - Liu S
AD  - First Clinical Medical College, Lanzhou University.
FAU - Li, Zijian
AU  - Li Z
AUID- ORCID: 0000-0002-6796-4176
AD  - Department of Hematology, First Hospital of Lanzhou University, Lanzhou, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aged, 80 and over
MH  - Aortic Valve Stenosis/diagnostic imaging/*surgery
MH  - Echocardiography/methods
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Tomography, X-Ray Computed/methods
MH  - Transcatheter Aortic Valve Replacement/*adverse effects/*methods
MH  - Treatment Outcome
PMC - PMC7402761
EDAT- 2020/08/07 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
AID - 10.1097/MD.0000000000021443 [doi]
AID - 00005792-202007310-00089 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21443. doi:
      10.1097/MD.0000000000021443.


PMID- 32756139
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20220416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Vitamin D for inflammation biomarkers in coronary artery disease: A protocol for 
      systematic review and meta-analysis.
PG  - e21407
LID - 10.1097/MD.0000000000021407 [doi]
AB  - BACKGROUND: Coronary artery disease (CAD) is a clinically common coronary heart
      disease. Vitamin D might be beneficial in CAD patients through its favorable
      effects on inflammation biomarkers. This study will be performed to examine the
      effects of Vitamin D supplementation on inflammatory markers in CAD patients.
      METHODS: We will search the electronical databases and hand-searching journals or
      reference lists. The study screening and data extraction will be carried out by 2
      investigators independently. The primary outcome is inflammatory biomarkers of
      peripheral blood. Secondary outcomes are triglyceride, total cholesterol,
      high-density lipoprotein cholesterol levels, low-density lipoprotein cholesterol,
      and blood pressure. Review Manager (RevMan, version 5.3; The Nordic Cochrane
      Centre, Copenhagen, Denmark: http://community.cochrane.org) V.5.3 software will
      be used to compute the data. RESULTS: The results of the study will provide a
      reliable evidence to assess the efficacy of Vitamin D supplement on inflammation 
      biomarkers of CAD patients. CONCLUSION: The conclusion of our systematic review
      will answer whether Vitamin D is an effective intervention to relieve
      inflammation of CAD patients. ETHICS: Because all of the data used in this review
      has been published, this review does not require ethical approval. REGISTRATION
      NUMBER: INPLASY202060072.
FAU - Wang, Yiru
AU  - Wang Y
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Zhang, Yifan
AU  - Zhang Y
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Wei, Jing
AU  - Wei J
AD  - Department of Traditional Chinese Medicine, Shanghai Xuhui Central Hospital,
      Shanghai, China.
FAU - Du, Wenting
AU  - Du W
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Ding, Jie
AU  - Ding J
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Zhang, Yiyi
AU  - Zhang Y
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Zhang, Na
AU  - Zhang N
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Mao, Meijiao
AU  - Mao M
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
FAU - Liu, Ping
AU  - Liu P
AD  - Longhua Hospital affiliated to Shanghai University of Traditional Chinese
      Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Biomarkers/blood
MH  - Coronary Artery Disease/*blood
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Systematic Reviews as Topic
MH  - Vitamin D/*blood
PMC - PMC7402871
EDAT- 2020/08/07 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
AID - 10.1097/MD.0000000000021407 [doi]
AID - 00005792-202007310-00069 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21407. doi:
      10.1097/MD.0000000000021407.


PMID- 32756113
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Efficacy of microsurgical varicocelectomy in the treatment of premature
      ejaculation: A protocol for systematic review and meta-analysis.
PG  - e21308
LID - 10.1097/MD.0000000000021308 [doi]
AB  - INTRODUCTION: Premature ejaculation (PE) is the most common type of sexual
      disorder among men which comprises a great of problems. Varicocele is defined as 
      the dilation of the pampiniform venous plexus draining the testicle. At present, 
      selective serotonin reuptake inhibitors antidepressants, topical anesthetics,
      tramadol, phosphodiesterase type 5 inhibitors are the common alternative strategy
      to improve PE. However, these therapeutic measures have several shortcomings and 
      side effects. Recently, the correlation between varicocele and PE has attracted
      the attention of some researchers. A few studies consider microsurgical
      varicocelectomy can be a new remedy for PE. But it is still absent enough a great
      deal of convincing evidence. The study will assess the effectiveness and safety
      of the microsurgical varicocelectomy treatment in PE patients. METHODS AND
      ANALYSIS: Electronic databases including English databases (PubMed, MEDLINE,
      EMBASE, Web of Science, Cochrane Library) and Chinese databases (China National
      Knowledge Infrastructure, China Biology Medicine Database, Wanfang Database, VIP 
      Database) will be searched from their inception to December 2020 to recognize
      related studies. All the randomized controlled trials of microsurgical
      varicocelectomy for the management of PE patients will be included. The potential
      outcome will include intravaginal ejaculation latency time, Chinese index of
      sexual function for premature ejaculation-5, visual analogue score, premature
      ejaculation diagnostic tool, success treatment rate, serum testosterone levels.
      We will conduct this study strictly according to the Cochrane Handbook for
      systematic reviews of interventions. RESULTS: The current study is a protocol for
      systematic review and meta-analysis without results, and data analysis will be
      carried out after the protocol. We will share our findings in the February 28,
      2021. CONCLUSION: This systematic review will provide more evidence to assess
      whether microsurgical varicocelectomy is an effective intervention for patients
      with PE. The results will be published in a public issue journal and offer the
      urologists and andrologists help to make clinical decisions. ETHICS AND
      DISSEMINATION: Formal ethical approval is not required in this protocol. We will 
      collect and analyze data based on published studies, and since there are no
      patients involved in this study, individual privacy will not be under concerns.
      The results of this review will be disseminated to peer-reviewed journals or
      submit to related conferences. PROTOCOL REGISTRATION NUMBER: INPLASY202060058.
FAU - Li, Fuhao
AU  - Li F
AUID- ORCID: 0000-0003-2909-0356
AD  - Department of Andrology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
FAU - Zhang, Song
AU  - Zhang S
AD  - Department of Andrology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
FAU - Yao, Hangyu
AU  - Yao H
AD  - Department of Andrology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
FAU - Fan, Yueyue
AU  - Fan Y
AD  - Shanghai University of TCM, Shanghai TCM-Integrated Hospital, Shanghai, China.
FAU - Shen, Yifeng
AU  - Shen Y
AD  - Department of Andrology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
FAU - Li, Guangsen
AU  - Li G
AD  - Department of Andrology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
FAU - Chang, Degui
AU  - Chang D
AD  - Department of Andrology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu, Sichuan Province.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Premature Ejaculation/*surgery
MH  - Systematic Reviews as Topic
MH  - Varicocele/surgery
MH  - *Vascular Surgical Procedures
PMC - PMC7402731
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021308 [doi]
AID - 00005792-202007310-00043 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21308. doi:
      10.1097/MD.0000000000021308.


PMID- 32756089
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - The efficacy and safety of Chinese traditional medicine injections on patients
      with coronavirus disease 2019: A protocol for systematic review and meta
      analysis.
PG  - e21024
LID - 10.1097/MD.0000000000021024 [doi]
AB  - INTRODUCTION: The pandemic caused by the coronavirus disease 2019 (COVID-19)
      infection has exposed vulnerable populations to an unprecedented global health
      crisis. Research reported that Chinese traditional medicine injections were used 
      in patients with COVID-19 infection and showed significant effects, and there
      have been no systematic review and meta-analyses to investigate the effects and
      safety of Chinese traditional medicine injections. MATERIALS AND METHODS: This
      systematic review and meta-analysis protocol is based on the Preferred Reporting 
      Items for Systematic Review and Meta-Analysis Protocols 2015 statement. The
      literature search will involve Cochran library, Web of science, PubMed, MEDLINE, 
      Embase, China Biology Medicine Database, China National Knowledge Infrastructure 
      Database, VIP, Wang Fang database, and China Clinical Trial Registration Center
      for articles and research published form December 2019. This search will include 
      randomized controlled trials and nonrandomized studies. The Cochrane
      Collaboration's tool for randomized controlled trial studies and the Quality
      Assessment Tool for Quantitative Studies for nonrandomized studies will be used
      to assess the risk of bias among the studies included in the systematic review.
      Review Manager 5.3 software will be used for the meta-analysis, and odds ratio
      are calculated as the primary outcomes. Subgroup analyses will then be performed 
      based on the characteristics of the interventions and populations included in the
      studies examined. ETHICS AND DISSEMINATION: This systematic review protocol is
      designed to provide evidence regarding the effects and safety of Chinese
      traditional medicine injections on patients with COVID-19, such evidence may be
      useful and important for clinical treatment decisions. The results should be
      disseminated through publication in a peer-reviewed journal. Since the data and
      results used in the systematic review will be extracted exclusively from
      published studies, approval from an ethics committee will not be required.
FAU - Li, Yulin
AU  - Li Y
AUID- ORCID: 0000-0003-0554-8457
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
FAU - Xu, Haonan
AU  - Xu H
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
FAU - Lang, Hui
AU  - Lang H
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
FAU - Li, Jing
AU  - Li J
AD  - Department of Evidence-Based Medicine and Clinical Epidemiology, West China
      Hospital, Sichuan University.
FAU - Bi, Lin
AU  - Bi L
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
FAU - Li, Yanqing
AU  - Li Y
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
FAU - Dong, Liang
AU  - Dong L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Chengdu Fifth People's Hospital, Chengdu, Sichuan, China.
FAU - Liang, Xin
AU  - Liang X
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
FAU - Zhu, Hongqiu
AU  - Zhu H
AD  - Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu
      University of Traditional Chinese Medicine, Sichuan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - COVID-19 drug treatment
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Humans
MH  - Injections
MH  - Male
MH  - Medicine, Chinese Traditional/*methods
MH  - Meta-Analysis as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7402801
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000021024 [doi]
AID - 00005792-202007310-00019 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21024. doi:
      10.1097/MD.0000000000021024.


PMID- 32756081
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Study on preventing adverse events in neonates (SEPREVEN): A stepped-wedge
      randomised controlled trial to reduce adverse event rates in the NICU.
PG  - e20912
LID - 10.1097/MD.0000000000020912 [doi]
AB  - INTRODUCTION: Adverse events (AE) in care are recognized as a leading cause of
      mortality and injury in patients. Improving patients' safety is difficult to
      achieve. Therefore, innovative research strategies are needed to identify errors 
      in subgroups of patients and related severity of outcomes as well as reliably
      measured efficiency of reproducible strategies to improve safety. This trial aims
      to evaluate the impact of a combined multiprofessional education program on the
      rate of AE in neonatal intensive care units (NICUs). METHODS AND ANALYSIS: This
      is a stepped-wedge cluster randomised controlled trial with 3 clusters each
      containing 4 units. The study time period will be 20 months. The education
      program will be implemented within each cluster following a random sequence with 
      a control period, a 4-month transition period and a post-educational intervention
      period. Eligibility criteria: for clusters: 6 NICUs from Ile-de-France and 6
      NICUs from different regions in France; for patients: in-hospital during the
      study period (November 23, 2015 and November 2, 2017 [inclusion start dates
      varying by unit]) in one of the 12 NICUs; corrected gestational age </=42 weeks
      upon admission; hospitalization period >2 days; and parents informed and not
      opposed to the use of their newborn's data. A routine occurrence reporting of
      medical errors and their consequence will take place during the entire study
      period. The intervention will combine an education to implement a standardized
      root cause analysis method, creation of bundles (insertion, daily goals,
      maintenance bundles) to prevent catheter-associated blood-stream infection and a 
      poster to prevent extravasation injuries. OUTCOME: We hypothesize a reduction
      from 60 (control) to 50 (intervention) AE/1000 patient-days. The primary outcome 
      will be the rate of AE/1000 patient-days in the NICU. TRIAL REGISTRATION NUMBER: 
      NCT02598609, trial registered November 6, 2015.
      https://clinicaltrials.gov/ct2/show/NCT02598609. ETHICS AND DISSEMINATION: Study 
      approved by the regional ethic committee CPP Ile-de-France III (no
      2014-A01751-46). The results will be published in peer-reviewed journals.
FAU - Caeymaex, Laurence
AU  - Caeymaex L
AUID- ORCID: 0000-0003-3822-5136
AD  - Faculty of Health and CEDITEC, University Paris East Creteil.
AD  - Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil.
AD  - Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Creteil,
      Creteil.
FAU - Lebeaux, Cecile
AU  - Lebeaux C
AD  - Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil.
FAU - Roze, Jean Christophe
AU  - Roze JC
AD  - Pediatric Intensive Care Unit Nantes, University Hospital Centre Nantes, Pays de 
      la Loire.
FAU - Danan, Claude
AU  - Danan C
AD  - Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil.
AD  - Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Creteil,
      Creteil.
FAU - Reynaud, Audrey
AU  - Reynaud A
AD  - Association SOS Prema, Boulogne Billancourt.
FAU - Jung, Camille
AU  - Jung C
AD  - Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Creteil,
      Creteil.
FAU - Audureau, Etienne
AU  - Audureau E
AD  - Faculty of Health and CEDITEC, University Paris East Creteil.
AD  - IMRB INSERM U 955 Team CEpiA (Clinical Epidemiology and Ageing Unit), Creteil,
      Val de Marne.
AD  - Assistance Publique Hopitaux de Paris (APHP), Hopital Henri-Mondor, Clinical
      Research Unit (URC), Public Health Department, Creteil, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT02598609
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Catheter-Related Infections/prevention & control
MH  - Education, Medical, Continuing/methods
MH  - Extravasation of Diagnostic and Therapeutic Materials/prevention & control
MH  - Humans
MH  - Infant, Newborn
MH  - *Intensive Care Units, Neonatal
MH  - Medical Errors/*prevention & control
MH  - Neonatology/*education
MH  - Patient Safety
MH  - Randomized Controlled Trials as Topic
PMC - PMC7402760
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000020912 [doi]
AID - 00005792-202007310-00011 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e20912. doi:
      10.1097/MD.0000000000020912.


PMID- 32756077
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in
      diabetes: A protocol for systematic review and meta analysis.
PG  - e20707
LID - 10.1097/MD.0000000000020707 [doi]
AB  - INTRODUCTION: There is a risk of cognitive impairment in diabetic patients. Some 
      studies have shown that dipeptidyl peptidase-4 inhibitors (DPP-4) inhibitors can 
      play a protective role in controlling blood glucose and blocking the DPP-4 to
      attach antibody glucagon-like peptide -1 degradation and prolong antibody
      glucagon-like peptide -1, promoting the growth of neurites and the formation of
      synapses. The purpose of this study is to explore the effect of the DPP-4
      inhibitor on cognitive impairment in diabetic patients by meta-analysis. METHODS:
      The system review plan will strictly follow the Systematic Review and
      Meta-Analysis Protocols entry for reporting. PubMed, EMBASE, Cochrane Library,
      Clinicaltrials(clinicaltrials.gov), Web of Science, China National Knowledge
      Infrastructure, China Science and Technology Journal Database and Wanfang
      Databases will be systematically searched, and all randomized controlled trials
      comparing DPP-4 inhibitors with placebo or other hypoglycemic drugs to study
      cognitive impairment in type 2 diabetic patients will be included. The inclusion,
      evaluation and data extraction of the literature will be conducted by 2 persons
      independently, and the dispute will be resolved by a third person. All the
      meta-analysis of the included literature and the research progress of the
      existing research are analyzed as the main results. ETHICS AND DISSEMINATION: It 
      is to evaluate and analyze the completed research, so there is no ethical
      problem. The research results will be published in a peer-reviewed journal.
      REGISTRATION: The protocol of this systematic review and meta-analysis was
      registered on International Platform of Registered Systematic Review and
      Meta-analysis Protocols (https://inplasy.com/) (number. 202040185).
FAU - Liu, Shiyu
AU  - Liu S
AUID- ORCID: 0000-0002-3410-1470
AD  - School of Clinical Medicine.
FAU - Wang, Xian
AU  - Wang X
AD  - School of Clinical Medicine.
FAU - Deng, Huan
AU  - Deng H
AD  - School of Clinical Medicine.
FAU - Xia, Yuguo
AU  - Xia Y
AD  - School of Clinical Medicine.
FAU - Yang, Xiaomei
AU  - Yang X
AD  - School of Clinical Medicine.
FAU - Chen, Qiu
AU  - Chen Q
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Cognitive Dysfunction/*drug therapy/etiology
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
PMC - PMC7402785
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000020707 [doi]
AID - 00005792-202007310-00007 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e20707. doi:
      10.1097/MD.0000000000020707.


PMID- 32756074
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Cardiovascular risk factors in children and adolescents with subclinical
      hypothyroidism: A protocol for meta-analysis and systematic review.
PG  - e20462
LID - 10.1097/MD.0000000000020462 [doi]
AB  - INTRODUCTION: Subclinical hypothyroidism (SH) is serum thyrotropin (TSH) slightly
      increased, while serum free thyroxine (FT4) levels are normal, and patients may
      have no abnormal symptoms, or only slight hypothyroidism, there are many studies 
      proving that SH does increase cardiovascular risk in adults. However, there are
      few studies in children and adolescents. In order to explore whether children
      with subclinical hypothyroidism have a higher cardiovascular risk, we designed
      this meta-analysis. METHODS: The protocol of this systematic review and
      meta-analysis was registered on the NPLASY (No. 202040182). The following
      electronic databases will be searched from the inception through the present to
      find studies that live up to our standard: PubMed, EMBASE, Web of Science,
      Cochrane Library, CNKI, Wanfang, and VIP. And we will include case-control
      studies, cohort studies, and cross-sectional studies. For including study, we
      will use the Newcastle-Ottawa Scale to evaluate their quality. Then 2 researchers
      will independently extract the required information. I statistics and subgroups
      will be used to analyze heterogeneity. We conduct a sensitivity analysis by
      excluding literature successively. When the system review contains >10 articles, 
      Egger test will be conducted to evaluate publication bias. RESULTS: From this
      study, we will assess the cardiovascular risk of children and adolescents with SH
      from multiple perspectives. CONCLUSION: The conclusion of this paper will provide
      evidence for cardiovascular risk of SH children and provide basis for prevention 
      and treatment of SH. ETHICS AND DISSEMINATION: This meta-analysis does not
      collect personal primary data, so there is no need for formal moral recognition. 
      The results of the system review will be presented to national and international 
      conferences for publication.
FAU - Deng, Huan
AU  - Deng H
AUID- ORCID: 0000-0003-3767-1142
AD  - School of Clinical Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Zhou, Shan
AU  - Zhou S
AD  - School of Clinical Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Wang, Xian
AU  - Wang X
AD  - School of Clinical Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Qiu, Xianliang
AU  - Qiu X
AD  - School of Clinical Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Wen, Qing
AU  - Wen Q
AD  - School of Clinical Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Liu, Shiyu
AU  - Liu S
AD  - School of Clinical Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Chen, Qiu
AU  - Chen Q
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Asymptomatic Diseases
MH  - Cardiovascular Diseases/*etiology
MH  - Child
MH  - Humans
MH  - Hypothyroidism/*complications
MH  - Risk Factors
PMC - PMC7402806
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1097/MD.0000000000020462 [doi]
AID - 00005792-202007310-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e20462. doi:
      10.1097/MD.0000000000020462.


PMID- 32755879
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20220531
IS  - 1305-3612 (Electronic)
IS  - 1305-3825 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Sep
TI  - Ethical considerations for artificial intelligence: an overview of the current
      radiology landscape.
PG  - 504-511
LID - 10.5152/dir.2020.19279 [doi]
AB  - Artificial intelligence (AI) has great potential to accelerate scientific
      discovery in medicine and to transform healthcare. In radiology, AI is about to
      enter into clinical practice and has a wide range of applications covering the
      whole diagnostic workflow. However, AI applications are not smooth sailing. It is
      crucial to understand the potential risks and hazards that come with this new
      technology. We have to implement AI in the best possible way to reflect the
      time-honored ethical and legal standards while ensuring the adequate protection
      of patient interests. These issues are discussed under the light of core
      biomedical ethics principles and principles for AI-specific ethical challenges
      while giving an overview of the statements that were proposed for the ethics of
      AI applications in radiology.
FAU - Akinci D'Antonoli, Tugba
AU  - Akinci D'Antonoli T
AD  - Department of Radiology and Nuclear Medicine, University Hospital Basel,
      University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Turkey
TA  - Diagn Interv Radiol
JT  - Diagnostic and interventional radiology (Ankara, Turkey)
JID - 101241152
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - Radiography
MH  - *Radiology
MH  - Workflow
PMC - PMC7490024
EDAT- 2020/08/07 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.5152/dir.2020.19279 [doi]
PST - ppublish
SO  - Diagn Interv Radiol. 2020 Sep;26(5):504-511. doi: 10.5152/dir.2020.19279.


PMID- 32755223
OWN - NLM
STAT- MEDLINE
DCOM- 20201118
LR  - 20201118
IS  - 1546-3141 (Electronic)
IS  - 0361-803X (Linking)
VI  - 215
IP  - 4
DP  - 2020 Oct
TI  - The Hippocratic Oath: A Radiologic Perspective.
PG  - 1039-1041
LID - 10.2214/AJR.20.22804 [doi]
AB  - OBJECTIVE. The purpose of this article is to revisit the Hippocratic Oath, the
      oldest extant document of medical ethics, and refamiliarize ourselves with the
      foundation of our profession of radiology. CONCLUSION. Many radiologists have
      taken the Hippocratic Oath. However, for many, it has been years, even decades,
      since they last read it. At a time when the field of radiology is undergoing
      rapid changes, it is important for radiologists to ponder the ethical foundation 
      of radiology.
FAU - Al-Khori, Noor A
AU  - Al-Khori NA
AD  - Weill Cornell Medicine-Qatar, Education City, Qatar.
FAU - Gunderman, Richard B
AU  - Gunderman RB
AD  - Indiana University School of Medicine, 702 N Barnhill Dr, Rm 1053, Indianapolis, 
      IN 46077.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
SB  - IM
MH  - *Hippocratic Oath
MH  - Humans
MH  - *Radiology
OTO - NOTNLM
OT  - *Hippocratic Oath
OT  - *ethics
OT  - *professionalism
OT  - *radiologists
OT  - *radiology
EDAT- 2020/08/07 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/08/07 06:00 [entrez]
AID - 10.2214/AJR.20.22804 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 2020 Oct;215(4):1039-1041. doi: 10.2214/AJR.20.22804. Epub
      2020 Jul 29.


PMID- 32754801
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1573-0980 (Electronic)
IS  - 1386-7415 (Linking)
VI  - 41
IP  - 2-3
DP  - 2020 Jun
TI  - Addressing complex hospital discharge by cultivating the virtues of acknowledged 
      dependence.
PG  - 99-114
LID - 10.1007/s11017-020-09525-w [doi]
AB  - Every day around the country, patients are discharged from hospitals without
      difficulty, as the interests of the hospital and the patient tend to align: both 
      the hospital and the patient want the patient to leave and go to a setting that
      will promote the patient's continued recovery. In some cases, however, this
      usually routine process does not go quite as smoothly. Patients may not want to
      leave the hospital, or they may insist on an unsafe discharge plan. In other
      cases, there may simply be no good place for the patient to go. These complex
      hospital discharge situations often involve ethical, legal, financial, and
      practical considerations, but the ethical issues inherent in these dilemmas have 
      received only sporadic attention from clinical ethicists at best, leaving
      patients, providers, administrators, and caregivers unsure about what to do. When
      the ethical issues are in fact brought to light, analysis usually proceeds based 
      on a consideration of the principles of autonomy, beneficence, nonmaleficence,
      and justice. However, principled analysis often fails to present patients and
      providers with a satisfactory solution, as the principles inevitably conflict
      (for example, when the patient's autonomous desire to remain in the hospital
      conflicts with the principles of beneficence and justice). In this paper, I argue
      that difficult discharges are ethical dilemmas worthy of scholarly attention that
      goes beyond principlism, and I argue that providers and those involved in
      discharge planning ought to cultivate what philosopher Alasdair MacIntyre calls
      "virtues of acknowledged dependence" in order to care for these patients and
      their families. I first trace the current conversation about difficult discharge 
      and show that the principled approach to resolving discharge dilemmas is not
      sufficient. I then argue that a new approach is needed, and to that end, I offer 
      practical ways in which MacIntyre's account of the virtues of acknowledged
      dependence may help patients, providers, and family members to navigate issues of
      difficult discharge.
FAU - Friedrich, Annie B
AU  - Friedrich AB
AUID- ORCID: 0000-0001-6326-751X
AD  - Saint Louis University, 3545 Lafayette Avenue, St. Louis, MO, 63104, USA.
      annie.friedrich@slu.edu.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Theor Med Bioeth
JT  - Theoretical medicine and bioethics
JID - 9805378
SB  - IM
MH  - Beneficence
MH  - *Ethical Theory
MH  - Humans
MH  - Patient Discharge/*standards
MH  - *Virtues
OTO - NOTNLM
OT  - *Acknowledged dependence
OT  - *Alasdair MacIntyre
OT  - *Clinical ethics
OT  - *Difficult discharge
OT  - *Virtues
EDAT- 2020/08/06 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2020/08/06 06:00 [entrez]
AID - 10.1007/s11017-020-09525-w [doi]
AID - 10.1007/s11017-020-09525-w [pii]
PST - ppublish
SO  - Theor Med Bioeth. 2020 Jun;41(2-3):99-114. doi: 10.1007/s11017-020-09525-w.


PMID- 32754518
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Role of fractal analysis in detection of dysplasia in potentially malignant
      disorders.
PG  - 2448-2453
LID - 10.4103/jfmpc.jfmpc_159_20 [doi]
AB  - BACKGROUND: Fractal analysis is, a noninvasive method, used to determine the
      intricate characteristics of the matter. Oral leukoplakia (OL), a potential
      malignant disorder, has definite propensity to turn in to malignancy. In such
      lesions, fractal dimension analysis (FDA) could be helpful in the early detection
      of malignant transformation. OBJECTIVES: To determine the efficacy of fractal
      dimension analysis in detecting malignancy potential of oral leukoplakia.
      MATERIALS AND METHODS: After ethical clearance, we enrolled 121 patients in our
      study. Lesions were photographed before and after toluidine staining. Image J
      software was used to analyze fractal dimensions (FDs) of digital image and
      results were compared with biopsy. RESULTS: Fractal dimension value is
      significantly higher in leukoplakia with dysplastic changes. FD values increase
      as age of patients increases. FD value in leukoplakia with different tobacco
      products showed more positive correlation with surti/khaini abusers. CONCLUSION: 
      Fractal dimension analysis is a useful method in determination of complication in
      OL cases and can be used as an effective, noninvasive screening tool at primary
      healthcare centers for early intervention.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Iqbal, Javed
AU  - Iqbal J
AD  - Department of Oral Medicine and Radiology, King George's Medical University,
      Lucknow, Uttar Pradesh, India.
FAU - Patil, Ranjitkumar
AU  - Patil R
AD  - Department of Oral Medicine and Radiology, King George's Medical University,
      Lucknow, Uttar Pradesh, India.
FAU - Khanna, Vikram
AU  - Khanna V
AD  - Department of Oral Medicine and Radiology, King George's Medical University,
      Lucknow, Uttar Pradesh, India.
FAU - Tripathi, Anurag
AU  - Tripathi A
AD  - Department of Oral Medicine and Radiology, King George's Medical University,
      Lucknow, Uttar Pradesh, India.
FAU - Singh, Vandana
AU  - Singh V
AD  - Department of Oral Medicine and Radiology, King George's Medical University,
      Lucknow, Uttar Pradesh, India.
FAU - Munshi, M A I
AU  - Munshi MAI
AD  - Department of Oral and Maxillofacial Surgery, Sri Ramakrishna Dental College and 
      Hospital, Coimbatore, Tamil Nadu, India.
FAU - Tiwari, Rahul
AU  - Tiwari R
AD  - Consultant Oral and Maxillofacial Surgeon, Clove Dental and OMNI Hospitals,
      Visakhapatnam, Andhra Pradesh, India.
LA  - eng
PT  - Journal Article
DEP - 20200531
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7380790
OTO - NOTNLM
OT  - Fractal analysis
OT  - oral leukoplakia
OT  - screening test
OT  - toluidine blue
COIS- There are no conflicts of interest.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
CRDT- 2020/08/06 06:00
PHST- 2020/01/25 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_159_20 [doi]
AID - JFMPC-9-2448 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 May 31;9(5):2448-2453. doi:
      10.4103/jfmpc.jfmpc_159_20. eCollection 2020 May.


PMID- 32754482
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Small group discussions as an effective teaching-learning methodology for
      learning the principles of family medicine among 2(nd)-year MBBS students.
PG  - 2248-2252
LID - 10.4103/jfmpc.jfmpc_1228_19 [doi]
AB  - Teaching methodology has a great impact on the learning outcomes in an
      undergraduate's education. OBJECTIVES: 1. To assess the effectiveness of small
      group discussions (SGD) over lecture in learning the principles of family
      medicine among 2(nd)-year MBBS students. 2. To assess the perception of students 
      on SGD over lecture in learning principles of family medicine among 2(nd)-year
      MBBS students. MATERIALS AND METHODS: This medical education, quasi-experimental 
      study was conducted at a medical college in north Kerala. Study subjects were the
      2(nd)-year MBBS students of this college. They participated after giving informed
      consent and were divided into two groups using serial roll number. The study was 
      conducted for 2 months after getting ethical clearance. Study tools included
      PowerPoint presentation slides, literature regarding principles of family
      medicine, structured questionnaire, and question paper for posttest. Statistical 
      analysis was done with an independent sample Z-test and Mann-Whitney test, using 
      SPSS 20 software. RESULTS: SGD show a definite advantage over lecture-based
      learning in improving the attention span of students, understanding the
      principles of family medicine, and recall. The scores for the overall learning
      experience was found to be significantly higher for SGD. Evaluating the
      effectiveness of training on the Kirkpatrick model showed that learners show
      better satisfaction and learning in small groups. CONCLUSION: Students strongly
      preferred SGD over lectures as the teaching-learning methodology for principles
      of family medicine. SGD is a more effective instructional tool in improving the
      attention span of students, understanding the principles of family medicine, and 
      recall. The overall learning satisfaction was found to be significantly higher
      with SGD for learning the principles of family medicine.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Roshni, M
AU  - Roshni M
AD  - Department of Family Medicine, DM WIMS Medical College, Wayanad, Kerala, India.
FAU - Rahim, A
AU  - Rahim A
AD  - Department of Community Medicine, Government Medical College, Manjeri, Kerala,
      India.
LA  - eng
PT  - Journal Article
DEP - 20200531
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7380748
OTO - NOTNLM
OT  - Innovative teaching-learning methods
OT  - lecture
OT  - small group discussion
OT  - student-centered
COIS- There are no conflicts of interest.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
CRDT- 2020/08/06 06:00
PHST- 2020/02/01 00:00 [received]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_1228_19 [doi]
AID - JFMPC-9-2248 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 May 31;9(5):2248-2252. doi:
      10.4103/jfmpc.jfmpc_1228_19. eCollection 2020 May.


PMID- 32754466
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Disability ethics in the coronavirus crisis.
PG  - 2167-2171
LID - 10.4103/jfmpc.jfmpc_588_20 [doi]
AB  - The disability viewpoint is fundamental for understanding and advancing social
      justice for everyone in the population. Despite this fact, it is regularly
      dismissed by public health experts and policymakers. Understanding of disability 
      rights is central in an all-inclusive COVID-19 preparedness. This paper attempts 
      to explore disability ethics in understanding structural discrimination,
      equitable practices, respect for disability culture and ways to safeguard health 
      care professionals with disabilities in the coronavirus pandemic. In crisis
      standards of care, resource allocations must not be solely based on a disabled
      person's subjective quality of life. Health professionals should avoid
      stereotypes about an individual's disability to ration care. Triage protocol
      committees and disaster risk reduction working groups should explicitly recruit
      people with disabilities and chronic illnesses in their response strategies.
      Disability ethics can reform medical rationing by removing prejudices and
      safeguarding fair protection of the interests of all patients, including those
      with a disability.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Singh, Satendra
AU  - Singh S
AD  - Medical Humanities Group, University College of Medical Sciences, Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200531
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7380818
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical ethics
OT  - coronavirus
OT  - disability studies
OT  - disabled persons
OT  - health equity
OT  - medical ethics
OT  - pandemics
OT  - resource allocation
OT  - social justice
OT  - standards of care/ethics*
OT  - triage
COIS- There are no conflicts of interest.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
CRDT- 2020/08/06 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_588_20 [doi]
AID - JFMPC-9-2167 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 May 31;9(5):2167-2171. doi:
      10.4103/jfmpc.jfmpc_588_20. eCollection 2020 May.


PMID- 32754319
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-9450 (Print)
IS  - 2049-9450 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Sep
TI  - [Comment] Ethical and practical considerations on cancer recommendations during
      COVID-19 pandemic.
PG  - 5
LID - 10.3892/mco.2020.2075 [doi]
AB  - National and international authorities and societies have recently published
      important cancer treatment recommendations in order to propose extra measures
      that should be taken during the COVID-19 pandemic, such as prioritisation of
      intend-to-cure treatments and younger patients, omission of non-urgent cases, and
      reduction of personnel present. These measures raise important ethical
      considerations, since they prioritise protection of Health Systems and
      Professionals without seemingly taking cancer patient feelings of stress into
      consideration. This could lead to an erosion of the physician-patient
      relationship, which is considered the core element of medical ethics. Moreover,
      they raise practical concerns about the continuous education of Health
      Professionals, the status of reference centres and the evaluation of the hitherto
      cancer treatments.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Melidis, Christos
AU  - Melidis C
AD  - Radiation Therapy Department, 20200 Bastia, France.
FAU - Vantsos, Miltiadis
AU  - Vantsos M
AD  - Faculty of Theology, Aristotle University of Thessaloniki, 54124 Thessaloniki,
      Greece.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC7391840
OTO - NOTNLM
OT  - COVID-19
OT  - cancer treatment
OT  - ethical considerations
OT  - pandemic
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
CRDT- 2020/08/06 06:00
PHST- 2020/05/22 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
AID - 10.3892/mco.2020.2075 [doi]
AID - MCO-0-0-02075 [pii]
PST - ppublish
SO  - Mol Clin Oncol. 2020 Sep;13(3):5. doi: 10.3892/mco.2020.2075. Epub 2020 Jun 24.


PMID- 32754115
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine
      in Young Females: What We Know and How to Investigate Open Questions. Review of
      the Literature and Results of a Multi-Registry Survey.
PG  - 381
LID - 10.3389/fendo.2020.00381 [doi]
AB  - Published studies on the risk of radiation-induced second primary malignancy
      (SPM) after radioiodine treatment (RAI) of differentiated thyroid cancer (DTC)
      refer mainly to patients treated as middle-aged or older adults and are not
      easily generalizable to those treated at a younger age. Here we review available 
      literature on the risk of breast cancer as an SPM after RAI of DTC with a focus
      on females undergoing such treatment in childhood, adolescence, or young
      adulthood. Additionally, we report the results of a preliminary international
      survey of patient registries from academic tertiary referral centers specializing
      in pediatric DTC. The survey sought to evaluate the availability of sufficient
      patient data for a potential international multicenter observational case-control
      study of females with DTC given RAI at an early age. Our literature review
      identified a bi-directional association of DTC and breast cancer. The general
      breast cancer risk in adult DTC survivors is low, ~2%, slightly higher in females
      than in males, but presumably lower, not higher, in those diagnosed as children
      or adolescents than in those diagnosed at older ages. RAI presumably does not
      substantially influence breast cancer risk after DTC. However, data from patients
      given RAI at young ages are sparse and insufficient to make definitive
      conclusions regarding age dependence of the risk of breast cancer as a SPM after 
      RAI of DTC. The preliminary analysis of data from 10 thyroid cancer registries
      worldwide, including altogether 6,449 patients given RAI for DTC and 1,116
      controls, i.e., patients not given RAI, did not show a significant increase of
      breast cancer incidence after RAI. However, the numbers of cases and controls
      were insufficient to draw statistically reliable conclusions, and the proportion 
      of those receiving RAI at the earliest ages was too low.In conclusion, a
      potential international multicenter study of female patients undergoing RAI of
      DTC as children, adolescents, or young adults, with a sufficient sample size, is 
      feasible. However, breast cancer screening of a larger cohort of DTC patients is 
      not unproblematic for ethical reasons, due to the likely, at most slightly,
      increased risk of breast cancer post-RAI and the expected ~10% false-positivity
      rate which potentially produced substantial "misdiagnosis."
CI  - Copyright (c) 2020 Reiners, Schneider, Platonova, Fridman, Malzahn, Mader,
      Vrachimis, Bogdanova, Krajewska, Elisei, Vaisman, Mihailovic, Costa and Drozd.
FAU - Reiners, Christoph
AU  - Reiners C
AD  - University Hospital, Wurzburg, Germany.
FAU - Schneider, Rita
AU  - Schneider R
AD  - University Hospital, Wurzburg, Germany.
FAU - Platonova, Tamara
AU  - Platonova T
AD  - The International Fund "Help for Patients With Radiation-Induced Thyroid Cancer
      'ARNICA"', Minsk, Belarus.
FAU - Fridman, Mikhail
AU  - Fridman M
AD  - The International Fund "Help for Patients With Radiation-Induced Thyroid Cancer
      'ARNICA"', Minsk, Belarus.
FAU - Malzahn, Uwe
AU  - Malzahn U
AD  - University Hospital, Wurzburg, Germany.
FAU - Mader, Uwe
AU  - Mader U
AD  - University Hospital, Wurzburg, Germany.
FAU - Vrachimis, Alexis
AU  - Vrachimis A
AD  - University Hospital, Munster, Germany.
FAU - Bogdanova, Tatiana
AU  - Bogdanova T
AD  - Institute of Endocrinology and Metabolism, Kiev, Ukraine.
FAU - Krajewska, Jolanta
AU  - Krajewska J
AD  - M. Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
FAU - Elisei, Rossella
AU  - Elisei R
AD  - University Hospital, Pisa, Italy.
FAU - Vaisman, Fernanda
AU  - Vaisman F
AD  - National Cancer Institute, Rio de Janeiro, Brazil.
FAU - Mihailovic, Jasna
AU  - Mihailovic J
AD  - Institute of Oncology Voijvodina, Sremska Kamenica, Serbia.
FAU - Costa, Gracinda
AU  - Costa G
AD  - University Hospital, Coimbra, Portugal.
FAU - Drozd, Valentina
AU  - Drozd V
AD  - The International Fund "Help for Patients With Radiation-Induced Thyroid Cancer
      'ARNICA"', Minsk, Belarus.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200710
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Iodine Radioisotopes)
SB  - IM
MH  - Breast Neoplasms/*chemically induced/epidemiology
MH  - Female
MH  - Humans
MH  - Iodine Radioisotopes/*adverse effects/therapeutic use
MH  - Neoplasms, Radiation-Induced/*chemically induced/epidemiology
MH  - Registries
MH  - Thyroid Neoplasms/epidemiology/*radiotherapy
MH  - Treatment Outcome
PMC - PMC7381297
OTO - NOTNLM
OT  - *breast cancer
OT  - *childhood and adolescence
OT  - *differentiated thyroid carcinoma
OT  - *iodine-131
OT  - *long-term complications
OT  - *radioiodine therapy
OT  - *second primary malignancy
OT  - *young females
EDAT- 2020/08/06 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.3389/fendo.2020.00381 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Jul 10;11:381. doi: 10.3389/fendo.2020.00381.
      eCollection 2020.


PMID- 32753983
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1179-1578 (Print)
IS  - 1179-1578 (Linking)
VI  - 13
DP  - 2020
TI  - Linking Burnout to Psychological Well-being: The Mediating Role of Social Support
      and Learning Motivation.
PG  - 545-554
LID - 10.2147/PRBM.S250961 [doi]
AB  - BACKGROUND: University academic setting consists of specific life stressors such 
      as burnout that influence a student's psychological well-being. Previous
      literature has shown the role of social support and learning motivation, but
      little research is known about how these variables, of social support and
      learning motivation, can mediate the relationship. METHODS: We recruited 486
      participants from three Chinese universities with an age range of 18-35 years.
      Measures in the study include Maslach Burnout inventory (MBI) for college
      students, Multidimensional Scale of Perceived Social Support (MSPSS), motivation 
      strategy learning scale, and psychological well-being by Ryff. Ethical approval
      was gained from the respondents. RESULTS: Findings suggest that social support
      plays a significant role in the link between burnout and subjective well-being.
      Indeed, the chain mediation model of social support and learning motivation
      significantly indicated the link between burnout and psychological well-being.
      These findings show that an increase in social support at an educational
      institute reduces the effects of burnout and enhances psychological well-being.
      CONCLUSION: The study indicates a sound interpretation of psychological
      well-being and reducing the level of burnout. Subsequent research has found that 
      social support and learning motivation could be an essential variable in
      calculating the educational success and learning motivation of the students.
CI  - (c) 2020 Rehman et al.
FAU - Rehman, Abaid Ur
AU  - Rehman AU
AD  - School of Psychology, Shaanxi Normal University, Xi'an, People's Republic of
      China.
AD  - Shaanxi Key Laboratory of Behavior and Cognitive Neuroscience, Shaanxi Normal
      University, Xi'an, People's Republic of China.
AD  - Department of Psychology, BZU Bahadur Sub Campus, Layyah, Pakistan.
FAU - Bhuttah, Tariq Mehmood
AU  - Bhuttah TM
AD  - School of Education, Shaanxi Normal University, Xi'an, People's Republic of
      China.
FAU - You, Xuqun
AU  - You X
AD  - School of Psychology, Shaanxi Normal University, Xi'an, People's Republic of
      China.
AD  - Shaanxi Key Laboratory of Behavior and Cognitive Neuroscience, Shaanxi Normal
      University, Xi'an, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - New Zealand
TA  - Psychol Res Behav Manag
JT  - Psychology research and behavior management
JID - 101514563
PMC - PMC7354910
OTO - NOTNLM
OT  - burnout
OT  - learning motivation
OT  - psychological well-being
OT  - social support
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
CRDT- 2020/08/06 06:00
PHST- 2020/02/23 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
AID - 10.2147/PRBM.S250961 [doi]
AID - 250961 [pii]
PST - epublish
SO  - Psychol Res Behav Manag. 2020 Jul 8;13:545-554. doi: 10.2147/PRBM.S250961.
      eCollection 2020.


PMID- 32753589
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210804
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Aug 4
TI  - Brain MRI features of methylmalonic acidemia in children: the relationship
      between neuropsychological scores and MRI findings.
PG  - 13099
LID - 10.1038/s41598-020-70113-y [doi]
AB  - Methylmalonic acidemia (MMA) is a severe, heterogeneous disorder of
      methylmalonate and cobalamin (cbl; vitamin B12) metabolism with a poor prognosis 
      that can cause brain damage. Identifying the magnetic resonance imaging (MRI)
      findings of MMA might help to make accurate diagnoses earlier in the disease
      course and exploring the relationship between neuropsychological scores and MRI
      findings, when therapy is more effective and to improve therapeutic efficacy.
      Cerebral MRI studies from 37 children with MMA were evaluated by a
      neuroradiologist. Clinical and imaging data were collected from each patient. All
      tests were performed during routine investigations and in accordance with the
      ethical principles of the Declaration of Helsinki. Informed consent was obtained 
      from the guardians of all patients for inclusion in the study. The most common
      and significant findings were periventricular white matter changes (78.4%),
      ventricular dilation (29.7%) and cerebral atrophy (40.5%). According to the
      developmental quotient, the 37 patients were divided into the normal intelligence
      subgroup (NI, developmental quotient >/= 85) and the low intelligence subgroup
      (LI, developmental quotient < 85). The incidence of corpus callosal thinning,
      cortical atrophy, subcortical white matter changes, and ventricular dilation
      (grades 0-3) was significantly higher in the LI subgroup than in the NI subgroup 
      (P < 0.05). The incidence of no-mild and moderate-severe ventricular dilation was
      significantly higher in the LI subgroup than in the NI subgroup (P < 0.05).
      Ventricular dilatation, cerebral atrophy, white matter changes, and corpus
      callosal thinning are the main MRI abnormalities in MMA patients, and these
      manifestations are significantly correlated with delayed development in children.
FAU - Yang, Linfeng
AU  - Yang L
AUID- ORCID: http://orcid.org/0000-0002-3228-6926
AD  - Jinan Maternal and Child Care Hospital, Jian-Guo Xiao Jing-San Road No. 2, Jinan,
      250001, Shandong, People's Republic of China.
FAU - Guo, Bin
AU  - Guo B
AUID- ORCID: http://orcid.org/0000-0002-8867-2535
AD  - Jinan Maternal and Child Care Hospital, Jian-Guo Xiao Jing-San Road No. 2, Jinan,
      250001, Shandong, People's Republic of China.
FAU - Li, Xue
AU  - Li X
AUID- ORCID: http://orcid.org/0000-0002-1961-6839
AD  - Jinan Maternal and Child Care Hospital, Jian-Guo Xiao Jing-San Road No. 2, Jinan,
      250001, Shandong, People's Republic of China.
FAU - Liu, Xiangyu
AU  - Liu X
AUID- ORCID: http://orcid.org/0000-0002-8126-7289
AD  - Jinan Maternal and Child Care Hospital, Jian-Guo Xiao Jing-San Road No. 2, Jinan,
      250001, Shandong, People's Republic of China.
FAU - Wei, Xinhong
AU  - Wei X
AUID- ORCID: http://orcid.org/0000-0003-2647-6595
AD  - Department of MRI Room, Shandong Medical Imaging Research Institute, Cheeloo
      College of Medicine, Shandong University, Jing-wu Road No. 324, Jinan, 250021,
      Shandong, People's Republic of China.
FAU - Guo, Lingfei
AU  - Guo L
AUID- ORCID: http://orcid.org/0000-0002-4885-625X
AD  - Department of MRI Room, Shandong Medical Imaging Research Institute, Cheeloo
      College of Medicine, Shandong University, Jing-wu Road No. 324, Jinan, 250021,
      Shandong, People's Republic of China. glfsci@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200804
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - Methylmalonic acidemia
SB  - IM
MH  - Amino Acid Metabolism, Inborn Errors/*diagnostic
      imaging/physiopathology/*psychology
MH  - Brain/*diagnostic imaging/*physiopathology
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - *Neuropsychological Tests
PMC - PMC7403351
EDAT- 2020/08/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/06 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-70113-y [doi]
AID - 10.1038/s41598-020-70113-y [pii]
PST - epublish
SO  - Sci Rep. 2020 Aug 4;10(1):13099. doi: 10.1038/s41598-020-70113-y.


PMID- 32753527
OWN - NLM
STAT- Publisher
LR  - 20200805
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 4
TI  - Non-directed postmortem sperm donation: some questions.
LID - medethics-2020-106263 [pii]
LID - 10.1136/medethics-2020-106263 [doi]
AB  - In their recent 'The ethical case for non-directed postmortem sperm donation',
      Hodson and Parker outline and defend the concept of voluntary non-directed
      postmortem sperm donation, the idea that men should be able to register their
      desire to donate their sperm after death for use by strangers since this would
      offer a potential means of increasing the quantity and heterogeneity of donor
      sperm. In this response, we raise some concerns about their proposal, focusing in
      particular on the fact that current methodologies do not make for a reliable way 
      of ensuring that sperm retrieved postmortem has a good chance of leading to
      conception, which is in turn likely to make potential recipients reluctant to use
      such sperm. These concerns add to the ethical doubts that attend aspects of the
      proposal, making the prospect of implementation of such a policy unlikely at
      best.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kroon, Frederick
AU  - Kroon F
AUID- ORCID: http://orcid.org/0000-0002-3785-5331
AD  - Philosophy, The University of Auckland, Auckland, New Zealand
      f.kroon@auckland.ac.nz.
FAU - Kroon, Ben
AU  - Kroon B
AD  - School of Medicine, The University of Queensland, Brisbane, Queensland,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - artificial insemination and surrogacy
COIS- Competing interests: None declared.
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:00 [medline]
AID - medethics-2020-106263 [pii]
AID - 10.1136/medethics-2020-106263 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 4. pii: medethics-2020-106263. doi:
      10.1136/medethics-2020-106263.


PMID- 32753455
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 4
TI  - Natural history of recovery after intracerebral haemorrhage: a scoping review
      protocol.
PG  - e039460
LID - 10.1136/bmjopen-2020-039460 [doi]
AB  - INTRODUCTION: Clinical trials for intracerebral haemorrhage typically measure
      outcomes in the same way and at the same time points as trials for ischaemic
      stroke. However, there is growing evidence that the trajectory of recovery
      following intracerebral haemorrhage may differ significantly from that following 
      ischaemic stroke. A better understanding of current approaches to outcome
      assessment is essential to ensure that future trials examining treatments for
      intracerebral haemorrhage are designed appropriately. OBJECTIVE: To determine
      when and how outcomes are measured in patients with intracerebral haemorrhage.
      METHODS AND ANALYSIS: With the assistance of an information specialist, we will
      conduct a scoping review by searching MEDLINE, Embase, Cochrane Central Register 
      of Controlled Trials and Web of Science for prospective studies of adults with
      primary intracerebral haemorrhage and documented outcomes with specified times.
      Two reviewers will independently collect data on included studies pertaining to
      publication data, study population information, timing of outcome and details of 
      the outcome measurement tools used. The extracted data will be used to
      demonstrate the type and timing of outcome measures. ETHICS AND DISSEMINATION:
      Primary data will not be collected therefore formal ethics is not required. The
      findings of this study will be disseminated through peer-reviewed publications
      and through presentation at academic conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Massicotte, Sara
AU  - Massicotte S
AUID- ORCID: 0000-0001-6462-3694
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada smass006@uottawa.ca.
FAU - Lun, Ronda
AU  - Lun R
AUID- ORCID: 0000-0001-8455-8201
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
FAU - Yogendrakumar, Vignan
AU  - Yogendrakumar V
AUID- ORCID: 0000-0001-8814-6853
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
FAU - Dewar, Brian
AU  - Dewar B
AUID- ORCID: 0000-0002-9222-5420
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
FAU - Davies, Alexandra
AU  - Davies A
AD  - Royal Ottawa Mental Health Center, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AUID- ORCID: 0000-0002-3389-2485
AD  - Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Shamy, Michel
AU  - Shamy M
AUID- ORCID: 0000-0002-0085-6816
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
FAU - Dowlatshahi, Dar
AU  - Dowlatshahi D
AUID- ORCID: 0000-0003-1379-3612
AD  - Department of Medicine, University of Ottawa and Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200804
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Brain Ischemia
MH  - Cerebral Hemorrhage/therapy
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Prospective Studies
MH  - Review Literature as Topic
MH  - *Stroke
PMC - PMC7406024
OTO - NOTNLM
OT  - *neurology
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039460 [pii]
AID - 10.1136/bmjopen-2020-039460 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 4;10(8):e039460. doi: 10.1136/bmjopen-2020-039460.


PMID- 32753453
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 4
TI  - Cross-sectional mixed-methods study protocol exploring the enablers and barriers 
      for people with severe and enduring mental illness in Jamaica when accessing
      healthcare for chronic physical illness.
PG  - e038245
LID - 10.1136/bmjopen-2020-038245 [doi]
AB  - INTRODUCTION: Extant international research suggests that people with severe and 
      enduring mental illness (PWSEMI) experience increased rates of chronic physical
      illness (CPI), reduced life expectancy and higher mortality than those in the
      general population. The high prevalence of CPI among PWSEMI is associated with a 
      number of barriers that this population experiences when accessing physical
      healthcare. Although substantial research has been conducted in North America,
      Europe and Australia, there appears to be a paucity of research exploring CPI
      among PWSEMI in the Caribbean region, although this region has reported very high
      rates of non-communicable diseases within its populations. The current study will
      be situated in Jamaica and will explore the enablers and barriers to PWSEMI
      accessing healthcare for CPI. METHODS AND ANALYSIS: A convergent mixed-method
      design will explore the enablers and barriers to accessing healthcare for CPI
      among PWSEMI. This cross-sectional study will collect data from PWSEMI,
      caregivers and family members, community health aides, primary care physicians,
      psychiatrists and health policymakers. ETHICS AND DISSEMINATION: The study
      findings will provide baseline data describing the prevalence of CPI among PWSEMI
      in Jamaica and will identify enablers for, and barriers to, PWSEMI accessing CPI 
      care. Findings will be disseminated widely in Jamaica and internationally to key 
      stakeholders through publications and conferences. Institutional ethical approval
      was granted from Jamaica's Ministry of Health and Wellness Medico-legal Ethics
      Review Panel (# 2019/49), the Curtin University Human Research and Ethics
      Committee (HRE 2020-0022) and the University of the West Indies FMS Ethics
      Committee (ECP 101, 19/20).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Whitehorne-Smith, Patrice
AU  - Whitehorne-Smith P
AUID- ORCID: 0000-0001-5102-0261
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia
      p.whitehor@postgrad.curtin.edu.au.
FAU - Burns, Sharyn
AU  - Burns S
AUID- ORCID: 0000-0002-1551-2805
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Milbourn, Ben
AU  - Milbourn B
AD  - School of Occupational Health, Social Work and Speech Pathology, Curtin
      University Faculty of Health Sciences, Perth, Western Australia, Australia.
FAU - Abel, Wendel
AU  - Abel W
AD  - Community Health & Psychiatry, University of the West Indies, Kingston, Kingston,
      Jamaica.
FAU - Martin, Robyn
AU  - Martin R
AD  - School of Occupational Health, Social Work and Speech Pathology, Curtin
      University Faculty of Health Sciences, Perth, Western Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200804
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Caribbean Region
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care
MH  - Europe
MH  - Humans
MH  - Jamaica/epidemiology
MH  - *Mental Disorders/epidemiology
MH  - North America
PMC - PMC7406117
OTO - NOTNLM
OT  - *Mental health
OT  - *Public health
OT  - *adult psychiatry
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/08/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038245 [pii]
AID - 10.1136/bmjopen-2020-038245 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 4;10(8):e038245. doi: 10.1136/bmjopen-2020-038245.


PMID- 32753452
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 4
TI  - FIRST-line support for assistance in breathing in children (FIRST-ABC): a master 
      protocol of two randomised trials to evaluate the non-inferiority of high-flow
      nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for
      non-invasive respiratory support in paediatric critical care.
PG  - e038002
LID - 10.1136/bmjopen-2020-038002 [doi]
AB  - INTRODUCTION: Even though respiratory support is a common intervention in
      paediatric critical care, there is no randomised controlled trial (RCT) evidence 
      regarding the effectiveness of two commonly used modes of non-invasive
      respiratory support (NRS), continuous positive airway pressure (CPAP) and
      high-flow nasal cannula therapy (HFNC). FIRST-line support for assistance in
      breathing in children is a master protocol of two pragmatic non-inferiority RCTs 
      to evaluate the clinical and cost-effectiveness of HFNC (compared with CPAP) as
      the first-line mode of support in critically ill children. METHODS AND ANALYSIS: 
      We will recruit participants over a 30-month period at 25 UK paediatric critical 
      care units (paediatric intensive care units/high-dependency units). Patients are 
      eligible if admitted/accepted for admission, aged >36 weeks corrected gestational
      age and <16 years, and assessed by the treating clinician to require NRS for an
      acute illness (step-up RCT) or within 72 hours of extubation following a period
      of invasive ventilation (step-down RCT). Due to the emergency nature of the
      treatment, written informed consent will be deferred to after randomisation.
      Randomisation will occur 1:1 to CPAP or HFNC, stratified by site and age (<12 vs 
      >/=12 months). The primary outcome is time to liberation from respiratory support
      for a continuous period of 48 hours. A total sample size of 600 patients in each 
      RCT will provide 90% power with a type I error rate of 2.5% (one sided) to
      exclude the prespecified non-inferiority margin of HR of 0.75. Primary analyses
      will be undertaken separately in each RCT in both the intention-to-treat and
      per-protocol populations. ETHICS AND DISSEMINATION: This master protocol received
      favourable ethical opinion from National Health Service East of England-Cambridge
      South Research Ethics Committee (reference: 19/EE/0185) and approval from the
      Health Research Authority (reference: 260536). Results will be disseminated via
      publications in peer-reviewed medical journals and presentations at national and 
      international conferences. TRIAL REGISTRATION NUMBER: ISRCTN60048867.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Richards-Belle, Alvin
AU  - Richards-Belle A
AUID- ORCID: 0000-0001-8577-9380
AD  - Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, 
      UK.
FAU - Davis, Peter
AU  - Davis P
AD  - Paediatric Intensive Care, Bristol Royal Hospital for Children, Bristol, UK.
FAU - Drikite, Laura
AU  - Drikite L
AD  - Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, 
      UK.
FAU - Feltbower, Richard
AU  - Feltbower R
AD  - Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
FAU - Grieve, Richard
AU  - Grieve R
AD  - Department of Health Services Research and Policy, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Harrison, David A
AU  - Harrison DA
AD  - Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, 
      UK.
FAU - Lester, Julie
AU  - Lester J
AD  - Parent representative, Sussex, UK.
FAU - Morris, Kevin P
AU  - Morris KP
AD  - Paediatric Intensive Care Unit, Birmingham Women's and Children's Hospitals NHS
      Foundation Trust, Birmingham, UK.
FAU - Mouncey, Paul R
AU  - Mouncey PR
AD  - Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, 
      UK.
FAU - Peters, Mark J
AU  - Peters MJ
AD  - Paediatric Intensive Care Unit, Great Ormond Street Hospital For Children NHS
      Trust, London, UK.
AD  - UCL Great Ormond Street Institute of Child Health, University College London,
      London, UK.
FAU - Rowan, Kathryn M
AU  - Rowan KM
AD  - Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, 
      UK.
FAU - Sadique, Zia
AU  - Sadique Z
AD  - Department of Health Services Research and Policy, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Tume, Lyvonne N
AU  - Tume LN
AD  - School of Health and Society, University of Salford, Salford, Greater Manchester,
      UK.
FAU - Ramnarayan, Padmanabhan
AU  - Ramnarayan P
AUID- ORCID: 0000-0003-0784-8154
AD  - Children's Acute Transport Service, Great Ormond Street Hospital For Children NHS
      Trust, London, UK p.ramnarayan@gosh.nhs.uk.
LA  - eng
SI  - ISRCTN/ISRCTN60048867
GR  - 17/94/28/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200804
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Cannula
MH  - Child
MH  - *Continuous Positive Airway Pressure
MH  - Critical Care
MH  - England
MH  - Humans
MH  - Infant
MH  - Oxygen Inhalation Therapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7406113
OTO - NOTNLM
OT  - *clinical trials
OT  - *paediatric intensive & critical care
OT  - *statistics & research methods
EDAT- 2020/08/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038002 [pii]
AID - 10.1136/bmjopen-2020-038002 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 4;10(8):e038002. doi: 10.1136/bmjopen-2020-038002.


PMID- 32753448
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 4
TI  - Meniscal Tear Outcome (METRO) review: a protocol for a systematic review
      summarising the clinical course and patient experiences of meniscal tears in the 
      current literature.
PG  - e036247
LID - 10.1136/bmjopen-2019-036247 [doi]
AB  - INTRODUCTION: Meniscal tears are a common knee injury with an incidence of 60 per
      100 000. Management of meniscal tears can include either non-operative measures
      or operative procedures such as arthroscopic partial meniscectomy (APM). Despite 
      substantial research evaluating the effectiveness of APM in the recent past,
      little is known about the clinical course or the experiences of patients with a
      meniscal tear. AIM: To summarise the short to long-term patterns of variability
      in outcome in patients with a meniscal tear.To summarise the evidence on patient 
      experiences of meniscal tears. In particular, we will focus on patient
      experiences of treatment options, treatment pathways and their views of the
      outcomes used in meniscal tear research. METHODS AND ANALYSIS: Two search
      strategies will be developed to identify citations from EMBASE, MEDLINE, AMED,
      CENTRAL, Web of Science and Sociofile. The date of our planned search is 14
      August 2020. For the quantitative review we will identify studies reporting
      patient-reported outcome measures in patients after a meniscal tear. The
      standardised mean change will be used to assess the variation in size of response
      and summarise the overall response to each treatment option. All studies will
      undergo quality assessment using either the Cochrane risk of bias or the
      Newcastle-Ottawa tool.A qualitative systematic review will be used to identify
      studies reporting views and experiences of patients with a meniscal tear. All
      studies will be assessed using the Critical Appraisal Skills Programme tool and
      if sufficient data are present a meta-synthesis will be performed to identify
      first, second and third-order constructs. ETHICS AND DISSEMINATION: Given the
      nature of this study, no formal ethical approval will be sought. Results from the
      review will be disseminated at national conferences and will be submitted to a
      peer-reviewed journal for publication. Lay summaries will be freely available via
      the study Twitter page. PROSPERO REGISTRATION NUMBER: CRD42019122179.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ahmed, Imran
AU  - Ahmed I
AUID- ORCID: 0000-0003-2774-9954
AD  - Clinical Trials Unit, University of Warwick, Coventry, UK imran.ahmed4@nhs.net.
FAU - Khatri, Chetan
AU  - Khatri C
AD  - Trauma and Orthopaedics, --University Hospital Coventry and Warwickshire,
      Coventry, West Midlands, UK.
FAU - Parsons, Nicholas
AU  - Parsons N
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Hutchinson, Charles E
AU  - Hutchinson CE
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Staniszewska, Sophie
AU  - Staniszewska S
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Price, Andrew James
AU  - Price AJ
AUID- ORCID: 0000-0002-4258-5866
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Metcalfe, Andrew
AU  - Metcalfe A
AUID- ORCID: 0000-0002-4515-8202
AD  - Clinical Trials Unit, University of Warwick, Coventry, UK.
LA  - eng
GR  - DRF-2018-11-ST2-030/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200804
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arthroscopy
MH  - Humans
MH  - *Knee Injuries/surgery
MH  - Meniscectomy
MH  - Patient Reported Outcome Measures
MH  - *Tibial Meniscus Injuries/surgery
PMC - PMC7406020
OTO - NOTNLM
OT  - *knee
OT  - *musculoskeletal disorders
OT  - *orthopaedic & trauma surgery
COIS- Competing interests: None declared.
EDAT- 2020/08/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036247 [pii]
AID - 10.1136/bmjopen-2019-036247 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 4;10(8):e036247. doi: 10.1136/bmjopen-2019-036247.


PMID- 32753147
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 95
IP  - 8
DP  - 2020 Aug
TI  - Disorders of Consciousness and Disability Law.
PG  - 1732-1739
LID - S0025-6196(20)30156-7 [pii]
LID - 10.1016/j.mayocp.2020.02.008 [doi]
AB  - In 2018, the American Academy of Neurology, the American Congress of
      Rehabilitation Medicine, and the National Institute on Disability, Independent
      Living, and Rehabilitation Research published a systematic evidence-based review 
      and an associated practice guideline for improved assessment, treatment, and
      rehabilitation of patients with disorders of consciousness. Patients with
      disorders of consciousness include individuals in the vegetative and minimally
      conscious states, as well as others with covert consciousness and cognitive motor
      dissociation. These landmark publications (concurrently published in Neurology
      and Archives of Physical Medicine and Rehabilitation) supplant the 1994 New
      England Journal of Medicine Multi-Society Task Force report on the vegetative
      state and the 2002 criteria establishing minimally conscious states. The
      guideline re-designates the permanent vegetative state as chronic. In our
      article, we consider the legal and ethical implications of the practice guideline
      for clinical practice and explain the vulnerability of these patients who suffer 
      from high rates of misdiagnosis, inadequate medical surveillance, undertreatment 
      of pain, inadequate rehabilitation, and segregation in chronic care. We argue
      that these deficiencies in medical care are inconsistent with our growing
      appreciation of the dynamic nature of these brain states and an emerging standard
      of care as articulated by the national guideline. These deficiencies also violate
      domestic and international disability law. To substantiate this latter claim, we 
      apply disability law to this population, focusing on key Americans with
      Disabilities Act mandates, the relevance of the 1999 Supreme Court, Olmstead v.
      L.C., and the utility of Olmstead enforcement actions to integrate the care of
      these individuals into the medical mainstream.
CI  - Copyright (c) 2020 Mayo Foundation for Medical Education and Research. Published 
      by Elsevier Inc. All rights reserved.
FAU - Fins, Joseph J
AU  - Fins JJ
AD  - Division of Medical Ethics, Weill Medical College of Cornell University; The
      Consortium for the Advanced Study of Brain Injury, Weill Cornell Medical College 
      and The Rockefeller University, New York NY; and Yale Law School, New Haven, CT. 
      Electronic address: jjfins@med.cornell.edu.
FAU - Wright, Megan S
AU  - Wright MS
AD  - Penn State Law, Pennsylvania State University, University Park, PA.
FAU - Bagenstos, Samuel R
AU  - Bagenstos SR
AD  - University of Michigan School of Law, Ann Arbor, MI.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
SB  - IM
MH  - Consciousness Disorders/*diagnosis/therapy
MH  - Consensus
MH  - Diagnostic Errors/legislation & jurisprudence
MH  - Disability Evaluation
MH  - Disabled Persons/*legislation & jurisprudence
MH  - Humans
MH  - Patient Rights/legislation & jurisprudence
MH  - Persistent Vegetative State/diagnosis
MH  - Practice Guidelines as Topic
MH  - Societies, Medical/standards
MH  - United States
EDAT- 2020/08/06 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/08/06 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/01/21 00:00 [revised]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - S0025-6196(20)30156-7 [pii]
AID - 10.1016/j.mayocp.2020.02.008 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2020 Aug;95(8):1732-1739. doi: 10.1016/j.mayocp.2020.02.008.


PMID- 32753095
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20200915
IS  - 1089-6287 (Print)
IS  - 1089-6287 (Linking)
VI  - 68
IP  - 1
DP  - 2020 Spring/Summer
TI  - James Meyrick Croker: A Model for Professional Behavior.
PG  - 12-28
LID - S0007-5132.2020.68.1.12 [pii]
AB  - The rationale that underpins volunteering has long fascinated behavioral
      scientists. James Meyrick Croker's personal life, professional career and
      community engagement conform to the classic twentieth century model for
      professional behavior. Accordingly, the authors use historical methods of
      investigation to evaluate the influences on and the legacies from a remarkable
      contribution to the professions and the community. The narrative demonstrates
      elements of altruism, collaboration, conviction, compassion, drive,
      entrepreneurialism, familial and grammar school influence, leadership, pragmatism
      and vision. Croker's professional and community service was multi-organizational.
      Concurrent demands on his time warranted discipline, energy and expertise. For
      the behavioral scientist, achievement, affiliation, nature and nurture appear
      relevant to the outcome. Available archives provide no evidence of ego-driven
      motivation. Leadership style was transformational not transactional. Major
      legacies to the national and state Australian Dental Associations are ADAQ
      Christensen House (1972-1980), the eventual financial stability for the
      Australian Dental Association Queensland Branch, formal dental assistant
      training, policies of the Australian and Queensland Councils of Professions, a
      notable Goddard Oration and the successful 24th Australian Dental Congress.
CI  - Copyright 2020 (c) American Academy of the History of Dentistry.
FAU - Akers, H F
AU  - Akers HF
AD  - Bowen Hills, Brisbane.
FAU - Foley, M A
AU  - Foley MA
AD  - Research and Advocacy Metro North Oral Health Services, Herston, Brisbane School 
      of Dentistry, University of Adelaide, Adelaide Bowen Hills, Brisbane.
FAU - Smith, R G
AU  - Smith RG
AD  - Bowen Hills, Brisbane.
FAU - Rusten, L M
AU  - Rusten LM
AD  - ADAQ Bowen Hills, Brisbane.
FAU - Olive, R J
AU  - Olive RJ
AD  - Adjunct Professor School of Dentistry University of Queensland, Herston, Brisbane
      Bowen Hills, Brisbane.
FAU - McCray, Rwa
AU  - McCray R
AD  - Bowen Hills, Brisbane.
FAU - El-Atem, K R
AU  - El-Atem KR
AD  - Bowen Hills, Brisbane.
FAU - Brown, J P
AU  - Brown JP
AD  - Professor Emeritus University of Texas Health Science Center, San Antonio.
FAU - Woodford, V
AU  - Woodford V
AD  - Metro North Oral Health Services, Herston, Brisbane.
FAU - Boi, A
AU  - Boi A
AD  - Archivist Bowen Hills, Brisbane.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Hist Dent
JT  - Journal of the history of dentistry
JID - 9609747
MH  - *Altruism
MH  - Australia
MH  - Dentistry
MH  - History of Dentistry
MH  - History, 20th Century
MH  - Humans
MH  - *Leadership
MH  - Queensland
MH  - Volunteers
PS  - Croker JM
FPS - Croker, James Meyrick
OTO - NOTNLM
OT  - Ethics
OT  - Family Relationships
OT  - Professional Practice
OT  - Professional Responsibilities
OT  - Professionalism
OT  - Queensland
EDAT- 2020/08/06 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - S0007-5132.2020.68.1.12 [pii]
PST - ppublish
SO  - J Hist Dent. 2020 Spring/Summer;68(1):12-28.


PMID- 32753041
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 4
TI  - Ophthalmological outcomes of unilateral coronal synostosis in young children.
PG  - 318
LID - 10.1186/s12886-020-01547-1 [doi]
AB  - BACKGROUND: To report refractive outcomes, describe types of strabismus and
      evaluate the outcomes of surgical intervention for unilateral coronal synostosis 
      (UCS) in paediatric patients. METHODS: This study retrospectively included 30 UCS
      cases. Patients aged from 3 months to 6 years (median: 1.8 years) were enrolled
      from January 2018 to December 2019 at Shanghai Children's Hospital. Sixteen
      patients had all types of strabismus; 15 of these patients underwent surgery.
      RESULTS: Refractive errors of 30 cases were included. In 60% of patients,
      astigmatism of 1.00D or more existed in not less than one eye at last record.
      Twenty (66.7%) patients had the larger amount of astigmatism in the contralateral
      eye. Fifteen patients received strabismus surgery, of whom 6 patients with
      monocular elevation deficiency (MED) underwent the standard Knapp procedure, with
      or without a horizontal deviation procedure. Fifteen cases were horizontally
      aligned within 5 prism dioptres (Delta). Six patients with MED (100%) had
      attained >/=25% elevation improvement after surgery, and the vertical deviation
      decreased from 25.83 Delta +/- 4.92 Delta (range, 20 Delta-30 Delta) to 0.83
      Delta +/- 4.92 Delta after surgery (range, 0 Delta-10 Delta), for an improvement 
      of 26.67 Delta +/- 4.08 Delta (t = 16 P < 0.05). In 1 patient with esotropia, the
      horizontal deviation decreased from + 80 Delta to + 5 Delta after surgery. One
      patient was diagnosed with trichiasis and one with contralateral lacrimal duct
      obstruction. CONCLUSIONS: Contralateral MED was also the main type of strabismus 
      in UCS. Superior oblique muscle palsy was still the most common, as previously
      reported. There is a risk of developing a higher astigmatism and anisometropia in
      the contralateral eye to synostosis. Other ophthalmic disorders should be treated
      in a timely manner. TRIAL REGISTRATION: The study was approved by the
      Institutional Review Board of Shanghai Children's Hospital (approval No.
      2020R023-E01) and adhered to the tenets of the Declaration of Helsinki. Ethics
      approval was procured on March 30, 2020. This was a retrospective study. Written 
      informed consent was sought from the patients' parents or legal guardians.
      Clinical Trials Registry number: ChiCTR2000034910 . Registration URL:
      http://www.chictr.org.cn/showproj.aspx?proj=56726 .
FAU - Luo, Wen-Ting
AU  - Luo WT
AD  - Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062,
      China.
FAU - Chen, Xin
AU  - Chen X
AD  - Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062,
      China.
FAU - Zhang, Yi-Dan
AU  - Zhang YD
AD  - Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062,
      China.
FAU - Liu, Qing-Yu
AU  - Liu QY
AD  - Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062,
      China.
FAU - Qiao, Tong
AU  - Qiao T
AUID- ORCID: http://orcid.org/0000-0002-3244-4541
AD  - Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, 200062,
      China. Qiaojoel@163.com.
LA  - eng
PT  - Journal Article
DEP - 20200804
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - China/epidemiology
MH  - *Craniosynostoses/surgery
MH  - Humans
MH  - Oculomotor Muscles
MH  - Ophthalmologic Surgical Procedures
MH  - Retrospective Studies
MH  - *Strabismus/surgery
PMC - PMC7405462
OTO - NOTNLM
OT  - Forced duction test
OT  - Monocular elevator deficiency
OT  - Standard Knapp procedure
OT  - Superior oblique muscle palsy
OT  - Unilateral coronal synostosis
EDAT- 2020/08/06 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/06 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12886-020-01547-1 [doi]
AID - 10.1186/s12886-020-01547-1 [pii]
PST - epublish
SO  - BMC Ophthalmol. 2020 Aug 4;20(1):318. doi: 10.1186/s12886-020-01547-1.


PMID- 32752235
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 1
TI  - Assessment of Hospital Rooming-in Practice in Abu Dhabi, United Arab Emirates: A 
      Cross-Sectional Multi-Center Study.
LID - E2318 [pii]
LID - 10.3390/nu12082318 [doi]
AB  - The World Health Organization (WHO) recommends rooming-in to reduce infant
      mortality rates. Little research has been done to assess practices such as
      rooming-in and its relation to breastfeeding in the United Arab Emirates (UAE).
      The aim of this study was to examine the prevalence of rooming-in during hospital
      stay among mothers with infants six months old and below, in addition to other
      associated factors in Abu Dhabi, UAE. This study utilized a sub-sample extracted 
      from a dataset based on a convenience sample of mothers who were recruited from
      governmental maternal and child health centers as well as from the community. The
      purpose of the original research was to evaluate infant and young children's
      feeding practices. A pre-tested questionnaire was used during interviews with
      mothers once ethical clearance was in place. Multivariable logistic regression
      was conducted to describe the results. The original sample included 1822
      participants, of which 804 infants met the inclusion criteria. The mean age for
      mothers and infants was 30.3 years and 3.5 months, respectively. The rate of
      rooming-in during hospital stay was 97.5%. Multivariable logistic regression
      analysis indicated factors associated with not rooming-in were low maternal age
      (Adjusted Odds Ratios (AOR) = 1.15, 95% confidence interval (CI): 1.03, 1.30),
      low gestational age (GA) (AOR = 1.90, 95% CI: 1.52, 2.36), abnormal pre-pregnancy
      body mass index (BMI) (AOR = 3.77, 95 % CI: 1.22, 11.76), and delayed initiation 
      of breastfeeding (AOR = 4.47, 95 % CI: 1.08, 18.48). In the context of the high
      rate of rooming-in revealed in this study, there should be a focus on those
      groups who do not room-in (i.e., younger women and those with babies of a younger
      gestational age). Rooming-in practice provides self-confidence in taking care of 
      a baby, knowledge about breastfeeding, and stimulates early-phase lactation.
FAU - Taha, Zainab
AU  - Taha Z
AUID- ORCID: 0000-0002-3915-3755
AD  - Department of Health Sciences, College of Natural and Health Sciences, Zayed
      University, Abu Dhabi P.O. Box 144534, UAE.
FAU - Ali Hassan, Ahmed
AU  - Ali Hassan A
AD  - Taami for Agricultural and Animal Production, Khartoum, Sudan.
FAU - Wikkeling-Scott, Ludmilla
AU  - Wikkeling-Scott L
AUID- ORCID: 0000-0001-9350-1186
AD  - Department of Health Sciences, College of Natural and Health Sciences, Zayed
      University, Abu Dhabi P.O. Box 144534, UAE.
FAU - Eltoum, Ruba
AU  - Eltoum R
AD  - Faculty of Medicine, Charles University, 500 03 Hradec Kralove, Czech Republic.
FAU - Papandreou, Dimitrios
AU  - Papandreou D
AUID- ORCID: 0000-0002-4923-484X
AD  - Department of Health Sciences, College of Natural and Health Sciences, Zayed
      University, Abu Dhabi P.O. Box 144534, UAE.
LA  - eng
GR  - R17042/Zayed University
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200801
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
MH  - Adult
MH  - Body Mass Index
MH  - Breast Feeding/*statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Feeding Behavior
MH  - Female
MH  - Gestational Age
MH  - Hospitals
MH  - Humans
MH  - Infant
MH  - Logistic Models
MH  - Maternal Age
MH  - Mothers
MH  - Pregnancy
MH  - Rooming-in Care/*standards
MH  - Surveys and Questionnaires
MH  - United Arab Emirates
MH  - World Health Organization
PMC - PMC7468932
OTO - NOTNLM
OT  - United Arab Emirates
OT  - body mass index
OT  - gestational age
OT  - initiation of breastfeeding
OT  - rooming-in
EDAT- 2020/08/06 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/06/16 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - nu12082318 [pii]
AID - 10.3390/nu12082318 [doi]
PST - epublish
SO  - Nutrients. 2020 Aug 1;12(8). pii: nu12082318. doi: 10.3390/nu12082318.


PMID- 32751904
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 15
DP  - 2020 Jul 31
TI  - Heroes or Villains? The Dark Side of Charismatic Leadership and Unethical
      Pro-organizational Behavior.
LID - E5546 [pii]
LID - 10.3390/ijerph17155546 [doi]
AB  - Although prior research has emphasized the disproportional contributions to
      organizations of charismatic leadership, an emerging line of research has started
      to examine the potentially negative consequences. In this paper, a theoretical
      framework was proposed for a study of unethical pro-organization behavior through
      psychological safety based on social information processing theory, which reveals
      the detrimental effect that charismatic leadership can have on workplace
      behavior. To explore this negative possibility, a time-lagged research design was
      applied for the hypotheses to be verified using 214 pieces of data collected from
      a service company in China. According to the results, unethical
      pro-organizational behavior was indirectly influenced by charismatic leadership
      through psychological safety. Moreover, when employees experienced high
      performance pressure, charismatic leadership was positively associated with
      unethical pro-organizational behavior through psychological safety. The
      implications of these findings were analyzed from the perspectives of charismatic
      leadership theory and organizational ethical activities to alter the unethical
      pro-organizational behavior.
FAU - Zhang, Xue
AU  - Zhang X
AD  - Harbin Institute of Technology, School of Management, Harbin 150001, China.
FAU - Liang, Liang
AU  - Liang L
AUID- ORCID: 0000-0003-1099-0055
AD  - Harbin Institute of Technology, School of Management, Harbin 150001, China.
FAU - Tian, Guyang
AU  - Tian G
AD  - Harbin Institute of Technology, School of Management, Harbin 150001, China.
FAU - Tian, Yezhuang
AU  - Tian Y
AD  - Harbin Institute of Technology, School of Management, Harbin 150001, China.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - China
MH  - *Ethics, Professional
MH  - Female
MH  - Humans
MH  - *Leadership
MH  - Male
MH  - Middle Aged
MH  - *Organizational Culture
MH  - Social Behavior
MH  - Workplace
MH  - Young Adult
PMC - PMC7432417
OTO - NOTNLM
OT  - *charismatic leadership
OT  - *performance pressure
OT  - *psychological safety
OT  - *unethical pro-organizational behavior
EDAT- 2020/08/06 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/05/25 00:00 [received]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/07/28 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - ijerph17155546 [pii]
AID - 10.3390/ijerph17155546 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jul 31;17(15). pii: ijerph17155546. doi:
      10.3390/ijerph17155546.


PMID- 32751747
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20211204
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 15
DP  - 2020 Jul 30
TI  - Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including
      Muscular Dystrophies.
LID - E5467 [pii]
LID - 10.3390/ijms21155467 [doi]
AB  - Induced pluripotent stem (iPS) cells are laboratory-produced cells that combine
      the biological advantages of somatic adult and stem cells for cell-based therapy.
      The reprogramming of cells, such as fibroblasts, to an embryonic stem cell-like
      state is done by the ectopic expression of transcription factors responsible for 
      generating embryonic stem cell properties. These primary factors are
      octamer-binding transcription factor 4 (Oct3/4), sex-determining region Y-box 2
      (Sox2), Kruppel-like factor 4 (Klf4), and the proto-oncogene protein homolog of
      avian myelocytomatosis (c-Myc). The somatic cells can be easily obtained from the
      patient who will be subjected to cellular therapy and be reprogrammed to acquire 
      the necessary high plasticity of embryonic stem cells. These cells have no
      ethical limitations involved, as in the case of embryonic stem cells, and display
      minimal immunological rejection risks after transplant. Currently, several
      clinical trials are in progress, most of them in phase I or II. Still, some
      inherent risks, such as chromosomal instability, insertional tumors, and teratoma
      formation, must be overcome to reach full clinical translation. However, with the
      clinical trials and extensive basic research studying the biology of these cells,
      a promising future for human cell-based therapies using iPS cells seems to be
      increasingly clear and close.
FAU - Gois Beghini, Daniela
AU  - Gois Beghini D
AD  - Laboratorio de Inovacoes em Terapias, Ensino e Bioprodutos, 2- Laboratorio de
      Comunicacao Celular, both at the Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz,
      Rio de Janeiro RJ 21040-900, Brazil.
FAU - Iwao Horita, Samuel
AU  - Iwao Horita S
AD  - Laboratorio de Inovacoes em Terapias, Ensino e Bioprodutos, 2- Laboratorio de
      Comunicacao Celular, both at the Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz,
      Rio de Janeiro RJ 21040-900, Brazil.
FAU - Cascabulho, Cynthia Machado
AU  - Cascabulho CM
AD  - Laboratorio de Inovacoes em Terapias, Ensino e Bioprodutos, 2- Laboratorio de
      Comunicacao Celular, both at the Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz,
      Rio de Janeiro RJ 21040-900, Brazil.
FAU - Anastacio Alves, Luiz
AU  - Anastacio Alves L
AD  - Laboratorio de Inovacoes em Terapias, Ensino e Bioprodutos, 2- Laboratorio de
      Comunicacao Celular, both at the Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz,
      Rio de Janeiro RJ 21040-900, Brazil.
FAU - Henriques-Pons, Andrea
AU  - Henriques-Pons A
AUID- ORCID: 0000-0001-9136-240X
AD  - Laboratorio de Inovacoes em Terapias, Ensino e Bioprodutos, 2- Laboratorio de
      Comunicacao Celular, both at the Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz,
      Rio de Janeiro RJ 21040-900, Brazil.
LA  - eng
GR  - 407711/2012-0 and 421803/2017-7/Conselho Nacional de Desenvolvimento Cientifico e
      Tecnologico
GR  - NA/Instituto Oswaldo Cruz
PT  - Journal Article
PT  - Review
DEP - 20200730
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (KLF4 protein, human)
RN  - 0 (Kruppel-Like Factor 4)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (MAS1 protein, human)
RN  - 0 (MYC protein, human)
RN  - 0 (Organic Cation Transport Proteins)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (SOX2 protein, human)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 0 (solute carrier family 22 (organic cation transporter), member 3)
SB  - IM
MH  - Cellular Reprogramming/*genetics
MH  - Gene Expression Regulation, Developmental/genetics
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology/*transplantation
MH  - Kruppel-Like Factor 4
MH  - Kruppel-Like Transcription Factors/genetics
MH  - Muscular Dystrophies/genetics/pathology/*therapy
MH  - Organic Cation Transport Proteins/genetics
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - SOXB1 Transcription Factors/genetics
PMC - PMC7432218
OTO - NOTNLM
OT  - cellular therapy
OT  - induced pluripotent stem cells
OT  - muscular dystrophy
OT  - regeneration
OT  - stem cells
EDAT- 2020/08/06 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/08/06 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - ijms21155467 [pii]
AID - 10.3390/ijms21155467 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Jul 30;21(15). pii: ijms21155467. doi: 10.3390/ijms21155467.


PMID- 32751550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Jul 30
TI  - A School Nurse Competency Framework for Continuing Education.
LID - E246 [pii]
LID - 10.3390/healthcare8030246 [doi]
AB  - BACKGROUND: This study develops a school nurse competency framework for
      continuing education based on focus group interviews and a literature review.
      METHODS: This study uses a qualitative content analysis with 12 school nurses.
      Six school nurses verify the content validity for the competency framework for
      continuing education using the content validity index. RESULTS: School nurse
      competencies are defined as the knowledge, skills, and attitudes required of
      school nurses to provide safe school nursing. Six core competencies are
      identified. These include the ability to (1) provide patient-centered care; (2)
      communicate and collaborate with students, teaching staff, and community
      resources; (3) think critically for evidence-based practice; (4) implement school
      health services and programs; (5) integrate legal and ethical nursing practice,
      and (6) conduct health education. CONCLUSION: It is necessary to develop and
      implement continuing education programs for school nurses based on the training
      needs and competency indicators identified in this study.
FAU - Shin, Eun Mi
AU  - Shin EM
AD  - Hwagok Health Management High School, Seoul 07638, Korea.
FAU - Roh, Young Sook
AU  - Roh YS
AUID- ORCID: 0000-0003-0312-321X
AD  - Red Cross College of Nursing, Chung-Ang University, 84 Heukseok-ro Dongjak-gu,
      Seoul 06974, Korea.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7551344
OTO - NOTNLM
OT  - competency
OT  - continuing education
OT  - focus group interview
OT  - school nurse
EDAT- 2020/08/06 06:00
MHDA- 2020/08/06 06:01
CRDT- 2020/08/06 06:00
PHST- 2020/07/10 00:00 [received]
PHST- 2020/07/28 00:00 [revised]
PHST- 2020/07/29 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2020/08/06 06:01 [medline]
AID - healthcare8030246 [pii]
AID - 10.3390/healthcare8030246 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Jul 30;8(3). pii: healthcare8030246. doi:
      10.3390/healthcare8030246.


PMID- 32750693
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1661-7819 (Electronic)
IS  - 1661-7800 (Linking)
VI  - 117
IP  - 5
DP  - 2020
TI  - Moral Distress and Considering Leaving in NICU Nurses: Direct Effects and
      Indirect Effects Mediated by Burnout and the Hospital Ethical Climate.
PG  - 646-649
LID - 10.1159/000509311 [doi]
AB  - BACKGROUND: Moral distress in neonatal intensive care unit (NICU) nurses predicts
      burnout, the hospital ethical climate, and considering leaving the position.
      However, the direct effect of moral distress on considering leaving and the
      indirect effects mediated by burnout and the hospital ethical climate remain
      unexamined in these nurses. OBJECTIVES: The aim of this study was to examine the 
      direct effect of moral distress on considering leaving and the indirect effects
      mediated by burnout and the hospital ethical climate in NICU nurses. METHODS:
      This is an observational, multicentre, self-report questionnaire study of NICU
      nurses currently providing direct newborn care on 6 Level 3-4 NICUs in New South 
      Wales, Australia. RESULTS: Of the estimated 585 eligible nurses, 136 (23%)
      participated in the study. Twenty-one percent of the nurses were considering
      leaving. After controlling for the other predictor variables, moral distress did 
      not predict considering leaving (p = 0.651). Burnout (odds ratio [OR] 4.25, p <
      0.001) and the hospital ethical climate (OR = 0.29, p = 0.020) were significant
      predictors of considering leaving. The direct effect of moral distress on
      considering leaving was not significant, but the indirect effects mediated by
      burnout (B = 0.32, 95% confidence interval [CI] [0.147-0.611]) and the hospital
      ethical climate (B = 0.19, 95% CI [0.085-0.382]) were significant. CONCLUSIONS:
      The support of NICU nurses considering leaving should include preventing and
      resolving moral distress, managing burnout, and enriching the ethical climate of 
      the hospital. This support may reduce psychological distress in NICU nurses and
      maintain or enhance the standard of care for sick newborns.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Barr, Peter
AU  - Barr P
AD  - Department of Neonatology, The Children's Hospital at Westmead, Sydney, New South
      Wales, Australia, peterbarr@bigpond.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200804
PL  - Switzerland
TA  - Neonatology
JT  - Neonatology
JID - 101286577
SB  - IM
MH  - Attitude of Health Personnel
MH  - Australia
MH  - *Burnout, Professional
MH  - Hospitals
MH  - Humans
MH  - Infant, Newborn
MH  - *Intensive Care Units, Neonatal
MH  - *Morals
MH  - *Nurses
MH  - Stress, Psychological
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Burnout
OT  - *Ethical climate
OT  - *Moral distress
OT  - *Nurses
OT  - *Work satisfaction
EDAT- 2020/08/05 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - 000509311 [pii]
AID - 10.1159/000509311 [doi]
PST - ppublish
SO  - Neonatology. 2020;117(5):646-649. doi: 10.1159/000509311. Epub 2020 Aug 4.


PMID- 32750673
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1878-0180 (Electronic)
IS  - 1878-0180 (Linking)
VI  - 111
DP  - 2020 Nov
TI  - Prediction of subdural haematoma based on a detailed numerical model of the
      cerebral bridging veins.
PG  - 103976
LID - S1751-6161(20)30528-2 [pii]
LID - 10.1016/j.jmbbm.2020.103976 [doi]
AB  - Traumatic brain injury is one of the major causes of death and disability in the 
      world. One of the most frequent and deadly injury resulted from a head trauma is 
      acute subdural haematoma (ASDH), which consists on the rupture of a bridging vein
      (BV). Given the importance of this type of injury, it is necessary to correctly
      assess thresholds and damage criteria, which is difficult to perform on human
      cadavers or animals, due to ethical and economical issues. Finite element (FE)
      models are a very good and cost-effective alternative. Once properly validated, a
      finite element head model (FEHM) becomes a valuable tool, that can be used in the
      development of head protective gear as a design tool and in the reconstruction of
      head traumas by predicting brain injuries under impact conditions. The YEt
      Another Head Model (YEAHM) is one example of a FE model that can be used to
      assist/replace the experimental tests. In this study, the bridging veins model
      from YEAHM was improved and validated by comparing its results with others
      reported in literature and estimating the success rate. At the end, it was
      developed a pressurised tubular shaped FE model of BVs, considering the blood
      pressure in cerebral veins. Results showed a maximum success rate of 90%, which
      in comparison with other FE models available in the literature, presents an equal
      or even better ASDH prediction success rate.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Costa, Jose M C
AU  - Costa JMC
AD  - Centre for Mechanical Technology and Automation, Mechanical Engineering
      Department, University of Aveiro, 3810-193, Aveiro, Portugal.
FAU - Fernandes, Fabio A O
AU  - Fernandes FAO
AD  - Centre for Mechanical Technology and Automation, Mechanical Engineering
      Department, University of Aveiro, 3810-193, Aveiro, Portugal. Electronic address:
      fabiofernandes@ua.pt.
FAU - Alves de Sousa, Ricardo J
AU  - Alves de Sousa RJ
AD  - Centre for Mechanical Technology and Automation, Mechanical Engineering
      Department, University of Aveiro, 3810-193, Aveiro, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - Netherlands
TA  - J Mech Behav Biomed Mater
JT  - Journal of the mechanical behavior of biomedical materials
JID - 101322406
SB  - IM
MH  - Animals
MH  - Biomechanical Phenomena
MH  - *Cerebral Veins
MH  - Head
MH  - Hematoma, Subdural
MH  - *Hematoma, Subdural, Acute
MH  - Humans
OTO - NOTNLM
OT  - *Brain injury
OT  - *Finite element model
OT  - *Tubular structure
OT  - *subdural Haematoma bridging veins
EDAT- 2020/08/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/05 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/04 00:00 [accepted]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - S1751-6161(20)30528-2 [pii]
AID - 10.1016/j.jmbbm.2020.103976 [doi]
PST - ppublish
SO  - J Mech Behav Biomed Mater. 2020 Nov;111:103976. doi: 10.1016/j.jmbbm.2020.103976.
      Epub 2020 Jul 28.


PMID- 32750549
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1878-1454 (Electronic)
IS  - 1570-9639 (Linking)
VI  - 1868
IP  - 11
DP  - 2020 Nov
TI  - Molecular trait of follicular-patterned thyroid neoplasms defined by
      MALDI-imaging.
PG  - 140511
LID - S1570-9639(20)30158-8 [pii]
LID - 10.1016/j.bbapap.2020.140511 [doi]
AB  - In the field of thyroid neoplasms, the most interesting recent change regards the
      introduction of a new terminology for follicular-patterned thyroid tumors, named 
      Noninvasive Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP). This
      pre-malignant tumor is considered to be the putative precursor of invasive
      carcinoma. However, given that several issues are still unresolved, the
      application of ancillary tools, based on omics-techniques, may improve the
      clinical management of these challenging cases. The present paper highlights the 
      proteomic profiles of a series of NIFTPs submitted to Fine Needle Aspirations
      (FNAs) and analysed by MALDI-imaging in order to confirm the heterogeneous
      phenotype of nodules included in the present NIFTP terminology and to underline
      the necessity of more accurate biomarkers that can be used for their
      characterization. Ethical and economic implications in terms of healthcare costs,
      operative risks, morbidity, as well as the potential need for lifelong hormone
      replacement therapy, seem to be significant reasons to approach the
      characterization of NIFTPs using alternative tools such as MALDI-MSI.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Piga, Isabella
AU  - Piga I
AD  - Proteomics and Metabolomics, School of Medicine and Surgery, University of
      Milano-Bicocca, Vedano al Lambro, Italy.
FAU - Capitoli, Giulia
AU  - Capitoli G
AD  - Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine
      and Surgery, University of Milano-Bicocca, Monza, Italy.
FAU - Clerici, Francesca
AU  - Clerici F
AD  - Proteomics and Metabolomics, School of Medicine and Surgery, University of
      Milano-Bicocca, Vedano al Lambro, Italy.
FAU - Brambilla, Virginia
AU  - Brambilla V
AD  - Department of Medicine and surgery, UNIMIB, Pathology, Monza, Italy.
FAU - Leni, Davide
AU  - Leni D
AD  - Radiology, ASST Monza, San Gerardo Hospital, Monza, Italy.
FAU - Scardilli, Marcella
AU  - Scardilli M
AD  - Surgery, ASST Monza, San Gerardo Hospital, Monza, Italy.
FAU - Canini, Valentina
AU  - Canini V
AD  - Department of Medicine and surgery, UNIMIB, Pathology, Monza, Italy.
FAU - Cipriani, Nicole
AU  - Cipriani N
AD  - Gross Pathology and Anatomic Pathology Informatics, University of Chicago,
      Chicago, USA.
FAU - Bono, Francesca
AU  - Bono F
AD  - Department of Medicine and surgery, UNIMIB, Pathology, Monza, Italy.
FAU - Valsecchi, Maria Grazia
AU  - Valsecchi MG
AD  - Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine
      and Surgery, University of Milano-Bicocca, Monza, Italy.
FAU - Galimberti, Stefania
AU  - Galimberti S
AD  - Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine
      and Surgery, University of Milano-Bicocca, Monza, Italy.
FAU - Magni, Fulvio
AU  - Magni F
AD  - Proteomics and Metabolomics, School of Medicine and Surgery, University of
      Milano-Bicocca, Vedano al Lambro, Italy.
FAU - Pagni, Fabio
AU  - Pagni F
AD  - Department of Medicine and surgery, UNIMIB, Pathology, Monza, Italy. Electronic
      address: fabio.pagni@unimib.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200801
PL  - Netherlands
TA  - Biochim Biophys Acta Proteins Proteom
JT  - Biochimica et biophysica acta. Proteins and proteomics
JID - 101731734
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biopsy, Fine-Needle
MH  - Carcinoma, Papillary/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proteomics
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Thyroid Neoplasms/*metabolism/pathology
OTO - NOTNLM
OT  - *MALDI-MSI
OT  - *NIFTP
OT  - *Papillary thyroid carcinoma
OT  - *Thyroid fine needle aspiration biopsy
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/08/05 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/02/29 00:00 [received]
PHST- 2020/07/16 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - S1570-9639(20)30158-8 [pii]
AID - 10.1016/j.bbapap.2020.140511 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Proteins Proteom. 2020 Nov;1868(11):140511. doi:
      10.1016/j.bbapap.2020.140511. Epub 2020 Aug 1.


PMID- 32750282
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20211207
IS  - 1558-9110 (Electronic)
IS  - 1058-0360 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Aug 4
TI  - Beyond Scores: Using Converging Evidence to Determine Speech and Language
      Services Eligibility for Dual Language Learners.
PG  - 1116-1132
LID - 10.1044/2020_AJSLP-19-00179 [doi]
AB  - Purpose Speech-language pathologists have both a professional and ethical
      responsibility to provide culturally competent services to dual language learners
      (DLLs). In this tutorial, we recommend that clinicians use a comprehensive
      assessment of converging evidence to make diagnostic decisions in DLLs in
      accordance with the American Speech-Language-Hearing Association's Code of
      Ethics. The content of this tutorial is most appropriate for Spanish-English DLLs
      between the ages of 4 and 8 years. Method We propose a converging evidence
      approach, in which one single method is not the deciding factor in making
      diagnostic decisions regarding the dual language and speech production skills of 
      DLLs. Converging evidence refers to the idea that multiple pieces of assessment
      data must come together and trend in the same direction to make a diagnostic
      decision. We recommend gathering assessment data using a combination of language 
      experience questionnaires, bilingual language sample analysis using large-scale
      reference databases, evaluation of learning potential, and standardized testing. 
      These four assessment methods allow clinicians to examine the child in different 
      contexts to determine their strengths and weakness in communication abilities.
      Conclusion We illustrate the converging evidence framework using two case studies
      to guide the clinician through the diagnostic decision-making process.
FAU - Castilla-Earls, Anny
AU  - Castilla-Earls A
AD  - Department of Communication Sciences and Disorders, University of Houston, TX.
FAU - Bedore, Lisa
AU  - Bedore L
AD  - Temple University, Philadelphia, PA.
FAU - Rojas, Raul
AU  - Rojas R
AD  - The University of Texas at Dallas.
FAU - Fabiano-Smith, Leah
AU  - Fabiano-Smith L
AD  - The University of Arizona, Tucson.
FAU - Pruitt-Lord, Sonja
AU  - Pruitt-Lord S
AD  - San Diego State University, CA.
FAU - Restrepo, Maria Adelaida
AU  - Restrepo MA
AD  - Arizona State University, Tempe.
FAU - Pena, Elizabeth
AU  - Pena E
AD  - University of California, Irvine.
LA  - eng
GR  - K23 DC015835/DC/NIDCD NIH HHS/United States
GR  - R15 DC013670/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200804
PL  - United States
TA  - Am J Speech Lang Pathol
JT  - American journal of speech-language pathology
JID - 9114726
SB  - IM
MH  - Child
MH  - Child Language
MH  - Child, Preschool
MH  - Humans
MH  - Language
MH  - Language Tests
MH  - *Multilingualism
MH  - *Speech
PMC - PMC7893524
EDAT- 2020/08/05 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1044/2020_AJSLP-19-00179 [doi]
PST - ppublish
SO  - Am J Speech Lang Pathol. 2020 Aug 4;29(3):1116-1132. doi:
      10.1044/2020_AJSLP-19-00179. Epub 2020 Aug 4.


PMID- 32750084
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20201007
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 8
DP  - 2020
TI  - Informed consent approaches for clinical trial participation of infants with
      minor parents in sub-Saharan Africa: A systematic review.
PG  - e0237088
LID - 10.1371/journal.pone.0237088 [doi]
AB  - BACKGROUND: Regulations are vague regarding the appropriate decision-maker and
      authority to consent for children of minor parents participating in clinical
      trials. In countries with high rates of underage mothers, such as in sub-Saharan 
      Africa, this lack of guidance may affect the rights of potential paediatric
      participants already bearing increased vulnerability. It can also influence the
      recruitment and generalizability of the research. We provide evidence and discuss
      informed consent management in such cases to inform best practice. MATERIALS AND 
      METHODS: We searched PubMed/MEDLINE, Embase, CINAHL, and Google Scholar for
      articles published up to March 2019. In total, 4382 articles were screened, of
      which 16 met our inclusion criteria. Studies addressing informed consent in
      clinical trials involving children with minor parents in sub-Saharan Africa were 
      included. We performed descriptive and qualitative framework analyses. The review
      was registered in PROSPERO: CRD42018074220. RESULTS: Various informed consent
      approaches were reported. Articles supporting individual consent by minor parents
      based on emancipation or "mature minor" status lacked evidence in the context of 
      research. National laws on medical care guided consent instead. When no laws or
      guidance existed an interpretation of the local decision-making culture,
      including community engagement and collaboration with local ethics committees,
      defined the informed consent approach. CONCLUSIONS: The review emphasises that
      the implementation of informed consent for children with minor parents may be
      variable and hampered by absent or ambiguous clinical trial regulations, as well 
      as divergent local realities. It may further be influenced by the research area
      and study-specific risks. Clear guidance is required to help address these
      challenges proactively in clinical trial planning. We provided a set of questions
      to be considered in the development of an ethically acceptable informed consent
      approach and proposed information that should be integrated into international
      clinical trial guidelines.
FAU - De Pretto-Lazarova, Angela
AU  - De Pretto-Lazarova A
AUID- ORCID: 0000-0003-3685-3526
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Brancati-Badarau, Domnita Oana
AU  - Brancati-Badarau DO
AUID- ORCID: 0000-0002-9031-3566
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
AD  - University of Basel, Basel, Switzerland.
AD  - Life and Health Sciences and Aston Brain Centre, Aston University, Birmingham,
      United Kingdom.
FAU - Burri, Christian
AU  - Burri C
AD  - Department of Medicine, Swiss Tropical and Public Health Institute, Basel,
      Switzerland.
AD  - University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200804
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adolescent
MH  - Africa South of the Sahara
MH  - Child, Preschool
MH  - Clinical Trials as Topic/*legislation & jurisprudence/standards
MH  - Humans
MH  - Infant
MH  - Informed Consent By Minors/*legislation & jurisprudence/standards
MH  - Minors/legislation & jurisprudence
MH  - Parental Consent/*legislation & jurisprudence
MH  - Parents
PMC - PMC7402474
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/05 06:00
MHDA- 2020/10/08 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
AID - 10.1371/journal.pone.0237088 [doi]
AID - PONE-D-20-02525 [pii]
PST - epublish
SO  - PLoS One. 2020 Aug 4;15(8):e0237088. doi: 10.1371/journal.pone.0237088.
      eCollection 2020.


PMID- 32749995
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 4
TI  - Evaluation of More Stamina, a Mobile App for Fatigue Management in Persons with
      Multiple Sclerosis: Protocol for a Feasibility, Acceptability, and Usability
      Study.
PG  - e18196
LID - 10.2196/18196 [doi]
AB  - BACKGROUND: Multiple sclerosis (MS) is one of the world's most common neurologic 
      disorders leading to severe disability in young adults. MS-related fatigue
      directly impacts on the quality of life and activity levels of people with MS.
      Self-management strategies are used to support them in the care of their health. 
      Mobile health (mHealth) solutions can offer tools to help symptom management.
      Following a user-centered design and evidence-based process, an mHealth solution 
      called More Stamina was created to help persons with MS manage their fatigue.
      OBJECTIVE: The overall study aims are to explore the feasibility, acceptability, 
      and usability of More Stamina, a mobile app for fatigue self-management for
      persons with MS. METHODS: A mixed-methods, multicenter study will be used to
      assess the feasibility, acceptability, and usability of More Stamina. The study
      will take place during the third and fourth quarters of 2020 (Q3-Q4 2020) in 3
      locations: Argentina, Spain, and Switzerland. A longitudinal cohort study will
      take place, and think-aloud protocols, open-ended interviews, and short answer
      questionnaires will be used. Persons with MS will be recruited from the different
      locations. This study seeks to enroll at least 20 patients that meet the criteria
      from each site for the longitudinal cohort study (total n=60). RESULTS: Ethical
      approval has been granted in Argentina and is pending in Spain and Switzerland.
      Outcomes will be published in peer-reviewed medical journals and presented at
      international conferences. CONCLUSIONS: Findings from this study will be used to 
      help understand the role that mHealth can play in fatigue management in MS. TRIAL
      REGISTRATION: ClinicalTrials.gov NCT04244214;
      https://clinicaltrials.gov/ct2/show/NCT04244214. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): PRR1-10.2196/18196.
CI  - (c)Guido Giunti, Octavio Rivera-Romero, Jan Kool, Jens Bansi, Jose Luis
      Sevillano, Anabel Granja-Dominguez, Guillermo Izquierdo-Ayuso, Diego Giunta.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 04.08.2020.
FAU - Giunti, Guido
AU  - Giunti G
AUID- ORCID: https://orcid.org/0000-0003-0836-9825
AD  - University of Oulu, Oulu, Finland.
FAU - Rivera-Romero, Octavio
AU  - Rivera-Romero O
AUID- ORCID: https://orcid.org/0000-0001-7212-9805
AD  - Universidad de Sevilla, Sevilla, Spain.
FAU - Kool, Jan
AU  - Kool J
AUID- ORCID: https://orcid.org/0000-0002-7074-8589
AD  - Kliniken Valens, Valens, Switzerland.
FAU - Bansi, Jens
AU  - Bansi J
AUID- ORCID: https://orcid.org/0000-0002-2953-2233
AD  - Kliniken Valens, Valens, Switzerland.
FAU - Sevillano, Jose Luis
AU  - Sevillano JL
AUID- ORCID: https://orcid.org/0000-0002-1392-1832
AD  - Universidad de Sevilla, Sevilla, Spain.
FAU - Granja-Dominguez, Anabel
AU  - Granja-Dominguez A
AUID- ORCID: https://orcid.org/0000-0002-2274-8496
AD  - Hospital Nisa Sevilla, Sevilla, Spain.
FAU - Izquierdo-Ayuso, Guillermo
AU  - Izquierdo-Ayuso G
AUID- ORCID: https://orcid.org/0000-0002-6340-5609
AD  - Hospital Nisa Sevilla, Sevilla, Spain.
FAU - Giunta, Diego
AU  - Giunta D
AUID- ORCID: https://orcid.org/0000-0002-8427-6033
AD  - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
LA  - eng
SI  - ClinicalTrials.gov/NCT04244214
PT  - Journal Article
DEP - 20200804
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7435635
OTO - NOTNLM
OT  - apps
OT  - chronic conditions
OT  - eHealth
OT  - fatigue
OT  - fatigue management
OT  - gamification
OT  - mHealth
OT  - multiple sclerosis
OT  - usability, physical activity
OT  - user-centered design
EDAT- 2020/08/05 06:00
MHDA- 2020/08/05 06:01
CRDT- 2020/08/05 06:00
PHST- 2020/02/11 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/08/05 06:01 [medline]
AID - v9i8e18196 [pii]
AID - 10.2196/18196 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 4;9(8):e18196. doi: 10.2196/18196.


PMID- 32749798
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 164
DP  - 2020 Jun 17
TI  - [Physician-assisted death in psychiatry].
LID - D4783 [pii]
AB  - In recent years, more patients with psychiatric disorders are receiving
      physician-assisted death (PAD). In the Netherlands, since more than 25 years
      psychiatric suffering is seen as a legitimate reason for PAD, but an additional
      independent assessment is required. Scarce empirical research shows that patients
      who receive PAD on the basis of psychiatric suffering have long-standing and
      complex complaints. Among these patients, depression and personality disorders
      are relatively common. The ethical justification of PAD for patients with
      psychiatric disorders has been the subject of debate for decades. Decisions about
      competence and the irremediability of suffering are challenging and for many
      authors reason enough to reject PAD based on psychiatric suffering. Others regard
      the exclusion of all patients with mental disorders as unjust. Empirical research
      and ethical consideration are needed for better founded considerations and a more
      widely supported practice concerning patients with a mental disorder who request 
      PAD.
FAU - van Veen, S M P
AU  - van Veen SMP
AD  - UMC Utrecht, afd. Psychiatrie, Utrecht.
AD  - Contact: S. M.P. van Veen (s.vanveen4@amsterdamumc.nl).
FAU - Widdershoven, G A M
AU  - Widdershoven GAM
AD  - Amsterdam UMC, afd. Ethiek, Recht en Humaniora, Amsterdam.
LA  - dut
PT  - Journal Article
TT  - Euthanasie in de psychiatrie.
DEP - 20200617
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
SB  - IM
MH  - Adult
MH  - Humans
MH  - Mental Disorders/*psychology
MH  - Morals
MH  - Netherlands
MH  - Psychiatry/*ethics
MH  - Suicide, Assisted/*ethics/psychology
EDAT- 2020/08/05 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PST - epublish
SO  - Ned Tijdschr Geneeskd. 2020 Jun 17;164.


PMID- 32749648
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Editorial: Shaping Ethical Futures in Brain-Based and Artificial Intelligence
      Research.
PG  - 2371-2379
LID - 10.1007/s11948-020-00235-z [doi]
FAU - Hildt, Elisabeth
AU  - Hildt E
AD  - Center for the Study of Ethics in the Professions, Illinois Institute of
      Technology, 10 W. 35th Street, Chicago, IL, 60616, USA. ehildt@iit.edu.
FAU - Laas, Kelly
AU  - Laas K
AD  - Center for the Study of Ethics in the Professions, Illinois Institute of
      Technology, 10 W. 35th Street, Chicago, IL, 60616, USA.
FAU - Sziron, Monika
AU  - Sziron M
AD  - Center for the Study of Ethics in the Professions, Illinois Institute of
      Technology, 10 W. 35th Street, Chicago, IL, 60616, USA.
LA  - eng
PT  - Editorial
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Brain
MH  - Forecasting
MH  - Humans
MH  - *Morals
EDAT- 2020/08/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - 10.1007/s11948-020-00235-z [doi]
AID - 10.1007/s11948-020-00235-z [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2371-2379. doi: 10.1007/s11948-020-00235-z.


PMID- 32749647
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Computational Goals, Values and Decision-Making.
PG  - 2487-2495
LID - 10.1007/s11948-020-00244-y [doi]
AB  - Considering the popular framing of an artificial intelligence as a rational agent
      that always seeks to maximise its expected utility, referred to as its goal, one 
      of the features attributed to such rational agents is that they will never select
      an action which will change their goal. Therefore, if such an agent is to be
      friendly towards humanity, one argument goes, we must understand how to specify
      this friendliness in terms of a utility function. Wolfhart Totschnig (Fully
      Autonomous AI, Science and Engineering Ethics, 2020), argues in contrast that a
      fully autonomous agent will have the ability to change its utility function and
      will do so guided by its values. This commentary examines computational accounts 
      of goals, values and decision-making. It rejects the idea that a rational agent
      will never select an action that changes its goal but also argues that an
      artificial intelligence is unlikely to be purely rational in terms of always
      acting to maximise a utility function. It nevertheless also challenges the idea
      that an agent which does not change its goal cannot be considered fully
      autonomous. It does agree that values are an important component of
      decision-making and explores a number of reasons why.
FAU - Dennis, Louise A
AU  - Dennis LA
AD  - Center for Autonomous Systems Technology, Department of Computer Science,
      University of Liverpool, Liverpool, UK. L.A.Dennis@liverpool.ac.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - *Goals
MH  - Humans
MH  - Motivation
PMC - PMC7550297
EDAT- 2020/08/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - 10.1007/s11948-020-00244-y [doi]
AID - 10.1007/s11948-020-00244-y [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2487-2495. doi: 10.1007/s11948-020-00244-y.


PMID- 32749646
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Limits of Neural Computation in Humans and Machines.
PG  - 2547-2553
LID - 10.1007/s11948-020-00249-7 [doi]
AB  - Aicardi et al. (Ethical and social aspects of neurorobotics, Science and
      Engineering Ethics, 2020) look to neuroscience to mitigate the limitations of
      current robotics technology. They propose that robotics technology guided by
      neuroscience has the capacity to create intelligent robots that function with
      awareness and capacity for abstraction and reasoning. As neurorobotics extends
      the capability of robotics technology, it introduces new social and ethical
      concerns, in particular co-opting civilian applications for military use
      (dual-use), conflicts between industry and the academy (industry-academy
      partnerships), and data security (data governance). However, here we argue that
      empirical evidence has shown that human cognition is faulty; therefore there is
      not a clear motivation to build intelligent robots on a human model;
      representation of meaning in the brain is not well-understood; therefore
      neuro-robotics is limited; and to the extent that intelligent robots become a
      reality, the ethics of robot rights will be of central concern.
FAU - Taraban, Roman
AU  - Taraban R
AD  - Department of Psychological Sciences, Texas Tech University, Lubbock, TX, 79409, 
      USA. roman.taraban@ttu.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Brain
MH  - Cognition
MH  - Humans
MH  - Morals
MH  - *Neurosciences
MH  - *Robotics
OTO - NOTNLM
OT  - *Information processing
OT  - *Neural networks
OT  - *Probabilistic models
OT  - *Robot rights
EDAT- 2020/08/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - 10.1007/s11948-020-00249-7 [doi]
AID - 10.1007/s11948-020-00249-7 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2547-2553. doi: 10.1007/s11948-020-00249-7.


PMID- 32749225
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2291-5222 (Electronic)
IS  - 2291-5222 (Linking)
VI  - 8
IP  - 8
DP  - 2020 Aug 4
TI  - User Experiences With and Recommendations for Mobile Health Technology for
      Hypertensive Disorders of Pregnancy: Mixed Methods Study.
PG  - e17271
LID - 10.2196/17271 [doi]
AB  - BACKGROUND: Hypertensive disorders of pregnancy (HDP) are a primary cause of
      adverse maternal and neonatal outcomes worldwide. For women at risk of
      hypertensive complications, guidelines recommend frequent surveillance of blood
      pressure and signs of preeclampsia. Clinic visits range from every 2 weeks to
      several times a week. Given the wide ubiquity of smartphones and computers in
      most countries and a growing attention for self-management, digital technologies,
      including mobile health (mHealth), constitute a promising component of monitoring
      (self-measured) blood pressure during pregnancy. Currently, little is known about
      the experiences of women using such platforms and how mHealth can be aligned with
      their needs and preferences. OBJECTIVE: The objectives were twofold: (1) to
      explore the experiences of Dutch women who had an increased risk of HDP with a
      blended care approach (mHealth combined with face-to-face care) for remote
      self-monitoring of blood pressure and preeclampsia symptoms and (2) to formulate 
      recommendations for the use and integration of mHealth in clinical care. METHODS:
      Alongside a prospective blended care study (SAFE@home study) that monitors
      pregnant women at increased risk of HPD with mHealth technology, a mixed methods 
      study was conducted, including questionnaires (n=52) and interviews (n=11).
      Results were analyzed thematically. RESULTS: Of the 4 themes, 2 themes were
      related to the technologies themselves (expectations, usability), and 2 themes
      were related to the interaction and use of mHealth (autonomy and responsibilities
      of patients, responsibilities of health care professionals). First, the digital
      platform met the expectations of patients, which contributed to user
      satisfaction. Second, the platform was considered user-friendly, and patients
      favored different moments and frequencies for measuring their blood pressure.
      Third, patient autonomy was mentioned in terms of increased insight about their
      own condition and being able to influence clinical decision making. Fourth,
      clinical expertise of health care professionals was considered essential to
      interpret the data, which translates to subsequent responsibilities for clinical 
      management. Data from the questionnaires and interviews corresponded.
      CONCLUSIONS: Blended care using an mHealth tool to monitor blood pressure in
      pregnancy was positively evaluated by its users. Insights from participants led
      to 7 recommendations for designing and implementing similar interventions and to 
      enhance future, morally sound use of digital technologies in clinical care.
CI  - (c)Karin Rolanda Jongsma, Josephus F M van den Heuvel, Jasmijn Rake, Annelien L
      Bredenoord, Mireille N Bekker. Originally published in JMIR mHealth and uHealth
      (http://mhealth.jmir.org), 04.08.2020.
FAU - Jongsma, Karin Rolanda
AU  - Jongsma KR
AUID- ORCID: 0000-0001-8135-6786
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, Utrecht, Netherlands.
FAU - van den Heuvel, Josephus F M
AU  - van den Heuvel JFM
AUID- ORCID: 0000-0002-1285-1019
AD  - Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht
      University, Utrecht, Netherlands.
FAU - Rake, Jasmijn
AU  - Rake J
AUID- ORCID: 0000-0001-7321-1608
AD  - Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht
      University, Utrecht, Netherlands.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AUID- ORCID: 0000-0002-7542-8963
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, Utrecht, Netherlands.
FAU - Bekker, Mireille N
AU  - Bekker MN
AUID- ORCID: 0000-0002-7372-4291
AD  - Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht
      University, Utrecht, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200804
PL  - Canada
TA  - JMIR Mhealth Uhealth
JT  - JMIR mHealth and uHealth
JID - 101624439
SB  - IM
MH  - Adult
MH  - Biomedical Technology
MH  - Blood Pressure
MH  - Female
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced/diagnosis/epidemiology/therapy
MH  - Pregnancy
MH  - Prospective Studies
MH  - *Telemedicine
PMC - PMC7435610
OTO - NOTNLM
OT  - *digital health
OT  - *ethics
OT  - *high-risk pregnancy
OT  - *hypertension
OT  - *mobile health
OT  - *preeclampsia
OT  - *telemonitoring
EDAT- 2020/08/05 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/08/05 06:00
PHST- 2019/12/01 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - v8i8e17271 [pii]
AID - 10.2196/17271 [doi]
PST - epublish
SO  - JMIR Mhealth Uhealth. 2020 Aug 4;8(8):e17271. doi: 10.2196/17271.


PMID- 32748773
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20220317
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 3
DP  - 2020 Sep
TI  - Global Governing Bodies: A Pathway for Gene Drive Governance for Vector Mosquito 
      Control.
PG  - 976-985
LID - 10.4269/ajtmh.19-0941 [doi]
LID - tpmd190941 [pii]
AB  - Gene drive technologies represent powerful tools to develop vector control
      strategies that will complement the current approaches to mitigate
      arthropod-borne infectious diseases. The characteristics of gene drive
      technologies have raised additional concerns to those for standard genetically
      engineered organisms. This generates a need for adaptive governance that has not 
      been met yet because of the rapid rate of progress in gene drive research. For
      the eventual release of gene drive insects into wild populations, an
      international governance network would be helpful in guiding scientists,
      stakeholders, public opinion, and affected communities in its use. We examined
      the current institutions and governing bodies among various continents that could
      have an impact on gene drive governance or the potential to adapt to its future
      use. Possible governance strategies also are proposed that seek to bridge gaps
      and promote an ethically sound policy framework. Ideally, governance strategies
      should be developed before or at the same pace as gene drive research to
      anticipate field releases and maximize their impact as a public health tool.
      However, this is not likely to happen as it takes years to develop global
      accords, and some countries may choose to move ahead independently on the new
      technology.
FAU - Kelsey, Adam
AU  - Kelsey A
FAU - Stillinger, Drusilla
AU  - Stillinger D
FAU - Pham, Thai Binh
AU  - Pham TB
FAU - Murphy, Jazmin
AU  - Murphy J
FAU - Firth, Sean
AU  - Firth S
FAU - Carballar-Lejarazu, Rebeca
AU  - Carballar-Lejarazu R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
SB  - IM
MH  - Agriculture/ethics/methods
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Biomedical Research/ethics/methods
MH  - Culicidae/*genetics
MH  - Gene Drive Technology/ethics/*legislation & jurisprudence
MH  - Humans
MH  - International Cooperation/*legislation & jurisprudence
MH  - Mosquito Control/*legislation & jurisprudence/organization & administration
MH  - Mosquito Vectors/*genetics
MH  - Public Health
MH  - Quantitative Trait, Heritable
PMC - PMC7470596
EDAT- 2020/08/05 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - 10.4269/ajtmh.19-0941 [doi]
AID - tpmd190941 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Sep;103(3):976-985. doi: 10.4269/ajtmh.19-0941.


PMID- 32747964
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 113
IP  - 8
DP  - 2020 Aug
TI  - Toward a New Ethic in Global Health Practice: Perspectives from Central America.
PG  - 374-377
LID - 10.14423/SMJ.0000000000001126 [doi]
FAU - Ventres, William
AU  - Ventres W
AD  - From the Department of Family and Preventive Medicine, University of Arkansas for
      Medical Sciences, Little Rock.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
SB  - IM
MH  - Central America
MH  - Developing Countries
MH  - Ethics, Medical
MH  - Global Health/*ethics
MH  - Humans
EDAT- 2020/08/05 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - 10.14423/SMJ.0000000000001126 [doi]
AID - SMJ50813 [pii]
PST - ppublish
SO  - South Med J. 2020 Aug;113(8):374-377. doi: 10.14423/SMJ.0000000000001126.


PMID- 32747963
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 113
IP  - 8
DP  - 2020 Aug
TI  - The Medical Ethics of Poor Supervision.
PG  - 372-373
LID - 10.14423/SMJ.0000000000001127 [doi]
FAU - Fisher, John F
AU  - Fisher JF
AD  - From the Medical College of Georgia, Augusta.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
SB  - IM
MH  - Abdominal Pain/diagnosis/etiology
MH  - Clinical Clerkship/*ethics
MH  - Clinical Competence
MH  - Humans
MH  - Male
MH  - Medical Staff, Hospital/*ethics
MH  - Middle Aged
EDAT- 2020/08/05 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - 10.14423/SMJ.0000000000001127 [doi]
AID - SMJ50814 [pii]
PST - ppublish
SO  - South Med J. 2020 Aug;113(8):372-373. doi: 10.14423/SMJ.0000000000001127.


PMID- 32747924
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 2066-8279 (Electronic)
IS  - 1220-0522 (Linking)
VI  - 61
IP  - 1
DP  - 2020
TI  - A research on abortion: ethics, legislation and socio-medical outcomes. Case
      study: Romania.
PG  - 283-294
LID - 10.47162/RJME.61.1.35 [doi]
AB  - This article presents a research study on abortion from a theoretical and
      empirical point of view. The theoretical part is based on the method of social
      documents analysis, and presents a complex perspective on abortion, highlighting 
      items of medical, ethical, moral, religious, social, economic and legal elements.
      The empirical part presents the results of a sociological survey, based on the
      opinion survey method through the application of the enquiry technique, conducted
      in Romania, on a sample of 1260 women. The purpose of the survey is to identify
      Romanians perception on the decision to voluntary interrupt pregnancy, and to
      determine the core reasons in carrying out an abortion.
FAU - Nita, Andreea Mihaela
AU  - Nita AM
AD  - Faculty of Social Sciences, University of Craiova, Romania;
      andreea_nita2005@yahoo.com, cristin_il@yahoo.com, cristina_ilie.goga@ucv.ro.
FAU - Ilie Goga, Cristina
AU  - Ilie Goga C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Romania
TA  - Rom J Morphol Embryol
JT  - Romanian journal of morphology and embryology = Revue roumaine de morphologie et 
      embryologie
JID - 9112454
SB  - IM
MH  - Abortion, Induced/*ethics
MH  - *Ethics, Medical
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Romania
PMC - PMC7728127
EDAT- 2020/08/05 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 610120283294 [pii]
AID - 10.47162/RJME.61.1.35 [doi]
PST - ppublish
SO  - Rom J Morphol Embryol. 2020;61(1):283-294. doi: 10.47162/RJME.61.1.35.


PMID- 32747923
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201219
IS  - 2066-8279 (Electronic)
IS  - 1220-0522 (Linking)
VI  - 61
IP  - 1
DP  - 2020
TI  - Ethical review of patient safety and public health in EU clinical trials
      legislation: impact of COVID-19 pandemic.
PG  - 277-281
LID - 10.47162/RJME.61.1.34 [doi]
AB  - PURPOSE: The study considers the ethical review of the European Union (EU)
      clinical trials (CTs) legislation, namely the Clinical Trials Regulation (CTR)
      (EU) 2014536, the Directive 200120EC and the "Guidance on the management of
      clinical trials during the COVID-19 (coronavirus) pandemic" (GMCT) (version 3)
      issued on 28 April 2020 by the European authorities in the field. BACKGROUND: The
      Directive 200120EC focuses the legal provisions for the conduct of CTs by
      acknowledging the screening role of the Ethics Committees (ECs) and of the
      national competent authorities (NCA) in the Member States (MS) to protect the CT 
      subject and the personal data. CONTENT: The present article displays the ethical 
      requirements for conducting, monitoring and reporting of the CTs by raising
      awareness on the: (i) new conceptual framework of the "clinical trial",
      "low-intervention clinical trial", "non-interventional study" and "ethics
      committee"; (ii) ethical considerations addressed in Part I and Part II of the
      assessment report; (iii) evaluation of the coronavirus disease 2019 (COVID-19)
      pandemic on the current regulatory framework. CONCLUSIONS: The CTR stimulates the
      EU clinical research and enables an independent control with regard to the
      respect of the interests of the CT subject.
FAU - Olimid, Anca Parmena
AU  - Olimid AP
AD  - Faculty of Social Sciences, University of Craiova, Romania;
      parmena2002@yahoo.com.
FAU - Olimid, Daniel Alin
AU  - Olimid DA
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Rom J Morphol Embryol
JT  - Romanian journal of morphology and embryology = Revue roumaine de morphologie et 
      embryologie
JID - 9112454
SB  - IM
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics/*legislation & jurisprudence
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - *Ethical Review
MH  - Ethics Committees
MH  - *Ethics, Research
MH  - European Union
MH  - *Health Policy
MH  - Humans
MH  - Informed Consent
MH  - Pandemics
MH  - Patient Safety
MH  - Pneumonia, Viral/*epidemiology/*therapy
MH  - Public Health
MH  - Research Design
PMC - PMC7728112
EDAT- 2020/08/05 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 610120277281 [pii]
AID - 10.47162/RJME.61.1.34 [doi]
PST - ppublish
SO  - Rom J Morphol Embryol. 2020;61(1):277-281. doi: 10.47162/RJME.61.1.34.


PMID- 32747891
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 2066-8279 (Electronic)
IS  - 1220-0522 (Linking)
VI  - 61
IP  - 1
DP  - 2020
TI  - Microfluidic endothelium-on-a-chip development, from in vivo to in vitro
      experimental models.
PG  - 15-23
LID - 10.47162/RJME.61.1.02 [doi]
AB  - In the last years, animal testing in medical research has been a controversial
      topic because of various reasons, such as ethical considerations and species
      differences. Therefore, more attention has been given to develop new technologies
      that can replace animal experiments and create in vitro models. Organ-on-a-chip
      (OOC) technology is a new and advanced technology based on microfluidic devices
      that can mimic the structure and function of entire organs and tissues as in
      vitro models. OOC models are miniature tissues and organs that assign
      characteristics for three-dimensional (3D) cell culture representation that
      resemble the original organs, together with their specific microenvironment
      microfluidic systems and specific biophysical processes, in order to mimic the
      normal physiological conditions and functionalities of the organs. Existing OOC
      models, such as liver, pancreas, heart, skin, brain, kidney, vessels, have been
      developed and designed for a specific function study. This review focuses on the 
      main knowledge concerning OOC research and especially vascular
      endothelium-on-a-chip (EOC) model, developed in order to offer specific tools for
      studying vascular functions in physiological and pathological conditions. The
      field of OOC devices is still at the beginning, but in the future, this
      technology may have important roles in developing novel therapeutic approaches,
      offering new therapeutic molecules and providing the first step towards
      personalized medicine.
FAU - Bulboaca, Adriana Elena
AU  - Bulboaca AE
AD  - Discipline of Histology, Department of Morphological Sciences, Iuliu Hatieganu
      University of Medicine and Pharmacy, Cluj-Napoca, Romania;
      cmelincovici@yahoo.com.
FAU - Boarescu, Paul Mihai
AU  - Boarescu PM
FAU - Melincovici, Carmen Stanca
AU  - Melincovici CS
FAU - Mihu, Carmen Mihaela
AU  - Mihu CM
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Rom J Morphol Embryol
JT  - Romanian journal of morphology and embryology = Revue roumaine de morphologie et 
      embryologie
JID - 9112454
SB  - IM
MH  - Animals
MH  - Endothelial Cells/*metabolism
MH  - Humans
MH  - Lab-On-A-Chip Devices/*standards
MH  - Microfluidics/*methods
MH  - Models, Biological
PMC - PMC7728109
EDAT- 2020/08/05 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 610120015023 [pii]
AID - 10.47162/RJME.61.1.02 [doi]
PST - ppublish
SO  - Rom J Morphol Embryol. 2020;61(1):15-23. doi: 10.47162/RJME.61.1.02.


PMID- 32747524
OWN - NLM
STAT- Publisher
LR  - 20200804
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Aug 3
TI  - Challenges faced by patients, relatives and clinicians in end-stage dementia
      decision-making: a qualitative study of swallowing problems.
LID - medethics-2020-106222 [pii]
LID - 10.1136/medethics-2020-106222 [doi]
AB  - BACKGROUND: Decision-making in end-stage dementia (ESD) is a complex process
      involving medical, social, legal and ethical issues. In ESD, the person suffers
      from severe cognitive problems leading to a loss of capacity to decide matters
      regarding health and end-of-life issues. The decisional responsibility is usually
      passed to clinicians and relatives who can face significant difficulty in making 
      moral decisions, particularly in the presence of life-threatening swallowing
      problems. AIM: This study aimed to understand the decision-making processes of
      clinical teams and relatives in addressing life-threatening swallowing
      difficulties in ESD in long-term care in Malta. METHOD: The study followed a
      qualitative approach where six case studies, involving six different teams and
      relatives of six different patients, were interviewed retrospectively to
      understand their decision-making in connection with the management of swallowing 
      difficulties in ESD. Data were collected through semistructured interviews with
      each stakeholder. All data were transcribed and subjected to thematic analysis.
      RESULTS: Four themes were identified: the vulnerability of patients in dementia
      decision-making; the difficult role of relatives in decision-making; the
      decisional conflict between aggressive care through tube feeding versus oral
      comfort feeding; a consensus-building decision-making process as ideal to
      facilitate agreement and respect for patient's dignity. CONCLUSION:
      Decision-making to manage swallowing difficulties in ESD is a challenging
      process, which involves an interpretation of personal values, beliefs, patient
      preferences, care needs and clinical practice. Better communication between
      clinicians and relatives in dementia helps promote agreement between stakeholders
      leading to a care plan that respects the dignity of patients at their end of
      life.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Dimech, Joseph
AU  - Dimech J
AUID- ORCID: http://orcid.org/0000-0003-2687-8957
AD  - Government of Malta, Ministry for the Family and Social Solidarity, Valletta,
      Malta dimechjoseph@gmail.com.
AD  - Barts and The London School of Medicine and Dentistry, QMUL, Malta Campus, Gozo, 
      Malta.
FAU - Agius, Emmanuel
AU  - Agius E
AD  - Department of Moral Theology, University of Malta, Msida, Malta.
AD  - European Group of Ethics in Science and New Technologies, European Commission,
      Brussels, Belgium.
FAU - Hughes, Julian C
AU  - Hughes JC
AD  - University of Bristol, Bristol, UK.
AD  - Policy, Ethics and Life Sciences Research Centre, Newcastle University, Newcastle
      upon Tyne, UK.
FAU - Bartolo, Paul
AU  - Bartolo P
AD  - Department of Psychology, Faculty for Social Wellbeing, University of Malta,
      Msida, Malta.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - decision-making
OT  - deglutition disorders
OT  - dementia
OT  - end of life care
OT  - human dignity
COIS- Competing interests: None declared.
EDAT- 2020/08/05 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/10 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
AID - medethics-2020-106222 [pii]
AID - 10.1136/medethics-2020-106222 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Aug 3. pii: medethics-2020-106222. doi:
      10.1136/medethics-2020-106222.


PMID- 32747351
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 3
TI  - Protocol for economic evaluation alongside the SHINE (Supporting Healthy Image,
      Nutrition and Exercise) cluster randomised controlled trial.
PG  - e038050
LID - 10.1136/bmjopen-2020-038050 [doi]
AB  - INTRODUCTION: Limited evidence exists on the cost-effectiveness of interventions 
      to prevent obesity and promote healthy body image in adolescents. The SHINE
      (Supporting Healthy Image, Nutrition and Exercise) study is a cluster randomised 
      control trial (cRCT) aiming to deliver universal education about healthy
      nutrition and physical activity to adolescents, as well as targeted advice to
      young people with body image concerns who are at risk of developing disordered
      eating behaviours. This paper describes the methods for the economic evaluation
      of the SHINE cRCT, to determine whether the intervention is cost-effective as an 
      obesity prevention measure. METHODS AND ANALYSIS: A public payer perspective will
      be adopted, with intervention costs collected prospectively. Within-trial
      cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) will quantify
      the incremental costs and health gains of the intervention as compared with usual
      practice (ie, teacher-delivered curriculum). CEA will present results as cost per
      body mass index unit saved. CUA will present results as cost per quality-adjusted
      life year gained. A modelled CUA will extend the target population, time horizon 
      and decision context to provide valuable information to policymakers on the
      potential for incremental cost offsets attributable to disease prevention arising
      from intervention. Intervention costs and effects will be extrapolated to the
      population of Australian adolescents in Grade 7 of secondary school (approximate 
      age 13 years) and modelled over the cohort's lifetime. Modelled CUA results will 
      be presented as health-adjusted life years saved and healthcare cost-savings of
      diseases averted. Incremental cost-effectiveness ratios will be calculated as the
      difference in costs between the intervention and comparator divided by the
      difference in benefit. Semi-structured interviews with key intervention
      stakeholders will explore the potential impact of scalability on
      cost-effectiveness. These data will be thematically analysed to inform
      sensitivity analysis of the base case economic evaluation, such that
      cost-effectiveness evidence is reflective of the potential for scalability.
      ETHICS AND DISSEMINATION: Ethics approval was obtained from the Deakin University
      Human Research Ethics Committee (#2017-269) and the Victorian Department of
      Education and Training (#2018_003630). Study findings will be disseminated
      through peer-reviewed academic papers and participating schools will receive
      annual reports over the 3 years of data collection. TRIAL REGISTRATION NUMBER:
      ACTRN 12618000330246; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Brown, Victoria
AU  - Brown V
AUID- ORCID: 0000-0003-2891-9476
AD  - Deakin University, Geelong, Deakin Health Economics, Institute for Health
      Transformation, Geelong, Victoria, Australia victoria.brown@deakin.edu.au.
FAU - Williams, Joanne
AU  - Williams J
AD  - Deakin University, Geelong, Institute for Health Transformation, School of Health
      and Social Development, Geelong, Victoria, Australia.
FAU - McGivern, Lisa
AU  - McGivern L
AD  - Deakin University, Geelong, Institute for Health Transformation, School of Health
      and Social Development, Geelong, Victoria, Australia.
FAU - Sawyer, Susan
AU  - Sawyer S
AD  - Department of Paediatrics, The University of Melbourne; Centre for Adolescent
      Health Royal Children's Hospital, Melbourne, Victoria, Australia.
FAU - Orellana, Liliana
AU  - Orellana L
AD  - Deakin University, Geelong, Faculty of Health, Geelong, Victoria, Australia.
FAU - Luo, Wei
AU  - Luo W
AD  - Deakin University, Geelong, School of Information Technology, Geelong, Victoria, 
      Australia.
FAU - Hesketh, Kylie D
AU  - Hesketh KD
AD  - Deakin University, Geelong, Institute for Physical Activity and Nutrition,
      Faculty of Health, Geelong, Victoria, Australia.
FAU - Wilfley, Denise E
AU  - Wilfley DE
AD  - School of Medicine, Washington University in St. Louis, Missouri, Missouri, USA.
FAU - Moodie, Marj
AU  - Moodie M
AD  - Deakin University, Geelong, Deakin Health Economics, Institute for Health
      Transformation, Geelong, Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618000330246
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200803
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia
MH  - Cost-Benefit Analysis
MH  - *Exercise
MH  - Humans
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - *Schools
PMC - PMC7402000
OTO - NOTNLM
OT  - *health economics
OT  - *paediatrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/08/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038050 [pii]
AID - 10.1136/bmjopen-2020-038050 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 3;10(8):e038050. doi: 10.1136/bmjopen-2020-038050.


PMID- 32747347
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 8
DP  - 2020 Aug 3
TI  - Exploring the factors that affect new graduates' transition from students to
      health professionals: a systematic integrative review protocol.
PG  - e033734
LID - 10.1136/bmjopen-2019-033734 [doi]
AB  - INTRODUCTION: To become a competent health professional, the nature of new
      graduates' transition plays a fundamental role. The systematic integrative review
      will aim to identify the existing literature pertaining to the barriers during
      transition, the facilitators and the evidence-based coping strategies that assist
      new graduate health professionals to successfully transition from students to
      health professionals. METHODS AND ANALYSIS: The integrative review will be
      conducted using Whittemore and Knafl's integrative review methodology. Boolean
      search terms have been developed in consultation with an experienced librarian,
      using Medical Subject Heading terms on Medline. The following electronic
      databases have been chosen to ensure that all relevant literature are captured
      for this review: PubMed, EBSCOhost (including Cumulative Index of Nursing and
      Allied Health Literature (CINAHL), Medline, Academic Search Premier, Health
      Science: Nursing and Academic Edition), Scopus and Web of Science. A follow-up on
      the reference list of selected articles will be done to ensure that all relevant 
      literature is included. The Covidence platform will be used to facilitate the
      process. ETHICS AND DISSEMINATION: Ethical approval is not required for this
      integrative review since the existing literature will be synthesised. The
      integrative review will be published in a peer-reviewed journal once all the
      steps have been completed. The findings will also be presented at international
      and national conferences to ensure maximum dissemination.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Opoku, Eric Nkansah
AU  - Opoku EN
AUID- ORCID: 0000-0002-8970-0059
AD  - Department of Occupational Therapy, College of Health Sciences; University of
      Ghana, Accra, Greater Accra Region, Ghana Enopoku@ug.edu.gh.
AD  - Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,
      Western Cape, South Africa.
FAU - Van Niekerk, Lana
AU  - Van Niekerk L
AUID- ORCID: 0000-0003-0003-6006
AD  - Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,
      Western Cape, South Africa.
FAU - Jacobs-Nzuzi Khuabi, Lee-Ann
AU  - Jacobs-Nzuzi Khuabi LA
AUID- ORCID: 0000-0003-0684-5373
AD  - Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,
      Western Cape, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adaptation, Psychological
MH  - *Health Personnel
MH  - Humans
MH  - *Students
MH  - Systematic Reviews as Topic
PMC - PMC7402005
OTO - NOTNLM
OT  - *clinical practice
OT  - *new graduate
OT  - *professional competence
OT  - *student
OT  - *transition
COIS- Competing interests: None declared.
EDAT- 2020/08/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033734 [pii]
AID - 10.1136/bmjopen-2019-033734 [doi]
PST - epublish
SO  - BMJ Open. 2020 Aug 3;10(8):e033734. doi: 10.1136/bmjopen-2019-033734.


PMID- 32746993
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1532-3072 (Electronic)
IS  - 0040-8166 (Linking)
VI  - 65
DP  - 2020 Aug
TI  - Umbilical cord stem cells: Background, processing and applications.
PG  - 101351
LID - S0040-8166(19)30527-0 [pii]
LID - 10.1016/j.tice.2020.101351 [doi]
AB  - Stem cells have currently gained attention in the field of medicine not only due 
      to their ability to repair dysfunctional or damaged cells, but also they could be
      used as drug delivery system after being engineered to do so. Human umbilical
      cord is attractive source for autologous and allogenic stem cells that are
      currently amenable to treatment of various diseases. Human umbilical cord stem
      cells are -in contrast to embryonic and fetal stem cells- ethically
      noncontroversial, inexpensive and readily available source of cells. Umbilical
      cord, umbilical cord vein, amnion/placenta and Wharton's jelly are all rich of
      many types of multipotent stem cell populations capable of forming many different
      cell types. This review will focus on umbilical cord stem cells processing and
      current application in medicine.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Alatyyat, Shumukh M
AU  - Alatyyat SM
AD  - Pharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Alasmari, Houton M
AU  - Alasmari HM
AD  - Pharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Aleid, Omamah A
AU  - Aleid OA
AD  - Pharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Abdel-Maksoud, Mohamed S
AU  - Abdel-Maksoud MS
AD  - Department of Pharmacology & Toxicology, Faculty of Pharmacy, University of
      Tabuk, Tabuk, Saudi Arabia.
FAU - Elsherbiny, Nehal
AU  - Elsherbiny N
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk,
      Tabuk, Saudi Arabia; Department of Biochemistry, Faculty of Pharmacy, Mansoura
      University, Mansoura, Egypt. Electronic address: nelsherbiny@ut.edu.sa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200319
PL  - Scotland
TA  - Tissue Cell
JT  - Tissue & cell
JID - 0214745
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Humans
MH  - Specimen Handling
MH  - Stem Cell Transplantation
MH  - Stem Cells/classification/*cytology
MH  - Umbilical Cord/*cytology
OTO - NOTNLM
OT  - Applications
OT  - Processing
OT  - Umbilical cord stem cells
EDAT- 2020/08/05 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/08/05 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/15 00:00 [revised]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
AID - S0040-8166(19)30527-0 [pii]
AID - 10.1016/j.tice.2020.101351 [doi]
PST - ppublish
SO  - Tissue Cell. 2020 Aug;65:101351. doi: 10.1016/j.tice.2020.101351. Epub 2020 Mar
      19.


PMID- 32746941
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20220416
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 3
TI  - Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major
      depression. Study protocol of the VESPA study: a pragmatic, multicentre,
      open-label, parallel-group, superiority, randomized trial.
PG  - 695
LID - 10.1186/s13063-020-04460-6 [doi]
AB  - INTRODUCTION: Depression is a highly prevalent condition in the elderly, with a
      vast impact on quality of life, life expectancy, and medical outcomes. Selective 
      serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed agents in 
      this condition and, although generally safe, tolerability issues cannot be
      overlooked. Vortioxetine is an antidepressant with a novel mechanism of action.
      Based on studies to date, it may have a promising tolerability profile in the
      elderly, as it does not adversely affect psychomotor or cognitive performance and
      does not alter cardiovascular and endocrine parameters. The present study aims to
      assess the tolerability profile of vortioxetine in comparison with the SSRIs
      considered as a single group in elderly participants with depression. The rate of
      participants withdrawing from treatment due to adverse events after 6 months of
      follow up will be the primary outcome. METHODS AND ANALYSIS: This is a pragmatic,
      multicentre, open-label, parallel-group, superiority, randomized trial funded by 
      the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco). Thirteen
      Italian Community Psychiatric Services will consecutively enrol elderly
      participants suffering from an episode of major depression over a period of 12
      months. Participants will be assessed at baseline and after 1, 3 and 6 months of 
      follow up. At each time point, the following validated rating scales will be
      administered: Montgomery-Asberg Depression Rating Scale (MADRS), Antidepressant
      Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test
      (SBT), and Charlson Age-Comorbidity Index (CACI). Outcome assessors and the
      statistician will be masked to treatment allocation. A total of 358 participants 
      (179 in each group) will be enrolled. ETHICS AND DISSEMINATION: This study will
      fully adhere to the ICH E6 Guideline for Good Clinical Practice. Participants'
      data will be managed and safeguarded according to the European Data Protection
      Regulation 2016/679. An external Ethical Advisory Board will help guarantee high 
      ethical standards. TRIAL REGISTRATION: Clinicaltrials.gov: NCT03779789 ,
      Registered on 19 December 2018. Submitted on 19 December. EudraCT number:
      2018-001444-66. TRIAL STATUS: Protocol version 1.5; 09/06/2018. Recruitment
      started In February 2019 and it is ongoing. It is expected to end approximately
      on 30 September 2021.
FAU - Ostuzzi, Giovanni
AU  - Ostuzzi G
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Gastaldon, Chiara
AU  - Gastaldon C
AUID- ORCID: http://orcid.org/0000-0001-7257-2962
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy. chiara.gastaldon@univr.it.
FAU - Barbato, Angelo
AU  - Barbato A
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
FAU - D'Avanzo, Barbara
AU  - D'Avanzo B
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
FAU - Tettamanti, Mauro
AU  - Tettamanti M
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
FAU - Monti, Igor
AU  - Monti I
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
FAU - Aguglia, Andrea
AU  - Aguglia A
AD  - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics Maternal and 
      Child Health, University of Genoa, Genoa, Italy.
AD  - Section of Psychiatry, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
FAU - Aguglia, Eugenio
AU  - Aguglia E
AD  - Department of Clinical and Experimental Medicine, Psychiatry Unit, University of 
      Catania, U.O.C. Clinica Psichiatrica, A.O.U. Policlinico-Vittorio Emanuele,
      Presidio "G. Rodolico", Catania, Italy.
FAU - Alessi, Maria Chiara
AU  - Alessi MC
AD  - Dipartimento di Neuroscienze, Imaging e Scienze Cliniche Universita "G.
      D'Annunzio Chieti-Pescara", Chieti, Italy.
FAU - Amore, Mario
AU  - Amore M
AD  - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics Maternal and 
      Child Health, University of Genoa, Genoa, Italy.
AD  - Section of Psychiatry, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
FAU - Bartoli, Francesco
AU  - Bartoli F
AD  - Dipartimento di Medicina e Chirurgia, Universita di Milano Bicocca, Milan, Italy.
FAU - Biondi, Massimo
AU  - Biondi M
AD  - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
FAU - Bortolaso, Paola
AU  - Bortolaso P
AD  - Department of Medicine and Surgery, Division of Psychiatry, University of
      Insubria, Varese, Italy.
FAU - Callegari, Camilla
AU  - Callegari C
AD  - Department of Medicine and Surgery, Division of Psychiatry, University of
      Insubria, Varese, Italy.
FAU - Carra, Giuseppe
AU  - Carra G
AD  - Dipartimento di Medicina e Chirurgia, Universita di Milano Bicocca, Milan, Italy.
AD  - Division of Psychiatry, University College London, London, UK.
FAU - Caruso, Rosangela
AU  - Caruso R
AD  - Institute of Psychiatry, Department of Biomedical and Specialty Surgical
      Sciences, University of Ferrara, Ferrara, Italy.
FAU - Cavallotti, Simone
AU  - Cavallotti S
AD  - Department of Mental Health, ASST Santi Paolo e Carlo, Milan, Italy.
FAU - Crocamo, Cristina
AU  - Crocamo C
AD  - Dipartimento di Medicina e Chirurgia, Universita di Milano Bicocca, Milan, Italy.
FAU - D'Agostino, Armando
AU  - D'Agostino A
AD  - Department of Mental Health, ASST Santi Paolo e Carlo, Milan, Italy.
AD  - Department of Health Sciences, Universita degli Studi di Milano, Milan, Italy.
FAU - De Fazio, Pasquale
AU  - De Fazio P
AD  - Azienda Ospedaliera Universitaria Mater Domini, Universita Magna Grecia,
      Catanzaro, Italy.
FAU - Di Natale, Chiara
AU  - Di Natale C
AD  - Dipartimento di Neuroscienze, Imaging e Scienze Cliniche Universita "G.
      D'Annunzio Chieti-Pescara", Chieti, Italy.
FAU - Giusti, Laura
AU  - Giusti L
AD  - Dipartimento di Medicina Clinica, Sanita Pubblica, Scienze della Vita e
      dell'Ambiente, Universita degli Studi dell'Aquila, L'Aquila, Italy.
FAU - Grassi, Luigi
AU  - Grassi L
AD  - Institute of Psychiatry, Department of Biomedical and Specialty Surgical
      Sciences, University of Ferrara, Ferrara, Italy.
FAU - Martinotti, Giovanni
AU  - Martinotti G
AD  - Dipartimento di Neuroscienze, Imaging e Scienze Cliniche Universita "G.
      D'Annunzio Chieti-Pescara", Chieti, Italy.
FAU - Nose, Michela
AU  - Nose M
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Papola, Davide
AU  - Papola D
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Purgato, Marianna
AU  - Purgato M
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Rodolico, Alessandro
AU  - Rodolico A
AD  - Department of Clinical and Experimental Medicine, Psychiatry Unit, University of 
      Catania, U.O.C. Clinica Psichiatrica, A.O.U. Policlinico-Vittorio Emanuele,
      Presidio "G. Rodolico", Catania, Italy.
FAU - Roncone, Rita
AU  - Roncone R
AD  - Dipartimento di Medicina Clinica, Sanita Pubblica, Scienze della Vita e
      dell'Ambiente, Universita degli Studi dell'Aquila, L'Aquila, Italy.
FAU - Tarsitani, Lorenzo
AU  - Tarsitani L
AD  - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
FAU - Turrini, Giulia
AU  - Turrini G
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Zanini, Elisa
AU  - Zanini E
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Amaddeo, Francesco
AU  - Amaddeo F
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Ruggeri, Mirella
AU  - Ruggeri M
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
FAU - Barbui, Corrado
AU  - Barbui C
AD  - Department of Neuroscience, Biomedicine and Movement Sciences, Section of
      Psychiatry, University of Verona, Verona, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT03779789
GR  - 2016 call for Independent Research on Drugs 2016-0234923/Agenzia Italiana del
      Farmaco, Ministero della Salute
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 3O2K1S3WQV (Vortioxetine)
SB  - IM
MH  - Aged
MH  - *Depressive Disorder, Major/diagnosis/drug therapy
MH  - Equivalence Trials as Topic
MH  - Humans
MH  - Italy
MH  - Multicenter Studies as Topic
MH  - Pragmatic Clinical Trials as Topic
MH  - Serotonin Uptake Inhibitors/*therapeutic use
MH  - Vortioxetine/*therapeutic use
PMC - PMC7397635
OTO - NOTNLM
OT  - Antidepressants
OT  - Depression
OT  - Elderly
OT  - Pragmatic trial
OT  - Randomized clinical trial
OT  - Vortioxetine
EDAT- 2020/08/05 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/08/05 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - 10.1186/s13063-020-04460-6 [doi]
AID - 10.1186/s13063-020-04460-6 [pii]
PST - epublish
SO  - Trials. 2020 Aug 3;21(1):695. doi: 10.1186/s13063-020-04460-6.


PMID- 32746870
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Aug 3
TI  - Designing and psychometric of reproductive health related behaviors assessment
      tool in Iranian males: an exploratory mixed method study protocol.
PG  - 118
LID - 10.1186/s12978-020-00966-z [doi]
AB  - BACKGROUND: Male reproductive health is a relatively new concept, and most men
      are neglected in reproductive health discussions. Therefore, it appears that
      there is insufficient information about the male reproductive health. This study 
      aims to design a psychometric instrument for assessing the male reproductive
      health-related behavior. METHODS/DESIGN: This is a sequential exploratory
      mixed-method study with a classical instrument development design. It will be
      conducted in two qualitative and quantitative phases on the studied units
      including the men living in Tehran. In the first phase, a qualitative study of a 
      contractual content analysis approach will be conducted in order to perceive the 
      concept of male reproductive health-related behavior, determine the dimensions of
      the questionnaire, and explore the items. In the second phase, a quantitative
      study will be carried out to evaluate the psychometric properties as well as
      (form, content, and construct) validity and reliability of the instrument
      designed in the first phase. Finally, the instrument will be scored and
      interpreted. DISCUSSION: Discovering men's perception of concept of reproductive 
      health-related behavior can help design a valid and reliable questionnaire which 
      can be used in studies evaluating the male reproductive health-related behavior. 
      ETHICAL CODE: IR.TUMS.FNM.REC.1397.157.
FAU - Geranmayeh, Mehrnaz
AU  - Geranmayeh M
AD  - Department of Midwifery, Faculty of Nursing and Midwifery, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Zareiyan, Armin
AU  - Zareiyan A
AD  - Public Health Department, Nursing Faculty, AjA University of Medical Sciences,
      Tehran, Iran.
FAU - Moghadam, Zahra Behboodi
AU  - Moghadam ZB
AD  - Reproductive Health Department of Reproductive Health Midwifery, School of
      Nursing & Midwifery Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mirghafourvand, Mojgan
AU  - Mirghafourvand M
AD  - Midwifery Department, Social determinants of Health Research Center, Tabriz
      University of Medical Sciences, Tabriz, Iran.
FAU - Sanaati, Fovziye
AU  - Sanaati F
AD  - Department of Midwifery, Faculty of Nursing and Midwifery, Tehran University of
      Medical Sciences, Tehran, Iran. sanaati.favziye@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
SB  - IM
MH  - Adult
MH  - *Health Behavior
MH  - Humans
MH  - Iran
MH  - Male
MH  - Psychometrics/*instrumentation
MH  - Qualitative Research
MH  - Reproducibility of Results
MH  - *Reproductive Health
MH  - Surveys and Questionnaires/*standards
PMC - PMC7398262
OTO - NOTNLM
OT  - Behavior
OT  - Instrument
OT  - Men
OT  - Mixed method
OT  - Qualitative method
OT  - Reproductive health
OT  - Tool
EDAT- 2020/08/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s12978-020-00966-z [doi]
AID - 10.1186/s12978-020-00966-z [pii]
PST - epublish
SO  - Reprod Health. 2020 Aug 3;17(1):118. doi: 10.1186/s12978-020-00966-z.


PMID- 32746819
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 3
TI  - Ethical practice in my work: community health workers' perspectives using
      photovoice in Wakiso district, Uganda.
PG  - 68
LID - 10.1186/s12910-020-00505-2 [doi]
AB  - BACKGROUND: Health service delivery should ensure ethical principles are observed
      at all levels of healthcare. Working towards this goal requires understanding the
      ethics-related priorities and concerns in the day-to-day activities among
      different health practitioners. These practitioners include community health
      workers (CHWs) who are involved in healthcare delivery in communities in many
      low-and middle-income countries such as Uganda. In this study, we used
      photovoice, an innovative community based participatory research method that uses
      photography, to examine CHWs' perspectives on ethical concerns in their work.
      METHODS: We explored perspectives of 10 CHWs (5 females and 5 males) on ethical
      dimensions of their work for 5 months using photovoice in a rural community in
      Wakiso district, Uganda. As part of the study, we: 1. Oriented CHWs on photovoice
      research and ethics; 2. Asked CHWs to take photographs of key ethical dimensions 
      of their work; 3. Held monthly meetings to discuss and reflect on the photos; and
      4. Disseminated the findings. The discussions from the monthly meetings were
      audio recorded, transcribed, and emerging data analysed using conventional
      content analysis with the help of Atlas ti version 6.0.15. RESULTS: CHWs were
      aware of and highly concerned about the need to observe ethical principles while 
      carrying out their roles. The ethical principles CHWs were aware of and
      endeavoured to observe during their work were: maintaining professional integrity
      and abiding by ethical principles of practice; ethical responsibility in patient 
      care; maintaining confidentiality while handling clients; respect for persons and
      communities; and enhancing their knowledge and skills for better practice.
      However, CHWs also identified challenges concerning their observance of ethical
      principles including: low commitment to their work due to other obligations;
      availability of some reference materials and guidelines in English yet majority
      could only read in the local language; and minimal avenues for knowledge
      enhancement such as trainings. CONCLUSIONS: CHWs were aware of and keen to
      discuss ethical issues in their work. However, there is need to address the
      challenges they face so as to facilitate observing ethical principles during the 
      course of their work in communities.
FAU - Musoke, David
AU  - Musoke D
AUID- ORCID: 0000-0003-3262-3918
AD  - Department of Disease Control and Environmental Health, School of Public Health, 
      College of Health Sciences, Makerere University, Kampala, Uganda.
      dmusoke@musph.ac.ug.
FAU - Ssemugabo, Charles
AU  - Ssemugabo C
AD  - Department of Disease Control and Environmental Health, School of Public Health, 
      College of Health Sciences, Makerere University, Kampala, Uganda.
FAU - Ndejjo, Rawlance
AU  - Ndejjo R
AD  - Department of Disease Control and Environmental Health, School of Public Health, 
      College of Health Sciences, Makerere University, Kampala, Uganda.
FAU - Molyneux, Sassy
AU  - Molyneux S
AD  - Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme,
      Kilifi, Kenya.
FAU - Ekirapa-Kiracho, Elizabeth
AU  - Ekirapa-Kiracho E
AD  - Department of Health Policy, Planning and Management, School of Public Health,
      College of Health Sciences, Makerere University, Kampala, Uganda.
LA  - eng
GR  - PO5683/Department for International Development/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200803
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Community Health Workers
MH  - Community-Based Participatory Research
MH  - Female
MH  - Humans
MH  - Male
MH  - *Motivation
MH  - Qualitative Research
MH  - Rural Population
MH  - Uganda
PMC - PMC7397610
OTO - NOTNLM
OT  - *Community health workers
OT  - *Ethical challenges
OT  - *Ethical principles
OT  - *Ethics
OT  - *Photovoice
OT  - *Practice
OT  - *Uganda
EDAT- 2020/08/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/01/28 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00505-2 [doi]
AID - 10.1186/s12910-020-00505-2 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 3;21(1):68. doi: 10.1186/s12910-020-00505-2.


PMID- 32746764
OWN - NLM
STAT- Publisher
LR  - 20200804
IS  - 1541-3764 (Electronic)
IS  - 0030-2228 (Linking)
DP  - 2020 Aug 3
TI  - UK Public's Views and Perceptions About the Legalisation of Assisted Dying and
      Assisted Suicide.
PG  - 30222820947254
LID - 10.1177/0030222820947254 [doi]
AB  - Current debates about assisted dying and assisted suicide cover a series of
      medical, legal, moral, ethical and religious aspects. Yet, public views on the
      subject remain underexplored and, therefore, not always accounted for in the
      formation of public policy. This paper reports on empirical data from a
      cross-sectional study in the UK in 2019, which examines public views about the
      legalisation of assisted dying and assisted suicide, by means of a
      self-administered Qualtrics-based survey (self-devised vignettes). A combination 
      of simple random and convenience sampling was used. Participants (n = 297) state 
      their preference that both assisted dying and assisted suicide should be
      legalised in the UK (n = 70%), while doctors should be legally allowed to support
      such wishes of patients with an incurable and painful illness from which they
      will die (n = 62.22%). The paper concludes that public opinion needs to be
      further accounted for in policymaking and discourses regarding patient autonomy
      and dignity of care.
FAU - Pentaris, Panagiotis
AU  - Pentaris P
AUID- ORCID: https://orcid.org/0000-0001-5593-8555
AD  - School of Human Sciences & Institute for Lifecourse Development, University of
      Greenwich, London, UK.
FAU - Jacobs, Lucy
AU  - Jacobs L
AD  - Social Work Alumni, School of Human Sciences, University of Greenwich, London,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - United States
TA  - Omega (Westport)
JT  - Omega
JID - 1272106
SB  - IM
OTO - NOTNLM
OT  - UK
OT  - assisted dying
OT  - assisted suicide
OT  - euthanasia
OT  - illness
OT  - public
EDAT- 2020/08/05 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [entrez]
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
AID - 10.1177/0030222820947254 [doi]
PST - aheadofprint
SO  - Omega (Westport). 2020 Aug 3:30222820947254. doi: 10.1177/0030222820947254.


PMID- 32746711
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20201218
IS  - 1552-7468 (Electronic)
IS  - 1527-1544 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Nov
TI  - The Ethics of Emergent Health Technologies: Implications of the 21st Century
      Cures Act for Nursing.
PG  - 195-201
LID - 10.1177/1527154420947028 [doi]
AB  - The 21st Century Cures Act, passed in December 2016 by the United States
      Congress, is a public law aimed at accelerating the time it takes to get
      pharmaceutical drugs and medical devices into the market, in addition to shifting
      connected review processes from randomized controlled trials to real-world
      efficacy tests. As of December 2019, efforts are underway to introduce a "Cures
      Act 2.0" bill, with particular attention to the implementation of digital health 
      within health systems. Research on the development of emergent health
      technologies is nascent; research examining health technology implications of
      21st Century Cures Act for the health care workforce is nonexistent. This article
      fills a crucial gap in public awareness, discussing ethical implications of the
      21st Century Cures Act and centering nursing. Nursing is a profession frequently 
      acknowledged as practicing on "the front lines of care" and frequently
      responsible for the trialing of products in clinical settings. The article
      summarizes and evaluates key components of the 21st Century Cures Act related to 
      health technology development. Discrete health technologies addressed are (a)
      breakthrough devices, (b) digital health software, and (c) combination products. 
      It then connects these provisions to ethical considerations for nursing practice,
      research, and policy. The article concludes by discussing the relevance of
      emerging digital health technologies to the crafting of a "Cures 2.0" bill, with 
      particular attention to this moment in light of digital care precedents set
      during the COVID-19 pandemic.
FAU - Martin, Margaret
AU  - Martin M
AUID- ORCID: https://orcid.org/0000-0001-6343-5122
AD  - Department of Social and Behavioral Sciences, School of Nursing, University of
      California, San Francisco.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - United States
TA  - Policy Polit Nurs Pract
JT  - Policy, politics & nursing practice
JID - 100901316
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Technology/*ethics/trends
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/therapy
MH  - Critical Care/ethics
MH  - Forecasting
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/therapy
MH  - Remote Sensing Technology/*ethics/trends
MH  - SARS-CoV-2
MH  - United States
OTO - NOTNLM
OT  - 21st century cures act
OT  - digital health
OT  - ethics
OT  - health equity
OT  - health policy
OT  - nursing
EDAT- 2020/08/05 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/08/05 06:00
PHST- 2020/08/05 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/08/05 06:00 [entrez]
AID - 10.1177/1527154420947028 [doi]
PST - ppublish
SO  - Policy Polit Nurs Pract. 2020 Nov;21(4):195-201. doi: 10.1177/1527154420947028.
      Epub 2020 Aug 3.


PMID- 32745186
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20200814
IS  - 1525-3163 (Electronic)
IS  - 0021-8812 (Linking)
VI  - 98
IP  - 8
DP  - 2020 Aug 1
TI  - Culture, meat, and cultured meat.
LID - skaa172 [pii]
LID - 10.1093/jas/skaa172 [doi]
AB  - Cultured meat grown in vitro from animal cells has the potential to address many 
      of the ethical, environmental, and public health issues associated with
      conventional meat production. However, as well as overcoming technical challenges
      to producing cultured meat, producers and advocates of the technology must
      consider a range of social issues, including consumer appeal and acceptance,
      media coverage, religious status, regulation, and potential economic impacts.
      Whilst much has been written on the prospects for consumer appeal and acceptance 
      of cultured meat, less consideration has been given to the other aspects of the
      social world that will interact with this new technology. Here, each of these
      issues is considered in turn, forming a view of cultured meat as a technology
      with a diverse set of societal considerations and far-reaching social
      implications. It is argued that the potential gains from a transition to cultured
      meat are vast, but that cultural phenomena and institutions must be navigated
      carefully for this nascent industry to meet its potential.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Society of Animal Science.
FAU - Bryant, Christopher J
AU  - Bryant CJ
AD  - Department of Psychology, University of Bath, Claverton Down, Bath, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Anim Sci
JT  - Journal of animal science
JID - 8003002
SB  - IM
MH  - Animals
MH  - *Consumer Behavior
MH  - Culture
MH  - Food Preferences
MH  - *Food Technology
MH  - Humans
MH  - Meat/*supply & distribution
MH  - Tissue Culture Techniques
PMC - PMC7398566
OTO - NOTNLM
OT  - cultured meat
OT  - food technology
OT  - meat alternatives
OT  - regulation
OT  - religion
OT  - social institutions
EDAT- 2020/08/04 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/08/04 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
AID - 5880017 [pii]
AID - 10.1093/jas/skaa172 [doi]
PST - ppublish
SO  - J Anim Sci. 2020 Aug 1;98(8). pii: 5880017. doi: 10.1093/jas/skaa172.


PMID- 32744754
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1099-1751 (Electronic)
IS  - 0749-6753 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Nov
TI  - Motivators for medical staff with a high gap in healthcare efficiency:
      Comparative research from Poland and Ukraine.
PG  - 1314-1334
LID - 10.1002/hpm.3037 [doi]
AB  - INTRODUCTION: This article examines different motivators for medical staff in
      countries with a high gap in healthcare efficiency by comparing them in two
      healthcare systems-Polish (ie efficient) and Ukrainian (ie inefficient). METHOD: 
      This survey-based study applies a six-stage conceptual framework to two Polish
      and two Ukrainian hospitals as well as medical faculties of one university from
      each country. Following ethical approval, data were collected in the first
      quarter of 2019, using the 'Evaluation of motivators questionnaire for medical
      staff'. FINDINGS: Medical staff perceived their working conditions in the
      inefficient healthcare system much worse than in the efficient system; however,
      they generally had a more optimistic outlook. Medical staff in efficient and
      inefficient healthcare systems has different motivational targets, including
      sizable differences from profession, gender, and age. These factors play an
      important role in developing a high-performance healthcare system. Results are
      illustrated in terms of motivators for medical staff. CONCLUSION: Optimising a
      healthcare system requires useful reform of enablers, especially in countries
      with inefficient systems, including policymaking and regulatory action. Best
      practices must incorporate all stakeholders interested in high healthcare
      performance-usage of suitable practices from abroad can act as an important
      resource.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Goncharuk, Anatoliy G
AU  - Goncharuk AG
AUID- ORCID: https://orcid.org/0000-0001-9870-4679
AD  - Department of Management, International Humanitarian University, Odessa, Ukraine.
FAU - Lewandowski, Roman
AU  - Lewandowski R
AD  - Faculty of Management, University of Social Sciences, Lodz, Poland.
AD  - Voivodeship Rehabilitation Hospital for Children in Ameryka, Ameryka, Poland.
FAU - Cirella, Giuseppe T
AU  - Cirella GT
AUID- ORCID: https://orcid.org/0000-0002-0810-0589
AD  - Faculty of Economics, University of Gdansk, Sopot, Poland.
LA  - eng
GR  - European Cooperation in Science and Technology
GR  - 2015/17/B/HS4/02747/Narodowe Centrum Nauki
PT  - Journal Article
DEP - 20200803
PL  - England
TA  - Int J Health Plann Manage
JT  - The International journal of health planning and management
JID - 8605825
MH  - *Delivery of Health Care
MH  - Humans
MH  - Medical Staff
MH  - *Motivation
MH  - Poland
MH  - Ukraine
OTO - NOTNLM
OT  - health professionals
OT  - healthcare system
OT  - incentives
OT  - motivation
OT  - survey methods
EDAT- 2020/08/04 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/08/04 06:00 [entrez]
AID - 10.1002/hpm.3037 [doi]
PST - ppublish
SO  - Int J Health Plann Manage. 2020 Nov;35(6):1314-1334. doi: 10.1002/hpm.3037. Epub 
      2020 Aug 3.


PMID- 32744518
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20201027
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 161
DP  - 2020 Jul 16
TI  - A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused
      Ultrasound System for Blood-Brain Barrier Opening in Rodents.
LID - 10.3791/61269 [doi]
AB  - The blood-brain barrier (BBB) has been a major hurdle for the treatment of
      various brain diseases. Endothelial cells, connected by tight junctions, form a
      physiological barrier preventing large molecules (>500 Da) from entering the
      brain tissue. Microbubble-mediated focused ultrasound (FUS) can be used to induce
      a transient local BBB opening, allowing larger drugs to enter the brain
      parenchyma. In addition to large-scale clinical devices for clinical translation,
      preclinical research for therapy response assessment of drug candidates requires 
      dedicated small animal ultrasound setups for targeted BBB opening. Preferably,
      these systems allow high-throughput workflows with both high-spatial precision as
      well as integrated cavitation monitoring, while still being cost effective in
      both initial investment and running costs. Here, we present a bioluminescence and
      X-ray guided stereotactic small animal FUS system that is based on commercially
      available components and fulfills the aforementioned requirements. A particular
      emphasis has been placed on a high degree of automation facilitating the
      challenges typically encountered in high-volume preclinical drug evaluation
      studies. Examples of these challenges are the need for standardization in order
      to ensure data reproducibility, reduce intra-group variability, reduce sample
      size and thus comply with ethical requirements and decrease unnecessary workload.
      The proposed BBB system has been validated in the scope of BBB opening
      facilitated drug delivery trials on patient-derived xenograft models of
      glioblastoma multiforme and diffuse midline glioma.
FAU - Haumann, Rianne
AU  - Haumann R
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center
      Amsterdam; Princess Maxima Center for Pediatric Oncology;
      r.haumann1@amsterdamumc.nl.
FAU - 't Hart, Elvin
AU  - 't Hart E
AD  - Princess Maxima Center for Pediatric Oncology.
FAU - Derieppe, Marc P P
AU  - Derieppe MPP
AD  - Princess Maxima Center for Pediatric Oncology.
FAU - Besse, Helena C
AU  - Besse HC
AD  - Imaging Division, Utrecht University.
FAU - Kaspers, Gertjan J L
AU  - Kaspers GJL
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center
      Amsterdam; Princess Maxima Center for Pediatric Oncology.
FAU - Hoving, Eelco
AU  - Hoving E
AD  - Princess Maxima Center for Pediatric Oncology.
FAU - van Vuurden, Dannis G
AU  - van Vuurden DG
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center
      Amsterdam; Princess Maxima Center for Pediatric Oncology.
FAU - Hulleman, Esther
AU  - Hulleman E
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center
      Amsterdam; Princess Maxima Center for Pediatric Oncology;
      E.Hulleman@prinsesmaximacentrum.nl.
FAU - Ries, Mario
AU  - Ries M
AD  - Imaging Division, Utrecht University.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
DEP - 20200716
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
SB  - IM
MH  - Animals
MH  - Blood-Brain Barrier/*diagnostic imaging
MH  - Disease Models, Animal
MH  - Humans
MH  - Imaging, Three-Dimensional/*methods
MH  - Mice
MH  - Neuronavigation/*methods
MH  - Rodentia
MH  - Ultrasonography/*methods
EDAT- 2020/08/04 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
AID - 10.3791/61269 [doi]
PST - epublish
SO  - J Vis Exp. 2020 Jul 16;(161). doi: 10.3791/61269.


PMID- 32743828
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1440-1630 (Electronic)
IS  - 0045-0766 (Linking)
VI  - 67
IP  - 4
DP  - 2020 Aug
TI  - Authorship statements: A commitment to publishing ethics and research integrity.
PG  - 285-286
LID - 10.1111/1440-1630.12688 [doi]
FAU - Gustafsson, Louise
AU  - Gustafsson L
AUID- ORCID: 0000-0001-5232-0987
LA  - eng
PT  - Editorial
PL  - Australia
TA  - Aust Occup Ther J
JT  - Australian occupational therapy journal
JID - 15420200R
SB  - IM
MH  - *Authorship
MH  - Conflict of Interest
MH  - *Editorial Policies
MH  - *Ethics, Professional
MH  - Humans
MH  - Occupational Therapy
MH  - Periodicals as Topic/*ethics
EDAT- 2020/08/04 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1111/1440-1630.12688 [doi]
PST - ppublish
SO  - Aust Occup Ther J. 2020 Aug;67(4):285-286. doi: 10.1111/1440-1630.12688.


PMID- 32743090
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 7
DP  - 2020 Jul
TI  - Making sense in the flood. How to cope with the massive flow of digital
      information in medical ethics.
PG  - e04426
LID - 10.1016/j.heliyon.2020.e04426 [doi]
AB  - Scientific publications have become the currency of Academia, hence the concept
      of 'publish or perish'. But there are consequences: the amount of existing
      literature and its proliferation rate have reached the point where keeping pace
      is just impossible. If this is true in general, it becomes a huge issue in
      interdisciplinary fields such as bioethics where knowing the state of the art in 
      more than one single discipline is a concrete necessity. If we accept the idea of
      building new science on an exhaustive comprehension of existing knowledge, a
      radical change is needed. Smart iterative search strategies, frequency analysis
      and text mining, techniques described in this paper, can't be a long run
      solution. But they might serve as a useful coping strategy.
CI  - (c) 2020 The Author.
FAU - Spitale, Giovanni
AU  - Spitale G
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7385457
OTO - NOTNLM
OT  - Content analysis
OT  - Data mining
OT  - Information extraction
OT  - Information management
OT  - Information science
OT  - Information systems management
OT  - Information technology
OT  - Knowledge representation
OT  - Publications' proliferation
OT  - Search strategies
OT  - Text mining
OT  - Topic tracking
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2019/10/08 00:00 [received]
PHST- 2020/01/20 00:00 [revised]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04426 [doi]
AID - S2405-8440(20)31270-6 [pii]
AID - e04426 [pii]
PST - epublish
SO  - Heliyon. 2020 Jul 24;6(7):e04426. doi: 10.1016/j.heliyon.2020.e04426. eCollection
      2020 Jul.


PMID- 32742876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 29
TI  - 25(OH)D Serum Level in Non-Diabetic and Type II Diabetic Patients: A
      Cross-Sectional Study.
PG  - e8910
LID - 10.7759/cureus.8910 [doi]
AB  - Background Diabetes mellitus is a major disease worldwide. In Saudi Arabia, it is
      considered to be the most common disease in the country. Diabetes mellitus has
      been also found to be associated with 25(OH)D (vitamin D) deficiency. In Saudi
      Arabia, sunlight is considered a major source for vitamin D. Saudi Arabia is
      popular for sunny weather most of the year, in which people can get vitamin D
      from the sun. However, vitamin D deficiency is common in Saudi Arabia, and its
      deficiency can increase blood glucose levels. We conducted a study to determine
      the reason for vitamin D deficiency in Saudi Arabia and to assess the
      relationship of diabetes mellitus with vitamin D. Aim of the work This study is
      aimed to assess the incidence of vitamin D deficiency in non-diabetic and type II
      diabetic patients in the King Faisal University (KFU) Health Center in the
      Al-Ahsa region. Methods Our study is a cross-sectional study that was carried out
      at the KFU Health Center in Saudi Arabia. Ethical approval was obtained from the 
      Ethics and Research Committee at the College of Medicine at King Faisal
      University. The study period was from January 2016 to April 2016. We collected
      each patient's vitamin D serum level, glycosylated hemoglobin (HbA1c), and
      fasting blood glucose at the same time for each patient's particular visit to the
      hospital. Data were analyzed using the Statistical Package for Social Sciences
      (SPSS) (IBM SPSS Statistics, Armonk, NY). Results Our results showed that 89.53% 
      of the patients had a vitamin D level below the normal range. There was a higher 
      incidence of vitamin D deficiency in females (81.67%) than in males (65.27%)
      (p-value = 0.001). The incidence of vitamin D deficiency was greater in Saudi
      (82.19%) than non-Saudi patients (68.40%) (p-value = 0.001), as well as in
      diabetics (89.68%) than non-diabetics (76.12%) patients (p-value = 0.001). Within
      each group, the incidence of vitamin D deficiency was higher in females than in
      males. The incidence of vitamin D deficiency was highest in the age group of 21
      to 40 years old (86.19%) and lowest in the age group of one to 20 years old
      (66.1%). The results showed an inverse relationship between the vitamin D level
      and both fasting blood glucose and HbA1c (independent sample t-test) were used
      for correlation. The mean fasting glucose was higher in the deficiency group
      (165.55) as compared to the insufficiency group (118.67). Also, the mean HbA1c
      was higher in the deficiency group (8.06) as compared to the insufficiency group 
      (7.23) (p-value = 0.030). Conclusions There was a high incidence of vitamin D
      deficiency among KFU Health Center patients. The vitamin D level was inversely
      proportional to the level of fasting glucose and HbA1c. There is an evident role 
      of vitamin D deficiency on glucose tolerance in diabetic patients.
CI  - Copyright (c) 2020, AlHewishel et al.
FAU - AlHewishel, Mohmmed A
AU  - AlHewishel MA
AD  - Internal Medicine, King Faisal University, Al-Ahsa, SAU.
FAU - Bahgat, Mohammed
AU  - Bahgat M
AD  - Biomedical Sciences, King Faisal University, Al-Ahsa, SAU.
FAU - Al Huwaiyshil, Abdullah
AU  - Al Huwaiyshil A
AD  - Internal Medicine, King Faisal University, Al-Ahsa, SAU.
FAU - Alsubie, Mustafa A
AU  - Alsubie MA
AD  - Internal Medicine, King Faisal University, Al-Ahsa, SAU.
FAU - Alhassan, Abdullah
AU  - Alhassan A
AD  - Internal Medicine, King Faisal University, Al-Ahsa, SAU.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7389939
OTO - NOTNLM
OT  - 25 hydroxyvitamin d
OT  - diabetes type ii
OT  - non-diabetic
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.7759/cureus.8910 [doi]
PST - epublish
SO  - Cureus. 2020 Jun 29;12(6):e8910. doi: 10.7759/cureus.8910.


PMID- 32742717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2055-2076 (Print)
IS  - 2055-2076 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - Exploring the equity impact of mobile health-based human immunodeficiency virus
      interventions: A systematic review of reviews and evidence synthesis.
PG  - 2055207620942360
LID - 10.1177/2055207620942360 [doi]
AB  - OBJECTIVE: While mobile health-based human immunodeficiency virus (HIV)
      interventions are often designed to promote health equity, systematic differences
      in the use of and access to mobile technologies may counteract that and widen
      treatment gaps. This systematic review applies an equity lens to investigate
      whether existing research provides adequate evidence on the ethical implications 
      of mHealth technologies in HIV treatment and prevention. METHODS: This study
      included a two-stage methodology, consisting of (a) a systematic review of
      systematic reviews and (b) an evidence synthesis of primary studies. For the
      review of reviews we searched eight electronic databases, eight electronic
      journals and Google Scholar. We also screened reference lists and consulted
      authors of included studies. Primary studies were extracted from eligible
      reviews. We based our data extraction and analysis on the Place of residence,
      Race, Occupation, Gender/Sex, Religion, Education, Socioeconomic status, Social
      capital and other disadvantage related characteristics (PROGRESS-Plus) framework 
      and the use of harvest plots, focusing on the socio-demographic distribution of
      mHealth effects. RESULTS: A total of 8786 citations resulted in 19 eligible
      reviews and 39 eligible primary studies. Existing reviews did not provide any
      analyses of the equity impacts of mobile health-based HIV initiatives.
      Information availability was higher in primary studies, predominantly suggesting 
      no social gradient of mobile health-based HIV interventions. Overall, evidence
      remains weak and not sufficient to allow for confident equity statements.
      CONCLUSIONS: Despite the negative force of socio-demographic inequities and the
      emerging nature of mobile health technologies, evidence on the equity
      implications of mobile health interventions for HIV care remains scarce. Not
      knowing how the effects of mobile health technologies differ across population
      subgroups inevitably limits our capacities to equitably adopt, adjust and
      integrate mobile health interventions towards reaching those disproportionally
      affected by the epidemic.
CI  - (c) The Author(s) 2020.
FAU - Nittas, Vasileios
AU  - Nittas V
AUID- ORCID: https://orcid.org/0000-0002-6685-8275
AD  - Department of Social Policy and Intervention, University of Oxford, UK.
AD  - Green Templeton College, University of Oxford, UK.
FAU - Ameli, Vira
AU  - Ameli V
AD  - Department of Social Policy and Intervention, University of Oxford, UK.
AD  - Green Templeton College, University of Oxford, UK.
FAU - Little, Madison
AU  - Little M
AD  - Department of Social Policy and Intervention, University of Oxford, UK.
AD  - Green Templeton College, University of Oxford, UK.
FAU - Humphreys, David K
AU  - Humphreys DK
AD  - Department of Social Policy and Intervention, University of Oxford, UK.
AD  - Green Templeton College, University of Oxford, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200720
PL  - United States
TA  - Digit Health
JT  - Digital health
JID - 101690863
PMC - PMC7375713
OTO - NOTNLM
OT  - Mobile health
OT  - eHealth
OT  - human immunodeficiency virus
OT  - inequalities
OT  - socioeconomic factors
OT  - telehealth
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.1177/2055207620942360 [doi]
AID - 10.1177_2055207620942360 [pii]
PST - epublish
SO  - Digit Health. 2020 Jul 20;6:2055207620942360. doi: 10.1177/2055207620942360.
      eCollection 2020 Jan-Dec.


PMID- 32742716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2055-2076 (Print)
IS  - 2055-2076 (Linking)
VI  - 6
DP  - 2020 Jan-Dec
TI  - How does the use of digital consulting change the meaning of being a patient
      and/or a health professional? Lessons from the Long-term Conditions Young People 
      Networked Communication study.
PG  - 2055207620942359
LID - 10.1177/2055207620942359 [doi]
AB  - BACKGROUND: While studies have examined the impact of digital communication
      technology on healthcare, there is little exploration of how new models of
      digital care change the roles and identities of the health professional and
      patient. The purpose of the current study is to generate multidisciplinary
      reflections and questions around the use of digital consulting and the way it
      changes the meaning of being a patient and/or a health professional. METHOD: We
      used a large pre-existing qualitative dataset from the Long-term Conditions Young
      People Networked Communication (LYNC) study which involved interviews with
      healthcare professionals and a group of 16-24 years patients with long-term
      physical and mental health conditions. We conducted a three-stage mixed methods
      analysis. First, using a small sample of interview data from the LYNC study, we
      identified three key themes to explore in the data and relevant academic
      literature. Second, in small groups we conducted secondary analysis of samples of
      patient and health professional LYNC interview data. Third, we ran a series of
      rapid evidence reviews. FINDINGS: We identified three key themes: workload/flow, 
      impact of increased access to healthcare and vulnerabilities. Both health
      professionals and patients were 'on duty' in their role more often. Increased
      access to healthcare introduced more responsibilities to both patients and health
      professionals. Traditional concepts in medical ethics, confidentiality, empathy, 
      empowerment/power, efficiency and mutual responsibilities are reframed in the
      context of digital consulting. CONCLUSIONS: Our collaboration identified
      conflicts and constraints in the construction of digital patients and digital
      clinicians. There is evidence that digital technologies change the nature of a
      medical consultation and with it the identities and the roles of clinicians and
      patients which, in turn, calls for a redefinition of traditional concepts of
      medical ethics. Overall, digital consulting has the potential to significantly
      reduce costs while maintaining or improving patient care and clinical outcomes.
      Timely study of digital engagement in the National Health Service is a matter of 
      critical importance.
CI  - (c) The Author(s) 2020.
FAU - Sturt, Jackie
AU  - Sturt J
AD  - The Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care,
      King's College London, UK.
FAU - Huxley, Caroline
AU  - Huxley C
AUID- ORCID: https://orcid.org/0000-0001-9755-6096
AD  - The Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care,
      King's College London, UK.
FAU - Ajana, Btihaj
AU  - Ajana B
AD  - Department of Digital Humanities, King's College London, UK.
FAU - Gainty, Caitjan
AU  - Gainty C
AD  - Department of History, King's College London, UK.
FAU - Gibbons, Chris
AU  - Gibbons C
AD  - Accenture Consulting, UK.
FAU - Graham, Tanya
AU  - Graham T
AD  - The Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care,
      King's College London, UK.
FAU - Khadjesari, Zarnie
AU  - Khadjesari Z
AUID- ORCID: https://orcid.org/0000-0002-2958-9555
AD  - School of Health Sciences, University of East Anglia, UK.
FAU - Lucivero, Federica
AU  - Lucivero F
AD  - Nuffield Department of Population Health, University of Oxford, UK.
FAU - Rogers, Rebecca
AU  - Rogers R
AD  - The Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care,
      King's College London, UK.
FAU - Smol, Annie
AU  - Smol A
AD  - Face Front Inclusive Theatre, UK.
FAU - Watkins, Jocelyn A
AU  - Watkins JA
AUID- ORCID: https://orcid.org/0000-0003-4984-1057
AD  - Warwick Medical School, University of Warwick, UK.
FAU - Griffiths, Frances
AU  - Griffiths F
AUID- ORCID: https://orcid.org/0000-0002-4173-1438
AD  - Warwick Medical School, University of Warwick, UK.
AD  - Centre for Health Policy, University of the Witwatersrand, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200720
PL  - United States
TA  - Digit Health
JT  - Digital health
JID - 101690863
PMC - PMC7375714
OTO - NOTNLM
OT  - Digital health
OT  - Long-term Conditions Young People Networked Communication
OT  - access
OT  - digital consulting
OT  - empowerment
OT  - healthcare professional
OT  - identity
OT  - patient
OT  - power
OT  - workload
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2019/10/21 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.1177/2055207620942359 [doi]
AID - 10.1177_2055207620942359 [pii]
PST - epublish
SO  - Digit Health. 2020 Jul 20;6:2055207620942359. doi: 10.1177/2055207620942359.
      eCollection 2020 Jan-Dec.


PMID- 32742662
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2051-6673 (Print)
IS  - 2051-6673 (Linking)
VI  - 7
DP  - 2020
TI  - Euthanasia and assisted suicide in patients with personality disorders: a review 
      of current practice and challenges.
PG  - 15
LID - 10.1186/s40479-020-00131-9 [doi]
AB  - BACKGROUND: Over the last two decades an increasing number of countries have
      legalized euthanasia and physician-assisted suicide (EAS) leading to considerable
      debate over the inherent ethical dilemmas. Increasing numbers of people with
      personality disorders, faced with unbearable suffering, have requested and
      received assistance in terminating their lives. EAS in people with personality
      disorders has, however, received very sparse attention from clinicians and
      researchers. In this paper, we examine the literature on the practice and
      prevalence of EAS in people with personality disorders to date and discuss the
      associated challenges for research and practice. METHODS: Narrative review of the
      literature combined with the authors' collective experience and knowledge of
      personality disorders. RESULTS: In six of the eight countries where EAS is
      currently legal, mental disorders are accepted as disorders for which EAS may be 
      granted. In four of these countries, EAS in minors with mental disorders is also 
      accepted. Our literature search resulted in 9 papers on the subject of EAS in
      people with personality disorders. These studies suggest that most clinicians who
      grant EAS have indeed perceived their patients' suffering as chronic, unbearable 
      and untreatable without prospect of improvement. The majority of patients with
      personality disorders had tried some form of psychotherapy, but very few had
      received any of the relevant evidence-based treatments. The decision to grant EAS
      based on a perception of the patient's illness as being untreatable with no
      prospect of improvement, could, thus, in many cases fail to meet the due care
      criteria listed in EAS laws. People with personality disorders more often wish
      for death for extended periods of time than people without these disorders.
      However, there is ample empirical data to show that suicidal tendencies and
      behaviour can be treated and that they fluctuate rapidly over time. CONCLUSIONS: 
      In light of our findings, we believe that the current legislation and practice of
      EAS for people with personality disorders is based on an inadequate understanding
      of underlying psychopathology and a lack of awareness about the contemporary
      treatment literature. Moreover, we assert that this practice neglects the
      individual's potential for having a life worth living.
CI  - (c) The Author(s) 2020.
FAU - Mehlum, Lars
AU  - Mehlum L
AUID- ORCID: 0000-0003-2813-0045
AD  - National Centre for Suicide Research and Prevention, Institute of Clinical
      Medicine, University of Oslo, Oslo, Norway.grid.5510.10000 0004 1936 8921
FAU - Schmahl, Christian
AU  - Schmahl C
AD  - Department of Psychosomatic Medicine and Psychotherapy, Central Institute of
      Mental Health, Heidelberg University, Mannheim, Germany.grid.7700.00000 0001 2190
      4373
FAU - Berens, Ann
AU  - Berens A
AD  - University Psychiatric Centre Duffel, CAPRI, faculty Medicine and Health
      Sciences, University Antwerp, Antwerp, Belgium.grid.5284.b0000 0001 0790 3681
FAU - Doering, Stephan
AU  - Doering S
AD  - Department of Psychoanalysis and Psychotherapy, Medical University of Vienna,
      Vienna, Austria.grid.22937.3d0000 0000 9259 8492
FAU - Hutsebaut, Joost
AU  - Hutsebaut J
AD  - De Viersprong Institute for Studies on Personality Disorders, Bergen op Zoom, The
      Netherlands.grid.487405.a
FAU - Kaera, Andres
AU  - Kaera A
AD  - Kanta-Hame Central Hospital, Hameenlinna, Finland.grid.413739.b0000 0004 0628
      3152
FAU - Kramer, Ueli
AU  - Kramer U
AD  - Department of Psychiatry, University of Lausanne, Lausanne,
      Switzerland.grid.9851.50000 0001 2165 4204
FAU - Moran, Paul Anthony
AU  - Moran PA
AD  - Centre for Academic Mental Health, Department of Population Health Sciences,
      Bristol Medical School, University of Bristol, Bristol, UK.grid.5337.20000 0004
      1936 7603
FAU - Renneberg, Babette
AU  - Renneberg B
AD  - Freie Universitat, Berlin, Germany.grid.14095.390000 0000 9116 4836
FAU - Ribaudi, Joaquim Soler
AU  - Ribaudi JS
AD  - Department of Psychiatry and Legal Medicine, Hospital de la Santa Creu i Sant
      Pau, Autonomous University of Barcelona, UAB, Barcelona, Spain.grid.7080.f
AD  - Centro de Investigacion Biomedica en Red de Salud Mental, CIBERSAM, Madrid,
      Spain.grid.469673.9
FAU - Simonsen, Sebastian
AU  - Simonsen S
AD  - Stolpegaard Psychotherapy Centre, Copenhagen, Denmark.
FAU - Swales, Michaela
AU  - Swales M
AD  - NWCPP, School of Psychology, Bangor University, Bangor,
      UK.grid.7362.00000000118820937
FAU - Taubner, Svenja
AU  - Taubner S
AD  - Institute for Psychosocial Prevention, University-Hospital Heidelberg,
      Heidelberg, Germany.grid.5253.10000 0001 0328 4908
FAU - di Giacomo, Ester
AU  - di Giacomo E
AD  - School of Medicine and Surgery, University of Milan-Bicocca, Milan,
      Italy.grid.7563.70000 0001 2174 1754
AD  - Psychiatric Department-ASST Monza, Monza, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - England
TA  - Borderline Personal Disord Emot Dysregul
JT  - Borderline personality disorder and emotion dysregulation
JID - 101650634
PMC - PMC7391495
OTO - NOTNLM
OT  - Euthanasia
OT  - Personality disorder
OT  - Physician-assisted suicide
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.1186/s40479-020-00131-9 [doi]
AID - 131 [pii]
PST - epublish
SO  - Borderline Personal Disord Emot Dysregul. 2020 Jul 30;7:15. doi:
      10.1186/s40479-020-00131-9. eCollection 2020.


PMID- 32742643
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 2048-6790 (Electronic)
IS  - 2048-6790 (Linking)
VI  - 9
DP  - 2020
TI  - Prevalence of overweight/obesity, anaemia and their associations among female
      university students in Dubai, United Arab Emirates: a cross-sectional study.
PG  - e26
LID - 10.1017/jns.2020.23 [doi]
AB  - The present study assessed the associations of overweight, obesity and anaemia
      with selected lifestyle factors, total body fat and abdominal obesity among
      female university students in Dubai. A total of 251 female students from a
      national university in Dubai participated in the present study. Weight, height,
      waist circumference, Hb level and total body fat percentage were measured.
      Participants also completed a self-reported questionnaire that included items
      related to the factors of obesity, anaemia and lifestyle. The study was approved 
      by the University Ethical Committee. Almost one-third of the participants were
      overweight/obese; 85 % had abdominal obesity while 181 % had anaemia. Out of the 
      total, 717 % reported that they have irregular meals and the highest percentages 
      were found among obese (893 %) and overweight (780 %) compared with normal-weight
      (654 %) students (P < 005). Overweight/obese students reported that they exercise
      more than those of normal weight (P = 005). Students with anaemia reported less
      exercise than students without anaemia (P = 005). Also, the percentage of total
      body fat was found to be the highest (389 %) among students with anaemia (P <
      005). Overweight, obesity and anaemia are prevalent among female university
      students. Anaemia seems to be associated with the percentage of total body fat,
      lack of physical activity and junk food. Further studies are required to
      investigate the detailed dietary habits of overweight and obese young adult
      females with anaemia.
CI  - (c) The Author(s) 2020.
FAU - Al Sabbah, Haleama
AU  - Al Sabbah H
AUID- ORCID: 0000-0001-7357-5823
AD  - Public Health Nutrition Department, Zayed University, Dubai, United Arab
      Emirates.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - J Nutr Sci
JT  - Journal of nutritional science
JID - 101590587
SB  - IM
MH  - Adolescent
MH  - Adolescent Health
MH  - Anemia/*epidemiology
MH  - Anthropometry
MH  - Cross-Sectional Studies
MH  - *Feeding Behavior
MH  - Female
MH  - Humans
MH  - Obesity/*epidemiology
MH  - Overweight/epidemiology
MH  - Prevalence
MH  - Students
MH  - United Arab Emirates/epidemiology
MH  - Universities
MH  - Women's Health
MH  - Young Adult
PMC - PMC7372161
OTO - NOTNLM
OT  - *Anaemia
OT  - *Females
OT  - *Obesity
OT  - *Overweight
OT  - *UAE, United Arab Emirates
OT  - *United Arab Emirates
OT  - *WC, waist circumference
EDAT- 2020/08/04 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
AID - 10.1017/jns.2020.23 [doi]
PST - epublish
SO  - J Nutr Sci. 2020 Jul 6;9:e26. doi: 10.1017/jns.2020.23. eCollection 2020.


PMID- 32742535
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210201
IS  - 1931-3918 (Print)
IS  - 1931-3918 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Feb
TI  - Guidelines and Recommendations for Training Ethical Alcohol Researchers.
PG  - 52-59
LID - 10.1037/tep0000257 [doi]
AB  - Research on alcohol use presents several ethical challenges, and therefore,
      training of ethical alcohol researchers is particularly important. While the
      Helsinki Declaration (World Medical Association, 2001), Belmont Report (National 
      Commission for the Protection of Human Subjects of Biomedical and Behavioral
      Research, 1978), and American Psychological Association's (APA) Ethics Code
      (2002) provide ethical guidelines and aspirational principles for researchers,
      there are a number of areas in which these principles allow for judgment. For
      trainees in particular, this ambiguity may be disconcerting. Along with these
      broader principles, there are also specific considerations for training alcohol
      researchers in the responsible conduct of research, which may further complicate 
      matters for trainees. Although alcohol research is an important avenue for
      understanding a large public health concern and investigating risk and protective
      factors associated with use, it also presents a number of ethical and legal
      challenges for researchers. Working with high-risk drinking populations presents 
      unique ethical and legal challenges in the areas of informed consent,
      confidentiality, compensation, and risk-benefit ratios. Additionally, alcohol
      administration studies present challenges for those supervising, as well as
      conducting, such experiments. New technology, such as the use of ecological
      momentary assessment (EMA) or other ambulatory assessment methods to examine
      risky and illegal behaviors, also presents new ethical challenges that are likely
      to continue to evolve in the coming years for trainees. Specific recommendations 
      for handling a variety of concerns that may arise when conducting alcohol
      research are provided. Additionally, suggestions for improving the training of
      ethical alcohol researchers are discussed.
FAU - Davis, Christal N
AU  - Davis CN
AD  - University of Missouri - Columbia, 12 McAlester Hall, Columbia, MO 65211, Voice: 
      (662) 816-1919.
LA  - eng
GR  - T32 AA013526/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Train Educ Prof Psychol
JT  - Training and education in professional psychology
JID - 101465137
PMC - PMC7394467
MID - NIHMS1025413
OTO - NOTNLM
OT  - alcohol research
OT  - research ethics
OT  - supervision
OT  - training
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.1037/tep0000257 [doi]
PST - ppublish
SO  - Train Educ Prof Psychol. 2020 Feb;14(1):52-59. doi: 10.1037/tep0000257.


PMID- 32742409
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 20
IP  - 2
DP  - 2020 Aug
TI  - Changes in the levels of IL-1beta, cortisol and chromogranin A in saliva of
      subjects with occupational fatigue.
PG  - 1782-1788
LID - 10.3892/etm.2020.8799 [doi]
AB  - Changes in the levels of interleukin-1beta (IL-1beta), cortisol and chromogranin 
      A (CgA) in saliva of subjects with occupational fatigue were investigated.
      Doctors in the Emergency Department were selected as research subjects. Saliva
      was collected before work (after full rest) and after work (>/=24 h).
      Electroencephalogram (EEG) was performed. Enzyme-linked immunosorbent assay
      (ELISA) was used to detect the levels of IL-1beta, cortisol and CgA in saliva. In
      order to obtain permission for human specimens, the study was approved by the
      Ethics Committee of the Affiliated Hospital of Hebei University of Engineering
      and registered for clinical trials (registration no. ChiC-TR-DCD-14005746). As
      there were only 4 subjects in this study without fatigue waves in EEG, and the
      number of these subjects was not sufficient to constitute a control group, the
      comparison of the contents of IL-1beta, cortisol and CgA of all subjects before
      and after working for 18 h was just a confirmation of the statistical results of 
      43 cases with fatigue waves in the EEG. According to the results, there was no
      change in the contents of IL-1beta and cortisol in the saliva of subjects with
      occupational fatigue before and after fatigue, whereas, there was a significant
      change in the content of CgA before and after fatigue. However, there was no
      correlation between the content of CgA and fatigue. The results of the present
      study revealed that IL-1beta, cortisol and CgA indicators are not suitable
      diagnostic markers for occupational fatigue.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Ding, Min
AU  - Ding M
AD  - Central Laboratory, Medical College, Hebei University of Engineering, Handan,
      Hebei 056038, P.R. China.
FAU - Zhao, Chaoxian
AU  - Zhao C
AD  - Department of Biochemistry, Medical College, Hebei University of Engineering,
      Handan, Hebei 056002, P.R. China.
FAU - Li, Yan
AU  - Li Y
AD  - Emergency Department, Affiliated Hospital of Hebei University of Engineering,
      Handan, Hebei 056002, P.R. China.
FAU - Liu, Xiaoxia
AU  - Liu X
AD  - Department of Biochemistry, Medical College, Hebei University of Engineering,
      Handan, Hebei 056002, P.R. China.
FAU - Wang, Xueling
AU  - Wang X
AD  - Central Laboratory, Medical College, Hebei University of Engineering, Handan,
      Hebei 056038, P.R. China.
FAU - Liu, Fengli
AU  - Liu F
AD  - Department of Epidemiology, Medical College, Hebei University of Engineering,
      Handan, Hebei 056038, P.R. China.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Biochemistry, Medical College, Hebei University of Engineering,
      Handan, Hebei 056002, P.R. China.
FAU - Xiong, Nanyan
AU  - Xiong N
AD  - Department of Biochemistry, Medical College, Hebei University of Engineering,
      Handan, Hebei 056002, P.R. China.
FAU - Song, Yonghong
AU  - Song Y
AD  - Department of Biochemistry, Medical College, Hebei University of Engineering,
      Handan, Hebei 056002, P.R. China.
FAU - Xu, Yanli
AU  - Xu Y
AD  - Department of Epidemiology, Medical College, Hebei University of Engineering,
      Handan, Hebei 056038, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7388265
OTO - NOTNLM
OT  - chromogranin A
OT  - cortisol
OT  - interleukin-1beta
OT  - occupational fatigue
OT  - saliva
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2019/04/23 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.3892/etm.2020.8799 [doi]
AID - ETM-0-0-8799 [pii]
PST - ppublish
SO  - Exp Ther Med. 2020 Aug;20(2):1782-1788. doi: 10.3892/etm.2020.8799. Epub 2020 May
      27.


PMID- 32742244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211105
IS  - 1556-5068 (Electronic)
IS  - 1556-5068 (Linking)
DP  - 2020 Jul 16
TI  - The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of
      Germinal Centers in COVID-19.
PG  - 3652322
LID - 10.2139/ssrn.3652322 [doi]
AB  - Humoral responses in COVID-19 disease are often of limited durability, as seen
      with other human coronavirus epidemics. To address the underlying etiology, we
      examined postmortem thoracic lymph nodes and spleens in acute SARS-CoV-2
      infection and observed the absence of germinal centers, a striking reduction in
      Bcl-6+ germinal center B cells but preservation of AID+ B cells. Absence of
      germinal centers correlated with an early specific block in Bcl-6+TFH&nbsp;cell
      differentiation together with an increase in T-bet+TH1 cells and aberrant
      extra-follicular TNF-a accumulation.&nbsp; Parallel peripheral blood studies
      revealed loss of transitional and follicular B cells in severe disease and
      accumulation of SARS-CoV-2-specific "disease-related" B cell populations. These
      data identify defective Bcl-6+TFH cell generation and dysregulated humoral immune
      induction early in COVID-19 disease, providing a mechanistic explanation for the 
      limited durability of antibody responses in coronavirus infections and suggest
      that achieving herd immunity through natural infection may be difficult. Funding:
      This work was supported by NIH U19 AI110495 to SP, NIH R01 AI146779 to AGS, NIH
      R01AI137057 and DP2DA042422 to DL, BMH was supported by NIGMS T32 GM007753, TMC
      was supported by T32 AI007245. Funding for these studies from the Massachusetts
      Consortium of Pathogen Readiness, the Mark and Lisa Schwartz Foundation and Enid 
      Schwartz is also acknowledged. Conflict of Interest: None. Ethical Approval: This
      study was performed with the approval of the Institutional Review Boards at the
      Massachusetts General Hospital and the Brigham and Women's Hospital.
FAU - Kaneko, Naoki
AU  - Kaneko N
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Kuo, Hsiao-Hsuan
AU  - Kuo HH
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Boucau, Julie
AU  - Boucau J
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Farmer, Jocelyn R
AU  - Farmer JR
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Allard-Chamard, Hugues
AU  - Allard-Chamard H
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Division of Rheumatology, Faculte de medecine et des sciences de la sante de l'
      Universite de Sherbrooke et Centre de Recherche Clinique Etienne-Le Bel,
      Sherbrooke, Quebec, J1K 2R1, Canada.
FAU - Mahajan, Vinay S
AU  - Mahajan VS
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115.
FAU - Piechocka-Trocha, Alicja
AU  - Piechocka-Trocha A
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Howard Hughes Medical Institute, Chevy Chase MD, 20815.
FAU - Lefteri, Kristina
AU  - Lefteri K
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Osborn, Matt
AU  - Osborn M
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Bals, Julia
AU  - Bals J
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Bartsch, Yannic C
AU  - Bartsch YC
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Bonheur, Nathalie
AU  - Bonheur N
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Caradonna, Timothy M
AU  - Caradonna TM
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Chevalier, Josh
AU  - Chevalier J
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Chowdhury, Fatema
AU  - Chowdhury F
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Diefenbach, Thomas J
AU  - Diefenbach TJ
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Einkauf, Kevin
AU  - Einkauf K
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Fallon, Jon
AU  - Fallon J
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Feldman, Jared
AU  - Feldman J
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Finn, Kelsey K
AU  - Finn KK
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Garcia-Broncano, Pilar
AU  - Garcia-Broncano P
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Hartana, Ciputra Adijaya
AU  - Hartana CA
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Hauser, Blake M
AU  - Hauser BM
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Jiang, Chenyang
AU  - Jiang C
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Kaplonek, Paulina
AU  - Kaplonek P
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Karpell, Marshall
AU  - Karpell M
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Koscher, Eric C
AU  - Koscher EC
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Lian, Xiaodong
AU  - Lian X
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Liu, Hang
AU  - Liu H
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Liu, Jinqing
AU  - Liu J
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Ly, Ngoc L
AU  - Ly NL
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Michell, Ashlin R
AU  - Michell AR
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Rassadkina, Yelizaveta
AU  - Rassadkina Y
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Seiger, Kyra
AU  - Seiger K
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Sessa, Libera
AU  - Sessa L
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Shin, Sally
AU  - Shin S
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Singh, Nishant
AU  - Singh N
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Sun, Weiwei
AU  - Sun W
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Sun, Xiaoming
AU  - Sun X
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Ticheli, Hannah J
AU  - Ticheli HJ
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Waring, Michael T
AU  - Waring MT
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Howard Hughes Medical Institute, Chevy Chase MD, 20815.
FAU - Zhu, Alex L
AU  - Zhu AL
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Li, Jonathan
AU  - Li J
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
FAU - Lingwood, Daniel
AU  - Lingwood D
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Schmidt, Aaron G
AU  - Schmidt AG
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Department of Microbiology, Harvard Medical School, Boston, MA 02115.
FAU - Lichterfeld, Matthias
AU  - Lichterfeld M
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
FAU - Walker, Bruce D
AU  - Walker BD
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
AD  - Howard Hughes Medical Institute, Chevy Chase MD, 20815.
AD  - Department of Biology and Institute of Medical Engineering and Science,
      Massachusetts Institute of Technology, Cambridge, MA 02139.
FAU - Yu, Xu
AU  - Yu X
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
FAU - Padera, Robert F Jr
AU  - Padera RF Jr
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115.
FAU - Pillai, Shiv
AU  - Pillai S
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
CN  - Massachusetts Consortium on Pathogen Readiness Specimen Working Group
LA  - eng
GR  - U19 AI110495/AI/NIAID NIH HHS/United States
GR  - T32 AI007245/AI/NIAID NIH HHS/United States
GR  - T32 GM007753/GM/NIGMS NIH HHS/United States
GR  - R01 AI146779/AI/NIAID NIH HHS/United States
GR  - DP2 DA042422/DA/NIDA NIH HHS/United States
GR  - T32 GM008313/GM/NIGMS NIH HHS/United States
GR  - R01 AI137057/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20200716
PL  - United States
TA  - SSRN
JT  - SSRN
JID - 101768030
CIN - Nat Rev Immunol. 2020 Oct;20(10):590. PMID: 32782355
UIN - Cell. 2020 Aug 19;:. PMID: 32877699
PMC - PMC7385482
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/07/15 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.2139/ssrn.3652322 [doi]
AID - 3652322 [pii]
PST - epublish
SO  - SSRN. 2020 Jul 16:3652322. doi: 10.2139/ssrn.3652322.


PMID- 32742242
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211117
IS  - 1556-5068 (Electronic)
IS  - 1556-5068 (Linking)
DP  - 2020 Jul 7
TI  - Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 (+) T Cells.
PG  - 3641939
LID - 10.2139/ssrn.3641939 [doi]
AB  - The contribution of CD4+ T cells to protective or pathogenic immune responses to 
      SARS-CoV-2 infection remains unknown. Here, we present large-scale single-cell
      transcriptomic analysis of viral antigen-reactive CD4+ T cells from 32 COVID-19
      patients. In patients with severe disease compared to mild disease, we found
      increased proportions of cytotoxic follicular helper (TFH) cells and cytotoxic T 
      helper cells (CD4-CTLs) responding to SARS-CoV-2, and reduced proportion of
      SARS-CoV-2 reactive regulatory T cells. Importantly, the CD4-CTLs were highly
      enriched for the expression of transcripts encoding chemokines that are involved 
      in the recruitment of myeloid cells and dendritic cells to the sites of viral
      infection. Polyfunctional T helper (TH)1 cells and TH17 cell subsets were
      underrepresented in the repertoire of SARS-CoV-2-reactive CD4+ T cells compared
      to influenza-reactive CD4+ T cells. Together, our analyses provide so far
      unprecedented insights into the gene expression patterns of SARS-CoV-2 reactive
      CD4+ T cells in distinct disease severities. Funding: This work was funded by NIH
      grants U19AI142742 (P.V., A.S., C.H.O), U19AI118626 (P.V., A.S., G.S.),
      R01HL114093 (P.V., F.A., G.S.,), R35-GM128938 (F.A), S10RR027366 (BD
      FACSAria-II), S10OD025052 (Illumina Novaseq6000), the William K. Bowes Jr
      Foundation (P.V.), and Whittaker foundation (P.V., C.H.O.). Supported by the
      Wessex Clinical Research Network and National Institute of Health Research UK.
      Conflict of Interest: The authors declare no competing financial interests.
      Ethical Approval: Ethical approval for this study from the Berkshire Research
      Ethics Committee 20/SC/0155 and the Ethics Committee of La Jolla Institute for
      Immunology (LJI) was in place. Written consent was obtained from all subjects.
FAU - Meckiff, Benjamin J
AU  - Meckiff BJ
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
AD  - These authors jointly contributed to the work.
FAU - Ramirez-Suastegui, Ciro
AU  - Ramirez-Suastegui C
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
AD  - These authors jointly contributed to the work.
FAU - Fajardo, Vicente
AU  - Fajardo V
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
AD  - These authors jointly contributed to the work.
FAU - Chee, Serena J
AU  - Chee SJ
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
AD  - These authors jointly contributed to the work.
FAU - Kusnadi, Anthony
AU  - Kusnadi A
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
FAU - Simon, Hayley
AU  - Simon H
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
FAU - Grifoni, Alba
AU  - Grifoni A
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
FAU - Pelosi, Emanuela
AU  - Pelosi E
AD  - Southampton Specialist Virology Center, University Hospitals NHS Foundation
      Trust, Southampton, UK.
FAU - Weiskopf, Daniela
AU  - Weiskopf D
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
FAU - Sette, Alessandro
AU  - Sette A
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
AD  - Department of Medicine, University of California San Diego, La Jolla, CA, USA.
FAU - Ay, Ferhat
AU  - Ay F
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
FAU - Seumois, Gregory
AU  - Seumois G
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
FAU - Ottensmeier, Christian H
AU  - Ottensmeier CH
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
AD  - Institute of Translational Medicine, Department of Molecular & Clinical Cancer
      Medicine, University of Liverpool, Liverpool, UK.
AD  - These authors jointly directed the work.
FAU - Vijayanand, Pandurangan
AU  - Vijayanand P
AD  - La Jolla Institute for Immunology, La Jolla, CA, USA.
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
AD  - Department of Medicine, University of California San Diego, La Jolla, CA, USA.
AD  - These authors jointly directed the work.
LA  - eng
GR  - S10 OD025052/OD/NIH HHS/United States
GR  - R35 GM128938/GM/NIGMS NIH HHS/United States
GR  - S10 RR027366/RR/NCRR NIH HHS/United States
GR  - R01 HL114093/HL/NHLBI NIH HHS/United States
GR  - U19 AI118626/AI/NIAID NIH HHS/United States
GR  - U19 AI142742/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20200707
PL  - United States
TA  - SSRN
JT  - SSRN
JID - 101768030
UIN - Cell. 2020 Oct 5;:. PMID: 33096020
PMC - PMC7385998
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/07 00:00 [revised]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.2139/ssrn.3641939 [doi]
AID - 3641939 [pii]
PST - epublish
SO  - SSRN. 2020 Jul 7:3641939. doi: 10.2139/ssrn.3641939.


PMID- 32742241
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1556-5068 (Electronic)
IS  - 1556-5068 (Linking)
DP  - 2020 Jul 21
TI  - Structure-Based Design with Tag-Based Purification and In-Process Biotinylation
      Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
PG  - 3639618
LID - 10.2139/ssrn.3639618 [doi]
AB  - Biotin-labeled molecular probes, comprising specific regions of the SARS-CoV-2
      spike, would be helpful in the isolation and characterization of antibodies
      targeting this recently emerged pathogen. To develop such probes, we designed
      constructs incorporating an N-terminal purification tag, a site-specific
      protease-cleavage site, the probe region of interest, and a C-terminal sequence
      targeted by biotin ligase. Probe regions included full-length spike ectodomain as
      well as various subregions, and we also designed mutants to eliminate recognition
      of the ACE2 receptor. Yields of biotin-labeled probes from transient transfection
      ranged from ~0.5 mg/L for the complete ectodomain to &gt;5 mg/L for several
      subregions. Probes were characterized for antigenicity and ACE2 recognition, and 
      the structure of the spike ectodomain probe was determined by cryo-electron
      microscopy. We also characterized antibody-binding specificities and cell-sorting
      capabilities of the biotinylated probes. Altogether, structure-based design
      coupled to efficient purification and biotinylation processes can thus enable
      streamlined development of SARS-CoV-2 spike-ectodomain probes. Funding: Support
      for this work was provided by the Intramural Research Program of the Vaccine
      Research Center, National Institute of Allergy and Infectious Diseases (NIAID).
      Support for this work was also provided by COVID-19 Fast Grants, the Jack Ma
      Foundation, the Self Graduate Fellowship Program, and NIH grants DP5OD023118,
      R21AI143407, and R21AI144408. Some of this work was performed at the Columbia
      University Cryo-EM Center at the Zuckerman Institute, and some at the Simons
      Electron Microscopy Center (SEMC) and National Center for Cryo-EM Access and
      Training (NCCAT) located at the New York Structural Biology Center, supported by 
      grants from the Simons Foundation (SF349247), NYSTAR, and the NIH National
      Institute of General Medical Sciences (GM103310). Conflict of Interest: The
      authors declare that they have no conflict of interest. Ethical Approval:
      Peripheral blood mononuclear cells (PBMCs) for B cell sorting were obtained from 
      a convalescent SARS-CoV-2 patient (collected 75 days post symptom onset under an 
      IRB approved clinical trial protocol, VRC 200 - ClinicalTrials.gov Identifier:
      NCT00067054) and a healthy control donor from the NIH blood bank pre-SARS-CoV-2
      pandemic.
FAU - Zhou, Tongqing
AU  - Zhou T
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Teng, I-Ting
AU  - Teng IT
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - These authors contributed equally.
FAU - Olia, Adam S
AU  - Olia AS
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - These authors contributed equally.
FAU - Cerutti, Gabriele
AU  - Cerutti G
AD  - Department of Biochemistry and Molecular Biophysics, Columbia University, New
      York, NY 10032, USA.
AD  - These authors contributed equally.
FAU - Gorman, Jason
AU  - Gorman J
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - These authors contributed equally.
FAU - Nazzari, Alexandra
AU  - Nazzari A
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - These authors contributed equally.
FAU - Shi, Wei
AU  - Shi W
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Tsybovsky, Yaroslav
AU  - Tsybovsky Y
AD  - Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos
      Biomedical Research Inc., Frederick National Laboratory for Cancer Research,
      Frederick, MD 21701, USA.
FAU - Wang, Lingshu
AU  - Wang L
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Wang, Shuishu
AU  - Wang S
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Zhang, Baoshan
AU  - Zhang B
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Katsamba, Phinikoula S
AU  - Katsamba PS
AD  - Department of Biochemistry and Molecular Biophysics, Columbia University, New
      York, NY 10032, USA.
FAU - Petrova, Yuliya
AU  - Petrova Y
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Banach, Bailey B
AU  - Banach BB
AD  - Bioengineering Graduate Program, The University of Kansas, Lawrence, KS 66045,
      USA.
FAU - Fahad, Ahmed S
AU  - Fahad AS
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
FAU - Liu, Lihong
AU  - Liu L
AD  - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Acevedo, Sheila N Lopez
AU  - Acevedo SNL
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
FAU - Madan, Bharat
AU  - Madan B
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
FAU - de Souza, Matheus Olivera
AU  - de Souza MO
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
FAU - Pan, Xiaoli
AU  - Pan X
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
FAU - Wang, Pengfei
AU  - Wang P
AD  - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Wolfe, Jacy R
AU  - Wolfe JR
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
FAU - Yin, Michael
AU  - Yin M
AD  - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Ho, David D
AU  - Ho DD
AD  - Aaron Diamond AIDS Research Center, Columbia University Vagelos College of
      Physicians and Surgeons, New York, NY 10032, USA.
FAU - Phung, Emily
AU  - Phung E
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - DiPiazza, Anthony
AU  - DiPiazza A
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Chang, Lauren
AU  - Chang L
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Abiona, Olubukula
AU  - Abiona O
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Corbett, Kizzmekia S
AU  - Corbett KS
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - DeKosky, Brandon J
AU  - DeKosky BJ
AD  - Bioengineering Graduate Program, The University of Kansas, Lawrence, KS 66045,
      USA.
AD  - Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS
      66045, USA.
AD  - Department of Chemical Engineering, The University of Kansas, Lawrence, KS 66045,
      USA.
FAU - Graham, Barney S
AU  - Graham BS
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Mascola, John R
AU  - Mascola JR
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Misasi, John
AU  - Misasi J
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Ruckwardt, Tracy
AU  - Ruckwardt T
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Sullivan, Nancy J
AU  - Sullivan NJ
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Shapiro, Lawrence
AU  - Shapiro L
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Department of Biochemistry and Molecular Biophysics, Columbia University, New
      York, NY 10032, USA.
FAU - Kwong, Peter D
AU  - Kwong PD
AD  - Vaccine Research Center, National Institute of Allergy and Infectious Diseases,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Department of Biochemistry and Molecular Biophysics, Columbia University, New
      York, NY 10032, USA.
AD  - Lead Contact: Peter D. Kwong.
LA  - eng
SI  - ClinicalTrials.gov/NCT00067054
GR  - DP5 OD023118/OD/NIH HHS/United States
GR  - P41 GM103310/GM/NIGMS NIH HHS/United States
GR  - R21 AI143407/AI/NIAID NIH HHS/United States
GR  - R21 AI144408/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20200721
PL  - United States
TA  - SSRN
JT  - SSRN
JID - 101768030
UIN - Cell Rep. 2020 Oct 12;:108322. PMID: 33091382
PMC - PMC7385481
OTO - NOTNLM
OT  - COVID-19
OT  - HRV3C protease
OT  - antibody
OT  - biotinylated probe
OT  - single-chain Fc
OT  - structurebased design
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/06/30 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.2139/ssrn.3639618 [doi]
AID - 3639618 [pii]
PST - epublish
SO  - SSRN. 2020 Jul 21:3639618. doi: 10.2139/ssrn.3639618.


PMID- 32742069
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0353-8109 (Print)
IS  - 0353-8109 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Jun
TI  - Delving Inside the Enigmatic Central Neurocytoma: Electronic Hospital Database
      Retrieval.
PG  - 146-151
LID - 10.5455/aim.2020.28.146-151 [doi]
AB  - INTRODUCTION: Central neurocytomas (CNCs) appear as a rare benign
      intraventricular lesions involving <0.5% of primary brain tumors. There are no
      consensus guidelines for the optimal management strategy, so that this entity
      still enigmatic. AIM: This review aims to highpoint the entity of central
      neurocytoma in patients managed by our department and the unique surgical
      considerations, to review the epidemiology and demographics in patients treated
      in our institution. METHODS: This retrospective analysis was conducted by
      reviewing tall patients managed at King Hussein Medical Center (KHMC) and their
      medical records. Patient reports were retrieved from the electronic hospital
      database for a 14-year period (2004 _ 2018). The review was permitted by the
      Royal Medical Services Institutional ethics committee. As this study was a
      retrospective chart review, the requirement for consent was waived. RESULTS:
      Study revealed 33- patients who had Central neurocytoma as the underlying cause
      for admission. Of the final population 42.4% of the patients were males. Mean age
      at diagnosis was 29.48+/-9.78 years. Two cases were extra-ventricular, to cases
      were anaplastc. Only one patient developed recurrence. CONCLUSION: We have one
      the large series of Central neurocytomas in literature. They are benign and total
      resection is feasible. New adjuvant therapies are flourishing. Supplementary
      studies are required clarify the cardinal factors responsible for its
      pathogenesis; diagnosis; and to consolidate management approaches protocol.
CI  - (c) 2020 Rami Y. Alqroom, Khraisat Wesam, Krashan Hanada, Qabaha Anan, Al-Zoubi
      Mohamad, Arabiyat Lamees, Nserat Rima, Malabeh Qamar, Al Shurbaji Faisal, Elayyan
      Maher, Al-Kadasi Wagdy, Amer A. Al Shurbaji.
FAU - Alqroom, Rami Y
AU  - Alqroom RY
AD  - Neurosurgery Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Wesam, Khraisat
AU  - Wesam K
AD  - Anesthesia Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Hanada, Krashan
AU  - Hanada K
AD  - Anesthesia Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Anan, Qabaha
AU  - Anan Q
AD  - Anesthesia Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Mohamad, Al-Zoubi
AU  - Mohamad AZ
AD  - Neurosurgery Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Lamees, Arabiyat
AU  - Lamees A
AD  - Plastic Surgery Department, Farah Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Rima, Nserat
AU  - Rima N
AD  - Pathology Department at Princess Iman Research and Laboratory Sciences Center,
      Amman, Jordan.
FAU - Qamar, Malabeh
AU  - Qamar M
AD  - Radiology Department, King Hussein Medical Center, Royal medical services, Amman,
      Jordan.
FAU - Faisal, Al Shurbaji
AU  - Faisal AS
AD  - Neurosurgery Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Maher, Elayyan
AU  - Maher E
AD  - Neurosurgery Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Wagdy, Al-Kadasi
AU  - Wagdy AK
AD  - Neurosurgery Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
FAU - Al Shurbaji, Amer A
AU  - Al Shurbaji AA
AD  - Neurosurgery Department, King Hussein Medical Center, Royal medical services,
      Amman-Jordan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Bosnia and Herzegovina
TA  - Acta Inform Med
JT  - Acta informatica medica : AIM : journal of the Society for Medical Informatics of
      Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH
JID - 101147064
PMC - PMC7382777
OTO - NOTNLM
OT  - benign tumor
OT  - central neurocytoma
OT  - extra- ventricular neurocytoma
OT  - intraventricular
OT  - maximum safe resection
COIS- The authors declare that the research was conducted in the absence of any
      commercial or financial relationships that could be construed as a potential
      conflict of interest.
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
AID - 10.5455/aim.2020.28.146-151 [doi]
AID - AIM-28-146 [pii]
PST - ppublish
SO  - Acta Inform Med. 2020 Jun;28(2):146-151. doi: 10.5455/aim.2020.28.146-151.


PMID- 32741989
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - Veterinary Medical Ethics.
PG  - 817-818
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7350148
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_817 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):817-818.


PMID- 32741986
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 - Responses to comments.
PG  - 810-811
FAU - Gyles, Carlton
AU  - Gyles C
AD  - Editor, The Canadian Veterinary Journal.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350095
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_810b [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):810-811.


PMID- 32741985
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 - Responses to comments.
PG  - 810
CN  - Executive Committee of the Canadian Veterinary Medical Association, June 12, 2020
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350092
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_810a [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):810.


PMID- 32741984
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 response - Comments.
PG  - 809-810
FAU - Aarbo, Kirsten
AU  - Aarbo K
AD  - President, Alberta Veterinary Medical Association.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350090
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_809c [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):809-810.


PMID- 32741983
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 response - Comments.
PG  - 809
FAU - Johnson, Marian
AU  - Johnson M
AD  - Rimbey, Alberta.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350060
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_809a [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):809.


PMID- 32741982
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 response - Comments.
PG  - 809
FAU - Van De Weyer, Leanne
AU  - Van De Weyer L
AD  - Weyburn, Saskatchewan.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350059
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_809b [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):809.


PMID- 32741981
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 response - Comments.
PG  - 808
FAU - Jalbert, Alexandre
AU  - Jalbert A
AD  - Navan, Ontario.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350121
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_808 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):808.


PMID- 32741980
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 response - Comments.
PG  - 807-808
FAU - Klopfenstein, Christian
AU  - Klopfenstein C
AD  - President of CASV, on behalf of the members of the Board, Canadian Association of
      Swine Veterinarians, Elmira, Ontario.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
PMC - PMC7350143
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_807b [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):807-808.


PMID- 32741979
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 8
DP  - 2020 Aug
TI  - February 2020 ethical question of the month and May 2020 response - Comments.
PG  - 807
FAU - Gillies, Murray
AU  - Gillies M
AD  - Technical Services Veterinarian, CVMA Dairy Subject Matter Expert, Canadian
      Association of Bovine Veterinarians (CABV) and American Association of Bovine
      Practitioners (AABP) board member, Canadian Dairy Producer.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
MH  - Ethics, Medical
PMC - PMC7350122
EDAT- 2020/08/04 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - cvj_08_807a [pii]
PST - ppublish
SO  - Can Vet J. 2020 Aug;61(8):807.


PMID- 32740829
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 1437-9813 (Electronic)
IS  - 0179-0358 (Linking)
VI  - 36
IP  - 10
DP  - 2020 Oct
TI  - Lysosomal overloading and necrotizing enterocolitis.
PG  - 1157-1165
LID - 10.1007/s00383-020-04724-x [doi]
AB  - PURPOSE: Intestinal absorption in premature infants occurs via direct epithelial 
      cellular endocytosis and degradation by intracellular lysosomes. Autophagy is a
      mechanism by which cytoplasmic organelles contribute to lysosomal degradation.
      However, excessive autophagy can lead to cell death. The purpose of this study
      was to investigate whether autophagy and endocytosis are present in the small
      intestinal mucosa during experimental necrotizing enterocolitis (NEC). METHODS:
      NEC was induced by gavage feeding of hyperosmolar formula, lipopolysaccharide and
      hypoxia between P5 and P9 (ethical approval 44032). Breastfed mice were used as
      control. Distal ileum was harvested on P5, P7 and P9 and analyzed for intestinal 
      epithelial cellular morphology as well as autophagy/lysosomal activity, and cell 
      death. Groups were compared using Student's t test. RESULTS: During NEC, giant
      lysosomes were present in the intestinal villi, with some exceeding their
      degradation ability leading to their rupture. The NEC group had significantly
      increased inflammation and autophagy activity, decreased lysosome activity, and
      increased apoptosis compared to control. CONCLUSIONS: NEC induction causes
      excessive autophagy and endocytosis leading to lysosomal overloading, lysosomal
      membrane permeabilization and rupture which results in cell death. These novel
      findings may help to clarify the pathogenesis of NEC. Reduction of lysosome
      overload and assisting in their degradation capability may reduce the burden of
      NEC.
FAU - Yamoto, Masaya
AU  - Yamoto M
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
AD  - Department of Pediatric Surgery, Shizuoka Children's Hospital, Shizuoka, Japan.
FAU - Alganabi, Mashriq
AU  - Alganabi M
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
FAU - Chusilp, Sinobol
AU  - Chusilp S
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
AD  - Division of Pediatric Surgery, Department of Surgery, Khon Kaen University, Khon 
      Kaen, Thailand.
FAU - Lee, Dorothy
AU  - Lee D
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
FAU - Yazaki, Yuta
AU  - Yazaki Y
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
FAU - Lee, Carol
AU  - Lee C
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
FAU - Li, Bo
AU  - Li B
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada.
FAU - Pierro, Agostino
AU  - Pierro A
AUID- ORCID: http://orcid.org/0000-0002-6742-6570
AD  - Division of General and Thoracic Surgery, Translational Medicine Program, The
      Hospital for Sick Children, University of Toronto, 1526-555 University Ave,
      Toronto, ON, M5G 1X8, Canada. agostino.pierro@sickkids.ca.
AD  - Department of Surgery, University of Toronto, Toronto, Canada.
      agostino.pierro@sickkids.ca.
LA  - eng
GR  - Foundation Grant 353857/CAPMC/ CIHR/Canada
GR  - Robert M. Filler Chair of Surgery/Hospital for Sick Children
GR  - Foundation Grant 353857/CAPMC/ CIHR/Canada
PT  - Journal Article
DEP - 20200801
PL  - Germany
TA  - Pediatr Surg Int
JT  - Pediatric surgery international
JID - 8609169
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Autophagy
MH  - Disease Models, Animal
MH  - Enterocolitis, Necrotizing/metabolism/*pathology
MH  - Epithelial Cells/metabolism/pathology
MH  - Ileum/*pathology
MH  - Intestinal Mucosa/metabolism/*pathology
MH  - Lysosomes/metabolism/*pathology
MH  - Mice
MH  - Mice, Inbred C57BL
OTO - NOTNLM
OT  - Autophagy
OT  - Endocytosis
OT  - Lysosomal membrane permeabilization
OT  - Necrotizing enterocolitis
EDAT- 2020/08/03 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - 10.1007/s00383-020-04724-x [doi]
AID - 10.1007/s00383-020-04724-x [pii]
PST - ppublish
SO  - Pediatr Surg Int. 2020 Oct;36(10):1157-1165. doi: 10.1007/s00383-020-04724-x.
      Epub 2020 Aug 1.


PMID- 32740693
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1432-0827 (Electronic)
IS  - 0171-967X (Linking)
VI  - 107
IP  - 5
DP  - 2020 Nov
TI  - Osteoporosis is a Predictive Factor for Nephrolithiasis in an Adult Free-Living
      Caucasian Population From Southern Italy: A Longitudinal Retrospective Study
      Based on a General Practice Database.
PG  - 446-452
LID - 10.1007/s00223-020-00737-9 [doi]
AB  - Osteoporosis and nephrolithiasis are common multifactorial disorders with high
      incidence and prevalence in the adult population worldwide. Both are associated
      with high morbidity and mortality if not correctly diagnosed and accurately
      treated. Nephrolithiasis is considered a risk factor for reduced bone mineral
      density. Aim of this retrospective longitudinal study was to evaluate if
      osteoporosis is a predictive factor for the nephrolithiasis occurrence.
      Free-living subjects referring to "COMEGEN" general practitioners cooperative
      operating in Naples, Southern Italy. Twelve thousand seven hundred ninety-four
      Caucasian subjects (12,165 female) who performed bone mineral density by
      dual-energy X-ray absorptiometry and have a negative personal history for
      nephrolithiasis. Subjects aged less than 40 years or with signs or symptoms
      suggestive of secondary osteoporosis were excluded from the study. In a mean
      lapse of time of 19.5 months, 516 subjects had an incident episode of
      nephrolithiasis. Subjects with osteoporosis had an increased risk of
      nephrolithiasis than subjects without osteoporosis (Hazard Ratio = 1.33, 95%
      Confidence Interval 1.01-1.74, p = 0.04). Free-living adult subjects over the age
      of 40 with idiopathic osteoporosis have an increased risk of incident
      nephrolithiasis, suggesting the advisability of appropriate investigation and
      treatment of the metabolic alterations predisposing to nephrolithiasis in
      patients with osteoporosis. The study protocol was approved by the ASL Napoli 1
      Ethical Committee, protocol number 0018508/2018.
FAU - Rendina, Domenico
AU  - Rendina D
AUID- ORCID: 0000-0002-0331-0392
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio
      Pansini 5, 80131, Naples, Italy. domenico.rendina@unina.it.
FAU - D'Elia, Lanfranco
AU  - D'Elia L
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio
      Pansini 5, 80131, Naples, Italy.
FAU - Evangelista, Marco
AU  - Evangelista M
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio
      Pansini 5, 80131, Naples, Italy.
FAU - De Filippo, Gianpaolo
AU  - De Filippo G
AD  - Hopital Robert Debre, Paris, France.
FAU - Giaquinto, Alfonso
AU  - Giaquinto A
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio
      Pansini 5, 80131, Naples, Italy.
FAU - Barone, Biagio
AU  - Barone B
AD  - Department of Neuroscience Reproductive Sciences and Dentistry, Federico II
      University, Naples, Italy.
FAU - Piccinocchi, Gaetano
AU  - Piccinocchi G
AD  - "COMEGEN" Medical Cooperative, Naples, Italy.
FAU - Prezioso, Domenico
AU  - Prezioso D
AD  - Department of Neuroscience Reproductive Sciences and Dentistry, Federico II
      University, Naples, Italy.
FAU - Strazzullo, Pasquale
AU  - Strazzullo P
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio
      Pansini 5, 80131, Naples, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200801
PL  - United States
TA  - Calcif Tissue Int
JT  - Calcified tissue international
JID - 7905481
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adult
MH  - Bone Density
MH  - Female
MH  - General Practice
MH  - Humans
MH  - Italy/epidemiology
MH  - Longitudinal Studies
MH  - Male
MH  - Nephrolithiasis/*epidemiology
MH  - Osteoporosis/*epidemiology
MH  - Retrospective Studies
PMC - PMC7546977
OTO - NOTNLM
OT  - *Epidemiological survey
OT  - *Nephrolithiasis
OT  - *Osteoporosis
EDAT- 2020/08/03 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - 10.1007/s00223-020-00737-9 [doi]
AID - 10.1007/s00223-020-00737-9 [pii]
PST - ppublish
SO  - Calcif Tissue Int. 2020 Nov;107(5):446-452. doi: 10.1007/s00223-020-00737-9. Epub
      2020 Aug 1.


PMID- 32739976
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1473-656X (Electronic)
IS  - 1040-872X (Linking)
VI  - 32
IP  - 5
DP  - 2020 Oct
TI  - Consenting and ethical considerations in embryo cryopreservation.
PG  - 380-384
LID - 10.1097/GCO.0000000000000653 [doi]
AB  - PURPOSE OF REVIEW: An emerging body of literature has elucidated the growing
      burden of surplus embryos left in storage without any clear disposition. An out
      dated consent process is a significant but easily remedied contributor to this
      problem. We propose a novel approach to consenting for disposition of surplus
      embryos. RECENT FINDINGS: Decisional conflicts that stem from the moral status of
      embryos and from evolving personal values contribute to surplus embryos being
      left in storage. Barriers to donation of embryos to research or to other patients
      also discourage embryo disposition decisions. A flawed informed consent process
      compromises the physician--provider relationship and complicates decision-making.
      SUMMARY: Centralizing the process of donating embryos to research and to patients
      would lower barriers to these disposition options. The informed consent protocol 
      must be redesigned as a longitudinal, narrative process compatible with the
      evolving values and fertility outcomes of patients. Counselors should be
      integrated into all discussions regarding embryo disposition from the onset of
      fertility treatment through its conclusion to facilitate the decision-making
      process.
FAU - Khorshid, Arian
AU  - Khorshid A
AD  - Department of Obstetrics and Gynecology, Stanford University School of Medicine, 
      Stanford, California.
FAU - Alvero, Ruben
AU  - Alvero R
AD  - Fertility and Reproductive Health, Division of Reproductive Endocrinology.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Obstet Gynecol
JT  - Current opinion in obstetrics & gynecology
JID - 9007264
SB  - IM
MH  - Choice Behavior
MH  - Counseling
MH  - Cryopreservation/ethics/methods
MH  - Embryo Disposition/*psychology
MH  - Embryo Research
MH  - Female
MH  - Humans
MH  - Informed Consent/psychology
MH  - Male
MH  - *Physician's Role
EDAT- 2020/08/03 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - 10.1097/GCO.0000000000000653 [doi]
AID - 00001703-202010000-00011 [pii]
PST - ppublish
SO  - Curr Opin Obstet Gynecol. 2020 Oct;32(5):380-384. doi:
      10.1097/GCO.0000000000000653.


PMID- 32739931
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20210505
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 11
DP  - 2020 Nov
TI  - An Incentive to Innovate: Improving Health Care Value and Restoring Physician
      Autonomy Through Physician-Directed Reinvestment.
PG  - 1702-1706
LID - 10.1097/ACM.0000000000003650 [doi]
AB  - PROBLEM: Many health care systems in the United States are shifting from a
      fee-for-service reimbursement model to a value-based payment model. To remain
      competitive, health care administrators must engage frontline clinicians in their
      efforts to reduce costs and improve patient outcomes. Engaging physicians and
      other clinicians is challenging, however, as many feel overwhelmed with clinical 
      responsibilities and do not view cost reduction as in their purview. Even if they
      are willing, providing a direct financial incentive to clinicians to control
      costs poses ethical and legal challenges. An effective incentive in the current
      system must motivate clinicians to engage in creative problem solving and
      mitigate ethical and legal risk. APPROACH: Evidence suggests the most successful 
      behavior change interventions in physicians are multifaceted and combine
      intrinsic motivators, such as increased autonomy, with extrinsic motivators, such
      as access to funding or social recognition. Two academic health centers-the
      University of Utah Health and Stanford Health Care-have begun experimenting with 
      an alternative value-sharing arrangement. Physician-directed reinvestment is an
      explicit agreement in which a health care system reinvests a portion of savings
      attributed to physician-led cost reduction initiatives back into areas of the
      physician's choosing, such as capital investment, research, or education.
      OUTCOMES: Both organizations reported similar positive outcomes, including
      increased engagement from clinicians and administrators, sustained or improved
      quality of care, reduced costs of care, and benefits from reinvested funds. Many 
      savings opportunities were previously unknown to administrators. NEXT STEPS:
      Physician-directed reinvestment appears to effectively engage physicians in
      ongoing efforts to improve value in health care, although formal evaluation is
      still needed. This incentive structure may hold promise in other configurations, 
      such as inviting nonphysicians to apply as project leaders (clinician-directed
      reinvestment) and expanding the program to nonacademic and ambulatory settings.
FAU - Vilendrer, Stacie M
AU  - Vilendrer SM
AD  - S.M. Vilendrer is a Stanford-Intermountain Population Health Fellow, Department
      of Medicine, Stanford School of Medicine, Stanford, California.
FAU - Asch, Steven M
AU  - Asch SM
AD  - S.M. Asch is director, Center for Innovation to Implementation, VA Palo Alto
      Health Care Systems, and co-chief, Stanford Division of Primary Care and
      Population Health, Department of Medicine, Stanford School of Medicine, Stanford,
      California.
FAU - Anzai, Yoshimi
AU  - Anzai Y
AD  - Y. Anzai is associate chief medical quality officer, University of Utah
      Healthcare, Salt Lake City, Utah.
FAU - Maggio, Paul
AU  - Maggio P
AD  - P. Maggio is associate professor, Stanford Health Care, Department of Surgery,
      Stanford School of Medicine, Stanford, California.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
MH  - Academic Medical Centers
MH  - Capital Financing
MH  - *Cost Control
MH  - Humans
MH  - *Motivation
MH  - *Organizational Innovation
MH  - *Physicians
MH  - *Professional Autonomy
MH  - *Quality Improvement
MH  - Reimbursement Mechanisms
MH  - Research Support as Topic
MH  - Training Support
EDAT- 2020/08/03 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - 10.1097/ACM.0000000000003650 [doi]
AID - 00001888-202011000-00050 [pii]
PST - ppublish
SO  - Acad Med. 2020 Nov;95(11):1702-1706. doi: 10.1097/ACM.0000000000003650.


PMID- 32739780
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 130
DP  - 2020 Sep
TI  - Assessing the impact of posture on diaphragm morphology and function using an
      open upright MRI system-A pilot study.
PG  - 109196
LID - S0720-048X(20)30385-5 [pii]
LID - 10.1016/j.ejrad.2020.109196 [doi]
AB  - PURPOSE: The diaphragm is the most important muscle of respiration. Disorders of 
      the diaphragm can have a deleterious impact on respiratory function. We aimed to 
      evaluate the use of an open-configuration upright low-field MRI system to assess 
      diaphragm morphology and function in patients with bilateral diaphragm weakness
      (BDW) and chronic obstructive pulmonary disease (COPD) with hyperinflation.
      METHOD: The study was approved by the National Research Ethics Committee, and
      written consent was obtained. We recruited 20 healthy adult volunteers, six
      subjects with BDW, and five subjects with COPD with hyperinflation. We measured
      their vital capacity in the upright and supine position, after which they were
      scanned on the 0.5T MRI system during 10-s breath-holds at end-expiration and
      end-inspiration in both positions. We developed and applied image analysis
      methods to measure the volume under the dome, maximum excursion of
      hemidiaphragms, and anterior-posterior and left-right extension of the diaphragm.
      RESULTS: All participants were able to complete the scanning protocol. The
      patients found scanning in the upright position more comfortable than the supine 
      position. All differences in the supine inspiratory-expiratory parameters,
      excluding left-right extension, were significantly smaller in the BDW and COPD
      groups compared with healthy volunteers. No significant correlation was found
      between the postural change in diaphragm morphology and vital capacity in either 
      group. CONCLUSION: Our combined upright-supine MR imaging approach facilitates
      the assessment of the impact of posture on diaphragm morphology and function in
      patients with BDW and those with COPD with hyperinflation.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Safavi, Shahideh
AU  - Safavi S
AD  - Respiratory Medicine Department, School of Medicine, University of Nottingham,
      Queen's Medical Centre Campus, Nottingham, UK; NIHR Nottingham Biomedical
      Research Centre, Queen's Medical Centre, Nottingham NG7 2UH, UK. Electronic
      address: Shahideh.Safavi@nottingham.ac.uk.
FAU - Arthofer, Christoph
AU  - Arthofer C
AD  - NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, Nottingham
      NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University of Nottingham,
      University Park, Nottingham, UK. Electronic address:
      christoph.arthofer@ndcn.ox.ac.uk.
FAU - Cooper, Andrew
AU  - Cooper A
AD  - Sir Peter Mansfield Imaging Centre, University of Nottingham, University Park,
      Nottingham, UK. Electronic address: mszadc@nottingham.ac.uk.
FAU - Harkin, James W
AU  - Harkin JW
AD  - Respiratory Medicine Department, School of Medicine, University of Nottingham,
      Queen's Medical Centre Campus, Nottingham, UK. Electronic address:
      msxjh14@nottingham.ac.uk.
FAU - Prayle, Andrew P
AU  - Prayle AP
AD  - Paediatric Respiratory Medicine Department, Queen's Medical Centre, Nottingham,
      UK. Electronic address: msaap18@nottingham.ac.uk.
FAU - Sovani, Milind P
AU  - Sovani MP
AD  - Respiratory Medicine Department, Queen's Medical Centre, Nottingham University
      Hospitals NHS Trust, Nottingham, UK. Electronic address:
      Milind.sovani@nuh.nhs.uk.
FAU - Bolton, Charlotte E
AU  - Bolton CE
AD  - NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, Nottingham
      NG7 2UH, UK; Respiratory Medicine, School of Medicine, University of Nottingham, 
      Nottingham City Hospital Campus, Hucknall Road, Nottingham, UK. Electronic
      address: charlotte.bolton@nottingham.ac.uk.
FAU - Gowland, Penny A
AU  - Gowland PA
AD  - Sir Peter Mansfield Imaging Centre, University of Nottingham, University Park,
      Nottingham, UK. Electronic address: penny.gowland@nottingham.ac.uk.
FAU - Hall, Ian P
AU  - Hall IP
AD  - Respiratory Medicine Department, School of Medicine, University of Nottingham,
      Queen's Medical Centre Campus, Nottingham, UK; NIHR Nottingham Biomedical
      Research Centre, Queen's Medical Centre, Nottingham NG7 2UH, UK. Electronic
      address: ian.hall@nottingham.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200725
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
SB  - IM
MH  - Adult
MH  - Diaphragm/*diagnostic imaging/*physiopathology
MH  - Exhalation/physiology
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging/*instrumentation/methods
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Posture/*physiology
MH  - Pulmonary Disease, Chronic Obstructive/diagnostic imaging/physiopathology
MH  - Respiration
MH  - Tidal Volume/physiology
MH  - Vital Capacity/physiology
OTO - NOTNLM
OT  - Bilateral diaphragm weakness
OT  - COPD
OT  - Diaphragm
OT  - Upright MRI
EDAT- 2020/08/03 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/04/19 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - S0720-048X(20)30385-5 [pii]
AID - 10.1016/j.ejrad.2020.109196 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 Sep;130:109196. doi: 10.1016/j.ejrad.2020.109196. Epub 2020
      Jul 25.


PMID- 32739605
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 142
DP  - 2020 Sep
TI  - Palliative care undergraduate education: Do medical and nursing students need
      more skills in ethical and legal issues?
PG  - 110138
LID - S0306-9877(20)31400-6 [pii]
LID - 10.1016/j.mehy.2020.110138 [doi]
AB  - This study aimed to analyze the schools that teach ethical and legal aspects
      within the subject of palliative care in the degrees of medicine and nursing in
      Spain. MATERIAL AND METHODS: Descriptive Analysis of the palliative care subject 
      and their ethical and legal curricular competencies in the Spanish Nursing and
      Physicians undergraduate. The training received in legal ethical aspects related 
      to palliative care was compared with the criteria established by the European
      Association for Palliative Care (EAPC). DATA SOURCES: The National Conference of 
      Nursing Deans, The National Conference of Spanish Medical Faculty Deans and The
      Ministry of Science, Innovation, and Universities databases were searched.
      RESULTS: Twenty-one universities have an undergraduate in medicine with
      palliative care in their curricular training explicitly. The degree in nursing is
      present in fifty-six universities, palliative care is present in 62.5% of the
      cases. The degrees of nursing and medicine receive approximately the same level
      of training in ethical and legal aspects of palliative care. CONCLUSION: The
      specific training received in ethical and legal issues of palliative care must be
      improved in medical and nursing to meet the EAPC levels.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Rubio, Leticia
AU  - Rubio L
AD  - Department of Human Anatomy, Legal Medicine and History of Science. Area of Legal
      and Forensic Medicine, University of Malaga, Spain.
FAU - Lopez-Garcia, Monica
AU  - Lopez-Garcia M
AD  - Department of Human Anatomy, Legal Medicine and History of Science. Area of Legal
      and Forensic Medicine, University of Malaga, Spain; Fundacion CUDECA Cuidados
      Paliativos. Cudeca Hospice. IBIMA CA-15, Spain.
FAU - Gaitan-Arroyo, Maria J
AU  - Gaitan-Arroyo MJ
AD  - Department of Human Anatomy, Legal Medicine and History of Science. Area of Legal
      and Forensic Medicine, University of Malaga, Spain.
FAU - Martin-Martin, Jaime
AU  - Martin-Martin J
AD  - Department of Human Anatomy, Legal Medicine and History of Science. Area of Legal
      and Forensic Medicine, University of Malaga, Spain; Biomedical Research Institute
      of Malaga (IBIMA), Clinometric Group (F-14), Spain. Electronic address:
      jaimemartinmartin@uma.es.
FAU - Santos-Amaya, Ignacio
AU  - Santos-Amaya I
AD  - Department of Human Anatomy, Legal Medicine and History of Science. Area of Legal
      and Forensic Medicine, University of Malaga, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200726
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
SB  - IM
MH  - Curriculum
MH  - Humans
MH  - Palliative Care
MH  - Spain
MH  - *Students, Medical
MH  - *Students, Nursing
MH  - Universities
OTO - NOTNLM
OT  - Education
OT  - Ethical
OT  - Legal
OT  - Medical
OT  - Nursing
OT  - Palliative care
OT  - Skills
OT  - Undergraduate
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/08/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/07/20 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/03 06:00 [entrez]
AID - S0306-9877(20)31400-6 [pii]
AID - 10.1016/j.mehy.2020.110138 [doi]
PST - ppublish
SO  - Med Hypotheses. 2020 Sep;142:110138. doi: 10.1016/j.mehy.2020.110138. Epub 2020
      Jul 26.


PMID- 32738915
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Aug 1
TI  - Usage of do-not-attempt-to-resuscitate orders in a Swedish community hospital -
      patient involvement, documentation and compliance.
PG  - 67
LID - 10.1186/s12910-020-00510-5 [doi]
AB  - BACKGROUND: To characterize patients dying in a community hospital with or
      without attempting cardiopulmonary resuscitation (CPR) and to describe patient
      involvement in, documentation of, and compliance with decisions on resuscitation 
      (Do-not-attempt-to-resuscitate orders; DNAR). METHODS: All patients who died in
      Kalmar County Hospital during January 1, 2016 until December 31, 2016 were
      included. All information from the patients' electronic chart was analysed.
      RESULTS: Of 660 patients (mean age 77.7 +/- 12.1 years; range 21-101; median 79; 
      321 (48.6%) female), 30 (4.5%) were pronounced dead in the emergency department
      after out-of-hospital CPR. Of the remaining 630 patients a DNAR order had been
      documented in 558 patients (88.6%). Seventy had no DNAR order and 2 an explicit
      order to do CPR. In 43 of these 70 patients CPR was unsuccessfully attempted
      while the remaining 27 patients died without attempting CPR. In 2 of 558 (0.36%) 
      patients CPR was attempted despite a DNAR order in place. In 412 patients (73.8%)
      the DNAR order had not been discussed with neither patient nor family/friends.
      Moreover, in 75 cases (13.4%) neither patient nor family/friends were even
      informed about the decision on code status. CONCLUSIONS: In general, a large
      percentage of patients in our study had a DNAR order in place (88.6%). However,
      27 patients (4.3%) died without CPR attempt or DNAR order. DNAR orders had not
      been discussed with the patient/surrogate in almost three fourths of the
      patients. Further work has to be done to elucidate the barriers to discussions of
      CPR decisions with the patient.
FAU - Bertilsson, Emilie
AU  - Bertilsson E
AD  - Department of Medicine, Section of Cardiology, Kalmar County Hospital, Kalmar,
      Sweden.
FAU - Semark, Birgitta
AU  - Semark B
AD  - Faculty of Health and Life Sciences, Linnaeus University, Kalmar/Vaxjo, Sweden.
FAU - Schildmeijer, Kristina
AU  - Schildmeijer K
AD  - Faculty of Health and Life Sciences, Linnaeus University, Kalmar/Vaxjo, Sweden.
FAU - Bremer, Anders
AU  - Bremer A
AD  - Faculty of Health and Life Sciences, Linnaeus University, Kalmar/Vaxjo, Sweden.
FAU - Carlsson, Jorg
AU  - Carlsson J
AUID- ORCID: 0000-0002-0549-7138
AD  - Department of Medicine, Section of Cardiology, Kalmar County Hospital, Kalmar,
      Sweden. Jorg.carlsson@regionkalmar.se.
AD  - Faculty of Health and Life Sciences, Linnaeus University, Kalmar/Vaxjo, Sweden.
      Jorg.carlsson@regionkalmar.se.
LA  - eng
GR  - n a/Landstinget i Kalmar lan/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200801
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cardiopulmonary Resuscitation
MH  - Documentation
MH  - Female
MH  - Hospitals, Community
MH  - Humans
MH  - Middle Aged
MH  - *Patient Participation
MH  - Resuscitation Orders
MH  - Sweden
MH  - Young Adult
PMC - PMC7395331
OTO - NOTNLM
OT  - *Autonomy
OT  - *CPR
OT  - *DNAR order
OT  - *Ethics
OT  - *Informed consent
EDAT- 2020/08/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/03 06:00
PHST- 2019/06/11 00:00 [received]
PHST- 2020/07/26 00:00 [accepted]
PHST- 2020/08/03 06:00 [entrez]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00510-5 [doi]
AID - 10.1186/s12910-020-00510-5 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Aug 1;21(1):67. doi: 10.1186/s12910-020-00510-5.


PMID- 32738553
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 292
DP  - 2020 Oct
TI  - Multimorbidity and psychotropic polypharmacy among participants with autism
      spectrum disorder with intellectual disability.
PG  - 113321
LID - S0165-1781(20)30743-5 [pii]
LID - 10.1016/j.psychres.2020.113321 [doi]
AB  - Nowadays, adults with autism spectrum disorder (ASD) experience several
      comorbidities whose treatment implies a wide range of psychotropic prescriptions.
      This study aimed to evaluate medication-related safety, drug-drug interactions,
      and psychotropics prescription trends. We conducted an observational and
      multicentric pharmacovigilance study in subjects with ASD and Intellectual
      disability (ID, n = 83). Clinical information (diagnoses, ongoing medications,
      comorbidities [multimorbidity >/= 4 chronic health conditions]) and psychotropic 
      prescriptions (polypharmacy >/= 4 chronic drugs, daily drug doses,
      co-prescription) were registered. Ethical approval for this study was obtained.
      Participants (30+/-10 years old, 86% men, BMI 27+/-6 kg/m2) displayed 37%
      multimorbidity (mean of 3, IQR 2-4), and 57% polypharmacy (13% out of dose
      recommended range). Most drugs prescribed were psychotropic risperidone which is 
      related to nervous system comorbidities (18% epilepsy, 16% insomnia, and 14%
      psychotic agitations). Risperidone and quetiapine were co-prescribed in 60% of
      the cases without any monitoring adverse event routine. The rates of
      multimorbidity and polypharmacy, among our young adults with ASD and ID, are
      concerning. Data suggest the need to develop a pharmacovigilance monitoring
      system to evaluate prescription accuracy, long-term safety of ongoing
      medications, and the fixed doses in this autistic population with associated ID.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Espadas, Cristina
AU  - Espadas C
AD  - Occupational Observatory, Miguel Hernandez University of Elche, Alicante, Spain.
FAU - Ballester, Pura
AU  - Ballester P
AD  - Neuropharmacology on Pain (NED) group, Alicante Institute for Health and
      Biomedical Research (ISABIAL Foundation), Alicante, Spain. Electronic address:
      maria.ballester04@umh.es.
FAU - Londono, Ana Carolina
AU  - Londono AC
AD  - Psychiatry Service, Department of Health of Alicante - General Hospital,
      Alicante, Spain; Clinical Pharmacology Unit, Department of Health of Alicante -
      General Hospital, Alicante, Spain.
FAU - Almenara, Susana
AU  - Almenara S
AD  - Clinical Pharmacology Unit, Department of Health of Alicante - General Hospital, 
      Alicante, Spain.
FAU - Aguilar, Victor
AU  - Aguilar V
AD  - Centro San Rafael, Residential facility, Alicante, Spain.
FAU - Belda, Cesar
AU  - Belda C
AD  - Centro Infanta Leonor, Autism Association, Alicante, Spain.
FAU - Perez, Enrique
AU  - Perez E
AD  - Psychiatry Service, Department of Health of Alicante - General Hospital,
      Alicante, Spain.
FAU - Peiro, Ana Maria
AU  - Peiro AM
AD  - Neuropharmacology on Pain (NED) group, Alicante Institute for Health and
      Biomedical Research (ISABIAL Foundation), Alicante, Spain; Clinical Pharmacology 
      Unit, Department of Health of Alicante - General Hospital, Alicante, Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200722
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Psychotropic Drugs)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Autism Spectrum Disorder/*drug therapy/*epidemiology
MH  - Cohort Studies
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Intellectual Disability/*drug therapy/*epidemiology
MH  - Male
MH  - Multimorbidity
MH  - Pharmacovigilance
MH  - *Polypharmacy
MH  - Psychotropic Drugs/*therapeutic use
MH  - Quetiapine Fumarate/therapeutic use
MH  - Risperidone/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - *Adverse events
OT  - *Autism spectrum disorder
OT  - *Intellectual disability
OT  - *Multimorbidity
OT  - *Pharmacovigilance
OT  - *Polypharmacy
COIS- Declaration of Competing Interest The authors declare there was no conflict of
      interest.
EDAT- 2020/08/02 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - S0165-1781(20)30743-5 [pii]
AID - 10.1016/j.psychres.2020.113321 [doi]
PST - ppublish
SO  - Psychiatry Res. 2020 Oct;292:113321. doi: 10.1016/j.psychres.2020.113321. Epub
      2020 Jul 22.


PMID- 32738543
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 83
DP  - 2020 Nov
TI  - Restricted access to innovative surgical technique related to a specific
      training, is it ethical? Example of the PIPAC procedure. A systematic review and 
      an experts survey.
PG  - 235-245
LID - S1743-9191(20)30539-2 [pii]
LID - 10.1016/j.ijsu.2020.07.004 [doi]
AB  - OBJECTIVE: Using the example of Pressurized Intra Peritoneal Aerosol Chemotherapy
      (PIPAC), we analyse the development model of this procedure and provide an
      ethical analysis of the involvement of the industry in a new development. SUMMARY
      BACKGROUND DATA: In the case of breakthrough innovation, medical training is
      essential for safe use of the new procedure. In some cases, pharmaceutical
      companies decide to organise this training. But when it becomes the only training
      opportunity to use the device, scientists and clinicians could be exposed to a
      conflict of interest? METHODS: We performed a literature review of PIPAC
      publications using the STROBE criteria. Then, we conducted interviews with an
      expert panel to analyse the ethical impact of involvement of the industry in the 
      development of the PIPAC procedure. RESULTS: The number of publications has
      increased every year since the first publication in Germany, where the technology
      was developed in 2013. The scientific production was of good quality, with a mean
      STROBE score of 18.2 +/- 2.4 out of 22 points. Ten of the 33 included studies
      declared a conflict of interest. From the interviews, the main axe concerning the
      implication of the industry was the training model. The company had decided that 
      only trained and approval surgeon could perform the PIPAC procedure. All four
      interviewed practitioners agreed that it was initially a good way to implement
      the procedure safely, but later they felt uncomfortable about the control and
      validation by the industry. CONCLUSION: Based on the growing number of published 
      papers from a growing number of international centres, the controlled training
      model is not limiting. However, the different levels of conflict of interest
      complicate transparency, and we postulated that this development model is limited
      to the beginning of the procedure diffusion. CLINICALTRIAL. GOV REGISTRATION:
      NCT04341337.
CI  - Copyright (c) 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All
      rights reserved.
FAU - Martellotto, S
AU  - Martellotto S
AD  - Sorbonne Universite, Department of Endocrine and Digestive Surgery, Hospital
      Pitie Salpetriere, Assistance Publique, Hopitaux de Paris, Paris, France.
      Electronic address: sophie.martellotto@aphp.fr.
FAU - Maillot, C
AU  - Maillot C
AD  - Department of Orthopedic and Traumatologic Surgery, Hospital Paris Nord Val de
      Seine, Bichat/Beaujon, Assistance Publique, Hopitaux de Paris, Paris, France.
      Electronic address: cedric.maillot@sfr.fr.
FAU - Villeneuve, L
AU  - Villeneuve L
AD  - Department of Public Health, Clinical and Epidemiological Research, Hospices
      Civils de Lyon, EMR 3738, Lyon 1 University, Lyon, France. Electronic address:
      laurent.villeneuve@chu-lyon.fr.
FAU - Eveno, C
AU  - Eveno C
AD  - Department of Digestive and Oncologic Surgery, Claude Huriez University Hospital,
      Centre Hospitalier Universitaire (CHU) Lille, Universite de Lille, INSERM Unite
      Mixte de Recherche 1172-JPARC Jean-Pierre Aubert Research Center, Team "Mucins,
      Epithelial Differentiation, and Carcinogenesis", Lille, France. Electronic
      address: clarisse.eveno@chru-lille.fr.
FAU - Sgarbura, O
AU  - Sgarbura O
AD  - Department, Montpellier Cancer Institute (ICM), University of Montpellier,
      Montpellier, France. Electronic address: olivia.sgarbura@icm.unicancer.fr.
FAU - Pocard, M
AU  - Pocard M
AD  - Universite de Paris, UMR 1275 CAP Paris-Tech, F-75010, Paris, France; Department 
      of Digestive and Oncologic Surgery, Hopital Lariboisiere, 2 Rue Ambroise Pare,
      75010, Paris, France. Electronic address: marc.pocard@inserm.fr.
LA  - eng
SI  - ClinicalTrials.gov/NCT04341337
PT  - Journal Article
PT  - Systematic Review
DEP - 20200729
PL  - England
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
RN  - 0 (Aerosols)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Aerosols/administration & dosage
MH  - Antineoplastic Agents/*administration & dosage
MH  - Drug Industry
MH  - Equipment and Supplies
MH  - General Surgery/*education/ethics
MH  - Humans
MH  - Injections, Intraperitoneal/methods
MH  - Peritoneal Neoplasms/*drug therapy
MH  - Peritoneum/drug effects
OTO - NOTNLM
OT  - Conflicts of interest
OT  - Ethics
OT  - Industrial development
OT  - PIPAC
OT  - Surgical training
COIS- Declaration of competing interest None.
EDAT- 2020/08/02 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - S1743-9191(20)30539-2 [pii]
AID - 10.1016/j.ijsu.2020.07.004 [doi]
PST - ppublish
SO  - Int J Surg. 2020 Nov;83:235-245. doi: 10.1016/j.ijsu.2020.07.004. Epub 2020 Jul
      29.


PMID- 32738167
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210920
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 34
IP  - 11
DP  - 2020 Nov
TI  - Physician and patient acceptance of policies to reduce kidney discard.
PG  - e14054
LID - 10.1111/ctr.14054 [doi]
AB  - Despite the shortage of kidneys for transplantation in the United States,
      approximately 18%-20% of deceased donor kidneys are discarded each year. These
      discarded kidneys can offer a survival benefit to suitable patients. Revisions to
      the current kidney allocation policy may be needed to reduce deceased donor
      kidney discard. We surveyed transplant physicians and patients to assess their
      perceived acceptability of policy proposals to reduce the discard of deceased
      donor kidneys. Members of professional societies (AST, ASTS) and a patient
      organization (AAKP) were invited to complete the survey. Responses were obtained 
      from 97 physicians and 107 patients. The majority of physicians (73.4%) and
      patients (73.8%) "somewhat" or "completely" accepted a policy for fast-tracking
      kidneys at risk of discard. Physicians and patients also supported returning a
      proportion of waiting time to patients who accept KDPI >85 kidneys and experience
      graft failure within the first 12 months, with 36% of physicians and 50% of
      patients electing to return 100% of the waiting time. The majority of physicians 
      (75%) "somewhat or completely" accepted a policy to skip less aggressive centers 
      for KDPI 90 + offers. Physicians and patients provided insights into factors
      researchers, and policymakers should consider in the design and implementation of
      these policies.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Mehrotra, Sanjay
AU  - Mehrotra S
AUID- ORCID: 0000-0003-1106-1901
AD  - Department of Engineering and Management Sciences, Northwestern University,
      Evanston, IL, USA.
FAU - Schantz, Karolina
AU  - Schantz K
AUID- ORCID: 0000-0002-5466-0536
AD  - Department of Engineering and Management Sciences, Northwestern University,
      Evanston, IL, USA.
FAU - Friedewald, John J
AU  - Friedewald JJ
AD  - Department of Engineering and Management Sciences, Northwestern University,
      Evanston, IL, USA.
FAU - Ladner, Daniela P
AU  - Ladner DP
AD  - Comprehensive Transplant Center Northwestern University Feinberg School of
      Medicine, Chicago, IL, USA.
FAU - Becker, Yolanda
AU  - Becker Y
AD  - University of Chicago Medicine, Chicago, IL, USA.
FAU - Formica, Richard
AU  - Formica R
AD  - Yale-New Haven Transplantation Center, New Haven, CT, USA.
FAU - Barah, Masoud
AU  - Barah M
AUID- ORCID: 0000-0003-0953-3789
AD  - Department of Engineering and Management Sciences, Northwestern University,
      Evanston, IL, USA.
FAU - Gu, Jiayi
AU  - Gu J
AD  - Department of Engineering and Management Sciences, Northwestern University,
      Evanston, IL, USA.
FAU - Gordon, Elisa J
AU  - Gordon EJ
AUID- ORCID: 0000-0003-0969-1998
AD  - Comprehensive Transplant Center Northwestern University Feinberg School of
      Medicine, Chicago, IL, USA.
LA  - eng
GR  - R01 DK118425/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001422/TR/NCATS NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200928
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
SB  - IM
MH  - Donor Selection
MH  - Graft Survival
MH  - Humans
MH  - Kidney
MH  - *Kidney Transplantation
MH  - *Physicians
MH  - Policy
MH  - Risk Factors
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
MH  - United States
PMC - PMC7929781
MID - NIHMS1673156
OTO - NOTNLM
OT  - *ethics
OT  - *kidney allocation
OT  - *kidney transplantation
OT  - *policy
EDAT- 2020/08/02 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/07/01 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1111/ctr.14054 [doi]
PST - ppublish
SO  - Clin Transplant. 2020 Nov;34(11):e14054. doi: 10.1111/ctr.14054. Epub 2020 Sep
      28.


PMID- 32737862
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1538-2443 (Electronic)
IS  - 1355-0284 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Effectiveness of virtual reality games for falls, postural oscillations, pain and
      quality of life of individual HAM/TSP: a randomized, controlled, clinical trial.
PG  - 676-686
LID - 10.1007/s13365-020-00880-x [doi]
AB  - People with HTLV-1 associated myelopathy or tropical spastic paraparesis
      (HAM/TSP) have sensorimotor losses and postural instability, resulting in
      frequent falls. These findings stimulate the use of exercise protocols associated
      with postural control. This study investigated the effectiveness of a balance
      training exercise protocol through a virtual game. This is a randomized crossover
      clinical trial performed in subjects with imbalance disorders (HAM/TSP). To
      evaluate postural oscillations by baropodometry (total area, anterior, posterior 
      and lateral projection), the Footwork(R) system was used and by cinemetry (angle 
      of the body, hip and ankle alignment in the lateral view), the CVMob system. In
      addition, the Brief Pain Inventory and the WHOQoL Bref were used to measure pain 
      intensity and quality of life. Comparison tests of the averages (intra and inter 
      groups) and correlations were applied considering an alpha of 5% and power of
      80%. The study was approved by the Ethics Committee of the Catholic University of
      Salvador and registered in the Clinical Trials database (NCT02877030). The final 
      sample consisted of 26, predominantly female subjects. An increase in the
      postural oscillations of the control subjects (p < 0.05), a reduction in the
      occurrence of falls (p = 0.039) and an improvement in the quality of life of the 
      control-test group (p < 0.05) were observed. Virtual game training did not
      improve the static balance, promoting an increase in postural oscillations.
      Immediately after the application of the protocol, there was a reduction in fall 
      occurrence and improvement in the quality of life.
FAU - Patricio, Naiane Araujo
AU  - Patricio NA
AD  - Doutoranda em Medicina e Saude pela Universidade Federal da Bahia, Salvador, BA, 
      Brazil. naianearaujopatricio@gmail.com.
FAU - Vidal, Diogo Guedes
AU  - Vidal DG
AD  - Unidade de Investigacao em Energia, Ambiente e Saude (FP-ENAS), Universidade
      Fernando Pessoa, Porto (Portugal), Colaborador de pesquisa da Escola Bahiana de
      Medicina e Saude Publica, Bahia, Brasil.
FAU - Pinto, Elen Beatriz
AU  - Pinto EB
AD  - Escola Bahiana de Medicina e Saude Publica, Salvador, Bahia, Brazil.
FAU - Sa, Katia Nunes
AU  - Sa KN
AD  - Escola Bahiana de Medicina e Saude Publica, Salvador, Bahia, Brazil.
FAU - Baptista, Abrahao Fontes
AU  - Baptista AF
AD  - Universidade Federal do ABC, Sao Bernardo, Sao Paulo, Brazil.
LA  - eng
SI  - ClinicalTrials.gov/NCT02877030
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - United States
TA  - J Neurovirol
JT  - Journal of neurovirology
JID - 9508123
SB  - IM
MH  - Accidental Falls/*prevention & control
MH  - Anthropometry/instrumentation/methods
MH  - Cross-Over Studies
MH  - Exercise/*psychology
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Human T-lymphotropic virus 1/pathogenicity
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/physiopathology/psychology/virology
MH  - Pain Management/methods
MH  - Pain Measurement/statistics & numerical data
MH  - Paraparesis, Tropical Spastic/physiopathology/psychology/*therapy/virology
MH  - Postural Balance/physiology
MH  - Quality of Life/*psychology
MH  - Treatment Outcome
MH  - Virtual Reality Exposure Therapy/methods
OTO - NOTNLM
OT  - *HAM/TSP
OT  - *Pain
OT  - *Postural balance
OT  - *Quality of life
OT  - *Virtual reality
EDAT- 2020/08/02 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/08/02 06:00
PHST- 2019/07/17 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1007/s13365-020-00880-x [doi]
AID - 10.1007/s13365-020-00880-x [pii]
PST - ppublish
SO  - J Neurovirol. 2020 Oct;26(5):676-686. doi: 10.1007/s13365-020-00880-x. Epub 2020 
      Jul 31.


PMID- 32737743
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - Emerging viral threats and the simultaneity of the non-simultaneous: zooming out 
      in times of Corona.
PG  - 589-602
LID - 10.1007/s11019-020-09970-3 [doi]
AB  - This paper addresses global bioethical challenges entailed in emerging viral
      diseases, focussing on their socio-cultural dimension and seeing them as
      symptomatic of the current era of globalisation. Emerging viral threats exemplify
      the extent to which humans evolved into a global species, with a pervasive and
      irreversible impact on the planetary ecosystem. To effectively address these
      disruptive threats, an attitude of preparedness seems called for, not only on the
      viroscientific, but also on bioethical, regulatory and governance levels. This
      paper analyses the global bioethical challenges of emerging viral threats from a 
      dialectical materialist (Marxist) perspective, focussing on three collisions: (1)
      the collision of expanding networks of globalisation with local husbandry
      practices; (2) the collision of global networks of mobility with disrupted
      ecosystems; and (3) the collision of viroscience as a globalised research field
      with existing regulatory frameworks. These collisions emerge in a force field
      defined by the simultaneity of the non-simultaneous. Evidence-based health
      policies invoke discontent as they reflect the normative logic of a globalised
      knowledge regime. The development of a global bioethics or macro-ethics requires 
      us to envision these collisions not primarily as issues of benefits and risks,
      but first and foremost as normative tensions closely entangled with broader
      socio-economic and socio-cultural developments.
FAU - Zwart, Hub
AU  - Zwart H
AUID- ORCID: http://orcid.org/0000-0001-8846-5213
AD  - Dean Erasmus School of Philosophy, Erasmus University Rotterdam, Bayle
      Building/Room J5-65/Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands.
      zwart@esphil.eur.nl.
LA  - eng
GR  - 91213058./ZonMW
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Bioethical Issues
MH  - COVID-19/*epidemiology
MH  - Disaster Planning/*organization & administration
MH  - Health Policy
MH  - Humans
MH  - *Internationality
MH  - *Philosophy, Medical
MH  - SARS-CoV-2
MH  - Socioeconomic Factors
MH  - Virology/*organization & administration
PMC - PMC7394271
OTO - NOTNLM
OT  - Dialectical materialism
OT  - Emerging viral threats
OT  - Global bioethics
OT  - Globalisation
OT  - Marxist bioethics
OT  - Simultaneity of the non-simultaneous
OT  - Virology
OT  - Viroscience
EDAT- 2020/08/02 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1007/s11019-020-09970-3 [doi]
AID - 10.1007/s11019-020-09970-3 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):589-602. doi: 10.1007/s11019-020-09970-3.


PMID- 32737712
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 184
IP  - 1
DP  - 2020 Nov
TI  - Minimally invasive breast cancer excision using the breast lesion excision system
      under ultrasound guidance.
PG  - 37-43
LID - 10.1007/s10549-020-05814-z [doi]
AB  - PURPOSE: To assess the feasibility of completely excising small breast cancers
      using the automated, image-guided, single-pass radiofrequency-based breast lesion
      excision system (BLES) under ultrasound (US) guidance. METHODS: From February
      2018 to July 2019, 22 patients diagnosed with invasive carcinomas </= 15 mm at US
      and mammography were enrolled in this prospective, multi-center, ethics
      board-approved study. Patients underwent breast MRI to verify lesion size.
      BLES-based excision and surgery were performed during the same procedure.
      Histopathology findings from the BLES procedure and surgery were compared, and
      total excision findings were assessed. RESULTS: Of the 22 patients, ten were
      excluded due to the lesion being > 15 mm and/or being multifocal at MRI, and one 
      due to scheduling issues. The remaining 11 patients underwent BLES excision. Mean
      diameter of excised lesions at MRI was 11.8 mm (range 8.0-13.9 mm). BLES revealed
      ten (90.9%) invasive carcinomas of no special type, and one (9.1%) invasive
      lobular carcinoma. Histopathological results were identical for the needle
      biopsy, BLES, and surgical specimens for all lesions. None of the BLES excisions 
      were adequate. Margins were usually compromised on both sides of the specimen,
      indicating that the excised volume was too small. Margin assessment was good for 
      all BLES specimens. One technical complication occurred (retrieval of an empty
      BLES basket, specimen retrieved during subsequent surgery). CONCLUSIONS: BLES
      allows accurate diagnosis of small invasive breast carcinomas. However, BLES
      cannot be considered as a therapeutic device for small invasive breast carcinomas
      due to not achieving adequate excision.
FAU - Sanderink, W B G
AU  - Sanderink WBG
AD  - Department of Medical Imaging/Radiology, Radboud University Medical Center, Geert
      Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.
FAU - Strobbe, L J A
AU  - Strobbe LJA
AD  - Department of Surgical Oncology, Canisius-Wilhelmina Hospital, Nijmegen, The
      Netherlands.
FAU - Bult, P
AU  - Bult P
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, The
      Netherlands.
FAU - Schlooz-Vries, M S
AU  - Schlooz-Vries MS
AD  - Department of Surgery, Radboud University Medical Center, Nijmegen, The
      Netherlands.
FAU - Lardenoije, S
AU  - Lardenoije S
AD  - Department of Medical Imaging/Radiology, Radboud University Medical Center, Geert
      Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.
FAU - Venderink, D J
AU  - Venderink DJ
AD  - Department of Radiology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
FAU - Sechopoulos, I
AU  - Sechopoulos I
AD  - Department of Medical Imaging/Radiology, Radboud University Medical Center, Geert
      Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.
FAU - Karssemeijer, N
AU  - Karssemeijer N
AD  - Department of Medical Imaging/Radiology, Radboud University Medical Center, Geert
      Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.
FAU - Vreuls, W
AU  - Vreuls W
AD  - Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
FAU - Mann, R M
AU  - Mann RM
AUID- ORCID: http://orcid.org/0000-0001-8111-1930
AD  - Department of Medical Imaging/Radiology, Radboud University Medical Center, Geert
      Grooteplein 10, 6525 GA, Nijmegen, The Netherlands. Ritse.Mann@radboudumc.nl.
LA  - eng
GR  - KUN 2015-8086/KWF Kankerbestrijding
PT  - Journal Article
DEP - 20200801
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
MH  - Breast
MH  - *Breast Diseases
MH  - *Breast Neoplasms/diagnostic imaging/surgery
MH  - Female
MH  - Humans
MH  - Mammography
MH  - Prospective Studies
PMC - PMC7568696
OTO - NOTNLM
OT  - Biopsy
OT  - Breast
OT  - Breast cancer
OT  - Minimally invasive
OT  - Vacuum
EDAT- 2020/08/02 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1007/s10549-020-05814-z [doi]
AID - 10.1007/s10549-020-05814-z [pii]
PST - ppublish
SO  - Breast Cancer Res Treat. 2020 Nov;184(1):37-43. doi: 10.1007/s10549-020-05814-z. 
      Epub 2020 Aug 1.


PMID- 32737622
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Sep
TI  - Clinical and Organizational Ethics: Challenges to Methodology and Practice.
PG  - 191-197
LID - 10.1007/s10730-020-09422-8 [doi]
AB  - The day-to-day work of clinical ethics consultants and healthcare ethics
      committees can easily become overly routine. Too much routine, however, comes
      with a risk that morally important practices will be reduced to mere bureaucratic
      formalities, while practitioners become desensitized to ethically significant
      distinctions between cases. Clinical ethics consultation and organizational
      ethics must be set within the broader social and cultural context of the
      healthcare environment. This practice requires looking beyond mere legal
      compliance and the routinely false assumption that there are unambiguous ethical 
      norms that easily govern clinical ethics and hospital policy formation. Together 
      the essays in this issue of HEC Forum challenge readers to rethink
      taken-for-granted assumptions regarding patient care, physician obligation,
      clinical ethics consultation, and organizational ethics.
FAU - Cherry, Mark J
AU  - Cherry MJ
AD  - Department of Philosophy, School of Arts and Humanities, St. Edward's University,
      3001 S. Congress Ave., Austin, TX, 78704, USA. markc@stedwards.edu.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Ethics Consultation/standards/*trends
MH  - *Ethics, Institutional
MH  - *Ethics, Medical
MH  - Humans
OTO - NOTNLM
OT  - Clinical ethics
OT  - Euthanasia
OT  - Medical aid in dying
OT  - Organizational ethics
OT  - Physician assisted suicide
EDAT- 2020/08/02 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1007/s10730-020-09422-8 [doi]
AID - 10.1007/s10730-020-09422-8 [pii]
PST - ppublish
SO  - HEC Forum. 2020 Sep;32(3):191-197. doi: 10.1007/s10730-020-09422-8.


PMID- 32737621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2197-1153 (Print)
IS  - 2197-1153 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jul 31
TI  - The diagnostic potential of low-field MRI in problematic total knee
      arthroplasties - a feasibility study.
PG  - 59
LID - 10.1186/s40634-020-00274-2 [doi]
AB  - PURPOSE: Low-field MRI, allowing imaging in supine and weight-bearing position,
      may be utilized as a non-invasive and affordable tool to differentiate between
      causes of dissatisfaction after TKA ('problematic TKA'). However, it remains
      unclear whether low-field MRI results in sufficient image quality with limited
      metal artefacts. Therefore, this feasibility study explored the diagnostic value 
      of low-field MRI concerning pathologies associated with problematic TKA's' by
      comparing low-field MRI findings with CT and surgical findings. Secondly,
      differences in patellofemoral parameters between supine and weight-bearing
      low-field MRI were evaluated. METHODS: Eight patients with a problematic TKA were
      scanned using low-field MRI in weight-bearing and supine conditions. Six of these
      patients underwent revision surgery. Scans were analysed by a radiologist for
      pathologies associated with a problematic TKA. Additional patellofemoral and
      alignment parameters were measured by an imaging expert. MRI observations were
      compared to those obtained with CT, the diagnosis based on the clinical work-up, 
      and findings during revision surgery. RESULTS: MRI observations of rotational
      malalignment, component loosening and patellofemoral arthrosis were comparable
      with the clinical diagnosis (six out of eight) and were confirmed during surgery 
      (four out of six). All MRI observations were in line with CT findings (seven out 
      of seven). Clinical diagnosis and surgical findings of collateral excessive
      laxity could not be confirmed with MRI (two out of eight). CONCLUSION: Low-field 
      MRI shows comparable diagnostic value as CT and might be a future low cost and
      ionizing radiation free alternative. Differences between supine and
      weight-bearing MRI did not yield clinically relevant information. The study was
      approved by the Medical Research Ethics Committees of Twente (Netherlands Trial
      Register: Trial NL7009 (NTR7207). Registered 5 March 2018,
      https://www.trialregister.nl/trial/7009 ).
FAU - Schroder, Femke F
AU  - Schroder FF
AUID- ORCID: http://orcid.org/0000-0003-0663-7873
AD  - OCON, centre for orthopaedic surgery, Geerdinksweg 141 postbus 546, 7550, AM,
      Hengelo, The Netherlands. f.schroder@ocon.nl.
AD  - University of Twente, Faculty of Engineering Technology, Biomechanical
      Engineering, postbus 217 7500 AE, Enschede, The Netherlands. f.schroder@ocon.nl.
FAU - Post, Corine E
AU  - Post CE
AD  - OCON, centre for orthopaedic surgery, Geerdinksweg 141 postbus 546, 7550, AM,
      Hengelo, The Netherlands.
AD  - University of Twente, Faculty of Engineering Technology, Biomechanical
      Engineering, postbus 217 7500 AE, Enschede, The Netherlands.
AD  - Orthopaedic Research Laboratory, Radboud University Medical Center, postbus, 9101
      6500, HB, Nijmegen, The Netherlands.
FAU - van Raak, Sjoerd M
AU  - van Raak SM
AD  - Department of Radiology, Ziekenhuisgroep Twente, Zilvermeeuw 1, 7609PP, Almelo,
      The Netherlands.
FAU - Simonis, Frank F J
AU  - Simonis FFJ
AD  - University of Twente, Faculty of science and technology, Magnetic Detection and
      Imaging, postbus 217 7500 AE, Enschede, The Netherlands.
FAU - Wagenaar, Frank-Christiaan B M
AU  - Wagenaar FBM
AD  - OCON, centre for orthopaedic surgery, Geerdinksweg 141 postbus 546, 7550, AM,
      Hengelo, The Netherlands.
FAU - Huis In't Veld, Rianne M H A
AU  - Huis In't Veld RMHA
AD  - OCON, centre for orthopaedic surgery, Geerdinksweg 141 postbus 546, 7550, AM,
      Hengelo, The Netherlands.
FAU - Verdonschot, Nico
AU  - Verdonschot N
AD  - University of Twente, Faculty of Engineering Technology, Biomechanical
      Engineering, postbus 217 7500 AE, Enschede, The Netherlands.
AD  - Orthopaedic Research Laboratory, Radboud University Medical Center, postbus, 9101
      6500, HB, Nijmegen, The Netherlands.
LA  - eng
GR  - 2016/Pioneers in Health Care Innovation Fund
PT  - Journal Article
DEP - 20200731
PL  - Germany
TA  - J Exp Orthop
JT  - Journal of experimental orthopaedics
JID - 101653750
PMC - PMC7394973
OTO - NOTNLM
OT  - Low field MRI
OT  - Problematic TKA
OT  - Total knee arthroplasty
OT  - Weight-bearing MRI
EDAT- 2020/08/02 06:00
MHDA- 2020/08/02 06:01
CRDT- 2020/08/02 06:00
PHST- 2020/05/28 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/08/02 06:01 [medline]
AID - 10.1186/s40634-020-00274-2 [doi]
AID - 10.1186/s40634-020-00274-2 [pii]
PST - epublish
SO  - J Exp Orthop. 2020 Jul 31;7(1):59. doi: 10.1186/s40634-020-00274-2.


PMID- 32737510
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1464-3790 (Electronic)
IS  - 0967-0742 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Aug 1
TI  - Getting the Balance Right: Medical Futility, Scientific Advancement, and the Role
      of Law.
PG  - 573-594
LID - 10.1093/medlaw/fwaa011 [doi]
AB  - The concept of medical futility as an applied ethical framework has seen a rise
      and fall in its popularity over the last 30 years. It is a term used in relation 
      to the assessment of a patient's health condition that is deemed untreatable,
      irreversible, and unresolvable. In four recent cases, Gard, Evans, Haastrup, and 
      Raqeeb, the concept has been brought to the fore once again. These cases
      highlight a mounting tension between clinicians and families. Parental desires to
      see their child's treatment continued, while understandable, should not dominate 
      treatment planning. This article analyses judicial interpretation of the factors 
      which determine an assessment of futility and in doing so, argues that the role
      of medical futility in judicial decisions of this kind is gaining prominence and 
      will continue to do so as scientific advancement blurs the limits of medicine
      even further.
CI  - (c) The Author(s) 2020. Published by Oxford University Press; All rights
      reserved. For permissions, please email: journals.permissions@oup.com.
FAU - Glover-Thomas, Nicola
AU  - Glover-Thomas N
AD  - School of Law, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Med Law Rev
JT  - Medical law review
JID - 9308945
SB  - IM
MH  - Dissent and Disputes/*legislation & jurisprudence
MH  - *Judicial Role
MH  - Medical Futility/*ethics/*legislation & jurisprudence
MH  - United Kingdom
MH  - Withholding Treatment/trends
OTO - NOTNLM
OT  - Best interests
OT  - Children's welfare
OT  - Life-sustaining treatment medical
OT  - Parental wishes
OT  - Withdrawal
OT  - futility
EDAT- 2020/08/02 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 5879501 [pii]
AID - 10.1093/medlaw/fwaa011 [doi]
PST - ppublish
SO  - Med Law Rev. 2020 Aug 1;28(3):573-594. doi: 10.1093/medlaw/fwaa011.


PMID- 32737393
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210710
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
VI  - 65
IP  - 12
DP  - 2020 Dec
TI  - Genetics experience impacts attitudes towards germline gene editing: a survey of 
      over 1500 members of the public.
PG  - 1055-1065
LID - 10.1038/s10038-020-0810-2 [doi]
AB  - CRISPR-Cas9 has revolutionised genome engineering and has the potential to
      radically change our approach to genetic disease. However, the potential for
      genetic modification of embryos has raised significant and complex ethical and
      social concerns. The scientific community have called for ongoing stakeholder
      consultation about Germline Gene Editing (GGE), in particular lay publics, to
      help guide policy, education, research and regulatory priorities. In response, we
      conducted a survey to gauge public support for GGE and describe the demographic, 
      experiential and contextual factors that influence individual attitudes.
      Respondent support was measured across nine hypothetical medical and enhancement 
      GGE applications. We received responses from 1537 participants across 67
      countries. Respondents were generally supportive of GGE, particularly for medical
      applications. While the most opposition observed was among religious respondents,
      those with work experience in genetics or genomics also reported greater
      resistance to GGE. Personal or family-related experience with genetics or
      genomics, identifying as female and tertiary education were also associated with 
      less support for GGE. Further research needs to explore a diverse range of
      community and group attitudes towards GGE; the reasons underlying demographic and
      experiential differences; and to determine where the public and genetics
      professionals draw the line on ethical implementation respectively.
FAU - Jedwab, Abbie
AU  - Jedwab A
AUID- ORCID: http://orcid.org/0000-0002-1754-7606
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC,
      Australia.
FAU - Vears, Danya F
AU  - Vears DF
AD  - Murdoch Children's Research Institute, Parkville, VIC, Australia.
AD  - Melbourne Law School, The University of Melbourne, Parkville, VIC, Australia.
FAU - Tse, Cheryl
AU  - Tse C
AD  - Monash Ultrasound for Women, Melbourne, VIC, Australia.
FAU - Gyngell, Christopher
AU  - Gyngell C
AD  - Department of Paediatrics, The University of Melbourne, Parkville, VIC,
      Australia. christopher.gyngell@unimelb.edu.au.
AD  - Murdoch Children's Research Institute, Parkville, VIC, Australia.
      christopher.gyngell@unimelb.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
SB  - IM
MH  - CRISPR-Cas Systems/*genetics
MH  - Female
MH  - Gene Editing/*trends
MH  - Genome/*genetics
MH  - Genomics/*trends
MH  - Germ-Line Mutation/genetics
MH  - Humans
MH  - Male
MH  - Surveys and Questionnaires
EDAT- 2020/08/02 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1038/s10038-020-0810-2 [doi]
AID - 10.1038/s10038-020-0810-2 [pii]
PST - ppublish
SO  - J Hum Genet. 2020 Dec;65(12):1055-1065. doi: 10.1038/s10038-020-0810-2. Epub 2020
      Jul 31.


PMID- 32737240
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200911
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Protection Versus Progress: The Challenge of Research on Cannabis Use During
      Pregnancy.
PG  - S93-S98
LID - 10.1542/peds.2020-0818R [doi]
AB  - A central tension in pediatric research ethics arises from our desire to protect 
      children from harm while also allowing progress toward discoveries that could
      improve child health. A prime example of this tension is research on a
      controversial yet increasingly common practice: the use of cannabis by women to
      treat nausea and vomiting of pregnancy. Studies of cannabis use in pregnancy face
      a combination of ethical hurdles because of the inclusion of pregnant women and
      involvement of a schedule I controlled substance. Given the growing need for
      research on the safety and efficacy of cannabis for nausea and vomiting of
      pregnancy, we reflect on the multiple historical contexts that have contributed
      to the challenge of studying cannabis use during pregnancy and make a case for
      the ethical rationale for such research.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - MacDuffie, Katherine E
AU  - MacDuffie KE
AD  - Departments of Speech and Hearing Sciences, kmacd@uw.edu.
AD  - Seattle Children's Hospital, Treuman Katz Center for Pediatric Bioethics,
      Seattle, Washington; and.
FAU - Kleinhans, Natalia M
AU  - Kleinhans NM
AD  - Radiology, and.
FAU - Stout, Kaeley
AU  - Stout K
AD  - Scripps College, Claremont, California.
FAU - Wilfond, Benjamin S
AU  - Wilfond BS
AD  - Seattle Children's Hospital, Treuman Katz Center for Pediatric Bioethics,
      Seattle, Washington; and.
AD  - Pediatrics, School of Medicine, University of Washington, Seattle, Washington.
LA  - eng
GR  - R21 DA046696/DA/NIDA NIH HHS/United States
GR  - F32 MH118689/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Antiemetics)
RN  - 0 (Drug Combinations)
RN  - 0 (Medical Marijuana)
RN  - 0 (Teratogens)
RN  - 0 (dicyclomine, doxylamine, pyridoxine drug combination)
RN  - 4AF302ESOS (Ondansetron)
RN  - 4KV4X8IF6V (Dicyclomine)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 95QB77JKPL (Doxylamine)
RN  - KV2JZ1BI6Z (Pyridoxine)
SB  - IM
MH  - Antiemetics/adverse effects
MH  - Dicyclomine/therapeutic use
MH  - Doxylamine/therapeutic use
MH  - Drug Approval
MH  - Drug Combinations
MH  - *Ethics, Research
MH  - Female
MH  - Humans
MH  - Medical Marijuana/adverse effects/*therapeutic use
MH  - Morning Sickness/*therapy
MH  - Ondansetron/therapeutic use
MH  - Pediatrics/*ethics
MH  - Pregnancy
MH  - *Pregnant Women
MH  - Pyridoxine/therapeutic use
MH  - *Research Subjects
MH  - Teratogens
MH  - Thalidomide/adverse effects
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818R [pii]
AID - 10.1542/peds.2020-0818R [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S93-S98. doi: 10.1542/peds.2020-0818R.


PMID- 32737239
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20211204
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Ferguson v. City of Charleston Redux: Motivated Reasoning and Coercive
      Interventions in Pregnancy.
PG  - S86-S92
LID - 10.1542/peds.2020-0818Q [doi]
AB  - Criminalization of perinatal substance use disorder and other coercive
      interventions in pregnancy (such as forced cesarean delivery or involuntary
      hospitalization for bed rest) directly affect the well-being of children and
      their families and, potentially, of all women of reproductive capacity. Untenable
      legal and policy approaches that occasion such incursions not only persist but
      affect a growing number of women. They are antithetical to healthy pregnancies,
      healthy children, and healthy families; they have the potential to reduce
      prenatal care seeking, divert attention and resources away from critical mental
      health and maternal and child support services, and epigenetically affect
      maternal and infant bonding. Punitive and coercive interventions contravene
      long-established guidance by professional associations that advocate for public
      health approaches and ethical frameworks to guide practice. Harmful policies
      persist because of motivated reasoning by clinicians, members of the judiciary,
      and ill-informed legislators who rely on personal experience and anecdote rather 
      than evidence to fashion policy. Compounding the problem are inadequate substance
      use treatment resources and professional associations that choose not to hold
      their members accountable for violating their ethical obligations to their
      patients. Pediatricians must advocate for the cessation of coercive interventions
      within their institutions and their larger communities. All health care
      professionals should collaborate at the local, state, and national level to
      provide policymakers and legislators with data emphasizing the negative effects
      of punitive and coercive policies aimed at pregnant women and their children.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Marshall, Mary Faith
AU  - Marshall MF
AD  - Center for Health Humanities and Ethics, University of Virginia, Charlottesville,
      Virginia; and mfm@virginia.edu.
FAU - Taylor, Julia
AU  - Taylor J
AD  - Center for Health Humanities and Ethics, University of Virginia, Charlottesville,
      Virginia; and.
FAU - DeBruin, Debra
AU  - DeBruin D
AD  - Center for Bioethics, University of Minnesota, Minneapolis, Minnesota.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Blacks
MH  - Child
MH  - Child Abuse/legislation & jurisprudence
MH  - *Child Welfare
MH  - *Coercion
MH  - *Family Health
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Involuntary Treatment/*legislation & jurisprudence
MH  - Practice Guidelines as Topic
MH  - Pregnancy
MH  - Pregnancy Complications/ethnology/*therapy
MH  - Pregnant Women/ethnology
MH  - Prenatal Care
MH  - Social Class
MH  - Societies, Medical
MH  - South Carolina
MH  - Substance-Related Disorders/ethnology/*therapy
MH  - United States
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818Q [pii]
AID - 10.1542/peds.2020-0818Q [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S86-S92. doi: 10.1542/peds.2020-0818Q.


PMID- 32737238
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Jahi McMath: Lessons Learned.
PG  - S81-S85
LID - 10.1542/peds.2020-0818P [doi]
AB  - Jahi McMath's story has been an important reference in medicine and ethics as the
      landscape of the understanding of death by neurologic criteria is shifting, with 
      families actively questioning the once-firm criterion. Palliative care providers 
      have a role in seeking understanding and collaborating with families and clinical
      teams to navigate the many challenges that arise when a medical team has
      determined that a child has died, and their parents disagree. In this case-based 
      narrative discussion we consider the complexity of the family experience of brain
      death.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Scott, Maya
AU  - Scott M
AD  - Seattle Children's Hospital, Seattle, Washington maya.scott@seattlechildrens.org.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Adolescent
MH  - Brain Death/*diagnosis
MH  - Faith Healing/psychology
MH  - *Family
MH  - Female
MH  - History, 21st Century
MH  - Humans
MH  - Maternal Behavior
MH  - Neurologic Examination
MH  - *Palliative Care
MH  - Professional-Family Relations
MH  - Prognosis
MH  - *Religion and Medicine
PS  - McMath J
FPS - McMath, Jahi
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential
      conflicts of interest to disclose
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818P [pii]
AID - 10.1542/peds.2020-0818P [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S81-S85. doi: 10.1542/peds.2020-0818P.


PMID- 32737237
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Defining Death: Lessons From the Case of Jahi McMath.
PG  - S75-S80
LID - 10.1542/peds.2020-0818O [doi]
AB  - Death is defined biologically as the irreversible loss of the functioning of the 
      organism as a whole, which typically occurs after the loss of cardiorespiratory
      function. In 1968, a Harvard committee proposed that death could also be defined 
      neurologically as the irreversible loss of brain function. Brain death has been
      considered to be equivalent to cardiorespiratory arrest on the basis of the
      belief that the brain is required to maintain functioning of the organism as a
      whole and that without the brain, cardiorespiratory arrest and biological death
      are both rapid and certain. Over the past 20 years, however, this equivalence has
      been shown to be false on the basis of numerous cases of patients correctly
      diagnosed as brain-dead who nevertheless continued to survive for many years. The
      issue reached national attention with the case of Jahi McMath, a young woman
      diagnosed as brain-dead after a surgical accident, who survived for almost 5
      years, mostly at home, supported with a ventilator and tube feedings. The fact
      that brain death is not biological death has many implications, notably including
      the concern that procurement of organs from brain-dead donors may not comply with
      the so-called dead donor rule, which requires that vital organs be procured from 
      patients only after they are dead. In this article, I conclude with an analysis
      of options for moving forward and among them advocate for reframing brain death
      as a "social construct," with implicit societal acceptance that patients
      diagnosed as brain-dead may be treated legally and ethically the same as if they 
      were biologically dead.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Truog, Robert D
AU  - Truog RD
AD  - Division of Critical Care Medicine, Department of Anesthesia, Critical Care, and 
      Pain Medicine, Boston Children's Hospital and Department of Global Health and
      Social Medicine, Harvard Medical School, Harvard University, Boston,
      Massachusetts robert_truog@hms.harvard.edu.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Adolescent
MH  - Attitude to Death
MH  - *Brain Death/diagnosis/legislation & jurisprudence/physiopathology
MH  - *Death
MH  - Female
MH  - *Heart Arrest/diagnosis/etiology/physiopathology
MH  - History, 21st Century
MH  - Humans
MH  - Neuroimaging/methods
MH  - Neurology/standards
MH  - Postoperative Hemorrhage/complications
MH  - Practice Guidelines as Topic
MH  - Respiration, Artificial
MH  - Survivorship
MH  - Time Factors
MH  - Unconsciousness
MH  - United States
PS  - McMath J
FPS - McMath, Jahi
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated he has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818O [pii]
AID - 10.1542/peds.2020-0818O [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S75-S80. doi: 10.1542/peds.2020-0818O.


PMID- 32737235
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - The Suffering Child: Claims of Suffering in Seminal Cases and What To Do About
      Them.
PG  - S66-S69
LID - 10.1542/peds.2020-0818M [doi]
AB  - In all of medicine, there is perhaps nothing so distressing as bearing witness to
      a patient's suffering, especially if that patient is a child. We want to do
      everything that we can to avoid or alleviate a child's suffering, yet what do
      clinicians, ethicists, lawyers, or family members mean when they use the term
      "suffering," and how should these claims of suffering factor into pediatric
      decision-making? This question of suffering and what to do about it has played a 
      key role in several prominent pediatric cases over the past decade, including the
      cases of Charlie Gard, Alfie Evans, and Baby Joseph. These cases have become
      seminal cases precisely because there is no clear resolution, and the "suffering 
      child" continues to challenge our moral ideals of what it means to live a good
      life. In this article, I explore the various ways in which the concept of
      suffering is used in these cases, and I offer new ways in which parents,
      providers, and all those who work with sick children can approach the suffering
      child.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Friedrich, Annie B
AU  - Friedrich AB
AD  - Albert Gnaegi Center for Health Care Ethics, Saint Louis University, St Louis,
      Missouri annie.friedrich@slu.edu.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Clinical Decision-Making/*ethics
MH  - History, 21st Century
MH  - Humans
MH  - Infant
MH  - *Leigh Disease/diagnosis/psychology/therapy
MH  - Male
MH  - *Mitochondrial Encephalomyopathies/therapy
MH  - *Neurodegenerative Diseases/diagnosis/psychology/therapy
MH  - Ontario
MH  - Parents/psychology
MH  - Persistent Vegetative State/psychology/therapy
MH  - Quality of Life
MH  - Respiration, Artificial/ethics
MH  - Stress, Psychological/diagnosis/psychology/therapy
MH  - *Terminology as Topic
MH  - Tracheostomy/psychology
MH  - United Kingdom
MH  - Withholding Treatment/*ethics/legislation & jurisprudence
PS  - Gard C
FPS - Gard, Charlie
PS  - Evans A
FPS - Evans, Alfie
PS  - Baby Joseph
FPS - Baby Joseph
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818M [pii]
AID - 10.1542/peds.2020-0818M [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S66-S69. doi: 10.1542/peds.2020-0818M.


PMID- 32737234
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Reflections on Charlie Gard and the Best Interests Standard From Both Sides of
      the Atlantic Ocean.
PG  - S60-S65
LID - 10.1542/peds.2020-0818L [doi]
AB  - Charlie Gard (August 4, 2016, to July 28, 2017) was an infant in the United
      Kingdom who was diagnosed with an encephalopathic form of mitochondrial DNA
      depletion syndrome caused by a mutation in the RRM2B gene. Charlie's parents
      raised pound1.3 million ( approximately $1.6 million US) on a crowdfunding
      platform to travel to New York to pursue experimental nucleoside bypass
      treatment, which was being used to treat a myopathic form of mitochondrial DNA
      depletion syndrome caused by mutations in a different gene (TK2). The case made
      international headlines about what was in Charlie's best interest. In the medical
      ethics community, it raised the question of whether best interest serves as a
      guidance principle (a principle that provides substantive directions as to how
      decisions are to be made), an intervention principle (a principle specifying the 
      conditions under which third parties are to intervene), both guidance and
      intervention, or neither. I show that the United Kingdom uses best interest as
      both guidance and intervention, and the United States uses best interest for
      neither. This explains why the decision to withdraw the ventilator without
      attempting nucleoside bypass treatment was the correct decision in the United
      Kingdom and why the opposite conclusion would have been reached in the United
      States.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Ross, Lainie Friedman
AU  - Ross LF
AD  - The College and Departments of Pediatrics, Medicine, and Surgery, University of
      Chicago, Chicago, Illinois lross@uchicago.edu.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
RN  - 0 (Cell Cycle Proteins)
RN  - EC 1.17.4.- (RRM2B protein, human)
RN  - EC 1.17.4.- (Ribonucleotide Reductases)
RN  - EC 2.7.1.- (thymidine kinase 2)
RN  - EC 2.7.1.21 (Thymidine Kinase)
SB  - IM
MH  - Cell Cycle Proteins/*genetics
MH  - Clinical Decision-Making/ethics
MH  - Crowdsourcing/economics
MH  - History, 21st Century
MH  - Humans
MH  - Infant
MH  - Male
MH  - Medical Futility/ethics
MH  - Mitochondrial Encephalomyopathies/genetics/*therapy
MH  - New York City
MH  - Parenting
MH  - Patient Advocacy/*ethics/legislation & jurisprudence
MH  - Patient Transfer/ethics/legislation & jurisprudence
MH  - Practice Guidelines as Topic
MH  - Respiration, Artificial/*ethics
MH  - Ribonucleotide Reductases/*genetics
MH  - Thymidine Kinase/genetics
MH  - United Kingdom
MH  - United States
MH  - Withholding Treatment/*ethics/legislation & jurisprudence
PS  - Gard C
FPS - Gard, Charlie
COIS- POTENTIAL CONFLICTS OF INTEREST: The author has indicated she has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818L [pii]
AID - 10.1542/peds.2020-0818L [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S60-S65. doi: 10.1542/peds.2020-0818L.


PMID- 32737233
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - The Charlie Gard Case, and the Ethics of Obstructing International Transfer of
      Seriously Ill Children.
PG  - S54-S59
LID - 10.1542/peds.2020-0818K [doi]
AB  - In 2017, the court case over medical treatment of UK infant, Charlie Gard,
      reached global attention. In this article, I will analyze one of the more
      distinctive elements of the case. The UK courts concluded that treatment of
      Charlie Gard was not in his best interests and that it would be permissible to
      withdraw life-sustaining treatment. However, in addition, the court ruled that
      Charlie should not be transferred overseas for the treatment that his parents
      sought, even though specialists in Italy and the US were willing to provide that 
      treatment. Is it ethical to prevent parents from pursuing life-prolonging
      treatment overseas for their children? If so, when is it ethical to do this? I
      will outline arguments in defense of obstructing transfer in some situations. I
      will argue, however, that this is only justified if there is good reason to think
      that the proposed treatment would cause harm.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AD  - Faculty of Philosophy, Oxford Uehiro Centre for Practical Ethics, University of
      Oxford, Oxford, United Kingdom; John Radcliffe Hospital, Oxford, United Kingdom; 
      and Murdoch Children's Research Institute, Melbourne, Victoria, Australia
      dominic.wilkinson@philosophy.ox.ac.uk.
LA  - eng
GR  - WT106587/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - *Bioethical Issues
MH  - Dissent and Disputes
MH  - History, 21st Century
MH  - Humans
MH  - Internationality
MH  - Intracranial Arteriovenous Malformations/therapy
MH  - Italy
MH  - Male
MH  - Medical Futility/*ethics/legislation & jurisprudence
MH  - Medical Tourism/ethics/legislation & jurisprudence
MH  - Parents
MH  - Patient Transfer/*ethics/legislation & jurisprudence
MH  - Refusal to Treat/ethics/legislation & jurisprudence
MH  - Texas
MH  - Tracheostomy/ethics/legislation & jurisprudence
MH  - United Kingdom
MH  - United States
MH  - Withholding Treatment/*ethics/legislation & jurisprudence
PS  - Gard C
FPS - Gard, Charlie
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated he has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818K [pii]
AID - 10.1542/peds.2020-0818K [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S54-S59. doi: 10.1542/peds.2020-0818K.


PMID- 32737232
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Public Appeals Challenging Criteria for Pediatric Organ Transplantation.
PG  - S48-S53
LID - 10.1542/peds.2020-0818J [doi]
AB  - In this article, I review the ethical issues that arise in the allocation of
      deceased-donor organs to children and young adults. By analyzing the public media
      cases of Sarah Murnaghan, Amelia Rivera, and Riley Hancey, I assess whether
      public appeals to challenge inclusion and exclusion criteria for organ
      transplantation are ethical and under which circumstances. The issues of
      pediatric allocation with limited evidence and candidacy affected by factors such
      as intellectual disability and marijuana use are specifically discussed. Finally,
      I suggest that ethical public advocacy can coexist with well-evidenced transplant
      allocation if and when certain conditions (morally defensible criteria, expert
      evidence, nonprioritization of the poster child, and greater advocacy for organ
      transplantation in general) are met.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Goldberg, Aviva M
AU  - Goldberg AM
AD  - Department of Pediatrics and Child Health, Max Rady College of Medicine,
      University of Manitoba, Winnipeg, Canada agoldberg@hsc.mb.ca.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Age Factors
MH  - Child
MH  - Child, Preschool
MH  - Cystic Fibrosis/surgery
MH  - Directed Tissue Donation/*ethics/legislation & jurisprudence
MH  - Female
MH  - Health Care Rationing/*ethics/legislation & jurisprudence/organization &
      administration
MH  - History, 21st Century
MH  - Humans
MH  - Intellectual Disability
MH  - Kidney Transplantation
MH  - Lung Transplantation/ethics/legislation & jurisprudence
MH  - Male
MH  - Online Social Networking
MH  - Parents
MH  - Patient Advocacy/*ethics/legislation & jurisprudence
MH  - Pneumonia/surgery
MH  - Prejudice
MH  - Public Opinion
MH  - Resource Allocation/*ethics/legislation & jurisprudence/organization &
      administration
MH  - Substance-Related Disorders
MH  - Tissue and Organ Procurement/ethics/organization & administration
MH  - Waiting Lists
MH  - Wolf-Hirschhorn Syndrome/surgery
MH  - Young Adult
PS  - Murnaghan S
FPS - Murnaghan, Sarah
PS  - Rivera A
FPS - Rivera, Amelia
PS  - Hancey R
FPS - Hancey, Riley
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818J [pii]
AID - 10.1542/peds.2020-0818J [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S48-S53. doi: 10.1542/peds.2020-0818J.


PMID- 32737230
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Ethical Issues Raised by the Media Portrayal of Adolescent Transplant Refusals.
PG  - S33-S41
LID - 10.1542/peds.2020-0818H [doi]
AB  - Cases of adolescents in organ failure who refuse solid organ transplant are not
      common, but several have been discussed in the media in the United States and the
      United Kingdom. Using the framework developed by Buchanan and Brock for surrogate
      decision-making, I examine what role the adolescent should morally play when
      deciding about therapy for life-threatening conditions. I argue that the greater 
      the efficacy of treatment, the less voice the adolescent (and the parent) should 
      have. I then consider how refusals of highly effective transplant cases are
      similar to and different from refusals of other lifesaving therapies (eg,
      chemotherapy for leukemia), which is more commonly discussed in the media and
      medical literature. I examine whether organ scarcity and the need for lifelong
      immunosuppression justify differences in whether the state intervenes when an
      adolescent and his or her parents refuse a transplant. I argue that the state, as
      parens patriae, has an obligation to provide the social supports needed for a
      successful transplant and follow-up treatment plan, although family refusals may 
      be permissible when the transplant is experimental or of low efficacy because of 
      comorbidities or other factors. I conclude by discussing the need to limit media 
      coverage of pediatric treatment refusals.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Ross, Lainie Friedman
AU  - Ross LF
AD  - Departments of Pediatrics, Medicine, and Surgery, University of Chicago, Chicago,
      Illinois lross@uchicago.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Adolescent
MH  - *Bioethical Issues
MH  - Family
MH  - Female
MH  - Humans
MH  - Informed Consent By Minors/ethics/legislation & jurisprudence
MH  - Male
MH  - Mass Media/*ethics
MH  - Organ Transplantation/*ethics/legislation & jurisprudence
MH  - Parental Consent/*ethics/legislation & jurisprudence
MH  - Patient Participation
MH  - Patient Self-Determination Act
MH  - Principle-Based Ethics
MH  - Treatment Refusal/*ethics/legislation & jurisprudence
MH  - Twins, Monozygotic
MH  - United Kingdom
MH  - United States
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818H [pii]
AID - 10.1542/peds.2020-0818H [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S33-S41. doi: 10.1542/peds.2020-0818H.


PMID- 32737227
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Uncertainty: An Uncomfortable Companion to Decision-making for Infants.
PG  - S13-S17
LID - 10.1542/peds.2020-0818E [doi]
AB  - Although parents are typically the most appropriate decision-makers for their
      children, there are limits to this authority. Medical providers may be ethically 
      obligated to seek state intervention against a parental decision if the parent
      places a child at significant and imminent risk of serious harm. When parents
      make medical decisions for their children, they assess both the projected
      benefits and risks of their choices for their family. These assessments are
      impacted by uncertainty, which is a common feature of neonatal intensive care.
      The relative presence or absence of uncertainty may impact perceptions of
      parental decisions and a medical provider's decision to seek state intervention
      to overrule parents. In this article, we propose a model integrating prognostic
      uncertainty into pediatric decision-making that may aid providers in such
      assessments. We will demonstrate how to apply this model to 3 neonatal cases and 
      propose that the presence of greater uncertainty ought to permit parents greater 
      latitude to incorporate family values into their decision-making even if these
      decisions are contradictory to the recommendations of the medical team.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Krick, Jeanne A
AU  - Krick JA
AD  - Departments of Pediatrics and jeanne.a.krick.mil@mail.mil.
FAU - Hogue, Jacob S
AU  - Hogue JS
AD  - Departments of Pediatrics and.
FAU - Reese, Tyler R
AU  - Reese TR
AD  - Family Medicine, Madigan Army Medical Center, Tacoma, Washington.
FAU - Studer, Matthew A
AU  - Studer MA
AD  - Departments of Pediatrics and.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - *Bioethical Issues
MH  - Clinical Decision-Making/*ethics
MH  - Family
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Hypoxia-Ischemia, Brain/etiology
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal
MH  - Male
MH  - Palliative Care
MH  - Parental Consent/ethics
MH  - *Parents
MH  - Prognosis
MH  - Pulmonary Valve Stenosis/surgery
MH  - Social Values
MH  - *Uncertainty
MH  - Withholding Treatment/ethics
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818E [pii]
AID - 10.1542/peds.2020-0818E [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S13-S17. doi: 10.1542/peds.2020-0818E.


PMID- 32737226
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20200903
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - Suppl 1
DP  - 2020 Aug
TI  - Who Is the Next "Baby Doe?" From Trisomy 21 to Trisomy 13 and 18 and Beyond.
PG  - S9-S12
LID - 10.1542/peds.2020-0818D [doi]
AB  - The "Baby Doe" case of the early 1980s was marked by considerable controversy,
      primarily regarding the legal response of the federal government to the case at
      the time. In the decades that followed, the decision-making for children with
      trisomy 21, like Baby Doe, has been substantially reevaluated. The data, the
      assumptions about quality of life that were based on those data, and the ethical 
      principles underpinning the decision-making in the Baby Doe case have all evolved
      significantly over time. The present strategies for decision-making for children 
      with trisomy 13 and 18 appear to be following a similar pattern. The data,
      quality-of-life assumptions based on those data, and even the ethical principles 
      underlying the decision-making for these children are currently being reexamined.
      Children with trisomy 13 and 18 are, in this regard, the next Baby Doe(s).
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Kett, Jennifer C
AU  - Kett JC
AD  - Mary Bridge Children's Hospital, Tacoma, Washington jkett@multicare.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Child Development
MH  - Clinical Decision-Making/*ethics
MH  - Down Syndrome/*therapy
MH  - Esophageal Atresia
MH  - Humans
MH  - Infant, Newborn
MH  - Kaplan-Meier Estimate
MH  - Parents
MH  - Quality of Life
MH  - Trisomy 13 Syndrome/mortality/*therapy
MH  - Trisomy 18 Syndrome/mortality/*therapy
MH  - Withholding Treatment/ethics/legislation & jurisprudence
COIS- POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential
      conflicts of interest to disclose.
EDAT- 2020/08/02 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
AID - peds.2020-0818D [pii]
AID - 10.1542/peds.2020-0818D [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(Suppl 1):S9-S12. doi: 10.1542/peds.2020-0818D.


PMID- 32737222
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 96
IP  - 1138
DP  - 2020 Aug
TI  - Why you should talk to yourself: internal dialogue and reflective practice.
PG  - 507-508
LID - 10.1136/postgradmedj-2020-138455 [doi]
FAU - Launer, John
AU  - Launer J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
MH  - Decision Making
MH  - Humans
MH  - Mental Processes
MH  - *Metacognition
MH  - Problem Solving
MH  - *Self-Assessment
MH  - Thinking
MH  - *Verbal Behavior
OTO - NOTNLM
OT  - *Education and training (see medical education and training)
OT  - *medical ethics
OT  - *medical history
OT  - *medical journalism
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - postgradmedj-2020-138455 [pii]
AID - 10.1136/postgradmedj-2020-138455 [doi]
PST - ppublish
SO  - Postgrad Med J. 2020 Aug;96(1138):507-508. doi: 10.1136/postgradmedj-2020-138455.


PMID- 32737101
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Distress and resilience of healthcare professionals during the COVID-19 pandemic 
      (DARVID): study protocol for a mixed-methods research project.
PG  - e039832
LID - 10.1136/bmjopen-2020-039832 [doi]
AB  - INTRODUCTION: The unprecedented COVID-19 pandemic has exposed healthcare
      professionals (HCPs) to exceptional situations that can lead to increased anxiety
      (ie, infection anxiety and perceived vulnerability), traumatic stress and
      depression. We will investigate the development of these psychological
      disturbances in HCPs at the treatment front line and second line during the
      COVID-19 pandemic over a 12-month period in different countries. Additionally, we
      will explore whether personal resilience factors and a work-related sense of
      coherence influence the development of mental health problems in HCPs. METHODS
      AND ANALYSIS: We plan to carry out a sequential qualitative-quantitative
      mixed-methods design study. The quantitative phase consists of a longitudinal
      online survey based on six validated questionnaires, to be completed at three
      points in time. A qualitative analysis will follow at the end of the pandemic to 
      comprise at least nine semistructured interviews. The a priori sample size for
      the survey will be a minimum of 160 participants, which we will extend to 400, to
      compensate for dropout. Recruitment into the study will be through personal
      invitations and the 'snowballing' sampling technique. Hierarchical linear
      regression combined with qualitative data analysis, will facilitate greater
      understanding of any associations between resilience and mental health issues in 
      HCPs during pandemics. ETHICS AND DISSEMINATION: The study participants will
      provide electronic informed consent. All recorded data will be stored on a
      secured research server at the study site, which will only be accessible to the
      investigators. The Bern Cantonal Ethics Committee has waiv ed the need for
      ethical approval (Req-2020-00355, 1 April 2020). There are no ethical, legal or
      security issues regarding the data collection, processing, storage and
      dissemination in this project. TRIAL REGISTRATION NUMBER: ISRCTN13694948.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fuchs, Alexander
AU  - Fuchs A
AUID- ORCID: 0000-0001-7188-1683
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, University Hospital
      Bern, University of Bern, Bern, Switzerland alexander.fuchs@insel.ch.
FAU - Abegglen, Sandra
AU  - Abegglen S
AD  - Department of Health Psychology and Behavioural Medicine, University of Bern,
      Bern, Switzerland.
FAU - Berger-Estilita, Joana
AU  - Berger-Estilita J
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, University Hospital
      Bern, University of Bern, Bern, Switzerland.
FAU - Greif, Robert
AU  - Greif R
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, University Hospital
      Bern, University of Bern, Bern, Switzerland.
AD  - School of Medicine, Sigmund Freud Private University Vienna, Wien, Austria.
FAU - Eigenmann, Helen
AU  - Eigenmann H
AD  - Department of Health Psychology and Behavioural Medicine, University of Bern,
      Bern, Switzerland.
LA  - eng
SI  - ISRCTN/ISRCTN13694948
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Anxiety/diagnosis/etiology
MH  - Attitude of Health Personnel
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/psychology/therapy
MH  - *Depression/diagnosis/etiology
MH  - Female
MH  - *Health Personnel/psychology/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Occupational Exposure
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/psychology/therapy
MH  - *Psychological Distress
MH  - Research Design
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
PMC - PMC7397979
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *depression and mood disorders
OT  - *mental health
OT  - *primary care
OT  - *public health
OT  - *statistics and research methods
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
AID - bmjopen-2020-039832 [pii]
AID - 10.1136/bmjopen-2020-039832 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e039832. doi: 10.1136/bmjopen-2020-039832.


PMID- 32737100
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for
      a systematic review and meta-analysis of randomised clinical trials.
PG  - e039730
LID - 10.1136/bmjopen-2020-039730 [doi]
AB  - INTRODUCTION: An outbreak of severe acute respiratory syndrome coronavirus-2
      (SARS-CoV-2) was reported in Wuhan, China, in mid-December 2019, and declared a
      pandemic by the WHO on 11 March 2020. Due to the unknown nature of the disease
      and the lack of specific drugs, several potential treatments were used for
      patients. This systematic review and meta-analysis will evaluate studies of the
      effects of favipiravir in COVID-19 pneumonia. METHODS AND ANALYSIS: We will
      search electronic databases including LitCovid hub, PubMed, Scopus, ISI Web of
      Sciences, Cochrane and Embase using keywords related to COVID-19 and favipiravir.
      We will search the reference lists of all included studies and reviews. We will
      also search for clinical trial registries, such as ClinicalTrials.gov, for the
      ongoing clinical trials. All randomised clinical trials investigating the safety 
      and efficacy of favipiravir compared with other control groups for the treatment 
      of patients with confirmed infection with SARS-CoV-2 will be included. Patients' 
      survival at the end of the treatment as well as the follow-up will be the primary
      outcome of the treatment, followed by the time and rate of the patient with a
      negative COVID-19 test. The desired secondary outcome will consist of a decreased
      rate of symptoms, proportion of intensive care unit (ICU) transfers, length of
      the hospital stay, ICU treatments, the quality of life and additional adverse
      events. Data synthesis will be conducted using CMA V.2. Two independent
      investigators will be screening titles, abstracts and full texts of included
      studies, based on eligibility criteria. These investigators will then
      independently extract the data and appraise the quality of said studies. All
      potential discrepancies will be resolved through consultation with the third
      reviewer. Statistical heterogeneity will be assessed using a standard I(2) test. 
      A funnel plot, Egger's test and Begg's test will be used for detecting asymmetry 
      to explore possible publication bias. ETHICS AND DISSEMINATION: All findings of
      this systematic review and meta-analysis will help identify the safety and
      efficacy of favipiravir for patients with COVID-19. Given that the design of the 
      study is a systematic review, there is no need to follow the code of ethics
      protocol. The results of this study will be published in a reputable journal.
      PROSPERO REGISTRATION NUMBER: CRD42020180032.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arab-Zozani, Morteza
AU  - Arab-Zozani M
AUID- ORCID: 0000-0001-7223-6707
AD  - Social Determinants of Health Research Center, Birjand University of Medical
      Sciences, Birjand, Iran arab.hta@gmail.com.
FAU - Hassanipour, Soheil
AU  - Hassanipour S
AD  - Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical
      Sciences, Rasht, Iran.
FAU - Ghoddoosi-Nejad, Djavad
AU  - Ghoddoosi-Nejad D
AD  - Department of Public Health, School of Health, Social Determinants of Health
      Research Center, Birjand University of Medical Sciences, Birjand, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Amides)
RN  - 0 (Antiviral Agents)
RN  - 0 (Pyrazines)
RN  - EW5GL2X7E0 (favipiravir)
SB  - IM
MH  - Adult
MH  - *Amides/administration & dosage/adverse effects
MH  - Antiviral Agents/administration & dosage/adverse effects
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/diagnosis/drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral/diagnosis/drug therapy/etiology/physiopathology
MH  - *Pyrazines/administration & dosage/adverse effects
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7397976
OTO - NOTNLM
OT  - *infection control
OT  - *infectious diseases
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
AID - bmjopen-2020-039730 [pii]
AID - 10.1136/bmjopen-2020-039730 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e039730. doi: 10.1136/bmjopen-2020-039730.


PMID- 32737099
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 30
TI  - Implementation of a community-based, physiotherapy-led, multidisciplinary model
      of care for the management of knee osteoarthritis: protocol for a feasibility
      study.
PG  - e039152
LID - 10.1136/bmjopen-2020-039152 [doi]
AB  - INTRODUCTION: There is a gap between the care people with knee osteoarthritis
      (OA) should receive according to evidence-based guidelines and the care they do
      receive. This feasibility study aims to test the feasibility of developing and
      implementing a codesigned, physiotherapy-led, multidisciplinary, evidence-based
      model of care for knee OA, among community physiotherapy practices in Australia, 
      where community practice is defined as a professional physiotherapy business that
      is not controlled or paid for by the government. METHODS AND ANALYSIS: A
      mixed-methods quasi-experimental (pre/postintervention) study. In the
      preintervention phase, all consented physiotherapists working in nine
      metropolitan-based, community physiotherapy practices, and 26 patients with knee 
      OA will be recruited. Patients will be recruited from all practices by the
      physiotherapists, using the outlined inclusion/exclusion criteria. An audit of
      physiotherapy treatment notes will occur using a proforma, to gain an
      understanding of current community physiotherapy treatment and documentation.
      Patient and physiotherapist interviews will be conducted to determine current
      practice for the management of knee OA. A codesign phase will follow, where a
      model of care will be developed by researchers, patients, clinical staff, members
      of the public and other stakeholders, based on current guidelines for
      conservative management of knee OA. In the postintervention phase, a further 26
      patients will be recruited, and the assessment process repeated to determine
      whether there is a change in practice. The feasibility outcome measures are: (1) 
      number of patients who are recorded as receiving care according to current
      evidence-based guidelines; (2) number of patients who have patient-reported
      outcomes incorporated into their assessment and management plan; and (3)
      acceptability of the developed model to patients and physiotherapists. The
      clinical outcomes will include assessment of patient-reported outcome measures
      (pain, function, etc) in the preintervention and postintervention phases
      (baseline and 12 weeks) to assess trends towards change in participant symptoms. 
      ETHICS AND DISSEMINATION: Ethical approval has been obtained from the University 
      of New South Wales human ethics committee (approval number HC180864, approval
      period 6 February 2019 to 5 February 2024). The preintervention stage of this
      study is complete. The next stage is to implement the intervention and compare
      outcomes between the preintervention and postintervention phases. The results
      will be disseminated via peer-reviewed publications and presentations at
      conferences. TRIAL REGISTRATION NUMBER: The preintervention phase of the study is
      retrospectively registered at ClinicalTrials.gov with registration number:
      ACTRN12620000188932. The intervention and postintervention phase of the study is 
      prospectively registered at ClinicalTrials.gov with registration number:
      ACTRN12620000218998.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Livings, Rebecca
AU  - Livings R
AUID- ORCID: 0000-0001-5079-7351
AD  - Neuroscience Research Australia, Randwick, New South Wales, Australia
      r.livings@neura.edu.au.
FAU - Naylor, Justine M
AU  - Naylor JM
AD  - South West Sydney Clinical School, University of New South Wales, Sydney, New
      South Wales, Australia.
AD  - Ingham Institute for Applied Medical Research, Liverpool, New South Wales,
      Australia.
FAU - Gibson, Kathryn
AU  - Gibson K
AD  - Rheumatology Department, Liverpool Hospital, Liverpool, New South Wales,
      Australia.
FAU - Dennis, Sarah
AU  - Dennis S
AD  - Ingham Institute for Applied Medical Research, Liverpool, New South Wales,
      Australia.
AD  - Clinical and Rehabilitation Sciences, Faculty of Health Sciences, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Thom, Jeanette
AU  - Thom J
AD  - School of Medical Sciences, University of New South Wales, Kensington, New South 
      Wales, Australia.
FAU - Mills, Kathryn
AU  - Mills K
AD  - Department of Health Professions, Macquarie University, Sydney, New South Wales, 
      Australia.
FAU - Schabrun, Siobhan M
AU  - Schabrun SM
AUID- ORCID: 0000-0002-9083-3107
AD  - Neuroscience Research Australia, Randwick, New South Wales, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12620000188932
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200730
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Feasibility Studies
MH  - Humans
MH  - *Osteoarthritis, Knee/therapy
MH  - Physical Therapy Modalities
MH  - Treatment Outcome
PMC - PMC7394177
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *quality in health care
OT  - *rheumatology
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf and declare no support from any organisation 
      for the submitted work; no financial relationships with any organisations that
      might have an interest in the submitted work in the previous three years; no
      other relationships or activities that could appear to have influenced the
      submitted work.
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039152 [pii]
AID - 10.1136/bmjopen-2020-039152 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 30;10(7):e039152. doi: 10.1136/bmjopen-2020-039152.


PMID- 32737098
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Contemporary trends in global mortality of sepsis among young infants less than
      90 days old: protocol for a systematic review and meta-analysis.
PG  - e038815
LID - 10.1136/bmjopen-2020-038815 [doi]
AB  - INTRODUCTION: Neonatal sepsis has a high mortality rate that varies across
      different populations. We aim to perform a contemporary global evidence synthesis
      to determine the case fatality rates of neonatal sepsis, in order to better
      delineate this public health urgency and inform strategies to reduce fatality in 
      this high-risk population. METHODS AND ANALYSIS: We will search PubMed, Cochrane 
      Central, Embase and Web of Science for articles in English language published
      between January 2010 and December 2019. All clinical trials and observational
      studies involving infants less than 90 days old with a clinical diagnosis of
      sepsis and reported case fatality rate will be included. Two independent
      reviewers will screen the studies and extract data on study variables chosen a
      priori. Quality of evidence and risk of bias will be assessed using Cochrane
      Collaboration's tool and ROBINS-I. Results will be synthesised qualitatively and 
      pooled for meta-analysis. ETHICS AND DISSEMINATION: No formal ethical approval is
      required as there is no collection of primary data. This systematic review and
      meta-analysis will be disseminated through conference meetings and peer-reviewed 
      publications. PROSPERO REGISTRATION NUMBER: CRD42020164321.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pek, Jen Heng
AU  - Pek JH
AUID- ORCID: 0000-0002-8356-7410
AD  - Emergency Medicine, Sengkang General Hospital, Singapore.
FAU - Gan, Ming Ying
AU  - Gan MY
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Yap, Bei Jun
AU  - Yap BJ
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Seethor, Shu Ting Tammie
AU  - Seethor STT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Greenberg, Rachel G
AU  - Greenberg RG
AD  - Department of Pediatrics, Duke University School of Medicine, Durham, North
      Carolina, USA.
FAU - Hornik, Christoph Paul Vincent
AU  - Hornik CPV
AD  - Division of Critical Care Medicine, Department of Pediatrics, Duke University
      School of Medicine, Durham, North Carolina, USA.
FAU - Tan, Bobby
AU  - Tan B
AD  - Department of Paediatrics, KK Women's and Children's Hospital, Singapore.
FAU - Lee, Jan Hau
AU  - Lee JH
AD  - Children's Intensive Care Unit, KK Women's and Children's Hospital, Singapore.
FAU - Chong, Shu-Ling
AU  - Chong SL
AUID- ORCID: 0000-0003-4647-0019
AD  - Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore
      chong.shu-ling@kkh.com.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - *Neonatal Sepsis
MH  - Public Health
MH  - Research Design
MH  - *Sepsis
MH  - Systematic Reviews as Topic
PMC - PMC7398098
OTO - NOTNLM
OT  - *epidemiology
OT  - *infectious diseases
OT  - *neonatology
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038815 [pii]
AID - 10.1136/bmjopen-2020-038815 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e038815. doi: 10.1136/bmjopen-2020-038815.


PMID- 32737097
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 30
TI  - Ensemble programme for early intervention in informal caregivers of psychiatric
      adult patients: a protocol for a randomised controlled trial.
PG  - e038781
LID - 10.1136/bmjopen-2020-038781 [doi]
AB  - INTRODUCTION: Informal caregivers play a major role in the support and
      maintenance of community patients with severe psychiatric disorders. A pilot
      study showed that an individualised brief intervention such as the Ensemble
      programme leads to significant improvements in psychological health state and
      optimism. METHODS AND ANALYSIS: This randomised controlled trial aims to compare 
      the efficacy of using Ensemble in improving informal caregivers' psychological
      health states and the ability to play an active role in their situations with
      that of support as usual. Improvements on the psychological health global index
      will be measured three times (T0-pre, T1-post and T3 2 months follow) with
      standardised questionnaires (the Global Severity Index of Brief Inventory
      Symptoms, the Life Orientation Test-Revised, the 36-item Medical Outcome Study
      Short-Form Health Survey and the French Zarit Burden Interview). Differences
      between groups in post-test and pretest values will be examined using an analysis
      of covariance for each outcome variable. The severity of illness measured by the 
      Social and Occupational Functioning Assessment Scale will also be collected at T0
      and T2 to compare eventual patient improvements. At the end of the programme, the
      experiences of the 20 patients participating in the Ensemble programme will be
      evaluated qualitatively. ETHICS AND DISSEMINATION: The research protocol received
      full authorisation from the Human Research Ethics Committee of the Vaud state,
      Switzerland. The principal paper will concern the results of the experimental
      design used to test the Ensemble programme. The research team will prioritise
      open access publications. TRIAL REGISTRATION NUMBER: NCT04020497.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rexhaj, Shyhrete
AU  - Rexhaj S
AUID- ORCID: 0000-0003-1149-6470
AD  - La Source, School of Nursing, University of Applied Sciences and Arts Western
      Switzerland, HES-SO, Lausanne, Vaud, Switzerland s.rexhaj@ecolelasource.ch.
FAU - Monteiro, Shadya
AU  - Monteiro S
AUID- ORCID: 0000-0002-5569-4105
AD  - La Source, School of Nursing, University of Applied Sciences and Arts Western
      Switzerland, HES-SO, Lausanne, Vaud, Switzerland.
FAU - Golay, Philippe
AU  - Golay P
AUID- ORCID: 0000-0002-2273-6241
AD  - Community Psychiatry Service, Department of Psychiatry, Lausanne, CHUV, Lausanne,
      VD, Switzerland.
FAU - Coloni-Terrapon, Claire
AU  - Coloni-Terrapon C
AUID- ORCID: 0000-0002-4793-1801
AD  - La Source, School of Nursing, University of Applied Sciences and Arts Western
      Switzerland, HES-SO, Lausanne, Vaud, Switzerland.
FAU - Wenger, Daniel
AU  - Wenger D
AUID- ORCID: 0000-0001-9951-5466
AD  - La Source, School of Nursing, University of Applied Sciences and Arts Western
      Switzerland, HES-SO, Lausanne, Vaud, Switzerland.
FAU - Favrod, Jerome
AU  - Favrod J
AUID- ORCID: 0000-0002-1132-9472
AD  - La Source, School of Nursing, University of Applied Sciences and Arts Western
      Switzerland, HES-SO, Lausanne, Vaud, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04020497
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200730
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Caregivers
MH  - Humans
MH  - Patients
MH  - Pilot Projects
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Switzerland
PMC - PMC7394301
OTO - NOTNLM
OT  - *clinical trials
OT  - *primary care
OT  - *psychiatry
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038781 [pii]
AID - 10.1136/bmjopen-2020-038781 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 30;10(7):e038781. doi: 10.1136/bmjopen-2020-038781.


PMID- 32737095
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Development and testing of Australian prehospital care quality indicators: study 
      protocol.
PG  - e038310
LID - 10.1136/bmjopen-2020-038310 [doi]
AB  - INTRODUCTION: Historically, ambulance services were established to provide rapid 
      transport of patients to hospital. Contemporary prehospital care involves
      provision of sophisticated 'mobile healthcare' to patients across the lifespan
      presenting with a range of injuries or illnesses of varying acuity. Because of
      its young age, the paramedicine profession has until recently experienced a lack 
      of research capacity which has led to paucity of a discipline-specific,
      scientific evidence-base. Therefore, the performance and quality of ambulance
      services has traditionally been measured using simple, evidence-poor indicators
      forming a deficient reflection of the true quality of care and providing little
      direction for quality improvement efforts. This paper reports the study protocol 
      for the development and testing of quality indicators (QIs) for the Australian
      prehospital care setting. METHODS AND ANALYSIS: This project has three phases. In
      the first phase, preliminary work in the form of a scoping review was conducted
      which provided an initial list of QIs. In the subsequent phase, these QIs will be
      developed by aggregating them and by performing related rapid reviews. The
      summarised evidence will be used to support an expert consensus process aimed at 
      optimising the clarity and evaluating the validity of proposed QIs. Finally, in
      the third phase those QIs deemed valid will be tested for acceptability,
      feasibility and reliability using mixed research methods. Evidence-based
      indicators can facilitate meaningful measurement of the quality of care provided.
      This forms the first step to identify unwarranted variation and direction for
      improvement work. This project will develop and test quality indicators for the
      Australian prehospital care setting. ETHICS AND DISSEMINATION: This project has
      been approved by the University of Adelaide Human Research Ethics Committee.
      Findings will be disseminated by publications in peer-reviewed journals,
      presentations at appropriate scientific conferences, as well as posts on social
      media and on the project's website.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pap, Robin
AU  - Pap R
AUID- ORCID: 0000-0002-7058-0341
AD  - JBI, University of Adelaide, Adelaide, South Australia, Australia
      r.pap@westernsydney.edu.au.
AD  - School of Health Sciences, Western Sydney University, Sydney, New South Wales,
      Australia.
FAU - Lockwood, Craig
AU  - Lockwood C
AD  - JBI, University of Adelaide, Adelaide, South Australia, Australia.
FAU - Stephenson, Matthew
AU  - Stephenson M
AD  - JBI, University of Adelaide, Adelaide, South Australia, Australia.
FAU - Simpson, Paul
AU  - Simpson P
AD  - School of Health Sciences, Western Sydney University, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Emergency Medical Services
MH  - Humans
MH  - Quality Improvement
MH  - *Quality Indicators, Health Care
MH  - Reproducibility of Results
PMC - PMC7398091
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health services administration & management
OT  - *quality in health care
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038310 [pii]
AID - 10.1136/bmjopen-2020-038310 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e038310. doi: 10.1136/bmjopen-2020-038310.


PMID- 32737091
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Choice of ANaesthesia for EndoVAScular treatment of acute ischaemic stroke at
      posterior circulation (CANVAS II): protocol for an exploratory randomised
      controlled study.
PG  - e036358
LID - 10.1136/bmjopen-2019-036358 [doi]
AB  - INTRODUCTION: Observational and interventional studies indicate that the type of 
      anaesthesia may be associated with the postprocedural neurological function in
      patients with anterior circulation acute ischaemic stroke undergoing endovascular
      treatment. Patients with acute posterior circulation ischaemic stroke may
      experience different physiological changes and result in severe neurological
      outcome. However, the effect of the type of anaesthesia on postprocedure
      neurological function remained unclear in this population. METHODS AND ANALYSIS: 
      This is an exploratory randomised controlled trial that will be carried out at
      Beijing Tiantan Hospital, Capital Medical University. Patients with acute
      posterior circulation ischaemic stroke and deemed suitable for emergency
      endovascular recanalisation will be recruited in this trial. Eighty-four patients
      will be randomised to receive either general anaesthesia or conscious sedation
      with 1:1 allocation ratio. The primary endpoint is the 90-day modified Rankin
      Scale. ETHICS AND DISSEMINATION: The study has been reviewed by and approved by
      Ethics Committee of Beijing Tiantan Hospital of Capital Medical University
      (KY2017-074-02). If the results are positive, the study will indicate whether the
      type of anaesthesia affects neurological outcome after endovascular treatment of 
      posterior stroke. The findings of the study will be published in peer-reviewed
      journals and presented at national or international conferences. TRIAL
      REGISTRATION NUMBER: NCT03317535.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liang, Fa
AU  - Liang F
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Yan, Xiang
AU  - Yan X
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Wu, Youxuan
AU  - Wu Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Li, Xiuheng
AU  - Li X
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Zhou, Yang
AU  - Zhou Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Jian, Minyu
AU  - Jian M
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Li, Shu
AU  - Li S
AUID- ORCID: 0000-0002-5625-067X
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Miao, Zhongrong
AU  - Miao Z
AD  - Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Han, Ruquan
AU  - Han R
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China.
FAU - Peng, Yuming
AU  - Peng Y
AUID- ORCID: 0000-0002-2630-2467
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, Beijing, China florapym766@163.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03317535
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acute Disease
MH  - *Anesthesia, General
MH  - Brain Infarction/complications/physiopathology/*surgery
MH  - *Conscious Sedation
MH  - Disability Evaluation
MH  - *Endovascular Procedures
MH  - Humans
MH  - Ischemic Stroke/complications/physiopathology/*surgery
MH  - Neurologic Examination
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7398089
OTO - NOTNLM
OT  - *anaesthesia in neurology
OT  - *neurology
OT  - *neuroradiology
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036358 [pii]
AID - 10.1136/bmjopen-2019-036358 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e036358. doi: 10.1136/bmjopen-2019-036358.


PMID- 32737088
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Quasiexperimental intervention study protocol to optimise the use of new
      antibiotics in Spain: the NEW_SAFE project.
PG  - e035460
LID - 10.1136/bmjopen-2019-035460 [doi]
AB  - INTRODUCTION: Ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam and
      ceftolozane-tazobactam are novel antibiotics used to treat infections caused by
      multidrug-resistant pathogens (MDR). Their use should be supervised and monitored
      as part of an antimicrobial stewardship programme (ASP). Appropriate use of the
      new antibiotics will be improved by including consensual indications for their
      use in local antibiotic guidelines, together with educational interventions
      providing advice to prescribers to ensure that the recommendations are clearly
      understood. METHODS AND ANALYSIS: This study will be implemented in two phases.
      First, a preliminary historical cohort (2017-2019) of patients from 13 Andalusian
      hospitals treated with novel antibiotics will be analysed. Second, a
      quasiexperimental intervention study will be developed with an interrupted
      time-series analysis (2020-2021). The intervention will consist of an educational
      interview between prescribers and ASP leaders at each hospital to reinforce the
      proper use of novel antibiotics. The educational intervention will be based on a 
      consensus guideline designed and disseminated by leaders after the retrospective 
      cohort data have been analysed. The outcomes will be acceptance of the
      intervention and appropriateness of prescription. Incidence of infection and
      colonisation with MDR organisms as well as incidence of Clostridioides difficile 
      infection will also be analysed. Changes in prescription quality between periods 
      and the safety profile of the antibiotics in terms of mortality rate and
      readmissions will also be measured. ETHICS AND DISSEMINATION: Ethical approval
      will be obtained from the Andalusian Coordinating Institutional Review Board. The
      study is being conducted in compliance with the protocol and regulatory
      requirements consistent with International Council of Harmonisation E6 Good
      Clinical Practice and the ethical principles of the latest version of the
      Declaration of Helsinki. The results will be published in peer-reviewed journals 
      and disseminated at national and international conferences. TRIAL REGISTRATION
      NUMBER: NCT03941951; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Palacios-Baena, Zaira R
AU  - Palacios-Baena ZR
AUID- ORCID: 0000-0002-1713-6807
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena/ Instituto de Biomedicina de Sevilla
      (IBiS), Seville, Spain zaira.palacios.baena@hotmail.com.
FAU - Valiente de Santis, Lucia
AU  - Valiente de Santis L
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital Universitario Regional de
      Malaga, Malaga, Spain.
FAU - Maldonado, Natalia
AU  - Maldonado N
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena/ Instituto de Biomedicina de Sevilla
      (IBiS), Seville, Spain.
FAU - Rosso-Fernandez, Clara M
AU  - Rosso-Fernandez CM
AD  - Unidad de Investigacion Clinica y Ensayos Clinicos (CTU), Hospital Universitario 
      Virgen del Rocio-Macarena, Seville, Spain.
FAU - Borreguero, Irene
AU  - Borreguero I
AD  - Unidad de Investigacion Clinica y Ensayos Clinicos (CTU), Hospital Universitario 
      Virgen del Rocio-Macarena, Seville, Spain.
FAU - Herrero-Rodriguez, Carmen
AU  - Herrero-Rodriguez C
AD  - Unidad Clinica de Enfermedades Infecciosas, Complejo Hospitalario de Jaen, Jaen, 
      Spain.
FAU - Lopez-Cardenas, Salvador
AU  - Lopez-Cardenas S
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital de Jerez de la Frontera,
      Cadiz, Spain.
FAU - Martinez-Marcos, Franciso J
AU  - Martinez-Marcos FJ
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital Juan Ramon Jimenez, Huelva, 
      Spain.
FAU - Martin-Aspas, Andres
AU  - Martin-Aspas A
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital Puerta del Mar, Cadiz,
      Spain.
FAU - Jimenez-Aguilar, Patricia
AU  - Jimenez-Aguilar P
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital Puerto Real, Cadiz, Spain.
FAU - Caston, Juan J
AU  - Caston JJ
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital Universitario Reina Sofia,
      Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Cordoba,
      Spain.
FAU - Anguita-Santos, Francisco
AU  - Anguita-Santos F
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital San Cecilio, Granada, Spain.
FAU - Ojeda-Burgos, Guillermo
AU  - Ojeda-Burgos G
AD  - Unidad Clinica de Enfermedades Infecciosas, Hospital Virgen de la Victoria,
      Malaga, Spain.
FAU - Aznarte-Padial, M Pilar
AU  - Aznarte-Padial MP
AD  - Unidad Clinica de Farmacia, Hospital Virgen de las Nieves, Granada, Spain.
FAU - Praena-Segovia, Julia
AU  - Praena-Segovia J
AD  - Unidad de Gestion Clinica de Enfermedades Infecciosas, Microbiologia y Medicina
      Preventiva, Hospital Universitario Virgen del Rocio/ Instituto de Biomedicina de 
      Sevilla (IBIS), Seville, Spain.
FAU - Corzo-Delgado, Juan E
AU  - Corzo-Delgado JE
AD  - Unidad Clinica de Enfermedades Infecciosas y Microbiologia, Hospital
      Universitario Virgen de Valme, Seville, Spain.
FAU - Esteban-Moreno, M Angeles
AU  - Esteban-Moreno MA
AD  - Unidad de Gestion Clinica de Enfermedades Infecciosas y Microbiologia, Hospital
      de Torrecardenas, Almeria, Spain.
FAU - Rodriguez-Bano, Jesus
AU  - Rodriguez-Bano J
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena/ Instituto de Biomedicina de Sevilla
      (IBiS), Seville, Spain.
AD  - Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain.
FAU - Retamar, Pilar
AU  - Retamar P
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena/ Instituto de Biomedicina de Sevilla
      (IBiS), Seville, Spain.
AD  - Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03941951
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Azabicyclo Compounds)
RN  - 0 (Cephalosporins)
RN  - 0 (Drug Combinations)
RN  - 0 (Oxazolidinones)
RN  - 0 (T 91825)
RN  - 0 (Tetrazoles)
RN  - 0 (avibactam, ceftazidime drug combination)
RN  - 0 (ceftolozane, tazobactam drug combination)
RN  - 61036-62-2 (Teicoplanin)
RN  - 808UI9MS5K (dalbavancin)
RN  - 97HLQ82NGL (tedizolid)
RN  - 9M416Z9QNR (Ceftazidime)
RN  - SE10G96M8W (Tazobactam)
SB  - IM
MH  - Antimicrobial Stewardship/methods/*standards
MH  - Azabicyclo Compounds/therapeutic use
MH  - Ceftazidime/therapeutic use
MH  - Cephalosporins/therapeutic use
MH  - *Clinical Protocols
MH  - Drug Combinations
MH  - Humans
MH  - Interrupted Time Series Analysis
MH  - Medication Systems/*standards
MH  - Oxazolidinones/therapeutic use
MH  - Practice Patterns, Physicians'/*standards
MH  - Spain
MH  - Tazobactam/therapeutic use
MH  - Teicoplanin/analogs & derivatives/therapeutic use
MH  - Tetrazoles/therapeutic use
PMC - PMC7398103
OTO - NOTNLM
OT  - *audit
OT  - *bacteriology
OT  - *education & training (see medical education & training)
OT  - *infectious diseases
OT  - *microbiology
COIS- Competing interests: ZRPB reports personal fees from Gilead for educational
      purposes outside the submitted work. PRG and JRB participated in accredited
      educational activities supported by Merck through unrestricted grants outside the
      submitted work.
EDAT- 2020/08/02 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035460 [pii]
AID - 10.1136/bmjopen-2019-035460 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e035460. doi: 10.1136/bmjopen-2019-035460.


PMID- 32737087
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - Open-label, multicentre, single-arm trial of monthly injections of depot
      buprenorphine in people with opioid dependence: protocol for the CoLAB study.
PG  - e034389
LID - 10.1136/bmjopen-2019-034389 [doi]
AB  - INTRODUCTION: Opioid agonist treatment is effective for opioid dependence and
      newer extended-release buprenorphine (BUP-XR) injections represent a significant 
      development. The Community Long-Acting Buprenorphine (CoLAB) study aims to
      evaluate client outcomes among people with opioid dependence receiving 48 weeks
      of BUP-XR treatment, and examines the implementation of BUP-XR in diverse
      community healthcare settings in Australia. METHODS AND ANALYSIS: The CoLAB study
      is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR
      injections in people with opioid dependence. Participants are being recruited
      from a network of general practitioner and specialist drug treatment services
      located in the states of New South Wales, Victoria and South Australia in
      Australia. Following a minimum 7 days on 8-32 mg of sublingual buprenorphine
      (+/-naloxone), participants will receive monthly subcutaneous BUP-XR injections
      administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). 
      The primary endpoint is participant retention in treatment at 48 weeks after
      treatment initiation. Secondary endpoints will evaluate dosing schedule
      variations, craving, withdrawal, substance use, health and well-being, and
      client-reported treatment experience. Qualitative and costing substudies will
      examine implementation barriers and facilitators at the client and provider
      level. ETHICS AND DISSEMINATION: The study has received ethics approval from the 
      St Vincent's Hospital Sydney Human Research Ethics Committee (Ref.
      HREC/18/SVH/221). The findings will be disseminated via publication in
      peer-reviewed journals, presentations at national and international scientific
      conferences, and in relevant community organisation publications and forums.
      TRIAL REGISTRATION NUMBER: NCT03809143 PROTOCOL IDENTIFIER: CoLAB1801, V.4.0
      dated 01 August 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Larance, Briony
AU  - Larance B
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
AD  - School of Psychology, University of Wollongong, Sydney, New South Wales,
      Australia.
AD  - Illawarra Health and Medical Research Institute, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Byrne, Marianne
AU  - Byrne M
AUID- ORCID: 0000-0002-3489-2532
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
AD  - The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
FAU - Lintzeris, Nicholas
AU  - Lintzeris N
AD  - Discipline of Addiction Medicine, University of Sydney, Surry Hills, New South
      Wales, Australia.
AD  - The Langton Centre, South East Sydney Local Health District, Surry Hills, New
      South Wales, Australia.
FAU - Nielsen, Suzanne
AU  - Nielsen S
AUID- ORCID: 0000-0001-5341-1055
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
AD  - Monash Addiction Research Centre and Eastern Health Clinical School, Monash
      University Peninsula Campus, Frankston, Victoria, Australia.
FAU - Grebely, Jason
AU  - Grebely J
AD  - The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
FAU - Degenhardt, Louisa
AU  - Degenhardt L
AUID- ORCID: 0000-0002-8513-2218
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
AD  - School of Population and Global Health, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Shahbazi, Jeyran
AU  - Shahbazi J
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
FAU - Shanahan, Marian
AU  - Shanahan M
AUID- ORCID: 0000-0001-9873-3576
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
FAU - Lancaster, Kari
AU  - Lancaster K
AD  - Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales,
      Australia.
FAU - Dore, Gregory
AU  - Dore G
AD  - The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
FAU - Ali, Robert
AU  - Ali R
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia.
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - Farrell, Michael
AU  - Farrell M
AD  - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, 
      Australia michael.farrell@unsw.edu.au.
CN  - CoLAB study team
LA  - eng
SI  - ClinicalTrials.gov/NCT03809143
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Narcotic Antagonists)
RN  - 40D3SCR4GZ (Buprenorphine)
SB  - IM
MH  - *Buprenorphine/therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Narcotic Antagonists/therapeutic use
MH  - New South Wales
MH  - *Opioid-Related Disorders/drug therapy
MH  - Prospective Studies
MH  - South Australia
MH  - Victoria
PMC - PMC7398105
OTO - NOTNLM
OT  - *buprenorphine
OT  - *drug dependence
OT  - *extended release formulation
OT  - *opiate medication-assisted treatment
OT  - *opioid dependence
COIS- Competing interests: Many of the investigators have received
      investigator-initiated, untied educational grants for opioid-related studies
      from: Indivior (Briony Larance, Louisa Degenhardt, Nicholas Lintzeris, Michael
      Farrell, Suzanne Neilsen); Reckitt Benckiser (Briony Larance, Louisa Degenhardt, 
      Nicholas Lintzeris, Michael Farrell, Suzanne Nielsen, Robert Ali, Adrian Dunlop);
      Mundipharma (Briony Larance, Louisa Degenhardt, Nicholas Lintzeris, Michael
      Farrell); and Seqirus (Briony Larance, Louisa Degenhardt, Michael Farrell,
      Suzanne Nielsen).
IR  - Degenhardt L
FIR - Degenhardt, Louisa
IR  - Lintzeris N
FIR - Lintzeris, Nicholas
IR  - Larance B
FIR - Larance, Briony
IR  - Nielsen S
FIR - Nielsen, Suzanne
IR  - Grebely J
FIR - Grebely, Jason
IR  - Dore G
FIR - Dore, Gregory
IR  - Ali R
FIR - Ali, Robert
IR  - Lancaster K
FIR - Lancaster, Kari
IR  - Shanahan M
FIR - Shanahan, Marian
IR  - Treloar C
FIR - Treloar, Carla
IR  - Byrne M
FIR - Byrne, Marianne
IR  - Shahbazi J
FIR - Shahbazi, Jeyran
IR  - Nalukwago S
FIR - Nalukwago, Stella
IR  - Rodgers C
FIR - Rodgers, Craig
IR  - Dunlop A
FIR - Dunlop, Adrian
IR  - McDonough M
FIR - McDonough, Michael
IR  - Cook J
FIR - Cook, Jon
IR  - Montebello M
FIR - Montebello, Mark
IR  - Aufgang M
FIR - Aufgang, Michael
IR  - Weiss R
FIR - Weiss, Robert
IR  - Griffin Z
FIR - Griffin, Zoe
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034389 [pii]
AID - 10.1136/bmjopen-2019-034389 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e034389. doi: 10.1136/bmjopen-2019-034389.


PMID- 32737086
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 30
TI  - Identifying the facilitators, constraints and barriers of community indoor
      walking programmes: protocol for a realist synthesis.
PG  - e034342
LID - 10.1136/bmjopen-2019-034342 [doi]
AB  - INTRODUCTION: Physical inactivity is a costly and leading health risk factor.
      Engaging in moderate or more intense regular physical activity reduces premature 
      mortality at the population level. Walking is a viable option for achieving the
      recommended level of physical activity. Yet, the sedentary lifestyle is trending.
      Determinants of physical activity may be personal, social or environmental.
      Health promotion endeavours aiming to enhance population-level physical activity 
      are reported in the literature. However, a full range of factors influencing the 
      development and implementation of sustainable indoor walking programmes is
      unclear. The current review protocol is aimed at describing a process of realist 
      synthesis to uncover contexts, mechanisms and outcomes of indoor walking
      intervention programmes, which might reveal facilitators, constraints and
      barriers of planning, implementing and participating in indoor walking
      initiatives open for the members of the general public. METHODS AND ANALYSIS: We 
      will employ a realist synthesis to determine successes or failures in certain
      circumstances for specific stakeholders, which will aid in developing a
      sustainable mall walking health promotion and community engagement programme.
      Qualitative, quantitative and mixed-method articles and reports will be screened 
      for intervention theories and models in order to identify elements of programmes 
      that may be linked to the success or failure of the interventions. Data related
      to the context, mechanism and outcome of the interventions will be collected,
      analysed and synthesised iteratively until a theoretical understanding develops, 
      which might explain the intricacies of the success and failure of identified
      indoor walking programmes. The review process will be conducted and evaluated by 
      using the recommended tools. ETHICS AND DISSEMINATION: Ethical approval, such as 
      Conjoint Health Research Ethics Board, was not required for this study because no
      direct interaction with patients will occur for data collection and analysis. We 
      will disseminate directly to the scholarly community through publication and
      presentation and may post on social media or websites. PROSPERO REGISTRATION
      NUMBER: CRD42020150415.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Singh, Shaminder
AU  - Singh S
AUID- ORCID: 0000-0002-5076-0863
AD  - Community Health Sciences, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada shasingh@ucalgary.ca.
FAU - Yang, Lin
AU  - Yang L
AD  - Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary,
      Alberta, Canada.
AD  - Department of Oncology, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Butalia, Sonia
AU  - Butalia S
AD  - Community Health Sciences, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
AD  - Department of Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Quan, Hude
AU  - Quan H
AD  - Community Health Sciences, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Turin, Tanvir C
AU  - Turin TC
AUID- ORCID: 0000-0002-7499-5050
AD  - Community Health Sciences, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200730
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - *Health Promotion
MH  - Humans
MH  - Research Design
MH  - Review Literature as Topic
MH  - Sedentary Behavior
MH  - *Walking
PMC - PMC7394178
OTO - NOTNLM
OT  - *health promotion
OT  - *public health
OT  - *realist review
OT  - *realist synthesis
OT  - *risk management
OT  - *walking
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034342 [pii]
AID - 10.1136/bmjopen-2019-034342 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 30;10(7):e034342. doi: 10.1136/bmjopen-2019-034342.


PMID- 32737085
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 31
TI  - 'Transgender Education for Affirmative and Competent HIV and Healthcare
      (TEACHH)': protocol of community-based intervention development and a
      non-randomised multisite pilot study with pre-post test design in Canada.
PG  - e034144
LID - 10.1136/bmjopen-2019-034144 [doi]
AB  - INTRODUCTION: Educational workshops are a promising strategy to increase
      healthcare providers' ability to provide gender-affirming care for transgender
      (trans) people. This strategy may also reduce healthcare providers' stigma
      towards trans people and people living with HIV. There is less evidence, however,
      of educational workshops that address HIV prevention and care among trans women. 
      This protocol details development and pilot testing of the Transgender Education 
      for Affirmative and Competent HIV and Healthcare intervention that aims to
      increase gender-affirming HIV care knowledge and perceived competency, and to
      reduce negative attitudes/biases, among providers. METHODS AND ANALYSIS: This
      community-based research (CBR) project involves intervention development and
      implementation of a non-randomised multisite pilot study with pre-post test
      design. First, we conducted a qualitative formative phase involving focus groups 
      with 30 trans women and individual interviews with 12 providers to understand HIV
      care access barriers for trans women and elicit feedback on a proposed workshop. 
      Second, we will pilot test the intervention with 90-150 providers (n=30-50x3
      in-person settings). For pilot studies, primary outcomes include feasibility (eg,
      completion rate) and acceptability (eg, workshop satisfaction). Secondary
      preintervention and postintervention outcomes, assessed directly preceding and
      following the workshop, include perceived competency, attitudes/biases towards
      trans women with HIV, and knowledge needed to provide gender-affirming HIV care. 
      Primary outcomes will be summarised as frequencies and proportions (categorical
      variables). We will conduct paired-sample t-tests to explore the direction of
      preintervention and postintervention differences for secondary outcomes. ETHICS
      AND DISSEMINATION: This study has been approved by the University of Toronto HIV 
      Research Ethics Board (Protocol Number: 00036238). Study findings will be
      disseminated through community forums with trans women and service providers;
      manuscripts submitted to peer reviewed journals; and conferences. Findings will
      inform a larger CBR research agenda to remove barriers to engagement in HIV
      prevention/care among trans women across Canada. TRIAL REGISTRATION NUMBER:
      NCT04096053; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lacombe-Duncan, Ashley
AU  - Lacombe-Duncan A
AUID- ORCID: 0000-0002-9023-8877
AD  - School of Social Work, University of Michigan, Ann Arbor, Michigan, USA
      lacombed@umich.edu.
AD  - Women's College Hospital, Toronto, Ontario, Canada.
FAU - Logie, Carmen H
AU  - Logie CH
AD  - Women's College Hospital, Toronto, Ontario, Canada.
AD  - Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Persad, Yasmeen
AU  - Persad Y
AD  - Women's College Hospital, Toronto, Ontario, Canada.
FAU - Leblanc, Gabrielle
AU  - Leblanc G
AD  - Action Sante Travesti(e)s & Transsexuel(le)s du Quebec, Montreal, Quebec, Canada.
FAU - Nation, Kelendria
AU  - Nation K
AD  - Prism Education Series, Vancouver Coastal Health Authority, Vancouver, British
      Columbia, Canada.
FAU - Kia, Hannah
AU  - Kia H
AD  - School of Social Work, The University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Scheim, Ayden I
AU  - Scheim AI
AD  - Epidemiology and Biostatistics, Drexel Dornsife School of Public Health, Drexel
      University, Philadelphia, Pennsylvania, USA.
FAU - Lyons, Tara
AU  - Lyons T
AD  - Department of Criminology, Kwantlen Polytechnic University, Surrey, British
      Columbia, Canada.
AD  - Center for Gender & Sexual Health Equity (CGSHE), The University of British
      Columbia, Vancouver, British Columbia, Canada.
FAU - Loutfy, Mona
AU  - Loutfy M
AD  - Women's College Hospital, Toronto, Ontario, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04096053
GR  - CTN 317/CAPMC/ CIHR/Canada
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Delivery of Health Care
MH  - Female
MH  - *HIV Infections/prevention & control
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Pilot Projects
MH  - *Transgender Persons
PMC - PMC7398088
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *education & training (see medical education & training)
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034144 [pii]
AID - 10.1136/bmjopen-2019-034144 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 31;10(7):e034144. doi: 10.1136/bmjopen-2019-034144.


PMID- 32736991
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1538-9375 (Electronic)
IS  - 1525-8610 (Linking)
VI  - 21
IP  - 12
DP  - 2020 Dec
TI  - Role of a Clinical Ethics Committee in Residential Aged Long-Term Care Settings: 
      A Systematic Review.
PG  - 1852-1861.e8
LID - S1525-8610(20)30478-3 [pii]
LID - 10.1016/j.jamda.2020.05.053 [doi]
AB  - OBJECTIVES: To conduct a systematic review of literature examining the
      establishment and operation of clinical ethical committees (CECs) in long-term
      care (LTC). DESIGN: Systematic review. SETTING AND PARTICIPANTS: LTC
      recipients/family or staff. METHODS: Five databases (Ovid Medline, Ovid Cochrane 
      Library, Ovid PsycINFO, Ovid EMBASE, and CINAHL via EbscoHost) were
      systematically searched from their inception to May 8, 2020. The initial search
      was conducted on August 22, 2017, and updated on May 8, 2020, to identify
      peer-reviewed studies, commentaries, or editorials. The quality of studies was
      assessed using the Mixed Methods Appraisal Tool. RESULTS: Thirty-three articles
      were identified for inclusion, of which 13 were primary studies. Most articles
      were set in the United States. The purpose of establishing a CEC in LTC was
      typically to assist in dealing with ethical issues and improve the quality of
      care. The articles described the roles of CECs to include prospective case
      consultation, case review, policy development, and ethics education. Articles
      rarely reported whether the CEC was required by or enshrined in law. Membership
      of CECs was between 4 and 20 members and most commonly included nursing staff,
      physicians, and directors/administrators. The rationale behind the membership was
      rarely described. For case consultation, articles described that CECs were
      typically convened upon referral. The resident issues which a CEC could address
      included end-of-life care decisions, autonomy/self-determination, and medical
      treatment decisions. The staff issues addressed by CECs included medical
      treatment decisions, end-of-life care decisions, and decision-making issues. The 
      decision-making process followed by CECs varied. The outcome of a CEC meeting was
      typically a recommendation, whereas the implementation of CEC recommendations and
      decisions were rarely reported. CONCLUSIONS AND IMPLICATIONS: This systematic
      review identifies how CECs operate in the LTC setting. CECs have the potential to
      provide valuable support in addressing complex ethical issues in LTC; however,
      empirical research is required to determine their efficacy in the LTC setting.
CI  - Copyright (c) 2020 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
      Published by Elsevier Inc. All rights reserved.
FAU - Holmes, Alice L
AU  - Holmes AL
AD  - Department of Forensic Medicine, Monash University, Southbank, Victoria,
      Australia.
FAU - Bugeja, Lyndal
AU  - Bugeja L
AD  - Department of Forensic Medicine, Monash University, Southbank, Victoria,
      Australia; Monash Nursing and Midwifery, Monash University, Clayton, Victoria,
      Australia.
FAU - Ibrahim, Joseph E
AU  - Ibrahim JE
AD  - Health Law and Aging Research Unit, Department of Forensic Medicine, Monash
      University, Southbank, Victoria, Australia. Electronic address:
      joseph.ibrahim@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20200728
PL  - United States
TA  - J Am Med Dir Assoc
JT  - Journal of the American Medical Directors Association
JID - 100893243
SB  - IM
MH  - Aged
MH  - Ethics Committees, Clinical
MH  - Humans
MH  - Long-Term Care
MH  - *Physicians
MH  - Prospective Studies
MH  - *Terminal Care
OTO - NOTNLM
OT  - *Clinical ethics committee
OT  - *ethical conflict
OT  - *long-term care
OT  - *systematic review
EDAT- 2020/08/02 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - S1525-8610(20)30478-3 [pii]
AID - 10.1016/j.jamda.2020.05.053 [doi]
PST - ppublish
SO  - J Am Med Dir Assoc. 2020 Dec;21(12):1852-1861.e8. doi:
      10.1016/j.jamda.2020.05.053. Epub 2020 Jul 28.


PMID- 32736914
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1769-664X (Electronic)
IS  - 0929-693X (Linking)
VI  - 27
IP  - 6
DP  - 2020 Aug
TI  - Acute osteomyelitis of the distal fibula in children: Treatment options and
      long-term follow-up.
PG  - 342-347
LID - S0929-693X(20)30143-3 [pii]
LID - 10.1016/j.arcped.2020.06.010 [doi]
AB  - INTRODUCTION: Acute osteomyelitis of the distal fibula is a rare disease in
      children and is characterized by special features compared with other sites. The 
      objective of this study was to report the functional outcome at long-term
      follow-up. METHODS: We reviewed retrospectively, between January 2000 and
      December 2010, all cases of acute osteomyelitis of the distal fibula.
      Epidemiological and bacteriological data as well as therapy and outcome factors
      were analyzed. At the last follow-up, functional outcome was studied based on
      ankle motion, growth disturbance, and radiological sequelae. RESULTS: Seven cases
      of acute osteomyelitis of the distal fibula were found. The mean age was patients
      was 7.71 years and the sex ratio was 2.5. The portal of entry of the pathogen was
      a skin injury in 57% of cases. Staphylococcusaureus was identified in 71% of
      cases. The mean duration of antibiotic therapy was 33.2 days. At a mean of 12.85 
      years of follow-up, no growth disturbance was found. The mean plantar and dorsal 
      flexion was 41 degrees and 27.7 degrees , respectively. The mean postoperative
      American Orthopedics Foot and Ankle score (AOFAS) was 96.71 points. CONCLUSION:
      Acute osteomyelitis of the distal fibula in children is scarce and rarely
      reported in the literature. It occurs more often in boys at an average age of 7
      years. Local symptoms are usually more obvious than general symptoms. Surgical
      debridement of the subperiosteal abscess without bone trepanation seems to lead
      to a satisfactory outcome. LEVEL OF EVIDENCE: Level IV - case series. IRB:
      Sahloul Hospital Human Research Ethics Committee.
CI  - Copyright (c) 2020 French Society of Pediatrics. Published by Elsevier Masson
      SAS. All rights reserved.
FAU - Kaziz, H
AU  - Kaziz H
AD  - Orthopaedics department, Hospital Sousse, Sahloul University, city 4000 9,
      Sousse, Tunisia. Electronic address: hamdi.kaziz@gmail.com.
FAU - Amine Triki, M
AU  - Amine Triki M
AD  - Orthopaedics department, Hospital Sousse, Sahloul University, city 4000 9,
      Sousse, Tunisia.
FAU - Chermiti, W
AU  - Chermiti W
AD  - Orthopaedics department, Hospital Sousse, Sahloul University, city 4000 9,
      Sousse, Tunisia.
FAU - Mouelhi, T
AU  - Mouelhi T
AD  - Orthopaedics department, Hospital Sousse, Sahloul University, city 4000 9,
      Sousse, Tunisia.
FAU - Naouar, N
AU  - Naouar N
AD  - Orthopaedics department, Hospital Sousse, Sahloul University, city 4000 9,
      Sousse, Tunisia.
FAU - Laziz Ben Ayeche, M
AU  - Laziz Ben Ayeche M
AD  - Orthopaedics department, Hospital Sousse, Sahloul University, city 4000 9,
      Sousse, Tunisia.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - France
TA  - Arch Pediatr
JT  - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
JID - 9421356
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Acute Disease
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Child
MH  - Combined Modality Therapy
MH  - Debridement/*methods
MH  - Drainage/*methods
MH  - Female
MH  - *Fibula/microbiology/surgery
MH  - Follow-Up Studies
MH  - Humans
MH  - *Immobilization
MH  - Male
MH  - Osteomyelitis/diagnosis/microbiology/physiopathology/*therapy
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute
OT  - Fibula
OT  - Osteomyelitis
OT  - Outcome
OT  - Treatment
EDAT- 2020/08/02 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/08/02 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - S0929-693X(20)30143-3 [pii]
AID - 10.1016/j.arcped.2020.06.010 [doi]
PST - ppublish
SO  - Arch Pediatr. 2020 Aug;27(6):342-347. doi: 10.1016/j.arcped.2020.06.010. Epub
      2020 Jul 28.


PMID- 32736753
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 0072-9752 (Print)
IS  - 0072-9752 (Linking)
VI  - 171
DP  - 2020
TI  - The ethics of neurologically complicated pregnancies.
PG  - 227-242
LID - B978-0-444-64239-4.00013-8 [pii]
LID - 10.1016/B978-0-444-64239-4.00013-8 [doi]
AB  - Bioethical conflicts in pregnancy are distinguished from those in other areas of 
      medicine due to competing interests between mother and fetus because of their
      shared biology. Historically, prior to the advent of fetal therapy and advances
      in medical technology, the maternal-fetal complex was considered to be a single
      entity. With advances in medicine, treatment options can now be directed at both 
      the mother and the fetus, and a duality has evolved in the maternal-fetal unit.
      Thus at some point during pregnancy, two individuals rather than just one are the
      responsibility of the physician. In determining how to properly care for the
      pregnant woman with a neurologic condition, therapeutic choices must take into
      consideration the impact a treatment will have on both the mother and the fetus. 
      Since what benefits one may harm the other, tension results from the need to
      choose. This chapter will highlight ethical conflicts arising at the interface of
      obstetrics and neurology. We will delve into situations where difficult
      reproductive and therapeutic decisions must be made in pregnant women with
      intellectual disabilities, stroke, brain tumors, and epilepsy. The complexity of 
      brain death in pregnancy will be analyzed, acknowledging the influence of
      politics, law, and religion that bears on ethical decision-making. In approaching
      ethical dilemmas encountered in pregnancies complicated by neurologic conditions,
      frameworks based on principles, virtues, care, and feminist ethics, and case
      precedents will be applied to facilitate ethically appropriate shared
      decision-making. We hope that this chapter will provide valuable guidance for
      providers caring for this complex obstetric population.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Smok, Dorothy
AU  - Smok D
AD  - Department of Obstetrics Gynecology, Columbia University Vagelos College of
      Physicians and Surgeons, New York, NY, United States. Electronic address:
      dp2073@columbia.edu.
FAU - Prager, Kenneth M
AU  - Prager KM
AD  - Department of Medicine, Columbia University Irving Medical Center, New York, NY, 
      United States.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Handb Clin Neurol
JT  - Handbook of clinical neurology
JID - 0166161
SB  - IM
MH  - Ethics, Medical
MH  - Female
MH  - Fetus
MH  - Humans
MH  - Morals
MH  - Pregnancy
MH  - *Pregnancy Complications/therapy
MH  - *Pregnant Women
OTO - NOTNLM
OT  - Brain death
OT  - Brain injury
OT  - Ethics
OT  - Fetus
OT  - Intellectual disability
OT  - Legal
OT  - Mother
OT  - Stroke
EDAT- 2020/08/02 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - B978-0-444-64239-4.00013-8 [pii]
AID - 10.1016/B978-0-444-64239-4.00013-8 [doi]
PST - ppublish
SO  - Handb Clin Neurol. 2020;171:227-242. doi: 10.1016/B978-0-444-64239-4.00013-8.


PMID- 32736559
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 31
TI  - Disparity of perspectives between teachers and learners on perioperative teaching
      and learning.
PG  - 244
LID - 10.1186/s12909-020-02172-8 [doi]
AB  - BACKGROUND: To build a consensus about learning objectives in the operating room,
      the aim of the study was to evaluate both surgical teacher and learner
      perspectives on perioperative teaching and learning in Taiwan. METHODS: Twelve
      main technical and non-technical learning objectives in the operating room were
      evaluated by learners and surgical teachers in Kaohsiung Medical University
      Hospital. The learners included postgraduate year (PGY) 1-3 residents (junior
      learner, JL) and PGY 4-7 residents (senior learner, SL). The definition of
      learning preferences were recommended learning objectives, and learning load was 
      defined as demands of learning preferences. During the survey, surgical teachers 
      evaluated the learning preferences for the learner, and learners evaluated their 
      learning preferences. The learners also evaluated the learning preferences that
      the surgical teachers should teach. RESULTS: Response rate of the questionnaire
      was 65.4%. A total of 31 learners and 39 surgical teachers completed the survey. 
      The consensus was that the need to increase the learning loads and ethical issues
      were the learning preferences for SL, and indications, details of procedure, and 
      teamwork were important to both JL and SL. The teachers intended to set specific 
      learning objectives for different learner levels, including (i) indications,
      details of procedure, teamwork, and postoperative care for both JL and SL; (ii)
      preoperative preparation, surgical anatomy, and instrument handling for JL (P =
      0.022, 0.021 and 0.006); and (iii) surgical technique, independent practice,
      clinical reasoning, complications, and ethical issues for SL (P = 0.010, < 0.001,
      < 0.001, 0.001, 0.011). Resident perspective on learning objectives differed
      between JL and SL, and there was discrepancy between resident's learning as
      perceived by teachers, particularly in the JL. CONCLUSIONS: Our study revealed
      significant disparity of perspectives between teachers and learners on
      perioperative teaching and learning. Surgical teachers should set specific
      learning objectives for different learner levels, since junior and senior
      residents have different learning preferences even though both scrub in the same 
      case. Effective communication between teachers and learners has the potential to 
      improve learning experience and create a positive environment in the operating
      room.
FAU - Chang, Yu-Tang
AU  - Chang YT
AD  - Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
AD  - School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung,
      Taiwan.
FAU - Lu, Peih-Ying
AU  - Lu PY
AD  - School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung,
      Taiwan.
AD  - College of Humanities and Social Sciences, Kaohsiung Medical University,
      Kaohsiung, Taiwan.
FAU - Lai, Chung-Sheng
AU  - Lai CS
AUID- ORCID: http://orcid.org/0000-0002-1298-9325
AD  - Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 
      chshla@kmu.edu.tw.
AD  - School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung,
      Taiwan. chshla@kmu.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - *Educational Personnel
MH  - Humans
MH  - *Internship and Residency
MH  - Learning
MH  - Surveys and Questionnaires
MH  - Taiwan
MH  - Teaching
PMC - PMC7393732
OTO - NOTNLM
OT  - Learning objectives
OT  - Operating room
OT  - Perioperative teaching and learning
OT  - Perspectives
OT  - Working hours
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02172-8 [doi]
AID - 10.1186/s12909-020-02172-8 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Jul 31;20(1):244. doi: 10.1186/s12909-020-02172-8.


PMID- 32736556
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 31
TI  - The ethics of DNR-decisions in oncology and hematology care: a qualitative study.
PG  - 66
LID - 10.1186/s12910-020-00508-z [doi]
AB  - BACKGROUND: In cancer care, do not resuscitate (DNR) orders are common in the
      terminal phase of the illness, which implies that the responsible physician in
      advance decides that in case of a cardiac arrest neither basic nor advanced
      Coronary Pulmonary Rescue should be performed. Swedish regulations prescribe that
      DNR decisions should be made by the responsible physician, preferably in
      co-operation with members of the team. If possible, the patient should consent,
      and significant others should be informed of the decision. Previous studies have 
      shown that physicians and nurses can experience ethical dilemmas in relation to
      DNR decisions, but knowledge about what ethical reasoning they perform is
      lacking. Therefore, the aim was to describe and explore what ethical reasoning
      physicians and nurses apply in relation to DNR-decisions in oncology and
      hematology care. METHODS: A qualitative, descriptive and explorative design was
      used, based on 287 free-text comments in a study-specific questionnaire, answered
      by 216 physicians and nurses working in 16 oncology and hematology wards in
      Sweden. Comments were given by 89 participants. RESULTS: The participants applied
      a situation-based ethical reasoning in relation to DNR-decisions. The reasons
      given for this were both deontological and utilitarian in kind. Also, expressions
      of care ethics were found in the material. Universal rules or guidelines were
      seen as problematic. Concerning the importance of the subject, nurses to a higher
      extent underlined the importance of discussing DNR-situations, while physicians
      described DNR-decisions as over-investigated and not such a big issue in their
      daily work. CONCLUSION: The study revealed that DNR-decisions in oncology and
      hematology care gave rise to ethical considerations. Important ethical values
      described by the participants were to avoid doing harm and to secure a peaceful
      and "natural" death with dignity for their dying patients. A preference for the
      expression "allow for natural death" instead of the traditional term "do not
      resuscitate" was found in the material.
FAU - Pettersson, Mona
AU  - Pettersson M
AUID- ORCID: http://orcid.org/0000-0002-3294-081X
AD  - Department of Public Health and Caring Sciences, Uppsala University, Box 564, 751
      22, Uppsala, Sweden. mona.pettersson@pubcare.uu.se.
FAU - Hedstrom, Mariann
AU  - Hedstrom M
AD  - Department of Public Health and Caring Sciences, Uppsala University, Box 564, 751
      22, Uppsala, Sweden.
FAU - Hoglund, Anna T
AU  - Hoglund AT
AD  - Department of Public Health and Caring Sciences, Uppsala University, Box 564, 751
      22, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Decision Making
MH  - *Hematology
MH  - Humans
MH  - Medical Oncology
MH  - *Physicians
MH  - Resuscitation Orders
MH  - Sweden
PMC - PMC7395367
OTO - NOTNLM
OT  - *Allow for natural death
OT  - *Do not resuscitate
OT  - *Ethics
OT  - *Hematology
OT  - *Nurses
OT  - *Oncology
OT  - *Physicians
OT  - *Sweden
EDAT- 2020/08/02 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00508-z [doi]
AID - 10.1186/s12910-020-00508-z [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 31;21(1):66. doi: 10.1186/s12910-020-00508-z.


PMID- 32736554
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 31
TI  - Public awareness of and attitudes towards research biobanks in Latvia.
PG  - 65
LID - 10.1186/s12910-020-00506-1 [doi]
AB  - BACKGROUND: Public awareness and engagement are among the main prerequisites for 
      protecting the rights of research participants and for successful and sustainable
      functioning of research biobanks. The aim of our study was to analyse public
      awareness and attitudes towards research biobanks in Latvia, and to compare these
      data with the results of the 2010 Eurobarometer study. We also analysed the
      influence of awareness and attitudes towards biobanks on willingness to
      participate in biobank studies and on preferred type of informed consent.
      METHODS: We developed a 12-question survey repeating seven questions about
      biobanks from the 2010 Eurobarometer questionnaire and adding five others. After 
      describing the study variables, we performed a two-stage analysis of the results.
      In the first stage we analysed differences between the answers from 2010 and 2019
      and conducted univariate analyses of relationships among particular variables,
      and between those variables and the socio-demographic characteristics of
      participants. In the second stage we investigated multivariable associations of
      willingness to participate and type of consent with awareness, trust and the
      socio-economic characteristics of participants. RESULTS: According to our study, 
      the general public in Latvia is still not well informed about research biobanks. 
      Fewer respondents have heard about research biobanks than in 2010. At the same
      time, the number of respondents who are willing to donate biological samples and 
      personal data to a biobank has increased, e.g. the number of respondents who
      would definitely or probably be willing to provide information about themselves
      has increased from 25.8.% to 40.7 since 2010. Overall, concerns about the
      donation of different types of biological samples and data to a biobank have
      slightly decreased. CONCLUSIONS: Public awareness about biobanks is important for
      their sustainability. It needs to be increased not only by traditional methods of
      informing the public, but also by more innovative and participatory approaches,
      e.g. by citizen science projects. There is a need to strengthen the public
      visibility and trustworthiness of ethics committees in Latvia in the field of
      biobanking.
FAU - Mezinska, S
AU  - Mezinska S
AUID- ORCID: 0000-0002-3190-100X
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Rainis
      Boulevard 19, Riga, LV-1586, Latvia. signe.mezinska@lu.lv.
FAU - Kaleja, J
AU  - Kaleja J
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Rainis
      Boulevard 19, Riga, LV-1586, Latvia.
FAU - Mileiko, I
AU  - Mileiko I
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Rainis
      Boulevard 19, Riga, LV-1586, Latvia.
FAU - Santare, D
AU  - Santare D
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Rainis
      Boulevard 19, Riga, LV-1586, Latvia.
FAU - Rovite, V
AU  - Rovite V
AD  - Latvian Biomedical Research and Study Centre, Ratsupites Str. 1-k1, Riga,
      LV-1067, Latvia.
FAU - Tzivian, L
AU  - Tzivian L
AD  - Institute of Clinical and Preventive Medicine, University of Latvia, Rainis
      Boulevard 19, Riga, LV-1586, Latvia.
LA  - eng
GR  - lzp-2018/2-0171/Latvijas Zinatnes Padome/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Attitude
MH  - *Biological Specimen Banks
MH  - Humans
MH  - Informed Consent
MH  - Latvia
MH  - Surveys and Questionnaires
PMC - PMC7393882
OTO - NOTNLM
OT  - *Informed consent
OT  - *Latvia
OT  - *Public attitudes
OT  - *Public opinion
OT  - *Research biobanks
EDAT- 2020/08/02 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00506-1 [doi]
AID - 10.1186/s12910-020-00506-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 31;21(1):65. doi: 10.1186/s12910-020-00506-1.


PMID- 32736552
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 31
TI  - A systematic scoping review of ethical issues in mentoring in medical schools.
PG  - 246
LID - 10.1186/s12909-020-02169-3 [doi]
AB  - BACKGROUND: Mentoring provides mentees and mentors with holistic support and
      research opportunities. Yet, the quality of this support has been called into
      question amidst suggestions that mentoring is prone to bullying and professional 
      lapses. These concerns jeopardise mentoring's role in medical schools and demand 
      closer scrutiny. METHODS: To better understand prevailing concerns, a novel
      approach to systematic scoping reviews (SSR) s is proposed to map prevailing
      ethical issues in mentoring in an accountable and reproducible manner. Ten
      members of the research team carried out systematic and independent searches of
      PubMed, Embase, ERIC, ScienceDirect, Scopus, OpenGrey and Mednar databases. The
      individual researchers employed 'negotiated consensual validation' to determine
      the final list of articles to be analysed. The reviewers worked in three
      independent teams. One team summarised the included articles. The other teams
      employed independent thematic and content analysis respectively. The findings of 
      the three approaches were compared. The themes from non-evidence based and grey
      literature were also compared with themes from research driven data. RESULTS:
      Four thousand six titles were reviewed and 51 full text articles were included.
      Findings from thematic and content analyses were similar and reflected the
      tabulated summaries. The themes/categories identified were ethical concerns,
      predisposing factors and possible solutions at the mentor and mentee, mentoring
      relationship and/or host organisation level. Ethical concerns were found to stem 
      from issues such as power differentials and lack of motivation whilst
      predisposing factors comprised of the mentor's lack of experience and personality
      conflicts. Possible solutions include better program oversight and the fostering 
      of an effective mentoring environment. CONCLUSIONS: This structured SSR found
      that ethical issues in mentoring occur as a result of inconducive mentoring
      environments. As such, further studies and systematic reviews of mentoring
      structures, cultures and remediation must follow so as to guide host
      organisations in their endeavour to improve mentoring in medical schools.
FAU - Kow, Cheryl Shumin
AU  - Kow CS
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Teo, Yao Hao
AU  - Teo YH
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Teo, Yao Neng
AU  - Teo YN
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Chua, Keith Zi Yuan
AU  - Chua KZY
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Quah, Elaine Li Ying
AU  - Quah ELY
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Kamal, Nur Haidah Binte Ahmad
AU  - Kamal NHBA
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Tan, Lorraine Hui En
AU  - Tan LHE
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Cheong, Clarissa Wei Shuen
AU  - Cheong CWS
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Ong, Yun Ting
AU  - Ong YT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Tay, Kuang Teck
AU  - Tay KT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore.
FAU - Chiam, Min
AU  - Chiam M
AD  - Division of Cancer Education, National Cancer Centre Singapore, 11 Hospital Dr,
      Singapore, 169610, Singapore.
FAU - Mason, Stephen
AU  - Mason S
AD  - Palliative Care Institute Liverpool, Cancer Research Centre, University of
      Liverpool, 200 London Rd, Liverpool, L3 9TA, UK.
FAU - Krishna, Lalit Kumar Radha
AU  - Krishna LKR
AUID- ORCID: http://orcid.org/0000-0002-7350-8644
AD  - Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower
      Block, 1E Kent Ridge Road, Level 11, Singapore, 119228, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 
      Hospital Dr, Singapore, 169610, Singapore. lalit.radha-krishna@liverpool.ac.uk.
AD  - Division of Cancer Education, National Cancer Centre Singapore, 11 Hospital Dr,
      Singapore, 169610, Singapore. lalit.radha-krishna@liverpool.ac.uk.
AD  - Palliative Care Institute Liverpool, Cancer Research Centre, University of
      Liverpool, 200 London Rd, Liverpool, L3 9TA, UK.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - Duke-NUS Medical School, National University of Singapore, 8 College Rd,
      Singapore, 169857, Singapore. lalit.radha-krishna@liverpool.ac.uk.
AD  - Centre of Biomedical Ethics, National University of Singapore, Blk MD 11, 10
      Medical Drive, #02-03, Singapore, 117597, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
AD  - PalC, The Palliative Care Centre for Excellence in Research and Education, PalC
      c/o Dover Park Hospice, 10 Jalan Tan Tock Seng, Singapore, 308436, Singapore.
      lalit.radha-krishna@liverpool.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200731
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Humans
MH  - *Mentoring
MH  - Mentors
MH  - Schools, Medical
PMC - PMC7395401
OTO - NOTNLM
OT  - Ethical issues in mentoring
OT  - Mentoring
OT  - Mentoring abuse
OT  - Mentoring environment
OT  - Mentoring in medical schools
OT  - Mentoring relationships
EDAT- 2020/08/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12909-020-02169-3 [doi]
AID - 10.1186/s12909-020-02169-3 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Jul 31;20(1):246. doi: 10.1186/s12909-020-02169-3.


PMID- 32736203
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210110
IS  - 1873-2054 (Electronic)
IS  - 1353-8292 (Linking)
VI  - 65
DP  - 2020 Sep
TI  - Public perception of urban companion animals during the COVID-19 outbreak in
      China.
PG  - 102399
LID - S1353-8292(20)30375-0 [pii]
LID - 10.1016/j.healthplace.2020.102399 [doi]
AB  - This paper responds to the increasing concern regarding the role of non-human
      life in shaping urban space by exploring the public perception of urban companion
      animals during the coronavirus disease 2019 (COVID-19) outbreak in China. We
      argue that the public's perception of urban companion animals during emerging
      infectious disease outbreaks is related to medical and life science issues and
      reflects the political, economic, and emotional struggles involved in
      human-animal multispecies cohabitation. We find that the public has mainly
      followed and reconstructed medical discourses about the risk of companion
      animal-to-human transmission and discussed sustainable ethical animal practices
      in urban public health emergency management during the COVID-19 outbreak.
      Concerns regarding the risk of companion animal-related infection reflect the
      increasing prominence of more-than-human families, the pet industry, and
      multispecies leisure conflicts in public space in Chinese cities. The public's
      attention to animal ethics has prompted Chinese policy makers to adopt a more
      morally acceptable model for urban public health emergency management that can be
      sustained and supported by responsible non-governmental organizations and ethical
      urban residents.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Yin, Duo
AU  - Yin D
AD  - School of Geographical Sciences, Guangzhou University, Higher Education Mega
      Center, Guangzhou, 510006, China. Electronic address: yinduo@m.scnu.edu.cn.
FAU - Gao, Quan
AU  - Gao Q
AD  - Department of Geography, Newcastle University, Newcastle, NE1 7RU, United
      Kingdom. Electronic address: q.gao2@newcastle.ac.uk.
FAU - Zhu, Hong
AU  - Zhu H
AD  - School of Geographical Sciences, Guangzhou University, Higher Education Mega
      Center, Guangzhou, 510006, China. Electronic address: zhuhong@gzhu.edu.cn.
FAU - Li, Jie
AU  - Li J
AD  - School of Geographical Sciences, Guangzhou University, Higher Education Mega
      Center, Guangzhou, 510006, China. Electronic address: lijie@lreis.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - England
TA  - Health Place
JT  - Health & place
JID - 9510067
MH  - Animals
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - *Disease Outbreaks
MH  - Emotions
MH  - Humans
MH  - Pandemics
MH  - *Perception
MH  - *Pets
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Zoonoses/prevention & control
PMC - PMC7386851
OTO - NOTNLM
OT  - *Animal ethics
OT  - *Companion animals
OT  - *Emerging infectious diseases
OT  - *Public health
OT  - *Urban resident
EDAT- 2020/08/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/07/12 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - S1353-8292(20)30375-0 [pii]
AID - 10.1016/j.healthplace.2020.102399 [doi]
PST - ppublish
SO  - Health Place. 2020 Sep;65:102399. doi: 10.1016/j.healthplace.2020.102399. Epub
      2020 Jul 28.


PMID- 32736165
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20201106
IS  - 1873-4162 (Electronic)
IS  - 1344-6223 (Linking)
VI  - 47
DP  - 2020 Nov
TI  - Applicability of 3.0 T MRI images in the estimation of full age based on shoulder
      joint ossification: Single-centre study.
PG  - 101767
LID - S1344-6223(20)30101-2 [pii]
LID - 10.1016/j.legalmed.2020.101767 [doi]
AB  - Skeletal maturity is evaluated by many radiological methods for forensic age
      estimation. Direct radiography and computed tomography lead to a rise in ethical 
      concerns due to radiation exposure. Therefore, magnetic resonance imaging (MRI)
      has currently been used in recent studies. In this study, the ossification stage 
      of the shoulder joint was determined retrospectively in 178 male and 109 female
      individuals in the age group 12 to 30 years using 3.0 T MRI. All the images were 
      evaluated with T1-weighted turbo spin echo (T1 TSE) sequence and T1 fast low
      angle shot two-dimensional sequence (T1 FL2D). The combined staging method, which
      was defined by Kellinghaus et al. and Schmeling et al., was used. The intra- and 
      inter-observer agreement levels were very good (kappa and kappaw). There were no 
      significant age differences between males and females in all stages. In most of
      the stages, the ossification of the proximal humeral epiphyses occurred earlier
      in females than in males. Stage 4 did not occur in either of the sexes before the
      18th birthday as the youngest patients in this stage was at 19 and 18 years of
      age in males and females, respectively. We concluded that evaluating the
      ossification of the proximal humeral epiphysis with MRI imaging for forensic age 
      estimation may be beneficial. Evaluating the same anatomical structure with
      different MRI sequences may be useful for accurate staging diagnosis.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Altinsoy, Hasan Baki
AU  - Altinsoy HB
AD  - Department of Radiology, Faculty of Medicine, Duzce University, Duzce, Turkey.
FAU - Gurses, Murat Serdar
AU  - Gurses MS
AD  - Department of Forensic Medicine, Faculty of Medicine, Sakarya University,
      Sakarya, Turkey. Electronic address: muratserdargurses@gmail.com.
FAU - Bogan, Mustafa
AU  - Bogan M
AD  - Department of Emergency Medicine, Faculty of Medicine, Duzce University, Duzce,
      Turkey.
FAU - Unlu, Nisa Elif
AU  - Unlu NE
AD  - Department of Radiology, Faculty of Medicine, Duzce University, Duzce, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - Ireland
TA  - Leg Med (Tokyo)
JT  - Legal medicine (Tokyo, Japan)
JID - 100889186
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Determination by Skeleton/*methods
MH  - *Aging
MH  - Child
MH  - Diffusion Tensor Imaging/*methods
MH  - Female
MH  - Forensic Anthropology/*methods
MH  - Humans
MH  - Male
MH  - *Osteogenesis
MH  - Retrospective Studies
MH  - Shoulder Joint/anatomy & histology/*diagnostic imaging/*physiology
MH  - Young Adult
OTO - NOTNLM
OT  - Anatomical structure
OT  - Forensic age estimation
OT  - Forensic anthropology
OT  - Magnetic resonance imaging
OT  - Proximal humeral epiphysis
OT  - Radiological methods
EDAT- 2020/08/01 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/07/03 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - S1344-6223(20)30101-2 [pii]
AID - 10.1016/j.legalmed.2020.101767 [doi]
PST - ppublish
SO  - Leg Med (Tokyo). 2020 Nov;47:101767. doi: 10.1016/j.legalmed.2020.101767. Epub
      2020 Jul 24.


PMID- 32736097
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 261
DP  - 2020 Sep
TI  - "Obviously there is a conflict between confidentiality and what you are required 
      to do by law": Chilean university faculty and student perspectives on reporting
      unlawful abortions.
PG  - 113220
LID - S0277-9536(20)30439-1 [pii]
LID - 10.1016/j.socscimed.2020.113220 [doi]
AB  - BACKGROUND AND OBJECTIVES: While Chile recently decriminalized abortion in cases 
      of rape, lethal fetal anomaly, and to save a woman's life, most abortions are
      still criminalized. We assessed medical and midwifery school faculty and
      students' views on punishing and reporting people involved in unlawful abortion, 
      and their understanding of their obligation to protect patient confidentiality
      and to report unlawful abortions. METHODS: We interviewed 30 medical and
      midwifery school clinician faculty from seven public, private, secular and
      Catholic-affiliated universities, all located in the metropolitan region of
      Santiago, Chile. Medical (n = 239) and midwifery (n = 79) students at these same 
      seven universities completed an online survey. We coded faculty interview
      transcripts, and analyzed codes related to maintaining patient confidentiality
      and reporting unlawful abortion. We summarized student views related to reporting
      and imprisoning people involved in unlawful abortion, and used general estimating
      equation (GEE) models to identify the factors associated with support for
      criminalization. RESULTS: Faculty and students generally did not support
      reporting or imprisoning anyone involved in an unlawful abortion and believed
      that protecting patient information takes precedence over reporting. Yet, faculty
      described pressures to report in the public sector and several cases where they
      or their colleagues were involved in reports. Most students somewhat/strongly
      agreed (78%) that patient information concerning an unlawful abortion should be
      kept confidential; 35% strongly/somewhat agreed that a clinician involved in an
      unlawful surgical abortion should be imprisoned, and 18% agreed that the woman
      involved should be imprisoned, with students from secular universities being
      significantly less likely to support reporting and punishing people involved in
      unlawful abortion, than students from Catholic universities. DISCUSSION: There is
      a need to clarify clinicians' ethical obligations in abortion care, in particular
      in Catholic universities, so that they can ensure that their patients have access
      to high quality confidential health care services.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Ramm, Alejandra
AU  - Ramm A
AD  - Escuela de Sociologia, Universidad de Valparaiso, El Litre 1028, Valparaiso,
      Chile; Instituto de Investigacion en Ciencias Sociales (ICSO), Universidad Diego 
      Portales, Chile. Electronic address: alejandra.ramm@uv.cl.
FAU - Casas, Lidia
AU  - Casas L
AD  - Centro de Derechos Humanos, Facultad de Derecho, Universidad Diego Portales,
      Chile.
FAU - Correa, Sara
AU  - Correa S
AD  - Instituto de Investigacion en Ciencias Sociales (ICSO), Universidad Diego
      Portales, Chile.
FAU - Baba, C Finley
AU  - Baba CF
AD  - Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global 
      Reproductive Health, Department of Obstetrics, Gynecology and Reproductive
      Sciences, University of California, San Francisco, Oakland, CA, USA.
FAU - Biggs, M Antonia
AU  - Biggs MA
AD  - Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global 
      Reproductive Health, Department of Obstetrics, Gynecology and Reproductive
      Sciences, University of California, San Francisco, Oakland, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200717
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - *Abortion, Induced
MH  - Chile
MH  - Confidentiality
MH  - Faculty
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Students
MH  - *Universities
OTO - NOTNLM
OT  - *Abortion
OT  - *Chile
OT  - *Confidentiality
OT  - *Healthcare systems
OT  - *Higher education
OT  - *Latin America
OT  - *Neoliberalism
OT  - *Religion
EDAT- 2020/08/01 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/06/13 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - S0277-9536(20)30439-1 [pii]
AID - 10.1016/j.socscimed.2020.113220 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Sep;261:113220. doi: 10.1016/j.socscimed.2020.113220. Epub 2020
      Jul 17.


PMID- 32736000
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1095-9572 (Electronic)
IS  - 1053-8119 (Linking)
VI  - 221
DP  - 2020 Nov 1
TI  - Ethical issues in global neuroimaging genetics collaborations.
PG  - 117208
LID - S1053-8119(20)30694-7 [pii]
LID - 10.1016/j.neuroimage.2020.117208 [doi]
AB  - Neuroimaging genetics is a rapidly developing field that combines
      neuropsychiatric genetics studies with imaging modalities to investigate how
      genetic variation influences brain structure and function. As both genetic and
      imaging technologies improve further, their combined power may hold translational
      potential in terms of improving psychiatric nosology, diagnosis, and treatment.
      While neuroimaging genetics studies offer a number of scientific advantages, they
      also face challenges. In response to some of these challenges, global
      neuroimaging genetics collaborations have been created to pool and compare brain 
      data and replicate study findings. Attention has been paid to ethical issues in
      genetics, neuroimaging, and multi-site collaborative research, respectively, but 
      there have been few substantive discussions of the ethical issues generated by
      the confluence of these areas in global neuroimaging genetics collaborations. Our
      discussion focuses on two areas: benefits and risks of global neuroimaging
      genetics collaborations and the potential impact of neuroimaging genetics
      research findings in low- and middle-income countries. Global neuroimaging
      genetics collaborations have the potential to enhance relations between countries
      and address global mental health challenges, however there are risks regarding
      inequity, exploitation and data sharing. Moreover, neuroimaging genetics research
      in low- and middle-income countries must address the issue of feedback of
      findings and the risk of essentializing and stigmatizing interpretations of
      mental disorders. We conclude by examining how the notion of solidarity, informed
      by an African Ethics framework, may justify some of the suggestions made in our
      discussion.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Palk, Andrea
AU  - Palk A
AD  - Department of Philosophy, Stellenbosch University, Bag X1, Matieland,
      Stellenbosch, 7602, South Africa. Electronic address: apalk@sun.ac.za.
FAU - Illes, Judy
AU  - Illes J
AD  - Neuroethics Canada, Division of Neurology, Department of Medicine, University of 
      British Columbia, Vancouver, BC, Canada.
FAU - Thompson, Paul M
AU  - Thompson PM
AD  - Imaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging &
      Informatics, Keck School of Medicine, University of Southern California, Los
      Angeles, CA, USA.
FAU - Stein, Dan J
AU  - Stein DJ
AD  - SA MRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry & 
      Neuroscience Institute, University of Cape Town, Groote Schuur Hospital, Cape
      Town 7925, South Africa.
LA  - eng
GR  - R01 MH116147/MH/NIMH NIH HHS/United States
GR  - R56 AG058854/AG/NIA NIH HHS/United States
GR  - P41 EB015922/EB/NIBIB NIH HHS/United States
GR  - RF1 AG041915/AG/NIA NIH HHS/United States
GR  - R01 MH111671/MH/NIMH NIH HHS/United States
GR  - U01 AG024904/AG/NIA NIH HHS/United States
GR  - P01 AG026572/AG/NIA NIH HHS/United States
GR  - U54 EB020403/EB/NIBIB NIH HHS/United States
GR  - RF1 MH117805/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - United States
TA  - Neuroimage
JT  - NeuroImage
JID - 9215515
SB  - IM
MH  - Developing Countries
MH  - Genetics, Medical/*ethics
MH  - Global Health
MH  - Humans
MH  - International Cooperation
MH  - Intersectoral Collaboration
MH  - Mental Disorders/*diagnostic imaging/*genetics
MH  - Multicenter Studies as Topic/*ethics
MH  - Neuroimaging/*ethics
OTO - NOTNLM
OT  - *Bioethics
OT  - *Genethics
OT  - *Global research collaborations
OT  - *Neuroethics
OT  - *Neuroimaging genetics
COIS- Declaration of Competing Interest PMT has received grant support from Biogen,
      Inc. (Boston, USA) for research unrelated to the topic of this manuscript. DJS
      has received support from Lundbeck and Sun for work unrelated to the topic of
      this manuscript.
EDAT- 2020/08/01 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/08/01 06:00
PHST- 2019/05/27 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - S1053-8119(20)30694-7 [pii]
AID - 10.1016/j.neuroimage.2020.117208 [doi]
PST - ppublish
SO  - Neuroimage. 2020 Nov 1;221:117208. doi: 10.1016/j.neuroimage.2020.117208. Epub
      2020 Jul 29.


PMID- 32735472
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1745-6924 (Electronic)
IS  - 1745-6916 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Sep
TI  - Doubting Driverless Dilemmas.
PG  - 1284-1288
LID - 10.1177/1745691620922201 [doi]
AB  - The alarm has been raised on so-called driverless dilemmas, in which autonomous
      vehicles will need to make high-stakes ethical decisions on the road. We argue
      that these arguments are too contrived to be of practical use, are an
      inappropriate method for making decisions on issues of safety, and should not be 
      used to inform engineering or policy.
FAU - De Freitas, Julian
AU  - De Freitas J
AUID- ORCID: 0000-0003-4912-1391
AD  - Department of Psychology, Harvard University.
FAU - Anthony, Sam E
AU  - Anthony SE
AD  - Perceptive Automata, Inc., Palo Alto, California.
FAU - Censi, Andrea
AU  - Censi A
AD  - Department of Mechanical and Process Engineering, ETH Zurich.
FAU - Alvarez, George A
AU  - Alvarez GA
AD  - Department of Psychology, Harvard University.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - United States
TA  - Perspect Psychol Sci
JT  - Perspectives on psychological science : a journal of the Association for
      Psychological Science
JID - 101274347
SB  - IM
MH  - *Automation
MH  - *Automobile Driving
MH  - *Decision Making
MH  - Humans
MH  - *Morals
MH  - *Motor Vehicles
MH  - Public Policy
OTO - NOTNLM
OT  - *autonomous vehicles
OT  - *driverless policy
OT  - *moral judgment
EDAT- 2020/08/01 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1177/1745691620922201 [doi]
PST - ppublish
SO  - Perspect Psychol Sci. 2020 Sep;15(5):1284-1288. doi: 10.1177/1745691620922201.
      Epub 2020 Jul 31.


PMID- 32735337
OWN - NLM
STAT- MEDLINE
DCOM- 20201225
LR  - 20211204
IS  - 2574-3805 (Electronic)
IS  - 2574-3805 (Linking)
VI  - 3
IP  - 7
DP  - 2020 Jul 1
TI  - Assessing Parent Decisions About Child Participation in a Behavioral Health
      Intervention Study and Utility of Informed Consent Forms.
PG  - e209296
LID - 10.1001/jamanetworkopen.2020.9296 [doi]
AB  - Importance: Obtaining informed consent is an important ethical obligation for
      clinical research participation that is imperfectly implemented. Research on
      improving consent processes often focuses on consent forms, but little is known
      about consent forms' influence on decision-making compared with other types of
      engagement. Objective: To evaluate whether parents decide whether to enroll their
      children in research before or after they receive the consent form. Design,
      Setting, and Participants: An online survey of 88 parents who enrolled or
      declined to enroll their child in a weight management intervention study between 
      January 2, 2018, and June 24, 2019, was conducted; surveys were completed between
      February 2, 2018, and July 9, 2019. A 31-item survey asked about impressions of
      the study throughout the enrollment process, timing of enrollment decisions, and 
      decision-making factors. Responses were summarized descriptively and subgroups
      were compared using the Fisher exact test or chi2 test. Main Outcomes and
      Measures: Self-reported timing of enrollment decision. Results: A total of 106
      parents were approached and gave permission for their contact information to be
      shared with the study team; 22 additional parents declined to allow their
      information to be shared, and 24 lost contact with the partner study before they 
      could be asked for permission. A total of 88 parents (67 enrollees, 21 decliners)
      completed the survey (83% participation rate); 79 of 88 reporting gender (instead
      of sex, as biological sex was not relevant to survey) information were women
      (91%), 66 participants (75%) were non-Hispanic White, and 63 participants (72%)
      had annual household incomes greater than or equal to $70000. No significant
      differences in respondent characteristics between enrollees and decliners were
      identified. Fifty-nine parents (67%) responded that they decided whether to
      enroll in the weight management study before receiving the consent form. Only 17 
      of 69 parents (25%) who remembered receiving the consent form responded that it
      taught them new information. Conclusions and Relevance: The findings of this
      study suggest that interventions to improve informed consent forms may have
      limited influence on decision-making because many research decisions occur before
      review of the consent form. It appears that regulatory review and interventions
      to improve decision-making should focus more on early engagement (eg, recruitment
      materials). Future studies should test timing of decisions in other types of
      research with different populations and clinical settings.
FAU - Kraft, Stephanie A
AU  - Kraft SA
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington.
AD  - University of Washington School of Medicine, Department of Pediatrics, Seattle.
FAU - Porter, Kathryn M
AU  - Porter KM
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington.
FAU - Duenas, Devan M
AU  - Duenas DM
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington.
FAU - Sullivan, Erin
AU  - Sullivan E
AD  - Seattle Children's Core for Biomedical Statistics, Seattle Children's Research
      Institute, Seattle, Washington.
FAU - Rowland, Maya
AU  - Rowland M
AD  - Center for Child Health, Behavior and Development, Seattle Children's Research
      Institute, Seattle, Washington.
FAU - Saelens, Brian E
AU  - Saelens BE
AD  - University of Washington School of Medicine, Department of Pediatrics, Seattle.
AD  - Center for Child Health, Behavior and Development, Seattle Children's Research
      Institute, Seattle, Washington.
FAU - Wilfond, Benjamin S
AU  - Wilfond BS
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research
      Institute, Seattle, Washington.
AD  - University of Washington School of Medicine, Department of Pediatrics, Seattle.
FAU - Shah, Seema K
AU  - Shah SK
AD  - Mary Ann & J. Milburn Smith Child Health Research, Outreach, and Advocacy Center;
      Stanley Manne Children's Research Institute; Ann & Robert H. Lurie Children's
      Hospital of Chicago, Chicago, Illinois.
AD  - Department of Pediatrics, Northwestern University Feinberg School of Medicine,
      Chicago, Illinois.
LA  - eng
GR  - R01 DK104863/DK/NIDDK NIH HHS/United States
GR  - UL1 TR002319/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200701
PL  - United States
TA  - JAMA Netw Open
JT  - JAMA network open
JID - 101729235
SB  - IM
MH  - Adult
MH  - Child
MH  - Consent Forms/*standards
MH  - *Decision Making
MH  - Disclosure
MH  - Ethnicity/psychology/statistics & numerical data
MH  - Female
MH  - Humans
MH  - *Informed Consent/ethics/psychology/statistics & numerical data
MH  - Male
MH  - Parents/*psychology
MH  - Patient Selection/*ethics
MH  - Research Subjects/*psychology
MH  - Sex Factors
MH  - Socioeconomic Factors
PMC - PMC7395235
EDAT- 2020/08/01 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 2768921 [pii]
AID - 10.1001/jamanetworkopen.2020.9296 [doi]
PST - epublish
SO  - JAMA Netw Open. 2020 Jul 1;3(7):e209296. doi: 10.1001/jamanetworkopen.2020.9296.


PMID- 32734930
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 31
TI  - Developing Effective Methods for Electronic Health Personalization: Protocol for 
      Health Telescope, a Prospective Interventional Study.
PG  - e16471
LID - 10.2196/16471 [doi]
AB  - BACKGROUND: Existing evaluations of the effects of mobile apps to encourage
      physical activity have been criticized owing to their common lack of external
      validity, their short duration, and their inability to explain the drivers of the
      observed effects. This protocol describes the setup of Health Telescope, a
      longitudinal panel study in which the long-term effects of mobile electronic
      health (eHealth) apps are investigated. By setting up Health Telescope, we aim to
      (1) understand more about the long-term use of eHealth apps in an externally
      valid setting, (2) understand the relationships between short-term and long-term 
      outcomes of the usage of eHealth apps, and (3) test different ways in which
      eHealth app allocation can be personalized. OBJECTIVE: The objectives of this
      paper are to (1) demonstrate and motivate the validity of the many choices that
      we made in setting up an intensive longitudinal study, (2) provide a resource for
      researchers interested in using data generated by our study, and (3) act as a
      guideline for researchers interested in setting up their own longitudinal data
      collection using wearable devices. For the third objective, we explicitly discuss
      the General Data Protection Regulation and ethical requirements that need to be
      addressed. METHODS: In this 4-month study, a group of approximately 450
      participants will have their daily step count measured and will be asked daily
      about their mood using experience sampling. Once per month, participants will
      receive an intervention containing a recommendation to download an app that
      focuses on increasing physical activity. The mechanism for assigning
      recommendations to participants will be personalized over time, using contextual 
      data obtained from previous interventions. RESULTS: The data collection software 
      has been developed, and all the legal and ethical checks are in place.
      Recruitment will start in Q4 of 2020. The initial results will be published in
      2021. CONCLUSIONS: The aim of Health Telescope is to investigate how different
      individuals respond to different ways of being encouraged to increase their
      physical activity. In this paper, we detail the setup, methods, and analysis plan
      that will enable us to reach this aim. INTERNATIONAL REGISTERED REPORT IDENTIFIER
      (IRRID): PRR1-10.2196/16471.
CI  - (c)Bastiaan Johannes Paulus Cornelis Willemse, Maurits Clemens Kaptein, Fleur
      Hasaart. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 31.07.2020.
FAU - Willemse, Bastiaan Johannes Paulus Cornelis
AU  - Willemse BJPC
AUID- ORCID: https://orcid.org/0000-0001-5913-4001
AD  - Jheronimus Academy of Data Science, 's-Hertogenbosch, Netherlands.
AD  - Department of Medical and Clinical Psychology, Tilburg University, Tilburg,
      Netherlands.
FAU - Kaptein, Maurits Clemens
AU  - Kaptein MC
AUID- ORCID: https://orcid.org/0000-0002-6316-7524
AD  - Jheronimus Academy of Data Science, 's-Hertogenbosch, Netherlands.
AD  - Department of Medical and Clinical Psychology, Tilburg University, Tilburg,
      Netherlands.
FAU - Hasaart, Fleur
AU  - Hasaart F
AUID- ORCID: https://orcid.org/0000-0002-3255-2390
AD  - CZ Zorgverzekeraars, Tilburg, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7428913
OTO - NOTNLM
OT  - eHealth
OT  - gdpr
OT  - longitudinal study
OT  - mHealth
OT  - panel study
OT  - personalization
OT  - persuasive technology
OT  - wearables
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - v9i7e16471 [pii]
AID - 10.2196/16471 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 31;9(7):e16471. doi: 10.2196/16471.


PMID- 32734829
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 14
DP  - 2020 Dec
TI  - Collaborative Filmmaking: A Participatory, Visual Research Method.
PG  - 2248-2264
LID - 10.1177/1049732320941826 [doi]
AB  - Filmmaking is a visual method that provides a unique opportunity for generating
      knowledge, but few studies have applied filmmaking in public health research. In 
      this article, we introduce Collaborative Filmmaking as a public health research
      method, including a description of the six steps for implementation and an
      illustrative example from Nepal. Collaborative Filmmaking is an embodied,
      participatory, and visual research method in which participants are trained to
      create, analyze, and screen films to answer a research question. The method is
      useful for exploring sensitive health topics and providing nuanced insight into
      practices, relationships, and spaces that are difficult to capture using existing
      methods; however, its use requires close attention to ethical considerations.
      Building upon the trajectory of other visual and community-based research
      methods, Collaborative Filmmaking is valuable for gathering granular details and 
      sensory data, co-analyzing data in partnership with participants, and producing
      participant-generated films that serve as powerful and authentic advocacy tools.
FAU - Baumann, Sara E
AU  - Baumann SE
AUID- ORCID: 0000-0002-6544-2825
AD  - University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Lhaki, Pema
AU  - Lhaki P
AD  - Nepal Fertility Care Center, Lalitpur, Nepal.
FAU - Burke, Jessica G
AU  - Burke JG
AD  - University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200731
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - *Community-Based Participatory Research
MH  - Humans
MH  - Mass Media
MH  - Motion Pictures
MH  - Nepal
MH  - *Research Design
OTO - NOTNLM
OT  - *Nepal
OT  - *arts-based research methods
OT  - *community-based participatory research
OT  - *film
OT  - *media advocacy
OT  - *menstrual health
OT  - *menstruation
OT  - *multisensory
OT  - *qualitative research
OT  - *video
OT  - *visual methods
EDAT- 2020/08/01 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1177/1049732320941826 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Dec;30(14):2248-2264. doi: 10.1177/1049732320941826. Epub
      2020 Jul 31.


PMID- 32734687
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201218
IS  - 2040-0861 (Electronic)
IS  - 1074-4797 (Linking)
VI  - 40
IP  - 2
DP  - 2020 Oct
TI  - The crisis standard of care: Considerations for risk management.
PG  - 28-33
LID - 10.1002/jhrm.21441 [doi]
AB  - Many writers and organizations have postulated that health care facilities and
      providers may need to implement a "crisis standard of care" to deal with the
      exigent circumstances associated with the massive influx of patients infected
      with the novel coronavirus and suffering from COVID-19. There is a relative
      scarcity of critical resources, such as intensive care unit beds, emergency
      department beds, ventilators, personal protective equipment, and medications.
      Facilities can become overwhelmed. A crisis standard of care can act as a
      guidepost for rationing supplies and care, should that become necessary. However,
      that is not without danger. Health care facilities and providers should plan
      carefully and then act with due deliberation in implementing a crisis standard of
      care to mitigate or prevent future liability.
CI  - (c) 2020 American Society for Healthcare Risk Management of the American Hospital
      Association.
FAU - West, John C
AU  - West JC
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - United States
TA  - J Healthc Risk Manag
JT  - Journal of healthcare risk management : the journal of the American Society for
      Healthcare Risk Management
JID - 9305245
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Emergency Service, Hospital/*standards
MH  - Humans
MH  - Intensive Care Units/*standards
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Practice Guidelines as Topic
MH  - Risk Management/*standards
MH  - Standard of Care/*standards
OTO - NOTNLM
OT  - claims and litigation
OT  - ethics in patient care
OT  - legal
EDAT- 2020/08/01 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1002/jhrm.21441 [doi]
PST - ppublish
SO  - J Healthc Risk Manag. 2020 Oct;40(2):28-33. doi: 10.1002/jhrm.21441. Epub 2020
      Jul 30.


PMID- 32734638
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20211122
IS  - 1749-4486 (Electronic)
IS  - 1749-4478 (Linking)
VI  - 45
IP  - 6
DP  - 2020 Nov
TI  - Surgiflo((R)) may have a potential impact on the healing process in cricotracheal
      resection anastomosis.
PG  - 870-876
LID - 10.1111/coa.13614 [doi]
AB  - OBJECTIVES: To evaluate the role of thrombin-based haemostatic agent
      Surgiflo((R)) (Ethicon) in improving the outcome of cricotracheal resection
      anastomosis. DESIGN: Randomised controlled clinical trial. SETTING:
      Otorhinolaryngology Department, Mansoura University Hospitals, Egypt.
      PARTICIPANTS: This study included 55 patients with grade III and IV subglottic
      and/or cervical tracheal stenosis, who underwent cricotracheal resection
      anastomosis. Patients were randomly assigned into two groups: Surgiflo group (n =
      20) and control group (n = 35). In Surgiflo patients, Surgiflo((R)) was applied
      at the end of surgery over the whole operative field including the line of airway
      anastomosis with the purpose of adequate haemostasis and enhancing healing of the
      anastomosis. MAIN OUTCOME MEASURES: The success rate and the incidence of
      complications in both groups were compared. RESULTS: At the end of treatment,
      decannulation rate was 95% (19/20) in the Surgiflo groups and 82.8% (29/35) in
      the control group. The overall incidence of complications was significantly lower
      in the Surgiflo group (P = .021). Need for further surgical airway interventions 
      in the form of repeated dilatation, granulation tissue removal or performing a
      tracheotomy was reported in 22.9% (8/35) of control group patients, in comparison
      with 5% (1/20) in Surgiflo group. CONCLUSION: Direct Surgiflo((R)) application in
      the operative field enhances the anastomotic healing, decreases the incidence of 
      anastomotic complications and subsequently improves the outcome. It can be
      recommended as an adjuvant to surgery in patients undergoing cricotracheal
      resection anastomosis.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - El-Fattah, Ahmed Musaad Abd
AU  - El-Fattah AMA
AUID- ORCID: https://orcid.org/0000-0002-7004-8697
AD  - Faculty of Medicine, Mansoura University, Mansoura, Egypt.
FAU - Ebada, Hisham Atef
AU  - Ebada HA
AUID- ORCID: https://orcid.org/0000-0003-4848-9223
AD  - Faculty of Medicine, Mansoura University, Mansoura, Egypt.
FAU - Tawfik, Ali
AU  - Tawfik A
AD  - Faculty of Medicine, Mansoura University, Mansoura, Egypt.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200917
PL  - England
TA  - Clin Otolaryngol
JT  - Clinical otolaryngology : official journal of ENT-UK ; official journal of
      Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
JID - 101247023
RN  - 0 (Hemostatics)
RN  - 0 (Surgiflo)
RN  - 9000-70-8 (Gelatin)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anastomosis, Surgical
MH  - Egypt/epidemiology
MH  - Female
MH  - Gelatin/*therapeutic use
MH  - Hemostatics/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Laryngostenosis/*surgery
MH  - Male
MH  - Postoperative Complications/epidemiology
MH  - Thrombin/*therapeutic use
MH  - Tracheal Stenosis/*surgery
MH  - *Wound Healing
OTO - NOTNLM
OT  - Surgiflo
OT  - anastomosis
OT  - complications
OT  - cricotracheal
OT  - healing
OT  - outcome
OT  - resection
OT  - tracheal
EDAT- 2020/08/01 06:00
MHDA- 2021/11/23 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1111/coa.13614 [doi]
PST - ppublish
SO  - Clin Otolaryngol. 2020 Nov;45(6):870-876. doi: 10.1111/coa.13614. Epub 2020 Sep
      17.


PMID- 32734600
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - What constitutes fair shared decision-making in global health research
      collaborations?
PG  - 984-993
LID - 10.1111/bioe.12793 [doi]
AB  - Funders (located primarily in high-income countries) and high-income country
      researchers have historically dominated decision-making within global health
      research collaborations: from setting agendas and research design to determining 
      how data are collected and analysed and what happens with findings and outputs.
      The ethical principle of shared decision-making has been proposed as a way to
      help address these imbalances within collaborations and to reduce semicolonial
      and exploitative forms of global health research. It is important to be clear
      about what shared decision-making means in order to ensure that it is not done in
      a tokenistic, shallow way. Thus far, the principle's content has not been
      examined and articulated in detail. This paper aims to start the process of
      delineating a concept of fair shared decision-making as a minimum standard for
      global health research. Using two hypothetical case examples, the paper will
      demonstrate that global health research practice is often inconsistent with ideal
      shared decision-making. In such instances, it can be difficult to decide whether 
      shared decision-making within collaborations is fair. The paper describes how the
      two cases do not meet criteria for unfair or non-ideal shared decision-making,
      despite having potentially morally troubling features. The nuances of these
      examples of research practice help to generate clearer ideas about how to judge
      fairness in shared decision-making. The paper concludes by presenting ideas about
      when soft power can be fairly employed between high-income-country and low- and
      middle-income-country partners and what fair compromise agreements may look like 
      in shared decision-making.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Pratt, Bridget
AU  - Pratt B
AUID- ORCID: 0000-0002-4934-3560
AD  - Centre for Health Equity, School of Population and Global Health, University of
      Melbourne, Australia.
LA  - eng
GR  - DE170100414/Australian Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200730
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Global Health
MH  - Humans
MH  - *Research Personnel
OTO - NOTNLM
OT  - *collaboration
OT  - *ethics
OT  - *fairness
OT  - *global health research
OT  - *partnership
OT  - *shared decision-making
EDAT- 2020/08/01 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1111/bioe.12793 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):984-993. doi: 10.1111/bioe.12793. Epub 2020 Jul 30.


PMID- 32734531
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - <<If you give them your little finger, they'll tear off your entire arm>>: losing
      trust in biobank research.
PG  - 565-576
LID - 10.1007/s11019-020-09969-w [doi]
AB  - Why do some people withdraw from biobank studies? To our knowledge, very few
      studies have been done on the reflections of biobank ex-participants. In this
      article, we report from such a study. 16 years ago, we did focus group interviews
      with biobank participants and ex-participants. We found that the two groups
      interestingly shared worries concerning the risks involved in possible novel uses
      of their biobank material, even though they drew opposite conclusions from their 
      worries. Revisiting these interviews today reveals a remarkable relevance to
      present concerns, since the possible developments that worried ex-participants
      and participants 16 years ago now are becoming realities. Drawing on conceptual
      distinctions by sociologist and philosopher Niklas Luhmann, we argue that while
      ex-participants express a loss of trust in the biobank institution to manage the 
      use of their biobank material in a legitimate way, remaining participants
      expressed confidence in the management of the biobank institution to secure their
      interests. This analysis brings out important aspects of emerging trends in
      biobank research participation.
FAU - Ursin, Lars
AU  - Ursin L
AUID- ORCID: http://orcid.org/0000-0001-5892-2823
AD  - Department of Philosophy and Religious Studies, NTNU, 7491, Trondheim, Norway.
      lars.ursin@ntnu.no.
FAU - Ytterhus, Borgunn
AU  - Ytterhus B
AD  - Department of Public Health and Nursing, NTNU, 7491, Trondheim, Norway.
FAU - Christensen, Erik
AU  - Christensen E
AD  - Faculty of Social Sciences, Nord University, 8049, Bodo, Norway.
FAU - Skolbekken, John-Arne
AU  - Skolbekken JA
AD  - Department of Public Health and Nursing, NTNU, 7491, Trondheim, Norway.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Biological Specimen Banks/*organization & administration/standards
MH  - Biomedical Research/*organization & administration/standards
MH  - Confidentiality/standards
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Informed Consent/standards
MH  - Male
MH  - Motivation
MH  - *Trust
PMC - PMC7538395
OTO - NOTNLM
OT  - Alienation
OT  - Confidence
OT  - Consent withdrawal
OT  - Ethics
OT  - Informed consent
EDAT- 2020/08/01 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1007/s11019-020-09969-w [doi]
AID - 10.1007/s11019-020-09969-w [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):565-576. doi: 10.1007/s11019-020-09969-w.


PMID- 32734517
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210110
IS  - 1573-6571 (Electronic)
IS  - 0022-4197 (Linking)
VI  - 59
IP  - 6
DP  - 2020 Dec
TI  - An Offering of Hope During COVID-19: A Personal Reflection.
PG  - 2692-2696
LID - 10.1007/s10943-020-01075-8 [doi]
AB  - This essay offers a philosophical and spiritual exploration of some of the
      language that has become part of daily life amidst the COVID-19 crisis.
FAU - Simmerling, Mary
AU  - Simmerling M
AUID- ORCID: http://orcid.org/0000-0002-5944-9617
AD  - Weill Cornell Medical College, Cornell University, New York, USA.
      mary.simmerling@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Relig Health
JT  - Journal of religion and health
JID - 2985199R
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*psychology
MH  - *Hope
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*psychology
MH  - SARS-CoV-2
MH  - *Spirituality
PMC - PMC7392123
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Grace
OT  - Healing
OT  - Hope
OT  - Language
OT  - Pandemic
OT  - Philosophy
OT  - Poetry
EDAT- 2020/08/01 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1007/s10943-020-01075-8 [doi]
AID - 10.1007/s10943-020-01075-8 [pii]
PST - ppublish
SO  - J Relig Health. 2020 Dec;59(6):2692-2696. doi: 10.1007/s10943-020-01075-8.


PMID- 32734394
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20220218
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 28
IP  - 10
DP  - 2020 Oct
TI  - COVID-19 management in a cancer center: the ICU storm.
PG  - 5037-5044
LID - 10.1007/s00520-020-05658-9 [doi]
AB  - A novel coronavirus, SARS-CoV-2, was first reported as a respiratory illness in
      December 2019 in Wuhan, China. Since then, the World Health Organization (WHO)
      Emergency Committee declared a global health. COVID-19 has now spread worldwide
      and is responsible of more than 472,216 persons, out of 9,100,090 officially
      diagnosed worldwide since 23 of June. In the context of cancer patients, COVID-19
      has a severe impact, regarding pulmonary infection but also cancer treatments in 
      this fragile and immunocompromised population, and ICU admission for cancer
      patients in the context of COVID-19 requires ethical and clinical consideration. 
      In our cancer center, intensivists, oncologists, pharmacists, and hospital
      administrators had to prepare for a substantial increase in critical care bed
      capacity (from 10 ICU beds, 6 medical intensive care beds, and 12 surgical
      intensive care beds, bed capacity was increased to 28 medical intensive care beds
      with ventilating capacity) and to adapt infrastructure (i.e., ICU beds), supplies
      (i.e., drugs, ventilators, protective materials), and staff (i.e., nurses and
      medical staff). Overall, thirty-three COVID-19 patients were admitted in our ICU,
      17 cancer-free and 16 with cancer, and 23 required mechanical ventilation,
      resulting in 4 deaths (of them two patients with cancer). We report here
      management of a dedicated intensive care unit of a cancer center during the
      COVID-19 infection pandemic, considering resource allocation and redistribution
      of healthcare workers.
FAU - Boileve, Alice
AU  - Boileve A
AUID- ORCID: http://orcid.org/0000-0003-3708-4909
AD  - Medical Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard
      Vaillant, Villejuif, France. alice.boileve@gmail.com.
FAU - Stoclin, Annabelle
AU  - Stoclin A
AD  - Intensive Care Unit, Gustave Roussy Cancer Campus, Villejuif, France.
AD  - Interdisciplinary Cancer Course Department (DIOPP), Gustave Roussy Cancer Campus,
      Villejuif, France.
FAU - Barlesi, Fabrice
AU  - Barlesi F
AD  - Medical Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard
      Vaillant, Villejuif, France.
FAU - Varin, Florent
AU  - Varin F
AD  - Department of Anesthesia, Gustave Roussy Cancer Campus, Villejuif, France.
FAU - Suria, Stephanie
AU  - Suria S
AD  - Department of Anesthesia, Gustave Roussy Cancer Campus, Villejuif, France.
FAU - Rieutord, Andre
AU  - Rieutord A
AD  - Pharmacy Department, Gustave Roussy Cancer Campus, Villejuif, France.
FAU - Blot, Francois
AU  - Blot F
AD  - Intensive Care Unit, Gustave Roussy Cancer Campus, Villejuif, France.
AD  - Interdisciplinary Cancer Course Department (DIOPP), Gustave Roussy Cancer Campus,
      Villejuif, France.
FAU - Netzer, Florence
AU  - Netzer F
AD  - Pharmacy Department, Gustave Roussy Cancer Campus, Villejuif, France.
FAU - Scotte, Florian
AU  - Scotte F
AD  - Interdisciplinary Cancer Course Department (DIOPP), Gustave Roussy Cancer Campus,
      Villejuif, France.
LA  - eng
PT  - Journal Article
DEP - 20200731
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - *Intensive Care Units
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/complications/epidemiology/*therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*complications
MH  - SARS-CoV-2
MH  - Young Adult
PMC - PMC7392620
OTO - NOTNLM
OT  - COVID-19
OT  - Cancer
OT  - Coronavirus
OT  - Intensive care unit
OT  - Management
OT  - Pandemic
EDAT- 2020/08/01 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1007/s00520-020-05658-9 [doi]
AID - 10.1007/s00520-020-05658-9 [pii]
PST - ppublish
SO  - Support Care Cancer. 2020 Oct;28(10):5037-5044. doi: 10.1007/s00520-020-05658-9. 
      Epub 2020 Jul 31.


PMID- 32734160
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2574-2531 (Electronic)
IS  - 2574-2531 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Jul
TI  - The anatomy of a distributed predictive modeling framework: online learning,
      blockchain network, and consensus algorithm.
PG  - 201-208
LID - 10.1093/jamiaopen/ooaa017 [doi]
AB  - OBJECTIVE: Cross-institutional distributed healthcare/genomic predictive modeling
      is an emerging technology that fulfills both the need of building a more
      generalizable model and of protecting patient data by only exchanging the models 
      but not the patient data. In this article, the implementation details are
      presented for one specific blockchain-based approach, ExplorerChain, from a
      software development perspective. The healthcare/genomic use cases of myocardial 
      infarction, cancer biomarker, and length of hospitalization after surgery are
      also described. MATERIALS AND METHODS: ExplorerChain's 3 main technical
      components, including online machine learning, metadata of transaction, and the
      Proof-of-Information-Timed (PoINT) algorithm, are introduced in this study.
      Specifically, the 3 algorithms (ie, core, new network, and new site/data) are
      described in detail. RESULTS: ExplorerChain was implemented and the design
      details of it were illustrated, especially the development configurations in a
      practical setting. Also, the system architecture and programming languages are
      introduced. The code was also released in an open source repository available at 
      https://github.com/tsungtingkuo/explorerchain. DISCUSSION: The designing
      considerations of semi-trust assumption, data format normalization, and
      non-determinism was discussed. The limitations of the implementation include
      fixed-number participating sites, limited join-or-leave capability during
      initialization, advanced privacy technology yet to be included, and further
      investigation in ethical, legal, and social implications. CONCLUSION: This study 
      can serve as a reference for the researchers who would like to implement and even
      deploy blockchain technology. Furthermore, the off-the-shelf software can also
      serve as a cornerstone to accelerate the development and investigation of future 
      healthcare/genomic blockchain studies.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association.
FAU - Kuo, Tsung-Ting
AU  - Kuo TT
AUID- ORCID: 0000-0002-8728-4477
AD  - UCSD Health Department of Biomedical Informatics, University of California San
      Diego, La Jolla, California, USA.
LA  - eng
GR  - OT3 OD025462/OD/NIH HHS/United States
GR  - R00 HG009680/HG/NHGRI NIH HHS/United States
GR  - R01 GM118609/GM/NIGMS NIH HHS/United States
GR  - R01 HL136835/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20200706
PL  - United States
TA  - JAMIA Open
JT  - JAMIA open
JID - 101730643
PMC - PMC7382618
OTO - NOTNLM
OT  - blockchain distributed ledger technology
OT  - clinical information systems
OT  - decision support systems
OT  - online machine learning
OT  - privacy-preserving predictive modeling
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1093/jamiaopen/ooaa017 [doi]
AID - ooaa017 [pii]
PST - epublish
SO  - JAMIA Open. 2020 Jul 6;3(2):201-208. doi: 10.1093/jamiaopen/ooaa017. eCollection 
      2020 Jul.


PMID- 32734150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2574-2531 (Electronic)
IS  - 2574-2531 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Jul
TI  - Stakeholder bias in best practice advisories: an ethical perspective.
PG  - 142-145
LID - 10.1093/jamiaopen/ooaa018 [doi]
AB  - Clinicians are increasingly being asked to heed and follow the guidance provided 
      by "best practice advisories." Such advisories, often in the form of electronic
      reminders or alerts, are meant to increase the efficiency and effectiveness of
      evidence-based medical practice. However, we argue that best practice advisories 
      can sometimes be infused with stakeholder bias, even if inadvertently. We
      specifically argue that best practice advisory biases can occur when an advisory 
      is not oriented to benefit patients at least as much or more than other
      stakeholders. To address this issue, we put forth the perspective that ethical
      consideration of biases is especially important in best practice advisory design 
      and revision processes.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association.
FAU - Baird, Aaron
AU  - Baird A
AD  - Institute of Health Administration, and Department of Computer Information
      Systems, Robinson College of Business, Georgia State University, Atlanta,
      Georgia, USA, and.
FAU - Kibbe, Bryan
AU  - Kibbe B
AD  - Ethics Department, WellStar Health System, Marietta, Georgia, USA.
FAU - Lesandrini, Jason
AU  - Lesandrini J
AD  - Ethics Department, WellStar Health System, Marietta, Georgia, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200628
PL  - United States
TA  - JAMIA Open
JT  - JAMIA open
JID - 101730643
PMC - PMC7382625
OTO - NOTNLM
OT  - best practice advisories
OT  - decision support systems
OT  - ethics
OT  - practice guidelines
OT  - stakeholder biases
OT  - technology
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2019/09/20 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1093/jamiaopen/ooaa018 [doi]
AID - ooaa018 [pii]
PST - epublish
SO  - JAMIA Open. 2020 Jun 28;3(2):142-145. doi: 10.1093/jamiaopen/ooaa018. eCollection
      2020 Jul.


PMID- 32733902
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Clinical Multi-Omics Study on the Gut Microbiota in Critically Ill Patients After
      Cardiovascular Surgery Combined With Cardiopulmonary Bypass With or Without
      Sepsis (MUL-GM-CSCPB Study): A Prospective Study Protocol.
PG  - 269
LID - 10.3389/fmed.2020.00269 [doi]
AB  - Introduction: Fever of unknown origin (FUO) and hemodynamic instability are
      complications that develop after cardiac surgery combined with cardiopulmonary
      bypass (CPB) for heart disease. Patients who develop fever with hemodynamic
      instability after cardiac surgery may have systemic inflammatory response
      syndrome or sepsis. Cardiopulmonary bypass (CPB) is a technique that temporarily 
      takes over the function of the heart and lungs during cardiac surgery. Recent
      reports suggest that early bloodstream infections of patients undergoing CPB are 
      due to gram-negative bacteria that are present in the intestinal flora. The
      theory of intestinal flora translocation has growing evidence. Intestinal
      ischemia-reperfusion that occurs during cardiac surgery with CPB will induce a
      systemic inflammatory reaction and may cause intestinal flora translocation. Does
      this systemic reaction cause sepsis? We therefore propose this protocol to
      determine whether the changes in the intestinal flora in patients after cardiac
      surgery with CPB are related to sepsis. Methods and Analysis: This study is a
      prospective observational case-control study to analyze the variation in the
      intestinal microflora and metabolites in patients undergoing cardiac surgery with
      CPB and to observe the outcomes of patients with routine clinical interventions. 
      The control group will include healthy people without intestinal illness. Feces
      and blood samples will be acquired 1 day before cardiac surgery and within 24-72 
      h after cardiac surgery, and will be used for genomics and metabolomics analyses.
      Demographic data describing age, sex, main diagnosis, and past medical history
      and data related to the CPB time and application of antibiotics are available.
      Sequential (sepsis-related) organ failure assessment, infection-related
      laboratory items, infection site, and pathogenic microorganisms, and nutrition,
      and gastrointestinal function assessment are additionally recorded. Group
      analysis of data will be conducted according to the outcomes (sepsis vs.
      non-sepsis and survivors vs. non-survivors). Ethics and Dissemination: This
      protocol has been ethically approved by the Ethics Committee of Peking Union
      Medical College (ID: ZS-1612). Informed consent will be obtained before subject
      enrolment, and data will be stored in a secured database. The results will be
      submitted to international peer-reviewed journals and presented at international 
      conferences. Trial Registration Number: NCT04032938.
CI  - Copyright (c) 2020 Ding, Liu, Zhou, Miao, Zheng, Zhou, Dou, Tong, Long and Su.
FAU - Ding, Wenyan
AU  - Ding W
AD  - Department of Critical Care Medicine, Peking Union Medical College Hospital,
      Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,
      China.
FAU - Liu, Jianzhou
AU  - Liu J
AD  - Department of Cardiac Surgery, Peking Union Medical College Hospital, Peking
      Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Zhou, Xiang
AU  - Zhou X
AD  - Department of Critical Care Medicine, Peking Union Medical College Hospital,
      Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,
      China.
FAU - Miao, Qi
AU  - Miao Q
AD  - Department of Cardiac Surgery, Peking Union Medical College Hospital, Peking
      Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Zheng, Haibo
AU  - Zheng H
AD  - Department of Cardiac Surgery, Peking Union Medical College Hospital, Peking
      Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Zhou, Baojin
AU  - Zhou B
AD  - Deepxomics Co., Ltd., Shenzhen, China.
FAU - Dou, Guifang
AU  - Dou G
AD  - Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine,
      Beijing, China.
FAU - Tong, Yigang
AU  - Tong Y
AD  - Beijing Advanced Innovation Center for Soft Matter Science and Engineering
      (BAIC-SM) College of Life Science and Technology, Beijing University of Chemical 
      Technology, Beijing, China.
FAU - Long, Yun
AU  - Long Y
AD  - Department of Critical Care Medicine, Peking Union Medical College Hospital,
      Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,
      China.
FAU - Su, Longxiang
AU  - Su L
AD  - Department of Critical Care Medicine, Peking Union Medical College Hospital,
      Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing,
      China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04032938
PT  - Journal Article
DEP - 20200708
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7360671
OTO - NOTNLM
OT  - cardiac surgery
OT  - gastrointestinal microbiome
OT  - metabolomics
OT  - metagenomics
OT  - sepsis
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2019/11/03 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.3389/fmed.2020.00269 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Jul 8;7:269. doi: 10.3389/fmed.2020.00269. eCollection
      2020.


PMID- 32733875
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-634X (Print)
IS  - 2296-634X (Linking)
VI  - 8
DP  - 2020
TI  - Midbrain Dopaminergic Neuron Development at the Single Cell Level: In vivo and in
      Stem Cells.
PG  - 463
LID - 10.3389/fcell.2020.00463 [doi]
AB  - Parkinson's disease (PD) is a progressive neurodegenerative disorder that
      predominantly affects dopaminergic (DA) neurons of the substantia nigra. Current 
      treatment options for PD are symptomatic and typically involve the replacement of
      DA neurotransmission by DA drugs, which relieve the patients of some of their
      motor symptoms. However, by the time of diagnosis, patients have already lost
      about 70% of their substantia nigra DA neurons and these drugs offer only
      temporary relief. Therefore, cell replacement therapy has garnered much interest 
      as a potential treatment option for PD. Early studies using human fetal tissue
      for transplantation in PD patients provided proof of principle for cell
      replacement therapy, but they also highlighted the ethical and practical
      difficulties associated with using human fetal tissue as a cell source. In recent
      years, advancements in stem cell research have made human pluripotent stem cells 
      (hPSCs) an attractive source of material for cell replacement therapy. Studies on
      how DA neurons are specified and differentiated in the developing mouse midbrain 
      have allowed us to recapitulate many of the positional and temporal cues needed
      to generate DA neurons in vitro. However, little is known about the developmental
      programs that govern human DA neuron development. With the advent of single-cell 
      RNA sequencing (scRNA-seq) and bioinformatics, it has become possible to analyze 
      precious human samples with unprecedented detail and extract valuable
      high-quality information from large data sets. This technology has allowed the
      systematic classification of cell types present in the human developing midbrain 
      along with their gene expression patterns. By studying human development in such 
      an unbiased manner, we can begin to elucidate human DA neuron development and
      determine how much it differs from our knowledge of the rodent brain.
      Importantly, this molecular description of the function of human cells has become
      and will increasingly be a reference to define, evaluate, and engineer cell types
      for PD cell replacement therapy and disease modeling.
CI  - Copyright (c) 2020 Asgrimsdottir and Arenas.
FAU - Asgrimsdottir, Emilia Sif
AU  - Asgrimsdottir ES
AD  - Division of Molecular Neurobiology, Department of Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
FAU - Arenas, Ernest
AU  - Arenas E
AD  - Division of Molecular Neurobiology, Department of Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200625
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC7357704
OTO - NOTNLM
OT  - Parkinson's disease
OT  - cell replacement
OT  - dopaminergic neuron
OT  - machine learning
OT  - progenitor
OT  - radial glia
OT  - single cell
OT  - stem cell
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.3389/fcell.2020.00463 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2020 Jun 25;8:463. doi: 10.3389/fcell.2020.00463.
      eCollection 2020.


PMID- 32733794
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal
      Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific
      Cancer Risk.
PG  - 989
LID - 10.3389/fonc.2020.00989 [doi]
AB  - Purpose: Proton radiotherapy (PRT) is potentially associated with a lower risk
      for secondary malignancies due to a decreased integral dose to the surrounding
      organs at risk (OARs). Prospective trials confirming this are lacking due to the 
      need for long-term follow-up and the ethical complexities of randomizing patients
      between modalities. The objective of the current study is to calculate the risk
      for secondary malignancies following PRT and photon-based intensity-modulated
      radiotherapy (IMRT). Materials and Methods: Twenty-three patients (16 female and 
      seven male), previously treated with active scanning PRT for malignant
      mediastinal lymphoma at Heidelberg Ion Beam Therapy Center, were retrospectively 
      re-planned using helical photon IMRT. The risk for radiation-induced secondary
      malignancies was estimated and evaluated using two distinct prediction models
      (1-4). Results: According to the Dasu model, the median absolute total risk for
      tumor induction following IMRT was 4.4% (range, 3.3-5.8%), 9.9% (range,
      2.0-27.6%), and 1.0% (range, 0.5-1.5%) for lung, breast, and esophageal cancer,
      respectively. For PRT, it was significantly lower for the aforementioned organs
      at 1.6% (range, 0.7-2.1%), 4.5% (range, 0.0-15.5), and 0.8% (range, 0.0-1.6%),
      respectively (p </= 0.01). The mortality risk from secondary malignancies was
      also significantly reduced for PRT relative to IMRT at 1.1 vs. 3.1% (p </=
      0.001), 0.9 vs. 1.9% (p </= 0.001), and 0.7 vs. 1.0% (p </= 0.001) for lung,
      breast, and esophageal tumors, respectively. Using the Schneider model, a
      significant risk reduction of 54.4% (range, 32.2-84.0%), 56.4% (range,
      16.0-99.4%), and 24.4% (range, 0.0-99.0%) was seen for secondary lung, breast,
      and esophageal malignancies, favoring PRT vs. X-ray-based IMRT (p </= 0.01).
      Conclusion: Based on the two prediction models, PRT for malignant mediastinal
      lymphoma is expected to reduce the risk for radiation-induced secondary
      malignancies compared with the X-ray-based IMRT. The young age and the long
      natural history of patients diagnosed with mediastinal lymphoma predisposes them 
      to a high risk of secondary malignancies following curative radiotherapy
      treatment and, as a consequence, potentially reducing this risk by utilizing
      advanced radiation therapy techniques such as PRT should be considered.
CI  - Copyright (c) 2020 Konig, Haering, Lang, Splinter, von Nettelbladt, Weykamp,
      Hoegen, Lischalk, Herfarth, Debus and Horner-Rieber.
FAU - Konig, Laila
AU  - Konig L
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Haering, Peter
AU  - Haering P
AD  - Department for Medical Physics in Radiation Oncology, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
FAU - Lang, Clemens
AU  - Lang C
AD  - Department for Medical Physics in Radiation Oncology, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
FAU - Splinter, Mona
AU  - Splinter M
AD  - Department for Medical Physics in Radiation Oncology, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
FAU - von Nettelbladt, Bastian
AU  - von Nettelbladt B
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Weykamp, Fabian
AU  - Weykamp F
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Hoegen, Philipp
AU  - Hoegen P
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Lischalk, Jonathan W
AU  - Lischalk JW
AD  - Department of Radiation Medicine, Georgetown University School of Medicine,
      Washington, DC, United States.
FAU - Herfarth, Klaus
AU  - Herfarth K
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Debus, Jurgen
AU  - Debus J
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
AD  - Department for Medical Physics in Radiation Oncology, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
FAU - Horner-Rieber, Juliane
AU  - Horner-Rieber J
AD  - Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
AD  - National Center for Tumor Diseases (NCT), Heidelberg, Germany.
AD  - Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT),
      Heidelberg University Hospital, Heidelberg, Germany.
AD  - Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
AD  - Department for Medical Physics in Radiation Oncology, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7358352
OTO - NOTNLM
OT  - intensity modulated radiotherapy
OT  - mediastinal lymphoma
OT  - photon radiotherapy
OT  - proton radiotherapy
OT  - risk
OT  - secondary malignancies
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/02/11 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.3389/fonc.2020.00989 [doi]
PST - epublish
SO  - Front Oncol. 2020 Jul 7;10:989. doi: 10.3389/fonc.2020.00989. eCollection 2020.


PMID- 32733692
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Management of Advanced Chronic Kidney Disease During the COVID-19 Pandemic:
      Suggestions From the Canadian Society of Nephrology COVID-19 Rapid Response Team.
PG  - 2054358120939354
LID - 10.1177/2054358120939354 [doi]
AB  - PURPOSE OF PROGRAM: To provide guidance on the management of patients with
      advanced chronic kidney disease (CKD) not requiring kidney replacement therapy
      during the COVID-19 pandemic. SOURCES OF INFORMATION: Program-specific documents,
      pre-existing, and related to COVID-19; documents from national and international 
      kidney agencies; national and international webinars, including webinars that we 
      hosted for input and feedback; with additional information from formal and
      informal review of published academic literature. METHODS: Challenges in the care
      of patients with advanced CKD during the COVID-19 pandemic were highlighted
      within the Canadian Senior Renal Leaders Forum discussion group. The Canadian
      Society of Nephrology (CSN) developed the COVID-19 rapid response team (RRT) to
      address these challenges. They identified a lead with expertise in advanced CKD
      who identified further nephrologists and administrators to form the workgroup. A 
      nation-wide survey of advanced CKD clinics was conducted. The initial guidance
      document was drafted and members of the workgroup reviewed and discussed all
      suggestions in detail via email and a virtual meeting. Disagreements were
      resolved by consensus. The document was reviewed by the CSN COVID-19 RRT, an
      ethicist and an infection control expert. The suggestions were presented at a
      CSN-sponsored interactive webinar, attended by 150 kidney health care
      professionals, for further peer input. The document was also sent for further
      feedback to experts who had participated in the initial survey. Final revisions
      were made based on feedback received until April 28, 2020. Canadian Journal of
      Kidney Health and Disease (CJKHD) editors reviewed the parallel process peer
      review and edited the manuscript for clarity. KEY FINDINGS: We identified 11
      broad areas of advanced CKD care management that may be affected by the COVID-19 
      pandemic: (1) clinic visit scheduling, (2) clinic visit type, (3) provision of
      multidisciplinary care, (4) bloodwork, (5) patient education/support, (6)
      home-based monitoring essentials, (7) new referrals to multidisciplinary care
      clinic, (8) kidney replacement therapy, (9) medications, (10) personal protective
      equipment, and (11) COVID-19 risk in CKD. We make specific suggestions for each
      of these areas. LIMITATIONS: The suggestions in this paper are expert opinion,
      and subject to the biases associated with this level of evidence. To expedite the
      publication of this work, a parallel review process was created that may not be
      as robust as standard arms' length peer-review processes. IMPLICATIONS: These
      suggestions are intended to provide guidance for advanced CKD directors,
      clinicians, and administrators on how to provide the best care possible during a 
      time of altered priorities and reduced resources.
CI  - (c) The Author(s) 2020.
FAU - White, Christine A
AU  - White CA
AD  - Queen's University, Kingston, ON, Canada.
FAU - Kappel, Joanne E
AU  - Kappel JE
AD  - University of Saskatchewan, Saskatoon, Canada.
FAU - Levin, Adeera
AU  - Levin A
AD  - The University of British Columbia, Vancouver, Canada.
FAU - Moran, Sarah M
AU  - Moran SM
AUID- ORCID: https://orcid.org/0000-0001-9377-4133
AD  - Queen's University, Kingston, ON, Canada.
FAU - Pandeya, Sanjay
AU  - Pandeya S
AD  - Halton Healthcare, Oakville, ON, Canada.
FAU - Thanabalasingam, Susan J
AU  - Thanabalasingam SJ
AUID- ORCID: https://orcid.org/0000-0002-8948-1730
AD  - Queen's University, Kingston, ON, Canada.
CN  - CSN COVID-19 Rapid Response Team
LA  - eng
PT  - Journal Article
DEP - 20200719
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7372621
OTO - NOTNLM
OT  - CKD (chronic kidney disease)
OT  - COVID-19
OT  - recommendations
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
IR  - Antonsen J
FIR - Antonsen, John
IR  - Banks C
FIR - Banks, Cheryl
IR  - Clark D
FIR - Clark, David
IR  - Clark E
FIR - Clark, Edward
IR  - Copland M
FIR - Copland, Michael
IR  - Davison SN
FIR - Davison, Sara N
IR  - Goldberg A
FIR - Goldberg, Aviva
IR  - Hammett J
FIR - Hammett, Juliya
IR  - Hiremath S
FIR - Hiremath, Swapnil
IR  - MacRae JM
FIR - MacRae, Jennifer M
IR  - Mac-Way F
FIR - Mac-Way, Fabrice
IR  - Mathew A
FIR - Mathew, Anna
IR  - Moist L
FIR - Moist, Louise
IR  - Ryz K
FIR - Ryz, Krista
IR  - Singh S
FIR - Singh, Suneet
IR  - Soroka S
FIR - Soroka, Steven
IR  - Suri R
FIR - Suri, Rita
IR  - Tennankore K
FIR - Tennankore, Karthik
IR  - Wald R
FIR - Wald, Ron
IR  - Weir M
FIR - Weir, Matthew
IR  - Mustafa RA
FIR - Mustafa, Reem A
IR  - Nesrallah G
FIR - Nesrallah, Gihad
IR  - Zimmerman D
FIR - Zimmerman, Deborah
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1177/2054358120939354 [doi]
AID - 10.1177_2054358120939354 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Jul 19;7:2054358120939354. doi:
      10.1177/2054358120939354. eCollection 2020.


PMID- 32733691
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220220
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Epistemic responsibility in the face of a pandemic.
PG  - lsaa033
LID - 10.1093/jlb/lsaa033 [doi]
AB  - Should non-experts defer to epidemiologists with regard to the response to the
      coronavirus pandemic? We argue that deference is required with regard to settled 
      science: non-experts (that is, people who may possess expertise of their own but 
      whose expertise is not relevant to a particular question) ought to defer with
      regard to climate science and the efficacy of vaccines. However, we suggest that 
      this deference is warranted because these questions have been appropriately
      probed many times by many different kinds of people. While non-experts should
      defer to epidemiologists with regard to matters within the sphere of epidemiology
      specifically, responding to the pandemic requires expertise from many fields. We 
      best build a consensus worth deferring to by contributing our expertise now.
      Ethicists and philosophers are not epistemically arrogant if they question policy
      responses. Rather, they play a responsible role in building a reliable consensus.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Levy, Neil
AU  - Levy N
AUID- ORCID: 0000-0002-5679-1986
AD  - University of Oxford, Uehiro Centre for Practical Ethics, Oxford, UK.
FAU - Savulescu, Julian
AU  - Savulescu J
AUID- ORCID: 0000-0003-1691-6403
AD  - University of Oxford, Uehiro Centre for Practical Ethics, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7381967
OTO - NOTNLM
OT  - Responsibility
OT  - deference
OT  - knowledge
OT  - testimony
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/04/19 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1093/jlb/lsaa033 [doi]
AID - lsaa033 [pii]
PST - epublish
SO  - J Law Biosci. 2020 May 28;7(1):lsaa033. doi: 10.1093/jlb/lsaa033. eCollection
      2020 Jan-Jun.


PMID- 32733688
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Research ethics in a pandemic: considerations for the use of research
      infrastructure and resources for public health activities.
PG  - lsaa028
LID - 10.1093/jlb/lsaa028 [doi]
AB  - The number and size of existing research studies with massive databases and
      biosample repositories that could be leveraged for public health response against
      SARS-CoV-2 (or other infectious disease pathogens) are unparalleled in history.
      What risks are posed by coopting research infrastructure-not just data and
      samples but also participant recruitment and contact networks, communications,
      and coordination functions-for public health activities? The case of the Seattle 
      Flu Study highlights the general challenges associated with utilizing research
      infrastructure for public health response, including the legal and ethical
      considerations for research data use, the return of the results of public health 
      activities relying upon research resources to unwitting research participants,
      and the possible impacts of public health reporting mandates on future research
      participation. While research, including public health research, is essential
      during a pandemic, careful consideration should be given to distinguishing and
      balancing the ethical mandates of public health activities against the existing
      ethical responsibilities of biomedical researchers.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Doerr, Megan
AU  - Doerr M
AD  - Sage Bionetworks, Seattle, WA 98121, USA.
FAU - Wagner, Jennifer K
AU  - Wagner JK
AD  - Center for Translational Bioethics & Health Care Policy at Geisinger, Danville,
      PA 17822, USA.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7381975
OTO - NOTNLM
OT  - informed consent
OT  - public health
OT  - research ethics
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1093/jlb/lsaa028 [doi]
AID - lsaa028 [pii]
PST - epublish
SO  - J Law Biosci. 2020 May 18;7(1):lsaa028. doi: 10.1093/jlb/lsaa028. eCollection
      2020 Jan-Jun.


PMID- 32733685
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Contagion, containment, consent: infectious disease pandemics and the ethics,
      rights, and legality of state-enforced vaccination.
PG  - lsaa021
LID - 10.1093/jlb/lsaa021 [doi]
FAU - Beazley, Ashlee
AU  - Beazley A
AUID- ORCID: 0000-0001-6357-9142
AD  - Institute of Criminal Law, KU Leuven, C/- Herbert Hooverplein 10, 3000 Leuven,
      Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200507
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7381984
OTO - NOTNLM
OT  - International Health Regulations
OT  - Siracusa Principles
OT  - compulsory vaccination
OT  - human rights
OT  - mandatory vaccination
OT  - public health emergency
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1093/jlb/lsaa021 [doi]
AID - lsaa021 [pii]
PST - epublish
SO  - J Law Biosci. 2020 May 7;7(1):lsaa021. doi: 10.1093/jlb/lsaa021. eCollection 2020
      Jan-Jun.


PMID- 32733683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Data protection and ethics requirements for multisite research with health data: 
      a comparative examination of legislative governance frameworks and the role of
      data protection technologies.
PG  - lsaa010
LID - 10.1093/jlb/lsaa010 [doi]
AB  - Personalised medicine can improve both public and individual health by providing 
      targeted preventative and therapeutic healthcare. However, patient health data
      must be shared between institutions and across jurisdictions for the benefits of 
      personalised medicine to be realised. Whilst data protection, privacy, and
      research ethics laws protect patient confidentiality and safety they also may
      impede multisite research, particularly across jurisdictions. Accordingly, we
      compare the concept of data accessibility in data protection and research ethics 
      laws across seven jurisdictions. These jurisdictions include Switzerland, Italy, 
      Spain, the United Kingdom (which have implemented the General Data Protection
      Regulation), the United States, Canada, and Australia. Our paper identifies the
      requirements for consent, the standards for anonymisation or pseudonymisation,
      and adequacy of protection between jurisdictions as barriers for sharing. We also
      identify differences between the European Union and other jurisdictions as a
      significant barrier for data accessibility in cross jurisdictional multisite
      research. Our paper concludes by considering solutions to overcome these
      legislative differences. These solutions include data transfer agreements and
      organisational collaborations designed to `front load' the process of ethics
      approval, so that subsequent research protocols are standardised. We also allude 
      to technical solutions, such as distributed computing, secure multiparty
      computation and homomorphic encryption.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Scheibner, James
AU  - Scheibner J
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, ETH Zurich, Zurich, Switzerland.
FAU - Ienca, Marcello
AU  - Ienca M
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, ETH Zurich, Zurich, Switzerland.
FAU - Kechagia, Sotiria
AU  - Kechagia S
AD  - Centre for Digital Trust, School of Computer and Communication Sciences, EPFL,
      Lausanne, Switzerland.
FAU - Troncoso-Pastoriza, Juan Ramon
AU  - Troncoso-Pastoriza JR
AD  - Laboratory for Data Security, School of Computer and Communication Sciences,
      EPFL, Lausanne, Switzerland.
FAU - Raisaro, Jean Louis
AU  - Raisaro JL
AD  - Unite de Medecine de Precision, CHUV, Lausanne, Switzerland.
FAU - Hubaux, Jean-Pierre
AU  - Hubaux JP
AD  - Laboratory for Data Security, School of Computer and Communication Sciences,
      EPFL, Lausanne, Switzerland.
FAU - Fellay, Jacques
AU  - Fellay J
AD  - Unite de Medecine de Precision, CHUV, Lausanne, Switzerland.
AD  - School of Life Sciences, EPFL, Lausanne, Switzerland.
AD  - Host-Pathogen Genomics Laboratory, Swiss Institute of Bioinformatics, Lausanne,
      Switzerland.
FAU - Vayena, Effy
AU  - Vayena E
AD  - Health Ethics and Policy Laboratory, Department of Health Sciences and
      Technology, ETH Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7381977
OTO - NOTNLM
OT  - Advanced cryptography
OT  - Biomedical data
OT  - Data protection
OT  - Data sharing
OT  - Multisite research
OT  - Personalised healthcare
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1093/jlb/lsaa010 [doi]
AID - lsaa010 [pii]
PST - epublish
SO  - J Law Biosci. 2020 May 6;7(1):lsaa010. doi: 10.1093/jlb/lsaa010. eCollection 2020
      Jan-Jun.


PMID- 32733323
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Differential Effects of Monetary and Social Rewards on Product Online Rating
      Decisions in E-Commerce in China.
PG  - 1440
LID - 10.3389/fpsyg.2020.01440 [doi]
AB  - Humans can change their behaviors to obtain environmental rewards (e.g., money,
      food, and sex). However, our knowledge regarding how rewards affect human
      behaviors by priming and whether there are differences among types of rewards is 
      limited. This study focused on whether monetary and social rewards have different
      priming effects on product rating decisions in e-commerce by using a behavioral
      experiment and event-related potentials (ERPs). Using cash/discount coupons as a 
      monetary reward and greeting cards as a social reward, the behavioral data showed
      that unsatisfactory products with a monetary reward induced a less negative
      consumer attitude than those with a social reward or no reward; additionally,
      such products were associated with a longer reaction time while rating products
      than those with a social reward, reflecting that monetary rewards made it more
      difficult for the subjects to rate unsatisfactory products than social rewards.
      The P2, N2, and P3 components of the ERP data were evaluated. Unsatisfactory
      products caused negative emotion, which could be compensated more by the monetary
      reward than the social reward as reflected by a smaller P2 amplitude. Due to the 
      compensation effect of the monetary reward, unsatisfactory products were
      associated with more decision conflict than the social reward as reflected by a
      more negative N2 amplitude, which is consistent with the behavioral results.
      However, in the subsequent controlled process, regardless of whether the products
      were satisfactory or unsatisfactory, the monetary reward caused more attention
      reallocation and was more motivating than the social reward as reflected by a
      larger P3 component. These findings have implications for the marketing strategy 
      of online sellers and value of online reviews and suggest attaching importance to
      ethical issues induced by monetary rewards in rating behaviors.
CI  - Copyright (c) 2020 Wang, Fu, Jin, Shang, Luo and Zhang.
FAU - Wang, Cuicui
AU  - Wang C
AD  - School of Management, Hefei University of Technology, Hefei, China.
AD  - Key Laboratory of Process Optimization and Intelligent Decision-Making, Ministry 
      of Education, Hefei University of Technology, Hefei, China.
AD  - Academy of Neuroeconomics and Neuromanagement, Ningbo University, Ningbo, China.
FAU - Fu, Weizhong
AU  - Fu W
AD  - School of Management, Hefei University of Technology, Hefei, China.
AD  - Key Laboratory of Process Optimization and Intelligent Decision-Making, Ministry 
      of Education, Hefei University of Technology, Hefei, China.
FAU - Jin, Jia
AU  - Jin J
AD  - School of Business and Management, Shanghai International Studies University,
      Shanghai, China.
AD  - Academy of Neuroeconomics and Neuromanagement, Ningbo University, Ningbo, China.
AD  - Center of Group Behavior and Social Psychological Service, Ningbo University,
      Ningbo, China.
FAU - Shang, Qian
AU  - Shang Q
AD  - School of Management, Hangzhou Dianzi University, Hangzhou, China.
FAU - Luo, Xuan
AU  - Luo X
AD  - School of Management, Hefei University of Technology, Hefei, China.
AD  - Key Laboratory of Process Optimization and Intelligent Decision-Making, Ministry 
      of Education, Hefei University of Technology, Hefei, China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - School of Management, Hefei University of Technology, Hefei, China.
AD  - Key Laboratory of Process Optimization and Intelligent Decision-Making, Ministry 
      of Education, Hefei University of Technology, Hefei, China.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7362955
OTO - NOTNLM
OT  - compensation effect
OT  - event-related potentials
OT  - monetary reward
OT  - product rating decision
OT  - social reward
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.3389/fpsyg.2020.01440 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 3;11:1440. doi: 10.3389/fpsyg.2020.01440. eCollection
      2020.


PMID- 32733309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Associations of Job Insecurity With Perceived Work-Related Symptoms, Job
      Satisfaction, and Turnover Intentions: The Mediating Role of Leader-Member
      Exchange and the Moderating Role of Organizational Support.
PG  - 1329
LID - 10.3389/fpsyg.2020.01329 [doi]
AB  - This study wants to examine effects of job insecurity on several work-related
      outcomes (perceived work-related symptoms, job satisfaction, and turnover
      intentions) by developing a moderated mediation model. The model emphasizes the
      role played by the quality of leader-member exchange (LMX) in mediating the
      relation between perceived job insecurity and outcomes related to work, and the
      moderating role of perceived organizational support (POS) in influencing the
      mediation. Survey data from 510 workers at Italian organizations were collected, 
      and regression was used to evaluate the hypotheses. After age, gender, education,
      and organizational tenure were controlled, results showed that perceived quality 
      of LMX carried the effect of job insecurity on all outcomes, and that this
      relationship was stronger for employees who reported higher levels of POS. This
      study makes important theoretical and practical contributions to job insecurity, 
      LMX, and POS research, underlining the importance of promoting the leader-member 
      relationship's quality in an ethical and supportive work environment.
CI  - Copyright (c) 2020 Di Stefano, Venza and Aiello.
FAU - Di Stefano, Giovanni
AU  - Di Stefano G
AD  - Department of Psychology, Educational Science and Human Movement, University of
      Palermo, Palermo, Italy.
FAU - Venza, Gaetano
AU  - Venza G
AD  - Department of Psychology, Educational Science and Human Movement, University of
      Palermo, Palermo, Italy.
FAU - Aiello, Davide
AU  - Aiello D
AD  - Department of Psychology, Educational Science and Human Movement, University of
      Palermo, Palermo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7358553
OTO - NOTNLM
OT  - job insecurity
OT  - job satisfaction
OT  - leader-member exchange
OT  - organizational support
OT  - perceived health
OT  - turnover intentions
OT  - work-related symptoms
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.3389/fpsyg.2020.01329 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jul 7;11:1329. doi: 10.3389/fpsyg.2020.01329. eCollection
      2020.


PMID- 32733095
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20220218
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 16
IP  - 10
DP  - 2020 Oct
TI  - The current and future landscape of dialysis.
PG  - 573-585
LID - 10.1038/s41581-020-0315-4 [doi]
AB  - The development of dialysis by early pioneers such as Willem Kolff and Belding
      Scribner set in motion several dramatic changes in the epidemiology, economics
      and ethical frameworks for the treatment of kidney failure. However, despite a
      rapid expansion in the provision of dialysis - particularly haemodialysis and
      most notably in high-income countries (HICs) - the rate of true patient-centred
      innovation has slowed. Current trends are particularly concerning from a global
      perspective: current costs are not sustainable, even for HICs, and globally, most
      people who develop kidney failure forego treatment, resulting in millions of
      deaths every year. Thus, there is an urgent need to develop new approaches and
      dialysis modalities that are cost-effective, accessible and offer improved
      patient outcomes. Nephrology researchers are increasingly engaging with patients 
      to determine their priorities for meaningful outcomes that should be used to
      measure progress. The overarching message from this engagement is that while
      patients value longevity, reducing symptom burden and achieving maximal
      functional and social rehabilitation are prioritized more highly. In response,
      patients, payors, regulators and health-care systems are increasingly demanding
      improved value, which can only come about through true patient-centred innovation
      that supports high-quality, high-value care. Substantial efforts are now underway
      to support requisite transformative changes. These efforts need to be catalysed, 
      promoted and fostered through international collaboration and harmonization.
FAU - Himmelfarb, Jonathan
AU  - Himmelfarb J
AUID- ORCID: http://orcid.org/0000-0002-3319-1224
AD  - Kidney Research Institute, Seattle, WA, USA.
      Jhimmelfarb@Nephrology.washington.edu.
AD  - Division of Nephrology, Department of Medicine, University of Washington,
      Seattle, WA, USA. Jhimmelfarb@Nephrology.washington.edu.
FAU - Vanholder, Raymond
AU  - Vanholder R
AUID- ORCID: http://orcid.org/0000-0003-2633-1636
AD  - Nephrology Section, Department of Internal Medicine and Pediatrics, University
      Hospital, Ghent, Belgium and European Kidney Health Alliance (EKHA), Brussels,
      Belgium.
FAU - Mehrotra, Rajnish
AU  - Mehrotra R
AUID- ORCID: http://orcid.org/0000-0003-2833-067X
AD  - Kidney Research Institute, Seattle, WA, USA.
AD  - Division of Nephrology, Department of Medicine, University of Washington,
      Seattle, WA, USA.
FAU - Tonelli, Marcello
AU  - Tonelli M
AUID- ORCID: http://orcid.org/0000-0002-0846-3187
AD  - Division of Nephrology, Department of Medicine, University of Calgary, Calgary,
      Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200730
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
SB  - IM
MH  - *Dialysis/instrumentation/methods/statistics & numerical data/trends
MH  - Forecasting
MH  - Global Health/economics/statistics & numerical data
MH  - Health Care Costs/statistics & numerical data
MH  - Humans
MH  - Inventions/trends
MH  - Kidneys, Artificial/ethics/statistics & numerical data
MH  - Peritoneal Dialysis/instrumentation/methods/statistics & numerical data/trends
MH  - Renal Dialysis/instrumentation/methods/statistics & numerical data/trends
MH  - Renal Insufficiency/epidemiology/therapy
PMC - PMC7391926
EDAT- 2020/08/01 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1038/s41581-020-0315-4 [doi]
AID - 10.1038/s41581-020-0315-4 [pii]
PST - ppublish
SO  - Nat Rev Nephrol. 2020 Oct;16(10):573-585. doi: 10.1038/s41581-020-0315-4. Epub
      2020 Jul 30.


PMID- 32732836
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20211109
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 104
IP  - 8
DP  - 2020 Aug
TI  - Delayed Implantation of Pumped Kidneys Decreases Renal Allograft Futility in
      Combined Liver-Kidney Transplantation.
PG  - 1591-1603
LID - 10.1097/TP.0000000000003040 [doi]
AB  - BACKGROUND: Combined liver-kidney transplantation (CLKT) improves survival for
      liver transplant recipients with renal dysfunction; however, the tenuous
      perioperative hemodynamic and metabolic milieu in high-acuity CLKT recipients
      increases delayed graft function and kidney allograft failure. We sought to
      analyze whether delayed KT through pumping would improve kidney outcomes
      following CLKT. METHODS: A retrospective analysis (University of California Los
      Angeles [n = 145], Houston Methodist Hospital [n = 79]) was performed in all
      adults receiving CLKT at 2 high-volume transplant centers from February 2004 to
      January 2017, and recipients were analyzed for patient and allograft survival as 
      well as renal outcomes following CLKT. RESULTS: A total of 63 patients (28.1%)
      underwent delayed implantation of pumped kidneys during CLKT (dCLKT) and 161
      patients (71.9%) received early implantation of nonpumped kidneys during CLKT
      (eCLKT). Most recipients were high-acuity with median biologic model of end-stage
      liver disease (MELD) score of, 35 for dCLKT and 34 for eCLKT (P = ns).
      Pretransplant, dCLKT had longer intensive care unit stay, were more often
      intubated, and had greater vasopressor use. Despite this, dCLKT exhibited
      improved 1-, 3-, and 5-year patient and kidney survival (P = 0.02) and decreased 
      length of stay (P = 0.001), kidney allograft failure (P = 0.012), and dialysis
      duration (P = 0.031). This reduced kidney allograft futility (death or continued 
      need for hemodialysis within 3 mo posttransplant) for dCLKT (6.3%) compared with 
      eCLKT (19.9%) (P = 0.013). CONCLUSIONS: Delayed implantation of pumped kidneys is
      associated with improved patient and renal allograft survival and decreased
      hospital length of stay despite longer kidney cold ischemia. These data should
      inform the ethical debate as to the futility of performing CLKT in high-acuity
      recipients.
FAU - Lunsford, Keri E
AU  - Lunsford KE
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Agopian, Vatche G
AU  - Agopian VG
AD  - Division of Liver and Pancreas Transplantation, Department of Surgery, David
      Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Yi, Stephanie G
AU  - Yi SG
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Nguyen, Duc T M
AU  - Nguyen DTM
AD  - Department of Pathology and Genomic Medicine, Houston Methodist Hospital and
      Research Institute, Houston, TX.
FAU - Graviss, Edward A
AU  - Graviss EA
AD  - Department of Pathology and Genomic Medicine, Houston Methodist Hospital and
      Research Institute, Houston, TX.
FAU - Harlander-Locke, Michael P
AU  - Harlander-Locke MP
AD  - Division of Liver and Pancreas Transplantation, Department of Surgery, David
      Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Saharia, Ashish
AU  - Saharia A
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Kaldas, Fady M
AU  - Kaldas FM
AD  - Division of Liver and Pancreas Transplantation, Department of Surgery, David
      Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Mobley, Constance M
AU  - Mobley CM
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Zarrinpar, Ali
AU  - Zarrinpar A
AD  - Division of Transplant and Hepatobiliary Surgery, Department of Surgery,
      University of Florida, Gainesville, FL.
FAU - Hobeika, Mark J
AU  - Hobeika MJ
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Veale, Jeffrey L
AU  - Veale JL
AD  - Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Podder, Hemangshu
AU  - Podder H
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Farmer, Douglas G
AU  - Farmer DG
AD  - Division of Liver and Pancreas Transplantation, Department of Surgery, David
      Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Knight, Richard J
AU  - Knight RJ
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Danovitch, Gabriel M
AU  - Danovitch GM
AD  - Division of Nephrology, Department of Medicine, David Geffen School of Medicine
      at UCLA, Los Angeles, CA.
FAU - Gritsch, H Albin
AU  - Gritsch HA
AD  - Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Li, Xian C
AU  - Li XC
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Ghobrial, R Mark
AU  - Ghobrial RM
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
FAU - Busuttil, Ronald W
AU  - Busuttil RW
AD  - Division of Liver and Pancreas Transplantation, Department of Surgery, David
      Geffen School of Medicine at UCLA, Los Angeles, CA.
FAU - Gaber, A Osama
AU  - Gaber AO
AD  - Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C.
      Walter Jr Transplant Center, Weill Cornell Medical College, Houston Methodist
      Hospital, Houston, TX.
LA  - eng
GR  - K08 DK118187/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
SB  - IM
CIN - J Urol. 2021 Apr;205(4):1214-1215. PMID: 33472373
MH  - Aged
MH  - Allografts/immunology/supply & distribution
MH  - Cold Ischemia/instrumentation/methods/statistics & numerical data
MH  - End Stage Liver Disease/complications/*surgery
MH  - Feasibility Studies
MH  - Female
MH  - Graft Rejection/*epidemiology/immunology/prevention & control
MH  - Graft Survival/immunology
MH  - Humans
MH  - Kidney/immunology
MH  - Kidney Transplantation/*adverse effects/ethics/methods/statistics & numerical
      data
MH  - Liver Transplantation/*adverse effects/ethics/methods/statistics & numerical data
MH  - Male
MH  - Medical Futility/ethics
MH  - Middle Aged
MH  - Organ Preservation/instrumentation/*methods/statistics & numerical data
MH  - Perfusion/instrumentation/methods/statistics & numerical data
MH  - Renal Insufficiency/etiology/surgery
MH  - Retrospective Studies
MH  - Time Factors
MH  - Time-to-Treatment/statistics & numerical data
MH  - Transplantation, Homologous/adverse effects/ethics/methods
MH  - Treatment Outcome
EDAT- 2020/08/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/TP.0000000000003040 [doi]
AID - 00007890-202008000-00018 [pii]
PST - ppublish
SO  - Transplantation. 2020 Aug;104(8):1591-1603. doi: 10.1097/TP.0000000000003040.


PMID- 32732830
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20210125
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 104
IP  - 8
DP  - 2020 Aug
TI  - Uncontrolled Donation After Circulatory Death: A Unique Opportunity.
PG  - 1542-1552
LID - 10.1097/TP.0000000000003139 [doi]
AB  - Uncontrolled donation after circulatory death (uDCD) refers to donation from
      persons who die following an unexpected and unsuccessfully resuscitated cardiac
      arrest. Despite the large potential for uDCD, programs of this kind only exist in
      a reduced number of countries with a limited activity. Barriers to uDCD are of a 
      logistical and ethical-legal nature, as well as arising from the lack of
      confidence in the results of transplants from uDCD donors. The procedure needs to
      be designed to reduce and limit the impact of the prolonged warm ischemia
      inherent to the uDCD process, and to deal with the ethical issues that this
      practice poses: termination of advanced cardiopulmonary resuscitation, extension 
      of advanced cardiopulmonary resuscitation beyond futility for organ preservation,
      moment to approach families to discuss donation opportunities, criteria for the
      determination of death, or the use of normothermic regional perfusion for the in 
      situ preservation of organs. Although the incidence of primary nonfunction and
      delayed graft function is higher with organs obtained from uDCD donors, overall
      patient and graft survival is acceptable in kidney, liver, and lung
      transplantation, with a proper selection and management of both donors and
      recipients. Normothermic regional perfusion has shown to be critical to achieve
      optimal outcomes in uDCD kidney and liver transplantation. However, the role of
      ex situ preservation with machine perfusion is still to be elucidated. uDCD is a 
      unique opportunity to improve patient access to transplantation therapies and to 
      offer more patients the chance to donate organs after death, if this is
      consistent with their wishes and values.
FAU - Coll, Elisabeth
AU  - Coll E
AD  - Organizacion Nacional de Trasplantes, Madrid, Spain.
FAU - Minambres, Eduardo
AU  - Minambres E
AD  - Intensive Care Unit and Donor Coordination Unit, Hospital Universitario Marques
      de Valdecilla-IDIVAL, Universidad de Cantabria, Santander, Spain.
FAU - Sanchez-Fructuoso, Ana
AU  - Sanchez-Fructuoso A
AD  - Nephrology Department, Hospital Universitario Clinico San Carlos, Facultad de
      Medicina, Universidad Complutense, Madrid, Spain.
FAU - Fondevila, Constantino
AU  - Fondevila C
AD  - Liver Transplant Unit, Hospital Clinic, Barcelona, Spain.
FAU - Campo-Canaveral de la Cruz, Jose Luis
AU  - Campo-Canaveral de la Cruz JL
AD  - Lung Transplant Unit, Hospital Universitario Puerta de Hierro, Majadahonda,
      Madrid, Spain.
FAU - Dominguez-Gil, Beatriz
AU  - Dominguez-Gil B
AD  - Organizacion Nacional de Trasplantes, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
SB  - IM
MH  - Allografts/supply & distribution
MH  - Donor Selection/ethics/legislation & jurisprudence/*methods
MH  - Graft Rejection/etiology/*prevention & control
MH  - Health Services Accessibility
MH  - Heart Arrest/*mortality/therapy
MH  - Humans
MH  - Organ Preservation/*methods
MH  - Organ Transplantation/adverse effects/ethics/legislation & jurisprudence/*methods
MH  - Perfusion/instrumentation/methods
MH  - Resuscitation/ethics
MH  - Treatment Outcome
MH  - Warm Ischemia/adverse effects
EDAT- 2020/08/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/TP.0000000000003139 [doi]
AID - 00007890-202008000-00012 [pii]
PST - ppublish
SO  - Transplantation. 2020 Aug;104(8):1542-1552. doi: 10.1097/TP.0000000000003139.


PMID- 32732803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200803
IS  - 1932-8095 (Electronic)
IS  - 1932-8087 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Sep/Oct
TI  - Essential Case Management Practices Amidst the Novel Coronavirus Disease 2019
      (COVID-19) Crisis: Part 2: End-of-Life Care, Workers' Compensation Case
      Management, Legal and Ethical Obligations, Remote Practice, and Resilience.
PG  - E17-E18
LID - 10.1097/NCM.0000000000000464 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prof Case Manag
JT  - Professional case management
JID - 101291585
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - 10.1097/NCM.0000000000000464 [doi]
AID - 01269241-202009000-00005 [pii]
PST - ppublish
SO  - Prof Case Manag. 2020 Sep/Oct;25(5):E17-E18. doi: 10.1097/NCM.0000000000000464.


PMID- 32732705
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 1932-8095 (Electronic)
IS  - 1932-8087 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Nov/Dec
TI  - The Professional Case Manager and Social Justice, Inclusion, and Equity: A Time
      for Reflection and Action.
PG  - 305-311
LID - 10.1097/NCM.0000000000000465 [doi]
AB  - Social justice, inclusion and equity are everyone's responsibility. We achieve
      these values when we recognize and accept the characteristics of every person as 
      a unique individual. Professional case managers, or other healthcare
      practitioners and leaders, have an obligation to advance the health, human and
      social outcomes of the people they serve, regardless of the social group they
      belong to and irrespective of their determinants of diversity. It is time to
      address social justice, inclusion and equity as ethical principles of practice
      for the professional case manager.
FAU - Tahan, Hussein M
AU  - Tahan HM
AD  - Hussein M. Tahan, PhD, RN, FAAN, is a case management consultant, expert, author,
      and researcher. Dr. Tahan has nearly 30 years of experience in hospital
      management and operations and professional case management practice; is a member 
      of the editorial advisory board of Professional Case Management journal; author
      of multiple textbooks, including the CMSA's Core Curriculum for Case Management
      and Case Management: A Practical Guide for Education and Practice; is the chief
      knowledge editor of the Case Management Body of Knowledge online portal sponsored
      by the Commission for Case Manager Certification; and the recipient of CMSA's
      2016 Lifetime Achievement Award for his contributions to the field of case
      management.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prof Case Manag
JT  - Professional case management
JID - 101291585
MH  - Adult
MH  - Case Managers/*ethics/*psychology
MH  - Cultural Diversity
MH  - Female
MH  - *Guidelines as Topic
MH  - Health Equity/*ethics/*standards
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Social Justice/*ethics/*psychology
MH  - United States
EDAT- 2020/08/01 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - 10.1097/NCM.0000000000000465 [doi]
AID - 01269241-202011000-00001 [pii]
PST - ppublish
SO  - Prof Case Manag. 2020 Nov/Dec;25(6):305-311. doi: 10.1097/NCM.0000000000000465.


PMID- 32732577
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210802
IS  - 1528-1132 (Electronic)
IS  - 0009-921X (Linking)
VI  - 478
IP  - 8
DP  - 2020 Aug
TI  - Percutaneous CO2 Treatment Accelerates Bone Generation During Distraction
      Osteogenesis in Rabbits.
PG  - 1922-1935
LID - 10.1097/CORR.0000000000001288 [doi]
AB  - BACKGROUND: Distraction osteogenesis has been broadly used to treat various
      structural bone deformities and defects. However, prolonged healing time remains 
      a major problem. Various approaches including the use of low-intensity pulsed
      ultrasound, parathyroid hormone, and bone morphogenetic proteins (BMPs) have been
      studied to shorten the treatment period with limited success. Our previous
      studies of rats have reported that the transcutaneous application of CO2
      accelerates fracture repair and bone-defect healing in rats by promoting
      angiogenesis, blood flow, and endochondral ossification. This therapy may also
      accelerate bone generation during distraction osteogenesis, but, to our
      knowledge, no study investigating CO2 therapy on distraction osteogenesis has
      been reported. QUESTIONS/PURPOSES: We aimed to investigate the effect of
      transcutaneous CO2 during distraction osteogenesis in rabbits, which are the most
      suitable animal as a distraction osteogenesis model for a lengthener in terms of 
      limb size. We asked: Does transcutaneous CO2 during distraction osteogenesis
      alter (1) radiographic bone density in the distraction gap during healing; (2)
      callus parameters, including callus bone mineral content, volumetric bone mineral
      density, and bone volume fraction; (3) the newly formed bone area, cartilage
      area, and angiogenesis, as well as the expression of interleukin-6 (IL-6), BMP-2,
      BMP-7, hypoxia-inducible factor (HIF) -1alpha, and vascular endothelial growth
      factor (VEGF); and (4) three-point bend biomechanical strength, stiffness, and
      energy? METHODS: Forty 24-week-old female New Zealand white rabbits were used
      according to a research protocol approved by our institutional ethical committee.
      A distraction osteogenesis rabbit tibia model was created as previously
      described. Briefly, an external lengthener was applied to the right tibia, and a 
      transverse osteotomy was performed at the mid-shaft. The osteotomy stumps were
      connected by adjusting the fixator to make no gap. After a 7-day latency phase,
      distraction was continued at 1 mm per day for 10 days. Beginning the day after
      the osteotomy, a 20-minute transcutaneous application of CO2 on the operated leg 
      using a CO2 absorption-enhancing hydrogel was performed five times per week in
      the CO2 group (n = 20). Sham treatment with air was administered in the control
      group (n = 20). Animals were euthanized immediately after the distraction period 
      (n = 10), 2 weeks (n = 10), and 4 weeks (n = 20) after completion of distraction.
      We performed bone density quantification on the plain radiographs to evaluate
      consolidation in the distraction gap with image analyzing software. Callus
      parameters were measured with micro-CT to assess callus microstructure. The newly
      formed bone area and cartilage area were measured histologically with safranin
      O/fast green staining to assess the progress of ossification. We also performed
      immunohistochemical staining of endothelial cells with fluorescein-labeled
      isolectin B4 and examined capillary density to evaluate angiogenesis. Gene
      expressions in newly generated callus were analyzed by real-time polymerase chain
      reaction. Biomechanical strength, stiffness, and energy were determined from a
      three-point bend test to assess the mechanical strength of the callus. RESULTS:
      Radiographs showed higher pixel values in the distracted area in the CO2 group
      than the control group at Week 4 of the consolidation phase (0.98 +/- 0.11 [95%
      confidence interval 0.89 to 1.06] versus 1.19 +/- 0.23 [95% CI 1.05 to 1.34]; p =
      0.013). Micro-CT demonstrated that bone volume fraction in the CO2 group was
      higher than that in the control group at Week 4 (5.56 +/- 3.21 % [95% CI 4.32 to 
      6.12 %] versus 11.90 +/- 3.33 % [95% CI 9.63 to 14.25 %]; p = 0.035). There were 
      no differences in any other parameters (that is, callus bone mineral content at
      Weeks 2 and 4; volumetric bone mineral density at Weeks 2 and 4; bone volume
      fraction at Week 2). At Week 2, rabbits in the CO2 group had a larger cartilage
      area compared with those in the control group (2.09 +/- 1.34 mm [95% CI 1.26 to
      2.92 mm] versus 5.10 +/- 3.91 mm [95% CI 2.68 to 7.52 mm]; p = 0.011). More newly
      formed bone was observed in the CO2 group than the control group at Week 4 (68.31
      +/- 16.32 mm [95% CI 58.19 to 78.44 mm] versus 96.26 +/- 19.37 mm [95% CI 84.25
      to 108.26 mm]; p < 0.001). There were no differences in any other parameters
      (cartilage area at Weeks 0 and 4; newly formed bone area at Weeks 0 and 2).
      Immunohistochemical isolectin B4 staining showed greater capillary densities in
      rabbits in the CO2 group than the control group in the distraction area at Week 0
      and surrounding tissue at Weeks 0 and 2 (distraction area at Week 0, 286.54 +/-
      61.55 /mm [95% CI 232.58 to 340.49] versus 410.24 +/- 55.29 /mm [95% CI 361.78 to
      458.71]; p < 0.001; surrounding tissue at Week 0 395.09 +/- 68.16/mm [95% CI
      335.34 to 454.83] versus 589.75 +/- 174.42/mm [95% CI 436.86 to 742.64]; p =
      0.003; at Week 2 271.22 +/- 169.42 /mm [95% CI 122.71 to 419.73] versus 508.46
      +/- 49.06/mm [95% CI 465.45 to 551.47]; p < 0.001 respectively). There was no
      difference in the distraction area at Week 2. The expressions of BMP -2 at Week
      2, HIF1-alpha at Week 2 and VEGF at Week 0 and 2 were greater in the CO2 group
      than in the control group (BMP -2 at Week 2 3.84 +/- 0.83 fold [95% CI 3.11 to
      4.58] versus 7.32 +/- 1.63 fold [95% CI 5.88 to 8.75]; p < 0.001; HIF1-alpha at
      Week 2, 10.49 +/- 2.93 fold [95% CI 7.91 to 13.06] versus 20.74 +/- 11.01 fold
      [95% CI 11.09 to 30.40]; p < 0.001; VEGF at Week 0 4.80 +/- 1.56 fold [95% CI
      3.43 to 6.18] versus 11.36 +/- 4.82 fold [95% CI 7.13 to 15.59]; p < 0.001; at
      Week 2 31.52 +/- 8.26 fold [95% CI 24.27 to 38.76] versus 51.05 +/- 15.52 fold
      [95% CI 37.44 to 64.66]; p = 0.034, respectively). There were no differences in
      any other parameters (BMP-2 at Week 0 and 4; BMP -7 at Weeks 0, 2 and 4;
      HIF-1alpha at Weeks 0 and 4; IL-6 at Weeks 0, 2 and 4; VEGF at Week 4). In the
      biomechanical assessment, ultimate stress and failure energy were greater in the 
      CO2 group than in the control group at Week 4 (ultimate stress 259.96 +/- 74.33 N
      [95% CI 167.66 to 352.25] versus 422.45 +/- 99.32 N [95% CI 299.13 to 545.77]; p 
      < 0.001, failure energy 311.32 +/- 99.01 Nmm [95% CI 188.37 to 434.25] versus
      954.97 +/- 484.39 Nmm [95% CI 353.51 to 1556.42]; p = 0.003, respectively). There
      was no difference in stiffness (216.77 +/- 143.39 N/mm [95% CI 38.73 to 394.81]
      versus 223.68 +/- 122.17 N/mm [95% CI 71.99 to 375.37]; p = 0.92). CONCLUSION:
      Transcutaneous application of CO2 accelerated bone generation in a distraction
      osteogenesis model of rabbit tibias. As demonstrated in previous studies, CO2
      treatment might affect bone regeneration in distraction osteogenesis by promoting
      angiogenesis, blood flow, and endochondral ossification. CLINICAL RELEVANCE: The 
      use of the transcutaneous application of CO2 may open new possibilities for
      shortening healing time in patients with distraction osteogenesis. However, a
      deeper insight into the mechanism of CO2 in the local tissue is required before
      it can be used in future clinical practice.
FAU - Kumabe, Yohei
AU  - Kumabe Y
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Fukui, Tomoaki
AU  - Fukui T
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Takahara, Shunsuke
AU  - Takahara S
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Kuroiwa, Yu
AU  - Kuroiwa Y
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Arakura, Michio
AU  - Arakura M
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Oe, Keisuke
AU  - Oe K
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Oda, Takahiro
AU  - Oda T
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Sawauchi, Kenichi
AU  - Sawauchi K
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Matsushita, Takehiko
AU  - Matsushita T
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Matsumoto, Tomoyuki
AU  - Matsumoto T
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Hayashi, Shinya
AU  - Hayashi S
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Kuroda, Ryosuke
AU  - Kuroda R
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
FAU - Niikura, Takahiro
AU  - Niikura T
AD  - Y. Kumabe, T. Fukui, S. Takahara, Y. Kuroiwa, M. Arakura, K. Oe, T. Oda, K.
      Sawauchi, T. Matsushita, T. Matsumoto, S. Hayashi, R. Kuroda, T. Niikura,
      Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine,
      Kobe, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Interleukin-6)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 142M471B3J (Carbon Dioxide)
SB  - IM
CIN - Clin Orthop Relat Res. 2020 Aug;478(8):1936-1938. PMID: 32732578
MH  - Animals
MH  - Bone Density/*physiology
MH  - Bone Morphogenetic Proteins/metabolism
MH  - Bone Regeneration/*physiology
MH  - Carbon Dioxide/*administration & dosage
MH  - Female
MH  - Hypoxia-Inducible Factor 1/metabolism
MH  - Interleukin-6/metabolism
MH  - Osteogenesis/*physiology
MH  - Osteogenesis, Distraction/*methods
MH  - Rabbits
MH  - Tibia/metabolism/*physiology
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - X-Ray Microtomography
PMC - PMC7371043
EDAT- 2020/08/01 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1097/CORR.0000000000001288 [doi]
AID - 00003086-202008000-00037 [pii]
PST - ppublish
SO  - Clin Orthop Relat Res. 2020 Aug;478(8):1922-1935. doi:
      10.1097/CORR.0000000000001288.


PMID- 32732557
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210802
IS  - 1528-1132 (Electronic)
IS  - 0009-921X (Linking)
VI  - 478
IP  - 8
DP  - 2020 Aug
TI  - Virtue Ethics in a Value-driven World: A Sliding Scale of Informed Consent.
PG  - 1725-1727
LID - 10.1097/CORR.0000000000001183 [doi]
FAU - Humbyrd, Casey Jo
AU  - Humbyrd CJ
AD  - C. J. Humbyrd, Associate Professor of Orthopaedic Surgery and Chief, Foot and
      Ankle Division, Johns Hopkins, University School of Medicine, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - Informed Consent/*ethics
MH  - *Virtues
PMC - PMC7371078
EDAT- 2020/08/01 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1097/CORR.0000000000001183 [doi]
AID - 00003086-202008000-00005 [pii]
PST - ppublish
SO  - Clin Orthop Relat Res. 2020 Aug;478(8):1725-1727. doi:
      10.1097/CORR.0000000000001183.


PMID- 32732263
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 2
DP  - 2020 Aug
TI  - Controversy About Withdrawal of Postresuscitation Care After Cardiac Arrest.
LID - e20194061 [pii]
LID - 10.1542/peds.2019-4061 [doi]
AB  - With increasing focus in the last decade on post-cardiac arrest care in
      pediatrics, return of spontaneous circulation, survival rates, and neurologic
      outcome have improved. As part of this postarrest care, both the American Heart
      Association and the American Academy of Neurology state it is reasonable to
      consider targeted temperature management in pediatric comatose patients, although
      this care is challenging and time sensitive, with many gaps in knowledge
      remaining. Many pediatric patients will still not survive or will suffer severe
      neurocognitive impairment despite the therapeutic arsenal provided. Adult
      guidelines suggest providing postarrest supportive care and limiting prognosis
      discussions with families until after 72 hours of therapy, but pediatric
      clinicians are advised to consider a multitude of factors given the lack of data.
      What, then, should clinicians do if family members of a patient who has been
      resuscitated request the withdrawal of all life support in the 24 hours
      immediately postarrest? In this Ethics Rounds, we present such a case and the
      responses of different clinicians and bioethicists.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Gardner, Kelly J
AU  - Gardner KJ
AD  - Massachusetts General Hospital, Boston, Massachusetts; kgardner3@partners.org.
FAU - Murphy, Sarah
AU  - Murphy S
AD  - Massachusetts General Hospital, Boston, Massachusetts.
FAU - Paris, John J
AU  - Paris JJ
AD  - Boston College, Chestnut Hill, Massachusetts; and.
FAU - Lantos, John D
AU  - Lantos JD
AD  - Children's Mercy Hospital, Kansas City, Missouri.
FAU - Cummings, Brian M
AU  - Cummings BM
AD  - Massachusetts General Hospital, Boston, Massachusetts.
LA  - eng
PT  - Letter
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Clinical Decision-Making/ethics
MH  - Electroencephalography
MH  - Euthanasia, Passive/*ethics
MH  - Heart Arrest/*therapy
MH  - Humans
MH  - Hypothermia, Induced
MH  - Infant
MH  - Prognosis
MH  - *Resuscitation
MH  - Withholding Treatment/*ethics
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/08/01 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - peds.2019-4061 [pii]
AID - 10.1542/peds.2019-4061 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(2). pii: peds.2019-4061. doi: 10.1542/peds.2019-4061.


PMID- 32732258
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 1473-0480 (Electronic)
IS  - 0306-3674 (Linking)
VI  - 54
IP  - 21
DP  - 2020 Nov
TI  - In the fight for racial justice, the sidelines are no longer an option.
PG  - 1245-1246
LID - 10.1136/bjsports-2020-102894 [doi]
FAU - Blake, Tracy
AU  - Blake T
AUID- ORCID: http://orcid.org/0000-0002-1888-2940
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada
      tracyablakeptphd@gmail.com.
AD  - Volleyball Canda, Ottawa, Ontario, Canada.
AD  - University Health Network-Toronto Western Hospital, Toronto, Ontario, Canada.
LA  - eng
PT  - Editorial
DEP - 20200730
PL  - England
TA  - Br J Sports Med
JT  - British journal of sports medicine
JID - 0432520
SB  - IM
MH  - Humans
MH  - Periodicals as Topic
MH  - Publishing/*standards
MH  - *Racism
MH  - *Social Justice
OTO - NOTNLM
OT  - athlete
OT  - ethics
OT  - prevention
OT  - protection
OT  - public health
COIS- Competing interests: Dr Tracy Blake is an Associated Editor of BJSM.
EDAT- 2020/08/01 06:00
MHDA- 2021/04/23 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - bjsports-2020-102894 [pii]
AID - 10.1136/bjsports-2020-102894 [doi]
PST - ppublish
SO  - Br J Sports Med. 2020 Nov;54(21):1245-1246. doi: 10.1136/bjsports-2020-102894.
      Epub 2020 Jul 30.


PMID- 32732058
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 252
DP  - 2020 Sep
TI  - EBCOG position statement on "Ethical analysis of cross-border reproductive care".
PG  - 568-569
LID - S0301-2115(20)30469-3 [pii]
LID - 10.1016/j.ejogrb.2020.07.027 [doi]
AB  - Cross border movement of couples to seek assisted conception treatments which are
      not available in their own countries are creating lots of ethical issues. Eu
      countires should work together to deliver couple centered care within a legal
      framework.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Shenfield, Francoise
AU  - Shenfield F
AD  - Reproductive Medicine Unit, University College Hospital, London, UK. Electronic
      address: mfi@easynet.co.uk.
FAU - Messinis, Ioannis
AU  - Messinis I
AD  - Chair Examination Standing Committee, European Board and College of Obstetrics
      and Gynaecology (EBCOG), Greece.
FAU - Mahmood, Tahir
AU  - Mahmood T
AD  - Chair Standards of Care and Position Statements Working Group, European Board and
      College of Obstetrics and Gynaecology (EBCOG), UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200715
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
SB  - IM
MH  - Ethical Analysis
MH  - Humans
MH  - *Medical Tourism
MH  - Reproductive Techniques, Assisted
OTO - NOTNLM
OT  - Cross border
OT  - Ethics
OT  - Europe
OT  - Infertility
OT  - Reproductive care
EDAT- 2020/08/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/08/01 06:00
PHST- 2020/07/05 00:00 [received]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
AID - S0301-2115(20)30469-3 [pii]
AID - 10.1016/j.ejogrb.2020.07.027 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:568-569. doi:
      10.1016/j.ejogrb.2020.07.027. Epub 2020 Jul 15.


PMID- 32731376
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Jul 28
TI  - Lighting Up the Tumor-Fluorescein-Guided Resection of Gangliogliomas.
LID - E2405 [pii]
LID - 10.3390/jcm9082405 [doi]
AB  - (1) Background: Gangliogliomas comprise a small number of brain tumors. They
      usually present as World Health Organization (WHO) grade I, and they delineate on
      gadolinium-enhanced MRI; the surgical goal is wide radical resection, and the
      course thereafter is usually benign. Fluorescein sodium (FL) tends to accumulate 
      in areas with altered blood-brain barrier (BBB). Thus far, the results provided
      by prospective and retrospective studies show that the utilization of this
      fluorophore may be associated with better visualization and improvement of
      resection for several tumors of the central nervous system. In this study, we
      retrospectively studied the effect of fluorescein sodium on visualization and
      resection of gangliogliomas. (2) Methods: Surgical databases in three
      neurosurgical departments (Regensburg University Hospital; Besta Institute,
      Milano, Italy; and Liv Hospital, Istanbul, Turkey), with approval by the local
      ethics committee, were retrospectively reviewed to find gangliogliomas surgically
      removed by a fluorescein-guided technique by the aid of a dedicated filter on the
      surgical microscope from April 2014 to February 2020. Eighteen patients (13
      women, 5 men; mean age 22.9 years, range 3 to 78 years) underwent surgical
      treatment for gangliogliomas during 19 operations. Fluorescein was intravenously 
      injected (5 mg/kg) after general anesthesia induction. Tumors were removed using 
      a microsurgical technique with the YELLOW 560 Filter (YE560) (KINEVO/PENTERO 900,
      Carl Zeiss Meditec, Oberkochen, Germany). (3) Results: No side effects related to
      fluorescein occurred. In all tumors, contrast enhancement on preoperative MRI
      correlated with bright yellow fluorescence during the surgical procedure (17
      gangliogliomas WHO grade I, 1 ganglioglioma WHO grade II). Fluorescein was
      considered helpful by the operating surgeon in distinguishing tumors from viable 
      tissue in all cases (100%). Biopsy was intended in two operations, and subtotal
      resection was intended in one operation. In all other operations considered
      preoperatively eligible, gross total resection (GTR) was achieved in 12 out of 16
      (75%) instances. (4) Conclusions: The use of FL and YE560 is a readily available 
      method for safe fluorescence-guided tumor resection, possibly visualizing tumor
      margins intraoperatively similar to contrast enhancement in T1-weighted MRI. Our 
      data suggested a positive effect of fluorescein-guided surgery on intraoperative 
      visualization and extent of resection during resection of gangliogliomas.
FAU - Hohne, Julius
AU  - Hohne J
AUID- ORCID: 0000-0002-8238-2211
AD  - Department of Neurosurgery, University Medical Center Regensburg, 93053
      Regensburg, Germany.
FAU - Acerbi, Francesco
AU  - Acerbi F
AD  - Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta,
      20133 Milano, Italy.
FAU - Falco, Jacopo
AU  - Falco J
AD  - Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta,
      20133 Milano, Italy.
FAU - Akcakaya, Mehmet Osman
AU  - Akcakaya MO
AD  - Department of Neurosurgery Liv Hospital Ulus Affiliated with Istinye University
      Medical Faculty, Istanbul 34340, Turkey.
FAU - Schmidt, Nils Ole
AU  - Schmidt NO
AUID- ORCID: 0000-0001-6910-8843
AD  - Department of Neurosurgery, University Medical Center Regensburg, 93053
      Regensburg, Germany.
FAU - Kiris, Talat
AU  - Kiris T
AD  - Department of Neurosurgery Liv Hospital Ulus Affiliated with Istinye University
      Medical Faculty, Istanbul 34340, Turkey.
FAU - de Laurentis, Camilla
AU  - de Laurentis C
AD  - Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta,
      20133 Milano, Italy.
FAU - Ferroli, Paolo
AU  - Ferroli P
AD  - Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta,
      20133 Milano, Italy.
FAU - Broggi, Morgan
AU  - Broggi M
AUID- ORCID: 0000-0001-8818-1317
AD  - Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta,
      20133 Milano, Italy.
FAU - Schebesch, Karl-Michael
AU  - Schebesch KM
AD  - Department of Neurosurgery, University Medical Center Regensburg, 93053
      Regensburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7465830
OTO - NOTNLM
OT  - KINEVO
OT  - PENTERO 900
OT  - YELLOW 560 nm filter
OT  - fluorescein sodium
OT  - fluorescence-guided surgery
OT  - ganglioglioma
OT  - neurosurgery
OT  - surgical microscope
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
CRDT- 2020/08/01 06:00
PHST- 2020/06/12 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
AID - jcm9082405 [pii]
AID - 10.3390/jcm9082405 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jul 28;9(8). pii: jcm9082405. doi: 10.3390/jcm9082405.


PMID- 35310921
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220322
IS  - 1458-6126 (Electronic)
IS  - 1455-0725 (Linking)
VI  - 37
IP  - 4
DP  - 2020 Aug
TI  - Successes and failures in treatment of substance abuse: Treatment system
      perspectives and lessons from the European continent.
PG  - 323-337
LID - 10.1177/1455072520941977 [doi]
AB  - Objective: The article offers an inventory of controversial basic issues related 
      to treatment responses and their sociocultural political context, highlighting
      policy failures and successes, with a focus on Europe. As a reference point for
      this assessment, serves a conceptual framework of an "ideal type of treatment
      system", which is built upon the following normative assumptions: the objective
      of harm minimisation or preventing substance-use-related consequences,
      evidence-based decision making, securing equity and accessibility also from a
      user perspective as well as efficiency in terms of the diversity and choice of
      treatment options. Method: Five major issues of addiction treatment systems, as
      identified and exemplified by an expert survey among 14 countries conducted in
      2014, served as a reference for discussing fundamental gaps between an assumed
      ideal type of treatment system and the treatment response in practice: (1)
      Resistance to change, consensus building and innovation, (2) Political influence 
      and target group bias beyond evidence, (3) Assumptions about rationality and
      universal evidence, (4) Myths of addiction and ethical deficits and (5) The
      treatment gap and user perspectives. Results/conclusions: Recommendations
      relevant for politicians, system planners, and clinicians are formulated for each
      of the five issues, specifically focusing on embeddedness of treatment systems in
      macro-societal conditions, the abstinence paradigm and outcome diversity,
      ethnocentric biases of the "evidence credo", learning from self-change as the
      major road to recovery, and questioning implicit conceptions of the "addict as a 
      human being". Furthermore, it is concluded that theories regarding the diffusion 
      of innovation and knowledge exchange can inform future research.
CI  - (c) The Author(s) 2020.
FAU - Klingemann, Harald
AU  - Klingemann H
AUID- ORCID: https://orcid.org/0000-0003-0957-7220
AD  - University of Applied Sciences Bern, Bern University of the Arts (BUA), Bern,
      Switzerland.30337
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - United States
TA  - Nordisk Alkohol Nark
JT  - Nordisk alkohol- & narkotikatidskrift : NAT
JID - 100937320
PMC - PMC8899245
OTO - NOTNLM
OT  - addiction treatment systems in Europe
OT  - ethnocentric bias
OT  - self-change
OT  - treatment ethics
OT  - treatment gap
OT  - user perspective vs. top down
COIS- Declaration of conflicting interests: The author declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2020/08/01 00:00
MHDA- 2020/08/01 00:01
CRDT- 2022/03/21 09:09
PHST- 2019/11/29 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2022/03/21 09:09 [entrez]
PHST- 2020/08/01 00:00 [pubmed]
PHST- 2020/08/01 00:01 [medline]
AID - 10.1177/1455072520941977 [doi]
AID - 10.1177_1455072520941977 [pii]
PST - ppublish
SO  - Nordisk Alkohol Nark. 2020 Aug;37(4):323-337. doi: 10.1177/1455072520941977. Epub
      2020 Aug 17.


PMID- 32730016
STAT- Publisher
DA  - 20200731
ISBN- 9780309672986
ISBN- 0309672988
PB  - National Academies Press (US)
CTI - The National Academies Collection: Reports funded by National Institutes of
      Health
DP  - 2020 Apr 9
BTI - Exploring Novel Clinical Trial Designs for Gene-Based Therapies: Proceedings of a
      Workshop
LID - 10.17226/25712 [doi]
AB  - Recognizing the potential design complexities and ethical issues associated with 
      clinical trials for gene therapies, the Forum on Regenerative Medicine of the
      National Academies of Sciences, Engineering, and Medicine held a 1-day workshop
      in Washington, DC, on November 13, 2019. Speakers at the workshop discussed
      patient recruitment and selection for gene-based clinical trials, explored how
      the safety of new therapies is assessed, reviewed the challenges involving dose
      escalation, and spoke about ethical issues such as informed consent and the role 
      of clinicians in recommending trials as options to their patients. The workshop
      also included discussions of topics related to gene therapies in the context of
      other available and potentially curative treatments, such as bone marrow
      transplantation for hemoglobinopathies. This publication summarizes the
      presentation and discussion of the workshop.
CI  - Copyright 2020 by the National Academy of Sciences. All rights reserved.
CN  - National Academies of Sciences, Engineering, and Medicine; Health and Medicine
      Division; Board on Health Sciences Policy; Forum on Regenerative Medicine
FED - Beachy, Sarah H.
ED  - Beachy SH
FED - Alper, Joe
ED  - Alper J
FED - Hackmann, Meredith
ED  - Hackmann M
FED - Addie, Siobhan
ED  - Addie S
LA  - eng
PT  - Review
PT  - Book
PL  - Washington (DC)
EDAT- 2020/07/31 06:01
MHDA- 2020/07/31 06:01
CDAT- 2020/07/31 06:01
AID - NBK559955 [bookaccession]
AID - 10.17226/25712 [doi]


PMID- 32731276
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20201218
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 145
IP  - 15
DP  - 2020 Jul
TI  - [COVID-19: a geriatric point-of-view].
PG  - 1039-1043
LID - 10.1055/a-1164-4261 [doi]
AB  - The pandemic due to the SARS-CoV-2 virus challenges all of us in the many areas
      of life. Our health systems are tested for their sustainability and load
      capacity. SARS-CoV-2 virus-infections will become part of our lives, but they
      mainly threaten vulnerable and multimorbid older adults. Older people with a
      frailty-syndrome are challenged not only in physical, but also psychological and 
      social domains. Adapted caring structures are required and the pandemic will
      introduce important ethical discussions. As examples, distribution of limited
      resources, requests for more Advance Care Planning as well as balancing between
      infection protection versus the drawbacks of long-lasting social isolation should
      be named. This article therefore focuses on ethical questions for older adults in
      times of the SARS-CoV-2 virus pandemic.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Sieber, Cornel
AU  - Sieber C
LA  - ger
PT  - Journal Article
TT  - COVID-19 aus Sicht der Geriatrie.
DEP - 20200730
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/physiopathology/prevention & control/therapy
MH  - Family
MH  - *Frail Elderly
MH  - Frailty
MH  - *Geriatric Assessment
MH  - Geriatrics
MH  - Humans
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/physiopathology/prevention & control/therapy
MH  - SARS-CoV-2
MH  - Social Isolation
MH  - Terminal Care
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/07/31 06:00
MHDA- 2020/08/14 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
AID - 10.1055/a-1164-4261 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2020 Jul;145(15):1039-1043. doi: 10.1055/a-1164-4261. Epub 
      2020 Jul 30.


PMID- 32730515
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 0717-6228 (Electronic)
IS  - 0370-4106 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jun
TI  - [An Early Obesity Prevention Program: HaViSa UC (2009-2019)].
PG  - 353-362
LID - S0370-41062020005000707 [pii]
LID - 10.32641/rchped.v91i3.1548 [doi]
AB  - INTRODUCTION: Prevention is the definitive solution to the serious nutritional
      epidemiological pro blem of children in our country and the world, obesity.
      OBJECTIVE: To describe the results of an obesi ty prevention program for infants 
      and preschoolers, ten years after its implementation. SUBJECTS AND METHODS:
      Retrospective, and quasi-experimental study of the overweight and obesity
      prevalence, in children attending three nursery and preschool centers located at 
      the Universidad Catolica de Chile, since the implementation of a multidimensional
      program for early promotion of healthy lifestyle habits (HaViSa-UC) between 2009 
      and 2019. This study obtained ethical approval. Annual records of anthropometric 
      assessment (WHO 2006) were analyzed using Minitab 17 software. The actions
      applied by the HaViSa-UC program were the assessment of nutritional status and
      communication with parents, delivery of healthy food, promotion of an active
      lifestyle, and education to encourage such healthy habits. RESULTS: The annual
      mean was 319 subjects, 14% younger than two years old, and 49.5% were girls. In
      March 2009 (baseline), 32.6% had overweight and 8.6% obesity; both figures
      decreased reaching 23.8% and 4.7% respectively, in March 2019. Normal weight
      increased from 56.9 to 67.4% and malnutrition presented no increase. In the same 
      period, zW/H dropped from 0.84 +/- 0.94 to 0.55 +/- 0.87 (p: 0.00), and zH/A
      increased from -0.36 +/- 0.87 to -0.32 +/- 0.90 (p > 0.05). Con clusion: Since
      the implementation of the HaViSa-UC Program, the frequency of obesity decreased
      by 45.4% and overweight by 27.2% in this sample of infants and preschoolers,
      remaining stable after 10 years.
FAU - Barja, S
AU  - Barja S
AD  - Division de Pediatria, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Loyola, M
AU  - Loyola M
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Ortiz, C
AU  - Ortiz C
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Araneda, Y
AU  - Araneda Y
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Undurraga, R
AU  - Undurraga R
AD  - Pontificia Universidad Catolica de Chile, Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Un programa de prevencion temprana de la obesidad: "HaViSa UC" (2009-2019).
PL  - Chile
TA  - Rev Chil Pediatr
JT  - Revista chilena de pediatria
JID - 0404261
SB  - IM
MH  - Child, Preschool
MH  - Chile/epidemiology
MH  - Female
MH  - Health Promotion/*methods
MH  - Healthy Lifestyle
MH  - Humans
MH  - Infant
MH  - Longitudinal Studies
MH  - Male
MH  - Pediatric Obesity/diagnosis/epidemiology/*prevention & control
MH  - Prevalence
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2020/07/31 06:00
MHDA- 2021/06/01 06:00
CRDT- 2020/07/31 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
AID - S0370-41062020005000707 [pii]
AID - 10.32641/rchped.v91i3.1548 [doi]
PST - ppublish
SO  - Rev Chil Pediatr. 2020 Jun;91(3):353-362. doi: 10.32641/rchped.v91i3.1548.


PMID- 32730503
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 2
DP  - 2020 Feb
TI  - [Conscientious objection in medical actions].
PG  - 252-257
LID - S0034-98872020000200252 [pii]
LID - 10.4067/s0034-98872020000200252 [doi]
AB  - Conscientious Objection arises as a response to a regulation that is judged as
      immoral. Faced with a law that is considered unfair, the citizen can respond
      accepting it against his will, exercising conscientious objection on a personal
      level or, collectively reaching civil disobedience or revolutionary violence.
      This is an old discussion known since ancient Greece. The current enactment of
      laws that allow actions previously judged as crime, and that contravene medical
      tradition, reactivated the discussion about such objection. Some people, such as 
      Savolescu, who denies the legitimacy of conscientious objection invoked by
      doctors, arguing that it is inefficient, leads to inequality and is inconsistent.
      He proposes that the values of these professionals can be tolerated privately but
      should not be determinant in the public sphere. These arguments are critically
      examined, mentioning pertinent answers from theoretical and practical points of
      view. We highlight that ethics should not differ in public and private spheres
      and the principles should be the same, but exercised in different fields. It is
      concluded that conscientious objection is acquiring legitimacy and that it is
      necessary to reflect on the underlying reasons that lead to invoke it. It should 
      be considered a civilized resource against determinations of power that are
      considered to be an attempt against personal values and moral integrity.
FAU - Echeverria B, Carlos
AU  - Echeverria B C
AD  - Hospital Naval "Almirante Nef", Vina del Mar, Chile.
FAU - Serani M, Alejandro
AU  - Serani M A
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Arriagada U, Anamaria
AU  - Arriagada U A
AD  - Facultad de Medicina, Universidad de Chile, Santiago, Chile.
FAU - Goic G, Alejandro
AU  - Goic G A
AD  - Academia Chilena de Medicina, Instituto de Chile, Santiago, Chile.
FAU - Rojas O, Alberto
AU  - Rojas O A
AD  - Facultad de Salud, Universidad Santo Tomas, Santiago, Chile.
FAU - Ruiz-Esquide, Gonzalo
AU  - Ruiz-Esquide G
AD  - Clinica Santa Maria, Santiago, Chile.
FAU - Salinas R, Rodrigo
AU  - Salinas R R
AD  - Facultad de Medicina, Universidad de Chile, Santiago, Chile.
FAU - Taboada R, Paulina
AU  - Taboada R P
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Quintana V, Carlos
AU  - Quintana V C
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Vacarezza Y, Ricardo
AU  - Vacarezza Y R
AD  - Facultad de Medicina, Universidad de Chile, Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Objecion de conciencia y acciones de salud.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - *Conscience
MH  - Dissent and Disputes
MH  - Humans
MH  - Male
MH  - *Physicians
MH  - Refusal to Treat
EDAT- 2020/07/31 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/07/31 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2019/12/06 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - S0034-98872020000200252 [pii]
AID - 10.4067/s0034-98872020000200252 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Feb;148(2):252-257. doi: 10.4067/s0034-98872020000200252.


PMID- 32730470
OWN - NLM
STAT- MEDLINE
DCOM- 20200805
LR  - 20201218
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 4
DP  - 2020 Apr
TI  - [Ethical considerations in the context of triage by COVID-19].
PG  - 562-563
LID - S0034-98872020000400562 [pii]
LID - 10.4067/s0034-98872020000400562 [doi]
FAU - Aurenque, Diana
AU  - Aurenque D
AD  - Universidad de Santiago de Chile, Santiago, Chile.
LA  - spa
PT  - Letter
TT  - Consideraciones eticas en contexto de triage por COVID-19.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - COVID-19
MH  - Chile/epidemiology
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Triage/*ethics
EDAT- 2020/07/31 06:00
MHDA- 2020/08/06 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/08/06 06:00 [medline]
AID - S0034-98872020000400562 [pii]
AID - 10.4067/s0034-98872020000400562 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Apr;148(4):562-563. doi: 10.4067/s0034-98872020000400562.


PMID- 32730464
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20210421
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 4
DP  - 2020 Apr
TI  - [Ethical arguments for and against the participation of the medical profession in
      assisted death: analysis of the Ethics Department of the Chilean Medical
      Association].
PG  - 542-547
LID - S0034-98872020000400542 [pii]
LID - 10.4067/s0034-98872020000400542 [doi]
FAU - Salas, SofIa P
AU  - Salas SP
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Salinas, Rodrigo A
AU  - Salinas RA
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Besio, Mauricio
AU  - Besio M
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Micolich, Constanza
AU  - Micolich C
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Arriagada, AnamarIa
AU  - Arriagada A
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Misseroni Raddatz, Adelio
AU  - Misseroni Raddatz A
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Valenzuela, Carlos Y
AU  - Valenzuela CY
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - Novoa, Fernando
AU  - Novoa F
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
FAU - BOrquez EstefO, Gladys
AU  - BOrquez EstefO G
AD  - Departamento de Etica, Colegio Medico de Chile A.G, Santiago, Chile.
LA  - spa
GR  - R25 TW001605/TW/FIC NIH HHS/United States
PT  - Journal Article
TT  - Argumentos eticos a favor y en contra de la participacion del profesional medico 
      en la muerte asistida. Analisis del Departamento de Etica del Colegio Medico de
      Chile.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Chile
MH  - Dissent and Disputes
MH  - Ethics, Medical
MH  - Humans
MH  - *Medicine
MH  - *Suicide, Assisted
PMC - PMC8056437
MID - NIHMS1692350
EDAT- 2020/07/31 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/07/31 06:00
PHST- 2019/08/14 00:00 [received]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - S0034-98872020000400542 [pii]
AID - 10.4067/s0034-98872020000400542 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Apr;148(4):542-547. doi: 10.4067/s0034-98872020000400542.


PMID- 32730445
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20210511
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 1
DP  - 2020 Jan
TI  - [Ethical issues related to Coronavirus epidemic].
PG  - 123-124
LID - S0034-98872020000100123 [pii]
LID - 10.4067/S0034-98872020000100123 [doi]
FAU - Salas, Sofia P
AU  - Salas SP
AD  - Centro de Bioetica, Facultad de Medicina, Clinica Alemana Universidad del
      Desarrollo, Santiago, Chile.
LA  - spa
GR  - R25 TW001605/TW/FIC NIH HHS/United States
PT  - Journal Article
TT  - Aspectos eticos de la epidemia del Coronavirus.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections/epidemiology
MH  - Decision Making/*ethics
MH  - Delivery of Health Care/*ethics
MH  - *Health Resources/ethics/supply & distribution
MH  - Humans
MH  - Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - Public Health/*ethics
MH  - SARS-CoV-2
PMC - PMC8104908
MID - NIHMS1692337
EDAT- 2020/07/31 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - S0034-98872020000100123 [pii]
AID - 10.4067/S0034-98872020000100123 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Jan;148(1):123-124. doi: 10.4067/S0034-98872020000100123.


PMID- 32730442
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 1
DP  - 2020 Jan
TI  - [Review Articles].
PG  - 103-108
LID - S0034-98872020000100103 [pii]
LID - 10.4067/S0034-98872020000100103 [doi]
AB  - This paper summarizes the main features of review articles in medical topics.
      Articles can be classified as narrative reviews, systematic reviews or
      meta-analysis. Narrative reviews are appropriate to update etiology,
      pathophysiology or clinical aspects of diseases, and advances in basic and
      preclinical sciences. In systematic reviews the authors define its purpose, limit
      its scope, describe the literature search, define the inclusion and exclusion
      criteria adopted to select primary studies, and the criteria applied to assess
      the quality of their results and conclusions. Meta-analysis are quantitative,
      statistically analysed systematic reviews that consider mainly primary studies
      conducted prospectively with simultaneous randomized controls, pooling the data
      obtained from each of these primary studies in order to get a single estimate of 
      effect. Systematic analysis and meta-analysis are important to evaluate new
      diagnostic and therapeutic tools, and they are most relevant to evidence-based
      medicine, mainly for the design of clinical guidelines and the adoption of new
      health care policies. Review articles published in Revista Medica de Chile were
      compared in one or two-year periods separated by ten years in between: in the
      "2001 period" 26 reviews were all narrative; in the "2010 period" 30 reviews were
      narrative and another 4 were systematic reviews; in the "2019 period" 14 reviews 
      were narrative and another 7 were systematic reviews. No meta-analysis had been
      published in these periods, in this journal. Meta-analysis including primary
      studies performed in Chile by Chilean investigators have been published in
      English language in other medical journals. The educational and professional role
      of review articles is recognised, with a word of caution on a strict adherence to
      ethical rules adopted by scientific and clinical publications, mainly with
      respect to authorship and potential conflicts of interest.
FAU - Reyes B, Humberto
AU  - Reyes B H
AD  - Revista Medica de Chile, Chile.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Articulos de Revision.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - *Authorship
MH  - Chile
MH  - *Evidence-Based Medicine
MH  - Health Policy
MH  - Language
EDAT- 2020/07/31 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - S0034-98872020000100103 [pii]
AID - 10.4067/S0034-98872020000100103 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Jan;148(1):103-108. doi: 10.4067/S0034-98872020000100103.


PMID- 32730402
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20200810
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 37
IP  - 1
DP  - 2020 Feb
TI  - [Reading Spallanzani today].
PG  - 64-68
LID - S0716-10182020000100064 [pii]
LID - 10.4067/S0716-10182020000100064 [doi]
AB  - We remember Lazaro Spallanzani (1729-1799) mainly for his controversy with
      Needham over spontaneous generation, but he was a man of multiple scientific
      activities in the fields of biology, mineralogy, physics, mathematics and...
      volcanology! Called "the biologist of biologists", he developed a series of
      investigations about reproduction of amphibian, in one of them -Experiences in
      service to the history of the generation of animals and plants- we have found
      horrific experiments with frogs, including severe and useless mutilation of
      males, in order to interrupt its copulation with females, acts he describes as
      "barbaric", and we estimate inadmissible in the ecclesiastic man he was, even in 
      an epoch in which animals were considered "anima vili" (something without value).
      A brief review of the use of animals in laboratories shows significant advances
      in the ethical regulations for this practice, but we believe that these
      achievements are not enough.
FAU - Ledermann D, Walter
AU  - Ledermann D W
AD  - Centro de Estudios Humanistas Julio Prado, Chile.
LA  - spa
PT  - Historical Article
PT  - Journal Article
PT  - Review
TT  - Leyendo a Spallanzani hoy en dia.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de
      Infectologia
JID - 9305754
SB  - IM
MH  - *Animal Welfare/history/standards
MH  - Animals
MH  - Animals, Laboratory
MH  - Female
MH  - History, 18th Century
MH  - *Laboratories/ethics
MH  - Male
MH  - Reproduction/physiology
MH  - Science/ethics/history
EDAT- 2020/07/31 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - S0716-10182020000100064 [pii]
AID - 10.4067/S0716-10182020000100064 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2020 Feb;37(1):64-68. doi: 10.4067/S0716-10182020000100064.


PMID- 32730397
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20200810
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 37
IP  - 1
DP  - 2020 Feb
TI  - [Prevalence of Neisseria gonorrhoeae, amongst inmates of the Preventive Reclusion
      Center in Arica].
PG  - 32-36
LID - S0716-10182020000100032 [pii]
LID - 10.4067/S0716-10182020000100032 [doi]
AB  - BACKGROUND: Sex workers, people with drug addiction, early onset of sexual
      activity population, and criminal population, are considered the groups most at
      risk of contracting sexually transmitted infections (STIs). AIM: To determine the
      prevalence of infection by Neisseria gonorrhoeae in inmates of the Preventive
      Detention Center (CDP) at Arica and Parinacota Region, Chile. The Scientific
      Ethical Committee of Universidad de Tarapaca approved this study. METHOD: 140
      inmates participated, who voluntarily agreed to be part of the study and signed
      an informed consent. A sample of urethral meatus was taken to investigate N.
      gonorrhoeae, and an epidemiological survey was applied, which included age, drug 
      use, overcrowding, among others. RESULTS: The prevalence of the agent was 16.4%
      in inmates of the Arica CDP, a result lower than that reported in other similar
      studies. CONCLUSION: Knowing the reality of the prevalence of this STI and some
      risk factors associated with the situation of deprivation of freedom in a
      tri-border area of northern Chile, contributes to the proposals for prevention
      programs in this vulnerable and at-risk population.
FAU - Reyes R, Teresa
AU  - Reyes R T
AD  - Departamento de Obstetricia, Facultad de Ciencias de la Salud, Universidad de
      Tarapaca, Arica, Chile.
FAU - Villanueva, Hilda
AU  - Villanueva H
AD  - Departamento de Obstetricia, Facultad de Ciencias de la Salud, Universidad de
      Tarapaca, Arica, Chile.
FAU - Borquez B, Celia
AU  - Borquez B C
AD  - Departamento de Tecnologia Medica, Facultad de Ciencias de la Salud, Universidad 
      de Tarapaca, Arica, Chile.
FAU - Casanova B, Dayana
AU  - Casanova B D
AD  - Departamento de Tecnologia Medica, Facultad de Ciencias de la Salud, Universidad 
      de Tarapaca, Arica, Chile.
FAU - Hahn A, Valeska
AU  - Hahn A V
AD  - Departamento de Tecnologia Medica, Facultad de Ciencias de la Salud, Universidad 
      de Tarapaca, Arica, Chile.
FAU - Matienzo S, Diego
AU  - Matienzo S D
AD  - Departamento de Tecnologia Medica, Facultad de Ciencias de la Salud, Universidad 
      de Tarapaca, Arica, Chile.
FAU - Villalobos R, Camila
AU  - Villalobos R C
AD  - Departamento de Tecnologia Medica, Facultad de Ciencias de la Salud, Universidad 
      de Tarapaca, Arica, Chile.
FAU - Vega, Juan
AU  - Vega J
AD  - Facultad de Ingenieria, Universidad de Tarapaca, Arica, Chile.
LA  - spa
PT  - Journal Article
TT  - Prevalencia de Neisseria gonorrhoeae, en reclusos del Centro de Detencion
      Preventiva de Arica.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de
      Infectologia
JID - 9305754
SB  - IM
MH  - Chile/epidemiology
MH  - *Gonorrhea/epidemiology/prevention & control
MH  - Humans
MH  - Neisseria gonorrhoeae/isolation & purification
MH  - Prevalence
MH  - *Prisoners/statistics & numerical data
MH  - Risk Factors
MH  - Sex Workers/statistics & numerical data
MH  - *Sexually Transmitted Diseases/epidemiology/prevention & control
EDAT- 2020/07/31 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/31 06:00
PHST- 2018/12/20 00:00 [received]
PHST- 2019/12/30 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - S0716-10182020000100032 [pii]
AID - 10.4067/S0716-10182020000100032 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2020 Feb;37(1):32-36. doi: 10.4067/S0716-10182020000100032.


PMID- 32730390
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 3
DP  - 2020 Mar
TI  - [Ethical elements in action to control pandemics].
PG  - 415-416
LID - S0034-98872020000300415 [pii]
LID - 10.4067/S0034-98872020000300415 [doi]
FAU - Bedregal, Paula
AU  - Bedregal P
AD  - Departamento de Salud Publica, Facultad de Medicina, Pontificia Universidad
      Catolica de Chile, Santiago, Chile.
FAU - Lermanda, Victoria
AU  - Lermanda V
AD  - Departamento de Salud Publica, Facultad de Medicina, Pontificia Universidad
      Catolica de Chile, Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Elementos eticos en la accion para el control de pandemias.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Civil Defense/*ethics
MH  - Health Plan Implementation/ethics/organization & administration
MH  - Humans
MH  - *Infection Control
MH  - Pandemics/*ethics/*prevention & control
EDAT- 2020/07/31 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - S0034-98872020000300415 [pii]
AID - 10.4067/S0034-98872020000300415 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Mar;148(3):415-416. doi: 10.4067/S0034-98872020000300415.


PMID- 32730386
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 3
DP  - 2020 Mar
TI  - [Ethics code of the medical college of Chile. Critical analysis of a
      modification].
PG  - 399-403
LID - S0034-98872020000300399 [pii]
LID - 10.4067/S0034-98872020000300399 [doi]
AB  - The code of ethics of the Medical College of Chile was modified in December 2019.
      The amendment was mainly to article 8, which refers to the doctor's duty to care 
      for the pregnant woman and the child she is carrying. The change maintains this
      duty, but allows doctors to perform abortions, introducing three considerations
      that act as new principles or values for the medical profession: the plurality of
      values existing in society, the autonomy of women and what is established by law.
      This paper is a reflection on codes of ethics, their relationship with values,
      and with legislation. Also it shows the consequences that this modification
      represents for the principles governing medical activity, the status of medical
      specialties, the commitment of doctors to their patients and the validity of the 
      code of ethics.
FAU - Besio R, Mauricio
AU  - Besio R M
AD  - Division de Obstetricia y Ginecologia, Pontificia Universidad Catolica de Chile, 
      Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Codigo de Etica del Colegio Medico de Chile. Analisis critico de una
      modificacion.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Abortion, Induced
MH  - Chile
MH  - *Codes of Ethics
MH  - Ethics, Medical
MH  - Female
MH  - Humans
MH  - Physicians
MH  - Pregnancy
EDAT- 2020/07/31 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - S0034-98872020000300399 [pii]
AID - 10.4067/S0034-98872020000300399 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Mar;148(3):399-403. doi: 10.4067/S0034-98872020000300399.


PMID- 32730385
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 3
DP  - 2020 Mar
TI  - [Ethical guidelines for medical decision-making during COVID-19 pandemic in
      Chile].
PG  - 393-398
LID - S0034-98872020000300393 [pii]
LID - 10.4067/S0034-98872020000300393 [doi]
AB  - The catastrophic emergency experienced by many countries with the COVID-19
      pandemic emphasized the importance of bioethics for decision-making, both at the 
      public health (equitable and effective policies) and at the clinical level. At
      the clinical level, the issues are the fulfillment of medical care demand with
      adequate health care teams, infrastructure, and supplies, and to cover critical
      care demands that surpass the available resources. Therefore, ethically correct
      approaches are required for the allocation of life sustaining resources. There
      are recommendations for the allocating life support during disasters based on
      multiple considerations, including ethical ones. However, the ethical criteria of
      existing guidelines are variable. Ethical principles usually considered are
      saving the greatest number of lives, saving the greatest number of years of life 
      and the principle of the life cycle or the goal to give each individual equal
      opportunity to live through the various phases of life. However, the centrality
      of the human being and the search for the common good should be considered.
      Knowledge of public perspectives and moral benchmarks on these issues is
      essential. A successful assignment effort will require everyone's trust and
      cooperation. Decision making should be planned and discussed in advance, since
      in-depth deliberation will be extremely complex during the disaster. Our goal is 
      to help the health care teams to wisely allocate resources in shortage periods.
FAU - Valera, Luca
AU  - Valera L
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Carrasco, Maria Alejandra
AU  - Carrasco MA
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Lopez, Rodrigo
AU  - Lopez R
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Ramos, Paulina
AU  - Ramos P
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - von Bernhardi, Rommy
AU  - von Bernhardi R
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Bedregal, Paula
AU  - Bedregal P
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Florenzano, Alejandra
AU  - Florenzano A
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Perez, Ivan
AU  - Perez I
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Olivares, Patricia
AU  - Olivares P
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Vargas, Ivonne
AU  - Vargas I
AD  - Escuela de Enfermeria, Pontificia Universidad Catolica de Chile, Santiago, Chile.
FAU - Gonzalez, Ximena
AU  - Gonzalez X
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Lopez, Paulo
AU  - Lopez P
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Duran, Gloria
AU  - Duran G
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Richards, Constanza
AU  - Richards C
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
FAU - Castro, Ricardo
AU  - Castro R
AD  - Centro de Bioetica, Facultad de Medicina, Pontificia Universidad Catolica de
      Chile, Santiago, Chile.
LA  - spa
PT  - Journal Article
TT  - Orientaciones eticas para la toma de decisiones medicas en el contexto de la
      pandemia de COVID-19 en Chile.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - COVID-19
MH  - Chile/epidemiology
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/*therapy
MH  - Practice Guidelines as Topic
EDAT- 2020/07/31 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - S0034-98872020000300393 [pii]
AID - 10.4067/S0034-98872020000300393 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Mar;148(3):393-398. doi: 10.4067/S0034-98872020000300393.


PMID- 32730383
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 0717-6163 (Electronic)
IS  - 0034-9887 (Linking)
VI  - 148
IP  - 3
DP  - 2020 Mar
TI  - [A proposal of the Chilean Academy of Medicine to improve organ procurement and
      transplantation in Chile].
PG  - 381-386
LID - S0034-98872020000300381 [pii]
LID - 10.4067/S0034-98872020000300381 [doi]
AB  - The Chilean Academy of Medicine designated a group of specialists to evaluate the
      practice and to propose reforms for organ donation and transplantation, due to
      the general insufficiencies at the national level with these procedures. In the
      last six years the mean number of organ transplants in Chile was 340 cases per
      year while effective cadaveric donors ranged between 6 and 10 per million
      inhabitants. These averages remained stable during this period and are among the 
      lowest in the region. Our analysis attributed these deficient results mainly to
      low organ donation and inefficient procurement due to lack of compliance with
      protocols and little accountability. The committee proposes several measures for 
      improvement. These are a systematic and obligatory report of potential organ
      donors by all emergency and critical care centers, frequent evaluation of
      results, empowering of health authorities to correct insufficiencies in organ
      procurement, education programs for primary, secondary, technical and university 
      students to improve their knowledge about the social significance and solidarity 
      required for transplantation policies and specialized updated training of all
      health professionals involved. Organ donation and transplantation must be based
      on clear and fair ethical considerations in order to be accepted by the general
      public.
FAU - Hepp, Juan
AU  - Hepp J
AD  - Academia Chilena de Medicina, Instituto de Chile, Chile.
FAU - Beca, Juan Pablo
AU  - Beca JP
AD  - Academia Chilena de Medicina, Instituto de Chile, Chile.
FAU - Moran, Sergio
AU  - Moran S
AD  - Academia Chilena de Medicina, Instituto de Chile, Chile.
FAU - Roessler, Emilio
AU  - Roessler E
AD  - Academia Chilena de Medicina, Instituto de Chile, Chile.
FAU - Uribe, Mario
AU  - Uribe M
AD  - Academia Chilena de Medicina, Instituto de Chile, Chile.
FAU - Palacios, Jose Manuel
AU  - Palacios JM
AD  - Sociedad Chilena de Trasplantes, Chile.
LA  - spa
PT  - Journal Article
TT  - Donacion y trasplante de organos: propuesta desde la Academia Chilena de
      Medicina.
PL  - Chile
TA  - Rev Med Chil
JT  - Revista medica de Chile
JID - 0404312
SB  - IM
MH  - Chile
MH  - Health Personnel
MH  - Humans
MH  - *Organ Transplantation
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
EDAT- 2020/07/31 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - S0034-98872020000300381 [pii]
AID - 10.4067/S0034-98872020000300381 [doi]
PST - ppublish
SO  - Rev Med Chil. 2020 Mar;148(3):381-386. doi: 10.4067/S0034-98872020000300381.


PMID- 32729761
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - Effects of using standardized patients on nursing students' moral skills.
PG  - 1587-1602
LID - 10.1177/0969733020935954 [doi]
AB  - BACKGROUND: Nurses and nursing students increasingly confront ethical problems in
      clinical practice. Moral sensitivity, moral reasoning, and ethical
      decision-making are therefore important skills throughout the nursing profession.
      Innovative teaching methods as part of the ethics training of nursing students
      help them acquire these fundamental skills. AIM: This study investigated the
      effects and potential benefits of using standardized patients in ethics education
      on nursing baccalaureate students' moral sensitivity, moral reasoning, and
      ethical decision-making by comparing this method with in-class case analyses.
      RESEARCH DESIGN: This is a quasi-experimental study. PARTICIPANTS AND RESEARCH
      CONTEXT: The sample comprised 89 students in Hacettepe University's Faculty of
      Nursing. Following lectures describing the theoretical components of ethics,
      students were randomly assigned to two working groups, one using standardized
      patients and the other using in-class case analyses. Data were collected using
      the Moral Sensitivity Questionnaire, Rest's Defining Issues Test, and the Nursing
      Dilemma Test. All data were analysed using IBM SPSS Statistics Version 23.
      ETHICAL CONSIDERATIONS: Ethical approval and official permission were obtained.
      All participating students completed informed consent forms. FINDINGS: According 
      to the results, the moral sensitivity of students in the standardized patient
      group significantly improved over time compared to those in the case analysis
      group, while the mean scores of students in both groups for moral reasoning and
      ethical decision-making were not statistically significant. CONCLUSION: Based on 
      our results, we recommend the use of both standardized patients and case analysis
      as appropriate teaching methods in ethics education.
FAU - Kucukkelepce, Gulhan Erkus
AU  - Kucukkelepce GE
AUID- ORCID: https://orcid.org/0000-0003-4914-6441
AD  - 162296Adiyaman University, Turkey.
AD  - 37515Hacettepe University, Turkey.
FAU - Dinc, Leyla
AU  - Dinc L
AD  - 37515Hacettepe University, Turkey.
FAU - Elcin, Melih
AU  - Elcin M
AD  - 37515Hacettepe University, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Curriculum/*standards/trends
MH  - Education, Nursing, Baccalaureate/methods/*standards/statistics & numerical data
MH  - Educational Measurement/methods/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - *Morals
MH  - Reference Standards
MH  - Students, Nursing/*psychology/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Turkey
MH  - Young Adult
OTO - NOTNLM
OT  - Case analysis
OT  - ethics
OT  - nursing education
OT  - nursing ethics
OT  - standardized patient
EDAT- 2020/07/31 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/07/31 06:00 [entrez]
AID - 10.1177/0969733020935954 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1587-1602. doi: 10.1177/0969733020935954. Epub 2020
      Jul 30.


PMID- 32729577
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20220531
IS  - 0253-1933 (Print)
IS  - 0253-1933 (Linking)
VI  - 39
IP  - 1
DP  - 2020 Apr
TI  - Animal welfare in the context of World Trade Organization dispute settlement.
PG  - 69-79
LID - 10.20506/rst.39.1.3063 [doi]
AB  - This paper was written to give veterinarians and decision-makers an overview of
      World Trade Organization (WTO) findings relevant to animal welfare. The article
      has a practical focus and does not attempt to provide a legal analysis of WTO
      dispute settlement. The author has simplified very technical legal language so
      that the paper will be useful to a broader audience. The global trade rules
      comprise a series of legal agreements that came into effect in 1995, when the WTO
      was established. The overarching objective of the WTO is to promote international
      trade by avoiding unjustified discrimination between trading partners. The
      harmonisation of national measures with relevant international standards is
      encouraged by the WTO to facilitate safe trade. The broad objective of the World 
      Organisation for Animal Health (OIE) is to promote global improvements in animal 
      health and welfare, and veterinary public health. To this end, the OIE sets
      intergovernmental standards and works to strengthen the capacities of Members to 
      implement them. The OIE standards are recognised as WTO references with respect
      to animal health and zoonotic diseases and a significant number of WTO disputes
      have addressed the relevance of these OIE standards to international trade
      measures. In addition to animal health standards, the OIE also sets standards for
      animal welfare, and has implemented regional and global strategies to encourage
      their adoption by Members. In comparison with measures to protect animal health
      or food safety, few WTO disputes have considered animal welfare related measures.
      A lack of WTO case law has contributed to uncertainty about the consistency of
      WTO animal welfare measures. This paper considers some WTO disputes and findings 
      relevant to animal welfare. The outcomes of these disputes suggest that WTO
      Panels and the Appellate Body are prepared to accept the right of Members to
      regulate for animal welfare purposes, providing that they respect the established
      WTO disciplines. This article draws two main conclusions. Firstly, regardless of 
      whether measures are adopted to protect animal welfare or animal health, for WTO 
      consistency, they must not result in unjustifiable, arbitrary or unnecessary
      discrimination. Secondly, regardless of how the WTO deals with animal welfare,
      governments must respond to the growing interest of consumers in farm animal
      welfare. The OIE standards, as recognised references for trading countries and
      the WTO, will continue to be influential in relation to global trade in animal
      products. It is important that the OIE update its animal welfare standards
      regularly, to ensure that they are consistent with latest scientific
      understanding and appropriate to consumer expectations for ethical food
      production.
FAU - Kahn, S
AU  - Kahn S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Rev Sci Tech
JT  - Revue scientifique et technique (International Office of Epizootics)
JID - 8712301
SB  - IM
MH  - *Animal Welfare
MH  - Animals
MH  - Commerce
MH  - *Dissent and Disputes
MH  - *International Cooperation
MH  - Internationality
OTO - NOTNLM
OT  - Animal welfare
OT  - International trade
OT  - World Trade Organization (WTO)
EDAT- 2020/07/31 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.20506/rst.39.1.3063 [doi]
PST - ppublish
SO  - Rev Sci Tech. 2020 Apr;39(1):69-79. doi: 10.20506/rst.39.1.3063.


PMID- 32729567
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 0253-1933 (Print)
IS  - 0253-1933 (Linking)
VI  - 39
IP  - 1
DP  - 2020 Apr
TI  - National official assurance systems for international trade in animals and animal
      products, with reference to the standards of the World Organisation for Animal
      Health.
PG  - 201-211
LID - 10.20506/rst.39.1.3073 [doi]
AB  - In the context of trade, national official assurance systems are the mechanism
      through which countries provide official assurance to other countries that their 
      products are safe to trade. Regardless of the form in which it is conveyed, an
      official assurance, for the most part, is a statement from one competent
      authority to another about the conformity of a consignment with agreed
      requirements. Effectively, one government is providing a level of guarantee to
      the other government about matters such as the disease or pest status that exists
      nationally or regionally and/ or about the risk management activities that have
      been undertaken as relevant to the traded consignment. Accordingly, the degree of
      confidence that the importing competent authority has in the ethics, competence
      and capability of the exporting country's competent authority is central to how
      much trust the importing country places in the official assurances from the
      exporting country. The World Organisation for Animal Health Terrestrial Animal
      Health Code and Aquatic Animal Health Code (Section 5 of both) set out veterinary
      certificate requirements relating to animal health and zoonoses for both
      importing and exporting countries engaging in the trade of animals and animal
      products. These requirements are supplemented by the guidance developed by the
      Codex Committee on Food Inspection and Certification Systems, which covers the
      inspection and certification system requirements related to food safety and other
      non-health-related technical matters (e.g. composition, grade or organic status),
      as relevant to the international trade in food. This review discusses the need
      for countries to further align the form and content of their official assurance
      requirements with the relevant international standards and recommendations. It
      also notes, however, that there is currently a paucity of recommended
      standardised attestations. It highlights the increasing movement towards
      electronic certification and the potential this brings for further amalgamation
      of different certificate types and the coordination of border clearance
      processes. The basic components and principles that apply to national official
      assurance systems are identified and explained. Lastly, future trends and
      challenges for national official assurance systems, such as the impact of
      electronic commerce and regional distribution hubs, and the increasing
      recognition of containment zones and/or risk mitigations, such as treatments, are
      discussed.
FAU - Jolly, W T
AU  - Jolly WT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Rev Sci Tech
JT  - Revue scientifique et technique (International Office of Epizootics)
JID - 8712301
SB  - IM
MH  - Animals
MH  - *Commerce
MH  - Global Health
MH  - *International Cooperation
MH  - Internationality
MH  - Reference Standards
OTO - NOTNLM
OT  - Assurance
OT  - Border
OT  - Certificates
OT  - Clearance
OT  - Electronic certification
OT  - Electronic commerce
OT  - Export
OT  - Officials
OT  - Systems
OT  - Trade
OT  - Verification
EDAT- 2020/07/31 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.20506/rst.39.1.3073 [doi]
PST - ppublish
SO  - Rev Sci Tech. 2020 Apr;39(1):201-211. doi: 10.20506/rst.39.1.3073.


PMID- 32729409
OWN - NLM
STAT- Publisher
LR  - 20201012
IS  - 1460-3659 (Electronic)
IS  - 0306-3127 (Linking)
DP  - 2020 Jul 30
TI  - Forensic DNA phenotyping and its politics of legitimation and contestation: Views
      of forensic geneticists in Europe.
PG  - 306312720945033
LID - 10.1177/0306312720945033 [doi]
AB  - Forensic DNA Phenotyping (FDP) is a set of techniques that aim to infer
      externally visible characteristics in humans - such as eye, hair and skin color -
      and biogeographical ancestry of an unknown person, based on biological material. 
      FDP has been applied in various jurisdictions in a limited number of high-profile
      cases to provide intelligence for criminal investigations. There are on-going
      controversies about the reliability and validity of FDP, which come together with
      debates about the ethical challenges emerging from the use of this technology in 
      the criminal justice system. Our study explores how, in the context of complex
      politics of legitimation of and contestation over the use of FDP, forensic
      geneticists in Europe perceive this technology's potential applications, utility 
      and risks. Forensic geneticists perform several forms of discursive boundary
      work, making distinctions between science and the criminal justice system,
      experts and non-experts, and good and bad science. Such forms of boundary work
      reconstruct the complex positioning vis-a-vis legal and scientific realities. In 
      particular, while mobilizing interest in FDP, forensic geneticists simultaneously
      carve out notions of risk, accountability and scientific conduct that perform
      distance from FDP' implications in the criminal justice system.
FAU - Granja, Rafaela
AU  - Granja R
AUID- ORCID: https://orcid.org/0000-0003-4430-9061
AD  - Universidade do Minho, Braga, Portugal.
FAU - Machado, Helena
AU  - Machado H
AD  - Universidade do Minho, Braga, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - United States
TA  - Soc Stud Sci
JT  - Social studies of science
JID - 7506743
OTO - NOTNLM
OT  - biolegality
OT  - boundary work
OT  - forensic DNA phenotyping
OT  - legitimation
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/07/31 06:00 [entrez]
AID - 10.1177/0306312720945033 [doi]
PST - aheadofprint
SO  - Soc Stud Sci. 2020 Jul 30:306312720945033. doi: 10.1177/0306312720945033.


PMID- 32729337
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1545-1569 (Electronic)
IS  - 1055-6656 (Linking)
VI  - 57
IP  - 10
DP  - 2020 Oct
TI  - Simulation-Based Comprehensive Cleft Care Workshops: A Reproducible Model for
      Sustainable Education.
PG  - 1238-1246
LID - 10.1177/1055665620944781 [doi]
AB  - OBJECTIVE: Evaluate simulation-based comprehensive cleft care workshops as a
      reproducible model for education with sustained impact. DESIGN: Cross-sectional
      survey-based evaluation. SETTING: Simulation-based comprehensive cleft care
      workshop. PARTICIPANTS: Total of 180 participants. INTERVENTIONS: Three-day
      simulation-based comprehensive cleft care workshop. MAIN OUTCOME MEASURES: Number
      of workshop participants stratified by specialty, satisfaction with the workshop,
      satisfaction with simulation-based workshops as educational tools, impact on
      cleft surgery procedural confidence, short-term impact on clinical practice,
      medium-term impact on clinical practice. RESULTS: The workshop included 180
      participants from 5 continents. The response rate was 54.5%, with participants
      reporting high satisfaction with all aspects of the workshop and with
      simulation-based workshops as educational tools. Participants reported a
      significant improvement in cleft lip (33.3 +/- 5.7 vs 25.7 +/- 7.6; P < .001) and
      palate (32.4 +/- 7.1 vs 23.7 +/- 6.6; P < .001) surgery procedural confidence
      following the simulation sessions. Participants also reported a positive
      short-term and medium-term impact on their clinical practices. CONCLUSION:
      Simulation-based comprehensive cleft care workshops are well received by
      participants, lead to improved cleft surgery procedural confidence, and have a
      sustained positive impact on participants' clinical practices. Future efforts
      should focus on evaluating and quantifying this perceived positive impact, as
      well reproducing these efforts in other areas of need.
FAU - Kantar, Rami S
AU  - Kantar RS
AUID- ORCID: 0000-0002-2245-2054
AD  - Global Smile Foundation, Norwood, MA, USA.
AD  - Department of Surgery, The University of Maryland Medical System, Baltimore, MD, 
      USA.
FAU - Breugem, Corstiaan C
AU  - Breugem CC
AD  - Department of Plastic, Reconstructive and Hand Surgery, Amsterdam University
      Medical Centers, Amsterdam, the Netherlands.
FAU - Keith, Kristen
AU  - Keith K
AD  - Global Smile Foundation, Norwood, MA, USA.
FAU - Kassam, Serena
AU  - Kassam S
AUID- ORCID: 0000-0001-5418-3568
AD  - Global Smile Foundation, Norwood, MA, USA.
AD  - Department of Pediatric Dentistry, British Columbia Children's Hospital,
      Vancouver, British Columbia, Canada.
FAU - Vijayakumar, Charanya
AU  - Vijayakumar C
AUID- ORCID: 0000-0003-1067-5506
AD  - Cleft and Craniofacial Center, Sri Ramachandra Institute of Higher Education and 
      Research (SRIHER), Chennai, Tamil Nadu, India.
FAU - Bow, Mikaela
AU  - Bow M
AD  - Global Smile Foundation, Norwood, MA, USA.
FAU - Alfonso, Allyson R
AU  - Alfonso AR
AUID- ORCID: 0000-0002-9858-4686
AD  - Global Smile Foundation, Norwood, MA, USA.
AD  - The Hansjorg Department of Plastic Surgery, New York University Langone Health,
      New York City, NY, USA.
FAU - Chahine, Elsa M
AU  - Chahine EM
AUID- ORCID: 0000-0002-4140-201X
AD  - Global Smile Foundation, Norwood, MA, USA.
FAU - Ghotmi, Lilian H
AU  - Ghotmi LH
AD  - Global Smile Foundation, Norwood, MA, USA.
FAU - Patel, Krishna G
AU  - Patel KG
AD  - Global Smile Foundation, Norwood, MA, USA.
AD  - Department of Otolaryngology-Head and Neck Surgery, Medical University of South
      Carolina, Charleston, SC, USA.
FAU - Shetye, Pradip R
AU  - Shetye PR
AD  - The Hansjorg Department of Plastic Surgery, New York University Langone Health,
      New York City, NY, USA.
FAU - Santiago, Pedro E
AU  - Santiago PE
AD  - Division of Plastic Surgery, Duke University, Durham, NC, USA.
FAU - Losee, Joseph E
AU  - Losee JE
AD  - Department of Plastic Surgery, Children's Hospital of Pittsburgh, University of
      Pittsburgh Medical Center, PA, USA.
FAU - Steinbacher, Derek M
AU  - Steinbacher DM
AUID- ORCID: 0000-0003-3165-5969
AD  - Division of Plastic Surgery, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Rossell-Perry, Percy
AU  - Rossell-Perry P
AUID- ORCID: 0000-0003-0423-7649
AD  - Edgardo Rebagliati Hospital ESSALUD and San Martin de Porres University, Lima,
      Peru.
FAU - Garib, Daniela G
AU  - Garib DG
AD  - Department of Orthodontics, Bauru Dental School and Hospital for Rehabilitation
      of Craniofacial Anomalies, University of Sao Paulo, Bauru, Sao Paulo, Brazil.
FAU - Alonso, Nivaldo
AU  - Alonso N
AD  - Department of Plastic Surgery, University of Sao Paulo, Sao Paulo, Brazil.
FAU - Mann, Robert J
AU  - Mann RJ
AD  - Division of Pediatric Plastic Surgery, Spectrum Health Medical Group, Michigan
      State College of Human Medicine, Grand Rapids, MI, USA.
FAU - Prada-Madrid, Jose Rolando
AU  - Prada-Madrid JR
AD  - Department of Plastic and Reconstructive Surgery, Hospital Infantil Universitario
      de San Jose, Bogota, Colombia.
FAU - Esenlik, Elcin
AU  - Esenlik E
AUID- ORCID: 0000-0002-5647-4630
AD  - Department of Orthodontics, Faculty of Dentistry, Akdeniz University, Antalya,
      Turkey.
FAU - Pamplona, Maria Del Carmen
AU  - Pamplona MDC
AUID- ORCID: 0000-0002-5798-8238
AD  - Hablarte e Integrarte, AC, Cleft Palate Clinic, Hospital Gea Gonzalez and
      Universidad San Sebastian, Mexico City, Mexico.
FAU - Collares, Marcus Vinicius Martins
AU  - Collares MVM
AD  - Plastic and Craniomaxillofacial Surgery Division, School of Medicine, Rio Grande 
      do Sul Federal University, Porto Alegre, Brazil.
FAU - Bennun, Ricardo D
AU  - Bennun RD
AD  - Asociacion PIEL and School of Medicine, National University of Buenos Aires,
      Buenos Aires, Argentina.
FAU - Kummer, Ann
AU  - Kummer A
AD  - Division of Speech-Language Pathology, Cincinnati Children's Hospital Medical
      Center, Cincinnati, OH, USA.
FAU - Giugliano, Carlos
AU  - Giugliano C
AD  - Plastic Surgery Unit, Alfredo Gantz Mann Foundation, and Clinica Alemana,
      Santiago, Chile.
FAU - Padwa, Bonnie L
AU  - Padwa BL
AD  - Department of Plastic and Oral Surgery, Boston Children's Hospital and Harvard
      Medical School, Boston, MA, USA.
FAU - Raposo-Amaral, Cassio Eduardo
AU  - Raposo-Amaral CE
AD  - Institute of Plastic and Craniofacial Surgery, SOBRAPAR Hospital, Campinas,
      Brazil.
FAU - Tse, Raymond
AU  - Tse R
AD  - University of Washington and Seattle Children's Hospital, Seattle, WA, USA.
FAU - Sommerlad, Brian
AU  - Sommerlad B
AD  - Great Ormond Street Hospital for Children NHS Foundation Trust, London, United
      Kingdom.
FAU - Flores, Roberto L
AU  - Flores RL
AD  - The Hansjorg Department of Plastic Surgery, New York University Langone Health,
      New York City, NY, USA.
FAU - Hamdan, Usama S
AU  - Hamdan US
AD  - Global Smile Foundation, Norwood, MA, USA.
AD  - Otology and Laryngology, Harvard Medical School, Boston, MA, USA.
AD  - Otolaryngology, Tufts University School of Medicine, Boston, MA, USA.
AD  - Otolaryngology, Boston University School of Medicine, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - United States
TA  - Cleft Palate Craniofac J
JT  - The Cleft palate-craniofacial journal : official publication of the American
      Cleft Palate-Craniofacial Association
JID - 9102566
SB  - IM
MH  - *Cleft Lip/surgery
MH  - *Cleft Palate/surgery
MH  - Computer Simulation
MH  - Cross-Sectional Studies
MH  - Humans
OTO - NOTNLM
OT  - *ethics/health policies
OT  - *lip form
OT  - *lip function
OT  - *oral health
OT  - *palatoplasty
EDAT- 2020/07/31 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/07/31 06:00 [entrez]
AID - 10.1177/1055665620944781 [doi]
PST - ppublish
SO  - Cleft Palate Craniofac J. 2020 Oct;57(10):1238-1246. doi:
      10.1177/1055665620944781. Epub 2020 Jul 30.


PMID- 32728769
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20220218
IS  - 2193-6226 (Electronic)
IS  - 2193-6218 (Linking)
VI  - 115
IP  - 6
DP  - 2020 Sep
TI  - [Decisions on the allocation of intensive care resources in the context of the
      COVID-19 pandemic : Clinical and ethical recommendations of DIVI, DGINA, DGAI,
      DGIIN, DGNI, DGP, DGP and AEM. German version].
PG  - 477-485
LID - 10.1007/s00063-020-00708-w [doi]
AB  - In view of the globally evolving Coronavirus Disease (COVID-19) pandemic, German 
      hospitals rapidly expanded their intensive care capacities. However, it is
      possible that even with an optimal use of the increased resources, these will not
      suffice for all patients in need. Therefore, recommendations for the allocation
      of intensive care resources in the context of the COVID-19 pandemic have been
      developed by a multidisciplinary authors group with support of eight scientific
      medical societies. The recommendations for procedures and criteria for
      prioritisations in case of resource scarcity are based on scientific evidence,
      ethico-legal considerations and practical experience. Medical decisions must
      always be based on the need and the treatment preferences of the individual
      patient. In addition to this patient-centred approach, prioritisations in case of
      resource scarcity require a supra-individual perspective. In such situations,
      prioritisations should be based on the criterion of clinical prospect of success 
      in order to minimize the number of preventable deaths due to resource scarcity
      and to avoid discrimination based on age, disabilities or social factors.
      Assessment of the clinical prospect of success should take into account the
      severity of the current illness, severe comorbidities and the patient's general
      health status prior to the current illness.
FAU - Marckmann, Georg
AU  - Marckmann G
AD  - Institut fur Ethik, Geschichte und Theorie der Medizin,
      Ludwig-Maximilians-Universitat Munchen, Munchen, Deutschland.
FAU - Neitzke, Gerald
AU  - Neitzke G
AD  - Institut fur Geschichte, Ethik und Philosophie der Medizin, Medizinische
      Hochschule Hannover, Hannover, Deutschland.
FAU - Schildmann, Jan
AU  - Schildmann J
AD  - Institut fur Geschichte und Ethik der Medizin, Profilzentrum
      Gesundheitswissenschaften (PZG), Martin-Luther-Universitat Halle-Wittenberg,
      Halle (Saale), Deutschland.
FAU - Michalsen, Andrej
AU  - Michalsen A
AD  - Klinik fur Anasthesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie, 
      Klinik Tettnang, Tettnang, Deutschland.
FAU - Dutzmann, Jochen
AU  - Dutzmann J
AD  - Universitatsklinik und Poliklinik fur Innere Medizin III, Universitatsklinikum
      Halle (Saale), Halle (Saale), Deutschland.
FAU - Hartog, Christiane
AU  - Hartog C
AD  - Klinik fur Anasthesiologie und Intensivmedizin, Charite Universitatsmedizin
      Berlin, Berlin, Deutschland.
AD  - Patienten- und Angehorigenzentrierte Versorgung (PAV), Klinik Bavaria, Kreischa, 
      Deutschland.
FAU - Jobges, Susanne
AU  - Jobges S
AD  - Institut fur Biomedizinische Ethik und Geschichte der Medizin, Universitat
      Zurich, Zurich, Schweiz.
FAU - Knochel, Kathrin
AU  - Knochel K
AD  - Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Klinikum
      der Universitat Munchen, Munchen, Deutschland.
FAU - Michels, Guido
AU  - Michels G
AD  - Klinik fur Akut- und Notfallmedizin, St.-Antonius-Hospital Eschweiler,
      Eschweiler, Deutschland.
FAU - Pin, Martin
AU  - Pin M
AD  - Zentrale Interdisziplinare Notaufnahme, Florence-Nightingale-Krankenhaus der
      Kaiserswerther Diakonie, Dusseldorf, Deutschland.
FAU - Riessen, Reimer
AU  - Riessen R
AD  - Internistische Intensivstation 93 im Department fur Innere Medizin,
      Universitatsklinikum Tubingen, Tubingen, Deutschland.
FAU - Rogge, Annette
AU  - Rogge A
AD  - Geschaftsbereichs der Medizinethik, Christian-Albrechts-Universitat zu Kiel,
      Kiel, Deutschland.
FAU - Taupitz, Jochen
AU  - Taupitz J
AD  - Abteilung Rechtswissenschaft, Universitat Mannheim, Mannheim, Deutschland.
FAU - Janssens, Uwe
AU  - Janssens U
AD  - Klinik fur Innere Medizin und Internistische Intensivmedizin,
      St.-Antonius-Hospital Eschweiler, Dechant-Deckers-Str. 8, 52249, Eschweiler,
      Deutschland. uwe.janssens@sah-eschweiler.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Entscheidungen uber die Zuteilung intensivmedizinischer Ressourcen im Kontext der
      COVID-19-Pandemie : Klinisch-ethische Empfehlungen der DIVI, der DGINA, der DGAI,
      der DGIIN, der DGNI, der DGP, der DGP und der AEM.
PL  - Germany
TA  - Med Klin Intensivmed Notfmed
JT  - Medizinische Klinik, Intensivmedizin und Notfallmedizin
JID - 101575086
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Care/*ethics
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Societies, Medical
PMC - PMC7387420
OTO - NOTNLM
OT  - Intensive care medicine
OT  - Justice
OT  - Prioritisation
OT  - Scarcity
OT  - Triage
EDAT- 2020/07/31 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/07/31 06:00 [entrez]
AID - 10.1007/s00063-020-00708-w [doi]
AID - 10.1007/s00063-020-00708-w [pii]
PST - ppublish
SO  - Med Klin Intensivmed Notfmed. 2020 Sep;115(6):477-485. doi:
      10.1007/s00063-020-00708-w.


PMID- 32728768
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20210110
IS  - 2193-6226 (Electronic)
IS  - 2193-6218 (Linking)
VI  - 115
IP  - Suppl 3
DP  - 2020 Dec
TI  - Decisions on the allocation of intensive care resources in the context of the
      COVID-19 pandemic : Clinical and ethical recommendations of DIVI, DGINA, DGAI,
      DGIIN, DGNI, DGP, DGP and AEM.
PG  - 115-122
LID - 10.1007/s00063-020-00709-9 [doi]
AB  - In view of the globally evolving coronavirus disease (COVID-19) pandemic, German 
      hospitals rapidly expanded their intensive care capacities. However, it is
      possible that even with an optimal use of the increased resources, these will not
      suffice for all patients in need. Therefore, recommendations for the allocation
      of intensive care resources in the context of the COVID-19 pandemic have been
      developed by a multidisciplinary group of authors with the support of eight
      scientific medical societies. The recommendations for procedures and criteria for
      prioritisations in case of resource scarcity are based on scientific evidence,
      ethicolegal considerations and practical experience. Medical decisions must
      always be based on the need and the treatment preferences of the individual
      patient. In addition to this patient-centred approach, prioritisations in case of
      resource scarcity require a supraindividual perspective. In such situations,
      prioritisations should be based on the criterion of clinical prospect of success 
      in order to minimize the number of preventable deaths due to resource scarcity
      and to avoid discrimination based on age, disabilities or social factors. The
      assessment of the clinical prospect of success should take into account the
      severity of the current illness, severe comorbidities and the patient's general
      health status prior to the current illness.
FAU - Marckmann, Georg
AU  - Marckmann G
AD  - Institute of Ethics, History, and Theory of Medicine,
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Neitzke, Gerald
AU  - Neitzke G
AD  - Institute for History, Ethics and Philosophy of Medicine, Hannover Medical
      School, Hannover, Germany.
FAU - Schildmann, Jan
AU  - Schildmann J
AD  - Institute for the History and Ethics of Medicine, Interdisciplinary Center for
      Health Sciences, Martin-Luther-University Halle-Wittenberg, Halle (Saale),
      Germany.
FAU - Michalsen, Andrej
AU  - Michalsen A
AD  - Clinic for Anaesthesiology, Intensive Care, Emergency Care and Analgesic Therapy,
      Hospital Tettnang, Tettnang, Germany.
FAU - Dutzmann, Jochen
AU  - Dutzmann J
AD  - Medical University and Polyclinic for Internal Medicine III, University Hospital 
      Halle (Saale), Halle (Saale), Germany.
FAU - Hartog, Christiane
AU  - Hartog C
AD  - Clinic for Anaesthesiology and Intensive Care, Charite Medical School Berlin,
      Berlin, Germany.
AD  - Hospital Bavaria Kreischa, Kreischa, Germany.
FAU - Jobges, Susanne
AU  - Jobges S
AD  - Institute for Biomedical Ethics and History of Medicine, University Zurich,
      Zurich, Switzerland.
FAU - Knochel, Kathrin
AU  - Knochel K
AD  - Paediatric Clinic and Paediatric Polyclinic Dr. von Haunerschen Kinderspital,
      University Hospital Munich, Munich, Germany.
FAU - Michels, Guido
AU  - Michels G
AD  - Department for Acute and Emergency Medicine, St. Antonius Hospital Eschweiler,
      Eschweiler, Germany.
FAU - Pin, Martin
AU  - Pin M
AD  - Central Interdisciplinary Emergency Department, Florence-Nightingale-Hospital
      Kaiserswerther Diakonie, Dusseldorf, Germany.
FAU - Riessen, Reimer
AU  - Riessen R
AD  - Medical Intensive Care Unit 93, Department for Internal Medicine, University
      Hospital Tubingen, Tubingen, Germany.
FAU - Rogge, Annette
AU  - Rogge A
AD  - Division Ethics of Medicine, Christian-Albrechts-University Kiel, Kiel, Germany.
FAU - Taupitz, Jochen
AU  - Taupitz J
AD  - Legal Research Department, University Mannheim, Mannheim, Germany.
FAU - Janssens, Uwe
AU  - Janssens U
AD  - Medical Clinic and Medical Intensive Care Medicine, St. Antonius Hospital
      Eschweiler, Dechant-Deckers-Str. 8, 52249, Eschweiler, Germany.
      uwe.janssens@sah-eschweiler.de.
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Entscheidungen uber die Zuteilung intensivmedizinischer Ressourcen im Kontext der
      COVID-19-Pandemie : Klinisch-ethische Empfehlungen der DIVI, der DGINA, der DGAI,
      der DGIIN, der DGNI, der DGP, der DGP und der AAEM.
PL  - Germany
TA  - Med Klin Intensivmed Notfmed
JT  - Medizinische Klinik, Intensivmedizin und Notfallmedizin
JID - 101575086
RN  - 0 (Methacrylates)
RN  - 7659-36-1 (2-aminoethylmethacrylate)
SB  - IM
MH  - *COVID-19
MH  - *Coronavirus
MH  - Critical Care
MH  - Humans
MH  - Methacrylates
MH  - Pandemics
MH  - Resource Allocation
MH  - SARS-CoV-2
PMC - PMC7387419
OTO - NOTNLM
OT  - Intensive care medicine
OT  - Justice
OT  - Prioritisation
OT  - Scarcity
OT  - Triage
EDAT- 2020/07/31 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/07/31 06:00 [entrez]
AID - 10.1007/s00063-020-00709-9 [doi]
AID - 10.1007/s00063-020-00709-9 [pii]
PST - ppublish
SO  - Med Klin Intensivmed Notfmed. 2020 Dec;115(Suppl 3):115-122. doi:
      10.1007/s00063-020-00709-9.


PMID- 32728652
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 23
DP  - 2020
TI  - Oral cancer screening using mobile phone-based(mHealth) approach versus
      conventional oral examination approach, protocol of a cluster randomized study
      with cost-effectiveness analysis.
PG  - 1-5
LID - 10.1016/j.isjp.2020.07.001 [doi]
AB  - INTRODUCTION: Oral cancer is a significant health problem in India. Diagnosis is 
      often delayed. The effectiveness of conventional oral screening has been shown in
      the Trivandrum oral cancer screening study. The present study will be a step
      forward to test a mobile phone-based (the mHealth approach) comparing it with the
      conventional approach. The purpose of this paper is to report the protocol for
      this study. The primary objective will be to compare both methods in diagnosing
      oral potentially malignant disorders and cancers. The secondary objective would
      be to study the cost-effectiveness. METHODS AND ANALYSIS: This will be a
      cluster-randomized clinical trial of the population in Ernakulam district of
      Kerala state in India. They will undergo oral cancer screening by community
      health workers, who will be pre-assigned to the randomly allotted intervention
      (mHealth) or control (conventional method) clusters. We will enrol a minimum of
      9696 subjects from all 6 clusters over 18 months. The cost-effectiveness of the
      two strategies for oral screening will be determined using data from this
      randomized controlled trial. The incremental cost per oral cancer/high-risk
      dysplasia detected, and the incremental cost per life saved will be reported. We 
      will conduct sensitivity and scenario analysis to evaluate the robustness of the 
      findings. ETHICS AND DISSEMINATION: When completed, this will be the first
      cluster randomized population-based study to test the technology-based approach
      in India. The knowledge from this study will indicate whether specialists can
      make a remote diagnosis of oral lesions accurately based on the information
      gathered using a mobile phone health application and whether the mHealth strategy
      will be cost-effective in Oral cancer screening. The study will follow the
      ethical guidelines and will be published in an indexed journal.
CI  - (c) 2020 The Author(s).
FAU - Thankappan, Krishnakumar
AU  - Thankappan K
AD  - Department of Head and Neck Surgery and Oncology, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
FAU - Birur, Praveen
AU  - Birur P
AD  - Department in Oral Medicine and Radiology, KLE Society's Institute of Dental
      Sciences, Bangalore, India.
FAU - Raj, Manu
AU  - Raj M
AD  - Division of Paediatrics and Public Health Research, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
FAU - Djalalov, Sandjar
AU  - Djalalov S
AD  - Westminster International University in Tashkent, Tashkent, Uzbekistan.
FAU - Subramanian, Sujha
AU  - Subramanian S
AD  - RTI International Waltham, MA, USA.
FAU - Iyer, Subramania
AU  - Iyer S
AD  - Department of Head and Neck Surgery and Oncology, Amrita Institute of Medical
      Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
FAU - Abraham Kuriakose, Moni
AU  - Abraham Kuriakose M
AD  - Cochin Cancer Research Centre, Kochi, India.
LA  - eng
GR  - R21 CA224387/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200715
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7381684
OTO - NOTNLM
OT  - Cluster randomized study
OT  - Head and neck cancer
OT  - Mobile-phone-based screening
OT  - Oral cancer
OT  - Screening
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/06/19 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.1016/j.isjp.2020.07.001 [doi]
AID - S2468-3574(20)30021-8 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Jul 15;23:1-5. doi: 10.1016/j.isjp.2020.07.001.
      eCollection 2020.


PMID- 32728649
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Protocol for a multicenter randomized, double blind, controlled pilot trial of
      higher neural function in overactive bladder patients after anticholinergic,
      beta-3 adrenergic agonist, or placebo.
PG  - 100621
LID - 10.1016/j.conctc.2020.100621 [doi]
AB  - INTRODUCTION: Overactive bladder (OAB) syndrome has a negative impact on quality 
      of life and prevalence increases with advanced age. Anticholinergics (AC) and
      beta-3 adrenergic agonists (beta3a) are commonly prescribed medications for
      treatment of OAB. AC medication has been associated with dementia in population
      studies and with cortical atrophy in imaging studies. Higher neural effects of
      both classes of OAB medications have not been evaluated with functional
      neuroimaging. Longitudinal clinical assessments of cognition after OAB therapy
      with AC has produced conflicting results. beta3a medication is has not been
      associated with dementia in clinical studies; however, higher neural effects are 
      unknown.Our multicenter, double blind, randomized, placebo-controlled trial uses 
      functional magnetic resonance imaging (fMRI) and cognitive testing to evaluate
      the effects of AC and beta3a on brain functional connectivity in females with
      non-neurogenic OAB. METHODS AND ANALYSIS: and analysis: Female patients with OAB 
      symptoms ages 50-90 years old without baseline cognitive impairment, moderate to 
      severe depression or anxiety, neurologic disorders, or significant incomplete
      bladder emptying are invited to participate. Subjects are randomized to one of
      three interventions for 29 +/- 1 day: AC (Solifenacin succinate, Teva), beta3a
      (Mirabegron, Myrbetriq, Astellas), or placebo. Functional neuroimaging data at
      baseline and post-intervention will be analyzed accordingly. Clinical cognitive
      assessments will be compared from baseline to post-intervention. ETHICS: All
      qualifying patients are properly consented before enrolling in this study that
      has been approved by the Institutional Review Board of participating
      institutions.
CI  - (c) 2020 The Authors. Published by Elsevier Inc.
FAU - High, Rachel A
AU  - High RA
AD  - Department of Obstetrics and Gynecology, Baylor Scott and White Health, 2401
      South 31st Street, Temple, TX, 76508, USA.
FAU - Danford, Jill M
AU  - Danford JM
AD  - Department of Urology, Baylor Scott and White Health, 2401 South 31st Street,
      Temple, TX, 76508, USA.
FAU - Shi, Zhaoyue
AU  - Shi Z
AD  - Department of MRI Core, Methodist Research Institute, 6670 Bertner Ave, Houston, 
      TX, 77030, USA.
FAU - Karmonik, Christof
AU  - Karmonik C
AD  - Department of MRI Core, Methodist Research Institute, 6670 Bertner Ave, Houston, 
      TX, 77030, USA.
FAU - Kuehl, Thomas J
AU  - Kuehl TJ
AD  - Department of Obstetrics and Gynecology, Baylor Scott and White Health, 2401
      South 31st Street, Temple, TX, 76508, USA.
FAU - Bird, Erin T
AU  - Bird ET
AD  - Department of Urology, Baylor Scott and White Health, 2401 South 31st Street,
      Temple, TX, 76508, USA.
FAU - Khavari, Rose
AU  - Khavari R
AD  - Department of Urology, Methodist Hospital, 6560 Fannin St. Ste 2100, Houston, TX,
      77030, USA.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
EIN - Contemp Clin Trials Commun. 2020 Dec 10;20:100690. PMID: 33392414
PMC - PMC7381509
OTO - NOTNLM
OT  - Cognitive dysfunction
OT  - Mirabegron
OT  - Overactive bladder syndrome
OT  - Solifenacin
OT  - Urinary incontinence
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.1016/j.conctc.2020.100621 [doi]
AID - S2451-8654(20)30105-8 [pii]
AID - 100621 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Jul 14;19:100621. doi:
      10.1016/j.conctc.2020.100621. eCollection 2020 Sep.


PMID- 32728563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2279-9028 (Print)
IS  - 2279-9028 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Jul 3
TI  - Application of the Health Belief Model on the intention to stop smoking behavior 
      among young adult women.
PG  - 1817
LID - 10.4081/jphr.2020.1817 [doi]
AB  - Background: The smoking behavior among young adult women causes health issues and
      has effects on ethical norms, especially femininity and gender. A woman smoker
      usually has an intention to quit and several factors have been perceived to be
      related to this action according to the Health Belief Model (HBM). Design and
      Methods: This study was conducted cross-sectionally to analyze the correlation
      between young adult women's intention to stop smoking with perceived factors in
      the construction of HBM. A sample of 58 young adult women smokers and aged
      between 15-30 years were selected through the use of a purposive sampling
      technique in 2018. Results: The results showed the intention to stop smoking has 
      a significant correlation with perceived susceptibility (P=0.036), perceived
      severity (P=0.028), perceived benefits (P=0.011), perceived barriers (P=0.003),
      and perceived self-efficacy (P=0.005). This means there was a significant
      correlation between the intention of young adult smokers to quit smoking and the 
      perceived factors of HBM. Conclusions: The intention of stop smoking behavior
      among women smokers has a significant correlation with the perceived factors of
      the Health Belief Model construct, which includes perceived susceptibility,
      perceived severity, perceived benefits, perceived barriers, and perceived
      self-efficacy.
CI  - (c)Copyright: the Author(s).
FAU - Pribadi, Eko Teguh
AU  - Pribadi ET
AD  - Doctoral Program of Public Health.
FAU - Devy, Shrimarti Rukmini
AU  - Devy SR
AD  - Department of Health Promotion and Behavioral Sciences, Faculty of Public Health,
      Universitas Airlangga, Mulyorejo, Surabaya, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - United States
TA  - J Public Health Res
JT  - Journal of public health research
JID - 101580775
PMC - PMC7376467
OTO - NOTNLM
OT  - Health Belief Model
OT  - intention
OT  - stop smoking
OT  - young adult women
COIS- Conflict of interest: The authors declare no potential conflict of interest.
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/06/13 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.4081/jphr.2020.1817 [doi]
PST - epublish
SO  - J Public Health Res. 2020 Jul 2;9(2):1817. doi: 10.4081/jphr.2020.1817.
      eCollection 2020 Jul 3.


PMID- 32728473
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury.
PG  - 2054358120941679
LID - 10.1177/2054358120941679 [doi]
AB  - PURPOSE: Severe acute kidney injury (AKI) is a potential complication of
      COVID-19-associated critical illness. This has implications for the management of
      COVID-19-associated AKI and the resulting increased need for kidney replacement
      therapy (KRT) in the intensive care unit (ICU) and elsewhere in the hospital. The
      Canadian Society of Nephrology COVID-19 Rapid Review Team has sought to collate
      and synthesize currently available resources to inform ethically justifiable
      decisions. The goal is the provision of the best possible care for the largest
      number of patients with kidney disease while considering how best to ensure the
      safety of the health care team. INFORMATION SOURCES: Local, provincial, national,
      and international guidance and planning documents related to the COVID-19
      pandemic; guidance documents available from nephrology and critical care-related 
      professional organizations; recent journal articles and preprints related to the 
      COVID-19 pandemic; expert opinion from nephrologists from across Canada. METHODS:
      A working group of kidney specialist physicians was established with
      representation from across Canada. Kidney physician specialists met via
      teleconference and exchanged e-mails to refine and agree on the proposed
      suggestions in this document. KEY FINDINGS: (1) Nephrology programs should work
      with ICU programs to plan for the possibility that up to 30% or more of
      critically ill patients with COVID-19 admitted to ICU will require kidney
      replacement therapy (KRT). (2) Specific suggestions pertinent to the optimal
      management of AKI and KRT in patients with COVID-19. These suggestions include,
      but are not limited to, aspects of fluid management, KRT vascular access, and KRT
      modality choice. (3) We describe considerations related to ensuring adequate
      provision of KRT, should resources become scarce during the COVID-19 pandemic.
      LIMITATIONS: A systematic review or meta-analysis was not conducted. Our
      suggestions have not been specifically evaluated in the clinical environment. The
      local context, including how the provision of acute KRT is organized, may impede 
      the implementation of many suggestions. Knowledge is advancing rapidly in the
      area of COVID-19 and suggestions may become outdated quickly. IMPLICATIONS: Given
      that most acute KRT related to COVID-19 is likely to be required initially in the
      ICU setting, close collaboration and planning between critical care and
      nephrology programs is required. Suggestions may be updated as newer evidence
      becomes available.
CI  - (c) The Author(s) 2020.
FAU - Clark, Edward G
AU  - Clark EG
AUID- ORCID: https://orcid.org/0000-0002-6767-1197
AD  - Division of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa
      Hospital Research Institute, University of Ottawa, ON, Canada.
FAU - Hiremath, Swapnil
AU  - Hiremath S
AUID- ORCID: https://orcid.org/0000-0003-0010-3416
AD  - Division of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa
      Hospital Research Institute, University of Ottawa, ON, Canada.
FAU - Soroka, Steven D
AU  - Soroka SD
AUID- ORCID: https://orcid.org/0000-0002-7278-1702
AD  - Division of Nephrology, Department of Medicine, Dalhousie University, Halifax,
      NS, Canada.
FAU - Wald, Ron
AU  - Wald R
AUID- ORCID: https://orcid.org/0000-0003-4411-8169
AD  - Division of Nephrology, St. Michael's Hospital and Department of Medicine,
      University of Toronto, ON, Canada.
FAU - Weir, Matthew A
AU  - Weir MA
AD  - Division of Nephrology, Department of Medicine, Western University, London, ON,
      Canada.
CN  - CSN COVID-19 Rapid Response Team
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7364799
OTO - NOTNLM
OT  - AKI
OT  - COVID-19
OT  - CRRT
OT  - KRT
OT  - critical care
OT  - dialysis
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
IR  - Antonsen J
FIR - Antonsen, John
IR  - Banks C
FIR - Banks, Cheryl
IR  - Clark D
FIR - Clark, David
IR  - Copland M
FIR - Copland, Michael
IR  - Davison SN
FIR - Davison, Sara N
IR  - Goldberg A
FIR - Goldberg, Aviva
IR  - Hemmett J
FIR - Hemmett, Juliya
IR  - Kappel J
FIR - Kappel, Joanne
IR  - MacRae JM
FIR - MacRae, Jennifer M
IR  - Mac-Way F
FIR - Mac-Way, Fabrice
IR  - Mathew A
FIR - Mathew, Anna
IR  - McCormick B
FIR - McCormick, Brendan
IR  - Moist L
FIR - Moist, Louise
IR  - Moran S
FIR - Moran, Sarah
IR  - Pandeya S
FIR - Pandeya, Sanjay
IR  - Qirjazi E
FIR - Qirjazi, Elena
IR  - Ryz K
FIR - Ryz, Krista
IR  - Singh S
FIR - Singh, Suneet
IR  - Suri R
FIR - Suri, Rita
IR  - Tennankore K
FIR - Tennankore, Karthik
IR  - Thanabalasingam S
FIR - Thanabalasingam, Susan
IR  - White C
FIR - White, Christine
IR  - Zimmerman D
FIR - Zimmerman, Deborah
IR  - Levin A
FIR - Levin, Adeera
IR  - Mustafa RA
FIR - Mustafa, Reem A
IR  - Nesrallah G
FIR - Nesrallah, Gihad
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/06/11 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.1177/2054358120941679 [doi]
AID - 10.1177_2054358120941679 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Jul 15;7:2054358120941679. doi:
      10.1177/2054358120941679. eCollection 2020.


PMID- 32728471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Understanding Autonomy: An Urgent Intervention.
PG  - lsaa037
LID - 10.1093/jlb/lsaa037 [doi]
AB  - In this paper, I argue that the principle of respect for autonomy can serve as
      the basis for laws that significantly limit conduct, including orders mandating
      isolation and quarantine. This thesis is fundamentally at odds with an
      overwhelming consensus in contemporary bioethics that the principle of respect
      for autonomy, while important in everyday clinical encounters, must be
      'curtailed', 'constrained', or 'overridden' by other principles in times of
      crisis. I contend that bioethicists have embraced an indefensibly 'thin' notion
      of autonomy that uproots the concept from its foundations in Kantian ethics.
      According to this thin conception, respect for autonomy, if unconditioned by
      competing principles (beneficence, justice, non-maleficence) would give competent
      adults the right to do anything they desired to do so long as they satisfied
      certain baseline psychological conditions. I argue that the dominant
      'principlist' model of bioethical reasoning depends on this thin view of autonomy
      and show how it deprives us of powerful analytical tools that would help us to
      think seriously about the foundations of human rights, justice, and law. Then, I 
      offer a brief sketch of a 'thick', historically grounded notion of autonomy and
      show what we could gain by taking it seriously.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Reis-Dennis, Samuel
AU  - Reis-Dennis S
AUID- ORCID: 0000-0002-5417-8002
AD  - Alden March Bioethics Institute Albany Medical College 47 New Scotland Ave, MC
      153, Albany, NY 12208.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7313844
OTO - NOTNLM
OT  - Autonomy
OT  - Isolation
OT  - Pandemic
OT  - Principlism
OT  - Public health
OT  - Quarantine
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.1093/jlb/lsaa037 [doi]
AID - lsaa037 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 4;7(1):lsaa037. doi: 10.1093/jlb/lsaa037. eCollection 2020
      Jan-Jun.


PMID- 32728465
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Jun
TI  - Modeling consent in the time of COVID-19.
PG  - lsaa020
LID - 10.1093/jlb/lsaa020 [doi]
AB  - Effective responses to the COVID-19 pandemic require novel solutions for research
      and responsible data sharing. Biobanking presents itself as a key priority in
      furthering our understanding of COVID-19. In this article, we propose a
      tripartite approach to consent to create resources for research relating to
      COVID-19. The approach aims to link three levels of participation: COVID-19
      patients, respiratory/infectious disease patients, and longitudinal study
      participants. We explore the potential approaches that can be taken to consent
      processes with these three participant groups. We furthermore describe an access 
      model for both single-site and multi-site data and sample storage. Through
      dealing with these topics at a high level, the model may be adapted to local
      legal and ethical requirements while still pursuing its ultimate goal: the
      creation of a research infrastructure that supports transparent, strong, and open
      science.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Knoppers, Bartha Maria
AU  - Knoppers BM
AD  - Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine,
      McGill University.
AD  - Canada Research Chair in Law and Medicine, McGill University.
FAU - Beauvais, Michael J S
AU  - Beauvais MJS
AD  - Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine,
      McGill University.
FAU - Joly, Yann
AU  - Joly Y
AD  - Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine,
      McGill University.
FAU - Zawati, Man H
AU  - Zawati MH
AD  - Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine,
      McGill University.
FAU - Rousseau, Simon
AU  - Rousseau S
AD  - Department of Medicine, Division of Experimental Medicine, McGill University.
FAU - Chasse, Michael
AU  - Chasse M
AD  - Department of Medicine, Universite de Montreal.
AD  - Centre de recherche du Centre hospitalier, de l'Universite de Montreal.
FAU - Mooser, Vincent
AU  - Mooser V
AD  - Canada Excellence Research Chair in Genomic Medicine, McGill University.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200508
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC7239167
OTO - NOTNLM
OT  - biobanking
OT  - consent
OT  - data sharing
OT  - pandemic
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.1093/jlb/lsaa020 [doi]
AID - lsaa020 [pii]
PST - epublish
SO  - J Law Biosci. 2020 May 8;7(1):lsaa020. doi: 10.1093/jlb/lsaa020. eCollection 2020
      Jan-Jun.


PMID- 32728381
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1754-6605 (Print)
IS  - 1754-6605 (Linking)
VI  - 14
DP  - 2020
TI  - Machine learning in oncology: a review.
PG  - 1065
LID - 10.3332/ecancer.2020.1065 [doi]
AB  - Machine learning is a set of techniques that promise to greatly enhance our
      data-processing capability. In the field of oncology, ML presents itself with a
      wealth of possible applications to the research and the clinical context, such as
      automated diagnosis and precise treatment modulation. In this paper, we will
      review the principal applications of ML techniques in oncology and explore in
      detail how they work. This will allow us to discuss the issues and challenges
      that ML faces in this field, and ultimately gain a greater understanding of ML
      techniques and how they can improve oncological research and practice.
CI  - (c) the authors; licensee ecancermedicalscience.
FAU - Nardini, Cecilia
AU  - Nardini C
AD  - European School of Molecular Medicine (SEMM), 20139 Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - England
TA  - Ecancermedicalscience
JT  - Ecancermedicalscience
JID - 101392236
PMC - PMC7373638
OTO - NOTNLM
OT  - big data
OT  - deep learning
OT  - ethics
OT  - image recognition
OT  - machine learning
OT  - methodology
OT  - neural network
COIS- None stated. The author is an independent researcher and does not receive
      funding.
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.3332/ecancer.2020.1065 [doi]
AID - can-14-1065 [pii]
PST - epublish
SO  - Ecancermedicalscience. 2020 Jun 30;14:1065. doi: 10.3332/ecancer.2020.1065.
      eCollection 2020.


PMID- 32728367
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1731-5530 (Print)
IS  - 1731-5530 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Efficacy of thymoquinone in the treatment of experimental
      lipopolysaccharide-induced acute lung injury.
PG  - 65-69
LID - 10.5114/kitp.2020.97259 [doi]
AB  - INTRODUCTION: Acute lung injury (ALI) and acute respiratory distress syndrome
      (ARDS) are acute onset syndromes affecting the lungs, which develop for several
      reasons and are characterized by hypoxemia and diffuse lung infiltration. The
      activity of thymoquinone (TQ) is known in acute lung injury. It is considered
      that it could be effective in ALI/ARDS treatment by ensuring possible COX-2
      inhibition. AIM: By this study was to show the protective activity of TQ in
      lipopolysaccharide (LPS) induced acute lung injury.Material and methods: A total 
      of 28 BALB/c male mice were randomized to 4 groups of 7 as the Control group, TQ 
      group (3 mg/kg), LPS group (5 mg/kg) and TQ treatment group. TQ was administered 
      intraperitoneally 1 hour before the intratracheal administration of LPS (5
      mg/kg). The mice were sacrificed 6 hours after the LPS administration and the
      lungs were extracted for histopathological examination. All experimental
      procedures complied with the requirements of the Animal Care and Ethics Committee
      of Dokuz Eylul University. RESULTS: When all the study groups were compared,
      significant differences were found between the groups in terms of the degrees of 
      neutrophil migration (p = 0.042), intra-alveolar hemorrhage (p = 0.004) and
      alveolar destruction (p < 0.0006). A significant recovery was observed in the
      lung histopathological changes (neutrophil migration, intra-alveolar hemorrhage
      and alveolar destruction) in the TQ treatment group. CONCLUSIONS: The results of 
      this study showed that TQ may have a protective effect against LPS-induced acute 
      lung injury. The possible mechanism could be considered to be cyclooxygenase 2
      (COX-2) inhibition.
CI  - Copyright (c) 2020 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo
      KardioTorakochirurgow) and the editors of the Polish Journal of Cardio-Thoracic
      Surgery (Kardiochirurgia i Torakochirurgia Polska).
FAU - Colak, Mustafa
AU  - Colak M
AD  - Chest Disease Department, Dokuz Eylul University, Izmir, Turkey.
FAU - Kalemci, Serdar
AU  - Kalemci S
AD  - Chest Diseases Department, Mugla Sitki Kocman University, Mugla, Turkey.
FAU - Alpaydin, Aylin Ozgen
AU  - Alpaydin AO
AD  - Chest Disease Department, Dokuz Eylul University, Izmir, Turkey.
FAU - Karacam, Volkan
AU  - Karacam V
AD  - Chest Surgery Department, Dokuz Eylul University, Izmir, Turkey.
FAU - Meteoglu, Ibrahim
AU  - Meteoglu I
AD  - Pathology Department, Adnan Menderese University, Aydin, Turkey.
FAU - Yilmaz, Osman
AU  - Yilmaz O
AD  - Laboratory Animal Science, Dokuz Eylul University, Izmir, Turkey.
FAU - Itil, Bahriye Oya
AU  - Itil BO
AD  - Chest Disease Department, Dokuz Eylul University, Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Poland
TA  - Kardiochir Torakochirurgia Pol
JT  - Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic
      surgery
JID - 101279148
PMC - PMC7379226
OTO - NOTNLM
OT  - acute lung injury
OT  - lipopolysaccharide
OT  - thymoquinone
COIS- Authors report no conflict of interest.
EDAT- 2020/07/31 06:00
MHDA- 2020/07/31 06:01
CRDT- 2020/07/31 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/07/31 06:01 [medline]
AID - 10.5114/kitp.2020.97259 [doi]
AID - 41313 [pii]
PST - ppublish
SO  - Kardiochir Torakochirurgia Pol. 2020 Jun;17(2):65-69. doi:
      10.5114/kitp.2020.97259. Epub 2020 Jul 20.


PMID- 32727741
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 29
TI  - Ways Ahead: developing a supported self-management programme for people living
      with low- and intermediate-grade gliomas - a protocol for a multi-method study.
PG  - e041465
LID - 10.1136/bmjopen-2020-041465 [doi]
AB  - INTRODUCTION: Living with and beyond a diagnosis of a low- and intermediate-grade
      glioma (LIGG) can adversely impact many aspects of people's lives and their
      quality of life (QoL). In people with chronic conditions, self-management can
      improve QoL. This is especially true if people are supported to self-manage.
      Supported self-management programmes have been developed for several cancers, but
      the unique challenges experienced by LIGG survivors mean these programmes may not
      be readily transferable to this group. The Ways Ahead study aims to address this 
      gap by exploring the needs of LIGG survivors to develop a prototype for a
      supported self-management programme tailored to this group. METHODS AND ANALYSIS:
      Ways Ahead will follow three sequential phases, underpinned by a systematic
      review of self-management interventions in cancer. In phase 1, qualitative
      methods will be used to explore and understand the issues faced by LIGG
      survivors, as well as the barriers and facilitators to self-management. Three
      sets of interviews will be conducted with LIGG survivors, their informal carers
      and professionals. Thematic analysis will be conducted with reference to the
      Theoretical Domains Framework and Normalisation Process Theory. Phase 2 will
      involve co-production workshops to generate ideas for the design of a supported
      self-management programme. Workshop outputs will be translated into a design
      specification for a prototype programme. Finally, phase 3 will involve a health
      economic assessment to examine the feasibility and benefits of incorporating the 
      proposed programme into the current survivorship care pathway. This prototype
      will then be ready for testing in a subsequent trial. ETHICS AND DISSEMINATION:
      The study has been reviewed and approved by an National Health Service Research
      Ethics Committee (REC ref: 20/WA/0118). The findings will be disseminated through
      peer-reviewed journals, conference presentations, broadcast media, the study
      website, The Brain Tumour Charity and stakeholder engagement activities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rimmer, Ben
AU  - Rimmer B
AUID- ORCID: 0000-0003-4110-0588
AD  - Population Health Sciences Institute, Newcastle University Centre for Cancer,
      Newcastle University, Newcastle upon Tyne, UK ben.rimmer@newcastle.ac.uk.
FAU - Dutton, Lizzie
AU  - Dutton L
AD  - Population Health Sciences Institute, Newcastle University Centre for Cancer,
      Newcastle University, Newcastle upon Tyne, UK.
FAU - Lewis, Joanne
AU  - Lewis J
AD  - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
FAU - Burns, Richeal
AU  - Burns R
AD  - Institute of Technology Sligo, Sligo, Ireland.
FAU - Gallagher, Pamela
AU  - Gallagher P
AD  - School of Psychology, Dublin City University, Dublin, Ireland.
FAU - Williams, Sophie
AU  - Williams S
AD  - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
FAU - Araujo-Soares, Vera
AU  - Araujo-Soares V
AD  - Population Health Sciences Institute, Newcastle University Centre for Cancer,
      Newcastle University, Newcastle upon Tyne, UK.
FAU - Finch, Tracy
AU  - Finch T
AD  - Department of Nursing, Midwifery and Health, Northumbria University, Newcastle
      upon Tyne, UK.
FAU - Sharp, Linda
AU  - Sharp L
AD  - Population Health Sciences Institute, Newcastle University Centre for Cancer,
      Newcastle University, Newcastle upon Tyne, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Glioma/therapy
MH  - Humans
MH  - Quality of Life
MH  - Research Design
MH  - *Self-Management
MH  - State Medicine
MH  - Systematic Reviews as Topic
PMC - PMC7394298
OTO - NOTNLM
OT  - *adult oncology
OT  - *health economics
OT  - *neurological oncology
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/07/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041465 [pii]
AID - 10.1136/bmjopen-2020-041465 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 29;10(7):e041465. doi: 10.1136/bmjopen-2020-041465.


PMID- 32727739
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 29
TI  - Quality of life measured by EQ-5D at different treatment time points for coronary
      artery disease: protocol for a systematic review and meta-analysis.
PG  - e039311
LID - 10.1136/bmjopen-2020-039311 [doi]
AB  - INTRODUCTION: Cardiovascular disease is estimated to affect 423 million people
      globally. It caused 18 million deaths in 2017 and is projected to cost US$1
      trillion by 2030 worldwide. Coronary artery disease (CAD) is the most common type
      of cardiovascular disease; CAD treatments can affect patients' quality of life.
      Valuations of quality of life or health utilities are important for economic
      evaluations to ascertain relative health benefit when comparing treatments, and
      can be expected to change for individuals over time. The purpose of this
      systematic review is to estimate the quality of life of patients with CAD
      reported through the EuroQol 5 Dimension (EQ-5D) questionnaire, from short to
      longer term time points following different treatments. METHODS AND ANALYSIS:
      PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews and
      the EuroQol website will be systematically searched from January 2003-March 2020.
      Published, peer-reviewed, English language studies assessing quality of life of
      patients with CAD using the EQ-5D will be included. One researcher will conduct
      the search; two researchers will independently screen titles and abstracts for
      potential inclusion. Full texts of potentially eligible studies will be retrieved
      for a second round of independent screening against inclusion and exclusion
      criteria by two researchers. The final list of included studies will be assessed 
      for risk of bias using the RoB 2 and Risk Of Bias In Non-randomized Studies - of 
      Interventions (ROBINS-I) tools for randomised and non-randomised studies,
      respectively. Data extraction will be done by one researcher, with data
      extraction for a random 10% of included studies checked by a second researcher.
      Mean utility weights for individual studies will be combined using random effects
      model meta-analyses. A model will be run separately for each time point and
      treatment. Treatment time points of interest include baseline, 30 days, 6 months,
      12-24 months and more than 24 months. Subgroup analysis of patients with diabetes
      who received interventional treatments-coronary artery bypass graft or
      percutaneous coronary intervention with or without stents, will be conducted for 
      the same selected time points. ETHICS AND DISSEMINATION: Ethics approval is not
      required for systematic reviews. Results of the review will be disseminated via
      publication in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lum, Elaine
AU  - Lum E
AUID- ORCID: 0000-0002-0853-3018
AD  - Health Services & Systems Research, Duke-NUS Medical School, Singapore
      elaine_lum@duke-nus.edu.sg.
AD  - School of Clinical Sciences, Queensland University of Technology, Brisbane,
      Queensland, Australia.
FAU - McCreanor, Victoria
AU  - McCreanor V
AUID- ORCID: 0000-0002-0589-8521
AD  - Jamieson Trauma Institute, Royal Brisbane and Women's Hospital, Metro North
      Hospital and Health Service, Brisbane, Queensland, Australia.
AD  - Australian Centre for Health Services Innovation, Queensland University of
      Technology, Brisbane, Queensland, Australia.
FAU - Luo, Nan
AU  - Luo N
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.
FAU - Graves, Nicholas
AU  - Graves N
AD  - Health Services & Systems Research, Duke-NUS Medical School, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Coronary Artery Disease/therapy
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Systematic Reviews as Topic
PMC - PMC7394179
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *health economics
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039311 [pii]
AID - 10.1136/bmjopen-2020-039311 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 29;10(7):e039311. doi: 10.1136/bmjopen-2020-039311.


PMID- 32727738
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 29
TI  - Menstrual health and period poverty among young people who menstruate in the
      Barcelona metropolitan area (Spain): protocol of a mixed-methods study.
PG  - e035914
LID - 10.1136/bmjopen-2019-035914 [doi]
AB  - INTRODUCTION: The importance of menstrual health has been historically neglected,
      mostly due to taboos and misconceptions around menstruation and androcentrism
      within health knowledge and health systems around the world. There has also been 
      a lack of attention on 'period poverty', which refers to the financial, social,
      cultural and political barriers to access menstrual products and education. The
      main aim of this research is to explore menstrual health and experiences of
      period poverty among young people who menstruate (YPM). METHODS AND ANALYSIS:
      This is a convergent mixed-methods study, which will combine a quantitative
      transversal study to identify the prevalence of period poverty among YPM (11-16
      years old), and a qualitative study that will focus on exploring
      menstruation-related experiences of YPM and other groups (young people who do not
      menstruate (YNM); primary healthcare professionals; educators and policy-makers).
      The study will be conducted in the Barcelona metropolitan area between 2020 and
      2021. Eighteen schools and 871 YPM will be recruited for the quantitative study. 
      Sixty-five YPM will participate in the qualitative study. Forty-five YNM and 12
      professionals will also be recruited to take part in the qualitative study.
      Socioeconomic and cultural diversity will be main vectors for recruitment, to
      ensure the findings are representative to the social and cultural context.
      Descriptive statistics will be performed for each variable to identify asymmetric
      distributions and differences among groups will be evaluated. Thematic analysis
      will be used for qualitative data analyses ETHICS AND DISSEMINATION: Several
      ethical issues have been considered, especially as this study includes the
      participation of underage participants. The study has received ethical approval
      by the IDIAPJGol Research Ethics Committee (19/178 P). Research findings will be 
      disseminated to key audiences, such as YPM, YNM, parents/legal tutors, health
      professionals, educators, youth (and other relevant) organisations, general
      community members, stakeholders and policy-makers, and academia.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Medina-Perucha, Laura
AU  - Medina-Perucha L
AUID- ORCID: 0000-0002-2981-2614
AD  - Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut
      Jordi Gol i Gurina (IDIAPJGol), Barcelona, Catalunya, Spain
      lmedina@idiapjgol.info.
FAU - Jacques-Avino, Constanza
AU  - Jacques-Avino C
AD  - Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut
      Jordi Gol i Gurina (IDIAPJGol), Barcelona, Catalunya, Spain.
AD  - Universitat Autonoma de Barcelona, Cerdanyola del Valles, Catalunya, Spain.
FAU - Valls-Llobet, Carme
AU  - Valls-Llobet C
AD  - Centro de Analisis y Programas Sanitarios (CAPS), Barcelona, Spain.
FAU - Turbau-Valls, Rosa
AU  - Turbau-Valls R
AD  - Institut Catala de la Salut, Barcelona, Catalunya, Spain.
FAU - Pinzon, Diana
AU  - Pinzon D
AD  - SomiArte Taller, Barcelona, Spain.
AD  - Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain.
FAU - Hernandez, Lola
AU  - Hernandez L
AD  - La Caravana Roja, Murcia, Spain.
FAU - Briales Canseco, Paula
AU  - Briales Canseco P
AD  - Comunidad de Madrid Consejeria de Educacion, Madrid, Spain.
FAU - Lopez-Jimenez, Tomas
AU  - Lopez-Jimenez T
AD  - Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut
      Jordi Gol i Gurina (IDIAPJGol), Barcelona, Catalunya, Spain.
AD  - Universitat Autonoma de Barcelona, Cerdanyola del Valles, Catalunya, Spain.
FAU - Solana Lizarza, Enara
AU  - Solana Lizarza E
AD  - Department of Education, Universidad Internacional de la Rioja - Campus de
      Logrono, Logrono, La Rioja, Spain.
FAU - Munros Feliu, Jordina
AU  - Munros Feliu J
AD  - Atencio a la Salut Sexual i Reproductiva (ASSIR) Muntanya/La Mina, Institut
      Catala de la Salut, Barcelona, Catalunya, Spain.
FAU - Berenguera, Anna
AU  - Berenguera A
AUID- ORCID: 0000-0002-0889-2002
AD  - Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut
      Jordi Gol i Gurina (IDIAPJGol), Barcelona, Catalunya, Spain.
AD  - Universitat Autonoma de Barcelona, Barcelona, Catalunya, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Administrative Personnel
MH  - Adolescent
MH  - Child
MH  - Cities
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Feminine Hygiene Products
MH  - *Health Education
MH  - Health Personnel
MH  - Humans
MH  - Interviews as Topic
MH  - *Menstruation/ethnology
MH  - Politics
MH  - Qualitative Research
MH  - Research Design
MH  - School Teachers
MH  - Socioeconomic Factors
MH  - Spain
MH  - Surveys and Questionnaires
PMC - PMC7394147
OTO - NOTNLM
OT  - *education
OT  - *health services
OT  - *menstrual health
OT  - *public health
OT  - *social medicine
OT  - *young people
EDAT- 2020/07/31 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035914 [pii]
AID - 10.1136/bmjopen-2019-035914 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 29;10(7):e035914. doi: 10.1136/bmjopen-2019-035914.


PMID- 32727554
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Jul 29
TI  - Human ex vivo spinal cord slice culture as a useful model of neural development, 
      lesion, and allogeneic neural cell therapy.
PG  - 320
LID - 10.1186/s13287-020-01771-y [doi]
AB  - BACKGROUND: There are multiple promising treatment strategies for central nervous
      system trauma and disease. However, to develop clinically potent and safe
      treatments, models of human-specific conditions are needed to complement in vitro
      and in vivo animal model-based studies. METHODS: We established human brain stem 
      and spinal cord (cross- and longitudinal sections) organotypic cultures (hOCs)
      from first trimester tissues after informed consent by donor and ethical approval
      by the Regional Human Ethics Committee, Stockholm (lately referred to as Swedish 
      Ethical Review Authority), and The National Board of Health and Welfare, Sweden. 
      We evaluated the stability of hOCs with a semi-quantitative hOC score,
      immunohistochemistry, flow cytometry, Ca(2+) signaling, and electrophysiological 
      analysis. We also applied experimental allogeneic human neural cell therapy after
      injury in the ex vivo spinal cord slices. RESULTS: The spinal cord hOCs presented
      relatively stable features during 7-21 days in vitro (DIV) (except a slightly
      increased cell proliferation and activated glial response). After contusion
      injury performed at 7 DIV, a significant reduction of the hOC score, increase of 
      the activated caspase-3(+) cell population, and activated microglial populations 
      at 14 days postinjury compared to sham controls were observed. Such elevation in 
      the activated caspase-3(+) population and activated microglial population was not
      observed after allogeneic human neural cell therapy. CONCLUSIONS: We conclude
      that human spinal cord slice cultures have potential for future structural and
      functional studies of human spinal cord development, injury, and treatment
      strategies.
FAU - Lin, Chenhong
AU  - Lin C
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
FAU - Calzarossa, Cinzia
AU  - Calzarossa C
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
AD  - Department of Neurology and Laboratory of Neuroscience, Universita degli Studi
      diMilan, Milan, Italy.
FAU - Fernandez-Zafra, Teresa
AU  - Fernandez-Zafra T
AD  - Division of Molecular Neurobiology, Departmentof Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
AD  - Department of Neurology, Shengjing Hospital of China Medical University,
      Shenyang, People's Republic of China.
FAU - Li, Xiaofei
AU  - Li X
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
FAU - Ekblad-Nordberg, Asa
AU  - Ekblad-Nordberg A
AD  - Department of Clinical Science, Intervention and Technology, Div. of Obstetrics
      and Gynecology, Karolinska Institutet, Stockholm, Sweden.
FAU - Vazquez-Juarez, Erika
AU  - Vazquez-Juarez E
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
FAU - Codeluppi, Simone
AU  - Codeluppi S
AD  - Division of Molecular Neurobiology, Departmentof Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
FAU - Holmberg, Lena
AU  - Holmberg L
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
FAU - Lindskog, Maria
AU  - Lindskog M
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden.
FAU - Uhlen, Per
AU  - Uhlen P
AD  - Division of Molecular Neurobiology, Departmentof Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
FAU - Akesson, Elisabet
AU  - Akesson E
AUID- ORCID: 0000-0002-8227-9118
AD  - Department of Neurobiology, Care Sciences and Society, Div. of Neurogeriatrics,
      Karolinska Institutet, Stockholm, Sweden. elisabet.akesson@ki.se.
AD  - The R&D Unit, Stockholms Sjukhem, Stockholm, Sweden. elisabet.akesson@ki.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
EIN - Stem Cell Res Ther. 2020 Aug 27;11(1):369. PMID: 32854777
MH  - Animals
MH  - Cell- and Tissue-Based Therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Neurons
MH  - Spinal Cord
MH  - *Spinal Cord Injuries/therapy
PMC - PMC7390865
OTO - NOTNLM
OT  - *Human organotypic culture
OT  - *Spinal cord injury
OT  - *Stem cell therapy
EDAT- 2020/07/31 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13287-020-01771-y [doi]
AID - 10.1186/s13287-020-01771-y [pii]
PST - epublish
SO  - Stem Cell Res Ther. 2020 Jul 29;11(1):320. doi: 10.1186/s13287-020-01771-y.


PMID- 32727514
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jul 29
TI  - The generic Informed Consent Service gICS((R)): implementation and benefits of a 
      modular consent software tool to master the challenge of electronic consent
      management in research.
PG  - 287
LID - 10.1186/s12967-020-02457-y [doi]
AB  - BACKGROUND: Defining and protecting participants' rights is the aim of several
      ethical codices and legal regulations. According to these regulations, the
      Informed Consent (IC) is an inevitable element of research with human subjects.
      In the era of "big data medicine", aspects of IC become even more relevant since 
      research becomes more complex rendering compliance with legal and ethical
      regulations increasingly difficult. METHODS: Based on literature research and
      practical experiences gathered by the Institute for Community Medicine (ICM),
      University Medicine Greifswald, requirements for digital consent management
      systems were identified. RESULTS: To address the requirements, the
      free-of-charge, open-source software "generic Informed Consent Service"
      (gICS((R))) was developed by ICM to provide a tool to facilitate and enhance
      usage of digital ICs for the international research community covering various
      scenarios. gICS facilitates IC management based on IC modularisation and supports
      various workflows within research, including (1) electronic depiction of
      paper-based consents and (2) fully electronic consents. Numerous projects applied
      gICS and documented over 336,000 ICs and 2400 withdrawals since 2014. DISCUSSION:
      Since the consent's content is a prerequisite for securing participants' rights, 
      application of gICS is no guarantee for legal compliance. However, gICS supports 
      fine-granular consents and accommodation of differentiated consent states, which 
      can be directly exchanged between systems, allowing automated data processing.
      CONCLUSION: gICS simplifies and supports sustained IC management as a major key
      to successfully conduct studies and build trust in research with human subjects. 
      Therefore, interested researchers are invited to use gICS and provide feedback
      for further improvements.
FAU - Rau, Henriette
AU  - Rau H
AUID- ORCID: 0000-0003-0816-0693
AD  - Trusted Third Party of the University Medicine Greifswald, Ellernholzstr. 1-2,
      17475, Greifswald, Germany. henriette.rau@uni-greifswald.de.
FAU - Geidel, Lars
AU  - Geidel L
AD  - Trusted Third Party of the University Medicine Greifswald, Ellernholzstr. 1-2,
      17475, Greifswald, Germany.
FAU - Bialke, Martin
AU  - Bialke M
AD  - Institute for Community Medicine Section Epidemiology of Health Care and
      Community Health, University Medicine Greifswald, Ellernholzstr. 1-2, 17475,
      Greifswald, Germany.
FAU - Blumentritt, Arne
AU  - Blumentritt A
AD  - Trusted Third Party of the University Medicine Greifswald, Ellernholzstr. 1-2,
      17475, Greifswald, Germany.
FAU - Langanke, Martin
AU  - Langanke M
AD  - Protestant University of Applied Sciences in Bochum, Immanuel-Kant-Str. 18-20,
      44803, Bochum, Germany.
FAU - Liedtke, Wenke
AU  - Liedtke W
AD  - Faculty of Theology, University of Greifswald, Am Rubenowplatz 2-3, 17487,
      Greifswald, Germany.
FAU - Pasewald, Sandra
AU  - Pasewald S
AD  - Trusted Third Party of the University Medicine Greifswald, Ellernholzstr. 1-2,
      17475, Greifswald, Germany.
FAU - Stahl, Dana
AU  - Stahl D
AD  - Trusted Third Party of the University Medicine Greifswald, Ellernholzstr. 1-2,
      17475, Greifswald, Germany.
FAU - Bahls, Thomas
AU  - Bahls T
AD  - Institute for Community Medicine Section Epidemiology of Health Care and
      Community Health, University Medicine Greifswald, Ellernholzstr. 1-2, 17475,
      Greifswald, Germany.
FAU - Maier, Christian
AU  - Maier C
AD  - Chair of Medical Informatics, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 
      Wetterkreuz 13, 91058, Erlangen, Germany.
FAU - Prokosch, Hans-Ulrich
AU  - Prokosch HU
AD  - Chair of Medical Informatics, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 
      Wetterkreuz 13, 91058, Erlangen, Germany.
FAU - Hoffmann, Wolfgang
AU  - Hoffmann W
AD  - Institute for Community Medicine Section Epidemiology of Health Care and
      Community Health, University Medicine Greifswald, Ellernholzstr. 1-2, 17475,
      Greifswald, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
SB  - IM
MH  - Electronics
MH  - Humans
MH  - *Informed Consent
MH  - Research Design
MH  - Research Personnel
MH  - *Software
PMC - PMC7391490
OTO - NOTNLM
OT  - *Consent management
OT  - *GDPR
OT  - *General data protection regulation
OT  - *Informed consent
EDAT- 2020/07/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12967-020-02457-y [doi]
AID - 10.1186/s12967-020-02457-y [pii]
PST - epublish
SO  - J Transl Med. 2020 Jul 29;18(1):287. doi: 10.1186/s12967-020-02457-y.


PMID- 32727505
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1749-799X (Electronic)
IS  - 1749-799X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Jul 29
TI  - Clinical features and treatment of "Non-dislocated hyperextension tibial plateau 
      fracture".
PG  - 289
LID - 10.1186/s13018-020-01806-3 [doi]
AB  - BACKGROUND: To explore the epidemiological characteristics, clinical
      characteristics, treatment strategies, and clinical results of non-dislocated
      hyperextension tibial plateau fracture. METHOD: A total of 25 cases of
      non-dislocated hyperextension tibial plateau fracture patients were collected (12
      males and 13 females), aged 27-79 years. Preoperative tibial plateau posterior
      slope angle was - 10~0 degrees (average - 5.2 degrees ). Preoperative MRI showed 
      5 cases of MCL injury, 3 cases of PLC complex injury, and 2 cases of PLC + PCL
      injury. The change of tibial plateau posterior slope angle was more than 10
      degrees in patients with ligament injury, and the patients with a tibial plateau 
      posterior slope angle change less than 10 degrees had no ligament injury; 6
      patients with simple column fracture had a ligament injury, 2 patients with
      bilateral column fracture had a ligament injury, and 2 patients with three column
      fracture had a ligament injury. RESULTS: Patients were followed up for 12-24
      months (average 16.4 months). The operative time was 65-180 min (average 124
      min), and the blood loss was 20-200 ml (average 106 ml). The plate was placed on 
      the anterior part of tibial plateau. Evaluation of postoperative fracture
      reduction was as follows: 20 cases reached anatomic reduction, 5 cases reached
      good reduction (between 2 and 5 mm articular surface collapse), and the excellent
      rate of fracture reduction was 100%. The fracture healing time was 3-6 months
      (average 3.3 months). The postoperative knee Rasmussen score was 18-29 (average
      24.9), and the postoperative knee joint mobility was 90-130 degrees (average 118 
      degrees ). Two patients suffered superficial infection. CONCLUSIONS: The main
      imaging characteristic of "non-dislocated hyperextension tibial plateau fracture"
      is the change of tibial plateau posterior slope angle. The injury of single
      anteromedial column/anterolateral column fracture is easy to combine with
      "diagonal" injury, and when the tPSA changes more than 10 degrees , it is easy to
      be combined with ligament injury. By reducing the joint articular surface and
      lower limb force line, repairing the soft tissue structure, and reconstructing
      the knee joint stability, we can get satisfactory results. TRIAL REGISTRATION: It
      was a retrospective study. This study was consistent with the ethical standards
      of the Second Affiliated Hospital of Zhejiang University Medical College and was 
      approved by the hospital ethics committee and the trial registration number of
      our hospital was 20180145 .
FAU - Liangjun, Jiang
AU  - Liangjun J
AD  - The orthopedics department, 2nd affiliated hospital of medical college of
      Zhejiang university, The jiefang road 88#, Hangzhou, Zhejiang, China.
      lyjlj@zju.edu.cn.
FAU - Qiang, Zheng
AU  - Qiang Z
AD  - The orthopedics department, 2nd affiliated hospital of medical college of
      Zhejiang university, The jiefang road 88#, Hangzhou, Zhejiang, China.
FAU - Zhijun, Pan
AU  - Zhijun P
AD  - The orthopedics department, 2nd affiliated hospital of medical college of
      Zhejiang university, The jiefang road 88#, Hangzhou, Zhejiang, China.
FAU - Hanxiao, Zhu
AU  - Hanxiao Z
AD  - The orthopedics department, 2nd affiliated hospital of medical college of
      Zhejiang university, The jiefang road 88#, Hangzhou, Zhejiang, China.
FAU - Erman, Chen
AU  - Erman C
AD  - The orthopedics department, 2nd affiliated hospital of medical college of
      Zhejiang university, The jiefang road 88#, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - J Orthop Surg Res
JT  - Journal of orthopaedic surgery and research
JID - 101265112
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Loss, Surgical/statistics & numerical data
MH  - Female
MH  - Follow-Up Studies
MH  - Fracture Fixation
MH  - Humans
MH  - Joint Instability/epidemiology
MH  - Knee Joint
MH  - Ligaments/injuries
MH  - Male
MH  - Middle Aged
MH  - Operative Time
MH  - Postoperative Complications/epidemiology
MH  - Retrospective Studies
MH  - Tibial Fractures/diagnostic imaging/*pathology/*surgery
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7391511
OTO - NOTNLM
OT  - Knee joint stability
OT  - Ligament injury
OT  - Non-dislocated hyperextension tibial plateau fracture
OT  - Tibial plateau posterior slope angle
EDAT- 2020/07/31 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1186/s13018-020-01806-3 [doi]
AID - 10.1186/s13018-020-01806-3 [pii]
PST - epublish
SO  - J Orthop Surg Res. 2020 Jul 29;15(1):289. doi: 10.1186/s13018-020-01806-3.


PMID- 32727481
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 29
TI  - A concept analysis of dignity-protective continence care for care dependent older
      people in long-term care settings.
PG  - 266
LID - 10.1186/s12877-020-01673-x [doi]
AB  - BACKGROUND: Although codes of conduct, guidelines and standards call for
      healthcare practitioners to protect patients' dignity, there are widespread
      concerns about a lack of attention to the dignity of older people who need
      assistance with toileting, incontinence or bladder or bowel care in health or
      social care settings that provide long-term care. Incontinence and care
      dependence threatens patient dignity. The aim of this research was to explore,
      describe and explain the concept of dignity as it relates to continence care for 
      older people requiring long-term care. METHODS: The first four steps of Rodgers
      evolutionary method of concept analysis were followed. First, a comprehensive and
      systematic search of databases and key guidelines about continence care was
      undertaken to identify empirical research about dignity and continence care in
      older people in facilities that provide permanent residential or inpatient care
      of older people for day-to-day living. Data were extracted on the authors, date, 
      sample, country of origin, and key definitions, attributes, contexts and
      consequences from each included record. Findings were inductively analysed and
      grouped according to whether they were the key attributes and antecedents of
      dignity in relation to continence care or the consequences of undignified
      continence care. RESULTS: Of 625 articles identified, 18 were included in the
      final analysis. Fifty individual attributes were identified that were categorised
      in 6 domains (respect, empathy, trust, privacy, autonomy and communication). A
      further 15 were identified that related to the environment (6 physical and 9
      social). Key consequences of undignified continence care were also identified and
      categorised into 3 levels of impact (resident/family member, staff or
      organisation). CONCLUSIONS: This research resulted in a conceptual understanding 
      of dignity that can be used as a value or guiding principle in an ethic of care
      for older people who need assistance with toileting, incontinence or bladder or
      bowel care in long-term care settings.
FAU - Ostaszkiewicz, Joan
AU  - Ostaszkiewicz J
AUID- ORCID: 0000-0003-4159-4493
AD  - Centre for Quality and Patient Safety Research - Barwon Health Partnership,
      Institute for Healthcare Transformation, Deakin University, Geelong, VIC, 3220,
      Australia. j.ostaszkiewicz@nari.edu.au.
AD  - School of Nursing and Midwifery, Deakin University, Gheringhap St, Geelong, VIC, 
      3220, Australia. j.ostaszkiewicz@nari.edu.au.
AD  - National Ageing Research Institute, P.O Box 2127, Royal Melbourne Hospital, 21,
      Melbourne, VIC, 3530, Australia. j.ostaszkiewicz@nari.edu.au.
FAU - Dickson-Swift, Virginia
AU  - Dickson-Swift V
AD  - Centre for Quality and Patient Safety Research - Barwon Health Partnership,
      Institute for Healthcare Transformation, Deakin University, Geelong, VIC, 3220,
      Australia.
AD  - School of Nursing and Midwifery, Deakin University, Gheringhap St, Geelong, VIC, 
      3220, Australia.
FAU - Hutchinson, Alison
AU  - Hutchinson A
AD  - Centre for Quality and Patient Safety Research - Monash Health Partnership,
      Institute for Healthcare Transformation, Deakin University, Burwood, VIC, 3125,
      Australia.
FAU - Wagg, Adrian
AU  - Wagg A
AD  - Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta,
      Edmonton, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200729
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Attitude of Health Personnel
MH  - Humans
MH  - Long-Term Care
MH  - *Respect
MH  - *Urinary Incontinence/therapy
PMC - PMC7392826
OTO - NOTNLM
OT  - *Concept analysis
OT  - *Continence care
OT  - *Dignity
OT  - *Dignity-protective continence care
OT  - *Long-term care
OT  - *Person-centred care
EDAT- 2020/07/31 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12877-020-01673-x [doi]
AID - 10.1186/s12877-020-01673-x [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Jul 29;20(1):266. doi: 10.1186/s12877-020-01673-x.


PMID- 32727446
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20210110
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 29
TI  - SARS-CoV-2 specific serological pattern in healthcare workers of an Italian
      COVID-19 forefront hospital.
PG  - 203
LID - 10.1186/s12890-020-01237-0 [doi]
AB  - BACKGROUND: COVID-19 is an infectious disease caused by a novel coronavirus
      (SARS-CoV-2). The immunopathogenesis of the infection is currently unknown.
      Healthcare workers (HCWs) are at highest risk of infection and disease. Aim of
      the study was to assess the sero-prevalence of SARS-CoV-2 in an Italian cohort of
      HCWs exposed to COVID-19 patients. METHODS: A point-of-care lateral flow
      immunoassay (BioMedomics IgM-IgG Combined Antibody Rapid Test) was adopted to
      assess the prevalence of IgG and IgM against SARS-CoV-2. It was ethically
      approved ("Milano Area 1" Ethical Committee prot. n. 2020/ST/057). RESULTS: A
      total of 202 individuals (median age 45 years; 34.7% males) were retrospectively 
      recruited in an Italian hospital (Milan, Italy). The percentage (95% CI) of
      recruited individuals with IgM and IgG were 14.4% (9.6-19.2%) and 7.4%
      (3.8-11.0%), respectively. IgM were more frequently found in males (24.3%), and
      in individuals aged 20-29 (25.9%) and 60-69 (30.4%) years. No relationship was
      found between exposure to COVID-19 patients and IgM and IgG positivity.
      CONCLUSIONS: The present study did show a low prevalence of SARS-CoV-2 IgM in
      Italian HCWs. New studies are needed to assess the prevalence of SARS-CoV-2
      antibodies in HCWs exposed to COVID-19 patients, as well the role of neutralizing
      antibodies.
FAU - Sotgiu, Giovanni
AU  - Sotgiu G
AUID- ORCID: http://orcid.org/0000-0002-1600-4474
AD  - Clinical Epidemiology and Medical Statistics Unit, Department of Medical,
      Surgical, Experimental Sciences, University of Sassari, Sassari, Italy.
      gsotgiu@uniss.it.
AD  - Clinical Epidemiology and Medical Statistics Unit, Department of Clinical and
      Experimental Medicine, University of Sassari, Sassari, Italy. gsotgiu@uniss.it.
FAU - Barassi, Alessandra
AU  - Barassi A
AD  - Laboratory of Clinical Chemistry, ASST Santi Paolo e Carlo, San Paolo Hospital,
      Department of Health Sciences, Universita degli Studi di Milano, Milan, Italy.
FAU - Miozzo, Monica
AU  - Miozzo M
AD  - Department of Pathophysiology and Transplantation, Universita degli Studi di
      Milano, Milan, Italy.
AD  - Fondazione IRCCS Ca' GrandaOspedale Maggiore Policlinico, Milan, Italy.
FAU - Saderi, Laura
AU  - Saderi L
AD  - Clinical Epidemiology and Medical Statistics Unit, Department of Medical,
      Surgical, Experimental Sciences, University of Sassari, Sassari, Italy.
FAU - Piana, Andrea
AU  - Piana A
AD  - Clinical Epidemiology and Medical Statistics Unit, Department of Medical,
      Surgical, Experimental Sciences, University of Sassari, Sassari, Italy.
FAU - Orfeo, Nicola
AU  - Orfeo N
AD  - Medical Direction ASST Santi Paolo e Carlo, Milan, Italy.
FAU - Colosio, Claudio
AU  - Colosio C
AD  - Occupational Health Unit, International Center for Rural Health, ASST Santi Paolo
      e Carlo, Department of Health Sciences, Universita degli Studi di Milano, Milan, 
      Italy.
FAU - Felisati, Giovanni
AU  - Felisati G
AD  - Head and Neck Dapartment, ASST Santi Paolo e Carlo, San Paolo Hospital,
      Department of Health Sciences, Universita degli Studi di Milano, Milan, Italy.
FAU - Davi, Matteo
AU  - Davi M
AD  - Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of
      Health Sciences, Universita degli Studi di Milano, Milan, Italy.
FAU - Gerli, Alberto Giovanni
AU  - Gerli AG
AD  - Management Engineering Tourbillon Tech srl, Padova, Italy.
FAU - Centanni, Stefano
AU  - Centanni S
AD  - Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of
      Health Sciences, Universita degli Studi di Milano, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - *Antibodies, Viral/analysis/classification
MH  - Betacoronavirus/*immunology/isolation & purification
MH  - COVID-19
MH  - COVID-19 Testing
MH  - *Clinical Laboratory Techniques/methods/statistics & numerical data
MH  - *Coronavirus Infections/diagnosis/epidemiology/immunology
MH  - Female
MH  - Health Personnel/*statistics & numerical data
MH  - Humans
MH  - *Infectious Disease Transmission, Patient-to-Professional/prevention &
      control/statistics & numerical data
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Occupational Exposure/statistics & numerical data
MH  - *Pandemics
MH  - *Pneumonia, Viral/diagnosis/epidemiology/immunology
MH  - SARS-CoV-2
MH  - Seroepidemiologic Studies
MH  - Sex Factors
PMC - PMC7388425
OTO - NOTNLM
OT  - COVID-19
OT  - HCWs
OT  - IG
OT  - SARS-CoV-2
OT  - Seroprevalence
EDAT- 2020/07/31 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/31 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/07/31 06:00 [entrez]
PHST- 2020/07/31 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1186/s12890-020-01237-0 [doi]
AID - 10.1186/s12890-020-01237-0 [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Jul 29;20(1):203. doi: 10.1186/s12890-020-01237-0.


PMID- 32726810
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - Response to Commentaries.
PG  - 560-579
LID - 10.1093/jmp/jhaa011 [doi]
AB  - After expressing our gratitude to the commentators for their valuable analyses
      and assessments of Principles of Biomedical Ethics, we respond to several
      particular critiques raised by the commentators under the following rubrics: the 
      compatibility of different sets of principles and rules; challenges to the
      principle of respect for autonomy; connecting principles to cases and resolving
      their conflicts; the value of and compatibility of virtues and principles; common
      morality theory; and moral status. We point to areas where we see common
      agreement with our commentators and respond to their critical evaluations.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Beauchamp, Tom L
AU  - Beauchamp TL
AD  - Georgetown University, Washington, District of Columbia, USA.
FAU - Childress, James F
AU  - Childress JF
AD  - University of Virginia, Charlottesville, Virginia, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CON - J Med Philos. 2020 Jul 29;45(4-5):410-416. PMID: 32533700
CON - J Med Philos. 2020 Jul 29;45(4-5):521-539. PMID: 32619222
CON - J Med Philos. 2020 Jul 29;45(4-5):540-559. PMID: 32651590
CON - J Med Philos. 2020 Jul 29;45(4-5):427-440. PMID: 32726805
CON - J Med Philos. 2020 Jul 29;45(4-5):504-520. PMID: 32726806
CON - J Med Philos. 2020 Jul 29;45(4-5):471-503. PMID: 32726807
CON - J Med Philos. 2020 Jul 29;45(4-5):396-409. PMID: 32726808
CON - J Med Philos. 2020 Jul 29;45(4-5):441-470. PMID: 32726809
MH  - *Bioethics
MH  - Ethical Theory
MH  - Humans
MH  - *Principle-Based Ethics
MH  - Virtues
OTO - NOTNLM
OT  - * Principles of Biomedical Ethics
OT  - *balancing moral principles
OT  - *common morality
OT  - *moral status
OT  - *normative ethical theory
OT  - *principlism
OT  - *respect for autonomy
OT  - *specification of moral principles
OT  - *the four principles
OT  - *value theory
OT  - *virtue theory
EDAT- 2020/07/30 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 5878083 [pii]
AID - 10.1093/jmp/jhaa011 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):560-579. doi: 10.1093/jmp/jhaa011.


PMID- 32726809
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - Principlism's Balancing Act: Why the Principles of Biomedical Ethics Need a
      Theory of the Good.
PG  - 441-470
LID - 10.1093/jmp/jhaa014 [doi]
AB  - Principlism, the bioethical theory championed by Tom Beauchamp and James
      Childress, is centered on the four moral principles of beneficence,
      non-maleficence, respect for autonomy, and justice. Two key processes related to 
      these principles are specification-adding specific content to general
      principles-and balancing-determining the relative weight of conflicting
      principles. I argue that both of these processes necessarily involve an appeal to
      human goods and evils, and therefore require a theory of the good. A significant 
      problem with principlism is that it lacks a theory of the good and consequently
      does not have an adequate solution to the problems of specification and
      balancing. My conclusion is that principlism must adopt some account of human
      well-being in order to be a satisfactory bioethical framework.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Shea, Matthew
AU  - Shea M
AD  - University of Scranton, Scranton, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - Beneficence
MH  - *Bioethics
MH  - Ethical Analysis
MH  - Ethical Theory
MH  - Humans
MH  - Moral Obligations
MH  - Personal Autonomy
MH  - Philosophy, Medical
MH  - *Principle-Based Ethics
MH  - Respect
OTO - NOTNLM
OT  - *Beauchamp and Childress
OT  - *axiology
OT  - *balancing moral principles
OT  - *biomedical ethics
OT  - *moral dilemmas
OT  - *normative ethical theory
OT  - *practical wisdom
OT  - *principlism
OT  - *specification of moral principles
OT  - *the four principles
OT  - *value theory
OT  - *well-being
EDAT- 2020/07/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 5878081 [pii]
AID - 10.1093/jmp/jhaa014 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):441-470. doi: 10.1093/jmp/jhaa014.


PMID- 32726807
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - Virtues and Principles in Biomedical Ethics.
PG  - 471-503
LID - 10.1093/jmp/jhaa013 [doi]
AB  - In the seventh and most recent edition of their classic book, Principles of
      Biomedical Ethics, Tom Beauchamp and James Childress define a virtue as a
      character trait that is "socially valuable and reliably present" and a moral
      virtue as such a trait that is also both "dispositional" and "morally valuable"
      (2013, 31, 377). The virtues that they single out as "focal" within biomedical
      ethics are compassion, discernment, trustworthiness, integrity, and
      conscientiousness (Beauchamp and Childress, 2013, 37-44). Not all is well in
      their treatment of virtue. Beauchamp and Childress seem to worry that an ethical 
      theory in which virtues are fundamental will neglect duties, rights, and societal
      needs. Further, they insist that there is no reason to think that, within ethical
      theory, one family of ethical concepts is the most important, nor that one
      theoretical approach is correct, or even superior to others. I will try to show, 
      that there are (and that we have) strong reasons to see language, concepts, and
      matters of virtue as fundamental within normative ethical theory, both generally 
      and in such specialized subareas as medical ethics. These reasons reveal
      themselves when we analyze concepts at the core of the alternative approaches to 
      theorizing ethics that Beauchamp and Childress identify.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Garcia, Jorge L A
AU  - Garcia JLA
AD  - Boston College, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - *Bioethics
MH  - *Ethical Theory
MH  - Humans
MH  - *Morals
MH  - Philosophy, Medical
MH  - *Virtues
OTO - NOTNLM
OT  - *Beauchamp and Childress
OT  - *meta-ethics
OT  - *virtue theory
EDAT- 2020/07/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 5878078 [pii]
AID - 10.1093/jmp/jhaa013 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):471-503. doi: 10.1093/jmp/jhaa013.


PMID- 32726806
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - Moral Status and the Architects of Principlism.
PG  - 504-520
LID - 10.1093/jmp/jhaa019 [doi]
AB  - In this article, we discuss Beauchamp and Childress's treatment of the issue of
      moral status. In particular, we (1) introduce the five different perspectives on 
      moral status that Beauchamp and Childress consider in Principles of Biomedical
      Ethics and explain their alternative to those perspectives, (2) raise some
      critical questions about their approach, and (3) offer a different way to think
      about one of the five theories of moral status (the theory based on human
      properties) that is more in line with what we believe some of its leading
      advocates affirm.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Beckwith, Francis
AU  - Beckwith F
AD  - Baylor University, Waco, Texas, USA.
FAU - Thornton, Allison Krile
AU  - Thornton AK
AD  - University of South Alabama, Mobile, Alabama, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - *Bioethics
MH  - Ethical Analysis
MH  - *Ethical Theory
MH  - Humans
MH  - Interpersonal Relations
MH  - Moral Obligations
MH  - *Moral Status
MH  - Personal Autonomy
MH  - Philosophy, Medical
MH  - *Principle-Based Ethics
OTO - NOTNLM
OT  - *biomedical ethics
OT  - *human properties
OT  - *moral status
OT  - *personhood
OT  - *substance view of persons
EDAT- 2020/07/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 5878076 [pii]
AID - 10.1093/jmp/jhaa019 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):504-520. doi: 10.1093/jmp/jhaa019.


PMID- 32726805
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - The Authority of the Common Morality.
PG  - 427-440
LID - 10.1093/jmp/jhaa015 [doi]
AB  - In the third and subsequent editions of Principles of Biomedical Ethics, Tom
      Beauchamp and James Childress articulate a series of ethical norms that they
      regard as "derived" from, and hence carrying, the "authority" of the common
      morality. Although Beauchamp and Childress do not claim that biomedical norms
      they derive from the common morality automatically become constituents of the
      common morality, or that every detail of their account carries the authority of
      the common morality, they regard these derived norms as provisionally binding in 
      a way that does not apply to the norms of mere "particular" moralities. Whereas
      particular moralities "do not bind other persons or communities," Beauchamp and
      Childress have designed the norms of Principles of Biomedical Ethics to be
      "extensions" of the common morality that universally binds other persons and
      communities. Beauchamp and Childress seem to hold that (1) the norms they
      articulate in Principles of Biomedical Ethics are derived in an objective way
      from the common morality, and also that by virtue of being so derived (2) they
      carry a moral authority that objectively exceeds the authority of norms
      constituting particular moralities. My thesis in this essay is that both of these
      claims are false.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Trotter, Griffin
AU  - Trotter G
AD  - Saint Louis University, St. Louis, Missouri, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - *Bioethics
MH  - *Ethical Theory
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - *bioethics
OT  - *common morality
OT  - *ethical principles
OT  - *moral anthropology
OT  - *moral authority
OT  - *principlism
EDAT- 2020/07/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 5878075 [pii]
AID - 10.1093/jmp/jhaa015 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):427-440. doi: 10.1093/jmp/jhaa015.


PMID- 32726491
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 74
IP  - 12
DP  - 2020 Dec
TI  - Clinical evaluation of plasma coagulation parameters in patients with
      advanced-stage non-small cell lung cancer treated with palliative chemotherapy in
      China.
PG  - e13619
LID - 10.1111/ijcp.13619 [doi]
AB  - AIMS OF THE STUDY: Blood coagulation parameters are colossally important for
      clinical evaluation of palliative chemotherapy; however, this niche was not
      explored earlier for advanced-stage non-small cell lung cancer (NSCLC). Study
      focuses to explore the clinical relevancy of Coagulation parameters; prothrombin 
      time (PT), activated partial thromboplastin time (APTT), thrombin time (TT),
      fibrinogen (FIB), D-dimer and international normalised ratio (INR) and their
      response to palliative chemotherapy in advanced-stage NSCLC. METHODS: A
      retrospective study was conducted between 2013 and 2019 in Jiangsu Cancer
      hospital, Nanjing, PR. China. Medical records of 5445 patients were succinctly
      reviewed and classified accordingly to the inclusion and exclusion criteria. A
      total of 216 advanced NSCLC patients who used a first-line chemotherapy and
      antiangiogenic therapy regimen were enrolled in this study under ethical approval
      (JSCH-2020C-009). Blood samples were collected from these patients to measure the
      response levels of these coagulation parameters at time of admission to hospital 
      and at the beginning of 4 cycles of Palliative therapy. We find the clinical
      value of all these coagulation parameters by using SPSS 24. Univariate Cox
      regression and Multivariate Cox regression models were used to identify the
      factors that were associated with progression-free survival (PFS) and the
      response to palliative chemotherapy. RESULTS: In the Kaplan-Meier survival
      analysis for overall median (95% CI) survival of high pre-treatment coagulation
      parameters showed shorter PFS compared with normal pre-treatment except TT and
      their overall median (95% CI) follow-up was 3.3 (3.12-3.47). Coagulation
      parameters have showed clinical relevance as a potential independent prognostic
      factor of PFS in the Univariate Cox regression. In multivariable model, Age
      (>/=60 years vs < 60 years), cancer differentiation (Unknown vs Poor), PT (High
      vs Normal) range, FIB (High vs Normal) range and D-dimer (High vs Normal) range, 
      (P = .025, P = .045, P = .029, P = .049 and P = .011, respectively) were
      associated as a prognostic factor of PFS in NSCLC. Patients on 3-drugs regimen
      found to have better PFS compared with the ones taking the 2-drugs treatment
      regimen (P = .043). CONCLUSION: The high range of PT, FIB and D-dimers was
      associated with poor prognosis of advanced-stage NSCLC. Our findings also
      confirmed that patients on 3-drugs regimen showed longer PFS compared with
      2-drugs regimen.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Abbas, Muhammad
AU  - Abbas M
AUID- ORCID: https://orcid.org/0000-0002-4453-0981
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University,
      Nanjing, PR China.
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of
      Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University,
      Nanjing, China.
FAU - Kassim, Said Abasse
AU  - Kassim SA
AD  - Faculte des sciences de l'administration, Universite Laval, Quebec, QC, Canada.
FAU - Wang, Zhong-Chang
AU  - Wang ZC
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University,
      Nanjing, PR China.
FAU - Shi, Meiqi
AU  - Shi M
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of
      Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University,
      Nanjing, China.
FAU - Hu, Yiqiao
AU  - Hu Y
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University,
      Nanjing, PR China.
AD  - Institute of Drug R&D, Medical School of Nanjing University, Nanjing, PR China.
FAU - Zhu, Hai-Liang
AU  - Zhu HL
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University,
      Nanjing, PR China.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Blood Coagulation
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - China
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Middle Aged
MH  - Palliative Care
MH  - *Pharmaceutical Preparations
MH  - Plasma
MH  - Prognosis
MH  - Retrospective Studies
EDAT- 2020/07/30 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1111/ijcp.13619 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2020 Dec;74(12):e13619. doi: 10.1111/ijcp.13619. Epub 2020 Sep 
      3.


PMID- 32726155
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201218
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 11
DP  - 2020 Nov
TI  - Breathing life into bedside teaching in the era of COVID-19.
PG  - 1310-1312
LID - 10.1080/0142159X.2020.1798368 [doi]
AB  - Bedside skills have been declining over the last two decades, with multiple
      studies reporting increasing reliance on investigations and technology in making 
      diagnostic decisions. During the Covid-19 crisis, even less time is spent at the 
      bedside, and physical examinations seem markedly truncated or non-existent. It is
      possible that cost of health care, doctor-patient relationships, and the clinical
      reasoning skills could be seriously impacted by ongoing decrease in bedside
      skills and the teaching of these skills. Careful history taking and
      hypothesis-driven physical examination still form the backbone of clinical
      reasoning and lead to parsimonious investigations. Overreliance on investigations
      could drive up costs of healthcare if every diagnosis depends on a head to toe
      scan. In this paper, we describe strategies for bedside teaching that are
      relevant and applicable even during the pandemic and an era of physical
      distancing. These strategies are categorised as: before, during and after patient
      interactions at the bedside. These strategies can be adapted to normal clinical
      teaching situations as well as challenging situations such as the current
      pandemic when physical distancing is mandated.
FAU - Dam, Marjel van
AU  - Dam MV
AUID- ORCID: 0000-0001-9802-7516
AD  - Intensive Care Center, University Medical Center Utrecht, Utrecht, The
      Netherlands.
FAU - Ramani, Subha
AU  - Ramani S
AUID- ORCID: 0000-0002-8360-4031
AD  - Department of Medicine, Harvard Medical School, Boston, MA, USA.
FAU - Ten Cate, Olle
AU  - Ten Cate O
AUID- ORCID: 0000-0002-6379-8780
AD  - Center for Research and Development of Education, University Medical Center
      Utrecht, Utrecht, The Netherlands.
AD  - Department of Medicine, University of California, San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - Attitude of Health Personnel
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Clinical Competence
MH  - Coronavirus Infections/*diagnosis/therapy
MH  - Humans
MH  - Inservice Training
MH  - Pandemics
MH  - Patients' Rooms/organization & administration
MH  - Physical Examination/methods
MH  - *Physician-Patient Relations
MH  - Pneumonia, Viral/*diagnosis/therapy
MH  - Point-of-Care Testing/*organization & administration
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Clinical skills
OT  - *communication skills
OT  - *ethics/attitudes
OT  - *staff development
EDAT- 2020/07/30 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1080/0142159X.2020.1798368 [doi]
PST - ppublish
SO  - Med Teach. 2020 Nov;42(11):1310-1312. doi: 10.1080/0142159X.2020.1798368. Epub
      2020 Jul 29.


PMID- 32725709
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 62
IP  - 5
DP  - 2020 Nov
TI  - A crisis in US drug pricing: Consequences for patients with neuromuscular
      diseases, physicians, and society, part 2.
PG  - 573-578
LID - 10.1002/mus.27018 [doi]
AB  - Escalating drug costs place patients at risk for financial toxicity and demand
      that physicians understand and act on the ethical and economic principles related
      to drug pricing. This manuscript reviews these principles and provides clinicians
      with a framework to think about the value of the drugs prescribed for patients
      with neuromuscular diseases. A key component of addressing the drug pricing
      crisis will be establishing a value based (benefit/cost) drug pricing framework. 
      Determining the value of a drug is difficult and requires estimating the benefit 
      and costs to patients and society while integrating indirect and contextual
      variables. Other considerations in drug pricing include "externality," the value 
      to society derived from innovation. The Institute for Clinical and Economic
      Review (ICER) is a leading independent research organization providing clinicians
      with value-based price "benchmarks." All physicians must educate themselves in
      drug pricing principles and be prepared to have conversations regarding
      individual and societal value with the patients they serve.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Burns, Ted M
AU  - Burns TM
AD  - Department of Neurology, University of Virginia, Charlottesville, VA, USA.
FAU - Crowell, Jason L
AU  - Crowell JL
AD  - Beth Israel Deaconess Medical Center, Jerome H. Grossman M.D. Graduate Fellow,
      Harvard Kennedy School, Boston, MA, USA.
FAU - Smith, A Gordon
AU  - Smith AG
AD  - Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200729
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Prescription Drugs)
SB  - IM
MH  - Clinical Decision-Making/ethics
MH  - *Drug Costs
MH  - Humans
MH  - Neuromuscular Diseases/*drug therapy/*economics
MH  - Physicians
MH  - Prescription Drugs/*economics
MH  - United States
OTO - NOTNLM
OT  - *bioethics
OT  - *drug pricing
OT  - *economics
OT  - *orphan drug act
OT  - *quality
OT  - *value
EDAT- 2020/07/30 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1002/mus.27018 [doi]
PST - ppublish
SO  - Muscle Nerve. 2020 Nov;62(5):573-578. doi: 10.1002/mus.27018. Epub 2020 Jul 29.


PMID- 32725209
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1468-2834 (Electronic)
IS  - 0002-0729 (Linking)
VI  - 49
IP  - 4
DP  - 2020 Jul 1
TI  - COVID-19 outbreak: organisation of a geriatric assessment and coordination unit. 
      A French example.
PG  - 516-522
LID - 10.1093/ageing/afaa092 [doi]
AB  - Older people are particularly affected by the COVID-19 outbreak because of their 
      vulnerability as well as the complexity of health organisations, particularly in 
      the often-compartmentalised interactions between community, hospital and nursing 
      home actors. In this endemic situation, with massive flows of patients requiring 
      holistic management including specific and intensive care, the appropriate
      assessment of each patient's level of care and the organisation of specific
      networks is essential. To that end, we propose here a territorial organisation of
      health care, favouring communication between all actors. This organisation of
      care is based on three key points: To use the basis of territorial organisation
      of health by facilitating the link between hospital settings and geriatric
      sectors at the regional level.To connect private, medico-social and hospital
      actors through a dedicated centralised unit for evaluation, geriatric
      coordination of care and decision support. A geriatrician coordinates this
      multidisciplinary unit. It includes an emergency room doctor, a supervisor from
      the medical regulation centre (Centre 15), an infectious disease physician, a
      medical hygienist and a palliative care specialist.To organise an ad hoc
      follow-up channel, including the necessary resources for the different levels of 
      care required, according to the resources of the territorial network, and the
      creation of a specific COVID geriatric palliative care service. This organisation
      meets the urgent health needs of all stakeholders, facilitating its deployment
      and allows the sustainable implementation of a coordinated geriatric management
      dynamic between the stakeholders on the territory.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      British Geriatrics Society. All rights reserved. For permissions, please email:
      journals.permissions@oup.com.
FAU - Koeberle, Severine
AU  - Koeberle S
AD  - Geriatrics Department, CHU, Besancon, France.
AD  - "Ethics and Medical Progress" reseach team, INSERM CIC 1431, CHU Besancon,
      France.
FAU - Tannou, Thomas
AU  - Tannou T
AD  - Geriatrics Department, CHU, Besancon, France.
AD  - "Ethics and Medical Progress" reseach team, INSERM CIC 1431, CHU Besancon,
      France.
AD  - EA 481 Neurosciences, Universite de Franche-comte, Besancon, France.
AD  - Research Centre, Geriatric University Institute of Montreal (IUGM), Montreal, Qc,
      Canada.
FAU - Bouiller, Kevin
AU  - Bouiller K
AD  - Infectious Disease Department, CHU de Besancon, Besancon, France.
FAU - Becoulet, Nicolas
AU  - Becoulet N
AD  - Palliative Care Department, CHU de Besancon, Besancon, France.
FAU - Outrey, Justin
AU  - Outrey J
AD  - Emergency Department, CHU de Besancon, Besancon, France.
FAU - Chirouze, Catherine
AU  - Chirouze C
AD  - Infectious Disease Department, CHU de Besancon, Besancon, France.
AD  - Laboratoire Chrono-environnement - UMR 6249 CNRS-UFC, Besancon, France.
FAU - Aubry, Regis
AU  - Aubry R
AD  - Geriatrics Department, CHU, Besancon, France.
AD  - "Ethics and Medical Progress" reseach team, INSERM CIC 1431, CHU Besancon,
      France.
AD  - EA 481 Neurosciences, Universite de Franche-comte, Besancon, France.
AD  - Palliative Care Department, CHU de Besancon, Besancon, France.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Age Ageing
JT  - Age and ageing
JID - 0375655
SB  - IM
MH  - Aged
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Community Networks/organization & administration
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - France/epidemiology
MH  - Geriatric Assessment/*methods
MH  - Health Care Rationing/trends
MH  - *Health Services for the Aged/ethics/organization & administration/trends
MH  - Humans
MH  - Organizational Innovation
MH  - Palliative Care/methods
MH  - *Pandemics/prevention & control
MH  - *Patient Care Management/ethics/organization & administration/trends
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - Regional Medical Programs/*organization & administration
MH  - SARS-CoV-2
MH  - Semantic Web
MH  - Stakeholder Participation
PMC - PMC7239239
OTO - NOTNLM
OT  - *COVID-19
OT  - *decision-making
OT  - *ethics
OT  - *geriatrics
OT  - *healthcare organisation
OT  - *older people
OT  - *palliative care
EDAT- 2020/07/30 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/03/28 00:00 [received]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 5831132 [pii]
AID - 10.1093/ageing/afaa092 [doi]
PST - ppublish
SO  - Age Ageing. 2020 Jul 1;49(4):516-522. doi: 10.1093/ageing/afaa092.


PMID- 32725140
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Linking)
VI  - 22
IP  - 11
DP  - 2020 Nov 1
TI  - Remote monitoring of cardiac implanted electronic devices: legal requirements and
      ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force
      report.
PG  - 1742-1758
LID - 10.1093/europace/euaa168 [doi]
AB  - The European Union (EU) General Data Protection Regulation (GDPR) imposes legal
      responsibilities concerning the collection and processing of personal information
      from individuals who live in the EU. It has particular implications for the
      remote monitoring of cardiac implantable electronic devices (CIEDs). This report 
      from a joint Task Force of the European Heart Rhythm Association and the
      Regulatory Affairs Committee of the European Society of Cardiology (ESC)
      recommends a common legal interpretation of the GDPR. Manufacturers and hospitals
      should be designated as joint controllers of the data collected by remote
      monitoring (depending upon the system architecture) and they should have a mutual
      contract in place that defines their respective roles; a generic template is
      proposed. Alternatively, they may be two independent controllers. Self-employed
      cardiologists also are data controllers. Third-party providers of monitoring
      platforms may act as data processors. Manufacturers should always collect and
      process the minimum amount of identifiable data necessary, and wherever feasible 
      have access only to pseudonymized data. Cybersecurity vulnerabilities have been
      reported concerning the security of transmission of data between a patient's
      device and the transceiver, so manufacturers should use secure communication
      protocols. Patients need to be informed how their remotely monitored data will be
      handled and used, and their informed consent should be sought before their device
      is implanted. Review of consent forms in current use revealed great variability
      in length and content, and sometimes very technical language; therefore, a
      standard information sheet and generic consent form are proposed. Cardiologists
      who care for patients with CIEDs that are remotely monitored should be aware of
      these issues.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved.
      (c) The Author(s) 2020. For permissions, please email:
      journals.permissions@oup.com.
FAU - Nielsen, Jens Cosedis
AU  - Nielsen JC
AD  - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens
      Boulevard 99, DK-8200 Aarhus N, Denmark.
FAU - Kautzner, Josef
AU  - Kautzner J
AD  - Institute for Clinical and Experimental Medicine, Prague and Palacky University
      Medical School, Olomouc, Czech Republic.
FAU - Casado-Arroyo, Ruben
AU  - Casado-Arroyo R
AD  - Department of Cardiology, Erasme University Hospital, Universite Libre de
      Bruxelles, Brussels, Belgium.
FAU - Burri, Haran
AU  - Burri H
AD  - Cardiac Pacing Unit, Cardiology Service, University Hospital of Geneva, Geneva,
      Switzerland.
FAU - Callens, Stefaan
AU  - Callens S
AD  - Centre for Biomedical Ethics and Law, KU Leuven, Leuven, Belgium.
FAU - Cowie, Martin R
AU  - Cowie MR
AD  - Imperial College London (Royal Brompton Hospital) & National Heart and Lung
      Institute, Dovehouse Street, London SW3 6LY, UK.
FAU - Dickstein, Kenneth
AU  - Dickstein K
AD  - University of Bergen, Stavanger University Hospital, Stavanger, Norway.
FAU - Drossart, Inga
AU  - Drossart I
AD  - ESC Patient Forum member, Brussels, Belgium.
FAU - Geneste, Ginger
AU  - Geneste G
AD  - Cyber Security Group, Delft University of Technology, Delft, The Netherlands.
FAU - Erkin, Zekeriya
AU  - Erkin Z
AD  - Cyber Security Group, Delft University of Technology, Delft, The Netherlands.
FAU - Hyafil, Fabien
AU  - Hyafil F
AD  - Department Medico-Universitaire DREAM, Bichat University Hospital, APHP.7, Inserm
      1148, Universite de Paris, Paris, France.
FAU - Kraus, Alexander
AU  - Kraus A
AD  - BIOTRONIK SE & Co. KG, Berlin, Germany.
FAU - Kutyifa, Valentina
AU  - Kutyifa V
AD  - University of Rochester Medical Center, Clinical Cardiovascular Research Center, 
      Rochester, NY, USA.
FAU - Marin, Eduard
AU  - Marin E
AD  - School of Computer Science, University of Birmingham, Birmingham, UK.
AD  - Telefonica Research, Spain.
FAU - Schulze, Christian
AU  - Schulze C
AD  - Division of Cardiology, Angiology, Pneumonology and Intensive Medical Care,
      Department of Internal Medicine I, University Hospital Jena,
      Friedrich-Schiller-University Jena, Am Klinikum 1, Jena, Germany.
FAU - Slotwiner, David
AU  - Slotwiner D
AD  - Division of Cardiology, New York Presbyterian Queens and School of Health Policy 
      and Research, Weill Cornell Medical College, New York, NY, USA.
FAU - Stein, Kenneth
AU  - Stein K
AD  - Boston Scientific, Arden Hills, MN, USA.
FAU - Zanero, Stefano
AU  - Zanero S
AD  - Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano,
      Milan, Italy.
FAU - Heidbuchel, Hein
AU  - Heidbuchel H
AD  - Department of Cardiology, UniversityHospital Antwerp, University of Antwerp,
      Antwerp, Belgium.
FAU - Fraser, Alan G
AU  - Fraser AG
AD  - School of Medicine, Cardiff University, Cardiff, UK.
AD  - Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven,
      Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular
      electrophysiology of the European Society of Cardiology
JID - 100883649
SB  - IM
EIN - Europace. 2021 Jun 7;23(6):843. PMID: 33693688
MH  - Advisory Committees
MH  - *Cardiology
MH  - Computer Security
MH  - Electronics
MH  - Humans
MH  - Monitoring, Physiologic
OTO - NOTNLM
OT  - *Cardiac implantable electronic device
OT  - *Cybersecurity
OT  - *Data controller
OT  - *Data processor
OT  - *EHRA
OT  - *ESC Regulatory Affairs Committee
OT  - *General Data Protection Regulation
OT  - *Informed consent
OT  - *Informed consent form
OT  - *Joint data controller
OT  - *Remote monitoring
EDAT- 2020/07/30 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 5877304 [pii]
AID - 10.1093/europace/euaa168 [doi]
PST - ppublish
SO  - Europace. 2020 Nov 1;22(11):1742-1758. doi: 10.1093/europace/euaa168.


PMID- 32725089
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1678-4464 (Electronic)
IS  - 0102-311X (Linking)
VI  - 36
IP  - 7
DP  - 2020
TI  - Quaternary prevention: a concept relevant to public health? A bibliometric and
      descriptive content analysis.
PG  - e00231819
LID - S0102-311X2020000702002 [pii]
LID - 10.1590/0102-311x00231819 [doi]
AB  - According to the World Organization of Family Doctors (WONCA), quaternary
      prevention (P4) is a recent concept that aims to prevent medical overuse. Thus,
      this study aimed to measure and map research output on P4 as outline research
      trends, evaluating its current international status through a bibliometric and
      descriptive content analysis. We reviewed scientific articles on P4 recorded in
      PubMed, LILACS, SciELO or CINAHL with the outcomes: publication year, first
      authors' name and nationality, journals' name, country and ranking, publication
      language, used methods and main reported subjects. The analysis included 65
      articles published in 33 journals of 16 countries between 2003 and 2018 with a
      peak of publications in 2015. The first authors came from 17 different countries,
      23% Brazilian, with Uruguay as the leading nation in scientific production per
      capita. Q1 or Q2 journals amassed 28% of published papers. Bibliographic research
      comprised 88% of articles and 38% of all focused on specific examples of medical 
      overuse. P4 represents an ethical and valid approach to prevent iatrogenic events
      and achieve equal and fair access to health services. Conceptual, geographical,
      and linguistic elements, as well as WONCA conferences and type of healthcare
      systems in the authors' country were fundamental factors that affected research
      output. The available studies are still of limited quality and quantity, with
      further investigations needed to assess the effective impact of P4 on public
      health.
FAU - Depallens, Miguel Andino
AU  - Depallens MA
AD  - Universidade Federal do Sul da Bahia, Itabuna, Brazil.
FAU - Guimaraes, Jane Mary de Medeiros
AU  - Guimaraes JMM
AD  - Universidade Federal do Sul da Bahia, Itabuna, Brazil.
FAU - Almeida Filho, Naomar
AU  - Almeida Filho N
AD  - Instituto de Saude Coletiva, Universidade Federal da Bahia, Salvador, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
SB  - IM
MH  - *Bibliometrics
MH  - Brazil
MH  - Humans
MH  - *Public Health
MH  - Uruguay
EDAT- 2020/07/30 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/30 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S0102-311X2020000702002 [pii]
AID - 10.1590/0102-311x00231819 [doi]
PST - ppublish
SO  - Cad Saude Publica. 2020;36(7):e00231819. doi: 10.1590/0102-311x00231819. Epub
      2020 Jul 24.


PMID- 32725084
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20201218
IS  - 1678-4464 (Electronic)
IS  - 0102-311X (Linking)
VI  - 36
IP  - 7
DP  - 2020
TI  - COVID-19, fake news, and the sleep of communicative reason producing monsters:
      the narrative of risks and the risks of narratives.
PG  - e00101920
LID - S0102-311X2020000703001 [pii]
LID - 10.1590/0102-311x00101920 [doi]
AB  - Since the beginning of the COVID-19 outbreak, the world has witnessed growing
      tension from the pandemic dimension of a disease with severe epidemiological
      impacts and wide-reaching sociocultural and political spinoffs. In ideal
      conditions of public communication, the authorities would be aligned with a
      totally transparent system supplying abundant information and ease of
      understanding to generate credibility, confidence, and partnership with the
      media. In the hiatuses of acceptable versions and in the midst of
      indeterminations, individuals become their own experts, consuming fake news and
      reproducing fallacious risk narratives with disastrous consequences. The article 
      discusses various aspects of fake news and the use of communicative reason by
      public authorities, citing the case of Iran and drawing parallels with the
      antivaccination movement and its consequences. The authors address the challenge 
      of coordinated orientation of society with information, competing with
      pseudo-scientific pastiches that proliferate at breakneck speed in the absence of
      official data. All this raises the following question: which communication models
      should back the official narrative to create the conditions for collaboration and
      partnership with the media? What impacts would such models have on the
      proliferation of misleading narratives that citizens turn to during crises of
      appropriate orientation? The authors conclude that it is also the government's
      role to use its broad visibility to create references of safety under the primacy
      of communicative reason, sensitive to society's genuine questions and concerns.
      In short, government should produce responsible references on a monumental scale,
      oriented by the ethics of accountability in line with the common good.
FAU - Vasconcellos-Silva, Paulo R
AU  - Vasconcellos-Silva PR
AD  - Instituto Oswado Cruz, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
FAU - Castiel, Luis David
AU  - Castiel LD
AD  - Escola Nacional de Saude Publica Sergio Arouca, Fundacao Oswaldo Cruz, Rio de
      Janeiro, Brazil.
LA  - eng
LA  - por
PT  - Journal Article
TT  - COVID-19, as fake news e o sono da razao comunicativa gerando monstros: a
      narrativa dos riscos e os riscos das narrativas.
DEP - 20200724
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Communication
MH  - Coronavirus Infections/*epidemiology/*psychology
MH  - Government
MH  - Humans
MH  - Iran
MH  - *Judgment
MH  - Mass Media
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*psychology
MH  - Risk
MH  - SARS-CoV-2
EDAT- 2020/07/30 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
AID - S0102-311X2020000703001 [pii]
AID - 10.1590/0102-311x00101920 [doi]
PST - ppublish
SO  - Cad Saude Publica. 2020;36(7):e00101920. doi: 10.1590/0102-311x00101920. Epub
      2020 Jul 24.


PMID- 32724866
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201121
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?
PG  - 100614
LID - 10.1016/j.conctc.2020.100614 [doi]
AB  - Given the high case fatality rate of SARS-CoV-2, for which there is no cure and
      no vaccine, clinicians are forced to make decisions about how best to manage
      patients with limited high-quality evidence to guide treatment. Traditional
      randomized controlled trials provide strong experimental evidence, however, tend 
      to be slow, inflexible, and have limited generalizability. Adaptive and pragmatic
      designs are an attractive alternative, which meet our ethical obligation during
      the SARS-CoV-2 pandemic to balance speed, agility, and generalizability with both
      prospective study and scientific rigor.
FAU - Branch-Elliman, Westyn
AU  - Branch-Elliman W
AD  - VA Boston Healthcare System, Department of Medicine, Boston, MA, USA.
AD  - VA Boston Center for Healthcare Organization and Implementation Research (CHOIR),
      Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Lehmann, Lisa Soleymani
AU  - Lehmann LS
AD  - VA Boston Healthcare System, Department of Medicine, Boston, MA, USA.
AD  - VA Boston Center for Healthcare Organization and Implementation Research (CHOIR),
      Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Boden, William E
AU  - Boden WE
AD  - VA Boston Healthcare System, Department of Medicine, Boston, MA, USA.
AD  - Boston University School of Medicine, Boston, MA, USA.
FAU - Ferguson, Ryan
AU  - Ferguson R
AD  - Boston University School of Medicine, Boston, MA, USA.
AD  - Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC),
      Boston, MA, USA.
AD  - Boston University School of Public Health, Boston, MA, USA.
FAU - Monach, Paul
AU  - Monach P
AD  - VA Boston Healthcare System, Department of Medicine, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
AD  - Division of Rheumatology Inflammation and Immunity, Brigham and Women's Hospital,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7366075
COIS- All authors have no conflicts of interest to report.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/04/26 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - 10.1016/j.conctc.2020.100614 [doi]
AID - S2451-8654(20)30098-3 [pii]
AID - 100614 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Jul 17;19:100614. doi:
      10.1016/j.conctc.2020.100614. eCollection 2020 Sep.


PMID- 32724864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220323
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Methodological rigor of prognostic models for predicting in-hospital paediatric
      mortality in low- and middle-income countries: a systematic review protocol.
PG  - 106
LID - 10.12688/wellcomeopenres.15955.1 [doi]
AB  - Introduction: In low- and middle-income countries (LMICs) where healthcare
      resources are often limited, making decisions on appropriate treatment choices is
      critical in ensuring reduction of paediatric deaths as well as instilling proper 
      utilisation of the already constrained healthcare resources. Well-developed and
      validated prognostic models can aid in early recognition of potential risks thus 
      contributing to the reduction of mortality rates. The aim of the planned
      systematic review is to identify and appraise the methodological rigor of
      multivariable prognostic models predicting in-hospital paediatric mortality in
      LMIC in order to identify statistical and methodological shortcomings deserving
      special attention and to identify models for external validation. Methods and
      analysis: This protocol has followed the guidelines of the Preferred Reporting
      Items for Systematic Reviews and Meta-Analyses for Protocols. A search of
      articles will be conducted in MEDLINE, Google Scholar, and CINAHL (via EbscoHost)
      from inception to 2019 without any language restriction. We will also perform a
      search in Web of Science to identify additional reports that cite the identified 
      studies. Data will be extracted from relevant articles in accordance with the
      Cochrane Prognosis Methods' guidance; the CHecklist for critical Appraisal and
      data extraction for systematic Reviews of prediction Modelling Studies.
      Methodological quality assessment will be performed based on prespecified domains
      of the Prediction study Risk of Bias Assessment Tool. Ethics and dissemination:
      Ethical permission will not be required as this study will use published data.
      Findings from this review will be shared through publication in peer-reviewed
      scientific journals and, presented at conferences. It is our hope that this study
      will contribute to the development of robust multivariable prognostic models
      predicting in-hospital paediatric mortality in low- and middle-income countries. 
      Registration: PROSPERO ID CRD42018088599; registered on 13 February 2018.
CI  - Copyright: (c) 2020 Ogero M et al.
FAU - Ogero, Morris
AU  - Ogero M
AUID- ORCID: https://orcid.org/0000-0003-0117-6289
AD  - Health Service Unit, KEMRI / Wellcome Trust Research Programme, Nairobi, P.O Box 
      43640-00100, Kenya.
AD  - School of Mathematics, University of Nairobi, Nairobi, P. O. Box 30197 - 00100,
      Kenya.
FAU - Sarguta, Rachel
AU  - Sarguta R
AD  - School of Mathematics, University of Nairobi, Nairobi, P. O. Box 30197 - 00100,
      Kenya.
FAU - Malla, Lucas
AU  - Malla L
AD  - Health Service Unit, KEMRI / Wellcome Trust Research Programme, Nairobi, P.O Box 
      43640-00100, Kenya.
FAU - Aluvaala, Jalemba
AU  - Aluvaala J
AUID- ORCID: https://orcid.org/0000-0002-0851-3711
AD  - Health Service Unit, KEMRI / Wellcome Trust Research Programme, Nairobi, P.O Box 
      43640-00100, Kenya.
FAU - Agweyu, Ambrose
AU  - Agweyu A
AD  - Health Service Unit, KEMRI / Wellcome Trust Research Programme, Nairobi, P.O Box 
      43640-00100, Kenya.
FAU - Akech, Samuel
AU  - Akech S
AUID- ORCID: https://orcid.org/0000-0001-5126-1225
AD  - Health Service Unit, KEMRI / Wellcome Trust Research Programme, Nairobi, P.O Box 
      43640-00100, Kenya.
LA  - eng
GR  - MR/R006083/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7364185
OTO - NOTNLM
OT  - Prognostic models
OT  - in-hospital paediatric mortality
OT  - model
OT  - prediction
COIS- No competing interests were disclosed.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - 10.12688/wellcomeopenres.15955.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 May 27;5:106. doi: 10.12688/wellcomeopenres.15955.1.
      eCollection 2020.


PMID- 32724747
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 24
TI  - An Observational Study of Vaping Knowledge and Perceptions in a Sample of U.S.
      Adults.
PG  - e8800
LID - 10.7759/cureus.8800 [doi]
AB  - Background Vaping is the use of e-cigarettes that contain inhalants such as
      nicotine, tetrahydrocannabinol, and cannabidiol. Vaping is associated with
      e-cigarette or vaping product use associated lung injury (EVALI) and is a
      recognized public health crisis. Despite rising numbers of hospitalizations due
      to EVALI, public knowledge and perceptions of the dangers of vaping require
      further investigation. Objectives This exploratory study assessed knowledge and
      perceptions of vaping in U.S. adults. Methods This study was approved by an
      ethical board, and informed consent was obtained from all participants. A cohort 
      of U.S. adults was recruited by shared links on social media. Participants
      completed an anonymous online survey that contained vaping knowledge and
      perceptions items. An a priori power analysis was conducted at 95% power and
      alpha = 0.05. Statistics were calculated using IBM SPSS Statistics Version 26
      (IBM Corp., Armonk, NY, USA). Results A sample of 413 (N = 413) U.S. adults
      participated in the survey. The majority of participants (79.18%) were females,
      and 65.62% were between 18 and 24 years of age. Over half (62.71%) of
      participants were never asked about vaping use by a clinician at any visit, and
      56.51% agreed that vaping can reduce stress. Of all participants, 70.91% agreed
      that drinking alcohol makes someone more inclined to vape. Significant positive
      Spearman's rho correlations were found between vaping and the use of cannabis,
      cocaine, ecstasy, hallucinogens, and inhalants (p < 0.05). Conclusions We found a
      significant correlation between vaping and drug use. We also found that if the
      dangers of vaping are discussed by their health care providers, participants are 
      more inclined to quit vaping. Unfortunately, many physicians report that they
      avoid discussing vaping with their patients due to lack of vaping knowledge. Our 
      results illuminate the communication gap between patients and physicians. All
      clinicians need to counsel patients on the dangers of vaping, which might help
      prevent EVALI and related conditions.
CI  - Copyright (c) 2020, Bellisario et al.
FAU - Bellisario, Alexandra
AU  - Bellisario A
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - Bourbeau, Karissa
AU  - Bourbeau K
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - Crespo, Danielle A
AU  - Crespo DA
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - DeLuzio, Nicole
AU  - DeLuzio N
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - Ferro, Alexandra
AU  - Ferro A
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - Sanchez, Alexandra
AU  - Sanchez A
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - Jackson, Tracy
AU  - Jackson T
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - Kunath-Tiburzi, Gail
AU  - Kunath-Tiburzi G
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
FAU - D'Antoni, Anthony V
AU  - D'Antoni AV
AD  - Physician Assistant Program, Wagner College, Staten Island, USA.
AD  - Radiology, Weill Cornell Medicine, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7381874
OTO - NOTNLM
OT  - addiction
OT  - e-cigarette and vaping product use associated lung injury (evali)
OT  - electronic cigarettes
OT  - lung injury
OT  - pulmonary
OT  - vaping
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - 10.7759/cureus.8800 [doi]
PST - epublish
SO  - Cureus. 2020 Jun 24;12(6):e8800. doi: 10.7759/cureus.8800.


PMID- 32724733
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 23
TI  - Parkinsonism: A Rare Adverse Effect of Valproic Acid.
PG  - e8782
LID - 10.7759/cureus.8782 [doi]
AB  - Valproic acid (VPA) is an anti-epileptic drug (AED) used as a first-choice agent 
      for most forms of epilepsy. It is used in the treatment of manic episodes,
      bipolar disorder, migraine prevention, and impulse control. Hence it is one of
      the most commonly prescribed drugs by physicians nowadays. VPA acts by increasing
      gama amino butyric acid (GABA) levels, and also reduces neuronal activation by
      blocking voltage-gated sodium, potassium, and calcium channels. VPA has various
      adverse effects like thrombocytopenia, hyperammonemia, teratogenicity causing
      spina bifida in newborns when exposed in utero. The focus of this review is to
      research one such easily overlooked adverse effect of VPA, which is VPA-induced
      Parkinsonism. We carried out a review of literature and gathered all
      comprehensive peer-reviewed articles from PubMed. The data for this research were
      collected ethically and legally after a thorough examination of the literature.
      Data obtained from the studies have suggested that Parkinsonism is an adverse
      effect of VPA. Chronic usage of VPA causes Parkinsonism. It occurs equally in
      males and females, more common in older people usually above the age of 55 years 
      and not dose-dependent. According to the data obtained, all patients who
      developed Parkinsonism had serum levels in the therapeutic range (50-100 mcg/mL).
      Thus the chronic intake of maintenance dose of VPA seems to be the leading cause.
      The symptoms usually improve over a few weeks and fully resolve in a few months
      after stopping the drug. When the patient's symptoms do not improve, it means VPA
      has unmasked the underlying potential for developing Parkinson's disease. Such
      patients benefit from levodopa therapy. However, the mechanism of how VPA causes 
      Parkinsonism remains unknown. Based on the articles reviewed, we hypothesize that
      VPA's mechanism of neuronal inactivation by blocking membrane channels across the
      neuronal membrane, primarily when used chronically could be the mechanism by
      which it causes Parkinsonism. VPA causes down regulation of sodium and potassium 
      channels on neuronal membrane in order to stop the neurons from firing. Thereby a
      decrease in action potential across the neurons causes a temporary physiological 
      inactivation of the neuron. When multiple neurons are inactivated in the basal
      ganglia of the brain, the patient develops symptoms of Parkinsonism. As the
      neurons are only temporarily inactivated physiologically, when the drug is
      stopped the membrane receptors are reactivated on the neuronal membranes. This
      leads to neuronal activation and neuronal membrane potential becomes the same as 
      before. The above mechanism clarifies why the symptoms settle down when the
      medication is stopped.
CI  - Copyright (c) 2020, Muralidharan et al.
FAU - Muralidharan, Abilash
AU  - Muralidharan A
AD  - Internal Medicine, California Institute of Behavioral Neurosciences and
      Psychology, Fairfield, USA.
AD  - Internal Medicine, Kiruba Hospital, Coimbatore, IND.
FAU - Rahman, Jawaria
AU  - Rahman J
AD  - Pathology, City of Hope Comprehensive Cancer Center, Monrovia, USA.
FAU - Banerjee, Dipanjan
AU  - Banerjee D
AD  - Neuroscience, California Institute of Behavioral Neurosciences and Psychology,
      Fairfield, USA.
AD  - Geriatrics, Queen's Medical Center, Nottingham University Hospitals NHS Trust,
      Nottingham, GBR.
FAU - Hakim Mohammed, Abdul Rub
AU  - Hakim Mohammed AR
AD  - Internal Medicine, California Institute of Behavioral Neurosciences and
      Psychology, Fairfield, USA.
FAU - Malik, Bilal Haider
AU  - Malik BH
AD  - Internal Medicine, California Institute of Behavioral Neurosciences and
      Psychology, Fairfield, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200623
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7381881
OTO - NOTNLM
OT  - drug induced parkinsonism
OT  - parkinsonism
OT  - valproic acid
OT  - vaproic acid induced parkinsonism
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - 10.7759/cureus.8782 [doi]
PST - epublish
SO  - Cureus. 2020 Jun 23;12(6):e8782. doi: 10.7759/cureus.8782.


PMID- 32724353
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 20
IP  - 2
DP  - 2020 Aug
TI  - Effective pressure and treatment duration of high hydrostatic pressure to prepare
      melanoma vaccines.
PG  - 1135-1142
LID - 10.3892/ol.2020.11657 [doi]
AB  - Current therapeutic methods for melanoma have numerous limitations, and thus the 
      improvement of such treatment methods are essential. One possible option is the
      vaccination of autologous inactivated tumor cells. The primary indispensable
      principles of a cell-based melanoma vaccine include: i) Entire inactivation of
      melanoma cells; ii) retaining the immunogenicity of melanoma cells; and iii)
      adherence to laws and ethical guidelines. However, traditional methods for the
      production of the vaccine, such as ultrasonic, chemotherapeutics and
      freeze-thawing, have some juridical or therapeutic constraints. Therefore, the
      present study used high hydrostatic pressure (HHP) to inactivate malignant cells,
      and treated B16-F10 tumor cells with different pressures (>/=50 MPa) and
      different durations (>/=1 min). It was identified that tumor cells in vitro lost 
      their proliferative ability, but retained their immunogenicity following
      treatment. Furthermore, the vaccination of the melanoma cells significantly
      suppressed their oncogenesis. Collectively, the present results suggest that HHP 
      treatment may be an economically viable and effective measure to develop a
      melanoma vaccine, when pressure was >/=200 MPa and the treatment duration was
      >/=30 min.
CI  - Copyright: (c) Liu et al.
FAU - Liu, Kai
AU  - Liu K
AD  - Department of Hand and Foot Surgery, The First Hospital of Jilin University,
      Changchun, Jilin 130021, P.R. China.
FAU - Yan, Shuai
AU  - Yan S
AD  - Department of Operating Room, The First Hospital of Jilin University, Changchun, 
      Jilin 130021, P.R. China.
FAU - Ma, Zhanchuan
AU  - Ma Z
AD  - Institute of Immunology, The First Hospital of Jilin University, Changchun, Jilin
      130021, P.R. China.
FAU - Liu, Bin
AU  - Liu B
AD  - Department of Hand and Foot Surgery, The First Hospital of Jilin University,
      Changchun, Jilin 130021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7377178
OTO - NOTNLM
OT  - HHP
OT  - effective pressure
OT  - immunogenicity
OT  - melanoma vaccine
OT  - treatment duration
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - 10.3892/ol.2020.11657 [doi]
AID - OL-0-0-11657 [pii]
PST - ppublish
SO  - Oncol Lett. 2020 Aug;20(2):1135-1142. doi: 10.3892/ol.2020.11657. Epub 2020 May
      21.


PMID- 32724147
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20211204
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7818
DP  - 2020 Jul
TI  - Make Black history core to degrees, tie tenure to anti-racism efforts.
PG  - 683
LID - 10.1038/d41586-020-02235-2 [doi]
FAU - Gore-Felton, Cheryl
AU  - Gore-Felton C
FAU - Khan, Christina Tara
AU  - Khan CT
FAU - Njenga, Jacqueline
AU  - Njenga J
LA  - eng
PT  - Historical Article
PT  - Letter
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - *Blacks/history
MH  - *Curriculum
MH  - *Faculty
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Leadership
MH  - Racism/*prevention & control
MH  - *Universities/organization & administration
OTO - NOTNLM
OT  - *Education
OT  - *Ethics
OT  - *Institutions
EDAT- 2020/07/30 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1038/d41586-020-02235-2 [doi]
AID - 10.1038/d41586-020-02235-2 [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7818):683. doi: 10.1038/d41586-020-02235-2.


PMID- 32723761
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Sex, money and luck in sport.
PG  - 591-592
LID - 10.1136/medethics-2020-106509 [doi]
FAU - Chambers, Clare
AU  - Chambers C
AUID- ORCID: 0000-0002-0843-2313
AD  - Faculty of Philosophy, Jesus College, University of Cambridge, Cambridge CB5 8BL,
      UK cec66@cam.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200728
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Sep;46(9):584-590. PMID: 32690761
CIN - J Med Ethics. 2020 Sep;46(9):599-600. PMID: 32826302
MH  - Athletes
MH  - *Feminism
MH  - Humans
MH  - *Social Justice
OTO - NOTNLM
OT  - *distributive justice
OT  - *ethics
OT  - *feminism
OT  - *political philosophy
OT  - *women
COIS- Competing interests: None declared.
EDAT- 2020/07/30 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/06/23 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - medethics-2020-106509 [pii]
AID - 10.1136/medethics-2020-106509 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):591-592. doi: 10.1136/medethics-2020-106509. Epub
      2020 Jul 28.


PMID- 32723760
OWN - NLM
STAT- Publisher
LR  - 20200729
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 28
TI  - Moral distress and moral residue experienced by transplant coordinators.
LID - medethics-2019-105593 [pii]
LID - 10.1136/medethics-2019-105593 [doi]
AB  - Transplant coordinators play a pivotal role in the process of obtaining consent
      for live or dead donation of organs. The objective of the project is to unveil
      emotional experiences and ethical conduct of transplant coordinators using a
      qualitative research methodology. Ten transplant coordinators who have worked for
      more than 20 years in this job were recruited by using a purposive sampling
      technique. The transplant coordinators spoke of negative feelings and moral
      distress with regard to futile care of family members of deceased donors as well 
      as of living donors. Transplant coordinators experience moral distress on a daily
      basis; being compelled to compromise their integrity causes moral distress and
      moral residue, hence, training and support should be offered to them.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Tarabeih, Mahdi
AU  - Tarabeih M
AD  - School of Nursing, The Academic College of Tel Aviv-Jaffa, Tel Aviv, Israel.
FAU - Bokek-Cohen, Ya'arit
AU  - Bokek-Cohen Y
AUID- ORCID: http://orcid.org/0000-0001-9549-9040
AD  - School of Nursing, The Academic College of Tel Aviv-Jaffa, Tel Aviv, Israel
      ybokek@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - ethics
OT  - health workforce
OT  - kidneys
OT  - malpractice
COIS- Competing interests: None declared.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/07/30 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2020/02/17 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
AID - medethics-2019-105593 [pii]
AID - 10.1136/medethics-2019-105593 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 28. pii: medethics-2019-105593. doi:
      10.1136/medethics-2019-105593.


PMID- 32723747
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 28
TI  - Systematic survey of the causal language use in systematic reviews of
      observational studies: a study protocol.
PG  - e038571
LID - 10.1136/bmjopen-2020-038571 [doi]
AB  - INTRODUCTION: Sometimes, observational studies may provide important evidence
      that allow inferences of causality between exposure and outcome (although on most
      occasions only low certainty evidence). Authors, frequently and perhaps usually
      at the behest of the journals to which they are submitting, avoid using causal
      language when addressing evidence from observational studies. This is true even
      when the issue of interest is the causal effect of an intervention or exposure.
      Clarity of thinking and appropriateness of inferences may be enhanced through the
      use of language that reflects the issue under consideration. The objectives of
      this study are to systematically evaluate the extent and nature of causal
      language use in systematic reviews of observational studies and to relate that to
      the actual intent of the investigation. METHODS AND ANALYSIS: We will conduct a
      systematic survey of systematic reviews of observational studies addressing
      modifiable exposures and their possible impact on patient-important outcomes. We 
      will randomly select 200 reviews published in 2019, stratified in a 1:1 ratio by 
      use and non-use of the Grading of Recommendations Assessment, Development, and
      Evaluation (GRADE). Teams of two reviewers will independently assess study
      eligibility and extract data using a standardised data extraction forms, with
      resolution of disagreement by discussion and, if necessary, by third party
      adjudication. Through examining the inferences, they make in their papers'
      discussion, we will evaluate whether the authors' intent was to address causation
      or association. We will summarise the use of causal language in the study title, 
      abstract, study question and results using descriptive statistics. Finally, we
      will assess whether the language used is consistent with the intention of the
      authors. We will determine whether results in reviews that did or did not use
      GRADE differ. ETHICS AND DISSEMINATION: Ethics approval for this study is not
      required. We will disseminate the results through publication in a peer-reviewed 
      journals. REGISTRATION: Open Science Framework (osf.io/vh8yx).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Han, Mi Ah
AU  - Han MA
AUID- ORCID: 0000-0003-1213-6952
AD  - Department of Preventive Medicine, College of Medicine, Chosun University,
      Gwangju, The Republic of Korea mahan@chosun.ac.kr.
FAU - Guyatt, Gordon
AU  - Guyatt G
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200728
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Causality
MH  - Humans
MH  - *Language
MH  - *Observational Studies as Topic
MH  - Research Design
MH  - Surveys and Questionnaires
PMC - PMC7389485
OTO - NOTNLM
OT  - *basic sciences
OT  - *epidemiology
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/07/30 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038571 [pii]
AID - 10.1136/bmjopen-2020-038571 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 28;10(7):e038571. doi: 10.1136/bmjopen-2020-038571.


PMID- 32723736
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 28
TI  - Reducing paediatric overweight and obesity through motivational interviewing:
      study protocol for a randomised controlled trial in the AAP PROS research
      network.
PG  - e035720
LID - 10.1136/bmjopen-2019-035720 [doi]
AB  - INTRODUCTION: Primary care remains an underused venue for prevention and
      management of paediatric overweight and obesity. A prior trial demonstrated a
      significant impact of paediatrician/nurse practitioner (Ped/NP)-and registered
      dietitian (RD)-delivered motivational interviewing (MI) on child body mass index 
      (BMI). The study described here will test the effectiveness of an enhanced
      version of this primary care-based MI counselling intervention on child BMI.
      METHODS AND ANALYSIS: This cluster randomised effectiveness trial includes 24
      Ped/NPs from 18 paediatric primary care practices that belong to the American
      Academy of Pediatrics (AAP) national Pediatric Research in Office Settings (PROS)
      practice-based research network. To date, practices have been randomised (nine to
      intervention and nine to usual care). Intervention Ped/NPs have been trained in
      MI, behavioural therapy, billing/coding for weight management and study
      procedures. Usual care Ped/NPs received training in billing/coding and study
      procedures only. Children 3- 11 years old with BMI >the 85th percentile were
      identified via electronic health records (EHRs). Parents from intervention
      practices have been recruited and enrolled. Over about 2 years, these parents are
      offered approximately 10 MI-based counselling sessions (about four in person
      sessions with their child's Ped/NP and up to six telephonic sessions with a
      trained RD). The primary outcome is change in child BMI (defined as per cent from
      median BMI for age and sex) over the study period. The primary comparison is
      between eligible children in intervention practices whose parents enrol in the
      study and all eligible children in usual care practices. Data sources will
      include EHRs, billing records, surveys and counselling call notes. ETHICS AND
      DISSEMINATION: Institutional Review Board approval was obtained from the AAP. All
      Ped/NPs provided written informed consent, and intervention group parents
      provided consent and Health Insurance Portability and Accountability Act (HIPAA) 
      authorisation. Findings will be disseminated through peer-reviewed publications, 
      conference presentations and appropriate AAP channels. TRIAL REGISTRATION NUMBER:
      NCT03177148; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wright, Margaret E
AU  - Wright ME
AUID- ORCID: 0000-0002-4410-4157
AD  - Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA
      mewright@uic.edu.
AD  - Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca,
      Illinois, USA.
FAU - Delacroix, Emerson
AU  - Delacroix E
AD  - School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Sonneville, Kendrin R
AU  - Sonneville KR
AD  - School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Considine, Shannon
AU  - Considine S
AD  - School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Proctor, Tim
AU  - Proctor T
AD  - Physician's Computer Company, Winooski, Vermont, USA.
FAU - Steffes, Jennifer
AU  - Steffes J
AD  - Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA.
AD  - Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca,
      Illinois, USA.
FAU - Harris, Donna
AU  - Harris D
AD  - Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA.
AD  - Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca,
      Illinois, USA.
FAU - Shone, Laura P
AU  - Shone LP
AD  - Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA.
AD  - Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca,
      Illinois, USA.
FAU - Woo, Heide
AU  - Woo H
AD  - Department of Paediatrics, University of California Los Angeles, Los Angeles,
      California, USA.
FAU - Vaughan, Roger
AU  - Vaughan R
AD  - Department of Hospital Biostatistics, The Rockefeller University, New york City, 
      New york, USA.
FAU - Grundmeier, Robert W
AU  - Grundmeier RW
AD  - Department of Paediatrics, Children's Hospital of Philadelphia, Philadelphia,
      Pennsylvania, USA.
FAU - Fiks, Alexander G
AU  - Fiks AG
AD  - Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca,
      Illinois, USA.
AD  - Department of Paediatrics, Children's Hospital of Philadelphia, Philadelphia,
      Pennsylvania, USA.
FAU - Stockwell, Melissa S
AU  - Stockwell MS
AD  - Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca,
      Illinois, USA.
AD  - Departments of Pediatrics and Population and Family Health, Columbia University
      Irving Medical Center, New york City, New york, USA.
FAU - Resnicow, Ken
AU  - Resnicow K
AD  - School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03177148
GR  - R01 HL128231/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200728
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Body Mass Index
MH  - Child
MH  - Child, Preschool
MH  - *Clinical Protocols
MH  - Female
MH  - Humans
MH  - Male
MH  - Motivational Interviewing/methods/*standards
MH  - Obesity/psychology/*therapy
MH  - Overweight/psychology/*therapy
MH  - Pediatrics/methods
MH  - Primary Health Care/methods
PMC - PMC7390232
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *paediatrics
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared
EDAT- 2020/07/30 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035720 [pii]
AID - 10.1136/bmjopen-2019-035720 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 28;10(7):e035720. doi: 10.1136/bmjopen-2019-035720.


PMID- 32723734
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 28
TI  - Detection of risk for depression among adolescents in diverse global settings:
      protocol for the IDEA qualitative study in Brazil, Nepal, Nigeria and the UK.
PG  - e034335
LID - 10.1136/bmjopen-2019-034335 [doi]
AB  - INTRODUCTION: Globally, depression is a leading cause of disability among
      adolescents, and suicide rates are increasing among youth. Treatment alone is
      insufficient to address the issue. Early identification and prevention efforts
      are necessary to reduce morbidity and mortality. The Identifying Depression Early
      in Adolescence (IDEA) consortium is developing risk detection strategies that
      incorporate biological, psychological and social factors that can be evaluated in
      diverse global populations. In addition to epidemiological and neuroscience
      research, the IDEA consortium is conducting a qualitative study to explore three 
      domains of inquiry: (1) cultural heterogeneity of biopsychosocial risk factors
      and lived experience of adolescent depression in low-income and middle-income
      countries (LMIC); (2) the feasibility, acceptability and ethics of a risk
      calculator tool for adolescent depression that can be used in LMIC and
      high-income countries and (3) capacity for biological research into biomarkers
      for depression risk among adolescents in LMIC. This is a multisite qualitative
      study being conducted in Brazil, Nepal, Nigeria and the UK. METHODS AND ANALYSIS:
      A systematic set of qualitative methods will be used in this study. The Delphi
      method, Theory of Change (ToC) workshops, key-informant interviews and focus
      group discussions will be used to elicit perspectives on the study topics from a 
      broad range of stakeholders (adolescents, parents, policy-makers, teachers,
      health service providers, social workers and experts). Delphi panellists will
      participate in three survey rounds to generate consensus through facilitated
      feedback. Stakeholders will create ToC models via facilitated workshops in the
      LMIC sites. The framework approach will be used to analyse data from the study.
      ETHICS AND DISSEMINATION: Ethical approvals were received from the Ethics Review 
      Board of George Washington University and from site-specific institutions in
      Brazil, Nepal, Nigeria and the UK. The findings generated from this study will be
      reported in highly accessed, peer-reviewed, scientific and health policy
      journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Wahid, Syed Shabab
AU  - Wahid SS
AUID- ORCID: 0000-0003-0355-0537
AD  - Division of Global Mental Health, George Washington University, Washington,
      District of Columbia, USA.
FAU - Pedersen, Gloria A
AU  - Pedersen GA
AUID- ORCID: 0000-0003-3427-3464
AD  - Division of Global Mental Health, George Washington University, Washington,
      District of Columbia, USA.
FAU - Ottman, Katherine
AU  - Ottman K
AUID- ORCID: 0000-0002-8233-8472
AD  - Division of Global Mental Health, George Washington University, Washington,
      District of Columbia, USA.
FAU - Burgess, Abigail
AU  - Burgess A
AD  - SGDP Centre, King's College London, Institute of Psychiatry, Psychology &
      Neuroscience, London, United Kingdom.
FAU - Gautam, Kamal
AU  - Gautam K
AUID- ORCID: 0000-0001-9401-9359
AD  - Transcultural Psychosocial Organization Nepal, Kathmandu, Nepal.
FAU - Martini, Thais
AU  - Martini T
AD  - Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto
      Alegre, RS, Brazil.
FAU - Viduani, Anna
AU  - Viduani A
AUID- ORCID: 0000-0002-6289-6397
AD  - Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto
      Alegre, RS, Brazil.
FAU - Momodu, Olufisayo
AU  - Momodu O
AD  - Department of Psychiatry, Lagos Island General Hospital, Lagos, Nigeria.
FAU - Lam, Crystal
AU  - Lam C
AD  - Department of Global Health, George Washington University, Washington, District
      of Columbia, USA.
FAU - Fisher, Helen L
AU  - Fisher HL
AUID- ORCID: 0000-0003-4174-2126
AD  - SGDP Centre, King's College London, Institute of Psychiatry, Psychology &
      Neuroscience, London, United Kingdom helen.2.fisher@kcl.ac.uk.
AD  - ESRC Centre for Society and Mental Health, King's College London, London, United 
      Kingdom.
FAU - Kieling, Christian
AU  - Kieling C
AUID- ORCID: 0000-0001-7691-4149
AD  - Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto
      Alegre, RS, Brazil.
AD  - Child & Adolescent Psychiatry Division, Hospital de Clinicas de Porto Alegre,
      Porto Alegre, RS, Brazil.
FAU - Adewuya, Abiodun O
AU  - Adewuya AO
AD  - Department of Behavioural Medicine, Lagos State University College of Medicine,
      Lagos, Nigeria.
FAU - Mondelli, Valeria
AU  - Mondelli V
AUID- ORCID: 0000-0001-8690-6839
AD  - Department of Psychological Medicine, King's College London, Institute of
      Psychiatry, Psychology & Neuroscience, London, United Kingdom.
FAU - Kohrt, Brandon A
AU  - Kohrt BA
AUID- ORCID: 0000-0002-3829-4820
AD  - Division of Global Mental Health, George Washington University, Washington,
      District of Columbia, USA.
LA  - eng
GR  - K01 MH104310/MH/NIMH NIH HHS/United States
GR  - R21 MH111280/MH/NIMH NIH HHS/United States
GR  - MC_PC_MR/R019460/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Brazil
MH  - *Depression/diagnosis/epidemiology
MH  - Humans
MH  - Nepal
MH  - Nigeria
MH  - United Kingdom
MH  - Washington
PMC - PMC7389769
OTO - NOTNLM
OT  - *adolescent
OT  - *depression
OT  - *protective factors
OT  - *qualitative
OT  - *risk factors
COIS- Competing interests: None declared.
EDAT- 2020/07/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034335 [pii]
AID - 10.1136/bmjopen-2019-034335 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 28;10(7):e034335. doi: 10.1136/bmjopen-2019-034335.


PMID- 32723733
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 28
TI  - Estimating direct medical costs of type 2 diabetes mellitus in the Philippines: a
      protocol.
PG  - e025696
LID - 10.1136/bmjopen-2018-025696 [doi]
AB  - INTRODUCTION: Diabetes and its complications are a major cause of morbidity and
      mortality in the Philippines. The prevalence of diabetes in the Philippines has
      increased from 3.4 million in 2010 to 3.7 million in 2017. The government has
      formulated strategies to control this increase, for example, through its
      non-communicable disease prevention and control plan. However, there is scarce
      research on the financial burden of diabetes. Filling this gap may further help
      policymakers to make informed decisions while developing and implementing
      resource planning for relevant interventions. The primary objective of the
      current study is to estimate the direct medical costs associated with type 2
      diabetes mellitus (T2DM). METHODS AND ANALYSIS: This is a 1-year retrospective
      cohort study of patients with T2DM in 2016. Data will be collected from: (1)
      hospital databases from public institutions to estimate the cost of diabetes
      treatment and (2) physician interviews to estimate the cost of management of
      diabetes in outpatient care. We will perform descriptive and comparative analyses
      on direct medical costs and healthcare resource utilisation, stratified by the
      presence of diabetes-associated complications. ETHICS AND DISSEMINATION: Research
      ethics board approval has been obtained from the Department of Health Single
      Joint Research Ethics Board and Cardinal Santos Medical Center Research Ethics
      Review Committee. Findings from the study will be reported in peer-reviewed
      scientific journals and local researcher meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ng, Junice Yi Siu
AU  - Ng JYS
AD  - Real-World Insights, IQVIA, Asia-Pacific, Singapore junice.ng@iqvia.com.
FAU - Clement, Ivan John
AU  - Clement IJ
AD  - Real-World Insights, IQVIA, Asia-Pacific, Singapore.
FAU - Jimeno, Cecilia
AU  - Jimeno C
AD  - Department of Pharmacology and Toxicology, University of the Philippines Manila
      College of Medicine, Manila, Metro Manila, Philippines.
FAU - Sy, Rosa Allyn
AU  - Sy RA
AD  - Section of Endocrinology, Diabetes, Metabolism and Nutrition, Ospital Ng Makati, 
      Makati, Metro Manila, Philippines.
FAU - Mirasol, Roberto
AU  - Mirasol R
AD  - Section of Endocrinology, Diabetes and Metabolism, St. Luke's Medical Center,
      Quezon City, Metro Manila, Philippines.
FAU - De La Pena, Pepito
AU  - De La Pena P
AD  - Division of Internal Medicine, National Kidney and Transplant Institute, Quezon
      City, National Capital Region, Philippines.
FAU - Panelo, Araceli
AU  - Panelo A
AD  - Department of Medicine, University of the East, Ramon Magasaysay Memorial Medical
      Center, Quezon City, Metro Manila, Philippines.
FAU - Tan, Rima
AU  - Tan R
AD  - Institute for Studies on Diabetes Foundation Inc, Marikina City, Metro Manila,
      Philippines.
FAU - Santillan, Melanie
AU  - Santillan M
AD  - Benefits Development and Research Department, Philippine Health Insurance
      Corporation, Manila, Metro Manila, Philippines.
FAU - Bayani, Dana
AU  - Bayani D
AD  - Department of Health, Health Research Division, Health Policy Development and
      Planning Bureau, Manila, Metro Manila, Philippines.
FAU - Wiebols, Erik
AU  - Wiebols E
AD  - Market Access, Health Economics, and Public Affairs, Novo Nordisk Region
      Southeast Asia, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Costs and Cost Analysis
MH  - *Diabetes Complications
MH  - *Diabetes Mellitus, Type 2/epidemiology/therapy
MH  - Humans
MH  - Philippines/epidemiology
MH  - Retrospective Studies
PMC - PMC7389482
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *primary care
OT  - *public health
COIS- Competing interests: JYSN and IJC served as consultants to Novo Nordisk and CJ,
      RAS, RM, PDLP, AP, RT and DB receive research support from Novo Nordisk. EW is an
      employee of Novo Nordisk.
EDAT- 2020/07/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2018-025696 [pii]
AID - 10.1136/bmjopen-2018-025696 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 28;10(7):e025696. doi: 10.1136/bmjopen-2018-025696.


PMID- 32723720
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2561-7605 (Electronic)
IS  - 2561-7605 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Jul 29
TI  - Challenges and Recommendations for the Deployment of Information and
      Communication Technology Solutions for Informal Caregivers: Scoping Review.
PG  - e20310
LID - 10.2196/20310 [doi]
AB  - BACKGROUND: Information and communication technology (ICT)-based solutions have
      the potential to support informal caregivers in home care delivery. However,
      there are many challenges to the deployment of these solutions. OBJECTIVE: The
      aim of this study was to review literature to explore the challenges of the
      deployment of ICT-based support solutions for informal caregivers and provide
      relevant recommendations on how to overcome these challenges. METHODS: A scoping 
      review methodology was used following the Arksey and O'Malley methodological
      framework to map the relevant literature. A search was conducted using PubMed,
      IEEE library, and Scopus. Publication screening and scrutiny were conducted
      following inclusion criteria based on inductive thematic analysis to gain insight
      into patterns of challenges rising from deploying ICT-based support solutions for
      informal caregivers. The analysis took place through an iterative process of
      combining, categorizing, summarizing, and comparing information across studies.
      Through this iterative process, relevant information was identified and coded
      under emergent broader themes as they pertain to each of the research questions. 
      RESULTS: The analysis identified 18 common challenges using a coding scheme
      grouping them under four thematic categories: technology-related, organizational,
      socioeconomic, and ethical challenges. These range from specific challenges
      related to the technological component of the ICT-based service such as design
      and usability of technology, to organizational challenges such as fragmentation
      of support solutions to socioeconomic challenges such as funding of technology
      and sustainability of solutions to ethical challenges around autonomy and privacy
      of data. For each identified challenge, recommendations were created on how to
      overcome it. The recommendations from this study can provide guidance for the
      deployment of ICT-based support solutions for informal caregivers. CONCLUSIONS:
      Despite a growing interest in the potential offered by ICT solutions for informal
      caregiving, diverse and overlapping challenges to their deployment still remain. 
      Designers for ICTs for informal caregivers should follow participatory design and
      involve older informal caregivers in the design process as much as possible. A
      collaboration between designers and academic researchers is also needed to ensure
      ICT solutions are designed with the current empirical evidence in mind. Taking
      actions to build the digital skills of informal caregivers early in the
      caregiving process is crucial for optimal use of available ICT solutions.
      Moreover, the lack of awareness of the potential added-value and trust toward
      ICT-based support solutions requires strategies to raise awareness among all
      stakeholders-including policy makers, health care professionals, informal
      caregivers, and care recipients-about support opportunities offered by ICT. On
      the macro-level, policies to fund ICT solutions that have been shown to be
      effective at supporting and improving informal caregiver health outcomes via
      subsidies or other incentives should be considered.
CI  - (c)Alhassan Yosri Ibrahim Hassan. Originally published in JMIR Aging
      (http://aging.jmir.org), 29.07.2020.
FAU - Hassan, Alhassan Yosri Ibrahim
AU  - Hassan AYI
AUID- ORCID: https://orcid.org/0000-0003-3375-061X
AD  - Centre for Socio-Economic Research on Ageing, Italian National Institute of
      Health & Science on Ageing, Ancona, Italy.
AD  - Department of Economics and Social Sciences, Faculty of Economics "Giorgio Fua", 
      Universita Politecnica delle Marche, Ancona, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200729
PL  - Canada
TA  - JMIR Aging
JT  - JMIR aging
JID - 101740387
PMC - PMC7424480
OTO - NOTNLM
OT  - ICT
OT  - ageing
OT  - digital health
OT  - digital solutions
OT  - eHealth
OT  - health economics
OT  - health technology
OT  - home care
OT  - informal caregivers
OT  - internet
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - v3i2e20310 [pii]
AID - 10.2196/20310 [doi]
PST - epublish
SO  - JMIR Aging. 2020 Jul 29;3(2):e20310. doi: 10.2196/20310.


PMID- 32723487
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1879-1883 (Electronic)
IS  - 0002-9610 (Linking)
VI  - 220
IP  - 5
DP  - 2020 Nov
TI  - Ethical thinking machines in surgery and the requirement for clinical leadership.
PG  - 1372-1374
LID - S0002-9610(20)30427-X [pii]
LID - 10.1016/j.amjsurg.2020.06.073 [doi]
FAU - Buchlak, Quinlan D
AU  - Buchlak QD
AD  - School of Medicine, The University of Notre Dame Australia, Sydney, NSW,
      Australia. Electronic address: quinlan.buchlak1@my.nd.edu.au.
FAU - Esmaili, Nazanin
AU  - Esmaili N
AD  - School of Medicine, The University of Notre Dame Australia, Sydney, NSW,
      Australia; Department of Medicine, University of Toronto, Toronto, ON, Canada;
      Faculty of Engineering and IT, University of Technology Sydney, Ultimo, NSW,
      Australia.
FAU - Leveque, Jean-Christophe
AU  - Leveque JC
AD  - Neuroscience Institute, Virginia Mason Medical Center, Seattle, WA, USA.
FAU - Bennett, Christine
AU  - Bennett C
AD  - School of Medicine, The University of Notre Dame Australia, Sydney, NSW,
      Australia.
FAU - Piccardi, Massimo
AU  - Piccardi M
AD  - Faculty of Engineering and IT, University of Technology Sydney, Ultimo, NSW,
      Australia.
FAU - Farrokhi, Farrokh
AU  - Farrokhi F
AD  - Neuroscience Institute, Virginia Mason Medical Center, Seattle, WA, USA.
LA  - eng
PT  - Editorial
DEP - 20200708
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
SB  - IM
MH  - Clinical Decision-Making/*ethics/methods
MH  - Decision Support Systems, Clinical/*ethics
MH  - Humans
MH  - *Leadership
MH  - Machine Learning/*ethics
MH  - *Patient Safety
MH  - Specialties, Surgical/*ethics/methods
MH  - *Thinking
COIS- Declaration of competing interest All authors have reviewed and approved this
      manuscript and have no relevant financial or other conflicts of interest with
      regard to this research and its publication.
EDAT- 2020/07/30 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2020/06/27 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - S0002-9610(20)30427-X [pii]
AID - 10.1016/j.amjsurg.2020.06.073 [doi]
PST - ppublish
SO  - Am J Surg. 2020 Nov;220(5):1372-1374. doi: 10.1016/j.amjsurg.2020.06.073. Epub
      2020 Jul 8.


PMID- 32723459
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20211015
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 30
IP  - 6
DP  - 2020 Jun
TI  - COVID-19 Pandemic: Public Trust and Guiding Ethics Where Ventilators Equal Lives.
PG  - 74-75
LID - 10.29271/jcpsp.2020.Supp1.S74 [doi]
FAU - Sheikh, Sadaf
AU  - Sheikh S
AD  - Department of Emergency Medicine, Sultan Qaboos University Hospital, Muscat,
      Oman.
FAU - Baig, Muhammad Akbar
AU  - Baig MA
AD  - Department of Emergency Medicine, The Aga Khan University Hospital, Karachi,
      Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - *Decision Making
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Resource Allocation/*ethics
MH  - Respiration, Artificial/*ethics/instrumentation
MH  - SARS-CoV-2
MH  - *Trust
MH  - Ventilators, Mechanical/*supply & distribution
EDAT- 2020/07/30 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/04/04 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - 040579197 [pii]
AID - 10.29271/jcpsp.2020.Supp1.S74 [doi]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2020 Jun;30(6):74-75. doi:
      10.29271/jcpsp.2020.Supp1.S74.


PMID- 32723388
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1471-2288 (Electronic)
IS  - 1471-2288 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 28
TI  - The influence of social media on recruitment to surgical trials.
PG  - 201
LID - 10.1186/s12874-020-01072-1 [doi]
AB  - BACKGROUND: Social media has changed the way surgeons communicate worldwide,
      particularly in dissemination of trial results. However, it is unclear if social 
      media could be used in recruitment to surgical trials. This study aimed to
      investigate the influence of Twitter in promoting surgical recruitment in The
      Emergency Laparotomy and Frailty (ELF) Study. METHODS: The ELF Study was a
      UK-based, prospective, observational cohort that aimed to assess the influence of
      frailty on 90-day mortality in older adults undergoing emergency surgery. A power
      calculation required 500 patients to be recruited to detect a 10% change in
      mortality associated with frailty. A 12-week recruitment period was selected,
      calculated from information submitted by participating hospitals and the numbers 
      of emergency surgeries performed in adults aged > 65 years. A Twitter handle was 
      designed (@ELFStudy) with eye-catching logos to encourage enrolment and inform
      the public and clinicians involved in the study. Twitter Analytics and Twitonomy 
      (Digonomy Pty Ltd) were used to analyse user engagement in relation to patient
      recruitment. RESULTS: After 90 days of data collection, 49 sites from Scotland,
      England and Wales recruited 952 consecutive patients undergoing emergency
      laparotomy, with data logged into a database created on REDCap. Target
      recruitment (n = 500) was achieved by week 11. A total of 591 tweets were
      published by @ELFStudy since its conception, making 218,136 impressions at time
      of writing. The number of impressions (number of times users see a particular
      tweet) prior to March 20th 2017 (study commencement date) was 23,335 (343.2 per
      tweet), compared to the recruitment period with 114,314 impressions (256.3 per
      tweet), ending June 20th 2017. Each additional tweet was associated with an
      increase in recruitment of 1.66 (95%CI 1.36 to 1.97; p < 0.001). CONCLUSION: The 
      ELF Study over-recruited by nearly 100%, reaching over 200,000 people across the 
      U.K. Branding enhanced tweet aesthetics and helped increase tweet engagement to
      stimulate discussion and healthy competition amongst clinicians to aid trial
      recruitment. Other studies may draw from the social media experiences of the ELF 
      Study to optimise collaboration amongst researchers. TRIAL REGISTRATION: This
      study is registered online at www.clinicaltrials.gov (registration number
      NCT02952430 ) and has been approved by the National Health Service Research
      Ethics Committee.
FAU - Bisset, Carly Nichola
AU  - Bisset CN
AUID- ORCID: 0000-0003-3331-4420
AD  - Department of General Surgery, Royal Alexandra Hospital, Paisley, PA2 9PN, UK.
      cbisset@nhs.net.
FAU - Carter, Ben
AU  - Carter B
AD  - Department of Biostatistics and Health Informatics, Institute of Psychiatry,
      Psychology & Neuroscience, King's College London, London, UK.
FAU - Law, Jennifer
AU  - Law J
AD  - Department of General Surgery, Blackpool Victoria Hospital, Blackpool, UK.
FAU - Hewitt, Jonathan
AU  - Hewitt J
AD  - Department of Population Medicine, Cardiff University, Cardiff, UK.
FAU - Parmar, Kat
AU  - Parmar K
AD  - Department of General Surgery, Manchester Royal Infirmary, Manchester, UK.
FAU - Moug, Susan Joan
AU  - Moug SJ
AD  - Department of General Surgery, Royal Alexandra Hospital, Paisley, PA2 9PN, UK.
CN  - ELF Study Group Collaborative Authorship
LA  - eng
SI  - ClinicalTrials.gov/NCT02952430
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - England
TA  - BMC Med Res Methodol
JT  - BMC medical research methodology
JID - 100968545
SB  - IM
MH  - Aged
MH  - England
MH  - Humans
MH  - Prospective Studies
MH  - Scotland
MH  - *Social Media
MH  - State Medicine
PMC - PMC7388470
OTO - NOTNLM
OT  - *Recruitment
OT  - *Social media
OT  - *Surgical trials
IR  - Ross B
FIR - Ross, Bryony
IR  - Oleksiewicz J
FIR - Oleksiewicz, Julia
IR  - Fearnhead N
FIR - Fearnhead, Nicola
IR  - Jump C
FIR - Jump, Christopher
IR  - Boyle J
FIR - Boyle, Jemma
IR  - Shaw A
FIR - Shaw, Alex
IR  - Barker J
FIR - Barker, Jonathan
IR  - Hughes J
FIR - Hughes, Jane
IR  - Randall J
FIR - Randall, Jonathan
IR  - Tonga I
FIR - Tonga, Isileli
IR  - Kynaston J
FIR - Kynaston, James
IR  - Boal M
FIR - Boal, Matthew
IR  - Eardley N
FIR - Eardley, Nicola
IR  - Kane E
FIR - Kane, Elizabeth
IR  - Reader H
FIR - Reader, Harriet
IR  - Mahapatra SR
FIR - Mahapatra, Sunanda Roy
IR  - Garner-Jones M
FIR - Garner-Jones, Michael
IR  - Tan JJ
FIR - Tan, Jessica Juliana
IR  - Mohamed S
FIR - Mohamed, Said
IR  - George R
FIR - George, Rina
IR  - Whiteman E
FIR - Whiteman, Ed
IR  - Malik K
FIR - Malik, Kamran
IR  - Smart CJ
FIR - Smart, Christopher J
IR  - Bogdan M
FIR - Bogdan, Monica
IR  - Chaudhury MP
FIR - Chaudhury, Madhu Parna
IR  - Sharma V
FIR - Sharma, Videha
IR  - Subar D
FIR - Subar, Daren
IR  - Patel P
FIR - Patel, Panna
IR  - Chok SM
FIR - Chok, Sok-Moi
IR  - Lim E
FIR - Lim, Evelyn
IR  - Adhiyaman V
FIR - Adhiyaman, Vedamurthy
IR  - Davies G
FIR - Davies, Glesni
IR  - Ross E
FIR - Ross, Ellen
IR  - Maitra R
FIR - Maitra, Rudra
IR  - Steele CW
FIR - Steele, Colin W
IR  - Roxburgh C
FIR - Roxburgh, Campbell
IR  - Griffiths S
FIR - Griffiths, Shelly
IR  - Blencowe NS
FIR - Blencowe, Natalie S
IR  - Kirkham EN
FIR - Kirkham, Emily N
IR  - Abraham JS
FIR - Abraham, John S
IR  - Griffiths K
FIR - Griffiths, Kirsty
IR  - Abdulaal Y
FIR - Abdulaal, Yasser
IR  - Iqbal MR
FIR - Iqbal, Muhammad Rafaih
IR  - Tarazi M
FIR - Tarazi, Munir
IR  - Hill J
FIR - Hill, James
IR  - Khan A
FIR - Khan, Azam
IR  - Farrell I
FIR - Farrell, Ian
IR  - Conn G
FIR - Conn, Gemma
IR  - Patel J
FIR - Patel, Jugal
IR  - Reddy H
FIR - Reddy, Hyder
IR  - Sarveswaran J
FIR - Sarveswaran, Janahan
IR  - Arunachalam L
FIR - Arunachalam, Lakshmanan
IR  - Malik A
FIR - Malik, Afaq
IR  - Ponchietti L
FIR - Ponchietti, Luca
IR  - Pawelec K
FIR - Pawelec, Krystian
IR  - Goh YM
FIR - Goh, Yan Mei
IR  - Vitish-Sharma P
FIR - Vitish-Sharma, Parveen
IR  - Saad A
FIR - Saad, Ahmed
IR  - Smyth E
FIR - Smyth, Edward
IR  - Crees A
FIR - Crees, Amy
IR  - Merker L
FIR - Merker, Louise
IR  - Bashir N
FIR - Bashir, Nahida
IR  - Williams G
FIR - Williams, Gethin
IR  - Hayes J
FIR - Hayes, Jennifer
IR  - Walters K
FIR - Walters, Kelly
IR  - Harries R
FIR - Harries, Rhiannon
IR  - Singh R
FIR - Singh, Rahulpreet
IR  - Henderson NA
FIR - Henderson, Nikola A
IR  - Polignano FM
FIR - Polignano, Francesco M
IR  - Knight B
FIR - Knight, Ben
IR  - Alder L
FIR - Alder, Louise
IR  - Kenchington A
FIR - Kenchington, Alexandra
IR  - Goh YL
FIR - Goh, Yan Li
IR  - Dicurzio I
FIR - Dicurzio, Ilaria
IR  - Griffiths E
FIR - Griffiths, Ewen
IR  - Alani A
FIR - Alani, Ahmed
IR  - Knight K
FIR - Knight, Katrina
IR  - MacGoey P
FIR - MacGoey, Patrick
IR  - Ng GS
FIR - Ng, Guat Shi
IR  - Mackenzie N
FIR - Mackenzie, Naomi
IR  - Maitra I
FIR - Maitra, Ishaan
IR  - Moug S
FIR - Moug, Susan
IR  - Ong K
FIR - Ong, Kelly
IR  - McGrath D
FIR - McGrath, Daniel
IR  - Gammeri E
FIR - Gammeri, Emanuele
IR  - Lafaurie G
FIR - Lafaurie, Guillame
IR  - Faulkner G
FIR - Faulkner, Gemma
IR  - Benedetto GD
FIR - Benedetto, Gabriele Di
IR  - McGovern J
FIR - McGovern, Julia
IR  - Subramanian B
FIR - Subramanian, Bharathi
IR  - Narang SK
FIR - Narang, Sunil Kumar
IR  - Nowers J
FIR - Nowers, Jennifer
IR  - Smart NJ
FIR - Smart, Neil J
IR  - Daniels IR
FIR - Daniels, Ian R
IR  - Varcada M
FIR - Varcada, Massimo
IR  - Gala T
FIR - Gala, Tanzeela
IR  - Cornish J
FIR - Cornish, Julie
IR  - Barber Z
FIR - Barber, Zoe
IR  - O'Neill S
FIR - O'Neill, Stephen
IR  - McGregor R
FIR - McGregor, Richard
IR  - Robertson AG
FIR - Robertson, Andrew G
IR  - Paterson-Brown S
FIR - Paterson-Brown, Simon
IR  - Raymond T
FIR - Raymond, Thomas
IR  - Thaha MA
FIR - Thaha, Mohamed A
IR  - English WJ
FIR - English, William J
IR  - Forde CT
FIR - Forde, Cillian T
IR  - Paine H
FIR - Paine, Heidi
IR  - Morawala A
FIR - Morawala, Alpa
IR  - Date R
FIR - Date, Ravindra
IR  - Casey P
FIR - Casey, Patrick
IR  - Bolton T
FIR - Bolton, Thomas
IR  - Gleaves X
FIR - Gleaves, Xuan
IR  - Fasuyi J
FIR - Fasuyi, Joshua
IR  - Durakovic S
FIR - Durakovic, Sanja
IR  - Dunstan M
FIR - Dunstan, Matt
IR  - Allen S
FIR - Allen, Sophie
IR  - Riga A
FIR - Riga, Angela
IR  - Epstein J
FIR - Epstein, Jonathan
IR  - Pearce L
FIR - Pearce, Lyndsay
IR  - Gaines E
FIR - Gaines, Emily
IR  - Howe A
FIR - Howe, Anthony
IR  - Choonara H
FIR - Choonara, Halima
IR  - Dewi F
FIR - Dewi, Ffion
IR  - Bennett J
FIR - Bennett, Joanne
IR  - King E
FIR - King, Emile
IR  - McCarthy K
FIR - McCarthy, Kathryn
IR  - Taylor G
FIR - Taylor, Greg
IR  - Harris D
FIR - Harris, Dean
IR  - Nageswaran H
FIR - Nageswaran, Hari
IR  - Stimpson A
FIR - Stimpson, Amy
IR  - Siddiqui K
FIR - Siddiqui, Kamran
IR  - In Lim L
FIR - In Lim, Lay
IR  - Ray C
FIR - Ray, Christopher
IR  - Smith L
FIR - Smith, Laura
IR  - McColl G
FIR - McColl, Gillian
IR  - Rahman M
FIR - Rahman, Mohammed
IR  - Kler A
FIR - Kler, Aaron
IR  - Sharma A
FIR - Sharma, Abhi
IR  - Parmar K
FIR - Parmar, Kat
IR  - Patel N
FIR - Patel, Neil
IR  - Crofts P
FIR - Crofts, Perry
IR  - Baldari C
FIR - Baldari, Claudio
IR  - Thomas R
FIR - Thomas, Rhys
IR  - Stechman M
FIR - Stechman, Michael
IR  - Aldridge R
FIR - Aldridge, Roland
IR  - O'Kelly J
FIR - O'Kelly, James
IR  - Wilson G
FIR - Wilson, Graeme
IR  - Gallegos N
FIR - Gallegos, Nicholas
IR  - Kalaiselvan R
FIR - Kalaiselvan, Ramya
IR  - Rajaganeshan R
FIR - Rajaganeshan, Rajasundaram
IR  - Mackenzie A
FIR - Mackenzie, Aliya
IR  - Naik P
FIR - Naik, Prashant
IR  - Singh K
FIR - Singh, Kaushiki
IR  - Gandraspulli H
FIR - Gandraspulli, Harinath
IR  - Wilson J
FIR - Wilson, Jeremy
IR  - Hancorn K
FIR - Hancorn, Kate
IR  - Khawaja A
FIR - Khawaja, Amir
IR  - Nicholas F
FIR - Nicholas, Felix
IR  - Marks T
FIR - Marks, Thomas
IR  - Abbott C
FIR - Abbott, Cameron
IR  - Chandler S
FIR - Chandler, Susan
EDAT- 2020/07/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s12874-020-01072-1 [doi]
AID - 10.1186/s12874-020-01072-1 [pii]
PST - epublish
SO  - BMC Med Res Methodol. 2020 Jul 28;20(1):201. doi: 10.1186/s12874-020-01072-1.


PMID- 32723317
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 28
TI  - MANTRA: development and localization of a mobile educational health game
      targeting low literacy players in low and middle income countries.
PG  - 1171
LID - 10.1186/s12889-020-09246-8 [doi]
AB  - BACKGROUND: Mobile technology is increasingly important for delivering public
      health interventions to remote populations. This research study developed,
      piloted, and assessed a serious game for mobile devices that teaches geohazard,
      maternal, and neonatal health messages. This unique mHealth intervention aimed at
      low-literacy audiences in low resource settings is part of the Maternal and
      Neonatal Technologies in Rural Areas (MANTRA) project: Increasing maternal and
      child health resilience before, during, and after disasters using mobile
      technology in Nepal. METHODS: The serious game was developed through a
      co-creation process between London and Kathmandu based researchers by email and
      video-calling, and face-to-face with local stakeholders in Nepal. The process
      identified core needs, developed appropriate pictograms and mechanics, and
      tailored the pilot serious game to the local cultural context. Evaluations and
      feedback from end users took place in rural villages and suburban Kathmandu in
      Province Three. Field evaluation sessions used mixed methods. Researchers
      observed game play and held focus group discussions to elicit qualitative
      feedback and understand engagement, motivation, and usability, and conducted a
      paired pre- and post-game knowledge assessment. RESULTS: The MANTRA serious game 
      is contextualized to rural Nepal. The game teaches 28 learning objectives in
      three modules: maternal health, neonatal health, and geohazards, through picture 
      matching with immediate audio and visual feedback. User feedback from focus
      groups demonstrated high engagement, motivation, and usability of the game.
      CONCLUSIONS: This MANTRA study is a unique mHealth intervention of a serious game
      to teach core health and geohazards messages to low-literacy audiences in rural
      Nepal. Although the mobile game is tailored for this specific context, the
      developmental process and insights could be transferable to the development of
      other games-based interventions and contextualized for any part of the world.
      Successfully targeting this low-literacy and illiterate audience makes the MANTRA
      development process the first of its kind and a novel research endeavor with
      potential for widespread impact and adoption following further game development. 
      TRIAL REGISTRATION: This project was approved by the University College London
      Ethics Committee in London, United Kingdom [10547/001], and the Nepal Health
      Research Council in Kathmandu, Nepal [Reg. No. 105/2017]. All participants
      provided informed written consent.
FAU - Mueller, Sonja
AU  - Mueller S
AUID- ORCID: http://orcid.org/0000-0001-6529-5135
AD  - Institute for Risk and Disaster Reduction, University College London, Gower
      Street, London, WC1E 6BT, UK. sonja.mueller.14@ucl.ac.uk.
AD  - Centre for Digital Public Health in Emergencies (dPHE), University College
      London, Gower Street, London, WC1E 6BT, UK. sonja.mueller.14@ucl.ac.uk.
FAU - Soriano, Delphine
AU  - Soriano D
AD  - Institute for Risk and Disaster Reduction, University College London, Gower
      Street, London, WC1E 6BT, UK.
AD  - Centre for Digital Public Health in Emergencies (dPHE), University College
      London, Gower Street, London, WC1E 6BT, UK.
FAU - Boscor, Andrei
AU  - Boscor A
AD  - Institute for Risk and Disaster Reduction, University College London, Gower
      Street, London, WC1E 6BT, UK.
AD  - Centre for Digital Public Health in Emergencies (dPHE), University College
      London, Gower Street, London, WC1E 6BT, UK.
FAU - Saville, Naomi
AU  - Saville N
AD  - Institute for Global Health, University College London, 30 Guilford Street,
      London, WC1N 1EH, UK.
FAU - Arjyal, Abriti
AU  - Arjyal A
AD  - Health Research and Social Development Forum, Prasuti Griha Marg, Kathmandu,
      44600, Nepal.
FAU - Baral, Sushil
AU  - Baral S
AD  - Health Research and Social Development Forum, Prasuti Griha Marg, Kathmandu,
      44600, Nepal.
FAU - Fordham, Maureen
AU  - Fordham M
AD  - Institute for Risk and Disaster Reduction, University College London, Gower
      Street, London, WC1E 6BT, UK.
AD  - Centre for Gender and Disaster, University College London, Gower Street, London, 
      WC1E 6BT, UK.
FAU - Hearn, Gareth
AU  - Hearn G
AD  - Hearn GeoServe, Ltd, London, UK.
FAU - Le Masson, Virginie
AU  - Le Masson V
AD  - Overseas Development Institute, 203 Blackfriars Road, London, SE1 8NJ, UK.
FAU - Kayastha, Rachya
AU  - Kayastha R
AD  - Institute for Risk and Disaster Reduction, University College London, Gower
      Street, London, WC1E 6BT, UK.
AD  - Institute for Global Health, University College London, 30 Guilford Street,
      London, WC1N 1EH, UK.
FAU - Kostkova, Patty
AU  - Kostkova P
AD  - Institute for Risk and Disaster Reduction, University College London, Gower
      Street, London, WC1E 6BT, UK.
AD  - Centre for Digital Public Health in Emergencies (dPHE), University College
      London, Gower Street, London, WC1E 6BT, UK.
LA  - eng
GR  - 173142/Research Councils UK
PT  - Journal Article
DEP - 20200728
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Developing Countries
MH  - Female
MH  - Health Education/*methods
MH  - Humans
MH  - Literacy
MH  - Mobile Applications/*statistics & numerical data
MH  - Nepal
MH  - *Play and Playthings
MH  - Rural Health Services/*organization & administration
MH  - Rural Population/statistics & numerical data
MH  - Telemedicine/methods
PMC - PMC7385876
OTO - NOTNLM
OT  - Educational game
OT  - Serious game
OT  - mHealth
EDAT- 2020/07/30 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/30 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12889-020-09246-8 [doi]
AID - 10.1186/s12889-020-09246-8 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Jul 28;20(1):1171. doi: 10.1186/s12889-020-09246-8.


PMID- 32723312
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 28
TI  - Pre- and during- labour predictors of dystocia in active phase of labour: a
      case-control study.
PG  - 425
LID - 10.1186/s12884-020-03113-5 [doi]
AB  - BACKGROUND: Labour dystocia (LD) is associated with maternal and foeto-neonatal
      complications and increased rate of caesarean section. There are scant studies on
      predictive factors of labour dystocia in Iran, as well as in other countries.
      Therefore, this study aimed to identify the predictive factors of LD using an
      integrated and collaborative pre- and during- labour factors to help formulate
      more effective intervention strategies for prevention and management of LD.
      METHODS: In this case-control study, 350 women with and 350 women without LD,
      matched individually in terms of parity and hospital, were compared. The
      participants were in active labor, had singleton pregnancy, live foetus with a
      cephalic presentation, gestational age of 37(+ 0)-41(+ 6) weeks, and were
      hospitalized for vaginal birth in two teaching hospitals in Tabriz, Iran. Data
      related to the socio-demographic characteristics, anxiety status (using the
      Spielberger State Anxiety Inventory), and woman dehydration were collected at
      cervical dilatation between 4 and 6 cm (before dystocia detection) and the other 
      data at different phases of labour, and after birth (before discharge). The
      multivariate logistic regression was used to determine the predictors. RESULTS:
      The predictors of LD were severe [OR 58.0 (95% CI 26.9 to 125.1)] and moderate
      [8.6 (4.2 to 17.4)] anxiety, woman dehydration > 3 h [18.67 (4.0 to 87.3)] and
      </= 3 h [2.8 (1.7 to 4.8], insufficient support by the medical staff in the
      delivery room [5.8 (1.9 to 17.9)], remifentanil administration [3.1 (1.5 to
      6.2)], labour induction [4.2 (2.5 to 7.2], low income [2.0 (1.2 to 3.3)], woman's
      height < 160 cm [2.0 (1.1 to 3.3)], and woman age of 16-20 y [0.3 (0.2 to 0.6)]. 
      The proportion of the variance explained by all these factors was 74%.
      CONCLUSION: The controllable predictors, such as woman anxiety and dehydration,
      and insufficient support from medical staff during labour were strongly
      associated with the risk of LD. Therefore, it seems that responding to woman
      physical, psychological, and supportive needs during labour can play a
      significant role in LD prevention and control. ETHICAL CODE:
      IR.TBZMED.REC.1397.624.
FAU - Nahaee, Jila
AU  - Nahaee J
AD  - Students' Research Committee, Faculty of Nursing and Midwifery, Tabriz University
      of Medical Sciences, Tabriz, Iran.
FAU - Abbas-Alizadeh, Fatemeh
AU  - Abbas-Alizadeh F
AD  - Women's Reproductive Health Research Center, Tabriz University of Medical
      Sciences, Tabriz, Iran.
FAU - Mirghafourvand, Mojgan
AU  - Mirghafourvand M
AD  - Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Tabriz, Iran.
FAU - Mohammad-Alizadeh-Charandabi, Sakineh
AU  - Mohammad-Alizadeh-Charandabi S
AUID- ORCID: http://orcid.org/0000-0003-4785-9333
AD  - Social Determinants of Health Research Center, Department of Midwifery, Faculty
      of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.
      alizades@tbzmed.ac.ir.
LA  - eng
GR  - code IR.TBZMED.REC.1397.624./This study was financially supported by Tabriz
      University of Medical Sciences in Iran.
PT  - Journal Article
DEP - 20200728
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anxiety/physiopathology
MH  - Case-Control Studies
MH  - Dehydration/physiopathology
MH  - Dystocia/*etiology
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Iran
MH  - Labor Stage, First
MH  - Labor, Induced/adverse effects
MH  - Labor, Obstetric
MH  - Parity
MH  - Parturition
MH  - Pregnancy
MH  - Young Adult
PMC - PMC7388514
OTO - NOTNLM
OT  - Childbirth
OT  - Iran
OT  - Labour dystocia
OT  - Predictor
OT  - Risk factor
EDAT- 2020/07/30 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/07/30 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.1186/s12884-020-03113-5 [doi]
AID - 10.1186/s12884-020-03113-5 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Jul 28;20(1):425. doi: 10.1186/s12884-020-03113-5.


PMID- 32723158
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201218
IS  - 1744-4144 (Electronic)
IS  - 1385-4046 (Linking)
VI  - 34
IP  - 7-8
DP  - 2020 Oct - Nov
TI  - Initial changes in neuropsychologists clinical practice during the COVID-19
      pandemic: A survey study.
PG  - 1251-1266
LID - 10.1080/13854046.2020.1800098 [doi]
AB  - Objective: In light of the COVID-19 pandemic, a majority of clinicians have had
      to quickly and dramatically alter their clinical practices. Two surveys were
      administered on 3/26/2020 and 3/30/2020, respectively, to document immediate
      changes and challenges in clinical practice.Method: Two surveys were administered
      between 3/26/2020 and 3/30/2020, via SurveyMonkey and Google Forms, asking
      clinicians questions pertaining to practice issues during the early stages of the
      COVID-19 pandemic. Quantitative responses from the second survey were stratified 
      by clinical setting (Medical Hospital vs. Private Practice) prior to analysis.
      Qualitative, free-response items were coded by the authors to better understand
      immediate changes in practice and other concerns.Results: 266 neuropsychologists 
      completed Survey 1 and 230 completed Survey 2. Results suggest that practices
      immediately moved towards remote service provision. A meaningful proportion of
      clinicians and their staff were immediately affected economically by the
      pandemic, with clinicians in private practice differentially affected.
      Furthermore, a small but significant minority of respondents faced ethical
      dilemmas related to service provision and expressed concerns with initial
      communication from their employment organizations. Respondents requested clear
      best-practice guidelines from neuropsychological practice
      organizations.Conclusions: It is clear that field of neuropsychology has
      drastically shifted clinical practices in response to COVID-19 and is likely to
      continue to evolve. While these responses were collected in the early stages of
      stay-at-home orders, policy changes continue to occur and it is paramount that
      practice organizations consider the initial challenges expressed by clinicians
      when formulating practice recommendations and evaluating the clinical utility of 
      telehealth services.
FAU - Marra, David E
AU  - Marra DE
AUID- ORCID: 0000-0002-7392-6555
AD  - Department of Clinical and Health Psychology, University of Florida, McKnight
      Brain Institute, Gainesville, FL, USA.
FAU - Hoelzle, James B
AU  - Hoelzle JB
AD  - Department of Psychology, Marquette University, Milwaukee, WI, USA.
FAU - Davis, Jeremy J
AU  - Davis JJ
AD  - Division of Physical Medicine and Rehabilitation, University of Utah School of
      Medicine, Salt Lake City, UT, USA.
FAU - Schwartz, Eben S
AU  - Schwartz ES
AD  - Department of Psychology, Marquette University, Milwaukee, WI, USA.
LA  - eng
PT  - Journal Article
DEP - 20200729
PL  - England
TA  - Clin Neuropsychol
JT  - The Clinical neuropsychologist
JID - 8806548
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Communication
MH  - Coronavirus Infections/*epidemiology/psychology/*therapy
MH  - Employment/methods/trends
MH  - Female
MH  - Humans
MH  - Male
MH  - Neuropsychological Tests
MH  - Neuropsychology/methods/*trends
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/psychology/*therapy
MH  - SARS-CoV-2
MH  - *Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - *COVID-19
OT  - *clinical practice
OT  - *neuropsychology
OT  - *practice survey
EDAT- 2020/07/30 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1080/13854046.2020.1800098 [doi]
PST - ppublish
SO  - Clin Neuropsychol. 2020 Oct - Nov;34(7-8):1251-1266. doi:
      10.1080/13854046.2020.1800098. Epub 2020 Jul 29.


PMID- 32722669
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - A computational fluid dynamics modelling of maternal-fetal heat exchange and
      blood flow in the umbilical cord.
PG  - e0231997
LID - 10.1371/journal.pone.0231997 [doi]
AB  - Human fetal thermoregulation, maternal-fetal heat exchange, and the role of the
      umbilical cord in these processes are not well understood. Ethical and technical 
      limitations have restricted current knowledge to animal studies, that do not
      reflect human morphology. Here, we present the first 3-dimensional computational 
      model of the human umbilical cord with finite element analysis, aiming to compute
      the maternal-fetal heat exchange. By modelling both the umbilical vein and the
      two umbilical arteries, we found that the coiled geometry of the umbilical
      artery, in comparison with the primarily straight umbilical vein, affects blood
      flow parameters such as velocity, pressure, temperature, shear strain rate and
      static entropy. Specifically, by enhancing the heat transfer coefficient, we have
      shown that the helical structure of the umbilical arteries plays a vital role in 
      the temperature drop of the blood, along the arterial length from the fetal end
      to the placental end. This suggests the importance of the umbilical cord
      structure in maternal-fetal heat exchange and fetal heat loss, opening the way
      for future research with modified models and scenarios, as the basis for early
      detection of potential heat-transfer related complications, and/or assurance of
      fetal wellbeing.
FAU - Kasiteropoulou, Dorothea
AU  - Kasiteropoulou D
AD  - Department of Environmental Sciences, University of Thessaly, Larissa, Greece.
FAU - Topalidou, Anastasia
AU  - Topalidou A
AUID- ORCID: 0000-0003-0280-6801
AD  - Research in Childbirth and Health Unit, School of Community Health and Midwifery,
      Faculty of Health and Wellbeing, University of Central Lancashire, Preston,
      United Kingdom.
FAU - Downe, Soo
AU  - Downe S
AD  - Research in Childbirth and Health Unit, School of Community Health and Midwifery,
      Faculty of Health and Wellbeing, University of Central Lancashire, Preston,
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200728
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Blood Flow Velocity/physiology
MH  - Computer Simulation
MH  - Entropy
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - *Maternal-Fetal Exchange
MH  - *Models, Biological
MH  - Pregnancy
MH  - Pressure
MH  - Temperature
MH  - Umbilical Cord/*blood supply
MH  - Umbilical Veins/blood supply
PMC - PMC7386597
COIS- The authors declare that they have no competing interests.
EDAT- 2020/07/30 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
AID - 10.1371/journal.pone.0231997 [doi]
AID - PONE-D-20-01604 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 28;15(7):e0231997. doi: 10.1371/journal.pone.0231997.
      eCollection 2020.


PMID- 32722508
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-328X (Print)
IS  - 2076-328X (Linking)
VI  - 10
IP  - 8
DP  - 2020 Jul 25
TI  - Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service
      at a Community Substance Misuse Service.
LID - E121 [pii]
LID - 10.3390/bs10080121 [doi]
AB  - (1) Introduction: Drug-related deaths in the UK are at concerning high levels.
      The unknown content and purity of illicit substances can cause unpredictable
      adverse effects and thus a public health risk with no sign of abating. On-site
      drug checking is a public health strategy that has previously been implemented,
      predominantly in festival settings, but without Home Office licensing. (2) Aims: 
      The aim of this study was to pilot the UK's first pharmacist-led, Home
      Office-licensed community drug checking service. (3) Methods: A bespoke protocol 
      incorporating legally, professionally and ethically binding documents was
      implemented. This free, confidential service ran between February and March 2019,
      was available to anyone over 18 who were purposefully recruited, gave informed
      consent and agreed to relinquish their drug sample. Samples were checked on-site 
      within an established Substance Misuse Service (SMS) using a handheld Raman
      spectrometer to determine likely drug content and adulterants. In parallel,
      participants completed a questionnaire about their substance use and the drug
      sample(s) being tested. A pharmacist-led multidisciplinary approach was adopted
      to discuss the analytical findings. Informed by the results of the analysis and
      the questionnaire, people who used the service received tailored harm reduction
      advice. (4) Results and Discussion: The pilot operated for a total of four days
      over four weeks. Eleven people visited and relinquished a total of thirteen
      samples. Half of the participants had previously overdosed and were known to the 
      SMS. Seventy per cent were male, all were White British individuals, 30% were
      employed and two people disclosed visiting from another nearby town. Samples
      included what was thought to be heroin, synthetic cannabinoids, stimulants,
      benzodiazepines and LSD and none required activation of the "alerts cascade"
      process. Most participants drank alcohol regularly and the concomitant use of
      traditional illicit drugs and prescribed medication (including opioids,
      anxiolytics and antidepressants) with sedating profiles was common. Given some of
      the ethical decisions and interpretation of the results, specialist pharmacist
      involvement was deemed essential. (5) Conclusions: This pilot demonstrated the
      proof-of-concept that a pharmacist-led Home Office-licensed drug checking service
      can be successfully implemented in community SMSs.
FAU - Guirguis, Amira
AU  - Guirguis A
AD  - Swansea University Medical School, Institute of Life Sciences, Swansea
      University, Swansea SA2-8PP, Wales, UK.
AD  - Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, 
      University of Hertfordshire, Hatfield AL10-9AB, UK.
FAU - Gittins, Rosalind
AU  - Gittins R
AD  - Humankind Charity, Inspiration House, Unit 22, Bowburn North Industrial Estate,
      Durham DH6 5PF, UK.
FAU - Schifano, Fabrizio
AU  - Schifano F
AD  - Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, 
      University of Hertfordshire, Hatfield AL10-9AB, UK.
LA  - eng
GR  - 11.101336.3367/University of Hertfordshire
PT  - Journal Article
DEP - 20200725
PL  - Switzerland
TA  - Behav Sci (Basel)
JT  - Behavioral sciences (Basel, Switzerland)
JID - 101576826
PMC - PMC7465824
OTO - NOTNLM
OT  - Home Office
OT  - Raman spectroscopy
OT  - cannabinoids
OT  - drug checking
OT  - drug testing
OT  - harm reduction
OT  - opiates
OT  - opioids
OT  - overdose
OT  - pill testing
OT  - substance misuse
COIS- Page: 17The authors declare no conflict of interest.
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/06/25 00:00 [received]
PHST- 2020/07/12 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - bs10080121 [pii]
AID - 10.3390/bs10080121 [doi]
PST - epublish
SO  - Behav Sci (Basel). 2020 Jul 25;10(8). pii: bs10080121. doi: 10.3390/bs10080121.


PMID- 32722156
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201027
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Jul 24
TI  - Job Satisfaction among Swedish Pharmacists.
LID - E127 [pii]
LID - 10.3390/pharmacy8030127 [doi]
AB  - Understanding the role of pharmacists' job satisfaction is important because a
      lack of job satisfaction might have negative impacts on patient care and safety. 
      The aim of this cross-sectional study was to explore and compare job satisfaction
      among pharmacists graduating from the pharmacy programs at Umea University,
      Sweden. Data concerning job satisfaction and associated factors were collected
      using an alumni survey conducted among pharmacists graduating between 2015 and
      2018. Ethical committee approval is not required for this type of study in
      Sweden. A majority (92.6%) of the pharmacy graduates were female. A majority of
      the graduates (91.4%) were satisfied with their job most of the time or all of
      the time, which was similar to a previous investigation among pharmacists
      graduating between 2006 and 2014. High access to continuous professional
      development (CPD) was associated with higher job satisfaction (odds ratio (OR):
      18.717 (95% confidence interval (CI): 1.685-207.871)). In total, 65.6% considered
      access to CPD to be high (i.e., satisfactory to very good). Variables like
      gender, age, employee category, workplace, years since graduation, and income did
      not affect job satisfaction. Knowledge regarding job satisfaction will enable
      employers to respond to employees' needs, decrease turnover, and improve the work
      environment.
FAU - Mattsson, Sofia
AU  - Mattsson S
AD  - Department of Integrative Medical Biology, Umea University, SE-901 87 Umea,
      Sweden.
FAU - Gustafsson, Maria
AU  - Gustafsson M
AD  - Department of Integrative Medical Biology, Umea University, SE-901 87 Umea,
      Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC7559484
OTO - NOTNLM
OT  - continuous professional development
OT  - job satisfaction
OT  - pharmacy graduate
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
AID - pharmacy8030127 [pii]
AID - 10.3390/pharmacy8030127 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2020 Jul 24;8(3). pii: pharmacy8030127. doi:
      10.3390/pharmacy8030127.


PMID- 32721891
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2210-2612 (Print)
IS  - 2210-2612 (Linking)
VI  - 73
DP  - 2020
TI  - Conjoined twins: A report of four cases.
PG  - 289-293
LID - S2210-2612(20)30475-2 [pii]
LID - 10.1016/j.ijscr.2020.06.072 [doi]
AB  - BACKGROUND: Conjoined twin is a rarely seen congenital anomaly associated with
      significant morbidity and mortality. The most common types of conjoined twins are
      thoracopagus. Conjoined twins are either symmetrical twins or asymmetrical or
      heteropagus. This report records the successful separation of 2 cases of
      asymmetrical twins and one symmetrical twin with fused livers and diaphragm and
      communicating peritoneal cavities. PATIENTS AND METHODS: This study amended and
      strictly followed the ethical guidelines of the Helsinki declaration, our study
      included 4 case reports on conjoined twins (CT), 2 male and three female
      patients; 3 of them were parasitic and one was conjoined. We operated upon 2
      parasitics and one conjoined. The 1st case died preoperatively. RESULTS: Four
      living children is our result. CONCLUSION: As connections between the bowel and
      bone of the parasite and the respective organs in the autosite are often absent, 
      the parasite could be excised easily without any effect on the autosite. We
      recommend the separation of the parasite and the autosite as early as possible.
      In many cases, surgery results in the death of one or both of the conjoined
      twins, particularly if they are joined at the head or share a vital organ. Our
      separated twins are yet the youngest living separated twins. TRIAL REGISTRATION: 
      ClinicalTrials.gov Identifier: NCT03388684.
CI  - Copyright (c) 2020 Assiut University faculty of medicine. Published by Elsevier
      Ltd.. All rights reserved.
FAU - Takrouney, Mohammed Hamada
AU  - Takrouney MH
AD  - Pediatric Surgery Department, Faculty of Medicine, Assiut University, Assiut,
      Egypt. Electronic address: m.takrouney1988@aun.edu.eg.
FAU - Ibrahim, Ibrahim Ali
AU  - Ibrahim IA
AD  - Pediatric Surgery Department, Faculty of Medicine, Assiut University, Assiut,
      Egypt. Electronic address: Dr.ibrahimali@yahoo.com.
FAU - Abdel-Ghaffar, Hala Saad
AU  - Abdel-Ghaffar HS
AD  - Anesthesia and Intensive Care Department, Faculty of Medicine, Assiut University,
      Assiut, Egypt. Electronic address: hallasaad@yahoo.com.
FAU - Abdel-Wahhab, Ahmed Ibrahim
AU  - Abdel-Wahhab AI
AD  - Cardiothoracic Surgery Department, Faculty of Medicine, Assiut University,
      Assiut, Egypt. Electronic address: wahhabeg@yahoo.com.
FAU - Mostafa, Mahmoud Mohamed
AU  - Mostafa MM
AD  - Pediatric Surgery Department, Faculty of Medicine, Assiut University, Assiut,
      Egypt. Electronic address: profmmmostafa@gmail.com.
FAU - Ali, Wesam Nashat
AU  - Ali WN
AD  - Anesthesia and Intensive Care Department, Faculty of Medicine, Assiut University,
      Assiut, Egypt. Electronic address: dr.wesamnashat2015@gmail.com.
FAU - Abd-Elaal, Mohamed Sayed
AU  - Abd-Elaal MS
AD  - Anesthesia and Intensive Care Department, Faculty of Medicine, Assiut University,
      Assiut, Egypt. Electronic address: Saikl-201S@hotmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03388684
PT  - Journal Article
DEP - 20200620
PL  - Netherlands
TA  - Int J Surg Case Rep
JT  - International journal of surgery case reports
JID - 101529872
PMC - PMC7388169
OTO - NOTNLM
OT  - Conjoined twins
OT  - Heteropagus
OT  - Omphalopagus
OT  - Parasitic twins
OT  - Siame
EDAT- 2020/07/30 06:00
MHDA- 2020/07/30 06:01
CRDT- 2020/07/30 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/06/14 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2020/07/30 06:01 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - S2210-2612(20)30475-2 [pii]
AID - 10.1016/j.ijscr.2020.06.072 [doi]
PST - ppublish
SO  - Int J Surg Case Rep. 2020;73:289-293. doi: 10.1016/j.ijscr.2020.06.072. Epub 2020
      Jun 20.


PMID- 32721847
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210726
IS  - 1879-0380 (Electronic)
IS  - 0959-437X (Linking)
VI  - 62
DP  - 2020 Jun
TI  - Generations of genomes: advances in paleogenomics technology and engagement for
      Indigenous people of the Americas.
PG  - 91-96
LID - S0959-437X(20)30110-6 [pii]
LID - 10.1016/j.gde.2020.06.010 [doi]
AB  - For decades, scientists have collected genomic information from Indigenous
      peoples and their ancestors with the goal of elucidating human migration events, 
      understanding ancestral origins, and identifying ancestral variants contributing 
      to disease. However, such studies may not have offered much benefit to the
      Indigenous groups who contributed DNA, and many have instead perpetuated
      stereotypes and other harms. With recent advances in genomic technology
      facilitating the study of both ancient and present-day DNA, researchers and
      Indigenous communities have new opportunities to begin collaboratively addressing
      important questions about human health and history. Yet, while there are
      increased efforts to ethically engage Indigenous communities, more work is still 
      needed as the discipline struggles to absolve itself of the racialized science
      and extractive biocolonialism that defined its past.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Tsosie, Krystal S
AU  - Tsosie KS
AD  - Vanderbilt University, Nashville, TN 37325, USA; Native BioData Consortium, Eagle
      Butte, SD 57625, USA.
FAU - Begay, Rene L
AU  - Begay RL
AD  - Centers for American Indian and Alaska Native Health, University of Colorado
      Anschutz Medical Campus, Aurora, CO 80045, USA.
FAU - Fox, Keolu
AU  - Fox K
AD  - Department of Anthropology, University of California, San Diego, La Jolla, CA
      92093, USA; Department of Global Health, University of California, San Diego, La 
      Jolla, CA 92093, USA; Indigenous Futures Lab, University of California, San
      Diego, La Jolla, CA 92093, USA; Native BioData Consortium, Eagle Butte, SD 57625,
      USA.
FAU - Garrison, Nanibaa' A
AU  - Garrison NA
AD  - Institute for Society and Genetics, University of California, Los Angeles, Los
      Angeles, CA 90095, USA; Institute for Precision Health, David Geffen School of
      Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA;
      General Internal Medicine and Health Services Research, David Geffen School of
      Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
      Electronic address: nanibaa@socgen.ucla.edu.
LA  - eng
GR  - K01 HG008818/HG/NHGRI NIH HHS/United States
GR  - P20 GM103442/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200725
PL  - England
TA  - Curr Opin Genet Dev
JT  - Current opinion in genetics & development
JID - 9111375
SB  - IM
MH  - *Genome, Human
MH  - Genomics/*methods
MH  - *Human Migration
MH  - Humans
MH  - Indigenous Peoples/*genetics
MH  - *Paleontology
MH  - Population Groups/*genetics
MH  - United States
PMC - PMC7484015
MID - NIHMS1608230
EDAT- 2020/07/30 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - S0959-437X(20)30110-6 [pii]
AID - 10.1016/j.gde.2020.06.010 [doi]
PST - ppublish
SO  - Curr Opin Genet Dev. 2020 Jun;62:91-96. doi: 10.1016/j.gde.2020.06.010. Epub 2020
      Jul 25.


PMID- 32721655
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1873-7838 (Electronic)
IS  - 0010-0277 (Linking)
VI  - 203
DP  - 2020 Oct
TI  - Do ethics classes influence student behavior? Case study: Teaching the ethics of 
      eating meat.
PG  - 104397
LID - S0010-0277(20)30216-X [pii]
LID - 10.1016/j.cognition.2020.104397 [doi]
AB  - Do university ethics classes influence students' real-world moral choices? We
      aimed to conduct the first controlled study of the effects of ordinary
      philosophical ethics classes on real-world moral choices, using non-self-report, 
      non-laboratory behavior as the dependent measure. We assigned 1332 students in
      four large philosophy classes to either an experimental group on the ethics of
      eating meat or a control group on the ethics of charitable giving. Students in
      each group read a philosophy article on their assigned topic and optionally
      viewed a related video, then met with teaching assistants for 50-minute group
      discussion sections. They expressed their opinions about meat ethics and
      charitable giving in a follow-up questionnaire (1032 respondents after
      exclusions). We obtained 13,642 food purchase receipts from campus restaurants
      for 495 of the students, before and after the intervention. Purchase of meat
      products declined in the experimental group (52% of purchases of at least $4.99
      contained meat before the intervention, compared to 45% after) but remained the
      same in the control group (52% both before and after). Ethical opinion also
      differed, with 43% of students in the experimental group agreeing that eating the
      meat of factory farmed animals is unethical compared to 29% in the control group.
      We also attempted to measure food choice using vouchers, but voucher redemption
      rates were low and no effect was statistically detectable. It remains unclear
      what aspect of instruction influenced behavior.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Schwitzgebel, Eric
AU  - Schwitzgebel E
AD  - University of California at Riverside, USA. Electronic address: eschwitz@ucr.edu.
FAU - Cokelet, Bradford
AU  - Cokelet B
AD  - University of Kansas, USA.
FAU - Singer, Peter
AU  - Singer P
AD  - Princeton University, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200725
PL  - Netherlands
TA  - Cognition
JT  - Cognition
JID - 0367541
SB  - IM
MH  - Animals
MH  - Humans
MH  - Meat
MH  - *Morals
MH  - *Students
MH  - Surveys and Questionnaires
MH  - Teaching
OTO - NOTNLM
OT  - *Consumer choice
OT  - *Ethics instruction
OT  - *Experimental philosophy
OT  - *Moral psychology
OT  - *Moral reasoning
OT  - *Vegetarianism
COIS- Declaration of competing interest None.
EDAT- 2020/07/30 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/07/30 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/04 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - S0010-0277(20)30216-X [pii]
AID - 10.1016/j.cognition.2020.104397 [doi]
PST - ppublish
SO  - Cognition. 2020 Oct;203:104397. doi: 10.1016/j.cognition.2020.104397. Epub 2020
      Jul 25.


PMID- 32721240
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1945-0257 (Electronic)
IS  - 1945-0257 (Linking)
VI  - 24
IP  - 9
DP  - 2020 Sep
TI  - Intelligent Ratio: A New Method for Carrier and Newborn Screening in Spinal
      Muscular Atrophy.
PG  - 569-577
LID - 10.1089/gtmb.2020.0085 [doi]
AB  - Aim: Spinal muscular atrophy (SMA) is an inherited, autosomal recessive
      neuromuscular disease that causes high morbidity and mortality. The prevalence is
      1-2/100,000, while the incidence is 1/6000-1/10,000 among live births. Due to the
      high carrier frequency (1/40-1/60) of SMA-associated alleles, screening can
      prevent new cases. The aim of the current study was to present the development of
      a new, quantitative, real-time, polymerase chain reaction (PCR)-based screening
      test that uses an intelligent ratio (IR) for analyses, as well as a comparison of
      the results with the gold standard. Materials and Methods: Included in the study 
      were 100 patients with various risk genotypes for survivor motor neuron 1 (SMN1) 
      and SMN2 genes whose genetics had been previously investigated using multiplex
      ligation probe amplification (MLPA). A combination of the 5' nuclease assay and
      allele-specific PCR was used to quantify the SMN1 deletion mutation with
      real-time PCR using the FII gene as a reference. All of the optimized standards
      were adapted to software that provided automated analyses. The approval number of
      the institutional ethics committee for the study is 2012-KAEK-15/1497. Results:
      The results of the screening test were completely compatible with the MLPA
      results; it achieved 100% sensitivity and specificity compared with the gold
      standard. The use of the IR in the analyses provided a user-independent method
      that quickly and accurately provided results, regardless of the amount of DNA
      used of the extraction method. Conclusion: Carrier or newborn screening of SMA is
      essential in countries that have high rates of consanguineous marriages. The
      screening test presented in this study that uses FII as a reference gene proved
      to be low-cost, reliable, applicable, accurate, and amenable to use in an
      automated system for SMA screening.
FAU - Cavdarli, Busranur
AU  - Cavdarli B
AD  - Department of Medical Genetics, Ankara Numune Training and Research Hospital,
      Ankara, Turkey.
FAU - Ozturk, Fatma Nihal
AU  - Ozturk FN
AD  - Department of Medical Genetics, Dr Sami Ulus Gynecology Obstetrics and Child
      Health and Diseases Training and Research Hospital, Ankara, Turkey.
FAU - Guntekin Ergun, Sezen
AU  - Guntekin Ergun S
AD  - Department of Biological Sciences, Molecular Biology and Genetics, Middle East
      Technical University, Ankara, Turkey.
FAU - Ergun, Mehmet Ali
AU  - Ergun MA
AD  - Department of Medical Genetics, Faculty of Medicine, Gazi University, Ankara,
      Turkey.
FAU - Dogan, Ozlem
AU  - Dogan O
AD  - SNP Biotechnology Ltd., Hacettepe University Technopolis, Ankara, Turkey.
FAU - Percin, Emriye Ferda
AU  - Percin EF
AD  - Department of Medical Genetics, Faculty of Medicine, Gazi University, Ankara,
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - United States
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
RN  - 0 (DNA Primers)
RN  - 0 (SMN1 protein, human)
RN  - 0 (Survival of Motor Neuron 1 Protein)
SB  - IM
MH  - Alleles
MH  - DNA Primers/genetics
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Muscular Atrophy, Spinal/*diagnosis/genetics
MH  - Neonatal Screening/*methods
MH  - Real-Time Polymerase Chain Reaction/methods
MH  - Sensitivity and Specificity
MH  - Survival of Motor Neuron 1 Protein/*genetics/metabolism
MH  - Turkey
OTO - NOTNLM
OT  - carrier screenig
OT  - new kit
OT  - newborn screening
OT  - spinal muscular atrophy
EDAT- 2020/07/30 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1089/gtmb.2020.0085 [doi]
PST - ppublish
SO  - Genet Test Mol Biomarkers. 2020 Sep;24(9):569-577. doi: 10.1089/gtmb.2020.0085.
      Epub 2020 Jul 24.


PMID- 32720763
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20200731
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 7
DP  - 2020 Jul
TI  - [DOCTORS' ATTITUDES TOWARDS EUTHANASIA].
PG  - 477-482
AB  - BACKGROUND: Euthanasia is a highly controversial issue due to ethical, legal,
      religious, social and psychological aspects. OBJECTIVES: To examine the attitudes
      of physicians regarding euthanasia and the background variables related to these 
      attitudes. METHODS: A survey was administered to 131 physicians working at
      Barzilai Medical Center. Physicians were queried about their attitudes regarding 
      euthanasia. RESULTS: Most doctors have encountered terminally ill patients within
      their work or personal lives; 62% agreed that a person has the right to decide
      whether to expedite their own death; 56% thought they should accept a patient's
      request to prevent/stop life-preserving treatment; 53% agreed that euthanasia
      should be allowed, while about 20% thought that in any case, doctors should
      preserve the patient's life, even despite the patient's wishes to die. Forty
      percent of doctors faced the dilemma of ordering DNR (Do Not Resuscitate). Only
      half of the physicians had a familiarity with the law, and 41% didn't know if a
      DNR procedure exists in their department. Doctors specializing in internal
      professions held more positive attitudes toward euthanasia than other
      professions. In addition, the doctor's years of experience, level of secularity, 
      and number of encounters with terminally ill patients each had a positive
      correlation with their respective attitudes towards euthanasia. DISCUSSION:
      Attitudes toward euthanasia are quite positive, although data shows a conflict of
      values: the sacredness of human life versus the desire to alleviate the patient's
      suffering and to respect their autonomy. It is recommended to re-discuss the law,
      and to inform physicians that the DNR procedure exists.
FAU - Dopelt, Keren
AU  - Dopelt K
AD  - Department of Public Health, School of Health Professions, Ashkelon Academic
      College, Ashkelon.
AD  - Department of Health Systems Management, School of Public Health, Faculty of
      Health Sciences, Ben Gurion University of the Negev, Beer Sheva.
FAU - Cohen, Dganit
AU  - Cohen D
AD  - Department of Public Health, School of Health Professions, Ashkelon Academic
      College, Ashkelon.
AD  - Barzilai University Medical Center, Ashkelon.
FAU - Amar, Einat
AU  - Amar E
AD  - Department of Public Health, School of Health Professions, Ashkelon Academic
      College, Ashkelon.
AD  - Department of Health Systems Management, School of Public Health, Faculty of
      Health Sciences, Ben Gurion University of the Negev, Beer Sheva.
FAU - Levy, Chezy
AU  - Levy C
AD  - Department of Health Systems Management, School of Public Health, Faculty of
      Health.
AD  - Ministry of Health.
LA  - heb
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - *Attitude of Health Personnel
MH  - *Euthanasia
MH  - Humans
MH  - *Physicians
MH  - Surveys and Questionnaires
EDAT- 2020/07/29 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Jul;159(7):477-482.


PMID- 32720570
OWN - NLM
STAT- Publisher
LR  - 20200728
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 28
TI  - Self-care as an ethical obligation for nurses.
PG  - 969733020940371
LID - 10.1177/0969733020940371 [doi]
AB  - As members of the largest and most trusted healthcare profession, nurses are role
      models and critical partners in the ongoing quest for the health of their
      patients. Findings from the American Nurses Association Health Risk Appraisal
      suggested that nurses give the best patient care when they are operating at the
      peak of their own wellness. They also revealed that 68% of the surveyed nurses
      place their patients' health, safety, and wellness before their own. Globally,
      several nursing codes of ethics include the requirement of self-care. Often,
      these codes embed the responsibility to protect and promote one's own health
      within the clearly described obligation to provide safe patient care. The
      American Nurses Association Code of Ethics for Nurses is unique in that it states
      explicitly that nurses must adopt self-care as a duty to self in addition to
      their duty to provide care to patients. One of the basic assumptions of Watson's 
      Philosophy and Science of Caring is that caring science is the essence of nursing
      and the foundational disciplinary core of the profession. Watson's theory of
      human caring provides support for the engagement in self-care. Two important
      value assumptions of Watson's Caritas are that "we have to learn how to offer
      caring, love, forgiveness, compassion, and mercy to ourselves before we can offer
      authentic caring and love to others" and we also must "treat ourselves with
      loving-kindness and equanimity, gentleness, and dignity before we can accept,
      respect, and care for others within a professional caring-healing model."
      Embedded within several caritas processes is an outline for a holistic approach
      to caring for self and others that can guide nurses to improve their mental,
      physical, emotional, and spiritual health.
FAU - Linton, Mary
AU  - Linton M
AUID- ORCID: https://orcid.org/0000-0002-5785-5400
AD  - University of Michigan-Flint, USA.
FAU - Koonmen, Jamie
AU  - Koonmen J
AD  - University of Michigan-Flint, USA.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
OTO - NOTNLM
OT  - Caritas
OT  - Watson
OT  - duty
OT  - ethics
OT  - nursing
OT  - self-care
EDAT- 2020/07/29 06:00
MHDA- 2020/07/29 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/07/29 06:00 [medline]
AID - 10.1177/0969733020940371 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 28:969733020940371. doi: 10.1177/0969733020940371.


PMID- 32720566
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Indigenous nurses' practice realities of cultural safety and socioethical
      nursing.
PG  - 1472-1483
LID - 10.1177/0969733020940376 [doi]
AB  - BACKGROUND: Persistent healthcare emphasis on universal moral philosophy has not 
      advantaged indigenous and marginalised groups. Centralising cultural components
      of care is vital to provide ethical healthcare services to indigenous people and 
      cultural minorities internationally. Woods' theoretical explication of how nurses
      can integrate cultural safety into a socioethical approach signposts ethical
      practice that reflects culturally congruent relational care and systemic
      critique. AIM: To demonstrate the empirical utility of Woods' ethical elements of
      cultural safety within a socioethical model, through analysis of indigenous
      nurses' practice realities in Aotearoa New Zealand. RESEARCH DESIGN: The study
      used a qualitative indigenous narrative inquiry. PARTICIPANTS AND RESEARCH
      CONTEXT: Participants were recruited nationally. Twelve Maori registered nurses
      and nurse practitioners were interviewed. All participants provided direct care
      in either primary or secondary health services. ETHICAL CONSIDERATIONS: Research 
      approval was gained from the Human Ethics Committee of the lead author's tertiary
      institution. Participation was voluntary, and written informed consent was
      obtained. FINDINGS: Analysis highlighted the following: (1) cultural needs, which
      for Maori were integral to care, were easily subsumed by clinical care being
      prioritised; (2) ethical care by non-indigenous nurses requires critical
      reflection about broader equity issues that impact Maori disengagement from
      healthcare; (3) retention of indigenous nurses was seen as essential because
      their advocacy and the cultural 'fit' for Maori contributed to positive
      healthcare outcomes; and (4) committed leadership ensured culturally safe care
      was not eroded through workplace efficiencies. DISCUSSION: The data provide rich 
      representation of Woods' model. The data indicate that nurses must engage
      reflexively with a relational ethic of care and social justice dimensions in
      order to deliver culturally safe care. CONCLUSION: Woods' model provides a
      critical lens for nurses to examine their relational practice and systemic
      factors that enhance or detract from culturally safe care when caring for members
      of any indigenous group.
FAU - Hunter, Kiri
AU  - Hunter K
AUID- ORCID: https://orcid.org/0000-0001-5931-6518
AD  - 5734Nelson Marlborough Institute of Technology, New Zealand.
FAU - Cook, Catherine
AU  - Cook C
AD  - 1410Auckland University of Technology, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Cultural Competency/*psychology
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Indigenous Peoples
MH  - Interviews as Topic/methods
MH  - Native Hawaiian or Other Pacific Islander/*ethnology/psychology
MH  - New Zealand/ethnology
MH  - Nurses/*psychology/statistics & numerical data
MH  - Qualitative Research
OTO - NOTNLM
OT  - Cultural safety
OT  - Maori
OT  - equity
OT  - indigenous
OT  - registered nurse
OT  - social justice
OT  - socioethical
EDAT- 2020/07/29 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 10.1177/0969733020940376 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1472-1483. doi: 10.1177/0969733020940376. Epub 2020
      Jul 28.


PMID- 32720523
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 0840-4704 (Print)
IS  - 0840-4704 (Linking)
VI  - 33
IP  - 6
DP  - 2020 Nov
TI  - The importance of a positive moral culture within healthcare organizations.
PG  - 293-295
LID - 10.1177/0840470420943406 [doi]
AB  - Organizations possess a moral agency that affects all aspects of the care they
      provide and reflects the perception of morality within the organization. In
      practice, the method in which moral agency is applied and maintained within an
      organization directly influences its moral culture. Organizations function
      through a series of systems that work dynamically to achieve success. In order to
      implement the systems effectively, all employees, at every level, are responsible
      for cooperating and working together to uphold the mission, vision, and values of
      an organization, thereby contributing to a positive moral culture. Considerations
      must be made at a high organizational level, as well as at each individual level 
      within an institution. This ensures that at its core, a healthcare organization
      is considered ethical, and all staff, students, and volunteers within it are
      acting in accordance with the established moral belief system. By creating and
      maintaining a positive moral culture, everyone benefits: patients receive
      effective and compassionate care, employees experience a feeling of pride in
      their work, and the community being served develops a relationship of trust with 
      their local healthcare institution.
FAU - Lukich, Nikolija
AU  - Lukich N
AD  - Department of Clinical and Organizational Ethics, Champlain Centre for Health
      Care Ethics, 27337The Ottawa Hospital, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200728
PL  - United States
TA  - Healthc Manage Forum
JT  - Healthcare management forum
JID - 8805307
MH  - *Delivery of Health Care
MH  - Empathy
MH  - Health Facilities
MH  - Humans
MH  - *Morals
MH  - Organizational Culture
MH  - Organizations
EDAT- 2020/07/29 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 10.1177/0840470420943406 [doi]
PST - ppublish
SO  - Healthc Manage Forum. 2020 Nov;33(6):293-295. doi: 10.1177/0840470420943406. Epub
      2020 Jul 28.


PMID- 32720394
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20220417
IS  - 1540-8191 (Electronic)
IS  - 0886-0440 (Linking)
VI  - 35
IP  - 10
DP  - 2020 Oct
TI  - Sex-related differences in outcomes after coronary artery bypass surgery-A
      patient-level pooled analysis of randomized controlled trials: rationale and
      study protocol.
PG  - 2754-2758
LID - 10.1111/jocs.14903 [doi]
AB  - INTRODUCTION: The impact of sex on the outcomes after coronary artery bypass
      grafting (CABG) is controversial. The majority of CABG studies are
      retrospectively collected clinical or registry data, women comprise only a
      minority, and the reported findings represent the male predominated cohort. This 
      individual patient meta-analysis is aimed at evaluating sex-related differences
      in outcomes after CABG using high quality data from randomized controlled trials 
      (RCTs). METHODS AND ANALYSIS: A systematic literature search will be performed to
      identify all CABG RCTs (minimum follow-up: 5 years). Detailed specification for
      the minimum deidentified patient records' data requirements will be provided to
      RCT primary contact to request their deidentified data for pooling. The pooled
      analysis will follow the prospective register of systematic reviews (PROSPERO)
      and the preferred reporting items for systematic reviews and meta-analyses for
      individual patient data systematic reviews (PRISMA-IPD) recommendations and will 
      compare sex-related outcomes after CABG. The main hypothesis is that outcomes
      after CABG are worse in women than in men. We will also test whether treatment
      effects for off-pump and the use of multiple arterial grafts are present within
      each sex, and also, whether there are differential treatment effects between
      sexes. The primary endpoint will be a composite of all-cause mortality,
      myocardial infarction, stroke, and repeat revascularization at long-term follow
      up. ETHICS AND DISSEMINATION: Ethics approval and participant consent for the
      study will be obtained locally by each study team if needed. Data will be
      disseminated and submitted to peer-reviewed scientific journals and meetings
      irrespective of study outcome.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Gaudino, Mario
AU  - Gaudino M
AUID- ORCID: http://orcid.org/0000-0003-4680-0815
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Alexander, John H
AU  - Alexander JH
AD  - Department of Medicine, Duke Clinical Research Institute, Duke University Medical
      Center, Durham, North Carolina.
FAU - Egorova, Natalia
AU  - Egorova N
AD  - Department of Population Health Science and Policy, Icahn School of Medicine at
      Mount Sinai, New York, New York.
FAU - Kurlansky, Paul
AU  - Kurlansky P
AD  - Department of Surgery, Center for Innovation and Outcomes Research, Columbia
      University Medical Center, New York, New York.
FAU - Lamy, Andre
AU  - Lamy A
AD  - Department of Surgery, Population Health Research Institute, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Bakaeen, Faisal
AU  - Bakaeen F
AUID- ORCID: http://orcid.org/0000-0001-9546-936X
AD  - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland,
      Ohio.
FAU - Hameed, Irbaz
AU  - Hameed I
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Di Franco, Antonino
AU  - Di Franco A
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Demetres, Michelle
AU  - Demetres M
AD  - Samuel J. Wood Library and C.V. Starr Biomedical Information Center, Weill
      Cornell Medicine, New York, New York.
FAU - Robinson, N Bryce
AU  - Robinson NB
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Chikwe, Joanna
AU  - Chikwe J
AD  - Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai
      Medical Center, Los Angeles, California.
FAU - Lawton, Jennifer S
AU  - Lawton JS
AD  - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University
      School of Medicine, Baltimore, Maryland.
FAU - Devereaux, P J
AU  - Devereaux PJ
AD  - Department of Surgery, Population Health Research Institute, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Taggart, David P
AU  - Taggart DP
AD  - Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of 
      Oxford, Oxford, UK.
FAU - Flather, Marcus
AU  - Flather M
AD  - Research and Development Unit, Norfolk and Norwich University Hospitals NHS
      Foundation Trust, Norwich, UK.
FAU - Reents, Wilko
AU  - Reents W
AD  - Department Cardiac Surgery, Cardiovascular Center Bad Neustadt/Saale, Bad
      Neustadt, Saale, Germany.
FAU - Boening, Andreas
AU  - Boening A
AD  - Department of Cardiovascular Surgery, Justus-Liebig University Giessen, Giessen, 
      Germany.
FAU - Diegeler, Anno
AU  - Diegeler A
AD  - Department Cardiac Surgery, Cardiovascular Center Bad Neustadt/Saale, Bad
      Neustadt, Saale, Germany.
FAU - Girardi, Leonard N
AU  - Girardi LN
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.
FAU - Fremes, Stephen E
AU  - Fremes SE
AUID- ORCID: http://orcid.org/0000-0003-1723-3049
AD  - Department of Surgery, Schulich Heart Centre Sunnybrook Health Sciences Centre,
      University of Toronto, Toronto, Canada.
FAU - Benedetto, Umberto
AU  - Benedetto U
AD  - Bristol Heart Institute, University of Bristol, Bristol, UK.
LA  - eng
GR  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200727
PL  - United States
TA  - J Card Surg
JT  - Journal of cardiac surgery
JID - 8908809
SB  - IM
MH  - Clinical Trial Protocols as Topic
MH  - Coronary Artery Bypass/*methods/mortality
MH  - Coronary Artery Bypass, Off-Pump
MH  - Coronary Artery Disease/mortality/*surgery
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction
MH  - Postoperative Complications
MH  - Randomized Controlled Trials as Topic
MH  - Reoperation
MH  - Sex Factors
MH  - Stroke
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CABG
OT  - outcomes
OT  - sex
EDAT- 2020/07/29 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/15 00:00 [received]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 10.1111/jocs.14903 [doi]
PST - ppublish
SO  - J Card Surg. 2020 Oct;35(10):2754-2758. doi: 10.1111/jocs.14903. Epub 2020 Jul
      27.


PMID- 32720241
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211002
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 35
IP  - 10
DP  - 2020 Oct
TI  - When Disease Strikes Leaders: What Should We Know?
PG  - 3053-3056
LID - 10.1007/s11606-020-06060-1 [doi]
AB  - Diseases of heads of state can affect national policy. Yet, cases of cover-up are
      numerous and involve not only dictatorships but also open and democratic
      societies. No system of full disclosure is currently in place to ensure that the 
      public has access to all the information needed to establish whether a candidate 
      to the presidency or an elected leader can discharge the powers and duties of the
      office. Hence, this essay reviews how the illnesses of democratically elected
      heads of state have changed history; addresses how to ensure greater
      transparency, so that leaders will not only be unable to conceal incapacitating
      disabilities, but also be removed from office once impaired; and lastly discusses
      how illness does not necessarily imply incapacitation, even though separating the
      two might often be difficult. These are issues of great relevance to national
      politics and medical ethics. They are particularly important as the 2020
      presidential election is underway, and four out of the five leading candidates
      are well into their 70s.
FAU - Mangione, Salvatore
AU  - Mangione S
AUID- ORCID: http://orcid.org/0000-0001-5180-0858
AD  - Sidney Kimmel Medical College of Thomas Jefferson University , Philadelphia, PA, 
      USA. Salvatore.Mangione@Jefferson.edu.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
SB  - IM
MH  - Humans
MH  - *Politics
MH  - United States
PMC - PMC7573095
EDAT- 2020/07/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 10.1007/s11606-020-06060-1 [doi]
AID - 10.1007/s11606-020-06060-1 [pii]
PST - ppublish
SO  - J Gen Intern Med. 2020 Oct;35(10):3053-3056. doi: 10.1007/s11606-020-06060-1.
      Epub 2020 Jul 27.


PMID- 32719657
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - Prospect of Stem Cell Therapy and Regenerative Medicine in Osteoporosis.
PG  - 430
LID - 10.3389/fendo.2020.00430 [doi]
AB  - The field of cell therapy and regenerative medicine can hold the promise of
      restoring normal tissues structure and function. Additionally, the main targets
      of stem cell-based therapies are chronic diseases and lifelong disabilities
      without definite cures such as osteoporosis. Osteoporosis as one of the important
      causes of morbidity in older men and post-menopausal women is characterized by
      reduced bone quantity or skeletal tissue atrophy that leads to an increased risk 
      of osteoporotic fractures. The common therapeutic methods for osteoporosis only
      can prevent the loss of bone mass and recover the bone partially. Nevertheless,
      stem cell-based therapy is considered as a new approach to regenerate the bone
      tissue. Herein, mesenchymal stem cells as pivotal candidates for regenerative
      medicine purposes especially bone regeneration are the most common type of cells 
      with anti-inflammatory, immune-privileged potential, and less ethical concerns
      than other types of stem cells which are investigated in osteoporosis. Based on
      several findings, the mesenchymal stem cells effectiveness near to a great extent
      depends on their secretory function. Indeed, they can be involved in the
      establishment of normal bone remodeling via initiation of specific molecular
      signaling pathways. Accordingly, the aim herein was to review the effects of stem
      cell-based therapies in osteoporosis.
CI  - Copyright (c) 2020 Arjmand, Sarvari, Alavi-Moghadam, Payab, Goodarzi, Gilany,
      Mehrdad and Larijani.
FAU - Arjmand, Babak
AU  - Arjmand B
AD  - Cell Therapy and Regenerative Medicine Research Center, Endocrinology and
      Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical
      Sciences, Tehran, Iran.
AD  - Metabolomics and Genomics Research Center, Endocrinology and Metabolism
      Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences,
      Tehran, Iran.
FAU - Sarvari, Masoumeh
AU  - Sarvari M
AD  - Metabolomics and Genomics Research Center, Endocrinology and Metabolism
      Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences,
      Tehran, Iran.
FAU - Alavi-Moghadam, Sepideh
AU  - Alavi-Moghadam S
AD  - Cell Therapy and Regenerative Medicine Research Center, Endocrinology and
      Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Payab, Moloud
AU  - Payab M
AD  - Obesity and Eating Habits Research Center, Endocrinology and Metabolism
      Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences,
      Tehran, Iran.
FAU - Goodarzi, Parisa
AU  - Goodarzi P
AD  - Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Gilany, Kambiz
AU  - Gilany K
AD  - Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
AD  - Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer
      Institute, Academic Center for Education, Culture and Research (ACER), Tehran,
      Iran.
AD  - Reproductive Immunology Research Center, Avicenna Research Institute, Academic
      Center for Education, Culture and Research (ACER), Tehran, Iran.
FAU - Mehrdad, Neda
AU  - Mehrdad N
AD  - Elderly Health Research Center, Endocrinology and Metabolism Population Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism
      Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200703
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Animals
MH  - *Bone Regeneration
MH  - Humans
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Mesenchymal Stem Cells/*cytology
MH  - Osteoporosis/*therapy
MH  - *Regenerative Medicine
PMC - PMC7347755
OTO - NOTNLM
OT  - *cell therapy
OT  - *chronic diseases
OT  - *mesenchymal stem cells
OT  - *osteoporosis
OT  - *regenerative medicine
EDAT- 2020/07/29 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/07/29 06:00
PHST- 2019/08/27 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - 10.3389/fendo.2020.00430 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Jul 3;11:430. doi: 10.3389/fendo.2020.00430.
      eCollection 2020.


PMID- 32719491
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20210727
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jul 27
TI  - The 'Threat of Scream' paradigm: a tool for studying sustained physiological and 
      subjective anxiety.
PG  - 12496
LID - 10.1038/s41598-020-68889-0 [doi]
AB  - Progress in understanding the emergence of pathological anxiety depends on the
      availability of paradigms effective in inducing anxiety in a simple, consistent
      and sustained manner. The Threat-of-Shock paradigm has typically been used to
      elicit anxiety, but poses ethical issues when testing vulnerable populations.
      Moreover, it is not clear from past studies whether anxiety can be sustained in
      experiments of longer durations. Here, we present empirical support for an
      alternative approach, the 'Threat-of-Scream' paradigm, in which shocks are
      replaced by screams. In two studies, participants were repeatedly exposed to
      blocks in which they were at risk of hearing aversive screams at any time vs.
      blocks in which they were safe from screams. Contrary to previous
      'Threat-of-Scream' studies, we ensured that our screams were neither harmful nor 
      intolerable by presenting them at low intensity. We found higher subjective
      reports of anxiety, higher skin conductance levels, and a positive correlation
      between the two measures, in threat compared to safe blocks. These results were
      reproducible and we found no significant change over time. The unpredictable
      delivery of low intensity screams could become an essential part of a psychology 
      toolkit, particularly when investigating the impact of anxiety in a diversity of 
      cognitive functions and populations.
FAU - Beaurenaut, Morgan
AU  - Beaurenaut M
AD  - Laboratoire de Neurosciences Cognitives et Computationnelles, ENS, PSL Research
      University, INSERM, Departement d'etudes Cognitives, Paris, France.
      beaurenaut.morgan@gmail.com.
FAU - Tokarski, Elliot
AU  - Tokarski E
AD  - Laboratoire de Neurosciences Cognitives et Computationnelles, ENS, PSL Research
      University, INSERM, Departement d'etudes Cognitives, Paris, France.
FAU - Dezecache, Guillaume
AU  - Dezecache G
AD  - Department of Experimental Psychology, Division of Psychology and Language
      Sciences, University College London, London, UK.
AD  - Universite Clermont Auvergne, CNRS, LAPSCO, Clermont-Ferrand, France.
FAU - Grezes, Julie
AU  - Grezes J
AD  - Laboratoire de Neurosciences Cognitives et Computationnelles, ENS, PSL Research
      University, INSERM, Departement d'etudes Cognitives, Paris, France.
      julie.grezes@ens.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200727
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Anxiety/*physiopathology/*psychology
MH  - Female
MH  - Galvanic Skin Response
MH  - Humans
MH  - Male
MH  - Reproducibility of Results
MH  - Young Adult
PMC - PMC7385655
EDAT- 2020/07/29 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/29 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-68889-0 [doi]
AID - 10.1038/s41598-020-68889-0 [pii]
PST - epublish
SO  - Sci Rep. 2020 Jul 27;10(1):12496. doi: 10.1038/s41598-020-68889-0.


PMID- 32719275
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20220415
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 16
IP  - 3
DP  - 2020 Apr-Jun
TI  - Usefulness of salivary sialic acid as a tumor marker in tobacco chewers with oral
      cancer.
PG  - 605-611
LID - 10.4103/jcrt.JCRT_337_19 [doi]
AB  - AIM: This study aims to assess the usefulness of salivary sialic acid (SA) as a
      tumor marker in the detection of oral squamous cell carcinoma (OSCC) among
      tobacco chewers. MATERIALS AND METHODS: After the approval of study protocol by
      the Institutional Ethics Committee and informed voluntary consent, salivary
      samples were collected from 96 participants in each group of tobacco chewers with
      OSCC, tobacco chewers without precancerous or cancerous lesion, and healthy
      controls. Salivary protein-bound SA (PBSA) and salivary-free SA (FSA) were
      measured by Yao et al.'s method of acid ninhydrin reaction, and the data were
      subjected to appropriate statistical analysis. RESULTS: The salivary PBSA and FSA
      levels in the Groups 1, 2, and 3 participants were 31.17 +/- 7.6 mg/dL and 63.45 
      +/- 9.8 mg/dL, 25.45 +/- 16.61 mg/dL and 33.18 +/- 11.38 mg/dL, and 22.73 +/-
      3.01 mg/dL and 21.62 +/- 8.86 mg/dL, respectively. Salivary FSA levels were
      significantly increased among the tobacco chewers with OSCC patients (Group 1)
      and tobacco chewers with no premalignant lesions of the oral cavity (Group 2)
      compared to the healthy controls (Group 3) with P < 0.05 being statistically
      significant. Salivary FSA levels were significantly increased in Group 1 as
      compared with Group 2. The salivary PBSA was high among Group 1 as compared to
      the control Group 3; there was however no significant difference in the levels of
      salivary PBSA between Group 1 and Group 2. There was no significant difference in
      the PBSA levels between OSCC patients of Group 1 and the tobacco chewers without 
      precancerous or cancerous lesion in the oral cavity of Group 2. CONCLUSION:
      Salivary PBSA and FSA are significantly raised in both tobacco chewers with OSCC 
      and in tobacco chewers with no precancerous or cancerous lesions in the oral
      cavity. SA should therefore be used cautiously while considering it as a marker
      for the early detection of oral cancer. Tobacco can be a crucial confounding
      factor when SA is used as a biomarker in OSCC since their levels are elevated to 
      some extent even in tobacco chewers without any clinically obvious precancerous
      or cancerous lesions in the oral cavity.
FAU - Azeem, Mahnaaz Sultana
AU  - Azeem MS
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Sri Devaraj Urs
      Academy of Higher Education and Research, Kolar, Karnataka, India.
FAU - Yesupatham, Susanna Theophilus
AU  - Yesupatham ST
AD  - Department of Biochemistry, Sri Devaraj Urs Academy of Higher Education and
      Research, Kolar, Karnataka, India.
FAU - Mohiyuddin, S M Azeem
AU  - Mohiyuddin SMA
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Sri Devaraj Urs
      Academy of Higher Education and Research, Kolar, Karnataka, India.
FAU - Sumanth, V
AU  - Sumanth V
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Sri Devaraj Urs
      Academy of Higher Education and Research, Kolar, Karnataka, India.
FAU - Ravishankar, S
AU  - Ravishankar S
AD  - Department of Community Medicine, Sri Devaraj Urs Academy of Higher Education and
      Research, Kolar, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Biomarkers, Tumor)
RN  - GZP2782OP0 (N-Acetylneuraminic Acid)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/metabolism
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/chemically induced/diagnosis/*metabolism/pathology
MH  - N-Acetylneuraminic Acid/*metabolism
MH  - Precancerous Conditions/chemically induced/diagnosis/*metabolism/pathology
MH  - Saliva/chemistry/*metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/etiology/*metabolism/pathology
MH  - Tobacco Use/*adverse effects/*metabolism/pathology
OTO - NOTNLM
OT  - Oral cancer
OT  - saliva
OT  - sialic acid
OT  - tobacco chewers
COIS- None
EDAT- 2020/07/29 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - JCanResTher_2020_16_3_605_289969 [pii]
AID - 10.4103/jcrt.JCRT_337_19 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2020 Apr-Jun;16(3):605-611. doi: 10.4103/jcrt.JCRT_337_19.


PMID- 32719270
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20220415
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 16
IP  - 3
DP  - 2020 Apr-Jun
TI  - Volume changes during head-and-neck radiotherapy and its impact on the parotid
      dose - A single-institution observational study.
PG  - 575-580
LID - 10.4103/jcrt.JCRT_589_19 [doi]
AB  - AIMS: This study aims at assessing the volume changes that occur in the targets
      (gross tumor volume and planning target volume [PTV]) and the organs at risk in
      squamous cell carcinoma of the head and neck during radiotherapy and assessing
      the dose changes that occur as a result of them. SETTINGS AND DESIGN: This was a 
      prospective observational study in a tertiary care center after obtaining the
      appropriate scientific and ethics committee clearance. SUBJECTS AND METHODS:
      Forty-five patients diagnosed with squamous cell carcinoma of the head and neck, 
      who were treated with intensity-modulated radiotherapy in the time period from
      March 2018 to May 2019, were enrolled in the study. A planning computed
      tomography (CT) scan (CTplan) was done for all patients, followed by scans after 
      15 fractions (CT15) and after 25 fractions (CT25). The volume changes and the
      subsequent dose changes were assessed and recorded. STATISTICAL ANALYSIS USED:
      Data entry was done in MS Excel spreadsheet. The continuous variables were
      expressed as mean + standard deviation. The comparison of normally distributed
      continuous variables was done by paired t-test. Data analysis was done by SPSS
      (Statistical Package for the Social Sciences) version 16.0. P < 0.05 was
      considered statistically significant. A multivariate linear regression model was 
      constructed to study the correlation between mean dose to the parotid glands and 
      the other variables. All statistical modeling and analysis were done using SAS
      (Statistical Analysis Software) version 9.4. RESULTS: Of the 45 patients, 25 were
      male and 20 were female. The majority of the patients had malignancies in the
      oral cavity (16) and hypopharynx (14). Most of them had Stage III/IV (AJCC v 8)
      disease (41). There were a 36% decrease in the PTV-high risk (PTV-HR) volume and 
      a 6.05% decrease in the PTV-intermediate risk (PTV-IR) volume CT15. In CT25, the 
      volume decrease in the PTV-HR and the PTV-IR was 47% and 9.06%, respectively. The
      parotid glands also underwent a reduction in their volume which has been
      quantified as 21.7% and 20.9% in the ipsilateral and contralateral parotids in
      CT15 and 36% and 33.6% in CT25, respectively. The D2 (dose received by 2% of the 
      volume) and D98 (dose received by 98% of the volume) of the PTV-IR showed changes
      of +3.5% and -0.2% in CT15 and + 4.6% and -0.31% in CT25, respectively. The
      homogeneity index and conformity number of the PTV-IR changes by 0.03 and 0.08 in
      CT15 and by 0.04 and 0.12 in CT25, respectively. The mean dose to the ipsilateral
      parotid gland increased by 14% in CT15 and 19% in CT25. The mean dose to the
      contralateral parotid gland increased by 17% in CT15 and 25% in CT25. CONCLUSION:
      The dose to the parotid glands increases as a result of the changes that occur
      during the course of radiation. The changes are significant after 15 fractions of
      radiation. A replanning at this juncture might be considered to reduce the dose
      to the parotid glands.
FAU - Ilangovan, Bhargavi
AU  - Ilangovan B
AD  - Department of Radiotherapy, Apollo Cancer Institute, Chennai, Tamil Nadu, India.
FAU - Venkatraman, Murali
AU  - Venkatraman M
AD  - Department of Radiotherapy, Apollo Cancer Institute, Chennai, Tamil Nadu, India.
FAU - Balasundaram, Subathira
AU  - Balasundaram S
AD  - Department of Radiotherapy, Apollo Cancer Institute, Chennai, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
SB  - IM
MH  - Female
MH  - Head and Neck Neoplasms/pathology/*radiotherapy
MH  - Humans
MH  - Male
MH  - Neoplasm Staging
MH  - Parotid Gland/pathology/*radiation effects
MH  - Prospective Studies
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Radiotherapy, Intensity-Modulated/*methods
MH  - Squamous Cell Carcinoma of Head and Neck/pathology/*radiotherapy
OTO - NOTNLM
OT  - Head-and-neck radiotherapy
OT  - intensity-modulated radiotherapy
OT  - parotid glands
OT  - volume changes
COIS- None
EDAT- 2020/07/29 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
AID - JCanResTher_2020_16_3_575_289976 [pii]
AID - 10.4103/jcrt.JCRT_589_19 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2020 Apr-Jun;16(3):575-580. doi: 10.4103/jcrt.JCRT_589_19.


PMID- 32719133
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 32
DP  - 2020 Aug 11
TI  - Objecting to experiments even while approving of the policies or treatments they 
      compare.
PG  - 18948-18950
LID - 10.1073/pnas.2009030117 [doi]
AB  - We resolve a controversy over two competing hypotheses about why people object to
      randomized experiments: 1) People unsurprisingly object to experiments only when 
      they object to a policy or treatment the experiment contains, or 2) people can
      paradoxically object to experiments even when they approve of implementing either
      condition for everyone. Using multiple measures of preference and test criteria
      in five preregistered within-subjects studies with 1,955 participants, we find
      that people often disapprove of experiments involving randomization despite
      approving of the policies or treatments to be tested.
CI  - Copyright (c) 2020 the Author(s). Published by PNAS.
FAU - Heck, Patrick R
AU  - Heck PR
AUID- ORCID: 0000-0003-0819-3890
AD  - Center for Translational Bioethics and Health Care Policy, Geisinger Health
      System, Danville, PA 17822; pheck1000@gmail.com.
AD  - Autism and Developmental Medicine Institute, Geisinger Health System, Lewisburg, 
      PA 17837.
FAU - Chabris, Christopher F
AU  - Chabris CF
AUID- ORCID: 0000-0002-7379-7378
AD  - Autism and Developmental Medicine Institute, Geisinger Health System, Lewisburg, 
      PA 17837.
FAU - Watts, Duncan J
AU  - Watts DJ
AUID- ORCID: 0000-0001-5005-4961
AD  - Annenberg School for Communication, University of Pennsylvania, Philadelphia, PA 
      19104.
FAU - Meyer, Michelle N
AU  - Meyer MN
AUID- ORCID: 0000-0001-5497-8803
AD  - Center for Translational Bioethics and Health Care Policy, Geisinger Health
      System, Danville, PA 17822.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - Ethics, Research
MH  - Humans
MH  - Random Allocation
MH  - Randomized Controlled Trials as Topic/ethics/*standards
MH  - Research/*standards
PMC - PMC7430984
OTO - NOTNLM
OT  - *A/B tests
OT  - *field experiments
OT  - *pragmatic trials
OT  - *randomized controlled trials
OT  - *research ethics
EDAT- 2020/07/29 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 2009030117 [pii]
AID - 10.1073/pnas.2009030117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18948-18950. doi:
      10.1073/pnas.2009030117. Epub 2020 Jul 27.


PMID- 32719089
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 2
DP  - 2020 Aug
TI  - Diagnosis, Management, and Treatment of Female Genital Mutilation or Cutting in
      Girls.
LID - e20201012 [pii]
LID - 10.1542/peds.2020-1012 [doi]
AB  - Female genital mutilation or cutting (FGM/C) involves medically unnecessary
      cutting of parts or all of the external female genitalia. It is outlawed in the
      United States and much of the world but is still known to occur in more than 30
      countries. FGM/C most often is performed on children, from infancy to
      adolescence, and has significant morbidity and mortality. In 2018, an estimated
      200 million girls and women alive at that time had undergone FGM/C worldwide.
      Some estimate that more than 500 000 girls and women in the United States have
      had or are at risk for having FGM/C. However, pediatric prevalence of FGM/C is
      only estimated given that most pediatric cases remain undiagnosed both in
      countries of origin and in the Western world, including in the United States. It 
      is a cultural practice not directly tied to any specific religion, ethnicity, or 
      race and has occurred in the United States. Although it is mostly a pediatric
      practice, currently there is no standard FGM/C teaching required for health care 
      providers who care for children, including pediatricians, family physicians,
      child abuse pediatricians, pediatric urologists, and pediatric urogynecologists. 
      This clinical report is the first comprehensive summary of FGM/C in children and 
      includes education regarding a standard-of-care approach for examination of
      external female genitalia at all health supervision examinations, diagnosis,
      complications, management, treatment, culturally sensitive discussion and
      counseling approaches, and legal and ethical considerations.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Young, Janine
AU  - Young J
AD  - Department of General Pediatrics, Denver Health Refugee Clinic, and Human Rights 
      Clinic, Denver Health and Hospitals and School of Medicine, University of
      Colorado Denver, Denver, Colorado; janine.young@dhha.org.
FAU - Nour, Nawal M
AU  - Nour NM
AD  - African Women's Health Center, Department of Obstetrics and Gynecology, Brigham
      and Women's Hospital and Harvard Medical School, Harvard University, Boston,
      Massachusetts.
FAU - Macauley, Robert C
AU  - Macauley RC
AD  - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
FAU - Narang, Sandeep K
AU  - Narang SK
AD  - Division of Child Abuse Pediatrics, Ann and Robert H. Lurie Children's Hospital
      of Chicago and Department of Pediatrics, Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois; and.
FAU - Johnson-Agbakwu, Crista
AU  - Johnson-Agbakwu C
AD  - Refugee Women's Health Clinic, Department of Obstetrics and Gynecology,
      Valleywise Health Medical Center and Office of Refugee Health, Southwest
      Interdisciplinary Research Center, School of Social Work, Watts College of Public
      Service and Community Solutions, Arizona State University, Phoenix, Arizona.
CN  - SECTION ON GLOBAL HEALTH
CN  - COMMITTEE ON MEDICAL LIABILITY AND RISK MANAGEMENT
CN  - COMMITTEE ON BIOETHICS
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Child
MH  - Child Abuse
MH  - Cicatrix/etiology
MH  - *Circumcision, Female/adverse effects/classification/legislation &
      jurisprudence/psychology
MH  - Clinical Competence
MH  - Confidentiality
MH  - Documentation
MH  - Female
MH  - Female Urogenital Diseases/etiology
MH  - Gynecologic Surgical Procedures
MH  - Humans
MH  - Infections/etiology
MH  - Infertility, Female/etiology
MH  - Informed Consent
MH  - International Classification of Diseases
MH  - Mandatory Reporting
MH  - Medical History Taking
MH  - Mental Health
MH  - Pain/etiology
MH  - Pediatricians
MH  - Physical Examination
MH  - Prevalence
MH  - Refugees/legislation & jurisprudence
MH  - Sexuality
COIS- POTENTIAL CONFLICT OF INTEREST: Dr Johnson-Agbakwu has a grant relationship with 
      Arizona State University from the 2018 copyright of "Female Genital
      Mutilation/Cutting (FGM/C): A Visual Reference and Learning Tool for Health Care 
      Professionals."
IR  - Suchdev P
FIR - Suchdev, Parminder
IR  - Chan KJ
FIR - Chan, Kevin J
IR  - Howard CR
FIR - Howard, Cynthia R
IR  - McGann P
FIR - McGann, Patrick
IR  - St Clair NE
FIR - St Clair, Nicole E
IR  - Yun K
FIR - Yun, Katherine
IR  - Arnold LD
FIR - Arnold, Linda D
IR  - Fanaroff JM
FIR - Fanaroff, Jonathan M
IR  - Altman RL
FIR - Altman, Robin L
IR  - Bondi SA
FIR - Bondi, Steven A
IR  - Oken RL
FIR - Oken, Richard L
IR  - Rusher JW
FIR - Rusher, John W
IR  - Santucci KA
FIR - Santucci, Karen A
IR  - Scibilia JP
FIR - Scibilia, James P
IR  - Scott SM
FIR - Scott, Susan M
IR  - Sigman LJ
FIR - Sigman, Laura J
IR  - Geis GM
FIR - Geis, Gina Marie
IR  - Laventhal NT
FIR - Laventhal, Naomi Tricot
IR  - Opel DJ
FIR - Opel, Douglas John
IR  - Sexson WR
FIR - Sexson, William R
IR  - Statter MB
FIR - Statter, Mindy B
EDAT- 2020/07/29 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - peds.2020-1012 [pii]
AID - 10.1542/peds.2020-1012 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(2). pii: peds.2020-1012. doi: 10.1542/peds.2020-1012.
      Epub 2020 Jul 27.


PMID- 32718927
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 27
TI  - Are prolonged sitting and sleep restriction a dual curse for the modern
      workforce? a randomised controlled trial protocol.
PG  - e040613
LID - 10.1136/bmjopen-2020-040613 [doi]
AB  - INTRODUCTION: Prolonged sitting and inadequate sleep are a growing concern in
      society and are associated with impairments to cardiometabolic health and
      cognitive performance. However, the combined effect of prolonged sitting and
      inadequate sleep on measures of health and cognitive performance are unknown. In 
      addition, the circadian disruption caused by shiftwork may further impact
      workers' cardiometabolic health and cognitive performance. This protocol paper
      outlines the methodology for exploring the impact of simultaneous exposure to
      prolonged sitting, sleep restriction and circadian disruption on cardiometabolic 
      and cognitive performance outcomes. METHODS AND ANALYSIS: This between-subjects
      study will recruit 208 males and females to complete a 7-day in-laboratory
      experimental protocol (1 Adaptation Day, 5 Experimental Days and 1 Recovery Day).
      Participants will be allocated to one of eight conditions that include all
      possible combinations of the following: dayshift or nightshift, sitting or
      breaking up sitting and 5 hour or 9 hour sleep opportunity. On arrival to the
      laboratory, participants will be provided with a 9 hour baseline sleep
      opportunity (22:00 to 07:00) and complete five simulated work shifts (09:00 to
      17:30 in the dayshift condition and 22:00 to 06:30 in the nightshift condition)
      followed by a 9 hour recovery sleep opportunity (22:00 to 07:00). During the work
      shifts participants in the sitting condition will remain seated, while
      participants in the breaking up sitting condition will complete 3-min bouts of
      light-intensity walking every 30 mins on a motorised treadmill. Sleep
      opportunities will be 9 hour or 5 hour. Primary outcome measures include
      continuously measured interstitial blood glucose, heart rate and blood pressure, 
      and a cognitive performance and self-perceived capacity testing battery completed
      five times per shift. Analyses will be conducted using linear mixed models.
      ETHICS AND DISSEMINATION: The CQUniversity Human Ethics Committee has approved
      this study (0000021914). All participants who have already completed the protocol
      have provided informed consent. Study findings will be disseminated via
      scientific publications and conference presentations. TRIAL REGISTRATION DETAILS:
      This study has been registered on Australian New Zealand Clinical Trials Registry
      (12619001516178) and is currently in the pre-results stage.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vincent, Grace E
AU  - Vincent GE
AUID- ORCID: 0000-0002-7036-7823
AD  - Appleton Institute, Central Queensland University - Adelaide Campus, Wayville,
      South Australia, Australia g.vincent@cqu.edu.au.
FAU - Gupta, Charlotte C
AU  - Gupta CC
AUID- ORCID: 0000-0003-2436-3327
AD  - Appleton Institute, Central Queensland University - Adelaide Campus, Wayville,
      South Australia, Australia.
FAU - Sprajcer, Madeline
AU  - Sprajcer M
AUID- ORCID: 0000-0002-4966-871X
AD  - Appleton Institute, Central Queensland University - Adelaide Campus, Wayville,
      South Australia, Australia.
FAU - Vandelanotte, Corneel
AU  - Vandelanotte C
AUID- ORCID: 0000-0002-4445-8094
AD  - School of Health Medical and Applied Sciences, Central Queensland University,
      Rockhampton, Queensland, Australia.
FAU - Duncan, Mitch J
AU  - Duncan MJ
AUID- ORCID: 0000-0002-9166-6195
AD  - School of Medicine & Public Health, Faculty of Health and Medicine, The
      University of Newcastle, Callaghan, NSW, Australia.
AD  - Priority Research Centre for Physical Activity and Nutrition, The University of
      Newcastle, Callaghan, NSW, Australia.
FAU - Tucker, Phil
AU  - Tucker P
AUID- ORCID: 0000-0002-8105-0901
AD  - Psychology Department, Swansea University, Swansea, United Kingdom.
AD  - Stress Research Institute, Department of Psychology, Stocklholm University,
      Stockholm, Sweden.
FAU - Lastella, Michele
AU  - Lastella M
AUID- ORCID: 0000-0003-1793-3811
AD  - Appleton Institute, Central Queensland University - Adelaide Campus, Wayville,
      South Australia, Australia.
FAU - Tuckwell, Georgia A
AU  - Tuckwell GA
AUID- ORCID: 0000-0003-4607-7698
AD  - Appleton Institute, Central Queensland University - Adelaide Campus, Wayville,
      South Australia, Australia.
FAU - Ferguson, Sally A
AU  - Ferguson SA
AUID- ORCID: 0000-0002-9682-7971
AD  - Appleton Institute, Central Queensland University - Adelaide Campus, Wayville,
      South Australia, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200727
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - *Sedentary Behavior
MH  - *Sitting Position
MH  - Sleep
MH  - Workforce
PMC - PMC7389768
OTO - NOTNLM
OT  - *cardiology
OT  - *public health
OT  - *sleep medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040613 [pii]
AID - 10.1136/bmjopen-2020-040613 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 27;10(7):e040613. doi: 10.1136/bmjopen-2020-040613.


PMID- 32718924
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 27
TI  - Implementation of blood glucose self-monitoring among insulin-dependent patients 
      with type 2 diabetes in three rural districts in Rwanda: 6 months open randomised
      controlled trial.
PG  - e036202
LID - 10.1136/bmjopen-2019-036202 [doi]
AB  - INTRODUCTION: Most patients diagnosed with diabetes in sub-Saharan Africa (SSA)
      present with poorly controlled blood glucose, which is associated with increased 
      risks of complications and greater financial burden on both the patients and
      health systems. Insulin-dependent patients with diabetes in SSA lack appropriate 
      home-based monitoring technology to inform themselves and clinicians of the daily
      fluctuations in blood glucose. Without sufficient home-based data, insulin
      adjustments are not data driven and adopting individual behavioural change for
      glucose control in SSA does not have a systematic path towards improvement.
      METHODS AND ANALYSIS: This study explores the feasibility and impact of
      implementing self-monitoring of blood glucose (SMBG) in patients with type 2
      diabetes in rural Rwandan districts. This is an open randomised controlled trial 
      comprising of two arms: (1) Intervention group-participants will receive a
      glucose metre, blood test strips, logbook, waste management box and training on
      how to conduct SMBG in additional to usual care and (2) Control
      group-participants will receive usual care, comprising of clinical consultations 
      and routine monthly follow-up. We will conduct qualitative interviews at
      enrolment and at the end of the study to assess knowledge of diabetes. At the end
      of the study period, we will interview clinicians and participants to assess the 
      perceived usefulness, facilitators and barriers of SMBG. The primary outcomes are
      change in haemoglobin A1c, fidelity to SMBG protocol by patients, appropriateness
      and adverse effects resulting from SMBG. Secondary outcomes include reliability
      and acceptability of SMBG and change in the quality of life of the participants. 
      ETHICS AND DISSEMINATION: This study has been approved by the Rwanda National
      Ethics Committee (Kigali, Rwanda No.102/RNEC/2018). We will disseminate the
      findings of this study through presentations within our study settings,
      scientific conferences and publication in a peer-reviewed journal. TRIAL
      REGISTRATION NUMBER: PACTR201905538846394; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ng'ang'a, Loise
AU  - Ng'ang'a L
AUID- ORCID: 0000-0002-1045-0780
AD  - Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda
      loisehaks@gmail.com.
FAU - Ngoga, Gedeon
AU  - Ngoga G
AD  - Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.
AD  - NCD Synergies, Partners in Health, Boston, Massachusetts, United States.
FAU - Dusabeyezu, Symaque
AU  - Dusabeyezu S
AD  - Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.
FAU - Hedt-Gauthier, Bethany L
AU  - Hedt-Gauthier BL
AD  - Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts,
      USA.
FAU - Ngamije, Patient
AU  - Ngamije P
AD  - Kirehe District Hospital, Ministry of Health, Kigali, Rwanda.
FAU - Habiyaremye, Michel
AU  - Habiyaremye M
AD  - Rwinkwavu District Hospital, Ministry of Health, Kigali, Rwanda.
FAU - Harerimana, Emmanuel
AU  - Harerimana E
AD  - Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.
FAU - Ndayisaba, Gilles
AU  - Ndayisaba G
AD  - Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.
FAU - Rusangwa, Christian
AU  - Rusangwa C
AD  - Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.
FAU - Niyonsenga, Simon Pierre
AU  - Niyonsenga SP
AD  - Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.
FAU - Bavuma, Charlotte M
AU  - Bavuma CM
AD  - Internal Medicine, University of Rwanda College of Medicine and Health Sciences, 
      Kigali, Rwanda.
FAU - Bukhman, Gene
AU  - Bukhman G
AD  - NCD Synergies, Partners in Health, Boston, Massachusetts, United States.
AD  - Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts,
      USA.
AD  - Division of Global Health Equity, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
FAU - Adler, Alma J
AU  - Adler AJ
AD  - Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts,
      USA.
FAU - Kateera, Fredrick
AU  - Kateera F
AD  - Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.
FAU - Park, Paul H
AU  - Park PH
AD  - NCD Synergies, Partners in Health, Boston, Massachusetts, United States.
AD  - Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts,
      USA.
AD  - Division of Global Health Equity, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
LA  - eng
SI  - PACTR/PACTR201905538846394
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Attitude of Health Personnel
MH  - *Blood Glucose Self-Monitoring/adverse effects
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Feasibility Studies
MH  - Glycated Hemoglobin A/metabolism
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Interviews as Topic
MH  - Patient Compliance
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Rural Population
MH  - Rwanda
PMC - PMC7389513
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *general diabetes
COIS- Competing interests: None declared.
EDAT- 2020/07/29 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036202 [pii]
AID - 10.1136/bmjopen-2019-036202 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 27;10(7):e036202. doi: 10.1136/bmjopen-2019-036202.


PMID- 32718922
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 27
TI  - PROMISE (Program Refinements to Optimize Model Impact and Scalability based on
      Evidence): a cluster-randomised, stepped-wedge trial assessing effectiveness of
      the revised versus original Ryan White Part A HIV Care Coordination Programme for
      patients with barriers to treatment in the USA.
PG  - e034624
LID - 10.1136/bmjopen-2019-034624 [doi]
AB  - INTRODUCTION: Growing evidence supports combining social, behavioural and
      biomedical strategies to strengthen the HIV care continuum. However, combination 
      interventions can be resource-intensive and challenging to scale up. Research is 
      needed to identify intervention components and delivery models that maximise
      uptake, engagement and effectiveness. In New York City (NYC), a multicomponent
      Ryan White Part A-funded medical case management intervention called the Care
      Coordination Programme (CCP) was launched at 28 agencies in 2009 in order to
      address barriers to care and treatment. Effectiveness estimates based on >7000
      clients enrolled by April 2013 and their controls indicated modest CCP benefits
      over 'usual care' for short-term and long-term viral suppression, with
      substantial room for improvement. METHODS AND ANALYSIS: Integrating evaluation
      findings and CCP service-provider and community-stakeholder input on
      modifications, the NYC Health Department packaged a Care Coordination Redesign
      (CCR) in a 2017 request for proposals. Following competitive re-solicitation, 17 
      of the original CCP-implementing agencies secured contracts. These agencies were 
      randomised within matched pairs to immediate or delayed CCR implementation. Data 
      from three 9-month periods (pre-implementation, partial implementation and full
      implementation) will be examined to compare CCR versus CCP effects on timely
      viral suppression (TVS, within 4 months of enrolment) among individuals with
      unsuppressed HIV viral load newly enrolling in the CCR/CCP. Based on current
      enrolment (n=933) and the pre-implementation outcome probability (TVS=0.54), the 
      detectable effect size with 80% power is an OR of 2.75 (relative risk: 1.41).
      ETHICS AND DISSEMINATION: This study was approved by the NYC Department of Health
      and Mental Hygiene Institutional Review Board (IRB, Protocol 18-009) and the City
      University of New York Integrated IRB (Protocol 018-0057) with a waiver of
      informed consent. Findings will be disseminated via publications, conferences,
      stakeholder meetings, and Advisory Board meetings with implementing agency
      representatives. TRIAL REGISTRATION NUMBER: Registered with ClinicalTrials.gov
      under identifier: NCT03628287, V.2, 25 September 2019; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Irvine, Mary K
AU  - Irvine MK
AUID- ORCID: 0000-0003-1852-7559
AD  - Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New
      York, USA mirvine@health.nyc.gov.
FAU - Levin, Bruce
AU  - Levin B
AD  - Department of Biostatistics, Mailman School of Public Health (MSPH), Columbia
      University, New York, New York, USA.
FAU - Robertson, McKaylee M
AU  - Robertson MM
AUID- ORCID: 0000-0002-8426-6572
AD  - Institute for Implementation Science in Population Health, Graduate School of
      Public Health and Health Policy, City University of New York, New York, New York,
      USA.
FAU - Penrose, Katherine
AU  - Penrose K
AD  - Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New
      York, USA.
FAU - Carmona, Jennifer
AU  - Carmona J
AD  - Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New
      York, USA.
FAU - Harriman, Graham
AU  - Harriman G
AD  - Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New
      York, USA.
FAU - Braunstein, Sarah L
AU  - Braunstein SL
AD  - Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New
      York, USA.
FAU - Nash, Denis
AU  - Nash D
AD  - Institute for Implementation Science in Population Health, Graduate School of
      Public Health and Health Policy, City University of New York, New York, New York,
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03628287
GR  - R01 MH117793/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200727
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Continuity of Patient Care
MH  - *HIV Infections/therapy
MH  - Humans
MH  - New York City
MH  - United States
PMC - PMC7389516
OTO - NOTNLM
OT  - *HIV viral suppression
OT  - *care coordination
OT  - *implementation science
OT  - *practice-driven research
OT  - *statistics & research methods
OT  - *stepped-wedge trial
COIS- Competing interests: The authors have reported only federal government grants to 
      their institutions for this work. (See Funding statement above)
EDAT- 2020/07/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034624 [pii]
AID - 10.1136/bmjopen-2019-034624 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 27;10(7):e034624. doi: 10.1136/bmjopen-2019-034624.


PMID- 32718921
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220323
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 27
TI  - Predicting major adverse cardiovascular events for secondary prevention: protocol
      for a systematic review and meta-analysis of risk prediction models.
PG  - e034564
LID - 10.1136/bmjopen-2019-034564 [doi]
AB  - INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of morbidity and 
      mortality globally. With advances in early diagnosis and treatment of CVD and
      increasing life expectancy, more people are surviving initial CVD events.
      However, models for stratifying disease severity risk in patients with
      established CVD for effective secondary prevention strategies are inadequate.
      Multivariable prognostic models to stratify CVD risk may allow personalised
      treatment interventions. This review aims to systematically review the existing
      multivariable prognostic models for the recurrence of CVD or major adverse
      cardiovascular events in adults with established CVD diagnosis. METHODS AND
      ANALYSIS: Bibliographic databases (Ovid MEDLINE, EMBASE, PsycINFO and Web of
      Science) will be searched, from database inception to April 2020, using terms
      relating to the clinical area and prognosis. A hand search of the reference lists
      of included studies will also be done to identify additional published studies.
      No restrictions on language of publications will be applied. Eligible studies
      present multivariable models (derived or validated) of adults (aged 16 years and 
      over) with an established diagnosis of CVD, reporting at least one of the
      components of the primary outcome of major adverse cardiovascular events (defined
      as either coronary heart disease, stroke, peripheral artery disease, heart
      failure or CVD-related mortality). Reviewing will be done by two reviewers
      independently using the pre-defined criteria. Data will be extracted for included
      full-text articles. Risk of bias will be assessed using the Prediction model
      study Risk Of Bias ASsessment Tool (PROBAST). Prognostic models will be
      summarised narratively. If a model is tested in multiple validation studies, the 
      predictive performance will be summarised using a random-effects meta-analysis
      model to account for any between-study heterogeneity. ETHICS AND DISSEMINATION:
      Ethics approval is not required. The results of this study will be submitted to
      relevant conferences for presentation and a peer-reviewed journal for
      publication. PROSPERO REGISTRATION NUMBER: CRD42019149111.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Akyea, Ralph K
AU  - Akyea RK
AUID- ORCID: 0000-0003-4529-8237
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK
      mszrka@nottingham.ac.uk.
FAU - Leonardi-Bee, Jo
AU  - Leonardi-Bee J
AD  - Division of Epidemiology and Public Health, University of Nottingham, Nottingham,
      UK.
FAU - Asselbergs, Folkert W
AU  - Asselbergs FW
AD  - Department of Cardiology, Division Heart & Lungs, University Medical Centre
      Utrecht, Utrecht University, Utrecht, The Netherlands.
AD  - Institute of Cardiovascular Science, Faculty of Population Health Sciences,
      University College London, London, UK.
FAU - Patel, Riyaz S
AU  - Patel RS
AD  - Institute of Cardiovascular Science, Faculty of Population Health Sciences,
      University College London, London, UK.
FAU - Durrington, Paul
AU  - Durrington P
AD  - Cardiovascular Research Group, Faculty of Biology, Medicine and Health,
      University of Manchester, Manchester, UK.
FAU - Wierzbicki, Anthony S
AU  - Wierzbicki AS
AD  - Guy's and St. Thomas' NHS Foundation Trust, London, UK.
FAU - Ibiwoye, Oluwaseun H
AU  - Ibiwoye OH
AD  - Division of Epidemiology and Public Health, University of Nottingham, Nottingham,
      UK.
FAU - Kai, Joe
AU  - Kai J
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK.
FAU - Qureshi, Nadeem
AU  - Qureshi N
AUID- ORCID: 0000-0003-4909-0644
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK.
FAU - Weng, Stephen F
AU  - Weng SF
AD  - Division of Primary Care, University of Nottingham, Nottingham, UK.
LA  - eng
GR  - FS/14/76/30933/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200727
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Heart Failure
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neoplasm Recurrence, Local
MH  - Review Literature as Topic
MH  - Risk Assessment
MH  - *Stroke/prevention & control
PMC - PMC7389481
OTO - NOTNLM
OT  - *cardiovascular disease
OT  - *prognostic
OT  - *prognostic multivariable models
OT  - *protocol
OT  - *secondary prevention
OT  - *systematic review and meta-analysis
COIS- Competing interests: NQ is a member of the most recent NICE Familial
      Hypercholesterolaemia and Lipid Modification Guideline Development Groups (CG71
      and CG181). SFW is a member of the Clinical Practice Research Datalink (CPRD)
      Independent Scientific Advisory Committee (ISAC). RKA currently holds an
      NIHR-SPCR funded studentship (2018-2021). SFW previously held an NIHR-SCPR career
      launching fellowship award (2015-2018).
EDAT- 2020/07/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034564 [pii]
AID - 10.1136/bmjopen-2019-034564 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 27;10(7):e034564. doi: 10.1136/bmjopen-2019-034564.


PMID- 32718864
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20210110
IS  - 1878-7886 (Electronic)
IS  - 1878-7886 (Linking)
VI  - 157
IP  - 4
DP  - 2020 Aug
TI  - A crisis of ethics in the ethics of crisis.
PG  - 365-366
LID - S1878-7886(20)30184-3 [pii]
LID - 10.1016/j.jviscsurg.2020.07.002 [doi]
FAU - Zarzavadjian Le Bian, A
AU  - Zarzavadjian Le Bian A
AD  - Avicenne Hospital, Assistance Publique-Hopitaux de Paris, University hospital of 
      Seine Saint-Denis, Digestive, Bariatric and Endocrine Surgery Department,
      Sorbonne Paris Nord University, 93000 Bobigny, France. Electronic address:
      alban.lebian@aphp.fr.
FAU - Tresallet, C
AU  - Tresallet C
AD  - Avicenne Hospital, Assistance Publique-Hopitaux de Paris, University hospital of 
      Seine Saint-Denis, Digestive, Bariatric and Endocrine Surgery Department,
      Sorbonne Paris Nord University, 93000 Bobigny, France.
FAU - Martinod, E
AU  - Martinod E
AD  - Avicenne Hospital, Assistance Publique-Hopitaux de Paris, University Hospital of 
      Seine Saint-Denis, Thoracic and Vascular Surgery Department, Sorbonne Paris Nord 
      University, 93000 Bobigny, France.
LA  - eng
PT  - Letter
DEP - 20200724
PL  - France
TA  - J Visc Surg
JT  - Journal of visceral surgery
JID - 101532664
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/ethics
MH  - Coronavirus Infections/*prevention & control
MH  - Health Care Rationing/*ethics
MH  - Health Services Accessibility/*ethics
MH  - Humans
MH  - Infection Control
MH  - Pandemics/*ethics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - Surgeons/*ethics
MH  - Surgical Procedures, Operative/ethics
PMC - PMC7380912
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *Pandemia
OT  - *Surgery
EDAT- 2020/07/29 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - S1878-7886(20)30184-3 [pii]
AID - 10.1016/j.jviscsurg.2020.07.002 [doi]
PST - ppublish
SO  - J Visc Surg. 2020 Aug;157(4):365-366. doi: 10.1016/j.jviscsurg.2020.07.002. Epub 
      2020 Jul 24.


PMID- 32718520
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20200804
IS  - 0241-6972 (Print)
IS  - 0241-6972 (Linking)
VI  - 41
IP  - 326
DP  - 2020 Jan - Feb
TI  - [Clinical aspects and therapeutic positioning in addictology].
PG  - 12-15
LID - S0241-6972(20)30014-1 [pii]
LID - 10.1016/S0241-6972(20)30014-1 [doi]
AB  - The concept of addiction emerged subsequent to the moral approaches of the end
      ofthe 19th century as a pathological behaviour. The manuals which classify mental
      disorders, together with the notion of substance-related disorders, enable them
      to be approached with a medical vision. The subject of numerous, often heated or 
      divisive debates, addictology requires a clinical approach. The treatment of
      addiction must involve professionals from the medical, nursing, psychological and
      social fields. This multi-disciplinarity encourages each player to consider their
      own nursing identity while taking into account that of each other.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Laqueille, Xavier
AU  - Laqueille X
AD  - GHU Psychiatrie et neurosciences, service d'addictologie, centre hospitalier
      Sainte-Anne, 1 rue Cabanis, 75014 Paris, France; Universite de Paris, faculte de 
      medecine Paris centre, 15 rue de l'Ecole-de-Medecine, 75006 Paris, France.
      Electronic address: x.laqueille@ghu-paris.fr.
FAU - Lucet, Chloe
AU  - Lucet C
AD  - GHU Psychiatrie et neurosciences, service d'addictologie, centre hospitalier
      Sainte-Anne, 1 rue Cabanis, 75014 Paris, France; Universite de Paris, faculte de 
      medecine Paris centre, 15 rue de l'Ecole-de-Medecine, 75006 Paris, France.
LA  - fre
PT  - Journal Article
TT  - Aspects cliniques et positionnement therapeutique en addictologie.
PL  - France
TA  - Soins Psychiatr
JT  - Soins. Psychiatrie
JID - 8203334
MH  - *Addiction Medicine
MH  - Behavior, Addictive/*therapy
MH  - Humans
OTO - NOTNLM
OT  - abus de substance
OT  - addictologie
OT  - addictology
OT  - approche clinique
OT  - clinical approach
OT  - ethics
OT  - prise en charge
OT  - stigmatisation
OT  - substance abuse
OT  - treatment
OT  - ethique
EDAT- 2020/07/29 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
AID - S0241-6972(20)30014-1 [pii]
AID - 10.1016/S0241-6972(20)30014-1 [doi]
PST - ppublish
SO  - Soins Psychiatr. 2020 Jan - Feb;41(326):12-15. doi:
      10.1016/S0241-6972(20)30014-1.


PMID- 32718516
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 1879-1972 (Electronic)
IS  - 1054-139X (Linking)
VI  - 67
IP  - 2S
DP  - 2020 Aug
TI  - Artificial Intelligence for Personalized Preventive Adolescent Healthcare.
PG  - S52-S58
LID - S1054-139X(20)30095-1 [pii]
LID - 10.1016/j.jadohealth.2020.02.021 [doi]
AB  - Recent advances in artificial intelligence (AI) are creating new opportunities
      for personalizing technology-based health interventions to adolescents. This
      article provides a computer science perspective on how emerging AI
      technologies-intelligent learning environments, interactive narrative generation,
      user modeling, and adaptive coaching-can be utilized to model adolescent learning
      and engagement and deliver personalized support in adaptive health technologies. 
      Many of these technologies have emerged from human-centered applications of AI in
      education, training, and entertainment. However, their application to improving
      healthcare, to date, has been comparatively limited. We illustrate the
      opportunities provided by AI-driven adaptive technologies for adolescent
      preventive healthcare by describing a vision of how future adolescent preventive 
      health interventions might be delivered both inside and outside of the clinic.
      Key challenges posed by AI-driven health technologies are also presented,
      including issues of privacy, ethics, encoded bias, and integration into clinical 
      workflows and adolescent lives. Examples of empirical findings about the
      effectiveness of AI technologies for user modeling and adaptive coaching are
      presented, which underscore their promise for application toward adolescent
      health. The article concludes with a brief discussion of future research
      directions for the field, which is well positioned to leverage AI to improve
      adolescent health and well-being.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Rowe, Jonathan P
AU  - Rowe JP
AD  - Department of Computer Science, College of Engineering, North Carolina State
      University, Raleigh, North Carolina. Electronic address: jprowe@ncsu.edu.
FAU - Lester, James C
AU  - Lester JC
AD  - Department of Computer Science, College of Engineering, North Carolina State
      University, Raleigh, North Carolina.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - J Adolesc Health
JT  - The Journal of adolescent health : official publication of the Society for
      Adolescent Medicine
JID - 9102136
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health Services
MH  - *Artificial Intelligence
MH  - Deep Learning
MH  - *Delivery of Health Care
MH  - Forecasting
MH  - Humans
MH  - Narration
MH  - *Preventive Health Services
OTO - NOTNLM
OT  - *Adaptive learning technologies
OT  - *Adolescents
OT  - *Artificial intelligence
OT  - *Health information technology
OT  - *Interactive narrative generation
OT  - *Prevention
OT  - *User modeling
EDAT- 2020/07/29 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/07/29 06:00
PHST- 2019/09/13 00:00 [received]
PHST- 2019/12/01 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - S1054-139X(20)30095-1 [pii]
AID - 10.1016/j.jadohealth.2020.02.021 [doi]
PST - ppublish
SO  - J Adolesc Health. 2020 Aug;67(2S):S52-S58. doi: 10.1016/j.jadohealth.2020.02.021.


PMID- 32718493
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20220531
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 151
IP  - 8
DP  - 2020 Aug
TI  - Ethical dilemmas in treating a colleague's patients.
PG  - 637-638
LID - S0002-8177(20)30419-0 [pii]
LID - 10.1016/j.adaj.2020.05.022 [doi]
FAU - Clark, Alma
AU  - Clark A
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - IM
MH  - *Ethics, Dental
MH  - Humans
MH  - *Interprofessional Relations
EDAT- 2020/07/29 06:00
MHDA- 2020/08/14 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
AID - S0002-8177(20)30419-0 [pii]
AID - 10.1016/j.adaj.2020.05.022 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2020 Aug;151(8):637-638. doi: 10.1016/j.adaj.2020.05.022.


PMID- 32718352
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 27
TI  - Ethical and social implications of approaching death prediction in humans - when 
      the biology of ageing meets existential issues.
PG  - 64
LID - 10.1186/s12910-020-00502-5 [doi]
AB  - BACKGROUND: The discovery of biomarkers of ageing has led to the development of
      predictors of impending natural death and has paved the way for personalised
      estimation of the risk of death in the general population. This study intends to 
      identify the ethical resources available to approach the idea of a long-lasting
      dying process and consider the perspective of death prediction. The reflection on
      human mortality is necessary but not sufficient to face this issue. Knowledge
      about death anticipation in clinical contexts allows for a better understanding
      of it. Still, the very notion of prediction and its implications must be
      clarified. This study outlines in a prospective way issues that call for further 
      investigation in the various fields concerned: ethical, psychological, medical
      and social. METHODS: The study is based on an interdisciplinary approach, a
      combination of philosophy, clinical psychology, medicine, demography, biology and
      actuarial science. RESULTS: The present study proposes an understanding of death 
      prediction based on its distinction with the relationship to human mortality and 
      death anticipation, and on the analogy with the implications of genetic testing
      performed in pre-symptomatic stages of a disease. It leads to the identification 
      of a multi-layered issue, including the individual and personal relationship to
      death prediction, the potential medical uses of biomarkers of ageing, the social 
      and economic implications of the latter, especially in regard to the way
      longevity risk is perceived. CONCLUSIONS: The present study work strives to
      propose a first sketch of what the implications of death prediction as such could
      be - from an individual, medical and social point of view. Both with anti-ageing 
      medicine and the transhumanist quest for immortality, research on biomarkers of
      ageing brings back to the forefront crucial ethical matters: should we, as human 
      beings, keep ignoring certain things, primarily the moment of our death, be it an
      estimation of it? If such knowledge was available, who should be informed about
      it and how such information should be given? Is it a knowledge that could be
      socially shared?
FAU - Gaille, Marie
AU  - Gaille M
AUID- ORCID: 0000-0001-5572-1065
AD  - Universite de Paris, SPHERE, UMR 7219, CNRS-Universite Paris Diderot, batiment
      Condorcet, case 7093, 5 rue Thomas Mann, 75205, Paris, France.
      Marie.gaille@cnrs.fr.
FAU - Araneda, Marco
AU  - Araneda M
AD  - Universite de Paris, CRPMS - EA 3522, IUH - EA 3518, batiment Olympe de Gouges, 8
      rue Albert Einstein, 75013, Paris, France.
FAU - Dubost, Clement
AU  - Dubost C
AD  - Head of intensive care unit, Begin military hospital & CognacG research unit, UMR
      CNRS-Paris Descartes-SSA, Paris, France.
FAU - Guillermain, Clemence
AU  - Guillermain C
AD  - Universite de Paris, SPHERE, UMR 7219, CNRS-Universite Paris Diderot, batiment
      Condorcet, case 7093, 5 rue Thomas Mann, 75205, Paris, France.
FAU - Kaakai, Sarah
AU  - Kaakai S
AD  - Laboratoire Manceau de Mathematiques, Institut du Risque et de l'Assurance, Le
      Mans Universite, 72000, Le Mans, France.
FAU - Ricadat, Elise
AU  - Ricadat E
AD  - Universite de Paris, CRPMS - EA 3522, IUH - EA 3518, batiment Olympe de Gouges, 8
      rue Albert Einstein, 75013, Paris, France.
FAU - Todd, Nicolas
AU  - Todd N
AD  - Max Planck Institute for Demographic Research, Rostock, Germany.
FAU - Rera, Michael
AU  - Rera M
AD  - Center for Research and Interdisciplinarity (CRI), Universite de Paris, INSERM
      U1284. Sorbonne Universite, IBPS, B2A, CNRS, Institut de Biologie Paris - Seine, 
      75005, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200727
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Aging
MH  - Biology
MH  - Existentialism
MH  - Humans
MH  - *Morals
MH  - Prospective Studies
PMC - PMC7385957
OTO - NOTNLM
OT  - *Ageing
OT  - *Anticipation
OT  - *Death
OT  - *Longevity risk
OT  - *Medical care
OT  - *Mortality
OT  - *Pre-symptomatic test
OT  - *Prediction
OT  - *Program
EDAT- 2020/07/29 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/29 06:00
PHST- 2019/10/25 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00502-5 [doi]
AID - 10.1186/s12910-020-00502-5 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 27;21(1):64. doi: 10.1186/s12910-020-00502-5.


PMID- 32718340
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Jul 27
TI  - Provision of ECPR during COVID-19: evidence, equity, and ethical dilemmas.
PG  - 462
LID - 10.1186/s13054-020-03172-2 [doi]
AB  - The use of extracorporeal cardiopulmonary resuscitation (ECPR) to restore
      circulation during cardiac arrest is a time-critical, resource-intensive
      intervention of unproven efficacy. The current COVID-19 pandemic has brought
      additional complexity and significant barriers to the ongoing provision and
      implementation of ECPR services. The logistics of patient selection, expedient
      cannulation, healthcare worker safety, and post-resuscitation care must be
      weighed against the ethical considerations of providing an intervention of
      contentious benefit at a time when critical care resources are being overwhelmed 
      by pandemic demand.
FAU - Worku, Elliott
AU  - Worku E
AUID- ORCID: 0000-0002-1824-9870
AD  - Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland,
      Australia. Elliott.worku@health.qld.gov.au.
AD  - University of Queensland, Brisbane, Queensland, Australia.
      Elliott.worku@health.qld.gov.au.
FAU - Gill, Denzil
AU  - Gill D
AD  - Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland,
      Australia.
FAU - Brodie, Daniel
AU  - Brodie D
AD  - Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York,
      USA.
AD  - Columbia University College of Physicians and Surgeons/New York-Presbyterian
      Hospital, New York, USA.
FAU - Lorusso, Roberto
AU  - Lorusso R
AD  - Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht
      University Medical Centre (MUMC), Cardiovascular Research Institute Maastricht
      (CARIM), Maastricht, The Netherlands.
FAU - Combes, Alain
AU  - Combes A
AD  - Institute of Cardiometabolism and Nutrition, Sorbonne Universites, UPMC Univ
      Paris 06, 75651, Paris Cedex 13, France.
AD  - Medical Intensive Care Unit, Assistance Publique-Hopitaux de Paris,
      Pitie-Salpetriere Hospital, 75651, Paris Cedex 13, France.
FAU - Shekar, Kiran
AU  - Shekar K
AD  - Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland,
      Australia.
AD  - University of Queensland, Brisbane, Queensland, Australia.
AD  - Bond University, Gold Coast, Queensland, Australia.
AD  - Critical Care Research Group and Centre of Research Excellence for Advanced
      Cardio-respiratory Therapies Improving OrgaN Support (ACTIONS), Brisbane,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
SB  - IM
MH  - Bioethical Issues
MH  - COVID-19
MH  - Cardiopulmonary Resuscitation/*methods
MH  - Coronavirus Infections/*epidemiology
MH  - Evidence-Based Practice
MH  - *Extracorporeal Membrane Oxygenation
MH  - Health Equity
MH  - Heart Arrest/*therapy
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
PMC - PMC7384274
EDAT- 2020/07/29 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/06/27 00:00 [received]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - 10.1186/s13054-020-03172-2 [doi]
AID - 10.1186/s13054-020-03172-2 [pii]
PST - epublish
SO  - Crit Care. 2020 Jul 27;24(1):462. doi: 10.1186/s13054-020-03172-2.


PMID- 32718312
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 27
TI  - Comparison of general maternal and neonatal conditions and clinical outcomes
      between embryo transfer and natural conception.
PG  - 422
LID - 10.1186/s12884-020-03066-9 [doi]
AB  - BACKGROUND: To examine the differences between pregnant women who underwent
      embryo transfer (ET) and those who conceived naturally, as well as differences in
      their respective babies, and to determine the causes for these differences, to
      provide recommendations for women who are planning to undergo ET. METHODS: A
      retrospective cohort study was performed of women who had received ET and those
      who had natural conception (NC) who received medical services during pregnancy
      and had their babies delivered at the Shunde Women and Children's Hospital of
      Guangdong Medical University, China between January 2016 and December 2018. In
      line with the requirements of the ethics committee, before the formal
      investigation, we first explained the content of the informed consent of the
      patient to the patient, and all the subjects included agreed to the content of
      the informed consent of the patient. Respondents agreed to visit and analyze
      their medical records under reasonable conditions. Each case in an ET group of
      321 women was randomly matched with three cases of NC (963 cases) who delivered
      on the same day. The demographic information, past history, pregnancy and
      delivery history, and maternal and neonatal outcomes of the two groups were
      compared using univariate analysis. RESULTS: Age, duration of hospitalization,
      number of pregnancies, number of miscarriages, induced abortion, ectopic
      pregnancy, gestational diabetes mellitus, preeclampsia, gestational anemia,
      pregnancy risk, mode of fetal delivery, and number of births were significantly
      different between the two groups (all P < 0.05). However, there were no
      significant differences in the disease, allergy, infection and blood transfusion 
      histories of the pregnant women, or differences in prevalence of gestational
      hypothyroidism, gestational respiratory infection, premature rupture of membrane,
      placental abruption, fetal death, stillbirth, amniotic fluid volume and amniotic 
      fluid clarity between the two groups (all P > 0.05). The percentages for low
      birth weight and premature birth were significantly higher in the ET group than
      in the NC group. In contrast, infant gender and prevalence of fetal macrosomia,
      fetal anomaly, neonatal asphyxia, and extremely low birth weight were not
      significantly different between the two groups (all P > 0.05). CONCLUSIONS: The
      clinical outcomes of mothers and the birth status of infants were better in the
      NC group than in the ET group. Maternal health must be closely monitored and
      improved in the ET group to reduce the incidence of gestational comorbidity and
      enhance the quality of fetal life.
FAU - Pan, Haiyan
AU  - Pan H
AD  - School of Public Health, Guangdong Medical University, Dongguan, 523808,
      Guangdong Province, China.
FAU - Zhang, Xingshan
AU  - Zhang X
AD  - School of Public Health, Guangdong Medical University, Dongguan, 523808,
      Guangdong Province, China.
FAU - Rao, Jiawei
AU  - Rao J
AD  - School of Public Health, Guangdong Medical University, Dongguan, 523808,
      Guangdong Province, China.
FAU - Lin, Bing
AU  - Lin B
AD  - Shunde Women and Children's Hospital of Guangdong Medical University, Shunde,
      528399, Guangdong Province, China.
FAU - He, Jie Yun
AU  - He JY
AD  - Shunde Women and Children's Hospital of Guangdong Medical University, Shunde,
      528399, Guangdong Province, China.
FAU - Wang, Xingjie
AU  - Wang X
AD  - School of Public Health, Guangdong Medical University, Dongguan, 523808,
      Guangdong Province, China.
FAU - Han, Fengqiong
AU  - Han F
AD  - Shunde Women and Children's Hospital of Guangdong Medical University, Shunde,
      528399, Guangdong Province, China. fengqiong__han@163.com.
FAU - Zhang, Jinfeng
AU  - Zhang J
AUID- ORCID: http://orcid.org/0000-0001-9142-4148
AD  - Shunde Women and Children's Hospital of Guangdong Medical University, Shunde,
      528399, Guangdong Province, China. jinfeng__zhangjf@163.com.
LA  - eng
GR  - B2019087/Medical Science and Technology Foundation of Guangdong Province
GR  - 2018KQNCX096/Young Innovative Talents Project of Guangdong Province
GR  - 2019A1515010875/Nature Science Foundation of Guangdong Province
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Abruptio Placentae/epidemiology
MH  - Adult
MH  - China/epidemiology
MH  - Diabetes, Gestational/epidemiology
MH  - Embryo Transfer/*statistics & numerical data
MH  - Female
MH  - Fertilization
MH  - Fetal Macrosomia/epidemiology
MH  - Humans
MH  - Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Pre-Eclampsia/epidemiology
MH  - Pregnancy
MH  - Pregnancy Complications/*epidemiology
MH  - Pregnancy Outcome/*epidemiology
MH  - Premature Birth/epidemiology
MH  - Retrospective Studies
PMC - PMC7385858
OTO - NOTNLM
OT  - Assisted reproductive technology
OT  - Clinical outcome
OT  - Embryo transfer
OT  - Natural conception
EDAT- 2020/07/29 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - 10.1186/s12884-020-03066-9 [doi]
AID - 10.1186/s12884-020-03066-9 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Jul 27;20(1):422. doi: 10.1186/s12884-020-03066-9.


PMID- 32718262
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20210507
IS  - 1469-9567 (Electronic)
IS  - 1356-1820 (Linking)
VI  - 34
IP  - 5
DP  - 2020 Sep-Oct
TI  - Doing interprofessional research in the COVID-19 era: a discussion paper.
PG  - 600-606
LID - 10.1080/13561820.2020.1791808 [doi]
AB  - The COVID-19 pandemic, and ensuing physical distancing measures, poses challenges
      for researchers in the field of interprofessional care. Pandemic management has
      highlighted the centrality of interprofessional working to effective healthcare
      delivery during crises. It is essential to find ways to maintain
      interprofessional research that has commenced, while also designing research to
      capture important learning from pandemic management and response. However, it
      also creates opportunities for new research projects and novel research designs. 
      This discussion paper explores ways of adapting existing research methodologies
      and outlines potential avenues for new research. Specifically, considerations to 
      bear in mind when designing interprofessional research during the pandemic
      include research ethics and integrity, research design, data collection methods, 
      research opportunities, implications and limitations. Interprofessional research 
      can continue to make a valuable contribution in informing global responses to
      COVID-19 and in planning for future global health crises. We call for, insofar as
      possible, for interprofessional research to continue to be developed during this 
      time.
FAU - Sy, Michael
AU  - Sy M
AUID- ORCID: https://orcid.org/0000-0003-0849-2874
AD  - National Teacher Training Center for the Health Professions, University of the
      Philippines Manila , Manila, Philippines.
FAU - O'Leary, Noreen
AU  - O'Leary N
AUID- ORCID: https://orcid.org/0000-0002-1148-2186
AD  - School of Allied Health, University of Limerick , Limerick, Ireland.
FAU - Nagraj, Shobhana
AU  - Nagraj S
AUID- ORCID: https://orcid.org/0000-0002-0045-9896
AD  - Nuffield Department of Women's & Reproductive Health, University of Oxford ,
      Oxford, UK.
AD  - The George Institute for Global Health , Oxford, UK.
FAU - El-Awaisi, Alla
AU  - El-Awaisi A
AUID- ORCID: https://orcid.org/0000-0001-7930-3351
AD  - College of Pharmacy, Qatar University , Doha, Qatar.
FAU - O'Carroll, Veronica
AU  - O'Carroll V
AUID- ORCID: https://orcid.org/0000-0001-5777-104X
AD  - QU Health Chair of the Interprofessional Education Committee, Qatar
      UniversityCollege of Pharmacy , Doha, Qatar.
AD  - School of Medicine, University of St Andrews , St Andrews, UK.
FAU - Xyrichis, Andreas
AU  - Xyrichis A
AUID- ORCID: https://orcid.org/0000-0002-2359-4337
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London , London, UK.
LA  - eng
GR  - MR/R017182/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - J Interprof Care
JT  - Journal of interprofessional care
JID - 9205811
SB  - IM
MH  - *Biomedical Research
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Delivery of Health Care/organization & administration
MH  - Fellowships and Scholarships
MH  - Focus Groups
MH  - Humans
MH  - *Interdisciplinary Communication
MH  - Interviews as Topic
MH  - Observation
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral
MH  - Qualitative Research
MH  - Severe Acute Respiratory Syndrome
OTO - NOTNLM
OT  - Coronavirus pandemic
OT  - interprofessional research
OT  - interprofessional scholarship
OT  - remote data collection
EDAT- 2020/07/29 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 10.1080/13561820.2020.1791808 [doi]
PST - ppublish
SO  - J Interprof Care. 2020 Sep-Oct;34(5):600-606. doi: 10.1080/13561820.2020.1791808.
      Epub 2020 Jul 27.


PMID- 32718240
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1557-7422 (Electronic)
IS  - 1043-0342 (Linking)
VI  - 31
IP  - 15-16
DP  - 2020 Aug
TI  - Gene Editing for Treatment and Prevention of Human Diseases: A Global Survey of
      Gene Editing-Related Researchers.
PG  - 852-862
LID - 10.1089/hum.2020.136 [doi]
AB  - In the next decades, gene editing technologies are expected to be used in the
      treatment and prevention of human diseases. Yet, the future uses of gene editing 
      in medicine are still unknown, including its applicability and effectiveness to
      the treatment and prevention of infectious diseases, cancer, and monogenic and
      polygenic hereditary diseases. This study aims to address this gap by analyzing
      the views of over 1,000 gene editing-related researchers from all over the world.
      Some of our survey results show that, in the next 10 years, DNA double-strand
      breaks are expected to be the main method for gene editing, and CRISPR-Cas
      systems to be the mainstream programmable nuclease. In the same period, gene
      editing is expected to have more applicability and effectiveness to treat and
      prevent infectious diseases and cancer. Off-targeting mutations, reaching
      therapeutic levels of editing efficiency, difficulties in targeting specific
      tissues in vivo, and regulatory and ethical challenges are among the most
      relevant factors that might hamper the use of gene editing in humans. In
      conclusion, our results suggest that gene editing might become a reality to the
      treatment and prevention of a variety of human diseases in the coming 10 years.
      If the future confirms these researchers' expectations, gene editing could change
      the way medicine, health systems, and public health deal with the treatment and
      prevention of human diseases.
FAU - Rocha, Leonardo Fernandes Moutinho
AU  - Rocha LFM
AD  - Center for Strategic Studies, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
FAU - Braga, Luiza Amara Maciel
AU  - Braga LAM
AD  - Center for Strategic Studies, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
FAU - Mota, Fabio Batista
AU  - Mota FB
AD  - Center for Strategic Studies, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Gene Ther
JT  - Human gene therapy
JID - 9008950
SB  - IM
MH  - *CRISPR-Cas Systems
MH  - *Gene Editing
MH  - Genetic Diseases, Inborn/genetics/*therapy
MH  - Genetic Research
MH  - *Genetic Therapy
MH  - *Genome, Human
MH  - Humans
MH  - Research Personnel/psychology/*statistics & numerical data
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *future
OT  - *gene editing
OT  - *human diseases
OT  - *prevention
OT  - *treatment
EDAT- 2020/07/29 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/07/29 06:00
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/07/29 06:00 [entrez]
AID - 10.1089/hum.2020.136 [doi]
PST - ppublish
SO  - Hum Gene Ther. 2020 Aug;31(15-16):852-862. doi: 10.1089/hum.2020.136.


PMID- 32715274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - Barriers and enablers to Caregivers Responsive feeding Behaviour (CRiB): A mixed 
      method systematic review protocol.
PG  - 2
LID - 10.12688/hrbopenres.12980.2 [doi]
AB  - Background: Childhood overweight and obesity is a major public health issue.
      Responsive feeding has been identified as having a protective effect against
      child overweight and obesity, and is associated with healthy weight gain during
      infancy. Responsive feeding occurs when the caregiver recognises and responds in 
      a timely and developmentally appropriate manner to infant hunger and satiety
      cues. Despite its benefits, responsive feeding is not ubiquitous. To better
      support caregivers to engage in responsive feeding behaviours, it is necessary to
      first systematically identify the barriers and enablers associated with this
      behaviour. This mixed-methods systematic review therefore aims to synthesise
      evidence on barriers and enablers to responsive feeding using the COM-B model of 
      behavioural change. Methods: 7 electronic databases will be searched (Maternal
      and Infant Care, CINAHL, Cochrane, PubMed, Medline, PsycINFO, EMBASE). Studies
      examining factors associated with parental responsive and non-responsive feeding 
      of infants and children (<2 years) will be included. Papers collecting primary
      data, or analysing primary data through secondary analysis will be included. All 
      titles, abstracts and full texts will be screened by two reviewers. Quantitative 
      and qualitative data from all eligible papers will be independently extracted by 
      at least two reviewers using pre-determined standardised data extraction forms.
      Two reviewers will independently assess the methodological quality of the studies
      using the Mixed Methods Appraisal Tool (MMAT). This review will be reported
      according to the Preferred Reporting Items for Systematic reviews and Meta
      Analyses (PRISMA). Ethics and dissemination: Ethical approval is not required for
      this review as no primary data will be collected, and no identifying personal
      information will be present. The review will be disseminated in a peer reviewed
      journal. PROSPERO registration: CRD42019144570 (06/08/2019).
CI  - Copyright: (c) 2020 Slater V et al.
FAU - Slater, Vicki
AU  - Slater V
AUID- ORCID: https://orcid.org/0000-0002-4603-9280
AD  - Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University,
      Cambridge, CB1 1PT, UK.
FAU - Rose, Jennie
AU  - Rose J
AUID- ORCID: https://orcid.org/0000-0003-0242-6999
AD  - Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University,
      Cambridge, CB1 1PT, UK.
FAU - Olander, Ellinor
AU  - Olander E
AUID- ORCID: https://orcid.org/0000-0001-7792-9895
AD  - Centre for Maternal and Child Health Research, City, University of London,
      London, EC1V 0HB, UK.
FAU - Matvienko-Sikar, Karen
AU  - Matvienko-Sikar K
AUID- ORCID: https://orcid.org/0000-0003-2777-6581
AD  - School of Public Health, University College Cork, Cork, T12 HY8E, Ireland.
FAU - Redsell, Sarah
AU  - Redsell S
AUID- ORCID: https://orcid.org/0000-0002-2176-2325
AD  - Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University,
      Cambridge, CB1 1PT, UK.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7333359
OTO - NOTNLM
OT  - Responsive feeding
OT  - caregiver
OT  - infant
OT  - obesity
OT  - overweight
OT  - protocol
OT  - systematic review
COIS- No competing interests were disclosed.
EDAT- 2020/07/29 06:00
MHDA- 2020/07/29 06:01
CRDT- 2020/07/29 06:00
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/29 06:00 [entrez]
PHST- 2020/07/29 06:00 [pubmed]
PHST- 2020/07/29 06:01 [medline]
AID - 10.12688/hrbopenres.12980.2 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Jun 10;3:2. doi: 10.12688/hrbopenres.12980.2. eCollection
      2020.


PMID- 32717724
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 12
IP  - 14
DP  - 2020 Aug 5
TI  - Circular RNA hsa_circ_0076690 acts as a prognostic biomarker in osteoporosis and 
      regulates osteogenic differentiation of hBMSCs via sponging miR-152.
PG  - 15011-15020
LID - 10.18632/aging.103560 [doi]
AB  - OBJECTIVE: Osteoporosis is the most common skeletal disease world-wide. The aim
      of this study is to identify potential circRNA biomarkers for osteoporosis
      diagnosis and treatment, as well as their roles in regulating osteogenic
      differentiation. RESULTS: Hsa_circ_0076690 expression was significantly decreased
      in osteoporosis patients compared to control and showed an acceptable diagnostic 
      value in clinical samples. Subsequently, hsa_circ_0076690 was identified to act
      as a sponge of miR-152. The expression of hsa_circ_0076690 was gradually
      increased during osteogenic differentiation while miR-152 showed a decreased
      expression trend. Moreover, osteogenic differentiation was promoted by
      hsa_circ_0076690 over-expression and remain unchanged by miR-152/hsa_circ_0076690
      co-overexpression. CONCLUSIONS: In conclusion, our study revealed that
      hsa_circ_0076690 may act as a potential diagnostic biomarker for osteoporosis
      patients and hsa_circ_0076690 could regulate osteogenic differentiation of hBMSCs
      via sponging miR-152. MATERIALS AND METHODS: A total of 114 participants were
      enrolled in this study with ethics approvals. CircRNAs were identified by means
      of RNA-sequencing and qRT-PCR experiment. The clinical significance was measured 
      by ROC curve analysis. Target relationship was validated by luciferase reporter
      assay. The osteogenic-associated biomarkers and ALP activity were detected by
      western blots.
FAU - Han, Shijie
AU  - Han S
AD  - Department of Orthopedics, The Provincial Hospital Affiliated to Shandong First
      Medical University, Jinan 250021, Shandong, PR China.
FAU - Kuang, Mingjie
AU  - Kuang M
AD  - Department of Orthopedics, The Provincial Hospital Affiliated to Shandong First
      Medical University, Jinan 250021, Shandong, PR China.
FAU - Sun, Chao
AU  - Sun C
AD  - Department of Orthopedics, The Provincial Hospital Affiliated to Shandong First
      Medical University, Jinan 250021, Shandong, PR China.
FAU - Wang, Haifeng
AU  - Wang H
AD  - Department of Orthopedics, The Provincial Hospital Affiliated to Shandong First
      Medical University, Jinan 250021, Shandong, PR China.
FAU - Wang, Dachuan
AU  - Wang D
AD  - Department of Orthopedics, The Provincial Hospital Affiliated to Shandong First
      Medical University, Jinan 250021, Shandong, PR China.
FAU - Liu, Qian
AU  - Liu Q
AD  - Department of Pain, Qilu Hospital of Shandong University, Jinan 250012, Sahndong,
      PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (Biomarkers)
RN  - 0 (MIRN152 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
SB  - IM
MH  - Apoptosis
MH  - Biomarkers/analysis
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Gene Expression Profiling/methods
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - Osteogenesis/*genetics
MH  - *Osteoporosis/genetics/metabolism
MH  - Prognosis
MH  - RNA Stability
MH  - RNA, Circular/*metabolism
MH  - ROC Curve
MH  - Sequence Analysis, RNA
PMC - PMC7425508
OTO - NOTNLM
OT  - *biomarker
OT  - *hBMSCs
OT  - *hsa_circ_0076690
OT  - *miR-152
OT  - *osteoporosis
EDAT- 2020/07/28 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 103560 [pii]
AID - 10.18632/aging.103560 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2020 Aug 5;12(14):15011-15020. doi: 10.18632/aging.103560.


PMID- 32717421
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
VI  - 518
DP  - 2020 Dec 1
TI  - Value of circulating miRNA-21 in the diagnosis of subclinical diabetic
      cardiomyopathy.
PG  - 110944
LID - S0303-7207(20)30244-6 [pii]
LID - 10.1016/j.mce.2020.110944 [doi]
AB  - BACKGROUND: Diabetic cardiomyopathy (DCM) is a type of cardiac dysfunction that
      affects approximately 12% of diabetic patients, ultimately leading to heart
      failure or even death. However, there is currently no efficient or specific
      biomarker for DCM diagnosis. METHODS: A total of 266 subjects with type II
      diabetes (T2DM) were enrolled in this study and were divided into the T2DM with
      cardiac dysfunction (DCM) group and T2DM without cardiac dysfunction (non-DCM)
      group. The diagnostic efficacy of miR-21 was determined and compared with that of
      serum hemoglobin A1c% (HbA1c%). Db/db mice and H9c2 cells stimulated with high
      glucose (HG)/high fatty acid (PA) were used as in vivo and in vitro models of
      DCM, respectively. RESULTS: Through echocardiography and gated-myocardial
      perfusion imaging (gated-MPI), 49 patients were selected to be enrolled in the
      DCM group, with 49 matched controls in the non-DCM group. The circulating miR-21 
      levels were significantly decreased in the DCM group compared to the non-DCM
      group (P < 0.001). The diagnostic efficiency of miR-21 (area under the curve AUC 
      = 0.899) was higher than that of other parameters, including HbA1c%. Moreover,
      when miR-21 was combined with the duration of diabetes, HbA1c%, and lipid
      profiles, the AUC was the highest (AUC = 0.939) and had the highest diagnostic
      efficiency. Furthermore, overexpression of miR-21 improved the impaired
      mitochondrial biogenesis and decreased the cardiomyocyte apoptosis induced by
      HG/PA, while inhibition of miR-21 exerted the opposite effects. CONCLUSIONS: Our 
      findings identify circulating miR-21 as a novel biomarker in the diagnosis of DCM
      and provide an underlying mechanism for miRNA-based therapy for the treatment of 
      DCM. TRIAL REGISTRATION: The study was approved by the Ethics Committee of the
      Third Affiliated Hospital of Soochow University and has been registered in the
      Chinese Clinical Trial Registry (ChiCTR1900027080).
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Tao, Lichan
AU  - Tao L
AD  - Department of Cardiology, The Third Affiliated Hospital of Soochow University,
      Changzhou City, 213003, China.
FAU - Huang, Xiaoli
AU  - Huang X
AD  - Department of Endocrinology, The Third Affiliated Hospital of Soochow University,
      Changzhou City, 213003, China.
FAU - Xu, Min
AU  - Xu M
AD  - Department of Echocardiography, The Third Affiliated Hospital of Soochow
      University, Changzhou City, 213003, China.
FAU - Qin, Zihan
AU  - Qin Z
AD  - Department of Endocrinology, The Third Affiliated Hospital of Soochow University,
      Changzhou City, 213003, China.
FAU - Zhang, Feifei
AU  - Zhang F
AD  - Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow
      University, Changzhou City, 213003, China.
FAU - Hua, Fei
AU  - Hua F
AD  - Department of Endocrinology, The Third Affiliated Hospital of Soochow University,
      Changzhou City, 213003, China. Electronic address: huafei1970@suda.edu.cn.
FAU - Jiang, Xiaohong
AU  - Jiang X
AD  - Department of Endocrinology, The Third Affiliated Hospital of Soochow University,
      Changzhou City, 213003, China. Electronic address: 1617141689@qq.com.
FAU - Wang, Yuetao
AU  - Wang Y
AD  - Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow
      University, Changzhou City, 213003, China. Electronic address: yuetao.w@163.com.
LA  - eng
SI  - ChiCTR/ChiCTR1900027080
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200724
PL  - Ireland
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
RN  - 0 (Biomarkers)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Asymptomatic Diseases
MH  - Biomarkers/blood
MH  - Cells, Cultured
MH  - Diabetes Mellitus, Type 2/*blood/complications/diagnosis
MH  - Diabetic Cardiomyopathies/blood/*diagnosis/etiology
MH  - Early Diagnosis
MH  - Echocardiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - MicroRNAs/*blood/physiology
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Radionuclide Ventriculography/methods
MH  - Rats
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - *Apoptosis
OT  - *Diabetic cardiomyopathy
OT  - *HbA1c%
OT  - *Mitochondrial biogenesis
OT  - *miR-21
EDAT- 2020/07/28 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/07/05 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - S0303-7207(20)30244-6 [pii]
AID - 10.1016/j.mce.2020.110944 [doi]
PST - ppublish
SO  - Mol Cell Endocrinol. 2020 Dec 1;518:110944. doi: 10.1016/j.mce.2020.110944. Epub 
      2020 Jul 24.


PMID- 32717351
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Linking)
VI  - 96
DP  - 2020 Sep
TI  - Key considerations in the design of real-world studies.
PG  - 106091
LID - S1551-7144(20)30169-5 [pii]
LID - 10.1016/j.cct.2020.106091 [doi]
AB  - Randomized controlled clinical trials (RCTs) are the gold standard for evaluating
      the safety and efficacy of pharmaceutical drugs, but in many cases their costs,
      duration, limited generalizability, and ethical or technical feasibility have
      caused some to look for real-world studies as alternatives. However, real-world
      studies may be less convincing due to the lack of randomization and blinding. In 
      this article, we discuss some key considerations in the design of real-world
      studies, which include experimental studies (e.g., hybrid or pragmatic clinical
      trials and non-randomized single-arm clinical trials with external controls) and 
      non-experimental studies (e.g., cohort studies, cross-sectional studies, and
      case-control studies). Causal inference plays a critical role in the derivation
      of robust real-world evidence (RWE) from the analysis of real-world data (RWD).
      Therefore, we apply the hypothetical strategy, along with the concept of
      potential outcome, to lay out these key considerations, and we hope these
      considerations are helpful for the design, conduct, and analysis of real-world
      studies.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Fang, Yixin
AU  - Fang Y
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL 60064, United States of America.
      Electronic address: yixin.fang@abbvie.com.
FAU - He, Weili
AU  - He W
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL 60064, United States of America.
FAU - Wang, Hongwei
AU  - Wang H
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL 60064, United States of America.
FAU - Wu, Meijing
AU  - Wu M
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL 60064, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20200725
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
SB  - IM
OTO - NOTNLM
OT  - *Causal inference
OT  - *Confounding bias
OT  - *Real-world evidence
OT  - *Real-world studies
OT  - *Study design
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - S1551-7144(20)30169-5 [pii]
AID - 10.1016/j.cct.2020.106091 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2020 Sep;96:106091. doi: 10.1016/j.cct.2020.106091. Epub
      2020 Jul 25.


PMID- 32717208
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Need for sustainable biobanking networks for COVID-19 and other diseases of
      epidemic potential.
PG  - e268-e273
LID - S1473-3099(20)30461-8 [pii]
LID - 10.1016/S1473-3099(20)30461-8 [doi]
AB  - Outbreaks of infectious diseases are occurring with increasing frequency and
      unpredictability. The rapid development and deployment of diagnostics that can
      accurately and quickly identify pathogens as part of epidemic preparedness is
      needed now for the COVID-19 pandemic. WHO has developed a global research and
      innovation forum to facilitate, accelerate, and deepen research collaboration
      among countries and funders. Great progress has been made in the past decade, but
      access to specimens remains a major barrier for the development and evaluation of
      needed quality diagnostics. We present a sustainable model for a global network
      of country-owned biobanks with standardised methods for collection,
      characterisation, and archiving of specimens and pathogens to facilitate and
      accelerate diagnostics development and evaluation for COVID-19 and other diseases
      of epidemic potential. The biobanking network should be run on the guiding
      principles of transparency, equitable access, ethics, and respect for national
      laws that support country ownership and sustainability. Adapting the Nagoya
      Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of
      Benefits, sharing of specimens from national biobanks can be rewarded through
      mechanisms such as equitable access to diagnostics at negotiated prices. Such
      networks should be prepared for any pathogen of epidemic potential.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Peeling, Rosanna W
AU  - Peeling RW
AD  - Clinical Research Department, London School of Hygiene & Tropical Medicine,
      London, UK. Electronic address: rosanna.peeling@lshtm.ac.uk.
FAU - Boeras, Debrah
AU  - Boeras D
AD  - Global Health Impact Group, Atlanta, GA, USA.
FAU - Wilder-Smith, Annelies
AU  - Wilder-Smith A
AD  - Department of Disease Control, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Sall, Amadou
AU  - Sall A
AD  - Institut Pasteur de Dakar, Dakar, Senegal.
FAU - Nkengasong, John
AU  - Nkengasong J
AD  - Africa Centres for Disease Control and Prevention, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200724
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
SB  - IM
CIN - Nature. 2020 Nov;587(7833):197. PMID: 33173224
MH  - Betacoronavirus/isolation & purification
MH  - Biological Specimen Banks/*organization & administration/*standards
MH  - COVID-19
MH  - Communicable Disease Control
MH  - Communicable Diseases/*diagnosis/epidemiology
MH  - Coronavirus Infections/*diagnosis/epidemiology/prevention & control
MH  - Diagnostic Tests, Routine
MH  - Epidemics/prevention & control
MH  - Humans
MH  - International Cooperation
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/*diagnosis/epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Specimen Handling/standards
MH  - Sustainable Development
PMC - PMC7380944
EDAT- 2020/07/28 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - S1473-3099(20)30461-8 [pii]
AID - 10.1016/S1473-3099(20)30461-8 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2020 Oct;20(10):e268-e273. doi: 10.1016/S1473-3099(20)30461-8.
      Epub 2020 Jul 24.


PMID- 32717072
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211002
IS  - 2332-4260 (Electronic)
IS  - 2332-4252 (Linking)
VI  - 19
IP  - 6
DP  - 2020 Nov 16
TI  - A Tailored Approach to Cortical Bone Track for Spine Fixation Surgery:
      3-Dimensional Printed Custom Made Guides for Screws Placement: 2-Dimensional
      Operative Video.
PG  - E600-E601
LID - 10.1093/ons/opaa219 [doi]
AB  - Cortical bone trajectory (CBT) screw fixation is an attractive technique.1-4
      However, the ideal insertion of those screws could be technically demanding.5,6
      The use of 3-dimensional (3D) patient-matched guides increase safety for CBT
      screws implantation.7 In this video, the case of a 46 yr old male is presented.
      He complained low back pain with left sciatica. magnetic resonance imaging showed
      an L5/S1 degenerative disc disease with left herniation. The patient was
      positioned prone; the L5 spinous process was identified under fluoroscopic
      guidance than skin incision was performed. Preserving the cranial facet joints,
      spinous processes and laminae of L5 and S1 vertebrae were exposed. Guides were
      positioned on the corresponding vertebra and the contact areas checked to avoid
      any discrepancy. With a high-speed drill the cortical bone was violated through
      the guide tubes. The drill itself has a stop mechanism provided by the guides.
      With this mechanism the drilling can be safely performed up to the planned depth.
      Guidewires were than introduced into the pedicle and body of the vertebra;
      undertapping could be performed with cannulated instrument. Laminectomy and
      facetectomy were performed. Diskectomy was performed, then a titanium
      kidney-shaped pivoting cage was implanted. Four Screws were finally placed.
      Proper positioning of the implants were verified on fluoroscopy and on the
      postoperative computed tomography scan confirming the accuracy of the trajectory.
      All procedures performed for this study were in accordance with the ethical
      standards of our Institute and with the 1964 Helsinki declaration and its later
      amendments or comparable ethical standards. Written informed consent was obtained
      from the patient who is operated in this video.
CI  - Copyright (c) 2020 by the Congress of Neurological Surgeons.
FAU - Marengo, Nicola
AU  - Marengo N
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Ajello, Marco
AU  - Ajello M
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Cofano, Fabio
AU  - Cofano F
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Santonio, Filippo Veneziani
AU  - Santonio FV
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Monticelli, Matteo
AU  - Monticelli M
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Di Perna, Giuseppe
AU  - Di Perna G
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Zenga, Francesco
AU  - Zenga F
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
FAU - Garbossa, Diego
AU  - Garbossa D
AD  - Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", AOU Citta
      della Salute e della Scienza, Universita degli Studi di Torino, Turin, Italy.
LA  - eng
GR  - MIUR
PT  - Journal Article
PL  - United States
TA  - Oper Neurosurg (Hagerstown)
JT  - Operative neurosurgery (Hagerstown, Md.)
JID - 101635417
SB  - IM
OTO - NOTNLM
OT  - 3D patient-matched guides
OT  - CBT screws
OT  - Lumbar spinal surgery
OT  - Minimally invasive spinal surgery
OT  - Navigation system
OT  - Screws placement accuracy
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 5876912 [pii]
AID - 10.1093/ons/opaa219 [doi]
PST - ppublish
SO  - Oper Neurosurg (Hagerstown). 2020 Nov 16;19(6):E600-E601. doi:
      10.1093/ons/opaa219.


PMID- 32716810
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical Triage Demands a Better Triage Survivability Score.
PG  - 75-77
LID - 10.1080/15265161.2020.1779412 [doi]
FAU - Wynia, Matthew K
AU  - Wynia MK
AD  - University of Colorado School of Medicine.
AD  - University of Colorado Center for Bioethics and Humanities.
FAU - Sottile, Peter D
AU  - Sottile PD
AD  - University of Colorado School of Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - Humans
MH  - *Morals
MH  - *Triage
EDAT- 2020/07/28 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1779412 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):75-77. doi: 10.1080/15265161.2020.1779412.


PMID- 32716808
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical Considerations for "Reopening" Health Care Organizations Amid COVID-19.
PG  - 95-97
LID - 10.1080/15265161.2020.1779851 [doi]
FAU - Harter, Thomas D
AU  - Harter TD
AD  - Gundersen Health System.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):15-27. PMID: 32511078
MH  - *Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/07/28 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - 10.1080/15265161.2020.1779851 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):95-97. doi: 10.1080/15265161.2020.1779851.


PMID- 32716803
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical Challenges in Advance Care Planning During the COVID-19 Pandemic.
PG  - 202-204
LID - 10.1080/15265161.2020.1779855 [doi]
FAU - Janwadkar, Anveet S
AU  - Janwadkar AS
AD  - Baylor College of Medicine.
FAU - Bibler, Trevor M
AU  - Bibler TM
AD  - Baylor College of Medicine.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):62-66. PMID: 32464081
CON - Am J Bioeth. 2020 Jul;20(7):15-27. PMID: 32511078
CON - Am J Bioeth. 2020 Jul;20(7):67-74. PMID: 32552455
MH  - Advance Care Planning
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
EDAT- 2020/07/28 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - 10.1080/15265161.2020.1779855 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):202-204. doi: 10.1080/15265161.2020.1779855.


PMID- 32716802
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - The Shield and Sword of Biosecurity: Balancing the Ethics of Public Safety and
      Global Preparedness.
PG  - 142-144
LID - 10.1080/15265161.2020.1779859 [doi]
FAU - DiEuliis, Diane
AU  - DiEuliis D
AD  - National Defense University.
FAU - Giordano, James
AU  - Giordano J
AD  - Georgetown University Medical Center, and US Naval War College.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):62-66. PMID: 32464081
CON - Am J Bioeth. 2020 Jul;20(7):44-54. PMID: 32485131
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Global Health
MH  - Humans
MH  - *International Cooperation
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/07/28 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1080/15265161.2020.1779859 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):142-144. doi: 10.1080/15265161.2020.1779859.


PMID- 32716801
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - To Procure or Not to Procure: Hospitals Face Significant Ethical Dilemmas
      Regarding Organ Donation During the COVID-19 Pandemic.
PG  - 193-195
LID - 10.1080/15265161.2020.1779861 [doi]
FAU - Potter, Jordan
AU  - Potter J
AUID- ORCID: 0000-0002-8306-7782
AD  - WellStar Health System.
FAU - Ginsberg, Jessica
AU  - Ginsberg J
AUID- ORCID: 0000-0002-6344-670X
AD  - WellStar Health System.
FAU - Lesandrini, Jason
AU  - Lesandrini J
AUID- ORCID: 0000-0003-4584-3784
AD  - WellStar Health System.
FAU - Andrelchik, Amy
AU  - Andrelchik A
AUID- ORCID: 0000-0001-5511-8776
AD  - WellStar Health System.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):15-27. PMID: 32511078
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Organ Transplantation
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Tissue and Organ Procurement
EDAT- 2020/07/28 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - 10.1080/15265161.2020.1779861 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):193-195. doi: 10.1080/15265161.2020.1779861.


PMID- 32716800
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Implementing VA's Authoritative Ethical Guidance in a Pandemic.
PG  - 145-147
LID - 10.1080/15265161.2020.1779860 [doi]
FAU - Schonfeld, Toby
AU  - Schonfeld T
AD  - National Center for Ethics in Health Care.
FAU - Alfandre, David
AU  - Alfandre D
AD  - National Center for Ethics in Health Care.
FAU - Berkowitz, Kenneth
AU  - Berkowitz K
AD  - National Center for Ethics in Health Care.
FAU - Chanko, Barbara
AU  - Chanko B
AD  - National Center for Ethics in Health Care.
FAU - Foglia, Mary Beth
AU  - Foglia MB
AD  - National Center for Ethics in Health Care.
FAU - Geppert, Cynthia
AU  - Geppert C
AD  - National Center for Ethics in Health Care.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):15-27. PMID: 32511078
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United States
MH  - United States Department of Veterans Affairs
EDAT- 2020/07/28 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1080/15265161.2020.1779860 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):145-147. doi: 10.1080/15265161.2020.1779860.


PMID- 32716799
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - From Ventilators to Vaccines: Reframing the Ethics of Resource Allocation.
PG  - W15-W16
LID - 10.1080/15265161.2020.1782530 [doi]
FAU - Day, R Thomas
AU  - Day RT
AD  - Vanderbilt University School of Medicine.
FAU - Guidry, Bradley S
AU  - Guidry BS
AUID- ORCID: 0000-0002-2815-9625
AD  - Vanderbilt University School of Medicine.
FAU - Drolet, Brian C
AU  - Drolet BC
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
FAU - Clayton, Ellen W
AU  - Clayton EW
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
AD  - Vanderbilt University School of Law.
LA  - eng
PT  - Letter
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
RN  - 0 (Vaccines)
SB  - IM
MH  - Ethics
MH  - Humans
MH  - *Resource Allocation
MH  - *Vaccines
MH  - Ventilators, Mechanical
EDAT- 2020/07/28 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1782530 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):W15-W16. doi: 10.1080/15265161.2020.1782530.


PMID- 32716797
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Using a Public Health Ethics Framework to Unpick Discrimination in COVID-19
      Responses.
PG  - 114-116
LID - 10.1080/15265161.2020.1779403 [doi]
FAU - Chung, Roger Yat-Nork
AU  - Chung RY
AUID- ORCID: 0000-0003-4407-8208
AD  - The Chinese University of Hong Kong.
FAU - Erler, Alexandre
AU  - Erler A
AD  - The Chinese University of Hong Kong.
FAU - Li, Hon-Lam
AU  - Li HL
AD  - The Chinese University of Hong Kong.
FAU - Au, Derrick
AU  - Au D
AD  - The Chinese University of Hong Kong.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - *Healthcare Disparities
MH  - Humans
MH  - *Models, Theoretical
MH  - Pandemics/ethics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - United States/epidemiology
EDAT- 2020/07/28 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1080/15265161.2020.1779403 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):114-116. doi: 10.1080/15265161.2020.1779403.


PMID- 32716794
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethics as Usual? Unilateral Withdrawal of Treatment in a State of Exception.
PG  - 210-211
LID - 10.1080/15265161.2020.1779401 [doi]
FAU - Eberl, Jason T
AU  - Eberl JT
AD  - Saint Louis University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - Humans
MH  - *Withholding Treatment
EDAT- 2020/07/28 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1779401 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):210-211. doi: 10.1080/15265161.2020.1779401.


PMID- 32716792
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - A Conceptual Framework for Clearer Ethical Discussions About COVID-19 Response.
PG  - 98-101
LID - 10.1080/15265161.2020.1779400 [doi]
FAU - Persad, Govind C
AU  - Persad GC
AD  - University of Denver.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):37-43. PMID: 32400291
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - Infant
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/07/28 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - 10.1080/15265161.2020.1779400 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):98-101. doi: 10.1080/15265161.2020.1779400.


PMID- 32716775
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Research Ethics during a Pandemic: A Call for Normative and Empirical Analysis.
PG  - 82-84
LID - 10.1080/15265161.2020.1779868 [doi]
FAU - Sisk, Bryan A
AU  - Sisk BA
AD  - Washington University School of Medicine.
FAU - DuBois, James
AU  - DuBois J
AD  - Washington University School of Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - Empirical Research
MH  - *Ethical Theory
MH  - Ethics, Research
MH  - Humans
MH  - *Pandemics
EDAT- 2020/07/28 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1779868 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):82-84. doi: 10.1080/15265161.2020.1779868.


PMID- 32716772
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201210
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - A Novel Approach Using Social Media to Solve Medical Ethical Dilemmas and Legal
      Risks in the Emergencies of COVID-19.
PG  - W12-W14
LID - 10.1080/15265161.2020.1782529 [doi]
FAU - Wan, Jing
AU  - Wan J
AD  - Zhongnan Hospital of Wuhan University.
FAU - Huang, Yuqiong
AU  - Huang Y
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and
      Technology.
FAU - Aljaafreh, Amaneh Abdel Hafez A
AU  - Aljaafreh AAHA
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and
      Technology.
FAU - Dong, Dandan
AU  - Dong D
AD  - Wuhan No. 7 Hospital.
FAU - Cong, Yali
AU  - Cong Y
AUID- ORCID: 0000-0001-8036-0054
AD  - Peking University Health Science Centre.
FAU - Lin, Jun
AU  - Lin J
AD  - Zhongnan Hospital of Wuhan University.
FAU - Chen, Hongxiang
AU  - Chen H
AD  - Union Hospital, Tongji Medical College, Huazhong University of Science and
      Technology.
AD  - Huazhong University of Science and Technology Union Shenzhen Hospital.
LA  - eng
PT  - Case Reports
PT  - Letter
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
RN  - COVID-19 serotherapy
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - China
MH  - Coronavirus Infections/*diagnosis/epidemiology/therapy
MH  - Decision Making/ethics
MH  - Female
MH  - Humans
MH  - Immunization, Passive
MH  - Jurisprudence
MH  - Middle Aged
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/*diagnosis/epidemiology/therapy
MH  - Risk
MH  - SARS-CoV-2
MH  - Social Media/*instrumentation
EDAT- 2020/07/28 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1080/15265161.2020.1782529 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):W12-W14. doi: 10.1080/15265161.2020.1782529.


PMID- 32716771
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical Dilemmas in Covid-19 Medical Care: Is a Problematic Triage Protocol
      Better or Worse than No Protocol at All?
PG  - 1-5
LID - 10.1080/15265161.2020.1788663 [doi]
FAU - Fink, Sheri
AU  - Fink S
AD  - Harvard University.
LA  - eng
PT  - Editorial
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - *Ethics, Medical
MH  - Humans
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Triage/*ethics
MH  - United States/epidemiology
EDAT- 2020/07/28 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1080/15265161.2020.1788663 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):1-5. doi: 10.1080/15265161.2020.1788663.


PMID- 32716770
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20220531
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical Allocation of Remdesivir.
PG  - 84-86
LID - 10.1080/15265161.2020.1779395 [doi]
FAU - Crutchfield, Parker
AU  - Crutchfield P
AUID- ORCID: 0000-0002-8729-8561
AD  - Western Michigan University Homer Stryker M.D. School of Medicine.
FAU - Gibb, Tyler S
AU  - Gibb TS
AUID- ORCID: 0000-0003-4426-8597
AD  - Western Michigan University Homer Stryker M.D. School of Medicine.
FAU - Redinger, Michael J
AU  - Redinger MJ
AUID- ORCID: 0000-0001-8424-4384
AD  - Western Michigan University Homer Stryker M.D. School of Medicine.
FAU - Fales, William
AU  - Fales W
AUID- ORCID: 0000-0003-2070-6898
AD  - Western Michigan University Homer Stryker M.D. School of Medicine.
AD  - Michigan Department of Health and Human Services.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - OF5P57N2ZX (Alanine)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adenosine Monophosphate/analogs & derivatives
MH  - *Alanine/analogs & derivatives
MH  - *COVID-19/drug therapy
MH  - Humans
MH  - Resource Allocation
EDAT- 2020/07/28 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 10.1080/15265161.2020.1779395 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):84-86. doi: 10.1080/15265161.2020.1779395.


PMID- 32716769
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Periviability in a Pandemic: Good Ethics Still Considered Essential.
PG  - 177-180
LID - 10.1080/15265161.2020.1779394 [doi]
FAU - Dirksen, Kevin M
AU  - Dirksen KM
AD  - Providence Center for Health Care Ethics.
FAU - Kaempf, Joseph W
AU  - Kaempf JW
AD  - Providence St. Vincent Medical Center.
FAU - Kockler, Nicholas J
AU  - Kockler NJ
AD  - Providence Center for Health Care Ethics.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 May 13;:1-7. PMID: 32400291
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - Infant, Extremely Premature
MH  - Infant, Newborn
MH  - *Influenza, Human
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/07/28 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1080/15265161.2020.1779394 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):177-180. doi: 10.1080/15265161.2020.1779394.


PMID- 32716757
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - From Research to Clinical Practice: Ethical Issues with Neurotechnology and
      Industry Relationships.
PG  - 210-212
LID - 10.1080/21507740.2020.1778122 [doi]
FAU - McIntosh, Tristan
AU  - McIntosh T
AUID- ORCID: 0000-0002-1931-4793
AD  - Washington University School of Medicine.
FAU - DuBois, James M
AU  - DuBois JM
AUID- ORCID: 0000-0002-3712-7051
AD  - Washington University School of Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - *Conflict of Interest
MH  - *Industry
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778122 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):210-212. doi: 10.1080/21507740.2020.1778122.


PMID- 32716755
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210524
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - The BRAIN Initiative and Neuroethics: Enabling and Enhancing Neuroscience
      Advances for Society.
PG  - 135-139
LID - 10.1080/21507740.2020.1778121 [doi]
AB  - As the Brain Research through Advancing Neurotechnologyies, better known as the
      BRAIN Initiative moves forward at a rapid pace increasing attention has focused
      on neuroethics. The National Institutes of Health recently mandated a review of
      the progress of the BRAIN Initiative progress with the goal of fine-tuning its
      future directions. The BRAIN Working Group 2 focused its discussion on science
      while the BRAIN Neuroethics Subgroup focused on neuroethics. The Brain
      Neuroethics Subgroup deliberated for over a year collecting information and
      recommendations through in person and video meetings, a public one-day
      neuroethics symposium and soliciting input from neuroscientists and
      neuroethicist's. The resulting report entitled "The BRAIN Initiative and
      Neuroethics: Enabling and Enhancing Neuroscience Advances for Society" was
      accepted by Director of NIH in October of 2019. The recommendations span many
      BRAIN research neuroethics concerns including privacy considerations, the use of 
      nonhuman primate model systems, neural modulation and enhancement, subject
      participation in BRAIN research and equity in neuroscience research. Further the 
      group recommended a transformative project whose goal of detailing the scientific
      mechanisms and ethical underpinnings of consciousness is one of the most daunting
      issues that impact our perceptions of ourselves. It is anticipated that the
      report?s recommendations will provide a foundation or "roadmap" for ensuring that
      neuroethics and BRAIN research move forward as an integrated effort thereby
      insuring that BRAIN research is of the highest quality.
FAU - Eberwine, James
AU  - Eberwine J
AUID- ORCID: 0000-0002-9363-0858
AD  - University of Pennsylvania.
FAU - Kahn, Jeffrey
AU  - Kahn J
AUID- ORCID: 0000-0003-2493-2016
AD  - Johns Hopkins Berman Institute of Bioethics.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - Animals
MH  - Brain
MH  - Morals
MH  - National Institutes of Health (U.S.)
MH  - *Neurosciences
MH  - Societies
MH  - United States
OTO - NOTNLM
OT  - *Brain Initiative
OT  - *Consciousness
OT  - *Neuroethics Roadmap
OT  - *Neurotechnology
OT  - *Privacy
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778121 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):135-139. doi: 10.1080/21507740.2020.1778121.


PMID- 32716753
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210702
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Fostering Neuroethics Integration with Neuroscience in the BRAIN Initiative:
      Comments on the NIH Neuroethics Roadmap.
PG  - 184-188
LID - 10.1080/21507740.2020.1778120 [doi]
AB  - The BRAIN 2.0 roadmap lauds the neuroscientific advances made in the first decade
      of the BRAIN Initiative, but also calls attention to the need to carefully
      consider how these advances will inform and perhaps alter our understanding of
      "those deepest behaviors that, as humans we hold dear" (Roadmap, Executive
      Summary). In this short statement, we briefly consider several features of the
      BRAIN Neuroethics subgroup's roadmap that lie within our area of expertise,
      including the recommendations to (1) enhance integration of neuroscience and
      neuroethics, and (2) provide additional tools and resources for neuroscientists
      to recognize neuroethics issues and opportunities for neuroethics research.
FAU - Goering, Sara
AU  - Goering S
AD  - University of Washington.
FAU - Klein, Eran
AU  - Klein E
AD  - University of Washington.
AD  - Oregon Health And Science University.
LA  - eng
GR  - RF1 MH117800/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):212-216. PMID: 32716756
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):219-220. PMID: 34029492
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - Brain
MH  - Humans
MH  - *Neurosciences
PMC - PMC7466934
MID - NIHMS1618325
OTO - NOTNLM
OT  - *Brain computer interfaces
OT  - *deep brain stimulation
OT  - *ethics integration
OT  - *neuroethics
OT  - *neuroscience
OT  - *neurotechnology
OT  - *responsibility
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778120 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):184-188. doi: 10.1080/21507740.2020.1778120.


PMID- 32716751
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210702
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Neuroethics in the Shadow of a Pandemic.
PG  - W1-W4
LID - 10.1080/21507740.2020.1778130 [doi]
AB  - Neuroethics under the BRAIN Initiative has been focused upon both the
      neuroethical implications of basic advances in neuroscience, as well as the
      ethics attending the development of ever more powerful tools to both understand
      the brain and treat dysfunction. It has focused on health and disease in the
      context of the pre-pandemic status quo, essentially divorced from issues like
      infectious disease and large-scale disruption of social and economic structures. 
      The questions animating the neuroethics of the BRAIN Initiative, on first glance,
      seemingly fail to intersect with the primary concerns of a post-Covid world, but 
      careful consideration shows that they of course do. After all, the brain's job is
      to model and respond to the pressures of our environment, and the environment of 
      virtually all of humanity has changed in a dramatic way, unprecedented since the 
      rise of modern neuroscience. Here we consider ways in which neuroethics work
      aligned with the BRAIN Initiative can inform our response to the Covid crisis, as
      well as ways in which the pandemic may shape future work in neuroethics. In
      particular we focus on neuroethics work on agency.
FAU - Roskies, Adina L
AU  - Roskies AL
AD  - Dartmouth College.
FAU - Walton, Ashley
AU  - Walton A
AD  - Dartmouth College.
LA  - eng
GR  - RF1 MH117813/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - Brain
MH  - *COVID-19
MH  - Humans
MH  - *Neurosciences
MH  - Pandemics
MH  - SARS-CoV-2
PMC - PMC7477764
MID - NIHMS1618323
OTO - NOTNLM
OT  - *Neuroethics
OT  - *bioethics
OT  - *cognition
OT  - *deep brain stimulation
OT  - *mental health
OT  - *neuroscience
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778130 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):W1-W4. doi: 10.1080/21507740.2020.1778130.


PMID- 32716749
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210524
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - The Road Not Mapped: The Neuroethics Roadmap on Research with Nonhuman Primates.
PG  - 176-183
LID - 10.1080/21507740.2020.1778115 [doi]
AB  - We have arrived at an inflection point, a moment in history when the sentience,
      consciousness, intelligence, agency, and even the moral agency of many nonhuman
      animals can no longer be questioned without ignoring centuries of accumulated
      scientific knowledge. Nowhere is this more true than in our understanding of
      nonhuman primates (NHPs). A neuroethics committed to probing the ethical
      implications of brain research must be able to respond to and anticipate the
      challenges ahead as brain projects globally prepare to increase the use of NHPs
      in research. This requires adopting a less anthropocentric focus that includes
      nonhuman animals within its scope. But the Neuroethics Roadmap represents a
      missed opportunity to critically examine the future direction of research with
      NHPs in an ethically-responsive neuroscience.
FAU - Johnson, L Syd M
AU  - Johnson LSM
AUID- ORCID: 0000-0002-9486-4613
AD  - SUNY Upstate Medical University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):189-191. PMID: 34029493
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - Animals
MH  - Consciousness
MH  - Morals
MH  - *Neurosciences
MH  - Primates
OTO - NOTNLM
OT  - *Animal ethics
OT  - *neuroethics
OT  - *nonhuman primates
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778115 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):176-183. doi: 10.1080/21507740.2020.1778115.


PMID- 32716747
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210524
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - NeuroEthics and the BRAIN Initiative: Where Are We? Where Are We Going?
PG  - 140-147
LID - 10.1080/21507740.2020.1778119 [doi]
AB  - From its inception, the NIH Brain Research through Advancing Innovative
      Neurotechnologies (BRAIN) Initiative, an ambitious project focused on
      understanding the human brain, has made a concerted effort to integrate
      neuroethics into its science. In the past five years, the BRAIN Initiative has
      given rise to powerful tools and neurotechnologies capable of probing deeply into
      the brain circuits in animal models. As these tools mature and move to human
      applications they will raise a host of important neuroethical considerations not 
      just for the medical community but for society as a whole. Now marks a pivotal
      moment to assess the status and consider the future of the BRAIN Initiative's
      neuroethics efforts. Here we describe core issues of neuroscience advances, the
      state of neurotechnologies in human neuroscience, and how ethics will be
      incorporated into the BRAIN Initiative as this ten-year project enters its second
      phase. BRAIN Initiative neurotechnologies have immense potential to transform the
      way we diagnose and treat neurological disease; therefore, they may become more
      commonplace in research, medicine, and society. We also discuss future global
      efforts to ensure continued guidance and open dialogue surrounding neuroethics.
FAU - Koroshetz, Walter J
AU  - Koroshetz WJ
AD  - National Institute of Neurolgogical Disorders and Stroke.
FAU - Ward, Jackie
AU  - Ward J
AD  - National Institute of Neurolgogical Disorders and Stroke.
FAU - Grady, Christine
AU  - Grady C
AD  - National Institutes of Health.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - Animals
MH  - Brain
MH  - Brain Mapping
MH  - Central Nervous System
MH  - Humans
MH  - Models, Animal
MH  - *Neurosciences
OTO - NOTNLM
OT  - *Consciousness
OT  - *brain
OT  - *brain computer interfaces
OT  - *brain fingerprinting
OT  - *deep brain stimulation
OT  - *neural networks
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778119 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):140-147. doi: 10.1080/21507740.2020.1778119.


PMID- 32716746
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210702
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Insiders and Outsiders: Lessons for Neuroethics from the History of Bioethics.
PG  - 155-166
LID - 10.1080/21507740.2020.1778118 [doi]
AB  - Recent disputes over the NIH Neuroethics Roadmap have revealed underlying
      tensions between neuroethics and the broader neuroscience community. These
      controversies should spur neuroethicists to more clearly articulate an oft-cited 
      ideal of "integrating" neuroethics in neuroscience. In this, it is useful to
      consider the integration of bioethics in medical practice as both historical
      precedent and context for integration in neuroethics. Bioethics began as
      interdisciplinary scholars joined biomedical institutions to serve on
      newly-created IRBs and hospital ethics committees. These early bioethicists
      identified as outsiders and their presence was initially resisted by some in the 
      medical establishment, but over time they became integrated into the very
      institutions that many had originally come to critique. This work has transformed
      medical practice, but also required compromises and intellectual costs. Also, the
      successful integration of bioethics relied in part on structural features of
      postwar medicine with no clear analogue in contemporary neuroscience; for
      neuroethics, imaginative new approaches will also be needed. While neuroethics to
      date has focused somewhat narrowly on questions in neurotechnology, I argue that 
      successful integration in neuroethics will likely require a broader vision,
      encompassing the clinical neurosciences as well as questions at the interface of 
      neuroscience and society.
FAU - Chiong, Winston
AU  - Chiong W
AD  - University of California San Francisco.
LA  - eng
GR  - R01 MH114860/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):212-216. PMID: 32716756
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):207-209. PMID: 34029491
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - *Bioethics
MH  - Ethics Committees, Clinical
MH  - *Neurosciences
MH  - Societies
PMC - PMC7485591
MID - NIHMS1618316
OTO - NOTNLM
OT  - *Bioethics
OT  - *neuroethics
OT  - *neurotechnology
OT  - *non-human primates
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778118 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):155-166. doi: 10.1080/21507740.2020.1778118.


PMID- 32716745
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210524
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Neuroethics: Fostering Collaborations to Enable Neuroscientific Discovery.
PG  - 148-154
LID - 10.1080/21507740.2020.1778117 [doi]
AB  - The NIH-funded Brain Research through Advancing Innovative Neurotechnologies((R))
      (BRAIN) Initiative has led to significant advances in what we know about the
      functions and capacities of the brain. This multifaceted and expansive effort
      supports a range of experimentation from cells to circuits, and its outputs
      promise to ease suffering from various neurological injuries, diseases, and
      neuropsychiatric conditions. At the midway point of the 10-year BRAIN Initiative,
      we pause to consider how these studies, and neuroscience research more broadly,
      may bear on human characteristics and moral concepts such as identity, agency,
      and others. This midway point also offers us an opportunity to evaluate the
      sociology and impacts of BRAIN Initiative-funded investigations to ensure that
      ethical standards of fairness and justice pervade the scientific process itself. 
      Neuroethics inquiry provides a mechanism to invite relevant, novel expertise from
      the wide array of disciplines that intersect with biomedicine in neuroscience
      research. As the BRAIN Initiative and the broader field of neuroscience proceed, 
      neuroethics serves as a central component of neuroscience inquiry to i) foster
      necessary and beneficial collaborations for responsible discovery; ii) ensure a
      rigorous, reproducible, and representative neuroscience research process; and
      iii) explore the unique nature of study of the human brain through accurate and
      representative models of its function and dysfunction.
FAU - Farahany, Nita
AU  - Farahany N
AUID- ORCID: 0000-0003-4808-6256
AD  - Duke University.
FAU - Ramos, Khara M
AU  - Ramos KM
AUID- ORCID: 0000-0003-3275-1370
AD  - National Institute of Neurological Disorders and Stroke NIH.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):203-206. PMID: 32716750
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):212-216. PMID: 32716756
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - Brain
MH  - Human Characteristics
MH  - Humans
MH  - Moral Obligations
MH  - Morals
MH  - *Neurosciences
OTO - NOTNLM
OT  - *Brain
OT  - *Neuroethics
OT  - *neuroscience
OT  - *neurotechnology
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778117 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):148-154. doi: 10.1080/21507740.2020.1778117.


PMID- 32716744
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210524
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Of Ethical Frameworks and Neuroethics in Big Neuroscience Projects: A View from
      the HBP.
PG  - 167-175
LID - 10.1080/21507740.2020.1778116 [doi]
AB  - The recently published BRAIN 2.0 Neuroethics Report offers a very helpful
      overview of the possible ethical, social, philosophical, and legal issues raised 
      by neuroscience in the context of BRAIN's research priorities thus contributing
      to the attempt to develop ethically sound neuroscience. In this article, we turn 
      to a running theme of the document: the need for an ethical framework for the
      BRAIN Initiative and for further integration of neuroethics and neuroscience. We 
      assess some of the issues raised and provide an explanation of how we have
      addressed them in the Human Brain Project. We offer our experience in the HBP as 
      a potential contribution to the international debate about neuroethics in the big
      brain initiatives. Our hope is that among other things, the type of exchange
      proposed by this AJOB special issue will prove productive in further identifying 
      and discussing the issues and in inspiring appropriate solutions.
FAU - Salles, Arleen
AU  - Salles A
AUID- ORCID: 0000-0002-1397-7932
AD  - Uppsala University.
AD  - Centro de Investigaciones Filosoficas.
FAU - Farisco, Michele
AU  - Farisco M
AUID- ORCID: 0000-0002-3298-7829
AD  - Uppsala University.
AD  - Biogem, Biology and Molecular Genetics Institute.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
CIN - AJOB Neurosci. 2020;11(3):194-196. PMID: 33868762
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):219-220. PMID: 34029492
CIN - AJOB Neurosci. 2020 Jul-Sep;11(3):131-134. PMID: 34029494
MH  - Brain
MH  - Humans
MH  - Morals
MH  - *Neurosciences
OTO - NOTNLM
OT  - *Culture
OT  - *Ethical framework
OT  - *RRI
OT  - *neuroethics
OT  - *neuroscience
OT  - *philosophy
EDAT- 2020/07/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1080/21507740.2020.1778116 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Jul-Sep;11(3):167-175. doi: 10.1080/21507740.2020.1778116.


PMID- 32716354
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 77
IP  - 1
DP  - 2020
TI  - Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical
      Landscape.
PG  - 339-353
LID - 10.3233/JAD-191300 [doi]
AB  - BACKGROUND: Dementia has been described as the greatest global health challenge
      in the 21st Century on account of longevity gains increasing its incidence,
      escalating health and social care pressures. These pressures highlight ethical,
      social, and political challenges about healthcare resource allocation, what
      health improvements matter to patients, and how they are measured. This study
      highlights the complexity of the ethical landscape, relating particularly to the 
      balances that need to be struck when allocating resources; when measuring and
      prioritizing outcomes; and when individual preferences are sought. OBJECTIVE:
      Health outcome prioritization is the ranking in order of desirability or
      importance of a set of disease-related objectives and their associated cost or
      risk. We analyze the complex ethical landscape in which this takes place in the
      most common dementia, Alzheimer's disease. METHODS: Narrative review of
      literature published since 2007, incorporating snowball sampling where necessary.
      We identified, thematized, and discussed key issues of ethical salience. RESULTS:
      Eight areas of ethical salience for outcome prioritization emerged: 1) Public
      health and distributive justice, 2) Scarcity of resources, 3) Heterogeneity and
      changing circumstances, 4) Knowledge of treatment, 5) Values and circumstances,
      6) Conflicting priorities, 7) Communication, autonomy and caregiver issues, and
      8) Disclosure of risk. CONCLUSION: These areas highlight the difficult balance to
      be struck when allocating resources, when measuring and prioritizing outcomes,
      and when individual preferences are sought. We conclude by reflecting on how
      tools in social sciences and ethics can help address challenges posed by resource
      allocation, measuring and prioritizing outcomes, and eliciting stakeholder
      preferences.
FAU - McKeown, Alex
AU  - McKeown A
AD  - Department of Psychiatry and Wellcome Centre for Ethics and Humanities,
      University of Oxford, Oxford, UK.
FAU - Turner, Andrew
AU  - Turner A
AD  - The National Institute for Health Research Applied Research Collaboration West
      [NIHR ARC West] at University Hospitals Bristol NHS Foundation Trust, University 
      of Bristol, Bristol, UK.
FAU - Angehrn, Zuzanna
AU  - Angehrn Z
AD  - Certara, Loerrach, Germany.
FAU - Gove, Dianne
AU  - Gove D
AD  - Alzheimer Europe, Luxembourg.
FAU - Ly, Amanda
AU  - Ly A
AD  - MRC Integrative Epidemiology Unit & Centre for Academic Mental Health, University
      of Bristol, Bristol, UK.
FAU - Nordon, Clementine
AU  - Nordon C
AD  - CESP, INSERM U1178, Paris, France.
FAU - Nelson, Mia
AU  - Nelson M
AD  - Usher Institute of Population Health Sciences and Informatics, University of
      Edinburgh, Edinburgh, UK.
FAU - Tochel, Claire
AU  - Tochel C
AD  - Usher Institute of Population Health Sciences and Informatics, University of
      Edinburgh, Edinburgh, UK.
FAU - Mittelstadt, Brent
AU  - Mittelstadt B
AD  - Oxford Internet Institute, University of Oxford, Oxford, UK.
FAU - Keenan, Alex
AU  - Keenan A
AD  - Janssen Pharmaceutica NV, Titusville, NJ, USA.
FAU - Smith, Michael
AU  - Smith M
AD  - Alzheimer Scotland Centre for Policy and Practice, University of the West of
      Scotland, Paisley, Scotland, UK.
FAU - Singh, Ilina
AU  - Singh I
AD  - Department of Psychiatry and Wellcome Centre for Ethics and Humanities,
      University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - MC_PC_17215/MRC_/Medical Research Council/United Kingdom
GR  - IS-BRC-1215-20005/DH_/Department of Health/United Kingdom
GR  - 104825/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
MH  - Alzheimer Disease/*diagnosis/psychology/*therapy
MH  - Delivery of Health Care/*ethics/methods
MH  - Humans
MH  - Outcome Assessment, Health Care/*ethics/methods
PMC - PMC7592677
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *dementia
OT  - *ethics
OT  - *health priorities
EDAT- 2020/07/28 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - JAD191300 [pii]
AID - 10.3233/JAD-191300 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;77(1):339-353. doi: 10.3233/JAD-191300.


PMID- 32716266
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Sep
TI  - Systemic Modelling in Bioethics.
PG  - 197-209
LID - 10.1080/20502877.2020.1796258 [doi]
AB  - We present here a new method for bioethics: systemic modelling. In this method,
      the complex phenomenon being studied (e.g. personalized medicine, genetic
      testing, gene therapy, genetically modified organisms) is modelled as a whole, to
      shed light on its organization and functioning, and major (bio)ethical issues and
      solutions for their resolution are then identified. This systemic modelling
      method is ideal for use in the identification of solutions, rather than their
      validation, with other methods then used to test the solutions found. We provide 
      a description and reproducible instructions for the application of systemic
      modelling in bioethics, together with a brief example of the application of this 
      method to the study of the impact of personalized medicine on French society.
FAU - Stoekle, Henri-Corto
AU  - Stoekle HC
AD  - Department of Ethics and Scientific Integrity, Foch Hospital, Suresnes, France.
FAU - Charlier, Philippe
AU  - Charlier P
AD  - Laboratoire Anthropologie, Archeologie, Biologie (LAAB), Universite Paris-Saclay 
      (UVSQ), 2, avenue de la Source-de-la-Bievre, 78180 Montigny-Le-Bretonneux,
      France; Musee du Quai Branly - Jacques-Chirac, 222, rue de l'Universite, 75007
      Paris, France.
FAU - Mamzer-Bruneel, Marie-France
AU  - Mamzer-Bruneel MF
AD  - Centre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de
      Paris, Laboratoire ETRES, F-75006, Paris, France; Cancer Research for
      Personalized Medicine (CARPEM), Paris Descartes, APHP (HEGP, Cochin, Necker)
      INSERM, Paris, France; Assistance Publique-Hopitaux de Paris AP-HP,
      Necker-Enfants Malades Hospital, Paris, France.
FAU - Herve, Christian
AU  - Herve C
AD  - Department of Ethics and Scientific Integrity, Foch Hospital, Suresnes, France;
      Medical School, University of Paris, Paris, France; International Academy of
      Medical Ethics and Public Health, Universite de Paris, Paris, France.
FAU - Vogt, Guillaume
AU  - Vogt G
AD  - Laboratoire Neglected Human Genetics, Inserm, Universite Paris Descartes, Paris, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - *Bioethics
MH  - Ethical Analysis/*methods
MH  - Genetic Testing
MH  - Genetic Therapy
MH  - Humans
MH  - Models, Theoretical
MH  - Organisms, Genetically Modified
MH  - Precision Medicine
MH  - Systems Analysis
OTO - NOTNLM
OT  - Bioethics
OT  - complex phenomena
OT  - personalized medicine
OT  - systemic modelling
EDAT- 2020/07/28 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1080/20502877.2020.1796258 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Sep;26(3):197-209. doi: 10.1080/20502877.2020.1796258. Epub 2020
      Jul 27.


PMID- 32716003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 27
TI  - Visual Fixations and Motion Sensitivity: Protocol for an Exploratory Study.
PG  - e16805
LID - 10.2196/16805 [doi]
AB  - BACKGROUND: Motion sensitivity after vestibular disorders is associated with
      symptoms of nausea, dizziness, and imbalance in busy environments. Dizziness and 
      imbalance are reported in places such as supermarkets and shopping malls which
      have unstable visual backgrounds; however, the mechanism of motion sensitivity is
      poorly understood. OBJECTIVE: The main aim of this exploratory observational
      study is to investigate visual fixations and postural sway in response to
      increasingly complex visual environments in healthy adults and adults with motion
      sensitivity. METHODS: A total of 20 healthy adults and 20 adults with motion
      sensitivity will be recruited for this study. Visual fixations, postural sway,
      and body kinematics will be measured with a mobile eye tracker device, force
      plate, and 3D motion capture system, respectively. Participants will be exposed
      to experimental tasks requiring visual fixation on letters, projected on a range 
      of backgrounds on a large screen during quiet stance. Descriptive statistics
      (mean and standard deviation) will be calculated for each of the variables.
      One-way independent-measures analyses of variance will be performed to
      investigate the differences between groups for all variables. RESULTS: Data
      collection was started in May 2019 and was completed by February 2020. It was
      approved by Health and Disability Ethics Committees, Ministry of Health, New
      Zealand on November 2, 2018 (Ethics ref: 18/CEN/193). We are currently processing
      the data and will begin data analysis in July 2020. We expect the results to be
      available for publication by the end of 2020. The trial was funded by the
      Neurology Special Interest Group, Physiotherapy New Zealand, and the Eisdell
      Moore Centre in November 2018. CONCLUSIONS: This study will provide a detailed
      investigation of visual fixations in response to increasingly complex visual
      environments. Investigating characteristics of visual fixations in healthy adults
      and those with motion sensitivity will provide insight into this disabling
      condition and may inform the development of new intervention strategies which
      explicitly cater to the needs of this population. TRIAL REGISTRATION: Australian 
      New Zealand Clinical Trials Registry, ACTRN12619000254190;
      https://tinyurl.com/yxbn7nks. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      PRR1-10.2196/16805.
CI  - (c)Shikha Chaudhary, Nicola Saywell, Arun Kumar, Denise Taylor. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      27.07.2020.
FAU - Chaudhary, Shikha
AU  - Chaudhary S
AUID- ORCID: https://orcid.org/0000-0003-1067-5063
AD  - Auckland University of Technology, Auckland, New Zealand.
FAU - Saywell, Nicola
AU  - Saywell N
AUID- ORCID: https://orcid.org/0000-0003-4676-3444
AD  - Auckland University of Technology, Auckland, New Zealand.
FAU - Kumar, Arun
AU  - Kumar A
AUID- ORCID: https://orcid.org/0000-0001-5018-0538
AD  - Manipal Institute of Technology, Manipal, Karnataka, India.
FAU - Taylor, Denise
AU  - Taylor D
AUID- ORCID: https://orcid.org/0000-0002-0955-5702
AD  - Auckland University of Technology, Auckland, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7418000
OTO - NOTNLM
OT  - complex environments
OT  - inner ear
OT  - kinematics
OT  - motion sensitivity
OT  - postural control
OT  - posture
OT  - vestibular disorder
OT  - visual
OT  - visual fixations
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2019/10/26 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - v9i7e16805 [pii]
AID - 10.2196/16805 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 27;9(7):e16805. doi: 10.2196/16805.


PMID- 32715988
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Sep
TI  - GnRHa ('Puberty Blockers') and Cross Sex Hormones for Children and Adolescents:
      Informed Consent, Personhood and Freedom of Expression.
PG  - 224-237
LID - 10.1080/20502877.2020.1796257 [doi]
AB  - Ethical concerns have been raised about routine practice in paediatric gender
      clinics. We discuss informed consent and the risk of iatrogenesis in the
      prescribing of gonadotropin-releasing hormone analogues (GnRHas) and cross sex
      hormones to children and adolescents respectively. We place those clinical
      concerns in a wider societal context and invite consideration of two further
      relevant ethical domains: competing rights-based claims about male and female
      personhood; and freedom of expression about those claims. When reflecting on the 
      assessment and medicalization of children and adolescents presenting at gender
      clinics, the matters of informed consent and iatrogenic risk should be the most
      pressing for clinicians. However, this is not just a matter of medical ethics, it
      also implies the need for a full ethical debate on competing notions of
      personhood and the defence of freedom of expression about transgender and its
      implications within contemporary democracies.
FAU - Pilgrim, David
AU  - Pilgrim D
AD  - Department of Psychology, University of Southampton, Southampton, UK.
FAU - Entwistle, Kirsty
AU  - Entwistle K
AD  - Independent Practice, Guimaraes, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
RN  - 0 (Gonadal Steroid Hormones)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 79561-22-1 (LHRH, Ala(6)-Gly(10)-ethylamide-)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child Health
MH  - Delivery of Health Care/*ethics
MH  - Female
MH  - *Freedom
MH  - *Gender Dysphoria/drug therapy
MH  - *Gender Identity
MH  - *Gonadal Steroid Hormones/therapeutic use
MH  - Gonadotropin-Releasing Hormone/analogs & derivatives/therapeutic use
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - *Personhood
MH  - Puberty
MH  - *Transgender Persons
MH  - Transsexualism
OTO - NOTNLM
OT  - Sex
OT  - capacity
OT  - gender
OT  - iatrogenesis
OT  - transgender
EDAT- 2020/07/28 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1080/20502877.2020.1796257 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Sep;26(3):224-237. doi: 10.1080/20502877.2020.1796257. Epub 2020
      Jul 27.


PMID- 32715948
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20220420
IS  - 1460-3659 (Electronic)
IS  - 0306-3127 (Linking)
VI  - 50
IP  - 5
DP  - 2020 Oct
TI  - Ethics in retrospect: Biomedical research, colonial violence, and Inupiat
      sovereignty in the Alaskan Arctic.
PG  - 778-801
LID - 10.1177/0306312720943678 [doi]
AB  - Kaare Rodahl, a scientist with the US Air Force's Arctic Aeromedical Laboratory, 
      spent much of the 1950s traveling to villages in the Alaskan Arctic to conduct
      research on cold acclimatization. Four decades later, it was discovered that
      during one such study, he had administered radioactive isotopes of iodine-131 to 
      over one hundred Alaska Native research subjects without their knowledge or
      consent. This news broke just as Alaska Native communities were attempting to
      recover from a series of revelations surrounding other instances of Cold War
      radiation exposure. In response, two major federal investigations attempted to
      determine whether Rodahl had adhered to ethical regulations and whether his
      actions could be expected to have a lasting health impact on former research
      subjects. The National Research Council, framing the study as a singular event in
      the Cold War past, found that research subjects had been 'wronged, but not
      harmed'. The North Slope Borough, a powerful Alaska Native municipal government, 
      countered this finding with their own investigation, which identified both the
      study and the subsequent federal inquiries as facets of the still-unfolding
      process of American settler colonialism in Alaska. In doing so, the North Slope
      Borough contested the authority of federal agencies to set the terms by which
      ethics could be retrospectively judged. This article argues that exploring how
      competing ethical regimes represent the relationship between violence and time
      can help us better understand how institutionalized bioethics reproduces settler 
      colonial power relations.
FAU - Lanzarotta, Tess
AU  - Lanzarotta T
AUID- ORCID: 0000-0003-1042-1215
AD  - University of Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200727
PL  - United States
TA  - Soc Stud Sci
JT  - Social studies of science
JID - 7506743
MH  - Arctic Regions
MH  - *Biomedical Research
MH  - Humans
MH  - *Inuits
MH  - Male
MH  - Retrospective Studies
MH  - Violence
OTO - NOTNLM
OT  - *alaska native studies
OT  - *arctic science
OT  - *bioethics
OT  - *cold war
OT  - *indigenous peoples
OT  - *settler colonialism
EDAT- 2020/07/28 06:00
MHDA- 2022/04/21 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1177/0306312720943678 [doi]
PST - ppublish
SO  - Soc Stud Sci. 2020 Oct;50(5):778-801. doi: 10.1177/0306312720943678. Epub 2020
      Jul 27.


PMID- 32715497
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Reexamining the categorical exclusion of pediatric participants from controlled
      human infection trials.
PG  - 785-796
LID - 10.1111/bioe.12788 [doi]
AB  - Controlled human infection (CHI) models have been developed for numerous
      pathogens in order to better understand disease processes and accelerate drug and
      vaccine testing. In the past, some researchers conducted highly controversial
      CHIs with vulnerable populations, including children. Ethical frameworks for CHIs
      now recommend vulnerable populations be excluded because they cannot consent to
      high risk research. In this paper we argue that CHI studies span a wide spectrum 
      of benefit and risk, and that some CHI studies may involve minimal risk. The
      categorical exclusion of children from CHIs therefore departs from the standard
      approach to evaluating research risks, as international regulations and ethical
      guidance for pediatric research generally permit non-beneficial research with low
      risks. The paradigm in research ethics has also shifted from focusing on
      protecting vulnerable participants to recognizing that inclusion can be important
      as a matter of justice, providing new reasons to question this default exclusion 
      of children from CHIs. Recognizing that pediatric CHIs can raise complex ethical 
      issues and are easy to sensationalize in ways that may threaten the public's
      trust in research and sponsor institutions, we conclude by describing additional 
      complexities that must be addressed before pediatric CHIs beyond licensed vaccine
      studies might be ethically acceptable.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Murphy, Sean C
AU  - Murphy SC
AUID- ORCID: 0000-0002-2048-0131
AD  - Departments of Laboratory Medicine and Microbiology and the Center for Emerging
      and Re-emerging Infectious Diseases, University of Washington, 750 Republican
      St., F873, Seattle, WA, 98109, United States of America.
AD  - Seattle Malaria Clinical Trials Center, Fred Hutch Cancer Research Center, 1100
      Fairview Ave. N., E3-300, Seattle, WA, 98109, United States of America.
FAU - Duenas, Devan M
AU  - Duenas DM
AD  - Treuman Katz Center for Pediatric Bioethics, Seattle Children's Hospital and
      Research Institute, 1900 Ninth Ave., M/S JMB-6, Seattle, WA, 98101, United States
      of America.
FAU - Richie, Thomas L
AU  - Richie TL
AD  - Sanaria Inc., 9800 Medical Center Drive, Suite A209, Rockville, MD, 20850, United
      States of America.
FAU - Shah, Seema K
AU  - Shah SK
AUID- ORCID: 0000-0001-7726-1186
AD  - Department of Pediatrics, Northwestern University Feinberg School of Medicine,
      680 N Lake Shore Drive, Suite 13-111, Chicago, IL, 60611, United States of
      America.
LA  - eng
GR  - Brocher Foundation/International
GR  - Making a Difference Grant/Greenwall Foundation/International
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200726
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Biomedical Research
MH  - Child
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent
MH  - Research Design
MH  - Research Personnel
MH  - Vulnerable Populations
OTO - NOTNLM
OT  - *Controlled Human Infection (CHI)
OT  - *Controlled Human Malaria Infection
OT  - *human challenge trials
OT  - *pediatric research
OT  - *research ethics
EDAT- 2020/07/28 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/07/28 06:00
PHST- 2019/05/16 00:00 [received]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1111/bioe.12788 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):785-796. doi: 10.1111/bioe.12788. Epub 2020 Jul 26.


PMID- 32715477
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1095-8649 (Electronic)
IS  - 0022-1112 (Linking)
VI  - 97
IP  - 4
DP  - 2020 Oct
TI  - Fish species in estuaries - from partial association to complete dependency.
PG  - 1262-1264
LID - 10.1111/jfb.14476 [doi]
AB  - Estuarine dependency by certain fish species has been clearly demonstrated in a
      number of studies, but the term has also been used for those species and guilds
      that are not dependent on estuaries. The origins and development of the term are 
      explored, and definitions for four types of estuarine fish association are
      provided which may be helpful in facilitating classification and comparisons
      between fish taxa using estuarine systems in different parts of the world. In
      addition, a diagrammatic representation of more recent estuary-associated guild
      categories is presented to provide context and clarity on the estuarine
      dependency issue, and the fact that a continuum in terms of dependency is perhaps
      most appropriate for describing fish species relationships with estuaries.
      ETHICAL STATEMENT: This brief communication is a philosophical discussion and did
      not involve the capture, use or care of any living or dead fish. Therefore, no
      permit or animal ethics clearance was required to undertake the literature
      review.
CI  - (c) 2020 Fisheries Society of the British Isles.
FAU - Whitfield, Alan K
AU  - Whitfield AK
AUID- ORCID: https://orcid.org/0000-0003-1452-7367
AD  - South African Institute for Aquatic Biodiversity, Grahamstown, South Africa.
LA  - eng
GR  - N/A/The financial and infrastructural support of SAIAB-NRF is gratefully
      acknowledged.
GR  - SAIAB-NRF
PT  - Journal Article
PT  - Review
DEP - 20200813
PL  - England
TA  - J Fish Biol
JT  - Journal of fish biology
JID - 0214055
SB  - IM
MH  - Animals
MH  - *Biodiversity
MH  - *Estuaries
MH  - *Fishes/classification
OTO - NOTNLM
OT  - estuarine dependency
OT  - estuarine species
OT  - estuary-associated species
OT  - fish life cycles
EDAT- 2020/07/28 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/05/30 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/23 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1111/jfb.14476 [doi]
PST - ppublish
SO  - J Fish Biol. 2020 Oct;97(4):1262-1264. doi: 10.1111/jfb.14476. Epub 2020 Aug 13.


PMID- 32715292
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2590-1613 (Electronic)
IS  - 2590-1613 (Linking)
VI  - 7
DP  - 2020 Jul
TI  - The role of transforming growth factor-ss (TGF-ss1) in postmenopausal women with 
      pelvic organ prolapse: An immunohistochemical study.
PG  - 100111
LID - 10.1016/j.eurox.2020.100111 [doi]
AB  - OBJECTIVE: Aim of the study was to investigate the expression of transforming
      growth factor-beta1 (TGF-beta1), a key regulator of the extracellular matrix
      composition, in the uterosacral ligaments (USLs) of women with pelvic organ
      prolapse (POP) compared with controls. We hypothesized that the expression
      pattern of TGF-beta1 differs between postmenopausal women with or without POP.
      METHODS: Under ethical approval, USL samples were obtained from postmenopausal
      women undergoing vaginal hysterectomy for stage two or greater pelvic organ
      prolapse (cases, n = 70) and from postmenopausal women without pelvic organ
      prolapse undergoing vaginal hysterectomy for benign indications (controls, n =
      30). Immunohistochemical staining was performed from paraffin embedded tissue
      using anti-TGF-beta1 antibodies. The expression of TGF-beta1 was evaluated by the
      pathologist, who was blinded to all clinical data. RESULTS: The expression of
      TGF-ss1 was similar in patients with symptomatic POP (89 % positive) and in
      controls (90 % positive) without any signs of prolapse (p = 0.091). Age-adjusted 
      analysis did not significantly alter these results. Regarding POP-Q stages,
      TGF-ss1 was significantly more frequently expressed in severe prolapse cases
      compared to moderate/mild cases (POP-Q stage IV versus POP-Q stage II and III; p 
      = 0.001). No significant association could be detected between TGF-ss1 expression
      and age, BMI and parity in cases with POP (p > 0.05). As published previously,
      advanced patients' age as well as early menopausal age remained independent risk 
      factors associated with POP in multiple logistic regression analysis (p = 0.001; 
      p = 0.02). CONCLUSION: Although our study detected POP-Q stage related
      alterations in USL composition and TGF-ss1 expression, there was no significant
      difference in the expression of TGF-beta1 in cases with or without prolapse.
CI  - (c) 2020 The Authors.
FAU - Carlin, Greta Lisa
AU  - Carlin GL
AD  - Department of General Gynecology and Gynecologic Oncology, Medical University of 
      Vienna, Austria.
FAU - Bodner, Klaus
AU  - Bodner K
AD  - Department of General Gynecology and Gynecologic Oncology, Medical University of 
      Vienna, Austria.
FAU - Kimberger, Oliver
AU  - Kimberger O
AD  - Department of Anesthesiology, Medical University of Vienna, Austria.
FAU - Haslinger, Peter
AU  - Haslinger P
AD  - Department of Obstetrics and Gynecology, Medical University of Vienna, Austria.
FAU - Schneeberger, Christian
AU  - Schneeberger C
AD  - Department of Obstetrics and Gynecology, Medical University of Vienna, Austria.
FAU - Horvat, Reinhard
AU  - Horvat R
AD  - Institute for Pathology, Medical University of Vienna, Austria.
FAU - Kolbl, Heinz
AU  - Kolbl H
AD  - Department of General Gynecology and Gynecologic Oncology, Medical University of 
      Vienna, Austria.
FAU - Umek, Wolfgang
AU  - Umek W
AD  - Department of General Gynecology and Gynecologic Oncology, Medical University of 
      Vienna, Austria.
AD  - Karl Landsteiner Institute of Specialised Obstetrics and Gynecology, Austria.
FAU - Bodner-Adler, Barbara
AU  - Bodner-Adler B
AD  - Department of General Gynecology and Gynecologic Oncology, Medical University of 
      Vienna, Austria.
AD  - Karl Landsteiner Institute of Specialised Obstetrics and Gynecology, Austria.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - Netherlands
TA  - Eur J Obstet Gynecol Reprod Biol X
JT  - European journal of obstetrics & gynecology and reproductive biology: X
JID - 101750520
PMC - PMC7379135
OTO - NOTNLM
OT  - Immunohistochemistry
OT  - Pelvic organ prolapse
OT  - Postmenopausal women
OT  - TGF-ss1 expression
OT  - Uterosacral ligament
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.1016/j.eurox.2020.100111 [doi]
AID - S2590-1613(20)30005-3 [pii]
AID - 100111 [pii]
PST - epublish
SO  - Eur J Obstet Gynecol Reprod Biol X. 2020 May 11;7:100111. doi:
      10.1016/j.eurox.2020.100111. eCollection 2020 Jul.


PMID- 32715151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Assessing the impact of Social Networking Site use on older people's loneliness
      and social isolation. A randomized controlled trial: The Aging in a Networked
      Society-Social Experiment Study (ANS-SE).
PG  - 100615
LID - 10.1016/j.conctc.2020.100615 [doi]
AB  - INTRODUCTION: An ageing society poses unprecedented challenges to societies.
      Information and Communication Technologies (ICTs), including Social Networking
      Sites (SNSs), may contribute to contrast loneliness and social isolation in old
      age. Despite of the potentialities of SNSs, there is only a handful of studies
      assessing the causal relationship of SNS use and older people's well-being. This 
      paper aims to provide further evidence on the design of randomised controlled
      trials exploring the causal impact of SNS use on loneliness and social isolation 
      in old age. METHODS AND ANALYSIS: The Aging in a Networked Society-Social
      Experiment Study (ANS-SE) is a randomised controlled trial conducted on people
      aged 75 and over residing in a town located in the Milan area (Italy) aiming to
      assess the impact of SNS use on loneliness and social isolation (i.e. the primary
      outcomes of this study). The study is constituted of two stages, i.e. the
      baseline and the follow up. The experiment is structured into one treatment group
      and two control groups; the interventions are the attendance to a course on SNS
      use (T1) and lifestyle education and brain functioning (C1). The inactive control
      group (C) is constituted of a waiting list. We will perform bivariate and
      regression analysis. ETHICS AND DISSEMINATION: The study has been approved by the
      Ethic Committee of the University of Milano Bicocca (prot. 431/2019) and was
      registered at Clinical Trials.gov (NCT04242628). Written consent was obtained
      from all respondents. Results from the study will be discussed with the local
      community and stakeholders, presented in national and international conferences
      and published in leading peer-review journals. The consent forms, the anonymised 
      dataset, and the relevant statistical codes will be deposited with the Italian
      Unidata archive, also in charge of releasing the data to the public, upon a short
      embargo period.
CI  - (c) 2020 Published by Elsevier Inc.
FAU - Zaccaria, Daniele
AU  - Zaccaria D
AD  - University of Applied Sciences and Arts of Southern Switzerland, Department of
      Business Economics, Health and Social Care, Centre of Competence on Ageing,
      Manno, Switzerland.
FAU - Guaita, Antonio
AU  - Guaita A
AD  - Golgi Cenci Foundation, Abbiategrasso, Italy.
FAU - Vaccaro, Roberta
AU  - Vaccaro R
AD  - Golgi Cenci Foundation, Abbiategrasso, Italy.
FAU - Casanova, Georgia
AU  - Casanova G
AD  - IRCCS-INRCA-National Institute of Health & Science on Ageing, Centre for
      Socio-Economic Research on Ageing, Ancona, Italy.
FAU - Abbondanza, Simona
AU  - Abbondanza S
AD  - Golgi Cenci Foundation, Abbiategrasso, Italy.
FAU - Pettinato, Laura
AU  - Pettinato L
AD  - University of Milan Bicocca, Department of Sociology and Social Research, Milan, 
      Italy.
FAU - Cerati, Gabriele
AU  - Cerati G
AD  - Golgi Cenci Foundation, Abbiategrasso, Italy.
FAU - Rolandi, Elena
AU  - Rolandi E
AD  - Golgi Cenci Foundation, Abbiategrasso, Italy.
FAU - Sala, Emanuela
AU  - Sala E
AD  - University of Milan Bicocca, Department of Sociology and Social Research, Milan, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7362852
OTO - NOTNLM
OT  - *Loneliness
OT  - *Older people
OT  - *Social Networking Sites use
OT  - *Social isolation
COIS- None.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.1016/j.conctc.2020.100615 [doi]
AID - S2451-8654(20)30099-5 [pii]
AID - 100615 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Jul 15;19:100615. doi:
      10.1016/j.conctc.2020.100615. eCollection 2020 Sep.


PMID- 32715010
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2328-4277 (Print)
IS  - 2328-4277 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Feb
TI  - Integrating the Water Planetary Boundary With Water Management From Local to
      Global Scales.
PG  - e2019EF001377
LID - 10.1029/2019EF001377 [doi]
AB  - The planetary boundaries framework defines the "safe operating space for
      humanity" represented by nine global processes that can destabilize the Earth
      System if perturbed. The water planetary boundary attempts to provide a global
      limit to anthropogenic water cycle modifications, but it has been challenging to 
      translate and apply it to the regional and local scales at which water problems
      and management typically occur. We develop a cross-scale approach by which the
      water planetary boundary could guide sustainable water management and governance 
      at subglobal contexts defined by physical features (e.g., watershed or aquifer), 
      political borders (e.g., city, nation, or group of nations), or commercial
      entities (e.g., corporation, trade group, or financial institution). The
      application of the water planetary boundary at these subglobal contexts occurs
      via two approaches: (i) calculating fair shares, in which local water cycle
      modifications are compared to that context's allocation of the global safe
      operating space, taking into account biophysical, socioeconomic, and ethical
      considerations; and (ii) defining a local safe operating space, in which
      interactions between water stores and Earth System components are used to define 
      local boundaries required for sustaining the local water system in stable
      conditions, which we demonstrate with a case study of the Cienaga Grande de Santa
      Marta wetlands in Colombia. By harmonizing these two approaches, the water
      planetary boundary can ensure that water cycle modifications remain within both
      local and global boundaries and complement existing water management and
      governance approaches.
CI  - (c)2020 The Authors.
FAU - Zipper, Samuel C
AU  - Zipper SC
AD  - Kansas Geological Survey University of Kansas Lawrence KS USA.
AD  - Department of Civil Engineering University of Victoria Victoria British Columbia 
      Canada.
FAU - Jaramillo, Fernando
AU  - Jaramillo F
AD  - Department of Physical Geography Stockholm University Stockholm Sweden.
AD  - Baltic Sea Centre Stockholm University Stockholm Sweden.
FAU - Wang-Erlandsson, Lan
AU  - Wang-Erlandsson L
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
FAU - Cornell, Sarah E
AU  - Cornell SE
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
FAU - Gleeson, Tom
AU  - Gleeson T
AD  - Department of Civil Engineering University of Victoria Victoria British Columbia 
      Canada.
FAU - Porkka, Miina
AU  - Porkka M
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
AD  - Bolin Centre for Climate Research Stockholm University Stockholm Sweden.
FAU - Hayha, Tiina
AU  - Hayha T
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
AD  - International Institute for Applied Systems Analysis Laxenburg Austria.
FAU - Crepin, Anne-Sophie
AU  - Crepin AS
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
AD  - Beijer Institute of Ecological Economics Royal Swedish Academy of Sciences
      Stockholm Sweden.
FAU - Fetzer, Ingo
AU  - Fetzer I
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
FAU - Gerten, Dieter
AU  - Gerten D
AD  - Potsdam Institute for Climate Impact Research, Member of the Leibniz Association 
      Potsdam Germany.
AD  - Department of Geography Humboldt-Universitat zu Berlin Berlin Germany.
FAU - Hoff, Holger
AU  - Hoff H
AD  - Potsdam Institute for Climate Impact Research, Member of the Leibniz Association 
      Potsdam Germany.
AD  - Stockholm Environment Institute Stockholm Sweden.
FAU - Matthews, Nathanial
AU  - Matthews N
AD  - Global Resilience Partnership Stockholm Sweden.
FAU - Ricaurte-Villota, Constanza
AU  - Ricaurte-Villota C
AD  - Instituto de Investigaciones Marinas y Costeras "Jose Benito Vives de Andreis"
      Santa Marta Colombia.
FAU - Kummu, Matti
AU  - Kummu M
AD  - Water and Development Research Group Aalto University Espoo Finland.
FAU - Wada, Yoshihide
AU  - Wada Y
AD  - International Institute for Applied Systems Analysis Laxenburg Austria.
FAU - Gordon, Line
AU  - Gordon L
AD  - Stockholm Resilience Centre Stockholm University Stockholm Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200213
PL  - United States
TA  - Earths Future
JT  - Earth's future
JID - 101637948
PMC - PMC7375053
OTO - NOTNLM
OT  - Anthropocene
OT  - Earth Systems
OT  - cross-scale
OT  - planetary boundaries
OT  - water cycle
OT  - water management
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2020/01/03 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.1029/2019EF001377 [doi]
AID - EFT2618 [pii]
PST - ppublish
SO  - Earths Future. 2020 Feb;8(2):e2019EF001377. doi: 10.1029/2019EF001377. Epub 2020 
      Feb 13.


PMID- 32714912
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Plant Tissues as 3D Natural Scaffolds for Adipose, Bone and Tendon Tissue
      Regeneration.
PG  - 723
LID - 10.3389/fbioe.2020.00723 [doi]
AB  - Decellularized tissues are a valid alternative as tissue engineering scaffolds,
      thanks to the three-dimensional structure that mimics native tissues to be
      regenerated and the biomimetic microenvironment for cells and tissues growth.
      Despite decellularized animal tissues have long been used, plant tissue
      decellularized scaffolds might overcome availability issues, high costs and
      ethical concerns related to the use of animal sources. The wide range of features
      covered by different plants offers a unique opportunity for the development of
      tissue-specific scaffolds, depending on the morphological, physical and
      mechanical peculiarities of each plant. Herein, three different plant tissues
      (i.e., apple, carrot, and celery) were decellularized and, according to their
      peculiar properties (i.e., porosity, mechanical properties), addressed to
      regeneration of adipose tissue, bone tissue and tendons, respectively.
      Decellularized apple, carrot and celery maintained their porous structure, with
      pores ranging from 70 to 420 mum, depending on the plant source, and were stable 
      in PBS at 37 degrees C up to 7 weeks. Different mechanical properties (i.e.,
      Eapple = 4 kPa, Ecarrot = 43 kPa, Ecelery = 590 kPa) were measured and no
      indirect cytotoxic effects were demonstrated in vitro after plants
      decellularization. After coating with poly-L-lysine, apples supported 3T3-L1
      preadipocytes adhesion, proliferation and adipogenic differentiation; carrots
      supported MC3T3-E1 pre-osteoblasts adhesion, proliferation and osteogenic
      differentiation; celery supported L929 cells adhesion, proliferation and guided
      anisotropic cells orientation. The versatile features of decellularized plant
      tissues and their potential for the regeneration of different tissues are proved 
      in this work.
CI  - Copyright (c) 2020 Contessi Negrini, Toffoletto, Fare and Altomare.
FAU - Contessi Negrini, Nicola
AU  - Contessi Negrini N
AD  - Department of Chemistry, Materials and Chemical Engineering "G. Natta",
      Politecnico di Milano, Milan, Italy.
AD  - National Interuniversity Consortium of Materials Science and Technology, Local
      Unit Politecnico di Milano, Milan, Italy.
FAU - Toffoletto, Nadia
AU  - Toffoletto N
AD  - Department of Chemistry, Materials and Chemical Engineering "G. Natta",
      Politecnico di Milano, Milan, Italy.
AD  - National Interuniversity Consortium of Materials Science and Technology, Local
      Unit Politecnico di Milano, Milan, Italy.
FAU - Fare, Silvia
AU  - Fare S
AD  - Department of Chemistry, Materials and Chemical Engineering "G. Natta",
      Politecnico di Milano, Milan, Italy.
AD  - National Interuniversity Consortium of Materials Science and Technology, Local
      Unit Politecnico di Milano, Milan, Italy.
FAU - Altomare, Lina
AU  - Altomare L
AD  - Department of Chemistry, Materials and Chemical Engineering "G. Natta",
      Politecnico di Milano, Milan, Italy.
AD  - National Interuniversity Consortium of Materials Science and Technology, Local
      Unit Politecnico di Milano, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7344190
OTO - NOTNLM
OT  - adipose tissue engineering
OT  - bone tissue engineering
OT  - decellularization
OT  - plant tissues
OT  - tendon tissue engineering
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.3389/fbioe.2020.00723 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 Jun 30;8:723. doi: 10.3389/fbioe.2020.00723.
      eCollection 2020.


PMID- 32714474
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 92
DP  - 2020
TI  - Parental Experience of Potential Adverse Drug Reactions Related to Their Oral
      Administration of Antipyretic Analgesic Medicines in Children in Saudi Arabia.
PG  - 100592
LID - 10.1016/j.curtheres.2020.100592 [doi]
AB  - BACKGROUND: Oral antipyretic analgesic medicines are commonly used in children
      and have the potential for adverse drug reactions (ADRs). OBJECTIVE: The aim of
      this study was to explore parental experiences of potential ADRs related to their
      oral administration of antipyretic analgesics in children in the Kingdom of Saudi
      Arabia. METHODS: For this cross-sectional survey, a paper-based questionnaire,
      consent form and information sheet were handed out to 1000 parents who had
      administered an oral antipyretic analgesic medicine to their children during the 
      previous 3 months. Data were entered and analyzed using SPSS version 21.0
      (IBM-SPSS Inc, Armonk, NY). Simple descriptive and inferential statistics were
      used. Management and ethical approvals were attained. RESULTS: During March to
      April 2017, 661 parents agreed to participate, giving a response rate of 66.1%.
      Of the surveyed sample, 208 parents had observed 1 or more potential ADRs (31.5%,
      n=208 out of 661). Parents' (n=208) most commonly reported potential ADRs (n=523)
      were loss of appetite (23%, n=120 out of 523), stomachache (20.3%, n=106 out of
      523), abdominal colic (13%, n=68 out of 523), and diarrhea (10.3%, n=54 out of
      523). Parents described severity of the ADRs as slight (71.8%, n=342 out of 476),
      annoying to the child (7.9%, n=85 to of 476), significant and affecting daily
      tasks (3.6%, n=17 out of 476) and significant and led to the hospital (6.7%, n=32
      out of 476). Fever was the top-ranked reason for using antipyretic analgesic
      medicines (41.0%, n=271 out of 661), followed by toothache (25.0%, n=165 out of
      661) and tonsillitis/laryngitis (24.7%, n=163 out of 661). Among parents, 34.7%
      (n=165 out of 476) did not seek medical attention when a potential ADR occurred, 
      whereas 26.3% (n=125 out of 476) of parents took their children to hospital
      clinics. CONCLUSIONS: Although the majority of parentally reported (but not
      proven) ADRs were mild, a number of significant ADRs were reported. Future
      research should consider whether there is a role for physicians and pharmacists
      in educating parents in Saudi Arabia, and perhaps more widely, about the optimal 
      use of oral antipyretic and analgesic medicines in children. (Curr Ther Res Clin 
      Exp. 2020; 81:XXX-XXX)(c) 2020 Elsevier HS Journals, Inc.
CI  - (c) 2020 The Author(s).
FAU - Tobaiqy, Mansour
AU  - Tobaiqy M
AD  - Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah,
      P.O. Box 45311 Jeddah 21512, Makkah, Saudi Arabia.
FAU - MacLure, Katie
AU  - MacLure K
AD  - School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen,
      Scotland, United Kingdom.
FAU - Radwi, Mansoor
AU  - Radwi M
AD  - Department of Hematology, College of Medicine, University of Jeddah, Jeddah,
      Makkah, Saudi Arabia.
FAU - Almalki, Ashwaq M
AU  - Almalki AM
AD  - Department of Ophthalmology, King Abdulaziz Medical City, Jeddah, Makkah, Saudi
      Arabia.
FAU - Alhasan, Ahmed H
AU  - Alhasan AH
AD  - Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah,
      P.O. Box 45311 Jeddah 21512, Makkah, Saudi Arabia.
FAU - Tannoury, Maya
AU  - Tannoury M
AD  - Faculty of Health Sciences, American University of Science and Technology,
      Beirut, Lebanon.
FAU - Attieh, Zouhair
AU  - Attieh Z
AD  - Faculty of Health Sciences, American University of Science and Technology,
      Beirut, Lebanon.
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC7378853
OTO - NOTNLM
OT  - adverse drug reactions
OT  - antipyretic analgesics
OT  - children
OT  - parents
OT  - survey
COIS- The authors have indicated that they have no conflicts of interest regarding the 
      content of this article.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/06/13 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.1016/j.curtheres.2020.100592 [doi]
AID - S0011-393X(20)30018-7 [pii]
AID - 100592 [pii]
PST - epublish
SO  - Curr Ther Res Clin Exp. 2020 Jun 20;92:100592. doi:
      10.1016/j.curtheres.2020.100592. eCollection 2020.


PMID- 32714125
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210919
IS  - 1556-5068 (Electronic)
IS  - 1556-5068 (Linking)
DP  - 2020 Jun 16
TI  - Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon
      Signaling.
PG  - 3628297
LID - 10.2139/ssrn.3628297 [doi]
AB  - Severe Acute Respiratory Syndrome- Coronavirus 2 (SARS-Cov-2) has caused over
      5,000,000 cases of Coronavirus disease (COVID-19) with significant fatality
      rate.&nbsp;Due to the urgency of this global pandemic, numerous therapeutic and
      vaccine trials have begun without customary safety and efficacy studies.
      &nbsp;Laboratory mice have been the stalwart of these types of studies; however, 
      they do not support infection by SARS-CoV-2 due to the inability of its spike (S)
      protein to engage the mouse ortholog of its human entry receptor
      angiotensin-converting enzyme 2 (hACE2). While hACE2 transgenic mice support
      infection and pathogenesis,&nbsp;these mice are currently limited in availability
      and are restricted to a single genetic background. Here we report the development
      of a mouse model of SARS-CoV-2 based on adeno associated virus (AAV)-mediated
      expression of hACE2. These mice support viral replication and antibody production
      and exhibit pathologic findings found in COVID-19 patients as well as non-human
      primate models. Moreover, we show that type I interferons are unable to control
      SARS-CoV2 replication and drive pathologic responses. Thus, the hACE2-AAV mouse
      model enables rapid deployment for in-depth analysis following robust SARS-CoV-2 
      infection with authentic patient-derived virus in mice of diverse genetic
      backgrounds.&nbsp; This represents a much-needed platform for rapidly testing
      prophylactic and therapeutic strategies to combat COVID-19. Funding: This study
      was supported by awards from National Institute of Health grants, 2T32AI007517-16
      (to BI), T32GM007205 and F30CA239444 (to ES), AI054359 and AI127429 (to AI),
      T32AI007019 (to TM),K08 AI128043 (to CBW), as well as Women's Health Research at 
      Yale Pilot Project Program (AI, AR), Fast Grant from Emergent Ventures at the
      Mercatus Center (AI, ES), Mathers Foundation (AR, CBW, AI), and the Ludwig Family
      Foundation (AI, AR, CBW). A.I. is an investigator of the Howard Hughes Medical
      Institute. Conflict of Interest: None of the authors declare interests related to
      the manuscript. Ethical Approval: All procedures were performed in a BSL-3
      facility (for SARS-CoV-2 infected mice) with approval from the Yale Environmental
      Health and Safety office.
FAU - Israelow, Benjamin
AU  - Israelow B
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
AD  - Department of Internal Medicine, Section of Infectious Diseases, Yale University 
      School of Medicine, New Haven, CT, USA.
FAU - Song, Eric
AU  - Song E
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Mao, Tianyang
AU  - Mao T
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Lu, Peiwen
AU  - Lu P
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Meir, Amit
AU  - Meir A
AD  - Department of Microbial Pathogenesis, Yale University School of Medicine, New
      Haven, CT, USA.
FAU - Liu, Feimei
AU  - Liu F
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Alfajaro, Mia Madel
AU  - Alfajaro MM
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
AD  - Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
      Connecticut, USA.
FAU - Wei, Jin
AU  - Wei J
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
AD  - Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
      Connecticut, USA.
FAU - Dong, Huiping
AU  - Dong H
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Homer, Robert J
AU  - Homer RJ
AD  - Department of Pathology, Yale University School of Medicine, New Haven,
      Connecticut, USA.
FAU - Ring, Aaron
AU  - Ring A
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Wilen, Craig B
AU  - Wilen CB
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
AD  - Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
      Connecticut, USA.
FAU - Iwasaki, Akiko
AU  - Iwasaki A
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
AD  - Howard Hughes Medical Institute, Chevy Chase, MD, USA.
LA  - eng
GR  - T32 AI007019/AI/NIAID NIH HHS/United States
GR  - R01 AI127429/AI/NIAID NIH HHS/United States
GR  - T32 AI007517/AI/NIAID NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
GR  - R01 AI054359/AI/NIAID NIH HHS/United States
GR  - T32 GM007205/GM/NIGMS NIH HHS/United States
GR  - F30 CA239444/CA/NCI NIH HHS/United States
GR  - K08 AI128043/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20200616
PL  - United States
TA  - SSRN
JT  - SSRN
JID - 101768030
UIN - J Exp Med. 2020 Dec 7;217(12):. PMID: 32750141
PMC - PMC7366812
OTO - NOTNLM
OT  - COVID-19
OT  - infectious disease
OT  - inflammation
OT  - interferons
OT  - pathogenesis
OT  - respiratory virus
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/06/16 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.2139/ssrn.3628297 [doi]
AID - 3628297 [pii]
PST - epublish
SO  - SSRN. 2020 Jun 16:3628297. doi: 10.2139/ssrn.3628297.


PMID- 32714117
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1556-5068 (Electronic)
IS  - 1556-5068 (Linking)
DP  - 2020 May 27
TI  - Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent
      VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
PG  - 3606354
LID - 10.2139/ssrn.3606354 [doi]
AB  - Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality,
      and possibly disrupt epidemic transmission. An anticipated correlate of such
      countermeasures is the level of neutralizing antibodies against the SARS-CoV-2
      spike protein, yet there is no consensus as to which assay should be used for
      such measurements. Using an infectious molecular clone of vesicular stomatitis
      virus (VSV) that expresses eGFP as a marker of infection, we replaced the
      glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) 
      and developed a high-throughput imaging-based neutralization assay at biosafety
      level 2. We also developed a focus reduction neutralization test with a clinical 
      isolate of SARS-CoV-2 at biosafety level 3. We compared the neutralizing
      activities of monoclonal and polyclonal antibody preparations, as well as ACE2-Fc
      soluble decoy protein in both assays and find an exceptionally high degree of
      concordance. The two assays will help define correlates of protection for
      antibody-based countermeasures including therapeutic antibodies, immune
      gamma-globulin or plasma preparations, and vaccines against SARS-CoV-2.
      Replication-competent VSV-eGFP-SARS-CoV-2 provides a rapid assay for testing
      inhibitors of SARS-CoV-2 mediated entry that can be performed in 7.5 hours under 
      reduced biosafety containment. Funding: This study was supported by NIH contracts
      and grants (75N93019C00062, HHSN272201700060C and R01 AI127828, R37 AI059371 and 
      U01 AI151810) and the Defense Advanced Research Project Agency (HR001117S0019)
      and gifts from Washington University in Saint Louis. J.B.C. is supported by a
      Helen Hay Whitney Foundation postdoctoral fellowship. Conflict of Interest:
      M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and
      on the Scientific Advisory Board of Moderna. D.C. and H.W.V. are employees of Vir
      Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. S.P.J.W. and
      P.W.R. have filed a disclosure with Washington University for the recombinant
      VSV. Ethical Approval: This study was approved by the Mayo Clinic Institutional
      Review Board.
FAU - Case, James Brett
AU  - Case JB
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Rothlauf, Paul W
AU  - Rothlauf PW
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Program in Virology, Harvard Medical School, Boston, MA, USA.
FAU - Chen, Rita E
AU  - Chen RE
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Liu, Zhuoming
AU  - Liu Z
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Zhao, Haiyan
AU  - Zhao H
AD  - Biochemistry & Molecular Biophysics, Washington University School of Medicine,
      St. Louis, MO, USA.
FAU - Kim, Arthur S
AU  - Kim AS
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Bloyet, Louis-Marie
AU  - Bloyet LM
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Zeng, Qiru
AU  - Zeng Q
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Tahan, Stephen
AU  - Tahan S
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Droit, Lindsay
AU  - Droit L
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Ilagan, Ma Xenia G
AU  - Ilagan MXG
AD  - Biochemistry & Molecular Biophysics, Washington University School of Medicine,
      St. Louis, MO, USA.
FAU - Tartell, Michael A
AU  - Tartell MA
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Program in Virology, Harvard Medical School, Boston, MA, USA.
FAU - Amarasinghe, Gaya
AU  - Amarasinghe G
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Biochemistry & Molecular Biophysics, Washington University School of Medicine,
      St. Louis, MO, USA.
FAU - Henderson, Jeffrey P
AU  - Henderson JP
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Miersch, Shane
AU  - Miersch S
AD  - The Donnelly Centre, University of Toronto, Toronto, Canada.
FAU - Ustav, Mart
AU  - Ustav M
AD  - The Donnelly Centre, University of Toronto, Toronto, Canada.
FAU - Sidhu, Sachdev
AU  - Sidhu S
AD  - The Donnelly Centre, University of Toronto, Toronto, Canada.
FAU - Virgin, Herbert W
AU  - Virgin HW
AD  - Vir Biotechnology, San Francisco, CA, USA.
FAU - Wang, David
AU  - Wang D
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Ding, Siyuan
AU  - Ding S
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
FAU - Corti, Davide
AU  - Corti D
AD  - Humabs BioMed SA, a subsidiary of Vir Biotechnology, Inc., CH-6500, Bellinzona,
      Switzerland.
FAU - Theel, Elitza S
AU  - Theel ES
AD  - Division of Clinical Microbiology, Department of Laboratory Medicine and
      Pathology, Mayo Clinic, Rochester, MN, USA.
FAU - Fremont, Daved H
AU  - Fremont DH
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Biochemistry & Molecular Biophysics, Washington University School of Medicine,
      St. Louis, MO, USA.
AD  - The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy
      Programs, Washington University School of Medicine, St. Louis, MO, USA.
FAU - Diamond, Michael S
AU  - Diamond MS
AD  - Department of Medicine, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
AD  - Biochemistry & Molecular Biophysics, Washington University School of Medicine,
      St. Louis, MO, USA.
AD  - The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy
      Programs, Washington University School of Medicine, St. Louis, MO, USA.
FAU - Whelan, Sean P J
AU  - Whelan SPJ
AD  - Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 
      USA.
LA  - eng
PT  - Preprint
DEP - 20200527
PL  - United States
TA  - SSRN
JT  - SSRN
JID - 101768030
UIN - Cell Host Microbe. 2020 Jul 3;:. PMID: 32735849
PMC - PMC7366811
OTO - NOTNLM
OT  - Neutralization Assay
OT  - SARS-CoV-2
OT  - coronavirus spike
OT  - vesicular stomatitis virus
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.2139/ssrn.3606354 [doi]
AID - 3606354 [pii]
PST - epublish
SO  - SSRN. 2020 May 27:3606354. doi: 10.2139/ssrn.3606354.


PMID- 32713850
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 26
TI  - Self-directed multimedia process for delivering participant informed consent.
PG  - e036977
LID - 10.1136/bmjopen-2020-036977 [doi]
AB  - OBJECTIVE: Obtaining informed consent is a cornerstone requirement of conducting 
      ethical research. Traditional paper-based consent is often excessively lengthy
      and may fail to achieve the desired participant understanding of study
      requirements. Multimedia tools including video and audio may be a useful
      alternative. This study aimed to determine the efficacy, usability and
      acceptability of self-directed multimedia delivery of participant consent.
      DESIGN: It is a single-centre, randomised, prospective study to determine the
      efficacy, usability and acceptability of a self-directed multimedia consent
      process (intervention) compared with the traditional paper-based approach
      (control). The intervention was free of research staff, with computer-based
      finger-signed consent. SETTING: Pathology blood collection services in Tasmania, 
      Australia. PARTICIPANTS: 298 participants (63+/-8 years; 51% female individuals) 
      referred from general practice were randomised to intervention (n=146) and
      control (n=152). OUTCOME MEASURES: Efficacy, usability and acceptability of the
      allocated consent process were assessed by a questionnaire. RESULTS: All
      participants successfully completed the allocated interventions. Efficacy
      parameters were higher among intervention participants, including a better
      understanding of study requirements compared with controls (p<0.05 all).
      Intervention participants were more likely to engage with the study information
      and spend more time on the consent process (p=<0.001 and p=0.006, respectively). 
      Both groups reported similar levels of acceptability, although more control
      participants reported that the study information was too long (24% vs 14%;
      p=0.020). CONCLUSION: A self-directed multimedia consent process is effective for
      achieving participant understanding and obtaining consent free of research staff.
      Thus, multimedia represents a viable method to reduce the burden on researchers, 
      meet participant needs and achieve informed consent in clinical research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chapman, Niamh
AU  - Chapman N
AUID- ORCID: 0000-0001-6317-5594
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - McWhirter, Rebekah
AU  - McWhirter R
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
AD  - Faculty of Law, Centre for Law and Genetics, University of Tasmania, Hobart,
      Tasmania, Australia.
FAU - Armstrong, Matthew K
AU  - Armstrong MK
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Fonseca, Ricardo
AU  - Fonseca R
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Campbell, Julie A
AU  - Campbell JA
AUID- ORCID: 0000-0002-1820-6758
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Nelson, Mark
AU  - Nelson M
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Schultz, Martin G
AU  - Schultz MG
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Sharman, James E
AU  - Sharman JE
AD  - Menzies Institute for Medical Research, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia James.Sharman@utas.edu.au.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200726
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Australia
MH  - Female
MH  - Humans
MH  - *Informed Consent
MH  - Male
MH  - Middle Aged
MH  - *Multimedia
MH  - Prospective Studies
MH  - Tasmania
PMC - PMC7383955
OTO - NOTNLM
OT  - *clinical trials
OT  - *ethics (see medical ethics)
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-036977 [pii]
AID - 10.1136/bmjopen-2020-036977 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 26;10(7):e036977. doi: 10.1136/bmjopen-2020-036977.


PMID- 32713847
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 26
TI  - Evaluation of the teaching recovery techniques community-based intervention for
      accompanied refugee children experiencing post-traumatic stress symptoms
      (Accompanied refugeeS In Sweden Trial; ASsIST): study protocol for a cluster
      randomised controlled trial.
PG  - e035459
LID - 10.1136/bmjopen-2019-035459 [doi]
AB  - BACKGROUND: Refugee children have often experienced traumas and are at
      significant risk of developing mental health problems, such as symptoms of
      post-traumatic stress disorder (PTSD), depression and anxiety, which can continue
      for years after resettlement. The Accompanied refugeeS In Sweden Trial (ASsIST)
      aims to evaluate a community-based intervention, called 'Teaching Recovery
      Techniques' (TRT), for accompanied refugee minors experiencing PTSD symptoms.
      METHODS/DESIGN: A cluster randomised controlled trial will be conducted in which 
      participants will be randomly allocated to one of the two possible arms: the
      intervention arm (n=113) will be offered the TRT programme and the
      waitlist-control arm (n=113) will receive services as usual, followed by the TRT 
      programme around 20 weeks later. Outcome data will be collected at three points: 
      pre-intervention (T1), post-intervention (T2; c.8 weeks after randomisation) and 
      follow-up (T3; c.20 weeks after randomisation). ETHICS AND DISSEMINATION: Ethical
      approval was granted by the Regional Ethical Review Board in Uppsala (Ref.
      2018/382) (24(th) February 2019). Results will be published in scientific
      journals. TRIAL REGISTRATION DETAILS: ISRCTN17754931. Prospectively registered on
      4(th) June 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Warner, Georgina
AU  - Warner G
AUID- ORCID: 0000-0002-7850-9136
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden georgina.warner@pubcare.uu.se.
FAU - Durbeej, Natalie
AU  - Durbeej N
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Salari, Raziye
AU  - Salari R
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Fangstrom, Karin
AU  - Fangstrom K
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Lampa, Elin
AU  - Lampa E
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Baghdasaryan, Zaruhi
AU  - Baghdasaryan Z
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Osman, Fatumo
AU  - Osman F
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Gupta Lofving, Sandra
AU  - Gupta Lofving S
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Perez Aronsson, Anna
AU  - Perez Aronsson A
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Feldman, Inna
AU  - Feldman I
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Sampaio, Filipa
AU  - Sampaio F
AUID- ORCID: 0000-0002-5540-9853
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Ssegonja, Richard
AU  - Ssegonja R
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
FAU - Bjarta, Anna
AU  - Bjarta A
AD  - Department of Psychology, Mid Sweden University, Ostersund, Sweden.
FAU - Rondung, Elisabet
AU  - Rondung E
AD  - Department of Psychology, Mid Sweden University, Ostersund, Sweden.
FAU - Leiler, Anna
AU  - Leiler A
AD  - Department of Psychology, Mid Sweden University, Ostersund, Sweden.
FAU - Wasteson, Elisabet
AU  - Wasteson E
AD  - Department of Psychology, Mid Sweden University, Ostersund, Sweden.
FAU - Calam, Rachel
AU  - Calam R
AD  - Division of Clinical Psychology, The University of Manchester, Manchester, UK.
FAU - Oppedal, Brit
AU  - Oppedal B
AD  - Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway.
FAU - Keeshin, Brooks
AU  - Keeshin B
AD  - Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
FAU - Sarkadi, Anna
AU  - Sarkadi A
AD  - Child Health and Parenting, Department of Public Health and Caring Sciences,
      Uppsala University, Uppsala, Sweden.
LA  - eng
SI  - ISRCTN/ISRCTN17754931
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200726
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - *Clinical Protocols
MH  - Delivery of Health Care
MH  - Humans
MH  - Psychology, Child/methods
MH  - Refugees/*psychology
MH  - Stress Disorders, Post-Traumatic/psychology/*therapy
MH  - Sweden
PMC - PMC7383950
OTO - NOTNLM
OT  - *health economics
OT  - *mental health
OT  - *paediatrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035459 [pii]
AID - 10.1136/bmjopen-2019-035459 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 26;10(7):e035459. doi: 10.1136/bmjopen-2019-035459.


PMID- 32713845
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 26
TI  - Overlap between child protection services and the youth justice system: protocol 
      for a retrospective population-based cohort study using linked administrative
      data in Manitoba, Canada.
PG  - e034895
LID - 10.1136/bmjopen-2019-034895 [doi]
AB  - INTRODUCTION: Children who have a history of involvement in child protection
      services (CPS) are over-represented in the youth and adult criminal justice
      systems. There are significant health and socioeconomic implications for
      individuals involved in either or both CPS and the justice system. Understanding 
      the 'overlap' between these two systems would provide insight into the health and
      social needs of this population. This protocol describes a research programme on 
      the relationship between the child welfare and the youth justice systems, looking
      specifically at the population involved in both CPS and the youth justice system.
      We will examine the characteristics associated with involvement in these systems,
      justice system trajectories of individuals with a history of CPS involvement and 
      early adult outcomes of children involved in both systems. METHODS AND ANALYSIS: 
      Administrative data sets will be linked at the individual level for three cohorts
      born 1991, 1994 and 1998 in Manitoba, Canada. Involvement in CPS will be
      categorised as 'placed in out-of-home care', 'received in-home services, but was 
      not placed in care' or 'no involvement'. Involvement in the youth justice system 
      will be examined through contacts with police between ages 12 and 17 that either 
      led to charges or did not proceed. Individual, maternal and neighbourhood
      characteristics will be examined to identify individuals at greatest risk of
      involvement in one or both systems. ETHICS AND DISSEMINATION: The study was
      approved by the University of Manitoba Health Research Ethics Board and
      permission to access data sets has been granted by all data providers. We also
      received approval for the study from the First Nations Health and Social
      Secretariat of Manitoba's Health Information Research Governance Committee and
      the Manitoba Metis Federation. Strategies to disseminate study results will
      include engagement of stakeholders and policymakers through meetings and
      workshops, scientific publications and presentations, and social media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nickel, Nathan C
AU  - Nickel NC
AUID- ORCID: 0000-0001-5836-5297
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
      Nathan_Nickel@cpe.umanitoba.ca.
FAU - Turnbull, Lorna
AU  - Turnbull L
AD  - Faculty of Law, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Wall-Wieler, Elizabeth
AU  - Wall-Wieler E
AD  - Department of Pediatrics, Stanford University, Stanford, California, USA.
FAU - Au, Wendy
AU  - Au W
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Ekuma, Okechukwu
AU  - Ekuma O
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - MacWilliam, Leonard
AU  - MacWilliam L
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Enns, Jennifer Emily
AU  - Enns JE
AUID- ORCID: 0000-0001-7805-7582
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Lee, Janelle Boram
AU  - Lee JB
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - McCulloch, Scott
AU  - McCulloch S
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Burchill, Charles
AU  - Burchill C
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Brownell, Marni
AU  - Brownell M
AD  - Department of Community Health Sciences, Max Rady College of Medicine, Rady
      Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200726
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child Protective Services/*statistics & numerical data
MH  - *Child Welfare
MH  - Cohort Studies
MH  - Criminal Law/*statistics & numerical data
MH  - Humans
MH  - Manitoba
MH  - Retrospective Studies
PMC - PMC7383946
OTO - NOTNLM
OT  - *child protection
OT  - *community child health
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034895 [pii]
AID - 10.1136/bmjopen-2019-034895 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 26;10(7):e034895. doi: 10.1136/bmjopen-2019-034895.


PMID- 32713843
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 26
TI  - Money-oriented risk-takers or deliberate decision-makers: a cross-sectional
      survey study of participants in controlled human infection trials.
PG  - e033796
LID - 10.1136/bmjopen-2019-033796 [doi]
AB  - OBJECTIVE: To quantitatively investigate the motivations, decision-making and
      experience of participants in controlled human infection (CHI) studies. DESIGN:
      Cross-sectional descriptive survey study. SETTING: Previous participants of CHI
      studies at the Leiden Controlled Human Infection Center, control group of
      students from Leiden University. PARTICIPANTS: 61 previous participants and 156
      controls. MEASUREMENTS: Ranking of motivational and decisional factors, risk
      propensity score and multiple-choice questions on experience of trial
      participation and ethical aspects of CHI studies. RESULTS: Motivating factors for
      participants were contributing to science (81%), contributing to research that
      may benefit developing countries (72%) and the financial compensation (63%). For 
      51% of participants, a reason other than financial compensation was the most
      important motivational factor. Participants considered trust in the study team
      (70%), time investment (63%), severity of symptoms (54%), chance of developing
      symptoms (54%) and whether it is an easy way to make money (54%) in their
      decision to participate. Most CHI participants (84%) were proud of their
      participation, would advise others to participate (89%) and would participate in 
      a similar trial again (85%). CHI participants had a higher risk propensity score 
      than students (estimated difference 0.9, p<0.001). CONCLUSION: Although financial
      compensation is important, the motivations for participants in a CHI study are
      diverse and participants make a balanced appraisal of risks and burden before
      participating.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hoogerwerf, Marie-Astrid
AU  - Hoogerwerf MA
AUID- ORCID: 0000-0002-3088-3380
AD  - Parasitology, Leiden University Medical Center, Leiden, Zuid-Holland, The
      Netherlands.
FAU - de Vries, Martine
AU  - de Vries M
AD  - Medical Ethics and Health Law, Leiden University Medical Center, Leiden,
      Zuid-Holland, The Netherlands.
FAU - Roestenberg, Meta
AU  - Roestenberg M
AD  - Parasitology, Leiden University Medical Center, Leiden, Zuid-Holland, The
      Netherlands m.roestenberg@lumc.nl.
AD  - Infectious Diseases, Leiden University Medical Center, Leiden, Zuid-Holland, The 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200726
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Motivation
MH  - Surveys and Questionnaires
MH  - *Trust
PMC - PMC7383945
OTO - NOTNLM
OT  - *controlled human infections
OT  - *healthy volunteers
OT  - *motivation
OT  - *quantitative research
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033796 [pii]
AID - 10.1136/bmjopen-2019-033796 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 26;10(7):e033796. doi: 10.1136/bmjopen-2019-033796.


PMID- 32713791
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-4898 (Electronic)
IS  - 1477-5131 (Linking)
VI  - 16
IP  - 5
DP  - 2020 Oct
TI  - Structured opioid-free protocol following outpatient hypospadias repair - A
      prospective SQUIRE 2.0-compliant quality improvement initiative.
PG  - 647.e1-647.e9
LID - S1477-5131(20)30388-0 [pii]
LID - 10.1016/j.jpurol.2020.06.012 [doi]
AB  - BACKGROUND: Prescription opioids have been extensively to manage postoperative
      pain in children. A growing body of evidence from the adult literature, suggests 
      however, that healthcare providers may be prescribing far more opioids than
      required, with some studies demonstrating equivalent post-operative pain and
      clinical outcomes with their omission. OBJECTIVE: The objectives of this
      prospective study were to assess the current heterogeneity of practice in
      post-operative opioids prescription following day case hypospadias surgery, to
      establish a streamlined discharge protocol, and to reduce the use of
      post-operative opioid prescription by 30% within a 4 month period through the use
      of systemic forcing functions and education. STUDY DESIGN: This prospective study
      was approved by the Quality Improvement (QI) sub-committee of the hospital's
      Research and Ethics Board (REB) and was compliant with the Standards for Quality 
      Improvement Reporting Excellence (SQUIRE 2.0) guidelines. Recruited parents (n = 
      84) were contacted for telephone interview following a combined intervention of
      education and omission of post-operative opioids from the discharge prescription.
      A mixture of qualitative and quantitative techniques were employed including an
      initial process analysis to assess current opioid use, the creation of balancing 
      measures, and the creation of Plan-Do-Study-Act cycles. Age, procedure,
      post-operative outcomes and opioid prescription data were recorded over a period 
      of 6 months in 2019. RESULTS: Initial measures in our process analysis
      demonstrated significant institutional practice variation amongst our 84
      post-intervention patients. Our process and fidelity measures confirmed 100%
      information provision. Following the point of intervention, there was a
      significant and sustained drop in opioid prescription, with an absolute reduction
      of 35%, and a relative reduction of 56%. There was no significant difference in
      patient age, pain scores, or outcomes pre- and post-intervention. DISCUSSION: We 
      have shown in this study that a sustainable decrease in post-operative opioid
      prescriptions following hypospadias surgery is possible. We managed to achieve a 
      relative reduction 56% which is comparable to other specialties, however, did it 
      within a quality improvement framework to ensure fidelity and no adverse
      balancing measures. We also managed to reduce the number of doses prescribed in
      those receiving opioids post-intervention at week 9. CONCLUSION: Our study
      demonstrates opioids can be safely omitted in hypospadias cohorts without any
      adverse clinical outcomes or balancing measures. We recommend that opioids be
      used extremely judiciously in this population in order to minimize exposure in
      children.
CI  - Copyright (c) 2020 Journal of Pediatric Urology Company. Published by Elsevier
      Ltd. All rights reserved.
FAU - O'Kelly, F
AU  - O'Kelly F
AD  - Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada;
      Centre for Quality Improvement and Patient Safety (C-QuIPS), University of
      Toronto, Toronto, Canada. Electronic address: fokelly@rcsi.ie.
FAU - Pokarowski, M
AU  - Pokarowski M
AD  - Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada.
FAU - DeCotiis, K N
AU  - DeCotiis KN
AD  - Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada;
      Centre for Quality Improvement and Patient Safety (C-QuIPS), University of
      Toronto, Toronto, Canada.
FAU - McDonnell, C
AU  - McDonnell C
AD  - Department of Anaesthesiology and Pain Medicine, The Hospital for Sick Children, 
      Toronto, Canada.
FAU - Milford, K
AU  - Milford K
AD  - Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada;
      Department of Anaesthesiology and Pain Medicine, The Hospital for Sick Children, 
      Toronto, Canada.
FAU - Koyle, M A
AU  - Koyle MA
AD  - Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada;
      Centre for Quality Improvement and Patient Safety (C-QuIPS), University of
      Toronto, Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200621
PL  - England
TA  - J Pediatr Urol
JT  - Journal of pediatric urology
JID - 101233150
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Adult
MH  - *Analgesics, Opioid
MH  - Child
MH  - Humans
MH  - *Hypospadias/surgery
MH  - Infant
MH  - Male
MH  - Outpatients
MH  - Pain, Postoperative/drug therapy/prevention & control
MH  - Practice Patterns, Physicians'
MH  - Prospective Studies
MH  - Quality Improvement
OTO - NOTNLM
OT  - Hypospadias
OT  - Ishikawa
OT  - Opioid
OT  - Quality improvement
OT  - Run chart
OT  - Stewardship
COIS- Conflicts of interest The authors have no potential, perceived, or real conflicts
      of interest.
EDAT- 2020/07/28 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - S1477-5131(20)30388-0 [pii]
AID - 10.1016/j.jpurol.2020.06.012 [doi]
PST - ppublish
SO  - J Pediatr Urol. 2020 Oct;16(5):647.e1-647.e9. doi: 10.1016/j.jpurol.2020.06.012. 
      Epub 2020 Jun 21.


PMID- 32713434
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1878-0555 (Electronic)
IS  - 0065-3411 (Linking)
VI  - 54
DP  - 2020 Sep
TI  - Increasing Importance of Ethics in Surgical Decision Making.
PG  - 251-263
LID - S0065-3411(20)30015-4 [pii]
LID - 10.1016/j.yasu.2020.05.008 [doi]
FAU - Paredes, Anghela Z
AU  - Paredes AZ
AD  - Department of Surgery, Division of Surgical Oncology, The Ohio State University
      Wexner Medical Center, 395 West 12th Avenue, Suite 670, Columbus, OH 43210, USA.
FAU - Aquina, Christopher T
AU  - Aquina CT
AD  - Department of Surgery, Division of Surgical Oncology, The Ohio State University
      Wexner Medical Center, 395 West 12th Avenue, Suite 670, Columbus, OH 43210, USA.
FAU - Selby, Luke V
AU  - Selby LV
AD  - Department of Surgery, Division of Surgical Oncology, The Ohio State University
      Wexner Medical Center, 395 West 12th Avenue, Suite 670, Columbus, OH 43210, USA.
FAU - DiFilippo, Stephanie
AU  - DiFilippo S
AD  - Department of Surgery, Division of Surgical Oncology, The Ohio State University
      Wexner Medical Center, 395 West 12th Avenue, Suite 670, Columbus, OH 43210, USA.
FAU - Pawlik, Timothy M
AU  - Pawlik TM
AD  - Department of Surgery, Division of Surgical Oncology, The Ohio State University
      Wexner Medical Center, 395 West 12th Avenue, Suite 670, Columbus, OH 43210, USA. 
      Electronic address: tim.pawlik@osumc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200617
PL  - United States
TA  - Adv Surg
JT  - Advances in surgery
JID - 0045335
SB  - IM
MH  - Bioethical Issues
MH  - Clinical Decision-Making/*ethics
MH  - Decision Making, Shared
MH  - Hippocratic Oath
MH  - Humans
MH  - Medical Futility/ethics
MH  - Palliative Care/ethics
MH  - Patient Rights
MH  - Surgical Procedures, Operative/*ethics
OTO - NOTNLM
OT  - *Ethics
OT  - *Shared decision making
OT  - *Surgeons
COIS- Disclosure The authors have no commercial or financial conflicts of interest or
      any funding sources to disclose.
EDAT- 2020/07/28 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
AID - S0065-3411(20)30015-4 [pii]
AID - 10.1016/j.yasu.2020.05.008 [doi]
PST - ppublish
SO  - Adv Surg. 2020 Sep;54:251-263. doi: 10.1016/j.yasu.2020.05.008. Epub 2020 Jun 17.


PMID- 32713384
OWN - NLM
STAT- Publisher
LR  - 20200828
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
DP  - 2020 Jul 27
TI  - SARS-CoV-2 Viral and Serological Testing When College Campuses Reopen: Some
      Practical Considerations.
PG  - 1-5
LID - 10.1017/dmp.2020.266 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic prompted universities across the
      United States to close campuses in Spring 2020. Universities are deliberating
      whether, when, and how they should resume in-person instruction in Fall 2020. In 
      this essay, we discuss some practical considerations for the use of 2 potentially
      useful control strategies based on testing: (1) severe acute respiratory syndrome
      coronavirus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction
      (RT-PCR) testing followed by case-patient isolation and quarantine of close
      contacts, and (2) serological testing followed by an "immune shield" approach,
      that is, low social distancing requirements for seropositive persons. The
      isolation of case-patients and quarantine of close contacts may be especially
      challenging, and perhaps prohibitively difficult, on many university campuses.
      The "immune shield" strategy might be hobbled by a low positive predictive value 
      of the tests used in populations with low seroprevalence. Both strategies carry
      logistical, ethical, and financial implications. The main nonpharmaceutical
      interventions will remain methods based on social distancing (eg, capping class
      size) and personal protective behaviors (eg, universal facemask wearing in public
      space) until vaccines become available, or unless the issues discussed herein can
      be resolved in such a way that using mass testing as main control strategies
      becomes viable.
FAU - Fung, Isaac Chun-Hai
AU  - Fung IC
AUID- ORCID: https://orcid.org/0000-0001-5496-2529
AD  - Department of Biostatistics, Epidemiology, and Environmental Health Sciences,
      Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro,
      Georgia.
FAU - Cheung, Chi-Ngai
AU  - Cheung CN
AUID- ORCID: https://orcid.org/0000-0003-2020-4679
AD  - Department of Psychology and Criminal Justice, Middle Georgia State University,
      Macon, Georgia.
FAU - Handel, Andreas
AU  - Handel A
AD  - Department of Epidemiology and Biostatistics, College of Public Health,
      University of Georgia, Athens, Georgia.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
PMC - PMC7450242
OTO - NOTNLM
OT  - communicable diseases
OT  - digital health
OT  - epidemics
OT  - infectious disease transmission
OT  - social media
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - S1935789320002669 [pii]
AID - 10.1017/dmp.2020.266 [doi]
PST - aheadofprint
SO  - Disaster Med Public Health Prep. 2020 Jul 27:1-5. doi: 10.1017/dmp.2020.266.


PMID- 32713203
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 1753-8564 (Electronic)
IS  - 0073-2753 (Linking)
VI  - 58
IP  - 4
DP  - 2020 Dec
TI  - Clinical trials and the origins of pharmaceutical fraud: Parke, Davis & Company, 
      virtue epistemology, and the history of the fundamental antagonism.
PG  - 533-558
LID - 10.1177/0073275320942435 [doi]
AB  - This paper describes one possible origin point for fraudulent behavior within the
      American pharmaceutical industry. We argue that during the late nineteenth
      century therapeutic reformers sought to promote both laboratory science and
      increasingly systematized forms of clinical experiment as a new basis for
      therapeutic knowledge. This process was intertwined with a transformation in the 
      ethical framework in which medical science took place, one in which monopoly
      status was replaced by clinical utility as the primary arbiter of pharmaceutical 
      legitimacy. This new framework fundamentally altered the set of epistemic
      virtues-a phrase we draw from the philosophical field of virtue
      epistemology-considered necessary to conduct reliable scientific inquiry
      regarding drugs. In doing so, it also made possible new forms of fraud in which
      newly emergent epistemic virtues were violated. To make this argument, we focus
      on the efforts of Francis E. Stewart and George S. Davis of Parke, Davis &
      Company. Therapeutic reformers within the pharmaceutical industry, such as
      Stewart and Davis, were an important part of the broader normative and epistemic 
      transformation we describe in that they sought to promote laboratory science and 
      systematized clinical trials toward the twin goals of improving pharmaceutical
      science and promoting their own commercial interests. Yet, as we suggest, Parke, 
      Davis & Company also serves as an example of a company that violated the very
      norms that Stewart and Davis helped introduce. We thus seek to describe one
      possible origin point for the widespread fraudulent practices that now
      characterize the pharmaceutical industry. We also seek to describe an origin
      point for why we conceptualize such practices as fraudulent in the first place.
FAU - Gabriel, Joseph M
AU  - Gabriel JM
AUID- ORCID: 0000-0002-2770-3051
AD  - Florida State University, USA.
FAU - Holman, Bennett
AU  - Holman B
AD  - Yonsei University, South Korea.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200725
PL  - United States
TA  - Hist Sci
JT  - History of science
JID - 17340520R
RN  - 0 (Nonprescription Drugs)
MH  - American Medical Association/history
MH  - Bioethical Issues/history
MH  - Clinical Trials as Topic/*history
MH  - Drug Industry/ethics/*history/legislation & jurisprudence
MH  - Fraud/ethics/*history
MH  - Government Regulation
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Knowledge
MH  - Legislation, Drug/ethics/history
MH  - Nonprescription Drugs/history
MH  - Quackery/history
MH  - United States
PS  - Stewart F
FPS - Stewart, Francis
PS  - Davis G
FPS - Davis, George
OTO - NOTNLM
OT  - *& Company
OT  - *Davis
OT  - *Francis Stewart
OT  - *George Davis
OT  - *Parke
OT  - *clinical trials
OT  - *corruption
OT  - *historical epistemology
OT  - *history of medicine
OT  - *history of science
OT  - *pharmaceutical industry
OT  - *philosophy of science
OT  - *virtue epistemology
EDAT- 2020/07/28 06:00
MHDA- 2021/06/01 06:00
CRDT- 2020/07/28 06:00
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
AID - 10.1177/0073275320942435 [doi]
PST - ppublish
SO  - Hist Sci. 2020 Dec;58(4):533-558. doi: 10.1177/0073275320942435. Epub 2020 Jul
      25.


PMID- 32712670
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201210
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 8
DP  - 2020 Aug 1
TI  - Periconceptional exposure to lopinavir, but not darunavir, impairs
      decidualization: a potential mechanism leading to poor birth outcomes in
      HIV-positive pregnancies.
PG  - 1781-1796
LID - 10.1093/humrep/deaa151 [doi]
AB  - STUDY QUESTION: Does HIV protease inhibitor (PI)-based combination antiretroviral
      therapy (cART) initiated at periconception affect key events in early pregnancy, 
      i.e. decidualization and spiral artery remodeling? SUMMARY ANSWER: Two PIs,
      lopinavir and darunavir, currently offered as cART options in HIV-positive
      pregnancies were evaluated, and we found that lopinavir-based cART, but not
      darunavir-based cART, impaired uterine decidualization and spiral artery
      remodeling in both human ex vivo and mouse in vivo experimental models. WHAT IS
      KNOWN ALREADY: Early initiation of cART is recommended for pregnant women living 
      with HIV. However, poor birth outcomes are frequently observed in HIV-positive
      pregnancies exposed to PI-based cART, especially when it is initiated prior to
      conception. The correlation between early initiation of PI-cART and adverse birth
      outcomes is poorly understood, due to lack of data on the specific effects of
      PI-cART on the early stages of pregnancy involving uterine decidualization and
      spiral artery remodeling. STUDY DESIGN, SIZE, DURATION: Lopinavir and darunavir
      were evaluated in clinically relevant combinations using an ex vivo human
      first-trimester placenta-decidua explant model, an in vitro human primary
      decidual cell culture system, and an in vivo mouse pregnancy model. The
      first-trimester (gestational age, 6-8 weeks) human placenta-decidua tissue was
      obtained from 11 to 15 healthy women undergoing elective termination of
      pregnancy. C57Bl/6 female mice (four/treatment group) were administered either
      lopinavir-cART, darunavir-cART or water by oral gavage once daily starting on the
      day of plug detection until sacrifice. PARTICIPANTS/MATERIALS, SETTING, METHODS: 
      Human: Spiral artery remodeling was assessed by immunohistochemical analysis of
      first-trimester placenta-decidua explant co-culture system. Trophoblast migration
      was measured using a placental explant culture. A primary decidual cell culture
      was used to evaluate the viability of immune cell populations by flow cytometry. 
      Soluble factors, including biomarkers of decidualization and angiogenesis, were
      quantified by ELISA and Luminex assay using decidua-conditioned media. Mouse: In 
      the mouse pregnancy model, gestational day 6.5 or 9.5 implantation sites were
      used to assess decidualization, spiral artery remodeling and uterine natural
      killer (uNK) cell numbers by immunohistochemistry. Transcription factor STAT3 was
      assayed by immunohistochemistry in both human decidua and mouse implantation
      sites. MAIN RESULTS AND THE ROLE OF CHANCE: Lopinavir-cART, but not
      darunavir-cART, impaired uterine decidualization and spiral artery remodeling in 
      both experimental models. Lopinavir-cART treatment was also associated with
      selective depletion of uNK cells, reduced trophoblast migration and defective
      placentation. The lopinavir-associated decidualization defects were attributed to
      a decrease in expression of transcription factor STAT3, known to regulate
      decidualization. Our results suggest that periconceptional initiation of
      lopinavir-cART, but not darunavir-cART, causes defective maturation of the
      uterine endometrium, leading to impairments in spiral artery remodeling and
      placentation, thus contributing to the poor birth outcomes. LARGE SCALE DATA:
      N/A. LIMITATIONS, REASONS FOR CAUTION: The human first-trimester placenta/decidua
      samples could only be obtained from healthy females undergoing elective
      termination of pregnancy. As biopsy is the only way to obtain first-trimester
      decidua from pregnant women living with HIV on PI-cART, ethics approval and
      participant consent are difficult to obtain. Furthermore, our animal model is
      limited to the study of cART and does not include HIV. HIV infection is also
      associated with immune dysregulation, inflammation, alterations in angiogenic
      factors and complement activation, all of which could influence decidual and
      placental vascular remodeling and modify any cART effects. WIDER IMPLICATIONS OF 
      THE FINDINGS: Our findings provide mechanistic insight with direct clinical
      implications, rationalizing why the highest adverse birth outcomes are reported
      in HIV-positive pregnancies exposed to lopinavir-cART from conception. We
      demonstrate that dysregulation of decidualization is the mechanism through which 
      lopinavir-cART, but not darunavir-cART, use in early pregnancy leads to poor
      birth outcomes. Although lopinavir is no longer a first-line regimen in
      pregnancy, it remains an alternate regimen and is often the only PI available in 
      low resource settings. Our results highlight the need for reconsidering current
      guidelines recommending lopinavir use in pregnancy and indicate that lopinavir
      should be avoided especially in the first trimester, whereas darunavir is safe to
      use and should be the preferred PI in pregnancy.Further, in current times of the 
      COVID-19 pandemic, lopinavir is among the top drug candidates which are being
      repurposed for inclusion in clinical trials world-over, to assess their
      therapeutic potential against the dangerous respiratory disease. Current trials
      are also testing the efficacy of lopinavir given prophylactically to protect
      health care workers and people with potential exposures. Given the current
      extraordinary numbers, these might include women with early pregnancies, who may 
      or may not be cognizant of their gestational status. This is a matter of concern 
      as it could mean that women with early pregnancies might be exposed to this drug,
      which can cause decidualization defects. Our findings provide evidence of safety 
      concerns surrounding lopinavir use in pregnancy, that women of reproductive age
      considering participation in such trials should be made aware of, so they can
      make a fully informed decision. STUDY FUNDING/COMPETING INTEREST(S): This work
      was supported by funding from the Canadian Institutes of Health Research (CIHR)
      (PJT-148684 and MOP-130398 to L.S.). C.D. received support from CIHR Foundation
      (FDN143262 to Stephen Lye). S.K. received a TGHRI postdoctoral fellowship. The
      authors declare that there are no conflicts of interest. L.S. reports personal
      fees from ViiV Healthcare for participation in a Women and Transgender Think
      Tank.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Kala, Smriti
AU  - Kala S
AD  - Toronto General Hospital Research Institute, University Health Network, Toronto, 
      ON, Canada.
FAU - Dunk, Caroline
AU  - Dunk C
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON,
      Canada.
FAU - Acosta, Sebastian
AU  - Acosta S
AD  - Toronto General Hospital Research Institute, University Health Network, Toronto, 
      ON, Canada.
FAU - Serghides, Lena
AU  - Serghides L
AD  - Toronto General Hospital Research Institute, University Health Network, Toronto, 
      ON, Canada.
AD  - Department of Immunology and Institute of Medical Sciences, University of
      Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 2494G1JF75 (Lopinavir)
RN  - YO603Y8113 (Darunavir)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Animals
MH  - Betacoronavirus/drug effects
MH  - COVID-19
MH  - Cells, Cultured
MH  - Clinical Trials as Topic
MH  - Coculture Techniques
MH  - Coronavirus Infections/complications/*drug therapy/virology
MH  - Darunavir/adverse effects
MH  - Decidua/blood supply/cytology/drug effects
MH  - Disease Models, Animal
MH  - Drug Repositioning
MH  - Drug Therapy, Combination/adverse effects/methods
MH  - Embryo Implantation/drug effects
MH  - Endometrium/blood supply/drug effects
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Lopinavir/*adverse effects
MH  - Maternal Exposure/adverse effects
MH  - Mice
MH  - Pandemics
MH  - Placentation/*drug effects
MH  - Pneumonia, Viral/*drug therapy/virology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*drug therapy
MH  - Pregnancy Trimester, First/drug effects
MH  - Primary Cell Culture
MH  - SARS-CoV-2
MH  - Trophoblasts
MH  - Vascular Remodeling/drug effects
PMC - PMC7398624
OTO - NOTNLM
OT  - *COVID-19
OT  - *HIV protease inhibitors
OT  - *birth outcomes
OT  - *darunavir
OT  - *decidualization
OT  - *drug safety
OT  - *lopinavir
OT  - *spiral artery remodeling
OT  - *trophoblasts
OT  - *uterine natural killer cells
EDAT- 2020/07/28 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/27 06:00
PHST- 2020/04/03 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/07/27 06:00 [entrez]
AID - 5876549 [pii]
AID - 10.1093/humrep/deaa151 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Aug 1;35(8):1781-1796. doi: 10.1093/humrep/deaa151.


PMID- 32712668
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1460-2369 (Electronic)
IS  - 1355-4786 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Nov 1
TI  - Modelling human embryogenesis: embryo-like structures spark ethical and policy
      debate.
PG  - 779-798
LID - 10.1093/humupd/dmaa027 [doi]
AB  - BACKGROUND: Studying the human peri-implantation period remains hindered by the
      limited accessibility of the in vivo environment and scarcity of research
      material. As such, continuing efforts have been directed towards developing
      embryo-like structures (ELS) from pluripotent stem cells (PSCs) that recapitulate
      aspects of embryogenesis in vitro. While the creation of such models offers
      immense potential for studying fundamental processes in both pre- and early
      post-implantation development, it also proves ethically contentious due to
      wide-ranging views on the moral and legal reverence due to human embryos. Lack of
      clarity on how to qualify and regulate research with ELS thus presents a
      challenge in that it may either limit this new field of research without valid
      grounds or allow it to develop without policies that reflect justified ethical
      concerns. OBJECTIVE AND RATIONALE: The aim of this article is to provide a
      comprehensive overview of the existing scientific approaches to generate ELS from
      mouse and human PSCs, as well as discuss future strategies towards innovation in 
      the context of human development. Concurrently, we aim to set the agenda for the 
      ethical and policy issues surrounding research on human ELS. SEARCH METHODS: The 
      PubMed database was used to search peer-reviewed articles and reviews using the
      following terms: 'stem cells', 'pluripotency', 'implantation', 'preimplantation',
      'post-implantation', 'blastocyst', 'embryoid bodies', 'synthetic embryos',
      'embryo models', 'self-assembly', 'human embryo-like structures', 'artificial
      embryos' in combination with other keywords related to the subject area. The
      PubMed and Web of Science databases were also used to systematically search
      publications on the ethics of ELS and human embryo research by using the
      aforementioned keywords in combination with 'ethics', 'law', 'regulation' and
      equivalent terms. All relevant publications until December 2019 were critically
      evaluated and discussed. OUTCOMES: In vitro systems provide a promising way
      forward for uncovering early human development. Current platforms utilize PSCs in
      both two- and three-dimensional settings to mimic various early developmental
      stages, including epiblast, trophoblast and amniotic cavity formation, in
      addition to axis development and gastrulation. Nevertheless, much hinges on the
      term 'embryo-like'. Extension of traditional embryo frameworks to research with
      ELS reveals that (i) current embryo definitions require reconsideration, (ii)
      cellular convertibility challenges the attribution of moral standing on the basis
      of 'active potentiality' and (iii) meaningful application of embryo protective
      directives will require rethinking of the 14-day culture limit and moral weight
      attributed to (non-)viability. Many conceptual and normative (dis)similarities
      between ELS and embryos thus remain to be thoroughly elucidated. WIDER
      IMPLICATIONS: Modelling embryogenesis holds vast potential for both human
      developmental biology and understanding various etiologies associated with
      infertility. To date, ELS have been shown to recapitulate several aspects of
      peri-implantation development, but critically, cannot develop into a fetus. Yet, 
      concurrent to scientific innovation, considering the extent to which the use of
      ELS may raise moral concerns typical of human embryo research remains paramount. 
      This will be crucial for harnessing the potential of ELS as a valuable research
      tool, whilst remaining within a robust moral and legal framework of
      professionally acceptable practices.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Pereira Daoud, Ana M
AU  - Pereira Daoud AM
AD  - Department of Health Ethics and Society, Maastricht University, Maastricht, The
      Netherlands.
AD  - Department of Medical Humanities, Utrecht University Medical Center, Utrecht, The
      Netherlands.
AD  - School for Oncology and Developmental Biology (GROW), Maastricht University,
      Maastricht, The Netherlands.
FAU - Popovic, Mina
AU  - Popovic M
AD  - Ghent-Fertility And Stem cell Team (G-FAST), Department for Reproductive
      Medicine, Ghent University Hospital, Ghent, Belgium.
FAU - Dondorp, Wybo J
AU  - Dondorp WJ
AD  - Department of Health Ethics and Society, Maastricht University, Maastricht, The
      Netherlands.
AD  - School for Oncology and Developmental Biology (GROW), Maastricht University,
      Maastricht, The Netherlands.
AD  - School for Care and Public Health Research (CAPHRI), Maastricht University,
      Maastricht, The Netherlands.
AD  - Socrates chair Ethics of Reproductive Genetics endowed by the Dutch Humanist
      Association, Amsterdam, The Netherlands.
FAU - Trani Bustos, Marc
AU  - Trani Bustos M
AD  - Ghent-Fertility And Stem cell Team (G-FAST), Department for Reproductive
      Medicine, Ghent University Hospital, Ghent, Belgium.
AD  - Oncode Institute, Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and 
      Sciences) and University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AD  - Department of Medical Humanities, Utrecht University Medical Center, Utrecht, The
      Netherlands.
FAU - Chuva de Sousa Lopes, Susana M
AU  - Chuva de Sousa Lopes SM
AD  - Ghent-Fertility And Stem cell Team (G-FAST), Department for Reproductive
      Medicine, Ghent University Hospital, Ghent, Belgium.
AD  - Department of Anatomy and Embryology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - van den Brink, Susanne C
AU  - van den Brink SC
AD  - Oncode Institute, Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and 
      Sciences) and University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Roelen, Bernard A J
AU  - Roelen BAJ
AD  - Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht
      University, Utrecht, the Netherlands.
FAU - de Wert, Guido M W R
AU  - de Wert GMWR
AD  - Department of Health Ethics and Society, Maastricht University, Maastricht, The
      Netherlands.
AD  - School for Oncology and Developmental Biology (GROW), Maastricht University,
      Maastricht, The Netherlands.
AD  - School for Care and Public Health Research (CAPHRI), Maastricht University,
      Maastricht, The Netherlands.
FAU - Heindryckx, Bjorn
AU  - Heindryckx B
AD  - Ghent-Fertility And Stem cell Team (G-FAST), Department for Reproductive
      Medicine, Ghent University Hospital, Ghent, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Hum Reprod Update
JT  - Human reproduction update
JID - 9507614
SB  - IM
MH  - Animals
MH  - Embryo Implantation/physiology
MH  - Embryo Research/*ethics/legislation & jurisprudence
MH  - Embryo, Mammalian/*cytology
MH  - Embryonic Development/*physiology
MH  - Humans
MH  - Mice
MH  - *Models, Biological
MH  - Morals
MH  - *Public Policy
OTO - NOTNLM
OT  - *blastoids
OT  - *embryo-like structures
OT  - *embryogenesis
OT  - *embryoids
OT  - *embryonic stem cells
OT  - *ethics
OT  - *gastruloids
OT  - *pluripotency
OT  - *stem cells
OT  - *trophoblast stem cells
EDAT- 2020/07/28 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/07/27 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2020/07/27 06:00 [entrez]
AID - 5876550 [pii]
AID - 10.1093/humupd/dmaa027 [doi]
PST - ppublish
SO  - Hum Reprod Update. 2020 Nov 1;26(6):779-798. doi: 10.1093/humupd/dmaa027.


PMID- 32712210
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 225
DP  - 2020 Oct 15
TI  - The ethics of excise taxes on sugar-sweetened beverages.
PG  - 113105
LID - S0031-9384(20)30419-4 [pii]
LID - 10.1016/j.physbeh.2020.113105 [doi]
AB  - Sugar-sweetened beverage (SSB) taxation has emerged as a priority policy for
      promoting health and funding investments in communities most affected by
      diet-related disease. There are now 8 U.S. jurisdictions and over 40 countries
      that have implemented SSB taxes. Evaluations show that these policies reduce SSB 
      consumption and purchasing while raising revenues to fund public health,
      education, and equity. However, there have been few analyses of the ethical
      considerations of SSB taxation. Using a framework for evaluating the ethics of
      public health interventions, this paper considers the ethical aspects of SSB
      excise taxes with respect to: physical health, psychosocial well-being, equality,
      informed choice, liberty, social and cultural values, and responsibility.
      Available evidence suggests there is a strong ethical case for levying SSB excise
      taxes on manufacturers and distributors. SSB excise taxes reduce consumption and 
      purchasing of SSBs and are expected to meaningfully reduce obesity and
      diet-related morbidity and mortality. Because SSB taxes are specific to a product
      and its manufacturers, they are unlikely to harm psychosocial health by
      stigmatizing people who are overweight. SSB excise taxes should lead to greater
      equality because the health and social benefits are progressive (i.e., low-income
      individuals are likely to accrue the largest benefits from the tax, even more so 
      when revenues are spent on health and social equity). Meanwhile, the average
      consumer cost burden that would result if distributors raise SSB prices in
      reponse to the tax is minimally regressive. Regarding liberty, SSB taxes do not
      eliminate the option of buying SSBs, but if SSB distributors raise SSB prices, it
      becomes somewhat more expensive to continue purchasing the same amount of SSBs.
      Meanwhile, the taxes expand beverage options by funding drinking water
      availability and prompting industry to expand offerings of unsweetened drinks and
      SSBs containing less sugar. Furthermore, by averting poor health, SSB taxes
      should expand overall freedom to pursue one's goals. Informed choice could be
      facilitated by seeing a higher SSB shelf price (which indicates a drink contains 
      added sugar) and exposure to nutrition education funded with tax revenues. SSB
      taxation is unlikely to negatively interfere with social or cultural values
      because taxation would not eliminate having SSBs for special occasions, and SSBs 
      are not a staple of traditional diets. Lastly, SSB taxation attributes
      responsibility for health in a manner that reflects industry's contribution to
      obesity and the multisectoral solutions that are needed to prevent diet-related
      disease.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Falbe, Jennifer
AU  - Falbe J
AD  - Human Development and Family Studies Program, Department of Human Ecology, UC
      Davis. 1 Shields Ave, Davis, CA, 95616, United States. Electronic address:
      jfalbe@ucdavis.edu.
LA  - eng
GR  - K01 DK113068/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200724
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
RN  - 0 (Sweetening Agents)
SB  - IM
MH  - Beverages
MH  - Consumer Behavior
MH  - Humans
MH  - *Sugar-Sweetened Beverages
MH  - Sweetening Agents
MH  - Taxes
PMC - PMC7377978
OTO - NOTNLM
OT  - *Ethics
OT  - *Excise taxes
OT  - *Obesity
OT  - *Policy
OT  - *Sugar sweetened beverages
OT  - *Taxation
EDAT- 2020/07/28 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/27 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/27 06:00 [entrez]
AID - S0031-9384(20)30419-4 [pii]
AID - 10.1016/j.physbeh.2020.113105 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Oct 15;225:113105. doi: 10.1016/j.physbeh.2020.113105. Epub
      2020 Jul 24.


PMID- 32711907
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201119
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
VI  - 72
IP  - 2
DP  - 2020 Aug
TI  - RETRACTED: Invited commentary.
PG  - 672
LID - S0741-5214(19)32588-1 [pii]
LID - 10.1016/j.jvs.2019.11.002 [doi]
AB  - This article has been retracted: please see Elsevier Policy on Article Withdrawal
      (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This
      article has been retracted at the request of the Editor-in-Chief and Author. This
      article has not been retracted for any ethics infringement but because the
      article on which it is commenting has been retracted.
FAU - DiMuzio, Paul
AU  - DiMuzio P
AD  - Division of Vascular and Endovascular Surgery, Thomas Jefferson University,
      Philadelphia, Pa.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
SB  - IM
RIN - J Vasc Surg. 2020 Oct;72(4):1514. PMID: 32972596
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/27 06:00
PHST- 2019/10/23 00:00 [received]
PHST- 2019/11/03 00:00 [accepted]
PHST- 2020/07/27 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - S0741-5214(19)32588-1 [pii]
AID - 10.1016/j.jvs.2019.11.002 [doi]
PST - ppublish
SO  - J Vasc Surg. 2020 Aug;72(2):672. doi: 10.1016/j.jvs.2019.11.002.


PMID- 32711534
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 25
TI  - Changing medical education scenario: a wakeup call for reforms in Anatomy Act.
PG  - 63
LID - 10.1186/s12910-020-00507-0 [doi]
AB  - BACKGROUND: Anatomy Act provides legal ambit to medical educationists for the
      acquisition of cadavers. The changing medical education scenario,
      socio-demographic change, and ethical concerns have necessitated an urgent review
      of its legal and ethical framework. Suitable amendments addressing the current
      disparities and deficiencies are long overdue. METHODS: Anatomy Act in India is a
      state Act, which ensures the provision of human bodies for medical education and 
      research. The methodology included three components namely: Comparison of various
      Anatomy Acts clause by clause, Feedback from anatomists, and Formulation of
      comprehensive model Anatomy Act. RESULTS: Various Acts studied showed
      discrepancies in the purpose of the Act, roles and duties of stakeholders,
      regulation for body donation, the procedure to handle unclaimed bodies, disposal 
      of dissected bodies, etc. No Act defines a donor and neither addresses the issue 
      of transport of anatomical material. Only ten states have a clause for body
      donation. Acts of only six states have been amended over the last 50 years. Three
      states denied having an Act. The whole exercise of review of Acts, extensive
      feedback received from end-users, and taking into account global good practices, 
      culminated in drafting a comprehensive model Anatomy Act founded on ethical
      principles. CONCLUSION: India, with the largest number of medical colleges, is
      not only at the forefront but also a hub of medical education in the Southeast
      Asia region. Legal reform can be a torchbearer to promote ethical and transparent
      practices for obtaining cadavers for other countries of the region with similar
      socio-demography and shall also motivate anatomic fraternity across the globe for
      critical analysis of their respective Anatomy Acts.
FAU - Lalwani, Rekha
AU  - Lalwani R
AD  - Department of Anatomy, All India Institute of Medical Sciences, Bhopal, 462020,
      India.
FAU - Kotgirwar, Sheetal
AU  - Kotgirwar S
AD  - Department of Anatomy, All India Institute of Medical Sciences, Bhopal, 462020,
      India.
FAU - Athavale, Sunita Arvind
AU  - Athavale SA
AUID- ORCID: 0000-0003-3003-1257
AD  - Department of Anatomy, All India Institute of Medical Sciences, Bhopal, 462020,
      India. sunita.anatomy@aiimsbhopal.edu.in.
LA  - eng
PT  - Journal Article
DEP - 20200725
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Cadaver
MH  - *Education, Medical
MH  - Humans
MH  - India
MH  - Morals
MH  - *Tissue Donors
PMC - PMC7382862
OTO - NOTNLM
OT  - *Cadaver
OT  - *Dissection
OT  - *Medical education
OT  - *Southeast Asia
EDAT- 2020/07/28 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/27 06:00
PHST- 2020/05/10 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/07/27 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00507-0 [doi]
AID - 10.1186/s12910-020-00507-0 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 25;21(1):63. doi: 10.1186/s12910-020-00507-0.


PMID- 32711479
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 25
TI  - PhysIOpathology of NEuromuscular function rElated to fatigue in chronic Renal
      disease in the elderly (PIONEER): study protocol.
PG  - 305
LID - 10.1186/s12882-020-01976-6 [doi]
AB  - BACKGROUND: Chronic Kidney Disease (CKD) is associated with reduced muscular
      strength resulting in profound fatigue. The physiopathology of these changes,
      their prevalence and evolution are still debated. Moreover, we have little data
      on elderly CKD patients. The present study protocol aims to 1) quantify the
      prevalence of low muscle strength (dynapenia) in a cohort of elderly patients
      with advanced CKD and to 2) characterize their force production coupled with
      electromyographic features and the symptoms of fatigue compared to a matched
      control group. METHODS: This is a case-control, prospective, interventional
      study. INCLUSION CRITERIA: age >/= 60 years; CKD Stage 3b-5; clinical stability
      (i.e. no hospitalization and </= 25% in creatinine increase in the previous 3
      months). Controls with normal kidney function will be matched in terms of age,
      gender and diabetes mellitus (requisite: estimated glomerular filtration rate >/=
      60 ml/min/1.73m(2) available in the last 6 months). Exclusion criteria for cases 
      and controls: neuromuscular disease, life expectancy < 3 months. The handgrip
      strength protocol is an intermittent test consisting in 6 series of 9 repetitions
      of 3-s sub-maximum contractions at 40% of the maximum voluntary contraction (MVC)
      and 2 s of resting time between contractions. Each series is separated by one
      fast sub-maximum contraction and one MVC. Strength is assessed with a
      high-frequency handgrip dynamometer paired with surface electromyography.
      Symptoms of fatigue are assessed using MFI-20 and FACIT-F questionnaires. In
      order to reach a statistical power of 96%, we plan to enroll 110 subjects in each
      group. DISCUSSION: The novelty of this study resides in the application of an
      already validated set of tests in a population in which this combination
      (dynamometer, electromyography and questionnaires) has not previously been
      explored. We expect a high prevalence of dynapenia and a higher fatigability in
      CKD patients. A positive correlation is expected between reported fatigue and
      fatigability. Better appreciation of the prevalence and the relationship between 
      fatigability and a sensation of fatigue can help us target interventions in CKD
      patients to improve quality of life and survival. TRIAL REGISTRATION: The study
      was approved by Ethical Committee EST III n degrees 20.03.01 and was recorded as 
      a Clinical Trial (NCT04330807) on April 2, 2020.
FAU - Chatrenet, Antoine
AU  - Chatrenet A
AUID- ORCID: 0000-0002-4853-180X
AD  - Nephrology, Centre Hospitalier Le Mans, Le Mans, France.
      antoine.chatrenet@gmail.com.
AD  - Laboratory "Movement, Interactions, Performance" (EA 4334), Le Mans University,
      Le Mans, France. antoine.chatrenet@gmail.com.
FAU - Beaune, Bruno
AU  - Beaune B
AD  - Laboratory "Movement, Interactions, Performance" (EA 4334), Le Mans University,
      Le Mans, France.
FAU - Fois, Antioco
AU  - Fois A
AD  - Nephrology, Centre Hospitalier Le Mans, Le Mans, France.
FAU - Pouliquen, Camille
AU  - Pouliquen C
AD  - Laboratory "Movement, Interactions, Performance" (EA 4334), Le Mans University,
      Le Mans, France.
FAU - Audebrand, Jean-Michel
AU  - Audebrand JM
AD  - Endocrinology and diabetology, Centre Hospitalier Le Mans, Le Mans, France.
FAU - Torreggiani, Massimo
AU  - Torreggiani M
AD  - Nephrology, Centre Hospitalier Le Mans, Le Mans, France.
FAU - Paris, Damien
AU  - Paris D
AD  - Nephrology, Centre Hospitalier Le Mans, Le Mans, France.
AD  - Laboratory "Movement, Interactions, Performance" (EA 4334), Le Mans University,
      Le Mans, France.
FAU - Durand, Sylvain
AU  - Durand S
AD  - Laboratory "Movement, Interactions, Performance" (EA 4334), Le Mans University,
      Le Mans, France.
FAU - Piccoli, Giorgina Barbara
AU  - Piccoli GB
AD  - Nephrology, Centre Hospitalier Le Mans, Le Mans, France.
AD  - Department of clinical and biological sciences, University of Torino, Torino,
      Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT04330807
GR  - 2018/1255/Convention Industrielle de Formation par la REcherche
      (CIFRE)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200725
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
SB  - IM
MH  - Aged
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Electromyography
MH  - Fatigue/*epidemiology/physiopathology
MH  - *Hand Strength
MH  - Humans
MH  - Kidney Failure, Chronic/epidemiology
MH  - Middle Aged
MH  - *Muscle Contraction
MH  - *Muscle Fatigue
MH  - Muscle Strength
MH  - Muscle Strength Dynamometer
MH  - Muscle Weakness/*epidemiology/physiopathology
MH  - Prevalence
MH  - Prospective Studies
MH  - Renal Insufficiency, Chronic/*epidemiology
PMC - PMC7382847
OTO - NOTNLM
OT  - *Electromyographic features
OT  - *Muscle fatigue
OT  - *Pre-dialysis
OT  - *Tiredness
EDAT- 2020/07/28 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/07/27 06:00
PHST- 2020/07/15 00:00 [received]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/07/27 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.1186/s12882-020-01976-6 [doi]
AID - 10.1186/s12882-020-01976-6 [pii]
PST - epublish
SO  - BMC Nephrol. 2020 Jul 25;21(1):305. doi: 10.1186/s12882-020-01976-6.


PMID- 32711311
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 744
DP  - 2020 Nov 20
TI  - Climate change fostered cultural dynamics of human resilience in Europe in the
      past 2500 years.
PG  - 140842
LID - S0048-9697(20)34366-7 [pii]
LID - 10.1016/j.scitotenv.2020.140842 [doi]
AB  - Humans possess limited knowledge on what generated cultural dynamics to
      strengthen human resilience to overcome climate-induced stresses. Although the
      highly developed mental ability of humans could have enabled significant human
      resilience in history, no study has empirically explained or has even
      scientifically confirmed how and when such dynamics arose. To fill the current
      research gap, this study therefore explores the associations among climatic
      conditions, the evolutional dynamics of human thinkers and their thoughts, and
      human ecological-socioeconomic conditions in the past 2500 years in Europe.
      Results from quantitative modellings and causal analyses confirm that
      climatic-ecological stresses led to human ecological-socioeconomic crises, and
      thereby dramatically increased twice of the thinkers' number and their thoughts' 
      impact across different philosophies in truth, knowledge, and ethics for
      adaptation at multi-decadal to centennial temporal scales, especially in
      spirituality oriented mentality. The process of the stress-generated cultural
      dynamics displays some similarities with the stress-induced mutagenesis in
      organism evolution. Ultimately, climatic-ecological stresses prompt the
      escalation in the number of thinkers and impacts of their thoughts and
      flourishing of philosophy. Such stress-regenerated cultural dynamics imply that
      the current climate change threat may stimulate another thriving phase of
      cultural selection and lift humans to the next homeostatic plateau of
      civilization. Findings also extend the cognate scope of psychological,
      sociological, and civilization studies.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Zhang, David D
AU  - Zhang DD
AD  - School of Geographic Sciences, Guangzhou University, Guangzhou 510006, China.
      Electronic address: dzhang@gzhu.edu.cn.
FAU - Pei, Qing
AU  - Pei Q
AD  - Department of Social Sciences, Education University of Hong Kong, Hong Kong.
      Electronic address: qingpei@eduhk.hk.
FAU - Lee, Harry F
AU  - Lee HF
AD  - Department of Geography and Resource Management, Chinese University of Hong Kong,
      Hong Kong; Cold and Arid Regions Environmental and Engineering Research
      Institute, Chinese Academy of Sciences, Lanzhou 730000, China.
FAU - Jim, C Y
AU  - Jim CY
AD  - Department of Social Sciences, Education University of Hong Kong, Hong Kong.
FAU - Li, Guodong
AU  - Li G
AD  - Department of Statistics and Actuarial Science, University of Hong Kong, Hong
      Kong.
FAU - Zhang, Mandy
AU  - Zhang M
AD  - Department of Religious Studies, University of the West, Rosemead, CA 91770, USA.
FAU - Li, Jinbao
AU  - Li J
AD  - Department of Geography, University of Hong Kong, Hong Kong.
FAU - Wu, Zhifeng
AU  - Wu Z
AD  - School of Geographic Sciences, Guangzhou University, Guangzhou 510006, China.
FAU - Wang, Leibin
AU  - Wang L
AD  - School of Geographic Sciences, Guangzhou University, Guangzhou 510006, China.
FAU - Yue, Ricci P H
AU  - Yue RPH
AD  - Department of Geography and Resource Management, Chinese University of Hong Kong,
      Hong Kong.
FAU - Zhang, Shengda
AU  - Zhang S
AD  - School of Geographic Sciences, Guangzhou University, Guangzhou 510006, China.
LA  - eng
PT  - Journal Article
DEP - 20200712
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
SB  - IM
MH  - Acclimatization
MH  - *Adaptation, Physiological
MH  - *Climate Change
MH  - Europe
MH  - Humans
OTO - NOTNLM
OT  - Climate change
OT  - Cultural dynamics
OT  - Europe
OT  - Human ecological-socio-economic conditions
OT  - Resilience
COIS- Declaration of competing interest The authors declare no competing financial
      interests.
EDAT- 2020/07/28 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/07/26 06:00 [entrez]
AID - S0048-9697(20)34366-7 [pii]
AID - 10.1016/j.scitotenv.2020.140842 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Nov 20;744:140842. doi: 10.1016/j.scitotenv.2020.140842. 
      Epub 2020 Jul 12.


PMID- 32710918
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 736
DP  - 2020 Sep 25
TI  - Gait analysis correlates mechanical hyperalgesia in a model of
      streptozotocin-induced diabetic neuropathy: A CatWalk dynamic motor function
      study.
PG  - 135253
LID - S0304-3940(20)30523-1 [pii]
LID - 10.1016/j.neulet.2020.135253 [doi]
AB  - Peripheral neuropathy is a complication of diabetes commonly associated with pain
      and decline in motor compound action potential, leading to alterations in plantar
      pressure during gait. We identified motor impairments in streptozotocin
      (STZ)-induced diabetic neuropathic rats and correlated with mechanical withdrawal
      thresholds, establishing this correlation as a complementary method to
      investigate the development of chronic hyperalgesia in diabetic neuropathy.
      METHODS: UNICAMP's Ethics Committee (protocol number 3902-1) approved all
      experiments. Male Lewis rats (200-250g) received a STZ-low-dose (25mg/kg/day)
      (STZ group) or 0.1M sodium citrate buffer (SCB, control group) once a day, during
      five consecutive days. Diabetic rats (250mg/dL blood glucose) were submitted to
      electronic von Frey and CatWalk tests at 0, 7, 14, 21, and 28 days after
      treatment. RESULTS: STZ, but not SCB, induced diabetes. After the 14(th) day
      (STZ)-induced diabetic rats showed mechanical hyperalgesia and a reduction in the
      hind limbs footprint intensities. At the 28(th) day, rats presented alterations
      in spatial parameters (Maximum Contact Area; Stride Length; Print Area), which
      showed a strong correlation with mechanical withdrawal thresholds (r(2)=0.97;
      0.99, and 0.93, respectively). CONCLUSIONS: Correlation between gait parameters
      and mechanical withdrawal thresholds enables a better experimental approach to
      evaluate the development of chronic hyperalgesia in the STZ-induced diabetes
      model. It allows a concise crosstalk of motor and sensorial functions, which are 
      usually analyzed individually. CatWalk gait parameters can be used as a
      complementary tool to investigate the development of hyperalgesia in STZ-induced 
      diabetic neuropathic rats.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Vieira, Willians Fernando
AU  - Vieira WF
AD  - Department of Structural and Functional Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic
      address: williansfvieira@gmail.com.
FAU - Malange, Kaue Franco
AU  - Malange KF
AD  - Department of Structural and Functional Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic
      address: malangefc@gmail.com.
FAU - de Magalhaes, Silviane Fernandes
AU  - de Magalhaes SF
AD  - Department of Structural and Functional Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic
      address: silviane.fernandes@hotmail.com.
FAU - Dos Santos, Gilson Goncalves
AU  - Dos Santos GG
AD  - Department of Structural and Functional Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil; Department of
      Anesthesiology, University of California (UCSD), San Diego, La Jolla, United
      States. Electronic address: ggoncalvesdossantos@health.ucsd.edu.
FAU - de Oliveira, Alexandre Leite Rodrigues
AU  - de Oliveira ALR
AD  - Department of Structural and Functional Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic
      address: alroliv@unicamp.br.
FAU - da Cruz-Hofling, Maria Alice
AU  - da Cruz-Hofling MA
AD  - Department of Biochemistry and Tissue Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic
      address: hofling@unicamp.br.
FAU - Parada, Carlos Amilcar
AU  - Parada CA
AD  - Department of Structural and Functional Biology, Institute of Biology, State
      University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. Electronic
      address: caparada@unicamp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200722
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus, Experimental/complications
MH  - *Diabetic Neuropathies/complications
MH  - Gait Analysis/*methods
MH  - *Gait Disorders, Neurologic/etiology
MH  - *Hyperalgesia/etiology
MH  - Male
MH  - Rats
MH  - Rats, Inbred Lew
OTO - NOTNLM
OT  - *CatWalk
OT  - *diabetic neuropathy
OT  - *gait analysis
OT  - *mechanical hyperalgesia
OT  - *von Frey test
EDAT- 2020/07/28 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
PHST- 2020/07/26 06:00 [entrez]
AID - S0304-3940(20)30523-1 [pii]
AID - 10.1016/j.neulet.2020.135253 [doi]
PST - ppublish
SO  - Neurosci Lett. 2020 Sep 25;736:135253. doi: 10.1016/j.neulet.2020.135253. Epub
      2020 Jul 22.


PMID- 32710718
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 1548-923X (Electronic)
IS  - 1548-923X (Linking)
VI  - 17
IP  - 1
DP  - 2020 Jul 27
TI  - Facilitating and hindering experiences to the development of humanistic caring in
      the academic and clinical settings: an interpretive phenomenological study with
      nursing students and nurses.
LID - 10.1515/ijnes-2019-0036 [doi]
LID - /j/ijnes.2020.17.issue-1/ijnes-2019-0036/ijnes-2019-0036.xml [pii]
AB  - Objectives This paper reports on nursing students' and nurses' lived experiences 
      mediating their development of humanistic caring. Methods Using interpretive
      phenomenology, 26 participants were individually interviewed. A five-stage
      phenomenological analysis based on Benner's (Benner, P. (1994). Interpretive
      phenomenology: Embodiment, caring, and ethics in health and illness. Thousand
      Oaks, CA: SAGE) method occurred simultaneously. Results The analysis highlighted 
      that the development of humanistic caring is affected by role models and
      counterexamples, environments in which humanistic caring is exalted or
      trivialized, communication-related courses, patient storytelling, and work
      overload. Conclusions It might be valuable to raise the awareness of nurse
      educators about their opportunity in shaping the development of students'
      humanistic caring.
FAU - Letourneau, Dimitri
AU  - Letourneau D
AUID- ORCID: https://orcid.org/0000-0001-5174-4024
AD  - Faculty of Nursing, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Goudreau, Johanne
AU  - Goudreau J
AD  - Faculty of Nursing, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Cara, Chantal
AU  - Cara C
AD  - Faculty of Nursing, Universite de Montreal, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - Germany
TA  - Int J Nurs Educ Scholarsh
JT  - International journal of nursing education scholarship
JID - 101214977
SB  - IM
MH  - Empathy
MH  - *Holistic Health
MH  - *Humanism
MH  - Humans
MH  - Nurse's Role/*psychology
MH  - *Nurse-Patient Relations
MH  - Nursing Methodology Research
MH  - Nursing Staff, Hospital/*psychology
MH  - Philosophy, Nursing
MH  - Students, Nursing/*psychology
OTO - NOTNLM
OT  - caring
OT  - competency
OT  - facilitating and hindering experiences
OT  - humanism
OT  - nursing education
OT  - phenomenology
EDAT- 2020/07/28 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/07/26 06:00
PHST- 2019/03/28 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/07/26 06:00 [entrez]
AID - 10.1515/ijnes-2019-0036 [doi]
AID - /j/ijnes.ahead-of-print/ijnes-2019-0036/ijnes-2019-0036.xml [pii]
PST - epublish
SO  - Int J Nurs Educ Scholarsh. 2020 Jul 27;17(1). pii:
      /j/ijnes.ahead-of-print/ijnes-2019-0036/ijnes-2019-0036.xml. doi:
      10.1515/ijnes-2019-0036.


PMID- 32710191
OWN - NLM
STAT- MEDLINE
DCOM- 20211006
LR  - 20211006
IS  - 1572-9249 (Electronic)
IS  - 1380-7870 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Oct
TI  - Measuring the temporal prognostic utility of a baseline risk score.
PG  - 856-871
LID - 10.1007/s10985-020-09503-3 [doi]
AB  - In the time-to-event setting, the concordance probability assesses the relative
      level of agreement between a model-based risk score and the survival time of a
      patient. While it provides a measure of discrimination over the entire follow-up 
      period of a study, the probability does not provide information on the
      longitudinal durability of a baseline risk score. It is possible that a baseline 
      risk model is able to segregate short-term from long-term survivors but unable to
      maintain its discriminatory strength later in the follow-up period. As a
      consequence, this would motivate clinicians to re-evaluate the risk score
      longitudinally. This longitudinal re-evaluation may not, however, be feasible in 
      many scenarios since a single baseline evaluation may be the only data
      collectible due to treatment or other clinical or ethical reasons. In these
      scenarios, an attenuation of the discriminatory power of the patient risk score
      over time would indicate decreased clinical utility and call into question
      whether this score should remain a prognostic tool at later time points. Working 
      within the concordance probability paradigm, we propose a method to address this 
      clinical scenario and evaluate the discriminatory power of a baseline derived
      risk score over time. The methodology is illustrated with two examples: a
      baseline risk score in colorectal cancer defined at the time of tumor resection, 
      and for circulating tumor cells in metastatic prostate cancer.
FAU - Devlin, Sean M
AU  - Devlin SM
AUID- ORCID: 0000-0002-6801-720X
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA. devlins@mskcc.org.
FAU - Gonen, Mithat
AU  - Gonen M
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Heller, Glenn
AU  - Heller G
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
LA  - eng
GR  - R01 CA207220/CA/NCI NIH HHS/United States
GR  - P50 CA092629/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01CA207220/NH/NIH HHS/United States
GR  - P30CA008748/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200724
PL  - United States
TA  - Lifetime Data Anal
JT  - Lifetime data analysis
JID - 9516348
SB  - IM
MH  - Computer Simulation
MH  - Humans
MH  - *Prognosis
MH  - *Proportional Hazards Models
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Time
PMC - PMC8445092
MID - NIHMS1614970
OTO - NOTNLM
OT  - *Concordance probability
OT  - *Prognostic modeling
OT  - *Proportional hazards
EDAT- 2020/07/28 06:00
MHDA- 2021/10/07 06:00
CRDT- 2020/07/26 06:00
PHST- 2019/06/24 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/10/07 06:00 [medline]
PHST- 2020/07/26 06:00 [entrez]
AID - 10.1007/s10985-020-09503-3 [doi]
AID - 10.1007/s10985-020-09503-3 [pii]
PST - ppublish
SO  - Lifetime Data Anal. 2020 Oct;26(4):856-871. doi: 10.1007/s10985-020-09503-3. Epub
      2020 Jul 24.


PMID- 32709755
OWN - NLM
STAT- Publisher
LR  - 20200725
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 24
TI  - Open data, trials and new ethics of using others' work.
LID - medethics-2019-105898 [pii]
LID - 10.1136/medethics-2019-105898 [doi]
AB  - Data and ideas are the capital of research productivity. Is it ethical to preempt
      the publication of another researcher's unpublished data or preliminary analysis,
      perhaps without citation? The long-established answer is 'certainly not'-but
      recent 'open data' use suggests otherwise. A research competition was held using 
      data from The Systolic Blood Pressure Intervention Trial (SPRINT). This SPRINT
      Data Analysis Challenge created a novel environment for using open data as data
      became open early. This allowed third-party researchers the opportunity to assess
      some of the trial's outcomes before trialists. Could this infringe on trialists' 
      right to analyse their data? Simultaneously, trialists had access to analyses
      from submissions to the competition that were not formally 'published' with a
      typical author credit or citation. Therefore, trialists had the opportunity to
      view the competition submissions and published on those ideas first without a
      typical way to cite the source of that idea. Could this infringe on researchers' 
      right to be credited for their ideas? This is not intended as a criticism of open
      data, the SPRINT Data Analysis Challenge, or similar systems/ventures, but is an 
      effort to objectively note what may be remediable flaws in the worthwhile,
      growing and dynamic uses of open data. We offer preliminary analytics to shed
      more light and provide fodder for additional discussion.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Carris, Nicholas W
AU  - Carris NW
AD  - University of South Florida, Taneja College of Pharmacy, Tampa, Florida, USA
      carris@usf.edu.
FAU - Cheon, Byron
AU  - Cheon B
AD  - University of South Florida, Morsani College of Medicine, Tampa, Florida, United 
      States.
FAU - Wolfson, Jay
AU  - Wolfson J
AD  - University of South Florida, College of Public Health, Tampa, Florida, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - education for health care professionals
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/26 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - medethics-2019-105898 [pii]
AID - 10.1136/medethics-2019-105898 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 24. pii: medethics-2019-105898. doi:
      10.1136/medethics-2019-105898.


PMID- 32709754
OWN - NLM
STAT- Publisher
LR  - 20211217
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 24
TI  - The need for empathetic healthcare systems.
LID - medethics-2019-105921 [pii]
LID - 10.1136/medethics-2019-105921 [doi]
AB  - Medicine is not merely a job that requires technical expertise, but a profession 
      concerned with making the best decisions and recommendations with reference to,
      and in consultation with, the patient. This means that the skill set required for
      healthcare professionals in order to provide good care is a combination of
      scientific knowledge, technical aptitude, and affective qualities or virtues such
      as compassion and empathy.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kerasidou, Angeliki
AU  - Kerasidou A
AD  - The Ethox Centre and the Wellcome Centre for Ethics and Humanities, Nuffield
      Department of Population Health, University of Oxford, Oxford, UK
      angeliki.kerasidou@ethox.ox.ac.uk.
FAU - Baeroe, Kristine
AU  - Baeroe K
AD  - Department of Global Public Health and Primary Care, University of Bergen,
      Bergen, Norway.
FAU - Berger, Zackary
AU  - Berger Z
AUID- ORCID: http://orcid.org/0000-0002-5871-0342
AD  - Berman Institute of Bioethics, Johns Hopkins University School of Medicine and
      Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
FAU - Caruso Brown, Amy E
AU  - Caruso Brown AE
AUID- ORCID: http://orcid.org/0000-0002-3228-2992
AD  - Centre for Bioethics and Humanities, SUNY Upstate Medical University, Syracuse,
      New York, USA.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200724
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639938
OTO - NOTNLM
OT  - ethics
OT  - general
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/26 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - medethics-2019-105921 [pii]
AID - 10.1136/medethics-2019-105921 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 24. pii: medethics-2019-105921. doi:
      10.1136/medethics-2019-105921.


PMID- 32709753
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20220716
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Forever young? The ethics of ongoing puberty suppression for non-binary adults.
PG  - 743-752
LID - 10.1136/medethics-2019-106012 [doi]
AB  - In this article, we analyse the novel case of Phoenix, a non-binary adult
      requesting ongoing puberty suppression (OPS) to permanently prevent the
      development of secondary sex characteristics, as a way of affirming their gender 
      identity. We argue that (1) the aim of OPS is consistent with the proper goals of
      medicine to promote well-being, and therefore could ethically be offered to
      non-binary adults in principle; (2) there are additional equity-based reasons to 
      offer OPS to non-binary adults as a group; and (3) the ethical defensibility of
      facilitating individual requests for OPS from non-binary adults also depends on
      other relevant considerations, including the balance of potential benefits over
      harms for that specific patient, and whether the patient's request is
      substantially autonomous. Although the broadly principlist ethical approach we
      take can be used to analyse other cases of non-binary adults requesting OPS apart
      from the case we evaluate, we highlight that the outcome will necessarily depend 
      on the individual's context and values. However, such clinical provision of OPS
      should ideally be within the context of a properly designed research study with
      long-term follow-up and open publication of results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Notini, Lauren
AU  - Notini L
AUID- ORCID: 0000-0001-5055-9505
AD  - Melbourne Law School, University of Melbourne, Melbourne, Victoria, Australia
      lauren.notini@unimelb.edu.au.
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Parkville, Victoria, Australia.
FAU - Earp, Brian D
AU  - Earp BD
AUID- ORCID: 0000-0001-9691-2888
AD  - Yale-Hastings Program in Ethics and Health Policy, Yale University, New Haven,
      Connecticut, United States and The Hastings Center, Garrison, New York, United
      States.
AD  - The Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford,
      United Kingdom.
FAU - Gillam, Lynn
AU  - Gillam L
AUID- ORCID: 0000-0001-6481-5004
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
FAU - McDougall, Rosalind J
AU  - McDougall RJ
AUID- ORCID: 0000-0002-3809-2575
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Savulescu, Julian
AU  - Savulescu J
AUID- ORCID: 0000-0003-1691-6403
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Parkville, Victoria, Australia.
AD  - The Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford,
      United Kingdom.
AD  - University of Oxford, Oxford, United Kingdom.
AD  - University of Melbourne, Melbourne, Victoria, Australia.
FAU - Telfer, Michelle
AU  - Telfer M
AUID- ORCID: 0000-0002-3000-5297
AD  - Department of Adolescent Medicine, The Royal Children's Hospital Melbourne,
      Parkville, Victoria, Australia.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Pang, Ken C
AU  - Pang KC
AUID- ORCID: 0000-0002-6881-775X
AD  - Department of Adolescent Medicine, The Royal Children's Hospital Melbourne,
      Parkville, Victoria, Australia.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
AD  - The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria,
      Australia.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - WT203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - WT104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - 203132/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200724
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Nov;46(11):759-760. PMID: 32839229
CIN - J Med Ethics. 2020 Nov;46(11):757-758. PMID: 32878919
CIN - J Med Ethics. 2020 Nov;46(11):755-756. PMID: 32883708
CIN - J Med Ethics. 2020 Nov;46(11):753-754. PMID: 33033114
CIN - J Med Ethics. 2020 Nov;46(11):761-762. PMID: 33087409
MH  - Adult
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Male
MH  - Morals
MH  - *Puberty
PMC - PMC7656150
OTO - NOTNLM
OT  - *autonomy
OT  - *clinical ethics
OT  - *concept of health
OT  - *philosophy of the health professions
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/07/26 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/07/26 06:00 [entrez]
AID - medethics-2019-106012 [pii]
AID - 10.1136/medethics-2019-106012 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):743-752. doi: 10.1136/medethics-2019-106012. Epub
      2020 Jul 24.


PMID- 32709704
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20201218
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 7
DP  - 2020 Jul
TI  - 'I exist because of we': shielding as a communal ethic of maintaining social
      bonds during the COVID-19 response in Ethiopia.
LID - e003204 [pii]
LID - 10.1136/bmjgh-2020-003204 [doi]
FAU - Seifu Estifanos, Abiy
AU  - Seifu Estifanos A
AD  - Department of Reproductive, Family and Population Health, School of Health
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Alemu, Getnet
AU  - Alemu G
AD  - Development Economics, Institute of Development and Policy Research, Addis Ababa 
      University, Addis Ababa, Ethiopia.
FAU - Negussie, Solomon
AU  - Negussie S
AD  - College of Law and Governance Studies, Addis Ababa University, Addis Ababa,
      Ethiopia.
FAU - Ero, Debebe
AU  - Ero D
AD  - College of Social Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Mengistu, Yewondwossen
AU  - Mengistu Y
AD  - School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Addissie, Adamu
AU  - Addissie A
AD  - Department of Preventive Medicine, School of Public Health, College of Health
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Gebrehiwot, Yirgu
AU  - Gebrehiwot Y
AD  - School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Yifter, Helen
AU  - Yifter H
AD  - School of Public Health, College of Health Sciences, Addis Ababa University,
      Addis Ababa, Ethiopia.
FAU - Melkie, Addisu
AU  - Melkie A
AD  - School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Gebrekiros, Damen Hailemariam
AU  - Gebrekiros DH
AD  - Department of Internal Medicine, School of Medicine, Addis Ababa University,
      Addis Ababa, Ethiopia.
FAU - Gebremariam Kotecho, Messay
AU  - Gebremariam Kotecho M
AUID- ORCID: 0000-0002-4884-9041
AD  - School of Social Work, College of Social Sciences, Addis Ababa University, Addis 
      Ababa, Ethiopia.
FAU - Soklaridis, Sophie
AU  - Soklaridis S
AUID- ORCID: 0000-0001-5119-8473
AD  - The Centre for Addiction and Mental Health, Toronto, Ontario, Canada
      sophie.soklaridis@camh.ca.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Family and Community Medicine, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Cartmill, Carrie
AU  - Cartmill C
AUID- ORCID: 0000-0001-6996-7293
AD  - Wilson Centre, University Health Network, Toronto, Ontario, Canada.
FAU - Whitehead, Cynthia Ruth
AU  - Whitehead CR
AUID- ORCID: 0000-0002-0134-9074
AD  - Department of Family and Community Medicine, University of Toronto, Toronto,
      Ontario, Canada.
AD  - Wilson Centre, University Health Network, Toronto, Ontario, Canada.
FAU - Wondimagegn, Dawit
AU  - Wondimagegn D
AD  - School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/ethnology/prevention & control/therapy
MH  - Ethiopia/ethnology
MH  - Humans
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/ethnology/prevention & control/therapy
MH  - *Public Health
MH  - SARS-CoV-2
MH  - *Social Support
PMC - PMC7387313
OTO - NOTNLM
OT  - *health policies and all other topics
OT  - *health policy
OT  - *health services research
OT  - *prevention strategies
OT  - *public Health
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/06/19 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
AID - bmjgh-2020-003204 [pii]
AID - 10.1136/bmjgh-2020-003204 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Jul;5(7). pii: bmjgh-2020-003204. doi:
      10.1136/bmjgh-2020-003204.


PMID- 32709689
OWN - NLM
STAT- Publisher
LR  - 20200725
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
DP  - 2020 Jul 24
TI  - How many children with severe neurodisability are being sent home on parenteral
      nutrition?
LID - archdischild-2020-319623 [pii]
LID - 10.1136/archdischild-2020-319623 [doi]
FAU - Cernat, Elena
AU  - Cernat E
AUID- ORCID: http://orcid.org/0000-0001-7686-5690
AD  - Department of Paediatric Gastroenterology, Leeds Teaching Hospitals NHS Trust,
      Leeds, UK elena_nefy@yahoo.com.
FAU - Puntis, John W
AU  - Puntis JW
AD  - Department of Paediatric Gastroenterology, Leeds Teaching Hospitals NHS Trust,
      Leeds, UK.
LA  - eng
PT  - Letter
DEP - 20200724
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
SB  - IM
OTO - NOTNLM
OT  - ethics
OT  - gastroenterology
OT  - neurology
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - archdischild-2020-319623 [pii]
AID - 10.1136/archdischild-2020-319623 [doi]
PST - aheadofprint
SO  - Arch Dis Child. 2020 Jul 24. pii: archdischild-2020-319623. doi:
      10.1136/archdischild-2020-319623.


PMID- 32709658
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - Characteristics of activity-based therapy interventions for people living with
      spinal cord injury or disease across the continuum of care: a scoping review
      protocol.
PG  - e040014
LID - 10.1136/bmjopen-2020-040014 [doi]
AB  - INTRODUCTION: Individuals living with spinal cord injury and disease (SCI/D)
      experience sensory and motor impairments below their neurological level of
      injury. Activity-based therapies (ABT) are interventions that provide activation 
      of the neuromuscular system below the level of lesion with the goal of retraining
      the nervous system to recover a specific motor task. ABT can lead to increased
      function and improved quality of life; however, research and clinical settings
      currently lack tools to track participation in ABT. As a first step towards
      developing such a tool, a scoping review will be conducted with the objective of 
      identifying the characteristics of ABT that individuals with SCI/D participate in
      across the continuum of care. METHODS AND ANALYSIS: The review will follow the
      Joanna Briggs Institute scoping review framework. Studies that involve at least
      two sessions of ABT for individuals with SCI/D aged >/=16 years will be included.
      Seven databases were searched from their inception to 4 March 2020: Medline,
      Embase, Emcare, Cumulative Index to Nursing and Allied Health Literature, APA
      PsycINFO, Physiotherapy Evidence Database, Cochrane Database of Systematic
      Reviews and the Cochrane Central Register of Controlled Trials. The search will
      be rerun in November 2020 prior to manuscript submission. Screening of titles and
      abstracts will be followed by a review of full texts to identify articles meeting
      inclusion criteria. Stakeholders will be consulted for the creation of the data
      extraction table. The Downs and Black Checklist or the Mixed Methods Appraisal
      Tool will be used to assess article quality. Results will be reported according
      to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      Extension for Scoping Reviews checklist. ETHICS AND DISSEMINATION: Ethical
      approval is not required for this scoping review. Study findings will be shared
      with key stakeholder groups through academic, clinical and public venues.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kaiser, Anita
AU  - Kaiser A
AD  - KITE, Toronto Rehab-University Health Network, Toronto, Ontario, Canada.
AD  - Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Canadian Spinal Research Organization, Toronto, Ontario, Canada.
FAU - Chan, Katherine
AU  - Chan K
AUID- ORCID: 0000-0003-2356-4100
AD  - KITE, Toronto Rehab-University Health Network, Toronto, Ontario, Canada.
FAU - Pakosh, Maureen
AU  - Pakosh M
AD  - KITE, Toronto Rehab-University Health Network, Toronto, Ontario, Canada.
FAU - Musselman, Kristin E
AU  - Musselman KE
AD  - KITE, Toronto Rehab-University Health Network, Toronto, Ontario, Canada
      Kristin.Musselman@uhn.ca.
AD  - Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Continuity of Patient Care
MH  - Humans
MH  - Physical Therapy Modalities
MH  - *Quality of Life
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Spinal Cord Injuries/therapy
MH  - Systematic Reviews as Topic
PMC - PMC7380728
OTO - NOTNLM
OT  - *neurological injury
OT  - *rehabilitation medicine
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040014 [pii]
AID - 10.1136/bmjopen-2020-040014 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e040014. doi: 10.1136/bmjopen-2020-040014.


PMID- 32709657
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - Bridging the gap between physical and mental illness in community pharmacy
      (PharMIbridge): protocol for an Australian cluster randomised controlled trial.
PG  - e039983
LID - 10.1136/bmjopen-2020-039983 [doi]
AB  - INTRODUCTION: There is a significant life expectancy gap attributable to physical
      comorbidities for people living with severe and persistent mental illness (SPMI) 
      compared with the general population. Medications are a major treatment for SPMI 
      management and physical illnesses, hence pharmacists are well positioned to
      support mental healthcare and comorbidities. The randomised controlled trial
      (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led,
      support service for people experiencing SPMI focusing on medication adherence and
      physical comorbidity management, compared with standard care (a
      medication-management service; MedsCheck). METHODS AND ANALYSIS: PharMIbridge is 
      a cluster RCT, whereby community pharmacies in four Australian regions will be
      randomised (1:1 ratio), to either Intervention Group (IG) or Comparator Group
      (CG). All IG and CG pharmacy staff will receive Blended-Mental Health First Aid
      training. Additionally, IG pharmacists will receive further training on
      medication adherence, goal setting, motivational interviewing, managing physical 
      health concerns and complex issues relating to psychotropic medication. CG
      pharmacists will not receive additional training, and will provide standard care 
      (MedsCheck). The primary outcome will be change in participants medication
      adherence for psychotropic medication over 6-months. Using mixed-effects logistic
      regression model and a cluster size of 48 pharmacies, a total of 190 participants
      will need to be recruited to each arm to find a statistically significant
      difference in medication adherence. Secondary outcomes will be changes in factors
      associated with cardiometabolic risk and quality of life, emphasising physical
      and psychological well-being; medication-related problems; adherence to other
      prescribed medication; pharmacists knowledge, confidence and ability to support
      people experiencing SPMI; and effects on healthcare utilisation. A within
      RCT-based economic evaluation comparing the intervention with standard care will 
      be undertaken. ETHICS AND DISSEMINATION: The protocol and pharmacist training
      programme received Griffith University Human Research Ethics Committee approval
      (HREC/2019/473 and HREC/2019/493 respectively). Results will be published in
      peer-reviewed journals and available at the Sixth Community Pharmacy Agreement
      website (http://6cpa.com.au/about-6cpa/). TRIAL REGISTRATION NUMBER:
      ANZCTR12620000577910.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wheeler, Amanda J
AU  - Wheeler AJ
AUID- ORCID: 0000-0001-9755-674X
AD  - Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland,
      Australia a.wheeler@griffith.edu.au.
AD  - Faculty of Medical and Health Sciences, Auckland University, Auckland, New
      Zealand.
FAU - O'Reilly, Claire L
AU  - O'Reilly CL
AUID- ORCID: 0000-0001-6416-8150
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Sydney, New South Wales, Australia.
FAU - El-Den, Sarira
AU  - El-Den S
AUID- ORCID: 0000-0001-7500-3351
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Sydney, New South Wales, Australia.
FAU - Byrnes, Joshua
AU  - Byrnes J
AD  - Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland,
      Australia.
FAU - Ware, Robert S
AU  - Ware RS
AD  - Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland,
      Australia.
FAU - McMillan, Sara S
AU  - McMillan SS
AUID- ORCID: 0000-0003-3427-4467
AD  - Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland,
      Australia.
AD  - School of Pharmacy and Pharmacology, Griffith University, Gold Coast, Queensland,
      Australia.
LA  - eng
SI  - ANZCTR/ANZCTR12620000577910
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Humans
MH  - Medication Adherence
MH  - *Mental Disorders/drug therapy
MH  - *Pharmacies
MH  - Pharmacists
MH  - Randomized Controlled Trials as Topic
PMC - PMC7380878
OTO - NOTNLM
OT  - *education and training (see medical education and training)
OT  - *mental health
OT  - *protocols and guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039983 [pii]
AID - 10.1136/bmjopen-2020-039983 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e039983. doi: 10.1136/bmjopen-2020-039983.


PMID- 32709656
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - Efficacy, cost-utility and physiological effects of Acceptance and Commitment
      Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in
      patients with chronic low back pain and depression: study protocol of a
      randomised, controlled trial including mobile-technology-based ecological
      momentary assessment (IMPACT study).
PG  - e038107
LID - 10.1136/bmjopen-2020-038107 [doi]
AB  - INTRODUCTION: The IMPACT study focuses on chronic low back pain (CLBP) and
      depression symptoms, a prevalent and complex problem that represents a challenge 
      for health professionals. Acceptance and Commitment Therapy (ACT) and Brief
      Behavioural Activation Treatment for Depression (BATD) are effective treatments
      for patients with persistent pain and depression, respectively. The objectives of
      this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine
      the efficacy and cost-utility of adding a group-based form of ACT or BATD to
      treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of 
      depressive symptoms; (ii) identify pre-post differences in levels of some
      physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 
      gene, psychological process measures and physiological variables as mediators or 
      moderators of long-term clinical changes. METHODS AND ANALYSIS: Participants will
      be 225 patients with CLBP and moderate to severe depression symptoms recruited at
      Parc Sanitari Sant Joan de Deu (St. Boi de Llobregat, Spain) and Hospital del Mar
      (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs
      TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables
      and costs will be conducted pretreatment, post-treatment and at 12 months
      follow-up, being pain interference the primary outcome measure. The following
      physiological variables will be considered at pretreatment and post-treatment
      assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and 
      cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D.
      Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and
      rs4713916) will be analysed at baseline assessment. Moreover, we will include
      mobile-technology-based ecological momentary assessment, through the Pain Monitor
      app, to track ongoing clinical status during ACT and BATD treatments. Linear
      mixed-effects models using restricted maximum likelihood, and a full economic
      evaluation applying bootstrapping techniques, acceptability curves and
      sensitivity analyses will be computed. ETHICS AND DISSEMINATION: This study has
      been approved by the Ethics Committee of the Fundacio Sant Joan de Deu and
      Hospital del Mar. The results will be actively disseminated through peer-reviewed
      journals, conference presentations, social media and various community engagement
      activities. TRIAL REGISTRATION NUMBER: NCT04140838.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sanabria-Mazo, Juan P
AU  - Sanabria-Mazo JP
AUID- ORCID: 0000-0003-1688-435X
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
AD  - Department of Medicine, International University of Catalunya, Barcelona, Spain.
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.
FAU - Forero, Carlos G
AU  - Forero CG
AD  - Department of Medicine, International University of Catalunya, Barcelona, Spain.
FAU - Cristobal-Narvaez, Paula
AU  - Cristobal-Narvaez P
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.
AD  - Network Centre for Biomedical Research in Mental Health (CIBERSAM), Institute of 
      Health Carlos III, Madrid, Spain.
FAU - Suso-Ribera, Carlos
AU  - Suso-Ribera C
AD  - Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume 
      I, Castello de la Plana, Spain.
AD  - Biomedical Research Centre in Physiopathology of Obesity and Nutrition
      (CIBERobn), Institute of Health Carlos III, Madrid, Spain.
FAU - Garcia-Palacios, Azucena
AU  - Garcia-Palacios A
AD  - Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume 
      I, Castello de la Plana, Spain.
AD  - Biomedical Research Centre in Physiopathology of Obesity and Nutrition
      (CIBERobn), Institute of Health Carlos III, Madrid, Spain.
FAU - Colomer-Carbonell, Ariadna
AU  - Colomer-Carbonell A
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.
FAU - Perez-Aranda, Adrian
AU  - Perez-Aranda A
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
AD  - Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.
FAU - Andres-Rodriguez, Laura
AU  - Andres-Rodriguez L
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
FAU - McCracken, Lance M
AU  - McCracken LM
AD  - Psychology Department, Uppsala University, Uppsala, Sweden.
FAU - D'Amico, Francesco
AU  - D'Amico F
AD  - Personal Social Services Research Unit, London School of Economics and Political 
      Science, London, UK.
FAU - Estivill-Rodriguez, Pere
AU  - Estivill-Rodriguez P
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.
FAU - Carreras-Marcos, Bernat
AU  - Carreras-Marcos B
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.
FAU - Montes-Perez, Antonio
AU  - Montes-Perez A
AD  - Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.
FAU - Comps-Vicente, Olga
AU  - Comps-Vicente O
AD  - Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.
FAU - Esteve, Montserrat
AU  - Esteve M
AD  - Biomedical Research Centre in Physiopathology of Obesity and Nutrition
      (CIBERobn), Institute of Health Carlos III, Madrid, Spain.
AD  - Department of Biochemistry and Molecular Biomedicine, University of Barcelona,
      Barcelona, Spain.
AD  - Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
FAU - Grasa, Mar
AU  - Grasa M
AD  - Biomedical Research Centre in Physiopathology of Obesity and Nutrition
      (CIBERobn), Institute of Health Carlos III, Madrid, Spain.
AD  - Department of Biochemistry and Molecular Biomedicine, University of Barcelona,
      Barcelona, Spain.
AD  - Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
FAU - Rosa, Araceli
AU  - Rosa A
AD  - Network Centre for Biomedical Research in Mental Health (CIBERSAM), Institute of 
      Health Carlos III, Madrid, Spain.
AD  - Department of Evolutionary Biology, Ecology and Environmental Sciences,
      University of Barcelona, Barcelona, Spain.
FAU - Cuesta-Vargas, Antonio I
AU  - Cuesta-Vargas AI
AUID- ORCID: 0000-0002-8880-4315
AD  - Faculty of Health, Queensland University of Technology, Brisbane, Queensland,
      Australia.
AD  - Department of Physiotherapy, University of Malaga & Biomedical Research Institute
      of Malaga (IBIMA), Malaga, Spain.
FAU - Maes, Michael
AU  - Maes M
AD  - Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand.
FAU - Borras, Xavier
AU  - Borras X
AUID- ORCID: 0000-0003-3972-1385
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
FAU - Edo, Silvia
AU  - Edo S
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
FAU - Sanz, Antoni
AU  - Sanz A
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
FAU - Feliu-Soler, Albert
AU  - Feliu-Soler A
AD  - Department of Basic, Developmental and Educational Psychology, Autonomous
      University of Barcelona, Barcelona, Spain.
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.
FAU - Castano-Asins, Juan R
AU  - Castano-Asins JR
AD  - Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.
FAU - Luciano, Juan V
AU  - Luciano JV
AUID- ORCID: 0000-0003-0750-1599
AD  - Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain
      jvluciano@pssjd.org.
LA  - eng
SI  - ClinicalTrials.gov/NCT04140838
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - Depression/therapy
MH  - Ecological Momentary Assessment
MH  - Humans
MH  - *Low Back Pain/therapy
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Spain
MH  - Technology
PMC - PMC7380881
OTO - NOTNLM
OT  - *Clinical trials
OT  - *Depression & mood disorders
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038107 [pii]
AID - 10.1136/bmjopen-2020-038107 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e038107. doi: 10.1136/bmjopen-2020-038107.


PMID- 32709655
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - New model of integrated care for uncontrolled type 2 diabetes in a retrospective,
      underserved adult population in the USA: a study protocol for an effectiveness
      and cost-effectiveness analysis.
PG  - e038084
LID - 10.1136/bmjopen-2020-038084 [doi]
AB  - INTRODUCTION: Type 2 diabetes prevalence is increasing in the USA, especially in 
      underserved populations. Patient outcomes can be improved by providing access to 
      specialty care within Federally Qualified Health Centers, possibly improving the 
      cost-effectiveness of diabetes care. METHODS AND ANALYSIS: A new model of
      diabetes care based on multidisciplinary teams of clinical fellows, supported by 
      an endocrinologist for underserved adult populations, is presented. The study
      uses a retrospective, non-randomised cohort of patients with diabetes who visited
      the community clinic between 1 January 2012 and 31 December 2018. A
      quasi-experimental method to analyse the causal evidence of the effect of the new
      model is presented. Discontinuity regression is used to compare two
      interventions, the intervention by a Clinical Fellow Endocrinology Programme and 
      usual care by a primary care physician. Patients are referred to the Clinical
      Fellow Endocrinology Programme in case of uncontrolled diabetes (glycated
      haemoglobin (HbA1c)>/=9%). The regression discontinuity design allows the
      construction of a treatment group for patients with an HbA1c equal or above the
      threshold in comparison with a control group for patients with an HbA1c below the
      threshold. The patient outcomes and cost-effectiveness of the new model are
      analysed. Regression models will be used to assess the differences between
      treatment and control groups. ETHICS AND DISSEMINATION: Quantitative patient data
      are received by the study team in a de-identified format for analysis via an
      institutional review board-approved protocol. The quantitative study has been
      approved by the Houston Methodist Research Institute Institutional Review Board, 
      Houston, Texas, USA. Anticipated results will not only provide evidence about the
      impact of patient outcomes in underserved diabetic populations, but also give an 
      idea of the cost-effectiveness of the new model and whether or not cost savings
      can be attained for patients, third-party payers and society. The results will
      help set up evidence-based policy guidelines in diabetes care. Results will be
      disseminated through papers, conferences and public health/policy fora.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bosetti, Rita
AU  - Bosetti R
AUID- ORCID: 0000-0002-0398-2834
AD  - Center for Outcomes Research, Houston Methodist Research Institute, Houston,
      Texas, USA rbosetti@houstonmethodist.org.
FAU - Tabatabai, Laila
AU  - Tabatabai L
AD  - Division of Endocrinology, Houston Methodist Hospital, Houston, Texas, USA.
FAU - Naufal, George
AU  - Naufal G
AD  - Center for Outcomes Research, Houston Methodist Research Institute, Houston,
      Texas, USA.
AD  - Public Policy Research Institute, Texas A&M University System, College Station,
      Texas, USA.
FAU - Brito, Rosbel
AU  - Brito R
AD  - Office of Graduate Medical Education, Houston Methodist Research Institute,
      Houston, Texas, USA.
FAU - Kash, Bita
AU  - Kash B
AD  - Center for Outcomes Research, Houston Methodist Research Institute, Houston,
      Texas, USA.
AD  - School of Public Health, Texas A&M University System, College Station, Texas,
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cost-Benefit Analysis
MH  - *Delivery of Health Care, Integrated
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Humans
MH  - Retrospective Studies
MH  - Texas
MH  - United States
MH  - Vulnerable Populations
PMC - PMC7380724
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *health economics
OT  - *health policy
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038084 [pii]
AID - 10.1136/bmjopen-2020-038084 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e038084. doi: 10.1136/bmjopen-2020-038084.


PMID- 32709653
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - SEPSIS project: a protocol for studying biomarkers of neonatal sepsis and immune 
      responses of infants in a malaria-endemic region.
PG  - e036905
LID - 10.1136/bmjopen-2020-036905 [doi]
AB  - INTRODUCTION: Neonatal sepsis outreaches all causes of neonatal mortality
      worldwide and remains a major societal burden in low and middle income countries.
      In addition to limited resources, endemic morbidities, such as malaria and
      prematurity, predispose neonates and infants to invasive infection by altering
      neonatal immune response to pathogens. Nevertheless, thoughtful epidemiological, 
      diagnostic and immunological evaluation of neonatal sepsis and the impact of
      gestational malaria have never been performed. METHODS AND ANALYSIS: A
      prospective longitudinal multicentre follow-up of 580 infants from birth to 3
      months of age in urban and suburban Benin will be performed. At delivery, and
      every other week, all children will be examined and clinically evaluated for
      occurrence of sepsis. At delivery, cord blood systematic analysis of selected
      plasma and transcriptomic biomarkers (procalcitonin, interleukin (IL)-6, IL-10,
      IP10, CD74 and CX3CR1) associated with sepsis pathophysiology will be evaluated
      in all live births as well as during the follow-up, and when sepsis will be
      suspected. In addition, whole blood response to selected innate stimuli and
      extensive peripheral blood mononuclear cells phenotypic characterisation will be 
      performed. Reference intervals specific to sub-Saharan neonates will be
      determined from this cohort and biomarkers performances for neonatal sepsis
      diagnosis and prognosis tested. ETHICS AND DISSEMINATION: Ethical approval has
      been obtained from the Comite d'Ethique de la Recherche - Institut des Sciences
      Biomedicales Appliquees (CER-ISBA 85 - 5 April 2016, extended on 3 February
      2017). Results will be disseminated through international presentations at
      scientific meetings and publications in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: ClinicalTrials.gov registration number: NCT03780712.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fievet, Nadine
AU  - Fievet N
AD  - Institut de Recherche pour le Developpement (IRD), Mere et enfant face aux
      infections tropicales (UMR216), Paris, France.
AD  - COMUE Sorbonne Paris Cite, Universite Paris Descartes, Paris, Ile-de-France,
      France.
FAU - Ezinmegnon, Sem
AU  - Ezinmegnon S
AD  - Department of Microbiology, Institut de Biologie Integrative de la Cellule,
      Gif-sur-Yvette, France.
AD  - Medical Diagnostic Discovery Department (MD3), bioMerieux SA, Marcy l'Etoile,
      Rhone-Alpes, France.
FAU - Agbota, Gino
AU  - Agbota G
AD  - UMR216-MERIT, French National Research Institute for Sustainable Development
      (IRD), Universite Paris Descartes, Paris, France.
AD  - Institut de Recherche Clinique du Benin, Calavi, Benin.
FAU - Sossou, Darius
AU  - Sossou D
AD  - Institut de Recherche Clinique du Benin, Calavi, Benin.
FAU - Ladekpo, Rodolphe
AU  - Ladekpo R
AD  - Institut de Recherche Clinique du Benin, Calavi, Benin.
FAU - Gbedande, Komi
AU  - Gbedande K
AD  - Institut de Recherche Clinique du Benin, Cotonou, Benin.
FAU - Briand, Valerie
AU  - Briand V
AD  - Institut de Recherche pour le Developpement (IRD), Mere et enfant face aux
      infections tropicales (UMR216), Paris, France.
FAU - Cottrell, Gilles
AU  - Cottrell G
AD  - UMR216, Institut de Recherche pour le Developpement, Cotonou, Benin.
AD  - Faculte de Pharmacie, Universite Paris Descartes, Paris, France.
FAU - Vachot, Laurence
AU  - Vachot L
AD  - Medical Diagnostic Discovery Department (MD3), bioMerieux SA, Marcy l'Etoile,
      Rhone-Alpes, France.
FAU - Yugueros Marcos, Javier
AU  - Yugueros Marcos J
AD  - Medical Diagnostic Discovery Department (MD3), bioMerieux SA, Marcy l'Etoile,
      Rhone-Alpes, France.
FAU - Pachot, Alexandre
AU  - Pachot A
AD  - EA 7426 Pathophysiology of Injury-Induced Immunosuppression, bioMerieux, LYON
      cedex 03, France.
FAU - Textoris, Julien
AU  - Textoris J
AUID- ORCID: 0000-0002-3821-9337
AD  - EA 7426 Pathophysiology of Injury-Induced Immunosuppression, bioMerieux, LYON
      cedex 03, France.
AD  - Departement d'Anesthesie et de Reanimation, Hospices Civils de Lyon, LYON Cedex
      03, France.
FAU - Blein, Sophie
AU  - Blein S
AD  - Medical Diagnostic Discovery Department (MD3), bioMerieux SA, Marcy l'Etoile,
      Rhone-Alpes, France.
AD  - EA 7426 Pathophysiology of Injury-Induced Immunosuppression, bioMerieux, LYON
      cedex 03, France.
FAU - Lausten-Thomsen, Ulrik
AU  - Lausten-Thomsen U
AD  - Pediatric Intensive Care, Hopitaux Universitaires Paris-Sud, Le Kremlin-Bicetre, 
      France.
FAU - Massougbodji, Achille
AU  - Massougbodji A
AD  - Faculte des Sciences de la Sante (FSS), Cotonou, Benin.
FAU - Bagnan, Lehila
AU  - Bagnan L
AD  - Institut de Recherche Clinique du Benin, Calavi, Benin.
AD  - Department of Paediatric, National University Hospital Center (CNHU), Cotonou,
      Benin.
FAU - Tchiakpe, Nicole
AU  - Tchiakpe N
AD  - Institut de Recherche Clinique du Benin, Calavi, Benin.
AD  - Department of Paediatric, Centre Hospitalier Universitaire de la Mere et de
      l'Enfant Lagune (CHUMEL), Cotonou, Benin.
FAU - d'Almeida, Marceline
AU  - d'Almeida M
AD  - Department of Paediatric, National University Hospital Center (CNHU), Cotonou,
      Benin.
AD  - Institut de Recherche Clinique du Benin, Calavi, Ile-de-France, Benin.
FAU - Alao, Jules
AU  - Alao J
AD  - CHU-MEL Hospital, Cotonou, Benin.
FAU - Dossou-Dagba, Ida
AU  - Dossou-Dagba I
AD  - Calavi Hospital, Calavi, Benin.
FAU - Tissieres, Pierre
AU  - Tissieres P
AUID- ORCID: 0000-0001-5423-5532
AD  - Department of Microbiology, Institut de Biologie Integrative de la Cellule,
      Gif-sur-Yvette, France pierre.tissieres@aphp.fr.
AD  - Pediatric Intensive Care, Hopitaux Universitaires Paris-Sud, Le Kremlin-Bicetre, 
      France.
CN  - SEPSIS study group collaborators
CN  - SEPSIS study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03780712
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
SB  - IM
MH  - Africa, Northern
MH  - Benin
MH  - Biomarkers
MH  - Child
MH  - Humans
MH  - Immunity
MH  - Infant
MH  - Infant, Newborn
MH  - Leukocytes, Mononuclear
MH  - *Malaria/diagnosis/epidemiology
MH  - *Neonatal Sepsis/diagnosis/epidemiology
MH  - Prospective Studies
MH  - *Sepsis/diagnosis/epidemiology
PMC - PMC7380952
OTO - NOTNLM
OT  - *immunology
OT  - *neonatal intensive & critical care
OT  - *neonatology
OT  - *paediatric infectious disease & immunisation
COIS- Competing interests: JYM, LV, JT, AP and SB are employed by an in vitro
      diagnostic company, bioMerieux SA. The remaining authors declare that this
      research was conducted in the absence of any commercial or financial relationship
      that could cause potential conflict of interest.
IR  - Fernando A
FIR - Fernando, Aurax
IR  - Ahouayito U
FIR - Ahouayito, Urbain
IR  - Agossou B
FIR - Agossou, Basile
IR  - Ezinmegnon C
FIR - Ezinmegnon, Caleb
IR  - Fortunato A
FIR - Fortunato, Anauel
IR  - Fiagbenou J
FIR - Fiagbenou, Josue
IR  - Dossa D
FIR - Dossa, Djamirou
IR  - Abdou D
FIR - Abdou, Dramane
IR  - Fantodji C
FIR - Fantodji, Canisius
IR  - Sare N
FIR - Sare, Nawal
IR  - Bara W
FIR - Bara, Wilisto
IR  - Monde R
FIR - Monde, Razack
IR  - Gbagidi E
FIR - Gbagidi, Erasme
IR  - Allokpe L
FIR - Allokpe, Larissa
IR  - Housemenou A
FIR - Housemenou, Armand
IR  - Assongba L
FIR - Assongba, Landry
IR  - Accrombessi M
FIR - Accrombessi, Manfred
IR  - Kouhouenou F
FIR - Kouhouenou, Florent
IR  - Hounsemenou A
FIR - Hounsemenou, Armand
IR  - Ridagba A
FIR - Ridagba, Amour
IR  - Aguemon C
FIR - Aguemon, Christiane
IR  - Affolabi D
FIR - Affolabi, Dissou
IR  - Perrin R
FIR - Perrin, Rene
IR  - Hounkpatin B
FIR - Hounkpatin, Benjamin
IR  - Dagba D
FIR - Dagba, Dossou
IR  - Augusto L
FIR - Augusto, Luis
IR  - Thibault S
FIR - Thibault, Sophie
IR  - Bartolo F
FIR - Bartolo, Francois
IR  - Mommert M
FIR - Mommert, Marine
IR  - Brengel-Pesce K
FIR - Brengel-Pesce, Karen
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036905 [pii]
AID - 10.1136/bmjopen-2020-036905 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e036905. doi: 10.1136/bmjopen-2020-036905.


PMID- 32709646
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - Predicting the risk of asthma attacks in children, adolescents and adults:
      protocol for a machine learning algorithm derived from a primary care-based
      retrospective cohort.
PG  - e036099
LID - 10.1136/bmjopen-2019-036099 [doi]
AB  - INTRODUCTION: Most asthma attacks and subsequent deaths are potentially
      preventable. We aim to develop a prognostic tool for identifying patients at high
      risk of asthma attacks in primary care by leveraging advances in machine
      learning. METHODS AND ANALYSIS: Current prognostic tools use logistic regression 
      to develop a risk scoring model for asthma attacks. We propose to build on this
      by systematically applying various well-known machine learning techniques to a
      large longitudinal deidentified primary care database, the Optimum Patient Care
      Research Database, and comparatively evaluate their performance with the existing
      logistic regression model and against each other. Machine learning algorithms
      vary in their predictive abilities based on the dataset and the approach to
      analysis employed. We will undertake feature selection, classification (both
      one-class and two-class classifiers) and performance evaluation. Patients who
      have had actively treated clinician-diagnosed asthma, aged 8-80 years and with 3 
      years of continuous data, from 2016 to 2018, will be selected. Risk factors will 
      be obtained from the first year, while the next 2 years will form the outcome
      period, in which the primary endpoint will be the occurrence of an asthma attack.
      ETHICS AND DISSEMINATION: We have obtained approval from OPCRD's Anonymous Data
      Ethics Protocols and Transparency (ADEPT) Committee. We will seek ethics approval
      from The University of Edinburgh's Research Ethics Group (UREG). We aim to
      present our findings at scientific conferences and in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Hussain, Zain
AU  - Hussain Z
AD  - Usher Institute, Edinburgh Medical School, The University of Edinburgh,
      Edinburgh, UK.
FAU - Shah, Syed Ahmar
AU  - Shah SA
AUID- ORCID: 0000-0001-5672-0443
AD  - Usher Institute, Edinburgh Medical School, The University of Edinburgh,
      Edinburgh, UK ahmar.shah@ed.ac.uk.
AD  - Asthma UK Centre for Applied Research (AUKCAR), The University of Edinburgh,
      Edinburgh, UK.
FAU - Mukherjee, Mome
AU  - Mukherjee M
AUID- ORCID: 0000-0002-3083-436X
AD  - Usher Institute, Edinburgh Medical School, The University of Edinburgh,
      Edinburgh, UK.
AD  - Asthma UK Centre for Applied Research (AUKCAR), The University of Edinburgh,
      Edinburgh, UK.
FAU - Sheikh, Aziz
AU  - Sheikh A
AD  - Usher Institute, Edinburgh Medical School, The University of Edinburgh,
      Edinburgh, UK.
AD  - Asthma UK Centre for Applied Research (AUKCAR), The University of Edinburgh,
      Edinburgh, UK.
AD  - Division of Community Health Sciences, The University of Edinburgh, Edinburgh,
      UK.
LA  - eng
GR  - MC_PC_19004/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Algorithms
MH  - *Asthma/diagnosis
MH  - Child
MH  - Humans
MH  - *Machine Learning
MH  - Middle Aged
MH  - Primary Health Care
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Young Adult
PMC - PMC7380838
OTO - NOTNLM
OT  - *asthma
OT  - *epidemiology
OT  - *health informatics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036099 [pii]
AID - 10.1136/bmjopen-2019-036099 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e036099. doi: 10.1136/bmjopen-2019-036099.


PMID- 32709645
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - Infant formula composition and educational performance: a protocol to extend
      follow-up for a set of randomised controlled trials using linked administrative
      education records.
PG  - e035968
LID - 10.1136/bmjopen-2019-035968 [doi]
AB  - INTRODUCTION: The effect of infant nutrition on long-term cognition is important 
      for parents and policy makers. However, most clinical trials typically have short
      follow-up periods, when measures of cognition are poorly predictive of later
      function. The few trials with longer-term follow-up have high levels of
      attrition, which can lead to selection bias, and in turn to erroneous
      interpretation of long-term harms and benefits of infant nutrition. We address
      the need for unbiased, long-term follow-up, by linking measures of educational
      performance from administrative education records. Educational performance is a
      meaningful marker of cognitive function in children and it is strongly correlated
      with IQ. We aim to evaluate educational performance for children who, as infants,
      were part of a series of trials that randomised participants to either
      nutritionally modified infant formula or standard formula. Most trialists
      anticipated positive effects of these interventions on later cognitive function. 
      METHODS AND ANALYSIS: Using data from 1923 participants of seven randomised
      infant formula trials linked to the English National Pupil Database (NPD), this
      study will provide new insights into the effect of nutrient intake in infancy on 
      school achievement. Our primary outcome will be the mean differences in z-scores 
      between intervention and control groups for a compulsory Mathematics exam sat at 
      age 16. Secondary outcomes will be z-scores for a compulsory English exam at age 
      16 and z-scores for compulsory Mathematics and English exams at age 11. We will
      also evaluate intervention effects on the likelihood of receiving special
      educational needs (SEN) support. All analyses will be performed separately by
      trial. ETHICS AND DISSEMINATION: Research ethics approval, and approval from the 
      Health Research Authority Confidentiality Advisory Group, has been obtained for
      this study. The results of this study will be disseminated to scientific,
      practitioner, and lay audiences, submitted for publication in peer-reviewed
      journals, and will contribute towards a PhD dissertation.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Verfurden, Maximiliane
AU  - Verfurden M
AUID- ORCID: 0000-0003-2204-8251
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK m.verfuerden@ucl.ac.uk.
FAU - Harron, Katie
AU  - Harron K
AUID- ORCID: 0000-0002-3418-2856
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Jerrim, John
AU  - Jerrim J
AD  - Institute of Education, University College London, London, UK.
FAU - Fewtrell, Mary
AU  - Fewtrell M
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Gilbert, Ruth
AU  - Gilbert R
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
LA  - eng
GR  - 103975/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Eating
MH  - Educational Status
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - *Infant Formula
MH  - Mathematics
MH  - Randomized Controlled Trials as Topic
PMC - PMC7380883
OTO - NOTNLM
OT  - *clinical trials
OT  - *nutrition & dietetics
OT  - *paediatric neurology
OT  - *public health
COIS- Competing interests: MF has been a member of the Infant Nutrition Working Group
      at EFSA (European Food Safety Authority) since 2013. She was involved in data
      analysis and publication of randomised trials of LCPUFA-supplemented infant
      formulas funded by grants from Numico Res BV and Heinz UK. The companies also
      provided the infant formulas for the studies. She was also involved in follow-up 
      studies (including cognitive outcome) of children and adolescents from randomised
      trials of LCPUFA-supplemented formulas, with funding from the Medical Research
      Council and European Union (FP6-FOOD-2005-0 07 036).
EDAT- 2020/07/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035968 [pii]
AID - 10.1136/bmjopen-2019-035968 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e035968. doi: 10.1136/bmjopen-2019-035968.


PMID- 32709641
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 23
TI  - Interventions to reduce inequalities in avoidable hospital admissions:
      explanatory framework and systematic review protocol.
PG  - e035429
LID - 10.1136/bmjopen-2019-035429 [doi]
AB  - INTRODUCTION: Internationally there is pressure to contain costs due to rising
      numbers of hospital admissions. Alongside age, socioeconomic disadvantage is the 
      strongest risk factor for avoidable hospital admission. This equity-focussed
      systematic review is required for policymakers to understand what has been shown 
      to work to reduce inequalities in hospital admissions, what does not work and
      where the current gaps in the evidence-base are. METHODS AND ANALYSIS: An initial
      framework shows how interventions are hypothesised to reduce socioeconomic
      inequalities in avoidable hospital admissions. Studies will be included if the
      intervention focusses exclusively on socioeconomically disadvantaged populations 
      or if the study reports differential effects by socioeconomic status (education, 
      income, occupation, social class, deprivation, poverty or an area-based proxy for
      deprivation derived from place of residence) with respect to hospital admission
      or readmission (overall or condition-specific for those classified as ambulatory 
      care sensitive). Studies involving individuals of any age, undertaken in OECD
      (Organisation for Economic Co-operation and Development) countries, published
      from 2000 to 29(th) February 2020 in any language will be included. Electronic
      searches will include MEDLINE, Embase, CINAHL, Cochrane CENTRAL and the Web of
      Knowledge platform. Electronic searches will be supplemented with full citation
      searches of included studies, website searches and retrieval of relevant
      unpublished information. Study inclusion, data extraction and quality appraisal
      will be conducted by two reviewers. Narrative synthesis will be conducted and
      also meta-analysis where possible. The main analysis will examine the
      effectiveness of interventions at reducing socioeconomic inequalities in hospital
      admissions. Interventions will be characterised by their domain of action and
      approach to addressing inequalities. For included studies, contextual information
      on where, for whom and how these interventions are organised, implemented and
      delivered will be examined where possible. ETHICS AND DISSEMINATION: Ethical
      approval was not required for this protocol. The research will be disseminated
      via peer-reviewed publication, conferences and an open-access policy-orientated
      paper. PROSPERO REGISTRATION NUMBER: CRD42019153666.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Sowden, Sarah
AU  - Sowden S
AUID- ORCID: 0000-0001-9359-3463
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK sarah.sowden@newcastle.ac.uk.
FAU - Nezafat-Maldonado, Behrouz
AU  - Nezafat-Maldonado B
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Wildman, Josephine
AU  - Wildman J
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Cookson, Richard
AU  - Cookson R
AD  - Centre for Health Economics, University of York, York, North Yorkshire, UK.
FAU - Thomson, Richard
AU  - Thomson R
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Lambert, Mark
AU  - Lambert M
AD  - North East Centre, Public Health England, Newcastle upon Tyne, UK.
FAU - Beyer, Fiona
AU  - Beyer F
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Bambra, Clare
AU  - Bambra C
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
LA  - eng
GR  - ICA-CL-2018-04-ST2-010/DH_/Department of Health/United Kingdom
GR  - MR/K02325X/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Clinical Protocols
MH  - *Healthcare Disparities
MH  - Humans
MH  - Patient Admission/*standards
MH  - Risk Factors
MH  - Socioeconomic Factors
MH  - Systematic Reviews as Topic
PMC - PMC7380849
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *health policy
OT  - *organisation of health services
OT  - *preventive medicine
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/28 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035429 [pii]
AID - 10.1136/bmjopen-2019-035429 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 23;10(7):e035429. doi: 10.1136/bmjopen-2019-035429.


PMID- 32709235
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1475-9276 (Electronic)
IS  - 1475-9276 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jul 24
TI  - "Bayis Ilh Tus - a strong breath" a community-based research project to estimate 
      the prevalence of chronic obstructive pulmonary disease in remote and rural first
      nations communities in Canada: research protocol.
PG  - 123
LID - 10.1186/s12939-020-01240-1 [doi]
AB  - BACKGROUND: Respiratory health conditions appear to be more common among First
      Nations people versus non-First Nations people in Canada. However, the prevalence
      of chronic obstructive pulmonary disease (COPD) and its associated risk factors
      in First Nations communities are unknown. This project aims to estimate the
      prevalence of COPD in several First Nations communities in British Columbia,
      Canada and to characterize respiratory symptoms, COPD risk factors, and
      healthcare utilization. METHODS: This project is approved by both the University 
      of British Columbia and Carrier Sekani Family Services Research Ethics Boards. We
      will randomly sample 220 adults, 30 years and older, from 11 participating First 
      Nations. Each participant will complete pre- and post-bronchodilator spirometry
      tests and the adapted American Thoracic Society Epidemiological Questionnaire
      with items about smoking history, respiratory symptoms, co-morbidities, and
      exposures, in order to identify the presence of COPD and its associated
      individual, occupational, and community risk factors. Homes will be assessed for 
      air quality measures including particulate matter, carbon monoxide and carbon
      dioxide, and humidity. Health care utilization will be abstracted from the
      electronic medical record. DISCUSSION: This is the first project in Canada to
      estimate the prevalence of COPD in First Nations communities using a
      random-sampling approach to recruitment. Additionally, although this study will
      collect detailed information on smoking history, we will also characterize past
      and current risk factors beyond cigarette smoking. Finally, our methodology
      ensures that the benefits to the communities are realized during the study
      period. Individual results will be shared with individuals and health providers
      to facilitate care. Air quality results will be sent to each Nation's governing
      council to facilitate remediation where necessary. TRIAL REGISTRATION: The study 
      has been retrospectively registered at clinicaltrials.gov ( NCT04105088 ).
FAU - Turner, Justin
AU  - Turner J
AUID- ORCID: 0000-0002-2332-2091
AD  - Rehabilitation Sciences Graduate Program, University of British Columbia,
      Vancouver, Canada.
AD  - Centre for Heart Lung Innovation, University of British Columbia, St. Paul's
      Hospital, 166-1081 Burrard Street, Vancouver, V6Z 1Y6, Canada.
FAU - Holyk, Travis
AU  - Holyk T
AD  - Carrier Sekani Family Services, Prince George, Canada.
FAU - Bartlett, Karen
AU  - Bartlett K
AD  - School of Population and Public Health, University of British Columbia,
      Vancouver, Canada.
FAU - Rathburn, Benna
AU  - Rathburn B
AD  - Carrier Sekani Family Services, Prince George, Canada.
FAU - Karlen, Barbara
AU  - Karlen B
AD  - Centre for Heart Lung Innovation, University of British Columbia, St. Paul's
      Hospital, 166-1081 Burrard Street, Vancouver, V6Z 1Y6, Canada.
FAU - Ervin, Francis
AU  - Ervin F
AD  - Ridge Meadows Hospital, Fraser Health Authority, Maple Ridge, Canada.
FAU - Wilson, Jennifer
AU  - Wilson J
AD  - Fraser Health Authority, Surrey, Canada.
FAU - Camp, Pat G
AU  - Camp PG
AD  - Rehabilitation Sciences Graduate Program, University of British Columbia,
      Vancouver, Canada. pat.camp@hli.ubc.ca.
AD  - Centre for Heart Lung Innovation, University of British Columbia, St. Paul's
      Hospital, 166-1081 Burrard Street, Vancouver, V6Z 1Y6, Canada.
      pat.camp@hli.ubc.ca.
AD  - Department of Physical Therapy, University of British Columbia, Vancouver,
      Canada. pat.camp@hli.ubc.ca.
LA  - eng
SI  - ClinicalTrials.gov/NCT04105088
GR  - 389553/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200724
PL  - England
TA  - Int J Equity Health
JT  - International journal for equity in health
JID - 101147692
SB  - IM
MH  - Adult
MH  - Aged
MH  - Air Pollution/analysis
MH  - Air Pollution, Indoor/adverse effects
MH  - British Columbia/epidemiology
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - *Indians, North American
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Pulmonary Disease, Chronic Obstructive/*epidemiology/ethnology/etiology
MH  - Research Design
MH  - Risk Factors
MH  - *Rural Population
MH  - Smoking/adverse effects
PMC - PMC7379798
OTO - NOTNLM
OT  - *Chronic obstructive pulmonary disease
OT  - *First nations
OT  - *Prevalence
EDAT- 2020/07/28 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1186/s12939-020-01240-1 [doi]
AID - 10.1186/s12939-020-01240-1 [pii]
PST - epublish
SO  - Int J Equity Health. 2020 Jul 24;19(1):123. doi: 10.1186/s12939-020-01240-1.


PMID- 32709184
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20201124
IS  - 2150-1149 (Electronic)
IS  - 1533-3159 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Jul
TI  - Therapeutic Effectiveness of Percutaneous Endoscopic Spinal Surgery for
      Intraspinal Cement Leakage Following Percutaneous Vertebroplasty: An Early
      Clinical Study of 12 Cases.
PG  - E377-E388
AB  - BACKGROUND: Intraspinal cement leakage is a catastrophic complication of
      percutaneous vertebroplasty (PVP). Percutaneous endoscopic spinal surgery (PESS) 
      for intraspinal cement leakage has rarely been reported. OBJECTIVES: To evaluate 
      the therapeutic effectiveness of PESS for intraspinal cement leakage following
      PVP. STUDY DESIGN: This was a retrospective study approved by the ethics
      committee of our institution. SETTING: Department of Orthopedics from an
      affiliated hospital. METHODS: Twelve patients with neurologic impairments
      resulting from intraspinal cement leakage after PVP were treated with PESS for
      spinal decompression from May 2014 to June 2018. Computed tomography and
      3-dimensional reconstruction were used to confirm the vertebral level of cement
      leakage. The surgical index, neurologic function, and clinical results were
      recorded in this study. RESULTS: The leaked cement of all patients was
      successfully removed under PESS, and no severe intraoperative complications were 
      reported in our study. The operation time ranged from 43 to 119 minutes (mean,
      65.5 minutes). The amount of intraoperative blood loss was 64.25 +/- 9.62 mL. The
      lengths of postoperative hospital stays were 5.25 +/- 2.53 days. The follow-up
      rate was 83.3% (10/12). The follow-up time ranged from 14 to 30 months (mean, 22 
      months). The Visual Analog Scale scores of foraminal leaks improved from 6.50 +/-
      0.93 preoperatively to 1.75 +/- 0.71 at the last follow-up (P < 0.05). Neurologic
      function was evaluated by Japanese Orthopaedic Association 29 scores, which
      improved from 18.75 +/- 1.06 to 22.70 +/- 1.64 (P < 0.0001). The good and
      excellent rates were 80% according to the modified Macnab criteria. LIMITATIONS: 
      This study is limited by the volume of patients and the deep learning curve
      needed for PESS. CONCLUSIONS: PESS, as a minimally invasive technique, can
      achieve targeted spinal cord decompression and may be a safe and effective
      alternative approach to conventional procedures for cement leakage after PVP. KEY
      WORDS: Endoscopes, cement leakage, minimally invasive surgery, percutaneous
      vertebroplasty.
FAU - Yu, Qingshuai
AU  - Yu Q
AD  - Department of Orthopedics, The Second Affiliated Hospital of Congqing Medical
      University, Chongqing, P.R. China.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Orthopedics, the Second Affiliated Hospital of Chongqing Medical
      University, Chongqing, China; Geriatric Clinical Research Center of Chongqing,
      Chongqing, China.
FAU - Xu, Zhou
AU  - Xu Z
AD  - Department of Orthopedics, the Second Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Ren, Youliang
AU  - Ren Y
AD  - Department of Orthopedics, The Second Affiliated Hospital of Congqing Medical
      University, Chongqing, P.R. China.
FAU - Yang, Junsong
AU  - Yang J
AD  - Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 
      Shaanxi, P.R. China.
FAU - Zhou, Yingjie
AU  - Zhou Y
AD  - Luoyang Orthopedic-Traumatological Hospital of Henan Province, Luoyang, Henan,
      P.R. China.
FAU - Deng, Zhongliang
AU  - Deng Z
AD  - Department of Orthopedics, The Second Affiliated Hospital of Chongqing Medical
      University, Chongqing, China; Geriatric Clinical Research Center of Chongqing,
      Chongqing, China.
FAU - Chu, Lei
AU  - Chu L
AD  - Department of Orthopedics, The Second Affiliated Hospital of Chongqing Medical
      University, Chongqing, China; Geriatric Clinical Research Center of Chongqing,
      Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pain Physician
JT  - Pain physician
JID - 100954394
RN  - 0 (Bone Cements)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Cements/*adverse effects
MH  - Decompression, Surgical/methods
MH  - Female
MH  - Fractures, Compression/diagnostic imaging/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Minimally Invasive Surgical Procedures/methods
MH  - Neuroendoscopy/*methods
MH  - Neurosurgical Procedures/methods
MH  - Postoperative Complications/*diagnostic imaging/*surgery
MH  - Retrospective Studies
MH  - Spinal Fractures/diagnostic imaging/surgery
MH  - Tomography, X-Ray Computed/methods
MH  - Vertebroplasty/*adverse effects/methods
EDAT- 2020/07/28 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/07/26 06:00
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PST - ppublish
SO  - Pain Physician. 2020 Jul;23(4):E377-E388.


PMID- 32709096
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 17
TI  - Attitudes and Beliefs of Eastern European Consumers Towards Animal Welfare.
LID - E1220 [pii]
LID - 10.3390/ani10071220 [doi]
AB  - The aim of this exploratory work, because of the existing bias on the size of the
      sample and some of the sociodemographic characteristics of the participants, was 
      to investigate the Eastern European consumers' beliefs and attitudes toward
      animal welfare, to perform a cross-country segmentation analysis and to observe
      possible differences with their Western European counterparts. For this purpose, 
      a survey was conducted with 5508 consumers from 13 Eastern European countries
      (Bosnia and Herzegovina, Bulgaria, Czech Republic, Croatia, North Macedonia,
      Hungary, Moldova, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine) using
      a questionnaire with nine statements about consumers beliefs regarding animal
      welfare (aspects of management, ethical issues about animals, and consequences of
      animal welfare on meat quality and price), one statement about the willingness to
      pay more for meat produced under better welfare conditions, and four statements
      regarding attitudes toward animal welfare. Differences between countries were
      detected for all the statements. Moreover, three clusters of consumers were
      identified: one with consumers indifferent towards animal welfare; one with
      consumers concerned about animal welfare, but they believe it is difficult to
      achieve; and one with consumers concerned about animal welfare, and they believe 
      it is possible to achieve it.
FAU - Tomasevic, Igor
AU  - Tomasevic I
AUID- ORCID: 0000-0002-1611-2264
AD  - Faculty of Agriculture, University of Belgrade, Nemanjina 6, 11080 Belgrade,
      Serbia.
FAU - Bahelka, Ivan
AU  - Bahelka I
AD  - Czech University of Life Sciences, Kamycka 129, 165 21 Prague, Czech Republic.
FAU - Citek, Jaroslav
AU  - Citek J
AUID- ORCID: 0000-0001-8726-8592
AD  - Research Institute for Animal Production, Hlohovecka 2, 951 41 Luzianky,
      Slovakia.
FAU - Candek-Potokar, Marjeta
AU  - Candek-Potokar M
AUID- ORCID: 0000-0003-0231-126X
AD  - Agricultural Institute of Slovenia, Hacquetova ul. 17, 1000 Ljubljana, Slovenia.
FAU - Djekic, Ilija
AU  - Djekic I
AUID- ORCID: 0000-0002-8132-8299
AD  - Faculty of Agriculture, University of Belgrade, Nemanjina 6, 11080 Belgrade,
      Serbia.
FAU - Getya, Andriy
AU  - Getya A
AUID- ORCID: 0000-0002-4747-9261
AD  - National University of Life and Environmental Sciences of Ukraine, Heroiv Oborony
      str., 12, 03041 Kyiv, Ukraine.
FAU - Guerrero, Luis
AU  - Guerrero L
AUID- ORCID: 0000-0001-7062-874X
AD  - IRTA-Food Industries, Granja Camps i Armet, E-17121 Monells, Spain.
FAU - Ivanova, Sonya
AU  - Ivanova S
AD  - Agricultural Academy, 30 Suhodolska str., 1373 Sofia, Bulgaria.
FAU - Kusec, Goran
AU  - Kusec G
AD  - Faculty of Agrobiotechnical Sciences Osijek, Josip Juraj Strossmayer University
      of Osijek, Vladimira Preloga 1, 31 000 Osijek, Croatia.
FAU - Nakov, Dimitar
AU  - Nakov D
AD  - Faculty of Agricultural Sciences and Food, University Ss.Cyril and Methodius in
      Skopje, blvd. Aleksandar Makedonski bb, 1000 Skopje, North Macedonia.
FAU - Solowiej, Bartosz
AU  - Solowiej B
AUID- ORCID: 0000-0002-1805-5494
AD  - Faculty of Food Sciences and Biotechnology, University of Life Sciences in
      Lublin, Skromna 8, 20-704 Lublin, Poland.
FAU - Stoica, Maricica
AU  - Stoica M
AD  - Cross-Border Faculty, Dunarea de Jos University, 47 Domneasca str., 800008
      Galati, Romania.
FAU - Szabo, Csaba
AU  - Szabo C
AUID- ORCID: 0000-0002-2234-204X
AD  - Faculty of Agricultural and Food Sciences and Environmental Management,
      University of Debrecen, Boszormenyi ut 138., 4032 Debrecen, Hungary.
FAU - Tudoreanu, Liliana
AU  - Tudoreanu L
AUID- ORCID: 0000-0002-9865-826X
AD  - University of Agronomic Sciences and Veterinary Medicine, Bd Marasti 59, 011464
      Bucuresti, Romania.
FAU - Weiler, Ulrike
AU  - Weiler U
AD  - Universitaet Hohenheim, 460 f Garben str. 17/208, 70593 Stuttgart, Germany.
FAU - Font-I-Furnols, Maria
AU  - Font-I-Furnols M
AUID- ORCID: 0000-0002-2979-5113
AD  - IRTA-Food Industries, Granja Camps i Armet, E-17121 Monells, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7401545
OTO - NOTNLM
OT  - cluster
OT  - ethical
OT  - management
OT  - meat quality
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/26 06:00
PHST- 2020/06/10 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - ani10071220 [pii]
AID - 10.3390/ani10071220 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Jul 17;10(7). pii: ani10071220. doi: 10.3390/ani10071220.


PMID- 32708508
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1996-1944 (Print)
IS  - 1996-1944 (Linking)
VI  - 13
IP  - 14
DP  - 2020 Jul 18
TI  - Adipose Tissue-Derived Stem Cells: The Biologic Basis and Future Directions for
      Tissue Engineering.
LID - E3210 [pii]
LID - 10.3390/ma13143210 [doi]
AB  - Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues using 
      different methods. Active research have confirmed that the most accessible site
      to collect them is the adipose tissue; which has a significantly higher
      concentration of MSCs. Moreover; harvesting from adipose tissue is less invasive;
      there are no ethical limitations and a lower risk of severe complications. These 
      adipose-derived stem cells (ASCs) are also able to increase at higher rates and
      showing telomerase activity, which acts by maintaining the DNA stability during
      cell divisions. Adipose-derived stem cells secret molecules that show important
      function in other cells vitality and mechanisms associated with the immune
      system, central nervous system, the heart and several muscles. They release
      cytokines involved in pro/anti-inflammatory, angiogenic and hematopoietic
      processes. Adipose-derived stem cells also have immunosuppressive properties and 
      have been reported to be "immune privileged" since they show negative or low
      expression of human leukocyte antigens. Translational medicine and basic research
      projects can take advantage of bioprinting. This technology allows precise
      control for both scaffolds and cells. The properties of cell adhesion, migration,
      maturation, proliferation, mimicry of cell microenvironment, and differentiation 
      should be promoted by the printed biomaterial used in tissue engineering.
      Self-renewal and potency are presented by MSCs, which implies in an open-source
      for 3D bioprinting and regenerative medicine. Considering these features and
      necessities, ASCs can be applied in the designing of tissue engineering products.
      Understanding the heterogeneity of ASCs and optimizing their properties can
      contribute to making the best therapeutic use of these cells and opening new
      paths to make tissue engineering even more useful.
FAU - Camara, Diana Aparecida Dias
AU  - Camara DAD
AD  - Nicell-Pesquisa e Desenvolvimento Cientifico LTDA, Sao Paulo 04006-000, Brazil.
FAU - Shibli, Jamil Awad
AU  - Shibli JA
AD  - M3 Health Ind. Com. de Prod. Med. Odont. e Correlatos S.A., Jundiai 13212-213,
      Brazil.
AD  - Department of Periodontology and Oral Implantology, Dental Research Division,
      University of Guarulhos, Guarulhos 07040-170, Brazil.
FAU - Muller, Eduardo Alexandre
AU  - Muller EA
AD  - Department of Periodontology and Oral Implantology, Dental Research Division,
      University of Guarulhos, Guarulhos 07040-170, Brazil.
FAU - De-Sa-Junior, Paulo Luiz
AU  - De-Sa-Junior PL
AD  - Villa Lobos Campus, University Mogi das Cruzes (UMC), Sao Paulo 08780-911,
      Brazil.
FAU - Porcacchia, Allan Saj
AU  - Porcacchia AS
AUID- ORCID: 0000-0002-0133-9036
AD  - Department of Psychobiology, Federal University of Sao Paulo, Sao Paulo
      04021-001, Brazil.
FAU - Blay, Alberto
AU  - Blay A
AD  - M3 Health Ind. Com. de Prod. Med. Odont. e Correlatos S.A., Jundiai 13212-213,
      Brazil.
FAU - Lizier, Nelson Foresto
AU  - Lizier NF
AD  - Nicell-Pesquisa e Desenvolvimento Cientifico LTDA, Sao Paulo 04006-000, Brazil.
AD  - Department of Psychobiology, Federal University of Sao Paulo, Sao Paulo
      04021-001, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200718
PL  - Switzerland
TA  - Materials (Basel)
JT  - Materials (Basel, Switzerland)
JID - 101555929
PMC - PMC7420246
OTO - NOTNLM
OT  - *adipose-derived stem cells
OT  - *heterogeneity
OT  - *tissue engineering
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/26 06:00
PHST- 2020/06/11 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - ma13143210 [pii]
AID - 10.3390/ma13143210 [doi]
PST - epublish
SO  - Materials (Basel). 2020 Jul 18;13(14). pii: ma13143210. doi: 10.3390/ma13143210.


PMID- 32708281
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 21
TI  - Evolution of the Teaching of Animal Welfare Science, Ethics and Law in European
      Veterinary Schools (2012-2019).
LID - E1238 [pii]
LID - 10.3390/ani10071238 [doi]
AB  - Nowadays, animal welfare is seen as a 'common good' and a societal expectation.
      Veterinarians are expected to promote and ensure the welfare of animals under
      their care by using their scientific knowledge and skills in ethical reasoning
      and advocacy. Veterinary education must equip veterinary graduates with the
      necessary competences to fulfil these roles. In 2013, the Federation of
      Veterinarians of Europe (FVE) and the European Association of Establishment of
      Veterinary Education (EAEVE) adopted the Day-1 competences on animal welfare
      science, ethics and law for veterinary undergraduate education after having
      surveyed European veterinary schools in 2012. In 2019, the FVE carried out a
      follow-up survey to monitor the evolution of animal welfare teaching in Europe. A
      total of 82 responses were received, representing 57 faculties from 25 European
      countries. Overall results showed that the teaching of animal welfare science,
      ethics and law has increased in response to growing societal needs, and that
      welfare is more and more internally embedded in the profession, which is
      reflected in the curriculum. Nevertheless, at least one quarter of European
      schools still only partially meet the 2013 Day-1 competencies. This indicates the
      need for greater efforts, both from the EAEVE and from individual schools, to
      ensure that the teaching of animal welfare across Europe is standardised.
FAU - De Briyne, Nancy
AU  - De Briyne N
AUID- ORCID: 0000-0002-2348-930X
AD  - Federation of Veterinarians of Europe, 12B-1040 Brussels, Belgium.
FAU - Vidovic, Jovana
AU  - Vidovic J
AUID- ORCID: 0000-0001-6007-531X
AD  - Department of Veterinary Medicine, Faculty of Agriculture, University of Novi
      Sad, Trg Dositeja Obradovica 8, 21000 Novi Sad, Serbia.
FAU - Morton, David B
AU  - Morton DB
AUID- ORCID: 0000-0003-0170-4184
AD  - School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK.
FAU - Magalhaes-Sant'Ana, Manuel
AU  - Magalhaes-Sant'Ana M
AUID- ORCID: 0000-0001-8317-3633
AD  - CIISA-Centre for Interdisciplinary Research in Animal Health, Faculty of
      Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal.
AD  - Ordem dos Medicos Veterinarios, Av. Filipe Folque, 10J, 4 degrees Dto., 1050-113 
      Lisboa, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7401564
OTO - NOTNLM
OT  - Day-1 competences
OT  - animal ethics
OT  - animal welfare science
OT  - ethics
OT  - law
OT  - model curriculum
OT  - veterinary education
OT  - veterinary ethics
OT  - veterinary faculty
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/26 06:00
PHST- 2020/06/08 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/07/18 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - ani10071238 [pii]
AID - 10.3390/ani10071238 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Jul 21;10(7). pii: ani10071238. doi: 10.3390/ani10071238.


PMID- 32704548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220324
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Social, ethical and behavioural aspects of COVID-19.
PG  - 90
LID - 10.12688/wellcomeopenres.15813.2 [doi]
AB  - Introduction: Vaccines and drugs for the treatment and prevention of COVID-19
      require robust evidence generated from clinical trials before they can be used.
      Decisions on how to apply non-pharmaceutical interventions such as quarantine,
      self-isolation, social distancing and travel restrictions should also be based on
      evidence. There are some experiential and mathematical modelling data for these
      interventions, but there is a lack of data on the social, ethical and behavioural
      aspects of these interventions in the literature. Therefore, our study aims to
      produce evidence to inform (non-pharmaceutical) interventions such as
      communications, quarantine, self-isolation, social distancing, travel
      restrictions and other public health measures for the COVID-19 pandemic. Methods:
      The study will be conducted in the United Kingdom, Italy, Malaysia, Slovenia and 
      Thailand. We propose to conduct 600-1000 quantitative surveys and 25-35
      qualitative interviews per country. Data collection will follow the following
      four themes: (1) Quarantine and self-isolation (2) social distancing and travel
      restrictions (3) wellbeing and mental health (4) information, misinformation and 
      rumours. In light of limitations of travel and holding in-person meetings, we
      will primarily use online/remote methods for collecting data. Study participants 
      will be adults who have provided informed consent from different demographic,
      socio-economic and risk groups. Discussion: At the time of the inception of the
      study, United Kingdom, Italy, Malaysia, Slovenia and Thailand have initiated
      strict public health measures and varying degrees of "lockdowns" to curb the
      pandemic. These public health measures will change in the coming weeks and months
      depending on the number of cases of COVID-19 in the respective countries. The
      data generated from our study could inform these strategies in real time.
CI  - Copyright: (c) 2020 Pan-ngum W et al.
FAU - Pan-Ngum, Wirichada
AU  - Pan-Ngum W
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University,
      Bangkok, 10400, Thailand.
FAU - Poomchaichote, Tassawan
AU  - Poomchaichote T
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - The SoNAR-Global Network, Mahidol University, Bangkok, 10400, Thailand.
FAU - Cuman, Giulia
AU  - Cuman G
AUID- ORCID: https://orcid.org/0000-0001-6243-8487
AD  - Paediatric Ethics Committee; Research Ethics Committee, University Hospital of
      Padua, Padua, Italy.
FAU - Cheah, Phee-Kheng
AU  - Cheah PK
AUID- ORCID: https://orcid.org/0000-0002-2523-2997
AD  - Sabah Women & Children's Hospital, Ministry of Health, Malaysia, Kota Kinabalu,
      Sabah, Malaysia.
FAU - Waithira, Naomi
AU  - Waithira N
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Mukaka, Mavuto
AU  - Mukaka M
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Naemiratch, Bhensri
AU  - Naemiratch B
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Kulpijit, Natinee
AU  - Kulpijit N
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Chanviriyavuth, Rita
AU  - Chanviriyavuth R
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Asarath, Supa-At
AU  - Asarath SA
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Ruangkajorn, Supanat
AU  - Ruangkajorn S
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
FAU - Silan, Margherita
AU  - Silan M
AD  - Department of Statistical Sciences, University of Padua, Padua, Italy.
FAU - Stoppa, Silvia
AU  - Stoppa S
AD  - Luoghi di Prevenzione, Reggio Emilia, Italy.
FAU - Zuanna, Gianpiero Della
AU  - Zuanna GD
AD  - Department of Statistical Sciences, University of Padua, Padua, Italy.
FAU - Ongkili, Darlene
AU  - Ongkili D
AD  - Queen Elizabeth Hospital, Ministry of Health, Kota Kinabalu, Sabah, Malaysia.
FAU - Cheah, Phaik Kin
AU  - Cheah PK
AD  - Faculty of Arts & Social Science, Universiti Tunku Abdul Rahman, Kampar,
      Malaysia.
FAU - Osterrieder, Anne
AU  - Osterrieder A
AUID- ORCID: https://orcid.org/0000-0003-3378-4211
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Schneiders, Mira
AU  - Schneiders M
AUID- ORCID: https://orcid.org/0000-0002-4149-3484
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Mackworth-Young, Constance R S
AU  - Mackworth-Young CRS
AUID- ORCID: https://orcid.org/0000-0002-9725-7931
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Cheah, Phaik Yeong
AU  - Cheah PY
AUID- ORCID: https://orcid.org/0000-0001-6327-3266
AD  - Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,
      Mahidol University, Bangkok, 10400, Thailand.
AD  - The SoNAR-Global Network, Mahidol University, Bangkok, 10400, Thailand.
AD  - Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 210599/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200625
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7355217
OTO - NOTNLM
OT  - COVID-19
OT  - Italy
OT  - Malaysia
OT  - Thailand
OT  - United Kingdom
OT  - ethics
OT  - qualitative
OT  - social
COIS- No competing interests were disclosed.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
CRDT- 2020/07/28 06:00
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
AID - 10.12688/wellcomeopenres.15813.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Jun 25;5:90. doi: 10.12688/wellcomeopenres.15813.2.
      eCollection 2020.


PMID- 32707486
OWN - NLM
STAT- Publisher
LR  - 20200831
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 47
DP  - 2020 Jun 27
TI  - Access to stem cell data and registration of pluripotent cell lines: The Human
      Pluripotent Stem Cell Registry (hPSCreg).
PG  - 101887
LID - S1873-5061(20)30188-4 [pii]
LID - 10.1016/j.scr.2020.101887 [doi]
AB  - The value of human pluripotent stem cells (hPSC) in regenerative medicine has yet
      to reach its full potential. The road from basic research tool to clinically
      validated PSC-derived cell therapy products is a long and winding one, leading
      researchers, clinicians, industry and regulators alike into undiscovered
      territory. All stakeholders must work together to ensure the development of safe 
      and effective cell therapies. Similarly, utilization of hPSC in meaningful and
      controlled disease modeling and drug screening applications requires information 
      on the quality and suitability of the applied cell lines. Central to these common
      goals is the complete documentation of hPSC data, including the ethical
      provenance of the source material, the hPSC line derivation, culture conditions
      and genetic constitution of the lines. Data surrounding hPSC is scattered amongst
      diverse sources, including publications, supplemental data, researcher lab books,
      accredited lab reports, certificates of analyses and public data repositories.
      Not all of these data sources are publicly accessible nor associated with
      metadata nor stored in a standard manner, such that data can be easily found and 
      retrieved. The Human Pluripotent Stem Cell Registry (hPSCreg;
      https://hpscreg.eu/) was started in 2007 to impart provenance and transparency
      towards hPSC research by registering and collecting standard properties of hPSC
      lines. In this chapter, we present a short primer on the history of stem
      cell-based products, summarize the ethical and regulatory issues introduced in
      the course of working with hPSC-derived products and their associated data, and
      finally present the Human Pluripotent Stem Cell Registry as a valuable resource
      for all stakeholders in therapies and disease modeling based on hPSC-derived
      cells.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Mah, Nancy
AU  - Mah N
AD  - Berlin-Brandenburger Centrum fur Regenerative Therapien (BCRT), Charite -
      Universitatsmedizin Berlin, Berlin, Germany. Electronic address:
      nancy.mah@ibmt.fraunhofer.de.
FAU - Seltmann, Stefanie
AU  - Seltmann S
AD  - Berlin-Brandenburger Centrum fur Regenerative Therapien (BCRT), Charite -
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Aran, Begona
AU  - Aran B
AD  - Stem Cell Bank, Regenerative Medicine Program, Institut d'Investigacio Biomedica 
      de Bellvitge (IDIBELL), Barcelona, Spain.
FAU - Steeg, Rachel
AU  - Steeg R
AD  - Fraunhofer UK Research Ltd, Technology and Innovation Centre, Glasgow, UK.
FAU - Dewender, Johannes
AU  - Dewender J
AD  - Berlin-Brandenburger Centrum fur Regenerative Therapien (BCRT), Charite -
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Bultjer, Nils
AU  - Bultjer N
AD  - Berlin-Brandenburger Centrum fur Regenerative Therapien (BCRT), Charite -
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Veiga, Anna
AU  - Veiga A
AD  - Stem Cell Bank, Regenerative Medicine Program, Institut d'Investigacio Biomedica 
      de Bellvitge (IDIBELL), Barcelona, Spain.
FAU - Stacey, Glyn N
AU  - Stacey GN
AD  - ISCBI, Barley, UKSSCBio Ltd, Barley, UK; National Stem Cell Resource Centre,
      Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China;
      Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences,
      Beijing 100101, China.
FAU - Kurtz, Andreas
AU  - Kurtz A
AD  - Berlin-Brandenburger Centrum fur Regenerative Therapien (BCRT), Charite -
      Universitatsmedizin Berlin, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
SB  - IM
COIS- Declaration of Competing Interest The authors declared that there is no conflict 
      of interest.
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/05/27 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - S1873-5061(20)30188-4 [pii]
AID - 10.1016/j.scr.2020.101887 [doi]
PST - aheadofprint
SO  - Stem Cell Res. 2020 Jun 27;47:101887. doi: 10.1016/j.scr.2020.101887.


PMID- 32707143
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20210110
IS  - 1873-1570 (Electronic)
IS  - 0300-9572 (Linking)
VI  - 154
DP  - 2020 Sep
TI  - Reply to: Coronavirus disease 2019 and ethical considerations for extracorporeal 
      cardiopulmonary resuscitation.
PG  - 129-130
LID - S0300-9572(20)30287-2 [pii]
LID - 10.1016/j.resuscitation.2020.07.012 [doi]
FAU - Kandori, Kenji
AU  - Kandori K
AD  - Department of Emergency and Critical Care Medicine, Japanese Red Cross Society,
      Kyoto Daini Hospital, Japan. Electronic address: knj.kandori@gmail.com.
FAU - Narumiya, Hiromichi
AU  - Narumiya H
AD  - Department of Emergency and Critical Care Medicine, Japanese Red Cross Society,
      Kyoto Daini Hospital, Japan. Electronic address: pyroli1117@gmail.com.
FAU - Iizuka, Ryoji
AU  - Iizuka R
AD  - Department of Emergency and Critical Care Medicine, Japanese Red Cross Society,
      Kyoto Daini Hospital, Japan. Electronic address: iizukar@kyoto2.jrc.or.jp.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200722
PL  - Ireland
TA  - Resuscitation
JT  - Resuscitation
JID - 0332173
SB  - IM
CON - Resuscitation. 2020 Sep;154:127-128. PMID: 32702394
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Cardiopulmonary Resuscitation
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7373673
EDAT- 2020/07/25 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/08 00:00 [received]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - S0300-9572(20)30287-2 [pii]
AID - 10.1016/j.resuscitation.2020.07.012 [doi]
PST - ppublish
SO  - Resuscitation. 2020 Sep;154:129-130. doi: 10.1016/j.resuscitation.2020.07.012.
      Epub 2020 Jul 22.


PMID- 32707000
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 10
DP  - 2020 Oct
TI  - Why use indicators to measure and monitor the inclusion of climate change and
      environmental sustainability in health professions' education?
PG  - 1119-1122
LID - 10.1080/0142159X.2020.1795106 [doi]
AB  - Currently, health professionals are inadequately prepared to meet the challenges 
      that climate change and environmental degradation pose to health systems. Health 
      professions' education (HPE) has an ethical responsibility to address this and
      must include the health effects of climate change and environmental
      sustainability across all curricula. As there is a narrow, closing window in
      which to take action to avoid the worst health outcomes from climate change,
      urgent, systematic, system-level change is required by the education sector.
      Measuring, monitoring, and reporting activity using indicators have been
      demonstrated to support change by providing a focus for action. A review of the
      literature on the use of indicators in medical education for climate change and
      health, however, yielded no publications. The framework of targets and indicators
      developed for implementation of the Sustainable Development Goals (SDGs) by 2030 
      and the UNESCO initiative of the Education for Sustainable Development provide a 
      guide for the development of indicators for HPE. Engaging stakeholders and
      achieving consensus on an approach to indicator development is essential and,
      where they exist, accreditation standards may have a supporting role. Creating
      capacity for environmentally sustainable health care at scale and pace should be 
      our collective goal as health professions' educators.
FAU - Madden, Diana Lynne
AU  - Madden DL
AUID- ORCID: 0000-0003-2829-7195
AD  - School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia.
FAU - McLean, Michelle
AU  - McLean M
AUID- ORCID: 0000-0002-9912-2483
AD  - Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia.
FAU - Brennan, Meagan
AU  - Brennan M
AUID- ORCID: 0000-0002-3281-7643
AD  - School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia.
FAU - Moore, Aishah
AU  - Moore A
AUID- ORCID: 0000-0002-4482-5798
AD  - School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200724
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - *Climate Change
MH  - Curriculum
MH  - *Education, Medical
MH  - Health Occupations
MH  - Health Personnel
MH  - Humans
OTO - NOTNLM
OT  - *Evaluation
OT  - *climate change
OT  - *curriculum
OT  - *environmentally sustainable healthcare
OT  - *health professions' education
OT  - *indicators
OT  - *multiprofessional
OT  - *sustainable development goals
EDAT- 2020/07/25 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1080/0142159X.2020.1795106 [doi]
PST - ppublish
SO  - Med Teach. 2020 Oct;42(10):1119-1122. doi: 10.1080/0142159X.2020.1795106. Epub
      2020 Jul 24.


PMID- 32706777
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - A micro-PRNT for the detection of Ross River virus antibodies in mosquito blood
      meals: A useful tool for inferring transmission pathways.
PG  - e0229314
LID - 10.1371/journal.pone.0229314 [doi]
AB  - INTRODUCTION: Many arboviruses of public health significance are maintained in
      zoonotic cycles with complex transmission pathways. The presence of serum
      antibody against arboviruses in vertebrates provides evidence of their historical
      exposure but reveals nothing about the vector-reservoir relationship. Moreover,
      collecting blood or tissue samples from vertebrate hosts is ethically and
      logistically challenging. We developed a novel approach for screening the immune 
      status of vertebrates against Ross River virus that allows us to implicate the
      vectors that form the transmission pathways for this commonly notified Australian
      arboviral disease. METHODS: A micro-plaque reduction neutralisation test
      (micro-PRNT) was developed and validated on koala (Phascolarctos cinereus) sera
      against a standard PRNT. The ability of the micro-PRNT to detect RRV antibodies
      in mosquito blood meals was then tested using two mosquito models.
      Laboratory-reared Aedes aegypti were fed, via a membrane, on sheep blood
      supplemented with RRV seropositive and seronegative human sera. Aedes
      notoscriptus were fed on RRV seropositive and seronegative human volunteers.
      Blood-fed mosquitoes were harvested at various time points after feeding and
      their blood meals analysed for the presence of RRV neutralising antibodies using 
      the micro-PRNT. RESULTS: There was significant agreement of the plaque
      neutralisation resulting from the micro-PRNT and standard PRNT techniques (R2 =
      0.65; P<0.0001) when applied to RRV antibody detection in koala sera. Sensitivity
      and specificity of the micro-PRNT assay were 88.2% and 96%, respectively, in
      comparison with the standard PRNT. Blood meals from mosquitoes fed on sheep blood
      supplemented with RRV antibodies, and on blood from RRV seropositive humans
      neutralised the virus by >/=50% until 48 hr post feeding. The vertebrate origin
      of the blood meal was also ascertained for the same samples, in parallel, using
      established molecular techniques. CONCLUSIONS: The small volumes of blood present
      in mosquito abdomens can be used to identify RRV antibodies and therefore host
      exposure to arbovirus infection. In tandem with the accurate identification of
      the mosquito, and diagnostics for the host origin of the blood meal, this
      technique has tremendous potential for exploring RRV transmission pathways. It
      can be adapted for similar studies on other mosquito borne zoonoses.
FAU - Gyawali, Narayan
AU  - Gyawali N
AUID- ORCID: 0000-0003-1738-8315
AD  - Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
      Queensland, Australia.
FAU - Murphy, Amanda K
AU  - Murphy AK
AD  - Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
      Queensland, Australia.
FAU - Hugo, Leon E
AU  - Hugo LE
AD  - Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
      Queensland, Australia.
FAU - Devine, Gregor J
AU  - Devine GJ
AD  - Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200724
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Aedes/*metabolism/virology
MH  - Alphavirus Infections/diagnosis/transmission/veterinary
MH  - Animal Feed/*analysis/virology
MH  - Animals
MH  - Antibodies, Viral/*analysis/blood
MH  - Disease Vectors
MH  - Female
MH  - Humans
MH  - Neutralization Tests/*methods
MH  - Phascolarctidae/virology
MH  - Ross River virus/*immunology
MH  - Sensitivity and Specificity
PMC - PMC7380888
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/25 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/02/01 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - 10.1371/journal.pone.0229314 [doi]
AID - PONE-D-20-02979 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 24;15(7):e0229314. doi: 10.1371/journal.pone.0229314.
      eCollection 2020.


PMID- 32706741
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 21
TI  - Extended Support Within a Person-Centered Practice After Surgery for Patients
      With Pituitary Tumors: Protocol for a Quasiexperimental Study.
PG  - e17697
LID - 10.2196/17697 [doi]
AB  - BACKGROUND: Patients with pituitary tumors often live with lifelong consequences 
      of their disease. Treatment options include surgery, radiotherapy, and medical
      therapy. Symptoms associated with the tumor or its treatment affect several areas
      of life. Patients need to adhere to long-term contact with both specialist and
      general health care providers due to the disease, complex treatments, and
      associated morbidity. The first year after pituitary surgery constitutes an
      important time period, with medical evaluations after surgery and decisions on
      hormonal substitution. The development and evaluation of extended patient support
      during this time are limited. OBJECTIVE: The aim of this study is to evaluate
      whether support within a person-centered care practice increases wellbeing for
      patients with pituitary tumors. Our main hypothesis is that the extended support 
      will result in increased psychological wellbeing compared with the support given 
      within standard of care. Secondary objectives are to evaluate whether the
      extended support, compared with standard care, will result in (1) better health
      status, (2) less fatigue, (3) higher satisfaction with care, (4) higher
      self-efficacy, (5) increased person-centered content in care documentation, and
      (6) sustained patient safety. METHODS: Within a quasiexperimental design,
      patients diagnosed with a pituitary tumor planned for neurosurgery are
      consecutively included in a pretest-posttest study performed at a specialist
      endocrine clinic. The control group receives standard of care after surgery, and 
      the interventional group receives structured patient support for 1 year after
      surgery based on person-centeredness covering self-management support,
      accessibility, and continuity. A total of 90 patients are targeted for each
      group. RESULTS: Recruitment into the control group was performed between Q3 2015 
      and Q4 2017. Recruitment into the intervention group started in Q4 2017 and is
      ongoing until Q4 2020. The study is conducted according to the Declaration of
      Helsinki, and the protocol has received approval from a regional ethical review
      board. CONCLUSIONS: This study entails an extensive intervention constructed in
      collaboration between clinicians, patients, and researchers that acknowledges
      accessibility, continuity, and self-management support within
      person-centeredness. The study has the potential to compare standard care to
      person-centered practice adapted specifically for patients with pituitary tumors 
      and evaluated with a combination of patient-reported outcomes and
      patient-reported experience measures. Following the results, the person-centered 
      practice may also become a useful model to further develop and explore
      person-centered care for patients with other rare, lifelong conditions. TRIAL
      REGISTRATION: Researchweb.org.
      https://www.researchweb.org/is/sverige/project/161671. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/17697.
CI  - (c)Sofie Jakobsson, Daniel S Olsson, Eva Andersson, Tobias Hallen, David Krabbe, 
      Ann-Charlotte Olofsson, Oskar Ragnarsson, Thomas Skoglund, Gudmundur Johannsson, 
      Eva Jakobsson Ung. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 21.07.2020.
FAU - Jakobsson, Sofie
AU  - Jakobsson S
AUID- ORCID: https://orcid.org/0000-0001-5223-6363
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Olsson, Daniel S
AU  - Olsson DS
AUID- ORCID: https://orcid.org/0000-0002-9734-0786
AD  - Department of Medicine, Sahlgrenska University Hospital, Region Vastra Gotaland, 
      Gothenburg, Sweden.
AD  - Department of Internal Medicine and Clinical Nutrition, Institute of Medicine,
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Andersson, Eva
AU  - Andersson E
AUID- ORCID: https://orcid.org/0000-0002-1114-8102
AD  - Department of Medicine, Sahlgrenska University Hospital, Region Vastra Gotaland, 
      Gothenburg, Sweden.
FAU - Hallen, Tobias
AU  - Hallen T
AUID- ORCID: https://orcid.org/0000-0002-3628-7686
AD  - Department of Neurosurgery, Sahlgrenska University Hospital, Region Vastra
      Gotaland, Gothenburg, Sweden.
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Krabbe, David
AU  - Krabbe D
AUID- ORCID: https://orcid.org/0000-0002-9363-9991
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Department of Rehabilitation Medicine, Sahlgrenska University Hospital, Region
      Vastra Gotaland, Gothenburg, Sweden.
FAU - Olofsson, Ann-Charlotte
AU  - Olofsson AC
AUID- ORCID: https://orcid.org/0000-0001-9676-2656
AD  - Department of Medicine, Sahlgrenska University Hospital, Region Vastra Gotaland, 
      Gothenburg, Sweden.
FAU - Ragnarsson, Oskar
AU  - Ragnarsson O
AUID- ORCID: https://orcid.org/0000-0003-0204-9492
AD  - Department of Medicine, Sahlgrenska University Hospital, Region Vastra Gotaland, 
      Gothenburg, Sweden.
AD  - Department of Internal Medicine and Clinical Nutrition, Institute of Medicine,
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Skoglund, Thomas
AU  - Skoglund T
AUID- ORCID: https://orcid.org/0000-0003-2645-3529
AD  - Department of Neurosurgery, Sahlgrenska University Hospital, Region Vastra
      Gotaland, Gothenburg, Sweden.
AD  - Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Johannsson, Gudmundur
AU  - Johannsson G
AUID- ORCID: https://orcid.org/0000-0003-3484-8440
AD  - Department of Medicine, Sahlgrenska University Hospital, Region Vastra Gotaland, 
      Gothenburg, Sweden.
AD  - Department of Internal Medicine and Clinical Nutrition, Institute of Medicine,
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Jakobsson Ung, Eva
AU  - Jakobsson Ung E
AUID- ORCID: https://orcid.org/0000-0002-8955-6552
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Department of Medicine, Sahlgrenska University Hospital, Region Vastra Gotaland, 
      Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7404015
OTO - NOTNLM
OT  - clinical pathway
OT  - intervention
OT  - person-centered care
OT  - pituitary tumor
OT  - quasiexperimental
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:01
CRDT- 2020/07/25 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:01 [medline]
AID - v9i7e17697 [pii]
AID - 10.2196/17697 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 21;9(7):e17697. doi: 10.2196/17697.


PMID- 32706703
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 22
TI  - Acceptability and Usability of the Mobile Digital Health App NoObesity for
      Families and Health Care Professionals: Protocol for a Feasibility Study.
PG  - e18068
LID - 10.2196/18068 [doi]
AB  - BACKGROUND: Almost a quarter or more than a fifth of children in the United
      Kingdom are overweight or obese by the time they start school. The UK Department 
      of Health and Social Care's national policy for combating childhood obesity has
      critical outcomes centered on sugar and caloric consumption reduction. Health
      Education England has developed two digital apps for families with children up to
      15 years and for their associated health care professionals to provide a digital 
      learning resource and tool aimed at encouraging healthy lifestyles to prevent
      obesity. OBJECTIVE: This feasibility study assesses the usability and
      acceptability of Health Education England's NoObesity app for undertaking
      activities to improve families' diet and physical activity. The purpose of the
      study is to evaluate the app's influence on self-efficacy and goal setting and to
      determine what can be learnt to improve its design for future studies, if there
      is evidence of adoption and sustainability. METHODS: The study population will
      include 20 to 40 families and their linked health care professionals. Considering
      issues related to digital access associated with socioeconomic status and the
      impact on information technology use, study recruitment will be regionally
      focused in a low socioeconomic status area. The study will last for 9 months
      (3-month intervention period and 6-month follow-up). The evaluations of
      feasibility, acceptability, and usability will be conducted using the following
      scales and theoretical frameworks: (1) system usability scale; (2) Reach
      Effectiveness Adoption Implementation Maintenance framework; (3) Bandura model of
      health promotion; and (4) Nonadoption, Abandonment, and Challenges to the
      Scale-up, Spread, and Suitability framework. App use will be captured and
      quantitatively analyzed for net use patterns (eg, number of screens viewed,
      number of logins, cumulative minutes using the app, number of plans made, and
      number of times goals met) and to triangulate qualitative feedback from study
      participants. RESULTS: This study was funded in March 2019 by Health Education
      England and received University of Oxford Medical Sciences Interdivisional
      Research Ethics Committee approval on January 31, 2020 (R62092/RE001). At
      manuscript submission, study recruitment is pending, and expected results will be
      published in 2021. CONCLUSIONS: This study will provide evidence on the NoObesity
      app's influence on self-efficacy and goal-setting and determine what can be
      learnt to improve its design for future studies, if there is evidence of adoption
      and sustainability. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      PRR1-10.2196/18068.
CI  - (c)Edward Meinert, Em Rahman, Alison Potter, Wendy Lawrence, Michelle Van
      Velthoven. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 22.07.2020.
FAU - Meinert, Edward
AU  - Meinert E
AUID- ORCID: https://orcid.org/0000-0003-2484-3347
AD  - Digitally Enabled PrevenTative Health (DEPTH) Research Group, Department of
      Paediatrics, Univeristy of Oxford, Oxford, United Kingdom.
FAU - Rahman, Em
AU  - Rahman E
AUID- ORCID: https://orcid.org/0000-0002-0417-5049
AD  - Health Education England, Southhampton, United Kingdom.
FAU - Potter, Alison
AU  - Potter A
AUID- ORCID: https://orcid.org/0000-0002-0952-4105
AD  - Health Education England, Southhampton, United Kingdom.
FAU - Lawrence, Wendy
AU  - Lawrence W
AUID- ORCID: https://orcid.org/0000-0003-1264-0438
AD  - Medical Research Council Lifecourse Epidemiology Unit, University of Southampton,
      Southampton, United Kingdom.
AD  - National Institute for Health Research, Southampton Biomedical Research Centre,
      University Hospital Southampton NHS Foundation Trust, Southampton, United
      Kingdom.
FAU - Van Velthoven, Michelle
AU  - Van Velthoven M
AUID- ORCID: https://orcid.org/0000-0003-1245-8759
AD  - Digitally Enabled PrevenTative Health (DEPTH) Research Group, Department of
      Paediatrics, Univeristy of Oxford, Oxford, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7407263
OTO - NOTNLM
OT  - cell phone
OT  - child health
OT  - digital health
OT  - digital technology
OT  - mHealth
OT  - mobile health
OT  - obesity
OT  - overweight
OT  - telecommunication
OT  - weight loss
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:01
CRDT- 2020/07/25 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:01 [medline]
AID - v9i7e18068 [pii]
AID - 10.2196/18068 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 22;9(7):e18068. doi: 10.2196/18068.


PMID- 32706653
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20211204
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 7
DP  - 2020 Jul 23
TI  - Considerations for Health Researchers Using Social Media for Knowledge
      Translation: Multiple Case Study.
PG  - e15121
LID - 10.2196/15121 [doi]
AB  - BACKGROUND: Despite extensive literature describing the use of social media in
      health research, a gap exists around best practices in establishing,
      implementing, and evaluating an effective social media knowledge translation (KT)
      and exchange strategies. OBJECTIVE: This study aims to examine successes,
      challenges, and lessons learned from using social media within health research
      and to create practical considerations to guide other researchers. METHODS: The
      Knowledge Translation Platform of the Alberta Strategy for Patient-Oriented
      Research SUPPORT Unit formed a national working group involving platform staff,
      academics, and a parent representative with experience using social media for
      health research. We collected and analyzed 4 case studies that used a variety of 
      social media platforms and evaluation methods. The case studies covered a
      spectrum of initiatives from participant recruitment and data collection to
      dissemination, engagement, and evaluation. Methods and findings from each case
      study as well as barriers and facilitators encountered were summarized. Through
      iterative discussions, we converged on recommendations and considerations for
      health researchers planning to use social media for KT. RESULTS: We provide
      recommendations for elements to consider when developing a social media KT
      strategy: (1) set a clear goal and identify a theory, framework, or model that
      aligns with the project goals and objectives; (2) understand the intended
      audience (use social network mapping to learn what platforms and social
      influences are available); (3) choose a platform or platforms that meet the needs
      of the intended audience and align well with the research team's capabilities
      (can you tap into an existing network, and what mode of communication does it
      support?); (4) tailor messages to meet user needs and platform requirements (eg, 
      plain language and word restrictions); (5) consider timing, frequency, and
      duration of messaging as well as the nature of interactions (ie, social filtering
      and negotiated awareness); (6) ensure adequate resources and personnel are
      available (eg, content creators, project coordinators, communications experts,
      and audience stakeholder or patient advocate); (7) develop an evaluation plan a
      priori driven by goals and types of data available (ie, quantitative and
      qualitative); and (8) consider ethical approvals needed (driven by evaluation and
      type of data collection). CONCLUSIONS: In the absence of a comprehensive
      framework to guide health researchers using social media for KT, we provide
      several key considerations. Future research will help validate the proposed
      components and create a body of evidence around best practices for using and
      evaluating social media as part of a KT strategy.
CI  - (c)Sarah A Elliott, Michele P Dyson, Gilbert V Wilkes, Gabrielle L Zimmermann,
      Christine T Chambers, Kristy DM Wittmeier, Dianne J Russell, Shannon D Scott,
      Denise Thomson, Lisa Hartling. Originally published in the Journal of Medical
      Internet Research (http://www.jmir.org), 23.07.2020.
FAU - Elliott, Sarah A
AU  - Elliott SA
AUID- ORCID: 0000-0001-9588-2226
AD  - Alberta Research Center for Health Evidence, Department of Pediatrics, University
      of Alberta, Edmonton, AB, Canada.
AD  - Alberta SPOR SUPPORT Unit, Department of Pediatrics, University of Alberta,
      Edmonton, AB, Canada.
AD  - Cochrane Child Health, Edmonton, AB, Canada.
FAU - Dyson, Michele P
AU  - Dyson MP
AUID- ORCID: 0000-0003-4856-2283
AD  - Alberta Research Center for Health Evidence, Department of Pediatrics, University
      of Alberta, Edmonton, AB, Canada.
FAU - Wilkes, Gilbert V
AU  - Wilkes GV
AUID- ORCID: 0000-0003-1541-5367
AD  - School of Communication Studies, Mount Royal University, Calgary, AB, Canada.
FAU - Zimmermann, Gabrielle L
AU  - Zimmermann GL
AUID- ORCID: 0000-0002-5060-4385
AD  - Alberta SPOR SUPPORT Unit, Department of Pediatrics, University of Alberta,
      Edmonton, AB, Canada.
AD  - Department of Community Health Sciences, University of Calgary, Calgary, AB,
      Canada.
FAU - Chambers, Christine T
AU  - Chambers CT
AUID- ORCID: 0000-0002-7138-916X
AD  - Departments of Psychology & Neuroscience and Pediatrics, Dalhousie University,
      Halifax, NS, Canada.
AD  - Centre for Pediatrics Pain Research, IWK Health Centre, Hallifax, NS, Canada.
FAU - Wittmeier, Kristy Dm
AU  - Wittmeier KD
AUID- ORCID: 0000-0002-2385-3722
AD  - Department of Pediatrics and Child Health, Rady Faculty of Health Sciences,
      University of Manitoba, Winnipeg, MB, Canada.
AD  - Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.
FAU - Russell, Dianne J
AU  - Russell DJ
AUID- ORCID: 0000-0001-7486-4643
AD  - CanChild Centre for Childhood Disability Research, McMaster University, Hamilton,
      ON, Canada.
FAU - Scott, Shannon D
AU  - Scott SD
AUID- ORCID: 0000-0002-2251-3742
AD  - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada.
FAU - Thomson, Denise
AU  - Thomson D
AUID- ORCID: 0000-0002-4972-5331
AD  - Alberta SPOR SUPPORT Unit, Department of Pediatrics, University of Alberta,
      Edmonton, AB, Canada.
AD  - Cochrane Child Health, Edmonton, AB, Canada.
FAU - Hartling, Lisa
AU  - Hartling L
AUID- ORCID: 0000-0001-8341-3991
AD  - Alberta Research Center for Health Evidence, Department of Pediatrics, University
      of Alberta, Edmonton, AB, Canada.
AD  - Alberta SPOR SUPPORT Unit, Department of Pediatrics, University of Alberta,
      Edmonton, AB, Canada.
AD  - Cochrane Child Health, Edmonton, AB, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Health Resources
MH  - Humans
MH  - Research Personnel/psychology/*standards
MH  - *Social Media
MH  - Translational Research, Biomedical/*methods
PMC - PMC7413271
OTO - NOTNLM
OT  - *dissemination
OT  - *engagement
OT  - *evaluation
OT  - *exchange
OT  - *health research
OT  - *knowledge translation
OT  - *social media
EDAT- 2020/07/25 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/06/21 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
AID - v22i7e15121 [pii]
AID - 10.2196/15121 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jul 23;22(7):e15121. doi: 10.2196/15121.


PMID- 32706532
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20200806
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 383
IP  - 4
DP  - 2020 Jul 23
TI  - Border Babies - Medical Ethics and Human Rights in Immigrant Detention Centers.
PG  - 297-299
LID - 10.1056/NEJMp2003050 [doi]
FAU - Crosby, Sondra S
AU  - Crosby SS
AD  - From the Center for Health Law, Ethics, and Human Rights, Boston University
      School of Public Health, Boston.
FAU - Annas, George J
AU  - Annas GJ
AD  - From the Center for Health Law, Ethics, and Human Rights, Boston University
      School of Public Health, Boston.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - IM
MH  - Bioethical Issues
MH  - Child
MH  - *Child Abuse/ethics/legislation & jurisprudence
MH  - Child Welfare/*ethics
MH  - *Emigrants and Immigrants
MH  - *Ethics, Medical
MH  - Human Rights/*ethics
MH  - Humans
MH  - Infant
MH  - Mexico
MH  - *Physician's Role
MH  - Prisoners
MH  - United States
EDAT- 2020/07/25 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
AID - 10.1056/NEJMp2003050 [doi]
PST - ppublish
SO  - N Engl J Med. 2020 Jul 23;383(4):297-299. doi: 10.1056/NEJMp2003050.


PMID- 32706522
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 67
IP  - 11
DP  - 2020 Nov
TI  - Outcomes with nondose-dense chemotherapy for Ewing sarcoma: A practical approach 
      for the developing world.
PG  - e28604
LID - 10.1002/pbc.28604 [doi]
AB  - BACKGROUND: The current multidisciplinary approach in the treatment of Ewing
      sarcoma has improved cure rates, with contemporary dose-dense chemotherapy
      attaining 5-year event-free survival (EFS) of 73% in localized cases.
      Dose-intense and dose-dense chemotherapy is difficult in the majority of
      resource-limited settings with limited access to optimal supportive care. We
      report on patients with Ewing sarcoma treated on EFT-2001, a nondose-dense
      chemotherapy protocol. PROCEDURE: A retrospective analysis was conducted of
      patients (<15 years) with Ewing sarcoma treated with curative intent during
      January 2013-June 2017 with an institutional ethics committee-approved
      nondose-dense protocol (EFT-2001). Local therapy was planned after 9-12 weeks of 
      chemotherapy with metastatic sites addressed with radiotherapy. The study
      assessed outcomes and prognostic factors. RESULTS: We analysed 200 patients with 
      M:F ratio of 1.27:1 and metastases in 41 patients (20.5%). At a median follow up 
      of 41.5 months (range 4.5-81.8 months), respective 3-year EFS and overall
      survival (OS) of the whole cohort is 65.3% (95% confidence interval [CI]:
      58.1-71.7%) and 79.3% (95% CI: 72.8-84.5%); for localized and metastatic cohort, 
      70.9% (95% CI: 62.9-77.5%) and 82.8% (95% CI: 75.7-89.0%); and for metastatic
      cohort, 42.8% (95% CI: 28.0-58.6%) and 65.3% (95% CI: 47.7-78.3%). Presence of
      residual disease (morphologic/metabolic) on positron emission tomography-computed
      tomography scan done 3 months post definitive radiotherapy (hazard ratio [HR]
      7.92 [95% CI: 3.46-18.14]) and delay in any form of local control >4 months (HR
      3.42 [95% CI: 1.32-8.89]) affected outcomes. Nonrelapse mortality during
      treatment was 6.5%, mainly due to cardiomyopathy (3.0%) and bacterial sepsis
      (1.5%). Cardiotoxicity was seen in 11.5% of patients. CONCLUSIONS: Nondose-dense 
      chemotherapy provides good outcomes with manageable toxicities in a
      multidisciplinary treatment approach, while reducing cumulative drug exposures in
      the developing world where dose-intense or dose-dense chemotherapy could
      potentially increase toxicity, and hence seems a feasible approach in
      resource-limited settings. Presence of any residual disease post definitive
      radiotherapy or delay in local control portends poor outcome.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Parambil, Badira Cheriyalinkal
AU  - Parambil BC
AUID- ORCID: 0000-0001-6459-2058
AD  - Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Vora, Tushar
AU  - Vora T
AUID- ORCID: 0000-0001-5469-056X
AD  - Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Sankaran, Hari
AU  - Sankaran H
AD  - Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Prasad, Maya
AU  - Prasad M
AUID- ORCID: 0000-0003-0127-7987
AD  - Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Bakshi, Asish
AU  - Bakshi A
AD  - Department of Medical Oncology, Dr L.H. Hiranandani Hospital, Mumbai,
      Maharashtra, India.
FAU - Puri, Ajay
AU  - Puri A
AUID- ORCID: 0000-0002-4323-753X
AD  - Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Gulia, Ashish
AU  - Gulia A
AD  - Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Qureshi, Sajid
AU  - Qureshi S
AUID- ORCID: 0000-0002-6770-5887
AD  - Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Laskar, Siddhartha
AU  - Laskar S
AUID- ORCID: 0000-0001-8558-4225
AD  - Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Khanna, Nehal
AU  - Khanna N
AD  - Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Shah, Sneha
AU  - Shah S
AUID- ORCID: 0000-0002-9654-6694
AD  - Department of Nuclear Medicine, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Ramadwar, Mukta
AU  - Ramadwar M
AD  - Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute
      (HBNI), Mumbai, Maharashtra, India.
FAU - Kembhavi, Seema
AU  - Kembhavi S
AD  - Department of Radiodiagnosis, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Chinnaswamy, Girish
AU  - Chinnaswamy G
AD  - Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
FAU - Banavali, Shripad
AU  - Banavali S
AD  - Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National
      Institute (HBNI), Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200724
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bone Neoplasms/drug therapy/*mortality/pathology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sarcoma, Ewing/drug therapy/*mortality/pathology
MH  - Survival Rate
OTO - NOTNLM
OT  - *Ewing sarcoma
OT  - *nondose-dense chemotherapy
OT  - *outcome
OT  - *prognostic factors | developing world
EDAT- 2020/07/25 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/11/16 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1002/pbc.28604 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2020 Nov;67(11):e28604. doi: 10.1002/pbc.28604. Epub 2020
      Jul 24.


PMID- 32706506
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20201218
IS  - 1466-769X (Electronic)
IS  - 1466-7681 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Jul
TI  - COVID-19, the year of the nurse and the ethics of witnessing.
PG  - e12311
LID - 10.1111/nup.12311 [doi]
FAU - Monteverde, Settimio
AU  - Monteverde S
AUID- ORCID: 0000-0002-7041-2663
AD  - Department of Health Professions, Bern University of Applied Sciences, Bern,
      Switzerland.
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Zurich, Switzerland.
FAU - Gallagher, Ann
AU  - Gallagher A
AUID- ORCID: 0000-0002-2264-024X
AD  - International Care Ethics Observatory, University of Surrey, Guildford, UK.
LA  - eng
PT  - Editorial
PL  - England
TA  - Nurs Philos
JT  - Nursing philosophy : an international journal for healthcare professionals
JID - 100897394
SB  - IM
MH  - Anniversaries and Special Events
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*nursing
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/*nursing
PMC - PMC7404411
EDAT- 2020/07/25 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/06/10 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
AID - 10.1111/nup.12311 [doi]
PST - ppublish
SO  - Nurs Philos. 2020 Jul;21(3):e12311. doi: 10.1111/nup.12311.


PMID- 32706386
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20210108
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 324
IP  - 6
DP  - 2020 Aug 11
TI  - Clinical, Legal, and Ethical Aspects of Artificial Intelligence-Assisted
      Conversational Agents in Health Care.
PG  - 552-553
LID - 10.1001/jama.2020.2724 [doi]
FAU - McGreevey, John D 3rd
AU  - McGreevey JD 3rd
AD  - University of Pennsylvania Health System, Perelman School of Medicine, Section of
      Hospital Medicine, Division of General Internal Medicine, Institute for
      Biomedical Informatics, University of Pennsylvania, Philadelphia.
FAU - Hanson, C William 3rd
AU  - Hanson CW 3rd
AD  - Perelman School of Medicine, University of Pennsylvania, University of
      Pennsylvania Health System, Philadelphia.
AD  - School of Engineering and Applied Science, University of Pennsylvania,
      Philadelphia.
FAU - Koppel, Ross
AU  - Koppel R
AD  - Perelman School of Medicine, University of Pennsylvania, University of
      Pennsylvania Health System, Philadelphia.
AD  - Department of Medical Informatics, Jacobs School of Medicine, University at
      Buffalo, State University of New York, Buffalo.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
SB  - IM
CIN - JAMA. 2020 Dec 15;324(23):2444. PMID: 33320217
MH  - *Artificial Intelligence/ethics/legislation & jurisprudence/standards
MH  - *Bioethical Issues
MH  - *Communication
MH  - Computer Security
MH  - Delivery of Health Care/*methods
MH  - Federal Government
MH  - *Government Regulation
MH  - Humans
MH  - Natural Language Processing
MH  - Speech Recognition Software
EDAT- 2020/07/25 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 2768927 [pii]
AID - 10.1001/jama.2020.2724 [doi]
PST - ppublish
SO  - JAMA. 2020 Aug 11;324(6):552-553. doi: 10.1001/jama.2020.2724.


PMID- 32706372
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 1930-6180 (Electronic)
IS  - 1084-2020 (Linking)
VI  - 60
IP  - 2
DP  - 2020 Oct 19
TI  - The Influence of Feed and Drinking Water on Terrestrial Animal Research and Study
      Replicability.
PG  - 175-196
LID - 10.1093/ilar/ilaa012 [doi]
AB  - For more than 50 years, the research community has made strides to better
      determine the nutrient requirements for many common laboratory animal species.
      This work has resulted in high-quality animal feeds that can optimize growth,
      maintenance, and reproduction in most species. We have a much better
      understanding of the role that individual nutrients play in physiological
      responses. Today, diet is often considered as an independent variable in
      experimental design, and specialized diet formulations for experimental purposes 
      are widely used. In contrast, drinking water provided to laboratory animals has
      rarely been a consideration in experimental design except in studies of specific 
      water-borne microbial or chemical contaminants. As we advance in the precision of
      scientific measurements, we are constantly discovering previously unrecognized
      sources of experimental variability. This is the nature of science. However,
      science is suffering from a lack of experimental reproducibility or replicability
      that undermines public trust. The issue of reproducibility/replicability is
      especially sensitive when laboratory animals are involved since we have the
      ethical responsibility to assure that laboratory animals are used wisely. One way
      to reduce problems with reproducibility/replicability is to have a strong
      understanding of potential sources of inherent variability in the system under
      study and to provide "...a clear, specific, and complete description of how the
      reported results were reached [1]." A primary intent of this review is to provide
      the reader with a high-level overview of some basic elements of laboratory animal
      nutrition, methods used in the manufacturing of feeds, sources of drinking water,
      and general methods of water purification. The goal is to provide background on
      contemporary issues regarding how diet and drinking water might serve as a source
      of extrinsic variability that can impact animal health, study design, and
      experimental outcomes and provide suggestions on how to mitigate these effects.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      National Academies of Sciences, Engineering, and Medicine. All rights reserved.
      For permissions, please email: journals.permissions@oup.com.
FAU - Kurtz, David M
AU  - Kurtz DM
AD  - National Institute of Environmental Health Sciences, Research Triangle Park,
      North Carolina.
FAU - Feeney, William P
AU  - Feeney WP
AD  - Global Comparative and Translational Sciences, Integrated Biological Platform
      Sciences Department, GlaxoSmithKline, Collegeville, Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - ILAR J
JT  - ILAR journal
JID - 9516416
RN  - 0 (Drinking Water)
RN  - 0 (Metals, Heavy)
RN  - 0 (Mycotoxins)
RN  - 0 (Nitrosamines)
RN  - 0 (Pesticides)
SB  - IM
MH  - Animal Feed
MH  - Animals
MH  - Animals, Laboratory
MH  - *Drinking Water/analysis
MH  - Female
MH  - Male
MH  - Metals, Heavy/*analysis
MH  - Mycotoxins/analysis
MH  - Nitrosamines/analysis
MH  - Pesticides/*analysis
MH  - Reproducibility of Results
PMC - PMC7583730
OTO - NOTNLM
OT  - *contaminants
OT  - *diet
OT  - *drinking water
OT  - *feed
OT  - *laboratory animals
OT  - *nutrition
OT  - *replicability
OT  - *reproducibility
OT  - *variability
EDAT- 2020/07/25 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/03/16 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 5875722 [pii]
AID - 10.1093/ilar/ilaa012 [doi]
PST - ppublish
SO  - ILAR J. 2020 Oct 19;60(2):175-196. doi: 10.1093/ilar/ilaa012.


PMID- 32706101
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 2543-6031 (Electronic)
IS  - 2451-4934 (Linking)
VI  - 88
IP  - 3
DP  - 2020
TI  - Role of GeneXpert in the diagnosis of mycobacterium tuberculosis.
PG  - 183-188
LID - 10.5603/ARM.2020.0102 [doi]
AB  - INTRODUCTION: GeneXpert (GX) is a novel, integrated, cartridge-based, nucleic
      acid amplification test with an established role for rapid diagnosis of
      Mycobacterium tuberculosis and detection of rifampicin resistance. AIM: To
      evaluate the role of GX in pulmonary and extrapulmonary tuberculosis (TB) cases. 
      MATERIAL AND METHODS: A prospective study was conducted in the pulmonary medicine
      department of a tertiary care hospital after the Ethics Comittee permission. Data
      of 257 presumptive TB patients was retrieved for GX, acid fast bacilli smear and 
      cul-ture (AFB smear and culture) and drug susceptibility test (DST). Sensitivity,
      specificity, positive predictive value (PPV), negative predictive value (NPV) of 
      GX in diagnosis and determination of rifampicin resistance in pulmonary and
      extrapulmonary TB cases were calculated and compared with culture and DST
      results. RESULTS: Our study included 132 pulmonary and 125 extrapulmonary cases. 
      On the basis of clinicoradiological and microbiological correlation, diagnosis of
      TB was confirmed in 104 pulmonary and 103 extrapulmonary cases. Out of a total of
      104 pulmonary TB cases, 73 were rifampicin-sensitive and 31 were
      rifampicin-resistant cases. 103 extrapulmonary TB patients included 66
      rifampicin-sensitive and 37 rifampicin-resistant cases. The sensitivity,
      specificity, PPV, NPV of GX in diagnosis and detection of rifampicin resistance
      in pulmonary TB was 95%, 93%, 98%, 84% and 96%, 100%, 100%, 96%, respectively.
      The sensitivity, specificity, PPV, NPV of GX in diagnosis and detection of
      rifampicin resistance in extrapulmonary TB cases was 79%, 86%, 96%, 47% and 97%, 
      95%, 97%, 95%, respectively. CONCLUSIONS: GX results are superior to smear
      microscopy and comparable to culture with shorter turnaround time.We recom-mend
      using it in routine TB diagnosis as this will expedite the management of patients
      with presumptive TB.
FAU - Sasikumar, Chinnu
AU  - Sasikumar C
AD  - Department of Pulmonary Medicine, Topiwala National Medical College & BYL Nair
      Hospital, Mumbai, Maharashtra, India.
FAU - Utpat, Ketaki
AU  - Utpat K
AD  - Department of Pulmonary Medicine, Topiwala National Medical College & BYL Nair
      Hospital, Mumbai, Maharashtra, India.
FAU - Desai, Unnati
AU  - Desai U
AD  - Department of Pulmonary Medicine, Topiwala National Medical College & BYL Nair
      Hospital, Mumbai, Maharashtra, India.
FAU - Joshi, Jyotsna
AU  - Joshi J
AD  - Department of Pulmonary Medicine, Topiwala National Medical College & BYL Nair
      Hospital, Mumbai, Maharashtra, India. drjoshijm@gmail.com.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Adv Respir Med
JT  - Advances in respiratory medicine
JID - 101697329
RN  - 0 (Antibiotics, Antitubercular)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Adult
MH  - Antibiotics, Antitubercular/therapeutic use
MH  - *Drug Resistance, Bacterial
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molecular Diagnostic Techniques/*methods
MH  - Mycobacterium tuberculosis/*isolation & purification
MH  - Prospective Studies
MH  - Rifampin/therapeutic use
MH  - Sputum/microbiology
MH  - Tuberculosis, Pulmonary/*diagnosis/drug therapy
OTO - NOTNLM
OT  - AFB culture
OT  - GeneXpert
OT  - presumptive TB cases
EDAT- 2020/07/25 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/01/19 00:00 [revised]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - VM/OJS/J/66154 [pii]
AID - 10.5603/ARM.2020.0102 [doi]
PST - ppublish
SO  - Adv Respir Med. 2020;88(3):183-188. doi: 10.5603/ARM.2020.0102.


PMID- 32705774
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20220716
IS  - 1935-9780 (Electronic)
IS  - 1935-9772 (Linking)
VI  - 13
IP  - 5
DP  - 2020 Sep
TI  - Ethical Responses to the Covid-19 Pandemic: Implications for the Ethos and
      Practice of Anatomy as a Health Science Discipline.
PG  - 549-555
LID - 10.1002/ase.2003 [doi]
AB  - The move of much anatomy teaching online in response to the Covid-19 pandemic has
      been successfully implemented within very short time frames. This has
      necessitated a high degree of dependence upon the use of digitized cadaveric
      resources, has entailed immense workload demands on staff, and has disrupted
      students' studies. These educational exigencies have been accompanied by ethical 
      uncertainties for a discipline centered on study of the dead human body. An
      ethical framework for anatomy is suggested based on the principles of equal
      concern and respect, minimization of harm, fairness, and reciprocity, in which
      all staff and students are to be treated with respect and as moral equals. A
      series of ethical obligations are proposed as a means of maintaining the ethos of
      anatomy, coping with the suspension of body donation, providing adequate
      resources, and responding to increased dependence upon external providers. Good
      academic practice raises more general obligations stemming from the welfare of
      students, the increased workload of staff, and checking on online assessment and 
      invigilation. As anatomists respond to the educational and ethical lessons
      prompted by this pandemic, they should plan for future disruptions to normal work
      patterns by adopting a sustainable and equitable course of action.
CI  - (c) 2020 American Association for Anatomy.
FAU - Jones, David Gareth
AU  - Jones DG
AUID- ORCID: https://orcid.org/0000-0002-4671-6819
AD  - Department of Anatomy, Division of Health Sciences, University of Otago, Dunedin,
      New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - United States
TA  - Anat Sci Educ
JT  - Anatomical sciences education
JID - 101392205
SB  - IM
MH  - Anatomy/education/*ethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Education, Distance/*ethics
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
PMC - PMC7404418
OTO - NOTNLM
OT  - Covid-19 pandemic
OT  - body bequests
OT  - ethical framework
OT  - ethics
OT  - gross anatomy education
OT  - online delivery
EDAT- 2020/07/25 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/07/15 00:00 [revised]
PHST- 2020/07/17 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1002/ase.2003 [doi]
PST - ppublish
SO  - Anat Sci Educ. 2020 Sep;13(5):549-555. doi: 10.1002/ase.2003. Epub 2020 Aug 10.


PMID- 32705663
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 1019-5149 (Print)
IS  - 1019-5149 (Linking)
VI  - 30
IP  - 6
DP  - 2020
TI  - Assesment of Functional Results for the Lesions Located in Eloquent Areas with
      Using Intraoperative Cortical-Subcortical Stimulation and Cortical Mapping.
PG  - 854-863
LID - 10.5137/1019-5149.JTN.27551-19.2 [doi]
AB  - AIM: To assess the classical and functional imaging features of patients with
      pathology located in the eloquent areas of the brain who were admitted to our
      centre between October 2012 and February 2018. We also studied intraoperative
      somatosensory evoked potential (SEP), motor evoked potentials (MEP), phase
      reversal, cortical mapping, the extent of resection and the calculation of
      postoperative morbidity. MATERIAL AND METHODS: We compared our results with
      previous studies in which this technique was not used. The patient records of 163
      patients were reviewed retrospectively after approval by the institutional ethics
      committee and comparisons were made with reports in the literature. RESULTS: The 
      lesion was localised in the visual cortex in eight of the 163 patients. We did
      not encounter any abnormality in the VEP recordings, so the surgeries were
      continued. The remaining 155 cases were followed by intraoperative SEP and MEP
      monitoring. We observed a greater than 50% decrease in the amplitude and an
      increase in latencies that was greater than 10% in intraoperative MEP and SEP
      monitoring in 24 patients of 155. Although 8 of 24 patients with abnormal SEP and
      MEP values were corrected with manuveurs, 6 patients developed increased
      neurological deficits postoperatively. CONCLUSION: In conclusion, all of these
      methods should not be seen as competitive with each other; they could be
      considered as complementary. All of these methods are helpful for a surgical team
      regarding loss of neurological function. The rate of loss might be up to 100% and
      irreversible despite corrective maneveurs.
FAU - Mammadkhanli, Orkhan
AU  - Mammadkhanli O
AD  - Yuksek Ihtisas University, Medical Park Ankara Hospital, Department of
      Neurosurgery, Ankara, Turkey.
FAU - Bozkurt, Melih
AU  - Bozkurt M
FAU - Caglar, Yusuf Sukru
AU  - Caglar YS
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk Neurosurg
JT  - Turkish neurosurgery
JID - 9423821
SB  - IM
MH  - Adult
MH  - Aged
MH  - Brain Diseases/*surgery
MH  - Brain Mapping/*methods
MH  - Female
MH  - Humans
MH  - Intraoperative Neurophysiological Monitoring/*methods
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures/methods
MH  - Retrospective Studies
EDAT- 2020/07/25 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.5137/1019-5149.JTN.27551-19.2 [doi]
PST - ppublish
SO  - Turk Neurosurg. 2020;30(6):854-863. doi: 10.5137/1019-5149.JTN.27551-19.2.


PMID- 32705538
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Creative Anticipatory Ethical Reasoning with Scenario Analysis and Design
      Fiction.
PG  - 2985-3016
LID - 10.1007/s11948-020-00253-x [doi]
AB  - This paper presents an experimental approach for engaging undergraduate STEM
      students in anticipatory ethical reasoning, or ethical reasoning applied to the
      analysis of potential mid- to long-term implications and outcomes of
      technological innovation. The authors implemented two variations of an approach
      that integrates three key components-scenario analysis, design fiction, and
      ethical frameworks-into five sections of an introductory course on the social
      contexts of science and technology that is required of STEM majors. The authors
      dub this approach Creative Anticipatory Ethical Reasoning, or CAER. Scenario
      analysis is a strategy emerging from business consulting for grounded analysis of
      plausible future trajectories to inform planning. Design fiction is a creative
      hands-on activity that blends science fiction and design prototyping to
      facilitate critical thinking with respect to the societal dimensions of a
      plausible future technology. The authors present the following findings: in each 
      of the variations, students demonstrated significant engagement with CAER and a
      substantive shift in their conception of what constitutes responsible innovation 
      and ethical conduct in science and technology. Specifically, their integration of
      ethical reasoning with stakeholder perspectives and scenario analysis reframed
      technologies, from unproblematic solutions for societal problems to
      socially-embedded forms of life that might diverge from designers' intentions.
      This suggests that CAER could be a useful pedagogical intervention for expanding 
      students' ethical engagement to consider the potential unintended consequences of
      technological innovation.
FAU - York, Emily
AU  - York E
AUID- ORCID: 0000-0001-9253-9174
AD  - School of Integrated Sciences, James Madison University, 702 Carrier Drive MSC
      4302, Harrisonburg, VA, 22807, USA. yorker@jmu.edu.
FAU - Conley, Shannon N
AU  - Conley SN
AD  - School of Integrated Sciences, James Madison University, 701 Carrier Drive MSC
      4102, Harrisonburg, VA, 22807, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humans
MH  - Morals
MH  - *Problem Solving
MH  - Students
MH  - Technology
MH  - *Thinking
OTO - NOTNLM
OT  - *Anticipatory governance
OT  - *Design fiction
OT  - *Ethical reasoning
OT  - *Responsible innovation
OT  - *STEM education
OT  - *STS pedagogy
OT  - *Scenario analysis
EDAT- 2020/07/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/09/21 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1007/s11948-020-00253-x [doi]
AID - 10.1007/s11948-020-00253-x [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):2985-3016. doi: 10.1007/s11948-020-00253-x. Epub
      2020 Jul 23.


PMID- 32705494
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 15
IP  - 6
DP  - 2020 Sep
TI  - Methodological aspects of superiority, equivalence, and non-inferiority trials.
PG  - 1085-1091
LID - 10.1007/s11739-020-02450-9 [doi]
AB  - Depending on the scientific hypothesis to be addressed, randomized-controlled
      trials (RCT) are accordingly designed. RCTs that aim to determine whether a
      novel, experimental therapeutic intervention (either a drug or a treatment) is
      superior to a placebo or control intervention, are called superiority trials.
      Less common are the non-inferiority RCTs, designed to assess whether a new
      intervention is not unacceptably worse than an already existing reference
      intervention. An equivalence RCT is designed to investigate whether a novel
      treatment is equivalently effective to another, already existing, control
      intervention. In equivalence and non-inferiority RCTs, the efficacy of the
      reference intervention (active comparator) is already established, and therefore,
      an untreated control group would not be ethical. In this review, using a series
      of examples derived from equivalence and non-inferiority/superiority RCTs, we
      describe the main differences and methodological aspects among these three
      different types of RCTs.
FAU - Stefanos, Roumeliotis
AU  - Stefanos R
AUID- ORCID: http://orcid.org/0000-0002-9423-649X
AD  - Division of Nephrology and Hypertension, 1st Department of Internal Medicine,
      School of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, St.
      Kyriakidi 1, 54636, Thessaloniki, Greece. st_roumeliotis@Hotmail.com.
AD  - Institute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and
      Physiopathology of Renal Diseases and Hypertension, Ospedali Riuniti, via Vallone
      Petrara, Reggio Calabria, Italy. st_roumeliotis@Hotmail.com.
FAU - Graziella, D 'Arrigo
AU  - Graziella D'
AUID- ORCID: http://orcid.org/0000-0003-1831-7340
AD  - Institute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and
      Physiopathology of Renal Diseases and Hypertension, Ospedali Riuniti, via Vallone
      Petrara, Reggio Calabria, Italy.
FAU - Giovanni, Tripepi
AU  - Giovanni T
AUID- ORCID: http://orcid.org/0000-0002-3580-4602
AD  - Institute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and
      Physiopathology of Renal Diseases and Hypertension, Ospedali Riuniti, via Vallone
      Petrara, Reggio Calabria, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200723
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
SB  - IM
EIN - Intern Emerg Med. 2020 Sep 22;:. PMID: 32960430
MH  - *Equivalence Trials as Topic
MH  - Humans
MH  - Research Design/*trends
OTO - NOTNLM
OT  - *Equivalence
OT  - *Non-inferiority
OT  - *Randomized-controlled trial
OT  - *Superiority
EDAT- 2020/07/25 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1007/s11739-020-02450-9 [doi]
AID - 10.1007/s11739-020-02450-9 [pii]
PST - ppublish
SO  - Intern Emerg Med. 2020 Sep;15(6):1085-1091. doi: 10.1007/s11739-020-02450-9. Epub
      2020 Jul 23.


PMID- 32705422
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1179-1934 (Electronic)
IS  - 1172-7047 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Aug
TI  - Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative
      Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review.
PG  - 801-826
LID - 10.1007/s40263-020-00747-z [doi]
AB  - BACKGROUND: Refractory status epilepticus (RSE) represents a serious medical
      condition requiring early and targeted therapy. Given the increasing number of
      elderly or multimorbid patients with a limitation of life-sustaining therapy
      (LOT) or within a palliative care setting (PCS), guidelines-oriented therapy
      escalation options for RSE have to be omitted frequently. OBJECTIVES: This
      systematic review sought to summarize the evidence for fourth-line antiseizure
      drugs (ASDs) and other minimally or non-invasive therapeutic options beyond
      guideline recommendations in patients with RSE to elaborate on possible treatment
      options for patients undergoing LOT or in a PCS. METHODS: A systematic review of 
      the literature in accordance with the Preferred Reporting Items for Systematic
      Reviews and Meta-Analyses (PRISMA) guidelines, focusing on fourth-line ASDs or
      other minimally or non-invasive therapeutic options was performed in February and
      June 2020 using the MEDLINE, EMBASE and Cochrane databases. The search
      terminology was constructed using the name of the specific ASD or therapy option 
      and the term 'status epilepticus' with the use of Boolean operators, e.g.
      "(brivaracetam) AND (status epilepticus)". The respective Medical Subject
      Headings (MeSH) and Emtree terms were used, if available. RESULTS: There is
      currently no level 1, grade A evidence for the use of ASDs in RSE. The best
      evidence was found for the use of lacosamide and topiramate (level 3, grade C),
      followed by brivaracetam, perampanel (each level 4, grade D) and stiripentol,
      oxcarbazepine and zonisamide (each level 5, grade D). Regarding non-medicinal
      options, there is little evidence for the use of the ketogenic diet (level 4,
      grade D) and magnesium sulfate (level 5, grade D) in RSE. The broad use of
      immunomodulatory or immunosuppressive treatment options in the absence of a
      presumed autoimmune etiology cannot be recommended; however, if an autoimmune
      etiology is assumed, steroid pulse, intravenous immunoglobulins and plasma
      exchange/plasmapheresis should be considered (level 4, grade D). Even if several 
      studies suggested that the use of neurosteroids (level 5, grade D) is beneficial 
      in RSE, the current data situation indicates that there is formal evidence
      against it. CONCLUSIONS: RSE in patients undergoing LOT or in a PCS represents a 
      challenge for modern clinicians and epileptologists. The evidence for the use of 
      ASDs in RSE beyond that in current guidelines is low, but several effective and
      well-tolerated options are available that should be considered in this patient
      population. More so than in any other population, advance care planning, advance 
      directives, and medical ethical aspects have to be considered carefully before
      and during therapy.
FAU - Willems, Laurent M
AU  - Willems LM
AUID- ORCID: http://orcid.org/0000-0001-8226-1674
AD  - Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery,
      Goethe-University Frankfurt, Schleusenweg 2-16, 60528, Frankfurt am Main,
      Germany. laurent.willems@kgu.de.
AD  - Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
      laurent.willems@kgu.de.
AD  - LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe
      University Frankfurt, Frankfurt am Main, Germany. laurent.willems@kgu.de.
FAU - Bauer, Sebastian
AU  - Bauer S
AUID- ORCID: http://orcid.org/0000-0001-7571-8496
AD  - Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery,
      Goethe-University Frankfurt, Schleusenweg 2-16, 60528, Frankfurt am Main,
      Germany.
AD  - Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
AD  - LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe
      University Frankfurt, Frankfurt am Main, Germany.
FAU - Jahnke, Kolja
AU  - Jahnke K
AD  - Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
FAU - Voss, Martin
AU  - Voss M
AUID- ORCID: http://orcid.org/0000-0001-8469-8204
AD  - Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
AD  - Dr. Senckenberg Institute of Neuro-Oncology, Goethe University Frankfurt,
      University Hospital Frankfurt, Frankfurt am Main, Germany.
AD  - Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt am Main,
      Germany.
FAU - Rosenow, Felix
AU  - Rosenow F
AUID- ORCID: http://orcid.org/0000-0002-3989-7471
AD  - Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery,
      Goethe-University Frankfurt, Schleusenweg 2-16, 60528, Frankfurt am Main,
      Germany.
AD  - Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
AD  - LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe
      University Frankfurt, Frankfurt am Main, Germany.
FAU - Strzelczyk, Adam
AU  - Strzelczyk A
AUID- ORCID: http://orcid.org/0000-0001-6288-9915
AD  - Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery,
      Goethe-University Frankfurt, Schleusenweg 2-16, 60528, Frankfurt am Main,
      Germany.
AD  - Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
AD  - LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe
      University Frankfurt, Frankfurt am Main, Germany.
AD  - Department of Neurology, Epilepsy Center Hessen, Philipps University Marburg,
      Marburg (Lahn), Germany.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - New Zealand
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
RN  - 0 (Anticonvulsants)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
EIN - CNS Drugs. 2021 Aug;35(8):921. PMID: 34313954
MH  - Anticonvulsants/*therapeutic use
MH  - Autoimmunity/drug effects
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Palliative Care
MH  - Status Epilepticus/*drug therapy
PMC - PMC8316215
EDAT- 2020/07/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1007/s40263-020-00747-z [doi]
AID - 10.1007/s40263-020-00747-z [pii]
PST - ppublish
SO  - CNS Drugs. 2020 Aug;34(8):801-826. doi: 10.1007/s40263-020-00747-z.


PMID- 32705092
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
VI  - 2020
DP  - 2020 Apr
TI  - Relational, Flexible, Everyday: Learning from Ethics in Dementia Research.
LID - 10.1145/3313831.3376627 [doi]
AB  - Engaging in participatory research in HCI raises numerous ethical complexities
      such as consent, researcher relationships, and participant compensation. Doing
      HCI work in the area of dementia amplifies these issues, and researchers in this 
      area are modelling ethical stances to ensure researcher-participant relationships
      focus on meaningful engagement and care. This paper presents an insight into the 
      kinds of ethical foci required when doing design research with people living with
      dementia and their carers. We interviewed 22 HCI researchers with experience
      working in dementia care contexts. Our qualitative analysis outlines subsequent
      lessons-learned, such as recognition of the participants, self-care, research
      impact, and subjectivity in ethical review boards. Furthermore, we found the
      complexity of navigating both "everyday" and more formal, institutional ethics in
      dementia research has implications beyond the context of working with people with
      dementia and outline key considerations for ethical practices in socially
      orientated HCI research.
FAU - Hodge, James
AU  - Hodge J
AD  - Open Lab, Newcastle University, Newcastle upon Tyne, UK.
FAU - Foley, Sarah
AU  - Foley S
AD  - School of Applied Psychology, University College Cork, Ireland.
FAU - Brankaert, Rens
AU  - Brankaert R
AD  - Industrial Design, University of Technology & Institute of Allied Health
      Professions, Fontys University of Applied Sciences, Eindhoven, Netherlands.
FAU - Kenning, Gail
AU  - Kenning G
AD  - University of Technology Sydney, Australia.
FAU - Lazar, Amanda
AU  - Lazar A
AD  - College of Information Studies, University of Maryland, College Park, Maryland,
      United States.
FAU - Boger, Jennifer
AU  - Boger J
AD  - University of Waterloo, Waterloo, Ontario, Canada.
FAU - Morrissey, Kellie
AU  - Morrissey K
AD  - School of Design, University of Limerick, Limerick, Ireland.
LA  - eng
GR  - 90REGE0008/ACL/ACL HHS/United States
PT  - Journal Article
PL  - United States
TA  - Proc SIGCHI Conf Hum Factor Comput Syst
JT  - Proceedings of the SIGCHI conference on human factors in computing systems. CHI
      Conference
JID - 101620299
PMC - PMC7377302
MID - NIHMS1609045
OTO - NOTNLM
OT  - Dementia
OT  - Human-centered Computing~Empirical studies in HCI
OT  - Human-centered Computing~User studies
OT  - care
OT  - emotion
OT  - ethics
OT  - lived experience
OT  - relational
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:01
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:01 [medline]
AID - 10.1145/3313831.3376627 [doi]
PST - ppublish
SO  - Proc SIGCHI Conf Hum Factor Comput Syst. 2020 Apr;2020. doi:
      10.1145/3313831.3376627.


PMID- 32704537
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Jul 15
TI  - What You Need to Know About Cannabis: An Evidence-Based Crash Course for Mental
      Health Trainees.
PG  - 10923
LID - 10.15766/mep_2374-8265.10923 [doi]
AB  - Introduction: Although increasing numbers of states are legalizing cannabis for
      both medical and recreational purposes, health care providers and students report
      low comfort levels and limited knowledge regarding cannabis, highlighting current
      deficits in medical training. Methods: We developed a structured cannabis
      curriculum for a general psychiatry residency program at the University of
      Colorado. In constructing our curriculum, we initially surveyed advanced
      psychiatry residents and attending psychiatrists in the university outpatient
      clinic regarding attitudes and approaches to psychiatric patients using cannabis.
      Prior to implementation in the following year's core curriculum for first-year
      postgraduates (PGY 1s), pretest assessments evaluated PGY 1s' attitudes towards
      cannabis use and identified learning expectations, challenges, and confidence
      levels. After the seminars were completed, residents provided posttest
      assessments and general course evaluations. Utilizing initial survey information,
      we constructed a Marijuana and Medicine introduction curriculum for psychiatry
      PGY 1s. Topics included strains and formulations, pharmacokinetics, the
      endocannabinoid system, local Colorado laws, monitoring, evidence regarding use
      in psychiatric disorders, use in pregnancy, and ethical issues. These topics were
      covered via case-based discussion, interactive quizzes, direct instruction, and
      facilitated discussion. Results: Posttest assessments indicated improvement in
      trainees' confidence and knowledge base and requests for additional instruction
      on topics such as adolescent use. Discussion: The positive posttest assessments
      support the value of incorporating a cannabis curriculum into psychiatric
      training. Now in its second year, the course has been expanded to 4 hours. As
      cannabis is medicalized, it is increasingly important that psychiatrists be able 
      to knowledgably counsel their patients.
CI  - (c) 2020 Thant and Nussbaum.
FAU - Thant, Thida
AU  - Thant T
AD  - Assistant Professor, Department of Psychiatry, University of Colorado School of
      Medicine.
FAU - Nussbaum, Abraham
AU  - Nussbaum A
AD  - Chief Education Officer, Office of Education, Denver Health; Department of
      Psychiatry, University of Colorado School of Medicine.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - Adolescent
MH  - *Cannabis
MH  - Colorado
MH  - Curriculum
MH  - Humans
MH  - *Internship and Residency
MH  - Mental Health
PMC - PMC7373353
OTO - NOTNLM
OT  - *Addiction
OT  - *Cannabinoids
OT  - *Cannabis
OT  - *Case-Based Learning
OT  - *Ethics/Bioethics
OT  - *Marijuana
OT  - *Medical Marijuana
OT  - *Mental Health
OT  - *Pharmacology and Toxicology
OT  - *Psychiatry
OT  - *Psychology and Behavioral Science
EDAT- 2020/07/25 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10923 [doi]
AID - 10923 [pii]
PST - epublish
SO  - MedEdPORTAL. 2020 Jul 15;16:10923. doi: 10.15766/mep_2374-8265.10923.


PMID- 32704469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201210
IS  - 2212-4268 (Print)
IS  - 2212-4268 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Oct-Dec
TI  - Strengthening health care research and academics during and after COVID19
      pandemic- an Indian perspective.
PG  - 343-346
LID - 10.1016/j.jobcr.2020.06.015 [doi]
AB  - The world-wide crisis of COVID-19 pandemic has disrupted daily lives, global
      economies, intra/inter-countries political outlook and educational systems.
      Schools and colleges in India and abroad are under lock-down to maximize social
      distancing and minimize the spread of infection amongst students and teaching
      staff. Health sciences related universities and researchers are forced to adopt
      non-contact teaching and research. Present article highlights the positive impact
      and opportunities provided by COVID-19 crisis to health care research and
      academic set-up. We have compiled ethical, effective and practical guidelines to 
      mitigate the impact on health care related research and academic front during
      these pandemic times in an Indian perspective. These guidelines and management
      suggestions can be modified to suit region based cases and can be applied in
      global perspective also. The suggestions in the current article provide a working
      collaboration of students and teachers to effectively connect on virtual
      platforms to strengthen their research output, giving suggestions of data-sharing
      and rapid review of proposals by online review ethical boards. This time is
      proposed to be used for generating a positive impact on health and research
      sector to use each adversity as an opportunity.
CI  - (c) 2020 Craniofacial Research Foundation. Published by Elsevier B.V. All rights 
      reserved.
FAU - Chowdhry, Aman
AU  - Chowdhry A
AD  - Department of Oral Pathology, Faculty of Dentistry, Jamia Millia Islamia, New
      Delhi, India.
FAU - Kapoor, Priyanka
AU  - Kapoor P
AD  - Department of Orthodontics and Dentofacial Orthopedics, Faculty of Dentistry,
      Jamia Millia Islamia, New Delhi, India.
FAU - Popli, Deepika Bablani
AU  - Popli DB
AD  - Department of Oral Pathology, Faculty of Dentistry, Jamia Millia Islamia, New
      Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - Netherlands
TA  - J Oral Biol Craniofac Res
JT  - Journal of oral biology and craniofacial research
JID - 101619156
PMC - PMC7333619
OTO - NOTNLM
OT  - COVID-19
OT  - Communicable diseases
OT  - Pandemics
OT  - Research
OT  - SARS corona virus
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:01
CRDT- 2020/07/25 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:01 [medline]
AID - 10.1016/j.jobcr.2020.06.015 [doi]
AID - S2212-4268(20)30091-9 [pii]
PST - ppublish
SO  - J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):343-346. doi:
      10.1016/j.jobcr.2020.06.015. Epub 2020 Jul 3.


PMID- 32704336
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1880-487X (Print)
IS  - 1880-487X (Linking)
VI  - 15
IP  - 3
DP  - 2020 Jul
TI  - Interprofessional case conferences to bridge perception gaps regarding ethical
      dilemmas in home-based end-of-life care: a qualitative study.
PG  - 104-115
LID - 10.2185/jrm.2020-002 [doi]
AB  - Objective: The aim of this study was to examine the effectiveness and efficiency 
      of interprofessional case conferences on home-based end-of-life care to bridge
      perceptions gaps regarding ethical dilemmas among different healthcare
      professionals and analyze essential issues extracted the interprofessional
      discussions. Patients and Methods: The participants could spend only a limited
      amount of time after their working hours. Therefore, we shortened and simplified 
      each of three case scenarios so that the discussions do not last longer than 90
      minutes. For the case conferences, we selected 3 cases, which entailed the
      following ethical dilemmas pertaining to home-based end-of-life care: refusal of 
      hospital admission, passive euthanasia, and emergency transport. Participant
      responses were audio-recorded, transcribed, and analyzed using qualitative
      content analysis and Jonsen's four topics approach. Results: A total of 136
      healthcare professionals (11 physicians, 35 nurses, and 90 care workers)
      participated in the case conferences. The physicians, nurses, and care workers
      differed in their perceptions of and attitudes toward each case, but there were
      no interprofessional conflicts. Despite the short duration of each case
      conference (90 minutes), the participants were able to discuss a wide range of
      medical ethical issues that were related to the provision of appropriate
      home-based end-of-life care to older adults. These issues included discrimination
      against older adults (ageism), self-determination, an unmet desire for
      caregiver-patient communication, insufficient end-of-life care skills and
      education, healthcare costs, and legal issues. Conclusion: The physicians,
      nurses, and care workers differed in their perceptions of and attitudes toward
      each case, but there were no interprofessional conflicts.
CI  - (c)2020 The Japanese Association of Rural Medicine.
FAU - Hirakawa, Yoshihisa
AU  - Hirakawa Y
AD  - Department of Public Health and Health Systems, Nagoya University Graduate School
      of Medicine, Japan.
FAU - Chiang, Chifa
AU  - Chiang C
AD  - Department of Public Health and Health Systems, Nagoya University Graduate School
      of Medicine, Japan.
FAU - Muraya, Tsukasa
AU  - Muraya T
AD  - Faculty of Design, Kyushu University Graduate School of Design, Japan.
FAU - Andoh, Hideaki
AU  - Andoh H
AD  - Department of Clinical Nursing, Akita University Graduate School of Health
      Science, Japan.
FAU - Aoyama, Atsuko
AU  - Aoyama A
AD  - Department of Public Health and Health Systems, Nagoya University Graduate School
      of Medicine, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - Japan
TA  - J Rural Med
JT  - Journal of rural medicine : JRM
JID - 101274897
PMC - PMC7369408
OTO - NOTNLM
OT  - advance care planning
OT  - ageism
OT  - interprofessional education
OT  - palliative care
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:01
CRDT- 2020/07/25 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:01 [medline]
AID - 10.2185/jrm.2020-002 [doi]
AID - 2020-002 [pii]
PST - ppublish
SO  - J Rural Med. 2020 Jul;15(3):104-115. doi: 10.2185/jrm.2020-002. Epub 2020 Jul 17.


PMID- 32704266
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 5
DP  - 2020 Jul-Aug
TI  - Comparison of efficacy of Tranexamic Acid Mesotherapy versus 0.9% normal Saline
      for Melasma; A split face study in a Tertiary Care Hospital of Karachi.
PG  - 930-934
LID - 10.12669/pjms.36.5.2379 [doi]
AB  - OBJECTIVES: To compare the efficacy of tranexamic acid mesotherapy versus 0.9%
      normal saline for melasma by split-face study. METHODS: It was a non-randomized
      clinical trial performed at the Dermatology ward of JPMC from September 2018 to
      June 2019 after getting approval from the Ethical Committee. A total of sixty
      patients were recruited in the study, who had symmetrical melasma on their faces.
      Both halves of the face were treated by Injection Tranexamic Acid (TA) with a
      dose of 4mg/ml and Normal Saline (NS) two weekly for twelve weeks. Hemi Modified 
      Melasma Area and Severity Scoring (H-mMASI) was calculated at the start and end
      of the study. Analyses were done by SPSS version 23. P < 0.05 was taken as
      significant. RESULTS: Mean of H-mMASI score was compared on both sides at the end
      of study, which showed significant reduction in mean score from 3.19 +/-2.57 to
      1.52 +/- 1.2 (P < 0.05) on A side as compared to decline in scores on NS side
      from 3.46 +/- 2.7 to 3.45 +/- 2.6 (P > 0.05). Erythema, swelling, and burning
      were documented as temporary side effects on both sides. CONCLUSION: Tranexamic
      Acid (TA) mesotherapy can be considered as the most cost-effective, safe and
      directly observed therapy for melasma which showed significant improvement when
      old prior therapies have failed.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Kaleem, Sana
AU  - Kaleem S
AD  - Dr. Sana Kaleem, MBBS, FCPS II Trainee., Department of Dermatology, Jinnah
      Postgraduate Medical Centre, Karachi, Pakistan.
FAU - Ghafoor, Rabia
AU  - Ghafoor R
AD  - Dr. Rabia Ghafoor, MBBS, FCPS. Assistant Professor, Department of Dermatology,
      Jinnah Postgraduate Medical Centre, Karachi, Pakistan.
FAU - Khan, Sidra
AU  - Khan S
AD  - Dr. Sidra Khan, MBBS, FCPS II Trainee., Department of Dermatology, Jinnah
      Postgraduate Medical Centre, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7372652
OTO - NOTNLM
OT  - Melasma
OT  - Mesotherapy
OT  - Tranexamic acid
COIS- Conflict of Interest: No conflict of interest.
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:01
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:01 [medline]
AID - 10.12669/pjms.36.5.2379 [doi]
AID - PJMS-36-930 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Jul-Aug;36(5):930-934. doi: 10.12669/pjms.36.5.2379.


PMID- 32703842
OWN - NLM
STAT- Publisher
LR  - 20200724
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 23
TI  - Pharmaceutical industry sponsorship of academic conferences: ethics of conflict
      of interest.
LID - medethics-2020-106224 [pii]
LID - 10.1136/medethics-2020-106224 [doi]
AB  - Sponsorship of medical conferences by the pharmaceutical industry has led to many
      ethical issues, especially in resource-poor developing countries. The core issue 
      in these instances is to reduce or avoid conflicts of interests (COIs). COI is a 
      set of circumstances that creates a risk that professional judgment or actions
      regarding a primary interest will be unduly influenced by secondary interests.
      Disruption of social trust should also be considered. This deontological approach
      should be complemented by a consequentialist approach. Towards this, the concept 
      of distal interests (DI) is introduced. DI lies beyond the immediately visible
      COIs and the consequences of immediate decisions. They are 'distal' in time or
      place: 'DI in time' means consequence of the decision in future scenarios, while 
      'DI in space' means those that impinge on other institutions or bodies. In
      judging the consequences, it is also necessary to consider the reality of the
      existing relationship between the pharmaceutical industry and organisers of
      conferences. In more developed countries, these relationships are governed by
      stricter regulations, adherence to codes of conduct by both parties and stronger 
      institutional oversights. In contrast, developing countries such as Sri Lanka the
      regulatory environment is lax and the demarcation of interests between the
      pharmaceutical industry and the medical profession is considerably blurred.
      Therefore, establishing clear rules of engagement between the stakeholders should
      be considered as an attempt to clear the muddy waters. The paper proposes a set
      of guidelines to capture these approaches.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Jayasinghe, Saroj
AU  - Jayasinghe S
AUID- ORCID: http://orcid.org/0000-0003-1460-6073
AD  - Department of Medical Humanities and Department of Clinical Medicine, Faculty of 
      Medicine, University of Colombo, Colombo 00800, Sri Lanka
      saroj@clinmed.cmb.ac.lk.
LA  - eng
PT  - Journal Article
DEP - 20200723
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - education for health care professionals
COIS- Competing interests: I was appointed as the Co-Chairperson of the Organizing
      Committee of the Colombo Medical Congress 2020 which was described in the case
      study.
EDAT- 2020/07/25 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/03/21 00:00 [received]
PHST- 2020/05/23 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
AID - medethics-2020-106224 [pii]
AID - 10.1136/medethics-2020-106224 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 23. pii: medethics-2020-106224. doi:
      10.1136/medethics-2020-106224.


PMID- 32703214
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20210604
IS  - 1472-698X (Electronic)
IS  - 1472-698X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 23
TI  - International norm development and change: can international law play a
      meaningful role in curbing the lifestyle disease pandemic?
PG  - 18
LID - 10.1186/s12914-020-00239-7 [doi]
AB  - BACKGROUND: The magnitude of the noncommunicable epidemic is difficult to
      overstate. The projected cost of the epidemic is substantial. It
      disproportionately affects people in low- and middle-income countries as well as 
      poorer and marginalised communities in high-income countries. The international
      community has taken various steps to address the four modifiable risk factors
      causing the majority of noncommunicable diseases (NCDs), however, action has so
      far fallen short of expectations. Both analysts and international institutions
      are advocating the adoption of a new international legal norm to address the NCD 
      crisis. MAIN TEXT: Drawing on existing knowledge from international relations and
      international legal studies, this article argues that a new international treaty 
      is not only currently improbable, but also not strictly desirable. In-depth
      critical analysis and reflection is needed regarding the strengths and weaknesses
      of a legal approach to addressing the NCD pandemic. The argument is set out in
      three sections - the first reviews contributions of agentic constructivism, which
      focus on the process of normative emergence and change, and draws on empirical
      examples to highlight overlooked aspects of normative development and how they
      relate to NCD politics. The second engages with the critique of legal principles.
      Critical approaches to law seek to expose the myths that legal principles are
      neutral, objective, good. The third section discusses the characteristics of
      practice in the NCD field and its implications on process and principles for the 
      pursuit of a legal solution to the NCD crisis. CONCLUSIONS: Any advocacy for an
      international norm to address NCDs needs to be nuanced and demonstrate awareness 
      of the nature and character of both the norm development process and resulting
      international legal principles. As analysts, we are responsible for advocating
      inclusive and ethical norms, but also for highlighting the implications of
      inequalities and differences between and within states and societies. There may
      be a viable international legal instrument that would support dedicated policies 
      to curb the NCD epidemic, but such an instrument needs to be actively advocated
      for and negotiated with a wide range of stakeholders, navigating a complex
      international framework of existing norms and conflicting, powerful interests.
FAU - Stoeva, Preslava
AU  - Stoeva P
AUID- ORCID: 0000-0002-8626-4079
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK.
      Preslava.stoeva@lshtm.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200723
PL  - England
TA  - BMC Int Health Hum Rights
JT  - BMC international health and human rights
JID - 101088678
SB  - IM
MH  - Developing Countries
MH  - Humans
MH  - *International Cooperation
MH  - *International Law
MH  - *Life Style
MH  - *Noncommunicable Diseases/epidemiology/prevention & control
MH  - *Politics
MH  - Poverty
MH  - Risk Factors
MH  - *Social Norms
PMC - PMC7376856
OTO - NOTNLM
OT  - *Agentic constructivism
OT  - *Critical legal studies
OT  - *International legal principles
OT  - *International relations
OT  - *Noncommunicable diseases
OT  - *Norm development
OT  - *Politics
EDAT- 2020/07/25 06:00
MHDA- 2021/06/05 06:00
CRDT- 2020/07/25 06:00
PHST- 2019/04/05 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
AID - 10.1186/s12914-020-00239-7 [doi]
AID - 10.1186/s12914-020-00239-7 [pii]
PST - epublish
SO  - BMC Int Health Hum Rights. 2020 Jul 23;20(1):18. doi: 10.1186/s12914-020-00239-7.


PMID- 32702927
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210902
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 29
DP  - 2020 Jul 17
TI  - A systematic review and meta-analysis of acupuncture treatment for oral ulcer.
PG  - e21314
LID - 10.1097/MD.0000000000021314 [doi]
AB  - BACKGROUND: Oral ulcers (OU) is a common oral mucosal disease manifested with
      obvious pain; in some studies, the efficacy of acupuncture in OU has been
      confirmed, but the systematic reviews and meta-analyses for them are lacking. Our
      aim is to evaluate the efficacy and safety of acupuncture in the treatment of OU.
      METHODS: Relevant randomized controlled trials (RCTs), quasi RCTs and non-RCTs
      will be identified by systematic searching from the following electronic
      databases: PubMed, Embase, the Cochrane Library, Chinese Biomedical Literature
      Database, China National Knowledge Infrastructure, China Science and Technology
      Journal database, and Wanfang Data (since inception of the databases to present).
      In addition, ongoing trials will be retrieved from the Chinese Clinical Trial
      Register, World Health Organization International Clinical Trials Registry
      Platform, Clinical Trials, and The Clinical Trials Register. Grey literature will
      be also taken into consideration, including academic dissertation, minutes of the
      meeting from Chinese Biomedical Literature Database, China National Knowledge
      Infrastructure, China Science and Technology Journal database, and Wanfang Data. 
      There are no language restrictions. RESULTS: Ethical approval is not required
      because this study is based on published papers. After peer-review, the study
      will be disseminated in scientific journals and conferences. CONCLUSION: This
      systematic review will provide evidence for the efficacy and safety of
      acupuncture for Oral ulcers. TRIAL REGISTRATION NUMBER: CRD42020144911.
FAU - Yan, Hang
AU  - Yan H
AUID- ORCID: 0000-0002-4106-2115
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Jin, Zhao
AU  - Jin Z
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
FAU - Jin, Wenqin
AU  - Jin W
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zhong, Yanmei
AU  - Zhong Y
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
FAU - Ai, Huangping
AU  - Ai H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wu, Yeke
AU  - Wu Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Xu, Qianrong
AU  - Xu Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Bai, Xiaoyan
AU  - Bai X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Liu, Donghao
AU  - Liu D
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
FAU - Nie, Wenhan
AU  - Nie W
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zuo, Yuling
AU  - Zuo Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
EIN - Medicine (Baltimore). 2020 Aug 14;99(33):e21984. PMID: 32872085
MH  - *Acupuncture Therapy/methods
MH  - Humans
MH  - Oral Ulcer/*therapy
MH  - Treatment Outcome
PMC - PMC7373506
EDAT- 2020/07/25 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000021314 [doi]
AID - 00005792-202007170-00123 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 17;99(29):e21314. doi:
      10.1097/MD.0000000000021314.


PMID- 32702909
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 29
DP  - 2020 Jul 17
TI  - Viral shedding in patients with hand, foot and mouth disease induced by EV71,
      CA16, or CA6: A protocol for systematic review and meta analysis.
PG  - e21258
LID - 10.1097/MD.0000000000021258 [doi]
AB  - INTRODUCTION: Hand, foot, and mouth disease (HFMD) has been an important public
      health concern worldwide, especially in the Asia-Pacific region. Unfortunately,
      the effect of current measures on preventing and controlling HFMD may be limited.
      Isolation of infectious sources is reported as an important way to prevent and
      control this disease. The isolation period is determined on the basis of duration
      of viral shedding in patients with HFMD. However, the results of previous
      researches on duration of viral shedding remain controversial. Here, we present a
      protocol of a systematic review and single-arm meta-analysis for assessing the
      duration of viral shedding in patients with HFMD induced by Enterovirus 71
      (EV71), Coxsackievirus A16 (CA16), or Coxsackievirus A6 (CA6). METHODS AND
      ANALYSIS: A comprehensive literature search will be performed in PubMed, EMBASE, 
      the Cochrane library, Chinese National Knowledge Infrastructure (CNKI), Chinese
      Biomedical Literature Database (CBM), and Wanfang Database, covering the period
      from inception to May 1, 2019. Point estimate of positive rate with corresponding
      95% confidence intervals (CIs) of EV71, CA16, or CA6 in HFMD patients' fecal or
      throat samples will be carried out using STATA 14.0. Subgroup analyses will be
      performed for mild cases, severe cases, and close contacts. Sensitive analysis
      will also be performed to evaluate the influences of individual studies on the
      final effect by exclusion of a few articles of poor quality. We will assess the
      risk of bias for the final studies included in our meta-analysis using previously
      available tools and the modified risk of bias tool. RESULTS: The results of this 
      systematic review and meta-analysis will be published in a peer-reviewed journal.
      CONCLUSION: To the best of our knowledge, this paper will be the first systematic
      review and meta-analysis for assessing the duration of viral shedding in patients
      with HFMD induced by EV71, CA16, or CA6. The conclusions drawn from this review
      will provide the scientific basis to formulate the isolation period of HFMD.
      ETHICS AND DISSEMINATION: Ethical review is not required as this article is for a
      systematic review since there is no direct involvement of patients in the whole
      process. We will publish the results of this systematic review and meta-analysis 
      of single-arm studies in a peer-reviewed journal. REGISTRATION NUMBER: Prospero
      CRD42020139999.
FAU - Li, Xianzhi
AU  - Li X
AD  - Department of Epidemiology and Health Statistics, West China School of Public
      Health and West China Fourth Hospital, Sichuan University, Chengdu.
FAU - Wang, Qiuxia
AU  - Wang Q
AD  - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan.
FAU - Chen, Zhenhua
AU  - Chen Z
AD  - Department of Microbiology Laboratory, Chengdu Municipal Center for Disease
      Control and Prevention, Sichuan, China.
FAU - Duan, Xiaoxia
AU  - Duan X
AD  - Department of Epidemiology and Health Statistics, West China School of Public
      Health and West China Fourth Hospital, Sichuan University, Chengdu.
FAU - Han, Yutong
AU  - Han Y
AD  - Department of Epidemiology and Health Statistics, West China School of Public
      Health and West China Fourth Hospital, Sichuan University, Chengdu.
FAU - Luan, Rongsheng
AU  - Luan R
AD  - Department of Epidemiology and Health Statistics, West China School of Public
      Health and West China Fourth Hospital, Sichuan University, Chengdu.
FAU - Long, Lu
AU  - Long L
AD  - Department of Epidemiology and Health Statistics, West China School of Public
      Health and West China Fourth Hospital, Sichuan University, Chengdu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Enterovirus/*physiology
MH  - Enterovirus A, Human/*physiology
MH  - Hand, Foot and Mouth Disease/*virology
MH  - Humans
MH  - Time Factors
MH  - *Virus Shedding
PMC - PMC7373557
EDAT- 2020/07/25 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000021258 [doi]
AID - 00005792-202007170-00104 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 17;99(29):e21258. doi:
      10.1097/MD.0000000000021258.


PMID- 32702893
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220716
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 29
DP  - 2020 Jul 17
TI  - The effectiveness and safety of acupuncture for allergic rhinitis: Protocol for
      an overview of systematic reviews and meta-analyses.
PG  - e21225
LID - 10.1097/MD.0000000000021225 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR) is one of the most common allergic disorders
      globally. Several systematic reviews and meta-analyses have reported the
      effectiveness of acupuncture for patients with AR. However, the evidence has not 
      been systematically synthesized. This overview aims to map, synthesize, and
      assess the reliability of evidence generated from these systematic reviews (SRs) 
      and meta-analyses of acupuncture for AR. METHODS: A Comprehensive literature
      search will be conducted through the PubMed, Embase, the Cochrane Library of
      Systematic Reviews, the China National Knowledge Infrastructure Database, Wanfang
      Database, Chinese Biomedical Literature Database, and Chinese Scientific Journal 
      Database from inception until January 2020. Additionally, the PROSPERO database
      and the reference list of included studies will be searched for unpublished,
      ongoing, or recently completed SRs and meta-analyses. The reviewers will identify
      reviews independently and extract data according to the methodological guidelines
      for overviews provided by the Cochrane Collaboration. The risk of bias will be
      assessed based on the Risk of Bias in Systematic Reviews. The methodological and 
      reporting quality of the included reviews will be assessed using the Assessing
      the Methodological Quality of Systematic Reviews (V.2) tool and the Preferred
      Reporting Items for Systematic Review and Meta-Analyses statement. The outcomes
      of interest include total nasal symptom score, rhinoconjunctivitis
      quality-of-life questionnaire, immunoglobulin E, visual analog scale, laboratory 
      examination, and side effects. The quality of evidence of outcomes will be
      evaluated using the Grading of Recommendations Assessment, Development and
      Evaluation. The evidence will be synthesized where appropriate based on patient
      subgroups and outcomes. ETHICS AND DISSEMINATION: Ethical approval is not
      required for overviews. We plan to publish results in peer-reviewed journals and 
      present at international and national academic, clinical, and patient
      conferences. RESULTS: The results will be published in a peer-reviewed journal.
      CONCLUSION: This overview will provide comprehensive evidence of acupuncture for 
      patients with AR. PROSPERO REGISTRATION NUMBER: CRD42019140756.
FAU - Yang, Jun
AU  - Yang J
AD  - Jiangxi University of TCM.
FAU - Xiong, Jun
AU  - Xiong J
AD  - The Affiliated Hospital of Jiangxi University of TCM, Nanchang, Jiangxi, China.
FAU - Wang, Xue
AU  - Wang X
AD  - Jiangxi University of TCM.
FAU - Yuan, Ting
AU  - Yuan T
AD  - Jiangxi University of TCM.
FAU - Fu, Yong
AU  - Fu Y
AD  - The Affiliated Hospital of Jiangxi University of TCM, Nanchang, Jiangxi, China.
FAU - Jiang, Yunfeng
AU  - Jiang Y
AD  - The Affiliated Hospital of Jiangxi University of TCM, Nanchang, Jiangxi, China.
FAU - Zhou, Xiaohong
AU  - Zhou X
AD  - The Affiliated Hospital of Jiangxi University of TCM, Nanchang, Jiangxi, China.
FAU - Liao, Kai
AU  - Liao K
AD  - The Affiliated Hospital of Jiangxi University of TCM, Nanchang, Jiangxi, China.
FAU - Xu, Lingling
AU  - Xu L
AD  - The Affiliated Hospital of Jiangxi University of TCM, Nanchang, Jiangxi, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Rhinitis, Allergic/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7373564
EDAT- 2020/07/25 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000021225 [doi]
AID - 00005792-202007170-00088 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 17;99(29):e21225. doi:
      10.1097/MD.0000000000021225.


PMID- 32702830
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 29
DP  - 2020 Jul 17
TI  - Healthcare access for autistic adults: A systematic review.
PG  - e20899
LID - 10.1097/MD.0000000000020899 [doi]
AB  - BACKGROUND: People with autism spectrum disorder (ASD) have an increased
      susceptibility for many chronic health conditions compared with their peers. An
      increasing number of adolescents are transitioning from pediatric to adult
      healthcare services. Thus, being able to access appropriate healthcare services
      that can not only address specific needs of the person but enable them to better 
      manage healthcare conditions and decrease the development of preventable disease 
      is necessary. A systematic review was conducted to identify barriers and enablers
      of healthcare access for autistic adults. METHODS: The studies included in the
      review were quantitative and qualitative and were published between 2003 and
      2019. The participants for the review are considered to be adults (over 18 years 
      of age) with a primary diagnosis of ASD. RESULTS: In total, 1290 studies were
      initially identified and 13 studies were included based on the inclusion and
      exclusion criteria outlined in a previous protocol paper. The analysis of these
      studies identified areas of concern to access appropriate healthcare, such as
      clinician knowledge, the environment, and life events. CONCLUSION: Identifying
      the barriers to healthcare, highlights ways healthcare services can regulate
      scope of practice, the physical environment, and the process of managing health
      conditions, thus, autistic adults can strive for optimal health. This review
      contributes to peer-reviewed evidence for future research and up-to-date
      information when developing and piloting health interventions for autistic
      adults. ETHICS AND DISSEMINATION: There are no human participants, data, or
      tissue being directly studied for the purposes of the review; therefore, ethics
      approval and consent to participate is not applicable. REGISTRATION AND STATUS:
      PROSPERO 2018 CRD42018116093.
FAU - Calleja, Shenae
AU  - Calleja S
AD  - Faculty of Health, Arts and Design, Swinburne University of Technology, Hawthorn.
FAU - Islam, Fakir M Amirul
AU  - Islam FMA
FAU - Kingsley, Jonathan
AU  - Kingsley J
FAU - McDonald, Rachael
AU  - McDonald R
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - *Autism Spectrum Disorder
MH  - Clinical Competence
MH  - Communication Barriers
MH  - Delivery of Health Care
MH  - Environment
MH  - *Health Services Accessibility
MH  - Humans
MH  - Needs Assessment
MH  - Transition to Adult Care
PMC - PMC7373620
EDAT- 2020/07/25 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000020899 [doi]
AID - 00005792-202007170-00025 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 17;99(29):e20899. doi:
      10.1097/MD.0000000000020899.


PMID- 32702822
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 29
DP  - 2020 Jul 17
TI  - Efficacy of integrative Traditional Chinese and Western medicine for the
      treatment of patients infected with 2019 novel coronavirus (COVID-19): A protocol
      for systematic review and meta analysis.
PG  - e20781
LID - 10.1097/MD.0000000000020781 [doi]
AB  - BACKGROUND: No specific anti-virus drugs or vaccines have been available for the 
      treatment of COVID-19. Integrative traditional Chinese and western medicine has
      been proposed as a therapeutic option with substantial applications in China.
      This protocol is proposed for a systematic review and meta-analysis that aims to 
      evaluate the efficacy of integrative traditional Chinese and western medicine
      treatment on patients with COVID-19. METHODS: Ten databases including PubMed,
      EMBASE, Cochrane Library, CIHAHL, Web of Science, Chinese National Knowledge
      Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang
      database, China Biomedical Literature Database (CBM) and Chinese Biomedical
      Literature Service System (SinoMed) will be searched. All published randomized
      controlled trials, clinical controlled trials, case-control, and case series that
      meet the pre-specified eligibility criteria will be included. Primary outcome
      measures include mortality, clinical recovery rate, duration of fever,
      progression rate from mild or moderate to severe, improvement of symptoms,
      biomarkers of laboratory examination and changes in computed tomography.
      Secondary outcomes include dosage of hormonotherapy, incidence and severity of
      adverse events and quality of life. Study selection, data extraction and
      assessment of bias risk will be conducted by 2 reviewers independently. RevMan
      software (V.5.3.5) will be used to perform data synthesis. Subgroup and
      sensitivity analysis will be performed when necessary. The strength of evidence
      will be assessed by the GRADE system. RESULTS: This study will provide a
      well-reported and high-quality synthesis on the efficacy of integrative
      traditional Chinese and western medicine treatment on patients with COVID-19.
      CONCLUSION: This systematic review protocol will be helpful for providing
      evidence of whether integrative traditional Chinese and western medicine
      treatment is an effective therapeutic approach for patients with COVID-19. ETHICS
      AND DISSEMINATION: Ethical approval is unnecessary as no individual patient or
      privacy data is collected. The results of this study will be disseminated in a
      peer-reviewed scientific journal and/or conference presentation. SYSTEMATIC
      REVIEW REGISTRATION: PROSPERO CRD42020167205.
FAU - Liu, Dan
AU  - Liu D
AUID- ORCID: 0000-0001-7707-9341
AD  - West China Hospital, Sichuan University, South Renmin Road, Wu Hou District,
      Chengdu.
FAU - You, Yanyan
AU  - You Y
AD  - West China Hospital, Sichuan University, South Renmin Road, Wu Hou District,
      Chengdu.
FAU - Chen, Yunhui
AU  - Chen Y
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Tang, Songqi
AU  - Tang S
AD  - College of Traditional Chinese Medicine, Hainan Medical University, Haikou,
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
SB  - IM
MH  - Betacoronavirus/*isolation & purification
MH  - Biomarkers/analysis
MH  - COVID-19
MH  - Case-Control Studies
MH  - China/epidemiology
MH  - Coronavirus Infections/diagnostic imaging/epidemiology/mortality/*therapy
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Outcome Assessment, Health Care
MH  - Pandemics
MH  - Pneumonia, Viral/diagnostic imaging/epidemiology/mortality/*therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
PMC - PMC7373591
EDAT- 2020/07/25 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
AID - 10.1097/MD.0000000000020781 [doi]
AID - 00005792-202007170-00017 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 17;99(29):e20781. doi:
      10.1097/MD.0000000000020781.


PMID- 32702818
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 29
DP  - 2020 Jul 17
TI  - Clinical efficacy and safety of Chinese herbal medicine for the treatment of
      patients with early diabetic nephropathy: A protocol for systematic review and
      meta-analysis.
PG  - e20678
LID - 10.1097/MD.0000000000020678 [doi]
AB  - BACKGROUND: Diabetic nephropathy (DN) is among the common and serious
      complications of diabetes and is also a major cause of end-stage kidney disease. 
      Early DN is also called diabetic microalbumin period, the main treatment is in
      the control of blood sugar on the basis of kidney protection and urine lowering
      protein. There are few effective methods of western medicine treatment, and most 
      of them are accompanied by adverse reactions. But some studies have shown that
      traditional Chinese medicine has achieved the curative effect and has certain
      superiority. However, there are few systematic reviews on the treatment of
      traditional Chinese herbal medicine for early DN currently. Therefore, this study
      conducted a systematic review of clinical efficacy and safety of Chinese herbal
      medicine for the treatment of patients with early DN, aim to comprehensively
      analyze the role of traditional Chinese herbal medicine in the treatment of early
      DN. METHODS AND ANALYSIS: The protocol of this systematic review and
      meta-analysis was registered on the INPLASY website
      (https://inplasy.com/inplasy-2020-4-0139/) and INPLASY registration number is
      INPLASY202040139. A systematic literature search will be conducted in 3 English
      database and 4 Chinese databases with a language limitation of English and
      Chinese. Search for clinical research literature on Chinese herbal medicine
      treatment of DN published in domestic and foreign biomedical journals. The time
      is limited from January 2010 to February 2020. We will investigate heterogeneity 
      across studies and publication bias. To assess the risk of bias and quality of
      the included studies, we will use the Cochrane Collaboration's ROB tool.
      According to the relevant standards in the Cochrane Intervention System
      Evaluation Manual, it will be divided into low risk, high risk, and unclear. We
      will also use the RevMan 5.3 software and Stata 13.0 software for meta-analysis
      of the effectiveness and symptom scores of DN proteinuria. ETHICS AND
      DISSEMINATION: The ethical considerations are not required because the systematic
      review is based on published studies. The systematic review and meta-analysis
      will be published in a peer-reviewed Journal.
FAU - Yang, Xiaomei
AU  - Yang X
AUID- ORCID: 0000-0002-8722-9267
AD  - School of Clinical Medicine.
FAU - Hu, Chenling
AU  - Hu C
AD  - School of Clinical Medicine.
FAU - Wang, Shengju
AU  - Wang S
AD  - School of Clinical Medicine.
FAU - Chen, Qiu
AU  - Chen Q
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Diabetes Complications/epidemiology
MH  - Diabetic Nephropathies/classification/complications/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/etiology
MH  - Male
MH  - Medicine, Chinese Traditional/*methods
MH  - Proteinuria/diagnosis/etiology/urine
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
PMC - PMC7373501
EDAT- 2020/07/25 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [entrez]
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000020678 [doi]
AID - 00005792-202007170-00013 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 17;99(29):e20678. doi:
      10.1097/MD.0000000000020678.


PMID- 32702721
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220721
DP  - 2020 Jul 16
TI  - Online Education for Undergraduate Health Professional Education during the
      COVID-19 Pandemic: Attitudes, Barriers, and Ethical Issues.
LID - rs.3.rs-42336 [pii]
LID - 10.21203/rs.3.rs-42336/v1 [doi]
AB  - Background : The online teaching demand has increased tremendously to promote the
      implementation of online teaching-leaning system to meet the need of students
      during the outbreaks of emerging infectious disease. This study aims to explore
      whether the pandemic of COVID-19, which requires universities to rapidly offer
      online learning, will affect attitudes about online education for undergraduate
      health sciences students. Also, it investigates the barriers for using online
      tools. Method : A cross-sectional survey using online social media was used to
      recruit eligible participants. The data for this study were focused on students' 
      experiences utilizing an online education method offered by the Jordanian
      government universities. This study is utilizing newly developed measuring tools 
      that are expected to enable students to evaluate online teaching in terms of
      their own learning progress. Results : A total of 1,210 participants agreed to
      complete the online survey questionnaire. The mean score preparedness and
      attitude toward online education was average. The majority of students agreed
      that online courses helped assign reading and homework time better than on-campus
      approach (75.0%) and felt comfortable to actively communicate with my classmates 
      and instructors online. Zoom and eLearning were the most common online platforms 
      utilized by students. The geographic locations, lack of past experience on using 
      online tools, and lack of past experience on using online tools were identified
      by students as the main barrier to online educations. Conclusions : Although the 
      pandemic of COVID-19 appeared as uncommon catalyst for promoting eLearning,
      further research is needed to assess whether learners are ready and willing to
      make greater use of online education to obtain high quality teaching and learning
      opportunities, which could totally change educators' and students' attitudes and 
      impression, and subsequently the general themes of online education.
FAU - Muflih, Suhaib
AU  - Muflih S
AUID- ORCID: https://orcid.org/0000-0002-6214-3168
FAU - Abuhammad, Sawsan
AU  - Abuhammad S
FAU - Karasneh, Reema
AU  - Karasneh R
FAU - Al-Azzam, Sayer
AU  - Al-Azzam S
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
FAU - Muflih, Mohammad
AU  - Muflih M
LA  - eng
GR  - R25 TW010026/TW/FIC NIH HHS/United States
PT  - Preprint
DEP - 20200716
PL  - United States
TA  - Res Sq
JT  - Research square
JID - 101768035
PMC - PMC7373140
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.21203/rs.3.rs-42336/v1 [doi]
PST - epublish
SO  - Res Sq. 2020 Jul 16. doi: 10.21203/rs.3.rs-42336/v1.


PMID- 32702651
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 111
DP  - 2020 Oct
TI  - Evaluation of the efficiency of the web-based epilepsy education program (WEEP)
      for youth with epilepsy and parents: A randomized controlled trial.
PG  - 107142
LID - S1525-5050(20)30321-8 [pii]
LID - 10.1016/j.yebeh.2020.107142 [doi]
AB  - BACKGROUND: When youth with epilepsy and their parents have insufficient
      information about the disease, they are known to have more problems with disease 
      management, and they show poor compliance. Providing accurate, reliable, and
      accessible information with no time and space limitations is extremely important 
      for individuals with epilepsy as well as for their caregivers. AIM: In this
      study, we aimed to evaluate the content, quality, usability, and efficacy of our 
      web-based epilepsy education program (WEEP) that we developed for youth with
      epilepsy and their parents. METHODS: The sample of this randomized controlled
      trail was composed of youth with epilepsy who were between the ages of 9 and
      18years and their parents who had applied to the Pediatric Neurology Unit of a
      tertiary healthcare hospital in Turkey between November 2017 and April 2018. This
      study was conducted in two stages: (1) the preparation phase, during which we
      developed a WEEP for epilepsy, and tested its content, quality, and usability;
      and (2) the implementation phase, during which we evaluated the efficacy of the
      website by assessing users' knowledge of epilepsy, seizure self-efficacy,
      attitudes, and e-health literacy. Before the implementation phase, data
      collection tools were used to test the prior knowledge of epilepsy of the
      participants and control groups. Next, the youth and their parents were asked to 
      use the WEEP for 12weeks, while a control group was not provided with additional 
      education tools. Written consent was obtained from the participants prior to the 
      study in addition to obtaining approval from the ethics committee and permission 
      from the institution where the research was conducted. The data were finally
      analyzed using SAS 9.4 software. RESULTS: During the preparation phase, the
      website was developed and tested for content, quality, and usability. The WEEP
      was graded 72.7+/-3.4 points by experts, 92.4+/-1.63 by youth with epilepsy, and 
      92.31+/-1.94 by the parents. During the implementation phase, the efficacy of the
      web site was evaluated through the assessment of participants' scores. We found
      that the mean knowledge, seizure self-efficacy, attitude, and e-health literacy
      scores of youth with epilepsy in the experimental group had significantly
      increased after the WEEP (p<0.05). An increase in the scores of knowledge,
      anxiety, self-management, and e-health literacy scale was also found among the
      parents in the intervention group (p<0.05). CONCLUSION: The content, quality, and
      usability of the WEEP were adequate and effective in improving knowledge,
      self-efficacy, attitudes, and e-health literacy of youth with epilepsy as well as
      those of their parents.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Tutar Guven, Serife
AU  - Tutar Guven S
AD  - Department of Pediatric Nursing, Faculty of Health Sciences, Suleyman Demirel
      University, Isparta, Turkey. Electronic address: serifeguven@sdu.edu.tr.
FAU - Isler Dalgic, Aysegul
AU  - Isler Dalgic A
AD  - Department of Pediatric Nursing, Faculty of Nursing, Akdeniz University, Antalya,
      Turkey. Electronic address: aisler@akdeniz.edu.tr.
FAU - Duman, Ozgur
AU  - Duman O
AD  - Department of Pediatric Neurology, Faculty of Medicine, Akdeniz University,
      Antalya, Turkey. Electronic address: oduman@akdeniz.edu.tr.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200721
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Epilepsy/epidemiology/psychology/*therapy
MH  - Female
MH  - Health Literacy/methods/standards
MH  - Humans
MH  - Internet/standards
MH  - Male
MH  - Parents/*education/psychology
MH  - Patient Education as Topic/methods/*standards
MH  - Self Efficacy
MH  - Self-Management/*education/methods/psychology
MH  - Telemedicine/methods/*standards
MH  - Treatment Outcome
MH  - Turkey/epidemiology
OTO - NOTNLM
OT  - *Parent education
OT  - *Pediatric nursing
OT  - *Web-based epilepsy education program
OT  - *Youth with epilepsy
COIS- Declaration of competing interest The authors declare no conflict of interest in 
      this study.
EDAT- 2020/07/24 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/07/24 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - S1525-5050(20)30321-8 [pii]
AID - 10.1016/j.yebeh.2020.107142 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2020 Oct;111:107142. doi: 10.1016/j.yebeh.2020.107142. Epub 2020 
      Jul 21.


PMID- 32702587
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 260
DP  - 2020 Sep
TI  - The ethics of AI in health care: A mapping review.
PG  - 113172
LID - S0277-9536(20)30391-9 [pii]
LID - 10.1016/j.socscimed.2020.113172 [doi]
AB  - This article presents a mapping review of the literature concerning the ethics of
      artificial intelligence (AI) in health care. The goal of this review is to
      summarise current debates and identify open questions for future research. Five
      literature databases were searched to support the following research question:
      how can the primary ethical risks presented by AI-health be categorised, and what
      issues must policymakers, regulators and developers consider in order to be
      'ethically mindful? A series of screening stages were carried out-for example,
      removing articles that focused on digital health in general (e.g. data sharing,
      data access, data privacy, surveillance/nudging, consent, ownership of health
      data, evidence of efficacy)-yielding a total of 156 papers that were included in 
      the review. We find that ethical issues can be (a) epistemic, related to
      misguided, inconclusive or inscrutable evidence; (b) normative, related to unfair
      outcomes and transformative effectives; or (c) related to traceability. We
      further find that these ethical issues arise at six levels of abstraction:
      individual, interpersonal, group, institutional, and societal or sectoral.
      Finally, we outline a number of considerations for policymakers and regulators,
      mapping these to existing literature, and categorising each as epistemic,
      normative or traceability-related and at the relevant level of abstraction. Our
      goal is to inform policymakers, regulators and developers of what they must
      consider if they are to enable health and care systems to capitalise on the dual 
      advantage of ethical AI; maximising the opportunities to cut costs, improve care,
      and improve the efficiency of health and care systems, whilst proactively
      avoiding the potential harms. We argue that if action is not swiftly taken in
      this regard, a new 'AI winter' could occur due to chilling effects related to a
      loss of public trust in the benefits of AI for health care.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Morley, Jessica
AU  - Morley J
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS, UK.
      Electronic address: jessica.morley@oii.ox.ac.uk.
FAU - Machado, Caio C V
AU  - Machado CCV
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS, UK.
FAU - Burr, Christopher
AU  - Burr C
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS, UK.
FAU - Cowls, Josh
AU  - Cowls J
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS, UK;
      Alan Turing Institute, British Library, 96 Euston Rd, London, NW1 2DB, UK.
FAU - Joshi, Indra
AU  - Joshi I
AD  - NHSX, Skipton House, 80 London Road, SE1 6LH, UK.
FAU - Taddeo, Mariarosaria
AU  - Taddeo M
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS, UK;
      Alan Turing Institute, British Library, 96 Euston Rd, London, NW1 2DB, UK;
      Department of Computer Science, University of Oxford, 15 Parks Rd, Oxford, OX1
      3QD, UK.
FAU - Floridi, Luciano
AU  - Floridi L
AD  - Oxford Internet Institute, University of Oxford, 1 St Giles, Oxford, OX1 3JS, UK;
      Alan Turing Institute, British Library, 96 Euston Rd, London, NW1 2DB, UK;
      Department of Computer Science, University of Oxford, 15 Parks Rd, Oxford, OX1
      3QD, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200715
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - *Artificial Intelligence
MH  - *Delivery of Health Care
MH  - Humans
MH  - Morals
MH  - Ownership
MH  - Privacy
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Ethics
OT  - *Health policies
OT  - *Healthcare
OT  - *Machine learning
EDAT- 2020/07/24 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/06/22 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - S0277-9536(20)30391-9 [pii]
AID - 10.1016/j.socscimed.2020.113172 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Sep;260:113172. doi: 10.1016/j.socscimed.2020.113172. Epub 2020
      Jul 15.


PMID- 32702394
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20210110
IS  - 1873-1570 (Electronic)
IS  - 0300-9572 (Linking)
VI  - 154
DP  - 2020 Sep
TI  - Coronavirus disease 2019 and ethical considerations for extracorporeal
      cardiopulmonary resuscitation.
PG  - 127-128
LID - S0300-9572(20)30288-4 [pii]
LID - 10.1016/j.resuscitation.2020.06.040 [doi]
FAU - Mentzelopoulos, Spyros D
AU  - Mentzelopoulos SD
AD  - First Department of Intensive Care Medicine, University of Athens Medical School,
      Evaggelismos General Hospital, Athens, Greece. Electronic address:
      sdmentzelopoulos@yahoo.com.
FAU - Bossaert, Leo
AU  - Bossaert L
AD  - University of Antwerp, Belgium; European Resuscitation Council, Niel, Belgium.
FAU - Greif, Robert
AU  - Greif R
AD  - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University
      Hospital, University of Bern, Bern, Switzerland; School of Medicine, Sigmund
      Freud University Vienna, Vienna, Austria.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200720
PL  - Ireland
TA  - Resuscitation
JT  - Resuscitation
JID - 0332173
SB  - IM
CON - Resuscitation. 2020 Aug;153:6-7. PMID: 32492456
CIN - Resuscitation. 2020 Sep;154:129-130. PMID: 32707143
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Cardiopulmonary Resuscitation
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7370914
EDAT- 2020/07/24 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/06/18 00:00 [received]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - S0300-9572(20)30288-4 [pii]
AID - 10.1016/j.resuscitation.2020.06.040 [doi]
PST - ppublish
SO  - Resuscitation. 2020 Sep;154:127-128. doi: 10.1016/j.resuscitation.2020.06.040.
      Epub 2020 Jul 20.


PMID- 32702213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1738-1088 (Print)
IS  - 1738-1088 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Aug 31
TI  - A Review of Behavioral Tests to Evaluate Different Types of Anxiety and
      Anti-anxiety Effects.
PG  - 341-351
LID - 10.9758/cpn.2020.18.3.341 [doi]
AB  - Behavioral tests are very useful to understand the Neuro-psychotic disease and
      also helpful in finding the treatment of the particular disease. Nowadays various
      tests are available to evaluate the anxiolytics effect of a new entity or even
      for comparative studies with the standard drug. As per the ethics, a new compound
      or drug believes to have possible pharmacological effects should be tested on
      animals before tested on humans which have similar physiology than humans. First,
      rats were used for behavioral test for evaluation of anti-anxiety drug but later 
      on the various strain of mice were added for evaluation of anxiolytics because of
      better genetic possibilities than rats. In this review article, we have discussed
      the most commonly used behavioral tests used to evaluate the anti-anxiety effect.
      Anxiolytics are the agent which are used to elevate anxiety effect produced due
      to any cause. The various parameter will be undertaken for the better and precise
      evaluation of anxiolytics.
CN  - Himanshu
AUID- ORCID: https://orcid.org/0000-0003-3165-6857
AD  - HIMT College of Pharmacy, Greater Noida, India.
CN  - Dharmila
AUID- ORCID: https://orcid.org/0000-0001-8804-5075
AD  - School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
FAU - Sarkar, Deepa
AU  - Sarkar D
AUID- ORCID: https://orcid.org/0000-0001-5369-2926
AD  - HIMT College of Pharmacy, Greater Noida, India.
CN  - Nutan
AUID- ORCID: https://orcid.org/0000-0002-2961-0975
AD  - HIMT College of Pharmacy, Greater Noida, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Clin Psychopharmacol Neurosci
JT  - Clinical psychopharmacology and neuroscience : the official scientific journal of
      the Korean College of Neuropsychopharmacology
JID - 101207332
PMC - PMC7382999
OTO - NOTNLM
OT  - Anxiety
OT  - Elevated plus maze
OT  - Marble-burying behavior
OT  - The hole-board test
OT  - The light and dark box
OT  - The open-field test
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - cpn.2020.18.3.341 [pii]
AID - 10.9758/cpn.2020.18.3.341 [doi]
PST - ppublish
SO  - Clin Psychopharmacol Neurosci. 2020 Aug 31;18(3):341-351. doi:
      10.9758/cpn.2020.18.3.341.


PMID- 32701615
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Sep
TI  - Updates in diagnosis of the inherited platelet disorders.
PG  - 333-340
LID - 10.1097/MOH.0000000000000604 [doi]
AB  - PURPOSE OF REVIEW: To provide a comprehensive update on the current available
      methodologies and techniques for diagnosis of inherited platelet disorders (IPD).
      RECENT FINDINGS: The contributions of many groups have resulted in the
      significant progress in the molecular diagnosis of IPD including the
      identification of many genes responsible for the various phenotypes. The
      widespread use and availability of next-generation sequencing has brought to the 
      forefront ethical challenges associated with nontargeted sequencing as well as
      provided us with novel variants to functionally validate. These requirements have
      driven the development of novel tools for functional assessment of platelets,
      although none of the novel techniques beyond sequencing have yet taken clinical
      hold. SUMMARY: Much work is ongoing on functional and molecular assessment of
      platelet disorders and the incorporation of combined assessments is likely to
      yield the highest diagnostic results.
FAU - Lambert, Michele P
AU  - Lambert MP
AD  - Division of Hematology, The Children's Hospital of Philadelphia.
AD  - Department of Pediatrics, Perelman School of Medicine at the University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
SB  - IM
MH  - Blood Platelet Disorders/*diagnosis
MH  - Humans
EDAT- 2020/07/24 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1097/MOH.0000000000000604 [doi]
AID - 00062752-202009000-00007 [pii]
PST - ppublish
SO  - Curr Opin Hematol. 2020 Sep;27(5):333-340. doi: 10.1097/MOH.0000000000000604.


PMID- 32700963
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1469-2910 (Electronic)
IS  - 1364-8470 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Dec
TI  - 'Fixing my life': young people's everyday efforts towards recovery from
      persistent bodily complaints.
PG  - 412-427
LID - 10.1080/13648470.2020.1719456 [doi]
AB  - Little is known about the perspectives of young people suffering from medically
      unexplained symptoms. This study aims to explore the experiences and strategies
      of young Norwegians related to incipient and persistent health complaints
      affecting everyday life functioning. The study draws on field notes, video
      material and interview transcripts from a multi-sited ethnographic study of
      healthcare services and select schools in a small Norwegian town between 2015 and
      2016. A central theme is the emphasis upon social and existential constraints
      seemingly framed by a social imaginary of youth rather than a medical imaginary, 
      and their active engagements to 'fix' their lives through what we identify as two
      main modalities of self-care. Navigating temporal and relational aspects of
      sociocultural configurations of youth in their social environments, they imagine 
      and enact alternative qualifying positions better adapted to constraints,
      personal preferences and needs. Our findings may add to understandings of the
      needs and strategies of young sufferers of medically unexplained symptoms,
      relevant for health and social care encounters.
FAU - Kvamme, Maria Fredriksen
AU  - Kvamme MF
AD  - Department of Community Medicine, General Practice Research Unit, Faculty of
      Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
FAU - Wang, Catharina Elisabeth Arfwedson
AU  - Wang CEA
AD  - Faculty of Health Sciences, Department of Psychology, UiT The Arctic University
      of Norway, Tromso, Norway.
FAU - Waage, Trond
AU  - Waage T
AD  - Department of Social Sciences, Visual Cultural Studies, UiT The Arctic University
      of Norway, Tromso, Norway.
FAU - Risor, Mette Bech
AU  - Risor MB
AD  - Department of Community Medicine, General Practice Research Unit, Faculty of
      Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200723
PL  - England
TA  - Anthropol Med
JT  - Anthropology & medicine
JID - 9709920
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anthropology, Medical
MH  - Attitude to Health/*ethnology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medically Unexplained Symptoms
MH  - Norway/ethnology
MH  - *Self Care
MH  - Self Concept
MH  - Young Adult
OTO - NOTNLM
OT  - Youth
OT  - film
OT  - medically unexplained symptoms
OT  - ordinary ethics
OT  - self-care
OT  - subjectivity
EDAT- 2020/07/24 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1080/13648470.2020.1719456 [doi]
PST - ppublish
SO  - Anthropol Med. 2020 Dec;27(4):412-427. doi: 10.1080/13648470.2020.1719456. Epub
      2020 Jul 23.


PMID- 32700649
OWN - NLM
STAT- Publisher
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 23
TI  - Moral distress in emergency and critical care nurses: A metaethnography.
PG  - 969733020935952
LID - 10.1177/0969733020935952 [doi]
AB  - BACKGROUND: Moral distress has detrimental effects on nurses which impacts the
      entire healthcare cycle. Described as a crescendo effect, resolved situations of 
      moral distress leave residue on the nurse with three potential outcomes: moral
      numbing, conscious objection to the situation, and burnout. OBJECTIVE: This
      metaethnography strives to achieve a fuller understanding of moral distress by
      interpreting the body of qualitative work of moral distress in emergency and
      critical care nurses. METHOD: This study used the Noblit and Hare's approach of
      interpretative synthesis. Ten studies met the criteria and were used in this
      synthesis. ETHICAL CONSIDERATIONS: Ethical issues were minimal since no human
      subjects were involved. Ethical requirements were respected in all study phases. 
      RESULTS: The synthesis of qualitative research on moral distress resulted in one 
      central theme, "the battle within," and five subthemes. CONCLUSIONS: The unique
      nature of this nursing specialty resulted in a lasting inner conflict for nurses 
      that is consistent with the previously described crescendo effect. The effects
      are complex and long lasting and may potentially affect the nurses' future
      patient care.
FAU - Arnold, Tracey C
AU  - Arnold TC
AUID- ORCID: https://orcid.org/0000-0002-0312-0599
AD  - University of Connecticut, USA.
LA  - eng
PT  - Journal Article
DEP - 20200723
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
OTO - NOTNLM
OT  - Metaethnography
OT  - critical care
OT  - literature review
OT  - metasynthesis
OT  - moral distress
OT  - qualitative synthesis
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
AID - 10.1177/0969733020935952 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 23:969733020935952. doi: 10.1177/0969733020935952.


PMID- 32700443
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1613-6829 (Electronic)
IS  - 1613-6810 (Linking)
VI  - 16
IP  - 36
DP  - 2020 Sep
TI  - Embedding Ethical Impact Assessment in Nanosafety Decision Support.
PG  - e2002901
LID - 10.1002/smll.202002901 [doi]
AB  - Nanotechnology is a key enabling technology, which is developing fast and
      influences many aspects of life. Nanomaterials are already included in a broad
      range of products and industrial sectors. Nanosafety issues are still a matter of
      concern for policy makers and stakeholders, but currently, there is no platform
      where all stakeholders can meet and discuss these issues. A comprehensive
      overview of all the issues in one single dashboard presenting the output of a
      decision support system is also lacking. This article outlines a strategy for
      developing one innovative part of a modular decision support system, designed to 
      support the work of a new Risk Governance Council (RGC) for nanomaterials which
      will be established through the combined efforts of the GOV4NANO, NANORIGO, and
      RiskGONE H2020 projects. This new module will consist of guidelines for Ethical
      Impact Assessment (EIA) for nanomaterials and nanoenabled products. This article 
      offers recommendations for adapting the European Committee for Standardization
      (CEN) prestandard on Ethical Impact Assessment CWA (CEN Workshop Agreement)
      17145-2:2017 (E), to fit into the more-encompassing decision support system for
      risk governance of nanomaterials within the RiskGONE project.
CI  - (c) 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Malsch, Ineke
AU  - Malsch I
AUID- ORCID: 0000-0002-2128-0609
AD  - Malsch TechnoValuation, PO Box 455, Utrecht, AL, 3500, The Netherlands.
FAU - Isigonis, Panagiotis
AU  - Isigonis P
AD  - Department of Environmental Sciences, Informatics and Statistics, Ca' Foscari
      University of Venice, via Torino 155, Mestre-Venezia, Venice, 30172, Italy.
FAU - Dusinska, Maria
AU  - Dusinska M
AD  - Environmental Chemistry Department, NILU, Instituttveien 18, Kjeller, 2007,
      Norway.
FAU - Bouman, Evert A
AU  - Bouman EA
AD  - Environmental Impacts and Sustainability, NILU, Instituttveien 18, Kjeller, 2007,
      Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200723
PL  - Germany
TA  - Small
JT  - Small (Weinheim an der Bergstrasse, Germany)
JID - 101235338
SB  - IM
MH  - *Decision Support Techniques
MH  - European Union
MH  - *Nanostructures/toxicity
MH  - *Nanotechnology/ethics/trends
MH  - Safety
OTO - NOTNLM
OT  - *ethics
OT  - *guidelines
OT  - *nanomaterials
OT  - *nanosafety
OT  - *regulation
EDAT- 2020/07/24 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1002/smll.202002901 [doi]
PST - ppublish
SO  - Small. 2020 Sep;16(36):e2002901. doi: 10.1002/smll.202002901. Epub 2020 Jul 23.


PMID- 32700402
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 29
IP  - 19-20
DP  - 2020 Oct
TI  - Riding an elephant: A qualitative study of nurses' moral journeys in the context 
      of Medical Assistance in Dying (MAiD).
PG  - 3870-3881
LID - 10.1111/jocn.15427 [doi]
AB  - AIMS AND OBJECTIVES: To describes nurses' moral experiences with Medical
      Assistance in Dying in the Canadian context. BACKGROUND: Nurses perform important
      roles in Medical Assistance in Dying in Canada and do so within a unique context 
      in which Medical Assistance in Dying is provided through healthcare services and 
      where accessibility is an important principle. International literature indicates
      that participating in Medical Assistance in Dying can be deeply impactful for
      nurses and requires a high degree of moral sense-making. DESIGN: A qualitative
      interview study guided by Interpretive Description using the COREQ checklist.
      RESULTS: Fifty-nine nurses from across Canada participated in the study. The
      decision to participate in Medical Assistance in Dying was influenced by family
      and community, professional experience and nurses' proximity to the act of
      Medical Assistance in Dying. Nurses described a range of deep and sometimes
      conflicting emotional reactions provoked by Medical Assistance in Dying. Nurses
      used a number of moral waypoints to make sense of their decision including
      patient choice, control and certainty; an understanding that it was not about the
      nurse; a commitment to staying with patients through suffering; consideration of 
      moral consistency; issues related to the afterlife; and the peace and gratitude
      demonstrated by patients and families. DISCUSSION: The depth of nurses'
      intuitional moral responses and their need to make sense of these responses are
      consistent with Haidt's theory of moral experience in which individuals use
      reasoning primarily to explain their moral intuition and in which moral change
      occurs primarily through compassionate social interaction. Further, work on the
      moral identity of nursing provides robust explanation of how nurses' moral
      decisions are contextually and relationally mediated and how they seek to guard
      patient vulnerability, even at their own emotional cost. CONCLUSION: Medical
      Assistance in Dying is impactful for nurses, and for some, it requires intensive 
      and ongoing moral sense-making. RELEVANCE TO CLINICAL PRACTICE: There is a need
      to provide support for nurses' moral deliberation and emotional well-being in the
      context of Medical Assistance in Dying care.
CI  - (c) 2020 The Authors. Journal of Clinical Nursing published by John Wiley & Sons 
      Ltd.
FAU - Pesut, Barbara
AU  - Pesut B
AUID- ORCID: https://orcid.org/0000-0002-1063-7190
AD  - University of British Columbia, Okanagan, Kelowna, BC, Canada.
FAU - Thorne, Sally
AU  - Thorne S
AUID- ORCID: https://orcid.org/0000-0002-1156-9425
AD  - University of British Columbia, Vancouver, BC, Canada.
FAU - Storch, Janet
AU  - Storch J
AD  - University of Victoria, Victoria, BC, Canada.
FAU - Chambaere, Kenneth
AU  - Chambaere K
AD  - Ghent University, Ghent, Belgium.
AD  - Vrije Universeteit Brussel (VUB), Brussels, Belgium.
FAU - Greig, Madeleine
AU  - Greig M
AD  - University of British Columbia, Okanagan, Kelowna, BC, Canada.
FAU - Burgess, Michael
AU  - Burgess M
AD  - University of British Columbia, Okanagan, Kelowna, BC, Canada.
LA  - eng
GR  - 201610PJT-376065/Institute of Aging
GR  - Canadian Foundation for Innovation
GR  - Canada Research Chairs Program
PT  - Journal Article
DEP - 20200805
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
MH  - Animals
MH  - Canada
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Assistance
MH  - Morals
MH  - *Suicide, Assisted
PMC - PMC7540490
OTO - NOTNLM
OT  - Canada
OT  - Interpretive Description
OT  - Medical Assistance in Dying (MAiD)
OT  - ethics
OT  - euthanasia
OT  - moral
OT  - nursing
OT  - physician-assisted death
OT  - qualitative
EDAT- 2020/07/24 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/07/24 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/06/27 00:00 [revised]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1111/jocn.15427 [doi]
PST - ppublish
SO  - J Clin Nurs. 2020 Oct;29(19-20):3870-3881. doi: 10.1111/jocn.15427. Epub 2020 Aug
      5.


PMID- 32700383
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1098-2345 (Electronic)
IS  - 0275-2565 (Linking)
VI  - 82
IP  - 9
DP  - 2020 Sep
TI  - Researchers' ethical concerns regarding habituating wild-nonhuman primates and
      perceived ethical duties to their subjects: Results of an online survey.
PG  - e23178
LID - 10.1002/ajp.23178 [doi]
AB  - While the process of habituation is essential for researchers to observe primates
      in their natural habitats, ethical dilemmas may arise from its consequences. We
      collected data from 286 participants via an online survey to investigate: (a) how
      primatologists perceive their ethical duties toward their subjects; (b) the
      extent to which primatologists are concerned about the potential ethical
      consequences of habituation; and (c) the methods primatologists use to reduce
      potential harms caused by habituation. Overall, primatologists felt an extremely 
      strong duty to mitigate harms that they may cause (e.g., to not stress
      individuals during observation, treat injuries, and reunite separated
      individuals) and expressed very high concern for habituation's potential to
      increase the vulnerability of their subjects to poaching and disease transfer.
      Ratings for those items were so high that they could not be included in
      subsequent exploratory factor analyses that were designed to reveal constructs
      underlying respondents' ratings of their ethical duties and concerns. Factor
      analysis of ratings of ethical duties revealed that primatologists reported a
      strong duty to mitigate harms caused by other humans and a lower perceived duty
      to mitigate naturally occurring harmful events. Factor analysis on ethical
      concern ratings revealed that respondents were concerned about harms during the
      habituation process, the presence of unhabituated behavior after habituation had 
      been established, and indirect harms of habituation. Concerns for unhabituated
      behavior and indirect harms were rated slightly higher than concern for harms
      during the habituation process. To mitigate potential harms, primatologists
      primarily reported engaging in strategies to reduce stress in their subjects. Our
      findings reveal a disconnect between primatologists' ratings of their ethical
      concerns and their reported mitigation practices that may, in part, stem from
      gaps in knowledge about the true impacts of habituation. We suggest areas of
      discussion and research in the field necessary to address those gaps.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Green, Victoria M
AU  - Green VM
AUID- ORCID: 0000-0001-7393-9842
AD  - Primate Behavior Program, Central Washington University, Ellensburg, Washington.
FAU - Gabriel, Kara I
AU  - Gabriel KI
AD  - Department of Psychology, Central Washington University, Ellensburg, Washington.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200723
PL  - United States
TA  - Am J Primatol
JT  - American journal of primatology
JID - 8108949
SB  - IM
MH  - Animals
MH  - *Ethics, Research
MH  - Habituation, Psychophysiologic/*ethics
MH  - Human Activities
MH  - Humans
MH  - Primates/*physiology
MH  - Surveys and Questionnaires
MH  - Zoology/ethics
OTO - NOTNLM
OT  - *ethics
OT  - *ethnoprimatology
OT  - *habituation
OT  - *methodology
OT  - *survey
EDAT- 2020/07/24 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1002/ajp.23178 [doi]
PST - ppublish
SO  - Am J Primatol. 2020 Sep;82(9):e23178. doi: 10.1002/ajp.23178. Epub 2020 Jul 23.


PMID- 32700245
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Ethical and Social Aspects of Neurorobotics.
PG  - 2533-2546
LID - 10.1007/s11948-020-00248-8 [doi]
AB  - The interdisciplinary field of neurorobotics looks to neuroscience to overcome
      the limitations of modern robotics technology, to robotics to advance our
      understanding of the neural system's inner workings, and to information
      technology to develop tools that support those complementary endeavours. The
      development of these technologies is still at an early stage, which makes them an
      ideal candidate for proactive and anticipatory ethical reflection. This article
      explains the current state of neurorobotics development within the Human Brain
      Project, originating from a close collaboration between the scientific and
      technical experts who drive neurorobotics innovation, and the humanities and
      social sciences scholars who provide contextualising and reflective capabilities.
      This article discusses some of the ethical issues which can reasonably be
      expected. On this basis, the article explores possible gaps identified within
      this collaborative, ethical reflection that calls for attention to ensure that
      the development of neurorobotics is ethically sound and socially acceptable and
      desirable.
FAU - Aicardi, Christine
AU  - Aicardi C
AD  - King's College London, London, UK.
FAU - Akintoye, Simisola
AU  - Akintoye S
AD  - Institute for Law, Justice and Society, De Montfort University, The Gateway,
      Leicester, LE1 9BH, UK.
FAU - Fothergill, B Tyr
AU  - Fothergill BT
AD  - Centre for Computing and Social Responsibility, De Montfort University, The
      Gateway, Leicester, LE1 9BH, UK.
FAU - Guerrero, Manuel
AU  - Guerrero M
AD  - Centre for Research Ethics & Bioethics (CRB), Uppsala University, Uppsala,
      Sweden.
AD  - Department of Bioethics and Medical Humanities, University of Chile, Santiago,
      Chile.
FAU - Klinker, Gudrun
AU  - Klinker G
AD  - Technical University Munich, Munich, Germany.
FAU - Knight, William
AU  - Knight W
AD  - Centre for Computing and Social Responsibility, De Montfort University, The
      Gateway, Leicester, LE1 9BH, UK.
FAU - Kluver, Lars
AU  - Kluver L
AD  - The Danish Board of Technology, Copenhagen, Denmark.
FAU - Morel, Yannick
AU  - Morel Y
AD  - University of Maastricht, Maastricht, Netherlands.
FAU - Morin, Fabrice O
AU  - Morin FO
AD  - Technical University Munich, Munich, Germany.
FAU - Stahl, Bernd Carsten
AU  - Stahl BC
AD  - Centre for Computing and Social Responsibility, De Montfort University, The
      Gateway, Leicester, LE1 9BH, UK. bstahl@dmu.ac.uk.
FAU - Ulnicane, Inga
AU  - Ulnicane I
AUID- ORCID: http://orcid.org/0000-0003-2051-1265
AD  - Centre for Computing and Social Responsibility, De Montfort University, The
      Gateway, Leicester, LE1 9BH, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humanities
MH  - Humans
MH  - Morals
MH  - *Neurosciences
MH  - *Social Sciences
MH  - Technology
PMC - PMC7550362
OTO - NOTNLM
OT  - *Ethics
OT  - *Human Brain Project
OT  - *Neurorobotics
OT  - *Responsible Research and Innovation
EDAT- 2020/07/24 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1007/s11948-020-00248-8 [doi]
AID - 10.1007/s11948-020-00248-8 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2533-2546. doi: 10.1007/s11948-020-00248-8.


PMID- 32699919
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1433-7347 (Electronic)
IS  - 0942-2056 (Linking)
VI  - 28
IP  - 8
DP  - 2020 Aug
TI  - ACL reconstruction using a quadruple semitendinosus graft with cortical fixations
      gives suitable isokinetic and clinical outcomes after 2 years.
PG  - 2468-2477
LID - 10.1007/s00167-020-06121-2 [doi]
AB  - PURPOSE: The objective of this single-center randomized single-blinded trial was 
      to assess the hypothesis that anterior cruciate ligament reconstruction (ACLR)
      using a four-strand semitendinosus (ST) graft with adjustable femoral and tibial 
      cortical fixation produced good outcomes compared to an ST/gracilis (ST/G) graft 
      with femoral pin transfixation and tibial bioscrew fixation. Follow-up was 2
      years. METHODS: Patients older than 16 years who underwent primary isolated ACLR 
      included for 1 year until August 2017 were eligible. The primary outcome measures
      were the subjective International Knee Documentation Committee (IKDC) score,
      isokinetic muscle strength recovery, and return to work within 2 years. The study
      was approved by the ethics committee. RESULTS: Of 66 eligible patients, 60
      completed the study and were included, 33 in the 4ST group and 27 in the ST/G
      group. Mean age was 30.5 +/- 8.9 years in the 4ST group and 30.3 +/- 8.5 in the
      ST/G group (n.s.). No significant between-group differences were found for mean
      postoperative subjective IKDC (4ST group, 80.2 +/- 12.5; ST/G group, 83.6 +/-
      13.6; n.s.), side-to-side percentage deficits in isokinetic hamstring strength
      (at 60 degrees /s: ST group, 17% +/- 16%; ST/G group, 14% +/- 11%; n.s.) or
      quadriceps strength (at 60 degrees /s: ST group, 14% +/- 12%; ST/G group, 19% +/-
      17%; n.s.), return to work, pain during physical activities, side-to-side
      differential laxity, balance, loss of flexion/extension, or surgical
      complications. CONCLUSION: This trial demonstrates that functional outcomes after
      4ST for ACLR with cortical fixations could be as good, although not better, than 
      those obtained using ST/G. The 4ST technique spares the gracilis tendon, which
      thus preserves the medial sided muscle and thereby could improve function and
      limit donor-side morbidity. LEVEL OF EVIDENCE: Level I.
FAU - Roger, Julien
AU  - Roger J
AUID- ORCID: http://orcid.org/0000-0001-6609-3973
AD  - Division of Orthopaedic Surgery, Department of Surgery, Hopital de La Croix
      Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix Rousse, 69004, Lyon, 
      France. julien.roger@chu-lyon.fr.
FAU - Bertani, Antoine
AU  - Bertani A
AD  - Division of Orthopaedic Surgery, Department of Surgery, Hopital Edouard Herriot, 
      Hospices Civils de Lyon, Lyon, France. antoine.bertani@chu-lyon.fr.
FAU - Vigouroux, Florence
AU  - Vigouroux F
AD  - Division of Orthopaedic Surgery, Department of Surgery, Hopital d'Instruction des
      Armees Begin, Service de Sante des Armees, Saint-Mande, France.
FAU - Mottier, Franck
AU  - Mottier F
AD  - Division of Orthopaedic Surgery, Department of Surgery, Centre Hospitalier Pierre
      Oudot, Bourgoin-Jallieu, France.
FAU - Gaillard, Romain
AU  - Gaillard R
AD  - Division of Orthopaedic Surgery, Department of Surgery, Hopital de La Croix
      Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix Rousse, 69004, Lyon, 
      France.
FAU - Have, Laurence
AU  - Have L
AD  - Department of Physical and Medical Rehabilitation, Hopital Edouard Herriot,
      Hospices Civils de Lyon, Lyon, France.
FAU - Rongieras, Frederic
AU  - Rongieras F
AD  - Division of Orthopaedic Surgery, Department of Surgery, Hopital Edouard Herriot, 
      Hospices Civils de Lyon, Lyon, France.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200722
PL  - Germany
TA  - Knee Surg Sports Traumatol Arthrosc
JT  - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
JID - 9314730
SB  - IM
MH  - Adult
MH  - Anterior Cruciate Ligament Injuries/physiopathology/*surgery
MH  - Anterior Cruciate Ligament Reconstruction/adverse effects/*methods
MH  - Arthralgia/etiology
MH  - Female
MH  - Femur/surgery
MH  - Gracilis Muscle/transplantation
MH  - Hamstring Muscles/physiology/*transplantation
MH  - Humans
MH  - Joint Instability/etiology
MH  - Male
MH  - Muscle Strength/physiology
MH  - Postoperative Complications
MH  - Postural Balance
MH  - Quadriceps Muscle/physiopathology
MH  - Range of Motion, Articular
MH  - Return to Work
MH  - Single-Blind Method
MH  - Tibia/surgery
MH  - Young Adult
OTO - NOTNLM
OT  - ACL fixation devices
OT  - Arthrometer ACL
OT  - Isokinetic strength
OT  - Posturography
OT  - Short semitendinosus graft
EDAT- 2020/07/24 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 10.1007/s00167-020-06121-2 [doi]
AID - 10.1007/s00167-020-06121-2 [pii]
PST - ppublish
SO  - Knee Surg Sports Traumatol Arthrosc. 2020 Aug;28(8):2468-2477. doi:
      10.1007/s00167-020-06121-2. Epub 2020 Jul 22.


PMID- 32699889
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20210410
IS  - 1940-8250 (Electronic)
IS  - 0279-5442 (Linking)
VI  - 40
IP  - 6
DP  - 2020 Dec 1
TI  - Increasing Critical Care Nurse Engagement of Palliative Care During the COVID-19 
      Pandemic.
PG  - e28-e36
LID - 10.4037/ccn2020946 [doi]
AB  - BACKGROUND: The coronavirus disease 2019 pandemic has led to escalating infection
      rates and associated deaths worldwide. Amid this public health emergency, the
      urgent need for palliative care integration throughout critical care settings has
      never been more crucial. OBJECTIVE: To promote palliative care engagement in
      critical care; share palliative care resources to support critical care nurses in
      alleviating suffering during the coronavirus disease 2019 pandemic; and make
      recommendations to strengthen nursing capacity to deliver high-quality,
      person-centered critical care. METHODS: Palliative and critical care literature
      and practice guidelines were reviewed, synthesized, and translated into
      recommendations for critical care nursing practice. RESULTS: Nurses are ideally
      positioned to drive full integration of palliative care into the critical care
      delivery for all patients, including those with coronavirus disease 2019, given
      their relationship-based approach to care, as well as their leadership and
      advocacy roles. Recommendations include the promotion of healthy work
      environments and prioritizing nurse self-care in alignment with critical care
      nursing standards. CONCLUSIONS: Nurses should focus on a strategic integration of
      palliative care, critical care, and ethically based care during times of normalcy
      and of crisis. Primary palliative care should be provided for each patient and
      family, and specialist services sought, as appropriate. Nurse educators are
      encouraged to use these recommendations and resources in their curricula and
      training. Palliative care is critical care. Critical care nurses are the
      frontline responders capable of translating this holistic, person-centered
      approach into pragmatic services and relationships throughout the critical care
      continuum.
CI  - (c)2020 American Association of Critical-Care Nurses.
FAU - Rosa, William E
AU  - Rosa WE
AD  - William E. Rosa is a Robert Wood Johnson Foundation Future of Nursing Scholar,
      University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania.
FAU - Ferrell, Betty R
AU  - Ferrell BR
AD  - Betty R. Ferrell is a professor and the Director of Nursing Research, City of
      Hope National Medical Center, Duarte, California.
FAU - Wiencek, Clareen
AU  - Wiencek C
AD  - Clareen Wiencek is an associate professor of nursing and the Advanced Practice
      Program Director for MSN and DNP programs, University of Virginia School of
      Nursing, Charlottesville, Virginia.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - T32 CA009461/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Crit Care Nurse
JT  - Critical care nurse
JID - 8207799
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/*nursing
MH  - Critical Care Nursing/*organization & administration/*standards
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Nurse's Role
MH  - Palliative Care/*organization & administration/*standards
MH  - Pandemics
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
PMC - PMC8034497
MID - NIHMS1685282
EDAT- 2020/07/24 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 31109 [pii]
AID - 10.4037/ccn2020946 [doi]
PST - ppublish
SO  - Crit Care Nurse. 2020 Dec 1;40(6):e28-e36. doi: 10.4037/ccn2020946.


PMID- 32699860
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210406
DP  - 2020 Jul 14
TI  - Interest in COVID-19 vaccine trials participation among young adults in China:
      Willingness, reasons for hesitancy, and demographic and psychosocial
      determinants.
LID - 2020.07.13.20152678 [pii]
LID - 10.1101/2020.07.13.20152678 [doi]
AB  - BACKGROUND: With the demand for rapid COVID-19 vaccine development and
      evaluation, this paper aimed to describe the prevalence and correlates of
      willingness to participate in COVID-19 vaccine trials among university students
      in China. METHODS: A cross-sectional survey with 1,912 Chinese university
      students was conducted during March and April 2020. Bivariate and multivariate
      analyses were performed to identify variables associated with willingness to
      participate. RESULTS: The majority of participants (64.01%) indicated willingness
      to participate in COVID-19 vaccine trials. Hesitancy over signing informed
      consent documents, concerns over time necessary for participating in a medical
      study, and perceived COVID-19 societal stigma were identified as deterrents,
      whereas lower socioeconomic status, female gender, perception of likely COVID-19 
      infection during the pandemic, and COVID-19 prosocial behaviors were facilitative
      factors. Further, public health mistrust and hesitancy over signing informed
      consent documents had a significant interactive effect on vaccine trial
      willingness. CONCLUSIONS: High standards of ethical and scientific practice are
      needed in COVID-19 vaccine research, including providing potential participants
      full and accurate information and ensuring participation free of coercion,
      socioeconomic inequality, and stigma. Attending to the needs of marginalized
      groups and addressing psychosocial factors including stigma and public health
      mistrust may also be important to COVID-19 vaccine development and future uptake.
FAU - Sun, Shufang
AU  - Sun S
AD  - Brown University Alpert Medical School, Department of Psychiatry and Human
      Behavior.
FAU - Lin, Danhua
AU  - Lin D
AD  - Beijing Normal University, Department of Psychology.
FAU - Operario, Don
AU  - Operario D
AD  - Brown University School of Public Health, Department of Behavioral and Social
      Sciences.
LA  - eng
GR  - P30 AI042853/AI/NIAID NIH HHS/United States
GR  - T32 MH078788/MH/NIMH NIH HHS/United States
PT  - Preprint
DEP - 20200714
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Prev Med Rep. 2021 Jun;22:101350. PMID: 33816087
PMC - PMC7373149
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1101/2020.07.13.20152678 [doi]
PST - epublish
SO  - medRxiv. 2020 Jul 14. doi: 10.1101/2020.07.13.20152678.


PMID- 32699775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Linking)
VI  - 24
IP  - 2
DP  - 2020 Mar-Apr
TI  - Endocrinology, Epidemics and Ethics.
PG  - 123-125
LID - 10.4103/ijem.IJEM_151_20 [doi]
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
FAU - Bantwal, Ganapathy
AU  - Bantwal G
AD  - Department of Endocrinology, St John's Medical College, Bangalore, Karnataka,
      India.
FAU - Sahay, Rakesh
AU  - Sahay R
AD  - Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana,
      India.
LA  - eng
PT  - Editorial
DEP - 20200430
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC7333751
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/03/30 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.4103/ijem.IJEM_151_20 [doi]
AID - IJEM-24-123 [pii]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2020 Mar-Apr;24(2):123-125. doi:
      10.4103/ijem.IJEM_151_20. Epub 2020 Apr 30.


PMID- 32699690
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 18
TI  - Laparoscopic Transabdominal Preperitoneal Technique for Inguinal Hernia Repair in
      Adults.
PG  - e8692
LID - 10.7759/cureus.8692 [doi]
AB  - Background Inguinal hernia repair is one of the most commonly performed
      operations in general surgery, especially in the digestive field. Since the
      introduction of laparoscopic repair as well as using a synthetic mesh, the
      surgical trends have changed in the last decade in treating inguinal hernias. The
      laparoscopic transabdominal preperitoneal gives a better view of the inguinal
      anatomy, and the procedure also has a short learning curve. We aim to evaluate
      the safety and early outcome of the laparoscopic transabdominal preperitoneal
      technique for inguinal hernia repair using a Prolene((R)) mesh (Ethicon
      Somerville, NJ, USA). Methods A prospective study was carried out among 31 adult 
      patients with 34 inguinal hernia cases. They underwent the laparoscopic
      transabdominal preperitoneal technique with a Prolene mesh at the Hue Central
      Hospital from December 2018 through May 2019. Results The mean age was 60.4 +/-
      11.8, and 96.8% of cases were male. Strangulated hernia and incarcerated hernia
      accounted for 2.9% and 8.8% of cases, respectively. The mean duration of
      unilateral inguinal hernia repair and bilateral inguinal repair was 57.1 +/- 17.3
      minutes and 80.3 +/- 10.6 minutes, respectively. The mean duration of the
      postoperative hospital stay was 3.9 +/- 1.4 days. One (3.2%) case with
      contralateral inguinal hernia was detected intraoperatively. An early and
      three-month postoperative evaluation showed that 93.5% and 96.8% of cases were
      categorized as "very good", respectively. At the three-month evaluation, one case
      was reported with sensation disorder of the inguinal area, and there was no
      recurrence. Conclusions Laparoscopic transabdominal preperitoneal inguinal hernia
      repair is a safe and feasible technique. It allows surgeons to explore the
      opposite site and resolve the combined peritoneal diseases.
CI  - Copyright (c) 2020, Thanh Xuan et al.
FAU - Thanh Xuan, Nguyen
AU  - Thanh Xuan N
AD  - Department of Abdominal Emergency and Pediatric Surgery, Hue Central Hospital,
      Hue, VNM.
FAU - Huu Son, Nguyen
AU  - Huu Son N
AD  - Pediatrics, Hue Central Hospital, Hue, VNM.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7370685
OTO - NOTNLM
OT  - complication
OT  - inguinal hernia
OT  - outcome
OT  - prolene mesh
OT  - transabdominal preperitoneal (tapp)
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.7759/cureus.8692 [doi]
PST - epublish
SO  - Cureus. 2020 Jun 18;12(6):e8692. doi: 10.7759/cureus.8692.


PMID- 32699517
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1958-5969 (Electronic)
IS  - 1294-8322 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Jun
TI  - Virtual reality as a clinical tool in mental health research and practice.
PG  - 169-177
LID - 10.31887/DCNS.2020.22.2/lvalmaggia [doi]
AB  - Virtual reality (VR) is a potentially powerful technology for enhancing
      assessment in mental health. At any time or place, individuals can be transported
      into immersive and interactive virtual worlds that are fully controlled by the
      researcher or clinician. This capability is central to recent interest in how VR 
      might be harnessed in both treatment and assessment of mental health conditions. 
      The current review provides a summary of the advantages of using VR for
      assessment in mental health, focusing on increasing ecological validity of highly
      controlled environments, enhancing personalization and engagement, and capturing 
      real-time, automated data in real-world contexts. Considerations for the
      implementation of VR in research and clinical settings are discussed, including
      current issues with cost and access, developing evidence base, technical
      challenges, and ethical implications. The opportunities and challenges of VR are 
      important to understand as researchers and clinicians look to harness this
      technology to improve mental health outcomes..
CI  - (c) 2020, AICHServier GroupCopyright (c) 2020 AICH Servier Group. All rights
      reserved.
FAU - Bell, Imogen H
AU  - Bell IH
AD  - Orygen, Melbourne, Australia; Centre for Youth Mental Health, The University of
      Melbourne, Australia.
FAU - Nicholas, Jennifer
AU  - Nicholas J
AD  - Orygen, Melbourne, Australia; Centre for Youth Mental Health, The University of
      Melbourne, Australia.
FAU - Alvarez-Jimenez, Mario
AU  - Alvarez-Jimenez M
AD  - Orygen, Melbourne, Australia; Centre for Youth Mental Health, The University of
      Melbourne, Australia.
FAU - Thompson, Andrew
AU  - Thompson A
AD  - Orygen, Melbourne, Australia; Centre for Youth Mental Health, The University of
      Melbourne, Australia; University of Warwick - Division of Mental Health and
      Wellbeing, University of Warwick, UK.
FAU - Valmaggia, Lucia
AU  - Valmaggia L
AD  - King's College London, Institute of Psychiatry, Psychology & Neuroscience,
      London, UK; South London and Maudsley NHS Foundation Trust, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Dialogues Clin Neurosci
JT  - Dialogues in clinical neuroscience
JID - 101238198
SB  - IM
MH  - Biomedical Research/methods/statistics & numerical data/*trends
MH  - Clinical Trials as Topic/methods/statistics & numerical data
MH  - Computer Systems/statistics & numerical data/trends
MH  - Data Collection/methods/statistics & numerical data/trends
MH  - Humans
MH  - Mental Disorders/diagnosis/psychology/*therapy
MH  - Mental Health/statistics & numerical data/*trends
MH  - Virtual Reality Exposure Therapy/methods/statistics & numerical data/*trends
PMC - PMC7366939
OTO - NOTNLM
OT  - *assessment
OT  - *digital technology
OT  - *mental disorders
OT  - *mental health
OT  - *psychiatry
OT  - *virtual reality
EDAT- 2020/07/24 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
AID - 10.31887/DCNS.2020.22.2/lvalmaggia [doi]
PST - ppublish
SO  - Dialogues Clin Neurosci. 2020 Jun;22(2):169-177. doi:
      10.31887/DCNS.2020.22.2/lvalmaggia.


PMID- 32699445
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210802
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - Mass Production of Human "Embryoid" Cells from Developmentally Frozen Embryos: Is
      It Ethical?
PG  - 347-350
LID - 10.1177/0024363920926013 [doi]
FAU - Pullicino, Patrick
AU  - Pullicino P
AUID- ORCID: https://orcid.org/0000-0001-6865-8333
AD  - Saint Louis University, MO, USA.
FAU - Richard, Edward J
AU  - Richard EJ
AD  - Our Lady of Prompt Succor Parish, Sulphur, LA, USA.
FAU - Burke, William J
AU  - Burke WJ
AUID- ORCID: https://orcid.org/0000-0002-9101-4306
AD  - Saint Louis University, MO, USA.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350113
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363920926013 [doi]
AID - 10.1177_0024363920926013 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):347-350. doi: 10.1177/0024363920926013. Epub 2020 May
      22.


PMID- 32699443
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - Pregnancy Centers: A Clear Purpose of Medicine with Coherent Ethics.
PG  - 334-340
LID - 10.1177/0024363920920397 [doi]
AB  - What is the purpose of medicine? This fundamental question is at the heart of the
      criticisms faced by pregnancy centers (PCs) and accusations that they are
      unethical. PCs maintain that the purpose of medicine is to treat and prevent
      disease. Because pregnancy is not a disease, PCs do not advocate for elective
      abortion or contraceptives. PCs view the function of values (e.g., autonomy) as
      constraints upon physicians that prevent physical and ethical harms. Their
      critics either embrace an ill-defined purpose of medicine such as promoting
      well-being or conflate the value of autonomy with medicine's purpose. This leads 
      to a subjective view of medicine and changes the relationship from
      physician-patient to vendor-customer. This subjective nature along with its
      attendant vendor-customer relationship cannot solve for current or future ethical
      problems such as sex-selective abortion and its fatal discrimination against
      females. SUMMARY: Pregnancy Centers embrace a traditional "treat and prevent
      disease" purpose of medicine. This clear and objective purpose logically leads to
      not advocating for abortion or contraceptives. The authors outline a coherent
      ethical structure outlining the role values play in regards to this purpose. This
      is contrasted with the current ill-defined purpose within medicine today that has
      led to an inconsistent change of the physician-patient relationship to a
      vendor-customer one, ethical incoherence, and several attendant harms, most
      notably sex-selective abortion.
CI  - (c) Catholic Medical Association 2020.
FAU - Lisanti, Christopher
AU  - Lisanti C
AUID- ORCID: https://orcid.org/0000-0003-1940-4374
AD  - Department of Radiology, Brooke Army Medical Center, Fort Sam Houston, TX, USA.
AD  - Department of Radiology & Radiological Sciences, Uniformed Services University of
      the Health Sciences, Bethesda, MD, USA.
AD  - Pregnancy Care Center, San Antonio, TX, USA.
FAU - Christiansen, Sandy
AU  - Christiansen S
AD  - Division of Graduate, Continuing and Professional Education, Mount St. Mary's
      University, Emmitsburg, MD, USA.
AD  - Care Net, Lansdowne, VA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350117
OTO - NOTNLM
OT  - Abortion
OT  - Autonomy
OT  - Bioethics
OT  - Consumer-directed care
OT  - Ethics
OT  - Philosophy of medicine
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363920920397 [doi]
AID - 10.1177_0024363920920397 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):334-340. doi: 10.1177/0024363920920397. Epub 2020 May
      12.


PMID- 32699442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - Does the Uniform Determination of Death Act Need to Be Revised?
PG  - 317-333
LID - 10.1177/0024363920926018 [doi]
AB  - Prompted by concerns raised by the rise in litigations, which challenge the legal
      status of brain death (BD), Lewis and colleagues recently proposed a revision of 
      the Uniform Determination of Death Act (UDDA). The revision consists of (i)
      narrowing down the definition of BD to the loss of specific brain functions,
      namely those functions that can be assessed on bedside neurological examination; 
      (ii) requiring that the determination of BD must be in accordance with the
      specific guidelines designated in the revision; and (iii) eliminating the
      necessity for obtaining consent prior to performing the tests for BD
      determination. By analyzing Lewis and colleagues' revision, this article shows
      that this revision is fraught with difficulties. Therefore, this article also
      proposes two approaches for an ethical revision of the UDDA; the first is in
      accordance with scientific realism and Christian anthropology, while the second
      is grounded in trust and respect for persons. If the UDDA is to be revised, then 
      it should be based on sound ethical principles in order to resolve the ongoing BD
      controversies and rebuild public trust. SUMMARY: This article critically examines
      the recent revision of the Uniform Determination of Death Act (UDDA) advanced by 
      Lewis and colleagues. The revision only further reinforces the status quo of
      brain death without taking into account the root cause of the litigations and
      controversies about the declaration of death by neurological criteria. In view of
      this deficiency, this article offers two approaches to revising the UDDA, both of
      which are founded on sound moral principles.
CI  - (c) Catholic Medical Association 2020.
FAU - Nguyen, Doyen
AU  - Nguyen D
AUID- ORCID: https://orcid.org/0000-0002-4405-4081
AD  - St. Mary Seminary and Graduate School of Theology, Wickliffe, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350098
OTO - NOTNLM
OT  - Brain death
OT  - Ethical revision of the Uniform Determination of Death Act
OT  - Informed consent
OT  - Legal definition of death
OT  - Religious exemption
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363920926018 [doi]
AID - 10.1177_0024363920926018 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):317-333. doi: 10.1177/0024363920926018. Epub 2020 Jun
      2.


PMID- 32699441
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210802
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - Fetal Pain: The Science Behind Why It Is the Medical Standard of Care.
PG  - 311-316
LID - 10.1177/0024363920924877 [doi]
AB  - Despite pain as the fifth vital sign in adult and pediatric care, many still
      dismiss the fact that immature human beings (whether a fetus, a preterm, or term 
      baby) are capable of being affected by pain. Studies have demonstrated that
      avoiding, minimizing, and treating pain in babies, particularly when premature,
      improves their outcomes. Informed by the evidence, treating neonatal pain has
      become the medical standard of care for physicians in neonatology and
      anesthesiology. This article provides a brief overview of relevant publications
      that explain the clinical evolution that has led to the treatment of neonatal
      pain. This article also examines three arguments against the existence of fetal
      pain and presents evidence that refutes them. Informed by the research, a revised
      definition of pain is offered.
CI  - (c) Catholic Medical Association 2020.
FAU - Pierucci, Robin
AU  - Pierucci R
AUID- ORCID: https://orcid.org/0000-0001-7592-4206
AD  - Southwest Michigan Neonatology, PC, Bronson Children's Hospital, Kalamazoo, MI,
      USA.
AD  - Homer Stryker Medical School, Western Michigan University, Kalamazoo, MI, USA.
AD  - NICU, Bronson Children's Hospital, Kalamazoo, MI, USA.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350116
OTO - NOTNLM
OT  - Abortion
OT  - Applied ethics
OT  - Difficult moral questions
OT  - Ethics at the lower limit of neonatal viability
OT  - Maternal-fetal medicine
OT  - Medical research
OT  - Neonatology
OT  - Neuroscience
OT  - Patient care
OT  - Personhood at the beginning and end of life
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363920924877 [doi]
AID - 10.1177_0024363920924877 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):311-316. doi: 10.1177/0024363920924877. Epub 2020 May
      21.


PMID- 32699438
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - The Mathematics (and Metaphysics) of Identical Twins.
PG  - 278-291
LID - 10.1177/0024363920920396 [doi]
AB  - The metaphysics of early embryos is a hotly debated topic in contemporary
      bioethics and metaphysics. Many contemporary Aristotelians believe that a human
      being is present from the moment of conception. At the same time, certain
      findings in modern embryology about the formation of identical twins challenge
      this belief. It becomes much harder when these theories are taken into account to
      understand the continued identity over time of the embryo(s) given the twinning
      process. In this article, I will consider the philosophical implications of two
      models of monozygotic twinning within an Aristotelian metaphysical schema one of 
      which is the standard, or traditional, model. The other of which is a new model
      recently put forward by Herranz. For the sake of completeness, I will also
      consider the philosophical implications of chimeras for the Aristotelian
      position. I will explain how Aristotelians can understand the process of twinning
      while holding on to their belief that a human being is present from the moment of
      conception. SUMMARY: I will argue that a human being is present from the moment
      of conception. I will argue for this on Aristotelian grounds, and I will then
      defend this claim from criticisms based on a number of findings in modern
      embryology.
CI  - (c) Catholic Medical Association 2020.
FAU - Playford, Richard
AU  - Playford R
AUID- ORCID: https://orcid.org/0000-0003-3879-1357
AD  - Institute of Theology, St Mary's University, London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350103
OTO - NOTNLM
OT  - Abortion
OT  - Aquinas
OT  - Aristotle
OT  - Bioethics
OT  - Ethics
OT  - Metaphysics of the human rational soul
OT  - Personhood
OT  - Personhood at the beginning and end of life
OT  - Philosophy
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363920920396 [doi]
AID - 10.1177_0024363920920396 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):278-291. doi: 10.1177/0024363920920396. Epub 2020 May
      12.


PMID- 32699437
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210802
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - Women's Reproductive Health Education in Catholic Academic Healthcare
      Institutions: Time for Transparency, Authenticity, and Reflection.
PG  - 268-277
LID - 10.1177/0024363920923466 [doi]
AB  - This article illustrates the tensions between the precepts of the Ethical and
      Religious Directives for Catholic Healthcare Services and the Accreditation
      Council for Graduate Medical Education as they apply to education in obstetrics
      and gynecology, and argues that moving forward, Catholic sponsorship of obstetric
      and gynecologic residencies now requires transparency, authenticity, and
      reflection in order to mitigate these inherent tensions.
CI  - (c) Catholic Medical Association 2020.
FAU - Smith, James F Jr
AU  - Smith JF Jr
AUID- ORCID: https://orcid.org/0000-0001-9308-8299
AD  - Department of Medical Education, Creighton University School of Medicine, Omaha, 
      NE, USA.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350102
OTO - NOTNLM
OT  - Abortion
OT  - Contraception
OT  - Medical education
OT  - Reproductive ethics
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363920923466 [doi]
AID - 10.1177_0024363920923466 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):268-277. doi: 10.1177/0024363920923466. Epub 2020 May
      12.


PMID- 32699435
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 3
DP  - 2020 Aug
TI  - Testing for Down Syndrome in Catholic Health Care: Complicity in Eugenic
      Abortion.
PG  - 259-264
LID - 10.1177/0024363919895366 [doi]
AB  - Catholic healthcare institutions, physicians, and midwives routinely employ
      testing for Down syndrome as a part of prenatal care. This testing is an
      essential part of eugenic abortion and often leads to it. Catholic teaching
      clearly forbids such testing when undertaken with abortive intent if the baby has
      Down syndrome or other abnormalities. This article discusses (1) the evolution of
      prenatal genetic testing and abortion, (2) how this testing may involve
      complicity in eugenic abortion, and (3) offers proposals to avoid and end
      Catholic healthcare's cooperation with this evil. SUMMARY: This article discusses
      why prenatal genetic testing as practiced in many Catholic healthcare
      institutions is ethically problematic and then proposes solutions.
CI  - (c) Catholic Medical Association 2019.
FAU - Linn, James G
AU  - Linn JG
AUID- ORCID: https://orcid.org/0000-0002-9058-3515
AD  - Independent Author, Shorewood, WI, USA.
LA  - eng
PT  - Journal Article
DEP - 20191222
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7350118
OTO - NOTNLM
OT  - Abortion
OT  - Bioethics
OT  - Catholic identity in health care
OT  - Catholic social teaching
OT  - Cooperation with evil
OT  - Down syndrome
OT  - Ethics
OT  - Obstetrical care
OT  - Prenatal diagnosis
OT  - Prenatal genetics/genetic testing in pregnancy
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/24 06:01
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/24 06:01 [medline]
AID - 10.1177/0024363919895366 [doi]
AID - 10.1177_0024363919895366 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Aug;87(3):259-264. doi: 10.1177/0024363919895366. Epub 2019 Dec
      22.


PMID- 32699396
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20200925
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7817
DP  - 2020 Jul
TI  - Publishers: let transgender scholars correct their names.
PG  - 493
LID - 10.1038/d41586-020-02145-3 [doi]
FAU - Tanenbaum, Theresa Jean
AU  - Tanenbaum TJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - *Authorship
MH  - Female
MH  - Humans
MH  - Male
MH  - Metadata
MH  - *Names
MH  - Prejudice/legislation & jurisprudence/prevention & control
MH  - Publishing/*legislation & jurisprudence/*trends
MH  - *Transgender Persons/psychology
OTO - NOTNLM
OT  - *Authorship
OT  - *Ethics
OT  - *Society
EDAT- 2020/07/24 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - 10.1038/d41586-020-02145-3 [doi]
AID - 10.1038/d41586-020-02145-3 [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7817):493. doi: 10.1038/d41586-020-02145-3.


PMID- 32699242
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20210722
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jul 22
TI  - Helicobacter pylori infection, a risk factor for Type 2 diabetes mellitus: a
      hospital-based cross-sectional study among dyspeptic patients in Douala-Cameroon.
PG  - 12141
LID - 10.1038/s41598-020-69208-3 [doi]
AB  - Diabetic mellitus patients are usually prone to chronic infections. However,
      there have been contradictory reports about the association between H. pylori
      infection and type II diabetes. The present study is aimed at evaluating the
      prevalence of Helicobacter pylori infection among type 2 dyspeptic diabetic
      patients in the littoral region of Cameroon. This cross sectional study comprised
      93 type 2 diabetic dyspeptic patients and 112 non-diabetic dyspeptic patients
      attending the Gastroenterology Department at two reference hospitals in
      Douala-Cameroon. The study was approved by the local Ethical Committee of Medical
      Sciences. Participants were screened for the presence of both type 2 diabetes and
      H. pylori infection. Body mass index (BMI) of all the participants was also
      recorded. Data was analyzed using SSPS statistical package. H. pylori infection
      was found in 73.11% of diabetic patients versus 58.05% in non-diabetic
      participants, this difference was found to be significant (OR = 1.472, p =
      0.0279). This relationship persists even when adjusted to factors such as age and
      income level of participants. Infected participants from age group >/= 55 years
      and those with high income were those with a higher risk to develop diabetes.
      Infected patients with high BMI were more prone to develops diabetic mellitus
      compared with infected patients with normal BMI (p = 0.0034). Also, participant
      with high BMI were more prone to develops diabetic mellitus whether they were
      infected or not. Patients having both H. pylori + ve and BMI >/= 25 kg/m(2) were 
      significantly more affected by diabetic mellitus than those in the others
      combined groups (p < 0.0001), suggested that high BMI and H. pylori infection
      together or not are factors that favor diabetes mellitus development. Separately 
      or not, H. pylori infection and high BMI were risk factor for diabetes mellitus
      in our milieu.
FAU - Kouitcheu Mabeku, Laure Brigitte
AU  - Kouitcheu Mabeku LB
AD  - Microbiology and Pharmacology Laboratory, Department of Biochemistry, Faculty of 
      Science, University of Dschang, P. O. Box 67, Dschang, Cameroon.
      laurebkouitcheu@yahoo.fr.
FAU - Noundjeu Ngamga, Michelle Larissa
AU  - Noundjeu Ngamga ML
AD  - Microbiology and Pharmacology Laboratory, Department of Biochemistry, Faculty of 
      Science, University of Dschang, P. O. Box 67, Dschang, Cameroon.
FAU - Leundji, Hubert
AU  - Leundji H
AD  - Gastroenterology Department, Laquintinie Hospital of Douala, P. O. Box 4035,
      Douala, Cameroon.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Body Mass Index
MH  - Cameroon
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*diagnosis/etiology
MH  - Female
MH  - Glycated Hemoglobin A/analysis
MH  - Helicobacter Infections/complications/microbiology/*pathology
MH  - Helicobacter pylori/isolation & purification
MH  - Hospitals
MH  - Humans
MH  - Income
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk Factors
MH  - Social Class
PMC - PMC7376106
EDAT- 2020/07/24 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-69208-3 [doi]
AID - 10.1038/s41598-020-69208-3 [pii]
PST - epublish
SO  - Sci Rep. 2020 Jul 22;10(1):12141. doi: 10.1038/s41598-020-69208-3.


PMID- 32699168
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 22
TI  - Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a 
      glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive
      airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and
      obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of
      weight loss on the apnea-hypnoea index (AHI).
PG  - e038856
LID - 10.1136/bmjopen-2020-038856 [doi]
AB  - INTRODUCTION: Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) 
      often occur concurrently, and untreated OSA may potentially amplify the high risk
      of cardiovascular disease in T2DM. Compliance with continuous positive airway
      pressure (CPAP), the conventional treatment for OSA, can be poor and considering 
      weight loss is the most effective treatment for OSA. This trial examines whether 
      the glucagon-like peptide-1 receptor agonist liraglutide, a glucose-lowering
      therapy associated with significant weight loss used in T2DM, can improve the
      severity and symptoms of OSA. METHODS AND ANALYSIS: This is an outpatient,
      single-centred, open-labelled, prospective, phase IV randomised controlled trial 
      in a two-by-two factorial design. One hundred and thirty-two patients with newly 
      diagnosed OSA (apnoea-hypopnoea index (AHI) >/=15 events/hour), and existing
      obesity and T2DM (glycated haemoglobin (HbA1c) >/=47 mmol/mol), will be recruited
      from diabetes and sleep medicine outpatient clinics in primary and secondary care
      settings across Liverpool. Patients will be allocated equally, using
      computer-generated random, permuted blocks of unequal sizes, to each of the four 
      treatment arms for 26 weeks: (i) liraglutide (1.8 mg once per day) alone, (ii)
      liraglutide 1.8 mg once per day with CPAP, (iii) CPAP alone (conventional care)
      or (iv) no treatment (control). The primary outcome measure is change in OSA
      severity, determined by AHI. Secondary outcome measures include effects on
      glycaemic control (glycated haemoglobin (HbA1c)), body weight and quality of life
      measures. Exploratory measures include measures of physical activity, MRI-derived
      measures of regional body composition including fat mass (abdominal subcutaneous,
      visceral, neck and liver fat) and skeletal muscle mass (cross-sectional analysis 
      of thigh), indices of cardiac function (using transthoracic echocardiography) and
      endothelial function. ETHICAL APPROVAL: The study has been approved by the North 
      West Liverpool Central Research Ethics Committee (14/NW/1019) and it is being
      conducted in accordance with the Declaration of Helsinki and Good Clinical
      Practice. TRIAL REGISTRATION NUMBERS: ISRCTN16250774. EUDRACT No. 2014-000988-41.
      UTN U1111-1139-0677.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sprung, Victoria S
AU  - Sprung VS
AUID- ORCID: 0000-0002-2666-4986
AD  - Research Institute for Sport & Exercise Sciences, Liverpool John Moores
      University, Liverpool, UK v.s.sprung@ljmu.ac.uk.
AD  - Department of Cardiovascular & Metabolic Medicine, University of Liverpool,
      Liverpool, UK.
AD  - Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS
      Foundation Trust, Liverpool, Merseyside, UK.
FAU - Kemp, Graham J
AU  - Kemp GJ
AD  - Department of Musculoskeletal & Ageing Science, University of Liverpool,
      Liverpool, Merseyside, UK.
AD  - Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool,
      Liverpool, UK.
FAU - Wilding, John Ph
AU  - Wilding JP
AD  - Department of Cardiovascular & Metabolic Medicine, University of Liverpool,
      Liverpool, UK.
AD  - Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS
      Foundation Trust, Liverpool, Merseyside, UK.
FAU - Adams, Valerie
AU  - Adams V
AD  - Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool,
      Liverpool, UK.
FAU - Murphy, Kieran
AU  - Murphy K
AD  - Liverpool Magnetic Resonance Imaging Centre (LiMRIC), University of Liverpool,
      Liverpool, UK.
FAU - Burgess, Malcolm
AU  - Burgess M
AD  - Department of Cardiology, Liverpool University Hospitals NHS Foundation Trust,
      Liverpool, UK.
FAU - Emegbo, Stephen
AU  - Emegbo S
AD  - Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation
      Trust, Liverpool, UK.
FAU - Thomas, Matthew
AU  - Thomas M
AD  - Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation
      Trust, Liverpool, UK.
FAU - Needham, Alexander J
AU  - Needham AJ
AD  - Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.
FAU - Weimken, Andrew
AU  - Weimken A
AD  - Center for Sleep & Circadian Neurobiology, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Schwab, Richard J
AU  - Schwab RJ
AD  - Center for Sleep & Circadian Neurobiology, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Manuel, Ari
AU  - Manuel A
AD  - Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation
      Trust, Liverpool, UK.
FAU - Craig, Sonya E
AU  - Craig SE
AD  - Liverpool Sleep & Ventilation Unit, Aintree University Hospitals NHS Foundation
      Trust, Liverpool, UK.
FAU - Cuthbertson, Daniel J
AU  - Cuthbertson DJ
AD  - Department of Cardiovascular & Metabolic Medicine, University of Liverpool,
      Liverpool, UK.
AD  - Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS
      Foundation Trust, Liverpool, Merseyside, UK.
LA  - eng
SI  - ISRCTN/ISRCTN16250774
SI  - EudraCT/2014-000988-41
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200722
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Continuous Positive Airway Pressure
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Liraglutide/therapeutic use
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Sleep Apnea, Obstructive/complications/therapy
MH  - Treatment Outcome
MH  - Weight Loss
PMC - PMC7380950
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *protocols & guidelines
OT  - *sleep medicine
COIS- Competing interests: DJC has competing interests with AstraZeneca, Boehringer
      Ingelheim, Janssen Pharmaceuticals and Lilly & Novo Nordisk. JW has acted as a
      consultant, received institutional grants and given lectures on behalf of
      pharmaceutical companies developing or marketing medicines used for the treatment
      of diabetes, specifically AstraZeneca, Boehringer Ingelheim, Janssen
      Pharmaceuticals, Lilly, Novo Nordisk and Sanofi & Takeda.
EDAT- 2020/07/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038856 [pii]
AID - 10.1136/bmjopen-2020-038856 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 22;10(7):e038856. doi: 10.1136/bmjopen-2020-038856.


PMID- 32699167
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 22
TI  - Artificial intelligence mobile health platform for early detection of COVID-19 in
      quarantine subjects using a wearable biosensor: protocol for a randomised
      controlled trial.
PG  - e038555
LID - 10.1136/bmjopen-2020-038555 [doi]
AB  - INTRODUCTION: There is an outbreak of COVID-19 worldwide. As there is no
      effective therapy or vaccine yet, rigorous implementation of traditional public
      health measures such as isolation and quarantine remains the most effective tool 
      to control the outbreak. When an asymptomatic individual with COVID-19 exposure
      is being quarantined, it is necessary to perform temperature and symptom
      surveillance. As such surveillance is intermittent in nature and highly dependent
      on self-discipline, it has limited effectiveness. Advances in biosensor
      technologies made it possible to continuously monitor physiological parameters
      using wearable biosensors with a variety of form factors. OBJECTIVE: To explore
      the potential of using wearable biosensors to continuously monitor
      multidimensional physiological parameters for early detection of COVID-19
      clinical progression. METHOD: This randomised controlled open-labelled trial will
      involve 200-1000 asymptomatic subjects with close COVID-19 contact under
      mandatory quarantine at designated facilities in Hong Kong. Subjects will be
      randomised to receive a remote monitoring strategy (intervention group) or
      standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine
      period. In addition to fever and symptom surveillance in the control group,
      subjects in the intervention group will wear wearable biosensors on their arms to
      continuously monitor skin temperature, respiratory rate, blood pressure, pulse
      rate, blood oxygen saturation and daily activities. These physiological
      parameters will be transferred in real time to a smartphone application called
      Biovitals Sentinel. These data will then be processed using a cloud-based
      multivariate physiology analytics engine called Biovitals to detect subtle
      physiological changes. The results will be displayed on a web-based dashboard for
      clinicians' review. The primary outcome is the time to diagnosis of COVID-19.
      ETHICS AND DISSEMINATION: Ethical approval has been obtained from institutional
      review boards at the study sites. Results will be published in peer-reviewed
      journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wong, Chun Ka
AU  - Wong CK
AUID- ORCID: 0000-0001-5205-9440
AD  - Division of Cardiology, Department of Medicine, University of Hong Kong, Hong
      Kong, Hong Kong.
FAU - Ho, Deborah Tip Yin
AU  - Ho DTY
AD  - Division of Infectious Diseases, Department of Medicine, University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Tam, Anthony Raymond
AU  - Tam AR
AD  - Division of Infectious Diseases, Department of Medicine, University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Zhou, Mi
AU  - Zhou M
AUID- ORCID: 0000-0002-0864-9512
AD  - Division of Cardiology, Department of Medicine, University of Hong Kong, Hong
      Kong, Hong Kong.
FAU - Lau, Yuk Ming
AU  - Lau YM
AD  - Division of Cardiology, Department of Medicine, University of Hong Kong, Hong
      Kong, Hong Kong.
FAU - Tang, Milky Oi Yan
AU  - Tang MOY
AD  - Division of Infectious Diseases, Department of Medicine, University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Tong, Raymond Cheuk Fung
AU  - Tong RCF
AD  - Harmony Medical Inc, Hong Kong, Hong Kong.
FAU - Rajput, Kuldeep Singh
AU  - Rajput KS
AD  - Biofourmis, Singapore.
FAU - Chen, Gengbo
AU  - Chen G
AD  - Research and Development, Biofourmis, Singapore.
FAU - Chan, Soon Chee
AU  - Chan SC
AD  - Research and Development, Biofourmis, Singapore.
FAU - Siu, Chung Wah
AU  - Siu CW
AD  - Division of Cardiology, Department of Medicine, University of Hong Kong, Hong
      Kong, Hong Kong cwdsiu@hku.hk.
FAU - Hung, Ivan Fan Ngai
AU  - Hung IFN
AD  - Division of Infectious Diseases, Department of Medicine, University of Hong Kong,
      Hong Kong, Hong Kong.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200722
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Artificial Intelligence
MH  - Betacoronavirus
MH  - Blood Gas Monitoring, Transcutaneous
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques
MH  - Cloud Computing
MH  - Coronavirus Infections/*diagnosis/physiopathology
MH  - Early Diagnosis
MH  - Heart Rate
MH  - Hong Kong
MH  - Humans
MH  - *Mobile Applications
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/physiopathology
MH  - *Quarantine
MH  - Respiratory Rate
MH  - SARS-CoV-2
MH  - Skin Temperature
MH  - *Smartphone
MH  - Telemedicine
MH  - *Wearable Electronic Devices
PMC - PMC7380847
OTO - NOTNLM
OT  - *infection control
OT  - *telemedicine
OT  - *virology
COIS- Competing interests: RCFT is employed by Harmony Medical, which donated the
      Everion wearable devices. KSR, GC and SCC are employed by Biofourmis, which
      donated the Everion wearable devices.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - bmjopen-2020-038555 [pii]
AID - 10.1136/bmjopen-2020-038555 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 22;10(7):e038555. doi: 10.1136/bmjopen-2020-038555.


PMID- 32699166
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 22
TI  - A multicentre observational study on neonates exposed to SARS-CoV-2 in China: the
      Neo-SARS-CoV-2 Study protocol.
PG  - e038004
LID - 10.1136/bmjopen-2020-038004 [doi]
AB  - INTRODUCTION: An outbreak of severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) occurred in Wuhan, China starting in December 2019. Yet the clinical
      features and long-term outcomes of neonates with SARS-CoV-2 exposure are lacking.
      The purpose of this study is to describe the clinical course and prognosis of the
      neonates exposed to SARS-CoV-2. METHODS AND ANALYSIS: This is a multicentre
      observational study conducted at the designated children and maternal and child
      hospitals in the mainland of China. Neonates exposed to SARS-CoV-2 infection will
      be recruited. The data to be collected via case report forms include demographic 
      details, clinical features, laboratory and imaging results, as well as outcomes. 
      Primary outcomes are the mortality of neonates with COVID-19 and SARS-CoV-2
      infection of neonates born to mothers with COVID-19. Secondary outcomes are the
      birth weight, premature delivery and neurological development of neonates exposed
      to SARS-CoV-2. The neurological development is assessed by the Chinese
      standardised Denver Developmental Screening Test at the corrected age of 6
      months. ETHICS AND DISSEMINATION: This study has been approved by the Children's 
      Hospital of Fudan University ethics committee (No. (2020)31). The study findings 
      will be disseminated in peer-reviewed journals and presented at national and
      international conferences in order to improve the understanding of the clinical
      course among neonates exposed to SARS-CoV-2 and to provide evidence-based
      treatment and prevention strategies for this group. TRIAL REGISTRATION NUMBER:
      NCT04279899.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xiao, Tiantian
AU  - Xiao T
AUID- ORCID: 0000-0002-8045-9190
AD  - Department of Neonatology, Children's Hospital of Fudan University, Shanghai,
      China.
AD  - Department of Neonatology, Chengdu Women's and Children's Central Hospital,
      School of Medicine, University of Electronic Science and Technology of China,
      Chengdu, China.
FAU - Xia, Shiwen
AU  - Xia S
AD  - Department of Neonatology, Hubei Maternal and Child Health Hospital, Wuhan,
      China.
FAU - Zeng, Linkong
AU  - Zeng L
AD  - Department of Neonatology, Wuhan Children's Hospital, Wuhan, China.
FAU - Lin, Guang
AU  - Lin G
AD  - Department of Pediatrics, Zhu Hai Maternal and Children's Hospital, Zhuhai,
      China.
FAU - Wei, Qiufen
AU  - Wei Q
AD  - Department of Neonatology, The Maternal and Child Health Hospital of Guangxi
      Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region, China.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Department of Neonatology, Guangzhou Women and Children's Medical Centre,
      Guangzhou Medical University, Guangzhou, China.
FAU - Zhuang, Deyi
AU  - Zhuang D
AD  - Department of Pediatrics, Xiamen Children's Hospital, Xiamen, China.
FAU - Chen, Xiao
AU  - Chen X
AD  - Department of Pediatrics, First Affiliated Hospital of Nanchang University,
      Nanchang, Jiangxi, China.
FAU - Yi, Bin
AU  - Yi B
AD  - Department of Neonatology, Gansu provincial maternity and child-care hospital,
      Lanzhou, China.
FAU - Li, Long
AU  - Li L
AD  - Department of Neonatology, People's Hospital of Xinjiang Your Autonomous Region, 
      Xinjiang, China.
FAU - Mi, Hongying
AU  - Mi H
AD  - Department of Neonatology, The First People's Hospital Of Yunnan Province,
      Kunming, China.
FAU - Yin, Zhaoqing
AU  - Yin Z
AD  - Department of Neonatology, Dehong People Hospital, Dehong, China.
FAU - Cheng, Xiuyong
AU  - Cheng X
AD  - Department of Neonatology, The First Affiliated Hospital of Zhengzhou University,
      Zhengzhou, China.
FAU - Wang, Laishuan
AU  - Wang L
AD  - Department of Pediatrics, Children's Hospital of Fudan University, Shanghai,
      China.
FAU - Hu, Xiaojing
AU  - Hu X
AD  - Department of Neonatology, Children's Hospital of Fudan University, Shanghai,
      China.
FAU - Zhou, Wenhao
AU  - Zhou W
AD  - Department of Neonatology, Children's Hospital of Fudan University, Shanghai,
      China zhouwenhao@fudan.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT04279899
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200722
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Child Development
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology/mortality/physiopathology
MH  - Female
MH  - Hospitals, Maternity
MH  - Hospitals, Pediatric
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Neurodevelopmental Disorders/*epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/mortality/physiopathology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*epidemiology
MH  - Premature Birth/*epidemiology
MH  - Prospective Studies
MH  - SARS-CoV-2
MH  - Severity of Illness Index
PMC - PMC7380854
OTO - NOTNLM
OT  - *infectious diseases
OT  - *neonatal intensive & critical care
OT  - *perinatology
COIS- Competing interests: None declared.
EDAT- 2020/07/24 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - bmjopen-2020-038004 [pii]
AID - 10.1136/bmjopen-2020-038004 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 22;10(7):e038004. doi: 10.1136/bmjopen-2020-038004.


PMID- 32699165
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 22
TI  - Hospital-based chronic disease care model: protocol for an effectiveness and
      implementation evaluation.
PG  - e037843
LID - 10.1136/bmjopen-2020-037843 [doi]
AB  - INTRODUCTION: Novel and efficient healthcare approaches are needed to better
      serve increasingly older chronic disease patients. Many effective integrated
      chronic disease management strategies have emerged from the primary care sector. 
      However, in many Asian and developing countries, primary care is underdeveloped, 
      and patients prefer secondary-based services. The Integrated Generalist-led
      Hospital (IGH) care model is a new approach, which may be better suited for
      chronic disease patients in the local context. METHODS AND ANALYSIS: A hybrid
      type I study on the effectiveness and implementation of the IGH care model will
      be conducted. Implementation evaluation will be informed by the Consolidated
      Framework of Implementation Research (CFIR). Quantitative and qualitative data
      will be collected through in-depth interviews and focus group discussions with
      staff, a staff survey, patient interviews, clinical outcomes and cost data.
      Clinical outcomes include the length of stay, readmission, emergency room visit
      rate and mortality. Clinical outcomes will be summarised and compared with a
      propensity-matched 'usual care' group (derived from the general medicine ward(s) 
      at a separate hospital). The Kaplan-Meier approach will be used to estimate time 
      until death and time until first readmission (both within 30 days of discharge)
      and time until discharge. Multivariate regression models will be used to
      investigate the association between the care model and occurrence of readmission,
      emergency room visit and death, all within 30 days of discharge. Qualitative data
      will be analysed using a thematic analysis method. Qualitative and quantitative
      data will also be coded according to the five domains of the CFIR. ETHICS AND
      DISSEMINATION: This protocol was reviewed and approved by the National Healthcare
      Group Domain Specific Review Board (NHG DSRB 2019/00308). Results will be
      published in peer-reviewed scientific journals and conference presentations.
      Findings will also be discussed with key stakeholders through local dissemination
      events.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sumner, Jennifer
AU  - Sumner J
AUID- ORCID: 0000-0002-2200-3275
AD  - Medical Affairs - Research, Innovation & Enterprise, Alexandra Hospital,
      Singapore jenny.sumner@york.ac.uk.
AD  - Yong Loo Lin School of Medicine, Department of Medicine, National University of
      Singapore, Singapore.
FAU - Phua, Jason
AU  - Phua J
AD  - Fast and Chronic Programmes, Alexandra Hospital, Singapore.
AD  - Division of Respiratory and Critical Care Medicine, University Medicine Cluster, 
      National University Health System, Singapore.
FAU - Lim, Yee Wei
AU  - Lim YW
AD  - Medical Affairs - Research, Innovation & Enterprise, Alexandra Hospital,
      Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200722
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - *Delivery of Health Care
MH  - Hospitals
MH  - Humans
MH  - *Research Design
PMC - PMC7380726
OTO - NOTNLM
OT  - *general medicine (see internal medicine)
OT  - *international health services
OT  - *organisation of health services
COIS- Competing interests: None declared.
EDAT- 2020/07/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037843 [pii]
AID - 10.1136/bmjopen-2020-037843 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 22;10(7):e037843. doi: 10.1136/bmjopen-2020-037843.


PMID- 32699147
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20201218
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 32
DP  - 2020 Aug 11
TI  - Opinion: It's ethical to test promising coronavirus vaccines against
      less-promising ones.
PG  - 18898-18901
LID - 10.1073/pnas.2014154117 [doi]
FAU - Eyal, Nir
AU  - Eyal N
AD  - Center for Population-Level Bioethics and Department of Philosophy, Rutgers
      University, New Brunswick, NJ 08901; nir.eyal@rutgers.edu.
AD  - Department of Health Behavior, Society, and Policy, Rutgers School of Public
      Health, Piscataway, NJ 08854.
FAU - Lipsitch, Marc
AU  - Lipsitch M
AD  - Center for Communicable Disease Dynamics, Department of Epidemiology, and
      Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of
      Public Health, Boston, MA 02115N.E. declares no competing interest. M.L. receives
      research support from Pfizer, unrelated to COVID-19.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/prevention & control
MH  - Humans
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/prevention & control
MH  - Viral Vaccines/adverse effects/*standards
PMC - PMC7431044
EDAT- 2020/07/24 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/07/24 06:00 [entrez]
AID - 2014154117 [pii]
AID - 10.1073/pnas.2014154117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18898-18901. doi:
      10.1073/pnas.2014154117. Epub 2020 Jul 22.


PMID- 32699133
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 21
TI  - Prospective, multicentre, single-arm phase II trial of pembrolizumab combined
      with carboplatin and pemetrexed in elderly patients with advanced, non-squamous
      non-small cell lung cancer.
PG  - e037746
LID - 10.1136/bmjopen-2020-037746 [doi]
AB  - INTRODUCTION: Triplet regimen of carboplatin or cisplatin with pemetrexed and
      pembrolizumab is a standard treatment for patients with advanced, chemo-naive,
      non-squamous non-small cell lung cancer. However, subgroup analysis for patients 
      aged >/=75 years indicated that elderly patients who received the triplet regimen
      may have had shorter survival times than if they had chemotherapy alone (HR of
      2.09). Treatments in the elderly are not always as effective or safe as for
      non-elderly patients, so there remains concern over whether the triplet regimen
      can be widely used in the elderly. METHODS AND ANALYSIS: This is a single-arm,
      prospective, multicentre phase II study. The primary endpoint is set as the
      overall response rate according to Response Evaluation Criteria in Solid Tumors
      V.1.1. Secondary endpoints are progression-free survival, disease control rate
      and safety. This trial will enrol 22 patients. ETHICS AND DISSEMINATION: This
      study was approved by the Wakayama Medical University Central Review Board on 2
      December 2019 (approval number: W-32). Patients have been enrolled since February
      2020. As the study will complete accrual in January 2022, results will be
      submitted for publication in peer-reviewed medical journals within 2023 and
      international scientific meetings. This study will provide significant
      information on whether the triplet regimens are clinically beneficial to elderly 
      patients. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials
      (jRCTs051190095).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ozawa, Yuichi
AU  - Ozawa Y
AUID- ORCID: 0000-0003-3798-3488
AD  - Internal Medicine III, Wakayama Medical University, Wakayama, Japan
      u1.ozawa@wakayama-med.ac.jp.
FAU - Sugimoto, Takeya
AU  - Sugimoto T
AD  - Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
FAU - Azuma, Yuichiro
AU  - Azuma Y
AD  - Department of Respiratory Medicine, National Hospital Organization Wakayama
      Hospital, Mihama, Japan.
FAU - Harutani, Yuhei
AU  - Harutani Y
AD  - Department of Respiratory Medicine, National Hospital Organization Minami
      Wakayama Medical Center, Tanabe, Japan.
FAU - Yoshikawa, Takanori
AU  - Yoshikawa T
AD  - Clinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
FAU - Yamamoto, Nobuyuki
AU  - Yamamoto N
AD  - Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
FAU - Kanai, Kuninobu
AU  - Kanai K
AD  - Department of Respiratory Medicine, Naga Municipal Hospital, Kinokawa, Japan.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200721
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - BG3F62OND5 (Carboplatin)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Carboplatin
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Humans
MH  - Japan
MH  - *Lung Neoplasms/drug therapy
MH  - Middle Aged
MH  - Pemetrexed/therapeutic use
MH  - Prospective Studies
PMC - PMC7375432
OTO - NOTNLM
OT  - *chemotherapy
OT  - *clinical trials
OT  - *oncology
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at http://www.icmje.org/coi_disclosure.pdf and declare no support from any
      organisation for the submitted work; YO has received personal fees from MSD K.K. 
      and Eli Lilly, YH received personal fees from Bristle-Myers Squibb, NY received
      personal fees from MSD K.K. and Eli Lilly, Bristle-Myers Squibb, and Nichi-iko
      Pharmaceutical; no other relationships or activities that could appear to have
      influenced the submitted work.
EDAT- 2020/07/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037746 [pii]
AID - 10.1136/bmjopen-2020-037746 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 21;10(7):e037746. doi: 10.1136/bmjopen-2020-037746.


PMID- 32699131
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 21
TI  - Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE): protocol
      for a multisite prospective observational study of the causes of fever in Africa 
      and Asia.
PG  - e035632
LID - 10.1136/bmjopen-2019-035632 [doi]
AB  - INTRODUCTION: Fever commonly leads to healthcare seeking and hospital admission
      in sub-Saharan Africa and Asia. There is only limited guidance for clinicians
      managing non-malarial fevers, which often results in inappropriate treatment for 
      patients. Furthermore, there is little evidence for estimates of disease burden, 
      or to guide empirical therapy, control measures, resource allocation,
      prioritisation of clinical diagnostics or antimicrobial stewardship. The Febrile 
      Illness Evaluation in a Broad Range of Endemicities (FIEBRE) study seeks to
      address these information gaps. METHODS AND ANALYSIS: FIEBRE investigates febrile
      illness in paediatric and adult outpatients and inpatients using standardised
      clinical, laboratory and social science protocols over a minimum 12-month period 
      at five sites in sub-Saharan Africa and Southeastern and Southern Asia. Patients 
      presenting with fever are enrolled and provide clinical data, pharyngeal swabs
      and a venous blood sample; selected participants also provide a urine sample.
      Laboratory assessments target infections that are treatable and/or preventable.
      Selected point-of-care tests, as well as blood and urine cultures and
      antimicrobial susceptibility testing, are performed on site. On day 28, patients 
      provide a second venous blood sample for serology and information on clinical
      outcome. Further diagnostic assays are performed at international reference
      laboratories. Blood and pharyngeal samples from matched community controls enable
      calculation of AFs, and surveys of treatment seeking allow estimation of the
      incidence of common infections. Additional assays detect markers that may
      differentiate bacterial from non-bacterial causes of illness and/or prognosticate
      illness severity. Social science research on antimicrobial use will inform future
      recommendations for fever case management. Residual samples from participants are
      stored for future use. ETHICS AND DISSEMINATION: Ethics approval was obtained
      from all relevant institutional and national committees; written informed consent
      is obtained from all participants or parents/guardians. Final results will be
      shared with participating communities, and in open-access journals and other
      scientific fora. Study documents are available online
      (https://doi.org/10.17037/PUBS.04652739).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hopkins, Heidi
AU  - Hopkins H
AUID- ORCID: 0000-0003-1076-6758
AD  - Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical 
      Medicine, London, UK heidi.hopkins@lshtm.ac.uk.
FAU - Bassat, Quique
AU  - Bassat Q
AD  - ISGlobal, Hospital Clinic - Universitat de Barcelona, Barcelona, Spain.
AD  - Centro de Investigacao em Saude de Manhica (CISM), Maputo, Mozambique.
AD  - ICREA, Pg. Lluis Companys 23, Barcelona, Spain.
AD  - Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de 
      Deu (University of Barcelona), Barcelona, Spain.
FAU - Chandler, Clare Ir
AU  - Chandler CI
AD  - Department of Global Health and Development, London School of Hygiene & Tropical 
      Medicine, London, UK.
FAU - Crump, John A
AU  - Crump JA
AD  - Centre for International Health, University of Otago, Dunedin, New Zealand.
FAU - Feasey, Nicholas A
AU  - Feasey NA
AD  - Department of Clinical Sciences, Liverpool School of Tropical Medicine,
      Liverpool, UK.
AD  - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
FAU - Ferrand, Rashida A
AU  - Ferrand RA
AD  - Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical 
      Medicine, London, UK.
AD  - Biomedical Research and Training Institute, Harare, Zimbabwe.
FAU - Kranzer, Katharina
AU  - Kranzer K
AD  - Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical 
      Medicine, London, UK.
AD  - Biomedical Research and Training Institute, Harare, Zimbabwe.
AD  - National and Supranational Reference Center for Mycobacteria, Research Center
      Borstel, Leibniz Lung Center, Borstel, Germany.
FAU - Lalloo, David G
AU  - Lalloo DG
AD  - Liverpool School of Tropical Medicine, Liverpool, UK.
FAU - Mayxay, Mayfong
AU  - Mayxay M
AD  - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Mahosot
      Hospital, Vientiane, Lao People's Democratic Republic.
AD  - Institute of Research and Education Development, University of Health Sciences,
      Ministry of Health, Vientiane, Lao People's Democratic Republic.
FAU - Newton, Paul N
AU  - Newton PN
AD  - Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical 
      Medicine, London, UK.
AD  - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Mahosot
      Hospital, Vientiane, Lao People's Democratic Republic.
AD  - Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
FAU - Mabey, David
AU  - Mabey D
AD  - Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical 
      Medicine, London, UK.
CN  - FIEBRE Consortium
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200721
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Aug 31;10(8):e035632corr1. PMID: 32868371
MH  - Africa
MH  - Asia
MH  - Child
MH  - Child, Preschool
MH  - *Clinical Protocols
MH  - Female
MH  - Fever/*diagnosis/*physiopathology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Prospective Studies
MH  - Symptom Assessment/*methods/trends
PMC - PMC7375419
OTO - NOTNLM
OT  - *diagnostic microbiology
OT  - *epidemiology
OT  - *infectious diseases
OT  - *public health
OT  - *tropical medicine
COIS- Competing interests: JC reports grants from UK Department for International
      Development during the conduct of the study; RF reports grants from Wellcome
      Trust during the conduct of the study; FCF reports grants from Academy of Medical
      Sciences, from Healthcare Infection Society, from Wellcome Trust, and
      non-financial support from UCL and Great Ormond Street BRC, outside the submitted
      work; KCK reports grants from Canadian Institutes of Health Research and from
      Canada Research Chair Programme during the conduct of the study, and is a named
      inventor on patents owned by his institution related to the use of angiopoietin
      markers, entitled 'Angiopoietin-1 and -2 biomarkers for infectious diseases that 
      compromise endothelial integrity' (application WO2009059404) and 'Biomarkers for 
      early determination of a critical or life threatening response to illness and
      monitoring response to treatment' (application CA2769433) with royalties paid.
      All other co-authors declare: no financial relationships with any organisations
      that might have an interest in the submitted work, and no other relationships or 
      activities that could appear to have influenced the submitted work.
IR  - Amos B
FIR - Amos, Benjamin
IR  - Bell D
FIR - Bell, David
IR  - Blacksell SD
FIR - Blacksell, Stuart D
IR  - Bradley J
FIR - Bradley, John
IR  - Chandler CI
FIR - Chandler, Clare Ir
IR  - Chansamouth V
FIR - Chansamouth, Vilada
IR  - Chimenya M
FIR - Chimenya, Mabvuto
IR  - Craig SB
FIR - Craig, Scott B
IR  - Dance DA
FIR - Dance, David Ab
IR  - Dauya E
FIR - Dauya, Ethel
IR  - Lamballerie X
FIR - Lamballerie, Xavier de
IR  - Graves SR
FIR - Graves, Stephen R
IR  - Green EW
FIR - Green, Edward W
IR  - Haigh KA
FIR - Haigh, Kate A
IR  - Handley BL
FIR - Handley, Becca L
IR  - Hibberd ML
FIR - Hibberd, Martin L
IR  - Hutchison CD
FIR - Hutchison, Coll D
IR  - Jones J
FIR - Jones, Jayne
IR  - Kain KC
FIR - Kain, Kevin C
IR  - Lal P
FIR - Lal, Pankaj
IR  - Lal S
FIR - Lal, Sham
IR  - Lubell Y
FIR - Lubell, Yoel
IR  - Marlais T
FIR - Marlais, Tegwen
IR  - Maurer FP
FIR - Maurer, Florian P
IR  - Olaru ID
FIR - Olaru, Ioana D
IR  - Parry CM
FIR - Parry, Christopher M
IR  - Roberts CH
FIR - Roberts, Chrissy H
IR  - Stenos J
FIR - Stenos, John
IR  - Tembe N
FIR - Tembe, Nelson
IR  - Ussher JE
FIR - Ussher, James E
IR  - Valente M
FIR - Valente, Marta
IR  - Vitorino P
FIR - Vitorino, Pio
IR  - Voice MA
FIR - Voice, Marie A
IR  - Joseph Wheat L
FIR - Joseph Wheat, L
IR  - Dixon J
FIR - Dixon, Justin
IR  - Dubot-Peres A
FIR - Dubot-Peres, Audrey
IR  - Durkin MM
FIR - Durkin, Michelle M
IR  - Fink C
FIR - Fink, Colin
IR  - Fitzgerald FC
FIR - Fitzgerald, Felicity C
EDAT- 2020/07/24 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035632 [pii]
AID - 10.1136/bmjopen-2019-035632 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 21;10(7):e035632. doi: 10.1136/bmjopen-2019-035632.


PMID- 32699128
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 21
TI  - Early Parenting Intervention - Biobehavioral Outcomes in infants with
      Neurodevelopmental Disabilities (EPI-BOND): study protocol for an Italian
      multicentre randomised controlled trial.
PG  - e035249
LID - 10.1136/bmjopen-2019-035249 [doi]
AB  - INTRODUCTION: Neurodevelopmental disability (ND) represents an adverse condition 
      for infants' socio-emotional and behavioural development as well as for
      caregiving (eg, parental sensitivity) and mother-infant interaction. Adverse
      exposures are associated with altered neuroendocrine hormones concentrations (eg,
      oxytocin and cortisol) and epigenetic regulation (eg, methylation of
      stress-related genes), which in turn may contribute to less-than-optimal
      mother-infant interaction. Parental sensitivity is a protective factor for
      childrens' development and early parental interventions (eg, video-feedback
      intervention) can promote parental caregiving and better developmental outcomes
      in children. The present multi-centric and longitudinal randomised controlled
      trial aims to assess if and to which extent early VFI could benefit both infants 
      and mothers in terms of behavioural outcomes as well as neuroendocrine and
      epigenetic regulation. METHODS AND ANALYSIS: Dyads will be randomly assigned to
      the video-feedback Intervention Group or Control Group ('dummy' intervention:
      telephone calls). Infants with ND aged 3 to 18 months will be recruited from
      three major child neuropsychiatric units in northern Italy. A multi-layer
      approach to intervention effects will include videotapes of mother-infant
      interaction, maternal reports as well as saliva samples for hormones
      concentrations and target-gene methylation analysis (eg, BDNF, NR3C1, OXTR and
      SCL6A4) that will be obtained at each of the four assessment sessions: T0,
      baseline; T1, post-intervention; T2, short-term follow-up (3 month); T3,
      long-term follow-up (6 month). Primary effectiveness measures will be infant
      socio-emotional behaviour and maternal sensitivity. Neuroendocrine hormones
      concentrations and DNA methylation status of target genes will be secondary
      outcomes. Feasibility, moderation and confounding variables will be measured and 
      controlled between the two groups. ETHICS AND DISSEMINATION: Ethics approval has 
      been obtained in all three participating units. Results of the main trial and
      each of the secondary endpoints will be submitted for publication in
      peer-reviewed journals and international conferences. TRIAL REGISTRATION NUMBER: 
      NCT03853564; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Montirosso, Rosario
AU  - Montirosso R
AD  - 0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio
      Parini, Lecco, Italy rosario.montirosso@lanostrafamiglia.it.
FAU - Rosa, Elisa
AU  - Rosa E
AD  - 0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio
      Parini, Lecco, Italy.
FAU - Giorda, Roberto
AU  - Giorda R
AD  - Biology Lab, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.
FAU - Fazzi, Elisa
AU  - Fazzi E
AD  - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,
      Italy.
AD  - Unit of Child and Adolescence Neuropsychiatry, ASST Spedali Civili, Brescia,
      Italy.
FAU - Orcesi, Simona
AU  - Orcesi S
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
AD  - Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
FAU - Cavallini, Anna
AU  - Cavallini A
AD  - Neuropsychiatry and Neurorehabilitation Unit, Scientific Institute IRCCS E.
      Medea, Bosisio Parini, Lecco, Italy.
FAU - Provenzi, Livio
AU  - Provenzi L
AUID- ORCID: 0000-0001-7424-8744
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
CN  - Early Intervention Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03853564
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200721
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 50-56-6 (Oxytocin)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - *DNA Methylation
MH  - *Developmental Disabilities
MH  - Early Intervention, Educational/*methods
MH  - Epigenesis, Genetic
MH  - Female
MH  - Formative Feedback
MH  - Humans
MH  - Hydrocortisone/analysis
MH  - Infant
MH  - Italy
MH  - Male
MH  - *Mother-Child Relations
MH  - Multicenter Studies as Topic
MH  - *Nervous System Diseases
MH  - Oxytocin/analysis
MH  - Randomized Controlled Trials as Topic
MH  - Saliva/chemistry
MH  - Stress, Psychological/enzymology/genetics
PMC - PMC7375429
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *genetics
OT  - *paediatrics
COIS- Competing interests: None declared.
IR  - Borgatti R
FIR - Borgatti, Renato
IR  - Caporali C
FIR - Caporali, Camilla
IR  - Gasparini L
FIR - Gasparini, Linda
IR  - Micheletti S
FIR - Micheletti, Serena
IR  - Naboni C
FIR - Naboni, Cecilia
IR  - Scarano E
FIR - Scarano, Elisa
IR  - Visintin E
FIR - Visintin, Eleonora
IR  - Pisoni C
FIR - Pisoni, Camilla
EDAT- 2020/07/24 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-035249 [pii]
AID - 10.1136/bmjopen-2019-035249 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 21;10(7):e035249. doi: 10.1136/bmjopen-2019-035249.


PMID- 32699123
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 21
TI  - Auditory electrophysiological assessments of Alzheimer's disease and preclinical 
      stages: protocol for a systematic review and meta-analysis.
PG  - e033308
LID - 10.1136/bmjopen-2019-033308 [doi]
AB  - INTRODUCTION: Investigating auditory functions in populations at risk of
      developing Alzheimer's disease (AD) using auditory neurophysiological
      measurements can potentially identify a crucial and sensitive diagnostic window
      of opportunity in preclinical AD. Auditory electrophysiological assessments have 
      gained interest as possible tools for early diagnosis of AD. This paper outlines 
      the protocol that will be used to systematically review the published literature 
      currently available on auditory electrophysiological assessments that have been
      used to assess the auditory functions of adults over the age of 60 years
      diagnosed with AD or its preclinical stages. METHODS AND ANALYSIS: All
      full-length peer-reviewed publications of original data that use auditory
      electrophysiological assessments in AD and its preclinical stages (subjective
      cognitive decline (SCD) and mild cognitive impairment (MCI)) will be considered
      in this review. The search will be performed on major electronic databases (Ovid 
      MEDLINE, Ovid Embase, PsycINFO, PubMed, Scopus and CINAHL Plus) using keywords
      alone or in combination with Medical Subject Headings divided into two domains;
      (i) auditory tests and (ii) AD. The database search will be conducted on the
      7(th) of May 2019. Data analysis will be completed and reported in the full
      review. A random effects meta-analysis will also be conducted using the
      Comprehensive Meta-Analysis software, V.3. This review will describe which
      auditory electrophysiological tests have been found to be useful in assessing the
      auditory function in cognitively impaired adults (MCI and AD) or adults with
      serious complaints about their cognition (SCD). This review will also identify
      and describe which auditory electrophysiological test demonstrates the most
      sensitivity in differentiating people at different stages of cognitive decline.
      ETHICS AND DISSEMINATION: This systematic review focusses on analysing already
      available literature. Therefore, there will be no requirement for ethical
      approval. The systematic review findings will be disseminated through
      peer-reviewed publication as well as relevant media platforms, for example,
      conferences. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019133553.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tarawneh, Hadeel Y
AU  - Tarawneh HY
AUID- ORCID: 0000-0003-1860-9167
AD  - School of Human Sciences, University of Western Australia, Crawley, Western
      Australia, Australia hadeel.tarawneh@research.uwa.edu.au.
AD  - Ear Science Institute Australia, Subiaco, Western Australia, Australia.
AD  - Ear Science Centre, School of Surgery, University of Western Australia, Crawley, 
      Western Australia, Australia.
FAU - Mulders, Wilhelmina H A M
AU  - Mulders WHAM
AD  - School of Human Sciences, University of Western Australia, Crawley, Western
      Australia, Australia.
FAU - Sohrabi, Hamid R
AU  - Sohrabi HR
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences,
      Macquarie University, Macquarie, New South Wales, Australia.
FAU - Martins, Ralph N
AU  - Martins RN
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences,
      Macquarie University, Macquarie, New South Wales, Australia.
FAU - Jayakody, Dona M P
AU  - Jayakody DMP
AD  - Ear Science Institute Australia, Subiaco, Western Australia, Australia.
AD  - Ear Science Centre, School of Surgery, University of Western Australia, Crawley, 
      Western Australia, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Alzheimer Disease/diagnosis
MH  - Cognition
MH  - *Cognitive Dysfunction/diagnosis
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Systematic Reviews as Topic
PMC - PMC7375420
OTO - NOTNLM
OT  - *auditory evoked potentials
OT  - *cognitive impairment
OT  - *dementia
EDAT- 2020/07/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033308 [pii]
AID - 10.1136/bmjopen-2019-033308 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 21;10(7):e033308. doi: 10.1136/bmjopen-2019-033308.


PMID- 32698869
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 22
TI  - Use of AI-based tools for healthcare purposes: a survey study from consumers'
      perspectives.
PG  - 170
LID - 10.1186/s12911-020-01191-1 [doi]
AB  - BACKGROUND: Several studies highlight the effects of artificial intelligence (AI)
      systems on healthcare delivery. AI-based tools may improve prognosis,
      diagnostics, and care planning. It is believed that AI will be an integral part
      of healthcare services in the near future and will be incorporated into several
      aspects of clinical care. Thus, many technology companies and governmental
      projects have invested in producing AI-based clinical tools and medical
      applications. Patients can be one of the most important beneficiaries and users
      of AI-based applications whose perceptions may affect the widespread use of
      AI-based tools. Patients should be ensured that they will not be harmed by
      AI-based devices, and instead, they will be benefited by using AI technology for 
      healthcare purposes. Although AI can enhance healthcare outcomes, possible
      dimensions of concerns and risks should be addressed before its integration with 
      routine clinical care. METHODS: We develop a model mainly based on value
      perceptions due to the specificity of the healthcare field. This study aims at
      examining the perceived benefits and risks of AI medical devices with clinical
      decision support (CDS) features from consumers' perspectives. We use an online
      survey to collect data from 307 individuals in the United States. RESULTS: The
      proposed model identifies the sources of motivation and pressure for patients in 
      the development of AI-based devices. The results show that technological, ethical
      (trust factors), and regulatory concerns significantly contribute to the
      perceived risks of using AI applications in healthcare. Of the three categories, 
      technological concerns (i.e., performance and communication feature) are found to
      be the most significant predictors of risk beliefs. CONCLUSIONS: This study sheds
      more light on factors affecting perceived risks and proposes some recommendations
      on how to practically reduce these concerns. The findings of this study provide
      implications for research and practice in the area of AI-based CDS. Regulatory
      agencies, in cooperation with healthcare institutions, should establish normative
      standard and evaluation guidelines for the implementation and use of AI in
      healthcare. Regular audits and ongoing monitoring and reporting systems can be
      used to continuously evaluate the safety, quality, transparency, and ethical
      factors of AI-based services.
FAU - Esmaeilzadeh, Pouyan
AU  - Esmaeilzadeh P
AUID- ORCID: 0000-0002-3885-8112
AD  - Department of Information Systems and Business Analytics, College of Business,
      Florida International University, Miami, FL, 33199, USA. pesmaeil@fiu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - Adult
MH  - *Artificial Intelligence
MH  - *Decision Support Systems, Clinical
MH  - Delivery of Health Care
MH  - Female
MH  - Health Facilities
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - United States
MH  - Young Adult
PMC - PMC7376886
OTO - NOTNLM
OT  - *AI medical devices
OT  - *Artificial intelligence (AI)
OT  - *Clinical decision support
OT  - *Intention to use
OT  - *Perceived benefits
OT  - *Perceived risks
EDAT- 2020/07/24 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/07/24 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/07/24 06:00 [entrez]
PHST- 2020/07/24 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
AID - 10.1186/s12911-020-01191-1 [doi]
AID - 10.1186/s12911-020-01191-1 [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Jul 22;20(1):170. doi: 10.1186/s12911-020-01191-1.


PMID- 32697452
STAT- Publisher
DA  - 20200723
PB  - NIHR Journals Library
CTI - Efficacy and Mechanism Evaluation
DP  - 2020 Jul
BTI - Spironolactone to improve exercise tolerance in people with permanent atrial
      fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
LID - 10.3310/eme07040 [doi]
AB  - INTRODUCTION: Patients with atrial fibrillation frequently suffer from heart
      failure despite having a normal ejection fraction. There is no proven therapy to 
      improve physical capacity and quality of life in patients with permanent atrial
      fibrillation with preserved cardiac contractility. OBJECTIVE: The IMproved
      exercise tolerance in heart failure with PReserved Ejection fraction by
      Spironolactone on myocardial fibrosiS in Atrial Fibrillation (IMPRESS-AF) trial
      addressed whether or not 2 years of treatment with spironolactone, as compared
      with placebo, improves exercise tolerance, quality of life and diastolic function
      in patients with permanent atrial fibrillation and preserved left ventricular
      ejection fraction. DESIGN: A randomised, single-centre, double-blind,
      placebo-controlled trial. SETTING: Two hundred and fifty ambulatory patients
      [mean age 72.3 years (standard deviation 7.4 years); 23.6% female] with permanent
      atrial fibrillation and left ventricular ejection fraction >/= 55% [mean 60.5%
      (standard deviation 5.5%)]. INTERVENTIONS: Treatment with either 25 mg of
      spironolactone (n = 125) or placebo (n = 125) daily. MAIN OUTCOME MEASURES: The
      primary efficacy end point was exercise tolerance at 2 years as measured by peak 
      oxygen consumption (VO2) on cardiopulmonary exercise testing. Secondary end
      points were quality of life, the ratio of mitral peak velocity of early filling
      (E) to early diastolic mitral annular velocity (E') (E/E'; a marker of diastolic 
      dysfunction), all-cause hospital admissions and spontaneous return to sinus
      rhythm. Treatment effects were estimated by adjusting for baseline values. STUDY 
      ETHICS: The study was approved by the National Research and Ethics Committee West
      Midlands - Coventry and Warwickshire (reference 14/WM/1211). All patients
      provided informed written consent. RESULTS: There was no difference in the peak
      oxygen consumption at 2 years between the spironolactone group [analysed, n =
      103; mean VO2 14.03 ml/minute/kg (standard deviation 5.38 ml/minute/kg)] and the 
      placebo group [analysed, n = 106; mean VO2 14.45 ml/minute/kg (standard deviation
      5.14 ml/minute/kg)] (adjusted treatment effect -0.28 ml/minute/kg, 95% confidence
      interval -1.27 to 0.71 ml/minute/kg; p = 0.58). The findings were consistent
      across all sensitivity analyses. For secondary efficacy end points, there was no 
      significant change in the mean 6-minute walking distance (treatment effect -8.47 
      m, 95% confidence interval -31.87 to 14.93 m; p = 0.48). This also held true for 
      the mean ratio of mitral peak velocity of early filling (E) to early diastolic
      mitral annular velocity (E') (i.e. E/E'), a measure of left ventricular diastolic
      function (treatment effect -0.64, 95% confidence interval -1.48 to 0.20; p =
      0.13). The study treatment was also not associated with a significant treatment
      effect for quality-of-life scores [p = 0.67 for the EuroQol-5 Dimensions,
      five-level version (EQ-5D-5L), questionnaire and p = 0.84 for the Minnesota
      Living with Heart Failure (MLWHF) questionnaire at 2 years]. The findings
      remained consistent after adjustment for age, sex and body mass index.
      Spontaneous return to sinus rhythm on electrocardiography, performed at 2 years, 
      was uncommon in both study groups [4% (standard deviation 3.8%) in the placebo
      group and 8% (standard deviation 7.9%) in the spironolactone group; p = 0.21]. At
      least one hospitalisation for any reason was required by 15.3% of patients in the
      spironolactone group and 22.8% in the placebo group (p = 0.15; after adjustment
      for age, sex and body mass index, p = 0.12). The estimated glomerular filtration 
      rate was reduced by 6 ml/minute/1.73 m(2) at 2 years in patients allocated to
      spironolactone (with no reduction in those receiving placebo, resulting in a
      reduction in the p-value of the difference in the estimated glomerular filtration
      rate between patients in the spironolactone group and those in the placebo group 
      of < 0.001). LIMITATIONS: This was a relatively small study. CONCLUSIONS:
      Spironolactone therapy does not improve exercise capacity, cardiac function or
      quality of life in patients with atrial fibrillation and preserved ejection
      fraction. FUTURE WORK: Further testing of spironolactone in patients with atrial 
      fibrillation and preserved ejection fraction would be difficult to justify. TRIAL
      REGISTRATION: Current Controlled Trials ISRCTN10259346, European Union Clinical
      Trials Register 2014-003702-33 and ClinicalTrials.gov NCT02673463. FUNDING: This 
      project was funded by the Efficacy and Mechanism Evaluation programme, a Medical 
      Research Council and National Institute for Health Research (NIHR) partnership.
      This will be published in full in Efficacy and Mechanism Evaluation; Vol. 7, No. 
      4. See the NIHR Journals Library website for further project information. This
      project received support from the NIHR Clinical Research Network.
CI  - Copyright (c) Queen's Printer and Controller of HMSO 2020. This work was produced
      by Shantsila et al. under the terms of a commissioning contract issued by the
      Secretary of State for Health and Social Care. This issue may be freely
      reproduced for the purposes of private research and study and extracts (or
      indeed, the full report) may be included in professional journals provided that
      suitable acknowledgement is made and the reproduction is not associated with any 
      form of advertising. Applications for commercial reproduction should be addressed
      to: NIHR Journals Library, National Institute for Health Research, Evaluation,
      Trials and Studies Coordinating Centre, Alpha House, University of Southampton
      Science Park, Southampton SO16 7NS, UK.
FAU - Shantsila, Eduard
AU  - Shantsila E
FAU - Shahid, Farhan
AU  - Shahid F
FAU - Sun, Yongzhong
AU  - Sun Y
FAU - Deeks, Jonathan J
AU  - Deeks JJ
FAU - Haynes, Ronnie
AU  - Haynes R
FAU - Calvert, Melanie
AU  - Calvert M
FAU - Fisher, James P
AU  - Fisher JP
FAU - Kirchhof, Paulus
AU  - Kirchhof P
FAU - Gill, Paramjit S
AU  - Gill PS
FAU - Lip, Gregory YH
AU  - Lip GYH
LA  - eng
PT  - Review
PT  - Book
PL  - Southampton (UK)
OTO - NLM
OT  - ATRIAL FIBRILLATION
OT  - HEART FAILURE
OT  - SPIRONOLACTONE
OT  - CLINICAL TRIAL
OT  - HEART FAILURE WITH PRESERVED EJECTION FRACTION
EDAT- 2020/07/23 06:01
MHDA- 2020/07/23 06:01
CDAT- 2020/07/23 06:01
AID - NBK559639 [bookaccession]
AID - 10.3310/eme07040 [doi]


PMID- 32698208
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 82
IP  - 7
DP  - 2020 Jul
TI  - [DNVF Memorandum Health Literacy (Part 1) - Background, Relevance, Research
      Topics and Questions in Health Services Research].
PG  - e77-e93
LID - 10.1055/a-1191-3689 [doi]
AB  - More than half of the German population has difficulties in dealing with health
      information. It is an important task of health services research to examine how
      healthcare professionals and health care organizations can meet this challenge.
      The DNVF Memorandum Health Literacy (Part 1) defines the terms of individual and 
      organizational health literacy, presents the national and international state of 
      research and ethical aspects of health literacy research in health care settings.
      The relevance of health literacy research is worked out in different phases of
      life, for different target groups and in different healthcare contexts. Central
      research topics and future research desiderata are derived.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Ernstmann, Nicole
AU  - Ernstmann N
AD  - Forschungsstelle fur Gesundheitskommunikation und Versorgungsforschung (CHSR),
      Klinik und Poliklinik fur Psychosomatische Medizin und Psychotherapie,
      Universitatsklinikum Bonn, Bonn.
AD  - Institut fur Patientensicherheit (IfPS), Universitatsklinikum Bonn, Rheinische
      Friedrich-Wilhelms-Universitat Bonn, Bonn.
FAU - Bauer, Ullrich
AU  - Bauer U
AD  - Fakultat fur Erziehungswissenschaft, AG 2 Sozialisation, Interdisziplinares
      Zentrum fur Pravention und Intervention im Kindes- und Jugendalter (ZPI),
      Universitat Bielefeld, Bielefeld.
FAU - Berens, Eva-Maria
AU  - Berens EM
AD  - Interdisziplinares Zentrum fur Gesundheitskompetenzforschung, Universitat
      Bielefeld, Bielefeld.
FAU - Bitzer, Eva Maria
AU  - Bitzer EM
AD  - Fachrichtung Public Health & Health Education, Padagogische Hochschule Freiburg, 
      Freiburg.
FAU - Bollweg, Torsten Michael
AU  - Bollweg TM
AD  - Fakultat fur Erziehungswissenschaft, AG 2 Sozialisation, Interdisziplinares
      Zentrum fur Pravention und Intervention im Kindes- und Jugendalter (ZPI),
      Universitat Bielefeld, Bielefeld.
FAU - Danner, Martin
AU  - Danner M
AD  - Bundesarbeitsgemeinschaft Selbsthilfe von Menschen mit Behinderung, chronischer
      Erkrankungen und ihren Angehorigen e. V., BAG SELBSTHILFE, Dusseldorf.
FAU - Dehn-Hindenberg, Andrea
AU  - Dehn-Hindenberg A
AD  - Medizinische Psychologie, Medizinische Hochschule Hannover, Hannover.
FAU - Dierks, Marie Luise
AU  - Dierks ML
AD  - Institut fur Epidemiologie, Sozialmedizin und Gesundheitssystemforschung,
      Hannover, Medizinische Hochschule Hannover.
FAU - Farin, Erik
AU  - Farin E
AD  - Sektion Versorgungsforschung und Rehabilitationsforschung, Medizinische Fakultat 
      der Universitat Freiburg, Universitatsklinikum Freiburg, Freiburg.
FAU - Grobosch, Sandra
AU  - Grobosch S
AD  - Institut fur Versorgungsforschung und Gesundheitsokonomie, Deutsches
      Diabetes-Zentrum (DDZ), Leibniz-Zentrum fur Diabetes-Forschung an der
      Heinrich-Heine-Universitat Dusseldorf, Dusseldorf.
FAU - Haarig, Frederik
AU  - Haarig F
AD  - Zentrum fur evidenzbasierte Gesundheitsversorgung (ZEGV), Medizinische Fakultat
      Carl Gustav Carus der Technischen Universitat Dresden, Dresden.
FAU - Halbach, Sarah
AU  - Halbach S
AD  - Forschungsstelle fur Gesundheitskommunikation und Versorgungsforschung (CHSR),
      Klinik und Poliklinik fur Psychosomatische Medizin und Psychotherapie,
      Universitatsklinikum Bonn, Bonn.
AD  - Bundeszentrale fur gesundheitliche Aufklarung (BzgA), Koln.
FAU - Hollederer, Alfons
AU  - Hollederer A
AD  - Fachbereich 01 Humanwissenschaften, Universitat Kassel, Kassel.
FAU - Icks, Andrea
AU  - Icks A
AD  - Institut fur Versorgungsforschung und Gesundheitsokonomie, Centre for Health and 
      Society, Medizinische Fakultat, Heinrich Heine Universitat Dusseldorf,
      Duesseldorf.
FAU - Kowalski, Christoph
AU  - Kowalski C
AD  - Deutsche Krebsgesellschaft e.V., Berlin.
FAU - Kramer, Ursula
AU  - Kramer U
AD  - Initiative Praventionspartner c/o sanawork Gesundheitskommunikation, Healthon e. 
      V., Freiburg.
FAU - Neugebauer, Edmund
AU  - Neugebauer E
AD  - Campus Neuruppin, Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin.
FAU - Okan, Orkan
AU  - Okan O
AD  - Fakultat fur Erziehungswissenschaft, AG 2 Sozialisation, Interdisziplinares
      Zentrum fur Pravention und Intervention im Kindes- und Jugendalter (ZPI),
      Universitat Bielefeld, Bielefeld.
FAU - Pelikan, Jurgen
AU  - Pelikan J
AD  - Competence Centre for Health Promotion in Hospitals and Health Care, Gesundheit
      Osterreich GmbH, Wien, Austria.
FAU - Pfaff, Holger
AU  - Pfaff H
AD  - IMVR - Institut fur Medizinsoziologie, Versorgungsforschung und
      Rehabilitationswissenschaft, Humanwissenschaftliche Fakultat und Medizinische
      Fakultat, Universitat zu Koln, Koln.
FAU - Sautermeister, Jochen
AU  - Sautermeister J
AD  - Moraltheologisches Seminar, Katholisch-Theologische Fakultat, Rheinische
      Friedrich-Wilhelms-Universitat Bonn, Bonn.
FAU - Schaeffer, Doris
AU  - Schaeffer D
AD  - Interdisziplinares Zentrum fur Gesundheitskompetenzforschung, Universitat
      Bielefeld, Bielefeld.
FAU - Schang, Laura
AU  - Schang L
AD  - Fachbereich Health Services Management, Ludwig-Maximilians-Universitat Munchen,
      Munchen.
FAU - Schulte, Hilde
AU  - Schulte H
AD  - Frauenselbsthilfe Krebs, Bonn.
FAU - Siegel, Achim
AU  - Siegel A
AD  - Institut fur Arbeitsmedizin, Sozialmedizin und Versorgungsforschung,
      Universitatsklinikum Tubingen, Tubingen.
FAU - Sundmacher, Leonie
AU  - Sundmacher L
AD  - Fachbereich Health Services Management, Ludwig-Maximilians-Universitat Munchen,
      Munchen.
FAU - Vogt, Dominique
AU  - Vogt D
AD  - Fakultat fur Gesundheitswissenschaften, Universitat Bielefeld, Bielefeld.
FAU - Vollmar, Horst Christian
AU  - Vollmar HC
AUID- ORCID: 0000-0002-0117-7188
AD  - Medizinische Fakultat, Abteilung fur Allgemeinmedizin, Ruhr-Universitat Bochum,
      Bochum.
FAU - Stock, Stephanie
AU  - Stock S
AD  - Institut fur Gesundheitsokonomie und Klinische Epidemiologie (IGKE), Klinikum der
      Universitat zu Koln, Koln.
LA  - ger
PT  - Journal Article
TT  - DNVF Memorandum Gesundheitskompetenz (Teil 1) - Hintergrund, Relevanz, Gegenstand
      und Fragestellungen in der Versorgungsforschung.
DEP - 20200722
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes
      (Germany))
JID - 9204210
SB  - IM
MH  - Delivery of Health Care
MH  - Germany
MH  - *Health Literacy
MH  - Health Personnel
MH  - Health Services Research
MH  - Humans
COIS- Dr. Christoph Kowalski ist Mitarbeiter der Deutschen Krebsgesellschaft. Alle
      anderen Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/07/23 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 10.1055/a-1191-3689 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2020 Jul;82(7):e77-e93. doi: 10.1055/a-1191-3689. Epub 2020 Jul
      22.


PMID- 32698207
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 82
IP  - 7
DP  - 2020 Jul
TI  - [DNVF Memorandum Health Literacy (Part 1) - Background, Relevance, Research
      Topics and Questions in Health Services Research: Short Version].
PG  - 639-645
LID - 10.1055/a-1191-3401 [doi]
AB  - More than half of the German population has difficulties in dealing with health
      information. It is an important task of health services research to examine how
      healthcare professionals and health care organizations can meet this challenge.
      This short version of the DNVF Memorandum Health Literacy (Part 1) defines the
      terms of individual and organizational health literacy, presents the national and
      international state of research and ethical aspects of health literacy research
      in health care settings. Central research topics and future research desiderata
      are derived.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Ernstmann, Nicole
AU  - Ernstmann N
AD  - Klinik und Poliklinik fur Psychosomatische Medizin und Psychotherapie,
      Forschungsstelle fur Gesundheitskommunikation und Versorgungsforschung (CHSR),
      Universitatsklinikum Bonn, Bonn.
AD  - Institut fur Patientensicherheit (IfPS), Universitatsklinikum Bonn, Rheinische
      Friedrich-Wilhelms-Universitat Bonn, Bonn.
FAU - Bauer, Ullrich
AU  - Bauer U
AD  - Fakultat fur Erziehungswissenschaft, AG 2 Sozialisation, Interdisziplinares
      Zentrum fur Gesundheitskompetenzforschung (IZGK), Zentrum fur Pravention und
      Intervention im Kindes- und Jugendalter (ZPI), Universitat Bielefeld, Bielefeld.
FAU - Berens, Eva-Maria
AU  - Berens EM
AD  - Interdisziplinares Zentrum fur Gesundheitskompetenzforschung, Universitat
      Bielefeld, Bielefeld.
FAU - Bitzer, Eva Maria
AU  - Bitzer EM
AD  - Fachrichtung Public Health & Health Education, Padagogische Hochschule Freiburg, 
      Freiburg im Breisgau.
FAU - Bollweg, Torsten Michael
AU  - Bollweg TM
AD  - Fakultat fur Erziehungswissenschaft, AG 2 Sozialisation, Interdisziplinares
      Zentrum fur Gesundheitskompetenzforschung (IZGK), Zentrum fur Pravention und
      Intervention im Kindes- und Jugendalter (ZPI), Universitat Bielefeld, Bielefeld.
FAU - Danner, Martin
AU  - Danner M
AD  - Bundesarbeitsgemeinschaft Selbsthilfe von Menschen mit Behinderung, chronischer
      Erkrankungen und ihren Angehorigen e. V., Dusseldorf, BAG SELBSTHILFE.
FAU - Dehn-Hindenberg, Andrea
AU  - Dehn-Hindenberg A
AD  - Medizinische Psychologie, Medizinische Hochschule Hannover, Hannover.
FAU - Dierks, Marie Luise
AU  - Dierks ML
AD  - Institut fur Epidemiologie, Sozialmedizin und Gesundheitssystemforschung,
      Medizinische Hochschule Hannover, Hannover.
FAU - Farin, Erik
AU  - Farin E
AD  - Sektion Versorgungsforschung und Rehabilitationsforschung, Medizinische Fakultat 
      der Universitat Freiburg, Universitatsklinikum Freiburg, Freiburg.
FAU - Grobosch, Sandra
AU  - Grobosch S
AD  - Institut fur Versorgungsforschung und Gesundheitsokonomie, Deutsches
      Diabetes-Zentrum (DDZ), Leibniz-Zentrum fur Diabetes-Forschung an der
      Heinrich-Heine-Universitat Dusseldorf, Dusseldorf.
FAU - Haarig, Frederik
AU  - Haarig F
AD  - Zentrum fur evidenzbasierte Gesundheitsversorgung (ZEGV), Medizinische Fakultat
      Carl Gustav Carus der Technischen Universitat Dresden, Dresden.
FAU - Halbach, Sarah
AU  - Halbach S
AD  - Klinik und Poliklinik fur Psychosomatische Medizin und Psychotherapie,
      Forschungsstelle fur Gesundheitskommunikation und Versorgungsforschung (CHSR),
      Universitatsklinikum Bonn, Bonn.
AD  - Bundeszentrale fur gesundheitliche Aufklarung (BzgA), Koln.
FAU - Hollederer, Alfons
AU  - Hollederer A
AD  - Fachbereich 01 Humanwissenschaften, Universitat Kassel, Kassel.
FAU - Icks, Andrea
AU  - Icks A
AD  - Institut fur Versorgungsforschung und Gesundheitsokonomie, Centre for Health and 
      Society, Medizinische Fakultat, Heinrich Heine Universitat Dusseldorf,
      Dusseldorf.
FAU - Kowalski, Christoph
AU  - Kowalski C
AD  - Deutsche Krebsgesellschaft e.V., Berlin.
FAU - Kramer, Ursula
AU  - Kramer U
AD  - Initiative Praventionspartner c/o sanawork Gesundheitskommunikation, Healthon e. 
      V., Freiburg.
FAU - Neugebauer, Edmund
AU  - Neugebauer E
AD  - Campus Neuruppin, Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin.
FAU - Okan, Orkan
AU  - Okan O
AD  - Fakultat fur Erziehungswissenschaft, AG 2 Sozialisation, Interdisziplinares
      Zentrum fur Gesundheitskompetenzforschung (IZGK), Zentrum fur Pravention und
      Intervention im Kindes- und Jugendalter (ZPI), Universitat Bielefeld, Bielefeld.
FAU - Pelikan, Jurgen
AU  - Pelikan J
AD  - Competence Centre for Health Promotion in Hospitals and Health Care, Gesundheit
      Osterreich GmbH, Wien, Austria.
FAU - Pfaff, Holger
AU  - Pfaff H
AD  - IMVR - Institut fur Medizinsoziologie, Versorgungsforschung und
      Rehabilitationswissenschaft, Humanwissenschaftliche Fakultat und Medizinische
      Fakultat, Universitat zu Koln, Koln.
FAU - Sautermeister, Jochen
AU  - Sautermeister J
AD  - Moraltheologisches Seminar, Katholisch-Theologische Fakultat, Rheinische
      Friedrich-Wilhelms-Universitat Bonn, Bonn.
FAU - Schaeffer, Doris
AU  - Schaeffer D
AD  - Interdisziplinares Zentrum fur Gesundheitskompetenzforschung, Universitat
      Bielefeld, Bielefeld.
FAU - Schang, Laura
AU  - Schang L
AD  - Fachbereich Health Services Management, Ludwig-Maximilians-Universitat Munchen,
      Munchen.
FAU - Schulte, Hilde
AU  - Schulte H
AD  - Frauenselbsthilfe Krebs, Bonn.
FAU - Siegel, Achim
AU  - Siegel A
AD  - Institut fur Arbeitsmedizin, Sozialmedizin und Versorgungsforschung,
      Universitatsklinikum Tubingen, Tubingen.
FAU - Sundmacher, Leonie
AU  - Sundmacher L
AD  - Fachbereich Health Services Management, Ludwig-Maximilians-Universitat Munchen,
      Munchen.
FAU - Vogt, Dominique
AU  - Vogt D
AD  - Fakultat fur Gesundheitswissenschaften, Universitat Bielefeld, Bielefeld.
FAU - Vollmar, Horst Christian
AU  - Vollmar HC
AUID- ORCID: 0000-0002-0117-7188
AD  - Medizinische Fakultat, Abteilung fur Allgemeinmedizin, Ruhr-Universitat Bochum,
      Bochum.
FAU - Stock, Stephanie
AU  - Stock S
AD  - Institut fur Gesundheitsokonomie und Klinische Epidemiologie (IGKE), Klinikum der
      Universitat zu Koln, Koln.
LA  - ger
PT  - Journal Article
TT  - DNVF Memorandum Gesundheitskompetenz (Teil 1) - Hintergrund, Relevanz, Gegenstand
      und Fragestellungen in der Versorgungsforschung: Kurzfassung.
DEP - 20200722
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes
      (Germany))
JID - 9204210
SB  - IM
MH  - Germany
MH  - *Health Literacy
MH  - Health Personnel
MH  - Health Services Research
MH  - Humans
COIS- Dr. Christoph Kowalski ist Mitarbeiter der Deutschen Krebsgesellschaft. Alle
      anderen Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/07/23 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 10.1055/a-1191-3401 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2020 Jul;82(7):639-645. doi: 10.1055/a-1191-3401. Epub 2020 Jul
      22.


PMID- 32697739
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1571-8093 (Electronic)
IS  - 0929-0273 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Jun 15
TI  - Introduction: Special Issue on Innovative Medicine and Research: Ethical, Legal
      and Regulatory Issues.
PG  - 187-193
LID - 10.1163/15718093-BJA10019 [doi]
FAU - Altavilla, Annagrazia
AU  - Altavilla A
AD  - Guest Editor.
LA  - eng
PT  - Introductory Journal Article
DEP - 20200615
PL  - Netherlands
TA  - Eur J Health Law
JT  - European journal of health law
JID - 9431861
SB  - IM
MH  - Biomedical Research/*ethics/*legislation & jurisprudence
MH  - Biomedical Technology/*ethics/*legislation & jurisprudence
MH  - *Congresses as Topic
MH  - *Diffusion of Innovation
MH  - Europe
MH  - European Union
MH  - Female
MH  - Health Services Accessibility/ethics/legislation & jurisprudence
MH  - Human Rights/ethics/legislation & jurisprudence
MH  - Humans
MH  - Information Dissemination/ethics/legislation & jurisprudence
MH  - Machine Learning/ethics/legislation & jurisprudence
MH  - Male
MH  - Patient Rights/ethics/legislation & jurisprudence
EDAT- 2020/07/23 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
AID - 10.1163/15718093-BJA10019 [doi]
PST - epublish
SO  - Eur J Health Law. 2020 Jun 15;27(3):187-193. doi: 10.1163/15718093-BJA10019.


PMID- 32697025
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1440-1800 (Electronic)
IS  - 1320-7881 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Jul
TI  - Learning from Florence Nightingale: A slow ethics approach to nursing during the 
      pandemic.
PG  - e12369
LID - 10.1111/nin.12369 [doi]
FAU - Gallagher, Ann FRCN
AU  - Gallagher A FRCN
AUID- ORCID: 0000-0002-2264-024X
AD  - Faculty of Health and Medical Science, International Care Ethics Observatory,
      School of Health Science, University of Surrey, Guildford, UK.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - Australia
TA  - Nurs Inq
JT  - Nursing inquiry
JID - 9505881
MH  - *Ethics, Nursing
MH  - History, 19th Century
MH  - Learning
MH  - Nursing/*methods/trends
MH  - Pandemics/*prevention & control
PMC - PMC7404359
EDAT- 2020/07/23 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/06/08 00:00 [received]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - 10.1111/nin.12369 [doi]
PST - ppublish
SO  - Nurs Inq. 2020 Jul;27(3):e12369. doi: 10.1111/nin.12369.


PMID- 32696926
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20200806
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Linking)
VI  - 28
DP  - 2020
TI  - Association between moral distress and supporting elements of moral deliberation 
      in nurses.
PG  - e3332
LID - S0104-11692020000100375 [pii]
LID - 10.1590/1518-8345.3990.3332 [doi]
AB  - OBJECTIVE: to identify the association between moral distress and the supporting 
      elements of moral deliberation in Brazilian nurses. METHOD: a cross-sectional
      study conducted with Brazilian nurses working in health services at different
      complexity levels. The research protocol consisted of the Brazilian Scale of
      Moral Distress in Nurses, a sociodemographic and labor questionnaire, and a list 
      of bases and ethical elements used for moral deliberation. For analysis,
      descriptive statistics, chi-square test, and Poisson regression were used.
      RESULTS: 1,226 nurses took part in the study. The 12 elements associated with the
      moral deliberation process were classified as important for nurses' actions,
      especially the professional experience acquired, code of ethics/law of
      professional practice, and ethical and bioethical principles. The relationship of
      moral distress showed higher prevalence in the Beliefs, culture and values of the
      patient, Beliefs and personal values, and Intuition and Subjectivity elements.
      CONCLUSION: the results showed a balance between the subjective criteria of
      professional experience and the objective ones of deontology for moral
      deliberation.
FAU - Ramos, Flavia Regina Souza
AU  - Ramos FRS
AD  - Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.
FAU - Brehmer, Laura Cavalcanti de Farias
AU  - Brehmer LCF
AD  - Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.
FAU - Dalmolin, Graziele de Lima
AU  - Dalmolin GL
AD  - Departamento de Enfermagem, Universidade Federal de Santa Maria, Santa Maria, RS,
      Brazil.
FAU - Silveira, Luciana Ramos
AU  - Silveira LR
AD  - Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.
FAU - Schneider, Dulcineia Ghizoni
AU  - Schneider DG
AD  - Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.
FAU - Vargas, Mara Ambrosina de Oliveira
AU  - Vargas MAO
AD  - Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.
LA  - por
LA  - spa
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - Brazil
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Brazil
MH  - Cross-Sectional Studies
MH  - Ethics, Nursing
MH  - Humans
MH  - *Morals
MH  - *Nurses
MH  - Stress, Psychological
MH  - Surveys and Questionnaires
PMC - PMC7365614
EDAT- 2020/07/23 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/10/24 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
AID - S0104-11692020000100375 [pii]
AID - 10.1590/1518-8345.3990.3332 [doi]
PST - ppublish
SO  - Rev Lat Am Enfermagem. 2020;28:e3332. doi: 10.1590/1518-8345.3990.3332. Epub 2020
      Jul 15.


PMID- 32696880
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20200807
IS  - 1806-9282 (Electronic)
IS  - 0104-4230 (Linking)
VI  - 66
IP  - 6
DP  - 2020 Jun
TI  - Perception of risk factors for cancer in the ABC population.
PG  - 757-761
LID - S0104-42302020000600757 [pii]
LID - 10.1590/1806-9282.66.6.757 [doi]
AB  - OBJECTIVE To evaluate the knowledge about risk factors for cancer in patients
      treated at the ABC Medical School (FMABC). METHODS Cross-sectional observational 
      study conducted in 2019. The American Cancer Institute's Cancer Risk Awareness
      Survey questionnaire was used with 29 cancer risk factors, 14 of which were
      proven to cause cancer and 15 without consensus or scientific evidence of
      causality with cancer but that are often reminded by most of the population.
      Qualitative variables were described by frequency and percentage, and
      quantitative variables by mean and standard deviation or median and range
      depending on normality, assessed by the Shapiro-Wilk test. The study was
      conducted in accordance with the Helsinki Declaration for Research and approved
      by the Research Ethics Committee. RESULTS 191 patients were included. Median age 
      54 (20 to 90), 64% female. 35.6% reported current or previous smoking. 3.1%
      consumed alcohol more than 5 drinks/week. 56% reported sedentary lifestyle. 44%
      had at least 1 case of cancer in relatives up to 2nd degree. The average of
      correct answers in the analyzed population was 12.83 +/- 3.06. A weak positive
      correlation was observed between income and number of cases (rho = 0.177, p =
      0.02). No relationship was observed between the number of correct answers and
      level of education, age, sex, marital status, race or patients with a positive
      family history for cancer. CONCLUSION The knowledge about risk factors for cancer
      in the ABC population is low, which may contribute to the adoption of risk
      behaviors for the disease.
FAU - Turke, Karine Corcione
AU  - Turke KC
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Canonaco, Juliana Seidler
AU  - Canonaco JS
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Artioli, Thiago
AU  - Artioli T
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Sarafyan, Aline Hernandez Marquez
AU  - Sarafyan AHM
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Aoki, Erika Toshie
AU  - Aoki ET
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Muszkat, Daniel
AU  - Muszkat D
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Gutierrez, Marcel
AU  - Gutierrez M
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Cortez, Rafaela Villegas
AU  - Cortez RV
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Lima Junior, Willian Ferreira
AU  - Lima Junior WF
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
FAU - Del Giglio, Auro
AU  - Del Giglio A
AD  - Centro Universitario Saude ABC, Santo Andre, SP, Brasil.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Neoplasms
MH  - Risk Factors
MH  - Risk-Taking
MH  - Surveys and Questionnaires
MH  - United States
EDAT- 2020/07/23 06:00
MHDA- 2020/08/08 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2019/12/08 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
AID - S0104-42302020000600757 [pii]
AID - 10.1590/1806-9282.66.6.757 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2020 Jun;66(6):757-761. doi:
      10.1590/1806-9282.66.6.757. Epub 2020 Jul 20.


PMID- 32696731
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Linking)
VI  - 20
IP  - 3
DP  - 2020
TI  - Occurrence of blaTEM and blaROB in Haemophilus species Causing Respiratory Tract 
      Infections.
PG  - 385-388
LID - 10.2174/1871526519666190118103148 [doi]
AB  - BACKGROUND: Emergence of resistance to some antibiotics in Haemophilus
      influenzae, a respiratory pathogen is a cause of concern. The aim is to study the
      antibiotic susceptibility pattern of Haemophilus isolates from respiratory
      infections with reference to beta-lactam resistance. METHODS: This is a
      laboratory based prospective study done in the department of microbiology in a
      tertiary care center after institutional ethics committee clearance. Haemophilus 
      influenzae isolates from respiratory tract specimens over a period of one year
      were subjected to antibiotic susceptibility tests. Beta-lactamase production was 
      detected by nitrocefin disc. hpd gene, blaTEM and blaROB genes were detected by
      PCR. The data was analysed using SPSS 11.5 version. RESULTS: Of the 162 isolates,
      89.5% were from sputum specimens. Ampicillin resistance was seen in 5 (3.09%)
      isolates. The ampicillin resistant strains were positive for beta-lactamase
      enzyme and blaTEM gene. BLNAR and isolates with blaROB gene were not found.
      CONCLUSION: In case of Haemophilus influenzae respiratory tract infection
      empirical treatment with amoxicillin clavulanate or third generation
      cephalosporin may be the drugs of choice in our geographic area.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Khurana, Prerna
AU  - Khurana P
AD  - Senior Resident, Clinical Microbiology and Infectious Diseases, CNBC, Delhi,
      India.
FAU - Shenoy, Suchitra
AU  - Shenoy S
AD  - Kasturba Medical College, Mangalore, Manipal Academy of Higher Education,
      Manipal, Karnataka 576104, India.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (DNA, Bacterial)
RN  - 7C782967RD (Ampicillin)
RN  - EC 3.5.2.6 (beta-Lactamases)
SB  - IM
MH  - Ampicillin/pharmacology
MH  - Ampicillin Resistance/genetics
MH  - Anti-Bacterial Agents/*pharmacology
MH  - DNA, Bacterial/*genetics
MH  - Drug Resistance, Bacterial/genetics
MH  - Haemophilus influenzae/*drug effects/enzymology/*genetics
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - Prospective Studies
MH  - Respiratory Tract Infections/*microbiology
MH  - Sputum/microbiology
MH  - beta-Lactamases/*genetics
OTO - NOTNLM
OT  - Haemophilus
OT  - Haemophilus influenzae
OT  - ROB
OT  - TEM
OT  - respiratory pathogen
OT  - sputum specimens
EDAT- 2020/07/23 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/07/23 06:00
PHST- 2018/10/25 00:00 [received]
PHST- 2019/01/08 00:00 [revised]
PHST- 2019/01/09 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - IDDT-EPUB-95879 [pii]
AID - 10.2174/1871526519666190118103148 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2020;20(3):385-388. doi:
      10.2174/1871526519666190118103148.


PMID- 32696504
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 7
DP  - 2020 Sep
TI  - Ectogenesis and gender-based oppression: Resisting the ideal of assimilation.
PG  - 727-734
LID - 10.1111/bioe.12789 [doi]
AB  - In a recent article in this journal, Kathryn MacKay advances a defence of
      ectogenesis that is grounded in this technology's potential to end-or at least
      mitigate the effects of-gender-based oppression. MacKay raises important issues
      concerning the socialization of women as 'mothers', and the harms that this
      socialization causes. She also considers ectogenesis as an ethically preferable
      alternative to gestational surrogacy and uterine transplantation, one that is
      less harmful to women and less subject to being co-opted to further oppressive
      ends. In this article, I challenge some of the assumptions that underlie MacKay's
      case in favour of ectogenesis by questioning whether the relationship between
      women's capacity to gestate and birth children and gender-based oppression is as 
      strong as MacKay makes it out to be. I subsequently argue that-even if MacKay's
      reading of this relationship is accurate-ectogenesis is not a desirable means to 
      end gender-based oppression. It embodies a strategy that could be used to pursue 
      liberating projects that follow what Iris Marion Young defines as 'the ideal of
      assimilation', but that must be resisted. I then concur with MacKay's contention 
      that ectogenesis is better than gestational surrogacy and uterine
      transplantation. My argument is that many of the problematic issues that MacKay
      herself sees as features of these practices will not disappear with ectogenesis. 
      Finally, I conclude that MacKay's narrow focus on women's biology and ectogenesis
      as a solution to gender-based oppression results in the overlooking of broader
      systemic issues that contribute to the upholding of oppressive norms.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Cavaliere, Giulia
AU  - Cavaliere G
AUID- ORCID: 0000-0001-8703-1499
AD  - Lancaster Medical School, Faculty of Health & Medicine, Furness College,
      Lancaster University, Lancaster, United Kingdom of Great Britain and Northern
      Ireland.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200722
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
CON - Bioethics. 2020 May;34(4):346-353. PMID: 31943247
MH  - Child
MH  - Dissent and Disputes
MH  - *Ectogenesis
MH  - Female
MH  - Humans
MH  - Reproduction
MH  - Uterus
MH  - *Women's Rights
OTO - NOTNLM
OT  - *ectogenesis
OT  - *equality
OT  - *gender-based oppression
OT  - *gestational surrogacy
OT  - *uterine transplantation
EDAT- 2020/07/23 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/05/22 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - 10.1111/bioe.12789 [doi]
PST - ppublish
SO  - Bioethics. 2020 Sep;34(7):727-734. doi: 10.1111/bioe.12789. Epub 2020 Jul 22.


PMID- 32696113
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - From Sufficient Health to Sufficient Responsibility.
PG  - 423-433
LID - 10.1007/s11673-020-09992-9 [doi]
AB  - The idea of using responsibility in the allocation of healthcare resources has
      been criticized for, among other things, too readily abandoning people who are
      responsible for being very badly off. One response to this problem is that while 
      responsibility can play a role in resource allocation, it cannot do so if it will
      leave those who are responsible below a "sufficiency" threshold. This paper
      considers first whether a view can be both distinctively sufficientarian and
      allow responsibility to play a role even for those who will be left with very
      poor health. It then draws several further distinctions that may affect the
      application of responsibility at this level. We conclude that a more plausible
      version of the sufficientarian view is to allow a role for responsibility where
      failure to do so will leave someone else who is not responsible below the
      sufficiency threshold. However, we suggest that individuals must exhibit
      "sufficient responsibility" in order for this to apply, involving both a
      sufficient level of control and an avoidable failure to respond adequately to
      reasons for action.
FAU - Davies, Ben
AU  - Davies B
AUID- ORCID: http://orcid.org/0000-0003-4612-7894
AD  - Uehiro Centre for Practical Ethics, University of Oxford, Suite 8, Littlegate
      House, St Ebbe's Street, Oxford, OX1 1PT, UK.
      benjamin.davies@philosophy.ox.ac.uk.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Uehiro Centre for Practical Ethics, University of Oxford, Suite 8, Littlegate
      House, St Ebbe's Street, Oxford, OX1 1PT, UK.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200721
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *Bioethical Issues
MH  - Humans
PMC - PMC7557480
OTO - NOTNLM
OT  - Ethics
OT  - Healthcare funding
OT  - Luck egalitarianism
OT  - Responsibility
OT  - Sufficiency
OT  - Sufficientarianism
EDAT- 2020/07/23 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/09/10 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - 10.1007/s11673-020-09992-9 [doi]
AID - 10.1007/s11673-020-09992-9 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Sep;17(3):423-433. doi: 10.1007/s11673-020-09992-9. Epub 2020 
      Jul 21.


PMID- 32695975
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2589-790X (Electronic)
IS  - 2589-790X (Linking)
VI  - 2
IP  - 4
DP  - 2020 Jul
TI  - Practice Variation in Establishing the Adequacy of Beta-Blockers as an
      Antiarrhythmic Agent in School-Aged Children and Adolescents.
PG  - 244-248
LID - 10.1016/j.cjco.2020.03.008 [doi]
AB  - BACKGROUND: Beta-blockers (BBs) are commonly prescribed to manage arrhythmias in 
      children and adolescents without any standardised approach to establish BB
      adequacy. We invited all Canadian pediatric cardiologists to participate in an
      anonymous survey to understand practice variation in the assessment of BB
      adequacy in school-aged children and adolescents with arrhythmia or the potential
      for arrhythmia. METHODS: An electronic survey approved by the Institutional
      Ethics Board was distributed by e-mail to 96 Canadian pediatric cardiologists who
      had been active in practice for at least 1 year. Incomplete surveys were
      excluded. RESULTS: Forty-one cardiologists (43%) responded to all questions in
      the survey. Thirteen cardiologists (32%) reported always assessing BB adequacy,
      17 (41%) did so only for specific arrhythmias, and 11 (27%) reported never
      performing such an assessment. A total of 19 cardiologists (46%) and 18
      cardiologists (44%) reported using Holter monitoring and exercise testing,
      respectively, to assess beta receptor blockade adequacy. Thirteen cardiologists
      (32%) considered BB therapy adequate if Holter demonstrated a 20% decrease in
      heart rate (HR) from baseline, and 10 respondents (24%) defined adequate BB
      therapy using exercise testing as a 20% decrease in maximal HR or blood pressure 
      from baseline. CONCLUSION: Despite wide variation in practice, Holter monitoring 
      and exercise testing are commonly used methods to measure the adequacy of BB
      therapy. There are no standard criteria, but the majority (56%) reported using a 
      20% decrease in HR or blood pressure from the pretreatment state as a criterion
      for adequate BB therapy in children and adolescents with arrhythmia or the
      potential for arrhythmia.
CI  - (c) 2020 Canadian Cardiovascular Society. Published by Elsevier Inc.
FAU - Al Riyami, Hilal
AU  - Al Riyami H
AD  - Division of Cardiology, Department of Pediatrics, University of Alberta,
      Edmonton, Alberta, Canada.
FAU - Hussain, Arif
AU  - Hussain A
AD  - Division of Cardiology, Department of Pediatrics, Dalhousie
      University/Izaak-Walton-Killam, Health Centre, Halifax, Nova Scotia, Canada.
FAU - Warren, Andrew
AU  - Warren A
AD  - Division of Cardiology, Department of Pediatrics, Dalhousie
      University/Izaak-Walton-Killam, Health Centre, Halifax, Nova Scotia, Canada.
FAU - Dhillon, Santokh S
AU  - Dhillon SS
AD  - Division of Cardiology, Department of Pediatrics, Dalhousie
      University/Izaak-Walton-Killam, Health Centre, Halifax, Nova Scotia, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - United States
TA  - CJC Open
JT  - CJC open
JID - 101763635
PMC - PMC7365819
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.1016/j.cjco.2020.03.008 [doi]
AID - S2589-790X(20)30032-9 [pii]
PST - epublish
SO  - CJC Open. 2020 Mar 27;2(4):244-248. doi: 10.1016/j.cjco.2020.03.008. eCollection 
      2020 Jul.


PMID- 32695954
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 22
DP  - 2020
TI  - Effectiveness of home-based rehabilitation program in minimizing disability and
      secondary falls after a hip fracture: Protocol for a randomized controlled trial.
PG  - 24-28
LID - 10.1016/j.isjp.2020.06.002 [doi]
AB  - INTRODUCTION: Hip fractures are a major health problem globally and are
      associated with increased morbidity, mortality, and substantial economic costs.
      Successful operative treatment of hip fracture patients is necessary for the
      optimization of post-op mobility and functional recovery of the patient.
      Rehabilitation after surgical stabilization of a hip fracture is crucial in order
      to restore pre-fracture function and to avoid long-term institutionalization. In 
      particular ongoing exercise which targets balance can prevent up to 40% of falls.
      Therefore, we have designed a post-discharge home-based physical rehabilitation
      intervention program to minimize disability and falls in this high-risk elderly
      population. METHODS AND ANALYSIS: The study will be an open label, simple
      randomized controlled trial at a single hospital. The two arms will be equally
      allocated on a 1:1 ratio into intervention and control groups. The control arm
      will receive the usual standard postoperative rehabilitation. The intervention
      group will receive an extended home-based rehabilitation program twice a week
      continued for 3months (12weeks) after discharge. The Primary outcome of the study
      is occurrence of falls. Falls will be measured at 3, 6, 12, and 24months by
      research-assistant follow-up telephone calls for both the groups.
      Mobility-related disability will be measured with a self-reported test at every
      routine follow-up for up to two years using a performance-based short battery
      tool. Negative binomial regression model will be used to compare number of falls 
      in both the groups by computing incidence ratio rates. ETHICS AND DISSEMINATION: 
      Approval for the conduction of this study has been taken from the Ethical Review 
      Committee (ERC) of the institution. Evidences which will be obtained from this
      study will facilitate to propose changes in existing guidelines and policies for 
      treating fall and hip fracture patients.Trial registrationThis trial is
      registered on clinicaltrials.gov ID: NCT04108793.
CI  - (c) 2020 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.
FAU - Sadruddin Pidani, Anum
AU  - Sadruddin Pidani A
AD  - Department of Surgery, Aga Khan University, Karachi, Pakistan.
FAU - Sabzwari, Saniya
AU  - Sabzwari S
AD  - Department of Family Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Ahmad, Khabir
AU  - Ahmad K
AD  - Department of Surgery, Aga Khan University, Karachi, Pakistan.
FAU - Mohammed, Ata
AU  - Mohammed A
AD  - Department of Physiotherapy, Aga Khan University, Karachi, Pakistan.
FAU - Noordin, Shahryar
AU  - Noordin S
AD  - Department of Surgery, Aga Khan University, Karachi, Pakistan.
LA  - eng
SI  - ClinicalTrials.gov/NCT04108793
PT  - Journal Article
DEP - 20200618
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7360882
OTO - NOTNLM
OT  - CTU, Clinical trial unit
OT  - Disability
OT  - ERC, Ethical Review committee
OT  - Elderly population
OT  - Hip fracture
OT  - Physical activity
OT  - Rehabilitation
OT  - Secondary falls
OT  - THR, Total hip replacement
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/06/06 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.1016/j.isjp.2020.06.002 [doi]
AID - S2468-3574(20)30019-X [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Jun 18;22:24-28. doi: 10.1016/j.isjp.2020.06.002.
      eCollection 2020.


PMID- 32695897
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 7
DP  - 2020 Jul
TI  - An exploratory study of the application of mindsight in email communication.
PG  - e04305
LID - 10.1016/j.heliyon.2020.e04305 [doi]
AB  - RESEARCH PROBLEM: Email communication is a type of virtual communication with
      specific characteristics: - it is a form of written communication; it is
      asynchronous, i.e. not occurring at the same time for the sender and recipients. 
      Email does not include face to face communication and thus the capacity to
      develop a sense of connection, shared knowledge and trust are distorted due to
      the lack of interpersonal cues and may become a problem. Communication is a
      process where one mind affects another, and it is through the process of
      communication that individuals develop shared perceptions and coordinate their
      behaviours. This implies creating social worlds rather than disseminating
      information between people. The fact that communication is not a mere means of
      disseminating information but also a means of developing social entities for
      co-creation of understanding requires that individuals approach communication
      with a sense of awareness of themselves and others. PROPOSED SOLUTIONS: In this
      article the theory of Mindsight is proposed as an approach of mindful observation
      of the act of communication resulting in deeper awareness, reflection and
      potential impact on behaviour. Although Mindsight has been extensively used in
      addressing self-awareness and communication in real spaces, there is a gap in the
      existing relevant literature about the application of Mindsight in virtual/email 
      communication. METHODS: A Mindsight Utility for Virtual Communication (MUVC) was 
      developed for use in engaging with email. The MUVC is a set of exercises enabling
      users to identify and manage their email habits over a period of time. The
      utility was developed to engage users in experiencing self-awareness and
      awareness of others and provides an aid to formulate personal guidelines in email
      communication. It was implemented with nineteen participants as part of action
      research allowing each individual to develop their own guidelines grounded in the
      experience of using the observation practice. DATA: Qualitative data was
      collected in the form of diaries for a period of 6 days from two group of
      participants: -university students; - employees of a social enterprise. Ethics
      approval was granted from Northumbria University prior to data collection.
      Thematic analysis was used. RESULTS: The study uncovered potential problems and
      solution strategies, inhibitors and facilitators of communication. Problems with 
      email were perceived as: not knowing one another, difficulties in connecting,
      lack of trust, lack of interpersonal clues, reduction in communication quality,
      emotional and psychological discomfort. Solution strategies included:
      open-mindedness, empathy, compassion, attention focus, clear language, awareness 
      practice, addressing physical and emotional discomfort.
CI  - (c) 2020 The Authors.
FAU - Ogwu, Suzannah
AU  - Ogwu S
AD  - Department of Computer and Information Sciences, University of Northumbria,
      Newcastle Ellison Building, Ellison Terrace, Newcastle upon Tyne, NE1 8ST, UK.
FAU - Sice, Petia
AU  - Sice P
AD  - Department of Computer and Information Sciences, University of Northumbria,
      Newcastle Ellison Building, Ellison Terrace, Newcastle upon Tyne, NE1 8ST, UK.
FAU - Keogh, Shelagh
AU  - Keogh S
AD  - Department of Computer and Information Sciences, University of Northumbria,
      Newcastle Ellison Building, Ellison Terrace, Newcastle upon Tyne, NE1 8ST, UK.
FAU - Goodlet, Colin
AU  - Goodlet C
AD  - Department of Computer and Information Sciences, University of Northumbria,
      Newcastle Ellison Building, Ellison Terrace, Newcastle upon Tyne, NE1 8ST, UK.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7364031
OTO - NOTNLM
OT  - Compassion
OT  - Email communications
OT  - Empathy
OT  - Information science
OT  - Mindsight
OT  - Psychology
OT  - Virtual communication
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2019/10/21 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04305 [doi]
AID - S2405-8440(20)31149-X [pii]
AID - e04305 [pii]
PST - epublish
SO  - Heliyon. 2020 Jul 15;6(7):e04305. doi: 10.1016/j.heliyon.2020.e04305. eCollection
      2020 Jul.


PMID- 32695801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2306-9759 (Print)
IS  - 2306-9759 (Linking)
VI  - 7
DP  - 2020
TI  - Current state of stem cell-based therapies: an overview.
PG  - 8
LID - 10.21037/sci-2020-001 [doi]
AB  - Recent research reporting successful translation of stem cell therapies to
      patients have enriched the hope that such regenerative strategies may one day
      become a treatment for a wide range of vexing diseases. In fact, the past few
      years witnessed, a rather exponential advancement in clinical trials revolving
      around stem cell-based therapies. Some of these trials resulted in remarkable
      impact on various diseases. In this review, the advances and challenges for the
      development of stem-cell-based therapies are described, with focus on the use of 
      stem cells in dentistry in addition to the advances reached in regenerative
      treatment modalities in several diseases. The limitations of these treatments and
      ongoing challenges in the field are also discussed while shedding light on the
      ethical and regulatory challenges in translating autologous stem cell-based
      interventions, into safe and effective therapies.
CI  - 2020 Stem Cell Investigation. All rights reserved.
FAU - Aly, Riham Mohamed
AU  - Aly RM
AD  - Department of Basic Dental Science, National Research Centre, Cairo, Egypt.
AD  - Stem Cell Laboratory, Center of Excellence for Advanced Sciences, National
      Research Centre, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200515
PL  - China
TA  - Stem Cell Investig
JT  - Stem cell investigation
JID - 101672113
PMC - PMC7367472
OTO - NOTNLM
OT  - Stem cells
OT  - clinical trials
OT  - therapies
OT  - translation
COIS- Conflicts of Interest: The author has completed the ICMJE uniform disclosure form
      (available at http://dx.doi.org/10.21037/sci-2020-001). The author has no
      conflicts of interest to declare.
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.21037/sci-2020-001 [doi]
AID - sci-07-2020-001 [pii]
PST - epublish
SO  - Stem Cell Investig. 2020 May 15;7:8. doi: 10.21037/sci-2020-001. eCollection
      2020.


PMID- 32695792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-875X (Print)
IS  - 2296-875X (Linking)
VI  - 7
DP  - 2020
TI  - Corrigendum: Analysis of donor motivations in living donor liver transplantation.
PG  - 34
LID - 10.3389/fsurg.2020.00034 [doi]
AB  - [This corrects the article DOI: 10.3389/fsurg.2014.00025.].
CI  - Copyright (c) 2020 Abdeldayem, Kashkoush, Hegab, Aziz, Shoreem and Saleh.
FAU - Abdeldayem, Hesham
AU  - Abdeldayem H
AD  - National Liver Institute, Menofeyia University, Cairo, Egypt.
FAU - Kashkoush, Samy
AU  - Kashkoush S
AD  - National Liver Institute, Menofeyia University, Cairo, Egypt.
FAU - Hegab, Bassem Soliman
AU  - Hegab BS
AD  - National Liver Institute, Menofeyia University, Cairo, Egypt.
FAU - Aziz, Amr
AU  - Aziz A
AD  - National Liver Institute, Menofeyia University, Cairo, Egypt.
FAU - Shoreem, Hany
AU  - Shoreem H
AD  - National Liver Institute, Menofeyia University, Cairo, Egypt.
FAU - Saleh, Shereef
AU  - Saleh S
AD  - National Liver Institute, Menofeyia University, Cairo, Egypt.
LA  - eng
PT  - Published Erratum
DEP - 20200630
PL  - Switzerland
TA  - Front Surg
JT  - Frontiers in surgery
JID - 101645127
EFR - Front Surg. 2014 Jul 08;1:25. PMID: 25593949
PMC - PMC7338888
OTO - NOTNLM
OT  - LDLT
OT  - altruism
OT  - coercion
OT  - ethics
OT  - living donor
OT  - motivations
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2020/05/02 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.3389/fsurg.2020.00034 [doi]
PST - epublish
SO  - Front Surg. 2020 Jun 30;7:34. doi: 10.3389/fsurg.2020.00034. eCollection 2020.


PMID- 32695698
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 11
IP  - 3
DP  - 2020 May-Jun
TI  - Nailfold Capillaroscopy and Retinal Findings in Patients with Systemic Sclerosis:
      Is There An Association?
PG  - 382-386
LID - 10.4103/idoj.IDOJ_264_19 [doi]
AB  - INTRODUCTION: Systemic sclerosis (SSc) is characterized by fibrosis and intimal
      proliferation of cutaneous and visceral small vessels. These architectural
      abnormalities can be visualized with nailfold capillaroscopy (NFC); the changes
      being quite characteristic. At the same time, morphological alterations in
      retinal vascular bed are expected but sparsely described. AIM: We aimed to
      characterize the frequency and type of retinal microvascular changes in patients 
      with SSc and to analyze any association with NFC changes. PATIENTS AND METHODS:
      With institutional ethical committee approval, we recruited 45 consecutive
      patients with SSc (diagnosed based on American College of Rheumatology and
      European League against Rheumatism [ACR/EULAR-2013] criteria). NFC was done for
      all of them with a Universal Serial Bus (USB) dermatoscope; additionally,
      fundoscopy, fundus photography, and optical coherence tomography (OCT) were
      analyzed. Disease characteristics in patients with and without retinal disease
      were compared. RESULTS: Among the 45 SSc patients, 12 (26.67%) had limited
      cutaneous SSc (lSSc) while 33 (73.33%) had diffuse cutaneous disease (dSSc).
      Retinal microvascular changes seen as mild arteriolar alteration and
      arteriovenous crossing changes were recorded in 13 patients (28.89%); mostly in
      those with dSSc (12/13). The NFC architectural changes were more severe in
      patients with retinal disease, though the difference was not statistically
      significant. CONCLUSION: Patients with SSc can often have retinal microvascular
      abnormalities commensurate with the vascular changes characteristic of SSc. The
      severity of retinal changes correlates with changes in NFC. NFC, which is now an 
      essential tool for the management of SSc, could be a surrogate marker for retinal
      involvement in these patients.
CI  - Copyright: (c) 2020 Indian Dermatology Online Journal.
FAU - Jakhar, Deepak
AU  - Jakhar D
AD  - Department of Dermatology and STD, University College of Medical Sciences and GTB
      Hospital, New Delhi, India.
FAU - Grover, Chander
AU  - Grover C
AD  - Department of Dermatology and STD, University College of Medical Sciences and GTB
      Hospital, New Delhi, India.
FAU - Singal, Archana
AU  - Singal A
AD  - Department of Dermatology and STD, University College of Medical Sciences and GTB
      Hospital, New Delhi, India.
FAU - Das, G K
AU  - Das GK
AD  - Department of Ophthalmology, University College of Medical Sciences and GTB
      Hospital, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200510
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC7367578
OTO - NOTNLM
OT  - Eye
OT  - fundoscopy
OT  - nailfold capillaroscopy
OT  - retina
OT  - systemic sclerosis
COIS- There are no conflicts of interest.
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2019/06/03 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2019/12/15 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.4103/idoj.IDOJ_264_19 [doi]
AID - IDOJ-11-382 [pii]
PST - epublish
SO  - Indian Dermatol Online J. 2020 May 10;11(3):382-386. doi:
      10.4103/idoj.IDOJ_264_19. eCollection 2020 May-Jun.


PMID- 32695694
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 11
IP  - 3
DP  - 2020 May-Jun
TI  - A Cross-Sectional Observational Study of Clinical Spectrum and Prevalence of
      Fixed Food Eruption in a Tertiary Care Hospital.
PG  - 361-366
LID - 10.4103/idoj.IDOJ_340_19 [doi]
AB  - BACKGROUND: Fixed food eruption (FFE) is a rare type of hypersensitivity reaction
      occurring after ingestion of some food items in the form of recurrent
      erythematous patches, bullae, vesicle, or pustule at the same site after
      ingestion of same or related food products. Various items listed responsible for 
      causing FFE include tree nuts, groundnuts, legumes, lentils, eggs, fruits like
      kiwi, strawberry, tonic water, and tartrazine. Its more commonly reported in
      developed countries with no Indian studies as of yet. We studied the clinical
      spectrum and prevalence of FFE in a tertiary care hospital. OBJECTIVE: To study
      the prevalence and pattern of FFE after eliminating all other possible causes
      including drug rash. MATERIALS AND METHODS: A cross-section observational study
      of 27 consecutive patients suspected to have fixed food eruption after
      eliminating all possibilities of any drug reaction to the best of our knowledge. 
      Informed consent was obtained from the patients, and ethical clearance was taken 
      from the hospital ethical committee. RESULTS: A total of 27 patients were studied
      out of which 18 (66.66%) were females and 9 (33.33%) were males. The prevalence
      of fixed food eruption was calculated to be 0.072%.Fixed food eruption was noted 
      secondary to cashew nuts (14.8%), almonds (7.4%), walnut (7.4%), pistachio
      (3.7%), strawberry (3.7%), kiwi (3.7%), and cheese crisps (3.7%). CONCLUSION:
      This observational study highlights the varied patterns of fixed food eruptions
      as well as the burden of disease in population secondary to certain diets.
CI  - Copyright: (c) 2020 Indian Dermatology Online Journal.
FAU - Sharma, Loknandini
AU  - Sharma L
AD  - Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India.
FAU - Agarwal, Reetu
AU  - Agarwal R
AD  - Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India.
FAU - Chopra, Ajay
AU  - Chopra A
AD  - Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India.
FAU - Mitra, Barnali
AU  - Mitra B
AD  - Department of Paediatrics, Base Hospital Delhi Cantt, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200510
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC7367575
OTO - NOTNLM
OT  - Fixed food eruption
OT  - Indian population
OT  - open oral challenge test
OT  - prevalence
COIS- There are no conflicts of interest.
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2019/09/28 00:00 [received]
PHST- 2019/09/28 00:00 [revised]
PHST- 2019/09/28 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.4103/idoj.IDOJ_340_19 [doi]
AID - IDOJ-11-361 [pii]
PST - epublish
SO  - Indian Dermatol Online J. 2020 May 10;11(3):361-366. doi:
      10.4103/idoj.IDOJ_340_19. eCollection 2020 May-Jun.


PMID- 32695178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1687-9589 (Print)
IS  - 1687-9597 (Linking)
VI  - 2020
DP  - 2020
TI  - Perception of Women regarding Respectful Maternity Care during Facility-Based
      Childbirth.
PG  - 5142398
LID - 10.1155/2020/5142398 [doi]
AB  - BACKGROUND: Respectful care during childbirth has been described as "a universal 
      human right that encompasses the principles of ethics and respect for women's
      feelings, dignity, choices, and preferences." Many women experience a lack of
      respectful and abusive care during childbirth across the globe. OBJECTIVE: This
      study aimed to determine women's perception of respectful maternity care (RMC)
      during facility-based childbirth. METHOD: A descriptive cross-sectional study was
      conducted among 150 mothers admitted to the maternity ward of Nepal Medical
      College and Teaching Hospital using a purposive sampling technique. Data were
      collected through an interview technique by using a validated tool containing 15 
      items each measured on a scale of 5. Statistical Package for Social Science
      (SPSS) version 16 was used for data analysis. Frequency, percentage, mean score, 
      standard deviation, chi-square test, and binary logistic regression were used to 
      analyze descriptive and inferential statistics. RESULTS: In total, 84.7% of the
      women reported that they have experienced overall RMC services with a mean score 
      +/- SD (61.70 +/- 12.12). Though the majority of the women reported that they
      have experienced RMC services, they also revealed that they have experienced
      disrespectful care in various forms such as being shouted upon (30.0%), being
      slapped (18.7%), delayed service provision (22.7%), and not talking positively
      about pain and relief during childbirth (28.0%). Likewise, length of stay,
      parity, and time of delivery were found as factors that influenced friendly care 
      (COR = 0.383, 95% CI: 0.157-0.934), abuse-free care (COR = 3.663, 95% CI:
      1.607-8.349), and timely care (COR = 2.050, 95% CI: 1.031-4.076) dimensions of
      RMC, respectively. CONCLUSION: Even though RMC emphasizes eliminating
      disrespectful and abusive environment from health facilities, 15.0% of
      participants perceived that they have not experienced overall RMC services. So,
      the health facility should focus on the interventions which ensure that every
      woman receives this basic human dignity during one of the most vulnerable times
      in their lives.
CI  - Copyright (c) 2020 Pratima Pathak and Bijaya Ghimire.
FAU - Pathak, Pratima
AU  - Pathak P
AUID- ORCID: https://orcid.org/0000-0003-3461-6527
AD  - Nepal Medical College, Department of Nursing, Kathmandu University, P. O. Box
      13344, Fax No. 977-1-4912118, Jorpati, Kathmandu, Nepal.
FAU - Ghimire, Bijaya
AU  - Ghimire B
AUID- ORCID: https://orcid.org/0000-0001-7109-1577
AD  - Nepal Medical College, Department of Nursing, Kathmandu University, P. O. Box
      13344, Fax No. 977-1-4912118, Jorpati, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200704
PL  - United States
TA  - Obstet Gynecol Int
JT  - Obstetrics and gynecology international
JID - 101517078
PMC - PMC7355368
COIS- The authors do not have any conflicts of interest regarding this publication.
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2019/08/16 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.1155/2020/5142398 [doi]
PST - epublish
SO  - Obstet Gynecol Int. 2020 Jul 4;2020:5142398. doi: 10.1155/2020/5142398.
      eCollection 2020.


PMID- 32695050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Organizational Prevention and Management Strategies for Workplace Aggression
      Among Child Protection Workers: A Project Protocol for the Oslo Workplace
      Aggression Survey (OWAS).
PG  - 1401
LID - 10.3389/fpsyg.2020.01401 [doi]
AB  - BACKGROUND: Previous research has established exposure to workplace aggression as
      a significant risk factor for employee functioning, well-being, and health.
      However, less is known about effective prevention and management strategies. The 
      main objectives of the current project were to determine the impact of physical
      and psychological aggression on the well-being, health, and work ability of
      employees in the child welfare service and to establish whether a strong
      psychosocial safety climate and an ethical infrastructure are effective with
      regard to protecting employees against aggression. This project may help identify
      the specific risks child welfare workers are exposed to, the impact of workplace 
      aggression on their health and well-being, and the most effective strategies to
      manage the problem. Furthermore, the findings should be central for developing
      laws and regulations and to any political decision on measures to tackle
      aggression in the workplace. METHODS: The study will employ two prospective data 
      collections. Firstly, a three-wave longitudinal survey with a 6-month time lag
      between measurement points will be conducted among all 1,500 employees in the
      child welfare services in Oslo Municipality, Norway. Data will have a multilevel 
      structure and will be linked to registry data on sickness absence. Secondly, a
      quantitative daily diary study over a 14-day period will include 150 of the
      respondents from the main survey study. The survey questionnaires mainly comprise
      well-established and psychometrically validated indicators of workplace
      aggression, health and well-being, psychosocial safety climate, ethical
      infrastructure, and other relevant factors. The Regional Committees for Medical
      and Health Research Ethics (REC) in Norway (REC South East) have approved this
      project (project no. 28496). DISCUSSION: This project will identify the impact of
      workplace aggression on child protection workers as well as provide information
      on how organizations can actively manage exposure to workplace aggression. The
      findings may serve as a starting point for intervention studies as well as the
      development of policies and guidelines on how to handle workplace aggression.
CI  - Copyright (c) 2020 Nielsen, Christensen, Hetland and Finne.
FAU - Nielsen, Morten Birkeland
AU  - Nielsen MB
AD  - National Institute of Occupational Health, Oslo, Norway.
FAU - Christensen, Jan Olav
AU  - Christensen JO
AD  - National Institute of Occupational Health, Oslo, Norway.
FAU - Hetland, Jorn
AU  - Hetland J
AD  - Department of Psychosocial Science, University of Bergen, Bergen, Norway.
FAU - Finne, Live Bakke
AU  - Finne LB
AD  - National Institute of Occupational Health, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7339981
OTO - NOTNLM
OT  - aggression
OT  - harassment
OT  - health
OT  - prevention and management
OT  - safety
OT  - violence
EDAT- 2020/07/23 06:00
MHDA- 2020/07/23 06:01
CRDT- 2020/07/23 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/07/23 06:01 [medline]
AID - 10.3389/fpsyg.2020.01401 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jun 30;11:1401. doi: 10.3389/fpsyg.2020.01401. eCollection
      2020.


PMID- 32694666
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20220208
IS  - 1471-0064 (Electronic)
IS  - 1471-0056 (Linking)
VI  - 21
IP  - 10
DP  - 2020 Oct
TI  - Responsible, practical genomic data sharing that accelerates research.
PG  - 615-629
LID - 10.1038/s41576-020-0257-5 [doi]
AB  - Data sharing anchors reproducible science, but expectations and best practices
      are often nebulous. Communities of funders, researchers and publishers continue
      to grapple with what should be required or encouraged. To illuminate the
      rationales for sharing data, the technical challenges and the social and cultural
      challenges, we consider the stakeholders in the scientific enterprise. In
      biomedical research, participants are key among those stakeholders. Ethical
      sharing requires considering both the value of research efforts and the privacy
      costs for participants. We discuss current best practices for various types of
      genomic data, as well as opportunities to promote ethical data sharing that
      accelerates science by aligning incentives.
FAU - Byrd, James Brian
AU  - Byrd JB
AUID- ORCID: http://orcid.org/0000-0002-0509-3520
AD  - Department of Internal Medicine, Medical School, University of Michigan, Ann
      Arbor, MI, USA.
FAU - Greene, Anna C
AU  - Greene AC
AUID- ORCID: http://orcid.org/0000-0002-7356-4937
AD  - Alex's Lemonade Stand Foundation, Bala Cynwyd, PA, USA.
FAU - Prasad, Deepashree Venkatesh
AU  - Prasad DV
AUID- ORCID: http://orcid.org/0000-0001-5756-4083
AD  - Childhood Cancer Data Lab, Alex's Lemonade Stand Foundation, Philadelphia, PA,
      USA.
FAU - Jiang, Xiaoqian
AU  - Jiang X
AD  - School of Biomedical Informatics, The University of Texas Health Science Center
      at Houston, Houston, TX, USA.
FAU - Greene, Casey S
AU  - Greene CS
AUID- ORCID: http://orcid.org/0000-0001-8713-9213
AD  - Childhood Cancer Data Lab, Alex's Lemonade Stand Foundation, Philadelphia, PA,
      USA. greenescientist@gmail.com.
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman
      School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
      greenescientist@gmail.com.
LA  - eng
GR  - K23 HL128909/HL/NHLBI NIH HHS/United States
GR  - R01 CA237170/CA/NCI NIH HHS/United States
GR  - R01 HG010067/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200721
PL  - England
TA  - Nat Rev Genet
JT  - Nature reviews. Genetics
JID - 100962779
SB  - IM
MH  - Biomedical Research/*methods/*trends
MH  - Cooperative Behavior
MH  - Genomics/*ethics
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - Privacy
MH  - Research Personnel/*trends
PMC - PMC7974070
MID - NIHMS1669466
EDAT- 2020/07/23 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - 10.1038/s41576-020-0257-5 [doi]
AID - 10.1038/s41576-020-0257-5 [pii]
PST - ppublish
SO  - Nat Rev Genet. 2020 Oct;21(10):615-629. doi: 10.1038/s41576-020-0257-5. Epub 2020
      Jul 21.


PMID- 32694344
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210125
IS  - 2162-0989 (Electronic)
IS  - 2162-0989 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Jul-Aug
TI  - Deployment of Artificial Intelligence in Real-World Practice: Opportunity and
      Challenge.
PG  - 299-307
LID - 10.1097/APO.0000000000000301 [doi]
AB  - Artificial intelligence has rapidly evolved from the experimental phase to the
      implementation phase in many image-driven clinical disciplines, including
      ophthalmology. A combination of the increasing availability of large datasets and
      computing power with revolutionary progress in deep learning has created
      unprecedented opportunities for major breakthrough improvements in the
      performance and accuracy of automated diagnoses that primarily focus on image
      recognition and feature detection. Such an automated disease classification would
      significantly improve the accessibility, efficiency, and cost-effectiveness of
      eye care systems where it is less dependent on human input, potentially enabling 
      diagnosis to be cheaper, quicker, and more consistent. Although this technology
      will have a profound impact on clinical flow and practice patterns sooner or
      later, translating such a technology into clinical practice is challenging and
      requires similar levels of accountability and effectiveness as any new medication
      or medical device due to the potential problems of bias, and ethical, medical,
      and legal issues that might arise. The objective of this review is to summarize
      the opportunities and challenges of this transition and to facilitate the
      integration of artificial intelligence (AI) into routine clinical practice based 
      on our best understanding and experience in this area.
FAU - He, Mingguang
AU  - He M
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
AD  - Centre for Eye Research Australia, Royal Victorian Eye & Ear Hospital, Melbourne,
      Australia.
FAU - Li, Zhixi
AU  - Li Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Liu, Chi
AU  - Liu C
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
AD  - School of Computer Science, University of Technology Sydney, Ultimo NSW,
      Australia.
FAU - Shi, Danli
AU  - Shi D
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Tan, Zachary
AU  - Tan Z
AD  - Faculty of Medicine, The University of Queensland, Brisbane, Australia.
AD  - Schwarzman College, Tsinghua University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Asia Pac J Ophthalmol (Phila)
JT  - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
JID - 101583622
SB  - IM
MH  - Algorithms
MH  - Artificial Intelligence/*trends
MH  - Humans
MH  - Ophthalmology/*trends
MH  - Professional Practice/*trends
EDAT- 2020/07/23 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - 10.1097/APO.0000000000000301 [doi]
AID - 01599573-202008000-00005 [pii]
PST - ppublish
SO  - Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):299-307. doi:
      10.1097/APO.0000000000000301.


PMID- 32694284
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210506
IS  - 1536-481X (Electronic)
IS  - 1057-0829 (Linking)
VI  - 29
IP  - 9
DP  - 2020 Sep
TI  - A Case of Annular Iris Cyst Diagnosed With the Help of Ultrasound Biomicroscopy.
PG  - e103-e105
LID - 10.1097/IJG.0000000000001612 [doi]
AB  - PURPOSE: To report a case of annular iris cyst presenting as a secondary angle
      closure managed with Nd:YAG laser iridotomy. DESIGN: Case report. METHODS:
      Institutional review board exemption for this case report was obtained from the
      institutional ethics committee, Aravind eye hospital, Tirunelveli. All research
      adhered to the tenets of the Declaration of Helsinki. Informed consent was
      obtained.A 45-year-old woman presented with a 2-week history of sudden onset of
      pain and redness in the right eye. Slit-lamp biomicroscopy showed corneal edema, 
      with the shallow anterior chamber, convex bowing of iris, irregular shape of the 
      pupil, and glaucomflecken on the clear lens. Ultrasound biomicroscopy revealed an
      annular iris cyst of the iris pigment epithelium. Nd:YAG laser iridotomy was done
      to drain the cyst and relieve the angle closure. RESULTS: Laser treatment
      resulted in the collapse of the cyst, confirmed by ultrasound biomicroscopy and
      disappearance of the subject symptoms. CONCLUSION: Iris cysts are usually benign 
      in nature. An annular iris cyst is a rare presentation. They can present with a
      secondary angle closure as in our report. Correct diagnosis and timely
      intervention bring about a desirable result. With this report, the authors aim to
      catalog and familiarize ophthalmologists with a rare ocular pathology and its
      management.
FAU - Segi, Ashwin
AU  - Segi A
AD  - Glaucoma Clinic, Aravind Eye Hospital, Tirunelveli, Tamil Nadu, India.
FAU - Maheshwari, Devendra
AU  - Maheshwari D
FAU - Dabke, Shylesh
AU  - Dabke S
FAU - Rao, Sanjana
AU  - Rao S
FAU - Kadar, Mohideen A
AU  - Kadar MA
FAU - Rengappa, Ramakrishna
AU  - Rengappa R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
SB  - IM
MH  - Cysts/*diagnostic imaging/surgery
MH  - Female
MH  - Glaucoma, Angle-Closure/diagnosis/surgery
MH  - Gonioscopy
MH  - Humans
MH  - Intraocular Pressure
MH  - Iris Diseases/*diagnostic imaging/surgery
MH  - Laser Therapy
MH  - Lasers, Solid-State/therapeutic use
MH  - *Microscopy, Acoustic
MH  - Middle Aged
EDAT- 2020/07/23 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - 10.1097/IJG.0000000000001612 [doi]
AID - 00061198-202009000-00019 [pii]
PST - ppublish
SO  - J Glaucoma. 2020 Sep;29(9):e103-e105. doi: 10.1097/IJG.0000000000001612.


PMID- 32694266
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20210410
IS  - 1531-7021 (Electronic)
IS  - 1040-8738 (Linking)
VI  - 31
IP  - 5
DP  - 2020 Sep
TI  - Artificial intelligence for retinopathy of prematurity.
PG  - 312-317
LID - 10.1097/ICU.0000000000000680 [doi]
AB  - PURPOSE OF REVIEW: In this article, we review the current state of artificial
      intelligence applications in retinopathy of prematurity (ROP) and provide insight
      on challenges as well as strategies for bringing these algorithms to the bedside.
      RECENT FINDINGS: In the past few years, there has been a dramatic shift from
      machine learning approaches based on feature extraction to 'deep' convolutional
      neural networks for artificial intelligence applications. Several artificial
      intelligence for ROP approaches have demonstrated adequate proof-of-concept
      performance in research studies. The next steps are to determine whether these
      algorithms are robust to variable clinical and technical parameters in practice. 
      Integration of artificial intelligence into ROP screening and treatment is
      limited by generalizability of the algorithms to maintain performance on unseen
      data and integration of artificial intelligence technology into new or existing
      clinical workflows. SUMMARY: Real-world implementation of artificial intelligence
      for ROP diagnosis will require massive efforts targeted at developing standards
      for data acquisition, true external validation, and demonstration of feasibility.
      We must now focus on ethical, technical, clinical, regulatory, and financial
      considerations to bring this technology to the infant bedside to realize the
      promise offered by this technology to reduce preventable blindness from ROP.
FAU - Gensure, Rebekah H
AU  - Gensure RH
AD  - Department of Ophthalmology & Visual Sciences, John A. Moran Eye Center,
      University of Utah, Salt Lake City, Utah.
FAU - Chiang, Michael F
AU  - Chiang MF
AD  - Department of Ophthalmology, Oregon Health & Science University, Portland,
      Oregon, USA.
FAU - Campbell, John P
AU  - Campbell JP
AD  - Department of Ophthalmology, Oregon Health & Science University, Portland,
      Oregon, USA.
LA  - eng
GR  - R01 EY019474/EY/NEI NIH HHS/United States
GR  - P30 EY010572/EY/NEI NIH HHS/United States
GR  - R01 HD107493/HD/NICHD NIH HHS/United States
GR  - R01 EY031331/EY/NEI NIH HHS/United States
GR  - K12 EY027720/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Ophthalmol
JT  - Current opinion in ophthalmology
JID - 9011108
SB  - IM
MH  - Algorithms
MH  - *Artificial Intelligence
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/*methods
MH  - Infant, Newborn
MH  - Machine Learning
MH  - Neural Networks, Computer
MH  - Retinopathy of Prematurity/*diagnosis
PMC - PMC7891849
MID - NIHMS1666030
EDAT- 2020/07/23 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - 10.1097/ICU.0000000000000680 [doi]
AID - 00055735-202009000-00003 [pii]
PST - ppublish
SO  - Curr Opin Ophthalmol. 2020 Sep;31(5):312-317. doi: 10.1097/ICU.0000000000000680.


PMID- 32694091
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 2050-0521 (Electronic)
IS  - 2050-0521 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Oct
TI  - Historical and Ethical Perspectives on Vulvoplasty.
PG  - 542-547
LID - S2050-0521(20)30062-7 [pii]
LID - 10.1016/j.sxmr.2020.06.002 [doi]
AB  - INTRODUCTION: Surgical and other procedures to alter the shape of the female
      external genitalia, especially the labia minora, are increasingly popular and
      controversial worldwide. OBJECTIVES: This article aims to delineate and
      complicate the medical and moral controversy around these vulvoplasty procedures,
      by describing how female genital aesthetics, their interpretation, and alteration
      vary over time, space, and culture. METHODS: The history of the Hottentot Venus
      is used as a pivot about which to consider current biomedical, anthropological,
      and ethical literatures regarding female genital appearance and its manipulation.
      Intersectionality describes how different systems influence each other to affect 
      the agency of certain individuals or groups, and is therefore an ideal analytic
      method for biopsychosocial concerns of sex and informed consent. RESULTS: The
      19th century anatomic study and display of Sarah "Saartjie" Baartman, the
      Hottentot Venus, defined a European vulvar ideal by demonstrating its opposite.
      Today, the ideal appearance of the labia minora is variable across cultures and
      nationalities, and various mechanical and surgical manipulations are sought or
      imposed upon women to bring their bodies into conformity with these ideals.
      CONCLUSION: For European audiences, Baartman exemplified a stereotypical
      association between genital appearance, sexual availability, and accessibility as
      a biomedical subject. These logical linkages were a by-product of sexist, racist,
      and colonial ideologies that have since fallen out of favor. However, their
      genital effects continue to influence bioethical considerations of genitoplasty
      into the present day. Chubak B. Historical and Ethical Perspectives on
      Vulvoplasty. Sex Med Rev 2020;8:542-547.
CI  - Copyright (c) 2020 International Society for Sexual Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Chubak, Barbara
AU  - Chubak B
AD  - Department of Urology, Mount Sinai Icahn School of Medicine, New York, NY, USA.
      Electronic address: Barbara.Chubak@mountsinai.org.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20200718
PL  - Netherlands
TA  - Sex Med Rev
JT  - Sexual medicine reviews
JID - 101614773
SB  - IM
MH  - *Body Image
MH  - *Cultural Characteristics
MH  - Female
MH  - Gynecologic Surgical Procedures/*ethics/history/legislation &
      jurisprudence/trends
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - *Internationality
MH  - Vulva/anatomy & histology/*surgery
OTO - NOTNLM
OT  - Bioethics
OT  - Body Dismorphic Disorder
OT  - Female Genital Cosmetic Surgery
OT  - Female Genital Mutilation
OT  - Labiaplasty
OT  - Vulvoplasty
EDAT- 2020/07/23 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/07/23 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/06/06 00:00 [revised]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2020/07/23 06:00 [entrez]
AID - S2050-0521(20)30062-7 [pii]
AID - 10.1016/j.sxmr.2020.06.002 [doi]
PST - ppublish
SO  - Sex Med Rev. 2020 Oct;8(4):542-547. doi: 10.1016/j.sxmr.2020.06.002. Epub 2020
      Jul 18.


PMID- 32693800
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210407
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jul 22
TI  - Processes of consent in research for adults with impaired mental capacity nearing
      the end of life: systematic review and transparent expert consultation
      (MORECare_Capacity statement).
PG  - 221
LID - 10.1186/s12916-020-01654-2 [doi]
AB  - BACKGROUND: Involving adults lacking capacity (ALC) in research on end of life
      care (EoLC) or serious illness is important, but often omitted. We aimed to
      develop evidence-based guidance on how best to include individuals with impaired 
      capacity nearing the end of life in research, by identifying the challenges and
      solutions for processes of consent across the capacity spectrum. METHODS: Methods
      Of Researching End of Life Care_Capacity (MORECare_C) furthers the MORECare
      statement on research evaluating EoLC. We used simultaneous methods of systematic
      review and transparent expert consultation (TEC). The systematic review involved 
      four electronic databases searches. The eligibility criteria identified studies
      involving adults with serious illness and impaired capacity, and methods for
      recruitment in research, implementing the research methods, and exploring public 
      attitudes. The TEC involved stakeholder consultation to discuss and generate
      recommendations, and a Delphi survey and an expert 'think-tank' to explore
      consensus. We narratively synthesised the literature mapping processes of consent
      with recruitment outcomes, solutions, and challenges. We explored recommendation 
      consensus using descriptive statistics. Synthesis of all the findings informed
      the guidance statement. RESULTS: Of the 5539 articles identified, 91 met
      eligibility. The studies encompassed people with dementia (27%) and in palliative
      care (18%). Seventy-five percent used observational designs. Studies on research 
      methods (37 studies) focused on processes of proxy decision-making, advance
      consent, and deferred consent. Studies implementing research methods (30 studies)
      demonstrated the role of family members as both proxy decision-makers and
      supporting decision-making for the person with impaired capacity. The TEC
      involved 43 participants who generated 29 recommendations, with consensus that
      indicated. Key areas were the timeliness of the consent process and maximising an
      individual's decisional capacity. The think-tank (n = 19) refined equivocal
      recommendations including supporting proxy decision-makers, training
      practitioners, and incorporating legislative frameworks. CONCLUSIONS: The
      MORECare_C statement details 20 solutions to recruit ALC nearing the EoL in
      research. The statement provides much needed guidance to enrol individuals with
      serious illness in research. Key is involving family members early and designing 
      study procedures to accommodate variable and changeable levels of capacity. The
      statement demonstrates the ethical imperative and processes of recruiting adults 
      across the capacity spectrum in varying populations and settings.
FAU - Evans, C J
AU  - Evans CJ
AUID- ORCID: 0000-0003-0034-7402
AD  - Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence
      Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College
      London, Bessemer Road, London, SE5 9PJ, UK. catherine.evans@kcl.ac.uk.
AD  - Sussex Community NHS Foundation Trust, Brighton General Hospital, Brighton, UK.
      catherine.evans@kcl.ac.uk.
FAU - Yorganci, E
AU  - Yorganci E
AD  - Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence
      Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College
      London, Bessemer Road, London, SE5 9PJ, UK.
FAU - Lewis, P
AU  - Lewis P
AD  - Centre of Medical Law and Ethics, The Dickson Poon School of Law, King's College 
      London, London, UK.
FAU - Koffman, J
AU  - Koffman J
AD  - Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence
      Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College
      London, Bessemer Road, London, SE5 9PJ, UK.
FAU - Stone, K
AU  - Stone K
AD  - Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence
      Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College
      London, Bessemer Road, London, SE5 9PJ, UK.
FAU - Tunnard, I
AU  - Tunnard I
AD  - Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence
      Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College
      London, Bessemer Road, London, SE5 9PJ, UK.
FAU - Wee, B
AU  - Wee B
AD  - Oxford University Hospitals NHS Foundation Trust and Harris Manchester College,
      University of Oxford, Oxford, UK.
FAU - Bernal, W
AU  - Bernal W
AD  - King's College Hospital, London, UK.
FAU - Hotopf, M
AU  - Hotopf M
AD  - Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience,
      King's College London, London, UK.
FAU - Higginson, I J
AU  - Higginson IJ
AD  - Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, Florence
      Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College
      London, Bessemer Road, London, SE5 9PJ, UK.
CN  - MORECare_Capacity
LA  - eng
GR  - G0802654/MRC_/Medical Research Council/United Kingdom
GR  - MCCC-RP-11-A12544/MCCC_/Marie Curie/United Kingdom
GR  - C38812/A12533/MCCC_/Marie Curie/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200722
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
MH  - Adult
MH  - Consensus
MH  - Decision Making/*ethics
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Mental Disorders/*psychology
MH  - Referral and Consultation
MH  - Research Design/*standards
MH  - Terminal Care/*methods
MH  - Young Adult
PMC - PMC7374835
OTO - NOTNLM
OT  - *Consensus
OT  - *Consent
OT  - *Decision-making
OT  - *Ethics
OT  - *Methods
OT  - *Palliative care
OT  - *Systematic review
OT  - *Terminal care
IR  - Tanner D
FIR - Tanner, Deborah
IR  - Henry C
FIR - Henry, Claire
IR  - Grande G
FIR - Grande, Gunn
IR  - Dewar S
FIR - Dewar, Steve
IR  - Owen G
FIR - Owen, Gareth
IR  - Burman R
FIR - Burman, Rachel
IR  - Adamis D
FIR - Adamis, Dimitrios
IR  - Dunn M
FIR - Dunn, Michael
IR  - Kim S
FIR - Kim, Scott
IR  - Woods S
FIR - Woods, Simon
IR  - Vohora R
FIR - Vohora, Rowena
EDAT- 2020/07/23 06:00
MHDA- 2021/02/11 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
AID - 10.1186/s12916-020-01654-2 [doi]
AID - 10.1186/s12916-020-01654-2 [pii]
PST - epublish
SO  - BMC Med. 2020 Jul 22;18(1):221. doi: 10.1186/s12916-020-01654-2.


PMID- 32693788
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jul 21
TI  - Exploring the attitudes of health science students in Spain and Bolivia towards
      death. A cross sectional survey.
PG  - 111
LID - 10.1186/s12904-020-00615-z [doi]
AB  - BACKGROUND: One of the most difficult and stressful tasks faced by health science
      students is having to cope with death and dying due to the emotional burden of
      the same. Furthermore, the moral, ethical and professional values of future
      health professionals are influenced by the cultures where they live. PURPOSE:
      This study sought to compare and analyze the perception on end of life among a
      sample of health science students in Spain and Bolivia. METHODS: A descriptive,
      cross-sectional and multi-centric study. The total sample (548 students) was
      comprised of three groups: medical, nursing and physiotherapy students, of whom
      245 were from Bolivia, and 303 were Spanish students. The measurement instruments
      used were the Bugen's Coping with Death Scale and the Death Self-Efficacy Scale
      by Robbins. RESULTS: No statistically significant differences were observed
      between Spanish and Bolivian students (t (546) = - 0.248, p = 0.804) using the
      Bugen scale. This implies that there are no differences between the perception of
      both groups of students and that both groups use similar strategies to cope with 
      death. Additionally, the beliefs and attitudes of both groups were similar, with 
      Bolivian students presenting a trend towards improved scores. No differences were
      found between Spain and Bolivia in the results obtained on the Robbins scale,
      with students from both countries displaying similar skills and capabilities for 
      facing death. CONCLUSIONS: The beliefs on death of health science students from
      Spain and Bolivia were not affected by the respective cultures, type of degree
      studied, students' age, or the country of origin, however, we found that students
      in Bolivia value death as something more natural than their Spanish counterparts.
      PRACTICE IMPLICATIONS: To appropriately prepare students for this topic,
      education on coping with death and dying must be included within the university
      curriculum. TRIAL REGISTRATION: 2016DEC018.
FAU - Perez-de la Cruz, Sagrario
AU  - Perez-de la Cruz S
AD  - Department of Nursing, Physiotherapy and Medicine, University of Almeria, Crta
      del Sacramento s/n, La Canada de San Urbano, 04250, Almeria, Spain.
      spd205@ual.es.
FAU - Ramirez, Ivonne
AU  - Ramirez I
AD  - University of San Francisco Xavier de Chuquisaca, Sucre, Bolivia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200721
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
SB  - IM
MH  - Adolescent
MH  - *Attitude of Health Personnel
MH  - *Attitude to Death
MH  - Bolivia
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Psychometrics/instrumentation/methods
MH  - Spain
MH  - Students/*psychology/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7374858
OTO - NOTNLM
OT  - Education
OT  - End-of-life
OT  - Medicine
OT  - Nursing
OT  - Physiotherapy
OT  - Students
EDAT- 2020/07/23 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/09/03 00:00 [received]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
AID - 10.1186/s12904-020-00615-z [doi]
AID - 10.1186/s12904-020-00615-z [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 Jul 21;19(1):111. doi: 10.1186/s12904-020-00615-z.


PMID- 32693420
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20201218
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 82
IP  - 8-09
DP  - 2020 Sep
TI  - [Contact-Tracing Apps in Contact Tracing of COVID-19].
PG  - 664-669
LID - 10.1055/a-1195-2474 [doi]
AB  - Contact tracing is currently one of the most effective measures to contain the
      COVID-19 pandemic. In order to identify persons that would otherwise not be known
      or remembered and to keep the time delay when reporting an infection and when
      contacting people as short as possible, digital contact tracing using smartphones
      seems to be a reasonable measure additional to manual contact tracing. Although
      first modelling studies predicted a positive effect in terms of prompt contact
      tracing, no empirically reliable data are as yet available, neither on the
      population-wide benefit nor on the potential risks of contact tracing apps.
      Risk-benefit assessment of such an app includes investigating whether such an app
      fulfils its purpose, as also research on the effectiveness, risks and side
      effects, and implementation processes (e. g. planning and inclusion of different 
      participants). The aim of this article was to give an overview of possible public
      health benefits as well as technical, social, legal and ethical aspects of a
      contact-tracing app in the context of the COVID-19 pandemic. Furthermore,
      conditions for the widest possible use of the app are presented.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Jahnel, Tina
AU  - Jahnel T
AUID- ORCID: 0000-0002-8367-4574
AD  - Abteilung 1: Versorgungsforschung - Department for Health Services Research,
      Institut fur Public Health und Pflegeforschung, Universitat Bremen, Bremen.
AD  - Research Cluster Framework Development, Leibniz-WissenschaftsCampus Digital
      Public Health, Bremen.
FAU - Kernebeck, Sven
AU  - Kernebeck S
AD  - Lehrstuhl fur Didaktik und Bildungsforschung im Gesundheitswesen - Fakultat fur
      Gesundheit, Universitat Witten Herdecke, Witten.
FAU - Bobel, Simone
AU  - Bobel S
AD  - Institut fur Public Health und Pflegeforschung, Abteilung 1:
      Versorgungsforschung, Universitat Bremen, Bremen.
FAU - Buchner, Benedikt
AU  - Buchner B
AD  - Institut fur Informations-, Gesundheits- und Medizinrecht, Universitat Bremen,
      Universitat Bremen, Bremen.
AD  - Leibniz-WissenschaftsCampus Digital Public Health, Bremen.
FAU - Grill, Eva
AU  - Grill E
AD  - Institut fur Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, 
      Ludwig-Maximilians-Universitat Munchen, Munchen.
FAU - Hinck, Sebastian
AU  - Hinck S
AD  - Deutsche Gesellschaft fur Public Health, Deutsche Gesellschaft fur Public Health 
      eV, Bochum.
FAU - Ranisch, Robert
AU  - Ranisch R
AD  - Internationales Zentrum fur Ethik in den Wissenschaften, Universitat Tubingen
      Institut fur Ethik und Geschichte der Medizin, Tubingen.
FAU - Rothenbacher, Dietrich
AU  - Rothenbacher D
AD  - Institut fur Epidemiologie und Medizinische Biometrie, Universitat Ulm, Ulm.
FAU - Schuz, Benjamin
AU  - Schuz B
AD  - Leibniz-WissenschaftsCampus Digital Public Health, Bremen.
AD  - Institut fur Public Health und Pflegeforschung, Abteilung 2: Pravention und
      Gesundheitsforderung, Universitat Bremen, Bremen.
FAU - Starke, Dagmar
AU  - Starke D
AD  - Referentin fur Epidemiologie und Gesundheitsberichterstattung, Akademie fur
      Offentliches Gesundheitswesen, Dusseldorf.
FAU - Wienert, Julian
AU  - Wienert J
AUID- ORCID: 0000-0003-1246-7591
AD  - Pravention und Evaluation, Leibniz-Institut fur Praventionsforschung und
      Epidemiologie - BIPS GmbH, Bremen.
AD  - Research Cluster Evaluation, Leibniz-WissenschaftsCampus Digital Public Health,
      Bremen.
FAU - Zeeb, Hajo
AU  - Zeeb H
AD  - Leibniz-WissenschaftsCampus Digital Public Health, Bremen.
AD  - Pravention und Evaluation, Leibniz-Institut fur Praventionsforschung und
      Epidemiologie - BIPS GmbH, Bremen.
AD  - Health Sciences Bremen, Universitat Bremen, Bremen.
FAU - Gerhardus, Ansgar
AU  - Gerhardus A
AD  - Research Cluster Framework Development, Leibniz-WissenschaftsCampus Digital
      Public Health, Bremen.
AD  - Health Sciences Bremen, Universitat Bremen, Bremen.
AD  - Department for Health Sciences, Abteilung 1: Versorgungsforschung, Universitat
      Bremen, Bremen.
LA  - ger
PT  - Journal Article
TT  - Contact-Tracing-Apps als unterstutzende Massnahme bei der
      Kontaktpersonennachverfolgung von COVID-19.
DEP - 20200721
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes
      (Germany))
JID - 9204210
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Contact Tracing
MH  - Coronavirus Infections/*epidemiology
MH  - Germany/epidemiology
MH  - Humans
MH  - *Mobile Applications
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7536383
COIS- EG war vom 14.04.2020 bis zum 25.04.2020 Mitglied des Beraterteams zur
      Entwicklung der epidemiologischen Spezifikationen der PEPP-PT App. Alle anderen
      Autor/innen geben an, dass keine Interessenkonflikte bestehen.
EDAT- 2020/07/22 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - 10.1055/a-1195-2474 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2020 Sep;82(8-09):664-669. doi: 10.1055/a-1195-2474. Epub 2020 
      Jul 21.


PMID- 32693405
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1559-7776 (Electronic)
IS  - 1559-7768 (Linking)
VI  - 31
IP  - 3
DP  - 2020 Sep 15
TI  - Applying E-PAUSE to Ethical Challenges in a Pandemic.
PG  - 334-339
LID - 10.4037/aacnacc2020216 [doi]
FAU - Rushton, Cynda Hylton
AU  - Rushton CH
AD  - Cynda Hylton Rushton is Anne and George L. Bunting Professor of Clinical Ethics, 
      Johns Hopkins University School of Nursing and Berman Institute of Bioethics, 525
      N Wolfe St, Box 420, Baltimore, MD 21205 (crushto1@jhu.edu).
FAU - Reller, Nancy
AU  - Reller N
AD  - Nancy Reller is President, Sojourn Communications, McLean, Virginia.
FAU - Swoboda, Sandra M
AU  - Swoboda SM
AD  - Sandra M. Swoboda is Department of Surgery Research Program Coordinator and
      Pre-licensure Masters Entry Program Simulation Coordinator/Educator, Johns
      Hopkins University Schools of Medicine and Nursing, Baltimore, Maryland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - AACN Adv Crit Care
JT  - AACN advanced critical care
JID - 101269322
MH  - *Adaptation, Psychological
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - COVID-19/epidemiology/*nursing
MH  - Critical Care Nursing/*standards
MH  - *Ethics, Medical
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Staff, Hospital/*psychology
MH  - Pandemics/*ethics
MH  - *Practice Guidelines as Topic
MH  - Stress, Psychological
MH  - United States
EDAT- 2020/07/22 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - 31110 [pii]
AID - 10.4037/aacnacc2020216 [doi]
PST - ppublish
SO  - AACN Adv Crit Care. 2020 Sep 15;31(3):334-339. doi: 10.4037/aacnacc2020216.


PMID- 32693315
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1879-3460 (Electronic)
IS  - 0168-1605 (Linking)
VI  - 333
DP  - 2020 Nov 16
TI  - An agent-based simulator for the gastrointestinal pathway of Listeria
      monocytogenes.
PG  - 108776
LID - S0168-1605(20)30270-1 [pii]
LID - 10.1016/j.ijfoodmicro.2020.108776 [doi]
AB  - We developed an agent-based gastric simulator for a human host to illustrate the 
      within host survival mechanisms of Listeria monocytogenes. The simulator
      incorporates the gastric physiology and digestion processes that are critical for
      pathogen survival in the stomach. Mathematical formulations for the pH dynamics, 
      stomach emptying time, and survival probability in the presence of gastric acid
      are integrated in the simulator to evaluate the portion of ingested bacteria that
      survives in the stomach and reaches the small intestine. The parameters are
      estimated using in vitro data relevant to the human stomach and L. monocytogenes.
      The simulator predicts that 5%-29% of ingested bacteria can survive a human
      stomach and reach the small intestine. In the absence of extensive scientific
      experiments, which are not feasible on the grounds of ethical and safety
      concerns, this simulator may provide a supplementary tool to evaluate pathogen
      survival and subsequent infection, especially with regards to the ingestion of
      small doses.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Rahman, Ashrafur
AU  - Rahman A
AD  - Department of Mathematics and Statistics, Oakland University, Rochester, MI
      48309, United States of America; Laboratory for Industrial and Applied
      Mathematics, Centre for Disease Modelling, Department of Mathematics and
      Statistics, York University, Toronto, ON M3J 1P3, Canada. Electronic address:
      rahman2@oakland.edu.
FAU - Asgary, Ali
AU  - Asgary A
AD  - Disaster & Emergency Management, York University, Toronto, ON M3J 1P3, Canada.
FAU - Munther, Daniel
AU  - Munther D
AD  - Department of Mathematics, Cleveland State University, Cleveland, OH 44115,
      United States of America.
FAU - Fazil, Aamir
AU  - Fazil A
AD  - National Microbiology Laboratory, Public Health Agency of Canada, Guelph, ON N1H 
      7M7, Canada.
FAU - Smith, Ben A
AU  - Smith BA
AD  - National Microbiology Laboratory, Public Health Agency of Canada, Guelph, ON N1H 
      7M7, Canada.
FAU - Wu, Jianhong
AU  - Wu J
AD  - Laboratory for Industrial and Applied Mathematics, Centre for Disease Modelling, 
      Department of Mathematics and Statistics, York University, Toronto, ON M3J 1P3,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - Netherlands
TA  - Int J Food Microbiol
JT  - International journal of food microbiology
JID - 8412849
SB  - IM
MH  - Digestion/physiology
MH  - Eating
MH  - Gastric Acid/metabolism
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Intestine, Small/*microbiology
MH  - Listeria monocytogenes/*pathogenicity
MH  - Models, Biological
MH  - Stomach/*microbiology
OTO - NOTNLM
OT  - Food matrix
OT  - Foodborne pathogen
OT  - Individual-based model
OT  - Pathogen survival
OT  - Stomach emptying time
OT  - Stomach pH dynamics
EDAT- 2020/07/22 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/22 06:00
PHST- 2019/07/28 00:00 [received]
PHST- 2019/11/29 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - S0168-1605(20)30270-1 [pii]
AID - 10.1016/j.ijfoodmicro.2020.108776 [doi]
PST - ppublish
SO  - Int J Food Microbiol. 2020 Nov 16;333:108776. doi:
      10.1016/j.ijfoodmicro.2020.108776. Epub 2020 Jul 10.


PMID- 32692387
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20200730
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 324
IP  - 3
DP  - 2020 Jul 21
TI  - Public Attitudes Regarding Hospitals and Physicians Encouraging Donations From
      Grateful Patients.
PG  - 270-278
LID - 10.1001/jama.2020.9442 [doi]
AB  - Importance: Philanthropy is an increasingly important source of support for
      health care institutions. There is little empirical evidence to inform ethical
      guidelines. Objective: To assess public attitudes regarding specific practices
      used by health care institutions to encourage philanthropic donations from
      grateful patients. Design, Setting, and Participants: Using the Ipsos
      KnowledgePanel, a probability-based sample representative of the US population, a
      survey solicited opinions from a primary cohort representing the general
      population and 3 supplemental cohorts (with high income, cancer, and with heart
      disease, respectively). Exposures: Web-based questionnaire. Main Outcomes and
      Measures: Descriptive analyses (with percentages weighted to make the sample
      demographically representative of the US population) evaluated respondents'
      attitudes regarding the acceptability of strategies hospitals may use to
      identify, solicit, and thank donors; perceptions of the effect of physicians
      discussing donations with their patients; and opinions regarding gift use and
      stewardship. Results: Of 831 individuals targeted for the general population
      sample, 513 (62%) completed surveys, of whom 246 (48.0%) were women and 345
      (67.3%) non-Hispanic white. In the weighted sample, 47.0% (95% CI, 42.3%-51.7%)
      responded that physicians giving patient names to hospital fundraising staff
      after asking patients' permission was definitely or probably acceptable; 8.5%
      (95% CI, 5.7%-11.2%) endorsed referring without asking permission. Of the
      participants, 79.5% (95% CI, 75.6%-83.4%) reported it acceptable for physicians
      to talk to patients about donating if patients have brought it up; 14.2% (95% CI,
      10.9%-17.6%) reported it acceptable when patients have not brought it up; 9.9%
      (95% CI, 7.1%-12.8%) accepted hospital development staff performing wealth
      screening using publicly available data to identify patients capable of large
      donations. Of the participants, 83.2% (95% CI, 79.5%-86.9%) agreed that
      physicians talking with their patients about donating may interfere with the
      patient-physician relationship. For a hypothetical patient who donated $1
      million, 50.1% (95% CI, 45.4%-54.7%) indicated it would be acceptable for the
      hospital to show thanks by providing nicer hospital rooms, 26.0% (95% CI,
      21.9%-30.1%) by providing expedited appointments, and 19.8% (95% CI, 16.1%-23.5%)
      by providing physicians' cell phone numbers. Conclusions and Relevance: In this
      survey study of participants drawn from the general US population, a substantial 
      proportion did not endorse legally allowable approaches for identifying,
      engaging, and thanking patient-donors.
FAU - Jagsi, Reshma
AU  - Jagsi R
AD  - University of Michigan, Ann Arbor.
FAU - Griffith, Kent A
AU  - Griffith KA
AD  - University of Michigan, Ann Arbor.
FAU - Carrese, Joseph A
AU  - Carrese JA
AD  - Johns Hopkins University, Baltimore, Maryland.
FAU - Collins, Megan
AU  - Collins M
AD  - Johns Hopkins University, Baltimore, Maryland.
FAU - Kao, Audiey C
AU  - Kao AC
AD  - American Medical Association, Chicago, Illinois.
FAU - Konrath, Sara
AU  - Konrath S
AD  - Indiana University-Purdue University Indianapolis.
FAU - Tovino, Stacey A
AU  - Tovino SA
AD  - University of Oklahoma College of Law, Norman.
FAU - Wheeler, Jane L
AU  - Wheeler JL
AD  - Johns Hopkins University, Baltimore, Maryland.
FAU - Wright, Scott M
AU  - Wright SM
AD  - Johns Hopkins University, Baltimore, Maryland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - *Attitude to Health
MH  - Cohort Studies
MH  - Economics, Hospital
MH  - Female
MH  - Fund Raising/ethics/*methods
MH  - *Gift Giving/ethics
MH  - Heart Diseases
MH  - *Hospitals/ethics
MH  - Humans
MH  - Income
MH  - Male
MH  - Middle Aged
MH  - Neoplasms
MH  - Patients/*psychology/statistics & numerical data
MH  - Physician's Role/*psychology
MH  - Probability
MH  - Sex Distribution
MH  - Socioeconomic Factors
MH  - Surveys and Questionnaires/statistics & numerical data
MH  - United States
MH  - Young Adult
EDAT- 2020/07/22 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - 2768465 [pii]
AID - 10.1001/jama.2020.9442 [doi]
PST - ppublish
SO  - JAMA. 2020 Jul 21;324(3):270-278. doi: 10.1001/jama.2020.9442.


PMID- 32692128
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210914
IS  - 1538-1145 (Electronic)
IS  - 1527-4160 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Jul
TI  - Therapeutic Risk Management for Violence: Clinical Risk Assessment.
PG  - 313-319
LID - 10.1097/PRA.0000000000000481 [doi]
AB  - Violence risk assessment is a requisite component of mental health treatment.
      Adhering to standards of care and ethical and legal requirements necessitates a
      cogent process for conducting (and documenting) screening, assessment, and
      management of other-directed violence risk. In this 5-part series, we describe a 
      model for achieving therapeutic risk management of the potentially violent
      patient, with essential elements involving a clinical interview augmented by
      structured screening or assessment tools; risk stratification in terms of
      temporality and severity; chain analysis to intervene on the functions of violent
      ideation and behavior; and development of a personalized safety plan. This first 
      column of the series focuses on essential aspects of the clinical interview.
FAU - Wortzel, Hal S
AU  - Wortzel HS
FAU - Borges, Lauren M
AU  - Borges LM
FAU - Barnes, Sean M
AU  - Barnes SM
FAU - Nazem, Sarra
AU  - Nazem S
FAU - McGarity, Suzanne
AU  - McGarity S
FAU - Clark, Kaily
AU  - Clark K
FAU - Bahraini, Nazanin H
AU  - Bahraini NH
FAU - Matarazzo, Bridget B
AU  - Matarazzo BB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Psychiatr Pract
JT  - Journal of psychiatric practice
JID - 100901141
SB  - IM
MH  - Adult
MH  - Humans
MH  - Male
MH  - *Patient Safety
MH  - Risk Assessment
MH  - Risk Management
MH  - Suicide/prevention & control/psychology
MH  - Violence/*prevention & control/*psychology
EDAT- 2020/07/22 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.1097/PRA.0000000000000481 [doi]
AID - 00131746-202007000-00008 [pii]
PST - ppublish
SO  - J Psychiatr Pract. 2020 Jul;26(4):313-319. doi: 10.1097/PRA.0000000000000481.


PMID- 32691491
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20211102
IS  - 1744-6171 (Electronic)
IS  - 1073-6077 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Nov
TI  - Considerations for working with youth with socially complex needs.
PG  - 209-220
LID - 10.1111/jcap.12288 [doi]
AB  - TOPIC: The presence of adverse childhood experiences offers a glimpse into the
      social complexity in the lives of youth. Thus far, youth have been categorized as
      "at-risk" or "vulnerable,"-identifiers which highlight a deficits-based framework
      and continue to stigmatize youth. To combat this systemic marginalization, we
      propose using the term youth with socially complex needs. These youth, often
      minority ethnic/racial and/or sexual/gender minorities, experience repeated
      adversity and discrimination. PURPOSE: The purpose of this paper is to
      conceptualize the unique considerations of working with youth with socially
      complex needs-who have an increased vulnerability for social marginalization.
      SOURCES USED: Given the adversity experienced and challenges inherent in working 
      with youth with socially complex needs, ethical principles, and relevant care
      delivery models were explored. CONCLUSIONS: Delivering mental health care and/or 
      conducting research in collaboration with youth with socially complex needs
      requires thoughtful consideration of ethical principles and models of care. In
      conclusion, we propose a strengths-based, individualized approach to working with
      youth with socially complex needs that requires a dynamic, fluid, multisystemic
      approach to care and research.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Bounds, Dawn T
AU  - Bounds DT
AUID- ORCID: 0000-0002-4116-0217
AD  - Rush University College of Nursing, Chicago, Illinois, USA.
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
FAU - Winiarski, Dominka A
AU  - Winiarski DA
AUID- ORCID: 0000-0002-9954-0490
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
FAU - Otwell, Caitlin H
AU  - Otwell CH
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
FAU - Tobin, Valerie
AU  - Tobin V
AUID- ORCID: 0000-0001-8485-9442
AD  - Rush University College of Nursing, Chicago, Illinois, USA.
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
FAU - Glover, Angela C
AU  - Glover AC
AUID- ORCID: 0000-0002-4514-0379
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
FAU - Melendez, Adrian
AU  - Melendez A
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
FAU - Karnik, Niranjan S
AU  - Karnik NS
AUID- ORCID: 0000-0001-7650-3008
AD  - Department of Psychiatry and Behavioral Sciences, Rush University Medical Center,
      Chicago, Illinois, USA.
LA  - eng
GR  - KL2 TR002387/TR/NCATS NIH HHS/United States
GR  - R25 DA035692/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200720
PL  - England
TA  - J Child Adolesc Psychiatr Nurs
JT  - Journal of child and adolescent psychiatric nursing : official publication of the
      Association of Child and Adolescent Psychiatric Nurses, Inc
JID - 9431738
MH  - Adolescent
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Health Services
MH  - Vulnerable Populations/*psychology
MH  - Young Adult
PMC - PMC7970826
MID - NIHMS1624281
OTO - NOTNLM
OT  - *adversity
OT  - *socially complex needs
OT  - *youth
EDAT- 2020/07/22 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/07/22 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - 10.1111/jcap.12288 [doi]
PST - ppublish
SO  - J Child Adolesc Psychiatr Nurs. 2020 Nov;33(4):209-220. doi: 10.1111/jcap.12288. 
      Epub 2020 Jul 20.


PMID- 32691458
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1524-4741 (Electronic)
IS  - 1075-122X (Linking)
VI  - 26
IP  - 8
DP  - 2020 Aug
TI  - The contemporary landscape of genetic testing and breast cancer: Emerging issues.
PG  - 1549-1555
LID - 10.1111/tbj.13968 [doi]
AB  - The landscape of genetic testing for breast cancer susceptibility has transformed
      dramatically over the last decade and a half. Traditionally, the process of
      genetic testing resided fully within a medical infrastructure, from
      identification of appropriate testing candidates to gene selection to risk
      mitigation recommendations. More recently, decreasing costs, advancing
      technology, and a growing understanding of therapeutic implications of certain
      genetic test results have led to more widespread uptake of testing that
      increasingly involves broad multigene panels. Germline genetic testing for breast
      cancer susceptibility can now be obtained through one of three approaches:
      through clinical care; a direct-to-consumer (DTC) approach that is entirely
      consumer-driven; or a hybrid, patient-initiated, provider-mediated model.
      Increased access to testing has led to extensive dialogue about the best way to
      conduct testing and act on results. Points of discussion include: selection of
      appropriate candidates for genetic testing; optimal composition of genes on
      panels; informed consent; safe return of results; privacy; and legal protections 
      for those found to have relevant pathogenic or likely pathogenic variants. As
      more individuals undergo genetic testing, a growing population of individuals
      with inherited breast cancer predisposition informs optimal management of cancer 
      risk and also highlights unanswered questions. This article aims to review the
      current state of genetic testing for inherited breast cancer susceptibility
      including testing approaches, the legal, ethical and social landscape, and
      selected contemporary management issues.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Shah, Payal D
AU  - Shah PD
AUID- ORCID: 0000-0001-5874-3390
AD  - Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania,
      Philadelphia, Pennsylvania.
AD  - Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
      Pennsylvania.
FAU - Domchek, Susan M
AU  - Domchek SM
AD  - Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania,
      Philadelphia, Pennsylvania.
AD  - Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
      Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - United States
TA  - Breast J
JT  - The breast journal
JID - 9505539
SB  - IM
MH  - *Breast Neoplasms/diagnosis/genetics
MH  - Female
MH  - Genetic Counseling
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Humans
OTO - NOTNLM
OT  - *BRCA
OT  - *direct-to-consumer
OT  - *genetic information nondiscrimination Act
OT  - *genetic testing
EDAT- 2020/07/22 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - 10.1111/tbj.13968 [doi]
PST - ppublish
SO  - Breast J. 2020 Aug;26(8):1549-1555. doi: 10.1111/tbj.13968. Epub 2020 Jul 20.


PMID- 32691079
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1433-0407 (Electronic)
IS  - 0028-2804 (Linking)
VI  - 91
IP  - 8
DP  - 2020 Aug
TI  - [Appearances are not deceptive: clinical evidence and new research approaches to 
      open-label placebo].
PG  - 708-713
LID - 10.1007/s00115-020-00953-6 [doi]
AB  - The efficacy of placebo effects is proven in experimental, clinical and
      meta-analytical studies. However, harnessing placebo effects in clinical
      treatment contexts is hampered legally and ethically, since it has been
      considered necessary to conceal the inert nature of a placebo application.
      Interestingly, the results of recently published small, randomized trials suggest
      that patients can experience symptom relief after taking pills that they know
      lack any medication. In particular, these so-called open-label placebos (OLP)
      improved strongly fluctuating and individually distressing complaints such as
      gastrointestinal, neurological, psychosomatic and pain symptoms. Although the
      mechanisms are largely unknown, the open-label placebo application might be a
      promising way of fostering placebo effects in clinical settings. Initial study
      protocols already provide schedules for OLP use as an additional treatment in
      opioid use disorders. Likewise, the reduction of side effects, conversion effects
      or withdrawal symptoms through OLP applications in pharmacologically active
      treatments appear to serve as appropriate therapy goals. Further mechanistic
      studies are urgently needed to investigate the thus far only hypothetically
      proposed underlying mechanisms of OLP.
FAU - Nestoriuc, Y
AU  - Nestoriuc Y
AD  - Klinische Psychologie, Helmut-Schmidt-Universitat, Holstenhofweg 85, 22053,
      Hamburg, Deutschland. y.nestoriuc@hsu-hh.de.
AD  - Systemische Neurowissenschaften, Universitatsklinikum Hamburg-Eppendorf,
      Martinistrasse 52, 20251, Hamburg, Deutschland. y.nestoriuc@hsu-hh.de.
FAU - Kleine-Borgmann, J
AU  - Kleine-Borgmann J
AD  - Klinik fur Neurologie, Universitatsmedizin Essen, Hufelandstrasse 55, 45147,
      Essen, Deutschland. julian.kleine-borgmann@uk-essen.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Der Schein trugt nicht - klinische Evidenz und neue Forschungsansatze zum
      Open-label-Placebo.
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
SB  - IM
MH  - Humans
MH  - Pain/drug therapy/prevention & control
MH  - *Placebo Effect
MH  - *Research Design
OTO - NOTNLM
OT  - Clinical implications
OT  - Pain management
OT  - Placebo analgesia
OT  - Placebo effect
OT  - Placebo, non-deceptive
EDAT- 2020/07/22 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - 10.1007/s00115-020-00953-6 [doi]
AID - 10.1007/s00115-020-00953-6 [pii]
PST - ppublish
SO  - Nervenarzt. 2020 Aug;91(8):708-713. doi: 10.1007/s00115-020-00953-6.


PMID- 32690761
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Caster Semenya, athlete classification, and fair equality of opportunity in
      sport.
PG  - 584-590
LID - 10.1136/medethics-2019-105937 [doi]
AB  - According to the Differences of Sex Development (DSD) Regulations of the
      International Association of Athletics Federations (IAAF), Caster Semenya and
      other athletes with heightened testosterone levels are considered non-eligible
      for middle distance running races in the women's class. Based on an analysis of
      fair equality of opportunity in sport, I take a critical look at the Semenya case
      and at IAAF's DSD Regulations. I distinguish between what I call stable and
      dynamic inequalities between athletes. Stable inequalities are those that
      athletes cannot impact or control in any significant way such as inequalities in 
      biological sex, body size and chronological age. Dynamic inequalities, such as
      inequalities in strength, speed and endurance, or in technical and tactical
      skills, can be impacted and to a certain extent controlled by athletes. If stable
      inequalities exert significant and systematic impact on performance, they provide
      a rationale for classification. If high testosterone level is an inborn, strong
      and systemic driver of performance development, inequalities in such levels can
      provide a rationale for classification. As is emphasised by the Court of
      Arbitration for Sport (CAS), this leads to a dilemma of rights: the right of
      Semenya to compete in sport according to her legal sex and gender identity, and
      the right of other athletes within the average female testosterone range to
      compete under fair conditions. I conclude with providing conditional support of
      the CAS decision in the Semenya case and of IAAF's DSD Regulations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Loland, Sigmund
AU  - Loland S
AD  - Department of Sport and Social Sciences, The Norwegian School of Sport Sciences, 
      Oslo, Norway sigmund.loland@nih.no.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 3XMK78S47O (Testosterone)
SB  - IM
CIN - J Med Ethics. 2020 Sep;46(9):591-592. PMID: 32723761
CIN - J Med Ethics. 2020 Sep;46(9):593-594. PMID: 32792348
CIN - J Med Ethics. 2020 Sep;46(9):597-598. PMID: 32817411
CIN - J Med Ethics. 2020 Sep;46(9):599-600. PMID: 32826302
CIN - J Med Ethics. 2020 Sep;46(9):595-596. PMID: 32826303
CIN - J Med Ethics. 2020 Sep;46(9):563-564. PMID: 32855283
MH  - Athletes
MH  - Female
MH  - Gender Identity
MH  - Humans
MH  - *Hyperandrogenism
MH  - Male
MH  - *Sports
MH  - Testosterone
OTO - NOTNLM
OT  - *applied and professional ethics
OT  - *distributive justice
OT  - *sexuality/gender
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
AID - medethics-2019-105937 [pii]
AID - 10.1136/medethics-2019-105937 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):584-590. doi: 10.1136/medethics-2019-105937. Epub
      2020 Jul 20.


PMID- 32690754
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Protocol of a retrospective, multicentre observational study on hyperthermic
      intrathoracic chemotherapy in Germany.
PG  - e041511
LID - 10.1136/bmjopen-2020-041511 [doi]
AB  - INTRODUCTION: Objective of the 'German hyperthermic intrathoracic chemotherapy
      (HITOC) study' is to evaluate the HITOC as additional treatment after surgical
      cytoreduction for malignant pleural tumours. Even though HITOC is applied with
      increasing frequency, there is no standardised therapy protocol concerning the
      technique of HITOC, the selection as well as dosage of chemotherapeutic agents
      and perioperative management in order to provide a safe and comparable,
      standardised treatment regime. METHODS AND ANALYSIS: This trial is a
      retrospective, multicentre observational study, which is funded by the German
      Research Foundation. Approximately 300 patients will be included. Four
      departments of thoracic surgery, which are performing the most HITOC procedures
      in Germany, are contributing to this study: Center for Thoracic Surgery at the
      University Hospital Regensburg, Thoracic Clinic Heidelberg of the University of
      Heidelberg, Center for Thoracic Surgery of the Hospital University of Munich and 
      the Department of Thoracic Surgery at the University Hospital Freiburg. All
      patients who underwent surgical cytoreduction and subsequent HITOC at one of the 
      four centres between starting the HITOC programme in 2008 and December 2019 will 
      be included. Information on the performed HITOC will be obtained, focusing on the
      technique as well as the applied perfusion solution including the
      chemotherapeutic agent. Furthermore, parameters of the patient's postoperative
      recovery will be analysed to determine 30-day morbidity and mortality. ETHICS AND
      DISSEMINATION: The approvals by the local ethics committee of the respective
      clinic and the three participating clinics have been obtained. The results will
      be presented in conferences and published in a peer-reviewed journal. TRIAL
      REGISTRATION NUMBER: German Clinical Trials Registry (DRKS00015012; Pre-results).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Markowiak, Till
AU  - Markowiak T
AUID- ORCID: 0000-0002-5364-6206
AD  - Department of Thoracic Surgery, Universitatsklinikum Regensburg, Regensburg,
      Bayern, Germany.
FAU - Koller, Michael
AU  - Koller M
AD  - Center for Clinical Studies, Universitatsklinikum Regensburg, Regensburg, Bayern,
      Germany.
FAU - Zeman, Florian
AU  - Zeman F
AD  - Center for Clinical Studies, Universitatsklinikum Regensburg, Regensburg, Bayern,
      Germany.
FAU - Huppertz, Gunnar
AU  - Huppertz G
AD  - Center for Clinical Studies, Universitatsklinikum Regensburg, Regensburg, Bayern,
      Germany.
FAU - Hofmann, Hans-Stefan
AU  - Hofmann HS
AD  - Department of Thoracic Surgery, Universitatsklinikum Regensburg, Regensburg,
      Bayern, Germany.
FAU - Ried, Michael
AU  - Ried M
AD  - Department of Thoracic Surgery, Universitatsklinikum Regensburg, Regensburg,
      Bayern, Germany michael.ried@ukr.de.
CN  - HITOC Study Group
LA  - eng
SI  - DRKS/DRKS00015012
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cytoreduction Surgical Procedures
MH  - Germany
MH  - Humans
MH  - *Hyperthermia, Induced
MH  - Multicenter Studies as Topic
MH  - Observational Studies as Topic
MH  - *Pleural Neoplasms/drug therapy/surgery
MH  - Retrospective Studies
PMC - PMC7375498
OTO - NOTNLM
OT  - *adult oncology
OT  - *thoracic medicine
OT  - *thoracic surgery
COIS- Competing interests: None declared.
IR  - Winter H
FIR - Winter, Hauke
IR  - Eichhorn M
FIR - Eichhorn, Martin
IR  - Klotz L
FIR - Klotz, Laura
IR  - Hatz R
FIR - Hatz, Rudolf
IR  - Zimmermann J
FIR - Zimmermann, Julia
IR  - Kovacs J
FIR - Kovacs, Julia
IR  - Passlick B
FIR - Passlick, Bernward
IR  - Schmid S
FIR - Schmid, Severin
IR  - Hassan M
FIR - Hassan, Mohamed
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-041511 [pii]
AID - 10.1136/bmjopen-2020-041511 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e041511. doi: 10.1136/bmjopen-2020-041511.


PMID- 32690753
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Protocol for a nationwide prospective, observational cohort study of foreign-body
      airway obstruction in Japan: the MOCHI registry.
PG  - e039689
LID - 10.1136/bmjopen-2020-039689 [doi]
AB  - INTRODUCTION: Foreign body airway obstruction (FBAO) is a major public health
      issue worldwide. In 2017, there were more than 5000 fatal choking cases in the
      USA alone, and it was the fourth leading cause of preventable injury-related
      death in the home and community. In Japan, FBAO is the leading cause of
      accidental death and with almost 9000 fatalities annually. However, research on
      FBAO is limited, particularly on the impact of a foreign body (FB) removal
      manoeuvres by bystanders. The primary objective of this study is to determine the
      impact of bystander FB removal manoeuvres on 1 month neurological outcome. Our
      secondary objectives include (1) evaluating the efficacy of a variety of FB
      removal manoeuvres; (2) identifying risk factors for unsuccessful removal and (3)
      evaluating the impact of time intervals from incidents of FBAO to FB removal on
      neurological outcome. METHODS AND ANALYSIS: We will conduct a nationwide
      multi-centre prospective cohort study of patients with FBAO who present to
      approximately 100 emergency departments in both urban and rural areas in Japan.
      Research personnel at each participating site will collect variables including
      patient demographics, type of FB and prehospital variables, such as bystander FB 
      removal manoeuvres, medical interventions by prehospital personnel, advanced
      airway management and diagnostic findings. Our primary outcome is 1 month
      favourable neurological outcome defined as cerebral performance category 1 or 2. 
      Our secondary outcomes include success of FB removal manoeuvres and complications
      from the manoeuvres. We hypothesise that bystander FB removal manoeuvres improve 
      patient survival with a favourable neurological outcome. ETHICS AND
      DISSEMINATION: This study received research ethics approval from Nippon Medical
      School Hospital (B-2019-019). Research ethics approval will be obtained from all 
      participating sites before entering patients into the registry. The study was
      registered at the University Hospital Medical Information Network (UMIN) Clinical
      Trials Registry. TRIAL REGISTRATION NUMBER: UMIN 000039907.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Norii, Tatsuya
AU  - Norii T
AUID- ORCID: 0000-0001-7428-5625
AD  - Department of Emergency Medicine, University of New Mexico, Albuquerque, New
      Mexico, USA tanorii@salud.unm.edu.
AD  - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate
      School of Medicine, Suita, Osaka, Japan.
FAU - Igarashi, Yutaka
AU  - Igarashi Y
AD  - Department of Emergency and Critical Care Medicine, Nippon Medical School
      Hospital, Bunkyo-ku, Tokyo, Japan.
FAU - Sung-Ho, Kim
AU  - Sung-Ho K
AD  - Department of Critical Care Medicine, Osaka Habikino Medical Center, Habikino,
      Osaka, Japan.
FAU - Nagata, Shimpei
AU  - Nagata S
AD  - Department of Emergency Medicine, Osaka Police Hospital, Osaka, Japan.
FAU - Tagami, Takashi
AU  - Tagami T
AD  - Department of Emergency and Critical Care Medicine, Nippon Medical School Musashi
      Kosugi Hospital, Kawasaki, Kanagawa, Japan.
FAU - Yoshino, Yudai
AU  - Yoshino Y
AD  - Department of Emergency Medicine, Aidu Chuo Hospital, Aizuwakamatsu, Fukushima,
      Japan.
FAU - Hamaguchi, Takuro
AU  - Hamaguchi T
AD  - Department of Emergency and Critical Care Medicine, Nippon Medical School Musashi
      Kosugi Hospital, Kawasaki, Kanagawa, Japan.
FAU - Maejima, Riko
AU  - Maejima R
AD  - Department of Emergency Medicine, Japanese Red Cross Ashikaga Hospital, Ashikaga,
      Tochigi, Japan.
FAU - Nakao, Shunichiro
AU  - Nakao S
AD  - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate
      School of Medicine, Suita, Osaka, Japan.
FAU - Albright, Danielle
AU  - Albright D
AD  - Department of Emergency Medicine, University of New Mexico, Albuquerque, New
      Mexico, USA.
FAU - Yokobori, Shoji
AU  - Yokobori S
AD  - Department of Emergency and Critical Care Medicine, Nippon Medical School
      Hospital, Bunkyo-ku, Tokyo, Japan.
FAU - Yokota, Hiroyuki
AU  - Yokota H
AD  - Department of Emergency and Critical Care Medicine, Nippon Medical School
      Hospital, Bunkyo-ku, Tokyo, Japan.
FAU - Shimazu, Takeshi
AU  - Shimazu T
AD  - Department of Traumatology and Acute Critical Medicine, Osaka University Graduate
      School of Medicine, Suita, Osaka, Japan.
FAU - Crandall, Cameron
AU  - Crandall C
AD  - Department of Emergency Medicine, University of New Mexico, Albuquerque, New
      Mexico, USA.
LA  - eng
SI  - UMIN-CTR/UMIN000039907
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Airway Obstruction/epidemiology/etiology/therapy
MH  - *Cardiopulmonary Resuscitation
MH  - *Emergency Medical Services
MH  - *Foreign Bodies/epidemiology
MH  - Humans
MH  - Japan/epidemiology
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Registries
PMC - PMC7375623
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *epidemiology
OT  - *intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039689 [pii]
AID - 10.1136/bmjopen-2020-039689 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e039689. doi: 10.1136/bmjopen-2020-039689.


PMID- 32690751
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Risk factors for delirium among older adults in the emergency department: a
      systematic review protocol.
PG  - e039175
LID - 10.1136/bmjopen-2020-039175 [doi]
AB  - INTRODUCTION: Delirium is commonly missed in older adults presenting to the
      emergency department (ED). Although current recommendations for active screening 
      of delirium in the ED, this might not be feasible or practical. Identifying
      patients at high risk for prevalent and incident delirium in the ED will help to 
      improve the screening process and to build interventions. There is currently
      scattered synthesis of evidence on risk factors associated with delirium in the
      ED. To address this gap, we are conducting a systematic review to describe the
      risk factors (patient vulnerability factors and precipitating factors) for
      delirium in the ED. METHODS AND ANALYSIS: A literature search was performed from 
      inception to March 2020 in Ovid EBM Reviews, Ovid EMBASE, Ovid MEDLINE, Scopus
      and Web of Science. We will include original research studies that report a
      quantitative relationship between at least one risk factor and delirium in the ED
      setting. Two investigators will use eligibility criteria from this protocol to
      independently screen titles and abstracts, and select studies based on full-text 
      review of potentially eligible studies. After arriving at a final set of included
      studies, two investigators will extract data using a standardised data collection
      form. If appropriate, data regarding each risk factor will be pooled through a
      random-effect meta-analysis. The Grading of Recommendations Assessment,
      Development and Evaluation approach will be used to evaluate the overall quality 
      of evidence. ETHICS AND DISSEMINATION: To our knowledge, this will be the first
      systematic review evaluating risk factors for prevalent and incident delirium
      specifically related to the ED setting. Results of this study will aid in the
      identification of older adults at risk for delirium in the ED. We aim to publish 
      the results of this systematic review in a peer-reviewed journal with good
      visibility for the fields of emergency medicine and geriatrics.PROSPERO
      registration numberCDR42020175261.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oliveira J E Silva, Lucas
AU  - Oliveira J E Silva L
AUID- ORCID: 0000-0001-5388-9163
AD  - Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA
      lojesilva@gmail.com.
FAU - Berning, Michelle J
AU  - Berning MJ
AD  - Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.
AD  - Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Stanich, Jessica A
AU  - Stanich JA
AD  - Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Gerberi, Danielle J
AU  - Gerberi DJ
AUID- ORCID: 0000-0002-1522-3915
AD  - Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Han, Jin
AU  - Han J
AD  - Department of Emergency Medicine, Vanderbilt University, Nashville, Tennessee,
      USA.
AD  - Geriatric Research, Education, and Clinical Center, VA Tennessee Valley
      Healthcare System Nashville Campus, Nashville, Tennessee, USA.
FAU - Bellolio, Fernanda
AU  - Bellolio F
AD  - Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Delirium/diagnosis/epidemiology
MH  - Delivery of Health Care
MH  - *Emergency Service, Hospital
MH  - Humans
MH  - Mass Screening
MH  - Meta-Analysis as Topic
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7375496
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *delirium & cognitive disorders
OT  - *geriatric medicine
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039175 [pii]
AID - 10.1136/bmjopen-2020-039175 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e039175. doi: 10.1136/bmjopen-2020-039175.


PMID- 32690750
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - ADAPT study: adaptation of evidence-informed complex population health
      interventions for implementation and/or re-evaluation in new contexts: protocol
      for a Delphi consensus exercise to develop guidance.
PG  - e038965
LID - 10.1136/bmjopen-2020-038965 [doi]
AB  - INTRODUCTION: Complex population health interventions that are effective in one
      context may not be effective elsewhere, and may even be harmful. As such, an
      intervention may require adaptation to ensure it fits with a new context. To
      date, there is no overarching guidance to help researchers to adapt and evaluate 
      interventions in new contexts, and no criteria to support research funders or
      journals assess proposed or reported adaptations or evaluation. There is limited 
      assistance for policy-makers and practitioners to decide if evidence-informed
      interventions are appropriate to their context, or if adaptation and further
      evaluation is needed. This Delphi exercise will contribute to the development of 
      guidance for these communities to support the adaptation, implementation and/or
      re-evaluation of complex population health interventions in new contexts.
      METHODS: We will conduct a Delphi consensus exercise to gather expert opinion
      from researchers, research funders, journal editors and policy-makers. Expert
      opinion will be sought on: appropriate definitions and concepts, identifying key 
      methodological considerations and establishing adaptations and processes to be
      undertaken during adaptation of complex population health interventions in new
      contexts. ETHICS AND DISSEMINATION: Ethics approval for the Delphi exercise has
      been obtained from the University of Glasgow and and the RAND institutional
      research board. Dissemination of the results of this study will be through
      peer-reviewed publications, workshops at national and international conferences, 
      and a summary of the guidance developed for key organisations and stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Campbell, Mhairi
AU  - Campbell M
AUID- ORCID: 0000-0002-4416-7270
AD  - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow College of 
      Medical Veterinary and Life Sciences, Glasgow, UK Mhairi.Campbell@glasgow.ac.uk.
FAU - Moore, Graham
AU  - Moore G
AD  - The Centre for the Development and Evaluation of Complex Public Health
      Interventions, Cardiff University, Cardiff, South Glamorgan, UK.
FAU - Evans, Rhiannon E
AU  - Evans RE
AD  - The Centre for the Development and Evaluation of Complex Public Health
      Interventions, Cardiff University, Cardiff, South Glamorgan, UK.
FAU - Khodyakov, Dmitry
AU  - Khodyakov D
AD  - Pardee RAND Graduate School, RAND Corp, Santa Monica, California, USA.
FAU - Craig, Peter
AU  - Craig P
AD  - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow College of 
      Medical Veterinary and Life Sciences, Glasgow, UK.
CN  - ADAPT Study team
LA  - eng
GR  - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12 017-15/MRC_/Medical Research Council/United Kingdom
GR  - British Heart Foundation/International
GR  - MR/K023233/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R013357/1/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12017/13/MRC_/Medical Research Council/United Kingdom
GR  - Cancer Research UK/International
GR  - MC_UU_12 017-13 /MRC_/Medical Research Council/United Kingdom
GR  - SPHSU17/CSO_/Chief Scientist Office/United Kingdom
GR  - MC_UU_12017/15/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Consensus
MH  - Delphi Technique
MH  - *Exercise
MH  - Humans
MH  - *Population Health
PMC - PMC7375505
OTO - NOTNLM
OT  - *health policy
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
IR  - Littlecott H
FIR - Littlecott, Hannah
IR  - Segrott J
FIR - Segrott, Jeremy
IR  - Murphy S
FIR - Murphy, Simon
IR  - Copeland L
FIR - Copeland, Lauren
IR  - Moore L
FIR - Moore, Laurence
IR  - Rehfuess E
FIR - Rehfuess, Eva
IR  - Movsisyan A
FIR - Movsisyan, Ani
IR  - Arnold L
FIR - Arnold, Laura
IR  - Maria Pfadenhauer L
FIR - Maria Pfadenhauer, Lisa
IR  - Hoddinott P
FIR - Hoddinott, Pat
IR  - O'Cathain A
FIR - O'Cathain, Alicia
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038965 [pii]
AID - 10.1136/bmjopen-2020-038965 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e038965. doi: 10.1136/bmjopen-2020-038965.


PMID- 32690749
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Complex Large-Bore Radial percutaneous coronary intervention: rationale of the
      COLOR trial study protocol.
PG  - e038042
LID - 10.1136/bmjopen-2020-038042 [doi]
AB  - INTRODUCTION: The radial artery has become the standard access site for
      percutaneous coronary intervention (PCI) in stable coronary artery disease and
      acute coronary syndrome, because of less access site related bleeding
      complications. Patients with complex coronary lesions are under-represented in
      randomised trials comparing radial with femoral access with regard to safety and 
      efficacy. The femoral artery is currently the most applied access site in
      patients with complex coronary lesions, especially when large bore guiding
      catheters are required. With slender technology, transradial PCI may be
      increasingly applied in patients with complex coronary lesions when large bore
      guiding catheters are mandatory and might be a safer alternative as compared with
      the transfemoral approach. METHODS AND ANALYSIS: A total of 388 patients
      undergoing complex PCI will be randomised to radial 7 French access with Terumo
      Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator. The
      primary outcome is the incidence of the composite end point of clinically
      relevant access site related bleeding and/or vascular complications requiring
      intervention. Procedural success and major adverse cardiovascular events up to 1 
      month will also be compared between both groups. ETHICS AND DISSEMINATION:
      Ethical approval for the study was granted by the local Ethics Committee at each 
      recruiting center ('Medisch Ethische Toetsing Commissie Isala Zwolle', 'Commissie
      voor medische ethiek ZNA', 'Comite Medische Ethiek Ziekenhuis Oost-Limburg',
      'Comite d'ethique CHU-Charleroi-ISPPC', 'Commission cantonale d'ethique de la
      recherche CCER-Republique et Canton de Geneve', 'Ethik Kommission de Arztekammer 
      Nordrhein' and 'Riverside Research Ethics Committee'). The trial outcomes will be
      published in peer-reviewed journals of the concerned literature. TRIAL
      REGISTRATION NUMBER: NCT03846752.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Meijers, Thomas A
AU  - Meijers TA
AUID- ORCID: 0000-0002-4298-1607
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands.
FAU - Aminian, Adel
AU  - Aminian A
AD  - Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Wallonie,
      Belgium.
FAU - Teeuwen, Koen
AU  - Teeuwen K
AD  - Cardiology, Catharina Hospital, Eindhoven, Noord Brabant, The Netherlands.
FAU - van Wely, Marleen
AU  - van Wely M
AD  - Cardiology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
FAU - Schmitz, Thomas
AU  - Schmitz T
AD  - Cardiology, Elisabeth-Krankenhaus-Essen GmbH, Essen, Nordrhein-Westfalen,
      Germany.
FAU - Dirksen, Maurits T
AU  - Dirksen MT
AD  - Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, Noord-Holland, The Netherlands.
FAU - van der Schaaf, Rene J
AU  - van der Schaaf RJ
AD  - Cardiology, OLVG, Amsterdam, Noord-Holland, The Netherlands.
FAU - Iglesias, Juan F
AU  - Iglesias JF
AD  - Cardiology, Geneva University Hospitals, Geneve, Geneve, Switzerland.
FAU - Agostoni, Pierfrancesco
AU  - Agostoni P
AD  - Cardiology, ZNA, Antwerpen, Belgium.
FAU - Dens, Joseph
AU  - Dens J
AD  - Cardiology, Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium.
FAU - Knaapen, Paul
AU  - Knaapen P
AD  - Cardiology, Amsterdam UMC - Locatie VUMC, Amsterdam, Noord-Holland, The
      Netherlands.
FAU - Rathore, Sudhir
AU  - Rathore S
AD  - Cardiology, Frimley Health NHS Foundation Trust, Frimley, Surrey, UK.
FAU - Ottervanger, Jan Paul
AU  - Ottervanger JP
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands.
FAU - Dambrink, Jan-Henk E
AU  - Dambrink JE
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands.
FAU - Roolvink, Vincent
AU  - Roolvink V
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands.
FAU - Gosselink, A T Marcel
AU  - Gosselink ATM
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands.
FAU - Hermanides, Renicus S
AU  - Hermanides RS
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands.
FAU - van Royen, Niels
AU  - van Royen N
AD  - Cardiology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
FAU - van Leeuwen, Maarten A H
AU  - van Leeuwen MAH
AUID- ORCID: 0000-0002-4264-4280
AD  - Cardiology, Isala Hospitals, Zwolle, The Netherlands m.a.h.van.leeuwen@isala.nl.
LA  - eng
SI  - ClinicalTrials.gov/NCT03846752
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Coronary Angiography
MH  - Femoral Artery/surgery
MH  - Humans
MH  - Japan
MH  - *Percutaneous Coronary Intervention
MH  - *Radial Artery/surgery
MH  - Treatment Outcome
PMC - PMC7375502
OTO - NOTNLM
OT  - *cardiology
OT  - *coronary heart disease
OT  - *coronary intervention
COIS- Competing interests: MAHvL, AA and and JFI are consultants for Terumo. JFI and TS
      have received honoraria/speakers fee for Terumo, the other authors have no
      conflicts of interest to declare.
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038042 [pii]
AID - 10.1136/bmjopen-2020-038042 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e038042. doi: 10.1136/bmjopen-2020-038042.


PMID- 32690748
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Validation of the diagnostic performance of 'HeartMedi V.1.0', a novel CT-derived
      fractional flow reserve measurement, for patients with coronary artery disease: a
      study protocol.
PG  - e037780
LID - 10.1136/bmjopen-2020-037780 [doi]
AB  - INTRODUCTION: Coronary CT angiography (CCTA) is widely used for non-invasive
      coronary artery evaluation, but it is limited in identifying the nature of
      functional characteristics that cause ischaemia. Recent computational fluid
      dynamic (CFD) techniques applied to CCTA images permit non-invasive computation
      of fractional flow reserve (FFR), a measure of lesion-specific ischaemia.
      However, this technology has limitations, such as long computational time and the
      need for expensive equipment, which hinder widespread use. METHODS AND ANALYSIS: 
      This study is a prospective, multicentre, comparative and confirmatory trial
      designed to evaluate the diagnostic performance of HeartMedi V.1.0, a novel
      CT-derived FFR measurement for the detection of haemodynamically significant
      coronary artery stenoses identified by CCTA, based on invasive FFR as a reference
      standard. The invasive FFR values </=0.80 will be considered haemodynamically
      significant. The study will enrol 184 patients who underwent CCTA, invasive
      coronary angiography and invasive FFR. Computational FFR (c-FFR) will be analysed
      by CFD techniques using a lumped parameter model based on vessel length method.
      Blinded core laboratory interpretation will be performed for CCTA, invasive
      coronary angiography, invasive FFR and c-FFR. The primary objective of the study 
      is to compare the area under the receiver-operator characteristic curve between
      c-FFR and CCTA to non-invasively detect the presence of haemodynamically
      significant coronary stenosis. The secondary endpoints include diagnostic
      accuracy, sensitivity, specificity, positive predictive value, negative
      predictive value and correlation of c-FFR with invasive FFR. ETHICS AND
      DISSEMINATION: The study has ethic approval from the ethics committee of Seoul
      National University Bundang Hospital (E-1709/420-001) and informed consent will
      be obtained for all enrolled patients. The result will be published in a
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: KCT0002725; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kim, Soo-Hyun
AU  - Kim SH
AD  - Division of Cardiology, Department of Internal Medicine, Seoul National
      University Bundang Hospital, Seongnam-si, Gyeonggi-do, The Republic of Korea.
FAU - Kang, Si-Hyuck
AU  - Kang SH
AD  - Division of Cardiology, Department of Internal Medicine, Seoul National
      University Bundang Hospital, Seongnam-si, Gyeonggi-do, The Republic of Korea.
FAU - Chung, Woo-Young
AU  - Chung WY
AD  - Department of Internal Medicine, Seoul Metropolitan Boramae Hospital, Dongjak-gu,
      Seoul, The Republic of Korea.
FAU - Yoon, Chang-Hwan
AU  - Yoon CH
AD  - Division of Cardiology, Department of Internal Medicine, Seoul National
      University Bundang Hospital, Seongnam-si, Gyeonggi-do, The Republic of Korea.
FAU - Park, Sang-Don
AU  - Park SD
AD  - Division of Cardiology, Department of Internal Medicine, Inha University
      Hospital, Incheon, The Republic of Korea.
FAU - Nam, Chang-Wook
AU  - Nam CW
AD  - Department of Medicine, Keimyung University Dongsan Medical Center, Daegu, The
      Republic of Korea.
FAU - Kwon, Ki-Hwan
AU  - Kwon KH
AD  - Division of Cardiology, Department of Internal Medicine, Ewha Womans University
      School of Medicine, Seoul, The Republic of Korea.
FAU - Doh, Joon-Hyung
AU  - Doh JH
AD  - Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang-si, 
      Gyeonggi-do, The Republic of Korea.
FAU - Byun, Young-Sup
AU  - Byun YS
AD  - Division of Cardiology, Department of Internal Medicine, Inje University Sanggye 
      Paik Hospital, Seoul, The Republic of Korea.
FAU - Bae, Jang-Whan
AU  - Bae JW
AD  - Department of Internal Medicine, College of Medicine, Chungbuk National
      University, Cheongju, The Republic of Korea.
FAU - Youn, Tae-Jin
AU  - Youn TJ
AUID- ORCID: 0000-0001-9957-4204
AD  - Division of Cardiology, Department of Internal Medicine, Seoul National
      University Bundang Hospital, Seongnam-si, Gyeonggi-do, The Republic of Korea
      ytjmd@snubh.org.
FAU - Chae, In-Ho
AU  - Chae IH
AUID- ORCID: 0000-0003-1644-2105
AD  - Division of Cardiology, Department of Internal Medicine, Seoul National
      University Bundang Hospital, Seongnam-si, Gyeonggi-do, The Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Coronary Angiography
MH  - *Coronary Artery Disease/diagnostic imaging
MH  - *Coronary Stenosis/diagnostic imaging
MH  - *Fractional Flow Reserve, Myocardial
MH  - Humans
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Seoul
MH  - Tomography, X-Ray Computed
PMC - PMC7375628
OTO - NOTNLM
OT  - *cardiovascular imaging
OT  - *computed tomography
OT  - *coronary heart disease
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037780 [pii]
AID - 10.1136/bmjopen-2020-037780 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e037780. doi: 10.1136/bmjopen-2020-037780.


PMID- 32690740
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Mapping of modifiable barriers and facilitators with interdisciplinary chronic
      obstructive pulmonary disease (COPD) guidelines concordance within hospitals to
      the Theoretical Domains Framework: a mixed methods systematic review protocol.
PG  - e036060
LID - 10.1136/bmjopen-2019-036060 [doi]
AB  - INTRODUCTION: Multifarious chronic obstructive pulmonary disease (COPD)
      guidelines have been published by local, national and global respiratory
      societies. These guidelines subsume holistic evidence based on recommendations to
      diagnose, treat, prevent and manage acute exacerbation with COPD. Despite the
      existing comprehensive recommendations, readmission rates and hospitalisations
      have increased in the last decade. Evidence to date has reported suboptimal
      clinical guidelines concordance. Acute exacerbations of COPD (AECOPD) is a common
      hospital presentation due to varied causes such as infective exacerbations,
      worsening disease condition, medication non-adherence, lack of education and
      incomprehensive discharge planning. AECOPD directly and indirectly causes
      economic burden, disrupts health-related quality of life (HRQol), hasten lung
      function decline and increases overall morbidity and mortality. COPD being a
      multimodal chronic disease, consistent interdisciplinary interventions from the
      time of admission to discharge may reduce readmissions and enhance HRQol among
      these patients and their families. METHODS AND ANALYSIS: This protocol adheres to
      the Joanna Briggs Institute methodology for mixed methods systematic reviews and 
      the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension 
      for Scoping Reviews reporting guidelines. Qualitative, quantitative and mixed
      methods studies will append this study to explore determinants of COPD guidelines
      concordance. Comprehensive three-tier search strategies will be used to search
      nine databases (COCHRANE, EBSCO HOST, MEDLINE, SCIENCE DIRECT, JBI, SCOPUS, WEB
      OF SCIENCE, WILEY and DARE) in May 2020. Two independent reviewers will screen
      abstracts and full-text articles in consonance with inclusion criteria. The
      convergent integrative method narrative review will contribute a deeper
      understanding of any discrepancies found in the existing evidence. Quality of the
      studies will be reported and Theoretical Domains Framework (TDF) will be used as 
      a priori to synthesis data. Identified barriers, facilitators and corresponding
      clinical behavioural change solutions will be categorised using TDF indicators to
      provide future research and implementation recommendations. ETHICS AND
      DISSEMINATION: Ethical approval is not required and results dissemination will
      occur through peer-reviewed publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Issac, Hancy
AU  - Issac H
AUID- ORCID: 0000-0003-3778-1157
AD  - School of Nursing and Midwifery, University of Southern Queensland, Toowoomba,
      Queensland, Australia hancy.issac@usq.edu.au.
FAU - Moloney, Clint
AU  - Moloney C
AD  - School of Nursing and Midwifery, University of Southern Queensland, Toowoomba,
      Queensland, Australia.
FAU - Taylor, Melissa
AU  - Taylor M
AD  - School of Nursing and Midwifery, University of Southern Queensland, Toowoomba,
      Queensland, Australia.
FAU - Lea, Jackie
AU  - Lea J
AD  - School of Nursing and Midwifery, University of Southern Queensland, Toowoomba,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Hospitals
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive/therapy
MH  - *Quality of Life
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7375635
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *emphysema
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036060 [pii]
AID - 10.1136/bmjopen-2019-036060 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e036060. doi: 10.1136/bmjopen-2019-036060.


PMID- 32690739
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Study protocol for the POPART study-Prophylactic Oropharyngeal surfactant for
      Preterm infants: A Randomised Trial.
PG  - e035994
LID - 10.1136/bmjopen-2019-035994 [doi]
AB  - INTRODUCTION: Many preterm infants develop respiratory distress syndrome (RDS), a
      condition characterised by a relative lack of surfactant. Endotracheal surfactant
      therapy revolutionised the care of preterm infants in the 1990s. However,
      supporting newborns with RDS with continuous positive airway pressure (CPAP) and 
      reserving endotracheal surfactant for those who develop respiratory failure
      despite CPAP yield better results than intubating all infants for surfactant.
      Half of preterm infants born before 29 weeks gestation initially managed with
      CPAP are intubated for surfactant. Intubation is difficult to learn and
      associated with adverse effects. Surfactant administration into the oropharynx
      has been reported in preterm animals and humans and may be effective. We wished
      to determine whether giving oropharyngeal surfactant at birth reduces the rate of
      endotracheal intubation for respiratory failure in preterm infants within 120
      hours of birth. METHODS AND ANALYSIS: Prophylactic Oropharyngeal surfactant for
      Preterm infants: A Randomised Trial (POPART, Eudract No. 2016-004198-41) is an
      investigator-led, unblinded, multicentre, randomised, parallel group, controlled 
      trial. Infants are eligible if born at a participating centre before 29 weeks
      gestational age (GA) and there is a plan to offer intensive care. Infants are
      excluded if they have major congenital anomalies. Infants are randomised at birth
      to treatment with oropharyngeal surfactant (120 mg vial <26 weeks GA stratum; 240
      mg vial 26-28(+6) weeks GA stratum) in addition to CPAP or CPAP alone. The
      primary outcome is intubation within 120 hours of birth, for bradycardia and/or
      apnoea despite respiratory support in the delivery room or respiratory failure in
      the intensive care unit. Secondary outcomes include incidence of mechanical
      ventilation, endotracheal surfactant use, chronic lung disease and death before
      hospital discharge. ETHICS AND DISSEMINATION: Approval for the study has been
      granted by the Research Ethics Committees at the National Maternity Hospital,
      Dublin, Ireland (EC31.2016) and at each participating site. The trial is being
      conducted at nine centres in six European countries. The study results will be
      submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: 
      2016-004198-41; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Murphy, Madeleine Claire
AU  - Murphy MC
AUID- ORCID: 0000-0002-9960-4378
AD  - Department of Neonatology, National Maternity Hospital, Dublin, Ireland.
AD  - National Children's Research Centre, Dublin, Ireland.
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
FAU - Galligan, Marie
AU  - Galligan M
AD  - UCD Clinical Research Centre, School of Medicine, University College Dublin,
      Dublin, Ireland.
FAU - Molloy, Brenda
AU  - Molloy B
AD  - UCD Clinical Research Centre, School of Medicine, University College Dublin,
      Dublin, Ireland.
FAU - Hussain, Rabia
AU  - Hussain R
AD  - UCD Clinical Research Centre, School of Medicine, University College Dublin,
      Dublin, Ireland.
FAU - Doran, Peter
AU  - Doran P
AD  - UCD Clinical Research Centre, School of Medicine, University College Dublin,
      Dublin, Ireland.
FAU - O'Donnell, Colm
AU  - O'Donnell C
AD  - Department of Neonatology, National Maternity Hospital, Dublin, Ireland
      codonnell@nmh.ie.
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Surface-Active Agents)
SB  - IM
EIN - BMJ Open. 2020 Sep 9;10(9):e035994corr1. PMID: 32912959
MH  - Continuous Positive Airway Pressure
MH  - Europe
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - Ireland
MH  - Oropharynx
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - *Respiratory Distress Syndrome, Newborn/therapy
MH  - Surface-Active Agents
PMC - PMC7375508
OTO - NOTNLM
OT  - *neonatology
OT  - *paediatrics
OT  - *perinatology
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035994 [pii]
AID - 10.1136/bmjopen-2019-035994 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e035994. doi: 10.1136/bmjopen-2019-035994.


PMID- 32690737
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Establishing reference costs for the health benefit packages under universal
      health coverage in India: cost of health services in India (CHSI) protocol.
PG  - e035170
LID - 10.1136/bmjopen-2019-035170 [doi]
AB  - INTRODUCTION: To achieve universal health coverage, the Government of India has
      introduced Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana (AB - PMJAY), a
      large tax-funded national health insurance scheme for the provision of secondary 
      and tertiary care services in public and private hospitals. AB - PMJAY reimburses
      care for 1573 health benefit packages (HBPs). HBPs are designed to cover the
      treatment of diseases/conditions with high incidence/prevalence or which
      contribute to high out-of-pocket expenditure. However, there is a dearth of
      reference cost data against which provider payment rates can be assessed. METHODS
      AND ANALYSIS: The CHSI (Cost of Health Services in India) study will collect cost
      data from 13 Indian states covering 52 public and 40 private hospitals, using a
      mixed economic costing methodology (top-down and bottom-up), to generate unit
      costs for the HBPs. States will be sampled to capture economic status,
      development indicators and health service utilisation heterogeneity. The public
      sector hospitals will be chosen at secondary and tertiary care level. One
      tertiary facility will be selected from each state. At secondary level, three
      districts per state will be selected randomly from the district composite
      development score ranking. The private sector hospital sample will be stratified 
      by nature of ownership (for-profit and not-for-profit), type of city (tier 1, 2
      or 3) and size of the hospital (number of beds). Average costs for each HBP will 
      be calculated across the different facility types. Multiple scenarios will be
      used to suggest rates which could be negotiated with the providers. Overall, the 
      study will provide economic cost data for price setting, strategic purchasing,
      health technology assessment and a national cost database of India. ETHICS AND
      DISSEMINATION: The approval has been obtained from the Institutional Ethics
      Committee and Institutional Collaborative Committee of the Post Graduate
      Institute of Medical Education and Research, Chandigarh, India. The results shall
      be disseminated in conferences and peer-reviewed articles.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Prinja, Shankar
AU  - Prinja S
AUID- ORCID: 0000-0001-7396-1273
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, Chandigarh, India
      shankarprinja@gmail.com.
FAU - Singh, Maninder Pal
AU  - Singh MP
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
FAU - Guinness, Lorna
AU  - Guinness L
AD  - Independent Researcher, Imperial College, London, UK.
AD  - Global Health and Development, London School of Hygiene & Tropical Medicine,
      London, London, UK.
FAU - Rajsekar, Kavitha
AU  - Rajsekar K
AD  - Department of Health Research, Ministry of Health & Family welfare, New Delhi,
      India.
FAU - Bhargava, Balram
AU  - Bhargava B
AD  - Department of Health Research, Ministry of Health & Family welfare, New Delhi,
      India.
AD  - Indian Council of Medical Research, New Delhi, Delhi, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Health Care Reform
MH  - Hospitals, Private/economics
MH  - Hospitals, Public/economics
MH  - Humans
MH  - India
MH  - Universal Health Insurance/*economics
PMC - PMC7375634
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035170 [pii]
AID - 10.1136/bmjopen-2019-035170 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e035170. doi: 10.1136/bmjopen-2019-035170.


PMID- 32690736
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - National suicide management guidelines with family as an interv'ention and
      suicide mortality rates: a systematic review protocol.
PG  - e034694
LID - 10.1136/bmjopen-2019-034694 [doi]
AB  - INTRODUCTION: Suicidal behaviour remains a major public health challenge
      worldwide. Several countries have developed national suicide guidelines aimed at 
      raising awareness of and preventing deaths by suicide. One of the interventions
      often mentioned in these national guidelines is the involvement of family members
      as a protective factor in suicide prevention. However, the level or type of
      family involvement required to reduce suicidal behaviour is not well understood. 
      Thus, in this systematic review, we seek to determine the effectiveness of
      family-based interventions as a suicide prevention tool, by comparing suicide
      mortality rates between countries whose national suicide prevention guidelines
      include family-based interventions and those whose do not. METHODS AND ANALYSIS: 
      MEDLINE, EMBASE, PsycINFO, Web of Science and WHO MiNDbank databases as well as
      grey literature such as National Guideline Clearinghouse will be searched.
      National guidelines for suicide prevention published within the last 20 years
      (between 1999 and 2019) will be included. Results will be analysed using thematic
      and qualitative analyses. ETHICS AND DISSEMINATION: The findings of the study
      will help improve the efficacy of national suicide prevention strategies.
      Findings will be disseminated using easily accessible summary reports and
      resources to primary end users. PROSPERO REGISTRATION NUMBER: This protocol has
      been registered on PROSPERO (CRD42019130195).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Panesar, Balpreet
AU  - Panesar B
AUID- ORCID: 0000-0002-5492-3615
AD  - Health Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Soni, Divya
AU  - Soni D
AD  - McMaster University Michael G DeGroote School of Medicine, Hamilton, Ontario,
      Canada.
FAU - Khan, Mohammed I
AU  - Khan MI
AUID- ORCID: 0000-0003-4116-0097
AD  - Life Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Bdair, Faris
AU  - Bdair F
AD  - Blue Valley Southwest High School, Overland Park, Kansas, USA.
FAU - Holek, Matthew
AU  - Holek M
AD  - Health Sciences, McMaster University, Hamilton, Ontario, Canada.
FAU - Tahir, Talha
AU  - Tahir T
AD  - McMaster University Michael G DeGroote School of Medicine, Hamilton, Ontario,
      Canada.
FAU - Woo, Julia
AU  - Woo J
AD  - University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
FAU - Khumalo, Nonhlanhla
AU  - Khumalo N
AD  - Department of Medicine, Groote Schuur Hospital and the University of Cape Town,
      Observatory, Western Cape, South Africa.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Clinical Epidemiology & Biostatistics; Health Research Methods Evidence and
      Impact, Centre for Evaluation of Medicines; Programs for Assessment of Technology
      in Health (PATH) Research Institute, McMaster University, Hamilton, Ontario,
      Canada.
FAU - Samaan, Zainab
AU  - Samaan Z
AD  - Psychiatry and Behavioral Neurosciences; Health Research Methods, Evidence and
      Impact, McMaster University, Hamilton, Ontario, Canada samaanz@mcmaster.ca.
LA  - eng
GR  - 156306/CIHR/Canada
GR  - PJT-153429 /CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Family
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Research Design
MH  - Suicide/*prevention & control
MH  - *Systematic Reviews as Topic
PMC - PMC7375499
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *psychiatry
OT  - *suicide & self-harm
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034694 [pii]
AID - 10.1136/bmjopen-2019-034694 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e034694. doi: 10.1136/bmjopen-2019-034694.


PMID- 32690735
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Assessing the impact on intestinal microbiome and clinical outcomes of
      antibiotherapy optimisation strategies in haematopoietic stem cell transplant
      recipients: study protocol for the prospective multicentre OptimBioma study.
PG  - e034570
LID - 10.1136/bmjopen-2019-034570 [doi]
AB  - INTRODUCTION: Haematopoietic stem cell transplantation (HSCT) is a life-saving
      treatment for a number of haematological diseases. Graft versus host disease
      (GVHD) is its main complication and hampers survival. There is strong evidence
      that intestinal microbiota diversity of the recipient may increase the risk of
      GVHD worsening survival. Antibiotic regimens used during the early phase of the
      transplant may influence clinical outcomes by reducing intestinal microbiota
      diversity. Present guidelines of European Conference on Infections in Leukaemia
      exhort to optimising antibiotic use in haematological patients including HSCT
      recipients. The present study aims to investigate if, in HSCT recipients, the
      optimisation of antibacterial use may preserve intestinal microbiota composition 
      reducing the incidence and severity of acute GVHD and improving relevant clinical
      outcomes. METHODS AND ANALYSIS: This is a prospective longitudinal observational 
      study of two cohorts of HSCT recipients: (1) the intervention cohort includes
      patients treated in centres in which a predefined strategy of antibiotherapy
      optimisation is implemented, with the objective of optimising and reducing
      antibiotic administration according to clinical criteria and (2) the control
      cohort includes patients treated in centres in which a classic permissive
      strategy of antibiotic prophylaxis and treatment is used. Adult patient receiving
      a first HSCT as a treatment for any haematological condition are included.
      Clinical variables are prospectively recorded and up to five faecal samples are
      collected for microbiota characterisation at prestablished peritransplant time
      points. Patients are followed since the preconditioning phase throughout 1-year
      post-transplant and four follow-up visits are scheduled. Faecal microbiota
      composition and diversity will be compared between both cohorts along with acute 
      GVHD incidence and severity, severe infections rate, mortality and overall and
      disease-free survival. ETHICS AND DISSEMINATION: The study was approved between
      2017 and 2018 by the Ethical Committees of participant centres. Study results
      will be disseminated through peer-reviewed journals and national and
      international scientific conferences. TRIAL REGISTRATION NUMBER: NCT03727113.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jimenez-Jorge, Silvia
AU  - Jimenez-Jorge S
AD  - Clinical Trial Unit, University Hospital Virgen del Rocio/University of
      Seville/CSIC/Institute of Biomedicine of Seville, Seville, Spain.
FAU - Labrador-Herrera, Gema
AU  - Labrador-Herrera G
AD  - Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine,
      University Hospital Virgen del Rocio/University of Seville/CSIC/Institute of
      Biomedicine of Seville, Seville, Spain.
FAU - Rosso-Fernandez, Clara M
AU  - Rosso-Fernandez CM
AD  - Clinical Trial Unit, University Hospital Virgen del Rocio/University of
      Seville/CSIC/Institute of Biomedicine of Seville, Seville, Spain.
AD  - Clinical Pharmacology Department, University Hospital Virgen del Rocio, Seville, 
      Spain.
FAU - Rodriguez-Torres, Nancy
AU  - Rodriguez-Torres N
AD  - Department of Hematology, University Hospital Virgen del Rocio/University of
      Seville/CSIC/Institute of Biomedicine of Seville, Seville, Spain.
FAU - Pachon-Ibanez, Maria Eugenia
AU  - Pachon-Ibanez ME
AD  - Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine,
      University Hospital Virgen del Rocio/University of Seville/CSIC/Institute of
      Biomedicine of Seville, Seville, Spain.
AD  - Department of Medicine, School of Medicine, University of Seville, Seville,
      Spain.
FAU - Smani, Younes
AU  - Smani Y
AD  - Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine,
      University Hospital Virgen del Rocio/University of Seville/CSIC/Institute of
      Biomedicine of Seville, Seville, Spain.
FAU - Marquez-Malaver, Francisco Jose
AU  - Marquez-Malaver FJ
AD  - Department of Hematology, University Hospital Virgen del Rocio/University of
      Seville/CSIC/Institute of Biomedicine of Seville, Seville, Spain.
FAU - Limon Ramos, Carmen
AU  - Limon Ramos C
AD  - Department of Hematology, University Hospital Virgen del Rocio/University of
      Seville/CSIC/Institute of Biomedicine of Seville, Seville, Spain.
FAU - Solano, Carlos
AU  - Solano C
AD  - Department of Hematology, Hospital Clinico Universitario, Institute for Research 
      INCLIVA, Valencia, Spain.
AD  - Department of Medicine, School of Medicine, University of Valencia, Valencia,
      Spain.
FAU - Vazquez-Lopez, Lourdes
AU  - Vazquez-Lopez L
AD  - Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
FAU - Kwon, Mi
AU  - Kwon M
AD  - Department of Hematology, Hospital General Universitario Gregorio Maranon,
      Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain.
FAU - Mora Barrios, Joan Manuel
AU  - Mora Barrios JM
AD  - Department of Hematology, University Hospital Marques de Valdecilla, Santander,
      Spain.
FAU - Aguilar-Guisado, Manuela
AU  - Aguilar-Guisado M
AD  - Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine,
      University Hospital Virgen del Rocio/University of Seville/CSIC/Institute of
      Biomedicine of Seville, Seville, Spain.
FAU - Espigado, Ildefonso
AU  - Espigado I
AUID- ORCID: 0000-0001-5945-0186
AD  - Department of Hematology, University Hospital Virgen del Rocio/University of
      Seville/CSIC/Institute of Biomedicine of Seville, Seville, Spain
      ildefonso.espigado.sspa@juntadeandalucia.es.
CN  - GETH (Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular)
LA  - eng
SI  - ClinicalTrials.gov/NCT03727113
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Antibiotic Prophylaxis
MH  - *Antimicrobial Stewardship
MH  - Case-Control Studies
MH  - Feces/microbiology
MH  - *Gastrointestinal Microbiome
MH  - Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Longitudinal Studies
MH  - Multicenter Studies as Topic
MH  - *Observational Studies as Topic
MH  - Prospective Studies
MH  - Research Design
MH  - *Transplant Recipients
PMC - PMC7375627
OTO - NOTNLM
OT  - *antibiotics
OT  - *graft versus host disease
OT  - *hematopoietic stem cell transplantation
OT  - *infections
OT  - *microbiome
OT  - *microbiota
COIS- Competing interests: None declared.
IR  - Martinez AP
FIR - Martinez, Ariadna Perez
IR  - F PM
FIR - F, Pena-Munoz
IR  - Almorox RB
FIR - Almorox, Rebeca Bailen
IR  - Yanez L
FIR - Yanez, Lucrecia
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034570 [pii]
AID - 10.1136/bmjopen-2019-034570 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e034570. doi: 10.1136/bmjopen-2019-034570.


PMID- 32690732
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Evaluation of the effectiveness of a comprehensive care plan to reduce hospital
      acquired complications in an Australian hospital: protocol for a mixed-method
      preimplementation and postimplementation study.
PG  - e034121
LID - 10.1136/bmjopen-2019-034121 [doi]
AB  - INTRODUCTION: A new healthcare standard (Standard 5: Comprehensive Care) has been
      introduced by the Australian Commission on Safety and Quality in Healthcare.
      Standard 5 advocates for organisational leadership to develop and maintain
      systems and processes to deliver patient-centred comprehensive care plans that
      include appropriate screening to identify and mitigate risks associated with
      hospitalisation. The aim of this study is to evaluate the effectiveness and cost 
      effectiveness of a comprehensive care and risk evaluation (Comprehensive
      Assessment and Risk Evaluation (CARE)) plan to reduce hospital acquired
      complications (HACs) in an Australian hospital network. METHODS AND ANALYSIS:
      This study will comprise a mixed-method pre and post implementation concurrent
      triangulation evaluation design. The primary clinical outcome will assess the
      reduction of routinely reported HACs (pressure care and falls), selected based on
      the likely reliability of routinely collected data prior to implementation.
      Secondary clinical outcomes will include length of stay and activity-based
      costing data for each episode, in-hospital mortality, expected and unplanned
      readmissions within 28 days, compliance with CARE plan completion and referrals
      for at risk patients, staff satisfaction, patient satisfaction and barriers and
      enablers to implementation. We expect that the incidence of other HACs
      (malnutrition, delirium, violence and aggression, and suicide and self-harm) may 
      increase as routine methods for assessing risk were not in place prior to
      implementation of the CARE plan. We will therefore collect data on incidence of
      these HACs as tertiary outcomes. Our primary cost-effectiveness outcome will be
      calculation of an incremental cost-effectiveness ratio. ETHICS AND DISSEMINATION:
      Ethics approval has been received from Northern Health Low Risk Ethics Committee.
      The results of this study will be published in peer-reviewed journals and
      presented at conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jessup, Rebecca Leigh
AU  - Jessup RL
AUID- ORCID: 0000-0003-2211-5231
AD  - Allied Health, Northern Health, Epping, Victoria, Australia
      rebecca.jessup@nh.org.au.
AD  - Academic & Research Collaborative in Health (Northern ARCH), School of Allied
      Health, Human Services and Sport, La Trobe University, Melbourne, Victoria,
      Australia, La Trobe University, Melbourne, Victoria, Australia.
FAU - Tacey, Mark
AU  - Tacey M
AD  - Research, Northern Health, Epping, Victoria, Australia.
AD  - Department of Medicine and Radiology, The University of Melbourne-Parkville
      Campus, Parkville, Victoria, Australia.
FAU - Glynn, Maree
AU  - Glynn M
AD  - Clinical Practice Improvement, Northern Health, Epping, Victoria, Australia.
FAU - Kirk, Michael
AU  - Kirk M
AD  - Medical Services, Northern Health, Epping, Victoria, Australia.
FAU - McKeown, Liz
AU  - McKeown L
AD  - Clinical Practice Improvement, Northern Health, Epping, Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Accidental Falls/prevention & control
MH  - Aggression
MH  - Attitude of Health Personnel
MH  - Australia
MH  - Delirium/prevention & control
MH  - Hospital Mortality
MH  - *Hospitalization
MH  - Humans
MH  - Length of Stay
MH  - Malnutrition/prevention & control
MH  - *Patient Care Planning
MH  - Patient Readmission
MH  - Patient Satisfaction
MH  - Patient-Centered Care
MH  - Pressure Ulcer/prevention & control
MH  - Quality of Health Care
MH  - Referral and Consultation
MH  - *Research Design
MH  - Self-Injurious Behavior/prevention & control
MH  - Suicide/prevention & control
MH  - Violence/prevention & control
PMC - PMC7375497
OTO - NOTNLM
OT  - *care standards
OT  - *cost-effectiveness
OT  - *health service evaluation
OT  - *hospital acquired complications
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034121 [pii]
AID - 10.1136/bmjopen-2019-034121 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e034121. doi: 10.1136/bmjopen-2019-034121.


PMID- 32690731
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and
      observational study to assess incidence and natural history of fetal/neonatal
      alloimmune thrombocytopenia and identifying pregnancies at risk.
PG  - e034071
LID - 10.1136/bmjopen-2019-034071 [doi]
AB  - INTRODUCTION: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) may lead to 
      severe fetal or neonatal bleeding and/or perinatal death. Maternal
      alloantibodies, targeted against fetal human platelet antigens (HPAs), can result
      thrombocytopenia and bleeding complications. In pregnancies with known
      immunisation, fetal bleeding can be prevented by weekly maternal intravenous
      immunoglobulin infusions. Without population-based screening, immunisation is
      only detected after birth of an affected infant. Affected cases that might have
      been prevented, when timely identified through population-based screening.
      Implementation is hampered by the lack of knowledge on incidence, natural history
      and identification of pregnancies at high risk of bleeding. We designed a study
      aimed to obtain this missing knowledge. METHODS AND ANALYSIS: The HIP
      (HPA-screening in pregnancy) study is a nationwide, prospective and observational
      cohort study aimed to assess incidence and natural history of FNAIT as well as
      identifying pregnancies at high risk for developing bleeding complications. For
      logistic reasons, we invite rhesus D-negative or rhesus c-negative pregnant
      women, who take part in the Dutch population-based prenatal screening programme
      for erythrocyte immunisation, to participate in our study. Serological HPA-1a
      typing is performed and a luminex-based multiplex assay will be performed for the
      detection of anti-HPA-1a antibodies. Results will not be communicated to patients
      or caregivers. Clinical data of HPA-1a negative women and an HPA-1a positive
      control group will be collected after birth. Samples of HPA-1a immunised
      pregnancies with and without signs of bleeding will be compared with identify
      parameters for identification of pregnancies at high risk for bleeding
      complications. ETHICS AND DISSEMINATION: Ethical approval for this study has been
      obtained from the Medical Ethical Committee Leiden-The Hague-Delft (P16.002).
      Study enrolment began in March 2017. All pregnant women have to give informed
      consent for testing according to the protocol. Results of the study will be
      disseminated through congresses and publication in relevant peer-reviewed
      journals. TRIAL REGISTRATION NUMBER: NCT04067375.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Winkelhorst, Dian
AU  - Winkelhorst D
AUID- ORCID: 0000-0002-6538-5752
AD  - Obstetrics, Leiden University Medical Center, Leiden, Zuid-Holland, The
      Netherlands.
AD  - Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands.
FAU - de Vos, Thijs W
AU  - de Vos TW
AUID- ORCID: 0000-0002-3653-3234
AD  - Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands.
AD  - Pediatrics, Leiden University Medical Center, Leiden, Zuid-Holland, The
      Netherlands.
FAU - Kamphuis, Marije M
AU  - Kamphuis MM
AD  - Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord-Holland,
      The Netherlands.
FAU - Porcelijn, Leendert
AU  - Porcelijn L
AD  - Immunohaematology Diagnostics, Sanquin Blood Supply Foundation, Amsterdam,
      Noord-Holland, The Netherlands.
FAU - Lopriore, Enrico
AU  - Lopriore E
AD  - Pediatrics, Leiden University Medical Center, Leiden, Zuid-Holland, The
      Netherlands.
FAU - Oepkes, Dick
AU  - Oepkes D
AD  - Obstetrics, Leiden University Medical Center, Leiden, Zuid-Holland, The
      Netherlands.
FAU - van der Schoot, C Ellen
AU  - van der Schoot CE
AD  - Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands 
      e.vanderschoot@sanquin.nl.
AD  - Landsteiner Laboratory, Academic Medical Center Amsterdam and Department of
      Experimental Immunohematology, University of Amsterdam and Sanquin, Amsterdam,
      The Netherlands.
FAU - de Haas, Masja
AU  - de Haas M
AUID- ORCID: 0000-0002-7044-0525
AD  - Department of Immunohaematology Diagnostics, Sanquin, Amsterdam, The Netherlands.
AD  - Immunohaematology and Blood Transfusion, Leiden University Medical Center,
      Leiden, Noord-Holland, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT04067375
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Antigens, Human Platelet/*immunology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Infant, Newborn
MH  - Isoantibodies/*blood
MH  - *Maternal Serum Screening Tests
MH  - *Observational Studies as Topic
MH  - Pregnancy
MH  - Prenatal Care
MH  - Prospective Studies
MH  - Research Design
MH  - Risk Assessment
MH  - Thrombocytopenia, Neonatal Alloimmune/blood/*diagnosis
PMC - PMC7375633
OTO - NOTNLM
OT  - *fetal medicine
OT  - *neonatology
OT  - *prenatal diagnosis
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034071 [pii]
AID - 10.1136/bmjopen-2019-034071 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e034071. doi: 10.1136/bmjopen-2019-034071.


PMID- 32690728
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Cardiac donation after circulatory determination of death: protocol for a
      mixed-methods study of healthcare provider and public perceptions in Canada.
PG  - e033932
LID - 10.1136/bmjopen-2019-033932 [doi]
AB  - INTRODUCTION: Cardiac transplantation remains the best treatment for patients
      with end-stage heart disease that is refractory to medical or device therapies,
      however, a major challenge for heart transplantation is the persistent
      discrepancy between the number of patients on waiting lists and the number of
      available hearts. While other countries (eg, UK, Australia and Belgium) have
      explored and implemented alternative models of transplantation, such as cardiac
      donation after circulatory determination of death (DCDD) to alleviate
      transplantation wait times, ethical concerns have hindered implementation in some
      countries. This study aims to explore the attitudes and opinions of healthcare
      providers and the public about cardiac DCDD in order to identify and describe
      opportunities and challenges in ensuring that proposed cardiac DCDD procedures in
      Canada are consistent with Canadian values and ethical norms. METHODS AND
      ANALYSIS: This study will include two parts that will be conducted concurrently. 
      Part 1 is a qualitative study consisting of semi-structured interviews with
      Canadian healthcare providers who routinely care for organ donors and/or
      transplant recipients to describe their perceptions about cardiac DCDD. Part 2 is
      a convergent parallel mixed-methods design consisting of a series of focus groups
      and follow-up surveys with members of the Canadian general public to describe
      their perceptions about cardiac DCDD. ETHICS AND DISSEMINATION: This study has
      been approved by the Research Ethics Board at Western University. The findings
      will be presented at regional and national conferences and reported in
      peer-reviewed publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Honarmand, Kimia
AU  - Honarmand K
AUID- ORCID: 0000-0002-7583-1445
AD  - Department of Medicine, Western University, London, Ontario, Canada
      kimia.honarmand@medportal.ca.
FAU - Ball, Ian
AU  - Ball I
AD  - Department of Medicine, Western University, London, Ontario, Canada.
AD  - Department of Epidemiology and Biostatistics, Western University, London,
      Ontario, Canada.
FAU - Weiss, Matthew
AU  - Weiss M
AD  - CHU de Quebec - Universite Laval Research Center, Population Health and Optimal
      Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine,
      Universite Laval Faculte de Medecine, Quebec, Quebec, Canada.
AD  - Transplant Quebec, Montreal, Quebec, Canada.
FAU - Slessarev, Marat
AU  - Slessarev M
AD  - Department of Medicine, Western University, London, Ontario, Canada.
FAU - Sibbald, Robert
AU  - Sibbald R
AD  - Department of Family Medicine, Western University, London, Ontario, Canada.
FAU - Sarti, Aimee
AU  - Sarti A
AD  - Department of Critical Care, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Meade, Maureen
AU  - Meade M
AD  - Department of Medicine, Department of Health Research Methods, Evidence and
      Impact, McMaster University, Hamilton, Ontario, Canada.
FAU - D'Aragon, Frederick
AU  - D'Aragon F
AD  - Department of Anesthesiology, Universite de Sherbrooke Faculte de Medecine et des
      Sciences de la Sante, Sherbrooke, Quebec, Canada.
AD  - Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada.
FAU - Chasse, Michael
AU  - Chasse M
AD  - University of Montreal Research Center, Innovation Hub and Department of Medicine
      (Critical Care), University of Montreal, Montreal, Quebec, Canada.
FAU - Basmaji, John
AU  - Basmaji J
AD  - Department of Medicine, Western University, London, Ontario, Canada.
FAU - Parsons Leigh, Jeanna
AU  - Parsons Leigh J
AD  - School of Health Administration, Faculty of Health, Dalhousie University,
      Halifax, New Brunswick, Canada.
AD  - Department of Epidemiology and Biostatistics, Cummings School of Medicine,
      University of Calgary, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Canada
MH  - Focus Groups
MH  - *Heart Transplantation
MH  - Humans
MH  - Interviews as Topic
MH  - *Public Opinion
MH  - *Research Design
MH  - *Tissue and Organ Procurement
PMC - PMC7375636
OTO - NOTNLM
OT  - *ETHICS (see Medical Ethics)
OT  - *cardiac donation
OT  - *cardiac transplantation
OT  - *donation after circulatory determination of death
OT  - *healthcare professional perceptions
OT  - *mixed methods research
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033932 [pii]
AID - 10.1136/bmjopen-2019-033932 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e033932. doi: 10.1136/bmjopen-2019-033932.


PMID- 32690727
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 20
TI  - Sensitivity and specificity of different imaging modalities in diagnosing
      necrotising enterocolitis in a Polish population of preterm infants: a diagnostic
      test accuracy study protocol.
PG  - e033519
LID - 10.1136/bmjopen-2019-033519 [doi]
AB  - INTRODUCTION: Necrotising enterocolitis (NEC) is one of the most serious
      conditions in newborn infants, affecting up to 10% of very low birth weight
      (VLBW) infants. Mortality rates can rise as high as 60%.The suspected diagnosis
      is confirmed with typical findings on abdominal radiography (AR) such as
      pneumatosis intestinalis (PI), portal vein gas (PVG) and in extreme cases
      pneumoperitoneum. Abdominal ultrasound (AUS) can depict PI, PVG and
      pnuemoperitoneum (in some cases ahead of AR), but it also provides other crucial 
      information such as bowel wall viability (thickness or thinning) and free
      abdominal fluid. These additional findings are helpful in diagnosing and managing
      NEC. METHODS AND ANALYSIS: The hypothesis being tested is that preforming an AR
      in patients with clinical symptoms of NEC, but inconclusive/normal AR will
      enhance detection rates, and expedite treatment in infants born at <32 weeks.
      Additionally, the time needed to initiate treatment, according to decision made
      based on AR or AR and AUS will also be compared. The use of AUS together with AR 
      as an add-on test may increase the accuracy of diagnosing NEC and expedite
      life-saving treatment. We plan to recruit 200 VLBW infants, who are most prone to
      NEC. It will also be the first multicentre study evaluating the use of AUS as an 
      add-on test, enabling us to recruit a significantly higher number of patients
      compared with published studies. ETHICS AND DISSEMINATION: The Bioethical
      Committee of the Medical University of Warsaw has approved the study (KB
      130/2017). We plan to submit our findings to international peer-reviewed
      journals. Abstract will be submitted to local and international conferences.
      TRIAL REGISTRATION NUMBER: NCT03188380; Protocol version: V.2.08.2019;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Seliga-Siwecka, Joanna
AU  - Seliga-Siwecka J
AUID- ORCID: 0000-0002-4628-0541
AD  - Neonatal and Intensive Care Department, Medical University of Warsaw, Warsaw,
      Poland.
FAU - Rutkowski, Jakub
AU  - Rutkowski J
AD  - HTA Consulting, Cracow, Poland.
FAU - Margas, Wojciech
AU  - Margas W
AD  - HTA Consulting, Cracow, Poland.
FAU - Puskarz-Gasowska, Joanna
AU  - Puskarz-Gasowska J
AD  - Neonatal and Intensive Care Department, Medical University of Warsaw, Warsaw,
      Poland.
FAU - Bokiniec, Renata
AU  - Bokiniec R
AD  - Neonatal and Intensive Care Department, Medical University of Warsaw, Warsaw,
      Poland renata.bokiniec@wum.edu.pl.
LA  - eng
SI  - ClinicalTrials.gov/NCT03188380
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Enterocolitis, Necrotizing/*diagnostic imaging
MH  - Humans
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - Infant, Premature, Diseases/diagnostic imaging
MH  - *Infant, Very Low Birth Weight
MH  - Multimodal Imaging
MH  - Observational Studies as Topic/*methods
MH  - Poland
MH  - *Radiography, Abdominal
MH  - Research Design
MH  - Sensitivity and Specificity
MH  - *Ultrasonography
PMC - PMC7375631
OTO - NOTNLM
OT  - *necrotising enterocolitis
OT  - *preterm infant
OT  - *ultrasound
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033519 [pii]
AID - 10.1136/bmjopen-2019-033519 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 20;10(7):e033519. doi: 10.1136/bmjopen-2019-033519.


PMID- 32690539
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Walking-related digital mobility outcomes as clinical trial endpoint measures:
      protocol for a scoping review.
PG  - e038704
LID - 10.1136/bmjopen-2020-038704 [doi]
AB  - INTRODUCTION: Advances in wearable sensor technology now enable frequent,
      objective monitoring of real-world walking. Walking-related digital mobility
      outcomes (DMOs), such as real-world walking speed, have the potential to be more 
      sensitive to mobility changes than traditional clinical assessments. However, it 
      is not yet clear which DMOs are most suitable for formal validation. In this
      review, we will explore the evidence on discriminant ability, construct validity,
      prognostic value and responsiveness of walking-related DMOs in four disease
      areas: Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary
      disease and proximal femoral fracture. METHODS AND ANALYSIS: Arksey and
      O'Malley's methodological framework for scoping reviews will guide study conduct.
      We will search seven databases (Medline, CINAHL, Scopus, Web of Science, EMBASE, 
      IEEE Digital Library and Cochrane Library) and grey literature for studies which 
      (1) measure differences in DMOs between healthy and pathological walking, (2)
      assess relationships between DMOs and traditional clinical measures, (3) assess
      the prognostic value of DMOs and (4) use DMOs as endpoints in interventional
      clinical trials. Two reviewers will screen each abstract and full-text manuscript
      according to predefined eligibility criteria. We will then chart extracted data, 
      map the literature, perform a narrative synthesis and identify gaps. ETHICS AND
      DISSEMINATION: As this review is limited to publicly available materials, it does
      not require ethical approval. This work is part of Mobilise-D, an Innovative
      Medicines Initiative Joint Undertaking which aims to deliver, validate and obtain
      regulatory approval for DMOs. Results will be shared with the scientific
      community and general public in cooperation with the Mobilise-D communication
      team. REGISTRATION: Study materials and updates will be made available through
      the Center for Open Science's OSFRegistry (https://osf.io/k7395).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Polhemus, Ashley Marie
AU  - Polhemus AM
AUID- ORCID: 0000-0002-5056-5785
AD  - Epidemiology, Biostatistics, and Prevention Institute, University of Zurich,
      Zurich, Switzerland ashley.polhemus@uzh.ch.
FAU - Bergquist, Ronny
AU  - Bergquist R
AD  - Department of Neuromedicine and Movement Science, Norwegian University of Science
      and Technology (NTNU), Trondheim, Norway.
FAU - Bosch de Basea, Magda
AU  - Bosch de Basea M
AD  - Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
FAU - Brittain, Gavin
AU  - Brittain G
AD  - Department of Neuroscience and Sheffield NIHR Translational Neuroscience BRC,
      Sheffield, UK.
AD  - Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield,
      Sheffield, UK.
FAU - Buttery, Sara Catherine
AU  - Buttery SC
AUID- ORCID: 0000-0001-9410-414X
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Chynkiamis, Nikolaos
AU  - Chynkiamis N
AD  - Department of Sport, Exercise and Rehabilitation, Faculty of Health and Life
      Sciences, Northumbria University, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Dalla Costa, Gloria
AU  - Dalla Costa G
AD  - Department of Neurology, San Raffaele Hospital, Milan, Italy.
FAU - Delgado Ortiz, Laura
AU  - Delgado Ortiz L
AD  - Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
FAU - Demeyer, Heleen
AU  - Demeyer H
AD  - Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium.
AD  - Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.
FAU - Emmert, Kirsten
AU  - Emmert K
AD  - Department of Neurology, University Medical Center Schleswig-Holstein Campus
      Kiel, Kiel, Schleswig-Holstein, Germany.
FAU - Garcia Aymerich, Judith
AU  - Garcia Aymerich J
AD  - Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
FAU - Gassner, Heiko
AU  - Gassner H
AD  - Department of Molecular Neurology, Erlangen University Hospital, Erlangen,
      Bayern, Germany.
FAU - Hansen, Clint
AU  - Hansen C
AD  - Department of Neurology, University Medical Center Schleswig-Holstein Campus
      Kiel, Kiel, Schleswig-Holstein, Germany.
FAU - Hopkinson, Nicholas
AU  - Hopkinson N
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Klucken, Jochen
AU  - Klucken J
AD  - Department of Molecular Neurology, Erlangen University Hospital, Erlangen,
      Bayern, Germany.
FAU - Kluge, Felix
AU  - Kluge F
AD  - Machine Learning and Data Analytics Lab, Department of Computer Science,
      Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany.
FAU - Koch, Sarah
AU  - Koch S
AD  - Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
AD  - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
FAU - Leocani, Letizia
AU  - Leocani L
AD  - Department of Neurology, San Raffaele Hospital, Milan, Italy.
FAU - Maetzler, Walter
AU  - Maetzler W
AD  - Department of Neurology, University Medical Center Schleswig-Holstein Campus
      Kiel, Kiel, Schleswig-Holstein, Germany.
FAU - Mico-Amigo, M Encarna
AU  - Mico-Amigo ME
AD  - Translational and Clinical Research Institute, Newcastle University Faculty of
      Medical Sciences, Newcastle upon Tyne, Newcastle upon Tyne, UK.
FAU - Mikolaizak, A Stefanie
AU  - Mikolaizak AS
AD  - Department of Clinical Gerontology, Robert Bosch Hospital, Stuttgart,
      Baden-Wurttemberg, Germany.
FAU - Piraino, Paolo
AU  - Piraino P
AD  - Department of Research & Early Development Statistics, Bayer AG, Berlin, Germany.
FAU - Salis, Francesca
AU  - Salis F
AD  - Department of Biomedical Sciences, University of Sassari, Sassari, Sardegna,
      Italy.
FAU - Schlenstedt, Christian
AU  - Schlenstedt C
AUID- ORCID: 0000-0002-3838-6848
AD  - Department of Neurology, University Medical Center Schleswig-Holstein Campus
      Kiel, Kiel, Schleswig-Holstein, Germany.
FAU - Schwickert, Lars
AU  - Schwickert L
AD  - Department of Clinical Gerontology, Robert Bosch Hospital, Stuttgart,
      Baden-Wurttemberg, Germany.
FAU - Scott, Kirsty
AU  - Scott K
AD  - INSIGNEO Institute for in Silico Medicine, The University of Sheffield,
      Sheffield, Sheffield, UK.
AD  - Department of Mechanical Engineering, The University of Sheffield, Sheffield,
      Sheffield, UK.
FAU - Sharrack, Basil
AU  - Sharrack B
AD  - Department of Neuroscience and Sheffield NIHR Translational Neuroscience BRC,
      Sheffield, UK.
AD  - Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield,
      Sheffield, UK.
FAU - Taraldsen, Kristin
AU  - Taraldsen K
AD  - Department of Neuromedicine and Movement Science, Norwegian University of Science
      and Technology (NTNU), Trondheim, Norway.
FAU - Troosters, Thierry
AU  - Troosters T
AD  - Department of Rehabilitation Sciences, KU Leuven, Leuven, Flanders, Belgium.
FAU - Vereijken, Beatrix
AU  - Vereijken B
AD  - Department of Neuromedicine and Movement Science, Norwegian University of Science
      and Technology (NTNU), Trondheim, Norway.
FAU - Vogiatzis, Ioannis
AU  - Vogiatzis I
AD  - Department of Sport, Exercise and Rehabilitation, Faculty of Health and Life
      Sciences, Northumbria University, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Yarnall, Alison
AU  - Yarnall A
AD  - Translational and Clinical Research Institute, Newcastle University Faculty of
      Medical Sciences, Newcastle upon Tyne, Newcastle upon Tyne, UK.
FAU - Mazza, Claudia
AU  - Mazza C
AD  - INSIGNEO Institute for in Silico Medicine, The University of Sheffield,
      Sheffield, Sheffield, UK.
AD  - Department of Mechanical Engineering, The University of Sheffield, Sheffield,
      Sheffield, UK.
FAU - Becker, Clemens
AU  - Becker C
AD  - Department of Clinical Gerontology, Robert Bosch Hospital, Stuttgart,
      Baden-Wurttemberg, Germany.
FAU - Rochester, Lynn
AU  - Rochester L
AD  - Translational and Clinical Research Institute, Newcastle University Faculty of
      Medical Sciences, Newcastle upon Tyne, Newcastle upon Tyne, UK.
FAU - Puhan, Milo Alan
AU  - Puhan MA
AD  - Epidemiology, Biostatistics, and Prevention Institute, University of Zurich,
      Zurich, Switzerland.
FAU - Frei, Anja
AU  - Frei A
AD  - Epidemiology, Biostatistics, and Prevention Institute, University of Zurich,
      Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Research Design
MH  - *Walking
PMC - PMC7371223
OTO - NOTNLM
OT  - *Parkinson-s disease
OT  - *chronic airways disease
OT  - *geriatric medicine
OT  - *multiple sclerosis
OT  - *orthopaedic & trauma surgery
OT  - *telemedicine
COIS- Competing interests: AMP is a part-time employee of Merck, Sharpe and Dohme AG,
      but does not own stock or stock options. PP is an employee of Bayer AG, and may
      own stock/stock options. WM receives or received funding from the European Union,
      the German Federal Ministry of Education of Research, Michael J. Fox Foundation, 
      Robert Bosch Foundation, Neuroalliance, Lundbeck and Janssen. He received speaker
      honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Rolke Pharma and UCB,
      was invited to Advisory Boards of Abbvie, Biogen, Lundbeck and Market Access &
      Pricing Strategy GmbH, and is an advisory board member of the Critical Path for
      Parkinson's Consortium. He serves as the cochair of the MDS Technology Task
      Force.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-038704 [pii]
AID - 10.1136/bmjopen-2020-038704 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e038704. doi: 10.1136/bmjopen-2020-038704.


PMID- 32690536
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Study protocol for a randomised controlled trial evaluating the effects of the
      orexin receptor antagonist suvorexant on sleep architecture and delirium in the
      intensive care unit.
PG  - e038474
LID - 10.1136/bmjopen-2020-038474 [doi]
AB  - INTRODUCTION: Insomnia frequently occurs in patients admitted to an intensive
      care unit (ICU). Sleep-promoting agents may reduce rapid eye movement sleep and
      have deliriogenic effects. Suvorexant (Belsomra) is an orexin receptor antagonist
      with Food and Drug Administration (FDA) approval for the treatment of adult
      insomnia, which improves sleep onset and maintenance as well as subjective
      measures of quality of sleep. This trial will evaluate the efficacy of
      postoperative oral suvorexant treatment on night-time wakefulness after
      persistent sleep onset as well as the incidence and duration of delirium among
      adult cardiac surgical patients. METHODS AND ANALYSIS: In this single-centre,
      randomised, double-blind, placebo-controlled trial, we will enrol 120 patients,
      aged 60 years or older, undergoing elective cardiac surgery with planned
      postoperative admission to the ICU. Participants will be randomised to receive
      oral suvorexant (20 mg) or placebo one time a day starting the night after
      extubation. The primary outcome will be wakefulness after persistent sleep onset.
      The secondary outcome will be total sleep time. Exploratory outcomes will include
      time to sleep onset, incidence of postoperative in-hospital delirium, number of
      delirium-free days and subjective sleep quality. ETHICS AND DISSEMINATION: Ethics
      approval was obtained through the 'Committee on Clinical Investigations' at Beth 
      Israel Deaconess Medical Center (protocol number 2019P000759). The findings will 
      be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: This trial has
      been registered at clinicaltrials.gov on 17 September 2019 (NCT04092894).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Azimaraghi, Omid
AU  - Azimaraghi O
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Hammer, Maximilian
AU  - Hammer M
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Santer, Peter
AU  - Santer P
AUID- ORCID: 0000-0002-1735-0774
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Platzbecker, Katharina
AU  - Platzbecker K
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Althoff, Friederike C
AU  - Althoff FC
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Patrocinio, Maria
AU  - Patrocinio M
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Grabitz, Stephanie D
AU  - Grabitz SD
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Wongtangman, Karuna
AU  - Wongtangman K
AD  - Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol
      University, Bangkok, Thailand.
FAU - Rumyantsev, Sandra
AU  - Rumyantsev S
AD  - Pharmacy, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Xu, Xinling
AU  - Xu X
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Schaefer, Maximilian S
AU  - Schaefer MS
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Fuller, Patrick M
AU  - Fuller PM
AD  - Department of Neurology, Program in Neuroscience and Division of Sleep Medicine, 
      Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
FAU - Subramaniam, Balachundhar
AU  - Subramaniam B
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Eikermann, Matthias
AU  - Eikermann M
AUID- ORCID: 0000-0002-7893-0596
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess 
      Medical Center, Harvard Medical School, Boston, Massachusetts, USA
      meikerma@bidmc.harvard.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT04092894
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Azepines)
RN  - 0 (Orexin Receptor Antagonists)
RN  - 0 (Triazoles)
RN  - 081L192FO9 (suvorexant)
SB  - IM
MH  - Adult
MH  - Azepines
MH  - *Delirium/drug therapy/prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Intensive Care Units
MH  - Middle Aged
MH  - Orexin Receptor Antagonists/pharmacology/therapeutic use
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Sleep/drug effects
MH  - Stroke Volume
MH  - Treatment Outcome
MH  - Triazoles
MH  - Ventricular Function, Left
PMC - PMC7371384
OTO - NOTNLM
OT  - *anaesthetics
OT  - *cardiac surgery
OT  - *clinical trials
OT  - *delirium & cognitive disorders
OT  - *sleep medicine
COIS- Competing interests: ME also received compensation for serving on the advisory
      board for Suvorexant in 2018.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-038474 [pii]
AID - 10.1136/bmjopen-2020-038474 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e038474. doi: 10.1136/bmjopen-2020-038474.


PMID- 32690533
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Does probe-tube verification of real-ear hearing aid amplification
      characteristics improve outcomes in adult hearing aid users? A protocol for a
      systematic review.
PG  - e038113
LID - 10.1136/bmjopen-2020-038113 [doi]
AB  - INTRODUCTION: Using a probe-tube microphone to measure and adjust the real-ear
      performance of the hearing aid to match the prescription target is recommended
      and widely used in clinical practice. Hearing aid fitting software can
      approximately match the amplification characteristics of the hearing aid to the
      prescription without real-ear measurements (REMs), but using REM improves the
      match to the prescribed target. What is unclear is if the improved match results 
      in a better patient-reported outcome. The primary objective of this review is to 
      determine whether the use of REM improves patient-reported outcomes in adult
      hearing aid users. METHODS AND ANALYSIS: The review's methods are in accordance
      with Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols
      guidelines. MEDLINE, EMBASE, PsycINFO, CINAHL, Web of Science and CENTRAL via
      Cochrane Library will be searched to identify relevant studies. The review's
      population of interest will include adults with any degree of sensorineural or
      mixed hearing loss who have been prescribed with acoustic hearing aids. The
      included studies should compare REM fitting to the initial fit provided by the
      manufacturer's fitting software. Hearing-specific health-related quality of life 
      is the primary outcome but secondary outcomes include self-reported listening
      ability, speech recognition scores, generic health-related quality of life, hours
      of use, number of required follow-up sessions and adverse events. Randomised and 
      non-randomised controlled trials will be included. The risk of bias in the
      included studies will be evaluated using Down and Black's checklist. The quality 
      of the overall evidence will be assessed using the Grading of Recommendations,
      Assessment, Development and Evaluations tool. ETHICS AND DISSEMINATION: Ethical
      approval will not be sought because this systematic review will only retrieve and
      analyse data from published studies. Review results will be published in a
      peer-reviewed journal and presented at relevant scientific conferences. PROSPERO 
      REGISTRATION NUMBER: CRD42020166074.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Almufarrij, Ibrahim
AU  - Almufarrij I
AUID- ORCID: 0000-0003-4043-7234
AD  - Manchester Centre for Audiology and Deafness, School of Health Sciences, The
      University of Manchester, Manchester, UK ialmufarrij@ksu.edu.sa.
AD  - Department of Rehabilitation Sciencess, College of Applied Medical Sciences, King
      Saud University, Riyadh, Kingdom of Saudi Arabia.
FAU - Munro, Kevin J
AU  - Munro KJ
AD  - Manchester Centre for Audiology and Deafness, School of Health Sciences, The
      University of Manchester, Manchester, UK.
AD  - Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health 
      Science Centre, Manchester, UK.
FAU - Dillon, Harvey
AU  - Dillon H
AD  - Manchester Centre for Audiology and Deafness, School of Health Sciences, The
      University of Manchester, Manchester, UK.
AD  - Department of Linguistics, Macquarie University, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Hearing
MH  - *Hearing Aids
MH  - *Hearing Loss
MH  - Hearing Tests
MH  - Humans
MH  - Quality of Life
PMC - PMC7371126
OTO - NOTNLM
OT  - *audiology
OT  - *neurotology
OT  - *otolaryngology
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-038113 [pii]
AID - 10.1136/bmjopen-2020-038113 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e038113. doi: 10.1136/bmjopen-2020-038113.


PMID- 32690530
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Implementation of health-focused interventions in vulnerable populations:
      protocol for a scoping review.
PG  - e036937
LID - 10.1136/bmjopen-2020-036937 [doi]
AB  - INTRODUCTION: Vulnerable populations face significant challenges in navigating
      the care continuum, ranging from diagnosis of illness to linkage and retention in
      healthcare. Understanding how best to move individuals within these vulnerable
      populations across the care continuum is critical to improving their health. A
      large body of literature has focused on evaluation of implementation of various
      health-focused interventions in this population. However, we do not fully
      understand the unique challenges to implementing healthcare interventions for
      vulnerable populations. This study aims to examine the literature describing
      implementation of health service interventions among vulnerable populations to
      identify how implementations using the Consolidated Framework for Implementation 
      Research are adapted. Findings from this review will be useful to implementation 
      scientists to identify gaps in evidence and for adapting similar interventions in
      unique settings. METHODS AND ANALYSIS: This study protocol outlines a scoping
      review of the peer-reviewed and grey literature, using established approaches
      delineated in Arksey and O'Malley's scoping review framework and the Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping
      Reviews Checklist. Search strategies will be developed and refined by a medical
      librarian in collaboration with the research team. Searches will be conducted in 
      electronic databases (CINAHL, Cochrane, PsychINFO, PubMed, Social Services
      Abstracts, Web of Science, Google and Google Scholar) and limited to studies
      published between 1 August 2009 and 1 June 2020. Additionally, hand searches will
      be conducted in three relevant journals-Implementation Science, Systematic
      Reviews and BMJ Open. English-language studies and reports meeting inclusion
      criteria will be screened independently by two reviewers and the final list will 
      be abstracted and charted in duplicate. ETHICS AND DISSEMINATION: This is a
      review of the literature; ethics approval is not indicated. We will disseminate
      findings from this study in peer-reviewed journals as well as presentations to
      relevant stakeholders and conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Midboe, Amanda M
AU  - Midboe AM
AD  - Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 
      Palo Alto, California, USA amanda.midboe@va.gov.
AD  - Department of Psychiatry, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Gray, Caroline
AU  - Gray C
AD  - Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 
      Palo Alto, California, USA.
FAU - Cheng, Hannah
AU  - Cheng H
AUID- ORCID: 0000-0001-8144-5340
AD  - Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 
      Palo Alto, California, USA.
AD  - Department of Psychiatry, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Okwara, Leonore
AU  - Okwara L
AD  - Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 
      Palo Alto, California, USA.
FAU - Gale, Randall C
AU  - Gale RC
AD  - Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, 
      Palo Alto, California, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Research Design
PMC - PMC7371133
OTO - NOTNLM
OT  - *mental health
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2020-036937 [pii]
AID - 10.1136/bmjopen-2020-036937 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036937. doi: 10.1136/bmjopen-2020-036937.


PMID- 32690525
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20211203
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - How does the intensity of physical therapy affect the Gross Motor Function
      Measure (GMFM-66) total score in children with cerebral palsy? A systematic
      review protocol.
PG  - e036630
LID - 10.1136/bmjopen-2019-036630 [doi]
AB  - INTRODUCTION: Intensive physical therapy (PT) interventions administered to
      children with cerebral palsy (CP) have received a significant amount of attention
      in published literature. However, there is considerable variability in therapy
      intensity among studies and notable lack of information on optimal intervention
      dosing. This makes it difficult for clinicians to use evidence to inform
      practice. Many studies use the Gross Motor Function Measure (GMFM-66) to assess
      functional progress in children with CP. The purpose of this systematic review
      will be to identify the GMFM-66 change score reported in published studies, with 
      outcomes based on intervention intensity. Whether the type of PT intervention,
      child's age, and Gross Motor Function Classification System level influence the
      GMFM-66 scores will be also assessed. METHODS AND ANALYSIS: This systematic
      review protocol was developed based on the Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 checklist. In
      March 2018, nine databases (PubMed, Ovid MEDLINE, Cochrane Library, Embase,
      Scopus, Web of Science, CINAHL, ClinicalTrials.gov, and REHABDATA) were searched 
      for controlled clinical trials and single-subject design studies of PT
      interventions of any kind and intensity that used the GMFM-66 as an outcome
      measure for children with CP, age up to 18 years. Two authors independently
      reviewed the titles and abstracts and arrived at consensus on paper selection for
      a full-text review. The same process was used for a full-text article screening
      based on further detailed inclusion criteria, with a final selection made for
      those suitable for data extraction. Prior to commencement of data extraction, all
      searches will be updated, and new results re-screened. ETHICS AND DISSEMINATION: 
      This study will involve a systematic review of published articles and no primary 
      data collection. Therefore, no ethical approval will be necessary. Results will
      be disseminated in a peer-reviewed publication and presented at scientific
      conferences. PROSPERO REGISTRATION NUMBER: CRD42020147669.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rahlin, Mary
AU  - Rahlin M
AUID- ORCID: 0000-0001-5126-4338
AD  - Department of Physical Therapy, Rosalind Franklin University of Medicine and
      Science, North Chicago, Illinois, USA Mary.Rahlin@rosalindfranklin.edu.
FAU - Duncan, Burris
AU  - Duncan B
AD  - Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public
      Health, University of Arizona, Tucson, Arizona, USA.
FAU - Howe, Carol L
AU  - Howe CL
AD  - Health Sciences Library, University of Arizona, Tucson, Arizona, USA.
FAU - Pottinger, Heidi L
AU  - Pottinger HL
AD  - Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public
      Health, University of Arizona, Tucson, Arizona, USA.
LA  - eng
GR  - R01 HD079498/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Cerebral Palsy
MH  - Child
MH  - Humans
MH  - Physical Therapy Modalities
MH  - Systematic Reviews as Topic
PMC - PMC7371020
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *paediatric neurology
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036630 [pii]
AID - 10.1136/bmjopen-2019-036630 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036630. doi: 10.1136/bmjopen-2019-036630.


PMID- 32690523
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Study protocol for a 9-month randomised controlled trial assessing the effects of
      almonds versus carbohydrate-rich snack foods on weight loss and weight
      maintenance.
PG  - e036542
LID - 10.1136/bmjopen-2019-036542 [doi]
AB  - INTRODUCTION: Epidemiological studies indicate an inverse association between nut
      consumption and body mass index (BMI). However, clinical trials evaluating the
      effects of nut consumption compared with a nut-free diet on adiposity have
      reported mixed findings with some studies reporting greater weight loss and
      others reporting no weight change. This paper describes the rationale and
      detailed protocol for a randomised controlled trial assessing whether the
      inclusion of almonds or carbohydrate-rich snacks in an otherwise nut-free
      energy-restricted diet will promote weight loss during 3 months of energy
      restriction and limit weight regain during 6 months of weight maintenance.
      METHODS AND ANALYSIS: One hundred and thirty-four adults aged 25-65 years with a 
      BMI of 27.5-34.9 kg/m(2) will be recruited and randomly allocated to either the
      almond-enriched diet (AED) (15% energy from almonds) or a nut-free control diet
      (NFD) (15% energy from carbohydrate-rich snack foods). Study snack foods will be 
      provided. Weight loss will be achieved through a 30% energy restriction over 3
      months, and weight maintenance will be encouraged for 6 months by increasing
      overall energy intake by ~120-180 kcal/day (~500-750kJ/day) as required. Food
      will be self-selected, based on recommendations from the study dietitian. Body
      composition, resting energy expenditure, total daily energy expenditure (via
      doubly labelled water), physical activity, appetite regulation, cardiometabolic
      health, gut microbiome, liver health, inflammatory factors, eating behaviours,
      mood and personality, functional mobility and pain, quality of life and sleep
      patterns will be measured throughout the 9-month trial. The effects of
      intervention on the outcome measures over time will be analysed using random
      effects mixed models, with treatment (AED or NFD) and time (baseline, 3 months
      and 9 months) being the between and within factors, respectively in the analysis.
      ETHICS AND DISSEMINATION: Ethics approval was obtained from the University of
      South Australia Human Research Ethics Committee (201436). Results from this trial
      will be disseminated through publication in peer-reviewed journals, national and 
      international presentations. TRIAL REGISTRATION NUMBER: Australian New Zealand
      Clinical Trials Registry (ACTRN12618001861246).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Carter, Sharayah
AU  - Carter S
AUID- ORCID: 0000-0002-8169-4483
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
FAU - Hill, Alison M
AU  - Hill AM
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
AD  - Clinical and Health Sciences, University of South Australia, Adelaide, South
      Australia, Australia.
FAU - Yandell, Catherine
AU  - Yandell C
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
FAU - Buckley, Jonathan D
AU  - Buckley JD
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
FAU - Tan, Sze-Yen
AU  - Tan SY
AD  - Institute for Physical Activity and Nutrition (IPAN), Deakin University, Burwood,
      Victoria, Australia.
FAU - Rogers, Geraint B
AU  - Rogers GB
AD  - Microbiome Research, South Australian Health and Medical Research Institute
      (SAHMRI), Adelaide, South Australia, Australia.
AD  - College of Medicine and Public Health, Flinders University, Adelaide, South
      Australia, Australia.
FAU - Childs, Jessie
AU  - Childs J
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
FAU - Matheson, Mark
AU  - Matheson M
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
FAU - Lamb, Kate
AU  - Lamb K
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
FAU - Ward, Susan
AU  - Ward S
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
FAU - Stanton, Tasha R
AU  - Stanton TR
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
AD  - IMPlementation And Clinical Translation (IIMPACT), University of South Australia,
      Adelaide, South Australia, Australia.
AD  - Neuroscience Research Australia, Sydney, New South Wales, Australia.
FAU - Fraysse, Francois
AU  - Fraysse F
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia.
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
FAU - Hills, Andrew P
AU  - Hills AP
AD  - School of Health Sciences, College of Health and Medicine, University of
      Tasmania, Launceston, Tasmania, Australia.
FAU - Coates, Alison M
AU  - Coates AM
AD  - Allied Health and Human Performance, University of South Australia, Adelaide,
      South Australia, Australia alison.coates@unisa.edu.au.
AD  - Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of 
      South Australia, Adelaide, South Australia, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618001861246
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Carbohydrates)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Body Weight Maintenance
MH  - Carbohydrates
MH  - Humans
MH  - Middle Aged
MH  - *Prunus dulcis
MH  - Quality of Life
MH  - Snacks
MH  - Weight Loss
PMC - PMC7371143
OTO - NOTNLM
OT  - *clinical physiology
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: AMC has consulted for Nuts for Life (an initiative of the
      Australian Tree Nut Industry).
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036542 [pii]
AID - 10.1136/bmjopen-2019-036542 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036542. doi: 10.1136/bmjopen-2019-036542.


PMID- 32690522
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Perioperative pain and addiction interdisciplinary network (PAIN): protocol for
      the perioperative management of cannabis and cannabinoid-based medicines using a 
      modified Delphi process.
PG  - e036472
LID - 10.1136/bmjopen-2019-036472 [doi]
AB  - INTRODUCTION: At the conception of this study (January 2019), a literature search
      by the authors found no evidence-based or consensus perioperative guidelines for 
      patients consuming cannabis products, or for those patients in whom a cannabinoid
      medication could be considered for perioperative treatment. Currently, there is a
      large global population that consumes cannabis. The availability of cannabis has 
      also increased this decade with greater legal access to cannabis products in some
      countries such as USA, Canada, Uruguay, Israel, Australia and Germany. There are 
      recognised possible therapeutic benefits for the use of cannabis in patients with
      chronic pain, chronic neuropathic pain and chemotherapy-induced nausea and
      vomiting. There are also potential side effects from cannabis use such as
      psychosis, cannabis hyperemesis syndrome, misuse disorder and cannabis withdrawal
      syndrome. There is evidence that cannabis may also affect factors in the
      perioperative period such as monitoring, quality of analgesia, sleep and opioid
      consumption. Given the large population of persons using cannabis, the
      heterogeneity of cannabis products and the paucity (and heterogeneity) of
      perioperative literature surrounding it, perioperative guidelines for cannabis
      consuming patients are both lacking and necessary. In this paper, we present the 
      design for a modified Delphi technique that has been started with the intent of
      deriving cannabis perioperative guidelines from the available medical literature 
      and the consensus of multidisciplinary experts. MATERIALS, METHODS AND ANALYSIS: 
      This study will use a scoping narrative literature review and modified Delphi
      process to generate cannabis perioperative guidelines. A scoping narrative review
      of cannabis in the perioperative period by the authors of this proposal was
      completed and provided to a panel of 17 experts. These experts were recruited for
      their knowledge and expertise regarding cannabis and/or perioperative medicine.
      They were asked to rate a series of indications and clinical scenarios in two
      rounds. During the first round, the expert panel was blinded to each other's
      participation. During the second round of this process, the expert panel met
      after being provided with an analysis of the first round's submissions so they
      could be discussed further and, if possible, reach a further consensus regarding 
      them. Using the results obtained from the Delphi review process, a draft of
      proposed cannabis perioperative guidelines will be generated. These proposed
      guidelines will be returned to the expert panel for critiquing prior to their
      finalisation. ETHICS AND DISSEMINATION: Study and panellist data will be
      deidentified and stored as per institutional (Toronto General Hospital)
      guidelines. Institutional research ethics board provided a waiver for this
      modified Delphi protocol. Findings will be presented and published in
      peer-reviewed publications and conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McLaren-Blades, Alexander
AU  - McLaren-Blades A
AUID- ORCID: 0000-0003-1466-4791
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada alexander.mclarenblades@one-mail.on.ca.
FAU - Ladha, Karim
AU  - Ladha K
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
AD  - Anesthesia and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, 
      Ontario, Canada.
FAU - Goel, Akash
AU  - Goel A
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
FAU - Manoo, Varuna
AU  - Manoo V
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
FAU - Kotteeswaran, Yuvaraj
AU  - Kotteeswaran Y
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
FAU - Gee, Yen-Yen
AU  - Gee YY
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
FAU - Fiorellino, Joseph
AU  - Fiorellino J
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
FAU - Clarke, Hance
AU  - Clarke H
AD  - Anesthesia and Pain Management, Toronto General Hospital, Toronto, Ontario,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cannabinoids)
SB  - IM
MH  - *Cannabinoids
MH  - *Cannabis
MH  - Delphi Technique
MH  - Humans
MH  - Pain, Postoperative/drug therapy
MH  - Perioperative Care
PMC - PMC7371125
OTO - NOTNLM
OT  - *anaesthesiology
OT  - *cannabinoids
OT  - *cannabis
OT  - *perioperative period
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036472 [pii]
AID - 10.1136/bmjopen-2019-036472 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036472. doi: 10.1136/bmjopen-2019-036472.


PMID- 32690521
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Foot orthoses for people with rheumatoid arthritis, involving quantitative and
      qualitative outcomes: protocol for a randomised controlled trial.
PG  - e036433
LID - 10.1136/bmjopen-2019-036433 [doi]
AB  - INTRODUCTION: Rheumatoid arthritis (RA) involves changes to foot structure and
      function, and there is an association between RA and foot pain. This pain affects
      those patient's physical activity and experience of daily living. While there is 
      clinical evidence for the value of foot orthoses (FO) on foot pain, there is a
      wide range of FO available and there is little evidence on the relative benefits 
      of one orthoses type over another, especially in terms of their impact on
      physical activity and associated well-being. The aim of this study is to compare 
      physical activity, general and foot health and foot health experiences in people 
      with RA when wearing three different types of FO. METHODS AND ANALYSIS: A
      randomised controlled trial with three arms will compare the effects of (1)
      custom FO made using a direct adaptation technique, (2) custom FO made through a 
      digital design and production process and (3) prefabricated orthoses. The primary
      outcome is physical activity measured using a GENEActiv bracelet. Secondary
      outcomes will be pain, function and disability and associated foot and general
      health evaluated using existing questionnaires. Semistructured interviews will
      identify patients' experiences of the orthoses and living with RA. ETHICS AND
      DISSEMINATION: The study has been approved by the Portal de Etica de la
      Investigacion Biomedica de Andalucia ethical committee (SPAR-001). The results
      will be disseminated regardless of the magnitude or direction of effect. TRIAL
      REGISTRATION NUMBER: NCT03170947; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ramos-Petersen, Laura
AU  - Ramos-Petersen L
AD  - Podiatry, Universidad Catolica San Antonio de Murcia - Campus de los Jeronimos,
      Murcia, Spain.
FAU - Nester, Christoper J
AU  - Nester CJ
AD  - University of Salford Faculty of Health and Society, Salford, UK.
FAU - Gijon-Nogueron, Gabriel
AU  - Gijon-Nogueron G
AUID- ORCID: 0000-0003-4558-3548
AD  - Nursing and Podiatry, Universidad de Malaga Facultad de Ciencias de la Salud,
      Malaga, Andalucia, Spain gagijon@uma.es.
FAU - Ortega-Avila, Ana Belen
AU  - Ortega-Avila AB
AD  - Nursing and Podiatry, Universidad de Malaga Facultad de Ciencias de la Salud,
      Malaga, Andalucia, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03170947
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Arthritis, Rheumatoid/complications/therapy
MH  - *Foot Diseases/therapy
MH  - *Foot Orthoses
MH  - Humans
MH  - Pain
MH  - Pain Measurement
PMC - PMC7371219
OTO - NOTNLM
OT  - *clinical trials
OT  - *foot & ankle
OT  - *qualitative research
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036433 [pii]
AID - 10.1136/bmjopen-2019-036433 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036433. doi: 10.1136/bmjopen-2019-036433.


PMID- 32690519
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Person-centred care by a combined digital platform and structured telephone
      support for people with chronic obstructive pulmonary disease and/or chronic
      heart failure: study protocol for the PROTECT randomised controlled trial.
PG  - e036356
LID - 10.1136/bmjopen-2019-036356 [doi]
AB  - BACKGROUND: A core feature of chronic obstructive pulmonary disorder (COPD) and
      chronic heart failure (CHF) is that symptoms may change rapidly because of
      illness progression. Thus, these chronic conditions are associated with high
      rehospitalisation rates. Person-centred care (PCC) has been shown to have several
      benefits for patients with COPD or CHF (or both disorders) but it has not yet
      been investigated through e-health services. AIM: The project aims to evaluate
      the effects of PCC by a combined digital platform and structured telephone
      support for people with COPD and/or CHF. METHODS AND ANALYSIS: A randomised
      controlled trial with open, parallel groups which employs a participatory design 
      process will be used. This project will also include process and health economic 
      evaluation of the intervention. ETHICS AND DISSEMINATION: Ethical approval has
      been secured from the Regional Ethical Review Board in Gothenburg, Sweden (Dnr
      063-17 and T063-18). Results will be presented at conferences and to healthcare
      professionals, participants and patient organisations. Findings will also be
      submitted for publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT03183817.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ali, Lilas
AU  - Ali L
AUID- ORCID: 0000-0001-7027-4371
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden lilas.ali@gu.se.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
AD  - Psychiatric department, Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Wallstrom, Sara
AU  - Wallstrom S
AUID- ORCID: 0000-0001-7579-4974
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
FAU - Barenfeld, Emmelie
AU  - Barenfeld E
AUID- ORCID: 0000-0002-4945-4623
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
FAU - Fors, Andreas
AU  - Fors A
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
AD  - Narhalsan Research and Development Primary Health Care, Region Vastra Gotaland,
      Sweden.
FAU - Fredholm, Eva
AU  - Fredholm E
AD  - Patient representative, The Swedish Heart & Lung Foundation, Stockholm, Sweden.
FAU - Gyllensten, Hanna
AU  - Gyllensten H
AUID- ORCID: 0000-0001-6890-5162
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
FAU - Swedberg, Karl
AU  - Swedberg K
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Internal medicine and geriatrics, Sahlgrenska university hospital, 
      Ostra, Gothenburg, Sweden.
AD  - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Ekman, Inger
AU  - Ekman I
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, Gothenburg, Sweden.
AD  - Centre for Person-Centred Care, University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Internal medicine and geriatrics, Sahlgrenska university hospital, 
      Ostra, Gothenburg, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03183817
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - *Heart Failure/therapy
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive/therapy
MH  - Quality of Life
MH  - Sweden
MH  - Telephone
PMC - PMC7371144
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiology
OT  - *heart failure
OT  - *thoracic medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036356 [pii]
AID - 10.1136/bmjopen-2019-036356 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036356. doi: 10.1136/bmjopen-2019-036356.


PMID- 32690517
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Effectiveness of intraoperative peritoneal lavage (IOPL) with saline in patient
      with intra-abdominal infections: a systematic review and meta-analysis protocol.
PG  - e036273
LID - 10.1136/bmjopen-2019-036273 [doi]
AB  - INTRODUCTION: Intra-abdominal infections (IAIs) are common surgical emergencies
      and cause a significant worldwide burden per year. Since the concept of
      intraoperative peritoneal lavage (IOPL) was proposed in 1905, it has been widely 
      used in the surgery practice. However, the effectiveness of IOPL in patients with
      IAIs has always been controversial. Our objective is to identify whether it is
      beneficial to flush the abdominal cavity with saline in IAIs surgery through a
      comprehensive systematic review and meta-analysis. METHODS AND ANALYSIS: This
      protocol is reported in line with the Preferred Reporting Items for Systematic
      Review and Meta-Analysis Protocols. Electronic databases (including the Cochrane 
      library, MEDLINE, EMBASE, Web of Science, etc) and clinical trial registry
      platforms will be searched from inception to 8 September 2019. Randomised
      controlled trials, quasi-randomised clinical trials and cohort studies comparing 
      IOPL and suction alone in IAIs will be included. The primary outcomes are
      mortality and abscess rate. Two independent reviewers will screen literature,
      collect data and assess risk of bias of included studies. Discussion or a third
      reviewer will be referred for any disagreements. The Grading of Recommendations
      Assessment, Development and Evaluation approach will be used to assess the
      quality of the evidence. We will perform meta-analysis using random-effects
      model. Subgroup analysis, sensitivity analysis and publication bias will be
      conducted if data are enough. ETHICS AND DISSEMINATION: Ethical approval is not
      required for this systematic review and meta-analysis protocol. Results of this
      study will be published in a peer-reviewed journal, presented at relevant
      conferences and disseminated to local and international policy makers. PROSPERO
      REGISTRATION NUMBER: CRD42019145109.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhou, Qi
AU  - Zhou Q
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Shi, Qianling
AU  - Shi Q
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
AD  - The First Hospital of Lanzhou University, Lanzhou University, Lanzhou, China.
FAU - Yu, Xuan
AU  - Yu X
AUID- ORCID: 0000-0002-9390-6009
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Wang, Zijun
AU  - Wang Z
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Zhang, Jingyi
AU  - Zhang J
AD  - School of Public Health, Lanzhou University, Lanzhou, China.
FAU - Yang, Nan
AU  - Yang N
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Wang, Jianjian
AU  - Wang J
AD  - School of Public Health, Lanzhou University, Lanzhou, China.
FAU - Ma, Yanfang
AU  - Ma Y
AUID- ORCID: 0000-0001-8882-2479
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
FAU - Luo, Xufei
AU  - Luo X
AD  - School of Public Health, Lanzhou University, Lanzhou, China.
FAU - Xun, Yangqin
AU  - Xun Y
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Zhao, Siya
AU  - Zhao S
AD  - School of Public Health, Lanzhou University, Lanzhou, China.
FAU - Zheng, Bobo
AU  - Zheng B
AD  - Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Meng, Wenbo
AU  - Meng W
AUID- ORCID: 0000-0003-2900-7671
AD  - Department of Special Minimally Invasive Surgery, The First Hospital of Lanzhou
      University, Lanzhou University, Lanzhou, China.
FAU - Yang, Kehu
AU  - Yang K
AUID- ORCID: 0000-0001-7864-3012
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China
      chenyaolong@lzu.edu.cn kehuyangebm2006@126.com.
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Chen, Yaolong
AU  - Chen Y
AUID- ORCID: 0000-0002-8598-6504
AD  - Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou
      University, Lanzhou, China chenyaolong@lzu.edu.cn kehuyangebm2006@126.com.
AD  - Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou, China.
AD  - WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, 
      Lanzhou University, Lanzhou, China.
FAU - Sawyer, Robert
AU  - Sawyer R
AD  - Department of Surgery, Western Michigan University, Kalamazoo, Michigan, USA.
AD  - College of Engineering and Applied Sciences, Western Michigan University,
      Kalamazoo, Michigan, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Intraabdominal Infections/therapy
MH  - *Peritoneal Lavage
MH  - Publication Bias
MH  - Research Design
PMC - PMC7371137
OTO - NOTNLM
OT  - *gastrointestinal infections
OT  - *protocols & guidelines
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036273 [pii]
AID - 10.1136/bmjopen-2019-036273 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036273. doi: 10.1136/bmjopen-2019-036273.


PMID- 32690516
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - HIV and other STIs self-testing to reduce risk compensation among men who have
      sex with men who use oral pre-exposure prophylaxis in China: protocol for a
      randomised waitlist-controlled trial.
PG  - e036231
LID - 10.1136/bmjopen-2019-036231 [doi]
AB  - INTRODUCTION: Pre-exposure prophylaxis (PrEP) reduces the risk of HIV infection
      among men who have sex with men by up to 99%. However, in real-world settings,
      PrEP users may exhibit risk compensation after uptake of PrEP, including more
      condomless anal intercourse (CAI) and increased sexually transmitted infection
      (STI) acquisition. HIV self-testing (HIVST) decreases CAI among men who have sex 
      with men (MSM) by providing awareness of the HIV status of oneself and one's
      sexual partners. Here, we describe the rationale and design of a randomised
      waitlist-controlled trial to examine the impact of HIVST on risk compensation
      among PrEP users. METHODS AND ANALYSIS: The study is a two-arm randomised
      waitlist-controlled trial with 1000 HIV-negative MSM in four major cities in
      China who will be taking oral PrEP (involving tenofovir disoproxil
      fumarate/emtricitabine) either daily (n=500) or in an event-driven regimen
      (n=500). The participants will be randomised (1:1) to either the immediate HIVST 
      intervention arm (HIVST plus standard facility-based counselling and testing from
      0 to 12 months) or the waitlist arm (standard facility-based counselling and
      testing from 0 to 6 months, then crossover to receive the HIVST intervention in
      months 7-12). Participants will provide blood samples to assess the incidence of 
      syphilis and herpes simplex virus type 2 (HSV-2) during a follow-up. The primary 
      outcomes will be the occurrence of CAI, number of sexual partners and incidence
      of syphilis and HSV-2 during a follow-up. The secondary outcomes will be the HIV 
      and STI testing frequency and STI treatment adherence during a follow-up. The
      planned start and end dates for the study is 26 December 2018 and 31 December
      2020. ETHICS AND DISSEMINATION: The Medical Science Research Ethics Committee of 
      The First Affiliated Hospital of China Medical University has approved the study 
      (IRB(2018)273). TRIAL REGISTRATION NUMBER: ChiCTR1800020374.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Jing
AU  - Zhang J
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Huang, Xiaojie
AU  - Huang X
AD  - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,
      Beijing, China.
AD  - Beijing Youan Hospital, Capital Medical University, Beijing, China.
FAU - Chen, Yaokai
AU  - Chen Y
AD  - Chongqing Public Health Medical Center, Chongqing, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen,
      China.
FAU - Zhang, Yonghui
AU  - Zhang Y
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Wang, Hongyi
AU  - Wang H
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Mei, Zhu
AU  - Mei Z
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Jia, Yueru
AU  - Jia Y
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Chu, ZhenXing
AU  - Chu Z
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Hu, Qing-Hai
AU  - Hu QH
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - He, Xiaoqing
AU  - He X
AUID- ORCID: 0000-0002-2134-3809
AD  - Chongqing Public Health Medical Center, Chongqing, China.
FAU - Zhang, Lukun
AU  - Zhang L
AD  - Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen,
      China.
FAU - Hu, Zhili
AU  - Hu Z
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Bao, Rantong
AU  - Bao R
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Li, Shangcao
AU  - Li S
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Ding, Haibo
AU  - Ding H
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Jiang, Yongjun
AU  - Jiang Y
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Geng, Wenqing
AU  - Geng W
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
FAU - Tang, Weiming
AU  - Tang W
AUID- ORCID: 0000-0002-9026-707X
AD  - University of North Carolina at Chapel Hill Project-China, Guangzhou, China.
FAU - Xu, Junjie
AU  - Xu J
AUID- ORCID: 0000-0003-4303-7295
AD  - NHC Key Laboratory of AIDS Immunology (China Medical University), National
      Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital
      of China Medical University, Shenyang, China xjjcmu@163.com.
AD  - Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang,
      China.
AD  - Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang, China.
AD  - Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Hangzhou, China.
CN  - CROPrEP Group
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - China/epidemiology
MH  - *HIV Infections/epidemiology/prevention & control
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Pre-Exposure Prophylaxis
MH  - Self-Testing
MH  - *Sexual and Gender Minorities
MH  - *Sexually Transmitted Diseases
MH  - Young Adult
PMC - PMC7371146
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036231 [pii]
AID - 10.1136/bmjopen-2019-036231 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036231. doi: 10.1136/bmjopen-2019-036231.


PMID- 32690515
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker
      of mortality in healthy, general and patient populations: protocol for a
      systematic review and meta-analysis.
PG  - e036125
LID - 10.1136/bmjopen-2019-036125 [doi]
AB  - INTRODUCTION: Chronic inflammation is increasingly recognised as a major
      contributor to disease, disability and ultimately death, but measuring the levels
      of chronic inflammation remains non-canonised, making it difficult to relate
      chronic inflammation and mortality. Soluble urokinase plasminogen activator
      receptor (suPAR), an emerging biomarker of chronic inflammation, has been
      proposed as a prognostic biomarker associated with future incidence of chronic
      disease and mortality in general as well as patient populations. Proper
      prognostic biomarkers are important as they can help improve risk stratification 
      in clinical settings and provide guidance in treatment or lifestyle decisions as 
      well as in the design of randomised trials. Here, we wish to summarise the
      evidence about the overall association of the biomarker suPAR with mortality in
      healthy, general and patient populations across diseases. METHODS AND ANALYSIS:
      The search will be conducted using Medline, Embase and Scopus databases from
      their inception to 03 June 2020 to identify studies investigating 'suPAR' and
      'mortality'. Observational studies and control groups from intervention studies
      written in English or Danish will be included. The 'Quality In Prognosis Studies'
      tool will be used to assess the risk of bias for the studies included. Unadjusted
      and adjusted mortality outcome measures (eg, risk ratios, ORs, HRs) with 95% CIs 
      will be extracted for healthy individuals, general and patient populations. The
      primary outcome is all-cause mortality within any given follow-up. Subgroup
      analyses will be performed based on time of outcome, cause of death, population
      type, adjustments for conventional risk factors and inflammation markers. ETHICS 
      AND DISSEMINATION: This systematic review will synthesise evidence on the use of 
      suPAR as a prognostic marker for mortality. The results will be disseminated by
      publication in a peer-reviewed journal. Data used will be obtained from published
      studies, and ethics approval is therefore not necessary for this systematic
      review. TRIAL REGISTRATION NUMBER PROSPERO: CRD42020167401.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Petersen, Jens Emil Vang
AU  - Petersen JEV
AD  - Division of Infectious Diseases, Duke University School of Medicine, Durham,
      North Carolina, USA.
FAU - Kallemose, Thomas
AU  - Kallemose T
AD  - Department of Clinical Research, Copenhagen University Hospital Amager and
      Hvidovre, Hvidovre, Denmark.
FAU - Barton, Karen D
AU  - Barton KD
AD  - Duke University Medical Center Library & Archives, Duke University, Durham, North
      Carolina, USA.
FAU - Caspi, Avshalom
AU  - Caspi A
AD  - Department of Psychology and Neuroscience, Duke University, Durham, North
      Carolina, USA.
AD  - Department of Psychiatry and Behavioral Sciences, Duke University School of
      Medicine, Durham, North Carolina, USA.
AD  - Center for Genomic and Computational Biology, Duke University, Durham, North
      Carolina, USA.
AD  - Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry,
      Psychology, and Neuroscience, King's College London, London, UK.
FAU - Rasmussen, Line Jee Hartmann
AU  - Rasmussen LJH
AUID- ORCID: 0000-0001-6613-2469
AD  - Department of Clinical Research, Copenhagen University Hospital Amager and
      Hvidovre, Hvidovre, Denmark line.jee.hartmann.rasmussen@duke.edu.
AD  - Department of Psychology and Neuroscience, Duke University, Durham, North
      Carolina, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
SB  - IM
MH  - Biomarkers
MH  - Humans
MH  - *Inflammation
MH  - Prognosis
MH  - Receptors, Urokinase Plasminogen Activator
MH  - Risk Factors
PMC - PMC7371134
OTO - NOTNLM
OT  - *clinical chemistry
OT  - *epidemiology
OT  - *immunology
OT  - *preventive medicine
OT  - *public health
OT  - *statistics and research methods
COIS- Competing interests: LJHR has received funding for travel outside the submitted
      work from ViroGates A/S.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036125 [pii]
AID - 10.1136/bmjopen-2019-036125 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036125. doi: 10.1136/bmjopen-2019-036125.


PMID- 32690514
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Effectiveness of psychological interventions on mental health, quality of life
      and relationship satisfaction for individuals and/or couples undergoing fertility
      treatment: a systematic review and meta-analysis protocol.
PG  - e036030
LID - 10.1136/bmjopen-2019-036030 [doi]
AB  - INTRODUCTION: Infertility is a global public health problem affecting men, women 
      and couples worldwide. The medical implications of infertility are often of
      primary focus in healthcare settings, but the experience of infertility also has 
      a considerable social, emotional and psychological impact. Interventions aimed at
      alleviating psychological symptoms in individual and/or couples undergoing
      fertility treatment requires a systematic and comprehensive review of the
      literature to determine the efficacy of psychological interventions. The
      objective of this review is to evaluate the effectiveness, feasibility and
      acceptability of psychological interventions for individuals and/or couples
      seeking fertility to treat anxiety, depression, distress, quality of life and
      relationship satisfaction, as well as improve pregnancy rates. METHODS AND
      ANALYSIS: The search strategy will involve 11 databases, including MEDLINE(R) and
      Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily (Ovid),
      EMBASE (Ovid), PsycINFO (Ovid), Cochrane Central Register of Controlled Trials
      (OVID), The Cumulative Index to Nursing and Allied Health Literature (CINAHL)
      with Full Text (EBSCO), Social Work Abstracts (EBSCO), SocINDEX with Full Text
      (EBSCO), Academic Search Complete (EBSCO), Family & Society Studies Worldwide
      (EBSCO), Family Studies Abstracts (EBSCO) and Scopus. These databases will be
      searched from their inception to September 2019. Independent reviewers will
      search peer-reviewed published studies through electronic databases and
      additional sources, will extract the data and assess the methodological quality. 
      Random-effects meta-analysis will be carried out by calculating effect sizes as
      Cohen's d indices. Heterogeneity will be examined by the I(2) and the Q
      statistics. ETHICS AND DISSEMINATION: The current review does not require ethics 
      approval. The results will be disseminated through publications in peer-reviewed 
      journals. PROSPERO REGISTRATION NUMBER: CRD42019133757.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bright, Katherine
AU  - Bright K
AUID- ORCID: 0000-0002-6607-7655
AD  - Department of Nursing, University of Calgary, Calgary, Alberta, Canada
      ksbright@ucalgary.ca.
AD  - Department of Outpatient Psychiatry, Alberta Health Services, Calgary, Alberta,
      Canada.
FAU - Dube, Loveness
AU  - Dube L
AD  - Department of Psychology, University of Regina, Regina, Saskatchewan, Canada.
FAU - Hayden, K Alix
AU  - Hayden KA
AD  - Department of Libraries and Cultural Resources, University of Calgary, Calgary,
      Alberta, Canada.
FAU - Gordon, Jennifer L
AU  - Gordon JL
AD  - Department of Psychology, University of Regina, Regina, Saskatchewan, Canada.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mental Health
MH  - Personal Satisfaction
MH  - Pregnancy
MH  - Psychosocial Intervention
MH  - *Quality of Life
MH  - Research Design
PMC - PMC7371139
OTO - NOTNLM
OT  - *mental health
OT  - *reproductive medicine
OT  - *subfertility
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036030 [pii]
AID - 10.1136/bmjopen-2019-036030 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036030. doi: 10.1136/bmjopen-2019-036030.


PMID- 32690513
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Can changes in spending on health and social care explain the recent mortality
      trends in Scotland? A protocol for an observational study.
PG  - e036025
LID - 10.1136/bmjopen-2019-036025 [doi]
AB  - INTRODUCTION: There have been steady reductions in mortality rates in the
      majority of high-income countries, including Scotland, since 1945. However,
      reductions in mortality rates have slowed down since 2012-2014 in these nations; 
      and have reversed in some cases. Deaths among those aged 55+ explain a large
      amount of these changing mortality trends in Scotland. Increased pressures on
      health and social care services have been suggested as one factor explaining
      these changes. This paper outlines a protocol for the approach to testing the
      extent to which health and social care pressures can explain recent mortality
      trends in Scotland. Although a slower rate of mortality improvements have
      affected people of all ages, certain ages have been more negatively affected than
      the others. The current analyses will be run by age-band to test if the service
      pressure-mortality link varies across age-group. METHODS AND ANALYSIS: This will 
      be an observational ecological study based on the Scottish population. The
      exposures of interest will be the absolute (primary outcome) and percentage
      (secondary outcome) change in real terms per capita spending on social and
      healthcare services between 2011 and 2017. The outcome of interest will be the
      absolute (primary outcome) and percentage (secondary outcome) change in
      age-standardised mortality rate between 2012 and 2018 for men and women
      separately. The units of analysis will be the 32 local authorities and the 14
      territorial health boards. The analyses will be run for both all age-groups
      combined and for the following age bands: <1, 1-15, 16-44, 45-64, 65-74, 75-84
      and 85+.A series of descriptive analyses will summarise the distribution of
      health and social care expenditure and mortality trends between 2011 and 2018.
      Linear regression analysis will be used to investigate the direct association
      between health care spending and mortality rates. ETHICS AND DISSEMINATION: The
      data used in this study will be publicly available and aggregated and will not be
      individually identifiable; therefore, ethical committee approval is not needed.
      This work will not result in the creation of a new data set. On completion, the
      study will be stored within the National Health Service research governance
      system. All of the results will be published once they have been shared with
      partner agencies.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wraw, Christina
AU  - Wraw C
AUID- ORCID: 0000-0002-7473-2138
AD  - Public Health Observatory, NHS Health Scotland, Edinburgh, UK
      christina.wraw@nhs.net.
FAU - Minton, Jon
AU  - Minton J
AD  - Public Health Observatory, NHS Health Scotland, Glasgow, UK.
FAU - Mitchell, Rory
AU  - Mitchell R
AD  - Public Health Observatory, NHS Health Scotland, Edinburgh, UK.
FAU - Wyper, Grant M A
AU  - Wyper GMA
AD  - Evaluation, NHS Health Scotland, Glasgow, UK.
FAU - Campbell, Clare
AU  - Campbell C
AD  - Cameron House, NHS Fife, Fife, UK.
FAU - McCartney, Gerry
AU  - McCartney G
AUID- ORCID: 0000-0001-6341-3521
AD  - Public Health Observatory, NHS Health Scotland, Glasgow, UK.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Delivery of Health Care
MH  - Female
MH  - *Health Expenditures
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Scotland/epidemiology
MH  - Social Support
MH  - State Medicine
MH  - Young Adult
PMC - PMC7371127
OTO - NOTNLM
OT  - *epidemiology
OT  - *health economics
OT  - *health services administration & management
OT  - *preventive medicine
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - bmjopen-2019-036025 [pii]
AID - 10.1136/bmjopen-2019-036025 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e036025. doi: 10.1136/bmjopen-2019-036025.


PMID- 32690511
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Empathy variation of undergraduate medical students after early clinical contact:
      a cross-sectional study in China.
PG  - e035690
LID - 10.1136/bmjopen-2019-035690 [doi]
AB  - OBJECTIVES: Empathy education is very important for medical students. There is
      little research on the influence of early clinical practice on the development of
      empathy and other aspects of professionalism in medical students. The aim of this
      study was to compare the self-reported empathy levels of first-year and
      second-year undergraduate medical students before and after their early clinical 
      contact curriculum. SETTING: The study was conducted at the Shanghai University
      of Medicine & Health Sciences, Shanghai, China. PARTICIPANTS: A total of 257
      undergraduate medical students participated in the study. The 154 first-year
      students were studying in 10 community-based teaching hospitals, and the 103
      second-year students were studying in 3 university-affiliated hospitals. PRIMARY 
      AND SECONDARY OUTCOME MEASURES: Primary measures: the Jefferson Scale of
      Empathy-Student version (JSE-S) was compared between students of different sexes 
      and in different academic years before their early clinical contact course.
      Secondary measures: comparisons were made after they finished the curriculum 3
      weeks later. RESULTS: A total of 219 of 257 students responded (85.21% response
      rate), and 214 answers could be analysed (135 first-year and 79 second-year
      students; 120 female and 94 male individuals). No significant differences in the 
      empathy scores before early clinical contact were observed between students of
      different sexes and in different academic years. After early clinical contact,
      the mean JSE-S score of the participants was significantly higher than the mean
      score at the beginning of the curriculum. CONCLUSIONS: Empathy-focused training
      during early clinical contact can improve the empathetic capacity of
      undergraduate medical students. Fostering empathetic attitudes among
      undergraduate medical students is necessary for the early stage of their medical 
      education. Further research is needed on the long-term effects of empathy-focused
      education in entry-level medical students.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ye, Xiong
AU  - Ye X
AD  - School of Clinical Medicine, Shanghai University of Medicine & Health Sciences,
      Shanghai, China.
FAU - Guo, Haiying
AU  - Guo H
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Xu, Zhou
AU  - Xu Z
AD  - Education Department, Shanghai General Hospital, Shanghai Jiao Tong University,
      Shanghai, China.
FAU - Xiao, Hui
AU  - Xiao H
AUID- ORCID: 0000-0002-1465-4596
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Jiao Tong
      University, Shanghai, China xiaohui771210@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - China
MH  - Cross-Sectional Studies
MH  - Education, Medical, Undergraduate/*methods
MH  - *Empathy
MH  - Female
MH  - Hospitals, Teaching
MH  - Humans
MH  - Male
MH  - Students, Medical/*psychology
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7371130
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *medical education & training
OT  - *medical ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035690 [pii]
AID - 10.1136/bmjopen-2019-035690 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e035690. doi: 10.1136/bmjopen-2019-035690.


PMID- 32690508
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20220525
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Effect of an innovative behavioural change strategy and small-quantity
      lipid-based nutrient supplements on stunting and obesity in children in Baja
      Verapaz, Guatemala: protocol for a randomised control trial.
PG  - e035528
LID - 10.1136/bmjopen-2019-035528 [doi]
AB  - INTRODUCTION: In Latin America, a rapid increase in obesity alongside persistent 
      malnutrition has resulted in a double burden of disease that affects the most
      vulnerable segments of the population. Infant and young child feeding practices
      are important factors that affect both sides of the growth curve. Interventions
      such as behavioural change strategies and home fortification using products like 
      small-quantity lipid-based nutrient supplements (SQ-LNS) have the potential to
      reduce the presence of both these conditions, especially if they are implemented 
      during the first 1000 days of life. This paper details the protocol for Sustained
      Programme for Improving Nutrition (SPOON), an innovative strategy to prevent
      stunting and reduce risk for obesity in children under 24 months old in
      high-poverty areas in Baja Verapaz, Guatemala. METHODS AND ANALYSIS: SPOON
      Guatemala is a three-arm randomised control trial: treatment group 1 will receive
      the SPOON behavioural change strategy and SQ-LNS, treatment group 2 will receive 
      the SPOON behavioural change strategy and micronutrient powders; the control
      group will receive the standard of care provided by the Ministry of Health, which
      includes micronutrient powders. A modified formula of SQ-LNS has been especially 
      developed for this trial. A total of 76 communities are included in the study and
      1628 households with a pregnant woman in the third trimester or a child under 4.5
      months were recruited at baseline. Baseline data were collected between September
      and November 2018. Follow-up data will be collected 2 years after the start of
      the intervention. The primary outcomes of interest are related to mothers' infant
      feeding knowledge and practice, and indicators of children's nutritional status
      and growth including height, weight, weight gain rate and prevalence of stunting,
      overweight, obesity and anaemia. After follow-up data have been collected,
      differences of simple means and regression models including covariates such as
      child's age and sex, characteristics of the primary caregiver and household
      socioeconomic indicators will be estimated. Heterogeneous effects will also be
      estimated within subgroups of age at exposure, sex, caregiver characteristics and
      household socioeconomic status. ETHICS AND DISSEMINATION: This study was approved
      by the National Health Ethics Committee of the Ministry of Health of Guatemala
      (resolution 10-2018). Informed consent was obtained from all mothers and
      caregivers prior to enrolment in the programme. Results will be submitted to a
      peer-reviewed medical or public health journal, and disseminated internally at
      the Inter-American Development Bank, with the Government and Stakeholders in
      Guatemala and through international conferences and seminars. TRIAL REGISTRATION 
      NUMBER: NCT03399617.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gonzalez Acero, Carolina
AU  - Gonzalez Acero C
AD  - Social Protection and Health Division, Inter- American Development Bank,
      Washington, District of Columbia, USA.
FAU - Martinez, Sebastian
AU  - Martinez S
AUID- ORCID: 0000-0002-7651-6674
AD  - Office of Strategic Planning and Development Effectiveness, Inter- American
      Development Bank, Washington, District of Columbia, USA SMARTINEZ@iadb.org.
FAU - Perez-Exposito, Ana
AU  - Perez-Exposito A
AD  - Social Protection and Health Division, Inter- American Development Bank,
      Washington, District of Columbia, USA.
FAU - Winters, Solis
AU  - Winters S
AD  - Office of Strategic Planning and Development Effectiveness, Inter- American
      Development Bank, Washington, District of Columbia, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03399617
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Dietary Fats)
RN  - 0 (Micronutrients)
SB  - IM
EIN - BMJ Open. 2022 May 24;12(5):e035528corr1. PMID: 35613824
MH  - Anemia/prevention & control
MH  - Dietary Fats/*administration & dosage
MH  - Dietary Supplements
MH  - Feeding Behavior
MH  - Female
MH  - Growth Disorders/*prevention & control
MH  - Guatemala
MH  - Health Education/methods
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Infant
MH  - Male
MH  - Malnutrition/prevention & control
MH  - Micronutrients/administration & dosage
MH  - Pediatric Obesity/*prevention & control
MH  - Pregnancy
PMC - PMC7371136
OTO - NOTNLM
OT  - *community child health
OT  - *nutrition
OT  - *nutritional support
COIS- Competing interests: All authors were employed by the Inter-American Development 
      Bank at the time of the study's conception and implementation. AP-E reports
      grants from PepsiCo Foundation, grants from The Government of Japan, provided to 
      the Inter-American Development Bank to implement and evaluate the SPOON
      ProgramProgramme. AP-E was a staff and subsequently a paid consultant for SPOON
      at the Inter-American Development Bank. All opinions in this paper are those of
      the authors and do not necessarily represent the views of the Government of
      Guatemala or the Inter-American Development Bank, its Executive Directors or the 
      governments they represent.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035528 [pii]
AID - 10.1136/bmjopen-2019-035528 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e035528. doi: 10.1136/bmjopen-2019-035528.


PMID- 32690507
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Abductor muscle strength deficit in patients after total hip arthroplasty for hip
      osteoarthritis: a protocol for a systematic review and meta-analysis.
PG  - e035413
LID - 10.1136/bmjopen-2019-035413 [doi]
AB  - INTRODUCTION: Conservation of abductor muscle strength is directly associated
      with physical function after total hip replacement (THA). Although many studies
      have tried to explore and quantify a potential abductor muscle strength deficit
      after THA as well as identify possible causes and treatment options, this topic
      has not been addressed systematically. METHODS AND ANALYSIS: Human-based studies 
      reporting measurements of hip abductor strength will be included in this review. 
      Studies reporting on hip abductor strength measured manually or isometric
      measurements at an abduction angle other than 0 degrees will not be considered.
      No restriction will be placed on study design, publication date operative
      approach, prosthesis design, age and sex of the patients or severity of OA. Data 
      sources will be Embase via embase.com, Medline ALL via Ovid and the Cochrane
      Central Register of Controlled Trials. The preliminary search was conducted on 5 
      May 2019. Data regarding absolute values or torque ratio of hip abductor torque
      between sides as well as patient demographic data, surgical approaches and
      rehabilitation protocols will be extracted. The assessment of quality and risk of
      bias will be performed with the modified Newcastle-Ottawa Scale. The screening,
      data extraction and quality assessment will be performed by two reviewers
      independently. Where necessary, a third review author will make a final
      judgement. Narrative synthesis as well as tabular presentation of the extracted
      data will be included. Whenever possible, metaregression and subgroup specific
      meta-analyses will be used to investigate the influence of time since THA and
      type of measurement (isokinetic or isometric) on the different outcomes. In case 
      of sufficient information, these analyses will be extended to include
      characteristics such as age, sex, surgical approach or rehabilitation programme. 
      ETHICS AND DISSEMINATION: No ethics approval is required. The results will be
      disseminated through peer-reviewed publications and conference presentations.
      PROSPERO REGISTRATION NUMBER: CRD42020153185.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ismailidis, Petros
AU  - Ismailidis P
AUID- ORCID: 0000-0003-1551-7902
AD  - Department of Orthopaedics and Traumatology, University Hospital of Basel, Basel,
      Switzerland petrosismailidis@gmail.com.
AD  - Department of Clinical Research, University of Basel, Basel, Switzerland.
FAU - Kvarda, Peter
AU  - Kvarda P
AUID- ORCID: 0000-0002-1623-4712
AD  - Department of Orthopaedics and Traumatology, University Hospital of Basel, Basel,
      Switzerland.
AD  - Department of Orthopaedic Surgery and Traumatology, Kantonsspital Baselland,
      Bruderholz, Basel-Landschaft, Switzerland.
FAU - Vach, Werner
AU  - Vach W
AD  - Department of Orthopaedics and Traumatology, University Hospital of Basel, Basel,
      Switzerland.
FAU - Appenzeller-Herzog, Christian
AU  - Appenzeller-Herzog C
AUID- ORCID: 0000-0001-7430-294X
AD  - University Medical Library, University of Basel, Basel, Switzerland.
FAU - Mundermann, Annegret
AU  - Mundermann A
AD  - Department of Orthopaedics and Traumatology, University Hospital of Basel, Basel,
      Switzerland.
AD  - Department of Clinical Research, University of Basel, Basel, Switzerland.
AD  - Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arthroplasty, Replacement, Hip/*adverse effects/*rehabilitation
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - *Muscle Strength
MH  - Muscle, Skeletal/*physiopathology
MH  - Osteoarthritis, Hip/rehabilitation/surgery
MH  - Systematic Reviews as Topic
PMC - PMC7371135
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *hip
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035413 [pii]
AID - 10.1136/bmjopen-2019-035413 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e035413. doi: 10.1136/bmjopen-2019-035413.


PMID- 32690505
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Universal mental health screening with a focus on suicidal behaviour using
      smartphones in a Mexican rural community: protocol for the SMART-SCREEN
      population-based survey.
PG  - e035041
LID - 10.1136/bmjopen-2019-035041 [doi]
AB  - INTRODUCTION: Mental disorders represent the second cause of years lived with
      disability worldwide. Suicide mortality has been targeted as a key public health 
      concern by the WHO. Smartphone technology provides a huge potential to develop
      massive and fast surveys. Given the vast cultural diversity of Mexico and its
      abrupt orography, smartphone-based resources are invaluable in order to
      adequately manage resources, services and preventive measures in the population. 
      The objective of this study is to conduct a universal suicide risk screening in a
      rural area of Mexico, measuring also other mental health outcomes such as
      depression, anxiety and alcohol and substance use disorders. METHODS AND
      ANALYSIS: A population-based cross-sectional study with a temporary sampling
      space of 9 months will be performed between September 2019 and June 2020. We
      expect to recruit a large percentage of the target population (at least 70%) in a
      short-term survey of Milpa Alta Delegation, which accounts for 137 927
      inhabitants in a territorial extension of 288 km(2).They will be recruited via an
      institutional call and a massive public campaign to fill in an online
      questionnaire through mobile-assisted or computer-assisted web app. This
      questionnaire will include data on general health, validated questionnaires
      including Well-being Index 5, Patient Health Questionnaire-9, Generalized Anxiety
      Disorder Scale 2, Alcohol Use Disorders Identification Test, selected questions
      of the Drug Abuse Screening Test and Columbia-Suicide Severity Rating Scales and 
      Diagnostic and statistical manual of mental disorders (DSM-5) questions about
      self-harm.We will take into account information regarding time to mobile app
      response and geo-spatial location, and aggregated data on social, demographical
      and environmental variables. Traditional regression modelling, multilevel mixed
      methods and data-driven machine learning approaches will be used to test
      hypotheses regarding suicide risk factors at the individual and the population
      level. ETHICS AND DISSEMINATION: Ethical approval (002/2019) was granted by the
      Ethics Review Board of the Hospital Psiquiatrico Yucatan, Yucatan (Mexico). This 
      protocol has been registered in ClinicalTrials.gov. The starting date of the
      study is 3 September 2019. Results will serve for the planning and healthcare of 
      groups with greater mental health needs and will be disseminated via publications
      in peer-reviewed journal and presented at relevant mental health conferences.
      TRIAL REGISTRATION NUMBER: NCT04067063.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arenas-Castaneda, Pavel E
AU  - Arenas-Castaneda PE
AD  - Secretaria de Salud de la Ciudad de Mexico, Jurisdiccion Sanitaria Milpa Alta,
      Milpa Alta, Mexico.
FAU - Aroca Bisquert, Fuensanta
AU  - Aroca Bisquert F
AD  - Instituto de Matematicas. Unidad de Cuernavaca. Universidad Nacional Autonoma de 
      Mexico, Cuernavaca, Mexico.
AD  - CNRS-UMI 4584 - LaSoL Laboratorio Internacional Solomon Lefschetz, Ciudad de
      Mexico, Mexico.
FAU - Martinez-Nicolas, Ismael
AU  - Martinez-Nicolas I
AD  - Faculty of Life Sciences, Catholic University of Murcia (UCAM), Murcia, Spain.
FAU - Castillo Espindola, Luis A
AU  - Castillo Espindola LA
AD  - Hospital General de Milpa Alta, Milpa Alta, Mexico.
FAU - Barahona, Igor
AU  - Barahona I
AD  - Catedra-Conacyt, Instituto de Matematicas, Unidad de Cuernavaca, Universidad
      Nacional Autonoma de Mexico, Cuernavaca, Mexico.
FAU - Maya-Hernandez, Cynthya
AU  - Maya-Hernandez C
AD  - Center for Evaluation and Surveys Research, National Institute of Public Health
      (INSP), Cuernavaca, Mexico.
FAU - Lavana Hernandez, Martha Miriam
AU  - Lavana Hernandez MM
AD  - Secretaria de Salud de la Ciudad de Mexico, Jurisdiccion Sanitaria Milpa Alta,
      Milpa Alta, Mexico.
FAU - Manrique Miron, Paulo Cesar
AU  - Manrique Miron PC
AD  - Catedra-Conacyt, Instituto de Matematicas, Unidad de Cuernavaca, Universidad
      Nacional Autonoma de Mexico, Cuernavaca, Mexico.
FAU - Alvarado Barrera, Daniela Guadalupe
AU  - Alvarado Barrera DG
AD  - Secretaria de Salud de la Ciudad de Mexico, Jurisdiccion Sanitaria Milpa Alta,
      Milpa Alta, Mexico.
FAU - Trevino Aguilar, Erik
AU  - Trevino Aguilar E
AD  - Instituto de Matematicas. Unidad de Cuernavaca. Universidad Nacional Autonoma de 
      Mexico, Cuernavaca, Mexico.
FAU - Barrios Nunez, Axayacatl
AU  - Barrios Nunez A
AD  - Servicios de Salud del Instituto de Educacion Media Superior CDMX, Ciudad de
      Mexico, Mexico.
FAU - De Jesus Carlos, Giovanna
AU  - De Jesus Carlos G
AD  - Instituto de Matematicas. Unidad de Cuernavaca. Universidad Nacional Autonoma de 
      Mexico, Cuernavaca, Mexico.
FAU - Vildosola Garces, Anabel
AU  - Vildosola Garces A
AD  - Servicios de Salud del Instituto de Educacion Media Superior CDMX, Ciudad de
      Mexico, Mexico.
FAU - Flores Mercado, Josselyne
AU  - Flores Mercado J
AD  - Unidad de Medicina Familiar ISSSTE, Ciudad de Mexico, Mexico.
FAU - Barrigon, Maria Luisa
AU  - Barrigon ML
AD  - Psychiatry, Autonomous University of Madrid, Madrid, Spain.
AD  - Psychiatry, University Hospital Jimenez Diaz Foundation, Madrid, Spain.
FAU - Artes, Antonio
AU  - Artes A
AD  - Department of Signal Theory and Communications, Universidad Carlos III de Madrid,
      Leganes, Madrid, Spain.
AD  - CIBERSAM (Centro de Investigacion en Salud Mental), Carlos III Institute of
      Health, Madrid, Spain.
FAU - de Leon, Santiago
AU  - de Leon S
AD  - Department of Signal Theory and Communications, Universidad Carlos III de Madrid,
      Madrid, Spain.
FAU - Molina-Pizarro, Cristian Antonio
AU  - Molina-Pizarro CA
AD  - Yucatan State Mental Health Institute, Merida, Mexico.
FAU - Rosado Franco, Arsenio
AU  - Rosado Franco A
AD  - Yucatan State Mental Health Institute, Merida, Mexico.
FAU - Perez-Rodriguez, Mercedes
AU  - Perez-Rodriguez M
AD  - Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
FAU - Courtet, Philippe
AU  - Courtet P
AD  - Department of Emergency Psychiatry and Acute Care, University of Montpellier,
      Hopital Lapeyronie, CHU Montpellier, Montpellier, France.
FAU - Martinez-Ales, Gonzalo
AU  - Martinez-Ales G
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA.
FAU - Baca-Garcia, Enrique
AU  - Baca-Garcia E
AUID- ORCID: 0000-0002-6963-6555
AD  - Psychiatry, Autonomous University of Madrid, Madrid, Spain ebacgar2@yahoo.es.
AD  - Psychiatry, University Hospital Jimenez Diaz Foundation, Madrid, Spain.
AD  - Universidad Catolica del Maule, Talca, Chile.
AD  - CIBERSAM, Madrid, Spain.
AD  - Department of psychiatry, Centre Hospitalier Universitaire de Nimes, Nimes,
      France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04067063
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Internet
MH  - Mental Disorders/*epidemiology
MH  - Mental Health
MH  - Mexico/epidemiology
MH  - Rural Population
MH  - *Smartphone
MH  - *Suicidal Ideation
MH  - Suicide/statistics & numerical data
MH  - *Surveys and Questionnaires
PMC - PMC7371217
OTO - NOTNLM
OT  - *health surveys
OT  - *mass screening
OT  - *mental health
OT  - *smartphone
OT  - *suicidal ideation
COIS- Competing interests: EBG designed the MeMind application.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035041 [pii]
AID - 10.1136/bmjopen-2019-035041 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e035041. doi: 10.1136/bmjopen-2019-035041.


PMID- 32690503
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Behaviour change physiotherapy intervention to increase physical activity
      following hip and knee replacement (PEP-TALK): study protocol for a pragmatic
      randomised controlled trial.
PG  - e035014
LID - 10.1136/bmjopen-2019-035014 [doi]
AB  - INTRODUCTION: While total hip replacement (THR) and total knee replacement (TKR) 
      successfully reduce pain associated with chronic joint pathology, this
      infrequently translates into increased physical activity. This is a challenge
      given that over 50% of individuals who undergo these operations are physically
      inactive and have medical comorbidities such as hypertension, heart disease,
      diabetes and depression. The impact of these diseases can be reduced with
      physical activity. This trial aims to investigate the effectiveness of a
      behaviour change physiotherapy intervention to increase physical activity
      compared with usual rehabilitation after THR or TKR. METHODS AND ANALYSIS: The
      PEP-TALK trial is a multicentre, open-labelled, pragmatic randomised controlled
      trial. 260 adults who are scheduled to undergo a primary unilateral THR or TKR
      and are moderately inactive or inactive, with comorbidities, will be recruited
      across eight sites in England. They will be randomised post-surgery, prior to
      hospital discharge, to either six, 30 min weekly group-based exercise sessions
      (control), or the same six weekly, group-based, exercise sessions each preceded
      by a 30 min cognitive behaviour approach discussion group. Participants will be
      followed-up to 12 months by postal questionnaire. The primary outcome is the
      University of California, Los Angeles (UCLA) Physical Activity Score at 12
      months. Secondary outcomes include: physical function, disability, health-related
      quality of life, kinesiophobia, perceived pain, self-efficacy and health resource
      utilisation. ETHICS AND DISSEMINATION: Research ethics committee approval was
      granted by the NRES Committee South Central (Oxford B - 18/SC/0423).
      Dissemination of results will be through peer-reviewed, scientific journals and
      conference presentations. TRIAL REGISTRATION NUMBER: ISRCTN29770908.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Smith, Toby O
AU  - Smith TO
AUID- ORCID: 0000-0003-1673-2954
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK toby.smith@ndorms.ox.ac.uk.
AD  - Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
FAU - Parsons, Scott
AU  - Parsons S
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Fordham, Beth
AU  - Fordham B
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Ooms, Alexander
AU  - Ooms A
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
AD  - Oxford Clinical Trials Unit, University of Oxford, Oxford, UK.
FAU - Dutton, Susan
AU  - Dutton S
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
AD  - Oxford Clinical Trials Unit, University of Oxford, Oxford, UK.
AD  - CSM, University of Oxford, Oxford, UK.
FAU - Hing, Caroline
AU  - Hing C
AD  - University of London St George's Molecular and Clinical Sciences Research
      Institute, London, UK.
FAU - Barber, Vicki S
AU  - Barber VS
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
AD  - Oxford Clinical Trials Unit, University of Oxford, Oxford, UK.
FAU - Png, May Ee
AU  - Png ME
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
AD  - Oxford Clinical Trials Unit, University of Oxford, Oxford, UK.
FAU - Lamb, Sarah
AU  - Lamb S
AD  - College of Medicine and Health Sciences, University of Exeter, Exeter, Devon, UK.
CN  - PEP-TALK Trial Collaborators
LA  - eng
SI  - ISRCTN/ISRCTN29770908
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arthroplasty, Replacement, Hip/psychology/*rehabilitation
MH  - Arthroplasty, Replacement, Knee/psychology/*rehabilitation
MH  - Cognitive Behavioral Therapy/*methods
MH  - Comorbidity
MH  - England
MH  - Exercise
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Multicenter Studies as Topic
MH  - Pragmatic Clinical Trials as Topic
MH  - Recovery of Function
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC7371148
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *hip
OT  - *knee
COIS- Competing interests: None declared.
IR  - Algar S
FIR - Algar, Steve
IR  - Hansen Z
FIR - Hansen, Zara
IR  - Karen IS
FIR - Karen, Ian Smith
IR  - McNamara I
FIR - McNamara, Iain
IR  - Dunn M
FIR - Dunn, Michael
IR  - Locke D
FIR - Locke, Dawn
IR  - Driver S
FIR - Driver, Sonny
IR  - Kassam J
FIR - Kassam, Jamila
IR  - Penny P
FIR - Penny, Peter
IR  - Woodhouse C
FIR - Woodhouse, Celia
IR  - Potter T
FIR - Potter, Tracey
IR  - Daniell H
FIR - Daniell, Helena
IR  - Herring A
FIR - Herring, Alex
IR  - Cunningham Y
FIR - Cunningham, Yan
IR  - Afzal I
FIR - Afzal, Irrum
IR  - Matharu M
FIR - Matharu, Maninderpal
IR  - Hughes T
FIR - Hughes, Tamsin
IR  - Hannink E
FIR - Hannink, Erin
IR  - Moynihan M
FIR - Moynihan, Michelle
IR  - Deehan D
FIR - Deehan, David
IR  - Godfrey E
FIR - Godfrey, Emma
IR  - Artz N
FIR - Artz, Neil
IR  - Algar S
FIR - Algar, Steve
IR  - Smith L
FIR - Smith, Lindsey
IR  - Mistry D
FIR - Mistry, Dipesh
IR  - Baker P
FIR - Baker, Paul
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035014 [pii]
AID - 10.1136/bmjopen-2019-035014 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e035014. doi: 10.1136/bmjopen-2019-035014.


PMID- 32690499
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in
      NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT
      imaging and biological markers (SENECA trial): a study protocol.
PG  - e034393
LID - 10.1136/bmjopen-2019-034393 [doi]
AB  - INTRODUCTION: Patients with metastatic or locally advanced, non-resectable, grade
      3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine
      carcinomas (NECs) are usually treated with in first-line platinum compounds.
      There is no standard second-line treatment on progression. Accurate biomarkers
      are needed to facilitate diagnosis and prognostic assessment of patients with
      NEC. METHODS AND ANALYSIS: The SEcond-line therapy in NEuroendocrine CArcinomas
      (SENECA) study is a randomised, non-comparative, multicentre phase II trial
      designed to evaluate the efficacy and safety of folinic acid, 5-fluorouracil and 
      irinotecan (FOLFIRI) or capecitabine plus temozolomide (CAPTEM) regimens after
      failure of first-line chemotherapy in patients with lung NEC and GEP-NEC.
      Secondary aims are to correlate the serum miRNA profile and primary mutational
      status of MEN1, DAXX, ATRX and RB-1 with prognosis and outcome and to investigate
      the prognostic and predictive role of the Ki-67 score and 18-fluorodeoxyglucose
      positron emission tomography/computed tomography ((18)F-FDG PET/CT) or
      (68)Ga-PET/CT. The main eligibility criteria are age >/=18 years; metastatic or
      locally advanced, non-resectable, grade 3 lung or GEP-NECs; progression to
      first-line platinum-based chemotherapy. A Bryant and Day design taking into
      account treatment activity and toxicity was used to estimate the sample size. All
      analyses will be performed separately for each treatment group in the
      intention-to-treat population. A total of 112 patients (56/arm) will be randomly 
      assigned (1:1) to receive FOLFIRI every 14 days or CAPTEM every 28 days until
      disease progression or unacceptable toxicity or for a maximum of 6 months.
      Patients undergo testing for specific biomarkers in primary tumour tissue and for
      miRNA in blood samples. MiRNA profiling will be performed in the first 20
      patients who agree to participate in the biological substudy. ETHICS AND
      DISSEMINATION: The SENECA trial, supported by Istituto Scientifico Romagnolo per 
      lo Studio e la Cura dei Tumori (IRST), was authorised by the locals Ethics
      Committee and the Italian Medicines Agency (AIFA). Results will be widely
      disseminated via peer-reviewed manuscripts, conference presentations and reports 
      to relevant authorities.The study is currently open in Italy. TRAIL REGISTRATION 
      NUMBER: NCT03387592; Pre-results. EudraCT-2016-000767-17. PROTOCOL VERSION:
      Clinical Study Protocol Version 1, 7 November 2016.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bongiovanni, Alberto
AU  - Bongiovanni A
AUID- ORCID: 0000-0002-3845-4687
AD  - Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio
      e la Cura dei Tumori IRCCS, Meldola, Italy alberto.bongiovanni@irst.emr.it.
FAU - Liverani, Chiara
AU  - Liverani C
AD  - Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio
      e la Cura dei Tumori IRCCS, Meldola, Italy.
FAU - Pusceddu, Sara
AU  - Pusceddu S
AD  - Department of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei
      Tumori, Milano, Lombardia, Italy.
FAU - Leo, Silvana
AU  - Leo S
AD  - Oncology Unit, Ospedale Vito Fazzi, Lecce, Puglia, Italy.
FAU - Di Meglio, Giovanni
AU  - Di Meglio G
AD  - Oncology Unit, Ospedale di Bolzano, Bolzano, Trentino-Alto Adige, Italy.
FAU - Tamberi, Stefano
AU  - Tamberi S
AD  - Oncology Unit, Ospedale degli Infermi di Faenza, Faenza, Emilia-Romagna, Italy.
FAU - Santini, Daniele
AU  - Santini D
AD  - Department of Medical Oncology, Campus Bio-Medico University, Roma, Lazio, Italy.
FAU - Gelsomino, Fabio
AU  - Gelsomino F
AD  - Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di
      Modena, Modena, Emilia-Romagna, Italy.
FAU - Pucci, Francesca
AU  - Pucci F
AD  - Medical Oncology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
FAU - Berardi, Rossana
AU  - Berardi R
AD  - Oncology Clinic, University Hospital of Ancona Umberto I G M Lancisi G Salesi,
      Ancona, Marche, Italy.
FAU - Lolli, Ivan
AU  - Lolli I
AD  - Department of Oncology, Istituto Nazionale di Ricovero e Cura a Carattere
      Scientifico Saverio de Bellis, Castellana Grotte, Puglia, Italy.
FAU - Bergamo, Francesca
AU  - Bergamo F
AD  - Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto
      Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Veneto, Italy.
FAU - Ricci, Sergio
AU  - Ricci S
AD  - Internal Medicine and Medical Oncology, Santa Chiara Hospital, Pisa, Toscana,
      Italy.
FAU - Foca, Flavia
AU  - Foca F
AD  - Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo 
      Studio e la Cura dei Tumori IRCCS, Meldola, Italy.
FAU - Severi, Stefano
AU  - Severi S
AD  - Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei
      Tumori IRCCS, Meldola, Italy.
FAU - Ibrahim, Toni
AU  - Ibrahim T
AD  - Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio
      e la Cura dei Tumori IRCCS, Meldola, Italy.
CN  - SENECA Study Team Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT03387592
SI  - EudraCT/2016-000767-17
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
RN  - 0 (MicroRNAs)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - Biomarkers/*analysis
MH  - Capecitabine/adverse effects/therapeutic use
MH  - Carcinoma, Neuroendocrine/diagnostic imaging/*drug therapy
MH  - Clinical Trials as Topic
MH  - Fluorouracil/adverse effects/therapeutic use
MH  - Gastrointestinal Neoplasms/drug therapy
MH  - Humans
MH  - Irinotecan/adverse effects/therapeutic use
MH  - Italy
MH  - Leucovorin/adverse effects/therapeutic use
MH  - Lung Neoplasms/drug therapy
MH  - MicroRNAs/blood
MH  - Multicenter Studies as Topic
MH  - Pancreatic Neoplasms/drug therapy
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Temozolomide/adverse effects/therapeutic use
MH  - Treatment Outcome
PMC - PMC7371236
OTO - NOTNLM
OT  - *CAPTEM
OT  - *FOLFIRI
OT  - *capecitabine, temozolomide
OT  - *neuroendocrine carcinoma
OT  - *second-line
COIS- Competing interests: None declared.
IR  - Cives M
FIR - Cives, Mauro
IR  - Campana D
FIR - Campana, Davide
IR  - Silvestris N
FIR - Silvestris, Nicola
IR  - Buonadonna A
FIR - Buonadonna, Angela
IR  - Badalamenti G
FIR - Badalamenti, Giuseppe
IR  - Brizzi MP
FIR - Brizzi, Maria Pia
IR  - Berruti A
FIR - Berruti, Alfredo
IR  - Spada F
FIR - Spada, Francesca
IR  - Cingarlini S
FIR - Cingarlini, Sara
IR  - Antonuzzo L
FIR - Antonuzzo, Lorenzo
IR  - Pastorelli D
FIR - Pastorelli, Davide
IR  - Cives M
FIR - Cives, Mauro
IR  - Campana D
FIR - Campana, Davide
IR  - Silvestris N
FIR - Silvestris, Nicola
IR  - Buonadonna A
FIR - Buonadonna, Angela
IR  - Badalamenti G
FIR - Badalamenti, Giuseppe
IR  - Brizzi MP
FIR - Brizzi, Maria Pia
IR  - Berruti A
FIR - Berruti, Alfredo
IR  - Spada F
FIR - Spada, Francesca
IR  - Cingarlini S
FIR - Cingarlini, Sara
IR  - Antonuzzo L
FIR - Antonuzzo, Lorenzo
IR  - Pastorelli D
FIR - Pastorelli, Davide
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034393 [pii]
AID - 10.1136/bmjopen-2019-034393 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393.


PMID- 32690497
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Core outcome set for studies on pregnant women with vasa previa (COVasP): a study
      protocol.
PG  - e034018
LID - 10.1136/bmjopen-2019-034018 [doi]
AB  - INTRODUCTION: Vasa previa is a condition where fetal blood vessels run
      unprotected in the membranes, outside the umbilical cord, and cross the internal 
      opening of the cervix. During rupture of membranes, these vessels can rupture and
      put the baby at serious risk of severe blood loss and death. Numerous studies are
      being conducted to improve diagnostic modalities and establish clear management
      plans to improve pregnancy outcomes. However, the lack of a standardised set of
      outcomes for studies on vasa previa makes it difficult to compare study findings 
      and draw meaningful conclusions. Through this project, we will be developing a
      core outcome set for studies on pregnant women with vasa previa (COVasP). METHODS
      AND ANALYSIS: The development of COVasP will involve five steps. The first will
      be a systematic review, in which we will generate a long list of outcomes based
      on published studies in pregnancies complicated with vasa previa. The second will
      involve in-depth interviews with current and former patients, their family
      members and healthcare providers who care for these patients. This will be
      followed by a two-round Delphi survey, which will aim to narrow down the long
      list of outcomes into those considered important by four groups of
      'stakeholders': (1) patients, family members and patient
      advocates/representatives, (2) healthcare providers, (3) researchers,
      epidemiologists and methodologists and (4) other stakeholders directly or
      indirectly involved in the management of these pregnancies such as
      administrators, guideline developers and policymakers. The fourth step will
      involve a face-to-face consensus meeting using a nominal group approach to
      establish a finalised core outcome set. The final step will involve measuring and
      defining the identified outcomes using a combination of systematic reviews and
      Delphi surveys. ETHICS AND DISSEMINATION: This study as well as consent forms for
      stakeholder participation have received approval from the Mount Sinai Hospital
      Research Ethics Board (REB number 18-0173-E) on 05 September 2018 and the Human
      Research Ethics Committee at The University of Technology Sydney, Australia on 30
      July 2019 (UTS HREC reference number ETH19-3718). All progress will be documented
      on the international prospective register of systematic reviews and Core Outcome 
      Measures in Effectiveness Trials databases. REGISTRATION DETAILS:
      http://www.comet-initiative.org/studies/details/1117.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - D'Souza, Rohan
AU  - D'Souza R
AUID- ORCID: 0000-0002-4049-2017
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology,
      Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
      Rohan.DSouza@sinaihealthsystem.ca.
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Villani, Linda
AU  - Villani L
AD  - University of Utah School of Medicine, Salt Lake City, Utah, USA.
FAU - Hall, Chelsea
AU  - Hall C
AD  - Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Seyoum, Meron
AU  - Seyoum M
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology,
      Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
FAU - Kingdom, John
AU  - Kingdom J
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology,
      Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Krznaric, Michael
AU  - Krznaric M
AD  - International Vasa Previa Foundation, Chester, Illinois, United States.
FAU - Donnolley, Natasha
AU  - Donnolley N
AD  - International Vasa Previa Foundation, Chester, Illinois, United States.
AD  - The National Perinatal Epidemiology and Statistics Unit, Centre for Big Data
      Research in Health, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Javid, Nasrin
AU  - Javid N
AD  - Faculty of Health, University of Technology Sydney, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Consensus Development Conferences as Topic
MH  - Delphi Technique
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*diagnosis/*prevention & control
MH  - Pregnancy Outcome
MH  - Research Design
MH  - Stakeholder Participation
MH  - Systematic Reviews as Topic
MH  - Vasa Previa/*diagnosis/*prevention & control
PMC - PMC7371138
OTO - NOTNLM
OT  - *core outcome set
OT  - *stakeholder and patient-reported outcomes
OT  - *vasa previa
OT  - *velamentous cord insertion
COIS- Competing interests: MK and ND are directors and NJ is a member of the
      International Vasa Previa Foundation that has provided part funding for this
      project. RD has received speaking honoraria from Ferring, Canada for
      presentations unrelated to this project.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034018 [pii]
AID - 10.1136/bmjopen-2019-034018 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e034018. doi: 10.1136/bmjopen-2019-034018.


PMID- 32690496
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - Development of a core outcome set for studies on prevention and management of
      pregnancy-associated venous thromboembolism (COSPVenTE): a study protocol.
PG  - e034017
LID - 10.1136/bmjopen-2019-034017 [doi]
AB  - INTRODUCTION: Pregnancy and post partum are times of heightened risk for the
      development of venous thromboembolism (VTE), which in turn is one of the leading 
      causes of maternal mortality and long-term morbidity. The current research aimed 
      at improving health guidelines for women with pregnancy-associated VTE is limited
      by inconsistency in outcome reporting preventing comparison across studies, and
      lack of input from patients with respect to outcomes they propose are most
      important to measure. A suggested solution is the development of a core outcome
      set (COS) that defines the minimum criteria for outcome reporting in clinical
      trials and prospective studies. COSs function to facilitate data harmonisation
      and increase homogeneity in outcome reporting while incorporating the voice of
      women in this population in the planning of research to inform their ongoing
      care. METHODS AND ANALYSIS: The development of a COS for studies on
      pregnancy-associated VTE will comprise five steps. First, a systematic review of 
      the published literature will identify currently reported outcomes, their
      definitions and measurements if applicable. This will be followed by in-person
      interviews with patients, clinicians, researchers, hospital administrators and
      policy-makers to identify outcomes they consider important. Third, the long list 
      of outcomes obtained from steps I and II will be condensed through online Delphi 
      surveys involving an international group of relevant stakeholders including
      patients. This will be followed by a face-to-face consensus meeting with
      representatives of all stakeholder groups to arrive at a consensus on the final
      COS. Lastly, to determine how the identified core outcomes should be measured,
      another literature review and Delphi process will be carried out as necessary.
      ETHICS AND DISSEMINATION: This study has been approved by the Mount Sinai
      Hospital Research Ethics Board (REB 18-0314-E). Study results will be published
      in open-access journals and presented at obstetrics, maternal-fetal medicine and 
      haematology conferences. All progress will be documented on the international
      prospective register of systematic reviews (PROSPERO) and Core Outcome Measures
      in Effectiveness Trials databases. PROSPERO REGISTRATION NUMBER: CRD42019111479.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - King, Alexandria
AU  - King A
AD  - Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, Canada.
FAU - D'Souza, Rohan
AU  - D'Souza R
AUID- ORCID: 0000-0002-4049-2017
AD  - Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, Canada.
AD  - Obstetrics & Gynaecology, Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto,
      Ontario, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Teshler, Lizabeth
AU  - Teshler L
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Shehata, Nadine
AU  - Shehata N
AUID- ORCID: 0000-0002-9267-6256
AD  - Medicine and Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Medicine, Division of Haematology, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Malinowski, Ann K
AU  - Malinowski AK
AD  - Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, Canada
      Ann.Malinowski@sinaihealthsystem.ca.
AD  - Obstetrics & Gynaecology, Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto,
      Ontario, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Consensus Development Conferences as Topic
MH  - Delphi Technique
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Postpartum Period
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*prevention & control/*therapy
MH  - Research Design/*standards
MH  - Stakeholder Participation
MH  - Systematic Reviews as Topic
MH  - Venous Thromboembolism/*prevention & control/*therapy
PMC - PMC7371150
OTO - NOTNLM
OT  - *core outcome set
OT  - *pregnancy
OT  - *venous thromboembolism
COIS- Competing interests: RD'S has received speaking honoraria from Ferring, Canada
      for presentations unrelated to this topic. NS has received speaking honoraria
      from Sanofi.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034017 [pii]
AID - 10.1136/bmjopen-2019-034017 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e034017. doi: 10.1136/bmjopen-2019-034017.


PMID- 32690492
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 19
TI  - ALADDIN study: does assisted hatching of vitrified/warmed blastocysts improve
      live birth rate? Protocol for a multicentric randomised controlled trial.
PG  - e031544
LID - 10.1136/bmjopen-2019-031544 [doi]
AB  - INTRODUCTION: Recent data suggest a higher clinical pregnancy rate performing
      assisted hatching (AH) on previously cryopreserved embryos but fail to
      demonstrate significant effects on live birth rate. However, current evidence is 
      based on studies with a small sample size and may hide a type II error. Moreover,
      poor attention has been given to the specific effect of AH on frozen/thawed
      blastocysts. To shed light on this topic, we developed the present protocol for a
      randomised trial to investigate the benefits of the laser-mediated partial
      removal of the zona pellucida in vitrified/warmed blastocysts. METHODS AND
      ANALYSIS: The pArtiaL zonA pelluciDa removal by assisteD hatchINg of blastocysts 
      (ALADDIN) study is a multicentric prospective comparative study with a parallel
      randomised controlled design aiming to investigate whether AH performed on warmed
      blastocysts before embryo transfer can improve live birth rate. Women allocated
      to the control group will undergo embryo transfer of blastocysts not previously
      subjected to AH. Two infertility units will be involved in the study. Enrolment
      of patients will last 18 months with quarterly monitoring and the entire study is
      foreseen to be closed in 36 months. Secondary outcomes include: proportion of
      transferred blastocysts/thawed blastocyst, morphological features of blastocysts 
      before embryo transfer, implantation, biochemical pregnancy, clinical pregnancy
      (ultrasound visible gestational sac), miscarriage, multiple pregnancy, preterm
      birth (<37 weeks of gestation), obstetrical and neonatal complications and
      congenital anomaly rates. ETHICS AND DISSEMINATION: This protocol received a
      favourable ethical opinion from the Ethical Committee of IRCCS San Raffaele
      Scientific Institute and the Ethical Committee Area 2 Milan. Each participant
      will provide written consent to participate and remain encoded during the study. 
      The trial results will be published in peer-reviewed journals and presented at
      conferences. TRIAL REGISTRATION NUMBER: NCT03623659; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alteri, Alessandra
AU  - Alteri A
AUID- ORCID: 0000-0003-3092-3546
AD  - Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute,
      Milan, Italy alteri.alessandra@hsr.it.
FAU - Guarneri, Cristina
AU  - Guarneri C
AD  - Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico,
      Milan, Italy.
FAU - Corti, Laura
AU  - Corti L
AD  - Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute,
      Milan, Italy.
FAU - Restelli, Liliana
AU  - Restelli L
AD  - Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico,
      Milan, Italy.
FAU - Reschini, Marco
AU  - Reschini M
AD  - Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico,
      Milan, Italy.
FAU - Giardina, Paolo
AU  - Giardina P
AD  - Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute,
      Milan, Italy.
FAU - Papaleo, Enrico
AU  - Papaleo E
AD  - Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute,
      Milan, Italy.
AD  - Reproductive Sciences Laboratory, Obstetrics and Gynaecology Department, IRCCS
      San Raffaele Scientific Institute, Milan, Italy.
FAU - Somigliana, Edgardo
AU  - Somigliana E
AD  - Infertility Unit, Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico,
      Milan, Italy.
FAU - Vigano, Paola
AU  - Vigano P
AD  - Reproductive Sciences Laboratory, Obstetrics and Gynaecology Department, IRCCS
      San Raffaele Scientific Institute, Milan, Italy.
FAU - Paffoni, Alessio
AU  - Paffoni A
AUID- ORCID: 0000-0003-3112-3161
AD  - Infertility Unit, ASST Lariana, Cantu, Como, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT03623659
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200719
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Birth Rate
MH  - Blastocyst/*physiology
MH  - Cryopreservation/methods
MH  - Embryo Transfer/methods
MH  - Female
MH  - Fertilization in Vitro/methods
MH  - Humans
MH  - *Lasers
MH  - Multicenter Studies as Topic
MH  - Pregnancy
MH  - Prospective Studies
MH  - Zona Pellucida/physiology
PMC - PMC7371140
OTO - NOTNLM
OT  - *assisted hatching
OT  - *assisted reproductive technology
OT  - *blastocyst cryopreservation
OT  - *implantation failure
OT  - *zona pellucida
COIS- Competing interests: None declared.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-031544 [pii]
AID - 10.1136/bmjopen-2019-031544 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 19;10(7):e031544. doi: 10.1136/bmjopen-2019-031544.


PMID- 32690477
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220716
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 370
DP  - 2020 Jul 20
TI  - Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice.
PG  - m1668
LID - 10.1136/bmj.m1668 [doi]
AB  - Despite their ubiquitous presence, placebos and placebo effects retain an
      ambiguous and unsettling presence in biomedicine. Specifically focused on chronic
      pain, this review examines the effect of placebo treatment under three distinct
      frameworks: double blind, deception, and open label honestly prescribed. These
      specific conditions do not necessarily differentially modify placebo outcomes.
      Psychological, clinical, and neurological theories of placebo effects are
      scrutinized. In chronic pain, conscious expectation does not reliably predict
      placebo effects. A supportive patient-physician relationship may enhance placebo 
      effects. This review highlights "predictive coding" and "bayesian brain" as
      emerging models derived from computational neurobiology that offer a unified
      framework to explain the heterogeneous evidence on placebos. These models invert 
      the dogma of the brain as a stimulus driven organ to one in which perception
      relies heavily on learnt, top down, cortical predictions to infer the source of
      incoming sensory data. In predictive coding/bayesian brain, both chronic pain
      (significantly modulated by central sensitization) and its alleviation with
      placebo treatment are explicated as centrally encoded, mostly non-conscious,
      bayesian biases. The review then evaluates seven ways in which placebos are used 
      in clinical practice and research and their bioethical implications. In this way,
      it shows that placebo effects are evidence based, clinically relevant, and
      potentially ethical tools for relieving chronic pain.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Kaptchuk, Ted J
AU  - Kaptchuk TJ
AD  - Beth Israel Hospital/Harvard Medical School, Boston, MA 02139, USA.
AD  - Contributed equally.
FAU - Hemond, Christopher C
AU  - Hemond CC
AD  - University of Massachusetts Medical School, Worcester, MA 01655, USA.
AD  - Contributed equally.
FAU - Miller, Franklin G
AU  - Miller FG
AD  - Weill Cornell Medicine, New York, NY 10065, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200720
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Placebos)
SB  - IM
MH  - Bayes Theorem
MH  - Chronic Pain/*drug therapy/psychology
MH  - Deception
MH  - Double-Blind Method
MH  - Ethics, Medical
MH  - Humans
MH  - Physician-Patient Relations/*ethics
MH  - Placebo Effect
MH  - Placebos/administration & dosage/*adverse effects
MH  - Practice Patterns, Physicians'/*ethics/statistics & numerical data
COIS- Competing interests: We have read and understood the BMJ policy on declaration of
      interests and declare the following interests: none.
EDAT- 2020/07/22 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1136/bmj.m1668 [doi]
PST - epublish
SO  - BMJ. 2020 Jul 20;370:m1668. doi: 10.1136/bmj.m1668.


PMID- 32690150
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 2405-4577 (Electronic)
IS  - 2405-4577 (Linking)
VI  - 38
DP  - 2020 Aug
TI  - Preoperative oral immunonutrition in gastrointestinal surgical patients: How the 
      tumour microenvironment can be modified.
PG  - 153-159
LID - S2405-4577(20)30102-9 [pii]
LID - 10.1016/j.clnesp.2020.05.012 [doi]
AB  - BACKGROUND & AIMS: This study is focused on the impact of enteral immunonutrition
      on the cell-mediated immune response in the microenvironment of gastric and
      colorectal cancers. METHODS: This is a prospective pilot study approved by the
      local Ethics Committee. The immunophenotypic structure of the immune cells before
      (on the biopsy) and after (on the surgical sample) the administration of the
      immunonutrition in 16 patients is compared with 8 patients receiving regular
      diet. The samples of non-tumour tissue from sleeve-gastrectomy are used as
      non-neoplastic control. Antibodies were tested: CD4, CD8, PD-1, FOX-P3, CD68,
      CD163, CD80, CD21, CD56, PD-L1. We applied already well-known scoring systems for
      the evaluation of the immunohistochemistry and compared our data in the different
      groups by statistical analysis. RESULTS: In treated patients, we detected a
      modulation of the immune response with higher number of cytotoxic and helper
      T-lymphocytes in the tumour microenvironment of the surgical specimens compared
      to the pre-operative biopsy, and a lower number of lymphocytes presenting an
      exhausted (i.e. double positive CD8 and PD-1 lymphocytes) and regulatory (i.e.
      double positive CD4 and FOX-P3 lymphocytes) phenotype. Moreover we observed the
      M1 polarization with a lower number of CD163 positive macrophages and the
      inhibition of the PD-1/PD-L1 pathway in treated patients. CONCLUSIONS: The
      immunonutrition impacts on the tumoral microenvironment of gastric and colorectal
      cancer activating the inflammatory pathway, in terms of humoral and cellular
      response.
CI  - Copyright (c) 2020 European Society for Clinical Nutrition and Metabolism.
      Published by Elsevier Ltd. All rights reserved.
FAU - D'Ignazio, Alessia
AU  - D'Ignazio A
AD  - Universita degli Studi di Siena, Siena, Italy. Electronic address:
      docalessia89@gmail.com.
FAU - Kabata, Pawel
AU  - Kabata P
AD  - Uniwersytet Gdanski, Gdansk, Poland.
FAU - Ambrosio, Maria Raffaella
AU  - Ambrosio MR
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Polom, Karol
AU  - Polom K
AD  - Uniwersytet Gdanski, Gdansk, Poland.
FAU - Marano, Luigi
AU  - Marano L
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Spagnoli, Luigi
AU  - Spagnoli L
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Ongaro, Alessandra
AU  - Ongaro A
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Pieretti, Linda
AU  - Pieretti L
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Marrelli, Daniele
AU  - Marrelli D
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Biviano, Ivano
AU  - Biviano I
AD  - Universita degli Studi di Siena, Siena, Italy.
FAU - Roviello, Franco
AU  - Roviello F
AD  - Universita degli Studi di Siena, Siena, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - England
TA  - Clin Nutr ESPEN
JT  - Clinical nutrition ESPEN
JID - 101654592
SB  - IM
MH  - *Gastrectomy
MH  - Humans
MH  - Immunity, Cellular
MH  - Pilot Projects
MH  - Prospective Studies
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - *Colorectal cancer
OT  - *Gastric cancer
OT  - *Immunonutrition
OT  - *Inflammation
OT  - *Macrophage polarization
OT  - *Microenvironment
COIS- Conflict of interest statement and funding sources The authors have no conflict
      of interest or financial ties to disclose, no founding source.
EDAT- 2020/07/22 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
AID - S2405-4577(20)30102-9 [pii]
AID - 10.1016/j.clnesp.2020.05.012 [doi]
PST - ppublish
SO  - Clin Nutr ESPEN. 2020 Aug;38:153-159. doi: 10.1016/j.clnesp.2020.05.012. Epub
      2020 Jun 30.


PMID- 32690034
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220531
IS  - 1478-4505 (Electronic)
IS  - 1478-4505 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jul 20
TI  - The value of case reports in democratising evidence from resource-limited
      settings: results of an exploratory survey.
PG  - 84
LID - 10.1186/s12961-020-00592-y [doi]
AB  - BACKGROUND: Following a knowledge management analysis, Medecins Sans Frontieres
      (MSF) - a medical humanitarian non-governmental organisation (NGO) - identified
      significant loss of medical knowledge from the field, owing primarily to the
      absence of a platform on which to share clinical lessons learned in humanitarian 
      and resource-limited settings (HRLS). Wishing to address these missed
      opportunities to retain important scientific and pragmatic knowledge, the NGO has
      begun to actively encourage its clinicians to publish case reports/series that
      bring new and/or practical insights of benefit to patients and population groups.
      In parallel, we wished to obtain a clearer understanding of how case reports
      (CRs)/series can best play their role as 'first-line evidence' from HRLS,
      especially in areas suffering from a significant lack of data. METHODS: We
      developed a survey with closed and open questions on 'The value of CRs from HRLS'
      to explore primarily (1) the reasons why this form of evidence from HRLS is often
      lacking, (2) what makes a case report/series worth sharing with the wider global 
      health community, and (3) how we can ensure that published case reports/series
      reach their target audience. RESULTS: Over a 6-month period, 1115 health
      professionals responded to the survey. Participants included clinicians and
      public health specialists from all over the world, with a majority based in
      Africa. The main reason cited for the dearth of CRs from HRLS was that
      practitioners are simply not writing and/or submitting reports (as versus having 
      their papers rejected) due mainly to (1) a lack of skills and (2) time
      constraints. A large majority of respondents felt the CRs are a valuable tool for
      HRLS given their ability to discuss how cases are managed with rudimentary means 
      as well as to draw attention to emerging or underestimated public health problems
      and neglected populations. CONCLUSION: We conclude that the clinical knowledge
      gained in resource-challenged settings is being underutilised in the interest of 
      patients and global health. Consequently, clinicians in HRLS need greater access 
      to basic training in scientific investigation and writing in addition to
      awareness as to the potential value of sharing their clinical experience with a
      view to broadening evidence production from high-income to low-income settings.
FAU - Balinska, Marta A
AU  - Balinska MA
AUID- ORCID: http://orcid.org/0000-0002-8210-2144
AD  - Vienna Evaluation Unit, Medecins Sans Frontieres Austria, Taborstrasse 10, 1020, 
      Vienna, Austria. mbalinska@gmail.com.
FAU - Watts, Richard A
AU  - Watts RA
AD  - Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
LA  - eng
GR  - MR/N011775/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200720
PL  - England
TA  - Health Res Policy Syst
JT  - Health research policy and systems
JID - 101170481
SB  - IM
MH  - Africa
MH  - Global Health
MH  - *Health Personnel
MH  - Humans
MH  - *Income
MH  - Surveys and Questionnaires
PMC - PMC7370517
OTO - NOTNLM
OT  - Capacity building
OT  - Case management
OT  - Case reports
OT  - Clinical ethics
OT  - Humanitarian and resource-limited settings
OT  - Low- and middle-income countries
OT  - Patient-centred care
OT  - Teaching
EDAT- 2020/07/22 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12961-020-00592-y [doi]
AID - 10.1186/s12961-020-00592-y [pii]
PST - epublish
SO  - Health Res Policy Syst. 2020 Jul 20;18(1):84. doi: 10.1186/s12961-020-00592-y.


PMID- 32689995
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 20
TI  - A qualitative study exploring stakeholder perspectives on the use of biological
      samples for future unspecified research in Malawi.
PG  - 61
LID - 10.1186/s12910-020-00503-4 [doi]
AB  - BACKGROUND: There is growing interest in the collection, storage and reuse of
      biological samples for future research. Storage and future use of biological
      samples raise ethical concerns and questions about approaches that safeguard the 
      interests of participants. The situation is further complicated in Africa where
      there is a general lack of governing ethical frameworks that could guide the
      research community on appropriate approaches for sample storage and use.
      Furthermore, there is limited empirical data to guide development of such
      frameworks. A qualitative study to address this gap was conducted with key
      stakeholders in Malawi to understand their experiences and perspectives regarding
      storage and usage of samples for future research. METHODS: This study conducted
      13 in-depth interviews with ethics committee members, regulators and researchers,
      and five focus group discussions with community representatives and clinical
      trial participants in Malawi. Interviews and focus group discussions were
      audio-recorded, transcribed verbatim, and thematically analysed. RESULTS: On the 
      current regulatory guidelines that governs the collection, storage and reuse of
      samples in Malawi, participants highlighted their different understanding of it, 
      with some indicating that it prohibited the reuse and sharing of samples, while
      others believed it permitted. Views on the informed consent model used in Malawi,
      some stakeholders expressed that the current model limited options for sample
      contributors regarding future use. Researchers supported storing samples for
      future use in order to maximize their value and reduce research costs. However,
      they expressed concern over the exportation of samples highlighting that it could
      lead to misuse and would not support the development of research capacity within 
      Malawi. They recommended use of broad consent or tiered consent and establishment
      of biobanks to address these concerns. CONCLUSIONS: Study findings highlighted
      the need for a review of the current regulatory guideline and the development of 
      infrastructure to support the use of stored biological samples for future use
      among the research community in Malawi. At the moment, there are ethical and
      practical concerns arising from the collection, storage and secondary use of
      biological samples make it hard to reconcile scientific progress and the
      protection of participants.
FAU - Matandika, Limbanazo
AU  - Matandika L
AUID- ORCID: 0000-0002-6932-9635
AD  - Centre for Bioethics in Eastern and Southern Africa, College of Medicine,
      University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi.
      limbamindiera@gmail.com.
FAU - Ngongola, Ruby Tionenji
AU  - Ngongola RT
AD  - Centre for Bioethics in Eastern and Southern Africa, College of Medicine,
      University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi.
FAU - Mita, Khama
AU  - Mita K
AD  - Centre for Bioethics in Eastern and Southern Africa, College of Medicine,
      University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi.
AD  - College of Medicine Research Ethics Committee, University of Malawi, Blantyre,
      Malawi.
FAU - Manda-Taylor, Lucinda
AU  - Manda-Taylor L
AD  - Centre for Bioethics in Eastern and Southern Africa, College of Medicine,
      University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi.
FAU - Gooding, Kate
AU  - Gooding K
AD  - Oxford Policy Management, Oxford, UK.
FAU - Mwale, Daniel
AU  - Mwale D
AD  - John Hopkins- One Community Project, Blantyre, Malawi.
FAU - Masiye, Francis
AU  - Masiye F
AD  - Centre for Bioethics in Eastern and Southern Africa, College of Medicine,
      University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi.
AD  - The Centre for Medical Ethics and Law (Department of Medicine), Stellenbosch
      University, Tygerberg Campus, Cape Town, South Africa.
AD  - Directorate of Postgraduate Studies, Research and Outreach, Malawi University of 
      Science and Technology, P.O Box 5196, Limbe, Malawi.
FAU - Mfutso-Bengo, Joseph
AU  - Mfutso-Bengo J
AD  - Centre for Bioethics in Eastern and Southern Africa, College of Medicine,
      University of Malawi, Private Bag 360, Chichiri, Blantyre 3, Malawi.
LA  - eng
GR  - none/University of Malawi, College of Medicine/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200720
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Biomedical Research
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Informed Consent
MH  - Malawi
MH  - Qualitative Research
PMC - PMC7372640
OTO - NOTNLM
OT  - *Biobanking
OT  - *Future use, biological samples and trust
OT  - *Informed consent
EDAT- 2020/07/22 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/22 06:00
PHST- 2019/08/09 00:00 [received]
PHST- 2020/07/14 00:00 [accepted]
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00503-4 [doi]
AID - 10.1186/s12910-020-00503-4 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 20;21(1):61. doi: 10.1186/s12910-020-00503-4.


PMID- 32689935
OWN - NLM
STAT- MEDLINE
DCOM- 20210923
LR  - 20210923
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 20
TI  - Effects of awake caudal anesthesia on mean arterial blood pressure in very low
      birthweight infants.
PG  - 175
LID - 10.1186/s12871-020-01094-8 [doi]
AB  - BACKGROUND: Intraoperative blood pressure is a relevant variable for
      postoperative outcome in infants undergoing surgical procedures. It is therefore 
      important to know whether the type of anesthesia has an impact on intraoperative 
      blood pressure management in very low birth weight infants. Here, we
      retrospectively analyzed intraoperative blood pressure in very low birthweight
      infants receiving either awake caudal anesthesia without sedation, or caudal
      block in combination with general anesthesia, both for open inguinal hernia
      repair. METHODS: Ethical approval was provided by the University of Tuebingen
      Ethical Committee on 05/29/2018 with the project number 403/2018BO2. Patient
      records of infants admitted by the neonatologist (median age at birth 31.1 +/-
      3.5 weeks, median weight at birth 1240 +/- 521 g) which were scheduled for
      inguinal hernia repair were retrospectively evaluated for the course of mean
      arterial blood pressure and perioperative interventions to stabilize blood
      pressure. A total of 42 patients were included, 16 patients (11 boys, 5 girls)
      received awake caudal anesthesia, 26 patients (22 boys, 4 girls) a combination of
      general anesthesia and caudal block. RESULTS: Approximately 3% of the measured
      mean arterial blood pressure values in the caudal anesthesia group were below a
      critical margin of 35 mmHg, in contrast to 47% in the combined anesthesia group
      (p < 0.001). Patients in the latter group showed a significantly larger drop of
      mean arterial blood pressure below 35 mmHg (4.7 +/- 2.7 mmHg vs. 1.9 +/- 1.6
      mmHg; p < 0.005) and a significantly longer time of mean arterial blood pressure 
      below 35 mmHg (25.6 +/- 26.0 min vs. 0.9 +/- 2.3 min; p < 0.001), although they
      received more volume and vasopressor boluses for stabilization (27 +/- 14.8 ml
      vs. 10 +/- 4.1 ml; p < 0.01 and 0.15 +/- 0.06 ml vs. 0 ml of
      cafedrine/theoadrenaline; p < 0.001). CONCLUSIONS: The study indicates that the
      use of caudal block as stand alone procedure for inguinal hernia repair in very
      low birthweight infants might be advantageous in preventing critical blood
      pressure drops compared to a combination of caudal block with general anesthesia.
FAU - Fideler, Frank
AU  - Fideler F
AUID- ORCID: 0000-0002-8667-8992
AD  - Departmnt of Anesthesiology and Intensive Care Medicine, University Hospital
      Tuebingen, Tubingen, Germany. frank.fideler@med.uni-tuebingen.de.
FAU - Walker, Michael
AU  - Walker M
AD  - Clinic for Anesthesiology, Intensive, Emergency- and Pain-Therapy, Ludwigsburg,
      Germany.
FAU - Grasshoff, Christian
AU  - Grasshoff C
AD  - Departmnt of Anesthesiology and Intensive Care Medicine, University Hospital
      Tuebingen, Tubingen, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
SB  - IM
MH  - Anesthesia, Caudal/*methods
MH  - Anesthesia, General/*methods
MH  - Arterial Pressure/*drug effects
MH  - Female
MH  - Hernia, Inguinal/*surgery
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Very Low Birth Weight
MH  - Male
MH  - Retrospective Studies
MH  - Wakefulness
PMC - PMC7370478
EDAT- 2020/07/22 06:00
MHDA- 2021/09/24 06:00
CRDT- 2020/07/22 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/09/24 06:00 [medline]
AID - 10.1186/s12871-020-01094-8 [doi]
AID - 10.1186/s12871-020-01094-8 [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 Jul 20;20(1):175. doi: 10.1186/s12871-020-01094-8.


PMID- 32689702
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20211009
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 160
IP  - 2
DP  - 2020 Aug
TI  - Cardiothoracic surgeons in pandemics: Ethical considerations.
PG  - 456-459
LID - S0022-5223(20)30817-5 [pii]
LID - 10.1016/j.jtcvs.2020.03.117 [doi]
FAU - Drake, Daniel
AU  - Drake D
AD  - Department of Surgery, Munson Healthcare, Traverse City, Mich.
FAU - Morrow, Cynthia D
AU  - Morrow CD
AD  - Independent Researcher, Ann Arbor, Mich.
FAU - Kinlaw, Kathleen
AU  - Kinlaw K
AD  - Department of Pediatrics, Emory Center for Ethics, Healthcare Ethics Consortium, 
      Emory University, Atlanta, Ga.
FAU - De Bonis, Michele
AU  - De Bonis M
AD  - Department of Cardiac Surgery, IRCCS San Raffaele Scientific Institute,
      Vita-Salute San Raffaele University, Milan, Italy.
FAU - Zangrillo, Alberto
AU  - Zangrillo A
AD  - Anesthesia and Intensive Care Department, IRCCS San Raffaele Scientific
      Institute, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Sade, Robert M
AU  - Sade RM
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Medical University of 
      South Carolina, Institute of Human Values in Health Care, Charleston, SC.
      Electronic address: sader@musc.edu.
CN  - Cardiothoracic Ethics Forum
LA  - eng
GR  - UL1 TR001450/TR/NCATS NIH HHS/United States
PT  - Editorial
DEP - 20200409
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
SB  - IM
MH  - *Clinical Competence
MH  - Extracorporeal Membrane Oxygenation/ethics/instrumentation
MH  - Health Care Rationing/*ethics
MH  - Health Services Needs and Demand/*ethics
MH  - Heart-Assist Devices/ethics/supply & distribution
MH  - Humans
MH  - *Pandemics
MH  - Respiration, Artificial/ethics/instrumentation
MH  - Surge Capacity/ethics
MH  - Surgeons/*ethics
MH  - Thoracic Surgical Procedures/*ethics
MH  - Ventilators, Mechanical/ethics/supply & distribution
PMC - PMC7146669
IR  - Blitzer D
FIR - Blitzer, David
IR  - Carpenter AJ
FIR - Carpenter, Andrea J
IR  - Ceppa DP
FIR - Ceppa, DuyKhanh P
IR  - Chen EP
FIR - Chen, Edward P
IR  - Cohen RG
FIR - Cohen, Robbin G
IR  - D'Amico TA
FIR - D'Amico, Thomas A
IR  - Drake DH
FIR - Drake, Daniel H
IR  - Entwistle JW 3rd
FIR - Entwistle, John W 3rd
IR  - Fedak PW
FIR - Fedak, Paul W
IR  - Fenton KN
FIR - Fenton, Kathleen N
IR  - Loebe M
FIR - Loebe, Matthias
IR  - Mayer JE
FIR - Mayer, John E
IR  - McKneally MF
FIR - McKneally, Martin F
IR  - Merrill WH
FIR - Merrill, Walter H
IR  - Millikan SJ
FIR - Millikan, Scott J
IR  - Moffatt-Bruce SD
FIR - Moffatt-Bruce, Susan D
IR  - Murthy SC
FIR - Murthy, Sudish C
IR  - Naunheim KS
FIR - Naunheim, Keith S
IR  - Orringer MB
FIR - Orringer, Mark B
IR  - Pickens A
FIR - Pickens, Allan
IR  - Ray S
FIR - Ray, Shuddhadeb
IR  - Romano JC
FIR - Romano, Jennifer C
IR  - Sade RM
FIR - Sade, Robert M
IR  - Starnes SL
FIR - Starnes, Sandra L
IR  - Swain JA
FIR - Swain, Julie A
IR  - Tweddell JS
FIR - Tweddell, James S
IR  - Whyte RI
FIR - Whyte, Richard I
IR  - Wood DD
FIR - Wood, Douglas D
IR  - Zwischenberger JB
FIR - Zwischenberger, Joseph B
EDAT- 2020/07/22 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/22 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - S0022-5223(20)30817-5 [pii]
AID - 10.1016/j.jtcvs.2020.03.117 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2020 Aug;160(2):456-459. doi:
      10.1016/j.jtcvs.2020.03.117. Epub 2020 Apr 9.


PMID- 32688106
OWN - NLM
STAT- Publisher
LR  - 20201012
IS  - 1872-6976 (Electronic)
IS  - 0167-4943 (Linking)
VI  - 91
DP  - 2020 Jul 15
TI  - The disruptive power of Artificial Intelligence. Ethical aspects of
      gerontechnology in elderly care.
PG  - 104186
LID - S0167-4943(20)30180-1 [pii]
LID - 10.1016/j.archger.2020.104186 [doi]
AB  - Gerontechnology based on Artificial Intelligence (AI) is expected to fulfill the 
      promise of the so-called 4p-medicine and enable a predictive, personalized,
      preventive, and participatory elderly care. Although empirical evidence shows
      positive health outcomes, commentators are concerned that AI-based
      gerontechnology could bring along the disruption of elderly care. A systematic
      conceptualization of these concerns is lacking. In this paper, such a
      conceptualization is suggested by analyzing the risks of AI in elderly care as
      "4d-risks": the depersonalization of care through algorithm-based
      standardization, the discrimination of minority groups through generalization,
      the dehumanization of the care relationship through automatization, and the
      disciplination of users through monitoring and surveillance. Based on the
      4d-model, strategies for a patient-centered AI in elderly care are outlined.
      Whether AI-based gerontechnology will actualize the 4p-perspective or bring about
      the 4d-scenario depends on whether joint efforts of users, caregivers, care
      providers, engineers, and policy makers will be made.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Rubeis, Giovanni
AU  - Rubeis G
AD  - Institute of History and Ethics of Medicine, Heidelberg University, Im
      Neuenheimer Feld 327, 69120 Heidelberg, Germany. Electronic address:
      giovanni.rubeis@histmed.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
SB  - IM
OTO - NOTNLM
OT  - 4p-medicine
OT  - Artificial intelligence
OT  - Big data
OT  - Elderly care
OT  - Ethics
OT  - Gerontechnology
COIS- Declaration of Competing Interest None.
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - S0167-4943(20)30180-1 [pii]
AID - 10.1016/j.archger.2020.104186 [doi]
PST - aheadofprint
SO  - Arch Gerontol Geriatr. 2020 Jul 15;91:104186. doi: 10.1016/j.archger.2020.104186.


PMID- 32688021
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20210727
IS  - 1618-0402 (Electronic)
IS  - 0940-9602 (Linking)
VI  - 232
DP  - 2020 Nov
TI  - The practice of ethics in the context of human dissection: Setting standards for 
      future physicians.
PG  - 151577
LID - S0940-9602(20)30121-7 [pii]
LID - 10.1016/j.aanat.2020.151577 [doi]
AB  - It is a much desirable skill among physicians that clinical practice should be
      guided by ethical norms. The dissection room experience provides an opportunity
      for nurturing the principles of ethical practice among medical students early in 
      the curriculum. When the exercise of human dissection is followed within the
      boundaries of ethics it effectively props an ideal example for the young minds to
      emulate in the future. Hence in every stage of dissection room activity precious 
      human body needs to be handled in an ethical manner so as to set a standard for
      the students. The present review is an attempt to collate the recommendations
      documented by researchers as per ethical guidelines in the context of human
      dissection. The review highlights on the ethical norms which needs to be adhered 
      to while receiving the human body of a donor and during preservation of the same.
      It reflects on ideal ethical behaviour in the dissection room during the act of
      dissection and finally emphasize on the respectful disposal of the human remains 
      in an ethical manner. The intended purpose of this article is to support uniform 
      adoption of the recommendations for ethical handling of human bodies used in
      anatomical dissection.
CI  - Copyright (c) 2020 Elsevier GmbH. All rights reserved.
FAU - Ghosh, Sanjib Kumar
AU  - Ghosh SK
AD  - Department of Anatomy, All India Institute of Medical Sciences, Phulwarisharif,
      Patna 801507, Bihar, India. Electronic address: drsanjib79@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200717
PL  - Germany
TA  - Ann Anat
JT  - Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische
      Gesellschaft
JID - 100963897
SB  - IM
MH  - *Body Remains/anatomy & histology/surgery
MH  - Dissection/*ethics
MH  - Education, Medical/*ethics/standards
MH  - Humans
MH  - Physicians/ethics/*standards
MH  - Students, Medical
PMC - PMC7366954
OTO - NOTNLM
OT  - Body donation
OT  - Dissection room behaviour
OT  - Ethical guidelines
OT  - Ethical practice
OT  - Ethical preservation
OT  - Professionalism
OT  - Respectful cremation
EDAT- 2020/07/21 06:00
MHDA- 2021/07/28 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - S0940-9602(20)30121-7 [pii]
AID - 10.1016/j.aanat.2020.151577 [doi]
PST - ppublish
SO  - Ann Anat. 2020 Nov;232:151577. doi: 10.1016/j.aanat.2020.151577. Epub 2020 Jul
      17.


PMID- 32687743
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 7
DP  - 2020 Oct 6
TI  - Institutional Review Board Quality, Private Equity, and Promoting Ethical Human
      Subjects Research.
PG  - 558-562
LID - 10.7326/M20-1674 [doi]
AB  - Evaluating the quality and effectiveness of the institutional review boards
      (IRBs) responsible for overseeing research involving human participants is
      critically important but perpetually challenging. Seemingly common-sense
      measures, such as the number of proposals approved with and without major
      modifications and the number of unexpected adverse events occurring in approved
      protocols, can be misleading indicators of participant protection, and regulatory
      compliance may not correspond to achieving ethical goals. These measurement
      challenges make it difficult to assess the validity of concerns about different
      IRB models. A group of U.S. senators recently raised questions about the
      increasing use of for-profit IRBs to review research proposals (as opposed to
      boards typically housed at academic medical centers and health care institutions)
      and, more specifically, about the growing trend of private equity ownership and
      consolidation of for-profit IRBs. Although all IRBs face pressure to speed
      reviews and none are entirely free of conflicts of interest, the private equity
      model is particularly susceptible to approaches that could undercut the ethical
      mission of IRBs to protect and promote the rights and welfare of research
      participants. Ideally, the quality of board oversight could be measured directly,
      rather than relying on the heuristic of board type; this article describes
      several current efforts toward this goal. In the meantime, one improvement may be
      to pursue a new model of IRB oversight: independent nonprofit boards that stand
      apart from research institutions, take advantage of business approaches to
      research review, and minimize conflicts of interest.
FAU - Lynch, Holly Fernandez
AU  - Lynch HF
AUID- ORCID: 0000-0001-7813-9879
AD  - Perelman School of Medicine and Leonard Davis Institute of Health Economics,
      University of Pennsylvania, Philadelphia, Pennsylvania (H.F.L.).
FAU - Rosenfeld, Stephen
AU  - Rosenfeld S
AUID- ORCID: 0000-0002-2886-0227
AD  - Freeport Research Systems, Freeport, Maine (S.R.).
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
SB  - IM
MH  - Conflict of Interest
MH  - Ethics Committees, Research/legislation & jurisprudence/standards
MH  - Government Regulation
MH  - *Human Experimentation/legislation & jurisprudence/standards
MH  - Humans
MH  - Private Sector/*ethics/organization & administration
MH  - United States
EDAT- 2020/07/21 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.7326/M20-1674 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Oct 6;173(7):558-562. doi: 10.7326/M20-1674. Epub 2020 Jul
      21.


PMID- 32687641
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 1365-2834 (Electronic)
IS  - 0966-0429 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Sep
TI  - Exploration of the expected and achieved competency levels of new graduate
      nurses.
PG  - 1418-1431
LID - 10.1111/jonm.13105 [doi]
AB  - AIM: To explore the expected and achieved competency levels of new graduate
      nurses. BACKGROUND: There are global concerns about a perceived disconnect
      between the educational preparation of new graduates and the expectations of
      employers about their work readiness. It is important to understand competency
      levels expected and achieved of new graduate nurses. METHOD(S): The study was
      conducted in three phases: the identification of competencies, development of a
      survey instrument and exploration of levels of competency from the perspectives
      of key stakeholders. RESULTS: New graduates were well prepared for demonstrating 
      respect to patients, but needed to be closely supported when providing emergency 
      care. Results highlighted that new graduates felt less competent than graduating 
      students in those competencies related to legal and ethical practice.
      Importantly, expectations about new graduates' competency varied between
      educators and managers. CONCLUSION(S): The findings provide important information
      about new graduates' competency levels, revealing a mismatch in the perception of
      key stakeholders about competency levels. This has important implications for
      building new graduates readiness for practice and highlights the importance of
      collaboration between key stakeholders to address competency gaps. IMPLICATIONS
      FOR NURSING MANAGEMENT: Supportive opportunities should be provided to new
      graduate nurses to fill gaps in beginner competency.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Hyun, Areum
AU  - Hyun A
AUID- ORCID: https://orcid.org/0000-0002-3440-3823
AD  - School of Nursing, Midwifery & Social Work, University of Queensland, Brisbane,
      QLD, Australia.
FAU - Tower, Marion
AU  - Tower M
AUID- ORCID: https://orcid.org/0000-0002-7962-5294
AD  - School of Nursing, Midwifery & Social Work, University of Queensland, Brisbane,
      QLD, Australia.
FAU - Turner, Catherine
AU  - Turner C
AUID- ORCID: https://orcid.org/0000-0002-2687-932X
AD  - College of Nursing and Midwifery, Charles Darwin University, Casuarina, NT,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200808
PL  - England
TA  - J Nurs Manag
JT  - Journal of nursing management
JID - 9306050
MH  - *Clinical Competence
MH  - *Education, Nursing, Graduate
MH  - Humans
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - competence
OT  - competency levels
OT  - new graduate nurses
OT  - nursing competencies
EDAT- 2020/07/21 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/07/09 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1111/jonm.13105 [doi]
PST - ppublish
SO  - J Nurs Manag. 2020 Sep;28(6):1418-1431. doi: 10.1111/jonm.13105. Epub 2020 Aug 8.


PMID- 32687536
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - Relationships and boundaries: Learning needs and preferences in clerkship medical
      environments.
PG  - e0236145
LID - 10.1371/journal.pone.0236145 [doi]
AB  - PURPOSE: Relationship boundaries recognition is an essential element of medical
      practice. The aim of the study was to assess final year medical students'
      perceived need for education regarding professional boundaries. MATERIALS AND
      METHODS: This was a cross-sectional study. An anonymous paper questionnaire was
      distributed to 128 final year medical students. Standard descriptive statistics, 
      unpaired t-test to evaluate differences between male and female groups and
      Pearson correlation to determine relationships between variables were used.
      RESULTS: The survey was completed by 84.4% of students who identified the need
      for more emphasis in the curriculum for all of topics during training and
      practice pertaining to boundaries and relationships (mean 6.61+/-1.32 on a scale 
      of 0 to 9; and 6.66+/-1.27 respectively). Topics with a high interest ranking
      requiring additional attention were mistreatment of medical students (mean
      7.22+/-1.96), coping with mistakes in clinical care (mean 7.25+/-1.63), reporting
      of medical mistakes (mean 7.58+/-1.36), and gender bias in clinical care (mean
      7.10+/-1.82). Women perceived a greater need for attention to all topics in the
      curriculum. Significant differences between the perceptions of female and male
      students were observed regarding topics such as responding to an impaired
      colleague (p<0.001), and a physician's social responsibilities (p = 0.001).
      CONCLUSION: Medical students recognized the need for more education and training 
      in the undergraduate medical ethics curriculum regarding patient-physician
      relationship boundaries.
FAU - AlMahmoud, Tahra
AU  - AlMahmoud T
AUID- ORCID: 0000-0003-0263-5168
AD  - Department of Surgery, College of Medicine and Health Sciences, United Arab
      Emirates University, Al Ain, UAE.
FAU - Hashim, M Jawad
AU  - Hashim MJ
AD  - Department of Family Medicine, College of Medicine and Health Sciences, United
      Arab Emirates University, Al Ain, UAE.
FAU - Naeem, Naghma
AU  - Naeem N
AD  - Department of Medical Education, College of Medicine and Health Sciences, United 
      Arab Emirates University, Al Ain, UAE.
FAU - Almahmoud, Rabah
AU  - Almahmoud R
AD  - Department of Clinical Sciences, College of Medicine, University of Sharjah,
      Sharjah, UAE.
FAU - Branicki, Frank
AU  - Branicki F
AD  - Department of Surgery, College of Medicine and Health Sciences, United Arab
      Emirates University, Al Ain, UAE.
FAU - Elzubeir, Margaret
AU  - Elzubeir M
AD  - Department of Medical Education, College of Medicine and Health Sciences, United 
      Arab Emirates University, Al Ain, UAE.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - *Clinical Clerkship
MH  - Cross-Sectional Studies
MH  - Ethics, Medical
MH  - Female
MH  - Humans
MH  - *Learning
MH  - Male
MH  - Physician-Patient Relations/*ethics
MH  - Sex Factors
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7371200
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/21 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/07/21 06:00
PHST- 2019/09/15 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1371/journal.pone.0236145 [doi]
AID - PONE-D-19-25927 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 20;15(7):e0236145. doi: 10.1371/journal.pone.0236145.
      eCollection 2020.


PMID- 32687241
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20220716
IS  - 1445-2197 (Electronic)
IS  - 1445-1433 (Linking)
VI  - 90
IP  - 9
DP  - 2020 Sep
TI  - Surgery triage during the COVID-19 pandemic.
PG  - 1558-1565
LID - 10.1111/ans.16196 [doi]
AB  - BACKGROUND: The novel coronavirus, SARS-CoV-2, caused the COVID-19 global
      pandemic. In response, the Australian and New Zealand governments activated their
      respective emergency plans and hospital frameworks to deal with the potential
      increased demand on scarce resources. Surgical triage formed an important part of
      this response to protect the healthcare system's capacity to respond to COVID-19.
      METHOD: A rapid review methodology was adapted to search for all levels of
      evidence on triaging surgery during the current COVID-19 outbreak. Searches were 
      limited to PubMed (inception to 10 April 2020) and supplemented with grey
      literature searches using the Google search engine. Further, relevant articles
      were also sourced through the Royal Australasian College of Surgeons COVID-19
      Working Group. Recent government advice (May 2020) is also included. RESULTS:
      This rapid review is a summary of advice from Australian, New Zealand and
      international speciality groups regarding triaging of surgical cases, as well as 
      the peer-reviewed literature. The key theme across all jurisdictions was to not
      compromise clinical judgement and to enable individualized, ethical and
      patient-centred care. The topics reported on include implications of COVID-19 on 
      surgical triage, competing demands on healthcare resources (surgery versus
      COVID-19 cases), and the low incidence of COVID-19 resulting in a possibility to 
      increase surgical caseloads over time. CONCLUSION: During the COVID-19 pandemic, 
      urgent and emergency surgery must continue. A carefully staged return of elective
      surgery should align with a decrease in COVID-19 caseload. Combining evidence and
      expert opinion, schemas and recommendations have been proposed to guide this
      process in Australia and New Zealand.
CI  - (c) 2020 Royal Australasian College of Surgeons.
FAU - Babidge, Wendy J
AU  - Babidge WJ
AUID- ORCID: 0000-0002-7063-7192
AD  - Research Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Melbourne, Victoria, Australia.
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, University of Adelaide,
      Adelaide, South Australia, Australia.
FAU - Tivey, David R
AU  - Tivey DR
AUID- ORCID: 0000-0003-2213-2576
AD  - Research Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Melbourne, Victoria, Australia.
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, University of Adelaide,
      Adelaide, South Australia, Australia.
FAU - Kovoor, Joshua G
AU  - Kovoor JG
AUID- ORCID: 0000-0002-3880-3840
AD  - University of Adelaide, Adelaide, South Australia, Australia.
FAU - Weidenbach, Kristin
AU  - Weidenbach K
AD  - Research Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Melbourne, Victoria, Australia.
FAU - Collinson, Trevor G
AU  - Collinson TG
AD  - General Surgeons Australia, Adelaide, South Australia, Australia.
FAU - Hewett, Peter J
AU  - Hewett PJ
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, University of Adelaide,
      Adelaide, South Australia, Australia.
FAU - Hugh, Thomas J
AU  - Hugh TJ
AUID- ORCID: 0000-0001-6690-342X
AD  - Northern Clinical School, University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Surgical Education, Research and Training Institute, Royal North Shore Hospital, 
      Sydney, New South Wales, Australia.
FAU - Padbury, Robert T A
AU  - Padbury RTA
AD  - Flinders University, Adelaide, South Australia, Australia.
AD  - Division of Surgery and Perioperative Medicine, Flinders Medical Centre,
      Adelaide, Australia.
FAU - Hill, Nicola M
AU  - Hill NM
AD  - Nelson-Marlborough District Health Board, New Zealand National Board, Royal
      Australasian College of Surgeons, Nelson, New Zealand.
FAU - Maddern, Guy J
AU  - Maddern GJ
AUID- ORCID: 0000-0003-2064-181X
AD  - Research Audit and Academic Surgery, Royal Australasian College of Surgeons,
      Melbourne, Victoria, Australia.
AD  - Discipline of Surgery, The Queen Elizabeth Hospital, University of Adelaide,
      Adelaide, South Australia, Australia.
LA  - eng
GR  - Medibank Better Health Foundation/International
PT  - Journal Article
PT  - Review
DEP - 20200817
PL  - Australia
TA  - ANZ J Surg
JT  - ANZ journal of surgery
JID - 101086634
SB  - IM
MH  - Australia/epidemiology
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*transmission
MH  - Disease Transmission, Infectious/*prevention & control
MH  - Elective Surgical Procedures/*standards
MH  - Humans
MH  - New Zealand/epidemiology
MH  - *Pandemics
MH  - Personal Protective Equipment/*supply & distribution
MH  - Pneumonia, Viral/epidemiology/*transmission
MH  - SARS-CoV-2
MH  - Triage/*methods
PMC - PMC7404945
OTO - NOTNLM
OT  - *COVID-19
OT  - *health resources
OT  - *personal protective equipment
OT  - *surgery
OT  - *surgical specialties
OT  - *triage
EDAT- 2020/07/21 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/05/17 00:00 [received]
PHST- 2020/07/08 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1111/ans.16196 [doi]
PST - ppublish
SO  - ANZ J Surg. 2020 Sep;90(9):1558-1565. doi: 10.1111/ans.16196. Epub 2020 Aug 17.


PMID- 32687128
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1117-1936 (Print)
VI  - 27
IP  - 3
DP  - 2020 Jul-Sep
TI  - A proposed research misconduct policy for universities and postgraduate colleges 
      in developing countries.
PG  - 250-258
LID - 10.4103/npmj.npmj_51_20 [doi]
AB  - Research misconduct policy (RMP) is a legal document that shows the definitions
      of the various types of misconduct, describes the inquiry and investigation of
      allegations, and the appropriate penalties that should be imposed. The presence
      of the adopted RMP on the website of a university or postgraduate college is an
      indication of the level of commitment to promote the proper handling of
      misconduct cases. Perusal of the websites of top universities in developing
      countries revealed that many do not have RMP on their websites. The probable
      starting point for combating research misconduct at the national or institutional
      level is by acquisition of RMP. The purpose of this article is to propose a
      modern, structured and cost-effective RMP for universities and postgraduate
      colleges in developing countries. The bibliographic database, PubMed, was
      searched using the terms 'research misconduct' and 'research misconduct policy'. 
      All relevant articles from the search and some RMPs of universities, national
      agencies and global health organisations available on the Internet were carefully
      studied. A formulated RMP, based on the Final Rule of the United States, Public
      Health Services Policies on Research Misconduct of 2005 and the Regulations of
      the University Grants Commission of India of 2018, is hereby presented. In the
      proposed RMP, plagiarism was stratified into four levels in ascending order of
      severity so that imposed penalties are commensurate with the seriousness of
      misconduct. The zero tolerance for plagiarism in the core work areas was adopted.
      The proposed RMP was designed to act as a template. It should be modified as
      required based on the prevailing local circumstances and made fit for purpose.
      Universities, postgraduate colleges and journals should have RMP on the homepage 
      of their websites.
FAU - Adesanya, Adedoyin Adekunle
AU  - Adesanya AA
AD  - Department of Surgery, College of Medicine, University of Lagos; Lagos University
      Teaching Hospital, Idi-Araba; Journal Unit, National Postgraduate Medical College
      of Nigeria, Ijanikin, Lagos, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Niger Postgrad Med J
JT  - The Nigerian postgraduate medical journal
JID - 9613595
SB  - IM
CIN - Niger Postgrad Med J. 2020 Jul-Sep;27(3):259-260. PMID: 32687129
MH  - Academies and Institutes
MH  - Authorship/*standards
MH  - Biomedical Research/*ethics
MH  - Developing Countries
MH  - Ethics, Research
MH  - Humans
MH  - Peer Review/standards
MH  - *Plagiarism
MH  - Publishing/*ethics/standards
MH  - Research Personnel/*ethics
MH  - Scientific Misconduct/*ethics
MH  - Universities
OTO - NOTNLM
OT  - Plagiarism
OT  - plagiarism policy
OT  - research ethics code
OT  - research misconduct
OT  - research misconduct policy
OT  - unethical authorship practices
COIS- None
EDAT- 2020/07/21 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - NigerPostgradMedJ_2020_27_3_250_289917 [pii]
AID - 10.4103/npmj.npmj_51_20 [doi]
PST - ppublish
SO  - Niger Postgrad Med J. 2020 Jul-Sep;27(3):250-258. doi: 10.4103/npmj.npmj_51_20.


PMID- 32686681
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210213
IS  - 2334-265X (Print)
IS  - 2334-265X (Linking)
VI  - 6
IP  - 1
DP  - 2020 Jul 20
TI  - Neuroethics at the interface of machine learning and schizophrenia.
PG  - 18
LID - 10.1038/s41537-020-0108-6 [doi]
AB  - Ethical discourse around machine learning analysis of free speech for the
      detection of schizophrenia has largely focused on consent and personal privacy.
      We focus here on additional ethics concerns and principles that must be addressed
      to move the pendulum of risk over to benefit and propose solutions to achieve
      that shift.
FAU - McFarlane, Jacob
AU  - McFarlane J
AD  - Cognitive Systems, Faculty of Arts, University of British Columbia, Vancouver,
      BC, Canada.
AD  - Neuroethics Canada, Division of Neurology, Department of Medicine, University of 
      British Columbia, Vancouver, BC, Canada.
FAU - Illes, Judy
AU  - Illes J
AD  - Neuroethics Canada, Division of Neurology, Department of Medicine, University of 
      British Columbia, Vancouver, BC, Canada. jilles@mail.ubc.ca.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - United States
TA  - NPJ Schizophr
JT  - NPJ schizophrenia
JID - 101657919
PMC - PMC7371680
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:01
CRDT- 2020/07/21 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:01 [medline]
AID - 10.1038/s41537-020-0108-6 [doi]
AID - 10.1038/s41537-020-0108-6 [pii]
PST - epublish
SO  - NPJ Schizophr. 2020 Jul 20;6(1):18. doi: 10.1038/s41537-020-0108-6.


PMID- 32686460
OWN - NLM
STAT- Publisher
LR  - 20200723
IS  - 1816-5370 (Electronic)
IS  - 0218-4923 (Linking)
DP  - 2020 Jul 19
TI  - Cardiac surgeons between apprehension and ethical duty in the COVID-19 pandemic.
PG  - 218492320943355
LID - 10.1177/0218492320943355 [doi]
AB  - BACKGROUND: Cardiothoracic surgeons are facing a big challenge in their surgical 
      practice in the era of the COVID-19 pandemic. The attitude towards performing
      surgery is influenced by the pandemic. Setting special recommendations for safe
      cardiothoracic surgery is of extreme importance. METHODS: This was an
      observational cross-sectional survey that included 77 Egyptian cardiothoracic
      surgeons. The survey consisted of a self-administered constructed questionnaire
      with six sections, and was delivered as a Google Forms questionnaire
      (https://www.google.com/forms/about) that was sent to individuals via social
      networks and email. RESULTS: More than 80% of Egyptian cardiothoracic surgeons
      believe they and their patients are at risk. Out of all participants, none had
      actually been infected with COVID-19 but 26% had encountered a positive COVID-19 
      person in their surgical team. Although 51% were testing patients before surgery,
      they reported 9 confirmed cases postoperatively. Computed tomography was the most
      recommended investigation prior to surgery (by 69%). Most had postponed elective 
      surgeries and only one-third of all surgeons recommended performing elective
      surgeries cautiously with pretesting for COVID-19 and maximizing protective
      measures, while more than 40% recommended not performing high-risk elective
      surgeries. CONCLUSION: We are committed to the safety of our patients, ourselves,
      our staff, and our families. Planning for the new phase of reopening, whether
      total reopening or step-by-step reopening, should carefully consider how we
      should utilize our resources, respect social distancing, and prevent exposure to 
      untested patients or health workers who might turn out to be an undetected
      positive case.
FAU - Bakry, Ahmed Ma
AU  - Bakry AM
AD  - Cardiothoracic Surgery Department, Zagazig University, Egypt.
FAU - Sobhy, Ehab
AU  - Sobhy E
AD  - Cardiothoracic Surgery Department, Zagazig University, Egypt.
FAU - Abdelmohty, Hysam
AU  - Abdelmohty H
AD  - Cardiothoracic Surgery Department, Mansoura University, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200719
PL  - England
TA  - Asian Cardiovasc Thorac Ann
JT  - Asian cardiovascular & thoracic annals
JID - 9503417
SB  - IM
PMC - PMC7372099
OTO - NOTNLM
OT  - Cardiac surgical procedures
OT  - coronavirus infections
OT  - egypt
OT  - operating rooms
OT  - thoracic surgical procedures
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - 10.1177/0218492320943355 [doi]
PST - aheadofprint
SO  - Asian Cardiovasc Thorac Ann. 2020 Jul 19:218492320943355. doi:
      10.1177/0218492320943355.


PMID- 32686188
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1098-2345 (Electronic)
IS  - 0275-2565 (Linking)
VI  - 82
IP  - 8
DP  - 2020 Aug
TI  - The human-primate interface in the New Normal: Challenges and opportunities for
      primatologists in the COVID-19 era and beyond.
PG  - e23176
LID - 10.1002/ajp.23176 [doi]
AB  - The emergence of SARS-CoV-2 in late 2019 and human responses to the resulting
      COVID-19 pandemic in early 2020 have rapidly changed many aspects of human
      behavior, including our interactions with wildlife. In this commentary, we
      identify challenges and opportunities at human-primate interfaces in light of
      COVID-19, focusing on examples from Asia, and make recommendations for
      researchers working with wild primates to reduce zoonosis risk and leverage
      research opportunities. First, we briefly review the evidence for zoonotic
      origins of SARS-CoV-2 and discuss risks of zoonosis at the human-primate
      interface. We then identify challenges that the pandemic has caused for primates,
      including reduced nutrition, increased intraspecific competition, and increased
      poaching risk, as well as challenges facing primatologists, including lost
      research opportunities. Subsequently, we highlight opportunities arising from
      pandemic-related lockdowns and public health messaging, including opportunities
      to reduce the intensity of problematic human-primate interfaces, opportunities to
      reduce the risk of zoonosis between humans and primates, opportunities to reduce 
      legal and illegal trade in primates, new opportunities for research on
      human-primate interfaces, and opportunities for community education. Finally, we 
      recommend specific actions that primatologists should take to reduce contact and 
      aggression between humans and primates, to reduce demand for primates as pets, to
      reduce risks of zoonosis in the context of field research, and to improve
      understanding of human-primate interfaces. Reducing the risk of zoonosis and
      promoting the well-being of humans and primates at our interfaces will require
      substantial changes from "business as usual." We encourage primatologists to help
      lead the way.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Lappan, Susan
AU  - Lappan S
AUID- ORCID: 0000-0002-0139-8837
AD  - Department of Anthropology, Appalachian State University, Boone, North Carolina.
AD  - School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia.
FAU - Malaivijitnond, Suchinda
AU  - Malaivijitnond S
AUID- ORCID: 0000-0003-0897-2632
AD  - National Primate Research Center of Thailand, Chulalongkorn University, Kaeng
      Khoi, Saraburi, Thailand.
AD  - Department of Biology, Faculty of Science, Chulalongkorn University, Bangkok,
      Thailand.
FAU - Radhakrishna, Sindhu
AU  - Radhakrishna S
AUID- ORCID: 0000-0002-0870-071X
AD  - National Institute of Advanced Studies, Indian Institute of Science, Bengaluru,
      India.
FAU - Riley, Erin P
AU  - Riley EP
AUID- ORCID: 0000-0002-2679-0595
AD  - Department of Anthropology, San Diego State University, San Diego, California.
FAU - Ruppert, Nadine
AU  - Ruppert N
AUID- ORCID: 0000-0002-9760-0058
AD  - School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia.
LA  - eng
GR  - RU/PBIOLOGI/8011063/Universiti Sains Malaysia/International
GR  - Wenner Gren Foundation/International
GR  - San Diego State University/International
GR  - The Habitat Foundation/International
GR  - awarded through Malaysian Primatological Society/Disney Conservation
      Fund/International
GR  - Appalachian State University/International
GR  - The Rufford Foundation/International
GR  - American Institute for Indonesian Studies/International
GR  - USA Fulbright Scholar Program/International
GR  - Hasanuddin University/International
GR  - SERB/F/I0032/2016-17/Department of Science and Technology, Government of
      India/International
GR  - RTA 6280010/Thailand Research Fund Senior Scholar Grant/International
GR  - FRGS/PBIOLOGI/6711649/Ministry of Higher Education Malaysia/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - United States
TA  - Am J Primatol
JT  - American journal of primatology
JID - 8108949
SB  - IM
MH  - Animals
MH  - COVID-19
MH  - Conservation of Natural Resources/trends
MH  - Coronavirus Infections/*prevention & control/transmission
MH  - Feeding Behavior/physiology
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control/transmission
MH  - Primate Diseases/*prevention & control/transmission/virology
MH  - Primates
MH  - Risk Factors
MH  - Zoonoses/*prevention & control/transmission
PMC - PMC7404331
OTO - NOTNLM
OT  - *SARS-CoV-2
OT  - *biosafety
OT  - *ethics
OT  - *human-primate conflict
OT  - *provisioning
OT  - *zoonosis
EDAT- 2020/07/21 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/05/10 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/07/04 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1002/ajp.23176 [doi]
PST - ppublish
SO  - Am J Primatol. 2020 Aug;82(8):e23176. doi: 10.1002/ajp.23176. Epub 2020 Jul 20.


PMID- 32686058
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20210121
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 15
IP  - 8
DP  - 2020 Nov
TI  - Medical professionalism in times of COVID-19 pandemic: is economic logic trumping
      medical ethics?
PG  - 1585-1586
LID - 10.1007/s11739-020-02446-5 [doi]
FAU - Curkovic, Marko
AU  - Curkovic M
AUID- ORCID: http://orcid.org/0000-0002-4855-2133
AD  - University Psychiatric Hospital Vrapce, Bolnicka Cesta 32, 10000, Zagreb,
      Croatia. markocurak@gmail.com.
AD  - School of Medicine, University of Zagreb, Salata 2, 10000, Zagreb, Croatia.
      markocurak@gmail.com.
FAU - Kosec, Andro
AU  - Kosec A
AD  - School of Medicine, University of Zagreb, Salata 2, 10000, Zagreb, Croatia.
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital 
      Center Sestre Milosrdnice, Vinogradska Cesta 29, 10000, Zagreb, Croatia.
FAU - Curkovic, Danijela
AU  - Curkovic D
AD  - Department of Dermatology and Venereology, University Hospital Center Zagreb,
      Kispaticeva 12, 10000, Zagreb, Croatia.
LA  - eng
PT  - Letter
DEP - 20200719
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - *Cost of Illness
MH  - *Ethics, Medical
MH  - Humans
MH  - Pandemics/economics/*ethics/statistics & numerical data
MH  - Pneumonia, Viral/*therapy
MH  - Professionalism/ethics/trends
PMC - PMC7368899
OTO - NOTNLM
OT  - *Allocation of resources
OT  - *Bioethics
OT  - *COVID-19
OT  - *Medical professionalism
OT  - *Pandemic
EDAT- 2020/07/21 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/05/30 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1007/s11739-020-02446-5 [doi]
AID - 10.1007/s11739-020-02446-5 [pii]
PST - ppublish
SO  - Intern Emerg Med. 2020 Nov;15(8):1585-1586. doi: 10.1007/s11739-020-02446-5. Epub
      2020 Jul 19.


PMID- 32686048
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 2210-7711 (Electronic)
VI  - 42
IP  - 4
DP  - 2020 Aug
TI  - Community pharmacists' professional practices for complementary medicines: a
      qualitative study in New Zealand.
PG  - 1109-1117
LID - 10.1007/s11096-020-01093-2 [doi]
AB  - Background Complementary medicines are a popular healthcare choice among
      patients/consumers, and most pharmacies sell these products. Pharmacists are
      well-placed to advise on complementary medicines, but their training and
      practices for these products are not optimal. Pharmacists' professional practices
      for complementary medicines ought to be influenced by professional codes of
      ethics and standards. Objective To examine community pharmacists' perspectives on
      complementary medicines in New Zealand, including motivations and justifications 
      for selling these products, and professional and ethical issues complementary
      medicines raise for pharmacists. Setting Community pharmacists in New Zealand.
      Method Qualitative, semi-structured interviews with 27 New Zealand practising
      community pharmacists identified through purposive and convenience sampling. Main
      outcome measure Participants' views, experiences, and professional practices for 
      complementary medicines. Results Participants struggled to clearly describe
      products they considered complementary medicines. Perspectives towards these
      products ranged from strongly supportive to somewhat sceptical; none was strongly
      opposed. Participants had several motivations for selling complementary
      medicines, particularly consumer demand and profits. Participants acknowledged
      ethical issues concerning complementary medicines, including lack of evidence of 
      efficacy and pharmacists' limited training/knowledge. Few referred explicitly to 
      complementary-medicines-related statements in the Pharmacy Council of New
      Zealand's Code of Ethics, or indicated these guided their practice. Conclusion
      Participants sold complementary medicines despite having limited knowledge on
      these products and concerns about efficacy; participants justified this as they
      believe they are providing an holistic option for patients, and/or ensuring
      complementary medicines do no harm. Participants were mindful of
      ethical/professional issues regarding complementary medicines, but were not
      necessarily aware of, or guided by, explicit statements in the Pharmacy Council
      of New Zealand's Code of Ethics.
FAU - Barnes, Joanne
AU  - Barnes J
AUID- ORCID: http://orcid.org/0000-0002-1522-8433
AD  - School of Pharmacy, Faculty of Medical and Health Sciences, University of
      Auckland, Private Bag 92019, Auckland, New Zealand. j.barnes@auckland.ac.nz.
FAU - Butler, Rachael
AU  - Butler R
AD  - , Auckland, New Zealand.
LA  - eng
GR  - 3608425/University of Auckland
GR  - 173/New Zealand Pharmacy and Education Fund
PT  - Journal Article
DEP - 20200720
PL  - Netherlands
TA  - Int J Clin Pharm
JT  - International journal of clinical pharmacy
JID - 101554912
SB  - IM
MH  - Adult
MH  - Aged
MH  - Community Pharmacy Services/*organization & administration
MH  - *Complementary Therapies
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - New Zealand
MH  - Pharmacists/*organization & administration
MH  - Professional Role
MH  - Young Adult
OTO - NOTNLM
OT  - CAD/CAM
OT  - Community pharmacists
OT  - Complementary/alternative medicines
OT  - Ethics
OT  - Interviews
OT  - New Zealand
OT  - Professional practice
OT  - Views
EDAT- 2020/07/21 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/03/15 00:00 [received]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1007/s11096-020-01093-2 [doi]
AID - 10.1007/s11096-020-01093-2 [pii]
PST - ppublish
SO  - Int J Clin Pharm. 2020 Aug;42(4):1109-1117. doi: 10.1007/s11096-020-01093-2. Epub
      2020 Jul 20.


PMID- 32685998
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 1573-6792 (Electronic)
IS  - 0896-0267 (Linking)
VI  - 33
IP  - 6
DP  - 2020 Nov
TI  - Identifying Resting-State Functional Connectivity Changes in the Motor Cortex
      Using fNIRS During Recovery from Stroke.
PG  - 710-719
LID - 10.1007/s10548-020-00785-2 [doi]
AB  - Resting-state functional imaging has been used to study the functional
      reorganization of the brain. The application of functional near-infrared
      spectroscopy (fNIRS) to assess resting-state functional connectivity (rsFC) has
      already been demonstrated in recent years. The present study aimed to identify
      the difference in rsFC patterns during the recovery from the upper-limb deficit
      due to stroke. Twenty patients with mild stroke having an onset of four to eight 
      weeks were recruited from the stroke clinic of our institute and an equal number 
      of healthy volunteers were included in the study after ethical committee
      approval. The fNIRS signals were recorded bilaterally over the premotor area and 
      supplementary motor area and over the primary motor cortex. Pearson Correlation
      is the method used to compute rsFC for the healthy group and patient group. For
      the healthy group, both intra-hemispheric and inter-hemispheric connections were 
      stronger. RSFC analysis demonstrated changes from the healthy pattern for the
      patient group with an upper-limb deficit. The left hemisphere affected group
      showed disrupted ipsilesional and an increased contra-lesional connectivity. The 
      longitudinal data analysis of rsFC showed improvement in the connections in the
      ipsilesional hemisphere between the primary motor area, somatosensory area, and
      premotor areas. In the future, the rsFC changes during the recovery could be used
      to predict the extent of recovery from stroke motor deficits.
FAU - Arun, K M
AU  - Arun KM
AUID- ORCID: 0000-0002-7984-0402
AD  - Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal 
      Institute for Medical Science and Technology, Trivandrum, 695011, Kerala, India.
FAU - Smitha, K A
AU  - Smitha KA
AUID- ORCID: 0000-0003-4882-399X
AD  - Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal 
      Institute for Medical Science and Technology, Trivandrum, 695011, Kerala, India.
FAU - Sylaja, P N
AU  - Sylaja PN
AUID- ORCID: 0000-0003-4896-8275
AD  - Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and
      Technology, Trivandrum, 695011, Kerala, India.
FAU - Kesavadas, Chandrasekharan
AU  - Kesavadas C
AUID- ORCID: 0000-0003-4914-8666
AD  - Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal 
      Institute for Medical Science and Technology, Trivandrum, 695011, Kerala, India. 
      chandkesav@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - United States
TA  - Brain Topogr
JT  - Brain topography
JID - 8903034
SB  - IM
MH  - Brain
MH  - Brain Mapping
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - *Motor Cortex/diagnostic imaging
MH  - Spectroscopy, Near-Infrared
MH  - *Stroke/diagnostic imaging
OTO - NOTNLM
OT  - *Functional near-infrared spectroscopy
OT  - *Resting-state functional connectivity
OT  - *Stroke
OT  - *Upper-limb deficit
EDAT- 2020/07/21 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/01/12 00:00 [received]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1007/s10548-020-00785-2 [doi]
AID - 10.1007/s10548-020-00785-2 [pii]
PST - ppublish
SO  - Brain Topogr. 2020 Nov;33(6):710-719. doi: 10.1007/s10548-020-00785-2. Epub 2020 
      Jul 19.


PMID- 32685681
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2379-6146 (Electronic)
IS  - 2379-6146 (Linking)
VI  - 4
IP  - 3
DP  - 2020 Jul
TI  - Learning health care systems: Highly needed but challenging.
PG  - e10211
LID - 10.1002/lrh2.10211 [doi]
AB  - BACKGROUND: Learning health care systems (LHSs) have the potential to transform
      health care. However, this transformation process faces significant challenges.
      MATERIALS AND METHODS: Based on proposals and early examples of LHSs in the
      literature and conceptual analysis of the LHS mission, we provide four models
      with distinct organizational and ethical implications that may facilitate the
      transformation. RESULTS: An LHS could be developed in the following ways: by
      taking away practical impediments that prevent patients and professionals from
      engaging in scientific research (model 1: optimization LHS); by routinely
      analyzing observational data from electronic health records and other sources
      (model 2: comprehensive data LHS); by making clinical decisions based on the
      outcomes of the aforementioned data analyses and directly evaluating the outcomes
      in order to continuously improve decision-making (model 3: real-time LHS); or by 
      embedding clinical trials into routine care delivery (model 4: full LHS).
      CONCLUSIONS: Each model has different ethical implications for consent and
      oversight. Also, the four-model approach shows that reorganizing a health care
      center into an LHS is not an all-or-nothing decision. Rather, it is a choice from
      a menu of possibilities. Instead of discussing the advantages and disadvantages
      of the LHS menu in its entirety, the medical community should focus on the
      designs and ethical aspects of each of the separate options.
CI  - (c) 2020 The Authors. Learning Health Systems published by Wiley Periodicals,
      Inc. on behalf of University of Michigan.
FAU - Wouters, Roel H P
AU  - Wouters RHP
AUID- ORCID: https://orcid.org/0000-0002-8686-9166
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary
      Care University Medical Center Utrecht/Utrecht University Utrecht The
      Netherlands.
FAU - van der Graaf, Rieke
AU  - van der Graaf R
AUID- ORCID: https://orcid.org/0000-0003-4907-7044
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary
      Care University Medical Center Utrecht/Utrecht University Utrecht The
      Netherlands.
FAU - Voest, Emile E
AU  - Voest EE
AUID- ORCID: https://orcid.org/0000-0001-8249-9586
AD  - Department of Medical Oncology Netherlands Cancer Institute Amsterdam The
      Netherlands.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AUID- ORCID: https://orcid.org/0000-0002-7542-8963
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary
      Care University Medical Center Utrecht/Utrecht University Utrecht The
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200113
PL  - United States
TA  - Learn Health Syst
JT  - Learning health systems
JID - 101708071
PMC - PMC7362679
OTO - NOTNLM
OT  - health policy
OT  - informed consent
OT  - learning health care system
OT  - learning health system
OT  - research ethics
COIS- The authors declare no conflicts of interest.
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:01
CRDT- 2020/07/21 06:00
PHST- 2019/06/28 00:00 [received]
PHST- 2019/09/16 00:00 [revised]
PHST- 2019/11/03 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:01 [medline]
AID - 10.1002/lrh2.10211 [doi]
AID - LRH210211 [pii]
PST - epublish
SO  - Learn Health Syst. 2020 Jan 13;4(3):e10211. doi: 10.1002/lrh2.10211. eCollection 
      2020 Jul.


PMID- 32685218
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-6447 (Print)
VI  - 2020
DP  - 2020
TI  - B.P.F.C.(R) Bio-Plasma(R) with Pure Growth Factors (BioPlasma(R)) Used for the
      Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated
      Tooth: A New Therapeutic Option.
PG  - 4876437
LID - 10.1155/2020/4876437 [doi]
AB  - The aim of this case report was to evaluate the efficacy of a new platelet-rich
      plasma preparation and its regenerative capacity of bone periapical tissue for
      the treatment of a very compromised endodontic treated tooth, with a periapical
      lesion of 1.5 cm in diameter, using a pure platelet concentrate. This is made
      without the use of anticoagulant or any type of activator, e.g., bovine thrombin,
      calcium chloride. For this reason, it has been called "Pure"; it is the
      B.P.F.C.(R) Bio-Plasma(R) with Pure Growth Factors (BioPlasma(R)) designed and
      developed by Dr. Raffaello Vigano. The patient has read and signed a written
      consent form. The study protocol was approved by the Ethics Committee for Human
      Studies, University of Varese. X-ray at 2 and 6 months and 4 years after
      endodontic surgery demonstrated the success of the treatment.
CI  - Copyright (c) 2020 Raffaello Vigano et al.
FAU - Vigano, Raffaello
AU  - Vigano R
AD  - DDS, Freelancer in Varese, Italy.
AD  - University of Milano, Milano, Italy.
FAU - Disconzi, Mirko
AU  - Disconzi M
AD  - University of Milano, Milano, Italy.
FAU - Bertini, Edoardo
AU  - Bertini E
AD  - University of Milano, Milano, Italy.
FAU - Vigano, Luca
AU  - Vigano L
AD  - Department of Oral Radiology, San Paolo Dental Building, University of Milano,
      Milano, Italy.
FAU - Casu, Cinzia
AU  - Casu C
AUID- ORCID: https://orcid.org/0000-0002-7962-2712
AD  - Private Dental Practice, Cagliari, Italy.
LA  - eng
PT  - Case Reports
DEP - 20200629
PL  - Egypt
TA  - Case Rep Dent
JT  - Case reports in dentistry
JID - 101573242
PMC - PMC7341431
COIS- The authors declare that there is no conflict of interest regarding the
      publication of this paper.
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:01
CRDT- 2020/07/21 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/05/22 00:00 [revised]
PHST- 2020/06/13 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:01 [medline]
AID - 10.1155/2020/4876437 [doi]
PST - epublish
SO  - Case Rep Dent. 2020 Jun 29;2020:4876437. doi: 10.1155/2020/4876437. eCollection
      2020.


PMID- 32685207
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2090-0724 (Print)
IS  - 2090-0724 (Linking)
VI  - 2020
DP  - 2020
TI  - Factors Associated with the Nutritional Status among Male Workers of Iron and
      Steel Industries in Bara District, Nepal.
PG  - 7432716
LID - 10.1155/2020/7432716 [doi]
AB  - BACKGROUND: Overweight and obesity are major serious public health problems,
      since their prevalence is accelerating rapidly not only in developed but also in 
      developing countries. The aim of this study was to find out the factors
      associated with the nutritional status of the industrial workers in Bara District
      of Nepal. METHODS: An industry-based analytical cross-sectional study was
      conducted among the 271 male workers using pretested semistructured
      questionnaires, food frequency questionnaire, 24-hour recall method, and
      anthropometric measurement after obtaining informed consent from the workers. For
      the categorical independent variables, bivariate and multivariate regression
      tests were used for the analysis, and for numerical independent variables,
      Student's t-test was used. A P value less than 0.05 was considered significant.
      Ethical approval was taken from the Research Committee of the College of Applied 
      Food and Diary Technology (CAFODAT). RESULTS: Overweight /obesity was observed
      among 27.3% of the participants of which 22.1% were overweight and 5.2% were
      obese. Age (OR: 2.54; 95% CI: 1.346-4.823); ethnicity, Brahmin/Chhetri (OR: 6.14;
      95% CI: 1.971-19.123) and Madhesi (OR: 4.641; 95% CI: 1.534-14.04); and smoking
      (OR: 4.165; 95% CI: 1.972-8.80) were associated with nutritional status of
      industrial workers. Additionally, food frequency (OR: 2.232; 95% CI:
      1.101-4.522), dietary diversity, and total calorie intake were also significantly
      associated with nutritional status of industrial workers. CONCLUSIONS: The study 
      has indicated that more than one-fourth of workers of iron and steel industries
      in Bara District of Nepal are overweight or obese. Different sociodemographic and
      socioeconomic factors and lifestyle-related factors were associated with
      overweight and obesity. There is need for programs for industrial workers focused
      on nutrition education to raise awareness about nutrition-related problems and
      risk factors.
CI  - Copyright (c) 2020 Raj Kumar Sangroula et al.
FAU - Sangroula, Raj Kumar
AU  - Sangroula RK
AUID- ORCID: https://orcid.org/0000-0002-3841-7819
AD  - College of Applied Food and Dairy Technology, New Baneshwar, Kathmandu, Nepal.
FAU - Subedi, Hari Prasad
AU  - Subedi HP
AUID- ORCID: https://orcid.org/0000-0002-4656-9388
AD  - College of Applied Food and Dairy Technology, New Baneshwar, Kathmandu, Nepal.
FAU - Tiwari, Kalpana
AU  - Tiwari K
AD  - College of Applied Food and Dairy Technology, New Baneshwar, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - United States
TA  - J Nutr Metab
JT  - Journal of nutrition and metabolism
JID - 101526296
PMC - PMC7338971
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:01
CRDT- 2020/07/21 06:00
PHST- 2020/01/04 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:01 [medline]
AID - 10.1155/2020/7432716 [doi]
PST - epublish
SO  - J Nutr Metab. 2020 Jun 12;2020:7432716. doi: 10.1155/2020/7432716. eCollection
      2020.


PMID- 32685062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1733-134X (Print)
IS  - 1733-134X (Linking)
VI  - 85
DP  - 2020
TI  - Which is the most affected muscle in lumbar back pain - multifidus or erector
      spinae?
PG  - e278-e286
LID - 10.5114/pjr.2020.96391 [doi]
AB  - PURPOSE: The purpose of this study is to evaluate the relationship between lumbar
      back pain, lumbar disc herniation, and erector spinae and multifidus muscle
      lipomatous degeneration. MATERIAL AND METHODS: After receiving approval from the 
      clinical studies Ethics Committee, magnetic resonance imaging (MRI) studies of
      patients who had physical examination in orthopaedic, neurology, neurosurgery,
      physical medicine and rehabilitation clinics were evaluated. Their pre-diagnoses 
      were 'herniated nucleus pulposus' or 'lumbar disc herniation' or 'back pain' and 
      their age range was between 18 and 64 years. Patients who had vertebral fracture,
      spondylitis-spondylodiscitis, tumours, structural anomalies such as
      spondylolisthesis, scoliosis and vertebral segmentation anomalies and previous
      surgery in the lumbar area were excluded. There were 205 patients in the case
      group who had lumbar disc herniation between L1-S1 level and there were 187
      patients in the control group who had no lumbar disc herniation. In the study,
      patient age, sex, herniation level and erector spinae and multifidus muscle
      lipomatous degeneration were compared. Muscle lipomatous degeneration were
      evaluated with a visual scale. RESULTS: There were 105 men and 100 women in the
      case group and 88 men and 99 women in the control group. In the case group,
      lumbar disc herniation was detected mostly at L4-5 and L5-S1 levels. There was no
      significant difference between case and control groups with regard to erector
      spinae and multifidus muscle lipomatous degeneration. In the case group,
      lipomatous degeneration of the erector spinae was higher compared to that of the 
      multifidus muscle. CONCLUSIONS: Patients with low back pain may have fatty
      degeneration in erector spina and multifidus muscles with or without LDH, but LDH
      accelerates this process rather than being a result of it. In patients with LDH, 
      fatty degeneration in the erector spina is more pronounced than in multifidus,
      and the erector spina is more affected by the LDH process.
CI  - Copyright (c) Polish Medical Society of Radiology 2020.
FAU - Ozturk, Piril Erbay
AU  - Ozturk PE
AD  - Department of Radiology, Faculty of Medicine, Canakkale Onsekiz Mart University, 
      Canakkale, Turkey.
FAU - Aylanc, Nilufer
AU  - Aylanc N
AD  - Department of Radiology, Faculty of Medicine, Canakkale Onsekiz Mart University, 
      Canakkale, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - Poland
TA  - Pol J Radiol
JT  - Polish journal of radiology
JID - 101175532
PMC - PMC7361368
OTO - NOTNLM
OT  - back pain
OT  - erector spinae
OT  - lumbar disc herniation
OT  - multifidus
COIS- The authors report no conflict of interest.
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:01
CRDT- 2020/07/21 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:01 [medline]
AID - 10.5114/pjr.2020.96391 [doi]
AID - 41032 [pii]
PST - epublish
SO  - Pol J Radiol. 2020 Jun 3;85:e278-e286. doi: 10.5114/pjr.2020.96391. eCollection
      2020.


PMID- 32684825
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1445-5781 (Print)
IS  - 1445-5781 (Linking)
VI  - 19
IP  - 3
DP  - 2020 Jul
TI  - The impact of parental unaffected allele combination on the diagnostic outcome in
      the preimplantation genetic testing for myotonic dystrophy type 1 in Japanese
      ancestry.
PG  - 265-269
LID - 10.1002/rmb2.12327 [doi]
AB  - PURPOSE: The objective is to clarify the practical problem of the preimplantation
      genetic testing (PGT) for myotonic dystrophy type 1 (DM1) in Japanese subjects.
      METHODS: For the 32 couples who consented to participate in PGT for DM1, CTG
      repeats number on the unaffected alleles was analyzed. Based on the allele
      combination, they were classified into 3 groups by the number of diagnostic
      allelic pattern; "full informative," "semi informative," and "noninformative."
      According to the Japan Society of Obstetrics and Gynecology (JSOG) principle, PGT
      was performed using the direct diagnosis to the 288 embryos from the 17 couples
      who received the ethical approval from both our institution and JSOG. RESULTS: In
      the 32 couples, the frequency of CTG repeats on the unaffected alleles showed
      bimodal distribution. The "full informative," "semi informative," and
      "noninformative" couples accounted for 46.9% (15/32 couples), 46.9% (15/32
      couples) and 6.2% (2/32 couples), respectively. The transferable embryos
      accounted for 28.9% (33/114 embryos) in the "full informative" couples, although 
      it was limited to 12.6% (22/174 embryos) in the "semi informative" couples.
      CONCLUSION: The loss of unaffected embryos which cannot be diagnosed as
      transferable was a clinically major problem and implied an increase in oocyte
      retrieval, especially for "semi informative" couples.
CI  - (c) 2020 The Authors. Reproductive Medicine and Biology published by John Wiley &
      Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.
FAU - Senba, Hiroshi
AU  - Senba H
AUID- ORCID: https://orcid.org/0000-0003-2627-423X
AD  - Department of Obstetrics and Gynecology Tachikawa Hospital Tachikawa Japan.
FAU - Sueoka, Kou
AU  - Sueoka K
AD  - Department of Obstetrics and Gynecology School of Medicine, Keio University Tokyo
      Japan.
FAU - Sato, Suguru
AU  - Sato S
AUID- ORCID: https://orcid.org/0000-0002-4695-4761
AD  - Department of Obstetrics and Gynecology School of Medicine, Keio University Tokyo
      Japan.
FAU - Higuchi, Nobuhiko
AU  - Higuchi N
AD  - Department of Obstetrics and Gynecology School of Medicine, Keio University Tokyo
      Japan.
FAU - Mizuguchi, Yuki
AU  - Mizuguchi Y
AD  - Department of Obstetrics and Gynecology School of Medicine, Keio University Tokyo
      Japan.
FAU - Sato, Kenji
AU  - Sato K
AUID- ORCID: https://orcid.org/0000-0001-7581-1746
AD  - Department of Obstetrics and Gynecology School of Medicine, Keio University Tokyo
      Japan.
FAU - Tanaka, Mamoru
AU  - Tanaka M
AUID- ORCID: https://orcid.org/0000-0002-1782-4271
AD  - Department of Obstetrics and Gynecology School of Medicine, Keio University Tokyo
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - Japan
TA  - Reprod Med Biol
JT  - Reproductive medicine and biology
JID - 101213278
PMC - PMC7360966
OTO - NOTNLM
OT  - CTG repeats number
OT  - direct diagnosis
OT  - myotonic dystrophy type 1
OT  - polymerase chain reaction
OT  - preimplantation genetic testing
COIS- Conflict of interest: Hiroshi Senba, Kou Sueoka, Suguru Sato, Nobuhiko Higuchi,
      Yuki Mizuguchi, Kenji Sato, Mamoru Tanaka declare that they have no conflict of
      interest. Human rights statements and informed consent: All procedures followed
      were in accordance with the ethical standards of the responsible committee on
      human experimentation (institutional and national) and with the Helsinki
      Declaration of 1964 and its later amendments. Informed consent was obtained from 
      all couples for being included in the study. Animal studies: The protocol and
      procedure of PGT were approved by the ethics committee both of our institution
      and the Japan Society of Obstetrics and Gynecology (JSOG) in every couple.
EDAT- 2020/07/21 06:00
MHDA- 2020/07/21 06:01
CRDT- 2020/07/21 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/07/21 06:00 [entrez]
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2020/07/21 06:01 [medline]
AID - 10.1002/rmb2.12327 [doi]
AID - RMB212327 [pii]
PST - epublish
SO  - Reprod Med Biol. 2020 Apr 29;19(3):265-269. doi: 10.1002/rmb2.12327. eCollection 
      2020 Jul.


PMID- 32684189
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210115
IS  - 1475-2654 (Electronic)
IS  - 1466-2523 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun
TI  - 'Big Data' in animal health research - opportunities and challenges.
PG  - 1-2
LID - 10.1017/S1466252319000215 [doi]
AB  - Automated systems for high-input data collection and data storage have led to
      exponential growth in the availability of information. Such datasets and the
      tools applied to them have been referred to as 'big data'. Starting with a
      systematic review of the terms 'informatics, bioinformatics and big data' in
      animal health this special issue of AHRR illustrates some big-data applications
      with papers on how the use of various omics methods may be used to facilitate the
      development of improved diagnostics, therapeutics, and vaccines for foodborne
      pathogens in poultry and on how a better understanding of rumen microbiota could 
      lead to improved feed absorption while minimizing methane production. Other
      papers in this issue cover the use of big data modeling in dairy cattle for more 
      effective disease interventions and machine learning tools for livestock
      breeding. The final two reviews describe the use of big data in better
      vector-borne pathogen forecasts with canine seroprevalence maps and modeling
      approaches to understand the transmission of avian influenza virus. Although a
      lot of technical and ethical issues remain with the use of big data, these
      reviews illustrate the tremendous potential that big-data systems have to
      revolutionize animal health research.
FAU - MacInnes, Janet I
AU  - MacInnes JI
AUID- ORCID: 0000-0002-1454-539X
AD  - Department of Pathobiology, Ontario Veterinary College, University of Guelph,
      Guelph, Canada.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200720
PL  - England
TA  - Anim Health Res Rev
JT  - Animal health research reviews
JID - 101083072
SB  - IM
MH  - Animals
MH  - *Big Data
MH  - Research/*trends
MH  - Veterinary Medicine/*methods/*trends
OTO - NOTNLM
OT  - *Animal health
OT  - *big data
OT  - *machine learning
OT  - *modeling
OT  - *prediction
EDAT- 2020/07/21 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/07/21 06:00
PHST- 2020/07/21 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
PHST- 2020/07/21 06:00 [entrez]
AID - 10.1017/S1466252319000215 [doi]
AID - S1466252319000215 [pii]
PST - ppublish
SO  - Anim Health Res Rev. 2020 Jun;21(1):1-2. doi: 10.1017/S1466252319000215. Epub
      2020 Jul 20.


PMID- 32683659
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 9
DP  - 2020 Sep
TI  - Insulin-Induced Skin Lipohypertrophy in Type 2 Diabetes: a Multicenter Regional
      Survey in Southern Italy.
PG  - 2001-2017
LID - 10.1007/s13300-020-00876-0 [doi]
AB  - INTRODUCTION: Lipohypertrophies (LHs) due to incorrect insulin injection
      techniques have been described in the literature for decades. Their rate averages
      38%, but this is still controversial because of the vast range reported by
      different publications, most of which fail to describe the selected detection
      protocol and therefore are not entirely reliable. We still need to identify the
      real LH rate, and only consistently using a standardized method in a large cohort
      of insulin-treated (IT) patients make this possible. METHODS: Our group performed
      thorough clinical skin examinations on patients suffering from type 2 diabetes
      mellitus (T2DM): 1247 IT T2DM outpatients were examined according to a
      standardized protocol, previously published elsewhere, as well as an ultrasound
      scan of the same skin areas to assess the degree of concordance between the two
      methods and to evaluate the demographic, clinical, and behavioral risk factors
      (RF) as well as metabolic consequences of identified LHs. RESULTS: The
      concordance between the two methods was 99%. Identified risk factors for LHs were
      needle reuse, failure to rotate injection sites, and ice-cold insulin injections.
      High HbA1c values, wide glycemic variability, and longstanding proneness to
      hypoglycemia with a high rate of ongoing hypoglycemic events proved to be
      significantly associated with LHs, too; the same applied to cardiovascular and
      renal complications as well as to living alone and being retired. CONCLUSIONS:
      Based on a strict well-structured methodology, our data confirmed what has
      already been reported in the literature on factors leading to, or associated
      with, LHs and, for the first time in adults, indicated cryotrauma from ice-cold
      insulin injections and specific social conditions as factors facilitating LH
      occurrence. HCPs should therefore plan a yearly clinical examination of all
      injection sites to improve patient quality of life through better glucose control
      and a reduced rate of hypoglycemic events. TRIAL REGISTRATION: Trial registration
      no. 127-11.01.2019, approved by the Scientific and Ethics Committee of Campania
      University "Luigi Vanvitelli," Naples, Italy.
FAU - Gentile, Sandro
AU  - Gentile S
AUID- ORCID: http://orcid.org/0000-0002-9059-6121
AD  - Department of Internal Medicine, Campania University "Luigi Vanvitelli" and
      Nefrocenter Research, Naples, Italy. s.gentile149@gmali.com.
AD  - Diabetes Unit AID Castellammare di Stabia, Castellammare di Stabia, Italy.
      s.gentile149@gmali.com.
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy. s.gentile149@gmali.com.
FAU - Guarino, Giuseppina
AU  - Guarino G
AD  - Department of Internal Medicine, Campania University "Luigi Vanvitelli" and
      Nefrocenter Research, Naples, Italy.
FAU - Corte, Teresa Della
AU  - Corte TD
AD  - Department of Internal Medicine, Campania University "Luigi Vanvitelli" and
      Nefrocenter Research, Naples, Italy.
AD  - Diabetes Unit AID Castellammare di Stabia, Castellammare di Stabia, Italy.
AD  - Diabetes Unit AID Portici, Portici, Italy.
AD  - Diabetes Unit AID Cava de' Tirreni, Cava de' Tirreni, Italy.
AD  - Endocrinology and Diabetes, San Raffaele Termini Pisana Research Institute, Rome,
      Italy.
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
FAU - Marino, Giampiero
AU  - Marino G
AD  - Department of Internal Medicine, Campania University "Luigi Vanvitelli" and
      Nefrocenter Research, Naples, Italy.
FAU - Fusco, Alessandra
AU  - Fusco A
AD  - Diabetes Unit AID Napoli, Napoli, Italy.
FAU - Corigliano, Gerardo
AU  - Corigliano G
AD  - Diabetes Unit AID Napoli, Napoli, Italy.
FAU - Colarusso, Sara
AU  - Colarusso S
AD  - Diabetes Unit AID Benevento, Benevento, Italy.
FAU - Piscopo, Marco
AU  - Piscopo M
AD  - Diabetes Unit AID Nola, Nola, Italy.
FAU - Improta, Maria Rosaria
AU  - Improta MR
AD  - Diabetes Unit AID Castellammare di Stabia, Castellammare di Stabia, Italy.
AD  - Diabetes Unit AID Portici, Portici, Italy.
AD  - Diabetes Unit AID Cava de' Tirreni, Cava de' Tirreni, Italy.
AD  - Endocrinology and Diabetes, San Raffaele Termini Pisana Research Institute, Rome,
      Italy.
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
FAU - Corigliano, Marco
AU  - Corigliano M
AD  - Diabetes Unit AID Napoli, Napoli, Italy.
AD  - Diabetes Unit AID Benevento, Benevento, Italy.
AD  - Diabetes Unit AID Nola, Nola, Italy.
AD  - Diabetes Unit AID Castellammare di Stabia, Castellammare di Stabia, Italy.
AD  - Diabetes Unit AID Portici, Portici, Italy.
AD  - Diabetes Unit AID Cava de' Tirreni, Cava de' Tirreni, Italy.
AD  - Endocrinology and Diabetes, San Raffaele Termini Pisana Research Institute, Rome,
      Italy.
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
FAU - MartedI, Emilia
AU  - MartedI E
AD  - Diabetes Unit AID Portici, Portici, Italy.
FAU - Oliva, Domenica
AU  - Oliva D
AD  - Diabetes Unit AID Cava de' Tirreni, Cava de' Tirreni, Italy.
AD  - Endocrinology and Diabetes, San Raffaele Termini Pisana Research Institute, Rome,
      Italy.
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
FAU - Russo, Viviana
AU  - Russo V
AD  - Diabetes Unit AID Napoli, Napoli, Italy.
FAU - Simonetti, Rosa
AU  - Simonetti R
AD  - Diabetes Unit AID Nola, Nola, Italy.
FAU - Satta, Ersilia
AU  - Satta E
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
FAU - Romano, Carmine
AU  - Romano C
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
FAU - Alfarone, Carmelo
AU  - Alfarone C
AD  - Diagest Dialysis Unit, Rome, Italy.
FAU - Vetrano, Antonio
AU  - Vetrano A
AD  - Diabetes Unit, AID, Naples, Italy.
FAU - Martino, Carmine
AU  - Martino C
AD  - Diabetes Unit AID Castellammare di Stabia, Castellammare di Stabia, Italy.
FAU - Lamberti, Clelia
AU  - Lamberti C
AD  - Diabetes Unit, AID Nocera Inferiore, Nocera Inferiore, Italy.
FAU - Vecchiato, Agostino
AU  - Vecchiato A
AD  - Diabetes Unit, AID Nocera Inferiore, Nocera Inferiore, Italy.
FAU - Cozzolino, Giuseppe
AU  - Cozzolino G
AD  - Diabetes Unit AID Nola, Nola, Italy.
FAU - Brancario, Clementina
AU  - Brancario C
AD  - Diabetes Unit AID Nola, Nola, Italy.
FAU - Strollo, Felice
AU  - Strollo F
AD  - Endocrinology and Diabetes, San Raffaele Termini Pisana Research Institute, Rome,
      Italy.
AD  - Nefrocenter Research and Nyx Start-Up, Naples, Italy.
CN  - AMD-OSDI Study Group on Injection Techniques and Nefrocenter Research & Nyx
      Start-up Study Group
LA  - eng
PT  - Journal Article
DEP - 20200718
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
PMC - PMC7435140
OTO - NOTNLM
OT  - Diabetes
OT  - Education
OT  - Glycemic variability
OT  - Hypoglycemia
OT  - Lipohypertrophy
EDAT- 2020/07/20 06:00
MHDA- 2020/07/20 06:01
CRDT- 2020/07/20 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2020/07/20 06:01 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - 10.1007/s13300-020-00876-0 [doi]
AID - 10.1007/s13300-020-00876-0 [pii]
PST - ppublish
SO  - Diabetes Ther. 2020 Sep;11(9):2001-2017. doi: 10.1007/s13300-020-00876-0. Epub
      2020 Jul 18.


PMID- 32683482
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20201217
IS  - 1432-0711 (Electronic)
IS  - 0932-0067 (Linking)
VI  - 302
IP  - 4
DP  - 2020 Oct
TI  - Sentinel lymph node biopsy in vulvar cancer: status, level of knowledge, and
      counseling in outpatient setting.
PG  - 1001-1007
LID - 10.1007/s00404-020-05701-4 [doi]
AB  - PURPOSE: Evaluating the counseling of patients with vulvar cancer in outpatient
      setting regarding the application of sentinel lymph node dissection (SLND), the
      selection of hospitals for further treatment, and level of knowledge. METHODS: A 
      questionnaire containing 29 questions about SLND in vulvar cancer was sent to
      gynecologists in Lower Saxony. The questionnaire contained multiple choice
      questions and open questions. The study was approved by the local ethics
      committee. RESULTS: The median age of the 86 respondents was 54 (26-66) years.
      Most participants (83.1%) reported to only treat one to five patients with vulvar
      cancer per year. Interestingly, 70.5% of the gynecologists send their patients to
      university hospitals and 64.1% to hospitals offering maximum care, respectively. 
      Of all, 32.7% replied that SLND was performed rarely or never in their patients. 
      The gynecologists answered that only 36.7% of the patients are well informed
      about advantages and possible disadvantages of SLND. Most (84%) felt responsible 
      to counsel patients on treatment decisions independently from or additionally to 
      the hospital. Of all, 72% replied that they are not completely sure about the
      exact recurrence rates after SLND. Of notice, 66% believe that SLND for vulvar
      cancer is safe if applied in specialized centers and 92% stated that focusing
      treatment on specialized centers is required for best results. CONCLUSION: SLND
      for vulvar cancer is widely accepted and regularly recommended among
      gynecologists. Outpatient doctors report to send most patients to specialized
      centers. However, it appears that patients remain uninformed after counseling in 
      the clinics and that there is a lack of detailed knowledge about risks and
      complication rates of groin treatment in the outpatient setting.
FAU - Rottger, Marlene
AU  - Rottger M
AD  - Department of Obstetrics and Gynecology, Hanover Medical School,
      Carl-Neuberg-Street 1, 30625, Hannover, Germany.
FAU - Hertel, Hermann
AU  - Hertel H
AD  - Department of Obstetrics and Gynecology, Hanover Medical School,
      Carl-Neuberg-Street 1, 30625, Hannover, Germany.
FAU - Kaukemuller, Laura
AU  - Kaukemuller L
AD  - Department of Obstetrics and Gynecology, Hanover Medical School,
      Carl-Neuberg-Street 1, 30625, Hannover, Germany.
FAU - Brodowski, Lars
AU  - Brodowski L
AD  - Department of Obstetrics and Gynecology, Hanover Medical School,
      Carl-Neuberg-Street 1, 30625, Hannover, Germany.
FAU - Flentje, Markus
AU  - Flentje M
AD  - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical
      School, Hannover, Germany.
FAU - Hillemanns, Peter
AU  - Hillemanns P
AD  - Department of Obstetrics and Gynecology, Hanover Medical School,
      Carl-Neuberg-Street 1, 30625, Hannover, Germany.
FAU - Klapdor, Rudiger
AU  - Klapdor R
AUID- ORCID: 0000-0002-0117-4366
AD  - Department of Obstetrics and Gynecology, Hanover Medical School,
      Carl-Neuberg-Street 1, 30625, Hannover, Germany. klapdor.ruediger@mh-hannover.de.
LA  - eng
PT  - Journal Article
DEP - 20200718
PL  - Germany
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
SB  - IM
MH  - Adult
MH  - Aged
MH  - Counseling/*methods
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Outpatients
MH  - Sentinel Lymph Node/*surgery
MH  - Sentinel Lymph Node Biopsy/*methods
MH  - Vulvar Neoplasms/pathology/*surgery
PMC - PMC7471199
OTO - NOTNLM
OT  - *Groin recurrence
OT  - *Outpatient setting
OT  - *Sentinel lymph node biopsy
OT  - *Vulvar cancer
EDAT- 2020/07/20 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/05/02 00:00 [received]
PHST- 2020/07/11 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - 10.1007/s00404-020-05701-4 [doi]
AID - 10.1007/s00404-020-05701-4 [pii]
PST - ppublish
SO  - Arch Gynecol Obstet. 2020 Oct;302(4):1001-1007. doi: 10.1007/s00404-020-05701-4. 
      Epub 2020 Jul 18.


PMID- 32683461
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20220218
IS  - 1432-5195 (Electronic)
IS  - 0341-2695 (Linking)
VI  - 44
IP  - 10
DP  - 2020 Oct
TI  - Post-COVID-19 return to elective orthopaedic surgery-is rescheduling just a
      reboot process? Which timing for tests? Is chest CT scan still useful? Safety of 
      the first hundred elective cases? How to explain the "new normality health
      organization" to patients?
PG  - 1905-1913
LID - 10.1007/s00264-020-04728-1 [doi]
AB  - PURPOSE: The long incubation period and asymptomatic spread of COVID-19 present
      considerable challenges for health care institutions when patients return to
      elective surgery. METHODS: A retrospective review of the first adult elective
      cases performed between May 18, 2020 and June 14, 2020, after the end of lockdown
      was analysed in Belgium to answer the following questions: (1) for the 236
      cancelled patients during the outbreak, how easy was rescheduling? (2) How useful
      was universal RT-PCR testing and chest CT scan for the 211 orthopaedic and trauma
      admissions? (3) How were surgical difficulty category, number of operations and
      complications different when compared to the pre-COVID period? (4) How would
      patients balance the benefit of surgery against the unknown risk of developing
      COVID-19? RESULTS: Before surgery, blood tests for anaesthesiology and imaging
      related to the surgical procedure were scheduled prior to universal testing
      (COVID-19 PCR and chest CT) performed 72-120 hours before surgery. Among the 211 
      asymptomatic patients who were tested before surgery, six had positive PCR, while
      no abnormality was found on the chest CT scan of all the patients. With this
      timing for tests, the 104 patients included in the current study for elective
      surgery were free of disease before undergoing surgery and remained without
      COVID-19 after surgery. Among the 366 cancelled patients during the outbreak,
      only 12% of the patients accepted to proceed with rescheduling immediately.
      Therefore, this resulted in a 70% reduction for elective surgery and in a 50%
      reduction for arthroplasties as compared to pre-COVID period. The rate of
      complications was not increased during the post-COVID period. A portion of
      patients have confused idea of screening and have difficulty to perceive the new 
      rules of health organization. CONCLUSIONS: Resumption of elective surgical
      procedures appears more difficult for patients than for surgeons with a low
      percentage of cancelled patients accepting to reschedule surgery. Universal
      testing allowed securing patients; however, surgeons must explore better patient 
      perceptions regarding COVID-19 to facilitate a fully informed decision in the
      current period.
FAU - Hernigou, Jacques
AU  - Hernigou J
AD  - Orthopedic Department, EpiCURA Baudour Hornu Hospital, Mons, Belgium.
FAU - Valcarenghi, Jerome
AU  - Valcarenghi J
AD  - Orthopedic Department, Tivoli hospital, La Louviere, Belgium.
FAU - Safar, Adonis
AU  - Safar A
AD  - Orthopedic Department, EpiCURA Baudour Hornu Hospital, Mons, Belgium.
FAU - Ferchichi, Mohamed Amine
AU  - Ferchichi MA
AD  - Orthopedic Department, EpiCURA Baudour Hornu Hospital, Mons, Belgium.
FAU - Chahidi, Esfandiar
AU  - Chahidi E
AD  - Orthopedic Department, Tivoli hospital, La Louviere, Belgium.
FAU - Jennart, Harold
AU  - Jennart H
AD  - Orthopedic Department, Tivoli hospital, La Louviere, Belgium.
FAU - Hernigou, Philippe
AU  - Hernigou P
AUID- ORCID: 0000-0002-8475-279X
AD  - Orthopedic Department, Clinique Geoffroy Saint Hilaire, 75005, Paris, France.
      philippe.hernigou@wanadoo.fr.
AD  - Hospital Henri Mondor, University Paris, Paris, France.
      philippe.hernigou@wanadoo.fr.
LA  - eng
PT  - Journal Article
DEP - 20200719
PL  - Germany
TA  - Int Orthop
JT  - International orthopaedics
JID - 7705431
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Belgium
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Orthopedic Procedures
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Tomography, X-Ray Computed
MH  - Young Adult
PMC - PMC7368853
OTO - NOTNLM
OT  - *Chest CT scan
OT  - *Elective surgery
OT  - *Ethics
OT  - *Fracture
OT  - *Hip arthroplasty
OT  - *Post-COVID-19
OT  - *Psychological burden
OT  - *Surgery cancellation
EDAT- 2020/07/20 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/06/24 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - 10.1007/s00264-020-04728-1 [doi]
AID - 10.1007/s00264-020-04728-1 [pii]
PST - ppublish
SO  - Int Orthop. 2020 Oct;44(10):1905-1913. doi: 10.1007/s00264-020-04728-1. Epub 2020
      Jul 19.


PMID- 32683161
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 260
DP  - 2020 Sep
TI  - The influence of local political trends on childhood vaccine completion in North 
      Carolina.
PG  - 113187
LID - S0277-9536(20)30406-8 [pii]
LID - 10.1016/j.socscimed.2020.113187 [doi]
AB  - BACKGROUND: In North Carolina (NC), a political swing state that permits both
      medical and religious exemptions to school vaccination, rapid changes in the
      electorate have coincided with a vigorous political debate over vaccine laws and 
      an increase in the number of exemptions claimed from vaccine requirements.
      OBJECTIVE: We aimed to determine whether county-level changes in political
      affiliation, determined from publicly available voting records, were associated
      with changes in the rate of vaccine exemptions reported at kindergarten entry in 
      NC. METHODS: We analyzed data from the 2009-2010 to the 2016-2017 school years
      for each of 100 NC counties. We used NC State Board of Elections and Ethics
      Enforcement data to track voter registration trends at the county level,
      comparing the percent of voters registered as Republican, Democrat, or other
      (mostly unaffiliated). Vaccination exemption rates were obtained via the NC DHHS 
      and represented a percentage of the cohort entering kindergarten in that year.
      RESULTS: Statewide, the rate of religious vaccine exemptions increased from 0.68%
      in 2009-2010 to 1.10% in 2016-2017. On multivariable analysis including 800
      county-years, a 1% increase in voters with neither Republican nor Democratic
      affiliation was associated with 0.04% increase in the county's vaccine exemption 
      rate. CONCLUSIONS: In NC, the increase in vaccine exemption rates was primarily
      associated with an increasing share of voters affiliating with neither major
      party. This finding suggests mistrust in social institutions, including both
      government and medicine, extends beyond the platforms of traditional political
      parties.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Buckman, Cierra
AU  - Buckman C
AD  - Brody School of Medicine at East Carolina University, Department of Pediatrics,
      Greenville, NC, USA. Electronic address: BuckmanC17@ecu.edu.
FAU - Liu, Indran C
AU  - Liu IC
AD  - Brody School of Medicine at East Carolina University, Department of Pediatrics,
      Greenville, NC, USA.
FAU - Cortright, Lindsay
AU  - Cortright L
AD  - Brody School of Medicine at East Carolina University, Department of Pediatrics,
      Greenville, NC, USA.
FAU - Tumin, Dmitry
AU  - Tumin D
AD  - Brody School of Medicine at East Carolina University, Department of Pediatrics,
      Greenville, NC, USA.
FAU - Syed, Salma
AU  - Syed S
AD  - Brody School of Medicine at East Carolina University, Department of Pediatrics,
      Greenville, NC, USA.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
RN  - 0 (Vaccines)
SB  - IM
MH  - Child
MH  - Humans
MH  - North Carolina
MH  - Politics
MH  - Schools
MH  - Vaccination
MH  - *Vaccines
OTO - NOTNLM
OT  - *Childhood vaccines
OT  - *North Carolina
OT  - *Political affiliation
OT  - *Political trends
OT  - *Vaccine exemption
OT  - *Vaccine hesitancy
EDAT- 2020/07/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - S0277-9536(20)30406-8 [pii]
AID - 10.1016/j.socscimed.2020.113187 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Sep;260:113187. doi: 10.1016/j.socscimed.2020.113187. Epub 2020
      Jul 10.


PMID- 32682749
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220105
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
VI  - 226
DP  - 2020 Nov
TI  - Death after Birth Asphyxia in the Cooling Era.
PG  - 289-293
LID - S0022-3476(20)30897-0 [pii]
LID - 10.1016/j.jpeds.2020.07.041 [doi]
AB  - In asphyxiated newborn infants treated with hypothermia, 31 of 50 (62%) deaths
      occurred in unstable infants electively extubated before completing hypothermia
      treatment. Later deaths occurred after consultation with palliative care (13/19) 
      or clinical ethics (6/19) services, suggesting these decisions were challenging
      and required support, particularly if nutrition and hydration were withdrawn (n =
      4).
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Al Amrani, Fatema
AU  - Al Amrani F
AD  - Division of Pediatric Neurology, Department of Pediatrics, Montreal Children's
      Hospital, McGill University, Montreal, Canada.
FAU - Racine, Eric
AU  - Racine E
AD  - Department of Medicine and Social and Preventive Medicine, University of
      Montreal, Montreal, Canada; Department of Neurology and Neurosurgery and
      Medicine, and Biomedical Ethics Unit, McGill University, Montreal, Canada.
FAU - Shevell, Michael
AU  - Shevell M
AD  - Division of Pediatric Neurology, Department of Pediatrics, Montreal Children's
      Hospital, McGill University, Montreal, Canada.
FAU - Wintermark, Pia
AU  - Wintermark P
AD  - Division of Newborn Medicine, Department of Pediatrics, Montreal Children's
      Hospital, McGill University, Montreal, Canada. Electronic address:
      pia.wintermark@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200716
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
SB  - IM
MH  - Asphyxia Neonatorum/complications/*mortality/*therapy
MH  - Female
MH  - Humans
MH  - *Hypothermia, Induced
MH  - Infant
MH  - Infant Mortality
MH  - Infant, Newborn
MH  - *Intensive Care, Neonatal
MH  - Male
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *autopsy
OT  - *birth asphyxia
OT  - *brain
OT  - *brain magnetic resonance imaging
OT  - *neonatal encephalopathy
EDAT- 2020/07/20 06:00
MHDA- 2022/01/06 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/07/12 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - S0022-3476(20)30897-0 [pii]
AID - 10.1016/j.jpeds.2020.07.041 [doi]
PST - ppublish
SO  - J Pediatr. 2020 Nov;226:289-293. doi: 10.1016/j.jpeds.2020.07.041. Epub 2020 Jul 
      16.


PMID- 32682631
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20210112
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 252
DP  - 2020 Sep
TI  - Ethical considerations relevant to infections in pregnancy: Application to
      Sars-Covid-19.
PG  - 563-567
LID - S0301-2115(20)30455-3 [pii]
LID - 10.1016/j.ejogrb.2020.07.013 [doi]
AB  - Despite wide diversity and scope, the ethical dimensions relevant to infections
      in pregnancy remain little explored. Important questions span topics with
      personal or wider societal and public health impact. The conceptualization of the
      status and responsibilities of the pregnant woman and the legitimate limits of
      third-party interests are key determinants of our appreciation of applicable
      ethical obligations.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Habiba, Marwan
AU  - Habiba M
AD  - Department of Obstetrics and Gynaecology, University Hospitals of Leicester and
      Department of Health Sciences, University of Leicester, UK. Electronic address:
      mah6@leicester.ac.uk.
FAU - Akkad, Andrea
AU  - Akkad A
AD  - University Hospitals of Leicester and Department Medical Education, University of
      Leicester, Leicester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200712
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Female
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*virology
MH  - Pregnant Women/psychology
MH  - Prenatal Care/*ethics
MH  - SARS-CoV-2
PMC - PMC7354768
OTO - NOTNLM
OT  - Ethics
OT  - Infections
OT  - Pregnancy
COIS- Declaration of Competing Interest The author declare that he has no conflicts of 
      interest.
EDAT- 2020/07/20 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - S0301-2115(20)30455-3 [pii]
AID - 10.1016/j.ejogrb.2020.07.013 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:563-567. doi:
      10.1016/j.ejogrb.2020.07.013. Epub 2020 Jul 12.


PMID- 32682520
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1873-491X (Electronic)
IS  - 0020-7489 (Linking)
VI  - 112
DP  - 2020 Dec
TI  - Exploring the meaning of night shift placement in nursing education: A European
      multicentre qualitative study.
PG  - 103687
LID - S0020-7489(20)30171-1 [pii]
LID - 10.1016/j.ijnurstu.2020.103687 [doi]
AB  - BACKGROUND: An appropriate clinical learning environment has been identified as
      pivotal in nursing undergraduate education and should be planned responsibly.
      Specifically, night shifts placements have been documented as an important
      opportunity for developing a full understanding of the nursing profession and the
      whole process of nursing care. However, night shifts during placement have been
      reported to be stressful and anxiety-provoking, so their usefulness for nursing
      students is still debated. OBJECTIVES: To elicit nursing students' perceptions of
      night shift placement through metaphors, with the aim of discussing the
      pedagogical and ethical implications. DESIGN: A descriptive qualitative study was
      performed based on metaphors collected in an international cross-sectional study 
      in 2016. SETTINGS: A network comprising five Bachelor of Nursing Science degrees 
      located in the Czech Republic, Italy, Poland, Portugal, and Slovakia was
      established. METHODS: A total of 907 out of 1347 eligible nursing students from
      the five European countries described their learning experience on night shifts
      using a metaphor. RESULTS: Overall, 288/907 (31.7%) metaphors emerged as being
      negative-oriented and 137/907 (15.1%) as positive, while the remaining students
      (482; 53.2%) did not report any metaphors. In all five countries, negative
      metaphors prevailed: 'Wasting time' (37/288), 'Useless' (32/288) and 'Handyman'
      (22/288) were the most negative reported metaphors on working a night shift.
      However, doing a night shift is also perceived as a 'Learning opportunity'
      (22/137), a 'New experience' (20/137) and an 'Opportunity to socialize with the
      profession' (14/137) as underlined by the positive metaphors. CONCLUSIONS:
      Students perceive night shift placements mainly as a negative experience, which
      has little to do with education. While planning night shift placements, nursing
      educators should responsibly consider the whole process of education, analysing
      not only the learning outcomes that should be achieved but also the position of
      students and their experience as a person. Clinical mentoring can be a key
      resource in supporting students in transforming their night shift placements'
      experiences into a more meaningful or worthwhile experience. Moreover, night
      shifts should be offered to more experienced students, independent in their
      self-learning processes and capable of managing the limited possibility of
      interacting with other team members and patients.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Dobrowolska, Beata
AU  - Dobrowolska B
AD  - Department of Development in Nursing, Faculty of Health Sciences, Medical
      University of Lublin, Poland. Electronic address: beata.dobrowolska@umlub.pl.
FAU - Visintini, Chiara
AU  - Visintini C
AD  - Department of Medical Sciences, University of Udine, Italy. Electronic address:
      visintini.chiara@spes.uniud.it.
FAU - Pokorna, Andrea
AU  - Pokorna A
AD  - Department of Nursing and Midwifery, Faculty of Medicine, Masaryk University,
      Czech Republic. Electronic address: apokorna@med.muni.cz.
FAU - Nascimento, Carla
AU  - Nascimento C
AD  - Escola Superior de Enfermagem de Lisboa, Portugal. Electronic address:
      carla.nascimento@esel.pt.
FAU - Ferrao, Sonia
AU  - Ferrao S
AD  - Escola Superior de Enfermagem de Lisboa, Portugal. Electronic address:
      sonia.ferrao@esel.pt.
FAU - Ziakova, Katarina
AU  - Ziakova K
AD  - Department of Nursing, Medical Faculty of Jessenius in Martin, Comenius
      University in Bratislava, Slovakia. Electronic address:
      katarina.ziakova@jfmed.uniba.sk.
FAU - Solgajova, Andrea
AU  - Solgajova A
AD  - Department of Nursing, Faculty of Social Sciences and Health Care, Constantine
      the Philosopher University in Nitra, Slovakia. Electronic address:
      asolgajova@ukf.sk.
FAU - Rybarova, Lubica
AU  - Rybarova L
AD  - Department of Midwifery, Faculty of Health Care, University of Presov, Slovakia. 
      Electronic address: lubica.rybarova@unipo.sk.
FAU - Machul, Michal
AU  - Machul M
AD  - Department of Development in Nursing, Faculty of Health Sciences, Medical
      University of Lublin, Poland. Electronic address: michal.machul@umlub.pl.
FAU - Lunazzi Gorizza, Giulia
AU  - Lunazzi Gorizza G
AD  - Department of Medical Sciences, University of Udine, Italy. Electronic address:
      lunazzigorizza.giulia@spes.uniud.it.
FAU - Palese, Alvisa
AU  - Palese A
AD  - Department of Medical Sciences, University of Udine, Italy. Electronic address:
      alvisa.palese@uniud.it.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200702
PL  - England
TA  - Int J Nurs Stud
JT  - International journal of nursing studies
JID - 0400675
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Education, Nursing
MH  - *Education, Nursing, Baccalaureate
MH  - Europe
MH  - Humans
MH  - Italy
MH  - Portugal
MH  - *Students, Nursing
OTO - NOTNLM
OT  - Clinical learning environment
OT  - Ethical implications
OT  - European study
OT  - Metaphors
OT  - Night placement
OT  - Night shift
OT  - Nursing students
COIS- Conflict of Interest The authors declare that there is no conflict of interest.
EDAT- 2020/07/20 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/02/16 00:00 [received]
PHST- 2020/06/06 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/07/20 06:00 [entrez]
AID - S0020-7489(20)30171-1 [pii]
AID - 10.1016/j.ijnurstu.2020.103687 [doi]
PST - ppublish
SO  - Int J Nurs Stud. 2020 Dec;112:103687. doi: 10.1016/j.ijnurstu.2020.103687. Epub
      2020 Jul 2.


PMID- 32682486
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 396
IP  - 10245
DP  - 2020 Jul 18
TI  - Temporary circulatory support for cardiogenic shock.
PG  - 199-212
LID - S0140-6736(20)31047-3 [pii]
LID - 10.1016/S0140-6736(20)31047-3 [doi]
AB  - Cardiogenic shock can occur due to acute ischaemic or non-ischaemic cardiac
      events, or from progression of long-standing underlying heart disease. When
      addressing the cause of underlying disease, the management of cardiogenic shock
      consists of vasopressors and inotropes; however, these agents can increase
      myocardial oxygen consumption, impair tissue perfusion, and are frequently
      ineffective. An alternative approach is to temporarily augment cardiac output
      using mechanical devices. The use of these devices-known as temporary circulatory
      support systems-has increased substantially in recent years, despite being
      expensive, resource intensive, associated with major complications, and lacking
      high-quality evidence to support their use. This Review summarises the
      physiological basis underlying the use of temporary circulatory support for
      cardiogenic shock, reviews the evidence informing indications and
      contraindications, addresses ethical considerations, and highlights the need for 
      further research.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Combes, Alain
AU  - Combes A
AD  - Sorbonne Universite, Institute of Cardiometabolism and Nutrition, Paris, France; 
      Service de Medecine Intensive-Reanimation, Hopitaux Universitaires Pitie
      Salpetriere, Assistance Publique-Hopitaux de Paris, Institut de Cardiologie,
      Paris, France. Electronic address: alain.combes@aphp.fr.
FAU - Price, Susanna
AU  - Price S
AD  - Adult Intensive Care Unit, Royal Brompton Hospital, London, UK; National Heart
      and Lung Institute, Imperial College, London, UK.
FAU - Slutsky, Arthur S
AU  - Slutsky AS
AD  - Interdepartmental Division of Critical Care Medicine, University of Toronto,
      Toronto, ON, Canada; Department of Medicine, Keenan Centre for Biomedical
      Research, Li Ka Shing Knowledge Institute, St Michael's Hospital, University of
      Toronto, Toronto, ON, Canada.
FAU - Brodie, Daniel
AU  - Brodie D
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University
      College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, NY,
      USA; Centre for Acute Respiratory Failure, New York-Presbyterian Hospital, New
      York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - IM
MH  - Extracorporeal Membrane Oxygenation/adverse effects/*methods
MH  - Heart-Assist Devices/adverse effects
MH  - Humans
MH  - Intra-Aortic Balloon Pumping/adverse effects/*methods
MH  - Shock, Cardiogenic/*therapy
EDAT- 2020/07/20 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/07/20 06:00 [entrez]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - S0140-6736(20)31047-3 [pii]
AID - 10.1016/S0140-6736(20)31047-3 [doi]
PST - ppublish
SO  - Lancet. 2020 Jul 18;396(10245):199-212. doi: 10.1016/S0140-6736(20)31047-3.


PMID- 32682445
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Jul 18
TI  - Platelet count as a biomarker for monitoring treatment response and disease
      recurrence in recurrent epithelial ovarian cancer.
PG  - 78
LID - 10.1186/s13048-020-00682-z [doi]
AB  - OBJECTIVES: We sought to determine the impact of pretreatment plasma platelet
      levels, dimerized plasmin fragment (D-dimer) and fibrinogen in recurrent
      epithelial ovarian cancer (EOC) and the impact of platelet levels on SKOV3 cell
      lines growth and responsiveness to chemotherapy. METHODS: Under approval of
      ethical committee, we identified 104 women with recurrent EOC who underwent
      treatment between January 2010 and February 2015. Reviewing clinical, laboratory,
      and pathologic records from this retrospective cohort, we analyzed the
      correlation between pretreatment plasma D-dimer, fibrinogen, platelet levels and 
      clinicopathological parameters, progression free survival (PFS) and overall
      survival (OS). Inco-culture experiments human ovarian cancer SKOV3 cell lines
      were used to test the effect of platelet levels on tumor growth and
      responsiveness to docetaxel. RESULTS: Of the 104 recurrent EOC, thrombocytosis at
      diagnosis and the decrease of platelet count by less than 25% after primary
      therapy were associated with worse median progression free survival (P = 0.003;P 
      = 0.021) and median overall survival (P = 0.009;P = 0.009). Mean platelet levels 
      declined at the end of primary therapy(P < 0.001) and rose at recurrence(P =
      0.007). In multivariate analysis, elevated platelet levels at primary therapy and
      the decrease of platelet count less than 25% after primary therapy were
      unfavorable prognostic factor for PFS(P = 0.022; P = 0.015) and OS(P = 0.013;P = 
      0.007) in recurrent EOC, but elevated plasma D-dimer and fibrinogen were not. In 
      SKOV-3 ovarian cancer cell lines, suitable concentration platelet co-culture
      protected against apoptosis (P < 0.05). CONCLUSIONS: Platelet count during
      treatment could be used as a biomarker used for monitoring the disease recurrence
      and predicting treatment response. And platelet with suitable concentration
      co-culture protected against apoptosis in SKOV3 cell line, which may explain
      clinical observations.
FAU - Hu, Qinghong
AU  - Hu Q
AUID- ORCID: https://orcid.org/0000-0002-7480-8366
AD  - Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou
      University, Zhengzhou, Henan, 450002, People's Republic of China.
FAU - Hada, Abha
AU  - Hada A
AD  - B.P. Koirala Institute of Health Sciences, Sunsari, Dharan, Nepal.
FAU - Han, Liping
AU  - Han L
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of
      Zhengzhou University, No.1, Jianshe East Road, Zhengzhou, Henan, 450002, P.R.
      China. hanliping0825@163.com.
LA  - eng
GR  - U1604172/National Natural Science Foundation of China (CN)
GR  - No. 201701002/Science and Technology Planning Project of Henan Province
      co-established by the province and the ministry
GR  - No. 18IRTSTHN024/Science and Technology Colleges Innovation Team Support Program 
      of Henan Province
PT  - Journal Article
DEP - 20200718
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Blood Platelets/*pathology
MH  - Carcinoma, Ovarian Epithelial/*pathology
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Neoplasm Recurrence, Local/*pathology
MH  - Ovarian Neoplasms/*pathology
MH  - Ovary/pathology
MH  - Platelet Count/methods
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Retrospective Studies
PMC - PMC7368983
OTO - NOTNLM
OT  - Apoptosis
OT  - D-dimer
OT  - Fibrinogen
OT  - Platelet count
OT  - Prognosis
OT  - Recurrent EOC
EDAT- 2020/07/20 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/07/20 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/20 06:00 [entrez]
PHST- 2020/07/20 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - 10.1186/s13048-020-00682-z [doi]
AID - 10.1186/s13048-020-00682-z [pii]
PST - epublish
SO  - J Ovarian Res. 2020 Jul 18;13(1):78. doi: 10.1186/s13048-020-00682-z.


PMID- 32681375
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 34
IP  - 10
DP  - 2020 Oct
TI  - Minimally invasive inguinal lymph node dissection: initial experience and
      reproducibility in a limited resource setting-with technique video.
PG  - 4669-4676
LID - 10.1007/s00464-020-07813-z [doi]
AB  - BACKGROUND: Conventional inguinal lymph node dissection comes with a high wound
      complication rate which increases hospital stay and may delay adjuvant treatment.
      Minimally invasive lymph node dissection (MILND) is a novel endoscopic technique 
      which aims to minimize complications of lymphadenectomy. Herein we present our
      technique and experience with MILND to examine safety, feasibility and
      reproducibility in a setting of limited resources. METHODS: All patients
      undergoing MILND in the National Cancer Institute, Cairo were prospectively
      included following informed consent, IRB and ethical committee approval.
      Demographics, clinical, pathological data and postoperative complications
      according to Clavien-Dindo classification were recorded. Footage collected was
      used to create a step-by-step video demonstrating the technique. RESULTS:
      Twenty-seven procedures were included in the study. The most common indications
      were vulval cancer (44%) and skin melanoma (19%). There were 5 (18%) conversions 
      to open procedure, all of them in the first 10 cases of the learning curve. The
      median (range) operative time was 120 (45-240) min and there was a trend towards 
      shorter operative time after the first 5 cases. Wound dehiscence occurred in 4
      cases (15%). Three of them (11%) required reoperation (grade III). Grade I/II
      complications in the form of seroma and wound infection occurred in 34%. The
      median (range) postoperative hospital stay was 2 (1-14). The median (range)
      number of retrieved lymph nodes was 12 (3-19). No grade III/IV lymphedema was
      recorded at 90 days after surgery. CONCLUSION: MILND is a safe, feasible
      technique associated with relatively low postoperative wound complications even
      when performed in a centre with relatively limited resources.
FAU - Abdel Mageed, Hisham
AU  - Abdel Mageed H
AUID- ORCID: 0000-0002-7874-2712
AD  - Surgical Oncology Department, National Cancer Institute, Cairo University, 27A
      Baghdad St. Heliopolis, Cairo, Egypt. Hisham.motaal@gmail.com.
FAU - Saad, Ihab
AU  - Saad I
AD  - Surgical Oncology Department, National Cancer Institute, Cairo University, 27A
      Baghdad St. Heliopolis, Cairo, Egypt.
FAU - Mostafa, Ahmed
AU  - Mostafa A
AD  - Surgical Oncology Department, National Cancer Institute, Cairo University, 27A
      Baghdad St. Heliopolis, Cairo, Egypt.
FAU - Elbaradie, Tarek
AU  - Elbaradie T
AD  - Surgical Oncology Department, National Cancer Institute, Cairo University, 27A
      Baghdad St. Heliopolis, Cairo, Egypt.
FAU - Safa, Mohammed
AU  - Safa M
AD  - Surgical Oncology Department, National Cancer Institute, Cairo University, 27A
      Baghdad St. Heliopolis, Cairo, Egypt.
FAU - Gamil, Mohammed
AU  - Gamil M
AD  - Surgical Oncology Department, National Cancer Institute, Cairo University, 27A
      Baghdad St. Heliopolis, Cairo, Egypt.
FAU - Lasithiotakis, Konstantinos
AU  - Lasithiotakis K
AD  - Department of Surgery, University Hospital of Heraklion, Crete, Greece.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Lymph Nodes/*surgery
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Video-Assisted Surgery/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - *Groin dissection
OT  - *Inguinal dissection
OT  - *Lymphadenectomy
OT  - *Minimally invasive
EDAT- 2020/07/19 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/07/19 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2020/07/19 06:00 [entrez]
AID - 10.1007/s00464-020-07813-z [doi]
AID - 10.1007/s00464-020-07813-z [pii]
PST - ppublish
SO  - Surg Endosc. 2020 Oct;34(10):4669-4676. doi: 10.1007/s00464-020-07813-z. Epub
      2020 Jul 27.


PMID- 32680920
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20220129
IS  - 1477-9129 (Electronic)
IS  - 0950-1991 (Linking)
VI  - 147
IP  - 14
DP  - 2020 Jul 17
TI  - Mechanisms of human embryo development: from cell fate to tissue shape and back.
LID - dev190629 [pii]
LID - 10.1242/dev.190629 [doi]
AB  - Gene regulatory networks and tissue morphogenetic events drive the emergence of
      shape and function: the pillars of embryo development. Although model systems
      offer a window into the molecular biology of cell fate and tissue shape,
      mechanistic studies of our own development have so far been technically and
      ethically challenging. However, recent technical developments provide the tools
      to describe, manipulate and mimic human embryos in a dish, thus opening a new
      avenue to exploring human development. Here, I discuss the evidence that supports
      a role for the crosstalk between cell fate and tissue shape during early human
      embryogenesis. This is a critical developmental period, when the body plan is
      laid out and many pregnancies fail. Dissecting the basic mechanisms that
      coordinate cell fate and tissue shape will generate an integrated understanding
      of early embryogenesis and new strategies for therapeutic intervention in early
      pregnancy loss.
CI  - (c) 2020. Published by The Company of Biologists Ltd.
FAU - Shahbazi, Marta N
AU  - Shahbazi MN
AUID- ORCID: 0000-0002-1599-5747
AD  - MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical
      Campus, Cambridge CB2 0QH, UK mshahbazi@mrc-lmb.cam.ac.uk.
LA  - eng
GR  - MC_UP_1201/24/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200717
PL  - England
TA  - Development
JT  - Development (Cambridge, England)
JID - 8701744
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Aneuploidy
MH  - Cell Cycle Proteins/genetics/metabolism
MH  - Cell Differentiation
MH  - Embryo, Mammalian/*metabolism
MH  - Embryonic Development/*genetics
MH  - Gene Expression Regulation, Developmental
MH  - Gene Regulatory Networks
MH  - Humans
MH  - Morphogenesis
MH  - Transcription Factors/genetics/metabolism
PMC - PMC7375473
OTO - NOTNLM
OT  - *Aneuploidy
OT  - *Cell fate
OT  - *Embryonic stem cells
OT  - *Human embryo
OT  - *Morphogenesis
OT  - *Polarisation
COIS- Competing interestsThe authors declare no competing or financial interests.
EDAT- 2020/07/19 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/07/19 06:00
PHST- 2020/07/19 06:00 [entrez]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - 147/14/dev190629 [pii]
AID - 10.1242/dev.190629 [doi]
PST - epublish
SO  - Development. 2020 Jul 17;147(14). pii: 147/14/dev190629. doi: 10.1242/dev.190629.


PMID- 32680889
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
VI  - 10
IP  - 3
DP  - 2020 Sep
TI  - Virtual visits in palliative care: about time or against the grain?
PG  - 331-336
LID - 10.1136/bmjspcare-2020-002498 [doi]
AB  - While the additional value from adding the option of virtual visits is not in
      question, numerous issues are raised around how to decide between face-to-face
      and virtual visits in individual cases and how best to set up such provision
      within an organisation. With only limited palliative care-specific literature and
      no time to set up and evaluate pilots, we had to get on and set up a prototype
      'virtual visits' model, retro-fitting guidance and a supporting ethical
      framework. We looked at the issues spanning clinical, ethical and logistics
      domains; identifying areas of benefit as well as drawbacks, some specific to the 
      rushed implementation because of COVID-19's infective risks and the 'rules' of
      lockdown, but many are generic areas to help guide longer term service design.
      Unsurprisingly, it appears clear that a 'one-size-fits-all' mentality is a poor
      fit for the individualised needs of the heterogeneous palliative care population.
      Virtual visits have great potential even if they are not a panacea.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hawkins, Joseph Paul
AU  - Hawkins JP
AUID- ORCID: http://orcid.org/0000-0001-6715-9540
AD  - Palliative Medicine, St Raphael's Hospice, Cheam, UK Joseph.hawkins@nhs.net.
FAU - Gannon, Craig
AU  - Gannon C
AD  - Palliative Medicine, Princess Alice Hospice, Esher, UK.
FAU - Palfrey, Jennifer
AU  - Palfrey J
AD  - Palliative Medicine, Princess Alice Hospice, Esher, UK.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
MH  - COVID-19/*therapy
MH  - Humans
MH  - Palliative Care/*methods
MH  - SARS-CoV-2
MH  - Telemedicine/*methods
MH  - Time
PMC - PMC7456669
OTO - NOTNLM
OT  - clinical decisions
OT  - communication
OT  - education and training
OT  - ethics
OT  - home care
OT  - hospice care
COIS- Competing interests: None declared.
EDAT- 2020/07/19 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/19 06:00
PHST- 2020/06/15 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/19 06:00 [entrez]
AID - bmjspcare-2020-002498 [pii]
AID - 10.1136/bmjspcare-2020-002498 [doi]
PST - ppublish
SO  - BMJ Support Palliat Care. 2020 Sep;10(3):331-336. doi:
      10.1136/bmjspcare-2020-002498. Epub 2020 Jul 17.


PMID- 32680760
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20210110
IS  - 1545-7214 (Electronic)
IS  - 1064-7481 (Linking)
VI  - 28
IP  - 9
DP  - 2020 Sep
TI  - How a Psychopharmacology Clinical Trial Site in the Seattle Area Managed Clinical
      Trials and Patient Care During the COVID-19 Pandemic.
PG  - 999-1003
LID - S1064-7481(20)30381-X [pii]
LID - 10.1016/j.jagp.2020.06.012 [doi]
AB  - OBJECTIVES: As the COVID-19 pandemic developed in March 2020 in greater Seattle, 
      our clinical trial site faced several ethical and clinical dilemmas. We remained 
      open to research patients including high-risk elderly patients and adapted to
      changing health recommendations. METHODS: Beginning March 14, 2020 we developed
      an in-person evaluation for potential risk of COVID-19. Included are the first 3 
      weeks of screening by our physicians for potential exposure to COVID-19, common
      symptoms, temperature, blood oxygen saturation, and heart rate. Individuals with 
      higher risk (n=23) were identified and managed. RESULTS: The 825 evaluations
      included 37 staff, 167 patients, and 152 visitors. No one needed isolation or
      transfer to acute care facility, staff attendance was 95%, all 33 geriatric
      patients continued in phase II trials, and others decreased by 5%. CONCLUSION: We
      share how we incorporated COVID-19 Center for Disease Control health
      recommendations to a clinical trial center and addition of pulse oximetry.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Schilling, Shirin
AU  - Schilling S
AD  - Northwest Clinical Research Center (SS, SM, AM, AK), Bellevue WA; Department of
      Clinical Medicine (SS, AK), Pacific Northwest University of Health Sciences
      College of Osteopathic Medicine, Yakima, WA. Electronic address:
      sschilling@nwcrc.net.
FAU - Mohanarajah, Sinthuja
AU  - Mohanarajah S
AD  - Northwest Clinical Research Center (SS, SM, AM, AK), Bellevue WA.
FAU - Mengstu, Abraham
AU  - Mengstu A
AD  - Northwest Clinical Research Center (SS, SM, AM, AK), Bellevue WA.
FAU - Khan, Arif
AU  - Khan A
AD  - Northwest Clinical Research Center (SS, SM, AM, AK), Bellevue WA; Department of
      Clinical Medicine (SS, AK), Pacific Northwest University of Health Sciences
      College of Osteopathic Medicine, Yakima, WA; Department of Psychiatry and
      Behavioral Sciences (AK), Duke University Medical Center, Durham, NC.
FAU - Brown, Walter A
AU  - Brown WA
AD  - Department of Psychiatry Brown University Providence (WAB), RI.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American
      Association for Geriatric Psychiatry
JID - 9309609
SB  - IM
MH  - Adult
MH  - Aged
MH  - Betacoronavirus
MH  - COVID-19
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Clinical Trials as Topic/*methods
MH  - Coronavirus Infections/diagnosis/*epidemiology/prevention & control/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oximetry
MH  - *Pandemics/prevention & control
MH  - Patient Care/*methods
MH  - Pneumonia, Viral/diagnosis/*epidemiology/prevention & control/*therapy
MH  - Psychopharmacology/*methods
MH  - SARS-CoV-2
MH  - United States
MH  - Washington
MH  - Young Adult
PMC - PMC7299855
OTO - NOTNLM
OT  - *COVID-19
OT  - *Clinical Trials
OT  - *Coronavirus
OT  - *Dementia
OT  - *Pulse oximeter
EDAT- 2020/07/19 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/07/19 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/02 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2020/07/19 06:00 [entrez]
AID - S1064-7481(20)30381-X [pii]
AID - 10.1016/j.jagp.2020.06.012 [doi]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2020 Sep;28(9):999-1003. doi:
      10.1016/j.jagp.2020.06.012. Epub 2020 Jun 18.


PMID- 32680753
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20210129
IS  - 1873-5150 (Electronic)
IS  - 0887-8994 (Linking)
VI  - 110
DP  - 2020 Sep
TI  - Allocating Medical Resources During a Mass Casualty Emergency: Sometimes It Is OK
      to Wait.
PG  - 3-4
LID - S0887-8994(20)30188-0 [pii]
LID - 10.1016/j.pediatrneurol.2020.05.013 [doi]
FAU - Weisleder, Pedro
AU  - Weisleder P
AD  - Division of Neurology, Department of Pediatrics, Nationwide Children's Hospital, 
      The Ohio State University, Columbus, Ohio; Center for Pediatric Bioethics,
      Nationwide Children's Hospital, Columbus, Ohio. Electronic address:
      Weisleder.1@osu.edu.
FAU - Vidaurre, Jorge
AU  - Vidaurre J
AD  - Division of Neurology, Department of Pediatrics, Nationwide Children's Hospital, 
      The Ohio State University, Columbus, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20200606
PL  - United States
TA  - Pediatr Neurol
JT  - Pediatric neurology
JID - 8508183
SB  - IM
MH  - Adolescent
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/methods
MH  - Coronavirus Infections/*diagnosis/physiopathology
MH  - Electroencephalography/methods
MH  - Emergency Medical Services/methods/supply & distribution
MH  - Health Resources/*supply & distribution
MH  - Humans
MH  - Intensive Care Units, Pediatric/*supply & distribution
MH  - Male
MH  - *Mass Casualty Incidents
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/physiopathology
MH  - SARS-CoV-2
MH  - Time Factors
PMC - PMC7833608
OTO - NOTNLM
OT  - *Crisis standard of care
OT  - *Crisis triage officer
OT  - *Ethics committee
OT  - *SARS-CoV-2
EDAT- 2020/07/19 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/19 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/19 06:00 [entrez]
AID - S0887-8994(20)30188-0 [pii]
AID - 10.1016/j.pediatrneurol.2020.05.013 [doi]
PST - ppublish
SO  - Pediatr Neurol. 2020 Sep;110:3-4. doi: 10.1016/j.pediatrneurol.2020.05.013. Epub 
      2020 Jun 6.


PMID- 32679797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-3425 (Print)
IS  - 2076-3425 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 15
TI  - Non-Invasive Brain Stimulation: Augmenting the Training and Performance Potential
      in Esports Players.
LID - E454 [pii]
LID - 10.3390/brainsci10070454 [doi]
AB  - During the last two decades, esports, a highly competitive sporting activity, has
      gained increasing popularity. Both performance and competition in esports require
      players to have fine motor skills and physical and cognitive abilities in
      controlling and manipulating digital activities in a virtual environment. While
      strategies for building and improving skills and abilities are crucial for
      successful gaming performance, few effective training approaches exist in the
      fast-growing area of competitive esports. In this paper, we describe a
      non-invasive brain stimulation (NIBS) approach and highlight the relevance and
      potential areas for research while being cognizant of various technical, safety, 
      and ethical issues related to NIBS when applied to esports.
FAU - Zhuang, Wei
AU  - Zhuang W
AD  - School of kinesiology, Shanghai University of Sport, Shanghai 200438, China.
FAU - Yin, Keyi
AU  - Yin K
AUID- ORCID: 0000-0002-9482-6190
AD  - School of kinesiology, Shanghai University of Sport, Shanghai 200438, China.
FAU - Zi, Yahua
AU  - Zi Y
AD  - School of kinesiology, Shanghai University of Sport, Shanghai 200438, China.
FAU - Liu, Yu
AU  - Liu Y
AD  - School of kinesiology, Shanghai University of Sport, Shanghai 200438, China.
LA  - eng
GR  - 81572213/National Natural Science Foundation of China
GR  - 2018YFF0300500/National Key Research and Development Program of China
PT  - Journal Article
DEP - 20200715
PL  - Switzerland
TA  - Brain Sci
JT  - Brain sciences
JID - 101598646
PMC - PMC7407750
OTO - NOTNLM
OT  - competitive computer gaming
OT  - electronic sports
OT  - performance
OT  - skill acquisition
OT  - sports
EDAT- 2020/07/19 06:00
MHDA- 2020/07/19 06:01
CRDT- 2020/07/19 06:00
PHST- 2020/06/19 00:00 [received]
PHST- 2020/07/10 00:00 [revised]
PHST- 2020/07/12 00:00 [accepted]
PHST- 2020/07/19 06:00 [entrez]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2020/07/19 06:01 [medline]
AID - brainsci10070454 [pii]
AID - 10.3390/brainsci10070454 [doi]
PST - epublish
SO  - Brain Sci. 2020 Jul 15;10(7). pii: brainsci10070454. doi:
      10.3390/brainsci10070454.


PMID- 32679566
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1933-0693 (Electronic)
IS  - 0022-3085 (Linking)
VI  - 134
IP  - 6
DP  - 2020 Jul 17
TI  - The neurosurgery residency interview: assessing applicant perspectives on
      question content, utility, and stress.
PG  - 1974-1982
LID - 10.3171/2020.4.JNS2046 [doi]
LID - 2020.4.JNS2046 [pii]
AB  - OBJECTIVE: Residency interviews are integral to the recruitment process yet
      imperfect. Through surveys of neurosurgery residency applicants, the authors
      describe interview content and the perceived utility and stress of topics from
      the applicant's perspective. METHODS: All 2018-2019 neurosurgery resident
      applicants applying to three particular programs were surveyed. Across 10
      interview topics, survey questions assessed topic frequency and the applicant's
      opinion of the utility and stress of each topic (Likert scale 1-5). Analyses
      included descriptive statistics, Spearman's rank correlation, and logistic
      regression. RESULTS: One hundred thirty-three of 265 surveyed US residency
      applicants (50%) responded. Extracurricular activities, research, future career, 
      non-medicine interests, and small talk were discussed in all interviews. The
      least frequent topics included neurosurgical knowledge assessment (79%) and
      manual dexterity tests (45%). The most useful topics according to respondents
      were future career objectives (4.78 +/- 0.49) and prior research (4.76 +/- 0.50);
      the least useful were neurosurgical knowledge assessment (2.67 +/- 1.09) and
      manual dexterity tests (2.95 +/- 1.05). The most stressful topics were
      neurosurgical knowledge assessment (3.66 +/- 1.23) and ethical/behavioral
      scenarios (2.94 +/- 1.28). The utility and stress of manual dexterity tests and
      neurosurgical knowledge assessments were inversely correlated (r = -0.40, p <
      0.01; r = -0.36, p < 0.01), whereas no such correlation existed for
      ethical/behavioral questions (r = -0.12, p = 0.18), indicating that
      ethical/behavioral questions may have been stressful but were potentially useful 
      topics. Respondents who attended >/= 15 interviews were more likely to be asked
      about the three most stressful topics (each p < 0.05). Respondents with children 
      were less likely to be asked about ethical/behavioral scenarios (OR 0.13, 95% CI 
      0.03-0.52, p < 0.01). CONCLUSIONS: Applicants found several of the most
      frequently discussed topics to be less useful, indicating a potential disconnect 
      between applicant opinion and the faculty's preferred questions.
      Ethical/behavioral scenarios were rated as stressful but still useful,
      representing a potentially worthwhile type of question. These data provide
      several avenues for potential standardization and improvement of the interview
      process.
FAU - Zuckerman, Scott L
AU  - Zuckerman SL
AD  - 1Department of Neurological Surgery, Vanderbilt University Medical Center,
      Nashville, Tennessee.
FAU - Limoges, Natalie
AU  - Limoges N
AD  - 2Division of Neurosurgery, University of Vermont Medical Center, Burlington,
      Vermont.
FAU - Yengo-Kahn, Aaron M
AU  - Yengo-Kahn AM
AD  - 1Department of Neurological Surgery, Vanderbilt University Medical Center,
      Nashville, Tennessee.
FAU - Graffeo, Christopher S
AU  - Graffeo CS
AD  - 3Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota; and.
FAU - Chambless, Lola B
AU  - Chambless LB
AD  - 1Department of Neurological Surgery, Vanderbilt University Medical Center,
      Nashville, Tennessee.
FAU - Chitale, Rohan
AU  - Chitale R
AD  - 1Department of Neurological Surgery, Vanderbilt University Medical Center,
      Nashville, Tennessee.
FAU - Mocco, J
AU  - Mocco J
AD  - 4Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York.
FAU - Durham, Susan
AU  - Durham S
AD  - 2Division of Neurosurgery, University of Vermont Medical Center, Burlington,
      Vermont.
LA  - eng
PT  - Journal Article
DEP - 20200717
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Internship and Residency/standards
MH  - *Job Application
MH  - Male
MH  - Neurosurgery/*education/*psychology/standards
MH  - Stress, Psychological/epidemiology/*psychology
MH  - *Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - *behavioral interviews
OT  - *education
OT  - *recruitment
OT  - *residency
EDAT- 2020/07/18 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - 10.3171/2020.4.JNS2046 [doi]
AID - 2020.4.JNS2046 [pii]
PST - epublish
SO  - J Neurosurg. 2020 Jul 17;134(6):1974-1982. doi: 10.3171/2020.4.JNS2046.


PMID- 32679401
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20210110
IS  - 1873-491X (Electronic)
IS  - 0020-7489 (Linking)
VI  - 110
DP  - 2020 Oct
TI  - Covid-19: Ethical issues for nurses.
PG  - 103673
LID - S0020-7489(20)30157-7 [pii]
LID - 10.1016/j.ijnurstu.2020.103673 [doi]
FAU - McKenna, Hugh
AU  - McKenna H
LA  - eng
PT  - Editorial
DEP - 20200606
PL  - England
TA  - Int J Nurs Stud
JT  - International journal of nursing studies
JID - 0400675
SB  - IM
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*nursing/virology
MH  - *Ethics, Nursing
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*nursing/virology
MH  - SARS-CoV-2
PMC - PMC7529394
EDAT- 2020/07/18 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - S0020-7489(20)30157-7 [pii]
AID - 10.1016/j.ijnurstu.2020.103673 [doi]
PST - ppublish
SO  - Int J Nurs Stud. 2020 Oct;110:103673. doi: 10.1016/j.ijnurstu.2020.103673. Epub
      2020 Jun 6.


PMID- 32678861
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - Abortion attitudes, religious and moral beliefs, and pastoral care among
      Protestant religious leaders in Georgia.
PG  - e0235971
LID - 10.1371/journal.pone.0235971 [doi]
AB  - OBJECTIVE: The purpose of this study is to explore Protestant religious leaders' 
      attitudes towards abortion and their strategies for pastoral care in Georgia,
      USA. Religious leaders may play an important role in providing sexual and
      reproductive health pastoral care given a long history of supporting healing and 
      health promotion. METHODS: We conducted 20 in-depth interviews with Mainline and 
      Black Protestant religious leaders on their attitudes toward abortion and how
      they provide pastoral care for abortion. The study was conducted in a county with
      relatively higher rates of abortion, lower access to sexual and reproductive
      health services, higher religiosity, and greater denominational diversity
      compared to other counties in the state. Interviews were audio-recorded,
      transcribed verbatim, and analyzed by thematic analysis. RESULTS: Religious
      leaders' attitudes towards abortion fell on a spectrum from "pro-life" to
      "pro-choice". However, most participants expressed attitudes in the middle of
      this spectrum and described more nuanced, complex, and sometimes contradictory
      views. Differences in abortion attitudes stemmed from varying beliefs on when
      life begins and circumstances in which abortion may be morally acceptable.
      Religious leaders described their pastoral care on abortion as "journeying with" 
      congregants by advising them to make well-informed decisions irrespective of the 
      religious leader's own attitudes. However, many religious leaders described a
      lack of preparation and training to have these conversations. Leaders emphasized 
      not condoning abortion, yet being willing to emotionally support women because
      spiritual leaders are compelled to love and provide pastoral care. Paradoxically,
      all leaders emphasized the importance of empathy and compassion for people who
      have unplanned pregnancies, yet only leaders whose attitudes were "pro-choice" or
      in the middle of the spectrum expressed an obligation to confront stigmatizing
      attitudes and behaviors towards people who experience abortion. Additionally,
      many leaders offer misinformation about abortion when offering pastoral care.
      CONCLUSION: These findings contribute to limited empirical evidence on pastoral
      care for abortion. We found religious leaders hold diverse attitudes and beliefs 
      about abortion, rooted in Christian scripture and doctrine that inform advice and
      recommendations to congregants. While religious leaders may have formal training 
      on pastoral care in general or theological education on the ethical issues
      related to abortion, they struggle to integrate their knowledge and training
      across these two areas. Still, leaders could be potentially important resources
      for empathy, compassion, and affirmation of agency in abortion decision-making,
      particularly in the Southern United States.
FAU - Dozier, Jessica L
AU  - Dozier JL
AD  - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg
      School of Public Health, Baltimore, Maryland, United States of America.
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
FAU - Hennink, Monique
AU  - Hennink M
AD  - Hubert Department of Global Health, Rollins School of Public Health, Emory
      University, Atlanta, Georgia, United States of America.
FAU - Mosley, Elizabeth
AU  - Mosley E
AUID- ORCID: 0000-0001-9534-2457
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Department of Behavioral, Social and Health Education Sciences, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
FAU - Narasimhan, Subasri
AU  - Narasimhan S
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Department of Behavioral, Social and Health Education Sciences, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
FAU - Pringle, Johanna
AU  - Pringle J
AUID- ORCID: 0000-0001-8755-7351
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Department of Behavioral, Social and Health Education Sciences, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
FAU - Clarke, Lasha
AU  - Clarke L
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Department of Epidemiology, Rollins School of Public Health, Emory University,
      Atlanta, Georgia, United States of America.
FAU - Blevins, John
AU  - Blevins J
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Hubert Department of Global Health, Rollins School of Public Health, Emory
      University, Atlanta, Georgia, United States of America.
AD  - Graduate Division of Religion, Laney Graduate School of Arts and Sciences, Emory 
      University, Atlanta, Georgia, United States of America.
FAU - James-Portis, Latishia
AU  - James-Portis L
AD  - Reproductive Justice Activist and Movement Chaplain, Atlanta, Georgia, United
      States of America.
FAU - Keithan, Rob
AU  - Keithan R
AD  - All Souls Church Unitarian, Washington, D.C., United States of America.
FAU - Hall, Kelli Stidham
AU  - Hall KS
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Department of Behavioral, Social and Health Education Sciences, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Heilbrunn Department of Population & Family Health, Mailman School of Public
      Health, Columbia University, New York, NY, United States of America.
FAU - Rice, Whitney S
AU  - Rice WS
AD  - The Center for Reproductive Health Research in the Southeast, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
AD  - Department of Behavioral, Social and Health Education Sciences, Rollins School of
      Public Health, Emory University, Atlanta, Georgia, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200717
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Abortion, Induced/*psychology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Attitude to Health
MH  - Christianity/*psychology
MH  - Female
MH  - Georgia
MH  - Humans
MH  - *Leadership
MH  - Male
MH  - Middle Aged
MH  - *Morals
MH  - Pastoral Care/*statistics & numerical data
MH  - Young Adult
PMC - PMC7367465
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/18 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - 10.1371/journal.pone.0235971 [doi]
AID - PONE-D-20-00472 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 17;15(7):e0235971. doi: 10.1371/journal.pone.0235971.
      eCollection 2020.


PMID- 32678735
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20201214
IS  - 1096-0953 (Electronic)
IS  - 0013-9351 (Linking)
VI  - 189
DP  - 2020 Oct
TI  - A fast-multiclass method for the determination of 21 endocrine disruptors in
      human urine by using vortex-assisted dispersive liquid-liquid microextraction
      (VADLLME) and LC-MS/MS.
PG  - 109883
LID - S0013-9351(20)30778-7 [pii]
LID - 10.1016/j.envres.2020.109883 [doi]
AB  - Simplicity, speed, and reduced cost are essential demands for routine analysis in
      human biomonitoring studies. Moreover, the availability of higher volumes of
      human specimens is becoming more restrictive due to ethical controls and to the
      costs associated with sample transportation and storage. Thus, analytical methods
      requiring much lower sample volumes associated with simultaneous detection
      capability (multiclass analysis) are with a very high claim. In this sense, the
      present approach aimed at the development of a method for preconcentration and
      simultaneous determination of four classes of endocrine disruptors (seven
      bisphenols, seven parabens, five benzophenones, and two antimicrobials) in the
      urine. The approach is based on vortex-assisted dispersive liquid-liquid
      microextraction (VADLLME) and high-performance liquid chromatography coupled to
      tandem mass spectrometry (LC-MS/MS). After optimization of the significant
      parameters of VADLLME extraction, the proposed procedure showed to be simple,
      fast, sensitive, requiring only 1.0 mL of urine, 400 muL of organic solvents with
      a total stirring time of 20 s. Moreover, a variation of inter-day and between-day
      runs were lower than 10.0% and 11.0%, respectively. Finally, the proposed method 
      was successfully applied to the analysis of 50 urine samples of Brazilian
      pregnant women to establish reference ranges.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Bocato, Mariana Zuccherato
AU  - Bocato MZ
AD  - Departamento de Analises Clinicas, Toxicologicas e Bromatologicas, Faculdade de
      Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo, 14040-903,
      Ribeirao Preto, SP, Brazil.
FAU - Cesila, Cibele Aparecida
AU  - Cesila CA
AD  - Departamento de Analises Clinicas, Toxicologicas e Bromatologicas, Faculdade de
      Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo, 14040-903,
      Ribeirao Preto, SP, Brazil.
FAU - Lataro, Beatriz Favero
AU  - Lataro BF
AD  - Faculdade de Ciencias Farmaceuticas, Universidade de Ribeirao Preto, 14096-900,
      Ribeirao Preto, SP, Brazil.
FAU - de Oliveira, Anderson Rodrigo Moraes
AU  - de Oliveira ARM
AD  - Departamento de Quimica, Faculdade de Filosofia, Ciencias e Letras de Ribeirao
      Preto, Universidade de Sao Paulo, 14040-901, Ribeirao Preto, SP, Brazil; National
      Institute for Alternative Technologies of Detection, Toxicological Evaluation and
      Removal of Micropollutants and Radioactives (INCT-DATREM), Unesp, Institute of
      Chemistry, 14800-900, Araraquara, SP, Brazil.
FAU - Campiglia, Andres Dobal
AU  - Campiglia AD
AD  - Department of Chemistry, University of Central Florida, P.O.Box 25000, 32816,
      Orlando, FL, USA.
FAU - Barbosa, Fernando Jr
AU  - Barbosa F Jr
AD  - Departamento de Analises Clinicas, Toxicologicas e Bromatologicas, Faculdade de
      Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo, 14040-903,
      Ribeirao Preto, SP, Brazil. Electronic address: fbarbosa@fcfrp.usp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200711
PL  - Netherlands
TA  - Environ Res
JT  - Environmental research
JID - 0147621
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Solvents)
SB  - IM
MH  - Brazil
MH  - Chromatography, High Pressure Liquid
MH  - Chromatography, Liquid
MH  - *Endocrine Disruptors/analysis
MH  - Female
MH  - Humans
MH  - Limit of Detection
MH  - *Liquid Phase Microextraction
MH  - Pregnancy
MH  - Solvents
MH  - Tandem Mass Spectrometry
OTO - NOTNLM
OT  - *Endocrine disruptors
OT  - *Human urine
OT  - *Liquid chromatography-tandem mass spectrometry
OT  - *Multiclass analysis
OT  - *Vortex-assisted dispersive liquid-liquid microextraction
EDAT- 2020/07/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/06/27 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - S0013-9351(20)30778-7 [pii]
AID - 10.1016/j.envres.2020.109883 [doi]
PST - ppublish
SO  - Environ Res. 2020 Oct;189:109883. doi: 10.1016/j.envres.2020.109883. Epub 2020
      Jul 11.


PMID- 32678525
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20201218
IS  - 2155-7780 (Electronic)
IS  - 2155-7780 (Linking)
VI  - 22
IP  - 4
DP  - 2020 Jul 16
TI  - Medical Ethics and Ventilator Allocation During the COVID-19 Pandemic.
LID - 10.4088/PCC.20com02687 [doi]
LID - 20com02687 [pii]
FAU - Yahya, Ahmed Saeed
AU  - Yahya AS
AD  - North East London NHS Foundation Trust, Waltham Forest Older Adults Mental Health
      Team, Red Oak Lodge, London, England E11 4HU, UK. a.yahya@nhs.net.
AD  - Waltham Forest Older Adults Mental Health Team, North East London Foundation
      Trust, Red Oak Lodge, London, England.
FAU - Khawaja, Shakil
AU  - Khawaja S
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - United States
TA  - Prim Care Companion CNS Disord
JT  - The primary care companion for CNS disorders
JID - 101547532
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - *Ethical Theory
MH  - *Ethics, Medical
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/*supply & distribution
EDAT- 2020/07/18 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
AID - 10.4088/PCC.20com02687 [doi]
PST - epublish
SO  - Prim Care Companion CNS Disord. 2020 Jul 16;22(4). doi: 10.4088/PCC.20com02687.


PMID- 32677891
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 16
TI  - Non-inferiority comparative clinical trial between early oral REFEEDING and usual
      oral REFEEDING in predicted mild acute biliary pancreatitis.
PG  - 228
LID - 10.1186/s12876-020-01363-3 [doi]
AB  - BACKGROUND: The aim of the study was to compare the onset of oral feeding in the 
      first 24 h after hospital admission with usual oral refeeding and determine
      whether the timing of the onset of oral feeding influences the recurrence of pain
      or alters the blood levels of pancreatic enzymes in patients with predicted mild 
      acute biliary pancreatitis. METHODS: This non-inferiority randomized controlled
      trial was carried out between September 2018 and June 2019 after receiving
      authorization from the ethics committee for health research. Patients with a
      diagnosis of predicted mild acute biliary pancreatitis were divided into Group A 
      (early oral refeeding, EOR) and Group B (usual oral refeeding, UOR). Outcome
      measures included pancreatic lipase levels, the systemic inflammatory response
      (concentrations of leukocytes), feasibility (evaluated by abdominal pain
      recurrence), the presence and recurrence of gastrointestinal symptoms and the
      length of hospital stay. RESULTS: Two patients in the EOR group experienced pain 
      relapse (3.2%), and four patients in the UOR group experienced pain relapse
      (6.77%) after oral refeeding (p = 0.379). The presence of nausea or vomiting
      after the onset of oral refeeding was not different between the two groups (p =
      0.293). The onset of oral refeeding was approximately 48 h later in the UOR
      group. The length of hospital stay was 5 days in the EOR group and 8 days in the 
      UOR group (p = 0.042), and this difference was also manifested in higher hospital
      costs in the UOR group (p = 0.0235). CONCLUSION: Compared with usual oral
      refeeding, early oral refeeding is safe in predicted mild acute biliary
      pancreatitis patients, does not cause adverse gastrointestinal events, and
      reduces the length of hospital stay and costs. TRIAL REGISTRATION: Early oral
      refeeding in mild acute pancreatitis (EORVsUOR). NCT04168801 , retrospectively
      registered (November 19, 2019).
FAU - Lozada-Hernandez, Edgard Efren
AU  - Lozada-Hernandez EE
AUID- ORCID: http://orcid.org/0000-0001-8614-9516
AD  - Department of Surgery and Clinical Research, Hospital Regional de Alta
      Especialidad del Bajio, Circuito Quinta los Naranjos # 145 B. Colonia Quinta los 
      Naranjos, Leon, Guanajuato, Mexico. edgardlozada@hotmail.com.
FAU - Barron-Gonzalez, Omar
AU  - Barron-Gonzalez O
AD  - Department of Surgery, Unidad Medica de Alta Especialidad Bajio, Instituto
      Mexicano del Seguro Social, Leon, Guanajuato, Mexico.
FAU - Vazquez-Romero, Santa
AU  - Vazquez-Romero S
AD  - Department of Surgery, Unidad Medica de Alta Especialidad Bajio, Instituto
      Mexicano del Seguro Social, Leon, Guanajuato, Mexico.
FAU - Cano-Rosas, Martin
AU  - Cano-Rosas M
AD  - Department of Surgery, Unidad Medica de Alta Especialidad Bajio, Instituto
      Mexicano del Seguro Social, Leon, Guanajuato, Mexico.
FAU - Apolinar-Jimenez, Evelia
AU  - Apolinar-Jimenez E
AD  - Department of Clinical Nutrition, Hospital Regional de Alta Especialidad del
      Bajio, Leon, Guanajuato, Mexico.
LA  - eng
SI  - ClinicalTrials.gov/NCT04168801
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200716
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
SB  - IM
MH  - Abdominal Pain/etiology
MH  - Acute Disease
MH  - Humans
MH  - *Pancreatitis/etiology/therapy
MH  - Prospective Studies
MH  - Recurrence
PMC - PMC7364543
OTO - NOTNLM
OT  - Mild acute biliary pancreatitis
OT  - Nil per os
OT  - Non-inferiority clinical trial
OT  - Oral feeding
EDAT- 2020/07/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/18 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12876-020-01363-3 [doi]
AID - 10.1186/s12876-020-01363-3 [pii]
PST - epublish
SO  - BMC Gastroenterol. 2020 Jul 16;20(1):228. doi: 10.1186/s12876-020-01363-3.


PMID- 32676951
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - Against Ulysses contracts for patients with borderline personality disorder.
PG  - 695-703
LID - 10.1007/s11019-020-09967-y [doi]
AB  - Patients with borderline personality disorder (BPD) sometimes request to be
      admitted to hospital under compulsory care, often under the argument that they
      cannot trust their suicidal impulses if treated voluntarily. Thus, compulsory
      care is practised as a form of Ulysses contract in such situations. In this
      normative study we scrutinize the arguments commonly used in favour of such
      Ulysses contracts: (1) the patient lacking free will, (2) Ulysses contracts as
      self-paternalism, (3) the patient lacking decision competence, (4) Ulysses
      contracts as a defence of the authentic self, and (5) Ulysses contracts as a
      practical solution in emergency situations. In our study, we have accepted
      consequentialist considerations as well as considerations of autonomy. We
      conclude that compulsory care is not justified when there is a significant
      uncertainty of beneficial effects or uncertainty regarding the patient's
      decision-making capacity. We have argued that such uncertainty is present
      regarding BPD patients. Hence, Ulysses contracts including compulsory care should
      not be used for this group of patients.
FAU - Lundahl, Antoinette
AU  - Lundahl A
AD  - Norra Stockholms Psykiatri, S:t Gorans Sjukhus, 112 81, Stockholm, Sweden.
      antoinette.lundahl@sll.se.
FAU - Helgesson, Gert
AU  - Helgesson G
AD  - Stockholm Centre for Healthcare Ethics (CHE), Karolinska Institutet, LIME, 171
      77, Stockholm, Sweden.
FAU - Juth, Niklas
AU  - Juth N
AD  - Stockholm Centre for Healthcare Ethics (CHE), Karolinska Institutet, LIME, 171
      77, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Advance Directives/ethics/*psychology
MH  - Borderline Personality Disorder/*psychology/*therapy
MH  - Humans
MH  - Mental Competency/*standards
MH  - Paternalism
MH  - *Personal Autonomy
PMC - PMC7538402
OTO - NOTNLM
OT  - Authenticity
OT  - Autonomy
OT  - Borderline personality disorder
OT  - Decision competence
OT  - Ethics
OT  - Psychiatry
OT  - Ulysses contract
EDAT- 2020/07/18 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - 10.1007/s11019-020-09967-y [doi]
AID - 10.1007/s11019-020-09967-y [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):695-703. doi: 10.1007/s11019-020-09967-y.


PMID- 32676590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2690-5949 (Electronic)
IS  - 2690-5949 (Linking)
VI  - 3
IP  - 1
DP  - 2020
TI  - Educational and Ethical Considerations for Genetic Test Implementation Within
      Health Care Systems.
PG  - 58-66
LID - 10.1089/nsm.2019.0010 [doi]
AB  - Introduction: The precision medicine (PM) era presents unprecedented
      proliferation of genetic/genomic initiatives, information, and bioinformatic
      tools to enhance targeted molecular diagnosis and therapeutic treatments. As of
      February 29, 2020, the National Institutes of Health (NIH) National Center for
      Biotechnology Information (NCBI) Genetic Testing Registry contained 64,860
      genetic tests for 12,268 conditions and 18,686 genes from 560 laboratories, and
      the Food and Drug Administration had 404 entries for pharmacogeneomic biomarkers 
      used in drug labeling. Population-based research initiatives including NIH's All 
      of Us and Veterans Affairs' Million Veteran Program, and the UK Biobank, combine 
      use of genomic biorepositories with electronic medical records (i.e., National
      Human Genome Research Institute's [NHGRI's] electronic Medical Records and
      Genomics [eMERGE] Network). Learning health care systems are implementing
      clinical genomics screening programs and precision oncology programs. However,
      there are insufficient medical geneticists, nurse geneticists, and genetics
      counselors to implement expanding number of clinical genetic tests that are
      required for PM implementation. Methods: A scoping review of current (2014-2019) 
      trends in U.S. genomic medicine translation, PM health care provider workforce
      education and training resources, and genomic clinical decision support (CDS)
      implementation tools was conducted. Results: Health care delivery institutions
      and systems are beginning to implement genetic tests that are driving PM,
      particularly in the areas of oncology, pharmacogenetics, obstetrics, and prenatal
      diagnostics. To ensure safe adoption and clinical translation of PM, health care 
      systems have an ethical responsibility to ensure their providers and front-line
      staff are adequately prepared to order, use, and interpret genetic test
      information. Conclusion: There are a number of high-quality evidenced-based
      educational resources and CDS tools available. Strong partnerships between health
      care system leaders, front-line providers and staff coupled with reasonable goal 
      setting can help drive PM translation interests.
CI  - (c) Emma Kurnat-Thoma 2020; Published by Mary Ann Liebert, Inc.
FAU - Kurnat-Thoma, Emma
AU  - Kurnat-Thoma E
AD  - Department of Intramural Research, DHHS/NIH/NINR, Bethesda, Maryland, USA.
AD  - School of Nursing and Health Studies, Georgetown University, Washington, District
      of Columbia, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200526
PL  - United States
TA  - Netw Syst Med
JT  - Network and systems medicine
JID - 101768842
PMC - PMC7357722
OTO - NOTNLM
OT  - ethical legal social implications
OT  - genetic tests
OT  - health care provider training and education
OT  - health care system implementation
COIS- No competing financial interests exist.
EDAT- 2020/07/18 06:00
MHDA- 2020/07/18 06:01
CRDT- 2020/07/18 06:00
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/18 06:01 [medline]
AID - 10.1089/nsm.2019.0010 [doi]
AID - 10.1089/nsm.2019.0010 [pii]
PST - epublish
SO  - Netw Syst Med. 2020 May 26;3(1):58-66. doi: 10.1089/nsm.2019.0010. eCollection
      2020.


PMID- 32675906
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 0312-8008 (Print)
IS  - 0312-8008 (Linking)
VI  - 43
IP  - 3
DP  - 2020 Jun
TI  - Principles of ethical prescribing for self and others: hydroxychloroquine in the 
      COVID-19 pandemic.
PG  - 76-77
LID - 10.18773/austprescr.2020.030 [doi]
FAU - Coombes, Ian
AU  - Coombes I
AD  - Royal Brisbane and Women's Hospital, Brisbane.
AD  - The University of Queensland, Brisbane.
AD  - Queensland Clinical Senate, Queensland Health, Brisbane.
FAU - Markwell, Alexandra
AU  - Markwell A
AD  - Royal Brisbane and Women's Hospital, Brisbane.
AD  - The University of Queensland, Brisbane.
AD  - Queensland Clinical Senate, Queensland Health, Brisbane.
FAU - Kubler, Paul
AU  - Kubler P
AD  - Royal Brisbane and Women's Hospital, Brisbane.
AD  - The University of Queensland, Brisbane.
AD  - Queensland Clinical Senate, Queensland Health, Brisbane.
FAU - Redmond, Andrew M
AU  - Redmond AM
AD  - Royal Brisbane and Women's Hospital, Brisbane.
AD  - The University of Queensland, Brisbane.
AD  - Queensland Clinical Senate, Queensland Health, Brisbane.
FAU - McGurk, Gordon
AU  - McGurk G
AD  - Royal Brisbane and Women's Hospital, Brisbane.
AD  - The University of Queensland, Brisbane.
AD  - Queensland Clinical Senate, Queensland Health, Brisbane.
FAU - Roberts, Jason A
AU  - Roberts JA
AD  - Royal Brisbane and Women's Hospital, Brisbane.
AD  - The University of Queensland, Brisbane.
AD  - Queensland Clinical Senate, Queensland Health, Brisbane.
LA  - eng
PT  - Editorial
DEP - 20200422
PL  - Australia
TA  - Aust Prescr
JT  - Australian prescriber
JID - 7804938
PMC - PMC7358057
OTO - NOTNLM
OT  - COVID-19
OT  - ethics
OT  - hydroxychloroquine
COIS- Ian Coombes is the Director of the Royal Brisbane and Women's Hospital pharmacy
      department, which has an interim licence to support pharmacy activities
      associated with COVID-19 clinical trials, including the Australasian COVID-19
      Trial (ASCOT) involving hydroxychloroquine. Andrew Redmond is an associate
      investigator and Jason Roberts is an investigator on the ASCOT study. Funding for
      this study has come from donors and the authors do not receive any financial
      advantage for their participation. Paul Kubler is principal site investigator for
      Abbvie for two phase III trials on drugs for psoriatic arthritis and systemic
      lupus erythematosus. He does not receive any financial benefit for participation.
      Funding goes to a public hospital research trust fund.
EDAT- 2020/07/18 06:00
MHDA- 2020/07/18 06:01
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/18 06:01 [medline]
AID - 10.18773/austprescr.2020.030 [doi]
AID - austprescr-43-76 [pii]
PST - ppublish
SO  - Aust Prescr. 2020 Jun;43(3):76-77. doi: 10.18773/austprescr.2020.030. Epub 2020
      Apr 22.


PMID- 32675851
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 0065-7778 (Print)
IS  - 0065-7778 (Linking)
VI  - 131
DP  - 2020
TI  - THE GORDON WILSON LECTURE: THE ETHICS OF HUMAN GENOME EDITING.
PG  - 99-118
AB  - Human genome editing has undergone major technological advances, raising the
      possibility of treating or preventing many illnesses. Somatic (nonheritable)
      genome editing, both in vitro and in vivo, is already being employed under a
      robust regulatory and ethical framework developed for human gene therapy. In
      contrast, the prospect of germline (heritable) genome editing is much more
      contentious, and there is currently no consensus on the proper path forward. The 
      2017 National Academy of Sciences (NAS) and National Academy of Medicine (NAM)
      report proposed a series of requirements designed to minimize ethical objections 
      while allowing couples to accept the risks of genome editing in order to have a
      biologically related child without passing on a known genetic disorder. It is
      vital to prevent gene editing from resulting in unintended negative consequences 
      for individuals with genetic variants. The utilization of genome editing to
      enhance human function is highly contentious; it may be better to focus on
      whether an edit creates an "unfair advantage" rather than an enhancement.
CI  - (c) 2020 The American Clinical and Climatological Association.
FAU - Coller, Barry S
AU  - Coller BS
AD  - NEW YORK, NEW YORK.
LA  - eng
GR  - UL1 TR001866/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Trans Am Clin Climatol Assoc
JT  - Transactions of the American Clinical and Climatological Association
JID - 7507559
SB  - IM
PMC - PMC7358513
COIS- Potential Conflicts of Interest: None disclosed.
EDAT- 2020/07/18 06:00
MHDA- 2020/07/18 06:01
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/18 06:01 [medline]
PST - ppublish
SO  - Trans Am Clin Climatol Assoc. 2020;131:99-118.


PMID- 32675808
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Jun
TI  - Veterinary Medical Ethics.
PG  - 573-574
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7236634
EDAT- 2020/07/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - cvj_06_573 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Jun;61(6):573-574.


PMID- 32675537
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20211216
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 2
DP  - 2020 Aug
TI  - Are Postoperative Intravenous Antibiotics Indicated After Laparoscopic
      Appendicectomy for Simple Appendicitis? A Prospective Double-blinded Randomized
      Controlled Trial.
PG  - 248-252
LID - 10.1097/SLA.0000000000003732 [doi]
AB  - BACKGROUND: There is limited evidence for the use of postoperative antibiotics
      for simple appendicitis (SA) in children. Our aim was to conduct a prospective
      double-blinded randomized controlled trial to investigate this after a
      laparoscopic appendicectomy. METHODS: Following ethical approval, children (</=16
      years) undergoing appendicectomy were recruited at a single institution. Patients
      were randomized intraoperatively to receive either 2 postoperative intravenous
      doses of placebo or antibiotics (Abx). All patients received a dose of Abx at
      induction of anesthesia. Primary outcome was the incidence of postoperative wound
      infection (WI), and secondary outcome was the incidence of intra-abdominal
      abscess formation. Data are reported as number of cases (%), median (range),
      relative risk, and analyzed using Mann Whitney U test, Chi-square test, as
      appropriate, a P-value </=0.05 was considered significant. RESULTS: A total of
      304 patients were randomized. Sixty-one were subsequently excluded due to
      protocol violations or recruitment errors; therefore, 243 were included in the
      final analysis. One hundred twenty-two patients received placebo and 121
      Intravenous Abx. There was no difference between the sex (50F/72 M vs 47F/74 M, P
      = 0.8), median age (12.4 vs 12.2 years, P = 0.5), and postoperative length of
      stay in a hospital (27.2 vs 25.6 hours, P = 0.7). There was also no difference in
      the preoperative blood results. A total of 9 WIs occurred: 8/122 (6.6%) placebo
      versus 1/121 (0.8%) Abx, P = 0.01 [relative risk for WI 7.9 (95% confidence
      interval: 1.0-62.4)]. There were no intra-abdominal abscess in either groups.
      CONCLUSIONS: This prospective randomized double blinded randomized controlled
      trial has revealed a significant decrease in WI rates by giving 2 postoperative
      intravenous doses of Abx, suggesting postoperative Abx are of benefit in SA.
FAU - Mennie, Nicole
AU  - Mennie N
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
FAU - Panabokke, Gayathri
AU  - Panabokke G
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
FAU - Chang, Annette
AU  - Chang A
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
FAU - Tanny, Sharman Tan
AU  - Tanny ST
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
FAU - Cheng, Wei
AU  - Cheng W
AD  - Department of Pediatrics, School of Clinical Sciences, Faculty of Medicine,
      Nursing and Health Sciences, Monash University, Melbourne, Australia.
AD  - New Century Healthcare, Hong Kong.
FAU - Pacilli, Maurizio
AU  - Pacilli M
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
AD  - Department of Pediatrics, School of Clinical Sciences, Faculty of Medicine,
      Nursing and Health Sciences, Monash University, Melbourne, Australia.
AD  - Department of Surgery, School of Clinical Sciences, Faculty of Medicine, Nursing 
      and Health Sciences, Monash University, Melbourne, Australia.
FAU - Ferguson, Peter
AU  - Ferguson P
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
FAU - Nataraja, Ramesh M
AU  - Nataraja RM
AD  - Department of Pediatric Surgery, Urology & Surgical Simulation, Monash Children's
      Hospital, Melbourne, Australia.
AD  - Department of Pediatrics, School of Clinical Sciences, Faculty of Medicine,
      Nursing and Health Sciences, Monash University, Melbourne, Australia.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
CIN - Ann Surg. 2021 Dec 1;274(6):e715. PMID: 32224731
CIN - Ann Surg. 2021 Dec 1;274(6):e715-e716. PMID: 32649453
CIN - Ann Surg. 2021 Dec 1;274(6):e810. PMID: 33201098
CIN - Ann Surg. 2021 Dec 1;274(6):e810-e812. PMID: 33201105
CIN - Ann Surg. 2021 Dec 1;274(6):e868-e869. PMID: 33443896
CIN - Ann Surg. 2021 Dec 1;274(6):e869-e870. PMID: 33443899
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Appendectomy/adverse effects/*methods
MH  - Appendicitis/diagnosis/*surgery
MH  - Australia
MH  - Chi-Square Distribution
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Intravenous
MH  - Laparoscopy/adverse effects/*methods
MH  - Length of Stay
MH  - Male
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Statistics, Nonparametric
MH  - Surgical Wound Infection/*prevention & control
MH  - Treatment Outcome
MH  - Wound Healing/*drug effects/physiology
EDAT- 2020/07/18 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1097/SLA.0000000000003732 [doi]
AID - 00000658-202008000-00057 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Aug;272(2):248-252. doi: 10.1097/SLA.0000000000003732.


PMID- 32675494
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210203
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 2
DP  - 2020 Aug
TI  - Apples to Oranges: Ethical Considerations in COVID-19 Surgical Recovery.
PG  - e52
LID - 10.1097/SLA.0000000000004082 [doi]
FAU - Eng, Oliver S
AU  - Eng OS
AD  - Department of Surgery, University of Chicago, Chicago, IL.
FAU - Tseng, Jennifer
AU  - Tseng J
AD  - Department of Surgery, University of Chicago, Chicago, IL.
FAU - Ejaz, Aslam
AU  - Ejaz A
AD  - Department of Surgery, The Ohio State University, Columbus, OH.
FAU - Pawlik, Timothy M
AU  - Pawlik TM
AD  - Department of Surgery, The Ohio State University, Columbus, OH.
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery, University of Chicago, Chicago, IL.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Decision Making/*ethics
MH  - Elective Surgical Procedures/ethics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Postoperative Care/*ethics
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Surgery Department, Hospital/*ethics
MH  - Surgical Procedures, Operative/*ethics
MH  - Time-to-Treatment
PMC - PMC7268873
EDAT- 2020/07/18 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/SLA.0000000000004082 [doi]
AID - 00000658-202008000-00014 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Aug;272(2):e52. doi: 10.1097/SLA.0000000000004082.


PMID- 32675445
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201218
IS  - 0972-2823 (Electronic)
IS  - 0022-3859 (Linking)
VI  - 66
IP  - 3
DP  - 2020 Jul-Sep
TI  - Ethics committees: Actions during pandemic and lockdown situations.
PG  - 119-122
LID - 10.4103/jpgm.JPGM_431_20 [doi]
FAU - Bavdekar, S B
AU  - Bavdekar SB
AD  - Department of Pediatrics, Surya Hospitals, Mumbai, Maharashtra, India.
LA  - eng
PT  - Editorial
PL  - India
TA  - J Postgrad Med
JT  - Journal of postgraduate medicine
JID - 2985196R
SB  - IM
MH  - *Biomedical Research
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - *Decision Making
MH  - *Ethics Committees
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology
PMC - PMC7542058
COIS- None
EDAT- 2020/07/18 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - jpgm_2020_66_3_119_287695 [pii]
AID - 10.4103/jpgm.JPGM_431_20 [doi]
PST - ppublish
SO  - J Postgrad Med. 2020 Jul-Sep;66(3):119-122. doi: 10.4103/jpgm.JPGM_431_20.


PMID- 32675163
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Jul
TI  - Ethical considerations.
PG  - e131
LID - 10.7861/clinmed.Let.20.4.1 [doi]
FAU - Porther, Ruth
AU  - Porther R
AD  - Aneurin Bevan Health Board, Abergavenny, UK.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
CON - Clin Med (Lond). 2020 May 1;:null. PMID: 32357976
MH  - *COVID-19
MH  - Health Personnel
MH  - Humans
MH  - *Pandemics
MH  - SARS-CoV-2
MH  - State Medicine
PMC - PMC7385765
EDAT- 2020/07/18 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 20/4/e131 [pii]
AID - 10.7861/clinmed.Let.20.4.1 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2020 Jul;20(4):e131. doi: 10.7861/clinmed.Let.20.4.1.


PMID- 32675068
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 7
DP  - 2020 Jul
TI  - Population health, economics and ethics in the age of COVID-19.
LID - e003259 [pii]
LID - 10.1136/bmjgh-2020-003259 [doi]
AB  - Are the steps that have been taken to arrest the spread of COVID-19 justifiable? 
      Specifically, are they likely to have improved public health understood according
      to widely used aggregate population health measures, such as Quality Adjusted
      Life Years (QALYs) and Disability Adjusted Life Years (DALYs) as much or more
      than alternatives? This is a reasonable question, since such measures have been
      promoted extensively in global and national health policy by influential actors, 
      and they have become almost synonymous with quantification of public health. If
      the steps taken against COVID-19 did not meet this test, then either the measures
      or the policies must be re-evaluated. There are indications that policies against
      COVID-19 may have been unbalanced and therefore not optimal. A balanced approach 
      to protecting population health should be proportionate in its effects across
      distinct health concerns at a moment, across populations over time and across
      populations over space. These criteria provide a guide to designing and
      implementing policies that diminish harm from COVID-19 while also providing due
      attention to other threats to aggregate population health. They should shape
      future policies in response to this pandemic and others.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Reddy, Sanjay G
AU  - Reddy SG
AUID- ORCID: 0000-0002-3270-143X
AD  - Economics, The New School for Social Research, New York, New York, USA
      reddysanjayg@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*economics/epidemiology
MH  - *Global Health
MH  - Health Policy
MH  - Humans
MH  - Pandemics/*economics/*ethics
MH  - Pneumonia, Viral/*economics/epidemiology
MH  - *Population Health
MH  - Public Health/*economics/*ethics
MH  - Quality-Adjusted Life Years
MH  - SARS-CoV-2
PMC - PMC7368475
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
OT  - *indices of health and disease and standardisation of rates
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/18 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - bmjgh-2020-003259 [pii]
AID - 10.1136/bmjgh-2020-003259 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Jul;5(7). pii: bmjgh-2020-003259. doi:
      10.1136/bmjgh-2020-003259.


PMID- 32674855
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1545-7206 (Electronic)
IS  - 0033-3182 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Nov - Dec
TI  - End-Stage Anorexia Nervosa: When to Say "When"-A Literature Review of an
      Ethically Complicated Case.
PG  - 779-786
LID - S0033-3182(20)30150-X [pii]
LID - 10.1016/j.psym.2020.05.011 [doi]
FAU - Sawhill, Christine
AU  - Sawhill C
AD  - University of South Carolina, Greenville, Prisma Health, Upstate, Greenville, SC.
      Electronic address: Christine.sawhill@prismahealth.org.
FAU - Fipps, David C
AU  - Fipps DC
AD  - University of South Carolina, Greenville, Prisma Health, Upstate, Greenville, SC.
FAU - Palomo, Jennifer V
AU  - Palomo JV
AD  - University of South Carolina, Greenville, Prisma Health, Upstate, Greenville, SC.
FAU - Miller, Melanie
AU  - Miller M
AD  - Consult Liaison Division, Department of Psychiatry, Prisma Health, Upstate,
      Greenville, SC.
LA  - eng
PT  - Case Reports
PT  - Review
DEP - 20200526
PL  - England
TA  - Psychosomatics
JT  - Psychosomatics
JID - 0376506
SB  - IM
MH  - *Anorexia Nervosa/complications
MH  - Humans
EDAT- 2020/07/18 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/07/18 06:00 [entrez]
AID - S0033-3182(20)30150-X [pii]
AID - 10.1016/j.psym.2020.05.011 [doi]
PST - ppublish
SO  - Psychosomatics. 2020 Nov - Dec;61(6):779-786. doi: 10.1016/j.psym.2020.05.011.
      Epub 2020 May 26.


PMID- 32674827
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20210709
IS  - 1538-9375 (Electronic)
IS  - 1525-8610 (Linking)
VI  - 21
IP  - 7
DP  - 2020 Jul
TI  - How a Barcelona Post-Acute Facility became a Referral Center for Comprehensive
      Management of Subacute Patients With COVID-19.
PG  - 954-957
LID - S1525-8610(20)30520-X [pii]
LID - 10.1016/j.jamda.2020.06.015 [doi]
AB  - The COVID-19 pandemic's greatest impact is among older adults. Management of the 
      situation requires a systemic response, and post-acute care (PAC) can provide an 
      adequate mix of active treatment, management of associated geriatric syndromes
      and palliative care, both in the acute phase, and in post-COVID-19 recovery. In
      the region of Catalonia, Spain, selected PAC centers have become sites to treat
      older patients with COVID-19. Referrals come from the emergency department or
      COVID-19 wards of the acute reference hospitals, nursing homes, or private homes.
      We critically review the actions taken by Parc Sanitari Pere Virgili, a PAC
      facility in Barcelona, to manage the pandemic, including its administration,
      health care, communication, psychological support, and ethical frameworks. We
      believe that the strategies we used and the lessons we learned can be useful for 
      other sites and countries where similar adaptation of existing facilities may be 
      implemented.
CI  - Copyright (c) 2020 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
      Published by Elsevier Inc. All rights reserved.
FAU - Inzitari, Marco
AU  - Inzitari M
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain;
      Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address:
      minzitari@perevirgili.cat.
FAU - Udina, Cristina
AU  - Udina C
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain;
      Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Len, Oscar
AU  - Len O
AD  - Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona,
      Spain.
FAU - Ars, Joan
AU  - Ars J
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain;
      Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Arnal, Cristina
AU  - Arnal C
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain;
      Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Badani, Hugo
AU  - Badani H
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
FAU - Davey, Vanessa
AU  - Davey V
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
FAU - Risco, Ester
AU  - Risco E
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
FAU - Ayats, Pere
AU  - Ayats P
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
FAU - de Andres, Ana M
AU  - de Andres AM
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
FAU - Mayordomo, Cristina
AU  - Mayordomo C
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
FAU - Ros, Francisco J
AU  - Ros FJ
AD  - Medical Oncology Department, Vall d'Hebron University Hospital and, Vall d'Hebron
      Institute of Oncology (VHIO), Barcelona, Spain.
FAU - Morandi, Alessandro
AU  - Morandi A
AD  - Research Group on Aging, Frailty and Care Transitions in Barcelona, Parc Sanitari
      Pere Virgili and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain;
      Ospedale Le Ancelle, Fondazione Teresa Camplani, Cremona, Italy.
FAU - Cesari, Matteo
AU  - Cesari M
AD  - Universita Statale and Policlinico Maggiore, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - United States
TA  - J Am Med Dir Assoc
JT  - Journal of the American Medical Directors Association
JID - 100893243
SB  - IM
MH  - Aged
MH  - COVID-19
MH  - Comprehensive Health Care/*organization & administration
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Female
MH  - Geriatrics/methods
MH  - Health Facilities/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Organizational Innovation
MH  - *Outcome Assessment, Health Care
MH  - Pandemics/prevention & control/statistics & numerical data
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Spain
MH  - Subacute Care/*organization & administration
MH  - Tertiary Care Centers/*organization & administration
MH  - Urban Population
PMC - PMC7287444
OTO - NOTNLM
OT  - COVID-19
OT  - geriatric syndromes
OT  - geriatrics
OT  - older adults
OT  - palliative care
OT  - post-acute care
EDAT- 2020/07/18 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
AID - S1525-8610(20)30520-X [pii]
AID - 10.1016/j.jamda.2020.06.015 [doi]
PST - ppublish
SO  - J Am Med Dir Assoc. 2020 Jul;21(7):954-957. doi: 10.1016/j.jamda.2020.06.015.
      Epub 2020 Jun 11.


PMID- 32674003
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210929
IS  - 1557-8615 (Electronic)
IS  - 0883-9441 (Linking)
VI  - 59
DP  - 2020 Oct
TI  - Conflicts of interest in the context of end of life care for potential organ
      donors in Australia.
PG  - 166-171
LID - S0883-9441(20)30601-8 [pii]
LID - 10.1016/j.jcrc.2020.06.016 [doi]
AB  - End-of-life (EOL) care has become an integral part of intensive care medicine and
      includes the exploration of possibilities for deceased organ and tissue donation.
      Donation physicians are specialist doctors with expertise in EOL processes
      encompassing organ and tissue donation, who contribute significantly to
      improvements in organ and tissue donation services in many countries around the
      world. Donation physicians are usually also intensive care physicians, and thus
      they may be faced with the dual obligation of caring for dying patients and their
      families in the intensive care unit (ICU), whilst at the same time ensuring organ
      and tissue donation is considered according to best practice. This dual
      obligation poses specific ethical challenges that need to be carefully understood
      by clinicians, institutions and health care networks. These obligations are
      complementary and provide a unique skillset to care for dying patients and their 
      families in the ICU. In this paper we review current controversies around EOL
      care in the ICU, including the use of palliative analgesia and sedation
      specifically with regards to withdrawal of cardiorespiratory support, the
      usefulness of the so-called doctrine of double effect to guide ethical
      decision-making, and the management of potential or perceived conflicts of
      interest in the context of dual professional roles.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - van Haren, Frank M P
AU  - van Haren FMP
AD  - Australian National University, Medical School, University of Canberra, Faculty
      of Health, Intensive Care Unit, Canberra Hospital, Canberra, Australia.
      Electronic address: frank.vanharen@anu.edu.au.
FAU - Carter, Angus
AU  - Carter A
AD  - Cairns and Hinterland Hospital and Health Service, James Cook University School
      of Medicine and Dentistry, Cairns, Australia.
FAU - Cavazzoni, Elena
AU  - Cavazzoni E
AD  - University of Sydney, Children's Hospital at Westmead, Sydney, Australia.
FAU - Chapman, Michael
AU  - Chapman M
AD  - Australian National University, Medical School, University of Technology Sydney, 
      ImPaCCT, Department of Palliative Care, Canberra Hospital, Canberra, Australia.
FAU - D'Costa, Rohit L
AU  - D'Costa RL
AD  - Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.
FAU - Jones, Sarah L
AU  - Jones SL
AD  - Intensive Care Unit, the Northern Hospital, Epping, Australia.
FAU - McGee, Andrew
AU  - McGee A
AD  - Australian Centre for Health Law Research, Faculty of Law, Queensland University 
      of Technology, Brisbane, Australia.
FAU - Moodie, Stewart
AU  - Moodie S
AD  - Department of Intensive Care, Royal Adelaide Hospital, Adelaide, Australia.
FAU - Nunnink, Leo
AU  - Nunnink L
AD  - University of Queensland, Brisbane, Australia.
FAU - O'Leary, Michael
AU  - O'Leary M
AD  - Intensive Care Service, Royal Prince Alfred Hospital, Sydney, Australia.
FAU - Opdam, Helen
AU  - Opdam H
AD  - Intensive Care Unit, Austin Health, Melbourne, Australia.
FAU - Radford, Sam
AU  - Radford S
AD  - Intensive Care Unit, Austin Health, Faculty of Medicine, Dentistry and Health
      Science, Melbourne University, Y, Australia.
FAU - Turner, Andrew J
AU  - Turner AJ
AD  - Department of Critical Care Medicine, Royal Hobart Hospital, Hobart, Australia.
FAU - Martin, Dominique
AU  - Martin D
AD  - School of Medicine, Faculty of Health, Deakin University. Geelong, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200704
PL  - United States
TA  - J Crit Care
JT  - Journal of critical care
JID - 8610642
SB  - IM
CIN - J Crit Care. 2021 Jun;63:273-274. PMID: 33012586
CIN - J Crit Care. 2021 Jun;63:272. PMID: 33097318
MH  - Australia
MH  - Conflict of Interest
MH  - Critical Care
MH  - Humans
MH  - Intensive Care Units
MH  - Palliative Care
MH  - Physicians
MH  - Terminal Care/*ethics
MH  - Tissue Donors/*ethics
MH  - Tissue and Organ Procurement
OTO - NOTNLM
OT  - *Conflict of interest
OT  - *Donation physician
OT  - *Dual roles
OT  - *End of life
OT  - *Ethics
OT  - *Organ donation
OT  - *Palliative care
EDAT- 2020/07/17 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/04/26 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - S0883-9441(20)30601-8 [pii]
AID - 10.1016/j.jcrc.2020.06.016 [doi]
PST - ppublish
SO  - J Crit Care. 2020 Oct;59:166-171. doi: 10.1016/j.jcrc.2020.06.016. Epub 2020 Jul 
      4.


PMID- 32673809
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 143
DP  - 2020 Nov
TI  - Cohesion Between Research Literature and Health System Level Efforts to Address
      Global Neurosurgical Inequity: A Scoping Review.
PG  - e88-e105
LID - S1878-8750(20)31515-1 [pii]
LID - 10.1016/j.wneu.2020.06.237 [doi]
AB  - BACKGROUND: Research output on global neurosurgery (GNS) has exponentially
      increased in recent years. As research efforts increase, we must first analyze
      how the current body of GNS literature fits into the macroscopic schema of
      systems-based policies. The aim of this study was to identify and categorize GNS 
      research based on health system domains. METHODS: PubMed, CINAHL, and Embase were
      searched for GNS literature published from 1999 to 2019. Then, health system
      domains were defined and itemized based on publicly available documents from the 
      Program in Global Surgery and Social Change. This items chart was subsequently
      used to categorize the GNS literature into health system domains. RESULTS: A
      total 63 articles were determined to focus on a health system domain. Of these
      articles, 6 focused on multiple domains, yielding an adjusted total of 70
      articles. Overall, the most represented health system domain was service delivery
      (21 articles), followed by workforce (19), infrastructure (15), financing (12)
      and information management (3). A total of 30 low- and middle-income countries
      (LMICs) were represented across all articles. In addition, the first author was
      affiliated with an institution from a high-income country for 71.4% of the
      articles. CONCLUSIONS: This review highlighted the pressing need for more
      research into information management in the context of GNS. In addition, health
      system-focused GNS literature represented only 20% of all LMICs (30/143). The
      trends in authorship should be noted, because many ethical (and practical) issues
      may arise if there is a disconnect in the objectives of the authors and the
      neurosurgeons in LMICs.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ham, Edward I
AU  - Ham EI
AD  - Stony Brook School of Medicine, Stony Brook, New York, USA; Program in Global
      Surgery and Social Change, Harvard Medical School, Boston, Massachusetts, USA.
      Electronic address: edward.ham@stonybrookmedicine.edu.
FAU - Kim, Jeongyoon
AU  - Kim J
AD  - Bowdoin College, Brunswick, Maine, USA.
FAU - Kanmounye, Ulrick Sidney
AU  - Kanmounye US
AD  - Program in Global Surgery and Social Change, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Lartigue, Jean Wilguens
AU  - Lartigue JW
AD  - Program in Global Surgery and Social Change, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Gupta, Saksham
AU  - Gupta S
AD  - Program in Global Surgery and Social Change, Harvard Medical School, Boston,
      Massachusetts, USA; Department of Neurosurgery, Brigham and Women's Hospital,
      Boston, Massachusetts, USA.
FAU - Esene, Ignatius N
AU  - Esene IN
AD  - Neurosurgery Division, Faculty of Health Sciences, University of Bamenda,
      Bamenda, Cameroon.
FAU - Park, Kee B
AU  - Park KB
AD  - Program in Global Surgery and Social Change, Harvard Medical School, Boston,
      Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200713
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
SB  - IM
MH  - *Delivery of Health Care
MH  - Developing Countries
MH  - *Global Health
MH  - Health Information Management
MH  - *Health Policy
MH  - *Health Services Research
MH  - Health Workforce
MH  - *Healthcare Disparities
MH  - Healthcare Financing
MH  - Humans
MH  - *Neurosurgery
MH  - Policy Making
OTO - NOTNLM
OT  - *Global health
OT  - *Global neurosurgery
OT  - *Health systems
OT  - *LMIC
OT  - *Scoping review
EDAT- 2020/07/17 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/06/28 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - S1878-8750(20)31515-1 [pii]
AID - 10.1016/j.wneu.2020.06.237 [doi]
PST - ppublish
SO  - World Neurosurg. 2020 Nov;143:e88-e105. doi: 10.1016/j.wneu.2020.06.237. Epub
      2020 Jul 13.


PMID- 32673381
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200718
IS  - 1188-4169 (Print)
IS  - 1188-4169 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun 4
TI  - A call for an ethical framework when using social media data for artificial
      intelligence applications in public health research.
PG  - 169-173
LID - 10.14745/ccdr.v46i06a03 [doi]
AB  - Advancements in artificial intelligence (AI), more precisely the subfield of
      machine learning, and their applications to open-source internet data, such as
      social media, are growing faster than the management of ethical issues for use in
      society. An ethical framework helps scientists and policy makers consider ethics 
      in their fields of practice, legitimize their work and protect members of the
      data-generating public. A central question for advancing the ethical framework is
      whether or not Tweets, Facebook posts and other open-source social media data
      generated by the public represent a human or not. The objective of this paper is 
      to highlight ethical issues that the public health sector will be or is already
      confronting when using social media data in practice. The issues include informed
      consent, privacy, anonymization and balancing these issues with the benefits of
      using social media data for the common good. Current ethical frameworks need to
      provide guidance for addressing issues arising from the use of social media data 
      in the public health sector. Discussions in this area should occur while the
      application of open-source data is still relatively new, and they should also
      keep pace as other problems arise from ongoing technological change.
FAU - Gilbert, Jean-Philippe
AU  - Gilbert JP
AD  - Universite Laval, Quebec, QC.
FAU - Ng, Victoria
AU  - Ng V
AD  - Public Health Agency of Canada, Ottawa, ON.
FAU - Niu, Jingcheng
AU  - Niu J
AD  - University of Toronto, Toronto, ON.
FAU - Rees, Erin E
AU  - Rees EE
AD  - Public Health Agency of Canada, Ottawa, ON.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - Canada
TA  - Can Commun Dis Rep
JT  - Canada communicable disease report = Releve des maladies transmissibles au Canada
JID - 9303729
PMC - PMC7343052
OTO - NOTNLM
OT  - artificial intelligence
OT  - ethical research
OT  - ethics
OT  - social media
COIS- Conflict of interest: None.
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.14745/ccdr.v46i06a03 [doi]
AID - 460603 [pii]
PST - epublish
SO  - Can Commun Dis Rep. 2020 Jun 4;46(6):169-173. doi: 10.14745/ccdr.v46i06a03.
      eCollection 2020 Jun 4.


PMID- 32673278
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 8
TI  - Effectiveness of the InCharge Prevention Program to Promote Healthier Lifestyles:
      Protocol for a Randomized Controlled Trial.
PG  - e17702
LID - 10.2196/17702 [doi]
AB  - BACKGROUND: InCharge is a newly developed school-based health intervention aimed 
      at older adolescents. It aims to promote a healthier lifestyle by increasing
      self-regulation skills. After the InCharge program's effectiveness was previously
      investigated in a pilot study, the content of the program was adapted. OBJECTIVE:
      This study describes the protocol of a cluster randomized controlled trial that
      aims to investigate the effectiveness of the InCharge program. METHODS: A cluster
      randomized controlled trial including 70 classes with older adolescents (aged 16 
      years or older) in the Netherlands will be conducted to test the effectiveness of
      the InCharge program. After schools are recruited, randomization occurs at the
      class level. The trial consists of the following two conditions: an experimental 
      condition and a control condition. Participants in the experimental condition
      will be given the InCharge intervention, consisting of four lessons of 50
      minutes, with each lesson containing three assignments of approximately 15
      minutes. While participants in the experimental condition will receive InCharge, 
      participants in the control condition will receive regular academic school
      courses. Surveys are administered 1 week before the intervention (baseline), 1
      week after the intervention (posttest), and 12 weeks after the intervention
      (follow-up). Variables of interest include, but are not limited to,
      self-regulation; predictors of snack intake, physical activity, and alcohol use; 
      and interpersonal communication regarding these health behaviors. In addition to 
      surveys, observations will be conducted during the first and fourth lessons,
      teachers will be interviewed, and focus groups will be held with a selection of
      students from the intervention condition. RESULTS: Enrollment started in
      September 2017. As of June 2019, a total of 1216 participants were enrolled for
      this trial. Findings will be published in peer-reviewed journals and presented at
      conferences. The trial has been approved by the Ethics Review Board of the
      Faculty of Social and Behavioral Sciences of the University of Amsterdam
      (reference no.: 2017-PC-8244). CONCLUSIONS: In this study protocol, the design of
      a cluster randomized controlled trial is described, which assesses how
      effectively the school-based intervention InCharge stimulates healthier
      lifestyles in late adolescents. We hypothesize that participants in the
      experimental condition will consume less alcohol, eat fewer unhealthy snacks, and
      be more physically active compared with participants in the control condition.
      TRIAL REGISTRATION: Netherlands Trial Register (NL6654);
      https://www.trialregister.nl/trial/6654. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): RR1-10.2196/17702.
CI  - (c)Mathijs Mesman, Simone Onrust, Renee Verkerk, Hanneke Hendriks, Bas Van den
      Putte. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 08.07.2020.
FAU - Mesman, Mathijs
AU  - Mesman M
AUID- ORCID: https://orcid.org/0000-0002-9229-766X
AD  - Amsterdam School of Communication Research, University of Amsterdam, Amsterdam,
      Netherlands.
FAU - Onrust, Simone
AU  - Onrust S
AUID- ORCID: https://orcid.org/0000-0001-6686-4299
AD  - Trimbos Institute, Utrecht, Netherlands.
FAU - Verkerk, Renee
AU  - Verkerk R
AUID- ORCID: https://orcid.org/0000-0002-9891-434X
AD  - Trimbos Institute, Utrecht, Netherlands.
FAU - Hendriks, Hanneke
AU  - Hendriks H
AUID- ORCID: https://orcid.org/0000-0003-4184-0252
AD  - Amsterdam School of Communication Research, University of Amsterdam, Amsterdam,
      Netherlands.
FAU - Van den Putte, Bas
AU  - Van den Putte B
AUID- ORCID: https://orcid.org/0000-0002-3635-6880
AD  - Amsterdam School of Communication Research, University of Amsterdam, Amsterdam,
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7381060
OTO - NOTNLM
OT  - adolescents
OT  - behavior change
OT  - health behavior
OT  - healthy lifestyle
OT  - quality of life
OT  - school-based health intervention
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/01/06 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - v9i7e17702 [pii]
AID - 10.2196/17702 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 8;9(7):e17702. doi: 10.2196/17702.


PMID- 32673272
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 9
TI  - Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in
      Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a
      Pilot Study.
PG  - e15113
LID - 10.2196/15113 [doi]
AB  - BACKGROUND: Despite the importance and popularity of mutual support groups, there
      have been no systematic attempts to implement and evaluate routine outcome
      monitoring (ROM) in these settings. Unlike other mutual support groups for
      addiction, trained facilitators lead all Self-Management and Recovery Training
      (SMART Recovery) groups, thereby providing an opportunity to implement ROM as a
      routine component of SMART Recovery groups. OBJECTIVE: This study protocol aims
      to describe a stage 1 pilot study designed to explore the feasibility and
      acceptability of a novel, purpose-built mobile health (mHealth) ROM and feedback 
      app (Smart Track) in SMART Recovery groups coordinated by SMART Recovery
      Australia (SRAU) The secondary objectives are to describe Smart Track usage
      patterns, explore psychometric properties of the ROM items (ie, internal
      reliability and convergent and divergent validity), and provide preliminary
      evidence for participant reported outcomes (such as alcohol and other drug use,
      self-reported recovery, and mental health). METHODS: Participants (n=100) from
      the SMART Recovery groups across New South Wales, Australia, will be recruited to
      a nonrandomized, prospective, single-arm trial of the Smart Track app. There are 
      4 modes of data collection: (1) ROM data collected from group participants via
      the Smart Track app, (2) data analytics summarizing user interactions with Smart 
      Track, (3) quantitative interview and survey data of group participants
      (baseline, 2-week follow-up, and 2-month follow-up), and (4) qualitative
      interviews with group participants (n=20) and facilitators (n=10). Feasibility
      and acceptability (primary objectives) will be analyzed using descriptive
      statistics, a cost analysis, and a qualitative evaluation. RESULTS: At the time
      of submission, 13 sites (25 groups per week) had agreed to be involved. Funding
      was awarded on August 14, 2017, and ethics approval was granted on April 26, 2018
      (HREC/18/WGONG/34; 2018/099). Enrollment is due to commence in July 2019. Data
      collection is due to be finalized in October 2019. CONCLUSIONS: To the best of
      our knowledge, this study is the first to use ROM and tailored feedback within a 
      mutual support group setting for addictive behaviors. Our study design will
      provide an opportunity to identify the acceptability of a novel mHealth ROM and
      feedback app within this setting and provide detailed information on what factors
      promote or hinder ROM usage within this context. This project aims to offer a new
      tool, should Smart Track prove feasible and acceptable, that service providers,
      policy makers, and researchers could use in the future to understand the impact
      of SMART Recovery groups. TRIAL REGISTRATION: Australian New Zealand Clinical
      Trials Registry (ANZCTR): ACTRN12619000686101;
      https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377336.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/15113.
CI  - (c)Peter J Kelly, Alison K Beck, Amanda L Baker, Frank P Deane, Leanne Hides,
      Victoria Manning, Anthony Shakeshaft, Briony Larance, Joanne Neale, John Kelly,
      Christopher Oldmeadow, Andrew Searles, Carla Treloar, Rebecca M Gray, Angela
      Argent, Ryan McGlaughlin. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 09.07.2020.
FAU - Kelly, Peter J
AU  - Kelly PJ
AUID- ORCID: https://orcid.org/0000-0003-0500-1865
AD  - Faculty of Social Sciences, School of Psychology, University of Wollongong,
      Wollongong, Australia.
AD  - Illawarra Health and Medical Research Institute, Wollongong, Australia.
FAU - Beck, Alison K
AU  - Beck AK
AUID- ORCID: https://orcid.org/0000-0002-9031-2117
AD  - Faculty of Social Sciences, School of Psychology, University of Wollongong,
      Wollongong, Australia.
FAU - Baker, Amanda L
AU  - Baker AL
AUID- ORCID: https://orcid.org/0000-0002-3328-7146
AD  - School of Medicine and Public Health, University of Newcastle, Callaghan,
      Australia.
FAU - Deane, Frank P
AU  - Deane FP
AUID- ORCID: https://orcid.org/0000-0002-6247-7416
AD  - Faculty of Social Sciences, School of Psychology, University of Wollongong,
      Wollongong, Australia.
AD  - Illawarra Health and Medical Research Institute, Wollongong, Australia.
FAU - Hides, Leanne
AU  - Hides L
AUID- ORCID: https://orcid.org/0000-0002-4550-8460
AD  - Centre for Youth Substance Abuse Research, Lives Lived Well Group, School of
      Psychology, University of Queensland, Brisbane St Lucia, Australia.
FAU - Manning, Victoria
AU  - Manning V
AUID- ORCID: https://orcid.org/0000-0003-3908-5980
AD  - Faculty of Medicine, Nursing and Health Sciences, Eastern Health Clinical School,
      Monash University, Melbourne, Australia.
FAU - Shakeshaft, Anthony
AU  - Shakeshaft A
AUID- ORCID: https://orcid.org/0000-0002-5472-0930
AD  - Faculty of Arts and Social Sciences, Centre for Social Research in Health,
      University of New South Wales, Sydney, Australia.
FAU - Larance, Briony
AU  - Larance B
AUID- ORCID: https://orcid.org/0000-0003-3800-7673
AD  - Faculty of Social Sciences, School of Psychology, University of Wollongong,
      Wollongong, Australia.
AD  - Illawarra Health and Medical Research Institute, Wollongong, Australia.
FAU - Neale, Joanne
AU  - Neale J
AUID- ORCID: https://orcid.org/0000-0003-1502-5983
AD  - Institute of Psychiatry, Psychology and Neuroscience, King's College London,
      London, United Kingdom.
FAU - Kelly, John
AU  - Kelly J
AUID- ORCID: https://orcid.org/0000-0001-6915-0750
AD  - Centre for Addiction Medicine, Harvard Medical School, Harvard University,
      Boston, MA, United States.
FAU - Oldmeadow, Christopher
AU  - Oldmeadow C
AUID- ORCID: https://orcid.org/0000-0001-6104-1322
AD  - Clinical Research Design, IT and Statistical Support Unit, Hunter Medical
      Research Institute, New Lambton, Australia.
FAU - Searles, Andrew
AU  - Searles A
AUID- ORCID: https://orcid.org/0000-0002-9452-9735
AD  - Health Research Economics Unit, Hunter Medical Research Institute, New Lambton,
      Australia.
FAU - Treloar, Carla
AU  - Treloar C
AUID- ORCID: https://orcid.org/0000-0002-8230-0386
AD  - Faculty of Arts and Social Sciences, Centre for Social Research in Health,
      University of New South Wales, Sydney, Australia.
FAU - Gray, Rebecca M
AU  - Gray RM
AUID- ORCID: https://orcid.org/0000-0002-5637-623X
AD  - Faculty of Arts and Social Sciences, Centre for Social Research in Health,
      University of New South Wales, Sydney, Australia.
FAU - Argent, Angela
AU  - Argent A
AUID- ORCID: https://orcid.org/0000-0002-8546-882X
AD  - SMART Recovery Australia, Sydney, Australia.
FAU - McGlaughlin, Ryan
AU  - McGlaughlin R
AUID- ORCID: https://orcid.org/0000-0002-7456-4541
AD  - SMART Recovery Australia, Sydney, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7380906
OTO - NOTNLM
OT  - SMART Recovery
OT  - addiction
OT  - mHealth
OT  - mobile phone
OT  - mutual aid
OT  - mutual support group
OT  - routine outcome monitoring
OT  - treatment progress feedback
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2019/06/19 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - v9i7e15113 [pii]
AID - 10.2196/15113 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 9;9(7):e15113. doi: 10.2196/15113.


PMID- 32673265
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 14
TI  - Del Nido Cardioplegia Versus Cold Blood Cardioplegia in Adult Cardiac Surgery:
      Protocol for a Randomized Controlled Trial.
PG  - e17826
LID - 10.2196/17826 [doi]
AB  - BACKGROUND: The use of cardioplegia solutions as a myocardial protection
      technique is essential during cardiac surgery with cardiopulmonary bypass. The
      del Nido cardioplegia solution (DNS) has been widely used as a myocardial
      preservation technique for pediatric patients undergoing cardiac surgery with
      cardiopulmonary bypass. Its unique pharmacological features have created growing 
      interest for adult cardiac surgery, especially for elderly patients or those with
      ventricular dysfunction who are more prone to ischemia-reperfusion injury. Ever
      since its implementation, several retrospective studies have been published to
      validate the efficacy, safety, and efficiency of DNS in adult patients undergoing
      coronary revascularization, valve replacement, or combined procedures. Recently, 
      a meta-analysis based on nine retrospective studies was published claiming the
      noninferiority of DNS compared to other conventional cardioplegia solutions. Few 
      prospective randomized studies have been conducted whose primary outcome was the 
      assessment of DNS clinical efficacy compared to other solutions commonly used in 
      adult patients. OBJECTIVE: The aim of this randomized clinical trial is to assess
      the benefits of DNS compared to Cardi-Braun blood cardioplegia solution in
      clinical and biochemical terms regarding myocardial protection during adult
      cardiac surgery. METHODS: This is the protocol of a controlled, randomized,
      single-center clinical trial carried out at the Puerta de Hierro Majadahonda
      University Hospital in Spain. A total of 474 participants over the age of 18
      years undergoing elective cardiac surgery with cardiopulmonary bypass will be
      assigned to groups by simple randomization to receive either DNS or Cardi-Braun
      blood cardioplegia solution. The primary outcome will be the differences between 
      groups in myocardial protection in biochemical terms (ie, perioperative troponin 
      levels) and clinical terms (ie, presence of the composite variable acute
      cardiovascular event). The clinical trial will be carried out under conditions of
      respect for the fundamental rights of the person and the ethical principles that 
      affect biomedical research with human beings, as well as in accordance with
      international recommendations contained in the Declaration of Helsinki and its
      subsequent revisions. RESULTS: The inclusion process started in 2018. Data
      cleaning and analyses are expected to take place in the fall of 2020 and the
      results are expected in January 2021. CONCLUSIONS: This study is particularly
      relevant as it will be one of the first to analyze the clinical effects of del
      Nido cardioplegia on the basis of direct myocardial protection parameters. In
      light of published studies, carrying out prospective studies based on primary
      clinical objectives with a larger sample, high-risk patients, and longer
      cardiopulmonary bypass times continues to be necessary. We believe that our study
      addresses an important gap in the knowledge of del Nido cardioplegia in adult
      patient cardiac surgery and will be able to clarify the possible benefits of this
      method in a large population of patients undergoing these procedures. TRIAL
      REGISTRATION: European Union Drug Regulating Authorities Clinical Trials Database
      (EudraCT) 2017-005144-14;
      https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005144-14+;
      ClinicalTrials.gov NCT04094168; https://clinicaltrials.gov/ct2/show/NCT04094168. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/17826.
CI  - (c)Jessica Garcia-Suarez, Javier Garcia Fernandez, Sergio Sanz, Daniel Martinez
      Lopez, Leticia Reques, Alberto Forteza Gil. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 14.07.2020.
FAU - Garcia-Suarez, Jessica
AU  - Garcia-Suarez J
AUID- ORCID: https://orcid.org/0000-0003-0287-2809
AD  - Department of Anesthesiology and Critical Care, Puerta de Hierro Majadahonda
      University Hospital, Madrid, Spain.
FAU - Garcia Fernandez, Javier
AU  - Garcia Fernandez J
AUID- ORCID: https://orcid.org/0000-0001-7978-5506
AD  - Department of Anesthesiology and Critical Care, Puerta de Hierro Majadahonda
      University Hospital, Madrid, Spain.
FAU - Sanz, Sergio
AU  - Sanz S
AUID- ORCID: https://orcid.org/0000-0001-7562-190X
AD  - Department of Anesthesiology and Critical Care, Puerta de Hierro Majadahonda
      University Hospital, Madrid, Spain.
FAU - Martinez Lopez, Daniel
AU  - Martinez Lopez D
AUID- ORCID: https://orcid.org/0000-0002-8076-4195
AD  - Department of Cardiovascular Surgery, Puerta de Hierro Majadahonda University
      Hospital, Majadahonda, Madrid, Spain.
FAU - Reques, Leticia
AU  - Reques L
AUID- ORCID: https://orcid.org/0000-0003-0988-7974
AD  - Department of Cardiovascular Surgery, Puerta de Hierro Majadahonda University
      Hospital, Majadahonda, Madrid, Spain.
FAU - Forteza Gil, Alberto
AU  - Forteza Gil A
AUID- ORCID: https://orcid.org/0000-0001-6811-132X
AD  - Department of Cardiovascular Surgery, Puerta de Hierro Majadahonda University
      Hospital, Majadahonda, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT04094168
PT  - Journal Article
DEP - 20200714
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7388037
OTO - NOTNLM
OT  - cardiac surgery
OT  - del Nido cardioplegia
OT  - myocardial protection
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - v9i7e17826 [pii]
AID - 10.2196/17826 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 14;9(7):e17826. doi: 10.2196/17826.


PMID- 32673261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 14
TI  - Evidence-Based Decision Aid for Patients With Parkinson Disease: Protocol for
      Interview Study, Online Survey, and Two Randomized Controlled Trials.
PG  - e17482
LID - 10.2196/17482 [doi]
AB  - BACKGROUND: Shared decision making is particularly important in situations with
      different treatment alternatives. For the treatment of idiopathic Parkinson
      disease, both pharmacological and surgical approaches can be applied. OBJECTIVE: 
      In this research project, a series of studies will be conducted to investigate
      how decision aids for patients with idiopathic Parkinson disease should be
      designed in order to support the decision-making process. METHODS: In Study 1a,
      qualitative interviews will be conducted to determine which needs frequently
      occur for patients with idiopathic Parkinson disease. In Study 1b, the identified
      needs will then be rated for personal relevance by an independent group of
      patients in an online survey. In Study 2, a randomized controlled trial will be
      used to pretest different decision aids in a sample group of people who do not
      have a medical background and who do not have Parkinson disease. In Study 3, a
      randomized controlled trial will be used to investigate the effect of the
      decision aids that had been evaluated as positive in Study 2 with patients who
      have idiopathic Parkinson disease. RESULTS: This series of studies received
      ethical approval in January 2020. As of June 2020, data collection for Study 1a
      has started, and it is estimated that Studies 1a, 1b, 2, and 3 will take
      approximately 4, 4, 6, and 6 months to complete, respectively. It is planned to
      present the results and analyses at international conferences and to submit the
      results to peer-reviewed journals for publication, once the studies have been
      completed. The findings will also be shared with clinicians and patients through 
      presentations at information events. CONCLUSIONS: This series of studies is
      intended to result in an evidence-based decision aid for patients with idiopathic
      Parkinson disease in order to support the informed and reflected shared
      decision-making process. We further intend to contribute to a deeper
      understanding of the individual preferences of patients with idiopathic Parkinson
      disease and the impact of those preferences on treatment decisions.
CI  - (c)Martina Bientzle, Joachim Kimmerle, Marie Eggeling, Idil Cebi, Daniel Weiss,
      Alireza Gharabaghi. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 14.07.2020.
FAU - Bientzle, Martina
AU  - Bientzle M
AUID- ORCID: https://orcid.org/0000-0002-1312-4032
AD  - Leibniz-Institut fur Wissensmedien, Tubingen, Germany.
FAU - Kimmerle, Joachim
AU  - Kimmerle J
AUID- ORCID: https://orcid.org/0000-0002-6345-9498
AD  - Leibniz-Institut fur Wissensmedien, Tubingen, Germany.
AD  - Department of Psychology, University of Tubingen, Tubingen, Germany.
FAU - Eggeling, Marie
AU  - Eggeling M
AUID- ORCID: https://orcid.org/0000-0001-9749-7321
AD  - Leibniz-Institut fur Wissensmedien, Tubingen, Germany.
FAU - Cebi, Idil
AU  - Cebi I
AUID- ORCID: https://orcid.org/0000-0002-1458-9173
AD  - Division of Functional and Restorative Neurosurgery and Tubingen NeuroCampus,
      University of Tubingen, Tubingen, Germany.
FAU - Weiss, Daniel
AU  - Weiss D
AUID- ORCID: https://orcid.org/0000-0003-0447-7132
AD  - Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain
      Research, University of Tubingen, Tubingen, Germany.
AD  - German Centre of Neurodegenerative Diseases, Tubingen, Germany.
FAU - Gharabaghi, Alireza
AU  - Gharabaghi A
AUID- ORCID: https://orcid.org/0000-0002-9782-5281
AD  - Division of Functional and Restorative Neurosurgery and Tubingen NeuroCampus,
      University of Tubingen, Tubingen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7388050
OTO - NOTNLM
OT  - Parkinson disease
OT  - decision aids
OT  - interview study
OT  - online survey
OT  - patients
OT  - randomized controlled trial
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2019/12/16 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - v9i7e17482 [pii]
AID - 10.2196/17482 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 14;9(7):e17482. doi: 10.2196/17482.


PMID- 32673255
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 14
TI  - Assessment of the Effectiveness and Cost-Effectiveness of Tailored Web- and
      Text-Based Smoking Cessation Support in Primary Care (iQuit in Practice II):
      Protocol for a Randomized Controlled Trial.
PG  - e17160
LID - 10.2196/17160 [doi]
AB  - BACKGROUND: The prevalence of smoking is declining; however, it continues to be a
      major public health burden. In England, primary care is the health setting that
      provides smoking cessation support to most smokers. However, this setting has one
      of the lowest success rates. The iQuit in practice intervention (iQuit) is a
      tailored web-based and text message intervention developed for use in primary
      care consultations as an adjunct to routine smoking cessation support with the
      aim of increasing success rates. iQuit has demonstrated feasibility,
      acceptability, and potential effectiveness. OBJECTIVE: This definitive trial aims
      to determine the effectiveness and cost-effectiveness of iQuit when used as an
      adjunct to the usual support provided to patients who wish to quit smoking,
      compared with usual care alone. METHODS: The iQuit in Practice II trial is a
      two-arm, parallel-group, randomized controlled trial (RCT) with a 1:1 individual 
      allocation comparing usual care (ie, pharmacotherapy combined with multisession
      behavioral support)-the control-with usual care plus iQuit-the intervention.
      Participants were recruited through primary care clinics and talked to a smoking 
      cessation advisor. Participants were randomized during the initial consultation, 
      and those allocated to the intervention group received a tailored advice report
      and 90 days of text messaging in addition to the standard support provided to all
      patients. RESULTS: The primary outcome is self-reported prolonged abstinence
      biochemically verified using saliva cotinine at 6 months after the quit date. A
      sample size of 1700 participants, with 850 per arm, would yield 90% power to
      detect a 4.3% difference in validated quit rates between the groups at the
      two-sided 5% level of significance. The Cambridge East Research Ethics Committee 
      approved the study in February 2016, and funding for the study was granted from
      May 2016. In total, 1671 participants were recruited between August 2016 and July
      2019. Follow-up for all participants was completed in January 2020. Data analysis
      will begin in the summer of 2020. CONCLUSIONS: iQuit in Practice II is a
      definitive, pragmatic RCT assessing whether a digital intervention can augment
      the impact of routine smoking cessation support in primary care. Previous
      research has found good acceptability and feasibility for delivering iQuit among 
      smoking cessation advisors working in primary care. If demonstrated to be
      cost-effective, iQuit could be delivered across primary care and other settings, 
      such as community pharmacies. The potential benefit would likely be highest where
      less behavioral support is delivered. TRIAL REGISTRATION: International Standard 
      Randomized Controlled Trial Number (ISRCTN): 44559004; http://www.isrctn.com
      /ISRCTN44559004. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/17160.
CI  - (c)Joanna Proctor, Felix Naughton, Melanie Sloan, Sarah Hopewell, James
      Brimicombe, A Toby Prevost, Edward C F Wilson, Tim Coleman, Stephen Sutton.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 14.07.2020.
FAU - Proctor, Joanna
AU  - Proctor J
AUID- ORCID: https://orcid.org/0000-0003-2138-3402
AD  - University of Cambridge, Cambridge, United Kingdom.
FAU - Naughton, Felix
AU  - Naughton F
AUID- ORCID: https://orcid.org/0000-0001-9790-2796
AD  - University of East Anglia, Norwich, United Kingdom.
FAU - Sloan, Melanie
AU  - Sloan M
AUID- ORCID: https://orcid.org/0000-0001-8153-9064
AD  - University of Cambridge, Cambridge, United Kingdom.
FAU - Hopewell, Sarah
AU  - Hopewell S
AUID- ORCID: https://orcid.org/0000-0003-1825-073X
AD  - University of Cambridge, Cambridge, United Kingdom.
FAU - Brimicombe, James
AU  - Brimicombe J
AUID- ORCID: https://orcid.org/0000-0002-3443-3256
AD  - University of Cambridge, Cambridge, United Kingdom.
FAU - Prevost, A Toby
AU  - Prevost AT
AUID- ORCID: https://orcid.org/0000-0003-1723-0796
AD  - Imperial College London, London, United Kingdom.
FAU - Wilson, Edward C F
AU  - Wilson ECF
AUID- ORCID: https://orcid.org/0000-0002-8369-1577
AD  - University of East Anglia, Norwich, United Kingdom.
FAU - Coleman, Tim
AU  - Coleman T
AUID- ORCID: https://orcid.org/0000-0002-7303-4805
AD  - University of Nottingham, Nottingham, United Kingdom.
FAU - Sutton, Stephen
AU  - Sutton S
AUID- ORCID: https://orcid.org/0000-0003-1610-0404
AD  - University of Cambridge, Cambridge, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7388034
OTO - NOTNLM
OT  - adults
OT  - internet-based intervention
OT  - primary care
OT  - smokers
OT  - smoking cessation
OT  - text messaging
OT  - tobacco
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - v9i7e17160 [pii]
AID - 10.2196/17160 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 14;9(7):e17160. doi: 10.2196/17160.


PMID- 32673240
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210108
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 7
DP  - 2020 Jul 7
TI  - Assessing Patient Experience and Healthcare Quality of Dental Care Using Patient 
      Online Reviews in the United States: Mixed Methods Study.
PG  - e18652
LID - 10.2196/18652 [doi]
AB  - BACKGROUND: Over the last two decades, patient review websites have emerged as an
      essential online platform for doctor ratings and reviews. Recent studies
      suggested the significance of such websites as a data source for patients to
      choose doctors for healthcare providers to learn and improve from patient
      feedback and to foster a culture of trust and transparency between patients and
      healthcare providers. However, as compared to other medical specialties, studies 
      of online patient reviews that focus on dentists in the United States remain
      absent. OBJECTIVE: This study sought to understand to what extent online patient 
      reviews can provide performance feedbacks that reflect dental care quality and
      patient experience. METHODS: Using mixed informatics methods incorporating
      statistics, natural language processing, and domain expert evaluation, we
      analyzed the online patient reviews of 204,751 dentists extracted from
      HealthGrades with two specific aims. First, we examined the associations between 
      patient ratings and a variety of dentist characteristics. Second, we identified
      topics from patient reviews that can be mapped to the national assessment of
      dental patient experience measured by the Patient Experience Measures from the
      Consumer Assessment of Healthcare Providers and Systems (CAHPS) Dental Plan
      Survey. RESULTS: Higher ratings were associated with female dentists
      (t71881=2.45, P<.01, g=0.01), dentists at a younger age (F7, 107128=246.97,
      P<.001, g=0.11), and those whose patients experienced a short wait time (F4,
      150055=10417.77, P<0.001, g=0.18). We also identified several topics that
      corresponded to CAHPS measures, including discomfort (eg, painful/painless root
      canal or deep cleaning), and ethics (eg, high-pressure sales, and unnecessary
      dental work). CONCLUSIONS: These findings suggest that online patient reviews
      could be used as a data source for understanding the patient experience and
      healthcare quality in dentistry.
CI  - (c)Ye Lin, Y Alicia Hong, Bradley S Henson, Robert D Stevenson, Simon Hong,
      Tianchu Lyu, Chen Liang. Originally published in the Journal of Medical Internet 
      Research (http://www.jmir.org), 07.07.2020.
FAU - Lin, Ye
AU  - Lin Y
AUID- ORCID: 0000-0003-0907-4375
AD  - College of Dental Medicine, Western University of Health Sciences, Pomona, CA,
      United States.
FAU - Hong, Y Alicia
AU  - Hong YA
AUID- ORCID: 0000-0002-1481-6495
AD  - College of Health and Human Services, George Mason University, Fairfax, VA,
      United States.
FAU - Henson, Bradley S
AU  - Henson BS
AUID- ORCID: 0000-0003-4392-509X
AD  - College of Dental Medicine, Western University of Health Sciences, Pomona, CA,
      United States.
FAU - Stevenson, Robert D
AU  - Stevenson RD
AUID- ORCID: 0000-0002-2151-2633
AD  - College of Dental Medicine, Western University of Health Sciences, Pomona, CA,
      United States.
FAU - Hong, Simon
AU  - Hong S
AUID- ORCID: 0000-0003-3753-1545
AD  - College of Dental Medicine, Western University of Health Sciences, Pomona, CA,
      United States.
FAU - Lyu, Tianchu
AU  - Lyu T
AUID- ORCID: 0000-0002-5937-4432
AD  - Arnold School of Public Health, University of South Carolina, Columbia, SC,
      United States.
FAU - Liang, Chen
AU  - Liang C
AUID- ORCID: 0000-0002-9803-9880
AD  - Arnold School of Public Health, University of South Carolina, Columbia, SC,
      United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200707
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Dental Care/*standards
MH  - Female
MH  - Humans
MH  - Internet
MH  - Male
MH  - Middle Aged
MH  - Quality of Health Care/*standards
MH  - United States
PMC - PMC7380989
OTO - NOTNLM
OT  - *consumer health informatics
OT  - *dental care
OT  - *healthcare quality
OT  - *natural language processing
OT  - *patient online reviews
OT  - *patient review websites
EDAT- 2020/07/17 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
AID - v22i7e18652 [pii]
AID - 10.2196/18652 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jul 7;22(7):e18652. doi: 10.2196/18652.


PMID- 32673014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200726
IS  - 1935-990X (Electronic)
IS  - 0003-066X (Linking)
VI  - 75
IP  - 5
DP  - 2020 Jul-Aug
TI  - Charles L. Brewer Award for Distinguished Teaching of Psychology: Linda M. Woolf.
PG  - 720-722
LID - 10.1037/amp0000670 [doi]
AB  - This award recognizes a significant career of contributions of a psychologist who
      has a proven track record as an exceptional teacher of psychology. The awardee
      receives a plaque, a $4,000 award and an all-expense paid round trip to the APA
      Annual Convention, where the award is presented. Awardees are also invited to
      give a special address. Respect for diversity, human rights, ethics, critical
      thinking, and depth of learning are primary to Linda M. Woolf's philosophy of
      teaching. For 30 years, Linda has encouraged fellow teachers to integrate issues 
      of social justice and global concerns into their courses-teaching to make a
      difference. Nationally, Linda is a tireless advocate for justice and human
      rights, and locally, she is a sought-after educator who comes to work each day
      excited about the classroom. Linda's vision, leadership, and advocacy have
      expanded psychology to make our discipline more globally relevant to students,
      researchers, teachers, and mental health professionals throughout the world.
      (PsycInfo Database Record (c) 2020 APA, all rights reserved).
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Psychol
JT  - The American psychologist
JID - 0370521
SB  - IM
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 2020-51214-008 [pii]
AID - 10.1037/amp0000670 [doi]
PST - ppublish
SO  - Am Psychol. 2020 Jul-Aug;75(5):720-722. doi: 10.1037/amp0000670.


PMID- 32672694
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 302
DP  - 2020 May
TI  - DIAGNOSTIC PARAMETERS OF IN VIVO (SKIN PRICK) AND IN VITRO (ELISA) TESTS FOR
      DETERMINATION OF EPIDERMAL CAT AND DOG ALLERGENS SENSITIZATION IN PATIENTS WITH
      ALLERGIC RHINITIS AND ATOPIC ASTHMA.
PG  - 76-81
AB  - Objective was to study and compare the parameters of the specificity and
      sensitivity of skin testing and serologic determination of specific cat and dog
      IgE. 88 patients with allergic rhinitis and / or asthma were examined by three
      different methods of specific allergic diagnosis (in vivo and in vitro) in
      accordance with the guidelines of the ethics committee of the National Pirogov
      memorial medical university, all were beyond the acute period. The inclusion
      criteria were allergic rhinitis diagnosis (both intermittent and persistent) and 
      \ or asthma. Skin prick test was carried out according to the classical testing
      procedure in accordance with regulatory documents with commercial extracts of
      allergens. Western blot testing for specific IgE levels was performed using RIDA 
      qLine test systems (R-Biopharm AG, Darmstadt, Germany) and Euroline (Euroimmun). 
      The sIgE concentration was converted to a nominal scale (grades) according to the
      following rules: < 0.35 IU mL-1-level 0 (negative), (0.36-0.69) IU mL-1-level 1
      (boundary levels ), (0.7- 3.49) IU mL-1-level 2 (slightly elevated), (3.50-17.4) 
      IU mL-1-level 3 (moderately elevated), (17.5-49 , 9) IU mL-1-level 4 (high
      levels), (50-100) IU mL-1-level 5 (very high levels) and > 100 IU mL-1-level 6
      (extremely high levels). Thus, the results of the two systems for the
      determination of specific IgE for dog allergen by the Rida AllergyScreen and
      Euroline methods do not agree very well due to the systematic divergence of
      indicators; the results of the two systems for the determination of specific IgE 
      for cat allergen by the Rida AllergyScreen and Euroline methods agree very well. 
      There is excellent agreement between the skin test with cat allergen and the
      detection of specific IgE by the Rida AllergyScreen test, between the skin test
      with cat allergen and the detection of specific IgE by the Euroline method. There
      is good agreement between the skin test with dog wool allergens and the detection
      of specific IgE by the Rida AllergyScreen test, between the skin test with dog
      hair allergen and the detection of specific IgE by the Euroline method there is
      satisfactory agreement. The systematic error of the measurement results between
      two in vitro tests for cat allergen was 0.1 ku/l, which indicates the presence of
      a small systematic difference, the systematic error of the measurement results
      between two in vitro tests for dog allergen was 0,26 ku/l, which indicates the
      presence of a moderate systematic difference.
FAU - Gogunskaya, I
AU  - Gogunskaya I
AD  - 1State institution <<O.S. Kolomiychenko Institute of otolaryngology of National
      Academy of Medical Sciences of Ukraine"; Ukraine.
FAU - Zaikov, S
AU  - Zaikov S
AD  - 2Shupyk National Medical Academy of Postgraduate Education, Kyiv; Ukraine.
FAU - Bogomolov, A
AU  - Bogomolov A
AD  - 3National Pirogov memorial medical university, Vinnytsya, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens
MH  - Animals
MH  - *Asthma
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Germany
MH  - Humans
MH  - Immunoglobulin E
MH  - *Rhinitis, Allergic
MH  - Skin Tests
EDAT- 2020/07/17 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2020 May;(302):76-81.


PMID- 32672682
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 302
DP  - 2020 May
TI  - BIOCHEMICAL PROPERTIES OF CARBOXYPEPTIDASE A OF THE UNTRANSFERRED TISSUE AND
      MALIGNANT NEOPLASM OF THE MAMMARY GLAND.
PG  - 12-17
AB  - To study biochemical properties of carboxypeptidase A of the untransformed tissue
      and malignant neoplasm of the mammalian gland. Sampling of anatomical materials
      for research was conducted with compliance of ethical and legal standards.
      Excretion of this enzymes includes gradual fractionation with the (NH4)2SO4,
      dialysis at the presence of 2,0 small em, Cyrilliccapital EM, Cyrillic Zn++ and
      gel chromatography on the sephadex - G 75. The investigation substrate
      specificity of the enzymes was held by hydrolysis of the substrate of
      carbobenzoxyphenylalanine, phenylalanylalanine, glutamyltyrosine, prolylalanine
      (2,0 mM), haemoglobin and casein (2,0 %). The influence of inhibitors and
      activators was determined in presence of: Zn++, cysteine, triton X-100, soybean
      trypsin inhibitor, leupeptin, pepstatin, PHMB, PMSF, dimethylmolyemydanhydride,
      tozylheptanol, mercaptoethanol, EDTA and 1,10 - phenanthroline. The maximal
      velocity (Vmax), Mihaelis constant (Km), inhibition type and inhibition constant 
      (Ki) analysed by Lineweaver - Burk method. Carboxypeptidase A from the
      untransformed tissue and malignant neoplasm of the mammalian gland better splits 
      the substrates, which have hydrophobic and aromatic amino acids. The activity of 
      carboxypeptidase A from the malignant tumor of the mammalian gland is inhibited
      most of all under influence of soybean trypsin inhibitor and PMSF, in contrast to
      untransformed tissue. For carboxypeptidase A from the untransformed tissue of the
      mammalian gland Km=0,24 mM and Ki=0,40 mM were determined, for carboxypeptidase A
      from the malignant neoplasm of the mammalian gland - Km=0,17 mM and Ki=0,65 mM.
      Carboxypeptidase A from the untransformed tissue and malignant neoplasm of the
      mammalian gland is identical as to the substrate specificity, inhibition by
      phenylalanine for noncompetitive type, inhibition and activation effect by
      reagent with the exclusion of soybean trypsin inhibitor and PMSF, but differ as
      to affinity to carbobenzoxyphenylalanine and sensitivity to phenylalanine.
FAU - Filiptsova, capital KA, Cyrillic
AU  - Filiptsova capital KA, Cyrillic
AD  - South Ukrainian National Pedagogical University named after K. D. Ushynsky,
      Odesa, Ukraine.
LA  - eng
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - EC 3.4.17.1 (Carboxypeptidases A)
SB  - IM
MH  - Animals
MH  - Carboxypeptidases A
MH  - *Neoplasms
MH  - *Renal Dialysis
MH  - Substrate Specificity
EDAT- 2020/07/17 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2020 May;(302):12-17.


PMID- 32672419
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Jul
TI  - The Pathway Forward: Insights on Factors that Facilitate Research with Pregnant
      Women.
PG  - 2-16
LID - 10.1002/eahr.500058 [doi]
AB  - The near-routine exclusion of pregnant women from clinical research has resulted 
      in evidence gaps that endanger the health of pregnant women and their future
      offspring. Although existing literature documents numerous obstacles along the
      clinical trial pathway that can stymie research involving pregnant women, there
      is little guidance on how to facilitate such research. This qualitative study
      aims to fill that void by examining the experiences of individuals involved in
      conducting, approving, or overseeing research involving pregnant women at one
      academic institution. The study identifies factors throughout the clinical
      pathway-from protocol development, to IRB review, and ultimately trial
      execution-that likely contribute to the successful conduct of research with
      pregnant women. Attention to those factors, coupled with agreement among
      stakeholders that research with pregnant women should and can be done ethically
      and legally, is critical to shifting the narrative from "why we cannot" do such
      research to "how we can."
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Mastroianni, Anna C
AU  - Mastroianni AC
AD  - Professor at the School of Law at the University of Washington and an associate
      director at the Institute for Public Health Genetics at the University of
      Washington.
FAU - Franceschini, Robert
AU  - Franceschini R
AD  - Director of policy and government relations at BluePath Health.
FAU - Wicks, Sarah L
AU  - Wicks SL
AD  - Associate at Goodwin Procter LLP.
FAU - Henry, Leslie Meltzer
AU  - Henry LM
AD  - Professor of law at the University of Maryland Carey School of Law and a member
      of the core faculty at the Johns Hopkins Berman Institute of Bioethics.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
RN  - 0 (Prescription Drugs)
SB  - IM
EIN - Ethics Hum Res. 2020 Sep;42(5):16. PMID: 32937034
MH  - Biomedical Research/*ethics
MH  - Ethics Committees, Research/*standards
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Pregnancy
MH  - *Pregnant Women
MH  - Prescription Drugs/*administration & dosage
MH  - Qualitative Research
MH  - *Research Design/legislation & jurisprudence/standards
MH  - Risk Assessment
OTO - NOTNLM
OT  - clinical trials
OT  - human subjects research
OT  - institutional review board (IRB)
OT  - pregnant research participants
EDAT- 2020/07/17 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1002/eahr.500058 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Jul;42(4):2-16. doi: 10.1002/eahr.500058.


PMID- 32671889
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1365-2834 (Electronic)
IS  - 0966-0429 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Sep
TI  - Nurses' preparation for transitioning into positions of leadership-A Caribbean
      perspective.
PG  - 1356-1363
LID - 10.1111/jonm.13089 [doi]
AB  - AIM: To explore perspectives of nurse managers about their preparation for
      transitioning into positions of leadership. BACKGROUND: There have been serious
      concerns about the level of preparation as well as availability of support
      systems for transitioning of nurses into positions of authority. METHODS: This
      was a quantitative study conducted in four Caribbean countries targeting nurses
      promoted to leadership positions within the last 5 years. Data were collected
      using a 30-item questionnaire. Ethical approvals were received from the
      University of the West Indies and the participating countries. RESULTS: Most
      participants were female, had 15 or more years' experience and an associate
      degree/diploma in nursing. They felt prepared through training and acting
      opportunities although many were not preceptored/mentored into the position.
      Preparation by training was positively correlated to acting opportunities,
      preceptorship programme and having a preceptor. CONCLUSION: Transitioning into
      positions of leadership requires readiness from a personal as well as an
      organisational perspective. There must be investment in the development
      opportunities to support nurses' transition into leadership positions.
      IMPLICATIONS FOR NURSING MANAGEMENT: Organisational continuity and effectiveness 
      will be dependent on a balance between investing in experienced nursing personnel
      while encouraging personal development of less-experienced nurses. Peer
      mentorship must be utilized to facilitate nurse transition.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Ocho, Oscar Noel
AU  - Ocho ON
AUID- ORCID: https://orcid.org/0000-0002-3620-4043
AD  - University of the West Indies School of Nursing (UWISoN), St Augustine, Trinidad 
      and Tobago.
FAU - Wheeler, Erica
AU  - Wheeler E
AD  - Pan American Health Organization, Country Office, Port of Spain, Trinidad and
      Tobago.
FAU - Sheppard, Claudine
AU  - Sheppard C
AD  - University of the West Indies School of Nursing (UWISoN), St Augustine, Trinidad 
      and Tobago.
FAU - Caesar-Greasley, Lu-Ann
AU  - Caesar-Greasley LA
AD  - University of the West Indies School of Nursing (UWISoN), St Augustine, Trinidad 
      and Tobago.
FAU - Rigby, Janet
AU  - Rigby J
AD  - Centre for Clinical Research, Nova Scotia Health Authority, Halifax, NS, USA.
FAU - Tomblin Murphy, Gail
AU  - Tomblin Murphy G
AD  - Centre for Clinical Research, Nova Scotia Health Authority, Halifax, NS, USA.
AD  - WHO/PAHO Collaborating Centre on Health Workforce Planning & Research, Dalhousie 
      University, Halifax, NS, Canada.
LA  - eng
GR  - CRP.3.MAR17.36/School of Graduate Studies and Research, University of the West
      Indies, St Augustine
PT  - Journal Article
DEP - 20200804
PL  - England
TA  - J Nurs Manag
JT  - Journal of nursing management
JID - 9306050
MH  - Caribbean Region
MH  - Female
MH  - Humans
MH  - Leadership
MH  - *Nurse Administrators
MH  - *Nurses
MH  - Preceptorship
MH  - West Indies
OTO - NOTNLM
OT  - mentorship
OT  - nursing leadership
OT  - organisational development
OT  - succession planning
OT  - transitioning
EDAT- 2020/07/17 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/07/17 06:00 [entrez]
AID - 10.1111/jonm.13089 [doi]
PST - ppublish
SO  - J Nurs Manag. 2020 Sep;28(6):1356-1363. doi: 10.1111/jonm.13089. Epub 2020 Aug 4.


PMID- 32671310
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 22
DP  - 2020
TI  - The use of intra-operative tranexamic acid in shoulder surgery: Protocol for a
      systematic review and meta-analysis.
PG  - 15-18
LID - 10.1016/j.isjp.2020.06.003 [doi]
AB  - INTRODUCTION: Blood loss is an important consideration in all types of shoulder
      surgery. Excessive bleeding is associated with increased morbidity. Tranexamic
      acid (TXA) is an antifibrinolytic agent. It has been demonstrated to be effective
      in reducing blood loss across multiple surgical specialties. The aim of this
      systematic review and meta-analysis is to review the literature evaluating
      clinical outcomes associated with the use of TXA in shoulder surgery. METHODS:
      The study protocol was designed and registered prospectively on PROSPERO
      (International prospective register for systematic reviews). Literature search
      will include the MEDLINE, EMBASE, PsycINFO, and Cochrane Library databases.
      Randomised controlled trials (RCTs) evaluating the use of TXA against placebo, in
      all types of shoulder surgery, will be included. Our primary outcome is total
      blood loss (ml). Secondary outcomes include patient-reported outcome measures
      (PROMs), adverse events, and number of blood transfusions required. Risk of bias 
      will be assessed within each study using The Cochrane Risk of Bias Tool 2.0 and
      the Jadad score. Inconsistency and bias across included studies will be assessed 
      statistically. Data from comparable outcomes will be pooled and analysed
      quantitatively or descriptively as appropriate. ETHICS AND DISSEMINATION: No
      ethical clearances required for this study. This systematic review and
      meta-analysis will be published in a peer-reviewed journal. It will be presented 
      a various national and international conferences.
CI  - (c) 2020 The Authors.
FAU - Hartland, Alexander W
AU  - Hartland AW
AD  - Trauma and Orthopaedics, Princess Alexandra Hospital, Hamstel Road, Harlow, Essex
      CM20 1QX, UK.
FAU - Teoh, Kar H
AU  - Teoh KH
AD  - Trauma and Orthopaedics, Princess Alexandra Hospital, Hamstel Road, Harlow, Essex
      CM20 1QX, UK.
FAU - Rashid, Mustafa S
AU  - Rashid MS
AD  - Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, 
      Windmill Road, Oxford OX3 7LD, UK.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7338573
OTO - NOTNLM
OT  - Meta-analysis
OT  - Protocol
OT  - Shoulder surgery
OT  - Systematic review
OT  - TXA
OT  - Tranexamic acid
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/06/07 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.1016/j.isjp.2020.06.003 [doi]
AID - S2468-3574(20)30020-6 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Jun 23;22:15-18. doi: 10.1016/j.isjp.2020.06.003.
      eCollection 2020.


PMID- 32671249
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 7
DP  - 2020 Jul
TI  - Patient's characteristics, management practices and outcome of re-laparotomies in
      a tertiary hospital in Tanzania.
PG  - e04295
LID - 10.1016/j.heliyon.2020.e04295 [doi]
AB  - BACKGROUND: Relaparotomy is an important indicator of the safety and quality of
      laparotomy in any surgical setting. Despite this, its measure in many low- and
      middle-income countries is scarce, Tanzania included. Understanding its existence
      will help curb it and mitigate its adverse outcomes by systematic improvement
      strategies. This study, therefore, aimed to examine characteristics of patients
      undergoing on-demand relaparotomy and their management outcomes at a tertiary
      level hospital in Tanzania. METHODS: A cross-sectional descriptive study was
      carried out in the department of surgery of Muhimbili National Hospital for one
      year in 2017-2018. All patients (of all ages and sex) who required an on-demand
      relaparotomy within 60 days of their index laparotomy were identified for
      inclusion into the study. Data were collected regarding patient's demography,
      clinical characteristics, index surgical procedure, indication for relaparotomy, 
      number of re-laparotomies, complications during re-laparotomy, ICU admission, and
      mortality. Data were entered into SPSS version 23 for analysis where continuous
      variables were summarized as means with standard deviations and categorical
      variables summarized as the frequency with proportions. Ethical approval for the 
      audit was obtained from the Muhimbili University of Health IRB. RESULTS: A total 
      of 101 patients had undergone relaparotomy, with a relaparotomy rate among those 
      primarily operated at our hospital of 7.6%. Their mean age was 37 years with
      equal sex distribution. The leading primary procedure had involved bowel
      resection and anastomosis (47.5%) with anastomotic leak being the leading reason 
      for relaparotomy (37.6%) followed by intra-abdominal collection (29.7%), bowel
      fistula (19.8%) and wound dehiscence (18.8%). Electrolyte imbalance was the
      leading complication among the patients (22.9%) followed by anemia (21.5%), wound
      infection (18.9%) and Septicemia (11%). The overall mortality of rate was 39.6%. 
      CONCLUSION: On-demand relaparotomy carries a high mortality and morbidity at
      Muhimbili National Hospital in Tanzania. Addressing predictors and improving
      post-operative services are urgently needed.
CI  - (c) 2020 The Authors.
FAU - Swallow, Andrew Y
AU  - Swallow AY
AD  - Muhimbili National Hospital, Dar es Salaam, Tanzania.
FAU - Akoko, Larry O
AU  - Akoko LO
AD  - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
FAU - Lema, Leonard E
AU  - Lema LE
AD  - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
LA  - eng
PT  - Journal Article
DEP - 20200704
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7339055
OTO - NOTNLM
OT  - Complications
OT  - Mortality
OT  - On-demand relaparotomy
OT  - Relaparotomy
OT  - Surgery
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2019/02/03 00:00 [received]
PHST- 2019/08/12 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04295 [doi]
AID - S2405-8440(20)31139-7 [pii]
AID - e04295 [pii]
PST - epublish
SO  - Heliyon. 2020 Jul 4;6(7):e04295. doi: 10.1016/j.heliyon.2020.e04295. eCollection 
      2020 Jul.


PMID- 32670833
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2229-3485 (Print)
IS  - 2229-3485 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Factors influencing recruitment and retention of participants in clinical studies
      conducted at a tertiary referral center: A five-year audit.
PG  - 81-85
LID - 10.4103/picr.PICR_198_18 [doi]
AB  - INTRODUCTION: A key determinant of the success of any study is the recruitment
      and subsequent retention of participants. Screen failure and dropouts impact both
      the scientific validity and financial viability of any study. We carried out this
      audit with the objective of evaluating the recruitment and retention of
      participants in clinical studies conducted over the last five years at our
      center. METHODS: Studies completed between 2014 and 2018 at our center were
      included. Screening ledgers and study trackers were hand searched for screen
      failures and dropouts. Four pre-identified predictors were evaluated - risk as
      per the classification of Indian Council of Medical Research 2017 Ethical
      Guideline, nature of funding, study design, and nature of participants.
      Association of the predictors with screen failures and dropouts was determined
      using crude odds ratios along with 95% confidence intervals. All analyses were
      done at 5% significance using Microsoft Excel 2016. RESULTS: A total of n = 19
      completed studies had n = 2567 screened and n = 2442 enrolled participants with a
      screen failure and dropout rate of 5% and 4%, respectively. We found 59% screen
      failures due to abnormal laboratory values. The main reasons for dropouts were
      lost to follow-up 86 (88%). High-risk and interventional studies were the
      predictors for both screen failures and dropouts, but pharmaceutical
      industry-funded studies and healthy participants were predictors for only screen 
      failures. CONCLUSION: Risk, funding, study design, and nature of participants are
      important to be considered while planning studies to minimize screen failures and
      dropouts.
CI  - Copyright: (c) 2020 Perspectives in Clinical Research.
FAU - Bose, Debdipta
AU  - Bose D
AD  - Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
      Mumbai, Maharashtra, India.
FAU - Saha, Shruti
AU  - Saha S
AD  - Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
      Mumbai, Maharashtra, India.
FAU - Saxena, Unnati
AU  - Saxena U
AD  - Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
      Mumbai, Maharashtra, India.
FAU - Kesari, Harshad
AU  - Kesari H
AD  - Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
      Mumbai, Maharashtra, India.
FAU - Thatte, Urmila M
AU  - Thatte UM
AD  - Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
      Mumbai, Maharashtra, India.
FAU - Gogtay, Nithya J
AU  - Gogtay NJ
AD  - Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital,
      Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - India
TA  - Perspect Clin Res
JT  - Perspectives in clinical research
JID - 101551517
PMC - PMC7342334
OTO - NOTNLM
OT  - Dropouts
OT  - healthy participants
OT  - high-risk studies
OT  - pharmaceutical industry-funded studies
OT  - screen failures
COIS- There are no conflicts of interest.
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2018/12/19 00:00 [received]
PHST- 2019/01/09 00:00 [revised]
PHST- 2019/02/25 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.4103/picr.PICR_198_18 [doi]
AID - PCR-11-81 [pii]
PST - ppublish
SO  - Perspect Clin Res. 2020 Apr-Jun;11(2):81-85. doi: 10.4103/picr.PICR_198_18. Epub 
      2020 May 6.


PMID- 32670829
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2229-3485 (Print)
IS  - 2229-3485 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Clinical trials during the COVID-19 pandemic: Challenges of putting scientific
      and ethical principles into practice.
PG  - 59-63
LID - 10.4103/picr.PICR_77_20 [doi]
AB  - Global pandemic of COVID-19 is a serious unmet medical need requiring clinical
      research into effective therapies. Clinical trials during pandemics of infections
      face complex challenges of putting scientific and ethical principles into
      practice. Some of these issues - selection of investigational product and
      participants, study design, assessment of efficacy and safety, ethics review,
      informed consent and publication, sample size, and publications - require
      in-depth consideration in planning and implementation of clinical trials during
      pandemics.
CI  - Copyright: (c) 2020 Perspectives in Clinical Research.
FAU - Bhatt, Arun
AU  - Bhatt A
AD  - Consultant-Clinical Research and Drug Development, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - India
TA  - Perspect Clin Res
JT  - Perspectives in clinical research
JID - 101551517
PMC - PMC7342332
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical trial
OT  - ethical
OT  - pandemic
OT  - scientific
COIS- There are no conflicts of interest.
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/03/28 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.4103/picr.PICR_77_20 [doi]
AID - PCR-11-59 [pii]
PST - ppublish
SO  - Perspect Clin Res. 2020 Apr-Jun;11(2):59-63. doi: 10.4103/picr.PICR_77_20. Epub
      2020 May 6.


PMID- 32669868
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Linking)
VI  - 13
DP  - 2020
TI  - Knowledge and Attitude of Medical Residents Towards Cancer Clinical Trials in
      Jordan.
PG  - 337-342
LID - 10.2147/IJGM.S258260 [doi]
AB  - BACKGROUND: Clinical trials are an important tool to test the efficacy of new
      treatment modalities for cancer patients. Physicians, including medical
      residents, should play a major role in carrying out clinical trials to generate a
      strong body of evidence to determine the best available treatment for their
      patients. Carrying out clinical trials demands adequate understanding of the
      research phases and requirements including ethical standards as well as
      presenting positive attitudes toward the clinical research. Hence, evaluating the
      knowledge and attitudes of medical residents toward running clinical trials is
      essential to assess their preparedness and willingness to participate in future
      studies. METHODS: This study was a questionnaire-based observational study. It
      involved medical residents from various specialties who served cancer patients
      admitted at King Abdullah University Hospital during the period from June 1 to
      August 15, 2017. RESULTS: A total number of 83 respondents completed the
      questionnaire. Of them, 56.7% and 53.0% of the respondents reported either
      current or previous participation in clinical trials research, respectively. Only
      10 residents (12.0%) had previous participation in clinical research where a new 
      investigational cancer treatment was tested. While, 91.6% of respondents believed
      that physicians should be involved in running clinical cancer research, only
      25.3% had previous experience in writing a cancer clinical trial protocol and
      28.9% wrote a scientific manuscript on cancer clinical trials for publication.
      Moreover, 67.5% of residents knew when informed consent should be obtained and
      62.7% were aware of the clinical equipoise concept in clinical trials.
      CONCLUSION: Much remains to be done to improve knowledge and attitudes of medical
      residents toward cancer clinical trials and the main ethical principles that
      should be followed to assure having an ideal research environment, which will
      pave the way for the generation of high quality clinical cancer research and
      reliable evidence-based clinical practice for cancer management.
CI  - (c) 2020 Al-Azayzih and Alzoubi.
FAU - Al-Azayzih, Ahmad
AU  - Al-Azayzih A
AUID- ORCID: 0000-0001-8426-0034
AD  - Department of Pharmacology and Therapeutics, College of Medicine and Health
      Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of
      Science and Technology, Irbid 22110, Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of
      Science and Technology, Irbid 22110, Jordan.
LA  - eng
GR  - R25 TW010026/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200702
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC7337444
OTO - NOTNLM
OT  - Jordan
OT  - cancer
OT  - clinical trials
OT  - medical residents
OT  - oncology
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.2147/IJGM.S258260 [doi]
AID - 258260 [pii]
PST - epublish
SO  - Int J Gen Med. 2020 Jul 2;13:337-342. doi: 10.2147/IJGM.S258260. eCollection
      2020.


PMID- 32669770
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0973-6131 (Print)
IS  - 0973-6131 (Linking)
VI  - 13
IP  - 2
DP  - 2020 May-Aug
TI  - A Comparative Study between Vedic and Contemporary Education Systems using
      Bio-Energy Markers.
PG  - 152-155
LID - 10.4103/ijoy.IJOY_61_19 [doi]
AB  - BACKGROUND/AIM: "The destiny of the whole world depends on the children. If you
      want to see the silver lining on the horizon it is not you and me, but the
      children who have to be spiritualized" says Swami Satyananda Saraswati. Sri
      Aurobindo states "Education to be complete must have five principal aspects
      corresponding to the five principal activities of the human being: the physical, 
      the vital, the mental, the psychic and the spiritual." Vedic education system
      (VES) focuses on inculcating all facets for overall development of personality.
      This study is an attempt to understand the lore of Vedic education followed by
      yoga as a way of lifestyle for physiological well-being and for successful
      unfoldment of children's personality. MATERIALS AND METHODS: The sample size was 
      378 (108 VES and 270 contemporary education system [CES]). We have excluded
      volunteers who had minor health problems from the study. The ethical clearance
      was taken from SVYASA University Ethics Committee, and informed consent was
      obtained for each individual undergoing the study. As it was aimed to collect
      one-time data, the yoga as a lifestyle in VES itself considered as an
      intervention. Thus, the two systems of educations are compared. The variables are
      measured using the Electro-photonic Image Bio-Well instrument. RESULTS: Bio-Well 
      variables for VES and CES were compared. There was a significant difference in
      VES and CES energy level scores, left-right symmetry scores, organ balance, and
      entropy coefficient scores. CONCLUSIONS: Results suggest that Vedic Education
      System to be better in the measured parameters compared to Contemporary Education
      System.
CI  - Copyright: (c) 2020 International Journal of Yoga.
FAU - Karisetty, Rajesha Halekote
AU  - Karisetty RH
AD  - Division of Yoga Spirituality, Swami Vivekananda Yoga Anusandhana Samsthana
      S-VYASA Yoga University, Bengaluru, Karnataka, India.
FAU - Shivanna, Sushrutha
AU  - Shivanna S
AD  - Department of Humanities and Social Sciences, MIT School of Vedic Science, Loni
      Kalbhor, Maharashtra, India.
FAU - Pradhan, Balaram
AU  - Pradhan B
AD  - Division of Humanities, Swami Vivekananda Yoga Anusandhana Samsthana University, 
      Bengaluru, Karnataka, India.
FAU - Srinivasan, T M
AU  - Srinivasan TM
AD  - Division of Yoga Spirituality, Swami Vivekananda Yoga Anusandhana Samsthana
      S-VYASA Yoga University, Bengaluru, Karnataka, India.
FAU - Bhat, Ramachandra G
AU  - Bhat RG
AD  - Division of Yoga Spirituality, Swami Vivekananda Yoga Anusandhana Samsthana
      S-VYASA Yoga University, Bengaluru, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - India
TA  - Int J Yoga
JT  - International journal of yoga
JID - 101313247
PMC - PMC7336939
OTO - NOTNLM
OT  - Ancient lifestyle
OT  - biological well-being
OT  - education
COIS- There are no conflicts of interest.
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2019/08/10 00:00 [received]
PHST- 2019/08/20 00:00 [revised]
PHST- 2019/08/26 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - 10.4103/ijoy.IJOY_61_19 [doi]
AID - IJY-13-152 [pii]
PST - ppublish
SO  - Int J Yoga. 2020 May-Aug;13(2):152-155. doi: 10.4103/ijoy.IJOY_61_19. Epub 2020
      May 1.


PMID- 32669633
OWN - NLM
STAT- MEDLINE
DCOM- 20201211
LR  - 20210715
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jul 15
TI  - Effects of weaning age and housing conditions on phenotypic differences in mice.
PG  - 11684
LID - 10.1038/s41598-020-68549-3 [doi]
AB  - Poor reproducibility is considered a serious problem in laboratory animal
      research, with important scientific, economic, and ethical implications. One
      possible source of conflicting findings in laboratory animal research are
      environmental differences between animal facilities combined with rigorous
      environmental standardization within studies. Due to phenotypic plasticity,
      study-specific differences in environmental conditions during development can
      induce differences in the animals' responsiveness to experimental treatments,
      thereby contributing to poor reproducibility of experimental results. Here, we
      studied how variation in weaning age (14-30 days) and housing conditions (single 
      versus group housing) affects the phenotype of SWISS mice as measured by a range 
      of behavioral and physiological outcome variables. Weaning age, housing
      conditions, and their interaction had little effect on the development of
      stereotypies, as well as on body weight, glucocorticoid metabolite
      concentrations, and behavior in the elevated plus-maze and open field test. These
      results are surprising and partly in conflict with previously published findings,
      especially with respect to the effects of early weaning. Our results thus
      question the external validity of previous findings and call for further research
      to identify the sources of variation between replicate studies and study designs 
      that produce robust and reproducible experimental results.
FAU - Bailoo, Jeremy D
AU  - Bailoo JD
AUID- ORCID: http://orcid.org/0000-0002-3767-2922
AD  - Division of Animal Welfare, University of Bern, Bern, Switzerland.
      jbailooscience@gmail.com.
AD  - Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech
      Health Sciences Center, Lubbock, TX, USA. jbailooscience@gmail.com.
AD  - Department of Civil, Environmental, and Construction Engineering, Texas Tech
      University, Lubbock, TX, USA. jbailooscience@gmail.com.
FAU - Voelkl, Bernhard
AU  - Voelkl B
AUID- ORCID: http://orcid.org/0000-0001-5454-2508
AD  - Division of Animal Welfare, University of Bern, Bern, Switzerland.
FAU - Varholick, Justin
AU  - Varholick J
AUID- ORCID: http://orcid.org/0000-0003-2822-9045
AD  - Division of Animal Welfare, University of Bern, Bern, Switzerland.
AD  - Department of Biology and UF Genetics Institute, University of Florida,
      Gainesville, USA.
FAU - Novak, Janja
AU  - Novak J
AD  - Division of Animal Welfare, University of Bern, Bern, Switzerland.
FAU - Murphy, Eimear
AU  - Murphy E
AD  - Department of Behavioural Biology, University of Munster, Munster, Germany.
FAU - Rosso, Marianna
AU  - Rosso M
AD  - Division of Animal Welfare, University of Bern, Bern, Switzerland.
FAU - Palme, Rupert
AU  - Palme R
AUID- ORCID: http://orcid.org/0000-0001-9466-3662
AD  - Department of Biomedical Sciences, University of Veterinary Medicine Vienna,
      Vienna, Austria.
FAU - Wurbel, Hanno
AU  - Wurbel H
AUID- ORCID: http://orcid.org/0000-0002-2934-3010
AD  - Division of Animal Welfare, University of Bern, Bern, Switzerland.
      hanno.wuerbel@vetsuisse.unibe.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200715
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Age Factors
MH  - Animal Experimentation/*standards
MH  - Animals
MH  - Animals, Laboratory/*physiology
MH  - Animals, Newborn
MH  - *Biological Variation, Individual
MH  - Body Weight
MH  - Female
MH  - Glucocorticoids/metabolism
MH  - Housing, Animal/*standards
MH  - Male
MH  - Maze Learning/physiology
MH  - Mice
MH  - Phenotype
MH  - Reproducibility of Results
MH  - Weaning
PMC - PMC7363894
EDAT- 2020/07/17 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-68549-3 [doi]
AID - 10.1038/s41598-020-68549-3 [pii]
PST - epublish
SO  - Sci Rep. 2020 Jul 15;10(1):11684. doi: 10.1038/s41598-020-68549-3.


PMID- 32669462
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20211026
IS  - 2379-5042 (Electronic)
IS  - 2379-5042 (Linking)
VI  - 5
IP  - 4
DP  - 2020 Jul 15
TI  - Human Infection Challenge Studies: a Test for the Social Value Criterion of
      Research Ethics.
LID - e00669-20 [pii]
LID - 10.1128/mSphere.00669-20 [doi]
AB  - Human infection challenge studies involving the intentional infection of research
      participants with a disease-causing agent have recently been suggested as a means
      to speed up the search for a vaccine for the ongoing coronavirus disease 2019
      (COVID-19) outbreak. Calls for challenge studies, however, rely on the expected
      social value of these studies. This value represents more than the simple
      possibility that a successful study will lead to the rapid development and
      dissemination of vaccines but also some expectation that this will actually
      occur. I show how this expectation may not be realistic in the current political 
      moment and offer potential ways to make sure that any challenge trials that arise
      actually achieve their goals.
CI  - Copyright (c) 2020 Evans.
FAU - Evans, Nicholas G
AU  - Evans NG
AUID- ORCID: 0000-0002-3330-0224
AD  - Department of Philosophy, University of Massachusetts Lowell, Lowell,
      Massachusetts, USA Nicholas_evans@uml.edu.
LA  - eng
GR  - 1734521/National Science Foundation/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200715
PL  - United States
TA  - mSphere
JT  - mSphere
JID - 101674533
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics/*methods
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/*drug therapy/*prevention & control
MH  - Ethics, Research
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*drug therapy/*prevention & control
MH  - SARS-CoV-2
MH  - Social Values
MH  - Viral Vaccines/therapeutic use
PMC - PMC7364225
OTO - NOTNLM
OT  - *COVID-19
OT  - *challenge studies
OT  - *coronavirus
OT  - *global health
OT  - *research ethics
EDAT- 2020/07/17 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 5/4/e00669-20 [pii]
AID - 10.1128/mSphere.00669-20 [doi]
PST - epublish
SO  - mSphere. 2020 Jul 15;5(4). pii: 5/4/e00669-20. doi: 10.1128/mSphere.00669-20.


PMID- 32669425
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Linking)
VI  - 12
IP  - 552
DP  - 2020 Jul 15
TI  - Ethical challenges for pediatric liver organoid transplantation.
LID - eaau8471 [pii]
LID - 10.1126/scitranslmed.aau8471 [doi]
AB  - Liver organoid transplantation may be a less invasive alternative to liver
      transplant, but is it ethically acceptable to include children with liver disease
      in a first-in-human clinical trial of this new intervention?
CI  - Copyright (c) 2020 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Schneemann, Sarah A
AU  - Schneemann SA
AUID- ORCID: 0000-0003-0946-0305
AD  - Julius Center for Health Sciences and Primary Care, Department of Medical
      Humanities, University Medical Center Utrecht, 3508 GA, Utrecht, Netherlands.
AD  - Department of Pediatrics, Wilhelmina Children's Hospital, University Medical
      Center Utrecht, 3508 AB, Utrecht, Netherlands.
FAU - Boers, Sarah N
AU  - Boers SN
AD  - Julius Center for Health Sciences and Primary Care, Department of Medical
      Humanities, University Medical Center Utrecht, 3508 GA, Utrecht, Netherlands.
FAU - van Delden, Johannes J M
AU  - van Delden JJM
AUID- ORCID: 0000-0002-5530-7275
AD  - Julius Center for Health Sciences and Primary Care, Department of Medical
      Humanities, University Medical Center Utrecht, 3508 GA, Utrecht, Netherlands.
FAU - Nieuwenhuis, Edward E S
AU  - Nieuwenhuis EES
AD  - Department of Pediatrics, Wilhelmina Children's Hospital, University Medical
      Center Utrecht, 3508 AB, Utrecht, Netherlands.
AD  - Science Department, University College Roosevelt, Middelburg, Netherlands.
FAU - Fuchs, Sabine A
AU  - Fuchs SA
AUID- ORCID: 0000-0001-9147-2406
AD  - Department of Metabolic Diseases, Wilhelmina Children's Hospital, University
      Medical Center Utrecht, 3508 AB, Utrecht, Netherlands. s.fuchs@umcutrecht.nl
      a.l.bredenoord@umcutrecht.nl.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AUID- ORCID: 0000-0002-7542-8963
AD  - Julius Center for Health Sciences and Primary Care, Department of Medical
      Humanities, University Medical Center Utrecht, 3508 GA, Utrecht, Netherlands.
      s.fuchs@umcutrecht.nl a.l.bredenoord@umcutrecht.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
SB  - IM
MH  - Child
MH  - Humans
MH  - *Liver Diseases
MH  - *Liver Transplantation
MH  - Organoids
EDAT- 2020/07/17 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/07/17 06:00
PHST- 2018/07/23 00:00 [received]
PHST- 2019/06/28 00:00 [revised]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
AID - 12/552/eaau8471 [pii]
AID - 10.1126/scitranslmed.aau8471 [doi]
PST - ppublish
SO  - Sci Transl Med. 2020 Jul 15;12(552). pii: 12/552/eaau8471. doi:
      10.1126/scitranslmed.aau8471.


PMID- 32669184
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1646-0758 (Electronic)
IS  - 0870-399X (Linking)
VI  - 33
IP  - 7-8
DP  - 2020 Jul 1
TI  - [Informed Consent in Clinical Research in Portugal: Promotion of Good Practices].
PG  - 453-455
LID - 10.20344/amp.13545 [doi]
FAU - Marina, Silvia
AU  - Marina S
AD  - Departamento de Medicina da Comunidade, Informacao e Decisao em Saude. Faculdade 
      de Medicina. Universidade do Porto. Porto; Centro de Investigacao em Tecnologias 
      e Servicos de Saude (CINTESIS). Porto. Portugal.
FAU - Duarte, Ivone
AU  - Duarte I
AD  - Departamento de Medicina da Comunidade, Informacao e Decisao em Saude. Faculdade 
      de Medicina. Universidade do Porto. Porto. Centro de Investigacao em Tecnologias 
      e Servicos de Saude (CINTESIS). Porto. Portugal.
FAU - Ricou, Miguel
AU  - Ricou M
AD  - Departamento de Medicina da Comunidade, Informacao e Decisao em Saude. Faculdade 
      de Medicina. Universidade do Porto. Porto. Centro de Investigacao em Tecnologias 
      e Servicos de Saude (CINTESIS). Porto. Portugal.
LA  - por
PT  - Journal Article
TT  - Consentimento Informado na Investigacao Clinica em Portugal: Promocao de Boas
      Praticas.
DEP - 20200701
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
SB  - IM
MH  - *Clinical Trials as Topic/ethics
MH  - Confidentiality/*ethics
MH  - Ethics, Research
MH  - Humans
MH  - *Informed Consent
MH  - Portugal
OTO - NOTNLM
OT  - Confidentiality/ethics
OT  - Informed Consent
OT  - Research
EDAT- 2020/07/17 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/07/17 06:00
PHST- 2020/02/04 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
AID - 10.20344/amp.13545 [doi]
PST - ppublish
SO  - Acta Med Port. 2020 Jul 1;33(7-8):453-455. doi: 10.20344/amp.13545. Epub 2020 Jul
      1.


PMID- 32669121
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 15
TI  - A Combined Randomised and Observational Study of Surgery for Fractures In the
      distal Radius in the Elderly (CROSSFIRE): a statistical analyses plan.
PG  - 651
LID - 10.1186/s13063-020-4228-0 [doi]
AB  - BACKGROUND: We are performing a combined randomised and observational study
      comparing internal fixation to non-surgical management for common wrist fractures
      in older patients. This paper describes the statistical analysis plan.
      METHODS/DESIGN: A Combined Randomised and Observational Study of Surgery for
      Fractures In the distal Radius in the Elderly (CROSSFIRE) is a randomised
      controlled trial comparing two types of usual care for treating wrist fractures
      in older patients, surgical fixation using volar locking plates and non-surgical 
      treatment using closed reduction and plaster immobilisation. The primary aim of
      this comparative-effectiveness study is to determine whether surgery is superior 
      to non-surgical treatment with respect to patient-reported wrist function at 12
      months post treatment. The secondary outcomes include radiographic outcomes,
      complication rates and patient-reported outcomes including quality of life, pain,
      treatment success and cosmesis. Primary analysis will use a two-sample t test and
      an intention-to-treat analysis using the randomised arm of the study. Statistical
      analyses will be two-tailed and significance will be determined by p < 0.05.
      Sensitivity analyses will be conducted to assess for differences in
      intention-to-treat, per-protocol and as-treated analyses. Sensitivity analyses
      will also be conducted to assess selection bias by evaluating differences in
      participants between the randomised and observational study arms, and for bias
      relating to any missing data. An economic analysis will be conducted separately
      if surgery is shown to provide superior outcomes to a level of clinical
      significance. DISCUSSION: This statistical analysis plan describes the analysis
      of the CROSSFIRE study which aims to provide evidence to aid clinical
      decision-making in the treatment of distal radius fractures in older patients.
      TRIAL REGISTRATION: CROSSFIRE was approved by The Hunter New England Human
      Research Ethics Committee (HNEHREC Reference No: 16/02/17/3.04). Registered on 22
      July 2016 with The Australian and New Zealand Clinical Trials Registry (ANZCTR
      Number; ACTRN12616000969460 ). This manuscript is based on v.11 of the
      statistical analysis plan. A copy of v.11, signed by the chief investigator and
      the senior statistician is kept at the administering institution.
FAU - Lawson, Andrew
AU  - Lawson A
AUID- ORCID: http://orcid.org/0000-0002-1367-6443
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical
      Research, Sydney, NSW, Australia. aalawson@tpg.com.au.
AD  - South Western Sydney Clinical School, UNSW, Sydney, NSW, Australia.
      aalawson@tpg.com.au.
FAU - Naylor, Justine
AU  - Naylor J
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical
      Research, Sydney, NSW, Australia.
AD  - South Western Sydney Clinical School, UNSW, Sydney, NSW, Australia.
FAU - Buchbinder, Rachelle
AU  - Buchbinder R
AD  - Monash University, Melbourne, VIC, Australia.
AD  - Cabrini Institute, Melbourne, VIC, Australia.
FAU - Ivers, Rebecca
AU  - Ivers R
AD  - School of Public Health and Community Medicine, UNSW Sydney, Sydney, NSW,
      Australia.
FAU - Balogh, Zsolt
AU  - Balogh Z
AD  - John Hunter Hospital, Newcastle, NSW, Australia.
FAU - Smith, Paul
AU  - Smith P
AD  - Canberra Hospital, Canberra, ACT, Australia.
FAU - Mittal, Rajat
AU  - Mittal R
AD  - South Western Sydney Clinical School, UNSW, Sydney, NSW, Australia.
FAU - Xuan, Wei
AU  - Xuan W
AD  - Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
FAU - Howard, Kirsten
AU  - Howard K
AD  - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
FAU - Vafa, Arezoo
AU  - Vafa A
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical
      Research, Sydney, NSW, Australia.
FAU - Yates, Piers
AU  - Yates P
AD  - Fiona Stanley Hospital, Perth, WA, Australia.
FAU - Rieger, Bertram
AU  - Rieger B
AD  - Fiona Stanley Hospital, Perth, WA, Australia.
FAU - Smith, Geoff
AU  - Smith G
AD  - St George and Sutherland Hospitals, Sydney, NSW, Australia.
FAU - Elkinson, Ilia
AU  - Elkinson I
AD  - Wellington Hospital, Wellington, New Zealand.
FAU - Kim, Woosung
AU  - Kim W
AD  - Wellington Hospital, Wellington, New Zealand.
FAU - Sungaran, Jai
AU  - Sungaran J
AD  - Concord Hospital, Sydney, NSW, Australia.
FAU - Latendresse, Kim
AU  - Latendresse K
AD  - Nambour Hospital and Sunshine Coast University Hospital, Nambour, QLD, Australia.
FAU - Wong, James
AU  - Wong J
AD  - Westmead Hospital, Sydney, NSW, Australia.
FAU - Viswanathan, Sameer
AU  - Viswanathan S
AD  - Campbelltown Hospital, Sydney, NSW, Australia.
FAU - Landale, Keith
AU  - Landale K
AD  - Campbelltown Hospital, Sydney, NSW, Australia.
FAU - Drobetz, Herwig
AU  - Drobetz H
AD  - Mackay Base Hospital, Mackay, QLD, Australia.
FAU - Tran, Phong
AU  - Tran P
AD  - Western Health, Melbourne, VIC, Australia.
FAU - Page, Richard
AU  - Page R
AD  - University Hospital Geelong, Barwon Health, Geelong, NSW, Australia.
AD  - School of Medicine, Deakin University, Geelong, VIC, Australia.
FAU - Hau, Raphael
AU  - Hau R
AD  - Northern Health, Melbourne, VIC, Australia.
FAU - Mulford, Jonathan
AU  - Mulford J
AD  - Launceston Hospital, Launceston, TAS, Australia.
FAU - Incoll, Ian
AU  - Incoll I
AD  - Gosford and Wyong Hospitals, Gosford, NSW, Australia.
FAU - Kale, Michael
AU  - Kale M
AD  - Gosford and Wyong Hospitals, Gosford, NSW, Australia.
FAU - Schick, Bernard
AU  - Schick B
AD  - Prince of Wales Hospital, Sydney, NSW, Australia.
FAU - Higgs, Andrew
AU  - Higgs A
AD  - St Vincent's Hospital, Sydney, NSW, Australia.
FAU - Oppy, Andrew
AU  - Oppy A
AD  - Royal Melbourne Hospital, Melbourne, VIC, Australia.
FAU - Perriman, Diana
AU  - Perriman D
AD  - Canberra Hospital, Canberra, ACT, Australia.
FAU - Harris, Ian
AU  - Harris I
AD  - Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical
      Research, Sydney, NSW, Australia.
AD  - South Western Sydney Clinical School, UNSW, Sydney, NSW, Australia.
AD  - Liverpool Hospital, Sydney, NSW, Australia.
LA  - eng
GR  - 2016, APP1098550/National Health and Medical Research Council
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20200715
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Aged
MH  - Australia
MH  - Bone Plates
MH  - Female
MH  - *Fracture Fixation, Internal
MH  - Humans
MH  - Male
MH  - Observational Studies as Topic
MH  - Patient Reported Outcome Measures
MH  - Quality of Life
MH  - *Radius/surgery
MH  - *Radius Fractures/surgery/therapy
MH  - Randomized Controlled Trials as Topic
MH  - Selection Bias
PMC - PMC7364640
OTO - NOTNLM
OT  - Aged
OT  - Fracture fixation
OT  - Plaster casts
OT  - Radius fractures
OT  - Randomised controlled trial
OT  - Recovery of function
OT  - Statistical analysis plan
EDAT- 2020/07/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/07/17 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.1186/s13063-020-4228-0 [doi]
AID - 10.1186/s13063-020-4228-0 [pii]
PST - epublish
SO  - Trials. 2020 Jul 15;21(1):651. doi: 10.1186/s13063-020-4228-0.


PMID- 32668756
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 13
TI  - New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
LID - E2222 [pii]
LID - 10.3390/jcm9072222 [doi]
AB  - Spinal muscular atrophy (SMA) is one of the most common autosomal recessive
      diseases with progressive weakness of skeletal and respiratory muscles, leading
      to significant disability. The disorder is caused by mutations in the survival
      motor neuron 1 (SMN1) gene and a consequent decrease in the SMN protein leading
      to lower motor neuron degeneration. Recently, Food and Drug Administration (FDA) 
      and European Medical Agency (EMA) approved the antisense oligonucleotide
      nusinersen, the first SMA disease-modifying treatment and gene replacement
      therapy by onasemnogene abeparvovec. Encouraging results from phase II and III
      clinical trials have raised hope that other therapeutic options will enter soon
      in clinical practice. However, the availability of effective approaches has
      raised up ethical, medical and financial issues that are routinely faced by the
      SMA community. This review covers the available data and the new challenges of
      SMA therapeutic strategies.
FAU - Messina, Sonia
AU  - Messina S
AUID- ORCID: 0000-0001-7994-3391
AD  - Department of Clinical and Experimental Medicine, University of Messina, 98125
      Messina, Italy.
AD  - NEuroMuscular Omnicentre (NEMO) Sud Clinical Centre, University Hospital "G.
      Martino", 98125 Messina, Italy.
FAU - Sframeli, Maria
AU  - Sframeli M
AD  - NEuroMuscular Omnicentre (NEMO) Sud Clinical Centre, University Hospital "G.
      Martino", 98125 Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200713
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7408870
OTO - NOTNLM
OT  - nusinersen
OT  - onasemnogene abeparvovec
OT  - risdiplam
OT  - spinal muscular atrophy
OT  - therapy
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
CRDT- 2020/07/17 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
AID - jcm9072222 [pii]
AID - 10.3390/jcm9072222 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jul 13;9(7). pii: jcm9072222. doi: 10.3390/jcm9072222.


PMID- 32668387
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1532-3099 (Electronic)
IS  - 0266-6138 (Linking)
VI  - 89
DP  - 2020 Oct
TI  - Towards an integrated perinatal care pathway for vulnerable women: The
      development and validation of quality indicators.
PG  - 102794
LID - S0266-6138(20)30166-2 [pii]
LID - 10.1016/j.midw.2020.102794 [doi]
AB  - OBJECTIVE: Development and validation of a set of quality indicators for
      vulnerable women during the perinatal period. DESIGN: A three-phase method was
      used. Phase 1 consisted of a literature review to identify publications for the
      development of care domains and potential QIs, as well as a quality assessment by
      the research team. In phase 2 an expert panel assessed the set of concept QIs in 
      a modified three-round Delphi survey. Finally, semi-structured interviews with
      vulnerable women were conducted as a final quality assessment of a set of
      indicators (phase 3). Ethical approval was obtained from the ethics committee of 
      the University Hospital Brussels and from the Ethics Committees of all the
      participating hospitals. SETTING: The Flemish Region and the Brussels Capital
      Region in Belgium. PARTICIPANTS: Healthcare and social care professionals (n =
      40) with expertise in the field of perinatal care provision for vulnerable
      families. Vulnerable women (n = 11) who gave birth in one of the participating
      hospitals. FINDINGS: The literature review resulted in a set of 49 potential
      quality indicators in five care domains: access to healthcare, assessment and
      screening, informal support, formal support and continuity of care. After
      assessment by the expert panel and vulnerable women, a final set of 21 quality
      indicators in five care domains was identified. First of all, organisation of
      care must involve an integrated multidisciplinary approach taking account of
      financial, administrative and social barriers (care domain 1: access to
      healthcare). Second, qualitative care includes the timely initiation of care, a
      general screening of the various aspects of vulnerability (biological,
      psychological, social and cognitive) and a risk assessment for all women (care
      domain 2: assessment and screening). Vulnerable women benefit from intensive
      formal and informal support taking account of individual needs and strengths
      (care domain 3: formal support; care domain 4: informal support). Finally,
      continuity of care needs to be guaranteed in line with vulnerable woman's
      individual needs (care domain 5: continuity of care). KEY CONCLUSIONS AND
      IMPLICATIONS FOR PRACTICE: Implementing quality indicators in existing and new
      care pathways offers an evidence-based approach facilitating an integrated view
      promoting a healthy start for woman and child. These quality indicators can
      assist healthcare providers, organisations and governmental agencies to improve
      the quality of perinatal care for vulnerable women.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - D'haenens, Florence
AU  - D'haenens F
AD  - Midwifery Department, Department Health Care, Knowledge Centre Brussels
      Integrated Care, Erasmus Brussels University of Applied Sciences and Arts,
      Belgium. Electronic address: Florence.dhaenens@ehb.be.
FAU - Helsloot, Kaat
AU  - Helsloot K
AD  - Midwifery Department, Artevelde University of Applied Sciences, Ghent, Belgium.
      Electronic address: Kaat.helsloot@arteveldehs.be.
FAU - Lauwaert, Karen
AU  - Lauwaert K
AD  - Midwifery Department, Artevelde University of Applied Sciences, Ghent, Belgium.
      Electronic address: Karen.lauwaert@arteveldehs.be.
FAU - Agache, Lien
AU  - Agache L
AD  - Social Care Department, Artevelde University of Applied Sciences, Ghent, Belgium.
      Electronic address: Lien.agache@arteveldehs.be.
FAU - de Velde, Griet Van
AU  - de Velde GV
AD  - Midwifery Department, Artevelde University of Applied Sciences, Ghent, Belgium;
      Midwifery Department, Department Health Care, Knowledge Centre Brussels
      Integrated Care, Erasmus Brussels University of Applied Sciences and Arts,
      Belgium. Electronic address: Griet.vandevelde@arteveldehs.be.
FAU - De Frene, Veerle
AU  - De Frene V
AD  - Midwifery Department, Artevelde University of Applied Sciences, Ghent, Belgium.
      Electronic address: Veerle.defrene@arteveldehs.be.
FAU - Embo, Mieke
AU  - Embo M
AD  - Midwifery Department, Artevelde University of Applied Sciences, Ghent, Belgium.
      Electronic address: Mieke.embo@arteveldehs.be.
FAU - Vermeulen, Joeri
AU  - Vermeulen J
AD  - Midwifery Department, Department Health Care, Knowledge Centre Brussels
      Integrated Care, Erasmus Brussels University of Applied Sciences and Arts,
      Belgium; Department of Public Health, Biostatistics and Medical Informatics,
      Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Belgium. Electronic
      address: Joeri.vermeulen@ehb.be.
FAU - Beeckman, Katrien
AU  - Beeckman K
AD  - University Hospital Brussels, Nursing and Midwifery Research Unit, Belgium; Vrije
      Universiteit Brussel (VUB), Nursing and Midwifery Research Unit, Faculty of
      Medicine and Pharmacy & Universitair Ziekenhuis Brussel, Belgium; Verpleeg- en
      vroedkunde, Centre for Research and Innovation in Care, Midwifery Research
      Education and Policymaking (MIDREP), Universiteit Antwerpen, Belgium. Electronic 
      address: Katrien.beeckman@uzbrussel.be.
FAU - Fobelets, Maaike
AU  - Fobelets M
AD  - Department of Public Health, Biostatistics and Medical Informatics, Faculty of
      Medicine and Pharmacy, Vrije Universiteit Brussel, Belgium; Department Health
      Care, Knowledge Centre Brussels Integrated Care, Erasmus Brussels University of
      Applied Sciences and Arts, Belgium. Electronic address: Maaike.fobelets@ehb.be.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Scotland
TA  - Midwifery
JT  - Midwifery
JID - 8510930
MH  - Adult
MH  - Belgium
MH  - Delivery of Health Care, Integrated/methods/*standards/statistics & numerical
      data
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Program Development/methods
MH  - Quality Indicators, Health Care/*standards/statistics & numerical data
MH  - Risk Assessment/methods
MH  - Vulnerable Populations/*psychology/statistics & numerical data
OTO - NOTNLM
OT  - Care pathway
OT  - Perinatal care
OT  - Quality indicators
OT  - Vulnerable woman
COIS- Declaration of Competing Interest None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - S0266-6138(20)30166-2 [pii]
AID - 10.1016/j.midw.2020.102794 [doi]
PST - ppublish
SO  - Midwifery. 2020 Oct;89:102794. doi: 10.1016/j.midw.2020.102794. Epub 2020 Jul 7.


PMID- 32668355
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 41
IP  - 6
DP  - 2020 Nov - Dec
TI  - Malignancy risk stratification and FNA recommendations for thyroid nodules: A
      comparison of ACR TI-RADS, AACE/ACE/AME and ATA guidelines.
PG  - 102625
LID - S0196-0709(20)30319-7 [pii]
LID - 10.1016/j.amjoto.2020.102625 [doi]
AB  - OBJECTIVE: To compare diagnostic performance and malignancy risk stratification
      among guidelines set forth by the American Thyroid Association (ATA) in 2015, the
      American Association of Clinical Endocrinologists (AACE), the American College of
      Endocrinology (ACE) and the Association Medici Endocrinologi (AME) in 2016, and
      the American College of Radiology (ACR) in 2017. METHODS: The retrospective study
      was approved by the hospital ethics committee, and the informed consent
      requirement was waived. From October 2015 to March 2016, a total of 230 patients 
      with 230 consecutive thyroid nodules were enrolled in this study. Each nodule was
      classified by one junior and one senior radiologist separately according to ACR
      TI-RADS, AACE/ACE/AME and ATA guidelines. The malignancy diagnostic performance
      and the number of FNA recommendations were pairwise compared among three
      guidelines using chi-square tests. RESULTS: Of the 230 thyroid nodules, 137 were 
      malignant, and 93 were benign. However, 19.6% of the nodules (45 of 230) did not 
      match any pattern using the ATA guidelines but with a high risk of malignancy
      (68.9%). The ACR TI-RADS derived the highest diagnostic performance, from both
      junior radiologist (AUC 0.815) and senior radiologist (AUC 0.864). The ACR
      guidelines also showed the greatest level of sensitivity (junior: 86.1%, senior: 
      94.9%), compared with AACE/ACE/AME and ATA guidelines. The number of thyroid
      nodules recommended to fine-needle aspiration (FNA) was the lowest (37.8%, 40.4%)
      by ACR TI-RADS, and meanwhile, the malignant detection rate within these nodules 
      was highest (64.4%, 68.8%). CONCLUSIONS: The ACR guidelines present a higher
      level of diagnostic indicators and may offer a meaningful reduction in FNA
      recommendations with a higher malignancy detection rate.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Peng, Jian-Yun
AU  - Peng JY
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Pan, Fu-Shun
AU  - Pan FS
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Wang, Zhu
AU  - Wang Z
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Shan, Quan-Yuan
AU  - Shan QY
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Lin, Jin-Hua
AU  - Lin JH
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Luo, Jia
AU  - Luo J
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Zheng, Yan-Ling
AU  - Zheng YL
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Hu, Hang-Tong
AU  - Hu HT
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Ruan, Si-Min
AU  - Ruan SM
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Liang, Jin-Yu
AU  - Liang JY
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China. Electronic address: ljyu@mail.sysu.edu.cn.
FAU - Xie, Xiao-Yan
AU  - Xie XY
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China.
FAU - Lu, Ming-De
AU  - Lu MD
AD  - Department of Medical Ultrasonics, Institute of Diagnostic and Interventional
      Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,
      China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Biopsy, Fine-Needle/statistics & numerical data
MH  - Endocrinology/*organization & administration
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Practice Guidelines as Topic
MH  - Radiology/*organization & administration
MH  - Retrospective Studies
MH  - Risk
MH  - Societies, Medical/*organization & administration
MH  - Thyroid Neoplasms/*diagnosis/*pathology
MH  - Thyroid Nodule/*diagnosis/*pathology
MH  - Young Adult
OTO - NOTNLM
OT  - Fine-needle aspiration
OT  - TI-RADS
OT  - Thyroid guidelines
OT  - Thyroid nodules
OT  - Ultrasonography
EDAT- 2020/07/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - S0196-0709(20)30319-7 [pii]
AID - 10.1016/j.amjoto.2020.102625 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2020 Nov - Dec;41(6):102625. doi: 10.1016/j.amjoto.2020.102625.
      Epub 2020 Jun 24.


PMID- 32667899
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Aug 14
TI  - Perceptions of Digital Health Education Among European Medical Students: Mixed
      Methods Survey.
PG  - e19827
LID - 10.2196/19827 [doi]
AB  - BACKGROUND: Digital health technologies hold promise to enhance patient-related
      outcomes, to support health care staff by reducing their workload, and to improve
      the coordination of care. As key users of digital health technologies, health
      care workers are crucial to enable a meaningful digital transformation of health 
      care. Digital health literacy and digital skills should become prerequisite
      competencies for health professionals to facilitate the implementation and
      leverage the potential of digital technologies to improve health. OBJECTIVE: We
      aimed to assess European medical students' perceived knowledge and opinions
      toward digital health, the status of digital health implementation in medical
      education, and the students' most pressing needs. METHODS: The explanatory design
      of our mixed methods study was based on an online, anonymous, self-administered
      survey targeted toward European medical students. A linear regression analysis
      was used to identify the influence of the year of medical studies on the
      responses. Additional analysis was performed by grouping the responses by the
      self-evaluated frequency of eHealth technology use. Written responses to four
      qualitative questions in the survey were analyzed using an inductive approach.
      RESULTS: The survey received a total of 451 responses from 39 European countries,
      and there were respondents for every year of medical studies. The majority of
      respondents saw advantages in the use of digital health. While 40.6% (183/451)
      felt prepared to work in a digitized health care system, more than half (240/451,
      53.2%) evaluated their eHealth skills as poor or very poor. Medical students
      considered lack of education to be the reason for this, with 84.9% (383/451)
      agreeing or strongly agreeing that more digital health education should be
      implemented in the medical curriculum. Students demanded introductory and
      specific eHealth courses covering data management, ethical aspects, legal
      frameworks, research and entrepreneurial opportunities, role in public health and
      health systems, communication skills, and practical training. The emphasis lay on
      tailoring learning to future job requirements and interprofessional education.
      CONCLUSIONS: This study shows a lack of digital health-related formats in medical
      education and a perceived lack of digital health literacy among European medical 
      students. Our findings indicate a gap between the willingness of medical students
      to take an active role by becoming key players in the digital transformation of
      health care and the education that they receive through their faculties.
CI  - (c)Felix Machleid, Robert Kaczmarczyk, Doreen Johann, Justinas Balciunas, Beatriz
      Atienza-Carbonell, Finn von Maltzahn, Lina Mosch. Originally published in the
      Journal of Medical Internet Research (http://www.jmir.org), 14.08.2020.
FAU - Machleid, Felix
AU  - Machleid F
AUID- ORCID: 0000-0002-6597-4178
AD  - Association Europeenne des Etudiants en Medecine (EMSA), Brussels, Belgium.
AD  - School of Medicine, Technical University of Munich, Munich, Germany.
FAU - Kaczmarczyk, Robert
AU  - Kaczmarczyk R
AUID- ORCID: 0000-0002-8570-1601
AD  - Association Europeenne des Etudiants en Medecine (EMSA), Brussels, Belgium.
AD  - School of Medicine, Technical University of Munich, Munich, Germany.
FAU - Johann, Doreen
AU  - Johann D
AUID- ORCID: 0000-0003-1973-5042
AD  - Geography Department, Humboldt-Universitat zu Berlin, Berlin, Germany.
FAU - Balciunas, Justinas
AU  - Balciunas J
AUID- ORCID: 0000-0002-0423-9153
AD  - Association Europeenne des Etudiants en Medecine (EMSA), Brussels, Belgium.
AD  - Lithuanian University of Health Sciences, Kaunas, Lithuania.
FAU - Atienza-Carbonell, Beatriz
AU  - Atienza-Carbonell B
AUID- ORCID: 0000-0002-9286-3676
AD  - Association Europeenne des Etudiants en Medecine (EMSA), Brussels, Belgium.
AD  - Medical Faculty, University of Valencia, Valencia, Spain.
FAU - von Maltzahn, Finn
AU  - von Maltzahn F
AUID- ORCID: 0000-0001-7122-7489
AD  - Association Europeenne des Etudiants en Medecine (EMSA), Brussels, Belgium.
AD  - Medical Faculty, Rheinisch-Westfalische Technische Hochschule Aachen University, 
      Aachen, Germany.
FAU - Mosch, Lina
AU  - Mosch L
AUID- ORCID: 0000-0003-3154-2745
AD  - Association Europeenne des Etudiants en Medecine (EMSA), Brussels, Belgium.
AD  - Charite - Universitatsmedizin Berlin (corporate member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health), Berlin, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Education, Distance/*methods
MH  - Education, Medical/*methods
MH  - Europe
MH  - Female
MH  - Humans
MH  - Male
MH  - Students, Medical/*statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7455864
OTO - NOTNLM
OT  - *curriculum
OT  - *digital literacy
OT  - *eHealth
OT  - *health workforce
OT  - *medical education
OT  - *medical students
OT  - *mixed method
EDAT- 2020/07/16 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - v22i8e19827 [pii]
AID - 10.2196/19827 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Aug 14;22(8):e19827. doi: 10.2196/19827.


PMID- 32667833
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20220417
IS  - 1748-880X (Electronic)
IS  - 0007-1285 (Linking)
VI  - 93
IP  - 1114
DP  - 2020 Oct 1
TI  - MR texture analysis in differentiating renal cell carcinoma from lipid-poor
      angiomyolipoma and oncocytoma.
PG  - 20200569
LID - 10.1259/bjr.20200569 [doi]
AB  - OBJECTIVES: To assess the utility of magnetic resonance texture analysis (MRTA)
      in differentiating renal cell carcinoma (RCC) from lipid-poor angiomyolipoma
      (lpAML) and oncocytoma. METHODS: After ethical approval, 42 patients with 54
      masses (34 RCC, 14 lpAML and six oncocytomas) who underwent MRI on a 1.5 T
      scanner (Avanto, Siemens, Erlangen, Germany) between January 2011 and December
      2012 were retrospectively included in the study. MRTA was performed on the TexRAD
      research software (Feedback Plc., Cambridge, UK) using free-hand polygonal region
      of interest (ROI) drawn on the maximum cross-sectional area of the tumor to
      generate six first-order statistical parameters. The Mann-Whitney U test was used
      to look for any statically significant difference. The receiver operating
      characteristic (ROC) curve analysis was done to select the parameter with the
      highest class separation capacity [area under the curve (AUC)] for each MRI
      sequence. RESULTS: Several texture parameters on MRI showed high-class separation
      capacity (AUC > 0.8) in differentiating RCC from lpAML and oncocytoma. The best
      performing parameter in differentiating RCC from lpAML was mean of positive
      pixels (MPP) at SSF 2 (AUC: 0.891) on DWI b500. In differentiating RCC from
      oncocytoma, the best parameter was mean at SSF 0 (AUC: 0.935) on DWI b1000.
      CONCLUSIONS: MRTA could potentially serve as a useful non-invasive tool for
      differentiating RCC from lpAML and oncocytoma. ADVANCES IN KNOWLEDGE: There is
      limited literature addressing the role of MRTA in differentiating RCC from lpAML 
      and oncocytoma. Our study demonstrated several texture parameters which were
      useful in this regard.
FAU - Razik, Abdul
AU  - Razik A
AD  - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, 
      New Delhi, India.
FAU - Goyal, Ankur
AU  - Goyal A
AD  - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, 
      New Delhi, India.
FAU - Sharma, Raju
AU  - Sharma R
AD  - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, 
      New Delhi, India.
FAU - Kandasamy, Devasenathipathy
AU  - Kandasamy D
AD  - Departments of Radiology, All India Institute of Medical Sciences, Ansari Nagar, 
      New Delhi, India.
FAU - Seth, Amlesh
AU  - Seth A
AD  - Departments of Urology, All India Institute of Medical Sciences, Ansari Nagar,
      New Delhi, India.
FAU - Das, Prasenjit
AU  - Das P
AD  - Departments of Pathology, All India Institute of Medical Sciences, Ansari Nagar, 
      New Delhi, India.
FAU - Ganeshan, Balaji
AU  - Ganeshan B
AD  - Institute of Nuclear Medicine, University College London Hospital NHS Trust,
      London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - Br J Radiol
JT  - The British journal of radiology
JID - 0373125
SB  - IM
MH  - Adenoma, Oxyphilic/*diagnostic imaging
MH  - Adult
MH  - Aged
MH  - Angiomyolipoma/*diagnostic imaging
MH  - Carcinoma, Renal Cell/*diagnostic imaging
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*diagnostic imaging
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
PMC - PMC7548360
EDAT- 2020/07/16 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - 10.1259/bjr.20200569 [doi]
PST - ppublish
SO  - Br J Radiol. 2020 Oct 1;93(1114):20200569. doi: 10.1259/bjr.20200569. Epub 2020
      Aug 26.


PMID- 32667577
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20201218
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73 Suppl 2
DP  - 2020
TI  - In defense of the Unified Health System in the context of SARS-CoV-2 pandemic.
PG  - e20200247
LID - S0034-71672020001400402 [pii]
LID - 10.1590/0034-7167-2020-0247 [doi]
AB  - OBJECTIVE: To discuss the political and structural conditions for establishing
      the Unified Health System (UHS - Sistema Unico de Saude, SUS) in coping with the 
      SARS-CoV-2 pandemic. METHODS: Theoretical-reflection study. RESULTS: At the first
      moment named "The global and the local in facing the SARS-CoV-2 pandemic" is
      presented the health crisis that took place worldwide and the government actions 
      to combat COVID-19. A second moment named "Between dismantling actions and
      resistance, the UHS is the best way to face the SARS-CoV-2 pandemic", reflects on
      the neoliberal attacks on the health system and how it resists, remaining the
      main pandemic response strategy. CONCLUSION: The strengthening of democracy and
      the defense of the UHS are the way out of the crisis. It is believed that this
      reflection generates - in everyone who deals with caretaking - the political
      action, the ethical attitude, the desire for valorization and the spirit of
      struggle in defense of the UHS and human life.
FAU - Araujo, Janieiry Lima de
AU  - Araujo JL
AD  - Universidade do Estado do Rio Grande do Norte, Pau dos Ferros, Rio Grande do
      Norte, Brazil.
FAU - Oliveira, Kalyane Kelly Duarte de
AU  - Oliveira KKD
AD  - Universidade do Estado do Rio Grande do Norte, Pau dos Ferros, Rio Grande do
      Norte, Brazil.
FAU - Freitas, Rodrigo Jacob Moreira de
AU  - Freitas RJM
AD  - Universidade do Estado do Rio Grande do Norte, Pau dos Ferros, Rio Grande do
      Norte, Brazil.
LA  - por
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - Betacoronavirus/*isolation & purification
MH  - Brazil
MH  - COVID-19
MH  - Coronavirus Infections/*diagnosis/*prevention & control/*therapy
MH  - Humans
MH  - *Organizational Objectives
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*diagnosis/*prevention & control/*therapy
MH  - SARS-CoV-2
MH  - Societies, Medical/*organization & administration
EDAT- 2020/07/16 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/04/04 00:00 [received]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - S0034-71672020001400402 [pii]
AID - 10.1590/0034-7167-2020-0247 [doi]
PST - ppublish
SO  - Rev Bras Enferm. 2020;73 Suppl 2:e20200247. doi: 10.1590/0034-7167-2020-0247.
      Epub 2020 Jul 10.


PMID- 32667430
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1983-1447 (Electronic)
IS  - 0102-6933 (Linking)
VI  - 41
DP  - 2020
TI  - Use of nursing technologies for safe perioperative pediatric care.
PG  - e20190251
LID - S1983-14472020000100425 [pii]
LID - 10.1590/1983-1447.2020.20190251 [doi]
AB  - OBJECTIVE: To understand the nursing team's perception about the use of
      technology for safe perioperative pediatric care, through photographs. METHOD: A 
      qualitative study using the theoretical framework of Nietsche Specific Nursing
      Technology, with a total of 18 perioperative nursing professionals from a general
      hospital in southern Brazil. Data collection occurred from June to August 2018,
      from a semi-structured interview and photograph production. They were analyzed
      through the Thematic Content Analysis. Approved by the Research Ethics Committee 
      of the Federal University of Santa Catarina. RESULTS: The Nursing Technologies
      category used for the safety of the pediatric patient in the perioperative
      period, with 250 photographs illustrating facts, situations and artifacts
      considered nursing technologies used in safe care. CONCLUSIONS: In the team's
      perception, patient safety involves the use of technologies integrated to
      perioperative care and structural, physical and input aspects.
FAU - Ferraz, Sheila Cristina da Silva
AU  - Ferraz SCDS
AD  - Hospital Unimed Litoral, Balneario Camboriu, Santa Catarina, Brasil.
FAU - Rocha, Patricia Kuerten
AU  - Rocha PK
AD  - Departamento de Enfermagem, Universidade Federal de Santa Catarina,
      Florianopolis, Santa Catarina, Brasil.
FAU - Tomazoni, Andreia
AU  - Tomazoni A
AD  - Departamento de Enfermagem, Universidade Federal de Santa Catarina,
      Florianopolis, Santa Catarina, Brasil.
FAU - Waterkemper, Roberta
AU  - Waterkemper R
AD  - Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Rio
      Grande do Sul, Brasil.
FAU - Schoeller, Soraia Dornelles
AU  - Schoeller SD
AD  - Departamento de Enfermagem, Universidade Federal de Santa Catarina,
      Florianopolis, Santa Catarina, Brasil.
FAU - Echevarria-Guanilo, Maria Elena
AU  - Echevarria-Guanilo ME
AD  - Departamento de Enfermagem, Universidade Federal de Santa Catarina,
      Florianopolis, Santa Catarina, Brasil.
LA  - por
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - Brazil
TA  - Rev Gaucha Enferm
JT  - Revista gaucha de enfermagem
JID - 8504882
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - *Biomedical Technology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Safety
MH  - Pediatric Nursing/*methods/*standards
MH  - Perioperative Care/*nursing
MH  - Qualitative Research
EDAT- 2020/07/16 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/07/16 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
AID - S1983-14472020000100425 [pii]
AID - 10.1590/1983-1447.2020.20190251 [doi]
PST - ppublish
SO  - Rev Gaucha Enferm. 2020;41:e20190251. doi: 10.1590/1983-1447.2020.20190251. Epub 
      2020 Jul 13.


PMID- 32667227
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1461-7005 (Electronic)
IS  - 1362-3613 (Linking)
VI  - 24
IP  - 8
DP  - 2020 Nov
TI  - Moral foundations theory in autism spectrum disorder: A qualitative
      investigation.
PG  - 2202-2212
LID - 10.1177/1362361320939331 [doi]
AB  - LAY ABSTRACT: Morality is important for how humans treat each other and non-human
      animals. Differences in moral thinking have been found between autistic and
      neurotypical individuals. This research has relied on ways of thinking about
      moral psychology that suggest that mature morals develop as individuals learn to 
      take the perspectives of others. Yet, even autistic individuals, who sometimes
      differ in their ability to take others' perspectives, make moral judgements that 
      are similar to neurotypical individuals. Moral foundations theory suggests that
      moral psychology is not hierarchical but differs depending on culture. This
      theory could therefore help make sense of similarities and differences in
      autistic and neurotypical moral thinking. Moral foundations theory has not yet
      been investigated among autistic individuals. In this study, we interviewed
      autistic adults as a first attempt at understanding how moral foundations theory 
      fits with autistic moral thinking. We found that all five moral foundations of
      moral foundations theory were represented in the interviews, yet certain
      foundations appeared more prominent than others. The autistic adults interviewed 
      in our study discussed issues of care and fairness more than of loyalty,
      authority or purity when prompted to discuss moral transgressions. Future
      research should use quantitative methods to compare groups of autistic and
      neurotypical individuals to clarify similarities and differences in moral
      thinking between the groups.
FAU - Dempsey, Erin E
AU  - Dempsey EE
AUID- ORCID: 0000-0002-3221-6370
AD  - Dalhousie University, Canada.
FAU - Moore, Chris
AU  - Moore C
AD  - Dalhousie University, Canada.
FAU - Richard, Annie E
AU  - Richard AE
AD  - Dalhousie University, Canada.
FAU - Smith, Isabel M
AU  - Smith IM
AUID- ORCID: 0000-0001-5525-2123
AD  - Dalhousie University, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200715
PL  - England
TA  - Autism
JT  - Autism : the international journal of research and practice
JID - 9713494
SB  - IM
MH  - Adult
MH  - *Autism Spectrum Disorder
MH  - *Autistic Disorder
MH  - Humans
MH  - Judgment
MH  - Learning
MH  - Morals
OTO - NOTNLM
OT  - *autism spectrum disorders
OT  - *commonsense psychology
OT  - *ethics
OT  - *moral emotion
OT  - *moral foundations theory
OT  - *morality
OT  - *social cognition and social behaviour
EDAT- 2020/07/16 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - 10.1177/1362361320939331 [doi]
PST - ppublish
SO  - Autism. 2020 Nov;24(8):2202-2212. doi: 10.1177/1362361320939331. Epub 2020 Jul
      15.


PMID- 32666876
OWN - NLM
STAT- Publisher
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 15
TI  - Nurse managers' perspectives on working with everyday ethics in long-term care.
PG  - 969733020935958
LID - 10.1177/0969733020935958 [doi]
AB  - BACKGROUND: Nurse managers are expected to continuously ensure that ethical
      standards are met and to support healthcare workers' ethical competence. Several 
      studies have concluded that nurses across various healthcare settings lack the
      support needed to provide safe, compassionate and competent ethical care.
      OBJECTIVE: The aim of this study was to explore and understand how nurse managers
      perceive their role in supporting their staff in conducting ethically sound care 
      in nursing homes and home nursing care. DESIGN AND PARTICIPANTS: Qualitative
      individual interviews were performed with 10 nurse managers with human resources 
      responsibilities for healthcare workers in four nursing home wards and six home
      nursing care districts. Content analysis was used to analyse the data. ETHICAL
      CONSIDERATIONS: The Norwegian Centre for Research Data granted permission for
      this study. FINDINGS: The analysis resulted in seven subcategories that were
      grouped into three main categories: managers' perception of the importance of the
      role, managers' experiences of exercising the role and managers' opportunities to
      fulfil the role. Challenges with conceptualizing ethics were highlighted, as well
      as lack of applicable tools or time and varying motivation among employees.
      DISCUSSION: The leaders tended to perceive ethics as a 'personal matter' and that
      the need for and benefit of ethical support (e.g., ethics reflection) depended on
      individuals' vulnerability, attitudes, commitment and previous experiences. The
      managers did not seem to distinguish between their own responsibility to support 
      ethical competence and the responsibility of the individual employee to provide
      ethical care. CONCLUSIONS: Our findings suggest that nurse managers need support 
      themselves, both to understand and to carry out their responsibilities to foster 
      their staffs' ethical conduct. Supporting staff in conducting ethically sound
      care requires more than organizing meeting places for ethical reflection; it also
      requires greater awareness and understanding of what ethical leadership means.
FAU - Devik, Siri Andreassen
AU  - Devik SA
AUID- ORCID: https://orcid.org/0000-0001-5890-203X
AD  - Centre of Care Research, Norway; Nord University, Norway.
FAU - Munkeby, Hilde
AU  - Munkeby H
FAU - Finnanger, Monica
AU  - Finnanger M
AD  - Nord University, Norway.
FAU - Moe, Aud
AU  - Moe A
AD  - Centre of Care Research, Norway; Nord University, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
PMC - PMC7564296
OTO - NOTNLM
OT  - Content analysis
OT  - ethics support
OT  - management
OT  - municipal healthcare services
OT  - nursing
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
AID - 10.1177/0969733020935958 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 15:969733020935958. doi: 10.1177/0969733020935958.


PMID- 32666868
OWN - NLM
STAT- Publisher
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 15
TI  - Ethical Coffee Room: An international collaboration in learning ethics digitally.
PG  - 969733020934145
LID - 10.1177/0969733020934145 [doi]
AB  - BACKGROUND: Ethics is a fundamental part of health care professionals' competence
      and one of the major quality factors in good nursing care. Research shows
      challenges in learning and applying ethics. Ethical Coffee Room is an electronic 
      platform, where the students, nurses and teachers discuss anonymously ethical
      issues during students' clinical practice. ECR offers 1 credit (27 working hours)
      for the students. This work included reading theoretical material, contributions 
      for discussion of ethical dilemmas and reflection of one's own learning. Every
      user - student, nurse supervisor or teacher - could choose her or his own
      pseudonym. AIM: The aim of this study was to describe how nursing students
      experience learning ethics with digital learning activity during clinical
      practice, how usable the Ethical Coffee Room platform is and how this learning
      activity should be developed further. RESEARCH DESIGN, PARTICIPANTS AND CONTEXT: 
      The study employed a qualitative descriptive design and was an EU project between
      Finland, Sweden and Latvia. In total, 34 second-year nursing students
      participated in the study. The data collection methods were semi-structured
      interviews and written comments in the discussion forum Ethical Coffee Room. The 
      data were analysed using content analysis. ETHICAL CONSIDERATIONS: Ethical
      approval and research permission were obtained from each partner organization,
      according to their national standards. FINDINGS: The results are presented under 
      three themes: positive learning experiences of Ethical Coffee Room, challenges in
      learning during Ethical Coffee Room and practical suggestions for future
      development of Ethical Coffee Room. The results showed that the Ethical Coffee
      Room was experienced as a novel type of learning activity and an interesting way 
      to learn ethics. DISCUSSION AND CONCLUSION: Ethical Coffee Room seems to be a
      promising learning activity enhancing students' ethical competence in clinical
      practice. However, active participation of the mentor nurses and teachers is
      essential. Therefore, mentor nurses and teachers need in-depth knowledge of
      ethical theories and concepts and how to apply them in clinical context.
FAU - Manninen, Katri
AU  - Manninen K
AUID- ORCID: https://orcid.org/0000-0002-9126-9149
AD  - The Swedish Red Cross University College, Sweden; Karolinska Institutet and
      Karolinska University Hospital, Sweden.
FAU - Bjorling, Gunilla
AU  - Bjorling G
AD  - Karolinska Institutet, Sweden; The Swedish Red Cross University College, Sweden.
FAU - Kuznecova, Jelena
AU  - Kuznecova J
AD  - Riga Medical College of the University of Latvia, Latvia.
FAU - Lakanmaa, Riitta-Liisa
AU  - Lakanmaa RL
AD  - Turku University of Applied Sciences, Finland; University of Turku, Finland.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
OTO - NOTNLM
OT  - Clinical practice
OT  - digital learning activity
OT  - ethical competence
OT  - nursing education
OT  - nursing student
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
AID - 10.1177/0969733020934145 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 15:969733020934145. doi: 10.1177/0969733020934145.


PMID- 32666436
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - Indeterminacy of identity and advance directives for death after dementia.
PG  - 705-715
LID - 10.1007/s11019-020-09965-0 [doi]
AB  - A persistent question in discussions of the ethics of advance directives for
      euthanasia is whether patients who go through deep psychological changes retain
      their identity. Rather than seek an account of identity that answers this
      question, I argue that responsible policy should directly address indeterminacy
      about identity directly. Three sorts of indeterminacy are distinguished. Two of
      these-epistemic indeterminacy and metaphysical indeterminacy-should be addressed 
      in laws/policies regarding advance directives for euthanasia.
FAU - Sneddon, Andrew
AU  - Sneddon A
AUID- ORCID: http://orcid.org/0000-0001-8013-6722
AD  - University of Ottawa, Ottawa, Canada. asneddon@uottawa.ca.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Advance Directives/ethics/*legislation & jurisprudence
MH  - Dementia/*epidemiology
MH  - Euthanasia/ethics/*legislation & jurisprudence
MH  - Humans
MH  - Mental Competency/*legislation & jurisprudence
MH  - Personal Autonomy
MH  - Philosophy, Medical
OTO - NOTNLM
OT  - Dementia
OT  - Derek Parfit
OT  - Medical assistance in dying
OT  - Personal identity
OT  - Ronald Dworkin
EDAT- 2020/07/16 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - 10.1007/s11019-020-09965-0 [doi]
AID - 10.1007/s11019-020-09965-0 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):705-715. doi: 10.1007/s11019-020-09965-0.


PMID- 32666191
OWN - NLM
STAT- MEDLINE
DCOM- 20210309
LR  - 20210309
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Jul 14
TI  - Legal and Ethical Challenges in the Psychiatric Treatment of College Students.
PG  - 50
LID - 10.1007/s11920-020-01168-x [doi]
AB  - PURPOSE OF REVIEW: This article will examine issues of autonomy, privacy,
      decision-making, and voluntariness of the psychiatric treatment of college
      students. There is little consensus on balancing the individual student's rights 
      with the university's duties. Conflicts between federal legislation, case law,
      and ethical recommendations will be explored. RECENT FINDINGS: Landmark legal
      cases assert that universities have a specific duty to protect their students
      from both violent peers and suicide. College students are vulnerable to a range
      of psychiatric symptoms but have low rates of adherence to psychiatric treatment.
      Many institutions require an urgent psychiatric evaluation when there is evidence
      that a student is at imminent risk of danger, and some may require psychiatric
      treatment as a condition of returning to either classes or dormitories. Legally, 
      patients are entitled to privacy and autonomous medical decision-making at 18
      years of age. Pragmatically, dependence on parents and university for basic
      resources limits both the privacy and the voluntariness of their treatment.
FAU - Conrad, Rachel
AU  - Conrad R
AD  - Department of Psychiatry, Brigham and Women's Hospital, 75 Francis Street,
      Boston, MA, 02115, USA. RConrad@Partners.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200714
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
SB  - IM
MH  - Humans
MH  - *Mental Disorders
MH  - *Morals
MH  - Psychotherapy
MH  - Students
MH  - Universities
OTO - NOTNLM
OT  - *College mental health
OT  - *Decision-making capacity
OT  - *Forensic psychiatry
OT  - *Medical ethics
OT  - *Safety risk assessment
OT  - *Transitional age youth
EDAT- 2020/07/16 06:00
MHDA- 2021/03/10 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/03/10 06:00 [medline]
AID - 10.1007/s11920-020-01168-x [doi]
AID - 10.1007/s11920-020-01168-x [pii]
PST - epublish
SO  - Curr Psychiatry Rep. 2020 Jul 14;22(9):50. doi: 10.1007/s11920-020-01168-x.


PMID- 32666039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - COVID-19: Public and patient involvement, now more than ever.
PG  - 35
LID - 10.12688/hrbopenres.13067.1 [doi]
AB  - The research community is responding with speed to the COVID-19 pandemic, with
      rapid response mechanisms to fund research, shortened application turnaround
      times, and expedited research ethics processes. Public and patient involvement
      (PPI) is under pressure in this rapid response research, where it is easy for
      researchers and funders to dismiss PPI as non-essential, an added extra, a "nice 
      to have". In this open letter, we, researchers and PPI contributors, argue that
      PPI is important, now more than ever. The pandemic is impacting everyone in
      society, with normal rules of engagement discarded. The solution to overcoming
      this virus will come from many different sources and many changes will emerge to 
      healthcare delivery and to how we live our lives. It is essential that the
      research to find solutions is shaped by all who will be impacted: the public and 
      the patient must be central contributors and their voice must be hear.
CI  - Copyright: (c) 2020 Murphy E et al.
FAU - Murphy, Edel
AU  - Murphy E
AUID- ORCID: https://orcid.org/0000-0002-9873-5376
AD  - PPI Ignite @ NUI Galway, NUI Galway, Galway, Ireland.
FAU - Tierney, Edel
AU  - Tierney E
AUID- ORCID: https://orcid.org/0000-0001-6393-8539
AD  - Public Advisory Panel, PPI Ignite @ NUI Galway, (voluntary co-facilitator),
      Ireland.
FAU - Ni She, Eidin
AU  - Ni She E
AUID- ORCID: https://orcid.org/0000-0002-1036-6044
AD  - UCD School of Nursing Midwifery and Health Systems, Belfield, Dublin, Ireland.
FAU - Killilea, Martha
AU  - Killilea M
AD  - PPI Ignite @ NUI Galway, NUI Galway, Galway, Ireland.
FAU - Donaghey, Casey
AU  - Donaghey C
AD  - Public Advisory Panel, PPI Ignite @ NUI Galway, Galway, Ireland.
FAU - Daly, Anne
AU  - Daly A
AD  - Public Advisory Panel, PPI Ignite @ NUI Galway, Galway, Ireland.
FAU - Roche, Mary
AU  - Roche M
AUID- ORCID: https://orcid.org/0000-0001-5967-9159
AD  - Public Advisory Panel, PPI Ignite @ NUI Galway, Galway, Ireland.
FAU - Mac Loughlin, Deirdre
AU  - Mac Loughlin D
AD  - Public Advisory Panel, PPI Ignite @ NUI Galway, Galway, Ireland.
CN  - PPI Ignite @ NUI Galway Public Advisory Panel
FAU - Dinneen, Sean
AU  - Dinneen S
AUID- ORCID: https://orcid.org/0000-0002-6636-0493
AD  - PPI Ignite @ NUI Galway, NUI Galway, Galway, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC7327728
OTO - NOTNLM
OT  - COVID-19
OT  - PPI
OT  - Public and patient involvement
COIS- No competing interests were disclosed.
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:01
CRDT- 2020/07/16 06:00
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:01 [medline]
AID - 10.12688/hrbopenres.13067.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 Jun 8;3:35. doi: 10.12688/hrbopenres.13067.1. eCollection
      2020.


PMID- 32665911
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1738-6055 (Print)
IS  - 1738-6055 (Linking)
VI  - 36
DP  - 2020
TI  - Guidelines for planning and conducting high-quality research and testing on
      animals.
PG  - 21
LID - 10.1186/s42826-020-00054-0 [doi]
AB  - There are important scientific, legal and ethical reasons for optimising the
      quality of animal research and testing. Concerns about the reproducibility and
      translatability of animal studies are now being voiced not only by those opposed 
      to animal use, but also by scientists themselves. Many of the attempts to improve
      reproducibility have, until recently, focused on ways in which the reporting of
      animal studies can be improved. Many reporting guidelines have been written.
      Better reporting cannot, however, improve the quality of work that has already
      been carried out - for this purpose better planning is required. Planning animal 
      studies should involve close collaboration with the animal facility where the
      work is to be performed, from as early a stage as possible. In this way,
      weaknesses in the protocol will be detected and changes can be made before it is 
      too late. Improved planning must focus on more than the "mathematical" elements
      of experimental design such as randomisation, blinding and statistical methods.
      This should include focus on practical details such as the standard of the
      facility, any need for education and training, and all the factors which can
      improve animal welfare. The PREPARE (Planning Research and Experimental
      Procedures on Animals: Recommendations for Excellence) checklist was developed to
      help scientists be more aware of all the issues which may affect their
      experiments. The checklist is supported by comprehensive webpages containing more
      information, with links to the latest resources that have been developed for each
      topic on the list.
CI  - (c) The Author(s) 2020.
FAU - Smith, Adrian J
AU  - Smith AJ
AUID- ORCID: 0000-0002-8375-0805
AD  - Norecopa, P.O. Box 750 Sentrum, 0106 Oslo, Norway.grid.410549.d0000 0000 9542
      2193
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200710
PL  - England
TA  - Lab Anim Res
JT  - Laboratory animal research
JID - 101560684
PMC - PMC7348107
OTO - NOTNLM
OT  - Animal
OT  - Guidelines
OT  - PREPARE
OT  - Planning
OT  - Reporting
OT  - Reproducibility
OT  - Research
OT  - Testing
OT  - Validity
COIS- Competing interestsAdrian Smith is lead author of the PREPARE guidelines and has 
      editorial responsibility for creation and updating of the Norecopa website
      (https://norecopa.no), both of which are cited several times in this paper. He
      has no other competing interests.
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:01
CRDT- 2020/07/16 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:01 [medline]
AID - 10.1186/s42826-020-00054-0 [doi]
AID - 54 [pii]
PST - epublish
SO  - Lab Anim Res. 2020 Jul 10;36:21. doi: 10.1186/s42826-020-00054-0. eCollection
      2020.


PMID- 32665882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 9
TI  - Medical Ethics and the Biopsychosocial Model for Patient Care: A Case Analysis
      for Improved Communication, Clinical Time, and Error Avoidance.
PG  - e8535
LID - 10.7759/cureus.8535 [doi]
AB  - The practice of interdisciplinary medicine is one of the most effective and
      cooperative forms of medical management, which optimizes clinical care and
      outcomes for a patient. This model of care affords the patient the benefit of
      receiving the best available therapeutic options from specialists who are experts
      in their respective disciplines, which would otherwise be limited when compared
      with the clinical expertise from a single provider managing multiple
      co-morbidities. However, poor communication between each specialized team
      managing a patient's care can result in redundancies and superfluous treatment
      that can have deleterious clinical outcomes that impede the physician-patient
      relationship and question the bioethical principles of clinical practice. Having 
      a medical provider like an internist who is the primary medical provider for a
      patient anchors reinforces the physician-patient relationship through familiarity
      and continuous involvement in the gross clinical course of a patient. Specialty
      care provides a very focused and limiting scope of practice. However, whether
      practicing specialty care or being a generalist, utilizing clinical tools, such
      as the biopsychosocial model and routinely using bioethical principles during
      clinical encounters, not only help extract pertinent information from the
      patient's medical history but also furthers the continuity of clinical care by
      understanding the global context of the patient's medical history. This is a case
      analysis that exemplifies sub-optimal outcomes in patient care due to undermining
      the critical role of an internist in patient care and clinical management in
      addition to challenging several bioethical principles of clinical care. It also
      highlights the importance of how using the biopsychosocial model of care can
      avoid clinical errors, improve interdisciplinary and patient communication, and, 
      ultimately, optimize the patient-physician relationship and clinical care.
CI  - Copyright (c) 2020, Persaud-Sharma et al.
FAU - Persaud-Sharma, Dharam
AU  - Persaud-Sharma D
AD  - Internal Medicine, Kendall Regional Medical Center, Herbert Wertheim College of
      Medicine Florida International University, Miami, USA.
FAU - Govea, Marien
AU  - Govea M
AD  - Internal Medicine, Florida International University, Herbert Wertheim College of 
      Medicine, Miami, USA.
FAU - Hernandez, Robert
AU  - Hernandez R
AD  - Internal Medicine/Infectious Disease, Kendall Regional Medical Center, Miami,
      USA.
LA  - eng
PT  - Case Reports
DEP - 20200609
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7352746
OTO - NOTNLM
OT  - bioethics
OT  - biopsychosocial model
OT  - clinical care
OT  - communication
OT  - cultural medicine
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:01
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:01 [medline]
AID - 10.7759/cureus.8535 [doi]
PST - epublish
SO  - Cureus. 2020 Jun 9;12(6):e8535. doi: 10.7759/cureus.8535.


PMID- 32665629
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20220531
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7816
DP  - 2020 Jul
TI  - Contact-tracing apps: contested answers to ethical questions.
PG  - 360
LID - 10.1038/d41586-020-02084-z [doi]
FAU - Braun, Matthias
AU  - Braun M
FAU - Hummel, Patrik
AU  - Hummel P
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Nature. 2020 Jun;582(7810):29-31. PMID: 32467596
MH  - COVID-19
MH  - *Contact Tracing
MH  - *Coronavirus Infections/epidemiology/transmission
MH  - *Mobile Applications
MH  - Morals
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/transmission
MH  - Privacy
OTO - NOTNLM
OT  - *Ethics
OT  - *Public health
OT  - *Technology
EDAT- 2020/07/16 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.1038/d41586-020-02084-z [doi]
AID - 10.1038/d41586-020-02084-z [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7816):360. doi: 10.1038/d41586-020-02084-z.


PMID- 32665394
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Advance Care Planning: Promoting Effective and Aligned Communication in the
      Elderly (ACP-PEACE): the study protocol for a pragmatic stepped-wedge trial of
      older patients with cancer.
PG  - e040999
LID - 10.1136/bmjopen-2020-040999 [doi]
AB  - INTRODUCTION: Advance care planning (ACP) is associated with improved health
      outcomes for patients with cancer, and its absence is associated with
      unfavourable outcomes for patients and their caregivers. However, older adults do
      not complete ACP at expected rates due to patient and clinician barriers. We
      present the original design, methods and rationale for a trial aimed at improving
      ACP for older patients with advanced cancer and the modified protocol in response
      to changes brought by the COVID-19 pandemic. METHODS AND ANALYSIS: The Advance
      Care Planning: Promoting Effective and Aligned Communication in the Elderly study
      is a pragmatic, stepped-wedge cluster randomised trial examining a Comprehensive 
      ACP Program. The programme combines two complementary evidence-based
      interventions: clinician communication skills training (VitalTalk) and patient
      video decision aids (ACP Decisions). We will implement the programme at 36
      oncology clinics across three unique US health systems. Our primary outcome is
      the proportion of eligible patients with ACP documentation completed in the
      electronic health record. Our secondary outcomes include resuscitation
      preferences, palliative care consultations, death, hospice use and final
      cancer-directed therapy. From a subset of our patient population, we will collect
      surveys and video-based declarations of goals and preferences. We estimate 11 000
      patients from the three sites will be enrolled in the study. ETHICS AND
      DISSEMINATION: Regulatory and ethical aspects of this trial include Institutional
      Review Board (IRB) approval via single IRB of record mechanism at Dana-Farber
      Cancer Institute, Data Use Agreements among partners and a Data Safety and
      Monitoring Board. We plan to present findings at national meetings and publish
      the results. TRIAL REGISTRATION NUMBER: NCT03609177; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lakin, Joshua R
AU  - Lakin JR
AUID- ORCID: 0000-0002-7659-6512
AD  - Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer
      Institute, Boston, Massachusetts, USA jlakin@partners.org.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Brannen, Elise N
AU  - Brannen EN
AD  - Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer
      Institute, Boston, Massachusetts, USA.
FAU - Tulsky, James A
AU  - Tulsky JA
AD  - Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer
      Institute, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Paasche-Orlow, Michael K
AU  - Paasche-Orlow MK
AD  - Department of General Internal Medicine, Boston University School of Medicine,
      Boston Medical Center, Boston, Massachusetts, USA.
FAU - Lindvall, Charlotta
AU  - Lindvall C
AD  - Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer
      Institute, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Chang, Yuchiao
AU  - Chang Y
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts,
      USA.
FAU - Gundersen, Daniel A
AU  - Gundersen DA
AD  - Department of Survey and Data Management Core, Dana Farber Cancer Institute,
      Boston, Massachusetts, USA.
FAU - El-Jawahri, Areej
AU  - El-Jawahri A
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Hematology-Oncology, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Volandes, Angelo
AU  - Volandes A
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts,
      USA.
CN  - ACP-PEACE Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT03609177
GR  - UG3 AG060626/AG/NIA NIH HHS/United States
GR  - UH3 AG060626/AG/NIA NIH HHS/United States
GR  - U24 AT009676/AT/NCCIH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Advance Care Planning
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*methods
MH  - Cluster Analysis
MH  - Coronavirus Infections/*prevention & control
MH  - Health Communication/*methods
MH  - Humans
MH  - Neoplasms/*therapy
MH  - Pandemics/*prevention & control
MH  - Patient Participation/*methods
MH  - Pneumonia, Viral/*prevention & control
MH  - Program Evaluation/methods
MH  - Research Design
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7365491
OTO - NOTNLM
OT  - *adult palliative care
OT  - *information management
OT  - *medical education & training
OT  - *oncology
OT  - *palliative care
COIS- Competing interests: JRL receives funding from the Cambia Health Foundation as
      part of the Sojourns Scholars Leadership Program. Dr. Barry receives grant
      support through Massachusetts General Hospital from Healthwise, a nonprofit
      patient education and decision support organization. Dr. Davis is the CEO of ACP 
      Decisions, a non-profit private foundation. JAT is a Founding Director of
      VitalTalk, a non-profit organization focused on clinician communication skills
      training, from which he receives no compensation. AV has a financial interest in 
      ACP Decisions Nous, a non-profit organization developing ACP video decision
      support tools. His interests were reviewed and are managed by Massachusetts
      General Hospital and Partners HealthCare in accordance with their conflict of
      interest policies.
IR  - Goldman J
FIR - Goldman, Julie
IR  - Sipin B
FIR - Sipin, Brian
IR  - Barry MJ
FIR - Barry, Michael J
IR  - Pollak KI
FIR - Pollak, Kathryn I
IR  - Sofela M
FIR - Sofela, Miji
IR  - Kennedy D
FIR - Kennedy, Danielle
IR  - Yousuf Zafar S
FIR - Yousuf Zafar, S
IR  - Carney MT
FIR - Carney, Maria Torroella
IR  - Martins-Welch D
FIR - Martins-Welch, Diana
IR  - Qiu M
FIR - Qiu, Michael
IR  - McLeggon JA
FIR - McLeggon, Jody-Ann
IR  - Devoe CE
FIR - Devoe, Craig E
IR  - Tilburt JC
FIR - Tilburt, Jon C
IR  - Loprinzi CL
FIR - Loprinzi, Charles L
IR  - Rahman PA
FIR - Rahman, Parvez A
IR  - Stout JJ
FIR - Stout, Jeremiah J
IR  - Davis AD
FIR - Davis, Aretha Delight
IR  - Quintiliani LM
FIR - Quintiliani, Lisa M
EDAT- 2020/07/16 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
AID - bmjopen-2020-040999 [pii]
AID - 10.1136/bmjopen-2020-040999 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e040999. doi: 10.1136/bmjopen-2020-040999.


PMID- 32665393
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Improving the HIV PrEP continuum of care using an intervention for healthcare
      providers: a stepped-wedge study protocol.
PG  - e040734
LID - 10.1136/bmjopen-2020-040734 [doi]
AB  - INTRODUCTION: Pre-exposure prophylaxis (PrEP) has demonstrated to be a highly
      effective method for preventing HIV; however, many individuals with PrEP
      indications are not receiving PrEP. Primary care settings provide an opportunity 
      to offer PrEP to a wide range of patients. In this paper, we describe the PrEP
      Optimisation Intervention (PrEP-OI), which includes a PrEP Coordinator and a
      web-based panel management tool (called PrEP-Rx), and is targeted at healthcare
      providers (HCPs) to increase PrEP uptake and persistence among those at risk for 
      acquiring HIV. METHODS AND ANALYSIS: The PrEP-OI study evaluates the efficacy of 
      the PrEP intervention (PrEP Coordinator + PrEP-Rx) to increase PrEP prescriptions
      through a stepped-wedge design among 10 primary care clinical sites in the San
      Francisco Department of Public Health. The number of PrEP initiation
      prescriptions constitute the primary outcome, and we hypothesise that the mean
      number of PrEP prescriptions written will significantly increase after the
      clinics initiate PrEP-OI versus before this intervention. Secondary objectives
      include: 1-differences in PrEP initiation, duration of use and reasons for
      discontinuation based on patient's age, race/ethnicity and sex/gender, and by
      clinic and HCP characteristics, 2-sustainability of the intervention during a
      12-month follow-up after the stepped-wedge phase, and 3-facilitators and barriers
      of PrEP delivery and experiences with the proposed PrEP intervention through
      qualitative interviews with HCPs. The results of this study can provide valuable 
      insight into methods to reduce the burden of PrEP care on HCPs and improve PrEP
      continuum of care. ETHICS AND DISSEMINATION: This study and its protocols have
      been approved by the University of California, San Francisco (UCSF) Institutional
      Review Board. Study staff will disseminate findings locally (eg, the UCSF Centre 
      for AIDS Prevention Studies' Community Engagement Core), statewide (eg, the
      California Department of Public Health's Office of AIDS) and nationally and
      internationally at conferences related to HIV. TRIAL REGISTRATION NUMBER:
      NCT03532191.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ming, Kristin
AU  - Ming K
AUID- ORCID: 0000-0002-0688-9002
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Shrestha, Isha
AU  - Shrestha I
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Vazquez, Alexander
AU  - Vazquez A
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Wendelborn, James
AU  - Wendelborn J
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Jimenez, Veronica
AU  - Jimenez V
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Lisha, Nadra
AU  - Lisha N
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Neilands, Torsten B
AU  - Neilands TB
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Scott, Hyman
AU  - Scott H
AD  - Bridge HIV, San Francisco Department of Public Health, San Francisco, California,
      USA.
FAU - Liu, Albert
AU  - Liu A
AD  - Bridge HIV, San Francisco Department of Public Health, San Francisco, California,
      USA.
FAU - Steward, Wayne
AU  - Steward W
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Johnson, Mallory O
AU  - Johnson MO
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Saberi, Parya
AU  - Saberi P
AUID- ORCID: 0000-0002-3793-5112
AD  - Department of Medicine, Center for AIDS Prevention Studies, University of
      California, San Francisco, San Francisco, California, USA Parya.Saberi@ucsf.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT03532191
GR  - R01 NR017573/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome/drug therapy
MH  - *Anti-HIV Agents/therapeutic use
MH  - Continuity of Patient Care
MH  - *HIV Infections/drug therapy/prevention & control
MH  - Health Personnel
MH  - Humans
MH  - *Pre-Exposure Prophylaxis
MH  - San Francisco
PMC - PMC7454188
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *general medicine (see internal medicine)
OT  - *quality in health care
COIS- Competing interests: AL has received an investigator sponsored research grant
      from Gilead Sciences, and has led studies in which Gilead has donated study drug.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-040734 [pii]
AID - 10.1136/bmjopen-2020-040734 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e040734. doi: 10.1136/bmjopen-2020-040734.


PMID- 32665392
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Protocol for a systematic review of economic analyses of nosocomial infection
      prevention and control interventions in OECD hospitals.
PG  - e037765
LID - 10.1136/bmjopen-2020-037765 [doi]
AB  - BACKGROUND: Nosocomial infections (NIs) are associated with extra treatment
      costs, medical complications, reduction of quality of life and mortality. This
      systematic review intends to consolidate the evidence on the economic evaluation 
      of four clinical best practices (CBPs) related to NI prevention and control
      interventions: hand hygiene, hygiene and sanitation, admission screening and
      basic and additional precautions. It will measure the return on investment of
      these CBPs. METHODS AND ANALYSIS: Electronic searches will be conducted on
      MEDLINE, CINAHL, EMBASE, Cochrane, Web of Science and JSTOR. OpenGrey will also
      be consulted for articles from 2000 to 2018, published in English or French. The 
      population includes studies undertaken in medical or surgical units of hospitals 
      of the Organisation for Economic Co-operation and Development countries. Studies 
      will report the prevention and control of Clostridium difficile-associated
      diarrhoea, methicillin-resistant Staphylococcus aureus, vancomycin-resistant
      enterococci and carbapenem-resistant Gram-negative bacilli. Interventions
      evaluating any of the four CBPs will be included. The design of articles will
      fall within randomised clinical trials, quasi-experimental, case-control, cohort,
      longitudinal and cross-sectional studies. Outcomes will include incremental
      cost-effectiveness ratio, incremental cost per quality-adjusted life-year,
      incremental cost per disability-adjusted life year and the incremental
      cost-benefit ratio, net costs and net cost savings. Two authors will
      independently screen studies, extract data and assess risk of bias using the
      Scottish Intercollegiate Guidelines, the Drummond Economic Evaluation criteria
      and the Cochrane criteria for Systematic Reviews of Interventions. Consolidated
      Health Economic Evaluation Reporting Standards will be used for data extraction. 
      All values will be adjusted to Canadian dollars ($C) indexed to 2019 using the
      discount rates (3%, 5% and 8%) for sensitivity analyses. This review will
      demonstrate the effectiveness of the CBPs in prevention and control of NIs.
      Decision-makers will thus have evidence to facilitate sound decision-making
      according to the financial gains generated. ETHICS AND DISSEMINATION: The results
      of this systematic review will be published in a peer-reviewed journal and
      presented at a relevant scientific conference. Ethical approval is not required
      because the data we will use do not include individual patient data.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tchouaket, Eric Nguemeleu
AU  - Tchouaket EN
AUID- ORCID: 0000-0002-4309-0478
AD  - Sciences Infirmieres, Universite du Quebec en Outaouais, Gatineau, Quebec, Canada
      eric.tchouaket@uqo.ca.
FAU - Beogo, Idrissa
AU  - Beogo I
AD  - School of Nursing and Health, Universite de Saint-Boniface, Winnipeg, Manitoba,
      Canada.
FAU - Sia, Drissa
AU  - Sia D
AD  - Nursing, Universite du Quebec en Outaouais, Gatineau, Quebec, Canada.
FAU - Kilpatrick, Kelley
AU  - Kilpatrick K
AUID- ORCID: 0000-0003-2137-6560
AD  - Nursing, McGill University, Montreal, Quebec, Canada.
FAU - Seguin, Catherine
AU  - Seguin C
AD  - Universite du Quebec en Outaouais, Gatineau, Quebec, Canada.
FAU - Baillot, Aurelie
AU  - Baillot A
AD  - Nursing, Universite du Quebec en Outaouais, Gatineau, Quebec, Canada.
FAU - Nadar, Mahmoud
AU  - Nadar M
AD  - Nursing, Universite du Quebec en Outaouais, Gatineau, Quebec, Canada.
FAU - Parisien, Natasha
AU  - Parisien N
AD  - Institut national de sante publique du Quebec, Quebec, Quebec, Canada.
FAU - Boivin, Sandra
AU  - Boivin S
AD  - CISSS des Laurentides, Saint-Jerome, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Cost-Benefit Analysis
MH  - *Cross Infection/prevention & control
MH  - Cross-Sectional Studies
MH  - Hospitals
MH  - Humans
MH  - *Methicillin-Resistant Staphylococcus aureus
MH  - Organisation for Economic Co-Operation and Development
MH  - Quality of Life
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7365490
OTO - NOTNLM
OT  - *health economics
OT  - *human resource management
OT  - *infection control
OT  - *protocols & guidelines
OT  - *quality in healthcare
OT  - *risk management
COIS- Competing interests: ET received a Junior 1 researcher award from the FRQS.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037765 [pii]
AID - 10.1136/bmjopen-2020-037765 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e037765. doi: 10.1136/bmjopen-2020-037765.


PMID- 32665391
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - 2BALANCE: a cognitive-motor dual-task protocol for individuals with vestibular
      dysfunction.
PG  - e037138
LID - 10.1136/bmjopen-2020-037138 [doi]
AB  - INTRODUCTION: Aside from primary vestibular symptoms such as vertigo and
      dizziness, persons with vestibular dysfunction frequently express cognitive and
      motor problems. These symptoms have mainly been assessed in single-task setting, 
      which might not represent activities of daily living accurately. Therefore, a
      dual-task protocol, consisting of the simultaneous performance of cognitive and
      motor tasks, was developed. This protocol assesses cognitive and motor
      performance in general, as well as cognitive-motor interference in specific.
      METHODS AND ANALYSIS: The motor component of the 2BALANCE protocol consists of a 
      static and dynamic postural task. These motor tasks are combined with different
      cognitive tasks assessing visuospatial cognition, processing speed, working
      memory and response inhibition. First, test-retest reliability will be assessed
      with an interval of 2 weeks in a group of young adults. Second, the 2BALANCE
      protocol will be validated in persons with bilateral vestibulopathy. Finally, the
      protocol will be implemented in persons with unilateral vestibular loss.
      DISCUSSION AND CONCLUSIONS: The 2BALANCE project aims to elucidate the impact of 
      vestibular dysfunction on cognitive and motor performance in dual-task setting.
      This protocol represents everyday situations better than single-task protocols,
      as dual-tasks such as reading street signs while walking are often encountered
      during daily activities. Ultimately, this project could enable individualised and
      holistic clinical care in these patients, taking into account single as well as
      dual-task performance. ETHICS AND DISSEMINATION: The current study was approved
      by the ethics committee of Ghent University Hospital on 5 July 2019 with
      registration number B670201940465. All research findings will be disseminated in 
      peer-reviewed journals and presented at vestibular as well as multidisciplinary
      international conferences and meetings. TRIALS REGISTRATION NUMBER: NCT04126798, 
      pre-results phase.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Danneels, Maya
AU  - Danneels M
AUID- ORCID: 0000-0002-6567-1521
AD  - Department of Rehabilitation Sciences, Ghent University, Gent, Belgium
      maya.danneels@ugent.be.
FAU - Van Hecke, Ruth
AU  - Van Hecke R
AD  - Department of Rehabilitation Sciences, Ghent University, Gent, Belgium.
FAU - Leyssens, Laura
AU  - Leyssens L
AD  - Department of Rehabilitation Sciences, Ghent University, Gent, Belgium.
FAU - Degeest, Sofie
AU  - Degeest S
AD  - Department of Rehabilitation Sciences, Ghent University, Gent, Belgium.
FAU - Cambier, Dirk
AU  - Cambier D
AD  - Department of Rehabilitation Sciences, Ghent University, Gent, Belgium.
FAU - van de Berg, Raymond
AU  - van de Berg R
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, Maastricht
      University Medical Centre+, Maastricht, Limburg, The Netherlands.
AD  - Faculty of Physics, Tomsk State University, Tomsk, Russian Federation.
FAU - Van Rompaey, Vincent
AU  - Van Rompaey V
AD  - Faculty of Medicine and Health Sciences, Universiteit Antwerpen, Antwerpen,
      Belgium.
AD  - Department of Otorhinolaryngology and Head & Neck Surgery, University Hospital
      Antwerp, Edegem, Belgium.
FAU - Maes, Leen
AU  - Maes L
AD  - Department of Rehabilitation Sciences, Ghent University, Gent, Belgium.
AD  - Department of Otorhinolaryngology, University Hospital Ghent, Gent, Belgium.
LA  - eng
SI  - ClinicalTrials.gov/NCT04126798
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - COVID-19
MH  - *Cognition
MH  - Gait
MH  - Humans
MH  - Pandemics
MH  - Postural Balance
MH  - Reproducibility of Results
MH  - SARS-CoV-2
PMC - PMC7365489
OTO - NOTNLM
OT  - *adult neurology
OT  - *adult otolaryngology
OT  - *audiology
OT  - *neurotology
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-037138 [pii]
AID - 10.1136/bmjopen-2020-037138 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e037138. doi: 10.1136/bmjopen-2020-037138.


PMID- 32665387
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Effect and feasibility of district level scale up of maternal, newborn and child 
      health interventions in Pakistan: a quasi-experimental study.
PG  - e036293
LID - 10.1136/bmjopen-2019-036293 [doi]
AB  - INTRODUCTION: Pakistan has a high burden of maternal, newborn and child morbidity
      and mortality. Several factors including weak scale-up of evidence-based
      interventions within the existing health system; lack of community awareness
      regarding health conditions; and poverty contribute to poor outcomes. Deaths and 
      morbidity are largely preventable if a combination of community and
      facility-based interventions are rolled out at scale. METHODS AND ANALYSIS:
      Umeed-e-Nau (UeN) (New Hope) project aims is to improve maternal, newborn and
      child health (MNCH) in eight high-burden districts of Pakistan by scaling up of
      evidence-based interventions. The project will assess interventions focused on,
      first, improving the quality of MNCH care at primary level and secondary level.
      Second, interventions targeting demand generation such as community mobilisation,
      creating awareness of healthy practices and expanding coverage of outreach
      services will be evaluated. Third, we will also evaluate interventions targeting 
      the improvement in quality of routine health information and promotion of use of 
      the data for decision-making. Hypothesis of the project is that roll out of
      evidence-based interventions at scale will lead to at least 20% reduction in
      perinatal mortality and 30% decrease in diarrhoea and pneumonia case fatality in 
      the target districts whereas two intervention groups will serve as internal
      controls. Monitoring and evaluation of the programme will be undertaken through
      conducting periodical population level surveys and quality of care assessments.
      Descriptive and multivariate analytical methods will be used for assessing the
      association between different factors, and difference in difference estimates
      will be used to assess the impact of the intervention on outcomes. ETHICS AND
      DISSEMINATION: The ethics approval was obtained from the Aga Khan University
      Ethics Review Committee. The findings of the project will be shared with relevant
      stakeholders and disseminated through open access peer-reviewed journal articles.
      TRIAL REGISTRATION NUMBER: NCT04184544; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Memon, Zahid Ali
AU  - Memon ZA
AUID- ORCID: 0000-0002-5321-8885
AD  - Centre of Excellence in Women and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Muhammad, Shah
AU  - Muhammad S
AD  - Centre of Excellence in Women and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Soofi, Sajid
AU  - Soofi S
AUID- ORCID: 0000-0003-4192-8406
AD  - Centre of Excellence in Women and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Khan, Nimra
AU  - Khan N
AD  - Centre of Excellence in Women and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Akseer, Nadia
AU  - Akseer N
AD  - Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario,
      Canada.
FAU - Habib, Atif
AU  - Habib A
AD  - Centre of Excellence in Women and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Bhutta, Zulfiqar
AU  - Bhutta Z
AD  - Centre of Excellence in Women and Child Health, Aga Khan University, Karachi,
      Pakistan zulfiqar.bhutta@aku.edu.
AD  - Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario,
      Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04184544
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Capacity Building
MH  - Child, Preschool
MH  - Community Health Services/organization & administration
MH  - *Evidence-Based Practice
MH  - Feasibility Studies
MH  - Female
MH  - *Health Education
MH  - Health Information Systems/standards
MH  - Health Personnel/*education
MH  - Health Services Accessibility
MH  - Health Services Needs and Demand
MH  - Health Workforce
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Maternal-Child Health Services/*organization & administration/standards/supply & 
      distribution
MH  - Pakistan
MH  - Program Evaluation
MH  - Public-Private Sector Partnerships
MH  - *Quality Improvement
MH  - Research Design
PMC - PMC7365487
OTO - NOTNLM
OT  - *community child health
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036293 [pii]
AID - 10.1136/bmjopen-2019-036293 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e036293. doi: 10.1136/bmjopen-2019-036293.


PMID- 32665384
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Protocol for a single-arm confirmatory trial of adjuvant chemoradiation for
      patients with high-risk rectal submucosal invasive cancer after local resection: 
      Japan Clinical Oncology Group Study JCOG1612 (RESCUE study).
PG  - e034947
LID - 10.1136/bmjopen-2019-034947 [doi]
AB  - INTRODUCTION: Intestinal resection with lymph node dissection is the current
      standard treatment for high-risk lower rectal submucosal invasive cancer after
      local resection; however, surgery affects patients' quality of life due to stoma 
      placement or impaired anal sphincter function. A recent study demonstrated that
      adjuvant chemoradiation yields promising results. METHODS AND ANALYSIS: This
      study aims to confirm the non-inferiority of adjuvant chemoradiation, consisting 
      of capecitabine and concurrent radiotherapy (45 Gy in 25 fractions), measured by 
      5-year relapse-free survival (RFS), over standard surgery in patients with
      high-risk lower rectal submucosal invasive cancer after local resection. The
      primary endpoint is 5 year RFS. The secondary endpoints are 10 years RFS, 5-year 
      and 10-year overall survival, 5-year and 10-year local RFS, 5-year and 10-year
      proportion of anus-preservation without stoma, Wexner score, low anterior
      resection syndrome score, adverse events and serious adverse events. During the
      5-year trial period, 210 patients will be accrued from 65 Japanese institutions. 
      ETHICS AND DISSEMINATION: The National Cancer Center Hospital East Certified
      Review Board approved this study protocol in October 2018. The study is conducted
      in accordance with the precepts established in the Declaration of Helsinki and
      Clinical Trials Act. Written informed consent will be obtained from all eligible 
      patients prior to registration. The primary results of this study will be
      published in an English article. In addition, the main results will be published 
      on the websites of Japan Clinical Oncology Group (www.jcog.jp) and jRCT
      (https://jrct.niph.go.jp/). As to data curation, it has not been prepared yet.
      TRIAL REGISTRATION NUMBER: jRCT1031180076.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kadota, Tomohiro
AU  - Kadota T
AUID- ORCID: 0000-0002-0408-3494
AD  - JCOG Data Center/Operations Office, National Cancer Center Hospital, Chuo-ku,
      Japan.
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center-Hospital
      East, Kashiwa, Chiba, Japan.
FAU - Ikematsu, Hiroaki
AU  - Ikematsu H
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center-Hospital
      East, Kashiwa, Chiba, Japan hikemats@east.ncc.go.jp.
FAU - Sasaki, Takeshi
AU  - Sasaki T
AD  - Department of Colorectal Surgery, National Cancer Center-Hospital East, Kashiwa, 
      Chiba, Japan.
FAU - Saito, Yutaka
AU  - Saito Y
AD  - Endoscopy Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
FAU - Ito, Masaaki
AU  - Ito M
AD  - Department of Colorectal Surgery, National Cancer Center-Hospital East, Kashiwa, 
      Chiba, Japan.
FAU - Mizutani, Tomonori
AU  - Mizutani T
AD  - JCOG Data Center/Operations Office, National Cancer Center Hospital, Chuo-ku,
      Tokyo, Japan.
FAU - Ogawa, Gakuto
AU  - Ogawa G
AD  - JCOG Data Center/Operations Office, National Cancer Center Hospital, Chuo-ku,
      Japan.
FAU - Shitara, Kohei
AU  - Shitara K
AD  - Department of Gastroenterology and Endoscopy, National Cancer Center-Hospital
      East, Kashiwa, Chiba, Japan.
FAU - Ito, Yoshinori
AU  - Ito Y
AD  - Department of Radiation Oncology, Showa University Graduate School of Medicine,
      Shinagawa-ku, Tokyo, Japan.
FAU - Kushima, Ryoji
AU  - Kushima R
AD  - Department of Clinical Laboratory Medicine (Diagnostic Pathology), Shiga
      University of Medical Science, Otsu, Shiga, Japan.
FAU - Kanemitsu, Yukihide
AU  - Kanemitsu Y
AD  - Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku,
      Japan.
FAU - Muto, Manabu
AU  - Muto M
AD  - Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine,
      Kyoto, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/*radiotherapy/surgery
MH  - Antimetabolites, Antineoplastic/therapeutic use
MH  - Capecitabine/*therapeutic use
MH  - *Chemoradiotherapy, Adjuvant
MH  - Colorectal Surgery/methods
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Multicenter Studies as Topic
MH  - Neoplasm Invasiveness
MH  - Rectal Neoplasms/*drug therapy/*radiotherapy/surgery
MH  - Rectum/surgery
PMC - PMC7365419
OTO - NOTNLM
OT  - *endoscopy
OT  - *gastroenterology
OT  - *gastrointestinal tumours
OT  - *radiation oncology
COIS- Competing interests: KS reports grants from reports research funding from Chugai.
EDAT- 2020/07/16 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034947 [pii]
AID - 10.1136/bmjopen-2019-034947 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e034947. doi: 10.1136/bmjopen-2019-034947.


PMID- 32665383
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Economic evaluation of intrahospital clinical practices in injury care: protocol 
      for a 10-year systematic review.
PG  - e034472
LID - 10.1136/bmjopen-2019-034472 [doi]
AB  - INTRODUCTION: Underuse of high-value clinical practices and overuse of low-value 
      practices are major sources of inefficiencies in modern healthcare systems.
      Injuries are second only to cardiovascular disease in terms of acute care costs
      but data on the economic impact of clinical practices for injury admissions are
      lacking. This study aims to summarise evidence on the economic value of
      intrahospital clinical practices for injury care. METHODS AND ANALYSIS: We will
      perform a systematic review to identify research articles in economic evaluation 
      of intrahospital clinical practices in acute injury care. We will search MEDLINE 
      and databases such as Embase, Web of Science, NHS Economic Evaluation Database,
      Cochrane CENTRAL, BIOSIS and CINAHL for randomised or non-randomised controlled
      trials and observational studies using a combination of keywords and controlled
      vocabulary. We will consider the following outcomes relative to economic
      evaluations: incremental cost-effectiveness ratio, incremental cost-utility
      ratio, incremental net health benefit, incremental net monetary benefit (iNMB)
      and incremental cost-benefit ratio. Pairs of independent reviewers will evaluate 
      studies that meet eligibility criteria and extract data from included articles
      using an electronic data extraction form. All outcomes will be converted into
      iNMB. We will report iNMB for practices classified by type of practice
      (hospitalisation, consultation, diagnostic, therapeutic-surgical,
      therapeutic-drugs, therapeutic-other). Results obtained with a ceiling ratio of
      $50 000 per quality-adjusted life year gained for identified clinical practices
      will be summarised by charting forest plots. In line with Cochrane
      recommendations for systematic reviews of economic evaluations, meta-analyses
      will not be conducted. ETHICS AND DISSEMINATION: Ethics approval is not required 
      as original data will not be collected. This study will summarise existing
      evidence on the economic value of clinical practices in injury care. Results will
      be used to advance knowledge on value-based care for injury admissions and will
      be disseminated through a peer-reviewed article, international scientific
      meetings and clinical and healthcare quality associations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Conombo, Blanchard
AU  - Conombo B
AUID- ORCID: 0000-0001-6636-8164
AD  - Department of Social and Preventive Medicine, Laval University, Quebec City,
      Quebec, Canada blanchard.conombo.1@ulaval.ca.
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
FAU - Guertin, Jason Robert
AU  - Guertin JR
AUID- ORCID: 0000-0003-1718-5307
AD  - Department of Social and Preventive Medicine, Laval University, Quebec City,
      Quebec, Canada.
FAU - Tardif, Pier-Alexandre
AU  - Tardif PA
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
FAU - Farhat, Imen
AU  - Farhat I
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
FAU - Moore, Thomas
AU  - Moore T
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
FAU - Bouderba, Samy
AU  - Bouderba S
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
FAU - Soltana, Kahina
AU  - Soltana K
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
FAU - Archambault, Patrick
AU  - Archambault P
AD  - Department of Family Medicine and Emergency Medicine, Laval University, Quebec
      City, Quebec, Canada.
FAU - Berthelot, Simon
AU  - Berthelot S
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
AD  - Department of Family Medicine and Emergency Medicine, Laval University, Quebec
      City, Quebec, Canada.
FAU - Lauzier, Francois
AU  - Lauzier F
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
AD  - Department of Anesthesia and Critical Care Medicine, Laval University, Quebec
      City, Quebec, Canada.
FAU - Turgeon, Alexis F
AU  - Turgeon AF
AUID- ORCID: 0000-0001-5675-8791
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
AD  - Department of Anesthesia and Critical Care Medicine, Laval University, Quebec
      City, Quebec, Canada.
FAU - Stelfox, Henry Thomas
AU  - Stelfox HT
AD  - Critical Care Medicine, University of Calgary, Calgary, Alberta, Canada.
FAU - Chasse, Michael
AU  - Chasse M
AD  - Department of Medicine, University of Montreal, Montreal, Quebec, Canada.
FAU - Hoch, Jeffrey
AU  - Hoch J
AD  - Department of Public Health Sciences, University of California, Sacramento,
      California, USA.
FAU - Moore, Lynne
AU  - Moore L
AD  - Department of Social and Preventive Medicine, Laval University, Quebec City,
      Quebec, Canada.
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec (Hopital de
      l'Enfant-Jesus), Laval University, Quebec City, Quebec, Canada.
LA  - eng
GR  - 353374 /CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - *Critical Care
MH  - Humans
MH  - *Quality of Health Care
MH  - Quality-Adjusted Life Years
MH  - Systematic Reviews as Topic
PMC - PMC7365427
OTO - NOTNLM
OT  - *health economics
OT  - *injury
OT  - *low-value clinical practices
OT  - *value-based care
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034472 [pii]
AID - 10.1136/bmjopen-2019-034472 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e034472. doi: 10.1136/bmjopen-2019-034472.


PMID- 32665381
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 14
TI  - Oral switch versus standard intravenous antibiotic therapy in left-sided
      endocarditis due to susceptible staphylococci, streptococci or enterococci
      (RODEO): a protocol for two open-label randomised controlled trials.
PG  - e033540
LID - 10.1136/bmjopen-2019-033540 [doi]
AB  - INTRODUCTION: Left-sided infective endocarditis (IE) is a serious infection with 
      a heavy burden for patients and healthcare system. Oral switch after initial
      intravenous antibiotic therapy may reduce costs and improve patients' discomfort 
      without increasing unfavourable outcomes. We describe the methodology of two
      simultaneously conducted open-label randomised trials aiming to assess
      non-inferiority of oral switch as compared with entirely intravenous antibiotic
      therapy for the treatment of left-sided IE. METHODS AND ANALYSIS: Two
      simultaneous multicentre open-label prospective randomised trials assessing
      non-inferiority of oral switch during antibiotic treatment as compared with
      entirely intravenous therapy in patients with left-sided IE are ongoing. One
      trial is dedicated to left-sided IE caused by multisusceptible staphylococci
      (Relais Oral Dans le traitement des Endocardites a staphylocoques ou
      streptOcoques (RODEO)-1) and the other is dedicated to left-sided IE caused by
      susceptible streptococci or enterococci (RODEO-2). It is planned to randomise 324
      patients in each trial after an initial course of at least 10 days of intravenous
      antibiotic therapy either to continue intravenous antibiotic therapy or to switch
      to oral antibiotic therapy. The primary outcome is treatment failure within 3
      months after the end of antibiotic treatment, a composite outcome defined by
      all-cause death and/or symptomatic embolic events and/or unplanned valvular
      surgery and/or microbiological relapse (with the primary pathogen). Secondary
      outcomes include patient quality of life, echocardiographic outcome, costs and
      efficiency associated with IE care. Statistical analysis will be performed with a
      non-inferiority margin of 10% and a one-sided 2.5% type I error. ETHICS AND
      DISSEMINATION: Written informed consent will be obtained from all participants.
      This study was approved by Tours Research ethics committee (CPP TOURS-Region
      Centre-Ouest 1, 2015-R26, 23 February 2016). Study findings will be published in 
      peer-reviewed journals and disseminated through presentation at relevant national
      and international conferences. TRIAL REGISTRATION NUMBER: EudraCT Number:
      2015-002371-16 and NCT02701608; NCT02701595.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lemaignen, Adrien
AU  - Lemaignen A
AUID- ORCID: 0000-0001-5974-5689
AD  - Service de Medecine Interne et Maladies Infectieuses, Centre Hospitalier Regional
      Universitaire de Tours, Tours, France.
AD  - Universite de Tours, Faculte de Medecine, PRES Centre-Val de Loire Universite,
      Tours, France.
FAU - Bernard, Louis
AU  - Bernard L
AUID- ORCID: 0000-0001-8127-7519
AD  - Service de Medecine Interne et Maladies Infectieuses, Centre Hospitalier Regional
      Universitaire de Tours, Tours, France louis.bernard@univ-tours.fr.
FAU - Tattevin, Pierre
AU  - Tattevin P
AD  - Service de Maladies Infectieuses et de Reanimation Medicale, Centre Hospitalier
      Universitaire de Rennes, Rennes, Bretagne, France.
FAU - Bru, Jean-Pierre
AU  - Bru JP
AD  - Service d'infectiologie et de medecine interne, Centre Hospitalier
      Annecy-Genevois, Epagny Metz-Tessy, Rhone-Alpes, France.
FAU - Duval, Xavier
AU  - Duval X
AD  - INSERM Clinical Investigation Center 1425, IAME 1138, Universite Paris Diderot,
      Sorbonne Paris-Cite, Paris, Ile-de-France, France.
AD  - Service de Maladies Infectieuses et Tropicales, Assistance Publique-Hopitaux de
      Paris, Hopital Bichat, Paris, France.
FAU - Hoen, Bruno
AU  - Hoen B
AD  - Service de Maladies Infectieuses et Tropicales, CHRU de Nancy,
      Vandoeuvre-les-Nancy, France.
FAU - Brunet-Houdard, Solene
AU  - Brunet-Houdard S
AD  - Unite d'Evaluation Medico-Economique, EA7505, Education Ethique, Sante, Centre
      Hospitalier Regional Universitaire de Tours, Universite de Tours, Tours, Centre, 
      France.
FAU - Mainardi, Jean-Luc
AU  - Mainardi JL
AD  - Service de Microbiologie, APHP, Hopital Europeen Georges Pompidou, Paris, France.
FAU - Caille, Agnes
AU  - Caille A
AD  - Unite d'Evaluation Medico-Economique, EA7505, Education Ethique, Sante, Centre
      Hospitalier Regional Universitaire de Tours, Universite de Tours, Tours, Centre, 
      France.
AD  - INSERM CIC1415, CHRU de Tours, Tours, France.
CN  - RODEO (Relais Oral Dans le traitement des Endocardites a staphylocoques ou
      streptOcoques) and AEPEI (Association pour l'Etude et la Prevention de
      l'Endocardite Infectieuse) study groups
LA  - eng
SI  - ClinicalTrials.gov/NCT02701608
SI  - ClinicalTrials.gov/NCT02701595
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Endocarditis
MH  - *Enterococcus
MH  - Humans
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Staphylococcus
PMC - PMC7365486
OTO - NOTNLM
OT  - *adult
OT  - *anti-bacterial agents
OT  - *infective endocarditis
OT  - *oral administration
OT  - *randomised controlled trial
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033540 [pii]
AID - 10.1136/bmjopen-2019-033540 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 14;10(7):e033540. doi: 10.1136/bmjopen-2019-033540.


PMID- 32665352
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 13
TI  - Effects of respiratory rehabilitation on patients with novel coronavirus
      (COVID-19) pneumonia in the rehabilitation phase: protocol for a systematic
      review and meta-analysis.
PG  - e039771
LID - 10.1136/bmjopen-2020-039771 [doi]
AB  - INTRODUCTION: The recent viral pneumonia caused by the COVID-19 has gained the
      attention of the people all over the world. We aim to investigate the effects of 
      respiratory rehabilitation therapy on patients infected with the novel
      coronavirus by conducting a systematic review and meta-analysis. METHODS AND
      ANALYSIS: This systematic review and meta-analysis have been registered in the
      International Prospective Register of Systematic Reviews (PROSPERO). The PubMed, 
      Embase, Web of Science, the Cochrane Central Register of Controlled Trials,
      Chinese Biomedical Literature Database, China National Knowledge Infrastructure, 
      Wanfang Data and Viper information databases will be searched from inception time
      to date without restricting research types to find relevant studies. We will also
      look into reference lists of relevant trials and reviews, and manually search
      grey literature, such as trial registries. Two reviewers will independently
      extract data and perform quality assessment of included studies. Review Manager
      V.5.3 (Cochrane Collaboration) and Stata V.16.0 software will be used to conduct 
      this meta-analysis. The mean difference or standardised mean difference with 95% 
      CIs is used in the computation of continuous variables to synthesise data. ETHICS
      AND DISSEMINATION: Ethical approval is not required due to the nature of this
      meta-analysis, which is based on published papers. The results of this systematic
      review and meta-analysis will be published in a peer-reviewed journal once we
      finish this study. PROSPERO REGISTRATION NUMBER: CRD42020180214.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhu, Feilong
AU  - Zhu F
AUID- ORCID: 0000-0001-5404-8745
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Zhang, Ming
AU  - Zhang M
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, China.
FAU - Gao, Min
AU  - Gao M
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, China.
FAU - Zeng, Cheng
AU  - Zeng C
AD  - Department of Rehabilitation Medicine, The First Hospital of Putian City, Putian,
      China.
FAU - Wang, Dan
AU  - Wang D
AUID- ORCID: 0000-0002-4688-8215
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Hong, Qianqin
AU  - Hong Q
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China.
FAU - Chen, Wei
AU  - Chen W
AD  - The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University,
      Xuzhou Medical University, Xuzhou, Jiangsu, China chenwei2339@163.com.
AD  - Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200713
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/*rehabilitation
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/complications/*etiology/*rehabilitation
MH  - SARS-CoV-2
PMC - PMC7365721
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *public health
OT  - *rehabilitation medicine
OT  - *respiratory infections
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
AID - bmjopen-2020-039771 [pii]
AID - 10.1136/bmjopen-2020-039771 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 13;10(7):e039771. doi: 10.1136/bmjopen-2020-039771.


PMID- 32665350
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 13
TI  - Pharmacists' roles in supporting people living with severe and persistent mental 
      illness: a systematic review protocol.
PG  - e038270
LID - 10.1136/bmjopen-2020-038270 [doi]
AB  - INTRODUCTION: Severe and persistent mental illness (SPMI) can significantly
      impact a person's social, personal and professional life. Previous studies have
      demonstrated pharmacists' roles in mental healthcare; however, limited studies to
      date have focused on pharmacists' roles in providing healthcare services,
      specifically, to people living with SPMI. The aim of this systematic review is to
      explore the pharmacists' roles in providing support to people living with SPMI.
      METHODS AND ANALYSIS: A systematic search will be conducted in Medline, Embase
      (Ovid), PsycINFO, CINAHL, Web of Science, Scopus, Cochrane Library, International
      Pharmaceutical Abstracts and ProQuest Dissertations and Theses to identify
      potentially relevant primary research for inclusion. This will be guided by the
      Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
      checklist for systematic reviews. All primary research publications regardless of
      study design exploring or reporting on pharmacists' involvement in supporting
      people living with SPMI will be considered for inclusion. A tabular summary will 
      be completed using data extracted from each included publication. Data synthesis 
      and quality assessment methods will be chosen based on included study designs.
      ETHICS AND DISSEMINATION: The results will be published in a peer-reviewed
      journal and used to inform the development of a pharmacist-specific training
      package to support people living with SPMI. PROSPERO REGISTRATION NUMBER:
      CRD42020170711.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - El-Den, Sarira
AU  - El-Den S
AUID- ORCID: 0000-0001-7500-3351
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney,
      Sydney, New South Wales, Australia.
FAU - McMillan, Sara S
AU  - McMillan SS
AUID- ORCID: 0000-0003-3427-4467
AD  - School of Pharmacy and Pharmacology, Griffith University, Southport, Queensland, 
      Australia.
AD  - Menzies Health Institute, Griffith University, Nathan, Queensland, Australia.
FAU - Wheeler, Amanda J
AU  - Wheeler AJ
AUID- ORCID: 0000-0001-9755-674X
AD  - Menzies Health Institute, Griffith University, Nathan, Queensland, Australia.
AD  - Faculty of Health and Medical Sciences, University of Auckland, Auckland, New
      Zealand.
FAU - Ng, Ricki
AU  - Ng R
AUID- ORCID: 0000-0002-1334-6487
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney,
      Sydney, New South Wales, Australia.
FAU - Roennfeldt, Helena
AU  - Roennfeldt H
AUID- ORCID: 0000-0002-4569-1226
AD  - Menzies Health Institute, Griffith University, Nathan, Queensland, Australia.
AD  - The University of Melbourne Centre for Psychiatric Nursing, Carlton, Victoria,
      Australia.
FAU - O'Reilly, Claire L
AU  - O'Reilly CL
AUID- ORCID: 0000-0001-6416-8150
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney,
      Sydney, New South Wales, Australia claire.oreilly@sydney.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - *Mental Disorders
MH  - Meta-Analysis as Topic
MH  - *Pharmacists
MH  - Systematic Reviews as Topic
PMC - PMC7359051
OTO - NOTNLM
OT  - *medical education & training
OT  - *quality in health care
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038270 [pii]
AID - 10.1136/bmjopen-2020-038270 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 13;10(7):e038270. doi: 10.1136/bmjopen-2020-038270.


PMID- 32665349
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 13
TI  - Delivery of community-centred public mental health interventions in diverse areas
      in England: a mapping study protocol.
PG  - e037631
LID - 10.1136/bmjopen-2020-037631 [doi]
AB  - BACKGROUND: Public mental health (PMH) is a global challenge and a UK priority
      area for action. However, to progress, practitioners require a stronger evidence 
      base regarding the effectiveness of approaches, particularly regarding promotion 
      and prevention through community-centred interventions. In addition,
      policy-makers need to understand what is being delivered, particularly in areas
      of high need, to identify promising practices or gaps in PMH provision. Finally, 
      and importantly, the public need better information regarding what approaches and
      services are available to them. We report a protocol designed to (1) identify the
      types of community-centred interventions used in purposively selected diverse
      geographical areas of England to improve PMH outcomes and (2) describe the type, 
      target population, content and outcome measures of each intervention. METHODS AND
      ANALYSIS: Five local authority areas of England were selected based on either
      high social deprivation or differing ethnic population statistics and
      geographical locations. Community-centred interventions in each area will be
      identified through: (1) desk-based data capture from standardised searches of
      publicly-available information (eg, policy, strategy and intervention
      advertising), (2) established professional networks and service contacts, (3)
      chain-referral sampling of individuals involved in local mental health promotion 
      and prevention and (4) peer researchers, who will use their personal experience
      and local knowledge to help identify potentially relevant organisations. Data on 
      the key features of the interventions will be extracted from individuals either
      by structured interviews or by electronic questionnaires with information
      regarding the intervention(s) of which they have knowledge. Initial data analysis
      will involve tabulating descriptive information and grouping interventions
      according to intervention type, target population, risk/protective factor and
      intended primary outcome. A descriptive comparison will be made between selected 
      geographical areas. ETHICS AND DISSEMINATION: Ethical approval was obtained from 
      Durham University's Department of Sport and Exercise Sciences Research Ethics
      Committee. We plan to disseminate our findings at relevant conferences, meetings 
      and through peer-reviewed journals. We also plan to disseminate to the public and
      intervention providers through social media and/or newsletters.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Duncan, Fiona H
AU  - Duncan FH
AUID- ORCID: 0000-0002-4929-5685
AD  - Department of Sport and Exercise Sciences, Durham University, Durham, UK
      fiona.h.duncan@durham.ac.uk.
FAU - McGrath, Mike
AU  - McGrath M
AD  - Division of Psychiatry, UCL, London, UK.
AD  - Department of Primary Care and Population Health, UCL, London, UK.
FAU - Baskin, Cleo
AU  - Baskin C
AD  - Department of Primary Care and Public Health, Imperial College, London, UK.
FAU - Osborn, David
AU  - Osborn D
AD  - Division of Psychiatry, UCL, London, UK.
FAU - Dykxhoorn, Jen
AU  - Dykxhoorn J
AD  - Division of Psychiatry, UCL, London, UK.
AD  - Department of Primary Care and Population Health, UCL, London, UK.
FAU - Kaner, Eileen F S
AU  - Kaner EFS
AD  - Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
FAU - Gnani, Shamini
AU  - Gnani S
AD  - Department of Primary Care and Public Health, Imperial College, London, UK.
FAU - LaFortune, Louise
AU  - LaFortune L
AD  - Institute of Public Health, University of Cambridge, Cambridge, UK.
FAU - Lee, Caroline
AU  - Lee C
AD  - Institute of Public Health, University of Cambridge, Cambridge, UK.
FAU - Walters, Kate R
AU  - Walters KR
AUID- ORCID: 0000-0003-2173-2430
AD  - Department of Primary Care and Population Health, UCL, London, UK.
FAU - Kirkbride, James
AU  - Kirkbride J
AD  - Division of Psychiatry, UCL, London, UK.
FAU - Fischer, Laura
AU  - Fischer L
AD  - McPin Foundation, London, UK.
FAU - Jones, Oli
AU  - Jones O
AD  - McPin Foundation, London, UK.
FAU - Pinfold, Vanessa
AU  - Pinfold V
AD  - McPin Foundation, London, UK.
FAU - Stansfield, Jude
AU  - Stansfield J
AUID- ORCID: 0000-0002-7989-5630
AD  - Health Improvement Directorate, Public Health England, London, UK.
FAU - Oliver, Emily J
AU  - Oliver EJ
AUID- ORCID: 0000-0002-1795-8448
AD  - Department of Sport and Exercise Sciences, Durham University, Durham, UK.
CN  - NIHR SPHR Public Mental Health Programme.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200713
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - England
MH  - Exercise
MH  - Health Promotion
MH  - Humans
MH  - *Mental Health
MH  - *Sports
PMC - PMC7359052
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *health policy
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037631 [pii]
AID - 10.1136/bmjopen-2020-037631 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 13;10(7):e037631. doi: 10.1136/bmjopen-2020-037631.


PMID- 32665344
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 13
TI  - Study protocol of the Health4Life initiative: a cluster randomised controlled
      trial of an eHealth school-based program targeting multiple lifestyle risk
      behaviours among young Australians.
PG  - e035662
LID - 10.1136/bmjopen-2019-035662 [doi]
AB  - INTRODUCTION: Lifestyle risk behaviours, including alcohol use, smoking, poor
      diet, physical inactivity, poor sleep (duration and/or quality) and sedentary
      recreational screen time ('the Big 6'), are strong determinants of chronic
      disease. These behaviours often emerge during adolescence and co-occur.
      School-based interventions have the potential to address risk factors prior to
      the onset of disease, yet few eHealth school-based interventions target multiple 
      behaviours concurrently. This paper describes the protocol of the Health4Life
      Initiative, an eHealth school-based intervention that concurrently addresses the 
      Big 6 risk behaviours among secondary school students. METHODS AND ANALYSIS: A
      multisite cluster randomised controlled trial will be conducted among year 7
      students (11-13 years old) from 72 Australian schools. Stratified block
      randomisation will be used to assign schools to either the Health4Life
      intervention or an active control (health education as usual). Health4Life
      consists of (1) six web-based cartoon modules and accompanying activities
      delivered during health education (once per week for 6 weeks), and a smartphone
      application (universal prevention), and (2) additional app content, for students 
      engaging in two or more risk behaviours when they are in years 8 and 9 (selective
      prevention). Students will complete online self-report questionnaires at
      baseline, post intervention, and 12, 24 and 36 months after baseline. Primary
      outcomes are consumption of sugar-sweetened beverages, moderate-to-vigorous
      physical activity, sleep duration, sedentary recreational screen time and uptake 
      of alcohol and tobacco use. ETHICS AND DISSEMINATION: This study has been
      approved by the University of Sydney (2018/882), NSW Department of Education
      (SERAP no. 2019006), University of Queensland (2019000037), Curtin University
      (HRE2019-0083) and relevant Catholic school committees. Results will be presented
      to schools and findings disseminated via peer-reviewed journals and scientific
      conferences. This will be the first evaluation of an eHealth intervention,
      spanning both universal and selective prevention, to simultaneously target six
      key lifestyle risk factors among adolescents. TRIAL REGISTRATION NUMBER:
      Australian New Zealand Clinical Trials Registry (ACTRN12619000431123), 18 March
      2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Teesson, Maree
AU  - Teesson M
AUID- ORCID: 0000-0002-6744-463X
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Champion, Katrina E
AU  - Champion KE
AUID- ORCID: 0000-0001-8319-9366
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia
      katrina.champion@sydney.edu.au.
FAU - Newton, Nicola C
AU  - Newton NC
AUID- ORCID: 0000-0001-6305-2623
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Kay-Lambkin, Frances
AU  - Kay-Lambkin F
AUID- ORCID: 0000-0002-4252-5572
AD  - Priority Research Centre for Brain and Mental Health, The University of Newcastle
      Faculty of Health and Medicine, Callaghan, New South Wales, Australia.
FAU - Chapman, Cath
AU  - Chapman C
AUID- ORCID: 0000-0002-2460-6862
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Thornton, Louise
AU  - Thornton L
AUID- ORCID: 0000-0001-7705-833X
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Slade, Tim
AU  - Slade T
AUID- ORCID: 0000-0002-1725-9188
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Sunderland, Matthew
AU  - Sunderland M
AUID- ORCID: 0000-0001-8452-364X
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Mills, Katherine
AU  - Mills K
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Gardner, Lauren A
AU  - Gardner LA
AUID- ORCID: 0000-0002-8592-6691
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Parmenter, Belinda
AU  - Parmenter B
AUID- ORCID: 0000-0001-8013-5658
AD  - Department of Exercise Physiology, University of NSW, Sydney, New South Wales,
      Australia.
FAU - Lubans, David R
AU  - Lubans DR
AUID- ORCID: 0000-0002-0204-8257
AD  - School of Education, University of Newcastle, Newcastle, New South Wales,
      Australia.
FAU - Hides, Leanne
AU  - Hides L
AUID- ORCID: 0000-0002-4550-8460
AD  - School of Psychology, University of Queensland, Brisbane, Queensland, Australia.
FAU - McBride, Nyanda
AU  - McBride N
AUID- ORCID: 0000-0003-1714-6631
AD  - National Drug Research Institute, Curtin University, Perth, Western Australia,
      Australia.
FAU - Allsop, Steve
AU  - Allsop S
AD  - National Drug Research Institute, Curtin University, Perth, Western Australia,
      Australia.
FAU - Spring, Bonnie J
AU  - Spring BJ
AUID- ORCID: 0000-0003-0692-9868
AD  - Preventive Medicine, Northwestern University Feinberg School of Medicine,
      Chicago, Illinois, USA.
FAU - Smout, Scarlett
AU  - Smout S
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Osman, Bridie
AU  - Osman B
AD  - The Matilda Centre for Research in Mental Health and Substance Use, The
      University of Sydney, Sydney, New South Wales, Australia.
CN  - Health4Life Team
LA  - eng
SI  - ANZCTR/ACTRN12619000431123
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200713
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Australia
MH  - Child
MH  - *Clinical Protocols
MH  - Cluster Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - *Risk Reduction Behavior
MH  - Schools/organization & administration
MH  - Students/*psychology/statistics & numerical data
MH  - Telemedicine/methods/*standards
PMC - PMC7359380
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *mental health
OT  - *nutrition & dietetics
OT  - *preventive medicine
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: None declared.
IR  - Barrett EL
FIR - Barrett, Emma L
IR  - Mewton L
FIR - Mewton, Louise
IR  - Stapinski L
FIR - Stapinski, Lexine
IR  - Birrell L
FIR - Birrell, Louise
EDAT- 2020/07/16 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035662 [pii]
AID - 10.1136/bmjopen-2019-035662 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 13;10(7):e035662. doi: 10.1136/bmjopen-2019-035662.


PMID- 32665342
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 13
TI  - Health of mothers of children with a life-limiting condition: a protocol for
      comparative cohort study using the Clinical Practice Research Datalink.
PG  - e034024
LID - 10.1136/bmjopen-2019-034024 [doi]
AB  - INTRODUCTION: There are now nearly 50 000 children with a life-limiting or
      life-threatening condition in the UK. These include conditions where there is no 
      reasonable hope of cure and from which they will die, as well as conditions for
      which curative treatment may be feasible but can fail, for example, cancer or
      heart failure. Having a child with a life-limiting condition involves being a
      coordinator and provider of healthcare in addition to the responsibilities and
      pressures of parenting a child who is expected to die young. This adversely
      affects the health and well-being of these mothers and affects their ability to
      care for their child, but the extent of the impact is poorly understood.This
      study aims to quantify the incidence and nature of mental and physical morbidity 
      in mothers of children with a life-limiting condition, their healthcare use and
      to assess whether there is a relationship between the health of the mother and
      the child's condition. METHODS AND ANALYSIS: A comparative cohort study using
      data from the Clinical Practice Research Datalink and linked hospital data will
      include three groups of children and their mothers (those with a life-limiting
      condition, those with a chronic condition and those with no long-term health
      condition total=20 000 mother-child dyads). Incidence rates and incidence rate
      ratios will be used to quantify and compare the outcomes between groups with
      multivariable regression modelling used to assess the relationship between the
      child's disease trajectory and mother's health. ETHICS AND DISSEMINATION: This
      study protocol has approval from the Independent Scientific Advisory Committee
      for the UK Medicines and Healthcare products Regulatory Agency Database Research.
      The results of this study will be reported according to the STROBE and RECORD
      guidelines. There will also be a lay summary for parents which will be available 
      to download from the Martin House Research Centre website (www.york.ac.uk/mhrc).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fraser, Lorna Katharine
AU  - Fraser LK
AUID- ORCID: 0000-0002-1360-4191
AD  - Health Sciences, University of York, York, North Yorkshire, UK
      lorna.fraser@york.ac.uk.
FAU - Murtagh, Fliss E M
AU  - Murtagh FEM
AD  - Wolfson Palliative Care Research Centre, Hull York Medical School, University of 
      Hull, Hull, UK.
FAU - Sheldon, Trevor
AU  - Sheldon T
AD  - Health Sciences, University of York, York, North Yorkshire, UK.
FAU - Gilbody, Simon
AU  - Gilbody S
AD  - Health Sciences, University of York, York, North Yorkshire, UK.
FAU - Hewitt, Catherine
AU  - Hewitt C
AD  - Health Sciences, University of York, York, North Yorkshire, UK.
LA  - eng
GR  - CDF-2018-11-ST2-002/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200713
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Chronic Disease
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - *Mothers
MH  - *Parenting
MH  - Parents
PMC - PMC7359378
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *life-limiting
OT  - *maternal health
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034024 [pii]
AID - 10.1136/bmjopen-2019-034024 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 13;10(7):e034024. doi: 10.1136/bmjopen-2019-034024.


PMID- 32665255
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Reed on expressivism at the end of life: a bridge too far.
PG  - 552
LID - 10.1136/medethics-2020-106533 [doi]
FAU - Malek, Janet
AU  - Malek J
AUID- ORCID: 0000-0003-1299-9803
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      TX 77030, USA janet.malek@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200714
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Aug;46(8):538-544. PMID: 32611620
CIN - J Med Ethics. 2020 Aug;46(8):553. PMID: 32675296
MH  - *Death
MH  - Humans
OTO - NOTNLM
OT  - *disabilities
OT  - *end-of-life
OT  - *ethics
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - medethics-2020-106533 [pii]
AID - 10.1136/medethics-2020-106533 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):552. doi: 10.1136/medethics-2020-106533. Epub 2020
      Jul 14.


PMID- 32665254
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210526
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Genetic testing in the acute setting: a round table discussion.
PG  - 533
LID - 10.1136/medethics-2020-106104 [doi]
FAU - Newman, William G
AU  - Newman WG
AUID- ORCID: 0000-0002-6382-4678
AD  - Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK 
      william.newman@manchester.ac.uk.
LA  - eng
GR  - II-LB-0417-20002/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200714
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Aug;46(8):531-532. PMID: 32651253
CIN - J Med Ethics. 2021 Feb;47(2):114-116. PMID: 33208480
MH  - *Ethics, Medical
MH  - *Genetic Testing
MH  - Humans
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/16 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - medethics-2020-106104 [pii]
AID - 10.1136/medethics-2020-106104 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):533. doi: 10.1136/medethics-2020-106104. Epub 2020
      Jul 14.


PMID- 32665034
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 14
TI  - Effect of intraoperative dexmedetomidine infusion on delirium in adult patients
      following cardiac valve surgery: a protocol of a randomized, double-blinded, and 
      placebo-controlled study.
PG  - 645
LID - 10.1186/s13063-020-04574-x [doi]
AB  - BACKGROUND: Delirium is an acute status of brain dysfunction that commonly occurs
      in patients who have undergone cardiac surgery, and increases morbidity and
      mortality. It is associated with risk factors, such as older age, use of
      narcotics, cardiopulmonary bypass, and hypothermia. Dexmedetomidine infusion
      might exert a neuroprotective effect. However, the effect of perioperative
      administration of dexmedetomidine on the incidence of postoperative delirium
      (POD) in patients undergoing cardiac or non-cardiac surgery is yet controversial.
      The present study aimed to reveal the effect of intraoperative dexmedetomidine
      administration on the incidence of delirium in adult patients following cardiac
      surgery. METHODS: This single-center, randomized, double-blinded, and
      placebo-controlled trial consisted of 652 patients randomly divided into two
      groups: dexmedetomidine and placebo. 0.6 mug/kg dexmedetomidine will be infused
      10 min after central vein catheterization, followed by a continuous infusion at a
      speed of 0.4 mug/kg/h until the end of surgery in the dexmedetomidine group,
      while normal saline will be administered at the same rate in the placebo group.
      The primary outcome is the incidence of POD during the first 7 days post-surgery.
      The secondary outcomes include duration of mechanical ventilation after surgery, 
      duration of stay in the intensive care unit and the hospital after surgery,
      incidence of hypotension during or after dexmedetomidine infusion, acute kidney
      injury and sudden arrhythmia during the hospital stay postoperatively, and
      all-cause mortality in 30 and 90 days after surgery, respectively. DISCUSSION:
      This study was approved by the Ethics Committee of the Chinese Academy of Medical
      Sciences Fuwai Hospital on 6 March 2019 (2019-1180). The results will be
      disseminated at academic conferences and submitted to peer-reviewed publications.
      Either positive or negative results will provide guidance for clinical practice. 
      TRIAL REGISTRATION: The Chinese Clinical Trial Registry (
      http://www.chictr.org.cn ) ChiCTR1900022583. Registered on 17 April 2019.
FAU - Wang, Hong-Bai
AU  - Wang HB
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng
      District, Beijing, China.
FAU - Zhang, Liang
AU  - Zhang L
AD  - Department of Anesthesiology, Chongqing Traditional Chinese Medicine Hospital,
      Chongqing, No. 6, 7 Branch Road, Panxi, Jiangbei District, Chongqing, China.
FAU - Zhang, Zhe
AU  - Zhang Z
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng
      District, Beijing, China.
FAU - Yuan, Su
AU  - Yuan S
AUID- ORCID: http://orcid.org/0000-0001-8601-6051
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng
      District, Beijing, China. fuwaiys@126.com.
FAU - Yan, Fu-Xia
AU  - Yan FX
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng
      District, Beijing, China.
FAU - Luo, Qi-Peng
AU  - Luo QP
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, Beijing, No. 167 North Lishi Road, Xicheng
      District, Beijing, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200714
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Neuroprotective Agents)
RN  - 67VB76HONO (Dexmedetomidine)
SB  - IM
MH  - Adult
MH  - *Cardiac Surgical Procedures/adverse effects
MH  - Delirium/diagnosis/*prevention & control
MH  - Dexmedetomidine/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Heart Valves
MH  - Humans
MH  - Neuroprotective Agents/*therapeutic use
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - Stroke Volume
MH  - Ventricular Function, Left
PMC - PMC7362632
OTO - NOTNLM
OT  - Adult
OT  - Cardiac valve surgery
OT  - Delirium
OT  - Dexmedetomidine
EDAT- 2020/07/16 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.1186/s13063-020-04574-x [doi]
AID - 10.1186/s13063-020-04574-x [pii]
PST - epublish
SO  - Trials. 2020 Jul 14;21(1):645. doi: 10.1186/s13063-020-04574-x.


PMID- 32664943
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 14
TI  - Pre- and during-labour predictors of low birth satisfaction among Iranian women: 
      a prospective analytical study.
PG  - 408
LID - 10.1186/s12884-020-03105-5 [doi]
AB  - BACKGROUND: Maternal childbirth dissatisfaction has short- and long-term negative
      effects on the mothers' health and life, as well as on relation with her child
      and family. Due to lack of studies in Iran and other counties, we aimed to
      determine pre- and during- labour predictors of low birth satisfaction. METHODS: 
      Seven hundred women with low risk singleton pregnancy participated in this
      prospective analytical study. The participants were hospitalized for vaginal
      delivery with fetus in cephalic presentation and gestational age of 37(0)-41(6)
      at two teaching centers in Tabriz (Iran). Woman characteristics, anxiety state
      (using Spielberger inventory) and dehydration were assessed at cervical
      dilatation of 4-6 cm. Iranian (Persian) birth satisfaction scale-revised was
      applied 12-24 h after birth. Multiple linear regression was used to determine the
      predictors. RESULTS: Excluding 26 women who were outliers, 674 women were
      analyzed. The mean birth satisfaction score was 23.8 (SD 6.5) from an attainable 
      score of 0-40. The during-labour predictors of low birth satisfaction score were 
      severe and moderate anxiety, labour dystocia, insufficient support by staff,
      vaginal birth with episiotomy and tear, emergency cesarean section, labour
      induction and labour augmentation with oxytocin, and woman dehydration. The
      pre-labour predictors included being primiparous, sexual and emotional violence
      during pregnancy, gestational age of 40(0)-41(6), preference for cesarean
      section, no attendance at pregnancy classes, and insufficient household income.
      The proportion of the variance explained by the during-labour variables was 75%, 
      by pre-labour variables was 14% and by overall was 76%. CONCLUSIONS: The
      controllable during-labour predictors explains most of the variance of the
      satisfaction score. It seems that responding to women's physical and
      psychological needs during labour and applying less interventions could improve
      women's childbirth satisfaction.
FAU - Nahaee, Jila
AU  - Nahaee J
AD  - Students' Research Committee, Faculty of Nursing and Midwifery, Tabriz University
      of Medical Sciences, Tabriz, Iran.
FAU - Mohammad-Alizadeh-Charandabi, Sakineh
AU  - Mohammad-Alizadeh-Charandabi S
AUID- ORCID: https://orcid.org/0000-0003-4785-9333
AD  - Social Determinants of Health Research Center, Department of Midwifery, Faculty
      of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.
      alizades@tbzmed.ac.ir.
FAU - Abbas-Alizadeh, Fatemeh
AU  - Abbas-Alizadeh F
AD  - Women's Reproductive Health Research CenterTabriz University of Medical Sciences,
      Tabriz, Iran.
FAU - Martin, Colin R
AU  - Martin CR
AD  - Institute for Clinical and Applied Health Research (ICAHR), University of Hull,
      Hull, UK.
FAU - Hollins Martin, Caroline J
AU  - Hollins Martin CJ
AD  - School of Health, Edinburgh Napier University, Edinburgh, UK.
FAU - Mirghafourvand, Mojgan
AU  - Mirghafourvand M
AD  - Department of Midwifery, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Tabriz, Iran.
FAU - Hassankhani, Hadi
AU  - Hassankhani H
AD  - Department of Medical and Surgical Nursing, Faculty of Nursing and Midwifery,
      Tabriz University of Medical Sciences, Tabriz, Iran.
LA  - eng
GR  - 60153/Vice-Chancellor for Research, Tabriz University of Medical Sciences (IR)
PT  - Journal Article
DEP - 20200714
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adult
MH  - Anxiety
MH  - Dehydration/psychology
MH  - Delivery, Obstetric/psychology
MH  - Dystocia/psychology
MH  - Female
MH  - Humans
MH  - Iran
MH  - Labor, Obstetric/*psychology
MH  - Obstetric Labor Complications/*psychology
MH  - Parturition/*psychology
MH  - Patient Satisfaction/*statistics & numerical data
MH  - Pregnancy
MH  - Prospective Studies
MH  - Young Adult
PMC - PMC7362575
OTO - NOTNLM
OT  - Childbirth
OT  - Ethical code: IR.TBZMED.REC.1397.624.
OT  - Iran
OT  - Labour
OT  - Predictors
OT  - Risk factors
OT  - Satisfaction
EDAT- 2020/07/16 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 10.1186/s12884-020-03105-5 [doi]
AID - 10.1186/s12884-020-03105-5 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Jul 14;20(1):408. doi: 10.1186/s12884-020-03105-5.


PMID- 32664908
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20210910
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 15
TI  - Bin it or pin it? Which professional ethical guidance on managing COVID-19 should
      I follow?
PG  - 60
LID - 10.1186/s12910-020-00491-5 [doi]
AB  - BACKGROUND: As the COVID-19 (coronavirus) pandemic develops, healthcare
      professionals are looking for support with, and guidance to inform, the difficult
      decisions they face. In the (current) absence of an authoritative national steer 
      in England, professional bodies and local organisations have been developing and 
      disseminating their own ethical guidance. Questions inevitably arise, some of
      which are particularly pressing during the pandemic, as events are unfolding
      quickly and the field is becoming crowded. My central question here is: which
      professional ethical guidance should the professional follow? MAIN BODY: Adopting
      a working definition of "professional ethical guidance", I offer three domains
      for a healthcare professional to consider, and some associated questions to ask, 
      when determining whether - in relation to any guidance document - they should
      "bin it or pin it". First, the professional should consider the source of the
      guidance: is the issuing body authoritative or, if not, at least sufficiently
      influential that its guidance should be followed? Second, the professional should
      consider the applicability of the guidance, ascertaining whether the guidance is 
      available and, if so, whether it is pertinent. Pertinence has various dimensions,
      including whether the guidance applies to this professional, this patient and/or 
      this setting, whether it is up-to-date, and whether the guidance addresses the
      situation the professional is facing. Third, the professional should consider the
      methodology and methods by which the guidance was produced. Although the
      substantive quality of the guidance is important, so too are the methods by which
      it was produced. Here, the professional should ask whether the guidance is
      sufficiently inclusive - in terms of who has prepared it and who contributed to
      its development - and whether it was rigorously developed, and thus utilised
      appropriate processes, principles and evidence. CONCLUSION: Asking and answering 
      such questions may be challenging, particularly during a pandemic. Furthermore,
      guidance will not do all the work: professionals will still need to exercise
      their judgment in deciding what is best in the individual case, whether or not
      this concerns COVID-19. But such judgments can and should be informed (and
      constrained) by guidance, and hopefully these preliminary observations will
      provide some useful pointers for time-pressed professionals.
FAU - Huxtable, Richard
AU  - Huxtable R
AUID- ORCID: 0000-0002-5802-1870
AD  - Centre for Ethics in Medicine, Population Health Sciences, Bristol Medical
      School, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
      R.Huxtable@bristol.ac.uk.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 209841/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200715
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Codes of Ethics
MH  - *Coronavirus Infections
MH  - *Ethics, Medical
MH  - Health Personnel/*ethics
MH  - Health Services Research
MH  - Humans
MH  - *Pandemics/ethics
MH  - *Pneumonia, Viral
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
PMC - PMC7360377
OTO - NOTNLM
OT  - *COVID-19
OT  - *Coronavirus
OT  - *Ethical guidance
OT  - *Professional guidance
EDAT- 2020/07/16 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 10.1186/s12910-020-00491-5 [doi]
AID - 10.1186/s12910-020-00491-5 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 15;21(1):60. doi: 10.1186/s12910-020-00491-5.


PMID- 32664904
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 14
TI  - Ethical perceptions towards real-world use of companion robots with older people 
      and people with dementia: survey opinions among younger adults.
PG  - 244
LID - 10.1186/s12877-020-01641-5 [doi]
AB  - BACKGROUND: Use of companion robots may reduce older people's depression,
      loneliness and agitation. This benefit has to be contrasted against possible
      ethical concerns raised by philosophers in the field around issues such as
      deceit, infantilisation, reduced human contact and accountability. Research
      directly assessing prevalence of such concerns among relevant stakeholders,
      however, remains limited, even though their views clearly have relevance in the
      debate. For example, any discrepancies between ethicists and stakeholders might
      in itself be a relevant ethical consideration while concerns perceived by
      stakeholders might identify immediate barriers to successful implementation.
      METHODS: We surveyed 67 younger adults after they had live interactions with
      companion robot pets while attending an exhibition on intimacy, including the
      context of intimacy for older people. We asked about their perceptions of ethical
      issues. Participants generally had older family members, some with dementia.
      RESULTS: Most participants (40/67, 60%) reported having no ethical concerns
      towards companion robot use when surveyed with an open question. Twenty (30%) had
      some concern, the most common being reduced human contact (10%), followed by
      deception (6%). However, when choosing from a list, the issue perceived as most
      concerning was equality of access to devices based on socioeconomic factors (m = 
      4.72 on a scale 1-7), exceeding more commonly hypothesized issues such as
      infantilising (m = 3.45), and deception (m = 3.44). The lowest-scoring issues
      were potential for injury or harm (m = 2.38) and privacy concerns (m = 2.17).
      Over half (39/67 (58%)) would have bought a device for an older relative. Cost
      was a common reason for choosing not to purchase a device. CONCLUSIONS: Although 
      a relatively small study, we demonstrated discrepancies between ethical concerns 
      raised in the philosophical literature and those likely to make the decision to
      buy a companion robot. Such discrepancies, between philosophers and 'end-users'
      in care of older people, and in methods of ascertainment, are worthy of further
      empirical research and discussion. Our participants were more concerned about
      economic issues and equality of access, an important consideration for those
      involved with care of older people. On the other hand the concerns proposed by
      ethicists seem unlikely to be a barrier to use of companion robots.
FAU - Bradwell, Hannah L
AU  - Bradwell HL
AUID- ORCID: 0000-0002-9103-1069
AD  - Center for Health Technology, University of Plymouth, Plymouth, Devon, UK.
      hannah.bradwell@plymouth.ac.uk.
FAU - Winnington, Rhona
AU  - Winnington R
AUID- ORCID: 0000-0002-2963-3421
AD  - Department of Nursing, Auckland University of Technology, 90 Akoranga Drive,
      Auckland, New Zealand.
FAU - Thill, Serge
AU  - Thill S
AUID- ORCID: 0000-0003-1177-4119
AD  - Donders Centre for Cognition, Radboud University, Nijmegen, 6525, HR, The
      Netherlands.
FAU - Jones, Ray B
AU  - Jones RB
AUID- ORCID: 0000-0002-6504-2856
AD  - Center for Health Technology, University of Plymouth, Plymouth, Devon, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Attitude
MH  - *Dementia
MH  - Humans
MH  - Perception
MH  - *Robotics
MH  - Surveys and Questionnaires
PMC - PMC7359562
OTO - NOTNLM
OT  - *Aged care
OT  - *Companion robots
OT  - *Gerontology
OT  - *Health and social care
OT  - *Machine ethics
OT  - *Older people
OT  - *Robot ethics
OT  - *Social robots
OT  - *Stakeholders
EDAT- 2020/07/16 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12877-020-01641-5 [doi]
AID - 10.1186/s12877-020-01641-5 [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Jul 14;20(1):244. doi: 10.1186/s12877-020-01641-5.


PMID- 32664841
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1875-6506 (Electronic)
IS  - 1573-4021 (Linking)
VI  - 16
IP  - 3
DP  - 2020
TI  - Artificial Intelligence and Medicine: History, Current State, and Forecasts for
      the Future.
PG  - 210-215
LID - 10.2174/1573402116666200714150953 [doi]
AB  - This article traces the history of the development of artificial intelligence as 
      a science that constantly responds to current problems that arise in medical
      practice. Attention is drawn to the fact that almost all modern neural systems of
      medical diagnostics are static. This means that they do not have a time axis, and
      therefore, can only make diagnoses of diseases at the current time. As a result, 
      doctors have to make prescriptions for prevention and treatment courses without
      checking on computer models what this may lead to in the future. Thus,
      consciously or unconsciously, doctors have to experiment on patients, which is an
      ethical problem. This article shows that this centuriesold ethical problem can be
      solved by further development and application of modern methods of artificial
      intelligence. Optimal selection of prevention and treatment courses can be made
      by virtual predictive experimentation on dynamic computer models of patients.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Yasnitsky, Leonid N
AU  - Yasnitsky LN
AD  - Perm State University, 15, Bukirev Street, 614600 Perm, Russian Federation.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Hypertens Rev
JT  - Current hypertension reviews
JID - 101239891
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *bioethics.
OT  - *diagnostics
OT  - *forecasting
OT  - *neural network
OT  - *virtual computer experiments
EDAT- 2020/07/16 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/01/19 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - CHYR-EPUB-108174 [pii]
AID - 10.2174/1573402116666200714150953 [doi]
PST - ppublish
SO  - Curr Hypertens Rev. 2020;16(3):210-215. doi: 10.2174/1573402116666200714150953.


PMID- 32664786
OWN - NLM
STAT- MEDLINE
DCOM- 20220411
LR  - 20220411
IS  - 1361-6609 (Electronic)
IS  - 0963-6625 (Linking)
VI  - 29
IP  - 7
DP  - 2020 Oct
TI  - A deliberative study of public attitudes towards sharing genomic data within NHS 
      genomic medicine services in England.
PG  - 702-717
LID - 10.1177/0963662520942132 [doi]
AB  - Whole genome (DNA) sequencing is becoming part of routine care healthcare in
      England. Genomic data are most useful when pooled with other patients' data,
      meaning that clinicians may need to share data to effectively treat patients. We 
      ran deliberative focus groups to explore views among 44 patients and members of
      the public about proposals for wider genomic data sharing for clinical care.
      Participants were briefed about genomic medicine and engaged in group and
      individual exercises to deliberate on the benefits and risks of using genomic
      data. Findings showed that participants supported wider sharing of genomic data
      within health services and naturally linked care and research activities.
      Nonetheless, they were concerned about managing flows of information to protect
      patient confidentiality and guard against unauthorised uses, now and over the
      long-term. Ongoing conversations with the public are needed to determine
      appropriate uses of genomic data and safeguards to inform service development.
FAU - Hassan, Lamiece
AU  - Hassan L
AUID- ORCID: 0000-0002-5888-422X
AD  - The University of Manchester, UK.
FAU - Dalton, Ann
AU  - Dalton A
FAU - Hammond, Carrie
AU  - Hammond C
AD  - Sheffield Children's NHS Foundation Trust, UK.
FAU - Tully, Mary Patricia
AU  - Tully MP
AUID- ORCID: 0000-0003-2100-3983
AD  - The University of Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200715
PL  - England
TA  - Public Underst Sci
JT  - Public understanding of science (Bristol, England)
JID - 9306503
MH  - Attitude
MH  - Confidentiality
MH  - *Genomic Medicine
MH  - Genomics
MH  - Humans
MH  - *State Medicine
PMC - PMC7539600
OTO - NOTNLM
OT  - *data sharing
OT  - *ethics
OT  - *genetic testing
OT  - *public understanding of science
OT  - *qualitative research
EDAT- 2020/07/16 06:00
MHDA- 2022/04/12 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2022/04/12 06:00 [medline]
PHST- 2020/07/16 06:00 [entrez]
AID - 10.1177/0963662520942132 [doi]
PST - ppublish
SO  - Public Underst Sci. 2020 Oct;29(7):702-717. doi: 10.1177/0963662520942132. Epub
      2020 Jul 15.


PMID- 32664567
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 11
TI  - Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of
      Aldiamed((R)) Versus Placebo.
LID - E2196 [pii]
LID - 10.3390/jcm9072196 [doi]
AB  - Xerostomia is a symptom frequently present in patients with type 1 (T1DM) and
      type 2 diabetes mellitus (T2DM). In the present trial, the activity of an
      artificial saliva (aldiamed((R)) spray) in comparison to a placebo spray were
      used to evaluate the xerostomia and the saliva antioxidant capacity (SAT). Sixty 
      patients of both genders with T1DM or T2DM were randomized into two groups of 30 
      subjects each. The experiment was a double-blind study approved by the Ethics
      Committee of the "G. d'Annunzio University" of Chieti and Pescara. Moreover,
      measurements of the stimulated saliva flow rate and the ultrasonography of the
      submandibular and parotid glands were performed at both the study time points.
      The results demonstrated statistically significant differences between the
      treatments in terms of the xerostomia average score. Specifically, the values
      were at baseline and after 30 days 2.9 +/- 1.31 and 3.0 +/- 1.44 and 1.4 +/- 1.48
      and 2.4 +/- 0.99 for aldiamed((R)) spray and the placebo, respectively.
      Meanwhile, no statistically significant differences were shown between the two
      groups for the other variables, such as the salivary flow rate, the antioxidant
      capacity of the saliva, and the ultrasonography of the major salivary glands.
FAU - Sinjari, Bruna
AU  - Sinjari B
AUID- ORCID: 0000-0002-4444-3343
AD  - Department of Medical, Oral and Biotechnological Sciences, University "G.
      d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Feragalli, Beatrice
AU  - Feragalli B
AUID- ORCID: 0000-0002-6222-024X
AD  - Department of Medical, Oral and Biotechnological Sciences, University "G.
      d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Cornelli, Umberto
AU  - Cornelli U
AD  - Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60611, USA.
FAU - Belcaro, Giovanni
AU  - Belcaro G
AD  - Irwin Labs, University of Chieti, 65010 Spoltore, Italy.
FAU - Vitacolonna, Ester
AU  - Vitacolonna E
AUID- ORCID: 0000-0003-1756-661X
AD  - Department of Medicine and Aging Sciences, University "G. d'Annunzio" of
      Chieti-Pescara, 66100 Chieti, Italy.
FAU - Santilli, Manlio
AU  - Santilli M
AUID- ORCID: 0000-0003-3833-1908
AD  - Department of Medical, Oral and Biotechnological Sciences, University "G.
      d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Rexhepi, Imena
AU  - Rexhepi I
AD  - Department of Medical, Oral and Biotechnological Sciences, University "G.
      d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - D'Addazio, Gianmaria
AU  - D'Addazio G
AUID- ORCID: 0000-0003-4110-0772
AD  - Department of Medical, Oral and Biotechnological Sciences, University "G.
      d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
FAU - Zuccari, Francesca
AU  - Zuccari F
AD  - Marchegiani Analysis Laboratory, 65122 Pescara, Italy.
FAU - Caputi, Sergio
AU  - Caputi S
AD  - Department of Medical, Oral and Biotechnological Sciences, University "G.
      d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200711
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7408818
OTO - NOTNLM
OT  - aldiamed(R)
OT  - antioxidant capacity of saliva
OT  - salivary flow
OT  - xerostomia
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:01
CRDT- 2020/07/16 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:01 [medline]
AID - jcm9072196 [pii]
AID - 10.3390/jcm9072196 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jul 11;9(7). pii: jcm9072196. doi: 10.3390/jcm9072196.


PMID- 32664277
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 14
DP  - 2020 Jul 10
TI  - The Role of Electrocardiography in Occupational Medicine, from Einthoven's
      Invention to the Digital Era of Wearable Devices.
LID - E4975 [pii]
LID - 10.3390/ijerph17144975 [doi]
AB  - Clinical-instrumental investigations, such as electrocardiography (ECG),
      represent a corollary of a procedures that, nowadays, is called upon as part of
      the principles of precision medicine. However when carrying out the professional 
      routine examinations, most tend to ignore how a "simple" instrument can offer
      indispensable support in clinical practice, even in occupational medicine. The
      advent of the digital age, made of silicon and printed circuit boards, has
      allowed the miniaturization of the electronic components of these electro-medical
      devices. Finally, the adoption of patient wearables in medicine has been rapidly 
      expanding worldwide for a number of years. This has been driven mainly by
      consumers' demand to monitor their own health. With the ongoing research and
      development of new features capable of assessing and transmitting real-time
      biometric data, the impact of wearables on cardiovascular management has become
      inevitable. Despite the potential offered by this technology, as evident from the
      scientific literature, the application of these devices in the field of health
      and safety in the workplace is still limited. This may also be due to the lack of
      targeted scientific research. While offering great potential, it is very
      important to consider and evaluate ethical aspects related to the use of these
      smart devices, such as the management of the collected data relating to the
      physiological parameters and the location of the worker. This technology is to be
      considered as being aimed at monitoring the subject's physiological parameters,
      and not at the diagnosis of any pathological condition, which should always be on
      charge of the medical specialist We conducted a review of the evolution of the
      role that electrophysiology plays as part of occupational health and safety
      management and on its possible future use, thanks to ongoing technological
      innovation.
FAU - Baldassarre, Antonio
AU  - Baldassarre A
AUID- ORCID: 0000-0002-6124-3570
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Mucci, Nicola
AU  - Mucci N
AUID- ORCID: 0000-0003-0579-1035
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Padovan, Martina
AU  - Padovan M
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Pellitteri, Alessia
AU  - Pellitteri A
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Viscera, Silvia
AU  - Viscera S
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Lecca, Luigi Isaia
AU  - Lecca LI
AUID- ORCID: 0000-0001-8310-411X
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
FAU - Galea, Raymond P
AU  - Galea RP
AD  - Postgraduate Training Programme, Mater Dei Hospital, MSD2090 Msida, Malta.
AD  - Faculty of Medicine and Surgery, University of Malta, MSD2090 Msida, Malta.
FAU - Arcangeli, Giulio
AU  - Arcangeli G
AD  - Department of Experimental and Clinical Medicine, University of Florence, 50134
      Florence, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200710
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Electrocardiography
MH  - Humans
MH  - Inventions
MH  - *Occupational Medicine
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - *Wearable Electronic Devices
PMC - PMC7400524
OTO - NOTNLM
OT  - *Internet of things
OT  - *biosensing techniques
OT  - *electrocardiography
OT  - *health promotion
OT  - *health surveillance
OT  - *history of medicine
OT  - *medical informatics
OT  - *occupational health and safety
OT  - *total worker health
OT  - *wearable electronic devices
EDAT- 2020/07/16 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - ijerph17144975 [pii]
AID - 10.3390/ijerph17144975 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jul 10;17(14). pii: ijerph17144975. doi:
      10.3390/ijerph17144975.


PMID- 32664195
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 10
TI  - Improving Translation by Identifying Evidence for More Human-Relevant Preclinical
      Strategies.
LID - E1170 [pii]
LID - 10.3390/ani10071170 [doi]
AB  - Preclinical animal studies are performed to analyse the safety and efficacy of
      new treatments, with the aim to protect humans. However, there are questions and 
      concerns about the quality and usefulness of preclinical animal research.
      Translational success rates vary between 0 and 100%, and no clear relationship
      has been found with possible predictive factors such as animal species or field
      of research. Therefore, it is not yet possible to indicate what factors predict
      successful translation. Translational strategies were therefore discussed at an
      international conference held in the Netherlands in November 2019, aiming to
      develop practical guidelines for more robust animal-to-human translation. The
      conference was organised during the course of a research project funded by the
      Dutch Research Council (313-99-310), addressing possible solutions for the low
      translational values that had been published for a multitude of animal studies in
      human health care. This article provides an overview of the project and the
      conference discussions. Based on the conference results and the findings from the
      research project, we define four points of attention that are crucial in the
      search for improved translational success rates: (a) optimising the methods and
      design of studies; (b) incorporation of the complexity of the human patient in
      research; (c) start with the patient rather than existing animal models as the
      gold standard; and (d) more and better collaboration within the chain from
      funding to pharmacy. We conclude that this requires improved organization and use
      of procedures, as well as a change of attitude and culture in research, including
      a consideration of the translational value of animal-free innovations and
      human-relevant science.
FAU - Ritskes-Hoitinga, Merel
AU  - Ritskes-Hoitinga M
AUID- ORCID: 0000-0001-5315-284X
AD  - SYRCLE, Department for Health Evidence (section HTA), Radboud Institute for
      Health Sciences, Radboud University Medical Centre, 6500 HB Nijmegen, The
      Netherlands.
FAU - Leenaars, Cathalijn
AU  - Leenaars C
AUID- ORCID: 0000-0002-8212-7632
AD  - Unit Animals in Science and Society, Department of Population Health Sciences,
      Faculty of Veterinary Medicine, Utrecht University, 3508 TD Utrecht, The
      Netherlands.
AD  - Institute for Laboratory Animal Science, Hannover Medical School, 30625 Hannover,
      Germany.
FAU - Beumer, Wouter
AU  - Beumer W
AD  - ProQR Therapeutics NV, 2333 CK Leiden, The Netherlands.
FAU - Coenen-de Roo, Tineke
AU  - Coenen-de Roo T
AD  - Central Animal Facility, Leiden University Medical Centre, 2300 RC Leiden, The
      Netherlands.
FAU - Stafleu, Frans
AU  - Stafleu F
AD  - Ethics Institute, Faculty of Humanities, Utrecht University, 3508 TC Utrecht, The
      Netherlands.
FAU - Meijboom, Franck L B
AU  - Meijboom FLB
AD  - Unit Animals in Science and Society, Department of Population Health Sciences,
      Faculty of Veterinary Medicine, Utrecht University, 3508 TD Utrecht, The
      Netherlands.
AD  - Ethics Institute, Faculty of Humanities, Utrecht University, 3508 TC Utrecht, The
      Netherlands.
LA  - eng
GR  - 313-99-310/Dutch Research Council (NWO)
PT  - Congress
DEP - 20200710
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7401546
OTO - NOTNLM
OT  - animal-to-human translation
OT  - ethics
OT  - systematic review
OT  - translational strategies
EDAT- 2020/07/16 06:00
MHDA- 2020/07/16 06:01
CRDT- 2020/07/16 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/07/02 00:00 [revised]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/16 06:01 [medline]
AID - ani10071170 [pii]
AID - 10.3390/ani10071170 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Jul 10;10(7). pii: ani10071170. doi: 10.3390/ani10071170.


PMID- 32664185
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20210112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Tuina (massage) therapy for diarrhea in COVID-19: A protocol for systematic
      review and meta-analysis.
PG  - e21293
LID - 10.1097/MD.0000000000021293 [doi]
AB  - BACKGROUND: In the beginning of December 2019, the novel coronavirus pneumonia
      was first detected in Wuhan, China. Its widespread infectivity and strong
      pathogenicity has posed a great threat to public health, seriously affecting
      social production and life. Accumulating evidence suggests that gastrointestinal 
      symptoms, such as diarrhea, are common among patients with COVID-19. Tuina
      (massage) therapy is 1 of the widely employed complementary and alternative
      medicine interventions in the world. It can act on the subcutaneous muscular
      layer, enhance the local blood circulation and tissue metabolism of the skin,
      thus exert its effects on digestive systems and alleviate aversive diarrhea
      symptoms. This systematic review and meta-analysis will summarize the current
      evidence of tuina (massage) used as an intervention for diarrhea symptoms in
      COVID-19. METHODS: We will search the following electronic databases for
      randomized controlled trials to evaluate the effectiveness and safety of massage 
      therapy in treating exercise-induced fatigue: China National Knowledge
      Infrastructure, Wanfang and Pubmed Database, Cochrane Central Register of
      Controlled Trials, Cumulative Index of Nursing and Allied Health Literature,
      Excerpta Medica database and MEDLINE. Each database will be searched from
      inception to June 2020. The entire process will include study selection, data
      extraction, risk of bias assessment and meta-analyses. RESULTS: This proposed
      study will evaluate the effectiveness and safety of massage therapy for diarrhea 
      symptoms in COVID-19 patients. The outcomes will include the improvement of
      diarrhea symptoms and adverse effect. CONCLUSIONS: This proposed systematic
      review will evaluate the existing evidence on the effectiveness and safety of
      massage therapy for diarrhea symptoms in COVID-19 patients.Dissemination and
      ethics: The results of this review will be disseminated through peer-reviewed
      publication. Because all of the data used in this systematic review and
      meta-analysis has been published, this review does not require ethical approval. 
      Furthermore, all data will be analyzed anonymously during the review process.
FAU - Zhou, Ke-Lin
AU  - Zhou KL
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Dong, Shuo
AU  - Dong S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
FAU - Fu, Guo-Bing
AU  - Fu GB
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
FAU - Cui, Shu-Sheng
AU  - Cui SS
AD  - Beijing Gulou Hospital of Traditional Chinese Medicine, Beijing, China.
FAU - Guo, Sheng
AU  - Guo S
AD  - Dongfang Hospital of Beijing University of Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/complications/physiopathology/therapy
MH  - *Diarrhea/etiology/physiopathology/therapy
MH  - *Fatigue/etiology/prevention & control
MH  - Humans
MH  - Massage/*methods
MH  - Meta-Analysis as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral/complications/physiopathology/therapy
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7360276
EDAT- 2020/07/16 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - 10.1097/MD.0000000000021293 [doi]
AID - 00005792-202007100-00135 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e21293. doi:
      10.1097/MD.0000000000021293.


PMID- 32664154
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - The impact of immune checkpoint inhibitors in patients with chronic lymphocytic
      leukemia (CLL): A protocol for a systematic review and meta-analysis of
      randomized controlled trials.
PG  - e21167
LID - 10.1097/MD.0000000000021167 [doi]
AB  - INTRODUCTION: The global burden of chronic lymphocytic leukemia (CLL) has
      constantly increased over the years, with a current incidence of 3.5 cases per
      100,000 people. Although the conventional drugs used to treat CLL patients have
      been effective treatment failure rate in some of the patients is alarming.
      Therefore, as a result, novel treatment strategies with improved outcomes such as
      the blockade of immune checkpoints have emerged. However, consensus on the
      risk-benefit effects of the using these drugs in patients with CLL is
      controversial and has not been comprehensively evaluated. This systemic review
      and meta-analysis provide a comprehensive synthesis of available data assessing
      adverse events associated with the use of immune checkpoint inhibitors in
      patients with CLL as well as their influence on the overall survival rate.
      METHODS: This protocol for a systematic review and meta-analysis has been
      prepared in accordance with Preferred Reporting Items for Systematic Review and
      Meta-Analysis Protocols 2015 guidelines. A search strategy will be developed
      using medical subject headings words in PubMed search engine with MEDLINE
      database. The search terms will also be adapted for gray literature, Embase, and 
      Cochrane Central Register of Controlled Trials electronic databases. Two
      reviewers (AN and SRN) will independently screen studies, with a third reviewer
      consulted in cases of disagreements using a defined inclusion and exclusion
      criteria. Data items will be extracted using a predefined data extraction sheet. 
      Moreover, the risk of bias and quality of the included studies will be appraised 
      using the Downs and Black checklist and the quality and strengths of evidence
      across selected studies will be assessed using the Grading of Recommendations
      Assessment Development and Evaluation approach. The Cochran's Q statistic and the
      I statistics will be used to analyze statistical heterogeneity across studies. If
      the included studies show substantial level of statistical heterogeneity (I >
      50%), a random-effects meta-analysis will be performed using R statistical
      software. ETHICS AND DISSEMINATION: The review and meta-analysis will not require
      ethical approval and the findings will be published in peer-reviewed journals and
      presented at local and international conferences. This review may help provide
      clarity on the risk-benefit effects of using immune checkpoint inhibitors in
      patients with CLL. SYSTEMATIC REVIEW REGISTRATION: International prospective
      Register of Systematic Reviews (PROSERO) number: CRD42020156926.
FAU - Ntsethe, Aviwe
AU  - Ntsethe A
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health
      Sciences, University of KwaZulu-Natal, Durban, South Africa.
FAU - Dludla, Phiwayinkosi Vusi
AU  - Dludla PV
AD  - Department of Life and Environmental Sciences, Polytechnic University of Marche, 
      Ancona, Italy.
AD  - Biomedical Research and Innovation Platform, South African Medical Research
      Council, Tygerberg, South Africa.
FAU - Nyambuya, Tawanda Maurice
AU  - Nyambuya TM
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health
      Sciences, University of KwaZulu-Natal, Durban, South Africa.
AD  - Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia
      University of Science and Technology, Windhoek, Namibia.
FAU - Ngcobo, Siphamandla Raphael
AU  - Ngcobo SR
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health
      Sciences, University of KwaZulu-Natal, Durban, South Africa.
FAU - Nkambule, Bongani Brian
AU  - Nkambule BB
AUID- ORCID: 0000-0001-8846-1992
AD  - School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health
      Sciences, University of KwaZulu-Natal, Durban, South Africa.
LA  - eng
GR  - D43 TW010131/TW/FIC NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents, Immunological)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Female
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/mortality
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Survival Analysis
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7360255
EDAT- 2020/07/16 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 10.1097/MD.0000000000021167 [doi]
AID - 00005792-202007100-00104 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e21167. doi:
      10.1097/MD.0000000000021167.


PMID- 32664124
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Safety and efficacy of plasma exchange for the treatment of optic neuritis in
      neuromyelitis optica spectrum disorders: A protocol for systematic review and
      meta-analysis.
PG  - e21067
LID - 10.1097/MD.0000000000021067 [doi]
AB  - BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory
      and heterogeneous astrocyte disorder of the central nervous system (CNS),
      concerned because of its high pathogenicity, high risk of recurrence, and poor
      prognosis. Optic neuritis (ON) is the first manifestation in 30% to 50% of NMOSD 
      patients, and eventually involved optic nerve in 70% of patients. The idiopathic 
      ON associated with NMO is called NMO-associated ON(NMO-ON). There are substantial
      costs to the countries and individuals associated with treatment of NMO-ON.
      Intravenous corticosteroids (IVCSs), as the first-line therapy, leads to
      unsatisfactory outcomes for NMO-ON and is associated with potential adverse
      events (AEs). Emerging evidences have proved the important value and potential
      prospect of plasma exchange (PLEX) in NMO-ON. Although PLEX is increasingly used 
      in NMO-ON, its therapeutic effect and safety are still controversial. There are
      no systematic reviews yet that evaluated the effects of PLEX against other
      therapies in patients with NMO-NO. It is therefore timely to perform a systematic
      review to assess the efficacy and safety of PLEX on current research for its
      potential use in clinical practice in treating NMO-ON. METHODS: The systematic
      review will include all of the randomized controlled trials (RCT) on the efficacy
      and safety of PLEX for NMO-ON. A relevant literature search by sensitive search
      strategies was conducted using the following electronic databases from their
      inception to November 30, 2019: PubMed, Web of Science, EMBASE, the Cochrane
      Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China 
      Science and Technology Journal database (VIP) and CBM. We will also search
      registers of clinical trials, potential gray literature, and conference
      abstracts. There are no limits on language and publication status. The literature
      screening, data extraction, and quality assessment will be conducted by 2
      reviewers independently. The reporting quality and risk of bias will be assessed 
      by other 2 researchers. Best-corrected visual acuity (BCVA), annualized relapse
      rate (ARR), the frequency and extent of adverse events (AEs) will be evaluated as
      the primary outcome. The secondary outcomes will include expanded disability
      status scales (EDSS), relapse-free rate, peri-papillary retinal nerve fibers
      layer (pRNFL) or macular volume, visual electrophysiology examinations, standard 
      automated perimetry examinations, time to the next attack. Meta-analysis will be 
      performed using RevMan5.3 software provided by the Cochrane Collaboration and
      Stata 12.0. RESULTS: This study will provide a comprehensive review based on
      current evidence of PLEX treatment for NMO-ON in several aspects, including BCVA,
      ARR, the frequency and extent of adverse events (AEs), EDSS, relapse-free rate,
      etc. CONCLUSION:: The conclusion of this study will provide evidence to determine
      whether PLEX is an effective and safe intervention for patients with NMO-ON.
      ETHICS AND DISSEMINATION: It is not necessary to obtain ethical approval for this
      study, given that this protocol is for a systematic review. The systematic review
      will be published in a peer-reviewed journal, presented at conferences and will
      be shared on social media platforms. PROSPERO REGISTRATION NUMBER: PROSPERO CRD
      42020162585.
FAU - Han, Mengyu
AU  - Han M
AUID- ORCID: 0000-0003-2342-268
AD  - Graduate School, Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Chen, You
AU  - Chen Y
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Nong, Luqi
AU  - Nong L
AD  - Graduate School, Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Liu, Ziqiang
AU  - Liu Z
AD  - Graduate School, Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Hao, Lu
AU  - Hao L
AD  - Science and education Department, Shenzhen Baoan Shiyan People's Hospital,
      Shenzhen.
FAU - Wang, Zhijun
AU  - Wang Z
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Neuromyelitis Optica/therapy
MH  - Optic Neuritis/*therapy
MH  - Plasma Exchange/*methods
MH  - Recurrence
MH  - *Research Design
MH  - Severity of Illness Index
MH  - Visual Acuity
PMC - PMC7360232
EDAT- 2020/07/16 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000021067 [doi]
AID - 00005792-202007100-00074 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e21067. doi:
      10.1097/MD.0000000000021067.


PMID- 32664114
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Comparative efficacy of Chinese herbal injections combined with GP regimen
      chemotherapy for patients with advanced NSCLC: A protocol for systematic review
      and network meta-analysis.
PG  - e21041
LID - 10.1097/MD.0000000000021041 [doi]
AB  - BACKGROUND: Many research has indicated that some Chinese herb injections (CHIs) 
      might be beneficial in combination with chemotherapy, however, with inconsistent 
      results. Hence, the purpose of this network meta-analysis is to evaluate
      different CHIs plus cisplatin and gemcitabine (GP) with GP alone in terms of
      clinical efficacy and safety for treating patients with advanced NSCLC. METHODS: 
      A comprehensive systematic search of clinical randomized controlled trials (RCTs)
      published in the PubMed, Embase, Web of Science (ISI), Cochrane Central Register 
      of Controlled Trials (CENTRAL), China National Knowledge Infrastructure Database 
      (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Database
      and China Biological Medicine Database (CBM) databases will be conducted to
      identify eligible studies up to the date of May 2020. The primary outcome
      measures objective response rate and adverse reactions (nausea and vomiting,
      leukopenia). The secondary outcome measures median survival time (MST), disease
      control rate, and quality of life. The methodological qualities, including the
      risk of bias, will be evaluated using the Cochrane risk of bias assessment tool, 
      while confidence in the cumulative evidence will be evaluated using the Grading
      of Recommendations Assessment, Development and Evaluation (GRADE) approach. The
      network meta-analysis will be performed using WinBUGS 14 and Stata 15.1 software.
      RESULTS: Based on the current evidence, the potential rank of the efficacy and
      safety of CHIs plus GP chemotherapy for advanced NSCLC will be assessed, and a
      prioritization regimen will be summarized. CONCLUSION: Evidence from this
      systematic review could be useful for patients, clinical practitioners, and
      guideline-makers to select an optimum proposal of CHIs plus GP for advanced
      NSCLC. ETHICS AND DISSEMINATION: It is not necessary for ethical approval because
      it is based on published studies. The protocol will be disseminated in a
      peer-reviewed journal or presented at a topic-related conference. PROSPERO
      REGISTRATION NUMBER: CRD42020167142.
FAU - Li, Juan
AU  - Li J
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
AD  - School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhu, Guang-Hui
AU  - Zhu GH
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
AD  - School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
FAU - Liu, Tong-Tong
AU  - Liu TT
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
FAU - Xu, Bo-Wen
AU  - Xu BW
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
AD  - School of Graduates, Beijing University of Chinese Medicine, Beijing, China.
FAU - Li, Jie
AU  - Li J
AUID- ORCID: 0000-0002-3461-8816
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical
      Sciences.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0W860991D6 (Deoxycytidine)
RN  - B76N6SBZ8R (gemcitabine)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration &
      dosage/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/therapeutic use
MH  - Deoxycytidine/analogs & derivatives/therapeutic use
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Network Meta-Analysis
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - Survival Analysis
PMC - PMC7360220
EDAT- 2020/07/16 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000021041 [doi]
AID - 00005792-202007100-00064 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e21041. doi:
      10.1097/MD.0000000000021041.


PMID- 32664112
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Prognostic factors for venous thrombosis in patients with peripherally inserted
      central catheters: Protocol for a systematic review and meta-analysis.
PG  - e21037
LID - 10.1097/MD.0000000000021037 [doi]
AB  - BACKGROUND: Peripherally inserted central catheters (PICCs) has become
      increasingly popular in clinical practice because of the ease and safety of
      insertion and lower cost-effectiveness. The precise incidence and risk of
      PICC-related venous thrombosis is important to be verified in the context of
      growing PICC use and an understanding of the risk of venous thrombosis is an
      important cost and patient safety question. METHOD: We will search seven
      electronic databases including the Cochrane Library, MEDLINE, EMBASE, Chinese
      BioMedical Database, China National Knowledge Infrastructure, Chinese VIP and
      Wangfang Database regardless of publication date or language. All studies with
      prognostic factor analysis will be included if they recruited participants with
      PICC. Primary outcomes will include venous thrombosis. The risk of bias will be
      assessed by 2 authors using quality in prognostic studies tool. If possible, a
      meta-analysis in fixed or random effects model will be conducted by R-3.5.1
      software, otherwise a narrative synthesis will ensue focusing on prognostic
      factors. The confidence in cumulative evidence will be assessed by Based on the
      Grading of Recommendations Assessment, Development and Evaluation. RESULTS: The
      aim of this study is to retrieve, appraise and summarize the clinical evidence of
      risk assessment for PICC-related venous thrombosis. CONCLUSIONS: This study will 
      assess the precise incidence and risk of venous thrombosis in patients with PICC 
      and provide references for establishing relevant assessment tools. ETHICS AND
      DISSEMINATION: This study is a protocol for systematic review and meta-analysis
      of prognostic factors for venous thrombosis in PICC patients. This review will be
      published in a journal and disseminated in print by peer-review.
FAU - Gao, Yanling
AU  - Gao Y
AUID- ORCID: 0000-0002-1499-0506
AD  - Department of Integrated Chinese and Western Medicine, Henan Cancer Hospital &
      Zhengzhou University Cancer Hospital, Zhengzhou, China.
FAU - Fan, Xiaoyi
AU  - Fan X
FAU - Han, Jie
AU  - Han J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Catheterization, Peripheral/*adverse effects
MH  - Humans
MH  - Prognosis
MH  - *Research Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Venous Thrombosis/*etiology
PMC - PMC7360327
EDAT- 2020/07/16 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1097/MD.0000000000021037 [doi]
AID - 00005792-202007100-00062 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e21037. doi:
      10.1097/MD.0000000000021037.


PMID- 32664086
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20220716
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Effectiveness and safety of indirect moxibustion for the treatment of allergic
      rhinitis: A protocol for systematic review and meta-analysis of RCTs.
PG  - e20911
LID - 10.1097/MD.0000000000020911 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR) is a common allergic disorder worldwide.
      Western medicine is not optimistic about the therapeutic effect of this disease. 
      However, moxibustion can enhance vital energy or immunity through a great number 
      of clinical trials. Thus, the aim of this systematic review and meta-analysis is 
      to systematically evaluate the effectiveness and safety of indirect moxibustion
      for treating AR. METHODS: We will conduct a comprehensive literature search in
      Medline, PubMed, Web of Science, Embase, the Cochrane Library, China National
      Knowledge Infrastructure Database, WanFang Database, Chinese Scientific Journal
      Database, and Chinese Biomedical Literature Database from inception to August
      2020 without any language restriction. In addition, we will retrieve the
      unpublished studies and the references of initially included literature manually.
      Reviewers will identify studies, extract data, and assess the quality
      independently. The outcomes of interest include: total effective rate, total
      nasal symptom score, total non-nasal symptom score, rhinitis quality of life
      questionnaire, visual analog scale, laboratory indicators (i.e., serum levels of 
      IgE, IgA, or IgG), and adverse events. Randomized clinical trials will be
      collected, methodological quality will be evaluated using the Cochrane
      risk-of-bias assessment tool, and the level of evidence will be rated using the
      Grading of Recommendations, Assessment, Development and Evaluation approach.
      Meta-analysis will be performed using RevMan 5.3.0 software. The heterogeneity
      test will be conducted between the studies, and P < .1 and I > 50% are the
      thresholds for the tests. We will utilize the fixed effects model or the random
      effects model according to the size of heterogeneity. RESULTS: Because the review
      is ongoing, no results can be reported. CONCLUSIONS: The results of this review
      will provide reliable evidence for effectiveness and safety of indirect
      moxibustion for treating AR. ETHICS AND DISSEMINATION: Ethical approval is not
      required for this study. This systematic review and meta-analysis will be
      disseminated online and on paper to help guide clinicians. PROSPERO REGISTRATION 
      NUMBER: CRD42019140944.
FAU - Yuan, Ting
AU  - Yuan T
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine.
FAU - Fu, Yong
AU  - Fu Y
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
FAU - Xiong, Jun
AU  - Xiong J
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
FAU - Zhang, Haifeng
AU  - Zhang H
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
FAU - Yang, Jun
AU  - Yang J
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine.
FAU - Wang, Xue
AU  - Wang X
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine.
FAU - Fan, Hao
AU  - Fan H
AD  - School of Acupuncture, Moxibustion and Tuina of Jiangxi University of Traditional
      Chinese Medicine.
FAU - Jiang, Yunfeng
AU  - Jiang Y
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
FAU - Zhou, Xiaohong
AU  - Zhou X
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
FAU - Liao, Kai
AU  - Liao K
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
FAU - Xu, Lingling
AU  - Xu L
AD  - Department of Acupuncture and Moxibustion, the Affiliated Hospital with Jiangxi
      University of Traditional Chinese Medicine, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - China/epidemiology
MH  - Humans
MH  - Immunity/*drug effects
MH  - Immunoglobulin A/blood
MH  - Immunoglobulin E/blood
MH  - Immunoglobulin G/blood
MH  - Moxibustion/adverse effects/*methods
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Rhinitis, Allergic/epidemiology/psychology/*therapy
MH  - Safety
MH  - Treatment Outcome
MH  - Visual Analog Scale
PMC - PMC7360216
EDAT- 2020/07/16 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - 10.1097/MD.0000000000020911 [doi]
AID - 00005792-202007100-00036 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e20911. doi:
      10.1097/MD.0000000000020911.


PMID- 32664065
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Effect of myrtol on chronic bronchitis or chronic obstructive pulmonary disease: 
      A protocol for systematic review and meta-analysis.
PG  - e20692
LID - 10.1097/MD.0000000000020692 [doi]
AB  - BACKGROUND: The key to the management of chronic obstructive (CB) and chronic
      obstructive pulmonary disease (COPD) is to control symptoms of the disease and to
      prevent deterioration in the health of affected patients. Myrtol has been proved 
      to be effective in treating the symptoms of patients with CB and COPD and
      preventing the deterioration in their health. However, there has been no
      systematic review of the efficacy and safety of myrtol in the treatment of CB or 
      COPD. The purpose of this study is going to evaluate the effects of myrtol on the
      management of CB or COPD based on randomized controlled trials. METHODS:
      Electronic literature and other ongoing studies will be searched before November 
      31, 2019. Randomized controlled trials that report the use of myrtol in the
      treatment of CB or COPD (in the absence and presence of concurrent treatments)
      will be selected for inclusion regardless of language. Primary outcomes will
      include cumulative numbers of exacerbation events and the number of days of
      disability including days in bed, days off work due to breathing complications,
      and days on which the participant was unable to undertake normal activities due
      to breathing complications. Study selection, data extraction, and deviation the
      derivation risk assessment will be carried out by 2 independent investigators.
      Meta-analysis will be carried out by the RevMan5.3 software. RESULTS: The study
      will provide summary results for estimating the efficacy and safety of myrtol for
      future treatments of CB or COPD. CONCLUSIONS: This systematic review will
      determine if myrtol is an effective and a safe intervention on the symptoms and
      the prevention of exacerbation of CB or COPD. ETHICS AND DISSEMINATION: Ethical
      approval will not be required for this study because no identifying patient data 
      will be used. The review will be published as an article or a conference
      presentation in a peer-reviewed journal. REGISTRATION: OSF registration number:
      DOI 10.17605/OSF.IO/PXRBV.
FAU - Liu, Liyun
AU  - Liu L
AD  - School of basic medical sciences, Chengdu University of Traditional Chinese
      Medicine, No. 1166 Liutai avenue, Wenjiang district.
FAU - Li, Shuiqin
AU  - Li S
AD  - Department of Gastroenterology, Hospital of Chengdu University of Traditional
      Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan Province, People's
      Republic of China.
FAU - Wu, Yongcan
AU  - Wu Y
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine, No. 39 Shi-er-qiao Road.
FAU - Wang, Xiaomin
AU  - Wang X
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine, No. 39 Shi-er-qiao Road.
FAU - Huang, Demei
AU  - Huang D
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine, No. 39 Shi-er-qiao Road.
FAU - Pei, Caixia
AU  - Pei C
AD  - Department of Geriatrics, Hospital of Chengdu University of Traditional Chinese
      Medicine, No. 39 Shi-er-qiao Road.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Geriatrics, Hospital of Chengdu University of Traditional Chinese
      Medicine, No. 39 Shi-er-qiao Road.
FAU - Wang, Zhenxing
AU  - Wang Z
AUID- ORCID: 0000-0001-6832-9652
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine, No. 39 Shi-er-qiao Road.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0 (Monoterpenes)
RN  - 0 (Plant Extracts)
RN  - 8002-55-9 (myrtol)
SB  - IM
MH  - Bronchitis, Chronic/*drug therapy
MH  - Drug Combinations
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Monoterpenes/*therapeutic use
MH  - Myrtaceae
MH  - Phytotherapy
MH  - Plant Extracts/therapeutic use
MH  - Systematic Reviews as Topic
PMC - PMC7360323
EDAT- 2020/07/16 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
AID - 10.1097/MD.0000000000020692 [doi]
AID - 00005792-202007100-00015 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e20692. doi:
      10.1097/MD.0000000000020692.


PMID- 32664064
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Safety and efficacy of an herbal formula, Gwakhyangjeonggi-san on atopic
      dermatitis with gastrointestinal symptoms: Protocol for a randomized controlled
      trial.
PG  - e20675
LID - 10.1097/MD.0000000000020675 [doi]
AB  - INTRODUCTION: Gwakhyangjeonggi-san (GJS) is an herbal formula with
      anti-inflammatory and anti-allergic properties that is broadly used to treat a
      wide range of diseases including gastrointestinal disorders and allergic
      diseases. There have been several clinical studies conducted on its effects on
      atopic dermatitis (AD). So far, no randomized controlled trials have been
      conducted. Here, we describe the protocol for a randomized controlled study
      designed to investigate the efficacy and safety of GJS for treating patients with
      AD that have gastrointestinal symptoms. METHODS AND ANALYSIS: A randomized,
      double-blind, placebo-controlled, parallel-group, clinical trial has been
      designed to investigate the clinical efficacy and safety of GJS on patients with 
      AD that have gastrointestinal symptoms. A total of 58 participants with AD will
      be recruited and randomly allocated to the GJS or placebo group in a 1:1 ratio.
      The participants will be administered GJS or placebo granules 3 times a day for 8
      weeks. Data will be collected from the participants at baseline and after 4 and 8
      weeks. The primary outcome measure will be the mean change in the SCORing of
      Atopic Dermatitis (SCORAD) index from baseline to 8 weeks. The secondary outcomes
      will include the eczema area and severity index (EASI), dermatology life quality 
      index (DLQI), EuroQoL 5 dimensions 5 levels (EQ-5D-5L), and immunological
      factors. The Korean Gastrointestinal Symptom Rating Scale (KGSRS), Nepean
      Dyspepsia Index will also be obtained for assessing the gastrointestinal status. 
      DISCUSSION: The findings of this study are expected to provide evidence on the
      safety and effectiveness of GJS and for treating patients with AD that have
      gastrointestinal symptoms. Additionally, the study will explore the mechanism of 
      GJS action via gut microbiome. This study will provide new perspectives on
      approaching treatment for AD. ETHICS AND DISSEMINATION: The study protocol was
      approved by the Institutional Review Board of Kyung Hee University Korean
      Medicine Hospital at Gangdong (KHNMCOH2019-06-002-001). TRIAL REGISTRATION
      NUMBER: This study has been registered at the Korean National Clinical Trial
      Registry, Clinical Research Information Service (KCT0004299).
FAU - Son, Mi Ju
AU  - Son MJ
AUID- ORCID: 0000-0003-1701-9122
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon.
FAU - Kim, Min Hee
AU  - Kim MH
AD  - Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine,
      Kyung Hee University Hospital at Gangdong, Seoul.
FAU - Kang, Minseo
AU  - Kang M
AD  - Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine,
      Kyung Hee University Hospital at Gangdong, Seoul.
FAU - Kim, Young-Eun
AU  - Kim YE
AD  - Future Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Republic
      of Korea.
FAU - Jung, Jeeyoun
AU  - Jung J
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon.
FAU - Choi, Inhwa
AU  - Choi I
AD  - Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine,
      Kyung Hee University Hospital at Gangdong, Seoul.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (gwakhyangjeonggi-san)
SB  - IM
MH  - Dermatitis, Atopic/complications/*drug therapy
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/pharmacology/*therapeutic use
MH  - Gastrointestinal Diseases/*drug therapy/immunology
MH  - Gastrointestinal Microbiome/*drug effects
MH  - Humans
MH  - Phytotherapy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7360236
EDAT- 2020/07/16 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
AID - 10.1097/MD.0000000000020675 [doi]
AID - 00005792-202007100-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e20675. doi:
      10.1097/MD.0000000000020675.


PMID- 32663974
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 274
DP  - 2020 Sep 1
TI  - A randomized controlled trial of a standard 4-week protocol of repetitive
      transcranial magnetic stimulation in severe treatment resistant depression.
PG  - 444-449
LID - S0165-0327(20)30235-4 [pii]
LID - 10.1016/j.jad.2020.05.055 [doi]
AB  - BACKGROUND: Treatment options for major depressive disorder (MDD) in individuals 
      who are depressed for at least 2 years and failed two or more different types of 
      therapeutic intervention, remain scarce. Being less invasive than
      electroconvulsive therapy, repetitive transcranial magnetic stimulation (rTMS)
      might be an alternative treatment option. RESEARCH QUESTION: Does high frequency 
      rTMS applied over the left prefrontal cortex ameliorate depressive symptoms in
      patients with treatment resistant major depressive disorder and is the efficacy
      dependent on treatment resistance? METHOD: We performed a randomized controlled
      trial investigating the effect of twenty sessions of real or sham-rTMS, during 4 
      consecutive weeks. Efficacy was blindly rated with the Hamilton depression rating
      scale (HDRS-17) at baseline and 1 week after end of treatment, and the Dutch
      method for quantification of treatment resistance in Depression (DM-TRD) was
      assessed at baseline. RESULTS: An interim analysis showed no differences in
      antidepressant response between real and sham rTMS and we therefore discontinued 
      the RCT after 31 patients. The mean difference of the HDRS score between baseline
      and post-treatment was 3.7 (+/- 4.0; change 16%), indicating a small but
      significant improvement across time (F(1,30)=25.4;p < 0.01). There were no
      differences however between the treatment arms (F(1.30) = 1.5;p = 0.23). We did
      find a negative correlation between the change in HDRS score and DM-TRD in the
      active rTMS group, but this correlation was not significantly different from the 
      sham group. CONCLUSION: "Standard" 4-week rTMS treatment is not effective in
      chronic, severe treatment-resistant depressed patients. While a replication of
      our data in this patient group may be ethically difficult, further research with 
      less treatment resistant patients might help in positioning rTMS within the
      current stepped care approach to depression.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - van Eijndhoven, P F P
AU  - van Eijndhoven PFP
AD  - Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen,
      The Netherlands; Department of Psychiatry, Radboud University Medical Center,
      Nijmegen, The Netherlands. Electronic address:
      Philip.vanEijndhoven@radboudumc.nl.
FAU - Bartholomeus, J
AU  - Bartholomeus J
AD  - Rijnstate Hospital Arnhem, Department of Psychiatry, The Netherlands.
FAU - Mobius, M
AU  - Mobius M
AD  - Behavioral Science Institute, Department of Clinical Psychology, Radboud
      University Nijmegen, The Netherlands.
FAU - de Bruijn, A
AU  - de Bruijn A
AD  - Depression Expertise Centre, Pro Persona Mental Health Care, Reinier Postlaan 6, 
      6525 GC Nijmegen,The Netherlands.
FAU - Ferrari, G R A
AU  - Ferrari GRA
AD  - Behavioral Science Institute, Department of Clinical Psychology, Radboud
      University Nijmegen, The Netherlands.
FAU - Mulders, P
AU  - Mulders P
AD  - Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen,
      The Netherlands; Department of Psychiatry, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Schene, A H
AU  - Schene AH
AD  - Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen,
      The Netherlands; Department of Psychiatry, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Schutter, D J L G
AU  - Schutter DJLG
AD  - Department of Experimental Psychology, Helmholtz Institute, Utrecht University,
      The Netherlands.
FAU - Spijker, J
AU  - Spijker J
AD  - Department of Psychiatry, Radboud University Medical Center, Nijmegen, The
      Netherlands; Depression Expertise Centre, Pro Persona Mental Health Care, Reinier
      Postlaan 6, 6525 GC Nijmegen,The Netherlands.
FAU - Tendolkar, I
AU  - Tendolkar I
AD  - Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen,
      The Netherlands; Department of Psychiatry, Radboud University Medical Center,
      Nijmegen, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200526
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
SB  - IM
MH  - *Depressive Disorder, Major/therapy
MH  - *Depressive Disorder, Treatment-Resistant/therapy
MH  - Humans
MH  - Prefrontal Cortex
MH  - Reference Standards
MH  - Transcranial Magnetic Stimulation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Chronic depression
OT  - *Repetitive transcranial magnetic stimulation
OT  - *Treatment resistant depression
COIS- Declaration of Competing Interest None.
EDAT- 2020/07/16 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/16 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - S0165-0327(20)30235-4 [pii]
AID - 10.1016/j.jad.2020.05.055 [doi]
PST - ppublish
SO  - J Affect Disord. 2020 Sep 1;274:444-449. doi: 10.1016/j.jad.2020.05.055. Epub
      2020 May 26.


PMID- 32663695
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 260
DP  - 2020 Sep
TI  - Fragmentation by design: Universal health coverage policies as governmentality in
      Senegal.
PG  - 113153
LID - S0277-9536(20)30372-5 [pii]
LID - 10.1016/j.socscimed.2020.113153 [doi]
AB  - There is increasing international consensus that countries need to reduce health 
      system fragmentation in order to achieve universal health coverage (UHC). Yet
      there is little agreement on what drives fragmentation, in particular the extent 
      to which fragmentation has a political purpose. This study analyses a highly
      fragmented health financing system through a UHC policy that aims to remove user 
      fees for people aged 60 and over in Senegal. 53 semi-structured interviews (SSIs)
      and focus group discussions with the target population were conducted in four
      regions in Senegal over a period of six months during 2012. A further 46 SSIs
      were conducted with key informants at the national level and in each of the four 
      regions. By analysing explanations of the successes and failures of policies, an 
      understanding of power relations in state institutions, communities and
      individuals is gained. The concept of governmentality is used to interpret the
      results. The interviewees' main concern was to implement or resist various
      techniques of control over the conduct of bureaucrats, health workers, patients
      and the wider population. These techniques included numeracy and calculation,
      referral letters, ID cards, data collection, new prudentialism, active
      citizenship and ethical self-formation through affinities of the community. The
      techniques sought to make two types of subjects; citizens subjects of rights and 
      obligations; and autonomous subjects of choice and self-identity. A key
      implication is that in Senegal, and perhaps elsewhere, fragmentation of the
      health system plays a key role in the formation and control of subjects, in the
      name of "freedom". As such, fragmentation may be an inherent feature of UHC.
      Interventions that aim to reduce fragmentation based on evidence of its
      inefficiency, inequity and ineffectiveness in reducing poverty and ill health may
      be missing this point.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Mladovsky, Philipa
AU  - Mladovsky P
AD  - Department of International Development, London School of Economics and Political
      Science, Houghton Street, London, WC2A 2AE, UK. Electronic address:
      p.mladovsky@lse.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Aged
MH  - Fees and Charges
MH  - *Health Policy
MH  - Healthcare Financing
MH  - Humans
MH  - Middle Aged
MH  - Senegal
MH  - *Universal Health Insurance
OTO - NOTNLM
OT  - *Africa
OT  - *Citizenship
OT  - *Fragmentation
OT  - *Governmentality
OT  - *Health systems
OT  - *Older people
OT  - *Senegal
OT  - *Universal health coverage
EDAT- 2020/07/15 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - S0277-9536(20)30372-5 [pii]
AID - 10.1016/j.socscimed.2020.113153 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Sep;260:113153. doi: 10.1016/j.socscimed.2020.113153. Epub 2020
      Jun 26.


PMID- 32663326
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 151
IP  - 1
DP  - 2020 Oct
TI  - Transsexuality: Legal and ethical challenges.
PG  - 163-167
LID - 10.1002/ijgo.13307 [doi]
AB  - Sex-change procedures, better described as gender-change procedures, involve
      preparing patients psychologically and surgically for gender transition to treat 
      their gender dysphoria. Physical treatment might include hysterectomy for female 
      to male transition, and post-castration fashioning of an artificial vagina for
      male to female transition. Conservative opposition to accommodating and
      recognizing such procedures remains in some countries, and where treated,
      transgender individuals might face social hostility and oppression. However,
      human rights laws increasingly provide for transgender non-discrimination and
      government re-issue of official documents such as birth certificates and social
      insurance cards in the changed gender. A UK legal decision required a
      transgendered male who retained his ovaries and uterus to be registered as mother
      on the birth certificate of the child he bore. Most challenging are decisions on 
      adolescents' requests for gender transition, especially over parents' objections.
      Laws increasingly recognize that legal minors with sufficiently evolved
      intellectual and emotional capacity can make decisions for themselves.
CI  - (c) 2020 International Federation of Gynecology and Obstetrics.
FAU - Dickens, Bernard M
AU  - Dickens BM
AD  - Faculty of Law, Joint Centre for Bioethics, University of Toronto, Toronto, ON,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200809
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the
      International Federation of Gynaecology and Obstetrics
JID - 0210174
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Female
MH  - Gender Dysphoria/psychology/therapy
MH  - Human Rights/*legislation & jurisprudence
MH  - Humans
MH  - Informed Consent By Minors/legislation & jurisprudence
MH  - Male
MH  - Parents
MH  - Sex Reassignment Procedures/*ethics
MH  - Transgender Persons
MH  - United Kingdom
OTO - NOTNLM
OT  - Adolescent evolving capacity
OT  - Gender dysphoria
OT  - Induced infertility
OT  - Legal minors
OT  - Male motherhood
OT  - Sex change
OT  - Transsexuality
EDAT- 2020/07/15 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1002/ijgo.13307 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2020 Oct;151(1):163-167. doi: 10.1002/ijgo.13307. Epub
      2020 Aug 9.


PMID- 32663206
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - The first nationwide study on facing and solving ethical dilemmas among
      healthcare professionals in Slovenia.
PG  - e0235509
LID - 10.1371/journal.pone.0235509 [doi]
AB  - BACKGROUND: Healthcare professionals (HCPs), patients and families are often
      faced with ethical dilemmas. The role of healthcare ethics committees (HECs) is
      to offer support in these situations. AIM: The primary objective was to study how
      often HCPs encounter ethical dilemmas. The secondary objective was to identify
      the main types of ethical dilemmas encountered and how HCPs solve them. SUBJECTS 
      AND METHODS: We conducted a cross-sectional, survey-based study among HCPs in 14 
      Slovenian hospitals. A questionnaire was designed and validated by HCPs who were 
      selected by proportional stratified sampling. Data collection took place between 
      April 2015 and April 2016. RESULTS: The final sample size was n = 485 (385 or
      79.4%, female). The response rates for HCPs working in secondary and tertiary
      level institutions were 45% and 51%, respectively. Three hundred and forty
      (70.4%) of 485 HCPs (very) frequently encountered ethical dilemmas. Frequent
      ethical dilemmas were waiting periods for diagnostics or treatment, suboptimal
      working conditions due to poor interpersonal relations on the ward, preserving
      patients' dignity, and relations between HCPs and patients. Physicians and nurses
      working in secondary level institutions, compared to their colleagues working in 
      tertiary level institutions, more frequently encountered ethical dilemmas with
      respect to preserving patients' dignity, protecting patients' information, and
      relations between HCPs and patients. In terms of solutions, all HCPs most
      frequently discussed ethical dilemmas with co-workers (colleagues), and with the 
      head of the department. According to HCPs, the most important role of HECs is
      staff education, followed by improving communication, and reviewing difficult
      ethical cases. CONCLUSIONS: Waiting periods for diagnostics and treatment and
      suboptimal working conditions due to poor interpersonal relations are considered 
      to be among the most important ethical issues by HCPs in Slovenian hospitals. The
      most important role of HECs is staff education, improving communication, and
      reviewing difficult ethical cases.
FAU - Grosek, Stefan
AU  - Grosek S
AD  - Division of Surgery, Department of Paediatric Surgery and Intensive Therapy,
      University Medical Centre Ljubljana, Ljubljana, Slovenia.
AD  - Chair of Paediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana,
      Slovenia.
AD  - Neonatology Section, Division of Obstetrics and Gynaecology, Department of
      Perinatology, University Medical Centre, Ljubljana, Slovenia.
FAU - Kucan, Rok
AU  - Kucan R
AD  - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Groselj, Jon
AU  - Groselj J
AD  - Theological Faculty, University of Ljubljana, Ljubljana, Slovenia.
FAU - Orazem, Miha
AU  - Orazem M
AD  - Department of Radiation Oncology, Ljubljana Institute of Oncology, Ljubljana,
      Slovenia.
FAU - Groselj, Urh
AU  - Groselj U
AD  - Department of Paediatric Endocrinology, Diabetes and Metabolic Diseases,
      University Children's Hospital, UMC Ljubljana, Ljubljana, Slovenia.
FAU - Erculj, Vanja
AU  - Erculj V
AD  - Rho Sigma Research & Statistics, Ljubljana, Slovenia.
AD  - Faculty of Criminal Justice and Security, University of Maribor, Slovenia.
FAU - Lajovic, Jaro
AU  - Lajovic J
AD  - Rho Sigma Research & Statistics, Ljubljana, Slovenia.
FAU - Borovecki, Ana
AU  - Borovecki A
AD  - Andrija Stampar School of Public Health, School of Medicine, University of
      Zagreb, Zagreb, Croatia.
FAU - Ivanc, Blaz
AU  - Ivanc B
AUID- ORCID: 0000-0003-4242-7611
AD  - Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200714
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Personnel/*ethics
MH  - Hospitals/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Slovenia
MH  - *Surveys and Questionnaires
PMC - PMC7360038
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/15 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1371/journal.pone.0235509 [doi]
AID - PONE-D-20-08547 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 14;15(7):e0235509. doi: 10.1371/journal.pone.0235509.
      eCollection 2020.


PMID- 32663153
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2291-9279 (Print)
VI  - 8
IP  - 3
DP  - 2020 Aug 10
TI  - Assessing Ethoshunt as a Gamification-Based Mobile App in Ethics Education: Pilot
      Mixed-Methods Study.
PG  - e18247
LID - 10.2196/18247 [doi]
AB  - BACKGROUND: Gamification has remarkable potential in the learning space. The
      process of creating a gamified system and its influence on human behavior reflect
      the interaction between educators and machines. OBJECTIVE: The purpose of this
      pilot study was to present Ethoshunt as a gamification-based mobile app that can 
      be used in teaching and learning ethics. METHODS: This study involved a
      mixed-methods research design. The researchers surveyed 39 undergraduate students
      who were introduced to Ethoshunt in order to examine the relationships between
      mobile app usability and positive emotions, ethical competency, and user
      experience. Affinity diagramming was used as a tool to organize the opinions and 
      experiences of participants using featured gamification elements. RESULTS: Game
      dynamics and game mechanics explained the functionality of Ethoshunt. In
      addition, the learning flow through Ethoshunt was discussed. Overall, the
      findings were positive, and mobile app usability had the strongest relationship
      with positive emotions (r=0.744, P<.001), followed by ethical competency
      (r=0.686, P<.001) and user experience (r=0.614, P<.001). CONCLUSIONS: Positive
      emotions could be perceived as an important dimension in the development and
      usability of Ethoshunt. The researchers suggest that the gamification-based
      mobile app advocated in this study may provide ideas for ethics educators who
      wish to develop a technology-mediated learning environment.
CI  - (c)Noor Syamilah Zakaria, M Iqbal Saripan, Neerushah Subarimaniam, Alyani Ismail.
      Originally published in JMIR Serious Games (http://games.jmir.org), 10.08.2020.
FAU - Zakaria, Noor Syamilah
AU  - Zakaria NS
AUID- ORCID: https://orcid.org/0000-0003-3345-0713
AD  - Department of Counselor Education and Counseling Psychology, Faculty of
      Educational Studies, Universiti Putra Malaysia, Selangor Darul Ehsan, Malaysia.
FAU - Saripan, M Iqbal
AU  - Saripan MI
AUID- ORCID: https://orcid.org/0000-0002-3005-5331
AD  - Department of Computer and Communication Systems Engineering, Faculty of
      Engineering, Universiti Putra Malaysia, Selangor Darul Ehsan, Malaysia.
FAU - Subarimaniam, Neerushah
AU  - Subarimaniam N
AUID- ORCID: https://orcid.org/0000-0003-4950-8887
AD  - Department of Counselor Education and Counseling Psychology, Faculty of
      Educational Studies, Universiti Putra Malaysia, Selangor Darul Ehsan, Malaysia.
FAU - Ismail, Alyani
AU  - Ismail A
AUID- ORCID: https://orcid.org/0000-0002-3085-4889
AD  - Department of Computer and Communication Systems Engineering, Faculty of
      Engineering, Universiti Putra Malaysia, Selangor Darul Ehsan, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200810
PL  - Canada
TA  - JMIR Serious Games
JT  - JMIR serious games
JID - 101645255
PMC - PMC7445620
OTO - NOTNLM
OT  - education
OT  - ethical competency
OT  - ethics
OT  - ethics education
OT  - gamification
OT  - mobile app
OT  - mobile app usability
EDAT- 2020/07/15 06:00
MHDA- 2020/07/15 06:01
CRDT- 2020/07/15 06:00
PHST- 2020/02/13 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/07/15 06:01 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - v8i3e18247 [pii]
AID - 10.2196/18247 [doi]
PST - epublish
SO  - JMIR Serious Games. 2020 Aug 10;8(3):e18247. doi: 10.2196/18247.


PMID- 32662744
OWN - NLM
STAT- Publisher
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 14
TI  - Giving nurses a voice during ethical conflict in the ICU.
PG  - 969733020934148
LID - 10.1177/0969733020934148 [doi]
AB  - BACKGROUND: Ethical conflict and subsequent nurse moral distress and burnout are 
      common in the intensive care unit. There is a gap in our understanding of nurses'
      perceptions of how organizational resources support them in addressing ethical
      conflict in the intensive care unit. RESEARCH QUESTION/OBJECTIVES/METHODS: The
      aim of this qualitative, descriptive study was to explore how nurses experience
      ethical conflict and use organizational resources to support them as they address
      ethical conflict in their practice. PARTICIPANTS AND RESEARCH CONTEXT: Responses 
      to two open-ended questions were collected from critical care nurses working in
      five intensive care units at a large, academic medical center in the Midwestern
      region of the United States. ETHICAL CONSIDERATIONS: This study was approved by
      the Institutional Review Board at the organization where the study took place.
      FINDINGS: Three main interwoven themes emerged: nurses perceive (1) intensive
      care unit culture, practices, and organizational priorities contribute to patient
      suffering; (2) nurses are marginalized during ethical conflict in the intensive
      care unit; and (3) organizational resources have the potential to reduce nurse
      moral distress. Nurses identified ethics education, interprofessional dialogue,
      and greater involvement of nurses as important strategies to improve the
      management of ethical conflict. DISCUSSION: Ethical conflict related to
      healthcare system challenges is intrinsic in the daily practice of critical care 
      nurses. Nurses want to be engaged in discussions about their perspectives on
      ethical conflict and play an active role in addressing ethical conflict in their 
      practice. Organizational resources that support nurses are vital to the
      resolution of ethical conflict. CONCLUSION: These findings can inform the
      development of interventions that aim to proactively and comprehensively address 
      ethical conflict in the intensive care unit to reduce nurse moral distress and
      improve the delivery of patient and family care.
FAU - McAndrew, Natalie S
AU  - McAndrew NS
AUID- ORCID: https://orcid.org/0000-0002-8572-6761
AD  - University of Wisconsin-Milwaukee, USA; Froedtert & the Medical College of
      Wisconsin, USA.
FAU - Hardin, Joshua B
AU  - Hardin JB
AD  - University of Wisconsin-Milwaukee, USA.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
OTO - NOTNLM
OT  - Ethical conflict
OT  - intensive care
OT  - moral distress
OT  - nurses
EDAT- 2020/07/15 06:00
MHDA- 2020/07/15 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
AID - 10.1177/0969733020934148 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 14:969733020934148. doi: 10.1177/0969733020934148.


PMID- 32662326
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - Healthcare workers' stress when caring for COVID-19 patients: An altruistic
      perspective.
PG  - 1490-1500
LID - 10.1177/0969733020934146 [doi]
AB  - BACKGROUND: When the contagious COVID-19 spread worldwide, the frontline staff
      faced unprecedented excessive work pressure and expectations of all of the
      society. OBJECTIVE: The aim was to explore healthcare workers' stress and
      influencing factors when caring for COVID-19 patients from an altruistic
      perspective. METHODS: A cross-sectional, descriptive study was conducted in a
      tertiary hospital during the outbreak of COVID-19 between February and March 2020
      in Wuhan, the capital city of Hubei province in China. Data were collected from
      1208 healthcare workers. Descriptive statistics and multiple linear regression
      were used to analyze the data. ETHICAL CONSIDERATIONS: Research ethics approval
      (with the code of TJ-IRB20200379) was obtained from Tongji Hospital, Tongji
      Medical College of Huazhong University of Science and Technology. Written
      informed consent was also received from participants. RESULTS: Less than 60% of
      participants chose moderate or severe stress on all stressors, indicating a low
      stress level among healthcare workers. The main source of stress among frontline 
      healthcare workers caring for COVID-19 patients came from the fear of being
      infected, the fear of family members being infected, and the discomfort caused by
      protective equipment. Frontline staff who were nurses, were married, and had
      worked more than 20 days suffered higher stress, whereas rescue staff showed
      lower stress. CONCLUSION: The healthcare workers caring for patients with
      COVID-19 had low stress level, although they still had the fear of being infected
      or uncomfortable feeling caused by personal protective equipment. A low stress
      level among healthcare workers indicated their professional devotion and altruism
      during COVID-19 epidemic. Medical institutions and the government should continue
      to strengthen infection prevention measures and provide more comprehensive care
      involving families of frontline healthcare workers, especially nurses and married
      staff. It will be a lesson to other countries that awaking healthcare workers'
      inside motivation and providing necessary support from government and society
      were significant.
FAU - Wang, Hui
AU  - Wang H
AUID- ORCID: https://orcid.org/0000-0002-3609-3662
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
FAU - Liu, Yu
AU  - Liu Y
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
FAU - Hu, Kaili
AU  - Hu K
AUID- ORCID: https://orcid.org/0000-0002-3073-6938
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
FAU - Zhang, Meng
AU  - Zhang M
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
FAU - Du, Meichen
AU  - Du M
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
FAU - Huang, Haishan
AU  - Huang H
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
FAU - Yue, Xiao
AU  - Yue X
AD  - 66375Tongji Hospital of Tongji Medical College, Huazhong University of Science
      and Technology, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - *Altruism
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Nursing Staff, Hospital/*psychology/statistics & numerical data
MH  - Occupational Stress/*epidemiology
MH  - Pandemics
MH  - Personnel, Hospital/*psychology/statistics & numerical data
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Risk Factors
MH  - Tertiary Care Centers
OTO - NOTNLM
OT  - Altruism
OT  - COVID-19
OT  - healthcare workers
OT  - nurses
OT  - stress
EDAT- 2020/07/15 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1177/0969733020934146 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1490-1500. doi: 10.1177/0969733020934146. Epub 2020
      Jul 14.


PMID- 32662219
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210110
IS  - 1531-8249 (Electronic)
IS  - 0364-5134 (Linking)
VI  - 88
IP  - 3
DP  - 2020 Sep
TI  - Ethical Justifications for Pandemic Rationing Strategies.
PG  - 433-435
LID - 10.1002/ana.25848 [doi]
FAU - Bernat, James L
AU  - Bernat JL
AUID- ORCID: 0000-0003-1128-0442
AD  - Neurology and Medicine, Active Emeritus, Dartmouth Geisel School of Medicine,
      Hanover, NH, USA.
LA  - eng
PT  - Editorial
DEP - 20200804
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
SB  - IM
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - *Pandemics
PMC - PMC7405136
EDAT- 2020/07/15 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/10 00:00 [received]
PHST- 2020/07/10 00:00 [revised]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1002/ana.25848 [doi]
PST - ppublish
SO  - Ann Neurol. 2020 Sep;88(3):433-435. doi: 10.1002/ana.25848. Epub 2020 Aug 4.


PMID- 32661741
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of
      Separation.
PG  - 173-189
LID - 10.1007/s11673-020-09982-x [doi]
AB  - There is overwhelming evidence that the opioid crisis-which has cost hundreds of 
      thousands of lives and trillions of dollars (and counting)-has been created or
      exacerbated by webs of influence woven by several pharmaceutical companies. These
      webs involve health professionals, patient advocacy groups, medical professional 
      societies, research universities, teaching hospitals, public health agencies,
      policymakers, and legislators. Opioid companies built these webs as part of
      corporate strategies of influence that were designed to expand the opioid market 
      from cancer patients to larger groups of patients with acute or chronic pain, to 
      increase dosage as well as opioid use, to downplay the risks of addiction and
      abuse, and to characterize physicians' concerns about the addiction and abuse
      risks as "opiophobia." In the face of these pervasive strategies, conflict of
      interest policies have proven insufficient for addressing corporate influence in 
      medical practice, medical research, and public health policy. Governments, the
      academy, and civil society need to develop counterstrategies to insulate
      themselves from corporate influence and to preserve their integrity and public
      trust. These strategies require a paradigm shift-from partnerships with the
      private sector, which are ordinarily vehicles for corporate influence, to a norm 
      of separation.
FAU - Marks, Jonathan H
AU  - Marks JH
AD  - Bioethics Program, Pennsylvania State University, 332 Pond Building, University
      Park, PA, 16802, USA. marks@psu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - *Analgesics, Opioid
MH  - Biomedical Research
MH  - *Chronic Pain
MH  - Humans
MH  - Opioid Epidemic
MH  - Public Health
PMC - PMC7357445
OTO - NOTNLM
OT  - Conflict of interest
OT  - Corporate influence
OT  - Institutional integrity
OT  - Opioids
OT  - Public health ethics
OT  - Public-private partnerships
EDAT- 2020/07/15 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/07/15 06:00
PHST- 2019/06/06 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1007/s11673-020-09982-x [doi]
AID - 10.1007/s11673-020-09982-x [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Jun;17(2):173-189. doi: 10.1007/s11673-020-09982-x. Epub 2020 
      Jul 13.


PMID- 32661740
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20200730
LR  - 20220218
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Life Goes On.
PG  - 157-160
LID - 10.1007/s11673-020-09986-7 [doi]
FAU - Ashby, Michael A
AU  - Ashby MA
AD  - Cancer, Chronic Disease and Sub-Acute Stream, Royal Hobart Hospital, Tasmanian
      Health Service, Medical Ethics and Death Studies, School of Medicine, College of 
      Health and Medicine, University of Tasmania, Repatriation Centre, 90 Davey
      Street, Hobart, TAS, 7000, Australia. michael.ashby@ths.tas.gov.au.
LA  - eng
PT  - Editorial
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
PMC - PMC7355132
OTO - NOTNLM
OT  - *Bioethics
OT  - *COVID-19
OT  - *Conflict of interest
OT  - *Conscientious objection
OT  - *Ethics
EDAT- 2020/07/15 06:00
MHDA- 2020/07/15 06:01
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/07/15 06:01 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - 10.1007/s11673-020-09986-7 [doi]
AID - 10.1007/s11673-020-09986-7 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Jun;17(2):157-160. doi: 10.1007/s11673-020-09986-7.


PMID- 32661074
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210914
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - Why continuing uncertainties are no reason to postpone challenge trials for
      coronavirus vaccines.
PG  - 808-812
LID - 10.1136/medethics-2020-106501 [doi]
AB  - To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development
      through controlled human infection (or 'challenge') trials. These trials would
      involve the deliberate exposure of relatively few young, healthy volunteers to
      SARS-CoV-2. We defend this proposal against the charge that there is still too
      much uncertainty surrounding the risks of COVID-19 to responsibly run such a
      trial.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Steel, Robert
AU  - Steel R
AUID- ORCID: 0000-0003-4879-2070
AD  - Center for Population-Level Bioethics and Department of Philosophy, Rutgers
      University, New Brunswick, New Jersey, USA.
FAU - Buchak, Lara
AU  - Buchak L
AD  - Department of Philosophy, Princeton University, Princeton, NJ, USA.
FAU - Eyal, Nir
AU  - Eyal N
AD  - Center for Population-Level Bioethics; Department of Philosophy, School of Arts
      and Sciences; Department of Health Behavior, Society and Policy, Rutgers School
      of Public Health, Rutgers University, New Brunswick, New Jersey, USA
      neyal@cplb.rutgers.edu.
LA  - eng
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
GR  - R56 AI114617/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200713
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (COVID-19 Vaccines)
SB  - IM
CIN - J Med Ethics. 2020 Dec;46(12):813-814. PMID: 32900846
MH  - Biomedical Research/ethics/*organization & administration/standards
MH  - COVID-19/*epidemiology/*prevention & control
MH  - COVID-19 Vaccines/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic/*organization & administration/standards
MH  - Healthy Volunteers
MH  - Humans
MH  - Informed Consent/standards
MH  - Pandemics
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Safety
PMC - PMC7371490
OTO - NOTNLM
OT  - *clinical trials
OT  - *ethics
OT  - *philosophical ethics
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/15 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/05/25 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - medethics-2020-106501 [pii]
AID - 10.1136/medethics-2020-106501 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):808-812. doi: 10.1136/medethics-2020-106501. Epub
      2020 Jul 13.


PMID- 32661072
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20220531
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Are healthcare workers obligated to risk themselves during the COVID-19 pandemic 
      according to Jewish law? A response to Solnica et al.
PG  - 736-737
LID - 10.1136/medethics-2020-106622 [doi]
AB  - Solnica et al argue that "Jewish law and modern secular approaches based on
      professional responsibilities obligate physicians to care for all patients even
      those with communicable diseases". The authors base their viewpoint on the
      opinion of Rabbi Eliezer Waldenberg and apply it to suggest that physicians are
      obligated to endanger themselves during epidemics, such as COVID-19. It is argued
      that Solnica et al's analysis of Rabbi Waldenberg's text and their conclusion
      that healthcare workers are obligated to endanger themselves while treating
      patient who suffer from contagious illness during epidemics according to Jewish
      law suffer from various shortcomings. Indeed, Jewish law looks favourably on
      healthcare workers who take a reasonable risk in treating their patients in the
      context of epidemics. However, it is considered a voluntary supererogatory
      act-not obligatory. Solnica et al may express a legitimate ethical viewpoint.
      However, it does not seem to represent the mainstream approach of what Jewish law
      would demand as obligatory from its practitioners.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Gold, Azgad
AU  - Gold A
AD  - Ambulatory Forensic Psychiatry unit, Yehuda Abarbanel Mental Health Center, Bat
      Yam, Israel azgadgo@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200713
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Jul;46(7):441-443. PMID: 32424060
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Ethics, Medical
MH  - Health Personnel
MH  - Humans
MH  - *Jews
MH  - Judaism
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Risk
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *applied and professional ethics
OT  - *clinical ethics
OT  - *health care for specific diseases/groups
OT  - *religious ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/15 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/06/23 00:00 [received]
PHST- 2020/07/03 00:00 [accepted]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - medethics-2020-106622 [pii]
AID - 10.1136/medethics-2020-106622 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):736-737. doi: 10.1136/medethics-2020-106622. Epub
      2020 Jul 13.


PMID- 32661065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200715
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 370
DP  - 2020 Jul 13
TI  - Covid-19: clinicians need continuing professional development in ethics.
PG  - m2793
LID - 10.1136/bmj.m2793 [doi]
FAU - O'Neill, Desmond J
AU  - O'Neill DJ
AD  - Trinity Centre for Health Sciences, Tallaght University Hospital, Dublin D24
      NR0A, Republic of Ireland.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200713
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
CON - N Engl J Med. 2020 May 21;382(21):2049-2055. PMID: 32202722
COIS- Competing interests: DJO'N is chair of a working group advising on developing
      clinical updates in medical humanities and ethics for the Royal College of
      Physicians of Ireland.
EDAT- 2020/07/15 06:00
MHDA- 2020/07/15 06:01
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/07/15 06:01 [medline]
AID - 10.1136/bmj.m2793 [doi]
PST - epublish
SO  - BMJ. 2020 Jul 13;370:m2793. doi: 10.1136/bmj.m2793.


PMID- 32660955
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 12
TI  - Australian treatment outcome study: protocol for the 18-20-year follow-up of a
      prospective longitudinal cohort examining the natural history of heroin
      dependence and associated mortality, psychiatric and physical health, and health 
      service use.
PG  - e039226
LID - 10.1136/bmjopen-2020-039226 [doi]
AB  - INTRODUCTION: Opioid dependence is a global health priority, currently making the
      biggest contribution to drug-related deaths. The chronic, long-term persistence
      of heroin dependence over the life course requires investigation in prospective
      longitudinal studies, to better understand patterns and predictors of remission
      and relapse, as well as the impact of changes in substance use on a range of
      physical and mental health outcomes. Such knowledge is critical in order to
      identify modifiable risk factors that can be targeted for intervention. Crucial
      unanswered questions include the following: What are the long-term rates of
      mortality? What are the long-term patterns and predictors of heroin use,
      remission, psychiatric health and health service use? What are the long-term
      physical health consequences of heroin use? METHODS AND ANALYSIS: The 18-20-year 
      follow-up of the Australian Treatment Outcome Study (ATOS) cohort will examine
      the natural history of heroin dependence of an existing cohort of 615 people with
      heroin dependence, who were recruited into the study in 2001-2002. Five waves of 
      follow-up interviews have since been completed, at 3-month, 1-year, 2-year,
      3-year and 10-11-year post-baseline. At the 18-20-year follow-up, the ATOS cohort
      is (on average) approaching their 50s and an average of 30 years have passed
      since they first used heroin. The 18-20-year follow-up will consist of: (1) a
      structured interview; (2) physical health assessment; and (3) data linkage. The
      results of this follow-up will improve our understanding and management of
      age-related disorders in this population, which if not addressed in the immediate
      future, has the capacity to overwhelm treatment centres and aged care facilities.
      ETHICS AND DISSEMINATION: Ethical approval has been granted for the study (Sydney
      Local Health District Royal Prince Alfred Zone, Human Research Ethics Committee
      X18-0512 & HREC/18/RPAH/733). The results of the study will be disseminated
      through published manuscripts, bulletins and technical reports, as well as
      conference, seminars, webinar and workshop presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Marel, Christina
AU  - Marel C
AUID- ORCID: 0000-0002-1371-6986
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia christina.marel@sydney.edu.au.
FAU - Mills, Katherine
AU  - Mills K
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Visontay, Rachel
AU  - Visontay R
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Wilson, Jack
AU  - Wilson J
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Darke, Shane
AU  - Darke S
AD  - National Drug and Alcohol Research Centre, UNSW, Sydney, New South Wales,
      Australia.
FAU - Ross, Joanne
AU  - Ross J
AD  - National Drug and Alcohol Research Centre, UNSW, Sydney, New South Wales,
      Australia.
FAU - Slade, Tim
AU  - Slade T
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Haber, Paul S
AU  - Haber PS
AD  - University of Sydney Addiction Medicine, Royal Prince Alfred Hospital,
      Camperdown, New South Wales, Australia.
AD  - Drug Health Services, Sydney Local Health District, Camperdown, New South Wales, 
      Australia.
FAU - Haasnoot, Katherine
AU  - Haasnoot K
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Keaveny, Madeleine
AU  - Keaveny M
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Tremonti, Chris
AU  - Tremonti C
AD  - Drug Health Services, Sydney Local Health District, Camperdown, New South Wales, 
      Australia.
FAU - Teesson, Maree
AU  - Teesson M
AD  - Matilda Centre for Research in Mental Health and Substance Use, University of
      Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200712
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Australia/epidemiology
MH  - Crime
MH  - Follow-Up Studies
MH  - Health Services
MH  - *Heroin Dependence/therapy
MH  - Humans
MH  - Prospective Studies
MH  - Treatment Outcome
PMC - PMC7359069
OTO - NOTNLM
OT  - *mental health
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/07/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039226 [pii]
AID - 10.1136/bmjopen-2020-039226 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 12;10(7):e039226. doi: 10.1136/bmjopen-2020-039226.


PMID- 32660954
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 12
TI  - Meniscal tear outcome Study (METRO Study): a study protocol for a multicentre
      prospective cohort study exploring the factors which affect outcomes in patients 
      with a meniscal tear.
PG  - e038681
LID - 10.1136/bmjopen-2020-038681 [doi]
AB  - INTRODUCTION: This study is designed to explore the baseline characteristics of
      patients under 55 years of age with a meniscal tear, and to describe the
      relationship between the baseline characteristics and patient-reported outcome
      measures (PROMs) over 12 months. Research has highlighted the need for a trial to
      investigate the effectiveness of arthroscopic meniscectomy in younger patients.
      Before this trial, we need to understand the patient population in greater
      detail. METHODS AND ANALYSIS: This is a multicentre prospective cohort study.
      Participants aged between 18 and 55 years with an MRI confirmed meniscal tear are
      eligible for inclusion. Baseline characteristics including age, body mass index, 
      gender, PROMs duration of symptoms and MRI will be collected. The primary outcome
      measure is the Western Ontario Meniscal Evaluation Tool at 12 months. Secondary
      outcome measures will include PROMs such as EQ5D, Knee Injury and Osteoarthritis 
      Outcome Score and patient global impression of change score at 3, 6 and 12
      months. ETHICS AND DISSEMINATION: The study obtained approval from the National
      Research Ethics Committee West Midlands-Black Country research ethics committee
      (19/WM/0079) on 12 April 2019. The study is sponsored by the University of
      Warwick. The results will be disseminated via peer-reviewed publication. TRIAL
      REGISTRATION NUMBER: UHCW R&D Reference: IA428119. University of Warwick Sponsor 
      ID: SC.08/18-19.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ahmed, Imran
AU  - Ahmed I
AUID- ORCID: 0000-0003-2774-9954
AD  - Warwick Clinical Trials Unit, University of Warwick Warwick Medical School,
      Coventry, UK imran.ahmed4@nhs.net.
FAU - Bowes, Mike
AU  - Bowes M
AD  - IMorphics Limited, Manchester, UK.
FAU - Hutchinson, Charles E
AU  - Hutchinson CE
AD  - Warwick Medical School, University of Warwick, Coventry, Coventry, UK.
FAU - Parsons, Nicholas
AU  - Parsons N
AD  - Warwick Medical School, University of Warwick, Coventry, Coventry, UK.
FAU - Staniszewska, Sophie
AU  - Staniszewska S
AD  - Warwick Medical School, University of Warwick, Coventry, Coventry, UK.
FAU - Price, Andrew James
AU  - Price AJ
AUID- ORCID: 0000-0002-4258-5866
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, UK.
FAU - Metcalfe, Andrew
AU  - Metcalfe A
AUID- ORCID: 0000-0002-4515-8202
AD  - Warwick Clinical Trials Unit, University of Warwick Warwick Medical School,
      Coventry, UK.
AD  - Trauma and Orthopaedics, University Hospitals Coventry and Warwickshire NHS
      Trust, Coventry, UK.
LA  - eng
GR  - DRF-2018-11-ST2-030/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200712
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Humans
MH  - Infant
MH  - *Knee Injuries/surgery
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Ontario
MH  - Outcome Assessment, Health Care
MH  - Prospective Studies
MH  - *Tibial Meniscus Injuries/diagnostic imaging/surgery
MH  - Young Adult
PMC - PMC7359070
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *knee
OT  - *orthopaedic & trauma surgery
COIS- Competing interests: MB is a senior director of clinical applications at
      IMorphics limited.
EDAT- 2020/07/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038681 [pii]
AID - 10.1136/bmjopen-2020-038681 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 12;10(7):e038681. doi: 10.1136/bmjopen-2020-038681.


PMID- 32660953
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 12
TI  - Novel education-based intervention to reduce inappropriate antibiotic prescribing
      for treatment of gonorrhoea in China: protocol for a cluster randomised
      controlled trial.
PG  - e037549
LID - 10.1136/bmjopen-2020-037549 [doi]
AB  - INTRODUCTION: Inappropriate use of antibiotics to treat gonorrhoea can lead to
      antibiotic resistance. Education programmes may be helpful for improving
      physician prescribing behaviours in accordance with treatment guidelines. As
      traditional education based on printed materials may have limited effect on
      guideline-based treatment, innovative education strategies are needed. The
      current trial aims to assess the effectiveness of a novel education intervention 
      to increase guideline-based treatment of gonorrhoea in China. METHODS AND
      ANALYSIS: We will conduct a two-arm cluster randomised control trial at 144
      hospitals (clusters) in eight Chinese provinces. The intervention will include an
      online training video developed on the WenJuanXing platform that covers workflows
      and requirements for managing a patient with uncomplicated gonorrhoea. Outpatient
      physicians in dermatology (dermatovenerology), urology, andrology and gynaecology
      will be given access to the video via a quick response code. In hospitals
      allocated to the control arm, physicians will continue to participate in their
      standard of care training programme. The primary outcome is the proportion of
      gonorrhoea antibiotic prescriptions adherent to Chinese national guidelines at
      the cluster level. In addition, to understand the reasons of physician's
      non-adherence to the intervention by conducting a questionnaire survey will be
      considered as the secondary outcome of the study. ETHICS AND DISSEMINATION:
      Ethical approval was obtained from the Medical Ethics Committee of the Chinese
      Academy of Medical Sciences Institute of Dermatology (2020-LS-004). All
      physicians will provide an informed consent prior to participating in the study. 
      Findings of the trial will be disseminated through conferences and peer-reviewed 
      journals, and will be used to develop training programmes for physicians. TRIAL
      REGISTRATION NUMBER: ChiCTR2000029591.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jiang, Ting-Ting
AU  - Jiang TT
AUID- ORCID: 0000-0002-0789-8816
AD  - Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union
      Medical College, Nanjing, China.
AD  - National Center for STD Control, Chinese Center for Disease Control and
      Prevention, Nanjing, China.
FAU - Yang, Yun-Qing
AU  - Yang YQ
AD  - Department of prevention and health care, Guangzhou Institute of Dermatology,
      Guangzhou, China.
FAU - Cao, Ning-Xiao
AU  - Cao NX
AD  - Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union
      Medical College, Nanjing, China.
AD  - National Center for STD Control, Chinese Center for Disease Control and
      Prevention, Nanjing, China.
FAU - Yin, Yue-Ping
AU  - Yin YP
AD  - Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union
      Medical College, Nanjing, China.
AD  - National Center for STD Control, Chinese Center for Disease Control and
      Prevention, Nanjing, China.
FAU - Chen, Xiang-Sheng
AU  - Chen XS
AUID- ORCID: 0000-0003-3927-2065
AD  - Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union
      Medical College, Nanjing, China chenxs@ncstdlc.org.
AD  - National Center for STD Control, Chinese Center for Disease Control and
      Prevention, Nanjing, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200712
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - China
MH  - *Gonorrhea/drug therapy
MH  - Humans
MH  - Inappropriate Prescribing
MH  - Primary Health Care
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Tract Infections/drug therapy
PMC - PMC7359379
OTO - NOTNLM
OT  - *infection control
OT  - *infectious diseases & infestations
OT  - *urinary tract infections
COIS- Competing interests: None declared.
EDAT- 2020/07/15 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-037549 [pii]
AID - 10.1136/bmjopen-2020-037549 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 12;10(7):e037549. doi: 10.1136/bmjopen-2020-037549.


PMID- 32660952
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 12
TI  - Catalonia Suicide Risk Code Epidemiology (CSRC-Epi) study: protocol for a
      population-representative nested case-control study of suicide attempts in
      Catalonia, Spain.
PG  - e037365
LID - 10.1136/bmjopen-2020-037365 [doi]
AB  - INTRODUCTION: Suicide attempts represent an important public health burden.
      Centralised electronic health record (EHR) systems have high potential to provide
      suicide attempt surveillance, to inform public health action aimed at reducing
      risk for suicide attempt in the population, and to provide data-driven clinical
      decision support for suicide risk assessment across healthcare settings. To
      exploit this potential, we designed the Catalonia Suicide Risk Code Epidemiology 
      (CSRC-Epi) study. Using centralised EHR data from the entire public healthcare
      system of Catalonia, Spain, the CSRC-Epi study aims to estimate reliable suicide 
      attempt incidence rates, identify suicide attempt risk factors and develop
      validated suicide attempt risk prediction tools. METHODS AND ANALYSIS: The
      CSRC-Epi study is registry-based study, specifically, a two-stage
      exposure-enriched nested case-control study of suicide attempts during the period
      2014-2019 in Catalonia, Spain. The primary study outcome consists of first and
      repeat attempts during the observation period. Cases will come from a case
      register linked to a suicide attempt surveillance programme, which offers
      in-depth psychiatric evaluations to all Catalan residents who present to clinical
      care with any suspected risk for suicide. Predictor variables will come from
      centralised EHR systems representing all relevant healthcare settings. The
      study's sampling frame will be constructed using population-representative
      administrative lists of Catalan residents. Inverse probability weights will
      restore representativeness of the original population. Analysis will include the 
      calculation of age-standardised and sex-standardised suicide attempt incidence
      rates. Logistic regression will identify suicide attempt risk factors on the
      individual level (ie, relative risk) and the population level (ie, population
      attributable risk proportions). Machine learning techniques will be used to
      develop suicide attempt risk prediction tools. ETHICS AND DISSEMINATION: This
      protocol is approved by the Parc de Salut Mar Clinical Research Ethics Committee 
      (2017/7431/I). Dissemination will include peer-reviewed scientific publications, 
      scientific reports for hospital and government authorities, and updated clinical 
      guidelines. TRIAL REGISTRATION NUMBER: NCT04235127.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mortier, Philippe
AU  - Mortier P
AUID- ORCID: 0000-0003-2113-6241
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain pmortier@imim.es.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
FAU - Vilagut, Gemma
AU  - Vilagut G
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
FAU - Puertolas Gracia, Beatriz
AU  - Puertolas Gracia B
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
FAU - De Ines Trujillo, Ana
AU  - De Ines Trujillo A
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - Department of Social Psychology, Autonomous University of Barcelona (UAB),
      Cerdanyola del Valles, Barcelona, Spain.
FAU - Alayo Bueno, Itxaso
AU  - Alayo Bueno I
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
FAU - Ballester Coma, Laura
AU  - Ballester Coma L
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
AD  - Department of Psychology, University of Girona (UdG), Girona, Spain.
FAU - Blasco Cubedo, Maria Jesus
AU  - Blasco Cubedo MJ
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
AD  - Department of Health & Experimental Sciences, Pompeu Fabra University (UPF),
      Barcelona, Spain.
FAU - Cardoner, Narcis
AU  - Cardoner N
AD  - Depression and Anxiety Program, Department of Mental Health, Parc Tauli Sabadell,
      Hospital Universitari, Sabadell, Spain.
AD  - Department of Psychiatry and Legal Medicine, Universitat Autonoma de Barcelona
      (UAB), Cerdanyola Del Valles, Barcelona, Spain.
AD  - Centro de Investigacion en Red de Salud Mental, CIBERSAM, Madrid, Spain.
AD  - Institut d'Investigacio i Innovacio Parc Tauli (I3PT), Sabadell, Barcelona,
      Spain.
FAU - Colls, Cristina
AU  - Colls C
AD  - Agencia de Qualitat i Avaluacio Sanitaries de Catalunya - Health Evaluation and
      Quality Agency of Catalonia (AQuAS), Catalan Health Department, Barcelona, Spain.
FAU - Elices, Matilde
AU  - Elices M
AD  - Centro de Investigacion en Red de Salud Mental, CIBERSAM, Madrid, Spain.
AD  - Neurosciences Research Programme, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
FAU - Garcia-Altes, Anna
AU  - Garcia-Altes A
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
AD  - Agencia de Qualitat i Avaluacio Sanitaries de Catalunya - Health Evaluation and
      Quality Agency of Catalonia (AQuAS), Catalan Health Department, Barcelona, Spain.
AD  - Institut d'Investigacio Biomedica (IIB Sant Pau), Barcelona, Spain.
FAU - Gene Badia, Manel
AU  - Gene Badia M
AD  - Legal Medicine Unit, Faculty of Medicine, University of Barcelona, Barcelona,
      Spain.
FAU - Gomez Sanchez, Javier
AU  - Gomez Sanchez J
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
FAU - Martin Sanchez, Mario
AU  - Martin Sanchez M
AD  - Preventive Medicine and Public Health Training Unit PSMar-UPF-ASPB, Parc de Salut
      Mar, Agencia de Salut Publica de Barcelona, Pompeu Fabra University, Barcelona,
      Spain.
FAU - Morros, Rosa
AU  - Morros R
AD  - Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut
      Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
AD  - Departament de Farmacologia, de Terapeutica i de Toxicologia, Universitat
      Autonoma de Barcelona, Barcelona, Spain.
AD  - Institut Catala de la Salut (ICS), Metropolitana Nord, Barcelona, Spain.
FAU - Prat Pubill, Bibiana
AU  - Prat Pubill B
AD  - Master Plan on Mental Health and Addictions, Ministry of Health, Catalan
      Government, Barcelona, Spain.
FAU - Qin, Ping
AU  - Qin P
AD  - National Centre for Suicide Research and Prevention, Institute of Clinical
      Medicine, University of Oslo, Oslo, Norway.
FAU - Mehlum, Lars
AU  - Mehlum L
AD  - National Centre for Suicide Research and Prevention, Institute of Clinical
      Medicine, University of Oslo, Oslo, Norway.
FAU - Kessler, Ronald C
AU  - Kessler RC
AD  - Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.
FAU - Palao, Diego
AU  - Palao D
AD  - Depression and Anxiety Program, Department of Mental Health, Parc Tauli Sabadell,
      Hospital Universitari, Sabadell, Spain.
AD  - Department of Psychiatry and Legal Medicine, Universitat Autonoma de Barcelona
      (UAB), Cerdanyola Del Valles, Barcelona, Spain.
AD  - Centro de Investigacion en Red de Salud Mental, CIBERSAM, Madrid, Spain.
AD  - Institut d'Investigacio i Innovacio Parc Tauli (I3PT), Sabadell, Barcelona,
      Spain.
FAU - Perez Sola, Victor
AU  - Perez Sola V
AD  - Department of Psychiatry and Legal Medicine, Universitat Autonoma de Barcelona
      (UAB), Cerdanyola Del Valles, Barcelona, Spain.
AD  - Centro de Investigacion en Red de Salud Mental, CIBERSAM, Madrid, Spain.
AD  - Neurosciences Research Programme, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain.
FAU - Alonso, Jordi
AU  - Alonso J
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research
      Institute), Barcelona, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
AD  - Department of Health & Experimental Sciences, Pompeu Fabra University (UPF),
      Barcelona, Spain.
CN  - CODIRISC Epidemiology Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT04235127
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200712
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Case-Control Studies
MH  - Humans
MH  - Risk
MH  - Risk Factors
MH  - Spain/epidemiology
MH  - *Suicidal Ideation
MH  - *Suicide, Attempted
PMC - PMC7359191
OTO - NOTNLM
OT  - *epidemiology
OT  - *mental health
OT  - *psychiatry
OT  - *public health
OT  - *statistics & research methods
OT  - *suicide & self-harm
COIS- Competing interests: DP has received grants and also served as consultant or
      advisor for Angelini, Janssen, Lundbeck and Servier. The other authors have no
      competing interests to declare.
EDAT- 2020/07/15 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-037365 [pii]
AID - 10.1136/bmjopen-2020-037365 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 12;10(7):e037365. doi: 10.1136/bmjopen-2020-037365.


PMID- 32660946
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 12
TI  - 'Barrier dysfunction in Atopic newBorns studY' (BABY): protocol of a Danish
      prospective birth cohort study.
PG  - e033801
LID - 10.1136/bmjopen-2019-033801 [doi]
AB  - INTRODUCTION: Skin barrier development and dysfunction in premature and mature
      newborns is important for the risk of atopic dermatitis (AD). METHODS AND
      ANALYSIS: The Barrier dysfunction in Atopic newBorns studY (BABY) Cohort is a
      prospective birth cohort study of 150 preterm children (gestational age (GA)
      below 37+0) and 300 term children (GA 37+0 to 41+6). Skin barrier is assessed
      through transepidermal water loss, tape stripping, Raman-spectroscopy and
      microbiome sampling. Clinical examinations are done and DNA from buccal swabs is 
      collected for genetic analyses. Thymus size is assessed by ultrasound
      examination. Information on pregnancy, delivery, parental exposures and diseases 
      are collected, and structured telephone interviews are conducted at 18 and 24
      months to assess exogenous exposures in the child and onset of AD. Hanifin and
      Rajka criteria as well as The UK Working Party's Diagnostic Criteria for Atopic
      Dermatitis are used to diagnose AD. Severity of AD is assessed using the Eczema
      Area and Severity Index (EASI) and Patient Oriented Eczema Measure (POEM). ETHICS
      AND DISSEMINATION: The study is approved by the scientific Ethical Committee of
      the Capital Region (H-16042289 and H-16042294).Outcomes will be presented at
      national and international conferences and in peer-reviewed publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gerner, Trine
AU  - Gerner T
AUID- ORCID: 0000-0002-5377-4013
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
FAU - Halling, Anne-Sofie
AU  - Halling AS
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
FAU - Rasmussen Rinnov, Maria
AU  - Rasmussen Rinnov M
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
FAU - Haarup Ravn, Nina
AU  - Haarup Ravn N
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
FAU - Hjorslev Knudgaard, Mette
AU  - Hjorslev Knudgaard M
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
FAU - Menne Bonefeld, Charlotte
AU  - Menne Bonefeld C
AD  - Department of Immunology and Microbiology, Skin Immunology Research Center,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Ewertsen, Caroline
AU  - Ewertsen C
AD  - Department of Radiology, Rigshospitalet, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Trautner, Simon
AU  - Trautner S
AD  - Department of Neonatology, Rigshospitalet, University of Copenhagen, Copenhagen, 
      Denmark.
FAU - Jakasa, Ivone
AU  - Jakasa I
AD  - Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry,
      Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb,
      Croatia.
FAU - Kezic, Sanja
AU  - Kezic S
AD  - Coronel Institute of Occupational Health, Amsterdam UMC, Amsterdam Public Health 
      Research Institute, University of Amsterdam, Amsterdam, The Netherlands.
FAU - Skov, Lone
AU  - Skov L
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
FAU - Thyssen, Jacob P
AU  - Thyssen JP
AD  - Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University
      of Copenhagen, Hellerup, Denmark Jacob.p.thyssen@regionh.dk.
AD  - Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte
      Hospital, Hellerup, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200712
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Cohort Studies
MH  - Denmark/epidemiology
MH  - *Dermatitis, Atopic/epidemiology
MH  - *Eczema/epidemiology
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Prospective Studies
PMC - PMC7359193
OTO - NOTNLM
OT  - *Raman
OT  - *TEWL
OT  - *atopic dermatitis
OT  - *birth cohort
OT  - *preterm
OT  - *skin barrier
COIS- Competing interests: JPT reports grants from The Leo Foundation, The Novo Nordisk
      Foundation, Pfizer, The Lundbeck Foundation and grants from Savvaerksejer Jeppe
      Juhl og hustru Ovita Juhls Mindelegat, during the conduct of the study. JPT has
      been an advisor, investigator and speaker for AbbVie, Regeneron, Pfizer, Sanofi
      Genzyme, LEO Pharma and Eli Lilly and Company.LS reports personal fees from
      AbbVie, Eli Lilly, Novartis, Sanofi, Celgene, LEO Pharma and Almirall, outside
      the submitted work. LS reports non-financial support from AbbVie, Sanofi, Janssen
      and grants from Novartis, Janssen and Sanofi.TG, A-SH-H, MRR, NHR and MHK report 
      grants from Herlev and Gentofte Hospital Research Foundation during the conduct
      of the study.
EDAT- 2020/07/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033801 [pii]
AID - 10.1136/bmjopen-2019-033801 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 12;10(7):e033801. doi: 10.1136/bmjopen-2019-033801.


PMID- 32660660
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
VI  - 14
IP  - 6
DP  - 2020 Dec
TI  - Clinical and Ethical Considerations in Allocation of Ventilators in an Influenza 
      Pandemic or Other Public Health Disaster: A Comparison of the 2007 and 2015 New
      York State Ventilator Allocation Guidelines.
PG  - e35-e44
LID - 10.1017/dmp.2020.232 [doi]
AB  - OBJECTIVES: During an influenza or coronavirus disease 2019 (COVID-19) pandemic
      that results in acute respiratory distress, the number of available ventilators
      will not meet demand. In 2007, the New York State Task Force on Life and the Law 
      and Department of Health released draft Guidelines for ethical allocation of
      ventilators for adults. In 2015, updated guidelines were released to ensure that:
      (1) revisions reflect the public's values and (2) the triage protocol is
      substantiated by evidence-based clinical data. We summarize the development and
      content of the 2015 Guidelines compared with the 2007 version, emphasizing
      new/revised aspects of the ethical considerations and clinical protocol. METHODS:
      We compared the 2007 and 2015 guidelines, with particular emphasis on the ethical
      issues and clinical protocols. RESULTS: The 2015 Guidelines retained much of the 
      ethical and clinical framework of the 2007 draft. The triage protocol was revised
      using evidence-based clinical data. Patients with the highest likelihood of
      short-term survival with ventilator therapy have priority access. Protocol
      consists of exclusion criteria, the sequential organ failure assessment (SOFA)
      score, and periodic clinical assessments. Guidance is provided on secondary
      triage criteria. Other forms of medical intervention/palliative care and review
      of triage decisions are discussed. CONCLUSIONS: The 2015 Guidelines reflect
      advances in medicine and societal values and provide an evidenced-based framework
      to save the most lives. The framework could be adapted in other emergencies, such
      as the COVID-19 pandemic, that require ventilators.
FAU - Han, Susie A
AU  - Han SA
AD  - New York State Task Force on Life and the Law, Venture Catalyst, New York, New
      York.
FAU - Koch, Valerie Gutmann
AU  - Koch VG
AD  - New York State Task Force on Life and the Law, New York, New York.
AD  - MacLean Center for Clinical Medical Ethics at the University of Chicago, Chicago,
      Illinois.
AD  - Health Law & Policy Institute at the University of Houston Law Center, Houston,
      Texas.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
MH  - Age Factors
MH  - COVID-19/*epidemiology
MH  - Clinical Protocols
MH  - Disaster Planning/*organization & administration/standards
MH  - Guidelines as Topic
MH  - Health Care Rationing/ethics/*organization & administration/standards
MH  - Humans
MH  - Influenza, Human/*epidemiology
MH  - Organ Dysfunction Scores
MH  - Palliative Care/organization & administration
MH  - Pandemics
MH  - Public Health
MH  - SARS-CoV-2
MH  - Survival Analysis
MH  - Triage/organization & administration
MH  - Ventilators, Mechanical/*supply & distribution
PMC - PMC7403745
OTO - NOTNLM
OT  - COVID-19/coronavirus
OT  - disaster planning
OT  - influenza pandemic
OT  - triage
OT  - ventilator
EDAT- 2020/07/15 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
AID - S1935789320002323 [pii]
AID - 10.1017/dmp.2020.232 [doi]
PST - ppublish
SO  - Disaster Med Public Health Prep. 2020 Dec;14(6):e35-e44. doi:
      10.1017/dmp.2020.232. Epub 2020 Jul 14.


PMID- 32660622
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 2040-2392 (Electronic)
VI  - 11
IP  - 1
DP  - 2020 Jul 13
TI  - Cerebral organoids as tools to identify the developmental roots of autism.
PG  - 58
LID - 10.1186/s13229-020-00360-3 [doi]
AB  - Some autism spectrum disorders (ASD) likely arise as a result of abnormalities
      during early embryonic development of the brain. Studying human embryonic brain
      development directly is challenging, mainly due to ethical and practical
      constraints. However, the recent development of cerebral organoids provides a
      powerful tool for studying both normal human embryonic brain development and,
      potentially, the origins of neurodevelopmental disorders including ASD.
      Substantial evidence now indicates that cerebral organoids can mimic normal
      embryonic brain development and neural cells found in organoids closely resemble 
      their in vivo counterparts. However, with prolonged culture, significant
      differences begin to arise. We suggest that cerebral organoids, in their current 
      form, are most suitable to model earlier neurodevelopmental events and processes 
      such as neurogenesis and cortical lamination. Processes implicated in ASDs which 
      occur at later stages of development, such as synaptogenesis and neural circuit
      formation, may also be modeled using organoids. The accuracy of such models will 
      benefit from continuous improvements to protocols for organoid differentiation.
FAU - Chan, Wai Kit
AU  - Chan WK
AD  - Centre for Discovery Brain Sciences and Simons Initiative for the Developing
      Brain, University of Edinburgh, George Square, Edinburgh, EH8 9XD, UK.
FAU - Griffiths, Rosie
AU  - Griffiths R
AD  - Centre for Discovery Brain Sciences and Simons Initiative for the Developing
      Brain, University of Edinburgh, George Square, Edinburgh, EH8 9XD, UK.
FAU - Price, David J
AU  - Price DJ
AD  - Centre for Discovery Brain Sciences and Simons Initiative for the Developing
      Brain, University of Edinburgh, George Square, Edinburgh, EH8 9XD, UK.
FAU - Mason, John O
AU  - Mason JO
AUID- ORCID: 0000-0002-0489-2400
AD  - Centre for Discovery Brain Sciences and Simons Initiative for the Developing
      Brain, University of Edinburgh, George Square, Edinburgh, EH8 9XD, UK.
      John.Mason@ed.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200713
PL  - England
TA  - Mol Autism
JT  - Molecular autism
JID - 101534222
SB  - IM
MH  - Autistic Disorder/*diagnosis/*pathology/physiopathology
MH  - Cerebrum/embryology/*pathology
MH  - Electrophysiological Phenomena
MH  - Humans
MH  - Neurons/pathology
MH  - Organoids/*pathology
MH  - Synapses/pathology
PMC - PMC7359249
OTO - NOTNLM
OT  - *Autism spectrum disorder
OT  - *Cerebral organoids
OT  - *Embryonic brain development
EDAT- 2020/07/15 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
AID - 10.1186/s13229-020-00360-3 [doi]
AID - 10.1186/s13229-020-00360-3 [pii]
PST - epublish
SO  - Mol Autism. 2020 Jul 13;11(1):58. doi: 10.1186/s13229-020-00360-3.


PMID- 32660550
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 13
TI  - Will my patients get their residence permit? A critical analysis of the ethical
      dilemmas involved in writing medical certificates for residence permits in
      France.
PG  - 59
LID - 10.1186/s12910-020-00500-7 [doi]
AB  - BACKGROUND: France has long been a country of immigration and in some respects
      may be seen to have a generous policy with respect to asylum seekers and access
      to health care for migrants. The French state notably provides healthcare access 
      for undocumented migrants, through state medical aid and since 1998 has had a
      humanitarian policy for granting temporary residence permits for medical reason
      (TRPMR) to migrants. Within a context of political debate, reform and tightening 
      immigration control we will examine this latter policy focusing especially on the
      dilemmas that arise for physicians of migrant patients when they are requested to
      write medical certificates as part of a TRPMR application. In a 2017 reform the
      key role of making recommendations on the granting or not of permits was handed
      over to Ministry of the Interior health inspectors. Recommendations are made
      after perusal of medical certificates established by the migrant's physician and 
      complementary evidence. MAIN BODY: The writing of medical certificates by a
      physician would seem straightforward. This is far from the case since it raises a
      number of ethical dilemmas. These occur within a physician-patient relationship
      embedded within a social contract between the State, the physician and the
      migrant patient. To clarify the ethical issues arising 3 vignettes based on
      practice within an infectious disease unit at a large Paris hospital have been
      developed. The vignettes highlight ethical dilemmas in the care for migrants with
      tuberculosis (dilemma in defining health and disease), chronic hepatitis (dilemma
      between beneficence and do not harm), and HIV / AIDS (issue of deservingness). We
      will go on to reflect on issues of social justice and responsibility for the
      health of migrants within a globalized world. CONCLUSIONS: Criteria for residence
      permit delivery appear less than clear-cut and are interpreted in a restrictive
      way. Neither are the consequences of refusing a residence permit taken into
      account. We call for an empirical transnational ethics study involving countries 
      implementing similar TRPMR policies. We also call for inclusion of lobbying
      competences into the medical undergraduate curricula, in order to breed future
      generations of physicians skilled in defending social justice.
FAU - Cailhol, Johann
AU  - Cailhol J
AUID- ORCID: 0000-0002-8367-9957
AD  - Laboratoire Educations et Pratiques de Sante, Universite Paris 13, 74 rue Marcel 
      Cachin, Bobigny, France. johann.cailhol@aphp.fr.
AD  - Infectious diseases unit, Avicenne teaching hospital, APHP, 125 route de
      Stalingrad, 93000, Bobigny, France. johann.cailhol@aphp.fr.
AD  - Institut Convergences Migrations, Campus Condorcet, Hotel a projets, 8 cours des 
      Humanites, 93300, Aubervilliers, France. johann.cailhol@aphp.fr.
FAU - Lebon, Marie-Christine
AU  - Lebon MC
AD  - Infectious diseases unit, Avicenne teaching hospital, APHP, 125 route de
      Stalingrad, 93000, Bobigny, France.
FAU - Sherlaw, William
AU  - Sherlaw W
AD  - Laboratoire d'Etudes et de Recherche en Sociologie, Universite de Bretagne
      Occidentale, 20 rue Duquesne, 29200, Brest, France.
AD  - Ecole des Hautes Etudes en Sante Publique, 15 avenue du Professeur Leon-Bernard, 
      35043, Rennes, France.
LA  - eng
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Beneficence
MH  - France
MH  - *Health Services Accessibility
MH  - Humans
MH  - Paris
MH  - *Writing
PMC - PMC7359478
OTO - NOTNLM
OT  - *Ethical dilemma
OT  - *France
OT  - *Ill-migrants
OT  - *Physicians
OT  - *Temporary residence permit
EDAT- 2020/07/15 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/15 06:00
PHST- 2019/05/23 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00500-7 [doi]
AID - 10.1186/s12910-020-00500-7 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 13;21(1):59. doi: 10.1186/s12910-020-00500-7.


PMID- 32660439
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20211204
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 13
TI  - A single-arm confirmatory trial of pazopanib in patients with
      paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology
      Group study (JCOG1605, JCOG-PCAS protocol).
PG  - 652
LID - 10.1186/s12885-020-07136-1 [doi]
AB  - BACKGROUND: Paclitaxel is a standard of care for patients with primary cutaneous 
      angiosarcoma of the scalp and face. However, no standard second-line treatment
      for paclitaxel-resistant patients has ever been established. Since primary
      cutaneous angiosarcoma expresses a high level of vascular endothelial growth
      factor receptor, the multitargeted tyrosine kinase inhibitor pazopanib seemed to 
      be the most promising agent, and several retrospective studies have demonstrated 
      its activity against this disease. However, the efficacy and safety of pazopanib 
      in paclitaxel-resistant patients with primary cutaneous angiosarcoma have never
      been evaluated in a clinical trial. METHODS: In February 2018 the Dermatologic
      Oncology Group of Japan Clinical Oncology Group started a single-arm confirmatory
      trial to evaluate the efficacy and safety of pazopanib as a second-line treatment
      for patients with primary cutaneous angiosarcoma whose disease was resistant to
      paclitaxel or who were unable to tolerate paclitaxel (JCOG1605, JCOG-PCAS).
      Patients with primary cutaneous angiosarcoma not associated with lymphedema or
      radiation, progressing despite first-line paclitaxel monotherapy are included in 
      the study. No prior systemic chemotherapy other than paclitaxel is permitted.
      Pazopanib is administered orally at an initial dosage of 800 mg once daily. Dose 
      modifications for adverse events are made according to the dose reduction
      criteria described in the protocol. Treatment is continued until recurrence,
      disease progression, unacceptable toxic effects, patient refusal, or death. The
      primary endpoint is progression-free survival, secondary endpoints include
      overall survival, response rate, disease control rate, adverse events, and
      serious adverse events. We plan to recruit 30 participants in 5.5 years from 23
      Japanese institutions. The follow-up period is set as 1 year after completion of 
      accrual. The study protocol was approved by the Japan Clinical Oncology Group
      Protocol Review Committee in December 2017. Ethical approval for this study was
      granted by Ethics Committee of each institute. DISCUSSION: If the primary
      endpoint is met, pazopanib will be regarded as a standard of care for
      paclitaxel-resistant patients for whom no standard second-line treatment is
      established. TRIALS REGISTRATION: Registry number: UMIN000031438 [
      http://www.umin.ac.jp/ctr/index.htm ]. Date of Registration: 23/Feb/2018. Date of
      First Participant Enrollment: 8/Mar/2018.
FAU - Oashi, Kohei
AU  - Oashi K
AUID- ORCID: http://orcid.org/0000-0002-0123-9430
AD  - Department of Dermatology, Saitama Cancer Center, 780 Komuro, Ina,
      Kita-adachi-gun, Saitama, 362-0806, Japan. oashi@cancer-c.pref.saitama.jp.
FAU - Shibata, Taro
AU  - Shibata T
AD  - JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo,
      Japan.
FAU - Namikawa, Kenjiro
AU  - Namikawa K
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Takahashi, Akira
AU  - Takahashi A
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Yokota, Kenji
AU  - Yokota K
AD  - Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya,
      Japan.
FAU - Nakano, Eiji
AU  - Nakano E
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Teramoto, Yukiko
AU  - Teramoto Y
AD  - Department of Skin Oncology/Dermatology, Saitama Medical University International
      Medical Center, Saitama, Japan.
FAU - Tsutsumida, Arata
AU  - Tsutsumida A
AD  - Department of Dermatologic Oncology, Dermatology, Cancer Institute Hospital,
      Tokyo, Japan.
FAU - Maeda, Taku
AU  - Maeda T
AD  - Department of Plastic and Reconstructive Surgery, Faculty of Medicine and
      Graduate School of Medicine Hokkaido University, Sapporo, Japan.
FAU - Yamazaki, Naoya
AU  - Yamazaki N
AD  - Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
CN  - Dermatologic Oncology Group of the Japan Clinical Oncology Group
LA  - eng
GR  - 2020-J-3/National Cancer Center Research and Development Fund of Japan
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Indazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Phytogenic/*therapeutic use
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Hemangiosarcoma/*drug therapy/pathology
MH  - Humans
MH  - Indazoles
MH  - Male
MH  - Middle Aged
MH  - Paclitaxel/*pharmacology
MH  - Prognosis
MH  - Pyrimidines/*therapeutic use
MH  - Research Design
MH  - *Salvage Therapy
MH  - Skin Neoplasms/*drug therapy/pathology
MH  - Sulfonamides/*therapeutic use
MH  - Young Adult
PMC - PMC7359578
OTO - NOTNLM
OT  - Angiosarcoma
OT  - Chemotherapy
OT  - Paclitaxel-resistant
OT  - Pazopanib
OT  - Single arm comfirmatory trial
EDAT- 2020/07/15 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/07/15 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
AID - 10.1186/s12885-020-07136-1 [doi]
AID - 10.1186/s12885-020-07136-1 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Jul 13;20(1):652. doi: 10.1186/s12885-020-07136-1.


PMID- 32660431
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 13
TI  - Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era 
      of HIV.
PG  - 226
LID - 10.1186/s12876-020-01372-2 [doi]
AB  - BACKGROUND: Patients co-infected with hepatitis B virus (HBV) and the human
      immunodeficiency virus (HIV) are at risk of developing hepatocellular carcinoma
      (HCC). In sub-Saharan Africa, the overlap between high HIV and HBV prevalence may
      increase the incidence of HCC. This study investigated the impact of HBV/HIV
      co-infection on age at presentation and survival of HCC. METHODS: Ethical
      approval was obtained to recruit, following informed written consent, patients
      diagnosed with HCC at oncology units at four South African hospitals. Between
      December 2012 and August 2015, patients newly diagnosed with HCC were recruited
      and provided demographic and clinical data and blood specimens. Patients were
      tested for HBV, hepatitis C virus (HCV) and HIV. Survival data was available for 
      a subset of patients. RESULTS: Of 107 HCC cases, 83 (78%) were male. Median age
      was 46 years (range 18 to 90 years), 68/106 (64%) were HBsAg-positive, and 22/100
      (22%) were HIV infected. Among HBV surface antigen (HBsAg)-positive HCC cases,
      18/66 (27%) were HIV-infected compared to 3/34 (9%) among those that were
      HBsAg-negative (p = 0.04). A greater proportion of HBV/HIV co-infected cases were
      female than HBV mono-infected (6/18, 33% vs 6/47, 13%; p = 0.005). In addition,
      HBV/HIV co-infected females presented at a younger mean age (36.8 years) than HBV
      mono-infected women (50.5 years) (p = 0.09). Median survival was 82 days among
      the HIV-infected HCC patients compared to 181 days among those without HIV (p =
      0.15). CONCLUSIONS: HCC is an important complication in the HIV/HBV infected
      patient. HIV-positive patients presented with HCC at a younger age than
      HIV-negative patients, this effect appears to be greater in women. These data
      provide more evidence supporting the call to address. HCC as a cause of morbidity
      and mortality in the HBV/HIV co-infected patient population. (281 words).
FAU - Maponga, Tongai Gibson
AU  - Maponga TG
AUID- ORCID: http://orcid.org/0000-0002-6876-3712
AD  - Division of Medical Virology, Stellenbosch University, Faculty of Medicine and
      Health Sciences, Cape Town, South Africa. tongai@sun.ac.za.
FAU - Glashoff, Richard H
AU  - Glashoff RH
AD  - Division of Medical Microbiology & Immunology, Stellenbosch University, Faculty
      of Medicine and Health Sciences, Cape Town, South Africa.
AD  - Tygerberg Business Unit, National Health Laboratory Service, Cape Town, South
      Africa.
FAU - Vermeulen, Hannali
AU  - Vermeulen H
AD  - Division of Radiation Oncology, Stellenbosch University, Faculty of Medicine and 
      Health Sciences, Cape Town, South Africa.
FAU - Robertson, Barbara
AU  - Robertson B
AD  - Division of Radiation Oncology, University of Cape Town, Cape Town, South Africa.
FAU - Burmeister, Sean
AU  - Burmeister S
AD  - Department of Surgery, University of Cape Town, Cape Town, South Africa.
FAU - Bernon, Marc
AU  - Bernon M
AD  - Department of Surgery, University of Cape Town, Cape Town, South Africa.
FAU - Omoshoro-Jones, Jones
AU  - Omoshoro-Jones J
AD  - Department of Surgery, University of Witwatersrand, Johannesburg, South Africa.
FAU - Ruff, Paul
AU  - Ruff P
AD  - Division of Medical Oncology, University of Witwatersrand, Johannesburg, South
      Africa.
FAU - Neugut, Alfred I
AU  - Neugut AI
AD  - Department of Medicine, College of Physicians and Surgeons, Columbia University, 
      New York, USA.
AD  - Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons,
      Columbia University, New York, USA.
AD  - Mailman School of Public Health, Columbia University, New York, USA.
FAU - Jacobson, Judith S
AU  - Jacobson JS
AD  - Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons,
      Columbia University, New York, USA.
AD  - Mailman School of Public Health, Columbia University, New York, USA.
FAU - Preiser, Wolfgang
AU  - Preiser W
AD  - Division of Medical Virology, Stellenbosch University, Faculty of Medicine and
      Health Sciences, Cape Town, South Africa.
AD  - Tygerberg Business Unit, National Health Laboratory Service, Cape Town, South
      Africa.
FAU - Andersson, Monique I
AU  - Andersson MI
AD  - Division of Medical Virology, Stellenbosch University, Faculty of Medicine and
      Health Sciences, Cape Town, South Africa.
AD  - Department of Microbiology, Oxford University Hospitals NHS Foundation Trust,
      Oxford, UK.
LA  - eng
GR  - 1D43CA153715/CA/NCI NIH HHS/United States
GR  - NA/Poliomyelitis Research Foundation
GR  - NA/Harry Crossley Foundation
GR  - NA/National Health Laboratory Services Research Trust (ZA)
PT  - Journal Article
DEP - 20200713
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Hepatitis B Surface Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Carcinoma, Hepatocellular/epidemiology
MH  - Female
MH  - *HIV Infections/complications/epidemiology
MH  - *Hepatitis B/complications/epidemiology
MH  - Hepatitis B Surface Antigens
MH  - Hepatitis B virus
MH  - Humans
MH  - *Liver Neoplasms/epidemiology
MH  - Male
MH  - Middle Aged
MH  - South Africa/epidemiology
MH  - Young Adult
PMC - PMC7359588
OTO - NOTNLM
OT  - Age at presentation
OT  - HIV infection
OT  - Hepatitis B infection
OT  - Hepatocellular carcinoma
OT  - Natural history
OT  - Survival
EDAT- 2020/07/15 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/15 06:00
PHST- 2019/05/31 00:00 [received]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12876-020-01372-2 [doi]
AID - 10.1186/s12876-020-01372-2 [pii]
PST - epublish
SO  - BMC Gastroenterol. 2020 Jul 13;20(1):226. doi: 10.1186/s12876-020-01372-2.


PMID- 32659998
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201020
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Jul 9
TI  - Exploring Pictorial Health Education Tools for Long-Term Home Care: A Qualitative
      Perspective.
LID - E205 [pii]
LID - 10.3390/healthcare8030205 [doi]
AB  - Regarding long-term home care needs, nurses need to communicate effectively and
      reasonably when teaching home caregivers. Designers can assist medical staff and 
      develop pictorial tools to enhance communication. The purpose of this study is to
      explore a theoretical basis from the perspective of designers, patients' home
      caregivers, and medical staff to construct a theoretical framework that can
      jointly develop pictorial health education tools and healthcare system. The
      qualitative methods, including in-depth interview and observation, are applied to
      this study; ground theory sets out to construct a framework from the verbatim
      transcript of the interviews. Based on interview results, six axial codes were
      extracted: (1) the method of interdisciplinary cooperation; (2) medical research 
      ethics; (3) communication methods; (4) forms of health education tools; (5)
      development of health education tools; (6) home care intubation procedure. Eight 
      groups of home caregivers offered suggestions from their experiences. The
      designers need to assist medical staff to solve real problems, pay attention to
      professional norms, and forms of cooperation. Health education tools need to meet
      the needs of medical staff and home caregivers and designers should pay attention
      to the processes of communication. This study can also assist in
      interdisciplinary cooperation to explore the theoretical basis of pictorial
      health education tools for nurses in the context of long-term care at home.
FAU - Lin, Fang-Suey
AU  - Lin FS
AD  - Graduate School of Design, National Yunlin University of Science and Technology, 
      Yunlin 64002, Taiwan.
FAU - Shi, Hong-Chun
AU  - Shi HC
AD  - Graduate School of Design, National Yunlin University of Science and Technology, 
      Yunlin 64002, Taiwan.
FAU - Fang, Kwo-Ting
AU  - Fang KT
AD  - Department of Information Management, National Yunlin University of Science and
      Technology, Douliu 64002, Taiwan.
LA  - eng
GR  - the Taiwan Ministry of Science and Technology: 106-2410-H-224-026-/undefined
      <span style="color:gray;font-size:10px;">undefined</span>
PT  - Journal Article
DEP - 20200709
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7551951
OTO - NOTNLM
OT  - a qualitative perspective
OT  - case study
OT  - communication
OT  - long-term home care
OT  - nurses and home caregivers
OT  - pictorial health education tools
EDAT- 2020/07/15 06:00
MHDA- 2020/07/15 06:01
CRDT- 2020/07/15 06:00
PHST- 2020/06/14 00:00 [received]
PHST- 2020/07/06 00:00 [revised]
PHST- 2020/07/06 00:00 [accepted]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2020/07/15 06:01 [medline]
AID - healthcare8030205 [pii]
AID - 10.3390/healthcare8030205 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Jul 9;8(3). pii: healthcare8030205. doi:
      10.3390/healthcare8030205.


PMID- 32659795
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20201113
IS  - 1439-0876 (Electronic)
IS  - 0303-4259 (Linking)
VI  - 47
IP  - 8
DP  - 2020 Nov
TI  - [The State of Application of Clinical Ethics Consultation in German Psychiatric
      Hospitals].
PG  - 446-451
LID - 10.1055/a-1179-4314 [doi]
AB  - This study provides for the first time a comprehensive overview of the
      state-of-the-practice of clinical ethics consultation in German psychiatric
      hospitals. Structures for ethics counselling were available in only 57 % of the
      hospitals. In about one third of the participating hospitals, structures of
      ethics counselling had not yet been considered or were actively dismissed. The
      remaining hospitals reported to be in the process of establishing ethical
      structures. With regard to team characteristics and concrete practical
      implementation, qualitative differences were found between the hospitals. In
      summary, ethical structures are already established in the more than half of the 
      German psychiatric hospitals, but still there is a clear need both in terms of
      dissemination and the quality of practical implementation.
CI  - Thieme. All rights reserved.
FAU - Wollenburg, Lisa Marie
AU  - Wollenburg LM
AD  - Zentrum fur psychische Gesundheit, Klinikum Ingolstadt.
FAU - Claus, Sylvia
AU  - Claus S
AD  - Pfalzklinikum Klingenmunster.
FAU - Kieser, Christian
AU  - Kieser C
AD  - Klinikum Ernst von Bergmann, Potsdam.
FAU - Pollmacher, Thomas
AU  - Pollmacher T
AD  - Zentrum fur psychische Gesundheit, Klinikum Ingolstadt.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Zum Stand der Anwendung klinischer Ethikberatung in deutschen Kliniken fur
      Psychiatrie und Psychotherapie.
DEP - 20200713
PL  - Germany
TA  - Psychiatr Prax
JT  - Psychiatrische Praxis
JID - 0423204
SB  - IM
MH  - *Ethics Consultation
MH  - Germany
MH  - *Hospitals, Psychiatric
MH  - Humans
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/07/14 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1055/a-1179-4314 [doi]
PST - ppublish
SO  - Psychiatr Prax. 2020 Nov;47(8):446-451. doi: 10.1055/a-1179-4314. Epub 2020 Jul
      13.


PMID- 32659642
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
VI  - 252
DP  - 2020 Sep
TI  - Obturator nerve injury in a chemo and radio-resistant patient with a
      locally-advanced cervical cancer after two previous uterine artery embolizations 
      for severe vaginal bleeding: Case report and review of literature.
PG  - 355-358
LID - S0301-2115(20)30442-5 [pii]
LID - 10.1016/j.ejogrb.2020.07.002 [doi]
AB  - Chemo and radiotherapy are actually the gold standard of treatment for
      locally-advanced cervical cancer. We report a case report showing a repaired
      (video 1) right obturator nerve after an incidental injury during a right
      internal iliac artery closure with 10 mm titanium clip for severe pelvic bleeding
      in a patient with locally-advanced cervical cancer. A 52 year-old postmenopausal 
      woman with a chemo and radio-resistant locally-advanced squamous cervical cancer 
      was admitted at our department for severe vaginal bleeding after two previous
      uterine artery embolizations. As a consequence of the increasing vaginal
      bleeding, and after a MRI-scan, an open surgical treatment was decided with a
      type C radical hysterectomy with bilateral salpingo-oophorectomy. During
      dissection of obturator, paravescical and pararectal spaces and removal of
      metastatic pelvic lymphnodes, a severe blood loss that required a right internal 
      iliac artery closure with 10 mm titanium clip was observed. A right obturator
      nerve incidental injury during this time occurred. After an immediate grasping of
      the two sides of the lesion, the obturator nerve was succesfully repaired using
      4-0 Prolene interrupted sutures (Ethicon, Johnson & Johnson, New Jersey, USA).
      The patient was regularly discharged four days after the surgical procedure
      without neurological deficit, paresthesia or side effects. In conclusion
      obturator nerve repair is an emergency procedure for treatment of patients with
      advanced cervical cancer, but it should be reserved for oncologic surgeons
      trained in extensive oncological procedures and repair of nerve and vascular
      injuries potentially associated with high mortality rate.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Tinelli, Raffaele
AU  - Tinelli R
AD  - Department of Obstetrics and Gynecology, "Valle d'Itria" Hospital, Martina
      Franca, via San Francesco da Paola, 74015 Taranto, Italy. Electronic address:
      raffaeletinelli@gmail.com.
FAU - Uccella, Stefano
AU  - Uccella S
AD  - Departments of Obstetrics and Gynecology, Ospedale degli Infermi, Biella, Italy.
FAU - Nappi, Luigi
AU  - Nappi L
AD  - Department of Obstetrics and Gynecology, University of Foggia, Italy.
FAU - D'Amato, Giuseppe
AU  - D'Amato G
AD  - Head of IVF Unit, "Jaja" Hospital, Conversano, Bari, Italy.
FAU - Cicinelli, Ettore
AU  - Cicinelli E
AD  - Department of Obstetrics and Gynecology, University of Bari, Italy.
FAU - Angioni, Stefano
AU  - Angioni S
AD  - Department of Obstetrics and Gynecology, Presidio Policlinico di Monserrato,
      University of Cagliari, Monserrato, Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20200702
PL  - Ireland
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
SB  - IM
MH  - Female
MH  - Humans
MH  - *Laparoscopy
MH  - Lymph Node Excision
MH  - Middle Aged
MH  - Obturator Nerve
MH  - *Uterine Artery Embolization
MH  - *Uterine Cervical Neoplasms/surgery
MH  - Uterine Hemorrhage
OTO - NOTNLM
OT  - Cervical cancer
OT  - Injury
OT  - Obturator nerve
OT  - Repair
COIS- Declaration of Competing Interest The authors declare that there are no conflicts
      of interest.
EDAT- 2020/07/14 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - S0301-2115(20)30442-5 [pii]
AID - 10.1016/j.ejogrb.2020.07.002 [doi]
PST - ppublish
SO  - Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:355-358. doi:
      10.1016/j.ejogrb.2020.07.002. Epub 2020 Jul 2.


PMID- 32659533
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 93
DP  - 2020 Oct
TI  - Advancing pedagogy of undergraduate nursing students' cultural awareness through 
      internationalization webinars: A qualitative study.
PG  - 104514
LID - S0260-6917(19)30700-2 [pii]
LID - 10.1016/j.nedt.2020.104514 [doi]
AB  - In today's world, nurses increasingly care for individuals from different
      cultures. Because culturally sensitive care can improve patient satisfaction in
      care, nurses need to develop cultural competence in their practice. To develop
      cultural competence, one option is to build cultural awareness by exposing
      students to nursing practices in other cultures through online
      internationalization-at-home activities. However, little is known about the
      process of cultural awareness development through internationalization
      activities. Therefore, this qualitative study aimed to identify the development
      process of cultural awareness in nursing students, who participated in a series
      of internationalization-at-home activities. A total of 31 nursing students from
      Australia, Hong Kong, and Sweden volunteered to participate in student-led
      learning groups. Groups consisted of two to four students from each university,
      who engaged in four weekly webinars and online reflections about nursing practice
      based on a case scenario. Data were collected from participants' ongoing
      reflective journal entries, and after the webinars ended, from three focus
      groups. A semi-structured interview guide was used to understand how the
      internationalization-at-home activities impacted their cultural awareness and
      knowledge of nursing. Data were analyzed using interpretive description.
      Following four levels of thematic analysis (i.e., comprehension, synthesis,
      theorizing, reconceptualization), we identified four themes in the development of
      cultural awareness: 1) nurturing reciprocity through comparisons of nursing
      culture; 2) discovering common ethical values of the nursing profession; 3)
      developing cultural awareness in nursing ideology and practice; and 4)
      transforming understanding of nursing in the context of their healthcare systems.
      By the end of the internationalization activities, students appeared to have
      developed relational skills to facilitate their own inner dialogue about ethical 
      ideals of "self" and "other" in the context of being part of the global nursing
      community. Future research should develop and assess teaching strategies that can
      further facilitate the four themes in cultural awareness development.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Leung, Doris Y L
AU  - Leung DYL
AD  - School of Nursing, The Hong Kong Polytechnic University, Hong Kong. Electronic
      address: doris.leung@polyu.edu.hk.
FAU - Chan, Engle Angela
AU  - Chan EA
AD  - School of Nursing, The Hong Kong Polytechnic University, Hong Kong.
FAU - Wong, Arkers K C
AU  - Wong AKC
AD  - School of Nursing, The Hong Kong Polytechnic University, Hong Kong.
FAU - Reisenhofer, Sonia
AU  - Reisenhofer S
AD  - College of Science, Health & Engineering, La Trobe University, Australia.
FAU - Stenberg, Marie
AU  - Stenberg M
AD  - Department of Care Science, Malmo University, Sweden.
FAU - Pui Sze, Chan
AU  - Pui Sze C
AD  - School of Nursing, The Hong Kong Polytechnic University, Hong Kong.
FAU - Lai, K H
AU  - Lai KH
AD  - School of Nursing, The Hong Kong Polytechnic University, Hong Kong.
FAU - Cruz, Enrique
AU  - Cruz E
AD  - School of Nursing and Midwifery, La Trobe University, Australia.
FAU - Carlson, Elisabeth
AU  - Carlson E
AD  - Department of Care Science, Malmo University, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Adult
MH  - Australia
MH  - *Awareness
MH  - Communication
MH  - *Cultural Competency
MH  - Education, Nursing, Baccalaureate
MH  - Female
MH  - Focus Groups
MH  - Hong Kong
MH  - Humans
MH  - *Internationality
MH  - *Learning
MH  - Male
MH  - Qualitative Research
MH  - *Students, Nursing
MH  - Sweden
OTO - NOTNLM
OT  - Cultural awareness
OT  - Cultural competence
OT  - Educational pedagogy
OT  - Internationalization
OT  - Nursing
OT  - Qualitative
EDAT- 2020/07/14 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/07/14 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - S0260-6917(19)30700-2 [pii]
AID - 10.1016/j.nedt.2020.104514 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Oct;93:104514. doi: 10.1016/j.nedt.2020.104514. Epub 2020 
      Jun 29.


PMID- 32659197
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 0098-8588 (Print)
IS  - 0098-8588 (Linking)
VI  - 46
IP  - 2-3
DP  - 2020 May
TI  - The Ethics of DNA Testing at the Border.
PG  - 253-273
LID - 10.1177/0098858820933498 [doi]
FAU - Makhlouf, Medha D
AU  - Makhlouf MD
AD  - Assistant Professor and Director, Medical-Legal Partnership Clinic, Penn State
      University - Dickinson Law; Assistant Professor, Department of Public Health
      Sciences, Penn State College of Medicine.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Law Med
JT  - American journal of law & medicine
JID - 7509572
SB  - IM
MH  - DNA Fingerprinting/*ethics/*legislation & jurisprudence
MH  - *Data Collection
MH  - *Databases, Nucleic Acid
MH  - Emigrants and Immigrants/*legislation & jurisprudence
MH  - Emigration and Immigration
MH  - Family Separation
MH  - Humans
MH  - *Information Dissemination
MH  - Privacy
MH  - Refugees
MH  - United States
MH  - United States Government Agencies
EDAT- 2020/07/14 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - 10.1177/0098858820933498 [doi]
PST - ppublish
SO  - Am J Law Med. 2020 May;46(2-3):253-273. doi: 10.1177/0098858820933498.


PMID- 32659196
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20200803
IS  - 0098-8588 (Print)
IS  - 0098-8588 (Linking)
VI  - 46
IP  - 2-3
DP  - 2020 May
TI  - Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence.
PG  - 275-296
LID - 10.1177/0098858820933499 [doi]
AB  - Corporate influence is one of the most pressing issues in public health. It cuts 
      across many of our most intractable problems-from obesity to the opioid epidemic.
      Companies develop close relationships with public health agencies, research
      universities, academic medical centers, professional societies, and patient
      advocacy organizations-often funding medical research and public health
      interventions intended to address the very challenges these corporations are
      creating or exacerbating. How we view relationships with industry, including how 
      these relationships are framed in ethical discourse, shapes our legal and policy 
      responses to them. In recent years, fueled in part by the opioid epidemic, the
      ethical framing of industry relationships has begun to evolve in significant
      ways. But legal and policy responses have not yet caught up. In this article, I
      develop a temporal account of corporate influence, and legal and policy responses
      to corporate influence. This account clarifies the limitations and adverse
      effects of conflicts of interest disclosure, especially when implemented as the
      sole legal or policy response. Disclosure can illuminate corporate influence-but 
      policymakers cannot and should not rely on disclosure to eliminate corporate
      influence or its effects. Nor should we allow disclosure to crowd out structural 
      and systemic responses to corporate influence-including sequestration of and
      separation from private-sector entities.
FAU - Marks, Jonathan H
AU  - Marks JH
AD  - Director of the Bioethics Program at the Pennsylvania State University, and
      Affiliate Faculty in Law, Philosophy, Public Policy, and International Affairs.
      The author is also a barrister and academic member of Matrix Chambers, London and
      Geneva. He is extremely grateful to Michele Mekel, Marc Rodwin, and Sunita Sah
      for comments on an earlier draft. Please excuse any errors or omissions-final
      revisions to this piece were made during the COVID-19 pandemic.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Law Med
JT  - American journal of law & medicine
JID - 7509572
SB  - IM
MH  - Biomedical Research/*legislation & jurisprudence
MH  - Conflict of Interest
MH  - Disclosure/*legislation & jurisprudence
MH  - *Ethics, Business
MH  - Humans
MH  - *Policy Making
MH  - Public Health/*legislation & jurisprudence
MH  - Research Support as Topic/legislation & jurisprudence
MH  - United States
EDAT- 2020/07/14 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1177/0098858820933499 [doi]
PST - ppublish
SO  - Am J Law Med. 2020 May;46(2-3):275-296. doi: 10.1177/0098858820933499.


PMID- 32659195
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 0098-8588 (Print)
IS  - 0098-8588 (Linking)
VI  - 46
IP  - 2-3
DP  - 2020 May
TI  - Opioid Prescribing and the Ethical Duty to Do No Harm.
PG  - 297-310
LID - 10.1177/0098858820933500 [doi]
AB  - Doctors have two ethical duties: to cure disease or ease suffering and, also, to 
      do no harm. The ethical duty to "Do No Harm" has been used to justify two sides
      of a pendulum swing in the philosophy of opioid prescribing for pain. In the
      1990s, it was invoked to expand prescribing, and more recently to justify
      dramatic reductions in prescription opioid use. In this Article, we explore
      whether prescribing opioids for pain presents challenges that differ from the
      ordinary mandate physicians face as they balance the call for action with the
      imperative to do no harm [DNH].We argue that the treatment of pain differs in
      three important ways. First, the fact that pain is present and occurrent reduces 
      uncertainty about the need for action, and thus strengthens the reasons to act.
      Second, while DNH applies to both physicians and policymakers, each has distinct 
      duties: physicians have a duty to the individual patient; policymakers have a
      duty to society. As a result, harm from drug diversion should weigh little when
      clinicians decide how to treat individual patients. Public health officials, by
      contrast, rightly consider societal effects. However, in doing so, they must
      adopt policies that mitigate the ethical burdens placed on physicians, respect
      the testimony of patients in pain, and pay particular attention to how policy
      guidance is likely to be implemented by others. Finally, we address what duties
      are owed to patients who are currently taking opioid medication, given evidence
      that they are experiencing significant barriers in receiving healthcare. We argue
      that once treatment has been initiated, there are special duties to these
      patients.
FAU - Nicholson, Kate M
AU  - Nicholson KM
AD  - Kate Nicholson is a civil rights attorney, formerly with the Department of
      Justice. She writes and speaks widely about pain, opioid prescribing and the
      overdose crisis.
FAU - Hellman, Deborah
AU  - Hellman D
AD  - Deborah Hellman is David Lurton Massee, Jr. Professor of Law and Roy L. and
      Rosamond Woodruff Morgan Professor of Law at the University of Virginia School of
      Law.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Law Med
JT  - American journal of law & medicine
JID - 7509572
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/*therapeutic use
MH  - Centers for Disease Control and Prevention, U.S.
MH  - *Drug Prescriptions
MH  - Guidelines as Topic
MH  - Humans
MH  - Pain/drug therapy
MH  - Pain Management/*ethics
MH  - Physicians/*ethics
MH  - *Policy Making
MH  - Practice Patterns, Physicians'/*ethics
MH  - *Public Health
MH  - United States
EDAT- 2020/07/14 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - 10.1177/0098858820933500 [doi]
PST - ppublish
SO  - Am J Law Med. 2020 May;46(2-3):297-310. doi: 10.1177/0098858820933500.


PMID- 32659190
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 0098-8588 (Print)
IS  - 0098-8588 (Linking)
VI  - 46
IP  - 2-3
DP  - 2020 May
TI  - Shedding Light on Telemedicine & Online Prescribing: The Need to Balance Access
      to Health Care and Quality of Care.
PG  - 237-251
LID - 10.1177/0098858820933497 [doi]
AB  - The issue of online prescribing through the use of telemedicine raises ethical
      concerns. In particular, several studies suggest a correlation between
      telemedicine and overprescribing. Meanwhile, new developments in the law also
      have the potential to significantly impact online prescribing using telemedicine.
      In the absence of concrete federal guidance and a continued delay in issuing
      required federal regulations, states have developed their own laws, which vary
      considerably, regarding the ability of physicians to engage in online prescribing
      through telemedicine. As legal developments open doors for physicians to
      prescribe through telemedicine, current evidence of overprescribing, although
      limited, suggests the need to carefully balance access to health care and quality
      of care in this context, especially when crafting innovative legislative
      responses.This article attempts to explore this dynamic issue by closely
      evaluating the research on overprescribing involving telemedicine and the ethical
      issues surrounding online prescribing. It will continue by analyzing the current 
      legal landscape for online prescribing for telemedicine at both the federal and
      state levels. Next, this article will examine ethics opinions offered by medical 
      groups that touch this issue. Finally, this article will suggest several
      recommendations for law and policy moving forward by shedding light on the
      ethical issues surrounding telemedicine and online prescribing and how to strike 
      a balance between access and quality of care.
FAU - Hoffman, Laura C
AU  - Hoffman LC
AD  - Dr. Laura C. Hoffman is an Assistant Professor of Law/Faculty Researcher for
      Seton Hall University School of Law's Center for Health and Pharmaceutical Law
      and Policy. She earned her Doctor of Juridical Science (S.J.D.) in Health Law and
      Policy from Loyola University Chicago School of Law in 2012.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Law Med
JT  - American journal of law & medicine
JID - 7509572
SB  - IM
MH  - *Drug Prescriptions
MH  - Health Services Accessibility
MH  - Humans
MH  - *Inappropriate Prescribing
MH  - *Internet-Based Intervention
MH  - Physician-Patient Relations
MH  - *Practice Patterns, Physicians'
MH  - Quality of Health Care
MH  - Telemedicine/*ethics/*legislation & jurisprudence
EDAT- 2020/07/14 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - 10.1177/0098858820933497 [doi]
PST - ppublish
SO  - Am J Law Med. 2020 May;46(2-3):237-251. doi: 10.1177/0098858820933497.


PMID- 32659189
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 0098-8588 (Print)
IS  - 0098-8588 (Linking)
VI  - 46
IP  - 2-3
DP  - 2020 May
TI  - Genome Editing 2020: Ethics and Human Rights in Germline Editing in Humans and
      Gene Drives in Mosquitoes.
PG  - 143-165
LID - 10.1177/0098858820933492 [doi]
AB  - The moon landing, now more than a half century in the past, has turned out to be 
      the culmination of human space travel, rather than its beginning. Genetic
      engineering, especially applications of CRISPR, now presents the most
      publicly-discussed engineering challenges-and not just technical, but ethical as 
      well. In this article, I will use the two most controversial genomic engineering 
      applications to help identify the ethics and human rights implications of these
      research projects. Each of these techniques directly modifies the mechanisms of
      evolution, threatens to alter our views of ourselves as humans and our planet as 
      our home, and presents novel informed consent and dual use challenges: human
      genome editing and gene drives in insects.I begin with a discussion of so far
      disastrously unsuccessful attempts to regulate germline editing in humans,
      including a summary of the first application of germline genome editing in humans
      and its aftermath. I then turn to a discussion of setting ethical standards for a
      genomic technology that has not yet been deployed in nature-gene drives. Finally,
      I end by suggesting that human rights can and should be directly applicable to
      defining the ethics of genomic research.
FAU - Annas, George J
AU  - Annas GJ
AD  - Warren Distinguished Professor, Boston University, and Director, Center for
      Health Law, Ethics & Human Rights, Boston University School of Public Health.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Law Med
JT  - American journal of law & medicine
JID - 7509572
SB  - IM
MH  - Animals
MH  - *Clustered Regularly Interspaced Short Palindromic Repeats
MH  - Codes of Ethics
MH  - Consent Forms/*standards
MH  - Culicidae/genetics
MH  - *Ethics, Research
MH  - Female
MH  - Gene Drive Technology/*ethics
MH  - Gene Editing/*ethics/methods
MH  - *Germ Cells
MH  - Human Rights
MH  - Humans
MH  - Male
MH  - Professional Misconduct
EDAT- 2020/07/14 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - 10.1177/0098858820933492 [doi]
PST - ppublish
SO  - Am J Law Med. 2020 May;46(2-3):143-165. doi: 10.1177/0098858820933492.


PMID- 32658848
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20201218
IS  - 1669-9106 (Electronic)
IS  - 0025-7680 (Linking)
VI  - 80 Suppl 3
DP  - 2020
TI  - [Ethical guides, criteria for admission in intensive care, palliative care.
      Multi-society recommendations for allocation of resources during the COVID-19
      pandemic].
PG  - 45-64
AB  - Guidelines on resource allocation, ethics, triage processes with admission and
      discharge criteria from critical care and palliative care units during the
      pandemia are here presented. The interdisciplinary and multi-society panel that
      prepared these guidelines represented by bioethicists and specialists linked to
      the end of life: clinicians, geriatricians, emergentologists, intensivists, and
      experts in palliative care and cardiopulmonary resuscitation. The available
      information indicates that approximately 80% of people with COVID-19 will develop
      mild symptoms and will not require hospital care, while 15% will require
      intermediate or general room care, and the remaining 5% will require assistance
      in intensive care units. The need to think about justice and establish ethical
      criteria for allocation patients arise in conditions of exceeding available
      resources, such as outbreaks of diseases and pandemics, with transparency being
      the main criterion for allocation. These guides recommend general criteria for
      the allocation of resources relies on bioethical considerations, rooted in Human 
      Rights and based on the value of the dignity of the human person and substantial 
      principles such as solidarity, justice and equity. The guides are recommendations
      of general scope and their usefulness is to accompany and sustain the technical
      and scientific decisions made by the different specialists in the care of
      critically ill patients, but given the dynamic nature of the pandemic, a process 
      of permanent revision and adaptation of recommendations must be ensured.
FAU - Maglio, Ignacio
AU  - Maglio I
AD  - Red Bioetica para Latinoamerica y El Caribe de UNESCO.
FAU - Valdez, Pascual
AU  - Valdez P
AD  - Sociedad Argentina de Medicina (SAM), Buenos Aires, Argentina. E-mail:
      rpascual46@gmail.com.
FAU - Camera, Luis
AU  - Camera L
AD  - Sociedad Argentina de Medicina (SAM), Buenos Aires, Argentina.
FAU - Finn, Barbara
AU  - Finn B
AD  - Sociedad Argentina de Medicina (SAM), Buenos Aires, Argentina.
FAU - Klein, Manuel
AU  - Klein M
AD  - Sociedad Argentina de Medicina (SAM), Buenos Aires, Argentina.
FAU - Pincemin, Isabel
AU  - Pincemin I
AD  - Asociacion Argentina de Medicina y Cuidados Paliativos (AAMYCP), Argentina.
FAU - Ferraro, Hector
AU  - Ferraro H
AD  - Sociedad Argentina de Terapia Intensiva (SATI), Argentina.
FAU - Galvalisi, Nazareno
AU  - Galvalisi N
AD  - Sociedad Argentina de Emergencias (SAE), Argentina.
FAU - Alessandrini, Graciana
AU  - Alessandrini G
AD  - Sociedad Argentina de Medicina Interna General (SAMIG), Argentina.
FAU - Manera, Jorge
AU  - Manera J
AD  - Asociacion de Medicina Interna de Rosario (AMIR), Santa Fe, Argentina.
FAU - Musacchio, Hector
AU  - Musacchio H
AD  - Sociedad de Medicina Interna De Santa Fe (SMISF), Provincia de Santa Fe,
      Argentina.
FAU - Contreras, Patricia
AU  - Contreras P
AD  - Consejo Argentino de Resucitacion (CAR), Argentina.
FAU - Garea, Monica
AU  - Garea M
AD  - Consejo Argentino de Resucitacion (CAR), Argentina.
FAU - Luthy, Viviana
AU  - Luthy V
AD  - Sociedad Cientifica de Emergentologia Argentina (SCEA), Argentina.
FAU - Nemerovsky, Julio
AU  - Nemerovsky J
AD  - Sociedad Argentina de Gerontologia y Geriatria (SAGG), Argentina.
FAU - Baldoma, Federico
AU  - Baldoma F
AD  - Asociacion de Medicina Interna de Venado Tuerto (AMIVET), Provincia de Santa Fe, 
      Argentina.
FAU - Cherro, Ariel
AU  - Cherro A
AD  - Consejo de Cuidados Paliativos de la SAM, Argentina.
FAU - Ranzuglia, Leandro
AU  - Ranzuglia L
AD  - Sociedad de Medicina Interna Pergamino (SMIP), Provincia de Buenos Aires,
      Argentina.
FAU - Malfante, Pablo
AU  - Malfante P
AD  - Sociedad de Medicina Interna de la Costa Atlantica (SoMICA), Provincia de Buenos 
      Aires, Argentina.
FAU - Salvioli, Maximiliano
AU  - Salvioli M
AD  - Sociedad de Medicina Interna de La Plata (SMILP), Provincia de Buenos Aires,
      Argentina.
FAU - Garcia, Analia
AU  - Garcia A
AD  - Sociedad de Medicina Interna de Cordoba (SMICBA), Cordoba, Argentina.
LA  - spa
PT  - Journal Article
TT  - Guias eticas para la atencion durante la pandemia COVID-19. Recomendaciones
      multisocietarias para asignacion de recursos.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Critical Care/ethics/standards
MH  - Decision Making/*ethics
MH  - Emergency Medical Services/*ethics
MH  - Health Care Rationing/*economics
MH  - Humans
MH  - Palliative Care
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Practice Guidelines as Topic
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Societies, Medical
MH  - Triage/*ethics
OTO - NOTNLM
OT  - COVID-19
OT  - bioethics
OT  - end of life
OT  - mechanical ventilation
OT  - pandemic
OT  - principle of justice
OT  - resource allocation
EDAT- 2020/07/14 06:00
MHDA- 2020/08/08 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
PST - ppublish
SO  - Medicina (B Aires). 2020;80 Suppl 3:45-64.


PMID- 32658739
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1879-0534 (Electronic)
IS  - 0010-4825 (Linking)
VI  - 122
DP  - 2020 Jul
TI  - AKUImg: A database of cartilage images of Alkaptonuria patients.
PG  - 103863
LID - S0010-4825(20)30221-3 [pii]
LID - 10.1016/j.compbiomed.2020.103863 [doi]
AB  - ApreciseKUre is a multi-purpose digital platform facilitating data collection,
      integration and analysis for patients affected by Alkaptonuria (AKU), an
      ultra-rare autosomal recessive genetic disease. We present an ApreciseKUre
      plugin, called AKUImg, dedicated to the storage and analysis of AKU
      histopathological slides, in order to create a Precision Medicine Ecosystem
      (PME), where images can be shared among registered researchers and clinicians to 
      extend the AKU knowledge network. AKUImg includes a new set of AKU images taken
      from cartilage tissues acquired by means of a microscopic technique. The
      repository, in accordance to ethical policies, is publicly available after a
      registration request, to give to scientists the opportunity to study, investigate
      and compare such precious resources. AKUImg is also integrated with a preliminary
      but accurate predictive system able to discriminate the presence/absence of AKU
      by comparing histopatological affected/control images. The algorithm is based on 
      a standard image processing approach, namely histogram comparison, resulting to
      be particularly effective in performing image classification, and constitutes a
      useful guide for non-AKU researchers and clinicians.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Rossi, Alberto
AU  - Rossi A
AD  - University of Florence, Department of Information Engineering, Via di Santa
      Marta, Florence, Italy; University of Siena, Department of Information
      Engineering and Mathematics, Via Roma 56, Siena, Italy. Electronic address:
      alberto.rossi@unifi.it.
FAU - Giacomini, Giorgia
AU  - Giacomini G
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy; University of Siena, Department of Information
      Engineering and Mathematics, Via Roma 56, Siena, Italy.
FAU - Cicaloni, Vittoria
AU  - Cicaloni V
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy; Toscana Life Sciences Foundation, Via Fiorentina 1,
      Siena, Italy.
FAU - Galderisi, Silvia
AU  - Galderisi S
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy.
FAU - Milella, Maria Serena
AU  - Milella MS
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy.
FAU - Bernini, Andrea
AU  - Bernini A
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy.
FAU - Millucci, Lia
AU  - Millucci L
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy.
FAU - Spiga, Ottavia
AU  - Spiga O
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy.
FAU - Bianchini, Monica
AU  - Bianchini M
AD  - University of Siena, Department of Information Engineering and Mathematics, Via
      Roma 56, Siena, Italy.
FAU - Santucci, Annalisa
AU  - Santucci A
AD  - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Via
      Aldo Moro 2, Siena, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Comput Biol Med
JT  - Computers in biology and medicine
JID - 1250250
SB  - IM
MH  - *Alkaptonuria/diagnostic imaging
MH  - Cartilage/diagnostic imaging
MH  - Databases, Factual
MH  - Ecosystem
MH  - Humans
MH  - Precision Medicine
OTO - NOTNLM
OT  - *Alkaptonuria
OT  - *Histopatological images
OT  - *Precision medicine
OT  - *Rare disease
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - S0010-4825(20)30221-3 [pii]
AID - 10.1016/j.compbiomed.2020.103863 [doi]
PST - ppublish
SO  - Comput Biol Med. 2020 Jul;122:103863. doi: 10.1016/j.compbiomed.2020.103863. Epub
      2020 Jun 18.


PMID- 32658328
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20220531
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 107
IP  - 9
DP  - 2020 Aug
TI  - Author response to: Ethics for surgeons during the COVID-19 pandemic.
PG  - e325
LID - 10.1002/bjs.11781 [doi]
FAU - Huxtable, R
AU  - Huxtable R
AD  - Centre for Ethics in Medicine and the Bristol Biomedical Research Centre, Medical
      School, University of Bristol.
FAU - Ives, J
AU  - Ives J
AD  - Centre for Ethics in Medicine and the Bristol Biomedical Research Centre, Medical
      School, University of Bristol.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200713
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - IM
CON - Br J Surg. 2020 Aug;107(9):e324. PMID: 32658319
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Ethics, Medical
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Surgeons/ethics
PMC - PMC7404577
EDAT- 2020/07/14 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1002/bjs.11781 [doi]
PST - ppublish
SO  - Br J Surg. 2020 Aug;107(9):e325. doi: 10.1002/bjs.11781. Epub 2020 Jul 13.


PMID- 32658319
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20220531
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 107
IP  - 9
DP  - 2020 Aug
TI  - Ethics for surgeons during the COVID-19 pandemic.
PG  - e324
LID - 10.1002/bjs.11779 [doi]
FAU - Harkin, D W
AU  - Harkin DW
AUID- ORCID: https://orcid.org/0000-0002-4701-8350
AD  - Royal Victoria Hospital, Belfast, Belfast Health & Social Care Trust, United
      Kingdom.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200713
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - IM
CON - Br J Surg. 2020 Aug;107(9):1089-1090. PMID: 32227595
CIN - Br J Surg. 2020 Aug;107(9):e325. PMID: 32658328
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Ethics, Medical
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Surgeons/ethics
PMC - PMC7404492
EDAT- 2020/07/14 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1002/bjs.11779 [doi]
PST - ppublish
SO  - Br J Surg. 2020 Aug;107(9):e324. doi: 10.1002/bjs.11779. Epub 2020 Jul 13.


PMID- 32657831
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20220420
IS  - 1945-2810 (Electronic)
IS  - 0888-0395 (Linking)
VI  - 52
IP  - 5
DP  - 2020 Oct
TI  - Challenges and Lessons Learned Tailoring a Behavioral Intervention for Stroke
      Survivor-Care Partner Dyads.
PG  - 239-244
LID - 10.1097/JNN.0000000000000532 [doi]
AB  - INTRODUCTION: Research is increasingly exploring interventions for
      patient-care-partner dyads, but little has been reported regarding challenges of 
      implementing dyad-focused interventions. This article reports the lessons learned
      in a pilot feasibility study of problem-solving therapy versus stroke education
      in stroke survivor-care partner dyads. CHALLENGES AND LESSONS LEARNED: Challenges
      arose in numerous aspects of intervention delivery. These ranged from
      personalizing the intervention to meet individual needs and balancing
      participation between dyad members to maintaining focus, managing conflict, and
      addressing ethical concerns, all of which required attention from the nurse
      researcher. These anticipated and unanticipated challenges were addressed using a
      variety of solutions, including engagement, active listening, redirection, and
      structured adaptation. IMPLICATIONS FOR PRACTICE: The knowledge gained and
      lessons learned in this study may be applied to other patient-care-partner dyads 
      and other behavioral therapies. Nurses may also identify opportunities to
      increase inclusion of care partners in other interventions. Awareness of these
      challenges may lead to greater success in working with dyads. CONCLUSIONS:
      Dyad-focused behavioral interventions hold promise for use with stroke survivors 
      and their care partners. They also present unique implementation challenges
      compared with survivor-only interventions.
FAU - Tierney, Meghan K
AU  - Tierney MK
FAU - Tracy, Mary Fran
AU  - Tracy MF
FAU - Everson-Rose, Susan A
AU  - Everson-Rose SA
FAU - Hadidi, Niloufar Niakosari
AU  - Hadidi NN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurosci Nurs
JT  - The Journal of neuroscience nursing : journal of the American Association of
      Neuroscience Nurses
JID - 8603596
SB  - IM
MH  - Caregivers/*psychology
MH  - *Cognitive Behavioral Therapy
MH  - Decision Making, Shared
MH  - Depression/psychology
MH  - Humans
MH  - *Psychiatric Rehabilitation
MH  - *Research
MH  - *Stroke
MH  - *Survivors
EDAT- 2020/07/14 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1097/JNN.0000000000000532 [doi]
AID - 01376517-202010000-00009 [pii]
PST - ppublish
SO  - J Neurosci Nurs. 2020 Oct;52(5):239-244. doi: 10.1097/JNN.0000000000000532.


PMID- 32657775
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1997-3322 (Electronic)
IS  - 1018-8185 (Linking)
VI  - 30
IP  - 1
DP  - 2020
TI  - Psychiatric experience with perpetrators.
PG  - 84-88
LID - 10.7146/torture.v30i1.118585 [doi]
AB  - Reprinted from: Lansen, J. (1991). Psychiatric experience with perpetrators and
      countertransference feelings in the therapist. Journal of Medical Ethics,
      17(Suppl), 55-57. doi: https:/doi.org/10.1136/jme.17.suppl.55 (c) 1991 BMJ
      Publishing Group Ltd and Institute of Medical Ethics. All rights reserved.
FAU - Lansen, Johan
AU  - Lansen J
AD  - In Memoriam.
LA  - eng
PT  - Classical Article
PT  - Journal Article
PL  - Denmark
TA  - Torture
JT  - Torture : quarterly journal on rehabilitation of torture victims and prevention
      of torture
JID - 9309086
SB  - IM
MH  - *Attitude of Health Personnel
MH  - *Countertransference
MH  - Humans
MH  - *Physician-Patient Relations
MH  - *Psychotherapy
MH  - *Torture
MH  - *Transference, Psychology
EDAT- 2020/07/14 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
AID - 10.7146/torture.v30i1.118585 [doi]
PST - ppublish
SO  - Torture. 2020;30(1):84-88. doi: 10.7146/torture.v30i1.118585.


PMID- 32657772
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1997-3322 (Electronic)
IS  - 1018-8185 (Linking)
VI  - 30
IP  - 1
DP  - 2020
TI  - Statement of the Independent Forensic Expert Group on Conversion Therapy.
PG  - 66-78
LID - 10.7146/torture.v30i1.119654 [doi]
AB  - Conversion therapy is a set of practices that aim to change or alter an
      individual's sexual orientation or gender identity. It is premised on a belief
      that an individual's sexual orientation or gender identity can be changed and
      that doing so is a desirable outcome for the individual, family, or community.
      Other terms used to describe this practice include sexual orientation change
      effort (SOCE), reparative therapy, reintegrative therapy, reorientation therapy, 
      ex-gay therapy, and gay cure. Conversion therapy is practiced in every region of 
      the world. We have identified sources confirming or indicating that conversion
      therapy is performed in over 60 countries. In those countries where it is
      performed, a wide and variable range of practices are believed to create change
      in an individual's sexual orientation or gender identity. Some examples of these 
      include: talk therapy or psychotherapy (e.g., exploring life events to identify
      the cause); group therapy; medication (including anti-psychotics, anti-
      depressants, anti-anxiety, and psychoactive drugs, and hormone injections); Eye
      Movement Desensitization and Reprocessing (where an individual focuses on a
      traumatic memory while simultaneously experiencing bilateral stimulation);
      electroshock or electroconvulsive therapy (ECT) (where electrodes are attached to
      the head and electric current is passed between them to induce seizure); aversive
      treatments (including electric shock to the hands and/or genitals or
      nausea-inducing medication administered with presentation of homoerotic stimuli);
      exorcism or ritual cleansing (e.g., beating the individual with a broomstick
      while reading holy verses or burning the individual's head, back, and palms);
      force-feeding or food deprivation; forced nudity; behavioural conditioning (e.g.,
      being forced to dress or walk in a particular way); isolation (sometimes for long
      periods of time, which may include solitary confinement or being kept from
      interacting with the outside world); verbal abuse; humiliation; hypnosis;
      hospital confinement; beatings; and "corrective" rape. Conversion therapy appears
      to be performed widely by health professionals, including medical doctors,
      psychiatrists, psychologists, sexologists, and therapists. It is also conducted
      by spiritual leaders, religious practitioners, traditional healers, and community
      or family members. Conversion therapy is undertaken both in contexts under state 
      control, e.g., hospitals, schools, and juvenile detention facilities, as well as 
      in private settings like homes, religious institutions, or youth camps and
      retreats. In some countries, conversion therapy is imposed by the order or
      instructions of public officials, judges, or the police. The practice is
      undertaken with both adults and minors who may be lesbian, gay, bisexual, trans, 
      or gender diverse. Parents are also known to send their children back to their
      country of origin to receive it. The practice supports the belief that
      non-heterosexual orientations are deviations from the norm, reflecting a disease,
      disorder, or sin. The practitioner conveys the message that heterosexuality is
      the normal and healthy sexual orientation and gender identity. The purpose of
      this medico-legal statement is to provide legal experts, adjudicators, health
      care professionals, and policy makers, among others, with an understanding of: 1)
      the lack of medical and scientific validity of conversion therapy; 2) the likely 
      physical and psychological consequences of undergoing conversion therapy; and 3) 
      whether, based on these effects, conversion therapy constitutes cruel, inhuman,
      or degrading treatment or torture when individuals are subjected to it forcibly2 
      or without their consent. This medico-legal statement also addresses the
      responsibility of states in regulating this practice, the ethical implications of
      offering or performing it, and the role that health professionals and medical and
      mental health organisations should play with regards to this practice.
      Definitions of conversion therapy vary. Some include any attempt to change,
      suppress, or divert an individual's sexual orientation, gender identity, or
      gender expression. This medico-legal statement only addresses those practices
      that practitioners believe can effect a genuine change in an individual's sexual 
      orientation or gender identity. Acts of physical and psychological violence or
      discrimination that aim solely to inflict pain and suffering or punish
      individuals due to their sexual orientation or gender identity, are not
      addressed, but are wholly condemned. This medico-legal statement follows along
      the lines of our previous publications on Anal Examinations in Cases of Alleged
      Homosexuality1 and on Forced Virginity Testing.2 In those statements, we opposed 
      attempts to minimise the severity of physical and psychological pain and
      suffering caused by these examinations by qualifying them as medical in nature.
      There is no medical justification for inflicting on individuals torture or other 
      cruel, inhuman, or degrading treatment or punishment. In addition, these
      statements reaffirmed that health professionals should take no role in attempting
      to control sexuality and knowingly or unknowingly supporting state-sponsored
      policing and punishing of individuals based on their sexual orientation or gender
      identity.
FAU - Alempijevic, Djordje
AU  - Alempijevic D
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Beriashvili, Rusudan
AU  - Beriashvili R
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Beynon, Jonathan
AU  - Beynon J
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Alempijevic Petersen, Djordje
AU  - Alempijevic Petersen D
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Birmanns, Bettina
AU  - Birmanns B
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Brasholt, Marie
AU  - Brasholt M
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Cohen, Juliet
AU  - Cohen J
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Alempijevic Petersen, Djordje
AU  - Alempijevic Petersen D
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Duque, Maximo
AU  - Duque M
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Duterte, Pierre
AU  - Duterte P
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Van Es, Adriaan
AU  - Van Es A
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Fernando, Ravindra
AU  - Fernando R
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Korur Fincanci, Sebnem
AU  - Korur Fincanci S
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Holger Hansen, Steen
AU  - Holger Hansen S
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Hamzeh, Sana
AU  - Hamzeh S
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Hardi, Lilla
AU  - Hardi L
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Heisler, Michele
AU  - Heisler M
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Iacopino, Vincent
AU  - Iacopino V
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Mygind Leth, Peter
AU  - Mygind Leth P
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Lin, James
AU  - Lin J
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Louahlia, Said
AU  - Louahlia S
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Luytkis, Hege
AU  - Luytkis H
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Louahlia, Said
AU  - Louahlia S
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Morcillo-Mendez, Maria-Dolores
AU  - Morcillo-Mendez MD
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Moreno, Alejandro
AU  - Moreno A
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Moscoso, Valeria
AU  - Moscoso V
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Oral, Resmiye
AU  - Oral R
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Ozkalipci, Onder
AU  - Ozkalipci O
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Payne-James, Jason
AU  - Payne-James J
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Quiroga, Jose
AU  - Quiroga J
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Ozkalipci, Onder
AU  - Ozkalipci O
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Reyes, Hernan
AU  - Reyes H
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Rogde, Sidsel
AU  - Rogde S
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Sajantilla, Antti
AU  - Sajantilla A
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Ozkalipci, Onder
AU  - Ozkalipci O
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Schick, Matthis
AU  - Schick M
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Terzidis, Agis
AU  - Terzidis A
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Lange Thomsen, Jorgen
AU  - Lange Thomsen J
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Tidball-Binz, Morris
AU  - Tidball-Binz M
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Treue, Felicitas
AU  - Treue F
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Vanezis, Peter
AU  - Vanezis P
AD  - IFEG. Correspondence to: irct@irct.org.
FAU - Viera, Duarte Nuno
AU  - Viera DN
AD  - IFEG. Correspondence to: irct@irct.org.
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Torture
JT  - Torture : quarterly journal on rehabilitation of torture victims and prevention
      of torture
JID - 9309086
RN  - 0 (Central Nervous System Agents)
SB  - IM
MH  - Aversive Therapy/*methods
MH  - Central Nervous System Agents
MH  - Consensus
MH  - Electroconvulsive Therapy
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Male
MH  - Psychotherapy
MH  - *Punishment
MH  - *Sexual Behavior
MH  - *Torture
EDAT- 2020/07/14 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
AID - 10.7146/torture.v30i1.119654 [doi]
PST - ppublish
SO  - Torture. 2020;30(1):66-78. doi: 10.7146/torture.v30i1.119654.


PMID- 32657718
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20200803
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 5
DP  - 2020 Apr 29
TI  - Guidelines for the use of WhatsApp groups in clinical settings in South Africa.
PG  - 364-368
LID - 10.7196/SAMJ.2020.v110i5.14558 [doi]
AB  - In everyday clinical practice, healthcare professionals (HCPs) are exposed to
      large quantities of confidential patient information, and many use WhatsApp
      groups to share this information. WhatsApp groups provide efficient mechanisms
      for clinical management advice, decision-making support and peer review. However,
      most HCPs do not fully understand the legal and ethical implications of sharing
      content in a WhatsApp group setting, which is often thought to be hosted on a
      secure platform and therefore removed from public scrutiny. In our paper, we
      unpack the legal and ethical issues that arise when information is shared in
      WhatsApp groups. We demonstrate that sharing content in this forum is tantamount 
      to the publication of content; in other words, those who share content are
      subject to the same legal ramifications as a journalist would be. We also examine
      the role of the WhatsApp group administrator, who bears an additional legal
      burden by default, often unknowingly so. We consider the recommendations made by 
      the Health Professions Council of South Africa in their guidelines for the use of
      social media, and highlight some areas where we feel the guidelines may not
      adequately protect HCPs from the legal repercussions of sharing content in a
      WhatsApp group. Finally, we provide a set of guidelines for WhatsApp group users 
      that should be regularly posted onto the group by the relevant group
      administrator to mitigate some of the legal liabilities that may arise. We also
      provide guidelines for group administrators.
FAU - Bouter, C
AU  - Bouter C
AD  - Wits Donald Gordon Medical Centre, Faculty of Health Sciences, University of the 
      Witwatersrand, Johannesburg, South Africa. carolynbouter@hotmail.com.
FAU - Venter, B
AU  - Venter B
FAU - Etheredge, H
AU  - Etheredge H
LA  - eng
PT  - Journal Article
PT  - Legal Case
DEP - 20200429
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
MH  - Clinical Decision-Making
MH  - Communication
MH  - Confidentiality/legislation & jurisprudence
MH  - Humans
MH  - *Liability, Legal
MH  - Mobile Applications/*ethics/*legislation & jurisprudence
MH  - Peer Review
MH  - Social Media/legislation & jurisprudence
MH  - South Africa
EDAT- 2020/07/14 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.7196/SAMJ.2020.v110i5.14558 [doi]
PST - epublish
SO  - S Afr Med J. 2020 Apr 29;110(5):364-368. doi: 10.7196/SAMJ.2020.v110i5.14558.


PMID- 32657716
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20201218
IS  - 2078-5135 (Electronic)
VI  - 110
IP  - 5
DP  - 2020 Apr 16
TI  - Critical care triaging in the shadow of COVID-19: Ethics considerations.
PG  - 355-359
AB  - Since the World Health Organization declared coronavirus disease 2019 (COVID-19) 
      a Public Health Emergency of International Concern, COVID-19 infection and the
      associated mortality have increased exponentially, globally. South Africa (SA) is
      no exception. Concerns abound over whether SA's healthcare system can withstand a
      demand for care that is disproportionate to current resources, both in the state 
      and private health sectors. While healthcare professionals in SA have become
      resilient and adept at making difficult decisions in the face of resource
      limitations, a surge in COVID-19 cases could place a severe strain on the
      country's critical care services and necessitate unprecedented rationing
      decisions. This could occur at two critical points: access to ventilation, and
      withdrawal of intensive care in non- responsive or deteriorating cases. The
      ethical dimensions of decision-making at both junctures merit urgent
      consideration.
FAU - Singh, J A
AU  - Singh JA
AD  - Centre for the AIDS Programme of Research in South Africa (CAPRISA), University
      of KwaZulu-Natal, Durban, South Africa. singhj9@ukzn.ac.za.
FAU - Moodley, K
AU  - Moodley K
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - South Africa
TA  - S Afr Med J
JT  - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
JID - 0404520
SB  - IM
CIN - S Afr Med J. 2020 Jun 05;110(8):700-703. PMID: 32880283
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - *Critical Care/ethics/methods/organization & administration
MH  - Emergencies/epidemiology
MH  - Emergency Service, Hospital/*organization & administration
MH  - Health Care Rationing/*trends
MH  - Health Services Needs and Demand/trends
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - *Resource Allocation/ethics/organization & administration
MH  - SARS-CoV-2
MH  - South Africa/epidemiology
MH  - *Triage/ethics/organization & administration
MH  - Ventilators, Mechanical/supply & distribution
EDAT- 2020/07/14 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
PST - epublish
SO  - S Afr Med J. 2020 Apr 16;110(5):355-359.


PMID- 32657666
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201218
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 11
DP  - 2020 Nov
TI  - Coaching skills for medical education in a VUCA world.
PG  - 1308-1309
LID - 10.1080/0142159X.2020.1788713 [doi]
AB  - The world is in the midst of the COVID-19 pandemic. Healthcare professionals and 
      students globally are experiencing an increasingly 'VUCA' (volatile, uncertain,
      complex and ambiguous) healthcare and educational climate. Our future medical
      workforce needs skillsets to manage the personal and emotional challenges of
      work, uncertainty and change. These include organization, time management,
      proactive and consistent clinical skill development, effective communication,
      person-centred approaches, self-reflection and self-care. This is critical for
      success during undergraduate medical education and ongoing clinical practice to
      build personal resilience, provide the best possible clinical care in a different
      healthcare ecosystem, innovate for better healthcare systems and advocate for
      more vulnerable communities. Our faculty and students have been eager to learn
      and apply solution-oriented coaching skills to help to mitigate against burnout, 
      hold more rewarding, person-centred conversations in clinical practice and enable
      them personally to respond flexibly and adapt constructively to change. Coaching 
      training should comprise an essential component of the undergraduate medical
      curriculum and continuing professional development, supporting our medical
      workforce to derive joy from the practice of humanistic healthcare and develop
      the leadership skills to help shape a way forward through the challenges we are
      experiencing in an increasingly VUCA healthcare climate.
FAU - Maini, Arti
AU  - Maini A
AUID- ORCID: 0000-0002-0951-5604
AD  - Imperial College London, Medical Education Innovation and Research Centre, School
      of Public Health, London, UK.
FAU - Saravanan, Yamini
AU  - Saravanan Y
AD  - Cambridge Health Alliance, Cambridge, MA, USA.
AD  - Harvard Medical School, Cambridge Integrated Clerkship, Boston, MA, USA.
FAU - Singh, Tara A
AU  - Singh TA
AD  - Cambridge Health Alliance, Cambridge, MA, USA.
AD  - Harvard Medical School, Cambridge Integrated Clerkship, Boston, MA, USA.
FAU - Fyfe, Molly
AU  - Fyfe M
AUID- ORCID: 0000-0002-3299-4893
AD  - Imperial College London, Medical Education Innovation and Research Centre, School
      of Public Health, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200711
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Clinical Competence
MH  - Coronavirus Infections/*epidemiology
MH  - Curriculum
MH  - Education, Medical/*organization & administration
MH  - Health Personnel/*education
MH  - Humans
MH  - Leadership
MH  - Mentoring
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Schools, Medical/organization & administration
OTO - NOTNLM
OT  - *Communication skills
OT  - *ethics/attitudes
OT  - *health promotion
OT  - *medicine
OT  - *undergraduate
EDAT- 2020/07/14 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1080/0142159X.2020.1788713 [doi]
PST - ppublish
SO  - Med Teach. 2020 Nov;42(11):1308-1309. doi: 10.1080/0142159X.2020.1788713. Epub
      2020 Jul 11.


PMID- 32657235
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 132
IP  - 8
DP  - 2020 Nov
TI  - The knowledge level and perceptions toward COVID-19 among Turkish final year
      medical students.
PG  - 764-772
LID - 10.1080/00325481.2020.1795486 [doi]
AB  - BACKGROUND: Coronavirus disease 2019 (COVID-19) has upended medical education as 
      well as the lives of healthcare professionals. Higher education institutions have
      a crucial role in the solution of public health problems by training young doctor
      candidates, and it is also essential to increase the knowledge level of physician
      candidates about the epidemic. So, in this study, we aimed to examine Turkish
      final year medical students' knowledge level and perceptions toward the COVID-19 
      pandemic. METHODS: The present descriptive multicentered study was conducted with
      the medical students in the final year of six medical schools located in six
      geographic regions of Turkey. After ethical approval, data were gathered using an
      online questionnaire through Google forms between 10 April 2020, and 20 April
      2020. RESULTS: In this national survey study, 860 volunteers answered the
      questions thoroughly. The median age was 24 (22-38) years. A total of 55.3% of
      the participants were female. The median knowledge level score was 69.0 (0-93.1).
      The knowledge level was moderate. A total of 34.2% of the participants had a high
      level of knowledge. A total of 48.7% of participants stated that they felt the
      most competent about performing CPR. Updates about COVID-19 were followed
      regularly by 84.5% of the participants. CONCLUSION: We determined that final year
      medical students are knowledgeable and aware of this pandemic. We, medical
      educators, should inculcate relevant knowledge and educate the medical students
      to improve practices in the current pandemic, as well as for future epidemics.
      Different learning techniques should be added to the curriculum, especially at
      the time which widespread panic and uncertainty are prevalent.
FAU - Caliskan, Fatih
AU  - Caliskan F
AUID- ORCID: https://orcid.org/0000-0001-7786-3929
AD  - Department of Emergency Medicine, Faculty of Medicine, Ondokuz Mayis University ,
      Samsun, Turkey.
FAU - Midik, Ozlem
AU  - Midik O
AUID- ORCID: https://orcid.org/0000-0002-0151-7461
AD  - Department of Medical Education, Faculty of Medicine, Ondokuz Mayis University , 
      Samsun, Turkey.
FAU - Baykan, Zeynep
AU  - Baykan Z
AUID- ORCID: https://orcid.org/0000-0001-9450-985X
AD  - Department of Medical Education, Faculty of Medicine, Erciyes University ,
      Kayseri, Turkey.
FAU - Senol, Yesim
AU  - Senol Y
AUID- ORCID: https://orcid.org/0000-0002-7842-3041
AD  - Department of Medical Education, Faculty of Medicine, Akdeniz University ,
      Antalya, Turkey.
FAU - Tanriverdi, Esra Cinar
AU  - Tanriverdi EC
AUID- ORCID: https://orcid.org/0000-0001-8857-3986
AD  - Department of Medical Education, Faculty of Medicine, Ataturk University ,
      Erzurum, Turkey.
FAU - Tengiz, Funda Ifakat
AU  - Tengiz FI
AUID- ORCID: https://orcid.org/0000-0002-8491-9190
AD  - Department of Medical Education, Faculty of Medicine, Katip Celebi University ,
      Izmir, Turkey.
FAU - Gayef, Albena
AU  - Gayef A
AUID- ORCID: https://orcid.org/0000-0002-1260-0631
AD  - Department of Medical Education, Faculty of Medicine, Trakya University , Edirne,
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200806
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - IM
MH  - Adult
MH  - *COVID-19/epidemiology/psychology
MH  - Curriculum/standards
MH  - Education, Medical, Undergraduate/*standards
MH  - *Educational Measurement/methods/statistics & numerical data
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Needs Assessment
MH  - SARS-CoV-2
MH  - *Social Perception
MH  - *Students, Medical/psychology/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Turkey/epidemiology
OTO - NOTNLM
OT  - COVID-19
OT  - internship
OT  - knowledge
OT  - medical education
OT  - perceptions
OT  - undergraduate
EDAT- 2020/07/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1080/00325481.2020.1795486 [doi]
PST - ppublish
SO  - Postgrad Med. 2020 Nov;132(8):764-772. doi: 10.1080/00325481.2020.1795486. Epub
      2020 Aug 6.


PMID- 32657230
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 10
DP  - 2020 Oct
TI  - Indigenous perspectives on education for sustainable healthcare.
PG  - 1085-1090
LID - 10.1080/0142159X.2020.1791320 [doi]
AB  - A range of global environmental changes are contributing to an increasing global 
      burden of disease. Since human health and well-being are intimately associated
      with the health of our planet, healthcare providers will not only be charged with
      caring for this expanding disease burden but will also need to become more
      environmentally sustainable in their professional practice. There is thus an
      urgent need in the health professions education community to prioritize
      environmentally sustainable healthcare practice, which must include and
      prioritize Indigenous voices and Indigenous knowledge systems. Critical global
      dialogue on the significance of Indigenous knowledge systems in educating health 
      professionals for a sustainable future will be required if we are ready to ensure
      the generations that follow us are able to live healthy lives. Indigenous ways of
      'being' in the world, which emphasize the importance of interconnection and
      reciprocal stewardship with everything in the natural world, are essential for
      advancing education for sustainable healthcare and overall well-being. Given the 
      colonial legacy however, Indigenous people, despite their essential knowledge
      systems and abilities, still face many barriers accessing safe decolonizing
      spaces and presence in health professions education, which needs to be addressed.
FAU - Redvers, Nicole
AU  - Redvers N
AUID- ORCID: 0000-0001-8521-2130
AD  - Family and Community Medicine-INMED Program, University of North Dakota School of
      Medicine and Health Sciences, Grand Forks, ND, USA.
AD  - Arctic Indigenous Wellness Foundation, Yellowknife, Canada.
FAU - Schultz, Clinton
AU  - Schultz C
AUID- ORCID: 0000-0002-9593-1371
AD  - Faculty of Medicine and Health Sciences, Bond University, Gold Coast, Australia.
FAU - Vera Prince, Melissa
AU  - Vera Prince M
AUID- ORCID: 0000-0002-9208-6248
AD  - School of Nursing, University of Washington's, Seattle, WA, USA.
FAU - Cunningham, Myrna
AU  - Cunningham M
AD  - Fondo para el Desarrollo de los Pueblos Indigenas de America Latina y El Caribe
      (FILAC), La Paz, Bolivia.
FAU - Jones, Rhys
AU  - Jones R
AUID- ORCID: 0000-0002-2424-3459
AD  - Te Kupenga Hauora Maori, University of Auckland, Auckland, New Zealand.
FAU - Blondin, Be'sha
AU  - Blondin B
AD  - Arctic Indigenous Wellness Foundation, Yellowknife, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200711
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - *Delivery of Health Care
MH  - Humans
MH  - *Knowledge
OTO - NOTNLM
OT  - *Community-oriented
OT  - *ethics/attitudes
OT  - *general
OT  - *multiprofessional
EDAT- 2020/07/14 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1080/0142159X.2020.1791320 [doi]
PST - ppublish
SO  - Med Teach. 2020 Oct;42(10):1085-1090. doi: 10.1080/0142159X.2020.1791320. Epub
      2020 Jul 11.


PMID- 32656798
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20201218
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 3
DP  - 2020 Aug
TI  - Management of adult cardiac arrest in the COVID-19 era: consensus statement from 
      the Australasian College for Emergency Medicine.
PG  - 126-133
LID - 10.5694/mja2.50699 [doi]
AB  - INTRODUCTION: The global pandemic of coronavirus disease 2019 (COVID-19) has
      caused significant worldwide disruption. Although Australia and New Zealand have 
      not been affected as much as some other countries, resuscitation may still pose a
      risk to health care workers and necessitates a change to our traditional
      approach. This consensus statement for adult cardiac arrest in the setting of
      COVID-19 has been produced by the Australasian College for Emergency Medicine
      (ACEM) and aligns with national and international recommendations. MAIN
      RECOMMENDATIONS: In a setting of low community transmission, most cardiac arrests
      are not due to COVID-19. Early defibrillation saves lives and is not considered
      an aerosol generating procedure. Compression-only cardiopulmonary resuscitation
      is thought to be a low risk procedure and can be safely initiated with the
      patient's mouth and nose covered. All other resuscitative procedures are
      considered aerosol generating and require the use of airborne personal protective
      equipment (PPE). It is important to balance the appropriateness of resuscitation 
      against the risk of infection. Methods to reduce nosocomial transmission of
      COVID-19 include a physical barrier such as a towel or mask over the patient's
      mouth and nose, appropriate use of PPE, minimising the staff involved in
      resuscitation, and use of mechanical chest compression devices when available. If
      COVID-19 significantly affects hospital resource availability, the ethics of
      resource allocation must be considered. CHANGES IN MANAGEMENT: The changes
      outlined in this document require a significant adaptation for many doctors,
      nurses and paramedics. It is critically important that all health care workers
      have regular PPE and advanced life support training, are able to access in situ
      simulation sessions, and receive extensive debriefing after actual
      resuscitations. This will ensure safe, timely and effective management of the
      patients with cardiac arrest in the COVID-19 era.
CI  - (c) 2020 AMPCo Pty Ltd.
FAU - Craig, Simon
AU  - Craig S
AUID- ORCID: 0000-0003-2594-1643
AD  - Monash Health, Melbourne, VIC.
AD  - Monash University, Melbourne, VIC.
FAU - Cubitt, Mya
AU  - Cubitt M
AUID- ORCID: 0000-0002-8399-7453
AD  - Royal Melbourne Hospital, Melbourne, VIC.
AD  - Centre for Integrated Critical Care, University of Melbourne, Melbourne, VIC.
FAU - Jaison, Ashish
AU  - Jaison A
AD  - Emergency and Trauma Centre, Alfred Health, Melbourne, VIC.
FAU - Troupakis, Steven
AU  - Troupakis S
AD  - Monash Health, Melbourne, VIC.
AD  - Epworth HealthCare, Melbourne, VIC.
FAU - Hood, Natalie
AU  - Hood N
AD  - Monash Health, Melbourne, VIC.
AD  - Surf Life Saving Australia, Sydney, NSW.
FAU - Fong, Christina
AU  - Fong C
AD  - Monash Health, Melbourne, VIC.
AD  - Epworth HealthCare, Melbourne, VIC.
FAU - Bilgrami, Adnan
AU  - Bilgrami A
AD  - Monash Health, Melbourne, VIC.
FAU - Leman, Peter
AU  - Leman P
AD  - Fiona Stanley Hospital, Perth, WA.
AD  - University of Western Australia, Perth, WA.
FAU - Ascencio-Lane, Juan Carlos
AU  - Ascencio-Lane JC
AD  - Royal Hobart Hospital, Hobart, TAS.
AD  - University of Tasmania, Hobart, TAS.
FAU - Nagaraj, Guruprasad
AU  - Nagaraj G
AD  - South Western Emergency Research Institute, Liverpool Hospital, Sydney, NSW.
AD  - University of New South Wales, Sydney, NSW.
FAU - Bonning, John
AU  - Bonning J
AD  - Australasian College for Emergency Medicine, Melbourne, VIC.
AD  - Council of Medical Colleges of Aotearoa New Zealand, Wellington, New Zealand.
FAU - Blecher, Gabriel
AU  - Blecher G
AUID- ORCID: 0000-0001-8537-2011
AD  - Monash University, Melbourne, VIC.
AD  - Monash Medical Centre, Melbourne, VIC.
FAU - Mitchell, Rob
AU  - Mitchell R
AD  - Monash University, Melbourne, VIC.
AD  - Emergency and Trauma Centre, Alfred Health, Melbourne, VIC.
FAU - Burkett, Ellen
AU  - Burkett E
AD  - Princess Alexandra Hospital, Brisbane, QLD.
AD  - Clinical Excellence Queensland, Brisbane, QLD.
FAU - McCarthy, Sally M
AU  - McCarthy SM
AD  - University of New South Wales, Sydney, NSW.
AD  - Prince of Wales Hospital and Community Health Services, Sydney, NSW.
FAU - Rojek, Amanda M
AU  - Rojek AM
AD  - Royal Melbourne Hospital, Melbourne, VIC.
AD  - Centre for Integrated Critical Care, University of Melbourne, Melbourne, VIC.
FAU - Hansen, Kim
AU  - Hansen K
AD  - St Andrew's War Memorial Hospital, Brisbane, QLD.
AD  - Prince Charles Hospital, Brisbane, QLD.
FAU - Psihogios, Helen
AU  - Psihogios H
AD  - Monash Health, Melbourne, VIC.
FAU - Allely, Peter
AU  - Allely P
AD  - University of Western Australia, Perth, WA.
AD  - Sir Charles Gairdner Hospital, Perth, WA.
FAU - Judkins, Simon
AU  - Judkins S
AD  - Austin Hospital, Melbourne, VIC.
FAU - Foong, Lai Heng
AU  - Foong LH
AD  - Bankstown-Lidcombe Hospital, Sydney, NSW.
AD  - University of Western Sydney, Sydney, NSW.
FAU - Bernard, Stephen
AU  - Bernard S
AD  - Centre for Research and Evaluation, Ambulance Victoria, Melbourne, VIC.
FAU - Cameron, Peter A
AU  - Cameron PA
AD  - Monash University, Melbourne, VIC.
AD  - Emergency and Trauma Centre, Alfred Health, Melbourne, VIC.
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
DEP - 20200712
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Adult
MH  - Algorithms
MH  - Australia/epidemiology
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cardiopulmonary Resuscitation/*methods/standards
MH  - Coronavirus Infections/*epidemiology/transmission
MH  - Cross Infection/prevention & control
MH  - Emergency Service, Hospital/*organization & administration
MH  - Heart Arrest/*therapy
MH  - Humans
MH  - Infection Control/methods/standards
MH  - Infectious Disease Transmission, Patient-to-Professional/prevention & control
MH  - New Zealand/epidemiology
MH  - *Pandemics
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*epidemiology/transmission
MH  - SARS-CoV-2
PMC - PMC7405166
OTO - NOTNLM
OT  - *COVID-19
OT  - *Infectious diseases
OT  - *Respiratory tract infections
OT  - *Resuscitation
EDAT- 2020/07/14 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.5694/mja2.50699 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Aug;213(3):126-133. doi: 10.5694/mja2.50699. Epub 2020 Jul 12.


PMID- 32656622
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 2629-3277 (Electronic)
IS  - 2629-3277 (Linking)
VI  - 16
IP  - 5
DP  - 2020 Oct
TI  - Of Mesenchymal Stem/Stromal Cells and Osteoarthritis: Time to Merge the Latest
      Breakthroughs.
PG  - 1016-1018
LID - 10.1007/s12015-020-10001-0 [doi]
AB  - Osteoarthritis (OA) is a degenerative joint disease of the articular cartilage
      with subchondral bone remodeling and synovial inflammation. There is currently no
      cure for OA, making effective management extremely challenging. During the last
      years, significant advances has been made to develop regenerative medicine based 
      on the use of stem cells as alternative for treating OA. Because of their several
      advantages including availability, expandability, transplantability, and ethical 
      implications. mesenchymal stem/stromal cells (MSCs) appear thus to be a promising
      tool for the field. Based on the recent paper of Klemen Camernik et al. in Stem
      Cell Reviews and Reports, we highlighted some challenges and possible strategies 
      to enhance the therapeutic potential of MSCs for OA.
FAU - Najar, Mehdi
AU  - Najar M
AD  - Osteoarthritis Research Unit, University of Montreal Hospital Research Center
      (CRCHUM), Montreal, Quebec, H2X 0A9, Canada.
FAU - Fahmi, Hassan
AU  - Fahmi H
AD  - Osteoarthritis Research Unit, University of Montreal Hospital Research Center
      (CRCHUM), Montreal, Quebec, H2X 0A9, Canada. h.fahmi@umontreal.ca.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Stem Cell Rev Rep
JT  - Stem cell reviews and reports
JID - 101752767
RN  - 0 (resolvin D1)
RN  - 25167-62-8 (Docosahexaenoic Acids)
SB  - IM
MH  - Docosahexaenoic Acids/pharmacology/therapeutic use
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*cytology
MH  - Osteoarthritis/diet therapy/*therapy
MH  - Periodontal Ligament/cytology
OTO - NOTNLM
OT  - *Empowering strategies
OT  - *Exhaustion
OT  - *MSCs
OT  - *OA
OT  - *Stem cell pool
EDAT- 2020/07/14 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1007/s12015-020-10001-0 [doi]
AID - 10.1007/s12015-020-10001-0 [pii]
PST - ppublish
SO  - Stem Cell Rev Rep. 2020 Oct;16(5):1016-1018. doi: 10.1007/s12015-020-10001-0.


PMID- 32656518
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2587-0831 (Print)
VI  - 16
IP  - 3
DP  - 2020 Jul
TI  - Men's Knowledge and Attitudes Towards Breast Cancer: A Descriptive Study.
PG  - 183-191
LID - 10.5152/ejbh.2020.5193 [doi]
AB  - OBJECTIVE: Breast cancer (BC) is an important disease for women. BC influences
      both patient's and relatives' lives. Especially, husbands/boyfriends/ lovers are 
      the ones that are affected mostly. In this study, it was aimed to introduce
      knowledge and attitudes of men toward BC and their sources of information about
      BC. MATERIALS AND METHODS: This descriptive study was conducted with men applied 
      to a University Hospital in Istanbul (Turkey-2018). The ethics permission was
      obtained from The Clinical Research Ethics Committee. Data regarding
      socio-demographic characteristics with the knowledge and attitudes towards BC
      were collected with a questionnaire specific to the research. Statistical
      significance level was accepted as p<0.05. RESULTS: In the study, 240 men (mean
      age: 36.2+/-10.6 years,min: 18.0, max: 63.0) were interviewed. Fifty four percent
      of men declared that they would not marry someone with BC and/or someone who had 
      mastectomy. Thirty four percent of participants thought that a woman with BC
      should conceal the disease. The mean BC knowledge score was 234.1+/-128.0
      (median: 227.5, min: 0, max: 571.0) among the total which was 600. CONCLUSION: A 
      significant proportion of men did not have sufficient and accurate knowledge
      about BC. If the BC knowledge scores increase, there was an association with more
      positive attitudes. Negative attitudes of men related with BC of a woman may be
      an indicator of stigmatization. If it is aimed to increase support of men for
      women dealing with BC, it is recommended that BC awareness activities should be
      prepared to include men in order to increase their knowledge and to change their 
      attitudes into a more positive way.
CI  - Copyright (c) 2020 Turkish Federation of Breast Diseases Associations.
FAU - Ozaydin, Ayse Nilufer
AU  - Ozaydin AN
AUID- ORCID: 0000-0002-2616-0710
AD  - Department of Public Health, Marmara University School of Medicine, Istanbul,
      Turkey.
FAU - Dogan, Emrah
AU  - Dogan E
AUID- ORCID: 0000-0003-3626-5329
AD  - Department of Public Health, Marmara University School of Medicine, Istanbul,
      Turkey.
FAU - Bozdogan, Berk
AU  - Bozdogan B
AUID- ORCID: 0000-0001-6974-9333
AD  - Marmara University School of Medicine, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - Turkey
TA  - Eur J Breast Health
JT  - European journal of breast health
JID - 101709357
PMC - PMC7337910
OTO - NOTNLM
OT  - Sexual partner
OT  - education
OT  - fertility
OT  - sexuality
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/07/14 06:00
MHDA- 2020/07/14 06:01
CRDT- 2020/07/14 06:00
PHST- 2019/09/24 00:00 [received]
PHST- 2020/01/11 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/07/14 06:01 [medline]
AID - 10.5152/ejbh.2020.5193 [doi]
AID - ejbh-16-3-183 [pii]
PST - epublish
SO  - Eur J Breast Health. 2020 Mar 31;16(3):183-191. doi: 10.5152/ejbh.2020.5193.
      eCollection 2020 Jul.


PMID- 32656381
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2414-469X (Print)
IS  - 2414-4630 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Jun
TI  - Unilateral biportal endoscopic decompression for degenerative lumbar canal
      stenosis.
PG  - 438-446
LID - 10.21037/jss.2020.03.08 [doi]
AB  - BACKGROUND: Unilateral biportal endoscopic (UBE) decompression is a minimally
      invasive (MI) approach to treat degenerative lumbar canal stenosis (DLCS).
      Decompression can be performed in a clear and magnified surgical field with
      proper control of normal saline inflow and outflow. METHODS: Clinical and
      radiographic data of 81 consecutive patients of DLCS treated between July 2018
      and Feb 2019 using UBE techniques were reviewed. They were 38 males and 43
      females with an average age of 70.2. Sixty-nine had pure canal stenosis and 12
      patients had associated spondylolisthesis. Bilateral decompression via unilateral
      laminotomy was performed from the side on patients with more severe neurological 
      symptoms. This is a retrospective study from chart review and image analysis.
      Therefore, we don't have formal ethical information for this study, and it is not
      mandatory in our hospital. RESULTS: At the final follow-up, the mean VAS for low 
      back pain was improved from 4.3+/-3.0 to 1.2+/-1.0 and the VAS for leg symptoms
      was improved from 7.3+/-2.2 to 0.9+/-0.7. The mean JOA score and ODI was
      significantly improved from 13.3+/-7.9 to 25.3+/-5.0 and from 54.6+/-16.9 to
      14.6+/-12.6, respectively. Modified Macnab criteria were excellent in 47 patients
      (58.0%), good in 29 (35.8%), fair in 5 (6.2%). The average hospital stay was
      3.6+/-2.4 days. MRI before and after the operation showed the cross-sectional
      dural area (CSDA) was significantly increased from 71.4+/-36.5 to 177.3+/-59.2
      mm(2), corresponding to a 201.9%+/-188.0% increase. The percentage of facet joint
      preservation was 84.2% on the approach side and 92.9% on the contralateral side. 
      Complications included 4 dural tears, 1 transient motor weakness, 1 inadequate
      decompression, and 1 epidural hematoma. CONCLUSIONS: With UBE techniques,
      decompression for DLCS can be performed safely and effectively. The soft tissue
      and facet joint destruction are minimized; therefore, it is possible to avoid
      spinal fusion as well as to preserve the segmental stability.
CI  - 2020 Journal of Spine Surgery. All rights reserved.
FAU - Pao, Jwo-Luen
AU  - Pao JL
AD  - Department of Orthopedic Surgery, Far-Eastern Memorial Hospital, New Taipei.
FAU - Lin, Shang-Ming
AU  - Lin SM
AD  - Department of Materials and Textiles, Oriental Institute of Technology, New
      Taipei.
FAU - Chen, Wen-Chi
AU  - Chen WC
AD  - Department of Orthopedic Surgery, Far-Eastern Memorial Hospital, New Taipei.
FAU - Chang, Chih-Hung
AU  - Chang CH
AD  - Department of Orthopedic Surgery, Far-Eastern Memorial Hospital, New Taipei.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Spine Surg
JT  - Journal of spine surgery (Hong Kong)
JID - 101685460
PMC - PMC7340817
OTO - NOTNLM
OT  - Minimally invasive surgery
OT  - biportal endoscopic spine surgery
OT  - lumbar canal stenosis
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/jss.2020.03.08). The series
      "Full-endoscopic Spine Surgery" was commissioned by the editorial office without 
      any funding or sponsorship. The authors have no other conflicts of interest to
      declare.
EDAT- 2020/07/14 06:00
MHDA- 2020/07/14 06:01
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/07/14 06:01 [medline]
AID - 10.21037/jss.2020.03.08 [doi]
AID - jss-06-02-438 [pii]
PST - ppublish
SO  - J Spine Surg. 2020 Jun;6(2):438-446. doi: 10.21037/jss.2020.03.08.


PMID- 32656249
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Stem Cells in Veterinary Medicine-Current State and Treatment Options.
PG  - 278
LID - 10.3389/fvets.2020.00278 [doi]
AB  - Regenerative medicine is a branch of medicine that develops methods to grow,
      repair, or replace damaged or diseased cells, organs or tissues. It has gained
      significant momentum in recent years. Stem cells are undifferentiated cells with 
      the capability to self-renew and differentiate into tissue cells with specialized
      functions. Stem cell therapies are therefore used to overcome the body's
      inability to regenerate damaged tissues and metabolic processes after acute or
      chronic insult. The concept of stem cell therapy was first introduced in 1991 by 
      Caplan, who proposed that massive differentiation of cells into the desired
      tissue could be achieved by isolation, cultivation, and expansion of stem cells
      in in vitro conditions. Among different stem cell types, mesenchymal stem cells
      (MSC) currently seem to be the most suitable for therapeutic purposes, based on
      their simple isolation and culturing techniques, and lack of ethical issues
      regarding their usage. Because of their remarkable immunomodulatory abilities,
      MSCs are increasingly gaining recognition in veterinary medicine. Developments
      are primarily driven by the limitations of current treatment options for various 
      medical problems in different animal species. MSCs represent a possible
      therapeutic option for many animal diseases, such as orthopedic, orodental and
      digestive tract diseases, liver, renal, cardiac, respiratory, neuromuscular,
      dermal, olfactory, and reproductive system diseases. Although we are
      progressively gaining an understanding of MSC behavior and their mechanisms of
      action, some of the issues considering their use for therapy are yet to be
      resolved. The aim of this review is first to summarize the current knowledge and 
      stress out major issues in stem cell based therapies in veterinary medicine and, 
      secondly, to present results of clinical usage of stem cells in veterinary
      patients.
CI  - Copyright (c) 2020 Voga, Adamic, Vengust and Majdic.
FAU - Voga, Metka
AU  - Voga M
AD  - Faculty of Veterinary Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Adamic, Neza
AU  - Adamic N
AD  - Faculty of Veterinary Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Vengust, Modest
AU  - Vengust M
AD  - Faculty of Veterinary Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Majdic, Gregor
AU  - Majdic G
AD  - University of Ljubljana, Ljubljana, Slovenia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7326035
OTO - NOTNLM
OT  - cats
OT  - clinical veterinary medicine
OT  - dogs
OT  - horses
OT  - regenerative medicine
OT  - stem cells
EDAT- 2020/07/14 06:00
MHDA- 2020/07/14 06:01
CRDT- 2020/07/14 06:00
PHST- 2019/07/12 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/07/14 06:01 [medline]
AID - 10.3389/fvets.2020.00278 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 May 29;7:278. doi: 10.3389/fvets.2020.00278. eCollection
      2020.


PMID- 32656117
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1793-5482 (Print)
VI  - 15
IP  - 2
DP  - 2020 Apr-Jun
TI  - The Ethical Dilemma in the Surgical Management of Low Grade Gliomas According to 
      the Variable Availability of Resources and Surgeon Experience.
PG  - 266-271
LID - 10.4103/ajns.AJNS_296_19 [doi]
AB  - Low grade gliomas (LGGs) affect young individuals in the prime of life.
      Management may alternatively include biopsy and observation or surgical
      resection. Recent evidence strongly favors maximal and supramaximal resection of 
      LGGs in optimizing survival metrics. Awake craniotomy with cortical mapping and
      electrical stimulation along with other preoperative and intraoperative surgical 
      adjuncts, including intraoperative magnetic resonance and diffusion tensor
      imaging, facilitates maximization of resection and eschews precipitating
      neurological deficits. Intraoperative imaging permits additional resection of
      identified residual to be completed within the same surgical session, improving
      extent of resection and consequently progression free and overall survival. These
      resources are available in only a few centers throughout the United States,
      raising an ethical dilemma as to where patients harboring LGGs should most
      appropriately be treated.
CI  - Copyright: (c) 2020 Asian Journal of Neurosurgery.
FAU - Lahiff, Marshall Norman
AU  - Lahiff MN
AD  - School of Law, University of Miami, Miami, Florida, USA.
AD  - Walton Lantaff Schoreder and Carson LLP, Miami, Florida, USA.
FAU - Ghali, Michael George Zaki
AU  - Ghali MGZ
AD  - Department of Neurological Surgery, Houston Methodist Hospital, Houston, Texas,
      Philadelphia, Pennsylvania, USA.
AD  - Department of Neurobiology and Anatomy, Drexel University College of Medicine,
      Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - India
TA  - Asian J Neurosurg
JT  - Asian journal of neurosurgery
JID - 101564712
PMC - PMC7335147
OTO - NOTNLM
OT  - Gliomas
OT  - intraoperative
OT  - magnetic resonance imaging
OT  - neuronavigation
OT  - supratotal resection
OT  - surgeon experience
OT  - survival
OT  - technology
COIS- There are no conflicts of interest.
EDAT- 2020/07/14 06:00
MHDA- 2020/07/14 06:01
CRDT- 2020/07/14 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2019/12/20 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/07/14 06:01 [medline]
AID - 10.4103/ajns.AJNS_296_19 [doi]
AID - AJNS-15-266 [pii]
PST - epublish
SO  - Asian J Neurosurg. 2020 May 29;15(2):266-271. doi: 10.4103/ajns.AJNS_296_19.
      eCollection 2020 Apr-Jun.


PMID- 32655753
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20220415
IS  - 1937-8688 (Electronic)
VI  - 35
DP  - 2020
TI  - Effects of counseling professional ethics principles on midwifery professional
      codes of ethics compliance and applicability rate among midwives in community
      health centers: a randomized clinical trial in Iran.
PG  - 139
LID - 10.11604/pamj.2020.35.139.20702 [doi]
AB  - INTRODUCTION: Compliance with ethical principles is regarded as one of the key
      components in providing services in midwifery profession. This study was to
      evaluate the effects of counseling professional ethics principles on midwifery
      professional codes of ethics compliance and applicability rate among midwives
      working in community health centers in the city of Karaj, Iran. METHODS: This
      randomized controlled trial (RCT) was conducted in 2018 on a total number of 84
      eligible midwives in two intervention and control groups, selected through
      multistage sampling method. The intervention group took part in six counseling
      sessions but the control group only received a training manual. Both groups then 
      completed the Self-Reporting Questionnaire of Ethical Codes of Reproductive
      Health Providers (including 95 items in 14 domains) at three time points (before,
      immediately, and four weeks after intervention). Finally, the data were analyzed 
      using the IBM SPSS Statistics (version 22) software via descriptive and
      inferential statistics. RESULTS: The findings showed that level of compliance and
      applicability rate in all 14 domains of midwifery professional codes of ethics
      were higher in the intervention group (after intervention) than those in the
      control group and trend of time changes in mean level of compliance and
      applicability rate of codes of ethics during the three time points were
      significantly different between both groups (p < 0.001). CONCLUSION: Given the
      effectiveness of counseling professional ethics principles on midwifery
      professional codes of ethics compliance and applicability rate among the midwives
      working in community health centers, designing and applying this counseling
      approach was recommended to improve quality of reproductive health care services.
CI  - (c) Soheila Shahabnia et al.
FAU - Shahabnia, Soheila
AU  - Shahabnia S
AD  - Student in Midwifery Counseling, Student Research Committee, Alborz University of
      Medical Sciences, Karaj, Iran.
FAU - Lotfi, Razieh
AU  - Lotfi R
AD  - Midwifery and Reproductive Health Department, School of Medicine, Alborz
      University of Medical Sciences, Karaj, Iran.
FAU - Rahimzadeh, Mitra
AU  - Rahimzadeh M
AD  - Social Determinants of Health Research Center, Alborz University of Medical
      Sciences, Karaj, Iran.
FAU - Yazdkhasti, Mansoureh
AU  - Yazdkhasti M
AD  - Midwifery and Reproductive Health Department, School of Medicine, Alborz
      University of Medical Sciences, Karaj, Iran.
FAU - Tourzani, Zahra Mehdizadeh
AU  - Tourzani ZM
AD  - Midwifery and Reproductive Health Department, School of Medicine, Alborz
      University of Medical Sciences, Karaj, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200429
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adult
MH  - *Codes of Ethics
MH  - Community Health Services/*ethics
MH  - Counseling/*methods
MH  - Ethics, Professional
MH  - Female
MH  - Humans
MH  - Iran
MH  - Midwifery/*ethics
MH  - Surveys and Questionnaires
PMC - PMC7335481
OTO - NOTNLM
OT  - Ethics
OT  - codes of ethics
OT  - counseling
OT  - professional
OT  - reproductive health
COIS- The authors declare no competing interests.
EDAT- 2020/07/14 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/07/14 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/01/10 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.11604/pamj.2020.35.139.20702 [doi]
AID - PAMJ-35-139 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Apr 29;35:139. doi: 10.11604/pamj.2020.35.139.20702.
      eCollection 2020.


PMID- 32655151
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210101
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 7
DP  - 2020 Jul
TI  - Veterinary Medical Ethics.
PG  - 677-678
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7296871
EDAT- 2020/07/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - cvj_07_677 [pii]
PST - ppublish
SO  - Can Vet J. 2020 Jul;61(7):677-678.


PMID- 32655134
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 1348-4214 (Electronic)
IS  - 0916-9636 (Linking)
VI  - 43
IP  - 11
DP  - 2020 Nov
TI  - The dawning of the digital era in the management of hypertension.
PG  - 1135-1140
LID - 10.1038/s41440-020-0506-1 [doi]
AB  - Awareness, treatment, and control of hypertension are of the utmost importance in
      conquering stroke and cardiovascular disease. To reduce the global burden of
      hypertension, the Japanese Society of Hypertension (JSH) established the "JSH
      Future Plan" based on an increasing need to transform the strategy for combating 
      hypertension. In addition to energizing conventional approaches in basic,
      translational, and clinical research, the application of rapidly evolving digital
      health technologies and artificial intelligence to hypertension healthcare and
      research (digital hypertension) holds promise for providing further insights into
      the pathophysiology and therapeutic targets and implementing predictive,
      personalized, and preemptive approaches in clinical practice. With great
      potential to revolutionize the landscape of hypertension, digital hypertension
      has some technical, legal, ethical, social, and financial issues to overcome.
      Given the multidisciplinary framework, digital hypertension requires
      comprehensive and strategic collaboration among industry, academia, and
      government to move forward toward the goal of "Future Medicine".
FAU - Matsuoka, Ryo
AU  - Matsuoka R
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
FAU - Akazawa, Hiroshi
AU  - Akazawa H
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan. akazawah-tky@umin.ac.jp.
FAU - Kodera, Satoshi
AU  - Kodera S
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
FAU - Komuro, Issei
AU  - Komuro I
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200713
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
SB  - IM
MH  - Artificial Intelligence
MH  - Big Data
MH  - *Digital Technology
MH  - *Disease Management
MH  - Humans
MH  - Hypertension/*therapy
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Big data
OT  - *Information and communication technology
OT  - *JSH Future Plan
OT  - *Mobile health
EDAT- 2020/07/14 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/05/31 00:00 [revised]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - 10.1038/s41440-020-0506-1 [doi]
AID - 10.1038/s41440-020-0506-1 [pii]
PST - ppublish
SO  - Hypertens Res. 2020 Nov;43(11):1135-1140. doi: 10.1038/s41440-020-0506-1. Epub
      2020 Jul 13.


PMID- 32654899
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 35
DP  - 2020 Jul 31
TI  - Ethics of a partially effective dengue vaccine: Lessons from the Philippines.
PG  - 5572-5576
LID - S0264-410X(20)30882-3 [pii]
LID - 10.1016/j.vaccine.2020.06.079 [doi]
AB  - Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by
      SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort
      study Dengvaxia was found to partially protect children who had prior dengue
      virus (DENV) infections but sensitized seronegative children to breakthrough DENV
      disease of enhanced severity. In 2019, the European Medicines Agency and the US
      FDA issued licenses that reconciled safety issues by restricting vaccine to
      individuals with prior dengue infections. Using revised Dengvaxia efficacy and
      safety data we sought to estimate hospitalized and severe dengue cases among the 
      more than 800,000 9 year-old children vaccinated in the Philippines. Despite an
      overall vaccine efficacy of 69% during 4 years post-vaccination we project there 
      will be more than one thousand vaccinated seronegative and seropositive children 
      hospitalized for severe dengue. Assisting these children through a program of
      enhanced surveillance leading to improved care deserves widespread support.
      Clinical responses observed during breakthrough dengue infections in vaccinated
      individuals counsel prudence in design of vaccine policies. Recommendations
      concerning continued use of this dengue vaccine are: (1) obtain a better
      definition of vaccine efficacy and safety through enhanced phase 4 surveillance, 
      (2) obtain a valid, accessible, sensitive, specific and affordable serological
      test that identifies past wild-type dengue virus infection and (3) clarify safety
      and efficacy of Dengvaxia in flavivirus immunes. In the absence of an acceptable 
      serological screening test these unresolved ethical issues suggest Dengvaxia be
      given only to those signing informed consent.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Halstead, Scott B
AU  - Halstead SB
AD  - Department of Preventive Medicine and Biostatistics, Uniformed Services
      University of the Health Sciences, Bethesda, MD 20817, United States. Electronic 
      address: halsteads@erols.com.
FAU - Katzelnick, Leah C
AU  - Katzelnick LC
AD  - Research Associate, Division of Infectious Diseases and Vaccinology, School of
      Public Health, University of California, Berkeley, Berkeley, CA 94720, United
      States; Department of Biology, University of Florida, Gainesville, FL 32611,
      United States.
FAU - Russell, Philip K
AU  - Russell PK
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United
      States.
FAU - Markoff, Lewis
AU  - Markoff L
AD  - Consultant, 6908 Nevis Road, Bethesda MD 20817, United States.
FAU - Aguiar, Maira
AU  - Aguiar M
AD  - Dipartimento di Matematica, Universita degli Studi di Trento, Via Sommarive 14,
      38123 Povo Trento, Italy; Basque Center for Applied Mathematics (BCAM), Alameda
      Mazarredo, 14, 48009 Bilbao, Spain; Ikerbasque, Basque Foundation for Science,
      Bilbao, Spain.
FAU - Dans, Leonila R
AU  - Dans LR
AD  - Department of Pediatrics, College of Medicine, University of the Philippines,
      Manila, 547 Pedro Gil Street, Ermita, Manila 1000, Philippines.
FAU - Dans, Antonio L
AU  - Dans AL
AD  - Department of Medicine, College of Medicine, University of the Philippines,
      Manila 547 Pedro Gil Streeet, Ermita, Manila 1000, Philippines.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200710
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Dengue Vaccines)
RN  - 0 (Vaccines, Attenuated)
SB  - IM
MH  - Antibodies, Viral
MH  - Child
MH  - Cohort Studies
MH  - *Dengue/prevention & control
MH  - *Dengue Vaccines/adverse effects
MH  - Humans
MH  - Philippines
MH  - Vaccines, Attenuated
PMC - PMC7347470
COIS- Declaration of Competing Interest The authors declare the following financial
      interests/personal relationships which may be considered as potential competing
      interests: SBH: Sanofipasteur, Takeda, GlaxoSmithKline and Merck within past 3
      years. PKR: Inviragen
EDAT- 2020/07/14 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/01/28 00:00 [received]
PHST- 2020/06/26 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - S0264-410X(20)30882-3 [pii]
AID - 10.1016/j.vaccine.2020.06.079 [doi]
PST - ppublish
SO  - Vaccine. 2020 Jul 31;38(35):5572-5576. doi: 10.1016/j.vaccine.2020.06.079. Epub
      2020 Jul 10.


PMID- 32654814
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 114
IP  - 2
DP  - 2020 Aug
TI  - An effective method for trophectoderm biopsy using mechanical blunt dissection: a
      step-by-step demonstration.
PG  - 438-439
LID - S0015-0282(20)30526-4 [pii]
LID - 10.1016/j.fertnstert.2020.05.035 [doi]
AB  - OBJECTIVE: To present an effective approach to trophectoderm biopsy for
      blastocysts of different stages and characteristics by mechanical blunt
      dissection (MBD). DESIGN: Stepwise demonstration with still pictures and
      operational video clips to explain tips and tricks for trophectoderm biopsy.
      (This demonstration was approved by the Reproductive Study Ethics Committee at
      Shengjing Hospital of China Medical University.) SETTING: In vitro fertilization 
      laboratory. PATIENT(S): Patients who underwent preimplantation genetic testing.
      INTERVENTION(S): The illustrated techniques of blastocyst trophectoderm biopsy
      using micromanipulation methods include artificial shrinkage, zona pellucida
      drilling, injecting media from the drilling, aspiration of trophectoderm cells
      into the biopsy pipette (outer diameter 27 mum for fully expanded blastocysts and
      peanut-shaped hatching blastocysts; outer diameter 20 mum for 8-shaped hatching
      and hatched blastocysts), detachment of the trophectoderm cells by laser pulse
      combined with MBD (performed using the rims of the biopsy and holding pipettes), 
      and release of the biopsy fragment. MAIN OUTCOME MEASURE(S): Successful biopsy
      rate and survival after warming. RESULT(S): Our biopsy strategy does not involve 
      assisted hatching on day-3 or day-4 embryos, which can leave the embryo
      undisturbed in culture up to the expanded blastocyst stage. Notably, this
      approach demonstrates several noteworthy advantages for sampling blastocysts of
      different stages and characteristics, and it maintains a desirable successful
      biopsy rate (95.4%, n = 1,872) and survival rate after warming (100%, n = 440).
      The MBD method may reduce thermal damage because fewer laser pulses are used,
      compared with the traditional laser-only biopsy techniques. For noncollapsed
      blastocysts after artificial shrinkage, the strategy of injecting medium from the
      zona pellucida drilling helps to separate the trophectoderm cells from the zona
      pellucida, thus facilitating the biopsy procedure. For peanut-shaped hatching
      blastocysts, this approach could provide better control over the aspiration of
      trophectoderm cells into the biopsy pipette. Especially if the inner cell mass is
      herniating from the zona pellucida, the trophectoderm biopsy can be performed
      away from the inner cell mass to avoid damaging it. In addition, the MBD approach
      combined with the biopsy pipette (outer diameter 20 mum) can effectively control 
      the target number of trophectoderm cells, thus simplifying the process of
      obtaining a biopsy from a hatched blastocyst. CONCLUSION(S): Our biopsy approach 
      demonstrates several noteworthy advantages. Considering its benefits and the
      simplicity of its execution, this systematic biopsy method for blastocysts of
      different stages and characteristic can be widely applied.
CI  - Copyright (c) 2020 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Yang, Dalei
AU  - Yang D
AD  - Center of Reproductive Medicine, Shengjing Hospital of China Medical University, 
      Shenyang, People's Republic of China.
FAU - Feng, Di
AU  - Feng D
AD  - Center of Reproductive Medicine, Shengjing Hospital of China Medical University, 
      Shenyang, People's Republic of China.
FAU - Gao, Yingzhuo
AU  - Gao Y
AD  - Center of Reproductive Medicine, Shengjing Hospital of China Medical University, 
      Shenyang, People's Republic of China.
FAU - Sagnelli, Matthew
AU  - Sagnelli M
AD  - Department of Medicine, School of Medicine, University of Connecticut,
      Farmington, Connecticut.
FAU - Wang, Xiuxia
AU  - Wang X
AD  - Center of Reproductive Medicine, Shengjing Hospital of China Medical University, 
      Shenyang, People's Republic of China.
FAU - Li, Da
AU  - Li D
AD  - Center of Reproductive Medicine, Shengjing Hospital of China Medical University, 
      Shenyang, People's Republic of China. Electronic address: leeda@ymail.com.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20200709
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
MH  - Biopsy
MH  - Blastocyst/*pathology
MH  - *Dissection
MH  - Embryo Culture Techniques
MH  - Female
MH  - *Fertilization in Vitro/adverse effects
MH  - Genetic Testing
MH  - Humans
MH  - Pregnancy
MH  - Preimplantation Diagnosis
OTO - NOTNLM
OT  - *Artificial shrinkage
OT  - *blastocyst
OT  - *preimplantation genetic testing
OT  - *trophectoderm biopsy
EDAT- 2020/07/14 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/07/14 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/05/22 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
AID - S0015-0282(20)30526-4 [pii]
AID - 10.1016/j.fertnstert.2020.05.035 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Aug;114(2):438-439. doi: 10.1016/j.fertnstert.2020.05.035.
      Epub 2020 Jul 9.


PMID- 32653419
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20210116
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 133
IP  - 11
DP  - 2020 Nov
TI  - Allocating Vaccines in a Pandemic: The Ethical Dimension.
PG  - 1241-1242
LID - S0002-9343(20)30554-4 [pii]
LID - 10.1016/j.amjmed.2020.06.007 [doi]
FAU - Wu, Joseph H
AU  - Wu JH
AD  - Warren Alpert Medical School, Brown University, Providence, RI. Electronic
      address: joseph_wu@brown.edu.
FAU - John, Stephen D
AU  - John SD
AD  - Hatton Lecturer, Philosophy of Public Health, Department of History and
      Philosophy of Science, University of Cambridge, Cambridge, UK.
FAU - Adashi, Eli Y
AU  - Adashi EY
AD  - Professor of Medical Science, Warren Alpert Medical School, Brown University,
      Providence, RI.
LA  - eng
PT  - Editorial
DEP - 20200710
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - COVID-19/epidemiology/*prevention & control/transmission
MH  - COVID-19 Vaccines/*supply & distribution/therapeutic use
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Immunity, Herd
PMC - PMC7347468
EDAT- 2020/07/13 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/13 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/07/13 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/13 06:00 [entrez]
AID - S0002-9343(20)30554-4 [pii]
AID - 10.1016/j.amjmed.2020.06.007 [doi]
PST - ppublish
SO  - Am J Med. 2020 Nov;133(11):1241-1242. doi: 10.1016/j.amjmed.2020.06.007. Epub
      2020 Jul 10.


PMID- 32653418
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20210116
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 133
IP  - 11
DP  - 2020 Nov
TI  - Proportionality, Pandemics, and Medical Ethics.
PG  - 1243-1244
LID - S0002-9343(20)30555-6 [pii]
LID - 10.1016/j.amjmed.2020.06.008 [doi]
FAU - Fins, Joseph J
AU  - Fins JJ
AD  - Division of Medical Ethics, Weill Cornell Medical College, New York, NY; Solomon 
      Center for Health Law and Policy, Yale Law School, New Haven, Conn. Electronic
      address: jjfins@med.cornell.edu.
FAU - Miller, Franklin G
AU  - Miller FG
AD  - Division of Medical Ethics, Weill Cornell Medical College, New York, NY.
LA  - eng
PT  - Editorial
DEP - 20200710
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
SB  - IM
MH  - COVID-19/*therapy/transmission
MH  - Ethical Theory
MH  - *Ethics, Medical
MH  - *Health Personnel
MH  - Humans
MH  - Infectious Disease Transmission, Patient-to-Professional/ethics
MH  - Medical Futility/*ethics
MH  - Palliative Care/*ethics
MH  - Personal Protective Equipment/*supply & distribution
MH  - Resuscitation Orders/*ethics
MH  - Risk Assessment
PMC - PMC7347467
EDAT- 2020/07/13 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/13 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/06/02 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/07/13 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/13 06:00 [entrez]
AID - S0002-9343(20)30555-6 [pii]
AID - 10.1016/j.amjmed.2020.06.008 [doi]
PST - ppublish
SO  - Am J Med. 2020 Nov;133(11):1243-1244. doi: 10.1016/j.amjmed.2020.06.008. Epub
      2020 Jul 10.


PMID- 32653090
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20201222
LR  - 20210104
IS  - 1873-1929 (Electronic)
IS  - 0160-9327 (Linking)
VI  - 44
IP  - 3
DP  - 2020 Sep
TI  - Cast iron street furniture: A historical review.
PG  - 100721
LID - S0160-9327(20)30038-7 [pii]
LID - 10.1016/j.endeavour.2020.100721 [doi]
AB  - The term "street furniture" indicates objects mostly made of cast iron alloys and
      aimed to improve the quality of life in urban settlements, such as street lamps, 
      fountains and gazebos. These objects are often ancient and relevant as cultural
      heritage. Despite the constant presence of street furniture in urban settlements,
      studies of its evolution along centuries are limited. Since functional aspects
      have been often considered prevalent against artistic and historical values, many
      objects have been considered obsolete, thus replaced or re-melted. Street
      furniture rarely received attention by scholars, and studies on this topic have
      been often incomplete. This study reviews the history of street furniture made of
      cast iron (CI street furniture), first examining the reasons behind the choice of
      this material, closely related to its diffusion during the First Industrial
      Revolution. The review discusses the relationship between CI street furniture and
      cultural heritage based on artistic, aesthetic and ethical issues, also examining
      historical catalogs. The development of CI street furniture in United Kingdom,
      France and Italy is reported, together with their local aspects. The production
      technique is discussed and the importance of preservation of CI street furniture 
      is highlighted, emphasizing the need for globally planned interventions in this
      field.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Soffritti, C
AU  - Soffritti C
AD  - Department of Engineering, University of Ferrara, Via Saragat 1, I-44122,
      Ferrara, Italy. Electronic address: chiara.soffritti@unife.it.
FAU - Calzolari, L
AU  - Calzolari L
AD  - Department of Engineering, University of Ferrara, Via Saragat 1, I-44122,
      Ferrara, Italy. Electronic address: laura.calzolari@student.unife.it.
FAU - Chicca, M
AU  - Chicca M
AD  - Department of Life Science and Biotechnologies, University of Ferrara, L. Borsari
      46, I-44121, Ferrara, Italy. Electronic address: milvia.chicca@unife.it.
FAU - Bassi Neri, R
AU  - Bassi Neri R
AD  - Neri Foundation - The Italian Museum of Cast Iron, Ss. Emilia 1626, I-47020,
      Longiano (FC), Italy. Electronic address: bassineri.ra@museoitalianoghisa.org.
FAU - Neri, A
AU  - Neri A
AD  - Neri Foundation - The Italian Museum of Cast Iron, Ss. Emilia 1626, I-47020,
      Longiano (FC), Italy. Electronic address: neri.antonio@neri.biz.
FAU - Bazzocchi, L
AU  - Bazzocchi L
AD  - Neri Foundation - The Italian Museum of Cast Iron, Ss. Emilia 1626, I-47020,
      Longiano (FC), Italy. Electronic address: staff@museoitalianoghisa.org.
FAU - Garagnani, G L
AU  - Garagnani GL
AD  - Department of Engineering, University of Ferrara, Via Saragat 1, I-44122,
      Ferrara, Italy. Electronic address: gian.luca.garagnani@unife.it.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - England
TA  - Endeavour
JT  - Endeavour
JID - 0375037
SB  - IM
EIN - Endeavour. 2020 Dec;44(4):100745. PMID: 33390265
OTO - NOTNLM
OT  - CI street furniture
OT  - Foundry process
OT  - France
OT  - Italy
OT  - Preservation
OT  - United Kingdom
EDAT- 2020/07/13 06:00
MHDA- 2020/07/13 06:01
CRDT- 2020/07/13 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/07/13 06:00 [pubmed]
PHST- 2020/07/13 06:01 [medline]
PHST- 2020/07/13 06:00 [entrez]
AID - S0160-9327(20)30038-7 [pii]
AID - 10.1016/j.endeavour.2020.100721 [doi]
PST - ppublish
SO  - Endeavour. 2020 Sep;44(3):100721. doi: 10.1016/j.endeavour.2020.100721. Epub 2020
      Jul 9.


PMID- 32652989
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 11
TI  - Implementation of data access and use procedures in clinical data warehouses. A
      systematic review of literature and publicly available policies.
PG  - 157
LID - 10.1186/s12911-020-01177-z [doi]
AB  - BACKGROUND: The promises of improved health care and health research through
      data-intensive applications rely on a growing amount of health data. At the core 
      of large-scale data integration efforts, clinical data warehouses (CDW) are also 
      responsible for data governance, managing data access and (re)use. As the
      complexity of the data flow increases, greater transparency and standardization
      of criteria and procedures are required in order to maintain objective oversight 
      and control. Therefore, the development of practice oriented and evidence-based
      policies is crucial. This study assessed the spectrum of data access and use
      criteria and procedures in clinical data warehouses governance internationally.
      METHODS: We performed a systematic review of (a) the published scientific
      literature on CDW and (b) publicly available information on CDW data access,
      e.g., data access policies. A qualitative thematic analysis was applied to all
      included literature and policies. RESULTS: Twenty-three scientific publications
      and one policy document were included in the final analysis. The qualitative
      analysis led to a final set of three main thematic categories: (1) requirements, 
      including recipient requirements, reuse requirements, and formal requirements;
      (2) structures and processes, including review bodies and review values; and (3) 
      access, including access limitations. CONCLUSIONS: The description of data access
      and use governance in the scientific literature is characterized by a high level 
      of heterogeneity and ambiguity. In practice, this might limit the effective data 
      sharing needed to fulfil the high expectations of data-intensive approaches in
      medical research and health care. The lack of publicly available information on
      access policies conflicts with ethical requirements linked to principles of
      transparency and accountability. CDW should publicly disclose by whom and under
      which conditions data can be accessed, and provide designated governance
      structures and policies to increase transparency on data access. The results of
      this review may contribute to the development of practice-oriented minimal
      standards for the governance of data access, which could also result in a
      stronger harmonization, efficiency, and effectiveness of CDW.
FAU - Pavlenko, Elena
AU  - Pavlenko E
AD  - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin,
      Germany.
AD  - QUEST - Center for Transforming Biomedical Research, Charite - University
      Medicine, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178,
      Berlin, Germany.
AD  - Institute for History, Ethics and Philosophy of Medicine, Hannover Medical School
      (MHH), Hannover, Germany.
FAU - Strech, Daniel
AU  - Strech D
AD  - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin,
      Germany.
AD  - QUEST - Center for Transforming Biomedical Research, Charite - University
      Medicine, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178,
      Berlin, Germany.
AD  - Institute for History, Ethics and Philosophy of Medicine, Hannover Medical School
      (MHH), Hannover, Germany.
FAU - Langhof, Holger
AU  - Langhof H
AUID- ORCID: 0000-0002-6633-6805
AD  - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat
      Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin,
      Germany. holger.langhof@alumni.charite.de.
AD  - QUEST - Center for Transforming Biomedical Research, Charite - University
      Medicine, Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178,
      Berlin, Germany. holger.langhof@alumni.charite.de.
AD  - Institute for History, Ethics and Philosophy of Medicine, Hannover Medical School
      (MHH), Hannover, Germany. holger.langhof@alumni.charite.de.
LA  - eng
GR  - 01ZZ1802C/Bundesministerium fur Bildung und Forschung/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200711
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - *Biomedical Research
MH  - Confidentiality
MH  - *Data Warehousing
MH  - Delivery of Health Care
MH  - Humans
MH  - Policy
PMC - PMC7353743
OTO - NOTNLM
OT  - *Clinical data warehouse
OT  - *Data access and use
OT  - *Data sharing
OT  - *Ethics
OT  - *Governance
EDAT- 2020/07/13 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/07/13 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/13 06:00 [entrez]
PHST- 2020/07/13 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1186/s12911-020-01177-z [doi]
AID - 10.1186/s12911-020-01177-z [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Jul 11;20(1):157. doi: 10.1186/s12911-020-01177-z.


PMID- 32652978
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 11
TI  - Comparison between surgical fusion and the growing-rod technique for early-onset 
      neurofibromatosis type-1 dystrophic scoliosis.
PG  - 455
LID - 10.1186/s12891-020-03460-6 [doi]
AB  - BACKGROUND: Spinal deformities constitute one of the most common types of
      manifestations of neurofibromatosis type-1 (NF-1), which can lead to either
      dystrophic or non-dystrophic early-onset scoliosis (EOS). Surgical treatment for 
      EOS with NF-1 is challenging, and the outcomes have rarely been reported. The
      anterior-posterior procedure is widely used, but posterior-only fusion is
      theoretically easier and safer to perform. Is it possible that a new surgery that
      accommodates growth is a better choice? A direct comparison between posterior
      fusion and growth-friendly surgery in terms of surgical outcomes has not yet been
      conducted in dystrophic EOS with NF-1 patients. METHODS: Baseline information was
      extracted from the NF-1 database at our institute with approval from the local
      ethics committee. All enrolled patients were diagnosed with NF-1. Clinical and
      radiographic data were recorded preoperatively, after the initial surgery, and at
      the final follow-up. Implant-related, alignment, neurological complication and
      unplanned revision surgery data were recorded. We compared the outcomes of these 
      two groups in terms of curve correction, growth parameters, complications and
      unplanned revision surgeries. RESULTS: There were eight patients in the PF group 
      and eight patients in the GR group, with a mean follow-up of 51.0 +/- 17.5
      months. The main curve size was similar (PF 67.38 degrees +/- 17.43 degrees
      versus GR 75.1 degrees +/- 26.43 degrees , P = 0.501), and there were no
      significant differences in the initial surgery correction rate or the rate of
      correction. However, the patients in the GR group exhibited more T1-S1 growth
      during the follow-up overall and per year than did those in the PF group. The
      operative time was significantly longer for the PF group than for the GR group
      (PF, 4.39 +/- 1.38 vs. GR, 3.00 +/- 0.42 h; p = 0.008). Significantly fewer
      segments were involved in the PF group (8.25 +/- 3.20) than in the GR group
      (13.00 +/- 1.60). CONCLUSION: For the initial treatment of dystrophic EOS in
      patients with NF-1, the GR technique is possibly a more appropriate treatment
      than is the PF technique in terms of trunk growth. However, the repeated
      procedures required for GR may be a considerable disadvantage. More studies with 
      direct measurement of pulmonary function must be conducted to determine the
      effect of GR on pulmonary development. More studies with larger sample sizes and 
      longer follow-up periods are needed to fully assess the treatment strategies.
FAU - Cai, Siyi
AU  - Cai S
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, No.1
      Shuai Fu Yuan, Wang Fu Jing Street, Beijing, Post Code: 100730, China.
FAU - Cui, Liqiang
AU  - Cui L
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, No.1
      Shuai Fu Yuan, Wang Fu Jing Street, Beijing, Post Code: 100730, China.
FAU - Qiu, Guixing
AU  - Qiu G
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, No.1
      Shuai Fu Yuan, Wang Fu Jing Street, Beijing, Post Code: 100730, China.
FAU - Shen, Jianxiong
AU  - Shen J
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, No.1
      Shuai Fu Yuan, Wang Fu Jing Street, Beijing, Post Code: 100730, China.
FAU - Zhang, Jianguo
AU  - Zhang J
AD  - Department of Orthopaedic Surgery, Peking Union Medical College Hospital, No.1
      Shuai Fu Yuan, Wang Fu Jing Street, Beijing, Post Code: 100730, China.
      zjgpumch@126.com.
LA  - eng
GR  - 7174337./Natural Science Foundation of Beijing Municipality
PT  - Journal Article
DEP - 20200711
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
SB  - IM
MH  - Humans
MH  - *Neurofibromatosis 1/diagnostic imaging/epidemiology/surgery
MH  - Prostheses and Implants
MH  - Retrospective Studies
MH  - *Scoliosis/diagnostic imaging/epidemiology/etiology
MH  - *Spinal Fusion/adverse effects
MH  - Treatment Outcome
PMC - PMC7354683
OTO - NOTNLM
OT  - Dystrophic early-onset scoliosis
OT  - Growing rod
OT  - Neurofibromatosis type-1
OT  - Posterior fusion
EDAT- 2020/07/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/13 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/13 06:00 [entrez]
PHST- 2020/07/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12891-020-03460-6 [doi]
AID - 10.1186/s12891-020-03460-6 [pii]
PST - epublish
SO  - BMC Musculoskelet Disord. 2020 Jul 11;21(1):455. doi: 10.1186/s12891-020-03460-6.


PMID- 32652706
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20211204
IS  - 1573-2770 (Electronic)
IS  - 0091-0562 (Linking)
VI  - 66
IP  - 3-4
DP  - 2020 Dec
TI  - Health Disparities Research with American Indian Communities: The Importance of
      Trust and Transparency.
PG  - 302-313
LID - 10.1002/ajcp.12445 [doi]
AB  - American Indian and Alaska Native (AI/AN) communities experience notable health
      disparities associated with substance use, including disproportionate rates of
      accidents/injuries, diabetes, liver disease, suicide, and substance use
      disorders. Effective treatments for substance use are needed to improve health
      equity for AI/AN communities. However, an unfortunate history of unethical and
      stigmatizing research has engendered distrust and reluctance to participate in
      research among many Native communities. In recent years, researchers have made
      progress toward engaging in ethical health disparities research by using a
      community-based participatory research (CBPR) framework to work in close
      partnership with community members throughout the research process. In this
      methodological process paper, we discuss the collaborative development of a
      quantitative survey aimed at understanding risk and protective factors for
      substance use among a sample of tribal members residing on a rural AI reservation
      with numerous systems-level barriers to recovery and limited access to treatment.
      By using a CBPR approach and prioritizing trust and transparency with community
      partners and participants, we were able to successfully recruit our target sample
      and collect quality data from nearly 200 tribal members who self-identified as
      having a substance use problem. Strategies for enhancing buy-in and recruiting a 
      community sample are discussed.
CI  - (c) 2020 Society for Community Research and Action.
FAU - Skewes, Monica C
AU  - Skewes MC
AUID- ORCID: 0000-0001-9362-9825
AD  - Department of Psychology, Montana State University, Bozeman, MT, USA.
FAU - Gonzalez, Vivian M
AU  - Gonzalez VM
AD  - Department of Psychology, University of Alaska Anchorage, Anchorage, AK, USA.
FAU - Gameon, Julie A
AU  - Gameon JA
AD  - Department of Psychology, Montana State University, Bozeman, MT, USA.
FAU - FireMoon, Paula
AU  - FireMoon P
AD  - Fort Peck Community College, Poplar, MT, USA.
FAU - Salois, Emily
AU  - Salois E
AD  - Center for American Indian and Rural Health Equity, Montana State University,
      Bozeman, MT, USA.
FAU - Rasmus, Stacy M
AU  - Rasmus SM
AD  - Center for Alaska Native Health Research, University of Alaska Fairbanks,
      Fairbanks, AK, USA.
FAU - Lewis, Jordan P
AU  - Lewis JP
AD  - Department of Family Medicine and Biobehavioral Health, University of Minnesota
      Medical School, Duluth Campus, Duluth, MN, USA.
FAU - Gardner, Scott A
AU  - Gardner SA
AD  - Department of Psychology, Montana State University, Bozeman, MT, USA.
FAU - Ricker, Adriann
AU  - Ricker A
AD  - Fort Peck Community College, Poplar, MT, USA.
FAU - Reum, Martel
AU  - Reum M
AD  - Fort Peck Community College, Poplar, MT, USA.
LA  - eng
GR  - P20 GM104417/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200711
PL  - England
TA  - Am J Community Psychol
JT  - American journal of community psychology
JID - 0364535
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Alaskan Natives/*statistics & numerical data
MH  - American Indians or Alaska Natives/*statistics & numerical data
MH  - Community-Based Participatory Research/*methods
MH  - Cultural Competency
MH  - Female
MH  - *Health Status Disparities
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Substance-Related Disorders/*therapy
MH  - Surveys and Questionnaires
MH  - Trust
MH  - Young Adult
PMC - PMC7772225
MID - NIHMS1629641
OTO - NOTNLM
OT  - *American Indian/Alaska Native
OT  - *Community-based participatory research
OT  - *Methods
OT  - *Process
OT  - *Substance use
EDAT- 2020/07/12 06:00
MHDA- 2021/09/10 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - 10.1002/ajcp.12445 [doi]
PST - ppublish
SO  - Am J Community Psychol. 2020 Dec;66(3-4):302-313. doi: 10.1002/ajcp.12445. Epub
      2020 Jul 11.


PMID- 32652511
OWN - NLM
STAT- MEDLINE
DCOM- 20210723
LR  - 20211109
IS  - 1090-2376 (Electronic)
IS  - 1053-8100 (Linking)
VI  - 83
DP  - 2020 Aug
TI  - Dream engineering: Simulating worlds through sensory stimulation.
PG  - 102955
LID - S1053-8100(20)30032-5 [pii]
LID - 10.1016/j.concog.2020.102955 [doi]
AB  - We explore the application of a wide range of sensory stimulation technologies to
      the area of sleep and dream engineering. We begin by emphasizing the causal role 
      of the body in dream generation, and describe a circuitry between the sleeping
      body and the dreaming mind. We suggest that nearly any sensory stimuli has
      potential for modulating experience in sleep. Considering other areas that might 
      afford tools for engineering sensory content in simulated worlds, we turn to
      Virtual Reality (VR). We outline a collection of relevant VR technologies,
      including devices engineered to stimulate haptic, temperature, vestibular,
      olfactory, and auditory sensations. We believe these technologies, which have
      been developed for high mobility and low cost, can be translated to the field of 
      dream engineering. We close by discussing possible future directions in this
      field and the ethics of a world in which targeted dream direction and sleep
      manipulation are feasible.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Carr, Michelle
AU  - Carr M
AD  - Sleep & Neurophysiology Research Laboratory, Department of Psychiatry, University
      of Rochester Medical Center, Rochester, NY, USA. Electronic address:
      Michelle_Carr@URMC.Rochester.edu.
FAU - Haar, Adam
AU  - Haar A
AD  - MIT Media Lab, MIT, Boston, MA, USA.
FAU - Amores, Judith
AU  - Amores J
AD  - MIT Media Lab, MIT, Boston, MA, USA.
FAU - Lopes, Pedro
AU  - Lopes P
AD  - University of Chicago, Chicago, IL, USA.
FAU - Bernal, Guillermo
AU  - Bernal G
AD  - MIT Media Lab, MIT, Boston, MA, USA.
FAU - Vega, Tomas
AU  - Vega T
AD  - MIT Media Lab, MIT, Boston, MA, USA.
FAU - Rosello, Oscar
AU  - Rosello O
AD  - MIT Media Lab, MIT, Boston, MA, USA.
FAU - Jain, Abhinandan
AU  - Jain A
AD  - MIT Media Lab, MIT, Boston, MA, USA.
FAU - Maes, Pattie
AU  - Maes P
AD  - MIT Media Lab, MIT, Boston, MA, USA.
LA  - eng
GR  - K12 GM106997/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200708
PL  - United States
TA  - Conscious Cogn
JT  - Consciousness and cognition
JID - 9303140
SB  - IM
MH  - Dreams/*physiology
MH  - Humans
MH  - *Physical Stimulation
MH  - Sensation/*physiology
MH  - Sleep, REM/*physiology
PMC - PMC7415562
MID - NIHMS1611129
OTO - NOTNLM
OT  - *Dreaming
OT  - *Haptic devices
OT  - *Human Computer interaction
OT  - *Simulation
OT  - *Sleep
OT  - *Virtual reality
EDAT- 2020/07/12 06:00
MHDA- 2021/07/24 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/04/19 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2021/07/24 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - S1053-8100(20)30032-5 [pii]
AID - 10.1016/j.concog.2020.102955 [doi]
PST - ppublish
SO  - Conscious Cogn. 2020 Aug;83:102955. doi: 10.1016/j.concog.2020.102955. Epub 2020 
      Jul 8.


PMID- 32652095
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20210226
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 158
IP  - 6
DP  - 2020 Dec
TI  - Addressing Reduced Laboratory-Based Pulmonary Function Testing During a Pandemic.
PG  - 2502-2510
LID - S0012-3692(20)31867-5 [pii]
LID - 10.1016/j.chest.2020.06.065 [doi]
AB  - To reduce the spread of the severe acute respiratory syndrome coronavirus 2, many
      pulmonary function testing (PFT) laboratories have been closed or have
      significantly reduced their testing capacity. Because these mitigation strategies
      may be necessary for the next 6 to 18 months to prevent recurrent peaks in
      disease prevalence, fewer objective measurements of lung function will alter the 
      diagnosis and care of patients with chronic respiratory diseases. PFT, which
      includes spirometry, lung volume, and diffusion capacity measurement, is
      essential to the diagnosis and management of patients with asthma, COPD, and
      other chronic lung conditions. Both traditional and innovative alternatives to
      conventional testing must now be explored. These may include peak expiratory flow
      devices, electronic portable spirometers, portable exhaled nitric oxide
      measurement, airwave oscillometry devices, and novel digital health tools such as
      smartphone microphone spirometers and mobile health technologies along with
      integration of machine learning approaches. The adoption of some novel approaches
      may not merely replace but could improve existing management strategies and alter
      common diagnostic paradigms. With these options comes important technical,
      privacy, ethical, financial, and medicolegal barriers that must be addressed.
      However, the coronavirus disease 19 pandemic also presents a unique opportunity
      to augment conventional testing by including innovative and emerging approaches
      to measuring lung function remotely in patients with respiratory disease. The
      benefits of such an approach have the potential to enhance respiratory care and
      empower patient self-management well beyond the current global pandemic.
CI  - Copyright (c) 2020 American College of Chest Physicians. Published by Elsevier
      Inc. All rights reserved.
FAU - Kouri, Andrew
AU  - Kouri A
AD  - Division of Respirology, Department of Medicine, St. Michael's Hospital, Unity
      Health Toronto, Toronto, ON. Electronic address: andrew.kouri@mail.utoronto.ca.
FAU - Gupta, Samir
AU  - Gupta S
AD  - Division of Respirology, Department of Medicine, St. Michael's Hospital, Unity
      Health Toronto, Toronto, ON; Department of Medicine, University of Toronto,
      Toronto, ON.
FAU - Yadollahi, Azadeh
AU  - Yadollahi A
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, ON; KITE-Toronto Rehabilitation Institute, University Health Network,
      Toronto, ON.
FAU - Ryan, Clodagh M
AU  - Ryan CM
AD  - Department of Medicine, University of Toronto, Toronto, ON; Division of
      Respirology, Department of Medicine, Toronto General Hospital, University Health 
      Network, Toronto, ON.
FAU - Gershon, Andrea S
AU  - Gershon AS
AD  - Department of Medicine, University of Toronto, Toronto, ON; Division of
      Respirology, Department of Medicine, Sunnybrook Health Sciences Center, Toronto, 
      ON.
FAU - To, Teresa
AU  - To T
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON;
      Dalla Lana Graduate School of Public Health, University of Toronto, Toronto, ON.
FAU - Tarlo, Susan M
AU  - Tarlo SM
AD  - Department of Medicine, University of Toronto, Toronto, ON; Division of
      Respirology, Department of Medicine, Toronto Western Hospital, University Health 
      Network, Toronto, ON.
FAU - Goldstein, Roger S
AU  - Goldstein RS
AD  - Department of Medicine, University of Toronto, Toronto, ON; Division of
      Respiratory Medicine, West Part Healthcare Centre, Toronto, ON, Canada.
FAU - Chapman, Kenneth R
AU  - Chapman KR
AD  - Department of Medicine, University of Toronto, Toronto, ON; Division of
      Respirology, Department of Medicine, Toronto Western Hospital, University Health 
      Network, Toronto, ON.
FAU - Chow, Chung-Wai
AU  - Chow CW
AD  - Department of Medicine, University of Toronto, Toronto, ON; Division of
      Respirology, Department of Medicine, Toronto General Hospital, University Health 
      Network, Toronto, ON.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200708
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - IM
MH  - Asthma/diagnosis/physiopathology/therapy
MH  - Breath Tests/instrumentation/methods
MH  - *COVID-19
MH  - Chronic Disease
MH  - Cystic Fibrosis/diagnosis/therapy
MH  - Delivery of Health Care/*methods
MH  - Humans
MH  - Hypertension, Pulmonary/diagnosis/therapy
MH  - Inventions
MH  - Lung Diseases/*diagnosis/physiopathology/*therapy
MH  - Lung Diseases, Interstitial/diagnosis/therapy
MH  - Lung Volume Measurements
MH  - Machine Learning
MH  - Oscillometry/instrumentation/methods
MH  - Peak Expiratory Flow Rate
MH  - Pulmonary Diffusing Capacity/instrumentation/methods
MH  - Pulmonary Disease, Chronic Obstructive/diagnosis/physiopathology/therapy
MH  - Respiratory Function Tests/*instrumentation/*methods
MH  - Self-Management
MH  - Smartphone
MH  - Spirometry/instrumentation/methods
PMC - PMC7345485
OTO - NOTNLM
OT  - *COPD
OT  - *COVID-19 pandemic
OT  - *SARS-CoV-2
OT  - *asthma
OT  - *pulmonary function test
OT  - *review
EDAT- 2020/07/12 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - S0012-3692(20)31867-5 [pii]
AID - 10.1016/j.chest.2020.06.065 [doi]
PST - ppublish
SO  - Chest. 2020 Dec;158(6):2502-2510. doi: 10.1016/j.chest.2020.06.065. Epub 2020 Jul
      8.


PMID- 32651773
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - The Boeing 737 MAX: Lessons for Engineering Ethics.
PG  - 2957-2974
LID - 10.1007/s11948-020-00252-y [doi]
AB  - The crash of two 737 MAX passenger aircraft in late 2018 and early 2019, and
      subsequent grounding of the entire fleet of 737 MAX jets, turned a global
      spotlight on Boeing's practices and culture. Explanations for the crashes
      include: design flaws within the MAX's new flight control software system
      designed to prevent stalls; internal pressure to keep pace with Boeing's chief
      competitor, Airbus; Boeing's lack of transparency about the new software; and the
      lack of adequate monitoring of Boeing by the FAA, especially during the
      certification of the MAX and following the first crash. While these and other
      factors have been the subject of numerous government reports and investigative
      journalism articles, little to date has been written on the ethical significance 
      of the accidents, in particular the ethical responsibilities of the engineers at 
      Boeing and the FAA involved in designing and certifying the MAX. Lessons learned 
      from this case include the need to strengthen the voice of engineers within large
      organizations. There is also the need for greater involvement of professional
      engineering societies in ethics-related activities and for broader focus on moral
      courage in engineering ethics education.
FAU - Herkert, Joseph
AU  - Herkert J
AD  - North Carolina State University, Raleigh, NC, USA. jherkert@ncsu.edu.
FAU - Borenstein, Jason
AU  - Borenstein J
AD  - Georgia Institute of Technology, Atlanta, GA, USA.
FAU - Miller, Keith
AU  - Miller K
AD  - University of Missouri - St. Louis, St. Louis, MO, USA.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Aircraft
MH  - *Engineering
MH  - *Ethics, Professional
MH  - Morals
MH  - Writing
PMC - PMC7351545
OTO - NOTNLM
OT  - Airline safety
OT  - Corporate culture
OT  - Engineering design
OT  - Engineering ethics
OT  - Regulation
OT  - Software engineering
EDAT- 2020/07/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - 10.1007/s11948-020-00252-y [doi]
AID - 10.1007/s11948-020-00252-y [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):2957-2974. doi: 10.1007/s11948-020-00252-y. Epub
      2020 Jul 10.


PMID- 32651590
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - Reconciling Lists of Principles in Bioethics.
PG  - 540-559
LID - 10.1093/jmp/jhaa017 [doi]
AB  - In celebration of the fortieth anniversary of the publication of Beauchamp and
      Childress's Principles of Biomedical Ethics, a review is undertaken to compare
      the lists of principles in various bioethical theories to determine the extent to
      which the various lists can be reconciled. Included are the single principle
      theories of utilitarianism, libertarianism, Hippocratism, and the theories of
      Pellegrino, Engelhardt, The Belmont Report, Beauchamp and Childress, Ross,
      Veatch, and Gert. We find theories all offering lists of principles (or the
      equivalent) numbering from one to ten. Many of the differences can be reconciled,
      but some critical differences remain.
CI  - (c) The Author 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Veatch, Robert M
AU  - Veatch RM
AD  - Georgetown University, Washington, D.C., USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - *Bioethics
MH  - Ethical Analysis
MH  - *Ethical Theory
MH  - Humans
MH  - Personal Autonomy
MH  - Respect
OTO - NOTNLM
OT  - *Beauchamp
OT  - *Childress
OT  - *ethical principles
OT  - *respect for persons
EDAT- 2020/07/12 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - 5870049 [pii]
AID - 10.1093/jmp/jhaa017 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):540-559. doi: 10.1093/jmp/jhaa017.


PMID- 32651580
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210629
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 26
IP  - 9
DP  - 2020 Sep
TI  - The ethics of deferred consent in times of pandemics.
PG  - 1328-1330
LID - 10.1038/s41591-020-0999-9 [doi]
FAU - van der Graaf, Rieke
AU  - van der Graaf R
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary
      Care, University Medical Center Utrecht, Utrecht, the Netherlands.
      r.vandergraaf@umcutrecht.nl.
FAU - Hoogerwerf, Marie-Astrid
AU  - Hoogerwerf MA
AUID- ORCID: http://orcid.org/0000-0002-3088-3380
AD  - Department of Parasitology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Infectious Diseases, Leiden University Medical Center, Leiden, the 
      Netherlands.
FAU - de Vries, Martine C
AU  - de Vries MC
AD  - Department of Medical Ethics and Health Law, Leiden University Medical Center,
      Leiden, the Netherlands.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Pandemics/*ethics
MH  - Patient Selection/*ethics
EDAT- 2020/07/12 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - 10.1038/s41591-020-0999-9 [doi]
AID - 10.1038/s41591-020-0999-9 [pii]
PST - ppublish
SO  - Nat Med. 2020 Sep;26(9):1328-1330. doi: 10.1038/s41591-020-0999-9.


PMID- 32651254
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - When patients refuse COVID-19 testing, quarantine, and social distancing in
      inpatient psychiatry: clinical and ethical challenges.
PG  - 579-580
LID - 10.1136/medethics-2020-106613 [doi]
AB  - The COVID-19 pandemic has introduced new ethical challenges in the care of
      patients with serious psychiatric illness who require inpatient treatment and who
      may have beeen exposed to COVID-19 or have mild to moderate COVID-19 but refuse
      testing and adherence to infection prevention protocols. Such situations increase
      the risk of infection to other patients and staff on psychiatric inpatient units.
      We discuss medical and ethical considerations for navigating this dilemma and
      offer a set of policy recommendations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Russ, Mark J
AU  - Russ MJ
AD  - Department of Psychiatry, Weill Cornell Medicine, New York, New York, USA.
FAU - Sisti, Dominic
AU  - Sisti D
AUID- ORCID: 0000-0002-2282-9253
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA sistid@upenn.edu.
FAU - Wilner, Philip J
AU  - Wilner PJ
AD  - Department of Psychiatry, Weill Cornell Medicine, New York, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Testing
MH  - *Clinical Laboratory Techniques
MH  - Coronavirus Infections/diagnosis/epidemiology/*prevention & control/virology
MH  - *Ethics, Medical
MH  - *Hospitalization
MH  - Humans
MH  - Infection Control/methods
MH  - Mental Disorders/*complications/therapy
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/diagnosis/epidemiology/*prevention & control/virology
MH  - Policy
MH  - Psychiatry
MH  - *Quarantine
MH  - *Refusal to Participate
MH  - SARS-CoV-2
MH  - Social Isolation
MH  - Treatment Refusal
PMC - PMC7371475
OTO - NOTNLM
OT  - *clinical ethics
OT  - *involuntary civil commitment
OT  - *psychiatry
OT  - *right to refuse treatment
COIS- Competing interests: None declared.
EDAT- 2020/07/12 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/06/22 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - medethics-2020-106613 [pii]
AID - 10.1136/medethics-2020-106613 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):579-580. doi: 10.1136/medethics-2020-106613. Epub
      2020 Jul 10.


PMID- 32651253
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Genetic testing in the acute setting: a round table discussion.
PG  - 531-532
LID - 10.1136/medethics-2019-106043 [doi]
AB  - Genetic testing has historically been performed in the context of chronic disease
      and cancer diagnostics. The timelines for these tests are typically measured in
      days or weeks, rather than in minutes. As such, the concept that genetic
      information might be generated and then used to alter management in the acute
      setting has, thus far, not been feasible. However, recent advances in genetic
      technologies have the potential to allow genetic information to be generated
      significantly quicker. The m.1555A>G genetic variant is present in one in 500
      individuals and predisposes to profound hearing loss following the administration
      of aminoglycoside antibiotics. These antibiotics are used frequently in cases of 
      neonatal sepsis and it is estimated that approximately 180 neonates in the UK are
      at risk of antibiotic induced hearing loss each year because of this genetic
      change. Knowledge of this variant in the acute setting would allow clinicians to 
      prescribe alternative antibiotics. The Pharmacogenetics to Avoid Loss of Hearing 
      study will implement a genetic point of care test (POCT) for the m.1555A>G
      variant within two major UK based neonatal intensive care units. This represents 
      the first trial of a genetic POCT aimed at altering management in the acute
      setting. This round table discussion outlines the novel ethical issues faced in
      the development of this trial and the legal barriers to implementation. We ask
      five stakeholders to provide their opinions on this trial and their perspectives 
      on the concept of genetic testing in the acute setting.Trial registration
      numberISRCTN-13704894.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - McDermott, John Henry
AU  - McDermott JH
AUID- ORCID: 0000-0002-5220-8837
AD  - Manchester Centre for Genomic, Manchester University NHS Foundation Trust,
      Manchester, UK john.mcdermott2@mft.nhs.uk.
LA  - eng
SI  - ISRCTN/ISRCTN13704894
GR  - II-LB-0417-20002/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (Aminoglycosides)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
CIN - J Med Ethics. 2020 Aug;46(8):536-537. PMID: 32661073
CIN - J Med Ethics. 2020 Aug;46(8):533. PMID: 32665254
CIN - J Med Ethics. 2020 Aug;46(8):534-535. PMID: 32669275
CIN - J Med Ethics. 2021 Feb;47(2):114-116. PMID: 33208480
CIN - J Med Ethics. 2021 Feb;47(2):117-118. PMID: 33335072
MH  - Aminoglycosides/administration & dosage/*adverse effects
MH  - Anti-Bacterial Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Deafness/drug therapy
MH  - Ethics, Clinical
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing/*methods
MH  - *Hearing Loss/chemically induced/genetics
MH  - Hearing Tests
MH  - Humans
MH  - Infant, Newborn
MH  - Neonatology
MH  - Pharmacogenetics
MH  - *Point-of-Care Testing
PMC - PMC7418589
OTO - NOTNLM
OT  - *clinical ethics
OT  - *genethics
OT  - *genetic information
OT  - *genetic screening/testing
OT  - *neonatology
COIS- Competing interests: None declared.
EDAT- 2020/07/12 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/07/12 06:00
PHST- 2019/12/26 00:00 [received]
PHST- 2020/02/02 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - medethics-2019-106043 [pii]
AID - 10.1136/medethics-2019-106043 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):531-532. doi: 10.1136/medethics-2019-106043. Epub
      2020 Jul 10.


PMID- 32651252
OWN - NLM
STAT- Publisher
LR  - 20200723
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 10
TI  - Ethicists, doctors and triage decisions: who should decide? And on what basis?
LID - medethics-2020-106499 [pii]
LID - 10.1136/medethics-2020-106499 [doi]
AB  - We report here an emerging dispute in Italy concerning triage criteria for
      critically ill covid-19 patients, and how best to support doctors having to make 
      difficult decisions in a context of insufficient life saving resources. The
      dispute we present is particularly significant as it juxtaposes two opposite
      views of who should make triage decisions, and how doctors should best be
      supported. There are both empirical and normative questions at stake here. The
      empirical questions pertain to the available level of evidence that healthcare
      professionals would rather not be left alone with their 'clinical judgments' to
      make triage decisions, and to the accounts of distributive justice that doctors
      and healthcare professionals rely on, when making triage decisions. The normative
      questions pertain to how this empirical evidence should inform guidelines on how 
      prioritisation decisions are made in a context of emergency, and who gets to have
      the authority to do so. This debate goes beyond the discussion of the care of
      critically ill patients with COVID-19 and has broader implications beyond the
      national context for the discussion of how to relieve moral distress in contexts 
      of imbalances between healthcare resources and clinical needs of a population.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Camporesi, Silvia
AU  - Camporesi S
AUID- ORCID: http://orcid.org/0000-0003-4135-1723
AD  - Global Health and Social Medicine, King's College London, London, UK
      silvia.camporesi@kcl.ac.uk.
FAU - Mori, Maurizio
AU  - Mori M
AD  - Department of Philosophy, University of Turin, Turin, Italy.
AD  - Consulta di Bioetica, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7371478
OTO - NOTNLM
OT  - ethics committees/consultation
OT  - history of health ethics/bioethics
OT  - policy guidelines/inst. review boards
OT  - research ethics
OT  - resource allocation
COIS- Competing interests: MM is a member of the Italian National Bioethics Committee
      (CNB) and sole author of a Minority Report to the CNB on 'COVID-19 and clinical
      decision-making in conditions of resource shortage' referenced in this article.
EDAT- 2020/07/12 06:00
MHDA- 2020/07/12 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/12 06:00 [entrez]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/07/12 06:00 [medline]
AID - medethics-2020-106499 [pii]
AID - 10.1136/medethics-2020-106499 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 10. pii: medethics-2020-106499. doi:
      10.1136/medethics-2020-106499.


PMID- 32651190
OWN - NLM
STAT- Publisher
LR  - 20200711
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 Jul 10
TI  - Current collaboration between palliative care and neurology: a survey of
      clinicians in Europe.
LID - bmjspcare-2020-002322 [pii]
LID - 10.1136/bmjspcare-2020-002322 [doi]
AB  - INTRODUCTION: The collaboration between palliative care and neurology has
      developed over the last 25 years and this study aimed to ascertain the
      collaboration between the specialties across Europe. METHODS: This online survey 
      aimed to look at collaboration across Europe, using the links of the European
      Association for Palliative Care and the European Academy of Neurology. RESULTS:
      298 people completed the survey-178 from palliative care and 120 from neurology
      from over 20 countries across Europe. They reported that there was good
      collaboration in the care for people with amyotrophic lateral sclerosis and
      cerebral tumours but less for other progressive neurological diseases. The
      collaboration included joint meetings and clinics and telephone contacts. All
      felt that the collaboration was helpful, particularly for maintaining quality of 
      life, physical symptom management, psychological support and complex decision
      making, including ethical issues. DISCUSSION: The study shows evidence for
      collaboration between palliative care and neurology, but with the need to develop
      this for all neurological illness, and there is a need for increased education of
      both areas.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Oliver, David
AU  - Oliver D
AUID- ORCID: http://orcid.org/0000-0001-9302-3225
AD  - Tizard Centre, University of Kent, Canterbury, Kent, UK drdjoliver@gmail.com.
FAU - Borasio, Gian Domenico
AU  - Borasio GD
AD  - Service de soins palliatifs, Centre Hospitalier Universitaire Vaudois, Lausanne, 
      Switzerland.
FAU - Veronese, Simone
AU  - Veronese S
AD  - Palliative Care, Fondazione FARO, Turin, Italy.
FAU - Voltz, Raymond
AU  - Voltz R
AD  - Department of Palliative Medicine, University of Cologne, Koln,
      Nordrhein-Westfalen, Germany.
FAU - Lorenzl, Stefan
AU  - Lorenzl S
AD  - Institute of Nursing Sciences and Practice, Paracelsus Medical University
      Salzburg, Salzburg, Austria.
FAU - Hepgul, Nilay
AU  - Hepgul N
AUID- ORCID: http://orcid.org/0000-0002-5980-1457
AD  - Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, London, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - education and training
OT  - neurological conditions
OT  - quality of life
OT  - service evaluation
COIS- Competing interests: None declared.
EDAT- 2020/07/12 06:00
MHDA- 2020/07/12 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/05/31 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/12 06:00 [entrez]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/07/12 06:00 [medline]
AID - bmjspcare-2020-002322 [pii]
AID - 10.1136/bmjspcare-2020-002322 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 Jul 10. pii: bmjspcare-2020-002322. doi:
      10.1136/bmjspcare-2020-002322.


PMID- 32651096
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20210110
IS  - 2352-5568 (Electronic)
IS  - 2352-5568 (Linking)
VI  - 39
IP  - 4
DP  - 2020 Aug
TI  - COVID-19 studies registration worldwide for prospective studies with a specific
      focus on the fast-tracking of French ethic procedures.
PG  - 481-482
LID - S2352-5568(20)30126-0 [pii]
LID - 10.1016/j.accpm.2020.06.010 [doi]
FAU - Gremi, Tea
AU  - Gremi T
AD  - EA 2992 IMAGINE, pole anesthesie-reanimation douleur urgence, CHU de Nimes,
      universite Montpellier, Nimes, France. Electronic address: gremi.tea@gmail.com.
FAU - Ginesy, Eric
AU  - Ginesy E
AD  - Inspection generale des affaires sociales, Paris, France.
FAU - Payen, Didier
AU  - Payen D
AD  - UMR Inserm 1160, UFR de medecine de l'universite Paris 7, Paris, France.
FAU - Lefrant, Jean-Yves
AU  - Lefrant JY
AD  - EA 2992 IMAGINE, pole anesthesie-reanimation douleur urgence, CHU de Nimes,
      universite Montpellier, Nimes, France.
FAU - Marin, Benoit
AU  - Marin B
AD  - Direction generale de la sante, ministere des Solidarites et de la Sante, Paris, 
      France.
LA  - eng
PT  - Letter
DEP - 20200630
PL  - France
TA  - Anaesth Crit Care Pain Med
JT  - Anaesthesia, critical care & pain medicine
JID - 101652401
SB  - IM
MH  - Advisory Committees
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Studies as Topic/*statistics & numerical data
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - France/epidemiology
MH  - Global Health/*statistics & numerical data
MH  - Humans
MH  - Observational Studies as Topic/statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Registries/*statistics & numerical data
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Therapeutic Human Experimentation/ethics
PMC - PMC7326406
EDAT- 2020/07/12 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/06/08 00:00 [received]
PHST- 2020/06/22 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - S2352-5568(20)30126-0 [pii]
AID - 10.1016/j.accpm.2020.06.010 [doi]
PST - ppublish
SO  - Anaesth Crit Care Pain Med. 2020 Aug;39(4):481-482. doi:
      10.1016/j.accpm.2020.06.010. Epub 2020 Jun 30.


PMID- 32650946
OWN - NLM
STAT- Publisher
LR  - 20210110
IS  - 1578-1860 (Electronic)
IS  - 0014-2565 (Linking)
DP  - 2020 Jul 7
TI  - Which are the most prevalent ethical conflicts for Spanish internists?
LID - S0014-2565(20)30150-8 [pii]
LID - 10.1016/j.rce.2020.05.011 [doi]
AB  - BACKGROUND AND OBJECTIVE: Clinicians face a multitude of ethical conflicts in
      their daily practice. There have been no studies on the types of ethical
      conflicts encountered most frequently and that are of most concern to clinicians 
      in Spain. The aim of this study is to report the most common ethical conflicts
      faced by Spanish internists, as well as the importance that the practitioners
      attribute to each conflict. MATERIALS AND METHODS: Our observational
      cross-sectional study employed a voluntary and anonymous survey aimed at Spanish 
      medical internists and distributed through an ad hoc platform of the Spanish
      Society of Internal Medicine. RESULTS: The most common and relevant ethical
      issues for Spanish internists are related to patients' end of life (decisions
      limiting therapeutic effort, use of palliative treatments, the establishment of
      do-not-resuscitate orders), the conflicts arising within the
      doctor-patient/family relationship, and making decisions with noncompetent
      patients. These results are similar to those of other English and European
      series. The ethical problems further complicate the healthcare activity of
      clinicians who more often notice these problems (50.3%) than those who do not
      notice them (16%). CONCLUSIONS: The most common and relevant ethical conflicts
      among Spanish internists are related to managing patients' end of life, followed 
      by those related to the doctor-patient relationship and the management of
      noncompetent patients. It is essential that training programs be designed to
      better address and recognise these problems.
CI  - Copyright (c) 2020 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina
      Interna (SEMI). All rights reserved.
FAU - Blanco Portillo, A
AU  - Blanco Portillo A
AD  - Unidad de Medicina Interna, Hospital Universitario Fundacion Alcorcon, Alcorcon, 
      Madrid, Espana. Electronic address: blanco131187@hotmail.com.
FAU - Garcia-Caballero, R
AU  - Garcia-Caballero R
AD  - Servicio de Medicina Interna, Hospital Universitario Infanta Sofia, San Sebastian
      de los Reyes, Madrid, Espana; Grupo de Trabajo de Bioetica y Profesionalismo,
      Sociedad Espanola de Medicina Interna , Madrid, Espana.
FAU - Real de Asua, D
AU  - Real de Asua D
AD  - Grupo de Trabajo de Bioetica y Profesionalismo, Sociedad Espanola de Medicina
      Interna , Madrid, Espana; Servicio de Medicina Interna, Hospital Universitario de
      La Princesa , Madrid, Espana; Instituto de Etica Clinica Francisco Valles,
      Universidad Europea, Madrid, Espana.
FAU - Herreros, B
AU  - Herreros B
AD  - Unidad de Medicina Interna, Hospital Universitario Fundacion Alcorcon, Alcorcon, 
      Madrid, Espana; Grupo de Trabajo de Bioetica y Profesionalismo, Sociedad Espanola
      de Medicina Interna , Madrid, Espana; Instituto de Etica Clinica Francisco
      Valles, Universidad Europea, Madrid, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - inverted question markCuales son los conflictos eticos mas frecuentes para los
      internistas espanoles?
DEP - 20200707
PL  - Spain
TA  - Rev Clin Esp
JT  - Revista clinica espanola
JID - 8608576
PMC - PMC7340392
OTO - NOTNLM
OT  - Bioethics
OT  - Bioetica
OT  - Clinical ethics
OT  - End of life
OT  - Ethical problems
OT  - Final de la vida
OT  - Problemas eticos
OT  - Etica clinica
EDAT- 2020/07/12 06:00
MHDA- 2020/07/12 06:00
CRDT- 2020/07/12 06:00
PHST- 2020/02/04 00:00 [received]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/07/12 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - S0014-2565(20)30150-8 [pii]
AID - 10.1016/j.rce.2020.05.011 [doi]
PST - aheadofprint
SO  - Rev Clin Esp. 2020 Jul 7. pii: S0014-2565(20)30150-8. doi:
      10.1016/j.rce.2020.05.011.


PMID- 32650154
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 92
DP  - 2020 Sep
TI  - Social and health care educators' perceptions of competence in digital pedagogy: 
      A qualitative descriptive study.
PG  - 104521
LID - S0260-6917(19)31297-3 [pii]
LID - 10.1016/j.nedt.2020.104521 [doi]
AB  - BACKGROUND: Digitalisation has made digital competence a necessity for those
      working in social and healthcare. A high degree of competence in digital pedagogy
      is required of educators to meet the challenge of educating future professionals 
      who are themselves highly digitally competent. OBJECTIVES: The aim of this study 
      was to describe the perceptions of competence in digital pedagogy that educators 
      in social and healthcare have. DESIGN: A qualitative descriptive study.
      PARTICIPANTS: The participants were Finnish-speaking social and healthcare
      educators (n=37) working at six Finnish universities of applied sciences (UAS).
      METHODS: Group interviews (n=12) were conducted during spring 2018. Each group
      consisted of 2-5 educators, with a total of 37 educators. The data was analysed
      using an inductive content analysis. RESULTS: According to the interviewed
      educators, competence in digital pedagogy involved pedagogical, digital, and
      ethical skills and awareness. The educators were aware of the possibilities
      afforded by digital technology and had a positive view on how the technology
      could be utilised in education. However, the educators were concerned that
      technology might solely be utilised for the sake of digitalisation instead of
      being pedagogically preferable. CONCLUSIONS: In the future, the results of this
      study can be utilised while developing an instrument to evaluate the level of
      competence in digital pedagogy. Examining the perceptions of the educators will
      allows us to better understand the phenomena from the educators' point of view.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Ryhta, Iina
AU  - Ryhta I
AD  - Faculty of Medicine, Department of Nursing Science, University of Turku, Turku,
      Finland. Electronic address: iikrry@utu.fi.
FAU - Elonen, Imane
AU  - Elonen I
AD  - Faculty of Medicine, Department of Nursing Science, University of Turku, Turku,
      Finland.
FAU - Saaranen, Terhi
AU  - Saaranen T
AD  - Faculty of Health Sciences, Department of Nursing Science, University of Eastern 
      Finland, Kuopio, Finland.
FAU - Sormunen, Marjorita
AU  - Sormunen M
AD  - Institute of Public Health and Clinical Nutrition, University or Eastern Finland,
      Kuopio, Finland.
FAU - Mikkonen, Kristina
AU  - Mikkonen K
AD  - Research Unit of Nursing Science and Health Management, University of Oulu, Oulu,
      Finland.
FAU - Kaariainen, Maria
AU  - Kaariainen M
AD  - Research Unit of Nursing Science and Health Management, University of Oulu, Oulu,
      Finland.
FAU - Koskinen, Camilla
AU  - Koskinen C
AD  - Faculty of Education and Welfare Studies, Abo Akademi University, Turku, Finland.
FAU - Koskinen, Monika
AU  - Koskinen M
AD  - Faculty of Education and Welfare Studies, Abo Akademi University, Turku, Finland.
FAU - Koivula, Meeri
AU  - Koivula M
AD  - Faculty of Social Sciences, University of Tampere, Tampere, Finland.
FAU - Koskimaki, Minna
AU  - Koskimaki M
AD  - Faculty of Social Sciences, University of Tampere, Tampere, Finland.
FAU - Lahteenmaki, Marja-Leena
AU  - Lahteenmaki ML
AD  - Degree Programme in Physiotherapy, Tampere University of Applied Sciences,
      Tampere, Finland.
FAU - Wallin, Outi
AU  - Wallin O
AD  - Degree Programme in Social Services, Tampere University of Applied Sciences,
      Tampere, Finland.
FAU - Sjogren, Tuulikki
AU  - Sjogren T
AD  - Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla,
      Finland.
FAU - Salminen, Leena
AU  - Salminen L
AD  - Faculty of Medicine, Department of Nursing Science, University of Turku, Turku,
      Finland.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Delivery of Health Care
MH  - Finland
MH  - *Health Educators
MH  - Humans
MH  - Perception
MH  - Qualitative Research
OTO - NOTNLM
OT  - Competence
OT  - Digital pedagogy
OT  - Digital technology
OT  - Education
OT  - Educator
OT  - Social and healthcare
COIS- Declaration of competing interest No conflict of interest has been declared by
      the authors.
EDAT- 2020/07/11 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/11 06:00
PHST- 2019/08/28 00:00 [received]
PHST- 2020/05/10 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - S0260-6917(19)31297-3 [pii]
AID - 10.1016/j.nedt.2020.104521 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Sep;92:104521. doi: 10.1016/j.nedt.2020.104521. Epub 2020 
      Jun 27.


PMID- 32649844
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 2578-5826 (Electronic)
IS  - 2578-5826 (Linking)
VI  - 43
IP  - 4
DP  - 2020 Dec
TI  - Cow milk exosomes activate NK cells and gammadeltaT cells in human PBMCs in
      vitro.
PG  - 161-170
LID - 10.1080/25785826.2020.1791400 [doi]
AB  - Cow milk is a nourishing food containing numerous essential nutrients. In Japan, 
      the consumption of cow milk is thought to enhance resistance to
      exhaustion-related diseases. Although several nutrients in cow milk, such as
      lactoferrin, are thought to modulate immune cells, the mechanisms remain unclear.
      Recently, the immunoregulatory functions of food-derived microRNAs or exosomes
      have been reported. Therefore, we studied the effects of exosomes derived from
      cow milk (CM-Exs) on immune cells in the present study. We obtained blood samples
      from healthy adult donors with the approval of the ethics committee. Peripheral
      blood mononuclear cells (PBMCs) were stimulated with CM-Exs in the absence or
      presence of interleukin-2 (IL-2) and IL-12. Cell surface markers and
      intracellular cytokine production were analysed by flow cytometry. CM-Ex
      stimulation enhanced the expression of CD69 on NK cells. Although CM-Ex
      stimulation alone did not induce interferon-gamma (IFN-gamma) production by NK
      cells or gammadeltaT cells, simultaneous stimulation with CM-Ex, IL-2 and IL-12
      significantly enhanced IFN-gamma production. In conclusion, cow milk consumption 
      alone may not activate immune cells; however, CM-Exs could enhance immune cells
      under inflammatory conditions.
FAU - Komine-Aizawa, Shihoko
AU  - Komine-Aizawa S
AD  - Division of Microbiology, Department of Pathology and Microbiology, Nihon
      University School of Medicine, Tokyo, Japan.
FAU - Ito, Shun
AU  - Ito S
AD  - Nihon University Itabashi Hospital, Tokyo, Japan.
FAU - Aizawa, Shu
AU  - Aizawa S
AD  - Department of Animal Science, College of Bioresource Sciences, Nihon University, 
      Kanagawa, Japan.
FAU - Namiki, Takahiro
AU  - Namiki T
AD  - Nihon University School of Medicine, Tokyo, Japan.
FAU - Hayakawa, Satoshi
AU  - Hayakawa S
AD  - Division of Microbiology, Department of Pathology and Microbiology, Nihon
      University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - Immunol Med
JT  - Immunological medicine
JID - 101736847
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD69 antigen)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-2)
RN  - 0 (Lectins, C-Type)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, T-Lymphocyte/metabolism
MH  - Cells, Cultured
MH  - Cytokines/metabolism
MH  - Exosomes/*immunology/*physiology
MH  - Flow Cytometry
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Interleukin-12/immunology
MH  - Interleukin-2/immunology
MH  - Killer Cells, Natural/*immunology/metabolism
MH  - Lectins, C-Type/metabolism
MH  - Leukocytes, Mononuclear/*immunology/metabolism
MH  - *Lymphocyte Activation
MH  - Milk/*cytology
MH  - T-Lymphocytes/*immunology/metabolism
OTO - NOTNLM
OT  - Cow milk
OT  - NK cell
OT  - exosome
OT  - iNKT cell
OT  - gammadeltaT cell
EDAT- 2020/07/11 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 10.1080/25785826.2020.1791400 [doi]
PST - ppublish
SO  - Immunol Med. 2020 Dec;43(4):161-170. doi: 10.1080/25785826.2020.1791400. Epub
      2020 Jul 10.


PMID- 32649807
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 17
DP  - 2020 Sep
TI  - Therapy preferences in melanoma treatment-Willingness to pay and preference of
      quality versus length of life of patients, physicians, healthy individuals and
      physicians with oncological disease.
PG  - 6132-6140
LID - 10.1002/cam4.3191 [doi]
AB  - BACKGROUND: In recent years, monoclonal antibodies such as ipilimumab, nivolumab,
      and pembrolizumab have made a significant impact on the treatment of advanced
      melanoma. Combination of immune checkpoint inhibitors leads to improved survival 
      and response rates of 58%-61% as compared to monotherapy (36%-44%). However, the 
      price for the better response rates is also a higher frequency of severe adverse 
      events (59%) as compared to monotherapy (17%-21%). This study examines attitudes 
      towards melanoma therapy options of physicians, healthy individuals, melanoma
      patients, and physicians with oncological disease, their willingness to pay, and 
      preference of quality versus length of life. METHODS: After obtaining ethical
      approval and informed consent surveys were conducted in 111 participants divided 
      into four groups: melanoma patients (n = 30), healthy individuals as controls (n 
      = 30), physicians (n = 27), and physicians with oncological disease (n = 24).
      Statistical analyses were conducted using SPSS statistics (version 25, IBM),
      applying the Pearson s chi-squared test, Spearman correlation coefficient,
      Wilcoxon-Mann-Whitney test, and Kruskal-Wallis test. RESULTS: Life prolongation
      is more valued by melanoma patients and physicians with oncological disease
      compared to healthy controls and healthy physicians. In total, 30% of melanoma
      patients opt for a life prolonging therapy in all cases, even if this life
      prolongation is only marginal. Physicians are the strongest proponents of
      combination immunotherapy. CONCLUSION: The valuation of the different treatment
      options differs in the four study groups with affected people valuing life
      prolongation much more. The individual value of cancer therapies is high, but
      differs from the societal standpoint.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Weiss, Julia
AU  - Weiss J
AUID- ORCID: 0000-0003-3238-147X
AD  - Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Erlangen, Germany.
AD  - Department of Dermatology, University Hospital Erlangen,
      Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Erlangen, Germany.
FAU - Kirchberger, Michael Constantin
AU  - Kirchberger MC
AD  - Department of Dermatology, University Hospital Erlangen,
      Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Erlangen, Germany.
FAU - Heinzerling, Lucie
AU  - Heinzerling L
AD  - Department of Dermatology, University Hospital Erlangen,
      Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use
MH  - Antineoplastic Agents, Immunological/adverse effects/economics/therapeutic use
MH  - Attitude of Health Personnel
MH  - Case-Control Studies
MH  - Decision Making
MH  - *Drug Costs
MH  - Family Characteristics
MH  - Female
MH  - Germany
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects/economics/therapeutic use
MH  - Ipilimumab/therapeutic use
MH  - *Longevity
MH  - Male
MH  - Melanoma/drug therapy/*psychology
MH  - Middle Aged
MH  - Nivolumab/therapeutic use
MH  - Palliative Care/psychology
MH  - Patient Preference/*psychology
MH  - Physicians/*psychology
MH  - Quality of Life/*psychology
MH  - Socioeconomic Factors
MH  - Statistics, Nonparametric
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7476834
OTO - NOTNLM
OT  - *cancer management
OT  - *clinical guidelines
OT  - *immunology
OT  - *quality of life
EDAT- 2020/07/11 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/04/19 00:00 [revised]
PHST- 2020/05/09 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 10.1002/cam4.3191 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Sep;9(17):6132-6140. doi: 10.1002/cam4.3191. Epub 2020 Jul 10.


PMID- 32649750
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Sep 1
TI  - Uterine lavage: ethics of research and clinical applications.
PG  - 1949-1953
LID - 10.1093/humrep/deaa140 [doi]
AB  - Uterine lavage is presented as a way to perform aneuploidy screening without IVF.
      The feasibility of this method was tested in a research study. This study
      combined a number of highly contentious ethical issues: the creation of embryos
      for research (very early), abortion and (moderate) payments to research
      participants. It is concluded that the study largely fulfils the criteria of
      ethical research but that the researchers should have avoided a number of steps. 
      These steps were the inclusion of infertility patients, the performance of the
      research in a middle-income country and the double destination of the embryos.
      The next question then becomes whether it would be acceptable to apply the method
      in a clinical setting. Two elements complicate the introduction in the clinic:
      low success rate of embryo collection and risk of unintended pregnancy. The
      application of the method in the clinic may lead to very complicated ethical and 
      legal situations for which both patients and doctors should be prepared.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Pennings, Guido
AU  - Pennings G
AD  - Department of Philosophy and Moral Science, Ghent University, Gent 9000, Belgium.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - *Abortion, Spontaneous
MH  - Aneuploidy
MH  - Embryo, Mammalian
MH  - Female
MH  - Fertilization in Vitro
MH  - Humans
MH  - *Infertility
MH  - Pregnancy
MH  - Therapeutic Irrigation
OTO - NOTNLM
OT  - *abortion
OT  - *ethics dumping
OT  - *research
OT  - *uterine flushing
OT  - *uterine lavage
OT  - *uterus
EDAT- 2020/07/11 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 5869824 [pii]
AID - 10.1093/humrep/deaa140 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Sep 1;35(9):1949-1953. doi: 10.1093/humrep/deaa140.


PMID- 32649715
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - Good death: An exploratory study on perceptions and attitudes of patients,
      relatives, and healthcare providers, in northern Tanzania.
PG  - e0233494
LID - 10.1371/journal.pone.0233494 [doi]
AB  - IMPORTANCE: In the Kilimanjaro region of Tanzania, there are no advance care
      planning (ACP) protocols being used to document patient preferences for
      end-of-life (EoL) care. There is a general avoidance of the topic and
      contemplating ACP in healthcare-limited regions can be an ethically complex
      subject. Nonetheless, evidence from similar settings indicate that an appropriate
      quality of life is valued, even as one is dying. What differs amongst cultures is
      the definition of a 'good death'. OBJECTIVE: Evaluate perceptions of quality of
      death and advance EoL preparation in Moshi, Tanzania. DESIGN: 13 focus group
      discussions (FGDs) were conducted in Swahili using a semi-structured guide. These
      discussions were audio-recorded, transcribed, translated, and coded using an
      inductive approach. SETTING: Kilimanjaro Christian Medical Centre (KCMC),
      referral hospital for northern Tanzania. PARTICIPANTS: A total of 122
      participants, including patients with life-threatening illnesses (34), their
      relatives/friends (29), healthcare professionals (29; HCPs; doctors and nurses), 
      and allied HCPs (30; community health workers, religious leaders, and social
      workers) from KCMC, or nearby within Moshi, participated in this study. FINDINGS:
      In characterizing Good Death, 7 first-order themes emerged, and, of these themes,
      Religious & Spiritual Wellness, Family & Interpersonal Wellness, Grief Coping &
      Emotional Wellness, and Optimal Timing comprised the second-order theme, EoL
      Preparation and Life Completion. The other first-order themes for Good Death were
      Minimal Suffering & Burden, Quality of Care by Formal Caregivers, and Quality of 
      Care by Informal Caregivers. INTERPRETATION: The results of this study provide a 
      robust thematic description of Good Death in northern Tanzania and they lay the
      groundwork for future clinical and research endeavors to improve the quality of
      EoL care at KCMC.
FAU - Gafaar, Temitope O
AU  - Gafaar TO
AUID- ORCID: 0000-0003-2148-0894
AD  - Duke University School of Medicine, Duke University, Durham, NC, United States of
      America.
FAU - Pesambili, Msafiri
AU  - Pesambili M
AD  - Duke University Research Collaboration, Kilimanjaro Christian Medical Center,
      Moshi, Tanzania.
FAU - Henke, Oliver
AU  - Henke O
AUID- ORCID: 0000-0002-9838-9805
AD  - Cancer Care Center, Kilimanjaro Christian Medical Center, Moshi, Tanzania.
FAU - Vissoci, Joao Ricardo Nickenig
AU  - Vissoci JRN
AD  - Duke Global Health Institute, Duke University, Durham, NC, United States of
      America.
AD  - Duke Emergency Medicine, Duke University Medical Center, Durham, NC, United
      States of America.
FAU - Mmbaga, Blandina Theophil
AU  - Mmbaga BT
AD  - Cancer Care Center, Kilimanjaro Christian Medical Center, Moshi, Tanzania.
AD  - Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
FAU - Staton, Catherine
AU  - Staton C
AD  - Duke Global Health Institute, Duke University, Durham, NC, United States of
      America.
AD  - Duke Emergency Medicine, Duke University Medical Center, Durham, NC, United
      States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200710
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Family/*psychology
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Male
MH  - Quality of Health Care
MH  - Religion
MH  - Social Workers/psychology
MH  - Tanzania
MH  - Terminal Care/*psychology
PMC - PMC7351142
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/11 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/07/11 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1371/journal.pone.0233494 [doi]
AID - PONE-D-19-21040 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 10;15(7):e0233494. doi: 10.1371/journal.pone.0233494.
      eCollection 2020.


PMID- 32648891
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20210711
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
VI  - 189
IP  - 11
DP  - 2020 Nov 2
TI  - Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious
      Disease Outbreaks.
PG  - 1324-1332
LID - 10.1093/aje/kwaa141 [doi]
AB  - Randomized controlled trials are crucial for the evaluation of interventions such
      as vaccinations, but the design and analysis of these studies during infectious
      disease outbreaks is complicated by statistical, ethical, and logistical factors.
      Attempts to resolve these complexities have led to the proposal of a variety of
      trial designs, including individual randomization and several types of cluster
      randomization designs: parallel-arm, ring vaccination, and stepped wedge designs.
      Because of the strong time trends present in infectious disease incidence,
      however, methods generally used to analyze stepped wedge trials might not perform
      well in these settings. Using simulated outbreaks, we evaluated various designs
      and analysis methods, including recently proposed methods for analyzing stepped
      wedge trials, to determine the statistical properties of these methods. While new
      methods for analyzing stepped wedge trials can provide some improvement over
      previous methods, we find that they still lag behind parallel-arm
      cluster-randomized trials and individually randomized trials in achieving
      adequate power to detect intervention effects. We also find that these methods
      are highly sensitive to the weighting of effect estimates across time periods.
      Despite the value of new methods, stepped wedge trials still have statistical
      disadvantages compared with other trial designs in epidemic settings.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Johns Hopkins Bloomberg School of Public Health. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Kennedy-Shaffer, Lee
AU  - Kennedy-Shaffer L
FAU - Lipsitch, Marc
AU  - Lipsitch M
LA  - eng
GR  - U01IP001121/ACL/ACL HHS/United States
GR  - F31 AI147745/AI/NIAID NIH HHS/United States
GR  - T32 AI007358/AI/NIAID NIH HHS/United States
GR  - U01 IP001121/IP/NCIRD CDC HHS/United States
GR  - U54 GM088558/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
SB  - IM
UOF - medRxiv. 2020 May 06;:. PMID: 32511544
MH  - Biometry/*methods
MH  - Cluster Analysis
MH  - Computer Simulation
MH  - *Data Interpretation, Statistical
MH  - Disease Outbreaks/*statistics & numerical data
MH  - Humans
MH  - *Models, Statistical
MH  - Randomized Controlled Trials as Topic/methods/*statistics & numerical data
MH  - Research Design
PMC - PMC7604531
OTO - NOTNLM
OT  - *cluster-randomized trials
OT  - *epidemics
OT  - *permutation tests
OT  - *simulation
OT  - *stepped wedge trials
OT  - *synthetic control
OT  - *vaccine trials
EDAT- 2020/07/11 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/07/03 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 5869594 [pii]
AID - 10.1093/aje/kwaa141 [doi]
PST - ppublish
SO  - Am J Epidemiol. 2020 Nov 2;189(11):1324-1332. doi: 10.1093/aje/kwaa141.


PMID- 32648850
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 8
DP  - 2020 Aug 3
TI  - Public Health in the Information Age: Recognizing the Infosphere as a Social
      Determinant of Health.
PG  - e19311
LID - 10.2196/19311 [doi]
AB  - Since 2016, social media companies and news providers have come under pressure to
      tackle the spread of political mis- and disinformation (MDI) online. However,
      despite evidence that online health MDI (on the web, on social media, and within 
      mobile apps) also has negative real-world effects, there has been a lack of
      comparable action by either online service providers or state-sponsored public
      health bodies. We argue that this is problematic and seek to answer three
      questions: why has so little been done to control the flow of, and exposure to,
      health MDI online; how might more robust action be justified; and what specific, 
      newly justified actions are needed to curb the flow of, and exposure to, online
      health MDI? In answering these questions, we show that four ethical
      concerns-related to paternalism, autonomy, freedom of speech, and pluralism-are
      partly responsible for the lack of intervention. We then suggest that these
      concerns can be overcome by relying on four arguments: (1) education is necessary
      but insufficient to curb the circulation of health MDI, (2) there is precedent
      for state control of internet content in other domains, (3) network dynamics
      adversely affect the spread of accurate health information, and (4) justice is
      best served by protecting those susceptible to inaccurate health information.
      These arguments provide a strong case for classifying the quality of the
      infosphere as a social determinant of health, thus making its protection a public
      health responsibility. In addition, they offer a strong justification for working
      to overcome the ethical concerns associated with state-led intervention in the
      infosphere to protect public health.
CI  - (c)Jessica Morley, Josh Cowls, Mariarosaria Taddeo, Luciano Floridi. Originally
      published in the Journal of Medical Internet Research (http://www.jmir.org),
      03.08.2020.
FAU - Morley, Jessica
AU  - Morley J
AUID- ORCID: 0000-0001-5221-4770
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
FAU - Cowls, Josh
AU  - Cowls J
AUID- ORCID: 0000-0002-8545-5068
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
AD  - Alan Turing Institute, London, United Kingdom.
FAU - Taddeo, Mariarosaria
AU  - Taddeo M
AUID- ORCID: 0000-0002-1181-649X
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
AD  - Alan Turing Institute, London, United Kingdom.
FAU - Floridi, Luciano
AU  - Floridi L
AUID- ORCID: 0000-0002-5444-2280
AD  - Oxford Internet Institute, University of Oxford, Oxford, United Kingdom.
AD  - Alan Turing Institute, London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - COVID-19
MH  - Communication
MH  - Coronavirus Infections/epidemiology
MH  - Health Education
MH  - Humans
MH  - *Internet
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology
MH  - *Public Health
MH  - *Social Determinants of Health
MH  - Social Media
PMC - PMC7402642
OTO - NOTNLM
OT  - *COVID-19
OT  - *disinformation
OT  - *infodemic
OT  - *infodemiology
OT  - *information ethics
OT  - *infosphere
OT  - *misinformation
OT  - *public health
OT  - *social determinants of health
EDAT- 2020/07/11 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/07/08 00:00 [accepted]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - v22i8e19311 [pii]
AID - 10.2196/19311 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Aug 3;22(8):e19311. doi: 10.2196/19311.


PMID- 32648498
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1369-1627 (Electronic)
IS  - 0954-0261 (Linking)
VI  - 32
IP  - 4
DP  - 2020 Jun
TI  - How coloniality shapes the making of Latin American psychologists: ethnographic
      evidence from Ecuador.
PG  - 348-358
LID - 10.1080/09540261.2020.1761777 [doi]
AB  - This paper provides ethnographic evidence on how coloniality shapes the making of
      Latin American psychologists. A critical ethnography was conducted at a
      psychology training institution in Ecuador, consisting of twelve months of
      participant observation; forty-one semi-structured interviews; and analysis of
      academic discourse, photos, videos and relevant social media content. The
      research was guided by the tradition of Critical Psychology - specifically
      Liberation Psychology - and Critical Discourse Analysis. Findings suggest the
      pervasiveness of coloniality in the making of Ecuadorian psychologists and,
      hypothetically, of others in Latin America and the wider Global South.
      Interpretations also highlight the non-essentialist, non-dichotomist, 'messy'
      nature of such processes, a consideration which may advance current ethical and
      analytical debates on decolonisation. Echoing ongoing critical arguments, authors
      suggest that a 'help-as-war' metaphor is a category with potential value to
      contribute to such advancement, an approach that has important theoretical and
      pragmatic implications for researchers and practitioners.
FAU - Capella Palacios, Manuel
AU  - Capella Palacios M
AUID- ORCID: 0000-0001-8087-8718
AD  - Faculty of Psychological Sciences, University of Guayaquil, Guayaquil, Ecuador.
FAU - Jadhav, Sushrut
AU  - Jadhav S
AUID- ORCID: 0000-0001-5325-8687
AD  - Division of Psychiatry, University College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200710
PL  - England
TA  - Int Rev Psychiatry
JT  - International review of psychiatry (Abingdon, England)
JID - 8918131
SB  - IM
MH  - Adult
MH  - *Anthropology, Cultural
MH  - *Colonialism
MH  - Ecuador
MH  - *Global Health
MH  - Humans
MH  - *Mental Health
MH  - *Psychology
OTO - NOTNLM
OT  - *Ecuador
OT  - *Global South
OT  - *Latin America
OT  - *Professional identity
OT  - *colonial
OT  - *critical discourse analysis
OT  - *critical ethnography
OT  - *global mental health
OT  - *metaphor
OT  - *psychology
EDAT- 2020/07/11 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 10.1080/09540261.2020.1761777 [doi]
PST - ppublish
SO  - Int Rev Psychiatry. 2020 Jun;32(4):348-358. doi: 10.1080/09540261.2020.1761777.
      Epub 2020 Jul 10.


PMID- 32648372
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1471-8847 (Electronic)
IS  - 1471-8731 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Sep
TI  - Toward a decolonized healthcare ethics: Colonial legacies and the Siamese
      crocodile.
PG  - 118-119
LID - 10.1111/dewb.12273 [doi]
FAU - Cordeiro-Rodrigues, Luis
AU  - Cordeiro-Rodrigues L
AUID- ORCID: 0000-0001-9571-2120
AD  - Department of Philosophy, Yuelu Academy, Hunan University, Changsha, PR China.
LA  - eng
GR  - 531118010426/Central Universities in China/International
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - England
TA  - Dev World Bioeth
JT  - Developing world bioethics
JID - 101120122
SB  - IM
MH  - COVID-19/epidemiology
MH  - *Delivery of Health Care
MH  - Humans
MH  - *International Cooperation
MH  - *Pandemics
MH  - SARS-CoV-2
EDAT- 2020/07/11 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 10.1111/dewb.12273 [doi]
PST - ppublish
SO  - Dev World Bioeth. 2020 Sep;20(3):118-119. doi: 10.1111/dewb.12273. Epub 2020 Jul 
      9.


PMID- 32647925
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2194-7791 (Print)
IS  - 2194-7791 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jul 9
TI  - Genotype-phenotype correlations in children and adolescents with nonclassical
      congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
PG  - 8
LID - 10.1186/s40348-020-00100-w [doi]
AB  - BACKGROUND: Nonclassical congenital adrenal hyperplasia due to 21-hydroxylase
      deficiency is caused by mutations in the active 21-hydroxylase gene (CYP21A2).
      The clinical symptoms can vary greatly. To date, no systematic studies have been 
      undertaken in Germany. AIMS: Description of the phenotype, evaluation of the
      diagnostics and genotype-phenotype correlation PATIENTS AND METHODOLOGY:
      Retrospective analysis of the data of 134 patients (age range 0.1-18.6 years) in 
      a multicentre study covering 10 paediatric endocrinology centres in Bavaria and
      Baden-Wurttemberg. The data was gathered on site from the medical records. Two
      hundred and thirty-three alleles with a mutation of the CYP21A2 gene were
      identified in 126 patients. A genotype-phenotype correlation of the mutation
      findings was undertaken (C1, severe/mild; C2, mild/mild). Individuals with a
      heterozygous mutation of the CYP21A2 were also included (C3). The data was
      collected with the approval of the ethics committee of the University Hospital of
      Erlangen during the period of 2014 and 2015. RESULTS (MW +/- SD): One hundred and
      seventeen out of 134 patients (115 f, 29 m) were symptomatic. The chronological
      age (CA) at diagnosis was 7.1 +/- 4.4 years. The most frequent symptom (73.5%)
      was premature pubarche. The height-SDS on diagnosis was 0.8 +/- 1.3 and the
      BMI-SDS was 0.8 +/- 1.2. Bone age (BA) was ascertained in 82.9% of the
      symptomatic patients. The difference between BA and CA was 1.9 +/- 1.4 years.
      Basal 17OHP concentrations were 14.5 +/- 19.1 ng/ml (18 patients < 2 ng/ml). In
      total, 58.1% mild and 34.7% severe mutations were found. The most common mutation
      was p.Val281Leu (39.1%); 65.8% of the patients could be allocated to group C1. No
      phenotypical differences were found between the 3 mutation groups. The 17OHP
      levels (basal and after ACTH) in the standard ACTH stimulation test were highest 
      in group C1 and also significantly higher in group C2 as in C3, the
      ACTH-stimulated cortisol levels (ng/ml) were significantly lower in groups C1
      (192.1 +/- 62.5) and C2 (218 +/- 50) than in C3 (297.3 +/- 98.7). CONCLUSION:
      Most of the patients have symptoms of mild androgenisation. Male patients are
      underdiagnosed. Diagnostics are not standardised. Differences between the types
      of mutations are found in the hormone concentrations but not in phenotype. We
      speculate that further, as yet not clearly defined, factors are responsible for
      the development of the respective phenotypes.
FAU - Dorr, Helmuth-Gunther
AU  - Dorr HG
AUID- ORCID: https://orcid.org/0000-0002-4838-6737
AD  - Paediatric Endocrinology, University Children's Hospital, Erlangen, Germany.
      helmuth-guenther.doerr@uk-erlangen.de.
FAU - Schulze, Nadja
AU  - Schulze N
AD  - Paediatric Endocrinology, University Children's Hospital, Erlangen, Germany.
FAU - Bettendorf, Markus
AU  - Bettendorf M
AD  - Paediatric Endocrinology, University Children's Hospital, Heidelberg, Germany.
FAU - Binder, Gerhard
AU  - Binder G
AD  - Paediatric Endocrinology, University Children's Hospital, Tubingen, Germany.
FAU - Bonfig, Walter
AU  - Bonfig W
AD  - Departement of Paediatrics, Hospital Wels-Grieskirchen, Wels, Austria.
FAU - Denzer, Christian
AU  - Denzer C
AD  - Paediatric Endocrinology, University Children's Hospital, Ulm, Germany.
FAU - Dunstheimer, Desiree
AU  - Dunstheimer D
AD  - University Children's Hospital I, Augsburg, Germany.
FAU - Salzgeber, Kirsten
AU  - Salzgeber K
AD  - Medical Office, Endokrinologikum, Ulm, Germany.
FAU - Schmidt, Heinrich
AU  - Schmidt H
AD  - Paediatric Endocrinology, University Children's Hospital, Munich, Germany.
FAU - Schwab, Karl Otfried
AU  - Schwab KO
AD  - Paediatric Endocrinology, University Children's Hospital, Freiburg, Germany.
FAU - Voss, Egbert
AU  - Voss E
AD  - Departament of Paediatrics, Cnopfsche Kinderklinik, Nuremberg, Germany.
FAU - Wabitsch, Martin
AU  - Wabitsch M
AD  - Paediatric Endocrinology, University Children's Hospital, Ulm, Germany.
FAU - Wolfle, Joachim
AU  - Wolfle J
AD  - Paediatric Endocrinology, University Children's Hospital, Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - Germany
TA  - Mol Cell Pediatr
JT  - Molecular and cellular pediatrics
JID - 101660689
PMC - PMC7347723
OTO - NOTNLM
OT  - 17OHP
OT  - 21-Hydroxylase deficiency
OT  - ACTH stimulation test
OT  - Androgenisation
OT  - CYP21A2 mutations
OT  - Premature pubarche
EDAT- 2020/07/11 06:00
MHDA- 2020/07/11 06:01
CRDT- 2020/07/11 06:00
PHST- 2020/06/28 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/11 06:01 [medline]
AID - 10.1186/s40348-020-00100-w [doi]
AID - 10.1186/s40348-020-00100-w [pii]
PST - epublish
SO  - Mol Cell Pediatr. 2020 Jul 9;7(1):8. doi: 10.1186/s40348-020-00100-w.


PMID- 32647047
OWN - NLM
STAT- Publisher
LR  - 20200723
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 9
TI  - How to fairly incentivise digital contact tracing.
LID - medethics-2020-106388 [pii]
LID - 10.1136/medethics-2020-106388 [doi]
AB  - Digital apps using Bluetooth to log proximity events (henceforth, digital contact
      tracing) are increasingly supported by technologists and governments. By and
      large, the public debate on this matter focuses on privacy, with experts from
      both law and technology offering very concrete proposals and participating to a
      lively debate. Far less attention is paid to effective incentives and their
      fairness. This paper aims to fill this gap by offering a practical, workable
      solution for a promising incentive, justified by the ethical principles of
      non-maleficence, beneficence, autonomy and justice. This incentive is a free
      phone optimised for running such app.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Loi, Michele
AU  - Loi M
AUID- ORCID: http://orcid.org/0000-0002-7053-4724
AD  - Institute of Biomedical Ethics and the History of Medicine and Digital Society
      Initiative, University of Zurich, Zurich, Switzerland michele.loi@ibme.uzh.ch.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7371477
OTO - NOTNLM
OT  - distributive justice
OT  - epidemiology
OT  - public health ethics
OT  - public policy
OT  - technology/risk assessment
COIS- Competing interests: ML reports personal fees from Health-Catalyst, outside the
      submitted work.
EDAT- 2020/07/11 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - medethics-2020-106388 [pii]
AID - 10.1136/medethics-2020-106388 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 9. pii: medethics-2020-106388. doi:
      10.1136/medethics-2020-106388.


PMID- 32647045
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile 
      on policy and clinical decision-making.
PG  - 574-578
LID - 10.1136/medethics-2020-106306 [doi]
AB  - The controversy surrounding the use of hydroxychloroquine (HCQ), an antimalarial 
      drug, for COVID-19 has raised numerous ethical and policy problems. Since the
      suggestion that HCQ has potential for COVID-19, there have been varying responses
      from clinicians and healthcare institutions, ranging from adoption of protocols
      using HCQ for routine care to the conduct of randomised controlled trials to an
      effective system-wide prohibition on its use for COVID-19. In this article, we
      argue that the concept of 'disease public profile' has become a prominent, if not
      the sole, determinant in decision-making across various healthcare responses to
      the pandemic. In the case of COVID-19, the disease's public profile is based on
      clinical and non-clinical factors that include contagiousness, clinical
      presentation and media coverage. In particular, we briefly examine the dangers of
      a heightened public profile in magnifying the inequality of diseases and
      undermining three key ethical concepts, namely (1) evidence-based practice, (2)
      sustainable allocation and (3) meaningful consent.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Aquino, Yves S J
AU  - Aquino YSJ
AUID- ORCID: 0000-0003-0981-0029
AD  - Department of Philosophy, Macquarie University, Sydney, New South Wales,
      Australia ysjames@gmail.com.
FAU - Cabrera, Nicolo
AU  - Cabrera N
AD  - Division of Infectious Diseases, Department of Internal Medicine, University of
      Texas Health Science Center at Houston, Houston, Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Awareness
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/*drug therapy
MH  - *Ethics, Medical
MH  - Evidence-Based Medicine
MH  - Health Care Rationing
MH  - Health Equity
MH  - Humans
MH  - Hydroxychloroquine/*therapeutic use
MH  - Informed Consent
MH  - *Mass Media
MH  - *Off-Label Use
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - *Policy
MH  - Risk Assessment
MH  - SARS-CoV-2
PMC - PMC7371492
OTO - NOTNLM
OT  - *clinical ethics
OT  - *distributive justice
OT  - *history of health ethics/bioethics
OT  - *informed consent
OT  - *public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/11 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - medethics-2020-106306 [pii]
AID - 10.1136/medethics-2020-106306 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):574-578. doi: 10.1136/medethics-2020-106306. Epub
      2020 Jul 9.


PMID- 32647043
OWN - NLM
STAT- Publisher
LR  - 20200710
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 9
TI  - Risk, double effect and the social benefit requirement.
LID - medethics-2019-106034 [pii]
LID - 10.1136/medethics-2019-106034 [doi]
AB  - Many ethicists maintain that medical research on human subjects that presents no 
      prospect of direct medical benefit must have a prospect of social benefit to be
      ethical. Payment is not the sort of benefit that justifies exposing subjects to
      risk. Alan Wertheimer has raised a serious challenge to this view, pointing out
      that in industry, social value is not considered necessary to make dangerous jobs
      ethical. This article argues that Wertheimer was correct to think that the ethics
      of hazard pay should be the same in medical research and in business.
      Nevertheless, a qualified social benefit requirement should apply in both fields.
      For a study or a job with significant net physical risk to be ethical, it must
      have social value beyond the satisfaction of ordinary preferences, including the 
      preference for money. The requirement derives from a non-absolutist version of
      the doctrine of double effect. If a risky study or a dangerous job has no
      distinctive social value, and hazard pay is subjects' or workers' only reason to 
      undergo risks, the very fact that they undergo risk is intended as a means to a
      financial end. Inviting people to enrol in such a study or to take such a job
      wrongfully treats people as mere means. By contrast, if a study or a job has
      social value, people can participate with a primary end other than money, even if
      they accept compensation. Researchers or employers do not intend but merely
      foresee risks to subjects or workers.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hughes, Robert C
AU  - Hughes RC
AUID- ORCID: http://orcid.org/0000-0002-8402-790X
AD  - Legal Studies and Business Ethics Department, The Wharton School, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA hughesrc@wharton.upenn.edu.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - philosophical ethics
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/07/11 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/07/11 06:00
PHST- 2019/12/16 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - medethics-2019-106034 [pii]
AID - 10.1136/medethics-2019-106034 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 9. pii: medethics-2019-106034. doi:
      10.1136/medethics-2019-106034.


PMID- 32647042
OWN - NLM
STAT- Publisher
LR  - 20200724
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 9
TI  - Mental capacity assessment: a descriptive, cross-sectional study of what doctors 
      think, know and do.
LID - medethics-2019-105819 [pii]
LID - 10.1136/medethics-2019-105819 [doi]
AB  - BACKGROUND: The Mental Capacity Act (MCA) (2005) was enacted in 2007 in England
      and Wales, but the assessment of mental capacity still remains an area of
      professional concern. Doctors' compliance with legal and professional standards
      is inconsistent, but the reasons for poor compliance are not well understood.
      This preliminary study investigates doctors' experiences of and attitudes toward 
      mental capacity assessment (MCAx). METHODS: This is a descriptive,
      cross-sectional study where a two-domain, study-specific structured questionnaire
      was developed, piloted and digitally disseminated to doctors at differing career 
      stages employed in a large, multi-site National Health Service Trust in London
      over 4 months in 2018. Descriptive statistics and frequency tables adjusted for
      missing data were generated and secondary analysis was conducted. RESULTS:
      Participants (n=92) were predominantly UK trained (82%), female (58%) and between
      the ages of 30 and 44 years (45%). Less than half (45%) of the participants
      reported receiving formal MCAx training. Only one-third (32%) of the participants
      self-rated themselves as very competent (29%) or extremely competent (4%).
      Self-reported MCA confidence was significantly affected by career stage with
      Consultants with over 10 years of experience reporting lowest confidence
      (p=0.001). CONCLUSIONS: This study describes significant variation in practice by
      doctors and low self-confidence in the practice of MCAx. These results raise
      concerns that MCAx continues to be inconsistently performed by doctors despite
      appropriate awareness of the law and professional guidance on best practice.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Penn, Dexter
AU  - Penn D
AUID- ORCID: http://orcid.org/0000-0003-0297-2260
AD  - Dementia Research Centre, UCL, London, UK.
FAU - Lanceley, Anne
AU  - Lanceley A
AD  - Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for
      Women's Health, UCL, London, UK.
FAU - Petrie, Aviva
AU  - Petrie A
AD  - UCL Eastman Dental Institute, UCL, London, UK.
FAU - Nicholls, Jacqueline
AU  - Nicholls J
AD  - Department of Reproductive Health, UCL Elizabeth Garrett Anderson Institute for
      Women's Health, UCL, London, UK j.nicholls@ucl.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200709
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - decision-making
OT  - health personnel
OT  - law
COIS- Competing interests: None declared.
EDAT- 2020/07/11 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/07/11 06:00
PHST- 2019/09/03 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - medethics-2019-105819 [pii]
AID - 10.1136/medethics-2019-105819 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 9. pii: medethics-2019-105819. doi:
      10.1136/medethics-2019-105819.


PMID- 32647024
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 9
TI  - Understanding key mechanisms of successfully leading integrated team-based
      services in health and social care: protocol for a realist synthesis.
PG  - e038591
LID - 10.1136/bmjopen-2020-038591 [doi]
AB  - INTRODUCTION: As systems of health and social care in England move towards more
      integrated and collaborative models, leaders will need different skills than
      their predecessors to enable system leadership, building partnerships and working
      across organisations and sectors. There is little understanding of what the
      mechanisms for effective leadership across integrated health and social care
      systems might be, the contexts that influence good leadership, or the nature of
      the resulting outcomes. This review aims to identify, refine and test programme
      theories of leadership of integrated team-based services in health and social
      care, exploring what works, for whom and in what circumstances. METHODS AND
      ANALYSIS: This study uses a realist synthesis approach, following RAMESES
      guidelines, supported by stakeholder consultation. Stage 1 will develop initial
      programme theories about leadership of integrated health and social care based on
      a review of the scientific and grey literature and a stakeholder consultation
      workshop. Stage 2 will involve focused searching of empirical literature, data
      extraction and synthesis to refine the initial programme theories and identify
      relationships between identified contexts, mechanisms and outcomes. A second
      stakeholder event will guide the focus of the review. Stage 3 will further refine
      and interrogate the theories testing them against substantive theory on
      leadership of complex systems and through the experiences and expertise of the
      stakeholder group. ETHICS AND DISSEMINATION: Our study does not require ethics
      committee approval. This research will contribute to building an in-depth
      understanding of what aspects of leadership of integrated team-based services
      work, for whom and in what circumstances. It will identify the professional
      development needs of leaders and provide recommendations about optimal
      organisational and interorganisational structures and processes that support
      effective leadership in integrated health and social care systems. Findings will 
      be disseminated through peer-reviewed journal publications, conference
      presentations and formal and informal reports. PROSPERO REGISTRATION NUMBER:
      CRD42018119291.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Harris, Ruth
AU  - Harris R
AUID- ORCID: 0000-0002-4377-5063
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, UK ruth.harris@kcl.ac.uk.
FAU - Fletcher, Simon
AU  - Fletcher S
AD  - Faculty of Health, Social Care and Education, Kingston University and St
      George's, University of London, London, UK.
FAU - Sims, Sarah
AU  - Sims S
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, UK.
FAU - Ross, Fiona
AU  - Ross F
AD  - Faculty of Health, Social Care and Education, Kingston University and St
      George's, University of London, London, UK.
FAU - Brearley, Sally
AU  - Brearley S
AD  - Faculty of Health, Social Care and Education, Kingston University and St
      George's, University of London, London, UK.
FAU - Manthorpe, Jill
AU  - Manthorpe J
AD  - NIHR Health & Social Care Workforce Research Unit, King's College London, London,
      UK.
LA  - eng
GR  - 18/01/06/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - England
MH  - *Leadership
MH  - *Referral and Consultation
MH  - Review Literature as Topic
MH  - Social Support
PMC - PMC7351270
OTO - NOTNLM
OT  - *health policy
OT  - *health services administration & management
OT  - *human resource management
OT  - *organisation of health services
OT  - *organisational development
COIS- Competing interests: None declared.
EDAT- 2020/07/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038591 [pii]
AID - 10.1136/bmjopen-2020-038591 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 9;10(7):e038591. doi: 10.1136/bmjopen-2020-038591.


PMID- 32647023
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 9
TI  - Prospective randomised controlled trial using the REthinking Clinical Trials
      (REaCT) platform and National Surgical Quality Improvement Program (NSQIP) to
      compare no preparation versus preoperative oral antibiotics alone for surgical
      site infection rates in elective colon surgery: a protocol.
PG  - e036866
LID - 10.1136/bmjopen-2020-036866 [doi]
AB  - INTRODUCTION: Despite 40 randomised controlled trials (RCTs) investigating
      preoperative oral antibiotics (OA) and mechanical bowel preparation (MBP) to
      reduce surgical site infection (SSI) rate following colon surgery, there has
      never been an RCT published comparing OA alone versus no preparation. Of the four
      possible regimens (OA alone, MBP alone, OA plus MBP and no preparation),
      randomised evidence is conflicting for studied groups. Furthermore, guidelines
      vary, with recommendations for OA alone, OA plus MBP or no preparation. The
      National Surgical Quality Improvement Program (NSQIP) has automated data
      collection for surgical patients. Similarly, the 'REthinking Clinical Trials'
      (REaCT) platform increases RCT enrolment by simplifying pragmatic trial design.
      In this novel RCT protocol, we combine REaCT and NSQIP to compare OA alone versus
      no preparation for SSI rate reduction in elective colon surgery. To our
      knowledge, this is the first published RCT protocol that leverages NSQIP for data
      collection. In our feasibility study, 67 of 74 eligible patients (90%) were
      enrolled and 63 of 67 (94%) were adherent to protocol. The 'REaCT-NSQIP' trial
      design has great potential to efficiently generate level I evidence for other
      perioperative interventions. METHODS AND ANALYSIS: SSI rates following elective
      colorectal surgery after preoperative OA or no preparation will be compared. We
      predict 45% relative rate reduction of SSI, improvement in length of stay,
      reduced costs and increased quality of life, with similar antibiotic-related
      complications. Consent, using the 'integrated consent model', and randomisation
      on a mobile device are completed by the surgeon in a single clinical encounter.
      Data collection for the primary end point is automatic through NSQIP. Analysis of
      cost per weighted case, cost utility and quality-adjusted life years will be
      done. ETHICS AND DISSEMINATION: This study is approved by The Ontario Cancer
      Research Ethics Board. Results will be disseminated in surgical conferences and
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT03663504; Pre-results,
      recruitment phase.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Apte, Sameer S
AU  - Apte SS
AUID- ORCID: 0000-0003-1099-8268
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Moloo, Husein
AU  - Moloo H
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, Ontario,
      Canada.
FAU - Jeong, Ahwon
AU  - Jeong A
AD  - Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Liu, Michelle
AU  - Liu M
AD  - Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Vandemeer, Lisa
AU  - Vandemeer L
AD  - Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Suh, Kathryn
AU  - Suh K
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, Ontario,
      Canada.
AD  - Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Thavorn, Kednapa
AU  - Thavorn K
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, Ontario,
      Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Clinical Epidemiology, The Ottawa Hospital Research Institute, Ottawa, Ontario,
      Canada.
FAU - Clemons, Mark
AU  - Clemons M
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Auer, Rebecca C
AU  - Auer RC
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada
      rauer@ohri.ca.
AD  - Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
AD  - Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03663504
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents
MH  - Colon/surgery
MH  - Humans
MH  - Ontario
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Quality Improvement
MH  - Quality of Life
MH  - *Surgical Wound Infection/prevention & control
PMC - PMC7351286
OTO - NOTNLM
OT  - *clinical trials
OT  - *colorectal surgery
OT  - *infection control
OT  - *statistics & research methods
OT  - *wound management
COIS- Competing interests: RCA, SSA, HM, AJ, KS and KT do not have any conflicts of
      interests to disclose. DAF is a senior scientist at Ottawa Methods Centre. DAF
      and MC are the founders and leads of the Ottawa REaCT study platform.
EDAT- 2020/07/11 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-036866 [pii]
AID - 10.1136/bmjopen-2020-036866 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 9;10(7):e036866. doi: 10.1136/bmjopen-2020-036866.


PMID- 32646915
OWN - NLM
STAT- MEDLINE
DCOM- 20211117
LR  - 20211117
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct 7
TI  - Clinical Genetic Screening in Adult Patients with Kidney Disease.
PG  - 1497-1510
LID - 10.2215/CJN.15141219 [doi]
AB  - Expanded accessibility of genetic sequencing technologies, such as chromosomal
      microarray and massively parallel sequencing approaches, is changing the
      management of hereditary kidney diseases. Genetic causes account for a
      substantial proportion of pediatric kidney disease cases, and with increased
      utilization of diagnostic genetic testing in nephrology, they are now also
      detected at appreciable frequencies in adult populations. Establishing a
      molecular diagnosis can have many potential benefits for patient care, such as
      guiding treatment, familial testing, and providing deeper insights on the
      molecular pathogenesis of kidney diseases. Today, with wider clinical use of
      genetic testing as part of the diagnostic evaluation, nephrologists have the
      challenging task of selecting the most suitable genetic test for each patient,
      and then applying the results into the appropriate clinical contexts. This review
      is intended to familiarize nephrologists with the various technical, logistical, 
      and ethical considerations accompanying the increasing utilization of genetic
      testing in nephrology care.
CI  - Copyright (c) 2020 by the American Society of Nephrology.
FAU - Cocchi, Enrico
AU  - Cocchi E
AUID- ORCID: 0000-0002-7532-956X
AD  - Division of Nephrology and Center for Precision Medicine and Genomics, Department
      of Medicine, Columbia University, New York, New York.
AD  - Department of Pediatrics, Universita' degli Studi di Torino, Torino, Italy.
FAU - Nestor, Jordan Gabriela
AU  - Nestor JG
AUID- ORCID: 0000-0003-1418-3103
AD  - Division of Nephrology and Center for Precision Medicine and Genomics, Department
      of Medicine, Columbia University, New York, New York.
FAU - Gharavi, Ali G
AU  - Gharavi AG
AD  - Division of Nephrology and Center for Precision Medicine and Genomics, Department
      of Medicine, Columbia University, New York, New York ag2239@cumc.columbia.edu.
AD  - Insititute of Genomic Medicine, Columbia University, New York, New York.
LA  - eng
GR  - TL1 TR001875/TR/NCATS NIH HHS/United States
GR  - U01 HG008680/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200709
PL  - United States
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
SB  - IM
MH  - Adult
MH  - Clinical Trials as Topic
MH  - Comparative Genomic Hybridization
MH  - Exome
MH  - *Genetic Testing/ethics/methods
MH  - Genome
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Kidney Diseases/*diagnosis/*genetics/therapy
MH  - Mutation
MH  - Oligonucleotide Array Sequence Analysis
MH  - Polymorphism, Genetic
MH  - *Sequence Analysis, DNA
PMC - PMC7536756
OTO - NOTNLM
OT  - *CGH array
OT  - *Chronic
OT  - *Genetic Testing
OT  - *High-Throughput Nucleotide Sequencing
OT  - *Kidney Genomics Series
OT  - *Patient Care
OT  - *Renal Insufficiency
OT  - *Sanger sequencing
OT  - *array techniques
OT  - *chronic kidney disease
OT  - *familial kidney disease
OT  - *familial nephropathy
OT  - *genetic renal disease
OT  - *genetics
OT  - *genomics
OT  - *human genetic testing
OT  - *human genetics
OT  - *kidney disease
OT  - *massive parallel sequencing
OT  - *medical genetics
OT  - *microarray techniques
OT  - *nephrology
OT  - *referral and consultation
OT  - *translations
OT  - *whole exome sequencing
OT  - *whole genome sequencing
EDAT- 2020/07/11 06:00
MHDA- 2021/11/18 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/11/18 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - CJN.15141219 [pii]
AID - 10.2215/CJN.15141219 [doi]
PST - ppublish
SO  - Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1497-1510. doi: 10.2215/CJN.15141219.
      Epub 2020 Jul 9.


PMID- 32646797
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20210519
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 5
DP  - 2020 Nov
TI  - [Changes from COVID-19. A perspective from internal pediatric medicine].
PG  - 343.e1-343.e8
LID - S1695-4033(20)30207-1 [pii]
LID - 10.1016/j.anpedi.2020.06.004 [doi]
AB  - SARS-CoV-2 pandemic dimension has affected the Hospital Pediatrics Medicine
      assistance in our country. New challenges generated by COVID-19 require a series 
      of proactive measures, based on existing scientific knowledge and standards of
      good practice, that allow the Pediatric Hospital services readiness and
      operability. Hospital Internal Pediatrics, as responsible of integral care of the
      hospitalized child, plays a leading role in the new hospital model emerging from 
      this crisis. This review analyzes the impact of the current SARS-CoV-2 epidemic
      on pediatric care, and perspective of new COVID-19 outbreaks in coexistence with 
      other viral infections. Changes secondary to pandemic involved in Hospital
      Pediatric units, how to prepare for future epidemics, also the involvement of
      pediatric units in adult care and the possible opportunities for improvement need
      to be revised. Assistance of patients with chronic complex conditions in epidemic
      circumstances, safety aspects, opportunities for teaching and ethical
      considerations are reviewed. The Spanish Society of Hospital Pediatrics Medicine 
      offers with this article a series of resources for Internal Pediatric Medicine
      practitioners responsible to face next challenges in pediatric hospitalization
      units.
CI  - Copyright (c) 2020 Asociacion Espanola de Pediatria. Publicado por Elsevier
      Espana, S.L.U. All rights reserved.
FAU - Alcala Minagorre, Pedro J
AU  - Alcala Minagorre PJ
AD  - Unidad de Hospitalizacion Pediatrica, Hospital General Universitario de Alicante,
      Alicante, Espana. Electronic address: alcala_ped@gva.es.
FAU - Villalobos Pinto, Enrique
AU  - Villalobos Pinto E
AD  - Servicio de Pediatria, Hospital Nino Jesus, Madrid, Espana.
FAU - Ramos Fernandez, Jose Miguel
AU  - Ramos Fernandez JM
AD  - Servicio de Pediatria, Hospital Regional Universitario Materno-Infantil de
      Malaga, Malaga, Espana.
FAU - Rodriguez-Fernandez, Rosa
AU  - Rodriguez-Fernandez R
AD  - Seccion de Pediatria Hospitalaria, Hospital Gregorio Maranon, Madrid, Espana.
FAU - Vazquez Ronco, Miguel
AU  - Vazquez Ronco M
AD  - Seccion de Pediatria Hospitalaria, Hospital Universitario Cruces, Barakaldo,
      Bizkaia, Espana.
FAU - Escosa-Garcia, Luis
AU  - Escosa-Garcia L
AD  - Servicio de Pediatria Hospitalaria, Enfermedades Infecciosas y Tropicales,
      Hospital Universitario La Paz, Madrid, Espana.
FAU - Montiano Jorge, Juan Ignacio
AU  - Montiano Jorge JI
AD  - Servicio de Pediatria, Hospital Universitario Araba, Vitoria-Gasteiz, Espana.
FAU - Garcia Garcia, Juan Jose
AU  - Garcia Garcia JJ
AD  - Unidad de Hospitalizacion Pediatrica, Hospital Sant Joan de Deu, Esplugues de
      Llobregat, Barcelona, Espana.
CN  - en representacion de la Sociedad Espanola de Pediatria Hospitalaria (SEPHO)
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Cambios a partir de la COVID-19. Una perspectiva desde la pediatria interna
      hospitalaria.
DEP - 20200619
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - Delivery of Health Care/*methods/organization & administration
MH  - Global Health
MH  - *Hospitalization
MH  - Hospitals, Pediatric/*organization & administration
MH  - Humans
MH  - Infection Control/methods/organization & administration
MH  - *Pandemics/prevention & control
MH  - Pediatrics/*methods/organization & administration
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - SARS-CoV-2
PMC - PMC7303654
OTO - NOTNLM
OT  - COVID-19
OT  - Hospital medicine
OT  - Hospitales pediatricos
OT  - Internal pediatric medicine
OT  - Medicina hospitalaria
OT  - Pediatric hospitals
OT  - Pediatria interna hospitalaria
OT  - SARS-CoV-2
EDAT- 2020/07/11 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/05/16 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - S1695-4033(20)30207-1 [pii]
AID - 10.1016/j.anpedi.2020.06.004 [doi]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Nov;93(5):343.e1-343.e8. doi:
      10.1016/j.anpedi.2020.06.004. Epub 2020 Jun 19.


PMID- 32646693
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 13
IP  - 13
DP  - 2020 Jul 13
TI  - Outcomes After Transcatheter Reintervention for Dysfunction of a Previously
      Implanted Transcatheter Pulmonary Valve.
PG  - 1529-1540
LID - S1936-8798(20)30823-2 [pii]
LID - 10.1016/j.jcin.2020.03.035 [doi]
AB  - OBJECTIVES: The aim of this analysis was to evaluate outcomes following
      transcatheter reintervention for degenerated transcatheter pulmonary valves
      (TPVs). BACKGROUND: TPV replacement (TPVR) with the Melody valve demonstrated
      sustained relief of right ventricular outflow tract (RVOT) obstruction and
      pulmonary regurgitation. METHODS: All patients who underwent TPVR with a Melody
      valve as part of 3 Medtronic-sponsored prospective multicenter studies were
      included. Transcatheter reinterventions included balloon dilation of the
      previously implanted Melody valve, placement of a bare-metal stent within the
      implanted TPV, or placement of a new TPV in the RVOT (TPV-in-TPV). Indications
      for reintervention, decisions to reintervene, and the method of reintervention
      were at physician discretion. All patients provided written informed consent to
      participate in the trials, and each trial was approved by local or central
      Institutional Review Boards or ethics committees at participating sites. RESULTS:
      A total of 309 patients who underwent TPVR were discharged from the implantation 
      hospitalization with Melody valves in place. Transcatheter reintervention on the 
      TPV was performed in 46 patients. The first transcatheter reintervention
      consisted of TPV-in-TPV in 28 patients (median 6.9 years [quartile 1 to quartile 
      3: 5.2 to 7.8 years] after TPVR), simple balloon dilation of the implanted Melody
      valve in 17 (median 4.9 years [quartile 1 to quartile 3: 4.0 to 6.0 years] after 
      TPVR), and bare-metal stent placement alone in 1 (4.4 years after TPVR). There
      were no major procedural complications. Overall, 4-year freedom from explant and 
      from any later RVOT reintervention after the first reintervention were 83% and
      60%, respectively. Freedom from repeat RVOT reintervention was longer in patients
      undergoing TPV-in-TPV than balloon dilation (71% vs. 46% at 4 years; p = 0.027). 
      CONCLUSIONS: TPV-in-TPV can be an effective and durable treatment for Melody
      valve dysfunction. Although balloon dilation of the Melody valve was also acutely
      effective at reducing RVOT obstruction, the durability of this therapy was
      limited in this cohort compared with TPV-in-TPV.
CI  - Copyright (c) 2020 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
FAU - Shahanavaz, Shabana
AU  - Shahanavaz S
AD  - St. Louis Children's Hospital, St. Louis, Missouri. Electronic address:
      shahanavaz_s@wustl.edu.
FAU - Berger, Felix
AU  - Berger F
AD  - German Heart Institute Berlin, Berlin, Germany.
FAU - Jones, Thomas K
AU  - Jones TK
AD  - Seattle Children's Hospital, Seattle, Washington.
FAU - Kreutzer, Jacqueline
AU  - Kreutzer J
AD  - UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Vincent, Julie A
AU  - Vincent JA
AD  - Columbia University Medical Center, New York, New York.
FAU - Eicken, Andreas
AU  - Eicken A
AD  - German Heart Center Munich, Munich, Germany.
FAU - Bergersen, Lisa
AU  - Bergersen L
AD  - Boston Children's Hospital, Boston, Massachusetts.
FAU - Rome, Jonathan J
AU  - Rome JJ
AD  - Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
FAU - Zahn, Evan
AU  - Zahn E
AD  - Cedars-Sinai Heart Institute, Los Angeles, California.
FAU - Sondergaard, Lars
AU  - Sondergaard L
AD  - The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
FAU - Cheatham, John P
AU  - Cheatham JP
AD  - The Heart Center, Nationwide Children's Hospital, Columbus, Ohio.
FAU - Weng, Shicheng
AU  - Weng S
AD  - Coronary and Structural Heart Biostatistics Department, Medtronic, Mounds View,
      Minnesota.
FAU - Balzer, David
AU  - Balzer D
AD  - St. Louis Children's Hospital, St. Louis, Missouri.
FAU - McElhinney, Doff
AU  - McElhinney D
AD  - Lucile Packard Children's Hospital Stanford, Palo Alto, California.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
SB  - IM
CIN - JACC Cardiovasc Interv. 2020 Jul 13;13(13):1541-1543. PMID: 32646694
MH  - Adolescent
MH  - Adult
MH  - Balloon Valvuloplasty
MH  - Cardiac Catheterization/adverse effects/*instrumentation
MH  - Child
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/adverse effects/*instrumentation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Prosthesis Failure
MH  - Pulmonary Valve/diagnostic imaging/physiopathology/*surgery
MH  - Pulmonary Valve Insufficiency/diagnostic imaging/physiopathology/*surgery
MH  - Recovery of Function
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Outflow Obstruction/diagnostic imaging/physiopathology/*surgery
MH  - Young Adult
OTO - NOTNLM
OT  - *Melody valve
OT  - *balloon dilation
OT  - *pulmonary valve replacement
OT  - *pulmonary valvuloplasty
EDAT- 2020/07/11 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/07/11 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - S1936-8798(20)30823-2 [pii]
AID - 10.1016/j.jcin.2020.03.035 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2020 Jul 13;13(13):1529-1540. doi:
      10.1016/j.jcin.2020.03.035.


PMID- 32646656
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210127
IS  - 1836-9561 (Electronic)
IS  - 1836-9561 (Linking)
VI  - 66
IP  - 3
DP  - 2020 Jul
TI  - Physiotherapists should consider joining an ethics review committee.
PG  - 141-142
LID - S1836-9553(20)30025-4 [pii]
LID - 10.1016/j.jphys.2020.03.008 [doi]
FAU - Elkins, Mark R
AU  - Elkins MR
AD  - Editor, Journal of Physiotherapy. Electronic address: mark.elkins@sydney.edu.au.
LA  - eng
PT  - Editorial
DEP - 20200706
PL  - Netherlands
TA  - J Physiother
JT  - Journal of physiotherapy
JID - 101528691
SB  - IM
MH  - *Ethical Review
MH  - *Ethics Committees
MH  - Humans
MH  - *Physical Therapists
PMC - PMC7336909
EDAT- 2020/07/11 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - S1836-9553(20)30025-4 [pii]
AID - 10.1016/j.jphys.2020.03.008 [doi]
PST - ppublish
SO  - J Physiother. 2020 Jul;66(3):141-142. doi: 10.1016/j.jphys.2020.03.008. Epub 2020
      Jul 6.


PMID- 32646522
OWN - NLM
STAT- MEDLINE
DCOM- 20200714
LR  - 20201218
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Jul 9
TI  - Challenges and recommendations for mental health providers during the COVID-19
      pandemic: the experience of China's First University-based mental health team.
PG  - 59
LID - 10.1186/s12992-020-00591-2 [doi]
AB  - Coronavirus Disease is impacting the entire world. As the first country that has 
      needed to confront this disease, China has responded with unprecedented and
      hugely successful public health initiatives. Almost simultaneous with the
      awareness of the potential for widespread loss of life, the first Chinese
      university recognizing the likely psychological impacts of COVID-19, assembled
      the first university-based professional team to offer pandemic-related mental
      health services to the Chinese public. This paper describes the work that we
      provided and the challenges encountered. The challenges are described in four
      contexts: the organizational/systemic level, the technical perspective, the
      therapeutic process, and the ethical aspects. We also provide recommendations on 
      what we can do in the short term, and future improvements that can be made.
FAU - Chen, Shitao
AU  - Chen S
AUID- ORCID: 0000-0001-5184-8501
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
      chenshitao@bnu.edu.cn.
FAU - Li, Feihan
AU  - Li F
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
FAU - Lin, Chaihua
AU  - Lin C
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
FAU - Han, Yuge
AU  - Han Y
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
FAU - Nie, Xilun
AU  - Nie X
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
FAU - Portnoy, Robert N
AU  - Portnoy RN
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
FAU - Qiao, Zhihong
AU  - Qiao Z
AD  - Faculty of Psychology, Beijing Normal University, Beijing, 100875, China.
LA  - eng
GR  - 2018NTSS36/Fundamental Research Funds for the Central Universities/International
PT  - Letter
DEP - 20200709
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
SB  - IM
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology/*psychology
MH  - Health Services Research
MH  - Humans
MH  - Mental Health Services/*organization & administration
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/*psychology
MH  - Universities
PMC - PMC7344043
OTO - NOTNLM
OT  - *COVID-19
OT  - *Challenges
OT  - *China
OT  - *Mental health provider
OT  - *Recommendations
EDAT- 2020/07/11 06:00
MHDA- 2020/07/15 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
AID - 10.1186/s12992-020-00591-2 [doi]
AID - 10.1186/s12992-020-00591-2 [pii]
PST - epublish
SO  - Global Health. 2020 Jul 9;16(1):59. doi: 10.1186/s12992-020-00591-2.


PMID- 32646502
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20220415
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 9
TI  - Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia
      without the need for admission as an opportunity to modify the course of the
      disease: A structured summary of a randomised controlled trial.
PG  - 632
LID - 10.1186/s13063-020-04575-w [doi]
AB  - OBJECTIVES: The aim of this study is to explore the effectiveness and safety of
      oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2
      pneumonia in patients who do not yet meet hospital admission criteria. TRIAL
      DESIGN: Randomized clinical trial, controlled, open, parallel group, to evaluate 
      the effectiveness of steroids in adult patients with confirmed COVID-19, with
      incipient pulmonary involvement, without hospital admission criteria. Patients
      will be stratified by the presence or not of radiological data on pneumonia.
      PARTICIPANTS: We will include patients with early stage SARS-Cov-2 pneumonia who 
      do not meet hospital admission criteria from the reference hospital, the Hospital
      Universitario de Burgos, in the region of Castilla y Leon, Spain. Patients will
      be followed-up by specialist physicians and Primary Health Care professionals.
      INCLUSION CRITERIA: - Men and women. - Age between 18 and 75 years old. -
      Diagnosed SARS-CoV-2 infection, by PCR and/or IgM+ antibody test and/or antigen
      test. - Clinical diagnosis of lung involvement: (respiratory symptoms +/-
      pathological auscultation +/- O2 desaturation) - Chest X-ray with mild-moderate
      alterations or normal. - Patients who give their verbal informed consent in front
      of witnesses, which will be reflected in the patients' medical records. EXCLUSION
      CRITERIA: - Oxygen desaturation below 93% or P02 < 62. - Moderate-severe dyspnea 
      or significant respiratory or general deterioration that makes admission
      advisable. - Chest X-ray with multifocal infiltrates. - Insulin-dependent
      diabetes with poor control or glycaemia in the emergency room test greater than
      300 mg/ml (fasting or not). - Other significant comorbidities: Severe renal
      failure (creatinine clearance < 30 mL/min); cirrhosis or chronic liver disease,
      poorly controlled hypertension. - Heart rhythm disturbances (including prolonged 
      QT). - Severe immunosuppression (HIV infection, long-term use of
      immunosuppressive agents); cancer. - Pregnant or breast-feeding women. - Patients
      under use of glucocorticoids for other diseases. - History of allergy or
      intolerance to any of the drugs in the study (prednisone, azithromycin or
      hydroxychloroquine). - Patients who took one or more of the study drugs in the 7 
      days prior to study inclusion. - Patients taking non-suppressible drugs with risk
      of QT prolongation or significant interactions. - Patients unwilling or unable to
      participate until study completion. - Participation in another study.
      INTERVENTION AND COMPARATOR: Eligible patients will be randomized to receive
      standard outpatient treatment only (group 1) or standard outpatient treatment
      plus prednisone (group 2). - Group 1: paracetamol 1 g/8 h (on demand) +
      hydroxychloroquine 400 mg/12h the first day, 200 mg/12 h for 4 days +
      azithromycin 500 mg/24h for 5 days. - Group 2: paracetamol 1 g/8 h (on demand) + 
      hydroxychloroquine 400 mg/12h the first day, 200 mg/12 h for 4 days +
      azithromycin 500 mg/24h for 5 days + prednisone 60 mg / 24 h for 3 days, 30 mg / 
      24 h for 3 days and 15 mg / 24 h for 3 days. MAIN OUTCOMES: If the patient
      requires ambulatory observation, according to the protocol established in this
      respect in the Emergency Department, meets all the criteria for inclusion and
      none for exclusion, data will be taken by the person responsible on the data
      collection sheet. The main result is admission after 30 days. Secondary outcomes 
      are 30-day ICU admission and hospital stay. The safety variable will be the
      occurrence of clinical symptoms or delirium related to the steroids. Also, the
      possible decompensations of diabetes will be measured. All tests will be on an
      intention-to-treat basis. RANDOMISATION: Treatment will be assigned according to 
      stratified randomization by the presence or absence of radiological data of lung 
      involvement (previously performed by random sequence 1:1 generated with Epidat
      and kept hidden by opaque, sealed envelopes, which will only be opened after
      inclusion and basal measurement). BLINDING (MASKING): Participants, caregivers
      and personnel responsible for outcomes measurement will not be blinded to group
      assignment, once the patient is included and the basal measurement performed, as 
      per protocol design. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The percentage of
      patients with incipient lung involvement is unknown, but given that pulmonary
      involvement already exists it is estimated to be around 20%. We consider that the
      intervention could reduce this percentage to 5%, so the necessary sample size
      would be 200 subjects (100 per group), with a power of 80% and an estimated loss 
      percentage of 10%. TRIAL STATUS: The protocol with code TAC-COVID-19, version 2.0
      on date: April 16, 2020 is approved by the Spanish Drug Agency (AEMPS) and the
      local Ethics Committee. The trial is in the recruitment phase. Recruitment began 
      19 April, 2020 and is anticipated to be complete by April 2021. TRIAL
      REGISTRATION: The trial was registered under the title "OUTPATIENT TREATMENT OF
      EARLY PULMONARY COVID19 WITH CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE
      COURSE OF THE DISEASE" with EudraCT number 2020-001622-64 , registered on 3 April
      2020. FULL PROTOCOL: The full protocol is attached as an additional file,
      accessible from the Trials website (Additional file 1). In the interest in
      expediting dissemination of this material, the familiar formatting has been
      eliminated; this Letter serves as a summary of the key elements of the full
      protocol.
FAU - Saiz-Rodriguez, Miriam
AU  - Saiz-Rodriguez M
AUID- ORCID: http://orcid.org/0000-0002-1660-3135
AD  - Research Unit, Hospital Universitario de Burgos, Burgos, Spain.
FAU - Pena, Teresa
AU  - Pena T
AD  - Neumology Department, Hospital Universitario de Burgos, Avda Islas Baleares, 3,
      Burgos, Spain.
FAU - Lazaro, Lourdes
AU  - Lazaro L
AD  - Neumology Department, Hospital Universitario de Burgos, Avda Islas Baleares, 3,
      Burgos, Spain.
FAU - Gonzalez, Angel
AU  - Gonzalez A
AD  - Gerencia de Atencion Primaria de Burgos, Burgos, Spain.
FAU - Martinez, Andres
AU  - Martinez A
AD  - Gerencia de Atencion Primaria de Burgos, Burgos, Spain.
FAU - Cordero, Jose A
AU  - Cordero JA
AD  - Instituto de Investigacion Sanitaria Bioaraba, Vitoria-Gasteiz, Alava, Spain.
FAU - Vicente, Juan T
AU  - Vicente JT
AD  - Emergency Department, Hospital Universitario de Burgos, Burgos, Spain.
FAU - Richard, Fernando
AU  - Richard F
AD  - Emergency Department, Hospital Universitario de Burgos, Burgos, Spain.
FAU - Coma, Maria Jesus
AU  - Coma MJ
AD  - Research Unit, Hospital Universitario de Burgos, Burgos, Spain.
FAU - de Frutos, Martin
AU  - de Frutos M
AD  - Research Unit, Hospital Universitario de Burgos, Burgos, Spain.
FAU - Labrador, Jorge
AU  - Labrador J
AD  - Research Unit, Hospital Universitario de Burgos, Burgos, Spain.
AD  - Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.
FAU - Pueyo, Ana
AU  - Pueyo A
AD  - Neumology Department, Hospital Universitario de Burgos, Avda Islas Baleares, 3,
      Burgos, Spain. pueyo@saludcastillayleon.es.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20200709
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antiviral Agents)
RN  - VB0R961HZT (Prednisone)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/*administration & dosage/adverse effects
MH  - Adult
MH  - Aged
MH  - *Ambulatory Care
MH  - Antiviral Agents/*administration & dosage/adverse effects
MH  - Betacoronavirus/*drug effects/pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/*drug therapy/virology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/*drug therapy/virology
MH  - Prednisone/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - SARS-CoV-2
MH  - Severity of Illness Index
MH  - Spain
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7344042
OTO - NOTNLM
OT  - COVID-19
OT  - Early pulmonary
OT  - Outpatients
OT  - Prednisone
OT  - Protocol
OT  - Randomised controlled trial
EDAT- 2020/07/11 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/06/26 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
AID - 10.1186/s13063-020-04575-w [doi]
AID - 10.1186/s13063-020-04575-w [pii]
PST - epublish
SO  - Trials. 2020 Jul 9;21(1):632. doi: 10.1186/s13063-020-04575-w.


PMID- 32646462
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1477-7827 (Electronic)
IS  - 1477-7827 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jul 9
TI  - Corifollitropin alfa for poor responders patients, a prospective randomized
      study.
PG  - 67
LID - 10.1186/s12958-020-00628-6 [doi]
AB  - BACKGROUND: Poor ovarian response remains one of the biggest challenges for
      reproductive endocrinologists. The introduction of corifollitropin alpha (CFA)
      offered an alternative option to other gonadotropins for its longer half-life,
      its more rapid achievement of the threshold and higher FSH levels. We compared
      two different protocols with CFA, a long agonist and a short antagonist, and a
      no-CFA protocol. METHODS: Patients enrolled fulfilled at least two of the
      followings: AFC < 5, AMH < 1,1 ng/ml, less than three oocytes in a previous
      cycle, age > 40 years. Ovarian stimulation with an antagonist protocol was
      performed either with 300 UI rFSH and 150 UI rLH or 300UI HMG. In the long
      agonist group, after pituitary suppression with triptorelin, CFA was given the
      1-2th day of cycle and 300 UI rFSH and 150 UI rLH the 5th day. In the short
      antagonist group CFA was given the 1-2th day of cycle and 300 UI rFSH and 150 UI 
      rLH the 5th day. The primary objective was the effect on the number of oocytes
      and MII oocytes. Secondary objective were pregnancy rates, ongoing pregnancies
      and ongoing pregnancies per intention to treat. RESULTS: The use of CFA resulted 
      in a shorter lenght of stimulation and a lower number of suspended treatments.
      Both the CFA protocols were significantly different from the no-CFA group in the 
      number of retrieved oocytes (p < 0,05), with a non-significant difference in
      favour of the long agonist protocol. Both CFA groups yielded higher pregnancy
      rates, especially the long protocol, due to the higher number of oocytes
      retrieved (p < 0,05), as implantation rates did not differ. The cumulative
      pregnancy rate was also different, due to the higher number of cryopreserved
      blastocysts (p < 0,02). CONCLUSIONS: The long agonist protocol with the addition 
      of rFSH and rLH showed the best results in all the parameters. A short antagonist
      protocol with CFA was less effective, but not significantly, although provided
      better results compared to the no-CFA group. We suggest that a long agonist
      protocol with CFA and recombinant gonadotropins might be a valuable option for
      poor responders. TRIAL REGISTRATION: The study was approved by the local Ethics
      Committee (EudraCT2015-002817-31).
FAU - Fusi, F M
AU  - Fusi FM
AUID- ORCID: http://orcid.org/0000-0003-1608-1901
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy. ffusi@asst-pg23.it.
FAU - Zanga, L
AU  - Zanga L
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy.
FAU - Arnoldi, M
AU  - Arnoldi M
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy.
FAU - Melis, S
AU  - Melis S
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy.
FAU - Cappato, M
AU  - Cappato M
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy.
FAU - Candeloro, I
AU  - Candeloro I
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy.
FAU - Di Pasqua, A
AU  - Di Pasqua A
AD  - Division of Reproductive Endocrinology, ASST Papa Giovanni XXIII, Piazza OMS 1,
      24127, Bergamo, Italy.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200709
PL  - England
TA  - Reprod Biol Endocrinol
JT  - Reproductive biology and endocrinology : RB&E
JID - 101153627
RN  - 0 (Follicle Stimulating Hormone, Human)
RN  - 0 (follicle stimulating hormone, human, with HCG C-terminal peptide)
SB  - IM
MH  - Adult
MH  - Female
MH  - Fertilization in Vitro/methods
MH  - Follicle Stimulating Hormone, Human/*therapeutic use
MH  - Humans
MH  - Infertility, Female/*drug therapy/therapy
MH  - Oocyte Retrieval/methods
MH  - Ovarian Reserve/drug effects/physiology
MH  - Ovulation Induction/*methods
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Treatment Outcome
PMC - PMC7346462
OTO - NOTNLM
OT  - Agonist
OT  - Antagonist
OT  - Corifollitropin alfa
OT  - Poor responders
EDAT- 2020/07/11 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
AID - 10.1186/s12958-020-00628-6 [doi]
AID - 10.1186/s12958-020-00628-6 [pii]
PST - epublish
SO  - Reprod Biol Endocrinol. 2020 Jul 9;18(1):67. doi: 10.1186/s12958-020-00628-6.


PMID- 32646379
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 9
TI  - 90 days impacts of remote ischemic preconditioning on patients undergoing open
      total aortic arch replacement: a post-hoc analysis of previous trial.
PG  - 169
LID - 10.1186/s12871-020-01085-9 [doi]
AB  - BACKGROUND: In the previous randomized controlled trial by our research group, we
      evaluated the effect of remote ischemic preconditioning (RIPC) in 130 patients
      (65 per arm) on acute kidney injury (AKI) within 7 days of open total aortic arch
      replacement. Significantly fewer RIPC-treated patients than sham-treated patients
      developed postoperative AKI, and, epically, RIPC significantly reduced serious
      AKI (stage II-III). However, the long-term effect of RIPC in patients undergoing 
      open total aortic arch replacement is unclear. METHODS: This study was a post-hoc
      analysis. We aimed to assess the roles of RIPC in major adverse kidney events
      (MAKE), defined as consisting persistent renal dysfunction, renal replacement
      therapy and mortality, within 90 days after surgery in patients receiving open
      total aortic arch replacement. RESULTS: In this 90-day follow-up study, data were
      available for all study participants. We found that RIPC failed to improve the
      presence of MAKE within 90 days after surgery (RIPC: 7 of 65[10.8%]) vs sham: 15 
      of 65[23.1%]; P = 0.061). In those patients who developed AKI after surgery, we
      found that the rate of MAKE within 90 days after surgery differed between the
      RIPC group and the sham group (RIPC: 4 of 36[11.2%]; sham: 14 of 48[29.2%]; P =
      0.046). CONCLUSIONS: At 90 days after open total aortic arch replacement, we
      failed to find a difference between the renoprotective effects of RIPC and sham
      treatment. The effectiveness or ineffectiveness of RIPC should be further
      investigated in a large randomized sham-controlled trial. TRIAL REGISTRATION:
      This study was approved by the Ethics Committee of Fuwai Hospital (No. 2016-835) 
      and our previous study was registered at clinicaltrials.gov before patient
      enrollment ( NCT03141385 ; principal investigator: G.W.; date of registration:
      March 5, 2017).
FAU - Chen, Yimeng
AU  - Chen Y
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, National Center for Cardiovascular Diseases,
      State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng
      District, Beijing, 100037, China.
FAU - Wang, Guyan
AU  - Wang G
AUID- ORCID: 0000-0003-3098-5472
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, National Center for Cardiovascular Diseases,
      State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng
      District, Beijing, 100037, China. guyanwang2006@163.com.
AD  - Department of Anesthesiology, Beijng Tongren Hospital, Capital Medical
      University, No. 1 Dongjiaominxiang, Dongcheng District, Beijing, 100730, China.
      guyanwang2006@163.com.
FAU - Zhou, Hui
AU  - Zhou H
AD  - Department of Anesthesiology, Ruijin Hospital, Shanghai Jiaotong University
      School of Medicine, Shanghai, China.
FAU - Yang, Lijing
AU  - Yang L
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, National Center for Cardiovascular Diseases,
      State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng
      District, Beijing, 100037, China.
FAU - Zhang, Congya
AU  - Zhang C
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, National Center for Cardiovascular Diseases,
      State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng
      District, Beijing, 100037, China.
FAU - Yang, Xiying
AU  - Yang X
AD  - Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences
      and Peking Union Medical College, National Center for Cardiovascular Diseases,
      State Key Laboratory of Cardiovascular Disease, Belishi road 167, Xicheng
      District, Beijing, 100037, China.
FAU - Lei, Guiyu
AU  - Lei G
AD  - Department of Anesthesiology, Beijng Tongren Hospital, Capital Medical
      University, No. 1 Dongjiaominxiang, Dongcheng District, Beijing, 100730, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03141385
GR  - 81770414/National Natural Science Foundation of China/International
GR  - 81970344/National Natural Science Foundation of China/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
SB  - IM
MH  - Acute Kidney Injury/*prevention & control
MH  - Adult
MH  - Aorta, Thoracic/*surgery
MH  - Humans
MH  - Ischemic Preconditioning/*methods
MH  - Middle Aged
MH  - Postoperative Complications/*prevention & control
PMC - PMC7346644
OTO - NOTNLM
OT  - *Major adverse kidney events
OT  - *Open total aortic arch replacement
OT  - *Remote ischemic preconditioning
EDAT- 2020/07/11 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
AID - 10.1186/s12871-020-01085-9 [doi]
AID - 10.1186/s12871-020-01085-9 [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 Jul 9;20(1):169. doi: 10.1186/s12871-020-01085-9.


PMID- 32646349
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 2171-8695 (Electronic)
IS  - 1130-6343 (Linking)
VI  - 44
IP  - 4
DP  - 2020 Jul 1
TI  - Spanish Society of Hospital Pharmacy Position Statement on Telepharmacy:
      Recommendations for its implementation and development.
PG  - 174-181
LID - 10.7399/fh.11515 [doi]
AB  - The use of information and communication technologies have nowadays become part
      and parcel of hospital pharmacy practice. Against this background, it is hardly
      surprising that Telepharmacy has sparked the interest of a large number of
      stakeholders. In this respect, the Spanish Society of Hospital Pharmacy has
      developed a definition of the concept and outlined the conditions under which
      Telepharmacy should operate. It has also shared its institutional stance on the
      subject through a position statement that states that Telepharmacy is the
      provision of pharmaceutical care at a distance through information and
      communication technologies. Telepharmacy practice includes activities such as
      therapeutic validation, drafting of clinical documents, provision of
      pharmaceutical care, therapeutic follow-up, adherence monitoring, drug education 
      and information, coordination between healthcare providers and evaluation of
      health outcomes. The clinical tasks performed as part of Telepharmacy practice
      must adhere to a standardized procedure and revolve around the patient's clinical
      record. Access to Telepharmacy must be provided without discrimination. The
      service comprises four main activities: pharmacotherapeutic follow-up; patient
      and caregiver-directed education and information-dissemination; coordination with
      healthcare providers from the same or different hospitals; and remote informed
      home drug delivery. Implementation of Telepharmacy requires an adjustment of
      human (training and capacity-building) and technological resources (validation,
      interoperability, confidentiality). It must also comply with the laws and
      regulations in force both at a regional and a national level. Telepharmacy
      procedures must also be adapted to the relevant ethical standards and codes of
      good practice. Appropriate indicators must be used to evaluate the performance of
      Telepharmacy and its impact on health outcomes. According to Spanish Society of
      Hospital Pharmacy Telepharmacy is a necessary complementary tool to provide
      specialized pharmaceutical care and thereby improve health outcomes and maximize 
      patient safety and satisfaction.
CI  - Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights
      reserved.
FAU - Morillo-Verdugo, Ramon
AU  - Morillo-Verdugo R
AD  - Department of Pharmacy, Virgen de Valme University Hospital, Seville. Spain.
      MAPEX Project Working Group: Strategic Telepharmacy Framework, Spanish Society of
      Hospital Pharmacy. Spain. luis.margusino.framinan@sergas.es.
FAU - Margusino-Framinan, Luis
AU  - Margusino-Framinan L
AD  - MAPEX Project Working Group: Strategic Telepharmacy Framework, Spanish Society of
      Hospital Pharmacy. Spain Department of Pharmacy, A Coruna University Hospital
      Complex, A Coruna. Spain.. luis.margusino.framinan@sergas.es.
FAU - Monte-Boquet, Emilio
AU  - Monte-Boquet E
AD  - MAPEX Project Working Group: Strategic Telepharmacy Framework, Spanish Society of
      Hospital Pharmacy. Spain Department of Pharmacy, La Fe University and Polytechnic
      Hospital, Valencia. Spain.. luis.margusino.framinan@sergas.es.
FAU - Morell-Baladron, Alberto
AU  - Morell-Baladron A
AD  - MAPEX Project Working Group: Strategic Telepharmacy Framework, Spanish Society of
      Hospital Pharmacy. Spain Department of Pharmacy, La Princesa University Hospital,
      Madrid. Spain.. luis.margusino.framinan@sergas.es.
FAU - Barreda-Hernandez, Dolores
AU  - Barreda-Hernandez D
AD  - Department of Pharmacy, Virgen de la Luz Hospital, Cuenca. Spain. Ethos Working
      Group of the Spanish Society of Hospital Pharmacy. Spain.
      luis.margusino.framinan@sergas.es.
FAU - Rey-Pineiro, Xose Manuel
AU  - Rey-Pineiro XM
AD  - MAPEX Project Working Group: Strategic Telepharmacy Framework, Spanish Society of
      Hospital Pharmacy. Spain Legal Department of the Spanish Society of Hospital
      Pharmacy. Spain. luis.margusino.framinan@sergas.es.
FAU - Negro-Vega, Eva
AU  - Negro-Vega E
AD  - Department of Pharmacy, Getafe University Hospital, Getafe (Madrid). Spain.
      Madrid Regional Director of the Spanish Society of Hospital Pharmacy. Spain.
      luis.margusino.framinan@sergas.es.
FAU - Delgado-Sanchez, Olga
AU  - Delgado-Sanchez O
AD  - Department of Pharmacy, Son Espases University Hospital, Palma de Majorca. Spain.
      Chair of the Spanish Society of Hospital Pharmacy. Spain.
      luis.margusino.framinan@sergas.es.
LA  - eng
PT  - Journal Article
TT  - Posicionamiento de la Sociedad Espanola de Farmacia Hospitalaria sobre
      Telefarmacia. Recomendaciones para su implantacion y desarrollo.
DEP - 20200701
PL  - Spain
TA  - Farm Hosp
JT  - Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad
      Espanola de Farmacia Hospitalaria
JID - 9440679
SB  - IM
CIN - Farm Hosp. 2020 Jul 01;44(4):125-126. PMID: 32646342
MH  - Communication
MH  - Hospitals
MH  - Humans
MH  - *Pharmacy Service, Hospital
MH  - *Telemedicine
EDAT- 2020/07/11 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
AID - 10.7399/fh.11515 [doi]
PST - epublish
SO  - Farm Hosp. 2020 Jul 1;44(4):174-181. doi: 10.7399/fh.11515.


PMID- 32646315
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Dec
TI  - Evaluation of Serious Adverse Event Reporting Forms for Clinical Trials: A
      Comparative Korean Study.
PG  - 415-424
LID - 10.1177/1556264620940563 [doi]
AB  - Safety surveillance, using appropriately consistent review criteria, could
      improve human participants' well-being in clinical trials. To establish a
      globally consistent framework, the quality of the current content for review by
      institutional review boards (IRBs), as mandatory oversight entities, requires
      evaluation. This study collected and analyzed forms reporting serious adverse
      events (SAEs) to IRBs/ Research Ethics Committees(RECs) to compare them with the 
      well-structured form presented in the literature using completeness and accuracy 
      scores. We found sub-optimal completeness and accuracy scores when compared with 
      perfect scores (p < .05). Less than half of the retrieved forms had queries on
      causality assessment (</=43.1%). Thus, contents of SAE forms require improvement 
      for IRB oversight and, further, there is a need to develop a well-structured form
      that could improve international consistency.
FAU - Lee, Heeyoung
AU  - Lee H
AUID- ORCID: 0000-0001-8099-5025
AD  - Konyang University, Republic of Korea.
FAU - Park, Cholong
AU  - Park C
AD  - Chung-Ang University, Seoul, Republic of Korea.
FAU - Choi, Jinwon
AU  - Choi J
AD  - Chung-Ang University, Seoul, Republic of Korea.
FAU - Jeong, Seongeun
AU  - Jeong S
AD  - Chung-Ang University, Seoul, Republic of Korea.
FAU - Cho, Hyunin
AU  - Cho H
AD  - Samsung Medical Center, Seoul, Republic of Korea.
FAU - Huh, Wooseong
AU  - Huh W
AD  - Samsung Medical Center, Seoul, Republic of Korea.
AD  - Sungkyukwan University, Seoul, Republic of Korea.
FAU - Kim, Eunyoung
AU  - Kim E
AUID- ORCID: 0000-0003-3525-8805
AD  - Chung-Ang University, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Republic of Korea
OTO - NOTNLM
OT  - *clinical trials
OT  - *forms
OT  - *institutional review board
OT  - *safety
OT  - *serious adverse events
EDAT- 2020/07/11 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 10.1177/1556264620940563 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Dec;15(5):415-424. doi:
      10.1177/1556264620940563. Epub 2020 Jul 9.


PMID- 32645842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201027
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Jul 7
TI  - Insights from Regulatory Data on Development Needs of Community Pharmacy
      Professionals.
LID - E111 [pii]
LID - 10.3390/pharmacy8030111 [doi]
AB  - The aim of this study was to use data available to a Canadian health professions 
      regulator (Ontario College of Pharmacists) to identify areas of opportunity where
      practitioners (pharmacists and pharmacy technicians) could benefit from further
      development, in order to optimize practice and improve the quality of care. Four 
      de-identified datasets were used to extract themes from areas of jurisprudence
      (1969 exam records), member practice assessments (2610 records), pharmacy
      assessments (2024 records) and conduct (640 case records). Outcome measures
      included performance in examinations and assessments and competency gaps
      identified in conduct investigations. Thematic analysis of outcomes was done in
      two stages. First, the four outcomes were derived independently for each dataset.
      Second, the top five issues were extracted for each dataset. It was hypothesized 
      that common themes in competency gaps across all four datasets would emerge from 
      this top five selection. We found three main common areas of opportunity where
      practitioners could benefit from further development: patient assessment and
      safety; documentation; and ethical, legal and professional responsibilities.
FAU - Morris, Katherine
AU  - Morris K
AUID- ORCID: 0000-0003-3981-1567
AD  - Information and Data Management, Ontario College of Pharmacists, Toronto, ON M5R 
      2R4, Canada.
FAU - Arzoomanian, Anita
AU  - Arzoomanian A
AD  - Registrant Competence, Ontario College of Pharmacists, Toronto, ON M5R 2R4,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC7558436
OTO - NOTNLM
OT  - competency gaps
OT  - continuing education
OT  - continuing professional development
OT  - health regulatory body
OT  - pharmacy education
OT  - pharmacy practice change management
OT  - pharmacy workforce development
OT  - remediation
OT  - scope of practice
EDAT- 2020/07/11 06:00
MHDA- 2020/07/11 06:01
CRDT- 2020/07/11 06:00
PHST- 2020/06/04 00:00 [received]
PHST- 2020/06/25 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2020/07/11 06:01 [medline]
AID - pharmacy8030111 [pii]
AID - 10.3390/pharmacy8030111 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2020 Jul 7;8(3). pii: pharmacy8030111. doi:
      10.3390/pharmacy8030111.


PMID- 32644324
STAT- Publisher
DA  - 20200710
PB  - Institute for Quality and Efficiency in Health Care (IQWiG), publisher
CTI - Institute for Quality and Efficiency in Health Care: Extracts
DP  - 2020 May 27
BTI - Cancer Can concomitant music therapy contribute to better treatment results?
      IQWiG Reports - Commission No. HT17-02
AB  - RESEARCH QUESTION OF THE HTA REPORT: The aims of this investigation are to -
      assess the benefit of music therapy (MT) as a therapy accompanying oncological
      standard therapy by comparing it to no accompanying therapy or other accompanying
      therapies in adult cancer patients with regard to patient-relevant outcomes, -
      determine the costs arising from accompanying MT in comparison with a different
      or no accompanying therapy in adult cancer patients (intervention costs), -
      assess the cost effectiveness of MT accompanying standard therapy in comparison
      with no accompanying therapy or other accompanying therapies in adult cancer
      patients as well as - review ethical, social, legal, and organizational aspects
      associated with the intervention. CONCLUSION OF THE HTA REPORT: MT as an
      accompanying therapy in oncology has already been established in the German
      healthcare system, particularly in the (acute and palliative) inpatient and
      rehabilitation settings, through service reimbursement as well as its mentions in
      national guidelines. The present HTA reveals indications and hints of a
      short-term benefit of MT in comparison with standard care with regard to fatigue,
      mood swings, anxiety, anxiety & depression, stress/tension, and health-related
      quality of life as well as, over the course of several sessions, with regard to
      cancer-related adverse events, fatigue, and mood swings. In comparison with other
      accompanying therapies (music medicine, mindfulness-based stress reduction), a
      hint of greater short-term benefit of MT was found with regard to fatigue and
      subjective well-being. Notably, the available evidence shows a positive effect
      particularly for comparatively short-term psychological outcomes and, in general,
      primarily for non-biological outcomes - soon after the intervention. For most
      biological (clinical) outcomes as well as for persistent psychological conditions
      such as depression, there is generally a lack of evidence in favour of MT.
      However, these short-term effects are to be considered in light of the typically 
      precarious, in some cases life-threatening, situation of patients. Furthermore,
      MT is a non-invasive intervention associated with few ethical concerns and is
      impossible to conduct without considerable patient motivation and cooperation.
      The results on the benefit of MT are transferable to Germany if a consistent
      professional concept and standardized training and/or certification can be
      assumed to be in place, which is, however, not entirely the case in view of the
      current lack of regulation. However, a uniform consensus has been reached on the 
      occupational profile as well as (voluntary) certification. Due to differences in 
      reimbursement and local availability, access to MT (in general and in oncology)
      is not uniformly regulated among inpatient care, the rehabilitation sector, and
      outpatient care. Due to a lack of data, some questions cannot be answered at this
      time: No studies were found on the outcomes of coping or activities of daily
      living, and no study investigating MT as a group intervention was found. Data are
      insufficient for performing a comparative analysis of the benefit of MT in
      different cancer entities or for a comparison of curative versus palliative
      therapy. In the direct comparison with alternative accompanying therapies, MT in 
      the form defined herein was studied in only 3 out of 10 studies, and no studies
      investigated it in comparison with "sham treatment". No data are available on
      cost-effectiveness, and estimating the intervention costs is hindered by a lack
      of data on average treatment duration and frequency of sessions. Only 1 out of
      the 10 studies was conducted in an outpatient setting. Two ongoing studies on MT 
      from Israel and Germany were found, and their design might potentially produce
      insights regarding longer-term effects and coping (outcome of "resilience").
CI  - (c) IQWiG (Institute for Quality and Efficiency in Health Care).
LA  - eng
PT  - Review
PT  - Book
PL  - Cologne (Germany)
OTO - NLM
OT  - Music Therapy
OT  - Neoplasms
OT  - Benefit Assessment
OT  - Systematic Review
OT  - Technology Assessment - Biomedical
EDAT- 2020/07/10 06:01
MHDA- 2020/07/10 06:01
CDAT- 2020/07/10 06:01
AID - NBK559343 [bookaccession]


PMID- 32645026
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - Health system actors' perspectives of prescribing practices in public health
      facilities in Eswatini: A Qualitative Study.
PG  - e0235513
LID - 10.1371/journal.pone.0235513 [doi]
AB  - BACKGROUND: Rational medicines use (RMU) is the prescribing/dispensing of good
      quality medicines to meet individual patient's clinical needs. Policy-makers,
      managers and frontline providers play critical roles in safeguarding medicine
      usage thus ensuring their rational use. This study investigated perspectives of
      key health system actors on prescribing practices and factors influencing these
      in Eswatini. Public sector healthcare service delivery is through health
      facilities (public sector, not-for-profit faith-based, industrial) and
      community-based care. METHODS: A qualitative, exploratory study using
      semi-structured in-depth interviews with seven policymakers and managers, and 32 
      facility-based actors was conducted. Drawing on Social Practice Theory, material 
      (health system context), competence (provider) and cultural (patient and
      provider) factors influencing prescribing practices were explored. RESULTS:
      Participants were aged between 21-57years, had been practicing for 1-30 years,
      and were a mix of doctors, nurses, pharmacists and pharmacy-technicians. Factors 
      contributing to irrational medicines use included: poor use of treatment
      guidelines, lack of RMU policies, poorly-functioning pharmaceutical and
      therapeutics committees, stock-outs of medicines, lack of pharmacy personnel in
      primary healthcare facilities, and restrictions of medicines by level of care.
      Provider-related factors included: knowledge, experience and practice ethic,
      symptomatic prescribing, high patient numbers. Patient-related factors included
      late presentation, language, and the need to be prescribed many medicines.
      CONCLUSION: In Eswatini, prescribing practices are influenced by the interaction 
      of factors (health system, provider and patient) that span levels (facility,
      region, and policy-making) of the health system. Promoting RMU thus goes beyond
      the availability of guidelines and provider training and requires concerted
      efforts of multiple stakeholders.
FAU - Ncube, Nondumiso B Q
AU  - Ncube NBQ
AUID- ORCID: 0000-0003-0478-9523
AD  - Department of Community and Health Sciences, School of Public Health, University 
      of the Western Cape, Bellville, Cape Town, South Africa.
FAU - Knight, Lucia
AU  - Knight L
AUID- ORCID: 0000-0001-9938-6887
AD  - Department of Community and Health Sciences, School of Public Health, University 
      of the Western Cape, Bellville, Cape Town, South Africa.
FAU - Bradley, Hazel Anne
AU  - Bradley HA
AUID- ORCID: 0000-0002-6384-9912
AD  - Department of Community and Health Sciences, School of Public Health, University 
      of the Western Cape, Bellville, Cape Town, South Africa.
FAU - Schneider, Helen
AU  - Schneider H
AD  - Department of Community and Health Sciences, School of Public Health, University 
      of the Western Cape, Bellville, Cape Town, South Africa.
FAU - Laing, Richard
AU  - Laing R
AD  - Department of Community and Health Sciences, School of Public Health, University 
      of the Western Cape, Bellville, Cape Town, South Africa.
AD  - Boston University School of Public Health, Boston, Massachusetts, United States
      of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - *Drug Prescriptions
MH  - *Drug Utilization
MH  - Eswatini
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*psychology/standards
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Guidelines as Topic
PMC - PMC7347100
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/10 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - 10.1371/journal.pone.0235513 [doi]
AID - PONE-D-20-01768 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 9;15(7):e0235513. doi: 10.1371/journal.pone.0235513.
      eCollection 2020.


PMID- 32643809
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Deliberately infecting healthy volunteers with malaria parasites: Perceptions and
      experiences of participants and other stakeholders in a Kenyan-based malaria
      infection study.
PG  - 819-832
LID - 10.1111/bioe.12781 [doi]
AB  - Controlled human malaria infection (CHMI) studies involve the deliberate
      infection of healthy volunteers with malaria parasites under controlled
      conditions to study immune responses and/or test drug or vaccine efficacy. An
      empirical ethics study was embedded in a CHMI study at a Kenyan research
      programme to explore stakeholders' perceptions and experiences of deliberate
      infection and moral implications of these. Data for this qualitative study were
      collected through focus group discussions, in-depth interviews and
      non-participant observation. Sixty-nine participants were involved, including
      CHMI study volunteers, community representatives and research staff. Data were
      managed using QSR Nvivo 10 and analysed using an inductive-deductive approach,
      guided by ethics literature. CHMI volunteers had reasonable understanding of the 
      study procedures. Decisions to join were influenced by study incentives, trust in
      the research institution, their assessment of associated burdens and motivation
      to support malaria vaccine development. However, deliberate malaria infection was
      a highly unusual research strategy for volunteers, community representatives and 
      some study staff. Volunteers' experiences of physical, emotional and social
      burdens or harms were often greater than anticipated initially, and fluctuated
      over time, related to specific procedures and events. Although unlikely to deter 
      volunteers' participation in similar studies in furture, we argue that the
      dissonance between level of understanding of the burdens involved and actual
      experiences are morally relevant in relation to community engagement, informed
      consent processes, and ongoing support for volunteers and research staff. We
      further argue that ethics oversight of CHMI studies should take account of these 
      issues in deciding whether consent, engagement and the balance of benefits and
      harms are reasonable in a given context.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Jao, Irene
AU  - Jao I
AUID- ORCID: 0000-0002-6645-510X
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
FAU - Marsh, Vicki
AU  - Marsh V
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Che Chi, Primus
AU  - Che Chi P
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
FAU - Kapulu, Melissa
AU  - Kapulu M
AUID- ORCID: 0000-0003-0321-7128
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Hamaluba, Mainga
AU  - Hamaluba M
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
FAU - Molyneux, Sassy
AU  - Molyneux S
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Bejon, Philip
AU  - Bejon P
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
FAU - Kamuya, Dorcas
AU  - Kamuya D
AD  - KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, Oxford, UK.
LA  - eng
GR  - 096527/Global Health Bioethics Network - Wellcome Trust Strategic
      Award/International
GR  - 203077/WT_/Wellcome Trust/United Kingdom
GR  - 205419-Z-16-Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Animals
MH  - Healthy Volunteers
MH  - Humans
MH  - Kenya
MH  - *Malaria/prevention & control
MH  - *Parasites
MH  - Perception
PMC - PMC7689838
OTO - NOTNLM
OT  - *Africa
OT  - *challenge studies
OT  - *controlled human infection studies
OT  - *deliberate infection
OT  - *developing countries
OT  - *ethics
EDAT- 2020/07/10 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/07/10 06:00
PHST- 2019/04/30 00:00 [received]
PHST- 2020/04/04 00:00 [revised]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.1111/bioe.12781 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):819-832. doi: 10.1111/bioe.12781. Epub 2020 Jul 9.


PMID- 32643205
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 60
IP  - 10
DP  - 2020 Oct
TI  - How do we design and report a high-quality survey?
PG  - 2178-2184
LID - 10.1111/trf.15861 [doi]
AB  - Every day, new surveys are planned, distributed, or reported by health care
      professionals. Surveys are an inexpensive and convenient research tool used with 
      increasing frequency as an approach to gather and collate information on
      attitudes and behaviors for a specific topic. However, surveys can squander the
      valuable time of respondents who may derive little, if any, benefit from
      participation. Similar to any other research methodology, a careful design is
      needed to avoid introducing bias and to obtain meaningful information. A recent
      study evaluating the quality of surveys addressing clinical topics in transfusion
      medicine (TM) identified common deficiencies in the quality and design, including
      the failure to report validity and reliability, to address nonresponse error, to 
      report funding and ethics/consent considerations, and to discuss the
      generalizability of results. Instructions to authors for reporting survey results
      are lacking in most journals. Inadequate survey design, analysis, and reporting
      can prevent accurate data collection and compromise the interpretation of the
      results, which is of critical relevance considering the high citation rates for
      some of these surveys. Further, survey results might be used to inform policies
      when no higher level of evidence is available. In this article, the authors seek 
      to provide practical recommendations for designing high-quality surveys based on 
      personal experience and published literature and to address frequently missing
      key elements in survey-based studies related to clinical TM.
CI  - (c) 2020 AABB.
FAU - Pagano, Monica B
AU  - Pagano MB
AUID- ORCID: 0000-0001-5183-6471
AD  - Division of Transfusion Medicine, Department of Laboratory Medicine, University
      of Washington, Seattle, Washington, USA.
FAU - Dunbar, Nancy M
AU  - Dunbar NM
AUID- ORCID: 0000-0001-8601-5438
AD  - Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical
      Center, Lebanon, New Hampshire, USA.
FAU - Stanworth, Simon J
AU  - Stanworth SJ
AUID- ORCID: 0000-0002-7414-4950
AD  - Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
AD  - Department of Haematology, Oxford University Hospitals, NHS Foundation Trust,
      Oxford, UK.
AD  - Radcliffe Department of Medicine, University of Oxford and NIHR Oxford Biomedical
      Research Centre (Haematology), Oxford, UK.
CN  - BEST Collaborative and the Clinical Studies Group
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
SB  - IM
MH  - Humans
MH  - *Research Design
MH  - *Surveys and Questionnaires
MH  - *Transfusion Medicine
EDAT- 2020/07/10 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/26 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.1111/trf.15861 [doi]
PST - ppublish
SO  - Transfusion. 2020 Oct;60(10):2178-2184. doi: 10.1111/trf.15861. Epub 2020 Jul 8.


PMID- 32643059
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Landscape of Machine Implemented Ethics.
PG  - 2381-2399
LID - 10.1007/s11948-020-00236-y [doi]
AB  - This paper surveys the state-of-the-art in machine ethics, that is,
      considerations of how to implement ethical behaviour in robots, unmanned
      autonomous vehicles, or software systems. The emphasis is on covering the breadth
      of ethical theories being considered by implementors, as well as the
      implementation techniques being used. There is no consensus on which ethical
      theory is best suited for any particular domain, nor is there any agreement on
      which technique is best placed to implement a particular theory. Another
      unresolved problem in these implementations of ethical theories is how to
      objectively validate the implementations. The paper discusses the dilemmas being 
      used as validating 'whetstones' and whether any alternative validation mechanism 
      exists. Finally, it speculates that an intermediate step of creating
      domain-specific ethics might be a possible stepping stone towards creating
      machines that exhibit ethical behaviour.
FAU - Nallur, Vivek
AU  - Nallur V
AD  - School of Computer Science, University College Dublin, Dublin, D04 V1W8, Republic
      of Ireland. vivek.nallur@ucd.ie.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Ethical Theory
MH  - *Morals
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Autonomous systems
OT  - Implementation and design
OT  - Machine ethics
OT  - Robotics
EDAT- 2020/07/10 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.1007/s11948-020-00236-y [doi]
AID - 10.1007/s11948-020-00236-y [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2381-2399. doi: 10.1007/s11948-020-00236-y.


PMID- 32643058
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Keeping the "Human in the Loop" in the Age of Artificial Intelligence :
      Accompanying Commentary for "Correcting the Brain?" by Rainey and Erden.
PG  - 2455-2460
LID - 10.1007/s11948-020-00241-1 [doi]
AB  - The benefits of Artificial Intelligence (AI) in medicine are unquestionable and
      it is unlikely that the pace of its development will slow down. From better
      diagnosis, prognosis, and prevention to more precise surgical procedures, AI has 
      the potential to offer unique opportunities to enhance patient care and improve
      clinical practice overall. However, at this stage of AI technology development it
      is unclear whether it will de-humanize or re-humanize medicine. Will AI allow
      clinicians to spend less time on administrative tasks and technology related
      procedures and more time being present in person to attend to the needs of their 
      patients? Or will AI dramatically increase the presence of smart technology in
      the clinical context to a point of undermining the humane dimension of the
      patient-physician relationship? In this brief commentary, we argue that
      technological solutions should be only integrated into clinical medicine if they 
      fulfill the following three conditions: (1) they serve human ends; (2) they
      respect personal identity; and (3) they promote human interaction. These three
      conditions form the moral imperative of humanity.
FAU - Jotterand, Fabrice
AU  - Jotterand F
AD  - Center for Bioethics and Medical Humanities, Medical College of Wisconsin, 8701
      Watertown Plank Road, Milwaukee, WI, 53226, USA. fjotterand@mcw.edu.
FAU - Bosco, Clara
AU  - Bosco C
AD  - Center for Bioethics and Medical Humanities, Medical College of Wisconsin, 8701
      Watertown Plank Road, Milwaukee, WI, 53226, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Brain
MH  - Humans
MH  - *Physician-Patient Relations
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Ethical imperatives
OT  - Humanity
OT  - Neurointerventions
OT  - Patient-physician relationship
OT  - Psychiatry
EDAT- 2020/07/10 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.1007/s11948-020-00241-1 [doi]
AID - 10.1007/s11948-020-00241-1 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2455-2460. doi: 10.1007/s11948-020-00241-1.


PMID- 32643017
OWN - NLM
STAT- MEDLINE
DCOM- 20200728
LR  - 20201218
IS  - 1613-7671 (Electronic)
IS  - 0043-5325 (Linking)
VI  - 132
IP  - 13-14
DP  - 2020 Jul
TI  - COVID-19 and ethical preparedness?
PG  - 400-402
LID - 10.1007/s00508-020-01709-7 [doi]
AB  - Mankind has to prepare for a pandemic with respect to medical and practical
      aspects, but also with respect to ethical issues. There are various ethical
      guidelines for managing infectious disease outbreaks, but they do not apply to
      the specific aspects of the COVID-19 pandemic, since they were formulated after
      the different kinds of outbreaks of avian influenza and Ebola. Today we are
      confronted with completely new issues endangering our fundamental human rights.
      As COVID-19 is spreading all over the world, we are in a desperate situation to
      find treatment solutions; however, despite the urgency, scientific rules have to 
      be applied as bad science is unethical since it might be harmful for patients.
      Fake news and alternative facts might not be easily recognized and are also
      threatening scientific values. Pandemics might be leading to a meltdown of the
      health system if no measures are being taken constraining fundamental human
      rights. Tracking of persons is violating human rights as well if not accepted on 
      a voluntary basis. A failure to have safeguards for times of crisis leads to a
      scarcity of medicinal products and goods resulting in a nationalistic approach
      and ignorance of international solidarity. And last but not least selective
      measures and triage in intensive care have to be taught to young physicians and
      nursing staff in medical schools in order to be prepared in times of an
      infectious disease outbreak and scarcity of resources.
FAU - Druml, Christiane
AU  - Druml C
AD  - UNESCO Chair on Bioethics at the Medical University of Vienna, Ethics,
      Collections and History of Medicine, Medical University of Vienna, 1090, Vienna, 
      Austria. christiane.druml@meduniwien.ac.at.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Civil Defense/ethics
MH  - *Coronavirus Infections/epidemiology
MH  - *Human Rights
MH  - Humans
MH  - Mass Media
MH  - Pandemics/*ethics
MH  - *Pneumonia, Viral/epidemiology
MH  - Resource Allocation/ethics
MH  - SARS-CoV-2
MH  - Truth Disclosure
PMC - PMC7341697
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Fundamental human rights
OT  - Infectious diseases
OT  - Pandemic
EDAT- 2020/07/10 06:00
MHDA- 2020/07/29 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/29 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.1007/s00508-020-01709-7 [doi]
AID - 10.1007/s00508-020-01709-7 [pii]
PST - ppublish
SO  - Wien Klin Wochenschr. 2020 Jul;132(13-14):400-402. doi:
      10.1007/s00508-020-01709-7. Epub 2020 Jul 8.


PMID- 32642989
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1432-086X (Electronic)
IS  - 0174-1551 (Linking)
VI  - 43
IP  - 10
DP  - 2020 Oct
TI  - Value of MRI/CT Image Fusion for Targeting "invisible" Lesions in Stereotactic
      Microwave Ablation (SMWA) of Malignant Liver Lesions: A Retrospective Analysis.
PG  - 1505-1514
LID - 10.1007/s00270-020-02565-8 [doi]
AB  - PURPOSE: To assess the technical feasibility of MRI/CT image fusion and
      completeness of ablation treatment for primary or metastatic liver lesions
      invisible on contrast-enhanced CT planning scans and outcome in patients treated 
      with stereotactic microwave ablation (SMWA). MATERIALS AND METHODS: The study was
      approved by the local ethics committee. Patients who underwent SMWA between
      January 2015 and December 2018 were retrospectively analyzed. All liver lesions
      for which MRI/CT fusion was performed due to invisibility on pre-interventional
      CT planning scans were included and reassessed. The outcome measurement was
      successful ablation of the lesion at first follow-up imaging. RESULTS: During the
      study period, 236 patients underwent 312 SMWAs with ablation of 496 lesions.
      Twenty-four lesions in 15 patients (mean age, 62 years; range, 43-80 years) were 
      included. Following MRI/CT image fusion, all 24 lesions could be sufficiently
      localized to perform SMWA. The first follow-up imaging showed complete ablation
      of 22 lesions. Two initially incompletely ablated lesions were hepatocellular
      carcinomas and were successfully re-ablated afterwards. CONCLUSION: SMWA with
      MRI/CT image fusion is an accurate and safe treatment option for patients with
      liver lesions not detectable on contrast-enhanced CT planning scans. MRI/CT image
      fusion may allow more patients with malignant liver lesions to benefit from local
      ablation treatment even if their lesions are not visible on CT planning
      examinations.
FAU - Cathomas, M
AU  - Cathomas M
AD  - Department of Visceral Surgery and Medicine, Inselspital, Bern University
      Hospital, University of Bern, Bern, Switzerland.
FAU - Mertineit, N
AU  - Mertineit N
AD  - Department of Radiology, Inselspital, Bern University Hospital, University of
      Bern, Freiburgstr. 10, 3010, Bern, Switzerland.
FAU - Kim-Fuchs, C
AU  - Kim-Fuchs C
AD  - Department of Visceral Surgery and Medicine, Inselspital, Bern University
      Hospital, University of Bern, Bern, Switzerland.
FAU - Lachenmayer, A
AU  - Lachenmayer A
AD  - Department of Visceral Surgery and Medicine, Inselspital, Bern University
      Hospital, University of Bern, Bern, Switzerland.
FAU - Maurer, M H
AU  - Maurer MH
AD  - Department of Radiology, Inselspital, Bern University Hospital, University of
      Bern, Freiburgstr. 10, 3010, Bern, Switzerland. martin.maurer@insel.ch.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - United States
TA  - Cardiovasc Intervent Radiol
JT  - Cardiovascular and interventional radiology
JID - 8003538
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Hepatocellular/diagnostic imaging/surgery
MH  - Female
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Liver/*diagnostic imaging/pathology/surgery
MH  - Liver Neoplasms/*diagnostic imaging/secondary/*surgery
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Microwaves
MH  - Middle Aged
MH  - Radiofrequency Ablation/*methods
MH  - Retrospective Studies
MH  - *Tomography, X-Ray Computed
EDAT- 2020/07/10 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/07/10 06:00
PHST- 2019/09/23 00:00 [received]
PHST- 2020/06/20 00:00 [accepted]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.1007/s00270-020-02565-8 [doi]
AID - 10.1007/s00270-020-02565-8 [pii]
PST - ppublish
SO  - Cardiovasc Intervent Radiol. 2020 Oct;43(10):1505-1514. doi:
      10.1007/s00270-020-02565-8. Epub 2020 Jul 8.


PMID- 32642968
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20210104
IS  - 1920-7476 (Electronic)
IS  - 0008-4263 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Aug
TI  - Social distancing, social justice, and risk during the COVID-19 pandemic.
PG  - 459-461
LID - 10.17269/s41997-020-00354-x [doi]
AB  - Social distancing is an important and necessary measure to help arrest the spread
      of SARS-CoV-2 during the COVID-19 pandemic. However, it does place persons who
      are socially or politically marginalized, including those who are of lower
      socio-economic status, at risk of further harms. In other words, marginalized or 
      disadvantaged persons are at risk of both contracting SARS-CoV-2 and the risk of 
      harms that may come about because of the social distancing measures themselves.
      Finally, a third layer of risk faced by marginalized persons would be the overuse
      of utility (i.e., maximize the benefit of resource x) as the primary ethics
      principle upon which to make allocation decisions, since oftentimes it is
      resource-intensive to help those in positions of social marginality. This
      three-fold risk of harm to which marginalized persons are subjected runs counter 
      to the very notion of social justice that underpins public health. Social
      distancing in a socially just manner requires dialoguing with affected
      populations and providing social supports to marginalized persons, regardless of 
      the associated costs.
FAU - Silva, Diego S
AU  - Silva DS
AD  - Sydney Health Ethics, Sydney School of Public Health, University of Sydney,
      Building 1, Level 1, Medical Foundations Building, 92/94 Parramatta Rd,
      Camperdown, NSW, 2050, Australia. diego.silva@sydney.edu.au.
AD  - Marie Bashir Institute for Infectious Diseases and Biosecurity, University of
      Sydney, Camperdown, Australia. diego.silva@sydney.edu.au.
FAU - Smith, Maxwell J
AU  - Smith MJ
AD  - School of Health Studies, Faculty of Health Sciences, Western University, Room
      222, Labatt Health Sciences Building, London, Ontario, N6A 5B9, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - Switzerland
TA  - Can J Public Health
JT  - Canadian journal of public health = Revue canadienne de sante publique
JID - 0372714
SB  - IM
MH  - COVID-19/*epidemiology/prevention & control
MH  - Canada/epidemiology
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - *Physical Distancing
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Risk
MH  - *Social Justice
PMC - PMC7342548
OTO - NOTNLM
OT  - *Bioethics
OT  - *Coronavirus
OT  - *Ethics
OT  - *Health policy
OT  - *Infectious diseases
EDAT- 2020/07/10 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/04/03 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/07/10 06:00 [entrez]
AID - 10.17269/s41997-020-00354-x [doi]
AID - 10.17269/s41997-020-00354-x [pii]
PST - ppublish
SO  - Can J Public Health. 2020 Aug;111(4):459-461. doi: 10.17269/s41997-020-00354-x.
      Epub 2020 Jul 8.


PMID- 32642711
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2632-2498 (Electronic)
IS  - 2632-2498 (Linking)
VI  - 2
IP  - 1
DP  - 2020 Jan-Dec
TI  - Missing diversity in brain tumor trials.
PG  - vdaa059
LID - 10.1093/noajnl/vdaa059 [doi]
AB  - BACKGROUND: Clinical trials for brain tumors represent a significant opportunity 
      for both patients and providers to understand and combat a disease with
      substantial morbidity. The aim of this study was to quantify and map ethnic and
      racial representation in brain tumor trials and examine the potential gaps in
      trial recruitment. We also show that these representation gaps persist even in
      large multicultural cities like New York City. METHODS: We analyzed brain tumor
      clinical trials registered on www.clinicaltrials.gov between July 1, 2005 and
      completed on or before November 11, 2017. We used a combination of PubMed/MEDLINE
      and Google Scholar to find associated publications and obtained trial information
      as well as patient demographic information (when available) including race or
      ancestry. RESULTS: Out of 471 trials, 27% had no published results. Only 28.4% of
      trials with results reported race or ethnicity of trial participants, with no
      observed upward trend by year. Whites were significantly overrepresented in
      trials for metastatic brain tumors (P < .001) and high-grade trials (P < .001).
      Blacks/African Americans (AAs), Hispanics, and Asians were significantly
      underrepresented (P < .001) in high-grade trials, while only Blacks/AAs were
      underrepresented in trials for metastatic brain tumors (P < .001). Representation
      gaps were not observed in pediatric trials. Despite being a multicultural hub,
      New York City displayed similar gaps in trial representation. CONCLUSIONS:
      Despite increasing representation in the American population, minorities are
      underrepresented in brain tumor trials. In addition, despite numerous legal
      requirements and ethical mandates, published results including race-based
      information are remarkably absent from 70% of brain tumor trials.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, the Society for
      Neuro-Oncology and the European Association of Neuro-Oncology.
FAU - Taha, Birra
AU  - Taha B
AD  - Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
FAU - Winston, Graham
AU  - Winston G
AUID- ORCID: 0000-0002-3878-992X
AD  - Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell
      Medical College, New York, NY, USA.
FAU - Tosi, Umberto
AU  - Tosi U
AUID- ORCID: 0000-0003-0847-2400
AD  - Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell
      Medical College, New York, NY, USA.
FAU - Hartley, Benjamin
AU  - Hartley B
AD  - Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell
      Medical College, New York, NY, USA.
FAU - Hoffman, Caitlin
AU  - Hoffman C
AD  - Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell
      Medical College, New York, NY, USA.
FAU - Dahmane, Nadia
AU  - Dahmane N
AD  - Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell
      Medical College, New York, NY, USA.
FAU - Mason, Christopher E
AU  - Mason CE
AD  - Department of Physiology and Biophysics and Institute for Computational
      Biomedicine, Weill Cornell Medical College, New York, NY, USA.
AD  - Feil Family Brain and Mind Research Institute, New York, NY, USA.
FAU - Greenfield, Jeffrey P
AU  - Greenfield JP
AUID- ORCID: 0000-0003-1904-1040
AD  - Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell
      Medical College, New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - England
TA  - Neurooncol Adv
JT  - Neuro-oncology advances
JID - 101755003
PMC - PMC7316223
OTO - NOTNLM
OT  - representation
OT  - New York City
OT  - clinical trials
OT  - diversity
OT  - neuro-oncology
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.1093/noajnl/vdaa059 [doi]
AID - vdaa059 [pii]
PST - epublish
SO  - Neurooncol Adv. 2020 May 13;2(1):vdaa059. doi: 10.1093/noajnl/vdaa059.
      eCollection 2020 Jan-Dec.


PMID- 32642572
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Jun
TI  - Accountants perception of the factors influencing auditors' ethical behaviour in 
      Nigeria.
PG  - e04271
LID - 10.1016/j.heliyon.2020.e04271 [doi]
AB  - This paper examines the perception of accountants (chartered and non-chartered)
      of the personal factors influencing auditors' ethical behaviours in Nigeria. Data
      were obtained from 152 accountants (80 chartered and 72 non-chartered) in Lagos
      State Nigeria through the use of a well-structured questionnaire. The data
      collected were analysed using nonparametric tests (Wilcoxon rank-sum test and
      Mann-Whitney test) to check for differences in the perceptions of chartered and
      non-chartered accountants of the personal factors influencing auditors' ethical
      behaviours. The results showed that, except for auditors' age, there is a
      consensus in the perceptions of both chartered and non-chartered accountants of
      the personal factors influencing auditors' ethical behaviours. While there were
      significant divergent views on whether age influences auditors' ethical
      behaviours, fear of sanction, religion, upbringing, conscience, gender, and
      personal values were found to be influencers of auditors' ethical behaviours. The
      study offers value to professional accounting bodies in that it provides
      empirical explanations to guide the pursuit of sustainable and resilient ethical 
      values among accounting professionals.
CI  - (c) 2020 The Authors.
FAU - Adekoya, Adeleke Clement
AU  - Adekoya AC
AD  - Afe Babalola University, Ado-Ekiti, Nigeria.
FAU - Oboh, Collins Sankay
AU  - Oboh CS
AD  - University of Lagos (UNILAG), Lagos, Nigeria.
FAU - Oyewumi, Obafemi Rufus
AU  - Oyewumi OR
AD  - University of Lagos (UNILAG), Lagos, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7334234
OTO - NOTNLM
OT  - Accounting
OT  - Auditors
OT  - Banking
OT  - Business
OT  - Chartered accountants
OT  - Corruption
OT  - Entrepreneurship
OT  - Ethical behaviours
OT  - Finance
OT  - Public finance
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2019/07/19 00:00 [received]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04271 [doi]
AID - S2405-8440(20)31115-4 [pii]
AID - e04271 [pii]
PST - epublish
SO  - Heliyon. 2020 Jul 1;6(6):e04271. doi: 10.1016/j.heliyon.2020.e04271. eCollection 
      2020 Jun.


PMID- 32642487
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Exploring medical teachers' and interns' experiences regarding professional
      ethics.
PG  - 131
LID - 10.4103/jehp.jehp_706_19 [doi]
AB  - CONTEXT: Medical ethics is a practical subject as well as a branch of ethical
      philosophy and an integral part of the proper practice in medicine. However, the 
      ethics changes in places and over time and is variable. Furthermore, many issues 
      that have occurred as a result of advances in technology add to the complexity of
      the ethical issues. Therefore, the objective of this research was to explore
      medical teachers' and interns' experiences regarding professional ethics.
      METHODS: This study was a qualitative content analysis conducted on 10
      professionals and 10 interns of the surgery and internal departments of medical
      and educational centers in Qom University of Medical Sciences to discover their
      experiences of the medical professional ethics. The sampling method was
      purposive, and data were collected through semi-structured interviews. Data
      analysis was performed using a qualitative content analysis method with a
      conventional approach. RESULTS: Three main categories were obtained from the data
      analysis, including adherence to professional values, organizational conditions, 
      and individual characteristics. CONCLUSIONS: Adherence to professional values,
      paying attention to individual characteristics, and organizational conditions are
      among the factors affecting the promotion of medical professional ethics;
      therefore, it seems that appropriate interventions on these important components 
      can help promote the professional ethics training in the clinical practice.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Khalajinia, Zohre
AU  - Khalajinia Z
AD  - Department of Midwifery, School of Nursing and Midwifery, Qom University of
      Medical Sciences, Qom, Iran.
FAU - Alipour, Zahra
AU  - Alipour Z
AD  - Department of Midwifery, School of Nursing and Midwifery, Qom University of
      Medical Sciences, Qom, Iran.
FAU - Safaeipour, Rohollah
AU  - Safaeipour R
AD  - Medical Education Development Center, Qom University of Medical Sciences, Qom,
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7325762
OTO - NOTNLM
OT  - Interns
OT  - medical professional ethics
OT  - medicine
OT  - promotion
COIS- There are no conflicts of interest.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2019/12/30 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.4103/jehp.jehp_706_19 [doi]
AID - JEHP-9-131 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 May 28;9:131. doi: 10.4103/jehp.jehp_706_19.
      eCollection 2020.


PMID- 32642428
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2214-031X (Print)
IS  - 2214-031X (Linking)
VI  - 24
DP  - 2020 Sep
TI  - Vascular endothelial growth factor for in vivo bone formation: A systematic
      review.
PG  - 46-57
LID - 10.1016/j.jot.2020.05.005 [doi]
AB  - BACKGROUND: To achieve optimal bone formation one of the most influential
      parameters has been mentioned to be adequate blood supply. Vascular endothelial
      growth factor (VEGF) is hereby of particular interest in bone regeneration,
      because of its primary ability to induce neovascularization and chemokine
      affection for endothelial cells (EC), and is considered to be the main regulator 
      of vascular formation. However, the growth factor has yet to be implemented in a 
      clinical setting in orthopaedic intervention surgery. We hypothesised that the
      development of VEGF in vivo for bone formation in the last decade had progressed 
      towards clinical application since the latest systematic review from 2008.
      OBJECTIVE: This systematic review recapped the last 13 years of in vivo bone
      regeneration using vascular endothelial growth factor (VEGF). METHOD: A total of 
      1374 articles were identified using the PubMed search string (vegf or "vascular
      endothelial growth factor") and (osteogen * or "bone formation" or "bone
      regeneration"). By 3 selection phases 24 published articles were included by the 
      criteria of being in vivo, using only VEGF for bone formation, published after
      2007 and written in English. Articles in vitro, written in different languages
      than English and older than 2007 was excluded. The most recent systematic review 
      on this subject was published in 2008, with the latest included study from 01 to 
      11-2007. All included studies were classified based on animal, type of defect,
      scaffold, control group, type of VEGF, release rate, dosage of VEGF, time of
      evaluation and results. Each study was evaluated for risk of bias by modified
      CAMARADES quality assessment for the use in experimental animal studies. The
      score was calculated by peer review journal publication, use of control group,
      randomisation of groups, justified VEGF dosage, blinding of results, details on
      animal model, sample size calculation, comply with ethics and no conflict of
      interest. RESULTS: No clinical trials or human application studies were obtained 
      from our search. Experimentally, 11 articles using solely VEGF for bone formation
      had a group or a timepoint significantly better than the corresponding control
      group. 18 articles revealed no significant difference of VEGF compared to the
      control group and 1 article reported a significant decreased bone growth using
      VEGF compared to control. CONCLUSION: Based on these results no clinical studies 
      have yet been performed. However, indications in the best use of VEGF from
      experimental studies could be made towards that the optimal release is within the
      first three weeks, in defect models, with the best effect before eight weeks.
      Future designs should incorporate this with standardised and reproducible models 
      for verification towards clinical practice. THE TRANSLATIONAL POTENTIAL OF THIS
      ARTICLE: This systematic review aims to assess the existing literature to focus
      on methodologies and outcomes that can provide future knowledge regarding the
      solitary use of VEGF for bone regeneration in a clinical setting.
CI  - (c) 2020 Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking 
      Orthopaedic Society.
FAU - Dreyer, Chris H
AU  - Dreyer CH
AD  - Orthopaedic Research Laboratory, Department of Orthopaedics & Traumatology,
      Odense University Hospital, Department of Clinical Research, University of
      Southern Denmark, 5000, Odense C, Denmark.
AD  - Musculoskeletal Research Laboratory, Department of Orthopaedic Surgery &
      Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, PR China.
AD  - Acute Medicine, Department of Emergency Medicine, Slagelse Hospital, Slagelse,
      Denmark.
FAU - Kjaergaard, Kristian
AU  - Kjaergaard K
AD  - Orthopaedic Research Laboratory, Department of Orthopaedics & Traumatology,
      Odense University Hospital, Department of Clinical Research, University of
      Southern Denmark, 5000, Odense C, Denmark.
FAU - Ding, Ming
AU  - Ding M
AD  - Orthopaedic Research Laboratory, Department of Orthopaedics & Traumatology,
      Odense University Hospital, Department of Clinical Research, University of
      Southern Denmark, 5000, Odense C, Denmark.
FAU - Qin, Ling
AU  - Qin L
AD  - Musculoskeletal Research Laboratory, Department of Orthopaedic Surgery &
      Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, PR China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200607
PL  - Singapore
TA  - J Orthop Translat
JT  - Journal of orthopaedic translation
JID - 101625127
PMC - PMC7334443
OTO - NOTNLM
OT  - Angiogenesis
OT  - Biomaterials
OT  - Growth factors
OT  - Osteogenesis
OT  - Tissue engineering
OT  - Vascular endothelial growth factor
COIS- The authors have no conflicts of interest to disclose in relation to this
      article.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.1016/j.jot.2020.05.005 [doi]
AID - S2214-031X(20)30071-1 [pii]
PST - epublish
SO  - J Orthop Translat. 2020 Jun 7;24:46-57. doi: 10.1016/j.jot.2020.05.005.
      eCollection 2020 Sep.


PMID- 32642368
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 5
TI  - Ethical Dilemma: Should Continuous Intravenous Drug Use Affect Appropriate
      Management in Prosthetic Valve Endocarditis?
PG  - e8458
LID - 10.7759/cureus.8458 [doi]
AB  - Drug use is a major challenge that negatively impacts many aspects of health. The
      issue of drug use is growing with every passing day. Efforts to mitigate its use 
      are countered by even more people succumbing to the intravenous drug use due to
      their relatively easy availability and patients' poor insight into their medical 
      condition. Infective endocarditis (IE) is a condition with high mortality and
      morbidity. It requires prolonged treatment with antibiotics, and, under some
      special circumstances, surgical management is also necessitated. Intravenous drug
      users who get valve replacement after index IE episode may continue to use drugs 
      despite our utmost efforts to prevent it. They can subsequently develop
      prosthetic valve endocarditis (PVE), which is one of the indications for surgical
      valve replacement, hence requiring a redo surgery. However, their irregular
      behavior can create reservations while considering a repeat valvular surgery and 
      delay the appropriate treatment. This can increase morbidity and mortality from
      PVE in intravenous drug users with otherwise no or few comorbidities.
CI  - Copyright (c) 2020, Ahmed et al.
FAU - Ahmed, Talha
AU  - Ahmed T
AD  - Internal Medicine, University of Maryland Medical Center, Baltimore, USA.
FAU - Safdar, Ayesha
AU  - Safdar A
AD  - Internal Medicine, Army Medical College, Rawalpindi, PAK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200605
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7336599
OTO - NOTNLM
OT  - continued drug use
OT  - indications for surgery
OT  - infective endocarditis
OT  - intravenous drug use
OT  - native valve endocarditis
OT  - prosthetic valve endocarditis
OT  - surgical valve replacement
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.7759/cureus.8458 [doi]
PST - epublish
SO  - Cureus. 2020 Jun 5;12(6):e8458. doi: 10.7759/cureus.8458.


PMID- 32642060
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 56
DP  - 2020 Aug
TI  - Diversity in approach to teaching and assessing ethics education for medical
      undergraduates: A scoping review.
PG  - 178-185
LID - 10.1016/j.amsu.2020.06.028 [doi]
AB  - There are diverse methods to teach medical ethics, and there is no single
      accepted approach towards its learning and assessment. The authors aim to explore
      the various strategies practised to teach undergraduate medical students the
      fundamentals of medical ethics and their evaluation. The authors reviewed the
      articles published from January 2014 to September 2019. The authors searched
      PubMed for the relevant publications and extracted the information using a data
      extraction sheet. Twenty-nine articles were included for the review, which
      fulfilled the inclusion criteria. Case-based discussions were a widely accepted
      strategy to learn ethics. The studies highlighted a mixed teaching approach using
      multiple teaching tools. A qualitative approach was preferred for the assessment 
      through reflections, simulated patient interactions, and development of
      portfolios. However, there are gaps in the existing literature on the assessment 
      strategies for ethics education. Heterogeneity still exists in the planning of
      the curricula, teaching, and assessment methods. These curricula suit the
      cultural and religious set up of that particular country. Case-based discussion
      is a popular teaching strategy, and there exist numerous innovative and
      cost-effective active teaching strategies. There is a need for studies that are
      more rigorous to address the evaluation of the ethics curricula. This review
      would help educators to choose their preferred approach based on their teaching
      environment.
CI  - (c) 2020 The Authors.
FAU - Souza, Anne D
AU  - Souza AD
AD  - Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, 
      576104, India.
FAU - Vaswani, Vina
AU  - Vaswani V
AD  - Head of Forensic Medicine Department, Centre for Ethics, Yenepoya Medical
      College, Yenepoya (Deemed to Be University), Deralakatte, Mangaluru, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200627
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7334795
OTO - NOTNLM
OT  - Assessment
OT  - Curriculum
OT  - Ethics education
OT  - Medical undergraduates
OT  - Review
OT  - Teaching methods
COIS- The authors state that there is no conflict of interest to declare.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/06/20 00:00 [revised]
PHST- 2020/06/20 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.1016/j.amsu.2020.06.028 [doi]
AID - S2049-0801(20)30167-9 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Jun 27;56:178-185. doi: 10.1016/j.amsu.2020.06.028.
      eCollection 2020 Aug.


PMID- 32641889
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0974-2069 (Print)
IS  - 0974-5149 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Apr-Jun
TI  - Supraventricular tachycardia in one of the twins: The ethical dilemmas involved
      in treatment.
PG  - 150-152
LID - 10.4103/apc.APC_204_19 [doi]
AB  - The pediatric cardiologist now has an important role to play in fetal medicine.
      They are often called upon to manage fetal cardiac problems such as arrhythmias
      or perform fetal cardiac interventions such as balloon valvuloplasty or atrial
      septostomy. In these scenarios, it becomes very important for the pediatric
      cardiologist to understand the concepts of "fetus as a patient," "viability,"
      etc., and their implications in management. We try to shed light on these
      principles through our case scenario of managing supraventricular tachycardia in 
      one of the fetuses of a twin pregnancy.
CI  - Copyright: (c) 2020 Annals of Pediatric Cardiology.
FAU - Doraiswamy, Vinoth
AU  - Doraiswamy V
AD  - Department of Cardiology, PSG Institute of Medical Sciences and Research,
      Coimbatore, Tamil Nadu, India.
FAU - Natarajan, Lalitha
AU  - Natarajan L
AD  - Department of Fetal Medicine, PSG Institute of Medical Sciences and Research,
      Coimbatore, Tamil Nadu, India.
FAU - Venkatesh, Chitra Tv
AU  - Venkatesh CT
AD  - Department of Obstetrics and Gynaecology, PSG Institute of Medical Sciences and
      Research, Coimbatore, Tamil Nadu, India.
LA  - eng
PT  - Case Reports
DEP - 20200413
PL  - India
TA  - Ann Pediatr Cardiol
JT  - Annals of pediatric cardiology
JID - 101495459
PMC - PMC7331848
OTO - NOTNLM
OT  - Beneficence
OT  - fetal arrhythmia
OT  - fetus as a patient
COIS- There are no conflicts of interest.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/10 06:01
CRDT- 2020/07/10 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/01/31 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/10 06:01 [medline]
AID - 10.4103/apc.APC_204_19 [doi]
AID - APC-13-150 [pii]
PST - ppublish
SO  - Ann Pediatr Cardiol. 2020 Apr-Jun;13(2):150-152. doi: 10.4103/apc.APC_204_19.
      Epub 2020 Apr 13.


PMID- 32641576
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics in Swallowing Disorders related to Neurological Diseases].
PG  - 797-802
LID - 10.11477/mf.1416201597 [doi]
AB  - Medical staff frequently face ethically difficult situations when patients with
      severe dysphagia request oral intake. The most important thing to assist them
      with better ethical decision-making is a discussion based on medically accurate
      facts. Although medical staff suffer from ethical dilemmas, clinical ethics
      conferences based on the four principles of clinical ethics are recommended. The 
      process leading to better ethical clinical decision-making is important.
FAU - Kunieda, Kenjiro
AU  - Kunieda K
AD  - Department of Neurology, Gifu University Graduate School of Medicine.
FAU - Fujishima, Ichiro
AU  - Fujishima I
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Clinical Decision-Making
MH  - Decision Making
MH  - *Deglutition Disorders/etiology/therapy
MH  - *Ethics, Clinical
MH  - Humans
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201597 [pii]
AID - 10.11477/mf.1416201597 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):797-802. doi: 10.11477/mf.1416201597.


PMID- 32641575
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Ethics in Pediatric Neurology].
PG  - 785-796
LID - 10.11477/mf.1416201596 [doi]
AB  - There are various types of serious pediatric neurological diseases, although the 
      absolute number of children with either of them is small. These children often
      have life-threatening conditions with severe disability and rely on medical
      technologies. Each child follows a different illness trajectory, which makes it
      difficult to predict his/her prognosis. Given the multiple treatment options, it 
      becomes harder to know when "enough" is enough and what is best for the child.
      When it comes to critical decision-making, we, as healthcare providers, need to
      develop a trustful relationship with the parents and promote shared
      decision-making to fulfill their child's best interest. It is crucial to know
      what the parents hope and fear, and provide them with access to comprehensive,
      evidence-based information about their child's current and potential healthcare
      needs. In this article, four complex ethical issues are reviewed. A broad and
      constructive discussion is long awaited to ensure that these children's lives are
      enhanced to their best potential and treated with dignity in our society.
FAU - Sasazuki, Momoko
AU  - Sasazuki M
AD  - Faculty of Health and Welfare, Seinan Jogakuin University.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Child
MH  - Decision Making
MH  - *Disabled Persons
MH  - Family
MH  - Female
MH  - Humans
MH  - Male
MH  - *Neurology/ethics
MH  - Parents
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201596 [pii]
AID - 10.11477/mf.1416201596 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):785-796. doi: 10.11477/mf.1416201596.


PMID- 32641574
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics in Stroke].
PG  - 777-783
LID - 10.11477/mf.1416201595 [doi]
AB  - In stroke, due to sudden onset, the patient's premorbid wishes cannot be
      confirmed in most cases. Specific guidelines for decisions regarding continuing
      treatment and care have not been established in cases where the patient's
      condition becomes irreversible due to a severe stroke, and decisions are left to 
      the staff at the clinical site, except, until recently, in legally determined
      brain death cases assuming organ donation. The Japan Stroke Society has
      established "Guidelines for end-of-life care in stroke" for the purpose of
      supporting decision-making for treatment and care by the medical team at the
      clinical site.
FAU - Kataoka, Hiroharu
AU  - Kataoka H
AD  - Department of Neurosurgery, Kyoto University, Graduate School of Medicine.
FAU - Miyamoto, Susumu
AU  - Miyamoto S
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Decision Making
MH  - *Ethics, Clinical
MH  - Humans
MH  - Japan
MH  - *Stroke/therapy
MH  - *Terminal Care
MH  - *Tissue and Organ Procurement
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201595 [pii]
AID - 10.11477/mf.1416201595 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):777-783. doi: 10.11477/mf.1416201595.


PMID- 32641573
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics in Neurological Emergencies and Critical Care].
PG  - 767-775
LID - 10.11477/mf.1416201594 [doi]
AB  - The author has examined the characteristics of clinical ethics regarding
      neurological emergencies and critical care. Ethics are involved in areas such as 
      emergency medicine standards, intensive care strategies for brain dead patients
      who are followed by organ donation as well as those who do not donate their
      organs, resulting in cardiac deaths, and serious problems about distributing
      medical resources among the elder in extremely aged society. We must understand
      not only that we encounter a variety of fluctuating patient emotions in emergency
      rooms, but also that it is difficult or even impossible for many patients with a 
      disturbance in consciousness to express what is on their minds. Therefore in many
      cases, we need to consider the patient's dignity be of the ultimate priority and 
      that one of the most important duties for medical personnel is to display
      autonomy in utilizing the principle of benevolence. Additionally, hospital
      administrative staff should fully support the autonomy of doctors and other
      medical personnel.
FAU - Aruga, Tohru
AU  - Aruga T
AD  - Japan Organization of Occupational Health and Safety.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Aged
MH  - Critical Care/ethics
MH  - *Emergencies
MH  - Ethics, Clinical
MH  - Humans
MH  - *Tissue and Organ Procurement/ethics
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201594 [pii]
AID - 10.11477/mf.1416201594 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):767-775. doi: 10.11477/mf.1416201594.


PMID- 32641572
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics in Hereditary Neuromuscular Diseases such as Duchenne Muscular
      Dystrophy].
PG  - 753-766
LID - 10.11477/mf.1416201593 [doi]
AB  - There are many ethical issues in the health care of hereditary neuromuscular
      diseases such as Duchenne muscular dystrophy. The problems lie in the protection 
      of personal genetic information in genetic diagnosis and genetic discrimination. 
      The idea that allocating expensive medical care to such patients with severe
      disabilities is futile should be avoided. QOL as patient's individual subjective 
      perception has not been completely understood in the academic field of clinical
      ethics. From the view of a third party it might be thought that the neuromuscular
      disease patients' QOL is extremely low. In such cases, ventilator therapy, PEG
      placement, and latest antisense nucleotide therapy might be considered wasteful. 
      However, these therapies must be necessary and appropriate from the patients' own
      view. These dilemma on clinical ethics can be solved by focusing on enhancing the
      patients' subjective QOL. This can be achieved by means of modern genetics,
      symptom control techniques and the use of a safety net medical care system with a
      multidisciplinary team.
FAU - Nakajima, Takashi
AU  - Nakajima T
AD  - Director of Niigata National Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Ethics, Clinical
MH  - Humans
MH  - *Muscular Dystrophy, Duchenne/genetics/therapy
MH  - *Neuromuscular Diseases
MH  - Quality of Life
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201593 [pii]
AID - 10.11477/mf.1416201593 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):753-766. doi: 10.11477/mf.1416201593.


PMID- 32641571
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics for Multiple System Atrophy].
PG  - 747-752
LID - 10.11477/mf.1416201592 [doi]
AB  - Clinical ethical issues may arise at any stage of multiple system atrophy. Even
      if there is "bad news," such as sudden death or dementia in the future, the
      patient has the right to know, but the notification should be made with prudence 
      and consideration for the patient. We also need to recognize that there is
      insufficient evidence to support clinical ethical judgment. In addition, it is
      important to promote clinical research and to actively carry out clinical ethical
      discussions on this disease.
FAU - Shimohata, Takayoshi
AU  - Shimohata T
AD  - Department of Neurology, Gifu University Graduate School of Medicine.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - *Ethics, Clinical
MH  - Humans
MH  - *Multiple System Atrophy/diagnosis/therapy
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201592 [pii]
AID - 10.11477/mf.1416201592 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):747-752. doi: 10.11477/mf.1416201592.


PMID- 32641570
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics on Amyotrophic Lateral Sclerosis: Focusing on Discussions and
      Future Challenges Regarding Withdrawal of Ventilator Support].
PG  - 737-745
LID - 10.11477/mf.1416201591 [doi]
AB  - Although there are many ethical issues related to amyotrophic lateral sclerosis, 
      one of the most controversial issue is the withdrawal of ventilator support. This
      problem has a significant impact not only on the decision to "remove", but also
      on the decision to "wear" it. In particular, if the withdrawal of ventilator
      support was to be legalized, there is a concern that its legislation may exert a 
      'silent pressure.' Therefore, rather than explicitly defining the withdrawal of
      ventilator support, as a "legal right," we prefer the installation of a policy in
      which the details of individual cases are carefully scrutinized, allowing for
      justifiable non-compliance with the law in special cases.
FAU - Itai, Koichiro
AU  - Itai K
AD  - Graduate School of Medicine and Veterinary Medicine, University of Miyazaki.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - *Amyotrophic Lateral Sclerosis/therapy
MH  - *Ethics, Clinical
MH  - *Euthanasia, Passive/ethics
MH  - Humans
MH  - Respiration, Artificial
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201591 [pii]
AID - 10.11477/mf.1416201591 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):737-745. doi: 10.11477/mf.1416201591.


PMID- 32641569
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Clinical Ethics of Dementia Care: Respecting the Dignity of Vulnerable and Frail
      Individuals].
PG  - 727-735
LID - 10.11477/mf.1416201590 [doi]
AB  - The New Clinical Ethics of Dementia Care is dedicated to the dignity of
      physically frail and cognitively vulnerable individuals. To deliberate on the
      dignity of a person with dementia, it is important to focus on their autonomy in 
      health care and daily life.
FAU - Minooka, Mako
AU  - Minooka M
AD  - Japan Association of Clinical Ethics.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Aged
MH  - *Dementia/therapy
MH  - *Ethics, Clinical
MH  - Frail Elderly
MH  - Humans
MH  - Personhood
MH  - *Respect
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201590 [pii]
AID - 10.11477/mf.1416201590 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):727-735. doi: 10.11477/mf.1416201590.


PMID- 32641568
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Ethical Issues of Genetic Testing towards Hereditary Neurological Disorders].
PG  - 719-725
LID - 10.11477/mf.1416201589 [doi]
AB  - The purpose of this paper is to review and introduce several topics regarding
      clinical ethics of hereditary neurological disorders. The author reflects the
      historical background about "right to know" and "right not to know" the results
      of genetic testing in 1990s, including pediatric genetic testing. Twenty years
      after, advanced genome sequencing technologies enable us to analyze whole genome 
      while they also encourage us to reconsider the ethical norms. The current topics 
      are such us secondary findings and actionability, support for telling the genetic
      secrets to biological relatives, duty of confidentiality and duty of care to
      third parties, indivisibility in research and diagnosis and pre-implantation
      genetic testing for monogenic/single gene defects.
FAU - Muto, Kaori
AU  - Muto K
AD  - Department of Public Policy, Human Genome Center, The Institute of Medical
      Science, The University of Tokyo.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Child
MH  - Confidentiality
MH  - Family
MH  - *Genetic Testing/ethics
MH  - Humans
MH  - *Nervous System Diseases/diagnosis/genetics
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201589 [pii]
AID - 10.11477/mf.1416201589 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):719-725. doi: 10.11477/mf.1416201589.


PMID- 32641567
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Mental Capacity of Brain Disease].
PG  - 711-717
LID - 10.11477/mf.1416201588 [doi]
AB  - The concept of mental capacity refers to the a bility to understand medical
      explanations and make decisions with reference to values. Evaluating mental
      capacity is associated with patient autonomy and mental capacity is clinically
      and ethically important. In competent patients, patient self-determination is
      respected. On the other hand, in incompetent patients, "best interest" is
      presumed in terms of medical fact and patient value.
FAU - Takimoto, Yoshiyuki
AU  - Takimoto Y
AD  - Department of Biomedical Ethics, Graduate School of Medicine, The University of
      Tokyo.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - *Brain Diseases
MH  - Comprehension
MH  - Decision Making
MH  - Humans
MH  - *Mental Competency
MH  - *Personal Autonomy
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201588 [pii]
AID - 10.11477/mf.1416201588 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):711-717. doi: 10.11477/mf.1416201588.


PMID- 32641566
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Current Status of Clinical Ethics and Creation of Ethical Organizational
      Culture].
PG  - 701-710
LID - 10.11477/mf.1416201587 [doi]
AB  - When an ethical problem arises in clinical practice, the process of discussion
      aimed towards a solution is important. The decision should be made by a
      multidisciplinary team rather than by an individual clinician. In clinical
      practice, highly feasible solutions are required. Clinical ethics consultation is
      useful as a service that supports the decision-making process. A future issue is 
      to foster an organizational culture of openness that enables professionals to
      solve the problem in practice.
FAU - Sugiura, Makoto
AU  - Sugiura M
AD  - Department of Neurology, Anjo Kosei Hospital.
FAU - Ando, Tetsuo
AU  - Ando T
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Decision Making
MH  - *Ethics Consultation
MH  - *Ethics, Clinical
MH  - Humans
MH  - *Organizational Culture
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201587 [pii]
AID - 10.11477/mf.1416201587 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):701-710. doi: 10.11477/mf.1416201587.


PMID- 32641565
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [End-of-Life Medical Care for Cranial Nerve Diseases from Ethical and Legal
      Perspective].
PG  - 689-700
LID - 10.11477/mf.1416201586 [doi]
AB  - After showing the basic knowledge of law, I examined the relation ship between
      law and ethics. Subsequently, I explained a related law about the end-of-life
      stage and neurological intractable diseases based on specific cases. I analyzed
      the structure of the guidelines for end-of-life and dementia guidelines, which
      have great significance in Japan. In addition, the issue of notification
      (informed consent) and removal of the ventilator were examined.
FAU - Inaba, Kazuto
AU  - Inaba K
AD  - Chukyo University.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - *Cranial Nerve Diseases/therapy
MH  - Humans
MH  - Informed Consent
MH  - Japan
MH  - *Terminal Care
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201586 [pii]
AID - 10.11477/mf.1416201586 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):689-700. doi: 10.11477/mf.1416201586.


PMID- 32641564
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [Basics of Clinical Ethics].
PG  - 677-687
LID - 10.11477/mf.1416201585 [doi]
AB  - Neurologists encounter patients who develop diseases that suddenly change their
      life one day, such as stroke, and diseases that are difficult to cure and
      progressive, such as intractable neurological diseases. There are many types of
      ethical issues, including the choice of medical intervention, caregiver conflict,
      genetic disease issues, end-of-life issues, etc. In this article, I will describe
      the matters advocated in general clinical ethics and discuss the interpretation
      and application in the field of neurology based on my own experience. The issue
      is why clinical ethics is necessary, methodologies and systems for dealing with
      ethical issues, four principles of clinical ethics, Jonsen's four contingency
      table, ethical consultation, application in neurological diseases, and issues to 
      be noted.
FAU - Ogino, Mieko
AU  - Ogino M
AD  - Office of Medical Education, International University of Health and Welfare,
      School of Medicine.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - Caregivers
MH  - Ethics, Clinical
MH  - Ethics, Medical
MH  - Humans
MH  - *Nervous System Diseases/therapy
MH  - *Neurology
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201585 [pii]
AID - 10.11477/mf.1416201585 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):677-687. doi: 10.11477/mf.1416201585.


PMID- 32641563
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1881-6096 (Print)
IS  - 1881-6096 (Linking)
VI  - 72
IP  - 7
DP  - 2020 Jul
TI  - [What is the Medical Professionalism for Japanese Clinical Neurologists?]
PG  - 667-675
LID - 10.11477/mf.1416201584 [doi]
AB  - Fundamental principles of medical ethics or medical professionalism in Western
      countries greatly influence our country, particularly in the field of medical
      education. Talent/ competency of physicians, included in the multiple domains of 
      medical professionalism, is now employed as an outcome measure of medical
      education. In this review, I would like to discuss what is the most essential
      issue of medical professionalism and medical education for Japanese clinical
      neurologists and what philosophy we should hand over to our successors. Among
      various elemental factors in medical professionalism, I regard "empathy" as the
      most important, which empowers patients and their families.
FAU - Nishizawa, Masatoyo
AU  - Nishizawa M
AD  - Niigata University of Health and Welfare.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Brain Nerve
JT  - Brain and nerve = Shinkei kenkyu no shinpo
JID - 101299709
SB  - IM
MH  - *Education, Medical
MH  - Ethics, Medical
MH  - Humans
MH  - Japan
MH  - *Neurologists
MH  - *Professionalism
EDAT- 2020/07/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 1416201584 [pii]
AID - 10.11477/mf.1416201584 [doi]
PST - ppublish
SO  - Brain Nerve. 2020 Jul;72(7):667-675. doi: 10.11477/mf.1416201584.


PMID- 32641369
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 7
TI  - Prevalence of acute liver injury and hypertransaminemia in patients with
      COVID-19: a protocol for a systematic review.
PG  - e040517
LID - 10.1136/bmjopen-2020-040517 [doi]
AB  - INTRODUCTION: COVID-19 has spread rapidly in China and around the world.
      Published studies have revealed that some patients with COVID-19 had abnormal
      liver function in laboratory tests. However, the results were inconsistent and
      the analysis of epidemiological data stratified by the severity of COVID-19 was
      not available in previous meta-analyses. Furthermore, these meta-analyses were
      suspected of overestimating the incidence of liver injury in patients with
      COVID-19 because some studies considered transaminase elevation as liver injury, 
      which might partially result from cardiac and muscle injury. This systematic
      review aims to enrol published literatures related to COVID-19 without language
      restriction, analyse the data based on the severity of the COVID-19 and explore
      the impact of varied definitions of liver injury on the incidence of liver
      injury. METHODS AND ANALYSIS: We have conducted a preliminary search on PubMed
      and Excerpta Medica Database on 13 April 2020, for the studies published after
      December 2019 on the prevalence of acute liver injury and hypertransaminemia in
      patients with COVID-19. Two reviewers will independently screen studies, extract 
      data and assess the risk of bias. We will estimate the pooled incidence of
      hypertransaminemia and acute liver injury in patients with COVID-19 by using the 
      random-effects model. The I((2)) test will be used to identify the extent of
      heterogeneity. Publication bias will be assessed by funnel plot and performing
      the Begg's and Egger's test if adequate studies are available. We will perform a 
      risk of bias assessment using the Joanna Briggs Institute's critical appraisal
      checklist. ETHICS AND DISSEMINATION: Since this study will be based on the
      published data, it does not require ethical approval. The final results of this
      study will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42020179462.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Gang
AU  - Li G
AUID- ORCID: 0000-0003-3601-3914
AD  - Department of General Surgery, Peking University Third Hospital, Beijing, China.
FAU - Xu, Yongxing
AU  - Xu Y
AUID- ORCID: 0000-0003-1216-235X
AD  - Department of Nephrology, PLA Strategic Support Force Characteristic Medical
      Center, Beijing, China.
FAU - Yang, Yi Tian
AU  - Yang YT
AD  - Department of Anesthesiology and Perioperative Medicine, Henan Provincial
      People's Hospital, Zhengzhou, Henan, China yangyitiansdu@126.com sfflpf@126.com.
FAU - Liu, Peng Fei
AU  - Liu PF
AUID- ORCID: 0000-0001-8098-8925
AD  - Department of Anesthesiology, Capital Medical University Affiliated Beijing
      Shijitan Hospital, Beijing, China yangyitiansdu@126.com sfflpf@126.com.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200707
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Acute Disease
MH  - Alanine Transaminase/blood
MH  - Alkaline Phosphatase/blood
MH  - Aspartate Aminotransferases/blood
MH  - Betacoronavirus
MH  - Bilirubin/blood
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Liver Diseases/blood/*epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Prevalence
MH  - SARS-CoV-2
PMC - PMC7342854
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - bmjopen-2020-040517 [pii]
AID - 10.1136/bmjopen-2020-040517 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 7;10(7):e040517. doi: 10.1136/bmjopen-2020-040517.


PMID- 32641367
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 7
TI  - Connectivity guided theta burst transcranial magnetic stimulation versus
      repetitive transcranial magnetic stimulation for treatment-resistant moderate to 
      severe depression: study protocol for a randomised double-blind controlled trial 
      (BRIGhTMIND).
PG  - e038430
LID - 10.1136/bmjopen-2020-038430 [doi]
AB  - INTRODUCTION: The BRIGhTMIND study aims to determine the clinical effectiveness, 
      cost-effectiveness and mechanism of action of connectivity guided intermittent
      theta burst stimulation (cgiTBS) versus standard repetitive transcranial magnetic
      stimulation (rTMS) in adults with moderate to severe treatment resistant
      depression. METHODS AND ANALYSIS: The study is a randomised double-blind
      controlled trial with 1:1 allocation to either 20 sessions of (1) cgiTBS or (2)
      neuronavigated rTMS not using connectivity guidance. A total of 368 eligible
      participants with a diagnosis of current unipolar major depressive disorder that 
      is both treatment resistant (defined as scoring 2 or more on the Massachusetts
      General Hospital Staging Score) and moderate to severe (scoring >16 on the
      17-item Hamilton Depression Rating Scale (HDRS-17)), will be recruited from
      primary and secondary care settings at four treatment centres in the UK. The
      primary outcome is depression response at 16 weeks (50% or greater reduction in
      HDRS-17 score from baseline). Secondary outcomes include assessments of
      self-rated depression, anxiety, psychosocial functioning, cognition and quality
      of life at 8, 16 and 26 weeks postrandomisation. Cost-effectiveness, patient
      acceptability, safety, mechanism of action and predictors of response will also
      be examined. ETHICS AND DISSEMINATION: Ethical approval was granted by East
      Midlands Leicester Central Research Ethics Committee (ref: 18/EM/0232) on 30
      August 2018. The results of the study will be published in relevant peer-reviewed
      journals, and then through professional and public conferences and media. Further
      publications will explore patient experience, moderators and mediators of outcome
      and mechanism of action. TRIAL REGISTRATION NUMBER: ISRCTN19674644.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Morriss, Richard
AU  - Morriss R
AUID- ORCID: 0000-0003-2910-4121
AD  - Psychiatry, University of Nottingham, Nottingham, UK
      richard.morriss@nottingham.ac.uk.
FAU - Webster, Lucy
AU  - Webster L
AD  - Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, Nottingham, UK.
FAU - Abdelghani, Mohamed
AU  - Abdelghani M
AD  - Camden and Islington NHS Foundation Trust, London, London, UK.
FAU - Auer, Dorothee P
AU  - Auer DP
AD  - Arthritis Research UK Pain Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
AD  - Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK.
FAU - Barber, Shaun
AU  - Barber S
AD  - University of Leicester, Leicester, Leicestershire, UK.
FAU - Bates, Peter
AU  - Bates P
AD  - Nottingham, UK.
FAU - Blamire, Andrew
AU  - Blamire A
AD  - University of Newcastle upon Tyne, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - Briley, Paul M
AU  - Briley PM
AD  - University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Brookes, Cassandra
AU  - Brookes C
AD  - Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.
FAU - Iwabuchi, Sarina
AU  - Iwabuchi S
AD  - University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - James, Marilyn
AU  - James M
AD  - School of Medicine, University of Nottingham, nottingham, UK.
FAU - Kaylor-Hughes, Catherine
AU  - Kaylor-Hughes C
AD  - University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Lankappa, Sudheer
AU  - Lankappa S
AD  - Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, Nottingham, UK.
FAU - Liddle, Peter
AU  - Liddle P
AD  - University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - McAllister-Williams, Hamish
AU  - McAllister-Williams H
AD  - University of Newcastle upon Tyne, Newcastle upon Tyne, Tyne and Wear, UK.
FAU - O'Neill-Kerr, Alex
AU  - O'Neill-Kerr A
AD  - Northamptonshire Healthcare NHS Foundation Trust, Kettering, Northamptonshire,
      UK.
FAU - Pszczolkowski Parraguez, Stefan
AU  - Pszczolkowski Parraguez S
AD  - Precision Imaging Beacon, University of Nottingham, Nottingham, UK.
FAU - Suazo Di Paola, Ana
AU  - Suazo Di Paola A
AD  - Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.
FAU - Thomson, Louise
AU  - Thomson L
AD  - Psychiatry, University of Nottingham, Nottingham, UK.
FAU - Walters, Yvette
AU  - Walters Y
AD  - Leicester Clinical Trials Unit, University of Leicester, Leicester, UK.
CN  - BRIGhTMIND study team
LA  - eng
SI  - ISRCTN/ISRCTN19674644
GR  - 16/44/22/DH_/Department of Health/United Kingdom
GR  - MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200707
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Depression
MH  - *Depressive Disorder, Major/therapy
MH  - *Depressive Disorder, Treatment-Resistant/therapy
MH  - Double-Blind Method
MH  - Humans
MH  - Massachusetts
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Transcranial Magnetic Stimulation
MH  - Treatment Outcome
PMC - PMC7342821
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *clinical trials
OT  - *depression & mood disorders
OT  - *health economics
OT  - *magnetic resonance imaging
COIS- Competing interests: AO-K has received fees for consultancy with Magstim.
IR  - Bastick L
FIR - Bastick, Lorraine
IR  - Carr R
FIR - Carr, Rosie
IR  - Cartlidge A
FIR - Cartlidge, Alison
IR  - Clark H
FIR - Clark, Harry
IR  - Cottam W
FIR - Cottam, William
IR  - Vai R
FIR - Vai, Robert De
IR  - Davison L
FIR - Davison, Linda
IR  - Gledhill J
FIR - Gledhill, John
IR  - Gregory A
FIR - Gregory, Adele
IR  - Griffiths C
FIR - Griffiths, Christopher
IR  - Hamilton A
FIR - Hamilton, Andrew
IR  - Harding D
FIR - Harding, Delilah
IR  - Heath K
FIR - Heath, Kelly
IR  - Hobson R
FIR - Hobson, Rachel
IR  - Ireoluwa G
FIR - Ireoluwa, Gbeminiyi
IR  - Khalifa N
FIR - Khalifa, Najat
IR  - Johnstone K
FIR - Johnstone, Kate
IR  - Kirkland C
FIR - Kirkland, Charlotte
IR  - Liddle M
FIR - Liddle, Mark
IR  - Lynch J
FIR - Lynch, Jessica
IR  - Nixon N
FIR - Nixon, Neil
IR  - Parikh J
FIR - Parikh, Jehill
IR  - Reid I
FIR - Reid, Isabel
IR  - Reiner N
FIR - Reiner, Noemi
IR  - Simpson S
FIR - Simpson, Sandra
IR  - Smith B
FIR - Smith, Beverley
IR  - Sore T
FIR - Sore, Tina
IR  - Stone J
FIR - Stone, Joseph
IR  - Taylorson C
FIR - Taylorson, Carly
IR  - Toney R
FIR - Toney, Rebecca
IR  - Turner C
FIR - Turner, Claire
IR  - Wilkinson S
FIR - Wilkinson, Sarah
IR  - Willis A
FIR - Willis, Andy
IR  - Willis T
FIR - Willis, Tom
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038430 [pii]
AID - 10.1136/bmjopen-2020-038430 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 7;10(7):e038430. doi: 10.1136/bmjopen-2020-038430.


PMID- 32641362
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 7
TI  - Role of optimism in adolescent mental health: a protocol for a systematic review.
PG  - e036177
LID - 10.1136/bmjopen-2019-036177 [doi]
AB  - INTRODUCTION: Adolescence is a critical period of human development, where
      adaptive or maladaptive experiences can happen. These experiences are associated 
      with psychological, social, biological and health factors. Previous empirical
      evidence suggests that mental health is associated with individual assets and
      positive states, whose presence may become a factor of protection and resistance 
      to mental disorders. Among these, optimism could play a fundamental role in
      sustaining physical and mental well-being and in dealing with threats potentially
      harmful to health. Given the rise of research on optimism and its importance in
      the various health outcomes, it is necessary to initiate processes of compilation
      and synthesis of this evidence to facilitate the understanding of the importance 
      of this variable on the mental health of adolescents. METHODS AND ANALYSIS: The
      included studies will be experimental, observational, cross-sectional and
      longitudinal focussed on the role of optimism on mental health in adolescents,
      regardless of whether they belong to clinical or non-clinical populations. This
      systematic review protocol will be carried out following the Cochrane Manual for 
      systematic reviews and will follow the statement on systematic reviews and
      meta-analysis of PRISMA-P (Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses Protocols). Searches will run from October 2019 to March 2020, and 
      will be carried out from the following electronic databases: APA PsycNet, BVS
      (Biblioteca Virtual em Saude), Web of Science, PubMed Central and Scopus. Two
      reviewers will obtain the eligible articles, published from January 2009 onward, 
      to assess the quality of each study and extract the data. For the presentation of
      the results, a narrative and quantitative synthesis will be carried out that
      groups the data found. ETHICS AND DISSEMINATION: The approval of an ethics
      committee is not required for a systematic review protocol. The results will be
      presented at congresses in social sciences and psychology and will be published
      in a peer-reviewed social or health science journal. PROSPERO REGISTRATION
      NUMBER: PROSPERO CRD42019142616.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rincon Uribe, Fabio Alexis
AU  - Rincon Uribe FA
AUID- ORCID: 0000-0001-9764-2429
AD  - Pos-Graduacao em Psicologia, Universidade Federal do Para, Belem, Para, Brazil
      faru1095@gmail.com.
FAU - Espejo, Cristian Ariel Neira
AU  - Espejo CAN
AUID- ORCID: 0000-0002-3565-9038
AD  - Programa de Pos-Graduacao em Teoria e Pesquisa do Comportamento, Universidade
      Federal do Para, Belem, Para, Brazil.
FAU - Pedroso, Janari da Silva
AU  - Pedroso JDS
AUID- ORCID: 0000-0001-7602-834X
AD  - Programa de Pos-Graduacao em Teoria e Pesquisa do Comportamento, Universidade
      Federal do Para, Belem, Para, Brazil.
AD  - Bolsista produtividade CNPq - Nivel 2. Programa de Pos-graduacao em Psicologia,
      Universidade Federal do Para, Belem, Para, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200707
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health
MH  - Humans
MH  - *Mental Health
MH  - Optimism/*psychology
MH  - *Psychology, Adolescent
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7342466
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *mental health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036177 [pii]
AID - 10.1136/bmjopen-2019-036177 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 7;10(7):e036177. doi: 10.1136/bmjopen-2019-036177.


PMID- 32641343
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20201210
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Intravenous high-dose vitamin C for the treatment of severe COVID-19: study
      protocol for a multicentre randomised controlled trial.
PG  - e039519
LID - 10.1136/bmjopen-2020-039519 [doi]
AB  - INTRODUCTION: The rapid worldwide spread of COVID-19 has caused a global health
      crisis. To date, symptomatic supportive care has been the most common treatment. 
      It has been reported that the mechanism of COVID-19 is related to cytokine storms
      and subsequent immunogenic damage, especially damage to the endothelium and
      alveolar membrane. Vitamin C (VC), also known as L-ascorbic acid, has been shown 
      to have antimicrobial and immunomodulatory properties. A high dose of intravenous
      VC (HIVC) was proven to block several key components of cytokine storms, and HIVC
      showed safety and varying degrees of efficacy in clinical trials conducted on
      patients with bacterial-induced sepsis and acute respiratory distress syndrome
      (ARDS). Therefore, we hypothesise that HIVC could be added to the treatment of
      ARDS and multiorgan dysfunction related to COVID-19. METHODS AND ANALYSIS: The
      investigators designed a multicentre prospective randomised placebo-controlled
      trial that is planned to recruit 308 adults diagnosed with COVID-19 and
      transferred into the intensive care unit. Participants will randomly receive HIVC
      diluted in sterile water or placebo for 7 days once enrolled. Patients with a
      history of VC allergy, end-stage pulmonary disease, advanced malignancy or
      glucose-6-phosphate dehydrogenase deficiency will be excluded. The primary
      outcome is ventilation-free days within 28 observational days. This is one of the
      first clinical trials applying HIVC to treat COVID-19, and it will provide
      credible efficacy and safety data. We predict that HIVC could suppress cytokine
      storms caused by COVID-19, help improve pulmonary function and reduce the risk of
      ARDS of COVID-19. ETHICS AND DISSEMINATION: The study protocol was approved by
      the Ethics Committee of Zhongnan Hospital of Wuhan University (identifiers:
      Clinical Ethical Approval No. 2020001). Findings of the trial will be
      disseminated through peer-reviewed journals and scientific conferences. TRIAL
      REGISTRATION NUMBER: NCT04264533.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liu, Fang
AU  - Liu F
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University,
      Wuhan, Hubei, China.
FAU - Zhu, Yuan
AU  - Zhu Y
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University,
      Wuhan, Hubei, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University,
      Wuhan, Hubei, China.
FAU - Li, Yiming
AU  - Li Y
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University,
      Wuhan, Hubei, China.
FAU - Peng, Zhiyong
AU  - Peng Z
AUID- ORCID: 0000-0002-0849-5648
AD  - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University,
      Wuhan, Hubei, China Pengzy5@hotmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04264533
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vitamins)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Administration, Intravenous
MH  - Ascorbic Acid/*administration & dosage
MH  - Betacoronavirus
MH  - COVID-19
MH  - China
MH  - Coronavirus Infections/complications/*drug therapy/immunology
MH  - Cytokine Release Syndrome/*drug therapy/etiology/immunology
MH  - Hospital Mortality
MH  - Humans
MH  - Intensive Care Units
MH  - Pandemics
MH  - Pneumonia, Viral/complications/*drug therapy/immunology
MH  - Respiration, Artificial
MH  - SARS-CoV-2
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Vitamins/*administration & dosage
PMC - PMC7348463
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *clinical trials
OT  - *infectious diseases
OT  - *respiratory infections
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - bmjopen-2020-039519 [pii]
AID - 10.1136/bmjopen-2020-039519 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e039519. doi: 10.1136/bmjopen-2020-039519.


PMID- 32641342
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Are we advancing universal health coverage through cataract services? Protocol
      for a scoping review.
PG  - e039458
LID - 10.1136/bmjopen-2020-039458 [doi]
AB  - INTRODUCTION: Universal health coverage (UHC) includes the dimensions of equity
      in access, quality services that improve health and protection against financial 
      hardship. Cataract continues to be the leading cause of blindness globally,
      despite cataract surgery being an efficacious intervention. The aim of this
      scoping review is to map the nature, extent and global distribution of data on
      cataract services for UHC in terms of equity, access, quality and financial
      protection. METHODS AND ANALYSIS: The search will be constructed by an
      Information Specialist and undertaken in MEDLINE, Embase and Global Health
      databases. We will include all published non-interventional primary research
      studies and systematic reviews that report a quantitative assessment of access,
      equity, quality or financial protection of cataract surgical services for adults 
      at the subnational, national, regional or global level from population-based
      surveys or routinely collected health service data since 1 January 2000 and
      published through to February 2020.Screening and data charting will be undertaken
      using Covidence systematic review software. Titles and abstracts of identified
      studies will be screened by two authors independently. Full-text articles of
      potentially relevant studies will be obtained and reviewed independently by two
      authors against the inclusion criteria. Any discrepancies between the authors
      will be resolved by discussion, and with a third author as necessary. A data
      charting form will be developed and piloted on three studies by three authors and
      amendments made as necessary. Data will be extracted by two reviewers
      independently and summarised narratively and using maps. ETHICS AND
      DISSEMINATION: Ethical approval was not sought as the scoping review will only
      use published and publicly accessible data. The review will be published in an
      open access peer-reviewed journal. A summary of the results will be developed for
      website posting, stakeholder meetings and inclusion in the ongoing Lancet Global 
      Health Commission on Global Eye Health.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Lee, Chan Ning
AU  - Lee CN
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
AD  - St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United
      Kingdom.
FAU - Ramke, Jacqueline
AU  - Ramke J
AUID- ORCID: 0000-0002-5764-1306
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom jacqueline.ramke@lshtm.ac.uk.
AD  - School of Optometry and Vision Science, University of Auckland, Auckland, New
      Zealand.
FAU - McCormick, Ian
AU  - McCormick I
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
FAU - Zhang, Justine H
AU  - Zhang JH
AUID- ORCID: 0000-0001-8385-2003
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
AD  - Manchester Royal Eye Hospital, Manchester, United Kingdom.
FAU - Aghaji, Ada
AU  - Aghaji A
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
AD  - Department of Opthalmology, University of Nigeria, Enugu, Nigeria.
FAU - Mwangi, Nyawira
AU  - Mwangi N
AUID- ORCID: 0000-0002-8236-470X
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
AD  - Department of Clinical Medicine, Kenya Medical Training College, Nairobi, Kenya.
FAU - Burn, Helen
AU  - Burn H
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
AD  - Department of Ophthalmology, Stoke Mandeville Hospital, Aylesbury, United
      Kingdom.
FAU - Gordon, Iris
AU  - Gordon I
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
FAU - Yusufu, Mayinuer
AU  - Yusufu M
AD  - Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren
      Hospital, Capital Medical University, Beijing, China.
FAU - He, Mingguang
AU  - He M
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, Guangdong, China.
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Silva, Juan Carlos
AU  - Silva JC
AD  - Division of Blindness Prevention, Pan American Health Organization, Bogota,
      Colombia.
FAU - Burton, Matthew J
AU  - Burton MJ
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, United Kingdom.
AD  - Moorfields Eye Hospital, London, United Kingdom.
LA  - eng
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cataract
MH  - Delivery of Health Care
MH  - Global Health
MH  - Humans
MH  - Review Literature as Topic
MH  - *Universal Health Insurance
PMC - PMC7348466
OTO - NOTNLM
OT  - *adult surgery
OT  - *cataract and refractive surgery
OT  - *epidemiology
OT  - *ophthalmology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-039458 [pii]
AID - 10.1136/bmjopen-2020-039458 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e039458. doi: 10.1136/bmjopen-2020-039458.


PMID- 32641340
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Impact of carbohydrate-reduced nutrition in septic patients on ICU: study
      protocol for a prospective randomised controlled trial.
PG  - e038532
LID - 10.1136/bmjopen-2020-038532 [doi]
AB  - INTRODUCTION: Sepsis is defined as detrimental immune response to an infection.
      This overwhelming reaction often abolishes a normal reconstitution of the immune 
      cell homeostasis that in turn increases the risk for further complications.
      Recent studies revealed a favourable impact of ketone bodies on resolution of
      inflammation. Thus, a ketogenic diet may provide an easy-to-apply and
      cost-effective treatment option potentially alleviating sepsis-evoked harm. This 
      study is designed to assess the feasibility, efficiency and safety of a ketogenic
      diet in septic patients. METHODS AND ANALYSIS: This monocentric study is a
      randomised, controlled and open-label trial, which is conducted on an intensive
      care unit of a German university hospital. As intervention enteral nutrition with
      reduced amount of carbohydrates (ketogenic) or standard enteral nutrition
      (control) is applied. The primary endpoint is the detection of ketone bodies in
      patients' blood and urine samples. As secondary endpoints, the impact on
      important safety-relevant issues (eg, glucose metabolism, lactate serum
      concentration, incidence of metabolic acidosis, thyroid function and 30-day
      mortality) and the effect on the immune system are analysed. ETHICS AND
      DISSEMINATION: The study has received the following approvals: Ethics Committee
      of the Medical Faculty of Ruhr-University Bochum (No. 18-6557-BR). Results will
      be made available to critical care survivors, their caregivers, the funders, the 
      critical care societies and other researchers by publication in a peer-reviewed
      journal. TRIAL REGISTRATION NUMBERS: German Clinical Trial Register
      (DRKS00017710); Universal Trial Number (U1111-1237-2493).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rahmel, Tim
AU  - Rahmel T
AUID- ORCID: 0000-0002-7039-6288
AD  - Klinik fur Anasthesiologie, Intensivmedizin und Schmerztherapie,
      Universitatsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany
      tim.rahmel@ruhr-uni-bochum.de.
FAU - Hubner, Max
AU  - Hubner M
AD  - Faculty of Medicine - LMU, Walter-Brendel Center of Experimental Medicine,
      Munchen, Germany.
FAU - Koos, Bjorn
AU  - Koos B
AD  - Klinik fur Anasthesiologie, Intensivmedizin und Schmerztherapie,
      Universitatsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.
FAU - Wolf, Alexander
AU  - Wolf A
AD  - Klinik fur Anasthesiologie, Intensivmedizin und Schmerztherapie,
      Universitatsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.
FAU - Willemsen, Katrin-Maria
AU  - Willemsen KM
AD  - Klinik fur Anasthesiologie, Intensivmedizin und Schmerztherapie,
      Universitatsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.
FAU - Strauss, Gabriele
AU  - Strauss G
AD  - Faculty of Medicine - LMU, Walter-Brendel Center of Experimental Medicine,
      Munchen, Germany.
FAU - Effinger, David
AU  - Effinger D
AD  - Faculty of Medicine - LMU, Walter-Brendel Center of Experimental Medicine,
      Munchen, Germany.
FAU - Adamzik, Michael
AU  - Adamzik M
AD  - Klinik fur Anasthesiologie, Intensivmedizin und Schmerztherapie,
      Universitatsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.
FAU - Kreth, Simone
AU  - Kreth S
AD  - Faculty of Medicine - LMU, Walter-Brendel Center of Experimental Medicine,
      Munchen, Germany.
LA  - eng
SI  - DRKS/DRKS00017710
SI  - UMIN-CTR/U1111-1237-2493
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Carbohydrates)
SB  - IM
MH  - Carbohydrates
MH  - Critical Care
MH  - Humans
MH  - *Intensive Care Units
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - *Sepsis/therapy
PMC - PMC7348645
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *immunology
OT  - *intensive & critical care
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038532 [pii]
AID - 10.1136/bmjopen-2020-038532 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e038532. doi: 10.1136/bmjopen-2020-038532.


PMID- 32641337
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - FitSkills: protocol for a stepped wedge cluster randomised trial of a
      community-based exercise programme to increase participation among young people
      with disability.
PG  - e037153
LID - 10.1136/bmjopen-2020-037153 [doi]
AB  - INTRODUCTION: There is a need to develop relevant, acceptable initiatives that
      facilitate physical activity participation in young people with disability.
      FitSkills was developed to support young people with disability to exercise. The 
      primary aims are to investigate if FitSkills can be scaled up from a small,
      university-led programme to run as a larger community-university partnership
      programme, and to determine its effectiveness in improving physical activity
      participation and health-related quality of life for young people with
      disability. The secondary aims are to evaluate cost-effectiveness, changes in
      attitudes towards disability and other health-related outcomes for young people
      with disability. METHODS AND ANALYSIS: A stepped wedge cluster randomised trial
      using a cohort design and embedded health economic evaluation will compare the
      effect of FitSkills with a control phase. FitSkills matches a young person with
      disability with a student mentor and the pair exercise together at their local
      gymnasium for 1 hour, two times per week for 12 weeks (24 sessions in total). One
      hundred and sixty young people with disability aged 13 to 30 years will be
      recruited. Eight community gymnasia will be recruited and randomised into four
      cluster units to have FitSkills introduced at 3-month intervals. Primary
      (feasibility, participation and health-related quality of life) and secondary
      outcomes will be collected longitudinally every 3 months from trial commencement,
      with eight data collection time points in total. The Practical Robust
      Implementation and Sustainability Model will be used to support knowledge
      translation and implementation of project findings into policy and practice.
      ETHICS AND DISSEMINATION: Ethical approval was obtained from the La Trobe
      University Human Ethics Committee (HEC17-012), Australian Catholic University
      (2017-63R), Deakin University (2017-206) and the Victorian Department of
      Education and Training (2018_003616). Results will be disseminated through
      published manuscripts, conference presentations, public seminars and practical
      resources for stakeholder groups. TRIAL REGISTRATION NUMBER: ACTRN12617000766314.
      TRIAL SPONSOR: La Trobe University.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shields, Nora
AU  - Shields N
AUID- ORCID: 0000-0002-6840-2378
AD  - Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe
      University, Melbourne, VIC, Australia n.shields@latrobe.edu.au.
FAU - Willis, Claire
AU  - Willis C
AUID- ORCID: 0000-0002-3794-2902
AD  - Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe
      University, Melbourne, VIC, Australia.
FAU - Imms, Christine
AU  - Imms C
AUID- ORCID: 0000-0001-9055-3554
AD  - Centre for Disability and Development Research, Australian Catholic University,
      Melbourne, VIC, Australia.
FAU - Prendergast, Luke A
AU  - Prendergast LA
AUID- ORCID: 0000-0002-9122-5429
AD  - Department of Mathematics and Statistics, La Trobe University, Melbourne, VIC,
      Australia.
FAU - Watts, Jennifer J
AU  - Watts JJ
AUID- ORCID: 0000-0001-8095-8638
AD  - School of Health and Social Development, Faculty of Health, Deakin University,
      Burwood, Victoria, Australia.
FAU - van Dorsselaer, Ben
AU  - van Dorsselaer B
AD  - Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe
      University, Melbourne, VIC, Australia.
FAU - McKenzie, Georgia
AU  - McKenzie G
AD  - Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe
      University, Melbourne, VIC, Australia.
FAU - Bruder, Andrea M
AU  - Bruder AM
AUID- ORCID: 0000-0001-5422-5756
AD  - Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe
      University, Melbourne, VIC, Australia.
FAU - Taylor, Nicholas F
AU  - Taylor NF
AUID- ORCID: 0000-0001-9474-2504
AD  - Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, La Trobe
      University, Melbourne, VIC, Australia.
AD  - Allied Health Clinical Research Office, Eastern Health, Melbourne, VIC,
      Australia.
CN  - FitSkills Partnership Project Group
CN  - FitSkills partnership project group
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - *Disabled Persons
MH  - Exercise
MH  - Exercise Therapy
MH  - Humans
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Young Adult
PMC - PMC7348474
OTO - NOTNLM
OT  - *clinical trials
OT  - *community child health
OT  - *developmental neurology & neurodisability
OT  - *public health
COIS- Competing interests: None declared.
IR  - Prendergast L
FIR - Prendergast, Luke
IR  - Calleja J
FIR - Calleja, Jason
IR  - Strickland D
FIR - Strickland, David
IR  - Stephenson S
FIR - Stephenson, Shawn
IR  - Walker MP
FIR - Walker, Michael P
IR  - Robbins J
FIR - Robbins, Justine
IR  - Barkley M
FIR - Barkley, Melissa
IR  - Geddes C
FIR - Geddes, Cameron
IR  - Lee S
FIR - Lee, Shane
IR  - Amon R
FIR - Amon, Richard
IR  - Ryan J
FIR - Ryan, Juliet
IR  - Shaw A
FIR - Shaw, Ayden
IR  - Power S
FIR - Power, Simone
IR  - McCabe R
FIR - McCabe, Rebecca
IR  - Cheal S
FIR - Cheal, Shannon
IR  - Cavelieros V
FIR - Cavelieros, Vicki
IR  - Fraumano D
FIR - Fraumano, Debby
IR  - Blandford S
FIR - Blandford, Sue
IR  - Bain L
FIR - Bain, Lucy
IR  - Bonadio S
FIR - Bonadio, Sonia
IR  - O'Riley S
FIR - O'Riley, Sue
IR  - Roberts B
FIR - Roberts, Bernadette
IR  - Summers J
FIR - Summers, John
IR  - Walker T
FIR - Walker, Troy
IR  - Kriaris F
FIR - Kriaris, Fiona
IR  - Taylor S
FIR - Taylor, Sam
IR  - Scanlan T
FIR - Scanlan, Tom
IR  - Elliot A
FIR - Elliot, Abigail
IR  - O'Brien L
FIR - O'Brien, Lachlan
IR  - Smith J
FIR - Smith, Jenni
IR  - Willis C
FIR - Willis, Claire
IR  - Cleary S
FIR - Cleary, Stacey
IR  - Adair B
FIR - Adair, Brooke
IR  - Moore M
FIR - Moore, Melissa
IR  - Kuek J
FIR - Kuek, Jess
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037153 [pii]
AID - 10.1136/bmjopen-2020-037153 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e037153. doi: 10.1136/bmjopen-2020-037153.


PMID- 32641335
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Integrated strategies to prevent intradialytic hypotension: research protocol of 
      the DialHypot study, a prospective randomised clinical trial in hypotension-prone
      haemodialysis patients.
PG  - e036893
LID - 10.1136/bmjopen-2020-036893 [doi]
AB  - INTRODUCTION: In patients on maintenance haemodialysis (HD), intradialytic
      hypotension (IDH) is a clinical problem that nephrologists and dialysis nurses
      face daily in their clinical routine. Despite the technological advances in the
      field of HD, the incidence of hypotensive events occurring during a standard
      dialytic treatment is still very high. Frequently recurring hypotensive episodes 
      during HD sessions expose patients not only to severe immediate complications but
      also to a higher mortality risk in the medium term. Various strategies aimed at
      preventing IDH are currently available, but there is lack of conclusive data on
      more integrated approaches combining different interventions. METHODS AND
      ANALYSIS: This is a prospective, randomised, open-label, crossover trial (each
      subject will be used as his/her own control) that will be performed in two
      distinct phases, each of which is divided into several subphases. In the first
      phase, 27 HD sessions for each patient will be used, and will be aimed at the
      validation of a new ultrafiltration (UF) profile, designed with an
      ascending/descending shape, and a standard dialysate sodium concentration. In the
      second phase, 33 HD sessions for each patient will be used and will be aimed at
      evaluating the combination of different UF and sodium profiling strategies
      through individualised dialysate sodium concentration. ETHICS AND DISSEMINATION: 
      The trial protocol has been reviewed and approved by the local Institutional
      Ethics Committee (Comitato Etico AVEN, prot. 43391 22.10.19). The results of the 
      trial will be presented at local and international conferences and submitted for 
      publication to a peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      ClinicalTrials.gov Registry (NCT03949088).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Peyronel, Francesco
AU  - Peyronel F
AUID- ORCID: 0000-0001-8470-1952
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy francesco.peyronel@gmail.com.
AD  - Scuola di Specializzazione in Nefrologia, Universita degli Studi di Parma
      Dipartimento di Medicina e Chirurgia, Parma, Emilia-Romagna, Italy.
FAU - Parenti, Elisabetta
AU  - Parenti E
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
FAU - Fenaroli, Paride
AU  - Fenaroli P
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
AD  - Scuola di Specializzazione in Nefrologia, Universita degli Studi di Parma
      Dipartimento di Medicina e Chirurgia, Parma, Emilia-Romagna, Italy.
FAU - Benigno, Giuseppe Daniele
AU  - Benigno GD
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
AD  - Scuola di Specializzazione in Nefrologia, Universita degli Studi di Parma
      Dipartimento di Medicina e Chirurgia, Parma, Emilia-Romagna, Italy.
FAU - Rossi, Giovanni Maria
AU  - Rossi GM
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
FAU - Maggiore, Umberto
AU  - Maggiore U
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
AD  - Scuola di Specializzazione in Nefrologia, Universita degli Studi di Parma
      Dipartimento di Medicina e Chirurgia, Parma, Emilia-Romagna, Italy.
FAU - Fiaccadori, Enrico
AU  - Fiaccadori E
AD  - Unita Operativa di Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma,
      Emilia-Romagna, Italy.
AD  - Scuola di Specializzazione in Nefrologia, Universita degli Studi di Parma
      Dipartimento di Medicina e Chirurgia, Parma, Emilia-Romagna, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT03949088
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - *Hypotension/etiology/prevention & control
MH  - *Kidney Failure, Chronic
MH  - Male
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Renal Dialysis/adverse effects
MH  - Sodium
PMC - PMC7348655
OTO - NOTNLM
OT  - *chronic renal failure
OT  - *dialysis
OT  - *end stage renal failure
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036893 [pii]
AID - 10.1136/bmjopen-2020-036893 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036893. doi: 10.1136/bmjopen-2020-036893.


PMID- 32641334
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Improving Primary Care After Stroke (IPCAS) randomised controlled trial: protocol
      for a multidimensional process evaluation.
PG  - e036879
LID - 10.1136/bmjopen-2020-036879 [doi]
AB  - INTRODUCTION: Primary care interventions are often multicomponent, with several
      targets (eg, patients and healthcare professionals). Improving Primary Care After
      Stroke (IPCAS) is a novel primary care-based model of long-term stroke care
      involving a review of stroke-related needs, a self-management programme, a direct
      point of contact in general practice, enhanced communication between care
      services, and a directory of national and local community services, currently
      being evaluated in a cluster randomised controlled trial (RCT). Informed by
      Medical Research Council guidance for complex interventions and the Behaviour
      Change Consortium fidelity framework, this protocol outlines the process
      evaluation of IPCAS within this RCT. The process evaluation aimed to explore how 
      the intervention was delivered in context and how participants engaged with the
      intervention. METHODS AND ANALYSIS: Mixed methods will be used: (1) design:
      intervention content will be compared with 'usual care'; (2) training:
      intervention training sessions will be audio/video-recorded where feasible; (3)
      delivery: healthcare professional self-reports, audio recordings of intervention 
      delivery and observations of My Life After Stroke course (10% of reviews and
      sessions) will be coded separately; semistructured interviews will be conducted
      with a purposive sample of healthcare professionals; (4) receipt and (5)
      enactment: where available, structured stroke review records will be analysed
      quantitatively; semistructured interviews will be conducted with a purposive
      sample of study participants. Self-reports, observations and audio/video
      recordings will be coded and scored using specifically developed checklists.
      Semistructured interviews will be analysed thematically. Data will be analysed
      iteratively, independent of primary endpoint analysis. ETHICS AND DISSEMINATION: 
      Favourable ethical opinion was gained from Yorkshire & The Humber-Bradford Leeds 
      NHS Research Ethics Committee (19 December 2017, 17/YH/0441). Study results will 
      be published in a peer-reviewed journal and presented at relevant conferences.
      TRIAL REGISTRATION NUMBER: NCT03353519; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Aquino, Maria Raisa Jessica Ryc
AU  - Aquino MRJR
AUID- ORCID: 0000-0002-3989-1221
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK ra532@medschl.cam.ac.uk.
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      Tyne and Wear, UK.
FAU - Mullis, Ricky
AU  - Mullis R
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Kreit, Elizabeth
AU  - Kreit E
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Johnson, Vicki
AU  - Johnson V
AD  - Leicester Diabetes Centre, University Hospital Leicester NHS Trust, Leicester,
      UK.
FAU - Grant, Julie
AU  - Grant J
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Lim, Lisa
AU  - Lim L
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Sutton, Stephen
AU  - Sutton S
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Mant, Jonathan
AU  - Mant J
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03353519
GR  - PTC-RP-PG-0213-20001/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Primary Health Care
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Review Literature as Topic
MH  - Self Report
MH  - *Self-Management
MH  - *Stroke/therapy
PMC - PMC7348649
OTO - NOTNLM
OT  - *intervention fidelity
OT  - *primary care
OT  - *process evaluation
OT  - *protocol
OT  - *randomised controlled trial
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036879 [pii]
AID - 10.1136/bmjopen-2020-036879 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036879. doi: 10.1136/bmjopen-2020-036879.


PMID- 32641333
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Exercise versus fixed-dose combination therapy for cardiovascular risk factors
      control and atherosclerotic disease prevention: a network meta-analysis protocol.
PG  - e036734
LID - 10.1136/bmjopen-2019-036734 [doi]
AB  - INTRODUCTION: Despite the consistent evidence of the benefits of physical
      activity on preventing atherosclerotic cardiovascular diseases (ASCVD) and some
      cardiovascular risk factors, such as hypertension and dyslipidaemia, the
      prescription of drugs remains the most widely used approach to prevent ASCVD in
      clinical settings. The purpose of this study protocol is to provide a
      meta-synthesis methodology for comparing the effect of fixed-dose combination
      therapy and physical exercise on controlling cardiovascular risk factors and
      preventing ASCVD. METHODS AND ANALYSIS: This protocol follows the Preferred
      Reporting Items for Systematic Review and Meta-Analysis Protocols and the
      recommendations of the Cochrane Collaboration Handbook. We plan to conduct a
      computerised search in Medline, Web of Science, Embase, Cochrane Database of
      Systematic Reviews and SPORTDiscus from inception to May 2020 for studies testing
      the effectiveness of physical exercise or fixed-dose combination drug therapy in 
      preventing ASCVD, all-cause and cardiovascular mortality and controlling some
      cardiovascular risk factors (hypertension and dyslipidaemia). Since performing
      network meta-analyses (NMA) is a statistical approach that allows direct and
      indirect comparisons of interventions, where sufficient studies are included, we 
      plan to perform the following NMA comparing the effect of fixed-dose combination 
      therapy and physical exercise interventions on (1) improving lipid profile, (2)
      reducing blood pressure, (3) preventing cardiovascular events and all-cause and
      cardiovascular mortality and (4) improving compliance with the therapeutic
      strategy and reducing adverse events. ETHICS AND DISSEMINATION: Ethical approval 
      will not be needed because data included in the NMA will be extracted from
      published trials that meet accepted ethical standards. The results will be
      published in academic peer-reviewed journals, and the evidence gathered by this
      project could be included in the preventive cardiovascular disease guidelines.
      PROSPERO REGISTRATION NUMBER: CRD42019122794.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pozuelo-Carrascosa, Diana P
AU  - Pozuelo-Carrascosa DP
AUID- ORCID: 0000-0002-0527-5498
AD  - Social and Health Care Research Center, Universidad de Castilla-La Mancha,
      Cuenca, Spain.
AD  - Facultad de Fisioterapia y Enfermeria, Universidad de Castilla-La Mancha, Toledo,
      Spain.
AD  - Multidisciplinary Research Group in Care (IMCU), Universidad de Castilla-La
      Mancha, Toledo, Spain.
FAU - Cavero-Redondo, Ivan
AU  - Cavero-Redondo I
AD  - Social and Health Care Research Center, Universidad de Castilla-La Mancha,
      Cuenca, Spain Ivan.Cavero@uclm.es.
AD  - Universidad Politecnica y Artistica del Paraguay, Asuncion, Paraguay.
FAU - Fernandez Rodriguez, Ruben
AU  - Fernandez Rodriguez R
AD  - Movi-fitness S.L, Universidad de Castilla-La Mancha-Campus de Cuenca, Cuenca,
      Cuenca, Spain.
FAU - Pascual Morena, Carlos
AU  - Pascual Morena C
AD  - Social and Health Care Research Center, Universidad de Castilla-La Mancha,
      Cuenca, Spain.
FAU - Sequi-Dominguez, Irene
AU  - Sequi-Dominguez I
AD  - Social and Health Care Research Center, Universidad de Castilla-La Mancha,
      Cuenca, Spain.
FAU - Martinez-Vizcaino, Vicente
AU  - Martinez-Vizcaino V
AD  - Social and Health Care Research Center, Universidad de Castilla-La Mancha,
      Cuenca, Spain.
AD  - Faculty of Health Sciences, Universidad Autonoma de Chile-Sede Talca, Talca,
      Chile.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiovascular Diseases/prevention & control
MH  - Exercise
MH  - Heart Disease Risk Factors
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7348467
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *ischaemic heart disease
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036734 [pii]
AID - 10.1136/bmjopen-2019-036734 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036734. doi: 10.1136/bmjopen-2019-036734.


PMID- 32641332
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - HELP-VDL: study protocol for a multicentre, open, randomised, controlled clinical
      trial comparing the use of the head-elevated laryngoscopy position and the use of
      a videolaryngoscope to facilitate orotracheal intubation in a patient population 
      without predictable difficulty of intubation.
PG  - e036570
LID - 10.1136/bmjopen-2019-036570 [doi]
AB  - INTRODUCTION: Tracheal intubation remains an everyday challenge for
      anaesthesiologists, even in patients without suspected difficult airways. The
      ideal positioning of the patient's head (flat, raised a few centimetres on a
      cushion in the sniffing position (SP), or raised to achieve horizontal alignment 
      between the external acoustic meatus and the sternal angle) and the use of
      videolaryngoscopy remain controversial. This trial aims to compare the efficacy
      for orotracheal intubation of the SP or the head-elevated laryngoscopy position
      (HELP), which has been shown to improve laryngeal visualization and the
      intubation condition particularly in obese patients, in combination with a
      McGrath Mac videolaryngoscope whose video screen is either on or off (Video or
      NoVideo). METHODS AND ANALYSIS: The HELP-VDL factorial trial is a prospective,
      randomised, parallel, multicentre, open study of 240 adult patients undergoing
      tracheal intubation under general anaesthesia. Patients will be allocated into
      four groups: SP-NoVideo, HELP-NoVideo, SP-Video and HELP-Video. The primary
      outcome is the proportion of orotracheal intubations that requires the assistance
      of a nurse anaesthetist. The secondary outcomes include the intubation duration, 
      the first intubation success rate, the quality of visualisation of the glottis,
      the glottis visualisation score, adjunctive manoeuvres and alternative techniques
      used, the occurrence of oesophageal intubation, failure of tracheal intubation,
      the incidence of arterial oxygen desaturation, the perception of a difficult
      intubation, the score on the Intubation Difficulty Scale, cooperation among the
      members of the anaesthesia team, the evolution of vital signs and the frequency
      and severity of intubation complications. Data will be analysed on the
      intention-to-treat principle and a per-protocol basis. ETHICS AND DISSEMINATION: 
      Ethics approval was obtained from the Ethical Committee Ile de France V (Paris,
      France). Participant recruitment began on 3 July 2019. The results will be
      submitted for publication in peer-reviewed journals.Trial registration
      numberNCT03987009; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Le Guen, Morgan
AU  - Le Guen M
AD  - Department of Anesthesiology, Hopital Foch, Suresnes, Ile-de-France, France.
FAU - Coppere, Zoe
AU  - Coppere Z
AD  - Department of Anaesthesiology, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, Ile-de-France, France.
FAU - Dufour, Guillaume
AU  - Dufour G
AD  - Department of Anaesthesiology, Institut Mutualiste Montsouris, Paris,
      Ile-de-France, France.
FAU - Ouattara, Jonathan
AU  - Ouattara J
AD  - Department of Anaesthesiology, Groupe hospitalier Paris Saint-Joseph, Paris,
      Ile-de-France, France.
FAU - Trichereau, Julie
AU  - Trichereau J
AD  - Research Unit, Hopital Foch, Suresnes, Ile-de-France, France.
FAU - Fischler, Marc
AU  - Fischler M
AUID- ORCID: 0000-0003-0729-5430
AD  - Department of Anesthesiology, Hopital Foch, Suresnes, Ile-de-France, France
      m.fischler@orange.fr.
LA  - eng
SI  - ClinicalTrials.gov/NCT03987009
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - France
MH  - Humans
MH  - Intubation, Intratracheal
MH  - *Laryngoscopes
MH  - *Laryngoscopy
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Video Recording
PMC - PMC7348472
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *adult surgery
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036570 [pii]
AID - 10.1136/bmjopen-2019-036570 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036570. doi: 10.1136/bmjopen-2019-036570.


PMID- 32641330
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Interventions with Music in PECTus excavatum treatment (IMPECT trial): a study
      protocol for a randomised controlled trial investigating the clinical effects of 
      perioperative music interventions.
PG  - e036380
LID - 10.1136/bmjopen-2019-036380 [doi]
AB  - INTRODUCTION: Pectus excavatum repair is associated with substantial
      postoperative pain, despite the use of epidural analgesia and other analgesic
      regimens. Perioperative recorded music interventions have been shown to alleviate
      pain and anxiety in adults, but evidence for children and adolescents is still
      lacking. This study protocol describes a randomised controlled trial that
      evaluates the effects of recorded music interventions on postoperative pain
      relief in children and adolescents after pectus excavatum repair. METHODS: A
      multicentre randomised controlled trial was set up comparing the effects of
      perioperative recorded music interventions in addition to standard care with
      those of standard care only in patients undergoing a Nuss procedure for pectus
      excavatum repair. One hundred and seventy subjects (12-18 years of age) will be
      included in three centres in the Netherlands. Patient inclusion has started in
      November 2018, and is ongoing. The primary outcome is self-reported perceived
      pain measured on the visual analogue scale. Secondary outcomes are anxiety level,
      analgesics consumption, vital parameters such as heart rate, blood pressure and
      respiratory rate, length of hospital stay, postoperative complications, quality
      of life and cost-effectiveness. ETHICS AND DISSEMINATION: This study is being
      conducted in accordance with the Declaration of Helsinki. The Medical Ethics
      Review Board of Erasmus University Medical Centre Rotterdam, The Netherlands, has
      approved this protocol. Results will be disseminated via peer-reviewed scientific
      journals and conference presentations. TRIAL REGISTRATION NUMBER: NL6863.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Billar, Ryan J
AU  - Billar RJ
AUID- ORCID: 0000-0002-3624-8222
AD  - Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam,
      Zuid-Holland, The Netherlands r.billar@erasmusmc.nl.
FAU - Kuhlmann, A Y Rosalie
AU  - Kuhlmann AYR
AD  - Anaesthesiology, Saint Antonius Hospital, Nieuwegein, Utrecht, The Netherlands.
FAU - Schnater, J Marco
AU  - Schnater JM
AD  - Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Vlot, John
AU  - Vlot J
AD  - Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Tomas, Jeremy J P
AU  - Tomas JJP
AD  - Anaesthesiology, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, 
      The Netherlands.
FAU - Zijp, Gerda W
AU  - Zijp GW
AD  - Paediatric Surgery, Haga Hospital Juliana Children's Hospital, Den Haag,
      Zuid-Holland, The Netherlands.
FAU - Rad, Mandana
AU  - Rad M
AD  - Anaesthesiology, Haga Hospital Juliana Children's Hospital, Den Haag,
      Zuid-Holland, The Netherlands.
FAU - de Beer, Sjoerd A
AU  - de Beer SA
AD  - Paediatric Surgery, Emma Children's Hospital AMC, Amsterdam, North Holland, The
      Netherlands.
FAU - Stevens, Markus F
AU  - Stevens MF
AD  - Anaesthesiology, Emma Children's Hospital AMC, Amsterdam, North Holland, The
      Netherlands.
FAU - Poley, Marten J
AU  - Poley MJ
AD  - Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam,
      Zuid-Holland, The Netherlands.
AD  - Institute for Medical Technology Assessment, Erasmus University Rotterdam,
      Rotterdam, The Netherlands.
FAU - van Rosmalen, Joost
AU  - van Rosmalen J
AD  - Biostatistics, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.
FAU - Jeekel, Johannes F
AU  - Jeekel JF
AD  - Neuroscience, Erasmus MC, Rotterdam, The Netherlands.
FAU - Wijnen, Rene M H
AU  - Wijnen RMH
AD  - Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam,
      Zuid-Holland, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Analgesics, Opioid
MH  - Child
MH  - *Funnel Chest/surgery
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Music
MH  - *Music Therapy
MH  - Netherlands
MH  - Pain, Postoperative/prevention & control
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7348468
OTO - NOTNLM
OT  - *paediatric anaesthesia
OT  - *paediatric thoracic surgery
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036380 [pii]
AID - 10.1136/bmjopen-2019-036380 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036380. doi: 10.1136/bmjopen-2019-036380.


PMID- 32641329
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - A/C study protocol: a cross-sectional study of HIV epidemiology among African,
      Caribbean and Black people in Ontario.
PG  - e036259
LID - 10.1136/bmjopen-2019-036259 [doi]
AB  - INTRODUCTION: African, Caribbean and Black (ACB) communities are
      disproportionately infected by HIV in Ontario, Canada. They constitute only 5% of
      the population of Ontario yet account for 25% of new diagnoses of HIV. The aim of
      this study is to understand underlying factors that augment the HIV risk in ACB
      communities and to inform policy and practice in Ontario. METHODS AND ANALYSIS:
      We will conduct a cross-sectional study of first-generation and second-generation
      ACB adults aged 15-64 in Toronto (n=1000) and Ottawa (n=500) and collect data on 
      sociodemographic information, sexual behaviours, substance use, blood donation,
      access and use of health services and HIV-related care. We will use dried blood
      spot testing to determine the incidence and prevalence of HIV infection among ACB
      people, and link participant data to administrative databases to investigate
      health service access and use. Factors associated with key outcomes (HIV
      infection, testing behaviours, knowledge about HIV transmission and acquisition, 
      HIV vulnerability, access and use of health services) will be evaluated using
      generalised linear mixed models, adjusted for relevant covariates. ETHICS AND
      DISSEMINATION: This study has been reviewed and approved by the following
      Research Ethics Boards: Toronto Public Health, Ottawa Public Health, Laurentian
      University; the University of Ottawa and the University of Toronto. Our findings 
      will be disseminated as community reports, fact sheets, digital stories, oral and
      poster presentations, peer-reviewed manuscripts and social media.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AUID- ORCID: 0000-0001-5855-5461
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada mbuagblc@mcmaster.ca.
FAU - Tharao, Wangari
AU  - Tharao W
AD  - Women's Health in Women's Hands Community Health Centre, Toronto, Ontario,
      Canada.
FAU - Husbands, Winston
AU  - Husbands W
AD  - Ontario HIV Treatment Network, Toronto, Ontario, Canada.
FAU - Nelson, Laron E
AU  - Nelson LE
AD  - School of Nursing, Yale University, West Haven, Connecticut, USA.
FAU - Aden, Muna
AU  - Aden M
AD  - Women's Health in Women's Hands Community Health Centre, Toronto, Ontario,
      Canada.
FAU - Arnold, Keresa
AU  - Arnold K
AD  - African and Caribbean Council on HIV/AIDS in Ontario, Toronto, Ontario, Canada.
FAU - Baidoobonso, Shamara
AU  - Baidoobonso S
AD  - African and Caribbean Council on HIV/AIDS in Ontario, Toronto, Ontario, Canada.
FAU - Dabone, Charles
AU  - Dabone C
AD  - Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Dryden, OmiSoore
AU  - Dryden O
AD  - Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Etowa, Egbe
AU  - Etowa E
AD  - Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Hamid, Jemila
AU  - Hamid J
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario,
      Canada.
FAU - Jackson-Best, Fatimah
AU  - Jackson-Best F
AD  - Black Health Alliance, Toronto, Ontario, Canada.
FAU - Kohoun, Bagnini
AU  - Kohoun B
AD  - Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Lawson, Daeria O
AU  - Lawson DO
AUID- ORCID: 0000-0002-6487-3367
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Lofters, Aisha K
AU  - Lofters AK
AD  - St Michael's Hospital Centre for Urban Health Solutions, Toronto, Ontario,
      Canada.
FAU - Luyombya, Henry
AU  - Luyombya H
AD  - Ontario HIV Treatment Network, Toronto, Ontario, Canada.
FAU - Mbulaheni, Tola
AU  - Mbulaheni T
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Mkandawire, Paul
AU  - Mkandawire P
AD  - Carleton University, Ottawa, Ontario, Canada.
FAU - Ndungu, Mary
AU  - Ndungu M
AD  - Africans in Partnership, Toronto, Ontario, Canada.
FAU - Nyambi, Agatha
AU  - Nyambi A
AD  - Ontario HIV Treatment Network, Toronto, Ontario, Canada.
FAU - Obiorah, Suzanne
AU  - Obiorah S
AD  - Somerset West Community Health Centre, Ottawa, Ontario, Canada.
FAU - Ongoiba, Fanta
AU  - Ongoiba F
AD  - Africans in Partnership, Toronto, Ontario, Canada.
FAU - Ongolo-Zogo, Clemence
AU  - Ongolo-Zogo C
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Oraka, Chinedu
AU  - Oraka C
AD  - Ottawa Public Health, Ottawa, Ontario, Canada.
FAU - Shahin, Rita
AU  - Shahin R
AD  - Toronto Public Health, Toronto, Ontario, Canada.
FAU - Yaya, Sanni
AU  - Yaya S
AD  - Faculty of Social Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Hendricks, Andrew
AU  - Hendricks A
AD  - Ottawa Public Health, Ottawa, Ontario, Canada.
FAU - Gebremeskel, Aster
AU  - Gebremeskel A
AD  - Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Inoua, Haoua
AU  - Inoua H
AD  - AIDS Commitee of Ottawa, Ottawa, Ontario, Canada.
FAU - Etowa, Josephine
AU  - Etowa J
AD  - Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada.
LA  - eng
GR  - R25 HD045810/HD/NICHD NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - African Americans
MH  - Blacks
MH  - Caribbean Region
MH  - Cross-Sectional Studies
MH  - *HIV Infections/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - Ontario/epidemiology
MH  - Young Adult
PMC - PMC7348322
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036259 [pii]
AID - 10.1136/bmjopen-2019-036259 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036259. doi: 10.1136/bmjopen-2019-036259.


PMID- 32641328
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 8
TI  - Provision of medical assistance in dying: a scoping review.
PG  - e036054
LID - 10.1136/bmjopen-2019-036054 [doi]
AB  - OBJECTIVES: The purpose of this study is to map the characteristics of the
      existing medical literature describing the medications, settings, participants
      and outcomes of medical assistance in dying (MAID) in order to identify knowledge
      gaps and areas for future research. DESIGN: Scoping review. SEARCH STRATEGY: We
      searched electronic databases (MEDLINE, EMBASE, PsychINFO, CINAHL and CENTRAL),
      clinical trial registries, conference abstracts and professional guidelines from 
      jurisdictions where MAID is legal, up to February 2020. Eligible report types
      included technical summaries, institutional policies, practice surveys, practice 
      guidelines and clinical studies that describe MAID provision in adults who have
      provided informed consent for MAID. RESULTS: 163 articles published between 1989 
      and 2020 met eligibility criteria. 75 studies described details for MAID
      administered by intravenous medications and 50 studies provided data on oral
      medications. In intravenous protocols, MAID was most commonly administered using 
      a barbiturate (34/163) or propofol (22/163) followed by a neuromuscular blocker. 
      Oral protocols most often used barbiturates alone (37/163) or in conjunction with
      an opioid medication (7/163) and often recommended using a prokinetic agent prior
      to lethal drug ingestion. Complications included prolonged duration of the dying 
      process, difficulty in obtaining intravenous access and difficulty in swallowing 
      oral agents. Most commonly, the role of physicians was prescribing (83/163) and
      administering medications (75/163). Nurses' roles included administering
      medications (17/163) and supporting the patient (16/163) or family (13/163). The 
      role of families involved providing support to the patient (17/163) and bringing 
      medications from the pharmacy for self-administration (4/163). CONCLUSIONS: We
      identified several trends in MAID provision including common medications and
      doses for oral and parenteral administration, roles of healthcare professionals
      and families, and complications that may cause patient, family and provider
      distress. Future research should aim to identify the medications, dosages, and
      administration techniques and procedures that produce the most predictable
      outcomes and mitigate distress for those involved.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zworth, Max
AU  - Zworth M
AUID- ORCID: 0000-0002-9120-998X
AD  - Department of Emergency Medicine, Faculty of Medicine, University of Ottawa,
      Ottawa, Ontario, Canada max.zworth@medportal.ca.
FAU - Saleh, Carol
AU  - Saleh C
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Ball, Ian
AU  - Ball I
AD  - Division of Critical Care Medicine, Western University, London, Ontario, Canada.
FAU - Kalles, Gaelen
AU  - Kalles G
AD  - Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Chkaroubo, Anatoli
AU  - Chkaroubo A
AD  - Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Kekewich, Mike
AU  - Kekewich M
AD  - Department of Clinical and Organizational Ethics, The Ottawa Hospital, Ottawa,
      Ontario, Canada.
FAU - Miller, Paul Q
AU  - Miller PQ
AD  - Hamilton Health Sciences, Hamilton, Ontario, Canada.
AD  - Division of Emergency Medicine, Department of Medicine, Hamilton Health Sciences,
      Hamilton, Ontario, Canada.
FAU - Dees, Marianne
AU  - Dees M
AD  - Department for Primary and Community Care, Radboudumc, Nijmegen, The Netherlands.
FAU - Frolic, Andrea
AU  - Frolic A
AD  - Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Oczkowski, Simon
AU  - Oczkowski S
AUID- ORCID: 0000-0002-2874-8948
AD  - Hamilton Health Sciences, Hamilton, Ontario, Canada.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200708
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Health Personnel
MH  - Humans
MH  - Informed Consent
MH  - Medical Assistance
MH  - Self Administration
MH  - *Suicide, Assisted
PMC - PMC7348461
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *medical ethics
OT  - *palliative care
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/07/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036054 [pii]
AID - 10.1136/bmjopen-2019-036054 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 8;10(7):e036054. doi: 10.1136/bmjopen-2019-036054.


PMID- 32641124
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 2041-1480 (Electronic)
VI  - 11
IP  - 1
DP  - 2020 Jul 8
TI  - Enabling ad-hoc reuse of private data repositories through schema extraction.
PG  - 6
LID - 10.1186/s13326-020-00223-z [doi]
AB  - BACKGROUND: Sharing sensitive data across organizational boundaries is often
      significantly limited by legal and ethical restrictions. Regulations such as the 
      EU General Data Protection Rules (GDPR) impose strict requirements concerning the
      protection of personal and privacy sensitive data. Therefore new approaches, such
      as the Personal Health Train initiative, are emerging to utilize data right in
      their original repositories, circumventing the need to transfer data. RESULTS:
      Circumventing limitations of previous systems, this paper proposes a configurable
      and automated schema extraction and publishing approach, which enables ad-hoc
      SPARQL query formulation against RDF triple stores without requiring direct
      access to the private data. The approach is compatible with existing Semantic
      Web-based technologies and allows for the subsequent execution of such queries in
      a safe setting under the data provider's control. Evaluation with four distinct
      datasets shows that a configurable amount of concise and task-relevant schema,
      closely describing the structure of the underlying data, was derived, enabling
      the schema introspection-assisted authoring of SPARQL queries. CONCLUSIONS:
      Automatically extracting and publishing data schema can enable the
      introspection-assisted creation of data selection and integration queries. In
      conjunction with the presented system architecture, this approach can enable
      reuse of data from private repositories and in settings where agreeing upon a
      shared schema and encoding a priori is infeasible. As such, it could provide an
      important step towards reuse of data from previously inaccessible sources and
      thus towards the proliferation of data-driven methods in the biomedical domain.
FAU - Gleim, Lars Christoph
AU  - Gleim LC
AUID- ORCID: 0000-0002-3550-1847
AD  - Informatik 5, RWTH Aachen University, Ahornstr. 55, Aachen, 52062, Germany.
      gleim@cs.rwth-aachen.de.
FAU - Karim, Md Rezaul
AU  - Karim MR
AD  - Informatik 5, RWTH Aachen University, Ahornstr. 55, Aachen, 52062, Germany.
AD  - Fraunhofer FIT, Schloss Birlinghoven, Sankt Augustin, 53754, Germany.
FAU - Zimmermann, Lukas
AU  - Zimmermann L
AD  - Institute for Translational Bioinformatics, University Hospital Tubingen, Sand
      14, Tubingen, 72076, Germany.
FAU - Kohlbacher, Oliver
AU  - Kohlbacher O
AD  - Institute for Translational Bioinformatics, University Hospital Tubingen, Sand
      14, Tubingen, 72076, Germany.
AD  - Applied Bioinformatics, Department of Computer Science, University of Tubingen,
      Sand 14, Tubingen, 72076, Germany.
AD  - Institute for Bioinformatics and Medical Informatics, University of Tubingen,
      Sand 14, Tubingen, 72076, Germany.
AD  - Quantitative Biology Center, University of Tubingen, Auf der Morgenstelle 10,
      Tubingen, 72076, Germany.
AD  - Biomolecular Interactions, Max Planck Institute for Developmental Biology,
      Max-Planck-Ring 5, Tubingen, 72076, Germany.
FAU - Stenzhorn, Holger
AU  - Stenzhorn H
AD  - Institute for Translational Bioinformatics, University Hospital Tubingen, Sand
      14, Tubingen, 72076, Germany.
AD  - Institute for Medical Biometry, Epidemiology und Medical Informatics, Saarland
      University Medical Center, Kirrberger Str., Building 86, Homburg, 66421, Germany.
FAU - Decker, Stefan
AU  - Decker S
AD  - Informatik 5, RWTH Aachen University, Ahornstr. 55, Aachen, 52062, Germany.
AD  - Fraunhofer FIT, Schloss Birlinghoven, Sankt Augustin, 53754, Germany.
FAU - Beyan, Oya
AU  - Beyan O
AD  - Informatik 5, RWTH Aachen University, Ahornstr. 55, Aachen, 52062, Germany.
AD  - Fraunhofer FIT, Schloss Birlinghoven, Sankt Augustin, 53754, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - J Biomed Semantics
JT  - Journal of biomedical semantics
JID - 101531992
SB  - IM
MH  - Computer Security/legislation & jurisprudence
MH  - Feasibility Studies
MH  - *Information Storage and Retrieval
MH  - Internet
MH  - *Privacy
PMC - PMC7341611
OTO - NOTNLM
OT  - *Data access
OT  - *Distributed systems
OT  - *FAIR data
OT  - *Linked data
OT  - *Personal health train
OT  - *Privacy
OT  - *Query design
OT  - *RDF
OT  - *SPARQL
OT  - *Schema extraction
OT  - *Semantic web
EDAT- 2020/07/10 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/07/10 06:00
PHST- 2018/10/25 00:00 [received]
PHST- 2019/07/23 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
AID - 10.1186/s13326-020-00223-z [doi]
AID - 10.1186/s13326-020-00223-z [pii]
PST - epublish
SO  - J Biomed Semantics. 2020 Jul 8;11(1):6. doi: 10.1186/s13326-020-00223-z.


PMID- 32641094
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 8
TI  - Evaluating interventions to improve test, treat, and track (T3) malaria strategy 
      among over-the-counter medicine sellers (OTCMS) in some rural communities of
      Fanteakwa North district, Ghana: study protocol for a cluster randomized
      controlled trial.
PG  - 623
LID - 10.1186/s13063-020-04509-6 [doi]
AB  - BACKGROUND: The World Health Organization initiated test, treat, and track (T3)
      malaria strategy to support malaria-endemic countries in their efforts to achieve
      universal coverage with diagnostic testing, antimalarial treatment, and
      strengthening surveillance systems. Unfortunately, T3 is not adopted by
      over-the-counter medicine sellers (OTCMS) where many patients with malaria-like
      symptoms first seek treatment. Sub-Saharan African countries are considering
      introducing and scaling up RDTs in these outlets to reduce malaria burden. In
      this context, this study is aimed at improving implementation of the T3 among
      OTCMS using a number of intervention tools that could be scaled-up easily at the 
      national level. METHODS/DESIGN: The interventions will be evaluated using a
      two-arm, cluster randomized trial across 8 rural communities (4 clusters per
      arm), in two adjacent districts (Fanteakwa North and Fanteakwa South districts)
      of Ghana. A total of 8 OTCMS in the intervention arm and 5 OTCMS in the control
      arm in the selected communities will participate in the study. In the
      intervention arm only, subsidized malaria rapid diagnostic test (mRDT) kits will 
      be introduced after the OTCMS have been trained on how to use the kit
      appropriately. Supervision, technical assistance, feedbacks, and collection of
      data will be provided on a regular basis at the participating medicine stores.
      The primary outcome is the proportion of children under 10 years with fever or
      suspected to have malaria visiting OTCMS and tested (using mRDT) before
      treatment. Secondary outcomes will include adherence to national malaria
      treatment guidelines and recommended mRDT retail price. Outcomes will be measured
      using mainly a household survey supplemented by mystery client survey and a
      surveillance register on malaria tests conducted by the OTCMS during patient
      consultations. Data collected will be double entered and verified using Microsoft
      Access 2010 (Microsoft Inc., Redmond, Washington) and analyzed using STATA
      version 11.0. DISCUSSION: The trial will provide evidence on the combined
      effectiveness of provider and community interventions in improving adherence to
      the T3 initiative among OTCMS in rural Ghana. ETHICAL CLEARANCE: NMIMR-IRB CPN
      086/18-19 TRIAL REGISTRATION: ISRCTN registry ISRCTN77836926 . Registered on 4
      November 2019.
FAU - Soniran, Olajoju Temidayo
AU  - Soniran OT
AD  - Noguchi Memorial Institute for Medical Research, College of Health Sciences,
      University of Ghana, Legon, Accra, Ghana.
AD  - Akanu Ibiam Federal Polytechnic, Unwana, Ebonyi State, Nigeria.
FAU - Abuaku, Benjamin
AU  - Abuaku B
AUID- ORCID: http://orcid.org/0000-0002-1840-6979
AD  - Noguchi Memorial Institute for Medical Research, College of Health Sciences,
      University of Ghana, Legon, Accra, Ghana. babuaku@noguchi.ug.edu.gh.
FAU - Ahorlu, Collins Stephen
AU  - Ahorlu CS
AD  - Noguchi Memorial Institute for Medical Research, College of Health Sciences,
      University of Ghana, Legon, Accra, Ghana.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200708
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Antimalarials)
RN  - 0 (Nonprescription Drugs)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Antimalarials/economics/*standards
MH  - Cluster Analysis
MH  - Community Pharmacy Services/*standards
MH  - Ghana
MH  - Guideline Adherence/organization & administration
MH  - Humans
MH  - Malaria/*diagnosis/*drug therapy/economics
MH  - Nonprescription Drugs/economics/*standards
MH  - Randomized Controlled Trials as Topic
MH  - Reagent Kits, Diagnostic
MH  - Rural Population
PMC - PMC7346649
OTO - NOTNLM
OT  - Interventions
OT  - Over-the-counter medicine sellers
OT  - T3 malaria strategy
OT  - mRDT
EDAT- 2020/07/10 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/07/10 06:00
PHST- 2019/11/05 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - 10.1186/s13063-020-04509-6 [doi]
AID - 10.1186/s13063-020-04509-6 [pii]
PST - epublish
SO  - Trials. 2020 Jul 8;21(1):623. doi: 10.1186/s13063-020-04509-6.


PMID- 32641080
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Jul 8
TI  - Online adaptive radiotherapy compared to plan selection for rectal cancer:
      quantifying the benefit.
PG  - 162
LID - 10.1186/s13014-020-01597-1 [doi]
AB  - BACKGROUND: To compare online adaptive radiation therapy (ART) to a clinically
      implemented plan selection strategy (PS) with respect to dose to the organs at
      risk (OAR) for rectal cancer. METHODS: The first 20 patients treated with PS
      between May-September 2016 were included. This resulted in 10 short (SCRT) and 10
      long (LCRT) course radiotherapy treatment schedules with a total of 300 Conebeam 
      CT scans (CBCT). New dual arc VMAT plans were generated using auto-planning for
      both the online ART and PS strategy. For each fraction bowel bag, bladder and
      mesorectum were delineated on daily Conebeam CTs. The dose distribution planned
      was used to calculate daily DVHs. Coverage of the CTV was calculated, as defined 
      by the dose received by 99% of the CTV volume (D99%). The volume of normal tissue
      irradiated with 95% of the prescribed fraction dose was calculated by calculating
      the volume receiving 95% of the prescribed fraction or more dose minus the volume
      of the CTV. For each fraction the difference between the plan selection and
      online adaptive strategy of each DVH parameter was calculated, as well as the
      average difference per patient. RESULTS: Target coverage remained the same for
      online ART. The median volume of the normal tissue irradiated with 95% of the
      prescribed dose dropped from 642 cm3 (PS) to 237 cm3 (online-ART)(p < 0.001).
      Online ART reduced dose to the OARs for all tested dose levels for SCRT and LCRT 
      (p < 0.001). For V15Gy of the bowel bag the median difference over all fractions 
      of all patients was - 126 cm(3) in LCRT, while the average difference per patient
      ranged from - 206 cm(3) to - 40 cm(3). For SCRT the median difference was - 62
      cm(3), while the range of the average difference per patient was - 105 cm3 to -
      51 cm(3). For V15Gy of the bladder the median difference over all fractions of
      all patients was 26% in LCRT, while the average difference per patient ranged
      from - 34 to 12%. For SCRT the median difference of V95% was - 8%, while the
      range of the average difference per patient was - 29 to 0%. CONCLUSIONS: Online
      ART for rectal cancer reduces dose the OARs significantly compared to a
      clinically implemented plan selection strategy, without compromising target
      coverage. TRIAL REGISTRATION: Medical Research Involving Human Subjects Act (WMO)
      does not apply to this study and was retrospectively approved by the Medical
      Ethics review Committee of the Academic Medical Center (W19_357 # 19.420;
      Amsterdam University Medical Centers, Location Academic Medical Center,
      Amsterdam, The Netherlands).
FAU - de Jong, R
AU  - de Jong R
AUID- ORCID: http://orcid.org/0000-0003-3833-3479
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands. m.a.j.dejong@amsterdamumc.nl.
FAU - Crama, K F
AU  - Crama KF
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
FAU - Visser, J
AU  - Visser J
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
FAU - van Wieringen, N
AU  - van Wieringen N
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
FAU - Wiersma, J
AU  - Wiersma J
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
FAU - Geijsen, E D
AU  - Geijsen ED
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
FAU - Bel, A
AU  - Bel A
AD  - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam,
      Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200708
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cone-Beam Computed Tomography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Online Systems
MH  - Organs at Risk
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Radiotherapy, Intensity-Modulated/adverse effects/*methods
MH  - Rectal Neoplasms/diagnostic imaging/*radiotherapy
PMC - PMC7371470
OTO - NOTNLM
OT  - Adaptive radiotherapy
OT  - Adaptive treatment
OT  - Library of plans
OT  - Normal tissue sparing
OT  - Plan of the day
OT  - Plan selection
OT  - Rectal cancer
EDAT- 2020/07/10 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
AID - 10.1186/s13014-020-01597-1 [doi]
AID - 10.1186/s13014-020-01597-1 [pii]
PST - epublish
SO  - Radiat Oncol. 2020 Jul 8;15(1):162. doi: 10.1186/s13014-020-01597-1.


PMID- 32641042
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jul 8
TI  - The association between glucose-related variables and plaque morphology in
      patients with ST-segment elevated myocardial infarction.
PG  - 109
LID - 10.1186/s12933-020-01074-9 [doi]
AB  - BACKGROUND: Plaque rupture (PR) and plaque erosion (PE) are main causes of acute 
      myocardial infarction with different demographic and histology characteristics
      and need different treatment strategy. PR and PE can be identified with optical
      coherence tomography (OCT) accurately, but convenient and effective noninvasive
      markers for them are rarely found. History of diabetes mellitus (DM) was reported
      to be a potential predictor of PR in ST-segment elevated myocardial infarction
      (STEMI) patients, but the predictive value of other glucose-related variables for
      it is still uncertain. Present study aimed to clear the relationship between some
      glucose-related variables and plaque morphology in patients with STEMI. METHODS: 
      We consecutively enrolled 872 STEMI patients and divided them into PR group (n = 
      616) and PE group (n = 256) based on OCT diagnostic criteria. The relationship of
      glucose-related variables, including random plasma glucose on admission (ARPG),
      glycosylated hemoglobin (HbA1c), post-PCI fasting plasma glucose (PFPG), DM
      history, glucose variable tendency (GVT) and the acute-to-chronic glycemic ratio 
      (A/C), to the PR risk of STEMI patients was analyzed. The correlation between the
      glucose-related variables and plaque morphology was analyzed meanwhile. RESULTS: 
      Among the glucose-related variables, ARPG and GVT were confirmed to be
      independent predictors for PR after adjusting for other traditional risk factors 
      in nondiabetic patients. The higher the ARPG level, the more PR risk the STEMI
      patients had. And high HbA1c and APPG were demonstrated to have a weak and
      positive correlation with lipid constituents and stenosis degree of culprit
      vessel. CONCLUSIONS: Compared to HbA1c, DM history, and some other
      glucose-related variables, ARPG and GVT were risk factors for PR in STEMI
      patients, especially those without DM. And high HbA1c and ARPG were positively
      correlated with the development of vulnerable plaque in culprit vessels. Trial
      registration Present study is a retrospective one and the population came from
      the EROSION study of our center previously. It was approved by the Ethics
      Committee of the Second Affiliated Hospital of Harbin Medical University
      (Approval reference number, KY2017-249), and all patients provided written
      informed consent prior to the inclusion in the study and the investigation
      conformed to the principles outlined in the Declaration of Helsinki.
FAU - Liu, Jinxin
AU  - Liu J
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China.
FAU - Wang, Shanjie
AU  - Wang S
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China.
FAU - Cui, Can
AU  - Cui C
AD  - Department of Endocrinology and Metabolism, The Second Affiliated Hospital of
      Harbin Medical University, Harbin, 150086, China.
FAU - Cai, Hengxuan
AU  - Cai H
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China.
FAU - Sun, Rong
AU  - Sun R
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China.
FAU - Pan, Weili
AU  - Pan W
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China.
FAU - Fang, Shaohong
AU  - Fang S
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China.
FAU - Yu, Bo
AU  - Yu B
AD  - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
      University, Harbin, 150086, China. dryu_hmu@163.com.
AD  - The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry
      Education, Harbin, 150086, Heilongjiang, China. dryu_hmu@163.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/*metabolism
MH  - Coronary Artery Disease/*diagnostic imaging/pathology/therapy
MH  - Coronary Vessels/*diagnostic imaging/pathology
MH  - Diabetes Mellitus/*blood/diagnosis
MH  - Glycated Hemoglobin A/metabolism
MH  - Humans
MH  - Percutaneous Coronary Intervention
MH  - *Plaque, Atherosclerotic
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Rupture, Spontaneous
MH  - ST Elevation Myocardial Infarction/*diagnostic imaging/pathology/therapy
MH  - Time Factors
MH  - *Tomography, Optical Coherence
PMC - PMC7341636
OTO - NOTNLM
OT  - *Admission glucose
OT  - *Plaque erosion
OT  - *Plaque rupture
OT  - *ST-segment elevated myocardial infarction
EDAT- 2020/07/10 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/07/10 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.1186/s12933-020-01074-9 [doi]
AID - 10.1186/s12933-020-01074-9 [pii]
PST - epublish
SO  - Cardiovasc Diabetol. 2020 Jul 8;19(1):109. doi: 10.1186/s12933-020-01074-9.


PMID- 32641010
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 8
TI  - Motivations for people with cognitive impairment to complete an advance research 
      directive - a qualitative interview study.
PG  - 360
LID - 10.1186/s12888-020-02741-7 [doi]
AB  - BACKGROUND: Research with persons with dementia is important to better understand
      the causes of dementia and to develop more effective diagnostics, therapies, and 
      preventive measures. Advance Research Directives (ARDs) have been suggested as a 
      possible solution to include persons with dementia in research in an ethically
      sound way. Little is known about how people, especially those affected by
      cognitive impairment, understand and regard the use of ARDs, as empirical studies
      are mainly conducted with healthy, non-cognitively impaired, participants.
      METHODS: This qualitative study, a sub-study of a larger study on the evaluation 
      of ARDs in the context of dementia research in Germany, consists of
      semi-structured in-depth interviews with 24 persons with cognitive impairment.
      RESULTS: Our results indicate that most participants consider ARDs a valuable
      tool for allowing them to make their own decisions. Many would prefer to draft an
      ARD when they are still healthy or soon after the diagnosis of cognitive
      impairment. Participants suggested that the completion of ARDs can be advanced
      with the provision of practical support and increased dissemination of
      information on ARDs in society. CONCLUSION: Persons with subjective or mild
      cognitive impairment (SCI/MCI) suggested several motivating factors and concerns 
      for completing an ARD. Clinicians need to be trained to accommodate patients'
      needs for sufficient and adequate information. Furthermore, a standardised,
      partly pre-formulated template could be helpful for drafting an ARD. As such
      tested templates are currently not yet available, this addresses the urgent need 
      for more translational and implementation research for the use of ARDs.
FAU - Jongsma, Karin
AU  - Jongsma K
AUID- ORCID: 0000-0001-8135-6786
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Humboldtallee 36, 37073, Gottingen, Germany.
      karin.jongsma@medizin.uni-goettingen.de.
AD  - Department of Medical Humanities, University Medical Center Utrecht, Po Box
      85500, 3508, GA, Utrecht, The Netherlands.
      karin.jongsma@medizin.uni-goettingen.de.
FAU - Perry, Julia
AU  - Perry J
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Humboldtallee 36, 37073, Gottingen, Germany.
FAU - Schicktanz, Silke
AU  - Schicktanz S
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Humboldtallee 36, 37073, Gottingen, Germany.
FAU - Radenbach, Katrin
AU  - Radenbach K
AD  - Department of Psychiatry and Psychotherapy, University Medical Center Gottingen, 
      Von-Siebold-Str. 5, 37075, Gottingen, Germany.
LA  - eng
GR  - 2017/the Research Funding Program of the University Medical Center
      Gottingen/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200708
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
MH  - *Cognitive Dysfunction
MH  - Germany
MH  - Humans
MH  - *Motivation
MH  - Qualitative Research
PMC - PMC7346429
OTO - NOTNLM
OT  - *Advance directives
OT  - *Alzheimer's disease
OT  - *Dementia
OT  - *Ethics
OT  - *Research participation
EDAT- 2020/07/10 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/07/10 06:00
PHST- 2019/11/17 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/10 06:00 [entrez]
PHST- 2020/07/10 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
AID - 10.1186/s12888-020-02741-7 [doi]
AID - 10.1186/s12888-020-02741-7 [pii]
PST - epublish
SO  - BMC Psychiatry. 2020 Jul 8;20(1):360. doi: 10.1186/s12888-020-02741-7.


PMID- 32640022
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1876-3405 (Electronic)
IS  - 1876-3405 (Linking)
VI  - 12
IP  - 5
DP  - 2020 Sep 1
TI  - The ethical case for global measles eradication-justice and the Rule of Rescue.
PG  - 375-377
LID - 10.1093/inthealth/ihaa038 [doi]
AB  - Measles causes a substantial disease burden for all countries, while mortality is
      greatest in underserved, marginalized populations. Global measles eradication is 
      feasible and the strategies critically rely upon well-functioning national
      immunisation programs and surveillance systems. All six regions of the World
      Health Organisation have adopted measles elimination targets. The Rule of Rescue 
      and the principle of justice leave no ethical place for health programs,
      governments, global public health bodies or donors to hide if they impede efforts
      to eradicate measles globally by not taking all necessary actions to establish a 
      global eradication target and committing the resources essential to achieve this 
      goal.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Royal
      Society of Tropical Medicine and Hygiene.
FAU - Durrheim, David N
AU  - Durrheim DN
AD  - School of Medicine and Public Health, University of Newcastle, Newcastle, New
      South Wales, Australia.
FAU - Andrus, Jon K
AU  - Andrus JK
AD  - Centre for Global Health, University of Colorado, Denver, Colorado, United State 
      of America.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int Health
JT  - International health
JID - 101517095
RN  - 0 (Measles Vaccine)
SB  - IM
MH  - Disease Eradication/*standards
MH  - Global Health/*ethics/standards
MH  - Guidelines as Topic
MH  - *Health Policy
MH  - Humans
MH  - Immunization Programs/*ethics/standards
MH  - Measles/*prevention & control
MH  - Measles Vaccine/*administration & dosage
MH  - Medically Underserved Area
MH  - Public Health/*ethics/standards
MH  - *Social Justice
MH  - Vulnerable Populations/statistics & numerical data
PMC - PMC7443714
OTO - NOTNLM
OT  - *eradication
OT  - *ethics
OT  - *justice
OT  - *measles
OT  - *rescue
EDAT- 2020/07/09 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 5868932 [pii]
AID - 10.1093/inthealth/ihaa038 [doi]
PST - ppublish
SO  - Int Health. 2020 Sep 1;12(5):375-377. doi: 10.1093/inthealth/ihaa038.


PMID- 32639916
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20220802
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - 8
DP  - 2020 Aug
TI  - Ethical Pandemic Control Through the Public Health Code of Ethics.
PG  - 1171-1172
LID - 10.2105/AJPH.2020.305785 [doi]
FAU - Thomas, James C
AU  - Thomas JC
AD  - James C. Thomas is with the Department of Epidemiology, Gillings School of Global
      Public Health, and the Carolina Population Center, University of North Carolina, 
      Chapel Hill. Nabarun Dasgupta is with the Injury Prevention Research Center,
      University of North Carolina, Chapel Hill.
FAU - Dasgupta, Nabarun
AU  - Dasgupta N
AD  - James C. Thomas is with the Department of Epidemiology, Gillings School of Global
      Public Health, and the Carolina Population Center, University of North Carolina, 
      Chapel Hill. Nabarun Dasgupta is with the Injury Prevention Research Center,
      University of North Carolina, Chapel Hill.
LA  - eng
PT  - Editorial
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
MH  - *Codes of Ethics
MH  - *Disaster Planning
MH  - Humans
MH  - Information Dissemination
MH  - *Pandemics
MH  - Public Health/*ethics
MH  - *Truth Disclosure
PMC - PMC7349427
EDAT- 2020/07/09 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - 10.2105/AJPH.2020.305785 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Aug;110(8):1171-1172. doi: 10.2105/AJPH.2020.305785.


PMID- 32639898
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Do we need empirical research on the use of trolley dilemmas in applied ethics?
      Reply to commentary by Heidi Matisonn.
PG  - 300-301
LID - 10.1177/1556264620939805 [doi]
FAU - Oftedal, Gry
AU  - Oftedal G
AUID- ORCID: 0000-0002-5578-1196
AD  - Department of Philosophy, Classics, History of Art and Ideas, University of Oslo,
      Oslo, Norway.
FAU - Ravn, Ingrid H
AU  - Ravn IH
AD  - Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo,
      Norway.
FAU - Dahl, Fredrik A
AU  - Dahl FA
AD  - Health Services Research Unit, Akershus University Hospital, Lorenskog, Norway.
LA  - eng
PT  - Letter
DEP - 20200708
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - Empirical Research
MH  - *Ethical Theory
MH  - Humans
MH  - *Judgment
MH  - Morals
PMC - PMC7488818
OTO - NOTNLM
OT  - *deontological positions
OT  - *ethical judgment
OT  - *immediacy
OT  - *trolley dilemmas
OT  - *vaccine
EDAT- 2020/07/09 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 10.1177/1556264620939805 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):300-301. doi:
      10.1177/1556264620939805. Epub 2020 Jul 8.


PMID- 32639546
OWN - NLM
STAT- Publisher
LR  - 20200708
IS  - 1471-8391 (Electronic)
IS  - 0007-1420 (Linking)
DP  - 2020 Jul 8
TI  - Corrigendum to: Ethical and policy issues raised by uterus transplants.
LID - ldaa020 [pii]
LID - 10.1093/bmb/ldaa020 [doi]
FAU - O'Donovan, Laura
AU  - O'Donovan L
AD  - Department of Politics, Philosophy, & Religion, County South, Lancaster
      University, Lancaster, LA1 4YQ, United Kingdom.
FAU - Williams, Nicola Jane
AU  - Williams NJ
AD  - Department of Politics, Philosophy, & Religion, County South, Lancaster
      University, Lancaster, LA1 4YQ, United Kingdom.
FAU - Wilkinson, Stephen
AU  - Wilkinson S
AD  - Department of Politics, Philosophy, & Religion, County South, Lancaster
      University, Lancaster, LA1 4YQ, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - England
TA  - Br Med Bull
JT  - British medical bulletin
JID - 0376542
SB  - IM
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:00
CRDT- 2020/07/09 06:00
PHST- 2019/04/11 00:00 [received]
PHST- 2019/06/09 00:00 [revised]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
AID - 5868817 [pii]
AID - 10.1093/bmb/ldaa020 [doi]
PST - aheadofprint
SO  - Br Med Bull. 2020 Jul 8. pii: 5868817. doi: 10.1093/bmb/ldaa020.


PMID- 32639423
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20210106
IS  - 1529-4242 (Electronic)
IS  - 0032-1052 (Linking)
VI  - 146
IP  - 4
DP  - 2020 Oct
TI  - The COVID-19 Pandemic and Plastic Surgery: Literature Review, Ethical Analysis,
      and Proposed Guidelines.
PG  - 482e-493e
LID - 10.1097/PRS.0000000000007268 [doi]
AB  - BACKGROUND: Coronavirus disease 2019 (COVID-19), known as the "coronavirus," has 
      spread to over 170 countries. In response, many organizations have spoken out and
      called for cancellation of all elective surgical procedures. This study aimed to 
      provide clear recommendations for plastic surgeons to follow by addressing the
      following issues: (1) What defines elective surgery, and where does one draw the 
      line between essential versus nonessential services? (2) How does this differ in 
      the hospital versus private practice setting? (3) If called on to operate on a
      patient with COVID-19, how do plastic surgeons protect themselves and still
      provide excellent medical care? METHODS: A Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses systematic review of the literature on
      plastic surgery in the setting of a pandemic was performed on March 19, 2020. An 
      ethical analysis was conducted using the four principles of medical ethics.
      RESULTS: The initial search yielded 118 articles. Eighteen articles were relevant
      and included for analysis. Only one editorial article was published in a plastic 
      surgery journal. Accordingly, no peer-reviewed published COVID-19 guidelines
      exist for plastic surgery. Given that this pandemic may place health care systems
      under undue stress with an unpredictable trajectory, it is the responsibility of 
      the plastic surgeon to assess and postpone cases whenever possible to properly
      contribute to adequate resource allocation and patient safety measures.
      CONCLUSIONS: This article fills an important gap in the literature by addressing 
      COVID-19 and providing guidelines for upholding ethics and responsible resource
      allocation. By upholding these standards, plastic surgeons can do their part to
      help minimize the spread of this virus.
FAU - Dorfman, Robert
AU  - Dorfman R
AD  - From the Division of Plastic and Reconstructive Surgery, University of
      California, Los Angeles, David Geffen School of Medicine.
FAU - Saadat, Sean
AU  - Saadat S
AD  - From the Division of Plastic and Reconstructive Surgery, University of
      California, Los Angeles, David Geffen School of Medicine.
FAU - Gupta, Nisha
AU  - Gupta N
AD  - From the Division of Plastic and Reconstructive Surgery, University of
      California, Los Angeles, David Geffen School of Medicine.
FAU - Roostaeian, Jason
AU  - Roostaeian J
AD  - From the Division of Plastic and Reconstructive Surgery, University of
      California, Los Angeles, David Geffen School of Medicine.
FAU - Da Lio, Andrew
AU  - Da Lio A
AD  - From the Division of Plastic and Reconstructive Surgery, University of
      California, Los Angeles, David Geffen School of Medicine.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Cross Infection/prevention & control
MH  - Elective Surgical Procedures/*ethics/methods
MH  - Ethical Analysis
MH  - Female
MH  - Humans
MH  - Infection Control/organization & administration
MH  - Male
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Patient Safety
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Practice Guidelines as Topic
MH  - Prognosis
MH  - Risk Assessment
MH  - Surgery, Plastic/*ethics/*methods
EDAT- 2020/07/09 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 10.1097/PRS.0000000000007268 [doi]
AID - 00006534-202010000-00041 [pii]
PST - ppublish
SO  - Plast Reconstr Surg. 2020 Oct;146(4):482e-493e. doi:
      10.1097/PRS.0000000000007268.


PMID- 32638930
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73
IP  - 5
DP  - 2020
TI  - Knowledge and health promotion practice of Family Health Strategy nurses.
PG  - e20190362
LID - S0034-71672020000500176 [pii]
LID - 10.1590/0034-7167-2019-0362 [doi]
AB  - OBJECTIVES: to analyze the knowledge and health promotion practice carried out by
      Family Health Strategy nurses. METHODS: a descriptive study and qualitative
      approach. The study was conducted with 18 Family Health Strategy nurses from the 
      city of Sao Carlos. Data were collected through semi-structured interviews and
      analyzed through thematic analysis. The study was approved by the Research Ethics
      Committee. RESULTS: the data revealed that nurses had difficulties to
      conceptualize health promotion, and it is common to describe the definition of
      disease prevention. Nurses also reported developing group activities for health
      promotion; however, individual actions and consultations were still predominant. 
      Final Considerations: it is necessary to develop sustainable strategies for
      collective health-promoting activities, in addition to strengthening
      multidisciplinary work and Continuing Education actions.
FAU - Silva, Nathalia Cristina do Carmo da
AU  - Silva NCDCD
AD  - Universidade Federal de Sao Carlos, Sao Carlos, Sao Paulo, Brazil.
FAU - Mekaro, Karen Sayuri
AU  - Mekaro KS
AD  - Universidade Federal de Sao Carlos, Sao Carlos, Sao Paulo, Brazil.
FAU - Santos, Rebeca Isis de Oliveira
AU  - Santos RIO
AD  - Universidade Federal de Sao Carlos, Sao Carlos, Sao Paulo, Brazil.
FAU - Uehara, Silvia Carla da Silva Andre
AU  - Uehara SCDSA
AD  - Universidade Federal de Sao Carlos, Sao Carlos, Sao Paulo, Brazil.
LA  - por
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Brazil
MH  - Family Health/*standards/statistics & numerical data
MH  - Family Nursing/*methods/statistics & numerical data
MH  - Female
MH  - Health Promotion/methods/*standards/statistics & numerical data
MH  - Humans
MH  - Nurses/*psychology/statistics & numerical data
MH  - Qualitative Research
EDAT- 2020/07/09 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/07/09 06:00
PHST- 2019/05/08 00:00 [received]
PHST- 2019/11/15 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - S0034-71672020000500176 [pii]
AID - 10.1590/0034-7167-2019-0362 [doi]
PST - ppublish
SO  - Rev Bras Enferm. 2020;73(5):e20190362. doi: 10.1590/0034-7167-2019-0362. Epub
      2020 Jul 6.


PMID- 32638703
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 18
TI  - Toi Meme, a Mobile Health Platform for Measuring Bipolar Illness Activity:
      Protocol for a Feasibility Study.
PG  - e18818
LID - 10.2196/18818 [doi]
AB  - BACKGROUND: The diagnosis and management of bipolar disorder are limited by the
      absence of available biomarkers. Patients with bipolar disorder frequently
      present with mood instability even during remission, which is likely associated
      with the risk of relapse, impaired functioning, and suicidal behavior, indicating
      that the illness is active. OBJECTIVE: This research protocol aimed to
      investigate the correlations between clinically rated mood symptoms and
      mood/behavioral data automatically collected using the Toi Meme app in patients
      with bipolar disorder presenting with different mood episodes. This study also
      aimed to assess the feasibility of this app for self-monitoring subjective and
      objective mood/behavior parameters in those patients. METHODS: This open-label,
      nonrandomized trial will enroll 93 (31 depressive, 31 euthymic, and 31 hypomanic)
      adults diagnosed with bipolar disorder type I/II (Diagnostic and Statistical
      Manual of Mental Disorders, 5th edition criteria) and owning an iPhone. Clinical 
      evaluations will be performed by psychiatrists at the baseline and after 2 weeks,
      1 month, 2 months, and 3 months during the follow-up. Rather than only accessing 
      the daily mood symptoms, the Toi Meme app also integrates ecological momentary
      assessments through 2 gamified tests to assess cognition speed (QUiCKBRAIN) and
      affective responses (PLAYiMOTIONS) in real-life contexts, continuously measures
      daily motor activities (eg, number of steps, distance) using the smartphone's
      motion sensors, and performs a comprehensive weekly assessment. RESULTS:
      Recruitment began in April 2018 and the completion of the study is estimated to
      be in December 2021. As of April 2019, 25 participants were enrolled in the
      study. The first results are expected to be submitted for publication in 2020.
      This project has been funded by the Perception and Memory Unit of the Pasteur
      Institute (Paris) and it has received the final ethical/research approvals in
      April 2018 (ID-RCB: 2017-A02450-53). CONCLUSIONS: Our results will add to the
      evidence of exploring other alternatives toward a more integrated approach in the
      management of bipolar disorder, including digital phenotyping, to develop an
      ethical and clinically meaningful framework for investigating, diagnosing, and
      treating individuals at risk of developing bipolar disorder or currently
      experiencing bipolar disorder. Further prospective studies on the validity of
      automatically generated smartphone data are needed for better understanding the
      longitudinal pattern of mood instability in bipolar disorder as well as to
      establish the reliability, efficacy, and cost-effectiveness of such an app
      intervention for patients with bipolar disorder. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT03508427; https://clinicaltrials.gov/ct2/show/NCT03508427. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18818.
CI  - (c)Aroldo A Dargel, Elise Mosconi, Marc Masson, Marion Plaze, Fabien Taieb,
      Cassandra Von Platen, Tan Phuc Buivan, Guillaume Pouleriguen, Marie Sanchez,
      Stephane Fournier, Pierre-Marie Lledo, Chantal Henry. Originally published in
      JMIR Research Protocols (http://www.researchprotocols.org), 18.08.2020.
FAU - Dargel, Aroldo A
AU  - Dargel AA
AUID- ORCID: https://orcid.org/0000-0002-5945-6497
AD  - Perception and Memory Unit, Neuroscience Department, Pasteur Institute, Paris,
      France.
AD  - Unite Mixte de Recherche 3571, Centre National de la Recherche Scientifique
      (CNRS), Paris, France.
AD  - Centre Therapeutique de Jour (CTPJ) Troubles Bipolaires, Clinique Bellevue,
      Meudon, France.
FAU - Mosconi, Elise
AU  - Mosconi E
AUID- ORCID: https://orcid.org/0000-0003-4832-3637
AD  - Centre Therapeutique de Jour (CTPJ) Troubles Bipolaires, Clinique Bellevue,
      Meudon, France.
FAU - Masson, Marc
AU  - Masson M
AUID- ORCID: https://orcid.org/0000-0001-7508-3515
AD  - Clinique du Chateau de Garches, Garches, France.
FAU - Plaze, Marion
AU  - Plaze M
AUID- ORCID: https://orcid.org/0000-0001-9022-4945
AD  - Department of Psychiatry, Service Hospitalo-Universitaire, GHU Paris Psychiatrie 
      & Neuroscience, Paris, France.
FAU - Taieb, Fabien
AU  - Taieb F
AUID- ORCID: https://orcid.org/0000-0002-0941-2859
AD  - Centre of Translational Research, Institut Pasteur, Paris, France.
FAU - Von Platen, Cassandra
AU  - Von Platen C
AUID- ORCID: https://orcid.org/0000-0002-1738-2143
AD  - Centre of Translational Research, Institut Pasteur, Paris, France.
FAU - Buivan, Tan Phuc
AU  - Buivan TP
AUID- ORCID: https://orcid.org/0000-0002-7806-1343
AD  - Centre of Translational Research, Institut Pasteur, Paris, France.
FAU - Pouleriguen, Guillaume
AU  - Pouleriguen G
AUID- ORCID: https://orcid.org/0000-0002-4602-8629
AD  - Department of Information Systems, Institut Pasteur, Paris, France.
FAU - Sanchez, Marie
AU  - Sanchez M
AUID- ORCID: https://orcid.org/0000-0002-8102-0139
AD  - Department of Information Systems, Institut Pasteur, Paris, France.
FAU - Fournier, Stephane
AU  - Fournier S
AUID- ORCID: https://orcid.org/0000-0003-1519-0401
AD  - Department of Information Systems, Institut Pasteur, Paris, France.
FAU - Lledo, Pierre-Marie
AU  - Lledo PM
AUID- ORCID: https://orcid.org/0000-0002-8156-7003
AD  - Perception and Memory Unit, Neuroscience Department, Pasteur Institute, Paris,
      France.
AD  - Unite Mixte de Recherche 3571, Centre National de la Recherche Scientifique
      (CNRS), Paris, France.
FAU - Henry, Chantal
AU  - Henry C
AUID- ORCID: https://orcid.org/0000-0002-1549-9604
AD  - Perception and Memory Unit, Neuroscience Department, Pasteur Institute, Paris,
      France.
AD  - Department of Psychiatry, Service Hospitalo-Universitaire, GHU Paris Psychiatrie 
      & Neuroscience, Paris, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03508427
PT  - Journal Article
DEP - 20200818
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7463390
OTO - NOTNLM
OT  - affective response
OT  - big data, machine learning
OT  - bipolar disorder
OT  - cognitive speed
OT  - digital phenotyping, smartphone app
OT  - ecological momentary assessment
OT  - mHealth
OT  - mood instability
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - v9i8e18818 [pii]
AID - 10.2196/18818 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 18;9(8):e18818. doi: 10.2196/18818.


PMID- 32638698
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 2051-6967 (Electronic)
IS  - 0790-9667 (Linking)
VI  - 37
IP  - 2
DP  - 2020 Jun
TI  - Patients and carers as teachers in psychiatric education: a literature review and
      discussion.
PG  - 126-133
LID - 10.1017/ipm.2016.45 [doi]
AB  - INTRODUCTION: The direct involvement of patients and carers in psychiatric
      education is driven by policy in the United Kingdom and Ireland. The benefits of 
      this involvement are well known, however, it is important to consider the ethical
      aspects. This paper suggests how further research could explore and potentially
      mitigate adverse outcomes. METHOD: A literature search evaluating the role of
      patients and carer involvement in psychiatric education was undertaken to
      summarise existing evidence relating to the following: methods of involvement,
      evidence of usefulness, patient's/carer's views and learners' views. RESULTS: The
      Medline search produced 231 articles of which 31 were included in the literature 
      review based on the key themes addressed in the paper. DISCUSSION/CONCLUSION: The
      available evidence is generally positive regarding the use of patients and carers
      in psychiatric education. However, available research is varied in approach and
      outcome with little information on the ethical consequences. More research is
      required to inform policies on teaching regarding potential adverse effects of
      service user involvement.
FAU - Miller, C
AU  - Miller C
AD  - Littlemore Mental Health Centre, Oxford, UK.
FAU - Pradeep, V
AU  - Pradeep V
AD  - Department of Psychiatry, University Hospital Limerick, Limerick, Republic of
      Ireland.
FAU - Mohamad, M
AU  - Mohamad M
AD  - Department of Psychiatry, University Hospital Limerick, Limerick, Republic of
      Ireland.
AD  - University of Limerick, Limerick, Republic of Ireland.
FAU - Izmeth, Z
AU  - Izmeth Z
AD  - Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
FAU - Reynolds, M T P
AU  - Reynolds MTP
AD  - Department of Psychiatry, University Hospital Limerick, Limerick, Republic of
      Ireland.
AD  - University of Limerick, Limerick, Republic of Ireland.
FAU - Gulati, G
AU  - Gulati G
AD  - Department of Psychiatry, University Hospital Limerick, Limerick, Republic of
      Ireland.
AD  - University College Cork, Cork, Republic of Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161121
PL  - England
TA  - Ir J Psychol Med
JT  - Irish journal of psychological medicine
JID - 8900208
SB  - IM
MH  - *Caregivers
MH  - Humans
MH  - Ireland
MH  - *Patients
MH  - Psychiatry/*education
MH  - Teaching/*ethics
MH  - United Kingdom
OTO - NOTNLM
OT  - *Carer
OT  - *education
OT  - *mental health
OT  - *patient
OT  - *psychiatry
OT  - *service user
OT  - *teaching
EDAT- 2020/07/09 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - S0790966716000458 [pii]
AID - 10.1017/ipm.2016.45 [doi]
PST - ppublish
SO  - Ir J Psychol Med. 2020 Jun;37(2):126-133. doi: 10.1017/ipm.2016.45. Epub 2016 Nov
      21.


PMID- 32638670
OWN - NLM
STAT- Publisher
LR  - 20200708
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
DP  - 2020 Jun 24
TI  - Review of real-world evidence studies in type 2 diabetes mellitus: Lack of good
      practices.
PG  - 1-8
LID - 10.1017/S0266462320000392 [doi]
AB  - OBJECTIVES: Unlike randomized controlled trials, lack of methodological rigor is 
      a concern about real-world evidence (RWE) studies. The objective of this study
      was to characterize methodological practices of studies collecting
      pharmacoeconomic data in a real-world setting for the management of type 2
      diabetes mellitus (T2DM). METHODS: A systematic literature review was performed
      using the PICO framework: population consisted of T2DM patients, interventions
      and comparators were any intervention for T2DM care or absence of intervention,
      and outcomes were resource utilization, productivity loss or utility. Only RWE
      studies were included, defined as studies that were not clinical trials and that 
      collected de novo data (no retrospective analysis). RESULTS: The literature
      search identified 1,158 potentially relevant studies, among which sixty were
      included in the literature review. Many studies showed a lack of transparency by 
      not mentioning the source for outcome and exposure measurement, source for
      patient selection, number of study sites, recruitment duration, sample size
      calculation, sampling method, missing data, approbation by an ethics committee,
      obtaining patient's consent, conflicts of interest, and funding. A significant
      proportion of studies had poor quality scores and was at high risk of bias.
      CONCLUSIONS: RWE from T2DM studies lacks transparency and credibility. There is a
      need for good procedural practices that can increase confidence in RWE studies.
      Standardized methodologies specifically adapted for RWE studies collecting
      pharmacoeconomic data for the management of T2DM could help future reimbursement 
      decision making in this major public health problem.
FAU - Lambert-Obry, Veronique
AU  - Lambert-Obry V
AUID- ORCID: https://orcid.org/0000-0002-2499-1377
AD  - The Faculty of Pharmacy, Universite de Montreal, 2940, Chemin de Polytechnique,
      Montreal, QuebecH3T 1J4, Canada.
FAU - Lafrance, Jean-Philippe
AU  - Lafrance JP
AD  - The Faculty of Medicine, Universite de Montreal, 2900, Boulevard
      Edouard-Montpetit, Montreal, QuebecH3T 1J4, Canada.
FAU - Savoie, Michelle
AU  - Savoie M
AD  - The Faculty of Pharmacy, Universite de Montreal, 2940, Chemin de Polytechnique,
      Montreal, QuebecH3T 1J4, Canada.
FAU - Henri, Sandrine
AU  - Henri S
AD  - The Faculty of Pharmacy, Universite de Montreal, 2940, Chemin de Polytechnique,
      Montreal, QuebecH3T 1J4, Canada.
FAU - Lachaine, Jean
AU  - Lachaine J
AD  - The Faculty of Pharmacy, Universite de Montreal, 2940, Chemin de Polytechnique,
      Montreal, QuebecH3T 1J4, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
SB  - IM
OTO - NOTNLM
OT  - Costs
OT  - Health-related quality of life
OT  - Real-world evidence
OT  - Resource use
OT  - Work productivity
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
AID - 10.1017/S0266462320000392 [doi]
AID - S0266462320000392 [pii]
PST - aheadofprint
SO  - Int J Technol Assess Health Care. 2020 Jun 24:1-8. doi:
      10.1017/S0266462320000392.


PMID- 32638669
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 2051-6967 (Electronic)
IS  - 0790-9667 (Linking)
VI  - 37
IP  - 2
DP  - 2020 Jun
TI  - What influences postgraduate psychiatric trainees' attitudes to clinical audit?
PG  - 106-110
LID - 10.1017/ipm.2017.6 [doi]
AB  - INTRODUCTION: Clinical audit is an important component of safe and ethical
      practice but many clinicians cite barriers to engagement in audit. METHODOLOGY: A
      total of 81 basic specialist trainees in psychiatry were surveyed in terms of
      their basic demographic details and their knowledge, direct experience and
      attitudes in relation to clinical audit. RESULTS: Among the 49 (60.5%) who
      responded, 57.1% had received formal training in audit, but only 20.4% had
      received more than four hours of training in their whole career. The median
      positivity score was 30 out of a possible 54 (range 12-40), suggesting that
      participating trainees were barely more than 'undecided' overall when it comes to
      positive attitudes to clinical audit. Age, nationality and specific training did 
      not predict attitudes to clinical audit. Gender, years of clinical experience and
      direct experience of clinical audit did not significantly predict attitudes to
      clinical audit, but these findings are at odds with some previous research.
      DISCUSSION: Much work is needed in improving postgraduate trainees' attitudes to 
      clinical audit, given that clinical audit is essential for good medical practice.
      Ours is an initial study of this area of training limited by sample size and the 
      narrowness of the group tested. Further study of other specialities, higher
      trainees and consultant trainers would further enhance our understanding.
FAU - McWilliams, S
AU  - McWilliams S
AD  - Saint John of God Hospital, Stillorgan, Co Dublin, Ireland.
FAU - Schofield, S
AU  - Schofield S
AD  - Centre for Medical Education, University of Dundee, Dundee, Scotland, UK.
LA  - eng
PT  - Journal Article
DEP - 20170403
PL  - England
TA  - Ir J Psychol Med
JT  - Irish journal of psychological medicine
JID - 8900208
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - *Clinical Audit
MH  - *Education, Medical, Graduate
MH  - Female
MH  - Humans
MH  - Male
MH  - Psychiatry/*education
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Attitudes
OT  - *clinical audit
OT  - *knowledge
OT  - *training
EDAT- 2020/07/09 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
AID - S0790966717000064 [pii]
AID - 10.1017/ipm.2017.6 [doi]
PST - ppublish
SO  - Ir J Psychol Med. 2020 Jun;37(2):106-110. doi: 10.1017/ipm.2017.6. Epub 2017 Apr 
      3.


PMID- 32638633
OWN - NLM
STAT- MEDLINE
DCOM- 20200903
LR  - 20201218
IS  - 0840-4704 (Print)
IS  - 0840-4704 (Linking)
VI  - 33
IP  - 5
DP  - 2020 Sep
TI  - Providing care for the 99.9% during the COVID-19 pandemic: How ethics, equity,
      epidemiology, and cost per QALY inform healthcare policy.
PG  - 239-242
LID - 10.1177/0840470420939854 [doi]
AB  - Managing healthcare in the Coronavirus Disease 2019 (COVID-19) era should be
      guided by ethics, epidemiology, equity, and economics, not emotion. Ethical
      healthcare policies ensure equitable access to care for patients regardless of
      whether they have COVID-19 or another disease. Because healthcare resources are
      limited, a cost per Quality Life Year (QALY) approach to COVID-19 policy should
      also be considered. Policies that focus solely on mitigating COVID-19 are likely 
      to be ethically or financially unsustainable. A cost/QALY approach could target
      resources to optimally improve QALYs. For example, most COVID-19 deaths occur in 
      long-term care facilities, and this problem is likely better addressed by a
      focused long-term care reform than by a society-wide non-pharmacological
      intervention. Likewise, ramping up elective, non-COVID-19 care in low prevalence 
      regions while expanding testing and case tracking in hot spots could reduce
      excess mortality from non-COVID-19 diseases and decrease adverse financial
      impacts while controlling the epidemic. Globally, only approximately 0.1% of
      people have had a COVID-19 infection. Thus, ethical healthcare policy must
      address the needs of the 99.9%.
FAU - Archer, Stephen L
AU  - Archer SL
AD  - 4257Queen's University, Kingston, Ontario, Canada.
AD  - 4257Queen's University, Kingston, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - United States
TA  - Healthc Manage Forum
JT  - Healthcare management forum
JID - 8805307
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Delivery of Health Care/*economics/*ethics
MH  - Health Equity/*economics/*ethics
MH  - Health Policy/*economics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - *Quality-Adjusted Life Years
MH  - SARS-CoV-2
EDAT- 2020/07/09 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 10.1177/0840470420939854 [doi]
PST - ppublish
SO  - Healthc Manage Forum. 2020 Sep;33(5):239-242. doi: 10.1177/0840470420939854. Epub
      2020 Jul 8.


PMID- 32638286
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - The Human Side of Artificial Intelligence.
PG  - 2427-2437
LID - 10.1007/s11948-020-00239-9 [doi]
AB  - Artificial moral agents raise complex ethical questions both in terms of the
      potential decisions they may make as well as the inputs that create their
      cognitive architecture. There are multiple differences between human and
      artificial cognition which create potential barriers for artificial moral agency,
      at least as understood anthropocentrically and it is unclear that artificial
      moral agents should emulate human cognition and decision-making. It is
      conceptually possible for artificial moral agency to emerge that reflects
      alternative ethical methodologies without creating ontological challenges or
      existential crises for human moral agents.
FAU - Butkus, Matthew A
AU  - Butkus MA
AD  - Department of Social Sciences, McNeese State University, Lake Charles, LA, USA.
      mbutkus@mcneese.edu.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Cognition
MH  - Decision Making
MH  - Existentialism
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Ethics
OT  - *Moral agency
OT  - *Neural modeling
OT  - *Ontology
OT  - *Popular culture
EDAT- 2020/07/09 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 10.1007/s11948-020-00239-9 [doi]
AID - 10.1007/s11948-020-00239-9 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2427-2437. doi: 10.1007/s11948-020-00239-9.


PMID- 32638285
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Towards Establishing Criteria for the Ethical Analysis of Artificial
      Intelligence.
PG  - 2413-2425
LID - 10.1007/s11948-020-00238-w [doi]
AB  - Ethical reflection on Artificial Intelligence (AI) has become a priority. In this
      article, we propose a methodological model for a comprehensive ethical analysis
      of some uses of AI, notably as a replacement of human actors in specific
      activities. We emphasize the need for conceptual clarification of relevant key
      terms (e.g., intelligence) in order to undertake such reflection. Against that
      background, we distinguish two levels of ethical analysis, one practical and one 
      theoretical. Focusing on the state of AI at present, we suggest that regardless
      of the presence of intelligence, the lack of morally relevant features calls for 
      caution when considering the role of AI in some specific human activities.
FAU - Farisco, Michele
AU  - Farisco M
AD  - Centre for Research Ethics and Bioethics, Uppsala University, Box 564, 751 22,
      Uppsala, Sweden. michele.farisco@crb.uu.se.
AD  - Science and Society Unit, Biogem, Biology and Molecular Genetics Institute, Via
      Camporeale, Ariano Irpino, AV, Italy. michele.farisco@crb.uu.se.
FAU - Evers, Kathinka
AU  - Evers K
AD  - Centre for Research Ethics and Bioethics, Uppsala University, Box 564, 751 22,
      Uppsala, Sweden.
FAU - Salles, Arleen
AU  - Salles A
AD  - Centre for Research Ethics and Bioethics, Uppsala University, Box 564, 751 22,
      Uppsala, Sweden.
AD  - Programa de Neuroetica, Centro de Investigaciones Filosoficas, Buenos Aires,
      Argentina.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - *Ethical Analysis
MH  - Humans
MH  - Intelligence
MH  - Morals
PMC - PMC7550314
OTO - NOTNLM
OT  - *Biological intelligence
OT  - *Ethics of artificial intelligence
OT  - *Ethics of robotics
OT  - *Philosophy of artificial intelligence
OT  - *Philosophy of intelligence
EDAT- 2020/07/09 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 10.1007/s11948-020-00238-w [doi]
AID - 10.1007/s11948-020-00238-w [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2413-2425. doi: 10.1007/s11948-020-00238-w.


PMID- 32637738
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2451-9936 (Electronic)
IS  - 2451-9936 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Absence of Severe Acute Respiratory Syndrome-Coronavirus-2 RNA in ocular tissues.
PG  - 100805
LID - 10.1016/j.ajoc.2020.100805 [doi]
AB  - PURPOSE: To evaluate the status of ocular donor tissues of a COVID-19 postmortem 
      donor. METHODS: SARS-CoV-2 was detected via a pharyngeal swab and
      broncho-alveolar lavage in the COVID-19 suspect. Postmortem tissue procurement
      and preparation were performed with personal protective equipment (PPE) and the
      necessary protective measures. qRT-PCR-testing was performed for the following
      ocular tissues and fluids: conjunctival fluid swabs, bulbar conjunctiva, corneal 
      epithelium, corneal stroma, corneal endothelium, anterior chamber fluid, lens,
      iris, vitreous, retina, uvea, sclera, and optic nerve. Informed consent and
      Institutional Review Board approval was obtained prior to this study
      (196/2020BO2; Date of approval: 03/26/2020; Ethics Committee of the University of
      Tuebingen). RESULTS: In all ocular tissue and fluid samples no SARS-CoV-2 RNA was
      detected via qRT-PCR of the confirmed COVID-19 postmortem donor. CONCLUSIONS AND 
      IMPORTANCE: Late-stage COVID-19 patients might not harbor an ocular reservoir of 
      SARS-CoV-2. The risk of transmitting SARS-CoV-2 via ocular tissues and fluids
      might be low. This may bear future implications for patient management in
      ophthalmological practice, surgery and transplantation.
CI  - (c) 2020 The Authors.
FAU - Bayyoud, Tarek
AU  - Bayyoud T
AD  - Department of Ophthalmology, University Hospital Tubingen, Tubingen, Germany.
FAU - Iftner, Angelika
AU  - Iftner A
AD  - Institute for Medical Virology, University Hospital Tubingen, Tubingen, Germany.
FAU - Iftner, Thomas
AU  - Iftner T
AD  - Institute for Medical Virology, University Hospital Tubingen, Tubingen, Germany.
FAU - Bartz-Schmidt, Karl Ulrich
AU  - Bartz-Schmidt KU
AD  - Department of Ophthalmology, University Hospital Tubingen, Tubingen, Germany.
FAU - Ueffing, Marius
AU  - Ueffing M
AD  - Department of Ophthalmology, University Hospital Tubingen, Tubingen, Germany.
AD  - Institute for Ophthalmic Research, University of Tubingen, Tubingen, Germany.
FAU - Schindler, Michael
AU  - Schindler M
AD  - Institute for Medical Virology, University Hospital Tubingen, Tubingen, Germany.
FAU - Thaler, Sebastian
AU  - Thaler S
AD  - Department of Ophthalmology, University Hospital Tubingen, Tubingen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - United States
TA  - Am J Ophthalmol Case Rep
JT  - American journal of ophthalmology case reports
JID - 101679941
PMC - PMC7324914
OTO - NOTNLM
OT  - COVID-19
OT  - Ophthalmological surgery
OT  - SARS-CoV-2
OT  - Transplantation
COIS- Tarek Bayyoud, MD: Conflicts of interest: none. Angelika Iftner: Conflicts of
      interest: none. Thomas Iftner, PhD: Conflicts of interest: none. Karl Ulrich
      Bartz-Schmidt, MD: Conflicts of interest: none. Marius Ueffing, PhD: Conflicts of
      interest: none. Michael Schindler, PhD: Conflicts of interest: none. Sebastian
      Thaler, MD: Conflicts of interest: none.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/06/28 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.1016/j.ajoc.2020.100805 [doi]
AID - S2451-9936(20)30138-9 [pii]
AID - 100805 [pii]
PST - epublish
SO  - Am J Ophthalmol Case Rep. 2020 Jun 30;19:100805. doi: 10.1016/j.ajoc.2020.100805.
      eCollection 2020 Sep.


PMID- 32637557
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2352-8532 (Electronic)
IS  - 2352-8532 (Linking)
VI  - 12
DP  - 2020 Dec
TI  - Vaping for weight control: Findings from a qualitative study.
PG  - 100275
LID - 10.1016/j.abrep.2020.100275 [doi]
AB  - INTRODUCTION: Smokers have expressed concern about weight gain once they stop
      smoking and weight gain is a risk factor associated with smoking relapse.
      Nicotine in e-cigarettes, as well as vaping behaviour, may support smoking
      cessation by reducing weight gain. This study explored the factors that influence
      attitudes towards, and awareness of, e-cigarettes and weight control post smoking
      cessation. METHODS: Qualitative study involving focus groups with adults in the
      UK (n = 58) who were either exclusive vapers or dual users. RESULTS: There was
      limited awareness and/or inclination to vape to prevent weight gain after
      stopping smoking. Reasons for this centred on: the health gains of stopping
      smoking outweighing any potential weight gain; a lack of understanding of the
      appetite supressing effects of nicotine; a belief that vaping could not suppress 
      appetite like a cigarette and could result in craving for certain flavours;
      concerns about the longer-term effects of e-cigarettes on health and the ethics
      of promoting vaping as way to support smoking cessation by limiting weight gain, 
      especially for young women. CONCLUSION: Participants in this study do not appear 
      inclined to use e-cigarettes to prevent weight gain after smoking cessation.
      There is a lack of understanding about why nicotine might help prevent weight
      gain and a concern that e-cigarette flavours could provoke cravings and that
      vaping may be unsafe in the long-term.
CI  - (c) 2020 The Authors.
FAU - Dobbie, Fiona
AU  - Dobbie F
AD  - Usher Institute and SPECTRUM Consortium, College of Medicine and Veterinary
      Medicine, University of Edinburgh, UK.
FAU - Uny, Isabelle
AU  - Uny I
AD  - Institute for Social Marketing, University of Stirling, UK.
FAU - Jackson, Sarah E
AU  - Jackson SE
AD  - Department of Behavioural Science and Health and SPECTRUM Consortium, University 
      College London, UK.
FAU - Brown, Jamie
AU  - Brown J
AD  - Department of Behavioural Science and Health and SPECTRUM Consortium, University 
      College London, UK.
FAU - Aveyard, Paul
AU  - Aveyard P
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford, UK.
FAU - Bauld, Linda
AU  - Bauld L
AD  - Usher Institute and SPECTRUM Consortium, College of Medicine and Veterinary
      Medicine, University of Edinburgh, UK.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - Netherlands
TA  - Addict Behav Rep
JT  - Addictive behaviors reports
JID - 101656077
PMC - PMC7330875
OTO - NOTNLM
OT  - E-cigarettes
OT  - Qualitative research
OT  - Vaping
OT  - Weight control
OT  - Weight loss
COIS- JB has received unrestricted research funding relating to smoking cessation from 
      Pfizer, who manufacture smoking cessation medications. All authors declare no
      financial links with tobacco companies or e-cigarette manufacturers or their
      representatives.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/04/11 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.1016/j.abrep.2020.100275 [doi]
AID - S2352-8532(20)30012-2 [pii]
AID - 100275 [pii]
PST - epublish
SO  - Addict Behav Rep. 2020 Apr 28;12:100275. doi: 10.1016/j.abrep.2020.100275.
      eCollection 2020 Dec.


PMID- 32637347
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2220-8372 (Print)
IS  - 2220-8372 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Jun 21
TI  - Challenges in expanding TB preventive therapy in high-burden settings: beyond
      logistics is evidence and ethics.
PG  - 82
LID - 10.5588/pha.20.0016 [doi]
FAU - Basu, S
AU  - Basu S
AD  - Department of Community Medicine, Maulana Azad Medical College, New Delhi, India.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Public Health Action
JT  - Public health action
JID - 101624961
PMC - PMC7316432
COIS- Conflicts of interest: None to declare.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.5588/pha.20.0016 [doi]
PST - ppublish
SO  - Public Health Action. 2020 Jun 21;10(2):82. doi: 10.5588/pha.20.0016.


PMID- 32637293
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jun
TI  - An Essential Service Decision Model for ABA Providers During Crisis.
PG  - 306-311
LID - 10.1007/s40617-020-00432-z [doi]
AB  - In the United States, applied behavior analysis (ABA) is broadly recognized as a 
      medically necessary treatment for individuals diagnosed with autism and related
      disorders (Association of Professional Behavior Analysts, 2020, Guidelines for
      practicing applied behavior analysis during COVID-19 pandemic, Retrieved from
      https://cdn.ymaws.com/www.apbahome.net/resource/collection/1FDDBDD2-5CAF-4B2A-AB3
      F-DAE5E72111BF/APBA_Guidelines_-_Practicing_During_COVID-19_Pandemic_040920.pdf).
      We argue that this designation should not be called into question in light of a
      particular disaster and that it is critical to consider that an interruption of
      services can have long-lasting effects on the treatment of the individual
      (practitioners are ethically obligated to uphold the continuity of services while
      doing no harm). This dilemma might be ameliorated by a decision model that
      considers the prioritization of immediate needs, the vulnerability of clients,
      and the competency of service providers. Just as the medical field prioritizes
      immediate needs during crisis situations and defers routine appointments (e.g.,
      physicals, checkups), the ABA field can make similar evidence-based decisions.
      The purpose of the current article is to provide a decision model for ABA
      practitioners who find themselves questioning the need for essential service
      delivery during the current COVID-19 pandemic. The impact of this model goes
      beyond the needs of this crisis and can be applied to any emergency situation
      where services are at risk of interruption.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - Colombo, Richard A
AU  - Colombo RA
AD  - Center for Applied Behavior Analysis, 11150 W. Olympic Blvd, Los Angeles, CA
      90064 USA.
FAU - Wallace, Michele
AU  - Wallace M
AD  - Center for Applied Behavior Analysis, 11150 W. Olympic Blvd, Los Angeles, CA
      90064 USA.
FAU - Taylor, Rachel
AU  - Taylor R
AD  - Center for Applied Behavior Analysis, 11150 W. Olympic Blvd, Los Angeles, CA
      90064 USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200522
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7243734
OTO - NOTNLM
OT  - COVID-19
OT  - autism
OT  - decision making
OT  - essential services
OT  - ethics
OT  - pandemic
COIS- Conflict of interestAll three authors declare they have no conflict of interest.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.1007/s40617-020-00432-z [doi]
AID - 432 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 May 22;13(2):306-311. doi: 10.1007/s40617-020-00432-z.
      eCollection 2020 Jun.


PMID- 32637143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Association Between Sex and Opiate and Benzodiazepine Prescription Among Patients
      With CKD: Research Letter.
PG  - 2054358120932673
LID - 10.1177/2054358120932673 [doi]
AB  - BACKGROUND: Opiate and benzodiazepine use is associated with increased mortality 
      and poorer transplant outcomes in patients with chronic kidney disease (CKD).
      OBJECTIVE: To determine the predictors of opiate and benzodiazepine prescription 
      in people with kidney disease. DESIGN: Cross-sectional, observational study.
      SETTING: Outpatient clinics at Kingston Health Sciences Centre or at affiliated
      sites as of June 2017. PATIENTS: Individuals with CKD being treated at clinics or
      with various dialysis modalities at Kingston Health Sciences Centre and
      affiliated sites. MEASUREMENTS: The total number of regular opioid and
      benzodiazepine prescriptions was recorded for each patient. Patients were
      stratified based on clinical (eg, dialysis modality) and demographic (sex, age,
      diabetes mellitus [DM], ethnicity) characteristics, as elicited below. METHODS:
      We evaluated opiate and benzodiazepine use by chart review in the following
      patient groups: conventional hemodialysis (HD) (n = 359), home hemodialysis (HHD)
      (n = 21), peritoneal dialysis (PD) (n = 95), patients attending the
      multidisciplinary chronic kidney disease clinic (MCKDC) (n = 322), and kidney
      transplant (KT) recipients (n = 176). Opiates and benzodiazepines were classified
      according to the American Hospital Formulary Service system. Patients were also
      stratified as white (n = 855), indigenous (n = 66), or all others (n = 48).
      RESULTS: The mean age was 66.2 +/- 14.9 years, 602 (61.9%) were men, and 439
      (45.1%) had DM. Opiates were prescribed to 223 patients (22.9%), most frequently 
      to HD (32.3%), followed by MCKDC (20.8%), HHD (19.0%), PD (14.7%), and KT (12.5%)
      (P < .001). The independent predictors of opiate prescription included DM (odds
      ratio [OR], 1.9; 95% confidence interval [CI], 1.4-2.6; P < 0.001), conventional 
      HD (vs all other treatment modalities) (OR, 1.8; 95% CI, 1.3-2.5; P < .001), and 
      female sex (OR, 1.4; 95% CI, 1.0-1.9; P = .041) after adjustment for age and
      ethnicity (R (2) = 0.037, P < .001). Benzodiazepines were prescribed to 106
      patients (10.9%), most frequently to HD (15.9%), followed by HHD (9.5%), KT
      (9.1%), MCKDC (7.5%), and PD (7.4%) (P = .005). The independent predictors of
      benzodiazepine use included female sex (OR, 2.3; 95% CI, 1.5-3.4; P < .001) and
      dialysis modality (excluding MCKDC and KT) (OR, 1.8; 95% CI, 1.2-2.8; P = .006)
      after adjustment for ethnicity, DM, and age (R (2) = 0.027, P < .001).
      LIMITATIONS: We were not able to ascertain the indication for prescription of
      these drugs or patient adherence. CONCLUSIONS: Women with kidney disease are
      significantly more likely to be prescribed opiates and benzodiazepines than men
      with kidney disease. Further research is required to determine whether these
      medications contribute to increased morbidity and mortality in women with kidney 
      disease. TRIAL REGISTRATION: This manuscript does not meet the criteria for
      requiring registration or a statement of written consent from study participants.
      The previous submission of this manuscript already made mention of Research
      Ethics Board approval.
CI  - (c) The Author(s) 2020.
FAU - Krishnan, Dhruv
AU  - Krishnan D
AUID- ORCID: https://orcid.org/0000-0002-1046-8868
AD  - Department of Medicine, Queen's University, Kingston, ON, Canada.
FAU - Hopman, Wilma M
AU  - Hopman WM
AD  - KGH Research Institute, Kingston, ON, Canada.
AD  - Department of Public Health Sciences, Queen's University, Kingston, ON, Canada.
FAU - Holden, Rachel M
AU  - Holden RM
AUID- ORCID: https://orcid.org/0000-0001-6431-3127
AD  - Department of Medicine, Queen's University, Kingston, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7323260
OTO - NOTNLM
OT  - benzodiazepine
OT  - chronic kidney disease
OT  - dialysis
OT  - opiate
OT  - sex
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2019/08/20 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.1177/2054358120932673 [doi]
AID - 10.1177_2054358120932673 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Jun 26;7:2054358120932673. doi:
      10.1177/2054358120932673. eCollection 2020.


PMID- 32636888
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1726-913X (Print)
IS  - 1726-913X (Linking)
VI  - 18
IP  - 2
DP  - 2020 Apr
TI  - The Principles of Biomedical Scientific Writing: Citation.
PG  - e102622
LID - 10.5812/ijem.102622 [doi]
AB  - Citation, the act of properly referring to others' ideas, thoughts, or concepts, 
      is a common and critical practice in scientific writing. Citations are used to
      give credit to own work, to support an argument, to acknowledge others' work, to 
      distinguish other authors' ideas from one's work, and to direct readers to
      sources of information. A good citation adds to the scientific prestige of the
      paper and makes it more valuable to the reader. The citation has three basic
      elements: quoting from others, an in-text reference to the source, and
      bibliographic details of the source. Beyond technical skills, the citation needs 
      an in-depth knowledge of the field and should follow basic rules, including the
      selection of relevant and valid sources, stating information/facts from others'
      work, and referring to others' work accurately and ethically. Several systems and
      styles are used to cite scientific sources; however, the most commonly used
      systems in medical sciences are 'author-date' systems (e.g., Harvard system) and 
      numerical systems (e.g., Vancouver system). Here, we discuss how to make an
      accurate, complete, and ethical citation, and provide simple and practical guides
      to organize references in a scientific medical paper.
CI  - Copyright (c) 2020, International Journal of Endocrinology and Metabolism.
FAU - Bahadoran, Zahra
AU  - Bahadoran Z
AUID- ORCID: https://orcid.org/0000-0003-4636-3977
AD  - Nutrition and Endocrine Research Center, Research Institute for Endocrine
      Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Mirmiran, Parvin
AU  - Mirmiran P
AD  - Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition
      Sciences and Food Technology, National Nutrition and Food Technology Research
      Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Kashfi, Khosrow
AU  - Kashfi K
AUID- ORCID: https://orcid.org/0000-0002-4060-7283
AD  - Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of
      Biomedical Education, City University of New York School of Medicine, New York,
      United States.
FAU - Ghasemi, Asghar
AU  - Ghasemi A
AUID- ORCID: https://orcid.org/0000-0001-6867-2151
AD  - Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, 
      Shahid Beheshti University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200427
PL  - Netherlands
TA  - Int J Endocrinol Metab
JT  - International journal of endocrinology and metabolism
JID - 101235597
PMC - PMC7322669
OTO - NOTNLM
OT  - Citation
OT  - Medical Scientific Journals
OT  - Reference
OT  - Scientific Writing
COIS- Conflict of Interests: The authors have no conflict of interest.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.5812/ijem.102622 [doi]
PST - epublish
SO  - Int J Endocrinol Metab. 2020 Apr 27;18(2):e102622. doi: 10.5812/ijem.102622.
      eCollection 2020 Apr.


PMID- 32636796
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201003
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Parkinson's Disease Research on the African Continent: Obstacles and
      Opportunities.
PG  - 512
LID - 10.3389/fneur.2020.00512 [doi]
AB  - The burden of Parkinson's disease (PD) is becoming increasingly important in the 
      context of an aging African population. Although PD has been extensively
      investigated with respect to its environmental and genetic etiology in various
      populations across the globe, studies on the African continent remain limited. In
      this Perspective article, we review some of the obstacles that are limiting
      research and creating barriers for future studies. We summarize what research is 
      being done in four sub-Saharan countries and what the key elements are that are
      needed to take research to the next level. We note that there is large variation 
      in neurological and genetic research capacity across the continent, and many
      opportunities for unexplored areas in African PD research. Only a handful of
      countries possess appropriate infrastructure and personnel, whereas the majority 
      have yet to develop such capacity. Resource-constrained environments strongly
      determines the possibilities of performing research locally, and unidirectional
      export of biological samples and genetic data remains a concern. Local-regional
      partnerships, in collaboration with global PD consortia, should form an ethically
      appropriate solution, which will lead to a reduction in inequality and promote
      capacity building on the African continent.
CI  - Copyright (c) 2020 Dekker, Coulibaly, Bardien, Ross, Carr and Komolafe.
FAU - Dekker, Marieke C J
AU  - Dekker MCJ
AD  - Department of Medicine and Pediatrics, Kilimanjaro Christian Medical Centre,
      Moshi, Tanzania.
FAU - Coulibaly, Toumany
AU  - Coulibaly T
AD  - Service de Neurologie, Centre Hospitalier Universitaire du Point "G", Bamako,
      Mali.
FAU - Bardien, Soraya
AU  - Bardien S
AD  - Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, Cape Town, South Africa.
FAU - Ross, Owen A
AU  - Ross OA
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
AD  - Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL, United States.
FAU - Carr, Jonathan
AU  - Carr J
AD  - Division of Neurology, Faculty of Medicine and Health Sciences, Stellenbosch
      University, Cape Town, South Africa.
FAU - Komolafe, Morenikeji
AU  - Komolafe M
AD  - Department of Medicine, College of Health Sciences, Obafemi Awolowo University,
      Ile-Ife, Nigeria.
LA  - eng
GR  - R21 NS098862/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20200619
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7317302
OTO - NOTNLM
OT  - Africa
OT  - Parkinson's disease
OT  - awareness
OT  - epidemiology
OT  - genetics
OT  - public health
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.3389/fneur.2020.00512 [doi]
PST - epublish
SO  - Front Neurol. 2020 Jun 19;11:512. doi: 10.3389/fneur.2020.00512. eCollection
      2020.


PMID- 32636767
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - The Significance of Justice in the Psychotherapeutic Treatment of Traumatized
      People After War and Crises.
PG  - 540
LID - 10.3389/fpsyt.2020.00540 [doi]
AB  - In the aftermath of crimes against humanity, human rights violations, and
      genocide, the question arises whether and how justice can be restored. A lack of 
      social justice and continuing injustice in post-conflict areas prevent survivors 
      from processing their traumatic experiences. As a consequence, the individuals
      and often their families, their community, and the whole society are changed in a
      lasting way. The trauma can even be passed on over generations. Yet, if war has a
      negative impact on health, then, programs that focus on achieving justice, peace,
      and stability should be able to offset or reduce this negative impact. For this
      reason, the importance of psychosocial well-being and mental health for the
      reconstruction of societies is acknowledged. Various political, legal, and social
      programs, like transitional justice, are being implemented in post-war regions to
      develop justice. Developing or restoring justice also requires good psychosocial 
      care, like a treatment that supports individuals when coping with injustice and
      gaining a new sense of justice. Such a psychological treatment can make an
      important contribution when it comes to building new trust and improving mental
      health. Ethical standards in coping with trauma and developing or restoring
      justice in post-conflict regions are indispensable to enable long-term peace. The
      course for new social justice can be set, through a just health system. Thereby, 
      only programs and legal processes, which try to do justice to the survivors and
      take their needs into account, are ethically justifiable. Human rights and health
      cannot be separated in psychotherapy with survivors of war and terror. Based on
      ethical principles, new approaches must be generated for psychotherapy in war
      regions and with survivors of war and terror. The aim will be to make an
      important contribution to the mental and social reconstruction of countries after
      mass violence.
CI  - Copyright (c) 2020 Kizilhan and Neumann.
FAU - Kizilhan, Jan Ilhan
AU  - Kizilhan JI
AD  - Institute for Psychotherapy and Psychotraumtology, University of Duhok, Duhok,
      Iraq.
AD  - Institute of Transcultural Health Science, Baden-Wuerttemberg Cooperative State
      University, Villingen-Schwenningen, Germany.
AD  - Transcultural Psychosomatic Department, MediClin, Donaueschingen, Germany.
FAU - Neumann, Johanna
AU  - Neumann J
AD  - Institute of Transcultural Health Science, Baden-Wuerttemberg Cooperative State
      University, Villingen-Schwenningen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7318071
OTO - NOTNLM
OT  - justice
OT  - post-traumatic stress disorder
OT  - psychotherapy
OT  - reparation
OT  - trauma
OT  - war
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.3389/fpsyt.2020.00540 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Jun 19;11:540. doi: 10.3389/fpsyt.2020.00540. eCollection 
      2020.


PMID- 32636715
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Emotions and feelings in critical and emergency caring situations: a qualitative 
      study.
PG  - 60
LID - 10.1186/s12912-020-00438-6 [doi]
AB  - BACKGROUND: Moral emotions are a key element of our human morals. Emotions play
      an important role in the caring process. Decision-making and assessment in
      emergency situations are complex and they frequently result in different emotions
      and feelings among health-care professionals. METHODS: The study had qualitative 
      deductive design based on content analysis. Individual interviews and focus
      groups were conducted with sixteen participants. RESULTS: The emerging category
      "emotions and feelings in caring" has been analysed according to Haidt,
      considering that moral emotions include the subcategories of "Condemning
      emotions", "Self-conscious emotions", "Suffering emotions" and "Praising
      emotions". Within these subcategories, we found that the feelings that nurses
      experienced when ethical conflicts arose in emergency situations were related to 
      caring and decisions associated with it, even when they had experienced
      situations in which they believed they could have helped the patient differently,
      but the conditions at the time did not permit it and they felt that the ethical
      conflicts in clinical practice created a large degree of anxiety and moral
      stress. The nurses felt that caring, as seen from a nursing perspective, has a
      sensitive dimension that goes beyond the patient's own healing and, when this
      dimension is in conflict with the environment, it has a dehumanising effect.
      Positive feelings and satisfaction are created when nurses feel that care has met
      its objectives and that there has been an appropriate response to the needs.
      CONCLUSIONS: Moral emotions can help nurses to recognise situations that allow
      them to promote changes in the care of patients in extreme situations. They can
      also be the starting point for personal and professional growth and an evolution 
      towards person-centred care.
CI  - (c) The Author(s) 2020.
FAU - Jimenez-Herrera, Maria F
AU  - Jimenez-Herrera MF
AUID- ORCID: 0000-0003-2599-3742
AD  - Nursing Department, Universitat Rovira i Virgili (URV), Av/ Catalunya, 35 43002
      Tarragona, Spain.grid.410367.70000 0001 2284 9230
FAU - Llaurado-Serra, Mireia
AU  - Llaurado-Serra M
AD  - Faculty of Medicine and Health science, Nursing Department, University
      Internacional of Catalonia (UIC), Barcelona, Spain.grid.410675.10000 0001 2325
      3084
FAU - Acebedo-Urdiales, Sagrario
AU  - Acebedo-Urdiales S
AD  - Nursing Department, Universitat Rovira i Virgili (URV), Av/ Catalunya, 35 43002
      Tarragona, Spain.grid.410367.70000 0001 2284 9230
FAU - Bazo-Hernandez, Leticia
AU  - Bazo-Hernandez L
AD  - Nursing Department, Universitat Rovira i Virgili (URV), Av/ Catalunya, 35 43002
      Tarragona, Spain.grid.410367.70000 0001 2284 9230
FAU - Font-Jimenez, Isabel
AU  - Font-Jimenez I
AD  - Nursing Department, Universitat Rovira i Virgili (URV), Av/ Catalunya, 35 43002
      Tarragona, Spain.grid.410367.70000 0001 2284 9230
FAU - Axelsson, Christer
AU  - Axelsson C
AD  - Prehospital and Emergency Care, Faculty of Caring Science, Work life and Social
      Welfare,The Center of Prehospital Research, University of Boras, Boras,
      Sweden.grid.412442.50000 0000 9477 7523
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7331129
OTO - NOTNLM
OT  - Critical care
OT  - Emergency care
OT  - Moral emotions
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2019/05/02 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - 10.1186/s12912-020-00438-6 [doi]
AID - 438 [pii]
PST - epublish
SO  - BMC Nurs. 2020 Jul 1;19:60. doi: 10.1186/s12912-020-00438-6. eCollection 2020.


PMID- 32636525
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210707
IS  - 2399-3642 (Electronic)
IS  - 2399-3642 (Linking)
VI  - 3
IP  - 1
DP  - 2020 Jul 7
TI  - A systemic approach to assess the potential and risks of wildlife culling for
      infectious disease control.
PG  - 353
LID - 10.1038/s42003-020-1032-z [doi]
AB  - The maintenance of infectious diseases requires a sufficient number of
      susceptible hosts. Host culling is a potential control strategy for animal
      diseases. However, the reduction in biodiversity and increasing public concerns
      regarding the involved ethical issues have progressively challenged the use of
      wildlife culling. Here, we assess the potential of wildlife culling as an
      epidemiologically sound management tool, by examining the host ecology, pathogen 
      characteristics, eco-sociological contexts, and field work constraints. We also
      discuss alternative solutions and make recommendations for the appropriate
      implementation of culling for disease control.
FAU - Miguel, Eve
AU  - Miguel E
AD  - Medical Research Council Centre for Global Infectious Disease Analysis,
      Department of Infectious Disease Epidemiology, Imperial College London, London,
      UK. eve.miguel@ird.fr.
AD  - MIVEGEC (Infectious Diseases and Vectors: Ecology, Genetics, Evolution and
      Control), IRD (Research Institute for Sustainable Development), CNRS (National
      Center for Scientific Research), Univ. Montpellier, Montpellier, France.
      eve.miguel@ird.fr.
AD  - CREES Centre for Research on the Ecology and Evolution of Disease, Montpellier,
      France. eve.miguel@ird.fr.
FAU - Grosbois, Vladimir
AU  - Grosbois V
AD  - ASTRE (Animal, Health, Territories, Risks, Ecosystems), CIRAD (Agricultural
      Research for Development), Univ. Montpellier, INRA (French National Institute for
      Agricultural Research), Montpellier, France.
FAU - Caron, Alexandre
AU  - Caron A
AUID- ORCID: http://orcid.org/0000-0002-5213-3273
AD  - ASTRE (Animal, Health, Territories, Risks, Ecosystems), CIRAD (Agricultural
      Research for Development), Univ. Montpellier, INRA (French National Institute for
      Agricultural Research), Montpellier, France.
FAU - Pople, Diane
AU  - Pople D
AD  - Medical Research Council Centre for Global Infectious Disease Analysis,
      Department of Infectious Disease Epidemiology, Imperial College London, London,
      UK.
FAU - Roche, Benjamin
AU  - Roche B
AD  - MIVEGEC (Infectious Diseases and Vectors: Ecology, Genetics, Evolution and
      Control), IRD (Research Institute for Sustainable Development), CNRS (National
      Center for Scientific Research), Univ. Montpellier, Montpellier, France.
AD  - UMMISCO (Unite Mixte Internationnale de Modelisation Mathematique et
      Informatiques des Systemes Complexes, IRD/Sorbonne Universite, Bondy, France.
AD  - Departamento de Etologia, Fauna Silvestre y Animales de Laboratorio, Facultad de 
      Medicina Veterinaria y Zootecnia, Universidad Nacional Autonoma de Mexico (UNAM),
      Ciudad de, Mexico, Mexico.
FAU - Donnelly, Christl A
AU  - Donnelly CA
AUID- ORCID: http://orcid.org/0000-0002-0195-2463
AD  - Medical Research Council Centre for Global Infectious Disease Analysis,
      Department of Infectious Disease Epidemiology, Imperial College London, London,
      UK.
AD  - Department of Statistics, University of Oxford, Oxford, UK.
LA  - eng
GR  - MR/R015600/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200707
PL  - England
TA  - Commun Biol
JT  - Communications biology
JID - 101719179
SB  - IM
MH  - *Animal Culling/methods
MH  - Animals
MH  - *Animals, Wild
MH  - Communicable Disease Control/*methods
MH  - Communicable Diseases/*veterinary
MH  - Conservation of Natural Resources/methods
MH  - Ecology
MH  - Risk Assessment
PMC - PMC7340795
EDAT- 2020/07/09 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/09 06:00
PHST- 2018/09/07 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1038/s42003-020-1032-z [doi]
AID - 10.1038/s42003-020-1032-z [pii]
PST - epublish
SO  - Commun Biol. 2020 Jul 7;3(1):353. doi: 10.1038/s42003-020-1032-z.


PMID- 32636520
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20200724
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7815
DP  - 2020 Jul
TI  - Don't ask if artificial intelligence is good or fair, ask how it shifts power.
PG  - 169
LID - 10.1038/d41586-020-02003-2 [doi]
FAU - Kalluri, Pratyusha
AU  - Kalluri P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Congresses as Topic
MH  - *Empowerment
MH  - Humans
MH  - *Machine Learning
MH  - *Power, Psychological
MH  - *Social Dominance
MH  - *Vulnerable Populations
OTO - NOTNLM
OT  - *Ethics
OT  - *Research data
OT  - *Research management
OT  - *Society
EDAT- 2020/07/09 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
AID - 10.1038/d41586-020-02003-2 [doi]
AID - 10.1038/d41586-020-02003-2 [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7815):169. doi: 10.1038/d41586-020-02003-2.


PMID- 32636519
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20220531
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7815
DP  - 2020 Jul
TI  - Fight prejudice at all levels: from airports to conferences.
PG  - 202
LID - 10.1038/d41586-020-02039-4 [doi]
FAU - Marin, Cesar
AU  - Marin C
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9284-9291. PMID: 32291335
MH  - Airports
MH  - *Congresses as Topic
MH  - *Prejudice
OTO - NOTNLM
OT  - *Conferences and meetings
OT  - *Ethics
OT  - *Society
EDAT- 2020/07/09 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1038/d41586-020-02039-4 [doi]
AID - 10.1038/d41586-020-02039-4 [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7815):202. doi: 10.1038/d41586-020-02039-4.


PMID- 32636518
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7815
DP  - 2020 Jul
TI  - Deconstruct racism in medicine - from training to clinical trials.
PG  - 202
LID - 10.1038/d41586-020-02033-w [doi]
FAU - Swartz, Talia H
AU  - Swartz TH
FAU - Titanji, Boghuma
AU  - Titanji B
LA  - eng
PT  - Letter
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - African Americans/*statistics & numerical data
MH  - COVID-19
MH  - *Clinical Trials as Topic
MH  - Coronavirus Infections/epidemiology
MH  - *Education, Medical
MH  - Healthcare Disparities
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology
MH  - Racism/*prevention & control
OTO - NOTNLM
OT  - *Ethics
OT  - *Medical research
EDAT- 2020/07/09 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - 10.1038/d41586-020-02033-w [doi]
AID - 10.1038/d41586-020-02033-w [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7815):202. doi: 10.1038/d41586-020-02033-w.


PMID- 32636311
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 7
DP  - 2020 Jul
TI  - Ethical issues in intervention studies on the prevention and management of
      diabetes and hypertension in sub-Saharan Africa.
LID - e002193 [pii]
LID - 10.1136/bmjgh-2019-002193 [doi]
FAU - Shayo, Elizabeth
AU  - Shayo E
AD  - National Institutes for Medical Research, Dar es Salaam, United Republic of
      Tanzania.
FAU - Van Hout, Marie Claire
AU  - Van Hout MC
AUID- ORCID: 0000-0002-0018-4060
AD  - Faculty of Education, Health & Community, Liverpool John Moores University,
      Liverpool, Merseyside, UK.
FAU - Birungi, Josephine
AU  - Birungi J
AD  - MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
FAU - Garrib, Anupam
AU  - Garrib A
AD  - Department of Clinical Sciences, Liverpool School of Tropical Medicine,
      Liverpool, United Kingdom.
FAU - Kivuyo, Sokoine
AU  - Kivuyo S
AD  - National Institutes for Medical Research, Dar es Salaam, United Republic of
      Tanzania.
FAU - Mfinanga, Sayoki
AU  - Mfinanga S
AD  - National Institutes for Medical Research, Dar es Salaam, United Republic of
      Tanzania.
FAU - Nyrienda, Moffat J
AU  - Nyrienda MJ
AD  - MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
AD  - Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical 
      Medicine, London, UK.
FAU - Namakoola, Ivan
AU  - Namakoola I
AD  - MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
FAU - Okebe, Joseph
AU  - Okebe J
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      Liverpool, UK.
FAU - Ramaiya, Kaushik
AU  - Ramaiya K
AD  - Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania.
FAU - Bachmann, Max Oscar
AU  - Bachmann MO
AUID- ORCID: 0000-0003-1770-3506
AD  - Norwich Medical School, Faculty of Medicine and Health Sciences, University of
      East Anglia, Norwich, UK.
FAU - Cullen, Walter
AU  - Cullen W
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
FAU - Lazarus, Jeffrey V
AU  - Lazarus JV
AUID- ORCID: 0000-0001-9618-2299
AD  - Hospital Clinic, University of Barcelona, Instituto de Salud Global de Barcelona,
      Barcelona, Spain.
AD  - CHIP, Rigshospitalet, Kobenhavn, Denmark.
FAU - Gill, Geoff
AU  - Gill G
AD  - Emeritus Professor of International Medicine, Liverpool School of Tropical
      Medicine, Liverpool, United Kingdom.
FAU - Shiri, Tinevimbo
AU  - Shiri T
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      Liverpool, UK.
FAU - Bukenya, Dominic
AU  - Bukenya D
AD  - MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
FAU - Snell, Hazel
AU  - Snell H
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      Liverpool, UK.
FAU - Nanfuka, Mastula
AU  - Nanfuka M
AD  - The AIDS Support Organisation, Kampala, Uganda.
FAU - Cuevas, Luis E
AU  - Cuevas LE
AUID- ORCID: 0000-0002-6581-0587
AD  - Department of Clinical Sciences, Liverpool School of Tropical Medicine,
      Liverpool, United Kingdom.
FAU - Shimwela, Meshack
AU  - Shimwela M
AD  - Temeke Hospital, Dar es Salaam, Tanzania.
FAU - Mutungi, Gerald
AU  - Mutungi G
AD  - Non-communicable Disease Control Programme, Ministry of Health, Kampala, Uganda.
FAU - Musinguzi, Joshua
AU  - Musinguzi J
AD  - AIDS Control Programme, Ministry of Health, Kampala, Uganda.
FAU - Mghamba, Janneth
AU  - Mghamba J
AD  - Department of Preventive Services, Ministry of Health and Social Welfare, Dar es 
      Salaam, Tanzania.
FAU - Mugisha, Kenneth
AU  - Mugisha K
AD  - The AIDS Support Organisation, Kampala, Uganda.
FAU - Jaffar, Shabbar
AU  - Jaffar S
AUID- ORCID: 0000-0002-9615-1588
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      Liverpool, UK shabbar.jaffar@lstmed.ac.uk.
FAU - Smith, Peter G
AU  - Smith PG
AD  - MRC Tropical Epidemiology Group, Faculty of Epidemiology and Population Health,
      London School of Hygiene and Tropical Medicine, London, UK.
FAU - Sewankambo, Nelson Kaulukusi
AU  - Sewankambo NK
AD  - College of Health Sciences, Makerere University, Kampala, Uganda.
LA  - eng
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - *Diabetes Mellitus/epidemiology/prevention & control
MH  - Humans
MH  - *Hypertension/epidemiology/prevention & control
PMC - PMC7342469
OTO - NOTNLM
OT  - *HIV
OT  - *diabetes
OT  - *hypertension
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/07/09 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/06/02 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2019-002193 [pii]
AID - 10.1136/bmjgh-2019-002193 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Jul;5(7). pii: bmjgh-2019-002193. doi:
      10.1136/bmjgh-2019-002193.


PMID- 32636292
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - Immediate parent-infant skin-to-skin study (IPISTOSS): study protocol of a
      randomised controlled trial on very preterm infants cared for in skin-to-skin
      contact immediately after birth and potential physiological, epigenetic,
      psychological and neurodevelopmental consequences.
PG  - e038938
LID - 10.1136/bmjopen-2020-038938 [doi]
AB  - INTRODUCTION: In Scandinavia, 6% of infants are born preterm, before 37
      gestational weeks. Instead of continuing in the in-utero environment, maturation 
      needs to occur in a neonatal unit with support of vital functions, separated from
      the mother's warmth, nutrition and other benefits. Preterm infants face health
      and neurodevelopment challenges that may also affect the family and society at
      large. There is evidence of benefit from immediate and continued skin-to-skin
      contact (SSC) for term and moderately preterm infants and their parents but there
      is a knowledge gap on its effect on unstable very preterm infants when initiated 
      immediately after birth. METHODS AND ANALYSIS: In this ongoing randomised
      controlled trial from Stavanger, Norway and Stockholm, Sweden, we are studying
      150 infants born at 28+0 to 32+6 gestational weeks, randomised to receive care
      immediately after birth in SSC with a parent or conventionally in an incubator.
      The primary outcome is cardiorespiratory stability according to the stability of 
      the cardiorespiratory system in the preterm score. Secondary outcomes are
      autonomic stability, thermal control, infection control, SSC time, breastfeeding 
      and growth, epigenetic profile, microbiome profile, infant behaviour, stress
      resilience, sleep integrity, cortical maturation, neurodevelopment, mother-infant
      attachment and attunement, and parent experience and mental health. ETHICS AND
      DISSEMINATION: The study has ethical approval from the Swedish Ethical Review
      Authority (2017/1135-31/3, 2019-03361) and the Norwegian Regional Ethical
      Committee (2015/889). The study is conducted according to good clinical practice 
      and the Helsinki declaration. The results of the study will increase the
      knowledge about the mechanisms behind the effects of SSC for very preterm infants
      by dissemination to the scientific community through articles and at conferences,
      and to the society through parenting classes and magazines. STUDY STATUS:
      Recruiting since April 2018. Expected trial termination June 2021. TRIAL
      REGISTRATION NUMBER: NCT03521310 (ClinicalTrials.gov).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Linner, Agnes
AU  - Linner A
AUID- ORCID: 0000-0002-2934-2771
AD  - Women's and Children's Health, Karolinska Institute, Stockholm, Sweden
      agnes.linner@ki.se.
AD  - Neonatal Unit, Karolinska University Hospital, Stockholm, Sweden.
FAU - Westrup, Bjorn
AU  - Westrup B
AD  - Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
FAU - Lode-Kolz, Karoline
AU  - Lode-Kolz K
AD  - Department of Paediatrics, Stavanger Universitetssjukehus, Stavanger, Norway.
FAU - Klemming, Stina
AU  - Klemming S
AD  - Neonatal Unit, Karolinska University Hospital, Stockholm, Sweden.
FAU - Lillieskold, Siri
AU  - Lillieskold S
AD  - Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
AD  - Neonatal Unit, Karolinska University Hospital, Stockholm, Sweden.
FAU - Markhus Pike, Hanne
AU  - Markhus Pike H
AD  - Department of Paediatrics, Stavanger Universitetssjukehus, Stavanger, Norway.
FAU - Morgan, Barak
AU  - Morgan B
AD  - Global Risk Governance Programme, Law Faculty, University of Cape Town,
      Rondebosch, Western Cape, South Africa.
AD  - NRF Centre of Excellence in Human Development, University of the Witwatersrand,
      Johannesburg-Braamfontein, Gauteng, South Africa.
FAU - Bergman, Nils Johannes
AU  - Bergman NJ
AD  - Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
FAU - Rettedal, Siren
AU  - Rettedal S
AD  - Department of Paediatrics, Stavanger Universitetssjukehus, Stavanger, Norway.
FAU - Jonas, Wibke
AU  - Jonas W
AD  - Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03521310
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Epigenesis, Genetic
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - Norway
MH  - *Parents
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Scandinavian and Nordic Countries
MH  - Sweden
PMC - PMC7342825
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *maternal medicine
OT  - *neonatal intensive & critical care
OT  - *neonatology
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038938 [pii]
AID - 10.1136/bmjopen-2020-038938 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e038938. doi: 10.1136/bmjopen-2020-038938.


PMID- 32636291
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - Broad Spectrum project: factors determining the quality of antibiotic use in
      primary care: an observational study protocol from Italy.
PG  - e038843
LID - 10.1136/bmjopen-2020-038843 [doi]
AB  - INTRODUCTION: The overuse of antibiotics is causing worldwide spread of
      antimicrobial resistance (AMR). Compared with other countries, Italy has both
      high antibiotic consumption rates and high rates of AMR. Due to the fact that
      around 90% of antibiotics are prescribed by general practitioners (GPs), this
      study aims to measure the impact of knowledge, attitudes and sociodemographic and
      workplace-related factors on the quality of antibiotic prescriptions filled by
      GPs in the Italian Region of Sardinia. METHODS AND ANALYSIS: Knowledge, attitude,
      sociodemographic and workplace-related factors deemed to influence physicians
      prescribing behaviour will be evaluated in a cross-sectional study conducted
      among all GPs of the Italian Region of Sardinia (n=1200). A knowledge and
      attitudes questionnaire (Knowledge and Attitudes on Antibiotics and Resistance - 
      Italian version: ITA-KAAR) accompanied by a sociodemographic form will be linked 
      to drug prescription data reimbursed by the National Health System. European
      Surveillance of Antibiotic Consumption quality indicators for outpatient
      antibiotic use will be calculated from drug prescription records. Every GP will
      be deemed to have demonstrated an adequate quality of prescriptions of
      antibiotics if half of the indicator score plus one is better than the median of 
      the region. A multivariate Poisson regression model with robust variance
      estimation will be used to evaluate the impact of the determinants of antibiotic 
      prescriptions on the actual prescribing quality of each physician. ETHICS AND
      DISSEMINATION: The project has been approved by the ethics committee of the
      Regional Health Trust of Sardinia (176/2019/CE, 24 September 2019). The results
      will be useful to inform evidence-based interventions to tackle irrational
      antibiotic use in the community.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kurotschka, Peter Konstantin
AU  - Kurotschka PK
AUID- ORCID: 0000-0003-3750-6147
AD  - Department of Medical Science and Public Health, University of Cagliari,
      Cagliari, Italy kurotschka@hotmail.com.
AD  - General Practitioner in Training, Primary Care Department, Regional Health Trust 
      of Sardinia, Cagliari, Italy.
FAU - Serafini, Alice
AU  - Serafini A
AD  - General Practitioner in Training, Primary Care Department, Local Health Trust
      Modena, Modena, Italy.
FAU - Massari, Marco
AU  - Massari M
AD  - National Centre for Pre-Clinical and Clinical Drug Research and Surveillance
      (CNRVF), Istituto Superiore di Sanita, Rome, Italy.
FAU - Da Cas, Roberto
AU  - Da Cas R
AD  - National Centre for Pre-Clinical and Clinical Drug Research and Surveillance
      (CNRVF), Istituto Superiore di Sanita, Rome, Italy.
FAU - Figueiras, Adolfo
AU  - Figueiras A
AD  - Department of Preventive Medicine and Public Health, Universidade de Santiago de 
      Compostela, Santiago de Compostela, Spain.
FAU - Forte, Viviana
AU  - Forte V
AD  - General Practitioner, Primary Care Department, Regional Health Trust, Cagliari,
      Italy.
FAU - Moro, Maria Francesca
AU  - Moro MF
AD  - Mailman School of Public Health, Columbia University, New York, New York, USA.
FAU - Massidda, Matteo
AU  - Massidda M
AD  - General Practitioner in Training, Primary Care Department, Regional Health Trust 
      of Sardinia, Cagliari, Italy.
FAU - Contu, Federico
AU  - Contu F
AD  - General Practitioner in Training, Primary Care Department, Regional Health Trust 
      of Sardinia, Cagliari, Italy.
FAU - Minerba, Luigi
AU  - Minerba L
AD  - Department of Medical Science and Public Health, University of Cagliari,
      Cagliari, Italy.
FAU - Marcias, Maurizio
AU  - Marcias M
AD  - Health Technology Assessment Unit, Regional Health Trust of Sardinia, Cagliari,
      Italy.
FAU - Nardelli, Marco
AU  - Nardelli M
AD  - Brayford Square Surgery, Tower Hamlets Primary Care Trust, London, UK.
FAU - Perra, Alessandra
AU  - Perra A
AD  - Department of Medical Science and Public Health, University of Cagliari,
      Cagliari, Italy.
FAU - Carta, Mauro Giovanni
AU  - Carta MG
AUID- ORCID: 0000-0003-0706-9687
AD  - Department of Medical Science and Public Health, University of Cagliari,
      Cagliari, Italy.
FAU - Spila Alegiani, Stefania
AU  - Spila Alegiani S
AD  - National Centre for Pre-Clinical and Clinical Drug Research and Surveillance
      (CNRVF), Istituto Superiore di Sanita, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - *Anti-Bacterial Agents/therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Prescriptions
MH  - Humans
MH  - Italy
MH  - Observational Studies as Topic
MH  - *Practice Patterns, Physicians'
MH  - Primary Health Care
PMC - PMC7342852
OTO - NOTNLM
OT  - *antibiotic
OT  - *appropriate
OT  - *attitudes
OT  - *consumption
OT  - *determinants
OT  - *factors
OT  - *family medicine
OT  - *general practice
OT  - *knowledge
OT  - *prescription
OT  - *questionnaire
OT  - *use
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038843 [pii]
AID - 10.1136/bmjopen-2020-038843 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e038843. doi: 10.1136/bmjopen-2020-038843.


PMID- 32636290
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - High INtensity Interval Training In pATiEnts with intermittent claudication
      (INITIATE): protocol for a multicentre, proof-of-concept, prospective
      interventional study.
PG  - e038825
LID - 10.1136/bmjopen-2020-038825 [doi]
AB  - INTRODUCTION: The first-line recommended treatment for patients with intermittent
      claudication (IC) is a supervised exercise programme (SEP), which includes a
      minimum of 2-hours of exercise per week over a 12-week period. However,
      provision, uptake and adherence rates for these SEP programmes are poor, with
      time constraints cited as a common participant barrier. High-intensity interval
      training (HIIT) is more time-efficient and therefore has the potential to
      overcome this barrier. However, evidence is lacking for the role of HIIT in those
      with IC. This proof-of-concept study aims to consider the safety, feasibility,
      tolerability and acceptability of a HIIT programme for patients with IC. METHODS 
      AND ANALYSIS: This multicentre, single-group, prospective, interventional
      feasibility study will recruit 40 patients with IC, who will complete 6 weeks of 
      HIIT, 3 times a week. HIIT will involve a supervised programme of 10x1 min
      high-intensity cycling intervals at 85%-90% peak power output (PPO), interspaced 
      with 10x1 min low intensity intervals at 20%-25% PPO. PPO will be determined from
      a baseline cardiopulmonary exercise test (CPET) and it is intended that patients 
      will achieve >/=85% of maximum heart rate from CPET, by the end of the second
      HIIT interval. Primary outcome measures are safety (occurrence of adverse events 
      directly related to the study), programme feasibility (including participant
      eligibility, recruitment and completion rates) and HIIT tolerability (ability to 
      achieve and maintain the required intensity). Secondary outcomes include patient 
      acceptability, walking distance, CPET cardiorespiratory fitness measures and
      quality of life outcomes. ETHICS AND DISSEMINATION: Ethical approval was obtained
      via a local National Health Service research ethics committee (Bradford Leeds -
      18/YH/0112) and recruitment began in August 2019 and will be completed in October
      2020. Results will be published in peer-reviewed journals and presented at
      international conferences and are expected to inform a future pilot randomised
      controlled trial of HIIT versus usual-care SEPs. TRIAL REGISTRATION NUMBER:
      NCT04042311; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Pymer, Sean
AU  - Pymer S
AUID- ORCID: 0000-0003-1685-2091
AD  - Academic Vascular Surgical Unit, Hull York Medical School, Hull, UK
      sean.pymer@hey.nhs.uk.
FAU - Harwood, Amy
AU  - Harwood A
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, New 
      South Wales, UK.
AD  - Department of Sport, Health and Exercise Science, University of Hull, Hull, UK.
FAU - Ibeggazene, Said
AU  - Ibeggazene S
AUID- ORCID: 0000-0001-9457-7887
AD  - Academic Vascular Surgical Unit, Hull York Medical School, Hull, UK.
FAU - McGregor, Gordon
AU  - McGregor G
AUID- ORCID: 0000-0001-8963-9107
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, New 
      South Wales, UK.
AD  - Department of Cardiac Rehabilitation, Centre for Exercise and Health, University 
      Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
AD  - Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick,
      Coventry, UK.
FAU - Huang, Chao
AU  - Huang C
AD  - Institute of Clinical and Applied Health Research, Hull York Medical School,
      University of Hull, Hull, UK.
FAU - Twiddy, Maureen
AU  - Twiddy M
AD  - Institute of Clinical and Applied Health Research, Hull York Medical School,
      University of Hull, Hull, UK.
FAU - Nicholls, Adam R
AU  - Nicholls AR
AD  - Department of Sport, Health and Exercise Science, University of Hull, Hull, UK.
FAU - Ingle, Lee
AU  - Ingle L
AD  - Department of Sport, Health and Exercise Science, University of Hull, Hull, UK.
FAU - Carroll, Sean
AU  - Carroll S
AD  - Department of Sport, Health and Exercise Science, University of Hull, Hull, UK.
FAU - Long, Judith
AU  - Long J
AD  - Academic Vascular Surgical Unit, Hull York Medical School, Hull, UK.
FAU - Rooms, Marjorie
AU  - Rooms M
AD  - Hull, UK.
FAU - Chetter, I C
AU  - Chetter IC
AD  - Academic Vascular Surgical Unit, Hull York Medical School, Hull, UK.
CN  - INITIATE investigator group
LA  - eng
SI  - ClinicalTrials.gov/NCT04042311
GR  - PB-PG-0418-20014/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Exercise Therapy
MH  - *High-Intensity Interval Training
MH  - Humans
MH  - Intermittent Claudication/therapy
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - State Medicine
PMC - PMC7342853
OTO - NOTNLM
OT  - *rehabilitation medicine
OT  - *vascular medicine
OT  - *vascular surgery
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038825 [pii]
AID - 10.1136/bmjopen-2020-038825 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e038825. doi: 10.1136/bmjopen-2020-038825.


PMID- 32636289
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - End-of-life care preferences of older patients with multimorbidity: protocol of a
      mixed-methods systematic review.
PG  - e038682
LID - 10.1136/bmjopen-2020-038682 [doi]
AB  - INTRODUCTION: End-of-life care is an essential task performed by most healthcare 
      providers and often involves decision-making about how and where patients want to
      receive care. To provide decision support to healthcare professionals and
      patients in this difficult situation, we will systematically review a knowledge
      cluster of the end-of-life care preferences of older patients with multimorbidity
      that we previously identified using an evidence map. METHODS AND ANALYSIS: We
      will systematically search for studies reporting end-of-life care preferences of 
      older patients (mean age >/=60) with multimorbidity (>/=2 chronic conditions) in 
      MEDLINE, CINAHL, PsycINFO, Social Sciences Citation Index, Social Sciences
      Citation Index Expanded, PSYNDEX and The Cochrane Library from inception to
      September 2019. We will include all primary studies that use quantitative,
      qualitative and mixed methodologies, irrespective of publication date and
      language.Two independent reviewers will assess eligibility, extract data and
      describe evidence in terms of study/population characteristics, preference
      assessment method and end-of-life care elements that matter to patients (eg,
      life-sustaining treatments). Risk of bias/applicability of results will be
      independently assessed by two reviewers using the Mixed-Methods Appraisal Tool.
      Using a convergent integrated approach on qualitative/quantitative studies, we
      will synthesise information narratively and, wherever possible, quantitatively.
      ETHICS AND DISSEMINATION: Due to the nature of the proposed systematic review,
      ethics approval is not required. Results from our research will be disseminated
      at relevant (inter-)national conferences and via publication in peer-reviewed
      journals. Synthesising evidence on end-of-life care preferences of older patients
      with multimorbidity will improve shared decision-making and satisfaction in this 
      final period of life. PROSPERO REGISTRATION NUMBER: CRD42020151862.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gonzalez-Gonzalez, Ana Isabel
AU  - Gonzalez-Gonzalez AI
AUID- ORCID: 0000-0002-1707-0596
AD  - Institute of General Practice, Goethe University, Frankfurt am Main, Germany
      gonzalezgonzalez@allgemeinmedizin.uni-frankfurt.de.
AD  - Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC),
      Madrid, Spain.
FAU - Schmucker, Christine
AU  - Schmucker C
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical
      Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Nothacker, Julia
AU  - Nothacker J
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical
      Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
FAU - Nguyen, Truc Sophia
AU  - Nguyen TS
AUID- ORCID: 0000-0002-9774-6751
AD  - Institute of General Practice, Goethe University, Frankfurt am Main, Germany.
FAU - Brueckle, Maria-Sophie
AU  - Brueckle MS
AD  - Institute of General Practice, Goethe University, Frankfurt am Main, Germany.
FAU - Blom, Jeanet
AU  - Blom J
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, Netherlands.
FAU - van den Akker, Marjan
AU  - van den Akker M
AUID- ORCID: 0000-0002-1022-8637
AD  - Institute of General Practice, Goethe University, Frankfurt am Main, Germany.
FAU - Rottger, Kristian
AU  - Rottger K
AD  - Federal Joint Committee "Gemeinsamer Bundesausschuss", Berlin, Germany.
FAU - Wegwarth, Odette
AU  - Wegwarth O
AUID- ORCID: 0000-0003-0885-2673
AD  - Center for Adaptive Rationality, Max Planck Institute for Human Development,
      Berlin, Germany.
FAU - Hoffmann, Tammy
AU  - Hoffmann T
AD  - Institute for Evidence-Based Healthcare, Faculty of Health Sciences and Medicine,
      Bond University, Gold Coast, Queensland, Australia.
FAU - Gerlach, Ferdinand M
AU  - Gerlach FM
AD  - Institute of General Practice, Goethe University, Frankfurt, Germany.
FAU - Straus, Sharon E
AU  - Straus SE
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Meerpohl, Joerg J
AU  - Meerpohl JJ
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical
      Center-University of Freiburg, Freiburg, Germany.
FAU - Muth, Christiane
AU  - Muth C
AUID- ORCID: 0000-0001-8987-182X
AD  - Institute of General Practice, Goethe University, Frankfurt, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - Humans
MH  - *Multimorbidity
MH  - Qualitative Research
MH  - Research Design
MH  - *Terminal Care
PMC - PMC7342816
OTO - NOTNLM
OT  - *adult palliative care
OT  - *ethics (see medical ethics)
OT  - *general medicine (see internal medicine)
OT  - *geriatric medicine
OT  - *internal medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038682 [pii]
AID - 10.1136/bmjopen-2020-038682 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e038682. doi: 10.1136/bmjopen-2020-038682.


PMID- 32636288
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - Realist Evaluation of Autism ServiCe Delivery (RE-ASCeD): which diagnostic
      pathways work best, for whom and in what context? Protocol for a rapid realist
      review.
PG  - e037846
LID - 10.1136/bmjopen-2020-037846 [doi]
AB  - INTRODUCTION: The National Health Service (NHS) Long-Term Plan (2019)
      acknowledges that children and young people with suspected autism wait too long
      for diagnostic assessment and sets out to reduce waiting times. However,
      diagnostic pathways vary with limited evidence on what model works best, for whom
      and in what circumstances. The National Autism Plan for Children (2003)
      recommended that assessment should be completed within 13 weeks but referral to
      diagnosis can take as long as 799 days.This Rapid Realist Review (RRR) is the
      first work package in a national programme of research: a Realist Evaluation of
      Autism ServiCe Delivery (RE-ASCeD). We explore how particular approaches may
      deliver high-quality and timely autism diagnostic services for children with
      possible autism; high quality is defined as compliant with National Institute for
      Heath and Care Excellence (2011) guidelines, and timely as a pathway lasting no
      more than one calendar year, based on previous work. METHODS AND ANALYSIS: RRR is
      a well-established approach to synthesising evidence within a compressed
      timeframe to identify models of service delivery leading to desired outcomes. RRR
      works backwards from intended outcomes, identified by NICE guidelines and the NHS
      England Long-Term Plan. The focus is a clearly defined intervention (the
      diagnostic pathway), associated with specific outcomes (high quality and timely),
      within a particular set of parameters (Autism and Child & Adolescent Mental
      Health services in the UK). Our Expert Stakeholder Group consists of
      policymakers, content experts and knowledge users with a wide range of experience
      to supplement, tailor and expedite the process. The RRR is consistent with
      Realist And Meta-narrative Evidence Syntheses: Evolving Standards (RAMESES) and
      includes identifying the research question, searching for information, quality
      appraisal, data extraction, synthesising the evidence, validation of findings
      with experts and dissemination. ETHICS AND DISSEMINATION: Ethical approval not
      required. Findings will inform the wider RE-ASCeD evaluation and be reported to
      NHS England. TRIAL REGISTRATION NUMBER: NCT04422483. This protocol relates to
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Abrahamson, Vanessa
AU  - Abrahamson V
AUID- ORCID: 0000-0002-1169-9457
AD  - Centre for Health Services Studies, University of Kent, Canterbury, Kent, UK
      v.j.abrahamson@kent.ac.uk.
FAU - Zhang, Wenjing
AU  - Zhang W
AUID- ORCID: 0000-0002-1810-791X
AD  - Centre for Health Services Studies, University of Kent, Canterbury, Kent, UK.
FAU - Wilson, Patricia
AU  - Wilson P
AUID- ORCID: 0000-0002-5787-9736
AD  - Centre for Health Services Studies, University of Kent, Canterbury, Kent, UK.
FAU - Farr, William
AU  - Farr W
AUID- ORCID: 0000-0003-3644-5311
AD  - Mid Sussex Child Development Centre, Sussex Community NHS Foundation Trust,
      Haywards Heath, West Sussex, UK.
AD  - Paediatrics, Brighton and Sussex Medical School, Brighton, UK.
FAU - Male, Ian
AU  - Male I
AUID- ORCID: 0000-0001-5426-6646
AD  - Mid Sussex Child Development Centre, Sussex Community NHS Foundation Trust,
      Haywards Heath, West Sussex, UK.
AD  - Paediatrics, Brighton and Sussex Medical School, Brighton, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04422483
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Autistic Disorder/diagnosis/therapy
MH  - Child
MH  - Delivery of Health Care
MH  - England
MH  - Humans
MH  - *State Medicine
PMC - PMC7342857
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *health policy
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037846 [pii]
AID - 10.1136/bmjopen-2020-037846 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e037846. doi: 10.1136/bmjopen-2020-037846.


PMID- 32636287
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210924
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - Detection of intracranial hypertension in children using optical coherence
      tomography: a systematic review protocol.
PG  - e037833
LID - 10.1136/bmjopen-2020-037833 [doi]
AB  - INTRODUCTION: Intracranial hypertension (ICH) in children can have deleterious
      effects on the brain and vision. It is notoriously difficult to estimate
      intracranial pressure (ICP) in children and existing methods deliver suboptimal
      diagnostic accuracy to be used as screening tools. Optical coherence tomography
      (OCT) may represent a valuable, non-invasive surrogate measure of ICP, as has
      been demonstrated in a number of associated conditions affecting adults. More
      recently, OCT has been employed within the paediatric age group. However, the
      role of OCT in detecting ICH in children has not been rigorously assessed in a
      systematic review for all relevant conditions. Here, we propose a systematic
      review protocol to examine the role of OCT in the detection of ICH in children.
      METHODS AND ANALYSIS: Electronic searches in the Cochrane Central Register of
      Controlled Trials, Medline, Embase, Web of Science and PubMed will identify
      studies featuring OCT in detecting ICH in children. Two independent screeners
      will identify studies for inclusion using a screening questionnaire. The
      systematic search and screening will take place between 2 April 2020 and 1 June
      2020, while we aim to complete data analysis by 1 September 2020. Quality
      assessment will be performed using the National Institutes of Health Quality
      Assessment Tool for Observational Cohort and Cross-Sectional Studies. The primary
      outcome measure is the sensitivity and specificity of OCT in detecting ICH in
      children. Secondary outcomes measures include conditions associated with ICH per 
      study, direct ICP monitoring, sensitivity and specificity of other measures for
      ICP and OCT parameters used. ETHICS AND DISSEMINATION: Ethical approval is not
      required for the proposed systematic review as no primary data will be collected.
      The findings will be disseminated through presentations at scientific meetings
      and peer-reviewed journal publication. PROSPERO REGISTRATION NUMBER:
      CRD42019154254.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Rufai, Sohaib R
AU  - Rufai SR
AUID- ORCID: 0000-0001-8134-6393
AD  - Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital
      for Children, London, United Kingdom.
AD  - University of Leicester Ulverscroft Eye Unit, Leicester Royal Infirmary,
      Leicester, United Kingdom.
FAU - Jeelani, Noor Ul Owase
AU  - Jeelani NUO
AD  - Craniofacial Unit, Great Ormond Street Hospital for Children, London, United
      Kingdom.
AD  - Developmental Biology & Cancer Dept, UCL GOS Institute of Child Health, London,
      United Kingdom.
FAU - McLean, Rebecca J
AU  - McLean RJ
AD  - University of Leicester Ulverscroft Eye Unit, Leicester Royal Infirmary,
      Leicester, United Kingdom rjm19@leicester.ac.uk.
LA  - eng
GR  - MR/N004566/1/MRC_/Medical Research Council/United Kingdom
GR  - NIHR300155/DH_/Department of Health/United Kingdom
GR  - MR/N004566/1/Medical Research Council [UK]/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Intracranial Hypertension/diagnostic imaging
MH  - Intracranial Pressure
MH  - Research Design
MH  - Sensitivity and Specificity
MH  - Systematic Reviews as Topic
MH  - *Tomography, Optical Coherence
PMC - PMC7342863
OTO - NOTNLM
OT  - *neuro-ophthalmology
OT  - *neurosurgery
OT  - *ophthalmology
OT  - *paediatric ophthalmology
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037833 [pii]
AID - 10.1136/bmjopen-2020-037833 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e037833. doi: 10.1136/bmjopen-2020-037833.


PMID- 32636286
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - Strength of the association between Turner syndrome and coeliac disease: protocol
      for a systematic review and meta-analysis.
PG  - e037478
LID - 10.1136/bmjopen-2020-037478 [doi]
AB  - INTRODUCTION: Coeliac disease (CD) is a genetic autoimmune disorder characterised
      by a permanent sensitivity to the gluten contained in some grains. Certain
      patient groups are considered high risk for the development of CD, including, but
      not limited to, those with chromosomal disorders such as Turner syndrome (TS).
      Here, we present a protocol for a systematic review and meta-analysis that aims
      to comprehensively summarise the literature, and quantitatively estimate the
      weighted strength of the association between TS and CD. METHODS AND ANALYSIS: Our
      protocol follows the Preferred Reporting Items for Systematic Review and
      Meta-Analysis Protocols 2015 guidelines. We will search PubMed, Scopus, Web of
      Science and Embase databases for relevant articles. Variant and broad search
      terms will be selected for identifying epidemiological studies reporting on the
      crude and/or adjusted association between TS and CD. Retrieved citations will be 
      screened, and data from the eligible research reports against specific
      eligibility criteria will be extracted. We will then assess the risk of bias
      associated with the eligible studies using the Newcastle-Ottawa Scale. The
      overall weighted strength of the pooled association will be quantified using the 
      random-effects model. ETHICS AND DISSEMINATION: This review will use data from
      published literature; hence, ethical approval will not be needed. The resulting
      review will be the first to produce a comprehensive synthesis of the strength of 
      the association between TS and CD. The results will be disseminated through a
      peer-reviewed journal as well as in local and international conferences and
      symposiums. Results dissemination would help healthcare providers and
      policy-makers to make informed decisions regarding the diagnosis and management
      of CD in high-risk individuals. PROSPERO REGISTRATION NUMBER: CRD42019131881,
      dated 3 September 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Al-Bluwi, Ghada S M
AU  - Al-Bluwi GSM
AUID- ORCID: 0000-0002-5850-7002
AD  - Department of Internal Medicine, College of Medicine and Health Sciences, United 
      Arab Emirates University, Al Ain, United Arab Emirates.
FAU - Alnababteh, Asma H
AU  - Alnababteh AH
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, Al Ain, United Arab Emirates.
FAU - Al-Shamsi, Saif
AU  - Al-Shamsi S
AUID- ORCID: 0000-0001-9755-3493
AD  - Department of Internal Medicine, College of Medicine and Health Sciences, United 
      Arab Emirates University, Al Ain, United Arab Emirates.
FAU - Al-Rifai, Rami H
AU  - Al-Rifai RH
AUID- ORCID: 0000-0001-6102-0353
AD  - Institute of Public Health, College of Medicine and Health Sciences, United Arab 
      Emirates University, Al Ain, United Arab Emirates rrifai@uaeu.ac.ae.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Celiac Disease/complications/epidemiology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Review Literature as Topic
MH  - *Turner Syndrome/complications/epidemiology
PMC - PMC7342855
OTO - NOTNLM
OT  - *coeliac disease
OT  - *epidemiology
OT  - *gastrointestinal tumours
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037478 [pii]
AID - 10.1136/bmjopen-2020-037478 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e037478. doi: 10.1136/bmjopen-2020-037478.


PMID- 32636285
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - How do patients and the public understand overtesting and overdiagnosis? A
      protocol for a thematic meta-synthesis of qualitative research.
PG  - e037283
LID - 10.1136/bmjopen-2020-037283 [doi]
AB  - INTRODUCTION: Examining patient and public understanding of overtesting and
      overdiagnosis (OverTD) is vital for reducing the burden of OverTD. Studies from
      disparate contexts, disciplines and focusing on disparate healthcare issues have 
      examined patient and public understanding of OverTD. A synthesis is needed to
      bring this literature together, examine common themes, strengthen conclusions and
      identify gaps. This will help steer further research, policy and practice to
      improve patient and public understanding of OverTD. The objective of this study
      is to synthesise qualitative research data about patient and public understanding
      of OverTD. METHODS AND ANALYSIS: A thematic meta-synthesis will be used to
      synthesise primary qualitative research and qualitative components of primary
      mixed-methods research about patient and public understanding of OverTD. Studies 
      published in English will be included. These will be identified using systematic 
      searches from inception to March 2020 in the Scopus, CINAHL, PsycINFO and MEDLINE
      databases. Studies that satisfy eligibility criteria will be assessed for
      methodological quality using the Critical Appraisal Skills Programme (CASP)
      checklist. Thematic meta-synthesis will comprise three stages: (1) line-by-line
      coding; (2) generation of descriptive themes and (3) generation of analytic
      themes. Confidence in the synthesis findings will be assessed using the Grading
      of Recommendations Assessment, Development and Evaluation Confidence in Evidence 
      (GRADE CERQual) approach. A summary of GRADE CERQual results will be presented
      alongside the key themes. Study eligibility screening, data extraction, analysis 
      and the CASP and GRADE CERQual assessments will be undertaken independently by
      two review authors. ETHICS AND DISSEMINATION: Ethics approval is not required for
      this secondary analysis of published data. The results will be disseminated in
      peer-reviewed journals and may be presented in conference papers and elsewhere.
      PROSPERO REGISTRATION NUMBER: CRD42020156838.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rozbroj, Tomas
AU  - Rozbroj T
AUID- ORCID: 0000-0002-3084-746X
AD  - Monash Department of Clinical Epidemiology, Cabrini Institute, Monash University,
      Clayton, Victoria, Australia tomas.rozbroj@monash.edu.
AD  - Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia.
FAU - Haas, Romi
AU  - Haas R
AD  - Monash Department of Clinical Epidemiology, Cabrini Institute, Monash University,
      Clayton, Victoria, Australia.
AD  - Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia.
FAU - O'Connor, Denise A
AU  - O'Connor DA
AD  - Monash Department of Clinical Epidemiology, Cabrini Institute, Monash University,
      Clayton, Victoria, Australia.
AD  - Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia.
FAU - Thomas, Rae
AU  - Thomas R
AUID- ORCID: 0000-0002-2165-5917
AD  - Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland,
      Australia.
FAU - McCaffery, Kirsten
AU  - McCaffery K
AD  - Sydney School of Public Health, Sydney Medical School, The University of Sydney, 
      Sydney, NSW, Australia.
FAU - Carter, Stacy
AU  - Carter S
AUID- ORCID: 0000-0003-2617-8694
AD  - Australian Centre for Health Engagement, Evidence and Values, University of
      Wollongong, Wollongong, New South Wales, Australia.
FAU - Buchbinder, Rachelle
AU  - Buchbinder R
AD  - Monash Department of Clinical Epidemiology, Cabrini Institute, Monash University,
      Clayton, Victoria, Australia.
AD  - Cabrini Institute, Cabrini Health, Malvern, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Medical Overuse
MH  - Qualitative Research
PMC - PMC7342480
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *public health
OT  - *qualitative research
OT  - *quality in health care
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037283 [pii]
AID - 10.1136/bmjopen-2020-037283 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e037283. doi: 10.1136/bmjopen-2020-037283.


PMID- 32636281
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 6
TI  - Protocol for a phase IV, open-label feasibility study investigating non-invasive 
      markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty
      liver disease randomised to receiving optimised background therapy (OBT) plus
      maraviroc or OBT alone.
PG  - e035596
LID - 10.1136/bmjopen-2019-035596 [doi]
AB  - INTRODUCTION: At least 30% of people living with HIV (PLWH) infection have
      non-alcoholic fatty liver disease (NAFLD), which has now become a leading cause
      of hepatic fibrosis and cirrhosis. Management is based largely on lifestyle
      modifications, which are difficult to achieve, and therapeutic options are
      urgently needed. Maraviroc (MVC), through antagonism of CCR5 receptors, may
      reduce hepatic fibrosis progression and could be an effective treatment for
      NAFLD. However, dosing is usually two times per day, unlike most currently
      recommended antiretroviral therapies. This study will investigate the feasibility
      and acceptability of addition of MVC to combination antiretroviral therapy in
      PLWH and NAFLD as a treatment for NAFLD. METHODS AND ANALYSIS: This is a phase
      IV, randomised, open-label, non-invasive feasibility study. Sixty individuals
      with well-controlled HIV-1 and NAFLD will be recruited from UK HIV clinics and
      randomised 1:1 to receive either optimised background therapy (OBT) plus MVC or
      OBT alone. Follow-up will be every 24 weeks for 96 weeks. The primary outcome
      measures will include recruitment and retention rates, adverse events and
      adherence. Secondary outcomes will include changes in markers of hepatic
      fibrosis, including the Enhanced Liver Fibrosis score, median liver stiffness
      measurement and controlled attenuation parameter scores on Fibroscan, and quality
      of life assessments. Analyses will be performed according to intention-to-treat
      principles. For secondary outcomes, estimated differences and 95% CIs between the
      groups using a t-method will be presented for continuous variables and as exact
      95% binomial CIs for categorical variables. ETHICS AND DISSEMINATION: Ethical
      approval was obtained through the London Dulwich UK Research Ethics Committee
      (reference 17/LO/2093). Results will be disseminated both through community
      groups and peer-reviewed scientific literature.Trial registration number
      SRCTN31461655. EudraCT number 2017-004141-24; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bradshaw, Daniel
AU  - Bradshaw D
AUID- ORCID: 0000-0001-7186-2482
AD  - Brighton and Sussex University Hospitals NHS Trust, Brighton
      daniel.bradshaw2@nhs.net.
FAU - Gilleece, Yvonne
AU  - Gilleece Y
AD  - Brighton and Sussex University Hospitals NHS Trust, Brighton.
FAU - Verma, Sumita
AU  - Verma S
AD  - Brighton and Sussex Medical School, Brighton, UK.
FAU - Abramowicz, Iga
AU  - Abramowicz I
AD  - Brighton and Sussex Medical School, Brighton, UK.
FAU - Bremner, Stephen
AU  - Bremner S
AD  - Brighton and Sussex Medical School, Brighton, UK.
FAU - Perry, Nicky
AU  - Perry N
AD  - Brighton and Sussex Medical School, Brighton, UK.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
RN  - MD6P741W8A (Maraviroc)
SB  - IM
MH  - Biomarkers/analysis
MH  - *Clinical Protocols
MH  - Feasibility Studies
MH  - HIV Infections/*complications/physiopathology
MH  - Humans
MH  - London
MH  - Maraviroc/adverse effects/*therapeutic use
MH  - Non-alcoholic Fatty Liver Disease/*complications/physiopathology
PMC - PMC7342479
OTO - NOTNLM
OT  - *Fibroscan
OT  - *HIV-1
OT  - *enhanced liver fibrosis (ELF)
OT  - *hepatic fibrosis
OT  - *maraviroc
OT  - *non-alcoholic fatty liver disease (NAFLD)
OT  - *non-invasive markers
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035596 [pii]
AID - 10.1136/bmjopen-2019-035596 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 6;10(7):e035596. doi: 10.1136/bmjopen-2019-035596.


PMID- 32636195
OWN - NLM
STAT- MEDLINE
DCOM- 20200709
LR  - 20220531
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 370
DP  - 2020 Jul 7
TI  - Is stratified shielding from covid-19 feasible and ethical?
PG  - m2660
LID - 10.1136/bmj.m2660 [doi]
FAU - Petersen, Irene
AU  - Petersen I
AD  - Department of Primary Care and Population Health, Institute of Epidemiology and
      Health Care, University College London, London, UK.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200707
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
CON - BMJ. 2020 May 28;369:m2063. PMID: 32467287
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Risk Assessment
MH  - SARS-CoV-2
COIS- Competing interests: None declared.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/10 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/10 06:00 [medline]
AID - 10.1136/bmj.m2660 [doi]
PST - epublish
SO  - BMJ. 2020 Jul 7;370:m2660. doi: 10.1136/bmj.m2660.


PMID- 32636140
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20211002
IS  - 1879-1972 (Electronic)
IS  - 1054-139X (Linking)
VI  - 67
IP  - 4
DP  - 2020 Oct
TI  - Adolescent Barriers to HIV Prevention Research: Are Parental Consent Requirements
      the Biggest Obstacle?
PG  - 495-501
LID - S1054-139X(20)30230-5 [pii]
LID - 10.1016/j.jadohealth.2020.05.011 [doi]
AB  - PURPOSE: One third of people newly living with HIV/AIDS are adolescents. Research
      on adolescent HIV prevention is critical owing to differences between adolescents
      and adults. Parental permission requirements are often considered a barrier to
      adolescent enrollment in research, but whether adolescents view this barrier as
      the most important one is unclear. METHODS: Adolescents were approached in
      schools in KwaZulu-Natal, South Africa, and at a sexually transmitted infection
      clinic at the Children's Hospital of Aurora, Colorado. Surveys with a
      hypothetical vignette about participation in a pre-exposure prophylaxis trial
      were conducted on smartphones or tablets with 75 adolescents at each site. We
      calculated descriptive statistics for all variables, using 2-sample tests for
      equality of proportions with continuity correction. Statistical significance was 
      calculated at p < 0.05. Multivariate analyses were also conducted. RESULTS: Most 
      adolescents thought side effects (77%) and parental consent requirements (69%)
      were very important barriers to research participation. When asked to rank
      barriers, adolescents did not agree on a single barrier as most important, but
      the largest group of adolescents ranked parental consent requirements as most
      important (29.5%). Parental consent was seen as more of a barrier for adolescents
      in South Africa than in the United States. Concerns about being experimented on
      or researchers' mandatory reporting to authorities were ranked much lower.
      Finally, most (71%, n = 106) adolescents said they would want to extra support
      from another adult if parental permission was not required. CONCLUSION:
      Adolescents consider both parental permission requirements and side effects
      important barriers to their enrollment in HIV prevention research. Legal reform
      and better communication strategies may help address these barriers.
CI  - Copyright (c) 2020 Society for Adolescent Health and Medicine. All rights
      reserved.
FAU - Shah, Seema K
AU  - Shah SK
AD  - Division of AIDS, Department of Bioethics, NIH Clinical Center, Bethesda,
      Maryland; Department of Pediatrics, Smith Child Health Research, Outreach, and
      Advocacy Center, Lurie Children's Hospital, Northwestern University Medical
      School, Chicago, Illinois. Electronic address: SeShah@luriechildrens.org.
FAU - Essack, Zaynab
AU  - Essack Z
AD  - Centre for Community-Based Research, Human Sciences Research Council (HSRC),
      Sweetwaters, KwaZulu-Natal, South Africa; HIV AIDS Vaccines Ethics Group (HAVEG),
      School of Applied Human Sciences, College of Humanities, University of
      KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal, South Africa.
FAU - Byron, Katherine
AU  - Byron K
AD  - Department of Bioethics, NIH Clinical Center, Bethesda, Maryland.
FAU - Slack, Catherine
AU  - Slack C
AD  - HIV AIDS Vaccines Ethics Group (HAVEG), School of Applied Human Sciences, College
      of Humanities, University of KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal,
      South Africa.
FAU - Reirden, Daniel
AU  - Reirden D
AD  - Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, 
      Colorado.
FAU - van Rooyen, Heidi
AU  - van Rooyen H
AD  - Centre for Community-Based Research, Human Sciences Research Council (HSRC),
      Sweetwaters, KwaZulu-Natal, South Africa; Faculty of Health Sciences, School of
      Clincial Medicine, University of the Witwatersrand, Johannesburg, South Africa.
FAU - Jones, Nathan R
AU  - Jones NR
AD  - University of Wisconsin Survey Center, Madison, Wisconsin.
FAU - Wendler, David S
AU  - Wendler DS
AD  - Department of Bioethics, NIH Clinical Center, Bethesda, Maryland.
LA  - eng
GR  - R01 AI094586/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20200705
PL  - United States
TA  - J Adolesc Health
JT  - The Journal of adolescent health : official publication of the Society for
      Adolescent Medicine
JID - 9102136
SB  - IM
CIN - J Adolesc Health. 2020 Oct;67(4):463-464. PMID: 32951679
MH  - *Acquired Immunodeficiency Syndrome
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Colorado
MH  - *HIV Infections/prevention & control
MH  - Humans
MH  - Parental Consent
MH  - South Africa
MH  - United States
PMC - PMC7508889
MID - NIHMS1610187
OTO - NOTNLM
OT  - *Adolescence
OT  - *Adolescents
OT  - *Barriers to research
OT  - *Consent
OT  - *Ethics
OT  - *HIV prevention research
OT  - *Parental permission
EDAT- 2020/07/09 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/07/09 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - S1054-139X(20)30230-5 [pii]
AID - 10.1016/j.jadohealth.2020.05.011 [doi]
PST - ppublish
SO  - J Adolesc Health. 2020 Oct;67(4):495-501. doi: 10.1016/j.jadohealth.2020.05.011. 
      Epub 2020 Jul 5.


PMID- 32636117
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 59
IP  - 4
DP  - 2020 Aug
TI  - Cell culture - Fact and fiction.
PG  - 102860
LID - S1473-0502(20)30165-8 [pii]
LID - 10.1016/j.transci.2020.102860 [doi]
FAU - Smit Sibinga, Cees Th
AU  - Smit Sibinga CT
AD  - IQM Consulting, Zuidhorn and University of Groningen, Netherlands. Electronic
      address: c.sibinga@planet.nl.
FAU - Seghatchian, Jerard
AU  - Seghatchian J
AD  - International Consultancy in Strategic Advices on Safety Improvements of
      Blood-Derived Bioproducts and Suppliers Quality Audit/Inspection, London, UK.
      Electronic address: jseghatchian@btopenworld.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200629
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
MH  - Cell Culture Techniques/*methods
MH  - Humans
PMC - PMC7323688
OTO - NOTNLM
OT  - *Cell culture
OT  - *Clinical practice
OT  - *Moral-ethical question
OT  - *Universal human rights
EDAT- 2020/07/09 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - S1473-0502(20)30165-8 [pii]
AID - 10.1016/j.transci.2020.102860 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2020 Aug;59(4):102860. doi: 10.1016/j.transci.2020.102860.
      Epub 2020 Jun 29.


PMID- 32635964
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1832-4274 (Print)
IS  - 1832-4274 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Jun
TI  - Human Genetics Society of Australasia Position Statement: Predictive and
      Presymptomatic Genetic Testing in Adults and Children.
PG  - 184-189
LID - 10.1017/thg.2020.51 [doi]
AB  - In 2020, the Human Genetics Society of Australasia released its Position
      Statement on Predictive and Presymptomatic Genetic Testing in Adults and
      Children. This Position Statement synthesizes the major practical, psychosocial
      and ethical considerations associated with presymptomatic and predictive genetic 
      testing in adults who have the capacity to make a decision, children and young
      people who lack capacity and adults living with reduced or fluctuating capacity. 
      Recommendations include that predictive testing in adults, young people and
      children should only be offered with pretest genetic counseling and the option of
      posttest genetic counseling. An individual considering (for themselves or on
      behalf of another) whether to have a predictive test should also be supported to 
      allow them to make an autonomous and informed decision. Predictive testing should
      only be offered to children and young people for conditions where there is likely
      to be a direct medical benefit to them through surveillance, use of prevention
      strategies or other medical interventions in the immediate future. Where symptoms
      are likely to develop in childhood, in the absence of options to implement
      surveillance or risk reduction measures, genetic health professionals and
      parents/guardians should discuss whether undertaking predictive testing is the
      best course of action for the child and the family as a whole. Where symptoms are
      likely to develop in adulthood, the default position should be to postpone
      predictive testing until the young person achieves the capacity to make their own
      autonomous and informed decision.
FAU - Vears, Danya F
AU  - Vears DF
AD  - Melbourne Law School, University of Melbourne, Melbourne, VIC, Australia.
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Melbourne, VIC, Australia.
FAU - Ayres, Samantha
AU  - Ayres S
AD  - Victorian Clinical Genetics Services, Murdoch Children's Research Institute,
      Melbourne, VIC, Australia.
AD  - Melbourne Genomics Health Alliance, Melbourne, VIC, Australia.
AD  - Australian Genomics Health Alliance, Melbourne, VIC, Australia.
FAU - Boyle, Jackie
AU  - Boyle J
AD  - Hunter Genetics, Waratah, NSW, Australia.
FAU - Mansour, Julia
AU  - Mansour J
AD  - Tasmanian Clinical Genetics Service, Royal Hobart Hospital, Hobart, TAS,
      Australia.
FAU - Newson, Ainsley J
AU  - Newson AJ
AD  - Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health
      Ethics, The University of Sydney, Sydney, NSW, Australia.
CN  - Education, Ethics and Social Issues Committee of the Human Genetics Society of
      Australasia
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Twin Res Hum Genet
JT  - Twin research and human genetics : the official journal of the International
      Society for Twin Studies
JID - 101244624
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Asymptomatic Diseases/epidemiology
MH  - Australasia/epidemiology
MH  - Child
MH  - Female
MH  - *Genetic Counseling
MH  - Genetic Predisposition to Disease/*genetics
MH  - *Genetic Testing
MH  - Humans
MH  - Male
OTO - NOTNLM
OT  - *Australia
OT  - *New Zealand
OT  - *adults
OT  - *children
OT  - *genetic testing
OT  - *predictive testing
OT  - *young people
EDAT- 2020/07/09 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
AID - S1832427420000511 [pii]
AID - 10.1017/thg.2020.51 [doi]
PST - ppublish
SO  - Twin Res Hum Genet. 2020 Jun;23(3):184-189. doi: 10.1017/thg.2020.51.


PMID- 32635912
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20220325
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jul 7
TI  - Exploring the acceptability of controlled human infection with SARSCoV2-a public 
      consultation.
PG  - 209
LID - 10.1186/s12916-020-01670-2 [doi]
AB  - Rapid development of an effective vaccine for SARSCoV2 is a global priority. A
      controlled human infection model (CHIM) would accelerate the efficacy assessment 
      of candidate vaccines. This strategy would require deliberate exposure of
      volunteers to SARSCoV2 with no currently available treatment and a small but
      definite risk of serious illness or death. This raises complex questions about
      the social and ethical acceptability of risk to individuals, given the potential 
      benefit to the wider population, and as such, a study cannot be done without
      public involvement. We conducted a structured public consultation with 57
      individuals aged 20-40 years to understand public attitudes to a CHIM, and
      pre-requisites for enrolment. The overall response to this strategy was positive,
      and many would volunteer altruistically. Carefully controlled infection is viewed
      as safer than natural exposure to wild virus. The prolonged social isolation
      required for the proposed CHIM is considered an obstacle but not insurmountable, 
      with reasonable compensation and supportive care. Given the significant level of 
      public interest, a CHIM should be done as open science with regular, controlled
      dissemination of information into the public domain. Importantly, there was a
      strong view that the final decision whether to conduct a CHIM should be in the
      hands of qualified and experienced clinician-scientists and the authorities.
FAU - Gbesemete, D
AU  - Gbesemete D
AD  - Faculty of Medicine and Institute for Life Sciences, University of Southampton,
      School of Clinical and Experimental Sciences, NIHR Clinical Research Facility and
      NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS 
      Foundation Trust Mailpoint 218, University Hospital Southampton NHS Foundation
      Trust Tremona Road, Southampton, SO16 6YD, UK.
FAU - Barker, M
AU  - Barker M
AD  - MRC Lifecourse Epidemiology Unit, University of Southampton, D08 Institute of
      Developmental Science and NIHR Southampton Biomedical Research Centre, University
      of Southampton and University Hospitals Southampton NHS Foundation Trust,
      Southampton, UK.
FAU - Lawrence, W T
AU  - Lawrence WT
AD  - MRC Lifecourse Epidemiology Unit, University of Southampton, D08 Institute of
      Developmental Science and NIHR Southampton Biomedical Research Centre, University
      of Southampton and University Hospitals Southampton NHS Foundation Trust,
      Southampton, UK.
FAU - Watson, D
AU  - Watson D
AD  - School of Human Development and Health, Faculty of Medicine, University of
      Southampton, D08 Institute of Developmental Science, University Hospitals
      Southampton NHS Foundation Trust, Southampton, UK.
FAU - de Graaf, H
AU  - de Graaf H
AD  - Faculty of Medicine and Institute for Life Sciences, University of Southampton,
      School of Clinical and Experimental Sciences, NIHR Clinical Research Facility and
      NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS 
      Foundation Trust Mailpoint 218, University Hospital Southampton NHS Foundation
      Trust Tremona Road, Southampton, SO16 6YD, UK.
FAU - Read, R C
AU  - Read RC
AUID- ORCID: 0000-0002-4297-6728
AD  - Faculty of Medicine and Institute for Life Sciences, University of Southampton,
      School of Clinical and Experimental Sciences, NIHR Clinical Research Facility and
      NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS 
      Foundation Trust, University of Southampton, Southampton General Hospital, South 
      Academic Block, Mailpoint 814, Tremona Road, Southampton, SO16 6YD, UK.
      r.c.read@soton.ac.uk.
LA  - eng
GR  - MR/N026993/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/N011848/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/N013204/1/MRC_/Medical Research Council/United Kingdom
GR  - IS-BRC-1215-20004/NIHR Southampton Biomedical Research Centre/International
GR  - RP-PG-0216-20004/DH_/Department of Health/United Kingdom
GR  - MC_UU_12011/4/MRC_/Medical Research Council/United Kingdom
PT  - Letter
DEP - 20200707
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CIN - Am J Respir Crit Care Med. 2022 May 1;205(9):1112. PMID: 35119971
MH  - Adult
MH  - *Attitude to Health
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control
MH  - Drug Development
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - Pandemics/*prevention & control
MH  - Patient Selection
MH  - Pneumonia, Viral/*prevention & control
MH  - Public Opinion
MH  - Referral and Consultation
MH  - SARS-CoV-2
MH  - United Kingdom
MH  - Viral Vaccines/*therapeutic use
MH  - Young Adult
PMC - PMC7339437
OTO - NOTNLM
OT  - *COVID-19
OT  - *Controlled human infection model
OT  - *Public consultation
OT  - *SARSCoV2
EDAT- 2020/07/09 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.1186/s12916-020-01670-2 [doi]
AID - 10.1186/s12916-020-01670-2 [pii]
PST - epublish
SO  - BMC Med. 2020 Jul 7;18(1):209. doi: 10.1186/s12916-020-01670-2.


PMID- 32635761
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20201218
IS  - 1724-6067 (Electronic)
IS  - 1120-7000 (Linking)
VI  - 30
IP  - 5
DP  - 2020 Sep
TI  - Resuming hip and knee arthroplasty after COVID-19: ethical implications for
      wellbeing, safety and the economy.
PG  - 492-499
LID - 10.1177/1120700020941232 [doi]
AB  - Reinstating elective hip and knee arthroplasty services presents significant
      challenges. We need to be honest about the scale of the obstacles ahead and
      realise that the health challenges and economic consequences of the COVID-19
      pandemic are potentially devastating.We must also prepare to make difficult
      ethical decisions about restarting elective hip and knee arthroplasty. These
      decisions should be based on the existing evidence-base, reliable data, the
      recommendations of experts, and regional circumstances.
FAU - Kort, Nanne P
AU  - Kort NP
AD  - CortoClinics, Schijndel, The Netherlands.
FAU - Zagra, Luigi
AU  - Zagra L
AD  - IRCCS Istituto Ortopedico Galeazzi, Hip Department, Milan, Italy.
FAU - Barrena, Enrique Gomez
AU  - Barrena EG
AUID- ORCID: https://orcid.org/0000-0003-1065-6137
AD  - Department of Orthopaedic Surgery and Traumatology, Hospital La Paz, Autonomous
      University of Madrid, Madrid, Spain.
FAU - Tandogan, Reha N
AU  - Tandogan RN
AD  - Ortoklinik and Cankaya Orthopaedics, Ankara, Turkey.
FAU - Thaler, Martin
AU  - Thaler M
AD  - Department of Orthopaedic Surgery, Medical University of Innsbruck, Innsbruck,
      Austria.
FAU - Berstock, James R
AU  - Berstock JR
AD  - Department of Orthopaedics, Royal United Hospital Bath, Bath, UK.
FAU - Karachalios, Theofilos
AU  - Karachalios T
AD  - Orthopaedic Department, University General Hospital of Larissa, School of Health 
      Sciences, Faculty of Medicine, University of Thessalia, Thessalia, Greece.
LA  - eng
PT  - Editorial
DEP - 20200707
PL  - United States
TA  - Hip Int
JT  - Hip international : the journal of clinical and experimental research on hip
      pathology and therapy
JID - 9200413
SB  - IM
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control/transmission
MH  - *Delivery of Health Care
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Patient Selection
MH  - Pneumonia, Viral/*epidemiology/prevention & control/transmission
MH  - SARS-CoV-2
PMC - PMC7345437
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus disease 2019
OT  - SARS-CoV-2
OT  - coronavirus 2
OT  - economic
OT  - ethical challenge
OT  - healthcare
OT  - orthopaedic
OT  - revision arthroplasty
OT  - severe acute respiratory syndrome
OT  - total hip arthroplasty
OT  - total knee arthroplasty
EDAT- 2020/07/09 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
AID - 10.1177/1120700020941232 [doi]
PST - ppublish
SO  - Hip Int. 2020 Sep;30(5):492-499. doi: 10.1177/1120700020941232. Epub 2020 Jul 7.


PMID- 32635284
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201120
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 13
DP  - 2020 Jul 3
TI  - Mapping the Structure of Food Waste Management Research: A Co-Keyword Analysis.
LID - E4798 [pii]
LID - 10.3390/ijerph17134798 [doi]
AB  - Food loss and waste represent a global problem in the ethical, social,
      environmental, and economic contexts. The aim of this article is to identify
      leading concepts in studies on food loss and waste in management research by
      network analysis of the co-occurrence of keywords, via mapping of knowledge
      domains, a method used in bibliometrics. We analyzed 2202 records from the Scopus
      database on food waste management with the aid of the VOSviewer software tool. In
      particular, keyword co-occurrence analysis was adopted to visually explore
      knowledge bases, topic distribution, and research fronts in the field of food
      waste management research. Ten representative areas were found concentrated in
      main keywords, namely, food waste, waste management, food, anaerobic digestion,
      waste disposal, recycling, waste treatment, municipal solid waste, solid waste,
      and refuse disposal.
FAU - Gorzen-Mitka, Iwona
AU  - Gorzen-Mitka I
AD  - Faculty of Management, Czestochowa University of Technology, 42-200 Czestochowa, 
      Poland.
FAU - Bilska, Beata
AU  - Bilska B
AD  - Department of Food Gastronomy and Food Hygiene, Institute of Human Nutrition
      Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.
FAU - Tomaszewska, Marzena
AU  - Tomaszewska M
AD  - Department of Food Gastronomy and Food Hygiene, Institute of Human Nutrition
      Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.
FAU - Kolozyn-Krajewska, Danuta
AU  - Kolozyn-Krajewska D
AUID- ORCID: 0000-0001-9876-5287
AD  - Department of Food Gastronomy and Food Hygiene, Institute of Human Nutrition
      Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200703
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Solid Waste)
SB  - IM
MH  - *Food
MH  - Recycling
MH  - Refuse Disposal
MH  - Solid Waste/analysis
MH  - *Waste Management
PMC - PMC7370176
OTO - NOTNLM
OT  - *co-occurrence analysis
OT  - *food loss
OT  - *food waste
OT  - *management
OT  - *network analysis
EDAT- 2020/07/09 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/07/09 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/22 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - ijerph17134798 [pii]
AID - 10.3390/ijerph17134798 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jul 3;17(13). pii: ijerph17134798. doi:
      10.3390/ijerph17134798.


PMID- 32634850
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1432-2277 (Electronic)
IS  - 0934-0874 (Linking)
VI  - 33
IP  - 9
DP  - 2020 Sep
TI  - Paired kidney exchange transplantation - pushing the boundaries.
PG  - 975-984
LID - 10.1111/tri.13693 [doi]
AB  - The scarcity of living organ donors makes it imperative to develop newer
      innovations to optimize and maximize the utilization of the available pool. ABO
      and HLA sensitization are important immunological barriers in renal transplant
      and can potentially lead to rejection of almost one-third of the willing living
      donors. Paired kidney exchange (PKE) is a rapidly growing method used to overcome
      these barriers and has grown in popularity over the last three decades since its 
      introduction in 1986. Evolution of the matching strategies and use of complex
      algorithms has led to increase in the number of possible matches thereby
      benefiting multiple recipients. The use of altruistic donors and compatible pairs
      has also helped in increasing the possible exchanges. This review provides an
      in-depth analysis of the evolution, the present global scenario, and the future
      of PKE. It also discusses the recent trends of advanced donation, trans-organ
      paired exchange and global kidney exchange and the associated ethical concerns.
CI  - (c) 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
FAU - Kher, Vijay
AU  - Kher V
AUID- ORCID: 0000-0003-1676-9810
AD  - Department of Nephrology & Transplant Medicine, Medanta - The Medicity, Gurgaon, 
      Harayana, India.
FAU - Jha, Pranaw Kumar
AU  - Jha PK
AUID- ORCID: 0000-0003-1612-9215
AD  - Department of Nephrology & Transplant Medicine, Medanta - The Medicity, Gurgaon, 
      Harayana, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200802
PL  - Switzerland
TA  - Transpl Int
JT  - Transplant international : official journal of the European Society for Organ
      Transplantation
JID - 8908516
SB  - IM
MH  - Altruism
MH  - Humans
MH  - Kidney
MH  - *Kidney Transplantation
MH  - Living Donors
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *domino kidney paired donation
OT  - *kidney paired donation
OT  - *paired kidney exchange
OT  - *renal transplant
EDAT- 2020/07/08 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/07/08 06:00
PHST- 2019/06/24 00:00 [received]
PHST- 2019/08/02 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1111/tri.13693 [doi]
PST - ppublish
SO  - Transpl Int. 2020 Sep;33(9):975-984. doi: 10.1111/tri.13693. Epub 2020 Aug 2.


PMID- 32634453
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 224
DP  - 2020 Oct 1
TI  - Plenary lecture: Eating our way through the anthropocene: the challenges, risks
      and ethics of actions.
PG  - 113050
LID - S0031-9384(20)30364-4 [pii]
LID - 10.1016/j.physbeh.2020.113050 [doi]
FAU - Hunter, Stephanie R
AU  - Hunter SR
AD  - Purdue University, Department of Nutrition Science, Ingestive Behavior Research
      Center, West Lafayette, IN, United States. Electronic address:
      hunter99@purdue.edu.
FAU - Fanzo, Jessica
AU  - Fanzo J
AD  - Bloomberg Distinguished Associate Professor of Global Food and Agricultural
      Policy and Ethics, John Hopkins University, Baltimore, MD, United States.
LA  - eng
PT  - Journal Article
PT  - Lecture
DEP - 20200704
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
MH  - *Ecosystem
EDAT- 2020/07/08 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/06/24 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - S0031-9384(20)30364-4 [pii]
AID - 10.1016/j.physbeh.2020.113050 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Oct 1;224:113050. doi: 10.1016/j.physbeh.2020.113050. Epub
      2020 Jul 4.


PMID- 32634406
OWN - NLM
STAT- MEDLINE
DCOM- 20220103
LR  - 20220103
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
VI  - 226
DP  - 2020 Nov
TI  - Epidemiology of Birth Defects in Very Low Birth Weight Infants in Japan.
PG  - 106-111.e10
LID - S0022-3476(20)30855-6 [pii]
LID - 10.1016/j.jpeds.2020.07.012 [doi]
AB  - OBJECTIVE: To evaluate the mortality and morbidity of very low birth weight
      (VLBW) preterm infants with birth defects in Japan. STUDY DESIGN: Data were
      collected prospectively for infants weighing <1501 g and born at <37 weeks of
      gestation admitted to centers of the Neonatal Research Network of Japan during
      2003-2016. We compared outcomes of infants with and without birth defects using
      Pearson chi(2) test, Wilcoxon rank-sum test, log-rank test, nominal logistic
      regression analysis, and stratified analysis by birth defect subgroups. This
      study was approved by the Ethics Committee of Kyoto University Graduate School
      and Faculty of Medicine. RESULTS: Among 57 730 VLBW preterm infants, 3557 infants
      (6.2%) were born with birth defects. Chromosomal abnormalities, congenital heart 
      defects, and congenital malformation of the digestive system were the most common
      categories. Among diseases, Trisomy 18, Down syndrome, and cleft palate were the 
      most prevalent. There were significant differences between perinatal
      characteristics of infants with and without birth defects. Most categories of
      morbidity occurred more frequently in infants with birth defects compared with
      those without birth defects. The aOR for mortality during the neonatal intensive 
      care unit admission was 10.6 (95% CI 9.5-11.7) for infants with birth defects. A 
      stratified analysis identified birth defect categories with good, moderate, and
      poor prognoses. CONCLUSIONS: This detailed information about mortality and
      morbidity of preterm VLBW infants with birth defects should be useful for genetic
      counseling as well as prenatal and neonatal care, with the limitation that we
      lacked information about the timing of diagnosis, abortion, or stillbirth.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Kawasaki, Hidenori
AU  - Kawasaki H
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
FAU - Yamada, Takahiro
AU  - Yamada T
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan. Electronic address: taka0197@kuhp.kyoto-u.ac.jp.
FAU - Takahashi, Yoshimitsu
AU  - Takahashi Y
AD  - Department of Health Informatics, Kyoto University School of Public Health,
      Kyoto, Japan.
FAU - Nakayama, Takeo
AU  - Nakayama T
AD  - Department of Health Informatics, Kyoto University School of Public Health,
      Kyoto, Japan.
FAU - Wada, Takahito
AU  - Wada T
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
FAU - Kosugi, Shinji
AU  - Kosugi S
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
CN  - Neonatal Research Network of Japan
LA  - eng
PT  - Journal Article
DEP - 20200705
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
SB  - IM
MH  - Congenital Abnormalities/*epidemiology
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Infant, Premature, Diseases/*epidemiology
MH  - Infant, Very Low Birth Weight
MH  - Intensive Care, Neonatal
MH  - Japan/epidemiology
MH  - Male
MH  - Survival Rate
OTO - NOTNLM
OT  - *congenital anomaly
OT  - *morbidity
OT  - *mortality
OT  - *preterm
EDAT- 2020/07/08 06:00
MHDA- 2022/01/04 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/02/11 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2022/01/04 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - S0022-3476(20)30855-6 [pii]
AID - 10.1016/j.jpeds.2020.07.012 [doi]
PST - ppublish
SO  - J Pediatr. 2020 Nov;226:106-111.e10. doi: 10.1016/j.jpeds.2020.07.012. Epub 2020 
      Jul 5.


PMID- 32633990
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 2223-6279 (Electronic)
IS  - 0379-8577 (Linking)
VI  - 43
IP  - 1
DP  - 2020 Jun 11
TI  - Lived experiences of psychiatric patients with mood disorders who attended group 
      therapy facilitated by professional psychiatric nurses.
PG  - e1-e9
LID - 10.4102/curationis.v43i1.2114 [doi]
AB  - BACKGROUND: According to the World Health Organization (WHO), up to 25% of people
      worldwide will develop mental health disorders during their lifetime. Patients
      admitted to acute inpatient units for mood disorders experience emotional
      distress. Group therapy has the potential to foster the therapeutic change
      through specific therapeutic mechanisms. Psychiatric nurses working in inpatient 
      units are in a unique position to offer group therapy. OBJECTIVES: Explore and
      describe stabilised acute psychiatric patients with mood disorders' lived
      experiences of group therapy facilitated by psychiatric nurses. Make specific
      recommendations for psychiatric nurses to facilitate constructive group therapy
      for stabilised acute psychiatric patients with mood disorders in an inpatient
      unit. METHOD: A qualitative, exploratory, descriptive and contextual design was
      used in the study. A purposive sample of all patients with mood disorders older
      than 18 years admitted to inpatient units who participated in group therapy was
      made. Data were collected through conducting phenomenological interviews,
      observation and field notes. Interviews focussed on the following open question: 
      'How did you experience group therapy facilitated by the psychiatric nurses?' An 
      independent coder analysed the data by using thematic coding. Measures to ensure 
      trustworthiness were applied. The following four ethical principles were adhered 
      to: autonomy, non-maleficence, beneficence and justice. RESULTS: Three themes
      emerged from this study. Theme 1 entailed the psychological experiences of
      patients attending group therapy. Theme 2 highlighted the interpersonal
      experiences of patients. Theme 3 evolved around patients' experiences outside
      group therapy. Patients initially experienced attending group therapy as anxiety 
      provoking. However, negative psychological experiences soon transformed into
      positive psychological experiences. CONCLUSION: The findings of this study were
      used to make specific recommendations to facilitate constructive group therapy
      for patients with mood disorders.
FAU - Visagie, Hester M P
AU  - Visagie HMP
AD  - Department of Nursing, University of Johannesburg, Johannesburg.
      217073137@student.uj.ac.za.
FAU - Poggenpoel, Marie
AU  - Poggenpoel M
FAU - Myburgh, Chris
AU  - Myburgh C
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - South Africa
TA  - Curationis
JT  - Curationis
JID - 7901092
MH  - Adult
MH  - Female
MH  - Humans
MH  - Interviews as Topic/methods
MH  - *Life Change Events
MH  - Male
MH  - Middle Aged
MH  - Mood Disorders/psychology/*therapy
MH  - Nurse-Patient Relations
MH  - Psychiatric Nursing/methods/standards/statistics & numerical data
MH  - Psychotherapy, Group/methods/*standards/statistics & numerical data
MH  - Qualitative Research
MH  - South Africa
PMC - PMC7343934
OTO - NOTNLM
OT  - acute inpatient unit
OT  - group therapy
OT  - lived experiences
OT  - psychiatric nurses
OT  - stabilised acute psychiatric patients
EDAT- 2020/07/08 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/07/08 06:00
PHST- 2019/09/13 00:00 [received]
PHST- 2020/01/25 00:00 [accepted]
PHST- 2019/11/18 00:00 [revised]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - 10.4102/curationis.v43i1.2114 [doi]
PST - epublish
SO  - Curationis. 2020 Jun 11;43(1):e1-e9. doi: 10.4102/curationis.v43i1.2114.


PMID- 32633818
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Rethinking Ethical Categories in the Age of Technology.
PG  - 3
LID - 10.1002/hast.1111 [doi]
AB  - Over time, ethical judgments evolve, but so do the phenomena they are applied to.
      For example, plagiarism is a modern concept. Before the early eighteenth century,
      works did not generally have references or acknowledgments, and ideas were freely
      exchanged. As writing became an occupation, copying others' words became
      "unethical." As cut and paste, music mash-up, and other technological forms of
      exchange make copying the works of others simple, the idea of plagiarism is
      eroding, and perhaps will eventually even be discarded. The same may be true with
      privacy. As with plagiarism, it was not really until the eighteenth century that 
      our modern idea of privacy was established. To younger generations, raised on
      social media, online life is predicated on trading personal information for
      access. The undermining of former standards of privacy may suggest that privacy
      may also eventually become an outmoded concept.
CI  - (c) 2020 The Hastings Center.
FAU - Wolpe, Paul Root
AU  - Wolpe PR
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Humans
MH  - *Plagiarism
MH  - Privacy
MH  - *Social Media
MH  - Technology
MH  - Writing
OTO - NOTNLM
OT  - *ethics
OT  - *history
OT  - *plagiarism
OT  - *privacy
EDAT- 2020/07/08 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1002/hast.1111 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):3. doi: 10.1002/hast.1111. Epub 2020 Jul 7.


PMID- 32633816
OWN - NLM
STAT- MEDLINE
DCOM- 20201228
LR  - 20210708
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Rethinking the Importance of the Individual within a Community of Data.
PG  - 9-11
LID - 10.1002/hast.1112 [doi]
AB  - The Covid-19 crisis has underscored the importance of the collection and analysis
      of clinical and research data and specimens for ongoing work. The federal
      government recently completed a related revision of the human subjects research
      regulations, founded in the traditional principles of research ethics, but in
      this commentary, we argue that the analysis underpinning this revision
      overemphasized the importance of informed consent, given the low risks of
      secondary research. Governing the interests of a community is different from
      governing the interests of individuals, and here we suggest that, moving forward,
      the analyses of the risks of secondary research protocols be assessed from the
      perspective of the former.
CI  - (c) 2020 The Hastings Center.
FAU - Spector-Bagdady, Kayte
AU  - Spector-Bagdady K
FAU - Beever, Jonathan
AU  - Beever J
LA  - eng
GR  - K01 HG010496/HG/NHGRI NIH HHS/United States
GR  - UL1 TR002240/TR/NCATS NIH HHS/United States
GR  - UL1TR002240/TR/NCATS NIH HHS/United States
GR  - K01HG010496/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200707
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Biomedical Research/*ethics
MH  - *COVID-19
MH  - Ethics Committees, Research
MH  - Federal Government
MH  - Government Regulation
MH  - Human Experimentation/ethics
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Policy Making
MH  - Research Design
MH  - *Research Subjects
PMC - PMC7771627
MID - NIHMS1655404
OTO - NOTNLM
OT  - *bioethics
OT  - *biospecimens
OT  - *data
OT  - *research
EDAT- 2020/07/08 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1002/hast.1112 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Jul;50(4):9-11. doi: 10.1002/hast.1112. Epub 2020 Jul 7.


PMID- 32633583
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201218
IS  - 1525-6073 (Electronic)
IS  - 0742-0528 (Linking)
VI  - 37
IP  - 7
DP  - 2020 Jul
TI  - COVID-19 and "natural" experiments arising from physical distancing: a
      hypothetical case study from chronobiology.
PG  - 1115-1117
LID - 10.1080/07420528.2020.1779993 [doi]
AB  - With countless "natural" experiments triggered by the COVID-19-associated
      physical distancing, one key question comes from chronobiology: "When confined to
      homes, how does the reduced exposure to natural daylight arising from the
      interruption of usual outdoor activities plus lost temporal organization
      ordinarily provided from workplaces and schools affect the circadian timing
      system (the internal 24 h clock) and, consequently, health of children and adults
      of all ages?" Herein, we discuss some ethical and scientific facets of exploring 
      such natural experiments by offering a hypothetical case study of circadian
      biology.
FAU - Erren, Thomas C
AU  - Erren TC
AUID- ORCID: 0000-0002-7110-1031
AD  - Institute and Policlinic for Occupational Medicine, Environmental Medicine and
      Prevention Research, University Hospital of Cologne , Cologne, Germany.
FAU - Lewis, Philip
AU  - Lewis P
AUID- ORCID: 0000-0002-5881-6032
AD  - Institute and Policlinic for Occupational Medicine, Environmental Medicine and
      Prevention Research, University Hospital of Cologne , Cologne, Germany.
FAU - Shaw, David M
AU  - Shaw DM
AUID- ORCID: 0000-0001-8180-6927
AD  - Institute for Biomedical Ethics, University of Basel , Basel, Switzerland.
AD  - Department of Health, Ethics and Society, CAPHRI Research Institute, Maastricht
      University , Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - England
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
SB  - IM
MH  - Adult
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Child
MH  - Circadian Rhythm/*physiology
MH  - Coronavirus Infections/*virology
MH  - Humans
MH  - Light
MH  - Pandemics
MH  - Pneumonia, Viral/*virology
MH  - SARS-CoV-2
MH  - Sleep/physiology
OTO - NOTNLM
OT  - *COVID-19
OT  - *Natural Experiment
OT  - *Sars-CoV-2
OT  - *circadian
OT  - *ethics
OT  - *light
OT  - *mood
OT  - *pandemic
OT  - *physical Distancing
OT  - *sleep
EDAT- 2020/07/08 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1080/07420528.2020.1779993 [doi]
PST - ppublish
SO  - Chronobiol Int. 2020 Jul;37(7):1115-1117. doi: 10.1080/07420528.2020.1779993.
      Epub 2020 Jul 7.


PMID- 32632937
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1399-6576 (Electronic)
IS  - 0001-5172 (Linking)
VI  - 64
IP  - 9
DP  - 2020 Oct
TI  - Clinical and ethical aspects of palliative sedation with propofol-A retrospective
      quantitative and qualitative study.
PG  - 1319-1326
LID - 10.1111/aas.13665 [doi]
AB  - BACKGROUND: The anesthetic propofol is often mentioned as a drug that can be used
      in palliative sedation. The existing literature of how to use propofol in
      palliative sedation is scarce, with lack of information about how propofol could 
      be initiated for palliative sedation, doses and treatment outcomes. AIM: To
      describe the patient population, previous and concomitant medication, and
      clinical outcome when propofol was used for palliative sedation. METHODS: A
      retrospective study with quantitative and qualitative data. All patients who
      during a 4.5-year period received propofol for palliative sedation at the
      Department of palliative medicine, Akershus University Hospital, Norway were
      included. RESULTS: Fourteen patients were included. In six patients the main
      indication for palliative sedation was pain, in seven dyspnoea and in one
      delirium. In eight of these cases propofol was chosen because of the
      pharmacokinetic properties (rapid effect), and in the remaining cases propofol
      was chosen because midazolam in spite of dose titration failed to provide
      sufficient symptom relief. In all patients sedation and adequate symptom control 
      was achieved during manual dose titration. During the maintenance phase three of 
      14 patients had spontaneous awakenings. At death, propofol doses ranged from 60
      to 340 mg/hour. CONCLUSIONS: Severe suffering at the end of life can be
      successfully treated with propofol for palliative sedation. This can be performed
      in palliative medicine wards, but skilled observation and dose titration
      throughout the period of palliative sedation is necessary. Successful initial
      sedation does not guarantee uninterrupted sedation until death. EDITORIAL
      COMMENT: In palliative care, some patients at the end of life can reach a stage
      where there have been maximal analgesic and or anxiolytic treatments though
      without achieving comfort in the awake state. This report describes and discusses
      use of propofol in these infrequent cases to relieve suffering as part of
      palliative care.
CI  - (c) 2020 The Acta Anaesthesiologica Scandinavica Foundation. Published by John
      Wiley & Sons Ltd.
FAU - Fredheim, Olav M
AU  - Fredheim OM
AUID- ORCID: 0000-0002-0931-0027
AD  - Department of Palliative Medicine, Akershus University Hospital, Lorenskog,
      Norway.
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian
      University of Science and Technology, Trondheim, Norway.
AD  - National Competence Centre for Complex Symptom Disorders, Department of Pain and 
      Complex Disorders, St. Olavs Hospital, Trondheim, Norway.
FAU - Skulberg, Ingeborg M
AU  - Skulberg IM
AD  - Department of Palliative Medicine, Akershus University Hospital, Lorenskog,
      Norway.
FAU - Magelssen, Morten
AU  - Magelssen M
AD  - Centre for Medical Ethics, Institute of Health and Society, University of Oslo,
      Oslo, Norway.
FAU - Steine, Siri
AU  - Steine S
AD  - Department of Palliative Medicine, Akershus University Hospital, Lorenskog,
      Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200715
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
RN  - 0 (Hypnotics and Sedatives)
RN  - R60L0SM5BC (Midazolam)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Conscious Sedation
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - Midazolam
MH  - Palliative Care
MH  - *Propofol
MH  - Retrospective Studies
EDAT- 2020/07/08 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1111/aas.13665 [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 2020 Oct;64(9):1319-1326. doi: 10.1111/aas.13665. Epub
      2020 Jul 15.


PMID- 32632904
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 43
IP  - 12
DP  - 2020 Dec
TI  - Vitamin D, sport and health: a still unresolved clinical issue.
PG  - 1689-1702
LID - 10.1007/s40618-020-01347-w [doi]
AB  - Vitamin D metabolites have a pleiotropic role in human physiology, both in static
      and dynamic conditions, and a lot of vitamin D-related biological effects could
      influence physical and sport performances in athletes. Probably due to different 
      factors (e.g., drugs, doping, nutrition, ultraviolet B radiation exposure), in
      athletes a very high prevalence of vitamin D inadequacy (i.e., deficiency or
      insufficiency) has been observed. Vitamin D inadequacy in athletes could be
      associated with specific health risks and to alterations of functional
      capacities, potentially influencing the fine adjustment of physical performances 
      during training and sport competitions. When risk factors for vitamin D
      inadequacy exist, a preventive vitamin D supplementation is indicated, and if a
      vitamin D inadequacy is diagnosed, its supplementation is recommended.
      Unfortunately, on these issues many concerns remain unresolved. Indeed, it is not
      clear if athletes should be classified as a special population at increased risk 
      for vitamin D inadequacy; moreover, in comparison to the non-athletic population,
      it is still not clear if athletes should have different reference ranges and
      different optimal target levels for serum vitamin D, if they have additional
      health risks, and if they need different type of supplementations (doses) for
      prevention and/or replacement therapy. Moreover, in athletes also the abuse of
      vitamin D supplements for ergogenic purposes raise different ethical and safety
      concerns. In this review, the main physio-pathological, functional and clinical
      issues that relate vitamin D to the world of athletes are described.
FAU - Di Luigi, L
AU  - Di Luigi L
AUID- ORCID: http://orcid.org/0000-0002-2522-126X
AD  - Unit of Endocrinology, Department of Movement, Human and Health Sciences,
      Universita Degli Studi Di Roma "Foro Italico", Piazza Lauro de Bosis, 6, 00135,
      Rome, Italy. luigi.diluigi@uniroma4.it.
FAU - Antinozzi, C
AU  - Antinozzi C
AD  - Unit of Endocrinology, Department of Movement, Human and Health Sciences,
      Universita Degli Studi Di Roma "Foro Italico", Piazza Lauro de Bosis, 6, 00135,
      Rome, Italy.
FAU - Piantanida, E
AU  - Piantanida E
AD  - Department of Medicine and Surgery, University of Insubria, Via Ravasi 2, 21100, 
      Varese, Italy.
FAU - Sgro, P
AU  - Sgro P
AD  - Unit of Endocrinology, Department of Movement, Human and Health Sciences,
      Universita Degli Studi Di Roma "Foro Italico", Piazza Lauro de Bosis, 6, 00135,
      Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200706
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 1406-16-2 (Vitamin D)
RN  - 1C6V77QF41 (Cholecalciferol)
SB  - IM
MH  - Athletes/statistics & numerical data
MH  - Cholecalciferol/administration & dosage
MH  - Dietary Supplements
MH  - Health
MH  - Humans
MH  - Nutritional Status/*physiology
MH  - Risk Factors
MH  - Sports/*physiology
MH  - Vitamin D/*blood
MH  - Vitamin D Deficiency/blood/complications/epidemiology
OTO - NOTNLM
OT  - Athletes
OT  - Cholecalciferol
OT  - Vitamin 25(OH)D
OT  - Vitamin D inadequacy
EDAT- 2020/07/08 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/05/28 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1007/s40618-020-01347-w [doi]
AID - 10.1007/s40618-020-01347-w [pii]
PST - ppublish
SO  - J Endocrinol Invest. 2020 Dec;43(12):1689-1702. doi: 10.1007/s40618-020-01347-w. 
      Epub 2020 Jul 6.


PMID- 32632787
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20210507
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Sep
TI  - Medical Isolation and Solitary Confinement: Balancing Health and Humanity in US
      Jails and Prisons During COVID-19.
PG  - 2738-2742
LID - 10.1007/s11606-020-05968-y [doi]
AB  - In the face of the continually worsening COVID-19 pandemic, jails and prisons
      have become the greatest vectors of community transmission and are a point of
      heightened crisis and fear within the global crisis. Critical public health tools
      to mitigate the spread of COVID-19 are medical isolation and quarantine, but use 
      of these tools is complicated in prisons and jails where decades of overuse of
      punitive solitary confinement is the norm. This has resulted in advocates
      denouncing the use of any form of isolation and attorneys litigating to end its
      use. It is essential to clarify the critical differences between punitive
      solitary confinement and the ethical use of medical isolation and quarantine
      during a pandemic. By doing so, then all those invested in stopping the spread of
      COVID-19 in prisons can work together to integrate medically sound, humane forms 
      of medical isolation and quarantine that follow community standards of care
      rather than punitive forms of solitary confinement to manage COVID-19.
FAU - Cloud, David H
AU  - Cloud DH
AD  - Division of Geriatrics, Department of Medicine, School of Medicine, University of
      California, San Francisco, San Francisco, CA, USA. david.cloud@ucsf.edu.
FAU - Ahalt, Cyrus
AU  - Ahalt C
AD  - Division of Geriatrics, Department of Medicine, School of Medicine, University of
      California, San Francisco, San Francisco, CA, USA.
FAU - Augustine, Dallas
AU  - Augustine D
AD  - Division of Geriatrics, Department of Medicine, School of Medicine, University of
      California, San Francisco, San Francisco, CA, USA.
FAU - Sears, David
AU  - Sears D
AD  - Division of Infectious Diseases, Department of Medicine, School of Medicine,
      University of California, San Francisco, San Francisco, CA, USA.
FAU - Williams, Brie
AU  - Williams B
AD  - Division of Geriatrics, Department of Medicine, School of Medicine, University of
      California, San Francisco, San Francisco, CA, USA.
LA  - eng
GR  - R24 AG065175/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200706
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control/psychology
MH  - Delivery of Health Care/*methods/standards
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Patient Isolation/*methods/psychology/standards
MH  - Pneumonia, Viral/*epidemiology/prevention & control/psychology
MH  - *Prisons/standards
MH  - Quarantine/methods/psychology/standards
MH  - SARS-CoV-2
MH  - *Social Isolation/psychology
MH  - United States/epidemiology
PMC - PMC7338113
EDAT- 2020/07/08 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1007/s11606-020-05968-y [doi]
AID - 10.1007/s11606-020-05968-y [pii]
PST - ppublish
SO  - J Gen Intern Med. 2020 Sep;35(9):2738-2742. doi: 10.1007/s11606-020-05968-y. Epub
      2020 Jul 6.


PMID- 32632786
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Blame-Laden Moral Rebukes and the Morally Competent Robot: A Confucian Ethical
      Perspective.
PG  - 2511-2526
LID - 10.1007/s11948-020-00246-w [doi]
AB  - Empirical studies have suggested that language-capable robots have the persuasive
      power to shape the shared moral norms based on how they respond to human norm
      violations. This persuasive power presents cause for concern, but also the
      opportunity to persuade humans to cultivate their own moral development. We argue
      that a truly socially integrated and morally competent robot must be willing to
      communicate its objection to humans' proposed violations of shared norms by using
      strategies such as blame-laden rebukes, even if doing so may violate other
      standing norms, such as politeness. By drawing on Confucian ethics, we argue that
      a robot's ability to employ blame-laden moral rebukes to respond to unethical
      human requests is crucial for cultivating a flourishing "moral ecology" of
      human-robot interaction. Such positive moral ecology allows human teammates to
      develop their own moral reflection skills and grow their own virtues.
      Furthermore, this ability can and should be considered as one criterion for
      assessing artificial moral agency. Finally, this paper discusses potential
      implications of the Confucian theories for designing socially integrated and
      morally competent robots.
FAU - Zhu, Qin
AU  - Zhu Q
AD  - Division of Humanities, Arts and Social Sciences, Colorado School of Mines,
      Golden, USA. qzhu@mines.edu.
FAU - Williams, Tom
AU  - Williams T
AD  - Department of Computer Science, Colorado School of Mines, Golden, USA.
FAU - Jackson, Blake
AU  - Jackson B
AD  - Department of Computer Science, Colorado School of Mines, Golden, USA.
FAU - Wen, Ruchen
AU  - Wen R
AD  - Department of Computer Science, Colorado School of Mines, Golden, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humans
MH  - Moral Development
MH  - Morals
MH  - *Robotics
MH  - Virtues
OTO - NOTNLM
OT  - *Blame-laden moral rebukes
OT  - *Confucian ethics
OT  - *Moral cultivation
OT  - *Morally competent robots
OT  - *Robot ethics
OT  - *Role ethics
EDAT- 2020/07/08 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1007/s11948-020-00246-w [doi]
AID - 10.1007/s11948-020-00246-w [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2511-2526. doi: 10.1007/s11948-020-00246-w.


PMID- 32632784
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Toward Implementing the ADC Model of Moral Judgment in Autonomous Vehicles.
PG  - 2461-2472
LID - 10.1007/s11948-020-00242-0 [doi]
AB  - Autonomous vehicles (AVs)-and accidents they are involved in-attest to the urgent
      need to consider the ethics of artificial intelligence (AI). The question
      dominating the discussion so far has been whether we want AVs to behave in a
      'selfish' or utilitarian manner. Rather than considering modeling self-driving
      cars on a single moral system like utilitarianism, one possible way to approach
      programming for AI would be to reflect recent work in neuroethics. The
      agent-deed-consequence (ADC) model (Dubljevic and Racine in AJOB Neurosci
      5(4):3-20, 2014a, Behav Brain Sci 37(5):487-488, 2014b) provides a promising
      descriptive and normative account while also lending itself well to
      implementation in AI. The ADC model explains moral judgments by breaking them
      down into positive or negative intuitive evaluations of the agent, deed, and
      consequence in any given situation. These intuitive evaluations combine to
      produce a positive or negative judgment of moral acceptability. For example, the 
      overall judgment of moral acceptability in a situation in which someone committed
      a deed that is judged as negative (e.g., breaking a law) would be mitigated if
      the agent had good intentions and the action had a good consequence. This
      explains the considerable flexibility and stability of human moral judgment that 
      has yet to be replicated in AI. This paper examines the advantages and
      disadvantages of implementing the ADC model and how the model could inform future
      work on ethics of AI in general.
FAU - Dubljevic, Veljko
AU  - Dubljevic V
AD  - Science Technology and Society Program, Department of Philosophy and Religious
      Studies, NC State University, 453 Withers Hall, 101 Lampe Dr, Raleigh, NC, 27607,
      USA. veljko_dubljevic@ncsu.edu.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Artificial Intelligence
MH  - *Automobile Driving
MH  - Ethical Theory
MH  - Humans
MH  - *Judgment
MH  - Morals
OTO - NOTNLM
OT  - Agent-deed-consequence (ADC) model
OT  - Artificial intelligence (AI)
OT  - Artificial morality
OT  - Artificial neural networks
OT  - Autonomous vehicles (AVs)
OT  - Neuroethics
EDAT- 2020/07/08 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1007/s11948-020-00242-0 [doi]
AID - 10.1007/s11948-020-00242-0 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2461-2472. doi: 10.1007/s11948-020-00242-0.


PMID- 32632783
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Correcting the Brain? The Convergence of Neuroscience, Neurotechnology,
      Psychiatry, and Artificial Intelligence.
PG  - 2439-2454
LID - 10.1007/s11948-020-00240-2 [doi]
AB  - The incorporation of neural-based technologies into psychiatry offers novel means
      to use neural data in patient assessment and clinical diagnosis. However, an
      over-optimistic technologisation of neuroscientifically-informed psychiatry risks
      the conflation of technological and psychological norms. Neurotechnologies
      promise fast, efficient, broad psychiatric insights not readily available through
      conventional observation of patients. Recording and processing brain signals
      provides information from 'beneath the skull' that can be interpreted as an
      account of neural processing and that can provide a basis to evaluate general
      behaviour and functioning. But it ought not to be forgotten that the use of such 
      technologies is part of a human practice of neuroscience informed psychiatry.
      This paper notes some challenges in the integration of neural technologies into
      psychiatry and suggests vigilance particularly in respect to normative
      challenges. In this way, psychiatry can avoid a drift toward reductive
      technological approaches, while nonetheless benefitting from promising advances
      in neuroscience and technology.
FAU - Rainey, Stephen
AU  - Rainey S
AD  - Oxford Uehiro Centre for Practical Ethics, Suite 8, Littlegate House, St Ebbes
      Street, Oxford, OX1 1PT, UK. stephen.rainey@philosophy.ox.ac.uk.
FAU - Erden, Yasemin J
AU  - Erden YJ
AD  - St. Mary's University, Twickenham, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Artificial Intelligence
MH  - Brain
MH  - Humans
MH  - *Neurosciences
MH  - *Psychiatry
MH  - Technology
PMC - PMC7550307
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Ethics
OT  - *Neurotechnology
OT  - *Normativity
OT  - *Psychiatry
OT  - *Psychology
EDAT- 2020/07/08 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1007/s11948-020-00240-2 [doi]
AID - 10.1007/s11948-020-00240-2 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2439-2454. doi: 10.1007/s11948-020-00240-2.


PMID- 32632782
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Expanding Nallur's Landscape of Machine Implemented Ethics.
PG  - 2401-2410
LID - 10.1007/s11948-020-00237-x [doi]
FAU - Bauer, William A
AU  - Bauer WA
AUID- ORCID: http://orcid.org/0000-0003-4860-2185
AD  - Department of Philosophy and Religious Studies, North Carolina State University, 
      Raleigh, USA. wabauer@ncsu.edu.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
EIN - Sci Eng Ethics. 2020 Sep 29;:. PMID: 32990876
MH  - *Ethics, Research
MH  - Humans
EDAT- 2020/07/08 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - 10.1007/s11948-020-00237-x [doi]
AID - 10.1007/s11948-020-00237-x [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2401-2410. doi: 10.1007/s11948-020-00237-x.


PMID- 32632537
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2509-9280 (Electronic)
IS  - 2509-9280 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Jul 6
TI  - Heavy metal in radiology: how to reliably differentiate between lodged copper and
      lead bullets using CT numbers.
PG  - 43
LID - 10.1186/s41747-020-00168-z [doi]
AB  - BACKGROUND: The in situ classification of bullets is of interest in forensic
      investigations when the bullet cannot be removed. Although computed tomography
      (CT) is usually performed on shooting victims, visual assessment, or caliber
      measurements using CT can be challenging or infeasible if the bullets are
      deformed or fragmented. Independent from the bullet's intactness, x-ray
      attenuation values (CT numbers) may provide information regarding the material of
      the bullet. METHODS: Ethical approval was not required (animal cadavers) or
      waived by the ethics committee (decedents). Copper and lead bullets were fired
      into animal cadavers, which then underwent CT scanning at four energy levels (80,
      100, 120, and 140 kVp). CT numbers were measured within regions of interest
      (ROIs). In addition to comparing CT numbers, the dual-energy index (DEI),
      representing the ratio between the CT numbers of two energy levels, was
      calculated. The most appropriate method was applied for decedents with fatal
      gunshot wounds. RESULTS: CT numbers demonstrated no significant difference
      between copper and lead bullets, and false classifications can easily occur. DEI 
      calculations revealed significant differences between the two groups of bullets. 
      The 120/140 DEIs calculated from the maximum CT numbers obtained from ROIs at the
      edge of copper versus lead bullets presented a significant difference (p = 0.002)
      and a gap between the CT numbers of copper and lead bullets and was successfully 
      applied for the decedents. CONCLUSIONS: This study presents a viable method for
      distinguishing copper and lead bullets in situ via CT and highlights the
      potential pitfalls of incorrect classifications.
FAU - Gascho, Dominic
AU  - Gascho D
AUID- ORCID: 0000-0001-9004-4362
AD  - Department of Forensic Medicine and Imaging, Institute of Forensic Medicine,
      University of Zurich, Winterthurerstrasse 190/52, CH-8057, Zurich, Switzerland.
      dominic.gascho@irm.uzh.ch.
FAU - Zoelch, Niklaus
AU  - Zoelch N
AD  - Department of Forensic Medicine and Imaging, Institute of Forensic Medicine,
      University of Zurich, Winterthurerstrasse 190/52, CH-8057, Zurich, Switzerland.
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of
      Psychiatry, University of Zurich, Zurich, Switzerland.
FAU - Richter, Henning
AU  - Richter H
AD  - Diagnostic Imaging Research Unit (DIRU), Clinic for Diagnostic Imaging, Vetsuisse
      Faculty, University of Zurich, Zurich, Switzerland.
FAU - Buehlmann, Alexander
AU  - Buehlmann A
AD  - Zurich Forensic Science Institute, Zurich Canton Police and Zurich City Police,
      Zurich, Switzerland.
FAU - Wyss, Philipp
AU  - Wyss P
AD  - Zurich Forensic Science Institute, Zurich Canton Police and Zurich City Police,
      Zurich, Switzerland.
FAU - Thali, Michael J
AU  - Thali MJ
AD  - Department of Forensic Medicine and Imaging, Institute of Forensic Medicine,
      University of Zurich, Winterthurerstrasse 190/52, CH-8057, Zurich, Switzerland.
FAU - Schaerli, Sarah
AU  - Schaerli S
AD  - Department of Forensic Medicine and Imaging, Institute of Forensic Medicine,
      University of Zurich, Winterthurerstrasse 190/52, CH-8057, Zurich, Switzerland.
AD  - Institute of Forensic Medicine, Health Department Basel, University of Basel,
      Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - Eur Radiol Exp
JT  - European radiology experimental
JID - 101721752
RN  - 2P299V784P (Lead)
RN  - 789U1901C5 (Copper)
SB  - IM
MH  - Animals
MH  - Cadaver
MH  - *Copper
MH  - Foreign Bodies/*classification/*diagnostic imaging
MH  - *Lead
MH  - Sheep, Domestic
MH  - Tomography, X-Ray Computed/*methods
MH  - Wounds, Gunshot/*diagnostic imaging
PMC - PMC7338321
OTO - NOTNLM
OT  - *Copper
OT  - *Forensic ballistics
OT  - *Lead
OT  - *Tomography (x-ray computed), Wounds (gunshot)
EDAT- 2020/07/08 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1186/s41747-020-00168-z [doi]
AID - 10.1186/s41747-020-00168-z [pii]
PST - epublish
SO  - Eur Radiol Exp. 2020 Jul 6;4(1):43. doi: 10.1186/s41747-020-00168-z.


PMID- 32632382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Jun
TI  - Prediction of guilt and shame proneness based on disruption to psychological
      contract: A new light for corruption prevention.
PG  - e04275
LID - 10.1016/j.heliyon.2020.e04275 [doi]
AB  - Amid controversy over plurality and contestation of the meanings of corruption,
      previous reviews and studies showed that proneness to moral emotions, i.e. shame 
      and guilt, can predict one's corruption behavior. To give a theoretical basis for
      the efforts of preventing corruption that is thick with emotional nuance, this
      present study employs disruption to psychological contract, i.e. psychological
      contract breach (PCB), as a predictor of moral emotions proneness. The study
      involving 265 employees (169 males, 96 females; M age = 32.32 years old; SD age =
      7.28 years) of four big private banks in Jakarta, the capital city of Indonesia, 
      shows that PCB-with noting that, in this study, its scale operational scoring
      represents, reversely, the contract fulfillment-can predict Guilt-negative
      behavior evaluation (Guilt-NBE), Guilt-repair (Guilt-REP), and Shame-negative
      self-evaluation (Shame-NSE); all in negative directions, proved via simple linear
      regression analyses. Further analysis showed a more dynamic relationship between 
      PCB and Guilt-NBE that fits to a cubic regression model. This study contributes
      to the axiological aspect of business psychology, especially in the ethical
      psychology of banking industry.
CI  - (c) 2020 The Author(s).
FAU - Abraham, Juneman
AU  - Abraham J
AD  - Psychology Department, Faculty of Humanities, Bina Nusantara University, DKI
      Jakarta, 11480, Indonesia.
FAU - Kurniadi, Melissa Amelia
AU  - Kurniadi MA
AD  - Psychology Department, Faculty of Humanities, Bina Nusantara University, DKI
      Jakarta, 11480, Indonesia.
FAU - Andangsari, Esther Widhi
AU  - Andangsari EW
AD  - Psychology Department, Faculty of Humanities, Bina Nusantara University, DKI
      Jakarta, 11480, Indonesia.
FAU - Ali, Moondore Madalina
AU  - Ali MM
AD  - Psychology Department, Faculty of Humanities, Bina Nusantara University, DKI
      Jakarta, 11480, Indonesia.
FAU - Manurung, Rudi Hartono
AU  - Manurung RH
AD  - Japanese Department, Faculty of Humanities, Bina Nusantara University, DKI
      Jakarta, 11480, Indonesia.
FAU - Warnars, Harco Leslie Hendric Spits
AU  - Warnars HLHS
AD  - Information System Concentration, Doctor of Computer Science Department, Bina
      Nusantara University, DKI Jakarta, 11530, Indonesia.
LA  - eng
SI  - figshare/10.6084/m9.figshare.12110910
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7323657
OTO - NOTNLM
OT  - Business psychology
OT  - Corruption
OT  - Guilt and shame
OT  - Moral emotion
OT  - Organizational psychology
OT  - Psychological contract
OT  - Psychology
EDAT- 2020/07/08 06:00
MHDA- 2020/07/08 06:01
CRDT- 2020/07/08 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/08 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04275 [doi]
AID - S2405-8440(20)31119-1 [pii]
AID - e04275 [pii]
PST - epublish
SO  - Heliyon. 2020 Jun 29;6(6):e04275. doi: 10.1016/j.heliyon.2020.e04275. eCollection
      2020 Jun.


PMID- 32631975
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1473-4265 (Electronic)
IS  - 1468-215X (Linking)
VI  - 46
IP  - 2
DP  - 2020 Jun
TI  - Special operations: a hidden chapter in the histories of facial surgery and human
      enhancement.
PG  - 115-123
LID - 10.1136/medhum-2019-011792 [doi]
AB  - During the Second World War, Britain's Special Operations Executive (SOE), a
      secret service established to encourage resistance and carry out sabotage,
      employed various techniques of enhancing the ability of its personnel to operate 
      undetected in enemy territory. One of these methods was surgery. Drawing on
      recently declassified records, this article illuminates SOE's reasons for
      commissioning this procedure, the needs and wants of those who received it, and
      the surgeons employed to carry it out. It also aims to underline the role of
      context in shaping perceptions of facial surgery, and the potential for surgery
      for wartime disguise to resonate with current debates about human enhancement.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Bailey, Roderick
AU  - Bailey R
AUID- ORCID: http://orcid.org/0000-0002-0055-3460
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, UK
      roderick.bailey@history.ox.ac.uk.
LA  - eng
GR  - 203132/WT_/Wellcome Trust/United Kingdom
PT  - Historical Article
PT  - Journal Article
DEP - 20200706
PL  - United States
TA  - Med Humanit
JT  - Medical humanities
JID - 100959585
SB  - IM
MH  - Esthetics/*history
MH  - Face/*surgery
MH  - History, 20th Century
MH  - Humanities/*history
MH  - Humans
MH  - Reconstructive Surgical Procedures/*history
MH  - World War II
PMC - PMC7402463
OTO - NOTNLM
OT  - aesthetic/plastic and reconstructive/cosmetic surgery
OT  - history
OT  - law
OT  - medical ethics/bioethics
OT  - medical humanities
COIS- Competing interests: None declared.
EDAT- 2020/07/08 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - medhum-2019-011792 [pii]
AID - 10.1136/medhum-2019-011792 [doi]
PST - ppublish
SO  - Med Humanit. 2020 Jun;46(2):115-123. doi: 10.1136/medhum-2019-011792. Epub 2020
      Jul 6.


PMID- 32631970
OWN - NLM
STAT- Publisher
LR  - 20211217
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 6
TI  - Conflict before the courtroom: challenging cognitive biases in critical
      decision-making.
LID - medethics-2020-106177 [pii]
LID - 10.1136/medethics-2020-106177 [doi]
AB  - Conflict is an important consideration in the intensive care unit (ICU). In this 
      setting, conflict most commonly occurs over the 'best interests' of the
      incapacitated adult patient; for instance, when families seek aggressive
      life-sustaining treatments, which are thought by the medical team to be
      potentially inappropriate. Indeed, indecision on futility of treatment and the
      initiation of end-of-life discussions are recognised to be among the greatest
      challenges of working in the ICU, leading to emotional and psychological
      'burnout' in ICU teams. When these disagreements occur, they may be within the
      clinical team or among those close to the patient, or between the clinical team
      and those close to the patient. It is, therefore, crucial to have a theoretical
      understanding of decision-making itself, as unpicking misalignments in the
      family's and clinical team's decision-making processes may offer strategies to
      resolve conflict. Here, we relate Kahneman and Tversky's work on cognitive biases
      and behavioural economics to the ICU environment, arguing that these biases could
      partly explain disparities in the decision-making processes for the two
      conflicting parties. We suggest that through the establishment of common ground, 
      challenging of cognitive biases and formulation of mutually agreeable solutions, 
      mediation may offer a pragmatic and cost-effective solution to conflict
      resolution. The litigation process is intrinsically adversarial and strains the
      doctor-patient-relative relationship. Thus an alternative external party should
      be considered, however mediation is not frequently used and more research is
      needed into its effectiveness in resolving conflicts in the ICU.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Johal, Harleen Kaur
AU  - Johal HK
AUID- ORCID: http://orcid.org/0000-0002-8665-8932
AD  - Centre for Ethics in Medicine, University of Bristol, Bristol, UK
      harleenkaurjohal@gmail.com.
FAU - Danbury, Christopher
AU  - Danbury C
AD  - Adult Intensive Care Unit, Royal Berkshire NHS Foundation Trust, Reading, UK.
AD  - School of Law, University of Reading, Reading, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639943
OTO - NOTNLM
OT  - capacity
OT  - decision-making
OT  - end of life care
OT  - ethics
OT  - psychology
COIS- Competing interests: Dr Christopher Danbury is a trained mediator, who is on the 
      clinical negligence panel of Trust Mediation. Trust Mediation is one of the panel
      organisations approved by NHS Resolution for its mediation.
EDAT- 2020/07/08 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - medethics-2020-106177 [pii]
AID - 10.1136/medethics-2020-106177 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 6. pii: medethics-2020-106177. doi:
      10.1136/medethics-2020-106177.


PMID- 32631969
OWN - NLM
STAT- Publisher
LR  - 20200707
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jul 6
TI  - A discussion on controversies and ethical dilemmas in prostate cancer screening.
LID - medethics-2019-105979 [pii]
LID - 10.1136/medethics-2019-105979 [doi]
AB  - Prostate cancer (PCa) is one of the the most common cancers in men. A blood test 
      called prostate-specific antigen (PSA) has a potential to pick up this cancer
      very early and is used for screening of this disease. However, screening for
      prostate cancer is a matter of debate. Level 1 evidence from randomised
      controlled trials suggests a reduction in cancer-specific mortality from PCa
      screening. However, there could be an associated impact on quality of life due to
      a high proportion of overdiagnosis and overtreatment as part of the screening.
      The US Preventive Services Task Force (USPSTF) in 2012 recommended that PSA-based
      PCa screening should not to be offered at any age. However, considering the
      current evidence, USPSTF recently revised its recommendation to offer the PSA
      test to men aged 55-69 years with shared decision-making, in line with earlier
      guidelines from the American Cancer Society and the American Urological
      Association. A shared decision making is necessary since the PSA test could
      potentially harm an individual. However, the literature suggests that clinicians 
      often neglect a discussion on this issue before ordering the test. This narrative
      discusses the main controversies regarding PCa screening including the PSA
      threshold for biopsy, the concept of overdiagnosis and overtreatment, the
      practical difficulties of active surveillance, the current level 1 evidence on
      the mortality benefit of screening, and the associated pitfalls. It offers a
      detailed discussion on the ethics involved in the PSA test and highlights the
      barriers to shared decision-making and possible solutions.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Mishra, Satish Chandra
AU  - Mishra SC
AUID- ORCID: http://orcid.org/0000-0001-6086-6541
AD  - Department of Surgery, WHO Collaboration Centre for Research in Surgical Care
      Delivery in LMIC, Bhabha Atomic Research Centre Hospital, Mumbai, MH 400094,
      India mishrasatishdr@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - decision-making
OT  - education for health care professionals
OT  - public health ethics
OT  - surgery
COIS- Competing interests: None declared.
EDAT- 2020/07/08 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/07/08 06:00
PHST- 2019/11/21 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - medethics-2019-105979 [pii]
AID - 10.1136/medethics-2019-105979 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jul 6. pii: medethics-2019-105979. doi:
      10.1136/medethics-2019-105979.


PMID- 32631500
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 59
IP  - 4
DP  - 2020 Aug
TI  - How do I see the production of engineered blood cells available for transfusion?
PG  - 102863
LID - S1473-0502(20)30168-3 [pii]
LID - 10.1016/j.transci.2020.102863 [doi]
AB  - The in vitro production of red blood cells and platelets is a groundbreaking
      technology that can-when optimized-surrogate for donated blood cells, in total or
      in part. Here we discuss questions that may arise when the technology is
      available, relative to safety issues (comprising both quantitative and
      qualitative parameters) and to ethics, an item often forgotten in the debates so 
      far.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Garraud, Olivier
AU  - Garraud O
AD  - Faculty of Medicine, University of Lyon, 42023, Saint-Etienne, France; Institut
      National de la Transfusion Sanguine, 75015, Paris, France; Palliative Care Unit, 
      The Ruffec Hospital, 16700, Ruffec, France. Electronic address:
      Olivier.garraud@univ-st-etienne.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200629
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
CIN - Transfus Clin Biol. 2020 Aug;27(3):170-171. PMID: 32139132
MH  - Blood Transfusion/*methods
MH  - Erythrocytes/*cytology
MH  - Humans
MH  - Tissue Engineering/*methods
PMC - PMC7323659
OTO - NOTNLM
OT  - blood components
OT  - engineering
OT  - in vitro
OT  - platelets
OT  - red blood cells
EDAT- 2020/07/08 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - S1473-0502(20)30168-3 [pii]
AID - 10.1016/j.transci.2020.102863 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2020 Aug;59(4):102863. doi: 10.1016/j.transci.2020.102863.
      Epub 2020 Jun 29.


PMID- 32631304
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 6
TI  - Evaluation of decision-making capacity in patients with dementia: challenges and 
      recommendations from a secondary analysis of qualitative interviews.
PG  - 55
LID - 10.1186/s12910-020-00498-y [doi]
AB  - BACKGROUND: Evaluation of decision-making capacity to consent to medical
      treatment has proved to be difficult in patients with dementia. Studies showed
      that physicians are often insufficiently trained in the evaluation of
      decision-making capacity. In this study, we present findings from a secondary
      analysis of a qualitative interviews with physicians. These interviews were
      initially used to assess usability of an instrument for the evaluation of
      decision-making capacity. By looking at difficult cases of decision-making
      capacity evaluation in patients with dementia, we provide recommendations for
      such evaluations in clinical practice. METHODS: We used thematic coding to
      analyse physicians' narratives of problematic decision-making capacity
      evaluations in patients with dementia to uncover challenging issues of
      decision-making capacity evaluation. RESULTS: In this study, decision-making
      capacity evaluations in patients with dementia were mainly perceived as
      challenging when they pertained to treatment refusals and treatment unrelated
      circumstances, such as psychiatric consultation, advance directives, and new
      living arrangements. Furthermore, the physicians reported training needs
      regarding situation-independent challenges with decision-making capacity
      evaluation. CONCLUSIONS: Upon further examining self-reported training needs and 
      challenging cases, we have developed recommendations to improve decision-making
      capacity evaluations in clinical practice. In these recommendations, we argue
      that being able to evaluate decision-making capacity is an integral part of the
      informed consent process.
FAU - Poppe, Christopher
AU  - Poppe C
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Elger, Bernice S
AU  - Elger BS
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
AD  - Center for Legal Medicine, University of Geneva, Geneva, Switzerland.
FAU - Wangmo, Tenzin
AU  - Wangmo T
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Trachsel, Manuel
AU  - Trachsel M
AUID- ORCID: 0000-0002-2697-3631
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, CH-8006, Zurich, Switzerland. manuel.trachsel@uzh.ch.
LA  - eng
GR  - 406740_139294/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen 
      Forschung/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Advance Directives
MH  - Decision Making
MH  - *Dementia
MH  - Humans
MH  - Informed Consent
MH  - *Physicians
PMC - PMC7339476
OTO - NOTNLM
OT  - *Autonomy
OT  - *Competence
OT  - *Decision-making capacity
OT  - *Dementia
OT  - *Ethics
OT  - *Informed consent
EDAT- 2020/07/08 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/08 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00498-y [doi]
AID - 10.1186/s12910-020-00498-y [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 6;21(1):55. doi: 10.1186/s12910-020-00498-y.


PMID- 32631279
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 6
TI  - Psychological and physical effects of breast cancer diagnosis and treatment on
      young Ghanaian women: a qualitative study.
PG  - 353
LID - 10.1186/s12888-020-02760-4 [doi]
AB  - BACKGROUND: Young women diagnosed with breast cancer face challenges that
      interfere with their entire life with psychological and physical effects. METHOD:
      We employed a qualitative exploratory descriptive design, and recruited twelve
      participants through purposive and snowball sampling methods to conduct 12 face
      to face individual interviews. A reputable review board in Ghana; Noguchi
      Memorial Institute for Medical Research, gave ethical clearance for data
      collection. Data were transcribed verbatim and analysed using thematic content
      analysis. RESULTS: Three themes emerged from the data; physical effects of breast
      cancer, effects of treatment on body image, and emotional effects of breast
      cancer diagnosis and treatment. The negative effects of treatment incapacitated
      most of the women and limited their activities of daily living. Some experienced 
      severe bodily weakness and stayed indoors for days. Most participants felt they
      looked unattractive because they have had a mastectomy done, and used pieces of
      rags and handkerchiefs as breast prostheses. Those who had hair loss through
      chemotherapy used different kinds of wigs to cover their baldness. Almost all the
      participants cried, felt depressed, and became emotionally unstable when they
      were told their diagnosis. Some denied their diagnoses and displaced their anger 
      on healthcare personnel. A few of them felt they had brought disgrace to their
      families because breast cancer is perceived, a disgraceful disease. CONCLUSION:
      Young women diagnosed with breast cancer require psychological interventions and 
      physical support from healthcare personnel and their families.
FAU - Iddrisu, Merri
AU  - Iddrisu M
AD  - Department of Adult Health, School of Nursing and Midwifery, University of Ghana,
      P. O. Box LG43, Legon, Accra, Ghana.
FAU - Aziato, Lydia
AU  - Aziato L
AUID- ORCID: 0000-0002-7813-5525
AD  - Department of Adult Health, School of Nursing and Midwifery, University of Ghana,
      P. O. Box LG43, Legon, Accra, Ghana. aziatol@yahoo.com.
FAU - Dedey, Florence
AU  - Dedey F
AD  - School of Medicine and Dentistry, University of Ghana Medical School, Accra,
      Ghana.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
MH  - Activities of Daily Living
MH  - Adaptation, Psychological
MH  - *Breast Neoplasms/surgery/therapy
MH  - Female
MH  - Ghana
MH  - Humans
MH  - Mastectomy
MH  - Qualitative Research
PMC - PMC7336427
EDAT- 2020/07/08 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12888-020-02760-4 [doi]
AID - 10.1186/s12888-020-02760-4 [pii]
PST - epublish
SO  - BMC Psychiatry. 2020 Jul 6;20(1):353. doi: 10.1186/s12888-020-02760-4.


PMID- 32631236
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 6
TI  - Iranian nurses' perceptions about using physical restraint for hospitalized
      elderly people: a cross-sectional descriptive-correlational study.
PG  - 233
LID - 10.1186/s12877-020-01636-2 [doi]
AB  - BACKGROUND: Using physical restraint (PR) for hospitalized elderly people is a
      major nursing challenge. It is associated with different physical and mental
      complications and ethical dilemmas, though many nurses still use it to ensure
      patient safety. Nurses' perceptions are one of the most important factors
      affecting PR use. This study aimed to evaluate Iranian nurses' perceptions about 
      PR use for hospitalized elderly people. METHODS: This cross-sectional
      descriptive-correlational study was conducted from July to December 2019.
      Participants were 270 hospital nurses who were purposively recruited from
      intensive care units and medical and surgical wards of three teaching hospitals
      in Kermanshah, Iran. Data were collected using a demographic questionnaire and
      the Perceptions of Restraint Use Questionnaire (PRUQ). The SPSS software (v.
      23.0) was used for data analysis through the independent-sample t test, the
      one-way analysis of variance, and the multiple regression analysis. RESULTS: The 
      total mean score of PRUQ was 4.08 +/- 0.12 in the possible range of 1-5. The most
      important reasons for PR use were to prevent patients from falling out of bed and
      to prevent them from pulling out catheters. The total mean score of PRUQ had
      significant relationship with participants' age, work experience, and history of 
      receiving PR-related educations (P < 0.05), but had no significant relationship
      with their gender, educational degree, and affiliated hospital ward (P > 0.05).
      CONCLUSION: This study suggests that nurses attach high importance to PR use for 
      hospitalized elderly people. Healthcare policy-makers at national and hospital
      levels are recommended to provide nurses with PR-related educations in order to
      reduce the rate of PR-related complications.
FAU - Sharifi, Azam
AU  - Sharifi A
AD  - Nursing Department, University of Social Welfare and Rehabilitation Sciences,
      Tehran, Iran.
FAU - Arsalani, Narges
AU  - Arsalani N
AD  - Nursing Department, University of Social Welfare and Rehabilitation Sciences,
      Tehran, Iran. n.arsalani@yahoo.com.
FAU - Fallahi-Khoshknab, Masoud
AU  - Fallahi-Khoshknab M
AD  - Nursing Department, University of Social Welfare and Rehabilitation Sciences,
      Tehran, Iran.
FAU - Mohammadi-Shahbolaghi, Farahnaz
AU  - Mohammadi-Shahbolaghi F
AD  - Nursing Department, University of Social Welfare and Rehabilitation Sciences,
      Tehran, Iran.
FAU - Ebadi, Abbas
AU  - Ebadi A
AD  - Nursing School, Baqiyatallah University of Medical Sciences, Tehran, Iran.
AD  - Behavioral Sciences Research Center, Life Style Institute, Baqiyatallah
      University of Medical Sciences, Tehran, Iran.
LA  - eng
GR  - Grant No. 982518/University of Social Welfare and Rehabilitation
      Sciences/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Aged
MH  - *Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Iran
MH  - Perception
MH  - *Restraint, Physical
MH  - Surveys and Questionnaires
PMC - PMC7339549
OTO - NOTNLM
OT  - *Elderly
OT  - *Hospital
OT  - *Nurse
OT  - *Physical restraint
EDAT- 2020/07/08 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12877-020-01636-2 [doi]
AID - 10.1186/s12877-020-01636-2 [pii]
PST - epublish
SO  - BMC Geriatr. 2020 Jul 6;20(1):233. doi: 10.1186/s12877-020-01636-2.


PMID- 32631183
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210602
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 2
DP  - 2020 Jun
TI  - Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: 
      An Analysis.
PG  - 259-267
LID - 10.1177/1073110520935337 [doi]
AB  - This manuscript describes the institutional and clinical considerations that
      apply to the question of whether to mandate opioid dose reduction in patients who
      have received opioids long-term. It describes how a calamitous rise in addiction 
      and overdose involving opioids has both led to a clinical recalibration by
      healthcare providers, and to strong incentives favoring forcible opioid reduction
      by policy making agencies. Neither the 2016 Guideline issued by the Centers for
      Disease Control and Prevention nor clinical evidence can justify or promote such 
      policies as safe or effective.
FAU - Kertesz, Stefan G
AU  - Kertesz SG
AD  - Stefan G. Kertesz, M.D., M.Sc., is a professor at the Department of Medicine, UAB
      School of Medicine and research investigator at the Birmingham VA Medical Center.
      He is a board-certified internal medicine (American Board of Internal Medicine)
      and addiction medicine physician (American Board of Addiction Medicine). His
      research career began in 2000 and he has been funded by both the National
      Institute on Drug Abuse and the Health Services Research & Development Branch of 
      the Department of Veterans Affairs. He received his MD from Harvard Medical
      School in Boston, MA and his MSc from Boston University School of Public Health
      in Boston, MA. Ajay Manhapra, M.D., is Lecturer at Yale School of Medicine in the
      Department of Psychiatry, Assistant Professor, at the Eastern Virginia Medical
      School in the Department of Physical Medicine and Rehabilitation and Psychiatry, 
      and Research Scientist at the VA New England Mental Illness Research, Education
      and Clinical Center. Dr. Manhapra is a board-certified Internist and Addiction
      Medicine physician with educational, clinical and research focus on pain and
      addiction. He runs a unique clinic for recovering patients with severe disabling 
      chronic pain and medication or substance dependence at Hampton VA Medical Center,
      where he is developing an interdisciplinary integrative model for treatment of
      pain and addiction. Dr. Manhapra received his medical degree from Government
      Medical College, Thrissur, Kerala, India, and completed his Addiction Medicine
      fellowship at Yale School of Medicine. Adam J. Gordon, M.D., M.P.H., is Professor
      of Medicine and Psychiatry at the University of Utah School of Medicine, Director
      of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy
      (PARCKA), and Chief of Addiction Medicine at VA Salt Lake City Health Care System
      and. He is a board-certified internal medicine (American Board of Internal
      Medicine) and addiction medicine physician (American Board of Preventive
      Medicine) with a 20-year track record of conducting research on the quality,
      equity, and efficiency of health care for vulnerable populations (e.g., persons
      with opioid use disorders, persons who are homeless, persons with hazardous
      alcohol use and other addiction disorders). He received his MD from University of
      Pittsburgh School of Medicine in Pittsburgh, PA and his MPH from the University
      of Pittsburgh Graduate School of Public Health in Pittsburgh, PA.
FAU - Manhapra, Ajay
AU  - Manhapra A
AD  - Stefan G. Kertesz, M.D., M.Sc., is a professor at the Department of Medicine, UAB
      School of Medicine and research investigator at the Birmingham VA Medical Center.
      He is a board-certified internal medicine (American Board of Internal Medicine)
      and addiction medicine physician (American Board of Addiction Medicine). His
      research career began in 2000 and he has been funded by both the National
      Institute on Drug Abuse and the Health Services Research & Development Branch of 
      the Department of Veterans Affairs. He received his MD from Harvard Medical
      School in Boston, MA and his MSc from Boston University School of Public Health
      in Boston, MA. Ajay Manhapra, M.D., is Lecturer at Yale School of Medicine in the
      Department of Psychiatry, Assistant Professor, at the Eastern Virginia Medical
      School in the Department of Physical Medicine and Rehabilitation and Psychiatry, 
      and Research Scientist at the VA New England Mental Illness Research, Education
      and Clinical Center. Dr. Manhapra is a board-certified Internist and Addiction
      Medicine physician with educational, clinical and research focus on pain and
      addiction. He runs a unique clinic for recovering patients with severe disabling 
      chronic pain and medication or substance dependence at Hampton VA Medical Center,
      where he is developing an interdisciplinary integrative model for treatment of
      pain and addiction. Dr. Manhapra received his medical degree from Government
      Medical College, Thrissur, Kerala, India, and completed his Addiction Medicine
      fellowship at Yale School of Medicine. Adam J. Gordon, M.D., M.P.H., is Professor
      of Medicine and Psychiatry at the University of Utah School of Medicine, Director
      of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy
      (PARCKA), and Chief of Addiction Medicine at VA Salt Lake City Health Care System
      and. He is a board-certified internal medicine (American Board of Internal
      Medicine) and addiction medicine physician (American Board of Preventive
      Medicine) with a 20-year track record of conducting research on the quality,
      equity, and efficiency of health care for vulnerable populations (e.g., persons
      with opioid use disorders, persons who are homeless, persons with hazardous
      alcohol use and other addiction disorders). He received his MD from University of
      Pittsburgh School of Medicine in Pittsburgh, PA and his MPH from the University
      of Pittsburgh Graduate School of Public Health in Pittsburgh, PA.
FAU - Gordon, Adam J
AU  - Gordon AJ
AD  - Stefan G. Kertesz, M.D., M.Sc., is a professor at the Department of Medicine, UAB
      School of Medicine and research investigator at the Birmingham VA Medical Center.
      He is a board-certified internal medicine (American Board of Internal Medicine)
      and addiction medicine physician (American Board of Addiction Medicine). His
      research career began in 2000 and he has been funded by both the National
      Institute on Drug Abuse and the Health Services Research & Development Branch of 
      the Department of Veterans Affairs. He received his MD from Harvard Medical
      School in Boston, MA and his MSc from Boston University School of Public Health
      in Boston, MA. Ajay Manhapra, M.D., is Lecturer at Yale School of Medicine in the
      Department of Psychiatry, Assistant Professor, at the Eastern Virginia Medical
      School in the Department of Physical Medicine and Rehabilitation and Psychiatry, 
      and Research Scientist at the VA New England Mental Illness Research, Education
      and Clinical Center. Dr. Manhapra is a board-certified Internist and Addiction
      Medicine physician with educational, clinical and research focus on pain and
      addiction. He runs a unique clinic for recovering patients with severe disabling 
      chronic pain and medication or substance dependence at Hampton VA Medical Center,
      where he is developing an interdisciplinary integrative model for treatment of
      pain and addiction. Dr. Manhapra received his medical degree from Government
      Medical College, Thrissur, Kerala, India, and completed his Addiction Medicine
      fellowship at Yale School of Medicine. Adam J. Gordon, M.D., M.P.H., is Professor
      of Medicine and Psychiatry at the University of Utah School of Medicine, Director
      of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy
      (PARCKA), and Chief of Addiction Medicine at VA Salt Lake City Health Care System
      and. He is a board-certified internal medicine (American Board of Internal
      Medicine) and addiction medicine physician (American Board of Preventive
      Medicine) with a 20-year track record of conducting research on the quality,
      equity, and efficiency of health care for vulnerable populations (e.g., persons
      with opioid use disorders, persons who are homeless, persons with hazardous
      alcohol use and other addiction disorders). He received his MD from University of
      Pittsburgh School of Medicine in Pittsburgh, PA and his MPH from the University
      of Pittsburgh Graduate School of Public Health in Pittsburgh, PA.
LA  - eng
GR  - UG1 DA049444/DA/NIDA NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
RN  - 0 (Analgesics, Opioid)
MH  - Analgesics, Opioid/*therapeutic use
MH  - Chronic Pain/*drug therapy
MH  - *Drug Tapering
MH  - Health Policy
MH  - Humans
MH  - *Mandatory Programs
MH  - Opioid-Related Disorders/prevention & control
MH  - *Quality of Health Care
MH  - United States/epidemiology
PMC - PMC7938366
MID - NIHMS1676333
EDAT- 2020/07/08 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1177/1073110520935337 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Jun;48(2):259-267. doi: 10.1177/1073110520935337.


PMID- 32631179
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 2
DP  - 2020 Jun
TI  - Opioids May be Appropriate for Chronic Pain.
PG  - 241-248
LID - 10.1177/1073110520935335 [doi]
AB  - Patients living with chronic pain require appropriate access to opioid therapy
      along with improved access to pain care and additional therapeutic options. It's 
      both medically reasonable and ethical to consider opioid therapy as a treatment
      option in the management of chronic, non-cancer pain for a subset of patients
      with severe pain that is unresponsive to other therapies (e.g., injections, other
      medications, integrative strategies), negatively impacts function or quality of
      life, and will likely outweigh the potential harms. This paper will examine
      opioid therapy in the setting of the opioid epidemic, why critics feel that the
      CDC guideline has resulted in harsh consequences for patients and their
      physicians, and the rationale for opioid therapy as a means of providing ethical 
      and compassionate pain care.
FAU - Christo, Paul J
AU  - Christo PJ
AD  - Paul J. Christo, M.D., M.B.A., is Associate Professor, Division of Pain Medicine,
      Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University
      School of Medicine. He earned a B.S. from University of Notre Dame, Notre Dame,
      IN, an M.D. from University of Louisville School of Medicine, Louisville, KY, and
      an M.B.A. from The Johns Hopkins Carey School of Business, Baltimore, MD.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Illicit Drugs)
RN  - 0 (Prescription Drugs)
MH  - Analgesics, Opioid/*therapeutic use
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Chronic Pain/*drug therapy
MH  - Guidelines as Topic
MH  - Humans
MH  - Illicit Drugs/poisoning
MH  - Opioid Epidemic/prevention & control
MH  - Pain Management/*methods
MH  - Prescription Drugs/*therapeutic use
MH  - Quality of Life
MH  - United States/epidemiology
EDAT- 2020/07/08 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1177/1073110520935335 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Jun;48(2):241-248. doi: 10.1177/1073110520935335.


PMID- 32630809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-3425 (Print)
IS  - 2076-3425 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Science Runs and the Debate Brakes: Somatic Gene-Editing as a New Tool for
      Gender-Specific Medicine in Alzheimer's Disease.
LID - E421 [pii]
LID - 10.3390/brainsci10070421 [doi]
AB  - Gender-specific medicine is a discipline that studies the influence of sex and
      gender on physiology, pathophysiology, and diseases. One example in light of how 
      a genetic-based disease among other diseases, that impact on sex, can be
      represented by the risk of developing dementia or Alzheimer's disease. The
      question that comes into focus is whether gene-editing can represent a new line
      of investigation to be explored in the development of personalized,
      gender-specific medicine that guarantees gender equity in health policies. This
      article aims to discuss the relevance of adopting a gender-specific focus on
      gene-editing research, considered as a way of contributing to the advance of
      medicine's understanding, treatment, and prevention of dementia, particularly
      Alzheimer's disease. The development or improvement of cures could take advantage
      of the knowledge of the gender diversity in order to ascertain and develop
      differential interventions also at the genetic level between women and men, and
      this deserves special attention and deep ethical reflection.
FAU - Tozzo, Pamela
AU  - Tozzo P
AD  - Department of Molecular Medicine, Laboratory of Forensic Genetics, University of 
      Padova, Via Falloppio 50, 35121 Padova, Italy.
FAU - Zullo, Silvia
AU  - Zullo S
AD  - Department of Legal Studies, University of Bologna, 40121 Bologna, Italy.
FAU - Caenazzo, Luciana
AU  - Caenazzo L
AD  - Department of Molecular Medicine, Laboratory of Forensic Genetics, University of 
      Padova, Via Falloppio 50, 35121 Padova, Italy.
LA  - eng
PT  - Editorial
DEP - 20200702
PL  - Switzerland
TA  - Brain Sci
JT  - Brain sciences
JID - 101598646
PMC - PMC7408320
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - ethics
OT  - genders
OT  - health and new technologies
OT  - somatic gene-editing
EDAT- 2020/07/08 06:00
MHDA- 2020/07/08 06:01
CRDT- 2020/07/08 06:00
PHST- 2020/06/12 00:00 [received]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/08 06:01 [medline]
AID - brainsci10070421 [pii]
AID - 10.3390/brainsci10070421 [doi]
PST - epublish
SO  - Brain Sci. 2020 Jul 2;10(7). pii: brainsci10070421. doi:
      10.3390/brainsci10070421.


PMID- 32629805
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 13
DP  - 2020 Jun 30
TI  - High-Value Compounds in Fruit, Vegetable and Cereal Byproducts: An Overview of
      Potential Sustainable Reuse and Exploitation.
LID - E2987 [pii]
LID - 10.3390/molecules25132987 [doi]
AB  - Food waste (FW) represents a global and ever-growing issue that is attracting
      more attention due to its environmental, ethical, social and economic
      implications. Although a valuable quantity of bioactive components is still
      present in the residuals, nowadays most FW is destined for animal feeding,
      landfill disposal, composting and incineration. Aiming to valorize and recycle
      food byproducts, the development of novel and sustainable strategies to reduce
      the annual food loss appears an urgent need. In particular, plant byproducts are 
      a plentiful source of high-value compounds that may be exploited as natural
      antioxidants, preservatives and supplements in the food industry, pharmaceuticals
      and cosmetics. In this review, a comprehensive overview of the main bioactive
      compounds in fruit, vegetable and cereal byproducts is provided. Additionally,
      the natural and suitable application of tailored enzymatic treatments and
      fermentation to recover high-value compounds from plant byproducts is discussed. 
      Based on these promising strategies, a future expansion of green biotechnologies 
      to revalorize the high quantity of byproducts is highly encouraging to reduce the
      food waste/losses and promote benefits on human health.
FAU - Tlais, Ali Zein Alabiden
AU  - Tlais AZA
AD  - Faculty of Sciences and Technology, Libera Universita di Bolzano, 39100 Bolzano, 
      Italy.
FAU - Fiorino, Giuseppina Maria
AU  - Fiorino GM
AD  - Faculty of Sciences and Technology, Libera Universita di Bolzano, 39100 Bolzano, 
      Italy.
FAU - Polo, Andrea
AU  - Polo A
AUID- ORCID: 0000-0002-3001-4927
AD  - Faculty of Sciences and Technology, Libera Universita di Bolzano, 39100 Bolzano, 
      Italy.
FAU - Filannino, Pasquale
AU  - Filannino P
AUID- ORCID: 0000-0002-1235-5138
AD  - Department of Soil, Plant and Food Science, University of Bari Aldo Moro, 70121
      Bari, Italy.
FAU - Di Cagno, Raffaella
AU  - Di Cagno R
AD  - Faculty of Sciences and Technology, Libera Universita di Bolzano, 39100 Bolzano, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
SB  - IM
MH  - Edible Grain/*chemistry
MH  - *Food-Processing Industry
MH  - Fruit/*chemistry
MH  - Humans
MH  - *Sustainable Development
MH  - Vegetables/*chemistry
MH  - *Waste Management
PMC - PMC7412346
OTO - NOTNLM
OT  - enzymatic treatments
OT  - fermentation
OT  - food waste
OT  - high-value compounds
OT  - plant byproducts
EDAT- 2020/07/08 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/05/28 00:00 [received]
PHST- 2020/06/23 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - molecules25132987 [pii]
AID - 10.3390/molecules25132987 [doi]
PST - epublish
SO  - Molecules. 2020 Jun 30;25(13). pii: molecules25132987. doi:
      10.3390/molecules25132987.


PMID- 32629779
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-666X (Print)
IS  - 2072-666X (Linking)
VI  - 11
IP  - 7
DP  - 2020 Jun 30
TI  - Novel Strategies in Artificial Organ Development: What Is the Future of Medicine?
LID - E646 [pii]
LID - 10.3390/mi11070646 [doi]
AB  - The technology of tissue engineering is a rapidly evolving interdisciplinary
      field of science that elevates cell-based research from 2D cultures through
      organoids to whole bionic organs. 3D bioprinting and organ-on-a-chip approaches
      through generation of three-dimensional cultures at different scales, applied
      separately or combined, are widely used in basic studies, drug screening and
      regenerative medicine. They enable analyses of tissue-like conditions that yield 
      much more reliable results than monolayer cell cultures. Annually, millions of
      animals worldwide are used for preclinical research. Therefore, the rapid
      assessment of drug efficacy and toxicity in the early stages of preclinical
      testing can significantly reduce the number of animals, bringing great ethical
      and financial benefits. In this review, we describe 3D bioprinting techniques and
      first examples of printed bionic organs. We also present the possibilities of
      microfluidic systems, based on the latest reports. We demonstrate the pros and
      cons of both technologies and indicate their use in the future of medicine.
FAU - Klak, Marta
AU  - Klak M
AUID- ORCID: 0000-0003-3901-586X
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Bryniarski, Tomasz
AU  - Bryniarski T
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Kowalska, Patrycja
AU  - Kowalska P
AUID- ORCID: 0000-0003-0635-7214
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Gomolka, Magdalena
AU  - Gomolka M
AUID- ORCID: 0000-0002-7067-5252
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Tymicki, Grzegorz
AU  - Tymicki G
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Kosowska, Katarzyna
AU  - Kosowska K
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Cywoniuk, Piotr
AU  - Cywoniuk P
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Dobrzanski, Tomasz
AU  - Dobrzanski T
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Turowski, Pawel
AU  - Turowski P
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
FAU - Wszola, Michal
AU  - Wszola M
AD  - Foundation of Research and Science Development, 01-793 Warsaw, Poland.
LA  - eng
GR  - STRATEGMED3/305813/2/NCBR/2017/Narodowe Centrum Badan i Rozwoju
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - Switzerland
TA  - Micromachines (Basel)
JT  - Micromachines
JID - 101640903
PMC - PMC7408042
OTO - NOTNLM
OT  - 3D bioprinting
OT  - bioink
OT  - bionic tissue
OT  - cell culture
OT  - organ-on-a-chip
EDAT- 2020/07/08 06:00
MHDA- 2020/07/08 06:01
CRDT- 2020/07/08 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/06/25 00:00 [revised]
PHST- 2020/06/26 00:00 [accepted]
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/08 06:01 [medline]
AID - mi11070646 [pii]
AID - 10.3390/mi11070646 [doi]
PST - epublish
SO  - Micromachines (Basel). 2020 Jun 30;11(7). pii: mi11070646. doi:
      10.3390/mi11070646.


PMID- 32629750
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - An observational study on diagnosis index of metabolic disease with blood-stasis.
PG  - e21140
LID - 10.1097/MD.0000000000021140 [doi]
AB  - INTRODUCTION: Treating blood stasis is effective in treating obesity and
      metabolic diseases in traditional Korean medicine. The aim of this prospective
      observational study is to determine the effectiveness of the diagnosis index for 
      metabolic diseases with blood stasis by analyzing clinical data and blood
      samples. METHODS AND ANALYSIS: We will perform a prospective observational study.
      Participants who meet the inclusion criteria will be recruited from the Dongguk
      university Ilsan Oriental hospital. The outcomes are resistin, serum amyloid P
      component, C-reactive protein, D-dimer, and blood stasis scores. In addition, the
      blood pressure, ankle-brachial pressure index, brachial-ankle pulse wave
      velocity, body mass index, waist circumference, and levels of blood lipid will be
      assessed. DISCUSSION: Through this study, we could collect specific data for
      diagnosing metabolic diseases with blood stasis. Therefore, the findings of this 
      study will provide a summary of the current state of evidence regarding the
      effectiveness of the diagnosis index in managing metabolic disease with blood
      stasis. ETHICS AND DISSEMINATION: The study was approved by the Institutional
      Review Board of the Dongguk University Ilsan Oriental Hospital
      (DUIOH-2018-09-001-007). The results will be published in a peer-reviewed journal
      and will be disseminated electronically and in print. TRIAL REGISTRATION NUMBER: 
      Clinical Research Information Service: KCT0003548.
FAU - Ko, Mi Mi
AU  - Ko MM
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon,
      Republic of Korea.
FAU - Jang, Soobin
AU  - Jang S
FAU - Jung, Jeeyoun
AU  - Jung J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Lipids)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ankle Brachial Index/methods
MH  - Blood Pressure/physiology
MH  - Body Mass Index
MH  - Female
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Medicine, Korean Traditional/*methods
MH  - Metabolic Diseases/complications/*diagnosis/metabolism/*therapy
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pulse Wave Analysis/methods
MH  - Republic of Korea/epidemiology
MH  - Tongue/*blood supply/pathology
MH  - Waist Circumference/physiology
PMC - PMC7337439
EDAT- 2020/07/08 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.1097/MD.0000000000021140 [doi]
AID - 00005792-202007020-00129 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e21140. doi: 10.1097/MD.0000000000021140.


PMID- 32629739
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Traditional medicine treatment for thoracic outlet syndrome: A protocol for
      systematic review of randomized controlled trials.
PG  - e21074
LID - 10.1097/MD.0000000000021074 [doi]
AB  - BACKGROUND: Diagnosis of thoracic outlet syndrome (TOS) is challenging; however, 
      proper evaluation and treatment ensure relief from symptoms in most patients. A
      comprehensive approach to treatment is important, considering the multifactorial 
      etiology of TOS. The objective of this systematic review is to describe the
      methods for evaluating the effectiveness and safety of acupuncture-based
      traditional medicine treatments for TOS. METHODS: A total of 13 databases will be
      searched, from their inception to the present date, for studies that have
      investigated the treatment of TOS. Databases that will be included are MEDLINE,
      Embase, AMED, Cochrane Library, CINAHL, and 4 Korean, 2 Chinese, and 2 Japanese
      databases.We will include randomized controlled trials (RCTs) assessing
      acupuncture-based traditional medicine for the treatment of any type of TOS. All 
      RCTs on traditional medicine with any form of acupuncture will be eligible for
      inclusion. The methodologic quality of the RCTs will be analyzed using the
      Cochrane Collaboration tool to assess the risk of bias, and the confidence in the
      cumulative evidence will be assessed using the grading of recommendations
      assessment, development, and evaluation instrument. ETHICS AND DISSEMINATION: The
      results of this systematic review will be published in a peer-reviewed journal
      and disseminated both electronically and in print. The review will be updated to 
      inform and guide health care practices. TRIAL REGISTRATION NUMBER: PROSPERO 2020 
      CRD42020164869.
FAU - Hwang, Ji Hye
AU  - Hwang JH
AUID- ORCID: 0000-0002-6304-1972
AD  - Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine,
      Gachon University, Seongnam.
FAU - Ku, Sujeong
AU  - Ku S
AD  - Department of Clinical Korean Medicine, Graduate School, Kyung Hee University.
FAU - Jeong, Jin-Ho
AU  - Jeong JH
AD  - Jisung-Kyunghee Korean Medicine Clinic, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Databases, Factual
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Medicine, Chinese Traditional
MH  - Medicine, Korean Traditional
MH  - Medicine, Traditional/*methods/trends
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Thoracic Outlet Syndrome/epidemiology/*therapy
MH  - Treatment Outcome
PMC - PMC7337591
EDAT- 2020/07/08 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.1097/MD.0000000000021074 [doi]
AID - 00005792-202007020-00118 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e21074. doi: 10.1097/MD.0000000000021074.


PMID- 32629736
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Association between arginine catabolism and major depressive disorder: A protocol
      for the systematic review and meta-analysis of metabolic pathway.
PG  - e21068
LID - 10.1097/MD.0000000000021068 [doi]
AB  - BACKGROUND: Alterations in the levels of arginine and its related catabolic
      products (ie, ornithine, citrulline, and argininosuccinate) in the urea and
      nitric oxide cycles were reported to play roles in the pathogenesis of major
      depressive disorder (MDD). The aim of this meta-analysis study is to explore the 
      associations between arginine with its related catabolic products and MDD, and to
      discuss the possible role of arginine catabolism in the pathoetiology of MDD.
      METHODS: This study will be conducted in accordance with the Preferred Reporting 
      Items for Systematic Reviews and Meta-Analyses guidelines. The English language
      literature published in the databases of PubMed, EMBASE, PsycINFO and Web of
      Science will be systematically searched. Forest plots will be used to estimate
      the associations between arginine and its related catabolic products with MDD.
      Subgroup analysis and meta-regression will also be performed to investigate the
      source of the potential heterogeneity. Sensitivity analysis will be performed to 
      strengthen the results and to investigate whether any single study would have a
      significant effect on the results of meta-analysis. Publication bias will be
      tested for using the funnel plot with Begg test and Egger test. The
      Newcastle-Ottawa Scale will be applied to assess the risk of bias of
      observational studies. RESULTS: An integrated assessment of arginine with its
      related catabolic products may contribute to predict the risk of MDD. ETHICS AND 
      DISSEMINATION: The results of associations between arginine with its related
      catabolic products and MDD will be reported in a peer-reviewed publication. With 
      our findings from this meta-analysis, we hope to provide the most up-to-date
      evidence for the contributions of arginine and related catabolic products to
      predict the risk of MDD. SYSTEMATIC REVIEW REGISTRATION: The protocol of current 
      meta-analysis has been registered at the Open Science Framework [Available at:
      https://doi.org/10.17605/osf.io/7fn59].
FAU - Cao, Bing
AU  - Cao B
AD  - Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of
      Education.
AD  - National Demonstration Center for Experimental Psychology Education, Southwest
      University.
FAU - Deng, Runze
AU  - Deng R
AD  - Chongqing University Three Gorges Hospital.
AD  - Chongqing Three Gorges Central Hospital.
FAU - Wang, Dongfang
AU  - Wang D
AD  - Chongqing Blood Center.
FAU - Li, Li
AU  - Li L
AD  - Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of
      Education.
FAU - Ren, Zhongyu
AU  - Ren Z
AD  - College of Physical Education, Southwest University, Chongqing, China.
FAU - Xu, Lixin
AU  - Xu L
AD  - Chongqing University Three Gorges Hospital.
AD  - Chongqing Three Gorges Central Hospital.
FAU - Gao, Xiao
AU  - Gao X
AUID- ORCID: 0000-0003-4042-8362
AD  - Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of
      Education.
AD  - National Demonstration Center for Experimental Psychology Education, Southwest
      University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Arginine/*metabolism
MH  - Depressive Disorder, Major/*metabolism/physiopathology
MH  - Humans
MH  - Metabolic Networks and Pathways/*physiology
MH  - Nitric Oxide/*metabolism
MH  - Risk Assessment
MH  - Sensitivity and Specificity
PMC - PMC7337538
EDAT- 2020/07/08 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.1097/MD.0000000000021068 [doi]
AID - 00005792-202007020-00115 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e21068. doi: 10.1097/MD.0000000000021068.


PMID- 32629704
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Prophylactic antibiotics for miscarriage surgery: A protocol for systematic
      review and meta-analysis.
PG  - e20959
LID - 10.1097/MD.0000000000020959 [doi]
AB  - BACKGROUND: Infection is a serious potential consequence of surgery to complete a
      spontaneous abortion. Antibiotic prophylaxis before some operations has been
      shown to reduce the risk of postoperative infections. However, for miscarriage
      surgery, evidence is lacking to show effectiveness. METHODS: In this systematic
      review, the electronic databases of Cochrane Central Register of Controlled
      Trials, EMBASE, and PUBMED will be searched from inception to May 1, 2020.
      Randomized controlled trials that assessed the effectiveness and safety of
      antibiotic prophylaxis for preventing infection for patients undergoing
      miscarriage surgery will be included. All process of the study selection, data
      extraction, and methodology evaluation will be carried out by two authors
      independently. RevMan 5.3 software will be utilized for statistical analysis.
      RESULTS: This study will provide a detailed summary of latest evidence related to
      the effectiveness and safety of antibiotic prophylaxis for preventing infection
      for patients undergoing miscarriage surgery. CONCLUSION: The findings of this
      study may provide possible guidance for the use of antibiotic prophylaxis for
      preventing infection for patients undergoing miscarriage surgery. DISSEMINATION
      AND ETHICS: Ethical approval is not required in this study, because it will not
      collect the original data from individual patient. The results are expected to
      publish through a peer-reviewed journal. SYSTEMATIC REVIEW REGISTRATION: PROSPERO
      CRD CRD42020155643.
FAU - Fu, Yu
AU  - Fu Y
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Jin, Ruirui
AU  - Jin R
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Wang, Xiaoxia
AU  - Wang X
AD  - Gansu Gem Flower Hospital, Lanzhou city, Gansu province, China.
FAU - Sun, Qingmei
AU  - Sun Q
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Lin, Xiaojuan
AU  - Lin X
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Wang, Xiaozhuan
AU  - Wang X
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Tang, Zhongfeng
AU  - Tang Z
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Song, Xiaoyu
AU  - Song X
AD  - Gansu Provincial Maternity and Child-care Hospital.
FAU - Zhao, Youhong
AU  - Zhao Y
AUID- ORCID: 0000-0001-9986-3727
AD  - Gansu Provincial Maternity and Child-care Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Abortion, Spontaneous/*surgery
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Antibiotic Prophylaxis/*methods
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pelvic Infection/*prevention & control
MH  - Postoperative Complications/*prevention & control
MH  - Pregnancy
MH  - Systematic Reviews as Topic
PMC - PMC7337539
EDAT- 2020/07/08 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.1097/MD.0000000000020959 [doi]
AID - 00005792-202007020-00083 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e20959. doi: 10.1097/MD.0000000000020959.


PMID- 32629659
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Traditional Chinese medicine on treating dilated cardiomyopathy: A protocol for
      systematic review and meta analysis.
PG  - e20777
LID - 10.1097/MD.0000000000020777 [doi]
AB  - BACKGROUND: Dilated cardiomyopathy (DCM) is a type of complex cardiomyopathy
      characterized by enlargement and contractile dysfunction of the left ventricle,
      right ventricle, or double ventricle. Modern studies have shown that the
      pathogenesis of DCM is closely related to factors such as heredity, gene
      mutation, autoimmunity, and viral infection. The etiology is complex and the
      mortality rate is high. Many clinical trials have proved that traditional Chinese
      medicine has a great therapeutic effect on DCM. In this systematic review, we aim
      to evaluate the effectiveness and safety of traditional Chinese medicine for DCM.
      METHODS: The databases of Pubmed, The Cochrane Library, Embase, China National
      Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (WANFANG
      Data), Weipu Information Chinese Periodical Service Platform (VIP), and China
      Biomedical Literature Service System (SinoMed) will be searched online to collect
      randomized controlled trials related to the treatment of DCM with Traditional
      Chinese medicine The time is limited from the construction of the library to
      December 2019. We will use the criteria provided by Cochrane 5.1.0 for quality
      assessment and risk assessment of the included studies, and use the Revman 5.3
      and Stata 13.0 software so as to systematically review the effectiveness of
      Traditional Chinese medicine for DCM. ETHICS AND DISSEMINATION: This systematic
      review will evaluate the efficacy and safety of traditional Chinese medicine for 
      DCM. Because all data used in this systematic review and meta-analysis have been 
      published, this review does not require ethical approval. In addition, all data
      will be analyzed anonymously during the review process. TRIAL REGISTRATION
      NUMBER: PROSPERO CRD42020163332.
FAU - Tan, Yuqing
AU  - Tan Y
AUID- ORCID: 0000-0001-9016-2043
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Chen, Hengwen
AU  - Chen H
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Li, Jun
AU  - Li J
AUID- ORCID: 0000-0002-8011-8089
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Wu, Qingjuan
AU  - Wu Q
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
FAU - Wu, Xiaobo
AU  - Wu X
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
AD  - Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Cardiomyopathy, Dilated/*drug therapy
MH  - Humans
MH  - Medicine, Chinese Traditional/adverse effects/*methods
MH  - Treatment Outcome
PMC - PMC7337424
EDAT- 2020/07/08 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
AID - 10.1097/MD.0000000000020777 [doi]
AID - 00005792-202007020-00038 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e20777. doi: 10.1097/MD.0000000000020777.


PMID- 32629658
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Inspection and polypectomy during both insertion and withdrawal or only during
      withdrawal of colonoscopy?: A protocol for systematic review and meta analysis.
PG  - e20775
LID - 10.1097/MD.0000000000020775 [doi]
AB  - INTRODUCTION: Current evidence supporting additional inspection and polypectomy
      during insertion of colonoscopy is limited. We plan to provide a systematic
      review and meta-analysis to compare the yield of inspection and polypectomy
      during both insertion and withdrawal versus the traditional practice of
      inspection and polypectomy during withdrawal only. METHODS AND ANALYSIS:
      Randomised controlled trials evaluating inspection and polypectomy during both
      insertion and withdrawal versus inspection and polypectomy during withdrawal only
      will be searched in MEDLINE, EMBASE, Web of Science, the Cochrane Library,
      ClinicalTrials.gov, and Google Scholar, from database inception to 31 May 2020.
      Data on study design, participant characteristics, and outcomes will be
      extracted. Primary outcomes to be assessed are adenoma detection rate. Secondary 
      outcomes include polyp detection rate, advanced adenoma detection rate, the mean 
      number of adenomas per patient, polyp miss rate, the mean number of adenomas per 
      colonoscopy, procedure duration, cecal intubation rate, procedure difficulty,
      patient discomfort, sedation dose, and adverse events. Study quality will be
      assessed using the Cochrane Risk of Bias Tool. Meta-analysis will be performed
      using RevMan V.5.3 statistical software. Data will be combined with random effect
      model. The results will be presented as a risk ratio (RR) for dichotomous data,
      and weighted/standard mean difference for continuous data. Publication bias will 
      be visualized using funnel plots. ETHICS AND DISSEMINATION: This study will not
      use primary data, and therefore formal ethical approval is not required. The
      findings will be disseminated through peer-reviewed journals and committee
      conferences. PROTOCOL REGISTRATION NUMBER: INPLASY202050051.
FAU - Wei, Yaping
AU  - Wei Y
AD  - Affiliated Hangzhou First People's Hospital, Zhejiang University School of
      Medicine, Hangzhou, China.
FAU - Shen, Guofan
AU  - Shen G
FAU - Yang, Yutong
AU  - Yang Y
FAU - Jin, Zheng
AU  - Jin Z
FAU - Hu, Wei
AU  - Hu W
FAU - Zhu, Ying
AU  - Zhu Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Colonic Polyps/diagnosis/*surgery
MH  - Colonoscopy/*methods
MH  - Humans
PMC - PMC7337486
EDAT- 2020/07/08 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
AID - 10.1097/MD.0000000000020775 [doi]
AID - 00005792-202007020-00037 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e20775. doi: 10.1097/MD.0000000000020775.


PMID- 32629656
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Efficacy and safety of remimazolam in procedural sedation and analgesia: A
      protocol for systematic review and meta analysis.
PG  - e20765
LID - 10.1097/MD.0000000000020765 [doi]
AB  - BACKGROUND: Remimazolam is a newly developed benzodiazepine as an alternative of 
      conventional sedatives in the procedure of anesthesia. For the purpose of
      evaluating the efficacy and safety of remimazolam sedation during an endoscopy,
      we will perform a systematic review and meta-analysis of randomized controlled
      trials that compared remimazolam with midazolam and/or placebo. METHODS: We will 
      search PubMed, Embase, Web of Science, and the Cochrane Controlled Register of
      Trials (CENTRAL) from inception to December 2019 for randomized controlled trials
      that investigated efficacy and safety of remimazolam during an endoscopy. The job
      will be performed without language restriction. Experimental groups will include 
      the interventions of remimazolam, while control groups will involve midazolam,
      placebo, or no controls. The primary outcome will be the onset time, followed by 
      the secondary outcomes of the recovery time, the incidence of hypotension, the
      incidence of hypoxia and the incidence of bradycardia. Relative ratio or
      standardized mean difference will be used to measure the effect size of
      remimazolam. We will use I statistics to assess the between-study heterogeneity
      in each meta-analysis, Eager's test to detect publication bias. RESULTS: The
      results of this study will be published in a peer-reviewed journal. ETHICS AND
      DISSEMINATION: There is no need for ethical approval because all data used in
      this meta-analysis have been published. In addition, all data will be analyzed
      anonymously during the review process. PROTOCOL REGISTRATION NUMBER:
      CRD42020170745.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Anesthesiology, Affiliated Hospital of Guizhou Medical University, 
      Gui yang, China.
FAU - Zhou, Qian
AU  - Zhou Q
FAU - Shen, Minhuan
AU  - Shen M
FAU - Quan, Jing
AU  - Quan J
FAU - Chen, Jiejuan
AU  - Chen J
FAU - Shi, Jing
AU  - Shi J
FAU - Zou, Xiaohua
AU  - Zou X
AUID- ORCID: 0000-0002-4122-9122
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hypnotics and Sedatives)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 7V4A8U16MB (remimazolam)
SB  - IM
MH  - Analgesia/adverse effects/*methods
MH  - *Benzodiazepines/adverse effects
MH  - Conscious Sedation/adverse effects/*methods
MH  - Humans
MH  - *Hypnotics and Sedatives/adverse effects
PMC - PMC7337542
EDAT- 2020/07/08 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
AID - 10.1097/MD.0000000000020765 [doi]
AID - 00005792-202007020-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e20765. doi: 10.1097/MD.0000000000020765.


PMID- 32629643
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Comparison of clinical efficacy between robotic-laparoscopic excision and
      traditional laparoscopy for rectal cancer: A protocol for systematic review and
      meta-analysis.
PG  - e20704
LID - 10.1097/MD.0000000000020704 [doi]
AB  - BACKGROUNDS: Laparoscopic surgery, robot-assisted surgery and open surgery are
      the most commonly consumed surgical techniques in daily living. Considering that 
      in recent years, the situation of choosing laparoscopic surgery and
      robot-assisted surgery to treat rectal cancer in China is prosperous. Meanwhile, 
      researches lacked in the comparison part between the 2, so we will systematically
      compare the clinical efficacy of robot-assisted resection and traditional
      laparoscopic resection for rectal cancer. METHODS AND ANALYSIS: We will search
      Clinical research literature published before January 2020 in PubMed, Embase, the
      Cochrane library, Science Network, Wan Fang database, Chinese national knowledge 
      infrastructure, and Chinese biomedicine that evaluate the correlation of rectal
      cancer with Leonardo's robot and traditional laparoscopy, from inception to July 
      2019. Weighted mean difference and odds ratio were used to compare the efficacy
      of robot-assisted resection versus conventional laparoscopic resection for rectal
      cancer, and the main indicators are operation time, complication rate, conversion
      rate, blood loss, and length of stay. RESULTS AND CONCLUSION: This study will
      systematically evaluate the clinical efficacy of robot-assisted resection and
      traditional laparoscopic resection for rectal cancer, thus providing evidence to 
      the clinical application. The results will be published in a peer-reviewed
      journal. ETHICS AND DISSEMINATION: No ethical approval and participant consent
      are required, since this study data is based on published literature. The results
      of the study will be submitted to a peer-reviewed journal.PROSPERO registration
      number: CRD42020172161.
FAU - Chen, Zhen
AU  - Chen Z
AD  - General Surgery Department, Dazhou Central Hospital, Tongchuan District, Dazhou, 
      Sichuan Province, China.
FAU - Zhu, Zhuo Li
AU  - Zhu ZL
FAU - Wang, Pingxi
AU  - Wang P
FAU - Zeng, Fanwei
AU  - Zeng F
AUID- ORCID: 0000-0003-2508-0011
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - *Laparoscopy/methods
MH  - Rectal Neoplasms/*surgery
MH  - *Robotic Surgical Procedures/methods
MH  - Treatment Outcome
PMC - PMC7337608
EDAT- 2020/07/08 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
AID - 10.1097/MD.0000000000020704 [doi]
AID - 00005792-202007020-00022 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e20704. doi: 10.1097/MD.0000000000020704.


PMID- 32629625
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 27
DP  - 2020 Jul 2
TI  - Effectiveness of a primary care clinical ultrasound classroom for family
      physicians as a formative intervention system, a quasi-experimental trial: Study 
      protocol.
PG  - e19914
LID - 10.1097/MD.0000000000019914 [doi]
AB  - INTRODUCTION: Clinical ultrasound is a technique that increases diagnostic
      capacity and facilitates clinical decision making. The objective is to develop
      and validate an ultrasound training methodology oriented to the clinical practice
      of the family physician. METHODS: Quasi-experimental study, with a before/after
      design, a control group, and 1 year of follow-up. Twenty family physicians
      working in primary care health centers with a list of over 800 patients will be
      included, as well as a control group of family physicians with similar
      characteristics in terms of age, sex, and patient list. A structured training
      process oriented to the clinical practice of the family physician, primary care
      clinical ultrasound classroom (AECAP), will be carried out, and the improvement
      of knowledge and skills of the participants will be evaluated, as well as the
      improvement of the quality of care based on clinical indicators. DISCUSSION: The 
      family physician is in a privileged situation allows increasing the performance
      of ultrasound in frequent clinical situations and reducing care hours. We hope
      that the results obtained in this study demonstrate the effectiveness of the
      structured training method (AECAP) and support the generalization of ultrasound
      in primary health care. ETHICS AND DISSEMINATION: The study was approved by the
      Medical Research Ethics Committee of Salamanca on December 17, 2018 (cod 2018 11 
      134). The trial was registered in ClinicalTrials.gov provided by the US National 
      Library of Medicine-number: NCT04283383.
FAU - Diego-Dominguez, Fernando
AU  - Diego-Dominguez F
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Unidad de
      Investigacion de Atencion Primaria de Salamanca (APISAL).
AD  - Centro de Salud de San Juan de Salamanca.
FAU - Torrecilla-Garcia, Miguel
AU  - Torrecilla-Garcia M
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Unidad de
      Investigacion de Atencion Primaria de Salamanca (APISAL).
AD  - Centro de Salud de San Juan de Salamanca.
FAU - Casado-Huerga, Jesus
AU  - Casado-Huerga J
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Unidad de
      Investigacion de Atencion Primaria de Salamanca (APISAL).
AD  - Centro de Salud de San Juan de Salamanca.
FAU - Paule-Sanchez, Maria Angeles
AU  - Paule-Sanchez MA
AD  - Centro de Salud de San Juan de Salamanca.
FAU - Soria-Lopez, Clara Isabel
AU  - Soria-Lopez CI
AD  - Centro de Salud de San Juan de Salamanca.
FAU - Iglesias-Clemente, Jose Manuel
AU  - Iglesias-Clemente JM
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Unidad de
      Investigacion de Atencion Primaria de Salamanca (APISAL).
AD  - Centro de Salud de San Juan de Salamanca.
FAU - de Dios-Hernandez, Jose Maria
AU  - de Dios-Hernandez JM
AD  - Unidad Docente Multiprofesional de Atencion Familiar y Comunitaria de Salamanca.
FAU - Diego-Mangas, Natalia
AU  - Diego-Mangas N
AD  - Centro de Salud de Periurbana Norte, Servicio de Salud de Castilla y Leon,
      Salamanca, Spain.
FAU - Cubillo-Jimenez, Maria
AU  - Cubillo-Jimenez M
AD  - Unidad Docente Multiprofesional de Atencion Familiar y Comunitaria de Salamanca.
FAU - Perez-Escanilla, Fernando
AU  - Perez-Escanilla F
AD  - Instituto de Investigacion Biomedica de Salamanca (IBSAL), Unidad de
      Investigacion de Atencion Primaria de Salamanca (APISAL).
AD  - Centro de Salud de San Juan de Salamanca.
LA  - eng
SI  - ClinicalTrials.gov/NCT04283383
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Education, Medical/*methods
MH  - Humans
MH  - Physicians, Family/*education
MH  - Primary Health Care/*methods
MH  - *Ultrasonography
PMC - PMC7337512
EDAT- 2020/07/08 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/08 06:00
PHST- 2020/07/08 06:00 [entrez]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.1097/MD.0000000000019914 [doi]
AID - 00005792-202007020-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 2;99(27):e19914. doi: 10.1097/MD.0000000000019914.


PMID- 32629372
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1872-6976 (Electronic)
IS  - 0167-4943 (Linking)
VI  - 90
DP  - 2020 Sep - Oct
TI  - Ethical frameworks for complex medical decision making in older patients: A
      narrative review.
PG  - 104160
LID - S0167-4943(20)30154-0 [pii]
LID - 10.1016/j.archger.2020.104160 [doi]
AB  - BACKGROUND: With an ageing population physicians are more and more faced with
      complex medical and moral situations. Medical professional guidelines are often
      of limited use in these cases. To assist the decision making process, several
      ethical frameworks have been proposed. Ethical frameworks are analytical tools
      that are designed to assist physicians and other involved healthcare workers in
      complex moral decision-making situations. Most frameworks are step-by-step plans 
      that can be followed chronologically during moral case deliberations. Some of
      these step-by-step plans provide specific moral guidance as to what would
      constitute a morally acceptable conclusion, while others do not. OBJECTIVE: In
      this narrative review we will present and discuss the ethical frameworks used for
      medically complex situations in older people that have been proposed in
      literature. METHODS: Three electronic databases (embase.com. Medline Ovid and
      PsychINFO Ovid) were searched from inception to January 24, 2020, with the help
      of expert librarians. RESULTS: Twenty-three studies were included in the review, 
      containing seventeen different frameworks. Twenty studies described
      step-by-step-frameworks, with the number of steps varying from three to twelve.
      In four studies suggestions were made as how to balance conflicting moral values.
      CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: Ethical frameworks are meant to
      assist healthcare professionals who are faced with morally complex decisions in
      older patients. In our view, these frameworks should contain a step-by-step plan,
      moral values and an approach to balancing moral values.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - van Bruchem-Visser, Rozemarijn Lidewij
AU  - van Bruchem-Visser RL
AD  - Department of Internal Medicine, Erasmus MC University Medical Center, PO box
      2040 3000 CA, Rotterdam, the Netherlands. Electronic address:
      r.l.visser@erasmusmc.nl.
FAU - van Dijk, Gert
AU  - van Dijk G
AD  - Department of Medical Ethics and Philosophy of Medicine, Erasmus MC University
      Medical Center, PO box 2040 3000 CA, Rotterdam, the Netherlands.
FAU - de Beaufort, Inez
AU  - de Beaufort I
AD  - Department of Medical Ethics and Philosophy of Medicine, Erasmus MC University
      Medical Center, PO box 2040 3000 CA, Rotterdam, the Netherlands.
FAU - Mattace-Raso, Francesco
AU  - Mattace-Raso F
AD  - Department of Internal Medicine, Erasmus MC University Medical Center, PO box
      2040 3000 CA, Rotterdam, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200623
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Clinical Decision-Making
MH  - Decision Making
MH  - Health Personnel
MH  - Humans
MH  - *Morals
MH  - *Physicians
OTO - NOTNLM
OT  - *Decision-making
OT  - *Ethics
OT  - *Frail elderly
OT  - *Gerontology
COIS- Declaration of Competing Interest None.
EDAT- 2020/07/07 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - S0167-4943(20)30154-0 [pii]
AID - 10.1016/j.archger.2020.104160 [doi]
PST - ppublish
SO  - Arch Gerontol Geriatr. 2020 Sep - Oct;90:104160. doi:
      10.1016/j.archger.2020.104160. Epub 2020 Jun 23.


PMID- 32629093
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-1570 (Electronic)
IS  - 0300-9572 (Linking)
VI  - 155
DP  - 2020 Oct
TI  - Immediate coronary angiogram in out-of-hospital cardiac arrest patients with
      non-shockable initial rhythm and without ST-segment elevation - Is there a
      clinical benefit?
PG  - 226-233
LID - S0300-9572(20)30258-6 [pii]
LID - 10.1016/j.resuscitation.2020.06.022 [doi]
AB  - AIM: Coronary angiogram (CA) may be useful after resuscitated out-of-hospital
      cardiac arrest (OHCA), but data regarding its benefit in patients with
      non-shockable initial rhythm without ST-segment elevation is scarce. We aimed to 
      evaluate the prevalence of acute coronary syndrome (ACS) and survival in OHCA
      patients with non-shockable initial rhythm without ST-segment elevation and
      compare them to patients with shockable initial rhythm without ST-segment
      elevation. METHODS: Retrospective single-centre study approved by the ethics
      committee of our institution, including adults successfully resuscitated from
      OHCA of presumed cardiac cause, undergoing routine CA on admission. Baseline
      characteristics, angiographic data including presence of ACS and survival were
      compared between patients with non-shockable and shockable initial rhythm
      focusing on patients without ST-segment elevation. RESULTS: Among 517 patients
      included between 2002 and 2018, 311 had no ST-elevation, of whom 179 had
      non-shockable and 132 shockable initial rhythm. Compared with shockable initial
      rhythm patients without ST-elevation, non-shockable initial rhythm patients
      without ST-elevation had longer no-flow duration, 5 (1-10) versus 2 (0-8) min,
      p=0.024, more frequent shock requiring vasopressors, 72% versus 47% p<0.0001, a
      lower prevalence of ACS, 2 (1%), versus 29 (22%), p<0.001 and higher mortality,
      85% versus 39% (p<0.0001). Among ACS patients, none survived in the non-shockable
      without ST-elevation group, while 20 (69%) survived in the shockable rhythm
      without ST-elevation group. CONCLUSIONS: Prevalence of ACS in patients without
      ST-segment elevation and non-shockable initial rhythm is extremely low, and
      survival extremely poor, therefore routine emergency CA does not seem beneficial 
      in these patients.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Voicu, Sebastian
AU  - Voicu S
AD  - Service de Reanimation Medicale et Toxicologique, Universite de Paris, APHP,
      Lariboisiere Hospital, 2 rue Ambroise Pare, 75475 Paris, France; INSERM UMRS -
      1144, Paris, France. Electronic address: sebastian.voicu@aphp.fr.
FAU - Bajoras, Vilhelmas
AU  - Bajoras V
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France; Clinic of Cardiac and Vascular Diseases,
      Institute of Clinical Medicine of the Faculty of Medicine, Vilnius University,
      Vilnius, Lithuania; Center of Cardiology and Angiology, Vilnius University
      Hospital Santaros Klinikos, Vilnius, Lithuania.
FAU - Gall, Emmanuel
AU  - Gall E
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France.
FAU - Deye, Nicolas
AU  - Deye N
AD  - Service de Reanimation Medicale et Toxicologique, Universite de Paris, APHP,
      Lariboisiere Hospital, 2 rue Ambroise Pare, 75475 Paris, France; INSERM U942,
      Paris, France.
FAU - Malissin, Isabelle
AU  - Malissin I
AD  - Service de Reanimation Medicale et Toxicologique, Universite de Paris, APHP,
      Lariboisiere Hospital, 2 rue Ambroise Pare, 75475 Paris, France; INSERM UMRS -
      1144, Paris, France.
FAU - Dillinger, Jean-Guillaume
AU  - Dillinger JG
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France; INSERM U942, Paris, France.
FAU - Benajiba, Chakib
AU  - Benajiba C
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France.
FAU - Logeart, Damien
AU  - Logeart D
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France; INSERM U942, Paris, France.
FAU - Henry, Patrick
AU  - Henry P
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France; INSERM U942, Paris, France.
FAU - Megarbane, Bruno
AU  - Megarbane B
AD  - Service de Reanimation Medicale et Toxicologique, Universite de Paris, APHP,
      Lariboisiere Hospital, 2 rue Ambroise Pare, 75475 Paris, France; INSERM UMRS -
      1144, Paris, France.
FAU - Sideris, Georgios
AU  - Sideris G
AD  - Service de Cardiologie, Universite de Paris, APHP, Lariboisiere Hospital, 2 rue
      Ambroise Pare, 75475 Paris, France; INSERM U942, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - Ireland
TA  - Resuscitation
JT  - Resuscitation
JID - 0332173
SB  - IM
CIN - Resuscitation. 2020 Oct;155:239-241. PMID: 32827585
MH  - Adult
MH  - Arrhythmias, Cardiac
MH  - *Cardiopulmonary Resuscitation
MH  - Coronary Angiography
MH  - Humans
MH  - *Out-of-Hospital Cardiac Arrest/diagnostic imaging/therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *Acute coronary syndrome
OT  - *Coronary angiogram
OT  - *Non-shockable initial rhythm
OT  - *Out-of-hospital cardiac arrest
EDAT- 2020/07/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - S0300-9572(20)30258-6 [pii]
AID - 10.1016/j.resuscitation.2020.06.022 [doi]
PST - ppublish
SO  - Resuscitation. 2020 Oct;155:226-233. doi: 10.1016/j.resuscitation.2020.06.022.
      Epub 2020 Jul 3.


PMID- 32628722
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20200911
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 7
DP  - 2020
TI  - Risk of suicidal ideation, suicide attempts, and suicide deaths in persons with
      sleep apnea: Protocol for a systematic review and meta-analysis.
PG  - e0235379
LID - 10.1371/journal.pone.0235379 [doi]
AB  - AIM: To estimate the pooled prevalence and incidence of suicidal ideation,
      attempts, and deaths in people with sleep apnea. METHOD: We will identify
      epidemiological studies reporting the prevalence or incidence rate of suicide in 
      people with sleep apnea. We will search the following databases: PubMed
      (MEDLINE), Scopus, Cochrane Library, OVID (HEALTH STAR), OVID (MEDLINE) and Joana
      Briggs Institute EBF Database. No age, geographical location, study-design or
      language limits will be applied. This protocol was developed in accordance with
      the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols 
      (PRISMA-P) guidelines. Two reviewers (YY and YP) will independently screen
      citations, abstracts and will identify full-text articles for inclusion, extract 
      data, and appraise the quality and bias of included studies. Discrepancies will
      be resolved by consulting with a third researcher (MC). Study quality will be
      assessed by the Newcastle-Ottawa Scale. The primary outcomes will be the overall 
      prevalence or incidence of suicidal ideation, attempts and completion and the
      risk of suicide in people with sleep apnea. For pooling of the studies, we will
      use a random-effects model with a logit transformation. The DerSimonian and Laird
      (DL) random-effects method will be used to estimate the pooled inter-study
      variance. We will assess the between-study heterogeneity using I2 statistics, and
      Cochrane's Q statistic (significance level < 0.05). If the I2 is high (>75%), we 
      will perform subgroup meta-analyses and conduct a meta-regression analysis to
      explore sources of study heterogeneity using study level median age, study-level 
      proportions of race, gender, depression and quality scores. We will report effect
      estimates as suicide risk per 1000 individuals. Egger's test and funnel plots
      will be used to assess publication bias, and adjusted estimates using trim and
      fill methods will be reported if publication bias is suspected. ETHICS AND
      DISSEMINATION: No ethics clearance is required as no primary data will be
      collected. The results of this systematic review and meta-analysis will be
      presented at scientific conferences and published in a peer-review journal. The
      results may shed more light on the burden of suicide risk among individuals with 
      sleep apnea and may guide future population-specific interventions. TRIAL
      REGISTRATION: PROSPERO registration number: CRD42020165404.
FAU - Yang, Yanxu
AU  - Yang Y
AD  - Department of Public Health Sciences, Penn State Hershey College of Medicine and 
      Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States of
      America.
AD  - Department of Surgery, Penn State Hershey College of Medicine and Milton S.
      Hershey Medical Center, Hershey, Pennsylvania, United States of America.
FAU - Ssentongo, Anna E
AU  - Ssentongo AE
AD  - Department of Public Health Sciences, Penn State Hershey College of Medicine and 
      Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States of
      America.
AD  - Department of Surgery, Penn State Hershey College of Medicine and Milton S.
      Hershey Medical Center, Hershey, Pennsylvania, United States of America.
FAU - Pan, Yunqi
AU  - Pan Y
AD  - Department of Public Health Sciences, Penn State Hershey College of Medicine and 
      Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States of
      America.
FAU - Ciarletta, Matt
AU  - Ciarletta M
AD  - Penn State Hershey College of Medicine and Milton S. Hershey Medical Center,
      Hershey, Pennsylvania, United States of America.
FAU - Chinchilli, Vernon M
AU  - Chinchilli VM
AD  - Penn State Hershey College of Medicine and Milton S. Hershey Medical Center,
      Hershey, Pennsylvania, United States of America.
FAU - Ssentongo, Paddy
AU  - Ssentongo P
AUID- ORCID: 0000-0003-1565-5731
AD  - Penn State Hershey College of Medicine and Milton S. Hershey Medical Center,
      Hershey, Pennsylvania, United States of America.
AD  - Penn State Hershey College of Medicine and Milton S. Hershey Medical Center,
      Hershey, Pennsylvania, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Humans
MH  - Incidence
MH  - Meta-Analysis as Topic
MH  - Prevalence
MH  - Qualitative Research
MH  - *Research Design
MH  - Sleep Apnea Syndromes/*complications/psychology
MH  - *Suicidal Ideation
MH  - Suicide, Attempted/psychology/*statistics & numerical data
MH  - Suicide, Completed/*statistics & numerical data
MH  - Systematic Reviews as Topic
PMC - PMC7337338
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/07 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1371/journal.pone.0235379 [doi]
AID - PONE-D-20-04283 [pii]
PST - epublish
SO  - PLoS One. 2020 Jul 6;15(7):e0235379. doi: 10.1371/journal.pone.0235379.
      eCollection 2020.


PMID- 32628637
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20210213
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 48
IP  - 9
DP  - 2020 Nov 26
TI  - Prenatal screening diagnosis and management in the era of coronavirus: the
      Sardinian experience.
PG  - 943-949
LID - 10.1515/jpm-2020-0208 [doi]
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new coronavirus, 
      was first identified in December 2019 in Wuhan, China and spread rapidly,
      affecting many other countries. The disease is now referred to as coronavirus
      disease 2019 (COVID-19).The Italian government declared a state of emergency on
      31st January 2020 and on 11th March World Health Organization (WHO) officially
      declared the COVID-19 outbreak a global pandemic. Although the COVID-19 incidence
      remained considerably lower in Sardinia than in the North Italy regions, which
      were the most affected, the field of prenatal screening and diagnosis was
      modified because of the emerging pandemic. Data on COVID-19 during pregnancy are 
      so far limited. Since the beginning of the emergency, our Ob/Gyn Department at
      Microcitemico Hospital, Cagliari offered to pregnant patients all procedures
      considered essential by the Italian Ministry of Health. To evaluate the influence
      of the COVID-19 pandemic on the activities of our center, we compared the number 
      of procedures performed from 10th March to 18th May 2020 with those of 2019.
      Despite the continuous local birth rate decline, during the 10-week pandemic
      period, we registered a 20% increment of 1st trimester combined screening and a
      slight rise of the number of invasive prenatal procedures with a further increase
      in chorionic villi sampling compared to amniocentesis. Noninvasive prenatal
      testing remained unvariated. The request for multifetal pregnancy reduction as a 
      part of the growing tendency of voluntary termination of pregnancy in Sardinia
      increased. The COVID-19 pandemic provides many scientific opportunities for
      clinical research and study of psychological and ethical issues in pregnant
      women.
FAU - Monni, Giovanni
AU  - Monni G
AD  - Department of Obstetrics and Gynecology, Prenatal and Preimplantation Genetic
      Diagnosis, Fetal Therapy, Microcitemico Pediatric Hospital "Antonio Cao",
      Cagliari, Sardinia, Italy.
FAU - Corda, Valentina
AU  - Corda V
AD  - Department of Obstetrics and Gynecology, Prenatal and Preimplantation Genetic
      Diagnosis, Fetal Therapy, Microcitemico Pediatric Hospital "Antonio Cao",
      Cagliari, Sardinia, Italy.
FAU - Iuculano, Ambra
AU  - Iuculano A
AD  - Department of Obstetrics and Gynecology, Prenatal and Preimplantation Genetic
      Diagnosis, Fetal Therapy, Microcitemico Pediatric Hospital "Antonio Cao",
      Cagliari, Sardinia, Italy.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
SB  - IM
MH  - Abortion, Induced/statistics & numerical data
MH  - Amniocentesis/statistics & numerical data
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Chorionic Villi Sampling
MH  - Coronavirus Infections/complications/*diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - Italy/epidemiology
MH  - Male
MH  - Pandemics/*statistics & numerical data
MH  - Pneumonia, Viral/complications/*diagnosis/epidemiology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*diagnosis/prevention & control/*virology
MH  - Pregnancy Reduction, Multifetal/statistics & numerical data
MH  - Pregnancy Trimester, First
MH  - Prenatal Diagnosis/methods/*statistics & numerical data
MH  - SARS-CoV-2
MH  - Ultrasonography, Prenatal/statistics & numerical data
OTO - NOTNLM
OT  - chorionic villous sampling
OT  - coronavirus disease 2019 (COVID-19)
OT  - fetal cell-free DNA
OT  - non-invasive prenatal screening
OT  - nuchal translucency
OT  - prenatal screening diagnosis
OT  - quantitative reverse transcription polymerase chain reaction
OT  - severe acute respiratory syndrome coronavirus 2
EDAT- 2020/07/07 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - 10.1515/jpm-2020-0208 [doi]
AID - jpm-2020-0208 [pii]
PST - ppublish
SO  - J Perinat Med. 2020 Nov 26;48(9):943-949. doi: 10.1515/jpm-2020-0208.


PMID- 32628636
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 48
IP  - 7
DP  - 2020 Sep 25
TI  - Violence against trainees: urgent ethical challenges for medical educators and
      academic leaders in perinatal medicine.
PG  - 728-732
LID - 10.1515/jpm-2020-0123 [doi]
LID - /j/jpme.2020.48.issue-7/jpm-2020-0123/jpm-2020-0123.xml [pii]
AB  - Objectives Violence against medical trainees confronts medical educators and
      academic leaders in perinatal medicine with urgent ethical challenges. Despite
      their evident importance, these ethical challenges have not received sufficient
      attention. The purpose of this paper is to provide an ethical framework to
      respond to these ethical challenges. Methods We used an existing critical
      appraisal tool to conduct a scholarly review, to identify publications on the
      ethical challenges of violence against trainees. We conducted web searches to
      identify reports of violence against trainees in Mexico. Drawing on professional 
      ethics in perinatal medicine, we describe an ethical framework that is unique in 
      the literature on violence against trainees in its appeal to the professional
      virtue of self-sacrifice and its justified limits. Results Our search identified 
      no previous publications that address the ethical challenges of violence against 
      trainees. We identified reports of violence and their limitations. The ethical
      framework is based on the professional virtue of self-sacrifice in professional
      ethics in perinatal medicine. This virtue creates the ethical obligation of
      trainees to accept reasonable risks of life and health but not unreasonable
      risks. Society has the ethical obligation to protect trainees from these
      unreasonable risks. Medical educators should protect personal safety. Academic
      leaders should develop and implement policies to provide such protection.
      Institutions of government should provide effective law enforcement and fair
      trials of those accused of violence against trainees. International societies
      should promulgate ethics statements that can be applied to violence against
      trainees. By protecting trainees, medical educators and academic leaders in
      perinatology will also protect pregnant, fetal, and neonatal patients.
      Conclusions This paper is the first to provide an ethical framework, based on the
      professional virtue of self-sacrifice and its justified limits, to guide medical 
      educators and academic leaders in perinatal medicine who confront ethical
      challenges of violence against their trainees.
FAU - Ayala-Yanez, Rodrigo
AU  - Ayala-Yanez R
AUID- ORCID: https://orcid.org/0000-0003-2548-3208
AD  - Department of Obstetrics and Gynecology, ABC Medical Center, Mexico City, Mexico.
FAU - Ruiz-Lopez, Regina
AU  - Ruiz-Lopez R
AD  - Department of Obstetrics and Gynecology, ABC Medical Center, Mexico City, Mexico.
FAU - McCullough, Laurence B
AU  - McCullough LB
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
FAU - Chervenak, Frank A
AU  - Chervenak FA
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
SB  - IM
MH  - *Education, Medical/ethics/methods/organization & administration
MH  - Ethics, Medical
MH  - Faculty, Medical/ethics/standards
MH  - Humans
MH  - Mexico
MH  - *Perinatology/education/ethics
MH  - Risk Management/*organization & administration
MH  - Social Environment
MH  - Students, Medical/*psychology
MH  - Teaching/organization & administration/standards
MH  - *Violence/ethics/prevention & control/psychology
OTO - NOTNLM
OT  - academic leader
OT  - ethical challenge
OT  - framework
OT  - medical educator
OT  - trainee
OT  - violence
EDAT- 2020/07/07 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/03/21 00:00 [received]
PHST- 2020/05/24 00:00 [accepted]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - 10.1515/jpm-2020-0123 [doi]
AID - /j/jpme.ahead-of-print/jpm-2020-0123/jpm-2020-0123.xml [pii]
PST - ppublish
SO  - J Perinat Med. 2020 Sep 25;48(7):728-732. doi: 10.1515/jpm-2020-0123.


PMID- 32628406
OWN - NLM
STAT- MEDLINE
DCOM- 20200708
LR  - 20210125
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Aug
TI  - The anesthesiologist and global climate change: an ethical obligation to act.
PG  - 577-583
LID - 10.1097/ACO.0000000000000887 [doi]
AB  - PURPOSE OF REVIEW: Pollution and global warming/climate change contribute to
      one-quarter of all deaths worldwide. Global healthcare as a whole is the world's 
      fifth largest emitter of greenhouse gases, and anesthetic gases, intravenous
      agents and supplies contribute significantly to the overall problem. It is the
      ethical obligation of all anesthesiologists to minimize the harmful impact of
      anesthesia practice on environmental sustainability. RECENT FINDINGS: Focused
      programs encouraging judicious selection of the use of anesthetic gas agents has 
      been shown to reduce CO2 equivalent emissions by 64%, with significant cost
      savings. Good gas flow management reduces nonscavenged anesthetic gas
      significantly, and has been shown to decrease the consumption of volatile
      anesthetic agent by about one-fifth. New devices may allow for recapture,
      reclamation and recycling of waste anesthetic gases. For propofol, a
      nonbiodegradable, environmentally toxic agent, simply changing the size of vials 
      on formulary has been shown to reduce wasted agent by 90%. SUMMARY: The 5 R's of 
      waste minimization in the operating room (OR) (Reduce, Reuse, Recycle, Rethink
      and Research) have proven benefit in reducing the environmental impact of the
      practice of anesthesiology, as well as in reducing costs.
FAU - Van Norman, Gail A
AU  - Van Norman GA
AD  - Department of Anesthesiology and Pain Medicine, Bioethics, University of
      Washington, Seattle, Washington.
FAU - Jackson, Stephen
AU  - Jackson S
AD  - Department of Anesthesiology, Good Samaritan Hospital, San Jose, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
RN  - 0 (Anesthetics, Inhalation)
SB  - IM
MH  - Air Pollution/prevention & control
MH  - Anesthesiologists/*ethics
MH  - Anesthesiology/*ethics
MH  - Anesthetics, Inhalation/administration & dosage/*adverse effects
MH  - *Climate Change
MH  - Greenhouse Effect
MH  - Humans
MH  - Operating Rooms
EDAT- 2020/07/07 06:00
MHDA- 2020/07/09 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
AID - 10.1097/ACO.0000000000000887 [doi]
AID - 00001503-202008000-00018 [pii]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2020 Aug;33(4):577-583. doi:
      10.1097/ACO.0000000000000887.


PMID- 32628396
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20210125
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Aug
TI  - Editorial: COVID-19 pandemic: urgent need for action in care homes and senior
      citizens' homes from a medical-ethics perspective.
PG  - 481-482
LID - 10.1097/ACO.0000000000000896 [doi]
FAU - Schone-Seifert, Bettina
AU  - Schone-Seifert B
AD  - Institute of Medical Ethics at the University of Munster.
FAU - Van Aken, Hugo K
AU  - Van Aken HK
AD  - Munster University Hospital, Munster, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
SB  - IM
MH  - Aged
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus
MH  - *Coronavirus Infections/epidemiology
MH  - Disease Outbreaks/*prevention & control
MH  - Germany
MH  - Health Services for the Aged/*ethics/organization & administration
MH  - *Homes for the Aged/ethics
MH  - Humans
MH  - *Nursing Homes/ethics
MH  - Pandemics/*prevention & control
MH  - *Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
PMC - PMC7363374
EDAT- 2020/07/07 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - 10.1097/ACO.0000000000000896 [doi]
AID - 00001503-202008000-00002 [pii]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2020 Aug;33(4):481-482. doi:
      10.1097/ACO.0000000000000896.


PMID- 32628222
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20201218
IS  - 1698-6997 (Electronic)
IS  - 1139-6121 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Jul 8
TI  - The Resurgence of Medical Ethics During the Coronavirus Disease (COVID)-19
      Outbreak.
PG  - 123-124
LID - 10.24875/AIDSRev.M20000034 [doi]
AB  - The unprecedented COVID-19 pandemic has risen a number of clinical situations
      where the principles of the medical act, the singularity of the patient-physician
      relationship and the need for revitalizing the medical vocation have all become
      at front line. Original articles, viewpoints, and perspectives addressing these
      aspects have appeared in major medical journals. Never before but perhaps with
      AIDS in the eighties, a disease awakened such feelings of commitment in medicine.
      Herein, we discuss some of these very sensitive issues for physicians that
      emerged during the past months of global COVID-19 crisis.
FAU - Del Rio, Rafael
AU  - Del Rio R
AD  - Neurophysiology and Sleep Disorders Unit, Vithas International Hospital, Madrid, 
      Spain.
FAU - de Ojeda, Joaquin
AU  - de Ojeda J
AD  - Department of Neurology, Infanta Sofia University Hospital, Madrid, Spain.
FAU - Soriano, Vicente
AU  - Soriano V
AD  - Department of Internal Medicine, UNIR Medical Center and Health Sciences School, 
      Madrid, Spain.
LA  - eng
PT  - News
DEP - 20200708
PL  - Spain
TA  - AIDS Rev
JT  - AIDS reviews
JID - 101134876
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/epidemiology
MH  - Ethics, Medical
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Intensive Care Units
MH  - Nursing Homes
MH  - Pandemics/*ethics
MH  - Physician's Role
MH  - Physician-Patient Relations
MH  - Physicians/ethics/psychology
MH  - Pneumonia, Viral/epidemiology
MH  - Respiration, Artificial
MH  - SARS-CoV-2
MH  - Social Identification
MH  - Stress, Psychological/psychology
MH  - Triage/ethics
EDAT- 2020/07/07 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.24875/AIDSRev.M20000034 [doi]
PST - epublish
SO  - AIDS Rev. 2020 Jul 8;22(2):123-124. doi: 10.24875/AIDSRev.M20000034.


PMID- 32628127
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Jul
TI  - The I in COVID: The importance of community and patient involvement in COVID-19
      research.
PG  - e120-e122
LID - 10.7861/clinmed.2020-0173 [doi]
AB  - The call for community and patient involvement in the COVID-19 response is yet to
      be heard and answered. There are practical and ethical reasons for researchers
      not to neglect patient and public involvement (PPI), which has become an
      important cornerstone of UK-based clinical research. There has been a commendable
      effort towards driving evidence-based research, particularly through clinical
      trials in the UK. This article presents a brief background to PPI and points for 
      consideration for clinical researchers currently active in or planning COVID-19
      research.
CI  - (c) Royal College of Physicians 2020. All rights reserved.
FAU - Ratneswaren, Anenta
AU  - Ratneswaren A
AD  - Imperial College London, London, UK anenta.ratneswaren@imperial.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
MH  - Biomedical Research/*standards
MH  - COVID-19
MH  - *Citizen Science
MH  - Clinical Trials as Topic
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Minority Groups
MH  - *Pandemics
MH  - *Patient Participation
MH  - Patient Selection
MH  - *Pneumonia, Viral
MH  - Socioeconomic Factors
PMC - PMC7385787
OTO - NOTNLM
OT  - *COVID-19
OT  - *Patient and public involvement
OT  - *clinical trials
OT  - *community
OT  - *engagement
EDAT- 2020/07/07 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - clinmed.2020-0173 [pii]
AID - 10.7861/clinmed.2020-0173 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2020 Jul;20(4):e120-e122. doi: 10.7861/clinmed.2020-0173. Epub
      2020 May 22.


PMID- 32627669
OWN - NLM
STAT- Publisher
LR  - 20220416
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 6
TI  - The use of therapeutic untruths by learning disability nursing students.
PG  - 969733020928130
LID - 10.1177/0969733020928130 [doi]
AB  - BACKGROUND: The use of therapeutic untruths raises a number of ethical issues,
      which have begun to be explored to some extent, particularly in dementia care
      services, where their use has been found to be high. Little is known, however,
      about their use by health professionals working in learning disability services. 
      RESEARCH QUESTION: The study aimed to explore the frequency of use of therapeutic
      untruths by student learning disability nurses, and by their colleagues; how
      effective the students perceived them to be as a means of responding to
      behaviours that challenge; and their level of comfort with using them. RESEARCH
      DESIGN: A correlational design was used to gather data from an online version of 
      the Best Interest Scale, adapted for a learning disability context. Participants 
      were 30 learning disability student nurses (female = 28, ages 18-48 years, M =
      26.8, standard deviation = 7.3) studying at a university in the North-East of
      England. ETHICAL CONSIDERATIONS: The study was reviewed and received ethical
      approval from the first author's university ethics committee. FINDINGS: Overall, 
      96% of participants reported using therapeutic untruths. 'Omission' was the most 
      frequently used type of therapeutic untruths, the most effective and the type
      that the students felt most comfortable using. Frequency of use of therapeutic
      untruths correlated significantly and positively with perceived effectiveness and
      the level of comfort that the students felt when using them, for all types of
      therapeutic untruths. CONCLUSION: The use of therapeutic untruths by the student 
      nurses was consistent with that found in research in dementia care services in
      the United Kingdom and abroad. Further research to explore the generalisability
      of the results to the wider context of learning disability services is needed.
      The study highlights that there may be a need for more formal guidance and
      educational input to student nurses in the use of therapeutic untruths with
      people with a learning disability.
FAU - McKenzie, Karen
AU  - McKenzie K
AUID- ORCID: https://orcid.org/0000-0002-0400-416X
FAU - Taylor, Suzanne
AU  - Taylor S
AD  - Northumbria University, UK.
FAU - Murray, George
AU  - Murray G
AD  - NHS Lothian, UK.
FAU - James, Ian
AU  - James I
AD  - Cumbria, Northumberland, Tyne and Wear (CNTW) NHS Foundation Trust, UK.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
PMC - PMC7564291
OTO - NOTNLM
OT  - Ethics
OT  - learning disability
OT  - student nurses
OT  - therapeutic untruths
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - 10.1177/0969733020928130 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 6:969733020928130. doi: 10.1177/0969733020928130.


PMID- 32627664
OWN - NLM
STAT- Publisher
LR  - 20201031
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 6
TI  - Conscience and conscientious objection: The midwife's role in abortion services.
PG  - 969733020928416
LID - 10.1177/0969733020928416 [doi]
AB  - Traditionally, the role of midwives has been to be with women throughout the
      pregnancy continuum, from conception until the end of the postnatal period.
      Midwives, however, have been named as key providers of abortion services. While
      freedom of conscience is legally protected within Europe, discrepancies exist
      between midwifery and conscientious objection to abortion-related services.
      Midwives are largely ignored within the academic discussion despite the care and 
      support they give to women undergoing abortions. Those discrepancies led to the
      aim of this article to address this issue by discussing some of the key ethical
      and legal concepts that are relevant to midwives' role in the provision of
      abortion services.This article shows that the decision to provide or object to
      abortion services remains ethically very complex because arguments exist both for
      and against its provision. Being with women can be interpreted differently and
      individual situations of care are multifaceted. Conscientious objection to
      abortion services is a highly contentious issue that has an overall importance to
      midwives. Noting that decisions are individual, may change or may be
      situationally dependant; a definitive position of midwives for or against
      conscientious objection cannot be assumed.Respecting conscience and acknowledging
      that there are various arguments for and against conscientious objection promotes
      widespread understanding. It accommodates both the opportunity for midwives to
      object on conscience grounds to the provision of abortion services and respect
      women's autonomy so that mutual agreement may be reached on issues that may have 
      far reaching consequences.
FAU - Ramsayer, Beate
AU  - Ramsayer B
AUID- ORCID: https://orcid.org/0000-0002-1470-4434
AD  - Liverpool John Moores University, UK.
FAU - Fleming, Valerie
AU  - Fleming V
AD  - Liverpool John Moores University, UK.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
PMC - PMC7575296
OTO - NOTNLM
OT  - Abortion
OT  - conscience
OT  - conscientious objection
OT  - midwifery
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - 10.1177/0969733020928416 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 6:969733020928416. doi: 10.1177/0969733020928416.


PMID- 32627661
OWN - NLM
STAT- Publisher
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
DP  - 2020 Jul 6
TI  - Nurses' refusals of patient involvement in their own palliative care.
PG  - 969733020929062
LID - 10.1177/0969733020929062 [doi]
AB  - BACKGROUND: Ideas of patient involvement are related to notions of
      self-determination and autonomy, which are not always in alignment with complex
      interactions and communication in clinical practice. AIM: To illuminate and
      discuss patient involvement in routine clinical care situations in nursing
      practice from an ethical perspective. METHOD: A case study based on an
      anthropological field study among patients with advanced cancer in Denmark.
      ETHICAL CONSIDERATIONS: Followed the principles of the Helsinki Declaration.
      FINDINGS: Two cases illustrated situations where nurses refused patient
      involvement in their own case. DISCUSSION: Focus on two ethical issues, namely
      'including patients' experiences in palliative nursing care' and 'relational
      distribution of power and knowledge', inspired primarily by Hannah Arendt's
      concept of thoughtlessness and a Foucauldian perspective on the medical clinic
      and power. The article discusses how patients' palliative care needs and
      preferences, knowledge and statements become part of the less significant
      background of nursing practice, when nurses have a predefined agenda for acting
      with and involvement of patients. Both structurally conditioned 'thoughtlessness'
      of the nurses and distribution of power and knowledge between patients and nurses
      condition nurses to set the agenda and assess when and at what level it is
      relevant to take up patients' invitations to involve them in their own case.
      CONCLUSION: The medical and institutional logic of the healthcare service sets
      the framework for the exchange between professional and patient, which has an
      embedded risk that 'thoughtlessness' appears among nurses. The consequences of
      neglecting the spontaneous nature of human action and refusing the invitations of
      the patients to be involved in their life situation call for ethical and
      practical reflection among nurses. The conditions for interaction with humans as 
      unpredictable and variable challenge nurses' ways of being ethically attentive to
      ensure that patients receive good palliative care, despite the structurally
      conditioned logic of healthcare.
FAU - Glasdam, Stinne
AU  - Glasdam S
AUID- ORCID: https://orcid.org/0000-0002-0893-3054
AD  - Lund University, Sweden.
FAU - Jacobsen, Charlotte Bredahl
AU  - Jacobsen CB
AD  - University College Copenhagen, Denmark.
FAU - Boelsbjerg, Hanne Bess
AU  - Boelsbjerg HB
AD  - Aarhus University, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
PMC - PMC7564292
OTO - NOTNLM
OT  - Patient involvement
OT  - nurse refusals
OT  - palliative care
OT  - power
OT  - thoughtlessness
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
AID - 10.1177/0969733020929062 [doi]
PST - aheadofprint
SO  - Nurs Ethics. 2020 Jul 6:969733020929062. doi: 10.1177/0969733020929062.


PMID- 32626827
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Efficacy of antiepileptic drugs in neonatal seizures: a systematic review
      protocol.
PG  - e000683
LID - 10.1136/bmjpo-2020-000683 [doi]
AB  - INTRODUCTION: Seizures are one of the most common neurological disorders of
      neonates, which is also an emergency in the neonatal intensive care unit. For
      neonates, the recommended first-line antiepileptic drugs (AEDs) include
      phenobarbitone, which may be effective in only 50% of seizures. Some new AEDs,
      such as levetiracetam, have been shown to be effective in adults and older
      children. However, their efficacy for neonatal seizures remains uncertain. The
      aim of this investigation is to conduct a systematic review to evaluate the
      efficacy of all AEDs in neonates. Additionally, the long-term outcomes following 
      neonatal seizures, in relation to the development of cerebral palsy and epilepsy,
      will be studied. METHOD: We will perform a systematic review including randomised
      controlled studies (RCTs), cohort studies, case-controlled studies and case
      series studies which evaluated the efficacy of AEDs and short-term and long-term 
      outcomes in neonatal seizures. PubMed, Embase, Web of Science, Cochrane Library
      and Clinical trial.gov will be searched. There will be no language restriction.
      Risk bias in RCTs will be evaluated by the Cochrane risk-of-bias tool, while
      cohort and case-control studies will be evaluated by the Newcastle-Ottawa Scale. 
      A network meta-analysis will be performed by the Bayesian model using WinBUGS
      V.1.4.3 and R software if there is a high degree of homogeneity among studies.
      Otherwise, we will perform a narrative review without pooling. Subgroup analyses 
      will be performed in different AEDs and dosage groups. OUTCOME: The primary
      outcomes will be seizure cessation confirmed by electroencephalogram and
      long-term neurodevelopmental outcome. Secondary outcomes will be neonatal
      mortality during hospitalisation and suspected drug toxicity. ETHICS AND
      DISSEMINATION: Formal ethical approval is not required as no primary data are
      collected. This systematic review will be disseminated through a peer-reviewed
      publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, Yang
AU  - He Y
AUID- ORCID: 0000-0003-0952-2465
AD  - Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth
      Defects of the Ministry of Education, Sichuan University, Chengdu, China.
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
FAU - Tang, Jun
AU  - Tang J
AD  - Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth
      Defects of the Ministry of Education, Sichuan University, Chengdu, China.
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth
      Defects of the Ministry of Education, Sichuan University, Chengdu, China.
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
FAU - Xiong, Tao
AU  - Xiong T
AUID- ORCID: 0000-0002-0408-1288
AD  - Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth
      Defects of the Ministry of Education, Sichuan University, Chengdu, China.
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
FAU - Ojha, Shalini
AU  - Ojha S
AUID- ORCID: 0000-0001-5668-4227
AD  - Academic Child Health, University of Nottingham, Nottingham, UK.
FAU - Choonara, Imti
AU  - Choonara I
AUID- ORCID: 0000-0002-3069-6323
AD  - School of Medicine, University of Nottingham, Derby, UK.
FAU - Mu, Dezhi
AU  - Mu D
AD  - Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth
      Defects of the Ministry of Education, Sichuan University, Chengdu, China.
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, China.
LA  - eng
PT  - Systematic Review
DEP - 20200629
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7326240
OTO - NOTNLM
OT  - evidence based medicine
OT  - neonatology
OT  - neurology
COIS- Competing interests: None declared.
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.1136/bmjpo-2020-000683 [doi]
AID - bmjpo-2020-000683 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Jun 29;4(1):e000683. doi: 10.1136/bmjpo-2020-000683.
      eCollection 2020.


PMID- 32626714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210215
IS  - 2296-634X (Print)
IS  - 2296-634X (Linking)
VI  - 8
DP  - 2020
TI  - Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The
      X-Factor.
PG  - 499
LID - 10.3389/fcell.2020.00499 [doi]
AB  - X-linked adrenoleukodystrophy (ALD) is a devastating metabolic disorder affecting
      the adrenal glands, brain and spinal cord. Males with ALD are at high risk for
      developing adrenal insufficiency or progressive cerebral white matter lesions
      (cerebral ALD) at an early age. If untreated, cerebral ALD is often fatal. Women 
      with ALD are not at risk for adrenal insufficiency or cerebral ALD. Newborn
      screening for ALD in males enables prospective monitoring and timely therapeutic 
      intervention, thereby preventing irreparable damage and saving lives. The Dutch
      Ministry of Health adopted the advice of the Dutch Health Council to add a
      boys-only screen for ALD to the newborn screening panel. The recommendation made 
      by the Dutch Health Council to only screen boys, without gathering any
      unsolicited findings, posed a challenge. We were invited to set up a prospective 
      pilot study that became known as the SCAN study (SCreening for ALD in the
      Netherlands). The objectives of the SCAN study are: (1) designing a boys-only
      screening algorithm that identifies males with ALD and without unsolicited
      findings; (2) integrating this algorithm into the structure of the Dutch newborn 
      screening program without harming the current newborn screening; (3) assessing
      the practical and ethical implications of screening only boys for ALD; and (4)
      setting up a comprehensive follow-up that is both patient- and parent-friendly.
      We successfully developed and validated a screening algorithm that can be
      integrated into the Dutch newborn screening program. The core of this algorithm
      is the "X-counter." The X-counter determines the number of X chromosomes without 
      assessing the presence of a Y chromosome. The X-counter is integrated as second
      tier in our 4-tier screening algorithm. Furthermore, we ensured that our
      screening algorithm does not result in unsolicited findings. Finally, we
      developed a patient- and parent-friendly, multidisciplinary, centralized
      follow-up protocol. Our boys-only ALD screening algorithm offers a solution for
      countries that encounter similar ethical considerations, for ALD as well as for
      other X-linked diseases. For ALD, this alternative boys-only screening algorithm 
      may result in a more rapid inclusion of ALD in newborn screening programs
      worldwide.
CI  - Copyright (c) 2020 Barendsen, Dijkstra, Visser, Alders, Bliek, Boelen, Bouva, van
      der Crabben, Elsinghorst, van Gorp, Heijboer, Jansen, Jaspers, van Lenthe,
      Metgod, Mooij, van der Sluijs, van Trotsenburg, Verschoof-Puite, Vaz, Waterham,
      Wijburg, Engelen, Dekkers and Kemp.
FAU - Barendsen, Rinse W
AU  - Barendsen RW
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
AD  - Pediatric Metabolic Diseases, Amsterdam UMC, Emma Children's Hospital, University
      of Amsterdam, Amsterdam, Netherlands.
FAU - Dijkstra, Inge M E
AU  - Dijkstra IME
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - Visser, Wouter F
AU  - Visser WF
AD  - Centre for Health Protection, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, Netherlands.
FAU - Alders, Marielle
AU  - Alders M
AD  - Department of Clinical Genetics, Amsterdam UMC, Amsterdam Reproduction &
      Development, University of Amsterdam, Amsterdam, Netherlands.
FAU - Bliek, Jet
AU  - Bliek J
AD  - Department of Clinical Genetics, Amsterdam UMC, Amsterdam Reproduction &
      Development, University of Amsterdam, Amsterdam, Netherlands.
FAU - Boelen, Anita
AU  - Boelen A
AD  - Department of Clinical Chemistry, Neonatal Screening Laboratory, Endocrine
      Laboratory, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University 
      of Amsterdam, Amsterdam, Netherlands.
FAU - Bouva, Marelle J
AU  - Bouva MJ
AD  - Reference Laboratory for Neonatal Screening, Centre for Health Protection,
      National Institute for Public Health and the Environment (RIVM), Bilthoven,
      Netherlands.
FAU - van der Crabben, Saskia N
AU  - van der Crabben SN
AD  - Department of Clinical Genetics, Amsterdam UMC, Amsterdam Reproduction &
      Development, University of Amsterdam, Amsterdam, Netherlands.
FAU - Elsinghorst, Ellen
AU  - Elsinghorst E
AD  - Centre for Population Screening, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, Netherlands.
FAU - van Gorp, Ankie G M
AU  - van Gorp AGM
AD  - Centre for Population Screening, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, Netherlands.
FAU - Heijboer, Annemieke C
AU  - Heijboer AC
AD  - Department of Clinical Chemistry, Neonatal Screening Laboratory, Endocrine
      Laboratory, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University 
      of Amsterdam, Amsterdam, Netherlands.
AD  - Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC, Amsterdam 
      Gastroenterology and Metabolism, Vrije Universiteit Amsterdam, Amsterdam,
      Netherlands.
FAU - Jansen, Mandy
AU  - Jansen M
AD  - Department for Vaccine Supply and Prevention Programmes, National Institute for
      Public Health and the Environment (RIVM), Bilthoven, Netherlands.
FAU - Jaspers, Yorrick R J
AU  - Jaspers YRJ
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - van Lenthe, Henk
AU  - van Lenthe H
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - Metgod, Ingrid
AU  - Metgod I
AD  - Department of Clinical Chemistry, Neonatal Screening Laboratory, Endocrine
      Laboratory, Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University 
      of Amsterdam, Amsterdam, Netherlands.
AD  - Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam UMC, Amsterdam 
      Gastroenterology and Metabolism, Vrije Universiteit Amsterdam, Amsterdam,
      Netherlands.
FAU - Mooij, Christiaan F
AU  - Mooij CF
AD  - Department of Pediatric Endocrinology, Amsterdam UMC, Emma Children's Hospital,
      University of Amsterdam, Amsterdam, Netherlands.
FAU - van der Sluijs, Elise H C
AU  - van der Sluijs EHC
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - van Trotsenburg, A S Paul
AU  - van Trotsenburg ASP
AD  - Department of Pediatric Endocrinology, Amsterdam UMC, Emma Children's Hospital,
      University of Amsterdam, Amsterdam, Netherlands.
FAU - Verschoof-Puite, Rendelien K
AU  - Verschoof-Puite RK
AD  - Department for Vaccine Supply and Prevention Programmes, National Institute for
      Public Health and the Environment (RIVM), Bilthoven, Netherlands.
FAU - Vaz, Frederic M
AU  - Vaz FM
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - Waterham, Hans R
AU  - Waterham HR
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - Wijburg, Frits A
AU  - Wijburg FA
AD  - Pediatric Metabolic Diseases, Amsterdam UMC, Emma Children's Hospital, University
      of Amsterdam, Amsterdam, Netherlands.
FAU - Engelen, Marc
AU  - Engelen M
AD  - Department of Pediatric Neurology, Amsterdam UMC, Amsterdam Leukodystrophy
      Center, Emma Children's Hospital, Amsterdam Neuroscience, University of
      Amsterdam, Amsterdam, Netherlands.
FAU - Dekkers, Eugenie
AU  - Dekkers E
AD  - Centre for Population Screening, National Institute for Public Health and the
      Environment (RIVM), Bilthoven, Netherlands.
FAU - Kemp, Stephan
AU  - Kemp S
AD  - Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases,
      Amsterdam UMC, Amsterdam Gastroenterology and Metabolism, University of
      Amsterdam, Amsterdam, Netherlands.
AD  - Department of Pediatric Neurology, Amsterdam UMC, Amsterdam Leukodystrophy
      Center, Emma Children's Hospital, Amsterdam Neuroscience, University of
      Amsterdam, Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
EIN - Front Cell Dev Biol. 2021 Jan 28;9:631655. PMID: 33585488
PMC - PMC7311642
OTO - NOTNLM
OT  - X chromosome
OT  - adrenoleukodystrophy
OT  - dried bloodspots
OT  - gender
OT  - heel prick
OT  - neonatal
OT  - newborn screening
OT  - peroxisomes
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.3389/fcell.2020.00499 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2020 Jun 17;8:499. doi: 10.3389/fcell.2020.00499.
      eCollection 2020.


PMID- 32626672
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2251-9920 (Print)
IS  - 2251-9920 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Jun
TI  - The Relationship between Nurses' Moral Sensitivity and Patients' Satisfaction
      with the Care Received in the Medical Wards.
PG  - 98-103
LID - 10.34172/JCS.2020.015 [doi]
AB  - Introduction: The quality of care affects patients' satisfaction. To provide high
      quality care, nurses face ethical challenges in daily practice. Moral sensitivity
      is the first phase in moral implementation. This study aimed to determine the
      relationship between nurses' moral sensitivity and patients' satisfaction in
      medical wards. Methods: In descriptive correlational study 198 nurses and 198
      patients in 17 medical wards filled out the Moral Sensitivity Questionnaire (MSQ)
      and Patient Satisfaction with Nursing Care Quality Questionnaire (PSNCQQ),
      respectively. Nurses were sampled by the census method. For each nurse, a patient
      was selected randomly from the same ward. Data were analyzed using SPSS version
      13. Results: The highest scores were in the dimensions of "relational
      orientation" and "following the rules", and the lowest scores were in the
      dimensions of "autonomy" and "experiencing moral conflicts". The highest level of
      patients' satisfaction was with "nurses' professional performance" 3.98 (1.09),
      and the lowest level was with "nurses' routine work" 2.69 (1.22). There was no
      significant relationship between the mean of patient satisfaction and moral
      sensitivity of nurses. Conclusion: Considering that nurses had a higher score in 
      dimension of "following the rules" and a lower score in dimension of "autonomy", 
      it seems ethical performance in the real situation is not merely due to the
      nurses' moral sensitivity and it seems the complexity of the organization causes 
      nurses face difficulties in making decisions related to clinical practice;
      therefore, policy makers in the health system should be able to identify
      barriers.
CI  - (c) 2020 The Author(s).
FAU - Amiri, Elham
AU  - Amiri E
AUID- ORCID: https://orcid.org/0000-0002-2497-0322
AD  - Psychiatric Nursing, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Iran.
FAU - Ebrahimi, Hossein
AU  - Ebrahimi H
AUID- ORCID: https://orcid.org/0000-0003-4119-5601
AD  - Psychiatric Nursing, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Iran.
FAU - Namdar Areshtanab, Hossein
AU  - Namdar Areshtanab H
AUID- ORCID: https://orcid.org/0000-0003-1440-6653
AD  - Psychiatric Nursing, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Iran.
FAU - Vahidi, Maryam
AU  - Vahidi M
AUID- ORCID: https://orcid.org/0000-0002-1452-8215
AD  - Psychiatric Nursing, Faculty of Nursing and Midwifery, Tabriz University of
      Medical Sciences, Iran.
FAU - Asghari Jafarabadi, Mohamad
AU  - Asghari Jafarabadi M
AUID- ORCID: https://orcid.org/0000-0003-3284-9749
AD  - Department of Statistics and Epidemiology, Faculty of Health, Tabriz University
      of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - Iran
TA  - J Caring Sci
JT  - Journal of caring sciences
JID - 101589637
PMC - PMC7322405
OTO - NOTNLM
OT  - Care
OT  - Moral sensitivity
OT  - Nurses
OT  - Patients
OT  - Personal satisfaction
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2019/03/16 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.34172/JCS.2020.015 [doi]
PST - epublish
SO  - J Caring Sci. 2020 Jun 1;9(2):98-103. doi: 10.34172/JCS.2020.015. eCollection
      2020 Jun.


PMID- 32626595
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2055-0294 (Print)
IS  - 2055-0294 (Linking)
VI  - 6
DP  - 2020
TI  - A sensitive method for analyzing fluconazole in extremely small volumes of
      neonatal serum.
PG  - 14
LID - 10.1186/s40780-020-00170-y [doi]
AB  - BACKGROUND: The need for a large volume of serum sample significantly reduces the
      feasibility of neonatal pharmacokinetic studies in daily practice, which must
      often rely on scavenged or opportunistic sampling. This problem is most apparent 
      in preterm newborns, where ethical and practical considerations prohibit the
      collection of large sample volumes. Most of the fluconazole analysis assays
      published thus far required a minimum serum sample of 50 to 100 muL for a single 
      assay. The purpose of the present study was to develop and validate a sensitive
      method requiring a smaller sample volume (10 muL) to satisfy clinically relevant 
      research requirements. METHODS: Following simple protein precipitation and
      centrifugation, the filtrated supernatant was injected into a liquid
      chromatography system and separated with a C18 reverse-phase column. Fluconazole 
      and the internal standard (IS, fluconazole-d4) were detected and quantified using
      tandem mass spectrometry. The method was validated with reference to the Food and
      Drug Administration's Guidance for Industry. Accuracy and precision were
      evaluated at six quality control concentration levels (ranging from 0.01 to 100
      mug/mL). RESULTS: Investigated calibration curves were linear in the 0.01-100
      mug/mL range. Intra- and inter-day accuracy (- 7.7 to 7.4%) and precision (0.3 to
      6.0%) were below 15%. The calculated limit of detection and the lower limit of
      quantification (LLOQ) was 0.0019 mug/mL and 0.0031 mug/mL, respectively.
      Fluconazole in the prepared samples was stable for at least 4 months at - 20
      degrees C and - 80 degrees C. This method was applied to analyze 234 serum
      samples from ten neonates who received fosfluconazole, a water-soluble phosphate 
      prodrug of fluconazole which converts to fluconazole in the body, as part of a
      pharmacokinetic study using daily scavenged laboratory samples. The median
      (range) concentration up to 72 h after fosfluconazole administration was 2.9
      (0.02 to 26.8 mug/mL) mug/mL, which was within the range of the calibration
      curve. CONCLUSION: Fluconazole was able to be detected in an extremely small
      volume (10 muL) of serum from neonates receiving fosfluconazole. The method
      presented here can be used to quantify fluconazole concentrations for
      pharmacokinetic studies of the neonatal population by using scavenged samples.
CI  - (c) The Author(s) 2020.
FAU - Saito, Jumpei
AU  - Saito J
AUID- ORCID: 0000-0003-4799-5562
AD  - Department of Pharmacy, National Center for Child Health and Development,
      157-8535, 2-10-1 Okura, Setagaya-ku, Tokyo, Japan.grid.63906.3a0000 0004 0377
      2305
FAU - Tanzawa, Ayano
AU  - Tanzawa A
AD  - Department of Pharmacy, National Center for Child Health and Development,
      157-8535, 2-10-1 Okura, Setagaya-ku, Tokyo, Japan.grid.63906.3a0000 0004 0377
      2305
FAU - Kojo, Yuka
AU  - Kojo Y
AD  - Department of Pharmacy, National Center for Child Health and Development,
      157-8535, 2-10-1 Okura, Setagaya-ku, Tokyo, Japan.grid.63906.3a0000 0004 0377
      2305
FAU - Maruyama, Hidehiko
AU  - Maruyama H
AD  - Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive
      Medicine, National Center for Child Health and Development, Tokyo,
      Japan.grid.63906.3a0000 0004 0377 2305
FAU - Isayama, Tetsuya
AU  - Isayama T
AD  - Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive
      Medicine, National Center for Child Health and Development, Tokyo,
      Japan.grid.63906.3a0000 0004 0377 2305
FAU - Shoji, Kensuke
AU  - Shoji K
AD  - Division of Infectious Diseases, Department of Medical Subspecialties, National
      Center for Child Health and Development, Tokyo, Japan.grid.63906.3a0000 0004 0377
      2305
FAU - Ito, Yushi
AU  - Ito Y
AD  - Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive
      Medicine, National Center for Child Health and Development, Tokyo,
      Japan.grid.63906.3a0000 0004 0377 2305
FAU - Yamatani, Akimasa
AU  - Yamatani A
AD  - Department of Pharmacy, National Center for Child Health and Development,
      157-8535, 2-10-1 Okura, Setagaya-ku, Tokyo, Japan.grid.63906.3a0000 0004 0377
      2305
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - J Pharm Health Care Sci
JT  - Journal of pharmaceutical health care and sciences
JID - 101672177
PMC - PMC7329421
OTO - NOTNLM
OT  - Fluconazole
OT  - Fosfluconazole
OT  - Liquid chromatography-tandem mass spectrometry
OT  - Neonate
OT  - Serum sample volume
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.1186/s40780-020-00170-y [doi]
AID - 170 [pii]
PST - epublish
SO  - J Pharm Health Care Sci. 2020 Jul 1;6:14. doi: 10.1186/s40780-020-00170-y.
      eCollection 2020.


PMID- 32625140
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Psychoanalytic Perspectives on the Psychological Effects of Stillbirth on
      Parents: A Protocol for Systematic Review and Qualitative Synthesis.
PG  - 1216
LID - 10.3389/fpsyg.2020.01216 [doi]
AB  - Introduction: Despite the fact that stillbirth has a broad economic impact on
      health systems and society and despite the fact that the importance of
      appropriate psychological and social support for parents has been highlighted,
      there is still a lack of research exploring the intrapsychic and interpersonal
      dynamics and issues triggered by the experience of stillbirth. Healthcare
      professionals attempting to provide effective psychological support to bereaved
      parents who have suffered perinatal loss continue to struggle to achieve better
      and deeper understanding of their psychological states and processes.
      Psychoanalysis could play a key role in improving this situation, but the studies
      available are confined to journals of psychoanalysis, and there is a lack of
      synthesis, leaving this knowledge beyond the reach of scientists from other
      theoretical approaches or disciplines. This protocol proposes the systematic
      review and qualitative synthesis of articles from journals of psychoanalysis on
      the psychological effects on parents of stillbirth. Methods and Analysis: This
      systematic review will follow, as far as possible, the Preferred Reporting Items 
      for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Psychoanalytic 
      Electronic Publishing Archive (1999-2019), the Single Case Archive (1999-2019),
      and PsycINFO (1999-2019) will be used to identify relevant articles. The review
      will include articles reporting clinical material and/or theoretical
      considerations concerning parent psychological states and processes triggered by 
      the experience of stillbirth, and a meta-synthesis will be performed. Ethics and 
      Dissemination: Formal ethical approval is not required for this study, as no
      primary data will be collected. The findings will be published in an
      international peer-reviewed journal.
CI  - Copyright (c) 2020 Cena and Stefana.
FAU - Cena, Loredana
AU  - Cena L
AD  - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,
      Italy.
FAU - Stefana, Alberto
AU  - Stefana A
AD  - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7315820
OTO - NOTNLM
OT  - clinical cases
OT  - parents
OT  - protocol for systematic review
OT  - psychoanalic therapy
OT  - psychoanalisis
OT  - stillbirth
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.3389/fpsyg.2020.01216 [doi]
PST - epublish
SO  - Front Psychol. 2020 Jun 19;11:1216. doi: 10.3389/fpsyg.2020.01216. eCollection
      2020.


PMID- 32625091
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Investigation of Invigorating Qi and Activating Blood Circulation Prescriptions
      in Treating Qi Deficiency and Blood Stasis Syndrome of Ischemic Stroke Patients: 
      Study Protocol for a Randomized Controlled Trial.
PG  - 892
LID - 10.3389/fphar.2020.00892 [doi]
AB  - Ischemic stroke (IS) is characterized by high morbidity and high mortality. The
      integration of Traditional Chinese medicine (TCM) and western medicine has shown 
      promising benefits in relieving symptoms, promoting neurological recovery, and
      improving the quality of life of patients with IS. In TCM, Qi-deficiency along
      with blood-stasis (QDBS) syndrome is one of the common types of IS that is
      treated by invigorating Qi and activating blood circulation. In TCM theory,
      improving the corresponding degree of prescription-syndrome correlation (PSC) is 
      helpful to improve clinical efficacy. In this study, we intend to use similar
      prescriptions that invigorate Qi and activate blood circulation: Buyang Huanwu
      granules (BHG), Naoxintong capsules (NXTC), and Yangyin Tongnao granules (YTG).
      The goal is to evaluate their level of PSC inpatients with IS with QDBS syndrome 
      and find relevant biomarkers to provide an objective basis for precise treatment 
      of TCM and improve the clinical therapeutic effects. A multicenter, randomized,
      double-blinded, and placebo-controlled intervention trial will be conducted in IS
      patients with QDBS syndrome, followed by an add-on of Chinese patent medicine. A 
      total of 160 subjects will be randomly assigned to the BHG, NXTC, YTG, and
      placebo groups in a 1:2:1:1 allocation ratio. All subjects will undergo 28 days
      of treatment and then followed for another 180 days. The primary outcome is the
      changes in the National Institutes of Health Stroke Scale score after 28 days of 
      medication. The secondary outcomes include the modified Rankin scale score,
      activity of daily living scale score, and TCM symptom score. Data will be
      analyzed in accordance with a predefined statistical analysis plan. Ethical
      approval of this trial has been granted by the Research Ethics Committee of the
      First Affiliated Hospital of Zhejiang Chinese Medical University (ID:
      2017-Y-004-02). Written informed consent of patients will be required. This trial
      is registered in the Chinese Clinical Trial Registry (ChiCTR1800015189), and the 
      results will be disseminated to the public through peer-reviewed journals and
      academic conferences.
CI  - Copyright (c) 2020 Wang, Zhang, Pan, Fu, Huang, Xu, Dou, Hou, Li, Yu, Zhou, Yang 
      and Wan.
FAU - Wang, Yu
AU  - Wang Y
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Pan, Yuan-Jiang
AU  - Pan YJ
AD  - Department of Chemistry, Zhejiang University, Hangzhou, China.
FAU - Fu, Wei
AU  - Fu W
AD  - Department of Cardiac-Cerebral Diseases, Yinchuan Cardiac-Cerebral Treatment
      Internet Hospital, Yinchuan, China.
FAU - Huang, Shu-Wei
AU  - Huang SW
AD  - Department of Cardiovascular Diseases, The Second Affiliated Hospital of Zhejiang
      Chinese Medical University, Hangzhou, China.
FAU - Xu, Bin
AU  - Xu B
AD  - Department of Neurology, The Second Affiliated Hospital of Zhejiang Chinese
      Medical University, Hangzhou, China.
FAU - Dou, Li-Ping
AU  - Dou LP
AD  - Department of Cardiovascular Diseases, The Second Affiliated Hospital of Zhejiang
      Chinese Medical University, Hangzhou, China.
FAU - Hou, Qun
AU  - Hou Q
AD  - Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese
      Medical University, Hangzhou, China.
FAU - Li, Chang
AU  - Li C
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Yu, Li
AU  - Yu L
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Zhou, Hui-Fen
AU  - Zhou HF
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Yang, Jie-Hong
AU  - Yang JH
AD  - Basic Medical and Public Health College, Zhejiang Chinese Medical University,
      Hangzhou, China.
FAU - Wan, Hai-Tong
AU  - Wan HT
AD  - Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University,
      Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7311665
OTO - NOTNLM
OT  - Qi deficiency and blood stasis syndrome
OT  - ischemic stroke
OT  - prescription-syndrome correlation
OT  - study protocol
OT  - traditional Chinese medicine
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.3389/fphar.2020.00892 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jun 17;11:892. doi: 10.3389/fphar.2020.00892. eCollection
      2020.


PMID- 32625048
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - A Deep Learning-Based Model for Classification of Different Subtypes of
      Subcortical Vascular Cognitive Impairment With FLAIR.
PG  - 557
LID - 10.3389/fnins.2020.00557 [doi]
AB  - Deep learning methods have shown their great capability of extracting high-level 
      features from image and have been used for effective medical imaging
      classification recently. However, training samples of medical images are
      restricted by the amount of patients as well as medical ethics issues, making it 
      hard to train the neural networks. In this paper, we propose a novel end-to-end
      three-dimensional (3D) attention-based residual neural network (ResNet)
      architecture to classify different subtypes of subcortical vascular cognitive
      impairment (SVCI) with single-shot T2-weighted fluid-attenuated inversion
      recovery (FLAIR) sequence. Our aim is to develop a convolutional neural network
      to provide a convenient and effective way to assist doctors in the diagnosis and 
      early treatment of the different subtypes of SVCI. The experiment data in this
      paper are collected from 242 patients from the Neurology Department of Renji
      Hospital, including 78 amnestic mild cognitive impairment (a-MCI), 70 nonamnestic
      MCI (na-MCI), and 94 no cognitive impairment (NCI). The accuracy of our proposed 
      model has reached 98.6% on a training set and 97.3% on a validation set. The test
      accuracy on an untrained testing set reaches 93.8% with robustness. Our proposed 
      method can provide a convenient and effective way to assist doctors in the
      diagnosis and early treatment.
CI  - Copyright (c) 2020 Chen, Wang, Qiu, Wu, Zhou and Zhai.
FAU - Chen, Qi
AU  - Chen Q
AD  - Institute of Image Communication and Network Engineering, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Wang, Yao
AU  - Wang Y
AD  - Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Qiu, Yage
AU  - Qiu Y
AD  - Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Wu, Xiaowei
AU  - Wu X
AD  - Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Zhou, Yan
AU  - Zhou Y
AD  - Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong
      University, Shanghai, China.
FAU - Zhai, Guangtao
AU  - Zhai G
AD  - Institute of Image Communication and Network Engineering, Shanghai Jiao Tong
      University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7315844
OTO - NOTNLM
OT  - cognitive impairment
OT  - convolutional neural network
OT  - deep learning
OT  - magnetic resonance imaging
OT  - subcortical ischemic vascular disease
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.3389/fnins.2020.00557 [doi]
PST - epublish
SO  - Front Neurosci. 2020 Jun 18;14:557. doi: 10.3389/fnins.2020.00557. eCollection
      2020.


PMID- 32624717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211130
IS  - 1531-0043 (Print)
IS  - 1530-9681 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Jul
TI  - Leadership and Ethics: Virtue Ethics as a Model for Leadership Development.
PG  - 217-220
LID - 10.1055/s-0040-1709437 [doi]
AB  - Leaders are held to the highest of standards in both performance and ethics. The 
      same is true for leaders in medicine. Thus, medical leaders must give attention
      to ethical development as well as performance development. Virtue ethics provide 
      a way for the leader to develop ethically. Virtue ethics is the oldest form of
      ethics. Although other ethical approaches focus on external considerations,
      virtue ethics focuses on the inward development of character. Following the
      examples of virtuous people and developing habits of virtue are critical with
      this approach. The cardinal virtues of prudence, courage, temperance, and justice
      are considered the most important. Specific virtue lists have also been developed
      for medical practitioners. All of these virtues can contribute to the enhancement
      of leadership skills. The virtue approach is especially helpful for leaders
      because it motivates one to excel in whatever endeavor pursued, whether medicine,
      leadership, relationships, or life.
CI  - (c) Thieme Medical Publishers.
FAU - Gentry, Lonnie
AU  - Gentry L
AD  - Department of Surgery, Baylor University Medical Center, Roberts Hospital,
      Dallas, Texas.
FAU - Fleshman, James W
AU  - Fleshman JW
AD  - Department of Surgery, Baylor University Medical Center, Roberts Hospital,
      Dallas, Texas.
LA  - eng
GR  - R01 EB010037/EB/NIBIB NIH HHS/United States
GR  - R01 HL119248/HL/NHLBI NIH HHS/United States
GR  - R44 OD018334/OD/NIH HHS/United States
GR  - R21 EB003547/EB/NIBIB NIH HHS/United States
GR  - R56 EB026490/EB/NIBIB NIH HHS/United States
GR  - R01 EB014305/EB/NIBIB NIH HHS/United States
GR  - R01 EB009362/EB/NIBIB NIH HHS/United States
GR  - R01 CA197491/CA/NCI NIH HHS/United States
GR  - R01 EB025241/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200603
PL  - United States
TA  - Clin Colon Rectal Surg
JT  - Clinics in colon and rectal surgery
JID - 101084157
PMC - PMC7329376
OTO - NOTNLM
OT  - ethics
OT  - leadership
OT  - virtues
COIS- Conflict of Interest None declared.
EDAT- 2020/07/07 06:00
MHDA- 2020/07/07 06:01
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/07 06:01 [medline]
AID - 10.1055/s-0040-1709437 [doi]
AID - 01003 [pii]
PST - ppublish
SO  - Clin Colon Rectal Surg. 2020 Jul;33(4):217-220. doi: 10.1055/s-0040-1709437. Epub
      2020 Jun 3.


PMID- 32624543
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20200715
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 61
IP  - 6
DP  - 2020
TI  - [Challenges of screening germline predispositions in children].
PG  - 682-686
LID - 10.11406/rinketsu.61.682 [doi]
AB  - Genetic predisposition is a major cause of childhood cancer. Multiple
      cancer-predisposing syndromes have been identified, including Li-Fraumeni
      syndrome (LFS), neurofibromatosis type 1, APC-related adenomatous polyposis,
      Beckwith-Wiedemann syndrome, multiple endocrine neoplasia 1, ataxia
      telangiectasia, RUNX1 deficiency, Fanconi anemia, Bloom syndrome, and PTEN
      hamartoma tumor syndrome. LFS is a prototypical genetically predisposing
      condition. Accordingly, individualized therapy, surveillance, risk reduction, and
      family counseling are needed when a patient is diagnosed with LFS. More ethically
      important problems are encountered in a pediatric LFS patient, including the
      identification of patients requiring screening, the age at screening, the process
      of obtaining informed consent from children, and the responsibility of following 
      a pediatric patient with a genetic predisposition. Therefore, it is crucial to
      determine whether planned genetic testing has direct benefits for pediatric
      patients. In this context, TP53 testing may be justified in a pediatric cancer
      patient with suspected LFS, given the importance of decisions such as the use of 
      radiotherapy and the screening of family members as hematopoietic stem cell
      transplantation donors, the surveillance of subsequent cancers, and counseling
      for family members. In this review article, I have discussed these issues and
      indicated some consensus among various clinicians, including adult hematologists.
FAU - Manabe, Atsushi
AU  - Manabe A
AD  - Department of Pediatrics, Hokkaido University Graduate School of Medicine.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
SB  - IM
MH  - Child
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Genotype
MH  - *Germ Cells
MH  - Humans
MH  - Li-Fraumeni Syndrome
OTO - NOTNLM
OT  - Children
OT  - Familial tumor syndrome
OT  - Genetic counseling
OT  - Germline predisposition
EDAT- 2020/07/07 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
AID - 10.11406/rinketsu.61.682 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2020;61(6):682-686. doi: 10.11406/rinketsu.61.682.


PMID- 32624521
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20210110
IS  - 1349-9092 (Electronic)
IS  - 0917-5040 (Linking)
VI  - 30
IP  - 9
DP  - 2020 Sep 5
TI  - Professional Commitment to Ethical Discussions Needed From Epidemiologists in the
      COVID-19 Pandemic.
PG  - 375-376
LID - 10.2188/jea.JE20200278 [doi]
FAU - Matsui, Kenji
AU  - Matsui K
AUID- ORCID: 0000-0001-9390-2959
AD  - Division of Bioethics and Healthcare Law, the National Cancer Center Japan.
FAU - Yamamoto, Keiichiro
AU  - Yamamoto K
AD  - Department of Biomedical Ethics, University of Tokyo Graduate School of Medicine.
AD  - Clinical Research Center, the National Center for Global Health and Medicine.
FAU - Inoue, Yusuke
AU  - Inoue Y
AD  - Department of Public Policy, University of Tokyo Institute of Medical Science.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200704
PL  - Japan
TA  - J Epidemiol
JT  - Journal of epidemiology
JID - 9607688
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Epidemiologists/*psychology
MH  - *Ethics
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
PMC - PMC7429145
OTO - NOTNLM
OT  - *COVID-19
OT  - *epidemiology
OT  - *ethics
OT  - *forum
OT  - *journals
EDAT- 2020/07/07 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - 10.2188/jea.JE20200278 [doi]
PST - ppublish
SO  - J Epidemiol. 2020 Sep 5;30(9):375-376. doi: 10.2188/jea.JE20200278. Epub 2020 Jul
      4.


PMID- 32624473
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 5
TI  - Safety and effectiveness of a Tai Chi-based cardiac rehabilitation programme for 
      chronic coronary syndrom patients: study protocol for a randomised controlled
      trial.
PG  - e036061
LID - 10.1136/bmjopen-2019-036061 [doi]
AB  - INTRODUCTION: Preliminary evidence from clinical observations suggests that Tai
      Chi exercise may offer potential benefits for patients with chronic coronary
      syndrom (CCS). However, the advantages for CCS patients to practice Tai Chi
      exercise as rehabilitation have not been rigorously tested and there is a lack of
      consensus on its benefits. This study aims to develop an innovative Tai Chi
      Cardiac Rehabilitation Program (TCCRP) for CCS patients and to assess the
      efficacy, safety and acceptability of the programme. METHODS AND ANALYSIS: We
      propose to conduct a multicentre randomised controlled clinical trial comprising 
      of 150 participants with CCS. The patients will be randomly assigned in a 1:1
      ratio into two groups. The intervention group will participate in a supervised
      TCCRP held three times a week for 3 months. The control group will receive
      supervised conventional exercise rehabilitation held three times a week for 3
      months. The primary and secondary outcomes will be assessed at baseline, 1 month,
      3 months after intervention and after an additional 3-month follow-up period.
      Primary outcome measures will include a score of 36-Item Short Form Survey and
      Chinese Perceived Stress Scale. The secondary outcome measures will include body 
      composition, cardiopulmonary exercise test, respiratory muscle function,
      locomotor skills, echocardiogram, New York Heart Association classification,
      heart rate recovery time and laboratory examination. Other measures also include 
      Seattle Angina Scale, Pittsburgh Sleep Quality Index, Patient Health
      Questionnaire-9, Generalized Anxiety Disorder-7 and Berg Balance Scale. All
      adverse events will be recorded and analysed. ETHICS AND DISSEMINATION: This
      study conforms to the principles of the Declaration of Helsinki and relevant
      ethical guidelines. Ethical approval has been obtained from the Ethics Committee 
      of Chinese People's Libration Army General Hospital (approval number:
      S2019-060-02). Findings from this study will be published and presented at
      conferences for widespread dissemination of the results. TRIAL REGISTRATION
      NUMBER: NCT03936504.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Cardiology, First Medical Center of Chinese People's Libration Army
      General Hospital, Beijing, China.
FAU - Zhang, Jian Wei
AU  - Zhang JW
AUID- ORCID: 0000-0002-8301-3047
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Li, Hua
AU  - Li H
AD  - Department of Cardiovascular Medicine, Anzhen Community Health Service Center,
      Chaoyang District, Beijing, China.
FAU - Zhao, Lian Shan
AU  - Zhao LS
AD  - Department of Cardiovascular Medicine, Beijing Shuili Hospital, Beijing, China.
FAU - Guo, Ai Ying
AU  - Guo AY
AD  - Department of Cardiovascular Medicine, Anzhen Community Health Service Center,
      Chaoyang District, Beijing, China.
FAU - Chen, Zai Hao
AU  - Chen ZH
AD  - College of Wushu, Beijing Sport University, Beijing, China.
FAU - Yuan, Wen
AU  - Yuan W
AD  - College of Wushu, Beijing Sport University, Beijing, China.
FAU - Gao, Tian Ming
AU  - Gao TM
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Li, Ya Meng
AU  - Li YM
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Li, Cui Han
AU  - Li CH
AD  - College of Wushu, Beijing Sport University, Beijing, China.
FAU - Wang, Hong Wei
AU  - Wang HW
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Song, Bo
AU  - Song B
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Lu, Yu Long
AU  - Lu YL
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Cui, Mei Ze
AU  - Cui MZ
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Wei, Qiu Yang
AU  - Wei QY
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China.
FAU - Lyu, Shao Jun
AU  - Lyu SJ
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China l13121860699@163.com shaojunl@hotmail.com yinhengchan@bnu.edu.cn.
FAU - Yin, Heng Chan
AU  - Yin HC
AD  - College of Physical Education and Sports, Beijing Normal University, Beijing,
      China l13121860699@163.com shaojunl@hotmail.com yinhengchan@bnu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03936504
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200705
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angina Pectoris/etiology
MH  - Anxiety/etiology
MH  - Cardiac Rehabilitation/*methods
MH  - Chronic Disease/psychology/rehabilitation
MH  - Coronary Disease/complications/physiopathology/psychology/*rehabilitation
MH  - Exercise Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Patient Acceptance of Health Care
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Stress, Psychological/etiology
MH  - *Tai Ji/adverse effects
MH  - Young Adult
PMC - PMC7337900
OTO - NOTNLM
OT  - *clinical trials
OT  - *complementary medicine
OT  - *coronary heart disease
OT  - *education & training (see medical education & training)
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/07 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036061 [pii]
AID - 10.1136/bmjopen-2019-036061 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 5;10(7):e036061. doi: 10.1136/bmjopen-2019-036061.


PMID- 32624471
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 5
TI  - Treatment strategies for asymptomatic carotid artery stenosis in the era of
      lipid-lowering drugs: protocol for a systematic review and network meta-analysis.
PG  - e035094
LID - 10.1136/bmjopen-2019-035094 [doi]
AB  - INTRODUCTION: Carotid endarterectomy (CEA), carotid artery stenting (CAS) and
      best medical therapy (BMT) are the major treatments used for significant
      asymptomatic carotid artery stenosis (ACAS, >/=50%). However, the widespread use 
      of lipid-lowering drugs in this century has improved BMT outcomes. This study
      aims to compare the treatment efficacy of current BMT, CEA+BMT and CAS+BMT in
      patients with significant ACAS. METHODS AND ANALYSIS: This protocol was designed 
      based on the guidelines of the Preferred Reporting Items for Systematic Review
      and Meta-Analysis Protocols. Publication time for studies will be set from 1
      January 2000 to 1 June 2020. We will search three databases: PubMed, EMBASE and
      The Cochrane Library. Suitable randomised controlled studies will be screened.
      The primary outcomes will include short-term and long-term mortality, stroke and 
      myocardial infarction. OR and HR for dichotomous data and time-to-event data with
      95% CIs will be calculated. Treatment effects among different therapies will be
      ranked according to the surface under the cumulative ranking curve and mean rank.
      A comprehensive evaluation of the risk of bias, heterogeneity and transitivity
      will be performed before data synthesis. Consistency and evidence quality will
      also be assessed. ETHICS AND DISSEMINATION: There will be no need for ethics
      approval as this systematic review is a summary and analysis of existing
      literature. Final results may be presented in international conferences or a
      peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42019138942.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bai, Xuesong
AU  - Bai X
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Feng, Yao
AU  - Feng Y
AUID- ORCID: 0000-0001-7923-8158
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Li, Long
AU  - Li L
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Yang, Kun
AU  - Yang K
AD  - Department of Evidence-based Medicine, Xuanwu Hospital, Beijing, China.
FAU - Wang, Tao
AU  - Wang T
AUID- ORCID: 0000-0003-1225-0173
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Luo, Jichang
AU  - Luo J
AUID- ORCID: 0000-0002-8341-0966
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Wang, Xue
AU  - Wang X
AD  - Medical Library, Xuanwu Hospital, Capital Medical University, Beijing, China.
FAU - Ling, Feng
AU  - Ling F
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Ma, Yan
AU  - Ma Y
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Jiao, Liqun
AU  - Jiao L
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China liqunjiao@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200705
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cardiovascular Agents)
SB  - IM
MH  - Asymptomatic Diseases/therapy
MH  - Cardiovascular Agents/*therapeutic use
MH  - Carotid Stenosis/complications/*drug therapy/mortality/*surgery
MH  - Endarterectomy, Carotid
MH  - Endovascular Procedures
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Stents
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7337893
OTO - NOTNLM
OT  - *neurosurgery
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/07 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-035094 [pii]
AID - 10.1136/bmjopen-2019-035094 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 5;10(7):e035094. doi: 10.1136/bmjopen-2019-035094.


PMID- 32624470
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 5
TI  - Nurses' decision-making about cancer patients' end-of-life skin care in Wales: an
      exploratory mixed-method vignette study protocol.
PG  - e034938
LID - 10.1136/bmjopen-2019-034938 [doi]
AB  - INTRODUCTION: Patients with cancer are at high risk of developing pressure ulcers
      at the end of life as a result of their underlying condition or cancer treatment.
      There are many guidelines which set out best practice with regard to end-of-life 
      skin care. However, the complexity of palliative cancer care often means that it 
      is challenging for nurses to make the appropriate person-centred decisions about 
      end-of-life skin care. This study seeks to explore the perceived importance that 
      nurses place on different factors in their end-of-life skin care for patients
      with cancer. The utility, face validity and content validity of a prototype
      decision-making tool for end-of-life skin care will also be evaluated. METHODS
      AND ANALYSIS: A mixed-method design will be used to gather data from primary and 
      secondary care nurses working in different hospitals and local authority areas
      across Wales. Clinical vignettes will be used to gather qualitative and
      quantitative data from nurses in individual interviews. Qualitative data will be 
      subject to thematic analysis and quantitative data will be subject to descriptive
      statistical analysis. Qualitative and quantitative data will then be synthesised,
      which will enhance the rigour of this study, and pertinently inform the further
      development of an end-of-life skin care decision-making tool for patients with
      cancer. ETHICS AND DISSEMINATION: Ethical approval to undertake the study has
      been granted by Cardiff University School of Healthcare Sciences Research
      Governance and Ethics Screening Committee. Informed consent will be obtained in
      writing from all the participants in this study. The results of this study will
      be disseminated through journal articles, as well as presentations at national
      and international conferences. We will also report our findings to patient and
      public involvement groups with an interest in improving cancer care, palliative
      care as well as skin care.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Samuriwo, Ray
AU  - Samuriwo R
AUID- ORCID: 0000-0001-5954-0501
AD  - School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, United Kingdom samuriwor@cardiff.ac.uk.
AD  - Wales Centre for Evidence Based Care, School of Healthcare Sciences, College of
      Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom.
FAU - Lovell-Smith, Candida
AU  - Lovell-Smith C
AD  - Patient and Public Involvement Representative, North Wales, UK.
FAU - Anstey, Sally
AU  - Anstey S
AD  - School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, United Kingdom.
FAU - Job, Claire
AU  - Job C
AD  - School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, United Kingdom.
FAU - Hopkinson, Jane
AU  - Hopkinson J
AD  - School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff
      University, Cardiff, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200705
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Decision Making
MH  - Decision Support Techniques
MH  - Hospice and Palliative Care Nursing/methods
MH  - Humans
MH  - Neoplasms/therapy
MH  - Nurses/*psychology
MH  - Pressure Ulcer/nursing/prevention & control
MH  - Skin Care/*nursing
MH  - *Terminal Care
MH  - Wales
PMC - PMC7337620
OTO - NOTNLM
OT  - *adult oncology
OT  - *adult palliative care
OT  - *wound management
COIS- Competing interests: None declared.
EDAT- 2020/07/07 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034938 [pii]
AID - 10.1136/bmjopen-2019-034938 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 5;10(7):e034938. doi: 10.1136/bmjopen-2019-034938.


PMID- 32624468
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 5
TI  - Breast cancer application protocol: a randomised controlled trial to evaluate a
      self-management app for breast cancer survivors.
PG  - e034655
LID - 10.1136/bmjopen-2019-034655 [doi]
AB  - INTRODUCTION: The eHealth technologies that are being designed for chronic
      disease constitute a global trend towards health assessment and self-management. 
      However, most of these approaches tend to focus on a single symptom or problem
      rather than on the multiple problems that are characteristic of many of these
      chronic illnesses. The aim of this study is to examine the effectiveness of and
      adherence to a self-management application (app) that identifies multiple problem
      areas related to surviving breast cancer as the targeted chronic illness. METHODS
      AND ANALYSIS: This is a randomised controlled study. Eligible participants will
      be allocated randomly into either an intervention group or a control group at a
      1:1 ratio. The intervention group will be assigned to the self-management app
      ('Be-with-You'), while the control group will use a general health app ('Sham'
      app). The primary outcomes will include the differences between the two groups in
      their health literacy, problem-solving skills and self-management skills. The
      secondary outcomes will include group differences in self-efficacy, readiness for
      change and health-related quality of life. All of these outcomes will be measured
      at baseline and at 4 weeks and 12 weeks after intervention. In addition,
      usability of these two mobile apps will be measured at 4 weeks and 12 weeks after
      intervention. The planned sample size is 476. ETHICS AND DISSEMINATION: The Human
      Subjects Ethics Sub-committee of The Hong Kong Polytechnic University approved
      the study (HSEARS20190922001, 24 September 2019). Dissemination of findings will 
      occur at the local, national and international levels. TRIAL REGISTRATION NUMBER:
      ChiCTR1900026244.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cheng, Andy S K
AU  - Cheng ASK
AUID- ORCID: 0000-0001-7503-5273
AD  - Department of Rehabilitation Sciences, The Hong Kong Polytechnic University,
      Kowloon, Hong Kong andy.cheng@polyu.edu.hk.
FAU - Liu, Xiangyu
AU  - Liu X
AD  - Department of Nursing, Hunan Cancer Hospital, Changsha, China.
FAU - Ng, Peter H F
AU  - Ng PHF
AD  - Department of Computing, The Hong Kong Polytechnic University, Kowloon, Hong
      Kong.
FAU - Kwok, Cindy T T
AU  - Kwok CTT
AD  - Department of Rehabilitation Sciences, The Hong Kong Polytechnic University,
      Kowloon, Hong Kong.
FAU - Zeng, Yingchun
AU  - Zeng Y
AUID- ORCID: 0000-0002-1525-6725
AD  - The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
FAU - Feuerstein, Michael
AU  - Feuerstein M
AD  - Consultant in Cancer Survivorship, Gaithersburg, Maryland, USA.
AD  - Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of
      Medicine, Central South University, Changsha, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200705
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Breast Neoplasms/therapy
MH  - *Cancer Survivors
MH  - Hong Kong
MH  - Humans
MH  - *Mobile Applications
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Management
PMC - PMC7337895
OTO - NOTNLM
OT  - *breast tumours
OT  - *information technology
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034655 [pii]
AID - 10.1136/bmjopen-2019-034655 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 5;10(7):e034655. doi: 10.1136/bmjopen-2019-034655.


PMID- 32624227
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201218
IS  - 1532-7361 (Electronic)
IS  - 0039-6060 (Linking)
VI  - 168
IP  - 3
DP  - 2020 Sep
TI  - Thoughts from a senior surgeon with an interest in ethics.
PG  - 397
LID - S0039-6060(20)30269-5 [pii]
LID - 10.1016/j.surg.2020.05.004 [doi]
LA  - eng
PT  - Editorial
PT  - Comment
DEP - 20200703
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
SB  - IM
CON - Surgery. 2020 Sep;168(3):388-391. PMID: 32616345
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Surgeons
EDAT- 2020/07/07 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - S0039-6060(20)30269-5 [pii]
AID - 10.1016/j.surg.2020.05.004 [doi]
PST - ppublish
SO  - Surgery. 2020 Sep;168(3):397. doi: 10.1016/j.surg.2020.05.004. Epub 2020 Jul 3.


PMID- 32624060
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1477-1128 (Electronic)
IS  - 1463-4236 (Linking)
VI  - 21
DP  - 2020 Jul 6
TI  - Development and validation of an instrument for measuring competencies on public 
      health informatics of primary health care worker (PHIC4PHC) in Indonesia.
PG  - e22
LID - 10.1017/S1463423620000018 [doi]
AB  - Because of the increasing adoption and use of technology in primary health care
      (PHC), public health informatics competencies (PHIC) are becoming essential for
      public health workers. Unfortunately, no studies have measured PHIC in
      resource-limited setting. This paper describes the process of developing and
      validating Public Health Informatics Competencies for Primary Health Care
      (PHIC4PHC), an instrument for measuring PHC workers' competencies in public
      health informatics. Method: This study developed a questionnaire that had three
      stages: the Delphi technique, a pretest, and field test. Eleven academicians from
      a university and 13 PHC workers joined 2 rounds of group discussion in the first 
      stage. The second stage comprised two pilot studies with 75 PHC workers in
      Semarang Municipality. The third stage involved validating the questionnaire with
      462 PHC workers in Kendal District. This study used Pearson's product-moment
      correlation for the validity check and Cronbach's alpha coefficient for
      determining the internal consistency. This study used the K-means algorithm for
      clustering the results of the PHIC4PHC questionnaire. Results and Conclusion:
      PHIC4PHC is the first comprehensive PHIC questionnaire administered in a
      resource-limited setting, consisting of 11 indicators and 42 measurement items
      concerning knowledge of health information systems, skills required for health
      data management, ethical aspects of data sharing and health information literacy.
      The final results of PHIC4PHC were clustered into three classes based on the
      K-means algorithm. Overall, 45.7% PHC workers achieved medium competency, whereas
      25.6% and 27.7% achieved low and high competency, respectively. Men had higher
      competency than women. The higher the worker's level of education, the higher the
      PHIC level; the longer the worker's work experience, the lower the PHIC score;
      and the greater the worker's age, the lower the PHIC score. Measuring and
      monitoring PHIC is vital to support successful health IT adoption in PHC.
FAU - Rachmani, Enny
AU  - Rachmani E
AUID- ORCID: 0000-0002-4582-288X
AD  - College of Medical Science and Technology, Graduate Institute of Biomedical
      Informatics, Taipei Medical University, Taipei City, Taiwan.
AD  - Department of Health Information Management, Faculty of Health Science,
      Universitas Dian Nuswantoro, Semarang, Jawa Tengah, Indonesia.
FAU - Hsu, Chien-Yeh
AU  - Hsu CY
AD  - Department of Information Management, National Taipei University of Nursing and
      Health Science, Taipei City, Taiwan.
AD  - Master Program in Global Health and Development, Taipei Medical University,
      Taipei City, Taiwan.
FAU - Chang, Peter WuShou
AU  - Chang PW
AD  - TUFTS University Medical School, Chung Shan Medical University, Taichung, Taiwan.
FAU - Fuad, Anis
AU  - Fuad A
AD  - College of Medical Science and Technology, Graduate Institute of Biomedical
      Informatics, Taipei Medical University, Taipei City, Taiwan.
AD  - Department of Biostatistics, Epidemiology and Population Health, Public Health,
      Faculty of Medicine, Gajah Mada University, Yogjakarta, Indonesia.
FAU - Nurjanah, Nurjanah
AU  - Nurjanah N
AD  - Department of Public Health, Faculty of Health Science, Universitas Dian
      Nuswantoro, Kota Semarang, Jawa Tengah, Indonesia.
FAU - Shidik, Guruh Fajar
AU  - Shidik GF
AD  - Department of Health Information Management, Faculty of Health Science,
      Universitas Dian Nuswantoro, Semarang, Jawa Tengah, Indonesia.
AD  - Department of Informatics, Faculty of Computer Science, Universitas Dian
      Nuswantoro, Semarang, Jawa Tengah, Indonesia.
FAU - Ningrum, Dina Nur Anggraini
AU  - Ningrum DNA
AD  - Department of Public Health, Semarang State University, Kota Semarang, Jawa
      Tengah, Indonesia.
FAU - Lin, Ming-Chin
AU  - Lin MC
AUID- ORCID: 0000-0001-9624-9705
AD  - College of Medical Science and Technology, Graduate Institute of Biomedical
      Informatics, Taipei Medical University, Taipei City, Taiwan.
AD  - Department of Surgery, Division of Neurosurgery, Taipei Medical University-Shuang
      Ho Hospital, New Taipei City, Taiwan.
AD  - International Center for Health Information Technology (ICHIT), Taipei Medical
      University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200706
PL  - England
TA  - Prim Health Care Res Dev
JT  - Primary health care research & development
JID - 100897390
SB  - IM
MH  - Adult
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Indonesia
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - *Primary Health Care
MH  - *Public Health Informatics
PMC - PMC7372181
OTO - NOTNLM
OT  - *computer literacy
OT  - *developing countries
OT  - *health information system
OT  - *primary health care
OT  - *public health informatics
EDAT- 2020/07/07 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [entrez]
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
AID - S1463423620000018 [pii]
AID - 10.1017/S1463423620000018 [doi]
PST - epublish
SO  - Prim Health Care Res Dev. 2020 Jul 6;21:e22. doi: 10.1017/S1463423620000018.


PMID- 32623956
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 2042-1818 (Electronic)
IS  - 0025-8024 (Linking)
VI  - 60
IP  - 4
DP  - 2020 Oct
TI  - The Islamic perspective on physician-assisted suicide and euthanasia.
PG  - 278-286
LID - 10.1177/0025802420934241 [doi]
AB  - Physician-assisted suicide (PAS) and euthanasia can be debated from ethical and
      legal perspectives, and there are a variety of views regarding their
      acceptability and usefulness. Religion is considered an important factor in
      determining attitudes towards such practices. This narrative review aims to
      provide an overview of the Islamic perspective on PAS and euthanasia and explore 
      the Islamic approach in addressing the related issues. The PubMed database was
      searched to retrieve relevant articles, then the references listed in the
      selected articles were checked for additional relevant publications.
      Additionally, religious books (Quran and hadith) and legal codes of selected
      countries were also consulted from appropriate websites. The Islamic code of law 
      discusses many issues regarding life and death, as it considers any act of taking
      one's life to be forbidden. Islam sanctifies life and depicts it as a gift from
      God (Allah). It consistently emphasises the importance of preserving life and
      well-being. Therefore Muslims, the followers of Islam, have no right to end their
      life. All Islamic doctrines consider PAS and euthanasia to be forbidden. However,
      if the patient has an imminently fatal illness, withholding or withdrawing a
      futile medical treatment is considered permissible. From a legal perspective,
      Islamic countries have not legalised PAS and euthanasia. Such practices are
      therefore considered suicides when patients consent to the procedure, and
      homicides when physicians execute the procedure.
FAU - Madadin, Mohammed
AU  - Madadin M
AUID- ORCID: https://orcid.org/0000-0002-8594-5868
AD  - Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal
      University, Dammam, Saudi Arabia.
FAU - Al Sahwan, Houria S
AU  - Al Sahwan HS
AD  - College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi
      Arabia.
FAU - Altarouti, Khadijah K
AU  - Altarouti KK
AD  - College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi
      Arabia.
FAU - Altarouti, Sarraa A
AU  - Altarouti SA
AD  - College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi
      Arabia.
FAU - Al Eswaikt, Zahra S
AU  - Al Eswaikt ZS
AD  - College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi
      Arabia.
FAU - Menezes, Ritesh G
AU  - Menezes RG
AUID- ORCID: https://orcid.org/0000-0002-2135-4161
AD  - Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal
      University, Dammam, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200705
PL  - England
TA  - Med Sci Law
JT  - Medicine, science, and the law
JID - 0400721
SB  - IM
MH  - *Attitude to Death
MH  - Euthanasia/*legislation & jurisprudence
MH  - Humans
MH  - *Islam
MH  - Suicide, Assisted/*legislation & jurisprudence
MH  - Withholding Treatment/*legislation & jurisprudence
OTO - NOTNLM
OT  - Islamic jurisprudence
OT  - Islamic perspective
OT  - Physician-assisted suicide
OT  - euthanasia
OT  - medical ethics
EDAT- 2020/07/07 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/07/07 06:00
PHST- 2020/07/07 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/07/07 06:00 [entrez]
AID - 10.1177/0025802420934241 [doi]
PST - ppublish
SO  - Med Sci Law. 2020 Oct;60(4):278-286. doi: 10.1177/0025802420934241. Epub 2020 Jul
      5.


PMID- 32623642
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210624
IS  - 1179-2035 (Electronic)
IS  - 0112-1642 (Linking)
VI  - 50
IP  - 10
DP  - 2020 Oct
TI  - Menthol as an Ergogenic Aid for the Tokyo 2021 Olympic Games: An Expert-Led
      Consensus Statement Using the Modified Delphi Method.
PG  - 1709-1727
LID - 10.1007/s40279-020-01313-9 [doi]
AB  - INTRODUCTION: Menthol topical application and mouth rinsing are ergogenic in hot 
      environments, improving performance and perception, with differing effects on
      body temperature regulation. Consequently, athletes and federations are beginning
      to explore the possible benefits to elite sport performance for the Tokyo 2021
      Olympics, which will take place in hot (~ 31 degrees C), humid (70% RH)
      conditions. There is no clear consensus on safe and effective menthol use for
      athletes, practitioners, or researchers. The present study addressed this
      shortfall by producing expert-led consensus recommendations. METHOD: Fourteen
      contributors were recruited following ethical approval. A three-step modified
      Delphi method was used for voting on 96 statements generated following literature
      consultation; 192 statements total (96/96 topical application/mouth rinsing).
      Round 1 contributors voted to "agree" or "disagree" with statements; 80%
      agreement was required to accept statements. In round 2, contributors voted to
      "support" or "change" their round 1 unaccepted statements, with knowledge of the 
      extant voting from round 1. Round 3 contributors met to discuss voting against
      key remaining statements. RESULTS: Forty-seven statements reached consensus in
      round 1 (30/17 topical application/rinsing); 14 proved redundant. Six statements 
      reached consensus in round 2 (2/4 topical application/rinsing); 116 statements
      proved redundant. Nine further statements were agreed in round 3 (6/3 topical
      application/rinsing) with caveats. DISCUSSION: Consensus was reached on 62
      statements in total (38/24 topical application/rinsing), enabling the development
      of guidance on safe menthol administration, with a view to enhancing performance 
      and perception in the heat without impairing body temperature regulation.
FAU - Barwood, M J
AU  - Barwood MJ
AUID- ORCID: http://orcid.org/0000-0002-1409-2191
AD  - Department of Sport, Health and Nutrition, Leeds Trinity University, Brownberrie 
      Lane, Horsforth, Leeds, LS18 5HD, UK. m.barwood@leedstrinity.ac.uk.
FAU - Gibson, O R
AU  - Gibson OR
AD  - Centre for Human Performance, Exercise and Rehabilitation (CHPER), Department
      Life Sciences, Division of Sport, Health and Exercise Sciences, Brunel University
      London, Kingston Lane, Uxbridge, UB8 3PH, UK.
FAU - Gillis, D J
AU  - Gillis DJ
AD  - Human Performance Laboratory, Department of Sport and Movement Science, Salem
      State University, Salem, MA, 01970, USA.
FAU - Jeffries, O
AU  - Jeffries O
AD  - School of Biomedical, Nutritional and Sport Sciences, Faculty of Medical
      Sciences, Newcastle University, Catherine Cookson Building, Newcastle Upon Tyne, 
      NE2 4HH, UK.
FAU - Morris, N B
AU  - Morris NB
AD  - Department of Nutrition, Exercise and Sports, University of Copenhagen, 2100,
      Copenhagen, Denmark.
FAU - Pearce, J
AU  - Pearce J
AD  - Performance Nutrition Technical Lead, High Performance Sport New Zealand,
      Auckland, New Zealand.
FAU - Ross, M L
AU  - Ross ML
AD  - Australian Institute of Sport, Bruce, 2617, Australia.
AD  - Mary Mackillop Institute for Health Research, Australian Catholic University,
      Melbourne, 3000, Australia.
FAU - Stevens, C
AU  - Stevens C
AD  - School of Health and Human Sciences, Southern Cross University, Hogbin Dr, Coffs 
      Harbour, NSW, 2450, Australia.
FAU - Rinaldi, K
AU  - Rinaldi K
AD  - Laboratoire ACTES (EA3596), Universite des Antilles et de la Guyane, BP 250,
      97157, Pointe-a-Pitre, France.
AD  - Arkea Samsic Pro Cycling Team, 35170, Bruz, France.
FAU - Kounalakis, S N
AU  - Kounalakis SN
AD  - Faculty of Physical and Cultural Education, Evelpidon Hellenic Army Academy,
      Vari, Greece.
FAU - Riera, F
AU  - Riera F
AD  - UPRES EA 35-96, UFR-STAPS, Universite des Antilles et de la Guyane, BP 250,
      97157, Pointe a Pitre Cedex, France.
AD  - Laboratoire Performance Sante Altitude, Universite de Perpignan Via Domitia, UFR 
      Sciences et Techniques des Activites Physiques et Sportives, 7 avenue Pierre de
      Coubertin, 66120, Font-Romeu, France.
FAU - Mundel, T
AU  - Mundel T
AD  - School of Sport Exercise and Nutrition, Massey University, Palmerston, New
      Zealand.
FAU - Waldron, M
AU  - Waldron M
AD  - College of Engineering, Applied Sports Science Technology and Medicine Research
      Centre (A-STEM), Swansea University Bay Campus, Swansea, Wales, UK.
AD  - School of Science and Technology, University of New England, Armidale, NSW,
      Australia.
FAU - Best, R
AU  - Best R
AD  - Centre for Sport Science and Human Performance, Waikato Institute of Technology, 
      Hamilton, 3200, New Zealand.
AD  - School of Health and Social Care, Teesside University, Middlesbrough, Tees
      Valley, TS1 3BX, UK.
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Sports Med
JT  - Sports medicine (Auckland, N.Z.)
JID - 8412297
RN  - 0 (Mouthwashes)
RN  - 0 (Performance-Enhancing Substances)
RN  - 1490-04-6 (Menthol)
SB  - IM
MH  - *Administration, Topical
MH  - Athletic Performance/*physiology
MH  - Delphi Technique
MH  - Humans
MH  - Menthol/*administration & dosage
MH  - *Mouthwashes
MH  - *Performance-Enhancing Substances
MH  - Tokyo
PMC - PMC7497433
EDAT- 2020/07/06 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - 10.1007/s40279-020-01313-9 [doi]
AID - 10.1007/s40279-020-01313-9 [pii]
PST - ppublish
SO  - Sports Med. 2020 Oct;50(10):1709-1727. doi: 10.1007/s40279-020-01313-9.


PMID- 32623496
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210711
IS  - 1433-0350 (Electronic)
IS  - 0256-7040 (Linking)
VI  - 36
IP  - 10
DP  - 2020 Oct
TI  - Ante-natal counseling in phacomatoses.
PG  - 2269-2277
LID - 10.1007/s00381-020-04776-3 [doi]
AB  - OBJECTIVES: Phacomatoses are a group of neuro-oculo-cutaneous syndromes/
      neurocutaneous disorders, involving structures arising from the embryonic
      ectoderm. Most of phacomatoses including the most common ones:, neurofibromatosis
      type I and type II (NF1, NF2) and tuberosclerosis complex (TSC), are autosomal
      dominant genetic disorders with full penetrance and variable expression. As no
      effective treatment exists, the only way to prevent the disease, is by prenatal
      genetic diagnosis (either chorionic villus sampling-CVS or amniocentesis-AC) and 
      termination of pregnancy or performing preimplantation genetic testing (PGT). As 
      the risk for an affected offspring is 50% in every pregnancy of an affected
      parent, prenatal, and preimplantation testing are of great importance. However,
      those procedures are associated with technical and ethical concerns. This chapter
      shortly reviews the common phacomatoses emphasizes their genetics and
      inheritance. We will review the common methods for prenatal and preimplantation
      diagnoses and discuss its use in common phacomatoses. CONCLUSION: Phacomatoses
      are common autosomal dominant genetic conditions with variable expression.
      Ante-natal genetic diagnosis is an appropriate approach for family planning in
      individuals affected by phacomatosis or parents of an affected child.
FAU - Brabbing-Goldstein, Dana
AU  - Brabbing-Goldstein D
AD  - Genetic Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
AD  - Department of Obstetrics and Gynecology, The Lis Maternity Hospital, Tel Aviv
      University, Tel Aviv, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Ben-Shachar, Shay
AU  - Ben-Shachar S
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
      shayb@clalit.org.il.
AD  - Clalit Research Institute, & Schneider Children's Medical Center, Ramat-Gan,
      Israel. shayb@clalit.org.il.
LA  - eng
PT  - Journal Article
DEP - 20200705
PL  - Germany
TA  - Childs Nerv Syst
JT  - Child's nervous system : ChNS : official journal of the International Society for
      Pediatric Neurosurgery
JID - 8503227
SB  - IM
MH  - Amniocentesis
MH  - Child
MH  - Chorionic Villi Sampling
MH  - Counseling
MH  - Female
MH  - Humans
MH  - *Neurocutaneous Syndromes
MH  - Pregnancy
MH  - Prenatal Diagnosis
OTO - NOTNLM
OT  - *Amniocentesis
OT  - *Chorionic villi sampling
OT  - *Germline gene editing
OT  - *Neurofibromatosis type 1
OT  - *Neurofibromatosis type 2
OT  - *Phacomatoses
OT  - *Preimplantation genetic testing
OT  - *Prenatal genetic counseling
OT  - *Prenatal genetic diagnosis
OT  - *Tuberosclerosis complex
EDAT- 2020/07/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/05/22 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - 10.1007/s00381-020-04776-3 [doi]
AID - 10.1007/s00381-020-04776-3 [pii]
PST - ppublish
SO  - Childs Nerv Syst. 2020 Oct;36(10):2269-2277. doi: 10.1007/s00381-020-04776-3.
      Epub 2020 Jul 5.


PMID- 32623481
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20201218
IS  - 1433-9285 (Electronic)
IS  - 0933-7954 (Linking)
VI  - 55
IP  - 8
DP  - 2020 Aug
TI  - COVID-19 epidemic and public mental health care in Italy: ethical considerations.
PG  - 1093-1094
LID - 10.1007/s00127-020-01907-8 [doi]
FAU - Pelizza, Lorenzo
AU  - Pelizza L
AUID- ORCID: 0000-0003-4746-2061
AD  - Parma Department of Mental Health and Pathological Addiction, Azienda USL di
      Parma, Largo Palli n. 1/A, 43100, Parma, Italy. lorpelizza@ausl.pr.it.
FAU - Pupo, Simona
AU  - Pupo S
AD  - Anesthesia and Resuscitation Service, Surgery Department, Azienda
      Ospedaliero-Universitaria Di Parma, Via Gramsci n. 14, 43100, Parma, Italy.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200704
PL  - Germany
TA  - Soc Psychiatry Psychiatr Epidemiol
JT  - Social psychiatry and psychiatric epidemiology
JID - 8804358
SB  - IM
CON - Soc Psychiatry Psychiatr Epidemiol. 2020 Aug;55(8):965-968. PMID: 32472197
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - Italy
MH  - Mental Health
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7335220
OTO - NOTNLM
OT  - *COVID-19
OT  - *Outpatient treatment
OT  - *Psychiatric services
OT  - *Public mental health
EDAT- 2020/07/06 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/06/06 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - 10.1007/s00127-020-01907-8 [doi]
AID - 10.1007/s00127-020-01907-8 [pii]
PST - ppublish
SO  - Soc Psychiatry Psychiatr Epidemiol. 2020 Aug;55(8):1093-1094. doi:
      10.1007/s00127-020-01907-8. Epub 2020 Jul 4.


PMID- 32623366
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 5
TI  - Adherence Tracking With Smart Watches for Shoulder Physiotherapy in Rotator Cuff 
      Pathology: Protocol for a Longitudinal Cohort Study.
PG  - e17841
LID - 10.2196/17841 [doi]
AB  - BACKGROUND: Physiotherapy is essential for the successful rehabilitation of
      common shoulder injuries and following shoulder surgery. Patients may receive
      some training and supervision for shoulder physiotherapy through private pay or
      private insurance, but they are typically responsible for performing most of
      their physiotherapy independently at home. It is unknown how often patients
      perform their home exercises and if these exercises are performed correctly
      without supervision. There are no established tools for measuring this. It is,
      therefore, unclear if the full benefit of shoulder physiotherapy treatments is
      being realized. OBJECTIVE: The proposed research will (1) validate a smartwatch
      and machine learning (ML) approach for evaluating adherence to shoulder exercise 
      participation and technique in a clinical patient population with rotator cuff
      pathology; (2) quantify the rate of home physiotherapy adherence, determine the
      effects of adherence on recovery, and identify barriers to successful adherence; 
      and (3) develop and pilot test an ethically conscious adherence-driven
      rehabilitation program that individualizes patient care based on their capacity
      to effectively participate in their home physiotherapy. METHODS: This research
      will be conducted in 2 phases. The first phase is a prospective longitudinal
      cohort study, involving 120 patients undergoing physiotherapy for rotator cuff
      pathology. Patients will be issued a smartwatch that will record 9-axis inertial 
      sensor data while they perform physiotherapy exercises both in the clinic and in 
      the home setting. The data collected in the clinic under supervision will be used
      to train and validate our ML algorithms that classify shoulder physiotherapy
      exercise. The validated algorithms will then be used to assess home physiotherapy
      adherence from the inertial data collected at home. Validated outcome measures,
      including the Disabilities of the Arm, Shoulder, and Hand questionnaire; Numeric 
      Pain Rating Scale; range of motion; shoulder strength; and work status, will be
      collected pretreatment, monthly through treatment, and at a final follow-up of 12
      months. We will then relate improvement in patient outcomes to measured
      physiotherapy adherence and patient baseline variables in univariate and
      multivariate analyses. The second phase of this research will involve the
      evaluation of a novel rehabilitation program in a cohort of 20 patients. The
      program will promote patient physiotherapy engagement via the developed
      technology and support adherence-driven care decisions. RESULTS: As of December
      2019, 71 patients were screened for enrollment in the noninterventional
      validation phase of this study; 65 patients met the inclusion and exclusion
      criteria. Of these, 46 patients consented and 19 declined to participate in the
      study. Only 2 patients de-enrolled from the study and data collection is ongoing 
      for the remaining 44. CONCLUSIONS: This study will provide new and important
      insights into shoulder physiotherapy adherence, the relationship between
      adherence and recovery, barriers to better adherence, and methods for addressing 
      them. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/17841.
CI  - (c)David Burns, Helen Razmjou, James Shaw, Robin Richards, Stewart McLachlin,
      Michael Hardisty, Patrick Henry, Cari Whyne. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 05.07.2020.
FAU - Burns, David
AU  - Burns D
AUID- ORCID: https://orcid.org/0000-0002-1617-596X
AD  - Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada.
AD  - Holland Bone and Joint Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada.
FAU - Razmjou, Helen
AU  - Razmjou H
AUID- ORCID: https://orcid.org/0000-0002-3162-4241
AD  - Holland Bone and Joint Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada.
AD  - Working Condition Program, Holland Orthopedic and Arthritic Centre, Toronto, ON, 
      Canada.
AD  - Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.
FAU - Shaw, James
AU  - Shaw J
AUID- ORCID: https://orcid.org/0000-0002-9522-0756
AD  - Women's College Research Institute, Toronto, ON, Canada.
AD  - Joint Centre for Bioethics, University of Toronto, Toronto, ON, Canada.
FAU - Richards, Robin
AU  - Richards R
AUID- ORCID: https://orcid.org/0000-0001-6561-5258
AD  - Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada.
AD  - Holland Bone and Joint Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada.
FAU - McLachlin, Stewart
AU  - McLachlin S
AUID- ORCID: https://orcid.org/0000-0002-8464-3032
AD  - Mechanical and Mechatronics Engineering, University of Waterloo, Waterloo, ON,
      Canada.
FAU - Hardisty, Michael
AU  - Hardisty M
AUID- ORCID: https://orcid.org/0000-0002-8941-3543
AD  - Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada.
AD  - Holland Bone and Joint Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada.
FAU - Henry, Patrick
AU  - Henry P
AUID- ORCID: https://orcid.org/0000-0001-9120-1964
AD  - Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada.
AD  - Holland Bone and Joint Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada.
FAU - Whyne, Cari
AU  - Whyne C
AUID- ORCID: https://orcid.org/0000-0002-6822-8314
AD  - Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada.
AD  - Holland Bone and Joint Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200705
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7381014
OTO - NOTNLM
OT  - machine learning
OT  - rehabilitation
OT  - rotator cuff
OT  - treatment adherence and compliance
OT  - wearable electronic devices
EDAT- 2020/07/06 06:00
MHDA- 2020/07/06 06:01
CRDT- 2020/07/06 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/03/26 00:00 [revised]
PHST- 2020/07/06 06:00 [entrez]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/07/06 06:01 [medline]
AID - v9i7e17841 [pii]
AID - 10.2196/17841 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 5;9(7):e17841. doi: 10.2196/17841.


PMID- 32623231
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 259
DP  - 2020 Aug
TI  - "You have to find a caring man, like your father!" gendering sickle cell and
      refashioning women's moral boundaries in Sierra Leone.
PG  - 113148
LID - S0277-9536(20)30367-1 [pii]
LID - 10.1016/j.socscimed.2020.113148 [doi]
AB  - Most research on sickle cell disorders has tended to be gender-blind. This
      qualitative study undertaken in 2018, explores if and how sickle cell disorders
      become gendered in Sierra Leone through the analytical framework of a feminist
      ethics of care. It argues that women have to navigate moral blame when they have 
      children with the condition. At the same time women refashion moral boundaries so
      that gendered norms around childhood and parenting for such children become
      suspended, in favour of creation of careful spaces. Parental fears of physical
      and sexual violence mean that gendered sexual norms are enforced for teenage boys
      as they are encouraged into early adulthood. In contrast, girls are kept in
      enforced ignorance about the consequences of sickle cell for reproduction and are
      encouraged to delay motherhood. This is because, as women relate, relationships
      and giving birth are fraught with embodied dangers and risks of violence.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Berghs, M
AU  - Berghs M
AD  - De Montfort University, Leicester School of Allied Health Sciences, The Gateway, 
      LE1 9BH, United Kingdom. Electronic address: Maria.Berghs@dmu.ac.uk.
FAU - Dyson, S M
AU  - Dyson SM
AD  - De Montfort University, Leicester School of Allied Health Sciences, The Gateway, 
      LE1 9BH, United Kingdom.
FAU - Gabba, A
AU  - Gabba A
AD  - Sierra Leone Sickle Cell Disease Society, Freetown, Sierra Leone.
FAU - Nyandemo, S E
AU  - Nyandemo SE
AD  - Sickle Cell Carers Awareness Network, Koidu, Sierra Leone.
FAU - Roberts, G
AU  - Roberts G
AD  - Sierra Leone Sickle Cell Disease Society, Freetown, Sierra Leone.
FAU - Deen, G
AU  - Deen G
AD  - Department of Internal Medicine, College of Medicine and Allied Health Sciences, 
      University of Sierra Leone, Freetown, Sierra Leone.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Anemia, Sickle Cell
MH  - Child
MH  - *Fathers
MH  - Female
MH  - Humans
MH  - Male
MH  - *Morals
MH  - Pregnancy
MH  - Qualitative Research
MH  - Sierra Leone
PMC - PMC7322450
OTO - NOTNLM
OT  - *Care
OT  - *Gender
OT  - *Sickle cell
OT  - *Sierra Leone
OT  - *Women
EDAT- 2020/07/06 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S0277-9536(20)30367-1 [pii]
AID - 10.1016/j.socscimed.2020.113148 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Aug;259:113148. doi: 10.1016/j.socscimed.2020.113148. Epub 2020
      Jun 29.


PMID- 32622907
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 224
DP  - 2020 Oct 1
TI  - An introduction to an international conference on "The ethics of eating:
      Promoting personal and global choices".
PG  - 113047
LID - S0031-9384(20)30361-9 [pii]
LID - 10.1016/j.physbeh.2020.113047 [doi]
FAU - Kinzig, Kimberly P
AU  - Kinzig KP
AD  - Department of Psychological Sciences, Neuroscience and Behavior, Purdue
      University, 703 Third Street, West Lafayette, IN 47907, United States. Electronic
      address: kkinzig@purdue.edu.
FAU - Running, Cordelia A
AU  - Running CA
AD  - Department of Nutrition Science, Purdue University, United States; Department of 
      Food Science, Purdue University, West Lafayette, IN, United States.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200702
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
EDAT- 2020/07/06 06:00
MHDA- 2020/07/06 06:01
CRDT- 2020/07/06 06:00
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/07/06 06:01 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S0031-9384(20)30361-9 [pii]
AID - 10.1016/j.physbeh.2020.113047 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Oct 1;224:113047. doi: 10.1016/j.physbeh.2020.113047. Epub
      2020 Jul 2.


PMID- 32622703
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1472-6491 (Electronic)
IS  - 1472-6483 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Sep
TI  - Forbidden medically assisted sex selection in Sunni Muslims: a qualitative study.
PG  - 534-542
LID - S1472-6483(20)30317-5 [pii]
LID - 10.1016/j.rbmo.2020.05.018 [doi]
AB  - RESEARCH QUESTION: Son preference is a phenomenon typically prevalent in
      traditional societies in the Middle East and in East and South Asia. Hence,
      various sex-selection practices, either natural or medically assisted, have
      emerged. Islamic law forbids medically assisted sex selection for social reasons.
      Our aim was to examine the narratives of Sunni Muslim couples who underwent sex
      selection treatment by using sperm sorting and to understand their reasons for
      doing so. DESIGN: A qualitative phenomenological study involving in-depth,
      face-to-face interviews with 31 women who gave birth to a male baby after
      undergoing sperm-sorting treatment, preimplantation genetic testing sex
      selection, or both, in a private clinic. RESULTS: Interviewees spoke about the
      ethical dilemma they faced in choosing to violate the religious prohibition
      against sex selection; they explained the reasons why they opted to undergo
      sperm-sorting treatment and why the utmost secrecy surrounded it. CONCLUSIONS:
      Some Sunni Muslim couples privately defy the Sunni Muslim orthodoxy on their way 
      to becoming parents to male offspring. Sons are preferred over daughters because 
      of the traditional value attached to male offspring in Muslim culture. Therefore,
      couples who have only daughters may face an ethical dilemma of whether to obey
      the religious prohibition against sex selection or to violate it and enjoy
      societal acceptance and recognition for having a son.
CI  - Copyright (c) 2020 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All
      rights reserved.
FAU - Bokek-Cohen, Ya'arit
AU  - Bokek-Cohen Y
AD  - School of Nursing, Tel Aviv Jaffa Academic College, 2 Rabenu Yerucham St, Tel
      Aviv 6161001, Israel. Electronic address: ybokek@gmail.com.
FAU - Tarabeih, Mahdi
AU  - Tarabeih M
AD  - School of Nursing, Tel Aviv Jaffa Academic College, 2 Rabenu Yerucham St, Tel
      Aviv 6161001, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200614
PL  - Netherlands
TA  - Reprod Biomed Online
JT  - Reproductive biomedicine online
JID - 101122473
SB  - IM
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - *Islam
MH  - Male
MH  - Middle East
MH  - *Psychological Distance
MH  - Qualitative Research
MH  - Sex Preselection/*ethics
OTO - NOTNLM
OT  - Gender
OT  - Islam
OT  - Religion
OT  - Sex selection
OT  - Sperm sorting
EDAT- 2020/07/06 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S1472-6483(20)30317-5 [pii]
AID - 10.1016/j.rbmo.2020.05.018 [doi]
PST - ppublish
SO  - Reprod Biomed Online. 2020 Sep;41(3):534-542. doi: 10.1016/j.rbmo.2020.05.018.
      Epub 2020 Jun 14.


PMID- 32622647
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1528-3968 (Electronic)
IS  - 0029-6554 (Linking)
VI  - 68
IP  - 5
DP  - 2020 Sep - Oct
TI  - Examining 'sticky' storytelling and moral claims as the essence of workplace
      bullying.
PG  - 647-656
LID - S0029-6554(20)30203-7 [pii]
LID - 10.1016/j.outlook.2020.05.007 [doi]
AB  - BACKGROUND: Fisher (1985) argued that "there is no genre...that is not an episode
      in the story of life" (p. 347). As they incorporate moral claims, stories become 
      'sticky,' even when they are not accurate of fact, shifting listener beliefs,
      values, and sense of self. PURPOSE: This study examined 'sticky' storytelling and
      moral claims inherent in workplace bullying. METHOD: Critical hermeneutic method 
      nested within an integrative review served as the research approach, extending
      findings reported in published research reports and gray literature. FINDINGS:
      Through polished use of rhetorical style and resource control strategies within
      tacitly or explicitly supportive workplace contexts, bullies construct convincing
      but morally disengaged narratives-sticky stories-that violate ethical principles 
      and yield moral ambiguity for their victims as they impede workplace
      productivity. DISCUSSION: Largely ineffective, policies aimed to stem bullying
      have done little to date to mitigate bullying's impact. Recognizing the moral
      storytelling characterizing workplace bullying might strengthen policy for
      constraining workplace bullying.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Dzurec, Laura Cox
AU  - Dzurec LC
AD  - Boston College, Chestnut Hill, MA. Electronic address: lcdzurec@outlook.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - United States
TA  - Nurs Outlook
JT  - Nursing outlook
JID - 0401075
SB  - IM
MH  - Bullying/*psychology
MH  - Humans
MH  - *Moral Status
MH  - *Narration
MH  - Surveys and Questionnaires
EDAT- 2020/07/06 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S0029-6554(20)30203-7 [pii]
AID - 10.1016/j.outlook.2020.05.007 [doi]
PST - ppublish
SO  - Nurs Outlook. 2020 Sep - Oct;68(5):647-656. doi: 10.1016/j.outlook.2020.05.007.
      Epub 2020 Jul 2.


PMID- 32622646
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 1528-3968 (Electronic)
IS  - 0029-6554 (Linking)
VI  - 68
IP  - 6
DP  - 2020 Nov - Dec
TI  - The ethics of sensor technology use in clinical research.
PG  - 720-726
LID - S0029-6554(20)30005-1 [pii]
LID - 10.1016/j.outlook.2020.04.011 [doi]
AB  - Sensor-based technologies are used today in clinical practice, research, and for 
      monitoring people's health in homes across the United States. Although the
      increasing growth and complexity of such technologies promises both direct and
      indirect benefits, significant ethical concerns are raised. We discuss several of
      these concerns, particularly those that arise in clinical research and outline
      ethical considerations that pertain to the concept of informed consent,
      participants' understanding of risks and benefits and the need for tailored and
      accessible information that will enable participants to fully understand research
      implications. Balancing the benefits with the potential risks of advanced
      information technology will require ethically astute researchers who can address 
      the challenges that might arise while advancing knowledge with innovation that
      can improve the lives of patients and families.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ulrich, Connie M
AU  - Ulrich CM
AD  - The University of Pennsylvania School of Nursing, Philadelphia, Pa; The
      University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.
      Electronic address: culrich@nursing.upenn.edu.
FAU - Demiris, George
AU  - Demiris G
AD  - The University of Pennsylvania School of Nursing, Philadelphia, Pa; The
      University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.
FAU - Kennedy, Rosemary
AU  - Kennedy R
AD  - CEO, eCare Informatics, Philadelphia, Pa.
FAU - Rothwell, Erin
AU  - Rothwell E
AD  - The University of Utah, Salt Lake City, Utah.
LA  - eng
GR  - R01 CA196131/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200702
PL  - United States
TA  - Nurs Outlook
JT  - Nursing outlook
JID - 0401075
SB  - IM
MH  - *Ethics, Nursing
MH  - Forecasting
MH  - Humans
MH  - Inventions/*ethics/*trends
MH  - Nursing Research/*ethics/*instrumentation/*trends
MH  - United States
OTO - NOTNLM
OT  - *Ethics
OT  - *Innovation
OT  - *Sensors
OT  - *Technology
EDAT- 2020/07/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S0029-6554(20)30005-1 [pii]
AID - 10.1016/j.outlook.2020.04.011 [doi]
PST - ppublish
SO  - Nurs Outlook. 2020 Nov - Dec;68(6):720-726. doi: 10.1016/j.outlook.2020.04.011.
      Epub 2020 Jul 2.


PMID- 32622474
OWN - NLM
STAT- MEDLINE
DCOM- 20200922
LR  - 20210110
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 158
IP  - 3
DP  - 2020 Sep
TI  - Principles of ethics and critical communication during the COVID-19 pandemic.
PG  - 526-530
LID - S0090-8258(20)32320-9 [pii]
LID - 10.1016/j.ygyno.2020.06.494 [doi]
FAU - Shalowitz, David I
AU  - Shalowitz DI
AD  - Section on Gynecologic Oncology, Department of Obstetrics and Gynecology, Wake
      Forest School of Medicine, Winston-Salem, NC, United States of America.
      Electronic address: dshalowi@wakehealth.edu.
FAU - Lefkowits, Carolyn
AU  - Lefkowits C
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
      University of Colorado, Denver, CO, United States of America.
FAU - Landrum, Lisa M
AU  - Landrum LM
AD  - Section of Gynecologic Oncology, Department of Obstetrics and Gynecology,
      University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
      of America.
FAU - von Gruenigen, Vivian E
AU  - von Gruenigen VE
AD  - Division of Gynecologic Oncology, University Hospitals Medical Center, Beachwood,
      OH, United States of America.
FAU - Spillman, Monique A
AU  - Spillman MA
AD  - Division of Gynecologic Oncology, Texas Oncology, Baylor University Medical
      Center, Dallas, TX, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
SB  - IM
MH  - Betacoronavirus/pathogenicity
MH  - COVID-19
MH  - *Communication
MH  - Coronavirus Infections/epidemiology/*prevention & control/transmission/virology
MH  - Critical Care/ethics/organization & administration
MH  - *Ethics, Medical
MH  - Female
MH  - Genital Neoplasms, Female/*therapy
MH  - Gynecology/ethics/organization & administration
MH  - Humans
MH  - Infection Control/*standards
MH  - Medical Oncology/ethics/organization & administration
MH  - Palliative Care/ethics/organization & administration
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control/transmission/virology
MH  - Resource Allocation/ethics
MH  - SARS-CoV-2
MH  - Standard of Care
PMC - PMC7315948
COIS- Declaration of Competing Interest Dr. Spillman reports that for this manuscript, 
      my role is the Chair of the SGO Professional Ethics Committee, the moderator of
      the SGO webinar on the topic and the senior author of the manuscript. My conflict
      disclosure is that I am also the Vice-Chair of the American Medical Association
      Council on Ethical and Judicial Affairs, but this manuscript does not represent
      policies of the AMA. The AMA CEJA position is a volunteer medical association
      leadership position. All other authors have nothing to disclose. Dr. Shalowitz
      reports serving as the current Chair of the Committee on Ethics for the American 
      College of Obstetricians and Gynecologists (ACOG). The views expressed in this
      manuscript do not necessarily represent the positions of ACOG.
EDAT- 2020/07/06 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/07/06 06:00
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
PHST- 2020/07/06 06:00 [entrez]
AID - S0090-8258(20)32320-9 [pii]
AID - 10.1016/j.ygyno.2020.06.494 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2020 Sep;158(3):526-530. doi: 10.1016/j.ygyno.2020.06.494. Epub
      2020 Jun 25.


PMID- 32622173
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210701
IS  - 1973-8102 (Electronic)
IS  - 0010-9452 (Linking)
VI  - 129
DP  - 2020 Aug
TI  - How to do things with (thousands of) words: Computational approaches to discourse
      analysis in Alzheimer's disease.
PG  - 446-463
LID - S0010-9452(20)30185-4 [pii]
LID - 10.1016/j.cortex.2020.05.001 [doi]
AB  - Natural Language Processing (NLP) is an ever-growing field of computational
      science that aims to model natural human language. Combined with advances in
      machine learning, which learns patterns in data, it offers practical capabilities
      including automated language analysis. These approaches have garnered interest
      from clinical researchers seeking to understand the breakdown of language due to 
      pathological changes in the brain, offering fast, replicable and objective
      methods. The study of Alzheimer's disease (AD), and preclinical Mild Cognitive
      Impairment (MCI), suggests that changes in discourse (connected speech or
      writing) may be key to early detection of disease. There is currently no
      disease-modifying treatment for AD, the leading cause of dementia in people over 
      the age of 65, but detection of those at risk of developing the disease could
      help with the identification and testing of medications which can take effect
      before the underlying pathology has irreversibly spread. We outline important
      components of natural language, as well as NLP tools and approaches with which
      they can be extracted, analysed and used for disease identification and risk
      prediction. We review literature using these tools to model discourse across the 
      spectrum of AD, including the contribution of machine learning approaches and
      Automatic Speech Recognition (ASR). We conclude that NLP and machine learning
      techniques are starting to greatly enhance research in the field, with measurable
      and quantifiable language components showing promise for early detection of
      disease, but there remain research and practical challenges for clinical
      implementation of these approaches. Challenges discussed include the availability
      of large and diverse datasets, ethics of data collection and sharing, diagnostic 
      specificity and clinical acceptability.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Clarke, Natasha
AU  - Clarke N
AD  - Neurosciences Research Centre, Molecular & Clinical Sciences Research Institute, 
      St George's, University of London, Cranmer Terrace, London, UK. Electronic
      address: p1607544@sgul.ac.uk.
FAU - Foltz, Peter
AU  - Foltz P
AD  - Institute of Cognitive Science, University of Colorado, Boulder, USA. Electronic 
      address: peter.foltz@colorado.edu.
FAU - Garrard, Peter
AU  - Garrard P
AD  - Neurosciences Research Centre, Molecular & Clinical Sciences Research Institute, 
      St George's, University of London, Cranmer Terrace, London, UK. Electronic
      address: pgarrard@sgul.ac.uk.
LA  - eng
GR  - MR/N013638/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200519
PL  - Italy
TA  - Cortex
JT  - Cortex; a journal devoted to the study of the nervous system and behavior
JID - 0100725
SB  - IM
CIN - Cortex. 2021 Mar;136:150-156. PMID: 33023751
MH  - *Alzheimer Disease
MH  - *Cognitive Dysfunction
MH  - Early Diagnosis
MH  - Humans
MH  - Language
MH  - Speech
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *Discourse
OT  - *Machine learning
OT  - *Mild Cognitive Impairment
OT  - *Natural Language Processing
COIS- Conflict of Interest We report no competing interests.
EDAT- 2020/07/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/07/05 06:00
PHST- 2019/08/15 00:00 [received]
PHST- 2020/01/30 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - S0010-9452(20)30185-4 [pii]
AID - 10.1016/j.cortex.2020.05.001 [doi]
PST - ppublish
SO  - Cortex. 2020 Aug;129:446-463. doi: 10.1016/j.cortex.2020.05.001. Epub 2020 May
      19.


PMID- 32622170
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 291
DP  - 2020 Sep
TI  - Children and adolescents attempting to participate in a worldwide online
      depression screener.
PG  - 113250
LID - S0165-1781(20)30278-X [pii]
LID - 10.1016/j.psychres.2020.113250 [doi]
AB  - Depression rates are increasing among minors. Internet is central to the lives of
      many minors, and many of them look online for depression information. This report
      describes minors who attempted to screen themselves for depression in a worldwide
      online study. Google Ads were used to recruit individuals to a multilingual
      depression screening study that was meant to target and recruit adults. Of
      158,170 individuals accessing the site, 30,396 (19.22%) were minors from 190
      countries. Proportions of minors varied considerably between different cultures. 
      Given youth's interest in depression information, online services to ethically
      and effectively address youth depression are needed.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Stephens, Taylor N
AU  - Stephens TN
AD  - Department of Psychology, Palo Alto University, Palo Alto, CA, USA.
FAU - Tran, Michelle M
AU  - Tran MM
AD  - Department of Psychology, Palo Alto University, Palo Alto, CA, USA.
FAU - Bunge, Eduardo L
AU  - Bunge EL
AD  - Department of Psychology, Palo Alto University, Palo Alto, CA, USA.
FAU - Liu, Nancy H
AU  - Liu NH
AD  - Department of Psychology, University of California, Berkeley, Berkeley, CA, USA.
FAU - Barakat, Suzanne
AU  - Barakat S
AD  - La Clinica de la Raza, Oakland, CA, USA; Sutter Health, San Francisco, CA, USA.
FAU - Garza, Monica
AU  - Garza M
AD  - Legacy Community Health, Houston, TX, USA.
FAU - Leykin, Yan
AU  - Leykin Y
AD  - Department of Psychology, Palo Alto University, Palo Alto, CA, USA; Department of
      Psychiatry, University of California, San Francisco, San Francisco, CA, USA.
      Electronic address: yleykin@paloaltou.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200625
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Depression/*diagnosis/*epidemiology/psychology
MH  - Female
MH  - Global Health/*trends
MH  - Humans
MH  - Internet/*trends
MH  - Male
MH  - Mass Screening/methods/*trends
OTO - NOTNLM
OT  - *Depression
OT  - *Online
OT  - *Youth
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/02/08 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/20 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - S0165-1781(20)30278-X [pii]
AID - 10.1016/j.psychres.2020.113250 [doi]
PST - ppublish
SO  - Psychiatry Res. 2020 Sep;291:113250. doi: 10.1016/j.psychres.2020.113250. Epub
      2020 Jun 25.


PMID- 32621906
OWN - NLM
STAT- MEDLINE
DCOM- 20210729
LR  - 20210729
IS  - 1953-8022 (Electronic)
IS  - 1246-7820 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Aug
TI  - [The limits of a principlist approach in the ethics of donation of elements and
      products of the human body. About some examples].
PG  - 191-199
LID - S1246-7820(20)30081-1 [pii]
LID - 10.1016/j.tracli.2020.06.007 [doi]
AB  - Voluntary, non-remunerated donations are fundamental principles with anonymity
      regarding donations of elements and products of the human body in France. Blood
      donation was a model to organize donation of organs, hematopoietic stem cell or
      gamete. These principles, which at first glance appear to be intangible, commonly
      accepted and transposable between the different types of donation, though reveal 
      singularities regarding to a collective imagination, a biological reality,
      evolution of society, medicine and science. Through the study of these different 
      principles applied to donated human body parts, this article aims to highlight
      the ethical limitations of a single principlist approach. The notions of
      anonymity, consent, voluntariness, non for profit, under their universal
      aknowledge, reveal variability of interpretation and scope due to the
      heterogeneous characteristics, implications and purposes between these donations 
      of different elements and the uses made of them.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Thibert, J-B
AU  - Thibert JB
AD  - EFS Bretagne, rue Pierre-Jean-Gineste, 35016 Rennes cedex, France. Electronic
      address: Jean-baptiste.thibert@efs.sante.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Les limites d'une approche principiste dans l'ethique du don d'elements et
      produits du corps humain. A propos d'exemples.
DEP - 20200701
PL  - France
TA  - Transfus Clin Biol
JT  - Transfusion clinique et biologique : journal de la Societe francaise de
      transfusion sanguine
JID - 9423846
SB  - IM
MH  - Altruism
MH  - Blood Donors/ethics/legislation & jurisprudence
MH  - Confidentiality
MH  - *Ethical Theory
MH  - France
MH  - *Human Body
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - Milk, Human
MH  - Motivation
MH  - Oocytes
MH  - Organ Transplantation
MH  - Personal Autonomy
MH  - Plasma
MH  - Remuneration
MH  - Social Justice
MH  - Spermatozoa
MH  - Tissue and Organ Procurement/*ethics/legislation & jurisprudence
MH  - Volunteers
OTO - NOTNLM
OT  - Bioethics
OT  - Bioethique
OT  - Blood donation
OT  - Don de gametes
OT  - Don de sang
OT  - Don d'organe
OT  - Elements and products of the human body
OT  - Gamete donation
OT  - Organ donation
OT  - Principisme
OT  - Principlism
OT  - Elements et produits du corps humain
OT  - Ethique
EDAT- 2020/07/06 06:00
MHDA- 2021/07/30 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/07/30 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - S1246-7820(20)30081-1 [pii]
AID - 10.1016/j.tracli.2020.06.007 [doi]
PST - ppublish
SO  - Transfus Clin Biol. 2020 Aug;27(3):191-199. doi: 10.1016/j.tracli.2020.06.007.
      Epub 2020 Jul 1.


PMID- 32621783
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1460-9592 (Electronic)
IS  - 1155-5645 (Linking)
VI  - 30
IP  - 12
DP  - 2020 Dec
TI  - 2020 guidelines for conducting plastic reconstructive short-term surgical
      projects in low-middle income countries.
PG  - 1308-1321
LID - 10.1111/pan.13960 [doi]
AB  - Many low- or middle-income countries (LMICs) continue to suffer from a lack of
      safe and timely essential and emergency surgery despite growing attention to this
      problem. Short-term surgical projects (STSPs) continue to play an important role 
      in addressing LMIC unmet surgical need and strengthening local healthcare
      systems. Guidelines here present recommendations for performing plastic
      reconstructive STSPs for pediatric patients in a safe, ethical, and effective
      manner. These guidelines represent consensus physician expert opinions, assembled
      collaboratively by members of Volunteers in Plastic Surgery and the Society for
      Pediatric Anesthesia's global health committee, with broad input from physicians 
      practicing daily in LMICs. Organizations must partner with hosts to thoughtfully 
      plan and carefully execute STSPs. We outline crucial items to STSP success,
      including choice of host facility, team selection, patient selection, staffing,
      ensuring proper equipment and supplies, disinfecting reusable equipment, creation
      of a safety culture, and data collection for quality assessment/improvement and
      research. Patient factors are discussed and recommendations given for developing 
      exclusion criteria, as well as for determining which patients and procedures may 
      require the team to include expertise in pediatric anesthesia or critical care.
      We recommend that educational opportunities for hosts are sought and advanced to 
      optimize education/training at both the resident and post-trainee levels. Host
      education during STSPs has become crucial as LMICs ramp up training at a time
      when their surgical volumes remain grossly behind well-resourced countries.
      Recommendations here aim to assist organizations, hosts, and volunteers as they
      navigate the enormously complex and ever changing STSP environment. Patient
      safety and transfer of knowledge and skills should be central concerns of all who
      participate in this highly rewarding endeavor.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Politis, George D
AU  - Politis GD
AUID- ORCID: 0000-0001-7160-2824
AD  - Department of Anesthesiology, University of Virginia Health System,
      Charlottesville, Virginia, USA.
FAU - Gregory, George
AU  - Gregory G
AD  - Department of Anesthesia & Perioperative Care, University of California, San
      Francisco, California, USA.
FAU - Yudkowitz, Francine S
AU  - Yudkowitz FS
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of
      Medicine at Mount Sinai, Mount Sinai Hospital, New York, New York, USA.
FAU - Fisher, Quentin A
AU  - Fisher QA
AD  - Department of Anesthesiology, Pain, and Perioperative Medicine, Children's
      National Medical Center, Washington, District of Columbia, USA.
FAU - Bhettay, Anisa Z
AU  - Bhettay AZ
AUID- ORCID: 0000-0003-4835-1777
AD  - Department of Anaesthesia and Perioperative Medicine, Red Cross War Memorial
      Children's Hospital, University of Cape Town, Cape Town, South Africa.
FAU - Wexler, Andrew
AU  - Wexler A
AD  - Department of Plastic and Reconstructive Surgery, Kaiser Permanente, Los Angeles,
      California, USA.
AD  - Division of Plastic and Reconstructive Surgery, University of Southern
      California, Los Angeles, California, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200828
PL  - France
TA  - Paediatr Anaesth
JT  - Paediatric anaesthesia
JID - 9206575
SB  - IM
MH  - *Anesthesia
MH  - Child
MH  - Consensus
MH  - Developing Countries
MH  - Humans
MH  - *Reconstructive Surgical Procedures
MH  - Volunteers
OTO - NOTNLM
OT  - *child
OT  - *complications
OT  - *developing world
OT  - *education
OT  - *general anesthesia
OT  - *infant
OT  - *plastic
OT  - *surgery
EDAT- 2020/07/06 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/06/27 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - 10.1111/pan.13960 [doi]
PST - ppublish
SO  - Paediatr Anaesth. 2020 Dec;30(12):1308-1321. doi: 10.1111/pan.13960. Epub 2020
      Aug 28.


PMID- 32621525
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 7
DP  - 2020 Sep
TI  - Rethinking counselling in prenatal screening: An ethical analysis of informed
      consent in the context of non-invasive prenatal testing (NIPT).
PG  - 671-678
LID - 10.1111/bioe.12760 [doi]
AB  - Informed consent is a key condition for prenatal screening programmes to reach
      their aim of promoting reproductive autonomy. Reaching this aim is currently
      being challenged with the introduction of non-invasive prenatal testing (NIPT) in
      first-trimester prenatal screening programmes: amongst others its procedural
      ease-it only requires a blood draw and reaches high levels of reliability-might
      hinder women's understanding that they should make a personal, informed decision 
      about screening. We offer arguments for a renewed recognition and use of informed
      consent compared to informed choice, and for a focus on value-consistent choices 
      and personalized informational preferences. We argue for a three-step counselling
      model in which three decision moments are distinguished and differently
      addressed: (1) professionals explore women's values concerning whether and why
      they wish to know whether their baby has a genetic disorder; (2) women receive
      layered medical-technical information and are asked to make a decision about
      screening; (3) during post-test counselling, women are supported in
      decision-making about the continuation or termination of their pregnancy. This
      model might also be applicable in other fields of genetic (pre-test) counselling,
      where techniques for expanding genome analysis and burdensome test-outcomes
      challenge counselling of patients.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Kater-Kuipers, Adriana
AU  - Kater-Kuipers A
AUID- ORCID: 0000-0001-8992-4928
AD  - Department of Medical Ethics and Philosophy of Medicine, Erasmus MC, University
      Medical Centre Rotterdam, Rotterdam, The Netherlands.
FAU - de Beaufort, Inez D
AU  - de Beaufort ID
AD  - Department of Medical Ethics and Philosophy of Medicine, Erasmus MC, University
      Medical Centre Rotterdam, Rotterdam, The Netherlands.
FAU - Galjaard, Robert-Jan H
AU  - Galjaard RH
AD  - Department of Clinical Genetics, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, The Netherlands.
FAU - Bunnik, Eline M
AU  - Bunnik EM
AUID- ORCID: 0000-0003-1481-6222
AD  - Department of Medical Ethics and Philosophy of Medicine, Erasmus MC, University
      Medical Centre Rotterdam, Rotterdam, The Netherlands.
LA  - eng
GR  - Erasmus MC Grants (Mrace)/International
PT  - Journal Article
DEP - 20200704
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Counseling/*ethics
MH  - Decision Making/*ethics
MH  - Female
MH  - Humans
MH  - Informed Consent/*ethics
MH  - *Noninvasive Prenatal Testing
MH  - Pregnancy
MH  - Pregnant Women/*psychology
PMC - PMC7586798
OTO - NOTNLM
OT  - *counselling
OT  - *informed choice
OT  - *informed consent
OT  - *non-invasive prenatal test
OT  - *prenatal screening
OT  - *reproductive autonomy
OT  - *stepwise counselling model
EDAT- 2020/07/06 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/07/05 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2020/01/02 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - 10.1111/bioe.12760 [doi]
PST - ppublish
SO  - Bioethics. 2020 Sep;34(7):671-678. doi: 10.1111/bioe.12760. Epub 2020 Jul 4.


PMID- 32620971
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 29
IP  - R2
DP  - 2020 Oct 20
TI  - The emerging field of polygenic risk scores and perspective for use in clinical
      care.
PG  - R165-R176
LID - 10.1093/hmg/ddaa136 [doi]
AB  - Genetic testing is used widely for diagnostic, carrier and predictive testing in 
      monogenic diseases. Until recently, there were no genetic testing options
      available for multifactorial complex diseases like heart disease, diabetes and
      cancer. Genome-wide association studies (GWAS) have been invaluable in
      identifying single-nucleotide polymorphisms (SNPs) associated with increased or
      decreased risk for hundreds of complex disorders. For a given disease, SNPs can
      be combined to generate a cumulative estimation of risk known as a polygenic risk
      score (PRS). After years of research, PRSs are increasingly used in clinical
      settings. In this article, we will review the literature on how both genome-wide 
      and restricted PRSs are developed and the relative merit of each. The validation 
      and evaluation of PRSs will also be discussed, including the recognition that PRS
      validity is intrinsically linked to the methodological and analytical approach of
      the foundation GWAS together with the ethnic characteristics of that cohort.
      Specifically, population differences may affect imputation accuracy, risk
      magnitude and direction. Even as PRSs are being introduced into clinical
      practice, there is a push to combine them with clinical and demographic risk
      factors to develop a holistic disease risk. The existing evidence regarding the
      clinical utility of PRSs is considered across four different domains: informing
      population screening programs, guiding therapeutic interventions, refining risk
      for families at high risk, and facilitating diagnosis and predicting prognostic
      outcomes. The evidence for clinical utility in relation to five well-studied
      disorders is summarized. The potential ethical, legal and social implications are
      also highlighted.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights
      reserved. For Permissions, please email: journals.permissions@oup.com.
FAU - Yanes, Tatiane
AU  - Yanes T
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      The University of Queensland, Brisbane, QLD 4102, Australia.
FAU - McInerney-Leo, Aideen M
AU  - McInerney-Leo AM
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      The University of Queensland, Brisbane, QLD 4102, Australia.
FAU - Law, Matthew H
AU  - Law MH
AD  - Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, Herston QLD 
      4006, Australia.
AD  - Faculty of Health, School of Biomedical Sciences, and Institute of Health and
      Biomedical Innovation, Queensland University of Technology, Kelvin Grove QLD
      4059, Australia.
FAU - Cummings, Shelly
AU  - Cummings S
AD  - Myriad Genetics Inc., Salt Lake City, UT 84108, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
SB  - IM
MH  - Disease/*genetics
MH  - *Genetic Predisposition to Disease
MH  - *Genome-Wide Association Study
MH  - Humans
MH  - *Multifactorial Inheritance
MH  - *Polymorphism, Single Nucleotide
MH  - Risk Assessment
MH  - Risk Factors
EDAT- 2020/07/06 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/07/01 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - 5867072 [pii]
AID - 10.1093/hmg/ddaa136 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2020 Oct 20;29(R2):R165-R176. doi: 10.1093/hmg/ddaa136.


PMID- 32620927
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20211204
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jul 3
TI  - Realistic simulation of virtual multi-scale, multi-modal patient trajectories
      using Bayesian networks and sparse auto-encoders.
PG  - 10971
LID - 10.1038/s41598-020-67398-4 [doi]
AB  - Translational research of many disease areas requires a longitudinal
      understanding of disease development and progression across all biologically
      relevant scales. Several corresponding studies are now available. However, to
      compile a comprehensive picture of a specific disease, multiple studies need to
      be analyzed and compared. A large number of clinical studies is nowadays
      conducted in the context of drug development in pharmaceutical research. However,
      legal and ethical constraints typically do not allow for sharing sensitive
      patient data. In consequence there exist data "silos", which slow down the
      overall scientific progress in translational research. In this paper, we suggest 
      the idea of a virtual cohort (VC) to address this limitation. Our key idea is to 
      describe a longitudinal patient cohort with the help of a generative statistical 
      model, namely a modular Bayesian Network, in which individual modules are
      represented as sparse autoencoder networks. We show that with the help of such a 
      model we can simulate subjects that are highly similar to real ones. Our approach
      allows for incorporating arbitrary multi-scale, multi-modal data without making
      specific distribution assumptions. Moreover, we demonstrate the possibility to
      simulate interventions (e.g. via a treatment) in the VC. Overall, our proposed
      approach opens the possibility to build sufficiently realistic VCs for multiple
      disease areas in the future.
FAU - Sood, Meemansa
AU  - Sood M
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for Information Technology (B-IT), University of
      Bonn, 53115, Bonn, Germany.
FAU - Sahay, Akrishta
AU  - Sahay A
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for Information Technology (B-IT), University of
      Bonn, 53115, Bonn, Germany.
FAU - Karki, Reagon
AU  - Karki R
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for Information Technology (B-IT), University of
      Bonn, 53115, Bonn, Germany.
FAU - Emon, Mohammad Asif
AU  - Emon MA
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for Information Technology (B-IT), University of
      Bonn, 53115, Bonn, Germany.
FAU - Vrooman, Henri
AU  - Vrooman H
AD  - Department of Radiology and Medical Informatics, Erasmus MC, University Medical
      Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
FAU - Hofmann-Apitius, Martin
AU  - Hofmann-Apitius M
AUID- ORCID: http://orcid.org/0000-0001-9012-6720
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany.
AD  - Bonn-Aachen International Center for Information Technology (B-IT), University of
      Bonn, 53115, Bonn, Germany.
FAU - Frohlich, Holger
AU  - Frohlich H
AUID- ORCID: http://orcid.org/0000-0002-5328-1243
AD  - Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific 
      Computing (SCAI), Schloss Birlinghoven, 53754, Sankt Augustin, Germany.
      holger.froehlich@scai.fraunhofer.de.
AD  - Bonn-Aachen International Center for Information Technology (B-IT), University of
      Bonn, 53115, Bonn, Germany. holger.froehlich@scai.fraunhofer.de.
AD  - UCB Biosciences GmbH, Alfred-Nobel Str. 10, 40789, Monheim, Germany.
      holger.froehlich@scai.fraunhofer.de.
LA  - eng
GR  - U01 AG024904/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200703
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Alzheimer Disease/diagnostic imaging/genetics
MH  - *Bayes Theorem
MH  - Brain/diagnostic imaging
MH  - Cohort Studies
MH  - Computer Simulation
MH  - Databases, Factual/statistics & numerical data
MH  - *Deep Learning
MH  - Disease Progression
MH  - Humans
MH  - Longitudinal Studies
MH  - Models, Statistical
MH  - Parkinson Disease/diagnosis
MH  - Polymorphism, Single Nucleotide
MH  - Translational Research, Biomedical/*methods/statistics & numerical data
MH  - User-Computer Interface
PMC - PMC7335180
EDAT- 2020/07/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/05 06:00
PHST- 2019/01/02 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/07/05 06:00 [entrez]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-67398-4 [doi]
AID - 10.1038/s41598-020-67398-4 [pii]
PST - epublish
SO  - Sci Rep. 2020 Jul 3;10(1):10971. doi: 10.1038/s41598-020-67398-4.


PMID- 32620640
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20200713
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 40
IP  - 7
DP  - 2020 Jul
TI  - Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-)
      Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.
PG  - 3973-3981
LID - 10.21873/anticanres.14390 [doi]
AB  - BACKGROUND/AIM: HER2-positive breast cancers eventually relapse in about one
      third of patients. Is anti-HER2-directed therapy with Herceptin(R) (trastuzumab) 
      effective in re-treatment? Between 2008 and 2018, 216 patients with recurrent
      HER2-positive breast cancer (BC) were re-treated with Herceptin (HER) during
      first-line therapy. This study assessed the effectiveness and tolerability of
      re-treatment with HER. PATIENTS AND METHODS: After approval from Ethical
      committee, the NIS was conducted according to German Drug Act. Re-treatment with 
      HER was documented at routine visits starting with a basic observational period
      of maximum 12 months and a follow-up period of maximum additional four years.
      RESULTS: HER2-positive BC relapsed after a median of 36.5 months (mos). Patients 
      were re-treated with HER +/- chemotherapy +/- endocrine therapy. HER-containing
      regimens resulted in median progression-free survival (mPFS) of 12.7
      (95%CI=10.5-14.8) mos and overall survival (OS-2) of 31.6 mos (95%CI=28.8-38.4)
      since recurrence diagnosis. Differentiation of recurrence types (local, visceral,
      non-visceral) unfolded worst prognosis for patients with visceral metastases.
      Cardiac monitoring within this non-interventional study (NIS) did not result in
      new safety concerns. CONCLUSION: Re-therapy with HER in the first-line setting of
      advanced HER2-positive breast cancer is effective and without unexpected or
      intensified adverse events.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Hanker, Lars Christian
AU  - Hanker LC
AD  - Gynecology and Obstetrics Department, University of Schleswig-Holstein, Campus
      Lubeck, Lubeck, Germany Lars.Hanker@uksh.de.
FAU - FOrster, Frank
AU  - FOrster F
AD  - Center for Gynecological Oncology and Palliative Medicine, University of Applied 
      Sciences, Chemnitz, Germany.
FAU - SchrOder, Jan
AU  - SchrOder J
AD  - Hematology and Oncology Practice, Mulheim an der Ruhr, Germany.
FAU - Grafe, Andrea
AU  - Grafe A
AD  - Health Care Center Nordhausen gGmbH, Nordhausen, Germany.
FAU - Hitschold, Thomas
AU  - Hitschold T
AD  - Klinikum Worms gGmbH, Worms, Germany.
FAU - Hesse, Tobias
AU  - Hesse T
AD  - Gynecology Department, Agaplesion Diakonieklinikum, Rotenburg an der Wumme,
      Germany.
FAU - Lattrich, Claus Richard
AU  - Lattrich CR
AD  - Roche Pharma AG, Grenzach, Germany.
FAU - Rody, Achim
AU  - Rody A
AD  - Gynecology and Obstetrics Department, University of Schleswig-Holstein, Campus
      Lubeck, Lubeck, Germany.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality/pathology
MH  - Progression-Free Survival
MH  - Proportional Hazards Models
MH  - Receptor, ErbB-2/*antagonists & inhibitors
MH  - Retreatment
MH  - Trastuzumab/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - HER2-positive
OT  - metastatic breast cancer
OT  - re-therapy
OT  - trastuzumab
EDAT- 2020/07/06 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/05 06:00 [entrez]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 40/7/3973 [pii]
AID - 10.21873/anticanres.14390 [doi]
PST - ppublish
SO  - Anticancer Res. 2020 Jul;40(7):3973-3981. doi: 10.21873/anticanres.14390.


PMID- 32620593
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20201218
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Sep
TI  - Refusal of viral testing during the SARS-CoV-2 pandemic.
PG  - e163-e164
LID - 10.7861/clinmed.2020-0388 [doi]
AB  - Widespread testing for the respiratory syndrome coronavirus-2 (SARS-CoV-2) will
      represent an important part of any strategy designed to safely reopen societies
      from lockdown. Healthcare settings have the potential to become reservoirs of
      infectivity, and therefore many hospital trusts are beginning to carry out
      routine screening of staff and patients. This could promote the effective
      cohorting of patients and reduce the rate of nosocomial infection. However, for
      various reasons, some individuals may refuse this testing. Here we highlight this
      as an emergent ethicolegal issue which we expect to become increasingly relevant 
      as testing becomes ubiquitous. We explore this position from an ethical and legal
      perspective, determining whether refusal of testing is acceptable under UK law.
      Individual patients refusing testing could undermine a hospital's testing
      strategy; therefore clinicians and policy makers must prospectively determine the
      best course of action if this were to occur.
CI  - (c) Royal College of Physicians 2020. All rights reserved.
FAU - McDermott, John H
AU  - McDermott JH
AD  - Manchester Centre for Genomic Medicine, Manchester, UK and University of
      Manchester, Manchester, UK john.mcdermott2@mft.nhs.uk.
FAU - Newman, William G
AU  - Newman WG
AD  - Manchester Centre for Genomic Medicine, Manchester, UK and University of
      Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200703
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques/*statistics & numerical data
MH  - Coronavirus Infections/*diagnosis/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Screening/organization & administration
MH  - Pandemics/*prevention & control/statistics & numerical data
MH  - Patient Compliance/*statistics & numerical data
MH  - Pneumonia, Viral/*diagnosis/*epidemiology
MH  - Refusal to Participate/statistics & numerical data
MH  - Risk Assessment
MH  - Severe Acute Respiratory Syndrome/*prevention & control
MH  - United Kingdom
PMC - PMC7539710
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *Testing
OT  - *ethics
EDAT- 2020/07/06 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - clinmed.2020-0388 [pii]
AID - 10.7861/clinmed.2020-0388 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2020 Sep;20(5):e163-e164. doi: 10.7861/clinmed.2020-0388. Epub
      2020 Jul 3.


PMID- 32620487
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20210110
IS  - 1532-8422 (Electronic)
IS  - 1053-0770 (Linking)
VI  - 34
IP  - 10
DP  - 2020 Oct
TI  - Cardiopulmonary Resuscitation in Intensive Care Unit Patients With Coronavirus
      Disease 2019.
PG  - 2595-2603
LID - S1053-0770(20)30514-0 [pii]
LID - 10.1053/j.jvca.2020.06.008 [doi]
AB  - Cardiopulmonary resuscitation (CPR) in patients with severe acute respiratory
      syndrome coronavirus-2-associated disease (coronavirus disease 2019) poses a
      unique challenge to health- care providers due to the risk of viral
      aerosolization and disease transmission. This has caused some centers to modify
      existing CPR procedures, limit the duration of CPR, or consider avoiding CPR
      altogether. In this review, the authors propose a procedure for CPR in the
      intensive care unit that minimizes the number of personnel in the immediate
      vicinity of the patient and conserves the use of scarce personal protective
      equipment. Highlighting the low likelihood of successful resuscitation in
      high-risk patients may prompt patients to decline CPR. The authors recommend the 
      preemptive placement of central venous lines in high-risk patients with
      intravenous tubing extensions that allow for medication delivery from outside the
      patients' rooms. During CPR, this practice can be used to deliver critical
      medications without delay. The use of a mechanical compression system for CPR
      further reduces the risk of infectious exposure to health- care providers.
      Extracorporeal membrane oxygenation should be reserved for patients with few
      comorbidities and a single failing organ system. Reliable teleconferencing tools 
      are essential to facilitate communication between providers inside and outside
      the patients' rooms. General principles regarding the ethics and
      peri-resuscitative management of coronavirus 2019 patients also are discussed.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Cheruku, Sreekanth
AU  - Cheruku S
AD  - Department of Anesthesiology and Pain Management, UT Southwestern Medical Center,
      Dallas, TX. Electronic address: Sreekanth.Cheruku@UTSouthwestern.edu.
FAU - Dave, Siddharth
AU  - Dave S
AD  - Department of Anesthesiology and Pain Management, UT Southwestern Medical Center,
      Dallas, TX.
FAU - Goff, Kristina
AU  - Goff K
AD  - Department of Anesthesiology and Pain Management, UT Southwestern Medical Center,
      Dallas, TX.
FAU - Park, Caroline
AU  - Park C
AD  - Department of Surgery, UT Southwestern Medical Center, Dallas, TX.
FAU - Ebeling, Callie
AU  - Ebeling C
AD  - Department of Anesthesiology and Pain Management, UT Southwestern Medical Center,
      Dallas, TX.
FAU - Cohen, Leah
AU  - Cohen L
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
FAU - Styrvoky, Kim
AU  - Styrvoky K
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
FAU - Choi, Christopher
AU  - Choi C
AD  - Department of Anesthesiology and Pain Management, UT Southwestern Medical Center,
      Dallas, TX.
FAU - Anand, Vikram
AU  - Anand V
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
FAU - Kershaw, Corey
AU  - Kershaw C
AD  - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200610
PL  - United States
TA  - J Cardiothorac Vasc Anesth
JT  - Journal of cardiothoracic and vascular anesthesia
JID - 9110208
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiopulmonary Resuscitation/*methods/standards
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Critical Care/*methods/standards
MH  - Heart Arrest/epidemiology/*therapy
MH  - Humans
MH  - *Intensive Care Units/standards
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - SARS-CoV-2
MH  - Workflow
PMC - PMC7286272
OTO - NOTNLM
OT  - *COVID-19
OT  - *cardiopulmonary resuscitation
OT  - *coronavirus
OT  - *coronavirus disease 2019
OT  - *critical care
OT  - *do-not-resuscitate
OT  - *mechanical compression device
OT  - *pandemic
OT  - *personal protection equipment
EDAT- 2020/07/06 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - S1053-0770(20)30514-0 [pii]
AID - 10.1053/j.jvca.2020.06.008 [doi]
PST - ppublish
SO  - J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2595-2603. doi:
      10.1053/j.jvca.2020.06.008. Epub 2020 Jun 10.


PMID- 32620317
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 2
DP  - 2020 Aug
TI  - [National recommendations on pediatric donation].
PG  - 134.e1-134.e9
LID - S1695-4033(20)30186-7 [pii]
LID - 10.1016/j.anpedi.2020.04.024 [doi]
AB  - Despite being an international reference in donation and transplantation, Spain
      needs to improve pediatric donation, including donation after the circulatory
      determination of death. The present article, a summary of the consensus report
      prepared by the Organizacion Nacional de Trasplantes and the Spanish Pediatrics
      Association, intends the facilitation of donation procedures in newborns and
      children and the analysis of associated ethical dilemma. The ethical basis for
      donation in children, the principles of clinical assessment of possible donors,
      the criteria for the determination of death in children, intensive care
      management of donors, basic concepts of donation after the circulatory
      determination of death and the procedures for donation in newborns with severe
      nervous system's malformation incompatible with life, as well as in children
      receiving palliative care are commented. Systematically considering the donation 
      of organs and tissues when a child dies in conditions consistent with donation is
      an ethical imperative and must become an ethical standard, not only because of
      the need of organs for transplantation, but also to ensure family centered care.
CI  - Copyright (c) 2020 Asociacion Espanola de Pediatria. Publicado por Elsevier
      Espana, S.L.U. All rights reserved.
FAU - Rodriguez Nunez, Antonio
AU  - Rodriguez Nunez A
AD  - Seccion de Pediatria Critica, Cuidados Intermedios y Paliativos Pediatricos,
      Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela,
      A Coruna, Espana. Electronic address: Antonio.Rodriguez.Nunez@sergas.es.
FAU - Perez Blanco, Alicia
AU  - Perez Blanco A
AD  - Organizacion Nacional de Trasplantes, Madrid, Espana.
CN  - Grupo de Trabajo de la AEP-ONT
CN  - Miembros del Grupo de Trabajo de la AEP-ONT, por orden alfabetico
LA  - spa
PT  - Journal Article
TT  - Recomendaciones nacionales sobre donacion pediatrica.
DEP - 20200630
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
SB  - IM
MH  - Child
MH  - Death
MH  - Humans
MH  - Infant, Newborn
MH  - Organ Transplantation/ethics/*methods
MH  - Pediatrics/ethics
MH  - Spain
MH  - *Tissue Donors/ethics
MH  - Tissue and Organ Procurement/ethics/*methods
PMC - PMC7326462
OTO - NOTNLM
OT  - Adecuacion de medidas terapeuticas
OT  - Asistolia controlada
OT  - Brain death
OT  - Children
OT  - Consentimiento informado
OT  - Cuidados centrados en la familia
OT  - Cuidados paliativos
OT  - Donacion de organos
OT  - Donation after the circulatory determination of death
OT  - Ethics
OT  - Family-centered care
OT  - Muerte encefalica
OT  - Neonatos
OT  - Newborns
OT  - Ninos
OT  - Organ donation
OT  - Palliative care
OT  - Surrogate consent
OT  - Transplantation
OT  - Trasplante
OT  - Withholding and withdrawal of life sustaining measures
OT  - Etica
IR  - Balcells Ramirez J
FIR - Balcells Ramirez, Joan
IR  - Bajo Rodilla R
FIR - Bajo Rodilla, Rebeca
IR  - Blanco Bravo D
FIR - Blanco Bravo, Dorotea
IR  - Camarena Grande C
FIR - Camarena Grande, Carmen
IR  - Caro Portela I
FIR - Caro Portela, Isabel
IR  - Caserio Carbonero S
FIR - Caserio Carbonero, Sonia
IR  - Dominguez-Gil Gonzalez B
FIR - Dominguez-Gil Gonzalez, Beatriz
IR  - Escrig Fernandez R
FIR - Escrig Fernandez, Raquel
IR  - Estebanez Montiel B
FIR - Estebanez Montiel, Belen
IR  - Galan Torres J
FIR - Galan Torres, Juan
IR  - Gomez Saez F
FIR - Gomez Saez, Fernando
IR  - Gordillo Brenes A
FIR - Gordillo Brenes, Antonio
IR  - Luis Lopez Del Moral Echevarria J
FIR - Luis Lopez Del Moral Echevarria, Jose
IR  - Navarro Mingorance A
FIR - Navarro Mingorance, Alvaro
IR  - Nieto Moro M
FIR - Nieto Moro, Montserrat
IR  - Perez Blanco A
FIR - Perez Blanco, Alicia
IR  - Perez Montejano R
FIR - Perez Montejano, Ruth
IR  - Pont Castellana T
FIR - Pont Castellana, Teresa
IR  - Rodriguez Nunez A
FIR - Rodriguez Nunez, Antonio
IR  - Vidal Tobar C
FIR - Vidal Tobar, Cristina
EDAT- 2020/07/06 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/07/05 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
AID - S1695-4033(20)30186-7 [pii]
AID - 10.1016/j.anpedi.2020.04.024 [doi]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Aug;93(2):134.e1-134.e9. doi:
      10.1016/j.anpedi.2020.04.024. Epub 2020 Jun 30.


PMID- 32620019
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 2511-705X (Electronic)
IS  - 0026-1270 (Linking)
VI  - 59
IP  - S 01
DP  - 2020 Jun
TI  - From Raw Data to FAIR Data: The FAIRification Workflow for Health Research.
PG  - e21-e32
LID - 10.1055/s-0040-1713684 [doi]
AB  - BACKGROUND: FAIR (findability, accessibility, interoperability, and reusability) 
      guiding principles seek the reuse of data and other digital research input,
      output, and objects (algorithms, tools, and workflows that led to that data)
      making them findable, accessible, interoperable, and reusable. GO FAIR - a
      bottom-up, stakeholder driven and self-governed initiative - defined a seven-step
      FAIRification process focusing on data, but also indicating the required work for
      metadata. This FAIRification process aims at addressing the translation of raw
      datasets into FAIR datasets in a general way, without considering specific
      requirements and challenges that may arise when dealing with some particular
      types of data. OBJECTIVES: This scientific contribution addresses the
      architecture design of an open technological solution built upon the
      FAIRification process proposed by "GO FAIR" which addresses the identified gaps
      that such process has when dealing with health datasets. METHODS: A common
      FAIRification workflow was developed by applying restrictions on existing steps
      and introducing new steps for specific requirements of health data. These
      requirements have been elicited after analyzing the FAIRification workflow from
      different perspectives: technical barriers, ethical implications, and legal
      framework. This analysis identified gaps when applying the FAIRification process 
      proposed by GO FAIR to health research data management in terms of data curation,
      validation, deidentification, versioning, and indexing. RESULTS: A technological 
      architecture based on the use of Health Level Seven International (HL7) FHIR
      (fast health care interoperability resources) resources is proposed to support
      the revised FAIRification workflow. DISCUSSION: Research funding agencies all
      over the world increasingly demand the application of the FAIR guiding principles
      to health research output. Existing tools do not fully address the identified
      needs for health data management. Therefore, researchers may benefit in the
      coming years from a common framework that supports the proposed FAIRification
      workflow applied to health datasets. CONCLUSION: Routine health care datasets or 
      data resulting from health research can be FAIRified, shared and reused within
      the health research community following the proposed FAIRification workflow and
      implementing technical architecture.
CI  - Georg Thieme Verlag KG Stuttgart . New York.
FAU - Sinaci, A Anil
AU  - Sinaci AA
AD  - SRDC Software Research Development and Consultancy Corporation, Ankara, Turkey.
FAU - Nunez-Benjumea, Francisco J
AU  - Nunez-Benjumea FJ
AD  - Group of Research and Innovation in Biomedical Informatics, Biomedical
      Engineering and Health Economy, Institute of Biomedicine of Seville/Virgen del
      Rocio University Hospital/CSIC/University of Seville, Seville, Spain.
FAU - Gencturk, Mert
AU  - Gencturk M
AD  - SRDC Software Research Development and Consultancy Corporation, Ankara, Turkey.
FAU - Jauer, Malte-Levin
AU  - Jauer ML
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Braunschweig, Germany.
FAU - Deserno, Thomas
AU  - Deserno T
AD  - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and
      Hannover Medical School, Braunschweig, Germany.
FAU - Chronaki, Catherine
AU  - Chronaki C
AD  - Health Level Seven International Foundation, Brussels, Belgium.
FAU - Cangioli, Giorgio
AU  - Cangioli G
AD  - Health Level Seven International Foundation, Brussels, Belgium.
FAU - Cavero-Barca, Carlos
AU  - Cavero-Barca C
AD  - Atos, Group of Health, Atos Research and Innovation (ARI), Madrid, Spain.
FAU - Rodriguez-Perez, Juan M
AU  - Rodriguez-Perez JM
AD  - Atos, Group of Health, Atos Research and Innovation (ARI), Madrid, Spain.
FAU - Perez-Perez, Manuel M
AU  - Perez-Perez MM
AD  - Atos, Group of Health, Atos Research and Innovation (ARI), Madrid, Spain.
FAU - Laleci Erturkmen, Gokce B
AU  - Laleci Erturkmen GB
AD  - SRDC Software Research Development and Consultancy Corporation, Ankara, Turkey.
FAU - Hernandez-Perez, Tony
AU  - Hernandez-Perez T
AD  - Department of Library and Information Sciences, Universidad Carlos III de Madrid,
      Madrid, Spain.
FAU - Mendez-Rodriguez, Eva
AU  - Mendez-Rodriguez E
AD  - Department of Library and Information Sciences, Universidad Carlos III de Madrid,
      Madrid, Spain.
FAU - Parra-Calderon, Carlos L
AU  - Parra-Calderon CL
AD  - Group of Research and Innovation in Biomedical Informatics, Biomedical
      Engineering and Health Economy, Institute of Biomedicine of Seville/Virgen del
      Rocio University Hospital/CSIC/University of Seville, Seville, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - Germany
TA  - Methods Inf Med
JT  - Methods of information in medicine
JID - 0210453
SB  - IM
MH  - Access to Information
MH  - *Biomedical Research
MH  - Health Information Interoperability
MH  - Health Level Seven
MH  - *Information Management
MH  - Metadata
MH  - *Software Design
MH  - Workflow
COIS- A.A.S. reports grants from EU H2020 Program, during the conduct of the study.
EDAT- 2020/07/04 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1055/s-0040-1713684 [doi]
PST - ppublish
SO  - Methods Inf Med. 2020 Jun;59(S 01):e21-e32. doi: 10.1055/s-0040-1713684. Epub
      2020 Jul 3.


PMID- 32619672
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1873-6513 (Electronic)
IS  - 0885-3924 (Linking)
VI  - 60
IP  - 5
DP  - 2020 Nov
TI  - Knowledge, Opinion, and Attitude About the Italian Law on Advance Directives: A
      Population-Based Survey.
PG  - 906-914.e4
LID - S0885-3924(20)30561-3 [pii]
LID - 10.1016/j.jpainsymman.2020.06.020 [doi]
AB  - CONTEXT: Advance directives are legal documents which individuals draw up to
      declare their treatment preferences and to appoint well-informed proxies to
      safeguard patient autonomy in critical situations when that individual is
      temporarily or no longer able to communicate these preferences. On December 22,
      2017, the Italian Parliament approved the first law on end of life ("Provisions
      for informed consent and advance directives" L.219/2017), after a heated public
      and political debate lasting almost 20 years. OBJECTIVE: The aim of this study
      was to investigate the awareness, knowledge, opinions, and attitudes regarding
      Italian Law 219/2017 and advance directives among the Italian population 15
      months after its entry into force. METHODS: A nationwide population-based survey 
      was conducted by a certified public opinion survey company. A sample size of 2000
      interviews was planned. A structured questionnaire was developed to investigate
      awareness, opinions, and attitudes concerning the law by a multiprofessional
      research team. The agreed-on version was pretested on a sample of 70 selected
      participants. RESULTS: The sample included 2000 valid interviews; 70.1% of
      respondents declared they had heard about the law on informed consent and advance
      directives. Respondents were asked to express their overall opinion on the law's 
      utility and importance: 88% declared that the law was quite or very important and
      76% had a positive attitude toward making/registering advance directives.
      CONCLUSION: The principles of Italian Law 219/2017 are aligned with the ethical
      sentiment of the vast majority of the Italian population. It is crucial to
      stimulate discussion to increase knowledge and awareness to increase the number
      of advance directives.
CI  - Copyright (c) 2020 American Academy of Hospice and Palliative Medicine. Published
      by Elsevier Inc. All rights reserved.
FAU - De Panfilis, Ludovica
AU  - De Panfilis L
AD  - Unit of Bioethics, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
      Electronic address: ludovica.depanfilis@ausl.re.it.
FAU - Rossi, Paolo Giorgi
AU  - Rossi PG
AD  - Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Mazzini, Elisa
AU  - Mazzini E
AD  - Medical Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Pistolesi, Luca
AU  - Pistolesi L
AD  - Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
FAU - Ghirotto, Luca
AU  - Ghirotto L
AD  - Unit of Qualitative Research, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, 
      Italy.
FAU - Noto, Antonio
AU  - Noto A
AD  - Noto Sondaggi, Roma, Italy.
FAU - Cuocolo, Sandra
AU  - Cuocolo S
AD  - Noto Sondaggi, Roma, Italy.
FAU - Costantini, Massimo
AU  - Costantini M
AD  - Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - United States
TA  - J Pain Symptom Manage
JT  - Journal of pain and symptom management
JID - 8605836
SB  - IM
MH  - *Advance Directives
MH  - Attitude
MH  - Humans
MH  - *Informed Consent
MH  - Italy
MH  - Proxy
OTO - NOTNLM
OT  - *Advance directives
OT  - *ethics
OT  - *informed consent
OT  - *survey
EDAT- 2020/07/04 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - S0885-3924(20)30561-3 [pii]
AID - 10.1016/j.jpainsymman.2020.06.020 [doi]
PST - ppublish
SO  - J Pain Symptom Manage. 2020 Nov;60(5):906-914.e4. doi:
      10.1016/j.jpainsymman.2020.06.020. Epub 2020 Jun 30.


PMID- 32619299
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20211204
IS  - 1573-2770 (Electronic)
IS  - 0091-0562 (Linking)
VI  - 66
IP  - 3-4
DP  - 2020 Dec
TI  - Muxeres en Accion: The Power of Community Cultural Wealth in Latinas Organizing
      for Health Equity.
PG  - 314-324
LID - 10.1002/ajcp.12442 [doi]
AB  - Community psychology, despite its commitment to social justice, is prone to
      engage in deficit-based perspectives that do not appropriately capture the
      strengths of Latinx communities. Given these limitations, we use a Community
      Cultural Wealth (CCW) (Yosso, 2005) framework to describe how muxeres, Latina
      women who identify as promotoras, madres, and mamas, leveraged their political
      power and culturally informed leadership to improve the health and well-being of 
      their communities. We highlight instances from our fieldwork, witnessing the
      agency of muxeres en accion for health equity. We offer three case studies to
      describe how we approached our collaborations with three groups of muxeres
      situated in different geographic locations in the state of California. The first 
      case study discusses how immigrant muxeres who identify as promotoras (e.g.,
      health workers) in the Central Valley developed their research skills through a
      promotora model that allowed them to build the capacity to advocate for the
      well-being of their communities. The second example offers reflections from a
      Community-Based Participatory Action Research (CBPAR) project with a group of
      Mexican immigrant madres in a gentrified community in San Jose. Lastly, the third
      case study describes how a group of mamas in the East Side of Los Angeles
      addressed issues of educational inequities. Together, these case studies
      illustrate muxeres' advocacy for their health and well-being. Because women in
      general, and muxeres in particular, are considered gatekeepers of culture and
      tradition within their families, it is crucial that community psychologists
      ground their work in ethically and culturally appropriate frameworks that
      highlight the power of muxeres.
CI  - (c) 2020 Society for Community Research and Action.
FAU - Fernandez, Jesica Siham
AU  - Fernandez JS
AUID- ORCID: 0000-0002-5513-7413
AD  - Ethnic Studies Department, Santa Clara University, Santa Clara, CA, USA.
FAU - Guzman, Bianca L
AU  - Guzman BL
AD  - California State University Los Angeles, Los Angeles, CA, USA.
FAU - Bernal, Ireri
AU  - Bernal I
AD  - California State University Los Angeles, Los Angeles, CA, USA.
FAU - Flores, Yvette G
AU  - Flores YG
AD  - University of California Davis, Davis, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - England
TA  - Am J Community Psychol
JT  - American journal of community psychology
JID - 0364535
SB  - IM
MH  - California
MH  - Community-Based Participatory Research
MH  - Emigrants and Immigrants
MH  - Female
MH  - *Health Equity
MH  - *Health Promotion
MH  - *Hispanic or Latino
MH  - Humans
OTO - NOTNLM
OT  - *Community cultural wealth
OT  - *Community-based participatory action research
OT  - *Health
OT  - *Latinas
OT  - *Well-being
EDAT- 2020/07/04 06:00
MHDA- 2021/09/10 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1002/ajcp.12442 [doi]
PST - ppublish
SO  - Am J Community Psychol. 2020 Dec;66(3-4):314-324. doi: 10.1002/ajcp.12442. Epub
      2020 Jul 3.


PMID- 32619233
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 7
DP  - 2020 Jul 1
TI  - Risk of bowel fistula following surgical management of deep endometriosis of the 
      rectosigmoid: a series of 1102 cases.
PG  - 1601-1611
LID - 10.1093/humrep/deaa131 [doi]
AB  - STUDY QUESTION: What are the risk factors and prevalence of bowel fistula
      following surgical management of deep endometriosis infiltrating the rectosigmoid
      and how can it be managed? SUMMARY ANSWER: In patients managed for deep
      endometriosis of the rectosigmoid, risk of fistula is increased by bowel opening 
      during both segmental colorectal resection and disc excision and rectovaginal
      fistula repair is more challenging than for bowel leakage. WHAT IS KNOWN ALREADY:
      Bowel fistula is known to be a severe complication of colorectal endometriosis
      surgery; however, there is little available data on its prevalence in large
      series or on specific management. STUDY DESIGN, SIZE, DURATION: A retrospective
      study employing data prospectively recorded in the North-West Inter Regional
      Female Cohort for Patients with Endometriosis (CIRENDO) from June 2009 to May
      2019, in three tertiary referral centres. PARTICIPANTS/MATERIALS, SETTING,
      METHODS: One thousand one hundred and two patients presenting with deep
      endometriosis infiltrating the rectosigmoid, who were managed by shaving, disc
      excision or colorectal resection. The prevalence of bowel fistula was assessed,
      and factors related to the complication and its surgical management. MAIN RESULTS
      AND THE ROLE OF CHANCE: Of 1102 patients enrolled in the study, 52.5% had a past 
      history of gynaecological surgery and 52.7% had unsuccessfully attempted to
      conceive for over 12 months. Digestive tract subocclusion/occlusion was recorded 
      in 12.7%, hydronephrosis in 4.5% and baseline severe bladder dysfunction in 1.5%.
      An exclusive laparoscopic approach was carried out in 96.8% of patients. Rectal
      shaving was performed in 31.9%, disc excision in 23.1%, colorectal resection in
      35.8% and combined disc excision and sigmoid colon resection in 2.9%. For various
      reasons, the nodule was not completely removed in 6.4%, while in 7.2% of cases
      complementary procedures on the ileum, caecum and right colon were required.
      Parametrium excision was performed in 7.8%, dissection and excision of sacral
      roots in 4%, and surgery for ureteral endometriosis in 11.9%. Diverting stoma was
      performed in 21.8%. Thirty-seven patients presented with bowel fistulae (3.4%) of
      whom 23 (62.2%) were found to have rectovaginal fistulae and 14 (37.8%) leakage. 
      Logistic regression model showed rectal lumen opening to increase risk of fistula
      when compared with shaving, regardless of nodule size: adjusted odds ratio (95%
      CI) for disc excision, colorectal resection and association of disc excision +
      segmental resection was 6.8 (1.9-23.8), 4.8 (1.4-16.9) and 11 (2.1-58.6),
      respectively. Repair of 23 rectovaginal fistulae required 1, 2, 3 or 4 additional
      surgical procedures in 12 (52.2%), 8 (34.8%), 2 (8.7%) and 1 patient (4.3%),
      respectively. Repair of leakage in 14 patients required 1 procedure (stoma) in 12
      cases (85.7%) and a second procedure (colorectal resection) in 2 cases (14.3%).
      All patients, excepted five women managed by delayed coloanal anastomosis,
      underwent a supplementary surgical procedure for stoma repair. The period of time
      required for diverting stoma following repair of rectovaginal fistulae was
      significantly longer than for repair of leakages (median values 10 and 5 months, 
      respectively, P = 0.008). LIMITATIONS, REASONS FOR CAUTION: The main limits
      relate to the heterogeneity of techniques used in removal of rectosigmoid nodules
      and repairing fistulae, the lack of accurate information about the level of
      nodules, the small number of centres and that a majority of patients were managed
      by one surgeon. WIDER IMPLICATIONS OF THE FINDINGS: Deep endometriosis
      infiltrating the rectosigmoid can be managed laparoscopically with a relatively
      low risk of bowel fistula. When the type of bowel procedure can be chosen,
      performance of shaving instead of disc excision or colorectal resection is
      suggested considering the lower risk of bowel fistula. Rectovaginal fistula
      repair is more challenging than for bowel leakage and may require up to four
      additional surgical procedures. STUDY FUNDING/COMPETING INTEREST(S): CIRENDO is
      financed by the G4 Group (The University Hospitals of Rouen, Lille, Amiens and
      Caen) and the ROUENDOMETRIOSE Association. No financial support was received for 
      this study. H.R. reports personal fees from ETHICON, Plasma Surgical, Olympus and
      Nordic Pharma outside the submitted work. The other authors declare no conflict
      of interests related to this topic.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology.
FAU - Roman, Horace
AU  - Roman H
AD  - Endometriosis Center, Clinique Tivoli-Ducos, Bordeaux, France.
AD  - Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus,
      Denmark.
FAU - Bridoux, Valerie
AU  - Bridoux V
AD  - Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
FAU - Merlot, Benjamin
AU  - Merlot B
AD  - Endometriosis Center, Clinique Tivoli-Ducos, Bordeaux, France.
FAU - Resch, Benoit
AU  - Resch B
AD  - Department of Gynecology and Obstetrics, Rouen University Hospital, Rouen,
      France.
AD  - Clinique Mathilde, Rouen, France.
FAU - Chati, Rachid
AU  - Chati R
AD  - Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
FAU - Coget, Julien
AU  - Coget J
AD  - Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
FAU - Forestier, Damien
AU  - Forestier D
AD  - Endometriosis Center, Clinique Tivoli-Ducos, Bordeaux, France.
FAU - Tuech, Jean-Jacques
AU  - Tuech JJ
AD  - Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Colon
MH  - *Endometriosis/complications/surgery
MH  - Female
MH  - Humans
MH  - *Laparoscopy
MH  - Postoperative Complications/epidemiology/etiology
MH  - *Rectal Diseases/etiology/surgery
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7368398
OTO - NOTNLM
OT  - *bowel suture
OT  - *deep endometriosis
OT  - *disc excision
OT  - *fistula
OT  - *full-thickness excision
OT  - *rectovaginal fistula
OT  - *rectum
OT  - *sigmoid colon
EDAT- 2020/07/04 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/01/11 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 5867021 [pii]
AID - 10.1093/humrep/deaa131 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Jul 1;35(7):1601-1611. doi: 10.1093/humrep/deaa131.


PMID- 32619222
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - The Unfinished Business of Respect for Autonomy: Persons, Relationships, and
      Nonhuman Animals.
PG  - 521-539
LID - 10.1093/jmp/jhaa016 [doi]
AB  - This essay explores three issues in respect for autonomy that pose unfinished
      business for the concept. By this, I mean that the dialogue over them is ongoing 
      and essentially unresolved. These are: (1) whether we ought to respect persons or
      their autonomous choices; (2) the role of relational autonomy; and (3) whether
      nonhuman animals can be autonomous. In attending to this particular set of
      unfinished business, I highlight some critical moral work left aside by the
      concept of respect for autonomy as understood in Beauchamp and Childress'
      Principles of Biomedical Ethics. Specifically, while significant pragmatic
      traction is gained by the authors' focus on autonomous choice, carving such a
      focus out from the broader questions of moral respect and the autonomy of the
      person leaves aside a number of questions that we might have thought a view about
      respect for autonomy in biomedicine ought to answer. These include: How should
      physicians respond when autonomous patients make decisions that appear
      nonautonomous? What is the impact of the view that autonomy is "relational" for
      cross-cultural differences in how autonomy is respected? If chimpanzees (and by
      extension young children) can be autonomous, what does that mean for how they
      should be treated?
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Walker, Rebecca L
AU  - Walker RL
AD  - University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - Animals
MH  - *Bioethics
MH  - Cultural Characteristics
MH  - *Decision Making
MH  - Humans
MH  - Interpersonal Relations
MH  - Morals
MH  - Pan troglodytes
MH  - *Personal Autonomy
MH  - Relational Autonomy
MH  - Respect
OTO - NOTNLM
OT  - *chimpanzees
OT  - *decisional capacity
OT  - *principles
OT  - *relational autonomy
OT  - *respect for persons
EDAT- 2020/07/04 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 5867123 [pii]
AID - 10.1093/jmp/jhaa016 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):521-539. doi: 10.1093/jmp/jhaa016.


PMID- 32619195
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 48
IP  - 6
DP  - 2020 Jul 28
TI  - Antenatal survey of women's birthing choices in Qatar.
PG  - 589-599
LID - 10.1515/jpm-2020-0148 [doi]
AB  - Objectives Attitudes towards labour care and women's choices for their preferred 
      mode of delivery are documented in studies from the around the world, however
      less is known about women's birth choices in the Middle East. This study was
      designed with the aim of exploring beliefs and attitudes in this region. Methods 
      Voluntary participation in an ethics-approved survey was offered to pregnant
      women attending the antenatal clinic at Sidra Medicine from August 2018 to
      January 2019 with no exclusion criteria. Results Of the 346 respondents, 58.1%
      were Arabic and the remainder expatriates. This group composition allowed
      comparison between women native and non-native to the Gulf region. Arabic and
      non-Arabic women differed significantly in previous birth experiences: the Arabs 
      had had more doctor-led deliveries (45 vs. 34%), epidurals (56.6 vs. 45%) and
      episiotomies (65.7 vs. 54%). 70.2% of the respondents chose a normal delivery as 
      their preferred birth mode though a smaller majority of the Arabic subgroup did
      (63.2 %). 60.4% preferred delivery by doctors and longer hospital stays (47.6),
      more so Arabic participants (64.7 and 68.6 %). Significantly less Arabs, would
      choose husbands as birth partners (51.2 vs. 86.2%) and more expressed a gender
      preference for doctors. Other group choices are presented. Conclusions Though
      women in this region made comparable choices about mode of delivery as their
      Western counterparts, they demonstrated an expectation of a culturally distinct
      and more medicalized approach to care in labour. The findings highlight the need 
      for further studies to inform regional obstetric care and health education
      interventions as well as tailoring maternity care services.
FAU - Mohan, Suruchi
AU  - Mohan S
AD  - Sidra Medicine, Qatar Foundation, Sidra Outpatient Building, Al Luqta Street,
      Education City North Campus, Doha, Qatar.
FAU - Ghani, Rauf
AU  - Ghani R
AD  - Women's Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar.
FAU - Lindow, Stephen
AU  - Lindow S
AD  - Sidra Medicine, Qatar Foundation, Sidra Outpatient Building, Al Luqta Street,
      Education City North Campus, Doha, Qatar.
FAU - Farrell, Tom
AU  - Farrell T
AD  - Women's Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
SB  - IM
MH  - Adult
MH  - Arabs
MH  - *Choice Behavior
MH  - Culture
MH  - Delivery, Obstetric/*methods
MH  - Female
MH  - Health Education
MH  - Health Knowledge, Attitudes, Practice/ethnology
MH  - Humans
MH  - *Maternal Health Services
MH  - Patient Satisfaction
MH  - Pregnancy
MH  - *Prenatal Care
MH  - Qatar
MH  - *Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - Qatar
OT  - birth choices
OT  - survey
EDAT- 2020/07/04 06:00
MHDA- 2021/06/11 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1515/jpm-2020-0148 [doi]
AID - jpm-2020-0148 [pii]
PST - ppublish
SO  - J Perinat Med. 2020 Jul 28;48(6):589-599. doi: 10.1515/jpm-2020-0148.


PMID- 32618919
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20210201
IS  - 1535-1386 (Electronic)
IS  - 0021-9355 (Linking)
VI  - 102
IP  - 13
DP  - 2020 Jul 1
TI  - Medical Ethics During a Public Health Crisis: COVID-19.
PG  - e71
LID - 10.2106/JBJS.20.00488 [doi]
FAU - White, Peter B
AU  - White PB
AUID- ORCID: 0000-0002-3168-6768
AD  - Department of Orthoepaedic Surgery, Donald and Barbara Zucker School of Medicine 
      at Hofstra/Northwell, Hempstead, New York.
FAU - Cohn, Randy M
AU  - Cohn RM
AUID- ORCID: 0000-0001-9876-1497
AD  - Department of Orthoepaedic Surgery, Donald and Barbara Zucker School of Medicine 
      at Hofstra/Northwell, Hempstead, New York.
FAU - Humbyrd, Casey Jo
AU  - Humbyrd CJ
AUID- ORCID: 0000-0001-9623-4212
AD  - Department of Orthopaedic Surgery, and the Berman Institute, Johns Hopkins
      University, Baltimore, Maryland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
SB  - IM
MH  - Arthroscopy
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/epidemiology/transmission
MH  - *Ethics, Medical
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pandemics/*ethics
MH  - Perioperative Care
MH  - Pneumonia, Viral/epidemiology/transmission
MH  - Public Health/*ethics
MH  - Rotator Cuff Injuries/diagnostic imaging/*surgery
MH  - SARS-CoV-2
MH  - Telemetry
EDAT- 2020/07/04 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.2106/JBJS.20.00488 [doi]
AID - 00004623-202007010-00013 [pii]
PST - ppublish
SO  - J Bone Joint Surg Am. 2020 Jul 1;102(13):e71. doi: 10.2106/JBJS.20.00488.


PMID- 32618689
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 48
IP  - 9
DP  - 2020 Sep
TI  - Conflict Management in the ICU.
PG  - 1349-1357
LID - 10.1097/CCM.0000000000004440 [doi]
AB  - OBJECTIVES: To provide a concise review of data and literature pertaining to the 
      etiologies of conflict in the ICU, as well as current approaches to conflict
      management. DATA SOURCES: Detailed search strategy using PubMed and OVID Medline 
      for English language articles describing conflict in the ICU as well as
      prevention and management strategies. STUDY SELECTION: Descriptive and
      interventional studies addressing conflict, bioethics, clinical ethics
      consultation, palliative care medicine, conflict management, and conflict
      mediation in critical care. DATA EXTRACTION: Relevant descriptions or studies
      were reviewed, and the following aspects of each manuscript were identified,
      abstracted, and analyzed: setting, study population, aims, methods, results, and 
      relevant implications for critical care practice and training. DATA SYNTHESIS:
      Conflict frequently erupts in the ICU between patients and families and care
      teams, as well as within and between care teams. Conflict engenders a host of
      untoward consequences for patients, families, clinicians, and facilities
      rendering abrogating conflict a key priority for all. Conflict etiologies are
      diverse but understood in terms of a framework of triggers. Identifying and
      de-escalating conflict before it become intractable is a preferred approach.
      Approaches to conflict management include utilizing clinical ethics consultation,
      and palliative care medicine clinicians. Conflict Management is a new technique
      that all ICU clinicians may use to identify and manage conflict. Entrenched
      conflict appears to benefit from Bioethics Mediation, an approach that uses a
      neutral, unaligned mediator to guide parties to a mutually acceptable resolution.
      CONCLUSIONS: Conflict commonly occurs in the ICU around difficult and complex
      decision-making. Patients, families, clinicians, and institutions suffer
      undesirable consequences resulting from conflict, establishing conflict
      prevention and resolution as key priorities. A variety of approaches may
      successfully identify, manage, and prevent conflict including techniques that are
      utilizable by all team members in support of clinical excellence.
FAU - Kayser, Joshua B
AU  - Kayser JB
AD  - Division of Pulmonary, Allergy and Critical Care, Department of Medicine,
      Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA.
AD  - Section of Medical Critical Care, Department of Medicine, Corporal Michael J.
      Crescenz VA Medical Center, Philadelphia, PA.
AD  - Division of Trauma, Surgical Critical Care and Emergency Surgery, Department of
      Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
      PA.
AD  - Section of Surgical Critical Care, Department of Surgery, Corporal Michael J
      Crescenz VA Medical Center, Philadelphia, PA.
FAU - Kaplan, Lewis J
AU  - Kaplan LJ
AD  - Division of Trauma, Surgical Critical Care and Emergency Surgery, Department of
      Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
      PA.
AD  - Section of Surgical Critical Care, Department of Surgery, Corporal Michael J
      Crescenz VA Medical Center, Philadelphia, PA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
SB  - IM
MH  - Critical Care/*organization & administration
MH  - Dissent and Disputes
MH  - Ethics, Medical
MH  - Group Processes
MH  - Humans
MH  - Intensive Care Units/*organization & administration
MH  - Negotiating/*methods/psychology
MH  - Palliative Care/*organization & administration
MH  - Patient Care Team/organization & administration
EDAT- 2020/07/04 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1097/CCM.0000000000004440 [doi]
AID - 00003246-202009000-00014 [pii]
PST - ppublish
SO  - Crit Care Med. 2020 Sep;48(9):1349-1357. doi: 10.1097/CCM.0000000000004440.


PMID- 32618602
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jul/Aug
TI  - Self-Medicating for Pain: A Public Health Perspective.
PG  - e387-e391
LID - 10.1097/MJT.0000000000001173 [doi]
AB  - BACKGROUND: Pain is one of the symptoms for which any man is willing not only to 
      go to the doctor but also to resort to any means, including self-medication, to
      "get rid" of it. Self-medication is not only a current practice but also a public
      health problem, under the circumstances that it can influence the way in which a 
      disease is diagnosed and/or treated in a timely manner, and, consequently,
      repercussions may occur on the cost of treatment, in the case of severe forms.
      Pain is a vital symptom, and the diminution until the disappearance of pain is a 
      fundamental right of each individual; the analysis of ethical issues in the case 
      of self-administration of analgesic medication has not been a major concern.
      AREAS OF UNCERTAINTY: Understanding the problem is important to realize whether
      self-medicating for pain is a necessity or an abuse, and in this respect, we
      review scientific articles from international databases: PubMed and ProQuest.
      DATA SOURCES: The study is based on the consultation of scientific articles from 
      international databases-PubMed and ProQuest, the main keywords in the search
      being pain and self-medication, to which a stigma or public health is
      sequentially added. RESULTS: Pain is becoming more and more a global problem and 
      the extent of its spread can substantiate our assertion about pathology with
      pandemic impact. Under the pressure of patient associations, of the media, and of
      nonmedical authorities, the opinion about the need for a stoic approach to pain
      has long become an outdated theory, and chronic pain, beyond a multidimensional
      approach, is increasingly considered not only a useless element but also even a
      destructive one. CONCLUSIONS: Pain and self-medication must be addressed,
      including in medical practice, starting from their multidimensionality from the
      following perspectives: medicobiological, sociocultural, instructive-educational,
      legal-political, and especially ethical. They are not only individual health
      problems but also become, when connected with a stigma, a public health problem.
FAU - Rogozea, Liliana
AU  - Rogozea L
AD  - Basic, Preventive and Clinical Sciences Department, Transilvania University of
      Brasov, Faculty of Medicine, Brasov, Romania.
FAU - Dinu, Eleonora A
AU  - Dinu EA
FAU - Constantin, Dan
AU  - Constantin D
FAU - Leasu, Florin-Gabriel
AU  - Leasu FG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Analgesics)
SB  - IM
MH  - Age Factors
MH  - Analgesics/administration & dosage/*therapeutic use
MH  - Cultural Characteristics
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Pain/*drug therapy
MH  - Pharmaceutical Services/standards
MH  - Professional Role
MH  - *Public Health
MH  - Risk Factors
MH  - Self Medication/ethics/psychology/standards/*trends
MH  - Sex Factors
EDAT- 2020/07/04 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
AID - 10.1097/MJT.0000000000001173 [doi]
AID - 00045391-202008000-00008 [pii]
PST - ppublish
SO  - Am J Ther. 2020 Jul/Aug;27(4):e387-e391. doi: 10.1097/MJT.0000000000001173.


PMID- 32618451
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20220531
IS  - 1757-9996 (Electronic)
IS  - 1602-1622 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Apr 1
TI  - Ergonomic Considerations in the Incidence of CTS in College of Dentistry, King
      Khalid University, Abha - Kingdom of Saudi Arabia.
PG  - 277-285
LID - 10.3290/j.ohpd.a44031 [doi]
AB  - PURPOSE: Ergonomics in dentistry poses some challenges to dentists and may
      require considerable concentration and attention to detail. This research enables
      early recognition and prevention of common ergonomic-related conditions, such as 
      carpel tunnel syndrome, back pain and neck pain. The purpose of this study was to
      determine the prevalence of ergonomic-related problems concerning carpel tunnel
      syndrome (CTS) and to know the efficacy of independent and combined clinical
      tests used in diagnosing it. MATERIALS AND METHODS: Initially the participants
      were instructed to complete a self-administered questionnaire regarding the
      severity of symptoms of their hands on a hand-wrist diagram and a visual analogue
      scale. The principle investigator evaluated all questionnaires independently and 
      four clinical tests were used on both hands in a systematic (non-randomised)
      order for subjects who had symptoms. Those with residual symptoms that exceeded
      beyond 1 min interval were identified and controlled for the statistical
      analyses. RESULTS: The most common symptom noted in the study group was tingling 
      and numbness of fingers (66.46%) followed by neck pain (66.34%). 29.26% of
      subjects reported moderate difficulty in typing and driving vehicles, whereas
      26.82% subjects felt moderate difficulty in grasping and carrying shopping bags. 
      61.94% of subjects with symptoms spent more than 1 h daily of their free time on 
      mobile phones or other smart devices. Individually, in our study the Tinsel's
      sign stood out as ineffective in ruling out CTS when compared with Phalen's test.
      Combination tests like Phalen's test and compression tests are confirmatory to
      CTS diagnosis and 66.34 % of the research group were hence diagnosed for CTS.
      CONCLUSIONS: A positive criteria for CTS, neck and shoulder pain is identified in
      our study as being due to long-term use of mobile devices. Further, combination
      tests like Phalen's with pressure provocation tests proved accurate in conforming
      CTS. Future research is needed to confirm the diagnostic utility of these
      independent and combined clinical tests in less prevalent settings, including
      general dental practitioners and occupational worksites. TRIAL REGISTRATION: The 
      current study is registered in King Khalid University, College of dentistry
      ethical committee SRC/REG/2016-17/107.
FAU - Kaleem, Sultan Mohammed
AU  - Kaleem SM
FAU - Asif, Shaik Mohammed
AU  - Asif SM
FAU - Kota, Mohammad Zahir
AU  - Kota MZ
FAU - Alam, Tanveer
AU  - Alam T
FAU - Assiri, Hassan
AU  - Assiri H
FAU - Zakirullah, Meer
AU  - Zakirullah M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200401
PL  - Germany
TA  - Oral Health Prev Dent
JT  - Oral health & preventive dentistry
JID - 101167768
SB  - IM
MH  - *Carpal Tunnel Syndrome
MH  - Dentistry
MH  - *Dentists
MH  - *Ergonomics
MH  - Humans
MH  - Incidence
MH  - Professional Role
MH  - Saudi Arabia
MH  - *Universities
OTO - NOTNLM
OT  - Phalen's test
OT  - Tinsel's sign
OT  - carpel tunnel syndrome
OT  - ergonomics
EDAT- 2020/07/04 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 842295 [pii]
AID - 10.3290/j.ohpd.a44031 [doi]
PST - epublish
SO  - Oral Health Prev Dent. 2020 Apr 1;18(1):277-285. doi: 10.3290/j.ohpd.a44031.


PMID- 32618203
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1545-1569 (Electronic)
IS  - 1055-6656 (Linking)
VI  - 57
IP  - 9
DP  - 2020 Sep
TI  - Sociodemographic Factors That Influence the Choice to Pursue Nasoalveolar
      Molding: One Pediatric Hospital's Experience.
PG  - 1069-1077
LID - 10.1177/1055665620936056 [doi]
AB  - OBJECTIVE: To identify demographic factors that influence choosing nasoalveolar
      molding (NAM) in the treatment of cleft lip with or without cleft palate
      (CL+/-P), and NAM treatment compliance. DESIGN: This work is a retrospective
      cohort study. SETTING: Tertiary pediatric hospital. PATIENTS, PARTICIPANTS: One
      hundred forty-nine patients with a diagnosis of unilateral complete CL+/-P
      receiving treatment when NAM was offered (January 1, 2008-July 26, 2016). MAIN
      OUTCOME MEASURE(S): Demographic variables collected included race, ethnicity, ZIP
      code, number of caregivers, caregiver employment status, and health insurance
      status. Medical variables collected included diagnosis, treatment pursued,
      compliance with NAM, completion of NAM, and the treating cleft surgeon and
      orthodontist. Data were analyzed via Fisher exact tests, chi(2) tests, and
      multivariate logistic regression to identify factors that influence the decision 
      to pursue NAM and treatment compliance. RESULTS: Univariate analyses identified
      the following significant factors predicting the pursuit of NAM: race and
      insurance type (both P < .001), surgeon (P = .005), income level (P = .009),
      comorbidities (P = .015), and syndromic diagnosis (P = .033). Driving distance
      trended toward significance (P = .078). Multivariate regression analyses
      indicated that Asian race (P = .047), insurance type (P = .046), driving distance
      (P = .019), and surgeon (P = .017) were significant predictors of pursuit of NAM.
      CONCLUSIONS: There are disparities in patient choice of NAM at our center for
      children with complete cleft lip. African American patient families were less
      likely to pursue this intervention. A stronger understanding of the barriers that
      lower income and minority patients face is needed in order to better characterize
      disparities in cleft care.
FAU - Kimia, Rotem
AU  - Kimia R
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
FAU - Butler, Paris D
AU  - Butler PD
AD  - Division of Plastic and Reconstructive Surgery, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Guajardo, Isabella
AU  - Guajardo I
AD  - Department of Surgery, UC San Diego School of Medicine, La Jolla, CA, USA.
FAU - Magee, Leanne
AU  - Magee L
AD  - Division of Plastic and Reconstructive Surgery, The Children's Hospital of
      Philadelphia, PA, USA.
FAU - Lowe, Kristen
AU  - Lowe K
AD  - Division of Plastic and Reconstructive Surgery, Children's Hospital Colorado,
      Aurora, CO, USA.
FAU - Scott, Michelle
AU  - Scott M
AD  - Division of Plastic and Reconstructive Surgery, The Children's Hospital of
      Philadelphia, PA, USA.
FAU - Wes, Ari
AU  - Wes A
AD  - Division of Plastic and Reconstructive Surgery, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Jackson, Oksana A
AU  - Jackson OA
AUID- ORCID: 0000-0001-8119-9442
AD  - Division of Plastic and Reconstructive Surgery, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
AD  - Division of Plastic and Reconstructive Surgery, The Children's Hospital of
      Philadelphia, PA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200703
PL  - United States
TA  - Cleft Palate Craniofac J
JT  - The Cleft palate-craniofacial journal : official publication of the American
      Cleft Palate-Craniofacial Association
JID - 9102566
SB  - IM
MH  - Alveolar Process
MH  - Child
MH  - *Cleft Lip/therapy
MH  - *Cleft Palate/therapy
MH  - Hospitals, Pediatric
MH  - Humans
MH  - Nasoalveolar Molding
MH  - Nose
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *esthetics
OT  - *ethics/health policies
OT  - *nonsyndromic clefting
OT  - *oral health
OT  - *orthodontics
OT  - *parental perception
OT  - *periodontal health
OT  - *prosthetics
EDAT- 2020/07/04 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1177/1055665620936056 [doi]
PST - ppublish
SO  - Cleft Palate Craniofac J. 2020 Sep;57(9):1069-1077. doi:
      10.1177/1055665620936056. Epub 2020 Jul 3.


PMID- 32617864
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210110
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Dec
TI  - Short and long term impacts of COVID-19 on the pharmaceutical sector.
PG  - 799-805
LID - 10.1007/s40199-020-00358-5 [doi]
AB  - BACKGROUND: The novel coronavirus disease 2019 (COVID-19) was characterized as a 
      global pandemic by the WHO on March 11th, 2020. This pandemic had major effects
      on the health market, the pharmaceutical sector, and was associated with
      considerable impacts; which may appear in short and long-term time-horizon and
      need identification and appropriate planning to reduce their socio-economic
      burden. OBJECTIVES: Current short communication study assessed pharmaceutical
      market crisis during the COVID-19 era; discussing short- and long-term impacts of
      the pandemic on the pharmaceutical sector. RESULTS: Short-term impacts of
      COVID-19 pandemic includes demand changes, regulation revisions, research and
      development process changes and the shift towards tele-communication and
      tele-medicine. In addition, industry growth slow-down, approval delays, moving
      towards self-sufficiency in pharm-production supply chain and trend changes in
      consumption of health-market products along with ethical dilemma could be
      anticipated as long-term impacts of COVID-19 pandemic on pharmaceutical sector in
      both global and local levels. CONCLUSION: The pandemic of COVID-19 poses
      considerable crisis on the health markets, including the pharmaceutical sector;
      and identification of these effects, may guide policy-makers towards more
      evidence-informed planning to overcome accompanying challenges. Graphical
      abstract .
FAU - Ayati, Nayyereh
AU  - Ayati N
AUID- ORCID: https://orcid.org/0000-0002-7346-9470
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Saiyarsarai, Parisa
AU  - Saiyarsarai P
AUID- ORCID: https://orcid.org/0000-0001-8015-1834
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group,
      Pharmaceutical Sciences Research Center (PSRC), and the Pharmaceutical Management
      and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences
      (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
FAU - Nikfar, Shekoufeh
AU  - Nikfar S
AUID- ORCID: https://orcid.org/0000-0002-5206-6197
AD  - Department of Pharmacoeconomics and Pharmaceutical Administration, School of
      Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
      nikfar_sh@tums.ac.ir.
AD  - Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group,
      Pharmaceutical Sciences Research Center (PSRC), and the Pharmaceutical Management
      and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences
      (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
      nikfar_sh@tums.ac.ir.
AD  - Personalized Medicine Research Center, Endocrinology and Metabolism Clinical
      Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
      nikfar_sh@tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20200703
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - COVID-19/*economics
MH  - Drug Industry/*economics/trends
MH  - Humans
MH  - Pharmaceutical Preparations/*economics/supply & distribution
MH  - Policy Making
MH  - Research/*economics/trends
MH  - Telemedicine/trends
MH  - Time Factors
PMC - PMC7332346
OTO - NOTNLM
OT  - COVID-19
OT  - Corona virus
OT  - Health market
OT  - Pharmaceutical industry
OT  - Pharmaceutical market
OT  - SARS-CoV-2
OT  - Tele-health
EDAT- 2020/07/04 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1007/s40199-020-00358-5 [doi]
AID - 10.1007/s40199-020-00358-5 [pii]
PST - ppublish
SO  - Daru. 2020 Dec;28(2):799-805. doi: 10.1007/s40199-020-00358-5. Epub 2020 Jul 3.


PMID- 32617643
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20210622
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 8
DP  - 2020 Aug
TI  - [Satellite data for recording health-relevant environmental conditions: examples 
      and interdisciplinary potential].
PG  - 936-944
LID - 10.1007/s00103-020-03177-w [doi]
AB  - Environmental conditions influence human health and interact with other factors
      such as DNA, lifestyle, or the social environment. Earth observations from space 
      provide data on the most diverse manifestations of these environmental conditions
      and make it possible to quantify them spatially. Using two examples - the
      availability of open and recreational space and the spatial distribution of air
      pollution - this article presents the potential of Earth observations for health 
      studies. In addition, possible applications for health-related issues are
      discussed. To this end, we try to outline key points for an interdisciplinary
      approach that meets the conceptual, data technology, and ethical challenges.
FAU - Taubenbock, Hannes
AU  - Taubenbock H
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland. hannes.taubenboeck@dlr.de.
AD  - Institut fur Geographie und Geologie, Julius-Maximilians-Universitat Wurzburg,
      Wurzburg, Deutschland. hannes.taubenboeck@dlr.de.
FAU - Schmich, Patrick
AU  - Schmich P
AD  - Robert Koch-Institut, Berlin, Deutschland.
FAU - Erbertseder, Thilo
AU  - Erbertseder T
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland.
FAU - Muller, Inken
AU  - Muller I
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland.
FAU - Tenikl, Julia
AU  - Tenikl J
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland.
FAU - Weigand, Matthias
AU  - Weigand M
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland.
FAU - Staab, Jeroen
AU  - Staab J
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland.
FAU - Wurm, Michael
AU  - Wurm M
AD  - Earth Observation Center (EOC) Wessling, Deutsches Zentrum fur Luft- und
      Raumfahrt (DLR), Oberpfaffenhofen, Munchener Str. 20, 82234, Wessling,
      Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Satellitendaten zur Erfassung gesundheitsrelevanter Umweltbedingungen: Beispiele 
      und interdisziplinare Potenziale.
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - *Air Pollution
MH  - *Environmental Monitoring
MH  - Germany
MH  - Humans
OTO - NOTNLM
OT  - Earth observation
OT  - Exposure
OT  - Health
OT  - Remote sensing
OT  - Spatial disparities
EDAT- 2020/07/04 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1007/s00103-020-03177-w [doi]
AID - 10.1007/s00103-020-03177-w [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Aug;63(8):936-944. doi: 10.1007/s00103-020-03177-w.


PMID- 32617632
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1433-0407 (Electronic)
IS  - 0028-2804 (Linking)
VI  - 91
IP  - 8
DP  - 2020 Aug
TI  - [Placebos and placeboids in clinical practice: conceptual and ethical
      considerations].
PG  - 684-690
LID - 10.1007/s00115-020-00943-8 [doi]
AB  - Reflecting on results of recent placebo research, this article analyzes relevant 
      key concepts and ethical positions. "Placeboids" and possibly open-label placebo 
      treatments should replace any deceptive use of sham medication. Their use should 
      give rise to a critical consideration of the modern patient-physician
      relationship.
FAU - Schone-Seifert, Bettina
AU  - Schone-Seifert B
AD  - Institut fur Ethik, Geschichte und Theorie der Medizin, Universitatsklinikum
      Munster, Von-Esmarch-Str. 62, 48149, Munster, Deutschland.
      schoeneb@ukmuenster.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Placebos und Placeboide in der therapeutischen Praxis - begriffliche und ethische
      Uberlegungen.
PL  - Germany
TA  - Nervenarzt
JT  - Der Nervenarzt
JID - 0400773
SB  - IM
MH  - Deception
MH  - Ethics, Medical
MH  - Humans
MH  - Morals
MH  - Physician-Patient Relations
MH  - *Placebo Effect
OTO - NOTNLM
OT  - Deception
OT  - Open-label placebo treatment
OT  - Paternalism
OT  - Physician-patient relations
OT  - Sham treatment
EDAT- 2020/07/04 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - 10.1007/s00115-020-00943-8 [doi]
AID - 10.1007/s00115-020-00943-8 [pii]
PST - ppublish
SO  - Nervenarzt. 2020 Aug;91(8):684-690. doi: 10.1007/s00115-020-00943-8.


PMID- 32617434
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - HAMAMATSU-ICG study: Protocol for a phase III, multicentre, single-arm study to
      assess the usefulness of indocyanine green fluorescent lymphography in assessing 
      secondary lymphoedema.
PG  - 100595
LID - 10.1016/j.conctc.2020.100595 [doi]
AB  - INTRODUCTION: Secondary lymphoedema of the extremities is an important
      quality-of-life issue for patients who were treated for their malignancies.
      Indocyanine green (ICG) fluorescent lymphography may be helpful for assessing
      lymphoedema and for planning lymphaticovenular anastomosis (LVA). The objective
      of the present clinical trial is to confirm whether or not ICG fluorescent
      lymphography using the near-infrared monitoring camera is useful for assessing
      the indication for LVA, for the identification of the lymphatic vessels before
      the conduct of LVA, and for the confirmation of the patency of the anastomosis
      site during surgery. METHODS AND ANALYSIS: This trial is a phase III,
      multicentre, single-arm, open-label clinical trial to assess the efficacy and
      safety of ICG fluorescent lymphography when assessing and treating lymphoedema of
      patients with secondary lymphoedema who are under consideration for LVA. The
      primary endpoint is the identification rate of the lymphatic vessels at the
      incision site based on ICG fluorescent lymphograms obtained before surgery. The
      secondary endpoints are 1) the sensitivity and specificity of dermal back flow
      determined by ICG fluorescent lymphography as compared with (99m)Tc
      lymphoscintigraphy-one of the standard diagnostic methods and 2) the usefulness
      of ICG fluorescent lymphography when confirming the patency of the anastomosis
      site after LVA. ETHICS AND DISSEMINATION: The protocol for the study was approved
      by the Institutional Review Board of each institution. The trial was filed for
      and registered at the Pharmaceuticals and Medical Devices Agency in Japan. The
      trial is currently on-going and is scheduled to end in June 2020. TRIAL
      REGISTRATION NUMBER: jRCT2031190064; Pre-results.
CI  - (c) 2020 The Authors.
FAU - Akita, Shinsuke
AU  - Akita S
AD  - Department of Plastic, Reconstructive, and Aesthetic Surgery, Chiba University
      Graduate School of Medicine, Chiba, Japan.
FAU - Unno, Naoki
AU  - Unno N
AD  - Department of Vascular Surgery, Hamamatsu Medical Center, Hamamatsu, Japan.
AD  - Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu,
      Japan.
FAU - Maegawa, Jiro
AU  - Maegawa J
AD  - Department of Plastic and Reconstructive Surgery, Yokohama City University,
      Graduate School of Medicine, Yokohama, Japan.
FAU - Kimata, Yoshihiro
AU  - Kimata Y
AD  - Department of Plastic and Reconstructive Surgery, Okayama University Graduate
      School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
FAU - Fukamizu, Hidekazu
AU  - Fukamizu H
AD  - Department of Plastic and Reconstructive Surgery, Hamamatsu University School of 
      Medicine, Hamamatsu, Japan.
FAU - Yabuki, Yuichiro
AU  - Yabuki Y
AD  - Department of Plastic and Reconstructive Surgery, Yokohama City University,
      Graduate School of Medicine, Yokohama, Japan.
FAU - Shinaoka, Akira
AU  - Shinaoka A
AD  - Department of Plastic and Reconstructive Surgery, Okayama University Graduate
      School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
FAU - Sano, Masaki
AU  - Sano M
AD  - Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu,
      Japan.
FAU - Kawasaki, Yohei
AU  - Kawasaki Y
AD  - Clinical Research Center, Chiba University Hospital, Chiba, Japan.
FAU - Fujiwara, Tadami
AU  - Fujiwara T
AD  - Clinical Research Center, Chiba University Hospital, Chiba, Japan.
FAU - Hanaoka, Hideki
AU  - Hanaoka H
AD  - Clinical Research Center, Chiba University Hospital, Chiba, Japan.
FAU - Mitsukawa, Nobuyuki
AU  - Mitsukawa N
AD  - Department of Plastic, Reconstructive, and Aesthetic Surgery, Chiba University
      Graduate School of Medicine, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7322679
OTO - NOTNLM
OT  - Indocyanine green fluorescent lymphography
OT  - Lymphaticovenular anastomosis
OT  - Secondary lymphoedema
COIS- The present clinical trial plans to be conducted under funding from Hamamatsu
      Photonics K.K. The possibility that conflict of interest occurs with respect to
      the conduct of the clinical trial and its outcomes should be controlled
      appropriately based on the conflict of interest management policies of each
      medical institution.
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2020/01/19 00:00 [received]
PHST- 2020/06/07 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.1016/j.conctc.2020.100595 [doi]
AID - S2451-8654(20)30079-X [pii]
AID - 100595 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Jun 16;19:100595. doi:
      10.1016/j.conctc.2020.100595. eCollection 2020 Sep.


PMID- 32617433
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 19
DP  - 2020 Sep
TI  - Parallel but connected: Nuances of conducting behavioral and social science
      research alongside ethically challenging HIV remission trials.
PG  - 100594
LID - 10.1016/j.conctc.2020.100594 [doi]
AB  - Collaborations between clinical investigators and behavioral and social science
      researchers (BSSR) produce many benefits, but also may generate challenges and
      complexities. Ongoing relationships between teams may affect the research carried
      out by the BSSR team and the way they interpret their findings. Here we describe 
      our experiences conducting the HIV Remission ('Cure') Trials Decision-Making
      Study (DMS), in Thailand; these trials include potentially risky interventions
      and interruption of standard antiretroviral treatment, with little personal
      benefit. The DMS is a longitudinal study of the experiences of individuals
      recruited to such early-phase trials, and conducted alongside these trials. It
      originated in clinical investigators' concerns about the ability of those
      recruited to make voluntary and informed decisions about scientifically complex
      studies, and is led by an independent group of BSSR and ethics researchers. In
      conducting this study, we experienced three overarching challenges to achieving a
      successful and dynamic collaboration: managing emerging findings as data were
      collected alongside clinical trial participation; evolving interconnectedness and
      shifting partnership boundaries among investigators; and the process of
      incorporating new research questions. By describing these challenges, we provide 
      experiential evidence on how to manage multidimensional aspects of these
      collaborations. We describe how our research teams came together as well as the
      challenges and opportunities we experienced along the way. Our aim is to raise
      awareness of the scientific, practical, and ethical complexities of establishing 
      and maintaining this kind of broad multidisciplinary collaboration over time. By 
      describing our experiences, we hope to advance an agenda for others who undertake
      similar partnerships.
CI  - (c) 2020 The Authors.
FAU - Henderson, Gail E
AU  - Henderson GE
AD  - Department of Social Medicine, University of North Carolina School of Medicine,
      Chapel Hill, NC, USA.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - Department of Social Medicine, University of North Carolina School of Medicine,
      Chapel Hill, NC, USA.
FAU - Corneli, Amy
AU  - Corneli A
AD  - Departments of Population Health Sciences and Medicine, Duke University, Durham, 
      NC, USA.
FAU - Meagher, Karen
AU  - Meagher K
AD  - Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
FAU - Cadigan, R Jean
AU  - Cadigan RJ
AD  - Department of Social Medicine, University of North Carolina School of Medicine,
      Chapel Hill, NC, USA.
FAU - Kroon, Eugene
AU  - Kroon E
AD  - The Thai Red Cross AIDS Research Centre, 104 Rajdumri Road Krung Thep Maha Nakhon
      10330 Krung Thep Maha Nakhon, Bangkok, 10330, Thailand.
FAU - Ananworanich, Jintanat
AU  - Ananworanich J
AD  - Department of Global Health, Amsterdam University Medical Centers, University of 
      Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, 
      The Netherlands, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
FAU - Peay, Holly L
AU  - Peay HL
AD  - RTI International, Research Trialngle Park, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200616
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7322675
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.1016/j.conctc.2020.100594 [doi]
AID - S2451-8654(20)30078-8 [pii]
AID - 100594 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Jun 16;19:100594. doi:
      10.1016/j.conctc.2020.100594. eCollection 2020 Sep.


PMID- 32617334
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2305-5839 (Print)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 11
DP  - 2020 Jun
TI  - Application of artificial intelligence in anterior segment ophthalmic diseases:
      diversity and standardization.
PG  - 714
LID - 10.21037/atm-20-976 [doi]
AB  - Artificial intelligence (AI) based on machine learning (ML) and deep learning
      (DL) techniques has gained tremendous global interest in this era. Recent studies
      have demonstrated the potential of AI systems to provide improved capability in
      various tasks, especially in image recognition field. As an image-centric
      subspecialty, ophthalmology has become one of the frontiers of AI research.
      Trained on optical coherence tomography, slit-lamp images and even ordinary eye
      images, AI can achieve robust performance in the detection of glaucoma, corneal
      arcus and cataracts. Moreover, AI models based on other forms of data also
      performed satisfactorily. Nevertheless, several challenges with AI application in
      ophthalmology have also arisen, including standardization of data sets,
      validation and applicability of AI models, and ethical issues. In this review, we
      provided a summary of the state-of-the-art AI application in anterior segment
      ophthalmic diseases, potential challenges in clinical implementation and our
      prospects.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Wu, Xiaohang
AU  - Wu X
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Liu, Lixue
AU  - Liu L
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Zhao, Lanqin
AU  - Zhao L
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Guo, Chong
AU  - Guo C
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Li, Ruiyang
AU  - Li R
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Wang, Ting
AU  - Wang T
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Yang, Xiaonan
AU  - Yang X
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Xie, Peichen
AU  - Xie P
AD  - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
FAU - Liu, Yizhi
AU  - Liu Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Lin, Haotian
AU  - Lin H
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
AD  - Center for Precision Medicine, Sun Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7327317
OTO - NOTNLM
OT  - Artificial intelligence (AI)
OT  - anterior eye segment
OT  - computer-assisted diagnosis
OT  - machine learning (ML)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/atm-20-976). The series "Medical
      Artificial Intelligent Research" was commissioned by the editorial office without
      any funding or sponsorship. HL served as the unpaid Guest Editor of the series.
      The other authors have no other conflicts of interest to declare.
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.21037/atm-20-976 [doi]
AID - atm-08-11-714 [pii]
PST - ppublish
SO  - Ann Transl Med. 2020 Jun;8(11):714. doi: 10.21037/atm-20-976.


PMID- 32617275
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200704
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - The experience of patients with bipolar disorder from diagnosis disclosure: A
      qualitative study.
PG  - 36
LID - 10.34171/mjiri.34.36 [doi]
AB  - Background: Disclosure of the diagnosis is an essential part of the treatment
      process and an important part of patient rights. However, it can be a very
      stressful experience, especially in mental health disorders. Patients with
      bipolar disorder have a unique experience of receiving and managing their
      diagnosis. The objective of the current study was to explore the experience of
      patients with bipolar disorder of diagnosis disclosure. Methods: This was a
      qualitative study. Participants were recruited from patients who knew their
      disorder's name using purposive sampling method. The inclusion criteria were
      being diagnosed by a psychiatrist as having bipolar disorder and the disclosure
      was conducted by a psychiatrist. Sixteen semi-structured, in-depth interviews
      were conducted with twelve patients. Data were analyzed using thematic content
      analysis. Results: Patients received their diagnosis name in three steps
      including Wandering in Unknowns, Limited Brightness and Reaching to a Relative
      Insight. Patients believed that disclosure of the diagnosis was not accompanied
      by enough information. Conclusion: The disclosure of diagnosis in patients with
      bipolar disorder without providing enough information is stressful and is not
      helpful in empowering these patients. Based on our results, disclosure of
      diagnosis to patients with bipolar disorder was not conducted with enough
      information and patients had problems for understanding their symptoms and
      treatments.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Zolfi Kashani, Azam
AU  - Zolfi Kashani A
AD  - Medical School, Iran University of Medical Sciences, Tehran, Iran.
FAU - Ranjbar, Hadi
AU  - Ranjbar H
AD  - Mental Health Research Center, Psychosocial Health Research Institute, Iran
      University of Medical Science, Tehran, Iran.
FAU - Rasoulian, Maryam
AU  - Rasoulian M
AD  - Mental Health Research Center, Tehran Institute of Psychiatry- School of
      Behavioral Sciences and Mental Health, Iran University of Medical Sciences,
      Tehran, Iran.
FAU - Shabani, Amir
AU  - Shabani A
AD  - Mental Health Research Center, Mood Disorders Research Group, Iran University of 
      Medical Sciences, Tehran, Iran.
FAU - Ghadirivasfi, Mohammad
AU  - Ghadirivasfi M
AD  - Mental Health Research Center, Tehran Institute of Psychiatry- School of
      Behavioral Sciences and Mental Health, Iran University of Medical Sciences,
      Tehran, Iran.
FAU - Mohammadsadeghi, Homa
AU  - Mohammadsadeghi H
AUID- ORCID: https://orcid.org/0000-0001-5930-762X
AD  - Mental Health Research Center, Tehran Institute of Psychiatry- School of
      Behavioral Sciences and Mental Health, Iran University of Medical Sciences,
      Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7320983
OTO - NOTNLM
OT  - Bipolar disorder
OT  - Disclosure
OT  - Medical ethics
OT  - Mental health
OT  - Patient rights
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2019/10/16 00:00 [received]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.34171/mjiri.34.36 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 Apr 20;34:36. doi: 10.34171/mjiri.34.36. eCollection
      2020.


PMID- 32617173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
DP  - 2020
TI  - The PTSD help app in a Danish PTSD population: research protocol of a randomized 
      controlled feasibility trial.
PG  - 92
LID - 10.1186/s40814-020-00633-x [doi]
AB  - BACKGROUND: Due to an increase in PTSD patients seeking help in the Danish mental
      health sector and the addition of Complex PTSD to the ICD-11, there is a need to 
      increase efficiency of existing treatments for PTSD. mHealth interventions have
      been shown to reduce PTSD symptoms. Therefore, the implementation of a mHealth
      intervention designed for psychiatric PTSD patients as a therapy add-on may
      improve treatment outcome. No study to date has explored the effects of mHealth
      interventions for PTSD in the Danish mental health sector, the feasibility and
      effect of this type of intervention needs testing. METHODS: The study is an
      investigator-initiated randomized controlled feasibility trial investigating the 
      clinical mHealth tool PTSD help combined with care as usual (CAU) compared to CAU
      for adults with PTSD. Seventy patients will be recruited and receive either the
      mHealth intervention combined with CAU or CAU alone. The primary feasibility
      outcome is the proportion of eligible patients that participate in the study
      until the end assessment. Secondary outcome data consists of the fraction of
      compliant patients in the experimental group and exploratory data on PTSD help on
      PTSD symptom severity, level of psychological distress, sleep quality,
      dissociation symptoms, therapy readiness, quality of life, disability levels, and
      recovery. DISCUSSION: This study may help increase our knowledge of possible
      benefits of, as well as potential barriers to, the implementation of mHealth
      tools in the psychiatric sector. It may also provide a cost-efficient means to
      increase therapy outcomes and decrease the duration of suffering for PTSD
      patients in the psychiatric sector. TRIAL REGISTRATION: The trial is registered
      at ClinicalTrials.gov (ID: NCT03862703)
      https://clinicaltrials.gov/ct2/show/NCT03862703 on the 27 of February 2019 and
      has been approved by the Danish Data Protection Agency (journal number:
      VD-2018-200 ISuite number 6443). Referring to the committee law section sign2,
      the National Committee on Health Research Ethics (DNVK) [H-18024180] decided that
      the study could proceed without approval as the use of PTSD help did not
      constitute a health science intervention according to Danish health science
      legislation.
CI  - (c) The Author(s) 2020.
FAU - Scharff, Frederik Bernt
AU  - Scharff FB
AUID- ORCID: 0000-0001-6004-0432
AD  - Unit for Psychotherapy Research, Psychotherapeutic Center Stolpegaard, Mental
      Health Services, Stolpegaardsvej 20, 2820 Gentofte, Capital Region of Denmark
      Denmark.grid.466916.a0000 0004 0631 4836
FAU - Lau, Marianne Engelbrecht
AU  - Lau ME
AD  - Unit for Psychotherapy Research, Psychotherapeutic Center Stolpegaard, Mental
      Health Services, Stolpegaardsvej 20, 2820 Gentofte, Capital Region of Denmark
      Denmark.grid.466916.a0000 0004 0631 4836
FAU - Riisager, Lisa Helena Gronberg
AU  - Riisager LHG
AD  - Unit for Psychotherapy Research, Psychotherapeutic Center Stolpegaard, Mental
      Health Services, Stolpegaardsvej 20, 2820 Gentofte, Capital Region of Denmark
      Denmark.grid.466916.a0000 0004 0631 4836
FAU - Moller, Stine Bjerrum
AU  - Moller SB
AD  - Unit for Psychotherapy Research, Psychotherapeutic Center Stolpegaard, Mental
      Health Services, Stolpegaardsvej 20, 2820 Gentofte, Capital Region of Denmark
      Denmark.grid.466916.a0000 0004 0631 4836
FAU - Salimi, Mehrak Lykkeberg
AU  - Salimi ML
AD  - Hejmdal Private Psychiatric Hospital, Martinsvej 7-9, 1926 Frederiksberg C,
      Denmark.grid.154185.c0000 0004 0512 597X
FAU - Gondan, Matthias
AU  - Gondan M
AD  - Unit for Psychotherapy Research, Psychotherapeutic Center Stolpegaard, Mental
      Health Services, Stolpegaardsvej 20, 2820 Gentofte, Capital Region of Denmark
      Denmark.grid.466916.a0000 0004 0631 4836
FAU - Folke, Sofie
AU  - Folke S
AD  - Department for Military Psychology, Danish Veteran Center, Danish Defence,
      Svanemollens Kaserne, Ryvangs Alle 1, 2100 Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03862703
PT  - Journal Article
DEP - 20200630
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
PMC - PMC7325563
OTO - NOTNLM
OT  - Feasibility
OT  - PTSD
OT  - mHealth
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.1186/s40814-020-00633-x [doi]
AID - 633 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 Jun 30;6:92. doi: 10.1186/s40814-020-00633-x.
      eCollection 2020.


PMID- 32616983
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0102-3616 (Print)
IS  - 0102-3616 (Linking)
VI  - 55
IP  - 3
DP  - 2020 Jun
TI  - Evaluation of the Southwick Angle in Two Hundred Hips of Asymptomatic Children
      and Adolescents.
PG  - 360-366
LID - 10.1055/s-0040-1701289 [doi]
AB  - Objectives To measure the mean value of the Southwick angle using two different
      methods, the manual (1) and digital (2) methods, and to establish a normality
      value. Methods A primarily descriptive study with 100 children and adolescents.
      Individuals with orthopedic complaints regarding the hips and/or knees or gait
      alterations were excluded. For each patient, an X-ray was performed on the
      lateral incidence of Lowenstein, totaling 100 radiographs and 200 hips. The
      Southwick angle was measured in two different ways by the same researcher: the
      conventional method (1), tracing the lines with pencils and measuring the angle
      with the use of a goniometer and negatoscope, and through the GNU Image
      Manipulation Program (GIMP) image editor (open source), version 2.7.0 (2), in
      which the lines were plotted and the angles of both hips were gauged on each
      radiograph. Later, we sought to evaluate the correlation between the two methods 
      and to verify the mean Southwick angle by categorically correlating it by gender,
      age group and body mass index (BMI) in asymptomatic children and adolescents. All
      radiographs were authorized by the children and adolescents' parents/legal
      guardians. The study was approved by the ethics committee of the institutions in 
      which the research was conducted. Results The mean of the Southwick angles
      obtained by the conventional method was of 8.7 degrees (+/-2.0 degrees ), and, by
      the digital method, it was of 9.9 degrees (+/-1.8 degrees ). The angle obtained
      by the two methods was statistically significant ( p < 0.001). The majority of
      the studied population (95%) had a body mass index (BMI) > 18.5, and the mean of 
      the angles was within the previously established value ( approximately 10 degrees
      ). Conclusion For the first time, using a substantial sample size, a normal value
      for the Southwick angle measured in asymptomatic individuals was demonstrated. In
      addition, the image editor proved to be a reliable method to measuring the
      Southwick angle.
FAU - Monte, Felipe Alves
AU  - Monte FA
AUID- ORCID: 0000-0001-9775-3612
AD  - Departamento de Ortopedia e Traumatologia, Hospital da Restauracao Governador
      Paulo Guerra, Recife, PE, Brasil.
FAU - Melo, Paulo Sergio
AU  - Melo PS
AUID- ORCID: 0000-0002-1362-3931
AD  - Departamento de Ortopedia e Traumatologia, Instituto Materno Infantil de
      Pernambuco, Recife, PE, Brasil.
FAU - Alves, Amaro
AU  - Alves A
AUID- ORCID: 0000-0001-5244-5106
AD  - Departamento de Ortopedia e Traumatologia, Hospital da Restauracao Governador
      Paulo Guerra, Recife, PE, Brasil.
FAU - Oliveira Junior, Jose Venancio
AU  - Oliveira Junior JV
AUID- ORCID: 0000-0002-1266-5128
AD  - Departamento de Ortopedia e Traumatologia, Instituto Materno Infantil de
      Pernambuco, Recife, PE, Brasil.
FAU - Alencar, George
AU  - Alencar G
AUID- ORCID: 0000-0002-6438-2314
AD  - Departamento de Ortopedia e Traumatologia, Instituto Materno Infantil de
      Pernambuco, Recife, PE, Brasil.
FAU - Soares, Fabio Couto
AU  - Soares FC
AUID- ORCID: 0000-0003-4248-9177
AD  - Departamento de Ortopedia e Traumatologia, Instituto Materno Infantil de
      Pernambuco, Recife, PE, Brasil.
LA  - eng
PT  - Journal Article
DEP - 20200323
PL  - Germany
TA  - Rev Bras Ortop (Sao Paulo)
JT  - Revista brasileira de ortopedia
JID - 0123326
PMC - PMC7316541
OTO - NOTNLM
OT  - adolescent
OT  - hip joint
OT  - slipped capital femoral epiphysis
COIS- Conflito de interesses Os autores declaram nao haver conflito de interesses.
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2018/10/11 00:00 [received]
PHST- 2019/03/26 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.1055/s-0040-1701289 [doi]
AID - 180424pt [pii]
PST - ppublish
SO  - Rev Bras Ortop (Sao Paulo). 2020 Jun;55(3):360-366. doi: 10.1055/s-0040-1701289. 
      Epub 2020 Mar 23.


PMID- 32616969
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0102-3616 (Print)
IS  - 0102-3616 (Linking)
VI  - 55
IP  - 3
DP  - 2020 Jun
TI  - Level of Evidence and Industry Sponsorship Associated with Favorable Outcomes in 
      Publications on Platelet-Rich-Plasma Therapy in Musculoskeletal Disorders.
PG  - 263-268
LID - 10.1055/s-0039-1700834 [doi]
AB  - Platelet-rich plasma is derived from centrifuging whole blood. There is
      increasing interest in the sports medicine and athlete community about providing 
      endogenous growth factors directly to the injury site, using autologous blood
      products such as platelet-rich plasma. The aim of the present study is to
      evaluate the association between research financing, conflict of interests, level
      of evidence and author affiliation with the interpretation of results in articles
      published on platelet-rich plasma therapy in musculoskeletal ailments. A review
      of the current literature was performed. The outcome was classified as favorable 
      or unfavorable. The declaration of conflict of interests and the type of funding 
      was extracted from each article. The financing was classified as
      industry-sponsored; not industry-sponsored; or unidentifiable. The level of
      evidence was categorized from I to IV. Higher positive outcomes were observed in 
      134 studies with industry sponsorship compared with not industry-sponsored
      studies (odds ratio [OR]: 0.26; 95% confidence interval [95%CI]: 0.08-0.85; p <
      0.05). Compared with level of evidence I, levels II and IV increase the
      probability of positive outcomes by 12.42 times ( p < 0.01) and 10.97 times ( p <
      0.01) respectively. Proportionally, industry-sponsored studies are more likely to
      present positive results, as well as articles with a lower quality of evidence.
FAU - Nesello, Pietro Felice Tomazini
AU  - Nesello PFT
AUID- ORCID: 0000-0002-2564-3892
AD  - Instituto de Medicina do Esporte e Ciencias Aplicadas ao Movimento Humano,
      Universidade de Caxias do Sul, Caxias do Sul, RS, Brasil.
FAU - Baroni, Allan Cassio
AU  - Baroni AC
AD  - Instituto de Medicina do Esporte e Ciencias Aplicadas ao Movimento Humano,
      Universidade de Caxias do Sul, Caxias do Sul, RS, Brasil.
FAU - Selistre, Luciano da Silva
AU  - Selistre LDS
AD  - Departamento de Bioestatistica, Hospital Geral, Universidade de Caxias do Sul,
      Caxias do Sul, RS, Brasil.
LA  - eng
PT  - Journal Article
DEP - 20191219
PL  - Germany
TA  - Rev Bras Ortop (Sao Paulo)
JT  - Revista brasileira de ortopedia
JID - 0123326
PMC - PMC7316539
OTO - NOTNLM
OT  - conflict of interest
OT  - ethics
OT  - industry
OT  - musculoskeletal diseases
OT  - platelet-rich plasma
COIS- Conflito de Interesses Os autores declaram nao haver conflito de interesses.
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2018/10/16 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.1055/s-0039-1700834 [doi]
AID - 180215pt [pii]
PST - ppublish
SO  - Rev Bras Ortop (Sao Paulo). 2020 Jun;55(3):263-268. doi: 10.1055/s-0039-1700834. 
      Epub 2019 Dec 19.


PMID- 32616960
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20211204
IS  - 1943-2836 (Electronic)
IS  - 0020-7284 (Linking)
VI  - 70
IP  - 2
DP  - 2020
TI  - Mas alla de las barreras: Competency and practice considerations in language,
      cultural, and social issues when delivering group CPT to Hispanic immigrants.
PG  - 212-243
LID - 10.1080/00207284.2019.1677469 [doi]
AB  - High rates of under-assessed trauma and psychiatric disorders, particularly
      posttraumatic stress disorder (PTSD) have been reported among Hispanic
      immigrants, especially as related to immigration trauma. Multiple studies have
      shown group cognitive processing therapy (CPT) to be an effective evidence-based 
      practice (EBP) for treatment of PTSD across a number of clinical populations. To 
      date, however, no studies have examined important competency and practice issues 
      in linguistic, cultural, and ethical areas that group CPT providers should
      consider when delivering group CPT to Hispanic immigrants. This paper aims to
      outline these and provide future directions for research.
FAU - Vasquez, Desi
AU  - Vasquez D
AD  - Texas A&M International University - Laredo.
FAU - Ponte, Luis
AU  - Ponte L
AD  - Texas A&M University - College Station.
FAU - Andrews, Arthur R 3rd
AU  - Andrews AR 3rd
AD  - University of Nebraska - Lincoln.
FAU - Garcia, Ediza
AU  - Garcia E
AD  - Texas A&M International University - Laredo.
FAU - Terrazas-Carrillo, Elizabeth
AU  - Terrazas-Carrillo E
AD  - Texas A&M International University - Laredo.
FAU - Ojeda, Lizette
AU  - Ojeda L
AD  - Texas A&M University - College Station.
FAU - de Arrellano, Michael A
AU  - de Arrellano MA
AD  - Medical University of South Carolina - Charleston.
LA  - eng
GR  - P20 GM130461/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20191113
PL  - England
TA  - Int J Group Psychother
JT  - International journal of group psychotherapy
JID - 0374720
SB  - IM
MH  - *Cognitive Behavioral Therapy
MH  - Emigrants and Immigrants
MH  - *Hispanic or Latino/psychology
MH  - Humans
MH  - *Psychotherapy, Group
MH  - *Stress Disorders, Post-Traumatic/ethnology/therapy
PMC - PMC7332161
MID - NIHMS1541399
OTO - NOTNLM
OT  - *Hispanic
OT  - *Latino
OT  - *cognitive processing therapy
OT  - *group therapy
OT  - *immigration trauma
EDAT- 2020/07/04 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - 10.1080/00207284.2019.1677469 [doi]
PST - ppublish
SO  - Int J Group Psychother. 2020;70(2):212-243. doi: 10.1080/00207284.2019.1677469.
      Epub 2019 Nov 13.


PMID- 32616623
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and
      treatments: bioethics in Utopia.
PG  - 569-573
LID - 10.1136/medethics-2020-106476 [doi]
AB  - A number of papers have appeared recently arguing for the conclusion that it is
      ethically acceptable to infect healthy volunteers with severe acute respiratory
      syndrome coronavirus 2 as part of research projects aimed at developing COVID-19 
      vaccines or treatments. This position has also been endorsed in a statement by a 
      working group for the WHO. The papers generally argue that controlled human
      infection (CHI) is ethically acceptable if (1) the risks to participants are low 
      and therefore acceptable, (2) the scientific quality of the research is high, (3)
      the research has high social value, (4) participants give full informed consent, 
      and (5) there is fair selection of participants. All five conditions are
      necessary premises in the overall argument that such research is ethically
      acceptable. The arguments concerning risk and informed consent have already been 
      critically discussed in the literature. This paper therefore looks specifically
      at the arguments relating to condition 3 'high social value' and condition 5
      'fair selection of participants' and shows that whereas they may be valid, they
      are not sound. It is highly unlikely that the conditions that are necessary for
      ethical CHI trials to take place will be fulfilled. Most, if not all, CHI trials 
      will thus be well intentioned but unethical.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Holm, Soren
AU  - Holm S
AUID- ORCID: 0000-0002-7200-5607
AD  - CSEP, Department of Law, School of Social Sciences, The University of Manchester,
      Manchester, UK soren.holm@manchester.ac.uk.
AD  - Center for Medical Ethics, HELSAM, Universitetet i Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200702
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CON - Science. 2020 May 22;368(6493):832-834. PMID: 32381590
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - *Coronavirus Infections/prevention & control
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Utopias
MH  - Viral Vaccines
PMC - PMC7371481
OTO - NOTNLM
OT  - *research ethics
OT  - *research on special populations
COIS- Competing interests: None declared.
EDAT- 2020/07/04 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - medethics-2020-106476 [pii]
AID - 10.1136/medethics-2020-106476 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):569-573. doi: 10.1136/medethics-2020-106476. Epub
      2020 Jul 2.


PMID- 32616622
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Community organisation-researcher partnerships: what concerns arise for community
      organisations and how can they be mitigated?
PG  - 693-699
LID - 10.1136/medethics-2018-105252 [doi]
AB  - Universities and research funders' growing emphasis on community partnerships,
      engagement and outreach has seen a rise in collaborations between university
      researchers and staff of community organisations (COs) on research projects. What
      ethical issues and concerns are experienced as part of these collaborations has
      largely not been described, particularly from the perspective of COs As part of a
      recent, broader qualitative study, several concerns arising during health
      research collaborations between COs and university researchers were captured
      during thematic analysis. The concerns were described in semistructured
      interviews by four staff of three COs that work with marginalised groups (ie,
      migrants and refugees, women who experience domestic violence, indigenous
      populations) in a high-income country. In this paper, the three concerns are
      taken as the starting point for ethical analysis. Interview data are first used
      to illustrate the three concerns: being restricted to a recruitment role in
      studies, reinforcement of stereotypes of marginalised groups and weakening
      CO-community relationships. The paper then explores why the concerns are morally 
      troubling and demonstrates how each concern generates feelings of disrespect,
      creates harm(s), and/or reflects or reinforces unfairness or injustice. It
      concludes by proposing three ethical criteria for CO-researcher partnerships:
      fair division of labour, balancing CO advocacy goals with research goals and
      balancing CO service goals with research goals. Where researchers and COs discuss
      how to meet these criteria at the start and during research collaborations, it
      can potentially help mitigate or prevent the occurrence of the concerns described
      in this paper.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Pratt, Bridget
AU  - Pratt B
AD  - School of Population and Global Health, University of Melbourne, Melbourne, VIC
      3053, Australia bridget.pratt@unimelb.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Female
MH  - Humans
MH  - Organizations
MH  - *Population Groups
MH  - Qualitative Research
MH  - *Research Personnel
OTO - NOTNLM
OT  - *collaboration
OT  - *community organisation
OT  - *ethics
OT  - *health research
OT  - *partnership
COIS- Competing interests: None declared.
EDAT- 2020/07/04 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/07/04 06:00
PHST- 2018/11/09 00:00 [received]
PHST- 2019/10/10 00:00 [revised]
PHST- 2019/10/17 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - medethics-2018-105252 [pii]
AID - 10.1136/medethics-2018-105252 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):693-699. doi: 10.1136/medethics-2018-105252. Epub
      2020 Jul 2.


PMID- 32616493
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Prevalence and predictors of road crash involvement among medical doctors in
      Malaysia: a cross-sectional study protocol.
PG  - e037653
LID - 10.1136/bmjopen-2020-037653 [doi]
AB  - INTRODUCTION: Medical doctors are often subjected to long working hours with
      minimal rest in between the shifts. This has led to many fatal and non-fatal road
      crash involvement (RCI). This study aims to determine the prevalence and
      predictors of RCI among medical doctors in Malaysia. METHODS AND ANALYSIS: This
      is a cross-sectional study among 375 Malaysian medical doctors who met the
      inclusion criteria. A predetermined self-administered questionnaires will be used
      to collect information regarding the sociodemographic, health status, workplace
      information, work commuting information, driving behaviour, history of RCI,
      fatigue, sleep quality, mental health status and work engagement. The
      questionnaires consist of the following instruments: (1) sociodemographic, health
      status, workplace information, work commuting information, driving behaviour and 
      history of RCI; (2) Checklist of Individual Strength Questionnaire; (3)
      Pittsburgh Sleep Quality Index; (4) 21-item Depression Anxiety and Stress Scale; 
      and (5) Utrecht's Work Engagement Scale. The data will be analysed using SPSS
      program V.24. Descriptive and inferential statistics will be used to determine
      the prevalence and predictors of RCI. ETHICS AND DISSEMINATION: This study
      protocol has received ethics approval from the Medical Research and Ethics
      Committee (MREC), Ministry of Health Malaysia (NMRR-18-3983-40609) and the Ethics
      Committee for Research Involving Human Subject, University Putra Malaysia
      (JKEUPM). Online written informed consent will be obtained from each study
      participant by the researchers. Results of the study will be disseminated through
      relevant journals and conferences. TRIAL REGISTRATION NUMBER: NCT04243291.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rashid, Aneesa Abdul
AU  - Rashid AA
AUID- ORCID: 0000-0002-7944-1364
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia aneesa@upm.edu.my.
AD  - Department of Research, Islamic Medical Association Malaysia, Cheras, Malaysia.
AD  - Malaysian Research Institute On Ageing (MYAGEING), Universiti Putra Malaysia,
      Serdang, Selangor, Malaysia.
FAU - Devaraj, Navin Kumar
AU  - Devaraj NK
AUID- ORCID: 0000-0002-9081-2162
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia.
AD  - Malaysian Research Institute On Ageing (MYAGEING), Universiti Putra Malaysia,
      Serdang, Selangor, Malaysia.
FAU - Mohd Yusof, Halidah
AU  - Mohd Yusof H
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia.
FAU - Mustapha, Fauzan
AU  - Mustapha F
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia.
FAU - Wong, Shaw Voon
AU  - Wong SV
AD  - Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Serdang,
      Malaysia.
FAU - Ismail, Ahmad Filza
AU  - Ismail AF
AD  - Department of Community Medicine, Universiti Sains Malaysia - Kampus Kesihatan,
      Kubang Kerian, Malaysia.
FAU - Ismail, Khairil Idham
AU  - Ismail KI
AD  - Department of Research, Islamic Medical Association Malaysia, Cheras, Malaysia.
AD  - Non-Communicable Disease (NCD) Unit, Putrajaya District Health Office, Ministry
      of Health Malaysia, Putrajaya, Malaysia.
FAU - Qureshi, Ahmad Munir
AU  - Qureshi AM
AD  - Visiting Faculty, Al-Shifa School of Public Health, Rawalpindi, Pakistan.
FAU - Nordin, Rusli Bin
AU  - Nordin RB
AD  - Department of Research, Islamic Medical Association Malaysia, Cheras, Malaysia.
AD  - Faculty of Health and Medical Sciences, School of Medicine, Taylor's University, 
      Subang Jaya, Malaysia.
LA  - eng
SI  - ClinicalTrials.gov/NCT04243291
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Health Status
MH  - Humans
MH  - Malaysia/epidemiology
MH  - *Physicians
MH  - Prevalence
PMC - PMC7333866
OTO - NOTNLM
OT  - *health & safety
OT  - *occupational & industrial medicine
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037653 [pii]
AID - 10.1136/bmjopen-2020-037653 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 2;10(7):e037653. doi: 10.1136/bmjopen-2020-037653.


PMID- 32616492
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Knowledge and attitude of healthcare professionals to frailty screening in
      primary care: a systematic review protocol.
PG  - e037523
LID - 10.1136/bmjopen-2020-037523 [doi]
AB  - INTRODUCTION: Frailty is an increasingly common condition in which physiological 
      decline as a result of accumulated deficits renders older people more vulnerable 
      to adverse outcomes. An increasing range of frailty screening programmes have
      been introduced in primary care to identify frail older people in order to
      deliver appropriate interventions. However, limited information on the knowledge 
      and attitude of healthcare professionals (HCPs) with respect to frailty screening
      is known. The aim of this systematic review is to provide evidence on the
      knowledge and attitude of HCP in terms of frailty screening, and potentially
      identify barriers and facilitators to frailty screening to improve implementation
      of frailty screening in primary care. METHODS/DESIGN: A systematic review of
      qualitative research will be conducted. Databases searched will be MEDLINE,
      Cumulative Index to Nursing and Allied Health Literature, PsycINFO and Web of
      Science from January 2001 to August 2019. Methods will be reported based on the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Population,
      interest, context and study design methodology was used to develop inclusion and 
      exclusion criteria with HCPs as population, frailty screening as interest and
      knowledge or attitude of HCPs to frailty screening as context. Studies with a
      qualitative methodology or a mixed-method design where the qualitative component 
      is analysed separately will also be included. Quality appraisal will be carried
      out using the Joanna Briggs Institute appraisal tool for qualitative studies.
      Data will be extracted from each selected study with thematic framework analysis 
      used to synthesise findings. ETHICS AND DISSEMINATION: This systematic review
      does not require ethical approval as primary data will not be collected. The
      findings will be disseminated at conferences and in a relevant academic journal. 
      This review will assist HCPs and relevant stakeholders to tackle the challenges
      of frailty screening in primary care. PROSPERO REGISTRATION NUMBER:
      CRD42019159007.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Okpechi, Ijeoma
AU  - Okpechi I
AUID- ORCID: 0000-0002-0850-1112
AD  - Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire,
      UK.
FAU - Randhawa, Gurch
AU  - Randhawa G
AUID- ORCID: 0000-0002-2289-5859
AD  - Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire,
      UK gurch.randhawa@beds.ac.uk.
FAU - Hewson, David
AU  - Hewson D
AUID- ORCID: 0000-0002-7656-4000
AD  - Institute for Health Research, University of Bedfordshire, Luton, Bedfordshire,
      UK.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200702
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Delivery of Health Care
MH  - *Frailty/diagnosis
MH  - Health Personnel
MH  - Humans
MH  - Primary Health Care
MH  - Qualitative Research
PMC - PMC7333811
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *health policy
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/07/04 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-037523 [pii]
AID - 10.1136/bmjopen-2020-037523 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 2;10(7):e037523. doi: 10.1136/bmjopen-2020-037523.


PMID- 32616489
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Impact of a nutritional supplement (Impryl) on male fertility: study protocol of 
      a multicentre, randomised, double-blind, placebo-controlled clinical trial
      (SUppleMent Male fERtility, SUMMER trial).
PG  - e035069
LID - 10.1136/bmjopen-2019-035069 [doi]
AB  - INTRODUCTION: Infertility is a worldwide problem and about 10%-15% of all couples
      will be affected by the inability to have children. In approximately 50% of
      infertile couples, a male factor is involved. Most of the male infertile cases
      are characterised as 'idiopathic', except for a small percentage of cases which
      are causative by a genetic aetiology. In the past decade, the role of oxidative
      stress related to sperm quality has been researched thoroughly and estimated to
      be the problem in 25%-87% of male infertility cases. Impryl is a nutritional
      supplement which works on the metabolic system and the regulation of oxidative
      stress by activating the 1-carbon cycle and therefore recycling of homocysteine. 
      We hypothesise that the nutritional supplement Impryl in men of infertile couples
      might improve the ongoing pregnancy rate. METHODS AND ANALYSIS: We designed a
      multicentre, randomised, double-blind, placebo-controlled clinical trial. We
      aimed to include 1200 male adults aged 18-50 years, part of a couple that is
      diagnosed with infertility. The couple will either start or has already been
      started with fertility treatment, that is, expectative management (duration of 6 
      months), intrauterine insemination (IUI) with or without mild ovarian stimulation
      or ovulation induction, either in vitro fertilisation (IVF) or intracytoplasmic
      sperm injection (ICSI) treatment. Male participants will be randomised in either 
      the Impryl or the placebo group, with identical appearance of the tablets to be
      distributed (doses: one tablet each day), for a total duration of maximal 6
      months. Patients can start directly with fertility treatment and/or natural
      conception. The primary outcome is the number of ongoing pregnancies confirmed by
      ultrasound at >/=10 to 12 weeks, and conceived in the time window between
      randomisation up to and including month 6 of intervention use. Secondary outcomes
      are change in semen parameters between baseline and after 3 months of
      intervention in the IUI/IVF/ICSI group, based on (prewash) total motile sperm
      count. Furthermore the number of pregnancies conceived in the optimal
      intervention time window (after full spermatogenesis of 72 days), overall number 
      of pregnancies, time to pregnancy, embryo fertilisation rate in IVF/ICSI,
      embryo-utilisation rate in IVF/ICSI, number of miscarriages, live birth rate and 
      adverse events are documented within the study period of 15 months. ETHICS AND
      DISSEMINATION: The protocol is approved by the local medical ethical review
      committee at the Radboud University Medical Centre and by the national Central
      Committee on Research Involving Human Subjects. Findings will be shared with the 
      academic and medical community, funding and patient organisations in order to
      contribute to optimisation of medical care and quality of life for patients with 
      infertility. TRIAL REGISTRATION NUMBERS: NCT03337360 and NTR6551.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Smits, Roos
AU  - Smits R
AUID- ORCID: 0000-0002-9949-2687
AD  - Obstetrics and Gynaecology, Radboudumc, Nijmegen, The Netherlands
      roos.smits@radboudumc.nl.
FAU - D'Hauwers, Kathleen
AU  - D'Hauwers K
AD  - Urology, Radboudumc, Nijmegen, The Netherlands.
FAU - IntHout, Joanna
AU  - IntHout J
AD  - Radboud Institute for Health Sciences, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Braat, Didi
AU  - Braat D
AD  - Obstetrics and Gynaecology, Radboudumc, Nijmegen, The Netherlands.
FAU - Fleischer, Kathrin
AU  - Fleischer K
AD  - Obstetrics and Gynaecology, Radboudumc, Nijmegen, The Netherlands.
AD  - MVZ VivaNeo Kinderwunschzentrum, Dusseldorf, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03337360
SI  - NTR/NTR6551
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 12001-76-2 (Vitamin B Complex)
SB  - IM
MH  - Adult
MH  - Birth Rate
MH  - *Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Infertility, Male/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Pregnancy
MH  - Pregnancy Rate
MH  - Randomized Controlled Trials as Topic
MH  - Reproductive Techniques, Assisted
MH  - Semen Analysis
MH  - Sperm Count
MH  - Vitamin B Complex/*therapeutic use
PMC - PMC7333867
OTO - NOTNLM
OT  - *male infertility
OT  - *nutritional support
OT  - *reproductive medicine
OT  - *subfertility
COIS- Competing interests: The study is conducted by the department of gynaecology and 
      obstetrics of the Radboudumc. As stated above in the funding section, an
      unrestricted grant from Goodlife Pharma B.V. was provided for the conduct of the 
      trial.
EDAT- 2020/07/04 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-035069 [pii]
AID - 10.1136/bmjopen-2019-035069 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 2;10(7):e035069. doi: 10.1136/bmjopen-2019-035069.


PMID- 32616487
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Prior surgical uterine evacuation of pregnancy and infertility: protocol for
      systematic review and meta-analysis.
PG  - e034837
LID - 10.1136/bmjopen-2019-034837 [doi]
AB  - INTRODUCTION: Prior surgical uterine evacuation is associated with an increased
      risk of infertility. However, findings are inconsistent, highlighting the need
      for a clear consensus on the effect of prior surgical uterine evacuation on the
      risk of infertility. Therefore, the aim of this systematic review and
      meta-analysis is to summarise the available evidence examining the association
      between prior surgical uterine evacuation and the risk of infertility. METHODS
      AND ANALYSIS: A systematic search of electronic databases (ie, PubMed, Scopus,
      ClinicalTrials.gov, EMBASE and ScienceDirect) will be conducted since their
      inception until October 2019 with no limit for language using a detailed
      prespecified search strategy. Both the authors will independently screen titles
      and abstracts and select full-text articles, perform data extraction and appraise
      the quality of included studies using a bias classification tool. Meta-analyses
      will be performed to calculate the overall pooled estimates using the generic
      inverse variance method. This systematic review and meta-analysis will follow the
      Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA)
      guidelines. ETHICS AND DISSEMINATION: Given that this is a protocol based on
      published data, there is no requirement for ethics approval. It is anticipated
      that the dissemination of results will be reported according to the PRISMA
      statement. The results will be published in peer-reviewed journals and presented 
      at scientific conferences. PROSPERO REGISTRATION NUMBER: CRD42019117266.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tu, Pengcheng
AU  - Tu P
AUID- ORCID: 0000-0001-7015-576X
AD  - National Research Institute for Family Planning, Beijing, China.
AD  - Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing, China.
FAU - Pei, Kaiyan
AU  - Pei K
AD  - National Research Institute for Family Planning, Beijing, China
      peikaiyan@nrifp.org.cn.
AD  - Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical
      College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Abortion, Induced/*adverse effects
MH  - Dilatation and Curettage/adverse effects
MH  - Female
MH  - Humans
MH  - Infertility, Female/*epidemiology/etiology
MH  - Meta-Analysis as Topic
MH  - Pregnancy
MH  - Systematic Reviews as Topic
MH  - Uterus/surgery
PMC - PMC7333799
OTO - NOTNLM
OT  - *gynaecology
OT  - *reproductive medicine
OT  - *subfertility
COIS- Competing interests: None declared.
EDAT- 2020/07/04 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034837 [pii]
AID - 10.1136/bmjopen-2019-034837 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 2;10(7):e034837. doi: 10.1136/bmjopen-2019-034837.


PMID- 32616486
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Scoping review protocol on maternal, newborn and child health research in
      Ethiopia.
PG  - e034307
LID - 10.1136/bmjopen-2019-034307 [doi]
AB  - INTRODUCTION: There has been a tremendous reduction in maternal and child
      mortality in the last decade. However, a significant number of deaths still occur
      disproportionately in low-income country settings. Ethiopia is the second-most
      populous nation in sub-Saharan Africa with a high maternal mortality rate of 412 
      deaths per 100 000 live births and an under-five mortality rate of 55 per 1000
      live births. This study presents a scoping review protocol to describe the
      current knowledge of maternal and child health in Ethiopia to identify gaps for
      prioritisation of future maternal, newborn and child health research. METHODS AND
      ANALYSES: A search strategy will be conducted in PubMed/MEDLINE, EMBASE and the
      WHO African Index Medicus. Researchers will independently screen title and
      abstracts followed by full texts for inclusion. Study characteristics, research
      topics, exposures and outcomes will be abstracted from articles meeting inclusion
      criteria using standardised forms. Descriptive analysis of abstracted data will
      be conducted. ETHICS AND DISSEMINATION: Data will be abstracted from published
      manuscripts and no additional ethical approval is required. The results of the
      review will be shared with maternal and child health experts in Ethiopia through 
      stakeholder meetings to prioritise research questions. Findings will be submitted
      to a peer-reviewed journal for publication, in addition to national-level and
      global-level disseminations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chan, Grace J
AU  - Chan GJ
AUID- ORCID: 0000-0002-2716-1643
AD  - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
      grace.chan@hsph.harvard.edu.
AD  - Department of Epidemiology, Harvard University T.H. Chan School of Public Health,
      Boston, Massachusetts, USA.
FAU - Getnet, Misrak
AU  - Getnet M
AD  - Health Systems Directorate, Ethiopian Public Health Institute, Addis Ababa,
      Ethiopia.
FAU - Olowojesiku, Ronke
AU  - Olowojesiku R
AD  - Department of Epidemiology, Harvard University T.H. Chan School of Public Health,
      Boston, Massachusetts, USA.
FAU - Min-Swe, Thein
AU  - Min-Swe T
AD  - Department of Epidemiology, Harvard University T.H. Chan School of Public Health,
      Boston, Massachusetts, USA.
FAU - Hunegnaw, Bezawit
AU  - Hunegnaw B
AD  - Department of Pediatrics, Saint Paul's Hospital Millennium Medical College, Addis
      Ababa, Ethiopia.
FAU - Bekele, Delayehu
AU  - Bekele D
AD  - Department of Obstetrics and Gynecology, Saint Paul's Hospital Millennium Medical
      College, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - *Child Health
MH  - *Child Mortality
MH  - Delivery of Health Care
MH  - Ethiopia/epidemiology
MH  - Humans
MH  - Infant, Newborn
MH  - Poverty
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7333800
OTO - NOTNLM
OT  - *Ethiopia
OT  - *child
OT  - *health
OT  - *maternal
OT  - *scoping review
COIS- Competing interests: None declared.
EDAT- 2020/07/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034307 [pii]
AID - 10.1136/bmjopen-2019-034307 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 2;10(7):e034307. doi: 10.1136/bmjopen-2019-034307.


PMID- 32616485
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220319
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 2
TI  - Is there an association between long-term antibiotics for acne and subsequent
      infection sequelae and antimicrobial resistance? A systematic review protocol.
PG  - e033662
LID - 10.1136/bmjopen-2019-033662 [doi]
AB  - INTRODUCTION: Antimicrobial resistance (AMR) is a global health emergency. Acne
      vulgaris is a highly prevalent condition and the dominant role antibiotics play
      in its treatment is a major concern. Antibiotics are widely used in the treatment
      of acne predominantly for their anti-inflammatory effect, hence their use in acne
      may not be optimal. Tetracyclines and macrolides are the two most common oral
      antibiotic classes prescribed, and their average use can extend from a few months
      to several years of intermittent or continuous use. The overall aim of this
      systematic review is to elucidate what is known about oral antibiotics for acne
      contributing to antibiotic treatment failure and AMR. METHODS AND ANALYSIS: A
      systematic review will be conducted to address the question: What is the existing
      evidence that long-term oral antibiotics used to treat acne in those over 8 years
      of age contribute towards antibiotic treatment failure or other outcomes
      suggestive of the impact of AMR? We will search the following databases: Embase, 
      MEDLINE, the Cochrane Library and Web of Science. Search terms will be developed 
      in collaboration with a librarian by identifying keywords from relevant articles 
      and by undertaking pilot searches. Randomised controlled trials, cohort and
      case-controlled studies conducted in any healthcare setting and published in any 
      language will be included. The searches will be re-run prior to final analyses to
      capture the recent literature. The Cochrane tool for bias assessment in
      randomised trials and ROBINS-I for the assessment of bias in non-randomised
      studies will be used to assess the risk of bias of included studies. GRADE will
      be used to make an overall assessment of the quality of evidence. A meta-analysis
      will be undertaken of the outcome measures if the individual studies are
      sufficiently homogeneous. If a meta-analysis is not possible, a qualitative
      assessment will be presented as a narrative review. ETHICS AND DISSEMINATION:
      Ethical approval is not required for this systematic-review. The results will be 
      published in a peer-reviewed journal and any deviations from the protocol will be
      clearly documented in the published manuscript of the full systematic-review.
      PROSPERO REGISTRATION NUMBER: CRD42019121738.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Bhate, Ketaki
AU  - Bhate K
AUID- ORCID: 0000-0001-5509-4428
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine Faculty of Epidemiology and Population Health, London, UK
      ketaki.bhate@lshtm.ac.uk.
FAU - Lin, Liang-Yu
AU  - Lin LY
AUID- ORCID: 0000-0003-4720-6738
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine Faculty of Epidemiology and Population Health, London, UK.
FAU - Barbieri, John
AU  - Barbieri J
AD  - Perelman School of Medicine, Department of Dermatology, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Leyrat, Clemence
AU  - Leyrat C
AD  - Department of Medical Statistics, London School of Hygiene and Tropical Medicine,
      London, UK.
FAU - Hopkins, Susan
AU  - Hopkins S
AD  - Public Health England, London, UK.
FAU - Stabler, Richard
AU  - Stabler R
AD  - London School of Hygiene and Tropical Medicine Faculty of Infectious and Tropical
      Diseases, London, UK.
FAU - Shallcross, Laura
AU  - Shallcross L
AD  - Institute of Health Informatics, Faculty of Pop Health Sciences, University
      College London, London, UK.
FAU - Smeeth, Liam
AU  - Smeeth L
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine Faculty of Epidemiology and Population Health, London, UK.
FAU - Francis, Nick A
AU  - Francis NA
AD  - School of Primary Care, Population Sciences and Medical Education, University of 
      Southampton, Southampton, UK.
FAU - Mathur, Rohini
AU  - Mathur R
AUID- ORCID: 0000-0002-3817-8790
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine Faculty of Epidemiology and Population Health, London, UK.
FAU - Langan, Sinead M
AU  - Langan SM
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine Faculty of Epidemiology and Population Health, London, UK.
FAU - Sinnott, Sarah-Jo
AU  - Sinnott SJ
AD  - Department of Non-communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine Faculty of Epidemiology and Population Health, London, UK.
LA  - eng
GR  - 205039/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - CS-2016-16-007/DH_/Department of Health/United Kingdom
GR  - DRF-2018-11-ST2-066/DH_/Department of Health/United Kingdom
GR  - T32 AR007465/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Macrolides)
SB  - IM
MH  - *Acne Vulgaris/drug therapy
MH  - *Anti-Bacterial Agents/therapeutic use
MH  - Drug Resistance, Bacterial
MH  - Humans
MH  - Macrolides
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
MH  - Treatment Failure
PMC - PMC7333805
OTO - NOTNLM
OT  - *acne
OT  - *antimicrobial resistance
OT  - *dermatological epidemiology
OT  - *epidemiology
COIS- Competing interests: JB is supported by the National Institute of Arthritis and
      Musculoskeletal and Skin Diseases of the National Institutes of Health under
      award number T32-AR-007465 and receives partial salary support through a Pfizer
      Fellowship grant to the Trustees of the University of Pennsylvania.
EDAT- 2020/07/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033662 [pii]
AID - 10.1136/bmjopen-2019-033662 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 2;10(7):e033662. doi: 10.1136/bmjopen-2019-033662.


PMID- 32616418
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1878-4046 (Electronic)
IS  - 1076-6332 (Linking)
VI  - 27
IP  - 9
DP  - 2020 Sep
TI  - Educating Radiologists to Fulfill Ethical and Professional Responsibilities as
      Sentinels.
PG  - 1325-1326
LID - S1076-6332(20)30369-X [pii]
LID - 10.1016/j.acra.2020.06.019 [doi]
FAU - Weger, Kendal
AU  - Weger K
AD  - Department of Radiology, Indiana University School of Medicine, 702 North
      Barnhill Drive, Room 1053, Indianapolis, IN 46202.
FAU - Gunderman, Richard B
AU  - Gunderman RB
AD  - Department of Radiology, Indiana University School of Medicine, 702 North
      Barnhill Drive, Room 1053, Indianapolis, IN 46202. Electronic address:
      rbgunder@iu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - United States
TA  - Acad Radiol
JT  - Academic radiology
JID - 9440159
SB  - IM
MH  - Humans
MH  - *Radiologists
EDAT- 2020/07/04 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/06/13 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - S1076-6332(20)30369-X [pii]
AID - 10.1016/j.acra.2020.06.019 [doi]
PST - ppublish
SO  - Acad Radiol. 2020 Sep;27(9):1325-1326. doi: 10.1016/j.acra.2020.06.019. Epub 2020
      Jun 30.


PMID- 32616345
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220224
IS  - 1532-7361 (Electronic)
IS  - 0039-6060 (Linking)
VI  - 168
IP  - 3
DP  - 2020 Sep
TI  - Reallocating ventilators during the coronavirus disease 2019 pandemic: Is it
      ethical?
PG  - 388-391
LID - 10.1016/j.surg.2020.04.044 [doi]
FAU - Chu, Quyen
AU  - Chu Q
AD  - Surgical Oncology, Louisiana State University Health Sciences Center-Shreveport, 
      Shreveport, LA.
FAU - Correa, Ricardo
AU  - Correa R
AD  - Department of Medicine, University of Arizona College of Medicine-Phoenix and
      Phoenix VAMC, Phoenix, AZ.
FAU - Henry, Tracey L
AU  - Henry TL
AD  - Grady Primary Care Center, Emory University School of Medicine, Atlanta, GA.
FAU - McGregor, Kyle A
AU  - McGregor KA
AD  - Lankenau Institute for Medical Research, Thomas Jefferson University,
      Philadelphia, PA.
FAU - Stoklosa, Hanni
AU  - Stoklosa H
AD  - Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston,
      MA.
FAU - Robinson, Loren
AU  - Robinson L
AD  - Christus St. Michael Hospital, Texarkana, TX.
FAU - Jha, Sachin
AU  - Jha S
AD  - Department of Anesthesia, University of Southern California, Los Angeles, CA.
FAU - Annamalai, Alagappan
AU  - Annamalai A
AD  - House Medicine, Los Angeles, CA.
FAU - Hsu, Benson S
AU  - Hsu BS
AD  - Department of Pediatrics, University of South Dakota Sanford School of Medicine, 
      Sioux Falls, SD.
FAU - Gupta, Rohit
AU  - Gupta R
AD  - Baylor College of Medicine, Houston, TX.
FAU - Patton, Desmond Upton
AU  - Patton DU
AD  - Department of Sociology, Columbia University, New York City, NY.
FAU - Moreno-Walton, Lisa A
AU  - Moreno-Walton LA
AD  - Department of Emergency Medicine, Louisiana State University - New Orleans, New
      Orleans, LA.
FAU - Butts, Christine
AU  - Butts C
AD  - Department of Emergency Medicine, Louisiana State University - New Orleans, New
      Orleans, LA.
FAU - Chai, Christy
AU  - Chai C
AD  - Department of Surgery, Baylor College of Medicine, Houston, TX.
FAU - Kuy, SreyRam
AU  - Kuy S
AD  - Department of Surgery, Baylor College of Medicine, Houston, TX.
LA  - eng
GR  - L40 MH117731/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200508
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
SB  - IM
CIN - Surgery. 2020 Sep;168(3):394-395. PMID: 32507627
CIN - Surgery. 2020 Sep;168(3):392-393. PMID: 32532467
CIN - Surgery. 2020 Sep;168(3):396. PMID: 32540037
CIN - Surgery. 2020 Sep;168(3):397. PMID: 32624227
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - *Decision Making
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - Resource Allocation/*methods
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/*supply & distribution
PMC - PMC7205622
EDAT- 2020/07/04 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - S0039-6060(20)30254-3 [pii]
AID - 10.1016/j.surg.2020.04.044 [doi]
PST - ppublish
SO  - Surgery. 2020 Sep;168(3):388-391. doi: 10.1016/j.surg.2020.04.044. Epub 2020 May 
      8.


PMID- 32616319
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1476-5616 (Electronic)
IS  - 0033-3506 (Linking)
VI  - 184
DP  - 2020 Jul
TI  - Spatial distribution of gambling exposure and vulnerability: an ecological tool
      to support health inequality reduction.
PG  - 46-55
LID - S0033-3506(20)30087-1 [pii]
LID - 10.1016/j.puhe.2020.03.023 [doi]
AB  - OBJECTIVES: Recent research by Public Health has redefined harmful gambling,
      shifting the focus from problematic people with irresponsible behaviour to
      'gamblogenic' environments. The aim of this research was to support this
      alternative perspective with concrete ecological tools for characterizing harmful
      environments. Studies that analyse the spatial distribution of gambling show that
      people living in the most disadvantaged areas have greater access to gambling and
      are more affected by the harms of gambling. Despite their quality methodology and
      usefulness, the scope of geographic access measures has been partially limited.
      These measures have been mostly structured around a single form of gambling,
      focus on only one dimension of accessibility (density or proximity) and few of
      them take into account the risks associated with each type of the game. The main 
      goal of our research was to propose an innovative method to characterize gambling
      environments in Quebec and address social inequality with respect to gambling
      exposure. This article more specifically describes the method we used to address 
      the aforementioned shortcomings by developing the gambling exposure index (GEI), 
      a more comprehensive ecological index of all games-weighted by their relative
      level of risk-to which populations are exposed. STUDY DESIGN: The study design is
      a cross-sectional ecological study. METHODS: The methodological approach was
      carried out in three stages. A GEI was operationalized and is composed of three
      dimensions: A dimension of spatial accessibility to gambling sites, a dimension
      of density of gambling places and a dimension of relative risk associated with
      different types of game. The two-step floating catchment area (2SFCA) method was 
      used to combine these three dimensions into an overall GEI index. Data were
      retrieved from a geocoded directory of all gambling sites from Loto-Quebec and
      other commercial databases. The relative risk of each type of game has been
      expressed by prevalence rates for those specific games in a Quebec population
      prevalence survey. A vulnerability to gambling index (VGI) was produced based on 
      6 socio-economic proxies of problem gambling from the 2016 Canadian census. The
      six variables were weighted and aggregated at the dissemination area (DA) level. 
      Spatial and descriptive statistical analyses were conducted to explore the
      relationship between VGI and GEI and to identify areas that are highly vulnerable
      and have a high gambling exposure. RESULTS: The findings of our analysis reveal
      widespread geographic exposure to gambling and a significant positive linear
      relationship between the GEI and the VGI. In many areas, increased accessibility 
      to gambling is significantly associated with a higher vulnerability to gambling. 
      Our findings demonstrate that in 1328 DAs in Quebec, there is a particularly
      unequal and potentially harmful geographical distribution of gambling, exposing
      9% of the population which are theoretically vulnerable to gambling to an
      increased presence of gambling. CONCLUSION: This research applied a spatial
      analytical approach to assess the association between environments, gambling and 
      vulnerability. The GEI and VGI at the DA level can serve as a monitoring tool for
      policy-makers regarding gambling exposure in the most vulnerable sectors and
      contribute to prevention and intervention strategies better adapted to the
      population. The general findings raise the ethical implications of increased
      marketing development in vulnerable neighbourhoods. As the GEI takes into account
      both the environmental determinants and the relative risk of games, it is in
      contributing to the shift in public and scientific discourse, redefining the
      subject from problematic people to problematic games and environments.
CI  - Copyright (c) 2020 The Royal Society for Public Health. Published by Elsevier
      Ltd. All rights reserved.
FAU - Papineau, E
AU  - Papineau E
AD  - National Institute of Public Health of Quebec (INSPQ), Safety, Well-being and
      Consumer Practices in Living Environments Unit, 190 Cremazie Est, Montreal,
      Quebec, H2P 1E2, Canada. Electronic address: https://collectif-jeu.ca/fr.
FAU - Robitaille, E
AU  - Robitaille E
AD  - National Institute of Public Health of Quebec (INSPQ), Safety, Well-being and
      Consumer Practices in Living Environments Unit, 190 Cremazie Est, Montreal,
      Quebec, H2P 1E2, Canada.
FAU - Samba, C P
AU  - Samba CP
AD  - National Institute of Public Health of Quebec (INSPQ), Safety, Well-being and
      Consumer Practices in Living Environments Unit, 190 Cremazie Est, Montreal,
      Quebec, H2P 1E2, Canada.
FAU - Lemetayer, F
AU  - Lemetayer F
AD  - National Institute of Public Health of Quebec (INSPQ), Safety, Well-being and
      Consumer Practices in Living Environments Unit, 190 Cremazie Est, Montreal,
      Quebec, H2P 1E2, Canada.
FAU - Kestens, Y
AU  - Kestens Y
AD  - School of Public Health, University of Montreal Department of Social and
      Preventive Medicine, 7101 Av du Parc, Montreal, Quebec, H3N 1X9, Canada.
FAU - Raynault, M-F
AU  - Raynault MF
AD  - School of Public Health, University of Montreal Department of Social and
      Preventive Medicine, 7101 Av du Parc, Montreal, Quebec, H3N 1X9, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Netherlands
TA  - Public Health
JT  - Public health
JID - 0376507
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Gambling/*epidemiology/prevention & control
MH  - Health Status Disparities
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quebec/epidemiology
MH  - Socioeconomic Factors
MH  - Spatial Analysis
MH  - *Vulnerable Populations
MH  - Young Adult
OTO - NOTNLM
OT  - Environmental analysis
OT  - Exposure
OT  - GIS
OT  - Gambling
OT  - Harmful gambling
OT  - Public health
OT  - Vulnerability
EDAT- 2020/07/04 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/04 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - S0033-3506(20)30087-1 [pii]
AID - 10.1016/j.puhe.2020.03.023 [doi]
PST - ppublish
SO  - Public Health. 2020 Jul;184:46-55. doi: 10.1016/j.puhe.2020.03.023. Epub 2020 Jun
      30.


PMID- 32616315
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20210110
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 155
IP  - 8
DP  - 2020 Oct 23
TI  - [Clinical and ethical recommendations for decision-making in nursing homes in the
      context of the COVID-19 crisis].
PG  - 356-359
LID - S0025-7753(20)30358-4 [pii]
LID - 10.1016/j.medcli.2020.06.003 [doi]
FAU - Amblas-Novellas, Jordi
AU  - Amblas-Novellas J
AD  - Catedra de Cuidados Paliativos, Centre d'Estudis Sanitaris i Socials (CESS),
      Universitat de Vic - Universitat Central de Catalunya (UVIC-UCC), Vic, Barcelona,
      Espana; Grupo de Investigacion en Cronicidad de la Cataluna Central (C3RG),
      Centre d'Estudis Sanitaris i Socials (CESS), Universitat de Vic - Universitat
      Central de Catalunya (UVIC-UCC), Vic, Barcelona, Espana; Departament de Salut,
      Generalitat de Catalunya. Electronic address: jordiamblas@gmail.com.
FAU - Gomez-Batiste, Xavier
AU  - Gomez-Batiste X
AD  - Catedra de Cuidados Paliativos, Centre d'Estudis Sanitaris i Socials (CESS),
      Universitat de Vic - Universitat Central de Catalunya (UVIC-UCC), Vic, Barcelona,
      Espana; Grupo de Investigacion en Cronicidad de la Cataluna Central (C3RG),
      Centre d'Estudis Sanitaris i Socials (CESS), Universitat de Vic - Universitat
      Central de Catalunya (UVIC-UCC), Vic, Barcelona, Espana; The Qualy
      Observatory/WHO Collaborating Centre for Public Health Palliative Care Programs
      (WHOCC), Instituto Catalan de Oncologia, Barcelona, Espana.
CN  - en representacion de los profesionales y organizaciones que han participado en el
      consenso
LA  - eng
LA  - spa
PT  - Consensus Development Conference
PT  - Journal Article
TT  - Recomendaciones eticas y clinicas para la toma de decisiones en el entorno
      residencial en contexto de la crisis de COVID-19.
DEP - 20200611
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics/methods
MH  - *Coronavirus Infections/diagnosis/therapy
MH  - Health Services for the Aged/*ethics/standards
MH  - Homes for the Aged/*ethics/standards
MH  - Humans
MH  - Interprofessional Relations/ethics
MH  - Nursing Homes/*ethics/standards
MH  - *Pandemics
MH  - Patient Participation
MH  - *Pneumonia, Viral/diagnosis/therapy
MH  - Professional-Family Relations/ethics
MH  - Professional-Patient Relations/ethics
MH  - SARS-CoV-2
MH  - Spain
PMC - PMC7287453
EDAT- 2020/07/04 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
PHST- 2020/07/04 06:00 [entrez]
AID - S0025-7753(20)30358-4 [pii]
AID - 10.1016/j.medcli.2020.06.003 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2020 Oct 23;155(8):356-359. doi: 10.1016/j.medcli.2020.06.003.
      Epub 2020 Jun 11.


PMID- 32616048
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 2
TI  - Moral competence, moral teamwork and moral action - the European Moral Case
      Deliberation Outcomes (Euro-MCD) Instrument 2.0 and its revision process.
PG  - 53
LID - 10.1186/s12910-020-00493-3 [doi]
AB  - BACKGROUND: Clinical Ethics Support (CES) services are offered to support
      healthcare professionals in dealing with ethically difficult situations.
      Evaluation of CES is important to understand if it is indeed a supportive service
      in order to inform and improve future implementation of CES. Yet, methods to
      measure outcomes of CES are scarce. In 2014, the European Moral Case Deliberation
      Outcomes Instrument (Euro-MCD) was developed to measure outcomes of Moral Case
      Deliberation (MCD). To further validate the instrument, we tested it in field
      studies and revised it. This paper presents the Euro-MCD 2.0 and describes the
      revision process. METHODS: The revision process comprised an iterative dialogue
      among the authors as Euro-MCD-project team, including empirical findings from six
      Euro-MCD field-studies and input from European experts in CES and theory.
      Empirical findings contained perceptions and experiences of MCD outcomes among
      healthcare professionals who participated in MCDs in various settings in Norway, 
      Sweden and the Netherlands. Theoretical viewpoints on CES, literature on goals of
      CES and MCD and ethics theory guided the interpretation of the empirical findings
      and final selection of MCD outcomes. RESULTS: The Euro-MCD 2.0 Instrument
      includes three domains: Moral Competence, Moral Teamwork and Moral Action. Moral 
      Competence consists of items about moral sensitivity, analytical skills and
      virtuous attitude. Moral Teamwork includes open dialogue and supportive
      relationships and Moral Action refers to moral decision-making and responsible
      care. During the revision process, we made decisions about adding and
      reformulating items as well as decreasing the number from 26 to 15 items. We also
      altered the sentence structure of items to assess the current status of outcomes 
      (e.g. 'now') instead of an assumed improvement over time (e.g. 'better') and we
      omitted the question about perceived importance. CONCLUSIONS: The Euro-MCD 2.0 is
      shorter, less complex and more strongly substantiated by an integration of
      empirical findings, theoretical reflections and dialogues with participants and
      experts. Use of the Euro-MCD 2.0 will facilitate evaluation of MCD and can
      thereby monitor and foster implementation and quality of MCD. The Euro-MCD 2.0
      will strengthen future research on evaluation of outcomes of MCD.
FAU - de Snoo-Trimp, J C
AU  - de Snoo-Trimp JC
AUID- ORCID: 0000-0002-6344-4886
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Humanities,
      Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the
      Netherlands. j.desnoo@amsterdamumc.nl.
FAU - de Vet, H C W
AU  - de Vet HCW
AUID- ORCID: 0000-0002-5454-2804
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and
      Biostatistics, Amsterdam Public Health research institute, De Boelelaan, 1117,
      Amsterdam, the Netherlands.
FAU - Widdershoven, G A M
AU  - Widdershoven GAM
AUID- ORCID: 0000-0001-7620-6812
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Humanities,
      Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the
      Netherlands.
FAU - Molewijk, A C
AU  - Molewijk AC
AUID- ORCID: 0000-0003-1944-9759
AD  - Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Medical Humanities,
      Amsterdam Public Health research institute, De Boelelaan, 1117, Amsterdam, the
      Netherlands.
AD  - Center for Medical Ethics, University of Oslo, Oslo, Norway.
FAU - Svantesson, M
AU  - Svantesson M
AUID- ORCID: 0000-0003-0679-5695
AD  - Faculty of Medicine and Health, University Health Care Research Center, Orebro
      University, Orebro, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Ethics Consultation
MH  - Humans
MH  - Morals
MH  - Netherlands
MH  - Norway
MH  - Sweden
PMC - PMC7331166
OTO - NOTNLM
OT  - *Clinical ethics support
OT  - *Evaluation research
OT  - *Instrument revision
OT  - *Mixed methods
OT  - *Moral case deliberation
OT  - *Outcomes
OT  - *Revision process
EDAT- 2020/07/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/04 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00493-3 [doi]
AID - 10.1186/s12910-020-00493-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 2;21(1):53. doi: 10.1186/s12910-020-00493-3.


PMID- 32615968
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 2
TI  - Modified paramedian versus conventional paramedian technique in the residency
      training: an observational study.
PG  - 211
LID - 10.1186/s12909-020-02118-0 [doi]
AB  - BACKGROUND: Residency training includes positive and negative aspects.
      Well-trained doctors must be educated, but the process may bring additional risks
      to patients. Anesthesiologists' performance when conducting neuraxial anesthesia 
      is related to their experience. We hypothesized that a modified neuraxial
      anesthesia method would improve both residency training and patient safety.
      METHODS: We recruited 518 patients who were scheduled for a cesarean section and 
      used spinal anesthesia (n = 256), epidural anesthesia (n = 154), and combined
      spinal-epidural anesthesia (SEA; n = 108). We observed and evaluated the
      anesthesia performance of five second-year resident anesthesiologists in elective
      cesarean sections using the conventional and modified methods. The number of
      attempts, implant error rate, and the incidence of complications were recorded
      and analyzed. RESULTS: Better success puncture attempts occurred in all three
      groups when the modified method was applied. For the groups with an implant
      assessment, the complication rate and implant error rate were lower when using
      the modified method. We employed generalized estimating equation (GEE) analysis
      to correct for possible confounding factors. When using the conventional method, 
      the resident anesthesiologists required more attempts, made more implant errors, 
      and caused more complications in patients. CONCLUSIONS: We found that a modified 
      method for neuraxial anesthesia could improve residency performance and patient
      safety. The modified method may be a suitable training process for resident
      anesthesiologists when practicing neuraxial anesthesia. TRIAL REGISTRATION: The
      study was approved by the Research Ethics Committee of National Taiwan University
      (IRB:200812040R) Clinicaltrials register: NCT03389672 .
FAU - Chen, Shih-Hong
AU  - Chen SH
AD  - Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical
      Foundation, New Taipei City, Taiwan.
FAU - Chen, Shiou-Sheng
AU  - Chen SS
AD  - Department of Urology, School of Medicine, National Yang-Ming University, Taipei,
      Taiwan.
AD  - Commission for General education, National Taiwan University of Science and
      Technology, Taipei, Taiwan.
AD  - University of Taipei, General Education Center, Taipei, Taiwan.
FAU - Lai, Chao-Lun
AU  - Lai CL
AD  - Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu
      Branch, Hsin-Chu, Taiwan.
AD  - Center for Critical Care Medicine, National Taiwan University Hospital Hsin-Chu
      Branch, Hsin-Chu, Taiwan.
AD  - Department of Internal Medicine, National Taiwan University College of Medicine, 
      Taipei, Taiwan.
AD  - Institute of Epidemiology and Preventive Medicine, College of Public Health,
      National Taiwan University, Taipei, Taiwan.
FAU - Su, Fang-Ying
AU  - Su FY
AD  - Biotechology R&D Center, National Taiwan University Hospital Hsin-Chu branch,
      Hsin-Chu, Taiwan.
FAU - Tzeng, I-Shiang
AU  - Tzeng IS
AD  - Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical
      Foundation, New Taipei City, Taiwan.
FAU - Chen, Li-Kuei
AU  - Chen LK
AD  - Anesthesiology Department of China Medical University, Taichung City, Taiwan.
      clk0619@ntu.edu.tw.
AD  - Anesthesiology Department of China Medical University Hospital, Taichung City,
      Taiwan. clk0619@ntu.edu.tw.
LA  - eng
SI  - ClinicalTrials.gov/NCT03389672
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
DEP - 20200702
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Adult
MH  - Anesthesia, Epidural/*methods
MH  - Anesthesia, Spinal/*methods
MH  - Anesthesiology/*education
MH  - Cesarean Section
MH  - Female
MH  - Humans
MH  - *Internship and Residency
MH  - Taiwan
PMC - PMC7330994
OTO - NOTNLM
OT  - Complication
OT  - Paramedian approach
OT  - Patient safety
OT  - Residency training
EDAT- 2020/07/04 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/07/04 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - 10.1186/s12909-020-02118-0 [doi]
AID - 10.1186/s12909-020-02118-0 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Jul 2;20(1):211. doi: 10.1186/s12909-020-02118-0.


PMID- 32615966
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jul 2
TI  - Pharmacists' viewpoint towards their professional role in healthcare system: a
      survey of hospital settings of Pakistan.
PG  - 610
LID - 10.1186/s12913-020-05459-0 [doi]
AB  - BACKGROUND: Pharmacy service is an essential part of a healthcare system. The
      profession of pharmacy is well recognized and is practiced to its full potential 
      in developed countries however, it is underutilized in developing countries such 
      as Pakistan. The recognition of pharmacist's role as healthcare professional is
      limited. This study aimed to document pharmacists' attitude towards their role in
      Pakistan's healthcare system, their experience with doctors and their perceptions
      towards involvement in medicines management. METHODS: A 4-month cross-sectional
      survey (Jan - Apr 18) was conducted targeting pharmacists practising in 26
      tertiary care hospitals across Pakistan using a developed and validated
      questionnaire in both Urdu/English languages. Chi square (chi(2)) test was used
      to report any associations between independent variables, i.e., education, type
      of hospital and work experience and, dependent variables, i.e., pharmacists'
      attitudes, experience, and perception. A p-value of </=0.01 with value of
      Cramer's V >/= 0.3 was considered cut-off for establishing statistical
      significance. The study was approved by ethical committee and local hospital
      committees. RESULTS: Three hundred ninety-six questionnaires were returned out of
      500, i.e., response rate = 87.9%. Most participants (92.2%) interacted with
      doctors at least once daily. Most interactions were related to drug availability 
      inquiry (72.5%). Most pharmacists (91.4%) mentioned that pharmacy duties are
      mostly clinical in nature. 93.4% of the respondents indicated that pharmacists
      are reliable source of information regarding general medicines. Furthermore,
      87.4% reasoned inadequate training for not being able to discuss issues of
      clinical nature with doctors. CONCLUSION: Pharmacists were willing to perform
      their duties and provide healthcare benefits to patients however, they seemed
      sceptical of advanced clinical pharmacy roles such as intervening in
      prescriptions and medication therapy, consultations and prescribing. There is a
      need to increase awareness regarding pharmacist's role. Therefore, it would be
      helpful if trainings and seminars are conducted on the importance of clinical
      pharmacy to improve the pharmacy services in Pakistan's healthcare system.
FAU - Khan, Nabeel
AU  - Khan N
AUID- ORCID: http://orcid.org/0000-0001-7267-2410
AD  - School of Pharmacy and Pharmaceutical Sciences, University of Sunderland,
      Sunderland, UK. nabeel.khan@research.sunderland.ac.uk.
FAU - McGarry, Ken
AU  - McGarry K
AD  - Faculty of Technology, School of Computer Science, University of Sunderland,
      Sunderland, UK.
FAU - Naqvi, Atta Abbas
AU  - Naqvi AA
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Iqbal, Muhammad Shahid
AU  - Iqbal MS
AD  - Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz
      University, Alkharj, Saudi Arabia.
FAU - Haider, Zaki
AU  - Haider Z
AD  - Department of Health and Science Management, Bahria University, Karachi,
      Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care/*organization & administration
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - Pakistan
MH  - Pharmacists/*psychology/statistics & numerical data
MH  - Pharmacy Service, Hospital/*organization & administration
MH  - Professional Role/*psychology
MH  - Surveys and Questionnaires
PMC - PMC7330985
OTO - NOTNLM
OT  - Clinical pharmacists
OT  - Clinical pharmacy service
OT  - Hospital pharmacy service
OT  - Pakistan
OT  - Pharmacists
EDAT- 2020/07/04 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/07/04 06:00
PHST- 2019/10/21 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
AID - 10.1186/s12913-020-05459-0 [doi]
AID - 10.1186/s12913-020-05459-0 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Jul 2;20(1):610. doi: 10.1186/s12913-020-05459-0.


PMID- 32615906
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201113
IS  - 1087-2981 (Electronic)
IS  - 1087-2981 (Linking)
VI  - 25
IP  - 1
DP  - 2020 Dec
TI  - The ethical advantages of video conferencing in medical education.
PG  - 1787310
LID - 10.1080/10872981.2020.1787310 [doi]
FAU - Kruger, Joshua M
AU  - Kruger JM
AUID- ORCID: 0000-0001-5742-8698
AD  - Department of Ophthalmology, Hadassah Medical Center , Jerusalem, Israel.
AD  - The Hebrew University-Hadassah School of Medicine , Jerusalem, Israel.
FAU - Chowers, Itay
AU  - Chowers I
AD  - Department of Ophthalmology, Hadassah Medical Center , Jerusalem, Israel.
AD  - The Hebrew University-Hadassah School of Medicine , Jerusalem, Israel.
LA  - eng
PT  - Letter
PL  - United States
TA  - Med Educ Online
JT  - Medical education online
JID - 9806550
SB  - IM
PMC - PMC7482868
OTO - NOTNLM
OT  - *-Medical Education
OT  - *Video conferencing
OT  - *environment
OT  - *ethics
OT  - *pharmaceutical industry
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
CRDT- 2020/07/04 06:00
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
AID - 10.1080/10872981.2020.1787310 [doi]
PST - ppublish
SO  - Med Educ Online. 2020 Dec;25(1):1787310. doi: 10.1080/10872981.2020.1787310.


PMID- 32615608
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 145
IP  - 13
DP  - 2020 Jul
TI  - [Invasive Mechanical Ventilation Therapy in the Dying Process - Step by Step].
PG  - 926-931
LID - 10.1055/a-0944-9670 [doi]
AB  - Invasive mechanical ventilation can be terminated by immediate (palliative)
      extubation or by gradual reduction of ventilation with the ventilation access
      left open (terminal weaning). Both procedures are ethically equivalent and can be
      performed in everyday life, so that individual patient factors and the experience
      of the treatment team are decisive. However, the primary goal is to ensure that
      the patient and relatives do not suffer. This article presents step by step which
      aspects are relevant: communication, adjust or stop monitoring, selection and
      implementation of the appropriate procedure, preparatory measures, recognition
      and treatment of distressing symptoms by means of drug or non-drug therapy
      options and last but not least accurate documentation.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Schwartz, Jacqueline
AU  - Schwartz J
FAU - Meier, Stefan
AU  - Meier S
FAU - Simon, Steffen T
AU  - Simon ST
FAU - Michels, Guido
AU  - Michels G
LA  - ger
PT  - Journal Article
TT  - Invasive Beatmungstherapie im Sterbeprozess beenden - Schritt fur Schritt.
DEP - 20200702
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EIN - Dtsch Med Wochenschr. 2020 Jul;145(13):e93. PMID: 32679605
MH  - Communication
MH  - Documentation/methods
MH  - Germany
MH  - Humans
MH  - Monitoring, Physiologic
MH  - Patient Acceptance of Health Care
MH  - Patient Care Team
MH  - Respiration, Artificial/adverse effects/*methods
MH  - Suction/methods
MH  - Terminal Care/*methods
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/07/03 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1055/a-0944-9670 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2020 Jul;145(13):926-931. doi: 10.1055/a-0944-9670. Epub
      2020 Jul 2.


PMID- 32615534
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1152
DP  - 2020 Sep 1
TI  - Development and validation of a combined enzymatic-digestion/mass spectrometry
      assay for Tacrolimus quantitation in cardiac biopsies.
PG  - 122215
LID - S1570-0232(20)30277-4 [pii]
LID - 10.1016/j.jchromb.2020.122215 [doi]
AB  - Recent studies report strategies for analysing immunosuppressive drugs in brain, 
      liver and renal tissue, mostly in animals: we developed and validated a two steps
      combined enzymatic digestion/mass spectrometry assay to quantify Tacrolimus (TAC)
      in heart biopsies. Our aims were to avoid sample loss and sample contamination
      during the laboratory preparation, and to limit matrix effects in the
      electrospray ionization source (ESI) of the mass spectrometer. Enzymatic tissue
      digestion followed by a liquid-liquid drug extraction in the same vial of
      reaction allowed us to reach both our aims. The assay was assessed for
      selectivity, matrix effect, linearity, Lower Limit of Quantification (LLOQ) and
      Detection (LOD), accuracy and precision, according to the "Guideline on
      Bioanalytical Method Validation (EMA). A stable isotopically labelled (SIL)
      analogue ((13)CD2-TAC) was used as internal standard. The chromatographic
      separation of the analyte took 6 min. The observed linear range of quantification
      was 0.0162-0.520 ng in terms of TAC added to the biopsies (by 50 muL of the
      corresponding working solutions). The limit of detection and the lower limit of
      quantification (LLOQ) were 0.008 and 0.0162 ng, respectively. Both the mobile
      phases contained ammonium acetate and formic acid that promote the formation of
      ammoniated precursor ions that can be easily fragmented ([M + NH4](+), TAC m/z
      821.3; (13)CD2-TAC m/z 824.3). The calibration curves were generated by plotting 
      analyte-to-internal standard peak area ratios versus TAC amount (ng) added to the
      biopsies, and using a weighted (1/x) linear regression. Curves were not forced to
      pass through the origin. Swine hearts were employed as blank matrix for all the
      analytical method validation procedures but, after approval by the ethics
      committee (by "Fondazione IRCCS Policlinico San Matteo": Protocol 20190032933),
      TAC was also quantified in endomyocardial biopsies from informed and consenting
      heart transplant patients. The study was funded by Fondazione IRCCS Policlinico
      San Matteo (RC08017617), as a part of the clinical studies on the maintenance of 
      immunosuppressive therapy in cardiac transplant patients. Tacrolimus
      concentrations in patients biopsies were expressed as ratio between the detected 
      amount of TAC (ng) in the tissue and the weight of the tissue itself (mg).
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Molinaro, Mariadelfina
AU  - Molinaro M
AD  - Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San
      Matteo, Pavia, Italy. Electronic address: m.molinaro@smatteo.pv.it.
FAU - Pellegrini, Carlo
AU  - Pellegrini C
AD  - Department of Cardiac Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia,
      Italy; Department of Clinical, Surgical, Diagnostic and Paediatric Sciences,
      University of Pavia, Italy. Electronic address: c.pellegrini@smatteo.pv.it.
FAU - Cattadori, Barbara
AU  - Cattadori B
AD  - Department of Cardiac Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia,
      Italy. Electronic address: b.cattadori@smatteo.pv.it.
FAU - De Gregori, Simona
AU  - De Gregori S
AD  - Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San
      Matteo, Pavia, Italy. Electronic address: s.degregori@smatteo.pv.it.
LA  - eng
PT  - Journal Article
DEP - 20200621
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Immunosuppressive Agents)
RN  - EC 3.4.21.64 (Endopeptidase K)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Animals
MH  - Biopsy/*methods
MH  - Drug Monitoring
MH  - Endopeptidase K
MH  - Graft Rejection
MH  - Heart Transplantation
MH  - Humans
MH  - Immunosuppressive Agents/*analysis
MH  - Limit of Detection
MH  - Linear Models
MH  - Liquid-Liquid Extraction
MH  - Mass Spectrometry/*methods
MH  - Myocardium/chemistry/*pathology
MH  - Reproducibility of Results
MH  - Swine
MH  - Tacrolimus/*analysis
OTO - NOTNLM
OT  - Enzymatic digestion
OT  - Heart biopsy
OT  - Mass spectrometry
OT  - Organ rejection
OT  - Tacrolimus
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/03 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/06/02 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - S1570-0232(20)30277-4 [pii]
AID - 10.1016/j.jchromb.2020.122215 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122215. doi:
      10.1016/j.jchromb.2020.122215. Epub 2020 Jun 21.


PMID- 32615478
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1476-5616 (Electronic)
IS  - 0033-3506 (Linking)
VI  - 185
DP  - 2020 Aug
TI  - Public health and local emergency ethics: vulnerability in Eastern Samar,
      Philippines.
PG  - 117-118
LID - S0033-3506(20)30194-3 [pii]
LID - 10.1016/j.puhe.2020.05.032 [doi]
FAU - Kahambing, J G S
AU  - Kahambing JGS
AD  - Curator and Research Coordinator for the Social Sciences, Political Science, and 
      Values Education, Leyte Normal University, Paterno Street, Tacloban City, 6500,
      Philippines. Electronic address: vince_jb7@hotmail.com.
LA  - eng
PT  - Letter
DEP - 20200629
PL  - Netherlands
TA  - Public Health
JT  - Public health
JID - 0376507
SB  - IM
PMC - PMC7324096
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - S0033-3506(20)30194-3 [pii]
AID - 10.1016/j.puhe.2020.05.032 [doi]
PST - ppublish
SO  - Public Health. 2020 Aug;185:117-118. doi: 10.1016/j.puhe.2020.05.032. Epub 2020
      Jun 29.


PMID- 32615058
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Differences in Conceptual Understanding of the "Actionability" of Incidental
      Findings and the Resultant Difference in Ethical Responsibility: An Empirical
      Study in Japan.
PG  - 187-194
LID - 10.1080/23294515.2020.1784308 [doi]
AB  - BACKGROUND: The issue of incidental findings encountered in medical researches
      and in clinical practices becomes controversial in recent years. In what
      situations should researchers and clinicians disclose incidental findings to
      study participants or patients? According to previous studies, the concept of
      "actionability" is one of most important notions in determining the management of
      incidental findings, however, the understanding of this concept is also
      inconsistent among people and the inconsistency can affect the management of
      incidental findings. That is why we surveyed the difference in conceptual
      understanding of "actionability" for incidental findings with genomic researches 
      in Japan. Methods: We conducted focus groups with individuals conducting genomics
      research or genetic testing at the National Centers in Japan, all of which are
      expected to contribute significantly to genomics research and subsequent clinical
      practice in Japan. Results: As far as our survey and analysis, there exists
      crucial discrepancy; one might consider that an "actionable" finding should be
      one that would be useful in treatment or prevention; another might consider if
      the finding could lead to a definitive diagnosis, it should be considered
      "actionable," regardless of the treatment potential of the disease; moreover
      another might considered that a finding that would lead to the opportunity to
      participate in a clinical trial was "actionable". Conclusion: Based on the
      present study which we conducted, we have examined thus far the concept of
      "actionability", which may influence the management of incidental findings. The
      present study revealed discrepancies in the understanding of this concept among
      the National Centers in Japan, which all bear similar expectations from society. 
      And this difference in "actionability" would lead to variations in management of 
      incidental findings.
FAU - Ibuki, Tomohide
AU  - Ibuki T
AD  - Faculty of Science and Technology, Tokyo University of Science, Noda-shi, Japan.
FAU - Yamamoto, Keiichiro
AU  - Yamamoto K
AUID- ORCID: 0000-0002-4763-4030
AD  - Department of Bioethics, Graduate School of Medicine, University of Tokyo, Tokyo,
      Japan.
FAU - Matsui, Kenji
AU  - Matsui K
AD  - Division of Bioethics and Division of Bioethics and Healthcare Law, National
      Cancer Center Japan, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - *Attitude of Health Personnel
MH  - *Comprehension
MH  - Disclosure/*ethics
MH  - Focus Groups
MH  - Genetic Testing/*ethics
MH  - Genomics/*ethics
MH  - Humans
MH  - *Incidental Findings
MH  - Japan
MH  - Moral Obligations
MH  - Research Personnel/*ethics
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Bioethics
OT  - *actionability
OT  - *empirical research
OT  - *focus group
OT  - *genetic research
OT  - *incidental findings
EDAT- 2020/07/03 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.1080/23294515.2020.1784308 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Jul-Sep;11(3):187-194. doi:
      10.1080/23294515.2020.1784308. Epub 2020 Jul 2.


PMID- 32615030
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1756-5391 (Electronic)
IS  - 1756-5391 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Aug
TI  - Are randomized controlled trials being conducted with the right justification?
PG  - 181-182
LID - 10.1111/jebm.12405 [doi]
AB  - OBJECTIVE: It has been estimated that much of health research may be wasted,
      resulting in billions of dollars in wasteful research spending worldwide each
      year. Given the increased use of randomized trials and their influence on
      medicine, one method to combat research waste is to conduct randomized clinical
      trials (RCTs) only when a systematic review (SR) suggests more data are needed or
      when no previous SRs are identified. Here, we analyzed RCTs to determine whether 
      SRs were cited as justification for conducting a trial. METHODS: We analyzed
      phase III RCTs published between 2016 and 2018 in New England Journal of
      Medicine, Lancet, and JAMA. We performed duplicate and independent data
      extraction to ensure the accuracy and validity of our data. For each trial, we
      extracted whether SRs were cited as justification for conducting the clinical
      trial. RESULTS: We examined 637 RCTs that cited 728 SRs. Overall, 38.1% (243/637)
      of RCTs cited an SR as either verbatim (6.9%, 44/637) or inferred (31.2%,
      199/637) for trial justification. The 79 remaining RCTs cited SRs in other ways. 
      Approximately, 49.5% (315/637) of RCTs did not cite a SR. CONCLUSIONS: Less than 
      half of the analyzed clinical trials cited a SRs as the basis for undertaking the
      trial. We believe trialists should be required to present relevant SRs to an
      ethics or peer review committee demonstrating an unmet need prior to initiating a
      trial. Eliminating research waste is both a scientific and ethical
      responsibility.
CI  - (c) 2020 Chinese Cochrane Center, West China Hospital of Sichuan University and
      John Wiley & Sons Australia, Ltd.
FAU - Walters, Corbin
AU  - Walters C
AD  - Department of Institutional Research, Oklahoma State University Center for Health
      Sciences, Tulsa, Oklahoma, USA.
FAU - Torgerson, Trevor
AU  - Torgerson T
AD  - Department of Institutional Research, Oklahoma State University Center for Health
      Sciences, Tulsa, Oklahoma, USA.
FAU - Fladie, Ian
AU  - Fladie I
AD  - Department of Institutional Research, Oklahoma State University Center for Health
      Sciences, Tulsa, Oklahoma, USA.
FAU - Clifton, Angela
AU  - Clifton A
AD  - Department of Institutional Research, Oklahoma State University Center for Health
      Sciences, Tulsa, Oklahoma, USA.
FAU - Meyer, Chase
AU  - Meyer C
AD  - Department of Institutional Research, Oklahoma State University Center for Health
      Sciences, Tulsa, Oklahoma, USA.
FAU - Vassar, Matt
AU  - Vassar M
AD  - Department of Institutional Research, Oklahoma State University Center for Health
      Sciences, Tulsa, Oklahoma, USA.
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - England
TA  - J Evid Based Med
JT  - Journal of evidence-based medicine
JID - 101497477
SB  - IM
MH  - Clinical Trials, Phase III as Topic/standards
MH  - Humans
MH  - Needs Assessment/standards
MH  - *Randomized Controlled Trials as Topic/standards
MH  - Systematic Reviews as Topic/standards
OTO - NOTNLM
OT  - evidence-based medicine
OT  - meta-analysis
OT  - randomized control trial
OT  - systematic review
EDAT- 2020/07/03 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/07/03 06:00
PHST- 2019/06/23 00:00 [received]
PHST- 2019/08/26 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.1111/jebm.12405 [doi]
PST - ppublish
SO  - J Evid Based Med. 2020 Aug;13(3):181-182. doi: 10.1111/jebm.12405. Epub 2020 Jul 
      2.


PMID- 32614729
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 6
DP  - 2020 Jun
TI  - Historical Perspectives on Ethical and Regulatory Aspects of Human Participants
      Research: Implications for Oncology Clinical Trials in Africa.
PG  - 959-965
LID - 10.1200/JGO.19.00196 [doi]
AB  - Clinical trials research involving human participants has led to numerous medical
      advances. Historically, however, clinical trials research was the source of major
      concerns for the safety and welfare of the human participants taking part in
      these studies. The ethical principles of autonomy, beneficence, and justice came 
      about in response to medical atrocities, and regulations were ultimately put in
      place to protect the rights and welfare of human participants and to maintain the
      public trust in the research enterprise. Today, clinical trials are one of the
      most heavily regulated practices in the world, and yet still not all people are
      provided the same oversights and protections, with improprieties
      disproportionately affecting poor-resource nations and vulnerable populations. As
      Africa approaches the post-communicable disease era, cancer is set to take the
      lead as the most burdensome disease, making the need for oncology clinical trials
      in Africa greater than ever before. Africa represents a heterogeneous market with
      55 countries, most with their own National Regulatory Agency (NRA) and each with 
      varying levels of regulatory maturity. This diversity creates a highly complex
      regulatory environment and causes challenges when bringing drugs to market. There
      is a large need for harmonization and increased collaboration between the African
      nations' NRAs. In addition, many African countries need to be better equipped to 
      handle research ethics committees and/or learn how to rely on neighboring
      countries with more established ethics committees. Well-run clinical trials offer
      solutions to national health care problems, and all people deserve equal access
      to their benefits.
FAU - Salhia, Bodour
AU  - Salhia B
AD  - Department of Translational Research, University of Southern California, Norris
      Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA.
FAU - Olaiya, Victoria
AU  - Olaiya V
AD  - Synteract Limited, Cambridgeshire, United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
SB  - IM
CIN - JCO Glob Oncol. 2020 Aug;6:1312-1313. PMID: 32795197
MH  - Africa
MH  - Beneficence
MH  - *Ethics Committees, Research
MH  - Humans
MH  - *Neoplasms
MH  - Social Justice
PMC - PMC7392783
EDAT- 2020/07/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1200/JGO.19.00196 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2020 Jun;6:959-965. doi: 10.1200/JGO.19.00196.


PMID- 32614545
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201218
IS  - 1606-7916 (Electronic)
IS  - 0036-3634 (Linking)
VI  - 62
IP  - 5
DP  - 2020 Sep-Oct
TI  - [Bioethics guide on scarce medical resource allocation in Mexico].
PG  - 607-609
LID - 10.21149/11747 [doi]
AB  - The bioethical inquiry about allocating fairly scarce health resources is not
      new, all countries around the world that were seriously afflicted by SARS-CoV-2
      have issued triage guidelines in order to address the dilemmas raised by the
      pandemic. There is no question about the need to create bioethical guidelines,
      since its creation provides a degree of certainty that fair and ethical decisions
      are taken. This also prevents that decisions are made in solitary and maybe
      motivated by corrupted actions. In Mexico, the creation of this guideline was a
      proactive and preventive measure to what was unavoidable, the exponential
      contagion phase of the pandemical scenario caused by Covid-19. On April 30, 2020 
      the General Sanitary Council published the Bioethical Guide to Allocate Scarce
      Resources on Critical Care Medicine in Emergency Situation. This guide has at its
      core that principle of utmost importance in social justice which main thesis is: 
      "All lives have the same value". The aim of this contribution is to provide the
      ethical and legal principles established in the aforementioned bioethi-cal
      guideline. In sum, a brief exploration of the ethical reasons that support a
      specific way to allocate scarce health resources is provided, as well as the
      foundations of the procedural part from a human rights-based approach.
FAU - Medina-Arellano, Maria de Jesus
AU  - Medina-Arellano MJ
AD  - Comite de etica del Consejo de Salubridad General. Ciudad de Mexico, Mexico.
FAU - Palacios-Gonzalez, Cesar
AU  - Palacios-Gonzalez C
AD  - Comite de etica del Consejo de Salubridad General. Ciudad de Mexico, Mexico.
FAU - Santos-Preciado, Jose Ignacio
AU  - Santos-Preciado JI
AD  - Consejo de Salubridad General. Ciudad de Mexico, Mexico.
LA  - spa
PT  - Journal Article
TT  - Guia bioetica de asignacion de recursos de medicina critica del Consejo de
      Salubridad General en Mexico.
DEP - 20200702
PL  - Mexico
TA  - Salud Publica Mex
JT  - Salud publica de Mexico
JID - 0404371
SB  - IM
MH  - Betacoronavirus
MH  - Bioethical Issues/*standards
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Decision Making
MH  - Government Agencies
MH  - Health Resources/*supply & distribution
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Mexico
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - *Practice Guidelines as Topic
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Social Justice
MH  - Triage/*ethics/standards
MH  - Value of Life
MH  - Withholding Treatment/ethics/standards
OTO - NOTNLM
OT  - *
OT  - *Covid-19
OT  - *bioethics
OT  - *triage
COIS- Declaration of conflict of interests. The authors declare that they have no
      conflict of interests.
EDAT- 2020/07/03 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/06/18 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.21149/11747 [doi]
PST - ppublish
SO  - Salud Publica Mex. 2020 Sep-Oct;62(5):607-609. doi: 10.21149/11747. Epub 2020 Jul
      2.


PMID- 32614461
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1468-4446 (Electronic)
IS  - 0007-1315 (Linking)
VI  - 71
IP  - 4
DP  - 2020 Sep
TI  - Max Weber's antinomies of the Fall: Paradisiacal ethics and the populist
      Zeitgeist.
PG  - 800-817
LID - 10.1111/1468-4446.12773 [doi]
AB  - This article points out that the way the biblical myth of the Fall has been
      interpreted in the Judeo-Christian tradition is a crucial heuristic in the works 
      of Max Weber, an assessment that hitherto largely remained unnoticed.
      Nevertheless, Weber's understanding of everyday action is closely related to the 
      various religious interpretations of what deprivations were suffered by humanity 
      as a consequence of Adam's original sin and the paradisiacal yearning for
      salvation it engenders. Moreover, Weber's interpretation of the Fall is
      characteristic for his tragic sociology in the sense that it guarantees the
      freedom to subjectively create self-conscious meaning that is, however, no longer
      embedded in a context of common knowledge. His solution to this epistemological
      problem involves a Nietzschean heroic existentialism whereby individuals give
      personality to one's character by freely choosing their own values. Yet, he also 
      realizes that many will not be able to choose by themselves and, therefore, will 
      be attracted by charismatic leaders that can invoke a paradisiacal community of
      choice. Weber's modern antinomical interpretation of the Fall is still relevant
      today because it provides insight in the epistemological underpinnings of the
      contemporary populist Zeitgeist.
CI  - (c) London School of Economics and Political Science 2020.
FAU - Thijssen, Peter
AU  - Thijssen P
AUID- ORCID: https://orcid.org/0000-0002-1202-8452
AD  - Department of Political Science, University of Antwerp, Antwerpen, Belgium.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
DEP - 20200702
PL  - England
TA  - Br J Sociol
JT  - The British journal of sociology
JID - 0373126
SB  - IM
MH  - Emotions
MH  - *Ethics
MH  - *Famous Persons
MH  - History, 20th Century
MH  - Humans
MH  - *Religion and Psychology
PS  - Weber M
FPS - Weber, M
OTO - NOTNLM
OT  - Weber
OT  - existentialism
OT  - paradisiacal yearning
OT  - populism
OT  - the Fall
EDAT- 2020/07/03 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/07/03 06:00
PHST- 2019/03/25 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.1111/1468-4446.12773 [doi]
PST - ppublish
SO  - Br J Sociol. 2020 Sep;71(4):800-817. doi: 10.1111/1468-4446.12773. Epub 2020 Jul 
      2.


PMID- 32614432
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210902
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 10
DP  - 2020 Oct 1
TI  - Unwitting Accomplices: Endocrine Disruptors Confounding Clinical Care.
LID - dgaa358 [pii]
LID - 10.1210/clinem/dgaa358 [doi]
AB  - Burgeoning evidence over the last 25 years has identified myriad synthetic
      chemicals with the capacity to alter various aspects of hormone synthesis and
      action. These endocrine-disrupting chemicals (EDCs) have been linked to various
      diseases, including reproductive disorders, metabolic diseases, and developmental
      abnormalities, among others. Exposure to EDCs arises from industrial activity,
      use of personal and home care products, and consumption of contaminated food and 
      water; however, the role of healthcare in exposing individuals to EDCs is grossly
      underappreciated. Indeed, through the use of medications as well as medical
      equipment and devices, healthcare providers are unknowing mediators of exposure
      to EDCs, chemicals that might not only promote disease but that may also
      antagonize the efficacy of treatments. The ethical implications of
      provider-dependent exposure are profound. A failure to disclose the
      endocrine-disrupting properties of medical interventions violates core principles
      of nonmaleficence, patient autonomy, and justice as well as the practice of
      informed consent. Furthermore, physicians' lack of knowledge regarding EDCs in
      medical practice artificially skews risk-benefit calculations that are
      fundamental to informed medical decision-making. To combat this underappreciated 
      ethical challenge, urgent action is required. Healthcare providers must be
      educated about endocrine disruption. Known EDCs, defined by endocrinologists,
      should be clearly labeled on all medical products, and all medication components 
      and devices should be screened for endocrine-disrupting properties. Finally,
      communication strategies must be devised to empower patients with knowledge about
      these risks. Providing ethically competent care requires an open acknowledgment
      of endocrine risks imposed by the medical community that have heretofore been
      ignored.
CI  - (c) Endocrine Society 2020.
FAU - Genco, Matthew
AU  - Genco M
AD  - Department of Medicine, University of Illinois at Chicago, Chicago, IL, US.
FAU - Anderson-Shaw, Lisa
AU  - Anderson-Shaw L
AD  - Department of Medical Education, University of Illinois at Chicago, Chicago, IL, 
      US.
FAU - Sargis, Robert M
AU  - Sargis RM
AD  - Department of Medicine, University of Illinois at Chicago, Chicago, IL, US.
AD  - Chicago Center for Health and Environment (CACHET); University of Illinois at
      Chicago, Chicago, IL, US.
LA  - eng
GR  - P30 DK020595/DK/NIDDK NIH HHS/United States
GR  - P30 ES027792/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
CIN - J Clin Endocrinol Metab. 2021 Jan 23;106(2):e1066-e1067. PMID: 33029632
CIN - J Clin Endocrinol Metab. 2021 Jan 23;106(2):e1062-e1063. PMID: 33029636
MH  - Drug Labeling/ethics/standards
MH  - Endocrine Disruptors/*adverse effects
MH  - Endocrine System/*drug effects/physiology
MH  - Environmental Exposure
MH  - Equipment and Supplies/adverse effects/standards
MH  - Humans
MH  - Iatrogenic Disease/prevention & control
MH  - Informed Consent/ethics/standards
MH  - Patient Care/*adverse effects/ethics/instrumentation
MH  - Pharmaceutical Preparations/chemistry
MH  - Truth Disclosure/*ethics
PMC - PMC7442273
EDAT- 2020/07/03 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 5862419 [pii]
AID - 10.1210/clinem/dgaa358 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Oct 1;105(10). pii: 5862419. doi:
      10.1210/clinem/dgaa358.


PMID- 32614312
OWN - NLM
STAT- MEDLINE
DCOM- 20201009
LR  - 20220415
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 36
IP  - 6-7
DP  - 2020 Jun-Jul
TI  - [Gene therapy for retinitis pigmentosa].
PG  - 607-615
LID - 10.1051/medsci/2020095 [doi]
AB  - Retinitis pigmentosa is the most common blinding inherited retinal dystrophy.
      Gene therapy is a burgeoning revolutionary approach that paves the way to
      treatment of previously incurable diseases. At the end of 2017 and 2018, a gene
      therapy, Luxturna((R)), obtained a marketing authorization by respectively the
      FDA (Food and Drug Administration) and the EMA (European Medicines Agency). This 
      treatment, with proven efficacy, is available to patients with Leber congenital
      amaurosis and retinitis pigmentosa associated with bi-allelic mutations of the
      RPE 65 gene. In this paper, we present the current advances in gene therapy for
      retinitis pigmentosa and discuss the technological, economic and ethical
      challenges to overcome for gene therapy to improve medical practices.
CI  - (c) 2020 medecine/sciences - Inserm.
FAU - Ducloyer, Jean-Baptiste
AU  - Ducloyer JB
AUID- ORCID: 0000-0002-1306-1908
AD  - Centre hospitalier universitaire de Nantes, Nantes Universite, service
      d'ophtalmologie, 1 place Alexis Ricordeau, 44093 Nantes, France - Inserm UMR
      1089, therapie genique translationnelle des maladies genetiques, IRS 2 - Nantes
      Biotech, 22 boulevard Benoni Goullin, 44200 Nantes, France.
FAU - Le Meur, Guylene
AU  - Le Meur G
AD  - Centre hospitalier universitaire de Nantes, Nantes Universite, service
      d'ophtalmologie, 1 place Alexis Ricordeau, 44093 Nantes, France - Inserm UMR
      1089, therapie genique translationnelle des maladies genetiques, IRS 2 - Nantes
      Biotech, 22 boulevard Benoni Goullin, 44200 Nantes, France.
FAU - Cronin, Therese
AU  - Cronin T
AD  - Inserm UMR 1089, therapie genique translationnelle des maladies genetiques, IRS 2
      - Nantes Biotech, 22 boulevard Benoni Goullin, 44200 Nantes, France.
FAU - Adjali, Oumeya
AU  - Adjali O
AD  - Inserm UMR 1089, therapie genique translationnelle des maladies genetiques, IRS 2
      - Nantes Biotech, 22 boulevard Benoni Goullin, 44200 Nantes, France.
FAU - Weber, Michel
AU  - Weber M
AD  - Centre hospitalier universitaire de Nantes, Nantes Universite, service
      d'ophtalmologie, 1 place Alexis Ricordeau, 44093 Nantes, France - Inserm UMR
      1089, therapie genique translationnelle des maladies genetiques, IRS 2 - Nantes
      Biotech, 22 boulevard Benoni Goullin, 44200 Nantes, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - La therapie genique des retinites pigmentaires hereditaires.
DEP - 20200702
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
MH  - Genetic Association Studies
MH  - *Genetic Therapy/economics/ethics/methods/trends
MH  - Humans
MH  - Mutation
MH  - Practice Patterns, Physicians'/standards/trends
MH  - Quality Improvement
MH  - Retinitis Pigmentosa/genetics/*therapy
EDAT- 2020/07/03 06:00
MHDA- 2020/10/10 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/10/10 06:00 [medline]
AID - 10.1051/medsci/2020095 [doi]
AID - msc190240 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2020 Jun-Jul;36(6-7):607-615. doi: 10.1051/medsci/2020095. Epub 
      2020 Jul 2.


PMID- 32613585
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20200731
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1262
DP  - 2020
TI  - Collect the Bones, Avoid the Cones: A Game-Based App for Public Engagement.
PG  - 203-216
LID - 10.1007/978-3-030-43961-3_9 [doi]
AB  - Game-based applications (apps) and serious games enable educationalists to teach 
      complex life sciences topics. Gamification principles (i.e. challenges, problem
      solving, critical thinking) improve learners' motivation and can also help
      science communicators discuss important scientific subjects and their real-world 
      context in an effective, enjoyable manner. The aim of this study was to design,
      develop and evaluate a science communication game-based app, entitled Collect the
      Bones, Avoid the Cones, on human skull anatomy for use in public engagement
      activities with younger audiences. Specifically, the app contextualised
      three-dimensional (3D) skull anatomy within a narrative about cycling and helmet 
      safety. The app was tested at the Glasgow Science Centre, with ethical approval
      from the Glasgow School of Art, to assess its potential pedagogical value, in
      terms of pre- and post-app knowledge and confidence, and general user evaluation.
      In total, 50 participants were recruited (mean age 15.6 +/- 1.647, range 7-64)
      with 62% of participants aged 7-12. Usability and educational value were rated
      highly with 70% of participants agreeing they could use the app without any
      external instructions and 90% agreeing they understand the anatomy of the skull
      better after app use. The enjoyability of the game was also positively perceived 
      with 94% of participants agreeing they enjoyed the game. Although there was no
      statistical significance in pre- and post-app knowledge scores, there was a
      statistically significant increase in players' confidence relating to skull
      anatomy (pre-app: 3.00 +/- 1.265, post-app: 4.00 +/- 1.00, Z = -5.111, p <
      0.001). These results provide promising insight into the potential of game-based 
      apps for public engagement in anatomical sciences. Future research on how the app
      influences attitudes towards helmet use in different demographic groups would be 
      valuable in identifying its full pedagogical potential.
FAU - Wong, Yasmin
AU  - Wong Y
AD  - Anatomy Facility, School of Life Sciences, College of Medical, Veterinary and
      Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
      yasminmeileiwong@gmail.com.
AD  - School of Simulation and Visualisation, The Glasgow School of Art, Glasgow, UK.
      yasminmeileiwong@gmail.com.
FAU - Rea, Paul M
AU  - Rea PM
AD  - Anatomy Facility, School of Life Sciences, College of Medical, Veterinary and
      Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
FAU - Loranger, Brian
AU  - Loranger B
AD  - School of Simulation and Visualisation, The Glasgow School of Art, Glasgow, UK.
FAU - Varsou, Ourania
AU  - Varsou O
AD  - Anatomy Facility, School of Life Sciences, College of Medical, Veterinary and
      Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - Adolescent
MH  - Bone and Bones
MH  - Child
MH  - Communication
MH  - *Health Education/methods/standards
MH  - Humans
MH  - Motivation
MH  - *Problem Solving
MH  - Skull/anatomy & histology
MH  - *Video Games/statistics & numerical data
OTO - NOTNLM
OT  - 3D modelling
OT  - Anatomical education
OT  - Public engagement
OT  - Science communication
OT  - Serious gaming
EDAT- 2020/07/03 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
AID - 10.1007/978-3-030-43961-3_9 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2020;1262:203-216. doi: 10.1007/978-3-030-43961-3_9.


PMID- 32613325
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Dec
TI  - Role-Playing Computer Ethics: Designing and Evaluating the Privacy by Design
      (PbD) Simulation.
PG  - 2911-2926
LID - 10.1007/s11948-020-00250-0 [doi]
AB  - There is growing consensus that teaching computer ethics is important, but there 
      is little consensus on how to do so. One unmet challenge is increasing the
      capacity of computing students to make decisions about the ethical challenges
      embedded in their technical work. This paper reports on the design, testing, and 
      evaluation of an educational simulation to meet this challenge. The privacy by
      design simulation enables more relevant and effective computer ethics education
      by letting students experience and make decisions about common ethical challenges
      encountered in real-world work environments. This paper describes the process of 
      incorporating empirical observations of ethical questions in computing into an
      online simulation and an in-person board game. We employed the Values at Play
      framework to transform empirical observations of design into a playable
      educational experience. First, we conducted qualitative research to discover when
      and how values levers-practices that encourage values discussions during
      technology development-occur during the design of new mobile applications. We
      then translated these findings into gameplay elements, including the goals,
      roles, and elements of surprise incorporated into a simulation. We ran the online
      simulation in five undergraduate computer and information science classes. Based 
      on this experience, we created a more accessible board game, which we tested in
      two undergraduate classes and two professional workshops. We evaluated the
      effectiveness of both the online simulation and the board game using two methods:
      a pre/post-test of moral sensitivity based on the Defining Issues Test, and a
      questionnaire evaluating student experience. We found that converting real-world 
      ethical challenges into a playable simulation increased student's reported
      interest in ethical issues in technology, and that students identified the
      role-playing activity as relevant to their technical coursework. This
      demonstrates that roleplaying can emphasize ethical decision-making as a relevant
      component of technical work.
FAU - Shilton, Katie
AU  - Shilton K
AUID- ORCID: 0000-0003-1816-6140
AD  - College of Information Studies, University of Maryland College Park, College
      Park, MD, USA. kshilton@umd.edu.
FAU - Heidenblad, Donal
AU  - Heidenblad D
AD  - College of Information Studies, University of Maryland College Park, College
      Park, MD, USA.
FAU - Porter, Adam
AU  - Porter A
AD  - Department of Computer Science, University of Maryland College Park, College
      Park, MD, USA.
FAU - Winter, Susan
AU  - Winter S
AD  - College of Information Studies, University of Maryland College Park, College
      Park, MD, USA.
FAU - Kendig, Mary
AU  - Kendig M
AD  - DELTA Resources, Inc, Washington, DC, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200701
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Computers
MH  - Humans
MH  - *Privacy
MH  - Role Playing
MH  - *Students
MH  - Surveys and Questionnaires
PMC - PMC7755628
OTO - NOTNLM
OT  - *Computer ethics
OT  - *Ethics education
OT  - *Ethics simulation
OT  - *Values at play
EDAT- 2020/07/03 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.1007/s11948-020-00250-0 [doi]
AID - 10.1007/s11948-020-00250-0 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Dec;26(6):2911-2926. doi: 10.1007/s11948-020-00250-0. Epub
      2020 Jul 1.


PMID- 32613151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 22
DP  - 2020
TI  - Venous thromboembolic events after bariatric surgery: Protocol for a systematic
      review and meta-analysis.
PG  - 10-14
LID - 10.1016/j.isjp.2020.06.001 [doi]
AB  - INTRODUCTION: Considerably large numbers of bariatric surgery (BS) procedures are
      undertaken globally, and are projected to increase with the obesity epidemic.
      Venous thromboembolic events (VTE) comprise an important cause of postoperative
      morbidity and mortality after BS and an important issue with wide clinical and
      financial repercussions. Yet, a precise extent of the prevalence of VTE after BS 
      for obesity and its mortality remains uncertain. METHODS AND ANALYSIS: In order
      to respond to this knowledge gap, we will conduct a systematic review and
      meta-analysis of the prevalence of and mortality associated with VTE after BS.
      This protocol outlines the methodology that will be used and the search
      strategies and eligibility criteria that will be utilized to identify and select 
      studies, as well as the method by which data from the selected studies will be
      extracted for analysis. PubMed, Cochrane Central Register of Controlled Trials
      (CENTRAL), WHO International Clinical Trials Registry Platform, Cochrane Library,
      MEDLINE, Scopus, clinicaltrials.gov and Google scholar will be searched from 01
      January 1990 through 10th April 2020, for original studies written in English
      that provided prevalence estimates of VTE after BS. Articles will also be
      searched for mortality estimates of VTE after BS. STROCSS (Strengthening the
      Reporting of Cohort Studies in Surgery) criteria will evaluate the methodological
      quality of the selected studies. The use of fixed effect or random effects model 
      will be subject to the findings of the statistical tests for heterogeneity.
      Publication bias will be visually estimated by inspecting the funnel plots.
      Pooled estimates will be computed. Th current protocol conforms to the Preferred 
      Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines and 
      has been submitted to the PROSPERO International Prospective Register of
      systematic reviews. No ethical clearance is required for this study. This
      systematic review and meta-analysis will be published in a peer-reviewed journal 
      and presented at national and international conferences.
CI  - (c) 2020 The Author(s).
FAU - El Ansari, Walid
AU  - El Ansari W
AD  - Department of Surgery, Hamad Medical Corporation, Doha 3050, Qatar.
AD  - College of Medicine, Qatar University, Doha 2713, Qatar.
AD  - Schools of Health and Education, University of Skovde, 541 28 Skovde, Sweden.
FAU - Sathian, Brijesh
AU  - Sathian B
AD  - Department of Surgery, Trauma and Vascular Surgery, Clinical Research, Hamad
      General Hospital, Doha 3050, Qatar.
FAU - El-Menyar, Ayman
AU  - El-Menyar A
AD  - Department of Surgery, Trauma and Vascular Surgery, Clinical Research, Hamad
      General Hospital, Doha 3050, Qatar.
AD  - Clinical Medicine, Weill Cornell Medical School, Doha 24144, Qatar.
LA  - eng
PT  - Journal Article
DEP - 20200613
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7317231
OTO - NOTNLM
OT  - Bariatric surgery
OT  - Embolism and thrombosis
OT  - Metanalysis
OT  - Morbid obesity
OT  - Obesity
OT  - Prevention and control
OT  - Systematic review
OT  - Venous thromboembolism
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.1016/j.isjp.2020.06.001 [doi]
AID - S2468-3574(20)30018-8 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Jun 13;22:10-14. doi: 10.1016/j.isjp.2020.06.001.
      eCollection 2020.


PMID- 32613084
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210705
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Inclusive innovation in telehealth.
PG  - 89
LID - 10.1038/s41746-020-0296-5 [doi]
AB  - It has been 30 years since the passage of the Americans with Disabilities Act and
      technological development has drastically changed the future for those with
      disabilities. As healthcare evolves toward promoting telehealth and
      patient-centered care, leaders must embrace persons with disabilities and
      caregivers as valued partners in design and implementation, not as passive
      "end-users". We call for a new era of inclusive innovation, a term proposed in
      this publication to describe accessible technological design for all. The next 30
      years of the ADA leading to year 2050, should reflect a new era of access,
      whereby digital health surmounts geographic, social, and economic barriers toward
      an inclusive virtual society.
CI  - (c) The Author(s) 2020.
FAU - Noel, Kimberly
AU  - Noel K
AUID- ORCID: 0000-0003-3039-6256
AD  - Stony Brook Renaissance School of Medicine, Stony Brook University Hospital, 101 
      Nicolls Rd, Stony Brook, NY United States.0000 0004 0437 5731grid.412695.d
FAU - Ellison, Brooke
AU  - Ellison B
AD  - Stony Brook School of Health Technology and Management, Stony Brook University
      Hospital, 101 Nicolls Rd, Stony Brook, NY United States.0000 0004 0437
      5731grid.412695.d
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7316740
OTO - NOTNLM
OT  - Medical ethics
OT  - Research management
COIS- Competing interestsThe authors declare no competing interests.
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.1038/s41746-020-0296-5 [doi]
AID - 296 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Jun 25;3:89. doi: 10.1038/s41746-020-0296-5. eCollection
      2020.


PMID- 32613080
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2382-1205 (Print)
IS  - 2382-1205 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - An Exploration of Knowledge and Attitudes of Medical Students and Rheumatologists
      to Placebo and Nocebo Effects: Threshold Concepts in Clinical Practice.
PG  - 2382120520930764
LID - 10.1177/2382120520930764 [doi]
AB  - INTRODUCTION: Understanding placebo and nocebo responses (context/meaning effects
      [CMEs]) is fundamental to physician agency. Specific instruction in CMEs is often
      lacking in medical education. Patient-practitioner interactions may challenge
      medical students' understanding of biomedical causality and the nexus between
      this, practical ethics and professionalism across various conceptual and applied 
      aspects of CMEs. This study compared the corpus of knowledge and phronesis
      related to CMEs between Australian graduate medical students and rheumatologists 
      to gain a sophisticated understanding of this relationship to inform curriculum
      development. METHOD: In 2013 and 2014, the authors surveyed third-year medical
      students undertaking a graduate programme in an Australian medical school and
      Australian rheumatologists to ascertain their understanding of placebo and nocebo
      responses. The survey ascertained (1) the alignment of the respondents'
      understanding of CMEs with accepted facts and concepts; (2) opinions on the
      ethical status of CMEs; and (3) responses to 2 scenarios designed to explore
      matters of biomedical causality, practical ethics and professionalism. RESULTS:
      There were 88 completed surveys returned, 53 rheumatologists and 35 students.
      Similar proportions within each group identified CMEs, with most (n = 79/88
      [89.8%]) correctly recognising a placebo (rheumatologists: 50 [94.3%], students: 
      29 [82.9%]) and approximately three-quarters (n = 65/88 [73.9%]) correctly
      recognising nocebo effects (rheumatologists: 39 [73.6%], students: 26 [74.3%]).
      Statistically significant differences between practitioners and students were
      observed in relation to the following: placebo responders and placebo
      responsiveness; placebos as a 'diagnostic tool'; placebos usage in clinical
      practice and research, and nocebo effects. CONCLUSIONS: Physicians require an
      awareness of CMEs and the fact that they arise from and influence the effective
      agency of health care professionals. Curricular emphasis is needed to permit an
      honest assessment of the components that influence when, how and why patient
      outcomes arise, and how one's agency might have neutral or negative effects but
      could be inclined towards positive and away from negative patient outcomes.
CI  - (c) The Author(s) 2020.
FAU - Arnold, Mark H
AU  - Arnold MH
AUID- ORCID: https://orcid.org/0000-0003-0546-8924
AD  - School of Rural Health (Dubbo/Orange), Sydney Medical School, Faculty of Medicine
      and Health, University of Sydney, NSW, Australia.
FAU - Finniss, Damien
AU  - Finniss D
AD  - Department of Anaesthesia & Pain Management Research Institute, Royal North Shore
      Hospital and; Faculty of Medicine and Health, University of Sydney, NSW,
      Australia.
FAU - Luscombe, Georgina M
AU  - Luscombe GM
AD  - School of Rural Health (Dubbo/Orange), Sydney Medical School, Faculty of Medicine
      and Health, University of Sydney, NSW, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, Faculty of Medicine and Health, University of Sydney, and
      Department of Haematology, Royal North Shore Hospital, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - United States
TA  - J Med Educ Curric Dev
JT  - Journal of medical education and curricular development
JID - 101690298
PMC - PMC7309386
OTO - NOTNLM
OT  - Context Effects
OT  - Nocebo Effects
OT  - Placebo Effects
OT  - Threshold Concepts
COIS- Declaration of conflicting interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/04/19 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.1177/2382120520930764 [doi]
AID - 10.1177_2382120520930764 [pii]
PST - epublish
SO  - J Med Educ Curric Dev. 2020 Jun 22;7:2382120520930764. doi:
      10.1177/2382120520930764. eCollection 2020 Jan-Dec.


PMID- 32612972
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210226
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Ethical Criteria for the Admission and Management of Patients in the ICU Under
      Conditions of Limited Medical Resources: A Shared International Proposal in View 
      of the COVID-19 Pandemic.
PG  - 284
LID - 10.3389/fpubh.2020.00284 [doi]
FAU - Tambone, Vittoradolfo
AU  - Tambone V
AD  - Institute of Philosophy of Scientific and Technological Practice (FAST), Campus
      Bio-Medico University of Rome, Rome, Italy.
FAU - Boudreau, Donald
AU  - Boudreau D
AD  - Department of Medicine, Institute of Health Sciences Education, McGill
      University, Montreal, QC, Canada.
FAU - Ciccozzi, Massimo
AU  - Ciccozzi M
AD  - Research Unit of Medical Statistic and Molecular Epidemiology, Campus Bio-Medico 
      University of Rome, Rome, Italy.
FAU - Sanders, Karen
AU  - Sanders K
AD  - Department of Business, Law and Society, St Mary's University, London, United
      Kingdom.
FAU - Campanozzi, Laura Leondina
AU  - Campanozzi LL
AD  - Institute of Philosophy of Scientific and Technological Practice (FAST), Campus
      Bio-Medico University of Rome, Rome, Italy.
FAU - Wathuta, Jane
AU  - Wathuta J
AD  - Institute for Family Studies & Ethics, Strathmore University, Nairobi, Kenya.
FAU - Violante, Luciano
AU  - Violante L
AD  - Fondazione Leonardo, Civilta delle Macchine, Rome, Italy.
FAU - Cauda, Roberto
AU  - Cauda R
AD  - Section of Infection Diseases, Department of Healthcare Surveillance and
      Bioethics, Catholic University of Sacred Heart, Rome, Italy.
FAU - Petrini, Carlo
AU  - Petrini C
AD  - Bioethics Unit, Italian National Institute of Health, Rome, Italy.
FAU - Abbate, Antonio
AU  - Abbate A
AD  - Department of Internal Medicine, Virginia Commonwealth University School of
      Medicine, Richmond, VA, United States.
FAU - Alloni, Rossana
AU  - Alloni R
AD  - Hospital Clinical Direction, Campus Bio-Medico University of Rome, Rome, Italy.
FAU - Argemi, Josepmaria
AU  - Argemi J
AD  - Division of Medicine, Gastroenterology and Hepatology Department, University of
      Pittsburgh, Pittsburgh, PA, United States.
FAU - Argemi Renom, Josep
AU  - Argemi Renom J
AD  - Department of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.
FAU - De Benedictis, Anna
AU  - De Benedictis A
AD  - Hospital Clinical Direction, Campus Bio-Medico University of Rome, Rome, Italy.
FAU - Galerneau, France
AU  - Galerneau F
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University
      School of Medicine, New Haven, CT, United States.
FAU - Garcia-Sanchez, Emilio
AU  - Garcia-Sanchez E
AD  - Department of Political Sciences, Ethics and Sociology, University CEU Cardenal
      Herrera, Valencia, Spain.
FAU - Ghilardi, Giampaolo
AU  - Ghilardi G
AD  - Institute of Philosophy of Scientific and Technological Practice (FAST), Campus
      Bio-Medico University of Rome, Rome, Italy.
FAU - Hafler, Janet Palmer
AU  - Hafler JP
AD  - Teaching and Learning Center, Yale University School of Medicine, New Haven, CT, 
      United States.
FAU - Linden, Magdalena
AU  - Linden M
AD  - Department of Medicine, Solna, Karolinska Institutet, Center for Molecular
      Medicine, Stockholm, Sweden.
FAU - Marcos, Alfredo
AU  - Marcos A
AD  - Department of Philosophy, Universidad de Valladolid, Valladolid, Spain.
FAU - Onetti Muda, Andrea
AU  - Onetti Muda A
AD  - Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
FAU - Pandolfi, Marco
AU  - Pandolfi M
AD  - Fondazione Leonardo, Civilta delle Macchine, Rome, Italy.
FAU - Pelaccia, Thierry
AU  - Pelaccia T
AD  - Prehospital Emergency Medical Service (SAMU 67), Strasbourg University Hospital, 
      Strasbourg, France.
FAU - Picozzi, Mario
AU  - Picozzi M
AD  - Center for Clinical Ethics, Insubria University, Varese, Italy.
FAU - Revello, Ruben Oscar
AU  - Revello RO
AD  - Instituto de Bioetica de la Facultad de Ciencias Medica, Pontificia Universidad
      Catolica Argentina, Buenos Aires, Argentina.
FAU - Ricci, Giovanna
AU  - Ricci G
AD  - School of Law, University of Camerino, Macerata, Italy.
FAU - Rohrbaugh, Robert
AU  - Rohrbaugh R
AD  - Department of Psychiatry, Yale University School of Medicine, New Haven, CT,
      United States.
FAU - Rossi, Patrizio
AU  - Rossi P
AD  - Central Medical Department, National Institute for Insurance against Accidents at
      Work (INAIL), Rome, Italy.
FAU - Sirignano, Ascanio
AU  - Sirignano A
AD  - School of Law, University of Camerino, Macerata, Italy.
FAU - Spagnolo, Antonio Gioacchino
AU  - Spagnolo AG
AD  - School of Medicine, Catholic University of Sacred Heart, Rome, Italy.
FAU - Stammers, Trevor
AU  - Stammers T
AD  - Centre for Bioethics and Emerging Technologies, Institute of Theology, St Mary's 
      University, London, United Kingdom.
FAU - Velazquez, Lourdes
AU  - Velazquez L
AD  - Interdisciplinary Bioethics Center, Universidad Panamericana, Mexico City,
      Mexico.
FAU - Agazzi, Evandro
AU  - Agazzi E
AD  - Interdisciplinary Bioethics Center, Universidad Panamericana, Mexico City,
      Mexico.
FAU - Mercurio, Mark
AU  - Mercurio M
AD  - Program for Biomedical Ethics, Yale University School of Medicine, New Haven, CT,
      United States.
LA  - eng
GR  - UL1 TR002649/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200616
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *COVID-19
MH  - Health Care Rationing/*ethics
MH  - *Hospitalization
MH  - Humans
MH  - Intensive Care Units/*organization & administration
MH  - *Internationality
MH  - Triage/*ethics
PMC - PMC7308475
OTO - NOTNLM
OT  - *COVID-19
OT  - *Intensive Care Unit
OT  - *common good
OT  - *disaster medicine
OT  - *ethical triage criteria
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.3389/fpubh.2020.00284 [doi]
PST - epublish
SO  - Front Public Health. 2020 Jun 16;8:284. doi: 10.3389/fpubh.2020.00284.
      eCollection 2020.


PMID- 32612848
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2055-6683 (Electronic)
IS  - 2055-6683 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Ethical research engagement with Indigenous communities.
PG  - 2055668320922706
LID - 10.1177/2055668320922706 [doi]
AB  - INTRODUCTION: Canada's colonial policies and practices have led to barriers for
      Indigenous older adults' access to healthcare and research. As a result, there is
      a need for Indigenous-led research and culturally safe practices. Morning Star
      Lodge is developing a training module to assist AgingTech researchers on ethical,
      culturally safe ways to engage Indigenous communities. This includes exploring
      Indigenous health research, community-based partnerships, reciprocal learning,
      and cultural safety; this is presented through a case study on ethically engaged 
      research. METHODS: Morning Star Lodge developed a research partnership agreement 
      with File Hills Qu'Appelle Tribal Council and established a Community Research
      Advisory Committee representing the eleven First Nations within the Tribal
      Council. The work designing the culturally safe training module is in
      collaboration with the Community Research Advisory Committee. RESULTS: Building
      research partnerships and capacities has changed the way the eleven First Nation 
      communities within File Hills Qu'Appelle Tribal Council view research. As a
      result, they now disseminate the knowledge within their own networks.
      CONCLUSIONS: Indigenous Peoples are resilient in ensuring their sustainability
      and have far more community engagement and direction. Developing culturally safe 
      approaches to care for Indigenous communities leads to self-determined research. 
      Culturally safe training modules can be applied to marginalized demographics.
CI  - (c) The Author(s) 2020.
FAU - Billan, Jennifer
AU  - Billan J
AUID- ORCID: https://orcid.org/0000-0002-8676-6407
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Starblanket, Danette
AU  - Starblanket D
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Anderson, Sadie
AU  - Anderson S
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Legare, Marlin
AU  - Legare M
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Hagel, Mikayla Caroline
AU  - Hagel MC
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Oakes, Nathan
AU  - Oakes N
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Jardine, Mackenzie
AU  - Jardine M
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Boehme, Gail
AU  - Boehme G
AD  - File Hills Qu'Appelle Tribal Council, Fort Qu'Appelle, Canada.
FAU - Dubois, Ethel
AU  - Dubois E
AD  - File Hills Qu'Appelle Tribal Council, Fort Qu'Appelle, Canada.
FAU - Spencer, Orval
AU  - Spencer O
AD  - File Hills Qu'Appelle Tribal Council, Fort Qu'Appelle, Canada.
FAU - Hotomani, Millie
AU  - Hotomani M
AD  - File Hills Qu'Appelle Tribal Council, Fort Qu'Appelle, Canada.
FAU - McKenna, Betty
AU  - McKenna B
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
FAU - Bourassa, Carrie
AU  - Bourassa C
AD  - Department of Community Health and Epidemiology, College of Medicine, University 
      of Saskatchewan, Regina, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - J Rehabil Assist Technol Eng
JT  - Journal of rehabilitation and assistive technologies engineering
JID - 101671667
PMC - PMC7309372
OTO - NOTNLM
OT  - Ethically engaged research
OT  - Indigenous community-based research
OT  - ageing
OT  - community-based partnerships
OT  - cultural safety
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.1177/2055668320922706 [doi]
AID - 10.1177_2055668320922706 [pii]
PST - epublish
SO  - J Rehabil Assist Technol Eng. 2020 Jun 22;7:2055668320922706. doi:
      10.1177/2055668320922706. eCollection 2020 Jan-Dec.


PMID- 32612826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-9361 (Print)
IS  - 2049-9361 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Antimicrobial stewardship programs; a two-part narrative review of step-wise
      design and issues of controversy Part I: step-wise design of an antimicrobial
      stewardship program.
PG  - 2049936120933187
LID - 10.1177/2049936120933187 [doi]
AB  - Regardless of one's opinion of antimicrobial stewardship programs (ASPs), it is
      hardly possible to work in hospital care and not be exposed to the term or its
      practical effects. Despite the term being relatively new, the number of
      publications in the field is vast, including several excellent reviews of general
      and specific aspects. Work in antimicrobial stewardship is complex, and includes 
      not only aspects of infectious disease and microbiology, but also of
      epidemiology, genetics, behavioural psychology, systems science, economics and
      ethics, to name a few. This review aims to take several of these aspects and the 
      scientific evidence of antimicrobial stewardship studies and merge them into two 
      questions: How should we design ASPs based on what we know today? And which are
      the most essential unanswered questions regarding antimicrobial stewardship on a 
      broader scale? This narrative review is written in two separate parts aiming to
      provide answers to the two questions. This first part is written as a step-wise
      approach to designing a stewardship intervention based on the pillars of unmet
      need, feasibility, scientific evidence and necessary core elements. It is written
      mainly as a guide to someone new to the field. It is sorted into five distinct
      steps: (a) focusing on designing aims; (b) assessing performance and local
      barriers to rational antimicrobial use; (c) deciding on intervention technique;
      (d) practical, tailored design including core element inclusion; and (e)
      evaluation and sustainability. The second part, published separately, formulates 
      ten critical questions on controversies in the field of antimicrobial
      stewardship. It is aimed at clinicians and researchers with stewardship
      experience and strives to promote discussion, not to provide answers.
CI  - (c) The Author(s), 2020.
FAU - Resman, Fredrik
AU  - Resman F
AUID- ORCID: https://orcid.org/0000-0002-3433-512X
AD  - Department of Translational Medicine, Clinical Infection Medicine, Lund
      University, Rut Lundskogs Gata 3, Plan 6, Malmo, 20502, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200619
PL  - England
TA  - Ther Adv Infect Dis
JT  - Therapeutic advances in infectious disease
JID - 101606715
PMC - PMC7307277
OTO - NOTNLM
OT  - antibiotics
OT  - antimicrobial stewardship
OT  - implementation science
COIS- Conflict of interest statement: The author declare that there is no conflict of
      interest.
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.1177/2049936120933187 [doi]
AID - 10.1177_2049936120933187 [pii]
PST - epublish
SO  - Ther Adv Infect Dis. 2020 Jun 19;7:2049936120933187. doi:
      10.1177/2049936120933187. eCollection 2020 Jan-Dec.


PMID- 32612512
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1662-5102 (Print)
IS  - 1662-5102 (Linking)
VI  - 14
DP  - 2020
TI  - The Synaptic Scaling Literature: A Systematic Review of Methodologies and Quality
      of Reporting.
PG  - 164
LID - 10.3389/fncel.2020.00164 [doi]
AB  - The maintenance of the excitability of neurons and circuits is a fundamental
      process for healthy brain functions. One of the main homeostatic mechanisms
      responsible for such regulation is synaptic scaling. While this type of
      plasticity is well-characterized through a robust body of literature, there are
      no systematic evaluations of the methodological and reporting features from these
      studies. Our review yielded 168 articles directly investigating synaptic scaling 
      mechanisms, which display relatively high impact, with a median impact factor of 
      7.76 for the publishing journals. Our methodological analysis identified that 86%
      of the articles made use of inhibitory interventions to induce synaptic scaling, 
      while only 41% of those studies contain excitatory manipulations. To verify the
      effects of synaptic scaling, the most assessed outcome was miniature excitatory
      postsynaptic current (mEPSC) recordings, performed in 71% of the articles. We
      could also observe that the field is mostly focused on mechanistic studies of the
      synaptic scaling pathways (70%), rather than the interaction with other types of 
      plasticity, such as Hebbian processes (4%). We found that more than half of the
      articles failed to describe simple features, such as regulatory compliance
      statements, ethics committee approval, or statements of conflict of interests. In
      light of these results, we discuss the strengths and pitfalls existing in
      synaptic scaling literature.
CI  - Copyright (c) 2020 Moulin, Rayee, Williams and Schioth.
FAU - Moulin, Thiago C
AU  - Moulin TC
AD  - Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de 
      Janeiro, Rio de Janeiro, Brazil.
AD  - Functional Pharmacology Unit, Department of Neuroscience, Uppsala University,
      Uppsala, Sweden.
FAU - Rayee, Danielle
AU  - Rayee D
AD  - Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de
      Janeiro, Brazil.
AD  - Department of Ophthalmology and Visual Sciences, Albert Einstein College of
      Medicine, New York, NY, United States.
FAU - Williams, Michael J
AU  - Williams MJ
AD  - Functional Pharmacology Unit, Department of Neuroscience, Uppsala University,
      Uppsala, Sweden.
FAU - Schioth, Helgi B
AU  - Schioth HB
AD  - Functional Pharmacology Unit, Department of Neuroscience, Uppsala University,
      Uppsala, Sweden.
AD  - Institute for Translational Medicine and Biotechnology, Sechenov First Moscow
      State Medical University, Moscow, Russia.
LA  - eng
PT  - Systematic Review
DEP - 20200616
PL  - Switzerland
TA  - Front Cell Neurosci
JT  - Frontiers in cellular neuroscience
JID - 101477935
PMC - PMC7309364
OTO - NOTNLM
OT  - electrophysiology
OT  - homeostatic plasticity
OT  - molecular methods
OT  - quality of reporting
OT  - risk of bias assessment
OT  - synaptic scaling
OT  - systematic review
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.3389/fncel.2020.00164 [doi]
PST - epublish
SO  - Front Cell Neurosci. 2020 Jun 16;14:164. doi: 10.3389/fncel.2020.00164.
      eCollection 2020.


PMID- 32612455
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Sexual harassment against female nurses: a systematic review.
PG  - 58
LID - 10.1186/s12912-020-00450-w [doi]
AB  - BACKGROUND: Sexual harassment is complex and has occupational hazards in nursing.
      Nurses experienced it than other employees. Female nurses are with the highest
      rate in the profession. Our aim was to determine the prevalence of sexual
      harassment against female nurses, the types, perpetrators, and health
      consequences of the harassment. METHOD: We undertook a systematic review to
      synthesize quantitative research studies found in Pubmed, Scopus, ProQuest, Web
      of Science and Google Scholar databases. The studies included were observational,
      on sexual harassment against female nurse, full text, and published in
      peer-reviewed English journals up to August 2018. Two independent reviewers
      searched the articles and extracted data from the articles. The quality of the
      articles was evaluated using the Modified Newcastle Ottawa Scale for
      Cross-Sectional Studies Quality Assessment Tool. A descriptive analysis was done 
      to determine the rate of items from the percentages or proportions of the
      studies. RESULT: The prevalence of sexual harassment against female nurses was
      43.15%. It ranged 10 to 87.30%. The 35% of the female nurses were verbally, 32.6%
      non-verbally, 31% physically and 40.8% were being harassed psychologically. The
      46.59% of them were harassed by patients, 41.10% by physicians, 27.74% by
      patients' family, 20% by nurses and 17.8% were by other coworker perpetrators.
      The 44.6% of them were developed mental problems, 30.19% physical health
      problems, 61.26% emotional, 51.79% had psychological disturbance and 16.02% with 
      social health problems. CONCLUSION: The prevalence of sexual harassment against
      female nurses is high. Female nurses are being sexually harassed by patients,
      patient families, physicians, nurses, and other coworkers. The harassment is
      affecting mental, physical, emotional, social and psychological health of female 
      nurses. It is recommended policymakers to develop guidelines on work ethics,
      legality and counseling programs. Nursing associations to initiate development of
      workplace safety policy. A safe and secure working environment is needed in the
      nursing practice and nursing curriculum in prevention strategy. Research is
      needed on factors associated with sexual harassment. Since only female nurses
      were the participants, it could not be representative of all nurses. There was no
      fund of this review.
CI  - (c) The Author(s) 2020.
FAU - Kahsay, Woldegebriel Gebregziabher
AU  - Kahsay WG
AD  - Department of Community Health and Geriatric Nursing, School of Nursing and
      Midwifery, International Campus, Tehran University of Medical Sciences (IC-TUMS),
      Tehran, Iran.grid.411705.60000 0001 0166 0922
AD  - Department of Midwifery, College of Medicine and Health Sciences, Adigrat
      University, Adigrat, Tigray Ethiopia.grid.472243.40000 0004 1783 9494
FAU - Negarandeh, Reza
AU  - Negarandeh R
AUID- ORCID: 0000-0002-7597-5094
AD  - Nursing and Midwifery Care Research Center, School of Nursing and Midwifery,
      Tehran University of Medical Sciences, Nosrat St., Tohid Sq., Tehran, Postal
      code: 1419733171 Iran.grid.411705.60000 0001 0166 0922
FAU - Dehghan Nayeri, Nahid
AU  - Dehghan Nayeri N
AD  - Department of Critical Care Nursing and Nursing Management, School of Nursing and
      Midwifery, Tehran University of Medical Sciences, Tehran, Iran.grid.411705.60000 
      0001 0166 0922
FAU - Hasanpour, Merzieh
AU  - Hasanpour M
AD  - Department of Pediatrics Nursing and Neonatal Intensive Care, School of Nursing
      and Midwifery, Tehran University of Medical Sciences, Tehran,
      Iran.grid.411705.60000 0001 0166 0922
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
EIN - BMC Nurs. 2020 Jul 13;19:64. PMID: 32684838
PMC - PMC7324991
OTO - NOTNLM
OT  - Female nurses
OT  - Health consequences
OT  - Perpetrators
OT  - Prevalence
OT  - Sexual harassment
COIS- Competing interestsWe do not have potential conflicts of interest with respect to
      the research, authorship, and publication of this article.
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.1186/s12912-020-00450-w [doi]
AID - 450 [pii]
PST - epublish
SO  - BMC Nurs. 2020 Jun 29;19:58. doi: 10.1186/s12912-020-00450-w. eCollection 2020.


PMID- 32612382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1178-7090 (Print)
IS  - 1178-7090 (Linking)
VI  - 13
DP  - 2020
TI  - Role of Inhaled Methoxyflurane in the Management of Acute Trauma Pain.
PG  - 1547-1555
LID - 10.2147/JPR.S252222 [doi]
AB  - Adequate treatment of trauma pain is an integral part of the management of trauma
      patients, not just for ethical reasons but also because undertreated pain can
      lead to increased morbidities and worse long-term outcomes. Trauma pain
      management presents challenges in the pre-hospital setting, particularly in
      adverse or hostile environments as well as in busy emergency departments (EDs).
      Inhaled methoxyflurane, administered at analgesic doses via a disposable inhaler,
      has recently become available in Europe for the emergency treatment of moderate
      to severe pain in conscious adult trauma patients. A growing body of evidence
      demonstrates that inhaled methoxyflurane is well tolerated and effective in
      providing a rapid onset of analgesia. In this paper, we discuss the rationale for
      methoxyflurane use in trauma pain management, data from clinical trials recently 
      conducted in Europe, its efficacy and safety profile compared to current standard
      treatments, its place in therapy and organizational impact. We conclude that
      inhaled methoxyflurane represents an effective treatment option in the different 
      settings where trauma patients require rapid and flexible pain resolution, with
      potential organizational advantages.
CI  - (c) 2020 Fabbri et al.
FAU - Fabbri, Andrea
AU  - Fabbri A
AUID- ORCID: 0000-0002-9837-4638
AD  - Department of Emergency Medicine, Morgagni-Pierantoni Hospital, Forli, Italy.
FAU - Ruggiano, Germana
AU  - Ruggiano G
AD  - Emergency Medicine Department, Santa Maria Annunziata Hospital, Florence, Italy.
FAU - Garcia Collado, Sergio
AU  - Garcia Collado S
AD  - Hospital Recoletas Campo Grande, Valladolid, Spain.
FAU - Ricard-Hibon, Agnes
AU  - Ricard-Hibon A
AD  - Service SAMU-SMUR-SAU, GHT Nord Ouest Vexin Val d'Oise, Pontoise 95, France.
FAU - Restelli, Umberto
AU  - Restelli U
AUID- ORCID: 0000-0001-6831-3044
AD  - Center for Health Economics, Social and Health Care Management, LIUC - Universita
      Cattaneo, Castellanza, VA, Italy.
AD  - School of Public Health, Faculty of Health Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
FAU - Sbrana, Giovanni
AU  - Sbrana G
AUID- ORCID: 0000-0002-6143-1387
AD  - Anaesthesia, Intensive Care, Emergency Medicine, Grosseto HEMS, ASL Toscana Sud
      Est, Grosseto, Italy.
FAU - Marinangeli, Franco
AU  - Marinangeli F
AUID- ORCID: 0000-0002-4931-7717
AD  - Department of Anesthesiology and Intensive Care, University of L'Aquila,
      L'Aquila, Italy.
FAU - Farina, Alberto
AU  - Farina A
AUID- ORCID: 0000-0003-1896-1179
AD  - Medical Affairs Department, Mundipharma Pharmaceuticals Srl, Milan, Italy.
FAU - Coffey, Frank
AU  - Coffey F
AUID- ORCID: 0000-0002-2096-6895
AD  - DREEAM - Department of Research and Education in Emergency Medicine Acute
      Medicine and Major Trauma, Nottingham University Hospitals' NHS Trust,
      Nottingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - New Zealand
TA  - J Pain Res
JT  - Journal of pain research
JID - 101540514
PMC - PMC7323816
OTO - NOTNLM
OT  - analgesia
OT  - emergency
OT  - non-opioid pain management
OT  - pre-hospital
COIS- Dr Umberto Restelli and Dr Frank Coffey report grants from Mundipharma, during
      the conduct of the study. Dr Alberto Farina is an employee for Mundipharma
      Pharmaceuticals srl. The authors report no other conflicts of interest in this
      work.
EDAT- 2020/07/03 06:00
MHDA- 2020/07/03 06:01
CRDT- 2020/07/03 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/03 06:01 [medline]
AID - 10.2147/JPR.S252222 [doi]
AID - 252222 [pii]
PST - epublish
SO  - J Pain Res. 2020 Jun 25;13:1547-1555. doi: 10.2147/JPR.S252222. eCollection 2020.


PMID- 32611746
OWN - NLM
STAT- MEDLINE
DCOM- 20200714
LR  - 20220415
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - Impact of COVID-19 pandemic on mental health of young people and adults: a
      systematic review protocol of observational studies.
PG  - e039426
LID - 10.1136/bmjopen-2020-039426 [doi]
AB  - INTRODUCTION: Since the WHO declared COVID-19 as a pandemic, the spread of the
      new coronavirus has been the focus of attention of scientists, governments and
      populations. One of the main concerns is the impact of this pandemic on health
      outcomes, mainly on mental health. Even though there are a few empirical studies 
      on COVID-19 and mental health, so far, there is no systematic review about the
      impact of COVID-19 on mental health of young people and adults yet. We aim to
      critically synthesise the scientific evidence about the impact of the COVID-19
      pandemic on the mental health of young people and adults. METHODS AND ANALYSIS: A
      systematic review will be performed through eight databases: MEDLINE (Medical
      Literature Analysis and Retrieval System Online), ISI-of-Knowledge, CENTRAL
      (Cochrane Central Register of Controlled Trials), EMBASE (Excerpta Medica
      Database), SCOPUS, LILACS (Latin American and Caribbean Health Sciences
      Literature), PsycINFO (Psychology Information) and CNKI (Chinese National
      Knowledge Infrastructure), from inception until 30 June 2020. No restriction
      regarding the publication date, setting or languages will be considered.
      Preliminary search strategies were carried out on 29 March 2020 and will be
      updated in June 2020. The primary outcomes will be the prevalence and the
      severity of psychological symptoms in young people and adults (>18 years old)
      resulting from the impact of COVID-19 pandemic. Study selection will follow the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist.
      Pooled standardised mean differences and 95% CIs will be calculated. The risk of 
      bias of the observational studies will be assessed through the Methodological
      Index for Non-Randomised Studies (MINORS). Additionally, if sufficient data are
      available, a meta-analysis will be conducted. Heterogeneity between the studies
      will be determined by the I(2) statistics. Subgroup analyses will also be
      performed. Publication bias will be checked with funnel plots and Egger's test.
      Heterogeneity will be explored by random-effects analysis. ETHICS AND
      DISSEMINATION: Ethical assessment was not required. Findings will be disseminated
      through peer-reviewed publication and will be presented at conferences related to
      this field. PROSPERO REGISTRATION NUMBER: CRD42020177366.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Silva Junior, Fernando Jose Guedes da
AU  - Silva Junior FJGD
AUID- ORCID: http://orcid.org/0000-0001-5731-632X
AD  - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil.
FAU - Sales, Jaqueline Carvalho E Silva
AU  - Sales JCES
AD  - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil.
FAU - Monteiro, Claudete Ferreira de Souza
AU  - Monteiro CFS
AD  - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil.
FAU - Costa, Ana Paula Cardoso
AU  - Costa APC
AD  - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil.
FAU - Campos, Luana Ruth Braga
AU  - Campos LRB
AD  - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil.
FAU - Miranda, Priscilla Ingrid Gomes
AU  - Miranda PIG
AUID- ORCID: http://orcid.org/0000-0001-8948-7158
AD  - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil.
FAU - Monteiro, Thiago Alberto de Souza
AU  - Monteiro TAS
AD  - Faculty of Medicine, Centro Universitario Uninovafapi, Teresina, Piaui, Brazil.
FAU - Lima, Regina Aparecida Garcia
AU  - Lima RAG
AD  - Maternal-Infant and Public Health Nursing Department, University of Sao Paulo at 
      Ribeirao Preto College of Nursing, Ribeirao Preto, Sao Paulo, Brazil.
FAU - Lopes-Junior, Luis Carlos
AU  - Lopes-Junior LC
AUID- ORCID: http://orcid.org/0000-0002-2424-6510
AD  - Health Sciences Center, Nursing Department, Universidade Federal do Espirito
      Santo, Vitoria, Espirito Santo, Brazil luisgen@usp.br.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Behavioral Symptoms/diagnosis/epidemiology/etiology
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/psychology
MH  - Humans
MH  - Mental Health/*statistics & numerical data
MH  - Pandemics/*statistics & numerical data
MH  - *Pneumonia, Viral/epidemiology/psychology
MH  - Psychiatric Status Rating Scales
MH  - Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
PMC - PMC7358102
OTO - NOTNLM
OT  - Adult Psychiatry
OT  - Adults
OT  - COVID-19
OT  - Coronavirus
OT  - Mental Health
OT  - Public Health Nursing
OT  - Young
OT  - adult psychiatry
OT  - mental health
OT  - public health
COIS- Competing interests: None declared.
EDAT- 2020/07/03 06:00
MHDA- 2020/07/15 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
AID - bmjopen-2020-039426 [pii]
AID - 10.1136/bmjopen-2020-039426 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e039426. doi: 10.1136/bmjopen-2020-039426.


PMID- 32611745
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - Flare-IBD: development and validation of a questionnaire based on patients'
      messages on an internet forum for early detection of flare in inflammatory bowel 
      disease: study protocol.
PG  - e037211
LID - 10.1136/bmjopen-2020-037211 [doi]
AB  - INTRODUCTION: Crohn's disease and ulcerative colitis, the two major forms of
      inflammatory bowel disease (IBD), are chronic disabling conditions characterised 
      by flares followed by periods of remission. However, patients with IBD are seen
      every 3-6 months in the outpatient clinic, and the occurrence of a flare between 
      two outpatient visits is not captured. To our knowledge, there is no validated
      patient-reported outcome (PRO) tool to measure the phenomenon of flare in IBD.
      This study aimed to use an innovative methodology to collect messages posted by
      patients in an internet forum for developing and validating a PRO measuring flare
      in IBD. METHODS AND ANALYSIS: The design involves (1) computer engineering
      sciences for scraping extraction of messages posted in an internet forum and for 
      identification of messages related to flare; (2) qualitative methods for thematic
      content analyse of the messages posted, for candidate items generation, for items
      selection (Delphi process) and for items adjustment ('think-aloud' interviews)
      and (3) quantitative methods for psychometric validation of the PRO. ETHICS AND
      DISSEMINATION: Ethical approval was obtained from the Comite de Protection des
      Personnes (CPP) CPP Nord-Ouest I (19.07.15.44139) in November 2019. The project
      aims to provide a tool to evaluate IBD flare in current medical practice that is 
      constructed with patients' perspectives. Items generation from a source
      corresponding to exchanges in an internet forum is an innovative method in this
      field and provides a wider coverage of qualitative data. If such a forum can
      result in interesting material, then this could be a new methodological
      perspective for generating items for questionnaires. Findings will be reported
      and disseminated widely through international peer-reviewed journal publications,
      oral and poster presentations at scientific conferences. TRIAL REGISTRATION
      NUMBER: NCT04180345.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ricci, Laetitia
AU  - Ricci L
AUID- ORCID: 0000-0002-6760-1674
AD  - CHRU-Nancy, INSERM, Universite de Lorraine, CIC 1433 Clinical Epidemiology,
      F-54000 Nancy, France, Nancy, France l.ricci@chru-nancy.fr.
FAU - Epstein, Jonathan
AU  - Epstein J
AD  - CHRU-Nancy, INSERM, Universite de Lorraine, CIC 1433 Clinical Epidemiology,
      F-54000 Nancy, France, Nancy, France.
AD  - Universite de Lorraine, APEMAC, F-54000, Nancy, France.
FAU - Buisson, Anne
AU  - Buisson A
AD  - AFA Crohn RCH France, Paris, France.
FAU - Devos, Corinne
AU  - Devos C
AD  - AFA Crohn RCH France, Paris, France.
FAU - Toussaint, Yannick
AU  - Toussaint Y
AD  - Laboratoire lorrain de recherche en informatique et ses applications, Universite 
      de Lorraine, Nancy, France.
FAU - Peyrin-Biroulet, Laurent
AU  - Peyrin-Biroulet L
AD  - INSERM, U1256 NGERE and gastroenterology Department, CHRU-Nancy, Universite de
      Lorraine, Nancy, France.
FAU - Guillemin, Francis
AU  - Guillemin F
AD  - CHRU-Nancy, INSERM, Universite de Lorraine, CIC 1433 Clinical Epidemiology,
      F-54000 Nancy, France, Nancy, France.
AD  - Universite de Lorraine, APEMAC, F-54000, Nancy, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04180345
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Inflammatory Bowel Diseases/diagnosis
MH  - Internet
MH  - Surveys and Questionnaires
PMC - PMC7332197
OTO - NOTNLM
OT  - *World Wide Web technology
OT  - *inflammatory bowel disease
OT  - *public health
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/07/03 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2020-037211 [pii]
AID - 10.1136/bmjopen-2020-037211 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e037211. doi: 10.1136/bmjopen-2020-037211.


PMID- 32611743
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - Effect of RaceRunning on cardiometabolic disease risk factors and functional
      mobility in young people with moderate-to-severe cerebral palsy: protocol for a
      feasibility study.
PG  - e036469
LID - 10.1136/bmjopen-2019-036469 [doi]
AB  - INTRODUCTION: There is consistent evidence that people with cerebral palsy (CP)
      do not engage in the recommended physical activity guidelines for the general
      population from a young age. Participation in moderate-to-vigorous physical
      activity is particularly reduced in people with CP who have a moderate-to-severe 
      disability. RaceRunning is a growing disability sport that provides an
      opportunity for people with moderate-to-severe disability to participate in
      physical activity in the community. It allows those who are unable to walk
      independently to propel themselves using a RaceRunning bike, which has a
      breastplate for support but no pedals. The aim of this study is to examine the
      feasibility and acceptability of RaceRunning for young people with
      moderate-to-severe CP and the feasibility of conducting a definitive study of the
      effect of RaceRunning on cardiometabolic disease risk factors and functional
      mobility. METHODS AND ANALYSIS: Twenty-five young people (age 5-21 years) with CP
      or acquired brain injury affecting coordination will be included in this
      single-arm intervention study. Participants will take part in one RaceRunning
      session each week for 24 weeks. Outcomes assessed at baseline, 12 and 24 weeks
      include body mass index, waist circumference, blood pressure, muscle strength,
      cardiorespiratory fitness, physical activity and sedentary behaviour, functional 
      mobility, activity competence and psychosocial impact. Adverse events will be
      systematically recorded throughout the 24 weeks. Focus groups will be conducted
      with participants and/or parents to explore their views and experiences of taking
      part in RaceRunning. ETHICS AND DISSEMINATION: Approval has been granted by Queen
      Margaret University Research Ethics Committee (REC) and the South East of
      Scotland REC. Results will be disseminated through peer-reviewed journals and
      distributed to people with CP and their families through RaceRunning and Athletic
      Clubs, National Health Service trusts and organisations for people with
      disabilities. TRIAL REGISTRATION NUMBER: NCT04034342; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ryan, Jennifer
AU  - Ryan J
AUID- ORCID: 0000-0003-3768-2132
AD  - College of Health and Life Sciences, Brunel University London, Uxbridge, UK
      jennifer.ryan@brunel.ac.uk.
AD  - Department of Public Health and Epidemiology, Royal College of Surgeons in
      Ireland, Dublin, Ireland.
FAU - Theis, Nicola
AU  - Theis N
AD  - School of Sport and Exercise, University of Gloucestershire, Cheltenham,
      Gloucestershire, UK.
FAU - Koufaki, Pelagia
AU  - Koufaki P
AD  - Centre for Health, Activity and Rehabilitation Research, Queen Margaret
      University Edinburgh, Musselburgh, East Lothian, UK.
FAU - Phillips, Shaun
AU  - Phillips S
AD  - Institute for Sport, Physical Education and Health Sciences, The University of
      Edinburgh, Edinburgh, UK.
FAU - Anokye, Nana
AU  - Anokye N
AD  - Health Economics Research Group, Brunel University, London, Middlesex, UK.
FAU - Andreopoulou, Georgia
AU  - Andreopoulou G
AD  - Centre for Health, Activity and Rehabilitation Research, Queen Margaret
      University Edinburgh, Musselburgh, East Lothian, UK.
FAU - Kennedy, Fiona
AU  - Kennedy F
AD  - Centre for Health, Activity and Rehabilitation Research, Queen Margaret
      University Edinburgh, Musselburgh, East Lothian, UK.
FAU - Jagadamma, Kavi C
AU  - Jagadamma KC
AD  - Centre for Health, Activity and Rehabilitation Research, Queen Margaret
      University Edinburgh, Musselburgh, East Lothian, UK.
FAU - vanSchie, Petra
AU  - vanSchie P
AD  - Department of Rehabilitation Medicine, Amsterdam University Medical Centres,
      Amsterdam, Noord-Holland, The Netherlands.
FAU - Dines, Hannah
AU  - Dines H
AD  - Department of Exercise and Sports Science, Manchester Metropolitan University,
      Manchester, Greater Manchester, UK.
FAU - van der Linden, Marietta L
AU  - van der Linden ML
AD  - Centre for Health, Activity and Rehabilitation Research, Queen Margaret
      University Edinburgh, Musselburgh, East Lothian, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04034342
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Cardiovascular Diseases
MH  - *Cerebral Palsy
MH  - Child
MH  - Child, Preschool
MH  - Feasibility Studies
MH  - Humans
MH  - Risk Factors
MH  - Scotland
MH  - State Medicine
MH  - Young Adult
PMC - PMC7332180
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *paediatric neurology
OT  - *preventive medicine
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/03 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - bmjopen-2019-036469 [pii]
AID - 10.1136/bmjopen-2019-036469 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e036469. doi: 10.1136/bmjopen-2019-036469.


PMID- 32611742
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - Cohort profile: Resettlement in Uprooted Groups Explored (REFUGE)-a longitudinal 
      study of mental health and integration in adult refugees from Syria resettled in 
      Norway between 2015 and 2017.
PG  - e036101
LID - 10.1136/bmjopen-2019-036101 [doi]
AB  - PURPOSE: In the field of forced migration and mental health research,
      longitudinal studies with large sample sizes and rigorous methodology are
      lacking. Therefore, the Resettlement in Uprooted Groups Explored (REFUGE)-study
      was initiated in order to enhance current knowledge on mental health, quality of 
      life and integration among adult refugees from Syria resettled in Norway. The
      main aims of the study are to investigate risk and protective factors for mental 
      ill health in a longitudinal perspective; to trace mental health trajectories and
      investigate important modifiers of these trajectories and to explore the
      association between mental health and integration in the years following
      resettlement. The aims will be pursued by combining data from a longitudinal,
      three-wave questionnaire survey with data from population-based registries on
      education; work participation and sick-leave; healthcare utilisation and drug
      prescription. The goal is to incorporate the data in an internationally shared
      database, the REFUGE-database, where collaborating researchers may access and use
      data from the study as well as deposit data from similar studies. PARTICIPANTS:
      Adult (>/=18 years), Syrian citizens who arrived in Norway as quota refugees,
      asylum seekers or through Norway's family reunion programme between 1 January
      2015 and 31 December 2017. Of the initial 9990 sampled individuals for the first 
      wave of the study (REFUGE-I), 8752 were reached by post or telephone and 902
      responded (response rate=10.3%). FINDINGS TO DATE: None published. FUTURE PLANS: 
      The REFUGE-cohort study will conduct two additional data collections (2020 and
      2021). Furthermore, questionnaire data will be linked to population-based
      registries after all three waves of data collection have been completed. Registry
      data will be obtained for time-periods both prior to and after the survey data
      collection points. Finally, pending ethics approval, we will begin the process of
      merging the Norwegian REFUGE-cohort with existing datasets in Sweden,
      establishing the extended REFUGE-database. TRIAL REGISTRATION NUMBER:
      ClincalTrials.gov Registry (NCT03742128).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nissen, Alexander
AU  - Nissen A
AUID- ORCID: 0000-0003-2879-0457
AD  - Division for Forced Migration and Disaster research, Norwegian Centre for
      Violence and Traumatic Stress Studies, Oslo, Norway a.f.w.nissen@nkvts.no.
AD  - Department of Health Sciences, Red Cross University College, Stockholm, Sweden.
FAU - Cauley, Prue
AU  - Cauley P
AD  - Division for Implementation and Treatment Research, Norwegian Centre for Violence
      and Traumatic Stress Studies, Oslo, Norway.
FAU - Saboonchi, Fredrik
AU  - Saboonchi F
AD  - Department of Health Sciences, Red Cross University College, Stockholm, Sweden.
AD  - Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
FAU - Andersen, Arnfinn
AU  - Andersen A
AD  - Division for Forced Migration and Disaster research, Norwegian Centre for
      Violence and Traumatic Stress Studies, Oslo, Norway.
FAU - Solberg, Oivind
AU  - Solberg O
AUID- ORCID: 0000-0002-0561-1893
AD  - Department of Health Sciences, Red Cross University College, Stockholm, Sweden.
AD  - Division for Implementation and Treatment Research, Norwegian Centre for Violence
      and Traumatic Stress Studies, Oslo, Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT03742128
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - *Mental Health
MH  - Middle Aged
MH  - Norway
MH  - Patient Selection
MH  - Quality of Life
MH  - Refugees/*psychology
MH  - Registries
MH  - Social Integration
MH  - Social Support
MH  - Stress, Psychological/etiology
MH  - Surveys and Questionnaires
MH  - Syria/ethnology
MH  - Young Adult
PMC - PMC7332190
OTO - NOTNLM
OT  - *epidemiology
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/03 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036101 [pii]
AID - 10.1136/bmjopen-2019-036101 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e036101. doi: 10.1136/bmjopen-2019-036101.


PMID- 32611739
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - International prospective observational study investigating the disease course
      and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of
      the PIBD-SETQuality inception cohort study.
PG  - e035538
LID - 10.1136/bmjopen-2019-035538 [doi]
AB  - INTRODUCTION: Patients with paediatric-onset inflammatory bowel disease (PIBD)
      may develop a complicated disease course, including growth failure, bowel
      resection at young age and treatment-related adverse events, all of which can
      have significant and lasting effects on the patient's development and quality of 
      life. Unfortunately, we are still not able to fully explain the heterogeneity
      between patients and their disease course and predict which patients will respond
      to certain therapies or are most at risk of developing a more complicated disease
      course. To investigate this, large prospective studies with long-term follow-up
      are needed. Currently, no such European or Asian international cohorts exist. In 
      this international cohort, we aim to evaluate disease course and which patients
      are most at risk of therapy non-response or development of complicated disease
      based on patient and disease characteristics, immune pathology and environmental 
      and socioeconomic factors. METHODS AND ANALYSIS: In this international
      prospective observational study, which is part of the PIBD Network for Safety,
      Efficacy, Treatment and Quality improvement of care (PIBD-SETQuality), children
      diagnosed with inflammatory bowel disease <18 years are included at diagnosis.
      The follow-up schedule is in line with standard PIBD care and is intended to
      continue up to 20 years. Patient and disease characteristics, as well as results 
      of investigations, are collected at baseline and during follow-up. In addition,
      environmental factors are being assessed (eg, parent's smoking behaviour, dietary
      factors and antibiotic use). In specific centres with the ability to perform
      extensive immunological analyses, blood samples and intestinal biopsies are being
      collected and analysed (flow cytometry, plasma proteomics, mRNA expression and
      immunohistochemistry) in therapy-naive patients and during follow-up. ETHICS AND 
      DISSEMINATION: Medical ethical approval has been obtained prior to patient
      recruitment for all sites. The results will be disseminated through peer-reviewed
      scientific publications. TRIAL REGISTRATION NUMBER: NCT03571373.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Aardoom, Martine A
AU  - Aardoom MA
AD  - Department of Paediatric Gastroenterology, Erasmus University Medical
      Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
FAU - Kemos, Polychronis
AU  - Kemos P
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Tindemans, Irma
AU  - Tindemans I
AD  - Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus
      University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
FAU - Aloi, Marina
AU  - Aloi M
AD  - Paediatric Gastroenterology and Liver Unit, Department of Paediatrics, Sapienza
      University of Rome, Rome, Italy.
FAU - Koletzko, Sibylle
AU  - Koletzko S
AD  - Department of Pediatrics, Dr. von Hauner Children's Hospital, University
      Hospital, Ludwig Maximilians University Munich, Munich, Germany.
AD  - Department of Pediatrics, Gastroenterology and Nutrition, School of Medicine
      Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.
FAU - Levine, Arie
AU  - Levine A
AD  - Paediatric Gastroenterology and Nutrition Unit, Edith Wolfson Medical Center, Tel
      Aviv University, Holon, Israel.
FAU - Turner, Dan
AU  - Turner D
AD  - Institute of Paediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew
      University of Jerusalem, Jerusalem, Israel.
FAU - Veereman, Gigi
AU  - Veereman G
AD  - Department of Paediatric Gastroenterology and Nutrition, UZ Brussel, Vrije
      Universiteit Brussel, Brussels, Belgium.
FAU - Neyt, Mattias
AU  - Neyt M
AD  - ME-TA Medical Evaluation and Technology Assessment, Merendree, Belgium.
FAU - Russell, Richard K
AU  - Russell RK
AUID- ORCID: 0000-0001-7398-4926
AD  - Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal
      Hospital for Children Glasgow, Glasgow, UK.
FAU - Walters, Thomas D
AU  - Walters TD
AD  - IBD Centre, Department of Paediatrics, SickKids Hospital, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Ruemmele, Frank M
AU  - Ruemmele FM
AD  - Department of Pediatric Gastroenterology, Universite Paris Descartes, Sorbonne
      Paris Cite, Assistance Publique-Hopitaux de Paris, Hopital Necker Enfants
      Malades, Paris, Ile-de-France, France.
FAU - Samsom, Janneke N
AU  - Samsom JN
AD  - Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus
      University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
FAU - Croft, Nicholas M
AU  - Croft NM
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of
      Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - de Ridder, Lissy
AU  - de Ridder L
AUID- ORCID: 0000-0002-6035-1182
AD  - Department of Paediatric Gastroenterology, Erasmus University Medical
      Center-Sophia Children's Hospital, Rotterdam, The Netherlands
      L.deRidder@erasmusmc.nl.
CN  - PIBD-SETQuality consortium and PIBD-NET
LA  - eng
SI  - ClinicalTrials.gov/NCT03571373
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - *Clinical Protocols
MH  - Cohort Studies
MH  - Disease Progression
MH  - Humans
MH  - Incidence
MH  - Inflammatory Bowel Diseases
MH  - *Internationality
MH  - Prospective Studies
MH  - Quality Improvement
MH  - Risk Factors
MH  - Surveys and Questionnaires
PMC - PMC7332186
OTO - NOTNLM
OT  - *immunology
OT  - *inflammatory bowel disease
OT  - *paediatric gastroenterology
COIS- Competing interests: MAA received consultation fee and honorarium from Abbvie. SK
      received consultation fee, research grant or honorarium from Danone,
      Nestec-Nutrition, Abbvie, Takeda, Celgene, Shire, Pfizer, Biogaia, Janssen,
      Berlin-Chemie, Mead Johnson, Vifor, Pharmacosmos and ThermoFisher. RKR is
      supported by an NHS Research Scotland Senior Research Fellowship and has received
      speakers's fees, travel support, and/or participated in medical board meetings
      with Nestle, MSD Immunology, AbbVie, Dr Falk, Takeda, Napp, Mead Johnson and
      Nutricia&4D Pharma. FR has received speaker fees from Shering-Plough, Nestle,
      MeadJohnson, Ferring, MSD, Johnson & Johnson, Centocor and AbbVie; has served as 
      a board member for SAC:DEVELOP (Johnson & Johnson), CAPE (AbbVie), LEA (AbbVie); 
      and has been invited to MSD France, Nestle Nutrition Institute, Nestle Health
      Science, Danone, MeadJohnson, Takeda, Celgene, Biogen, Shire, Pfizer and
      Therakos. NMC (into employer's investigator accounts) received speaker fees,
      advisory board fees and research funding from Eli-Lilly, Takeda, Abbvie Shire
      Pfizer and 4D Pharma. LdR had collaborations (such as involved in
      industry-sponsored studies, investigator-initiated study and consultancy) with
      Shire, Malinckrodt, Nestle, Celltrion, Abbvie and Pfizer; and received a grant
      from ZonMw, ECCO and Pfizer. Remaining authors: no competing interests declared.
EDAT- 2020/07/03 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035538 [pii]
AID - 10.1136/bmjopen-2019-035538 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e035538. doi: 10.1136/bmjopen-2019-035538.


PMID- 32611738
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - Mapping adolescent sexual and reproductive health research in sub-Saharan Africa:
      protocol for a scoping review.
PG  - e035335
LID - 10.1136/bmjopen-2019-035335 [doi]
AB  - INTRODUCTION: Previous studies have attempted to review the vast body of evidence
      on adolescent sexual and reproductive health (ASRH), but none has focused on a
      complete mapping and synthesis of the body of inquiry and evidence on ASRH in
      sub-Saharan Africa (SSA). Such a comprehensive scoping is needed, however, to
      offer direction to policy, programming and future research. We aim to undertake a
      scoping review of studies on ASRH in SSA to capture the landscape of extant
      research and findings and identify gaps for future research. METHODS AND
      ANALYSIS: This protocol is designed using the framework for scoping reviews
      developed by the Joanna Briggs Institute. We will include English and French
      language peer-reviewed publications and grey literature on ASRH (aged 10-19) in
      SSA published between January 2010 and June 2019. A three-step search strategy
      involving an initial search of three databases to refine the keywords, a full
      search of all databases and screening of references of previous review studies
      for relevant articles missing from our full search will be employed. We will
      search AJOL, JSTOR, HINARI, Scopus, Science Direct, Google Scholar and the
      websites for the WHO, UNICEF, UNFPA, UNESCO and Guttmacher Institute. Two
      reviewers will screen the titles, abstracts and full texts of publications for
      eligibility and inclusion-using Covidence (an online software). We will then
      extract relevant information from studies that meet the inclusion criteria using 
      a tailored extraction frame and template. Extracted data will be analysed using
      descriptive statistics and thematic analysis. Results will be presented using
      tables and charts and summaries of key themes arising from available research
      findings. ETHICS AND DISSEMINATION: Ethical approval is not required for a
      scoping review as it synthesises publicly available publications. Dissemination
      will be through publication in a peer-review journal and presentation at relevant
      conferences and convening of policymakers and civil society organisations working
      on ASRH in SSA.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ajayi, Anthony Idowu
AU  - Ajayi AI
AUID- ORCID: 0000-0002-6004-3972
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya ajayianthony@gmail.com.
FAU - Ushie, Boniface Ayanbekongshie
AU  - Ushie BA
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya.
FAU - Mwoka, Meggie
AU  - Mwoka M
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya.
FAU - Igonya, Emmy Kageha
AU  - Igonya EK
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya.
FAU - Ouedraogo, Ramatou
AU  - Ouedraogo R
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya.
FAU - Juma, Kenneth
AU  - Juma K
AUID- ORCID: 0000-0001-7742-9954
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya.
FAU - Aboderin, Isabella
AU  - Aboderin I
AD  - Population Dynamics and Sexual and Reproductive Health and Rights, African
      Population and Health Research Center, Nairobi, Kenya.
AD  - Perivoli Chair in Africa Research and Partnerships, Perivoli Africa Research
      Centre, University of Bristol, Bristol, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health
MH  - Africa South of the Sahara
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - Pregnancy in Adolescence
MH  - *Reproductive Health
MH  - *Sexual Behavior
MH  - Sexually Transmitted Diseases
PMC - PMC7332189
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *public health
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/03 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-035335 [pii]
AID - 10.1136/bmjopen-2019-035335 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e035335. doi: 10.1136/bmjopen-2019-035335.


PMID- 32611737
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 1
TI  - Protocol for a multinational risk-stratified randomised controlled trial in
      paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for
      maintaining remission in patients at low or high risk for aggressive disease
      course.
PG  - e034892
LID - 10.1136/bmjopen-2019-034892 [doi]
AB  - INTRODUCTION: Immunomodulators such as thiopurines (azathioprine
      (AZA)/6-mercaptopurine (6MP)), methotrexate (MTX) and biologics such as
      adalimumab (ADA) are well established for maintenance of remission within
      paediatric Crohn's disease (CD). It remains unclear, however, which maintenance
      medication should be used first line in specific patient groups. AIMS: To compare
      the efficacy of maintenance therapies in newly diagnosed CD based on
      stratification into high and low-risk groups for severe CD evolution; MTX versus 
      AZA/6MP in low-risk and MTX versus ADA in high-risk patients. Primary end point: 
      sustained remission at 12 months (weighted paediatric CD activity index </=12.5
      and C reactive protein </=1.5 fold upper limit) without relapse or ongoing
      requirement for exclusive enteral nutrition (EEN)/steroids 12 weeks after
      treatment initiation. METHODS AND ANALYSIS: REDUCE-RISK in CD is an international
      multicentre open-label prospective randomised controlled trial funded by EU
      within the Horizon2020 framework (grant number 668023). Eligible patients (aged
      6-17 years, new-onset disease receiving steroids or EEN for induction of
      remission for luminal +/- perianal CD are stratified into low and high-risk
      groups based on phenotype and response to induction therapy. Participants are
      randomised to one of two treatment arms within their risk group: low-risk
      patients to weekly subcutaneous MTX or daily oral AZA/6MP, and high-risk patients
      to weekly subcutaneous MTX or fortnightly ADA. Patients are followed up for 12
      months at prespecified intervals. Electronic case report forms are completed
      prospectively. The study aims to recruit 312 participants (176 low risk; 136 high
      risk). ETHICS AND DISSEMINATION: ClinicalTrials.gov Identifier: (NCT02852694),
      authorisation and approval from local ethics committees have been obtained prior 
      to recruitment. Individual informed consent will be obtained prior to
      participation in the study. Results will be published in a peer-reviewed journal 
      with open access. TRIAL REGISTRATION NUMBER: NCT02852694; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Harris, Rachel E
AU  - Harris RE
AUID- ORCID: 0000-0001-6507-3487
AD  - Department of Paediatric Gastroenterology, Royal Hospital for Children Glasgow,
      Glasgow, UK.
FAU - Aloi, Marina
AU  - Aloi M
AD  - Paediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Roma,
      Lazio, Italy.
FAU - de Ridder, Lissy
AU  - de Ridder L
AUID- ORCID: 0000-0002-6035-1182
AD  - Paediatrics, Erasmus MC/Sophia Childrens Hospital, Rotterdam, The Netherlands
      l.deridder@erasmusmc.nl.
FAU - Croft, Nicholas M
AU  - Croft NM
AD  - Department of Paediatric Gastroenterology, Barts and The London School of
      Medicine and Dentistry, London, UK.
FAU - Koletzko, Sibylle
AU  - Koletzko S
AD  - Pediatric Gastroenterology and Hepatology, Dr. V. Hauner Children's Hospital,
      Munich, Germany.
AD  - Department of Pediatrics, Collegium Medicum University of Warmia and Mazury,
      Olsztyn, Poland.
FAU - Levine, Arie
AU  - Levine A
AD  - Edith Wolfson Medical Center, Tel Aviv University, Tel Aviv, Israel.
FAU - Turner, Dan
AU  - Turner D
AD  - Department of Paediatric Gastroenterology, Hebrew University of Jerusalem,
      Jerusalem, Israel.
FAU - Veereman, Gigi
AU  - Veereman G
AD  - Pediatric GI, UZBrussels-VUB, Brussels, Belgium.
AD  - Free University Brussels, University Hospital, Brussels, Belgium.
FAU - Neyt, Mattias
AU  - Neyt M
AD  - ME-TA Medical Evaluation and Technology Assessment, Merendree, Belgium.
FAU - Bigot, Laetitia
AU  - Bigot L
AD  - PIBD-Net, Hopital universitaire Necker-Enfants malades, Paris, Ile-de-France,
      France.
FAU - Ruemmele, Frank M
AU  - Ruemmele FM
AD  - Service de Gastroenterologie Pediatrique, Hopital Universitaire Necker-Enfants
      Malades, Paris, Ile-de-France, France.
AD  - Department of Paediatric Gastroenterology, Universite Paris Descartes, Paris,
      Ile-de-France, France.
FAU - Russell, Richard K
AU  - Russell RK
AUID- ORCID: 0000-0001-7398-4926
AD  - Department of Paediatric Gastroenterology, Royal Hospital for Children Glasgow,
      Glasgow, UK.
CN  - PIBD SETQuality consortium and PIBDnet
LA  - eng
SI  - ClinicalTrials.gov/NCT02852694
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - FYS6T7F842 (Adalimumab)
RN  - MRK240IY2L (Azathioprine)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - Pediatric Crohn's disease
SB  - IM
MH  - Adalimumab/adverse effects/*therapeutic use
MH  - Adolescent
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Azathioprine/adverse effects/*therapeutic use
MH  - Child
MH  - Crohn Disease/*drug therapy
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Maintenance Chemotherapy
MH  - Male
MH  - Methotrexate/adverse effects/*therapeutic use
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Remission Induction
PMC - PMC7332179
OTO - NOTNLM
OT  - *clinical trials
OT  - *inflammatory bowel disease
OT  - *paediatric gastroenterology
COIS- Competing interests: RKR is supported by an NHS Research Scotland Senior Research
      Fellowship, and has received speaker's fees, travel support and/or participated
      in medical board meetings with Nestle, MSD Immunology, AbbVie, Dr Falk, Takeda,
      Napp, Mead Johnson, Nutricia & 4D Pharma. FMR has received speaker fees from
      Shering-Plough, Nestle, MeadJohnson, Ferring, MSD, Johnson & Johnson, Centocor,
      AbbVie; has served as a board member for SAC:DEVELOP(Johnson & Johnson), CAPE
      (AbbVie), LEA (AbbVie); and has been invited to MSD France, Nestle Nutrition
      Institute, Nestle Health Science, Danone, MeadJohnson, Takeda, Celgene, Biogen,
      Shire, Pfizer and Therakos. DT received consultation fee, research grant,
      royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children,
      Ferring, Abbvie, Takeda, Biogen, Atlantic Health, Shire, Celgene, Lilly,
      Neopharm, Roche. LdR received consultation fee, research grant, or honorarium
      from ZonMw, ECCO, Shire, Malinckrodt, Nestle, Celltrion, Abbvie and Pfizer. MA
      received consultation fee and honorarium from Abbvie. SK received consultation
      fee, research grant, or honorarium from Danone, Nestec-Nutrition, Abbvie, Takeda,
      Celgene, Shire, Pfizer, Biogaia, Janssen, Berlin-Chemie; Mead Johnson, Vifor,
      Pharmacosmos, ThermoFisher
EDAT- 2020/07/03 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034892 [pii]
AID - 10.1136/bmjopen-2019-034892 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jul 1;10(7):e034892. doi: 10.1136/bmjopen-2019-034892.


PMID- 32611619
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Against the use and publication of contemporary unethical research: the case of
      Chinese transplant research.
PG  - 678-684
LID - 10.1136/medethics-2019-106044 [doi]
AB  - Recent calls for retraction of a large body of Chinese transplant research and of
      Dr Jiankui He's gene editing research has led to renewed interest in the question
      of publication, retraction and use of unethical biomedical research. In Part 1 of
      this paper, we briefly review the now well-established consequentialist and
      deontological arguments for and against the use of unethical research. We argue
      that, while there are potentially compelling justifications for use under some
      circumstances, these justifications fail when unethical practices are ongoing-as 
      in the case of research involving transplantations in which organs have been
      procured unethically from executed prisoners. Use of such research displays a
      lack of respect and concern for the victims and undermines efforts to deter
      unethical practices. Such use also creates moral taint and renders those who use 
      the research complicit in continuing harm. In Part 2, we distinguish three
      dimensions of 'non-use' of unethical research: non-use of published unethical
      research, non-publication, and retraction and argue that all three types of
      non-use should be upheld in the case of Chinese transplant research. Publishers
      have responsibilities to not publish contemporary unethical biomedical research, 
      and where this has occurred, to retract publications. Failure to retract the
      papers implicitly condones the research, while uptake of the research through
      citations rewards researchers and ongoing circulation of the data in the
      literature facilitates subsequent use by researchers, policymakers and
      clinicians.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Higgins, Wendy C
AU  - Higgins WC
AUID- ORCID: 0000-0003-1357-8330
AD  - Department of Philosophy, Macquarie University, North Ryde, New South Wales,
      Australia.
FAU - Rogers, Wendy A
AU  - Rogers WA
AUID- ORCID: 0000-0001-9186-870X
AD  - Department of Philosophy, Macquarie University, North Ryde, New South Wales,
      Australia wendy.rogers@mq.edu.au.
FAU - Ballantyne, Angela
AU  - Ballantyne A
AD  - Centre for Biomedical Ethics, National University of Singapore; and Department of
      Primary Health Care and General Practice [Wellington], and Bioethics Centre
      [Dunedin], University of Otago, Wellington, New Zealand.
FAU - Lipworth, Wendy
AU  - Lipworth W
AUID- ORCID: 0000-0002-0234-657X
AD  - Sydney Health Ethics, The University of Sydney, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Oct;46(10):685-686. PMID: 32792347
CIN - J Med Ethics. 2020 Oct;46(10):689-690. PMID: 32817408
CIN - J Med Ethics. 2020 Oct;46(10):687-688. PMID: 32895297
CIN - J Med Ethics. 2020 Oct;46(10):691-692. PMID: 32928880
MH  - *Biomedical Research
MH  - China
MH  - Ethics, Research
MH  - Humans
MH  - *Organ Transplantation
MH  - Research Personnel
OTO - NOTNLM
OT  - *donation/procurement of organs/tissues
OT  - *prisoners
OT  - *publication ethics
OT  - *research ethics
OT  - *transplantation
COIS- Competing interests: WAR reports being a Director of the NGO 'International
      Coalition to End Transplant Abuse in China' and is chair of its international
      advisory committee. AB reports being a member of the International Advisory
      Committee and the New Zealand Advocacy & Initiatives Committee (NZAIC) of the
      International Coalition to End Transplant Abuse in China. WL reports grants from 
      National Health & Medical Research Council, grants from Australian Research
      Council, outside the submitted work.
EDAT- 2020/07/03 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/07/03 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/02/07 00:00 [revised]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - medethics-2019-106044 [pii]
AID - 10.1136/medethics-2019-106044 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):678-684. doi: 10.1136/medethics-2019-106044. Epub
      2020 Jul 1.


PMID- 32611436
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jul 1
TI  - Evaluating assessment tools of the quality of clinical ethics consultations: a
      systematic scoping review from 1992 to 2019.
PG  - 51
LID - 10.1186/s12910-020-00492-4 [doi]
AB  - BACKGROUND: Amidst expanding roles in education and policy making, questions have
      been raised about the ability of Clinical Ethics Committees (CEC) s to carry out 
      effective ethics consultations (CECons). However recent reviews of CECs suggest
      that there is no uniformity to CECons and no effective means of assessing the
      quality of CECons. To address this gap a systematic scoping review of prevailing 
      tools used to assess CECons was performed to foreground and guide the design of a
      tool to evaluate the quality of CECons. METHODS: Guided by Levac et al's (2010)
      methodological framework for conducting scoping reviews, the research team
      performed independent literature reviews of accounts of assessments of CECons
      published in six databases. The included articles were independently analyzed
      using content and thematic analysis to enhance the validity of the findings.
      RESULTS: Nine thousand sixty-six abstracts were identified, 617 full-text
      articles were reviewed, 104 articles were analyzed and four themes were
      identified - the purpose of the CECons evaluation, the various domains assessed, 
      the methods of assessment used and the long-term impact of these evaluations.
      CONCLUSION: This review found prevailing assessments of CECons to be piecemeal
      due to variable goals, contextual factors and practical limitations. The
      diversity in domains assessed and tools used foregrounds the lack of minimum
      standards upheld to ensure baseline efficacy. To advance a contextually
      appropriate, culturally sensitive, program specific assessment tool to assess
      CECons, clear structural and competency guidelines must be established in the
      curation of CECons programs, to evaluate their true efficacy and maintain
      clinical, legal and ethical standards.
FAU - Yoon, Nicholas Yue Shuen
AU  - Yoon NYS
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
FAU - Ong, Yun Ting
AU  - Ong YT
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
FAU - Yap, Hong Wei
AU  - Yap HW
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, 59 Nanyang
      Dr, Experimental Medicine Building, Singapore, 636921, Singapore.
FAU - Tay, Kuang Teck
AU  - Tay KT
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
FAU - Lim, Elijah Gin
AU  - Lim EG
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
FAU - Cheong, Clarissa Wei Shuen
AU  - Cheong CWS
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
FAU - Lim, Wei Qiang
AU  - Lim WQ
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
FAU - Chin, Annelissa Mien Chew
AU  - Chin AMC
AD  - Medical Library, National University of Singapore Libraries, National University 
      of Singapore, Blk MD6, Centre, 14 Medical Dr, #05-01 for Translational Medicine, 
      Singapore, 117599, Singapore.
FAU - Toh, Ying Pin
AU  - Toh YP
AD  - Department of Family Medicine, National University Health System, 5 Lower Kent
      Ridge Road, Singapore, 119074, Singapore.
FAU - Chiam, Min
AU  - Chiam M
AD  - Division of Cancer Education, National Cancer Centre Singapore, Level 4, 11
      Hospital Drive, Singapore, 169610, Singapore.
FAU - Mason, Stephen
AU  - Mason S
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, University of Liverpool, Liverpool, UK.
FAU - Krishna, Lalit Kumar Radha
AU  - Krishna LKR
AUID- ORCID: 0000-0002-7350-8644
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Level 4, 11 Hospital Drive, Singapore, 169610, Singapore.
      Lalit.Radha-Krishna@liverpool.ac.uk.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge 
      Road, NUHS Tower Block, Level 11, Singapore, 119228, Singapore.
      Lalit.Radha-Krishna@liverpool.ac.uk.
AD  - Division of Cancer Education, National Cancer Centre Singapore, Level 4, 11
      Hospital Drive, Singapore, 169610, Singapore.
      Lalit.Radha-Krishna@liverpool.ac.uk.
AD  - Palliative Care Institute Liverpool, Academic Palliative & End of Life Care
      Centre, University of Liverpool, Liverpool, UK.
      Lalit.Radha-Krishna@liverpool.ac.uk.
AD  - Cancer Research Centre, University of Liverpool, 200 London Road, Liverpool, L3
      9TA, UK. Lalit.Radha-Krishna@liverpool.ac.uk.
AD  - Centre of Biomedical Ethics, National University of Singapore, Blk MD11, 10
      Medical Drive, #02-03, Singapore, 117597, Singapore.
      Lalit.Radha-Krishna@liverpool.ac.uk.
AD  - Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
      Lalit.Radha-Krishna@liverpool.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200701
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Ethics Committees, Clinical
MH  - *Ethics Consultation
MH  - Ethics, Clinical
MH  - Humans
PMC - PMC7329412
OTO - NOTNLM
OT  - *CECs
OT  - *Clinical ethics
OT  - *Clinical ethics committees
OT  - *Clinical ethics consultations
OT  - *Medical ethics
EDAT- 2020/07/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00492-4 [doi]
AID - 10.1186/s12910-020-00492-4 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jul 1;21(1):51. doi: 10.1186/s12910-020-00492-4.


PMID- 32610872
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20201218
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 68
IP  - 6
DP  - 2020 Jun
TI  - Research and Ethics during the COVID-19 Pandemic.
PG  - 11-12
FAU - Um, Thatte
AU  - Um T
AD  - Professor and Head, Dept. of Clinical Pharmacology, Seth GS Medical College and
      KEM Hospital, Mumbai, Maharashtra.
FAU - Nj, Gogtay
AU  - Nj G
AD  - Professor, Dept. of Clinical Pharmacology, Seth GS Medical College and KEM
      Hospital, Mumbai, Maharashtra.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/07/03 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [entrez]
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2020 Jun;68(6):11-12.


PMID- 32610029
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - The Meaning of Care and Ethics to Mitigate the Harshness of Triage in Second-Wave
      Scenario Planning During the COVID-19 Pandemic.
PG  - W17-W19
LID - 10.1080/15265161.2020.1777355 [doi]
FAU - Wirth, Mathias
AU  - Wirth M
AUID- ORCID: 0000-0002-0450-640X
AD  - University of Bern.
FAU - Rauschenbach, Laurel
AU  - Rauschenbach L
AD  - University Hospital Essen.
FAU - Hurwitz, Brian
AU  - Hurwitz B
AD  - King's College London.
FAU - Schmiedebach, Heinz-Peter
AU  - Schmiedebach HP
AD  - Charite Medical Faculty Berlin.
FAU - Herdt, Jennifer A
AU  - Herdt JA
AD  - Yale University.
LA  - eng
PT  - Letter
DEP - 20200701
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - *Regional Health Planning
MH  - SARS-CoV-2
MH  - Triage/*ethics
MH  - United States/epidemiology
EDAT- 2020/07/02 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1080/15265161.2020.1777355 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):W17-W19. doi: 10.1080/15265161.2020.1777355. Epub
      2020 Jul 1.


PMID- 32609867
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jun 10
TI  - Decisional Capacity Determination In Patients With Cancer.
PG  - 203-210
AB  - Patients with cancer face many difficult decisions and encounter many clinical
      situations that undermine decisional capacity. For this reason, assessing
      decision-making capacity should be thought of at every medical encounter. The
      culmination of variable disease trajectories, following patients to the end of
      life, use of high-risk treatments, and other weighty personal decisions require
      attention to patients' ability to engage in decisions. Oncologists develop
      meaningful relationships with their patients. This familiarity may lead to
      forgoing the process of diligently assessing a patient's cognitive ability and/or
      decisional capacity when important decisions need to be made. While the process
      may feel like it takes place spontaneously, many subtle and overt details are
      involved with the decisions around cancer care that require pointed questioning
      and probing. Thus, there are many ways to fall short in determining decisional
      capacity. Clinicians are inconsistent in their decisional capacity determinations
      and generally assume more decisional capacity than the patient has. Consult and
      referral services such as ethics and psychiatry can help with treatment decisions
      and with assessing underlying psychosocial and psychiatric conditions. Decisional
      capacity may fluctuate and requires a variable amount of decisional ability
      depending on the clinical situation; hence, it is time-specific and
      decision-specific. This review is intended to provide a summary of key components
      of decisional capacity while highlighting areas in need of clinical refinement.
FAU - McFarland, Daniel C
AU  - McFarland DC
FAU - Blackler, Liz
AU  - Blackler L
FAU - Hlubocky, Fay J
AU  - Hlubocky FJ
FAU - Saracino, Rebecca
AU  - Saracino R
FAU - Masciale, James
AU  - Masciale J
FAU - Chin, Martin
AU  - Chin M
FAU - Alici, Yesne
AU  - Alici Y
FAU - Voigt, Louis
AU  - Voigt L
LA  - eng
GR  - L30 CA220778/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
SB  - IM
MH  - Decision Making/*ethics
MH  - Humans
MH  - Informed Consent/ethics/standards
MH  - Mental Competency/*psychology
MH  - Neoplasms/diagnosis/*psychology/*therapy
MH  - Oncologists/ethics
MH  - Patient Participation/*psychology
MH  - Physician-Patient Relations/ethics
MH  - Referral and Consultation/standards
MH  - Terminal Care/ethics/standards
EDAT- 2020/07/02 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PST - ppublish
SO  - Oncology (Williston Park). 2020 Jun 10;34(6):203-210.


PMID- 32609420
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1466-769X (Electronic)
IS  - 1466-7681 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Oct
TI  - Artificial Intelligence and Robotics in Nursing: Ethics of Caring as a Guide to
      Dividing Tasks Between AI and Humans.
PG  - e12306
LID - 10.1111/nup.12306 [doi]
AB  - Nurses have traditionally been regarded as clinicians that deliver compassionate,
      safe, and empathetic health care (Nurses again outpace other professions for
      honesty & ethics, 2018). Caring is a fundamental characteristic, expectation, and
      moral obligation of the nursing and caregiving professions (Nursing: Scope and
      standards of practice, American Nurses Association, Silver Spring, MD, 2015).
      Along with caring, nurses are expected to undertake ever-expanding duties and
      complex tasks. In part because of the growing physical, intellectual and
      emotional demandingness, of nursing as well as technological advances, artificial
      intelligence (AI) and AI care robots are rapidly changing the healthcare
      landscape. As technology becomes more advanced, efficient, and economical,
      opportunities and pressure to introduce AI into nursing care will only increase. 
      In the first part of the article, we review recent and existing applications of
      AI in nursing and speculate on future use. Second, situate our project within the
      recent literature on the ethics of nursing and AI. Third, we explore three
      dominant theories of caring and the two paradigmatic expressions of caring (touch
      and presence) and conclude that AI-at least for the foreseeable future-is
      incapable of caring in the sense central to nursing and caregiving ethics. We
      conclude that for AI to be implemented ethically, it cannot transgress the core
      values of nursing, usurp aspects of caring that can only meaningfully be carried 
      out by human beings, and it must support, open, or improve opportunities for
      nurses to provide the uniquely human aspects of care.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Stokes, Felicia
AU  - Stokes F
AUID- ORCID: https://orcid.org/0000-0001-7939-3078
AD  - American Nurses Association, Silver Spring, MD, USA.
FAU - Palmer, Amitabha
AU  - Palmer A
AD  - Bowling Green State University, Bowling Green, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - Nurs Philos
JT  - Nursing philosophy : an international journal for healthcare professionals
JID - 100897394
SB  - IM
MH  - Artificial Intelligence/*trends
MH  - Humans
MH  - Nursing/instrumentation/methods/*trends
MH  - Robotics/*trends
OTO - NOTNLM
OT  - artificial intelligence
OT  - ethics
OT  - ethics of caring
OT  - nursing
OT  - robotics
EDAT- 2020/07/02 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/26 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1111/nup.12306 [doi]
PST - ppublish
SO  - Nurs Philos. 2020 Oct;21(4):e12306. doi: 10.1111/nup.12306. Epub 2020 Jul 1.


PMID- 32609059
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 1746-076X (Electronic)
IS  - 1746-0751 (Linking)
VI  - 15
IP  - 5
DP  - 2020 May
TI  - Understanding voluntariness of consent in first-in-human cell therapy trials.
PG  - 1647-1660
LID - 10.2217/rme-2019-0126 [doi]
AB  - Consensus about contents of voluntariness in informed consent is lacking. Core
      criteria for voluntary consent are needed to ensure voluntariness. This article
      outlines the multidimensionality of voluntariness and identifies what could
      reduce voluntariness, especially in first-in-human clinical trials involving cell
      therapies. In such trials, truly voluntary consent is especially important
      because: such trials may involve risk of serious harm, while in case of some
      diseases, eligible patients often have potentially effective therapeutic
      alternatives; patients considering participation in high-risk first-in-human
      trials may feel more desperate and some may be dependent on their caregivers,
      including those in the family; implanted cells cannot be taken out of the
      patient's body if the patient wants to withdraw.
FAU - Hug, Kristina
AU  - Hug K
AUID- ORCID: 0000-0002-4316-5791
AD  - Medical Ethics, Department of Clinical Sciences, Faculty of Medicine, Lund
      University, BMC I12, 22184 Lund, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200701
PL  - England
TA  - Regen Med
JT  - Regenerative medicine
JID - 101278116
SB  - IM
MH  - Cell- and Tissue-Based Therapy/*ethics/*standards
MH  - Clinical Trials as Topic/*ethics
MH  - Humans
MH  - Informed Consent/ethics/*psychology
MH  - Patient Participation
MH  - Therapeutic Human Experimentation/*ethics
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *cell therapy
OT  - *first-in-human clinical trials
OT  - *informed consent
OT  - *regenerative medicine
OT  - *research ethics
OT  - *voluntariness
EDAT- 2020/07/02 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.2217/rme-2019-0126 [doi]
PST - ppublish
SO  - Regen Med. 2020 May;15(5):1647-1660. doi: 10.2217/rme-2019-0126. Epub 2020 Jul 1.


PMID- 32608375
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 7-S
DP  - 2020 Jun 30
TI  - The impact of stem cells in neuro-oncology: applications, evidence, limitations
      and challenges.
PG  - 51-60
LID - 10.23750/abm.v91i7-S.9955 [doi]
AB  - BACKGROUND: Stem cells (SCs) represent a recent and attractive therapeutic option
      for neuro-oncology, as well as for treating degenerative, ischemic and traumatic 
      pathologies of the central nervous system. This is mainly because of their homing
      capacity, which makes them capable of reaching the inaccessible SC niches of the 
      tumor, therefore, acting as living drugs. The target of the study is a
      comprehensive overview of the SC-based therapies in neuro-oncology, also
      highlighting the current translational challenges of this type of approach.
      METHODS: An online search of the literature was carried out on the PubMed/MEDLINE
      and ClinicalTrials.gov websites, restricting it to the most pertinent keywords
      regarding the systematization of the SCs and their therapeutic use for malignant 
      brain tumors. A large part of the search was dedicated to clinical trials. Only
      preclinical and clinical data belonging to the last 5 years were shortlisted. A
      further sorting was implemented based on the best match and relevance. RESULTS:
      The results consisted in 96 relevant articles and 31 trials. Systematization
      involves a distinction between human embryonic, fetal and adult, but also
      totipotent, pluripotent or multipotent SCs. Mesenchymal and neuronal SCs were the
      most studied for neuro-oncological illnesses. 30% and 50% of the trials were
      phase I and II, respectively. CONCLUSION: Mesenchymal and neuronal SCs are ideal 
      candidates for SCs-based therapy of malignant brain tumors. The spectrum of their
      possible applications is vast and is mainly based on the homing capacity toward
      the tumor microenvironment. Availability, delivery route, oncogenicity and
      ethical issues are the main translational challenges concerning the use of SCs in
      neuro-oncology.
FAU - Luzzi, Sabino
AU  - Luzzi S
AD  - Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric
      Sciences, University of Pavia, Pavia, Italy; Neurosurgery Unit, Department of
      Surgical Sciences, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
      sabino.luzzi@unipv.it.
FAU - Giotta Lucifero, Alice
AU  - Giotta Lucifero A
AD  - Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric
      Sciences, University of Pavia, Pavia, Italy. alicelucifero@gmail.com.
FAU - Brambilla, Ilaria
AU  - Brambilla I
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San
      Matteo, Uni-versity of Pavia, Pavia, Italy. i.brambilla@smatteo.pv.it.
FAU - Trabatti, Chiara
AU  - Trabatti C
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San
      Matteo, Uni-versity of Pavia, Pavia, Italy. chiara.trabatti@gmail.com.
FAU - Mosconi, Mario
AU  - Mosconi M
AD  - c and Traumatology Unit, Department of Clinical-Surgical, Diagnostic and
      Pediatric Sciences, University of Pavia, Pavia, Italy. mario.mosconi@unipv.it.
FAU - Savasta, Salvatore
AU  - Savasta S
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San
      Matteo, Uni-versity of Pavia, Pavia, Italy. S.Savasta@smatteo.pv.it.
FAU - Foiadelli, Thomas
AU  - Foiadelli T
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San
      Matteo, Uni-versity of Pavia, Pavia, Italy. thomas.foiadelli@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200630
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - Adult
MH  - *Brain Neoplasms/therapy
MH  - Humans
MH  - *Stem Cell Transplantation
MH  - Tumor Microenvironment
PMC - PMC7975826
EDAT- 2020/07/02 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/05/30 00:00 [received]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.23750/abm.v91i7-S.9955 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Jun 30;91(7-S):51-60. doi: 10.23750/abm.v91i7-S.9955.


PMID- 32608343
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - Newly graduated nurses' experiences of horizontal violence.
PG  - 1556-1568
LID - 10.1177/0969733020929063 [doi]
AB  - BACKGROUND: Horizontal violence, defined in the literature as 'interpersonal
      conflict between two nurses at the same hierarchical levels in organizations',
      often associated with bullying, affects the well-being of nurses, care recipients
      and the professional image of nursing and the organization due to increased
      turnover. One in every three newly graduated nurses is a victim of horizontal
      violence, although they do not always know how to define it. AIM: To investigate 
      the direct and indirect experiences of horizontal violence in newly graduated
      nurses as well as to shed light on the phenomenon, on its awareness and
      recognition. METHODS: A qualitative phenomenological study was conducted between 
      September and October 2018 with newly graduated nurses, with a work experience
      ranging between 6 months and 3 years. The interviews were conducted face-to-face,
      consisting of a first open general question, followed by semi-structured
      questions. ETHICAL CONSIDERATIONS: The study was conducted in accordance with the
      Declaration of Helsinki, and the protocol was approved by the Institution Review 
      Board. RESULTS: From the analysis of the interviews of the 21 participants, four 
      main themes were identified: the 'enemies', that is those who exercised violence,
      the 'weapons' used by them to exercise violence, the 'effects' and the types of
      'armor' identified to protect themselves. DISCUSSION: Horizontal violence is
      rarely recognized by newly graduated nurses, even though our sample had directly 
      or indirectly experienced horizontal violence. Tackling the phenomenon starting
      from the undergraduate degree courses, focusing on effective support and more
      protection by the organization leaders were the silent requests that emerged from
      this study. CONCLUSION: Preventing horizontal violence is important for nurses'
      professional and private well-being, for professional conduct and for the quality
      of care provided to patients.
FAU - Rosi, Ivana Maria
AU  - Rosi IM
AUID- ORCID: https://orcid.org/0000-0001-8879-7787
AD  - 9339Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; University 
      of Milan, Italy.
FAU - Contiguglia, Adriana
AU  - Contiguglia A
AUID- ORCID: https://orcid.org/0000-0002-5660-583X
AD  - 472674Fatebenefratelli and Ophthalmic Hospital, Italy.
FAU - Millama, Kim Randall
AU  - Millama KR
AD  - Nursing Home Igea - Milan, Italy.
FAU - Rancati, Stefania
AU  - Rancati S
AD  - 9339Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; University 
      of Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Bullying/*psychology/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Nurses/*psychology
MH  - Qualitative Research
MH  - Workplace/psychology/standards
OTO - NOTNLM
OT  - Bullying
OT  - horizontal violence
OT  - interpersonal conflict
OT  - interprofessional relations
OT  - newly graduated nurses
EDAT- 2020/07/02 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1177/0969733020929063 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1556-1568. doi: 10.1177/0969733020929063. Epub 2020
      Jul 1.


PMID- 32608027
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Compensation and reparations for victims and bystanders of the U.S. Public Health
      Service research studies in Tuskegee and Guatemala: Who do we owe what?
PG  - 893-898
LID - 10.1111/bioe.12784 [doi]
AB  - Using the infamous research studies in Tuskegee and Guatemala, the article
      examines the difference between victims and bystanders. The victims can include
      families, sexual partners, and children not just the participants. There are also
      the bystanders in the populations who are affected, even vaguely, decades after
      the initial studies took place. Differing reparations for victims and bystanders 
      through lawsuits and historical acknowledgments has to be part of broader
      discussions of historical justice, and the weighing of the impact of racism and
      imperial research endeavors.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Reverby, Susan M
AU  - Reverby SM
AUID- ORCID: 0000-0002-9272-2136
AD  - Women's and Gender Studies Department, Wellesley College, Wellesley,
      Massachusetts.
LA  - eng
GR  - 1 RO! AI114617-01A1/NH/NIH HHS/United States
GR  - 1 RO! AI114617-01A1/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200630
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Child
MH  - Compensation and Redress
MH  - Guatemala
MH  - Health Services
MH  - Human Experimentation
MH  - Humans
MH  - *Syphilis
MH  - United States
MH  - United States Public Health Service
OTO - NOTNLM
OT  - *Guatemala Experiments
OT  - *Tuskegee Syphilis Study
OT  - *bystanders
OT  - *compensation
OT  - *historical apologies
OT  - *human subjects research
OT  - *populations
OT  - *reparations
OT  - *research ethics
EDAT- 2020/07/02 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/01/05 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1111/bioe.12784 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):893-898. doi: 10.1111/bioe.12784. Epub 2020 Jun 30.


PMID- 32607925
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Financial Conflicts of Interest are of Higher Ethical Priority than
      "Intellectual" Conflicts of Interest.
PG  - 217-227
LID - 10.1007/s11673-020-09989-4 [doi]
AB  - The primary claim of this paper is that intellectual conflicts of interest (COIs)
      exist but are of lower ethical priority than COIs flowing from relationships
      between health professionals and commercial industry characterized by financial
      exchange. The paper begins by defining intellectual COIs and framing them in the 
      context of scholarship on non-financial COIs. However, the paper explains that
      the crucial distinction is not between financial and non-financial COIs but is
      rather between motivations for bias that flow from relationships and those that
      do not. While commitments to particular ideas or perspectives can cause all
      manner of cognitive bias, that fact does not justify denying the enormous power
      that relationships featuring pecuniary gain have on professional behaviour in
      term of care, policy, or both. Sufficient reason exists to take both intellectual
      COIs and financial COIs seriously, but this paper demonstrates why the latter is 
      of higher ethical priority. Multiple reasons will be provided, but the primary
      rationale grounding the claim is that intellectual COIs may provide reasons to
      suspect cognitive bias but they do not typically involve a loss of trust in a
      social role. The same cannot be said for COIs flowing from relationships between 
      health professionals and commercial industries involving financial exchange. The 
      paper then assumes arguendo that the primary rationale is mistaken and proceeds
      to show why the claims that intellectual COIs are more significant than
      relationship-based COIs are dubious on their own merits. The final section of the
      paper summarizes and concludes.
FAU - Goldberg, Daniel S
AU  - Goldberg DS
AUID- ORCID: http://orcid.org/0000-0003-1843-7422
AD  - Core Faculty, Center for Bioethics and Humanities, University of Colorado,
      Anschutz Medical Campus, Aurora, CO, USA. daniel.goldberg@cuanschutz.edu.
AD  - Department of Family Medicine (CU School of Medicine), University of Colorado,
      Anschutz Medical Campus, Aurora, CO, USA. daniel.goldberg@cuanschutz.edu.
AD  - Department of Epidemiology (CO School of Public Health), University of Colorado, 
      Anschutz Medical Campus, Fulginiti Pavilion - Room 205, 13080 E. 19th Avenue, CB 
      B137, Aurora, CO, 80045, USA. daniel.goldberg@cuanschutz.edu.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
CIN - J Bioeth Inq. 2021 Mar;18(1):187-188. PMID: 33405192
MH  - *Conflict of Interest
MH  - Disclosure
MH  - Humans
OTO - NOTNLM
OT  - Bioethics
OT  - Conflicts of interest
OT  - Financial
OT  - Interests
OT  - Public health ethics
EDAT- 2020/07/02 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/05/10 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1007/s11673-020-09989-4 [doi]
AID - 10.1007/s11673-020-09989-4 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Jun;17(2):217-227. doi: 10.1007/s11673-020-09989-4. Epub 2020 
      Jun 30.


PMID- 32607784
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1432-0932 (Electronic)
IS  - 0940-6719 (Linking)
VI  - 29
IP  - 11
DP  - 2020 Nov
TI  - 10 kHz spinal cord stimulation for chronic upper limb and neck pain: Australian
      experience.
PG  - 2786-2794
LID - 10.1007/s00586-020-06480-x [doi]
AB  - PURPOSE: Intractable upper limb and neck pain has traditionally been a
      challenging pain condition to treat, with conventional spinal cord stimulation
      (SCS) often inducing positional variation in paraesthesia and/or inadequate
      coverage of axial neck pain. The purpose of this Australian multi-centre
      prospective, clinical trial was to assess the safety and effectiveness of
      paraesthesia-independent 10 kHz SCS for the treatment of upper limb and neck
      pain. METHODS: Subjects with chronic, intractable neck and/or upper limb pain of 
      >/= 5 cm (on a 0-10-cm visual analogue scale) were enrolled (ACTRN12614000153617)
      following human research ethics committee approval. Subjects were implanted with 
      two epidural leads spanning C2-C6 vertebral bodies. Subjects with successful
      trial stimulation were implanted with a Senza((R)) system (Nevro Corp., Redwood
      City, CA, USA) and included in the safety and effectiveness evaluation at 3
      months post-implant (primary endpoint assessment, PEA) and followed to 12 months.
      RESULTS: Overall, 31/38 (82.6%) subjects reported a successful 10 kHz SCS trial
      and proceeded to a permanent implant. Twenty-three of 30 subjects (76.7%) met the
      PEA. Subjects reported a reduction in neck pain and upper limb pain from baseline
      at the PEA (8.1 +/- 0.2 cm vs. 2.9 +/- 0.5 cm, 7.3 +/- 0.3 cm vs. 2.5 +/- 0.5 cm,
      respectively, p </= 0.0001). Disability, as measured by pain disability index
      score, decreased from 42.6 +/- 2.6 at baseline to 22.7 +/- 3.2 at PEA. Results
      were maintained 12 months post-implant. No neurological deficits, nor reports of 
      paraesthesia, were observed. CONCLUSIONS: Stable, long-term results demonstrated 
      that 10 kHz SCS is a promising therapy option for intractable chronic upper limb 
      and neck pain.
FAU - Verrills, Paul
AU  - Verrills P
AD  - Metro Pain Group, Clayton, VIC, Australia.
FAU - Salmon, John
AU  - Salmon J
AD  - PainCare, Perth, WA, Australia.
FAU - Russo, Marc
AU  - Russo M
AD  - Genesis Research Services, Broadmeadow, NSW, Australia.
FAU - Gliner, Bradford
AU  - Gliner B
AD  - Nevro Corp, Redwood City, CA, USA.
FAU - Barnard, Adele
AU  - Barnard A
AD  - Nevro Corp, Redwood City, CA, USA. adele.barnard@nevro.com.
FAU - Caraway, David
AU  - Caraway D
AD  - Nevro Corp, Redwood City, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - Germany
TA  - Eur Spine J
JT  - European spine journal : official publication of the European Spine Society, the 
      European Spinal Deformity Society, and the European Section of the Cervical Spine
      Research Society
JID - 9301980
SB  - IM
MH  - Australia
MH  - *Chronic Pain/therapy
MH  - Humans
MH  - Neck Pain/therapy
MH  - Pain Management
MH  - Prospective Studies
MH  - Spinal Cord
MH  - *Spinal Cord Stimulation
MH  - Treatment Outcome
MH  - Upper Extremity
OTO - NOTNLM
OT  - *10 kHz SCS
OT  - *Chronic neck pain
OT  - *Chronic upper limb pain
OT  - *VAS
EDAT- 2020/07/02 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1007/s00586-020-06480-x [doi]
AID - 10.1007/s00586-020-06480-x [pii]
PST - ppublish
SO  - Eur Spine J. 2020 Nov;29(11):2786-2794. doi: 10.1007/s00586-020-06480-x. Epub
      2020 Jun 30.


PMID- 32607503
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2666-3341 (Electronic)
IS  - 2666-3341 (Linking)
VI  - 1
IP  - 1
DP  - 2020 Jun
TI  - Factors influencing postmortem disposition of cryopreserved sperm in men
      undergoing fertility preservation.
PG  - 21-24
LID - 10.1016/j.xfre.2020.04.002 [doi]
AB  - OBJECTIVE: To study the factors that influence men's disposition towards
      post-mortem disposition of their cryopreserved gametes. DESIGN: A retrospective
      chart review of sperm cryopreservations between June 2016 and January 2020 was
      performed. All patients >/= 18 years of age were included. Samples intended for
      donation or records with an unspecified reason for preservation were excluded.
      SETTING: A large academic health center. PATIENTS: Participants' (n=217) mean age
      was 35.8 +/- 10.8 years. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES:
      Patients' reason for undergoing sperm cryopreservation, method of retrieval, and 
      whether they chose to have the sample preserved or discarded post-mortem.
      RESULTS: A total of 217 men were analyzed; mean age was 35.8 +/- 10.8 years. Of
      those, 176 (81.1%) men decided to preserve their sperm for a spouse and 41
      (18.9%) elected to have the sample discarded when choosing the fate of their
      cryopreserved sample should they die. There was no significant difference in
      disposition towards sample fate based on age or method of collection. However,
      there was a significant difference based on the "reason for cryopreservation" (p 
      = 0.001). We found that compared to patients that underwent sperm
      cryopreservation due to cancer-related treatments, the patients that underwent
      sperm banking prior to vasectomy were more inclined to discard the sample (OR =
      3.45, 95% CI: 1.16 - 10.27, p = 0.026). Men that collected the sperm as an in
      vitro fertilization backup were less willing to discard the sample (OR = 0.42,
      95% CI: 0.18 - 0.97, p = 0.043). CONCLUSIONS: It appears that men's disposition
      towards post-mortem disposition of their cryopreserved sperm are influenced by
      their reason for cryopreservation, rather than their age or method used for
      collection. As cryopreservation has become more common and affordable,
      understanding the factors that impact men's disposition towards the post-mortem
      disposition of the cryopreserved gametes is imperative, as this knowledge has the
      potential to influence institutional policies and legislation, and may help solve
      future legal conflicts and ethical dilemmas.
FAU - Blachman-Braun, Ruben
AU  - Blachman-Braun R
AD  - Department of Urology, University of Miami, Miller School of Medicine, Miami,
      Florida, USA.
FAU - Best, Jordan C
AU  - Best JC
AD  - Department of Urology, University of Miami, Miller School of Medicine, Miami,
      Florida, USA.
FAU - Wyant, W Austin
AU  - Wyant WA
AD  - Department of Urology, University of Miami, Miller School of Medicine, Miami,
      Florida, USA.
FAU - Ramos, Libert
AU  - Ramos L
AD  - Department of Urology, University of Miami, Miller School of Medicine, Miami,
      Florida, USA.
FAU - Ibrahim, Emad
AU  - Ibrahim E
AD  - Department of Urology, University of Miami, Miller School of Medicine, Miami,
      Florida, USA.
FAU - Ramasamy, Ranjith
AU  - Ramasamy R
AD  - Department of Urology, University of Miami, Miller School of Medicine, Miami,
      Florida, USA.
LA  - eng
GR  - UL1 TR002736/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200423
PL  - United States
TA  - F S Rep
JT  - F&S reports
JID - 101766618
PMC - PMC7326375
MID - NIHMS1588802
OTO - NOTNLM
OT  - advanced directives
OT  - cryopreservation
OT  - sperm
COIS- Disclosure(s): The authors report no conflicts of interest in this work.
EDAT- 2020/07/02 06:00
MHDA- 2020/07/02 06:01
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/07/02 06:01 [medline]
AID - 10.1016/j.xfre.2020.04.002 [doi]
PST - ppublish
SO  - F S Rep. 2020 Jun;1(1):21-24. doi: 10.1016/j.xfre.2020.04.002. Epub 2020 Apr 23.


PMID- 32607482
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201016
IS  - 2574-2531 (Electronic)
IS  - 2574-2531 (Linking)
VI  - 3
IP  - 1
DP  - 2020 Apr
TI  - Stigma, biomarkers, and algorithmic bias: recommendations for precision
      behavioral health with artificial intelligence.
PG  - 9-15
LID - 10.1093/jamiaopen/ooz054 [doi]
AB  - Effective implementation of artificial intelligence in behavioral healthcare
      delivery depends on overcoming challenges that are pronounced in this domain.
      Self and social stigma contribute to under-reported symptoms, and under-coding
      worsens ascertainment. Health disparities contribute to algorithmic bias. Lack of
      reliable biological and clinical markers hinders model development, and model
      explainability challenges impede trust among users. In this perspective, we
      describe these challenges and discuss design and implementation recommendations
      to overcome them in intelligent systems for behavioral and mental health.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association.
FAU - Walsh, Colin G
AU  - Walsh CG
AD  - Biomedical Informatics, Medicine and Psychiatry, Vanderbilt University Medical
      Center, 2525 West End, Suite 1475, Nashville, TN, USA.
FAU - Chaudhry, Beenish
AU  - Chaudhry B
AD  - School of Computing and Informatics, University of Louisiana at Lafayette,
      Lafayette, Louisiana, USA.
FAU - Dua, Prerna
AU  - Dua P
AD  - Department of Health Informatics and Information Management, Louisiana Tech
      University, Ruston, Louisiana, USA.
FAU - Goodman, Kenneth W
AU  - Goodman KW
AD  - Institute for Bioethics and Health Policy, University of Miami, Miller School of 
      Medicine, Miami, Florida, USA.
FAU - Kaplan, Bonnie
AU  - Kaplan B
AD  - Yale Center for Medical Informatics, Yale Bioethics Center, Yale Information
      Society, Yale Solomon Center for Health Law & Policy, Yale University, New Haven,
      Connecticut, USA.
FAU - Kavuluru, Ramakanth
AU  - Kavuluru R
AD  - Division of Biomedical Informatics, Department of Internal Medicine, University
      of Kentucky, Lexington, Kentucky, USA.
FAU - Solomonides, Anthony
AU  - Solomonides A
AD  - Outcomes Research and Biomedical Informatics, NorthShore University HealthSystem,
      Research Institute, Evanston, Illinois, USA.
FAU - Subbian, Vignesh
AU  - Subbian V
AD  - Department of Biomedical Engineering, Department of Systems and Industrial
      Engineering, The University of Arizona, Tucson, Arizona, USA.
LA  - eng
GR  - R01 MH116269/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20200122
PL  - United States
TA  - JAMIA Open
JT  - JAMIA open
JID - 101730643
PMC - PMC7309258
OTO - NOTNLM
OT  - artificial intelligence
OT  - behavioral health
OT  - ethics
OT  - health disparities, algorithms, mental health
OT  - precision medicine
OT  - predictive modeling
EDAT- 2020/07/02 06:00
MHDA- 2020/07/02 06:01
CRDT- 2020/07/02 06:00
PHST- 2019/03/08 00:00 [received]
PHST- 2019/07/29 00:00 [revised]
PHST- 2019/10/30 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/07/02 06:01 [medline]
AID - 10.1093/jamiaopen/ooz054 [doi]
AID - ooz054 [pii]
PST - epublish
SO  - JAMIA Open. 2020 Jan 22;3(1):9-15. doi: 10.1093/jamiaopen/ooz054. eCollection
      2020 Apr.


PMID- 32606467
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20201218
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 583
IP  - 7814
DP  - 2020 Jul
TI  - Tribute to a Black professor lost to COVID-19.
PG  - 30
LID - 10.1038/d41586-020-01961-x [doi]
FAU - Reddy, Sushma
AU  - Reddy S
FAU - Wilhite, Ylanda
AU  - Wilhite Y
FAU - Von Konrat, Matt
AU  - Von Konrat M
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Nature. 2020 Jun;582(7811):147. PMID: 32518347
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Racism
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Ethics
OT  - *Funding
OT  - *SARS-CoV-2
OT  - *Society
EDAT- 2020/07/02 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
AID - 10.1038/d41586-020-01961-x [doi]
AID - 10.1038/d41586-020-01961-x [pii]
PST - ppublish
SO  - Nature. 2020 Jul;583(7814):30. doi: 10.1038/d41586-020-01961-x.


PMID- 32606230
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1943-5657 (Electronic)
IS  - 0033-8397 (Linking)
VI  - 91
IP  - 6
DP  - 2020 Jul
TI  - The Importance of Professional Values From Radiologic Technologists' Perspective.
PG  - 525-532
AB  - PURPOSE: To determine radiologic technologists' perception of professional
      values. METHODS: A sample of 3500 American Society of Radiologic Technologists
      members was emailed the Radiologic Technologists' Perceptions of Professional
      Values Scale survey-modified from the Professionalism in Physical Therapy: Core
      Values Self-Assessment tool-which captured participants' demographic information 
      (eg, education level, age, job title) and their ratings of 7 specific
      professional values. The mean item score was computed for each of the 7
      professional values as well as the mean item score for the 61 items. A 1-way
      analysis of variance (ANOVA) was used to compare the mean item score for several 
      demographic characteristics. RESULTS: Of those who were emailed the survey, 716
      consented to begin the survey. The mean scores of all 7 professional values were 
      above 3.0, indicating that radiologic technologists perceived each of the
      professional values listed as important. The between-group ANOVAs showed no
      significant difference in perceived importance of professional values based on
      demographic characteristics. DISCUSSION: Professional values encourage consistent
      patterns of behaviors, which motivate professionals to behave ethically.
      Therefore, professional values should be identified, adopted, and articulated for
      radiologic technologists by the bodies that lead the profession: the American
      Registry of Radiologic Technologists, the American Society of Radiologic
      Technologists, and the Joint Review Committee on Education in Radiologic
      Technology. CONCLUSION: Survey respondents perceived the listed professional
      values as important, which might be the first step to identifying a set of values
      to guide those in the radiologic sciences and set a benchmark of professionalism 
      that will help radiologic technology gain acknowledgement as a profession rather 
      than a trade or vocation.
CI  - (c) 2020 American Society of Radiologic Technologists.
FAU - Haynes, Kelli Welch
AU  - Haynes KW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Radiol Technol
JT  - Radiologic technology
JID - 0401256
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - *Professionalism
MH  - Self-Assessment
MH  - *Social Values
MH  - Surveys and Questionnaires
MH  - *Technology, Radiologic
MH  - United States
OTO - NOTNLM
OT  - allied health professionalism
OT  - perceptions of professionalism radiologic technologists and professionalism
OT  - professional behaviors
OT  - professional identity
OT  - professional values
OT  - professionalism
EDAT- 2020/07/02 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2019/11/12 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
AID - 91/6/525 [pii]
PST - ppublish
SO  - Radiol Technol. 2020 Jul;91(6):525-532.


PMID- 32606066
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - Global PRoMiSe (Perioperative Recommendations for Medication Safety): protocol
      for a mixed-methods study.
PG  - e038313
LID - 10.1136/bmjopen-2020-038313 [doi]
AB  - INTRODUCTION: Medication errors (MEs), which occur commonly in the perioperative 
      period, have the potential to cause patient harm or death. Many published
      recommendations exist for preventing perioperative MEs; however, many of these
      recommendations conflict and are often not applicable to middle-income and
      low-income countries. The goal of this study is to develop and disseminate
      consensus-based recommendations for perioperative medication safety that are
      tailored to country income level. METHODS AND ANALYSIS: The primary site of this 
      mixed-methods study is Massachusetts General Hospital/Harvard Medical School.
      Participants include a minimum of 108 international medication safety experts, 27
      from each of the World Bank's four country income groups (high, upper-middle,
      lower-middle and low-income). Using the Delphi method, participants will rate the
      appropriateness of candidate medication safety recommendations by completing
      online surveys using RedCAP. We will use Condorcet ranking methods to prioritise 
      the final recommendations for each country income group. We will execute a
      comprehensive dissemination strategy for the recommendations across each country 
      income group. Finally, we will conduct semistructured interviews with our
      participants to evaluate the initial adoption and implementation of the
      recommendations in each country income group. ETHICS AND DISSEMINATION: This
      study was approved by the Human Research Committee/Institutional Review Board at 
      Partners Healthcare (2019P003567). Findings will be published in peer-reviewed
      journals and presented at local and international conferences. TRIAL REGISTRATION
      NUMBER: NCT04240301.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nanji, Karen C
AU  - Nanji KC
AUID- ORCID: 0000-0002-1347-1640
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA KNANJI@mgh.harvard.edu.
AD  - Department of Anaestheisa, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Merry, Alan Forbes
AU  - Merry AF
AUID- ORCID: 0000-0001-7100-009X
AD  - Department of Anaesthesiology, University of Auckland, Auckland, New Zealand.
AD  - Department of Anaesthesia, Auckland City Hospital, Auckland, New Zealand.
FAU - Shaikh, Sofia D
AU  - Shaikh SD
AUID- ORCID: 0000-0003-2015-3402
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Pagel, Christina
AU  - Pagel C
AD  - Clinical Operational Research Unit, University College London, London, UK.
FAU - Deng, Hao
AU  - Deng H
AUID- ORCID: 0000-0002-0331-2427
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Wahr, Joyce A
AU  - Wahr JA
AUID- ORCID: 0000-0002-9216-8382
AD  - Anesthesiology, University of Minnesota Medical Center, Minneapolis, Minnesota,
      USA.
FAU - Gelb, Adrian W
AU  - Gelb AW
AUID- ORCID: 0000-0001-7004-4410
AD  - Anesthesia and Perioperative Care, University of California San Francisco, San
      Francisco, California, USA.
FAU - Orser, Beverley A
AU  - Orser BA
AUID- ORCID: 0000-0001-7292-2926
AD  - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto,
      Ontario, Canada.
AD  - Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, Ontario,
      Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04240301
GR  - K08 HS024764/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers, Pharmacological)
SB  - IM
MH  - Anesthesia
MH  - *Biomarkers, Pharmacological
MH  - Consensus
MH  - *Decision Support Systems, Clinical
MH  - Guidelines as Topic
MH  - Humans
MH  - Income
MH  - Medication Errors/prevention & control
MH  - Perioperative Care/*methods
MH  - Quality Control
MH  - Surveys and Questionnaires
PMC - PMC7328805
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *health & safety
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: KCN receives author royalties from UpToDate, Inc (Waltham
      MA). AFM has shares in Safersleep LLC (Auckland, New Zealand) and chairs its
      Board. JW received speaker honoraria from the Anesthesia Patient Safety
      Foundation (Rochester, Minnesota, USA) and the Aspen Institute (Aspen, Colorado, 
      USA). AWG receives consulting fees from Masimo Inc (Irvine, California, USA) and 
      Haisco Pharmaceutical (Shannan, China). He is also Secretary of the World
      Federation of Societies of Anesthesiologists (London, UK). BAO serves on the
      Board of Directors of the Institute for Safe Medication Practices (ISMP) Canada
      (Toronto, Canada).
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2020-038313 [pii]
AID - 10.1136/bmjopen-2020-038313 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e038313. doi: 10.1136/bmjopen-2020-038313.


PMID- 32606065
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - PRImary care Management of lower Urinary tract Symptoms in men: protocol for
      development and validation of a diagnostic and clinical decision support tool
      (the PriMUS study).
PG  - e037634
LID - 10.1136/bmjopen-2020-037634 [doi]
AB  - INTRODUCTION: Lower urinary tract symptoms (LUTS) is a bothersome condition
      affecting older men which can lead to poor quality of life. General practitioners
      (GPs) currently have no easily available assessment tools to help effectively
      diagnose causes of LUTS and aid discussion of treatment with patients. Men are
      frequently referred to urology specialists who often recommend treatments that
      could have been initiated in primary care. GP access to simple, accurate tests
      and clinician decision tools are needed to facilitate accurate and effective
      patient management of LUTS in primary care. METHODS AND ANALYSIS: PRImary care
      Management of lower Urinary tract Symptoms (PriMUS) is a prospective diagnostic
      accuracy study based in primary care. The study will determine which of a number 
      of index tests used in combination best predict three urodynamic observations in 
      men who present to their GP with LUTS. These are detrusor overactivity, bladder
      outlet obstruction and/or detrusor underactivity. Two cohorts of participants,
      one for development of the prototype diagnostic tool and other for validation,
      will undergo a series of simple index tests and the invasive reference standard
      (invasive urodynamics). We will develop and validate three diagnostic prediction 
      models based on each condition and then combine them with management
      recommendations to form a clinical decision support tool. ETHICS AND
      DISSEMINATION: Ethics approval is from the Wales Research Ethics Committee 6.
      Findings will be disseminated through peer-reviewed journals and conferences, and
      results will be of interest to professional and patient stakeholders. TRIAL
      REGISTRATION NUMBER: ISRCTN10327305.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Pell, Bethan
AU  - Pell B
AUID- ORCID: 0000-0002-0786-6339
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK pellb@cardiff.ac.uk.
FAU - Thomas-Jones, Emma
AU  - Thomas-Jones E
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Bray, Alison
AU  - Bray A
AD  - Medical Physics, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
      upon Tyne, UK.
AD  - Translational and Clinical Research Institute, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne, UK.
FAU - Agarwal, Ridhi
AU  - Agarwal R
AD  - Test Evaluation Research Group, Institute of Applied Health Research, University 
      of Birmingham, Birmingham, UK.
FAU - Ahmed, Haroon
AU  - Ahmed H
AD  - Division of Population Medicine, Cardiff University, Cardiff, South Glamorgan,
      UK.
FAU - Allen, A Joy
AU  - Allen AJ
AD  - NIHR In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon
      Tyne, UK.
FAU - Clarke, Samantha
AU  - Clarke S
AD  - North Bristol NHS Trust, Westbury on Trym, Bristol, UK.
FAU - Deeks, Jonathan J
AU  - Deeks JJ
AD  - Public Health, Epidemiology and Biostatistics, University of Birmingham,
      Birmingham, UK.
FAU - Drake, Marcus
AU  - Drake M
AD  - North Bristol NHS Trust, Westbury on Trym, Bristol, UK.
FAU - Drinnan, Michael
AU  - Drinnan M
AD  - Medical Physics, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
      upon Tyne, UK.
AD  - Translational and Clinical Research Institute, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust, Newcastle upon Tyne, UK.
FAU - Dyer, Calie
AU  - Dyer C
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Hood, Kerenza
AU  - Hood K
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Joseph-Williams, Natalie
AU  - Joseph-Williams N
AD  - Division of Population Medicine, Cardiff University, Cardiff, South Glamorgan,
      UK.
FAU - Marsh, Lucy
AU  - Marsh L
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Milosevic, Sarah
AU  - Milosevic S
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
FAU - Pickard, Robert
AU  - Pickard R
AD  - Department of Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust,
      Newcastle upon Tyne, UK.
FAU - Schatzberger, Tom
AU  - Schatzberger T
AD  - Corbridge Health Centre, NHS Northumberland Clinical Commissioning Group,
      Newcastle, Northumberland, UK.
FAU - Takwoingi, Yemisi
AU  - Takwoingi Y
AD  - Test Evaluation Research Group, Institute of Applied Health Research, University 
      of Birmingham, Birmingham, UK.
FAU - Harding, Chris
AU  - Harding C
AD  - Department of Urology, Newcastle upon Tyne Hospitals NHS Foundation Trust,
      Newcastle upon Tyne, UK.
FAU - Edwards, Adrian
AU  - Edwards A
AD  - Division of Population Medicine, Cardiff University, Cardiff, South Glamorgan,
      UK.
LA  - eng
SI  - ISRCTN/ISRCTN10327305
GR  - 15/40/05/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - *Decision Support Systems, Clinical
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*diagnosis/etiology/*therapy
MH  - Male
MH  - *Primary Health Care
MH  - Urinary Bladder Neck Obstruction/diagnosis/etiology/therapy
MH  - Urinary Bladder, Overactive/diagnosis/etiology/therapy
MH  - Urinary Bladder, Underactive/diagnosis/etiology/therapy
MH  - Urodynamics/physiology
PMC - PMC7328815
OTO - NOTNLM
OT  - *adult urology
OT  - *primary care
OT  - *urology
COIS- Competing interests: One of the index tests, Flowtaker, was developed by a team
      from Newcastle upon Tyne Hospitals (NuTH) and Newcastle University, including two
      individuals who are grant co-applicants, members of the study management team and
      co-authors (AB and MiD). In 2014, the device was licensed to MMS (Enschede, the
      Netherlands) and royalties from the sale of the device were paid to NuTH (not to 
      the individuals). MMS was subsequently acquired by Laborie who removed Flowtaker 
      from the market in January 2018.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2020-037634 [pii]
AID - 10.1136/bmjopen-2020-037634 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e037634. doi: 10.1136/bmjopen-2020-037634.


PMID- 32606062
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210918
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - Study protocol for the ACT response pilot intervention: development,
      implementation and evaluation of a systems-based Agitation Code Team (ACT) in the
      emergency department.
PG  - e036982
LID - 10.1136/bmjopen-2020-036982 [doi]
AB  - INTRODUCTION: Emergency department (ED) visits for behavioural conditions are
      rising, with 1.7 million associated episodes of patient agitation occurring
      annually in acute care settings. When de-escalation techniques fail during
      agitation management, patients are subject to use of physical restraints and
      sedatives, which are associated with up to 37% risk of hypotension, apnoea and
      physical injuries. At the same time, ED staff report workplace violence due to
      physical assaults during agitation events. We recently developed a theoretical
      framework to characterise ED agitation, which identified teamwork as a critical
      component to reduce harm. Currently, no structured team response protocol for ED 
      agitation addressing both patient and staff safety exists. METHODS AND ANALYSIS: 
      Our proposed study aims to develop and implement the agitation code team (ACT)
      response intervention, which will consist of a standardised, structured process
      with defined health worker roles/responsibilities, work processes and clinical
      protocols. First, we will develop the ACT response intervention in a two-step
      design loop; conceptual design will engage users in the creation of the
      prototype, and iterative refinement will occur through in situ simulated agitated
      patient encounters in the ED to assess and improve the design. Next, we will
      pilot the intervention in the clinical environment and use a controlled
      interrupted time series design to evaluate its effect on our primary outcome of
      patient restraint use. The intervention will be considered efficacious if we
      effectively lower the rate of restraint use over a 6-month period. ETHICS AND
      DISSEMINATION: Ethical approval by the Yale University Human Investigation
      Committee was obtained in 2019 (HIC #2000025113). Results will be disseminated
      through peer-reviewed publications and presentations at scientific meetings for
      each phase of the study. If this pilot is successful, we plan to formally
      integrate the ACT response intervention into clinical workflows at all EDs within
      our entire health system.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wong, Ambrose H
AU  - Wong AH
AUID- ORCID: 0000-0001-7471-1647
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA
      wongambrose@gmail.com.
FAU - Ray, Jessica M
AU  - Ray JM
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
FAU - Auerbach, Marc A
AU  - Auerbach MA
AD  - Department of Pediatrics and Emergency Medicine, Yale University, New Haven,
      Connecticut, USA.
FAU - Venkatesh, Arjun K
AU  - Venkatesh AK
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
FAU - McVaney, Caitlin
AU  - McVaney C
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
FAU - Burness, Danielle
AU  - Burness D
AD  - Department of Emergency Medicine, Yale-New Haven Hospital, New Haven,
      Connecticut, USA.
FAU - Chmura, Christopher
AU  - Chmura C
AD  - Department of Emergency Medicine, Yale-New Haven Hospital, New Haven,
      Connecticut, USA.
FAU - Saxa, Thomas
AU  - Saxa T
AD  - Department of Emergency Medicine, Yale-New Haven Hospital, New Haven,
      Connecticut, USA.
FAU - Sevilla, Mark
AU  - Sevilla M
AD  - Department of Emergency Medicine, Yale-New Haven Hospital, New Haven,
      Connecticut, USA.
FAU - Flood, Colin T
AU  - Flood CT
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
FAU - Patel, Amitkumar
AU  - Patel A
AD  - Department of Emergency Medicine, Yale-New Haven Hospital, New Haven,
      Connecticut, USA.
FAU - Whitfill, Travis
AU  - Whitfill T
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
FAU - Dziura, James D
AU  - Dziura JD
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
AD  - Department of Biostatistics, Yale School of Public Health, New Haven, CT, United 
      States.
FAU - Yonkers, Kimberly A
AU  - Yonkers KA
AD  - Department of Chronic Disease Epidemiology, Yale School of Public Health, New
      Haven, CT, United States.
AD  - Departments of Psychiatry and Obstetrics & Gynecology, Yale University, New
      Haven, Connecticut, USA.
FAU - Ulrich, Andrew
AU  - Ulrich A
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
FAU - Bernstein, Steven L
AU  - Bernstein SL
AD  - Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.
AD  - Department of Chronic Disease Epidemiology, Yale School of Public Health, New
      Haven, CT, United States.
LA  - eng
GR  - KL2 TR001862/TR/NCATS NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Emergency Service, Hospital/*organization & administration
MH  - Evaluation Studies as Topic
MH  - Feasibility Studies
MH  - Health Plan Implementation/*organization & administration
MH  - Humans
MH  - Patient Care Team
MH  - Pilot Projects
PMC - PMC7328814
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *mental health
OT  - *occupational & industrial medicine
OT  - *psychiatry
OT  - *quality in health care
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2020-036982 [pii]
AID - 10.1136/bmjopen-2020-036982 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e036982. doi: 10.1136/bmjopen-2020-036982.


PMID- 32606059
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - Effect of reactive balance training on physical fitness poststroke: study
      protocol for a randomised non-inferiority trial.
PG  - e035740
LID - 10.1136/bmjopen-2019-035740 [doi]
AB  - INTRODUCTION: Regular exercise is essential in the chronic phase of stroke
      recovery for improving or maintaining function, and reducing the risk of a second
      stroke. To achieve these goals, multiple components of fitness should be targeted
      with poststroke exercise, including aerobic capacity, strength and balance.
      However, following the recommended frequency and duration of each component
      separately can take a long time and lead to fatigue in people with stroke.
      Therefore, finding types of exercise that target multiple components of fitness
      all together is valuable.Reactive balance training (RBT) is a novel type of
      exercise where individuals repeatedly lose their balance in order to practise
      balance reactions. When people do RBT, they increase their heart rate and exert
      forces with their leg muscles which could improve aerobic fitness and muscle
      strength, respectively. This means that RBT could have the potential to improve
      multiple components of fitness, simultaneously. METHODS AND ANALYSIS: This is a
      randomised controlled non-inferiority trial with internal pilot study.
      Participants with chronic stroke will be randomly assigned to one of two groups: 
      (1) RBT or (2) aerobic and strength training (AST). Participants in both groups
      will complete 1 hour of exercise, three times/week for 12 weeks. The primary
      objective is to determine the effect of RBT on aerobic capacity and knee muscles'
      strength. The secondary objective is to determine the effects of RBT and AST on
      balance control and balance confidence. We expect to find that RBT is superior to
      AST in terms of improving balance control and balance confidence, yet not
      inferior to AST in terms of its effects on aerobic capacity and strength. ETHICS 
      AND DISSEMINATION: Research ethics approval has been received. Results will be
      disseminated directly to study participants at the end of the trial, and to other
      stakeholders via publication in a peer-reviewed journal. TRIAL REGISTRATION
      NUMBER: NCT04042961.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Barzideh, Azadeh
AU  - Barzideh A
AD  - Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Marzolini, Susan
AU  - Marzolini S
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Danells, Cynthia
AU  - Danells C
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
AD  - Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
FAU - Jagroop, David
AU  - Jagroop D
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Huntley, Andrew H
AU  - Huntley AH
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Inness, Elizabeth L
AU  - Inness EL
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
AD  - Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
FAU - Mathur, Sunita
AU  - Mathur S
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
AD  - Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
FAU - Mochizuki, George
AU  - Mochizuki G
AD  - Kinesiology, York University, Toronto, Ontario, Canada.
FAU - Oh, Paul
AU  - Oh P
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada.
FAU - Mansfield, Avril
AU  - Mansfield A
AUID- ORCID: 0000-0002-0396-5815
AD  - Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario,
      Canada avril.mansfield@uhn.ca.
AD  - Physical Therapy, University of Toronto, Toronto, Ontario, Canada.
AD  - Evaulative Clinical Sciences, Hurvitz Brain Sciences Program, Sunnybrook Research
      Institute, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04042961
GR  - MSH-141983/CAPMC/ CIHR/Canada
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Equivalence Trials as Topic
MH  - *Exercise
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Strength
MH  - *Physical Conditioning, Human
MH  - *Physical Fitness
MH  - Pilot Projects
MH  - *Postural Balance
MH  - *Resistance Training
MH  - Stroke Rehabilitation/*methods
MH  - Young Adult
PMC - PMC7328813
OTO - NOTNLM
OT  - *rehabilitation medicine
OT  - *sports medicine
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035740 [pii]
AID - 10.1136/bmjopen-2019-035740 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e035740. doi: 10.1136/bmjopen-2019-035740.


PMID- 32606057
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - Elastic-band resistance exercise or vibration treatment in combination with
      hydroxymethylbutyrate (HMB) supplement for management of sarcopenia in older
      people: a study protocol for a single-blinded randomised controlled trial in Hong
      Kong.
PG  - e034921
LID - 10.1136/bmjopen-2019-034921 [doi]
AB  - INTRODUCTION: Sarcopenia is a geriatric syndrome characterised by progressive
      loss of skeletal muscle mass and function with risks of adverse outcomes and
      becomes more prevalent due to ageing population. Elastic-band exercise, vibration
      treatment and hydroxymethylbutyrate (HMB) supplementation were previously proven 
      to have positive effects on the control of sarcopenia. The purpose of this study 
      is to evaluate the effectiveness of elastic-band exercise or vibration treatment 
      with HMB supplementation in managing sarcopenia. Our findings will provide a safe
      and efficient strategy to mitigate the progression of sarcopenia in older people 
      and contribute to higher quality of life as well as improved long-term health
      outcomes of elderly people. METHODS AND ANALYSIS: In this single-blinded,
      randomised controlled trial (RCT), subjects will be screened for sarcopenia based
      on the Asian Working Group for Sarcopenia (AWGS) definition and 144 sarcopenic
      subjects aged 65 or above will be recruited. This RCT will have three groups
      evaluated at two time points to measure changes over 3 months-the control and the
      groups with combined HMB supplement and elastic-band resistance exercise or
      vibration treatment. Changes in muscle strength in lower extremity will be the
      primary outcome. Muscle strength in the upper extremity, gait speed, muscle mass 
      (based on AWGS definition), functional performance in terms of balancing ability 
      and time-up-and-go test and quality of life will be taken as secondary outcomes. 
      In addition, each participant's daily activity will be monitored by a wrist-worn 
      activity tracker. Repeated-measures analysis of variance will be performed to
      compare within-subject changes between control and treatment groups at two time
      points of pretreatments and post-treatments. ETHICS AND DISSEMINATION: The
      procedures have been approved by the Joint CUHK-NTEC Clinical Research Management
      Office (Ref. CREC 2018.602) and conformed to the Declaration of Helsinki. Results
      will be disseminated through peer-reviewed publications, conferences and
      workshops. TRIAL REGISTRATION NUMBER: NCT04028206.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chow, Simon Kwoon-Ho
AU  - Chow SK
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Chim, Yu-Ning
AU  - Chim YN
AUID- ORCID: 0000-0002-6963-2538
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Cheng, Keith Yu-Kin
AU  - Cheng KY
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Ho, Chung-Yan
AU  - Ho CY
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Ho, Wing-Tung
AU  - Ho WT
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong.
FAU - Cheng, Kenneth Chik-Chee
AU  - Cheng KC
AD  - Department of Sports Science and Physical Education, The Chinese University of
      Hong Kong, New Territories, Hong Kong.
FAU - Wong, Ronald Man-Yeung
AU  - Wong RM
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong ronald.wong2002@gmail.com.
FAU - Cheung, Wing-Hoi
AU  - Cheung WH
AUID- ORCID: 0000-0003-3247-8255
AD  - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong,
      Hong Kong, Hong Kong.
LA  - eng
SI  - ClinicalTrials.gov/NCT04028206
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Valerates)
RN  - 3F752311CD (beta-hydroxyisovaleric acid)
SB  - IM
MH  - Activities of Daily Living/classification
MH  - Aged
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Gait/drug effects
MH  - Humans
MH  - Male
MH  - Muscle Strength/drug effects
MH  - Quality of Life
MH  - Resistance Training/instrumentation/*methods
MH  - Sarcopenia/*therapy
MH  - Single-Blind Method
MH  - Valerates/*therapeutic use
MH  - Vibration/*therapeutic use
MH  - Walking Speed/drug effects
PMC - PMC7328808
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *musculoskeletal disorders
OT  - *nutrition & dietetics
COIS- Competing interests: None declared.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034921 [pii]
AID - 10.1136/bmjopen-2019-034921 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e034921. doi: 10.1136/bmjopen-2019-034921.


PMID- 32606056
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - Risk factors for bleeding in haemato-oncology patients-a nested case-control
      study: The BITE study protocol (Bleeding In Thrombocytopenia Explained).
PG  - e034710
LID - 10.1136/bmjopen-2019-034710 [doi]
AB  - INTRODUCTION: Haemato-oncological patients often receive platelet count driven
      prophylactic platelet transfusions to prevent bleeding. However, many
      prophylactically transfused patients still bleed. More knowledge on risk factors 
      for bleeding is therefore needed. This will enable identification of bleeding
      risk profiles on which future transfusion policy can be optimised. The present
      BITE study (Bleeding In Thrombocytopenia Explained) aims to identify clinical
      conditions and biomarkers that are associated with clinically relevant bleeding
      events. METHODS AND ANALYSIS: A matched case-control study nested in a cohort of 
      haemato-oncological patients in the Netherlands. We collect a limited number of
      variables from all eligible patients, who together form the source population.
      These patients are followed for the occurrence of clinically relevant bleeding.
      Consenting patients of the source population form the cohort. Cases from the
      cohort are frequency matched to selected control patients for the nested
      case-control study. Of both case and control patients more detailed clinical data
      is collected. STUDY POPULATION: Adult haemato-oncological patients, who are
      admitted for intensive chemotherapeutic treatment or stem cell transplantation,
      or who received such treatments in the past and are readmitted for disease or
      treatment-related adverse events. STATISTICAL ANALYSIS: Bleeding incidences will 
      be calculated for the total source population, as well as for different
      subgroups. The association between potential risk factors and the occurrence of
      bleeding will be analysed using conditional logistic regression, to account for
      matching of case and control patients. ETHICS AND DISSEMINATION: The study was
      approved by the Medical Research Ethics Committee Leiden Den Haag and Delft, and 
      the Radboudumc Committee on Research Involving Human Subjects. Approval in seven 
      other centres is foreseen. Patients will be asked for written informed consent
      and data is coded before analyses, according to Dutch privacy law. Results will
      be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NL62499.058.17. NCT03505086; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cornelissen, Loes L
AU  - Cornelissen LL
AUID- ORCID: 0000-0003-1813-8780
AD  - Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden,
      The Netherlands.
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, Leiden, The Netherlands.
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - Caram-Deelder, Camila
AU  - Caram-Deelder C
AUID- ORCID: 0000-0003-3161-5684
AD  - Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden,
      The Netherlands.
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - van der Bom, Johanna G
AU  - van der Bom JG
AUID- ORCID: 0000-0001-9095-2475
AD  - Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden,
      The Netherlands.
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - Middelburg, Rutger A
AU  - Middelburg RA
AUID- ORCID: 0000-0002-6545-7277
AD  - Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden,
      The Netherlands.
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - Zwaginga, Jaap Jan
AU  - Zwaginga JJ
AUID- ORCID: 0000-0003-1228-7769
AD  - Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden,
      The Netherlands j.j.zwaginga@lumc.nl.
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, Leiden, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03505086
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Follow-Up Studies
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Hemorrhage/*etiology
MH  - Humans
MH  - Neoplasms/*complications/*therapy
MH  - Patient Readmission
MH  - Platelet Transfusion
MH  - Risk Factors
MH  - Stem Cell Transplantation
MH  - Thrombocytopenia/*etiology
PMC - PMC7328810
OTO - NOTNLM
OT  - *haemato-oncology
OT  - *haemorrhage
OT  - *platelet transfusion
OT  - *risk factors
COIS- Competing interests: JJZ reports that the Leiden University Medical Center, his
      employer, is structurally compensated for his work on blood transfusion medicine 
      by Dutch Blood Supply organisation Sanquin, also during the conduct of the study.
      The other authors declare no conflicts of interest.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034710 [pii]
AID - 10.1136/bmjopen-2019-034710 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e034710. doi: 10.1136/bmjopen-2019-034710.


PMID- 32606055
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 30
TI  - Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for
      a cluster randomised trial of a community-based intervention to improve treatment
      adherence and reduce the treatment gap for schizophrenia in Pakistan.
PG  - e034709
LID - 10.1136/bmjopen-2019-034709 [doi]
AB  - INTRODUCTION: There is a significant treatment gap, with only a few
      community-based services for people with schizophrenia in low-income and
      middle-income countries. Poor treatment adherence in schizophrenia is associated 
      with poorer health outcomes, suicide attempts and death. We previously reported
      the effectiveness of supervised treatment in outpatients for schizophrenia
      (STOPS) for improving treatment adherence in patients with schizophrenia.
      However, STOPS was evaluated in a tertiary care setting with no primary care
      involvement, limiting its generalisability to the wider at-risk population. We
      aim to evaluate the effectiveness of STOPS+ in scaling up the primary care
      treatment of schizophrenia to a real-world setting. METHODS AND ANALYSIS: The
      effectiveness of the STOPS+ intervention in improving the level of functioning
      and medication adherence in patients with schizophrenia in Pakistan will be
      evaluated using a cluster randomised controlled trial design. We aim to recruit
      526 participants from 24 primary healthcare centres randomly allocated in 1:1
      ratio to STOPS+ intervention and enhanced treatment as usual arms. Participants
      will be followed-up for 12 months postrecruitment. The sample size is estimated
      for two outcomes (1) the primary clinical outcome is level of functioning,
      measured using the Global Assessment of Functioning scale and (2) the primary
      process outcome is adherence to treatment regimen measured using a validated
      measure. An intention-to-treat approach will be used for the primary analysis.
      ETHICS AND DISSEMINATION: Ethical approval has been obtained from Keele
      University Ethical Review Panel (ref: MH-190017) and Khyber Medical University
      Ethical Review Board (ref: DIR-KMU-EB/ST/000648). The results of the STOPS+ trial
      will be reported in peer-reviewed journals and academic conferences and
      disseminated to local stakeholders and policymakers. TRIAL REGISTRATION NUMBER:
      ISRCTN93243890.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Shepherd, Thomas Andrew
AU  - Shepherd TA
AUID- ORCID: 0000-0002-8311-7452
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK.
FAU - Ul-Haq, Zia
AU  - Ul-Haq Z
AD  - Institute of Public Health & Social Sciences, Khyber Medical University,
      Peshawar, Khyber Pakhtunkhwa, Pakistan.
FAU - Ul-Haq, Mian
AU  - Ul-Haq M
AD  - Medical Teaching Institution, Lady Reading Hospital, Peshawar, Khyber
      Pakhtunkhwa, Pakistan.
FAU - Khan, Muhammad Firaz
AU  - Khan MF
AD  - Medical Teaching Institution, Lady Reading Hospital, Peshawar, Khyber
      Pakhtunkhwa, Pakistan.
FAU - Afridi, Adil
AU  - Afridi A
AD  - Medical Teaching Institution, Lady Reading Hospital, Peshawar, Khyber
      Pakhtunkhwa, Pakistan.
FAU - Dikomitis, Lisa
AU  - Dikomitis L
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK.
AD  - School of Medicine, Keele University, Keele, Staffordshire, UK.
FAU - Robinson, Michelle E
AU  - Robinson ME
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK.
FAU - Lewis, Martyn
AU  - Lewis M
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK.
FAU - Rahman, Atif
AU  - Rahman A
AD  - Child Mental Health Unit, University of Liverpool, Liverpool, UK.
FAU - Dziedzic, Krysia
AU  - Dziedzic K
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK.
FAU - Saeed, Umaima
AU  - Saeed U
AD  - Institute of Public Health & Social Sciences, Khyber Medical University,
      Peshawar, Khyber Pakhtunkhwa, Pakistan.
FAU - Awan, Naila Riaz
AU  - Awan NR
AD  - Medical Teaching Institution, Lady Reading Hospital, Peshawar, Khyber
      Pakhtunkhwa, Pakistan.
FAU - Mallen, Christian
AU  - Mallen C
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK.
AD  - Research and Innovation, Midlands Partnership Foundation Trust, Staffordshire,
      UK.
FAU - Farooq, Saeed
AU  - Farooq S
AD  - School of Primary, Community and Social Care, Keele University, Keele,
      Staffordshire, UK s.farooq@keele.ac.uk.
AD  - Research and Innovation, Midlands Partnership Foundation Trust, Staffordshire,
      UK.
LA  - eng
GR  - RP-PG-0617-20005/DH_/Department of Health/United Kingdom
GR  - RP_2014-04-026/DH_/Department of Health/United Kingdom
GR  - MR/S00243X/1/Medical Research Council UK/International
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ambulatory Care/*methods
MH  - *Developing Countries
MH  - Humans
MH  - Medication Adherence
MH  - *Organization and Administration
MH  - Outpatients/*psychology
MH  - Pakistan
MH  - Patient Compliance/*psychology
MH  - Schizophrenia/diagnosis/*therapy
MH  - *Schizophrenic Psychology
MH  - Treatment Outcome
PMC - PMC7328742
OTO - NOTNLM
OT  - *clinical trials
OT  - *mental health
OT  - *psychiatry
OT  - *public health
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: SF in the past 3 years has received honoraria and speaker's 
      fees from Otsuka, Lundbeck and Sunovian pharma and also research funding from
      Sunovian Pharmaceutical. MU-H and MFK received funding from different
      pharmaceuticals to attend scientific meetings.
EDAT- 2020/07/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034709 [pii]
AID - 10.1136/bmjopen-2019-034709 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 30;10(6):e034709. doi: 10.1136/bmjopen-2019-034709.


PMID- 32605864
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20210722
IS  - 1872-9177 (Electronic)
IS  - 1769-7255 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Jul
TI  - [Advance directives in hemodialysis patient: A feasibility study].
PG  - 191-196
LID - S1769-7255(20)30096-1 [pii]
LID - 10.1016/j.nephro.2019.12.004 [doi]
AB  - Respect of patient's autonomy is essential. So that patients are able to write
      their advance directives in case of a situation where they are unable to make
      decisions for themselves. Currently, few people have written advance directives. 
      We studied the feasibility of a systematic implementation of advance directives
      in haemodialysis patients. This prospective, single-center study was conducted in
      an ambulatory hemodialysis center. There were 4 steps: caregivers survey about
      advance directives; selection of patients and information about advance
      directives; writing advance directives with the interested patients; and finally,
      non-participation causes assessment of the other informed patients. Caregivers
      are not comfortable with advance directives, and have reluctances: the patient's 
      lack of medical knowledge; the anxiety generated by end-of-life talk. Fifty-six
      patients (51.6%) were included and received the information. Nine of them wanted 
      to write their advance directives on a suitable form. Eight finalised them (7.4% 
      of the initial population). The majority wanted a therapeutic limitation.
      Twenty-nine patients, who have received the information about advance directives,
      didn't want to write them, the main reason was that they felt healthy or that
      they thought that their relatives would take the right decisions. Eighteen
      patients left the centre during the study. The development of advance directives 
      requires information and training of caregivers and patient support. Few patients
      went to the end of the process. The limit of the patient's ability to decide for 
      himself is difficult to define. The role of the doctor is central to accompany
      the patient during this process.
CI  - Copyright (c) 2020 Societe francophone de nephrologie, dialyse et
      transplantation. Published by Elsevier Masson SAS. All rights reserved.
FAU - D'Halluin, Pauline
AU  - D'Halluin P
AD  - Service de nephrologie-hemodialyse, centre hospitalier de la Cote Basque, 13,
      avenue de l'interne J. Loeb, 64100 Bayonne, France. Electronic address:
      pdhalluin@ch-cotebasque.fr.
FAU - Sautenet, Benedicte
AU  - Sautenet B
AD  - Service de nephrologie et immunologie clinique, CHRU de Bretonneau, 2, boulevard 
      Tonnelle, 37044 Tours, France.
FAU - Francois, Maud
AU  - Francois M
AD  - Service de nephrologie et immunologie clinique, CHRU de Bretonneau, 2, boulevard 
      Tonnelle, 37044 Tours, France.
FAU - Birmele, Beatrice
AU  - Birmele B
AD  - Service de nephrologie et immunologie clinique, CHRU de Bretonneau, 2, boulevard 
      Tonnelle, 37044 Tours, France.
LA  - fre
PT  - Journal Article
TT  - Les directives anticipees chez des patients en hemodialyse chronique : etude de
      faisabilite.
DEP - 20200627
PL  - France
TA  - Nephrol Ther
JT  - Nephrologie & therapeutique
JID - 101248950
SB  - IM
MH  - Adult
MH  - *Advance Directives
MH  - Aged
MH  - Aged, 80 and over
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Renal Dialysis
OTO - NOTNLM
OT  - Advance directives
OT  - Directives anticipees
OT  - Ethics
OT  - Haemodialysis
OT  - Hemodialyse
OT  - Nephrology
OT  - Nephrologie
OT  - Personne de confiance
OT  - Support person
OT  - Ethique
EDAT- 2020/07/02 06:00
MHDA- 2021/07/23 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2019/12/16 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - S1769-7255(20)30096-1 [pii]
AID - 10.1016/j.nephro.2019.12.004 [doi]
PST - ppublish
SO  - Nephrol Ther. 2020 Jul;16(4):191-196. doi: 10.1016/j.nephro.2019.12.004. Epub
      2020 Jun 27.


PMID- 32605825
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220816
IS  - 2352-2291 (Electronic)
IS  - 0104-0014 (Linking)
VI  - 70
IP  - 3
DP  - 2020 May - Jun
TI  - [The anesthesiologist facing terminality: a survey-based observational study].
PG  - 225-232
LID - S0034-7094(20)30323-8 [pii]
LID - 10.1016/j.bjan.2020.03.008 [doi]
AB  - BACKGROUND AND OBJECTIVES: Advances in medicine, including anesthesiology and
      resuscitation, have made natural death increasingly rare. As a consequence,
      dysthanasia has become usual in a scenario for which there is not rationale. The 
      present study aimed to assess the level of knowledge of Brazilian
      anesthesiologists on the principles of dysthanasia and orthothanasia. Thence, we 
      studied the management preferences of these professionals, vis-a-vis those
      practices, as well as how medical school contributed to addressing death-related 
      issues. METHOD: Quantitative approach, prospective and descriptive cohort that
      included 150 anesthesiologists, members of the Brazilian Society of
      Anesthesiology, and who were invited to participate by email. An online
      questionnaire containing 38 questions was prepared by the authors. The study was 
      approved by the Instructional Research Ethics Committee. RESULTS:
      Anesthesiologists, although claiming to know dysthanasia and orthothanasia,
      mostly acquired knowledge outside medical school. If faced with their own end of 
      care, or of a patient or a loved one, they prefer orthothanasia, to die at home, 
      prioritizing dignity. However, the specialists claimed to have already practiced 
      dysthanasia, even when orthothanasia was the choice management, which caused them
      negative feelings. Almost all respondents stated that they did not have practical
      training in undergraduate school on how to face end-of-life issues, although they
      felt capable of identifying it. Most were not aware of Federal Council of
      Medicine Resolution 1.805/06 that makes practicing orthothanasia feasible.
      Anesthesiologists' religion or the political-administrative region of residence
      had no effect on their preferences. CONCLUSIONS: Anesthesiologists claim to have 
      knowledge on dysthanasia and orthothanasia, but prefer, in the face of a
      terminally ill patient, to practice orthothanasia, although dysthanasia is usual,
      and results in frustration and indignation. The medical school curriculum is
      unsatisfactory in addressing death-related issues.
CI  - Copyright (c) 2020 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier
      Editora Ltda. All rights reserved.
FAU - Cavalcante, Rodney Segura
AU  - Cavalcante RS
AD  - Universidade Estadual Paulista (UNESP), Faculdade de Medicina, Departamento de
      Anestesiologia, Campus de Botucatu, Botucatu, SP, Brazil. Electronic address:
      rradvogados@yahoo.com.br.
FAU - Barros, Guilherme Antonio Moreira de
AU  - Barros GAM
AD  - Universidade Estadual Paulista (UNESP), Faculdade de Medicina, Departamento de
      Anestesiologia, Campus de Botucatu, Botucatu, SP, Brazil; Comissao de Medicina
      Paliativa da Sociedade Brasileira de Anestesiologia, Botucatu, SP, Brazil.
FAU - Ganem, Eliana Marisa
AU  - Ganem EM
AD  - Universidade Estadual Paulista (UNESP), Faculdade de Medicina, Departamento de
      Anestesiologia, Campus de Botucatu, Botucatu, SP, Brazil; Sociedade Brasileira de
      Anestesiologia, Botucatu, SP, Brazil.
LA  - por
PT  - Journal Article
PT  - Observational Study
TT  - O anestesiologista frente a terminalidade.
DEP - 20200606
PL  - Brazil
TA  - Braz J Anesthesiol
JT  - Brazilian journal of anesthesiology (Elsevier)
JID - 101624623
SB  - IM
MH  - Adult
MH  - Anesthesiologists/*psychology
MH  - *Anesthesiology
MH  - *Attitude of Health Personnel
MH  - Death
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Life Support Care
MH  - Male
MH  - Middle Aged
MH  - Self Report
MH  - Terminally Ill
MH  - *Thanatology
PMC - PMC9373629
OTO - NOTNLM
OT  - Anestesiologia
OT  - Anesthesiology
OT  - Bioethics
OT  - Bioetica
OT  - Distanasia
OT  - Dysthanasia
OT  - Legalidade (Direito)
OT  - Legality (Law)
EDAT- 2020/07/02 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/07/02 06:00
PHST- 2019/02/17 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - S0034-7094(20)30323-8 [pii]
AID - 10.1016/j.bjan.2020.03.008 [doi]
PST - ppublish
SO  - Braz J Anesthesiol. 2020 May - Jun;70(3):225-232. doi:
      10.1016/j.bjan.2020.03.008. Epub 2020 Jun 6.


PMID- 32605730
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20210110
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 160
IP  - 4
DP  - 2020 Oct
TI  - Impact of coronavirus 2019 (COVID-19) on training and well-being in subspecialty 
      surgery: A national survey of cardiothoracic trainees in the United Kingdom.
PG  - 980-987
LID - S0022-5223(20)31275-7 [pii]
LID - 10.1016/j.jtcvs.2020.05.052 [doi]
AB  - OBJECTIVES: The coronavirus 2019 (COVID-19) pandemic has overwhelmed health care 
      systems and disrupted routine care internationally. Health care workers face
      disruption to their work routines and professional development, as well as an
      elevated risk of infection and morbidity. We sought to establish the impact of
      the COVID-19 pandemic on the well-being, practice, and progression of all
      trainees in cardiothoracic surgery in the United Kingdom. METHODS: A 31-item
      questionnaire was designed, validated, and disseminated via e-mail and an
      instant-messaging platform. RESULTS: In total, 76 (of 118, 64%) cardiothoracic
      surgical trainees responded, representing all training grades and programs
      nationally; 48 (63%) and 24 (32%) were concerned about their physical and mental 
      health, respectively, 25 (33%) had taken time off work due to COVID-19, 65 (86%) 
      had treated patients with COVID-19, 36 of whom (55%) were wearing satisfactory
      personal protective equipment at the time, 41 (54%) remain concerned about
      personal protective equipment provision at their institution, 42 (55%) had been
      redeployed to cover other specialties, and 23 (30%) had encountered ethical
      dilemmas related to care of patients. There was a significant impact on time
      spent in outpatient clinics (44% reduction), multidisciplinary team meetings (79%
      reduction), and operating theaters (78% reduction). In total, 67 (88%) of
      respondents were concerned about the impact on their training, and 54 (71%) felt 
      that the deviation may require an extension in their planned training time.
      CONCLUSIONS: The duration and impact of the current pandemic is, as yet,
      uncertain. Timely sharing of experiences, concerns, and expectations will inform 
      health care and education policy and influence practice in the pandemic era and
      beyond.
CI  - Copyright (c) 2020 The American Association for Thoracic Surgery. Published by
      Elsevier Inc. All rights reserved.
FAU - Caruana, Edward J
AU  - Caruana EJ
AD  - Department of Thoracic Surgery, Glenfield Hospital, University Hospitals of
      Leicester, Leicester, United Kingdom; NIHR Biomedical Research Centre, University
      of Nottingham, Nottingham, United Kingdom. Electronic address:
      edwardcaruana@nhs.net.
FAU - Patel, Akshay
AU  - Patel A
AD  - Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, 
      United Kingdom.
FAU - Kendall, Simon
AU  - Kendall S
AD  - Department of Cardiothoracic Surgery, James Cook University Hospital,
      Middlesborough, United Kingdom.
FAU - Rathinam, Sridhar
AU  - Rathinam S
AD  - Department of Thoracic Surgery, Glenfield Hospital, University Hospitals of
      Leicester, Leicester, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
SB  - IM
CIN - J Thorac Cardiovasc Surg. 2020 Oct;160(4):989-990. PMID: 32624304
CIN - J Thorac Cardiovasc Surg. 2020 Oct;160(4):988-989. PMID: 32811677
MH  - Adult
MH  - Attitude of Health Personnel
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/diagnosis/therapy/transmission
MH  - *Education, Medical, Graduate
MH  - Humans
MH  - Occupational Health
MH  - Occupational Stress/diagnosis/*etiology/psychology
MH  - *Pandemics
MH  - *Pneumonia, Viral/diagnosis/therapy/transmission
MH  - SARS-CoV-2
MH  - Students, Medical/*psychology
MH  - Surgeons/*psychology
MH  - Surveys and Questionnaires
MH  - Thoracic Surgery/*education
MH  - United Kingdom
PMC - PMC7262521
OTO - NOTNLM
OT  - *COVID-19
OT  - *medical education
OT  - *pandemic
OT  - *residency
OT  - *surgical education
OT  - *training
EDAT- 2020/07/02 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - S0022-5223(20)31275-7 [pii]
AID - 10.1016/j.jtcvs.2020.05.052 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2020 Oct;160(4):980-987. doi:
      10.1016/j.jtcvs.2020.05.052. Epub 2020 Jun 1.


PMID- 32605684
OWN - NLM
STAT- Publisher
LR  - 20200701
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
DP  - 2020 Jul 1
TI  - Beyond the numbers: a critique of quantitative multi-criteria decision analysis.
PG  - 1-5
LID - 10.1017/S0266462320000410 [doi]
AB  - When setting priorities for health, there is broad agreement that a range of
      social values and ethical principles beyond clinical and cost-effectiveness
      matter, but exactly how health technology assessment (HTA) should account for a
      broader set of criteria remains an area of ongoing debate. In light of this, we
      welcome a recent review paper by Baltussen et al. evaluating the potential of
      different multi-criteria decision analysis (MCDA) approaches to enable HTA
      agencies to incorporate a broader set of values in their appraisals. The authors 
      describe three approaches to MCDA-qualitative MCDA, quantitative MCDA, and MCDA
      with decision rules-laying out their relative advantages and disadvantages and
      providing recommendations for how they can best be implemented. While we endorse 
      many of the authors' assessments and conclusions, including the critical role of 
      deliberation in any MCDA approach and the undertaking of qualitative MCDA at a
      minimum, we take a stronger position regarding the flaws of quantitative MCDA and
      strongly caution against it. We find quantitative MCDA antithetical to at least
      two of the ways MCDA is intended to improve HTA recommendations: (i) enhancing
      quality and (ii) promoting transparency. Quantitative MCDA may mask the complex
      tradeoffs that exist within and between decision criteria and remain generally
      inaccessible to those who are not well-versed in its technical methods of
      appraisal. We advocate for a predominantly qualitative approach to MCDA appraisal
      centered around deliberation and supplemented with decision aids to help account 
      for health opportunity costs.
FAU - DiStefano, Michael J
AU  - DiStefano MJ
AUID- ORCID: https://orcid.org/0000-0002-5021-5347
AD  - Department of Health Policy & Management, Johns Hopkins Bloomberg School of
      Public Health, Baltimore, MD, USA.
AD  - Berman Institute of Bioethics, Johns Hopkins University, BaltimoreMD, USA.
FAU - Krubiner, Carleigh B
AU  - Krubiner CB
AD  - Berman Institute of Bioethics, Johns Hopkins University, BaltimoreMD, USA.
AD  - Center for Global Development, Washington, DC, USA.
LA  - eng
PT  - Journal Article
DEP - 20200701
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
SB  - IM
OTO - NOTNLM
OT  - Deliberation
OT  - Ethics
OT  - Legitimacy
OT  - Priority-setting
OT  - Transparency
EDAT- 2020/07/02 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
AID - 10.1017/S0266462320000410 [doi]
AID - S0266462320000410 [pii]
PST - aheadofprint
SO  - Int J Technol Assess Health Care. 2020 Jul 1:1-5. doi: 10.1017/S0266462320000410.


PMID- 32605637
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 30
TI  - Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
PG  - 609
LID - 10.1186/s12885-020-07104-9 [doi]
AB  - BACKGROUND: Chemotherapy induced cardio-toxicity has been recognized as a serious
      side effect since the first introduction to anthracyclines (ANT). Cardio-toxicity
      among patients with breast cancer is well studied but the impact on patients with
      sarcoma is limited, even though they are exposed to higher ANT doses. The
      commonly used term for cardio-toxicity is cancer therapeutics related cardiac
      dysfunction (CTRCD), defined as a left ventricular ejection fraction (LVEF)
      reduction of > 10%, to a value below 53%. The aim of our study was to estimate
      the prevalence of CTRCD in patients diagnosed with sarcoma and to describe the
      baseline risk factors and echocardiography parameters among that population.
      METHODS: Data were collected as part of the Israel Cardio-Oncology Registry
      (ICOR), enrolling all patients evaluated in the cardio-oncology clinic at our
      institution. The registry was approved by the local ethics committee and is
      registered in clinicaltrials.gov (Identifier: NCT02818517). All sarcoma patients 
      were enrolled and divided into two groups - CTRCD group vs. non-CTRCD group.
      RESULTS: Among 43 consecutive patients, 6 (14%) developed CTRCD. Baseline cardiac
      risk factors were more frequent among the non-CTRCD group. Elevated left
      ventricular end systolic diameter and reduced Global Longitudinal Strain were
      observed among the CTRCD group. During follow-up, 2 (33%) patients died in the
      CTRCD group vs. 3 (8.1%) patients in the non-CTRCD group. CONCLUSIONS: CTRCD is
      an important concern among patients with sarcoma, regardless of baseline risk
      factors. Echocardiography parameters may provide an early diagnosis of
      cardio-toxicity.
FAU - Shamai, Sivan
AU  - Shamai S
AD  - Department of Oncology and Tel-Aviv Sourasky Medical Center, Tel Aviv University,
      Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Rozenbaum, Zach
AU  - Rozenbaum Z
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, 
      64239, Tel Aviv, Israel.
FAU - Merimsky, Ofer
AU  - Merimsky O
AD  - Department of Oncology and Tel-Aviv Sourasky Medical Center, Tel Aviv University,
      Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Derakhshesh, Matthew
AU  - Derakhshesh M
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Moshkovits, Yonatan
AU  - Moshkovits Y
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Arnold, Joshua
AU  - Arnold J
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Topilsky, Yan
AU  - Topilsky Y
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, 
      64239, Tel Aviv, Israel.
FAU - Arbel, Yaron
AU  - Arbel Y
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, 
      64239, Tel Aviv, Israel.
FAU - Laufer-Perl, Michal
AU  - Laufer-Perl M
AUID- ORCID: http://orcid.org/0000-0001-6541-9863
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
      michalpela@gmail.com.
AD  - Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, 
      64239, Tel Aviv, Israel. michalpela@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02818517
PT  - Journal Article
PT  - Observational Study
DEP - 20200630
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Cardiotoxicity/diagnosis/drug therapy/epidemiology/etiology
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/chemically induced/diagnosis/drug therapy/*epidemiology
MH  - Heart Ventricles/diagnostic imaging/drug effects
MH  - Humans
MH  - Israel/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Registries/statistics & numerical data
MH  - Sarcoma/*drug therapy
MH  - Ventricular Function, Left/drug effects
PMC - PMC7325299
OTO - NOTNLM
OT  - CTRCD
OT  - Cardiotoxicity
OT  - Echocardiography
OT  - GLS
OT  - Sarcoma
EDAT- 2020/07/02 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - 10.1186/s12885-020-07104-9 [doi]
AID - 10.1186/s12885-020-07104-9 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Jun 30;20(1):609. doi: 10.1186/s12885-020-07104-9.


PMID- 32605576
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 30
TI  - The Melanoma Genomics Managing Your Risk Study randomised controlled trial:
      statistical analysis plan.
PG  - 594
LID - 10.1186/s13063-020-04351-w [doi]
AB  - BACKGROUND: The Melanoma Genomics Managing Your Risk Study is a randomised
      controlled trial that aims to evaluate the efficacy of providing information on
      personal genomic risk of melanoma in reducing ultraviolet radiation (UV)
      exposure, stratified by traditional risk group (low or high phenotypic risk) in
      the general population. The primary outcome is objectively measured total daily
      Standard Erythemal Doses at 12 months. Secondary outcomes include UV exposure at 
      specific time periods, self-reported sun protection and skin-examination
      behaviours, psychosocial outcomes, and ethical considerations surrounding
      offering genomic testing at a population level. A within-trial and modelled
      economic evaluation will be undertaken from an Australian health system
      perspective to assess the cost-effectiveness of the intervention. OBJECTIVE: To
      publish the pre-determined statistical analysis plan (SAP) before database lock
      and the start of analysis. METHODS: This SAP describes the data synthesis,
      analysis principles and statistical procedures for analysing the outcomes from
      this trial. The SAP was approved after closure of recruitment and before
      completion of patient follow-up. It outlines the planned primary analyses and a
      range of subgroup and sensitivity analyses. Health economic outcomes are not
      included in this plan but will be analysed separately. The SAP will be adhered to
      for the final data analysis of this trial to avoid potential analysis bias that
      may arise from knowledge of the outcome data. RESULTS: This SAP is consistent
      with best practice and should enable transparent reporting. CONCLUSION: This SAP 
      has been developed for the Melanoma Genomics Managing Your Risk Study and will be
      followed to ensure high-quality standards of internal validity and to minimise
      analysis bias. TRIAL REGISTRATION: Prospectively registered with the Australian
      New Zealand Clinical Trials Registry, ID: ACTR N12617000691347 . Registered on 15
      May 2017.
FAU - Lo, Serigne N
AU  - Lo SN
AD  - The University of Sydney, Melanoma Institute Australia, Sydney, NSW, Australia.
FAU - Smit, Amelia K
AU  - Smit AK
AD  - The University of Sydney, Melanoma Institute Australia, Sydney, NSW, Australia.
AD  - The University of Sydney, Faculty of Medicine and Health, Sydney School of Public
      Health, Cancer Epidemiology and Prevention Research, Sydney, NSW, Australia.
AD  - The University of Sydney, Faculty of Medicine and Health, Sydney School of Public
      Health, Sydney Health Ethics, Sydney, NSW, Australia.
FAU - Espinoza, David
AU  - Espinoza D
AD  - The University of Sydney, NHMRC Clinical Trials Centre, Sydney, NSW, Australia.
FAU - Cust, Anne E
AU  - Cust AE
AD  - The University of Sydney, Melanoma Institute Australia, Sydney, NSW, Australia.
      anne.cust@sydney.edu.au.
AD  - The University of Sydney, Faculty of Medicine and Health, Sydney School of Public
      Health, Cancer Epidemiology and Prevention Research, Sydney, NSW, Australia.
      anne.cust@sydney.edu.au.
CN  - Managing Your Risk Study Group
LA  - eng
GR  - 112822/National Health and Medical Research Council
GR  - 1147843/National Health and Medical Research Council
GR  - Research Training Program (RTP) Stipend Scholarship and a Merit Top Up
      Scholarship/The University of Sydney
GR  - Postgraduate Research Scholarship/Melanoma Institute Australia
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200630
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Australia
MH  - Cost-Benefit Analysis
MH  - *Data Interpretation, Statistical
MH  - Environmental Exposure/prevention & control
MH  - *Genetic Predisposition to Disease
MH  - Genetic Testing/*economics
MH  - Genomics/*economics
MH  - Health Behavior
MH  - Humans
MH  - Melanoma/economics/genetics/*prevention & control/psychology
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Skin Neoplasms/economics/genetics/*prevention & control/psychology
MH  - Ultraviolet Rays/adverse effects
PMC - PMC7329549
OTO - NOTNLM
OT  - Behaviours
OT  - Bioethics
OT  - Early detection
OT  - Genomic risk
OT  - Melanoma
OT  - Prevention
OT  - Psycho-oncology
OT  - Randomised controlled trial
OT  - Sun exposure
OT  - Sun protection
IR  - Cust AE
FIR - Cust, Anne E
IR  - Newson AJ
FIR - Newson, Ainsley J
IR  - Morton RL
FIR - Morton, Rachael L
IR  - Kimlin M
FIR - Kimlin, Michael
IR  - Keogh L
FIR - Keogh, Louise
IR  - Law MH
FIR - Law, Matthew H
IR  - Kirk J
FIR - Kirk, Judy
IR  - Dobbinson SJ
FIR - Dobbinson, Suzanne J
IR  - Kanetsky PA
FIR - Kanetsky, Peter A
IR  - Mann GJ
FIR - Mann, Graham J
IR  - Dawkins H
FIR - Dawkins, Hugh
IR  - Savard J
FIR - Savard, Jacqueline
IR  - Dunlop K
FIR - Dunlop, Kate
IR  - Trevena L
FIR - Trevena, Lyndal
IR  - Jenkins M
FIR - Jenkins, Mark
IR  - Allen M
FIR - Allen, Martin
IR  - Butow P
FIR - Butow, Phyllis
IR  - Wordsworth S
FIR - Wordsworth, Sarah
IR  - Lo SN
FIR - Lo, Serigne N
IR  - Low C
FIR - Low, Cynthia
IR  - Smit A
FIR - Smit, Amelia
IR  - Espinoza D
FIR - Espinoza, David
EDAT- 2020/07/02 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1186/s13063-020-04351-w [doi]
AID - 10.1186/s13063-020-04351-w [pii]
PST - epublish
SO  - Trials. 2020 Jun 30;21(1):594. doi: 10.1186/s13063-020-04351-w.


PMID- 32605569
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 30
TI  - Relational autonomy in end-of-life care ethics: a contextualized approach to
      real-life complexities.
PG  - 50
LID - 10.1186/s12910-020-00495-1 [doi]
AB  - BACKGROUND: Respect for autonomy is a paramount principle in end-of-life ethics. 
      Nevertheless, empirical studies show that decision-making, exclusively focused on
      the individual exercise of autonomy fails to align well with patients'
      preferences at the end of life. The need for a more contextualized approach that 
      meets real-life complexities experienced in end-of-life practices has been
      repeatedly advocated. In this regard, the notion of 'relational autonomy' may be 
      a suitable alternative approach. Relational autonomy has even been advanced as a 
      foundational notion of palliative care, shared decision-making, and advance-care 
      planning. However, relational autonomy in end-of-life care is far from being
      clearly conceptualized or practically operationalized. MAIN BODY: Here, we
      develop a relational account of autonomy in end-of-life care, one based on a
      dialogue between lived reality and conceptual thinking. We first show that the
      complexities of autonomy as experienced by patients and caregivers in end-of-life
      practices are inadequately acknowledged. Second, we critically reflect on how
      engaging a notion of relational autonomy can be an adequate answer to addressing 
      these complexities. Our proposal brings into dialogue different ethical
      perspectives and incorporates multidimensional, socially embedded, scalar, and
      temporal aspects of relational theories of autonomy. We start our reflection with
      a case in end-of-life care, which we use as an illustration throughout our
      analysis. CONCLUSION: This article develops a relational account of autonomy,
      which responds to major shortcomings uncovered in the mainstream interpretation
      of this principle and which can be applied to end-of-life care practices.
FAU - Gomez-Virseda, Carlos
AU  - Gomez-Virseda C
AUID- ORCID: 0000-0002-4801-7157
AD  - Centre for Biomedical Ethics and Law, KU Leuven, Kapucijnenvoer 35/3, 3000,
      Leuven, Belgium. carlos.gomezvirseda@student.kuleuven.be.
FAU - de Maeseneer, Yves
AU  - de Maeseneer Y
AD  - Faculty of Theology and Religious Studies (Theological and Comparative Ethics),
      KU Leuven, Sint-Michielsstraat 4 - box 3101, B-3000, Leuven, Belgium.
FAU - Gastmans, Chris
AU  - Gastmans C
AD  - Centre for Biomedical Ethics and Law, KU Leuven, Kapucijnenvoer 35 blok d - box
      7001, 3000, Leuven, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Advance Care Planning
MH  - Decision Making
MH  - Humans
MH  - Palliative Care
MH  - Patient Preference
MH  - Personal Autonomy
MH  - Relational Autonomy
MH  - *Terminal Care
PMC - PMC7325052
OTO - NOTNLM
OT  - *Advance Care Planning
OT  - *Decision making
OT  - *End-of-life
OT  - *Euthanasia
OT  - *Medical ethics
OT  - *Palliative Care
OT  - *Patient Preference
OT  - *Relational autonomy
EDAT- 2020/07/02 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00495-1 [doi]
AID - 10.1186/s12910-020-00495-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jun 30;21(1):50. doi: 10.1186/s12910-020-00495-1.


PMID- 32605493
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1552-7409 (Electronic)
IS  - 0894-3184 (Linking)
VI  - 33
IP  - 3
DP  - 2020 Jul
TI  - Consequences for Straight Thinking in Nursing Ethics.
PG  - 215-216
LID - 10.1177/0894318420920619 [doi]
AB  - The concepts of nursing ethics continue to be seen through the lens of medical
      science and the systematic study of bioethics. The discipline of nursing has
      chosen through its philosophical educational systems to focus on the systematic
      study of bioethics as foundational to doctoral, graduate, and advanced practice
      nursing programs. In choosing to focus outside of the discipline for this
      straight thinking inquiry, what are the consequences for the discipline as well
      as to humankind for the lack of discipline-specific inquiry and practice as
      articulated by the discipline of nursing? This article begins a conversation for 
      the straight thinking priorities that should be considered by the discipline of
      nursing for the study of nursing ethics.
FAU - Milton, Constance L
AU  - Milton CL
AUID- ORCID: 0000-0002-5848-6651
AD  - Professor of Doctoral Programs, School of Nursing, Azusa Pacific University,
      Azusa, CA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurs Sci Q
JT  - Nursing science quarterly
JID - 8805022
MH  - *Ethics, Nursing
MH  - *Humanism
MH  - Humans
MH  - *Thinking
OTO - NOTNLM
OT  - *bioethics
OT  - *humanbecoming
OT  - *nursing ethics
OT  - *nursing theory
EDAT- 2020/07/02 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
AID - 10.1177/0894318420920619 [doi]
PST - ppublish
SO  - Nurs Sci Q. 2020 Jul;33(3):215-216. doi: 10.1177/0894318420920619.


PMID- 32605266
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201119
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 13
DP  - 2020 Jun 28
TI  - How Do Hospital Medical and Nursing Managers Perceive Work-Related Strain on
      Their Employees?
LID - E4660 [pii]
LID - 10.3390/ijerph17134660 [doi]
AB  - Health-oriented supportive leadership behavior is a key factor in reducing work
      stress and promoting health. Employees in the health sector are subject to a
      heavy workload, and it has been shown that 40% of them show permanent health
      problems. A supportive leadership behavior requires the manager's awareness of
      the employees' well-being. However, little is yet known about how medical and
      nursing managers perceive the well-being of their staff. To explore this issue,
      we conducted a total of 37 semi-standardized interviews with 37 chief physicians 
      (CPs), senior physicians (SPs), and senior nurses (SNs) in one German hospital.
      The interviews were content-analyzed based on the definitions of strain of the
      'Federal Institute for Occupational Safety and Health'. Results show that
      hospital managers are aware of fatigue and further consequences such as
      deterioration of the team atmosphere, work ethics, treatment quality, and an
      increased feeling of injustice among employees. Most managers reported sick
      leaves as a result of psychosomatic complaints due to the permanent overstrain
      situation at work in the hospital. Results of this qualitative study are
      discussed in the light of health-oriented management relating to relevant stress 
      models and to findings concerning staff shortages.
FAU - Worringer, Britta
AU  - Worringer B
AD  - Institute for Occupational, Social and Environmental Medicine, Centre for Health 
      and Society, Medical Faculty, Dusseldorf University, 40225 Dusseldorf, Germany.
FAU - Genrich, Melanie
AU  - Genrich M
AD  - Institute of Psychology, Work & Organizational Psychology, University of
      Duisburg-Essen, 45141 Essen, Germany.
FAU - Muller, Andreas
AU  - Muller A
AD  - Institute of Psychology, Work & Organizational Psychology, University of
      Duisburg-Essen, 45141 Essen, Germany.
FAU - Junne, Florian
AU  - Junne F
AD  - Department of Psychosomatic Medicine and Psychotherapy, Medical University
      Hospital Tubingen, 72016 Tubingen, Germany.
FAU - Contributors Of The Seegen Consortium
AU  - Contributors Of The Seegen Consortium
FAU - Angerer, Peter
AU  - Angerer P
AUID- ORCID: 0000-0002-9602-7405
AD  - Institute for Occupational, Social and Environmental Medicine, Centre for Health 
      and Society, Medical Faculty, Dusseldorf University, 40225 Dusseldorf, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - *Leadership
MH  - Male
MH  - Middle Aged
MH  - Nurse Administrators
MH  - *Nursing Staff, Hospital/psychology
MH  - *Occupational Health
MH  - *Occupational Stress
MH  - *Physicians/psychology
MH  - Workload
PMC - PMC7369983
OTO - NOTNLM
OT  - *employee mental well-being
OT  - *healthcare
OT  - *leadership
OT  - *occupational health
OT  - *psychosocial stress
OT  - *qualitative research
COIS- The authors declare no conflict of interest.
EDAT- 2020/07/02 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - ijerph17134660 [pii]
AID - 10.3390/ijerph17134660 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 28;17(13). pii: ijerph17134660. doi:
      10.3390/ijerph17134660.


PMID- 32605227
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20201119
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 13
DP  - 2020 Jun 28
TI  - A Study on the Cause Analysis of Cyberbullying in Korean Adolescents.
LID - E4648 [pii]
LID - 10.3390/ijerph17134648 [doi]
AB  - With the development of information and communication technology, online
      communication is becoming more active than offline meetings in daily life. This
      online communication is accelerating, especially as smartphone distribution and
      utilization become more prevalent. This communication in cyberspace has the
      advantage of people being able to communicate anytime, anywhere beyond time and
      place, while causing a variety of inappropriate consequences. A typical one is
      cyberbullying, which is a serious problem for adolescents who have active
      communication online. The purpose of this study is to accurately investigate and 
      analyze the status of cyberbullying among adolescents. To this end, national
      survey data of the National Information Society Agency (NIA) was analyzed for the
      past three years. The population size and sample size from 2017 to 2019 were
      5.773.998 and 4500 (2017), 5,663,725 and 4662 (2018), 5,502,801 and 4779 (2019), 
      respectively. The statistical analysis shows that the biggest type of
      cyberbullying among adolescents is verbal abuse, and the biggest means is instant
      messaging. In addition, the most frequent forms of cyberbullying victims and
      cyberbullying perpetrators occur between individuals. In addition, the
      correlation between the interpersonal relationships of adolescents and the
      cyberbullying experience rate were analyzed, and various cyberbullying factors
      such as psychological factors were analyzed. As a result, we found that the
      interaction with parents and friendship reliability have a negative correlation
      with the cyberbullying experience rate. We expect the results of this study to be
      of great help to future research and policies of juvenile cyberbullying.
FAU - Jun, Woochun
AU  - Jun W
AD  - Department of Computer Education, Seoul National University of Education, Seoul
      06639, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adolescent
MH  - *Adolescent Behavior
MH  - *Bullying
MH  - *Crime Victims
MH  - Cyberbullying
MH  - Female
MH  - Humans
MH  - Internet
MH  - Male
MH  - Reproducibility of Results
MH  - Republic of Korea
PMC - PMC7369818
OTO - NOTNLM
OT  - *adolescent
OT  - *cyberbullying
OT  - *cybercrime
OT  - *information and communication technology
OT  - *information ethics
OT  - *instant message
OT  - *verbal abuse
COIS- The author declares no conflict of interest.
EDAT- 2020/07/02 06:00
MHDA- 2020/11/20 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
AID - ijerph17134648 [pii]
AID - 10.3390/ijerph17134648 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 28;17(13). pii: ijerph17134648. doi:
      10.3390/ijerph17134648.


PMID- 32604847
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 12
DP  - 2020 Jun 26
TI  - Resilience Scale Psychometric Study. Adaptation to the Spanish Population in
      Nursing Students.
LID - E4602 [pii]
LID - 10.3390/ijerph17124602 [doi]
AB  - Nursing students and professionals are exposed to highly stressful clinical
      situations. However, when confronted with stress, which is exacerbated by
      academic and professional situations, there is a great disparity between those
      who do not know how to respond suitably to the demands from patients or teachers 
      due to a lack of competence and personal resistance, and those who are more
      resilient and develop a greater range of strengths. This research aims to analyse
      the validity and psychometric characteristics of a questionnaire on resilience
      adapted to Spanish nursing bachelor's degree students. The participants were 434 
      undergraduate nursing students from the province of Valencia (Spain) between 17
      and 54 years of age (Mean, M = 21; Standard Deviation, SD = 0.320), 104 of whom
      were men (24%) and 330 women (76%). A cross-sectional group evaluation was
      carried out in the university itself, adhering to the ethical standards of the
      Declaration of Helsinki. Based on the descriptive, factorial, exploratory and
      confirmatory analyses, it was possible to confirm the suitability of the
      questionnaire and its adaptation to nursing students. The model is thus suitable 
      for evaluating the population under study. Furthermore, there are statistically
      significant differences depending on age and gender. The results show that the
      questionnaire analysed is suited to evaluating resilience among Spanish nursing
      students, thereby justifying the adaptation of a scale of this nature to foster
      resilience among nursing students and nurses in professional life, who are
      exposed to critical situations with patients' suffering, deterioration or death. 
      Our study highlights important practical implications: Spanish nursing studies
      involve theory and practice, but students and nurses in professional life have to
      confront critical situations of patients' suffering, deterioration, or death.
      These situations cause stress and feelings of impotence that may lead to chronic 
      stress and even suicidal thoughts.
FAU - Tur Porcar, Ana M
AU  - Tur Porcar AM
AUID- ORCID: 0000-0003-4132-7109
AD  - Faculty of Psychology, University of Valencia, Avda. Blasco Ibanez 21, 46010
      Valencia, Spain.
FAU - Cuartero Monteagudo, Noemi
AU  - Cuartero Monteagudo N
AD  - Pediatric Nurse Lecture, Catholic University of Valencia, C/Espartero 7, 46007
      Valencia, Spain.
FAU - Gea-Caballero, Vicente
AU  - Gea-Caballero V
AUID- ORCID: 0000-0001-8607-3195
AD  - Nursing School La Fe, Adscript Center of University of Valencia, 46026 Valencia, 
      Spain.
AD  - Research Group GREIACC, Research Health Institute La Fe, Pabellon Docente. Torre 
      H. Avda. de Fernando Abril Martorell 106, 46026 Valencia, Spain.
FAU - Juarez-Vela, Raul
AU  - Juarez-Vela R
AUID- ORCID: 0000-0003-3597-2048
AD  - Department of Nursing, University of La Rioja, C/Duquesa de la Victoria, 88,
      26003 Logrono, Spain.
AD  - Research Group BMP, Idi-Paz, Hospital La Paz, Paseo Castellana 261, 28046 Madrid,
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Education, Nursing, Baccalaureate
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychometrics
MH  - Spain
MH  - *Students, Nursing
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7344601
OTO - NOTNLM
OT  - *coping
OT  - *nursing students
OT  - *psychometric properties
OT  - *resilience
OT  - *scale validation
EDAT- 2020/07/02 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/05/24 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - ijerph17124602 [pii]
AID - 10.3390/ijerph17124602 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 26;17(12). pii: ijerph17124602. doi:
      10.3390/ijerph17124602.


PMID- 32604649
OWN - NLM
STAT- MEDLINE
DCOM- 20200714
LR  - 20200714
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 272
DP  - 2020 Jun 26
TI  - Urgent Need for Developing a Framework for the Governance of AI in Healthcare.
PG  - 253-256
LID - 10.3233/SHTI200542 [doi]
AB  - Lately, the application or integration of Artificial Intelligence in various
      areas of the Healthcare domain has been a prime attraction; this includes
      diagnostics, medicine/drugs, medical devices, interventions/procedures, imaging, 
      therapies as well as treatment regimes, and these areas are in direct relation
      with the patient care, which is the core subject of the improvements envisioned
      through the implementation of AI. Although carrying this practice with a focused 
      objective of improvisation in providing quality care, the overall concept of such
      implementations misses the governance path which can comply with any available
      regulatory environment, which unfortunately at this stage does not exist. As
      these implementations would have a direct impact on patients care, there is an
      urgent need to institute a robust governance and compliance framework in order to
      ensure the efficacy, safety, privacy, and ethical considerations. The onus of
      pioneering this initiative of building a governance framework for the
      implementation of healthcare artificial intelligence primarily rests with the
      Food and Drug Authority of the respective country, it is also important for this 
      authority to further organizing the governance framework in agreement or
      collaboration with other international authorities.
FAU - Baig, Mansoor Ali
AU  - Baig MA
AD  - King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
AD  - Department of Biostatistics Epidemiology & Scientific Computing, KFSHRC, KSA.
FAU - Almuhaizea, Mohamad A
AU  - Almuhaizea MA
AD  - King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
FAU - Alshehri, Jumanah
AU  - Alshehri J
AD  - Xellipsis Company, Riyadh, Saudi Arabia.
FAU - Bazarbashi, Mohammad Shouki
AU  - Bazarbashi MS
AD  - King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
FAU - Al-Shagathrh, Fahad
AU  - Al-Shagathrh F
AD  - Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Artificial Intelligence
MH  - *Delivery of Health Care
MH  - Humans
MH  - Morals
MH  - Privacy
MH  - Quality of Health Care
OTO - NOTNLM
OT  - Data Science
OT  - Ethics
OT  - Governance
OT  - Healthcare AI
EDAT- 2020/07/02 06:00
MHDA- 2020/07/15 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2020/07/15 06:00 [medline]
AID - SHTI200542 [pii]
AID - 10.3233/SHTI200542 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 26;272:253-256. doi: 10.3233/SHTI200542.


PMID- 32604443
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20201218
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 82
IP  - 6
DP  - 2020 Jun
TI  - [Covid-19: An ad hoc public health ethics consultation].
PG  - 507-513
LID - 10.1055/a-1174-0086 [doi]
AB  - In this paper we describe the process and content of our ad hoc public health
      ethics consultation for a Bavarian health authority in relation to Covid-19.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Wild, Verina
AU  - Wild V
AUID- ORCID: 0000-0003-3012-7662
AD  - Institut fur Ethik, Geschichte und Theorie der Medizin,
      Ludwig-Maximilians-Universitat Munchen.
FAU - Buyx, Alena
AU  - Buyx A
AD  - Institut fur Geschichte und Ethik der Medizin, Technische Universitat Munchen.
FAU - Hurst, Samia
AU  - Hurst S
AD  - Institute For Ethics, History, and The Humanities, University of Geneva,
      Switzerland.
FAU - Munthe, Christian
AU  - Munthe C
AD  - Department of philosophy, linguistics and theory of science and the Centre for
      antibiotic resistance research (CARe), University of Gothenburg, Gothenburg,
      Sweden.
FAU - Rid, Annette
AU  - Rid A
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health, USA,
      Bethesda, United States.
FAU - Schroder-Back, Peter
AU  - Schroder-Back P
AD  - Department of International Health, School for Public Health and Primary Care
      (caphri), Maastricht University, Maastricht, Netherlands.
AD  - Faculty of Human and Health Sciences, University of Bremen.
FAU - Strech, Daniel
AU  - Strech D
AD  - QUEST Center - Quality, Ethics, Open Science, Translation, Berlin Institute of
      Health (BIH).
AD  - Charite - Universitatsmedizin Berlin.
FAU - Thompson, Alison
AU  - Thompson A
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
LA  - ger
GR  - Bundesministerium fur Bildung/01GP1791
PT  - Journal Article
TT  - Covid-19: Eine Ad hoc Public-Health-Ethikberatung.
DEP - 20200630
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes
      (Germany))
JID - 9204210
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - *Ethics Consultation
MH  - Germany
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - *Public Health
MH  - SARS-CoV-2
PMC - PMC7365938
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/07/01 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1055/a-1174-0086 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2020 Jun;82(6):507-513. doi: 10.1055/a-1174-0086. Epub 2020 Jun
      30.


PMID- 32604322
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210608
IS  - 1538-943X (Electronic)
IS  - 1058-2916 (Linking)
VI  - 66
IP  - 7
DP  - 2020 Jul
TI  - Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim
      Guidelines: A Consensus Document from an International Group of Interdisciplinary
      Extracorporeal Membrane Oxygenation Providers.
PG  - 707-721
LID - 10.1097/MAT.0000000000001193 [doi]
AB  - Disclaimer: The Extracorporeal Life Support Organization (ELSO) Coronavirus
      Disease 2019 (COVID-19) Guidelines have been developed to assist existing
      extracorporeal membrane oxygenation (ECMO) centers to prepare and plan provision 
      of ECMO during the ongoing pandemic. The recommendations have been put together
      by a team of interdisciplinary ECMO providers from around the world.
      Recommendations are based on available evidence, existing best practice
      guidelines, ethical principles, and expert opinion. This is a living document and
      will be regularly updated when new information becomes available. ELSO is not
      liable for the accuracy or completeness of the information in this document.
      These guidelines are not meant to replace sound clinical judgment or specialist
      consultation but rather to strengthen provision and clinical management of ECMO
      specifically, in the context of the COVID-19 pandemic.
FAU - Shekar, Kiran
AU  - Shekar K
AD  - From Adult Intensive Care Services, The Prince Charles Hospital, Brisbane,
      Queensland, Australia.
FAU - Badulak, Jenelle
AU  - Badulak J
AD  - University of Washington, Seattle, Washington.
FAU - Peek, Giles
AU  - Peek G
AUID- ORCID: 0000-0002-1313-6498
AD  - University of Florida, Shands Hospital for Children, Gainesville, Florida.
FAU - Boeken, Udo
AU  - Boeken U
AUID- ORCID: 0000-0001-8128-9659
AD  - Department of Cardiac Surgery, University Hospital, Duesseldorf, Germany.
FAU - Dalton, Heidi J
AU  - Dalton HJ
AUID- ORCID: 0000-0001-9443-3533
AD  - INOVA Fairfax Medical Center, Falls Church, Virginia.
FAU - Arora, Lovkesh
AU  - Arora L
AUID- ORCID: 0000-0002-4142-2870
AD  - University of Iowa Hospital & Clinics, Iowa City, Iowa.
FAU - Zakhary, Bishoy
AU  - Zakhary B
AUID- ORCID: 0000-0002-8662-5911
AD  - Oregon Health and Science University, Portland, Oregon.
FAU - Ramanathan, Kollengode
AU  - Ramanathan K
AUID- ORCID: 0000-0003-1822-9455
AD  - National University Hospital, Singapore.
FAU - Starr, Joanne
AU  - Starr J
AD  - CHOC Children's Hospital, Orange, California.
FAU - Akkanti, Bindu
AU  - Akkanti B
AD  - UT McGovern Medical School, Houston, Texas.
FAU - Antonini, M Velia
AU  - Antonini MV
AD  - 1st Intensive Care Unit, University Hospital of Parma, Parma, Italy.
FAU - Ogino, Mark T
AU  - Ogino MT
AD  - Department of Paediatrics, Division of Neonatology, Nemours Alfred I duPont
      Hospital for Children, Wilmington, Delaware.
AD  - Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia,
      Pennsylvania.
FAU - Raman, Lakshmi
AU  - Raman L
AD  - University of Texas Southwestern Medical Center, Dallas, Texas.
FAU - Barret, Nicholas
AU  - Barret N
AD  - St. Thomas Hospital, London, United Kingdom.
FAU - Brodie, Daniel
AU  - Brodie D
AD  - Columbia University Medical Center/New York-Presbyterian Hospital, New York, New 
      York.
FAU - Combes, Alain
AU  - Combes A
AD  - Assitance Publique-Hopitaux de Paris, Pitie-Salpetriere Hospital, Paris, France.
FAU - Lorusso, Roberto
AU  - Lorusso R
AD  - Maastricht University Medical Centre, Maastricht, The Netherlands.
FAU - MacLaren, Graeme
AU  - MacLaren G
AD  - National University Hospital, Singapore.
FAU - Muller, Thomas
AU  - Muller T
AD  - University Hospital Regensburg, Regensburg, Germany.
FAU - Paden, Matthew
AU  - Paden M
AD  - Department of Pediatrics, Emory University, Atlanta, Georgia.
FAU - Pellegrino, Vincent
AU  - Pellegrino V
AD  - The Alfred, Melbourne, Victoria, Australia.
CN  - ELSO Guideline Working Group
LA  - eng
GR  - K08 HL143342/HL/NHLBI NIH HHS/United States
GR  - T32 GM112596/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - ASAIO J
JT  - ASAIO journal (American Society for Artificial Internal Organs : 1992)
JID - 9204109
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Consensus
MH  - Coronavirus Infections/*therapy
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
PMC - PMC7228451
EDAT- 2020/07/01 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 10.1097/MAT.0000000000001193 [doi]
AID - 00002480-202007000-00001 [pii]
PST - ppublish
SO  - ASAIO J. 2020 Jul;66(7):707-721. doi: 10.1097/MAT.0000000000001193.


PMID- 32604288
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210209
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Sep
TI  - Cleft Palate Repair: A New Maxillary Nerve Block Approach.
PG  - 1547-1550
LID - 10.1097/SCS.0000000000006633 [doi]
AB  - OBJECTIVE: To introduce a different approach for maxillary nerve block (MNB), in 
      cleft palate repair. To reduce the use of opioids during surgery and to prevent
      frequent respiratory complications by means of an adequate intra and
      postoperative pain relief. PATIENTS AND METHODS: A prospective clinical trial was
      planned, to collect scientific evidences between 2 groups of patients with
      primary cleft palate, receiving surgery in 2 Pediatric centers of Buenos Aires,
      utilizing a different protocol.Sixty patients undergoing primary cleft palate
      repair in both hospitals, from January 2017 to July 2018, by senior surgeons and 
      the same expert anesthesiologists' team, were included.Syndromic and secondary
      cases, and patients whose parents rejected to participate of this study were
      excluded. The first group called Hospital A included 45 children, the second
      group identified as Hospital B was formed by 15 patients.A combination of general
      whit local anesthesia and a bilateral regional MNB, was used in all the patients 
      of the Hospital A. Utilizing an aspirating syringe, children received 0.15 ml/kg 
      of lidocaine clorhidrate 2% with epinephrine 1:50.000, under direct vision
      through the spheno palatine holes, just before surgery. A traditional general
      anesthesia procedure plus local anesthesia, was utilized in all the patients
      treated at the Hospital B Medial blood pressure and cardiac frequency parameters 
      were tested during induction, along the surgical procedure and in the immediate
      post op, to detect any sign of pain (12). After surgery, patient reactivity,
      airway depression symptoms, time of initial feeding and discharge time, were also
      monitored (13).This study was approved by the Hospitals Ethics Committees of both
      hospitals, and is in accordance with the 1975 Helsinki Declaration, as amended in
      1983. The parents have signed an informed consent form for all the patients
      included. RESULTS: Patients of both groups did not show any significant variant
      in the monitored parameters to detect signals of pain, along the surgery. The
      rest of controls during and after surgery showed significant differences in favor
      of the patients of Hospital A. CONCLUSIONS: Bilateral regional MNB, under direct 
      vision trough the spheno palatine holes results an effective, easy, and safe
      method for pain relief during and after primary cleft palate repair surgeries.The
      combination of slight general anesthesia with local anesthesia and regional
      blocks, results a good option to reduce opioids utilization, to prevent
      neurotoxicity, respiratory depression, sickness, and vomiting facilitating early 
      feeding and patient discharge.
FAU - Moggi, Luis E
AU  - Moggi LE
AD  - Asociacion PIEL.
AD  - Ricardo Gutierrez Children's Hospital.
FAU - Ventorutti, Tatyana
AU  - Ventorutti T
AD  - Asociacion PIEL.
AD  - Ricardo Gutierrez Children's Hospital.
FAU - Bennun, Ricardo D
AU  - Bennun RD
AD  - Asociacion PIEL.
AD  - School of Medicine, National University of Buenos Aires.
AD  - Dental School, Maimonides University, Buenos Aires, Argentina.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
RN  - 98PI200987 (Lidocaine)
RN  - YKH834O4BH (Epinephrine)
MH  - Anesthesia, Local
MH  - Child, Preschool
MH  - Cleft Palate/*surgery
MH  - Epinephrine
MH  - Female
MH  - Humans
MH  - Infant
MH  - Lidocaine
MH  - Male
MH  - *Maxillary Nerve/surgery
MH  - Nerve Block/methods
MH  - Peripheral Nerves
MH  - Prospective Studies
EDAT- 2020/07/01 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 10.1097/SCS.0000000000006633 [doi]
AID - 00001665-202009000-00015 [pii]
PST - ppublish
SO  - J Craniofac Surg. 2020 Sep;31(6):1547-1550. doi: 10.1097/SCS.0000000000006633.


PMID- 32603309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-073X (Print)
IS  - 1929-073X (Linking)
VI  - 9
IP  - 3
DP  - 2020 Jul 8
TI  - Protection of Health Care Professionals During an Epidemic: Medical, Ethical, and
      Legal Ramifications.
PG  - e19144
LID - 10.2196/19144 [doi]
AB  - The welfare of health care professionals working in hazardous environments is a
      concerning issue. Personal protective equipment such as face masks, disposable
      gowns, hair covers, gloves, and shoe covers is often used to prevent
      contamination from patient contact and droplets. This is especially relevant
      during an epidemic, when health care professionals are at elevated risk of
      infection. Failure to provide adequate protection to health care workers during
      epidemics has medical, ethical, and legal ramifications.
CI  - (c)Achuta Guddati. Originally published in the Interactive Journal of Medical
      Research (http://www.i-jmr.org/), 08.07.2020.
FAU - Guddati, Achuta
AU  - Guddati A
AUID- ORCID: https://orcid.org/0000-0002-9390-0424
AD  - Augusta University, Augusta, NY, United States.
LA  - eng
PT  - Journal Article
DEP - 20200708
PL  - Canada
TA  - Interact J Med Res
JT  - Interactive journal of medical research
JID - 101598421
PMC - PMC7380978
OTO - NOTNLM
OT  - COVID-19
OT  - harm
OT  - medical ethics
OT  - protection
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/07/01 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - v9i3e19144 [pii]
AID - 10.2196/19144 [doi]
PST - epublish
SO  - Interact J Med Res. 2020 Jul 8;9(3):e19144. doi: 10.2196/19144.


PMID- 32603060
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20201218
IS  - 1784-3227 (Print)
IS  - 1784-3227 (Linking)
VI  - 83
IP  - 2
DP  - 2020 Apr-Jun
TI  - Liver transplantation during the COVID-19 epidemic : recommendations from the
      Belgian Liver Intestine Transplant Committee (BeLIAC).
PG  - 340-343
AB  - Since January 2020, the Novel Coronavirus Disease 2019 (COVID-19) pandemic has
      dramatically impacted the world. In March 2020, the COVID-19 epidemic reached
      Belgium creating uncertainty towards all aspects of life. There has been an
      impressive capacity and solidarity of all healthcare professionals to acutely
      reconvert facilities to treat these patients. In the context of liver
      transplantation (LTx), concerns are raised about organ donation shortage and
      safety, the ethics of using limited healthcare resources for LTx, selection
      criteria for LTx during the epidemic and the risk of de novo COVID-19 infection
      on the waiting list and after LTx. BeLIAC makes several recommendations to try to
      mitigate the deleterious effect that this epidemic has/will have on donation and 
      LTx, taking into account the available resources, and trying to maximize patients
      and healthcare professionals' safety.
CI  - (c) Acta Gastro-Enterologica Belgica.
FAU - Dahlqvist, G
AU  - Dahlqvist G
AD  - UCL Liver Transplant Program; Cliniques Universitaires Saint-Luc, Brussels,
      Belgium.
FAU - Ciccarelli, O
AU  - Ciccarelli O
AD  - UCL Liver Transplant Program; Cliniques Universitaires Saint-Luc, Brussels,
      Belgium.
FAU - Van Vlierberghe, H
AU  - Van Vlierberghe H
AD  - UZ Gent Liver Transplant Program, Universitair Ziekenhuis, Gent, Belgium.
FAU - Berrevoet, F
AU  - Berrevoet F
AD  - UZ Gent Liver Transplant Program, Universitair Ziekenhuis, Gent, Belgium.
FAU - Vanwolleghem, T
AU  - Vanwolleghem T
AD  - UZ Antwerpen Liver Transplant Program, Universitair Ziekenhuis, Antwerpen,
      Belgium.
FAU - Ysebaert, D
AU  - Ysebaert D
AD  - UZ Antwerpen Liver Transplant Program, Universitair Ziekenhuis, Antwerpen,
      Belgium.
FAU - Gustot, T
AU  - Gustot T
AD  - ULB Liver Transplant Program; Hopital Universitaire Erasme, Brussels, Belgium.
FAU - Lucidi, V
AU  - Lucidi V
AD  - ULB Liver Transplant Program; Hopital Universitaire Erasme, Brussels, Belgium.
FAU - Delwaide, J
AU  - Delwaide J
AD  - ULg Liver Transplant Program, Hopital Universitaire du Sart Tilman, Liege,
      Belgium.
FAU - Detry, O
AU  - Detry O
AD  - ULg Liver Transplant Program, Hopital Universitaire du Sart Tilman, Liege,
      Belgium.
FAU - Delbouille, M H
AU  - Delbouille MH
AD  - BTS Section of the Transplant Coordinators, Hopital Universitaire du Sart Tilman,
      Liege, Belgium.
FAU - Sokal, E
AU  - Sokal E
AD  - Pediatric Liver Transplantation, Cliniques Universitaires Saint-Luc, Brussels,
      Belgium.
FAU - Nevens, F
AU  - Nevens F
AD  - KUL Liver Transplant Program, Universitair Ziekenhuis Gasthuisberg, Leuven,
      Belgium.
FAU - Pirenne, J
AU  - Pirenne J
AD  - KUL Liver Transplant Program, Universitair Ziekenhuis Gasthuisberg, Leuven,
      Belgium.
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Acta Gastroenterol Belg
JT  - Acta gastro-enterologica Belgica
JID - 0414075
SB  - IM
MH  - Belgium
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus
MH  - *Coronavirus Infections/epidemiology/prevention & control/transmission
MH  - End Stage Liver Disease/epidemiology/*surgery
MH  - Humans
MH  - Infection Control/*methods
MH  - Liver Transplantation/*methods
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control/transmission
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19 epidemic
OT  - liver transplantation
OT  - resources
COIS- The authors declare that they have no conflict of interest
EDAT- 2020/07/01 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PST - ppublish
SO  - Acta Gastroenterol Belg. 2020 Apr-Jun;83(2):340-343.


PMID- 32602681
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20220415
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 68
IP  - 7
DP  - 2020 Jul
TI  - Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM) in Newly
      Diagnosed Hypertensive Patients.
PG  - 52-56
AB  - BACKGROUND: Ambulatory Blood Pressure Monitoring (ABPM) has an upper hand in
      diagnosing hypertension accurately. Parameters obtained by ABPM helps us in
      diagnosing white coat hypertension, BP variability, dipping status and blood
      pressure load on organs (Hyperbaric Index) reflecting possible end organ damage. 
      OBJECTIVES: To evaluate clinical utility of ABPM in stage 1 newly diagnosed
      hypertensive subjects, to compare ABPM readings with clinic blood pressure
      (Clinic BP), to study dipping pattern and White Coat Hypertension (WCH) in newly 
      labeled hypertensives. METHODOLOGY: After institutional ethics committee approval
      and written informed consent from participants, an observational cross sectional 
      prospective study was conducted in hypertension clinic of tertiary care hospital 
      over a period of one and half years on 138 newly diagnosed stage I hypertensive
      patients. ABPM results were analyzed and compared with clinic BP. RESULTS: 86/138
      (62.32%) patients were diagnosed to have true HT by ABPM. WCH was detected in
      52/138 (37.68%) which is higher than that reported in international studies
      (21%). The mean pulse, mean systolic/diastolic BP, mean pulse pressure and MAP
      were significantly higher (p<0.0001) by clinic BP than ABPM. True hypertensive
      patients were having higher weight (p <0.001), had higher fasting blood sugar
      values (p=0.008) and BUN levels (p=0.034) than WCH patients. Hyperbaric Index was
      significantly higher for systolic and diastolic BP in true hypertensive patients 
      as compared to WCH patients. Patients with WCH were predominantly males (71.15%),
      were younger (41.82 +/- 12.77 years) than true hypertensives (46.45 +/-
      12.20years), (p =0.037). Dipping was detected in 33 (38.37%), non-dipping in 44
      (51.16%) and reverse dipping in 9 (10.47%) patients. CONCLUSION: Our study
      reflects the clinical utility of ambulatory blood pressure monitoring not only
      for accurate diagnosis of hypertension but also for assessing the various
      parameters of blood pressure.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Salagre, Santosh B
AU  - Salagre SB
AD  - Professor (Addl.) and Head-Hypertension Services, Seth G. S. Medical College and 
      K.E.M. Hospital, Parel, Mumbai, Maharashtra.
FAU - Khobragade, Anup P
AU  - Khobragade AP
AD  - Ex Postgraduate Student, Department of Medicine, Seth G. S. Medical College and
      K.E.M. Hospital, Parel, Mumbai, Maharashtra.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
SB  - IM
MH  - Blood Pressure
MH  - *Blood Pressure Monitoring, Ambulatory
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Hypertension
MH  - Male
MH  - Prospective Studies
EDAT- 2020/07/01 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2020 Jul;68(7):52-56.


PMID- 32602222
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20210604
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 16
DP  - 2020 Aug
TI  - Quantitative ultrasound radiomics in predicting response to neoadjuvant
      chemotherapy in patients with locally advanced breast cancer: Results from
      multi-institutional study.
PG  - 5798-5806
LID - 10.1002/cam4.3255 [doi]
AB  - BACKGROUND: This study was conducted in order to develop a model for predicting
      response to neoadjuvant chemotherapy (NAC) in patients with locally advanced
      breast cancer (LABC) using pretreatment quantitative ultrasound (QUS) radiomics. 
      METHODS: This was a multicenter study involving four sites across North America, 
      and appropriate approval was obtained from the individual ethics committees.
      Eighty-two patients with LABC were included for final analysis. Primary tumors
      were scanned using a clinical ultrasound system before NAC was started. The
      tumors were contoured, and radiofrequency data were acquired and processed from
      whole tumor regions of interest. QUS spectral parameters were derived from the
      normalized power spectrum, and texture analysis was performed based on six QUS
      features using a gray level co-occurrence matrix. Patients were divided into
      responder or nonresponder classes based on their clinical-pathological response. 
      Classification analysis was performed using machine learning algorithms, which
      were trained to optimize classification accuracy. Cross-validation was performed 
      using a leave-one-out cross-validation method. RESULTS: Based on the clinical
      outcomes of NAC treatment, there were 48 responders and 34 nonresponders. A
      K-nearest neighbors (K-NN) approach resulted in the best classifier performance, 
      with a sensitivity of 91%, a specificity of 83%, and an accuracy of 87%.
      CONCLUSION: QUS-based radiomics can predict response to NAC based on pretreatment
      features with acceptable accuracy.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - DiCenzo, Daniel
AU  - DiCenzo D
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Quiaoit, Karina
AU  - Quiaoit K
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Fatima, Kashuf
AU  - Fatima K
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Bhardwaj, Divya
AU  - Bhardwaj D
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Sannachi, Lakshmanan
AU  - Sannachi L
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Gangeh, Mehrdad
AU  - Gangeh M
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Sadeghi-Naini, Ali
AU  - Sadeghi-Naini A
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
AD  - Department of Electrical Engineering and Computer Sciences, Lassonde School of
      Engineering, York University, Toronto, ON, Canada.
FAU - Dasgupta, Archya
AU  - Dasgupta A
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Kolios, Michael C
AU  - Kolios MC
AUID- ORCID: 0000-0002-9994-8293
AD  - Department of Physics, Ryerson University, Toronto, ON, Canada.
FAU - Trudeau, Maureen
AU  - Trudeau M
AD  - Medical Oncology, Department of Medicine, Sunnybrook Health Sciences Centre,
      Toronto, ON, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Gandhi, Sonal
AU  - Gandhi S
AD  - Medical Oncology, Department of Medicine, Sunnybrook Health Sciences Centre,
      Toronto, ON, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Eisen, Andrea
AU  - Eisen A
AD  - Medical Oncology, Department of Medicine, Sunnybrook Health Sciences Centre,
      Toronto, ON, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Wright, Frances
AU  - Wright F
AD  - Surgical Oncology, Department of Surgery, Sunnybrook Health Sciences Centre,
      Toronto, ON, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON, Canada.
FAU - Look Hong, Nicole
AU  - Look Hong N
AD  - Surgical Oncology, Department of Surgery, Sunnybrook Health Sciences Centre,
      Toronto, ON, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON, Canada.
FAU - Sahgal, Arjun
AU  - Sahgal A
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Stanisz, Greg
AU  - Stanisz G
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
FAU - Brezden, Christine
AU  - Brezden C
AD  - Medical Oncology, Saint Michael's Hospital, University of Toronto, Toronto, ON,
      Canada.
FAU - Dinniwell, Robert
AU  - Dinniwell R
AD  - Department of Radiation Oncology, Princess Margaret Hospital, University Health
      Network, Toronto, ON, Canada.
AD  - Radiation Oncology, London Health Sciences Centre, London, ON, Canada.
AD  - Department of Oncology, Schulich School of Medicine and Dentistry, Western
      University, London, ON, Canada.
FAU - Tran, William T
AU  - Tran WT
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
FAU - Yang, Wei
AU  - Yang W
AD  - Department of Diagnostic Radiology, University of Texas, Houston, TX, USA.
FAU - Curpen, Belinda
AU  - Curpen B
AD  - Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
FAU - Czarnota, Gregory J
AU  - Czarnota GJ
AUID- ORCID: 0000-0002-0519-2182
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON,
      Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
AD  - Department of Electrical Engineering and Computer Sciences, Lassonde School of
      Engineering, York University, Toronto, ON, Canada.
AD  - Department of Physics, Ryerson University, Toronto, ON, Canada.
LA  - eng
GR  - PJT 159 759/CIHR/Canada
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*diagnostic imaging/*drug therapy/pathology/surgery
MH  - Canada
MH  - Chemotherapy, Adjuvant/methods
MH  - Female
MH  - Humans
MH  - Machine Learning
MH  - Male
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
MH  - Ultrasonography/methods
MH  - United States
PMC - PMC7433820
OTO - NOTNLM
OT  - *imaging biomarker
OT  - *locally advanced breast cancer
OT  - *machine learning
OT  - *neoadjuvant chemotherapy
OT  - *quantitative ultrasound
OT  - *radiomics
OT  - *response prediction
OT  - *texture analysis
EDAT- 2020/07/01 06:00
MHDA- 2021/06/05 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/05/02 00:00 [revised]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 10.1002/cam4.3255 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Aug;9(16):5798-5806. doi: 10.1002/cam4.3255. Epub 2020 Jun 29.


PMID- 32601794
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210802
IS  - 0920-9069 (Print)
IS  - 0920-9069 (Linking)
VI  - 72
IP  - 4
DP  - 2020 Aug
TI  - Cord blood serum harvesting by hydroxyethyl starch: a fetal bovine serum
      alternative in expansion of umbilical cord-derived mesenchymal stem cells.
PG  - 551-567
LID - 10.1007/s10616-020-00404-9 [doi]
AB  - As a widely used cell culture supplement, fetal bovine serum (FBS) harbor high
      content of growth, proliferation, and adhesion factors. However, high cost,
      bio-safety, possible xenogeneic agent transmission, finite accessible, and
      ethical controversy are major obstacles that discourage the use of this additive.
      Accordingly, novel alternatives have been proposed with various pros and cons.
      Still, caution should be taken in choosing suitable substitute given that the
      alteration in the main aspects of cultured cells can be biased the consequences
      of clinical applications. Herein, the authors evaluated the impact of cord blood 
      serum harvesting by hydroxyethyl starch (CBS-HES), as an enriched source of
      growth factors, on the basic mesenchymal stem cells (MSCs) characteristics. In
      the present experiment, umbilical cord-derived MSCs were isolated and
      continuously nourished with Dulbecco's Modified Eagle Medium containing either
      10, 15, and 20% CBS-HES or FBSs to compare their morphology, immunophenotype,
      growth and proliferation rate, death rate, cell cycle, and gene expression
      profiles. Although all enriched media supported the expansion of MSCs with
      comparable morphology, cell surface markers, death rate, c-MYC and p16
      expression, and growth rate, CBS-HES treated cells significantly (P < 0.05)
      expressed more hTERT gene in a concentration-dependent manner. Yet no significant
      shift was observed in the cell cycle of cultured cells using the same
      concentrations of additives, a finding which further confirmed by Ki-67
      immunostaining. CBS-HES as an available and affordable additive, seems to be an
      optimal, relatively safe, and promising FBS alternative for cultivation,
      propagation, and subsequent clinical applications of MSCs.
FAU - Samareh Salavati Pour, Maryam
AU  - Samareh Salavati Pour M
AD  - Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
AD  - Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of
      Medical Sciences, Kerman, Iran.
AD  - Department of Hematology and Laboratory Sciences, Faculty of Allied Medicine,
      Kerman University of Medical Sciences, Kerman, Iran.
FAU - Vahidi, Reza
AU  - Vahidi R
AD  - Research Center for Hydatid Disease in Iran, Kerman University of Medical
      Sciences, Kerman, Iran. reza.vahidi2009@gmail.com.
AD  - Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of
      Medical Sciences, Kerman, Iran. reza.vahidi2009@gmail.com.
FAU - Lashkari, Mahla
AU  - Lashkari M
AD  - Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of
      Medical Sciences, Kerman, Iran.
AD  - Department of Hematology and Laboratory Sciences, Faculty of Allied Medicine,
      Kerman University of Medical Sciences, Kerman, Iran.
FAU - Derakhshani, Ali
AU  - Derakhshani A
AD  - Research Center for Hydatid Disease in Iran, Kerman University of Medical
      Sciences, Kerman, Iran.
AD  - Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of
      Medical Sciences, Kerman, Iran.
FAU - Ameri, Zahra
AU  - Ameri Z
AD  - Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of
      Medical Sciences, Kerman, Iran.
AD  - Department of Hematology and Laboratory Sciences, Faculty of Allied Medicine,
      Kerman University of Medical Sciences, Kerman, Iran.
FAU - Farsinejad, Alireza
AU  - Farsinejad A
AD  - Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of
      Medical Sciences, Kerman, Iran. farsinejad239@gmail.com.
AD  - Department of Hematology and Laboratory Sciences, Faculty of Allied Medicine,
      Kerman University of Medical Sciences, Kerman, Iran. farsinejad239@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - United States
TA  - Cytotechnology
JT  - Cytotechnology
JID - 8807027
PMC - PMC7450036
OTO - NOTNLM
OT  - FBS alternative
OT  - Fetal bovine serum
OT  - Hydroxyethyl starch
OT  - Mesenchymal stem cells
OT  - Umbilical cord
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/07/01 06:00
PHST- 2019/10/12 00:00 [received]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 10.1007/s10616-020-00404-9 [doi]
AID - 10.1007/s10616-020-00404-9 [pii]
PST - ppublish
SO  - Cytotechnology. 2020 Aug;72(4):551-567. doi: 10.1007/s10616-020-00404-9. Epub
      2020 Jun 29.


PMID- 32601171
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1473-4265 (Electronic)
IS  - 1468-215X (Linking)
VI  - 46
IP  - 4
DP  - 2020 Dec
TI  - A concerning display of medical indifference: reply to 'Chronic fatigue syndrome 
      and an illness-focused approach to care: controversy, morality and paradox'.
PG  - e4
LID - 10.1136/medhum-2019-011743 [doi]
AB  - In 'Chronic fatigue syndrome and an illness-focused approach to care:
      controversy, morality and paradox', authors Michael Sharpe and Monica Greco begin
      by characterising myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) as 
      illness-without-disease. On that basis they ask why patients reject treatments
      for illness-without-disease, and they answer with a philosophical idea.
      Whitehead's 'bifurcation of nature', they suggest, still dominates public and
      professional thinking, and that conceptual confusion leads patients to reject the
      treatment they need. A great deal has occurred, however, since Whitehead
      characterised his culture's confusions 100 years ago. In our time, I suggest,
      experience is no longer construed as an invalid second cousin of bodily states in
      philosophy, in medicine or in the culture at large. More importantly, we must
      evaluate medical explanations before we reach for philosophical alternatives. The
      National Institutes of Health and the Institute of Medicine have concluded that
      ME/CFS is, in fact, a biomedical disease, and all US governmental health
      organisations now agree. Although it would be productive for Sharpe and Greco to 
      state and support their disagreement with the other side of the disease debate,
      it is no longer tenable, or safe, to ignore the possibility of disease in
      patients with ME/CFS, or to recommend that clinicians should do so. When we find 
      ourselves in a framework that suggests the possibility of medical need is somehow
      beside the point for medical providers, it is time to reconsider our conceptual
      foundations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - O'Leary, Diane
AU  - O'Leary D
AUID- ORCID: http://orcid.org/0000-0002-1279-8377
AD  - Rotman Institute of Philosophy, Western University, London, ON N6A 5B7, Canada
      doleary8@uwo.ca.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - United States
TA  - Med Humanit
JT  - Medical humanities
JID - 100959585
SB  - IM
MH  - Dissent and Disputes
MH  - *Fatigue Syndrome, Chronic
MH  - Humans
MH  - Morals
OTO - NOTNLM
OT  - health policy
OT  - medical ethics/bioethics
OT  - medical humanities
OT  - philosophy of medicine/health care
OT  - psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/02/18 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - medhum-2019-011743 [pii]
AID - 10.1136/medhum-2019-011743 [doi]
PST - ppublish
SO  - Med Humanit. 2020 Dec;46(4):e4. doi: 10.1136/medhum-2019-011743. Epub 2020 Jun
      29.


PMID- 32601115
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 29
TI  - Study protocol: building an evidence base for epidemiology emergency response, a 
      mixed-methods study.
PG  - e037326
LID - 10.1136/bmjopen-2020-037326 [doi]
AB  - INTRODUCTION: Determinants and drivers for emergencies, such as political
      instability, weak health systems, climate change and forcibly displaced
      populations, are increasing the severity, complexity and frequency of public
      health emergencies. As emergencies become more complex, it is increasingly
      important that the required skillset of the emergency response workforce is
      clearly defined. To enable essential epidemiological activities to be implemented
      and managed during an emergency, a workforce is required with the right mix of
      skills, knowledge, experience and local context awareness. This study aims to
      provide local and international responders with an opportunity to actively
      contribute to the development of new thinking around emergency response roles and
      required competencies. In this study, we will develop recommendations using a
      broad range of evidence to address identified lessons and challenges so that
      future major emergency responses are culturally and contextually appropriate, and
      less reliant on long-term international deployments. METHOD AND ANALYSIS: We will
      conduct a mixed-methods study using an exploratory sequential study design. The
      integration of four data sources, including key informant interviews, a scoping
      literature review, survey and semistructured interviews will allow the research
      questions to be examined in a flexible, semistructured way, from a range of
      perspectives. The study is unequally weighted, with a qualitative emphasis. We
      will analyse all activities as individual components, and then together in an
      integrated analysis. Thematic analysis will be conducted in NVivo V.11 and
      quantitative analysis will be conducted in Stata V.15. ETHICS AND DISSEMINATION: 
      All activities have been approved by the Science and Medical Delegated Ethics
      Review Committee at the Australian National University (protocol numbers
      2018-521, 2018-641, 2019-068). Findings will be disseminated through
      international and local deployment partners, peer-reviewed publication,
      presentation at international conferences and through social media such as
      Twitter and Facebook.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Parry, Amy Elizabeth
AU  - Parry AE
AUID- ORCID: 0000-0001-6641-7149
AD  - National Centre for Epidemiology and Population Health, Australian National
      University, Canberra, Australian Capital Territory, Australia
      amy.parry@anu.edu.au.
FAU - Kirk, Martyn D
AU  - Kirk MD
AD  - National Centre for Epidemiology and Population Health, Australian National
      University, Canberra, Australian Capital Territory, Australia.
FAU - Durrheim, David N
AU  - Durrheim DN
AD  - School of Medicine and Public Health, University of Newcastle, Newcastle, NSW,
      Australia.
FAU - Olowokure, Babatunde
AU  - Olowokure B
AD  - Health Emergencies Programme, World Health Organization, Geneve, Switzerland.
FAU - Housen, Tambri
AU  - Housen T
AD  - National Centre for Epidemiology and Population Health, Australian National
      University, Canberra, Australian Capital Territory, Australia.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Civil Defense/methods
MH  - *Emergencies
MH  - Epidemiologic Methods
MH  - *Epidemiology
MH  - Evidence-Based Emergency Medicine/methods
MH  - Humans
MH  - Interviews as Topic
MH  - *Public Health Practice
MH  - Stakeholder Participation
MH  - Surveys and Questionnaires
PMC - PMC7328751
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037326 [pii]
AID - 10.1136/bmjopen-2020-037326 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 29;10(6):e037326. doi: 10.1136/bmjopen-2020-037326.


PMID- 32601114
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 29
TI  - Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale 
      and design of the SUNFLOWER longitudinal, observational cohort study.
PG  - e036367
LID - 10.1136/bmjopen-2019-036367 [doi]
AB  - INTRODUCTION: X-linked hypophosphataemic rickets/osteomalacia (XLH) is a chronic,
      debilitating genetic disease characterised by skeletal abnormalities and growth
      disorder. The burden of XLH begins in childhood and continues throughout life.
      Conventional medical therapy with phosphate, active vitamin D and surgery do not 
      address the underlying pathophysiology of the disease. While treatment during
      childhood may improve bone deformity and growth retardation, a large proportion
      of adult patients still fail to reach normal stature. Furthermore, adult patients
      with XLH report comorbidities associated with unresolved childhood disease, as
      well as newly developed disease-related complications and significantly impaired 
      quality of life (QOL). Despite the multiple negative aspects of XLH, Asian
      consensus statements for diagnosis and management are lacking. METHODS AND
      ANALYSIS: The Study of longitUdinal observatioN For patients with X-Linked
      hypOphosphataemic rickets/osteomalacia in collaboration With Asian partnERs study
      is a longitudinal observational cohort study of patients with XLH, designed to
      determine the medical characteristics and burdens (physical, emotional and
      financial) of this progressive disease and to evaluate the impact of treatment
      (including the use of burosumab) on clinical outcomes. The study was initiated in
      April 2018, and registration will remain open until 30 April 2022. The sample
      size planned for analyses is 160 patients, consisting of 100 patients in Japan
      and 60 patients in Korea. Up to 5 years of observation are planned per patient,
      from enrolment through to April 2023. Prospective and retrospective data will be 
      collected to evaluate variables, including height/growth, rickets severity score,
      QOL, motor function and biomarkers for phosphate metabolism and bone turnover.
      ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee 
      of Osaka University, the Ethics Committee of Kyowa Kirin Co and by the Ethics
      Committee of each participating medical institution. Two interim analyses and
      associated publications are planned using retrospective and enrolment data at
      year 1 and results at year 3. TRIAL REGISTRATION NUMBERS: NCT03745521;
      UMIN000031605.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kubota, Takuo
AU  - Kubota T
AUID- ORCID: 0000-0003-4483-4405
AD  - Department of Pediatrics, Graduate School of Medicine, Osaka University, Suita,
      Japan tkubota@ped.med.osaka-u.ac.jp.
FAU - Fukumoto, Seiji
AU  - Fukumoto S
AD  - Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical
      Sciences, Tokushima University, Tokushima, Japan.
FAU - Cheong, Hae Il
AU  - Cheong HI
AD  - Department of Pediatric Nephrology, Seoul National University Children's
      Hospital, Seoul, Republic of Korea.
FAU - Michigami, Toshimi
AU  - Michigami T
AD  - Department of Bone and Mineral Research, Osaka Women's and Children's Hospital,
      Izumi, Japan.
FAU - Namba, Noriyuki
AU  - Namba N
AD  - Department of Pediatrics and Perinatology, Faculty of Medicine, Tottori
      University, Tottori, Japan.
FAU - Ito, Nobuaki
AU  - Ito N
AD  - Division of Nephrology and Endocrinology, The University of Tokyo Hospital,
      Tokyo, Japan.
FAU - Tokunaga, Shin
AU  - Tokunaga S
AD  - Medical Affairs Department, Kyowa Kirin Co Ltd, Tokyo, Japan.
FAU - Gibbs, Yoshimi
AU  - Gibbs Y
AD  - Medical Affairs Department, Kyowa Kirin Co Ltd, Tokyo, Japan.
FAU - Ozono, Keiichi
AU  - Ozono K
AD  - Department of Pediatrics, Graduate School of Medicine, Osaka University, Suita,
      Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT03745521
SI  - UMIN-CTR/UMIN000031605
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - G9WJT6RD29 (burosumab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Asians
MH  - Child
MH  - Clinical Protocols
MH  - Disease Progression
MH  - Familial Hypophosphatemic Rickets/*drug therapy/pathology
MH  - Humans
MH  - Japan
MH  - Longitudinal Studies
MH  - Republic of Korea
MH  - Severity of Illness Index
MH  - Treatment Outcome
PMC - PMC7328740
OTO - NOTNLM
OT  - *bone diseases
OT  - *clinical trials
OT  - *health economics
OT  - *musculoskeletal disorders
COIS- Competing interests: TK has received personal fees from Kyowa Kirin Co for the
      submitted work and grants from Kyowa Kirin Co outside the submitted work. SF has 
      received grants from Teijin Pharma and Astellas Pharma; and held an endowed chair
      position with Chugai Pharmaceutical Co, Ono Pharmaceutical Co, Taisho
      Pharmaceutical Co and Kyowa Kirin Co outside the submitted work. TM has received 
      personal fees (honorarium) from Kyowa Kirin Co for serving as a member of the
      advisory board during the conduct of this study. NN has received personal fees
      from Kyowa Kirin Co for the submitted work; and grants from Kyowa Kirin Co
      outside the submitted work. NI has received research grants from Kyowa Kirin Co
      outside the submitted work. ST and YG are the employees of Kyowa Kirin Co. KO has
      received lecture fees from Kyowa Kirin Co, Alexion Pharmaceuticals and Novo
      Nordisk Pharma outside the submitted work.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036367 [pii]
AID - 10.1136/bmjopen-2019-036367 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 29;10(6):e036367. doi: 10.1136/bmjopen-2019-036367.


PMID- 32601111
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 29
TI  - Realist evaluation of a theory-based life skills programme aiming to prevent
      addictive behaviours in adolescents: the ERIEAS study protocol.
PG  - e034530
LID - 10.1136/bmjopen-2019-034530 [doi]
AB  - INTRODUCTION: Adolescence is a sensitive life stage during which tobacco, alcohol
      and cannabis are used as ways to learn and adopt roles. There is a great deal of 
      interest in substance use (SU) prevention programmes for young people that work
      to change representations of these products and help with mobilisation of life
      skills. Unfortunately, few existing programmes are evidence-based.In France, a
      programme called Experiences Animees (EA, Animated Experiences) has been
      developed, inspired by life skills development programmes that have been proven
      to be successful. The EA programme uses animated short movies and talks with high
      school and secondary school pupils about the use of psychoactive substances and
      addictions. By allowing life skills mobilisation and modifying representations
      and beliefs about SU, it is aimed at delaying initiation of use of psychoactive
      substances, preventing adolescents from becoming regular consumers, reducing the 
      risks and harms related to the use of these substances and opening the way for
      adapted support measures.We are interested in understanding how, under what
      circumstances, through which mechanisms and among which adolescents the EA
      programme works. Therefore, we have developed the ERIEAS study ('Evaluation
      Realiste de l'Intervention Experiences Animees en milieu Scolaire'; Realist
      Evaluation of the EA Intervention in Schools). METHODS AND ANALYSIS: EA will be
      conducted in 10 schools. A multi-case approach will be adopted with the aim of
      developing and adjusting an intervention theory. The study comes under the
      theory-driven evaluation framework. The investigation methodology will include
      four stages: (i) elaboration of a middle-range theory; (ii) data collection for
      validating/adjusting the theory; (iii) data analysis; and (iv) refinement and
      adjustment of the middle-range theory and definition of the programme's key
      functions. ETHICS AND DISSEMINATION: The study will provide evidence-based
      results to health authorities to help in the rollout of health promotion
      strategies in schools. It will provide knowledge about the strategic
      configurations most suitable for leading to life skills mobilisation and change
      young people's representations about SU. The project will be carried out with
      full respect of current relevant legislation (eg, the Charter of Fundamental
      Rights of the European Union) and international conventions (eg, Helsinki
      Declaration). It follows the relevant French legislation of the research category
      on interventional research protocol involving the human person. The protocol was 
      approved by the Comite et Protection des Personnes (CPP), that is, Committee for 
      the Protection of Persons CPP SUD-EST VI n degrees : AU 1525 and was reported to 
      the Agence Francaise de Securite Sanitaire des Produits de Sante (ANSM) that is, 
      the French National Agency for the Safety of Health Products. It is in conformity
      with reference methodology MR003 of Bordeaux University Hospital (CNIL n degrees 
      2 026 779 v0).Trial registration detailsThis research has been registered on
      ClinicalTrials.gov (No. NCT04110626).The research project is registered in the
      European database ID-RCB (No. 2019-A01003-54).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Martin-Fernandez, Judith
AU  - Martin-Fernandez J
AUID- ORCID: 0000-0002-7380-5497
AD  - CHU INSERM. Bordeaux Population Health Research Center. UMR 1219 CIC-EC 1401,
      Universite de Bordeaux, Bordeaux, France judith.martin-fernandez@u-bordeaux.fr.
AD  - University of Bordeaux, ISPED, Bordeaux, France.
FAU - Affret, Aurelie
AU  - Affret A
AUID- ORCID: 0000-0002-6070-1197
AD  - CHU INSERM. Bordeaux Population Health Research Center. UMR 1219 CIC-EC 1401,
      Universite de Bordeaux, Bordeaux, France.
AD  - University of Bordeaux, ISPED, Bordeaux, France.
FAU - Martel, Emma
AU  - Martel E
AD  - Faculty of Medical Sciences, University of Bordeaux, Bordeaux, France.
FAU - Gallard, Romain
AU  - Gallard R
AD  - University of Bordeaux, ISPED, Bordeaux, France.
AD  - Faculty of Medical Sciences, University of Bordeaux, Bordeaux, France.
FAU - Merchadou, Laurence
AU  - Merchadou L
AD  - Bordeaux Population Health Research Center, INSERM, Bordeaux, France.
FAU - Moinot, Laetitia
AU  - Moinot L
AD  - Bordeaux Population Health Research Center, INSERM, Bordeaux, France.
FAU - Termote, Monique
AU  - Termote M
AD  - Bordeaux Population Health Research Center, INSERM, Bordeaux, France.
FAU - Dejarnac, Vincent
AU  - Dejarnac V
AD  - DRCI, CHU de Bordeaux, Bordeaux, Aquitaine, France.
FAU - Alla, Francois
AU  - Alla F
AUID- ORCID: 0000-0002-5793-7190
AD  - CHU INSERM. Bordeaux Population Health Research Center. UMR 1219 CIC-EC 1401,
      Universite de Bordeaux, Bordeaux, France.
AD  - Prevention Unit, CHU, Bordeaux, Aquitaine, France.
FAU - Cambon, Linda
AU  - Cambon L
AUID- ORCID: 0000-0001-6040-9826
AD  - Bordeaux Population Health Research Center, INSERM, Bordeaux, France.
AD  - Prevention Chair, University of Bordeaux, ISPED, Bordeaux, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT04110626
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Behavior, Addictive/*prevention & control/psychology
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Psychological Theory
MH  - Psychology, Adolescent
MH  - School Health Services
MH  - Social Skills
MH  - Substance-Related Disorders/prevention & control/psychology
PMC - PMC7328977
OTO - NOTNLM
OT  - *addictions
OT  - *life skills
OT  - *preventive medicine
OT  - *realist evaluation
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034530 [pii]
AID - 10.1136/bmjopen-2019-034530 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 29;10(6):e034530. doi: 10.1136/bmjopen-2019-034530.


PMID- 32601110
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 29
TI  - Effects of adding adjunctive hyperbaric oxygen therapy to standard wound care for
      diabetic foot ulcers: a protocol for a systematic review with meta-analysis and
      trial sequential analysis.
PG  - e031708
LID - 10.1136/bmjopen-2019-031708 [doi]
AB  - INTRODUCTION: Diabetic foot ulcer represents a major health problem globally.
      Preliminary studies have indicated that systemic treatment of diabetic foot ulcer
      patients with hyperbaric oxygen therapy have beneficial effects on wound healing,
      risk of amputation, glycaemic control, atherosclerosis, inflammatory markers and 
      other clinical and laboratory parameters. This protocol for a systematic review
      aims at identifying the beneficial and harmful effects of adding hyperbaric
      oxygen therapy to standard wound care for diabetic foot ulcers. METHODS AND
      ANALYSIS: This protocol was performed following the recommendations of the
      Cochrane Collaboration and the eight-step assessment procedure suggested by
      Jakobsen and colleagues. We plan to include all relevant randomised clinical
      trials assessing the effects of hyperbaric oxygen therapy in the treatment of
      diabetic foot ulcer versus any control group with any intervention defined as
      standard wound care or similar, together with sham interventions. Our primary
      outcome will be: all-cause mortality, serious adverse events and quality of life.
      Our secondary outcomes will be: healing of index wound, major amputation and
      wound infection. Any eligible trial will be assessed and classified as either
      high risk of bias or low risk of bias, and our conclusions will be based on
      trials with low risk of bias. The analyses of the extracted data will be
      performed using Review Manager 5 and Trial Sequential Analysis. For both our
      primary and secondary outcomes, we will create a 'Summary of Findings' table and 
      use GRADE (Grading of Recommendations Assessment, Development and Evaluation)
      assessment to assess the quality of the evidence. ETHICS AND DISSEMINATION: We
      use publicly accessible documents as evidence, there is no participant
      involvement at an individual level and an institutional ethics approval is not
      required. The results of the review will be sought published in a peer-reviewed
      journals, also in the event of insignificant results or null results, and thereby
      it will be disseminated to clinicians and public available. PROSPERO REGISTRATION
      NUMBER: CRD42019139256.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vinkel, Julie
AU  - Vinkel J
AD  - Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University
      Hospital, Copenhagen, Rigshospitalet, Denmark julie.vinkel.clausen@regionh.dk.
FAU - Holm, Niels Frederich Rose
AU  - Holm NFR
AUID- ORCID: 0000-0002-2289-272X
AD  - Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University
      Hospital, Copenhagen, Rigshospitalet, Denmark.
FAU - Jakobsen, Janus C
AU  - Jakobsen JC
AD  - The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen 
      University Hospital, Copenhagen, Rigshospitalet, Denmark.
AD  - Department of Cardiology, Holbaek Sygehus, Holbaek, Sjaelland, Denmark.
AD  - Department of Regional Health Research, The Faculty of Heath Sciences University 
      of Southern Denmark, Odense, Denmark.
AD  - Department of Cardiology, Holbaek Hospital, Holbaek, Denmark.
FAU - Hyldegaard, Ole
AU  - Hyldegaard O
AD  - Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University
      Hospital, Copenhagen, Rigshospitalet, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Diabetic Foot/*therapy
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Wound Healing
PMC - PMC7328748
OTO - NOTNLM
OT  - *diabetic foot
OT  - *hyperbaric oxygen therapy
OT  - *meta-analysis
OT  - *systematic review
OT  - *trial sequential analysis
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-031708 [pii]
AID - 10.1136/bmjopen-2019-031708 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 29;10(6):e031708. doi: 10.1136/bmjopen-2019-031708.


PMID- 32601101
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 2054-4774 (Print)
IS  - 2054-4774 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jun
TI  - Colon capsule endoscopy in colorectal cancer screening: a randomised controlled
      trial.
LID - e000411 [pii]
LID - 10.1136/bmjgast-2020-000411 [doi]
AB  - INTRODUCTION: The use of capsule endoscopy has become an approved method in small
      bowel diagnostics, but the same level of integration is not seen in large bowel
      diagnostics. We will use colon capsule endoscopy (CCE) as a filter test in
      colorectal cancer (CRC) screening between the faecal immunochemical test (FIT)
      and colonoscopy. We aim to investigate the clinical performance, population
      acceptability, and economic implications of the procedure in a large-scale
      clinical trial. METHODS AND ANALYSIS: We will randomly allocate 124 214 Danish
      citizens eligible for participation in the national CRC screening programme
      within the Region of Southern Denmark to either an intervention group or a
      control group. Prior to submitting a FIT, citizens randomised to the intervention
      group will be informed about their opportunity to undergo CCE, instead of
      colonoscopy, if the FIT is positive. Suspected cancers; >3 adenomas <10 mm in
      size, 1 adenoma >10 mm in size or >4 adenomas regardless of size, detected during
      CCE will generate an invitation to colonoscopy as per regular screening
      guidelines, whereas citizens with suspected low risk polyps will re-enter the
      biennial screening programme. Citizens with no CCE findings will be excluded from
      screening for 8 years. In the control group, citizens will follow standard
      screening procedures. ETHICS AND DISSEMINATION: All participants must consent
      prior to capsule ingestion. All collected data will be handled and stored in
      accordance with current data protection legislation. Approvals from the regional 
      ethics committee (ref. S-20190100) and the Danish data protection agency have
      been obtained (ref. 19/29858). TRIAL REGISTRATION DETAILS: The study has been
      registered with ClinicalTrials.gov under: NCT04049357.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kaalby, Lasse
AU  - Kaalby L
AUID- ORCID: 0000-0002-6721-3604
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark
      lkm@rsyd.dk.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Deding, Ulrik
AU  - Deding U
AUID- ORCID: 0000-0002-8263-2989
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Kobaek-Larsen, Morten
AU  - Kobaek-Larsen M
AUID- ORCID: 0000-0002-5097-9283
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Havshoi, Anne-Line Volden
AU  - Havshoi AV
AUID- ORCID: 0000-0003-2376-7389
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
FAU - Zimmermann-Nielsen, Erik
AU  - Zimmermann-Nielsen E
AUID- ORCID: 0000-0002-7385-4969
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Thygesen, Marianne Kirstine
AU  - Thygesen MK
AUID- ORCID: 0000-0002-1811-7405
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
FAU - Kroeijer, Rasmus
AU  - Kroeijer R
AUID- ORCID: 0000-0003-4358-7916
AD  - Department of Surgery, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark.
FAU - Bjorsum-Meyer, Thomas
AU  - Bjorsum-Meyer T
AUID- ORCID: 0000-0001-5253-0802
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
FAU - Baatrup, Gunnar
AU  - Baatrup G
AUID- ORCID: 0000-0003-0300-5766
AD  - Department of Surgery, Odense University Hospital, Svendborg, Denmark.
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04049357
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Gastroenterol
JT  - BMJ open gastroenterology
JID - 101660690
SB  - IM
MH  - Adenoma/pathology
MH  - Capsule Endoscopy/economics/*methods/statistics & numerical data
MH  - Case-Control Studies
MH  - Colon/*diagnostic imaging/pathology
MH  - Colonic Polyps/diagnosis
MH  - Colonoscopy/methods
MH  - Colorectal Neoplasms/*diagnosis/prevention & control
MH  - Denmark/epidemiology
MH  - Early Detection of Cancer/methods
MH  - Feces/chemistry
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Screening/*methods
MH  - Occult Blood
MH  - Outcome Assessment, Health Care
MH  - Prospective Studies
PMC - PMC7326244
OTO - NOTNLM
OT  - *colorectal adenomas
OT  - *colorectal cancer screening
OT  - *diagnostic and therapeutic endoscopy
COIS- Competing interests: GB is financially supported by Medtronic but the company
      does not influence any scientific processes, and no investigator will receive any
      personal benefits.
EDAT- 2020/07/01 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - bmjgast-2020-000411 [pii]
AID - 10.1136/bmjgast-2020-000411 [doi]
PST - ppublish
SO  - BMJ Open Gastroenterol. 2020 Jun;7(1). pii: bmjgast-2020-000411. doi:
      10.1136/bmjgast-2020-000411.


PMID- 32600909
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20210110
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 34
DP  - 2020 Jul 22
TI  - Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and
      necessary measures for global immunity.
PG  - 5396-5397
LID - S0264-410X(20)30844-6 [pii]
LID - 10.1016/j.vaccine.2020.06.058 [doi]
FAU - Henn, Wolfram
AU  - Henn W
AD  - Institute of Human Genetics, Saarland University, University Clinic Bldg. 68,
      66421 Homburg-Saar, Germany. Electronic address: wolfram.henn@uks.eu.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200623
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CON - Lancet. 2020 Mar 28;395(10229):1054-1062. PMID: 32171076
MH  - Adult
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - China
MH  - *Coronavirus Infections/prevention & control
MH  - Humans
MH  - Inpatients
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Retrospective Studies
MH  - Risk Factors
MH  - SARS Virus/*immunology
MH  - SARS-CoV-2
MH  - *Viral Vaccines
PMC - PMC7309831
OTO - NOTNLM
OT  - *Ethics
OT  - *Health policy
OT  - *SARS-CoV-2 vaccine
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/01 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/24 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - S0264-410X(20)30844-6 [pii]
AID - 10.1016/j.vaccine.2020.06.058 [doi]
PST - ppublish
SO  - Vaccine. 2020 Jul 22;38(34):5396-5397. doi: 10.1016/j.vaccine.2020.06.058. Epub
      2020 Jun 23.


PMID- 32600591
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20200702
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 260-261
DP  - 2020 Apr - May
TI  - [Ethical decision making and septic shock].
PG  - 25-27
LID - S1293-8505(20)30147-0 [pii]
LID - 10.1016/S1293-8505(20)30147-0 [doi]
AB  - Nurses can contribute to the decision-making process in emergency situations in
      cases of septic shock, particularly if the patient has not drawn up advance
      directives and/or nominated a health care proxy. They can undertake or facilitate
      the collective decision making on the legal and ethical level. The team's habitus
      in terms of ethical analysis and the gathering of initial data can help to ensure
      the patients wishes are respected.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Rautureau, Pascal
AU  - Rautureau P
AD  - Association Ensemble coordonner et accompagner, 9-11, rue Guyton-de-Morveau,
      75013 Paris, France. Electronic address: p.rautureau@reseau-ensemble.org.
LA  - fre
PT  - Journal Article
TT  - Decision ethique et choc septique.
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - Decision Making/*ethics
MH  - Humans
MH  - Shock, Septic/*nursing
OTO - NOTNLM
OT  - advance directive
OT  - choc septique
OT  - decision
OT  - directive anticipee
OT  - decision
OT  - ethics
OT  - intensive care
OT  - quality of life
OT  - qualite de vie
OT  - reanimation
OT  - septic shock
OT  - ethique
EDAT- 2020/07/01 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - S1293-8505(20)30147-0 [pii]
AID - 10.1016/S1293-8505(20)30147-0 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Apr - May;69(260-261):25-27. doi: 10.1016/S1293-8505(20)30147-0.


PMID- 32600472
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1756-3305 (Electronic)
IS  - 1756-3305 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Jun 29
TI  - Characterization of vector communities and biting behavior in South Sulawesi with
      host decoy traps and human landing catches.
PG  - 329
LID - 10.1186/s13071-020-04205-z [doi]
AB  - BACKGROUND: Indonesia has high mosquito diversity, with circulating malaria and
      arboviruses. Human landing catches (HLC) are ethically questionable where
      arboviral transmission occurs. The host decoy trap (HDT) is an exposure-free
      alternative outdoor sampling device. To determine HDT efficacy for local
      culicids, and to characterize local mosquito fauna, the trapping efficacy of the 
      HDT was compared to that of HLCs in one peri-urban (Lakkang) and one rural
      (Pucak) village in Sulawesi, Indonesia. RESULTS: In Lakkang the outdoor HLCs
      collected significantly more Anopheles per night (n = 22 +/- 9) than the HDT (n =
      3 +/- 1), while the HDT collected a significantly greater nightly average of
      Culex mosquitoes (n = 110 +/- 42), than the outdoor HLC (n = 15.1 +/- 6.0). In
      Pucak, there was no significant difference in Anopheles collected between trap
      types; however, the HDT collected significantly more Culex mosquitoes than the
      outdoor HLC nightly average (n = 53 +/- 11 vs 14 +/- 3). Significantly higher
      proportions of blood-fed mosquitoes were found in outdoor HLC (n = 15 +/- 2%)
      compared to HDT (n = 2 +/- 0%). More blood-fed culicines were collected with
      outdoor HLC compared to the HDT, while Anopheles blood-fed proportions did not
      differ. For the HDT, 52.6%, 36.8% and 10.5% of identified blood meals were on
      cow, human, and dog, respectively. Identified blood meals for outdoor HLCs were
      91.9% human, 6.3% cow, and 0.9% each dog and cat. Mosquitoes from Pucak were
      tested for arboviruses, with one Culex pool and one Armigeres pool positive for
      flavivirus, and one Anopheles pool positive for alphavirus. CONCLUSIONS: The HDT 
      collected the highest abundance of culicine specimens. Outdoor HLCs collected the
      highest abundance of Anopheles specimens. Although the HDT can attract a range of
      different Asian mosquito genera and species, it remains to be optimized for
      Anopheles in Asia. The high proportion of human blood meals in mosquitoes
      collected by outdoor HLCs raises concerns on the potential exposure risk to
      collectors using this methodology and highlights the importance of continuing to 
      optimize a host-mimic trap such as the HDT.
FAU - Davidson, Jenna R
AU  - Davidson JR
AD  - Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana,
      46556, USA. jdavids2@nd.edu.
FAU - Baskin, Robert N
AU  - Baskin RN
AD  - Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana,
      46556, USA.
FAU - Hasan, Hajar
AU  - Hasan H
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
FAU - Burton, Timothy A
AU  - Burton TA
AD  - Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana,
      46556, USA.
FAU - Wardiman, Muhammad
AU  - Wardiman M
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
FAU - Rahma, Nur
AU  - Rahma N
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
FAU - Saputra, Fadly R
AU  - Saputra FR
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
FAU - Aulya, Muhammad Sultanul
AU  - Aulya MS
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
FAU - Wahid, Isra
AU  - Wahid I
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
FAU - Syafruddin, Din
AU  - Syafruddin D
AD  - Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar,
      90245, Indonesia.
AD  - Eijkman Institute of Molecular Biology, Jakarta, Indonesia.
FAU - Hawkes, Frances M
AU  - Hawkes FM
AD  - Natural Resources Institute, University of Greenwich, Central Avenue, Chatham
      Maritime, Kent, ME4 4TB, UK.
FAU - Lobo, Neil F
AU  - Lobo NF
AD  - Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana,
      46556, USA.
LA  - eng
GR  - 45114/Bill and Melinda Gates Foundation
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - Parasit Vectors
JT  - Parasites & vectors
JID - 101462774
SB  - IM
MH  - Alphavirus/isolation & purification
MH  - Animals
MH  - Anopheles
MH  - Arbovirus Infections/transmission
MH  - Culex
MH  - Data Collection/methods
MH  - Disease Vectors
MH  - Entomology/methods
MH  - *Feeding Behavior
MH  - Flavivirus/isolation & purification
MH  - Humans
MH  - Indonesia
MH  - Malaria/transmission
MH  - Mosquito Control/*methods
MH  - *Mosquito Vectors
MH  - Pathology, Molecular/methods
MH  - Rural Population
MH  - Vector Borne Diseases/transmission
PMC - PMC7324974
OTO - NOTNLM
OT  - Arbovirus
OT  - Behaviour
OT  - Culex
OT  - Host decoy trap
OT  - Indonesia
OT  - Malaria
OT  - Sampling device
OT  - Surveillance
EDAT- 2020/07/01 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/07/01 06:00
PHST- 2019/09/04 00:00 [received]
PHST- 2020/06/20 00:00 [accepted]
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.1186/s13071-020-04205-z [doi]
AID - 10.1186/s13071-020-04205-z [pii]
PST - epublish
SO  - Parasit Vectors. 2020 Jun 29;13(1):329. doi: 10.1186/s13071-020-04205-z.


PMID- 32600171
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 2042-1818 (Electronic)
IS  - 0025-8024 (Linking)
VI  - 60
IP  - 4
DP  - 2020 Oct
TI  - Cannabis knowledge and implications for health: Considerations regarding the
      legalization of non-medical cannabis.
PG  - 309-314
LID - 10.1177/0025802420934255 [doi]
AB  - Cannabis contains over a hundred of different cannabinoids, of which
      Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most well
      studied. The use of high-potency cannabis, containing high concentrations of THC 
      and low concentrations of CBD, has been linked to adverse health outcomes,
      particularly for adolescents and young adults. Recently, an increase in cannabis 
      potency has been observed in jurisdictions that legalized the sale of cannabis
      for non-medical purposes. Moreover, an increase of cannabis use and
      cannabis-related emergency treatment have also been observed in these
      jurisdictions. At the same time, risk perception regarding cannabis use has
      decreased in these populations. Trivializing language and an increased appearance
      of commercial cannabis in the public space may lead to a generalized
      underestimation of the risks of cannabis use. New regulation models principally
      focus on the creation of a legal cannabis market economy, the diversion of
      profits from illegal markets, and the reduction of costs associated with
      prohibition. However, an approach that specifically focuses on the rights to the 
      health and safety of the individual should be considered in order to reduce the
      risks associated with cannabis legalization. Such an approach should promote and 
      protect individual and social health and safety, establish a strict quality
      control of legal cannabis products regulated according to THC and CBD content,
      and eliminate all sorts of incentives to use, thus providing a more consistent,
      sustainable, and ethical framework for the legalization of non-medical cannabis
      use.
FAU - Zamengo, Luca
AU  - Zamengo L
AD  - Laboratory of Environmental Hygiene and Forensic Toxicology (LIATF), DMPO
      Department, AULSS 3, Italy.
FAU - Frison, Giampietro
AU  - Frison G
AD  - Laboratory of Environmental Hygiene and Forensic Toxicology (LIATF), DMPO
      Department, AULSS 3, Italy.
FAU - Zwitser, Guus
AU  - Zwitser G
AUID- ORCID: https://orcid.org/0000-0001-8739-3529
AD  - Mexico Unido Contra la Delincuencia, Mexico.
FAU - Salomone, Alberto
AU  - Salomone A
AD  - University of Turin, Department of Chemistry, Italy.
FAU - Freeman, Tom P
AU  - Freeman TP
AD  - Department of Psychology, University of Bath, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - Med Sci Law
JT  - Medicine, science, and the law
JID - 0400721
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cannabidiol/administration & dosage
MH  - *Cannabis
MH  - Commerce/legislation & jurisprudence
MH  - Dronabinol/administration & dosage
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Marijuana Abuse/*epidemiology
MH  - Marijuana Use/*adverse effects/economics/*legislation & jurisprudence/*trends
MH  - Prevalence
MH  - United States/epidemiology
MH  - Vulnerable Populations
MH  - Young Adult
OTO - NOTNLM
OT  - Non-medical cannabis
OT  - health outcomes
OT  - legalization
OT  - risk perception
OT  - young people
EDAT- 2020/07/01 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 10.1177/0025802420934255 [doi]
PST - ppublish
SO  - Med Sci Law. 2020 Oct;60(4):309-314. doi: 10.1177/0025802420934255. Epub 2020 Jun
      29.


PMID- 32600140
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210802
IS  - 2049-4408 (Electronic)
IS  - 2049-4394 (Linking)
VI  - 102-B
IP  - 7
DP  - 2020 Jul
TI  - [RETRACTED] Negative pressure wound therapy versus conventional dressing for open
      fractures in lower extremity trauma
PG  - 912-917
LID - 10.1302/0301-620X.102B7.BJJ-2019-1462.R1 [doi]
AB  - AIMS: It has been generally accepted that open fractures require early skeletal
      stabilization and soft-tissue reconstruction. Traditionally, a standard gauze
      dressing was applied to open wounds. There has been a recent shift in this
      paradigm towards negative pressure wound therapy (NPWT). The aim of this study
      was to compare the clinical outcomes in patients with open tibial fractures
      receiving standard dressing versus NPWT. METHODS: This multicentre randomized
      controlled trial was approved by the ethical review board of a public sector
      tertiary care institute. Wounds were graded using Gustilo-Anderson (GA)
      classification, and patients with GA-II to III-C were included in the study. To
      be eligible, the patient had to present within 72 hours of the injury. The
      primary outcome of the study was patient-reported Disability Rating Index (DRI)
      at 12 months. Secondary outcomes included quality of life assessment using
      12-Item Short-Form Health Survey questionnaire (SF-12), wound infection rates at 
      six weeks and nonunion rates at 12 months. Logistic regression analysis and
      independent-samples t-test were applied for secondary outcomes. Analyses of
      primary and secondary outcomes were performed using SPSS v. 22.0.1 and p-values
      of < 0.05 were considered significant. RESULTS: A total of 486 patients were
      randomized between January 2016 and December 2018. Overall 206 (49.04%) patients 
      underwent NPWT, while 214 (50.95%) patients were allocated to the standard
      dressing group. There was no statistically significant difference in DRI at 12
      months between NPWT and standard dressing groups (mean difference 0.5; 95%
      confidence interval (CI) -0.08 to 1.1; p = 0.581). Regarding SF-12 scores at 12
      months follow-up, there was no significant difference at any point from injury
      until 12 months (mean difference 1.4; 95% CI 0.7 to 1.9; p = 0.781). The 30-day
      deep infection rate was slightly higher in the standard gauze dressing group. The
      non-union odds were also comparable (odds ratio (OR) 0.90, 95% CI 0.56 to 1.45; p
      = 0.685). CONCLUSION: Our study concludes that NPWT therapy does not confer
      benefit over standard dressing technique for open fractures. The DRI, SF-12
      scores, wound infection, and nonunion rates were analogous in both study groups. 
      We suggest surgeons continue to use cheaper and more readily available standard
      dressings. Cite this article: Bone Joint J 2020;102-B(7):912-917.
FAU - Tahir, Muhammad
AU  - Tahir M
AD  - Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi,
      Pakistan.
FAU - Chaudhry, Ejaz A
AU  - Chaudhry EA
AD  - Department of Orthopaedics, Ghurkhi Trust Hospital, Lahore, Pakistan.
FAU - Zimri, Faridullah K
AU  - Zimri FK
AD  - Department of Orthopaedics, National Institute of Rehabilitation Medicine,
      Islamabad, Pakistan.
FAU - Ahmed, Nadeem
AU  - Ahmed N
AD  - Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi,
      Pakistan.
FAU - Shaikh, Saeed A
AU  - Shaikh SA
AD  - Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi,
      Pakistan.
FAU - Khan, Shoaib
AU  - Khan S
AD  - Department of Orthopaedics, Whiston Hospital, Prescot, United Kingdom.
FAU - Choudry, Usama K
AU  - Choudry UK
AD  - Shifa International Hopsital, Islamabad, Pakistan.
FAU - Aziz, Amer
AU  - Aziz A
AD  - Department of Orthopaedics, Ghurkhi Trust Hospital, Lahore, Pakistan.
FAU - Jamali, Allah R
AU  - Jamali AR
AD  - Department of Orthopaedics, Jinnah Postgraduate Medical Centre, Karachi,
      Pakistan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Retracted Publication
PL  - England
TA  - Bone Joint J
JT  - The bone & joint journal
JID - 101599229
SB  - IM
RIN - Bone Joint J. 2021 Jul 23;:1. PMID: 34293925
MH  - Adult
MH  - *Bandages
MH  - Debridement
MH  - Disability Evaluation
MH  - Female
MH  - Fractures, Open/*therapy
MH  - Humans
MH  - Leg Injuries/*therapy
MH  - Male
MH  - Negative-Pressure Wound Therapy/*methods
MH  - Therapeutic Irrigation
MH  - Tibial Fractures/*therapy
OTO - NOTNLM
OT  - *Gustilo-Anderson classification
OT  - *NPWT
OT  - *Open fractures
OT  - *Tibial fractures
OT  - *Trauma
OT  - *VAC
EDAT- 2020/07/01 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 10.1302/0301-620X.102B7.BJJ-2019-1462.R1 [doi]
PST - ppublish
SO  - Bone Joint J. 2020 Jul;102-B(7):912-917. doi:
      10.1302/0301-620X.102B7.BJJ-2019-1462.R1.


PMID- 32600129
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 6
DP  - 2020 Dec
TI  - Should Gender-Affirming Surgery Be Prioritized During the COVID-19 Pandemic?
PG  - 1140-1143
LID - 10.1177/0194599820939072 [doi]
FAU - Flaherty, Anna J
AU  - Flaherty AJ
AD  - Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University 
      School of Medicine, Springfield, Illinois, USA.
FAU - Sharma, Arun
AU  - Sharma A
AD  - Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University 
      School of Medicine, Springfield, Illinois, USA.
FAU - Crosby, Dana L
AU  - Crosby DL
AD  - Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University 
      School of Medicine, Springfield, Illinois, USA.
FAU - Nuara, Michael J
AU  - Nuara MJ
AD  - Department of Facial Plastic Surgery, Virginia Mason Medical Center, Seattle,
      Washington, USA.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - *COVID-19
MH  - *Elective Surgical Procedures
MH  - Female
MH  - Humans
MH  - Male
MH  - Otolaryngology
MH  - *Pandemics
MH  - Practice Guidelines as Topic
MH  - Reconstructive Surgical Procedures
MH  - *Sex Reassignment Surgery
MH  - Societies, Medical
MH  - *Transgender Persons
MH  - Transsexualism/surgery
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *coronavirus
OT  - *ethics
OT  - *facial feminization surgery
OT  - *facial plastic and reconstructive surgery
OT  - *gender-affirming care
OT  - *intersectionality
OT  - *otorhinolaryngology
OT  - *transgender
OT  - *transgender surgery
EDAT- 2020/07/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 10.1177/0194599820939072 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Dec;163(6):1140-1143. doi:
      10.1177/0194599820939072. Epub 2020 Jun 30.


PMID- 32599998
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20210525
IS  - 2208-7958 (Electronic)
VI  - 49
IP  - 7
DP  - 2020 Jul
TI  - A guide to differences/disorders of sex development/intersex in children and
      adolescents.
PG  - 417-422
LID - 10.31128/AJGP-03-20-5266 [doi]
AB  - BACKGROUND: Differences/disorders of sex development (DSD) or 'intersex'
      encompass a broad range of congenital variations in the complex pathways involved
      in the development of sex characteristics. Components of these pathways include
      sex chromosomes, genes involved in gonadal development, hormone production and
      action, and the development of internal and external genital structures. Many
      variations are rare, and some (eg congenital adrenal hyperplasia) are associated 
      with urgent medical needs. People born with variations in sex characteristics may
      present in the neonatal period with atypical genitalia, during childhood and
      adolescence with atypical pubertal development or in adulthood with hormone
      imbalance, fertility issues and/or sexual health concerns. OBJECTIVE: An overview
      of DSD is presented in relation to presenting features and management challenges 
      in the paediatric population. DISCUSSION: An experienced multidisciplinary team
      that uses a shared decision-making approach with a medical, surgical, ethical,
      psychological and human rights framework is required to maximise long-term
      positive outcomes for people born with variations in sex characteristics.
FAU - Vora, Komal A
AU  - Vora KA
AD  - MBBS, FRACP, Paediatric Endocrinologist, John Hunter Children@s Hospital, NSW;
      Cojoint Lecturer, School of Medicine and Public Health, Faculty of Health and
      Medicine, University of Newcastle, NSW.
FAU - Srinivasan, Shubha
AU  - Srinivasan S
AD  - BSc (Med), MBBS, PhD, MRCP (UK), FRACP, Senior Staff Specialist, Institute of
      Endocrinology and Diabetes, The Children@s Hospital at Westmead, NSW; Clinical
      Senior Lecturer, Sydney Medical School, Faculty of Medicine and Health,
      University of Sydney, NSW.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust J Gen Pract
JT  - Australian journal of general practice
JID - 101718099
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Disorders of Sex Development/*complications/*psychology/*therapy
MH  - Female
MH  - General Practice/methods/trends
MH  - Humans
MH  - Male
MH  - Pediatrics/methods/trends
EDAT- 2020/07/01 06:00
MHDA- 2021/05/26 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
AID - 10.31128/AJGP-03-20-5266 [doi]
PST - ppublish
SO  - Aust J Gen Pract. 2020 Jul;49(7):417-422. doi: 10.31128/AJGP-03-20-5266.


PMID- 32599945
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2079-4991 (Print)
IS  - 2079-4991 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 24
TI  - Translating Scientific Advances in the AOP Framework to Decision Making for
      Nanomaterials.
LID - E1229 [pii]
LID - 10.3390/nano10061229 [doi]
AB  - Much of the current innovation in advanced materials is occurring at the
      nanoscale, specifically in manufactured nanomaterials (MNs). MNs display unique
      attributes and behaviors, and may be biologically and physically unique, making
      them valuable across a wide range of applications. However, as the number,
      diversity and complexity of MNs coming to market continue to grow, assessing
      their health and environmental risks with traditional animal testing approaches
      is too time- and cost-intensive to be practical, and is undesirable for ethical
      reasons. New approaches are needed that meet current requirements for regulatory 
      risk assessment while reducing reliance on animal testing and enabling
      safer-by-design product development strategies to be implemented. The adverse
      outcome pathway (AOP) framework presents a sound model for the advancement of MN 
      decision making. Yet, there are currently gaps in technical and policy aspects of
      AOPs that hinder the adoption and use for MN risk assessment and regulatory
      decision making. This review outlines the current status and next steps for the
      development and use of the AOP framework in decision making regarding the safety 
      of MNs. Opportunities and challenges are identified concerning the advancement
      and adoption of AOPs as part of an integrated approach to testing and assessing
      (IATA) MNs, as are specific actions proposed to advance the development, use and 
      acceptance of the AOP framework and associated testing strategies for MN risk
      assessment and decision making. The intention of this review is to reflect the
      views of a diversity of stakeholders including experts, researchers,
      policymakers, regulators, risk assessors and industry representatives on the
      current status, needs and requirements to facilitate the future use of AOPs in MN
      risk assessment. It incorporates the views and feedback of experts that
      participated in two workshops hosted as part of an Organization for Economic
      Cooperation and Development (OECD) Working Party on Manufactured Nanomaterials
      (WPMN) project titled, "Advancing AOP Development for Nanomaterial Risk
      Assessment and Categorization", as well as input from several EU-funded
      nanosafety research consortia.
FAU - Ede, James D
AU  - Ede JD
AUID- ORCID: 0000-0002-9470-9859
AD  - Vireo Advisors, LLC, Boston, MA 02130, USA.
FAU - Lobaskin, Vladimir
AU  - Lobaskin V
AD  - School of Physics, University College Dublin, Belfield, Dublin 4, Ireland.
FAU - Vogel, Ulla
AU  - Vogel U
AUID- ORCID: 0000-0001-6807-1524
AD  - National Research Centre for the Working Environment, DK-2100 Copenhagen,
      Denmark.
FAU - Lynch, Iseult
AU  - Lynch I
AUID- ORCID: 0000-0003-4250-4584
AD  - School of Geography, Earth and Environmental Sciences, University of Birmingham, 
      Edgbaston, Birmingham B15 2TT, UK.
FAU - Halappanavar, Sabina
AU  - Halappanavar S
AD  - Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON K1A
      0K9, Canada.
FAU - Doak, Shareen H
AU  - Doak SH
AUID- ORCID: 0000-0002-6753-1987
AD  - Institute of Life Sciences, Swansea University Medical School, Singleton Park,
      Swansea SA2 8PP, UK.
FAU - Roberts, Megan G
AU  - Roberts MG
AD  - Department of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada.
FAU - Shatkin, Jo Anne
AU  - Shatkin JA
AD  - Vireo Advisors, LLC, Boston, MA 02130, USA.
LA  - eng
GR  - 686098; 760813; 731032/Horizon 2020
PT  - Journal Article
PT  - Review
DEP - 20200624
PL  - Switzerland
TA  - Nanomaterials (Basel)
JT  - Nanomaterials (Basel, Switzerland)
JID - 101610216
PMC - PMC7353114
OTO - NOTNLM
OT  - adverse outcome pathway
OT  - decision making
OT  - nanomaterials
OT  - risk assessment
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/07/01 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/18 00:00 [revised]
PHST- 2020/06/19 00:00 [accepted]
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - nano10061229 [pii]
AID - 10.3390/nano10061229 [doi]
PST - epublish
SO  - Nanomaterials (Basel). 2020 Jun 24;10(6). pii: nano10061229. doi:
      10.3390/nano10061229.


PMID- 32599935
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 24
TI  - Welfare of Free-Roaming Horses: 70 Years of Experience with Konik Polski Breeding
      in Poland.
LID - E1094 [pii]
LID - 10.3390/ani10061094 [doi]
AB  - To prevent abuse and to assure the welfare of domestic horses, attempts to assess
      welfare in a standardized way have been made. Welfare-assessment tools often
      refer to the physical and social environments of feral domestic horses as
      examples of welfare-friendly conditions for horses. However, free-roaming horses 
      are often exposed to conditions or states that may be regarded as welfare threats
      or abuse. The aim of this review was to present cases of welfare compromises as
      well as natural ways to restore high standards of welfare to Konik polski horses 
      (Koniks) living in semiferal conditions in a forest sanctuary over the course of 
      70 years. Welfare problems in Koniks related to feeding, locomotor, social,
      reproductive, and comfort behavior, as well as health issues concerning hoof
      trimming and parasitism in Koniks, are discussed. Periodic food scarcity or
      abundance, stressful events around weaning and gathering, the consequences of
      fights among stallions, exposure to sire aggression during dispersal, lameness
      during "self-trimming," exposure to insect harassment, high levels of parasitism,
      and specific landscape formations may endanger free-roaming horses. It has to be 
      underlined that despite the excellent adaptability of horses to free-roaming
      conditions, one should be aware that welfare problems are to be expected in any
      semiferal population. Here, we present the management system applied for 70 years
      in free-roaming Konik polski horses that minimizes welfare threats. It allows
      close follow-up of individual horses, the strict monitoring of health and welfare
      on a daily basis, and if necessary, instant reactions from caretakers in cases of
      emergency. Moreover, it addresses the problem of starvation due to overgrazing
      and thus, the ethical controversy related to the eradication of surplus animals
      causing environmental damage.
FAU - Gorecka-Bruzda, Aleksandra
AU  - Gorecka-Bruzda A
AD  - Department of Animal Behaviour, Institute of Genetics and Animal Breeding, Polish
      Academy of Sciences, 05-552 Jastrzebiec, Poland.
FAU - Jaworski, Zbigniew
AU  - Jaworski Z
AD  - Department of Horse Breeding and Riding, Faculty of Animal Bioengineering,
      University of Warmia and Mazury, 10-719 Olsztyn, Poland.
FAU - Jaworska, Joanna
AU  - Jaworska J
AD  - Department of Gamete and Embryo Biology, Institute of Animal Reproduction and
      Food Research, Polish Academy of Sciences, 10-243 Olsztyn, Poland.
FAU - Siemieniuch, Marta
AU  - Siemieniuch M
AD  - Department of Reproductive Immunology and Pathology, Institute of Animal
      Reproduction and Food Research, Polish Academy of Sciences, 10-243 Olsztyn,
      Poland.
AD  - The Research Station of the IARF PAS in Popielno, 12-222 Ruciane-Nida, Poland;.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200624
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7341202
OTO - NOTNLM
OT  - diet
OT  - feral horses
OT  - hoof
OT  - insects
OT  - management
OT  - parasites
OT  - reproduction
OT  - welfare
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/07/01 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/06/21 00:00 [accepted]
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - ani10061094 [pii]
AID - 10.3390/ani10061094 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Jun 24;10(6). pii: ani10061094. doi: 10.3390/ani10061094.


PMID- 32599775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 24
TI  - To Correct or Not Correct? Actual Evidence, Controversy and the Questions That
      Remain Open.
LID - E1975 [pii]
LID - 10.3390/jcm9061975 [doi]
AB  - Clinical studies and basic research have attempted to establish a relationship
      between myopia progression and single vision spectacle wear, albeit with unclear 
      results. Single vision spectacle lenses are continuously used as the control
      group in myopia control trials. Hence, it is a matter of high relevance to
      investigate further whether they yield any shift on the refractive state, which
      could have been masked by being used as a control. In this review, eye
      development in relation to eyes fully corrected versus those under-corrected is
      discussed, and new guidelines are provided for the analysis of structural eye
      changes due to optical treatments. These guidelines are tested and optimised,
      while ethical implications are revisited. This newly described methodology can be
      translated to larger clinical trials, finally exerting the real effect of full
      correction via single vision spectacle lens wear on eye growth and myopia
      progression.
FAU - Garcia Garcia, Miguel
AU  - Garcia Garcia M
AUID- ORCID: 0000-0001-7379-0080
AD  - Carl Zeiss Vision International GmbH, ZEISS Group, Turnstrasse 27, 73430 Aalen,
      Germany.
AD  - Ophthalmic Research Institute, Elfriede-Aulhorn-Strasse 7, 72076 Tuebingen,
      Germany.
FAU - Breher, Katharina
AU  - Breher K
AUID- ORCID: 0000-0001-9066-3745
AD  - Ophthalmic Research Institute, Elfriede-Aulhorn-Strasse 7, 72076 Tuebingen,
      Germany.
FAU - Ohlendorf, Arne
AU  - Ohlendorf A
AD  - Carl Zeiss Vision International GmbH, ZEISS Group, Turnstrasse 27, 73430 Aalen,
      Germany.
AD  - Ophthalmic Research Institute, Elfriede-Aulhorn-Strasse 7, 72076 Tuebingen,
      Germany.
FAU - Wahl, Siegfried
AU  - Wahl S
AUID- ORCID: 0000-0003-3437-6711
AD  - Carl Zeiss Vision International GmbH, ZEISS Group, Turnstrasse 27, 73430 Aalen,
      Germany.
AD  - Ophthalmic Research Institute, Elfriede-Aulhorn-Strasse 7, 72076 Tuebingen,
      Germany.
LA  - eng
GR  - 675137/H2020 Marie Sklodowska-Curie Actions
PT  - Journal Article
PT  - Review
DEP - 20200624
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7356996
OTO - NOTNLM
OT  - eye growth
OT  - myopia
OT  - near-sightedness
OT  - short-sightedness
OT  - spectacles
OT  - under-correction
OT  - vision
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/07/01 06:00
PHST- 2020/05/31 00:00 [received]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - jcm9061975 [pii]
AID - 10.3390/jcm9061975 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jun 24;9(6). pii: jcm9061975. doi: 10.3390/jcm9061975.


PMID- 32599031
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20210110
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
VI  - 225
DP  - 2020 Oct
TI  - Seeking Normalcy as the Curve Flattens: Ethical Considerations for Pediatricians 
      Managing Collateral Damage of Coronavirus Disease-2019.
PG  - 233-238
LID - S0022-3476(20)30820-9 [pii]
LID - 10.1016/j.jpeds.2020.06.067 [doi]
FAU - Feltman, Dalia M
AU  - Feltman DM
AD  - NorthShore University HealthSystem Evanston Hospital, Evanston, IL; University of
      Chicago Pritzker School of Medicine, Chicago, IL. Electronic address:
      dfeltman@northshore.org.
FAU - Moore, Gregory P
AU  - Moore GP
AD  - Division of Neonatology, Children's Hospital of Eastern Ontario and The Ottawa
      Hospital, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Beck, Andrew F
AU  - Beck AF
AD  - Cincinnati Children's Hospital Medical Center and University of Cincinnati
      College of Medicine, Cincinnati, OH.
FAU - Siffermann, Emily
AU  - Siffermann E
AD  - Advocate Children's Hospital, Oak Lawn, IL.
FAU - Bellieni, Carlo
AU  - Bellieni C
AD  - Pediatric Intensive Care Unit, Le Scotte University Hospital, Siena, Italy.
FAU - Lantos, John
AU  - Lantos J
AD  - Department of Pediatrics and Children's Mercy Bioethics Center, Children's Mercy 
      Hospital, Kansas City, MO.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/ethics
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*psychology
MH  - Health Priorities
MH  - Healthcare Disparities
MH  - Humans
MH  - Mental Health
MH  - Morals
MH  - Needs Assessment
MH  - Pandemics
MH  - Pediatricians/*ethics
MH  - Pneumonia, Viral/*epidemiology/*psychology
MH  - Psychological Distress
MH  - SARS-CoV-2
MH  - Social Determinants of Health
MH  - Socioeconomic Factors
PMC - PMC7319624
OTO - NOTNLM
OT  - health disparities
OT  - pandemic
OT  - resource allocation
OT  - triage
EDAT- 2020/07/01 06:00
MHDA- 2020/10/03 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - S0022-3476(20)30820-9 [pii]
AID - 10.1016/j.jpeds.2020.06.067 [doi]
PST - ppublish
SO  - J Pediatr. 2020 Oct;225:233-238. doi: 10.1016/j.jpeds.2020.06.067. Epub 2020 Jun 
      26.


PMID- 32598785
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 92
IP  - 3
DP  - 2020 Apr 27
TI  - [UNESCO: bioethical initiatives in 2019].
PG  - 4-6
LID - 10.26442/00403660.2020.03.000570 [doi]
AB  - The Universal Declaration on Bioethics and Human Rights was adopted at the UNESCO
      General Conference on October 19, 2005. From today's perspective, it must be
      recognized that it was adopted at a historically important period in the
      development of civilization; It has always been seen as a document that
      significantly expanded the declaration on human rights, as it gave a new
      interpretation of human activity in modern society. Next year marks 25 years of
      active implementation of the main provisions of the declaration in the field of
      education, research and cultural heritage. Scientific ideas about the world were 
      changing dynamically, new pedagogical technologies developed, society more than
      ever began to perceive cultural heritage more acutely. Under the influence of
      these processes, our ideas about moral values and ethical principles changed. An 
      idea of bioethics has formed; The term implies versatile human activities,
      including not only the doctor-patient relationship, but also the active
      participation of a person in the field of industry, climate change, as well as
      new areas such as editing the human genome, transplantology and much more.
FAU - Chuchalin, A G
AU  - Chuchalin AG
AD  - Pirogov Russian Research Medical University.
LA  - rus
PT  - Journal Article
DEP - 20200427
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
SB  - IM
MH  - *Bioethics
MH  - Human Rights
MH  - Humans
MH  - Physician-Patient Relations
MH  - UNESCO
MH  - *United Nations
OTO - NOTNLM
OT  - bioethics
EDAT- 2020/07/01 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.26442/00403660.2020.03.000570 [doi]
PST - epublish
SO  - Ter Arkh. 2020 Apr 27;92(3):4-6. doi: 10.26442/00403660.2020.03.000570.


PMID- 32598438
OWN - NLM
STAT- MEDLINE
DCOM- 20220114
LR  - 20220114
IS  - 1876-4479 (Electronic)
IS  - 1873-9946 (Linking)
VI  - 14
IP  - 12
DP  - 2020 Dec 2
TI  - Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD
      Clinical Research Activity in the UK.
PG  - 1769-1776
LID - 10.1093/ecco-jcc/jjaa137 [doi]
AB  - There have been immediate and profound impacts of SARS-CoV-2 and COVID-19 on
      health care services worldwide, with major consequences for non COVID-19 related 
      health care. Alongside efforts to reconfigure services and enable continued
      delivery of safe clinical care for patients with IBD, consideration must also be 
      given to management of IBD research activity. In many centres there has been an
      effective shutdown of IBD clinical trial activity as research sites have switched
      focus to either COVID-19 related research or clinical care only. As a result, the
      early termination of trial programmes, and loss of potentially effective
      therapeutic options for IBD, has become a real and worrying prospect. Moreover,
      in many countries research activity has become embedded into clinical care-with
      clinical trials often providing access to new therapies or strategies-which would
      otherwise not have been available in standard clinical pathways. This pandemic
      has significant implications for the design, conduct, analysis, and reporting of 
      clinical trials in IBD. In this Viewpoint, we share our experiences from a
      clinical and academic perspective in the UK, highlighting the early challenges
      encountered, and consider implications for patients and staff at research sites, 
      sponsors, research ethics committees, funders, and regulators. We also offer
      potential solutions both for now and for when we enter a recovery phase from the 
      pandemic.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Crohn's and Colitis Organisation. All rights reserved. For permissions, 
      please email: journals.permissions@oup.com.
FAU - Noor, Nurulamin M
AU  - Noor NM
AUID- ORCID: 0000-0003-3426-6408
AD  - Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University
      Hospitals NHS Trust, Cambridge, UK.
AD  - Department of Medicine, University of Cambridge School of Clinical Medicine,
      Cambridge, UK.
AD  - Medical Research Council Clinical Trials Unit, University College London, London,
      UK.
FAU - Hart, Ailsa L
AU  - Hart AL
AD  - St Mark's Hospital, IBD Unit, Harrow, London, UK.
FAU - Irving, Peter M
AU  - Irving PM
AD  - IBD Centre, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
AD  - School of Immunology and Microbial Sciences, King's College London, London, UK.
FAU - Ghosh, Subrata
AU  - Ghosh S
AD  - Institute of Translational Medicine, NIHR Biomedical Research Centre, University 
      of Birmingham, Birmingham, UK.
FAU - Parkes, Miles
AU  - Parkes M
AD  - Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University
      Hospitals NHS Trust, Cambridge, UK.
AD  - Department of Medicine, University of Cambridge School of Clinical Medicine,
      Cambridge, UK.
FAU - Raine, Tim
AU  - Raine T
AD  - Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University
      Hospitals NHS Trust, Cambridge, UK.
LA  - eng
GR  - MC_UU_171339/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PL  - England
TA  - J Crohns Colitis
JT  - Journal of Crohn's & colitis
JID - 101318676
SB  - IM
MH  - COVID-19/*prevention & control
MH  - Clinical Trials as Topic/methods/*statistics & numerical data
MH  - Health Services Accessibility/*trends
MH  - Humans
MH  - Inflammatory Bowel Diseases/*therapy
MH  - Patient Selection
MH  - Research Design/trends
MH  - United Kingdom
PMC - PMC7337665
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical trials
OT  - SARS-CoV-2
EDAT- 2020/07/01 06:00
MHDA- 2022/01/15 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2022/01/15 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 5864879 [pii]
AID - 10.1093/ecco-jcc/jjaa137 [doi]
PST - ppublish
SO  - J Crohns Colitis. 2020 Dec 2;14(12):1769-1776. doi: 10.1093/ecco-jcc/jjaa137.


PMID- 32597943
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2168-6211 (Electronic)
IS  - 2168-6203 (Linking)
VI  - 174
IP  - 10
DP  - 2020 Oct 1
TI  - Gene and Stem Cell Therapies for Fetal Care: A Review.
PG  - 985-991
LID - 10.1001/jamapediatrics.2020.1519 [doi]
AB  - Importance: Gene and stem cell therapies have become viable therapeutic options
      for many postnatal disorders. For select conditions, prenatal application would
      provide improved outcomes. The fetal state allows for several theoretical
      advantages over postnatal therapy, including immune immaturity and cellular niche
      accessibility. Observations: Advances in prenatal diagnostic accuracy and
      surgical precision, as well as improvements in stem cell and gene therapy
      methods, have made prenatal gene and stem cell therapy realistic. Studies in
      mouse models and early human trials demonstrate the feasibility of these
      approaches. Additional efforts are under way to streamline fetal applications of 
      stem cell and gene therapy while carefully considering best ethical practice and 
      following established regulatory pathways. Conclusions and Relevance: Fetal stem 
      cell and gene therapy bring important therapeutic opportunities for select
      disorders that present in the fetal and neonatal periods. While this field is in 
      its infancy, these therapies are starting to be available clinically, and
      clinicians should be aware of their benefits and challenges.
FAU - O'Connell, Amy E
AU  - O'Connell AE
AD  - Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts.
AD  - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
FAU - Guseh, Stephanie
AU  - Guseh S
AD  - Division of Maternal Fetal Medicine and Reproductive Genetics, Brigham and
      Women's Hospital, Boston, Massachusetts.
FAU - Lapteva, Larissa
AU  - Lapteva L
AD  - Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and
      Research, Food and Drug Administration, Silver Spring, Maryland.
FAU - Cummings, Christy L
AU  - Cummings CL
AD  - Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts.
AD  - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
FAU - Wilkins-Haug, Louise
AU  - Wilkins-Haug L
AD  - Division of Maternal Fetal Medicine and Reproductive Genetics, Brigham and
      Women's Hospital, Boston, Massachusetts.
FAU - Chan, Jerry
AU  - Chan J
AD  - Department of Reproductive Medicine, KK Women's and Children's Hospital,
      Singapore.
AD  - Duke-NUS Medical School, Academic Program in Obstetrics and Gynaecology,
      Singapore.
FAU - Peranteau, William H
AU  - Peranteau WH
AD  - Division of General, Thoracic and Fetal Surgery, The Children's Hospital of
      Philadelphia, Philadelphia, Pennsylvania.
FAU - Almeida-Porada, Graca
AU  - Almeida-Porada G
AD  - Wake Forest Institute for Regenerative Medicine, Fetal Research and Therapy
      Program, Winston Salem, North Carolina.
FAU - Kourembanas, Stella
AU  - Kourembanas S
AD  - Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts.
AD  - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
LA  - eng
GR  - R01 HL146128/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JAMA Pediatr
JT  - JAMA pediatrics
JID - 101589544
SB  - IM
CIN - JAMA Pediatr. 2020 Oct 1;174(10):929-930. PMID: 32597940
MH  - Animals
MH  - Female
MH  - Genetic Diseases, Inborn/*therapy
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - Pregnancy
MH  - Prenatal Care/*methods
MH  - Stem Cell Transplantation/*methods
EDAT- 2020/07/01 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 2767277 [pii]
AID - 10.1001/jamapediatrics.2020.1519 [doi]
PST - ppublish
SO  - JAMA Pediatr. 2020 Oct 1;174(10):985-991. doi: 10.1001/jamapediatrics.2020.1519.


PMID- 32597868
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20210421
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 160
DP  - 2020 Jun 12
TI  - Single Cell Collection of Trophoblast Cells in Peri-implantation Stage Human
      Embryos.
LID - 10.3791/61476 [doi]
AB  - Human implantation, the apposition and adhesion to the uterine surface epithelia 
      and subsequent invasion of the blastocyst into the maternal decidua, is a
      critical yet enigmatic biological event that has been historically difficult to
      study due to technical and ethical limitations. Implantation is initiated by the 
      development of the trophectoderm to early trophoblast and subsequent
      differentiation into distinct trophoblast sublineages. Aberrant early trophoblast
      differentiation may lead to implantation failure, placental pathologies, fetal
      abnormalities, and miscarriage. Recently, methods have been developed to allow
      human embryos to grow until day 13 post-fertilization in vitro in the absence of 
      maternal tissues, a time-period that encompasses the implantation period in
      humans. This has given researchers the opportunity to investigate human
      implantation and recapitulate the dynamics of trophoblast differentiation during 
      this critical period without confounding maternal influences and avoiding
      inherent obstacles to study early embryo differentiation events in vivo. To
      characterize different trophoblast sublineages during implantation, we have
      adopted existing two-dimensional (2D) extended culture methods and developed a
      procedure to enzymatically digest and isolate different types of trophoblast
      cells for downstream assays. Embryos cultured in 2D conditions have a relatively 
      flattened morphology and may be suboptimal in modeling in vivo three-dimensional 
      (3D) embryonic architectures. However, trophoblast differentiation seems to be
      less affected as demonstrated by anticipated morphology and gene expression
      changes over the course of extended culture. Different trophoblast sublineages,
      including cytotrophoblast, syncytiotrophoblast and migratory trophoblast can be
      separated by size, location, and temporal emergence, and used for further
      characterization or experimentation. Investigation of these early trophoblast
      cells may be instrumental in understanding human implantation, treating common
      placental pathologies, and mitigating the incidence of pregnancy loss.
FAU - Logsdon, Deirdre M
AU  - Logsdon DM
AD  - Colorado Center for Reproductive Medicine.
FAU - Kile, Rebecca A
AU  - Kile RA
AD  - Colorado Center for Reproductive Medicine.
FAU - Schoolcraft, William B
AU  - Schoolcraft WB
AD  - Colorado Center for Reproductive Medicine.
FAU - Krisher, Rebecca L
AU  - Krisher RL
AD  - Colorado Center for Reproductive Medicine.
FAU - Yuan, Ye
AU  - Yuan Y
AD  - Colorado Center for Reproductive Medicine; yyuan@flcolo.com.
LA  - eng
GR  - P30 NS048154/NS/NINDS NIH HHS/United States
GR  - R01 NS086839/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
DEP - 20200612
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
RN  - 0 (Biomarkers)
RN  - 0 (Chorionic Gonadotropin)
RN  - EC 3.4.21.4 (Trypsin)
SB  - IM
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Blastocyst/cytology
MH  - Cell Separation/*methods
MH  - Cell Shape
MH  - Cells, Cultured
MH  - Chorionic Gonadotropin/pharmacology
MH  - *Embryo Implantation
MH  - Embryo, Mammalian/*cytology
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Time-Lapse Imaging
MH  - Tissue Fixation
MH  - Trophoblasts/*cytology
MH  - Trypsin/metabolism
MH  - Vitrification
EDAT- 2020/07/01 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.3791/61476 [doi]
PST - epublish
SO  - J Vis Exp. 2020 Jun 12;(160). doi: 10.3791/61476.


PMID- 32597799
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 76
IP  - 3
DP  - 2020
TI  - Ethical and Social Implications of Using Predictive Modeling for Alzheimer's
      Disease Prevention: A Systematic Literature Review.
PG  - 923-940
LID - 10.3233/JAD-191159 [doi]
AB  - BACKGROUND: The therapeutic paradigm in Alzheimer's disease (AD) is shifting from
      symptoms management toward prevention goals. Secondary prevention requires the
      identification of individuals without clinical symptoms, yet "at-risk" of
      developing AD dementia in the future, and thus, the use of predictive modeling.
      OBJECTIVE: The objective of this study was to review the ethical concerns and
      social implications generated by this new approach. METHODS: We conducted a
      systematic literature review in Medline, Embase, PsycInfo, and Scopus, and
      complemented it with a gray literature search between March and July 2018. Then
      we analyzed data qualitatively using a thematic analysis technique. RESULTS: We
      identified thirty-one ethical issues and social concerns corresponding to eight
      ethical principles: (i) respect for autonomy, (ii) beneficence, (iii)
      non-maleficence, (iv) equality, justice, and diversity, (v) identity and stigma, 
      (vi) privacy, (vii) accountability, transparency, and professionalism, and (viii)
      uncertainty avoidance. Much of the literature sees the discovery of
      disease-modifying treatment as a necessary and sufficient condition to justify AD
      risk assessment, overlooking future challenges in providing equitable access to
      it, establishing long-term treatment outcomes and social consequences of this
      approach, e.g., medicalization. The ethical/social issues associated specifically
      with predictive models, such as the adequate predictive power and reliability,
      infrastructural requirements, data privacy, potential for personalized medicine
      in AD, and limiting access to future AD treatment based on risk stratification,
      were covered scarcely. CONCLUSION: The ethical discussion needs to advance to
      reflect recent scientific developments and guide clinical practice now and in the
      future, so that necessary safeguards are implemented for large-scale AD secondary
      prevention.
FAU - Angehrn, Zuzanna
AU  - Angehrn Z
AD  - Certara, Lorrach, Germany.
FAU - Sostar, Jelena
AU  - Sostar J
AD  - Certara, Lorrach, Germany.
FAU - Nordon, Clementine
AU  - Nordon C
AD  - INSERM U1178, CESP, Paris, France.
FAU - Turner, Andrew
AU  - Turner A
AD  - NIHR ARC West, University of Bristol, UK.
FAU - Gove, Dianne
AU  - Gove D
AD  - Alzheimer Europe, Luxembourg.
FAU - Karcher, Helene
AU  - Karcher H
AD  - Certara, Lorrach, Germany.
FAU - Keenan, Alexander
AU  - Keenan A
AD  - Janssen Pharmaceutical NV, USA.
FAU - Mittelstadt, Brent
AU  - Mittelstadt B
AD  - Oxford Internet Institute, University of Oxford, Oxford, UK.
FAU - de Reydet-de Vulpillieres, Frederic
AU  - de Reydet-de Vulpillieres F
AD  - Novartis Pharma AG, Basel, Switzerland.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
MH  - Alzheimer Disease/diagnosis/*physiopathology/*prevention & control
MH  - Beneficence
MH  - Bioethical Issues
MH  - Brain/*physiopathology
MH  - Humans
MH  - Publications
MH  - Reproducibility of Results
MH  - Social Justice
OTO - NOTNLM
OT  - *Biomedical ethics
OT  - *dementia
OT  - *early diagnosis
OT  - *early intervention
OT  - *prodromal symptoms
OT  - *qualitative research
OT  - *secondary prevention
EDAT- 2020/07/01 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - JAD191159 [pii]
AID - 10.3233/JAD-191159 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;76(3):923-940. doi: 10.3233/JAD-191159.


PMID- 32597785
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 6
DP  - 2020 Jun 29
TI  - Toward the Development of Data Governance Standards for Using Clinical Free-Text 
      Data in Health Research: Position Paper.
PG  - e16760
LID - 10.2196/16760 [doi]
AB  - BACKGROUND: Clinical free-text data (eg, outpatient letters or nursing notes)
      represent a vast, untapped source of rich information that, if more accessible
      for research, would clarify and supplement information coded in structured data
      fields. Data usually need to be deidentified or anonymized before they can be
      reused for research, but there is a lack of established guidelines to govern
      effective deidentification and use of free-text information and avoid damaging
      data utility as a by-product. OBJECTIVE: This study aimed to develop
      recommendations for the creation of data governance standards to integrate with
      existing frameworks for personal data use, to enable free-text data to be used
      safely for research for patient and public benefit. METHODS: We outlined data
      protection legislation and regulations relating to the United Kingdom for context
      and conducted a rapid literature review and UK-based case studies to explore data
      governance models used in working with free-text data. We also engaged with
      stakeholders, including text-mining researchers and the general public, to
      explore perceived barriers and solutions in working with clinical free-text.
      RESULTS: We proposed a set of recommendations, including the need for
      authoritative guidance on data governance for the reuse of free-text data, to
      ensure public transparency in data flows and uses, to treat deidentified
      free-text data as potentially identifiable with use limited to accredited data
      safe havens, and to commit to a culture of continuous improvement to understand
      the relationships between the efficacy of deidentification and reidentification
      risks, so this can be communicated to all stakeholders. CONCLUSIONS: By drawing
      together the findings of a combination of activities, we present a position paper
      to contribute to the development of data governance standards for the reuse of
      clinical free-text data for secondary purposes. While working in accordance with 
      existing data governance frameworks, there is a need for further work to take
      forward the recommendations we have proposed, with commitment and investment, to 
      assure and expand the safe reuse of clinical free-text data for public benefit.
CI  - (c)Kerina H Jones, Elizabeth M Ford, Nathan Lea, Lucy J Griffiths, Lamiece
      Hassan, Sharon Heys, Emma Squires, Goran Nenadic. Originally published in the
      Journal of Medical Internet Research (http://www.jmir.org), 29.06.2020.
FAU - Jones, Kerina H
AU  - Jones KH
AUID- ORCID: 0000-0001-8164-3718
AD  - Population Data Science, Medical School, Swansea University, Swansea, United
      Kingdom.
FAU - Ford, Elizabeth M
AU  - Ford EM
AUID- ORCID: 0000-0001-5613-8509
AD  - Brighton and Sussex Medical School, Brighton, United Kingdom.
FAU - Lea, Nathan
AU  - Lea N
AUID- ORCID: 0000-0001-5056-0602
AD  - Institute of Health Informatics, University College London, London, United
      Kingdom.
FAU - Griffiths, Lucy J
AU  - Griffiths LJ
AUID- ORCID: 0000-0001-9230-624X
AD  - Population Data Science, Medical School, Swansea University, Swansea, United
      Kingdom.
FAU - Hassan, Lamiece
AU  - Hassan L
AUID- ORCID: 0000-0002-5888-422X
AD  - Division of Informatics, Imaging & Data Sciences, University of Manchester,
      Manchester, United Kingdom.
FAU - Heys, Sharon
AU  - Heys S
AUID- ORCID: 0000-0002-3007-644X
AD  - Population Data Science, Medical School, Swansea University, Swansea, United
      Kingdom.
FAU - Squires, Emma
AU  - Squires E
AUID- ORCID: 0000-0003-0693-5846
AD  - Population Data Science, Medical School, Swansea University, Swansea, United
      Kingdom.
FAU - Nenadic, Goran
AU  - Nenadic G
AUID- ORCID: 0000-0003-0795-5363
AD  - Department of Computer Science, University of Manchester & The Alan Turing
      Institute, Manchester, United Kingdom.
LA  - eng
GR  - MR/S004025/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Data Analysis
MH  - Humans
MH  - Reference Standards
MH  - Text Messaging
PMC - PMC7367542
OTO - NOTNLM
OT  - *ethical
OT  - *free-text data
OT  - *information governance
OT  - *legal
OT  - *public engagement
OT  - *social implications
EDAT- 2020/07/01 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/06/30 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - v22i6e16760 [pii]
AID - 10.2196/16760 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jun 29;22(6):e16760. doi: 10.2196/16760.


PMID- 32597555
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1931-2393 (Electronic)
IS  - 1538-6341 (Linking)
VI  - 52
IP  - 2
DP  - 2020 Jul
TI  - "My Hands Are Tied": Abortion Restrictions and Providers' Experiences in
      Religious and Nonreligious Health Care Systems.
PG  - 107-115
LID - 10.1363/psrh.12148 [doi]
AB  - CONTEXT: Abortion is generally prohibited in Catholic hospitals, but less is
      known about abortion restrictions in other religiously affiliated health care
      facilities. As religiously affiliated health systems expand in the United States,
      it is important to understand how religious restrictions affect the practices of 
      providers who treat pregnant patients. METHODS: From September 2016 to May 2018, 
      in-depth interviews were conducted with 31 key informants (clinical providers,
      ethicists, chaplains and health system administrators) with experience working in
      secular, Protestant or Catholic health care systems in Illinois. A thematic
      content approach was used to identify themes related to participants' experiences
      with abortion policies, the role of ethics committees, the impact on patient care
      and conflicts with hospital policies. RESULTS: Few limitations on abortion were
      reported in secular hospitals, while Catholic hospitals prohibited most
      abortions, and a Protestant-affiliated system banned abortions deemed "elective."
      Religiously affiliated hospitals allowed abortions in specific cases, if approved
      through an ethics consultation. Interpretation of system-wide policies varied by 
      hospital, with some indication that institutional discomfort with abortion
      influenced policy as much as religious teachings did. Providers constrained by
      religious restrictions referred or transferred patients desiring abortion,
      including for pregnancy complications, with those in Protestant hospitals having 
      more latitude to directly refer such patients. As a result of religiously
      influenced policies, patients could encounter delays, financial obstacles,
      restrictions on treatment and stigmatization. CONCLUSIONS: Patients seeking
      abortion or presenting with pregnancy complications at Catholic and Protestant
      hospitals may encounter more delays and fewer treatment options than they would
      at secular hospitals. More research is needed to better understand the
      implications for women's access to reproductive health care.
CI  - Copyright (c) 2020 by the Guttmacher Institute.
FAU - Hasselbacher, Lee A
AU  - Hasselbacher LA
AD  - Center for Interdisciplinary Inquiry and Innovation in Sexual and Reproductive
      Health, University of Chicago, Chicago.
FAU - Hebert, Luciana E
AU  - Hebert LE
AD  - Institute for Research and Education to Advance Community Health, Washington
      State University, Seattle.
FAU - Liu, Yuan
AU  - Liu Y
AD  - Department of Psychiatry, Icahn School of Medicine, Mount Sinai Hospital, New
      York.
FAU - Stulberg, Debra B
AU  - Stulberg DB
AD  - Department of Family Medicine, University of Chicago.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200629
PL  - United States
TA  - Perspect Sex Reprod Health
JT  - Perspectives on sexual and reproductive health
JID - 101140654
SB  - IM
MH  - Abortion, Induced/*psychology
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Catholicism/*psychology
MH  - Clergy/psychology
MH  - Ethicists/psychology
MH  - Female
MH  - Health Facility Administrators/psychology
MH  - Health Personnel/psychology
MH  - Health Services Accessibility/*organization & administration
MH  - Hospitals, Religious
MH  - Humans
MH  - Illinois
MH  - Male
MH  - Middle Aged
MH  - *Organizational Policy
MH  - Pregnancy
MH  - Protestantism/*psychology
MH  - *Religion and Medicine
MH  - Secularism
MH  - United States
EDAT- 2020/07/01 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2019/07/26 00:00 [received]
PHST- 2020/02/06 00:00 [revised]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1363/psrh.12148 [doi]
PST - ppublish
SO  - Perspect Sex Reprod Health. 2020 Jul;52(2):107-115. doi: 10.1363/psrh.12148. Epub
      2020 Jun 29.


PMID- 32597531
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50 Suppl 1
DP  - 2020 May
TI  - Health for Whom? Bioethics and the Challenge of Justice for Genomic Medicine.
PG  - S2-S5
LID - 10.1002/hast.1149 [doi]
AB  - The guiding premise from which this special report begins is the conviction and
      hope that justice is at the normative heart of medicine and that it is the
      perpetual task of bioethics to bring concerns of justice to bear on medical
      practice. On such an account, justice is medicine's lifeblood, that by which it
      contributes to life as opposed to diminishing it. It is in this larger,
      historical, intersectional, critical, and ethically minded context that we must
      approach pressing questions facing medicine, including the question of the import
      and role of genomic knowledge for human life. The second premise is that, at
      least in principle, the knowledge generated by genomics can be a gift or a
      weight, or both at the same time. That is to say that, on the one hand, genomic
      knowledge is a gift, creating novel insights into the genetic drivers of disease 
      and into the geographical paths of our ancestors. And on the other hand, it is a 
      weight, creating new obligations, new forms of social classification, and new
      forms of surveillance. Because it is in many ways the "common sense" of the day
      that genomic knowledge is a gift, this special report, which contains nine
      essays, concentrates on the ways in which such knowledge can be a weight, a
      weight that has the potential to thwart-and historically has thwarted-medicine
      from genuinely advancing justice.
CI  - (c) 2020 The Hastings Center.
FAU - Reynolds, Joel Michael
AU  - Reynolds JM
LA  - eng
GR  - National Endowment for the Humanities and the Rice Family Postdoctoral Fellowship
      in Bioethics and the Humanities
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Bioethics
MH  - Delivery of Health Care/*ethics
MH  - Genomics/*ethics
MH  - Humans
MH  - *Social Justice
OTO - NOTNLM
OT  - bioethics
OT  - genomic knowledge
OT  - justice
EDAT- 2020/07/01 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
AID - 10.1002/hast.1149 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50 Suppl 1:S2-S5. doi: 10.1002/hast.1149.


PMID- 32597530
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20211230
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50 Suppl 1
DP  - 2020 May
TI  - Excavating the Personal Genome: The Good Biocitizen in the Age of Precision
      Health.
PG  - S54-S61
LID - 10.1002/hast.1156 [doi]
AB  - The rise of genomic technologies has catalyzed shifts in the health care
      landscape through the commercialization of genome sequencing and testing services
      in the genomics marketplace. The development of consumer genomics into a growing 
      array of information technologies aimed at collecting, curating, and broadly
      sharing personal data and biological materials reconstitutes the meaning of
      health and reframes patients into biocitizens. In this context, the good
      biocitizen is expected to assume personal responsibility for health through
      consumption of genomic information and acquiescence to public and private efforts
      at data surveillance and aggregation. These shifts raise fundamental questions
      about how competing interests of the public, the state, and corporate entities
      will be reconciled and what trade-offs are demanded for the promise of precision 
      health.
CI  - (c) 2020 The Hastings Center.
FAU - Lee, Sandra Soo-Jin
AU  - Lee SS
LA  - eng
GR  - R03 HG010178/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Commerce
MH  - *Genomics
MH  - Humans
MH  - Pedigree
MH  - *Precision Medicine
MH  - *Social Responsibility
PMC - PMC8715499
MID - NIHMS1760356
OTO - NOTNLM
OT  - big data
OT  - ethics
OT  - genetics
OT  - neoliberalism
OT  - precision medicine
EDAT- 2020/07/01 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
AID - 10.1002/hast.1156 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50 Suppl 1:S54-S61. doi: 10.1002/hast.1156.


PMID- 32597528
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50 Suppl 1
DP  - 2020 May
TI  - Does Solidarity Require "All of Us" to Participate in Genomics Research?
PG  - S62-S69
LID - 10.1002/hast.1157 [doi]
AB  - In this paper, I interrogate an ethical obligation to participate in genomics
      research on the basis of solidarity. I explore two different ways in which
      solidarity is used to motivate participation in genomics research: as an appeal
      to participate in genomic research because it cultivates solidarity and as an
      appeal to participate in genomic research because it expresses solidarity. I
      critique those appeals and draw lessons from them for how we ought to understand 
      solidarity. The working definition of solidarity that I defend is that solidarity
      involves recognizing another creature, person, or persons as, like ourselves,
      vulnerable to injustice and entails acting in ways that contribute to creating,
      reforming, and participating in institutions that are aimed at enhancing their
      flourishing. I argue that participating in genomics research is not an expression
      of solidarity. Participation in research may be praiseworthy, a "good thing to
      do," but actually cultivating and expressing solidarity requires much more of us.
CI  - (c) 2020 The Hastings Center.
FAU - Neuhaus, Carolyn P
AU  - Neuhaus CP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Community Participation
MH  - *Genomics
MH  - Humans
MH  - *Research
MH  - Social Justice
OTO - NOTNLM
OT  - genomics
OT  - health inequalities
OT  - public health ethics
OT  - research ethics
OT  - solidarity
EDAT- 2020/07/01 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
AID - 10.1002/hast.1157 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50 Suppl 1:S62-S69. doi: 10.1002/hast.1157.


PMID- 32597527
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50 Suppl 1
DP  - 2020 May
TI  - Disability and the Damaging Master Narrative of an Open Future.
PG  - S30-S36
LID - 10.1002/hast.1153 [doi]
AB  - It is sometimes argued that medical professionals should protect a future child's
      rights by prohibiting disabled parents from using technology to deliberately have
      a disabled child because disability is taken as an inevitable, severe threat to a
      child's otherwise "open" future. I will first argue that the open future that
      allegedly protects a child's future autonomy is precluded by the very conditions 
      needed to develop that future autonomy. Any child's future will be narrowed as
      they are socialized in a way that gives them the capacity for autonomous choice. 
      However, oppressive master narratives can diminish a future child's autonomy by
      distorting their narrative identity and constricting their agency. In fact, the
      open future argument does just this by advancing one of the most damaging master 
      narratives about disability: that disability inevitably and severely restricts a 
      person's autonomy and closes their future.
CI  - (c) 2020 The Hastings Center.
FAU - Stramondo, Joseph A
AU  - Stramondo JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Child
MH  - Choice Behavior
MH  - Disabled Children/*psychology
MH  - Humans
MH  - Parents
MH  - *Personal Autonomy
OTO - NOTNLM
OT  - disability
OT  - narrative ethics
OT  - narrative identity
OT  - open future
OT  - reproductive ethics
EDAT- 2020/07/01 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
AID - 10.1002/hast.1153 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50 Suppl 1:S30-S36. doi: 10.1002/hast.1153.


PMID- 32597525
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50 Suppl 1
DP  - 2020 May
TI  - Reading in the Postgenomic Age: On Contemporary Literature and the Good
      Bionarrative Citizen.
PG  - S37-S43
LID - 10.1002/hast.1154 [doi]
AB  - The "postgenomic age," whose start date roughly corresponds to the turn of the
      millennium, is characterized not only by the rapid development of genomic
      technologies and commercial products but also by the widespread publication of
      literary works focused on genomics and its cultural implications. Defining
      "postgenomic literature" as literature that is both of and about the postgenomic 
      age, this essay explores how works by nonfiction writer Rebecca Skloot and
      novelist Richard Powers exemplify a significant trend within the genre: the
      thematic exploration of ethical questions in the field of literature itself.
      While both authors address questions of medical and scientific ethics prompted by
      genomic research, with special emphasis on the exploitation of vulnerable
      populations, these questions lead readers directly to questions of narrative
      responsibility: who can tell whose story to whom-and for whose benefit? The
      Immortal Life of Henrietta Lacks and Generosity: An Enhancement, like other
      examples of postgenomic literature, invite readers to engage in critical reading 
      practices that resist both textual and genetic determinism.
CI  - (c) 2020 The Hastings Center.
FAU - Larkin, Lesley
AU  - Larkin L
LA  - eng
GR  - Northern Michigan University
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Genomics
MH  - *Publishing
MH  - *Science in Literature
OTO - NOTNLM
OT  - American literature
OT  - Henrietta Lacks
OT  - bioethics
OT  - medical racism
OT  - metafiction
OT  - postgenomic literature
EDAT- 2020/07/01 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
AID - 10.1002/hast.1154 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50 Suppl 1:S37-S43. doi: 10.1002/hast.1154.


PMID- 32597524
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50 Suppl 1
DP  - 2020 May
TI  - Coding the Self: The Infopolitics and Biopolitics of Genetic Sciences.
PG  - S6-S14
LID - 10.1002/hast.1150 [doi]
AB  - This essay compares three models for conceptualizing the political and ethical
      challenges of contemporary genetics, genomics, and postgenomics. The three
      analytical approaches are referred to as the state-politics model, the
      biopolitical model, and the infopolitical model. Each of these models is valuable
      for different purposes. In terms of their influence in contemporary discussions, 
      the first is by far the dominant approach, the second is gaining in importance,
      and the third is almost entirely neglected. The widespread neglect of the
      infopolitical dimensions of genetic sciences that are the focus of the third
      model is puzzling in light of the fact that genetics, genomics, and postgenomics 
      are all preeminent information sciences. The infopolitical model thus aims to
      bring into clearer view the specific political and ethical problems engendered by
      this informational nature of the genetic sciences. This model offers a way of
      understanding how ethically salient and politically fraught conceptual
      assumptions can be embedded in informational architectures such as algorithms and
      the formats (or data structures) upon which they rely.
CI  - (c) 2020 The Hastings Center.
FAU - Koopman, Colin
AU  - Koopman C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - *Bioethics
MH  - Genetic Code
MH  - Genomics/*ethics
MH  - Humans
MH  - Information Theory
MH  - Pedigree
MH  - *Politics
OTO - NOTNLM
OT  - algorithms
OT  - biopolitics
OT  - formats
OT  - genetics
OT  - genomics
OT  - infopolitics
OT  - information
EDAT- 2020/07/01 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
AID - 10.1002/hast.1150 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50 Suppl 1:S6-S14. doi: 10.1002/hast.1150.


PMID- 32597380
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Jun
TI  - Bioethics and Environmental Ethics: The Story of the Human Body as a Natural
      Ecosystem.
PG  - 91-97
LID - 10.1080/20502877.2020.1767919 [doi]
AB  - Is there a parallel between climate change and our body's temperature or
      non-compliance and failure to act on global warming? This paper proposes a model 
      which describes the human body as part of Nature's ecosystem. By utilising the
      power of observation to identify a problem, environmental and applied ethics can 
      guide action and instigate change, not only to change the predicted plot of
      climate change, but also the wellbeing of humans in life's story. Through a
      discussion on human autonomy and lessons learned from the past, earth's
      inhabitants can identify a balance between beneficence and non-maleficence for
      themselves and our planet.
FAU - Papalois, Zoe-Athena
AU  - Papalois ZA
AD  - King's College London Medical School, London, UK.
FAU - Papalois, Kyriaki-Barbara
AU  - Papalois KB
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - Beneficence
MH  - *Bioethical Issues
MH  - *Bioethics
MH  - Body Temperature
MH  - Climate Change
MH  - Ecology
MH  - *Ecosystem
MH  - Environment
MH  - *Environmental Health
MH  - *Global Warming
MH  - Health Promotion
MH  - *Human Body
MH  - Humans
MH  - Preventive Medicine
OTO - NOTNLM
OT  - Observational medicine
OT  - climate change
OT  - empirical bioethics
OT  - environmental theory
OT  - preventive health
OT  - responsibility
EDAT- 2020/07/01 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1080/20502877.2020.1767919 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Jun;26(2):91-97. doi: 10.1080/20502877.2020.1767919. Epub 2020
      Jun 27.


PMID- 32597343
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Jun
TI  - Going green: decreasing medical waste in a paediatric intensive care unit in the 
      United States.
PG  - 98-110
LID - 10.1080/20502877.2020.1767916 [doi]
AB  - The healthcare industry generates significant waste and carbon emissions that
      negatively impact the environment. Intensive care units (ICU) are a major
      contributor to the production of waste, due to patient complexity and needs
      requiring extensive equipment, cleaning practices and pre-emptive supplies. To
      quantify the extent of the problem, health care professionals collected all
      unused medical supplies destined to be discarded over three one-week periods in a
      paediatric intensive care unit, weighed the items, and created an inventory. This
      article argues for greener hospital standards and provides a specific example of 
      a project framework to reduce disposable waste with the hope that others can
      embark on similar initiatives for a more ethical and sustainable future for
      hospitals. Healthcare facilities must not just meet short-sighted safety
      standards of the now. In order to be a virtuous organization, one must consider
      all implications of daily decisions, including disposable supplies and cleaning.
FAU - Ghersin, Zelda J
AU  - Ghersin ZJ
AD  - Pediatric Critical Care Unit, Massachusetts General Hospital for Children,
      Harvard Medical School, Boston, MA, USA.
FAU - Flaherty, Michael R
AU  - Flaherty MR
AD  - Pediatric Critical Care Unit, Massachusetts General Hospital for Children,
      Harvard Medical School, Boston, MA, USA.
FAU - Yager, Phoebe
AU  - Yager P
AD  - Pediatric Critical Care Unit, Massachusetts General Hospital for Children,
      Harvard Medical School, Boston, MA, USA.
FAU - Cummings, Brian M
AU  - Cummings BM
AUID- ORCID: https://orcid.org/0000-0002-7701-9354
AD  - Pediatric Critical Care Unit, Massachusetts General Hospital for Children,
      Harvard Medical School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
RN  - 0 (Medical Waste)
SB  - IM
MH  - Adult
MH  - *Bioethical Issues
MH  - *Bioethics
MH  - Child
MH  - Delivery of Health Care/*ethics
MH  - *Environment
MH  - Equipment Reuse
MH  - Equipment and Supplies
MH  - *Hospitals, Pediatric
MH  - Humans
MH  - *Intensive Care Units, Pediatric
MH  - Medical Waste
MH  - Recycling
MH  - United States
MH  - Waste Management/*ethics/methods
OTO - NOTNLM
OT  - Green hospital teams
OT  - Medical waste
OT  - critical care units
OT  - reduction
OT  - sustainable healthcare
EDAT- 2020/07/01 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1080/20502877.2020.1767916 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Jun;26(2):98-110. doi: 10.1080/20502877.2020.1767916. Epub 2020 
      Jun 27.


PMID- 32597278
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 42
IP  - 1
DP  - 2020 Nov
TI  - Shear wave elastography findings in Immunoglobulin A Nephropathy patients: is it 
      more specific and sensitive for interstitial fibrosis or interstitial
      fibrosis/tubular atrophy?
PG  - 590-599
LID - 10.1080/0886022X.2020.1779087 [doi]
AB  - Background: Prediction of prognosis in Immunoglobulin A Nephropathy (IgAN) and
      taking appropriate precautions may reduce annual incidence of chronic kidney
      disease. This may be possible by close follow-up for the development and
      progression of interstitial fibrosis (IF) or interstitial fibrosis/tubular
      atrophy (IFTA) in IgAN patients.Aim: To investigate whether Young's elastic
      modulus (YM) which measured shear wave elastography (SWE) might be used for
      follow-up of IF or IFTA in IgAN patients.Methods: Prospective study was approved 
      by Human Research Ethics Committee. Group 1 consisted of patients with IgAN.
      Group 2 consisted of healthy control participants. Young's elastic modulus which 
      is a value of stiffness along with longitudinal stiffness was used to evaluate
      tissue elasticity. Specificity, sensitivity, positive predictive value (PPV) of
      YM for the presence of IF and IFTA were evaluated.Results: Group 1 consisted of
      30 participants, and group 2 consisted of 32 participants. Sensitivity and
      specificity of SWE to diagnose presence of IF for YM > 15 kPa were 89% and 90%,
      respectively. PPV among the ones whom IF was diagnosed by YM >15 kPa was 91%.
      Sensitivity and specificity of SWE to diagnose presence of IFTA for YM > 15 were 
      65% and 51%, respectively. PPV among the ones whom IFTA was diagnosed by YM >15
      kPa was 78.1%.Conclusions: YM which measured SWE is highly specific and sensitive
      in the diagnosis of IF, but not for IFTA in IgAN patients. Therefore, progression
      for IF in IgAN may be followed by SWE.
FAU - Turgutalp, Kenan
AU  - Turgutalp K
AUID- ORCID: http://orcid.org/0000-0003-0245-1844
AD  - Department of Internal Medicine, School of Medicine, Division of Nephrology,
      Mersin University, Mersin, Turkey.
FAU - Balci, Yuksel
AU  - Balci Y
AD  - Department of Radiology, School of Medicine, Mersin University, Mersin, Turkey.
FAU - Ozer, Caner
AU  - Ozer C
AD  - Department of Radiology, School of Medicine, Mersin University, Mersin, Turkey.
FAU - Bardak, Simge
AU  - Bardak S
AD  - Department of Nephrology, Lefkosa BN State Hospital, Lefkosa, Cyprus.
FAU - Gurses, Iclal
AU  - Gurses I
AD  - Department of Pathology Cerrahpasa School of Medicine, Istanbul University -
      Cerrahpasa, Istanbul, Turkey.
FAU - Karabulut, Yasemin
AU  - Karabulut Y
AD  - Department of Pathology, School of Medicine, Mersin University, Mersin, Turkey.
FAU - Helvaci, Ilter
AU  - Helvaci I
AD  - Department of Business Information and Biostatistic Management, Silifke School of
      Applied Technology and Management, Mersin University, Mersin, Turkey.
FAU - Dolarslan, Esra
AU  - Dolarslan E
AD  - Department of Internal Medicine, School of Medicine, Division of Nephrology,
      Mersin University, Mersin, Turkey.
FAU - Demir, Serap
AU  - Demir S
AD  - Department of Internal Medicine, School of Medicine, Division of Nephrology,
      Mersin University, Mersin, Turkey.
FAU - Kiykim, Ahmet
AU  - Kiykim A
AD  - Department of Internal Medicine, School of Medicine, Division of Nephrology,
      Mersin University, Mersin, Turkey.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
SB  - IM
MH  - Adult
MH  - Atrophy
MH  - Case-Control Studies
MH  - Elastic Modulus
MH  - *Elasticity Imaging Techniques
MH  - Female
MH  - Fibrosis
MH  - Glomerulonephritis, IGA/*classification/*diagnostic imaging/pathology
MH  - Humans
MH  - Kidney Tubules/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Sensitivity and Specificity
PMC - PMC7946010
OTO - NOTNLM
OT  - Immunoglobulin A Nephropathy; shear waveelastography; interstitial fibrosis
OT  - Young's Elastic Modulus
EDAT- 2020/07/01 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 10.1080/0886022X.2020.1779087 [doi]
PST - ppublish
SO  - Ren Fail. 2020 Nov;42(1):590-599. doi: 10.1080/0886022X.2020.1779087.


PMID- 32596970
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1099-1611 (Electronic)
IS  - 1057-9249 (Linking)
VI  - 29
IP  - 10
DP  - 2020 Oct
TI  - Sustaining factors, rewards, and challenges for psychologists providing clinical 
      care in psycho-oncology.
PG  - 1564-1570
LID - 10.1002/pon.5455 [doi]
AB  - OBJECTIVE: Many who choose to work in oncology manage an ongoing tension-the work
      is rewarding, yet simultaneously challenging. Given the need for psychosocial
      professionals to provide treatment for the increasing number of cancer survivors 
      in our aging society, it is important to consider what helps and hinders
      professionals in their work. Therefore, this study sought to understand the work 
      experiences of psychologists working in psycho-oncology, specifically clarifying 
      the rewards and challenges they experience as a result of their occupation.
      METHODS: Twenty psychologists with oncology work experience in the United States 
      completed semi-structured interviews; data were analyzed using the Consensual
      Qualitative Research method. RESULTS: In this paper, findings are presented for
      two of the domains that emerged from the data. In the domain of Sustaining
      Factors and Rewards, six themes were identified: (a) making a difference, (b)
      personal impact of the work on psychologists' lives and personal enrichment, (c) 
      sense of purpose and fit with the work, (d) important relationships, (e) unique
      aspects of psycho-oncology, and (f) benefits derived from the workplace. In the
      domain of Challenges, five themes were identified: (a) job-related challenges,
      (b) emotional intensity, (c) financial challenges, (d) ambiguity in professional 
      roles and psycho-oncology, and (e) ethical dilemmas. CONCLUSION: Psychologists
      employed in psycho-oncology found great meaning and purpose in their jobs, but
      also struggled with challenges related to the work and their workplaces. These
      findings can lead to better training, supervision, retention initiatives, and
      administrative policies to support productive employees.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Kracen, Amanda
AU  - Kracen A
AUID- ORCID: 0000-0001-8445-4007
AD  - Department of Psychology, Webster University, St. Louis, Missouri, USA.
FAU - Raque-Bogdan, Trisha L
AU  - Raque-Bogdan TL
AUID- ORCID: 0000-0002-9775-7725
AD  - University of Denver, Denver, Colorado, USA.
FAU - Taylor-Irwin, Nicole
AU  - Taylor-Irwin N
AUID- ORCID: 0000-0002-0481-5659
AD  - University of Denver, Denver, Colorado, USA.
FAU - Rowold, Hannah
AU  - Rowold H
AD  - Department of Psychology, Webster University, St. Louis, Missouri, USA.
AD  - Hannah Rowold is at MGH Institute of Health Professions, Boston, Massachusett,
      USA.
FAU - Nelson, Afton
AU  - Nelson A
AD  - Department of Psychology, Webster University, St. Louis, Missouri, USA.
AD  - Afton Nelson is at Ludwig Maximilians University, Munich, Germany.
FAU - Michl, Taylor
AU  - Michl T
AD  - Department of Psychology, Webster University, St. Louis, Missouri, USA.
FAU - Ross, Kaitlin V
AU  - Ross KV
AD  - University of Denver, Denver, Colorado, USA.
FAU - Engblom, Heather
AU  - Engblom H
AD  - Department of Psychology, Webster University, St. Louis, Missouri, USA.
AD  - Heather Engblom is at University of North Dakota, Grand Forks, North Dakota, USA.
FAU - Joseph, Ellen
AU  - Joseph E
AD  - University of Denver, Denver, Colorado, USA.
LA  - eng
PT  - Journal Article
DEP - 20200816
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
SB  - IM
MH  - Adult
MH  - Aged
MH  - Career Mobility
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - *Personal Satisfaction
MH  - *Psycho-Oncology
MH  - Psychology/*statistics & numerical data
MH  - Qualitative Research
MH  - *Reward
MH  - Workplace
OTO - NOTNLM
OT  - *cancer
OT  - *career development
OT  - *consensual qualitative research
OT  - *oncology
OT  - *psycho-oncology
OT  - *psychologists
OT  - *self-care
OT  - *training
EDAT- 2020/07/01 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/06/15 00:00 [revised]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1002/pon.5455 [doi]
PST - ppublish
SO  - Psychooncology. 2020 Oct;29(10):1564-1570. doi: 10.1002/pon.5455. Epub 2020 Aug
      16.


PMID- 32596915
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Communities Matter.
PG  - 63-64
LID - 10.1002/hast.1137 [doi]
AB  - Given the enduring inequities in US health and health care, it is no surprise
      that particular communities are bearing the disproportionate brunt of the
      Covid-19 pandemic and our responses to it. Many ethical aspects of the pandemic
      involve diverse communities bound by race, ethnicity, disability, income,
      residence, age, and more. How does bioethics engage these communities in theory
      and in practice? Only faintly, despite Covid-19's relentless reminder that
      communities matter morally. This article sketches initial directions for
      developing a community-inclusive bioethics, one that understands communities as
      critical moral participants in the work of bioethics as well as in health and
      health care.
CI  - (c) 2020 The Hastings Center.
FAU - Galarneau, Charlene
AU  - Galarneau C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Age Factors
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/ethnology/mortality
MH  - Health Services Accessibility/ethics
MH  - Humans
MH  - Morals
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/ethnology/mortality
MH  - Residence Characteristics/*statistics & numerical data
MH  - SARS-CoV-2
MH  - Social Capital
MH  - Socioeconomic Factors
MH  - United States/epidemiology
OTO - NOTNLM
OT  - Covid-19
OT  - bioethics
OT  - community
OT  - community justice
OT  - community-inclusive bioethics
OT  - justice
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1137 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):63-64. doi: 10.1002/hast.1137.


PMID- 32596911
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20211204
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - The Future of Bioethics: It Shouldn't Take a Pandemic.
PG  - 54-56
LID - 10.1002/hast.1133 [doi]
AB  - The Covid-19 pandemic has concentrated bioethics attention on the "lifeboat
      ethics" of rationing and fair allocation of scarce medical resources, such as
      testing, intensive care unit beds, and ventilators. This focus drives ethics
      resources away from persistent and systemic problems-in particular, the
      structural injustices that give rise to health disparities affecting
      disadvantaged communities of color. Bioethics, long allied with academic medicine
      and highly attentive to individual decision-making, has largely neglected its
      responsibility to address these difficult "upstream" issues. It is time to
      broaden our teaching, research, and practice to match the breadth of the field in
      order to help address these significant societal inequities and unmet health
      needs.
CI  - (c) 2020 The Hastings Center.
FAU - Churchill, Larry R
AU  - Churchill LR
FAU - King, Nancy M P
AU  - King NMP
FAU - Henderson, Gail E
AU  - Henderson GE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - Bioethics/*trends
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/ethics
MH  - Health Status Disparities
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Racial Groups
MH  - SARS-CoV-2
MH  - Social Justice/ethics
MH  - Socioeconomic Factors
OTO - NOTNLM
OT  - bioethics
OT  - health disparities
OT  - pandemic
OT  - social determinants of health
OT  - structural injustice
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1133 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):54-56. doi: 10.1002/hast.1133.


PMID- 32596910
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210115
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Dying during Covid-19.
PG  - 13-15
LID - 10.1002/hast.1122 [doi]
AB  - I had been on the phone with Madeleine's mother for fifteen minutes, and she had 
      sobbed throughout. She pleaded with me, "You won't even let our family visit her 
      together. If you really want to help my daughter, you will let us stay with her."
      Madeleine, who was twenty-four years old, was dying of end-stage acute myeloid
      leukemia and was intubated in one of our intensive care units. Her intensivist
      had requested a clinical ethics consultation for potentially inappropriate
      medical treatment-in my world of clinical ethics consultation, routine stuff.
      Except that, in March 2020, nothing was routine anymore. The Covid-19 pandemic
      calls for creative thinking about ad hoc and post hoc bereavement efforts, and it
      may result in efforts to revise existing accounts of what constitutes a good
      death in order to accommodate patients' and families' experiences at the end of
      life during a pandemic.
CI  - (c) 2020 The Hastings Center.
FAU - Moore, Bryanna
AU  - Moore B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
EIN - Hastings Cent Rep. 2020 Jul;50(4):47. PMID: 33448382
MH  - *Bereavement
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - *Death
MH  - Ethics Consultation
MH  - Family/*psychology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7361730
OTO - NOTNLM
OT  - Covid-19
OT  - bereavement
OT  - clinical ethics
OT  - end-of-life planning
OT  - palliative care
OT  - pandemic
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1122 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):13-15. doi: 10.1002/hast.1122.


PMID- 32596908
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Global Disparity and Solidarity in a Pandemic.
PG  - 65-67
LID - 10.1002/hast.1138 [doi]
AB  - While the domestic effect of structural racism and other social vulnerabilities
      on Covid-19 mortality in the United States has received some attention, there has
      been much less discussion (with some notable exceptions) of how structural global
      inequalities will further exacerbate Covid-related health disparity across the
      world. This may be partially due to the delayed availability of accurate and
      comparable data from overwhelmed systems, particularly in low- and middle-income 
      countries. However, early methods to procure and develop treatments and vaccines 
      by some high-income countries reflect ongoing protectionist and nationalistic
      attitudes that can systemically exclude access for people in regions with weaker 
      health systems. What's needed is a global coordinated effort, based on the
      principle of solidarity, to foster equitable health care access.
CI  - (c) 2020 The Hastings Center.
FAU - Ho, Anita
AU  - Ho A
FAU - Dascalu, Iulia
AU  - Dascalu I
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/mortality
MH  - Developing Countries
MH  - *Global Health
MH  - Health Services Accessibility/ethics/organization & administration
MH  - *Health Status Disparities
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/mortality
MH  - SARS-CoV-2
MH  - United States/epidemiology
PMC - PMC7362165
OTO - NOTNLM
OT  - Covid-19
OT  - disparity
OT  - global health
OT  - global health ethics
OT  - resource allocation
OT  - solidarity
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1138 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):65-67. doi: 10.1002/hast.1138.


PMID- 32596907
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Planetary Ethics: Russell Train and Richard Nixon at the Creation.
PG  - 23-24
LID - 10.1002/hast.1127 [doi]
AB  - This piece offers a retrospective review of a plenary speech at the 1969 Annual
      Meeting of the American Public Health Association by the leading environmentalist
      of the Nixon administration, attorney and judge Russell Train. Train's talk,
      titled "Prescription for a Planet," can be seen as an early argument for uniting 
      environmental health and public health as the two main determinants of both
      individual and population health and for the inclusion of these fields in the
      then-new field of "bioethics."
CI  - (c) 2020 The Hastings Center.
FAU - Annas, George J
AU  - Annas GJ
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Environmental Health/*ethics/*legislation & jurisprudence
MH  - History, 20th Century
MH  - *Public Health
MH  - Retrospective Studies
MH  - United States
PS  - Train R
FPS - Train, Russell
OTO - NOTNLM
OT  - bioethics
OT  - biology
OT  - climate change
OT  - ecology
OT  - environment
OT  - public health
EDAT- 2020/07/01 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1002/hast.1127 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):23-24. doi: 10.1002/hast.1127.


PMID- 32596905
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Our Next Pandemic Ethics Challenge? Allocating "Normal" Health Care Services.
PG  - 79-80
LID - 10.1002/hast.1145 [doi]
AB  - The pandemic creates unprecedented challenges to society and to health care
      systems around the world. Like all crises, these provide a unique opportunity to 
      rethink the fundamental limiting assumptions and institutional inertia of our
      established systems. These inertial assumptions have obscured deeply rooted
      problems in health care and deflected attempts to address them. As hospitals
      begin to welcome all patients back, they should resist the temptation to go back 
      to business as usual. Instead, they should retain the more deliberative,
      explicit, and transparent ways of thinking that have informed the development of 
      crisis standards of care. The key lesson to be learned from those exercises in
      rational deliberation is that justice must be the ethical foundation of all
      standards of care. Justice demands that hospitals take a safety-net approach to
      providing services that prioritizes the most vulnerable segments of society,
      continue to expand telemedicine in ways that improve access without exacerbating 
      disparities, invest in community-based care, and fully staff hospitals and
      clinics on nights and weekends.
CI  - (c) 2020 The Hastings Center.
FAU - Garrett, Jeremy R
AU  - Garrett JR
FAU - McNolty, Leslie Ann
AU  - McNolty LA
FAU - Wolfe, Ian D
AU  - Wolfe ID
FAU - Lantos, John D
AU  - Lantos JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/*ethics
MH  - Health Services Accessibility/ethics/organization & administration
MH  - Healthcare Disparities/ethics/organization & administration
MH  - Humans
MH  - Pandemics
MH  - Personnel Staffing and Scheduling/ethics/organization & administration
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Standard of Care/*ethics/organization & administration
MH  - Telemedicine/ethics/organization & administration
OTO - NOTNLM
OT  - Covid-19
OT  - crisis standard of care
OT  - justice
OT  - rationing
OT  - resource allocation
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1145 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):79-80. doi: 10.1002/hast.1145.


PMID- 32596904
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Interdependent Citizens: The Ethics of Care in Pandemic Recovery.
PG  - 56-58
LID - 10.1002/hast.1134 [doi]
AB  - The crisis of Covid-19 has forced us to notice two things: our human
      interdependence and American society's tolerance for what Nancy Krieger has
      called "inequalities embodied in health inequities," reflected in data on
      Covid-19 mortality and geographies. Care is integral to our recovery from this
      catastrophe and to the development of sustainable public health policies and
      practices that promote societal resilience and reduce the vulnerabilities of our 
      citizens. Drawing on the insights of Joan Tronto and Eva Feder Kittay, we argue
      that the ethics of care offers a critical alternative to utilitarian and
      deontological approaches and provides a street-ready framework for integration
      into public health deliberations to anchor public policy and investments
      concerning the recovery and future well-being of America's citizens and society.
CI  - (c) 2020 The Hastings Center.
FAU - Gary, Mercer
AU  - Gary M
FAU - Berlinger, Nancy
AU  - Berlinger N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Delivery of Health Care/*ethics
MH  - Health Personnel/*ethics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - United States/epidemiology
PMC - PMC7361911
OTO - NOTNLM
OT  - care ethics
OT  - care workers
OT  - health inequities
OT  - interdependence
OT  - pandemic
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1134 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):56-58. doi: 10.1002/hast.1134.


PMID- 32596903
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - The Hang Up.
PG  - 15-16
LID - 10.1002/hast.1123 [doi]
AB  - Over the past year, our ethics service has had numerous consultations involving
      patients who use the emergency department for regular dialysis. Sometimes, they
      have access to outpatient hemodialysis that they forgo; other times, they've been
      "fired" from this kind of outpatient facility, and so the ED is their last
      option. In most of these cases, we're called because the patient is disruptive
      once admitted to the ICU and behavior plans haven't helped. But the call from a
      resident this March 2020 morning was different, the patient had end-stage renal
      disease and often missed hemodialysis, but he wasn't disruptive. "It's just that 
      he comes in after using cocaine, and given scarcity with the coronavirus and ICU 
      beds...." I have come to think that this is one of the more insidious effects of 
      the pandemic: that there will be a resurgence of the view that some patients
      deserve health care by virtue of their compliant behavior and that those who are 
      nonadherent don't.
CI  - (c) 2020 The Hastings Center.
FAU - Sullivan, Laura Specker
AU  - Sullivan LS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cocaine-Related Disorders/epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - Emergency Service, Hospital/*ethics
MH  - Ethics Consultation
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - Kidney Failure, Chronic/epidemiology/*therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Renal Dialysis/*ethics/methods
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19
OT  - clinical ethics
OT  - duty to care
OT  - ethics consultation
OT  - patient noncompliance
OT  - scarce resources
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1123 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):15-16. doi: 10.1002/hast.1123.


PMID- 32596902
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Avoiding Ineffective End-of-Life Care: A Lesson from Triage?
PG  - 71-72
LID - 10.1002/hast.1141 [doi]
AB  - Ethicists and physicians all over the world have been working on triage protocols
      to plan for the possibility that the Covid-19 pandemic will result in shortages
      of intensive care unit beds, ventilators, blood products, or medications. In
      reflecting on those protocols, many health care workers have noticed that,
      outside the pandemic shortage situation, we routinely supply patients in the ICU 
      with invasive and painful care that will not help the patients survive even their
      hospitalization. This is the kind of pointless care that even the most basic
      protocol would triage against. Perhaps this widespread reflection on triage
      standards will draw our attention to our ongoing custom of supplying burdensome
      and inefficacious care to those near the end of life-care that most health care
      providers would not want for themselves. This essay argues that reflecting on
      triage could help us improve end-of-life care.
CI  - (c) 2020 The Hastings Center.
FAU - Latham, Stephen R
AU  - Latham SR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/*ethics/organization & administration
MH  - Humans
MH  - Intensive Care Units/*ethics/organization & administration
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Terminal Care/*ethics/organization & administration
MH  - Triage/*ethics/organization & administration
PMC - PMC7361385
OTO - NOTNLM
OT  - burdensome care
OT  - clinical ethics
OT  - end-of-life
OT  - triage
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1141 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):71-72. doi: 10.1002/hast.1141.


PMID- 32596901
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210409
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Rethinking "Elective" Procedures for Women's Reproduction during Covid-19.
PG  - 40-43
LID - 10.1002/hast.1130 [doi]
AB  - Common hospital and surgical center responses to the Covid-19 pandemic included
      curtailing "elective" procedures, which are typically determined based on
      implications for physical health and survival. However, in the focus solely on
      physical health and survival, procedures whose main benefits advance components
      of well-being beyond health, including self-determination, personal security,
      economic stability, equal respect, and creation of meaningful social
      relationships, have been disproportionately deprioritized. We describe how female
      reproduction-related procedures, including abortion, surgical sterilization,
      reversible contraception devices and in vitro fertilization, have been broadly
      categorized as "elective," a designation that fails to capture the value of these
      procedures or their impact on women's overall well-being. We argue that
      corresponding restrictions and delays of these procedures are problematically
      reflective of underlying structural views that marginalize women's rights and
      interests and therefore threaten to propagate gender injustice during the
      pandemic and beyond. Finally, we propose a framework for triaging
      reproduction-related procedures during Covid-19 that is more individualized,
      accounts for their significance for comprehensive well-being, and can be used to 
      inform resumption of operations as well as subsequent restriction phases.
CI  - (c) 2020 The Hastings Center.
FAU - Gross, Marielle S
AU  - Gross MS
FAU - Harrington, Bryna J
AU  - Harrington BJ
FAU - Sufrin, Carolyn B
AU  - Sufrin CB
FAU - Faden, Ruth R
AU  - Faden RR
LA  - eng
GR  - K23 DA045934/DA/NIDA NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Abortion, Induced/*ethics
MH  - Betacoronavirus
MH  - COVID-19
MH  - Contraception/*ethics
MH  - Coronavirus Infections/*epidemiology
MH  - Developing Countries
MH  - Elective Surgical Procedures/*ethics
MH  - Female
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Reproductive Rights/*ethics
MH  - SARS-CoV-2
MH  - Time Factors
MH  - Women's Health
PMC - PMC7362104
OTO - NOTNLM
OT  - abortion
OT  - assisted reproduction
OT  - elective surgery
OT  - reproductive ethics
OT  - well-being
OT  - women's reproduction
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1130 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):40-43. doi: 10.1002/hast.1130.


PMID- 32596899
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Disability Rights as a Necessary Framework for Crisis Standards of Care and the
      Future of Health Care.
PG  - 28-32
LID - 10.1002/hast.1128 [doi]
AB  - In this essay, we suggest practical ways to shift the framing of crisis standards
      of care toward disability justice. We elaborate on the vision statement provided 
      in the 2010 Institute of Medicine (National Academy of Medicine) "Summary of
      Guidance for Establishing Crisis Standards of Care for Use in Disaster
      Situations," which emphasizes fairness; equitable processes; community and
      provider engagement, education, and communication; and the rule of law. We argue 
      that interpreting these elements through disability justice entails a commitment 
      to both distributive and recognitive justice. The disability rights movement's
      demand "Nothing about us, without us" requires substantive inclusion of disabled 
      people in decision-making related to their interests, including in crisis
      planning before, during, and after a pandemic like Covid-19.
CI  - (c) 2020 The Hastings Center.
FAU - Guidry-Grimes, Laura
AU  - Guidry-Grimes L
FAU - Savin, Katie
AU  - Savin K
FAU - Stramondo, Joseph A
AU  - Stramondo JA
FAU - Reynolds, Joel Michael
AU  - Reynolds JM
FAU - Tsaplina, Marina
AU  - Tsaplina M
FAU - Burke, Teresa Blankmeyer
AU  - Burke TB
FAU - Ballantyne, Angela
AU  - Ballantyne A
FAU - Kittay, Eva Feder
AU  - Kittay EF
FAU - Stahl, Devan
AU  - Stahl D
FAU - Scully, Jackie Leach
AU  - Scully JL
FAU - Garland-Thomson, Rosemarie
AU  - Garland-Thomson R
FAU - Tarzian, Anita
AU  - Tarzian A
FAU - Dorfman, Doron
AU  - Dorfman D
FAU - Fins, Joseph J
AU  - Fins JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communication
MH  - Coronavirus Infections/*epidemiology
MH  - *Disabled Persons
MH  - Health Equity/*ethics/legislation & jurisprudence
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Social Justice/*ethics/legislation & jurisprudence
MH  - Standard of Care/*ethics/legislation & jurisprudence
OTO - NOTNLM
OT  - crisis standards of care
OT  - disability
OT  - equity
OT  - justice
OT  - pandemic ethics
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1128 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):28-32. doi: 10.1002/hast.1128.


PMID- 32596898
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Ventilators, Guidelines, Judgment, and Trust.
PG  - 5-6
LID - 10.1002/hast.1117 [doi]
AB  - Covid-19 confronts us with tragic choices, in which every option is unacceptable.
      On the New York State Task Force on Life and the Law, I worked on guidelines for 
      such situations. We did not envision the scale or character of Covid-19. To
      minimize fear that the decisions made in these situations might be unfair, we all
      must know what guidelines or mandates inform them. Only with transparency about
      how decisions will be made, by whom, and according to what requirements can we
      have confidence that fairness prevails. We now face many related questions about 
      process, goals, leadership, and trust. For example, how might ethical guidelines 
      evolve as scientific understanding advances? Should guidelines vary with
      different venues? And if, as I have argued, judgment is necessary even with the
      best of guidelines, how can we prepare clinicians to make good judgments? Are
      there implications for better training of personnel in nonemergency times for
      what they might face in the worst of times?
CI  - (c) 2020 The Hastings Center.
FAU - Gorovitz, Samuel
AU  - Gorovitz S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/ethics
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - Disaster Planning
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Judgment
MH  - Leadership
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*therapy
MH  - *Practice Guidelines as Topic
MH  - Respiration, Artificial/standards
MH  - SARS-CoV-2
MH  - Trust
PMC - PMC7361724
OTO - NOTNLM
OT  - Covid-19
OT  - decisions
OT  - guidelines
OT  - transparency
OT  - trust
OT  - ventilators
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1117 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):5-6. doi: 10.1002/hast.1117.


PMID- 32596896
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210115
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Black Lives in a Pandemic: Implications of Systemic Injustice for End-of-Life
      Care.
PG  - 58-60
LID - 10.1002/hast.1135 [doi]
AB  - In recent months, Covid-19 has devastated African American communities across the
      nation, and a Minneapolis police officer murdered George Floyd. The agents of
      death may be novel, but the phenomena of long-standing epidemics of premature
      black death and of police violence are not. This essay argues that racial health 
      and health care disparities, rooted as they are in systemic injustice, ought to
      carry far more weight in clinical ethics than they generally do. In particular,
      this essay examines palliative and end-of-life care for African Americans,
      highlighting the ways in which American medicine, like American society, has
      breached trust. In the experience of many African American patients struggling
      against terminal illness, health care providers have denied them a say in their
      own medical decision-making. In the midst of the Covid-19 pandemic, African
      Americans have once again been denied a say with regard to the rationing of
      scarce medical resources such as ventilators, in that dominant and ostensibly
      race-neutral algorithms sacrifice black lives. Is there such thing as a "good" or
      "dignified" death when African Americans are dying not merely of Covid-19 but of 
      structural racism?
CI  - (c) 2020 The Hastings Center.
FAU - Elbaum, Alan
AU  - Elbaum A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
EIN - Hastings Cent Rep. 2020 Jul;50(4):47. PMID: 33448380
MH  - *African Americans
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/ethics
MH  - Healthcare Disparities/ethics/*ethnology
MH  - Humans
MH  - Palliative Care/ethics/*organization & administration
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Racism
MH  - SARS-CoV-2
MH  - Social Determinants of Health/ethics/ethnology
MH  - Social Justice
MH  - Terminal Care/ethics/*organization & administration
MH  - Trust
MH  - United States/epidemiology
PMC - PMC7361345
OTO - NOTNLM
OT  - Black Lives Matter
OT  - health disparities
OT  - palliative care
OT  - rationing
OT  - structural racism
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1135 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):58-60. doi: 10.1002/hast.1135.


PMID- 32596895
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Learning from Covid.
PG  - 16-17
LID - 10.1002/hast.1124 [doi]
AB  - Mrs. Clark's case was an ordinary consult in an extraordinary time. She was
      refusing dialysis, but the psychiatric unit had concluded that she lacked
      capacity for such decision-making. The only difference between Mrs. Clark's
      current hospitalization and the last two was that it was April 2020 and a virus
      called Covid-19 had overtaken our hospital. As the chief of Montefiore Medical
      Center's bioethics service, when I received a consult before the virus, I always 
      saw the patient. Whether the patient had been in a vegetative state for a day or 
      for years, it didn't matter. I would lay my hand on a leg or an arm and observe. 
      But Covid-19 enforced physical boundaries between my team and our patients; I
      would not be able to meet Mrs. Clark. Our hospital responded to the attack on
      human connection by getting creative. We asked ourselves, which tools are still
      available to us? Answering this involved, in part, finding new ways for our team 
      of clinical ethicists to support the clinicians caring for Mrs. Clark.
CI  - (c) 2020 The Hastings Center.
FAU - Hulkower, Adira
AU  - Hulkower A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Ethics Consultation
MH  - Humans
MH  - Mental Competency/*psychology
MH  - Mental Disorders/*psychology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Renal Dialysis/ethics/methods
MH  - Renal Insufficiency, Chronic/therapy
MH  - SARS-CoV-2
MH  - *Social Media
OTO - NOTNLM
OT  - Covid-19
OT  - bioethics
OT  - clinical ethics consultation
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1124 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):16-17. doi: 10.1002/hast.1124.


PMID- 32596893
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Digital Contact Tracing, Privacy, and Public Health.
PG  - 43-46
LID - 10.1002/hast.1131 [doi]
AB  - Digital contact tracing, in combination with widespread testing, has been a focal
      point for many plans to "reopen" economies while containing the spread of
      Covid-19. Most digital contact tracing projects in the United States and Europe
      have prioritized privacy protections in the form of local storage of data on
      smartphones and the deidentification of information. However, in the
      prioritization of privacy in this narrow form, there is not sufficient attention 
      given to weighing ethical trade-offs within the context of a public health
      pandemic or to the need to evaluate safety and effectiveness of software-based
      technology applied to public health.
CI  - (c) 2020 The Hastings Center.
FAU - Martinez-Martin, Nicole
AU  - Martinez-Martin N
FAU - Wieten, Sarah
AU  - Wieten S
FAU - Magnus, David
AU  - Magnus D
FAU - Cho, Mildred K
AU  - Cho MK
LA  - eng
GR  - K01 MH118375/MH/NIMH NIH HHS/United States
GR  - Greenwall Foundation
GR  - 1R01HG010476/GF/NIH HHS/United States
GR  - K01 MH118375-01A1/NH/NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Contact Tracing/*ethics/*methods
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Mobile Applications
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - *Privacy
MH  - Public Health
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Smartphone/*ethics
PMC - PMC7361453
OTO - NOTNLM
OT  - Covid-19
OT  - contact tracing
OT  - digital health
OT  - public health
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1131 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):43-46. doi: 10.1002/hast.1131.


PMID- 32596892
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Realigning Pakistan's Bioethics Center during Covid-19.
PG  - 8-9
LID - 10.1002/hast.1120 [doi]
AB  - The arrival of the Covid-19 pandemic in Pakistan necessitated that the Centre of 
      Biomedical Ethics and Culture in Karachi realign its activities to changing
      realities in the country. As Pakistan's only bioethics center, and with no
      guidelines available for allocation of scarce medical resources, CBEC developed
      "Guidelines for Ethical Healthcare Decision-Making in Pakistan" with input from
      medical and civil society stakeholders. The CBEC blog connected to the center's
      bioethics programs for students from Pakistan and Kenya shifted to Covid-related 
      issues specific to the context of existing social and political realities within 
      these countries. As part of its outreach activities, CBEC initiated a popular
      Facebook series, #HumansofCovid, as an experience-sharing platform for health
      care professionals and members of the public. Narratives received vary from those
      by frustrated physicians under quarantine to those concerning street vendors left
      jobless and a transsexual person in whose opinion "social distancing" is not a
      new phenomenon for their communities.
CI  - (c) 2020 The Hastings Center.
FAU - Moazam, Farhat
AU  - Moazam F
FAU - Jafarey, Aamir
AU  - Jafarey A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Decision Making
MH  - Developing Countries
MH  - Humans
MH  - Pakistan/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
PMC - PMC7361414
OTO - NOTNLM
OT  - Covid narratives
OT  - Covid-19 guidelines
OT  - Pakistan and bioethics
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1120 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):8-9. doi: 10.1002/hast.1120.


PMID- 32596891
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210627
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - What Could "Fair Allocation" during the Covid-19 Crisis Possibly Mean in
      Sub-Saharan Africa?
PG  - 33-35
LID - 10.1002/hast.1129 [doi]
AB  - The Covid-19 pandemic has sparked rapid and voluminous production of bioethics
      commentary in popular media and academic publications. Many of the discussions
      are new twists on an old theme: how to fairly allocate scarce medical resources, 
      such as ventilators and intensive care unit beds. In this essay, we do not add
      another allocation scheme to the growing pile, partly out of appreciation that
      such schemes should be products of inclusive and transparent community engagement
      and partly out of recognition of their limited utility for physicians working in 
      the field. Instead, we make the more modest claim that context matters when
      making such decisions and, more specifically, that recommendations from
      high-income countries about fair allocation during Covid-19 should not be cut and
      pasted into low-income settings. We offer a few examples of why seemingly
      universal, well-intentioned ethical recommendations could have adverse
      consequences if unreflectively applied in sub-Saharan Africa.
CI  - (c) 2020 The Hastings Center.
FAU - Moodley, Keymanthri
AU  - Moodley K
FAU - Ravez, Laurent
AU  - Ravez L
FAU - Obasa, Adetayo Emmanuel
AU  - Obasa AE
FAU - Mwinga, Alwyn
AU  - Mwinga A
FAU - Jaoko, Walter
AU  - Jaoko W
FAU - Makindu, Darius
AU  - Makindu D
FAU - Behets, Frieda
AU  - Behets F
FAU - Rennie, Stuart
AU  - Rennie S
LA  - eng
GR  - D43 TW010511/TW/FIC NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
EIN - Hastings Cent Rep. 2021 Jul;51(4):6. PMID: 34106468
MH  - Africa South of the Sahara/epidemiology
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Communicable Disease Control/methods
MH  - Coronavirus Infections/*epidemiology/prevention & control/therapy
MH  - Decision Making
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control/therapy
MH  - *Poverty
MH  - SARS-CoV-2
PMC - PMC7362067
MID - NIHMS1712176
OTO - NOTNLM
OT  - Covid-19
OT  - fairness
OT  - scarce resources
OT  - sub-Saharan Africa
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1129 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):33-35. doi: 10.1002/hast.1129.


PMID- 32596890
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - The Ethics of Everyday Life in the Midst of a Pandemic.
PG  - 6-7
LID - 10.1002/hast.1118 [doi]
AB  - Elderly individuals are at higher risk of serious illness and death if they
      become infected by the coronavirus. During the current pandemic, my wife and I,
      at ages seventy-two and seventy-one, respectively, have been paying a person laid
      off from a job to purchase groceries-a practice that exposes the shopper to risk 
      of infection for our benefit. In this essay, I examine this practice with respect
      to the normative concepts of treating another person as a means, coercion,
      exploitation, and complicity.
CI  - (c) 2020 The Hastings Center.
FAU - Miller, Franklin G
AU  - Miller FG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Coercion
MH  - Coronavirus Infections/*epidemiology/psychology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/psychology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19
OT  - and complicity
OT  - coercion
OT  - exploitation
OT  - systemic injustice
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1118 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):6-7. doi: 10.1002/hast.1118.


PMID- 32596887
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - AI Surveillance during Pandemics: Ethical Implementation Imperatives.
PG  - 18-21
LID - 10.1002/hast.1125 [doi]
AB  - Artificial intelligence surveillance can be used to diagnose individual cases,
      track the spread of Covid-19, and help provide care. The use of AI for
      surveillance purposes (such as detecting new Covid-19 cases and gathering data
      from healthy and ill individuals) in a pandemic raises multiple concerns ranging 
      from privacy to discrimination to access to care. Luckily, there exist several
      frameworks that can help guide stakeholders, especially physicians but also AI
      developers and public health officials, as they navigate these treacherous
      shoals. While these frameworks were not explicitly designed for AI surveillance
      during a pandemic, they can be adapted to help address concerns regarding
      privacy, human rights, and due process and equality. In a time where the rapid
      implementation of all tools available is critical to ending a pandemic,
      physicians, public health officials, and technology companies should understand
      the criteria for the ethical implementation of AI surveillance.
CI  - (c) 2020 The Hastings Center.
FAU - Shachar, Carmel
AU  - Shachar C
FAU - Gerke, Sara
AU  - Gerke S
FAU - Adashi, Eli Y
AU  - Adashi EY
LA  - eng
GR  - Collaborative Research Program for Biomedical Innovation Law
GR  - NNF17SA0027784/Novo Nordisk Foundation
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Human Rights/ethics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Population Surveillance/*methods
MH  - Privacy
MH  - Racism/ethics
MH  - SARS-CoV-2
PMC - PMC7361418
OTO - NOTNLM
OT  - Covid-19
OT  - artificial intelligence
OT  - data privacy
OT  - equality
OT  - surveillance
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1125 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):18-21. doi: 10.1002/hast.1125.


PMID- 32596886
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Reassessing the Three Rs?
PG  - 75-76
LID - 10.1002/hast.1143 [doi]
AB  - In recent years, the established paradigm of the three Rs of animal
      research-refinement, replacement, and reduction-has come under scrutiny. A
      crucial weakness in use of the three Rs is uncertainty about how they should be
      prioritized. Events like pandemics have the power to alter the research
      landscape, fast-tracking innovation and setting new precedents. Existential
      threats can raise perceptions of social benefit and can lower animal-welfare
      thresholds. The rush to develop new research models may also undermine progress
      in reducing or replacing animal models. By circumventing the barrier posed by
      animal models that are poorly matched to human conditions, new technologies like 
      CRISPR can enhance the refinement component while undermining reduction and
      replacement. This pandemic has exposed the need for an urgent review of the
      efficacy of the three Rs, with the potential to establish a new set of protocols 
      for animal research, both inside and beyond the context of an emergency.
CI  - (c) 2020 The Hastings Center.
FAU - Challenger, Melanie
AU  - Challenger M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Animal Experimentation/*ethics
MH  - Animals
MH  - Models, Animal
OTO - NOTNLM
OT  - animal research
OT  - animal welfare
OT  - pandemic
OT  - research ethics
OT  - three Rs
EDAT- 2020/07/01 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 10.1002/hast.1143 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):75-76. doi: 10.1002/hast.1143.


PMID- 32596885
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Pandemics, Protocols, and the Plague of Athens: Insights from Thucydides.
PG  - 50-53
LID - 10.1002/hast.1132 [doi]
AB  - When confronted by the novel ethical challenges posed by a pandemic, it is
      helpful to turn to history for guidance and direction. In this essay, the author 
      revisits Thucydides's description of the Plague of Athens from The Peloponnesian 
      War as he considers the New York State Task Force on Life and the Law's 2015
      guidelines on ventilator allocation. Confronted by the exigencies of the Covid-19
      surge that struck New York, he questions the task force's decision not to give
      any degree of preference to health care workers who might become ill. He posits
      that they are due a compensatory ethic and some deference given the risks they
      have assumed, often with inadequate protective gear. Reflecting on his
      ambivalence, he asks if his change of heart reflects the impact of experiential
      learning or the erosion of nomos-or governing norms-described by Thucydides when 
      the plague struck Athens.
CI  - (c) 2020 The Hastings Center.
FAU - Fins, Joseph J
AU  - Fins JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Clinical Protocols/*standards
MH  - Coronavirus Infections/*epidemiology
MH  - Greece/epidemiology
MH  - *Health Personnel
MH  - Humans
MH  - New York City/epidemiology
MH  - Pandemics
MH  - Personal Protective Equipment/*supply & distribution
MH  - Plague/epidemiology
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19
OT  - New York Ventilator Allocation Guidelines
OT  - Plague of Athens
OT  - Thucydides
OT  - ethics
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1132 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):50-53. doi: 10.1002/hast.1132.


PMID- 32596884
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Walls.
PG  - 12-13
LID - 10.1002/hast.1121 [doi]
AB  - In a field that strives to care for patients and families together, what can
      palliative care clinicians do when patients' families are physically absent? The 
      Covid-19 pandemic has put both literal and figurative walls between health care
      professionals and families. How health care workers respond to these
      disconnections might have a lasting impact on patients, on families, and on our
      practice. Recently, I saw this in the case of a patient our palliative care team 
      was consulted to see. Mr. B was minimally responsive and dying from multisystem
      organ failure of unclear etiology. As in other cases during this pandemic, our
      team became a facilitator of interaction between the patient and the physically
      absent family, seeing an intimacy we normally would not, in this case, by being
      present while our intern held the phone to Mr. B's ear for an end-of-life call
      from his wife, son, and daughter. Such moments force us clinicians to be even
      more present for our families and patients, and they allow us to bear witness to 
      the strength and sadness and love that we might otherwise miss.
CI  - (c) 2020 The Hastings Center.
FAU - Hauser, Joshua M
AU  - Hauser JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Ethics Consultation
MH  - Family/*psychology
MH  - Humans
MH  - Palliative Care/*organization & administration/*psychology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Covid-19
OT  - clinical ethics
OT  - clinician-family relationship
OT  - end-of-life care
OT  - palliative care
OT  - patient-family relationship
EDAT- 2020/07/01 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1121 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):12-13. doi: 10.1002/hast.1121.


PMID- 32596866
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1365-2834 (Electronic)
IS  - 0966-0429 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Sep
TI  - Nursing and spirituality: A discussion paper on intertwining metaparadigms.
PG  - 1268-1274
LID - 10.1111/jonm.13076 [doi]
AB  - AIM: To explore connections between spiritual metaparadigm and the nursing
      metaparadigm and advocate for a progressive spiritualization of nursing
      management. BACKGROUND: Relationship between the spiritual holistic metaparadigm 
      of love, communion and gift and the holonic nursing metaparadigm of care,
      relationship and practice is not completely understood. METHOD: The construction 
      of a theoretical explanation on the basis of accumulated knowledge in the fields 
      of nursing and spirituality (especially Christian spirituality) for the purpose
      of constructing a meaningful description. RESULTS: Deep connectivity between the 
      elements of both metaparadigms: love and care, communion and relationship, and
      gift and practice. CONCLUSION: The connection between the spiritual and nursing
      metaparadigms is real in nursing education, practice and management because of
      the holistic character of spirituality. In collective intentions and cultural
      values are the main channels of interaction between the nursing and the spiritual
      metaparadigms. IMPLICATIONS FOR NURSING MANAGEMENT: Spirituality influences
      nursing management by, among other things, (a) providing meaning and purpose; (b)
      promoting cohesion in health communities; (c) fostering respect for ethics; (d)
      stimulating innovation; (e) encouraging leadership; and (f) illuminating the
      workplace.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Domingo-Osle, Marta
AU  - Domingo-Osle M
AUID- ORCID: https://orcid.org/0000-0002-3599-1794
AD  - Practical Teaching Unit, School of Nursing, University of Navarra Clinic,
      University of Navarra, Pamplona, Spain.
FAU - Domingo, Rafael
AU  - Domingo R
AUID- ORCID: https://orcid.org/0000-0003-0772-4661
AD  - Law and Religion, Emory University, Atlanta, GA, USA.
AD  - Institute of Culture and Society, University of Navarra, Pamplona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200714
PL  - England
TA  - J Nurs Manag
JT  - Journal of nursing management
JID - 9306050
MH  - Christianity
MH  - *Education, Nursing
MH  - *Holistic Nursing
MH  - Humans
MH  - Leadership
MH  - *Nursing Care
MH  - Spirituality
OTO - NOTNLM
OT  - care
OT  - communion
OT  - gift
OT  - holism
OT  - love
OT  - nursing management
OT  - relationship
OT  - spirituality
EDAT- 2020/07/01 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1111/jonm.13076 [doi]
PST - ppublish
SO  - J Nurs Manag. 2020 Sep;28(6):1268-1274. doi: 10.1111/jonm.13076. Epub 2020 Jul
      14.


PMID- 32596829
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20220731
IS  - 1399-3089 (Electronic)
IS  - 0908-665X (Linking)
VI  - 27
IP  - 5
DP  - 2020 Sep
TI  - How the COVID-19 pandemic may impact public support for clinical
      xenotransplantation in the United States?
PG  - e12623
LID - 10.1111/xen.12623 [doi]
AB  - Many patients who would undergo organ transplantation cannot proceed due to the
      inability of human organ donation to satisfy medical needs. Xenotransplantation
      has the potential to offer unlimited availability of pig organs for
      transplantation, and pig-to-non-human primate models have demonstrated outcomes
      that may soon justify clinical trials. However, one of the unique ethical
      challenges faced by xenotransplantation is that the risk of introducing potential
      zoonotic disease into the community must be weighed along with the benefit to the
      patient. While most experts believe that zoonosis is manageable, apprehension
      over disease transmission from animal donors to human recipients remains a
      frequent concern of many who are undecided or opposed to clinical
      xenotransplantation. The COVID-19 pandemic represents a scenario (rapid worldwide
      spread of a highly contagious novel zoonotic disease with no natural defense in
      humans) that would seem to justify apprehension, especially in the United States,
      which has largely avoided previous pandemic outbreaks. However, there are many
      differences between zoonosis found in the wild or after xenotransplantation that 
      favor the safety of the latter. Still, these differences, as well as the benefits
      of xenotransplantation, are not widely understood outside of the field. We must
      therefore ask what impact the COVID-19 pandemic will have on attitudes toward
      xenotransplantation.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Knoll, Michael F
AU  - Knoll MF
AD  - Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA,
      USA.
FAU - Cooper, David K C
AU  - Cooper DKC
AUID- ORCID: 0000-0002-8899-9431
AD  - Department of Surgery, Xenotransplantation Program, University of Alabama at
      Birmingham, Birmingham, AL, USA.
FAU - Bottino, Rita
AU  - Bottino R
AUID- ORCID: 0000-0003-1540-2996
AD  - Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA,
      USA.
AD  - Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA,
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200628
PL  - Denmark
TA  - Xenotransplantation
JT  - Xenotransplantation
JID - 9438793
SB  - IM
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/*complications
MH  - *Heterografts/virology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*complications
MH  - SARS-CoV-2
MH  - Tissue Donors/statistics & numerical data
MH  - Tissue and Organ Procurement/methods
MH  - *Transplantation, Heterologous/ethics
MH  - United States
PMC - PMC7361153
OTO - NOTNLM
OT  - *COVID-19
OT  - *PERV
OT  - *pandemic
OT  - *xenotransplantation
OT  - *zoonosis
EDAT- 2020/07/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1111/xen.12623 [doi]
PST - ppublish
SO  - Xenotransplantation. 2020 Sep;27(5):e12623. doi: 10.1111/xen.12623. Epub 2020 Jun
      28.


PMID- 32596393
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20220415
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Tripterygium wilfordii Hook F Treatment for Stage IV Diabetic Nephropathy:
      Protocol for a Prospective, Randomized Controlled Trial.
PG  - 9181037
LID - 10.1155/2020/9181037 [doi]
AB  - BACKGROUND: Diabetic nephropathy (DN) is a major cause of chronic kidney disease 
      (CKD). There are no effective treatments to prevent or reverse the progression of
      DN. A preliminary study showed that Tripterygium glycosides from Tripterygium
      wilfordii Hook F (TwHF) with valsartan decrease proteinuria in patients with DN. 
      OBJECTIVES: The objective of the present study is to investigate the efficacy and
      safety of Tripterygium glycosides from TwHF, a traditional Chinese medicine, for 
      the treatment of DN. Methods and Analysis. This is a prospective, single-center
      randomized controlled trial. Seventy participants diagnosed with DN were
      recruited and randomized 1 : 1 to two groups: (1) angiotensin receptor blocker
      (ARB) combined with TwHF and (2) ARB-only. The treatment period is 48 weeks. The 
      primary endpoint is 24 h proteinuria decreased level (reduction of 30% vs.
      baseline) after 48 weeks of treatment. The secondary endpoints are (1) all-cause 
      and cardiovascular-related mortality, (2) development of ESRD (serum creatinine >
      530.4 mumol/L or estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73
      m(2)), (3) the need for renal replacement therapy, and (4) increased serum
      creatinine (2-fold higher than the baseline value or >/=442 mumol/L, with
      confirmation of the initial results after 4 weeks). A health economics analysis
      will be carried out. Discussion. A meta-analysis of RCTs carried out in patients 
      with stage 4 (Mogensen classification) diabetic CKD showed that TwHF combined
      with an ARB was more effective than an ARB alone when considering 24 h
      proteinuria and serum albumin, but with an increase in adverse event (AE)
      frequency of 8%. This is a prospective clinical trial that may provide
      information on a safe and effective novel method for the treatment of DN,
      especially for patients with macroproteinuria. Ethics and Dissemination. The
      protocol is approved by the ethics committee of Beijing Hospital
      (2016BJYYEC-059-02). The results will be disseminated through peer-reviewed
      publications and international conferences. This trial is registered with
      ChiCTR-IOR-17010623.
CI  - Copyright (c) 2020 Xu Lengnan et al.
FAU - Lengnan, Xu
AU  - Lengnan X
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
FAU - Ban, Zhao
AU  - Ban Z
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
FAU - Haitao, Wang
AU  - Haitao W
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
FAU - Lili, Liu
AU  - Lili L
AUID- ORCID: https://orcid.org/0000-0002-4435-8552
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
FAU - Aiqun, Chen
AU  - Aiqun C
AUID- ORCID: https://orcid.org/0000-0003-4295-522X
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
FAU - Huan, Wang
AU  - Huan W
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
FAU - Ping, Zeng
AU  - Ping Z
AD  - The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of
      Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical
      Sciences, China.
FAU - Yonghui, Mao
AU  - Yonghui M
AUID- ORCID: https://orcid.org/0000-0002-1631-0885
AD  - Department of Nephrology, Beijing Hospital, National Center of Gerontology,
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200610
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetic Nephropathies/*drug therapy
MH  - Drugs, Chinese Herbal/pharmacology/*therapeutic use
MH  - Female
MH  - Glomerular Filtration Rate/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Renal Insufficiency, Chronic/*drug therapy
MH  - *Tripterygium
PMC - PMC7303734
COIS- All authors have completed the International Committee of Medical Journal Editors
      (ICMJE) uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and
      declare no support for the submitted work from any organization, no financial
      relationships with any organization that might have an interest in the submitted 
      work in the previous 3 years, and no other relationships or activities that could
      appear to have influenced the submitted work.
EDAT- 2020/07/01 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/06/30 06:00
PHST- 2019/10/23 00:00 [received]
PHST- 2020/03/21 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - 10.1155/2020/9181037 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Jun 10;2020:9181037. doi: 10.1155/2020/9181037. eCollection 
      2020.


PMID- 32596104
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2198-3844 (Print)
IS  - 2198-3844 (Linking)
VI  - 7
IP  - 12
DP  - 2020 Jun
TI  - Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine.
PG  - 1902552
LID - 10.1002/advs.201902552 [doi]
AB  - The development of clustered regularly interspaced short palindromic repeats
      (CRISPR) has spurred a successive wave of genome-engineering following zinc
      finger nucleases and transcription activator-like effector nucleases, and made
      gene-editing a promising strategy in the prevention and treatment of genetic
      diseases. However, gene-editing is not widely adopted in clinics due to some
      technical issues that challenge its safety and efficacy, and the lack of
      appropriate clinical regulations allowing them to advance toward improved human
      health without impinging on human ethics. By systematically examining the
      oncological applications of gene-editing tools and critical factors challenging
      their medical translation, genome-editing has substantial contributions to cancer
      driver gene discovery, tumor cell epigenome normalization, targeted delivery,
      cancer animal model establishment, and cancer immunotherapy and prevention in
      clinics. Gene-editing tools, epitomized by CRISPR, are predicted to represent a
      promising strategy toward the precise control of cancer initiation and
      development. However, some technical problems and ethical concerns are serious
      issues that need to be appropriately addressed before CRISPR can be incorporated 
      into the next generation of molecular precision medicine. In this light, new
      technical developments to limit off-target effects are discussed herein, and the 
      use of gene-editing approaches for treating otherwise incurable cancers is
      brought into focus.
CI  - (c) 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Dai, Xiaofeng
AU  - Dai X
AUID- ORCID: https://orcid.org/0000-0002-0006-4042
AD  - Wuxi School of Medicine Jiangnan University Wuxi 214122 China.
FAU - Blancafort, Pilar
AU  - Blancafort P
AD  - The Harry Perkins Institute of Medical Research Nedlands Western Australia 6009
      Australia.
AD  - School of Human Sciences The University of Western Australia Nedlands Western
      Australia 6009 Australia.
AD  - The Greehey Children's Cancer Research Institute The University of Texas Health
      Science Center at San Antonio San Antonio TX 78229 USA.
FAU - Wang, Peiyu
AU  - Wang P
AD  - Institute of Health and Biomedical Innovation Queensland University of Technology
      Brisbane Queensland 4059 Australia.
AD  - School of Biomedical Sciences Queensland University of Technology Brisbane
      Queensland 4059 Australia.
AD  - Translational Research Institute Woolloongabba Queensland 4102 Australia.
FAU - Sgro, Agustin
AU  - Sgro A
AD  - The Harry Perkins Institute of Medical Research Nedlands Western Australia 6009
      Australia.
AD  - School of Human Sciences The University of Western Australia Nedlands Western
      Australia 6009 Australia.
FAU - Thompson, Erik W
AU  - Thompson EW
AD  - Institute of Health and Biomedical Innovation Queensland University of Technology
      Brisbane Queensland 4059 Australia.
AD  - School of Biomedical Sciences Queensland University of Technology Brisbane
      Queensland 4059 Australia.
AD  - Translational Research Institute Woolloongabba Queensland 4102 Australia.
FAU - Ostrikov, Kostya Ken
AU  - Ostrikov KK
AD  - Translational Research Institute Woolloongabba Queensland 4102 Australia.
AD  - School of Chemistry and Physics Queensland University of Technology Brisbane
      Queensland 4000 Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200423
PL  - Germany
TA  - Adv Sci (Weinh)
JT  - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
JID - 101664569
PMC - PMC7312441
OTO - NOTNLM
OT  - CRISPR
OT  - genome-editing
OT  - precision medicine
OT  - transcription activator-like effector nucleases (TALENs)
OT  - zinc finger nucleases (ZFNs)
COIS- The authors declare no conflict of interest.
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/30 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2020/02/08 00:00 [revised]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - 10.1002/advs.201902552 [doi]
AID - ADVS1733 [pii]
PST - epublish
SO  - Adv Sci (Weinh). 2020 Apr 23;7(12):1902552. doi: 10.1002/advs.201902552.
      eCollection 2020 Jun.


PMID- 32596079
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 24
TI  - Colorectal Cancer Diagnosed During Pregnancy With Delayed Treatment.
PG  - e8261
LID - 10.7759/cureus.8261 [doi]
AB  - Colorectal cancer during pregnancy is rare. Because of a pattern of delay in
      childbearing and because colorectal cancer is now diagnosed more often in young
      adults, the incidence is expected to rise. Diagnosis during pregnancy is
      challenging as many of the symptoms mimic common pregnancy symptoms. Colonoscopy 
      is the gold standard for diagnosis, but pregnancy is a relative contraindication 
      to colonoscopy. Once diagnosed, pregnant women often have more advanced disease. 
      Due to its rarity, treatment is often based on case reports and limited studies. 
      A multidisciplinary team is important in the optimization of treatment. We
      present a case of a 29-year-old African-American primigravid with chronic
      gastrointestinal symptoms diagnosed with colorectal adenocarcinoma at 17 weeks of
      gestation. She delayed surgical intervention for several weeks due to fear of
      miscarriage, and ultimately underwent exploratory laparotomy with hemicolectomy
      and colostomy placement at 20 weeks. Abdominal ultrasound and magnetic resonance 
      imaging revealed non-specific hepatic lesions concerning for metastatic disease, 
      but the patient refused biopsy due to concern for radiation harm to the fetus.
      Chemotherapy was considered, but postponed until the postpartum period, for fear 
      of fetal harm. Computed tomography imaging after delivery noted an increased
      number of hepatic lesions, representing progression of her disease. She received 
      two rounds of chemotherapy in the postpartum period, but remained non-compliant
      with treatment recommendations and ultimately was lost to follow-up. This case
      presents a delayed diagnosis of colorectal cancer in pregnancy, as well as
      delayed treatment due to concerns for fetal harm with current therapies. It
      emphasizes the diagnostic challenges and the complexity and ethical issues
      involved when a pregnant patient faces a life-threatening terminal illness. This 
      case adds to the growing body of literature on colorectal cancer in pregnancy and
      highlights the importance of clinical suspicion, informed patient centered
      decision making, and tailored treatment goals.
CI  - Copyright (c) 2020, Cao et al.
FAU - Cao, Suzanne
AU  - Cao S
AD  - Department of Women's Health, Arrowhead Regional Medical Center, Colton, USA.
FAU - Okekpe, C Camille
AU  - Okekpe CC
AD  - Department of Women's Health, Arrowhead Regional Medical Center, Colton, USA.
FAU - Dombrovsky, Inessa
AU  - Dombrovsky I
AD  - Department of Women's Health, Arrowhead Regional Medical Center, Colton, USA.
FAU - Valenzuela, Guillermo J
AU  - Valenzuela GJ
AD  - Department of Women's Health, Arrowhead Regional Medical Center, Colton, USA.
FAU - Roloff, Kristina
AU  - Roloff K
AD  - Obstetrics and Gynecology, Arrowhead Regional Medical Center, Colton, USA.
LA  - eng
PT  - Case Reports
DEP - 20200524
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7313435
OTO - NOTNLM
OT  - colorectal cancer
OT  - high-risk pregnancy
OT  - treatment choices
OT  - treatment dilemma
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - 10.7759/cureus.8261 [doi]
PST - epublish
SO  - Cureus. 2020 May 24;12(5):e8261. doi: 10.7759/cureus.8261.


PMID- 32595586
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Epigenetic Effects on Pediatric Traumatic Brain Injury Recovery (EETR): An
      Observational, Prospective, Longitudinal Concurrent Cohort Study Protocol.
PG  - 460
LID - 10.3389/fneur.2020.00460 [doi]
AB  - Introduction: Unexplained heterogeneity in outcomes following pediatric traumatic
      brain injury (TBI) is one of the most critical barriers to the development of
      effective prognostic tools and therapeutics. The addition of personal biological 
      factors to our prediction models may account for a significant portion of
      unexplained variance and advance the field toward precision rehabilitation
      medicine. The overarching goal of the Epigenetic Effects on Pediatric Traumatic
      Brain Injury Recovery (EETR) study is to investigate an epigenetic biomarker
      involved in both childhood adversity and postinjury neuroplasticity to better
      understand heterogeneity in neurobehavioral outcomes following pediatric TBI. Our
      primary hypothesis is that childhood adversity will be associated with worse
      neurobehavioral recovery in part through an epigenetically mediated reduction in 
      brain-derived neurotrophic factor (BDNF) expression in response to TBI. Methods
      and analysis: EETR is an observational, prospective, longitudinal concurrent
      cohort study of children aged 3-18 years with either TBI (n = 200) or orthopedic 
      injury (n = 100), recruited from the UPMC Children's Hospital of Pittsburgh.
      Participants complete study visits acutely and at 6 and 12 months postinjury.
      Blood and saliva biosamples are collected at all time points-and cerebrospinal
      fluid (CSF) when available acutely-for epigenetic and proteomic analysis of BDNF.
      Additional measures assess injury characteristics, pre- and postinjury child
      neurobehavioral functioning, childhood adversity, and potential
      covariates/confounders. Recruitment began in July 2017 and will occur for ~6
      years, with data collection complete by mid-2023. Analyses will characterize BDNF
      DNA methylation and protein levels over the recovery period and investigate this 
      novel biomarker as a potential biological mechanism underlying the known
      association between childhood adversity and worse neurobehavioral outcomes
      following pediatric TBI. Ethics and dissemination: The study received ethics
      approval from the University of Pittsburgh Institutional Review Board.
      Participants and their parents provide informed consent/assent. Research findings
      will be disseminated via local and international conference presentations and
      manuscripts submitted to peer-reviewed journals. Trial Registration: The study is
      registered with clinicaltrials.org (ClinicalTrials.gov Identifier: NCT04186429).
CI  - Copyright (c) 2020 Treble-Barna, Patronick, Uchani, Marousis, Zigler, Fink,
      Kochanek, Conley and Yeates.
FAU - Treble-Barna, Amery
AU  - Treble-Barna A
AD  - Department of Physical Medicine and Rehabilitation, University of Pittsburgh
      School of Medicine, Pittsburgh, PA, United States.
FAU - Patronick, Jamie
AU  - Patronick J
AD  - Department of Physical Medicine and Rehabilitation, University of Pittsburgh
      School of Medicine, Pittsburgh, PA, United States.
FAU - Uchani, Srivatsan
AU  - Uchani S
AD  - Department of Physical Medicine and Rehabilitation, University of Pittsburgh
      School of Medicine, Pittsburgh, PA, United States.
FAU - Marousis, Noelle C
AU  - Marousis NC
AD  - Department of Physical Medicine and Rehabilitation, University of Pittsburgh
      School of Medicine, Pittsburgh, PA, United States.
FAU - Zigler, Christina K
AU  - Zigler CK
AD  - Department of Population Health Sciences, Duke University School of Medicine,
      Durham, NC, United States.
FAU - Fink, Ericka L
AU  - Fink EL
AD  - Safar Center for Resuscitation Research, Division of Pediatric Critical Care
      Medicine, UPMC Children's Hospital of Pittsburgh, Department of Critical Care and
      Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United
      States.
FAU - Kochanek, Patrick M
AU  - Kochanek PM
AD  - Safar Center for Resuscitation Research, Division of Pediatric Critical Care
      Medicine, UPMC Children's Hospital of Pittsburgh, Department of Critical Care and
      Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United
      States.
FAU - Conley, Yvette P
AU  - Conley YP
AD  - Department of Health Promotion and Development, School of Nursing, University of 
      Pittsburgh, Pittsburgh, PA, United States.
FAU - Yeates, Keith Owen
AU  - Yeates KO
AD  - Department of Psychology, Alberta Children's Hospital Research Institute,
      Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04186429
GR  - K01 HD097030/HD/NICHD NIH HHS/United States
GR  - KL2 TR001856/TR/NCATS NIH HHS/United States
GR  - T32 HD040686/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200612
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7303323
OTO - NOTNLM
OT  - brain-derived neurotrophic factor
OT  - childhood adversity
OT  - epigenetics
OT  - precision medicine
OT  - traumatic brain injury
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/30 06:00
PHST- 2019/12/08 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - 10.3389/fneur.2020.00460 [doi]
PST - epublish
SO  - Front Neurol. 2020 Jun 12;11:460. doi: 10.3389/fneur.2020.00460. eCollection
      2020.


PMID- 32595168
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Development of a core outcome set to use in the research and assessment of
      malignant bowel obstruction: protocol for the RAMBO study.
PG  - e039154
LID - 10.1136/bmjopen-2020-039154 [doi]
AB  - INTRODUCTION: Studies regarding the management of malignant bowel obstruction
      (MBO) report conflicting findings. This is partly due to different outcome
      measures being used to evaluate severity of MBO and the response to treatments.
      Furthermore, current outcome measures focus mainly on measurable physiological
      parameters which may not correlate strongly with patient-defined quality of life.
      The development of core outcome sets allows a consistent approach to evaluating
      clinical conditions taking into consideration patient, healthcare professional
      and researcher viewpoints. It follows an internationally recognised standard
      methodology. We present a protocol for the development of a core outcome set for 
      Research and Assessment of MBO (RAMBO). METHODS: RAMBO is a multicentre study,
      comprising of four phases: a systematic review to examine current scope of
      outcome measures associated with MBO (phase I). Interviews with patients,
      companions and healthcare professionals will explore priorities and preferences
      for care and outcomes (phase II). An expert panel meeting will collate the
      findings into a set of outcomes (phase III), refined by consensus through a
      Delphi survey with key stakeholders (phase IV). The final set of outcomes will be
      ratified at a consensus meeting. Each step will actively include patient
      partners. Thematic analysis and descriptive statistics will be used to analyse
      qualitative and quantitative data, respectively. ETHICS AND DISSEMINATION:
      Ethical approval was obtained (Wales REC 5, REF: 19/LO/1876). Study participants 
      and relevant stakeholders will be updated with newsletters and a lay summary at
      the end of the study. Abstracts will be submitted to national and international
      conferences, result papers will be submitted to peer-reviewed, open access
      journals. TRIAL AND PROSPERO REGISTRATION NUMBERS: Core Outcome Measures in
      Effectiveness Trials (1402); Systematic Literature Review (CRD42019150648); Rapid
      Review (CRD42020176393).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Baddeley, Elin
AU  - Baddeley E
AUID- ORCID: 0000-0002-7571-4820
AD  - Marie Curie Palliative Care Research Centre, Cardiff University School of
      Medicine, Cardiff, UK baddeleye1@cardiff.ac.uk.
FAU - Bravington, Alison
AU  - Bravington A
AD  - Wolfson Palliative Care Research Centre, Hull York Medical School, Hull, UK.
FAU - Johnson, Miriam
AU  - Johnson M
AD  - Wolfson Palliative Care Research Centre, Hull York Medical School, Hull, UK.
FAU - Currow, David C
AU  - Currow DC
AD  - Wolfson Palliative Care Research Centre, Hull York Medical School, Hull, UK.
AD  - University of Technology Sydney, Sydney, New South Wales, Australia.
FAU - Murtagh, Fliss Em
AU  - Murtagh FE
AD  - Wolfson Palliative Care Research Centre, Hull York Medical School, Hull, UK.
FAU - Boland, Elaine
AU  - Boland E
AD  - Queen's Centre for Oncology and Haematology, Hull, UK.
FAU - Obita, George
AU  - Obita G
AD  - Dove House Hospice, Hull, UK.
FAU - Nelson, Annmarie
AU  - Nelson A
AD  - Marie Curie Palliative Care Research Centre, Cardiff University School of
      Medicine, Cardiff, UK.
FAU - Seddon, Kathy
AU  - Seddon K
AD  - Marie Curie Palliative Care Research Centre, Cardiff University School of
      Medicine, Cardiff, UK.
FAU - Oliver, Alfred
AU  - Oliver A
AD  - Consumer Liaison Group, National Cancer Research Institute, London, UK.
AD  - Trans-Humber Consumer Research Panel, Hull, UK.
FAU - Noble, Simon
AU  - Noble S
AD  - Marie Curie Palliative Care Research Centre, Cardiff University School of
      Medicine, Cardiff, UK.
FAU - Boland, Jason
AU  - Boland J
AUID- ORCID: 0000-0001-5272-3057
AD  - Wolfson Palliative Care Research Centre, Hull York Medical School, Hull, UK.
LA  - eng
GR  - MCCC-FCO-11-C/MCCC_/Marie Curie/United Kingdom
GR  - MCRGS-20171220-8020/MCCC_/Marie Curie/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delphi Technique
MH  - Humans
MH  - Intestinal Neoplasms/*pathology/therapy
MH  - Intestinal Obstruction/*pathology/therapy
MH  - Multicenter Studies as Topic
MH  - Outcome Assessment, Health Care
MH  - Quality of Life
MH  - Research Design
MH  - Stakeholder Participation
MH  - Systematic Reviews as Topic
MH  - United Kingdom
PMC - PMC7322279
OTO - NOTNLM
OT  - *adult palliative care
OT  - *gastroenterology
OT  - *oncology
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-039154 [pii]
AID - 10.1136/bmjopen-2020-039154 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e039154. doi: 10.1136/bmjopen-2020-039154.


PMID- 32595165
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Generic outcome set for the international registry on Laser trEAtments in
      Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to
      measure.
PG  - e038145
LID - 10.1136/bmjopen-2020-038145 [doi]
AB  - INTRODUCTION: While laser technology has expanded the armamentarium of treatment 
      for various skin diseases during the past years, heterogeneity in study outcomes 
      hampers comparability and appropriate evidence synthesis. Part of these issues
      can be addressed by developing a generic outcome set. Using the Delphi method,
      this study aims to seek consensus between key stakeholders on relevant generic
      outcomes (what to measure) for implementation in the international registry on
      Laser trEAtments in Dermatology (LEAD). The registry is focused on collecting
      research data on various laser treatments for skin disorders. METHODS AND
      ANALYSIS: By reviewing the literature and involvement of key stakeholder groups
      and adult patients in need or after laser surgery and health professionals, a
      preliminary list of outcomes will be generated and categorised into domains.
      Using these outcomes, an international three-round Delphi study will be performed
      to rate the importance of outcomes in the selection of a generic outcome set.
      Participants are allowed to provide new outcomes to the preliminary list for
      revisions during the first Delphi round. Finally, results will be discussed
      during a consensus meeting to agree on generic outcomes to be used in the LEAD
      registry. ETHICS AND DISSEMINATION: An ethics approval was not applicable
      (W19_290 # 18.336). The study is registered with the Cochrane Skin Core OUtcome
      Set INitiative) and the Core Outcome Measures in Effectiveness Trials initiative.
      Procedures will be conducted according to the Declaration of Helsinki. The
      findings will be disseminated through peer-reviewed publications and conference
      presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fransen, Frederike
AU  - Fransen F
AUID- ORCID: 0000-0003-0550-7970
AD  - Dermatology, Amsterdam UMC, Amsterdam, Noord-Holland, The Netherlands
      frederikefransen@gmail.com m-alam@northwestern.edu.
FAU - Spuls, Phyllis
AU  - Spuls P
AD  - Dermatology, Amsterdam UMC, Amsterdam, Noord-Holland, The Netherlands.
AD  - Department of Dermatology, Amsterdam Public Health, Infection and Immunity,
      Amsterdam University Medical Center, Amsterdam, The Netherlands.
FAU - Alam, Murad
AU  - Alam M
AD  - Department of Dermatology, Feinberg School of Medicine, Northwestern University, 
      Chicago, Illinois (IL), United States frederikefransen@gmail.com
      m-alam@northwestern.edu.
AD  - Department of Dermatology, Northwestern Memorial Hospital, Arkes Family Pavilion,
      Chicago, Illinois (IL), United States.
FAU - Badawi, Ashraf
AU  - Badawi A
AD  - Dermatology Unit, Department of Medical Applications of Lasers, National
      Institute of Laser Enhanced Sciences, Cairo University, Giza, Egypt.
FAU - Boixeda, Pablo
AU  - Boixeda P
AD  - Dermatology Department, Ramon y Cajal Hospital, Madrid, Spain.
FAU - Haedersdal, Merete
AU  - Haedersdal M
AD  - Dermatology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.
AD  - Massachusetts General Hospital, Harvard Medical School Boston, Boston, United
      States.
FAU - Hamzavi, Iltefat
AU  - Hamzavi I
AD  - Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA.
FAU - Hedelund, Lene
AU  - Hedelund L
AD  - Dermatology, Aarhus Universitetshospital, Aarhus, Denmark.
FAU - Kelly, Kristen M
AU  - Kelly KM
AD  - Beckman Laser Institute, University of California, Irvine, California, USA.
FAU - Kono, Tara
AU  - Kono T
AD  - Department of Plastic and Reconstructive Surgery, Tokai University School of
      Medicine, Isehera, Japan.
FAU - Laubach, Hans Joachim
AU  - Laubach HJ
AD  - Dermatology and Venereology, Hopitaux Universitaires de Geneve, Geneva,
      Switzerland.
FAU - Manuskiatti, Woraphong
AU  - Manuskiatti W
AD  - Faculty of Medicine Siriraj Hospital, Department of Dermatology, Mahidol
      University, Bangkok, Thailand.
FAU - Marini, Leonardo
AU  - Marini L
AD  - Dermatology, SDC-The Skin Doctors' Center, Trieste, Italy.
FAU - Nouri, Keyvan
AU  - Nouri K
AD  - Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami,
      Florida, USA.
FAU - Paasch, Uwe
AU  - Paasch U
AD  - University of Leipzig, Leipzig, UK.
FAU - Passeron, Thierry
AU  - Passeron T
AD  - Dermatology, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Cote 
      d'Azu, France.
FAU - Prinsen, Cecilia A C Sanna
AU  - Prinsen CACS
AD  - Department of Epidemiology and Biostatistics, Amsterdam Public Health research
      institute, Amsterdam UMC, VU University Medical Center, Amsterdam, The
      Netherlands.
FAU - Verner, Ines
AU  - Verner I
AD  - Dermatology, Verner clinic, Tel Aviv, Israel.
FAU - Wolkerstorfer, Albert
AU  - Wolkerstorfer A
AD  - Dermatology, Amsterdam UMC, Amsterdam, Noord-Holland, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Consensus
MH  - Delphi Technique
MH  - Dermatology/*methods
MH  - Humans
MH  - Laser Therapy/*methods
MH  - Outcome Assessment, Health Care
MH  - Registries
MH  - Research Design
MH  - Stakeholder Participation
PMC - PMC7322331
OTO - NOTNLM
OT  - *dermatology
OT  - *laser therapy
OT  - *surgical dermatology
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038145 [pii]
AID - 10.1136/bmjopen-2020-038145 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e038145. doi: 10.1136/bmjopen-2020-038145.


PMID- 32595162
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Systematic review protocol examining sex differences in survival among low
      birthweight newborns and infants in sub-Saharan Africa.
PG  - e036645
LID - 10.1136/bmjopen-2019-036645 [doi]
AB  - INTRODUCTION: In sub-Saharan African countries, low birthweight (LBW) accounts
      for three-quarters of under-five mortality and morbidity. However, there is no
      systematic evidence of sex differences in LBW survival risk. The aim of this
      protocol is to outline the methodological process of a systematic review that
      will gather qualitative and quantitative data on sex differences in survival
      among LBW newborns and infants in sub-Saharan Africa. METHODS: This protocol
      adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis 
      Protocols reporting guidelines. We will conduct a systematic review to retrieve
      all qualitative and quantitative studies. Electronic search strategies are being 
      finalised on 24 February 2020 for Ovid Medline and EMBASE, and on 28 February
      2020 for CINAHL, Scopus and Global Health in collaboration with a Health Sciences
      librarian. The primary outcome of interest is indicating sex differences in
      survival among LBW newborns and infants. Secondary outcomes are sex-disaggregated
      differences in morbidity among LBW newborns and infants. Screening, data
      extraction and assessments of risk of bias will be performed independently.
      Narrative synthesis and a meta-analysis will be conducted with studies that are
      compatible based on population and outcome. The systematic review is focused on
      the analysis of secondary data and does not require ethics approval. ETHICS AND
      DISSEMINATION: As it will be a systematic review, without human participants'
      involvement, there will be no requirement for ethical approval. The systematic
      review will present key evidence of sex-disaggregated differences in mortality
      and morbidity among LBW newborns and infants in sub-Saharan Africa. Programme
      managers, policy-makers and researchers can use the findings to evaluate LBW
      health outcomes in different sexes. The final manuscript will be disseminated
      through a peer-reviewed journal and scientific conferences. PROSPERO REGISTRATION
      NUMBER: CRD42020163470.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gebremeskel, Akalewold T
AU  - Gebremeskel AT
AD  - School of International Development and Global Studies, Faculty of Social
      Sciences, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Fantaye, Arone W
AU  - Fantaye AW
AD  - Interdisciplinary School of Health Sciences, Faculty of Health Sciences,
      University of Ottawa, Ottawa, Ontario, Canada.
FAU - Faust, Lena E
AU  - Faust LE
AD  - Department of Epidemiology, Biostatistics and Occupational Health, Faculty of
      Medicine, McGill University, Montreal, Ontario, Canada.
FAU - Yaya, Sanni
AU  - Yaya S
AUID- ORCID: 0000-0002-4876-6043
AD  - School of International Development and Global Studies, Faculty of Social
      Sciences, University of Ottawa, Ottawa, Ontario, Canada sanni.yaya@uOttawa.ca.
AD  - The George Institute for Global Health, University of Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - Birth Weight
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant Mortality/*trends
MH  - *Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Male
MH  - Research Design
MH  - *Sex Characteristics
MH  - Systematic Reviews as Topic
PMC - PMC7322278
OTO - NOTNLM
OT  - *community child health
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036645 [pii]
AID - 10.1136/bmjopen-2019-036645 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e036645. doi: 10.1136/bmjopen-2019-036645.


PMID- 32595161
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Service users' experiences of contacting NHS patient medicines helpline services:
      a qualitative study.
PG  - e036326
LID - 10.1136/bmjopen-2019-036326 [doi]
AB  - OBJECTIVES: Patient medicines helpline services (PMHS) are available from some
      National Health Service (NHS) Trusts in the UK to provide medicines information
      to hospital patients and carers. To date, studies of PMHS have examined the views
      of service users via satisfaction surveys. This study used qualitative methods to
      explore service users' experiences of using a PMHS, including perceived benefits 
      and areas for improvement. DESIGN: Qualitative, using semi-structured interviews.
      SETTING: This study was conducted across seven NHS Trusts in England.
      PARTICIPANTS: Forty users of PMHS were individually interviewed over the
      telephone. Interviews were audio-recorded, transcribed verbatim and analysed
      using Braun and Clarke's inductive reflexive thematic analysis. Ethical approval 
      was obtained before study commencement. RESULTS: Participants predominantly
      called a PMHS for themselves (82%; carers: 18%). Two main themes were generated. 
      Theme 1: timeliness-PMHS provide support during the uncertain transition of care 
      period from hospital to home, when patients and carers often feel vulnerable
      because support is less available. PMHS met service users' needs for timely and
      easily accessible support, and quick resolution of their issues. PMHS could be
      improved with staffing beyond typical work week hours, and by having staff
      available to answer calls instead of using an answerphone. Theme 2: PMHS are
      best-placed to help-PMHS were perceived as best-placed to answer enquiries that
      arose from hospital care. Service users felt reassured from speaking to pharmacy 
      professionals, and PMHS were perceived as the optimal service in terms of
      knowledge and expertise regarding medicines-related questions. However, several
      participants were initially unaware that their PMHS existed. CONCLUSIONS: PMHS
      are perceived to be a valuable means of accessing timely medicines-related
      support when patients and carers may be feeling particularly vulnerable. However,
      their availability and promotion could be improved. We recommend that providers
      of PMHS consider whether this is achievable, in order to better meet the needs of
      service users.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Williams, Matt
AU  - Williams M
AUID- ORCID: 0000-0002-9122-1858
AD  - Department of Pharmacy & Pharmacology, University of Bath, Bath, UK.
FAU - Jordan, Abbie
AU  - Jordan A
AUID- ORCID: 0000-0003-1595-5574
AD  - Psychology and Centre for Pain Research, University of Bath, Bath, UK.
FAU - Scott, Jennifer
AU  - Scott J
AUID- ORCID: 0000-0002-4920-0914
AD  - Department of Pharmacy & Pharmacology, University of Bath, Bath, UK.
FAU - Jones, Matthew D
AU  - Jones MD
AUID- ORCID: 0000-0002-2617-4098
AD  - Department of Pharmacy & Pharmacology, University of Bath, Bath, UK
      m.d.jones@bath.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Prescription Drugs)
SB  - IM
MH  - Caregivers
MH  - *Consumer Health Information
MH  - England
MH  - *Hotlines
MH  - Humans
MH  - Interviews as Topic
MH  - Patients
MH  - *Prescription Drugs
MH  - Qualitative Research
MH  - State Medicine
MH  - Telephone
PMC - PMC7322281
OTO - NOTNLM
OT  - *National Health Service
OT  - *carers
OT  - *drug information services
OT  - *hospital discharge
OT  - *medicines information
OT  - *patient medicines helpline services
OT  - *patients
OT  - *qualitative
OT  - *service users
OT  - *thematic analysis
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036326 [pii]
AID - 10.1136/bmjopen-2019-036326 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e036326. doi: 10.1136/bmjopen-2019-036326.


PMID- 32595160
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Protocol for creating new warnings on cigarette packs and evaluating their
      efficacy in a randomised experimental setting.
PG  - e036166
LID - 10.1136/bmjopen-2019-036166 [doi]
AB  - INTRODUCTION: Tobacco smoking is one of the leading causes of preventable death. 
      This is not inevitable as tobacco control tools have become more powerful and
      more effective. Among these, warnings on cigarette packs have proven to be
      somewhat effective. Our objective is to increase the efficacy of antismoking
      warnings by using innovative psychological approaches and to create an
      experimental setting for the evaluation of these new warnings based on
      behavioural indicators. METHODS AND ANALYSIS: First, we created new warnings
      based on three categories of motivational leverage and on harm reduction. New
      warnings with innovative texts and pictures were designed for each category and
      inserted on plain packs. We will then use standard indicators to compare their
      effect to that of control packs: plain pack without warning, plain pack with
      conventional warning and branded pack with conventional warning. Second, the
      novelty of our approach will consist in designing an experimental protocol that
      uses monetary incentives to evaluate the effect of warnings. Subjects will be
      able to 'sacrifice' part of their participation defrayal to purchase a good whose
      subjective value is related to one's attitude towards smoking. These monetarily
      incentivised measures are designed to assess smokers' immediate/mid-term
      intention to quit and non-smokers' aversion to smoking. In both cases, the
      monetary amounts individuals accept to sacrifice may be a more reliable measure
      than declarative responses, which may be distorted by several hypothetical
      biases. In the end, we should be able to robustly measure the impact of our new
      warnings between intervention and control groups by using both traditional
      indicators and our new monetarily incentivised measure. ETHICS AND DISSEMINATION:
      The ethics committee of the Groupement des Hopitaux de l'Institut Catholique de
      Lille approved the research protocol on 5 July 2019 (CIER 2019-22). Results will 
      be presented at scientific meetings and published.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ben Lakhdar, Christian
AU  - Ben Lakhdar C
AUID- ORCID: 0000-0002-1572-3389
AD  - LEM UMR 9221 CNRS, University of Lille, Lille, Hauts-de-France, France
      christian.ben-lakhdar@univ-lille.fr.
FAU - Deplancke, Antoine
AU  - Deplancke A
AD  - ETHICS EA 7446, Lille Catholic University, Lille, Hauts-de-France, France.
FAU - Le Lec, Fabrice
AU  - Le Lec F
AD  - ETHICS EA 7446, Lille Catholic University, Lille, Hauts-de-France, France.
FAU - Massin, Sophie
AU  - Massin S
AD  - LEM UMR 9221 CNRS, Artois University, Arras, Hauts-de-France, France.
FAU - Piermatteo, Anthony
AU  - Piermatteo A
AD  - ETHICS EA 7446, Lille Catholic University, Lille, Hauts-de-France, France.
FAU - Vaillant, Nicolas
AU  - Vaillant N
AD  - LEM UMR 9221 CNRS, University of Lille, Lille, Hauts-de-France, France.
AD  - ETHICS EA 7446, Lille Catholic University, Lille, Hauts-de-France, France.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Harm Reduction
MH  - Humans
MH  - Motivation
MH  - *Product Labeling
MH  - Randomized Controlled Trials as Topic
MH  - *Smoking Prevention
MH  - Tobacco Products/*adverse effects
PMC - PMC7322509
OTO - NOTNLM
OT  - *health economics
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036166 [pii]
AID - 10.1136/bmjopen-2019-036166 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e036166. doi: 10.1136/bmjopen-2019-036166.


PMID- 32595159
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and
      Endotracheal Colonization Trial (E-PROSPECT): study protocol.
PG  - e036047
LID - 10.1136/bmjopen-2019-036047 [doi]
AB  - INTRODUCTION: Ventilator-associated pneumonia (VAP) is a common
      healthcare-associated infection in the intensive care unit (ICU). Probiotics are 
      defined as live microorganisms that may confer health benefits when ingested.
      Prior randomised trials suggest that probiotics may prevent infections such as
      VAP and Clostridioides difficile-associated diarrhoea (CDAD). PROSPECT
      (Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial) is a
      multicentre, double-blinded, randomised controlled trial comparing the efficacy
      of the probiotic Lactobacillus rhamnosus GG with usual care versus usual care
      without probiotics in preventing VAP and other clinically important outcomes in
      critically ill patients admitted to the ICU. METHODS AND ANALYSIS: The objective 
      of E-PROSPECT is to determine the incremental cost-effectiveness of L. rhamnosus 
      GG plus usual care versus usual care without probiotics in critically ill
      patients. E-PROSPECT will be performed from the public healthcare payer's
      perspective over a time horizon from ICU admission to hospital discharge.We will 
      determine probabilities of in-ICU and in-hospital events from all patients
      alongside PROSPECT. We will retrieve unit costs for each resource use item using 
      jurisdiction-specific public databases, supplemented by individual site unit
      costs if such databases are unavailable. Direct costs will include medications,
      personnel costs, radiology/laboratory testing, operative/non-operative procedures
      and per-day hospital 'hoteling' costs not otherwise encompassed. The primary
      outcome is the incremental cost per VAP prevented between the two treatment
      groups. Other clinical events such as CDAD, antibiotic-associated diarrhoea and
      in-hospital mortality will be included as secondary outcomes. We will perform
      pre-specified subgroup analyses (medical/surgical/trauma; age; frailty status;
      antibiotic use; prevalent vs no prevalent pneumonia) and probabilistic
      sensitivity analyses for VAP, then generate confidence intervals using the
      non-parametric bootstrapping approach. ETHICS AND DISSEMINATION: Study approval
      for E-PROSPECT was granted by the Hamilton Integrated Research Ethics Board of
      McMaster University on 29 July 2019. Informed consent was obtained from the
      patient or substitute decision-maker in PROSPECT. The findings of this study will
      be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT01782755;
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lau, Vincent Issac
AU  - Lau VI
AUID- ORCID: 0000-0002-9939-7348
AD  - Department of Critical Care, University of Alberta Faculty of Medicine and
      Dentistry, Edmonton, Alberta, Canada vinceissaclau@gmail.com.
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Cook, Deborah J
AU  - Cook DJ
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Division of Critical Care, McMaster University, Hamilton, Ontario, Canada.
FAU - Fowler, Robert
AU  - Fowler R
AD  - Sunnybrook Health Sciences Institute, Sunnybrook Research Institute, Toronto,
      Ontario, Canada.
FAU - Rochwerg, Bram
AU  - Rochwerg B
AUID- ORCID: 0000-0002-8293-7061
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Division of Critical Care, McMaster University, Hamilton, Ontario, Canada.
FAU - Johnstone, Jennie
AU  - Johnstone J
AD  - Public Health Ontario, University of Toronto Dalla Lana School of Public Health, 
      Toronto, Ontario, Canada.
FAU - Lauzier, Francois
AU  - Lauzier F
AD  - Population Health and Optimal Health Practices Research Unit
      (Trauma-Emergency-Critical Care Medicine), Centre de Recherche du CHU de
      Quebec-Universite Laval, Quebec, Quebec, Canada.
FAU - Marshall, John C
AU  - Marshall JC
AD  - Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
FAU - Basmaji, John
AU  - Basmaji J
AD  - Department of Medicine, Division of Critical Care, Western University, London,
      Ontario, Canada.
FAU - Heels-Ansdell, Diane
AU  - Heels-Ansdell D
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, 
      Canada.
FAU - Xie, Feng
AU  - Xie F
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
AD  - Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, 
      Canada.
CN  - PROSPECT Collaborators
LA  - eng
SI  - ClinicalTrials.gov/NCT01782755
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - Lactobacillus rhamnosus
MH  - Multicenter Studies as Topic
MH  - Pneumonia, Ventilator-Associated/*microbiology/*prevention & control
MH  - Probiotics/*economics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Trachea/*microbiology
PMC - PMC7322334
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *health economics
OT  - *infectious diseases
OT  - *microbiology
OT  - *preventive medicine
OT  - *statistics & research methods
COIS- Competing interests: None declared.
IR  - Cook D
FIR - Cook, Deborah
IR  - Duan E
FIR - Duan, Erick
IR  - Soth M
FIR - Soth, Mark
IR  - Clarke F
FIR - Clarke, France
IR  - Copland M
FIR - Copland, Mary
IR  - Hoad N
FIR - Hoad, Neala
IR  - Jakab M
FIR - Jakab, Marnie
IR  - Shears M
FIR - Shears, Melissa
IR  - Takaoka A
FIR - Takaoka, Alyson
IR  - Zytaruk N
FIR - Zytaruk, Nicole
IR  - Connolly C
FIR - Connolly, Christa
IR  - Davis D
FIR - Davis, Denise
IR  - Eaton C
FIR - Eaton, Catherine
IR  - Gallinas T
FIR - Gallinas, Tracy
IR  - Lee-Yoo J
FIR - Lee-Yoo, Jean
IR  - Lukinuk C
FIR - Lukinuk, Connie
IR  - Musielak L
FIR - Musielak, Leia
IR  - Pavunkovic N
FIR - Pavunkovic, Nancy
IR  - Pelayo J
FIR - Pelayo, Joy
IR  - Phillips K
FIR - Phillips, Kaitlyn
IR  - Pracsovics C
FIR - Pracsovics, Catherine
IR  - Raimondo J
FIR - Raimondo, Julia
IR  - Stankus V
FIR - Stankus, Vida
IR  - Wallace C
FIR - Wallace, Christine
IR  - Wright A
FIR - Wright, Angela
IR  - Young C
FIR - Young, Crystal
IR  - Meade M
FIR - Meade, Maureen
IR  - Belley-Cote E
FIR - Belley-Cote, Emilie
IR  - Fimiani K
FIR - Fimiani, Katrina
IR  - Hand L
FIR - Hand, Lori
IR  - Jagdey H
FIR - Jagdey, Harjot
IR  - Klotz L
FIR - Klotz, Lisa
IR  - Sabev A
FIR - Sabev, Alexana
IR  - Savija N
FIR - Savija, Nevena
IR  - Cosentino D
FIR - Cosentino, Deanne
IR  - Lourenco D
FIR - Lourenco, Diane
IR  - Misina J
FIR - Misina, Julie
IR  - Sobhi G
FIR - Sobhi, Gita
IR  - Karachi T
FIR - Karachi, Timothy
IR  - Rochwerg B
FIR - Rochwerg, Bram
IR  - Alghuroba M
FIR - Alghuroba, Mashari
IR  - Khaled A
FIR - Khaled, Alia
IR  - Locco L
FIR - Locco, Lauren
IR  - Millen T
FIR - Millen, Tina
IR  - Vaisler R
FIR - Vaisler, Ryan
IR  - Biljan M
FIR - Biljan, Maya
IR  - Cosentino D
FIR - Cosentino, Deanne
IR  - Marriott B
FIR - Marriott, Brittany
IR  - Marshall J
FIR - Marshall, John
IR  - Frieich J
FIR - Frieich, Jan
IR  - Hodder J
FIR - Hodder, Jennifer
IR  - Khalid I
FIR - Khalid, Imrana
IR  - Lee J
FIR - Lee, Julie
IR  - Lee Y
FIR - Lee, Yoon
IR  - Roy P
FIR - Roy, Pragma
IR  - Salway K
FIR - Salway, Kurtis
IR  - Sandhu G
FIR - Sandhu, Gyan
IR  - Santos M
FIR - Santos, Marlene
IR  - Smith O
FIR - Smith, Orla
IR  - Wang M
FIR - Wang, Melissa
IR  - Dewhurst N
FIR - Dewhurst, Norman
IR  - Dowbenka A
FIR - Dowbenka, Ann
IR  - Kosinski A
FIR - Kosinski, Ann
IR  - Norrie T
FIR - Norrie, Terri
IR  - Parhar R
FIR - Parhar, Ranjit
IR  - Parsons L
FIR - Parsons, Laura
IR  - Proceviat J
FIR - Proceviat, Johanna
IR  - Ramonas G
FIR - Ramonas, Gitana
IR  - Yuen M
FIR - Yuen, Mae
IR  - Dodek P
FIR - Dodek, Peter
IR  - Ayas N
FIR - Ayas, Najib
IR  - Agda M
FIR - Agda, Maria
IR  - Alcuaz V
FIR - Alcuaz, Victoria
IR  - Ashley BJ
FIR - Ashley, Betty Jean
IR  - Brewer K
FIR - Brewer, Kelsey
IR  - Palmer J
FIR - Palmer, Janice
IR  - Brown G
FIR - Brown, Glen
IR  - Pavan M
FIR - Pavan, Mara
IR  - Mehta G
FIR - Mehta, Geeta
IR  - Lapinsky S
FIR - Lapinsky, Stephen
IR  - Munshi L
FIR - Munshi, Laveena
IR  - Brown M
FIR - Brown, Maedean
IR  - Giacomino B
FIR - Giacomino, Brittany
IR  - Jakab M
FIR - Jakab, Marnie
IR  - Kraguljac A
FIR - Kraguljac, Alan
IR  - Shah S
FIR - Shah, Sumesh
IR  - Tamberg E
FIR - Tamberg, Erik
IR  - Vergeer L
FIR - Vergeer, Laura
IR  - Cheng D
FIR - Cheng, Doret
IR  - Grewal G
FIR - Grewal, Gagan
IR  - Han A
FIR - Han, Anew
IR  - Leung H
FIR - Leung, Holly
IR  - Mantas I
FIR - Mantas, Ioanna
IR  - Roigues H
FIR - Roigues, Hilary
IR  - Wyllie A
FIR - Wyllie, Anew
IR  - Lauzier F
FIR - Lauzier, Francois
IR  - Turgeon A
FIR - Turgeon, Alexis
IR  - Barriault D
FIR - Barriault, Danny
IR  - Bellemare D
FIR - Bellemare, David
IR  - Boivin A
FIR - Boivin, Anick
IR  - Breton SJ
FIR - Breton, Sarah-Judith
IR  - Cloutier E
FIR - Cloutier, Eve
IR  - Daigle M
FIR - Daigle, Marjorie
IR  - Delisle-Thibeault C
FIR - Delisle-Thibeault, Charles
IR  - Giannakouros P
FIR - Giannakouros, Panagiota
IR  - Grenier S
FIR - Grenier, Stephanie
IR  - Guilbault G
FIR - Guilbault, Gabrielle
IR  - Leger C
FIR - Leger, Caroline
IR  - Ouellet C
FIR - Ouellet, Catherine
IR  - Tremblay MC
FIR - Tremblay, Marie-Claude
IR  - Gagne E
FIR - Gagne, Elisabeth
IR  - Gaueau J
FIR - Gaueau, Julie
IR  - Gregoire C
FIR - Gregoire, Claire
IR  - Labbe V
FIR - Labbe, Veronique
IR  - Laprise-Rochette A
FIR - Laprise-Rochette, Ariane
IR  - Ouellet C
FIR - Ouellet, Caroline
IR  - Samson M
FIR - Samson, Melanie
IR  - Simoneau MD
FIR - Simoneau, Marie-David
IR  - Turcotte V
FIR - Turcotte, Virginie
IR  - Tran TV
FIR - Tran, Tuong-Vi
IR  - McIntyre L
FIR - McIntyre, Lauralyn
IR  - Pagilarello J
FIR - Pagilarello, Joe
IR  - Cardinal P
FIR - Cardinal, Pierre
IR  - D'Egidio G
FIR - D'Egidio, Gianni
IR  - English S
FIR - English, Shane
IR  - Hartwick M
FIR - Hartwick, Mike
IR  - Hooper J
FIR - Hooper, Jonathon
IR  - Jones G
FIR - Jones, Gwynne
IR  - Kim J
FIR - Kim, John
IR  - Kubelik D
FIR - Kubelik, Dal
IR  - Kyeremanteng K
FIR - Kyeremanteng, Kwadwo
IR  - Meggison H
FIR - Meggison, Hilary
IR  - Microys S
FIR - Microys, Sherissa
IR  - Neiliovitz D
FIR - Neiliovitz, Dave
IR  - Pagliarello G
FIR - Pagliarello, Guiseppe
IR  - Patel R
FIR - Patel, Rakesh
IR  - Po J
FIR - Po, Jo
IR  - Reardon P
FIR - Reardon, Peter
IR  - Rosenberg E
FIR - Rosenberg, Erin
IR  - Sarti A
FIR - Sarti, Aimee
IR  - Seely A
FIR - Seely, Anew
IR  - Acres S
FIR - Acres, Shelley
IR  - Gomes B
FIR - Gomes, Brigette
IR  - Langlois H
FIR - Langlois, Heather
IR  - Leclair L
FIR - Leclair, Liane
IR  - Miezitis S
FIR - Miezitis, Sydney
IR  - Montroy K
FIR - Montroy, Kaitlyn
IR  - Porteous R
FIR - Porteous, Rebecca
IR  - Reddie S
FIR - Reddie, Shawna
IR  - Beinum AV
FIR - Beinum, Amanda Van
IR  - Tol AV
FIR - Tol, Allyshia Van
IR  - Watpool I
FIR - Watpool, Irene
IR  - Aikens W
FIR - Aikens, Wendy
IR  - Cox M
FIR - Cox, Marianne
IR  - Dugal AM
FIR - Dugal, Anne-Marie
IR  - Fetzer S
FIR - Fetzer, Susan
IR  - Fraser K
FIR - Fraser, Kathy
IR  - Kuhn J
FIR - Kuhn, Jennifer
IR  - MacLeod R
FIR - MacLeod, Rob
IR  - Richard S
FIR - Richard, Susanne
IR  - Rose D
FIR - Rose, Dawn
IR  - Weir S
FIR - Weir, Sherry
IR  - Henderson B
FIR - Henderson, Bill
IR  - Griesdale D
FIR - Griesdale, Donald
IR  - Sekhon M
FIR - Sekhon, Mypinder
IR  - Foster D
FIR - Foster, Denise
IR  - Logie S
FIR - Logie, Suzie
IR  - Yip J
FIR - Yip, Judy
IR  - Herridge M
FIR - Herridge, Margaret
IR  - Goffi SA
FIR - Goffi, S Alberto
IR  - Golan E
FIR - Golan, Eyal
IR  - Granton J
FIR - Granton, John
IR  - McCredie V
FIR - McCredie, Victoria
IR  - Wilcox E
FIR - Wilcox, Elizabeth
IR  - Archer J
FIR - Archer, Jaimie
IR  - Chen D
FIR - Chen, Daniel
IR  - Farias P
FIR - Farias, Paulina
IR  - Fraser B
FIR - Fraser, Brooke
IR  - Geen-Smith C
FIR - Geen-Smith, Cheryl
IR  - Kosky B
FIR - Kosky, Barbara
IR  - Matte A
FIR - Matte, Anea
IR  - Pugliese C
FIR - Pugliese, Christina
IR  - Robles P
FIR - Robles, Priscila
IR  - Stenyk L
FIR - Stenyk, Lia
IR  - Urrea C
FIR - Urrea, Cristian
IR  - Walczak K
FIR - Walczak, Karolina
IR  - Ae K
FIR - Ae, Kyung
IR  - Ascroft J
FIR - Ascroft, Jane
IR  - Haji F
FIR - Haji, Fatima
IR  - Kaur R
FIR - Kaur, Rajvinder
IR  - Lui J
FIR - Lui, Jane
IR  - Mateo S
FIR - Mateo, Sophia
IR  - Pham N
FIR - Pham, Nga
IR  - Pham T
FIR - Pham, Tam
IR  - Suen M
FIR - Suen, Matthew
IR  - Teng J
FIR - Teng, Jennifer
IR  - Wood G
FIR - Wood, Gordon
IR  - Ovakim D
FIR - Ovakim, Daniel
IR  - Auld F
FIR - Auld, Fiona
IR  - Camey G
FIR - Camey, Gayle
IR  - Fleming R
FIR - Fleming, Ralph
IR  - Good J
FIR - Good, Jennifer
IR  - Manhas M
FIR - Manhas, Mandeep
IR  - Boyd K
FIR - Boyd, Karin
IR  - Dheere J
FIR - Dheere, Jane
IR  - Golan E
FIR - Golan, Eyal
IR  - Granton J
FIR - Granton, John
IR  - Archer J
FIR - Archer, Jaimie
IR  - Chen D
FIR - Chen, Daniel
IR  - Fraser B
FIR - Fraser, Brooke
IR  - Geen-Smith C
FIR - Geen-Smith, Cheryl
IR  - Matte A
FIR - Matte, Anea
IR  - Robles P
FIR - Robles, Priscilia
IR  - Urrea C
FIR - Urrea, Cristian
IR  - Ascroft J
FIR - Ascroft, Jane
IR  - Haji F
FIR - Haji, Fatima
IR  - Meng J
FIR - Meng, Jie
IR  - Suen M
FIR - Suen, Matthew
IR  - Walid M
FIR - Walid, Muhammad
IR  - Westlund J
FIR - Westlund, Jill
IR  - Charbonney E
FIR - Charbonney, Emmanuel
IR  - Lamarche Y
FIR - Lamarche, Yoan
IR  - Leguillan S
FIR - Leguillan, Soazig
IR  - Serri K
FIR - Serri, Karim
IR  - Verdant C
FIR - Verdant, Colin
IR  - Beaulieu Y
FIR - Beaulieu, Yanick
IR  - Bellemare P
FIR - Bellemare, Patrick
IR  - Bernard P
FIR - Bernard, Philippe
IR  - Giasson M
FIR - Giasson, Marc
IR  - Brunette V
FIR - Brunette, Veronique
IR  - Cavayas A
FIR - Cavayas, Alexanos
IR  - Levesque E
FIR - Levesque, Emilie
IR  - Labikova H
FIR - Labikova, Halina
IR  - Palacios JL
FIR - Palacios, Julia Lainer
IR  - Langlois ME
FIR - Langlois, Marie-Eve
IR  - Williams V
FIR - Williams, Virginie
IR  - Nguyen TA
FIR - Nguyen, Thuy Anh
IR  - Phaneuf V
FIR - Phaneuf, Valerie
IR  - Williamson D
FIR - Williamson, David
IR  - Lamontagne F
FIR - Lamontagne, Francois
IR  - D'Aragon F
FIR - D'Aragon, Frederick
IR  - St-Arnaud C
FIR - St-Arnaud, Charles
IR  - Quiroz H
FIR - Quiroz, Hector
IR  - Bolduc V
FIR - Bolduc, Virginie
IR  - Carbonneau E
FIR - Carbonneau, Elaine
IR  - Marchand J
FIR - Marchand, Joannie
IR  - Masse MH
FIR - Masse, Marie-Helene
IR  - Cloutier S
FIR - Cloutier, Sylvie
IR  - Guay M
FIR - Guay, Marianne
IR  - Morin L
FIR - Morin, Line
IR  - Nicolson J
FIR - Nicolson, Jessie
IR  - Paquette I
FIR - Paquette, Isabelle
IR  - Roy P
FIR - Roy, Patricia
IR  - Theberge F
FIR - Theberge, France
IR  - Kristof AS
FIR - Kristof, Arnold S
IR  - Goldberg P
FIR - Goldberg, Peter
IR  - Hatzakorzian R
FIR - Hatzakorzian, Roupen
IR  - Magder S
FIR - Magder, Sheldon
IR  - Shahin J
FIR - Shahin, Jason
IR  - Qureshi S
FIR - Qureshi, Salman
IR  - Campisi J
FIR - Campisi, Josie
IR  - Botan V
FIR - Botan, Vasilica
IR  - Capilnean A
FIR - Capilnean, Anissa
IR  - Corey A
FIR - Corey, Alyssa
IR  - Gagne A
FIR - Gagne, Annick
IR  - Mian J
FIR - Mian, Jasmine
IR  - Normandin K
FIR - Normandin, Kathleen
IR  - Khwaja K
FIR - Khwaja, Kosar
IR  - Deckelbaum D
FIR - Deckelbaum, Dan
IR  - Grushka J
FIR - Grushka, Jeremy
IR  - Gursahaney A
FIR - Gursahaney, Ash
IR  - Hornstein D
FIR - Hornstein, David
IR  - Jayaraman D
FIR - Jayaraman, Dev
IR  - Razek T
FIR - Razek, Tarek
IR  - Salasidis R
FIR - Salasidis, Robert
IR  - Zanelli P
FIR - Zanelli, Patrizia
IR  - Alam N
FIR - Alam, Norine
IR  - Garcia L
FIR - Garcia, Laura
IR  - Doerksen T
FIR - Doerksen, Tonia
IR  - Lessard A
FIR - Lessard, Ariane
IR  - Matte G
FIR - Matte, Gilbert
IR  - Robert MF
FIR - Robert, Marie-France
IR  - Girard M
FIR - Girard, Martin
IR  - Aslanian P
FIR - Aslanian, Pierre
IR  - Belisle S
FIR - Belisle, Sylvain
IR  - Carrier FM
FIR - Carrier, Francois-Martin
IR  - Chasse M
FIR - Chasse, Michael
IR  - Denault A
FIR - Denault, Ane
IR  - Guimond JG
FIR - Guimond, Jean-Gilles
IR  - Halwagi A
FIR - Halwagi, Antoine
IR  - Hebert P
FIR - Hebert, Paul
IR  - Kolan C
FIR - Kolan, Christopher
IR  - Mancebo J
FIR - Mancebo, Jordi
IR  - Robillard N
FIR - Robillard, Nicholas
IR  - Benettaib F
FIR - Benettaib, Fatna
IR  - Boumahni D
FIR - Boumahni, Dounia
IR  - Caporuscio CB
FIR - Caporuscio, Casey Bourdeau
IR  - Cantin ME
FIR - Cantin, Marie-Eve
IR  - Cote-Gravel V
FIR - Cote-Gravel, Virginy
IR  - Ghamraoui A
FIR - Ghamraoui, Ali
IR  - Lebrasseur M
FIR - Lebrasseur, Martine
IR  - Courville LL
FIR - Courville, Lancelot Legene
IR  - Lorio S
FIR - Lorio, Stephanie
IR  - Maid MT
FIR - Maid, Maria Trinidad
IR  - Poitras N
FIR - Poitras, Nicole
IR  - Rigal R
FIR - Rigal, Romain
IR  - Salame M
FIR - Salame, Maya
IR  - Tran V
FIR - Tran, Valerie
IR  - Bacon K
FIR - Bacon, Katie
IR  - Boueau N
FIR - Boueau, Nathalie
IR  - Carvajal C
FIR - Carvajal, Cecilia
IR  - Gauthier L
FIR - Gauthier, Lyne
IR  - Genon J
FIR - Genon, Julie
IR  - Jean K
FIR - Jean, Karine
IR  - Laforest L
FIR - Laforest, Louise
IR  - Lembo A
FIR - Lembo, Antonietta
IR  - Lim S
FIR - Lim, Sothun
IR  - Morrissette J
FIR - Morrissette, Jennifer
IR  - Page F
FIR - Page, France
IR  - Pelletier L
FIR - Pelletier, Lucie
IR  - Roigue MC
FIR - Roigue, Marie-Christine
IR  - Kutsiogiannis J
FIR - Kutsiogiannis, Jim
IR  - Chowdhury R
FIR - Chowdhury, Raiyan
IR  - Davidow J
FIR - Davidow, Jon
IR  - Johnston C
FIR - Johnston, Curt
IR  - Johnston R
FIR - Johnston, Richard
IR  - Macala K
FIR - Macala, Kim
IR  - Marcushamer S
FIR - Marcushamer, Sam
IR  - Markland D
FIR - Markland, Darren
IR  - Matheson D
FIR - Matheson, Doug
IR  - Paton-Gay D
FIR - Paton-Gay, Damian
IR  - Zygun D
FIR - Zygun, David
IR  - Grant N
FIR - Grant, Nadine
IR  - Hewer T
FIR - Hewer, Tayne
IR  - Thompson P
FIR - Thompson, Pat
IR  - Ge M
FIR - Ge, Maggie
IR  - Hall J
FIR - Hall, Janny
IR  - Matenchuk S
FIR - Matenchuk, Sharon
IR  - Loubani O
FIR - Loubani, Osama
IR  - Hall R
FIR - Hall, Rick
IR  - Green R
FIR - Green, Robert
IR  - Gillis D
FIR - Gillis, Diana
IR  - Julien L
FIR - Julien, Lisa
IR  - Magennis LL
FIR - Magennis, Laura Lee
IR  - Mitterer T
FIR - Mitterer, Tamara
IR  - Arsenault J
FIR - Arsenault, Joanna
IR  - Bruce-Payne K
FIR - Bruce-Payne, Kim
IR  - Gallant P
FIR - Gallant, Patti
IR  - Muscedere J
FIR - Muscedere, John
IR  - Boyd G
FIR - Boyd, Gord
IR  - D'Arsigny C
FIR - D'Arsigny, Christine
IR  - Over J
FIR - Over, John
IR  - Erb J
FIR - Erb, Jason
IR  - Maslove D
FIR - Maslove, David
IR  - Parker C
FIR - Parker, Chris
IR  - Sibley S
FIR - Sibley, Stephanie
IR  - Boyd T
FIR - Boyd, Tracy
IR  - Georgescu I
FIR - Georgescu, Ilinca
IR  - Hunt M
FIR - Hunt, Miranda
IR  - Muscedere D
FIR - Muscedere, Danielle
IR  - Baker C
FIR - Baker, Cathy
IR  - Engel J
FIR - Engel, Jennifer
IR  - Fleming J
FIR - Fleming, Jennifer
IR  - Roderick L
FIR - Roderick, Lisa
IR  - Silk S
FIR - Silk, Shelley
IR  - Spencer M
FIR - Spencer, Marcy
IR  - Tryon M
FIR - Tryon, Michelle
IR  - Zarychanski R
FIR - Zarychanski, Ryan
IR  - Blouw M
FIR - Blouw, Marcus
IR  - Olafson K
FIR - Olafson, Kendiss
IR  - Paunovic B
FIR - Paunovic, Bojan
IR  - Smith H
FIR - Smith, Heather
IR  - Gutieror O
FIR - Gutieror, Oliver
IR  - Lys J
FIR - Lys, Justin
IR  - Marten N
FIR - Marten, Nicole
IR  - Wingfield SL
FIR - Wingfield, Sherri Lynn
IR  - Boyle M
FIR - Boyle, Marnie
IR  - Ferens H
FIR - Ferens, Halyna
IR  - Hrabi D
FIR - Hrabi, Debbie
IR  - Kozak B
FIR - Kozak, Beata
IR  - MacDonald C
FIR - MacDonald, Chantal
IR  - Muise J
FIR - Muise, Julie
IR  - Ball I
FIR - Ball, Ian
IR  - Campbell E
FIR - Campbell, Eileen
IR  - Imerovski S
FIR - Imerovski, Susie
IR  - Ovsenek A
FIR - Ovsenek, Athena
IR  - Rondinelli R
FIR - Rondinelli, Rebecca
IR  - Longfield T
FIR - Longfield, Teresa
IR  - Moyer A
FIR - Moyer, Amy
IR  - Norris F
FIR - Norris, Faith
IR  - Sumpton J
FIR - Sumpton, Janice
IR  - Teterycz K
FIR - Teterycz, Karina
IR  - Reeve B
FIR - Reeve, Brenda
IR  - Bento K
FIR - Bento, Karen
IR  - Davis M
FIR - Davis, Megan
IR  - Dechert W
FIR - Dechert, Will
IR  - Gallo K
FIR - Gallo, Krista
IR  - Longo B
FIR - Longo, Barbara
IR  - Mullen C
FIR - Mullen, Courtney
IR  - Skrzypek E
FIR - Skrzypek, Elysia
IR  - Wierenga L
FIR - Wierenga, Laurenne
IR  - Abuzaiter W
FIR - Abuzaiter, Wesam
IR  - Amorim L
FIR - Amorim, Lynda
IR  - Bauer R
FIR - Bauer, Rosemarie
IR  - Damota R
FIR - Damota, Rachel
IR  - Ho T
FIR - Ho, Thoa
IR  - Macdougall N
FIR - Macdougall, Nicole
IR  - Thornewell M
FIR - Thornewell, Mary
IR  - Pe L
FIR - Pe, Lara
IR  - Visocchi J
FIR - Visocchi, Jennifer
IR  - Zarychanski R
FIR - Zarychanski, Ryan
IR  - Paunovic B
FIR - Paunovic, Bojan
IR  - Lys J
FIR - Lys, Justin
IR  - Marten N
FIR - Marten, Nicole
IR  - Bhairo A
FIR - Bhairo, Auey
IR  - Ferenes H
FIR - Ferenes, Halyna
IR  - Kozak B
FIR - Kozak, Beata
IR  - Kubin D
FIR - Kubin, Debra
IR  - McLaughlin DL
FIR - McLaughlin, Dawn-Lee
IR  - Valente M
FIR - Valente, Maria
IR  - Reynolds S
FIR - Reynolds, Steve
IR  - Willems S
FIR - Willems, Suzette
IR  - Sekhon T
FIR - Sekhon, Tina
IR  - Trop S
FIR - Trop, Sebastien
IR  - Binnie A
FIR - Binnie, Alexana
IR  - Heslegrave R
FIR - Heslegrave, Ronald
IR  - Sharman K
FIR - Sharman, Kim
IR  - Panchbhaya Z
FIR - Panchbhaya, Zaynab
IR  - Goel R
FIR - Goel, Rakhi
IR  - Kozluk K
FIR - Kozluk, Kim
IR  - Labelle J
FIR - Labelle, Julianne
IR  - Marsonia H
FIR - Marsonia, Hina
IR  - Scott C
FIR - Scott, Cecillia
IR  - Nagpal D
FIR - Nagpal, Dave
IR  - Ball I
FIR - Ball, Ian
IR  - Bentall T
FIR - Bentall, Tracey
IR  - Sturt-Smith J
FIR - Sturt-Smith, Jessica
IR  - Alexander M
FIR - Alexander, Michelle
IR  - Ellis T
FIR - Ellis, Tammy
IR  - Muylaert M
FIR - Muylaert, Mindy
IR  - Paczkowski C
FIR - Paczkowski, Cindy
IR  - Sligl W
FIR - Sligl, Wendy
IR  - Bagshaw S
FIR - Bagshaw, Sean
IR  - Baig N
FIR - Baig, Nadia
IR  - McCoshen L
FIR - McCoshen, Lorena
IR  - Alexanopoulos K
FIR - Alexanopoulos, Katrina
IR  - Bain S
FIR - Bain, Sherri
IR  - Brandt M
FIR - Brandt, Michelle
IR  - Constable C
FIR - Constable, Cathy
IR  - Douglas K
FIR - Douglas, Kari
IR  - Maharaj S
FIR - Maharaj, Shaleen
IR  - Travers S
FIR - Travers, Sabrina
IR  - Stelfox T
FIR - Stelfox, Tom
IR  - Couillard P
FIR - Couillard, Philippe
IR  - Doig C
FIR - Doig, Christopher
IR  - Parhar K
FIR - Parhar, Ken
IR  - Booth J
FIR - Booth, Joshua
IR  - Codan C
FIR - Codan, Cassidy
IR  - Ruddell S
FIR - Ruddell, Stacy
IR  - Cameron C
FIR - Cameron, Candice
IR  - Edison R
FIR - Edison, Rhonda
IR  - Martin A
FIR - Martin, Anne
IR  - Mina B
FIR - Mina, Breanna
IR  - Niven D
FIR - Niven, Dan
IR  - Berthiaume L
FIR - Berthiaume, Luc
IR  - Gaudet J
FIR - Gaudet, Jonathan
IR  - Booth J
FIR - Booth, Joshua
IR  - Codan C
FIR - Codan, Cassidy
IR  - Fleming G
FIR - Fleming, Gina
IR  - Ross K
FIR - Ross, Katie
IR  - Ruddell S
FIR - Ruddell, Stacy
IR  - Cameron C
FIR - Cameron, Candice
IR  - Edison R
FIR - Edison, Rhonda
IR  - Martin A
FIR - Martin, Anne
IR  - Mina B
FIR - Mina, Breanna
IR  - Tsang JL
FIR - Tsang, Jennifer Ly
IR  - Duan E
FIR - Duan, Erick
IR  - Carmargo M
FIR - Carmargo, Mercedes
IR  - Hoekstra B
FIR - Hoekstra, Beverly
IR  - Caporuscio R
FIR - Caporuscio, Rita
IR  - Falvo RK
FIR - Falvo, Rachel Kressner
IR  - Fleming D
FIR - Fleming, Dimitra
IR  - Maxwell C
FIR - Maxwell, Carmelina
IR  - Plantic K
FIR - Plantic, Karmen
IR  - Marquis F
FIR - Marquis, Francois
IR  - Wang HT
FIR - Wang, Han Tin
IR  - Toupin F
FIR - Toupin, Francis
IR  - Ahern S
FIR - Ahern, Stephane
IR  - Laufer B
FIR - Laufer, Brian
IR  - Brosseau M
FIR - Brosseau, Marc
IR  - Dul P
FIR - Dul, Pauline
IR  - Harvey J
FIR - Harvey, Johanne
IR  - Inthanavong L
FIR - Inthanavong, Lotthida
IR  - Tassy D
FIR - Tassy, Danae
IR  - Assayag H
FIR - Assayag, Helen
IR  - Bachand M
FIR - Bachand, Maude
IR  - Betournay M
FIR - Betournay, Marysa
IR  - Daoust K
FIR - Daoust, Karine
IR  - Goyette K
FIR - Goyette, Kristine
IR  - Lessard A
FIR - Lessard, Ariane
IR  - Quach M
FIR - Quach, Marceline
IR  - Hosek P
FIR - Hosek, Paul
IR  - Plaxton B
FIR - Plaxton, Bill
IR  - Armstrong C
FIR - Armstrong, Catherine
IR  - Barber R
FIR - Barber, Rhonda
IR  - Dechert W
FIR - Dechert, William
IR  - Ellis J
FIR - Ellis, Janelle
IR  - Fisk K
FIR - Fisk, Kayla
IR  - Gabnouri M
FIR - Gabnouri, Melissa
IR  - Gordon E
FIR - Gordon, Emilie
IR  - Haegens R
FIR - Haegens, Rebecca
IR  - Halford L
FIR - Halford, Lisa
IR  - Hillis B
FIR - Hillis, Brooklynn
IR  - Jesso R
FIR - Jesso, Rebecca
IR  - McLaren J
FIR - McLaren, Jenn
IR  - McMillan E
FIR - McMillan, Elliot
IR  - Pelkmans M
FIR - Pelkmans, Mariska
IR  - Rekman M
FIR - Rekman, Matthew
IR  - Sinkovitis S
FIR - Sinkovitis, Sylvia
IR  - Truong M
FIR - Truong, Monica
IR  - White M
FIR - White, Michelle
IR  - Bates N
FIR - Bates, Noah
IR  - Bryden-Cromwell S
FIR - Bryden-Cromwell, Susan
IR  - Cha L
FIR - Cha, Lisa
IR  - Cameron C
FIR - Cameron, Colleen
IR  - Deen A
FIR - Deen, Aminah
IR  - DiGiovanni S
FIR - DiGiovanni, Sheri
IR  - Foss A
FIR - Foss, Anders
IR  - Lee E
FIR - Lee, Esther
IR  - MacGregor H
FIR - MacGregor, Heidi
IR  - Galbraith E
FIR - Galbraith, Esther
IR  - McArthur R
FIR - McArthur, Robyn
IR  - McGregor J
FIR - McGregor, Julie
IR  - Miller K
FIR - Miller, Keith
IR  - Morris S
FIR - Morris, Sharon
IR  - Parker S
FIR - Parker, Shelley
IR  - Smith C
FIR - Smith, Candice
IR  - Stoglow J
FIR - Stoglow, Joanna
IR  - Tung J
FIR - Tung, Jennifer
IR  - Vos M
FIR - Vos, Melissa
IR  - Adhikari N
FIR - Adhikari, Neill
IR  - Amaral A
FIR - Amaral, Ane
IR  - Carlos A
FIR - Carlos, Ane
IR  - Cuthbertson B
FIR - Cuthbertson, Brian
IR  - Fowler R
FIR - Fowler, Rob
IR  - Scales D
FIR - Scales, Damon
IR  - Kaur N
FIR - Kaur, Navjot
IR  - Marinoff N
FIR - Marinoff, Nicole
IR  - Perez A
FIR - Perez, Adic
IR  - Wang J
FIR - Wang, Jane
IR  - Hatzifilalithis K
FIR - Hatzifilalithis, Katrina
IR  - Iazzetta J
FIR - Iazzetta, John
IR  - Kolos C
FIR - Kolos, Chrys
IR  - Quinton I
FIR - Quinton, Ingrid
IR  - Lysecki P
FIR - Lysecki, Paul
IR  - Berlingieri J
FIR - Berlingieri, Joseph
IR  - Shaikh S
FIR - Shaikh, Sameer
IR  - Skitch S
FIR - Skitch, Steven
IR  - Campbell T
FIR - Campbell, Tracy
IR  - Basheer H
FIR - Basheer, Hala
IR  - Bruder K
FIR - Bruder, Kathy
IR  - Cheng J
FIR - Cheng, Jane
IR  - Qureshi K
FIR - Qureshi, Kaiser
IR  - Thibault C
FIR - Thibault, Celeste
IR  - Lellouche F
FIR - Lellouche, Francois
IR  - Sia YT
FIR - Sia, Ying Tung
IR  - Simon M
FIR - Simon, Mathieu
IR  - Bouchard PA
FIR - Bouchard, Pierre-Alexane
IR  - Lizotte P
FIR - Lizotte, Patricia
IR  - Chateauvert N
FIR - Chateauvert, Nathalie
IR  - Grenier T
FIR - Grenier, Therese
IR  - Archambault P
FIR - Archambault, Patrick
IR  - Bellemare JF
FIR - Bellemare, Jean-Francois
IR  - Bordeleau S
FIR - Bordeleau, Simon
IR  - Ouin C
FIR - Ouin, Christine
IR  - Duhaime B
FIR - Duhaime, Benoit
IR  - Laberge A
FIR - Laberge, Ann
IR  - Lachance P
FIR - Lachance, Philippe
IR  - Constantin M
FIR - Constantin, Melanie
IR  - Deblois E
FIR - Deblois, Estel
IR  - Dionne M
FIR - Dionne, Maude
IR  - Lavoie L
FIR - Lavoie, Lise
IR  - Michel I
FIR - Michel, Isabelle
IR  - Pepin A
FIR - Pepin, Alexane
IR  - Poulin S
FIR - Poulin, Sanine
IR  - Anctil S
FIR - Anctil, Sarah
IR  - Chouinard A
FIR - Chouinard, Amelie
IR  - Marchand LE
FIR - Marchand, Louis-Etienne
IR  - Roy R
FIR - Roy, Robin
IR  - Cartin-Ceba R
FIR - Cartin-Ceba, Roigo
IR  - Oeckler R
FIR - Oeckler, Richard
IR  - Anderson B
FIR - Anderson, Brenda
IR  - Liedl L
FIR - Liedl, Lavonne
IR  - Meade L
FIR - Meade, Laurie
IR  - Weist S
FIR - Weist, Sueanne
IR  - Bartoo A
FIR - Bartoo, Anna
IR  - Bauer D
FIR - Bauer, Debbie
IR  - Brickley V
FIR - Brickley, Vince
IR  - Bridges S
FIR - Bridges, Shaun
IR  - Brunn G
FIR - Brunn, Greg
IR  - Eickstaedt J
FIR - Eickstaedt, Jennifer
IR  - Randolph J
FIR - Randolph, Jill
IR  - Showalter S
FIR - Showalter, Sandy
IR  - Stern E
FIR - Stern, Erin
IR  - Wendling M
FIR - Wendling, Melissa
IR  - Taylor R
FIR - Taylor, Robert
IR  - Cytron M
FIR - Cytron, Margaret
IR  - Fowler K
FIR - Fowler, Kim
IR  - Krause K
FIR - Krause, Katie
IR  - O'Brien J
FIR - O'Brien, Jackie
IR  - Tow M
FIR - Tow, Marianne
IR  - Ma J
FIR - Ma, John
IR  - Stassi K
FIR - Stassi, Kaitlin
IR  - Arabi Y
FIR - Arabi, Yaseen
IR  - Al-Dawood A
FIR - Al-Dawood, Abdulaziz
IR  - Tlayjeh H
FIR - Tlayjeh, Haytham
IR  - Ghanem A
FIR - Ghanem, Alaaeldien
IR  - Hassanien A
FIR - Hassanien, Ahmad
IR  - Hegazy M
FIR - Hegazy, Mohamed
IR  - Sharkawi AE
FIR - Sharkawi, Ashraf El
IR  - Humaid FB
FIR - Humaid, Felwa Bin
IR  - Alanizi H
FIR - Alanizi, Hala
IR  - Alanizy N
FIR - Alanizy, Nadyah
IR  - Bogami NA
FIR - Bogami, Njoud Al
IR  - Muhaidib M
FIR - Muhaidib, Mohammed
IR  - Gramish J
FIR - Gramish, Jawaher
IR  - Alsomali R
FIR - Alsomali, Randa
IR  - Devera N
FIR - Devera, Nora
IR  - Villafranca M
FIR - Villafranca, Marjane
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036047 [pii]
AID - 10.1136/bmjopen-2019-036047 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e036047. doi: 10.1136/bmjopen-2019-036047.


PMID- 32595158
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Investigating the relationship between changes in social security benefits and
      mental health: a protocol for a systematic review.
PG  - e035993
LID - 10.1136/bmjopen-2019-035993 [doi]
AB  - INTRODUCTION: Poor mental health is one of the greatest causes of disability in
      the world. Evidence increasingly shows that population mental health may be
      influenced by national social security policies. This systematic review aims to
      establish the relationship between social security and mental health in order to 
      help inform recommendations for policy-makers, practitioners and future research.
      METHODS AND ANALYSIS: A systematic review of quantitative observational studies
      investigating mental health outcomes related to changes in social security
      policies will be conducted. Six major databases, including Medline, PsychInfo,
      Embase, Cumulative Index to Nursing and Allied Health Literature, Applied Social 
      Sciences Index Abstracts and Scopus, as well as Research Papers in Economics will
      be searched from January 1979 to April 2020. The electronic database searches
      will be supplemented by reference and citation searches as well as hand-searching
      of key journals. The outcomes of interest are objective or subjective mental
      health outcomes, including stress, anxiety, depression, self-reported mental
      health scores, subjective well-being and suicide. Study selection will follow the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines,
      and the quality of the studies will be assessed by the validity assessment
      framework designed for appraising econometric studies. A narrative synthesis will
      be conducted for all included studies. If data permit, study findings will be
      synthesised by conducting a meta-analysis. ETHICS AND DISSEMINATION: As it will
      be a systematic review, without primary data collection, there will be no
      requirement for ethical approval. Findings will be disseminated through
      peer-reviewed publications and in various media, for example, conferences or
      symposia. PROSPERO REGISTRATION NUMBER: CRD42019154733.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Simpson, Julija
AU  - Simpson J
AUID- ORCID: 0000-0001-8540-5717
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK julija.stoniute@newcastle.ac.uk.
FAU - Brown, Heather
AU  - Brown H
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Bell, Zoe
AU  - Bell Z
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Albani, Viviana
AU  - Albani V
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Bambra, Clare
AU  - Bambra C
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
LA  - eng
GR  - MR/K02325X/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Mental Health
MH  - Observational Studies as Topic
MH  - Research Design
MH  - Social Security/*economics
MH  - Systematic Reviews as Topic
PMC - PMC7322275
OTO - NOTNLM
OT  - *mental health
OT  - *public health
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035993 [pii]
AID - 10.1136/bmjopen-2019-035993 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e035993. doi: 10.1136/bmjopen-2019-035993.


PMID- 32595157
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Barriers in care for children with life-threatening conditions: a qualitative
      interview study in the Netherlands.
PG  - e035863
LID - 10.1136/bmjopen-2019-035863 [doi]
AB  - OBJECTIVE: To identify barriers, as perceived by parents, to good care for
      children with life-threatening conditions. DESIGN: In a nationwide qualitative
      study, we held in-depth interviews regarding end-of-life care with parents of
      children (aged 1 to 12 years) who were living with a life-threatening illness or 
      who had died after a medical trajectory (a maximum of 5 years after the death of 
      the child). Sampling was aimed at obtaining maximum variety for a number of
      factors. The interviews were transcribed and analysed. SETTING: The Netherlands. 
      PARTICIPANTS: 64 parents of 44 children. RESULTS: Parents identified six
      categories of difficulties that create barriers in the care for children with a
      life-threatening condition. First, parents wished for more empathetic and open
      communication about the illness and prognosis. Second, organisational barriers
      create bureaucratic obstacles and a lack of continuity of care. Third, parents
      wished for more involvement in decision-making. Fourth, parents wished they had
      more support from the healthcare team on end-of-life decision-making. Fifth,
      parents experienced a lack of attention for the family during the illness and
      after the death of their child. Sixth, parents experienced an overemphasis on
      symptom-treatment and lack of attention for their child as a person. CONCLUSIONS:
      The barriers as perceived by parents focussed almost without exception on
      non-medical aspects: patient-doctor relationships; communication;
      decision-making, including end-of-life decision-making; and organisation. The
      perceived barriers indicate that care for children with a life-threatening
      condition focusses too much on symptoms and not enough on the human beings behind
      these symptoms.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brouwer, Marije
AU  - Brouwer M
AUID- ORCID: 0000-0002-5464-355X
AD  - Department of Pediatrics, University Medical Center Groningen, University of
      Groningen, Groningen, The Netherlands m.a.brouwer@umcg.nl.
FAU - Maeckelberghe, Els L M
AU  - Maeckelberghe ELM
AD  - Institute for Medical Education, University of Groningen, University Medical
      Center Groningen, Groningen, The Netherlands.
FAU - van der Heide, Agnes
AU  - van der Heide A
AD  - Department of Public Health, Erasmus MC, University Medical Center Rotterdam,
      Rotterdam, The Netherlands.
FAU - Hein, Irma
AU  - Hein I
AD  - Psychiatry, Academic Medical Center, Amsterdam, The Netherlands.
FAU - Verhagen, Eduard
AU  - Verhagen E
AD  - Department of Pediatrics, University Medical Center Groningen, University of
      Groningen, Groningen, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child
MH  - Child Care/*statistics & numerical data
MH  - Child, Preschool
MH  - Female
MH  - *Health Services Accessibility
MH  - Humans
MH  - Infant
MH  - Interviews as Topic
MH  - Male
MH  - Netherlands
MH  - Parents/*psychology
MH  - Qualitative Research
MH  - *Terminal Care
PMC - PMC7322336
OTO - NOTNLM
OT  - *medical ethics
OT  - *paediatric palliative care
OT  - *palliative care
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035863 [pii]
AID - 10.1136/bmjopen-2019-035863 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e035863. doi: 10.1136/bmjopen-2019-035863.


PMID- 32595153
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Concurrent validity of the alcohol purchase task in relation to alcohol
      involvement: protocol for a systematic review and meta-analysis.
PG  - e035400
LID - 10.1136/bmjopen-2019-035400 [doi]
AB  - INTRODUCTION: Alcohol demand, as measured by an alcohol purchase task (APT),
      provides a multidimensional assessment of the relative reinforcing efficacy of
      alcohol. The objective of this meta-analysis is to critically appraise the
      existing literature on the concurrent validity of the APT by meta-analysing the
      cross-sectional relationships between indices of the APT (ie, breakpoint, Omax,
      Pmax, elasticity and intensity) and alcohol-related measures. It also aims to
      examine methodological procedures used to obtain APT indices and individual
      variables as potential moderators on the assessed estimations. METHODS AND
      ANALYSIS: A comprehensive literature search conducted from inception to April
      2020 will be conducted in the PubMed, PsycINFO, Web of Science and Scopus
      databases. Two authors will independently screen and extract data from articles
      using a predefined protocol search and extraction forms. Disagreements will be
      resolved through discussion with two additional reviewers. All results will be
      tabulated, and a random-effect meta-analysis will be conducted. Participants'
      sex, number of prices and APT methodological procedures will be examined as
      potential moderators on the observed effect sizes. ETHICS AND DISSEMINATION:
      Results of this meta-analysis will characterise the concurrent validity of the
      APT in the existing literature. Further, the results are anticipated to provide
      evidence on which index (or indices) is most robustly associated with alcohol use
      and severity. Ethics approval was not required for this study and the results
      will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER:
      CRD42019137512.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gonzalez-Roz, Alba
AU  - Gonzalez-Roz A
AUID- ORCID: 0000-0003-4256-4835
AD  - Department of Psychology, University of Oviedo, Oviedo, Asturias, Spain.
FAU - Martinez-Loredo, Victor
AU  - Martinez-Loredo V
AUID- ORCID: 0000-0002-0403-5273
AD  - Department of Psychology, University of Oviedo, Oviedo, Asturias, Spain
      martinezlvictor@uniovi.es.
FAU - Secades-Villa, Roberto
AU  - Secades-Villa R
AUID- ORCID: 0000-0001-8106-6594
AD  - Department of Psychology, University of Oviedo, Oviedo, Asturias, Spain.
FAU - Amlung, Michael
AU  - Amlung M
AUID- ORCID: 0000-0003-4483-7155
AD  - Peter Boris Centre for Addictions Research, McMaster University, Hamilton,
      Ontario, Canada.
FAU - MacKillop, James
AU  - MacKillop J
AUID- ORCID: 0000-0002-8695-1071
AD  - Peter Boris Centre for Addictions Research, McMaster University, Hamilton,
      Ontario, Canada.
LA  - eng
GR  - R01 AA024930/AA/NIAAA NIH HHS/United States
GR  - R01 AA025911/AA/NIAAA NIH HHS/United States
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Alcohol Drinking
MH  - Alcoholic Beverages/*economics
MH  - *Consumer Behavior
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Validation Studies as Topic
PMC - PMC7322270
OTO - NOTNLM
OT  - *mental health
OT  - *public health
OT  - *substance misuse
COIS- Competing interests: JM is a principal in a private company, BEAM Diagnostics,
      but no commercial products will fall within the scope of the review.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035400 [pii]
AID - 10.1136/bmjopen-2019-035400 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e035400. doi: 10.1136/bmjopen-2019-035400.


PMID- 32595152
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Patient, physiotherapist and surgeon endorsement of the core domain set for total
      hip and total knee replacement in Germany: a study protocol for an OMERACT
      initiative.
PG  - e035207
LID - 10.1136/bmjopen-2019-035207 [doi]
AB  - INTRODUCTION: There is a lack of harmonising measures for clinical trials on
      total joint replacement (TJR) that would allow for results from TJR studies to be
      compared or pooled. The Outcome Measures in Rheumatology (OMERACT) TJR core
      domain set is already endorsed among patients and physicians in the USA and
      Australia. Physiotherapists use different types of measurements compared to
      orthopaedic surgeons while both make substantial contributions to research in the
      field of TJR. To achieve consensus on core measurements sets, patients,
      physiotherapists and orthopaedic surgeons need to achieve consensus on the core
      domains for TJR trials. METHODS AND ANALYSIS: For this multistage study, first,
      the OMERACT TJR core domain set survey will be translated to German and validated
      according to WHO guidelines. Next, the TJR core domain set will be considered for
      endorsement in different German stakeholder groups including patients,
      physiotherapists and orthopaedic surgeons. ETHICS AND DISSEMINATION: Ethical
      approval for this protocol was given by the ethics committee of the Brandenburg
      University of Technology Cottbus-Senftenberg (BTU-CS, EK 2019-2). This article is
      based on the protocol version 2.5 from 6 May 2020. Anonymous data will be
      presented only. We will publish the results in peer-reviewed publications and at 
      international conferences. TRIAL REGISTRATION NUMBER: German Clinical Trials
      Registry (DRKS00016015).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Prill, Robert
AU  - Prill R
AUID- ORCID: 0000-0002-4916-1206
AD  - Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg,
      Senftenberg, Germany robert.prill@outlook.de.
FAU - Singh, Jasvinder A
AU  - Singh JA
AUID- ORCID: 0000-0003-3485-0006
AD  - Division of Clinical Immunology and Rheumatology, University of Alabama at
      Birmingham, Birmingham, Alabama, USA.
AD  - Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham,
      Alabama, USA.
FAU - Seeber, Gesine H
AU  - Seeber GH
AD  - University Hospital of Orthopedics and Trauma Surgery Pius-Hospital, Medical
      Campus University Oldenburg, Oldenburg, Germany.
FAU - Nielsen, Sabrina Mai
AU  - Nielsen SM
AD  - Musculoskeletal Statistics Unit, The Parker Institute, Frederiksberg, Denmark.
FAU - Goodman, Susan
AU  - Goodman S
AD  - Integrative Rheumatology and Orthopedics Center of Excellence, Weill Cornell
      Medicine, Hospital for Special Surgery, New York, New York, USA.
FAU - Michel, Sven
AU  - Michel S
AD  - Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg,
      Senftenberg, Germany.
FAU - Kopkow, Christian
AU  - Kopkow C
AD  - Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg,
      Senftenberg, Germany.
FAU - Schulz, Robert
AU  - Schulz R
AUID- ORCID: 0000-0002-4830-309X
AD  - Therapy Sciences, Brandenburg University of Technology Cottbus-Senftenberg,
      Senftenberg, Germany.
FAU - Choong, Peter
AU  - Choong P
AD  - Department of Surgery, St. Vincent's Hospital Melbourne, The University of
      Melbourne, Melbourne, Victoria, Australia.
FAU - Hommel, Hagen
AU  - Hommel H
AD  - Klinik fur Orthopadie, Sportmedizin und Rehabilitation, Krankenhaus
      Markisch-Oderland GmbH, Wriezen, Germany.
LA  - eng
SI  - DRKS/DRKS00016015
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Arthroplasty, Replacement, Hip
MH  - *Arthroplasty, Replacement, Knee
MH  - Germany
MH  - Humans
MH  - Orthopedic Surgeons/*psychology
MH  - Outcome Assessment, Health Care
MH  - Patients/*psychology
MH  - Physical Therapists/*psychology
MH  - *Practice Guidelines as Topic
MH  - Research Design
PMC - PMC7322286
OTO - NOTNLM
OT  - *hip
OT  - *knee
OT  - *protocols & guidelines
OT  - *statistics & research methods
COIS- Competing interests: RP, GHS, SMN, SG, SM, CK, RS and HH do not have competing
      interests. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia,
      UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners,
      Putnam associates, Spherix, the National Institutes of Health and the American
      College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and
      Viking therapeutics. JAS is a member of the executive of OMERACT, an organisation
      that develops outcome measures in rheumatology and receives arms-length funding
      from 36 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is a
      member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the 
      editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite
      Center on Network Meta-analysis. JAS previously served as a member of the
      following committees: member, the American College of Rheumatology's (ACR) Annual
      Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of
      the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the cochair
      of the ACR Criteria and Response Criteria subcommittee. PC received institutional
      support from Medacta. PC also received consultancies from Johnson & Johnson and
      Stryker. PC received royalties from Johnson and Johnson as part of an instrument 
      design team. PC is part of a Federal Government (Australian) funded industry led 
      consortium (Innovative Manufacturing Cooperative Research Centre) investigating
      advanced manufacturing in prosthetic design and manufacture. PC is a recipient of
      National Health and Medical Research Council grants, as well as Australian
      Research Council grants.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035207 [pii]
AID - 10.1136/bmjopen-2019-035207 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e035207. doi: 10.1136/bmjopen-2019-035207.


PMID- 32595151
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Mortality of ethnic minority groups in the UK: a systematic review protocol.
PG  - e034903
LID - 10.1136/bmjopen-2019-034903 [doi]
AB  - INTRODUCTION: Growing ethnic diversity in the UK has made it increasingly
      important to determine the presence of ethnic health inequalities. There has been
      no systematic review that has drawn together research on ethnic differences in
      mortality in the UK. METHODS: All types of observational studies that compare
      all-cause mortality between major ethnic groups and the white majority population
      in the UK will be included. We will search Medline (OvidSP), Embase (OvidSP),
      Scopus and Web of Science and search the grey literature through conference
      proceedings and online thesis registries. Searches will be carried out from
      inception to 2 August 2019 with no language or other restrictions. Database
      searches will be repeated prior to publication to identify new articles published
      since the initial search. We will conduct forward and backward citation tracking 
      of identified references and consult with experts in the field to identify
      further publications and ongoing or unpublished studies. Two reviewers will
      independently screen studies and extract data. Two reviewers will independently
      assess the quality of included studies using the Newcastle-Ottawa Scale. If at
      least two studies are located for each ethnic group and studies are sufficiently 
      homogeneous, we will conduct a meta-analysis. If insufficient studies are located
      or if there is high heterogeneity we will produce a narrative summary of results.
      ETHICS AND DISSEMINATION: As no primary data will be collected, formal ethical
      approval is not required. The findings of this review will be disseminated
      through publication in peer reviewed journals and conference presentations.
      PROSPERO REGISTRATION NUMBER: CRD42019146143.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Stanaway, Fiona
AU  - Stanaway F
AUID- ORCID: 0000-0003-2104-3010
AD  - School of Public Health, University of Sydney, Sydney, New South Wales, Australia
      fiona.stanaway@sydney.edu.au.
FAU - Noguchi, Naomi
AU  - Noguchi N
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Mathieu, Erin
AU  - Mathieu E
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Khalatbari-Soltani, Saman
AU  - Khalatbari-Soltani S
AUID- ORCID: 0000-0001-8437-1906
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Bhopal, Raj
AU  - Bhopal R
AD  - Usher Intsitute, University of Edinburgh, Edinburgh, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ethnicity/*statistics & numerical data
MH  - Humans
MH  - Minority Groups/*statistics & numerical data
MH  - Mortality/*trends
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - United Kingdom/epidemiology
PMC - PMC7322291
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034903 [pii]
AID - 10.1136/bmjopen-2019-034903 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e034903. doi: 10.1136/bmjopen-2019-034903.


PMID- 32595149
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Racial and socioeconomic disparities in patient experience of clinician empathy: 
      a protocol for systematic review and meta-analysis.
PG  - e034247
LID - 10.1136/bmjopen-2019-034247 [doi]
AB  - INTRODUCTION: Clinician empathy is a vital component of high-quality healthcare. 
      Healthcare disparities may reflect a societal lack of empathy for disadvantaged
      persons in general, and recent research suggests that socioeconomic disparities
      exist in patient satisfaction with clinicians. However, it is currently unclear
      if there are disparities in patient experience of empathy from clinicians. Our
      objective is to systematically analyse the scientific literature to test the
      hypothesis that racial and socioeconomic status (SES) disparities exist in
      patient-reported experience of clinician empathy. METHODS AND ANALYSIS: In
      accordance with published methodological guidelines for conducting a systematic
      review, we will analyse studies reporting patient assessment of clinician empathy
      using the Consultation and Relational Empathy (CARE) measure, which to date is
      the most commonly used and well-validated methodology in clinical research for
      measuring clinician empathy from the patient's perspective. We will use a
      standardised data collection template and assess study quality (risk of bias)
      using the Newcastle-Ottawa Scale. We will abstract data for the CARE measure
      stratified by race and SES, and we will contact the corresponding authors to
      obtain stratified data by race/SES if not reported in the original manuscript.
      Where appropriate, we will pool the data and perform quantitative meta-analysis
      to test if non-white (compared to white) patients and low SES (compared to high
      SES) patients report lower scores for clinician empathy. ETHICS AND
      DISSEMINATION: No individual patient-level data will be collected and thus the
      proposed systematic review does not require ethical approval. This systematic
      review will test if racial and SES differences exist in patient experience of
      clinician empathy, and will inform future research to help promote healthcare
      equity. PROSPERO REGISTRATION NUMBER: CRD42019142809.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Roberts, Brian W
AU  - Roberts BW
AUID- ORCID: 0000-0002-7690-997X
AD  - Departments of Medicine and Emergency Medicine, Cooper University Health Care,
      Camden, New Jersey, USA roberts-brian-w@cooperhealth.edu.
AD  - Center for Humanism, Cooper Medical School of Rowan University, Camden, New
      Jersey, USA.
FAU - Trzeciak, Christian J
AU  - Trzeciak CJ
AD  - Departments of Medicine and Emergency Medicine, Cooper University Health Care,
      Camden, New Jersey, USA.
FAU - Puri, Nitin K
AU  - Puri NK
AD  - Departments of Medicine and Emergency Medicine, Cooper University Health Care,
      Camden, New Jersey, USA.
AD  - Center for Humanism, Cooper Medical School of Rowan University, Camden, New
      Jersey, USA.
FAU - Mazzarelli, Anthony J
AU  - Mazzarelli AJ
AD  - Departments of Medicine and Emergency Medicine, Cooper University Health Care,
      Camden, New Jersey, USA.
AD  - Center for Humanism, Cooper Medical School of Rowan University, Camden, New
      Jersey, USA.
FAU - Trzeciak, Stephen
AU  - Trzeciak S
AUID- ORCID: 0000-0002-7048-3330
AD  - Departments of Medicine and Emergency Medicine, Cooper University Health Care,
      Camden, New Jersey, USA.
AD  - Center for Humanism, Cooper Medical School of Rowan University, Camden, New
      Jersey, USA.
LA  - eng
PT  - Journal Article
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Empathy
MH  - Healthcare Disparities/*economics/*ethnology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Physician-Patient Relations
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7322320
OTO - NOTNLM
OT  - *public health
OT  - *quality in health care
OT  - *social medicine
COIS- Competing interests: AM and ST are authors of a book on compassion science,
      entitled 'Compassionomics'. None of the other authors have potential competing
      interests to disclose.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034247 [pii]
AID - 10.1136/bmjopen-2019-034247 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e034247. doi: 10.1136/bmjopen-2019-034247.


PMID- 32595144
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Implementation of interventions targeting the uptake of genetic testing services 
      for breast cancer risk: protocol for a systematic review.
PG  - e031727
LID - 10.1136/bmjopen-2019-031727 [doi]
AB  - INTRODUCTION: The timely identification of breast cancer-related pathogenic
      variants can help to identify the risk of potential disease development and
      determine healthcare choices. However, the uptake rate of genetic testing
      services for breast cancer risk remains low in many countries. Interventions
      targeting the uptake of these services among individuals potentially at risk for 
      inherited breast cancer are often complex and have multiple components, and are
      therefore difficult to implement, replicate and disseminate to new contexts. Our 
      aim is to systematically review studies targeting the uptake of genetic testing
      services for breast cancer risk and critically assess the quality of
      implementation outcomes and the reporting of intervention descriptions. METHODS
      AND ANALYSIS: PubMed, CINAHL, PsycINFO, Embase, Cochrane Library and all Campbell
      Coordinating Group databases will be searched for intervention studies that
      target individuals' participation in breast cancer genetic testing programmes.
      Papers published in English within the time period from January 2005 until
      October 2019 will be considered for inclusion. Titles, abstracts and full papers 
      will be screened for eligibility by two pairs of reviewers independently. For
      data analysis and synthesis, study-level and intervention-level characteristics
      will be abstracted. We will present all implementation outcomes that are
      mentioned in each of the studies and register the number of studies that do not
      at all look at or report implementation outcomes. The quality of implementation
      will be checked using a 5-point rubric item, and the quality and completeness of 
      reporting of intervention description will be evaluated using the 12-item
      Template for Intervention Description and Replication (TIDieR). ETHICS AND
      DISSEMINATION: Ethical approval is not required to conduct this review. Review
      findings will be disseminated to academic and non-specialist audiences via
      peer-reviewed academic journals and presented at appropriate conferences,
      workshops and meetings to policymakers, practitioners and organisations that work
      with our population of interest. PROSPERO REGISTRATION NUMBER: CRD42018105732.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Thapa, Subash
AU  - Thapa S
AUID- ORCID: 0000-0002-1182-8511
AD  - Research Unit of General Practice, University of Southern Denmark, J.B. Winslows 
      Vej 9, 5000 Odense, Denmark sthapa@health.sdu.dk.
FAU - Leppin, Anja
AU  - Leppin A
AD  - Unit for Health Promotion Research, University of Southern Denmark, Niels Bohrs
      Vej 9-10, 6700 Esbjerg, Denmark.
FAU - Kristensen, Rikke
AU  - Kristensen R
AD  - Unit for Health Promotion Research, University of Southern Denmark, Niels Bohrs
      Vej 9-10, 6700 Esbjerg, Denmark.
FAU - Just Bonde, Mette
AU  - Just Bonde M
AD  - Unit for Health Promotion Research, University of Southern Denmark, Niels Bohrs
      Vej 9-10, 6700 Esbjerg, Denmark.
FAU - Aro, Arja R
AU  - Aro AR
AD  - Unit for Health Promotion Research, University of Southern Denmark, Niels Bohrs
      Vej 9-10, 6700 Esbjerg, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - Breast Cancer, Familial
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - *Genetic Testing
MH  - Humans
MH  - *Patient Acceptance of Health Care
MH  - Research Design
MH  - Risk
MH  - Systematic Reviews as Topic
PMC - PMC7322324
OTO - NOTNLM
OT  - *cancer genetics
OT  - *international health services
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-031727 [pii]
AID - 10.1136/bmjopen-2019-031727 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e031727. doi: 10.1136/bmjopen-2019-031727.


PMID- 32595143
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Pain associated with psoriasis: systematic scoping review protocol.
PG  - e031461
LID - 10.1136/bmjopen-2019-031461 [doi]
AB  - INTRODUCTION: Psoriasis is a common chronic skin inflammatory disease. Its
      presentation, apart from affected skin areas, involves other unpleasant symptoms,
      such as pain. Pain deteriorates the patient's quality of life, impairing their
      daily behaviour and functioning. Therefore, the alleviation of pain in patients
      with psoriasis should be one of the most desired outcomes of successful
      treatment. The aim of this study is to summarise available evidence about pain in
      patients with psoriasis using systematic scoping review methodology in order to
      map the relevant literature. METHODS AND ANALYSES: Our scoping systematic review 
      will provide evidence synthesis of the literature, both quantitative and
      qualitative, about the pain associated with psoriasis, including pain associated 
      with psoriatic arthritis. Any types of studies will be eligible for inclusion,
      and we will not have any time, language or publication status restrictions. We
      will search MEDLINE, Embase and PsycINFO via OVID, as well as Cochrane Central
      Register of Clinical Trials, Cochrane Database of Systematic Reviews via Cochrane
      Library, CINAHL via EBSCO, OpenGrey and ProQuest Dissertations and Theses Global.
      All databases will be searched from the date of their inception. Retrieved
      bibliographic records and potentially relevant full texts will be screened by two
      authors independently. Two researchers will extract data independently. Any
      discrepancies will be resolved via discussion or consultation of the third
      author, if necessary. To appraise studies, we will use a Mixed Methods Appraisal 
      Tool, AMSTAR 2, Cochrane risk of bias tool and ROBINS. Our findings will be
      reported according to the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses Extension for Scoping Reviews. ETHICS AND DISSEMINATION: The
      proposed study will not be conducted with human participants. We will only use
      published data and therefore ethics approval is not required. Our findings will
      be disseminated via peer-reviewed manuscript and conference reports.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Sanader Vucemilovic, Ana
AU  - Sanader Vucemilovic A
AD  - Department of Dermatology, University Hospital Center Split Krizine, Split,
      Croatia.
FAU - Nujic, Danijela
AU  - Nujic D
AD  - Department of Public Health, Josip Juraj Strossmayer University of Osijek School 
      of Medicine, Osijek, Osijek-Baranja, Croatia.
FAU - Puljak, Livia
AU  - Puljak L
AUID- ORCID: 0000-0002-8467-6061
AD  - Center for Evidence-Based Medicine and Health Care, Catholic University of
      Croatia, Zagreb, Croatia livia.puljak@unicath.hr livia.puljak@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease
MH  - Humans
MH  - Pain/*etiology
MH  - Pain Management
MH  - Pain Measurement
MH  - Psoriasis/*complications
MH  - Quality of Life
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7322274
OTO - NOTNLM
OT  - *evidence
OT  - *pain management
OT  - *psoriasis
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-031461 [pii]
AID - 10.1136/bmjopen-2019-031461 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e031461. doi: 10.1136/bmjopen-2019-031461.


PMID- 32595142
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 28
TI  - Randomised, double-blinded, placebo-controlled trial to investigate the role of
      laparoscopic transversus abdominis plane block in gastric bypass surgery: a study
      protocol.
PG  - e025818
LID - 10.1136/bmjopen-2018-025818 [doi]
AB  - INTRODUCTION: Evaluating the efficacy of a laparoscopically guided, surgical
      transversus abdominis plane (TAP) and rectus sheath (RS) block in reducing
      analgesic consumption while improving functional outcomes in patients undergoing 
      laparoscopic bariatric surgery. METHODS: 150 patients Living with obesity
      undergoing elective laparoscopic Roux-En-Y gastric bypass for obesity will be
      recruited to this double-blinded, placebo-controlled randomised controlled trial 
      from a Bariatric Centre of Excellence over a period of 6 months. Patients will be
      electronically randomised on a 1:1 basis to either an intervention or placebo
      group. Those on the intervention arm will receive a total of 60 mL 0.25%
      ropivacaine, divided into four injections: two for TAP and two for RS block under
      laparoscopic visualisation. The placebo arm will receive normal saline in the
      same manner. A standardised surgical and anaesthetic protocol will be followed,
      with care in adherence to the Enhanced Recovery after Bariatric Surgery
      guidelines. ANALYSIS: Demographic information and relevant medical history will
      be collected from the 150 patients enrolled in the study. Our primary efficacy
      endpoint is cumulative postoperative narcotic use. Secondary outcomes are peak
      expiratory flow, postoperative pain score and the 6 min walk test. Quality of
      recovery (QoR) will be assessed using a validated questionnaire (QoR-40).
      Statistical analysis will be conducted to assess differences within and between
      the two groups. The repeated measures will be analysed by a mixed modelling
      approach and results reported through publication. ETHICS AND DISSEMINATION:
      Ethics approval was obtained (20170749-01H) through our institutional research
      ethics board (Ottawa Health Science Network Research Ethics Board) and the study 
      results, regardless of the outcome, will be reported in a manuscript submitted
      for a medical/surgical journal. TRIAL REGISTRATION NUMBER: Pre-results
      NCT03367728.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jarrar, Amer
AU  - Jarrar A
AUID- ORCID: 0000-0002-2057-1711
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada
      ajarrar.md@gmail.com.
FAU - Budiansky, Adele
AU  - Budiansky A
AD  - Department of Anesthesia, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Eipe, Naveen
AU  - Eipe N
AD  - Department of Anesthesia, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Walsh, Caolan
AU  - Walsh C
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Kolozsvari, Nicole
AU  - Kolozsvari N
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Neville, Amy
AU  - Neville A
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Mamazza, Joseph
AU  - Mamazza J
AD  - Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03367728
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200628
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Abdominal Muscles/*innervation
MH  - Double-Blind Method
MH  - *Gastric Bypass
MH  - Humans
MH  - Laparoscopy/*methods
MH  - Nerve Block/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7322332
OTO - NOTNLM
OT  - *ERAS
OT  - *TAP block
OT  - *gastric bypass
OT  - *morbid obesity
OT  - *opioid sparring
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/07/01 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2018-025818 [pii]
AID - 10.1136/bmjopen-2018-025818 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 28;10(6):e025818. doi: 10.1136/bmjopen-2018-025818.


PMID- 32594974
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20201218
IS  - 1172-6156 (Electronic)
IS  - 1172-6156 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jun
TI  - Guest Editorial: Ethics and equity in the time of Coronavirus.
PG  - 102-106
LID - 10.1071/HCv12n2_ED2 [doi]
FAU - Hall, Katherine H
AU  - Hall KH
AD  - Department of General Practice and Rural Health, University of Otago, Dunedin,
      New Zealand; and Corresponding author. Email: katherine.hall@otago.ac.nz.
FAU - Doolan-Noble, Fiona
AU  - Doolan-Noble F
AD  - Department of General Practice and Rural Health, University of Otago, Dunedin,
      New Zealand.
FAU - McKinlay, Eileen
AU  - McKinlay E
AD  - Department of Primary Health Care and General Practice, University of Otago,
      Wellington, New Zealand.
FAU - Currie, Olivia
AU  - Currie O
AD  - Department of General Practice, University of Otago, Christchurch, New Zealand.
FAU - Gray, Ben
AU  - Gray B
AD  - Department of Primary Health Care and General Practice, University of Otago,
      Wellington, New Zealand.
FAU - Gray, Lesley
AU  - Gray L
AD  - Department of Primary Health Care and General Practice, University of Otago,
      Wellington, New Zealand.
FAU - Richard, Lauralie
AU  - Richard L
AD  - Department of General Practice and Rural Health, University of Otago, Dunedin,
      New Zealand.
FAU - Stubbe, Maria
AU  - Stubbe M
AD  - Department of Primary Health Care and General Practice, University of Otago,
      Wellington, New Zealand.
FAU - Jaye, Chrystal
AU  - Jaye C
AD  - Department of General Practice and Rural Health, University of Otago, Dunedin,
      New Zealand.
LA  - eng
PT  - Editorial
PL  - Australia
TA  - J Prim Health Care
JT  - Journal of primary health care
JID - 101524060
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/organization & administration
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Cultural Characteristics
MH  - *Health Status Disparities
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Poverty
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Vulnerable Populations
EDAT- 2020/07/01 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - HCv12n2_ED2 [pii]
AID - 10.1071/HCv12n2_ED2 [doi]
PST - ppublish
SO  - J Prim Health Care. 2020 Jun;12(2):102-106. doi: 10.1071/HCv12n2_ED2.


PMID- 32594900
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Jun
TI  - The Climate Emergency: Are the Doctors who take Non-violent Direct Action to
      Raise Public Awareness Radical Activists, Rightminded Professionals, or Reluctant
      Whistleblowers?
PG  - 111-124
LID - 10.1080/20502877.2020.1775390 [doi]
AB  - When doctors become aware of a threat to public health, they have a professional 
      duty to try to mitigate the threat. Climate change is a recognized major threat
      to planetary and public health that requires actions to both mitigate, and adapt 
      to, climate change. The limited time and resources available to change what
      humankind are doing and protect planetary health add urgency to the threat. Some 
      doctors take non-violent direct actions if their governments fail to take the
      effective actions needed. Professional regulatory organizations like the UK's
      General Medical Council (GMC) are charged with protecting the health of patients 
      by setting standards for, giving ethical advice about, and supervising the
      behaviour of doctors. This article examines the conflict between climate activist
      doctors and the GMC interpretation of a doctor's duty of care when there is
      threat to public health from climate change.
FAU - Kemple, Terry
AU  - Kemple T
AUID- ORCID: https://orcid.org/0000-0002-9217-4598
AD  - General practitioner and Independent researcher.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - Awareness
MH  - Bioethical Issues
MH  - *Bioethics
MH  - *Climate Change
MH  - Environment
MH  - Government
MH  - Humans
MH  - *Moral Obligations
MH  - Physicians/*ethics
MH  - *Political Activism
MH  - *Professional Role
MH  - Professionalism
MH  - *Public Health
MH  - Social Control, Formal
MH  - Whistleblowing/ethics
OTO - NOTNLM
OT  - Ethics
OT  - environment and public health
OT  - government regulation
OT  - health care
OT  - professionalism
OT  - quality assurance
EDAT- 2020/07/01 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1080/20502877.2020.1775390 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Jun;26(2):111-124. doi: 10.1080/20502877.2020.1775390. Epub 2020
      Jun 27.


PMID- 32594898
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Jun
TI  - Will the plant-based movement redefine physicians' understanding of chronic
      disease?
PG  - 141-157
LID - 10.1080/20502877.2020.1767921 [doi]
AB  - The world is experiencing a cataclysmically increasing burden from chronic
      illnesses. Chronic diseases are on the advance worldwide and treatment strategies
      to counter this development are dominated by symptom control and polypharmacy.
      Thus, chronic conditions are often considered irreversible, implying a slow
      progression of disease that can only be hampered but not stopped. The current
      plant-based movement is attempting to alter this way of thinking. Applying a
      nutrition-first approach, the ultimate goal is either disease remission or
      reversal. Hereby, ethical questions arise as to whether physicians' current
      understanding of chronic illness is outdated and morally reprehensible. In this
      case, physicians may need to recommend plant-based diets to every patient
      suffering from chronic conditions, while determining what other socioecological
      factors and environmental aspects play a role in the chronic disease process.
      This article provides insights to aspects of diet and chronic illness and
      discusses how the plant-based movement could redefine current understanding of
      chronic disease. The ethical justifications for recommending of a plant-based
      diet are analyzed. The article concludes that not advocating for plant-based
      nutrition is unethical and harms the planet and patients alike.
FAU - Storz, Maximilian Andreas
AU  - Storz MA
AUID- ORCID: https://orcid.org/0000-0003-3277-0301
AD  - Medical doctor at Peter-Goessler-Strasse 14, 72076 Tubingen, Baden-Wurttemberg,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - *Bioethical Issues
MH  - Bioethics
MH  - Cardiovascular Diseases/diet therapy
MH  - Chronic Disease/*therapy
MH  - Comprehension
MH  - *Delivery of Health Care/economics/ethics
MH  - Diabetes Mellitus, Type 2/diet therapy
MH  - Diabetic Neuropathies/diet therapy
MH  - Diet
MH  - *Diet, Vegan/ethics
MH  - Ecology
MH  - *Environment
MH  - Ethics, Medical
MH  - Health Care Costs
MH  - Humans
MH  - Informed Consent
MH  - *Physicians
MH  - *Practice Patterns, Physicians'/ethics
MH  - Professional Role
MH  - Social Change
OTO - NOTNLM
OT  - Vegan
OT  - chronic disease
OT  - chronic illness
OT  - plant-based diet
OT  - remission
OT  - reversal
EDAT- 2020/07/01 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - 10.1080/20502877.2020.1767921 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Jun;26(2):141-157. doi: 10.1080/20502877.2020.1767921. Epub 2020
      Jun 27.


PMID- 32594675
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20220415
IS  - 0033-0205 (Print)
IS  - 0033-0205 (Linking)
VI  - 73
IP  - 1
DP  - 2020 Jan-Dec
TI  - [Triple Chronotherapy approach for reducing depressive symptoms and suicidal
      intent in hospitalized patients: Study protocol of a Randomized Controlled
      Trial].
PG  - 21-25
LID - 10.7429/pi.2020.731026 [doi]
AB  - BACKGROUND: Depressive disorders are a relevant burden for public health due to
      their prevalence and high levels of associated disability and mortality. Recent
      studies suggest that the combination of multiple chronotherapuetic interventions 
      may reveal effective in the rapid improvement of depressive symptoms. OBJECTIVES:
      This paper describes the protocol of a study that aims to test the efficacy of a 
      triple chronotherapy intervention (combined total sleep deprivation, light
      therapy and sleep phase advance) in the improvement of depressive symptoms in
      individuals diagnosed with unipolar or bipolar depression. METHODS: A randomized 
      controlled trial will be conducted in patients hospitalized with a unipolar or
      bipolar depression at the Servizio Psichiatrico di Diagnosi e Cura inpatient unit
      of the San Paolo - ASST Santi Paolo e Carlo Hospital in Milan, Italy. Individuals
      will be randomly assigned to the intervention (triple chronotherapy add-on to
      standard pharmacological treatment) or to the "control" group (standard
      pharmacological treatment). RESULTS: Enrolment began in December 2018 and will
      end in October 2020, or at any earlier point in which the expected sample size
      will be reached. The study protocol has already been approved by the local ethics
      committee and is registered as EudraCT 2019-000892-18. Outcome analyses aim to
      verify whether triple chronotherapy produces a rapid and stable improvement in
      depressive symptoms in individuals hospitalized for an acute unipolar or bipolar 
      depressive episode.
FAU - Ferrara, Paolo
AU  - Ferrara P
AD  - Corso di Laurea in Infermieristica, ASST Santi Paolo e Carlo, Milano.
FAU - D'Agostino, Armando
AU  - D'Agostino A
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Milano.
FAU - Terzoni, Stefano
AU  - Terzoni S
AD  - Corso di Laurea in Infermieristica, ASST Santi Paolo e Carlo, Milano.
FAU - Ostinelli, Edoardo Giuseppe
AU  - Ostinelli EG
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Milano.
FAU - Cavallotti, Simona
AU  - Cavallotti S
AD  - Dipartimento di Salute Mentale, ASST Santi Paolo e Carlo, Milano.
FAU - Basi, Clara
AU  - Basi C
AD  - Dipartimento di Salute Mentale, ASST Santi Paolo e Carlo, Milano.
FAU - Bertino, Vincenzo
AU  - Bertino V
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Milano.
FAU - Gambini, Orsola
AU  - Gambini O
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Milano.
FAU - Destrebecq, Anne
AU  - Destrebecq A
AD  - Dipartimento di scienze biomediche per la salute, Universita degli Studi di
      Milano.
LA  - ita
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - La Triple Chronotherapy come approccio per la riduzione della sintomatologia
      depressiva e dell'intenzionalita suicidaria in pazienti ospedalizzati: Protocollo
      di studio di un Trial Clinico randomizzato controllato.
PL  - Italy
TA  - Prof Inferm
JT  - Professioni infermieristiche
JID - 0244135
MH  - Bipolar Disorder/*therapy
MH  - Chronotherapy/*methods
MH  - Combined Modality Therapy
MH  - Depressive Disorder/*therapy
MH  - Humans
MH  - Inpatients
MH  - Italy
MH  - Phototherapy/methods
MH  - Sleep/physiology
MH  - Sleep Deprivation
MH  - Suicide/*prevention & control
EDAT- 2020/07/01 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - 10.7429/pi.2020.731026 [doi]
PST - ppublish
SO  - Prof Inferm. 2020 Jan-Dec;73(1):21-25. doi: 10.7429/pi.2020.731026.


PMID- 32594589
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 27
IP  - 10
DP  - 2020 Oct
TI  - Assessment of the quality of patient information sheets and informed consent
      forms for clinical trials at a hospital neurology service.
PG  - 1825-1831
LID - 10.1111/ene.14420 [doi]
AB  - BACKGROUND AND PURPOSE: Clinical trials (CTs) aimed at vulnerable groups, such as
      patients with mental disorders, create ethical complexity. The patient
      information sheet (PIS) should provide all of the information about the CT that
      is relevant to the subject's decision to participate. After being informed, the
      subject will decide freely whether to take part in the CT and will read and sign 
      the informed consent form (ICF). The objective was to assess the quality of
      PISs/ICFs from a hospital neurology service. The assessment was made using
      validated and reliable checklists of the information included in the PISs/ICFs of
      CTs with medicinal products. METHODS: The study comprised analyses of compliance 
      with the checklists of 21 PISs and ICFs reviewed/approved during 2016-2017 by a
      medicinal research ethics committee. RESULTS: All PISs/ICFs were from multicenter
      CTs sponsored by pharmaceutical companies in different therapeutic areas, mainly 
      Parkinson's (52.4%) and Alzheimer's (38.1%) diseases. The PISs from the neurology
      service demonstrated good compliance (>/=80%) with the checklist, whereas ICFs
      should be improved. Sponsors omitted some relevant information, such as the study
      title or that the participant be informed of any information arising from the
      research that may be relevant to the subject's health, although this information 
      may be in the PIS. CONCLUSIONS: The PISs/ICFs of CTs of medicinal products that
      are currently used need improvement. PISs and ICFs should be separate documents
      for each CT. In particular, the PISs/ICFs should consider the criteria related to
      the decision of participants, protect their rights and ensure that the
      information received is complete.
CI  - (c) 2020 European Academy of Neurology.
FAU - Jaramillo Velez, A G
AU  - Jaramillo Velez AG
AD  - Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and
      Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food
      Sciences, University of Barcelona, Barcelona, Spain.
FAU - Aguas Compaired, M
AU  - Aguas Compaired M
AD  - Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and
      Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food
      Sciences, University of Barcelona, Barcelona, Spain.
AD  - Research Ethics Committee (CEIm) Idcsalud a Catalunya, Hospital Universitari
      General de Catalunya, Barcelona, Spain.
FAU - Granados Plaza, M
AU  - Granados Plaza M
AD  - Research Ethics Committee (CEIm) Idcsalud a Catalunya, Hospital Universitari
      General de Catalunya, Barcelona, Spain.
FAU - Marino, E L
AU  - Marino EL
AUID- ORCID: 0000-0003-4386-9315
AD  - Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and
      Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food
      Sciences, University of Barcelona, Barcelona, Spain.
FAU - Modamio, P
AU  - Modamio P
AUID- ORCID: 0000-0003-3193-6285
AD  - Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and
      Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food
      Sciences, University of Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200720
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - *Consent Forms
MH  - Hospitals
MH  - Humans
MH  - Informed Consent
MH  - *Neurology
OTO - NOTNLM
OT  - *checklist
OT  - *consent form
OT  - *drugs
OT  - *neurosciences
OT  - *patient information sheet
OT  - *quality
OT  - *research ethics committee
EDAT- 2020/07/01 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/06/29 06:00 [entrez]
AID - 10.1111/ene.14420 [doi]
PST - ppublish
SO  - Eur J Neurol. 2020 Oct;27(10):1825-1831. doi: 10.1111/ene.14420. Epub 2020 Jul
      20.


PMID- 32594477
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20220328
IS  - 1300-2163 (Print)
IS  - 1300-2163 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - Ethical Discourse of Psychiatrists About Gender Identity and Sexual Orientation: 
      A Qualitative Study.
PG  - 31-40
AB  - OBJECTIVE: In Turkey, the studies that aim to elaborate on the experiences of
      people with gender identities and sexual orientations incongruent with social
      norms are limited both in bioethics and in psychiatry. The general aim of this
      study is to provide a deeper understanding about the value based problems related
      to the gender identity and sexual orientation of the patients who seek medical
      advice in psychiatry practice. In this study, psychiatrists' discourse on gender 
      identity and sexual orientation is discussed from an ethical perspective based on
      their experiences in providing healthcare to LGBT individuals. METHOD: In-depth
      interviews with 35 Psychiatry residents and specialists were conducted in the
      context of a qualitative field study. The data received from in-depth interviews 
      were evaluated using the thematic content analysis method. RESULTS: The raw data 
      received from the in-depth interviews with psychiatrists were analyzed and the
      themes and the contexts were derived. Discrimination, LGBTs access to healthcare 
      services, counselling practice, beneficence, non-maleficence, being empathic,
      self-improvement, communicating with the family and interaction with LGBTs are
      the main themes that emerged. These main themes were handled within the contexts 
      of providing healthcare services, professional responsibility of the
      psychiatrists, physician-patient/client and family relations. The relationship
      between the themes and the contexts were interpreted from an ethical perspective.
      CONCLUSION: The results of the study show that in the absence of comprehensive
      and adequate education on gender identity and sexual orientation, psychiatrists
      may tend to adopt scientifically debatable METHODS in diagnosis, observation and 
      treatment of LGBT patient/ counselee.
FAU - Keles, Sukru
AU  - Keles S
FAU - Yilmaz-Ozpolat, Ayse Gul
AU  - Yilmaz-Ozpolat AG
FAU - Yalim, Neyyire Yasemin
AU  - Yalim NY
LA  - eng
LA  - tur
PT  - Journal Article
TT  - Cinsiyet Kimligi ve Cinsel Yonelim Hakkinda Psikiyatristlerin Etik Soylemleri:
      Nitel Bir Arastirma.
PL  - Turkey
TA  - Turk Psikiyatri Derg
JT  - Turk psikiyatri dergisi = Turkish journal of psychiatry
JID - 9425936
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Ethics, Medical
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Internship and Residency
MH  - Interviews as Topic
MH  - Male
MH  - Psychiatry/*ethics
MH  - *Sexual Behavior
EDAT- 2020/07/01 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
AID - 1192 [pii]
AID - 10.5080/u23338 [doi]
PST - ppublish
SO  - Turk Psikiyatri Derg. 2020 Spring;31(1):31-40. doi: 10.5080/u23338.


PMID- 32594340
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20210110
IS  - 1573-6571 (Electronic)
IS  - 0022-4197 (Linking)
VI  - 59
IP  - 5
DP  - 2020 Oct
TI  - Community Calls: Lessons and Insights Gained from a Medical-Religious Community
      Engagement During the COVID-19 Pandemic.
PG  - 2256-2262
LID - 10.1007/s10943-020-01057-w [doi]
AB  - During the pandemic caused by the severe acute respiratory syndrome
      coronavirus-2, public health instructions were issued with the hope of curbing
      the virus' spread. In an effort to assure accordance with these instructions,
      equitable strategies for at-risk and vulnerable populations and communities are
      warranted. One such strategy was our community conference calls, implemented to
      disseminate information on the pandemic and allow community leaders to discuss
      struggles and successes. Over the first 6 weeks, we held 12 calls, averaging 125 
      (standard deviation 41) participants. Participants were primarily from
      congregations and faith-based organizations that had an established relationship 
      with the hospital, but also included school leaders, elected officials, and
      representatives of housing associations. Issues discussed included reasons for
      quarantining, mental health, social isolation, health disparities, and ethical
      concerns regarding hospital resources. Concerns identified by the community
      leaders as barriers to effective quarantining and adherence to precautions
      included food access, housing density, and access to screening and testing.
      Through the calls, ways to solve such challenges were addressed, with novel
      strategies and resources reaching the community. This medical-religious resource 
      has proven feasible and valuable during the pandemic and warrants discussions on 
      reproducing it for other communities during this and future infectious disease
      outbreaks.
FAU - Galiatsatos, Panagis
AU  - Galiatsatos P
AUID- ORCID: http://orcid.org/0000-0002-7752-3841
AD  - Office of Diversity, Inclusion, and Health Equity, Johns Hopkins Medicine,
      Baltimore, MD, USA. panagis@jhmi.edu.
AD  - Medicine for the Greater Good, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA. panagis@jhmi.edu.
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns
      Hopkins School of Medicine, 4940 Eastern Avenue, 4th Floor, Asthma and Allergy
      Building, Baltimore, MD, 21224, USA. panagis@jhmi.edu.
FAU - Monson, Kimberly
AU  - Monson K
AD  - Healthy Community Partnership, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
FAU - Oluyinka, MopeninuJesu
AU  - Oluyinka M
AD  - Medicine for the Greater Good, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
FAU - Negro, DanaRose
AU  - Negro D
AD  - Medicine for the Greater Good, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
FAU - Hughes, Natasha
AU  - Hughes N
AD  - Medicine for the Greater Good, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
FAU - Maydan, Daniella
AU  - Maydan D
AD  - Medicine for the Greater Good, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
FAU - Golden, Sherita H
AU  - Golden SH
AD  - Office of Diversity, Inclusion, and Health Equity, Johns Hopkins Medicine,
      Baltimore, MD, USA.
AD  - Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
FAU - Teague, Paula
AU  - Teague P
AD  - Department of Spiritual Care and Chaplaincy, Johns Hopkins Health System,
      Baltimore, MD, USA.
FAU - Hale, W Daniel
AU  - Hale WD
AD  - Medicine for the Greater Good, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
AD  - Healthy Community Partnership, Johns Hopkins Bayview Medical Center, Baltimore,
      MD, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Relig Health
JT  - Journal of religion and health
JID - 2985199R
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7320249
OTO - NOTNLM
OT  - COVID19
OT  - Community engagement
OT  - Medical-religious partnerships
EDAT- 2020/07/01 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
PHST- 2020/06/29 06:00 [entrez]
AID - 10.1007/s10943-020-01057-w [doi]
AID - 10.1007/s10943-020-01057-w [pii]
PST - ppublish
SO  - J Relig Health. 2020 Oct;59(5):2256-2262. doi: 10.1007/s10943-020-01057-w.


PMID- 32594060
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - FOXO3a as a sensor of unilateral nerve injury in sensory neurons ipsilateral,
      contralateral and remote to injury.
PG  - 2353-2361
LID - 10.4103/1673-5374.284999 [doi]
AB  - Emerging evidence supports that the stress response to peripheral nerve injury
      extends beyond the injured neuron, with alterations in associated transcription
      factors detected both locally and remote to the lesion. Stress-induced nuclear
      translocation of the transcription factor forkhead class box O3a (FOXO3a) was
      initially linked to activation of apoptotic genes in many neuronal subtypes.
      However, a more complex role of FOXO3a has been suggested in the injury response 
      of sensory neurons, with the injured neuron expressing less FOXO3a. To elucidate 
      this response and test whether non-injured sensory neurons also alter FOXO3a
      expression, the temporal impact of chronic unilateral L4-6 spinal nerve
      transection on FOXO3a expression and nuclear localization in adult rat dorsal
      root ganglion neurons ipsilateral, contralateral or remote to injury relative to 
      naive controls was examined. In naive neurons, high cytoplasmic and nuclear
      levels of FOXO3a colocalized with calcitonin gene related peptide, a marker of
      the nociceptive subpopulation. One hour post-injury, an acute increase in nuclear
      FOXO3a in small size injured neurons occurred followed by a significant decrease 
      after 1, 2 and 4 days, with levels increasing toward pre-injury levels by 1 week 
      post-injury. A more robust biphasic response to the injury was observed in
      uninjured neurons contralateral to and those remote to injury. Nuclear levels of 
      FOXO3a peaked at 1 day, decreased by 4 days, then increased by 1 week
      post-injury, a response mirrored in C4 dorsal root ganglion neurons remote to
      injury. This altered expression contralateral and remote to injury supports that 
      spinal nerve damage has broader systemic impacts, a response we recently reported
      for another stress transcription factor, Luman/CREB3. The early decreased
      expression and nuclear localization of FOXO3a in the injured neuron implicate
      these changes in the cell body response to injury that may be protective.
      Finally, the broader systemic changes support the existence of
      stress/injury-induced humeral factor(s) influencing transcriptional and
      potentially behavioral changes in uninjured dorsal root ganglion neurons.
      Approval to conduct this study was obtained from the University of Saskatchewan
      Animal Research Ethics Board (protocol #19920164).
FAU - Hasmatali, Jovan C D
AU  - Hasmatali JCD
AD  - Department of Anatomy, Physiology, and Pharmacology; Cameco MS Neuroscience
      Research Center; Department of Veterinary Microbiology, University of
      Saskatchewan, Saskatoon, SK; Current affiliation: Department of Critical Care
      Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, 
      Canada.
FAU - De Guzman, Jolly
AU  - De Guzman J
AD  - Department of Anatomy, Physiology, and Pharmacology; Cameco MS Neuroscience
      Research Center, University of Saskatchewan, Saskatoon, SK, Canada.
FAU - Johnston, Jayne M
AU  - Johnston JM
AD  - Department of Anatomy, Physiology, and Pharmacology; Cameco MS Neuroscience
      Research Center, University of Saskatchewan, Saskatoon, SK, Canada.
FAU - Noyan, Hossein
AU  - Noyan H
AD  - Department of Anatomy, Physiology, and Pharmacology; Cameco MS Neuroscience
      Research Center, University of Saskatchewan, Saskatoon, SK; Current affiliation: 
      Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada.
FAU - Juurlink, Bernhard H
AU  - Juurlink BH
AD  - Department of Anatomy, Physiology, and Pharmacology; Cameco MS Neuroscience
      Research Center, University of Saskatchewan, Saskatoon, SK, Canada.
FAU - Misra, Vikram
AU  - Misra V
AD  - Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK,
      Canada.
FAU - Verge, Valerie M K
AU  - Verge VMK
AD  - Department of Anatomy, Physiology, and Pharmacology; Cameco MS Neuroscience
      Research Center, University of Saskatchewan, Saskatoon, SK, Canada.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749464
OTO - NOTNLM
OT  - cell body response
OT  - contralateral response
OT  - dorsal root ganglion
OT  - peripheral nerve injury
OT  - plasticity
OT  - sciatic nerve
OT  - sensory neuron
OT  - stress
OT  - systemic
OT  - transcription factor
OT  - unilateral peripheral nerve injury
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2353_284999 [pii]
AID - 10.4103/1673-5374.284999 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2353-2361. doi: 10.4103/1673-5374.284999.


PMID- 32594058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Insulin-like growth factor 1 partially rescues early developmental defects caused
      by SHANK2 knockdown in human neurons.
PG  - 2335-2343
LID - 10.4103/1673-5374.285002 [doi]
AB  - SHANK2 is a scaffold protein that serves as a protein anchor at the postsynaptic 
      density in neurons. Genetic variants of SHANK2 are strongly associated with
      synaptic dysfunction and the pathophysiology of autism spectrum disorder. Recent 
      studies indicate that early neuronal developmental defects play a role in the
      pathogenesis of autism spectrum disorder, and that insulin-like growth factor 1
      has a positive effect on neurite development. To investigate the effects of
      SHANK2 knockdown on early neuronal development, we generated a sparse culture
      system using human induced pluripotent stem cells, which then differentiated into
      neural progenitor cells after 3-14 days in culture, and which were dissociated
      into single neurons. Neurons in the experimental group were infected with
      shSHANK2 lentivirus carrying a red fluorescent protein reporter (shSHANK2 group).
      Control neurons were infected with scrambled shControl lentivirus carrying a red 
      fluorescent protein reporter (shControl group). Neuronal somata and neurites were
      reconstructed based on the lentiviral red fluorescent protein signal.
      Developmental dendritic and motility changes in VGLUT1(+) glutamatergic neurons
      and TH(+) dopaminergic neurons were then evaluated in both groups. Compared with 
      shControl VGLUT1(+) neurons, the dendritic length and arborizations of shSHANK2
      VGLUT1(+) neurons were shorter and fewer, while cell soma speed was higher.
      Furthermore, dendritic length and arborization were significantly increased after
      insulin-like growth factor 1 treatment of shSHANK2 neurons, while cell soma speed
      remained unaffected. These results suggest that insulin-like growth factor 1 can 
      rescue morphological defects, but not the change in neuronal motility.
      Collectively, our findings demonstrate that SHANK2 deficiency perturbs early
      neuronal development, and that IGF1 can partially rescue the neuronal defects
      caused by SHANK2 knockdown. All experimental procedures and protocols were
      approved by the Laboratory Animal Ethics Committee of Jinan University, China
      (approval No. 20170228010) on February 28, 2017.
FAU - Chen, Shu-Ting
AU  - Chen ST
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Lai, Wan-Jing
AU  - Lai WJ
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory; Clinical Medicine, Jinan
      University, Guangzhou, Guangdong Province, China.
FAU - Zhang, Wei-Jia
AU  - Zhang WJ
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Chen, Qing-Pei
AU  - Chen QP
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Zhou, Li-Bing
AU  - Zhou LB
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - So, Kwok-Fai
AU  - So KF
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Shi, Ling-Ling
AU  - Shi LL
AD  - Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Ministry of Education
      CNS Regeneration Collaborative Joint Laboratory; Department of Psychiatry, the
      First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province;
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749486
OTO - NOTNLM
OT  - cells
OT  - factor
OT  - growth
OT  - in vitro
OT  - model
OT  - neural differentiation
OT  - neurogenesis
OT  - plasticity
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2335_285002 [pii]
AID - 10.4103/1673-5374.285002 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2335-2343. doi: 10.4103/1673-5374.285002.


PMID- 32594057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Enriched environment enhances histone acetylation of NMDA receptor in the
      hippocampus and improves cognitive dysfunction in aged mice.
PG  - 2327-2334
LID - 10.4103/1673-5374.285005 [doi]
AB  - The mechanisms of age-associated memory impairment may be associated with
      glutamate receptor function and chromatin modification. To observe the effect of 
      an enriched environment on the cognitive function of mice with age-associated
      memory impairment, 3-month-old C57BL/6 male mice ("young" mice) were raised in a 
      standard environment, while 24-month-old C57BL/6 male mice with memory impairment
      ("age-associated memory impairment" mice) were raised in either a standard
      environment or an enriched environment. The enriched environment included a
      variety of stimuli involving movement and sensation. A water maze test was then
      used to measure cognitive function in the mice. Furthermore, quantitative
      real-time polymerase chain reaction and western blot assays were used to detect
      right hippocampal GluN2B mRNA as well as protein expression of GluN2B and CREB
      binding protein in all mice. In addition, chromatin immunoprecipitation was used 
      to measure the extent of histone acetylation of the hippocampal GluN2B gene
      promoters. Compared with the young mice, the water maze performance of
      age-associated memory impairment mice in the standard environment was
      significantly decreased. In addition, there were significantly lower levels of
      total histone acetylation and expression of CREB binding protein in the
      hippocampus of age-associated memory impairment mice in the standard environment 
      compared with the young mice. There were also significantly lower levels of
      histone acetylation, protein expression, and mRNA expression of GluN2B in the
      hippocampus of these mice. In contrast, in the age-associated memory impairment
      mice with the enriched environment intervention, the water maze performance and
      molecular biological indexes were significantly improved. These data confirm that
      an enriched environment can improve cognitive dysfunction in age-associated
      memory impairment mice, and suggest that the mechanisms may be related to the
      increased expression of CREB binding protein and the increased degree of total
      histone acetylation in the hippocampus of age-associated memory impairment mice, 
      which may cause the increase of histone acetylation of GluN2B gene promoter and
      the enhancement of GluN2B mRNA transcription and protein expression in
      hippocampus. The animal experiment was approved by the Animal Ethics Committee of
      Yangzhou University, China (approval No. 20170312001) in March 2017.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Rehabilitation Medicine, Huashan Hospital, Fudan University,
      Shanghai; Department of Rehabilitation, Clinical Medical College, Yangzhou
      University, Yangzhou, Jiangsu Province, China.
FAU - Meng, Zhao-Xiang
AU  - Meng ZX
AD  - Department of Rehabilitation, Clinical Medical College, Yangzhou University,
      Yangzhou, Jiangsu Province, China.
FAU - Chen, Ying-Zhu
AU  - Chen YZ
AD  - Department of Rehabilitation, Clinical Medical College, Yangzhou University,
      Yangzhou, Jiangsu Province, China.
FAU - Li, Yu-Ping
AU  - Li YP
AD  - Department of Rehabilitation, Clinical Medical College, Yangzhou University,
      Yangzhou, Jiangsu Province, China.
FAU - Zhou, Hong-Yu
AU  - Zhou HY
AD  - Department of Rehabilitation, Clinical Medical College, Yangzhou University,
      Yangzhou, Jiangsu Province, China.
FAU - Yang, Man
AU  - Yang M
AD  - Department of Rehabilitation, First Affiliated Hospital, Dalian Medical
      University, Dalian, Liaoning Province, China.
FAU - Zhao, Ting-Ting
AU  - Zhao TT
AD  - Department of Rehabilitation, First Affiliated Hospital, Dalian Medical
      University, Dalian, Liaoning Province, China.
FAU - Gong, Yu-Lai
AU  - Gong YL
AD  - Department of Rehabilitation Medicine, Sichuan Provincial Rehabilitation Hospital
      Affiliated to Chengdu University of TCM, Chengdu, Sichuan Province, China.
FAU - Wu, Yi
AU  - Wu Y
AD  - Department of Rehabilitation Medicine, Huashan Hospital, Fudan University,
      Shanghai, China.
FAU - Liu, Tao
AU  - Liu T
AD  - South China Research Center for Acupuncture and Moxibustion, Medical College of
      Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou,
      Guangdong Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749489
OTO - NOTNLM
OT  - brain
OT  - central nervous system
OT  - factor
OT  - in vitro
OT  - mice
OT  - model
OT  - recovery
OT  - regenerations protein
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2327_285005 [pii]
AID - 10.4103/1673-5374.285005 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2327-2334. doi: 10.4103/1673-5374.285005.


PMID- 32594056
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Pentraxin 3 contributes to neurogenesis after traumatic brain injury in mice.
PG  - 2318-2326
LID - 10.4103/1673-5374.285001 [doi]
AB  - Emerging evidence indicates that pentraxin 3 is an acute-phase protein that is
      linked with the immune response to inflammation. It is also a newly discovered
      marker of anti-inflammatory A2 reactive astrocytes, and potentially has multiple 
      protective effects in stroke; however, its role in the adult brain after
      traumatic brain injury is unknown. In the present study, a moderate model of
      traumatic brain injury in mice was established using controlled cortical impact. 
      The models were intraventricularly injected with recombinant pentraxin 3 (the
      recombinant pentraxin 3 group) or an equal volume of vehicle (the control group).
      The sham-operated mice underwent craniotomy, but did not undergo the controlled
      cortical impact. The potential neuroprotective and neuroregenerative roles of
      pentraxin 3 were investigated on days 14 and 21 after traumatic brain injury.
      Western blot assay showed that the expression of endogenous pentraxin 3 was
      increased after traumatic brain injury in mice. Furthermore, the neurological
      severity test and wire grip test revealed that recombinant pentraxin 3 treatment 
      reduced the neurological severity score and increased the wire grip score,
      suggesting an improved recovery of sensory-motor functions. The Morris water maze
      results demonstrated that recombinant pentraxin 3 treatment reduced the latency
      to the platform, increased the time spent in the correct quadrant, and increased 
      the number of times traveled across the platform, thus suggesting an improved
      recovery of cognitive function. In addition, to investigate the effects of
      pentraxin 3 on astrocytes, specific markers of A2 astrocytes were detected in
      primary astrocyte cultures in vitro using western blot assay. The results
      demonstrated that pentraxin 3 administration activates A2 astrocytes. To explore 
      the protective mechanisms of pentraxin 3, immunofluorescence staining was used.
      Intraventricular injection of recombinant pentraxin 3 increased neuronal
      maintenance in the peri-injured cortex and ipsilateral hippocampus, increased the
      number of doublecortin-positive neural progenitor cells in the subventricular and
      subgranular zones, and increased the number of bromodeoxyuridine (proliferation) 
      and neuronal nuclear antigen (mature neuron) double-labeled cells in the
      hippocampus and peri-injured cortex. Pentraxin 3 administration also increased
      the number of neurospheres and the number of bromodeoxyuridine and doublecortin
      double-labeled cells in neurospheres, and enhanced the proliferation of neural
      progenitor cells in primary neural progenitor cell cultures in vitro. In
      conclusion, recombinant pentraxin 3 administration activated A2 astrocytes, and
      consequently improved the recovery of neural function by increasing neuronal
      survival and enhancing neurogenesis. All experiments were approved by the Animal 
      Ethics Committee of the First Affiliated Hospital of Chongqing Medical
      University, China on March 1, 2016.
FAU - Zhou, Chao
AU  - Zhou C
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Chen, Hong
AU  - Chen H
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Zheng, Jian-Feng
AU  - Zheng JF
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Guo, Zong-Duo
AU  - Guo ZD
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Huang, Zhi-Jian
AU  - Huang ZJ
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Wu, Yue
AU  - Wu Y
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Zhong, Jian-Jun
AU  - Zhong JJ
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Sun, Xiao-Chuan
AU  - Sun XC
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Cheng, Chong-Jie
AU  - Cheng CJ
AD  - Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749468
OTO - NOTNLM
OT  - brain injury
OT  - brain trauma
OT  - cells
OT  - neurogenesis
OT  - plasticity
OT  - protein
OT  - recovery
OT  - regeneration
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2318_285001 [pii]
AID - 10.4103/1673-5374.285001 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2318-2326. doi: 10.4103/1673-5374.285001.


PMID- 32594054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Human adipose tissue- and umbilical cord-derived stem cells: which is a better
      alternative to treat spinal cord injury?
PG  - 2306-2317
LID - 10.4103/1673-5374.284997 [doi]
AB  - Multiple types of stem cells have been proposed for the treatment of spinal cord 
      injury, but their comparative information remains elusive. In this study, a rat
      model of T10 contusion spinal cord injury was established by the impactor method.
      Human umbilical cord-derived mesenchymal stem cells (UCMSCs) or human adipose
      tissue-derived mesenchymal stem cells (ADMSCs) (2.5 muL/injection site, 1 x 10(5)
      cells/muL) was injected on rostral and caudal of the injury segment on the ninth 
      day after injury. Rats injected with mesenchymal stem cell culture medium were
      used as controls. Our results show that although transplanted UCMSCs and ADMSCs
      failed to differentiate into neurons or glial cells in vivo, both significantly
      improved motor and sensory function. After spinal cord injury, UCMSCs and ADMSCs 
      similarly promoted spinal neuron survival and axonal regeneration, decreased
      glial scar and lesion cavity formation, and reduced numbers of active
      macrophages. Bio-Plex analysis of spinal samples showed a specific increase of
      interleukin-10 and decrease of tumor necrosis factor alpha in the ADMSC group, as
      well as a downregulation of macrophage inflammatory protein 3alpha in both UCMSC 
      and ADMSC groups at 3 days after cell transplantation. Upregulation of
      interleukin-10 and interleukin-13 was observed in both UCMSC and ADMSC groups at 
      7 days after cell transplantation. Isobaric tagging for relative and absolute
      quantitation proteomics analyses showed that UCMSCs and ADMSCs induced changes of
      multiple genes related to axonal regeneration, neurotrophy, and cell apoptosis in
      common and specific manners. In conclusion, UCMSC and ADMSC transplants yielded
      quite similar contributions to motor and sensory recovery after spinal cord
      injury via anti-inflammation and improved axonal growth. However, there were some
      differences in cytokine and gene expression induced by these two types of
      transplanted cells. Animal experiments were approved by the Laboratory Animal
      Ethics Committee at Jinan University (approval No. 20180228026) on February 28,
      2018, and the application of human stem cells was approved by the Medical Ethics 
      Committee of Medical College of Jinan University of China (approval No.
      2016041303) on April 13, 2016.
FAU - Liu, Ai-Mei
AU  - Liu AM
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Chen, Bo-Li
AU  - Chen BL
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Yu, Ling-Tai
AU  - Yu LT
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Liu, Tao
AU  - Liu T
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Shi, Ling-Ling
AU  - Shi LL
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Yu, Pan-Pan
AU  - Yu PP
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province, China.
FAU - Qu, Yi-Bo
AU  - Qu YB
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou,
      Guangdong Province; Co-innovation Center of Neuroregeneration, Nantong
      University, Nantong, Jiangsu Province, China.
FAU - So, Kwok-Fai
AU  - So KF
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University; Guangzhou
      Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, Guangdong
      Province; Co-innovation Center of Neuroregeneration, Nantong University, Nantong,
      Jiangsu Province, China.
FAU - Zhou, Li-Bing
AU  - Zhou LB
AD  - Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS
      Regeneration Collaborative Joint Laboratory, Jinan University; Guangzhou
      Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, Guangdong
      Province; Co-innovation Center of Neuroregeneration, Nantong University, Nantong,
      Jiangsu Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749492
OTO - NOTNLM
OT  - behavior
OT  - central nervous system
OT  - factor
OT  - inflammation
OT  - model
OT  - spinal cord
OT  - stem cells
OT  - transplantation
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2306_284997 [pii]
AID - 10.4103/1673-5374.284997 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2306-2317. doi: 10.4103/1673-5374.284997.


PMID- 32594050
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Mechanism of delayed encephalopathy after acute carbon monoxide poisoning.
PG  - 2286-2295
LID - 10.4103/1673-5374.284995 [doi]
AB  - Many hypotheses exist regarding the mechanism underlying delayed encephalopathy
      after acute carbon monoxide poisoning (DEACMP), including the inflammation and
      immune-mediated damage hypothesis and the cellular apoptosis and direct neuronal 
      toxicity hypothesis; however, no existing hypothesis provides a satisfactory
      explanation for the complex clinical processes observed in DEACMP. Leucine-rich
      repeat and immunoglobulin-like domain-containing protein-1 (LINGO-1) activates
      the Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing
      protein kinase 2 (ROCK2) signaling pathway, which negatively regulates
      oligodendrocyte myelination, axonal growth, and neuronal survival, causing myelin
      damage and participating in the pathophysiological processes associated with many
      central nervous system diseases. However, whether LINGO-1 is involved in DEACMP
      remains unclear. A DEACMP model was established in rats by allowing them to
      inhale 1000 ppm carbon monoxide gas for 40 minutes, followed by 3000 ppm carbon
      monoxide gas for an additional 20 minutes. The results showed that compared with 
      control rats, DEACMP rats showed significantly increased water maze latency and
      increased protein and mRNA expression levels of LINGO-1, RhoA, and ROCK2 in the
      brain. Compared with normal rats, significant increases in injured neurons in the
      hippocampus and myelin sheath damage in the lateral geniculate body were observed
      in DEACMP rats. From days 1 to 21 after DEACMP, the intraperitoneal injection of 
      retinoic acid (10 mg/kg), which can inhibit LINGO-1 expression, was able to
      improve the above changes observed in the DEACMP model. Therefore, the
      overexpression of LINGO-1 appeared to increase following carbon monoxide
      poisoning, activating the RhoA/ROCK2 signaling pathway, which may be an important
      pathophysiological mechanism underlying DEACMP. This study was reviewed and
      approved by the Medical Ethics Committee of Xiangya Hospital of Central South
      Hospital (approval No. 201612684) on December 26, 2016.
FAU - Huang, Yan-Qing
AU  - Huang YQ
AD  - Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University,
      Changsha, Hunan Province, China.
FAU - Peng, Zheng-Rong
AU  - Peng ZR
AD  - Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University,
      Changsha, Hunan Province, China.
FAU - Huang, Fang-Ling
AU  - Huang FL
AD  - Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University,
      Changsha, Hunan Province, China.
FAU - Yang, A-Li
AU  - Yang AL
AD  - Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University,
      Changsha, Hunan Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749483
OTO - NOTNLM
OT  - brain injury
OT  - cell death
OT  - central nervous system
OT  - factor
OT  - injury
OT  - model
OT  - pathways
OT  - rat
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2286_284995 [pii]
AID - 10.4103/1673-5374.284995 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2286-2295. doi: 10.4103/1673-5374.284995.


PMID- 32594047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 12
DP  - 2020 Dec
TI  - Hub genes and key pathways of traumatic brain injury: bioinformatics analysis and
      in vivo validation.
PG  - 2262-2269
LID - 10.4103/1673-5374.284996 [doi]
AB  - The exact mechanisms associated with secondary brain damage following traumatic
      brain injury (TBI) remain unclear; therefore, identifying the critical molecular 
      mechanisms involved in TBI is essential. The mRNA expression microarray GSE2871
      was downloaded from the Gene Expression Omnibus (GEO) repository. GSE2871
      comprises a total of 31 cerebral cortex samples, including two post-TBI time
      points. The microarray features eight control and seven TBI samples, from 4 hours
      post-TBI, and eight control and eight TBI samples from 24 hours post-TBI. In this
      bioinformatics-based study, 109 and 66 differentially expressed genes (DEGs) were
      identified in a Sprague-Dawley (SD) rat TBI model, 4 and 24 hours post-TBI,
      respectively. Functional enrichment analysis showed that the identified DEGs were
      significantly enriched in several terms, such as positive regulation of nuclear
      factor-kappaB transcription factor activity, mitogen-activated protein kinase
      signaling pathway, negative regulation of apoptotic process, and tumor necrosis
      factor signaling pathway. Moreover, the hub genes with high connectivity degrees 
      were primarily related to inflammatory mediators. To validate the top five hub
      genes, a rat model of TBI was established using the weight-drop method, and
      real-time quantitative polymerase chain reaction analysis of the cerebral cortex 
      was performed. The results showed that compared with control rats, Tnf-alpha,
      c-Myc, Spp1, Cxcl10, Ptprc, Egf, Mmp9, and Lcn2 were upregulated, and Fn1 was
      downregulated in TBI rats. Among these hub genes, Fn1, c-Myc, and Ptprc may
      represent novel biomarkers or therapeutic targets for TBI. These identified
      pathways and key genes may provide insights into the molecular mechanisms of TBI 
      and provide potential treatment targets for patients with TBI. This study was
      approved by the Experimental Animal Ethics Committee of the First Affiliated
      Hospital of Nanchang University, China (approval No. 003) in January 2016.
FAU - Tang, Yun-Liang
AU  - Tang YL
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Fang, Long-Jun
AU  - Fang LJ
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Zhong, Ling-Yang
AU  - Zhong LY
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Jiang, Jian
AU  - Jiang J
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Dong, Xiao-Yang
AU  - Dong XY
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Feng, Zhen
AU  - Feng Z
AD  - Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7749465
OTO - NOTNLM
OT  - DEGs
OT  - Gene Ontology
OT  - Kyoto Encyclopedia of Genes and Genomes
OT  - bioinformatics
OT  - differentially expressed genes
OT  - hub genes
OT  - inflammation
OT  - molecular mechanism
OT  - traumatic brain injury
COIS- None
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
AID - NeuralRegenRes_2020_15_12_2262_284996 [pii]
AID - 10.4103/1673-5374.284996 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Dec;15(12):2262-2269. doi: 10.4103/1673-5374.284996.


PMID- 32594016
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 269
DP  - 2020 Jun 25
TI  - Health Literacy: Global Advances with a Focus Upon the Shanghai Declaration on
      Promoting Health in the 2030 Agenda for Sustainable Development.
PG  - 481-496
LID - 10.3233/SHTI200057 [doi]
AB  - In a steadily growing effort, the world has witnessed more than three decades of 
      effort in research, practice, and policy to socially construct what has been
      identified as health literacy. While much of the earlier work in health literacy 
      was in the United States, the extent of scholars and practitioners is now truly
      global. To advance international health literacy, the chapter highlights the role
      of the World Health Organization (WHO) and a series of international conferences 
      that began in 1980s. More specifically, the chapter outlines World Health
      Organization's overarching health literacy efforts, notes the importance of
      health literacy within WHO's new organization structure, briefly describes how
      the concept of health literacy emerged throughout a generation of the WHO's
      international conferences, suggests an ethical foundation for the WHO's health
      literacy work, and explains how the groundwork set by the WHO provides some
      challenges and foundations for future health literacy research and practice.
FAU - Pleasant, Andrew
AU  - Pleasant A
AD  - Health Literacy Media, St. Louis, MO.
FAU - O'Leary, Catina
AU  - O'Leary C
AD  - Health Literacy Media, St. Louis, MO.
FAU - Carmona, Richard
AU  - Carmona R
AD  - Health Literacy Media, St. Louis, MO.
AD  - Canyon Ranch, Tucson, AZ.
AD  - 17th Surgeon General of the United States.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - Global Health
MH  - *Health Literacy
MH  - *Sustainable Development
MH  - World Health Organization
OTO - NOTNLM
OT  - Ethics
OT  - Health literacy
OT  - Sustainable international development
OT  - World Health Organization
EDAT- 2020/07/01 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
AID - SHTI200057 [pii]
AID - 10.3233/SHTI200057 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 25;269:481-496. doi: 10.3233/SHTI200057.


PMID- 32593984
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20200901
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 269
DP  - 2020 Jun 25
TI  - Health Literacy: An Essential Element of Health Care Professionalism and
      Resilience.
PG  - 65-71
LID - 10.3233/SHTI200023 [doi]
AB  - This report discusses the importance of incorporating health literacy into health
      care professionalism and resilience. It defines health care management
      professionalism and its subcomponents. The report addresses the need for an
      improved definition of health care management professionalism. The inclusion of
      health literacy is not only important to the improved definition, but also to
      health care management education competencies. The report builds on the move
      towards competency-based education as a strategy to address health literacy in
      the areas of professionalism and ethics for healthcare professionals. This could 
      lead to building healthcare systems with healthcare professionals who encompass
      high levels of professionalism as well as incorporating tools to combat burnout
      and increasing resilience.
FAU - Parnell, Terri Ann
AU  - Parnell TA
AD  - Health Literacy Partners LLC, U.S.A.
AD  - Stony Brook University, U.S.A.
FAU - Agris, Julie
AU  - Agris J
AD  - Stony Brook University, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Burnout, Professional
MH  - Competency-Based Education
MH  - *Health Literacy
MH  - Health Personnel
MH  - Humans
MH  - *Professionalism
OTO - NOTNLM
OT  - Health literacy
OT  - burnout
OT  - health care management
OT  - health care professionalism
OT  - resilience
EDAT- 2020/07/01 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/06/29 06:00
PHST- 2020/06/29 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
AID - SHTI200023 [pii]
AID - 10.3233/SHTI200023 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 25;269:65-71. doi: 10.3233/SHTI200023.


PMID- 32593698
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 13
IP  - 14
DP  - 2020 Jul 27
TI  - Effect of Sex Difference of Coronary Microvascular Dysfunction on Long-Term
      Outcomes in Deferred Lesions.
PG  - 1669-1679
LID - S1936-8798(20)30869-4 [pii]
LID - 10.1016/j.jcin.2020.04.002 [doi]
AB  - OBJECTIVES: This study investigated the sex difference of long-term
      cardiovascular outcomes on coronary flow reserve (CFR) and index of
      microcirculatory resistance (IMR) in patients with deferred coronary artery
      lesions. BACKGROUND: Coronary microvascular dysfunction is associated with poorer
      long-term outcomes. It can be assessed by CFR and the IMR. METHODS: The study
      prospectively enrolled 434 patients (133 women and 301 men) and analyzed CFR,
      IMR, fractional flow reserve, and quantitative coronary angiography. Clinical
      outcomes were assessed by major adverse cardiovascular event(s) (MACE) of cardiac
      death, myocardial infarction, and revascularization during 5 years of follow-up. 
      The study protocol was approved by the Institutional Review Board or Ethics
      Committee at each participating center, and all patients provided written
      informed consent. The study protocol was in accordance with the Declaration of
      Helsinki. RESULTS: Women had milder epicardial disease compared with men
      (fractional flow reserve: 0.91 [interquartile range (IQR): 0.87 to 0.96] vs. 0.90
      [IQR: 0.86 to 0.95]; p = 0.037). IMR was similar between the sexes, but CFR was
      lower in women (2.69 [IQR: 2.08 to 3.90] vs. 3.20 [IQR: 2.20 to 4.31]; p = 0.006)
      due to a shorter resting mean transit time, whereas hyperemic mean transit times 
      were similar. At 5-year follow-up, MACE was significantly lower in women compared
      with men (1.1% vs. 5.5%; p = 0.017). Sex, diabetes mellitus, and CFR were
      independent predictors for MACE for all patients. The risk of MACE was
      significantly higher in men with low versus high CFR (hazard ratio: 4.58; 95%
      confidence interval: 1.85 to 11.30; p = 0.011) which was not seen in women.
      CONCLUSIONS: There was no sex difference in microvascular function by IMR. CFR
      was lower in women due to a higher resting coronary flow; however, long-term
      clinical outcomes in deferred lesions were better in women compared with men.
      (Clinical, Physiological and Prognostic Implication of Microvascular Status;
      NCT02186093).
CI  - Copyright (c) 2020 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
FAU - Chung, Ju-Hyun
AU  - Chung JH
AD  - Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center,
      Ulsan Hospital, Ulsan, Republic of Korea.
FAU - Lee, Kyung Eun
AU  - Lee KE
AD  - Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center,
      Ulsan Hospital, Ulsan, Republic of Korea; Department of Mechanical Engineering,
      Inha University, Incheon, Republic of Korea.
FAU - Lee, Joo Myung
AU  - Lee JM
AD  - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke
      Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine,
      Seoul, Republic of Korea.
FAU - Her, Ae-Young
AU  - Her AY
AD  - Division of Cardiology, Department of Internal Medicine, Kangwon National
      University School of Medicine, Chuncheon, Republic of Korea.
FAU - Kim, Chee Hae
AU  - Kim CH
AD  - Division of Cardiology, Department of Internal Medicine, VHS Medical Center,
      Seoul, Republic of Korea.
FAU - Choi, Ki Hong
AU  - Choi KH
AD  - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke
      Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine,
      Seoul, Republic of Korea.
FAU - Song, Young Bin
AU  - Song YB
AD  - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke
      Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine,
      Seoul, Republic of Korea.
FAU - Hahn, Joo-Yong
AU  - Hahn JY
AD  - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke
      Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine,
      Seoul, Republic of Korea.
FAU - Kim, Hyung Yoon
AU  - Kim HY
AD  - Heart Center, Chonnam National University Hospital, Gwangju, Republic of Korea.
FAU - Choi, Jin-Ho
AU  - Choi JH
AD  - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke
      Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine,
      Seoul, Republic of Korea; Department of Emergency Medicine, Samsung Medical
      Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Garg, Scot
AU  - Garg S
AD  - Department of Cardiology, Royal Blackburn Hospital, East Lancashire Hospitals NHS
      Trust, Blackburn, United Kingdom.
FAU - Doh, Joon-Hyung
AU  - Doh JH
AD  - Division of Cardiology, Inje University Ilsan Paik Hospital, Goyang, Republic of 
      Korea.
FAU - Nam, Chang-Wook
AU  - Nam CW
AD  - Department of Internal Medicine, Dongsan Medical Center, Keimyung University
      College of Medicine, Daegu, Republic of Korea.
FAU - Koo, Bon-Kwon
AU  - Koo BK
AD  - Department of Internal Medicine and Cardiovascular Center, Seoul National
      University Hospital, Seoul, Republic of Korea.
FAU - Shin, Eun-Seok
AU  - Shin ES
AD  - Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center,
      Ulsan Hospital, Ulsan, Republic of Korea. Electronic address:
      sesim1989@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02186093
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200624
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
SB  - IM
CIN - JACC Cardiovasc Interv. 2020 Jul 27;13(14):1680-1682. PMID: 32593697
MH  - Aged
MH  - *Cardiac Catheterization
MH  - Coronary Artery Disease/*diagnosis/physiopathology/therapy
MH  - Female
MH  - *Fractional Flow Reserve, Myocardial
MH  - Health Status Disparities
MH  - Healthcare Disparities
MH  - Humans
MH  - Male
MH  - *Microcirculation
MH  - Middle Aged
MH  - Myocardial Revascularization
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Republic of Korea
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sex Factors
MH  - Time Factors
MH  - Time-to-Treatment
MH  - Treatment Outcome
MH  - *Vascular Resistance
OTO - NOTNLM
OT  - *coronary artery disease
OT  - *coronary flow reserve
OT  - *fractional flow reserve
OT  - *index of microcirculatory resistance
OT  - *microvascular function
EDAT- 2020/07/01 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/06/29 06:00
PHST- 2019/08/29 00:00 [received]
PHST- 2020/03/30 00:00 [revised]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/06/29 06:00 [entrez]
AID - S1936-8798(20)30869-4 [pii]
AID - 10.1016/j.jcin.2020.04.002 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2020 Jul 27;13(14):1669-1679. doi:
      10.1016/j.jcin.2020.04.002. Epub 2020 Jun 24.


PMID- 34692151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211208
IS  - 2053-714X (Electronic)
IS  - 2053-714X (Linking)
VI  - 7
IP  - 7
DP  - 2020 Jul
TI  - The ethical cost of doing nothing.
PG  - 1260-1262
LID - 10.1093/nsr/nwaa095 [doi]
FAU - Parker, Andrew J
AU  - Parker AJ
AD  - University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford, UK.
LA  - eng
GR  - MR/K014382/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200604
PL  - China
TA  - Natl Sci Rev
JT  - National science review
JID - 101633095
PMC - PMC8288957
EDAT- 2020/07/01 00:00
MHDA- 2020/07/01 00:01
CRDT- 2021/10/25 06:34
PHST- 2021/10/25 06:34 [entrez]
PHST- 2020/07/01 00:00 [pubmed]
PHST- 2020/07/01 00:01 [medline]
AID - 10.1093/nsr/nwaa095 [doi]
AID - nwaa095 [pii]
PST - ppublish
SO  - Natl Sci Rev. 2020 Jul;7(7):1260-1262. doi: 10.1093/nsr/nwaa095. Epub 2020 Jun 4.


PMID- 34556946
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 0972-7531 (Print)
IS  - 0972-7531 (Linking)
VI  - 27
IP  - 3-4
DP  - 2020 Jul
TI  - What We Fail to See in Neuro-Genetic Diseases: A Bird's Eye View from the
      Developing World.
PG  - 91-97
LID - 10.1177/0972753120950069 [doi]
AB  - BACKGROUND: Progressive neurological genetic diseases are not rare. They cause
      psychosocial damages to its victims. This article focuses on common psychosocial 
      issues faced by those from the developing world. METHODS: A multicentre
      observational survey of 246 patients from teaching hospitals in Sri Lanka.
      Participants were clinically and genetically confirmed by neurologists and the
      Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience (ICIBN)
      respectively from 2014 to 2018. Convenience sample with random geographical
      distribution. Factors were equally weighted. ANOVA, Student's t-test and
      chi-square analysis were used. Statistical Software R Statistics-version 3.5 and 
      one-sample t-test with CI = 95% was used. This study meets the ethical guidelines
      of the local institutional review boards which are in compliance with the
      Helsinki Declaration. RESULTS: Sample included 184 males and 62 females of 3-76
      years with either Duchenne muscular dystrophy (n=121), spinocerebellar ataxia (n 
      = 87) or Huntington disease (n = 38). Mean income of the affected is lower than
      the standard average monthly income (P </= .001). Consultation visits depend on
      the monthly income (CI 20421.074-34709.361; P </= .001). CONCLUSION: Poverty is
      inversely proportionate to the patients' living conditions. As developing
      countries are financially challenged, it is a societal challenge to rebuild our
      values to enhance their living status.
CI  - (c) 2020 Indian Academy of Neurosciences (IAN).
FAU - Samaranayake, Navami
AU  - Samaranayake N
AD  - Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience,
      University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
FAU - Dissanayaka, Pulasthi
AU  - Dissanayaka P
AD  - Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience,
      University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
FAU - Gunarathna, Isuru
AU  - Gunarathna I
AD  - Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience,
      University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
FAU - Gonawala, Lakmal
AU  - Gonawala L
AD  - Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience,
      University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
FAU - Wijekoon, Nalaka
AU  - Wijekoon N
AD  - Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience,
      University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
FAU - Rathnayake, Pyara
AU  - Rathnayake P
AD  - Lady Ridgeway Hospital for Children, Colombo, Sri Lanka.
FAU - Sirisena, Darshana
AU  - Sirisena D
AD  - National Hospital of Sri Lanka, Colombo, Sri Lanka.
FAU - Gunasekara, Harsha
AU  - Gunasekara H
AD  - Sri Jayewardenepura General Hospital, Colombo, Sri Lanka.
FAU - Dissanayake, Athula
AU  - Dissanayake A
AD  - Teaching Hospital Karapitiya, Galle, Sri Lanka.
FAU - Senanayake, Sunethra
AU  - Senanayake S
AD  - National Hospital of Sri Lanka, Colombo, Sri Lanka.
FAU - Anand, Akshay
AU  - Anand A
AD  - Neuroscience Research Lab, Institute of Medical Education and Research (PGIMER), 
      Chandigarh.
FAU - Satyamoorthy, Kapaettu
AU  - Satyamoorthy K
AD  - Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal,
      India.
FAU - Dalal, Ashwin
AU  - Dalal A
AD  - Centre for DNA Fingerprinting and Diagnostics, Hyderabad, Telangana, India.
FAU - de Silva, K Ranil D
AU  - de Silva KRD
AUID- ORCID: https://orcid.org/0000-0002-8738-9412
AD  - Interdisciplinary Centre for Innovation in Biotechnology and Neuroscience,
      University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
LA  - eng
PT  - Journal Article
DEP - 20201113
PL  - United States
TA  - Ann Neurosci
JT  - Annals of neurosciences
JID - 101523367
PMC - PMC8454996
OTO - NOTNLM
OT  - Poverty
OT  - Sri Lanka
OT  - developing country
OT  - neurological disorder
COIS- The authors declared no potential conflicts of interest with respect to the
      research, authorship, and/or publication of this article.
EDAT- 2020/07/01 00:00
MHDA- 2020/07/01 00:01
CRDT- 2021/09/24 07:03
PHST- 2021/09/24 07:03 [entrez]
PHST- 2020/07/01 00:00 [pubmed]
PHST- 2020/07/01 00:01 [medline]
AID - 10.1177/0972753120950069 [doi]
AID - 10.1177_0972753120950069 [pii]
PST - ppublish
SO  - Ann Neurosci. 2020 Jul;27(3-4):91-97. doi: 10.1177/0972753120950069. Epub 2020
      Nov 13.


PMID- 35769346
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2671-8790 (Print)
IS  - 2671-8790 (Linking)
VI  - 34
IP  - 2
DP  - 2020 Jun 30
TI  - Ethical issues in uterine transplantation.
PG  - 78-83
LID - 10.4285/kjt.2020.34.2.78 [doi]
AB  - Despite a recent surge of bioethical attention, ethical analysis of uterine
      transplantation is still in its early stages, and many of the key ethical issues 
      remain underexamined and unresolved. In this paper, we briefly review some key
      ethical issues associated with uterine transplantation (beyond those associated
      with organ transplantation more generally). We structure our discussion in terms 
      of Beauchamp and Childress' four principles of biomedical ethics: beneficence,
      non-maleficence, autonomy, and justice. Our review highlights some ethical
      questions that require further bioethical attention before uterine
      transplantation can be fully embraced as a potential treatment for absolute
      uterine factor infertility. We close by arguing that the costs and benefits of
      uterine transplantation need to be considered in the context of other possible
      treatments for absolute uterine factor infertility and alternative methods of
      family creation.
CI  - (c) 2020 The Korean Society for Transplantation.
FAU - Koplin, Julian J
AU  - Koplin JJ
AUID- ORCID: https://orcid.org/0000-0002-2752-7334
AD  - Melbourne Law School, University of Melbourne, Parkville, Australia.
AD  - Biomedical Ethics Research Group, Murdoch Children's Research Institute,
      Parkville, Australia.
FAU - Kendal, Evie
AU  - Kendal E
AUID- ORCID: https://orcid.org/0000-0002-8414-0427
AD  - Deakin School of Medicine and Alfred Deakin Institute, Deakin University,
      Melbourne, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Korean J Transplant
JT  - Korean journal of transplantation
JID - 101775609
PMC - PMC9188934
OTO - NOTNLM
OT  - Allocation
OT  - Bioethics
OT  - Infertility
OT  - Medical ethics
OT  - Organ transplantation
OT  - Pregnancy
EDAT- 2020/06/30 00:00
MHDA- 2020/06/30 00:01
CRDT- 2022/06/30 02:32
PHST- 2020/02/20 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2022/06/30 02:32 [entrez]
PHST- 2020/06/30 00:00 [pubmed]
PHST- 2020/06/30 00:01 [medline]
AID - 10.4285/kjt.2020.34.2.78 [doi]
AID - KJT-34-2-078 [pii]
PST - ppublish
SO  - Korean J Transplant. 2020 Jun 30;34(2):78-83. doi: 10.4285/kjt.2020.34.2.78.


PMID- 34542504
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210923
IS  - 2254-9625 (Electronic)
IS  - 2174-8144 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Jun 29
TI  - Mechanisms of Moral Disengagement Used to Justify School Violence in Sicilian
      Primary School.
PG  - 682-690
LID - 10.3390/ejihpe10030050 [doi]
AB  - This study investigated the mechanisms of moral disengagement most commonly used 
      to justify school violence in Sicilian primary school. The main objective of this
      study was to analyze the mechanisms of moral disengagement that are set in motion
      by those involved in situations of school violence (victims, aggressors, and
      bystanders) in Sicilian primary school. Likewise, the differences by gender and
      age are investigated. A total of 113 subjects in primary school were recruited
      (56.6% girls). The ages ranged from 8 to 11 (M = 9.56, SD = 0.99). The first
      scale used was the Bullying Inventory by Olweus (1993) in the Italian translation
      by Genta, Menesini, Fonzi, Costabile, and Smith (1996) and the questionnaire on
      moral disengagement developed by Caprara, Barbaranelli, Vicino, and Bandura
      (1996) is also used. The regression analysis showed that the sociodemographic
      variables and the mechanisms of moral disengagement are different depending on a 
      person's role (aggressor, victim, or bystander). Moral justification predicted
      the role of victim in school violence, dehumanization predicted the role of the
      aggressor (and gender), and the disclosure of responsibility (and dehumanization)
      predicted the role of the bystander in school violence. The conclusions of this
      study will facilitate the prevention of school violence, for example, by
      promoting social integration and minimizing situations of school violence
      (emphasizing morality, ethics, etc.), thereby establishing balanced and
      satisfactory interpersonal relationships.
FAU - Mendez, Inmaculada
AU  - Mendez I
AUID- ORCID: 0000-0001-8458-5314
AD  - Department of Evolutionary Developmental and Educational Psychology, University
      of Murcia, 30100 Murcia, Spain.
FAU - Liccardi, Giuseppa
AU  - Liccardi G
AD  - Department of Evolutionary Developmental and Educational Psychology, University
      of Murcia, 30100 Murcia, Spain.
FAU - Ruiz-Esteban, Cecilia
AU  - Ruiz-Esteban C
AUID- ORCID: 0000-0002-5836-331X
AD  - Department of Evolutionary Developmental and Educational Psychology, University
      of Murcia, 30100 Murcia, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - Switzerland
TA  - Eur J Investig Health Psychol Educ
JT  - European journal of investigation in health, psychology and education
JID - 101751466
PMC - PMC8314290
OTO - NOTNLM
OT  - emotional management
OT  - moral disengagement
OT  - peer relationships
OT  - school climate
OT  - school violence
EDAT- 2020/06/29 00:00
MHDA- 2020/06/29 00:01
CRDT- 2021/09/20 12:20
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/24 00:00 [revised]
PHST- 2020/06/25 00:00 [accepted]
PHST- 2021/09/20 12:20 [entrez]
PHST- 2020/06/29 00:00 [pubmed]
PHST- 2020/06/29 00:01 [medline]
AID - ejihpe10030050 [pii]
AID - 10.3390/ejihpe10030050 [doi]
PST - epublish
SO  - Eur J Investig Health Psychol Educ. 2020 Jun 29;10(3):682-690. doi:
      10.3390/ejihpe10030050.


PMID- 32592360
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 21
IP  - 6
DP  - 2020 Jun 1
TI  - Conflict of Interest: Are Iranian Breast Cancer Specialists Prone to it?
PG  - 1653-1658
LID - 89114 [pii]
LID - 10.31557/APJCP.2020.21.6.1653 [doi]
AB  - INTRODUCTION: Giving gifts is a common way to promote and encourage the use of
      products of trading companies and increase the patient referrals to diagnostic
      centers. The present study aimed to assess the practice of physicians of
      different (sub) specialties/educational levels engaged in breast cancer
      management in some conflict of interest (COI) situations in their relation with
      pharmaceutical companies and paraclinical centers. METHODS: A self-administered
      online questionnaire including questions on demographic and professional
      information as well as the attitude of physicians toward COI by answering the
      questions in three different practical scenarios was developed. Respondents were 
      asked to answer each question by selecting one of the five options: strongly
      agree, agree, undecided/neutral, disagree, and strongly disagree in their own
      practices as well as the same questions asking the same subject for what they
      think of the other physicians. Descriptive statistical analysis was used to
      report qualitative and quantitative variables. RESULT: The response rate was
      66.24%. In general, physicians considered their performance better than that of
      other physicians in the situations asked. More than 90% stated that they would
      participate in the sponsorship congress for introducing new drugs. One fifth of
      the physicians stated that they would accept the 30% financial proposition for
      the referral of every single patient to other clinics. More than half of the
      physicians stated that they had considered the risks resulted from the COI for
      referring patients to private radiobiological centers. CONCLUSION: This study
      indicated that physicians in the field of breast cancer were at the risk of COI. 
      Even within the medical field, there is not sufficient trust in the proper
      functioning of doctors in dealing with COI situations.<br />.
FAU - Ebrahimi, Amirpasha
AU  - Ebrahimi A
AD  - Department of Surgery, Tehran University of Medical Sciences (TUMS), Tehran,
      Iran.
FAU - Zand, Sanaz
AU  - Zand S
AD  - Department of Research, Kaviani Breast Diseases Institute(KBDI), Tehran, Iran.
FAU - Bagheri Amiri, Fahimeh
AU  - Bagheri Amiri F
AD  - Urology and Nephrology Research Center, Shahid Beheshti University of Medical
      Sciences, Tehran, Iran.
FAU - Shahi, Farhad
AU  - Shahi F
AD  - Department of Internal Medicine, Cancer Institute, Tehran University of Medical
      Sciences (TUMS), Tehran, Iran.
FAU - Jafarian, Ali
AU  - Jafarian A
AD  - Department of Surgery, Tehran University of Medical Sciences (TUMS), Tehran,
      Iran.
FAU - Kaviani, Ahmad
AU  - Kaviani A
AD  - Department of Surgery, Tehran University of Medical Sciences (TUMS), Tehran,
      Iran.
AD  - Breast Diseases Research Center, Tehran University of Medical Sciences, Tehran,
      Iran.
AD  - Department of Surgical Oncology, University de Montreal, Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
SB  - IM
MH  - Breast Neoplasms/*drug therapy
MH  - *Conflict of Interest
MH  - Drug Industry/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Physicians/*ethics/standards
MH  - Specialization/*standards
MH  - Surveys and Questionnaires
PMC - PMC7568883
OTO - NOTNLM
OT  - Ethics
OT  - Industry
OT  - Key words: Conflict of interest
OT  - breast cancer
OT  - physician
EDAT- 2020/06/28 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/28 06:00
PHST- 2019/11/23 00:00 [received]
PHST- 2020/06/28 06:00 [entrez]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - 10.31557/APJCP.2020.21.6.1653 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2020 Jun 1;21(6):1653-1658. doi:
      10.31557/APJCP.2020.21.6.1653.


PMID- 32592076
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210211
IS  - 1573-2800 (Electronic)
IS  - 0004-0002 (Linking)
VI  - 49
IP  - 7
DP  - 2020 Oct
TI  - Dealing with Moral Challenges in Treatment of Transgender Children and
      Adolescents: Evaluating the Role of Moral Case Deliberation.
PG  - 2619-2634
LID - 10.1007/s10508-020-01762-3 [doi]
AB  - Treatment teams providing affirmative medical transgender care to young people
      frequently face moral challenges arising from the care they provide. An
      adolescent's capacity to consent, for example, could raise several issues and
      challenges. To deal with these challenges more effectively, several Dutch
      treatment teams started using a relatively well-established form of clinical
      ethics support (CES) called Moral Case Deliberation (MCD). MCD is a
      facilitator-led, collective moral inquiry based on a real case. This study's
      purpose is to describe the teams' perceived value and effectiveness of MCD. We
      conducted a mixed methods evaluation study using MCD session reports, individual 
      interviews, focus groups, and MCD evaluation questionnaires. Our results show
      that Dutch transgender care providers rated MCD as highly valuable in situations 
      where participants were confronted with moral challenges. The health care
      providers reported that MCD increased mutual understanding and open communication
      among team members and strengthened their ability to make decisions and take
      action when managing ethically difficult circumstances. However, the health care 
      providers also expressed criticisms of MCD: some felt that the amount of time
      spent discussing individual cases was excessive, that MCD should lead to more
      practical and concrete results, and that MCD needed better integration and
      follow-up in the regular work process. We recommend future research on three
      matters: studying how MCD contributes to the quality of care, involvement of
      transgender people themselves in MCD, and integration of CES into daily work
      processes.
FAU - Vrouenraets, Lieke Josephina Jeanne Johanna
AU  - Vrouenraets LJJJ
AD  - Curium-Department of Child and Adolescent Psychiatry, Leiden University Medical
      Center, Endegeesterstraatweg 27, 2342 AK, Oegstgeest, The Netherlands.
      l.j.j.j.vrouenraets@curium.nl.
FAU - Hartman, Laura A
AU  - Hartman LA
AD  - Department of Medical Humanities, Amsterdam Public Health Research Institute,
      Amsterdam University Medical Centers, location VU University Medical Center,
      Amsterdam, The Netherlands.
FAU - Hein, Irma M
AU  - Hein IM
AD  - Department of Child and Adolescent Psychiatry, Amsterdam University Medical
      Centers, location Academic Medical Center, Amsterdam, The Netherlands.
FAU - de Vries, Annelou L C
AU  - de Vries ALC
AD  - Department of Child and Adolescent Psychiatry, Amsterdam University Medical
      Centers, location VU University Medical Center, Amsterdam, The Netherlands.
FAU - de Vries, Martine C
AU  - de Vries MC
AD  - Department of Pediatrics, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Molewijk, Bert A C
AU  - Molewijk BAC
AD  - Department of Medical Humanities, Amsterdam Public Health Research Institute,
      Amsterdam University Medical Centers, location VU University Medical Center,
      Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - United States
TA  - Arch Sex Behav
JT  - Archives of sexual behavior
JID - 1273516
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Ethics Consultation/*standards
MH  - Female
MH  - Humans
MH  - Male
MH  - *Morals
MH  - Surveys and Questionnaires
MH  - Transgender Persons/*psychology
PMC - PMC7497454
OTO - NOTNLM
OT  - *Clinical ethics support (CES)
OT  - *Gender dysphoria
OT  - *Moral case deliberation (MCD)
OT  - *Moral challenges
OT  - *Transgender
EDAT- 2020/06/28 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/28 06:00
PHST- 2018/04/13 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/06/28 06:00 [entrez]
AID - 10.1007/s10508-020-01762-3 [doi]
AID - 10.1007/s10508-020-01762-3 [pii]
PST - ppublish
SO  - Arch Sex Behav. 2020 Oct;49(7):2619-2634. doi: 10.1007/s10508-020-01762-3. Epub
      2020 Jun 26.


PMID- 32592023
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20201218
IS  - 1920-7476 (Electronic)
IS  - 0008-4263 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Aug
TI  - Pandemics, privacy, and public health research.
PG  - 454-457
LID - 10.17269/s41997-020-00368-5 [doi]
AB  - Sharing data expediently for pandemic response purposes exposes healthcare
      providers in Canada to significant regulatory uncertainty. Duplicative and
      contradictory ethical and legal duties flowing from overlapping sources can
      stifle flows of medical data among clinicians, researchers, and institutions.
      Authorities should support caregivers and accelerate research by providing clear 
      guidance to the health sector. Institutions should foster robust data stewardship
      and standardize their practices to those recognized among the international
      health informatics community. Reform is critical to ensuring Canadian healthcare 
      providers can deliver efficient health responses that are integrated with
      dispersed and disparate national and international approaches.
FAU - Bernier, Alexander
AU  - Bernier A
AUID- ORCID: 0000-0001-8615-8375
AD  - Centre of Genomics and Policy, Faculty of Medicine, McGill University, 740,
      Avenue Dr. Penfield, Suite 5200, Montreal, Quebec, H3A 0G1, Canada.
      alexander.bernier@mail.mcgill.ca.
FAU - Knoppers, Bartha Maria
AU  - Knoppers BM
AD  - Centre of Genomics and Policy, Faculty of Medicine, McGill University, 740,
      Avenue Dr. Penfield, Suite 5200, Montreal, Quebec, H3A 0G1, Canada.
LA  - eng
GR  - One4ALL: "Sharing Big Data for Health Innovation Advancing the Objectives of the 
      Global Alliance for Genomics and Health (GA4GH) Regulatory and Ethics Work
      Stream" Genome Canada / CIHR (2019-2022)/Genome Canada/International
GR  - One4ALL: "Sharing Big Data for Health Innovation Advancing the Objectives of the 
      Global Alliance for Genomics and Health (GA4GH) Regulatory and Ethics Work
      Stream" Genome Canada / CIHR (2019-2022)/CIHR/Canada
GR  - One4ALL: "Sharing Big Data for Health Innovation Advancing the Objectives of the 
      Global Alliance for Genomics and Health (GA4GH) Regulatory and Ethics Work
      Stream" Genome Canada / CIHR (2019-2022)/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - Switzerland
TA  - Can J Public Health
JT  - Canadian journal of public health = Revue canadienne de sante publique
JID - 0372714
SB  - IM
EIN - Can J Public Health. 2020 Jul 13;:. PMID: 32661934
MH  - *Biomedical Research
MH  - COVID-19
MH  - Canada/epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*epidemiology
MH  - Privacy/*legislation & jurisprudence
MH  - *Public Health
PMC - PMC7318908
OTO - NOTNLM
OT  - *COVID-19
OT  - *Data sharing
OT  - *Health governance
OT  - *Health policy
OT  - *Pandemic
OT  - *Privacy
EDAT- 2020/06/28 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/06/28 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/06/28 06:00 [entrez]
AID - 10.17269/s41997-020-00368-5 [doi]
AID - 10.17269/s41997-020-00368-5 [pii]
PST - ppublish
SO  - Can J Public Health. 2020 Aug;111(4):454-457. doi: 10.17269/s41997-020-00368-5.
      Epub 2020 Jun 26.


PMID- 32591437
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20200825
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 1
DP  - 2020 Jul
TI  - Access to Transplantation for Undocumented Pediatric Patients.
LID - e20193692 [pii]
LID - 10.1542/peds.2019-3692 [doi]
AB  - Clinicians in the United States today regularly face dilemmas about health
      disparities. Many patients and families cannot afford the medical care that
      doctors recommend. These problems are most stark when the medical care that is
      needed is lifesaving and expensive and involves scarce resources. Transplants are
      the best example of this. The most ethically disturbing situations occur when an 
      undocumented immigrant child needs a transplant. We present such a case and
      analyze the ethical, legal, and policy issues that arise.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Charnaya, Olga
AU  - Charnaya O
AD  - Division of Pediatric Nephrology, School of Medicine, Johns Hopkins University,
      Baltimore, Maryland.
FAU - Verghese, Priya
AU  - Verghese P
AD  - Division of Pediatric Nephrology, Department of Pediatrics, Medical School,
      University of Minnesota, Minneapolis, Minnesota.
FAU - Goldberg, Aviva
AU  - Goldberg A
AD  - Section of Nephrology, Department of Pediatrics and Child Health, Max Rady
      College of Medicine, Rady Faculty of Health Sciences, University of Manitoba,
      Winnipeg, Manitoba, Canada.
FAU - Ladin, Keren
AU  - Ladin K
AD  - Research on Ethics, Aging, and Community Health Lab and.
AD  - Departments of Occupational Therapy and Community Health, School of Arts and
      Sciences, Tufts University, Medford, Massachusetts; and.
FAU - Porteny, Thalia
AU  - Porteny T
AD  - Research on Ethics, Aging, and Community Health Lab and.
FAU - Lantos, John D
AU  - Lantos JD
AD  - Bioethics Center, Children's Mercy Hospital, Kansas City, Missouri
      jlantos@cmh.edu.
LA  - eng
PT  - Case Reports
PT  - Letter
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Child, Preschool
MH  - *Emigrants and Immigrants
MH  - Health Resources/*statistics & numerical data
MH  - Humans
MH  - Kidney Transplantation/*methods
MH  - Male
MH  - Nephrotic Syndrome/ethnology/*surgery
MH  - *Transplant Recipients
MH  - *Undocumented Immigrants
MH  - United States/epidemiology
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/06/28 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/06/28 06:00
PHST- 2019/11/19 00:00 [accepted]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/06/28 06:00 [entrez]
AID - peds.2019-3692 [pii]
AID - 10.1542/peds.2019-3692 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Jul;146(1). pii: peds.2019-3692. doi: 10.1542/peds.2019-3692.


PMID- 32591436
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20210919
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 1
DP  - 2020 Jul
TI  - Ethical and Public Health Implications of Targeted Screening for Congenital
      Cytomegalovirus.
LID - e20200617 [pii]
LID - 10.1542/peds.2020-0617 [doi]
AB  - Congenital cytomegalovirus (cCMV) is the most common congenital infection and is 
      associated with sensorineural hearing loss, developmental delays, and visual
      impairment. The clinical presentation of cCMV is variable, and the majority
      (80%-90%) of newborns will never manifest any clinical symptoms. Given the
      clinical heterogeneity of cCMV infection, it is challenging to identify which
      newborns may benefit from testing. Recently, certain states have implemented a
      targeted screening program in which newborns who fail the newborn hearing screen 
      are tested for cCMV. Clinicians and legislative bodies have been propelled into
      debates about the ethical and moral permissibility of a targeted cCMV screening
      approach. Those who oppose this screening approach describe undue burden on
      patients, families, and the health care system because the majority of newborns
      who fail the newborn hearing screen and have cCMV will not go on to have any
      sequelae related to cCMV, including hearing loss. However, those who support this
      screening approach cite the importance of early detection and ongoing
      surveillance for hearing loss and developmental delays in this high-risk group of
      newborns. This debate will be considered by experts in the field.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Gievers, Ladawna L
AU  - Gievers LL
AD  - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon;
      gievers@ohsu.edu.
FAU - Holmes, Alison Volpe
AU  - Holmes AV
AD  - Department of Pediatrics, Geisel School of Medicine, Dartmouth College and
      Children's Hospital at Dartmouth-Hitchcock, Lebanon, New Hampshire; and.
FAU - Loyal, Jaspreet
AU  - Loyal J
AD  - Departments of Pediatrics and.
FAU - Larson, Ilse A
AU  - Larson IA
AD  - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
FAU - Oliveira, Carlos R
AU  - Oliveira CR
AD  - Departments of Pediatrics and.
AD  - Medicine, School of Medicine, Yale University, New Haven, Connecticut.
FAU - Waldman, Erik H
AU  - Waldman EH
AD  - Head and Neck Surgery, Section of Otolaryngology and.
FAU - Khaki, Sheevaun
AU  - Khaki S
AD  - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
LA  - eng
GR  - KL2 TR001862/TR/NCATS NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Cytomegalovirus
MH  - Cytomegalovirus Infections/complications/*congenital/diagnosis
MH  - *Early Diagnosis
MH  - Hearing Loss, Sensorineural/*diagnosis/etiology
MH  - Hearing Tests/methods
MH  - Humans
MH  - Infant, Newborn
MH  - Neonatal Screening/*methods
PMC - PMC8171256
MID - NIHMS1707002
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/06/28 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/06/28 06:00
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/06/28 06:00 [entrez]
AID - peds.2020-0617 [pii]
AID - 10.1542/peds.2020-0617 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Jul;146(1). pii: peds.2020-0617. doi: 10.1542/peds.2020-0617.


PMID- 32591415
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1521-009X (Electronic)
IS  - 0090-9556 (Linking)
VI  - 48
IP  - 9
DP  - 2020 Sep
TI  - Gestational Age-Dependent Abundance of Human Placental Transporters as Determined
      by Quantitative Targeted Proteomics.
PG  - 735-741
LID - 10.1124/dmd.120.000067 [doi]
AB  - Some women take medication during pregnancy to address a variety of clinical
      conditions. Because of ethical and logistical concerns, it is impossible to
      determine fetal drug exposure, and therefore fetal risk, during pregnancy. Hence,
      alternative approaches need to be developed to predict maternal-fetal drug
      exposure throughout pregnancy. To do so, we previously developed and verified a
      maternal-fetal physiologically based pharmacokinetic model, which can predict
      fetal exposure to drugs that passively cross the placenta. However, many drugs
      are actively transported by the placenta (e.g., human immunodeficiency virus
      protease inhibitors). To extend our maternal-fetal physiologically based
      pharmacokinetic model to these actively transported drugs, we determined the
      gestational age-dependent changes in the protein abundance of placental
      transporters. Total cellular membrane fractions from first trimester (T1; n =
      15), second trimester (T2; n = 19), and term (n = 15) human placentae obtained
      from uncomplicated pregnancies were isolated by ultracentrifugation. Transporter 
      protein abundance was determined by targeted quantitative proteomics using liquid
      chromatography tandem mass specrometry. We observed that breast cancer resistance
      protein and P-glycoprotein abundance significantly decreased from T1 to term by
      55% and 69%, respectively (per gram of tissue). Organic anion-transporting
      polypeptide (OATP) 2B1 abundance significantly decreased from T1 to T2 by 32%. In
      contrast, organic cation transporter (OCT) 3 and organic anion transporter 4
      abundance significantly increased with gestational age (2-fold from T1 to term,
      1.6-fold from T2 to term). Serotonin transporter and norepinephrine transporter
      did not change with gestational age. The abundance of bile salt export pump,
      multidrug resistance-associated protein 1-5, Na(+)-taurocholate cotransporting
      polypeptide, OATP1B1, OATP1B3, OCTN1-2, concentrative nucleoside transporter 1-3,
      equilibrative nucleoside transporter 2, and multidrug and toxin extrusion 1 could
      not be quantified. These data can be incorporated into our maternal-fetal
      physiologically based pharmacokinetic model to predict fetal exposure to drugs
      that are actively transported across the placenta. SIGNIFICANCE STATEMENT: We
      quantified the protein abundance of key placental uptake and efflux transporters 
      [organic cation transporter (OCT) 3, P-glycoprotein (P-gp), breast cancer
      resistance protein (BCRP)] across gestational ages (first trimester, second
      trimester, and term) using quantitative targeted proteomics. We observed that the
      protein abundance of P-gp and BCRP decreased, whereas that of OCT3 increased with
      gestational age. Incorporating the protein abundance determined in this study
      into maternal-fetal physiologically based pharmacokinetic model can help us
      better predict fetal drug exposure to substrates of these transporters.
CI  - Copyright (c) 2020 by The Author(s).
FAU - Anoshchenko, Olena
AU  - Anoshchenko O
AD  - Department of Pharmaceutics, University of Washington, Seattle, Washington.
FAU - Prasad, Bhagwat
AU  - Prasad B
AD  - Department of Pharmaceutics, University of Washington, Seattle, Washington.
FAU - Neradugomma, Naveen K
AU  - Neradugomma NK
AD  - Department of Pharmaceutics, University of Washington, Seattle, Washington.
FAU - Wang, Joanne
AU  - Wang J
AD  - Department of Pharmaceutics, University of Washington, Seattle, Washington.
FAU - Mao, Qingcheng
AU  - Mao Q
AD  - Department of Pharmaceutics, University of Washington, Seattle, Washington.
FAU - Unadkat, Jashvant D
AU  - Unadkat JD
AUID- ORCID: 0000-0002-4820-8455
AD  - Department of Pharmaceutics, University of Washington, Seattle, Washington
      jash@u.washington.edu.
LA  - eng
GR  - P01 DA032507/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - United States
TA  - Drug Metab Dispos
JT  - Drug metabolism and disposition: the biological fate of chemicals
JID - 9421550
RN  - 0 (Membrane Transport Proteins)
SB  - IM
EIN - Drug Metab Dispos. 2020 Dec;48(12):1347. PMID: 33234559
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - *Maternal-Fetal Exchange
MH  - Membrane Transport Proteins/analysis/*metabolism
MH  - Models, Biological
MH  - Placenta/*metabolism
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Trimesters/*metabolism
MH  - Proteomics/methods
PMC - PMC7469251
EDAT- 2020/06/28 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/06/28 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/06/28 06:00 [entrez]
AID - dmd.120.000067 [pii]
AID - 10.1124/dmd.120.000067 [doi]
PST - ppublish
SO  - Drug Metab Dispos. 2020 Sep;48(9):735-741. doi: 10.1124/dmd.120.000067. Epub 2020
      Jun 26.


PMID- 32590934
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20200918
IS  - 1347-4715 (Electronic)
IS  - 1342-078X (Linking)
VI  - 25
IP  - 1
DP  - 2020 Jun 26
TI  - Factors related to turnover intentions and work-related injuries and accidents
      among professional caregivers: a cross-sectional questionnaire study.
PG  - 24
LID - 10.1186/s12199-020-00863-8 [doi]
AB  - BACKGROUND: The Japanese health and welfare industry has a shortage of
      professional caregivers, and work-related accidents and injuries among this group
      are therefore especially critical issues. This study aimed to examine the factors
      associated with turnover intentions and work-related injuries and accidents among
      professional caregivers in Japan. METHODS: Self-report questionnaires were
      distributed to care workers (N = 1396) at 26 geriatric-care facilities. The
      questionnaire addressed basic attributes, work and organizational
      characteristics, wage adequacy, and intrinsic motivations for work (e.g., "being 
      suited to caring work"). Social-relational aspects of the work environment were
      assessed via three subscales of the Social Capital and Ethical Climate in the
      Workplace instrument (i.e., "Social Capital in the Workplace," "Exclusive
      Workplace Climate," and "Ethical Leadership"). Dependent variables were the
      experience of work-related accidents or injuries in the prior year and
      organizational and occupational turnover intentions. We used datasets of
      professional caregivers for analyses. RESULTS: The response rate was 68% (N =
      949). Among the 667 professional caregivers, 63% were female. On multivariable
      logistic regression analysis for work-related accidents and injuries for each
      sex, those with higher scores for "being suited to caring work" were found to
      experience significantly fewer work-related accidents and injuries (odds ratio
      [OR] = 0.78, p < 0.01) among female caregivers. Male caregivers who perceived an 
      exclusive workplace climate experienced more work-related accidents and injuries 
      (OR = 1.61, p < 0.01). However, experience of work-related accidents and injuries
      did not show significant relationships with organizational and occupational
      turnover intentions. Additionally, "being suited to caring work" (OR = 0.73, p < 
      0.01) and ethical leadership (OR = 0.76, p < 0.05) were found to be negatively
      associated with organizational turnover intentions. "Being suited to caring work"
      (OR = 0.61, p < 0.01), inadequacy of wage (OR = 2.22, p < 0.05), and marital
      status (OR = 2.69, p < 0.01) were also associated with occupational turnover
      intentions of professional caregivers. CONCLUSIONS: These findings highlight the 
      need to foster intrinsic motivations for work as well as providing a supportive
      and ethical work environment to reduce high turnover rates and work-related
      injuries and accidents among professional caregivers.
FAU - Tei-Tominaga, Maki
AU  - Tei-Tominaga M
AUID- ORCID: http://orcid.org/0000-0002-7000-9559
AD  - Faculty of Nursing, Setsunan University, 45-1 Nagaotoge-cho, Hirakata City,
      Osaka, 573-0101, Japan. maki.tominaga@nrs.setsunan.ac.jp.
FAU - Nakanishi, Miharu
AU  - Nakanishi M
AD  - Research Center for Social Science and Medicine, Tokyo Metropolitan Institute of 
      Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.
LA  - eng
GR  - JP16H05612/Japan Society for the Promotion of Science (JP)
PT  - Journal Article
DEP - 20200626
PL  - Japan
TA  - Environ Health Prev Med
JT  - Environmental health and preventive medicine
JID - 9609642
SB  - IM
MH  - Accidents, Occupational/*statistics & numerical data
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Caregivers/*psychology/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Intention
MH  - Japan
MH  - *Job Satisfaction
MH  - Male
MH  - Middle Aged
MH  - Occupational Injuries/*statistics & numerical data
MH  - Personnel Turnover/*statistics & numerical data
MH  - Self Report
PMC - PMC7320545
OTO - NOTNLM
OT  - Professional caregiver
OT  - Turnover
OT  - Work environment
OT  - Work-related accident and injury
EDAT- 2020/06/28 06:00
MHDA- 2020/09/20 06:00
CRDT- 2020/06/28 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/06/28 06:00 [entrez]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
AID - 10.1186/s12199-020-00863-8 [doi]
AID - 10.1186/s12199-020-00863-8 [pii]
PST - epublish
SO  - Environ Health Prev Med. 2020 Jun 26;25(1):24. doi: 10.1186/s12199-020-00863-8.


PMID- 32590791
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - Clinical massage therapy for patients with exercise-induced fatigue: A protocol
      for systematic review and meta analysis.
PG  - e20870
LID - 10.1097/MD.0000000000020870 [doi]
AB  - BACKGROUND: Exercise-induced fatigue (EF) has been a major area of interest
      within the field of sports and clinical medicine. Implemented on people's skin,
      muscles, and joints as an important part of complementary and alternative
      medicine , massage therapy has a positive effect on the recovery of EF and sports
      injuries. In this systematic review, we aim to evaluate the effectiveness and
      safety of massage therapy for patients with EF. METHODS: We will search the
      following electronic databases for randomized controlled trials to evaluate the
      effectiveness and safety of massage therapy in treating EF: China National
      Knowledge Infrastructure, Wanfang and PubMed Database, Cochrane Central Register 
      of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature,
      Excerpta Medica database, and Medical Literature Analysis and Retrieval System
      Online. Each database will be searched from inception to May 2020. The entire
      process will include study selection, data extraction, risk of bias assessment
      and meta-analyses. RESULTS: This proposed study will evaluate the effectiveness
      and safety of massage therapy for patients with EF. The outcomes will include
      change in fatigue relief and adverse effect. CONCLUSIONS: This proposed
      systematic review will evaluate the existing evidence on the effectiveness and
      safety of massage therapy for patients with EF. DISSEMINATION AND ETHICS: The
      results of this review will be disseminated through peer-reviewed publication.
      Because all of the data used in this systematic review and meta-analysis has been
      published, this review does not require ethical approval. Furthermore, all data
      will be analyzed anonymously during the review process.
FAU - Zhou, Ke-Lin
AU  - Zhou KL
AD  - Dongfang Hospital.
FAU - Dong, Shuo
AU  - Dong S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
FAU - Wang, Kang
AU  - Wang K
AD  - Dongfang Hospital.
FAU - Fu, Guo-Bing
AU  - Fu GB
AD  - Dongfang Hospital.
FAU - Cui, Shu-Sheng
AU  - Cui SS
AD  - Beijing Gulou Hospital of Traditional Chinese Medicine, Beijing, China.
FAU - Guo, Sheng
AU  - Guo S
AUID- ORCID: 0000-0002-9172-181
AD  - Dongfang Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Clinical Protocols
MH  - Exercise/*physiology
MH  - Fatigue/*etiology/physiopathology
MH  - Humans
MH  - Massage/methods/*standards
MH  - Systematic Reviews as Topic
PMC - PMC7328973
EDAT- 2020/06/27 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 10.1097/MD.0000000000020870 [doi]
AID - 00005792-202006260-00066 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20870. doi:
      10.1097/MD.0000000000020870.


PMID- 32590781
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - Aortic injury caused by esophageal foreign body-case reports of 3 patients and
      literature review.
PG  - e20849
LID - 10.1097/MD.0000000000020849 [doi]
AB  - OBJECTIVES: Ingestion of a foreign body can cause different degrees of damage to 
      esophagus, and several complications are potentially life-threatening if not
      properly handled. The aortic injury caused by a perforating esophageal foreign
      body is rare but lethal. The optimal management still remains controversial. The 
      purpose of this report is to describe our experience in the management of the
      aortic injury caused by esophageal foreign body ingestion. METHODS: Between
      January 2015 and December 2015, we retrospectively enrolled cases of esophageal
      perforation involving the aorta by foreign body. The general parameters,
      esophageal foreign body, types of aortic injury, treatment, and outcome were
      analyzed. Additionally, we reviewed the literature of the management of
      esophageal perforation involving the aorta caused by foreign bodies. The study
      was approved by the ethics committee of the First Affiliated Hospital, College of
      Medicine, Zhejiang University, and the need for informed consent was waived
      (Quick review 2019, No. 609). RESULTS: Three cases of esophageal perforation
      involving the aorta by foreign body was selected in the study. Two male and 1
      female patients (range, 51-58 years old) with the aorta involvement caused by a
      perforating foreign body in the esophagus in 3 forms were identified, including 1
      patient with mycotic aortic pseudoaneurysm, 1 patient with aortoesophageal
      fistula and 1 patient with the aortic intramural hematoma. One patient died of
      the rupture of the pseudoaneurysm during the preparation of the surgery. The
      other 2 patients were cured with a multidisciplinary approach, which is an urgent
      thoracic endovascular aortic repair followed by mediastinal debridement/drainage 
      or endoscopic retrieval. Two of 3 patients were survived until now. CONCLUSION:
      The management of the aortic injury caused by esophageal foreign body injury is
      challenging. Early diagnosis and multidisciplinary management is crucial.
FAU - Zeng, Liping
AU  - Zeng L
AD  - Department of Thoracic Surgery, The First Affiliated Hospital, College of
      Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
FAU - Shu, Wenbo
AU  - Shu W
FAU - Ma, Honghai
AU  - Ma H
FAU - Hu, Jian
AU  - Hu J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aneurysm, False/complications
MH  - Angiography/methods
MH  - Aorta/diagnostic imaging/*injuries/pathology
MH  - Eating/physiology
MH  - Esophageal Fistula/complications
MH  - Esophageal Perforation/complications
MH  - Female
MH  - Foreign Bodies/*complications/diagnostic imaging
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tomography, X-Ray Computed/methods
PMC - PMC7328905
EDAT- 2020/06/27 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - 10.1097/MD.0000000000020849 [doi]
AID - 00005792-202006260-00056 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20849. doi:
      10.1097/MD.0000000000020849.


PMID- 32590774
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - Effects of ipratropium bromide on the occurrence of postoperative respiratory
      complications in craniectomy patients with COPD: A nationwide multicenter
      retrospective study.
PG  - e20836
LID - 10.1097/MD.0000000000020836 [doi]
AB  - INTRODUCTION: Postoperative pulmonary complications (PPCs) are common and
      associated with increased morbidity, mortality, and medical cost. They are
      gaining increasing concerns among patients receiving neurological surgery.
      Chronic obstructive pulmonary disease (COPD) affect a large section of whole
      population and is also one of the risk factors of PPCs in the perioperative
      setting. Ipratropium bromide is the inhalation solution for the treatment of
      COPD. Studies showed the perioperative nebulization of ipratropium bromide could 
      increase the lung function and decrease the incidence of postoperative pneumonia 
      in COPD patients underwent thoracic surgery. The purpose of this study is to
      investigate the effect of perioperative nebulization of ipratropium bromide on
      PPCs in COPD patients underwent neurosurgical surgery. METHODS AND ANALYSIS: This
      study is a multicenter retrospective study in China. Patients who meet the
      inclusion/exclusion criteria are selected from 7 neurosurgical centers in China. 
      According to whether ipratropium bromide is used in perioperative period, the
      patients are divided into exposure group and control group. The primary outcome
      is the incidence of postoperative pneumonia. Secondary outcomes are unplanned
      intubation, postoperative mechanical ventilation >/= 48 hours, respiratory
      failure, atelectasis, death, and length of stay. ETHICS AND DISSEMINATION: This
      study was approved by the ethics committee (EC) of the School of Public Health,
      Fudan University, Shanghai, China. Waived by the ethics committee, no written
      consent form was obtained since we used the registry data. The study results will
      be communicated via publication. TRIAL REGISTRATION NUMBER: ChiCTR1900022552.
FAU - Du, Zhuoying
AU  - Du Z
AD  - Department of Neurosurgery, Huashan Hospital of Fudan University.
FAU - Huang, Xiaoqian
AU  - Huang X
AUID- ORCID: 0000-0003-3320-7828
AD  - Department of Biostatistics, School of Public Health, Fudan University.
AD  - NHC Key Laboratory of Health Technology Assessment (Fudan University).
AD  - Key Laboratory of Public Health Safety of Ministry of Education (Fudan
      University), Shanghai.
FAU - Feng, Yi
AU  - Feng Y
AD  - The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu.
FAU - Yan, Wei
AU  - Yan W
AD  - The Second Affiliated Hospital, School of Medicine, Zhejiang University,
      Hangzhou, Zhejiang.
FAU - Xu, Dan
AU  - Xu D
AD  - The First Affiliated Hospital of Chongqing Medical University, Chongqing.
FAU - Sun, Xiaoou
AU  - Sun X
AD  - The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu.
FAU - Wu, Chao
AU  - Wu C
AD  - The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu.
FAU - Zheng, Yongke
AU  - Zheng Y
AD  - Affiliated Hangzhou First People's Hospital Zhejiang University School of
      Medicine, Hangzhou, Zhejiang.
FAU - Zeng, Longhuan
AU  - Zeng L
AD  - Affiliated Hangzhou First People's Hospital Zhejiang University School of
      Medicine, Hangzhou, Zhejiang.
FAU - Xiong, Xiaowei
AU  - Xiong X
AD  - Affiliated Hangzhou First People's Hospital Zhejiang University School of
      Medicine, Hangzhou, Zhejiang.
FAU - Liu, Yuankun
AU  - Liu Y
AD  - Wu Xi People's Hospital, Wuxi, Jiangsu, China.
FAU - Zhang, Chenbo
AU  - Zhang C
AD  - Department of Biostatistics, School of Public Health, Fudan University.
FAU - Luo, Jianfeng
AU  - Luo J
AD  - Department of Biostatistics, School of Public Health, Fudan University.
AD  - NHC Key Laboratory of Health Technology Assessment (Fudan University).
AD  - Key Laboratory of Public Health Safety of Ministry of Education (Fudan
      University), Shanghai.
FAU - Hu, Jin
AU  - Hu J
AD  - Department of Neurosurgery, Huashan Hospital of Fudan University.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Bronchodilator Agents)
RN  - GR88G0I6UL (Ipratropium)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Bronchodilator Agents/standards/therapeutic use
MH  - Chi-Square Distribution
MH  - China/epidemiology
MH  - Craniotomy/*adverse effects/methods
MH  - Dyspnea/*drug therapy
MH  - Female
MH  - Humans
MH  - Ipratropium/*standards/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/drug therapy/epidemiology/*prevention & control
MH  - Propensity Score
MH  - Pulmonary Disease, Chronic Obstructive/*complications/drug therapy/epidemiology
MH  - Retrospective Studies
PMC - PMC7328966
EDAT- 2020/06/27 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - 10.1097/MD.0000000000020836 [doi]
AID - 00005792-202006260-00049 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20836. doi:
      10.1097/MD.0000000000020836.


PMID- 32590753
OWN - NLM
STAT- MEDLINE
DCOM- 20200708
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - The effectiveness and safety of Chinese medicines for the treatment of uveitis: A
      protocol for systematic review and meta-analysis.
PG  - e20766
LID - 10.1097/MD.0000000000020766 [doi]
AB  - BACKGROUND: Uveitis is an inflammatory and heterogeneous ocular disorder and has 
      a profound impact on patients' life, work and family. There are substantial costs
      to the countries and individuals associated with treatment of the complications
      of uveitis and blindness. Conventional therapies did not lead to satisfactory
      outcomes for uveitis and are associated with substantial adverse events (AEs).
      Emerging evidences have proved the important value and potential prospect of
      Chinese medicines and its compound in uveitis. However, although Chinese
      medicines are widely used in uveitis, its therapeutic effect and safety are still
      controversial. It is, therefore, timely to perform an objective and normative
      systematic review to assess the efficacy and safety of Chinese medicines in
      treating uveitis on current research. METHODS: The systematic review will include
      all of the randomized controlled trials (RCT) on the efficacy and safety of
      Chinese medicines for uveitis. A relevant literature search by sensitive search
      strategies was conducted using the following electronic databases from their
      inception to September 30, 2019: PubMed, Web of Science, EMBASE, the Cochrane
      Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China 
      Science and Technology Journal database (VIP) and Chinese Biomedical Literature
      database (CBM). The strategy combines treatment terms and disease: that is,
      "Medicine, Chinese Traditional" (e.g., "Medicine, Chinese Traditional", TCM,
      Traditional Chinese medicine, Zhong Yi Xue) and uveitis. We will also search
      registers of clinical trials, potential gray literature, and conference
      abstracts. There are no limits on language and publication status. The literature
      screening, data extraction, and quality assessment will be conducted by 2
      reviewers independently. The reporting quality and risk of bias will be assessed 
      by other two researchers. Best-corrected visual acuity (BCVA) and improvement in 
      disease activity were assessed as the primary outcome. The secondary outcomes
      will include laboratory efficacy indexes, score changes in the National Eye
      Institute Visual Functioning Questionnaire 25 (NEI-VFQ 25), uveitis-related
      tissue damage or complications, concurrent requirement of corticosteroids,
      immunosuppressive drugs or biologics, and AEs of treatment. Meta-analysis will be
      performed using RevMan5.3 software provided by the Cochrane Collaboration.
      RESULTS: This study will provide a comprehensive review based on current evidence
      of Chinese medicines treatment for uveitis in several aspects, including BCVA and
      improvement in disease activity, laboratory efficacy indexes, score changes in
      the NEI-VFQ 25, uveitis-related tissue damage or complications, etc. CONCLUSION::
      The conclusion of this study will provide evidence to determine whether Chinese
      medicines are an effective and safe intervention for patients with uveitis.
      ETHICS AND DISSEMINATION: It is not necessary to obtain ethical approval for this
      study, given that this protocol is for a systematic review. The systematic review
      will be published in a peer-reviewed journal, presented at conferences and will
      be shared on social media platforms. PROSPERO REGISTRATION NUMBER: PROSPERO
      CRD42020153620.
FAU - Han, Mengyu
AU  - Han M
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Chen, Yang
AU  - Chen Y
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Nong, Luqi
AU  - Nong L
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Liu, Ziqiang
AU  - Liu Z
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Qin, Yali
AU  - Qin Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Meng, Huan
AU  - Meng H
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Chen, You
AU  - Chen Y
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Wang, Zhijun
AU  - Wang Z
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Jin, Ming
AU  - Jin M
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Meta-Analysis as Topic
MH  - Outcome Assessment, Health Care
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Uveitis/*therapy
PMC - PMC7328941
EDAT- 2020/06/27 06:00
MHDA- 2020/07/09 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
AID - 10.1097/MD.0000000000020766 [doi]
AID - 00005792-202006260-00028 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20766. doi:
      10.1097/MD.0000000000020766.


PMID- 32590751
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - Mental health circumstances among health care workers and general public under
      the pandemic situation of COVID-19 (HOME-COVID-19).
PG  - e20751
LID - 10.1097/MD.0000000000020751 [doi]
AB  - BACKGROUND: After the spread of the coronavirus disease 2019 (COVID-19) globally,
      upgraded quarantine and physical distancing strategy, strict infection measures, 
      and government's strict lockdown have been abided to confront the spread of the
      COVID-19 in Thailand. During the COVID-19 pandemic, concerns about the mental
      health and psychosocial problems among health care workers and the general
      population are now arising. Yet, information on mental health and psychosocial
      problems among health care workers and the general population have not been
      comprehensively reported in Thailand. As such, we conduct a cross-sectional
      study, a national online survey to describe the short- and long-term consequences
      of the COVID-19 pandemic on mental health and psychosocial problems among health 
      care workers and the general population in Thailand. METHODS: This study is a
      repeated cross-sectional study, an open online voluntary national-based survey
      during the wave I (April 21-May 4, 2020) follow-up in the wave II (August 3-16,
      2020), wave III (November 15-28, 2020), and a 1-year follow-up survey (wave IV:
      April 21-May 4, 2021) in Thailand. Health care workers at the hospitals and the
      adult general population will be invited to participate in the online survey via 
      the SurveyMonkey that limits one-time participation per unique internet protocol 
      address. The target sample size of at least 1182 health care workers and 1310
      general populations will be required to complete the online survey for each wave 
      of the survey. Sociodemographic characteristics and a set of measurement tools
      for mental and psychosocial problems for each subcohort including depression,
      anxiety, stress, resilient copings, neuroticism, perceived social support,
      wellbeing, somatic symptoms, insomnia, burnout (for healthcare workers), and
      public stigma toward COVID-19 infection (for the general population) will be
      collected. For all estimates of prevalence, we will weigh data for all wave
      analyses under the complex design of the survey. Subgroup analyses stratified by 
      key characteristics will also be done to analyze the proportion differences. For 
      the repeated cross-sectional survey, we will combine the data from the wave I to 
      wave IV survey to analyze changes in the mental health status. We will perform
      multilevel logistic regression models with random intercepts to explore
      associations with individual-level and region-level/hospital-level predictors. We
      also plan to perform an ancillary systematic review and meta-analysis by
      incorporating data from our findings to all available evidence. RESULTS: Our
      findings will provide information on the short- and long-term mental health
      status as well as the psychosocial responses to the COVID-19 outbreak in a
      national sample of health care workers and the general population in Thailand.
      CONCLUSION: This prospective, nationally based, a repeated cross-sectional study 
      will describe the mental health status and psychosocial problems among health
      care workers and the general population in Thailand during the COVID-19 pandemic.
      ETHICS AND DISSEMINATION: Ethical approval for the study was obtained from the
      Faculty of Public Health and Faculty of Pharmacy, Chiang Mai University. The
      findings will be disseminated through public, scientific, and professional
      meetings, and publications in peer-reviewed journals. THAI CLINICAL TRIALS
      REGISTRY (TCTR) REGISTRATION NUMBER: TCTR20200425001.
FAU - Nochaiwong, Surapon
AU  - Nochaiwong S
AUID- ORCID: 0000-0003-1100-7171
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
FAU - Ruengorn, Chidchanok
AU  - Ruengorn C
AUID- ORCID: 0000-0001-7927-1425
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
FAU - Awiphan, Ratanaporn
AU  - Awiphan R
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
FAU - Ruanta, Yongyuth
AU  - Ruanta Y
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
FAU - Boonchieng, Waraporn
AU  - Boonchieng W
AD  - Faculty of Public Health, Chiang Mai University, Chiang Mai.
FAU - Nanta, Sirisak
AU  - Nanta S
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
AD  - Maesai Hospital, Maesai District, Chiang Rai Province.
FAU - Kowatcharakul, Woravut
AU  - Kowatcharakul W
AD  - Sansai Hospital, Sansai District.
FAU - Pumpaisalchai, Wanida
AU  - Pumpaisalchai W
AD  - Suanprung Psychiatric Hospital, Chiang Mai.
FAU - Kanjanarat, Penkarn
AU  - Kanjanarat P
AUID- ORCID: 0000-0002-8160-5444
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
FAU - Mongkhon, Pajaree
AU  - Mongkhon P
AUID- ORCID: 0000-0002-3050-1557
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
AD  - Division of Pharmacy Practice, Department of Pharmaceutical Care, School of
      Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
FAU - Thavorn, Kednapa
AU  - Thavorn K
AUID- ORCID: 0000-0003-4738-8447
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy.
AD  - Ottawa Hospital Research Institute, Ottawa Hospital.
AD  - Institute of Clinical and Evaluative Sciences, ICES uOttawa.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Hutton, Brian
AU  - Hutton B
AUID- ORCID: 0000-0001-5662-8647
AD  - Ottawa Hospital Research Institute, Ottawa Hospital.
AD  - Institute of Clinical and Evaluative Sciences, ICES uOttawa.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Wongpakaran, Nahathai
AU  - Wongpakaran N
AUID- ORCID: 0000-0001-8365-2474
AD  - Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai,
      Thailand.
FAU - Wongpakaran, Tinakon
AU  - Wongpakaran T
AUID- ORCID: 0000-0002-9062-3468
AD  - Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai,
      Thailand.
CN  - Health Outcomes and Mental Health Care Evaluation Survey Research Group
      (HOME-Survey)
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*psychology
MH  - Cross-Sectional Studies
MH  - Health Personnel/*psychology
MH  - Humans
MH  - *Mental Health
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - Prospective Studies
MH  - Thailand
PMC - PMC7329008
EDAT- 2020/06/27 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020751 [doi]
AID - 00005792-202006260-00026 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20751. doi:
      10.1097/MD.0000000000020751.


PMID- 32590745
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation 
      in cell-free DNA of patients with colorectal cancer: A protocol for systematic
      review and meta-analysis.
PG  - e20708
LID - 10.1097/MD.0000000000020708 [doi]
AB  - INTRODUCTION: Cetuximab and panitumumab have been used clinically to treat
      metastatic colorectal cancer for more than 15 years. Before the treatment is
      given, it is required to determine the KRAS mutation status since it would lead
      to drug resistance. Tumor tissue sample is traditionally used for cancer
      genotyping. In recent years, liquid biopsy sample has been intensively
      investigated as a surrogate for tumor tissue sample due to its non-invasiveness
      and better presentation of tumor heterogeneity. The aim of this study is to
      systematically summarize the accuracy of KRAS mutation measurement in colorectal 
      cancer using cell-free DNA in liquid biopsy samples, with tumor tissue sample as 
      reference (gold standard). METHODS AND ANALYSIS: We will search literatures in
      the following databases: Pubmed, Embase, and Cochrane Library. Systemic review
      and meta-analysis will be performed to summarize the accuracy of KRAS mutation
      measurement in colorectal cancer using liquid biopsy sample, and subgroup
      analysis will be performed on different testing platforms, and on metastatic and 
      non-metastatic colorectal cancer. TIMELINE: This study will start on June 1,
      2020, and is expected to be finished by November 1, 2020. ETHICS AND
      DISSEMINATION: Ethical approval will not be required since the data obtained and 
      analyzed in this study will not be on individual patients. Study results will be 
      disseminated as an official publication in a peer-reviewed journal.Registration: 
      PROSPERO CRD42020176682.
FAU - Ye, Peng
AU  - Ye P
AD  - Department of Anatomy and Histology, College of Medicine, Chengdu University.
FAU - Cai, Peiling
AU  - Cai P
AD  - Department of Anatomy and Histology, College of Medicine, Chengdu University.
FAU - Xie, Jing
AU  - Xie J
AD  - Department of Pathology and Clinical Laboratory, Sichuan Provincial Fourth
      People's Hospital.
FAU - Wei, Yuanyuan
AU  - Wei Y
AD  - Department of Physiology, College of Medicine, Chengdu University, Chengdu,
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cell-Free Nucleic Acids)
RN  - 0 (KRAS protein, human)
RN  - 6A901E312A (Panitumumab)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Cell-Free Nucleic Acids
MH  - Cetuximab/administration & dosage
MH  - Colorectal Neoplasms/drug therapy/*genetics
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Mutation
MH  - Panitumumab/administration & dosage
MH  - Polymerase Chain Reaction
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7328928
EDAT- 2020/06/27 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 10.1097/MD.0000000000020708 [doi]
AID - 00005792-202006260-00020 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20708. doi:
      10.1097/MD.0000000000020708.


PMID- 32590744
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - Efficacy and safety of acupuncture in treating post-traumatic stress disorder: A 
      protocol for systematic review and meta-analysis.
PG  - e20700
LID - 10.1097/MD.0000000000020700 [doi]
AB  - BACKGROUND: Post-traumatic stress disorder (PTSD) acts as a complex mental
      illness in which individuals are prone to long-lasting mental disorders after
      suffering traumatic events. PTSD is usually accompanied by some comorbidities,
      such as depressive disorder and sleep disorder, which seriously threaten
      patients' life and health. Evidences showed that acupuncture could remarkably
      relieve the symptoms of PTSD patients. The review aims at assessing the safety
      and effectiveness exhibited by acupuncture for treating PTSD patients. METHODS
      AND ANALYSIS: The literature identified by searching 8 English electronic
      databases and 5 Chinese electronic databases from their inception to April 20,
      2020 will be incorporated into the study. Two researchers will independently take
      charge of the research selection, the data extraction, as well as the assessment 
      on research quality. The primary outcomes will be total PTSD symptoms, measured
      by different instruments including interviews and self-report measures. Data
      analysis will be performed via the RevMan 5 software, and Grading of
      Recommendations Assessment, Development, and Evaluation will help to assess the
      evidence level. A heterogeneity x test, the Higgins' I test as well as visually
      inspecting the forest plot will help to investigate the heterogeneity of data. A 
      sensitivity analysis and subgroup analyses will assist in investigating the
      sources of heterogeneity. ETHICS AND DISSEMINATION: The review neither assesses
      the individual information of patients nor impacts their rights, so it is not
      necessary for it to be approved by ethical institution. The article will be
      published in a peer-reviewed journal and present at relevant conferences. OSF
      REGISTRATION NUMBER:: https://osf.io/dc3js.
FAU - Ding, Ning
AU  - Ding N
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Li, Linzhi
AU  - Li L
AUID- ORCID: 0000-0001-8131-7883
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Song, Kai
AU  - Song K
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Huang, Ailing
AU  - Huang A
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zhang, Hong
AU  - Zhang H
AUID- ORCID: 0000-0002-9030-5398
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Psychiatric Status Rating Scales
MH  - Research Design
MH  - Stress Disorders, Post-Traumatic/*therapy
MH  - Systematic Reviews as Topic
PMC - PMC7328930
EDAT- 2020/06/27 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 10.1097/MD.0000000000020700 [doi]
AID - 00005792-202006260-00019 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20700. doi:
      10.1097/MD.0000000000020700.


PMID- 32590730
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent
      kinase inhibition: An early phase trial.
PG  - e20458
LID - 10.1097/MD.0000000000020458 [doi]
AB  - INTRODUCTION: Targeted biologic therapies demonstrate similar efficacies in
      rheumatoid arthritis despite distinct mechanisms of action. They also exhibit a
      ceiling effect, with 10% to 20% of patients achieving remission in clinical
      trials. None of these therapies target synovial fibroblasts, which drive and
      maintain synovitis. Seliciclib (R-roscovitine) is an orally available
      cyclin-dependent kinase inhibitor that suppresses fibroblast proliferation, and
      is efficacious in preclinical arthritis models. We aim to determine the toxicity 
      and preliminary efficacy of seliciclib in combination with biologic therapies, to
      inform its potential as an adjunctive therapy in rheumatoid arthritis. METHODS
      AND ANALYSIS: TRAFIC is a non-commercial, multi-center, rolling phase Ib/IIa
      trial investigating the safety, tolerability, and efficacy of seliciclib in
      patients with moderate to severe rheumatoid arthritis receiving biologic
      therapies. All participants receive seliciclib with no control arm. The primary
      objective of part 1 (phase Ib) is to determine the maximum tolerated dose and
      safety of seliciclib over 4 weeks of dosing. Part 1 uses a restricted 1-stage
      Bayesian continual reassessment method based on a target dose-limiting toxicity
      probability of 35%. Part 2 (phase IIa) assesses the potential efficacy of
      seliciclib, and is designed as a single arm, single stage early phase trial based
      on a Fleming-A'Hern design using the maximum tolerated dose recommended from part
      1. The primary response outcome after 12 weeks of therapy is a composite of
      clinical, histological and magnetic resonance imaging scores. Secondary outcomes 
      include adverse events, pharmacodynamic and pharmacokinetic parameters,
      autoantibodies, and fatigue. ETHICS AND DISSEMINATION: The study has been
      reviewed and approved by the North East - Tyne & Wear South Research Ethics
      Committee (reference 14/NE/1075) and the Medicines and Healthcare Products
      Regulatory Agency (MHRA), United Kingdom. Results will be disseminated through
      publication in relevant peer-reviewed journals and presentation at national and
      international conferences. TRIALS REGISTRATION: ISRCTN, ISRCTN36667085.
      Registered on September 26, 2014; http://www.isrctn.com/ISRCTN36667085Current
      protocol version: Protocol version 11.0 (March 21, 2019).
FAU - Siebert, Stefan
AU  - Siebert S
AUID- ORCID: 0000-0002-1802-7311
AD  - Institute of Infection, Immunity and Inflammation, University of Glasgow,
      Glasgow.
FAU - Pratt, Arthur G
AU  - Pratt AG
AD  - Translational and Experimental Medicine Institute, Newcastle University and
      Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust,
      Newcastle upon Tyne.
FAU - Stocken, Deborah D
AU  - Stocken DD
AD  - Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
FAU - Morton, Miranda
AU  - Morton M
AD  - Institute of Health and Society, Newcastle University, Newcastle upon Tyne.
FAU - Cranston, Amy
AU  - Cranston A
AD  - Institute of Health and Society, Newcastle University, Newcastle upon Tyne.
FAU - Cole, Michael
AU  - Cole M
AD  - Institute of Health and Society, Newcastle University, Newcastle upon Tyne.
FAU - Frame, Sheelagh
AU  - Frame S
AD  - Cyclacel Ltd., Dundee.
FAU - Buckley, Christopher D
AU  - Buckley CD
AD  - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS
      Foundation Trust and Institute for Inflammation and Ageing, University of
      Birmingham, Birmingham.
AD  - Kennedy Institute of Rheumatology, Roosevelt Drive, Headington University of
      Oxford, Oxford, UK.
FAU - Ng, Wan-Fai
AU  - Ng WF
AD  - Translational and Experimental Medicine Institute, Newcastle University and
      Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust,
      Newcastle upon Tyne.
FAU - Filer, Andrew
AU  - Filer A
AD  - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS
      Foundation Trust and Institute for Inflammation and Ageing, University of
      Birmingham, Birmingham.
FAU - McInnes, Iain B
AU  - McInnes IB
AD  - Institute of Infection, Immunity and Inflammation, University of Glasgow,
      Glasgow.
FAU - Isaacs, John D
AU  - Isaacs JD
AD  - Translational and Experimental Medicine Institute, Newcastle University and
      Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust,
      Newcastle upon Tyne.
LA  - eng
GR  - MR/L005123/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/P020941/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0ES1C2KQ94 (Roscovitine)
RN  - 7D0YB67S97 (Abatacept)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Abatacept/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Maximum Tolerated Dose
MH  - Multicenter Studies as Topic
MH  - Protein Kinase Inhibitors/*administration & dosage
MH  - Roscovitine/*administration & dosage
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - United Kingdom
PMC - PMC7328978
EDAT- 2020/06/27 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 10.1097/MD.0000000000020458 [doi]
AID - 00005792-202006260-00005 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20458. doi:
      10.1097/MD.0000000000020458.


PMID- 32590667
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20210106
IS  - 1529-4242 (Electronic)
IS  - 0032-1052 (Linking)
VI  - 146
IP  - 1
DP  - 2020 Jul
TI  - Current Trends in the Use of Social Media by Plastic Surgeons.
PG  - 83e-91e
LID - 10.1097/PRS.0000000000006936 [doi]
AB  - BACKGROUND: As social media continue to be widely used, understanding the current
      trend in social media use by plastic surgeons will help determine how the
      specialty can better harness its power and respect its risks. In this study, the 
      authors performed a survey study of trainees, candidates, and members of the
      American Society of Plastic Surgeons to determine current use and consensus on
      social media in plastic surgery. METHODS: An electronic survey was sent to
      plastic surgery trainees, candidates, and members of the American Society of
      Plastic Surgeons using SurveyMonkey. Demographic data, social media use patterns,
      and views on social media use were collected. RESULTS: When compared with
      salaried surgeons, private practitioners used social media for the promotion of
      their practice, such as patient acquisition (74.3 percent versus 28.3 percent)
      and branding (61 percent versus 21.7 percent). The majority of nonusers felt
      social media was too time consuming and susceptible to breach of patient privacy.
      The majority of social media users agreed that acceptable use included
      before-and-after photographs, video testimonials, and patient reviews. Both
      social media users and nonusers alike agreed that plastic surgery residents
      should receive training on social media. CONCLUSIONS: This study showed that a
      majority of plastic surgeons use social media to brand their practice, attract
      patients, and educate the public. Without engaging in this valuable tool, plastic
      surgeons' voices will be lost in the conversation. To use social media to their
      greatest potential, this specialty needs to begin formal training in the proper
      and ethical use of social media.
FAU - Cho, Min-Jeong
AU  - Cho MJ
AD  - From the University of Texas Southwestern Medical Center; the Division of Plastic
      Surgery, Department of Surgery, Stanford University; and the Dallas Plastic
      Surgery Institute.
FAU - Li, Alexander Y
AU  - Li AY
AD  - From the University of Texas Southwestern Medical Center; the Division of Plastic
      Surgery, Department of Surgery, Stanford University; and the Dallas Plastic
      Surgery Institute.
FAU - Furnas, Heather J
AU  - Furnas HJ
AD  - From the University of Texas Southwestern Medical Center; the Division of Plastic
      Surgery, Department of Surgery, Stanford University; and the Dallas Plastic
      Surgery Institute.
FAU - Rohrich, Rod J
AU  - Rohrich RJ
AD  - From the University of Texas Southwestern Medical Center; the Division of Plastic
      Surgery, Department of Surgery, Stanford University; and the Dallas Plastic
      Surgery Institute.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Marketing of Health Services/trends
MH  - Middle Aged
MH  - Practice Patterns, Physicians'/*trends
MH  - Social Media/*statistics & numerical data
MH  - Surgeons/*statistics & numerical data
MH  - Surgery, Plastic/*statistics & numerical data
MH  - United States
EDAT- 2020/06/27 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
AID - 10.1097/PRS.0000000000006936 [doi]
AID - 00006534-202007000-00035 [pii]
PST - ppublish
SO  - Plast Reconstr Surg. 2020 Jul;146(1):83e-91e. doi: 10.1097/PRS.0000000000006936.


PMID- 32589938
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 1531-5053 (Electronic)
IS  - 0278-2391 (Linking)
VI  - 78
IP  - 11
DP  - 2020 Nov
TI  - Popescu Technique Revisited: Review of the Literature and Case Series.
PG  - 2000-2007
LID - S0278-2391(20)30552-8 [pii]
LID - 10.1016/j.joms.2020.05.028 [doi]
AB  - Management of vascular malformations depends on the size, type, age of the
      patient, location, dissemination, and depth of penetration. Treatment options
      include propranolol, which reduces endothelial vessel proliferation, minimally
      invasive sclerotherapy to induce fibrosis, or surgery. In 1985, Valerian Popescu 
      described a new approach to treatment consisting of intratumoral ligation by
      compartmentalization. This technique allows for high doses of the sclerosant
      agent to be delivered as systemic dissemination is restricted by a series of
      strangulating suture loops that divide the mass into segments. We describe the
      management and outcome of 2 patients who presented with vascular malformations in
      the orofacial region and were managed using a Popescu suturing technique.
      Vascular obliteration was achieved by a series of strangulating suture loops
      placed percutaneously throughout each lesion using a curved needle with a
      resorbable material (Vicryl; Ethicon, Somerville, NJ). The aim was to segment the
      vascular malformation into manageable sections for subsequent injection of a
      sclerosant. The compartmentalization also ensured that the sclerosant stayed
      within these compartments and was not washed out into the general circulation.
      Good esthetic outcomes were achieved in very visible areas such as the commissure
      and the vermillion border. In these areas, a surgical resection would have
      certainly caused a disruption of the esthetics of the lips and, in the second
      case, probably an alteration of function. Intratumoral ligation can be used
      safely to achieve control of vascular malformations with good esthetic outcomes.
CI  - Copyright (c) 2020 American Association of Oral and Maxillofacial Surgeons.
      Published by Elsevier Inc. All rights reserved.
FAU - Ferro, Ashley
AU  - Ferro A
AD  - Junior Clinical Fellow, Oral and Maxillofacial Surgery, Department of Oral and
      Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, United Kingdom. Electronic address:
      Ashley.ferro@nhs.net.
FAU - Otero-Rico, Ana
AU  - Otero-Rico A
AD  - Senior Clinical Fellow, Oral and Maxillofacial Surgery, Department of Oral and
      Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, United Kingdom.
FAU - Santhanam, Vijay
AU  - Santhanam V
AD  - Consultant Oral and Maxillofacial Surgeon and Department Head, Department of Oral
      and Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust,
      Cambridge Biomedical Campus, Cambridge, United Kingdom.
LA  - eng
PT  - Case Reports
PT  - Review
DEP - 20200525
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
RN  - 0 (Sclerosing Solutions)
SB  - IM
MH  - *Esthetics, Dental
MH  - Humans
MH  - Lip
MH  - Sclerosing Solutions/therapeutic use
MH  - Sclerotherapy
MH  - *Vascular Malformations
EDAT- 2020/06/27 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/05/10 00:00 [received]
PHST- 2020/05/16 00:00 [revised]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - S0278-2391(20)30552-8 [pii]
AID - 10.1016/j.joms.2020.05.028 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 2020 Nov;78(11):2000-2007. doi:
      10.1016/j.joms.2020.05.028. Epub 2020 May 25.


PMID- 32589598
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 2194-802X (Electronic)
IS  - 2194-802X (Linking)
VI  - 7
IP  - 3
DP  - 2020 Aug 27
TI  - Study design and ethical considerations related to using direct observation to
      evaluate physician behavior: reflections after a recent study.
PG  - 205-209
LID - 10.1515/dx-2020-0029 [doi]
LID - /j/dx.2020.7.issue-3/dx-2020-0029/dx-2020-0029.xml [pii]
AB  - In a recent study using direct observation of physicians, we demonstrated that
      physician-generated clinical documentation is vulnerable to error. In fact, we
      found that physicians consistently overrepresented their actions in certain areas
      of the medical record, such as the physical examination. Because of our
      experiences carrying out this study, we believe that certain investigations,
      particularly those evaluating physician behavior, should not rely on
      documentation alone. Investigators seeking to evaluate physician behavior should 
      instead consider using observation to obtain objective information about
      occurrences in the patient-physician encounter. In this article, we describe our 
      experiences using observation, and we offer investigators our perspectives
      related to study design and ethical questions to consider when performing similar
      work.
FAU - Berdahl, Carl T
AU  - Berdahl CT
AUID- ORCID: 0000-0002-4374-3280
AD  - Cedars-Sinai Medical Center, 8687 Melrose Ave G-562, West Hollywood, CA, USA.
FAU - Schriger, David L
AU  - Schriger DL
AD  - Department of Emergency Medicine, UCLA David Geffen School of Medicine, Los
      Angeles, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Diagnosis (Berl)
JT  - Diagnosis (Berlin, Germany)
JID - 101654734
SB  - IM
MH  - Documentation
MH  - Humans
MH  - Medical Records
MH  - Physical Examination
MH  - Physician-Patient Relations
MH  - *Physicians
OTO - NOTNLM
OT  - *documentation
OT  - *emergency medicine
OT  - *ethics
OT  - *observation
OT  - *study design
EDAT- 2020/06/27 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1515/dx-2020-0029 [doi]
AID - /j/dx.ahead-of-print/dx-2020-0029/dx-2020-0029.xml [pii]
PST - ppublish
SO  - Diagnosis (Berl). 2020 Aug 27;7(3):205-209. doi: 10.1515/dx-2020-0029.


PMID- 32589282
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68 Suppl 2
DP  - 2020 Jul
TI  - Building a National Program for Pilot Studies of Embedded Pragmatic Clinical
      Trials in Dementia Care.
PG  - S14-S20
LID - 10.1111/jgs.16618 [doi]
AB  - Sixteen million caregivers currently provide care to more than 5 million persons 
      living with dementia (PLWD) in the United States. Although this population is
      growing and highly complex, evidence-based management remains poorly integrated
      within healthcare systems. Therefore, the National Institute on Aging IMPACT
      Collaboratory was formed to build the nation's ability to conduct embedded
      pragmatic clinical trials (ePCTs) for PLWD and their caregivers. The pilot core
      of the IMPACT Collaboratory seeks to provide funds for upward of 40 pilots for
      ePCTs to accelerate the testing of nonpharmacologic interventions with the goal
      that these pilots lead to full-scale ePCTs and eventually the embedding of
      evidence-based care into healthcare systems. The first two challenges for the
      pilot core in building the pilot study program were (1) to develop a transparent,
      ethical, and open nationwide process for soliciting, reviewing, and selecting
      pilot studies; and (2) to begin the process of describing the necessary
      components of a pilot study for an ePCT. During our initial funding cycle, we
      received 35 letters of intent, of which 17 were accepted for a full proposal and 
      14 were submitted. From this process we learned that investigators lack knowledge
      in ePCTs, many interventions lack readiness for an ePCT pilot study, and many
      proposed studies lack key pragmatic design elements. We therefore have set three 
      key criteria that future pilot studies must meet at a minimum to be considered
      viable. We additionally discuss key design decisions investigators should
      consider in designing a pilot study for an ePCT. J Am Geriatr Soc 68:S14-S20,
      2020.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Brody, Abraham A
AU  - Brody AA
AUID- ORCID: 0000-0002-3405-7043
AD  - Hartford Institute for Geriatric Nursing, NYU Rory Meyers College of Nursing, New
      York, New York, USA.
AD  - Division of Geriatric Medicine and Palliative Care, NYU Grossman School of
      Medicine, New York, New York, USA.
FAU - Barnes, Deborah E
AU  - Barnes DE
AD  - Department of Psychiatry and Epidemiology & Biostatistics, University of
      California, San Francisco School of Medicine, San Francisco Veterans Affairs
      Health Care System, San Francisco, California, USA.
FAU - Chodosh, Joshua
AU  - Chodosh J
AD  - Division of Geriatric Medicine and Palliative Care, NYU Grossman School of
      Medicine, New York, New York, USA.
FAU - Galvin, James E
AU  - Galvin JE
AD  - Department of Neurology, University of Miami Miller School of Medicine, Miami,
      Florida, USA.
FAU - Hepburn, Kenneth W
AU  - Hepburn KW
AD  - Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia, USA.
FAU - Troxel, Andrea B
AU  - Troxel AB
AD  - Division of Biostatistics, NYU Grossman School of Medicine, New York, New York,
      USA.
FAU - Hom, Kimberly
AU  - Hom K
AD  - Hartford Institute for Geriatric Nursing, NYU Rory Meyers College of Nursing, New
      York, New York, USA.
FAU - McCarthy, Ellen P
AU  - McCarthy EP
AD  - Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife,
      Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts, USA.
FAU - Unroe, Kathleen T
AU  - Unroe KT
AD  - Center for Aging Research, Regenstrief Institute, Indiana University School of
      Medicine, Indianapolis, Indiana, USA.
LA  - eng
GR  - P30 AG066512/AG/NIA NIH HHS/United States
GR  - U54 AG063546/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Caregivers
MH  - Dementia/epidemiology/nursing/*therapy
MH  - Humans
MH  - National Institute on Aging (U.S.)
MH  - Pilot Projects
MH  - *Pragmatic Clinical Trials as Topic
MH  - *Program Development
MH  - *Research Design
MH  - Research Personnel/*standards
MH  - United States/epidemiology
PMC - PMC7393801
MID - NIHMS1608372
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *dementia
OT  - *nonpharmacologic interventions
OT  - *pilot study
OT  - *pragmatic trials
EDAT- 2020/06/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1111/jgs.16618 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Jul;68 Suppl 2:S14-S20. doi: 10.1111/jgs.16618.


PMID- 32589273
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210702
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68 Suppl 2
DP  - 2020 Jul
TI  - Ethical and Regulatory Issues for Embedded Pragmatic Trials Involving People
      Living with Dementia.
PG  - S37-S42
LID - 10.1111/jgs.16620 [doi]
AB  - Embedded pragmatic clinical trials (ePCTs) present an opportunity to improve care
      for people living with dementia (PLWD) and their care partners, but they also
      generate a complex constellation of ethical and regulatory challenges. These
      challenges begin with participant identification. Interventions may be delivered 
      in ways that make it difficult to identify who is a human subject and therefore
      who needs ethical and regulatory protections. The need for informed consent, a
      core human subjects protection, must be considered but can be in tension with the
      goals of pragmatic research design. Thus it is essential to consider whether a
      waiver or alteration of informed consent is justifiable. If informed consent is
      needed, the question arises of how it should be obtained because researchers must
      acknowledge the vulnerability of PLWD due in part to diminished capacity and also
      to increased dependence on others. Further, researchers should recognize that
      many sites where ePCTs are conducted will be unfamiliar with human subjects
      research regulations and ethics. In this report, the Regulation and Ethics Core
      of the National Institute on Aging Imbedded Pragmatic Alzheimer's disease (AD)
      and AD-related dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory
      discusses key ethical and regulatory challenges for ePCTs in PLWD. A central
      thesis is that researchers should strive to anticipate and address these
      challenges early in the design of their ePCTs as a means of both ensuring
      compliance and advancing science. J Am Geriatr Soc 68:S37-S42, 2020.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Largent, Emily A
AU  - Largent EA
AUID- ORCID: 0000-0002-7536-5077
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
FAU - Hey, Spencer Phillips
AU  - Hey SP
AD  - Center for Bioethics, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Harkins, Kristin
AU  - Harkins K
AD  - Department of Medicine, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Hoffman, Allison K
AU  - Hoffman AK
AD  - University of Pennsylvania Carey Law School, Philadelphia, Pennsylvania, USA.
FAU - Joffe, Steven
AU  - Joffe S
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
FAU - Lima, Julie C
AU  - Lima JC
AD  - Department of Health Services, Policy & Practice , Brown University School of
      Public Health, Providence, Rhode Island, USA.
AD  - Center for Gerontology and Health Care Research, Brown University School of
      Public Health, Providence, Rhode Island, USA.
FAU - London, Alex John
AU  - London AJ
AD  - Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh,
      Pennsylvania, USA.
FAU - Karlawish, Jason
AU  - Karlawish J
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
AD  - Department of Medicine, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
AD  - Department of Neurology, University of Pennsylvania Perelman School of Medicine, 
      Philadelphia, Pennsylvania, USA.
LA  - eng
GR  - K01 AG064123/AG/NIA NIH HHS/United States
GR  - K24 AG033640/AG/NIA NIH HHS/United States
GR  - U54 AG063546/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Dementia/*epidemiology
MH  - Ethics Committees, Research/ethics/*legislation & jurisprudence
MH  - Humans
MH  - Informed Consent/*legislation & jurisprudence
MH  - National Institute on Aging (U.S.)
MH  - Patient Selection
MH  - Pragmatic Clinical Trials as Topic/*ethics
MH  - Research Design
MH  - Research Personnel
MH  - *Research Subjects/legislation & jurisprudence
MH  - United States
PMC - PMC7323902
MID - NIHMS1592788
OTO - NOTNLM
OT  - *dementia
OT  - *ethics
OT  - *human subjects research
OT  - *informed consent
EDAT- 2020/06/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1111/jgs.16620 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Jul;68 Suppl 2:S37-S42. doi: 10.1111/jgs.16620.


PMID- 32589267
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20220716
IS  - 1545-5300 (Electronic)
IS  - 0014-7370 (Linking)
VI  - 59
IP  - 3
DP  - 2020 Sep
TI  - COVID-19 Interconnectedness: Health Inequity, the Climate Crisis, and Collective 
      Trauma.
PG  - 832-846
LID - 10.1111/famp.12572 [doi]
AB  - The COVID-19 pandemic brings to the forefront the complex interconnected dilemmas
      of globalization, health equity, economic security, environmental justice, and
      collective trauma, severely impacting the marginalized and people of color in the
      United States. This lack of access to and the quality of healthcare, affordable
      housing, and lack of financial resources also continue to have a more significant
      impact on documented and undocumented immigrants. This paper aims at examining
      these critical issues and developing a framework for family therapists to address
      these challenges by focusing on four interrelated dimensions: cultural values,
      social determinants of health, collective trauma, and the ethical and moral
      responsibility of family therapists. Given the fact that family therapists may
      unwittingly function as the best ally of an economic and political system that
      perpetuates institutionalized racism and class discrimination, we need to utilize
      a set of principles, values, and practices that are not just palliative or after 
      the fact but bring forth into the psychotherapeutic and policy work a politics of
      care. Therefore, a strong call to promote and advocate for the broader continuum 
      of health and critical thinking preparing professionals to meet the challenges of
      health equity, as well as economic and environmental justice, is needed. The
      issues discussed in this paper are specific to the United States despite their
      relevance to family therapy as a field. We are mindful not to generalize the
      United States' reality to the rest of the world, recognizing that issues
      discussed in this paper could potentially contribute to international discourse.
CI  - (c) 2020 Family Process Institute.
FAU - Watson, Marlene F
AU  - Watson MF
AD  - Department of Counseling and Family Therapy, Drexel University, Philadelphia, PA.
FAU - Bacigalupe, Gonzalo
AU  - Bacigalupe G
AUID- ORCID: 0000-0002-9302-3361
AD  - School of Education and Human Development, University of Massachusetts Boston,
      Boston, MA.
FAU - Daneshpour, Manijeh
AU  - Daneshpour M
AUID- ORCID: 0000-0003-4160-2350
AD  - Alliant International University, Irvine, CA.
FAU - Han, Wen-Jui
AU  - Han WJ
AUID- ORCID: 0000-0002-2054-2275
AD  - Silver School of Social Work, New York University, New York, NY.
FAU - Parra-Cardona, Ruben
AU  - Parra-Cardona R
AUID- ORCID: 0000-0003-0250-1012
AD  - Steve Hicks School of Social Work, University of Texas, Austin, TX, USA.
LA  - eng
GR  - CIGIDEN ANID/FONDAP/15110017/Fondo de Fomento al Desarrollo Cientifico y
      Tecnologico/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200803
PL  - United States
TA  - Fam Process
JT  - Family process
JID - 0400666
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Climate Change
MH  - Coronavirus Infections/ethnology/psychology
MH  - Family Therapy/*ethics
MH  - *Health Status Disparities
MH  - Healthcare Disparities
MH  - Humans
MH  - Morals
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/ethnology/psychology
MH  - *Politics
MH  - Racism/*ethics/psychology
MH  - SARS-CoV-2
MH  - Social Determinants of Health
MH  - Social Marginalization
MH  - Social Values
MH  - United States/epidemiology
PMC - PMC7361773
OTO - NOTNLM
OT  - *COVID-19
OT  - *Climate Crisis
OT  - *Collective Trauma
OT  - *Ethics of Care
OT  - *Health Inequity
OT  - *Social Determinants of Health
OT  - *crisis climatica
OT  - *determinantes sociales de la salud
OT  - *inequidad sanitaria
OT  - *trauma colectivo
OT  - *etica de asistencia
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
EDAT- 2020/06/27 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1111/famp.12572 [doi]
PST - ppublish
SO  - Fam Process. 2020 Sep;59(3):832-846. doi: 10.1111/famp.12572. Epub 2020 Aug 3.


PMID- 32589265
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20220716
IS  - 1545-5300 (Electronic)
IS  - 0014-7370 (Linking)
VI  - 59
IP  - 3
DP  - 2020 Sep
TI  - Reaching Up, Down, In, and Around: Couple and Family Coping During the
      Coronavirus Pandemic.
PG  - 847-864
LID - 10.1111/famp.12570 [doi]
AB  - The worldwide coronavirus (COVID-19) has had profound effects on all aspects of
      life: physical health, the ability to travel locally or to more distant
      destinations, material and financial resources, and psychosocial wellbeing.
      Couples, families, and communities and individual persons in those relationships 
      have struggled to cope with emerging depression, anxiety, and trauma, and the
      rise of relational conflict. In this article, we suggest that the existential
      nature of the pandemic's challenges requires more than just the usual
      psychosocial interventions. We propose a taxonomy of responses to foster coping
      and resilience-"Reaching Up, Down, In, and Around." "Reaching Up" includes
      accessing spiritual, religious, and ethical values. "Reaching Down" includes
      ideas and practices that foster a revised relationship with the Earth and its
      resources, and that engage families to participate in activities that aid the
      Earth's recovery from decades of human-caused damage. "Reaching In" represents a 
      turn towards experiences available in the mind and in shared minds in
      relationships that provide pleasure, excitement, joy, and peace, given that
      external sources of these emotions are of limited availability due to quarantine.
      "Reaching Around" involves reframing the mandate for "social distancing" as
      fostering social connection and support while maintaining physical distancing.
      The challenges for family therapists, whose practices are confined largely to
      online therapy, and who are struggling with the same fears and constraints as
      those persons they are attempting to help, are also discussed.
CI  - (c) 2020 Family Process Institute.
FAU - Fraenkel, Peter
AU  - Fraenkel P
AUID- ORCID: https://orcid.org/0000-0003-0159-6304
AD  - Department of Psychology, The City College of New York, New York, NY.
FAU - Cho, Wonyoung L
AU  - Cho WL
AUID- ORCID: https://orcid.org/0000-0003-4370-3817
AD  - Marriage, Couples, and Family Therapy Program, Lewis & Clark Graduate School of
      Education and Counseling, Portland, OR.
LA  - eng
PT  - Journal Article
DEP - 20200809
PL  - United States
TA  - Fam Process
JT  - Family process
JID - 0400666
SB  - IM
MH  - Adaptation, Psychological
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/prevention & control/*psychology
MH  - Family Therapy/*methods
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/prevention & control/*psychology
MH  - Quarantine/*psychology
MH  - Resilience, Psychological
MH  - SARS-CoV-2
PMC - PMC7361908
OTO - NOTNLM
OT  - Families and Environmental Crisis
OT  - Families and Health Disparities
OT  - Family Resilience
OT  - Family and Couple Coping COVID-19 Pandemic and Quarantine
OT  - Religious and Spiritual Factors
OT  - afrontamiento familiar de la pandemia de la COVID-19
OT  - afrontamiento familiar y de pareja
OT  - factores religiosos y espirituales
OT  - familias y desigualdad sanitaria
OT  - las familias y la crisis ambiental
OT  - resiliencia familiar
OT  - COVID-19
EDAT- 2020/06/27 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1111/famp.12570 [doi]
PST - ppublish
SO  - Fam Process. 2020 Sep;59(3):847-864. doi: 10.1111/famp.12570. Epub 2020 Aug 9.


PMID- 32589157
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 26
TI  - A Telerehabilitation Intervention for Youths With Arthrogryposis Multiplex
      Congenita: Protocol for a Pilot Study.
PG  - e18688
LID - 10.2196/18688 [doi]
AB  - BACKGROUND: Arthrogryposis multiplex congenita (AMC) is characterized by joint
      contractures present in at least two body areas. In addition to these
      contractures, individuals with AMC can have decreased muscle mass, leading to
      limitations in activities of daily living. Exercise has the potential to maintain
      or improve the range of motion and muscle strength. However, this type of
      intervention necessitates frequent follow ups that are currently difficult to
      provide for youths with AMC because they often live far from a specialized
      hospital. To overcome this distance challenge, telecommunication technologies can
      be used to deliver rehabilitation remotely, which is called telerehabilitation.
      The study protocol for one such type of rehabilitation will be presented in this 
      paper. OBJECTIVE: This pilot study aims to (1) evaluate the feasibility of using 
      telerehabilitation to provide a home exercise program for youths with AMC, and
      (2) assess the effectiveness of a home exercise program. METHODS: A total of 10
      youths aged 8-21 years with AMC will be recruited. The intervention consists of a
      12-week individualized home-based exercise program delivered remotely using
      telerehabilitation. At baseline, youths will complete the Physical Activity
      Questionnaire for Adolescents and the Pediatrics Outcomes Data Collection
      Instrument to assess pain, function, and level of physical activity. During the
      first telerehabilitation meeting, the rehabilitation therapists will measure
      range of motion using a virtual goniometer and assess the youth's functional
      level. The therapists will then use the Goal Attainment Scale to set objectives
      and develop the individualized intervention. Follow ups will occur every 3 weeks 
      to make sure exercises are performed safely and to progress the exercises when
      needed. At the end of the 12-week intervention, rehabilitation therapists will
      re-evaluate the youth using the same outcome measures as the initial evaluation. 
      The youths will be asked to complete the same questionnaires, with the addition
      of questions about their satisfaction regarding the intervention. Nonparametric
      and descriptive statistics will be used to evaluate the feasibility and
      effectiveness. RESULTS: Ethics approval was obtained in October 2018. Recruitment
      and data collection started in January 2019 and was completed in May 2020.
      CONCLUSIONS: This pilot study will help us learn how a large-scale project may
      work in practice to improve outcomes in physical activity, pain, and function,
      and goal attainment among youths with AMC, thus informing a future clinical
      trial. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18688.
CI  - (c)Marianne Gagnon, Jessica Collins, Caroline Elfassy, Gabriela Marino Merlo,
      Jacquelyn Marsh, Bonita Sawatzky, Rita Yap, Reggie Hamdy, Louis-Nicolas Veilleux,
      Noemi Dahan-Oliel. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 26.06.2020.
FAU - Gagnon, Marianne
AU  - Gagnon M
AUID- ORCID: https://orcid.org/0000-0002-8678-1746
AD  - Department of Surgery, McGill University, Montreal, QC, Canada.
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
FAU - Collins, Jessica
AU  - Collins J
AUID- ORCID: https://orcid.org/0000-0002-0186-8309
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
FAU - Elfassy, Caroline
AU  - Elfassy C
AUID- ORCID: https://orcid.org/0000-0003-0918-9316
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
AD  - School of Physical and Occupational Therapy, McGill University, Montreal, QC,
      Canada.
FAU - Marino Merlo, Gabriela
AU  - Marino Merlo G
AUID- ORCID: https://orcid.org/0000-0002-3751-2822
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
FAU - Marsh, Jacquelyn
AU  - Marsh J
AUID- ORCID: https://orcid.org/0000-0002-5334-1453
AD  - School of Physical Therapy, Western University, London, ON, Canada.
FAU - Sawatzky, Bonita
AU  - Sawatzky B
AUID- ORCID: https://orcid.org/0000-0002-8901-2301
AD  - Department of Orthopedics, University of British Columbia, Vancouver, BC, Canada.
FAU - Yap, Rita
AU  - Yap R
AUID- ORCID: https://orcid.org/0000-0002-8921-7390
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
FAU - Hamdy, Reggie
AU  - Hamdy R
AUID- ORCID: https://orcid.org/0000-0002-0664-2843
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
AD  - Division of Paediatric Orthopaedics, Department of Paediatric Surgery, Montreal
      Children Hospital, Montreal, QC, Canada.
FAU - Veilleux, Louis-Nicolas
AU  - Veilleux LN
AUID- ORCID: https://orcid.org/0000-0001-7672-8477
AD  - Department of Surgery, McGill University, Montreal, QC, Canada.
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
FAU - Dahan-Oliel, Noemi
AU  - Dahan-Oliel N
AUID- ORCID: https://orcid.org/0000-0001-8567-7173
AD  - Shriners Hospital for Children-Canada, Montreal, QC, Canada.
AD  - School of Physical and Occupational Therapy, McGill University, Montreal, QC,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7381253
OTO - NOTNLM
OT  - arthrogryposis multiplex congenita
OT  - occupational therapy
OT  - physical therapy
OT  - telerehabilitation
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - v9i6e18688 [pii]
AID - 10.2196/18688 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 26;9(6):e18688. doi: 10.2196/18688.


PMID- 32589056
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210802
IS  - 1740-7753 (Electronic)
IS  - 1740-7745 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Aug
TI  - Practical challenges in the conduct of pragmatic trials embedded in health plans:
      Lessons of IMPACT-AFib, an FDA-Catalyst trial.
PG  - 360-367
LID - 10.1177/1740774520928426 [doi]
AB  - IMPACT-AFib was an 80,000-patient randomized clinical trial implemented by five
      US insurance companies (health plans) aimed at increasing the use of oral
      anticoagulants by individuals with atrial fibrillation who were at high risk of
      stroke and not on treatment. The underlying thesis was that patients could be
      change agents to initiate prescribing discussions with their providers. We tested
      the effect of mailing information to both patients and their providers. We used
      administrative medical claims and pharmacy dispensing data to identify eligible
      patients, to randomize them to an early or delayed intervention, and to assess
      clinical outcomes. The core data were analysis-ready datasets each site had
      created and curated for the FDA's Sentinel System, supplemented by updated
      "fresh" pharmacy and enrollment data to ensure eligibility at the time of
      intervention. Following mutually agreed upon procedures, sites linked to
      additional internal source data to implement the intervention-educational
      information mailed to patients and their providers in the early intervention arm,
      and to providers of patients in the delayed intervention arm approximately 12
      months later. The primary analysis compares the early intervention arm to the
      delayed intervention arm, prior to the delayed intervention being conducted (i.e.
      compares intervention to non-intervention). The endpoints of interest were
      evidence of initiation of anticoagulation (primary) as well as clinical
      endpoints, including stroke and hospitalization for bleeding. Major challenges,
      some unanticipated, identified during the planning phase include convening
      multi-stakeholder investigator teams and advisors, addressing ethical concerns
      about not intervening in a usual care comparison group, and identifying and
      avoiding interference with sites' routine programs that were similar to the
      intervention. Needs and challenges during the implementation phase included the
      fact that even limited site-specific programming greatly increased time and
      effort, the need to refresh research data extracts immediately before outreach to
      patients and providers, potential difficulty identifying low-cost medications
      such as warfarin that may not be reimbursed by health plans and so not
      discoverable in dispensing data, the need to develop workarounds when "providers"
      in claims data were facilities, difficulty addressing clustering of patients by
      provider because providers can have multiple identifiers within and between
      health plans, and the need to anticipate loss to follow up because of health plan
      disenrollment or change in benefits. As pragmatic trials begin to shape evidence 
      generation within clinical practice, investigators should anticipate issues
      inherent to claims data and working with multiple large sites. In IMPACT-AFib, we
      found that investing in collaboration and communication among all parties
      throughout all phases of the study helped ensure common understanding, early
      identification of challenges, and streamlined actual implementation.
FAU - Garcia, Crystal J
AU  - Garcia CJ
AUID- ORCID: 0000-0002-9220-6078
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
      Health Care Institute, Boston, MA, USA.
FAU - Haynes, Kevin
AU  - Haynes K
AD  - HealthCore, Inc., Wilmington, DE, USA.
FAU - Pokorney, Sean D
AU  - Pokorney SD
AD  - Division of Cardiology and Duke Clinical Research Institute, Duke University,
      Durham, NC, USA.
FAU - Lin, Nancy D
AU  - Lin ND
AD  - OptumInsight Life Sciences, Inc., Boston, MA, USA.
FAU - McMahill-Walraven, Cheryl
AU  - McMahill-Walraven C
AD  - Aetna Inc., a CVS Health Company, Blue Bell, PA, USA.
FAU - Nair, Vinit
AU  - Nair V
AD  - Humana Healthcare Research, Humana Inc., Louisville, KY, USA.
FAU - Parlett, Lauren
AU  - Parlett L
AUID- ORCID: 0000-0003-1240-4566
AD  - HealthCore, Inc., Wilmington, DE, USA.
FAU - Martin, David
AU  - Martin D
AD  - U.S. Food and Drug Administration, Silver Spring, MD, USA.
FAU - Al-Khalidi, Hussein R
AU  - Al-Khalidi HR
AD  - Department of Biostatistics and Bioinformatics and Duke Clinical Research
      Institute, Duke University, Durham, NC, USA.
FAU - McCall, Debbe
AU  - McCall D
AD  - Rowan Tree Perspectives Consulting, Murrieta, CA, USA.
FAU - Granger, Christopher B
AU  - Granger CB
AD  - Division of Cardiology and Duke Clinical Research Institute, Duke University,
      Durham, NC, USA.
FAU - Platt, Richard
AU  - Platt R
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
      Health Care Institute, Boston, MA, USA.
FAU - Cocoros, Noelle M
AU  - Cocoros NM
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
      Health Care Institute, Boston, MA, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03259373
GR  - HHSF223201400030I/FD/FDA HHS/United States
GR  - U18 FD005292/FD/FDA HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200626
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Hemorrhage/epidemiology
MH  - Hospitalization
MH  - Humans
MH  - *Insurance, Health
MH  - Pragmatic Clinical Trials as Topic/economics/*methods
MH  - Randomized Controlled Trials as Topic/economics/methods
MH  - Research Design
MH  - Stroke/epidemiology/prevention & control
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC8293906
MID - NIHMS1720819
OTO - NOTNLM
OT  - *Pragmatic clinical trial
OT  - *Sentinel Initiative
OT  - *atrial fibrillation
OT  - *real-world data
OT  - *real-world evidence
OT  - *stroke
EDAT- 2020/06/27 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1177/1740774520928426 [doi]
PST - ppublish
SO  - Clin Trials. 2020 Aug;17(4):360-367. doi: 10.1177/1740774520928426. Epub 2020 Jun
      26.


PMID- 32588971
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211119
IS  - 1552-5279 (Electronic)
IS  - 1552-5260 (Linking)
VI  - 16
IP  - 9
DP  - 2020 Sep
TI  - A randomized controlled trial of amyloid positron emission tomography results
      disclosure in mild cognitive impairment.
PG  - 1330-1337
LID - 10.1002/alz.12129 [doi]
AB  - INTRODUCTION: Recent studies suggest that Alzheimer's disease (AD) biomarker
      disclosure has no discernable psychological impact on cognitively healthy
      persons. Far less is known about how such results affect symptomatic individuals 
      and their caregivers. METHODS: Randomized controlled trial of 82 mild cognitive
      impairment (MCI) patient and caregiver dyads (total n = 164) to determine the
      effect of receiving amyloid positron emission tomography results on understanding
      of, and perceived efficacy to cope with, MCI over 52 weeks of follow-up. RESULTS:
      Gains in the primary outcomes were not consistently observed. Amyloid negative
      patients reported greater perceived ambiguity regarding MCI at follow-up, while
      moderate and sustained emotional distress was observed in patients, and to a
      lesser extent, caregivers, of those who were amyloid positive. There was no
      corresponding increase in depressive symptoms. DISCUSSION: These findings point
      to the possibility that both MCI patients and caregivers may need emotional
      support after the disclosure of amyloid scan results.
CI  - (c) 2020 the Alzheimer's Association.
FAU - Lingler, Jennifer H
AU  - Lingler JH
AD  - Department of Health and Community Systems, School of Nursing, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
AD  - Alzheimer's Disease Research Center, School of Medicine, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Sereika, Susan M
AU  - Sereika SM
AD  - Department of Health and Community Systems, School of Nursing, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Butters, Meryl A
AU  - Butters MA
AD  - Department of Psychiatry, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
FAU - Cohen, Ann D
AU  - Cohen AD
AD  - Alzheimer's Disease Research Center, School of Medicine, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
AD  - Department of Psychiatry, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
FAU - Klunk, William E
AU  - Klunk WE
AD  - Alzheimer's Disease Research Center, School of Medicine, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
AD  - Department of Psychiatry, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
AD  - Department of Neurology, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
FAU - Knox, Melissa L
AU  - Knox ML
AD  - Department of Health and Community Systems, School of Nursing, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - McDade, Eric
AU  - McDade E
AD  - Department of Neurology, School of Medicine, Washington University, St. Louis,
      Missouri, USA.
FAU - Nadkarni, Neelesh K
AU  - Nadkarni NK
AD  - Alzheimer's Disease Research Center, School of Medicine, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
AD  - Department of Neurology, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
AD  - Department of Medicine (Geriatric Medicine), School of Medicine, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Roberts, J Scott
AU  - Roberts JS
AD  - University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Tamres, Lisa K
AU  - Tamres LK
AD  - Department of Health and Community Systems, School of Nursing, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Lopez, Oscar L
AU  - Lopez OL
AD  - Alzheimer's Disease Research Center, School of Medicine, University of
      Pittsburgh, Pittsburgh, Pennsylvania, USA.
AD  - Department of Psychiatry, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
AD  - Department of Neurology, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania, USA.
LA  - eng
GR  - P30 AG053760/AG/NIA NIH HHS/United States
GR  - P30 AG066468/AG/NIA NIH HHS/United States
GR  - P50 AG005133/AG/NIA NIH HHS/United States
GR  - R01 AG046906/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20200626
PL  - United States
TA  - Alzheimers Dement
JT  - Alzheimer's & dementia : the journal of the Alzheimer's Association
JID - 101231978
RN  - 0 (Amyloid)
SB  - IM
MH  - Adaptation, Psychological
MH  - Aged
MH  - Amyloid/*metabolism
MH  - Caregivers/psychology
MH  - Cognitive Dysfunction/*diagnosis
MH  - *Disclosure
MH  - Female
MH  - Humans
MH  - Male
MH  - *Positron-Emission Tomography
PMC - PMC7541680
MID - NIHMS1614254
OTO - NOTNLM
OT  - *amyloid positron emission tomography
OT  - *biomarker disclosure
OT  - *caregiving
OT  - *ethics
OT  - *mild cognitive impairment
EDAT- 2020/06/27 06:00
MHDA- 2021/11/20 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1002/alz.12129 [doi]
PST - ppublish
SO  - Alzheimers Dement. 2020 Sep;16(9):1330-1337. doi: 10.1002/alz.12129. Epub 2020
      Jun 26.


PMID- 32588810
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20220317
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 2
DP  - 2020 Aug
TI  - Threat of COVID-19 Vaccine Hesitancy in Pakistan: The Need for Measures to
      Neutralize Misleading Narratives.
PG  - 603-604
LID - 10.4269/ajtmh.20-0654 [doi]
LID - tpmd200654 [pii]
AB  - Immediately after declaring COVID-19 as a pandemic, numerous wild conspiracy
      theories sprouted through social media. Pakistan is quite vulnerable to such
      conspiracy narratives and has experienced failures of polio vaccination programs 
      because of such claims. Recently, two well-known political figures raised
      conspiracy theories against COVID-19 vaccines in Pakistan, stating that COVID-19 
      is a grand illusion and a conspiracy against Muslim countries. This theory is
      much discussed in the local community, supporting COVID-19 vaccine hesitancy. We 
      urge healthcare authorities in Pakistan to take necessary measures against such
      claims before they penetrate to the general community. Anti-vaccine movements
      could undermine efforts to end the COVID-19 pandemic. We believe that ethical and
      responsible behavior of mass media, a careful advisory from the Pakistan
      Electronic Media Regulatory Authority, stern measures from healthcare
      authorities, effective maneuvers to increase public awareness on COVID-19,
      vigorous analysis of information by data or communications scientists, and
      publication of counter opinions from health professionals against such theories
      will go a long way in neutralizing such misleading claims. Because Pakistan is
      experiencing a large burden of disease, with a sharp rise in confirmed cases,
      immediate action is of paramount importance to eradicate any potential barriers
      to a future COVID-19 vaccination program.
FAU - Khan, Yusra Habib
AU  - Khan YH
AD  - 1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka,
      Al-Jouf, Kingdom of Saudi Arabia.
FAU - Mallhi, Tauqeer Hussain
AU  - Mallhi TH
AD  - 1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka,
      Al-Jouf, Kingdom of Saudi Arabia.
FAU - Alotaibi, Nasser Hadal
AU  - Alotaibi NH
AD  - 1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka,
      Al-Jouf, Kingdom of Saudi Arabia.
FAU - Alzarea, Abdulaziz Ibrahim
AU  - Alzarea AI
AD  - 1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka,
      Al-Jouf, Kingdom of Saudi Arabia.
FAU - Alanazi, Abdullah Salah
AU  - Alanazi AS
AD  - 1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka,
      Al-Jouf, Kingdom of Saudi Arabia.
FAU - Tanveer, Nida
AU  - Tanveer N
AD  - 2Primary and Secondary Healthcare Department, Tehsil Head Quarter Hospital
      Jaranwala, Faisalabad, Punjab, Pakistan.
FAU - Hashmi, Furqan Khurshid
AU  - Hashmi FK
AD  - 3University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control
MH  - *Health Communication
MH  - Health Education
MH  - Health Personnel
MH  - Humans
MH  - Mass Media
MH  - Pakistan
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Religion
MH  - SARS-CoV-2
MH  - Vaccination
MH  - *Vaccination Refusal
MH  - *Viral Vaccines
PMC - PMC7410483
EDAT- 2020/06/27 06:00
MHDA- 2020/08/14 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.4269/ajtmh.20-0654 [doi]
AID - tpmd200654 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Aug;103(2):603-604. doi: 10.4269/ajtmh.20-0654. Epub 2020
      Jun 20.


PMID- 32588747
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1477-0334 (Electronic)
IS  - 0962-2802 (Linking)
VI  - 29
IP  - 11
DP  - 2020 Nov
TI  - Approximate Bayesian Bootstrap procedures to estimate multilevel treatment
      effects in observational studies with application to type 2 diabetes treatment
      regimens.
PG  - 3362-3380
LID - 10.1177/0962280220928109 [doi]
AB  - Randomized clinical trials are considered as the gold standard for estimating
      causal effects. Nevertheless, in studies that are aimed at examining adverse
      effects of interventions, randomized trials are often impractical because of
      ethical and financial considerations. In observational studies, matching on the
      generalized propensity scores was proposed as a possible solution to estimate the
      treatment effects of multiple interventions. However, the derivation of point and
      interval estimates for these matching procedures can become complex with
      non-continuous or censored outcomes. We propose a novel Approximate Bayesian
      Bootstrap algorithm that results in statistically valid point and interval
      estimates of the treatment effects with categorical outcomes. The procedure
      relies on the estimated generalized propensity scores and multiply imputes the
      unobserved potential outcomes for each unit. In addition, we describe a
      corresponding interpretable sensitivity analysis to examine the unconfoundedness 
      assumption. We apply this approach to examine the cardiovascular safety of
      common, real-world anti-diabetic treatment regimens for type 2 diabetes mellitus 
      in a large observational database.
FAU - Scotina, Anthony D
AU  - Scotina AD
AUID- ORCID: 0000-0003-1301-3209
AD  - Division of Mathematics, Computing, and Statistics, Simmons University, Boston,
      MA, USA.
FAU - Zullo, Andrew R
AU  - Zullo AR
AD  - Department of Health Services, Policy, and Practice, 6752Brown University,
      Providence, RI, USA.
FAU - Smith, Robert J
AU  - Smith RJ
AD  - Warren Alpert Medical School, 6752Brown University, Providence, RI, USA.
FAU - Gutman, Roee
AU  - Gutman R
AD  - Department of Biostatistics, 6752Brown University, Providence, RI, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - England
TA  - Stat Methods Med Res
JT  - Statistical methods in medical research
JID - 9212457
SB  - IM
MH  - Algorithms
MH  - Bayes Theorem
MH  - Causality
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - Propensity Score
OTO - NOTNLM
OT  - *Approximate Bayesian Bootstrap
OT  - *Causal inference
OT  - *generalized propensity score
OT  - *multiple imputation
OT  - *multiple treatments
EDAT- 2020/06/27 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1177/0962280220928109 [doi]
PST - ppublish
SO  - Stat Methods Med Res. 2020 Nov;29(11):3362-3380. doi: 10.1177/0962280220928109.
      Epub 2020 Jun 26.


PMID- 32588743
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - The effectiveness of a modified advance care planning programme.
PG  - 1569-1586
LID - 10.1177/0969733020922893 [doi]
AB  - BACKGROUND: Frailty is a natural consequence of the aging process. With the
      increasing aging population in Mainland China, the quality of life and
      end-of-life care for frail older people need to be taken into consideration.
      Advance Care Planning has also been used worldwide in long-term facilities,
      hospitals and communities to improve the quality of end-of-life care, increase
      patient and family satisfaction, and reduce healthcare costs and hospital
      admissions in Western countries. However, it has not been practiced in China.
      RESEARCH OBJECTIVE: This study aimed to evaluate the effectiveness of a modified 
      Advance Care Planning intervention in certainty of end-of-life care, preferences 
      for end-of-life care, quality of life concerns, and healthcare utilization among 
      frail older people. RESEARCH DESIGN: This study used a quasi-experimental design,
      with a single-blind, control group, pretest and repeated posttest approach.
      PARTICIPANTS AND RESEARCH CONTEXT: A convenience sample of 74 participates met
      the eligibility criteria in each nursing home. A total of 148 frail older people 
      were recruited in two nursing homes in Zhejiang Province, China. ETHICAL
      CONSIDERATIONS: The study received ethical approval from the Clinical Research
      Ethics Committee, the Faculty of Medicine, and The Chinese University of Hong
      Kong, CREC Ref. No: 2016.059. FINDINGS: The results indicated the Advance Care
      Planning programme was effective at increasing autonomy in decision making on
      end-of-life care issues, decreasing decision-making conflicts over end-of-life
      care issues, and increasing their expression about end-of-life care. DISCUSSION: 
      This study promoted the participants' autonomy and broke through the inherent
      custom of avoiding talking about death in China. CONCLUSION: The modified Advance
      Care Planning intervention is effective and recommended to support the frail
      older people in their end-of-life care decision in Chinese society.
FAU - Deng, Renli
AU  - Deng R
AUID- ORCID: https://orcid.org/0000-0001-8882-2540
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Zhang, Jianghui
AU  - Zhang J
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Chen, Liuliu
AU  - Chen L
AD  - 485858The Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University, China.
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Miao, Jiarui
AU  - Miao J
AD  - 398625Zunyi Medical University, China.
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Duan, Jiazhong
AU  - Duan J
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Qiu, Yeyin
AU  - Qiu Y
AD  - 485858The Fifth Affiliated (Zhuhai) Hospital of Zunyi Medical University, China.
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Leung, Doris
AU  - Leung D
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Chan, Helen
AU  - Chan H
AD  - 26451The Chinese University of Hong Kong, China.
FAU - Lee, Diana Tf
AU  - Lee DT
AD  - 26451The Chinese University of Hong Kong, China.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Advance Care Planning/*standards/statistics & numerical data
MH  - Aged
MH  - Aged, 80 and over
MH  - Chi-Square Distribution
MH  - China
MH  - Female
MH  - Frail Elderly/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Program Evaluation/methods
MH  - Quality of Life/psychology
MH  - Single-Blind Method
MH  - Terminal Care/methods/*standards/statistics & numerical data
OTO - NOTNLM
OT  - Advance care planning
OT  - end-of-life care
OT  - frail older people
OT  - nursing home
OT  - quality of life
EDAT- 2020/06/27 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1177/0969733020922893 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1569-1586. doi: 10.1177/0969733020922893. Epub 2020
      Jun 26.


PMID- 32588545
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1743-498X (Electronic)
IS  - 1743-4971 (Linking)
VI  - 17
IP  - 5
DP  - 2020 Oct
TI  - How to ... do longitudinal qualitative research.
PG  - 489-492
LID - 10.1111/tct.13203 [doi]
AB  - In health professions education, we are often interested in researching change
      over time, for example the development of professional identity or the adoption
      of new practices. Taking a longitudinal qualitative approach to such research can
      provide valuable insights. In this article, we present some longitudinal
      qualitative methods to support researchers interested in getting started with
      this type of research. We discuss what longitudinal qualitative approaches offer,
      consider the challenges and suggest how to go about it. We also highlight some
      specific ethical considerations that may arise in longitudinal studies.
CI  - (c) 2020 John Wiley & Sons Ltd and The Association for the Study of Medical
      Education.
FAU - Bennett, Deirdre
AU  - Bennett D
AUID- ORCID: 0000-0002-4469-9138
AD  - Medical Education Unit, University College Cork, Cork, Ireland.
FAU - Kajamaa, Anu
AU  - Kajamaa A
AUID- ORCID: 0000-0002-6397-545X
AD  - Faculty of Educational Sciences, University of Helsinki, Helsinki, Finland.
FAU - Johnston, Jenny
AU  - Johnston J
AUID- ORCID: 0000-0002-3999-8774
AD  - Centre for Medical Education, Queen's University Belfast School of Medicine
      Dentistry and Biomedical Sciences, Belfast, Northern Ireland, UK.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - England
TA  - Clin Teach
JT  - The clinical teacher
JID - 101227511
SB  - IM
MH  - Humans
MH  - *Qualitative Research
EDAT- 2020/06/27 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1111/tct.13203 [doi]
PST - ppublish
SO  - Clin Teach. 2020 Oct;17(5):489-492. doi: 10.1111/tct.13203. Epub 2020 Jun 25.


PMID- 32588459
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 1744-6198 (Electronic)
IS  - 0029-6473 (Linking)
VI  - 55
IP  - 4
DP  - 2020 Nov
TI  - Perception and opinion of nursing faculties regarding advocacy role: A
      qualitative research.
PG  - 637-644
LID - 10.1111/nuf.12480 [doi]
AB  - BACKGROUND: The nursing literature emphasizes that there are still inadequacies, 
      differences, and inconsistencies in the definition of nurses' advocacy role, and 
      that nursing education plays an important role in educating nurses for patient
      advocacy. OBJECTIVE: The aim of this descriptive qualitative study is to
      determine nurse academics' perception of and opinions about advocacy in nursing. 
      METHODS: The study group consisted of five academics working as nurse educators
      in a university. A questionnaire and focus group interview methods were used to
      collect the data. RESULTS: A framework that consisted of three categories,
      including the scope of advocacy in nursing; today's health system and advocacy;
      nurses' foundation/knowledge base for an advocacy role was set by considering the
      opinions of participants. CONCLUSION: It was emphasized that nurse academics
      regarded advocacy as an ethical obligation and saw it from a broad perspective
      including social justice, that changing health system has increased the
      importance of advocacy role in nursing, that the personality characteristics of
      prospective nurses are important, and that nursing education should be improved
      in terms of advocacy.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Akin, Belgin
AU  - Akin B
AUID- ORCID: http://orcid.org/0000-0002-8094-4110
AD  - Nursing Faculty, University of Selcuk, Konya, Turkey.
FAU - Kursun, Serife
AU  - Kursun S
AUID- ORCID: http://orcid.org/0000-0003-1960-3955
AD  - Nursing Faculty, University of Selcuk, Konya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Nurs Forum
JT  - Nursing forum
JID - 0401006
MH  - Adult
MH  - Faculty, Nursing/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Nurse's Role/psychology
MH  - Patient Advocacy/*standards/statistics & numerical data
MH  - *Perception
MH  - Qualitative Research
MH  - Skilled Nursing Facilities/organization & administration/*standards/statistics & 
      numerical data
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - education
OT  - nursing
OT  - nursing faculty
OT  - patient advocacy
OT  - qualitative
OT  - research
EDAT- 2020/06/27 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1111/nuf.12480 [doi]
PST - ppublish
SO  - Nurs Forum. 2020 Nov;55(4):637-644. doi: 10.1111/nuf.12480. Epub 2020 Jun 25.


PMID- 32588447
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Decision analysis approach to risk/benefit evaluation in the ethical review of
      controlled human infection studies.
PG  - 764-770
LID - 10.1111/bioe.12773 [doi]
AB  - Risks and benefit evaluation for controlled human infection studies, where
      healthy volunteers are deliberately exposed to infectious agents to evaluate
      vaccine efficacy, should be explicit, systematic, thorough, and non-arbitrary.
      Decision analysis promotes these qualities using four steps: (1) determining
      explicit criteria and measures for evaluation, (2) identifying alternatives to
      the study, (3) defining the models used to estimate the measures for each
      alternative, and (4) running the models to produce the estimates and compare the 
      alternatives. In this paper, we describe how decision analysis might be applied
      by funders and regulators, as well as by others contemplating the use of novel
      controlled human infection studies for vaccine development and evaluation.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Yu, Michael
AU  - Yu M
AUID- ORCID: 0000-0002-2445-4555
AD  - Centre de Recherche du CHUM, Montreal, Canada.
AD  - Biomedical Ethics Unit/Social Studies of Medicine, McGill University, Montreal,
      Canada.
FAU - Darton, Thomas C
AU  - Darton TC
AD  - Department of Infection, Immunity and Cardiovascular Disease, University of
      Sheffield Medical School, United Kingdom of Great Britain and Northern Ireland.
FAU - Kimmelman, Jonathan
AU  - Kimmelman J
AUID- ORCID: 0000-0003-1614-6779
AD  - Biomedical Ethics Unit/Social Studies of Medicine, McGill University, Montreal,
      Canada.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Biomedical Research
MH  - Decision Support Techniques
MH  - *Ethical Review
MH  - Humans
MH  - Research Design
MH  - Risk Assessment
OTO - NOTNLM
OT  - *controlled human infection
OT  - *decision analysis
OT  - *research ethics
OT  - *risk and benefit
OT  - *vaccine development
EDAT- 2020/06/27 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/06/27 06:00
PHST- 2019/05/30 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1111/bioe.12773 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):764-770. doi: 10.1111/bioe.12773. Epub 2020 Jun 26.


PMID- 32588181
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Conflict of Interest in Scientific Research in China: A Socio-ethical Analysis of
      He Jiankui's Human Genome-editing Experiment.
PG  - 191-201
LID - 10.1007/s11673-020-09978-7 [doi]
AB  - Extensive conflicts of interest (COI) at both individual and institutional levels
      are identifiable in scientific research and healthcare in China, as in many other
      parts of the world. A prominent new case from China is He Jiankui's experiment
      that produced the world's first gene-edited babies and that raises numerous
      ethical, political, socio-cultural, and transnational questions. Serious
      financial and other COI were involved in He's genetic adventure. Using He's
      infamous experiment as a case study, this paper explores the wider issue of
      financial and other COI in scientific research and healthcare in China,
      especially institutional conflict of interest (ICOI) and policy-related COI.
      Taking a socio-ethical perspective, it examines China's state policies and its
      massive efforts to transform and commercialize scientific research, the lack of
      policies and oversight mechanisms for regulating COI, as well as major ethical
      issues arising from COI including the undermining of public trust. Some practical
      suggestions are offered for institutional reform and institutional development so
      that COI, particularly ICOI, can be avoided or more effectively managed in
      scientific research in China.
FAU - Nie, Jing-Bao
AU  - Nie JB
AD  - Bioethics Centre, Dunedin School of Medicine, University of Otago, Box 56,
      Dunedin, PO, New Zealand. jing-bao.nie@otago.ac.anz.
FAU - Xie, Guangkuan
AU  - Xie G
AD  - School of Health Humanities, Peking University, 38 Xueyuan Road, Haidian
      District, Beijing, 100191, P. R. China.
FAU - Chen, Hua
AU  - Chen H
AD  - College of Marxism, Southern Medical University, 1023-1063 Shatai Road South,
      Baiyun District, Guangzhou, P. R. China.
FAU - Cong, Yali
AU  - Cong Y
AD  - School of Health Humanities, Peking University, 38 Xueyuan Road, Haidian
      District, Beijing, 100191, P. R. China.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - China
MH  - *Conflict of Interest
MH  - Disclosure
MH  - Ethical Analysis
MH  - *Gene Editing
MH  - Genome, Human
MH  - Humans
OTO - NOTNLM
OT  - China
OT  - Conflict of interest
OT  - Human genome editing
OT  - Research ethics
OT  - Science policy
OT  - Scientific integrity
EDAT- 2020/06/27 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/06/27 06:00
PHST- 2019/10/05 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1007/s11673-020-09978-7 [doi]
AID - 10.1007/s11673-020-09978-7 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Jun;17(2):191-201. doi: 10.1007/s11673-020-09978-7. Epub 2020 
      Jun 25.


PMID- 32587949
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2542-4823 (Electronic)
IS  - 2542-4823 (Linking)
VI  - 4
IP  - 1
DP  - 2020 May 20
TI  - The Complex Maze of the Informed Consent Process: Helping to Improve
      Comprehension in Clinical Trial Participants with Alzheimer's Disease.
PG  - 161-164
LID - 10.3233/ADR-200187 [doi]
AB  - We intend for this article to provide a foundation toward the creation of a more 
      patient-centric approach to the informed consent process. Our overall objectives 
      are to promote ethical clinical research standards and procedures toward enhanced
      supportive systems for clinical trial participants. We provide a suggested format
      which multidisciplinary clinical trial researchers can adapt for their own
      clinical trial setting.
CI  - (c) 2020 - IOS Press and the authors. All rights reserved.
FAU - Wong, Louis X
AU  - Wong LX
AD  - Department of Clinical Research and Leadership, The George Washington University 
      School of Medicine and Health Sciences, Washington, DC, USA.
AD  - Department of Hematology and Oncology, Gastrointestinal Oncology, University of
      California, San Francisco, San Francisco, CA, USA.
FAU - Bloom, Gail M
AU  - Bloom GM
AD  - Department of Clinical Research and Leadership, The George Washington University 
      School of Medicine and Health Sciences, Washington, DC, USA.
FAU - Chee, Bryant
AU  - Chee B
AD  - Department of Primary Care, Touro University College of Osteopathic Medicine -
      California, Vallejo, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Netherlands
TA  - J Alzheimers Dis Rep
JT  - Journal of Alzheimer's disease reports
JID - 101705500
PMC - PMC7306923
OTO - NOTNLM
OT  - Autonomy
OT  - decision-making
OT  - guidance
OT  - informed consent
OT  - participant
OT  - patient-centric approach
OT  - protection
OT  - trust-building
COIS- The authors have no conflict of interest to report.
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.3233/ADR-200187 [doi]
AID - ADR200187 [pii]
PST - epublish
SO  - J Alzheimers Dis Rep. 2020 May 20;4(1):161-164. doi: 10.3233/ADR-200187.


PMID- 32587938
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2473-1242 (Electronic)
IS  - 2473-1242 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Why a Right to Health Makes No Sense, and What Does.
PG  - 249-254
LID - 10.1089/heq.2019.0116 [doi]
AB  - There is a widely held belief in a universal right to the highest attainable
      standard of health. This essay shows how this right is conceptually unclear,
      unattainable, and a distraction from a more concrete and attainable right: a
      right to equitable access to available resources for health (RARH), including
      equitable access to the social determinants of health. It clarifies conceptual
      and theoretical issues in the RARH: its underlying theory rooted in historical,
      economic, and axiological rationales; its concept of component resources and
      their availability, equity, sustainability; and the redistribution of wealth and 
      power, metrics, and ethics. The advancement of global health equity requires
      explicit theorizing of what underlies a right to health. The right to the highest
      attainable standard of health fails in this regard. The RARH provides a
      desirable, actionable, and measurable foundation for global health equity.
CI  - (c) Robert A. Hahn and Carles Muntaner 2020; Published by Mary Ann Liebert, Inc.
FAU - Hahn, Robert A
AU  - Hahn RA
AD  - Department of Anthropology, Emory University, Atlanta, Georgia, USA.
FAU - Muntaner, Carles
AU  - Muntaner C
AD  - Dalla Lana School of Public Health, Social Equity and Health, University of
      Toronto, Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - United States
TA  - Health Equity
JT  - Health equity
JID - 101708316
PMC - PMC7310297
OTO - NOTNLM
OT  - equity
OT  - right to health
OT  - social determinants of health
COIS- No competing financial interests exist.
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.1089/heq.2019.0116 [doi]
AID - 10.1089/heq.2019.0116 [pii]
PST - epublish
SO  - Health Equity. 2020 Jun 12;4(1):249-254. doi: 10.1089/heq.2019.0116. eCollection 
      2020.


PMID- 32587904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210224
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Segmenting communities as public health strategy: a view from the social sciences
      and humanities.
PG  - 104
LID - 10.12688/wellcomeopenres.15975.1 [doi]
AB  - On the 5th of May 2020, a group of modellers, epidemiologists and biomedical
      scientists from the University of Edinburgh proposed a "segmenting and shielding"
      approach to easing the lockdown in the UK over the coming months. Their proposal,
      which has been submitted to the government and since been discussed in the media,
      offers what appears to be a pragmatic solution out of the current lockdown. The
      approach identifies segments of the population as at-risk groups and outlines
      ways in which these remain shielded, while 'healthy' segments would be allowed to
      return to some kind of normality, gradually, over several weeks. This proposal
      highlights how narrowly conceived scientific responses may result in unintended
      consequences and repeat harmful public health practices. As an interdisciplinary 
      group of researchers from the humanities and social sciences at the University of
      Edinburgh, we respond to this proposal and highlight how ethics, history, medical
      sociology and anthropology - as well as disability studies and decolonial
      approaches - offer critical engagement with such responses, and call for more
      creative and inclusive responses to public health crises.
CI  - Copyright: (c) 2020 Ganguli-Mitra A et al.
FAU - Ganguli-Mitra, Agomoni
AU  - Ganguli-Mitra A
AD  - Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK.
FAU - Young, Ingrid
AU  - Young I
AUID- ORCID: https://orcid.org/0000-0002-1242-5992
AD  - Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK.
FAU - Engelmann, Lukas
AU  - Engelmann L
AD  - Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK.
FAU - Harper, Ian
AU  - Harper I
AD  - School of Social and Political Sciences, University of Edinburgh, Edinburgh, UK.
FAU - McCormack, Donna
AU  - McCormack D
AUID- ORCID: https://orcid.org/0000-0002-2852-2180
AD  - Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK.
AD  - School of Literature and Languages, University of Surrey, Guildford, UK.
FAU - Marsland, Rebecca
AU  - Marsland R
AD  - School of Social and Political Sciences, University of Edinburgh, Edinburgh, UK.
FAU - Buch Segal, Lotte
AU  - Buch Segal L
AUID- ORCID: https://orcid.org/0000-0001-9996-3189
AD  - School of Social and Political Sciences, University of Edinburgh, Edinburgh, UK.
FAU - Sethi, Nayha
AU  - Sethi N
AUID- ORCID: https://orcid.org/0000-0002-2782-5382
AD  - Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK.
FAU - Stewart, Ellen
AU  - Stewart E
AUID- ORCID: https://orcid.org/0000-0003-3013-1477
AD  - Centre for Biomedicine, Self & Society, University of Edinburgh, Edinburgh, UK.
FAU - Tichenor, Marlee
AU  - Tichenor M
AUID- ORCID: https://orcid.org/0000-0001-6434-9795
AD  - School of Social and Political Sciences, University of Edinburgh, Edinburgh, UK.
LA  - eng
GR  - PDF/13/11/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
DEP - 20200526
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7309410
OTO - NOTNLM
OT  - COVID-19
OT  - disability
OT  - equity
OT  - ethics
OT  - ethnicity
OT  - inclusion
OT  - public health response
OT  - social justice
COIS- No competing interests were disclosed.
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.12688/wellcomeopenres.15975.1 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 May 26;5:104. doi: 10.12688/wellcomeopenres.15975.1.
      eCollection 2020.


PMID- 32587752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
DP  - 2020
TI  - A randomised controlled pilot trial of two interventions to manage dry mouth in
      pre-operative elective surgical patients.
PG  - 89
LID - 10.1186/s40814-020-00630-0 [doi]
AB  - BACKGROUND: Dry mouth is a common perioperative patient complaint. There are a
      number of treatments used for dry mouth in other settings which are effective.
      None have been tested previously in the perioperative setting. Interventions to
      Manage Dry mouth (IM DRY) compared the effect of water and a saliva substitute on
      mouth dryness. The primary objective was to demonstrate the feasibility of
      conducting a large randomised controlled trial and secondary scientific aims were
      to assess treatment potential efficacy. METHODS: Single blind, pilot randomised
      controlled trial (RCT) of 101 pre-operative elective surgical patients who were
      randomised to water or saliva substitute (Biotene oral rinse, GlaxoSmithKline,
      Australia) at a tertiary, university hospital. Dry mouth was assessed by 100 mm
      visual analogue scale (VAS) and 5-point Likert score. RESULTS: One hundred
      participants completed follow-up and comprised the analysis dataset. All
      feasibility outcomes were achieved (recruitment rate > 5 participants a week,
      >95% completeness of the dataset, study protocol acceptability to staff,
      acceptability to participants > 66% and adherence to time limits within the
      protocol). Mean recruitment rate was 6 participants per week. These data were 99%
      complete. There were no adverse side effects or complications noted. There were
      no concerns raised by staff regarding acceptability. Overall, there was a mean of
      30 min (+/- SD 5 min) between delivery of the intervention and the assessment, 30
      min being the target time. The difference in VAS post intervention was - 11.2 mm 
      (95% CI - 17.3 to - 5.1 mm) for water and - 12.7 mm (95% CI - 18.7 to - 6.7 mm)
      for saliva substitute. The proportion of patients who had improved dry mouth
      increased from 52% for water to 62% for saliva substitute. CONCLUSIONS: IM DRY
      successfully achieved its primary feasibility aims: recruitment rate,
      completeness of these, acceptability and protocol adherence. Saliva substitutes, 
      used in the perioperative management of dry mouth, may be a simple, inexpensive, 
      and low risk solution to help alleviate this common complaint. A large randomised
      controlled trial is feasible and is currently recruiting (ANZCTR 12619000132145).
      ETHICS AND TRIAL REGISTRATION: Northern A New Zealand Health and Disability
      Ethics Committee (reference 17/NTA/152). Australian New Zealand Clinical Trials
      Registry (Number: 12618001270202). Registered retrospectively 18 October 2018.
CI  - (c) The Author(s) 2020.
FAU - Morton, Leesa
AU  - Morton L
AUID- ORCID: 0000-0002-2562-6400
AD  - Department of Anaesthesia, Canterbury District Health Board, 2 Riccarton Avenue, 
      Christchurch Central, Christchurch, 8011 New Zealand.grid.410864.f0000 0001 0040 
      0934
FAU - Siu, Amanda Tsan Yue
AU  - Siu ATY
AD  - Department of Anaesthesia, Counties Manukau District Health Board, 100 Hospital
      Road, Otahuhu, Auckland 2025 New Zealand.grid.413188.70000 0001 0098 1855
FAU - Fowler, Samuel
AU  - Fowler S
AD  - Department of Anaesthesia and Perioperative Medicine, Auckland District Health
      Board, Level 8, Support Building, Auckland City Hospital, Park Road, Grafton,
      Auckland 1023 New Zealand.grid.414057.30000 0001 0042 379X
FAU - Zhou, Chen
AU  - Zhou C
AD  - Department of Anaesthesia, Counties Manukau District Health Board, 100 Hospital
      Road, Otahuhu, Auckland 2025 New Zealand.grid.413188.70000 0001 0098 1855
FAU - Nixon, Christopher
AU  - Nixon C
AD  - Department of Anaesthesia and Perioperative Medicine, Auckland District Health
      Board, Level 8, Support Building, Auckland City Hospital, Park Road, Grafton,
      Auckland 1023 New Zealand.grid.414057.30000 0001 0042 379X
FAU - Campbell, Doug
AU  - Campbell D
AD  - Department of Anaesthesia and Perioperative Medicine, Auckland District Health
      Board, Level 8, Support Building, Auckland City Hospital, Park Road, Grafton,
      Auckland 1023 New Zealand.grid.414057.30000 0001 0042 379X
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
PMC - PMC7313130
OTO - NOTNLM
OT  - Anaesthesia
OT  - Artificial saliva
OT  - Dry mouth
OT  - Elective surgery
OT  - Feasibility
OT  - Patient centred outcome
OT  - Pilot
OT  - Pre-operative
OT  - Randomised
OT  - Treatment
OT  - Xerostomia
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2019/09/12 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.1186/s40814-020-00630-0 [doi]
AID - 630 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 Jun 24;6:89. doi: 10.1186/s40814-020-00630-0.
      eCollection 2020.


PMID- 32587745
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2054-1058 (Print)
IS  - 2054-1058 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Jul
TI  - Ethical competence in a profession: Healthcare professionals' views.
PG  - 1249-1259
LID - 10.1002/nop2.501 [doi]
AB  - Aim: Ethical competence is a crucial component for enabling good quality care but
      there is insufficient qualitative research on healthcare professionals' views on 
      ethical competence. The aim of this study was to investigate healthcare
      professionals' views on ethical competence in a student healthcare context.
      Design: A qualitative design and a hermeneutical approach were used. Methods: The
      material consists of texts from interviews with healthcare professionals (N = 10)
      in a student healthcare context. The method was inspired by content analysis.
      Results: One main theme and four subthemes emerged. The main theme was as
      follows: safeguarding the vulnerability of the other. The subthemes were as
      follows: using sensitivity to establish a trustful relationship, acting in an
      objective and flexible manner, using a reflective process in decision-making, and
      maintaining confidentiality and honesty. Future research should focus on
      investigating ethical competence from various perspectives in student health
      care, for example the student perspective or observational studies.
CI  - (c) 2020 The Authors. Nursing Open published by John Wiley & Sons Ltd.
FAU - Hemberg, Jessica
AU  - Hemberg J
AUID- ORCID: 0000-0002-0829-8249
AD  - Department of Caring Sciences Faculty of Education and Welfare Studies Abo
      Akademi University Vaasa Finland.
FAU - Hemberg, Hakan
AU  - Hemberg H
AUID- ORCID: 0000-0003-3147-5466
AD  - Department of Public Administration Faculty of Social Sciences, Business and
      Economics Abo Akademi University Turku Finland.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - United States
TA  - Nurs Open
JT  - Nursing open
JID - 101675107
MH  - Delivery of Health Care
MH  - *Health Personnel
MH  - Humans
MH  - *Morals
MH  - Qualitative Research
MH  - Quality of Health Care
PMC - PMC7308671
OTO - NOTNLM
OT  - *competence
OT  - *ethics
OT  - *nurses
OT  - *nursing
COIS- The authors declare that there are no sources of conflicts.
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/03/02 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.1002/nop2.501 [doi]
AID - NOP2501 [pii]
PST - epublish
SO  - Nurs Open. 2020 May 18;7(4):1249-1259. doi: 10.1002/nop2.501. eCollection 2020
      Jul.


PMID- 32587708
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2054-1058 (Print)
IS  - 2054-1058 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Jul
TI  - The ethical challenges of antimicrobial resistance for Nurse practitioners.
PG  - 904-906
LID - 10.1002/nop2.453 [doi]
FAU - Oerther, Sarah
AU  - Oerther S
AUID- ORCID: 0000-0002-9990-6739
AD  - School of Nursing Saint Louis University St. Louis Missouri.
FAU - Oerther, Daniel B
AU  - Oerther DB
AD  - Fulbright Visiting Scholar King's College London London UK.
LA  - eng
PT  - Editorial
DEP - 20200122
PL  - United States
TA  - Nurs Open
JT  - Nursing open
JID - 101675107
RN  - 0 (Anti-Bacterial Agents)
MH  - Anti-Bacterial Agents/pharmacology
MH  - Drug Resistance, Bacterial
MH  - *Ethics, Nursing
MH  - Humans
MH  - *Nurse Practitioners
PMC - PMC7308707
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
AID - 10.1002/nop2.453 [doi]
AID - NOP2453 [pii]
PST - epublish
SO  - Nurs Open. 2020 Jan 22;7(4):904-906. doi: 10.1002/nop2.453. eCollection 2020 Jul.


PMID- 32587403
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20210217
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 16
IP  - 10
DP  - 2020 Oct
TI  - Ethical challenges in nephrology: a call for action.
PG  - 603-613
LID - 10.1038/s41581-020-0295-4 [doi]
AB  - The American Society of Nephrology, the European Renal Association-European
      Dialysis and Transplant Association and the International Society of Nephrology
      Joint Working Group on Ethical Issues in Nephrology have identified ten broad
      areas of ethical concern as priority challenges that require collaborative
      action. Here, we describe these challenges - equity in access to kidney failure
      care, avoiding futile dialysis, reducing dialysis costs, shared decision-making
      in kidney failure care, living donor risk evaluation and decision-making,
      priority setting in kidney disease prevention and care, the ethical implications 
      of genetic kidney diseases, responsible advocacy for kidney health and management
      of conflicts of interest - with the aim of highlighting the need for ethical
      analysis of specific issues, as well as for the development of tools and training
      to support clinicians who treat patients with kidney disease in practising
      ethically and contributing to ethical policy-making.
FAU - Martin, Dominique E
AU  - Martin DE
AUID- ORCID: http://orcid.org/0000-0001-9363-0770
AD  - School of Medicine, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC, 
      Australia. dominique.martin@deakin.edu.au.
FAU - Harris, David C H
AU  - Harris DCH
AD  - University of Sydney at Westmead Hospital, Westmead, NSW, Australia.
FAU - Jha, Vivekanand
AU  - Jha V
AD  - George Institute for Global Health, UNSW, New Delhi, India.
AD  - University of Oxford, Oxford, UK.
AD  - Manipal Academy of Higher Education, Manipal, India.
FAU - Segantini, Luca
AU  - Segantini L
AUID- ORCID: http://orcid.org/0000-0003-4949-8623
AD  - International Society of Nephrology, Brussels, Belgium.
AD  - European Society for Organ Transplantation - ESOT c/o ESOT, Padova, Italy.
FAU - Demme, Richard A
AU  - Demme RA
AD  - Renal Division and Department of Medical Humanities and Bioethics, University of 
      Rochester School of Medicine, Rochester, NY, USA.
FAU - Le, Thu H
AU  - Le TH
AD  - Nephrology Division, Department of Medicine, University of Rochester School of
      Medicine, Rochester, NY, USA.
FAU - McCann, Laura
AU  - McCann L
AD  - American Society of Nephrology, Washington, DC, USA.
FAU - Sands, Jeff M
AU  - Sands JM
AUID- ORCID: http://orcid.org/0000-0001-9822-0607
AD  - Renal Division, Emory University School of Medicine, Atlanta, GA, USA.
FAU - Vong, Gerard
AU  - Vong G
AUID- ORCID: http://orcid.org/0000-0002-1315-1858
AD  - Center for Ethics, Emory University, Atlanta, GA, USA.
FAU - Wolpe, Paul Root
AU  - Wolpe PR
AD  - Center for Ethics, Emory University, Atlanta, GA, USA.
FAU - Fontana, Monica
AU  - Fontana M
AD  - European Renal Association - European Dialysis and Transplant Association, Parma,
      Italy.
FAU - London, Gerard M
AU  - London GM
AD  - Manhes Hospital, Nephrology Department GEPIR, Fleury-Merogis, France.
FAU - Vanderhaegen, Bert
AU  - Vanderhaegen B
AD  - University Hospital, Gent, Belgium.
FAU - Vanholder, Raymond
AU  - Vanholder R
AUID- ORCID: http://orcid.org/0000-0003-2633-1636
AD  - Nephrology Section, Department of Internal Medicine and Pediatrics, University
      Hospital, Corneel Heymanslaan 10, B9000, Gent, Belgium.
CN  - ASN-ERA-EDTA-ISN Joint Working Group on Ethical Issues in Nephrology
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200625
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
SB  - IM
MH  - Conflict of Interest
MH  - Cost Control/ethics
MH  - Decision Making, Shared
MH  - Health Priorities/ethics
MH  - Health Services Accessibility/ethics
MH  - Healthcare Disparities/ethics
MH  - Humans
MH  - Kidney Diseases/genetics
MH  - Kidney Transplantation/ethics
MH  - Medical Futility/ethics
MH  - Nephrology/*ethics
MH  - Organ Trafficking/ethics
MH  - Patient Advocacy/ethics
MH  - Renal Dialysis/economics/ethics
MH  - Renal Insufficiency/therapy
MH  - Tissue and Organ Procurement/ethics
IR  - Martin DE
FIR - Martin, Dominique E
IR  - Harris DCH
FIR - Harris, David C H
IR  - Jha V
FIR - Jha, Vivekanand
IR  - Segantini L
FIR - Segantini, Luca
IR  - Demme RA
FIR - Demme, Richard A
IR  - Le TH
FIR - Le, Thu H
IR  - McCann L
FIR - McCann, Laura
IR  - Sands JM
FIR - Sands, Jeff M
IR  - Vong G
FIR - Vong, Gerard
IR  - Wolpe PR
FIR - Wolpe, Paul Root
IR  - Fontana M
FIR - Fontana, Monica
IR  - London GM
FIR - London, Gerard M
IR  - Vanderhaegen B
FIR - Vanderhaegen, Bert
IR  - Vanholder R
FIR - Vanholder, Raymond
EDAT- 2020/06/27 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - 10.1038/s41581-020-0295-4 [doi]
AID - 10.1038/s41581-020-0295-4 [pii]
PST - ppublish
SO  - Nat Rev Nephrol. 2020 Oct;16(10):603-613. doi: 10.1038/s41581-020-0295-4. Epub
      2020 Jun 25.


PMID- 32587044
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 186
IP  - 19
DP  - 2020 Jun 27
TI  - The ethics of Halal meat consumption: preferences of consumers in England
      according to the method of slaughter.
PG  - 644
LID - 10.1136/vr.105287 [doi]
AB  - BACKGROUND: The continued growth of the global Halal meat market has resulted in 
      many mainstream businesses in the developed world trading in Halal products. A
      good understanding of Halal consumer behaviour with regard to their preference of
      meat according to the method of slaughter (pre-stunned or not) and the frequency 
      of consumption is vital for the formulation of future animal welfare legislation,
      consumer protection policies and research strategies of educational institutions.
      METHODS: In this study, 250 Halal meat consumers in England were surveyed to
      obtain a better understanding of their meat consumption frequency, preference of 
      meat according to species of animals and the method of slaughter. RESULTS: The
      results show that the majority (50.8 per cent) of consumers ate meat at least
      once a week, 45.6 per cent at least once a day, 3.2 per cent at least once a
      month and 0.4 per cent ate meat occasionally. Poultry meat was marginally the
      most preferred meat among respondents overall, followed by lamb and beef, with
      the majority of respondents (approximately 70 per cent) indicating preference for
      meat from animals slaughtered without stunning over those stunned before
      slaughter. There were gender differences within some responses. CONCLUSION: The
      results give an insight into Halal consumer behaviour, and may be useful to
      retailers, researchers, consumer advocates, animal welfare charities and
      government.
CI  - (c) British Veterinary Association 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Fuseini, Awal
AU  - Fuseini A
AUID- ORCID: 0000-0002-7886-8729
AD  - School of Veterinary Science, University of Bristol, Bristol, UK
      awalfus@yahoo.com.
FAU - Knowles, Toby G
AU  - Knowles TG
AD  - School of Veterinary Science, University of Bristol, Bristol, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
SB  - IM
MH  - Abattoirs
MH  - Adult
MH  - Animals
MH  - Cattle
MH  - Consumer Behavior/*statistics & numerical data
MH  - Diet/*ethics
MH  - Electroshock/*veterinary
MH  - England
MH  - Female
MH  - Humans
MH  - *Islam
MH  - Male
MH  - *Meat
MH  - Middle Aged
MH  - Poultry
MH  - Sheep
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *animal welfare
OT  - *beef
OT  - *halal meat
OT  - *lamb
OT  - *slaughter
OT  - *stunning
COIS- Competing interests: None declared.
EDAT- 2020/06/27 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/06/27 06:00
PHST- 2018/11/27 00:00 [received]
PHST- 2019/12/02 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - vr.105287 [pii]
AID - 10.1136/vr.105287 [doi]
PST - ppublish
SO  - Vet Rec. 2020 Jun 27;186(19):644. doi: 10.1136/vr.105287.


PMID- 32586773
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-4898 (Electronic)
IS  - 1477-5131 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Aug
TI  - Sexual function and health status in adult patients with Congenital Adrenal
      Hyperplasia.
PG  - 464.e1-464.e6
LID - S1477-5131(20)30332-6 [pii]
LID - 10.1016/j.jpurol.2020.05.162 [doi]
AB  - INTRODUCTION: Congenital Adrenal Hyperplasia (CAH) is the most common reason for 
      undifferentiated genital appearance in new-borns. Psychosexual outcome in women
      with CAH has been rarely evaluated, but it seems to be one of the most important 
      factors determining the indications for the surgical treatment of CAH. OBJECTIVE:
      This is to assess sexual function and the health status (HS) in adult females
      with CAH who had feminizing genitoplasty in childhood. MATERIAL AND METHOD: The
      protocol was approved by the Ethical Committee, and the hospital database was
      searched for patients with CAH who had genitoplasty between 1975 and 2000. 57
      adult patients were identified, and 9 (18%) patients agreed to participate in the
      study. Mean age at operation was 5.4 years, and mean follow-up duration was 10.9 
      years. The Female Sexual Function Index (FSFI) was used to evaluate sexual
      function, and the 36-item Short Form Health Survey (SF-36) was used to evaluate
      their health status (HS). A FSFI score < 26,55 was classified as Female Sexual
      Dysfunction (FSD). The control group consisted of 10 adult female volunteers of
      comparable age, without any oncological or chronic diseases. Fisher's exact test 
      was used for statistical analysis. RESULTS: All patients in the CAH group had
      female gender identity. One was homosexual, and one reported not having any
      sexual activity. In the control group, all patients had female gender identity.
      All were heterosexual and one reported not having any sexual activity. The sexual
      function in five domains and total score were similar in both groups. More pain
      was reported in the CAH group as compared with the control group, and it was
      statistically significant. In the CAH group, 5/9 patients had FSD. In the control
      group, 4/10 patients had FSD. The difference was statistically insignificant (p =
      0.66). Mean SF-36 score in the CAH group was 47.1 points, while it was 46.7
      points in the control group. The testosterone level in all CAH patients was
      within the normal range (0.13-1.1 ng/ml). The 17-OH progesterone level was above 
      normal range in 5/9 (55.6%) patients with CAH. All women in the CAH group were
      hormonally treated. In the control group, all patients had a normal testosterone 
      level (0.15-0.68 ng/ml); the 17-OH progesterone level was in normal range in this
      group. DISCUSSION: We compared our results with the literature data, which used
      the same questionnaires as in our study. CONCLUSIONS: Health status and sexual
      function in the traceable CAH patients didn't differ from the control group.
CI  - Copyright (c) 2020 Journal of Pediatric Urology Company. Published by Elsevier
      Ltd. All rights reserved.
FAU - Dobrowolska-Glazar, Barbara
AU  - Dobrowolska-Glazar B
AD  - Department of Pediatric Urology, Jagiellonian University Medical College, Krakow,
      Poland. Electronic address: Barbara.Dobrowolska-Glazar@uj.edu.pl.
FAU - Honkisz, Ireneusz
AU  - Honkisz I
AD  - Department of Pediatric Urology, Jagiellonian University Medical College, Krakow,
      Poland.
FAU - Sulislawski, Janusz
AU  - Sulislawski J
AD  - Department of Pediatric Urology, Jagiellonian University Medical College, Krakow,
      Poland.
FAU - Tyrawa, Katarzyna
AU  - Tyrawa K
AD  - Department of Pediatric Endocrynology, Jagiellonian University Medical College,
      Krakow, Poland.
FAU - Wolnicki, Michal
AU  - Wolnicki M
AD  - Department of Pediatric Urology, Jagiellonian University Medical College, Krakow,
      Poland.
FAU - Chrzan, Rafal
AU  - Chrzan R
AD  - Department of Pediatric Urology, Jagiellonian University Medical College, Krakow,
      Poland.
LA  - eng
PT  - Journal Article
DEP - 20200531
PL  - England
TA  - J Pediatr Urol
JT  - Journal of pediatric urology
JID - 101233150
SB  - IM
MH  - *Adrenal Hyperplasia, Congenital/complications/surgery
MH  - Adult
MH  - *Disorders of Sex Development
MH  - Female
MH  - Gender Identity
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Sexual Behavior
OTO - NOTNLM
OT  - Congenital adrenal hyperplasia
OT  - Health status
OT  - Sexual function
COIS- Conflicts of interest We have no conflicts of interest to disclose.
EDAT- 2020/06/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/27 06:00
PHST- 2020/02/09 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/05/24 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - S1477-5131(20)30332-6 [pii]
AID - 10.1016/j.jpurol.2020.05.162 [doi]
PST - ppublish
SO  - J Pediatr Urol. 2020 Aug;16(4):464.e1-464.e6. doi: 10.1016/j.jpurol.2020.05.162. 
      Epub 2020 May 31.


PMID- 32586747
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
VI  - 17
IP  - 9
DP  - 2020 Sep
TI  - Language & Ethics in Transgender Health.
PG  - 1585-1586
LID - S1743-6095(20)30654-8 [pii]
LID - 10.1016/j.jsxm.2020.05.017 [doi]
FAU - T'Sjoen, Guy
AU  - T'Sjoen G
AD  - Department of Endocrinology and Center for Sexology and Gender, Ghent University 
      and Ghent University Hospital, Ghent, Belgium. Electronic address:
      guy.tsjoen@ugent.be.
FAU - Radix, Asa
AU  - Radix A
AD  - Department of Medicine, Callen-Lorde Community Health Center, New York, NY, USA.
FAU - Motmans, Joz
AU  - Motmans J
AD  - Transgender Infopunt, Ghent University Hospital, and Centre for Research on
      Culture and Gender, Ghent University, Ghent, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - Netherlands
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
SB  - IM
EDAT- 2020/06/27 06:00
MHDA- 2020/06/27 06:01
CRDT- 2020/06/27 06:00
PHST- 2020/05/15 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/06/27 06:01 [medline]
PHST- 2020/06/27 06:00 [entrez]
AID - S1743-6095(20)30654-8 [pii]
AID - 10.1016/j.jsxm.2020.05.017 [doi]
PST - ppublish
SO  - J Sex Med. 2020 Sep;17(9):1585-1586. doi: 10.1016/j.jsxm.2020.05.017. Epub 2020
      Jun 23.


PMID- 32586391
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20210317
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jun 25
TI  - Addressing challenges for clinical research responses to emerging epidemics and
      pandemics: a scoping review.
PG  - 190
LID - 10.1186/s12916-020-01624-8 [doi]
AB  - BACKGROUND: Major infectious disease outbreaks are a constant threat to human
      health. Clinical research responses to outbreaks generate evidence to improve
      outcomes and outbreak control. Experiences from previous epidemics have
      identified multiple challenges to undertaking timely clinical research responses.
      This scoping review is a systematic appraisal of political, economic,
      administrative, regulatory, logistical, ethical and social (PEARLES) challenges
      to clinical research responses to emergency epidemics and solutions identified to
      address these. METHODS: A scoping review. We searched six databases (MEDLINE,
      Embase, Global Health, PsycINFO, Scopus and Epistemonikos) for articles published
      from 2008 to July 2018. We included publications reporting PEARLES challenges to 
      clinical research responses to emerging epidemics and pandemics and solutions
      identified to address these. Two reviewers screened articles for inclusion,
      extracted and analysed the data. RESULTS: Of 2678 articles screened, 76 were
      included. Most presented data relating to the 2014-2016 Ebola virus outbreak or
      the H1N1 outbreak in 2009. The articles related to clinical research responses in
      Africa (n = 37), Europe (n = 8), North America (n = 5), Latin America and the
      Caribbean (n = 3) and Asia (n = 1) and/or globally (n = 22). A wide range of
      solutions to PEARLES challenges was presented, including a need to strengthen
      global collaborations and coordination at all levels and develop pre-approved
      protocols and equitable frameworks, protocols and standards for emergencies.
      Clinical trial networks and expedited funding and approvals were some solutions
      implemented. National ownership and community engagement from the outset were a
      key enabler for delivery. Despite the wide range of recommended solutions, none
      had been formally evaluated. CONCLUSIONS: To strengthen global preparedness and
      response to the COVID-19 pandemic and future epidemics, identified solutions for 
      rapid clinical research deployment, delivery, and dissemination must be
      implemented. Improvements are urgently needed to strengthen collaborations,
      funding mechanisms, global and national research capacity and capability,
      targeting regions vulnerable to epidemics and pandemics. Solutions need to be
      flexible to allow timely adaptations to context, and research led by governments 
      of affected regions. Research communities globally need to evaluate their
      activities and incorporate lessons learnt to refine and rehearse collaborative
      outbreak response plans in between epidemics.
FAU - Sigfrid, Louise
AU  - Sigfrid L
AUID- ORCID: 0000-0003-2764-1177
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, New Richards Building, Old Road Campus, Oxford, OX3 7LG,
      UK. louise.sigfrid@ndm.ox.ac.uk.
FAU - Maskell, Katherine
AU  - Maskell K
AD  - Deparment for Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, UK.
FAU - Bannister, Peter G
AU  - Bannister PG
AD  - Deparment for Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, UK.
FAU - Ismail, Sharif A
AU  - Ismail SA
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Collinson, Shelui
AU  - Collinson S
AD  - School of Population Health and Environmental Sciences, King's College London,
      London, UK.
FAU - Regmi, Sadie
AU  - Regmi S
AD  - Department of Primary Care and Public Health, Imperial College London, London,
      UK.
FAU - Blackmore, Claire
AU  - Blackmore C
AD  - University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
FAU - Harriss, Eli
AU  - Harriss E
AD  - Bodleian Health Care Libraries, University of Oxford, Oxford, UK.
FAU - Longuere, Kajsa-Stina
AU  - Longuere KS
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, New Richards Building, Old Road Campus, Oxford, OX3 7LG,
      UK.
FAU - Gobat, Nina
AU  - Gobat N
AD  - Nuffield Dep of Primary Care Health Sciences, University of Oxford, Oxford, UK.
FAU - Horby, Peter
AU  - Horby P
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, New Richards Building, Old Road Campus, Oxford, OX3 7LG,
      UK.
FAU - Clarke, Mike
AU  - Clarke M
AD  - Evidence Aid, Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Carson, Gail
AU  - Carson G
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
      University of Oxford, New Richards Building, Old Road Campus, Oxford, OX3 7LG,
      UK.
LA  - eng
GR  - G0901530/MRC_/Medical Research Council/United Kingdom
GR  - 643434/Horizon 2020 Framework Programme/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200625
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
MH  - Betacoronavirus
MH  - *Biomedical Research
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - Delivery of Health Care/organization & administration
MH  - *Disease Outbreaks
MH  - Ebolavirus
MH  - *Epidemics
MH  - Global Health
MH  - Health Services Needs and Demand/*trends
MH  - Humans
MH  - Influenza A Virus, H1N1 Subtype
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
PMC - PMC7315698
OTO - NOTNLM
OT  - *Barriers
OT  - *Challenges
OT  - *Clinical research
OT  - *Emerging infectious diseases
OT  - *Epidemic
OT  - *Facilitators
OT  - *Pandemic
OT  - *Preparedness
OT  - *Solutions
EDAT- 2020/06/27 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/06/27 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
AID - 10.1186/s12916-020-01624-8 [doi]
AID - 10.1186/s12916-020-01624-8 [pii]
PST - epublish
SO  - BMC Med. 2020 Jun 25;18(1):190. doi: 10.1186/s12916-020-01624-8.


PMID- 34386243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210813
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Dec
TI  - Is the European Data Protection Regulation sufficient to deal with emerging data 
      concerns relating to neurotechnology?
PG  - lsaa051
LID - 10.1093/jlb/lsaa051 [doi]
AB  - Research-driven technology development in the fields of the neurosciences
      presents interesting and potentially complicated issues around data in general
      and brain data specifically. The data produced from brain recordings are unlike
      names and addresses in that it may result from the processing of largely
      involuntarily brain activity, it can be processed and reprocessed for different
      aims, and it is highly sensitive. Consenting for brain recordings of a specific
      type, or for a specific purpose, is complicated by these factors. Brain data
      collection, retention, processing, storage, and destruction are each of high
      ethical importance. This leads us to ask: Is the present European Data Protection
      Regulation sufficient to deal with emerging data concerns relating to
      neurotechnology? This is pressing especially in a context of rapid advancement in
      the fields of brain computer interfaces (BCIs), where devices that can function
      via recorded brain signals are expanding from research labs, through medical
      treatments, and beyond into consumer markets for recreational uses. One notion we
      develop herein is that there may be no trivial data collection when it comes to
      brain recording, especially where algorithmic processing is involved. This
      article provides analysis and discussion of some specific data protection
      questions related to neurotechnology, especially BCIs. In particular, whether and
      how brain data used in BCI-driven applications might count as personal data in a 
      way relevant to data protection regulations. It also investigates how the nature 
      of BCI data, as it appears in various applications, may require different
      interpretations of data protection concepts. Importantly, we consider brain
      recordings to raise questions about data sensitivity, regardless of the purpose
      for which they were recorded. This has data protection implications.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Rainey, Stephen
AU  - Rainey S
AUID- ORCID: https://orcid.org/0000-0002-5540-6046
AD  - University of Oxford, Oxford, UK.
FAU - McGillivray, Kevin
AU  - McGillivray K
AD  - University of Oslo, Oslo, Norway.
FAU - Akintoye, Simi
AU  - Akintoye S
AD  - De Montfort University, Leicester, UK.
FAU - Fothergill, Tyr
AU  - Fothergill T
AD  - De Montfort University, Leicester, UK.
FAU - Bublitz, Christoph
AU  - Bublitz C
AD  - University of Hamburg, Hamburg, Germany.
FAU - Stahl, Bernd
AU  - Stahl B
AD  - De Montfort University, Leicester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200627
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC8355473
OTO - NOTNLM
OT  - BCIs
OT  - GDPR
OT  - brain data
OT  - brain recording
OT  - data governance
OT  - neurotechnology
EDAT- 2020/06/27 00:00
MHDA- 2020/06/27 00:01
CRDT- 2021/08/13 07:09
PHST- 2020/01/22 00:00 [received]
PHST- 2020/03/26 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2021/08/13 07:09 [entrez]
PHST- 2020/06/27 00:00 [pubmed]
PHST- 2020/06/27 00:01 [medline]
AID - 10.1093/jlb/lsaa051 [doi]
AID - lsaa051 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Jun 27;7(1):lsaa051. doi: 10.1093/jlb/lsaa051. eCollection
      2020 Jan-Dec.


PMID- 32585711
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Ethical Considerations for Healthcare Organizations.
PG  - 266-278
LID - 10.1055/s-0040-1710323 [doi]
AB  - Ethical misbehavior in the delivery of healthcare creates harm not only to
      individual therapists and administrators who might choose to overstep ethical
      boundaries but also, more broadly, causes harm to patients, to healthcare
      organizations, to professional organizations, and ultimately to society. Both
      corporate codes of conduct and professional codes of ethics are important,
      because they set standards of conduct and penalize noncompliant or unethical
      conduct. The purposes of this article are (1) to differentiate corporate
      compliance from ethics in a healthcare organization; (2) to explain the
      application of ethics principles to organizational and professional behaviors;
      (3) to discuss three important ethical issues (cultural competence, conflict of
      interest, and employer demands); and (4) to emphasize that, whether applying a
      corporate code of conduct or a professional code of ethics (or both), the
      integrity of each individual is essential to ethical behavior. To illustrate
      these concepts, ASHA's Code of Ethics is discussed in detail (including the
      ethics complaint adjudication process), and hypothetical case studies are
      presented under the macro headings of Cultural Competence, Conflict of Interest, 
      and Employer Demands.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Rao, Paul R
AU  - Rao PR
AD  - Rehabilitation Consultant, Catonsville, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - American Speech-Language-Hearing Association
MH  - Codes of Ethics
MH  - Delivery of Health Care/*ethics
MH  - Health Facilities/*ethics
MH  - Humans
MH  - United States
COIS- None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1710323 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):266-278. doi: 10.1055/s-0040-1710323. Epub 2020
      Jun 25.


PMID- 32585710
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Ethical Issues in Dysphagia Management.
PG  - 257-265
LID - 10.1055/s-0040-1710561 [doi]
AB  - Dysphagia management is complex and requires balancing individuals' preferences, 
      quality of life, and medical consequences. Ethical challenges are not uncommon
      given the complexity of dysphagia. Professionals must engage in ethical
      reflection and shared decision-making when managing dysphagia. Recognizing one's 
      own presuppositions and beliefs may be fundamental to ensuring an ethical
      approach. The goal of this article is to apply principles of ethics using
      hypothetical case studies of dysphagia. To this end, we will describe the
      challenges of working with the disorder of dysphagia; the influence of culture on
      decision-making about eating and feeding; the importance of information
      disclosure and respect for individuals' refusal of recommendations; and the
      interplay of ethical reflection, evidence, and clinical judgment when making
      complex dysphagia management decisions. These concepts should be kept in mind to 
      ensure compassionate and competent care of the person with eating, drinking, or
      swallowing problems and their family caregivers.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Leslie, Paula
AU  - Leslie P
AUID- ORCID: 0000-0002-0379-9044
AD  - School of Sport and Health Sciences, University of Central Lancashire, Preston,
      United Kingdom.
FAU - Lisiecka, Dominika
AU  - Lisiecka D
AD  - Department of Nursing and Healthcare Sciences, Institute of Technology Tralee,
      Co. Kerry, Ireland.
AD  - School of Nursing and Midwifery, University College Cork, Cork, Ireland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Bioethical Issues
MH  - Deglutition Disorders/*therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
COIS- P.L. reports other from J&R Press, outside the submitted work, and serves as
      associate coordinator of ASHA Special Interest Group no. 15 (Gerontology).
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1710561 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):257-265. doi: 10.1055/s-0040-1710561. Epub 2020
      Jun 25.


PMID- 32585709
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Ethical and Practical Challenges of the Communication and Behavioral
      Manifestations of Primary Progressive Aphasia.
PG  - 249-256
LID - 10.1055/s-0040-1710062 [doi]
AB  - The communication and behavioral manifestations of primary progressive aphasia
      (PPA) present ethical and practical challenges for individuals with this clinical
      syndrome as well as for individuals who are involved closely in their care. In
      this article, cases representing all three PPA variants (logopenic variant,
      nonfluent agrammatic, semantic variant) are presented to illustrate commonly
      encountered situations in which self-determination is at risk in decisions about 
      housing, driving, social interactions, finances, and treatment interventions.
      Potential approaches, including patient/family education, implementation of
      safeguards, redirection to meaningful activities, and protections against
      vulnerability in treatment decisions, are described to preserve autonomy in
      patients with this neurodegenerative clinical syndrome.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Tippett, Donna C
AU  - Tippett DC
AD  - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
      Maryland.
AD  - Physical Medicine and Rehabilitation, Johns Hopkins University School of
      Medicine, Baltimore, Maryland.
AD  - Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of
      Medicine, Baltimore, Maryland.
FAU - Hillis, Argye E
AU  - Hillis AE
AD  - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
      Maryland.
AD  - Physical Medicine and Rehabilitation, Johns Hopkins University School of
      Medicine, Baltimore, Maryland.
AD  - Department of Cognitive Science, Krieger School of Arts and Sciences, Johns
      Hopkins University, Baltimore, Maryland.
LA  - eng
GR  - R01 DC011317/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - Aphasia, Primary Progressive/*complications/*therapy
MH  - *Bioethical Issues
MH  - Communication Disorders/*etiology
MH  - Humans
MH  - Mental Disorders/*etiology
MH  - Speech Therapy/*ethics
COIS- None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1710062 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):249-256. doi: 10.1055/s-0040-1710062. Epub 2020
      Jun 25.


PMID- 32585708
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Ethical Responsibilities to Adults with Communication Impairments Involved in
      Group Therapy.
PG  - 241-248
LID - 10.1055/s-0040-1710049 [doi]
AB  - Ethical challenges can arise when providing group therapy to adults living with
      communication impairments. In addition to the ethical challenges that may be
      encountered when conducting one-to-one therapy intervention, practitioners must
      also consider dilemmas that are specific to group therapy. This article considers
      the principles and rules of the American Speech-Language-Hearing Association
      (ASHA) Code of Ethics via a series of clinical vignettes that illustrate four
      ethical challenges that may be encountered when providing group therapy:
      acquiring sufficient clinical competency to conduct group therapy; handling
      issues related to client confidentiality; resisting external pressure to provide 
      groups solely for financial gain and/or other administrative efficiencies; and
      handling practitioner-client boundaries.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Elman, Roberta J
AU  - Elman RJ
AD  - Aphasia Center of California, Oakland, California.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - Adult
MH  - American Speech-Language-Hearing Association
MH  - *Bioethical Issues
MH  - Codes of Ethics
MH  - Communication Disorders/*therapy
MH  - Humans
MH  - Psychotherapy, Group/*ethics
MH  - United States
COIS- None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1710049 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):241-248. doi: 10.1055/s-0040-1710049. Epub 2020
      Jun 25.


PMID- 32585707
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Autonomy and the Patient with Right Hemisphere Cognitive-Communication Deficits: 
      Ethical Considerations in Rehabilitation Practice.
PG  - 232-240
LID - 10.1055/s-0040-1710324 [doi]
AB  - Clinicians must often contend with ethical issues that arise during
      rehabilitation. When a patient has right hemisphere damage (RHD), these concerns 
      may be exacerbated because of the presence of cognitive deficits. In this
      article, we focus on the ethical principle of respect for autonomy, which raises 
      issues relevant to patients with RHD who have impaired executive control
      functions. Respect for autonomy involves respecting others in terms of their
      decision-making and subsequent actions. Disagreements may occur between members
      of the rehabilitation team, the patient, and family about the decisions that the 
      patient makes. Clinicians may have concerns about the patient's capacity to make 
      informed decisions. Indeed, in some cases, because the patient is "talking," the 
      verbal skills may mask the impairments in underlying cognitive processes. We
      provide two case examples of patients with RHD with sufficient language skills to
      express their choices, but cognitive deficits that affect their decision-making
      abilities. We use a clinical decision-making model adapted from Jonsen et al to
      discuss the cases. In both cases, the rehabilitation team strives to balance what
      they deem to be in the best interest of the patient while continuing to respect
      the patient's autonomy.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Cherney, Leora R
AU  - Cherney LR
AD  - Think and SpeakLab, Shirley Ryan AbilityLab, Chicago, Illinois.
AD  - Department of Physical Medicine and Rehabilitation, Department of Communication
      Sciences and Disorders, Northwestern University, Chicago, Illinois.
FAU - Kinsey, Laura
AU  - Kinsey L
AD  - Think and SpeakLab, Shirley Ryan AbilityLab, Chicago, Illinois.
FAU - Larkin Conlon, Elissa
AU  - Larkin Conlon E
AD  - Think and SpeakLab, Shirley Ryan AbilityLab, Chicago, Illinois.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - Adult
MH  - *Bioethical Issues
MH  - Cerebrum
MH  - Cognition Disorders/*rehabilitation
MH  - Communication Disorders/*rehabilitation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Personal Autonomy
MH  - Rehabilitation/ethics
COIS- None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1710324 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):232-240. doi: 10.1055/s-0040-1710324. Epub 2020
      Jun 25.


PMID- 32585706
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Assumptions about Decision-Making Capacity and Aphasia: Ethical Implications and 
      Impact.
PG  - 221-231
LID - 10.1055/s-0040-1712115 [doi]
AB  - This article explores the issue of aphasia and decision-making within the context
      of clinical ethics and patient rights. The cases described illustrate the danger 
      of making assumptions about the inherent competence of people with aphasia and
      the life-altering consequences if no attempt is made to "accommodate" or support 
      communication when competence may be masked by aphasia. Speech-language
      pathologists have a moral obligation and a key role to play in providing
      communication support that may serve to reveal a person's intact capacity to make
      specific decisions, as well as in supporting the steps involved in the
      decision-making process. This role also extends to providing guidance, education,
      and training for others involved in evaluating the decision-making capacity of
      people with aphasia. Communication support strategies useful at each stage of the
      decision-making process are detailed.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Kagan, Aura
AU  - Kagan A
AD  - Applied Research and Education, Aphasia Institute, Ontario, Canada.
FAU - Shumway, Elyse
AU  - Shumway E
AD  - Education, Training and Resources, Aphasia Institute, Ontario, Canada.
FAU - MacDonald, Sheila
AU  - MacDonald S
AD  - Sheila MacDonald and Associates, Ontario, Canada.
AD  - School of Rehabilitation Science, McMaster University, Ontario, Canada.
AD  - Speech-Language Pathology, University of Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - *Aphasia/therapy
MH  - *Bioethical Issues
MH  - Clinical Decision-Making/*ethics
MH  - Humans
MH  - Speech-Language Pathology/*ethics
COIS- The acronym "SCA" is trademarked by the Aphasia Institute, in relation to
      "Supported Conversation for Adults with Aphasia." Aura Kagan is a paid employee
      of the Aphasia Institute.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1712115 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):221-231. doi: 10.1055/s-0040-1712115. Epub 2020
      Jun 25.


PMID- 32585705
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Moral Features of the Therapeutic Relationship with Adults: Dignity, Trust,
      Autonomy, Vulnerability, and Resilience.
PG  - 212-220
LID - 10.1055/s-0040-1709203 [doi]
AB  - Using dignity as a foundational value of morality, this article defines trust,
      autonomy, vulnerability, and resilience in relational terms. A fictional
      narrative illustrates these attributes as well as solidarity and care, two core
      tenets of relational ethics. Medicine and rehabilitation are described as moral
      enterprises with respect for persons at the core of our professional obligations 
      to patients-namely, duties of care, trustworthiness, and loyalty. Clinically,
      promoting autonomy, decreasing vulnerability, and fostering resilience are
      encouraged, with particular emphasis on avoiding words or actions (or inactions) 
      that could cause patients to feel discouraged or depersonalized. In conclusion,
      the purpose of our work with persons with aphasia and other communication
      disorders is to help them live their lives as fully as possible, despite their
      life-changing losses. Viewing our therapeutic relationships with them in
      relational moral terms can enhance our work.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Horner, Jennifer
AU  - Horner J
AD  - College of Health Sciences and Professions, Ohio University, Athens, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
EIN - Semin Speech Lang. 2020 Jun;41(3):218. PMID: 33075821
MH  - Adult
MH  - Communication Disorders/*therapy
MH  - Humans
MH  - Morals
MH  - Personal Autonomy
MH  - Professional-Patient Relations/*ethics
MH  - Resilience, Psychological
MH  - Respect
MH  - Trust
COIS- None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1709203 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):212-220. doi: 10.1055/s-0040-1709203. Epub 2020
      Jun 25.


PMID- 32585704
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1098-9056 (Electronic)
IS  - 0734-0478 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Jun
TI  - Moral and Ethical Considerations....
PG  - 209-211
LID - 10.1055/s-0040-1710325 [doi]
FAU - Kearns, Kevin P
AU  - Kearns KP
AD  - Communication Disorders and Sciences, SUNY Fredonia, Fredonia, New York.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Semin Speech Lang
JT  - Seminars in speech and language
JID - 8405117
SB  - IM
MH  - *Aphasia/therapy
MH  - *Bioethical Issues
MH  - Humans
MH  - *Morals
COIS- None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
AID - 10.1055/s-0040-1710325 [doi]
PST - ppublish
SO  - Semin Speech Lang. 2020 Jun;41(3):209-211. doi: 10.1055/s-0040-1710325. Epub 2020
      Jun 25.


PMID- 32585698
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20210626
IS  - 1527-974X (Electronic)
IS  - 1067-5027 (Linking)
VI  - 27
IP  - 12
DP  - 2020 Dec 9
TI  - Patient safety and quality improvement: Ethical principles for a regulatory
      approach to bias in healthcare machine learning.
PG  - 2024-2027
LID - 10.1093/jamia/ocaa085 [doi]
AB  - Accumulating evidence demonstrates the impact of bias that reflects social
      inequality on the performance of machine learning (ML) models in health care.
      Given their intended placement within healthcare decision making more broadly, ML
      tools require attention to adequately quantify the impact of bias and reduce its 
      potential to exacerbate inequalities. We suggest that taking a patient safety and
      quality improvement approach to bias can support the quantification of
      bias-related effects on ML. Drawing from the ethical principles underpinning
      these approaches, we argue that patient safety and quality improvement lenses
      support the quantification of relevant performance metrics, in order to minimize 
      harm while promoting accountability, justice, and transparency. We identify
      specific methods for operationalizing these principles with the goal of attending
      to bias to support better decision making in light of controllable and
      uncontrollable factors.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association. All rights reserved. For permissions,
      please email: journals.permissions@oup.com.
FAU - McCradden, Melissa D
AU  - McCradden MD
AD  - Bioethics Department, The Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Joshi, Shalmali
AU  - Joshi S
AD  - Vector Institute, Toronto, Ontario, Canada.
FAU - Anderson, James A
AU  - Anderson JA
AD  - Bioethics Department, The Hospital for Sick Children, Toronto, Ontario, Canada.
AD  - Institute for Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Joint Centre for Bioethics, University of Toronto, Toronto, Ontario, Canada.
FAU - Mazwi, Mjaye
AU  - Mazwi M
AD  - Department of Critical Care Medicine, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
FAU - Goldenberg, Anna
AU  - Goldenberg A
AD  - Vector Institute, Toronto, Ontario, Canada.
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Peter Gilgan Centre 
      for Research and Learning, Toronto, Ontario, Canada.
AD  - Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
AD  - CIFAR, Toronto, Ontario, Canada.
FAU - Zlotnik Shaul, Randi
AU  - Zlotnik Shaul R
AD  - Bioethics Department, The Hospital for Sick Children, Toronto, Ontario, Canada.
AD  - Department of Paediatrics, University of Toronto, Toronto, ON, Canada.
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan
      Centre for Research, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Med Inform Assoc
JT  - Journal of the American Medical Informatics Association : JAMIA
JID - 9430800
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Data Collection
MH  - Government Regulation
MH  - Healthcare Disparities
MH  - Humans
MH  - *Patient Safety
MH  - *Prejudice
MH  - *Quality Improvement
MH  - Social Determinants of Health
PMC - PMC7727331
OTO - NOTNLM
OT  - *healthcare delivery
OT  - *machine learning
OT  - *patient safety
OT  - *quality improvement
OT  - *systematic bias
EDAT- 2020/06/26 06:00
MHDA- 2021/04/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - 5862600 [pii]
AID - 10.1093/jamia/ocaa085 [doi]
PST - ppublish
SO  - J Am Med Inform Assoc. 2020 Dec 9;27(12):2024-2027. doi: 10.1093/jamia/ocaa085.


PMID- 32585665
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Compassionate Communication and End-of-Life Care for Critically Ill Patients with
      SARS-CoV-2 Infection.
PG  - 191-193
LID - 2020312191 [pii]
AB  - Public health strategies recommend isolating patients with SARS-CoV-2 infection. 
      But compassionate care in the intensive care unit (ICU) is an ethical obligation 
      of modern medicine that cannot be justified by the risk of infection or the lack 
      of personal protective equipment. This article describes the experiences of
      clinicians in ICUs in the south of Spain promoted by the Andalusian Society of
      Intensive Care SAMIUC, in the hope it will serve to improve the conditions in
      which these patients die, and to help their families who suffer when they cannot 
      say good-bye to their loved ones. In the south of Spain, healthcare professionals
      use daily videoconferencing to improve communication between clinicians,
      patients, and their relatives who cannot visit them in the ICU. This close
      communication allows families to see their loved ones and extends communication
      between healthcare professionals, patients, and their relatives. To allow family 
      members to accompany patients at the end of life, it is possible to adapt public 
      health rules to the epidemic situation.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Estella, Angel
AU  - Estella A
AD  - Intensivist in the Intensive Care Unit, University Hospital of Jerez and the
      Department of Medicine, University of Cadiz in Cadiz, Spain; National Coordinator
      of the Bioethics Working Group of the Spanish Society of Intensive Medicine
      (SEMICYUC) Spain. litoestella@hotmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communication
MH  - Coronavirus Infections/*therapy
MH  - *Critical Illness
MH  - Empathy
MH  - Family
MH  - Humans
MH  - Intensive Care Units/organization & administration
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/*therapy
MH  - SARS-CoV-2
MH  - Spain
MH  - Terminal Care/*ethics
EDAT- 2020/06/26 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 2020312191 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):191-193.


PMID- 32585664
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Ways of Being in Generalist Practice: Using Five "T" Habits of Mind to Guide
      Ethical Behavior.
PG  - 184-190
LID - 2020312184 [pii]
AB  - The practice of generalist medicine differs from the practice of other clinical
      disciplines. We postulate that the application of ethics in generalist practice
      similarly differs from its application in other healthcare settings. In contrast 
      to the problem-focused practice of ethics in other medical specialties, the
      practice of ethics in generalist medicine blends habits of mind with behaviors
      applied routinely over time-an ethical way of being. Using a graphic summary and 
      tabular matrix, we present five "T" habits of mind (time, talk, tact, touch, and 
      trust), associate them with applicable practice characteristics, and link them to
      observable clinician behaviors to demonstrate how the application of ethics in
      generalist practice is a day-to-day endeavor and not simply a means to resolve
      episodic conflicts. We textually review key aspects of the matrix and present two
      case studies that illustrate how such habits of mind and practice behaviors
      inform the ethical way of being we espouse. We invite generalist practitioners to
      incorporate the five "T" habits and associated behaviors into their daily care of
      patients, and we encourage clinical ethicists and other clinical faculty members 
      to consider using them as a model for ethics education with medical students and 
      resident physicians.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Ventres, William
AU  - Ventres W
AD  - Ben Saltzman, MD, Distinguished Chair in Rural Family Medicine, Department of
      Family and Preventive Medicine, University of Arkansas for Medical Sciences,
      Little Rock, Arkansas USA. wventres@uams.edu.
FAU - Tunzi, Marc
AU  - Tunzi M
AD  - Associate Director of the Family Medicine Residency Program, Natividad Medical
      Center; Family Medicine Specialist, Salinas, California USA.
      tunzim@natividad.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Ethicists
MH  - *Ethics, Medical
MH  - Habits
MH  - Humans
MH  - Morals
MH  - *Students, Medical
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312184 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):184-190.


PMID- 32585663
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Financial Decision-Making Capacity and Patient-Centered Discharge.
PG  - 178-183
LID - 2020312178 [pii]
AB  - An ethically sound discharge from the hospital can be impeded by a number of
      factors, including a lack of payor for a patient's care, a lack of appropriate
      discharge options, and a lack of authority to sign a patient into a long-term
      facility. In some cases, the primary barrier involves the patient's lack of
      financial decision-making capacity. When a patient's income comes primarily from 
      government assistance, financial decision making is connected to both the
      individual's well-being and to fair allocation of resources. Taking away another 
      person's financial independence is a substantial intrusion on autonomy and should
      not be considered lightly. However, poor management of funds can lead to
      homelessness, medical noncompliance, vulnerability to financial exploitation, and
      other threats to human flourishing. As with medical decision-making capacity,
      poor decisions alone do not invalidate an individual's right to
      self-determination. And as with medical decision-making capacity, such
      determinations should not be made ad hoc or be capricious, but should rely on
      sound assessment criteria. When there are justified concerns that a patient may
      be vulnerable due to limited financial decision-making capacity, an evaluation
      should be completed and a surrogate payee be sought, when appropriate.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Mendola, Annette
AU  - Mendola A
AD  - Director of Clinical Ethics and Assistant Professor, Department of Medicine,
      University of Tennessee Graduate School of Medicine, Knoxville, Tennessee USA.
      AMendola@utmck.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Clinical Decision-Making
MH  - *Decision Making
MH  - *Financing, Personal
MH  - Humans
MH  - *Mental Competency
MH  - *Patient Discharge
MH  - *Patient-Centered Care/economics
MH  - Personal Autonomy
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312178 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):178-183.


PMID- 32585662
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Answering the Call for Standardized Reporting of Clinical Ethics Consultation
      Data.
PG  - 173-177
LID - 2020312173 [pii]
AB  - Benchmarks against which healthcare ethics consultation (HCEC) services can
      assess their performance are needed. As first-generation benchmarks continue to
      be developed, it is the obligation of the field to continually evaluate how these
      measures reflect the performance of any single HCEC service. This will be
      possible only with widespread reporting of standardized data points. In their
      article in this issue of The Journal of Clinical Ethics, Glover and colleagues
      provide a valuable preliminary approach for assessing appropriate consult volumes
      for a HCEC service. The limitations of their study read as a call to action for
      the field of clinical ethics to expand and standardize data reporting so that
      more robust metrics can be developed. In response to this call by Glover and
      colleagues, the Cleveland Clinic HCEC service provides consult data from 2015
      through 2019 for one of its medical centers, and offers an additional
      volume-based metric, consult-to-ICU-to-bed ratio (CiBR), that may add nuance to
      any normative assessment of HCEC service consult volume. Given that volume-based 
      metrics are the native language of the clinical environment, efforts to improve
      such metrics in the field through transparency and standardization are warranted.
      However, the expositive power of volume- based metrics is limited; additional
      domains related to quality and outcomes are needed.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Feldman, Sharon L
AU  - Feldman SL
AD  - Bioethics Fellow, Cleveland Clinic Center for Bioethics, Cleveland, Ohio USA.
      feldmas@ccf.org.
FAU - Rias, Sundus H
AU  - Rias SH
AD  - Administrative Program Coordinator, Cleveland Clinic, Cleveland, Ohio USA.
      riazs2@ccf.org.
FAU - Crites, Joshua S
AU  - Crites JS
AD  - Co-Director, Cleveland Fellowship in Advanced Bioethics; Staff, Center for
      Bioethics; Regional Ethicist (West), Cleveland Clinic, Cleveland, Ohio USA.
      critesj@ccf.org.
FAU - Jankowski, Jane
AU  - Jankowski J
AD  - Interim Director, Center for Bioethics, Cleveland Clinic, Cleveland, Ohio USA.
      jankow@ccf.org.
FAU - Ford, Paul J
AU  - Ford PJ
AD  - Staff, Center for Bioethics and Department of Neurology; Associate Professor,
      Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio USA. Fordp@ccf.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Delivery of Health Care
MH  - *Ethics Consultation/standards
MH  - Ethics, Clinical
MH  - Humans
MH  - Research Design
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312173 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):173-177.


PMID- 32585661
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - How Much Volume Should Healthcare Ethics Consult Services Have?
PG  - 158-172
LID - 2020312158 [pii]
AB  - BACKGROUND: No standard method exists to assess how many consults a healthcare
      ethics consultation (HCEC) service should perform. To address this, we developed 
      a method to estimate the volume of HCEC services based on a mixed-methods
      approach that included a systematic review and survey data on the volume of
      consult services requested. METHODS: Our investigation included a systematic
      review of studies that reported the volume of HCEC services that were requested
      from 2000 to 2017, institutional surveys, and statistical analyses that estimated
      the volume of HCEC services that were adjusted to the size of the hospitals in
      the survey and to population acuity. RESULTS: We contacted the authors of 19
      studies that met our inclusion criteria; 17 authors responded to the
      institutional survey and five provided annualized data points. We found that
      standard methods of reporting the volume of HCEC services led to inaccuracies in 
      estimating the growth of HCEC services over time. To rectify this, we proposed
      two means to estimate volume based on either the service goals of HCEC services
      or hospital size and acuity. DISCUSSION: The statistical limitations of our study
      highlight the need to standardize the sharing and reporting of data in clinical
      ethics. Future work should further standardize methods of HCEC quality assessment
      using measures similar to those we describe.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Glover, Avery C
AU  - Glover AC
AD  - MD/MBA Candidate 2023, Tufts University School of Medicine, Boston,
      Massachusetts; and Heller School for Social Policy and Management, Brandeis
      University, in Waltham, Massachusetts USA. avery.glover@tufts.edu.
FAU - Cunningham, Thomas V
AU  - Cunningham TV
AD  - Director of Bioethics, Kaiser Permanente Southern California Bioethics Program;
      Faculty Member, Loyola Marymount University Bioethics Institute, Los Angeles,
      California USA. thomas.v.cunningham@kp.org.
FAU - Sterling, Evelina W
AU  - Sterling EW
AD  - Assistant Professor, Department of Sociology and Criminal Justice, Kennesaw State
      University, Kennesaw, Georgia USA. esterlin @kennesaw.edu.
FAU - Lesandrini, Jason
AU  - Lesandrini J
AD  - Assistant Vice President Ethics, Advance Care Planning and Spiritual Health,
      WellStar Health System, Atlanta, Georgia USA. jason.lesandrini@wellstar.org.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Bioethics
MH  - Delivery of Health Care
MH  - *Ethics Consultation
MH  - Hospitals
MH  - Humans
MH  - Quality Assurance, Health Care
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312158 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):158-172.


PMID- 32585660
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Considering Uterus Transplantation for a Same-Sex Couple: A Case Study.
PG  - 154-157
LID - 2020312154 [pii]
AB  - A woman with congenital absence of a uterus applied for participation in a
      clinical trial for uterus transplantation. She was married to a woman who had the
      potential to carry a child without the need for aggressive medical intervention. 
      Thus, the question arose regarding whether the infertile partner should be
      considered for uterus transplantation. In this article we discuss the ethical
      issues with uterus transplantation for a member of a same-sex couple, whose
      partner could carry a pregnancy. We review the medical criteria for uterus
      transplantation, discuss the additional options for parenthood in same-sex
      couples, examine how to determine if this meets the criteria of just distribution
      of uterus grafts, and ultimately argue that the value of gestation is at the
      level of the individual rather than the couple.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Testa, Giuliano
AU  - Testa G
AD  - Abdominal Transplant Surgeon and Division Chief, Annette C. and Harold C. Simmons
      Transplant Institute, Baylor University Medical Center, Dallas, Texas USA.
FAU - Johannesson, Liza
AU  - Johannesson L
AD  - Ob-Gyn and Medical Director, uterus transplant program, Annette C. and Harold C. 
      Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas
      USA.
FAU - Wall, Anji E
AU  - Wall AE
AD  - Abdominal Transplant Surgeon, Annette C. and Harold C. Simmons Transplant
      Institute, Baylor University Medical Center, Dallas, Texas, USA.
      anji.wall@bswhealth.org.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Child
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - *Organ Transplantation/ethics
MH  - Pregnancy
MH  - Sexual and Gender Minorities
MH  - *Uterus/transplantation
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312154 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):154-157.


PMID- 32585659
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Conscientious Objection in Healthcare: Neither a Negative Nor a Positive Right.
PG  - 146-153
LID - 2020312146 [pii]
AB  - Conscientious objection in healthcare is often granted by many legislations
      regulating morally controversial medical procedures, such as abortion or medical 
      assistance in dying. However, there is virtually no protection of positive claims
      of conscience, that is, of requests by healthcare professionals to provide
      certain services that they conscientiously believe ought to be provided, but that
      are ruled out by institutional policies. Positive claims of conscience have
      received comparatively little attention in academic debates. Some think that
      negative and positive claims of conscience deserve equal protection in terms of
      measures that institutions ought to take to accommodate them. However, in this
      issue of The Journal of Clinical Ethics (JCE), Abram Brummett argues against this
      symmetry thesis.1 He suggests that the relevant distinction is not between
      negative and positive claims of conscience, but between negative and positive
      rights of conscience. He argues that conscientious refusals and positive claims
      of conscience are both already protected as negative rights of conscience, but
      that this does not require institutions to accommodate positive claims of
      conscience. In this article I will argue that both Brummett and the authors he
      criticizes share a wrong view about the existence of conscience rights in
      healthcare. I will argue that there is no right to conscientious objection in
      healthcare, whether positive or negative. Thus, contra Brummett, I argue that the
      question whether such rights are positive or negative is as irrelevant as the
      question whether the claims of conscience are positive or negative.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Giubilini, Alberto
AU  - Giubilini A
AD  - Senior Research Fellow, Oxford Uehiro Centre for Practical Ethics and the
      Wellcome Centre for Ethics and Humanities, University of Oxford, UK.
      alberto.giubilini@philosophy.ox.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Abortion, Induced
MH  - *Conscience
MH  - Delivery of Health Care
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - *Refusal to Treat/ethics/legislation & jurisprudence
MH  - Suicide, Assisted/ethics
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312146 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):146-153.


PMID- 32585658
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Positive or Negative? Consistency and Inconsistency in Claims of Conscience.
PG  - 143-145
LID - 2020312143 [pii]
AB  - The debate about positive and negative claims of conscience is, in large part,
      about ethical consistency. In this commentary I argue that there can be
      differences between conscientious provision of treatment and conscientious
      nonprovision of treatment that are ethically relevant. However, in many cases,
      including those described in this commentary, there is not sufficient ethical
      reason to treat them differently. This means that asymmetrical conscientious
      objection policies are potentially unjustified.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Wilkinson, Dominic Jc
AU  - Wilkinson DJ
AD  - Professor of Medical Ethics, Oxford Uehiro Centre for Practical Ethics and
      Faculty of Philosophy, University of Oxford, and Consultant in Newborn Intensive 
      Care, John Radcliffe Hospital, Oxford UK; Honorary Research Associate at Murdoch 
      Children's Research Institute, Melbourne, Australia.
      dominic.wilkinson@philosophy.ox.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Conscience
MH  - Humans
MH  - Morals
MH  - *Refusal to Treat
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312143 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):143-145.


PMID- 32585657
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20200707
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Fall
TI  - Should Positive Claims of Conscience Receive the Same Protection as Negative
      Claims of Conscience? Clarifying the Asymmetry Debate.
PG  - 136-142
LID - 2020312136 [pii]
AB  - In the debate over clinicians' conscience, there is a greater ethical, legal, and
      scholarly focus on negative, rather than positive, claims of conscience. This
      asymmetry produces a seemingly unjustified double standard with respect to
      clinicians' conscience under the law. For example, a Roman Catholic physician
      working at a secular institution may refuse to provide physician-aid-in-dying on 
      the basis of conscience, but a secular physician working at a Roman Catholic
      institution may not insist on providing physician-aid-in-dying on the basis of
      conscience. This article outlines arguments against this asymmetry and critiques 
      them for failing to distinguish between positive claims of conscience as positive
      or negative rights. I suggest the asymmetry debate should be focused on whether
      positive claims of conscience as positive rights ought to enjoy the same
      protections as negative claims of conscience. Clarifying the debate in this way
      helps elucidate some of the best reasons for the asymmetry, which these arguments
      have not addressed. This article does not take a definitive position on whether
      the asymmetry is justified, but attempts to bring some focus to the debate by
      directing arguments against the asymmetry to address the significant differences 
      between positive claims of conscience as positive rights and negative claims of
      conscience.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Brummett, Abram L
AU  - Brummett AL
AD  - Assistant Professor, Department of Foundational Medical Studies, Oakland
      University William Beaumont School of Medicine, Rochester, Michigan USA.
      a.brummett@oakland.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Conscience
MH  - *Dissent and Disputes
MH  - Humans
MH  - *Physicians
MH  - Refusal to Treat
EDAT- 2020/06/26 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 2020312136 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(2):136-142.


PMID- 32585655
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Abusive Head Trauma and Parental Participation in Pediatric Decision Making.
PG  - 121-125
LID - 202031121 [pii]
AB  - Decision making for children who suffer abusive head trauma invokes multiple
      ethical considerations. The degree to which parents are permitted to participate 
      in decision making after the injury has occurred is controversial. In particular,
      in this issue of The Journal of Clinical Ethics, Grigorian and colleagues raise
      concerns about the potential for conflict of interest in end-of-life decision
      making if the parents are facing criminal charges that could be escalated if the 
      child dies. There are additional concerns about the parents' capacity to make
      decisions that are best for the child, given that the injury occurred. We argue
      that there are important reasons not to exclude parents from the decision-making 
      process and that, with appropriate safeguards in place, parents are integral to
      determining what is best for the child.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Paquette, Erin Talati
AU  - Paquette ET
AD  - Assistant Professor of Pediatrics, Division Critical Care Medicine, Department of
      Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern 
      University Feinberg School of Medicine, Chicago, Illinois USA.
      Erin.talati@northwestern.edu.
FAU - Ross, Lainie Friedman
AU  - Ross LF
AD  - Carolyn and Matthew Bucksbaum Professor of Clinical Ethics; Professor,
      Departments of Pediatrics, Medicine, and Surgery; Co-Director of the Institute
      for Translational Medicine and Associate Director of the MacLean Center for
      Clinical Medical Ethics, University of Chicago, Chicago, Illinois USA.
      Lross@uchicago.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Child
MH  - *Child Abuse
MH  - *Craniocerebral Trauma
MH  - *Decision Making/ethics
MH  - Humans
MH  - *Parents
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312121 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):121-125.


PMID- 32585654
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Summer
TI  - Non-Accidental Trauma Associated with Withdrawal of Life-Sustaining Medical
      Treatment in Severe Pediatric Traumatic Brain Injury.
PG  - 111-125
LID - 2020312111 [pii]
AB  - INTRODUCTION: In highly developed countries, as many as 16 percent of children
      are physically abused each year. Traumatic brain injury (TBI) is the most common 
      injury in non-accidental trauma (NAT) and is responsible for 80 percent of fatal 
      NAT cases, with most deaths occurring in children younger than three years old.
      Cases of abusers who refuse withdrawal of life-sustaining medical treatment
      (LSMT) to avoid criminal charges have previously been reported. Therefore, we
      hypothesized that NAT is associated with a lower risk for withdrawal LSMT in
      pediatric TBI. METHODS: The pediatric Trauma Quality Improvement Program database
      was analyzed (2014 to 2016) for patients aged 16 and younger with TBI and Glasgow
      Coma Scale (GCS) of 8 and lower on admission. Patients with a head Abbreviated
      Injury Scale (AIS) of 2 or less or who died within 48 hours were excluded. A
      multivariable logistic regression model was used for analysis. RESULTS: Of 2,209 
      TBI patients, 92 (4.2 percent) had withdrawal of LSMT. Compared to those without 
      withdrawal of LMST, those with LMST had statistically similar median age (three
      years of age versus seven years) and a higher rate of NAT (33.7 percent versus
      13.5 percent). The most common specified perpetrator was a father/stepfather/male
      partner (70 percent). After adjusting for covariates, factors associated with
      higher risk for withdrawal of LSMT included age of less than three years (OR
      2.38, CI 1.34-4.23) and NAT (OR 1.86, CI 1.02-3.41). CONCLUSION: NAT is
      associated with increased risk for withdrawal of LSMT in pediatric TBI. Age of
      less than three years is similarly associated with a higher risk for withdrawal
      of LSMT. Future research in this population is needed to determine what other
      factors predict withdrawal of LSMT and what resources, such as social workers
      and/or ethics consults, are utilized.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Grigorian, Areg
AU  - Grigorian A
AD  - Resident Surgeon, University of California, Irvine, Department of Surgery,
      Division of Trauma, Burns, and Surgical Critical Care, Orange, California USA.
      agrigori@hs.uci.edu.
FAU - de Virgilio, Christian
AU  - de Virgilio C
AD  - Professor of Surgery, University of California, Harbor-Los Angeles, Department of
      Surgery, Los Angeles, California USA.
FAU - Lekawa, Michael
AU  - Lekawa M
AD  - Professor of Surgery, University of California, Irvine, Department of Surgery,
      Division of Trauma, Burns, and Surgical Critical Care, Orange, California USA.
FAU - Ramakrisnan, Divya
AU  - Ramakrisnan D
AD  - Medical Student, University of California, Irvine, Department of Surgery,
      Division of Trauma, Burns, and Surgical Critical Care, Orange, California USA.
FAU - Barros, Rebecca
AU  - Barros R
AD  - Pediatrician, Children's Hospital of Orange County, CHOC Medical Group, Orange,
      California USA.
FAU - Kuncir, Eric
AU  - Kuncir E
AD  - Professor of Surgery, University of California, Irvine, Department of Surgery,
      Division of Trauma, Burns, and Surgical Critical Care, Orange, California USA.
FAU - Nahmias, Jeffry
AU  - Nahmias J
AD  - Associate Professor of Surgery, University of California, Irvine, Department of
      Surgery, Division of Trauma, Burns, and Surgical Critical Care, Orange,
      California USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Adolescent
MH  - *Brain Injuries
MH  - *Brain Injuries, Traumatic
MH  - Child
MH  - Child, Preschool
MH  - Glasgow Coma Scale
MH  - Humans
MH  - *Life Support Care/ethics
MH  - Male
MH  - Retrospective Studies
MH  - *Withholding Treatment/ethics
EDAT- 2020/06/26 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 2020312111 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Summer;31(2):111-125.


PMID- 32584901
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 6
DP  - 2020
TI  - An experimentally induced osteoarthritis model in horses performed on both
      metacarpophalangeal and metatarsophalangeal joints: Technical, clinical, imaging,
      biochemical, macroscopic and microscopic characterization.
PG  - e0235251
LID - 10.1371/journal.pone.0235251 [doi]
AB  - Osteoarthritis is a common cause of pain and economic loss in both humans and
      horses. The horse is recognized as a suitable model for human osteoarthritis,
      because the thickness, structure, and mechanical properties of equine articular
      cartilage are highly comparable to those of humans. Although a number of equine
      experimental osteoarthritis models have been described in the literature, these
      cases generally involve the induction of osteoarthritis in just one joint of each
      animal. This approach necessitates the involvement of large numbers of horses to 
      obtain reliable data and thus limits the use of this animal model, for both
      economic and ethical reasons. This study adapts an established equine model of
      post-traumatic osteoarthritis to induce osteoarthritis-associated lesions in all 
      4 fetlock joints of the same horse in order to reduce the number of animals
      involved and avoid individual variability, thus obtaining a more reliable method 
      to evaluate treatment efficacy in future studies. The objectives are to assess
      the feasibility of the procedure, evaluate variability of the lesions according
      to interindividual and operated-limb position and describe the spontaneous
      evolution of osteoarthritis-associated pathological changes over a twelve-week
      period. The procedure was well tolerated by all 8 experimental horses and
      successfully induced mild osteoarthritis-associated changes in the four fetlock
      joints of each horse. Observations were carried out using clinical, radiographic,
      ultrasonographic, and magnetic resonance imaging methods as well as biochemical
      analyses of synovial fluid and postmortem microscopic and macroscopic evaluations
      of the joints. No significant differences were found in the progression of
      osteoarthritis-associated changes between horses or between the different limbs, 
      with the exception of higher synovial effusion in hind fetlocks compared to front
      fetlocks and higher radiographic scores for left fetlocks compared to the right. 
      This model thus appears to be a reliable means to evaluate the efficacy of new
      treatments in horses, and may be of interest for translational studies in human
      medicine.
FAU - Bertoni, Lelia
AU  - Bertoni L
AUID- ORCID: 0000-0001-6367-3040
AD  - CIRALE, USC 957, BPLC, INRA, Ecole Nationale Veterinaire d'Alfort,
      Maisons-Alfort, France.
FAU - Jacquet-Guibon, Sandrine
AU  - Jacquet-Guibon S
AD  - CIRALE, USC 957, BPLC, INRA, Ecole Nationale Veterinaire d'Alfort,
      Maisons-Alfort, France.
FAU - Branly, Thomas
AU  - Branly T
AD  - NORMANDIE UNIV, UNICAEN, BIOTARGEN, Caen, France.
FAU - Legendre, Florence
AU  - Legendre F
AD  - NORMANDIE UNIV, UNICAEN, BIOTARGEN, Caen, France.
FAU - Desance, Melanie
AU  - Desance M
AD  - NORMANDIE UNIV, UNICAEN, BIOTARGEN, Caen, France.
FAU - Mespoulhes, Celine
AU  - Mespoulhes C
AD  - Clinique Equine, Ecole Nationale Veterinaire d'Alfort, UPEC, Maisons-Alfort,
      France.
FAU - Melin, Martine
AU  - Melin M
AD  - NOVOTEC, ZAC du Chene, Europarc, Bron, France.
FAU - Hartmann, Daniel-Jean
AU  - Hartmann DJ
AD  - NOVOTEC, ZAC du Chene, Europarc, Bron, France.
FAU - Schmutz, Amandine
AU  - Schmutz A
AD  - CWD-VetLab, USC 957, BPLC, INRA, Ecole Nationale Veterinaire d'Alfort,
      Maisons-Alfort, France.
FAU - Denoix, Jean-Marie
AU  - Denoix JM
AD  - CIRALE, USC 957, BPLC, INRA, Ecole Nationale Veterinaire d'Alfort,
      Maisons-Alfort, France.
FAU - Galera, Philippe
AU  - Galera P
AD  - NORMANDIE UNIV, UNICAEN, BIOTARGEN, Caen, France.
FAU - Demoor, Magali
AU  - Demoor M
AD  - NORMANDIE UNIV, UNICAEN, BIOTARGEN, Caen, France.
FAU - Audigie, Fabrice
AU  - Audigie F
AD  - CIRALE, USC 957, BPLC, INRA, Ecole Nationale Veterinaire d'Alfort,
      Maisons-Alfort, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200625
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Horses
MH  - Magnetic Resonance Imaging
MH  - Metatarsal Bones/pathology
MH  - Metatarsophalangeal Joint/diagnostic imaging/*pathology/surgery
MH  - Osteoarthritis/diagnostic imaging/metabolism/*pathology
MH  - Severity of Illness Index
MH  - Synovial Fluid/chemistry
PMC - PMC7316256
COIS- The company NOVOTEC, specialized in tissue analysis services, was involved in the
      microscopic evaluation of the osteochondral sections. Two of their specialists
      (DJH and MM) were involved in the microscopic evaluation of the osteochondral
      sections. This does not alter our adherence to PLOS ONE policies on sharing data 
      and materials.
EDAT- 2020/06/26 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/06/26 06:00
PHST- 2019/04/02 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1371/journal.pone.0235251 [doi]
AID - PONE-D-19-09335 [pii]
PST - epublish
SO  - PLoS One. 2020 Jun 25;15(6):e0235251. doi: 10.1371/journal.pone.0235251.
      eCollection 2020.


PMID- 32584447
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20201218
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Penn Medicine Head and Neck Cancer Service Line COVID-19 management guidelines.
PG  - 1507-1515
LID - 10.1002/hed.26318 [doi]
AB  - INTRODUCTION: The COVID-19 pandemic caused by the severe acute respiratory
      syndrome coronavirus-2 (SARS-CoV-2) virus has altered the health care environment
      for the management of head and neck cancers. The purpose of these guidelines is
      to provide direction during the pandemic for rational Head and Neck Cancer
      management in order to achieve a medically and ethically appropriate balance of
      risks and benefits. METHODS: Creation of consensus document. RESULTS: The process
      yielded a consensus statement among a wide range of practitioners involved in the
      management of patients with head and neck cancer in a multihospital tertiary care
      health system. CONCLUSIONS: These guidelines support an ethical approach for the 
      management of head and neck cancers during the COVID-19 epidemic consistent with 
      both the local standard of care as well as the head and neck oncological
      literature.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Weinstein, Gregory S
AU  - Weinstein GS
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Cohen, Roger
AU  - Cohen R
AD  - Division of Medical Oncology, Department of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Lin, Alexander
AU  - Lin A
AD  - Department of Radiation Oncology, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
FAU - O'Malley, Bert W Jr
AU  - O'Malley BW Jr
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Lukens, John
AU  - Lukens J
AD  - Department of Radiation Oncology, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
FAU - Swisher-McClure, Samuel
AU  - Swisher-McClure S
AD  - Department of Radiation Oncology, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
FAU - Shanti, Rabie M
AU  - Shanti RM
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - Department of Oral and Maxillofacial Surgery, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Newman, Jason G
AU  - Newman JG
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Parhar, Harman S
AU  - Parhar HS
AUID- ORCID: https://orcid.org/0000-0001-7975-8452
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Tasche, Kendall
AU  - Tasche K
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Brody, Robert M
AU  - Brody RM
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Chalian, Ara
AU  - Chalian A
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Cannady, Steven
AU  - Cannady S
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Palmer, James N
AU  - Palmer JN
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Adappa, Nithin D
AU  - Adappa ND
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Kohanski, Michael A
AU  - Kohanski MA
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Bauml, Joshua
AU  - Bauml J
AD  - Division of Medical Oncology, Department of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Aggarwal, Charu
AU  - Aggarwal C
AD  - Division of Medical Oncology, Department of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Montone, Kathleen
AU  - Montone K
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Livolsi, Virginia
AU  - Livolsi V
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Baloch, Zubair W
AU  - Baloch ZW
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Jalaly, Jalal B
AU  - Jalaly JB
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Cooper, Kumarasen
AU  - Cooper K
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Rajasekaran, Karthik
AU  - Rajasekaran K
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Loevner, Laurie
AU  - Loevner L
FAU - Rassekh, Christopher
AU  - Rassekh C
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
SB  - IM
MH  - Ambulatory Care/standards
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Combined Modality Therapy
MH  - Continuity of Patient Care/standards
MH  - Coronavirus Infections/diagnosis/*prevention & control
MH  - Head and Neck Neoplasms/diagnosis/*therapy
MH  - Humans
MH  - Infection Control/*standards
MH  - Medical Oncology/*standards
MH  - Multi-Institutional Systems
MH  - Otorhinolaryngologic Surgical Procedures/standards
MH  - Palliative Care/standards
MH  - Pandemics/*prevention & control
MH  - Patient Safety
MH  - Pennsylvania
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/diagnosis/*prevention & control
MH  - SARS-CoV-2
MH  - Terminal Care/standards
MH  - Tertiary Care Centers
PMC - PMC7362039
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - coronavirus
OT  - head and neck cancer
EDAT- 2020/06/26 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - 10.1002/hed.26318 [doi]
PST - ppublish
SO  - Head Neck. 2020 Jul;42(7):1507-1515. doi: 10.1002/hed.26318. Epub 2020 Jun 25.


PMID- 32584321
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20220415
IS  - 0034-8376 (Print)
IS  - 0034-8376 (Linking)
VI  - 72
IP  - 3
DP  - 2020
TI  - CLINICAL DECISION MAKING IN OLDER ADULTS WITH COVID-19 IN DEVELOPING COUNTRIES:
      LOOKING BEYOND CHRONOLOGICAL AGE.
PG  - 127-134
LID - 10.24875/RIC.20000131 [doi]
AB  - BACKGROUND: The coronavirus disease 2019 (COVID-19) has been declared a global
      pandemic. Older adults have been found as a vulnerable group for developing
      severe forms of disease and increased mortality. OBJECTIVE: The objective of the 
      study was to propose a pathway to assist the decision-making process for hospital
      resource allocation for older adults with COVID-19 using simple geriatric
      assessment-based tools. METHODS: We reviewed the available literature at this
      point of the COVID-19 outbreak, focusing in older adult care to extract key
      recommendations for those health-care professionals who will be treating older
      adults in the hospital emergency ward (HEW) in developing countries during the
      COVID-19 pandemic. RESULTS: We listed a series of easy recommendations for
      non-geriatrician doctors in the HEW and suggested simple tools for hospital
      resource allocation during critical care evaluation of older adults with COVID-19
      in low- and middle-income countries. CONCLUSIONS: Age must not be used as the
      sole criterion for resource allocation among older adults with COVID-19. Simple
      and efficient tools are available to identify components of the comprehensive
      geriatric assessment, which could be useful to predict outcomes and provide
      high-quality care that would fit the particular needs of older adults in
      resource-limited settings amidst this global pandemic.
CI  - Copyright: (c) 2020 Permanyer.
FAU - Gomez-Moreno, Carolina
AU  - Gomez-Moreno C
AD  - Department of Emergency and Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran, Mexico City, Mexico.
FAU - Hernandez-Ruiz, Virgilio
AU  - Hernandez-Ruiz V
AD  - Department of Geriatrics, Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran, Mexico City, Mexico.
FAU - Hernandez-Gilsoul, Thierry
AU  - Hernandez-Gilsoul T
AD  - Department of Emergency and Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran, Mexico City, Mexico.
FAU - Avila-Funes, Jose A
AU  - Avila-Funes JA
AD  - Department of Geriatrics, Instituto Nacional de Ciencias Medicas y Nutricion
      Salvador Zubiran, Mexico City, Mexico.
AD  - Department of Centre de Recherche INSERM, Bordeaux, France.
LA  - eng
PT  - Journal Article
PL  - Mexico
TA  - Rev Invest Clin
JT  - Revista de investigacion clinica; organo del Hospital de Enfermedades de la
      Nutricion
JID - 9421552
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Clinical Decision-Making
MH  - *Coronavirus Infections/economics/epidemiology
MH  - *Developing Countries/economics
MH  - *Emergency Service, Hospital/economics
MH  - Female
MH  - Frail Elderly
MH  - Geriatric Assessment/methods
MH  - Humans
MH  - Male
MH  - *Pandemics/economics
MH  - Patient Preference
MH  - *Pneumonia, Viral/economics/epidemiology
MH  - Prognosis
MH  - Resource Allocation/ethics/*standards
MH  - SARS-CoV-2
MH  - Triage
MH  - Vulnerable Populations
OTO - NOTNLM
OT  - COVID-19
OT  - Emergency care
OT  - Ethics
OT  - Frailty
OT  - Resource-allocation
EDAT- 2020/06/26 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
AID - j72/3/127 [pii]
AID - 10.24875/RIC.20000131 [doi]
PST - ppublish
SO  - Rev Invest Clin. 2020;72(3):127-134. doi: 10.24875/RIC.20000131.


PMID- 32584103
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20201218
IS  - 1942-969X (Electronic)
IS  - 1942-969X (Linking)
VI  - 12
IP  - 5
DP  - 2020 Jul
TI  - A culturally-competent approach to emergency management: What lessons can we
      learn from the COVID-19?
PG  - 470-473
LID - 10.1037/tra0000790 [doi]
AB  - The COVID-19 pandemic, like other disasters, is exposing and exacerbating social,
      economic, and health care inequalities. Although the ethical and clinical
      imperative of providing culturally-competent health care has long been
      recognized, the influence of culturally-competent interventions within emergency 
      management has not been systematically examined. This paper discusses several
      culturally-competent strategies that were taken by the Israeli national and local
      authorities in high-risk areas and communities during the COVID-19 outbreak. In
      addition to controlling the pandemic outbreak, such an approach has the potential
      to reduce social disparities in health care, promote community resilience, and
      facilitate social cohesion. (PsycInfo Database Record (c) 2020 APA, all rights
      reserved).
FAU - Slobodin, Ortal
AU  - Slobodin O
AUID- ORCID: 0000-0002-1371-5254
AD  - Department of Education.
FAU - Cohen, Odeya
AU  - Cohen O
AUID- ORCID: 0000-0002-2427-6381
AD  - Nursing Department.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - United States
TA  - Psychol Trauma
JT  - Psychological trauma : theory, research, practice and policy
JID - 101495376
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - *Coronavirus Infections/prevention & control
MH  - *Culturally Competent Care
MH  - *Emergencies
MH  - *Health Status Disparities
MH  - Humans
MH  - *Infection Control
MH  - Israel/ethnology
MH  - *Minority Groups
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/prevention & control
MH  - *Religion
MH  - *Social Class
EDAT- 2020/06/26 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - 2020-43910-001 [pii]
AID - 10.1037/tra0000790 [doi]
PST - ppublish
SO  - Psychol Trauma. 2020 Jul;12(5):470-473. doi: 10.1037/tra0000790. Epub 2020 Jun
      25.


PMID- 32583762
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210802
IS  - 1741-203X (Electronic)
IS  - 1041-6102 (Linking)
VI  - 32
IP  - 8
DP  - 2020 Aug
TI  - Beyond artificial intelligence: exploring artificial wisdom.
PG  - 993-1001
LID - 10.1017/S1041610220000927 [doi]
AB  - BACKGROUND: The ultimate goal of artificial intelligence (AI) is to develop
      technologies that are best able to serve humanity. This will require advancements
      that go beyond the basic components of general intelligence. The term
      "intelligence" does not best represent the technological needs of advancing
      society, because it is "wisdom", rather than intelligence, that is associated
      with greater well-being, happiness, health, and perhaps even longevity of the
      individual and the society. Thus, the future need in technology is for artificial
      wisdom (AW). METHODS: We examine the constructs of human intelligence and human
      wisdom in terms of their basic components, neurobiology, and relationship to
      aging, based on published empirical literature. We review the development of AI
      as inspired and driven by the model of human intelligence, and consider possible 
      governing principles for AW that would enable humans to develop computers which
      can operationally utilize wise principles and result in wise acts. We review
      relevant examples of current efforts to develop such wise technologies. RESULTS: 
      AW systems will be based on developmental models of the neurobiology of human
      wisdom. These AW systems need to be able to a) learn from experience and
      self-correct; b) exhibit compassionate, unbiased, and ethical behaviors; and c)
      discern human emotions and help the human users to regulate their emotions and
      make wise decisions. CONCLUSIONS: A close collaboration among computer
      scientists, neuroscientists, mental health experts, and ethicists is necessary
      for developing AW technologies, which will emulate the qualities of wise humans
      and thus serve the greatest benefit to humanity. Just as human intelligence and
      AI have helped further the understanding and usefulness of each other, human
      wisdom and AW can aid in promoting each other's growth.
FAU - Jeste, Dilip V
AU  - Jeste DV
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA, USA.
AD  - Department of Neurosciences, University of California San Diego, La Jolla, CA,
      USA.
FAU - Graham, Sarah A
AU  - Graham SA
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA, USA.
FAU - Nguyen, Tanya T
AU  - Nguyen TT
AUID- ORCID: 0000-0002-9510-9564
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA, USA.
FAU - Depp, Colin A
AU  - Depp CA
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA, USA.
AD  - VA San Diego Healthcare System, San Diego, CA, USA.
FAU - Lee, Ellen E
AU  - Lee EE
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
AD  - Sam and Rose Stein Institute for Research on Aging, University of California San 
      Diego, La Jolla, CA, USA.
AD  - VA San Diego Healthcare System, San Diego, CA, USA.
FAU - Kim, Ho-Cheol
AU  - Kim HC
AD  - AI and Cognitive Software, IBM Research-Almaden, San Jose, CA, USA.
LA  - eng
GR  - K23 MH118435/MH/NIMH NIH HHS/United States
GR  - K23 MH119375/MH/NIMH NIH HHS/United States
GR  - R01 MH094151/MH/NIMH NIH HHS/United States
GR  - T32 MH019934/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200625
PL  - England
TA  - Int Psychogeriatr
JT  - International psychogeriatrics
JID - 9007918
SB  - IM
CIN - Int Psychogeriatr. 2020 Aug;32(8):909-911. PMID: 32933599
MH  - *Aging
MH  - *Artificial Intelligence
MH  - Humans
MH  - *Intelligence
MH  - Longevity
MH  - Neurobiology
PMC - PMC7942180
MID - NIHMS1674961
OTO - NOTNLM
OT  - *aging
OT  - *cognitive activity
EDAT- 2020/06/26 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - S1041610220000927 [pii]
AID - 10.1017/S1041610220000927 [doi]
PST - ppublish
SO  - Int Psychogeriatr. 2020 Aug;32(8):993-1001. doi: 10.1017/S1041610220000927. Epub 
      2020 Jun 25.


PMID- 32583723
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20211204
IS  - 1557-9891 (Electronic)
IS  - 1557-9883 (Linking)
VI  - 14
IP  - 3
DP  - 2020 May-Jun
TI  - 'Dudes Are Meant to be Tough as Nails': The Complex Nexus Between Masculinities, 
      Culture and Health Literacy From the Perspective of Young Aboriginal and Torres
      Strait Islander Males - Implications for Policy and Practice.
PG  - 1557988320936121
LID - 10.1177/1557988320936121 [doi]
AB  - Health literacy is generally conceptualized as skills related to successfully
      navigating health - ultimately linked to well-being and improved health outcomes.
      Culture, gender and age are considered to be influential determinants of health
      literacy. The nexus between these determinants, and their collective relationship
      with health literacy, remains understudied, especially with respect to Indigenous
      people globally. This article presents findings from a recent study that examined
      the intersections between masculinities, culture, age and health literacy among
      young Aboriginal and Torres Strait Islander males, aged 14-25 years in the
      Northern Territory, Australia. A mixed-methods approach was utilized to engage
      young Aboriginal and Torres Strait Islander males. The qualitative components
      included Yarning Sessions and Photovoice using Facebook, which are used in this
      article. Thematic Analysis and Framework Analysis were used to group and analyse 
      the data. Ethics approval was granted by Charles Darwin University Human Research
      Ethics Committee (H18043). This cohort constructs a complex interface comprising 
      Western and Aboriginal cultural paradigms, through which they navigate health.
      Alternative Indigenous masculinities, which embrace and resist hegemonic
      masculine norms simultaneously shaped this interface. External support structures
      - including family, friends and community engagement programs - were critical in 
      fostering health literacy abilities among this cohort. Young Aboriginal and
      Torres Strait Islander males possess health literacy abilities that enable them
      to support the well-being of themselves and others. Health policymakers,
      researchers and practitioners can help strengthen and expand existing support
      structures for this population by listening more attentively to their unique
      perspectives.
FAU - Smith, James A
AU  - Smith JA
AUID- ORCID: 0000-0003-4366-7422
AD  - Menzies School of Health Research, Casuarina, NT, Australia.
AD  - Charles Darwin University, Casuarina, Australia.
FAU - Merlino, Anthony
AU  - Merlino A
AD  - Menzies School of Health Research, Casuarina, NT, Australia.
FAU - Christie, Ben
AU  - Christie B
AD  - Menzies School of Health Research, Casuarina, NT, Australia.
FAU - Adams, Mick
AU  - Adams M
AD  - Menzies School of Health Research, Casuarina, NT, Australia.
AD  - Edith Cowan University, Mt Lawley, Australia.
FAU - Bonson, Jason
AU  - Bonson J
AD  - Menzies School of Health Research, Casuarina, NT, Australia.
AD  - Northern Territory Department of Health, Casuarina, Australia.
FAU - Osborne, Richard
AU  - Osborne R
AD  - Swinburne University of Technology, Hawthorn, VIC, Australia.
FAU - Judd, Barry
AU  - Judd B
AD  - Charles Darwin University, Casuarina, Australia.
AD  - University of Melbourne, Melbourne, Australia.
FAU - Drummond, Murray
AU  - Drummond M
AD  - Flinders University, Adelaide, Australia.
FAU - Aanundsen, David
AU  - Aanundsen D
AD  - Fred Hollows Foundation, Casuarina, NT, Australia.
FAU - Fleay, Jesse
AU  - Fleay J
AD  - Edith Cowan University, Mt Lawley, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Mens Health
JT  - American journal of men's health
JID - 101287723
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - *Culture
MH  - Health Equity
MH  - *Health Literacy
MH  - Health Policy
MH  - Humans
MH  - Male
MH  - *Masculinity
MH  - *Native Hawaiian or Other Pacific Islander
MH  - Qualitative Research
MH  - Social Determinants of Health
MH  - Social Media
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7318825
OTO - NOTNLM
OT  - *Aboriginal and Torres Strait Islander
OT  - *Health literacy
OT  - *Indigenous health
OT  - *health equity
OT  - *men's health
EDAT- 2020/06/26 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
AID - 10.1177/1557988320936121 [doi]
PST - ppublish
SO  - Am J Mens Health. 2020 May-Jun;14(3):1557988320936121. doi:
      10.1177/1557988320936121.


PMID- 32582946
OWN - NLM
STAT- MEDLINE
DCOM- 20220114
LR  - 20220114
IS  - 1876-4479 (Electronic)
IS  - 1873-9946 (Linking)
VI  - 14
IP  - 12
DP  - 2020 Dec 2
TI  - Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19
      Pandemic Is Not a Responsible Act.
PG  - 1765-1768
LID - 10.1093/ecco-jcc/jjaa127 [doi]
AB  - The intense competition for resources to combat COVID-19 has greatly reduced
      access to health care for patients with other diseases. After the disastrous
      overrun of hospitals through COVID-19 patients in some jurisdictions,
      availability of resources for 'elective' medical procedures, including care for
      the chronically ill, has been greatly reduced in many places as a pre-emptive
      measure before or during the blooming of infection clusters. Pharmaceutical
      companies have either stopped recruitment or even cancelled ongoing clinical
      trials in chronic diseases. Pre-emptive triage and its impact on medical ethics
      is discussed in the framework of care for inflammatory bowel disease.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Crohn's and Colitis Organisation. All rights reserved. For permissions, 
      please email: journals.permissions@oup.com.
FAU - Schreiber, Stefan
AU  - Schreiber S
AD  - Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, 
      Germany.
AD  - Excellence Cluster Precision Medicine in Inflammation,
      Christian-Albrechts-University, Kiel, Germany.
FAU - Dignass, Axel
AU  - Dignass A
AD  - Department of Medicine I, Agaplesion Markus Hospital, Frankfurt/Main, Germany.
FAU - Rogge, Annette
AU  - Rogge A
AD  - Institute of Experimental Medicine, Medical Ethics. University Hospital
      Schleswig-Holstein, Kiel, Germany.
FAU - Rubin, David T
AU  - Rubin DT
AUID- ORCID: 0000-0001-5647-1723
AD  - Inflammatory Bowel Disease Center, University of Chicago, Chicago, IL, USA.
AD  - MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL,
      USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Crohns Colitis
JT  - Journal of Crohn's & colitis
JID - 101318676
RN  - 0 (Anti-Inflammatory Agents)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - COVID-19/epidemiology/*prevention & control
MH  - Chronic Disease
MH  - Clinical Trials as Topic/*ethics
MH  - Drug Development/*ethics
MH  - Global Health
MH  - Health Care Rationing/*ethics
MH  - Health Services Accessibility/*ethics
MH  - Humans
MH  - Inflammatory Bowel Diseases/*drug therapy
MH  - Pandemics/prevention & control
MH  - Triage/ethics/methods
PMC - PMC7337647
OTO - NOTNLM
OT  - Crohn disease
OT  - drug development
OT  - ethics
OT  - registration trial
OT  - regulatory trials
OT  - ulcerative colitis
EDAT- 2020/06/26 06:00
MHDA- 2022/01/15 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2022/01/15 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - 5862397 [pii]
AID - 10.1093/ecco-jcc/jjaa127 [doi]
PST - ppublish
SO  - J Crohns Colitis. 2020 Dec 2;14(12):1765-1768. doi: 10.1093/ecco-jcc/jjaa127.


PMID- 32582943
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20201218
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 5
DP  - 2020 Aug 4
TI  - Ethical Implementation of Immunity Passports During the COVID-19 Pandemic.
PG  - 715-718
LID - 10.1093/infdis/jiaa352 [doi]
AB  - A number of countries are planning the use of "immunity passports" as a way to
      ease restrictive measures and allow infected and recovered people to return to
      work during the COVID-19 pandemic. This paper brings together key scientific
      uncertainties regarding the use of serological tests to assure immune status and 
      a public health ethics perspective to inform key considerations in the ethical
      implementation of immunity passport policies. Ill-conceived policies have the
      potential to cause severe unintended harms that could result in greater inequity,
      the stigmatization of certain sectors of society, and heightened risks and
      unequal treatment of individuals due to erroneous test results. Immunity
      passports could, however, be used to achieve collective benefits and benefits for
      specific populations besides facilitating economic recovery. We conclude that
      sector-based policies that prioritize access to testing based on societal need
      are likely to be fairer and logistically more feasible, while minimizing stigma
      and reducing incentives for fraud. Clear guidelines need to be set out for which 
      sectors of society should be prioritized for testing, and rigorous mechanisms
      should be in place to validate test results and identify cases of reinfection.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Voo, Teck Chuan
AU  - Voo TC
AD  - Centre of Biomedical Ethics, Yong Loo Lin School of Medicine, National University
      of Singapore and National University Health System, Singapore, Singapore.
FAU - Clapham, Hannah
AU  - Clapham H
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Singapore, Singapore.
FAU - Tam, Clarence C
AU  - Tam CC
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Singapore, Singapore.
AD  - London School of Hygiene and Tropical Medicine, London, United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Certification/ethics
MH  - Clinical Laboratory Techniques
MH  - Coronavirus Infections/diagnosis/*immunology/prevention & control
MH  - Health Policy
MH  - Humans
MH  - Immunity
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/*immunology/prevention & control
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - Serologic Tests/methods
PMC - PMC7337820
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *coronavirus
OT  - *disease control policy
OT  - *equity
OT  - *ethics
OT  - *immunity passports
OT  - *serological assays
OT  - *stigma
EDAT- 2020/06/26 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - 5862418 [pii]
AID - 10.1093/infdis/jiaa352 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Aug 4;222(5):715-718. doi: 10.1093/infdis/jiaa352.


PMID- 32582840
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2373-9878 (Print)
IS  - 2373-9878 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Jun 8
TI  - Bioengineering Vascular Networks to Study Angiogenesis and Vascularization of
      Physiologically Relevant Tissue Models in Vitro.
PG  - 3513-3528
LID - 10.1021/acsbiomaterials.0c00191 [doi]
AB  - Angiogenesis assays are essential for studying aspects of neovascularization and 
      angiogenesis and investigating drugs that stimulate or inhibit angiogenesis. To
      date, there are several in vitro and in vivo angiogenesis assays that are used
      for studying different aspects of angiogenesis. Although in vivo assays are the
      most representative of native angiogenesis, they raise ethical questions, require
      considerable technical skills, and are expensive. In vitro assays are inexpensive
      and easier to perform, but the majority of them are only two-dimensional cell
      monolayers which lack the physiological relevance of three-dimensional
      structures. Thus, it is important to look for alternative platforms to study
      angiogenesis under more physiologically relevant conditions in vitro.
      Accordingly, in this study, we developed polymeric vascular networks to be used
      to study angiogenesis and vascularization of a 3D human skin model in vitro. Our 
      results showed that this platform allowed the study of more than one aspect of
      angiogenesis, endothelial migration and tube formation, in vitro when combined
      with Matrigel. We successfully reconstructed a human skin model, as a
      representative of a physiologically relevant and complex structure, and assessed 
      the suitability of the developed in vitro platform for studying
      endothelialization of the tissue-engineered skin model.
CI  - Copyright (c) 2020 American Chemical Society.
FAU - Dikici, Serkan
AU  - Dikici S
AD  - Department of Materials Science and Engineering, Kroto Research Institute,
      University of Sheffield, Sheffield S3 7HQ, United Kingdom.
FAU - Claeyssens, Frederik
AU  - Claeyssens F
AD  - Department of Materials Science and Engineering, Kroto Research Institute,
      University of Sheffield, Sheffield S3 7HQ, United Kingdom.
FAU - MacNeil, Sheila
AU  - MacNeil S
AD  - Department of Materials Science and Engineering, Kroto Research Institute,
      University of Sheffield, Sheffield S3 7HQ, United Kingdom.
LA  - eng
GR  - MR/L012669/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200429
PL  - United States
TA  - ACS Biomater Sci Eng
JT  - ACS biomaterials science & engineering
JID - 101654670
MH  - Bioengineering
MH  - Biomedical Engineering
MH  - Humans
MH  - *Neovascularization, Pathologic
MH  - *Neovascularization, Physiologic
MH  - Tissue Engineering
PMC - PMC7304666
COIS- The authors declare no competing financial interest.
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.1021/acsbiomaterials.0c00191 [doi]
PST - ppublish
SO  - ACS Biomater Sci Eng. 2020 Jun 8;6(6):3513-3528. doi:
      10.1021/acsbiomaterials.0c00191. Epub 2020 Apr 29.


PMID- 32582741
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Challenges in Abdominal Organ Transplantation During the COVID-19 Pandemic.
PG  - 287
LID - 10.3389/fmed.2020.00287 [doi]
AB  - As the coronavirus disease 2019 (COVID-19) outbreak has rapidly evolved into a
      global pandemic, abdominal organ transplantation programs are currently facing
      multiple challenges. Transplant candidates and recipients are considered
      high-risk populations for severe disease and death due to COVID-19 as a result of
      their numerous underlying comorbidities, advanced age and impaired immune
      function. Emerging reports of atypical and delayed clinical presentations in
      these patients generate further concerns for widespread disease transmission to
      medical personnel and the community. The striking similarities between COVID-19
      and other outbreaks that took place over the past two decades, like Severe Acute 
      Respiratory Syndrome and Middle East Respiratory Syndrome, highlight the severity
      of the situation and dictate that extra measures should be taken by the
      transplant programs to avoid adverse outcomes. Transplant organizations are
      currently calling for strict screening and isolation protocols to be established 
      in all transplant programs, for both organ donors and recipients. As the
      situation escalates, more radical measures might be necessary, including a
      temporary hold on non-urgent transplantations, resulting in serious ethical
      dilemmas between the survival of these patients and the safety of the community. 
      Further data about these special populations could result in more individualized 
      guidelines for abdominal organ transplantation in the era of COVID-19.
CI  - Copyright (c) 2020 Esagian, Ziogas, Giannis, Hayat, Elias and Tsoulfas.
FAU - Esagian, Stepan M
AU  - Esagian SM
AD  - Surgery Working Group, Society of Junior Doctors, Athens, Greece.
FAU - Ziogas, Ioannis A
AU  - Ziogas IA
AD  - Surgery Working Group, Society of Junior Doctors, Athens, Greece.
AD  - Department of Surgery, Division of Hepatobiliary Surgery and Liver
      Transplantation, Vanderbilt University Medical Center, Nashville, TN, United
      States.
FAU - Giannis, Dimitrios
AU  - Giannis D
AD  - Surgery Working Group, Society of Junior Doctors, Athens, Greece.
AD  - Institute of Health Innovations and Outcomes Research, The Feinstein Institute
      for Medical Research, Manhasset, NY, United States.
FAU - Hayat, Muhammad H
AU  - Hayat MH
AD  - Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition,
      Vanderbilt University Medical Center, Nashville, TN, United States.
FAU - Elias, Nahel
AU  - Elias N
AD  - Department of Surgery, Transplantation Unit, Massachusetts General Hospital and
      Harvard Medical School, Boston, MA, United States.
FAU - Tsoulfas, Georgios
AU  - Tsoulfas G
AD  - First Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki, 
      Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200604
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7287204
OTO - NOTNLM
OT  - coronavirus
OT  - immunosuppression
OT  - kidney transplantation
OT  - liver transplantation
OT  - super-spreading events
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fmed.2020.00287 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Jun 4;7:287. doi: 10.3389/fmed.2020.00287. eCollection
      2020.


PMID- 32582619
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210108
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - The Science of the Future: Establishing a Citizen-Scientist Collaborative Agenda 
      After Covid-19.
PG  - 282
LID - 10.3389/fpubh.2020.00282 [doi]
FAU - Provenzi, Livio
AU  - Provenzi L
AD  - Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.
FAU - Barello, Serena
AU  - Barello S
AD  - EngageMinds HUB, Consumer, Food & Health Engagement Research Center, Department
      of Psychology, Universita Cattolica del Sacro Cuore, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200605
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *COVID-19
MH  - *Citizen Science
MH  - Communication
MH  - *Cooperative Behavior
MH  - *Forecasting
MH  - Humans
PMC - PMC7291379
OTO - NOTNLM
OT  - *COVID-19 (2019-nCoV)
OT  - *citizen science
OT  - *coronavirus
OT  - *ethics
OT  - *media
OT  - *public health
OT  - *science
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fpubh.2020.00282 [doi]
PST - epublish
SO  - Front Public Health. 2020 Jun 5;8:282. doi: 10.3389/fpubh.2020.00282. eCollection
      2020.


PMID- 32582602
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Social Determinants Predicting the Knowledge, Attitudes, and Practices of Women
      Toward Zika Virus Infection.
PG  - 170
LID - 10.3389/fpubh.2020.00170 [doi]
AB  - Objective: To investigate the factors predicting knowledge, attitude, and
      practices (KAP) toward Zika virus infection among women population in Cebu City, 
      Philippines. Study Design: A cross-sectional survey was conducted from March 2018
      to May 2018. Ethical practices were followed. A total of 702 women was approached
      and finally 516 completed the survey. Methods: Descriptive analysis was
      undertaken for the participants' characteristics. Kolmogorov-Smirnov test was
      applied to declare the nature of data distribution. To determine the role of
      socio-demographic characteristics on KAP, differences in socio-demographic status
      were compared with the KAP scores using the one-way analysis of variance or
      Kruskal-Wallis test with p < 0.05 as significant. Logistic regression analysis
      was used to determine the predictors of each KAP domain (good and poor). Results:
      There was a significant positive correlation between level of education and KAP
      scores. Also, there was a significant positive correlation between employment and
      KAP scores. Knowledge score was a significant predictor of practice score (b =
      1.261, p = 0.024), and attitude score was also a significant predictor of
      practice score (b = 0.183, p = 0.039). However, knowledge score was not a
      significant predictor of attitude score (b = 0.316, p = 0.247). Conclusions: The 
      present findings provided an overall view of KAP on Zika virus infection among
      females in Philippines and the socio-demographic factors that affected their KAP.
      Women with postgraduate education and being in higher profession were the
      predictors influencing the KAP scores of this female population. Women with
      postgraduate education was the strongest predictor.
CI  - Copyright (c) 2020 Maharajan, Rajiah, Belotindos and Basa.
FAU - Maharajan, Mari Kannan
AU  - Maharajan MK
AD  - Department of Pharmacy Practice, School of Pharmacy, International Medical
      University, Kuala Lumpur, Malaysia.
FAU - Rajiah, Kingston
AU  - Rajiah K
AD  - Department of Pharmacy Practice, School of Pharmacy, International Medical
      University, Kuala Lumpur, Malaysia.
FAU - Belotindos, Jo-Ann Singco
AU  - Belotindos JS
AD  - Master in Pharmacy Practice, School of Postgraduate Studies, International
      Medical University, Kuala Lumpur, Malaysia.
AD  - College of Pharmacy, Southwestern University PHINMA, Cebu, Philippines.
FAU - Basa, Marilou S
AU  - Basa MS
AD  - College of Pharmacy, Southwestern University PHINMA, Cebu, Philippines.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Philippines/epidemiology
MH  - Social Determinants of Health
MH  - *Zika Virus
MH  - *Zika Virus Infection/diagnosis
PMC - PMC7286053
OTO - NOTNLM
OT  - *Philippines
OT  - *infection
OT  - *pregnancy
OT  - *social determinants
OT  - *women
OT  - *zika virus
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fpubh.2020.00170 [doi]
PST - epublish
SO  - Front Public Health. 2020 Jun 3;8:170. doi: 10.3389/fpubh.2020.00170. eCollection
      2020.


PMID- 32582542
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage
      Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China.
PG  - 800
LID - 10.3389/fonc.2020.00800 [doi]
AB  - Aim: This study aims to analyze the prognostic value of seven tumor makers and
      also investigate the response of palliative chemotherapy in advanced NSCLC
      patients with advanced disease. Methods: Medical records of 278 advanced NSCLC
      Chinese patients who received six cycles of palliative chemotherapy were
      retrospectively reviewed under ethical approval (JSCH2019K-011). Univariate and
      multivariate Cox regression analyses were performed using SPSS 24 to find the
      clinical value of these tumor markers and to identify the factors that were
      associated with progression-free survival (PFS), as well as the response to
      palliative chemotherapy. Results: In baseline characteristic, the high levels of 
      CEA, CA-125, CA-199, AFP, NSE, CYFRA21-1, and CA15-3 were detected in 209
      (75.18%), 139 (50.0%), 62 (22.30%), 18 (6.47%), 155 (55.75%), 176 (63.30%), and
      180 (64.74%) patients, respectively. Univariate analysis revealed that patients
      with high vs. normal levels of all tumor markers had an increased risk of poor
      prognosis. In the multivariable Cox regression model, the patient with (high vs. 
      normal) CYFRA21-1 levels (HR = 1.454, P = 0.009) demonstrated an increased poor
      PFS. However, patients with (high vs. normal) CA19-9 levels (HR = 0.524, P <
      0.0001) and NSE levels (HR = 0.584, P < 0.0001) presented a decreased risk of
      PFS. Also, patients receiving 3-drugs regimen had better PFS compared to those on
      2-drugs regimen (P = 0.043). Conclusions: The high levels of CYFRA21-1 was
      correlated with a poor prognostic factor of PFS for Advanced NSCLC patients.
      However, the high levels of CA19-9 and NSE were associated with a better
      prognostic factor of PFS. Additionally, smoking habits and tumor status had a
      poor prognostic factor of PFS. Moreover, we found that antiangiogenic therapy has
      high efficacy with first-line chemotherapy and longer PFS of NSCLC patients.
CI  - Copyright (c) 2020 Abbas, Kassim, Habib, Li, Shi, Wang, Hu and Zhu.
FAU - Abbas, Muhammad
AU  - Abbas M
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Institute of Artificial
      Intelligence Biomedicine, Nanjing University, Nanjing, China.
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of 
      Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University,
      Nanjing, China.
FAU - Kassim, Said Abasse
AU  - Kassim SA
AD  - Centre de Recherche en Gestion des Services de Sante, Faculte des Sciences de
      L'administration (FSA), Universite Laval (UL), Centre Hospitaliere Universitaire 
      (CHU) de Quebec UL-IUCPQ-UL, Quebec, QC, Canada.
FAU - Habib, Murad
AU  - Habib M
AD  - Department of Surgery, Ayub Medical College, Abbottabad, Pakistan.
FAU - Li, Xiaoyou
AU  - Li X
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of 
      Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University,
      Nanjing, China.
FAU - Shi, Meiqi
AU  - Shi M
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of 
      Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University,
      Nanjing, China.
FAU - Wang, Zhong-Chang
AU  - Wang ZC
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Institute of Artificial
      Intelligence Biomedicine, Nanjing University, Nanjing, China.
FAU - Hu, Yiqiao
AU  - Hu Y
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Institute of Artificial
      Intelligence Biomedicine, Nanjing University, Nanjing, China.
AD  - Institute of Drug R&D, Medical School of Nanjing University, Nanjing, China.
FAU - Zhu, Hai-Liang
AU  - Zhu HL
AD  - State Key Laboratory of Pharmaceutical Biotechnology, Institute of Artificial
      Intelligence Biomedicine, Nanjing University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7292202
OTO - NOTNLM
OT  - non-small cell lung cancer
OT  - palliative chemotherapy
OT  - prognosis
OT  - serum tumor markers
OT  - six-cycles
OT  - stage IV
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2019/11/02 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fonc.2020.00800 [doi]
PST - epublish
SO  - Front Oncol. 2020 Jun 5;10:800. doi: 10.3389/fonc.2020.00800. eCollection 2020.


PMID- 32582366
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - Measuring the psychosocial, biological, and cognitive signatures of profound
      stress in humanitarian settings: impacts, challenges, and strategies in the
      field.
PG  - 40
LID - 10.1186/s13031-020-00286-w [doi]
AB  - BACKGROUND: Evidence of 'what works' in humanitarian programming is important for
      addressing the disruptive consequences of conflict and forced displacement.
      However, collecting robust scientific evidence, and ensuring contextual
      relevance, is challenging. We measured the biological, psychosocial, and
      cognitive impacts of a structured psychosocial intervention, implemented by Mercy
      Corps with Syrian refugees and Jordanian host-community youth. In this paper, we 
      present a case analysis of this evaluation study and reflect on the scientific
      contributions of the work, the challenges experienced in its delivery, and the
      strategies deployed to address them. DISCUSSION: We identified challenges with
      respect to study design, methods, and dissemination: these included the logistics
      and acceptability of implementing a randomized controlled trial in a humanitarian
      context, the selection and refinement of culturally-relevant research tools and
      community-based practices, and the dissemination of results to multiple
      stakeholders. We demonstrated beneficial and sustained impacts on self-reports of
      insecurity, stress, and mental health; developed a reliable and
      culturally-relevant measure of resilience; experimentally tested cognitive
      skills; and showed that levels of cortisol, a biomarker of chronic stress,
      reduced by one third in response to intervention. Using stress biomarkers offered
      proof-of-concept evidence, beyond self-reported data: interventions targeting
      mental health and psychosocial wellbeing can regulate physiological stress in the
      body as well as improve self-reported mental health and wellbeing. We built
      constructive dialogue between local communities, scholars, humanitarian
      practitioners, and policy-makers. CONCLUSIONS: Our work shows the value of
      rigorous research in humanitarian settings, emphasizing relevance for local
      communities and meaningful ways to build research ownership. Findings encourage
      the adoption of cognitive measures and stress biomarkers alongside self-report
      surveys in evaluating programme impacts. High-quality scientific research with
      youth can be feasible, useful, and ethical in humanitarian settings.
CI  - (c) The Author(s) 2020.
FAU - Panter-Brick, Catherine
AU  - Panter-Brick C
AUID- ORCID: 0000-0002-4635-2234
AD  - Department of Anthropology & Jackson Institute of Global Affairs, Yale
      University, New Haven, USA.grid.47100.320000000419368710
FAU - Eggerman, Mark
AU  - Eggerman M
AD  - MacMillan Center for International and Area Studies, Yale University, New Haven, 
      USA.grid.47100.320000000419368710
FAU - Ager, Alastair
AU  - Ager A
AD  - Institute for Global Health and Development, Queen Margaret University,
      Edinburgh, UK.grid.104846.f
FAU - Hadfield, Kristin
AU  - Hadfield K
AD  - Department of Biological and Experimental Psychology, Queen Mary University of
      London, London, UK.grid.4868.20000 0001 2171 1133
FAU - Dajani, Rana
AU  - Dajani R
AD  - Department of Biology and Biotechnology, Hashemite University, Zarqa,
      Jordan.grid.33801.390000 0004 0528 1681
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7310257
OTO - NOTNLM
OT  - Adolescent
OT  - Cognition
OT  - Conflict
OT  - Cortisol
OT  - Impact evaluation
OT  - Longitudinal
OT  - Mental health
OT  - Partnership
OT  - Refugee
OT  - Resilience
OT  - Stress
OT  - War
COIS- Competing interestsNone.
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.1186/s13031-020-00286-w [doi]
AID - 286 [pii]
PST - epublish
SO  - Confl Health. 2020 Jun 23;14:40. doi: 10.1186/s13031-020-00286-w. eCollection
      2020.


PMID- 32582308
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - COVID19-S4
DP  - 2020 May
TI  - Potential Barriers amongst Health Care Professionals of Pakistan in managing
      COVID-19 patients.
PG  - S17-S21
LID - 10.12669/pjms.36.COVID19-S4.2753 [doi]
AB  - OBJECTIVES: To evaluate basic knowledge of Health Care Professionals (HCPs) of
      Pakistan in managing COVID 19 patients. It includes information regarding
      infection control measures, administrative and professional support. This was
      followed by evaluation of psychological factor that can act as a barrier in
      effective management of these patients. METHODS: The survey was conducted on line
      using Google Form. After approval from hospital ethical committee survey link was
      disseminated to HCPs using social media. RESULTS: Four hundred fifteen HCPs were 
      participated. Most of them were younger than 30 years and majority of them were
      postgraduate trainees. Results showed gaps in the knowledge about basic infection
      control measure like donning/doffing and understanding about high-risk
      procedures. On job training, professional and administrative support is
      compromising. Many of HCPs are anxious nowadays, having symptoms related to burn 
      out with logical reasons behind. Even with all those hurdles they are committed
      and ready to volunteer themselves. CONCLUSION: The HCPs of Pakistan needs urgent 
      attention for providing them Formal training regarding infection control measure.
      Administrative and professional support is required from institutions and
      scientific societies. Online teaching modules and webinar is a suitable option.
      The symptoms of burn out are significant and would increase with passage of time.
      This needs to be supported by occupational health committees.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Haq, Muhammad Irfan Ul
AU  - Haq MIU
AD  - Muhammad Irfan Ul Haq, MBBS, FCPS. Department of Anaesthesiology, The Aga Khan
      University, Stadium Road, Karachi, Pakistan.
FAU - Shafiq, Faraz
AU  - Shafiq F
AD  - Faraz Shafiq, MBBS, MCPS, FCPS. Department of Anaesthesiology, The Aga Khan
      University, Stadium Road, Karachi, Pakistan.
FAU - Sheikh, Haris
AU  - Sheikh H
AD  - Haris Sheikh, MBBS. Department of Anaesthesiology, The Aga Khan University,
      Stadium Road, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7306964
OTO - NOTNLM
OT  - Attitude
OT  - COVID 19
OT  - Health Personnel
OT  - Pakistan
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.12669/pjms.36.COVID19-S4.2753 [doi]
AID - PJMS-36-S17 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 May;36(COVID19-S4):S17-S21. doi:
      10.12669/pjms.36.COVID19-S4.2753.


PMID- 32582107
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-302X (Print)
IS  - 1664-302X (Linking)
VI  - 11
DP  - 2020
TI  - Phage Therapy in the Year 2035.
PG  - 1171
LID - 10.3389/fmicb.2020.01171 [doi]
AB  - The emergence of multidrug resistant bacteria in both community- and
      hospital-acquired infections is recognized as a major public health threat. Phage
      therapy is increasingly mediatized and researched as an additional tool for
      combatting antibiotic resistant infections. However, phages exhibit a number of
      properties that differ from antibiotics and hamper their development as
      pharmaceutical products and their application in therapy. This paper advocates a 
      paradigm shift in the development and application of infectious disease
      therapeutics to cater for personalized phage therapy, which could be realized by 
      the year 2035. More specifically, it presents a sustainable and ethical supply
      chain of instant synthetic phages, based on a community effort, supported and
      steered by public health organizations, and managed by a platform combining
      Artificial Intelligence (AI) and Distributed Ledger (DL) Technology.
CI  - Copyright (c) 2020 Pirnay.
FAU - Pirnay, Jean-Paul
AU  - Pirnay JP
AD  - Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital,
      Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC7284012
OTO - NOTNLM
OT  - antibiotic resistance
OT  - antimicrobial resistance
OT  - artificial intelligence
OT  - distributed ledger technology
OT  - infectious diseases
OT  - machine learning
OT  - phage therapy
OT  - synthetic biology
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fmicb.2020.01171 [doi]
PST - epublish
SO  - Front Microbiol. 2020 Jun 3;11:1171. doi: 10.3389/fmicb.2020.01171. eCollection
      2020.


PMID- 32582061
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-302X (Print)
IS  - 1664-302X (Linking)
VI  - 11
DP  - 2020
TI  - Phage Therapy in Poland - a Centennial Journey to the First Ethically Approved
      Treatment Facility in Europe.
PG  - 1056
LID - 10.3389/fmicb.2020.01056 [doi]
AB  - Although phage discovery is an unquestionable merit of the English bacteriologist
      Frederick W. Twort and the Canadian-French microbiologist Felix d'Herelle, who
      both discovered phages over 100 years ago, the Polish history of phage studies
      also dates back to those years. In contrast to the Western world, developing
      phage treatment in Poland has never been abandoned despite the country's tense
      history marked by the Second World War (WWII) and the communism era. Today,
      Poland takes a prominent and remarkable place in the phage research area.
      Furthermore, established in 2005, the Phage Therapy Unit at the Hirszfeld
      Institute of Immunology and Experimental Therapy in Wroclaw, the first such
      center within European borders, has quickly become a model for other centers in
      the world facing the issue of widespread antibiotic resistance. This article
      constitutes an attempt to fill the gap in the scientific literature by providing 
      a comprehensive summary of the long tradition of phage research in Poland.
CI  - Copyright (c) 2020 Zaczek, Weber-Dabrowska, Miedzybrodzki, Lusiak-Szelachowska
      and Gorski.
FAU - Zaczek, Maciej
AU  - Zaczek M
AD  - Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental
      Therapy, Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
FAU - Weber-Dabrowska, Beata
AU  - Weber-Dabrowska B
AD  - Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental
      Therapy, Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
AD  - Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy,
      Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
FAU - Miedzybrodzki, Ryszard
AU  - Miedzybrodzki R
AD  - Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental
      Therapy, Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
AD  - Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy,
      Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
AD  - Department of Clinical Immunology, Transplantation Institute, Medical University 
      of Warsaw, Warsaw, Poland.
FAU - Lusiak-Szelachowska, Marzanna
AU  - Lusiak-Szelachowska M
AD  - Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental
      Therapy, Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
FAU - Gorski, Andrzej
AU  - Gorski A
AD  - Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental
      Therapy, Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
AD  - Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy,
      Polish Academy of Sciences (HIIET PAS), Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200605
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC7291835
OTO - NOTNLM
OT  - Hirszfeld Institute
OT  - Phage Therapy Unit
OT  - Polish history
OT  - phage discovery
OT  - phage research
OT  - phage therapy
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fmicb.2020.01056 [doi]
PST - epublish
SO  - Front Microbiol. 2020 Jun 5;11:1056. doi: 10.3389/fmicb.2020.01056. eCollection
      2020.


PMID- 32582051
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1664-302X (Print)
IS  - 1664-302X (Linking)
VI  - 11
DP  - 2020
TI  - An Invertebrate Burn Wound Model That Recapitulates the Hallmarks of Burn Trauma 
      and Infection Seen in Mammalian Models.
PG  - 998
LID - 10.3389/fmicb.2020.00998 [doi]
AB  - The primary reason for skin graft failure and the mortality of burn wound
      patients, particularly those in burn intensive care centers, is bacterial
      infection. Several animal models exist to study burn wound pathogens. The most
      commonly used model is the mouse, which can be used to study virulence
      determinants and pathogenicity of a wide range of clinically relevant burn wound 
      pathogens. However, animal models of burn wound pathogenicity are governed by
      strict ethical guidelines and hindered by high levels of animal suffering and the
      high level of training that is required to achieve consistent reproducible
      results. In this study, we describe for the first time an invertebrate model of
      burn trauma and concomitant wound infection. We demonstrate that this model
      recapitulates many of the hallmarks of burn trauma and wound infection seen in
      mammalian models and in human patients. We outline how this model can be used to 
      discriminate between high and low pathogenicity strains of two of the most common
      burn wound colonizers Pseudomonas aeruginosa and Staphylococcus aureus, and
      multi-drug resistant Acinetobacter baumannii. This model is less ethically
      challenging than traditional vertebrate burn wound models and has the capacity to
      enable experiments such as high throughput screening of both anti-infective
      compounds and genetic mutant libraries.
CI  - Copyright (c) 2020 Maslova, Shi, Sjoberg, Azevedo, Wareham and McCarthy.
FAU - Maslova, Evgenia
AU  - Maslova E
AD  - Division of Biosciences, Centre for Inflammation Research and Translational
      Medicine, Department of Life Sciences, College of Health and Life Sciences,
      Brunel University London, London, United Kingdom.
FAU - Shi, Yejiao
AU  - Shi Y
AD  - School of Engineering and Materials Science, Institute of Bioengineering, Queen
      Mary, University of London, London, United Kingdom.
FAU - Sjoberg, Folke
AU  - Sjoberg F
AD  - The Burn Centre, Department of Hand and Plastic Surgery, Linkoping University,
      Linkoping, Sweden.
AD  - Department of Clinical and Experimental Medicine, Faculty of Health Sciences,
      Linkoping University, Linkoping, Sweden.
FAU - Azevedo, Helena S
AU  - Azevedo HS
AD  - School of Engineering and Materials Science, Institute of Bioengineering, Queen
      Mary, University of London, London, United Kingdom.
FAU - Wareham, David W
AU  - Wareham DW
AD  - Antimicrobial Research Group, Blizard Institute, Queen Mary, University of
      London, London, United Kingdom.
FAU - McCarthy, Ronan R
AU  - McCarthy RR
AD  - Division of Biosciences, Centre for Inflammation Research and Translational
      Medicine, Department of Life Sciences, College of Health and Life Sciences,
      Brunel University London, London, United Kingdom.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200603
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC7283582
OTO - NOTNLM
OT  - Acinetobacter baumannii
OT  - Galleria mellonella
OT  - MRSA
OT  - Pseudomonas aeruginosa
OT  - biofilm
OT  - burn
OT  - infection
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fmicb.2020.00998 [doi]
PST - epublish
SO  - Front Microbiol. 2020 Jun 3;11:998. doi: 10.3389/fmicb.2020.00998. eCollection
      2020.


PMID- 32581995
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Evaluation of Chronotype Among Children and Associations With BMI, Sleep,
      Anxiety, and Depression.
PG  - 416
LID - 10.3389/fneur.2020.00416 [doi]
AB  - Objectives: To evaluate possible associations between chronotype, weight, sleep
      problems, anxiety, and depression among children from 6 to 12 years of age.
      Method: One-hundred children aged between 6 and 12 years were randomly recruited 
      in five pediatrician clinics in the capital city of Beirut, Lebanon. The protocol
      was approved by the ethics committee of Saint-Joseph University and Hotel-Dieu
      Hospital and an informed written formal consent was obtained from one of the
      parents. The Sleep Disturbance Scale for Children (CCTQ), the Revised Child
      Anxiety and Depression Scale (RCADS)-Parent version, and the Children's
      Chronotype Questionnaire (CCTQ) were used. Results: The majority of the sample
      (47%) presented an intermediate chronotype. There was a shift toward evening
      chronotype with increased age and a significant association between electronic
      devices use and an evening chronotype. Higher sleep disturbances were also
      observed among children with an evening chronotype. In particular, disorders of
      initiating and maintaining sleep, non-restorative sleep, excessive somnolence,
      and total SDSC were significantly higher among evening type children in our
      study. Finally, major depression domain scores were significantly higher among
      children with an evening chronotype. Conclusions: Several findings of this study 
      are important and explain factors associated to chronotype in children. Two
      important future perspectives can be highlighted: limiting electronic devices use
      among children in an effort to reduce circadian rhythm disturbances and
      identifying and treating sleep problems associated with eveningness, taking into 
      account the possible presence of major depression among this population.
CI  - Copyright (c) 2020 Eid, Bou Saleh, Melki, Torbey, Najem, Saber, El Osta and
      Rabbaa Khabbaz.
FAU - Eid, Bassam
AU  - Eid B
AD  - Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon.
AD  - Department of Pediatrics, Hotel-Dieu de France Hospital, Saint-Joseph University 
      of Beirut, Beirut, Lebanon.
FAU - Bou Saleh, Mary
AU  - Bou Saleh M
AD  - Laboratoire de Pharmacologie, Pharmacie clinique et Controle de qualite des
      medicaments, Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut,
      Lebanon.
FAU - Melki, Imad
AU  - Melki I
AD  - Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon.
AD  - Department of Pediatrics, Hotel-Dieu de France Hospital, Saint-Joseph University 
      of Beirut, Beirut, Lebanon.
FAU - Torbey, Paul-Henry
AU  - Torbey PH
AD  - Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon.
AD  - Department of Pediatrics, Hotel-Dieu de France Hospital, Saint-Joseph University 
      of Beirut, Beirut, Lebanon.
FAU - Najem, Joelle
AU  - Najem J
AD  - Laboratoire de Pharmacologie, Pharmacie clinique et Controle de qualite des
      medicaments, Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut,
      Lebanon.
FAU - Saber, Maroun
AU  - Saber M
AD  - Laboratoire de Pharmacologie, Pharmacie clinique et Controle de qualite des
      medicaments, Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut,
      Lebanon.
FAU - El Osta, Nada
AU  - El Osta N
AD  - Craniofacial Research Laboratory, Oral Health Unit, Faculty of Dental Medicine,
      Saint-Joseph University, Beirut, Lebanon.
AD  - Department of Prosthodontics, Faculty of Dental Medicine, Saint-Joseph
      University, Beirut, Lebanon.
FAU - Rabbaa Khabbaz, Lydia
AU  - Rabbaa Khabbaz L
AD  - Laboratoire de Pharmacologie, Pharmacie clinique et Controle de qualite des
      medicaments, Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut,
      Lebanon.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7291378
OTO - NOTNLM
OT  - anxiety
OT  - children
OT  - chronotype
OT  - depression
OT  - sleep
OT  - weight
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fneur.2020.00416 [doi]
PST - epublish
SO  - Front Neurol. 2020 Jun 5;11:416. doi: 10.3389/fneur.2020.00416. eCollection 2020.


PMID- 32581856
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - What are the Key Characteristics of a 'Good' Psychotherapy? Calling for Ethical
      Patient Involvement.
PG  - 406
LID - 10.3389/fpsyt.2020.00406 [doi]
AB  - OBJECTIVE: The evidence-based practice movement clearly defines the relevant
      components of a good treatment. In the present article, we elaborate on how the
      active involvement of patients within psychotherapy can and should be increased
      in order to respect ethical considerations. Our arguments complement the
      requirements of evidence-based practice, and are independent of the actual
      psychotherapeutic treatment approach being used. METHOD: Theoretical and ethical 
      analysis. RESULTS: In order to respect patient autonomy, psychotherapy needs to
      be transparent and honest when it comes to disclosing the relevant factors for
      promoting therapeutic change. It has been argued that ethical informed consent
      needs to include empirically supported patient information. In this paper we go
      one step further: we outline that fully respecting ethical considerations in
      psychotherapeutic treatment necessarily calls for acknowledging and strengthening
      the active role of patients in the course of psychotherapy. Accordingly, patients
      need not only to be informed openly and transparently about the planned
      treatment, the treatment rationale, and the expected prognosis of improvement in 
      the course of psychotherapy, but they also need to be actively involved in the
      decision-making process and during the entire process of psychotherapeutic
      treatment. CONCLUSIONS: Our arguments support the tendency that can be observed
      in health care in recent years towards more active patient involvement across
      different health-care domains, but also in clinical research. This article offers
      an ethical perspective on the question what defines a 'good psychotherapy',
      which, hopefully, will help to leave behind some of the ongoing psychotherapy
      debates and move the field forward.
CI  - Copyright (c) 2020 Gerger, Nascimento, Locher, Gaab and Trachsel.
FAU - Gerger, Heike
AU  - Gerger H
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
AD  - Department of General Practice, Erasmus MC University Medical Center, Rotterdam, 
      Netherlands.
FAU - Nascimento, Antje Frey
AU  - Nascimento AF
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
FAU - Locher, Cosima
AU  - Locher C
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
AD  - School of Psychology, University of Plymouth, Plymouth, United Kingdom.
AD  - Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's 
      Hospital, Harvard Medical School, Boston, MA, United States.
FAU - Gaab, Jens
AU  - Gaab J
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
FAU - Trachsel, Manuel
AU  - Trachsel M
AD  - Faculty of Medicine, Institute of Biomedical Ethics and History of Medicine,
      University of Zurich, Zurich, Switzerland.
AD  - Clinical Ethics Unit, University Hospital of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7292227
OTO - NOTNLM
OT  - empirically supported treatment
OT  - evidence-based practice
OT  - patient autonomy
OT  - patient-centered care
OT  - psychotherapy
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:01
CRDT- 2020/06/26 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:01 [medline]
AID - 10.3389/fpsyt.2020.00406 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Jun 2;11:406. doi: 10.3389/fpsyt.2020.00406. eCollection
      2020.


PMID- 32581400
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2186-3326 (Electronic)
IS  - 0027-7622 (Linking)
VI  - 82
IP  - 2
DP  - 2020 May
TI  - The ethics of blood transfusion refusal in clinical practice among legal and
      medical professions in Japan.
PG  - 193-204
LID - 10.18999/nagjms.82.2.193 [doi]
AB  - We investigated the differences in Japanese and United States medical and legal
      professional opinions on ethical support for clinical ethical issues using the
      refusal of blood transfusions on the grounds of religious principles as an
      example of a clinical ethical issue. In ethical support systems for medical
      institutions in Japan, 95.0% of "clinical training designation hospitals" have
      hospital ethics committees, and 63.1% have medical safety divisions; clinical
      ethical support is provided in accordance with their scale and function. In terms
      of clinical ethical support limits the discretion of physicians, 59.2% of lawyers
      responded "No" and 54.4% of doctors responded "Yes". In addition, on the
      feasibility of government or academic guidelines in clinical practice, 37.7% of
      lawyers responded "Yes" and 63.0% of doctors responded "No". In terms of
      "relative transfusion-free" policy, 83.2% of lawyers and 76.8% of doctors
      responded that it is "unavoidable," while 81.6% of U.S. committee heads responded
      that it is a "violation of rights." In terms of hospital transfers due to a
      hospital being unable to treat patients refusing blood transfusion, 62.6% of
      lawyers reported that it is "unavoidable" while 57.1% of U.S. committee heads
      reported that it "should be avoided". The results of this study indicate that
      medical and legal professionals and U.S. ethics committee heads recognize
      clinical ethical issues in slightly different ways.
FAU - Iijima, Yoshihiko
AU  - Iijima Y
AD  - Department of Medical Research and Clinical Ethics Promotion Office, Nagoya
      University Hospital, Nagoya, Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Nagoya J Med Sci
JT  - Nagoya journal of medical science
JID - 0412011
SB  - IM
MH  - *Blood Transfusion
MH  - Bloodless Medical and Surgical Procedures/*ethics
MH  - Ethicists
MH  - *Ethics Committees, Clinical
MH  - Ethics, Medical
MH  - Humans
MH  - Japan
MH  - *Lawyers
MH  - Patient Transfer/ethics
MH  - *Physicians
MH  - Practice Guidelines as Topic
MH  - Surveys and Questionnaires
MH  - Treatment Refusal/*ethics/legislation & jurisprudence
MH  - United States
PMC - PMC7276408
OTO - NOTNLM
OT  - blood transfusion rejection
OT  - clinical ethical support
OT  - clinical ethics
OT  - hospital ethics committee
OT  - medical practice
COIS- The author has no conflicts of interest to disclose.
EDAT- 2020/06/26 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.18999/nagjms.82.2.193 [doi]
PST - ppublish
SO  - Nagoya J Med Sci. 2020 May;82(2):193-204. doi: 10.18999/nagjms.82.2.193.


PMID- 32581211
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20220415
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Jun 25
TI  - [Ethical, legal and social issues publications on biobanks 2011-2018. A scoping
      review.]
LID - e202006031 [pii]
AB  - BACKGROUND: Human-based biobanks have been presented as intermediary agents
      between donors/participants, the scientific community, the healthcare system, and
      patients. The objective of this systematic review was to contribute with an
      updated thematic synthesis in Spanish of the international literature (2011-2018)
      regarding ethical, legal, and social issues on contemporary biobanks. METHODS: A 
      scoping review and thematic analysis were carried out on biobanks' ethical,
      legal, and social issues. The following databases were searched: Web of Science, 
      SciELO, and Dialnet. The review included 2011-2018 publications with the term
      "biobank" or "biobanco" in English, Spanish, Portuguese, and French. RESULTS: A
      total of 153 publications were analyzed. The most published themes were: informed
      consent, biobanks as a scientific tool, other ethical issues, public engagement, 
      and regulation. While documents published in English provide studies with a
      broader anthropologic approach and display the participatory turn, in Spanish a
      technical approach is more common. Aportar datos y cifras principales.
      CONCLUSIONS: Publications confirm and support biobanks' relevance in current and 
      future biomedical research, but also illustrate the entanglement of a diverse
      range of healthcare institutions and relations. Biobanks' techno-scientific
      issues cannot be split from the ethical, legal, and social ones or place them as 
      secondary; all of them are co-produced. This review points to current topics and 
      challenges which need to be addressed to establish transparent, accountable,
      dynamic, and trust-worthy biobanks.
FAU - Argudo-Portal, Violeta
AU  - Argudo-Portal V
AD  - Departamento de Psicologia Social. Universitat Autonoma de Barcelona. Barcelona. 
      Espana.
FAU - Domenech, Miquel
AU  - Domenech M
AD  - Departamento de Psicologia Social. Universitat Autonoma de Barcelona. Barcelona. 
      Espana.
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Publicaciones sobre los aspectos eticos, legales y sociales de los biobancos
      entre 2011-2018. Una revision panoramica.
DEP - 20200625
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Biological Specimen Banks/*ethics/*legislation & jurisprudence
MH  - Biomedical Research
MH  - Databases, Factual
MH  - Delivery of Health Care
MH  - Ethics, Medical
MH  - Humans
MH  - *Informed Consent
MH  - Social Responsibility
MH  - Spain
MH  - *Tissue Donors
MH  - Translational Research, Biomedical/organization & administration
OTO - NOTNLM
OT  - Biobank
OT  - Data curation
OT  - ELSI
OT  - Gift giving
OT  - Informed consent
OT  - Public engagement
OT  - Scoping review
OT  - Social science
OT  - Spain
OT  - Tissue donors
OT  - Translational medicine
EDAT- 2020/06/26 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/06/26 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Jun 25;94.


PMID- 32581013
OWN - NLM
STAT- Publisher
LR  - 20200625
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 24
TI  - More than just filler: an empirically informed ethical analysis of non-surgical
      cosmetic procedures in body dysmorphic disorder.
LID - medethics-2019-105746 [pii]
LID - 10.1136/medethics-2019-105746 [doi]
AB  - OBJECTIVES: To identify and analyse ethical considerations raised when
      individuals with body dysmorphic disorder (BDD) consult for non-surgical cosmetic
      procedures. METHODS: Ethical analysis was conducted addressing the issues of best
      interests and capacity to consent for non-surgical cosmetic procedures in
      individuals with BDD. Analysis was informed by the findings of semistructured
      interviews with non-surgical cosmetic practitioners and mental health
      professionals. FINDINGS: Non-surgical cosmetic interventions were viewed not to
      be in the best interests of individuals with BDD, as they fail to address core
      psychological issues, result in dissatisfaction post-procedure, and risk harm.
      Referral to mental health services was advocated, however numerous obstacles to
      this were perceived. The issue of capacity to consent to non-surgical cosmetic
      procedures raised questions regarding whether standard capacity assessment is
      sensitive to the manner in which BDD may influence decision-making processes. In 
      addition, concerns were voiced that decisions made by individuals with BDD in
      this context may be judged foolish, and thus wrongly equated with lack of
      capacity. DISCUSSION/CONCLUSIONS: Ethical analysis, informed by the available
      evidence base, suggests that it is generally not in the best interests of
      individuals with BDD to undergo non-surgical cosmetic intervention, and referral 
      to mental health services is indicated. Analysis of capacity draws parallels
      between BDD and anorexia nervosa, as decision-making capacity in both conditions 
      can be impaired by pathological values derived from the disorder. Means of
      differentiating clinical assessment of pathological values from inappropriate
      value judgements are advocated, in order to safeguard against the latter
      encroaching into capacity assessment.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Lane, Natalie M
AU  - Lane NM
AUID- ORCID: http://orcid.org/0000-0003-3586-6536
AD  - Department of Psychiatry, NHS Lanarkshire Mental Health Services, Glasgow,
      Scotland, UK natalie.lane@nhs.net.
AD  - Department of Global Health & Social Medicine, King's College London, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - capacity
OT  - informed consent
OT  - psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/06/26 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/26 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - medethics-2019-105746 [pii]
AID - 10.1136/medethics-2019-105746 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 24. pii: medethics-2019-105746. doi:
      10.1136/medethics-2019-105746.


PMID- 32580990
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - OASIS-a randomised, placebo-controlled trial of oral glucocorticoids for leg pain
      in patients with acute sciatica: trial protocol.
PG  - e040559
LID - 10.1136/bmjopen-2020-040559 [doi]
AB  - INTRODUCTION: Sciatica is a lower spine condition characterised by radiating leg 
      pain below the knee. It may be accompanied by motor and sensory loss in the
      distribution of a spinal nerve. There are few effective treatments for sciatica. 
      Orally administered glucocorticoids have shown some promise, however, any
      beneficial effects need to be confirmed and weighed against drug safety and
      cost-effectiveness, in a high-quality, definitive trial. METHODS AND ANALYSIS:
      The Oral Steroids In Sciatica (OASIS) trial is a randomised, placebo-controlled, 
      double-blind trial that will evaluate a tapering regimen of oral prednisolone in 
      200 participants with acute sciatica. Participants will be recruited on
      presentation to general practice, specialist outpatient clinics or hospital
      emergency departments and randomised to receive orally administered prednisolone 
      50 mg per day, up to 3 days then tapering to cessation over 10 days, or placebo, 
      for a maximum of 13 days, in addition to guideline advice. Participants will be
      followed for 1 year. The primary endpoint will be leg pain intensity at 2 weeks. 
      Secondary outcomes will include back pain intensity, disability, time to
      recovery, quality of life and treatment success rate. Adverse events will be
      assessed and a cost-effectiveness analysis will be conducted. ETHICS AND
      DISSEMINATION: Ethical approval has been granted from the Human Research Ethics
      Committee, The University of Sydney. Trial results will be disseminated by
      publications and conference presentations and via the media. TRIAL REGISTRATION
      NUMBER: ACTRN12619001716156.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Liu, Chang
AU  - Liu C
AUID- ORCID: 0000-0003-0597-6101
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia chang.liu1@sydney.edu.au.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Abdel Shaheed, Christina
AU  - Abdel Shaheed C
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - McLachlan, Andrew J
AU  - McLachlan AJ
AD  - Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Latimer, Jane
AU  - Latimer J
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Li, Qiang
AU  - Li Q
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Buchbinder, Rachelle
AU  - Buchbinder R
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and
      Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
AD  - Monash Department of Clinical Epidemiology, Cabrini Institute, Melbourne,
      Victoria, Australia.
FAU - Day, Richard O
AU  - Day RO
AUID- ORCID: 0000-0002-6045-6937
AD  - Department of Clinical Pharmacology & Toxicology, St Vincent Hospital, Sydney,
      New South Wales, Australia.
AD  - St Vincent's Clinical School, Faculty of Medicine, University of New South Wales,
      Sydney, New South Wales, Australia.
FAU - Maher, Christopher G
AU  - Maher CG
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Richards, Bethan
AU  - Richards B
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
AD  - Rheumatology Department, Institute of Rheumatology and Orthopaedics, Sydney, New 
      South Wales, Australia.
FAU - Oliveira, Juliana S
AU  - Oliveira JS
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Lin, Chung-Wei Christine
AU  - Lin CC
AD  - Institute for Musculoskeletal Health, The University of Sydney and Sydney Local
      Health District, Sydney, New South Wales, Australia.
AD  - School of Public Health, Faculty of Medicine and Health, The University of
      Sydney, Sydney, New South Wales, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001716156
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Acute Pain/*drug therapy
MH  - Administration, Oral
MH  - Adult
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Leg
MH  - Prednisolone/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sciatica/*drug therapy
MH  - Treatment Outcome
PMC - PMC7312281
OTO - NOTNLM
OT  - *clinical trials
OT  - *musculoskeletal disorders
OT  - *pain management
OT  - *spine
COIS- Competing interests: The study has been awarded funding from the National Health 
      and Medical Research Council (NHMRC), Australia. The investigators maintain full 
      autonomy in the design, conduct and reporting of the study. We have ethics
      approval to reimburse study clinicians for their time spent on study-specific
      tasks.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-040559 [pii]
AID - 10.1136/bmjopen-2020-040559 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e040559. doi: 10.1136/bmjopen-2020-040559.


PMID- 32580988
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - Identification of cardiovascular and molecular prognostic factors for the
      medium-term and long-term outcomes of sepsis (ICROS): protocol for a prospective 
      monocentric cohort study.
PG  - e036527
LID - 10.1136/bmjopen-2019-036527 [doi]
AB  - INTRODUCTION: Sepsis is one of the most prevalent life-threatening conditions in 
      the intensive care unit. Patients suffer from impaired organ function, reduced
      physical functional capacity and decreased quality of life even after surviving
      sepsis. The identification of prognostic factors for the medium-term and
      long-term outcomes of this condition is necessary to develop personalised
      theragnostic approaches. Sepsis can cause cardiac impairment. The impact of this 
      septic cardiomyopathy on patient's long-term outcome remains unclear. This study 
      aims to evaluate cardiovascular risk factors, particularly the occurrence of
      septic cardiomyopathy, regarding their suitability as prognostic factors for the 
      short-term and long-term outcomes of septic patients. Additionally, the study
      seeks to validate preclinical pathophysiological findings of septic
      cardiomyopathy in the clinical setting. METHODS AND ANALYSIS: In this prospective
      monocentric cohort study, patients will be clinically assessed during the acute
      and postacute phase of sepsis and two follow-ups after 6 and 12 months. To
      determine the effect of septic cardiomyopathy and concomitant cellular and
      molecular changes on patient mortality and morbidity, a comprehensive
      cardiovascular and molecular deep phenotyping of patients will be performed. This
      includes an echocardiographic and electrocardiographic assessment, and the
      evaluation of heart rate variability, body composition, mitochondrial oxygen
      metabolism, macrocirculation and microcirculation, and endothelial barrier
      function. These analyses are complemented by routine immunological,
      haematological and biochemical laboratory tests and analyses of the serum
      metabolome and lipidome, microbiome and epigenetic modifications of immune cells.
      The reversibility of patients' organ dysfunction, their quality of life and
      physical functional capacity will be investigated in the follow-ups. Patients
      with cardiomyopathy without infection and healthy subjects will serve as control 
      groups. ETHICS AND DISSEMINATION: Approval was obtained from the Ethics Committee
      of the Friedrich Schiller University Jena (5276-09/17). The results will be
      published in peer-reviewed journals and presented at appropriate conferences.
      TRIAL REGISTRATION NUMBERS: DRKS00013347; NCT03620409.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Coldewey, Sina M
AU  - Coldewey SM
AUID- ORCID: 0000-0002-7130-0006
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany sina.coldewey@med.uni-jena.de.
AD  - Septomics Research Centre, Jena University Hospital, Jena, Germany.
AD  - Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
FAU - Neu, Charles
AU  - Neu C
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
AD  - Septomics Research Centre, Jena University Hospital, Jena, Germany.
AD  - Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
FAU - Baumbach, Philipp
AU  - Baumbach P
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
AD  - Septomics Research Centre, Jena University Hospital, Jena, Germany.
FAU - Scherag, Andre
AU  - Scherag A
AUID- ORCID: 0000-0002-9406-4704
AD  - Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
AD  - Institute of Medical Statistics, Computer and Data Sciences, Jena University
      Hospital, Jena, Germany.
FAU - Goebel, Bjorn
AU  - Goebel B
AD  - Department of Cardiology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany.
FAU - Ludewig, Katrin
AU  - Ludewig K
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
AD  - Septomics Research Centre, Jena University Hospital, Jena, Germany.
FAU - Bloos, Frank
AU  - Bloos F
AUID- ORCID: 0000-0002-0767-7941
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
AD  - Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
FAU - Bauer, Michael
AU  - Bauer M
AD  - Department of Anaesthesiology and Intensive Care Medicine, Jena University
      Hospital, Jena, Germany.
AD  - Centre for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03620409
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cardiomyopathies/diagnosis/*etiology/pathology
MH  - Cardiovascular System/pathology/physiopathology
MH  - Case-Control Studies
MH  - Clinical Protocols
MH  - Humans
MH  - Prognosis
MH  - Prospective Studies
MH  - Sepsis/complications/*diagnosis
PMC - PMC7312455
OTO - NOTNLM
OT  - *cardiomyopathy
OT  - *infectious diseases
OT  - *intensive & critical care
OT  - *molecular diagnostics
COIS- Competing interests: None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036527 [pii]
AID - 10.1136/bmjopen-2019-036527 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e036527. doi: 10.1136/bmjopen-2019-036527.


PMID- 32580987
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - Study protocol for the ABERRANT study: antibiotic-induced disruption of the
      maternal and infant microbiome and adverse health outcomes - a prospective cohort
      study among children born at term.
PG  - e036275
LID - 10.1136/bmjopen-2019-036275 [doi]
AB  - INTRODUCTION: There is compositional overlap between the maternal intestinal
      microbiome, the breast milk microbiome and the infant oral and intestinal
      microbiome. Antibiotics cause profound changes in the microbiome. However, the
      effect of intrapartum and early-life antibiotics on the maternal intestinal and
      breast milk microbiome, and the infant oral and intestinal microbiome, and
      whether effects are only short term or persist long term remain uncertain.
      METHODS AND ANALYSES: In this prospective cohort study, we will use metagenomic
      sequencing to determine: (1) the effect of intrapartum antibiotics on the
      composition of the breast milk, and the infant oral and intestinal microbiome,
      including the development and persistence of antibiotic resistance; (2) the
      effect of antibiotic exposure in the first year of life on the composition of the
      infant oral and intestinal microbiome, including the development and persistence 
      of antibiotic resistance; (3) the effect of disruption of the infant oral and
      intestinal microbiome on health outcomes and (4) the compositional overlap
      between the maternal intestinal microbiome, the breast milk microbiome and the
      infant oral and intestinal microbiome. ETHICS AND DISSEMINATION: The ABERRANT
      study has been approved by the commission cantonale d'ethique de la recherche sur
      l'etre humain (CER-VD) du Canton de Vaud (#2019-01567). Outcomes will be
      disseminated through publication and will be presented at scientific conferences.
      TRIAL REGISTRATION NUMBER: NCT04091282.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Volery, Maryse
AU  - Volery M
AD  - Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
AD  - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland.
FAU - Scherz, Valentin
AU  - Scherz V
AD  - Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland.
AD  - Facultiy of Medicine, University of Lausanne, Lausanne, Switzerland.
FAU - Jakob, William
AU  - Jakob W
AD  - Microbiology Laboratory, Fribourg Hospital HFR, Fribourg, Switzerland.
FAU - Bandeira, Diane
AU  - Bandeira D
AD  - Microbiology Laboratory, Fribourg Hospital HFR, Fribourg, Switzerland.
FAU - Deggim-Messmer, Vanessa
AU  - Deggim-Messmer V
AD  - Microbiology Laboratory, Fribourg Hospital HFR, Fribourg, Switzerland.
FAU - Lauber-Biason, Anna
AU  - Lauber-Biason A
AD  - Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
AD  - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland.
FAU - Wildhaber, Johannes
AU  - Wildhaber J
AD  - Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
AD  - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland.
FAU - Falquet, Laurent
AU  - Falquet L
AD  - Department of Biology, University of Fribourg, Fribourg, Switzerland.
AD  - Swiss Institute of Bioinformatics, Lausanne, Switzerland.
FAU - Curtis, Nigel
AU  - Curtis N
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
AD  - Infectious Diseases Research Group, Murdoch Children's Research Institute,
      Parkville, Victoria, Australia.
AD  - Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville,
      Victoria, Australia.
FAU - Zimmermann, Petra
AU  - Zimmermann P
AUID- ORCID: 0000-0002-2388-4318
AD  - Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
      petra.zimmermann@unifr.ch.
AD  - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland.
AD  - Department of Paediatrics, The University of Melbourne, Parkville, Victoria,
      Australia.
AD  - Infectious Diseases Research Group, Murdoch Children's Research Institute,
      Parkville, Victoria, Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT04091282
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/*adverse effects
MH  - Clinical Protocols
MH  - Drug Resistance, Bacterial
MH  - Eczema/epidemiology
MH  - Female
MH  - Gastrointestinal Microbiome/*drug effects/genetics/physiology
MH  - Humans
MH  - Hypersensitivity/epidemiology
MH  - Infant
MH  - Infant, Newborn
MH  - Metagenomics
MH  - Milk, Human/chemistry/microbiology
MH  - Otitis Media/epidemiology
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/*chemically induced
MH  - Prospective Studies
MH  - Respiratory Tract Diseases/epidemiology
PMC - PMC7312317
OTO - NOTNLM
OT  - *immunology
OT  - *microbiology
OT  - *molecular diagnostics
OT  - *neonatology
OT  - *paediatric infectious disease & immunisation
COIS- Competing interests: None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036275 [pii]
AID - 10.1136/bmjopen-2019-036275 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e036275. doi: 10.1136/bmjopen-2019-036275.


PMID- 32580984
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - Occupational therapist-led mindfulness-based stress reduction for older adults
      living with subjective cognitive decline or mild cognitive impairment in primary 
      care: a feasibility randomised control trial protocol.
PG  - e035299
LID - 10.1136/bmjopen-2019-035299 [doi]
AB  - INTRODUCTION: Community-dwelling older adults living with subjective cognitive
      decline or mild cognitive impairment may experience decreased efficiency in their
      overall functional performance. This decreased cognitive efficiency may result in
      anxiety, low mood, perceived stress and decreased emotional well-being and
      quality-of-life. These psychological symptoms may further exacerbate cognitive
      decline.Exploring non-pharmacological interventions such as mindfulness within
      primary care is vital in enabling individuals to develop strategies to manage
      cognitive impairment or psychological symptoms. Mindfulness-based stress
      reduction (MBSR) is an 8-week programme that is beneficial in alleviating
      psychological symptoms; however, its impact on perceived satisfaction on overall 
      functional performance with this population has not been evaluated. The primary
      objective of this study is to explore the feasibility of conducting a randomised 
      controlled trial of an occupational therapist-led MBSR programme within primary
      care. METHODS: Convergent mixed-methods, randomised control feasibility trial
      with 40 participants from an interprofessional primary care team in Toronto,
      Ontario. Participants are randomised into the 8-week MBSR group or wait-list
      control will be compared at baseline, postintervention and 4weeks follow-up. The 
      primary aim is to determine the feasibility of the intervention with this
      population and setting. The secondary aim is to examine perceived satisfaction
      with functional performance as measured by the Canadian Occupational Performance 
      Measure. Secondary clinical outcomes include psychological symptoms. ANALYSIS:
      Investigators will analyse the quantitative and qualitative data strands
      separately. Descriptive statistics, focus group and interviews will then be
      merged and further analysed to best understand the feasibility and preliminary
      clinical outcomes from the study. ETHICS AND DISSEMINATION: The study is approved
      by Women's College Hospital (2017-0056-E), and Queen's University, Kingston,
      Ontario (6026418). The study will follow Standard Protocol Items: Recommendations
      for Interventional Trials. The results will be published in peer-reviewed
      academic journals and disseminated to patient organisations and media.Trial
      registration numberNCT03867474; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tran, Todd
AU  - Tran T
AUID- ORCID: 0000-0003-0926-5737
AD  - Family Practice, Women's College Hospital, Toronto, Ontario, Canada
      Todd.tran@wchospital.ca.
AD  - Aging and Health, Queen's University, Kingston, Ontario, Canada.
FAU - Donnelly, Catherine
AU  - Donnelly C
AD  - Rehabilitation Therapy, Queen's University Faculty of Health Sciences, Kingston, 
      Ontario, Canada.
FAU - Nalder, Emily Joan
AU  - Nalder EJ
AUID- ORCID: 0000-0001-9612-9420
AD  - Occupational Science and Occupational Therapy, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Trothen, Tracy
AU  - Trothen T
AD  - Rehabilitation Therapy, Queen's University Faculty of Health Sciences, Kingston, 
      Ontario, Canada.
FAU - Finlayson, Marcia
AU  - Finlayson M
AD  - Rehabilitation Therapy, Queen's University Faculty of Health Sciences, Kingston, 
      Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03867474
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Cognitive Dysfunction/psychology/*therapy
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Status and Dementia Tests
MH  - Middle Aged
MH  - Mindfulness/*methods
MH  - *Occupational Therapists
MH  - Primary Health Care/methods
MH  - Psychiatric Status Rating Scales
MH  - Randomized Controlled Trials as Topic
MH  - Stress, Psychological/*therapy
PMC - PMC7312340
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *delirium & cognitive disorders
OT  - *depression & mood disorders
OT  - *mental health
OT  - *old age psychiatry
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035299 [pii]
AID - 10.1136/bmjopen-2019-035299 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e035299. doi: 10.1136/bmjopen-2019-035299.


PMID- 32580982
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - Development of an implementation and evaluation strategy for the Australian 'Zero
      Childhood Cancer' (Zero) Program: a study protocol.
PG  - e034522
LID - 10.1136/bmjopen-2019-034522 [doi]
AB  - INTRODUCTION: Effective implementation of a research Program requires an
      actionable plan to guide execution. To assess the actionability and success of
      that plan, both scientific and implementation elements must be taken into
      account. The aim of this study is to assess the 'Zero Childhood Cancer
      Personalised Medicine Program' (the Zero Program), an Australian first-ever and
      most comprehensive personalised medicine programme for children with high-risk or
      relapsed cancer, in terms of its structure, process and implementational effect. 
      METHODS AND ANALYSIS: We will assess Program delivery mechanisms. The development
      of the implementation and evaluation strategy will concentrate on the work of the
      Zero Program as a complex whole. This includes the structure of collaborative
      links across stakeholder groups involved in Program development and delivery,
      changes to collaborative relationships over time and the impact of group working 
      on Program outcomes. We are applying a mixed-methods design including: a rapid
      ethnography (observations of stakeholder interactions and informal
      conversations), Program professionals' completion of a rapid health
      implementation proforma and a social network analysis. Formative evaluations of
      the implementation science effects, applying feedback techniques, for example,
      Formative Evaluation Feedback Loops and the Zero Program professionals' feedback,
      will determine where Program tailoring may be needed. A repeat of the social
      network analysis downstream will examine network changes over time, followed by
      an expert panel using the expert recommendations for implementing change to
      assess the integration of implementation strategies into the Program structure. A
      summative evaluation of the Program will bring the research elements together,
      leading to comprehensive data triangulation and determining the sustainability
      and implementational effects of Program delivery. ETHICS AND DISSEMINATION:
      Ethical approval for this study has been granted by Hunter New England Research
      Ethics Committee, New South Wales, Australia (approval ref: 2019/ETH12025).
      Knowledge translation will be achieved through publications, reports and
      conference presentations to healthcare professionals, patients, families and
      researchers. TRIAL REGISTRATION: NCT03336931; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rapport, Frances
AU  - Rapport F
AUID- ORCID: 0000-0002-4428-2826
AD  - Centre for Healthcare Resilience and Implementation Science, Australian Institute
      of Health Innovation, Macquarie University, North Ryde, New South Wales,
      Australia frances.rapport@mq.edu.au.
FAU - Smith, James
AU  - Smith J
AUID- ORCID: 0000-0002-0448-8774
AD  - Centre for Healthcare Resilience and Implementation Science, Australian Institute
      of Health Innovation, Macquarie University, North Ryde, New South Wales,
      Australia.
FAU - O'Brien, Tracey A
AU  - O'Brien TA
AD  - Faculty of Medicine, School of Women's and Children's Health, University of New
      South Wales, Sydney, NSW, Australia.
AD  - Kids Cancer Centre, Sydney Children's Hospital, Randwick, Sydney, Australia.
FAU - Tyrrell, Vanessa J
AU  - Tyrrell VJ
AD  - Lowy Cancer Research Centre, Children's Cancer Institute, University of New South
      Wales, Sydney, New South Wales, Sydney, Australia.
FAU - Mould, Emily Va
AU  - Mould EV
AD  - Lowy Cancer Research Centre, Children's Cancer Institute, University of New South
      Wales, Sydney, New South Wales, Sydney, Australia.
FAU - Long, Janet C
AU  - Long JC
AUID- ORCID: 0000-0002-0553-682X
AD  - Centre for Healthcare Resilience and Implementation Science, Australian Institute
      of Health Innovation, Macquarie University, North Ryde, New South Wales,
      Australia.
FAU - Gul, Hossai
AU  - Gul H
AD  - Centre for Healthcare Resilience and Implementation Science, Australian Institute
      of Health Innovation, Macquarie University, North Ryde, New South Wales,
      Australia.
FAU - Braithwaite, Jeffrey
AU  - Braithwaite J
AUID- ORCID: 0000-0003-0296-4957
AD  - Centre for Healthcare Resilience and Implementation Science, Australian Institute
      of Health Innovation, Macquarie University, North Ryde, New South Wales,
      Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03336931
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Child
MH  - Disease Eradication/methods/organization & administration
MH  - Evidence-Based Practice
MH  - Humans
MH  - Neoplasms/*prevention & control
MH  - Precision Medicine/methods
MH  - Program Development
MH  - Program Evaluation
MH  - Secondary Prevention/methods/organization & administration
PMC - PMC7312332
OTO - NOTNLM
OT  - *childhood cancer, genomics
OT  - *implementation science
OT  - *mixed methods research
OT  - *precision medicine
OT  - *rapid ethnography
OT  - *rapid-cycle evaluation
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf. JB reported grants from NSW Health during
      the conduct of the study. The other authors declared that there are no relevant
      conflicts of interests.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034522 [pii]
AID - 10.1136/bmjopen-2019-034522 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e034522. doi: 10.1136/bmjopen-2019-034522.


PMID- 32580980
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - Effectiveness of a comprehensive care protocol in patients with new diagnoses of 
      type 2 diabetes mellitus and associated comorbidities in primary care: study
      protocol of a quasi-experimental trial.
PG  - e033725
LID - 10.1136/bmjopen-2019-033725 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic
      disease in the Spanish population. Typically, T2DM is associated with other
      chronic conditions. Intensive medication at the time of diagnosis has proven
      effective in reducing cardiovascular risk, improving glycaemic control and
      preventing T2DM complications. However, it has not yet been demonstrated that a
      comprehensive and intensive health education protocol at the time of diagnosis
      has the benefits described previously. Currently, there is great variability in
      the practices of primary care nurses regarding health education at the time of
      disease diagnosis.We aimed to evaluate the effectiveness of a systematic protocol
      with a comprehensive care programme in people with newly diagnosed T2DM with
      associated comorbidities. METHODS AND ANALYSIS: A multicentre quasi-experimental 
      design comparing a group of individuals taking part in the intervention
      (intervention group (IG)) with a similar group receiving standard diabetes care
      (comparison group (CG)) is planned. The intervention will take place during the 3
      months after study enrolment. Data will be collected at baseline and at 3, 6 and 
      12 months. Ten primary care centres in Barcelona city will be selected for
      participation: 5 for the IG and 5 for the CG. The IG will include five structured
      individual visits postdiagnosis with the primary care nurse, during which aspects
      of diabetes education will be discussed with the patient and his/her family. The 
      results will be measured in terms of health-related quality of life and the
      change in main outcomes (glycated haemoglobin and weight). ETHICS AND
      DISSEMINATION: The study fully met the requirements of the Ethical Committee of
      Clinical Investigation of the IDIAP Jordi Gol (approval code: P13/118). Patients 
      will be informed that their data are confidential, and they have the right to
      withdraw at any time without penalty. Dissemination will include publishing the
      findings in peer-reviewed journals and sharing our findings at scientific
      conferences. TRIAL REGISTRATION NUMBER: NCT03990857; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lapena, Carolina
AU  - Lapena C
AUID- ORCID: 0000-0003-0040-6505
AD  - Centre d'Atencio Primaria Sanllehy, Gerencia d'Ambit d'Atencio Primaria Barcelona
      Ciutat, Institut Catala de la Salut, Barcelona, Spain clapena@gencat.cat.
AD  - Unitat de Suport a la Recerca Barcelona Ciutat, Fundacio Institut Universitari
      per a la recerca en Atencio Primaria de Salut Jordi Gol i Gurina (IDIAP Jordi
      Gol), Barcelona, Spain.
FAU - Borras, Enriqueta
AU  - Borras E
AD  - Gerencia Territorial de Barcelona Ciutat, Institut Catala de la Salut, Barcelona,
      Spain.
FAU - Digon, Clarisa
AU  - Digon C
AD  - Centre d'Atencio Primaria Sagrera, Gerencia d'Ambit d'Atencio Primaria Barcelona 
      Ciutat, Institut Catala de la Salut, Barcelona, Spain.
FAU - Aznar, Rosa
AU  - Aznar R
AD  - Centre d'Atencio Primaria Sanllehy, Gerencia d'Ambit d'Atencio Primaria Barcelona
      Ciutat, Institut Catala de la Salut, Barcelona, Spain.
FAU - Del Val Garcia, Jose Luis
AU  - Del Val Garcia JL
AD  - Unitat de Suport a la Recerca Barcelona Ciutat, Fundacio Institut Universitari
      per a la recerca en Atencio Primaria de Salut Jordi Gol i Gurina (IDIAP Jordi
      Gol), Barcelona, Spain.
AD  - Unidad de Evaluacion, Sistemas de Informacion y Calidad, Institut Catala de la
      Salut, Barcelona, Spain.
FAU - Castelblanco, Esmeralda
AU  - Castelblanco E
AUID- ORCID: 0000-0002-2061-6270
AD  - DAP-Cat Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut
      Universitari per a la Recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina
      (IDIAPJGol), Barcelona, Spain.
AD  - Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau &
      Institut d'Investigacio Biomedica Sant Pau (IIB Sant Pau) & Centre for Biomedical
      Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Barcelona,
      Spain.
FAU - Garaikoetxea, Ana
AU  - Garaikoetxea A
AD  - Centre d'Atencio Primaria Sanllehy, Gerencia d'Ambit d'Atencio Primaria Barcelona
      Ciutat, Institut Catala de la Salut, Barcelona, Spain.
FAU - Laguna, Vicencia
AU  - Laguna V
AD  - Centre d'Atencio Primaria Sanllehy, Gerencia d'Ambit d'Atencio Primaria Barcelona
      Ciutat, Institut Catala de la Salut, Barcelona, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03990857
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Comorbidity
MH  - *Comprehensive Health Care
MH  - Diabetes Mellitus, Type 2/*therapy
MH  - Humans
MH  - *Primary Health Care
MH  - Research Design
MH  - Spain
PMC - PMC7312326
OTO - NOTNLM
OT  - *comorbidities
OT  - *comprehensive care
OT  - *type 2 diabetes mellitus
COIS- Competing interests: None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-033725 [pii]
AID - 10.1136/bmjopen-2019-033725 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e033725. doi: 10.1136/bmjopen-2019-033725.


PMID- 32580978
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 23
TI  - Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial 
      devascularisation versus endoscopic therapy for secondary prophylaxis for
      variceal rebleeding in portal hypertension (CHESS1803): study protocol of a
      multicenter randomised controlled trial in China.
PG  - e030960
LID - 10.1136/bmjopen-2019-030960 [doi]
AB  - INTRODUCTION: Gastro-oesophageal variceal bleeding is one of the most common and 
      severe complications with high mortality in cirrhotic patients who developed
      portal hypertension. Hepatic venous pressure gradient (HVPG) is a globally
      recommended golden standard for the portal pressure assessment and an HVPG >/=16 
      mm Hg indicates a higher risk of death and rebleeding. This study aims to compare
      the effectiveness and safety of splenectomy and pericardial devascularisation
      (laparoscopic therapy) plus propranolol and endoscopic therapy plus propranolol
      for variceal rebleeding in cirrhotic patients with HVPG between 16 and 20 mm Hg. 
      METHODS AND ANALYSIS: This is a multicenter, randomised, controlled clinical
      trial. Participants will be 1:1 assigned randomly into either laparoscopic or
      endoscopic groups. Forty participants whose transjugular HVPG lies between 16 and
      20 mm Hg with a history of gastro-oesophageal variceal bleeding will be recruited
      from three sites in China. Participants will receive either endoscopic therapy
      plus propranolol or laparoscopic therapy plus propranolol. The primary outcome
      measure will be the occurrence of gastro-oesophageal variceal rebleeding.
      Secondary outcome measures will include overall survival, occurrence of
      hepatocellular carcinoma, the occurrence of venous thrombosis, the occurrence of 
      adverse events, quality of life and tolerability of treatment. Outcome measures
      will be evaluated at baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks and 60
      weeks. Multivariate COX regression model will be introduced for analyses of
      occurrence data and Kaplan-Meier analysis with the log-rank test for intergroup
      comparison. ETHICS AND DISSEMINATION: Ethical approval was obtained from all
      three participating sites. Primary and secondary outcome data will be submitted
      for publication in peer-reviewed journals and widely disseminated. TRIAL
      REGISTRATION NUMBER: NCT03783065; Pre-results. TRIAL STATUS: Recruitment for this
      study started in December 2018 while the first participant was randomised in
      January 2019. Recruitment is estimated to stop in October 2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shao, Ruoyang
AU  - Shao R
AUID- ORCID: 0000-0002-7939-2232
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
AD  - Department of Hematology, Nanfang Hospital, Southern Medical University,
      Guangzhou, China.
FAU - Li, Zhiwei
AU  - Li Z
AD  - Department of Hepatobiliary Surgery, The Third People's Hospital of Shenzhen,
      Shenzhen, China.
FAU - Wang, Jitao
AU  - Wang J
AD  - Department of Hepatobiliary Surgery, Xingtai Institute of Cancer Control,
      Xingtai, China.
FAU - Qi, Ruizhao
AU  - Qi R
AD  - Department of General Surgery, The Fifth Medical Center of PLA General Hospital, 
      Beijing, China.
FAU - Liu, Qingbo
AU  - Liu Q
AD  - Department of Hepatobiliary Surgery, Shunde Hospital, Southern Medical
      University, Foshan, China.
FAU - Zhang, Weijie
AU  - Zhang W
AD  - Department of Hepatobiliary Surgery, Shunde Hospital, Southern Medical
      University, Foshan, China.
FAU - Mao, Xiaorong
AU  - Mao X
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
FAU - Song, Xiaojing
AU  - Song X
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
FAU - Li, Lei
AU  - Li L
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
FAU - Liu, Yanna
AU  - Liu Y
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
FAU - Zhao, Xin
AU  - Zhao X
AD  - Department of Hepatobiliary Surgery, The Third People's Hospital of Shenzhen,
      Shenzhen, China.
FAU - Liu, Chuan
AU  - Liu C
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
FAU - Li, Xun
AU  - Li X
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China.
FAU - Zuo, Changzeng
AU  - Zuo C
AD  - Department of Hepatobiliary Surgery, Xingtai Institute of Cancer Control,
      Xingtai, China.
FAU - Wang, Weidong
AU  - Wang W
AD  - Department of Hepatobiliary Surgery, Shunde Hospital, Southern Medical
      University, Foshan, China qixiaolong@vip.163.com weiweih@126.com.
FAU - Qi, Xiaolong
AU  - Qi X
AD  - CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou
      University, Lanzhou, China qixiaolong@vip.163.com weiweih@126.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03783065
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - China
MH  - Combined Modality Therapy
MH  - Esophageal and Gastric Varices/*etiology/*surgery
MH  - Gastrointestinal Hemorrhage/*prevention & control
MH  - Humans
MH  - Hypertension, Portal/*complications
MH  - Laparoscopy/*methods
MH  - Multicenter Studies as Topic
MH  - Portal Pressure
MH  - Propranolol/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Research Design
MH  - Secondary Prevention
MH  - Splenectomy/*methods
PMC - PMC7312451
OTO - NOTNLM
OT  - *endoscopy
OT  - *hepatobiliary disease
OT  - *hepatobiliary surgery
OT  - *hepatology
COIS- Competing interests: None declared.
EDAT- 2020/06/26 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-030960 [pii]
AID - 10.1136/bmjopen-2019-030960 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 23;10(6):e030960. doi: 10.1136/bmjopen-2019-030960.


PMID- 32580828
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 6
DP  - 2020 Jun 1
TI  - Should Art About Child Abuse Be Exhibited in Corridors of Health Professional
      Schools?
PG  - E525-534
LID - amajethics.2020.525 [pii]
LID - 10.1001/amajethics.2020.525 [doi]
AB  - Imagine an exhibition-on a topic like child sexual abuse, dementia, or epilepsy, 
      for example-not typically considered by museums or galleries. The question, then,
      is Where might such an exhibit be displayed? How about a medical school, for
      instance? An exhibition of this kind might include visceral psychological
      portraits and explanatory text tailored to the learning activities of medical
      students. This article examines these curatorial and ethical considerations.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Abramson, Paul R
AU  - Abramson PR
AD  - Professor of psychology at the University of California, Los Angeles.
FAU - Abramson, Tania L
AU  - Abramson TL
AD  - Lecturer in the Honors Collegium at the University of California, Los Angeles.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Child
MH  - *Child Abuse
MH  - *Child Abuse, Sexual
MH  - Humans
MH  - Museums
MH  - Schools, Medical
MH  - *Students, Medical
EDAT- 2020/06/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.525 [pii]
AID - 10.1001/amajethics.2020.525 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Jun 1;22(6):E525-534. doi: 10.1001/amajethics.2020.525.


PMID- 32580824
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 6
DP  - 2020 Jun 1
TI  - Anthony and the Role of Silence in Portraiture in Clinical Settings.
PG  - E488-498
LID - amajethics.2020.488 [pii]
LID - 10.1001/amajethics.2020.488 [doi]
AB  - This article describes one collaborative arts-based research project. Portrait
      artist Mark Gilbert and coinvestigators consider lessons for art and healing from
      one patient, Anthony, whose experience of head and neck cancer diagnosis,
      surgery, and recovery suggests how silence is ethically, artistically, and
      clinically significant.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Gilbert, Mark
AU  - Gilbert M
AD  - Research associate with the Faculty of Medicine at Dalhousie University in
      Halifax, Nova Scotia, Canada.
FAU - Idoate, Regina
AU  - Idoate R
AD  - Assistant professor of health promotion in the College of Public Health at the
      University of Nebraska Medical Center in Omaha.
FAU - Desmarais, Michele Marie
AU  - Desmarais MM
AD  - Associate professor in religious studies and Native American studies and founding
      director of the medical humanities minor at the University of Nebraska Omaha.
FAU - Lydiatt, William M
AU  - Lydiatt WM
AD  - Vice president of medical affairs and chief medical officer of Methodist Hospital
      in Omaha, Nebraska.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Art
MH  - Humans
EDAT- 2020/06/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.488 [pii]
AID - 10.1001/amajethics.2020.488 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Jun 1;22(6):E488-498. doi: 10.1001/amajethics.2020.488.


PMID- 32580821
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 6
DP  - 2020 Jun 1
TI  - Practicing Regard in Clinical Portraiture.
PG  - E470-475
LID - amajethics.2020.470 [pii]
LID - 10.1001/amajethics.2020.470 [doi]
AB  - This article describes one collaborative arts-based research project. Portrait
      artist Mark Gilbert considers lessons for art and healing from one patient, John,
      whose cancer and portraiture experiences illuminate features of ethical and
      aesthetic significance about what it means to witness-to regard another's
      difficult health and health care experiences.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Gilbert, Mark
AU  - Gilbert M
AD  - Research associate with the Faculty of Medicine at Dalhousie University in
      Halifax, Nova Scotia, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Art
MH  - Esthetics
MH  - Humans
EDAT- 2020/06/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.470 [pii]
AID - 10.1001/amajethics.2020.470 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Jun 1;22(6):E470-475. doi: 10.1001/amajethics.2020.470.


PMID- 32580648
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20201218
IS  - 1477-111X (Electronic)
IS  - 0267-6591 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Sep
TI  - Ethics and extracorporeal membrane oxygenation during coronavirus disease 2019
      outbreak.
PG  - 562-564
LID - 10.1177/0267659120937545 [doi]
FAU - Di Nardo, Matteo
AU  - Di Nardo M
AUID- ORCID: 0000-0003-0051-8080
AD  - Pediatric Intensive Care Unit, Children's Hospital Bambino Gesu, Rome, Italy.
FAU - Dalle Ore, Anna
AU  - Dalle Ore A
AD  - Clinical Bioethics, Children's Hospital Bambino Gesu, Rome, Italy.
FAU - Starr, Joanne
AU  - Starr J
AD  - Division of Cardiothoracic Surgery, CHOC Children's Hospital Orange County,
      Orange, CA, USA.
FAU - Cecchetti, Corrado
AU  - Cecchetti C
AD  - Pediatric Intensive Care Unit, Children's Hospital Bambino Gesu, Rome, Italy.
FAU - Amodeo, Antonio
AU  - Amodeo A
AD  - ECMO and VAD Unit, Children's Hospital Bambino Gesu, Rome, Italy.
FAU - Testa, Giuseppina
AU  - Testa G
AD  - Pediatric Cardiac Intensive Care Unit, Children's Hospital Bambino Gesu, Rome,
      Italy.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200625
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
SB  - IM
CON - Lancet Respir Med. 2020 May;8(5):518-526. PMID: 32203711
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Communicable Diseases, Emerging
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Respiratory Distress Syndrome
MH  - SARS-CoV-2
EDAT- 2020/06/26 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/06/26 06:00
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/06/26 06:00 [entrez]
AID - 10.1177/0267659120937545 [doi]
PST - ppublish
SO  - Perfusion. 2020 Sep;35(6):562-564. doi: 10.1177/0267659120937545. Epub 2020 Jun
      25.


PMID- 32580213
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20201218
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Jun 15
TI  - COVID-19 and the role of imaging: early experiences in Central Switzerland.
PG  - w20304
LID - 10.4414/smw.2020.20304 [doi]
LID - Swiss Med Wkly. 2020;150:w20304 [pii]
AB  - The SARS-CoV-2 virus (COVID-19) was initially observed in a group of Chinese
      patients with unclear pneumonia in Wuhan, Hubei [1] in late December 2019. The
      first positive case in Switzerland was confirmed on 25 February 2020 in a patient
      from canton Tessin, who most likely caught the virus during a visit to Milan,
      Italy [2]. The country has since been preparing for an imminent public health
      emergency caused by the pandemic. As of 14 May 2020, the Swiss healthcare system 
      is facing a total of 30,463 corona virus-positive people [3]. With numbers of new
      infections decreasing after the first pandemic wave, the continuing endemic
      situation will continue to be a major challenge for the Swiss healthcare system. 
      It remains crucial to separate the clinically low-symptomatic from the severely
      affected patients in order to offer a specific therapeutic strategy to every
      SARS-CoV-2 patient. Reports from Chinese cohorts describe an increasing role of
      imaging strategies in the detection and surveillance of COVID-19 patients because
      of insufficient testing sensitivity of real-time reverse transcription polymerase
      chain reaction (RT-PCR) tests [4]. Chest computed tomography (CT), with a
      reported sensitivity of up to 97% [5, 6], gained importance particularly in
      patients with false negative RT-PCR results. In this short communication, we
      describe our first clinical experiences with 55 COVID-19 patients in Central
      Switzerland, who were either imaged with a standard chest x-ray, chest CT, or
      both. We provide an illustrative and schematic description of typical COVID-19
      imaging features and suggest that imaging plays an important role in the clinical
      work-up of suspected or confirmed COVID-19 patients. This study was approved by
      the national ethics review committee (EKNZ, Switzerland) and patients&rsquo;
      informed consent was waived.
FAU - Fechner, Carsten
AU  - Fechner C
AD  - Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Switzerland.
FAU - Strobel, Klaus
AU  - Strobel K
AD  - Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Switzerland.
FAU - Treumann, Thomas
AU  - Treumann T
AD  - Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Switzerland.
FAU - Sonderegger, Beat
AU  - Sonderegger B
AD  - Institute of Infectious Diseases, Cantonal Hospital Lucerne, Switzerland.
FAU - Azzola, Andrea
AU  - Azzola A
AD  - Institute of Pulmonology, Cantonal Hospital Lucerne, Switzerland.
FAU - Fornaro, Jurgen
AU  - Fornaro J
AD  - Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Switzerland.
FAU - Schrading, Simone
AU  - Schrading S
AD  - Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Switzerland.
FAU - Roos, Justus E
AU  - Roos JE
AD  - Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200622
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
CON - Thromb Res. 2020 Jul;191:145-147. PMID: 32291094
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Critical Illness
MH  - Humans
MH  - Incidence
MH  - Intensive Care Units
MH  - Italy
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Switzerland
EDAT- 2020/06/25 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
AID - 10.4414/smw.2020.20304 [doi]
AID - Swiss Med Wkly. 2020;150:w20304 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Jun 22;150:w20304. doi: 10.4414/smw.2020.20304. eCollection 
      2020 Jun 15.


PMID- 32580050
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20210209
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 153
DP  - 2020 Aug
TI  - Chick embryo chorioallantoic membrane as a suitable in vivo model to evaluate
      drug delivery systems for cancer treatment: A review.
PG  - 273-284
LID - S0939-6411(20)30179-X [pii]
LID - 10.1016/j.ejpb.2020.06.010 [doi]
AB  - Cancer represents a significant public health problem. More than 18.1 million
      people are annually diagnosed with cancer and 9.6 million die mainly due to
      metastatic disease. Chemotherapy has been one of the main cancer treatment
      modalities; however, most of the chemotherapeutic agents are non-specific,
      exhibiting several toxic side effects, which compromises the patient's quality of
      life. Therefore, it is necessary to search for new therapeutic alternatives,
      using for example, drug delivery systems (DDS) to target cancer cells, increasing
      the selectivity of chemotherapeutic drugs. This approach is promising; however,
      it is crucial to evaluate the biological performance of the systems. Although
      mammalian models continue to be explored for clinical applications, they are
      time-consuming and very restrictive from the ethical and legal perspectives.
      Hence, the chick embryo chorioallantoic membrane (CAM) has been shown to be a
      suitable in vivo model since it allows a more appropriate model for the study of 
      drugs and/or DDS performance than in vitro tests. Thereby, this article revises
      the recent advances of DDS for cancer therapy, evaluating the feasibility of the 
      CAM model.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Victorelli, Francesca Damiani
AU  - Victorelli FD
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Drugs and Medicines, Araraquara, SP ZIP Code 14800-903, Brazil. Electronic
      address: francesca.victorelli@unesp.com.
FAU - Cardoso, Valeria Maria de Oliveira
AU  - Cardoso VMO
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Drugs and Medicines, Araraquara, SP ZIP Code 14800-903, Brazil. Electronic
      address: vm.cardoso@unesp.br.
FAU - Ferreira, Natalia Noronha
AU  - Ferreira NN
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Drugs and Medicines, Araraquara, SP ZIP Code 14800-903, Brazil. Electronic
      address: natalia.noronha@unesp.br.
FAU - Calixto, Giovana Maria Fioramonti
AU  - Calixto GMF
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Drugs and Medicines, Araraquara, SP ZIP Code 14800-903, Brazil; UNICAMP,
      University of Campinas, Piracicaba Dental School Department of Biosciences,
      Piracicaba, SP ZIP Code 13414-903, Brazil. Electronic address:
      gcalixto@unicamp.br.
FAU - Fontana, Carla Raquel
AU  - Fontana CR
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Clinical Analysis, Araraquara, SP ZIP Code 14800-903, Brazil. Electronic
      address: carla.fontana@unesp.br.
FAU - Baltazar, Fatima
AU  - Baltazar F
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine,
      University of Minho, Braga ZIP Code 4710-057, Portugal; ICVS/3B's-PT Government
      Associate Laboratory, Braga/Guimaraes ZIP Code 4710-057/4806-909, Portugal.
      Electronic address: fbaltazar@med.uminho.pt.
FAU - Gremiao, Maria Palmira Daflon
AU  - Gremiao MPD
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Drugs and Medicines, Araraquara, SP ZIP Code 14800-903, Brazil. Electronic
      address: palmira.gremiao@unesp.br.
FAU - Chorilli, Marlus
AU  - Chorilli M
AD  - UNESP, Sao Paulo State University, School of Pharmaceutical Sciences, Department 
      of Drugs and Medicines, Araraquara, SP ZIP Code 14800-903, Brazil. Electronic
      address: marlus.chorilli@unesp.br.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200621
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/*therapeutic use
MH  - Chick Embryo
MH  - Chorioallantoic Membrane/*metabolism
MH  - Drug Delivery Systems/*methods
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Quality of Life
OTO - NOTNLM
OT  - Angiogenesis
OT  - Anti-angiogenic
OT  - CAM model
OT  - Cancer
OT  - Chicken embryos
OT  - Drug delivery systems
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/06/25 06:00
MHDA- 2021/02/10 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - S0939-6411(20)30179-X [pii]
AID - 10.1016/j.ejpb.2020.06.010 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2020 Aug;153:273-284. doi: 10.1016/j.ejpb.2020.06.010. Epub
      2020 Jun 21.


PMID- 32579700
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Jun 15
TI  - Deficiencies in paediatric research applications delaying ethics committee
      approval.
PG  - w20267
LID - 10.4414/smw.2020.20267 [doi]
LID - Swiss Med Wkly. 2020;150:w20267 [pii]
AB  - BACKGROUND: A clinical research application must be submitted for approval by a
      competent ethics committee (EC) before a study can be executed. There is very
      limited information on how such submissions could be optimised, especially
      regarding research in children and adolescents, which requires particular caution
      and age-adapted patient information. METHODS: We assessed all research
      applications from the University Children&rsquo;s Hospital Zurich submitted to
      the EC of the Canton of Zurich in 2014&ndash;2015, i.e., in the first two years
      after Switzerland&rsquo;s new Human Research Act came into effect. Moreover, we
      validated our findings by assessing a randomly selected sample of applications
      from the same hospital in 2018&ndash;2019. RESULTS: We assessed a total of 86
      applications from 2014&ndash;2015, originating from 29 departments and
      sub-specialties. The EC judged that it was not responsible for three applications
      and declined an assessment for another three because the studies had already been
      conducted. Thus, we included 80 applications in the present analysis (18 clinical
      trials, 52 research projects, 10 further use projects). Applicants withdrew four 
      applications before the EC&rsquo;s final decision and the EC rejected two after
      assessment. The EC had objections in 46 (62%) of the remaining 74 applications.
      Formal, including formal legal, objections (n = 503) and legal objections (n =
      287) accounted for the vast majority of objections. There were also 71 ethical
      and 82 scientific objections. The most frequent formal and formal legal
      objections were incomplete or missing age-adapted patient information (49%) and
      incorrect templates for informed consent and signature forms (46%). A review of
      the 20 randomly selected applications from 2018&ndash;2019 confirmed that four
      out of the five most frequent deficiencies relating to informed consent were
      identical to those observed in the 2014&ndash;2015 applications. CONCLUSIONS:
      Careful preparation of submission documents by the investigators and close
      adherence to formal and legal requirements have the potential to considerably
      optimise and expedite the EC review process, and thus the commencement of the
      clinical research. &nbsp; &nbsp.
FAU - Bergstraesser, Eva
AU  - Bergstraesser E
AD  - Department of Paediatric Palliative Care and Paediatric Oncology, University
      Children's Hospital Zurich, Switzerland.
FAU - Nadal, David
AU  - Nadal D
AD  - Department of Infectious Diseases and Children's Research Centre, University
      Children's Hospital Zurich, Switzerland.
FAU - Ozgu, Hilal
AU  - Ozgu H
AD  - Medical Faculty of the University of Zurich, Switzerland.
FAU - Kleist, Peter
AU  - Kleist P
AD  - Research Ethics Committee of the Canton of Zurich (Kantonale Ethikkommission),
      Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200619
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Ethics Committees
MH  - Ethics Committees, Research
MH  - Humans
MH  - *Informed Consent
EDAT- 2020/06/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.4414/smw.2020.20267 [doi]
AID - Swiss Med Wkly. 2020;150:w20267 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Jun 19;150:w20267. doi: 10.4414/smw.2020.20267. eCollection 
      2020 Jun 15.


PMID- 32579537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 17
TI  - Development of an International, Multicenter, Hyperbaric Oxygen Treatment
      Registry and Research Consortium: Protocol for Outcome Data Collection and
      Analysis.
PG  - e18857
LID - 10.2196/18857 [doi]
AB  - BACKGROUND: Hyperbaric oxygen (HBO2)-oxygen at pressures higher than
      atmospheric-is approved for 14 indications by the Undersea and Hyperbaric Medical
      Society. HBO2's main effect is to increase oxygen content in plasma and body
      tissues, which can counteract hypoxia or ischemia. Laboratory studies show that
      HBO2 has effects beyond relieving hypoxia (eg, promoting angiogenesis in
      irradiated tissue, anti-inflammatory effects, radiosensitization of tumors,
      hypoxia preconditioning, and fungal growth inhibition) and has potential to treat
      conditions such as inflammatory bowel disease and pyoderma gangrenosum. Lack of
      consistently collected outcome data on a large cohort of individuals receiving
      HBO2 therapy limits its use for both established and new indications. A course of
      therapy often involves 30-40 visits to a hyperbaric chamber, so the number of
      patients seen at any given center is constrained by chamber capacity. As a
      result, published HBO2 outcome data tend to be from small case series because few
      patients with a particular condition are treated at a given center. To solve this
      problem, a registry that collects and pools data systematically from multiple
      institutions has been established. OBJECTIVE: The aim of this study is to collect
      consistent outcome data across multiple hyperbaric centers to assess treatment
      effectiveness and establish a research consortium. METHODS: A consortium of
      hyperbaric centers who have agreed to collect consistent outcome data on all
      patients seen has been assembled. Data are collected at each participating center
      using Research Electronic Data Capture (REDCap), a web-based, data collection
      system used frequently for research. Standard outcome measures have been defined 
      for each condition, which are programmed into the REDCap data collection
      templates. Governance is through a consortium agreement that defines data
      security, data sharing, publications, liability, and other issues. Centers obtain
      Institutional Review Board (IRB) and ethics approval to participate, either from 
      their own institutions or by relying on the IRB at the coordinating center at
      Dartmouth College. Dissemination will occur through a yearly report and by
      publications based on the data in the registry. RESULTS: Early results from some 
      common indications show significant pretreatment to posttreatment changes.
      Additional indications and outcome measures are being added using the procedures 
      outlined in the consortium agreement. CONCLUSIONS: The registry collects
      consistent outcome information for a therapy that needs further study and a
      stronger evidence base. It also overcomes the challenge of collecting data from
      an adequate number of patients for both established and emerging indications by
      combining data collection from multiple centers. The data entry requirements
      should be within the capabilities of existing staff at any given hyperbaric
      center. By using REDCap, the registry can be expanded to include detailed
      information on particular indications and long-term follow-up on selected
      patients without significantly increasing the basic data entry requirements.
      Through the registry, a network of enrolled hyperbaric centers has been
      established that provides the basis for a clinical trial network. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18857.
CI  - (c)Nicole P Harlan, Judy A Ptak, Judy R Rees, Devin R Cowan, Abigail M Fellows,
      Judith A Kertis, Pamela M Hannigan, Janet L Peacock, Jay C Buckey. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      17.08.2020.
FAU - Harlan, Nicole P
AU  - Harlan NP
AUID- ORCID: https://orcid.org/0000-0002-0803-290X
AD  - Center for Hyperbaric Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 
      United States.
FAU - Ptak, Judy A
AU  - Ptak JA
AUID- ORCID: https://orcid.org/0000-0002-5379-5199
AD  - Center for Hyperbaric Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 
      United States.
FAU - Rees, Judy R
AU  - Rees JR
AUID- ORCID: https://orcid.org/0000-0002-8232-1056
AD  - Space Medicine Innovations Laboratory, Center for Hyperbaric Medicine, Geisel
      School of Medicine at Dartmouth, Lebanon, NH, United States.
FAU - Cowan, Devin R
AU  - Cowan DR
AUID- ORCID: https://orcid.org/0000-0003-4621-0559
AD  - Space Medicine Innovations Laboratory, Center for Hyperbaric Medicine, Geisel
      School of Medicine at Dartmouth, Lebanon, NH, United States.
FAU - Fellows, Abigail M
AU  - Fellows AM
AUID- ORCID: https://orcid.org/0000-0003-2473-3578
AD  - Space Medicine Innovations Laboratory, Center for Hyperbaric Medicine, Geisel
      School of Medicine at Dartmouth, Lebanon, NH, United States.
FAU - Kertis, Judith A
AU  - Kertis JA
AUID- ORCID: https://orcid.org/0000-0001-8726-3855
AD  - Center for Hyperbaric Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 
      United States.
FAU - Hannigan, Pamela M
AU  - Hannigan PM
AUID- ORCID: https://orcid.org/0000-0003-1536-7932
AD  - Center for Hyperbaric Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 
      United States.
FAU - Peacock, Janet L
AU  - Peacock JL
AUID- ORCID: https://orcid.org/0000-0002-0310-2518
AD  - Space Medicine Innovations Laboratory, Center for Hyperbaric Medicine, Geisel
      School of Medicine at Dartmouth, Lebanon, NH, United States.
FAU - Buckey, Jay C
AU  - Buckey JC
AUID- ORCID: https://orcid.org/0000-0003-4591-4431
AD  - Space Medicine Innovations Laboratory, Center for Hyperbaric Medicine, Geisel
      School of Medicine at Dartmouth, Lebanon, NH, United States.
LA  - eng
PT  - Journal Article
DEP - 20200817
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7459436
OTO - NOTNLM
OT  - effectiveness
OT  - health data
OT  - hyperbaric oxygenation
OT  - measure
OT  - outcome
OT  - oxygen treatment
OT  - patient reported
OT  - patient-reported outcome measures
OT  - registries
OT  - registry
OT  - treatment
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/06/19 00:00 [revised]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - v9i8e18857 [pii]
AID - 10.2196/18857 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 17;9(8):e18857. doi: 10.2196/18857.


PMID- 32579120
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2291-5222 (Electronic)
IS  - 2291-5222 (Linking)
VI  - 8
IP  - 6
DP  - 2020 Jun 24
TI  - Elderly Medication Adherence Intervention Using the My Interventional
      Drug-Eluting Stent Educational App: Multisite Randomized Feasibility Trial.
PG  - e15900
LID - 10.2196/15900 [doi]
AB  - BACKGROUND: A lifesaving treatment for myocardial infarction is the placement of 
      a stent in a closed or obstructed coronary artery. The largest modifiable risk
      factor after receiving a stent is medication adherence to Dual AntiPlatelet
      Therapy, a combination of P2Y12 inhibitors and aspirin. OBJECTIVE: This study
      aimed to determine the acceptability of a protocol and an intervention using the 
      My Interventional Drug-Eluting Stent Educational App (MyIDEA) and to evaluate
      medication adherence using the proportion of days covered (PDC) and platelet
      activation tests in a multisite randomized controlled trial. METHODS: Potential
      participants who received a post percutaneous coronary intervention (PCI)
      procedure with a drug-eluting stent were approached. All patients older than 50
      years and who spoke English were recruited. Participants were recruited, baseline
      demographics were collected, and the Hospital Anxiety and Depression Scale
      (HADS), Rapid Estimate of Adult Literacy in Medicine-Short Form, Burden-Benefit
      questionnaire, 36-Item Short Form Health Survey, and PCI knowledge questionnaire 
      were administered. Block randomization was used to randomize participants to
      either usual care or MyIDEA supplementation. MyIDEA is a personalized educational
      intervention based on the Kolb experiential learning theory using patient
      narratives for education. During the visits, participants' blood was collected to
      measure platelet suppression from medication. During the second and third
      encounters, the Morisky medication adherence score and cardiology outcomes were
      measured. The study was conducted at the University of Illinois Hospital and John
      H Stroger Jr Cook County Hospital with appropriate ethical approvals. Platelet
      suppression was measured through aspirin reactive units and P2Y12 reactive units.
      Medication adherence was measured using the PDC. The analysis team was blinded to
      the participants' group membership. The primary outcome was a feasibility
      analysis of recruitment and retention. RESULTS: The mean age of participants was 
      60.4 years (SD 7.1); the majority of patients were black and non-Hispanic. The
      majority of patients' reading levels were seventh grade or above, and they were
      not very familiar with other electronic devices for information and
      communication. The number of control subjects was 21, and the number of
      participants in the interventional arm was 24. The interventional group was able 
      to use MyIDEA in both the hospital and outpatient setting. However, there was no 
      significant difference in platelet suppression or medication adherence between
      groups. There were also differences between the groups in terms of depression and
      anxiety, initially, as measured by HADS. No documented adverse event associated
      with the intervention was found. CONCLUSIONS: Elderly patients are willing to use
      tablet devices to be educated about health conditions. Additional studies are
      required to measure the effectiveness and determine the most suitable timing and 
      location for patient education. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT04439864; https://clinicaltrials.gov/ct2/show/NCT04439864.
CI  - (c)Andrew Dallas Boyd, Chioma Iheanyi Ndukwe, Anandu Dileep, Olivia Frances
      Everin, Yingwei Yao, Betty Welland, Jerry Field, Matt Baumann, Jose D Flores Jr, 
      Adhir Shroff, Vicki Groo, Carolyn Dickens, Rami Doukky, Regeena Francis,
      Geraldine Peacock, Diana J Wilkie. Originally published in JMIR mHealth and
      uHealth (http://mhealth.jmir.org), 24.06.2020.
FAU - Boyd, Andrew Dallas
AU  - Boyd AD
AUID- ORCID: 0000-0002-3459-9379
AD  - Department of Biomedical and Health Information Science, University of Illinois
      at Chicago, Chicago, United States.
FAU - Ndukwe, Chioma Iheanyi
AU  - Ndukwe CI
AUID- ORCID: 0000-0002-7666-3615
AD  - Department of Biomedical and Health Information Science, University of Illinois
      at Chicago, Chicago, United States.
FAU - Dileep, Anandu
AU  - Dileep A
AUID- ORCID: 0000-0003-3622-114X
AD  - Department of Biomedical and Health Information Science, University of Illinois
      at Chicago, Chicago, United States.
FAU - Everin, Olivia Frances
AU  - Everin OF
AUID- ORCID: 0000-0002-9518-3115
AD  - Department of Biomedical and Health Information Science, University of Illinois
      at Chicago, Chicago, United States.
FAU - Yao, Yingwei
AU  - Yao Y
AUID- ORCID: 0000-0001-5389-2717
AD  - Biobehavioral Nursing Science, University of Florida, Gainesville, FL, United
      States.
FAU - Welland, Betty
AU  - Welland B
AUID- ORCID: 0000-0003-2654-157X
AD  - Patient Advisor, Department of Biomedical and Health Information Sciences,
      University of Illinois at Chicago, Chicago, IL, United States.
FAU - Field, Jerry
AU  - Field J
AUID- ORCID: 0000-0002-9252-3743
AD  - Patient Advisor, Department of Biomedical and Health Information Sciences,
      University of Illinois at Chicago, Chicago, IL, United States.
FAU - Baumann, Matt
AU  - Baumann M
AUID- ORCID: 0000-0003-0194-281X
AD  - Patient Advisor, Department of Biomedical and Health Information Sciences,
      University of Illinois at Chicago, Chicago, IL, United States.
FAU - Flores, Jose D Jr
AU  - Flores JD Jr
AUID- ORCID: 0000-0002-5909-5919
AD  - Patient Advisor, Department of Biomedical and Health Information Sciences,
      University of Illinois at Chicago, Chicago, IL, United States.
FAU - Shroff, Adhir
AU  - Shroff A
AUID- ORCID: 0000-0003-3964-9619
AD  - Department of Biomedical and Health Information Science, University of Illinois
      at Chicago, Chicago, United States.
FAU - Groo, Vicki
AU  - Groo V
AUID- ORCID: 0000-0003-1288-7430
AD  - Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, 
      United States.
FAU - Dickens, Carolyn
AU  - Dickens C
AUID- ORCID: 0000-0003-3395-8357
AD  - Department of Biomedical and Health Information Science, University of Illinois
      at Chicago, Chicago, United States.
FAU - Doukky, Rami
AU  - Doukky R
AUID- ORCID: 0000-0001-9767-9344
AD  - Divison of Cardiology, Cook County Health, Chicago, IL, United States.
FAU - Francis, Regeena
AU  - Francis R
AUID- ORCID: 0000-0001-5268-5150
AD  - Divison of Cardiology, Cook County Health, Chicago, IL, United States.
FAU - Peacock, Geraldine
AU  - Peacock G
AUID- ORCID: 0000-0001-7908-9121
AD  - Divison of Cardiology, Cook County Health, Chicago, IL, United States.
FAU - Wilkie, Diana J
AU  - Wilkie DJ
AUID- ORCID: 0000-0002-3954-8933
AD  - Biobehavioral Nursing Science, University of Florida, Gainesville, FL, United
      States.
LA  - eng
SI  - ClinicalTrials.gov/NCT04439864
GR  - P30 AG022849/AG/NIA NIH HHS/United States
GR  - P30 NR010680/NR/NINR NIH HHS/United States
GR  - UL1 TR000050/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20200624
PL  - Canada
TA  - JMIR Mhealth Uhealth
JT  - JMIR mHealth and uHealth
JID - 101624439
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Drug-Eluting Stents
MH  - Feasibility Studies
MH  - Humans
MH  - Medication Adherence
MH  - Middle Aged
MH  - *Mobile Applications
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/therapeutic use
PMC - PMC7381043
OTO - NOTNLM
OT  - *Kolb learning theory
OT  - *drug eluting stents
OT  - *medication adherence
OT  - *mobile application
OT  - *patient education
OT  - *percutaneous coronary intervention
EDAT- 2020/06/25 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/25 06:00
PHST- 2019/08/16 00:00 [received]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2019/12/20 00:00 [revised]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - v8i6e15900 [pii]
AID - 10.2196/15900 [doi]
PST - epublish
SO  - JMIR Mhealth Uhealth. 2020 Jun 24;8(6):e15900. doi: 10.2196/15900.


PMID- 32579117
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 24
TI  - Digital Game Interventions for Youth Mental Health Services (Gaming My Way to
      Recovery): Protocol for a Scoping Review.
PG  - e13834
LID - 10.2196/13834 [doi]
AB  - BACKGROUND: Digital or video games are played by millions of adolescents and
      young adults around the world and are one of the technologies used by youths to
      access mental health services. Youths with mental health problems strongly
      endorse the use of technologies, including mobile and online platforms, to
      receive information, support their treatment journeys (eg, decision-making
      tools), and facilitate recovery. A growing body of literature explores the
      advantages of playing digital games for improving attention span and memory,
      managing emotions, promoting behavior change, and supporting treatment for mental
      illness (eg, anxiety, depression, or posttraumatic stress disorder). The research
      field has also focused on the negative impact of video games, describing
      potential harms related to aggression, addiction, and depression. To promote
      clarity on this matter, there is a great need for knowledge synthesis offering
      recommendations on how video games can be safely and effectively adopted and
      integrated into youth mental health services. OBJECTIVE: The Gaming My Way to
      Recovery scoping review project assesses existing evidence on the use of digital 
      game interventions within the context of mental health services for youths (aged 
      11-29 years) using the stepped care model as the conceptual framework. The
      research question is as follows: For which youth mental health conditions have
      digital games been used and what broad objectives (eg, prevention, treatment)
      have they addressed? METHODS: Using the methodology proposed by Arksey and
      O'Malley, this scoping review will map the available evidence on the use of
      digital games for youths between 11 and 29 years old with mental health or
      substance use problems, or both. RESULTS: The review will bring together
      evidence-based knowledge to assist mental health providers and policymakers in
      evaluating the potential benefits and risks of these interventions. Following
      funding of the project in September 2018, we completed the search in November
      2018, and carried out data screening and stakeholder engagement activities during
      preparation of the protocol. We will conduct a knowledge synthesis based on
      specific disorders, treatment level and modality, type of service, population,
      settings, ethical practices, and user engagement and offer recommendations
      concerning the integration of video game technologies and programs, future
      research and practice, and knowledge dissemination. CONCLUSIONS: Digital game
      interventions employ unique, experiential, and interactive features that
      potentially improve skills and facilitate learning among players. Digital games
      may also provide a new treatment platform for youths with mental health
      conditions. Assessing current knowledge on video game technology and
      interventions may potentially improve the range of interventions offered by youth
      mental health services while supporting prevention, intervention, and treatment. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/13834.
CI  - (c)Manuela Ferrari, Sarah V McIlwaine, Jennifer Ann Reynolds, Suzanne Archie,
      Katherine Boydell, Shalini Lal, Jai L Shah, Joanna Henderson, Mario
      Alvarez-Jimenez, Neil Andersson, Jill Boruff, Rune Kristian Lundedal Nielsen,
      Srividya N Iyer. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 24.06.2020.
FAU - Ferrari, Manuela
AU  - Ferrari M
AUID- ORCID: https://orcid.org/0000-0002-7530-6210
AD  - Douglas Mental Health University Institute, Montreal, QC, Canada.
AD  - Department of Psychiatry, McGill University, Montreal, QC, Canada.
FAU - McIlwaine, Sarah V
AU  - McIlwaine SV
AUID- ORCID: https://orcid.org/0000-0003-4848-0712
AD  - Department of Psychiatry, McGill University, Montreal, QC, Canada.
FAU - Reynolds, Jennifer Ann
AU  - Reynolds JA
AUID- ORCID: https://orcid.org/0000-0001-5363-622X
AD  - Research Chair on Gambling, Concordia University, Montreal, QC, Canada.
FAU - Archie, Suzanne
AU  - Archie S
AUID- ORCID: https://orcid.org/0000-0003-1345-0468
AD  - Department of Psychiatry and Behavioural Neurosciences, McMaster University,
      Hamilton, ON, Canada.
FAU - Boydell, Katherine
AU  - Boydell K
AUID- ORCID: https://orcid.org/0000-0002-1464-8532
AD  - Black Dog Institute, Sydney, Australia.
FAU - Lal, Shalini
AU  - Lal S
AUID- ORCID: https://orcid.org/0000-0002-7501-5018
AD  - Douglas Mental Health University Institute, Montreal, QC, Canada.
AD  - School of Rehabilitation, Faculty of Medicine, University of Montreal, Montreal, 
      QC, Canada.
AD  - Health Innovation and Evaluation Hub, University of Montreal Hospital Research
      Centre, Montreal, QC, Canada.
FAU - Shah, Jai L
AU  - Shah JL
AUID- ORCID: https://orcid.org/0000-0002-7549-6990
AD  - Department of Psychiatry, McGill University, Montreal, QC, Canada.
FAU - Henderson, Joanna
AU  - Henderson J
AUID- ORCID: https://orcid.org/0000-0002-9387-5193
AD  - Centre for Addiction and Mental Health, Toronto, ON, Canada.
FAU - Alvarez-Jimenez, Mario
AU  - Alvarez-Jimenez M
AUID- ORCID: https://orcid.org/0000-0002-3535-9086
AD  - Orygen, University of Melbourne, Melbourne, Australia.
FAU - Andersson, Neil
AU  - Andersson N
AUID- ORCID: https://orcid.org/0000-0003-1121-6918
AD  - Department of Family Medicine, McGill University, Montreal, QC, Canada.
FAU - Boruff, Jill
AU  - Boruff J
AUID- ORCID: https://orcid.org/0000-0002-0338-7322
AD  - Department of Pharmacology and Therapeutics, McGill University, Montreal, QC,
      Canada.
FAU - Nielsen, Rune Kristian Lundedal
AU  - Nielsen RKL
AUID- ORCID: https://orcid.org/0000-0002-7209-9041
AD  - Centre for Computer Games Research, IT University of Copenhagen, Copenhagen,
      Denmark.
FAU - Iyer, Srividya N
AU  - Iyer SN
AUID- ORCID: https://orcid.org/0000-0001-5367-9086
AD  - Department of Psychiatry, McGill University, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7381025
OTO - NOTNLM
OT  - biomedical technology
OT  - mental disorders
OT  - mental health
OT  - mental health services
OT  - video games
OT  - virtual reality
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2019/04/10 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/01/27 00:00 [revised]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - v9i6e13834 [pii]
AID - 10.2196/13834 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 24;9(6):e13834. doi: 10.2196/13834.


PMID- 32579001
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
VI  - 112
IP  - 7
DP  - 2020 Jul
TI  - Patients with hepatitis C lost to follow-up: ethical-legal aspects and search
      results.
PG  - 532-537
LID - 10.17235/reed.2020.7077/2020 [doi]
AB  - INTRODUCTION: data on the prevalence and characteristics of hepatitis C patients 
      lost to follow-up are lacking. In addition, the identification of this population
      clashes with data protection regulations. METHODS: the identification and contact
      protocol was submitted to the Health Care Ethics Committee. The protocol was
      based on anti-HCV serology test results for 2010-2018, which were obtained from
      the Microbiology Department. In addition, the situation of the patients in the
      hospital and regional database was analyzed, based on the following
      classification: a) chronic hepatitis C, if the last HCV RNA determination was
      positive; b) cured hepatitis C, if the last HCV RNA determination was negative
      after 12 weeks of treatment; and c) possible hepatitis C, if anti-HCV antibodies 
      were positive with no result for HCV RNA. Lost patients were defined as those
      with chronic or possible hepatitis C and no follow-up in the Digestive Diseases
      or Internal Medicine Departments. The patients were contacted by postal mail and 
      then by telephone, so that they could be offered treatment. RESULTS: the Ethics
      Committee considered that the protocol fulfilled the bioethical principles of
      autonomy, beneficence, non-maleficence and justice and that contact was ethically
      desirable. From 4,816 positive anti-HCV serology results, 677 patients were
      identified who were lost to follow-up (14.06 %; 95 % CI, 13.2-15.2). The mean age
      was 54 years, 61 % were male, 12 % were foreign born and 95 % were mono-infected.
      The study of each serology result took 1.3 minutes. One-quarter (25 %) of the
      losses corresponded to the Digestive Diseases and Internal Medicine Departments. 
      Of the 677 losses, serology testing had only been ordered for 449 patients (66.3 
      %) and the remaining 228 (33.7 %) also had a positive HCV RNA result. CONCLUSION:
      a large number of patients with hepatitis C are lost to follow-up. Searching for 
      and contacting these patients is legally and ethically viable.
FAU - Andaluz Garcia, Irene
AU  - Andaluz Garcia I
AD  - Aparato Digestivo, Hospital Universitario La Paz, Espana.
FAU - Arcos Rueda, Maria Del Mar
AU  - Arcos Rueda MDM
AD  - Medicina Interna/Unidad VIH, Hospital Universitario La Paz, Espana.
FAU - Montero Vega, Maria Dolores
AU  - Montero Vega MD
AD  - Microbiologia, Hospital Universitario La Paz, Espana.
FAU - Castillo Grau, Pilar
AU  - Castillo Grau P
AD  - Aparato Digestivo, Hospital Universitario La Paz, Espana.
FAU - Martin Carbonero, Luz
AU  - Martin Carbonero L
AD  - Medicina Interna/Unidad VIH, Hospital Universitario La Paz.
FAU - Garcia-Samaniego Rey, Javier
AU  - Garcia-Samaniego Rey J
AD  - Aparato Digestivo, Hospital Universitario La Paz, Espana.
FAU - Romero Portales, Miriam
AU  - Romero Portales M
AD  - Aparato Digestivo, Hospital Universitario La Paz, Espana.
FAU - Garcia Sanchez, Araceli
AU  - Garcia Sanchez A
AD  - Aparato Digestivo, Hospital Universitario La Paz, Espana.
FAU - Busca Arenzana, Carmen
AU  - Busca Arenzana C
AD  - Medicina Interna/Unidad VIH, Hospital Universitario La Paz, Espana.
FAU - Gonzalez Garcia, Juan
AU  - Gonzalez Garcia J
AD  - Medicina Interna/Unidad VIH, Hospital Universitario La Paz, Espana.
FAU - Montes Ramirez, Maria Luisa
AU  - Montes Ramirez ML
AUID- ORCID: 0000-0003-1748-813X
AD  - Medicina Interna/Unidad VIH, Hospital Universitario La Paz, Espana.
FAU - Olveira Martin, Antonio
AU  - Olveira Martin A
AD  - Aparato Digestivo, Hospital Universitario La Paz, Espana.
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad
      Espanola de Patologia Digestiva
JID - 9007566
RN  - 0 (Hepatitis C Antibodies)
SB  - IM
MH  - Hepacivirus/genetics
MH  - *Hepatitis C/diagnosis/epidemiology
MH  - Hepatitis C Antibodies
MH  - *Hepatitis C, Chronic/drug therapy/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
EDAT- 2020/06/25 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - 10.17235/reed.2020.7077/2020 [doi]
PST - ppublish
SO  - Rev Esp Enferm Dig. 2020 Jul;112(7):532-537. doi: 10.17235/reed.2020.7077/2020.


PMID- 32578502
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - Pro-abortion attitude with context of traditional and professional identity
      dilemma.
PG  - 1529-1541
LID - 10.1177/0969733020923719 [doi]
AB  - BACKGROUND: Nurses are in a key position for reproduction health service
      delivery. Therefore, it is thought that it would be important to inspect opinions
      of student nurses, who will be health employees in the future, about self-induced
      abortion to develop women health and public health. OBJECTIVES: The goal of this 
      study is to inspect opinions of nursing students with different sociocultural
      specialties, about self-induced abortions. RESEARCH DESIGN: It is qualitative
      type and planned with ethnographic research pattern. PARTICIPANTS AND RESEARCH
      CONTEXT: The study was conducted with 20 last-term students of Kirsehir Ahi Evran
      University, Faculty of Health Sciences, Department of Nursing, who were chosen by
      maximum diversity sampling technique. Interviews were made with semi-structured
      interview form and voice records during the study; data were analyzed with
      content analyzing method. ETHICAL CONSIDERATIONS: Permission from the
      organization, university ethics committee, and personal approvals were taken from
      participants to conduct the research. FINDINGS: Based on the analysis, two major 
      themes on self-induced abortion in Turkish nursing students were found: dilemma
      of traditional perspective and professional identity and occupational awareness. 
      DISCUSSION AND CONCLUSION: It is seen that there is a dilemma between traditional
      point of view and professional identities about self-induced abortion for nursing
      students, but they had occupational awareness. It should be recommended to give
      information about national and international licit legislations for reproductive 
      health, self-induced abortion, and setting up ethical discussion environments for
      nursing students.
FAU - Bulucu Buyuksoy, Gizem Deniz
AU  - Bulucu Buyuksoy GD
AUID- ORCID: https://orcid.org/0000-0003-2957-2451
AD  - Faculty of Health Sciences, Nursing Department, 187470Kirsehir Ahi Evran
      University, Turkey.
FAU - Ozdil, Kamuran
AU  - Ozdil K
AUID- ORCID: https://orcid.org/0000-0003-0852-7854
AD  - Health Services Vocational School, Age Care Program, 121894Nevsehir Haci Bektas
      Veli University, Turkey.
FAU - Catiker, Aslihan
AU  - Catiker A
AD  - Faculty of Health Sciences, Nursing Department, 187474Ordu University, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Abortion, Induced/*ethics/*psychology
MH  - Anthropology, Cultural/methods
MH  - Attitude of Health Personnel
MH  - Female
MH  - Focus Groups/methods
MH  - Humans
MH  - Male
MH  - Qualitative Research
MH  - *Social Identification
MH  - Turkey
MH  - Young Adult
OTO - NOTNLM
OT  - Induced abortion
OT  - nursing students
OT  - opinions
OT  - reproductive rights
OT  - women's health
EDAT- 2020/06/25 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - 10.1177/0969733020923719 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1529-1541. doi: 10.1177/0969733020923719. Epub 2020
      Jun 24.


PMID- 32578490
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Invited Commentary on "No Correlation Between Ethical Judgment in Trolley
      Dilemmas and Vaccine Scenarios for Nurse Specialist Students".
PG  - 298-299
LID - 10.1177/1556264620937177 [doi]
FAU - Matisonn, Heidi
AU  - Matisonn H
AD  - University of KwaZulu-Natal, Pietermaritzburg, KZN, South Africa.
LA  - eng
PT  - Letter
DEP - 20200624
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
RN  - 0 (Vaccines)
SB  - IM
MH  - Decision Making
MH  - Humans
MH  - Judgment
MH  - Morals
MH  - *Nurse Specialists
MH  - Students
MH  - *Vaccines
OTO - NOTNLM
OT  - *analogies
OT  - *literature constitutes
OT  - *moral judgment
OT  - *neurosciences
OT  - *realistic dilemmas
EDAT- 2020/06/25 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - 10.1177/1556264620937177 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):298-299. doi:
      10.1177/1556264620937177. Epub 2020 Jun 24.


PMID- 32578249
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1466-7657 (Electronic)
IS  - 0020-8132 (Linking)
VI  - 67
IP  - 2
DP  - 2020 Jun
TI  - Challenging times: ethics, nursing and the COVID-19 pandemic.
PG  - 164-167
LID - 10.1111/inr.12598 [doi]
AB  - Globally nurses and midwives are working hard to detect cases of COVID-19, to
      save lives or give comfort in the face of death, to educate themselves and the
      public about protective measures to stop the viral spread, while still caring for
      those not infected with the virus. In many countries nurses are working under
      virtual siege from this pandemic, with not enough resources or personal
      protective equipment, overwhelming numbers of patients, staff shortages,
      underprepared health systems and supply chain failures. Nurses and other health
      and emergency workers are suffering physical and emotional stress, and moral
      distress from conflicting professional values. They are faced with unpalatable
      and complex ethical issues in practice, with moral conflicts, high levels of
      acuity and patient deaths, and long working hours. A rising number of nurses are 
      infected with SARS-CoV-2 or dying in the line of duty. Nurses need strong moral
      courage, stamina and resilience to work on the front lines of the pandemic, often
      while separated from their loved ones.
CI  - (c) 2020 International Council of Nurses.
FAU - Turale, Sue
AU  - Turale S
AUID- ORCID: https://orcid.org/0000-0001-8704-5161
AD  - International Nursing Review.
AD  - International Council of Nurses.
AD  - Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand.
FAU - Meechamnan, Chutima
AU  - Meechamnan C
AUID- ORCID: https://orcid.org/0000-0002-8212-225X
AD  - Surgical Nursing Department, Faculty of Nursing, Chiang Mai University, Chiang
      Mai, Thailand.
FAU - Kunaviktikul, Wipada
AU  - Kunaviktikul W
AUID- ORCID: https://orcid.org/0000-0001-9838-9007
AD  - WHO, Collaborating Center for Nursing & Midwifery Development.
AD  - Nursing Policy and Outcome Center, Faculty of Nursing, Chiang Mai University,
      Chiang Mai, Thailand.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int Nurs Rev
JT  - International nursing review
JID - 7808754
SB  - IM
MH  - *Betacoronavirus
MH  - Burnout, Professional/psychology
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/*nursing
MH  - Ethics, Nursing
MH  - Humans
MH  - Nurse's Role/psychology
MH  - Nursing Staff, Hospital/*ethics/psychology
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*nursing
MH  - SARS-CoV-2
MH  - Stress, Psychological/*psychology
MH  - United States
MH  - Workplace/psychology
PMC - PMC7361611
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Global health emergency
OT  - Moral courage
OT  - Moral distress
OT  - Nursing ethics
OT  - Pandemics
OT  - SARS-CoV-2
EDAT- 2020/06/25 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1111/inr.12598 [doi]
PST - ppublish
SO  - Int Nurs Rev. 2020 Jun;67(2):164-167. doi: 10.1111/inr.12598.


PMID- 32578062
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - An Ethical Framework for the Design, Development, Implementation, and Assessment 
      of Drones Used in Public Healthcare.
PG  - 2867-2891
LID - 10.1007/s11948-020-00233-1 [doi]
AB  - The use of drones in public healthcare is suggested as a means to improve
      efficiency under constrained resources and personnel. This paper begins by
      framing drones in healthcare as a social experiment where ethical guidelines are 
      needed to protect those impacted while fully realizing the benefits the
      technology offers. Then we propose an ethical framework to facilitate the design,
      development, implementation, and assessment of drones used in public healthcare. 
      Given the healthcare context, we structure the framework according to the four
      bioethics principles: beneficence, non-maleficence, autonomy, and justice, plus a
      fifth principle from artificial intelligence ethics: explicability. These
      principles are abstract which makes operationalization a challenge; therefore, we
      suggest an approach of translation according to a values hierarchy whereby the
      top-level ethical principles are translated into relevant human values within the
      domain. The resulting framework is an applied ethics tool that facilitates
      awareness of relevant ethical issues during the design, development,
      implementation, and assessment of drones in public healthcare.
FAU - Cawthorne, Dylan
AU  - Cawthorne D
AUID- ORCID: http://orcid.org/0000-0002-3068-0890
AD  - The Faculty of Engineering, Drone Center, Maersk Mc-Kinney Moller Institute,
      University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.
      dyca@sdu.dk.
FAU - Robbins-van Wynsberghe, Aimee
AU  - Robbins-van Wynsberghe A
AD  - Ethics/Philosophy of Technology Section, Department of Values, Technology and
      Innovation, Faculty of Technology, Policy and Management, Delft University of
      Technology, 2600 AA, Delft, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Beneficence
MH  - Delivery of Health Care
MH  - Humans
MH  - *Personal Autonomy
MH  - Social Justice
PMC - PMC7550294
OTO - NOTNLM
OT  - *Applied ethics
OT  - *Drones
OT  - *Public healthcare
OT  - *Robot ethics
OT  - *Value-sensitive design (VSD)
OT  - *Values hierarchy
EDAT- 2020/06/25 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - 10.1007/s11948-020-00233-1 [doi]
AID - 10.1007/s11948-020-00233-1 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2867-2891. doi: 10.1007/s11948-020-00233-1. Epub
      2020 Jun 23.


PMID- 32577962
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20200807
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
VI  - 27
IP  - 25
DP  - 2020 Sep
TI  - New approaches on the use of tunicates (Ciona robusta) for toxicity assessments.
PG  - 32132-32138
LID - 10.1007/s11356-020-09781-2 [doi]
AB  - After the accidental release of crude oil in marine environment, dispersants are 
      applied on sea surface transferring oil into the water column where it can be
      broken down by biodegradation, thereby reducing potential pollution to coastal
      areas. Before they can be used in the wild, the ecotoxicity of such dispersants
      is usually evaluated with toxicity assays using algae, crustacean and fishes.
      Nowadays, there is a need to find alternative species to reduce the use of
      vertebrates both for ethical considerations and for reducing the cost of
      bioassays. Ciona robusta is a solitary ascidian that inhabits shallow waters and 
      marine coastal areas. This species has been recently adopted as valuable
      biological model for ecotoxicity studies, thanks to its rapid embryonic and
      larval development, resemblance to vertebrates, and low risk of ethical issues.
      On this ground, the lethal and sublethal toxicity of two dispersants has been
      evaluated on Ciona juveniles. At this stage, the organisms become filter-feeders 
      and the morphological alterations of the organs can be easily observed. The
      median lethal concentrations at 96 h (96hLC50) for Dispersant 1 (non-ionic
      surfactant) and for Dispersant 2 (mixture of non-ionic surfactants and anionic
      surfactants) are 41.6 mg/L (38.6-44.9) and 92.5 mg/L (87.7-97.5), respectively.
      The Ciona juvenile model was compared to Dicentrarchus labrax fish juveniles
      test, and it showed increased sensitivity for Ciona to these compounds. These
      results suggest that 96 h mortality test bioassay could be a good alternative
      method to 96 h mortality assay with D. labrax, limiting the use of vertebrates
      for dispersant toxicity.
FAU - Eliso, Maria Concetta
AU  - Eliso MC
AD  - Department of Biology and Evolution of Marine Organisms,, Stazione Zoologica
      Anton Dohrn, 80121, Naples, Italy.
AD  - Department of Physical, Earth and Environmental Sciences, University of Siena,
      Siena, Italy.
FAU - Manfra, Loredana
AU  - Manfra L
AD  - Department of Marine Biotechnology, Stazione Zoologica Anton Dohrn, Villa
      Comunale, 80121, Naples, Italy. loredana.manfra@isprambiente.it.
AD  - Institute for Environmental Protection and Research (ISPRA), Rome, Italy.
      loredana.manfra@isprambiente.it.
FAU - Savorelli, Federica
AU  - Savorelli F
AD  - Regional Agency for Environmental Protection in Emilia-Romagna (ARPA ER),
      Ferrara, Italy.
FAU - Tornambe, Andrea
AU  - Tornambe A
AD  - Institute for Environmental Protection and Research (ISPRA), Rome, Italy.
FAU - Spagnuolo, Antonietta
AU  - Spagnuolo A
AD  - Department of Biology and Evolution of Marine Organisms,, Stazione Zoologica
      Anton Dohrn, 80121, Naples, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - Germany
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
RN  - 0 (Petroleum)
RN  - 0 (Surface-Active Agents)
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - Animals
MH  - *Ciona intestinalis
MH  - Lethal Dose 50
MH  - *Petroleum
MH  - Petroleum Pollution/*analysis
MH  - Surface-Active Agents
MH  - Water Pollutants, Chemical/*analysis
OTO - NOTNLM
OT  - Alternative biological pattern
OT  - Ascidian
OT  - Dispersants
OT  - Oil spill management
OT  - Toxicity
EDAT- 2020/06/25 06:00
MHDA- 2020/08/08 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - 10.1007/s11356-020-09781-2 [doi]
AID - 10.1007/s11356-020-09781-2 [pii]
PST - ppublish
SO  - Environ Sci Pollut Res Int. 2020 Sep;27(25):32132-32138. doi:
      10.1007/s11356-020-09781-2. Epub 2020 Jun 23.


PMID- 32577537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Where do we go from here? A child rights-based response to COVID-19.
PG  - e000714
LID - 10.1136/bmjpo-2020-000714 [doi]
FAU - Raman, Shanti
AU  - Raman S
AUID- ORCID: 0000-0002-4546-3231
AD  - Department of Community Paediatrics, South Western Sydney Local Health District, 
      Liverpool, New South Wales, Australia.
AD  - Women's & Children's Health, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - Harries, Maria
AU  - Harries M
AD  - Population and Public Health, The University of Western Australia Faculty of
      Health and Medical Sciences, Perth, Western Australia, Australia.
FAU - Nathawad, Rita
AU  - Nathawad R
AD  - Pediatrics, University of Florida, Jacksonville, Florida, USA.
FAU - Kyeremateng, Rosina
AU  - Kyeremateng R
AD  - British Association of Child and Adolescent Public Health, Royal College of
      Paediatrics and Child Health, London, UK.
FAU - Seth, Rajeev
AU  - Seth R
AD  - International Society for Prevention of Child Abuse & Neglect (ISPCAN), New
      Delhi, India.
FAU - Lonne, Bob
AU  - Lonne B
AD  - School of Health, University of New England, Armidale, New South Wales,
      Australia.
CN  - International Society for Social Pediatrics & Child Health (ISSOP) COVID 19
      Working Group
LA  - eng
PT  - Editorial
DEP - 20200615
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7299026
OTO - NOTNLM
OT  - adolescent health
OT  - child abuse
OT  - epidemiology
OT  - ethics
OT  - health services research
COIS- Competing interests: None declared.
IR  - Zwi K
FIR - Zwi, Karen
IR  - Spencer NJ
FIR - Spencer, Nicholas J
IR  - Goldhagen J
FIR - Goldhagen, Jeffery
IR  - Mercer R
FIR - Mercer, Raul
IR  - Rubio B
FIR - Rubio, Barbara
IR  - Tamburlini G
FIR - Tamburlini, Giorgio
IR  - Goldfeld S
FIR - Goldfeld, Sharon
IR  - Woolfenden S
FIR - Woolfenden, Susan
IR  - Gander S
FIR - Gander, Sarah
IR  - Oberg C
FIR - Oberg, Charles
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - 10.1136/bmjpo-2020-000714 [doi]
AID - bmjpo-2020-000714 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Jun 15;4(1):e000714. doi: 10.1136/bmjpo-2020-000714.
      eCollection 2020.


PMID- 32577533
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210704
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - What do medical students actually need to know about artificial intelligence?
PG  - 86
LID - 10.1038/s41746-020-0294-7 [doi]
AB  - With emerging innovations in artificial intelligence (AI) poised to substantially
      impact medical practice, interest in training current and future physicians about
      the technology is growing. Alongside comes the question of what, precisely,
      should medical students be taught. While competencies for the clinical usage of
      AI are broadly similar to those for any other novel technology, there are
      qualitative differences of critical importance to concerns regarding
      explainability, health equity, and data security. Drawing on experiences at the
      University of Toronto Faculty of Medicine and MIT Critical Data's "datathons",
      the authors advocate for a dual-focused approach: combining robust data
      science-focused additions to baseline health research curricula and
      extracurricular programs to cultivate leadership in this space.
CI  - (c) The Author(s) 2020.
FAU - McCoy, Liam G
AU  - McCoy LG
AUID- ORCID: 0000-0002-4468-2256
AD  - Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King's
      College Cir, Toronto, ON M5S 1A8 Canada.0000 0001 2157 2938grid.17063.33
AD  - Institute of Health Policy, Management and Evaluation, Dalla Lana School of
      Public Health, University of Toronto, 155 College St 4th Floor, Toronto, ON M5T
      3M6 Canada.0000 0001 2157 2938grid.17063.33
FAU - Nagaraj, Sujay
AU  - Nagaraj S
AUID- ORCID: 0000-0002-8231-7305
AD  - Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King's
      College Cir, Toronto, ON M5S 1A8 Canada.0000 0001 2157 2938grid.17063.33
AD  - Department of Computer Science, University of Toronto, 40 St. George Street, Room
      4283, Toronto, ON M5S 2E4 Canada.0000 0001 2157 2938grid.17063.33
FAU - Morgado, Felipe
AU  - Morgado F
AUID- ORCID: 0000-0003-3000-9455
AD  - Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King's
      College Cir, Toronto, ON M5S 1A8 Canada.0000 0001 2157 2938grid.17063.33
AD  - Department of Medical Biophysics, University of Toronto, 101 College St, Suite
      15-701, Toronto, ON M5G 1L7 Canada.0000 0001 2157 2938grid.17063.33
FAU - Harish, Vinyas
AU  - Harish V
AUID- ORCID: 0000-0001-6364-2439
AD  - Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King's
      College Cir, Toronto, ON M5S 1A8 Canada.0000 0001 2157 2938grid.17063.33
AD  - Institute of Health Policy, Management and Evaluation, Dalla Lana School of
      Public Health, University of Toronto, 155 College St 4th Floor, Toronto, ON M5T
      3M6 Canada.0000 0001 2157 2938grid.17063.33
FAU - Das, Sunit
AU  - Das S
AD  - Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King's
      College Cir, Toronto, ON M5S 1A8 Canada.0000 0001 2157 2938grid.17063.33
AD  - Centre for Ethics, University of Toronto, 15 Devonshire Pl, Toronto, ON M5S 1H8
      Canada.0000 0001 2157 2938grid.17063.33
FAU - Celi, Leo Anthony
AU  - Celi LA
AUID- ORCID: 0000-0001-6712-6626
AD  - Institute for Medical Engineering and Science, Massachusetts Institute of
      Technology, 77 Massachusetts Avenue, E25-505, Cambridge, MA 02139 USA.0000 0001
      2341 2786grid.116068.8
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess
      Medical Center, 330 Brookline Avenue, Boston, MA 02215 USA.0000 0000 9011
      8547grid.239395.7
AD  - Department of Biostatistics, Harvard T.H. Chan School of Public Health, 677
      Huntington Avenue, Boston, MA 02115 USA.000000041936754Xgrid.38142.3c
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7305136
OTO - NOTNLM
OT  - Health care
OT  - Medical ethics
COIS- Competing interestsThe authors declare no competing interests
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2020/01/26 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - 10.1038/s41746-020-0294-7 [doi]
AID - 294 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Jun 19;3:86. doi: 10.1038/s41746-020-0294-7. eCollection
      2020.


PMID- 32577303
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2055-7647 (Print)
IS  - 2055-7647 (Linking)
VI  - 6
IP  - 1
DP  - 2020
TI  - Enhanced injury prevention programme for recreational runners (the SPRINT study):
      design of a randomised controlled trial.
PG  - e000780
LID - 10.1136/bmjsem-2020-000780 [doi]
AB  - INTRODUCTION: Running-related injuries (RRIs) are frequent, but no effective
      injury prevention measures have been identified yet. Therefore, we have set up
      the INSPIRE trial in 2017, in which the effectiveness of an online injury
      prevention programme was tested. Although this programme was not effective in
      reducing the number of RRIs, we gained new insights from this study, which we
      used to design an enhanced, online multidisciplinary injury prevention programme.
      The aim of this study is to test the effectiveness of this enhanced injury
      prevention programme in a group of recreational runners. METHODS AND ANALYSIS:
      For this randomised controlled trial, we aim to include 3394 recreational runners
      aged 18 years or older who register for a running event (distances 10 to 42.2
      km). During the preparation for the running event, runners in the intervention
      group get access to the enhanced online injury prevention programme. This online 
      programme consists of 10 steps, all covering separate items of RRI prevention.
      Runners in the control group will follow their regular preparation. With three
      follow-up questionnaires (1 month before, 1 week before and 1 month after the
      running event), the proportions of self-reported RRIs in the intervention group
      and the control group are compared. ETHICS AND DISSEMINATION: An exemption for a 
      comprehensive application has been obtained by the Medical Ethical Committee of
      the Erasmus MC University Medical Center, Rotterdam, the Netherlands. The results
      of the study will be disseminated among the running population, published in
      peer-reviewed international journals and presented on international conferences. 
      TRIAL REGISTRATION NUMBER: NL7694.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fokkema, Tryntsje
AU  - Fokkema T
AUID- ORCID: 0000-0002-3767-2770
AD  - Department of General Practice, Erasmus MC Medical University Center, Rotterdam, 
      The Netherlands.
FAU - de Vos, Robert-Jan
AU  - de Vos RJ
AD  - Department of Orthopaedics, Erasmus MC Medical University Center, Rotterdam, The 
      Netherlands.
FAU - Visser, Edwin
AU  - Visser E
AD  - Department of Physiotherapy, Sport Medical Center 'Sportgeneeskunde Rotterdam',
      Rotterdam, The Netherlands.
FAU - Krastman, Patrick
AU  - Krastman P
AD  - Department of General Practice, Erasmus MC Medical University Center, Rotterdam, 
      The Netherlands.
AD  - Rotterdam Marathon Study Group, Rotterdam, The Netherlands.
FAU - IJzerman, John
AU  - IJzerman J
AD  - Dutch Athletic Federation, Arnhem, The Netherlands.
FAU - Koes, Bart W
AU  - Koes BW
AD  - Department of General Practice, Erasmus MC Medical University Center, Rotterdam, 
      The Netherlands.
AD  - Center for Muscle and Joint Health, University of Southern Denmark, Odense,
      Denmark.
FAU - Verhaar, Jan A N
AU  - Verhaar JAN
AD  - Department of Orthopaedics, Erasmus MC Medical University Center, Rotterdam, The 
      Netherlands.
FAU - Bierma-Zeinstra, Sita M A
AU  - Bierma-Zeinstra SMA
AD  - Department of General Practice, Erasmus MC Medical University Center, Rotterdam, 
      The Netherlands.
AD  - Department of Orthopaedics, Erasmus MC Medical University Center, Rotterdam, The 
      Netherlands.
FAU - van Middelkoop, Marienke
AU  - van Middelkoop M
AD  - Department of General Practice, Erasmus MC Medical University Center, Rotterdam, 
      The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - BMJ Open Sport Exerc Med
JT  - BMJ open sport & exercise medicine
JID - 101681007
PMC - PMC7299036
OTO - NOTNLM
OT  - injuries
OT  - prevention
OT  - randomised controlled trial
OT  - running
COIS- Competing interests: None declared.
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2020/05/24 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - 10.1136/bmjsem-2020-000780 [doi]
AID - bmjsem-2020-000780 [pii]
PST - epublish
SO  - BMJ Open Sport Exerc Med. 2020 Jun 16;6(1):e000780. doi:
      10.1136/bmjsem-2020-000780. eCollection 2020.


PMID- 32577294
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Canadian Society of Transplantation and Canadian Society of Nephrology Commentary
      on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of
      Living Kidney Donors.
PG  - 2054358120918457
LID - 10.1177/2054358120918457 [doi]
AB  - PURPOSE OF REVIEW: To review an international guideline on the evaluation and
      care of living kidney donors and provide a commentary on the applicability of the
      recommendations to the Canadian donor population. SOURCES OF INFORMATION: We
      reviewed the 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical
      Practice Guideline on the Evaluation and Care of Living Kidney Donors and
      compared this guideline to the Canadian 2014 Kidney Paired Donation (KPD)
      Protocol for Participating Donors. METHODS: A working group was formed consisting
      of members from the Canadian Society of Transplantation and the Canadian Society 
      of Nephrology. Members were selected to have representation from across Canada
      and in various subspecialties related to living kidney donation, including
      nephrology, surgery, transplantation, pediatrics, and ethics. KEY FINDINGS: Many 
      of the KDIGO Guideline recommendations align with the KPD Protocol
      recommendations. Canadian researchers have contributed to much of the evidence on
      donor evaluation and outcomes used to support the KDIGO Guideline
      recommendations. LIMITATIONS: Certain outcomes and risk assessment tools have yet
      to be validated in the Canadian donor population. IMPLICATIONS: Living kidney
      donors should be counseled on the risks of postdonation outcomes given recent
      evidence, understanding the limitations of the literature with respect to its
      generalizability to the Canadian donor population.
CI  - (c) The Author(s) 2020.
FAU - Lam, Ngan N
AU  - Lam NN
AUID- ORCID: https://orcid.org/0000-0002-0129-7091
AD  - Division of Nephrology, University of Calgary, AB, Canada.
FAU - Dipchand, Christine
AU  - Dipchand C
AD  - Division of Nephrology, Dalhousie University, Halifax, NS, Canada.
FAU - Fortin, Marie-Chantal
AU  - Fortin MC
AD  - Division of Nephrology, Universite de Montreal, QC, Canada.
FAU - Foster, Bethany J
AU  - Foster BJ
AD  - Division of Pediatric Nephrology, McGill University, Montreal, QC, Canada.
FAU - Ghanekar, Anand
AU  - Ghanekar A
AD  - Department of Surgery, University of Toronto, ON, Canada.
FAU - Houde, Isabelle
AU  - Houde I
AD  - Division of Nephrology, Centre Hospitalier de l'Universite de Quebec, Quebec
      City, Canada.
FAU - Kiberd, Bryce
AU  - Kiberd B
AD  - Division of Nephrology, Dalhousie University, Halifax, NS, Canada.
FAU - Klarenbach, Scott
AU  - Klarenbach S
AD  - Division of Nephrology, University of Alberta, Edmonton, Canada.
FAU - Knoll, Greg A
AU  - Knoll GA
AD  - Division of Nephrology, University of Ottawa, ON, Canada.
FAU - Landsberg, David
AU  - Landsberg D
AD  - Division of Nephrology, University of British Columbia, Vancouver, Canada.
FAU - Luke, Patrick P
AU  - Luke PP
AD  - Division of Urology, Western University, London, ON, Canada.
FAU - Mainra, Rahul
AU  - Mainra R
AD  - Division of Nephrology, University of Saskatchewan, Saskatoon, Canada.
FAU - Singh, Sunita K
AU  - Singh SK
AUID- ORCID: https://orcid.org/0000-0003-0560-0948
AD  - Division of Nephrology, University of Toronto, ON, Canada.
FAU - Storsley, Leroy
AU  - Storsley L
AD  - Section of Nephrology, University of Manitoba, Winnipeg, Canada.
FAU - Gill, Jagbir
AU  - Gill J
AD  - Division of Nephrology, University of British Columbia, Vancouver, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200609
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7288834
OTO - NOTNLM
OT  - Canada
OT  - assessment
OT  - evaluation
OT  - follow-up care
OT  - kidney transplantation
OT  - living kidney donor
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - 10.1177/2054358120918457 [doi]
AID - 10.1177_2054358120918457 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Jun 9;7:2054358120918457. doi:
      10.1177/2054358120918457. eCollection 2020.


PMID- 32577125
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - Research ethics and refugee health: a review of reported considerations and
      applications in published refugee health literature, 2015-2018.
PG  - 39
LID - 10.1186/s13031-020-00283-z [doi]
AB  - INTRODUCTION: Public health investigations, including research, in refugee
      populations are necessary to inform evidence-based interventions and care. The
      unique challenges refugees face (displacement, limited political protections,
      economic hardship) can make them especially vulnerable to harm, burden, or undue 
      influence. Acute survival needs, fear of stigma or persecution, and history of
      trauma may present challenges to ensuring meaningful informed consent and
      establishing trust. We examined the recently published literature to understand
      the application of ethics principles in investigations involving refugees.
      METHODS: We conducted a preliminary review of refugee health literature (research
      and non-research data collections) published from 2015 through 2018 available in 
      PubMed. Article inclusion criteria were: participants were refugees, topic was
      health-related, and methods used primary data collection. Information regarding
      type of investigation, methods, and reported ethics considerations was
      abstracted. RESULTS: We examined 288 articles. Results indicated 33% of
      investigations were conducted before resettlement, during the displacement period
      (68% of these were in refugee camps). Common topics included mental health (48%) 
      and healthcare access (8%). The majority (87%) of investigations obtained
      consent. Incentives were provided less frequently (23%). Most authors discussed
      the ways in which community stakeholders were engaged (91%), yet few noted
      whether refugee representatives had an opportunity to review investigational
      protocols (8%). Cultural considerations were generally limited to gender and
      religious norms, and 13% mentioned providing some form of post-investigation
      support. CONCLUSIONS: Our analysis is a preliminary assessment of the application
      of ethics principles reported within the recently published refugee health
      literature. From this analysis, we have proposed a list of best practices, which 
      include stakeholder engagement, respect for cultural norms, and post-study
      support. Investigations conducted among refugees require additional diligence to 
      ensure respect for and welfare of the participants. Development of a
      refugee-specific ethics framework with ethics and refugee health experts that
      addresses the need for stakeholder involvement, appropriate incentive use,
      protocol review, and considerations of cultural practices may help guide future
      investigations in this population.
CI  - (c) The Author(s) 2020.
FAU - Seagle, Emma E
AU  - Seagle EE
AD  - Division of Global Migration and Quarantine, Centers for Disease Control and
      Prevention, 1600 Clifton Road, MS EO3, Atlanta, GA 30333 USA.grid.416738.f0000
      0001 2163 0069
AD  - CDC/CSTE Applied Epidemiology Fellowship Program, Atlanta, Georgia
      USA.grid.416738.f0000 0001 2163 0069
AD  - Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee
      USA.grid.410547.30000 0001 1013 9784
FAU - Dam, Amanda J
AU  - Dam AJ
AD  - Division of Global Migration and Quarantine, Centers for Disease Control and
      Prevention, 1600 Clifton Road, MS EO3, Atlanta, GA 30333 USA.grid.416738.f0000
      0001 2163 0069
AD  - Eagle Global Scientific, LLC, Atlanta, Georgia USA.
FAU - Shah, Priti P
AU  - Shah PP
AD  - Division of Global Migration and Quarantine, Centers for Disease Control and
      Prevention, 1600 Clifton Road, MS EO3, Atlanta, GA 30333 USA.grid.416738.f0000
      0001 2163 0069
AD  - Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee
      USA.grid.410547.30000 0001 1013 9784
FAU - Webster, Jessica L
AU  - Webster JL
AD  - Division of Global Migration and Quarantine, Centers for Disease Control and
      Prevention, 1600 Clifton Road, MS EO3, Atlanta, GA 30333 USA.grid.416738.f0000
      0001 2163 0069
AD  - Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee
      USA.grid.410547.30000 0001 1013 9784
FAU - Barrett, Drue H
AU  - Barrett DH
AD  - Office of Scientific Integrity, Office of Science, Centers for Disease Control
      and Prevention, Atlanta, GA USA.grid.416738.f0000 0001 2163 0069
FAU - Ortmann, Leonard W
AU  - Ortmann LW
AD  - Office of Scientific Integrity, Office of Science, Centers for Disease Control
      and Prevention, Atlanta, GA USA.grid.416738.f0000 0001 2163 0069
FAU - Cohen, Nicole J
AU  - Cohen NJ
AD  - Division of Global Migration and Quarantine, Centers for Disease Control and
      Prevention, 1600 Clifton Road, MS EO3, Atlanta, GA 30333 USA.grid.416738.f0000
      0001 2163 0069
FAU - Marano, Nina N
AU  - Marano NN
AUID- ORCID: 0000-0003-4426-5425
AD  - Division of Global Migration and Quarantine, Centers for Disease Control and
      Prevention, 1600 Clifton Road, MS EO3, Atlanta, GA 30333 USA.grid.416738.f0000
      0001 2163 0069
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7305588
OTO - NOTNLM
OT  - Ethics
OT  - Framework
OT  - Health
OT  - Refugee
OT  - Research
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - 10.1186/s13031-020-00283-z [doi]
AID - 283 [pii]
PST - epublish
SO  - Confl Health. 2020 Jun 20;14:39. doi: 10.1186/s13031-020-00283-z. eCollection
      2020.


PMID- 32577097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Registered nurses' experiences of communication with patients when practising
      person-centred care over the phone: a qualitative interview study.
PG  - 54
LID - 10.1186/s12912-020-00448-4 [doi]
AB  - BACKGROUND: To explore registered nurses' (RNs') experiences of practising
      person-centred care (PCC) by telephone with people diagnosed with chronic
      obstructive pulmonary disease and/or chronic heart failure. METHODS: Qualitative 
      interview study. Four RNs were individually interviewed before, during, and after
      participating in an intervention practising PCC by telephone. The interviews were
      analysed using qualitative content analysis. RESULTS: The results reflect three
      categories of their experience: realize the complexity of practising PCC by
      distance, gain insight into what PCC communication meant to RNs and their
      approach, and develop the professional role by practising PCC theory and ethics. 
      CONCLUSIONS: PCC over the telephone facilitate healthcare and support patients.
      Through careful listening, the RNs (1) created space for the individual patients 
      to express their thoughts and feelings and (2) emphasized each patient's
      capabilities and resources. The RNs also gained an understanding of PCC and what 
      it means to patients and to themselves as practitioners. Potential implications
      are that it is important for RNs practising PCC by telephone to remould their
      role, to listen carefully, and to communicate as equals in conversations that
      respect both parties' knowledge and expertise. Health professionals need
      supervision and support to fully understand the person-centred approach and
      provide communications that support it.
CI  - (c) The Author(s) 2020.
FAU - Bostrom, Eva
AU  - Bostrom E
AUID- ORCID: 0000-0001-5598-0737
AD  - Department of Nursing, Umea University, Umea, Sweden.grid.12650.300000 0001 1034 
      3451
FAU - Ali, Lilas
AU  - Ali L
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, P.O. Box 457, 405 30 Gothenburg, Sweden.grid.8761.80000 0000 9919
      9582
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.grid.8761.80000 0000 9919 9582
FAU - Fors, Andreas
AU  - Fors A
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, P.O. Box 457, 405 30 Gothenburg, Sweden.grid.8761.80000 0000 9919
      9582
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.grid.8761.80000 0000 9919 9582
AD  - Narhalsan Research and Development Primary Health Care, Region Vastra, Gotaland, 
      Sweden.
FAU - Ekman, Inger
AU  - Ekman I
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, P.O. Box 457, 405 30 Gothenburg, Sweden.grid.8761.80000 0000 9919
      9582
AD  - Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg,
      Sweden.grid.8761.80000 0000 9919 9582
FAU - Andersson, Annette Erichsen
AU  - Andersson AE
AD  - Institute of Health and Care Sciences, Sahlgrenska Academy, University of
      Gothenburg, P.O. Box 457, 405 30 Gothenburg, Sweden.grid.8761.80000 0000 9919
      9582
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7304080
OTO - NOTNLM
OT  - Person-centred care
OT  - Professional role
OT  - Qualitative
OT  - Telephone
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:01
CRDT- 2020/06/25 06:00
PHST- 2019/02/15 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:01 [medline]
AID - 10.1186/s12912-020-00448-4 [doi]
AID - 448 [pii]
PST - epublish
SO  - BMC Nurs. 2020 Jun 19;19:54. doi: 10.1186/s12912-020-00448-4. eCollection 2020.


PMID- 32576625
OWN - NLM
STAT- Publisher
LR  - 20200624
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 23
TI  - Should mitochondrial replacement therapy be funded by the National Health
      Service?
LID - medethics-2019-106053 [pii]
LID - 10.1136/medethics-2019-106053 [doi]
AB  - A clinical trial on mitochondrial replacement therapy (MRT) is currently being
      conducted and if this technique proves effective, National Health Service (NHS)
      England will fund MRT through the highly specialised services (HSS) funding
      stream. This paper considers whether MRT should be publicly funded by the NHS.
      Given the current financial pressure the NHS is experiencing, a comprehensive
      discussion is essential. There is yet to be a thorough discussion on MRT funding,
      perhaps because this is a small-scale issue and presumed to be covered by the HSS
      budget. However, the source of funding has not been confirmed due to the trial's 
      incompletion. Upon its completion, reasoned decisions need to be made over the
      allocation of scarce NHS resources. It is therefore important to consider the
      following arguments in advance. Three arguments given against NHS funding of MRT 
      will be evaluated. The first argument against NHS funding examines the HSS
      overspending its budget in an underfunded NHS, suggesting funding must be
      carefully reprioritised. Second, the ethical issue of allowing public access to a
      technique with insufficient evidence behind it will be explored. The final point 
      considers the option of privately funding MRT and how this would affect the
      treatment's development. After illustrating the weaknesses of such arguments, it 
      will be concluded that MRT should be funded by the NHS.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Rhys-Evans, Sophie
AU  - Rhys-Evans S
AD  - School of Medicine, Faculty of Health and Life Sciences, University of Liverpool,
      Liverpool, UK sophie.rhysevans09@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - allocation of health care resources
OT  - clinical trials
OT  - disability
OT  - health care economics
OT  - in vitro fertilisation and embryo transfer
COIS- Competing interests: None declared.
EDAT- 2020/06/25 06:00
MHDA- 2020/06/25 06:00
CRDT- 2020/06/25 06:00
PHST- 2019/12/26 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
AID - medethics-2019-106053 [pii]
AID - 10.1136/medethics-2019-106053 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 23. pii: medethics-2019-106053. doi:
      10.1136/medethics-2019-106053.


PMID- 32576422
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20211002
IS  - 1873-5134 (Electronic)
IS  - 0738-3991 (Linking)
VI  - 103
IP  - 10
DP  - 2020 Oct
TI  - Making the most of video recorded clinical encounters: Optimizing impact and
      productivity through interdisciplinary teamwork.
PG  - 2178-2184
LID - S0738-3991(20)30323-2 [pii]
LID - 10.1016/j.pec.2020.06.005 [doi]
AB  - Patient-clinician interactions are central to technical and interpersonal
      processes of medical care. Video recordings of these interactions provide a rich 
      source of data and a stable record that allows for repeated viewing and analysis.
      Collecting video recordings requires navigating ethical and feasibility
      constraints; further, realizing the potential of video requires specialized
      research skills. Interdisciplinary collaborations involving practitioners,
      medical educators, and social scientists are needed to provide the clinical
      perspectives, methodological expertise, and capacity needed to make collecting
      video worthwhile. Such collaboration ensures that research questions will be
      based on scholarship from the social sciences, resonate with practice, and
      produce results that fit educational needs. However, the literature lacks
      suggested practices for building and sustaining interdisciplinary research
      collaborations involving video data. In this paper, we provide concrete advice
      based on our experience collecting and analyzing a single set of video-recorded
      clinical encounters and non-video data, which have so far yielded nine distinct
      studies. We present the research process, timeline, and advice based on our
      experience with interdisciplinary collaboration. We found that integrating
      disciplines and traditions required patience, compromise, and mutual respect;
      learning from each other enhanced our enjoyment of the process, our productivity,
      and the clinical relevance of our research.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Henry, Stephen G
AU  - Henry SG
AD  - Department of Internal Medicine, University of California, Davis, Sacramento,
      USA; University of California Davis Center for Healthcare Policy and Research,
      Sacramento, USA. Electronic address: sghenry@ucdavis.edu.
FAU - White, Anne Elizabeth Clark
AU  - White AEC
AD  - Department of Internal Medicine, University of California, Davis, Sacramento,
      USA; University of California Davis Center for Healthcare Policy and Research,
      Sacramento, USA.
FAU - Magnan, Elizabeth M
AU  - Magnan EM
AD  - University of California Davis Center for Healthcare Policy and Research,
      Sacramento, USA; Department of Family and Community Medicine, University of
      California Davis, Sacramento, USA.
FAU - Hood-Medland, Eve Angeline
AU  - Hood-Medland EA
AD  - Department of Internal Medicine, University of California, Davis, Sacramento,
      USA; University of California Davis Center for Healthcare Policy and Research,
      Sacramento, USA.
FAU - Gosdin, Melissa
AU  - Gosdin M
AD  - University of California Davis Center for Healthcare Policy and Research,
      Sacramento, USA.
FAU - Kravitz, Richard L
AU  - Kravitz RL
AD  - Department of Internal Medicine, University of California, Davis, Sacramento,
      USA; University of California Davis Center for Healthcare Policy and Research,
      Sacramento, USA.
FAU - Torres, Peter Joseph
AU  - Torres PJ
AD  - Department of Linguistics, University of California Davis, Davis, USA.
FAU - Gerwing, Jennifer
AU  - Gerwing J
AD  - Health Services Research Unit, Akershus University Hospital, Oslo, Norway.
LA  - eng
GR  - K23 DA043052/DA/NIDA NIH HHS/United States
GR  - R21 DA042269/DA/NIDA NIH HHS/United States
GR  - KL2 TR000134/TR/NCATS NIH HHS/United States
GR  - UL1 TR001860/TR/NCATS NIH HHS/United States
GR  - T32 HS022236/HS/AHRQ HHS/United States
GR  - UL1 TR000002/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200603
PL  - Ireland
TA  - Patient Educ Couns
JT  - Patient education and counseling
JID - 8406280
MH  - Humans
MH  - *Interdisciplinary Studies
MH  - *Interprofessional Relations
MH  - Video Recording
PMC - PMC7508819
MID - NIHMS1606295
OTO - NOTNLM
OT  - *Health communication
OT  - *Interdisciplinary research
OT  - *Professional-Patient relations
OT  - *Research methodology
OT  - *Video recording
COIS- Declaration of Competing Interest No authors have any conflicts of interest to
      declare.
EDAT- 2020/06/25 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - S0738-3991(20)30323-2 [pii]
AID - 10.1016/j.pec.2020.06.005 [doi]
PST - ppublish
SO  - Patient Educ Couns. 2020 Oct;103(10):2178-2184. doi: 10.1016/j.pec.2020.06.005.
      Epub 2020 Jun 3.


PMID- 32576419
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20210120
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 39
IP  - 8
DP  - 2020 Aug
TI  - Ethical considerations of thoracic transplant and circulatory support during the 
      COVID-19 pandemic: A closer look at pulmonary vascular disease.
PG  - 852-853
LID - S1053-2498(20)31575-8 [pii]
LID - 10.1016/j.healun.2020.05.014 [doi]
FAU - Bradley, Elisa A
AU  - Bradley EA
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio
      State University Wexner Medical Center, Columbus, Ohio. Electronic address:
      elisa.bradley@osumc.edu.
FAU - Boucly, Athenais
AU  - Boucly A
AD  - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France;
      Assistance publique - Hopitaux de Paris, Hopital Bicetre, Service de Pneumologie 
      et Soins Intensifs Respiratoires, Hopital Bicetre, Le Kremlin-Bicetre, INSERM
      UMR_S 999, Hopital Marie Lannelongue, Le Plessis Robinson, France.
FAU - Benza, Raymond L
AU  - Benza RL
AD  - Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio
      State University Wexner Medical Center, Columbus, Ohio.
LA  - eng
GR  - K08 HL148701/HL/NHLBI NIH HHS/United States
PT  - Letter
PT  - Comment
DEP - 20200606
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the
      International Society for Heart Transplantation
JID - 9102703
SB  - IM
CON - J Heart Lung Transplant. 2020 Jul;39(7):619-626. PMID: 32505492
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Lung Transplantation
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Vascular Diseases
PMC - PMC7274991
EDAT- 2020/06/25 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - S1053-2498(20)31575-8 [pii]
AID - 10.1016/j.healun.2020.05.014 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2020 Aug;39(8):852-853. doi:
      10.1016/j.healun.2020.05.014. Epub 2020 Jun 6.


PMID- 32576316
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210110
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
VI  - 14
IP  - 3
DP  - 2020 Jun
TI  - Do Paramedics Have a Professional Obligation to Work During a Pandemic? A
      Qualitative Exploration of Community Member Expectations.
PG  - 406-412
LID - 10.1017/dmp.2020.212 [doi]
AB  - OBJECTIVES: Previous research has identified a lack of clarification regarding
      paramedic professional obligation to work. Understanding community expectations
      of paramedics will provide some clarity around this issue. The objective of this 
      research was to explore the expectations of a sample of Australian community
      members regarding the professional obligation of paramedics to respond during
      pandemics. METHODS: The authors used qualitative methods to gather Australian
      community member perspectives immediately before the onset of the coronavirus
      disease 2019 (COVID-19) pandemic. Focus groups were used for data collection, and
      a thematic analysis was conducted. RESULTS: The findings revealed 9 key themes:
      context of obligation (normal operations versus crisis situation), hierarchy of
      obligation (individual versus organizational obligation), risk acceptability,
      acceptable occupational risk (it's part of the job), access to personal
      protective equipment, legal and ethical guidelines, education and training,
      safety, and acceptable limitations to obligation. The factors identified as being
      acceptable limitations to professional obligation are presented as further
      sub-themes: physical health, mental health, and competing personal obligations.
      CONCLUSIONS: The issue of professional obligation must be addressed by ambulance 
      services as a matter of urgency, especially in light of the COVID-19 coronavirus 
      pandemic. Further research is recommended to understand how community member
      expectations evolve during and after the COVID-19 coronavirus pandemic.
FAU - Anderson, Cameron
AU  - Anderson C
AUID- ORCID: https://orcid.org/0000-0002-1913-7109
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA,
      Australia.
FAU - Pooley, Julie Ann
AU  - Pooley JA
AD  - School of Arts and Humanities, Edith Cowan University, Joondalup, WA, Australia.
FAU - Mills, Brennen
AU  - Mills B
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA,
      Australia.
FAU - Anderson, Emma
AU  - Anderson E
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA,
      Australia.
FAU - Smith, Erin C
AU  - Smith EC
AUID- ORCID: https://orcid.org/0000-0002-8640-6006
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
MH  - Allied Health Personnel/*ethics/psychology/statistics & numerical data
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Focus Groups/methods
MH  - Humans
MH  - Motivation
MH  - Pandemics/ethics/statistics & numerical data
MH  - Pneumonia, Viral/*therapy
MH  - Professional Role
MH  - Qualitative Research
MH  - *Social Responsibility
PMC - PMC7360940
OTO - NOTNLM
OT  - disaster medicine
OT  - emergency medical services
OT  - mass casualty incidents
OT  - public health surveillance
OT  - triage
EDAT- 2020/06/25 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/06/25 06:00 [entrez]
AID - S1935789320002128 [pii]
AID - 10.1017/dmp.2020.212 [doi]
PST - ppublish
SO  - Disaster Med Public Health Prep. 2020 Jun;14(3):406-412. doi:
      10.1017/dmp.2020.212. Epub 2020 Jun 24.


PMID- 32576199
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Jun 23
TI  - ENG-releasing subdermal implants in postpartum teenagers - an open-label trial
      study protocol.
PG  - 100
LID - 10.1186/s12978-020-00952-5 [doi]
AB  - BACKGROUND: Higher than expected adolescent pregnancy high rates continue
      globally, with repeated unplanned pregnancy (UP) in this age group is a public
      health problem. In Brazil, 16% of pregnancies occur in adolescents under 18 years
      old, with high maternal morbidity and mortality rates in this age group.
      Effective and safe contraception is required to reduce UP rates. The objective of
      our study is to evaluate acceptance of etonogestrel (ENG)-releasing subdermal
      contraceptive implant after childbirth, before discharge, as well as clinical
      performance up to one year after placement. Comparison between teenagers who opt 
      for ENG-implant versus other contraceptive methods after childbirth will be also 
      evaluated, specifically regarding UP, continuation and discontinuation rates and 
      reasons, body composition, pelvic ultrasound characteristics and user
      satisfaction. METHODS: A non-randomized open-label trial will be conducted with
      teenagers after childbirth and followed up to one year at the Women's Hospital,
      University of Campinas (UNICAMP), Campinas, Brazil. The study group will consist 
      of patients who accepted to use ENG-implant and placed before discharge. The
      comparison group will include adolescents who choose to use other contraceptive
      methods at the first postpartum visit (42 +/- 3 days after childbirth). All women
      will follow-up at 40-60 days postpartum, as well as, at 6 and 12 months
      post-enrollment. Patient satisfaction, contraceptive effectiveness, reasons of
      discontinuation, continuation rate and body composition will be evaluated.
      Transvaginal ultrasound and electric bio impedance tests will be performed at all
      follow-up appointments. A 5% significance level was assumed, as well as, a
      sampling error (absolute) for 10% prevalence. The sample size was calculated at n
      = 100, obtaining an estimate of 50 to 70 adolescents who would accept the method 
      offered, according to the prevalence and sample error assumed. DISCUSSION:
      Long-acting reversible contraceptive (LARC) methods include subdermal implants
      and intrauterine contraceptives, are considered first line contraception for
      teenagers. Immediate postpartum use is a safe option, which significantly reduces
      rates of repeated UP and all the undesirable consequences inherent to this
      process. TRIAL REGISTRATION: This study was approved by the Ethics and Research
      Commission of UNICAMP (CAAE: 92869018.5.0000.5404) and the Brazilian Registry of 
      Clinical Trials (REBEC): http://www.ensaiosclinicos.gov.br/rg/RBR-4z7bc6, (number
      2.901.752).
FAU - Barbieri, M M
AU  - Barbieri MM
AD  - Department of Obstetrics and Gynecology, School of Medical Science, University of
      Campinas, Av. Alexander Fleming, Campinas, SP, 101, Brazil.
FAU - Juliato, C R T
AU  - Juliato CRT
AD  - Department of Obstetrics and Gynecology, School of Medical Science, University of
      Campinas, Av. Alexander Fleming, Campinas, SP, 101, Brazil.
FAU - Bahamondes, L
AU  - Bahamondes L
AD  - Department of Obstetrics and Gynecology, School of Medical Science, University of
      Campinas, Av. Alexander Fleming, Campinas, SP, 101, Brazil.
FAU - Surita, F G
AU  - Surita FG
AUID- ORCID: http://orcid.org/0000-0003-4335-0337
AD  - Department of Obstetrics and Gynecology, School of Medical Science, University of
      Campinas, Av. Alexander Fleming, Campinas, SP, 101, Brazil. surita@unicamp.br.
LA  - eng
GR  - 2018/20868-9/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
RN  - 0 (Contraceptive Agents, Female)
RN  - 0 (Drug Implants)
RN  - 304GTH6RNH (etonogestrel)
RN  - 81K9V7M3A3 (Desogestrel)
SB  - IM
MH  - Adolescent
MH  - Brazil
MH  - *Contraception
MH  - Contraceptive Agents, Female/*adverse effects
MH  - Desogestrel/*adverse effects
MH  - Drug Implants/*adverse effects
MH  - Female
MH  - Humans
MH  - Postnatal Care
MH  - *Postpartum Period
MH  - Pregnancy
PMC - PMC7310555
OTO - NOTNLM
OT  - Contraception
OT  - Puerperium
OT  - Subdermal implant
OT  - Teenagers
EDAT- 2020/06/25 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/25 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s12978-020-00952-5 [doi]
AID - 10.1186/s12978-020-00952-5 [pii]
PST - epublish
SO  - Reprod Health. 2020 Jun 23;17(1):100. doi: 10.1186/s12978-020-00952-5.


PMID- 32576163
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 23
TI  - Minimal important differences for the WOMAC osteoarthritis index and the
      Forgotten Joint Score-12 in total knee arthroplasty patients.
PG  - 401
LID - 10.1186/s12891-020-03415-x [doi]
AB  - BACKGROUND: Total knee arthroplasty (TKA) is an effective treatment for end-stage
      osteoarthritis. Patient reported-outcome measures (PROMs) capture the patients'
      perception of the success of an intervention. The minimal important difference
      (MID) is an important characteristic of the PROM, which helps to interpret
      results. The aim of this study was to identify the MID for the Forgotten Joint
      Score-12 (FJS-12) and Western Ontario and McMaster Universities (WOMAC)
      osteoarthritis index. METHODS: Data were collected in a prospective cohort study.
      Patients were asked to complete the FJS-12, WOMAC osteoarthritis index and
      transition items evaluating change over time to determine the MID. We employed an
      anchor-based methodology relating score change to the response categories of the 
      transition items using both binary logistic regression and receiver operating
      characteristic (ROC) analysis. RESULTS: Data from 199 patients were analysed.
      Mean age was 72.3 years, 58% were women. Employing binary logistic regression the
      MID for the FJS-12 was 10.8 points, for the WOMAC pain score 7.5 points and for
      the WOMAC function score 7.2 points. ROC analyses found a MID of 13.0 points for 
      the FJS-12, 12.5 points for WOMAC pain and 14.7 points for WOMAC function.
      CONCLUSION: We report MIDs for the FJS-12 and the WOMAC Pain and Function scales 
      in a TKA patient cohort, which can be used to interpret meaningful differences in
      score. In line with previous research, we found more advanced statistical methods
      to result in smaller MID estimates for both scores. TRIAL REGISTRATION: Written
      consent for this study was obtained from all participants and ethical approval
      was granted by the local ethics committee (Ethikkommission St. Gallen; EKSG
      14/973; Registered 03 July 2014;
      http://www.sg.ch/home/gesundheit/ethikkommission.html).
FAU - Holtz, N
AU  - Holtz N
AD  - Department of Orthopaedics and Traumatology, Kantonsspital St. Gallen,
      Rorschacher Strasse 95, CH-9000, St. Gallen, Switzerland.
FAU - Hamilton, D F
AU  - Hamilton DF
AD  - Department of Orthopaedics and Trauma, University of Edinburgh, Edinburgh, UK.
FAU - Giesinger, J M
AU  - Giesinger JM
AD  - Innsbruck Institute of Patient-Centered Outcome Research (IIPCOR), Innsbruck,
      Austria.
FAU - Jost, B
AU  - Jost B
AD  - Department of Orthopaedics and Traumatology, Kantonsspital St. Gallen,
      Rorschacher Strasse 95, CH-9000, St. Gallen, Switzerland.
FAU - Giesinger, K
AU  - Giesinger K
AD  - Department of Orthopaedics and Traumatology, Kantonsspital St. Gallen,
      Rorschacher Strasse 95, CH-9000, St. Gallen, Switzerland.
      karlmeinrad.giesinger@kssg.ch.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Arthroplasty, Replacement, Knee
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Joint Prosthesis
MH  - Knee Joint/*physiopathology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - Osteoarthritis, Knee/*surgery
MH  - Prospective Studies
MH  - ROC Curve
MH  - Range of Motion, Articular
MH  - Severity of Illness Index
MH  - Switzerland
MH  - Treatment Outcome
PMC - PMC7313217
OTO - NOTNLM
OT  - Forgotten Joint Score-12
OT  - Minimal important difference
OT  - Patient-reported outcomes
OT  - Total knee arthroplasty
OT  - WOMAC
OT  - Western Ontario and McMaster universities osteoarthritis index
EDAT- 2020/06/25 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/06/25 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - 10.1186/s12891-020-03415-x [doi]
AID - 10.1186/s12891-020-03415-x [pii]
PST - epublish
SO  - BMC Musculoskelet Disord. 2020 Jun 23;21(1):401. doi: 10.1186/s12891-020-03415-x.


PMID- 32575765
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201015
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 12
DP  - 2020 Jun 20
TI  - Ethical Conflicts Experienced by Nurses in Geriatric Hospitals in South Korea:
      "If You Can't Stand the Heat, Get Out of the Kitchen".
LID - E4442 [pii]
LID - 10.3390/ijerph17124442 [doi]
AB  - Ethical conflicts among nurses can undermine nurses' psychological comfort and
      compromise the quality of patient care. In the last decade, several empirical
      studies on the phenomena related to ethical conflicts, such as ethical dilemmas, 
      issues, problems, difficulties, or challenges, have been reported; however, they 
      have not always deeply explored the meaning of ethical conflicts experienced by
      nurses in geriatric care. This study aims to understand the lived experiences of 
      ethical conflict of nurses in geriatric hospitals in South Korea. A
      phenomenological study was conducted. In-depth, face-to-face interviews were
      performed with nine registered nurses who cared for elderly patients in geriatric
      hospitals in South Korea between August 2015 and January 2016. Three main themes 
      emerged from the analysis: (1) confusing values for good nursing, (2) distress
      resulting from not taking required action despite knowing about a problem, and
      (3) avoiding ethical conflicts as a last resort. It was found that for geriatric 
      nurses to cope with ethical conflicts successfully, clear ethical guidance,
      continuing ethics education to improve ethical knowledge and moral behaviors, and
      a supportive system or program to resolve ethical conflicts involving nurses
      should be established.
FAU - Kim, Moonok
AU  - Kim M
AD  - Department of Nursing, Donggang University, Dongmun-Daero 50, Gwangju 61200,
      Korea.
FAU - Oh, Younjae
AU  - Oh Y
AUID- ORCID: 0000-0001-5638-323X
AD  - College of Nursing, Research Institute of Nursing Science, Hallym University,
      Hallymdaehakgil 1, Chuncheon, Gangwon-do 24252, Korea.
FAU - Kong, Byunghye
AU  - Kong B
AD  - Department of Nursing, College of Medicine, Chosun University, Pilmun-Daero 309, 
      Dong-Gu, Gwangju 61452, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200620
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Aged
MH  - Attitude of Health Personnel
MH  - Female
MH  - *Geriatric Nursing/ethics
MH  - Humans
MH  - Middle Aged
MH  - Morals
MH  - *Nursing Staff, Hospital/ethics
MH  - Republic of Korea
PMC - PMC7345032
OTO - NOTNLM
OT  - *ethical conflicts
OT  - *geriatric hospital
OT  - *nurses
OT  - *phenomenological study
EDAT- 2020/06/25 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/25 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/12 00:00 [revised]
PHST- 2020/06/18 00:00 [accepted]
PHST- 2020/06/25 06:00 [entrez]
PHST- 2020/06/25 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - ijerph17124442 [pii]
AID - 10.3390/ijerph17124442 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 20;17(12). pii: ijerph17124442. doi:
      10.3390/ijerph17124442.


PMID- 32574642
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1872-678X (Electronic)
IS  - 0165-0270 (Linking)
VI  - 343
DP  - 2020 Sep 1
TI  - Cryopreserved astrocytes maintain biological properties: Support of neuronal
      survival and differentiation.
PG  - 108806
LID - S0165-0270(20)30229-6 [pii]
LID - 10.1016/j.jneumeth.2020.108806 [doi]
AB  - BACKGROUND: Astrocytes, one of the main glial cell types, play critical roles in 
      the central nervous system (CNS) development and function, including support of
      neuronal survival and differentiation, blood brain barrier formation, synapse
      homeostasis and injury response. Cell isolation and culture techniques have been 
      proved to be a powerful tool to study astrocyte physiology and function. Due to
      financial constraints and rigid biosafety and ethics rules to use animal models, 
      freezing techniques and the creation of cell banks emerged as alternatives to
      optimize the use of experimental animals. One of the main challenges, however, of
      these techniques is to guarantee that conserved cells keep their biological
      properties. NEW METHOD: In this work, we characterized morphologically and
      functionally murine secondary astrocyte cultures that have been submitted to
      freezing/thawing procedures. RESULTS: Morphological characterization of SAC
      (secondary astrocyte culture) and SFAC (secondary frozen-astrocyte culture) did
      not reveal significant differences on astrocyte morphology, confluence time and
      cell number along culture period. Functionally, SAC and SFAC did not reveal
      differences in their potential to support neuronal survival, maturation,
      neuritogenesis and synapse formation. CONCLUSIONS: Our results suggest that
      murine astrocytes that are submitted to freezing/thawing procedure maintain
      morphological and functional characteristics when compared with non-frozen
      astrocytes. Thus, this methodological approach is a valuable tool for in vitro
      research and might allow experimental optimization and reduction of animal use.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Meloni, Marcelo
AU  - Meloni M
AD  - Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de 
      Janeiro, Brazil; Programa de Pos-Graduacao Formacao de Pesquisadores, Instituto
      de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de 
      Janeiro, Brazil.
FAU - Morgado, Juliana
AU  - Morgado J
AD  - Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de 
      Janeiro, Brazil.
FAU - Garcia, Matheus
AU  - Garcia M
AD  - Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de 
      Janeiro, Brazil.
FAU - Stipursky, Joice
AU  - Stipursky J
AD  - Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de 
      Janeiro, Brazil.
FAU - Gomes, Flavia Carvalho Alcantara
AU  - Gomes FCA
AD  - Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de 
      Janeiro, Brazil. Electronic address: fgomes@icb.ufrj.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200620
PL  - Netherlands
TA  - J Neurosci Methods
JT  - Journal of neuroscience methods
JID - 7905558
SB  - IM
MH  - Animals
MH  - *Astrocytes
MH  - Cell Differentiation
MH  - Cell Survival
MH  - Cells, Cultured
MH  - Mice
MH  - Neurogenesis
MH  - *Neuroglia
OTO - NOTNLM
OT  - *Astroglia
OT  - *Cell culture
OT  - *Cryopreserved astrocytes
EDAT- 2020/06/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - S0165-0270(20)30229-6 [pii]
AID - 10.1016/j.jneumeth.2020.108806 [doi]
PST - ppublish
SO  - J Neurosci Methods. 2020 Sep 1;343:108806. doi: 10.1016/j.jneumeth.2020.108806.
      Epub 2020 Jun 20.


PMID- 32574584
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 1552-6909 (Electronic)
IS  - 0090-0311 (Linking)
VI  - 49
IP  - 4
DP  - 2020 Jul
TI  - Current Resources for Evidence-Based Practice, July 2020.
PG  - 391-404
LID - S0884-2175(20)30088-5 [pii]
LID - 10.1016/j.jogn.2020.06.002 [doi]
AB  - An extensive review of new resources to support the provision of evidence-based
      care for women and infants. The current column includes a discussion of whether
      it is ethical not to offer doula care to all women, and commentaries on reviews
      focused on folic acid and autism spectrum disorder, and timing of influenza
      vaccination during pregnancy.
CI  - Copyright (c) 2020 AWHONN, the Association of Women's Health, Obstetric and
      Neonatal Nurses. Published by Elsevier Inc. All rights reserved.
FAU - Bovbjerg, Marit L
AU  - Bovbjerg ML
FAU - Cheyney, Melissa
AU  - Cheyney M
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - United States
TA  - J Obstet Gynecol Neonatal Nurs
JT  - Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
JID - 8503123
SB  - IM
MH  - *Evidence-Based Nursing
MH  - Female
MH  - Health Resources
MH  - Humans
MH  - Infant, Newborn
MH  - *Maternal-Child Health Services
MH  - Pregnancy
PMC - PMC7305877
EDAT- 2020/06/24 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - S0884-2175(20)30088-5 [pii]
AID - 10.1016/j.jogn.2020.06.002 [doi]
PST - ppublish
SO  - J Obstet Gynecol Neonatal Nurs. 2020 Jul;49(4):391-404. doi:
      10.1016/j.jogn.2020.06.002. Epub 2020 Jun 20.


PMID- 32574541
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1742-5662 (Electronic)
IS  - 1742-5662 (Linking)
VI  - 17
IP  - 167
DP  - 2020 Jun
TI  - Zeroth-order finite similitude and scaling of complex geometries in biomechanical
      experimentation.
PG  - 20190806
LID - 10.1098/rsif.2019.0806 [doi]
AB  - Scaled experimentation provides an alternative approach to full-scale
      biomechanical (and biological) testing but is known to suffer from scale effects,
      where the underlying system behaviour changes with scale. This phenomenon is
      arguably the overriding principal obstacle to the many advantages that scaled
      experimentation provides. These include reduced costs, materials and time, along 
      with the eschewal of ethical compliance concerns with the application of
      substitute artificial materials as opposed to the use of hazardous biological
      agents. This paper examines the role scale effects play in biomechanical
      experimentation involving strain measurement and introduces a formulation that
      overtly captures scale dependencies arising from geometrical change. The basic
      idea underpinning the new scaling approach is the concept of space scaling, where
      a biomechanical experiment is scaled by the metaphysical mechanism of space
      contraction. The scaling approach is verified and validated with finite-element
      (FE) models and actual physical-trial experimentation using digital image
      correlation software applied to synthetic composite bone. The experimental design
      aspect of the approach allows for the selection of three-dimensional printing
      materials for trial-space analysis in a complex pelvis geometry. This aspect
      takes advantage of recent advancements in additive manufacturing technologies
      with the objective of countering behavioural distorting scale effects. Analysis
      is carried out using a laser confocal microscope to compare the trial and
      physical space materials and subsequently measured using surface roughness
      parameters. FE models were constructed for the left hemipelvis and results show
      similar strain patterns (average percentage error less than 10%) for two of the
      three trial-space material combinations. A Bland-Altman statistical analysis
      shows a good agreement between the FE models and physical experimentation and a
      good agreement between the physical-trial experimentation, providing good
      supporting evidence of the applicability of the new scaling approach in a wider
      range of experiments.
FAU - Ochoa-Cabrero, Raul
AU  - Ochoa-Cabrero R
AD  - Department of Materials Science, The University of Manchester, Manchester, UK.
FAU - Alonso-Rasgado, Teresa
AU  - Alonso-Rasgado T
AD  - Queen Mary University of London, London, UK.
FAU - Davey, Keith
AU  - Davey K
AD  - Department of Mechanical, Aerospace and Civil Engineering, The University of
      Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - J R Soc Interface
JT  - Journal of the Royal Society, Interface
JID - 101217269
SB  - IM
MH  - Biomechanical Phenomena
MH  - Finite Element Analysis
MH  - Models, Biological
MH  - Pelvis
MH  - *Research Design
MH  - *Software
PMC - PMC7328390
OTO - NOTNLM
OT  - *biomechanical
OT  - *scaling
OT  - *similitude
OT  - *trial experimentation
EDAT- 2020/06/24 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1098/rsif.2019.0806 [doi]
PST - ppublish
SO  - J R Soc Interface. 2020 Jun;17(167):20190806. doi: 10.1098/rsif.2019.0806. Epub
      2020 Jun 24.


PMID- 32573554
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 6
DP  - 2020 Jun
TI  - [Clinical experience and critical issues.]
PG  - 374-378
LID - 10.1701/3394.33760 [doi]
AB  - Bergamo is a rich and populous city of northern Italy and one of the epicentres
      of the worldwide pandemic CoViD-19. Despite the generosity of health workers, we 
      are undergoing a severe humanitarian crisis that is stressing every aspect of
      daily life. From outside it is very hard to understand, because houses are closed
      for lockdown and are not destroyed as they would be in an earthquake. An outbreak
      is not "only" a sudden mass lethal incident, like a natural disaster, neither
      "only" a disease, to be treated by doctors, but a social phenomenon too.
      Historical and social elements are key factors for development (for example,
      intensive promiscuity between animals and humans) and spread of an epidemic (for 
      example, health workers and ambulance rapidly become vector of the virus). Can
      medical responsibility change in times of pandemic? My answer, as anaesthetist
      and intensive care physician from Bergamo, is yes. When the global medical
      community is called on to face a pandemic of unprecedented scale, with little
      scientific evidence and "crazy numbers" describing the situation, honest and
      forthcoming advocacy is an ethical duty. Aim of this narrative report is to share
      a view point about the dilemma of moral responsibility.
FAU - Nacoti, Mirco
AU  - Nacoti M
AD  - Terapia Intensiva Pediatrica, Dipartimento di Anestesia e Rianimazione, ASST Papa
      Giovanni XXIII, Bergamo.
LA  - ita
PT  - Journal Article
TT  - Esperienza clinica e criticita.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/psychology
MH  - Humans
MH  - Italy/epidemiology
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/psychology
MH  - SARS-CoV-2
EDAT- 2020/06/24 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
AID - 10.1701/3394.33760 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Jun;111(6):374-378. doi: 10.1701/3394.33760.


PMID- 32573511
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 6-S
DP  - 2020 Jun 20
TI  - Use of traffic crash as a risk assessment scale in hospitalized seniors: a
      perspective observational study.
PG  - 92-99
LID - 10.23750/abm.v91i6-S.9673 [doi]
AB  - BACKGROUND AND AIM: According to the World Health Organization (WHO), falls
      represent the second main cause of accidental and involuntary deaths worldwide,
      which led to define them as one of the "four giants of the geriatrician" that
      particularly affect the elderly aged >/= 65 years. The study's aim is to evaluate
      whether the Traffic Crash scale is valid in identifying patients at risk of
      falling by comparing it to the Conley scale currently used. METHODS: Prospective 
      observational study evaluating the fall risk using TC on a sample of patients
      aged >/= 65 years, hospitalized in General Medicine Ward and Gastroenterology,
      after informed consent and favorable opinion of the AVEN Ethics Committee. The
      results are compared with those obtained from the Conley scale, and with those
      obtained from the indications of the Business Operating Instruction. The method
      of administration occurred concurrently and distinctly on the same patient by two
      researchers in order to demonstrate the scale inter-rater reliability. RESULTS:
      The final sample was made up of 88 patients. Data shows that 46 out of 55
      patients (84%) are medium / high risk for both scales. According to the
      indications of the Company Operating Instruction, the entire sample is at risk.
      The inter-rater reliability was confirmed with Cohen's K which is equal to p = 1.
      CONCLUSIONS: The TC scale is comparable to Conley scale, for the fall risk
      identification but specifically the stratification is low-medium-high. Therefore,
      in future, this will make it possible to implement personalized prevention
      interventions in care planning.
FAU - Guasconi, Massimo
AU  - Guasconi M
AD  - Department of Medicine and Surgery, University of Parma, Italy. School of
      Nursing, Piacenza. massimo.guasconi@unipr.it.
FAU - Pisaroni, Nicola
AU  - Pisaroni N
AD  - Casa Residenza per Anziani Istituto "E. Biazzi".
      nicola.pisaroni@istitutoemiliobiazzi.it.
FAU - Bertuol, Maria
AU  - Bertuol M
AD  - Department of Medicine and Surgery, University of Parma, Italy.
      maria.bertuol@gmail.com.
FAU - Scazzariello, Martina
AU  - Scazzariello M
AD  - Student of Nursing Degree, University of Parma, Italy.
      martina.scazzariello@studenti.unipr.it.
FAU - Delfino, Federica
AU  - Delfino F
AD  - Student of Nursing Degree, University of Parma, Italy.
      federica_delfino@libero.it.
FAU - Bolzoni, Marina
AU  - Bolzoni M
AD  - Azienda USL Piacenza. m.bolzoni@ausl.pc.it.
FAU - Grossi, Cinzia Franca
AU  - Grossi CF
AD  - Azienda USL Piacenza. c.grossi@ausl.pc.it.
FAU - Beretta, Maurizio
AU  - Beretta M
AD  - Department of Medicine and Surgery, University of Parma, Italy. School of
      Nursing, Piacenza. maurizio.beretta@unipr.it.
FAU - Marchetti, Annalisa
AU  - Marchetti A
AD  - Azienda USL Piacenza. a.marchetti@ausl.pc.it.
FAU - Boselli, Andrea
AU  - Boselli A
AD  - Azienda USL Piacenza. a.boselli@ausl.pc.it.
FAU - Sarli, Leopoldo
AU  - Sarli L
AD  - Department of Medicine and Surgery, University of Parma, Italy.
      leopoldo.sarli@unipr.it.
FAU - Artioli, Giovanna
AU  - Artioli G
AD  - Azienda USL -IRCCS, Reggio Emilia, Italy . giovanna.artioli@unipr.it.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20200620
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - Accidental Falls/*statistics & numerical data
MH  - Accidents, Traffic/*statistics & numerical data
MH  - Aged
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Prospective Studies
MH  - Reproducibility of Results
MH  - Risk Assessment/*methods
PMC - PMC7975834
EDAT- 2020/06/24 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
AID - 10.23750/abm.v91i6-S.9673 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Jun 20;91(6-S):92-99. doi: 10.23750/abm.v91i6-S.9673.


PMID- 32573063
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1471-8847 (Electronic)
IS  - 1471-8731 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Dec
TI  - Research ethics and Indigenous Peoples: Repercussions of returning Yanomami blood
      samples.
PG  - 209-215
LID - 10.1111/dewb.12264 [doi]
AB  - This work presents the case of the Yanomami indigenous people from Brazil that
      were the object of US ethnography initiated in the 1960s. The research brought
      harmful repercussions to the life of the Indigenous people of Brazil for several 
      decades, and it took more than 40 years until the beginning of a process of
      reparation involving the Brazilian government and American universities.
      Objective: to discuss the meaning of the return of Yanomami blood samples, as
      well as contributions from the epistemologies of traditional Indigenous knowledge
      to the debate about research ethics and the structuring of means for the social
      control of researchers and the protection of participants in scientific studies, 
      having as an example the Yanomami indigenous people from Brazil, subjected to
      noxious ethnography in the 1960s and the 1970s. This work used data reports
      recorded in secondary sources. In this article we argue that Bioethics needs to
      further diversify its epistemological foundations and to consider epistemologies 
      and cosmologies beyond the frontiers of Western science, as the case of the
      abusive research involving the Yanomami indigenous people in Brazil reveals. We
      argue that traditional knowledge, such as those of indigenous and quilombolas,
      with their epistemologies and cosmologies, are fundamental for the election of
      less colonized and more efficient principles of research ethics, regarding the
      protection of the participants' rights in scientific studies. Traditional
      indigenous populations can teach us a great deal about doing research.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Guedes, Cristiano
AU  - Guedes C
AUID- ORCID: 0000-0001-6908-2604
FAU - Guimaraes, Silvia
AU  - Guimaraes S
AUID- ORCID: 0000-0002-2097-2355
LA  - eng
GR  - Universidade de Brasilia/International
GR  - Fundacao de Apoio a Pesquisa do Distrito Federal/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200623
PL  - England
TA  - Dev World Bioeth
JT  - Developing world bioethics
JID - 101120122
SB  - IM
MH  - Anthropology, Cultural/*ethics
MH  - *Bioethics
MH  - Blood Specimen Collection/*ethics
MH  - Brazil
MH  - Cultural Competency/*ethics
MH  - Dissent and Disputes
MH  - *Ethics, Research
MH  - Government
MH  - *Human Rights
MH  - Humans
MH  - *Indigenous Peoples
MH  - Internationality
MH  - Knowledge
MH  - Research Subjects
MH  - United States
MH  - Universities
EDAT- 2020/06/24 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/06/24 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1111/dewb.12264 [doi]
PST - ppublish
SO  - Dev World Bioeth. 2020 Dec;20(4):209-215. doi: 10.1111/dewb.12264. Epub 2020 Jun 
      23.


PMID- 32572995
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1741-4520 (Electronic)
IS  - 0914-3505 (Linking)
VI  - 60
IP  - 6
DP  - 2020 Nov
TI  - Current status and legal/ethical problems in the research use of the tissues of
      aborted human fetuses in Japan.
PG  - 166-174
LID - 10.1111/cga.12381 [doi]
AB  - To date, there is no law regulating the research use of human aborted fetuses in 
      Japan. The aim was to review the current status with historical background and
      legal/ethical problems limiting the research use of the tissues of aborted human 
      fetuses. We reviewed literature via PubMed, Web of Science, Scopus, Japana Centra
      Revuo Medicina and CiNii, reports from various committees and research groups
      from Ministry of Health, Labour and Welfare (MHLW), and domestic books. Aborted
      human fetal tissues used for research purposes were first documented in the
      1920s. The first guideline, the Peel Code was released in 1972. Since then, in
      Western countries, the research use of aborted fetuses has been less restricted
      compared with that of embryos, due to the following guidelines outlined by expert
      groups. Currently, aborted fetal tissues are commercially available for research 
      purposes in the United States. In Japan, only four indications are presented in
      "a public statement permitting research use of deceased fetuses' and 'neonates'
      organs, etc." (1987). In the 2000s, expert committees of the MHLW concluded that 
      research use of human aborted fetuses should be discontinued, and that
      comprehensive rules and independent regulations should be implemented. This issue
      has not been discussed in the Japanese legislature since 2003. Establishment of
      laws and guidelines for this issue is insufficient not only in Japan but also in 
      other countries. It is important to secure transparency for making laws and
      guidelines and in obtaining public understanding.
CI  - (c) 2020 Japanese Teratology Society.
FAU - Kawasaki, Hidenori
AU  - Kawasaki H
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
FAU - Yamada, Takahiro
AU  - Yamada T
AUID- ORCID: https://orcid.org/0000-0002-5370-7873
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
FAU - Wada, Takahito
AU  - Wada T
AUID- ORCID: https://orcid.org/0000-0002-9540-1354
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
FAU - Kosugi, Shinji
AU  - Kosugi S
AD  - Department of Medical Ethics and Medical Genetics, Kyoto University School of
      Public Health, Kyoto, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Australia
TA  - Congenit Anom (Kyoto)
JT  - Congenital anomalies
JID - 9306292
SB  - IM
MH  - *Aborted Fetus
MH  - Abortion, Induced/*ethics
MH  - *Ethics, Research
MH  - Female
MH  - *Fetus
MH  - Guidelines as Topic
MH  - Humans
MH  - Japan
MH  - Pregnancy
MH  - *Research
OTO - NOTNLM
OT  - ELSI
OT  - fetal tissue
OT  - guideline
OT  - law
OT  - legal/ethical problem
EDAT- 2020/06/24 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1111/cga.12381 [doi]
PST - ppublish
SO  - Congenit Anom (Kyoto). 2020 Nov;60(6):166-174. doi: 10.1111/cga.12381. Epub 2020 
      Aug 14.


PMID- 32572809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201005
IS  - 1869-1889 (Electronic)
IS  - 1674-7305 (Linking)
VI  - 63
IP  - 10
DP  - 2020 Oct
TI  - Erratum to: Low dose of hydroxychloroquine reduces fatality of critically ill
      patients with COVID-19.
PG  - 1617-1618
LID - 10.1007/s11427-020-1751-3 [doi]
AB  - 1. In the abstract, we missed a piece of information. The correct sentence should
      be "In this retrospective study, we included 550 critically ill COVID-19 patients
      who need mechanical ventilation (63.5%) and oxygen therapy (35.6%) in Tongji
      Hospital, Wuhan, from February 1, 2020 to April 4, 2020." 2. We mistakenly put an
      approval number from Tongji Hospital ethics committee in the paper (IRBID:
      TJ-C20200113). The correct number should be TJ-IRB20200229. 3. We mistakenly
      filled some data in Table 1 and the correct Table 1 (the corrected data are in
      boldface) should be as follows.
FAU - Yu, Bo
AU  - Yu B
AD  - Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory 
      of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      430030, China.
FAU - Li, Chenze
AU  - Li C
AD  - Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory 
      of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      430030, China.
FAU - Chen, Peng
AU  - Chen P
AD  - Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory 
      of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      430030, China.
FAU - Zhou, Ning
AU  - Zhou N
AD  - Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory 
      of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      430030, China.
FAU - Wang, Luyun
AU  - Wang L
AD  - Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory 
      of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      430030, China.
FAU - Li, Jia
AU  - Li J
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
      Chinese Academy of Sciences, Shanghai, 201203, China.
FAU - Jiang, Hualiang
AU  - Jiang H
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
      Chinese Academy of Sciences, Shanghai, 201203, China.
AD  - Shanghai Institute for Advanced Immunochemical Studies and School of Life Science
      and Technology, Shanghai Tech University, Shanghai, 201210, China.
FAU - Wang, Dao-Wen
AU  - Wang DW
AD  - Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory 
      of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      430030, China. dwwang@tjh.tjmu.edu.cn.
LA  - eng
PT  - Published Erratum
DEP - 20200618
PL  - China
TA  - Sci China Life Sci
JT  - Science China. Life sciences
JID - 101529880
SB  - IM
EFR - Sci China Life Sci. 2020 Oct;63(10):1515-1521. PMID: 32418114
PMC - PMC7306565
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:01
CRDT- 2020/06/24 06:00
PHST- 2020/05/29 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:01 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1007/s11427-020-1751-3 [doi]
AID - 10.1007/s11427-020-1751-3 [pii]
PST - ppublish
SO  - Sci China Life Sci. 2020 Oct;63(10):1617-1618. doi: 10.1007/s11427-020-1751-3.
      Epub 2020 Jun 18.


PMID- 32572766
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210903
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Sep
TI  - Ethics and Spheres of Influence in Addressing Social Determinants of Health.
PG  - 2743-2745
LID - 10.1007/s11606-020-05973-1 [doi]
FAU - DeCamp, Matthew
AU  - DeCamp M
AUID- ORCID: 0000-0002-9371-8729
AD  - Center for Bioethics and Humanities and Division of General Internal Medicine,
      Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora,
      CO, USA. matthew.decamp@cuanschutz.edu.
FAU - DeSalvo, Karen
AU  - DeSalvo K
AD  - Google, Mountain View, CA, USA.
FAU - Dzeng, Elizabeth
AU  - Dzeng E
AD  - Division of Palliative Medicine, Department of Medicine, University of
      California-San Francisco, San Francisco, CA, USA.
LA  - eng
GR  - P30 AG044281/AG/NIA NIH HHS/United States
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200622
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
SB  - IM
MH  - *Health Status Disparities
MH  - Healthcare Disparities
MH  - Humans
MH  - *Social Determinants of Health
PMC - PMC7459019
EDAT- 2020/06/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1007/s11606-020-05973-1 [doi]
AID - 10.1007/s11606-020-05973-1 [pii]
PST - ppublish
SO  - J Gen Intern Med. 2020 Sep;35(9):2743-2745. doi: 10.1007/s11606-020-05973-1. Epub
      2020 Jun 22.


PMID- 32572765
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210903
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Sep
TI  - American College of Physicians Ethical Guidance for Electronic Patient-Physician 
      Communication: Aligning Expectations.
PG  - 2715-2720
LID - 10.1007/s11606-020-05884-1 [doi]
AB  - Communication is critical to strong patient-physician relationships and
      high-quality health care. In recent years, advances in health information
      technology have altered how patients and doctors interact and communicate.
      Increasingly, e-communication outside of in-person clinical encounters occurs in 
      many ways, including through e-mail, patient-portals, texting, and messaging
      applications. This American College of Physicians (ACP) position paper provides
      ethics and professionalism guidance for these forms of e-communication to help
      maintain trust in patient-physician relationships and the profession and
      alignment between patient and physician expectations.
FAU - Lee, Wei Wei
AU  - Lee WW
AD  - Department of Medicine, University of Chicago, Chicago, IL, USA.
FAU - Sulmasy, Lois Snyder
AU  - Sulmasy LS
AUID- ORCID: 0000-0002-0662-8945
AD  - Center for Ethics and Professionalism, American College of Physicians,
      Philadelphia, PA, USA. lsnyder@acponline.org.
CN  - American College of Physicians Ethics, Professionalism and Human Rights
      Committee*
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - United States
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
SB  - IM
MH  - Communication
MH  - Electronic Mail
MH  - Electronics
MH  - Humans
MH  - *Motivation
MH  - Physician-Patient Relations
MH  - *Physicians
MH  - United States
PMC - PMC7459080
OTO - NOTNLM
OT  - *electronic communication
OT  - *electronic health records
OT  - *ethics
OT  - *medical education
OT  - *patient-doctor communication
OT  - *patient-physician relationship
OT  - *professionalism
EDAT- 2020/06/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/24 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1007/s11606-020-05884-1 [doi]
AID - 10.1007/s11606-020-05884-1 [pii]
PST - ppublish
SO  - J Gen Intern Med. 2020 Sep;35(9):2715-2720. doi: 10.1007/s11606-020-05884-1. Epub
      2020 Jun 22.


PMID- 32572500
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201201
IS  - 1615-6692 (Electronic)
IS  - 0340-9937 (Linking)
VI  - 45
IP  - 7
DP  - 2020 Nov
TI  - Establishing an oncocardiology service.
PG  - 626-631
LID - 10.1007/s00059-020-04952-w [doi]
AB  - Oncocardiology is an emerging field in cardiovascular healthcare. Besides
      establishing surveillance and follow-up strategies for cancer patients, it will
      be essential to set up specialized oncocardiology services. However, there is a
      lack of clinical studies to give evidence-based recommendations regarding
      cardiological diagnostic and therapeutic approaches for cancer patients. An
      oncocardiology service is a patient-centered structure that aims to integrate
      research and interdisciplinary patient care to bridge this gap. We discuss the
      current challenges in developing an oncocardiology service and review the
      literature on this topic. We further provide an overview of the essential
      diagnostic tools and upcoming ethical issues to be considered in the management
      of oncology patients.
FAU - Lehmann, L H
AU  - Lehmann LH
AD  - Department of Cardiology, Angiology, Pneumology, Cardio-Oncology Unit, Heidelberg
      University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
      Lorenz.Lehmann@med.uni-heidelberg.de.
AD  - DZHK (German Centre for Cardiovascular Research), partner site
      Heidelberg/Mannheim, Heidelberg, Germany. Lorenz.Lehmann@med.uni-heidelberg.de.
AD  - Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
      Lorenz.Lehmann@med.uni-heidelberg.de.
FAU - Totzeck, M
AU  - Totzeck M
AD  - Department of Cardiology and Vascular Medicine, West German Heart and Vascular
      Center, University Hospital Essen, Medical Faculty, University of Duisburg-Essen,
      Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Aufbau einer onkokardiologischen Ambulanz.
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
SB  - IM
MH  - *Cardiology
MH  - Cardiotoxicity
MH  - Humans
MH  - Medical Oncology
MH  - *Neoplasms/diagnosis/therapy
PMC - PMC7306932
OTO - NOTNLM
OT  - Arrhythmia
OT  - Cardio-oncology
OT  - Cardiotoxicity
OT  - Comorbidities
OT  - Heart failure
EDAT- 2020/06/24 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1007/s00059-020-04952-w [doi]
AID - 10.1007/s00059-020-04952-w [pii]
PST - ppublish
SO  - Herz. 2020 Nov;45(7):626-631. doi: 10.1007/s00059-020-04952-w.


PMID- 32572482
OWN - NLM
STAT- Publisher
LR  - 20210624
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Linking)
DP  - 2020 Jun 23
TI  - Antipsychotic Medications: Flawed Concepts and Ethics.
LID - sbaa076 [pii]
LID - 10.1093/schbul/sbaa076 [doi]
FAU - Carpenter, William T
AU  - Carpenter WT
FAU - Buchanan, Robert W
AU  - Buchanan RW
AD  - Department of Psychiatry, Maryland Psychiatric Research Center, University of
      Maryland School of Medicine, Baltimore, MD.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
SB  - IM
PMC - PMC7505181
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
AID - 5861106 [pii]
AID - 10.1093/schbul/sbaa076 [doi]
PST - aheadofprint
SO  - Schizophr Bull. 2020 Jun 23. pii: 5861106. doi: 10.1093/schbul/sbaa076.


PMID- 32572386
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 2452-302X (Electronic)
IS  - 2452-302X (Linking)
VI  - 5
IP  - 6
DP  - 2020 Jun
TI  - The National Institute of Allergy and Infectious Diseases Decision to Stop the
      Adaptive COVID-19 Trial: On Solid Ethical and Scientific Grounds.
PG  - 645-647
LID - 10.1016/j.jacbts.2020.05.002 [doi]
FAU - Mozersky, Jessica
AU  - Mozersky J
AD  - Bioethics Research Center, Department of Medicine, Washington University School
      of Medicine in St. Louis, St. Louis, Missouri.
FAU - Mann, Douglas L
AU  - Mann DL
AD  - Center for Cardiovascular Research, Department of Medicine, Washington University
      School of Medicine in St. Louis, St. Louis, Missouri.
FAU - DuBois, James M
AU  - DuBois JM
AD  - Bioethics Research Center, Department of Medicine, Washington University School
      of Medicine in St. Louis, St. Louis, Missouri.
LA  - eng
PT  - Editorial
DEP - 20200526
PL  - United States
TA  - JACC Basic Transl Sci
JT  - JACC. Basic to translational science
JID - 101677259
PMC - PMC7250548
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:01
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:01 [medline]
AID - 10.1016/j.jacbts.2020.05.002 [doi]
AID - S2452-302X(20)30218-7 [pii]
PST - ppublish
SO  - JACC Basic Transl Sci. 2020 Jun;5(6):645-647. doi: 10.1016/j.jacbts.2020.05.002. 
      Epub 2020 May 26.


PMID- 32571865
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - A novel patient-reported outcome monitoring with clinical feedback system in
      bariatric surgery care: study protocol, design and plan for evaluation.
PG  - e037685
LID - 10.1136/bmjopen-2020-037685 [doi]
AB  - BACKGROUND: Consultations before and after bariatric surgery should include
      structured assessments of patients' health-related quality of life (HRQOL) and
      mental health. One way to conduct this assessment is to implement
      patient-reported outcome monitoring with a clinical feedback system (PRO/CFS).
      AIM: We will explore patients' and healthcare professionals' experiences when a
      PRO/CFS is an integrated part of bariatric surgery care. METHODS AND ANALYSES:
      This is a design paper in which a PRO/CFS will be implemented in two bariatric
      outpatient clinics. All patients who have an appointment with a healthcare
      professional prior to, and 3 and 12 months after surgery, will be asked to
      complete six digital questionnaires measuring HRQOL, mental health, bowel
      symptoms and eating self-efficacy prior to each consultation. A digital summary
      report generated from the patient's responses will form the basis for the
      clinical consultation. A team of patient representatives, healthcare
      professionals and researchers will be involved in all phases of designing the
      PRO/CFS to ensure its relevance for clinical consultations. The patients'
      experiences will be explored with a generic 12-item questionnaire, developed for 
      use in outpatient clinics, prior to and 12 months after bariatric surgery. We
      will conduct focus-group interviews with patients and healthcare professionals to
      explore their experiences when PRO/CFS is integrated into the consultations.
      ETHICS AND DISSEMINATION: Written informed consent will be obtained for all
      participants in the study. The project is approved by the Norwegian Centre for
      Research Data, Department of Data Protection Services (ref. no. 282738). The
      project has also undergone Data Protection Impact Assessments, both at Forde
      Hospital Trust and at St. Olav Hospital (registration no. 2016/3912). Data from
      the qualitative and quantitative studies will be kept in de-identified form in a 
      secured research database, and the findings will be published in international
      peer-reviewed journals and presented at scientific conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hegland, Pal Andre
AU  - Hegland PA
AUID- ORCID: 0000-0001-6524-5744
AD  - Faculty of Health and Social Sciences, Western Norway University of Applied
      Sciences-Forde Campus, Forde, Norway palaheg@hvl.no.
AD  - Department of Global Public Health and Primary Care, University of Bergen Faculty
      of Medicine and Dentistry, Bergen, Norway.
FAU - Aasprang, Anny
AU  - Aasprang A
AD  - Faculty of Health and Social Sciences, Western Norway University of Applied
      Sciences-Forde Campus, Forde, Norway.
FAU - Kolotkin, Ronette L
AU  - Kolotkin RL
AD  - Faculty of Health and Social Sciences, Western Norway University of Applied
      Sciences-Forde Campus, Forde, Norway.
AD  - Department of Family Medicine and Community Health, Duke University School of
      Medicine, Durham, North Carolina, USA.
AD  - Quality of Life Consulting, PLCC, Durham, North Carolina, United States.
FAU - Moltu, Christian
AU  - Moltu C
AD  - Department of Psychiatry, Forde Hospital Trust, Forde, Norway.
FAU - Tell, Grethe S
AU  - Tell GS
AD  - Department of Global Public Health and Primary Care, University of Bergen Faculty
      of Medicine and Dentistry, Bergen, Norway.
FAU - Andersen, John Roger
AU  - Andersen JR
AD  - Faculty of Health and Social Sciences, Western Norway University of Applied
      Sciences-Forde Campus, Forde, Norway.
AD  - Centre of Health Research, Forde Hospital Trust, Forde, Norway.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Bariatric Surgery
MH  - Evaluation Studies as Topic
MH  - *Feedback
MH  - Humans
MH  - *Patient Reported Outcome Measures
MH  - *Quality of Life
PMC - PMC7311033
OTO - NOTNLM
OT  - *gastroenterology
OT  - *mental health
OT  - *surgery
COIS- Competing interests: CM owns intellectual property in Norse Feedback, one of the 
      measures used in the protocol.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037685 [pii]
AID - 10.1136/bmjopen-2020-037685 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e037685. doi: 10.1136/bmjopen-2020-037685.


PMID- 32571863
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - Assessing the transparency of informed consent in feasibility and pilot studies: 
      a single-centre quality assurance study protocol.
PG  - e036226
LID - 10.1136/bmjopen-2019-036226 [doi]
AB  - INTRODUCTION: Pilot/feasibility studies assess the feasibility of conducting a
      larger study. Although researchers ought to communicate the feasibility
      objectives to their participants, many research ethics guidelines do not comment 
      on how informed consent applies to pilot studies. It is unclear whether
      researchers and research ethics boards clearly communicate the purpose of pilot
      studies to participants consenting.The primary objective of this study is to
      assess whether pilot/feasibility studies submitted for ethics approval to a
      research ethics board transparently communicate the purpose of the study to
      participants through their informed consent practice. A highly transparent
      consent practice entails the consent documents communicate: (1) the term 'pilot' 
      or 'feasibility' in the title; (2) the definition of a pilot/feasibility study;
      (3) the primary objectives of the study are to assess feasibility; (4) the
      specific feasibility objectives; and (5) the criteria for the study to
      successfully lead to the main study. The secondary objectives are to assess
      whether there is a difference between submitted and revised versions of the
      consent documents (revisions are made to obtain research ethics approval), to
      determine factors associated with transparent consent practices and to assess the
      consistency with which pilot and feasibility studies assess feasibility outcomes 
      as their primary objectives. METHODS AND ANALYSIS: This is a retrospective review
      of informed consent information for pilot/feasibility studies submitted to the
      Hamilton integrated Research Ethics Board, Canada. We will look at submitted and 
      revised consent documents for pilot/feasibility studies submitted over a 14-year 
      period. We will use descriptive statistics to summarise data, reporting results
      as percentages with 95% CIs, and conduct logistic regression to determine
      characteristics associated with transparent consent practices. ETHICS AND
      DISSEMINATION: The study protocol was approved by the Hamilton integrated
      Research Ethics Board, and the results of this study will be submitted for
      publication in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Khan, Mohammed I
AU  - Khan MI
AUID- ORCID: 0000-0003-4116-0097
AD  - Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
FAU - Holek, Matthew
AU  - Holek M
AD  - Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
FAU - Bdair, Faris
AU  - Bdair F
AD  - Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AUID- ORCID: 0000-0001-5855-5461
AD  - Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Eldridge, Sandra M
AU  - Eldridge SM
AD  - Barts and The London Pragmatic Clinical Trials Unit, Queen Mary University of
      London, London, UK.
FAU - Chan, Claire L
AU  - Chan CL
AD  - Centre for Primary Care and Public Health, Queen Mary University of London,
      London, UK.
FAU - Campbell, Michael J
AU  - Campbell MJ
AUID- ORCID: 0000-0003-3529-2739
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
FAU - Bond, Christine M
AU  - Bond CM
AD  - Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
FAU - Hopewell, Sally
AU  - Hopewell S
AD  - Centre for Statistics in Medicine, Nuffield Department of Orthopaedics,
      Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford,
      Oxfordshire, UK.
FAU - Lancaster, Gillian A
AU  - Lancaster GA
AD  - School of Primary, Community and Social Care; Keele Clinical Trials Unit, Keele
      University, Newcastle under Lyme, UK.
FAU - Thabane, Lehana
AU  - Thabane L
AD  - Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
      thabanl@mcmaster.ca.
AD  - Department of Health Research Methods, Evidence and Impact, McMaster University, 
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Feasibility Studies
MH  - Humans
MH  - Informed Consent/*standards
MH  - Pilot Projects
MH  - *Quality Assurance, Health Care
MH  - Retrospective Studies
PMC - PMC7311004
OTO - NOTNLM
OT  - *ethics (see medical ethics)
OT  - *medical ethics
OT  - *protocols & guidelines
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036226 [pii]
AID - 10.1136/bmjopen-2019-036226 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e036226. doi: 10.1136/bmjopen-2019-036226.


PMID- 32571862
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - How have predictors, moderators, mediators, treatment response, remission and
      resistance been defined and measured in randomised controlled trials for
      adolescent depression? A scoping review protocol.
PG  - e036171
LID - 10.1136/bmjopen-2019-036171 [doi]
AB  - INTRODUCTION: Among randomised controlled trials for depressed adolescents, the
      extent of variation in how depressive symptom outcomes are defined is unknown.
      The variability in which potential predictors of these outcomes are tested is
      also unclear. This paper is a protocol describing the methods of a planned
      scoping review. The scoping review will examine and summarise how change in
      depressive symptoms have been described in RCT treatment studies to date. This
      review will report the measures used to describe change in depressive symptoms
      and whether the measure was used as a continuous or binary outcome or both. This 
      review will describe how dichotomous outcome terms are defined to describe change
      in depression severity. This review will also examine predictors, moderators and 
      mediators of change in depressive symptoms within RCTs. METHODS AND ANALYSIS: In 
      this paper, we describe the protocol for our scoping review. Following the format
      outlined by the Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses extension for scoping reviews, a research librarian will develop an
      operationalised search strategy, which we will apply to the MEDLINE, Embase,
      PsycINFO and Cumulative Index to Nursing and Allied Health Literature databases. 
      We will search for papers from inception to 6 February 2020. A hand search for
      key citations will also be conducted. Investigator-raters will screen articles,
      first via the titles and abstracts and then through full-text reviews. We will
      include articles with randomised control design which assess the treatment of
      adolescents with major depressive disorder. We will systematically extract and
      synthesise prespecified data which includes: definition of depression used for
      participant inclusion, measures used to evaluate changes in depression, type of
      outcome used (continuous, binary or both), definitions of dichotomous terms to
      denote change in depression (eg, response, remission, recovery, etc) and reported
      predictors/moderators/mediators of change. ETHICS AND DISSEMINATION: Ethics
      approval is not required. Findings will be presented in journal publications and 
      at conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Courtney, Darren
AU  - Courtney D
AUID- ORCID: 0000-0003-1491-0972
AD  - Child, Youth and Family Services, Centre for Addiction and Mental Health,
      Toronto, Ontario, Canada dr.courtney.research@gmail.com.
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Watson, Priya
AU  - Watson P
AD  - Child, Youth and Family Services, Centre for Addiction and Mental Health,
      Toronto, Ontario, Canada.
AD  - Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Chan, Benjamin W C
AU  - Chan BWC
AD  - Toronto, Ontario, Canada.
FAU - Bennett, Kathryn J
AU  - Bennett KJ
AD  - Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and 
      Biostatistics), McMaster University Faculty of Health Sciences, Hamilton,
      Ontario, Canada.
FAU - Neprily, Kirsten
AU  - Neprily K
AD  - Psychology, University of Calgary, Calgary, Alberta, Canada.
FAU - Zentner, Tabitha
AU  - Zentner T
AD  - Child, Youth and Family Services, Centre for Addiction and Mental Health,
      Toronto, Ontario, Canada.
FAU - Rodak, Terri
AU  - Rodak T
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Narrandes, Renira
AU  - Narrandes R
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Szatmari, Peter
AU  - Szatmari P
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adolescent Health Services
MH  - Depressive Disorder, Major/*psychology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
PMC - PMC7311009
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *depression & mood disorders
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036171 [pii]
AID - 10.1136/bmjopen-2019-036171 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e036171. doi: 10.1136/bmjopen-2019-036171.


PMID- 32571861
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - Psychometric properties of the German version of the Clinician-Administered PTSD 
      Scale for DSM-5 (CAPS-5) in clinical routine settings: study design and protocol 
      of a multitrait-multimethod study.
PG  - e036078
LID - 10.1136/bmjopen-2019-036078 [doi]
AB  - INTRODUCTION: The aim of this study is to investigate the diagnostic accuracy,
      psychometric properties and clinical utility of the German version of the
      Clinician-Administered Post-Traumatic Stress Disorder (PTSD) Scale for Diagnostic
      and Statistical Manual of Mental Disorders-5 (DSM-5) (CAPS-5) in routine clinical
      settings. METHODS AND ANALYSIS: This study is a non-interventional,
      multitrait-multimethod design, multicentre study that will be carried out at
      German civil and military inpatient and outpatient clinics. A total sample size
      of n=219 participants who have experienced at least one traumatic event according
      to criteria as defined in the DSM-5 will be recruited. For the investigation of
      the diagnostic accuracy and clinical utility of the CAPS-5, participants will be 
      categorised into one of three groups, depending on their traumatic experiences
      and post-traumatic symptomatology: (1) monotraumatisation with PTSD; (2) multiple
      traumatisation with PTSD and (3) traumatisation without PTSD. Interviews will be 
      conducted face to face by interviewers in routine clinical settings. All
      participants will also be asked to complete a comprehensive set of questionnaires
      in order to investigate different facets of construct validity and clinical
      utility. First, differences between all three groups in CAPS-5 sum and subscale
      scores will be investigated. Test-retest reliability and inter-rater reliability 
      will be determined. Internal consistency will be calculated using structural
      equation modeling (SEM) based internal consistency coefficients. Construct
      validity will be measured with Spearman's rank correlation analyses and
      multivariate analyses of variance with Holm-Bonferroni corrected post hoc
      analysis of variances. In order to test diagnostic accuracy, receiver operating
      characteristics and sensitivity and specificity analyses will be conducted. The
      model structure of the German CAPS-5 will be analysed using confirmatory factor
      analyses. ETHICS AND DISSEMINATION: The study received ethical approval by the
      Ethics Committees of the Faculty of Psychology at the Ruhr-Universitat Bochum
      (reference numbers: 331 and 358). The results of the study will be presented
      nationally and internationally at scientific conferences and will be published in
      scientific journals. TRIAL REGISTRATION NUMBER: DRKS00015325.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Spies, Jan-Peter
AU  - Spies JP
AD  - Clinical Psychology and Psychotherapy, Universitat zu Koln, Koln, Germany.
FAU - Woud, Marcella Lydia
AU  - Woud ML
AUID- ORCID: 0000-0002-4974-505X
AD  - Faculty of Psychology, Mental Health Research and Treatment Center,
      Ruhr-Universitat Bochum, Bochum, Germany.
FAU - Kessler, Henrik
AU  - Kessler H
AD  - Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, 
      Ruhr-Universitat Bochum, Bochum, Germany.
FAU - Rau, Heinrich
AU  - Rau H
AD  - German Armed Forces Center for Military Mental Health, Berlin, Germany.
FAU - Willmund, Gerd Dieter
AU  - Willmund GD
AD  - German Armed Forces Center for Military Mental Health, Berlin, Germany.
FAU - Kohler, Kai
AU  - Kohler K
AD  - German Armed Forces Center for Military Mental Health, Berlin, Germany.
FAU - Herpertz, Stephan
AU  - Herpertz S
AD  - Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, 
      Ruhr-Universitat Bochum, Bochum, Germany.
FAU - Blackwell, Simon E
AU  - Blackwell SE
AUID- ORCID: 0000-0002-3313-7084
AD  - Faculty of Psychology, Mental Health Research and Treatment Center,
      Ruhr-Universitat Bochum, Bochum, Germany.
FAU - Bovin, Michelle
AU  - Bovin M
AD  - VA Boston Healthcare System, Massachusetts and Boston University School of
      Medicine, Boston, Massachusetts, USA.
FAU - Marx, Brian P
AU  - Marx BP
AD  - VA Boston Healthcare System, Massachusetts and Boston University School of
      Medicine, Boston, Massachusetts, USA.
FAU - Cwik, Jan Christopher
AU  - Cwik JC
AUID- ORCID: 0000-0002-2290-353X
AD  - Clinical Psychology and Psychotherapy, Universitat zu Koln, Koln, Germany
      jcwik@uni-koeln.de.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Germany
MH  - Humans
MH  - *Psychometrics
MH  - Stress Disorders, Post-Traumatic/*psychology
PMC - PMC7311000
OTO - NOTNLM
OT  - *Clinician-Administered PTSD Scale (CAPS-5) - posttraumatic stress disorder
      (PTSD) - psychometric properties - diagnostic interview - validation
COIS- Competing interests: None declared.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036078 [pii]
AID - 10.1136/bmjopen-2019-036078 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e036078. doi: 10.1136/bmjopen-2019-036078.


PMID- 32571860
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - Safety of tranexamic acid in thrombotic adverse events and seizure in patients
      with haemorrhage: a protocol for a systematic review and meta-analysis.
PG  - e036020
LID - 10.1136/bmjopen-2019-036020 [doi]
AB  - INTRODUCTION: Tranexamic acid (TXA) is a synthetic derivative of the amino acid
      lysine that inhibits fibrinolysis by blocking lysine-binding sites on
      plasminogen, which contribute to reduced bleeding, the need for transfusion and
      mortality. Although there is reliable evidence of the efficacy of TXA, its
      effects on other important outcomes, adverse events, including thrombotic events 
      and seizure, remain uncertain. METHODS AND ANALYSIS: We will conduct a systematic
      review and meta-analysis of randomised controlled trials with the objective of
      evaluating the incidence of thrombotic adverse events and seizure and how the
      effect of TXA varies by dose and underlying disease. We will include patients
      with bleeding in any underlying disease. We will search MEDLINE, EMBASE and
      Cochrane Central Register of Controlled Trials for randomised controlled trials. 
      The planned date of our systematic search is 1 June 2020. We will follow the
      recommendations of the Cochrane Collaboration and the Preferred Reporting Items
      for Systematic Review and Meta-Analysis statement. Subgroup and sensitivity
      analyses will be performed to explore residual heterogeneity and inconsistency.
      Meta-regression analysis will be carried out to investigate the association
      between the incidence of adverse events and the TXA dose. The risk of systematic 
      errors (bias) and random errors will be assessed and the overall quality of
      evidence will be evaluated using the Grading of Recommendations Assessment,
      Development and Evaluation approach. ETHICS AND DISSEMINATION: This study will
      not involve primary data collection, and formal ethics approval will therefore
      not be required. We aim to publish this systematic review in a peer-review
      journal. TRIAL REGISTRATION NUMBER: UMIN000039611.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Murao, Shuhei
AU  - Murao S
AD  - Division of Trauma and Surgical Critical Care, Osaka General Medical Center,
      Osaka, Japan.
FAU - Nakata, Hidekazu
AU  - Nakata H
AD  - Division of Trauma and Surgical Critical Care, Osaka General Medical Center,
      Osaka, Japan.
FAU - Yamakawa, Kazuma
AU  - Yamakawa K
AUID- ORCID: 0000-0003-2999-4021
AD  - Division of Trauma and Surgical Critical Care, Osaka General Medical Center,
      Osaka, Japan k.yamakawa0911@gmail.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
SB  - IM
MH  - Antifibrinolytic Agents/*adverse effects
MH  - Hemorrhage/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Patient Safety
MH  - Systematic Reviews as Topic
MH  - Thrombosis/*etiology
MH  - Tranexamic Acid/*adverse effects
PMC - PMC7311044
OTO - NOTNLM
OT  - *anaesthetics
OT  - *bleeding disorders & coagulopathies
OT  - *intensive & critical care
OT  - *surgery
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036020 [pii]
AID - 10.1136/bmjopen-2019-036020 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e036020. doi: 10.1136/bmjopen-2019-036020.


PMID- 32571859
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20211006
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - The EX-FRAIL CKD trial: a study protocol for a pilot randomised controlled trial 
      of a home-based EXercise programme for pre-frail and FRAIL, older adults with
      Chronic Kidney Disease.
PG  - e035344
LID - 10.1136/bmjopen-2019-035344 [doi]
AB  - INTRODUCTION: Frailty is highly prevalent in adults with chronic kidney disease
      (CKD) and is associated with adverse health outcomes including falls, poorer
      health-related quality of life (HRQOL), hospitalisation and mortality. Low
      physical activity and muscle wasting are important contributors to physical
      frailty in adults with CKD. Exercise training may improve physical function and
      frailty status leading to associated improvements in health outcomes, including
      HRQOL. The EX-FRAIL CKD trial aims to inform the design of a definitive
      randomised controlled trial (RCT) that investigates the effectiveness of a
      progressive, multicomponent home-based exercise programme in prefrail and frail
      older adults with CKD. METHODS AND ANALYSIS: The EX-FRAIL CKD trial is a two-arm 
      parallel group pilot RCT. Participants categorised as prefrail or frail,
      following Frailty Phenotype (FP) assessment, will be randomised to receive
      exercise or usual care. Participants randomised to the intervention arm will
      receive a tailored 12-week exercise programme, which includes weekly telephone
      calls to advise on exercise progression. Primary feasibility outcome measures
      include rate of recruitment, intervention adherence, outcome measure completion
      and participant attrition. Semistructured interviews with a purposively selected 
      group of participants will inform the feasibility of the randomisation
      procedures, outcome measures and intervention. Secondary outcome measures include
      physical function (walking speed and Short Physical Performance Battery), frailty
      status (FP), fall concern (Falls Efficacy Scale-International tool), activities
      of daily living (Barthel Index), symptom burden (Palliative care Outcome
      Scale-Symptoms RENAL) and HRQOL (Short Form-12v2). ETHICS AND DISSEMINATION:
      Ethical approval was granted by a National Health Service (NHS) Regional Ethics
      Committee and the NHS Health Research Authority. The study team aims to publish
      findings in a peer-reviewed journal and presents the results at relevant national
      and international conferences. A summary of findings will be provided to
      participants, a local kidney patient charity and the funding body. TRIAL
      REGISTRATION NUMBER: ISRCTN87708989.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nixon, Andrew Christopher
AU  - Nixon AC
AUID- ORCID: 0000-0002-4093-6204
AD  - Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust,
      Preston, Lancashire, UK andrew.nixon3@nhs.net.
AD  - Division of Cardiovascular Sciences, The University of Manchester, Manchester,
      UK.
AD  - Centre for Health Research and Innovation, NIHR Lancashire Clinical Research
      Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston,
      Lancashire, UK.
FAU - Bampouras, Theodoros M
AU  - Bampouras TM
AD  - Lancaster Medical School, Lancaster University, Lancaster, Lancashire, UK.
AD  - The Centre for Ageing Research, Lancaster University, Lancaster, Lancashire, UK.
FAU - Gooch, Helen J
AU  - Gooch HJ
AD  - Centre for Health Research and Innovation, NIHR Lancashire Clinical Research
      Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston,
      Lancashire, UK.
AD  - Core Therapies Department, Lancashire Teaching Hospitals NHS Foundation Trust,
      Preston, Lancashire, UK.
FAU - Young, Hannah M L
AU  - Young HML
AD  - Department of Respiratory Sciences, University of Leicester, Leicester, UK.
AD  - John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester,
      UK.
FAU - Finlayson, Kenneth William
AU  - Finlayson KW
AD  - Research in Childbirth and Health Unit, University of Central Lancashire,
      Preston, Lancashire, UK.
FAU - Pendleton, Neil
AU  - Pendleton N
AD  - Division of Neuroscience and Experimental Psychology, The University of
      Manchester, Manchester, UK.
FAU - Mitra, Sandip
AU  - Mitra S
AD  - Manchester Academic Health Sciences Centre, The University of Manchester,
      Manchester, UK.
AD  - Devices for Dignity, NIHR MedTech & In-vitro Diagnostics Co-operative, Sheffield,
      UK.
FAU - Brady, Mark E
AU  - Brady ME
AD  - Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust,
      Preston, Lancashire, UK.
FAU - Dhaygude, Ajay P
AU  - Dhaygude AP
AD  - Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust,
      Preston, Lancashire, UK.
LA  - eng
SI  - ISRCTN/ISRCTN87708989
GR  - DRF-2016-09-015/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Exercise Therapy
MH  - *Frail Elderly
MH  - Humans
MH  - Pilot Projects
MH  - Randomized Controlled Trials as Topic
MH  - *Renal Insufficiency, Chronic
PMC - PMC7311028
OTO - NOTNLM
OT  - *adult nephrology
OT  - *chronic renal failure
OT  - *end stage renal failure
OT  - *geriatric medicine
COIS- Competing interests: Unrelated to this body of work, APD has received lecture
      fees from speaking at the invitation of MSD and received travel support from
      Pharmacosmos.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035344 [pii]
AID - 10.1136/bmjopen-2019-035344 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e035344. doi: 10.1136/bmjopen-2019-035344.


PMID- 32571854
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 22
TI  - Systematic review protocol for assessing central auditory functions of
      Alzheimer's disease and its preclinical stages.
PG  - e033342
LID - 10.1136/bmjopen-2019-033342 [doi]
AB  - INTRODUCTION: A number of studies have reported an association between peripheral
      hearing impairment, central auditory processing and Alzheimer's disease (AD) and 
      its preclinical stages. Both peripheral hearing impairment and central auditory
      processing disorders are observed many years prior to the clinical manifestation 
      of AD symptoms, hence, providing a long window of opportunity to investigate
      potential interventions against neurodegenerative processes. This paper outlines 
      the protocol for a systematic review of studies examining the central auditory
      processing functions in AD and its preclinical stages, investigated through
      behavioural (clinical assessments that require active participation) central
      auditory processing tests. METHODS AND ANALYSIS: We will use the keywords and
      Medical Subject Heading terms to search the following electronic databases:
      MEDLINE, PsychINFO, PubMed, Scopus, EMBASE and CINAHL Plus. Studies including
      assessments of central auditory function in adults diagnosed with dementia, AD
      and its preclinical stages that were published before 8 May 2019 will be
      reviewed. This review protocol will be reported according to the Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines.
      Data analysis and search results will be reported in the full review. This
      manuscript has designed the protocols for a systematic review that will identify 
      the behavioural clinical central auditory processing measures that are sensitive 
      to the changes in auditory function in adults with AD and its preclinical stages.
      Such assessments may subsequently help to design studies to examine the potential
      impact of hearing and communication rehabilitation of individuals at risk of AD. 
      ETHICS AND DISSEMINATION: Ethical approval is not required as this manuscript
      only reports the protocols for conducting a systematic review as primary data
      will only be reviewed and not be collected. The results of this systematic review
      will be disseminated through publication and in scientific conferences. PROSPERO 
      REGISTRATION NUMBER: CRD42017078272.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jayakody, Dona M P
AU  - Jayakody DMP
AUID- ORCID: 0000-0001-5814-4355
AD  - Ear Sciences Centre- Faculty of Medical & Health Sciences, University of Western 
      Australia, Crawley, Western Australia, Australia
      hadeel.tarawneh@research.uwa.edu.au dona.jayakody@earscience.org.au.
AD  - Ear Science Institute Australia, Subiaco, Western Australia, Australia.
FAU - Tarawneh, Hadeel Y
AU  - Tarawneh HY
AUID- ORCID: 0000-0003-1860-9167
AD  - Ear Sciences Centre- Faculty of Medical & Health Sciences, University of Western 
      Australia, Crawley, Western Australia, Australia
      hadeel.tarawneh@research.uwa.edu.au dona.jayakody@earscience.org.au.
AD  - Ear Science Institute Australia, Subiaco, Western Australia, Australia.
AD  - School of Human Sciences, University of Western Australia, Crawley, Western
      Australia, Australia.
FAU - Menegola, Holly K
AU  - Menegola HK
AD  - Ear Sciences Centre- Faculty of Medical & Health Sciences, University of Western 
      Australia, Crawley, Western Australia, Australia.
AD  - Ear Science Institute Australia, Subiaco, Western Australia, Australia.
FAU - Yiannos, Jessica M
AU  - Yiannos JM
AD  - Ear Sciences Centre- Faculty of Medical & Health Sciences, University of Western 
      Australia, Crawley, Western Australia, Australia.
AD  - Ear Science Institute Australia, Subiaco, Western Australia, Australia.
FAU - Friedland, Peter L
AU  - Friedland PL
AD  - Ear Sciences Centre- Faculty of Medical & Health Sciences, University of Western 
      Australia, Crawley, Western Australia, Australia.
AD  - Department of Otolaryngology Head Neck Skull Base Surgery, Sir Charles Gairdner
      Hospital, Nedlands, Western Australia, Australia.
AD  - School of Medicine, University of Notre Dame Australia, Fremantle, Western
      Australia, Australia.
FAU - Wilson, Wayne J
AU  - Wilson WJ
AD  - School of Health and Rehabilitation Sciences, The University of Queensland, St
      Lucia, Queensland, Australia.
FAU - Martins, Ralph N
AU  - Martins RN
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences,
      Macquarie University, Sydney, New South Wales, Australia.
FAU - Sohrabi, Hamid R
AU  - Sohrabi HR
AD  - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western
      Australia, Australia.
AD  - Department of Biomedical Sciences, Faculty of Medicine and Health Sciences,
      Macquarie University, Sydney, New South Wales, Australia.
AD  - College of Science, Health, Engineering and Education, Murdoch University,
      Murdoch, Western Australia, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Alzheimer Disease/*complications
MH  - Auditory Diseases, Central/*complications/*diagnosis
MH  - Hearing Loss, Sensorineural/*complications/*diagnosis
MH  - Humans
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7311001
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *central auditory processing
OT  - *mild cognitive impairment
OT  - *subjective cognitive decline
COIS- Competing interests: None declared.
EDAT- 2020/06/24 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-033342 [pii]
AID - 10.1136/bmjopen-2019-033342 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 22;10(6):e033342. doi: 10.1136/bmjopen-2019-033342.


PMID- 32571849
OWN - NLM
STAT- Publisher
LR  - 20211223
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 22
TI  - Pros and cons of prosent as an alternative to traditional consent in medical
      research.
LID - medethics-2020-106443 [pii]
LID - 10.1136/medethics-2020-106443 [doi]
AB  - In their recent article, Porsdam Mann et al propose to share biomedical research 
      data more widely, securely and efficiently using blockchain technologies.1 They
      present compelling arguments for how the blockchain presents both a technological
      innovation, and a deontologically grounded policy innovation to traditional
      research consent. Their proposal can be read in conversation with a rich body of 
      evidence to suggest current consent processes are problematic on at least one of 
      tripartite bases in biomedical research: that it be fully informed. This response
      attempts to further the author's discussion of social justice discourse in, and
      of their proposed prosent model to enhance engagement among under-represented and
      vulnerable populations in research, specifically. Motivating this response is the
      view that advancing technological capabilities is no doubt necessary, but on its 
      own insufficient to reinvigorate distributive, procedural and social justice as
      guiding principles for con/prosent processes. I offer three pros and cons to
      consider in effort to deepen the model's commitments to social justice to
      historically marginalised groups in the biomedical research enterprise.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Rahimzadeh, Vasiliki Nataly
AU  - Rahimzadeh VN
AUID- ORCID: http://orcid.org/0000-0003-3537-7601
AD  - Center for Biomedical Ethics, Stanford University, Stanford, California, USA
      vrahim@stanford.edu.
LA  - eng
GR  - L40 HG011397/HG/NHGRI NIH HHS/United States
GR  - T32 HG008953/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7895339
MID - NIHMS1669102
OTO - NOTNLM
OT  - confidentiality/privacy
OT  - information technology
OT  - informed consent
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
AID - medethics-2020-106443 [pii]
AID - 10.1136/medethics-2020-106443 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 22. pii: medethics-2020-106443. doi:
      10.1136/medethics-2020-106443.


PMID- 32571847
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210217
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Revisiting the equity debate in COVID-19: ICU is no panacea.
PG  - 641-645
LID - 10.1136/medethics-2020-106460 [doi]
AB  - Throughout March and April 2020, debate raged about how best to allocate limited 
      intensive care unit (ICU) resources in the face of a growing COVID-19 pandemic.
      The debate was dominated by utility-based arguments for saving the most lives or 
      life-years. These arguments were tempered by equity-based concerns that triage
      based solely on prognosis would exacerbate existing health inequities, leaving
      disadvantaged patients worse off. Central to this debate was the assumption that 
      ICU admission is a valuable but scarce resource in the pandemic context.In this
      paper, we argue that the concern about achieving equity in ICU triage is
      problematic for two reasons. First, ICU can be futile and prolong or exacerbate
      suffering rather than ameliorate it. This may be especially true in patients with
      COVID-19 with emerging data showing that most who receive access to a ventilator 
      will still die. There is no value in admitting patients with poor prognostic
      indicators to ICU to meet an equity target when intensive critical care is
      contrary to their best interests. Second, the focus on ICU admission shifts focus
      away from important aspects of COVID-19 care where there is greater opportunity
      for mitigating suffering and enhancing equitable care.We propose that the focus
      on equity concerns during the pandemic should broaden to include providing all
      people who need it with access to the highest possible standard of end-of-life
      care. This requires attention to culturally safe care in the following
      interlinked areas: palliative care, communication and decision support and
      advanced care planning.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Ballantyne, Angela
AU  - Ballantyne A
AD  - Primary Health Care and General Practice, University of Otago Wellington,
      Wellington, New Zealand angela.ballantyne@otago.ac.nz.
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University Singapore, Singapore.
FAU - Rogers, Wendy A
AU  - Rogers WA
AUID- ORCID: 0000-0001-9186-870X
AD  - Philosophy and Medicine, Macquarie University, Sydney, New South Wales,
      Australia.
FAU - Entwistle, Vikki
AU  - Entwistle V
AUID- ORCID: 0000-0002-0856-4025
AD  - Health Services Research Unit and Philosophy, University of Aberdeen, Aberdeen,
      UK.
FAU - Towns, Cindy
AU  - Towns C
AD  - Department of Medicine, University of Otago, Wellington, New Zealand.
LA  - eng
GR  - HSRU2/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - *Intensive Care Units
MH  - Pandemics
MH  - *Patient Selection
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Triage/*ethics
PMC - PMC7335695
OTO - NOTNLM
OT  - *clinical ethics
OT  - *distributive justice
OT  - *end-of-life care
OT  - *living wills/advance directives
OT  - *palliative care
COIS- Competing interests: None declared
EDAT- 2020/06/24 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/05/17 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - medethics-2020-106460 [pii]
AID - 10.1136/medethics-2020-106460 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):641-645. doi: 10.1136/medethics-2020-106460. Epub
      2020 Jun 22.


PMID- 32571701
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20211204
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 8
DP  - 2020 Oct
TI  - Donor Klotho KL-VS Polymorphism Predicts Allograft Glomerulosclerosis and Early
      Post-Transplant Kidney Function.
PG  - 2371-2375
LID - S0041-1345(19)31842-1 [pii]
LID - 10.1016/j.transproceed.2020.02.086 [doi]
AB  - BACKGROUND: The Klotho protein, encoded by the KL (Klotho) gene, exerts antiaging
      and antifibrotic effects. The KL-VS genotype diminishes Klotho expression and
      correlates with cardiovascular death, heart failure, and chronic kidney disease
      progression. The aim of this study was to analyze the contribution of donor
      Klotho rs9536314 and rs9527025 polymorphisms (KL-VS genotype) to renal allograft 
      morphology and function in the early post-transplant period. METHODS: Clinical
      data and biopsy reports of 170 deceased donor transplantations were retrieved
      from standard medical files. Donor DNA was genotyped for rs9527025 and rs9536314 
      SNPs using custom TaqMan assays. RESULTS: As rs9527025 remained in full linkage
      with rs9536314, we report results for the latter. The analyses were performed for
      G dominant model (GG+GT vs TT). We found an association between reported SNP
      alleles, morphologic changes in the peritransplant biopsy, and kidney function 3 
      months after engraftment. A chronic glomerulopathy score of >0 was found in 12.2%
      of GG+GT cases and in 3.2% of TT cases (P = .023). For G allele carriers, the
      third month's median estimated glomerular filtration rate value was 35.0 (range, 
      20.4-76.6 mL/min), while for TT haplotype, the value was 46.3 (range, 15.5-96.8
      mL/min), P = .001. At the third post-transplant month, proteinuria incidence was 
      higher for organs with G allele than with TT haplotype (24.4% vs 9.5%; P = .030; 
      odds ratio 3.09; 95% confidence interval 1.22-7.69). CONCLUSION: Deceased donor
      KL-VS polymorphism, altering protein dimerization and coreceptor function,
      predicts early renal transplant glomerular lesions and function. Further analyses
      for mentioned effect durability are necessary. ETHICS STATEMENT: This study
      complies with the Helsinki Congress and the Istanbul Declaration regarding donor 
      source. Donors were not prisoners, and were not paid or coerced.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Pazik, Joanna
AU  - Pazik J
AD  - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Rembek, Karolina
AU  - Rembek K
AD  - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland. Electronic address:
      karolina.fejfer@gmail.com.
FAU - Sadowska-Jakubowicz, Anna
AU  - Sadowska-Jakubowicz A
AD  - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Sitarek, Elzbieta
AU  - Sitarek E
AD  - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Kosieradzki, Maciej
AU  - Kosieradzki M
AD  - Department and Clinic of General and Transplantation Surgery, Medical University 
      of Warsaw, Warsaw, Poland.
FAU - Durlik, Magdalena
AU  - Durlik M
AD  - Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical
      University of Warsaw, Warsaw, Poland.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200620
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - EC 3.2.1.31 (Klotho Proteins)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Female
MH  - Genotype
MH  - Glomerular Filtration Rate/genetics
MH  - Glomerulonephritis/*genetics
MH  - Glucuronidase/*genetics
MH  - Haplotypes
MH  - Humans
MH  - Kidney/metabolism
MH  - *Kidney Transplantation
MH  - Klotho Proteins
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Postoperative Complications/*genetics
MH  - Predictive Value of Tests
MH  - Tissue Donors/*statistics & numerical data
MH  - Transplants/metabolism
MH  - Treatment Outcome
EDAT- 2020/06/24 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/06/24 06:00
PHST- 2019/12/29 00:00 [received]
PHST- 2020/02/16 00:00 [revised]
PHST- 2020/02/22 00:00 [accepted]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - S0041-1345(19)31842-1 [pii]
AID - 10.1016/j.transproceed.2020.02.086 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Oct;52(8):2371-2375. doi:
      10.1016/j.transproceed.2020.02.086. Epub 2020 Jun 20.


PMID- 32571396
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 22
TI  - Protocol for a randomised controlled trial to investigate the effect of home- and
      gym-based resistance exercise training on glycaemic control, body composition and
      muscle strength.
PG  - 557
LID - 10.1186/s13063-020-04480-2 [doi]
AB  - BACKGROUND: Resistance exercise is known to be effective in reducing glycated
      haemoglobin (HbA1c) in people with type 2 diabetes. However, studies, so far,
      have employed supervised resistance exercise in a laboratory or gym facility
      which limits the future translation of such exercise in to clinical practice and 
      recommendations. Our primary aim, therefore, is to test the hypothesis, in a
      randomized controlled trial, that home-based resistance exercise training and
      gym-based resistance exercise training both reduce HbA1c levels in people with
      type 2 diabetes compared to control. We will also investigate the effects of
      home- and gym-based resistance exercise training on muscle strength and body
      composition. METHODS: The current study is a three-arm randomised controlled
      trial which will be conducted with 150 eligible people with type 2 diabetes to
      compare home-and gym-based resistance exercise training with usual care in
      Kuwait. The interventions will be delivered by exercise specialists and last for 
      32 weeks. The primary outcomes are HbA1c with secondary outcomes measuring muscle
      function, body composition, physical activity and quality of life. DISCUSSION:
      Ethical approval has been granted by the Dasman Diabetes Institute ethical review
      committee (RA/197/2019). Study findings will be disseminated through presentation
      at scientific conferences and in scientific journals. TRIAL REGISTRATION:
      NCT04136730: Retrospectively registered on 21 October 2019.
FAU - Al Ozairi, Ebaa
AU  - Al Ozairi E
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
FAU - Alsaeed, Dalal
AU  - Alsaeed D
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
AD  - Ministry of Health, Jamal Abdel Nasser Street, Sulaibkhat, 13001, Kuwait.
FAU - Taliping, Dennis
AU  - Taliping D
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
FAU - Jalali, Mohamad
AU  - Jalali M
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
AD  - Ministry of Health, Jamal Abdel Nasser Street, Sulaibkhat, 13001, Kuwait.
FAU - El Samad, Abeer
AU  - El Samad A
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
FAU - Mashankar, Anant
AU  - Mashankar A
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
FAU - Taghadom, Etab
AU  - Taghadom E
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
AD  - Ministry of Health, Jamal Abdel Nasser Street, Sulaibkhat, 13001, Kuwait.
FAU - Guess, Nicola
AU  - Guess N
AD  - Medical Division, Dasman Diabetes Institute, P.O.Box 1180, Dasman, Kuwait.
FAU - Gill, Jason M R
AU  - Gill JMR
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      G12 8TA, UK.
FAU - Sattar, Naveed
AU  - Sattar N
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      G12 8TA, UK.
FAU - Gray, Cindy
AU  - Gray C
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Welsh, Paul
AU  - Welsh P
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      G12 8TA, UK.
FAU - Gray, Stuart R
AU  - Gray SR
AUID- ORCID: http://orcid.org/0000-0001-8969-9636
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      G12 8TA, UK. stuart.gray@glasgow.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT04136730
GR  - NA/Montreal Medical International, Kuwait
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
EIN - Trials. 2020 Jul 15;21(1):650. PMID: 32669132
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Body Composition
MH  - Diabetes Mellitus, Type 2/blood/epidemiology/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin A/analysis
MH  - Glycemic Control/*methods
MH  - Humans
MH  - Kuwait/epidemiology
MH  - Male
MH  - Middle Aged
MH  - *Muscle Strength
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Resistance Training/*methods
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7310149
OTO - NOTNLM
OT  - Diabetes
OT  - Glycaemic control
OT  - Home-based
OT  - Resistance exercise
OT  - Unsupervised
EDAT- 2020/06/24 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/06/24 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.1186/s13063-020-04480-2 [doi]
AID - 10.1186/s13063-020-04480-2 [pii]
PST - epublish
SO  - Trials. 2020 Jun 22;21(1):557. doi: 10.1186/s13063-020-04480-2.


PMID- 32571382
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 22
TI  - Defining key design elements of registry-based randomised controlled trials: a
      scoping review.
PG  - 552
LID - 10.1186/s13063-020-04459-z [doi]
AB  - BACKGROUND: Traditional randomised controlled trials remain the gold standard for
      improving clinical care but they do have their limitations, including their
      associated high costs, high failure rate and limited external validity. An
      alternative methodology is the newly defined, prospective, registry-based
      randomised controlled trial (RRCT), where treatment and outcome data is collected
      in an existing registry. This scoping review explores the current literature
      regarding RRCTs to help identify the key design elements of RRCTs and the
      characteristics of clinical registries on which they are reliant on. METHODS: A
      scoping review methodology conducted in accordance with the Joanna Briggs
      Institute guidelines was performed. Four databases were searched for articles
      published from inception to June 2018: Medline; Embase; the Cumulative Index to
      Nursing and Allied Health Literature and; Scopus. The search strategy included
      MeSH and text words related to RRCT. RESULTS: We identified 2369 articles of
      which 75 were selected for full-text screening. Of these, only 17 articles
      satisfied our inclusion criteria. All studies were published between 1996 and
      2017 and all were investigator-initiated. Study designs were mainly multi-site
      comparative/effectiveness studies incorporating the use of disease registries (n 
      = 8), procedure registries (n = 8) and a health services registry (n = 1). The
      low cost, reduced administrative burden and enhanced external validity of RRCTs
      make them an attractive research methodology which can be used to address
      questions of public health importance. We identified that that there are variable
      definitions of what constituted a RRCT and that issues related to ethical conduct
      and data integrity, completeness, timeliness, validation and endpoint
      adjudication need to be carefully addressed. CONCLUSION: RRCTs potentially have
      an important role to play in informing best clinical practice and health policy. 
      There are a number of issues that need to be addressed to optimise the utility of
      this approach, including establishing universally accepted criteria for the
      definition of a RRCT.
FAU - Karanatsios, Bill
AU  - Karanatsios B
AUID- ORCID: http://orcid.org/0000-0002-0681-5986
AD  - Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.
      Bill.Karanatsios@wh.org.au.
AD  - Western Health Chronic Disease Alliance, Western Health, St Albans, VIC,
      Australia. Bill.Karanatsios@wh.org.au.
FAU - Prang, Khic-Houy
AU  - Prang KH
AD  - Centre for Health Policy, The University of Melbourne, Parkville, VIC, Australia.
FAU - Verbunt, Ebony
AU  - Verbunt E
AD  - Centre for Health Policy, The University of Melbourne, Parkville, VIC, Australia.
FAU - Yeung, Justin M
AU  - Yeung JM
AD  - Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.
AD  - Western Health Chronic Disease Alliance, Western Health, St Albans, VIC,
      Australia.
FAU - Kelaher, Margaret
AU  - Kelaher M
AD  - Centre for Health Policy, The University of Melbourne, Parkville, VIC, Australia.
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall
      Institute of Medical Research, Parkville, VIC, Australia.
AD  - Department of Medical Biology, The University of Melbourne, Parkville, VIC,
      Australia.
AD  - Department of Medical Oncology, Peter MacCallum Cancer Center, Parkville, VIC,
      Australia.
LA  - eng
GR  - NA/NA
PT  - Journal Article
PT  - Review
DEP - 20200622
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Pragmatic Clinical Trials as Topic
MH  - Prospective Studies
MH  - *Registries
MH  - *Research Design
PMC - PMC7310018
OTO - NOTNLM
OT  - Pragmatic trials
OT  - Real-world evidence
OT  - Registry
OT  - Registry trials
EDAT- 2020/06/24 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/06/24 06:00
PHST- 2019/08/13 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.1186/s13063-020-04459-z [doi]
AID - 10.1186/s13063-020-04459-z [pii]
PST - epublish
SO  - Trials. 2020 Jun 22;21(1):552. doi: 10.1186/s13063-020-04459-z.


PMID- 32571358
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20211204
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 22
TI  - Six-minute walking distance in healthy Chinese people older than 60 years.
PG  - 177
LID - 10.1186/s12890-020-01211-w [doi]
AB  - BACKGROUND: The six-minute walking test (6MWT) is a tool that plays a key role in
      evaluating the functional exercise capacity, prognosis and evaluation of
      treatment response of patients with various cardiopulmonary diseases. However,
      standard reference equations are currently unavailable for the six-minute walking
      distance (6MWD) for people aged 60-85 years in China. The purpose of this study
      was to 1) measure the 6MWD of healthy Chinese people aged 60-85 years, 2)
      establish reference equations for predicting the 6MWD, and 3) compare our
      reference equations with equations reported in previously published studies.
      METHOD: We obtained informed consent from each participant prior to the test, and
      the research design was approved by the Ethics Committee of Wenzhou People's
      Hospital. The demographic and anthropometric data and the 6MWD of healthy Chinese
      subjects aged 60-85 years old were measured using a standardized protocol. Every 
      subject completed two 6MWTs, and the longest 6MWD further analyzed. RESULTS: Two 
      hundred sixty-six subjects (128 males and 138 females) completed the 6MWT, and
      the mean walking distance was 518 +/- 72 m. Males achieved a longer walking
      distance than females (518 +/- 72 m vs. 487 +/- 70 m; p < 0.0001), and active
      subjects achieved a longer walking distance than nonactive subjects (512 +/- 76 m
      vs. 485 +/- 63 m; p < 0.0001). According to the univariate analysis, the 6MWD was
      significantly associated with age, height, body mass index (BMI), heart rate and 
      blood pressure after exercise and changes in heart rate before and after
      exercise. The stepwise multivariate regression analysis identified age, height
      and BMI as independent predictors of the 6MWD. The reference equations for
      Caucasians and South Americans tended to overestimate the 6MWD of our subjects,
      while the equations for Asian and African populations tended to underestimate the
      6MWD. CONCLUSIONS: This study is the first to describe the 6MWD of healthy
      Chinese people aged 60-85 years, and reference prediction equations were
      proposed. These findings will help to improve the evaluation of Chinese patients 
      with diseases that affect exercise capacity.
FAU - Zou, He
AU  - Zou H
AD  - Department of Cardiovascular Medicine, Wenzhou People's Hospital, the Wenzhou
      Third Clinical Institute Affiliated with Wenzhou Medical University, Wenzhou, Zhe
      Jiang, China.
FAU - Zhang, Jia
AU  - Zhang J
AD  - Department of Inspection Medical, Wenzhou People's Hospital, the Wenzhou Third
      Clinical Institute Affiliated with Wenzhou Medical University, Wenzhou, Zhe
      Jiang, China.
FAU - Zou, Yingying
AU  - Zou Y
AD  - Digestive System Department, The Third Affiliated Hospital of Qiqihar Medical
      College, Qiqihar, Heilongjiang, China.
FAU - Chen, Xiaoshu
AU  - Chen X
AD  - Department of Cardiovascular Medicine, Wenzhou People's Hospital, the Wenzhou
      Third Clinical Institute Affiliated with Wenzhou Medical University, Wenzhou, Zhe
      Jiang, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Cardiovascular Medicine, Wenzhou People's Hospital, the Wenzhou
      Third Clinical Institute Affiliated with Wenzhou Medical University, Wenzhou, Zhe
      Jiang, China.
FAU - Chen, Hao
AU  - Chen H
AD  - Department of Cardiovascular Medicine, Wenzhou People's Hospital, the Wenzhou
      Third Clinical Institute Affiliated with Wenzhou Medical University, Wenzhou, Zhe
      Jiang, China.
FAU - Ye, Fanhao
AU  - Ye F
AD  - Department of Cardiovascular Medicine, Wenzhou People's Hospital, the Wenzhou
      Third Clinical Institute Affiliated with Wenzhou Medical University, Wenzhou, Zhe
      Jiang, China.
FAU - Yu, Haizhu
AU  - Yu H
AUID- ORCID: http://orcid.org/0000-0003-1764-4032
AD  - Department of General Practice, Zhejiang Hospital, Hangzhou, Zhe Jiang, China.
      476159415@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Asians
MH  - Body Mass Index
MH  - Body Weight
MH  - China
MH  - Female
MH  - Healthy Volunteers
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Reference Values
MH  - Regression Analysis
MH  - *Walk Test
MH  - *Walking
PMC - PMC7310198
OTO - NOTNLM
OT  - Exercise testing
OT  - Healthy people
OT  - Reference equation
OT  - Six-minute walking test
EDAT- 2020/06/24 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/06/24 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1186/s12890-020-01211-w [doi]
AID - 10.1186/s12890-020-01211-w [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Jun 22;20(1):177. doi: 10.1186/s12890-020-01211-w.


PMID- 32571123
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1741-2854 (Electronic)
IS  - 0020-7640 (Linking)
VI  - 66
IP  - 7
DP  - 2020 Nov
TI  - mHealth for schizophrenia spectrum disorders management: A systematic review.
PG  - 642-665
LID - 10.1177/0020764020933287 [doi]
AB  - BACKGROUND: Various types of computational technologies can be used to access,
      store and wirelessly share private and sensitive user-related information. The
      'big data' provided by these technologies may enable researchers and clinicians
      to better identify behavioral patterns and to provide a more personalized
      approach to care. The information collected, however, can be misused or
      potentially abused, and therefore could be detrimental to the very people who
      provided their medical data with the hope of improving care. This article focuses
      on the use of emerging mobile technologies that allow the collection of data
      about patients experiencing schizophrenia spectrum and related disorders.
      Schizophrenia has been recognized by the Sustainable Development Goals of the
      United Nations for its burden on our health care system and society [1]. Our
      analysis provides an overview of the range of available mobile technologies for
      people with schizophrenia and related conditions along with the technology's
      reported capabilities and limitations, and efficacy of mHealth interventions
      based on the data from articles. Thus, the focus of this review is first and
      foremost to update the scope of existing technologies as previous systematic
      reviews such as the ones by Alvarez-Jimenez et al. and by Firth and Torous are
      outdated [2, 3]. Although we also examine the ethical issues arising from the use
      of these technologies, for an in-depth analysis of the ethical implications of
      mobile Health technologies (mHealth), we refer the readers to our follow-up
      article. In terms of the ubiquitous availability of technology on the internet,
      our article summarizes significant information for mental health specialists and 
      apprises the reader about the existence of these technologies. OBJECTIVES: In
      terms of the ubiquitous availability of technology on the internet, our article
      summarizes significant information for mental health specialists and apprises the
      reader about the existence of these technologies.
FAU - Chivilgina, Olga
AU  - Chivilgina O
AUID- ORCID: 0000-0003-1319-3692
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Wangmo, Tenzin
AU  - Wangmo T
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Elger, Bernice Simone
AU  - Elger BS
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
AD  - Center for Legal Medicine, Unit for Health Law and Humanitarian Medicine,
      University of Geneva, Switzerland.
FAU - Heinrich, Thomas
AU  - Heinrich T
AD  - Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Jotterand, Fabrice
AU  - Jotterand F
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
AD  - Medical College of Wisconsin, Milwaukee, WI, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200623
PL  - England
TA  - Int J Soc Psychiatry
JT  - The International journal of social psychiatry
JID - 0374726
SB  - IM
MH  - Delivery of Health Care
MH  - Humans
MH  - Mental Health
MH  - *Schizophrenia/therapy
MH  - Technology
MH  - *Telemedicine
OTO - NOTNLM
OT  - *Schizophrenia
OT  - *ethics
OT  - *mHealth
EDAT- 2020/06/24 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/24 06:00 [entrez]
AID - 10.1177/0020764020933287 [doi]
PST - ppublish
SO  - Int J Soc Psychiatry. 2020 Nov;66(7):642-665. doi: 10.1177/0020764020933287. Epub
      2020 Jun 23.


PMID- 32570916
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20211204
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 18
TI  - Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to
      Bedside.
LID - E1489 [pii]
LID - 10.3390/cells9061489 [doi]
AB  - Parkinson's Disease (PD) is a neurodegenerative disorder affecting the motor
      system. It is primarily due to substantial loss of midbrain dopamine (mDA)
      neurons in the substantia nigra pars compacta and to decreased innervation to the
      striatum. Although existing drug therapy available can relieve the symptoms in
      early-stage PD patients, it cannot reverse the pathogenic progression of PD.
      Thus, regenerating functional mDA neurons in PD patients may be a cure to the
      disease. The proof-of-principle clinical trials showed that human fetal
      graft-derived mDA neurons could restore the release of dopamine
      neurotransmitters, could reinnervate the striatum, and could alleviate clinical
      symptoms in PD patients. The invention of human-induced pluripotent stem cells
      (hiPSCs), autologous source of neural progenitors with less ethical
      consideration, and risk of graft rejection can now be generated in vitro. This
      advancement also prompts extensive research to decipher important developmental
      signaling in differentiation, which is key to successful in vitro production of
      functional mDA neurons and the enabler of mass manufacturing of the cells
      required for clinical applications. In this review, we summarize the biology and 
      signaling involved in the development of mDA neurons and the current progress and
      methodology in driving efficient mDA neuron differentiation from pluripotent stem
      cells.
FAU - Wang, Mengmeng
AU  - Wang M
AD  - Department of Neurobiology and Physiology, Xinxiang Medical University, Xinxiang 
      453003, Henan, China.
AD  - The International-Joint Lab for Non-invasive Neural Modulation/Key Laboratory for
      the Brain Research of Henan Province, Xinxiang Medical University, Xinxiang
      453003, Henan, China.
AD  - Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam 13200,
      Kepala Batas, Penang, Malaysia.
FAU - Ling, King-Hwa
AU  - Ling KH
AUID- ORCID: 0000-0002-3968-7263
AD  - Department of Biomedical Sciences, Faculty of Medicine, Universiti Putra
      Malaysia, Seri Kembangan 43400 Selangor, Malaysia.
AD  - Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Tan, Jun Jie
AU  - Tan JJ
AUID- ORCID: 0000-0002-7027-6657
AD  - Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam 13200,
      Kepala Batas, Penang, Malaysia.
FAU - Lu, Cheng-Biao
AU  - Lu CB
AD  - Department of Neurobiology and Physiology, Xinxiang Medical University, Xinxiang 
      453003, Henan, China.
AD  - The International-Joint Lab for Non-invasive Neural Modulation/Key Laboratory for
      the Brain Research of Henan Province, Xinxiang Medical University, Xinxiang
      453003, Henan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200618
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Cell- and Tissue-Based Therapy/methods
MH  - Dopaminergic Neurons/*cytology/*physiology
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology/physiology
MH  - Levodopa/therapeutic use
MH  - Mesencephalon/*cytology/growth & development/physiology
MH  - Models, Neurological
MH  - Nerve Regeneration/physiology
MH  - Neurogenesis/physiology
MH  - Parkinson Disease/*pathology/physiopathology/therapy
MH  - Translational Research, Biomedical
PMC - PMC7349799
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *differentiation
OT  - *midbrain dopaminergic neuron
OT  - *neurodevelopment
OT  - *pluripotent stem cells
OT  - *small molecules
EDAT- 2020/06/24 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - cells9061489 [pii]
AID - 10.3390/cells9061489 [doi]
PST - epublish
SO  - Cells. 2020 Jun 18;9(6). pii: cells9061489. doi: 10.3390/cells9061489.


PMID- 32570914
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 18
TI  - Too Cute to Kill? The Need for Objective Measurements of Quality of Life.
LID - E1054 [pii]
LID - 10.3390/ani10061054 [doi]
AB  - The recognition of animal suffering is influenced by cultural and societal
      prejudices and the cuteness of an animal leads to bias in the way it is treated. 
      It is important to consider the animal's behaviour and its environment-not just
      its physical condition-when assessing its quality of life. The Animal Welfare
      Assessment Grid (AWAG) is a useful tool for this purpose. The AWAG offers an
      evidence-based tool for continual welfare assessment, using technology where
      appropriate, such as digital activity recording, to facilitate decision-making
      and lead to improvements in the animals' quality of life. It is highly adaptable 
      to any species by assessing the four parameters of physical health, psychological
      wellbeing, environmental quality, and clinical and management procedural events. 
      The outcome of assessing welfare should be action to improve it. Societal ethics 
      and policy-making lead to legislation balancing the values we hold for different 
      species. Influencing policy development in such matters as animal welfare,
      ecological conservation, and risks to humans requires a focus on public attitudes
      to, and understanding of, science, as well as consideration of potential
      unforeseen consequences of the social/environmental/economic impacts of policies.
FAU - Wolfensohn, Sarah
AU  - Wolfensohn S
AUID- ORCID: 0000-0002-0985-3603
AD  - School of Veterinary Medicine, University of Surrey, Guildford, Surrey GU2 7AL,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7341278
OTO - NOTNLM
OT  - Welfare assessment
OT  - animal cuteness
OT  - public perception
OT  - quality of life
OT  - welfare legislation
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:01
CRDT- 2020/06/24 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/10 00:00 [revised]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:01 [medline]
AID - ani10061054 [pii]
AID - 10.3390/ani10061054 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Jun 18;10(6). pii: ani10061054. doi: 10.3390/ani10061054.


PMID- 32570573
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Addressing Ethics in the CrowdHEALTH RDI Project Concerned with Large Amounts of 
      Data to Support Health Policies.
PG  - 1189-1190
LID - 10.3233/SHTI200356 [doi]
AB  - CrowdHEALTH is a R&D project involving high volumes of health-related data.
      Although partners have been complying with all regulatory and ethical issues
      according to their context in different EU countries, ethical aspects related to 
      the adoption of the project results and possible impact on individuals and
      populations were not in the project agenda from the outset. Inspired by an
      increasing number of initiatives in the EU concerned with aspects related to
      ethics in research and innovation, future plans consider investigating the level 
      of awareness of all stakeholders involved in the project about the potential
      implications of their actions in terms of ethical acceptance of project outcomes.
FAU - Montandon, Lydia
AU  - Montandon L
AD  - Research & Innovation, Atos Spain, Spain.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Health Policy
MH  - Humans
MH  - Morals
OTO - NOTNLM
OT  - Ethical Issues
OT  - Ethics
OT  - RRI
OT  - Responsible Innovation
EDAT- 2020/06/24 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - SHTI200356 [pii]
AID - 10.3233/SHTI200356 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:1189-1190. doi: 10.3233/SHTI200356.


PMID- 32570559
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Legal and Ethical Issues in Secondary Use of Administrative Health Data: The Case
      of Latvian Healthcare Monitoring Datalink.
PG  - 1138-1142
LID - 10.3233/SHTI200340 [doi]
AB  - The paper presents analysis of the legal and ethical issues surrounding
      establishment of the Latvian Healthcare Monitoring Datalink. The paper covers
      three interconnected issues in the context of the use of administrative health
      data for research purposes - anonymization of data, concept of 'public interest' 
      and involvement of research ethics committees. The analysis has been put into
      broader context of interaction between General Data Protection Regulation (GDPR),
      national legislative measures and practical needs of researchers. Neither GDPR,
      nor Latvian legal framework regulate the particularities on the use of
      potentially identifiable health data in research. Also, the practical use of
      'public interest' as a basis for lawful processing of personal data concerning
      health for research purposes is not clear. More extended involvement of research 
      ethics committees might serve as useful tool for determination the 'public
      interest' and for the evaluation of proportionality when balancing the aims of
      the research and the personal data protection.
FAU - Mezinska, Signe
AU  - Mezinska S
AD  - University of Latvia, Faculty of Medicine.
FAU - Buka, Arnis
AU  - Buka A
AD  - University of Latvia, Faculty of Law.
FAU - Bankava, Agnese
AU  - Bankava A
AD  - University of Latvia, Faculty of Law.
FAU - Barzdins, Juris
AU  - Barzdins J
AD  - University of Latvia, Faculty of Medicine.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - Computer Security
MH  - Data Anonymization
MH  - *Delivery of Health Care
MH  - Ethics Committees, Research
MH  - Informed Consent
OTO - NOTNLM
OT  - Personal data
OT  - anonymization
OT  - data concerning health
OT  - informed consent
OT  - public interest
OT  - secondary use
EDAT- 2020/06/24 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - SHTI200340 [pii]
AID - 10.3233/SHTI200340 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:1138-1142. doi: 10.3233/SHTI200340.


PMID- 32570551
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Citizens' Participation in Health and Scientific Research in Switzerland.
PG  - 1098-1102
LID - 10.3233/SHTI200332 [doi]
AB  - Understanding motivation and resistance factors affecting citizen participation
      in health and scientific research allows to find solutions to improve citizen
      engagement and interest in science. Through a survey, we identified the main
      factors influencing citizens' participation in scientific research, and their
      wishes to be more informed. Results show that the respondents' reasons to
      participate in research were altruistic motivations, in line with other studies
      carried out in developed countries. The main factor influencing the
      non-participation is the lack of opportunity, highlighting the importance to
      better inform citizens about ongoing studies.
FAU - Rochat, Jessica
AU  - Rochat J
AD  - Faculty of medicine, University of Geneva, Switzerland.
FAU - Gaudet-Blavignac, Christophe
AU  - Gaudet-Blavignac C
AD  - Division of medical information sciences, University Hospitals of Geneva,
      Switzerland.
FAU - Del Zotto, Marzia
AU  - Del Zotto M
AD  - Division of medical information sciences, University Hospitals of Geneva,
      Switzerland.
FAU - Ruiz Garretas, Victor
AU  - Ruiz Garretas V
AD  - Division of medical information sciences, University Hospitals of Geneva,
      Switzerland.
FAU - Foufi, Vasiliki
AU  - Foufi V
AD  - Faculty of medicine, University of Geneva, Switzerland.
AD  - Division of medical information sciences, University Hospitals of Geneva,
      Switzerland.
FAU - Issom, David
AU  - Issom D
AD  - Division of medical information sciences, University Hospitals of Geneva,
      Switzerland.
FAU - Samer, Caroline
AU  - Samer C
AD  - Faculty of medicine, University of Geneva, Switzerland.
AD  - Division of clinical pharmacology and toxicology, University Hospitals of Geneva,
      Switzerland.
FAU - Hurst, Samia
AU  - Hurst S
AD  - Faculty of medicine, University of Geneva, Switzerland.
FAU - Lovis, Christian
AU  - Lovis C
AD  - Faculty of medicine, University of Geneva, Switzerland.
AD  - Division of medical information sciences, University Hospitals of Geneva,
      Switzerland.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Biomedical Research
MH  - Community Participation
MH  - Comprehension
MH  - Motivation
MH  - Surveys and Questionnaires
MH  - Switzerland
OTO - NOTNLM
OT  - Community participation
OT  - attitude
OT  - clinical trial
OT  - ethics
OT  - global health
OT  - motivation
OT  - research
EDAT- 2020/06/24 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - SHTI200332 [pii]
AID - 10.3233/SHTI200332 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:1098-1102. doi: 10.3233/SHTI200332.


PMID- 32570550
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Big Data, Information Technology and Information Professionals: Some
      Considerations for Digital Ethics.
PG  - 1094-1097
LID - 10.3233/SHTI200331 [doi]
AB  - It is generally accepted that the global evolution of health information
      technology, both in design and usage, raises ethical issues that should be
      addressed. However, the terms in which this concern is expressed are shrouded in 
      ambiguity. Even what constitutes an ethical issue itself is never clearly
      defined. The present discussion attempts to clarify the landscape and suggests
      how the concern should be addressed.
FAU - Kluge, E-H
AU  - Kluge EH
AD  - IMIA (SiHIS) and University of Victoria.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - Big Data
MH  - Humans
MH  - *Information Technology
MH  - *Medical Informatics
OTO - NOTNLM
OT  - Information technology
OT  - certification
OT  - digital ethics
EDAT- 2020/06/24 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - SHTI200331 [pii]
AID - 10.3233/SHTI200331 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:1094-1097. doi: 10.3233/SHTI200331.


PMID- 32570549
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Autonomous Systems and Artificial Intelligence in Healthcare Transformation to 5P
      Medicine - Ethical Challenges.
PG  - 1089-1093
LID - 10.3233/SHTI200330 [doi]
AB  - The paper introduces a structured approach to transforming healthcare towards
      personalized, preventive, predictive, participative precision (P5) medicine and
      the related organizational, methodological and technological requirements.
      Thereby, the deployment of autonomous systems and artificial intelligence is
      inevitably. The paper discusses opportunities and challenges of those
      technologies from a humanistic and ethical perspective. It shortly introduces the
      essential concepts and principles, and critically discusses some relevant
      projects. Finally, it offers ways for correctly representing, specifying,
      implementing and deploying autonomous and intelligent systems under an ethical
      perspective.
FAU - Blobel, Bernd
AU  - Blobel B
AD  - Medical Faculty, University of Regensburg, Germany.
AD  - eHealth Competence Center Bavaria, Deggendorf Institute of Technology, Germany.
AD  - First Medical Faculty, Charles University of Prague, Czech Republic.
FAU - Ruotsalainen, Pekka
AU  - Ruotsalainen P
AD  - Tampere University, Tampere, Finland.
FAU - Brochhausen, Mathias
AU  - Brochhausen M
AD  - College of Medicine, University of Florida, Gainesville, FL, USA.
FAU - Oemig, Frank
AU  - Oemig F
AD  - Deutsche Telekom Healthcare and Security Solutions GmbH, Bonn, Germany.
FAU - Uribe, Gustavo A
AU  - Uribe GA
AD  - The European Organization for Nuclear Research, Geneva, Switzerland.
AD  - Telematics Engineering Research Group, University of Cauca, Popayan, Colombia.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - *Artificial Intelligence
MH  - Delivery of Health Care
MH  - *Medicine
MH  - Morals
OTO - NOTNLM
OT  - P5 medicine
OT  - artificial intelligence
OT  - autonomous systems
OT  - ethical principles
OT  - pHealth
EDAT- 2020/06/24 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - SHTI200330 [pii]
AID - 10.3233/SHTI200330 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:1089-1093. doi: 10.3233/SHTI200330.


PMID- 32570440
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1879-8365 (Electronic)
IS  - 0926-9630 (Linking)
VI  - 270
DP  - 2020 Jun 16
TI  - Are Clinical Decision Support Systems Compatible with Patient-Centred Care?
PG  - 532-536
LID - 10.3233/SHTI200217 [doi]
AB  - Few, if any, of the Clinical Decision Support Systems developed and reported
      within the informatics literature incorporate patient preferences in the formal
      and quantitatively analytic way adopted for evidence. Preferences are assumed to 
      be 'taken into account' by the clinician in the associated clinical encounter.
      Many CDSS produce management recommendations on the basis of embedded algorithms 
      or expert rules. These are often focused on a single criterion, and the
      preference trade-offs involved have no empirical basis outside an expert panel.
      After illustrating these points with the Osteoporosis Adviser CDSS from Iceland, 
      we review an ambitious attempt to address both the monocriterial bias and lack of
      empirical preference-sensitivity, in the context of Early Rheumatoid Arthritis.
      It brings together the preference data from a Discrete Choice Experiment and the 
      best available evidence data, to arrive at the percentage of patients who would
      prefer particular treatments from those in the listed options. It is suggested
      that these percentages could assist a GRADE panel determine whether to produce a 
      strong or weak recommendation. However, any such group average preference-based
      recommendations are arguably in breach of both the reasonable patient legal
      standard for informed consent and simple ethical principles. The answer is not to
      localise, but personalise, decisions through the use of preference-sensitive
      multi-criteria decision support tools engaged with at the point of care.
FAU - Rajput, Vije Kumar
AU  - Rajput VK
AD  - Stonydelph Health Centre, Tamworth, UK.
FAU - Dowie, Jack
AU  - Dowie J
AD  - London School of Hygiene and Tropical Medicine.
AD  - University of Southern Denmark.
FAU - Kaltoft, Mette Kjer
AU  - Kaltoft MK
AD  - University of Southern Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Stud Health Technol Inform
JT  - Studies in health technology and informatics
JID - 9214582
MH  - Decision Making
MH  - *Decision Support Systems, Clinical
MH  - Humans
MH  - Iceland
MH  - Informed Consent
MH  - Patient-Centered Care
OTO - NOTNLM
OT  - Clinical Decision Support System
OT  - GRADE
OT  - guidelines
OT  - multi-criteria decision support
OT  - osteoporosis
OT  - rheumatoid arthritis
EDAT- 2020/06/24 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - SHTI200217 [pii]
AID - 10.3233/SHTI200217 [doi]
PST - ppublish
SO  - Stud Health Technol Inform. 2020 Jun 16;270:532-536. doi: 10.3233/SHTI200217.


PMID- 32566760
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210914
IS  - 2398-502X (Print)
IS  - 2398-502X (Linking)
VI  - 5
DP  - 2020
TI  - Estimating the burden of antimicrobial resistance in Malawi: protocol for a
      prospective observational study of the morbidity, mortality and economic cost of 
      third-generation cephalosporin resistant bloodstream infection.
PG  - 29
LID - 10.12688/wellcomeopenres.15719.2 [doi]
AB  - Introduction: Antimicrobial resistance (AMR) is a global public health concern,
      but the problems are context specific, with each county or setting facing
      differing challenges. In sub-Saharan Africa, third-generation cephalosporin
      resistant Enterobacterales (3GCR-E) are of particular concern, given the
      widespread reliance on ceftriaxone for treatment of severe infection in this
      setting. In Malawi, despite rising prevalence of 3GCR-E, the health-impact of
      these infections has not been described. This study is designed to estimate
      attributable mortality, morbidity and economic cost of 3GCR-E bloodstream
      infection (BSI) in a large, urban hospital. Methods: This study will investigate 
      the burden of AMR by recruiting a a prospective longitudinal cohort of patients
      who have bloodstream infection with 3GCR-E, at Queen Elizabeth Central Hospital, 
      Blantyre, Malawi. Patients whose blood culture is positive for either
      third-generation cephalosporin susceptible (3GC-S) or third-generation resistant 
      (3GC-R) Enterobacterales will be enrolled and provide clinical and healthcare
      economic data. Patients will be followed throughout their hospital stay and to
      6-months post discharge. The primary outcomes for the study are mortality and
      morbidity from 3GCR-E. Healthcare economic outcomes will be assessed by comparing
      healthcare provider costs, indirect patient costs and health-related quality of
      life outcomes in patients with 3GC-S and 3GC-R BSI. Based on our observation that
      some patients with clinical suspicion of sepsis and 3GC-R BSI are surviving
      without an effective antibiotic, we review each patient prospectively and
      classify what role the isolated bacteria is playing in the patient's clinical
      presentation. Each BSI episode will be classified into the following categories: 
      definite Gram-negative sepsis, probable Gram-negative sepsis, transient or occult
      bacteraemia, or contaminated blood culture. These classifications will be
      incorporated into our analysis. Ethics and dissemination: The study protocol has 
      been approved by the Malawi College of Medicine Research Ethics Committee and by 
      the Liverpool School of Tropical Medicine Research Ethics committee.
CI  - Copyright: (c) 2020 Lester R et al.
FAU - Lester, Rebecca
AU  - Lester R
AUID- ORCID: https://orcid.org/0000-0002-0259-9630
AD  - Liverpool School of Tropical Medicine, Liverpool, UK.
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
FAU - Maheswaran, Hendran
AU  - Maheswaran H
AUID- ORCID: https://orcid.org/0000-0002-7375-4845
AD  - Institute of Population Health Sciences, University of Liverpool, Liverpool, UK.
FAU - Jewell, Christopher P
AU  - Jewell CP
AUID- ORCID: https://orcid.org/0000-0002-7902-2178
AD  - Centre for Health Informatics, Computing and Statistics, Lancaster University,
      Lancaster, UK.
FAU - Lalloo, David G
AU  - Lalloo DG
AUID- ORCID: https://orcid.org/0000-0001-7680-2200
AD  - Liverpool School of Tropical Medicine, Liverpool, UK.
FAU - Feasey, Nicholas A
AU  - Feasey NA
AUID- ORCID: https://orcid.org/0000-0003-4041-1405
AD  - Liverpool School of Tropical Medicine, Liverpool, UK.
AD  - Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200601
PL  - England
TA  - Wellcome Open Res
JT  - Wellcome open research
JID - 101696457
PMC - PMC7290274
OTO - NOTNLM
OT  - Africa south of the Sahara
OT  - Antimicrobial resistance
OT  - Enterobacterales
OT  - Extended-spectrum beta-lactamase
OT  - Third-generation cephalosporin
COIS- No competing interests were disclosed.
EDAT- 2020/06/24 06:00
MHDA- 2020/06/24 06:01
CRDT- 2020/06/24 06:00
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2020/06/24 06:01 [medline]
AID - 10.12688/wellcomeopenres.15719.2 [doi]
PST - epublish
SO  - Wellcome Open Res. 2020 Jun 1;5:29. doi: 10.12688/wellcomeopenres.15719.2.
      eCollection 2020.


PMID- 35517343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 10
IP  - 40
DP  - 2020 Jun 19
TI  - In vitro toxicity assessment and enhanced drug solubility profile of green deep
      eutectic solvent derivatives (DESDs) combined with theoretical validation.
PG  - 24063-24072
LID - 10.1039/c9ra10320a [doi]
AB  - Green solvents are actively taking over as the absolute replacement of intrinsic 
      toxic volatile organic solvents. This is conspicuously analyzed in this study,
      which mentions the preparation of green deep eutectic solvent derivatives (DESDs)
      composed of choline chloride (ChCl) as the hydrogen bond acceptor (HBA) and two
      acids, viz., oxalic acid (OX) and citric acid (CA) as preliminary hydrogen bond
      donors (HBDs) with ethylene glycol (EG) and glycerol (GLY) as secondary HBDs in
      an equimolar ratio. This study exposes the vigilant choice of the type and mole
      ratio of HBA and HBDs, which permit the extended stability of the formulated
      DESDs in the liquid state even below the room temperature. The prepared DESDs
      were well-characterized by FT-IR spectroscopy. Furthermore, this work aimed at
      investigating their antimicrobial activity towards selected bacterial and fungal 
      strains expressed in terms of viscosity measurements. The in vitro toxicity
      profiles in terms of cytotoxicity (human cervical cancer cell line) and
      genotoxicity (DNA fragmentation), which have not been reported to date, were also
      assessed for the prepared DESDs. Tuning the HBA and HBDs in selected DESDs for
      promising biological activity was found to have ethical implications. In
      addition, this study focused on the solubilization enhancement of the local
      anaesthetic drug lidocaine (LDC) in the stated DESDs as a function of water
      composition, and higher solubility was observed due to the fair intermolecular
      hydrogen bonding interactions between LDC and DESDs, which was further validated 
      using the computational simulation approach. In addition, the electron-donating
      and accepting sites were depicted by 3D-molecular electrostatic potential
      (3D-MEP) for the examined systems. The observed variations were attributed to the
      changes in the solvation capacity, viscosity and ionic strength of pure DESDs as 
      a function of water concentration. Finally, this study supports the role of dual 
      HBDs in leading to the formation of stable DESDs with noteworthy action towards
      drug solubilization and a remarkable biological response.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Jangir, Anil Kumar
AU  - Jangir AK
AD  - Department of Applied Chemistry, Sardar Vallabhbhai National Institute of
      Technology Surat-395 007 Gujarat India ketankuperkar@gmail.com.
FAU - Lad, Bhoomi
AU  - Lad B
AD  - Department of Biotechnology, Shree Ramkrishna Institute of Computer Education and
      Applied Science Surat-395 001 Gujarat India.
FAU - Dani, Unnati
AU  - Dani U
AD  - Department of Chemistry, Bhagwan Mahavir College of Science and Technology
      Surat-395 017 Gujarat India.
FAU - Shah, Nehal
AU  - Shah N
AD  - Department of Biotechnology, Shree Ramkrishna Institute of Computer Education and
      Applied Science Surat-395 001 Gujarat India.
FAU - Kuperkar, Ketan
AU  - Kuperkar K
AUID- ORCID: https://orcid.org/0000-0001-9175-8906
AD  - Department of Applied Chemistry, Sardar Vallabhbhai National Institute of
      Technology Surat-395 007 Gujarat India ketankuperkar@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200624
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9055130
COIS- The author declares no conflict of interest.
EDAT- 2020/06/24 00:00
MHDA- 2020/06/24 00:01
CRDT- 2022/05/06 05:48
PHST- 2019/12/09 00:00 [received]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2022/05/06 05:48 [entrez]
PHST- 2020/06/24 00:00 [pubmed]
PHST- 2020/06/24 00:01 [medline]
AID - 10.1039/c9ra10320a [doi]
AID - c9ra10320a [pii]
PST - epublish
SO  - RSC Adv. 2020 Jun 24;10(40):24063-24072. doi: 10.1039/c9ra10320a. eCollection
      2020 Jun 19.


PMID- 32570292
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20220727
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 2
DP  - 2020 Jul
TI  - Tracking, tracing, trust: contemplating mitigating the impact of COVID-19 through
      technological interventions.
PG  - 94-94.e1
LID - 10.5694/mja2.50680 [doi]
FAU - Coghlan, Simon
AU  - Coghlan S
AUID- ORCID: 0000-0002-6021-9878
AD  - Centre for Artificial Intelligence and Digital Ethics, University of Melbourne,
      Melbourne, VIC.
FAU - Cheong, Marc
AU  - Cheong M
AD  - Centre for Artificial Intelligence and Digital Ethics, University of Melbourne,
      Melbourne, VIC.
FAU - Coghlan, Benjamin
AU  - Coghlan B
AD  - Centre for International Health, Burnet Institute, Melbourne, VIC.
AD  - Monash University, Melbourne, VIC.
LA  - eng
PT  - Letter
DEP - 20200622
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cell Phone
MH  - Contact Tracing/*statistics & numerical data
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Models, Theoretical
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Quarantine/statistics & numerical data
MH  - SARS-CoV-2
MH  - *Trust
PMC - PMC7361927
OTO - NOTNLM
OT  - *COVID-19
OT  - *Epidemics
OT  - *Ethics
OT  - *Public health
OT  - *Public policy
EDAT- 2020/06/23 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.5694/mja2.50680 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Jul;213(2):94-94.e1. doi: 10.5694/mja2.50680. Epub 2020 Jun 22.


PMID- 32570282
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 10
DP  - 2020 Oct
TI  - Improving the Quality of Ethical Decision Making in Oncology.
PG  - 2413-2414
LID - 10.1111/jgs.16668 [doi]
FAU - Mattes, Malcolm D
AU  - Mattes MD
AUID- ORCID: 0000-0002-1151-896X
AD  - Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New
      Brunswick, New Jersey, USA.
LA  - eng
PT  - Letter
DEP - 20200622
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Decision Making/*ethics
MH  - Humans
MH  - Medical Oncology/*ethics
MH  - Patient Care Team/*ethics
MH  - Quality of Health Care/*ethics
EDAT- 2020/06/23 06:00
MHDA- 2021/03/11 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1111/jgs.16668 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Oct;68(10):2413-2414. doi: 10.1111/jgs.16668. Epub 2020
      Jun 22.


PMID- 32570274
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220531
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 87
IP  - 6
DP  - 2020 Nov 16
TI  - Conservative Management of Type II Odontoid Fractures in Older People: A
      Retrospective Observational Comparison of Osseous Union Versus Nonunion.
PG  - E648-E654
LID - 10.1093/neuros/nyaa256 [doi]
AB  - BACKGROUND: Type II odontoid fractures are a common cervical fracture in older
      people. Lower osseous-union rates are reported in those treated conservatively
      compared to surgically; however, the clinical relevance of a nonunion is unknown.
      OBJECTIVE: To compare pain, disability, and quality of life in older people
      following conservative management of type II odontoid fractures demonstrating
      osseous-union and nonunion. METHODS: Electronic records were searched from 2008
      to 2018 for adults >/=65 yr with type II odontoid fracture, managed in a
      semi-rigid collar. Clinical and demographic data were retrieved from electronic
      patient notes. Surviving patients were invited to complete questionnaires to
      assess pain, disability, and quality of life. Ethical approval was granted.
      RESULTS: A total of 125 patients were identified: 36 (29%) demonstrated
      osseous-union, 89 (71%) had nonunion, of which 33 (40%) had radiological
      instability. Mean age at fracture was 84 yr (osseous-union 83 yr; nonunion 84
      yr). A total of 53 had deceased (41 nonunion). Median length of survival was 77
      mo for osseous-union vs 50 mo for nonunion; P = .02. No patient developed
      myelopathy during the follow-up period. Questionnaire response rate was 39 (58%).
      There were no statistically significant differences between the groups in terms
      of pain, disability, or quality of life (P > .05). Both groups reported mild
      disability and pain but low quality of life. CONCLUSION: Management with a
      semi-rigid collar in older people with type II odontoid fracture is associated
      with low levels of pain and disability without statistically significant
      differences between those demonstrating osseous-union or stable or unstable
      nonunions. Conservative management appears to be a safe treatment for older
      people with type II fractures.
CI  - Copyright (c) 2020 by the Congress of Neurological Surgeons.
FAU - McIlroy, Suzanne
AU  - McIlroy S
AUID- ORCID: 0000-0002-1863-9473
AD  - Physiotherapy Department, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
FAU - Lam, Jordan
AU  - Lam J
AD  - University College London, London, United Kingdom.
FAU - Khan, Muhammad Faheem
AU  - Khan MF
AD  - Neurosurgery Department, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
FAU - Mirza, Asfand Baig
AU  - Mirza AB
AD  - Neurosurgery Department, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
FAU - Philip, Jerry Ajayi
AU  - Philip JA
AD  - Neurosurgery Department, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
FAU - Grahovac, Gordan
AU  - Grahovac G
AD  - Neurosurgery Department, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
FAU - Bell, David
AU  - Bell D
AD  - Neurosurgery Department, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
SB  - IM
CIN - Neurosurgery. 2020 Nov 16;87(6):E655-E656. PMID: 32687593
MH  - Adult
MH  - Aged
MH  - Conservative Treatment
MH  - Humans
MH  - *Odontoid Process/diagnostic imaging/injuries/surgery
MH  - Quality of Life
MH  - Retrospective Studies
MH  - *Spinal Fractures/diagnostic imaging/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Aged
OT  - *Disability
OT  - *Follow-up studies
OT  - *Fractures, Bone
OT  - *Neck pain
OT  - *Odontoid process
OT  - *Quality of life
EDAT- 2020/06/23 06:00
MHDA- 2022/01/06 06:00
CRDT- 2020/06/23 06:00
PHST- 2019/09/07 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 5860970 [pii]
AID - 10.1093/neuros/nyaa256 [doi]
PST - ppublish
SO  - Neurosurgery. 2020 Nov 16;87(6):E648-E654. doi: 10.1093/neuros/nyaa256.


PMID- 32570061
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210127
IS  - 1872-8464 (Electronic)
IS  - 0165-5876 (Linking)
VI  - 136
DP  - 2020 Sep
TI  - Quality of life and parental care burden in cochlear implanted children: A
      case-control study.
PG  - 110164
LID - S0165-5876(20)30307-4 [pii]
LID - 10.1016/j.ijporl.2020.110164 [doi]
AB  - OBJECTIVES: Cochlear implantation is a widely accepted and effective surgical
      method used to treat severe hearing loss. What's more, it affects the lives of
      both cochlear implanted children and their parents. This study aims to compare
      cochlear-implanted children (CIC) and their parents with healthy counterparts and
      their parents in terms of the quality of life (QOL) and parental care burden
      (CB). METHODS: This study was conducted between February and December 2018 in
      Turkey after receiving approval from the ethics committee. The Case Group
      included 34 children between 3 and 7 years of age, who received a CI due to
      bilateral prelingual sensorineural hearing loss and were using it for at least 1 
      year, and their parents. The Control Group consisted of 68 healthy children and
      their parents. The data were collected using disease and age-specific quality of 
      life scales and burden interview. Normally distributed variables were analysed
      using parametric tests while non-normally distributed variables were analysed
      using nonparametric tests. The odds ratio (OR) and confidence interval (95%) were
      also calculated. Results were evaluated at significance level of p < 0.05.
      RESULTS: The mean age of the children and their parents in both Case and Control 
      Groups was 63.9 months and 33.8 years, and 61.3 months and 36.6 years,
      respectively. There was a positive correlation between PPQ social relationship
      subscale and KINDL subscale scores in CIC (p < 0.05). The Case Group obtained
      lower mean scores from the subscales of KINDL and WHOQOL-BREF (p < 0.001, p <
      0.01). The ZBI mean scores of the parents in Case and Control Groups were 43.18
      and 27.54, respectively (p = 0.000). CONCLUSION: It was determined that the QOL
      of the Case Group was lower than QOL of the Control Group, while the CB of the
      Case Group was higher than CB of the Control Group.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Vermi Sli Peker, Sevgi
AU  - Vermi Sli Peker S
AD  - Health Sciences University Tepecik Training and Research Hospital, Department of 
      Ear Nose Throat and Head Neck Surgery, Izmir, Turkey. Electronic address:
      sevgi0535@yahoo.com.
FAU - Demi R Korkmaz, Fatma
AU  - Demi R Korkmaz F
AD  - Ege University Faculty of Nursing, Department of Surgical Nursing, Izmir, Turkey.
      Electronic address: demir.fatos@gmail.com.
FAU - Cukurova, Ibrahim
AU  - Cukurova I
AD  - Health Sciences University Tepecik Training and Research Hospital, Department of 
      Ear Nose Throat and Head Neck Surgery, Izmir, Turkey. Electronic address:
      cukurova57@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200606
PL  - Ireland
TA  - Int J Pediatr Otorhinolaryngol
JT  - International journal of pediatric otorhinolaryngology
JID - 8003603
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - *Cochlear Implantation
MH  - *Cochlear Implants
MH  - Female
MH  - Health Status
MH  - Hearing Loss/psychology/*therapy
MH  - Humans
MH  - Male
MH  - Parents/*psychology
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Turkey
OTO - NOTNLM
OT  - Burden of illness
OT  - Cochlear implantation
OT  - Family caregivers
OT  - Parental notification
OT  - Quality of life
OT  - Sensorineural hearing loss
EDAT- 2020/06/23 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/05/10 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - S0165-5876(20)30307-4 [pii]
AID - 10.1016/j.ijporl.2020.110164 [doi]
PST - ppublish
SO  - Int J Pediatr Otorhinolaryngol. 2020 Sep;136:110164. doi:
      10.1016/j.ijporl.2020.110164. Epub 2020 Jun 6.


PMID- 32570047
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1532-3374 (Electronic)
IS  - 0959-289X (Linking)
VI  - 43
DP  - 2020 Aug
TI  - Inhalational induction of general anaesthesia for elective caesarean: ethical
      acceptability in treatment-resistant needle phobia?
PG  - 27-29
LID - S0959-289X(20)30068-6 [pii]
LID - 10.1016/j.ijoa.2020.05.007 [doi]
AB  - We describe the anaesthetic management of a parturient who, due to a severe
      needle phobia, requested an inhalational induction of general anaesthesia for an 
      elective caesarean section. If general anaesthesia is indicated, conventional
      practice in the UK is to perform a rapid sequence induction via an intravenous
      route of drug administration to allow rapid intubation of the trachea. This is
      because obstetric patients are considered to have a 'full stomach' due to the
      effects of pregnancy and labour on gastric emptying, and a higher risk of
      aspiration with consequent maternal and fetal adverse outcomes. Despite a
      thorough consent process highlighting these significant risks, the patient
      insisted on an inhalational induction of anaesthesia. We present the case and
      discuss the ethical dilemma (relating to patient care) in situations in which
      decisions made by patients deviate from medical recommendations.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Parrott, N
AU  - Parrott N
AD  - Department of Anaesthesia, Royal Surrey County Hospital, Guildford, United
      Kingdom. Electronic address: tashy13@hotmail.co.uk.
FAU - Prabhu, P
AU  - Prabhu P
AD  - Department of Anaesthesia, Royal Surrey County Hospital, Guildford, United
      Kingdom.
FAU - Yeow, C
AU  - Yeow C
AD  - Department of Anaesthesia, Royal Surrey County Hospital, Guildford, United
      Kingdom.
LA  - eng
PT  - Case Reports
DEP - 20200530
PL  - Netherlands
TA  - Int J Obstet Anesth
JT  - International journal of obstetric anesthesia
JID - 9200430
SB  - IM
MH  - Anesthesia, General/*methods
MH  - Anesthesia, Inhalation/ethics/*methods/psychology
MH  - Anesthesia, Obstetrical/*ethics/*methods/psychology
MH  - *Cesarean Section
MH  - Elective Surgical Procedures
MH  - Female
MH  - Humans
MH  - Phobic Disorders/*psychology
MH  - Pregnancy
OTO - NOTNLM
OT  - *Consent
OT  - *Inhalational induction
OT  - *Medical ethics
EDAT- 2020/06/23 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/06/23 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - S0959-289X(20)30068-6 [pii]
AID - 10.1016/j.ijoa.2020.05.007 [doi]
PST - ppublish
SO  - Int J Obstet Anesth. 2020 Aug;43:27-29. doi: 10.1016/j.ijoa.2020.05.007. Epub
      2020 May 30.


PMID- 32569622
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20210110
IS  - 0003-4509 (Print)
IS  - 0003-4509 (Linking)
VI  - 78
IP  - 5
DP  - 2020 Sep
TI  - [Ethics and biomedical research during the COVID-19 epidemic: Let's not confuse
      speed and precipitation!]
PG  - 365-367
LID - S0003-4509(20)30080-8 [pii]
LID - 10.1016/j.pharma.2020.05.004 [doi]
FAU - Bertrand, B
AU  - Bertrand B
AD  - Service pharmacie, centre hospitalier de Grasse, chemin de Clavary, 06135 Grasse 
      cedex, France; Comite de Protection des Personnes Sud Mediterranee V, Nice,
      France. Electronic address: ben.bertrand@ch-grasse.fr.
FAU - Bertrand, B
AU  - Bertrand B
AD  - Pole d'anesthesie reanimation, CHU Grenoble Alpes, Grenoble, France.
FAU - Bertrand, B
AU  - Bertrand B
AD  - Service de chirurgie plastique et reconstructrice, hopital de la Conception,
      Assistance publique-Hopitaux de Marseille, Marseille, France; UMR1263, Inserm,
      Inra, AMU, laboratoire C2VN, France.
FAU - Bertrand, P-M
AU  - Bertrand PM
AD  - Service de medecine intensive et reanimation, centre hospitalier de Cannes,
      Cannes, France; Comite d'ethique du centre hospitalier de Cannes, Cannes, France.
LA  - fre
PT  - Journal Article
PT  - Comment
TT  - Ethique et recherche biomedicale durant l'epidemie du COVID-19 : ne confondons
      pas vitesse et precipitation !
DEP - 20200620
PL  - France
TA  - Ann Pharm Fr
JT  - Annales pharmaceutiques francaises
JID - 2985176R
SB  - IM
CON - Ann Pharm Fr. 2020 Jul;78(4):285-286. PMID: 32389374
MH  - Betacoronavirus
MH  - *Biomedical Research
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Seroepidemiologic Studies
PMC - PMC7305705
EDAT- 2020/06/23 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - S0003-4509(20)30080-8 [pii]
AID - 10.1016/j.pharma.2020.05.004 [doi]
PST - ppublish
SO  - Ann Pharm Fr. 2020 Sep;78(5):365-367. doi: 10.1016/j.pharma.2020.05.004. Epub
      2020 Jun 20.


PMID- 32569517
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 1545-4509 (Electronic)
IS  - 0066-4154 (Linking)
VI  - 89
DP  - 2020 Jun 20
TI  - Synthetic Genomes.
PG  - 77-101
LID - 10.1146/annurev-biochem-013118-110704 [doi]
AB  - DNA synthesis technology has progressed to the point that it is now practical to 
      synthesize entire genomes. Quite a variety of methods have been developed, first 
      to synthesize single genes but ultimately to massively edit or write from scratch
      entire genomes. Synthetic genomes can essentially be clones of native sequences, 
      but this approach does not teach us much new biology. The ability to endow
      genomes with novel properties offers special promise for addressing questions not
      easily approachable with conventional gene-at-a-time methods. These include
      questions about evolution and about how genomes are fundamentally wired
      informationally, metabolically, and genetically. The techniques and technologies 
      relating to how to design, build, and deliver big DNA at the genome scale are
      reviewed here. A fuller understanding of these principles may someday lead to the
      ability to truly design genomes from scratch.
FAU - Zhang, Weimin
AU  - Zhang W
AD  - Institute for Systems Genetics and Department of Biochemistry and Molecular
      Pharmacology, New York University Langone Health, New York, NY 10016, USA; email:
      weimin.zhang@nyulangone.org, leslie.mitchell@nyulangone.org,
      jef.boeke@nyulangone.org.
FAU - Mitchell, Leslie A
AU  - Mitchell LA
AD  - Institute for Systems Genetics and Department of Biochemistry and Molecular
      Pharmacology, New York University Langone Health, New York, NY 10016, USA; email:
      weimin.zhang@nyulangone.org, leslie.mitchell@nyulangone.org,
      jef.boeke@nyulangone.org.
FAU - Bader, Joel S
AU  - Bader JS
AD  - Department of Biomedical Engineering, Whiting School of Engineering, Johns
      Hopkins University, Baltimore, Maryland 21218, USA; email: joel.bader@jhu.edu.
FAU - Boeke, Jef D
AU  - Boeke JD
AD  - Institute for Systems Genetics and Department of Biochemistry and Molecular
      Pharmacology, New York University Langone Health, New York, NY 10016, USA; email:
      weimin.zhang@nyulangone.org, leslie.mitchell@nyulangone.org,
      jef.boeke@nyulangone.org.
AD  - Department of Biomedical Engineering, New York University Tandon School of
      Engineering, New York, NY 11201, USA.
LA  - eng
GR  - RM1 HG009491/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Annu Rev Biochem
JT  - Annual review of biochemistry
JID - 2985150R
RN  - 0 (Oligonucleotides)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - CRISPR-Cas Systems
MH  - DNA/chemistry/*genetics/metabolism
MH  - Escherichia coli/genetics/metabolism
MH  - Gene Editing/*methods
MH  - *Gene Transfer Techniques
MH  - *Genes, Synthetic
MH  - Genetic Engineering/*methods
MH  - *Genome
MH  - Humans
MH  - Oligonucleotides/chemical synthesis/metabolism
MH  - Plasmids/chemistry/metabolism
MH  - Poliovirus/genetics/metabolism
MH  - Saccharomyces cerevisiae/genetics/metabolism
MH  - Spheroplasts/genetics/metabolism
OTO - NOTNLM
OT  - *DNA synthesis
OT  - *Sc2.0
OT  - *ethics
OT  - *genome design
OT  - *genome editing
EDAT- 2020/06/23 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
AID - 10.1146/annurev-biochem-013118-110704 [doi]
PST - ppublish
SO  - Annu Rev Biochem. 2020 Jun 20;89:77-101. doi:
      10.1146/annurev-biochem-013118-110704.


PMID- 32569281
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20211204
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 6
DP  - 2020
TI  - Low birth weight and its associated risk factors: Health facility-based
      case-control study.
PG  - e0234907
LID - 10.1371/journal.pone.0234907 [doi]
AB  - BACKGROUND: Low birth weight is a preventable public health problem. It is an
      important determinant of child survival and development, as well as long-term
      consequences like the onset of non-communicable disease in the life course. A
      large number of mortality and morbidity can be prevented by addressing the
      factors associated with low birth weight. The main objective of this study was to
      identify associated risk factors of low birth weight. METHODOLOGY: A health
      facility-based unmatched case-control study was carried out from July 2018 to
      March 2019 among the mothers who delivered in health facilities of Dang district 
      of Nepal from 17th August to 16th November 2018. The total sample size for the
      study was 369; 123 cases and 246 controls. Cases and controls were randomly
      selected independent of the exposure status in the ratio of 1:2. Information
      regarding exposure status was assessed through interviews and medical records.
      Mothers who delivered outside Dang districts were excluded from the study.
      Ethical clearance was obtained from the Institutional Review Committee (IRC) of
      the Institute of Medicine, Tribhuvan University and written consent was taken
      from each participant after explaining the objectives of the study. RESULTS:
      Multivariate logistic regression found that having the kitchen in the same living
      house (AOR 2.7, CI: 1.5-4.8), iron intake less than 180 tablets (AOR 3.2, CI:
      1.7-5.7), maternal weight gain during second and third trimester less than 6.53
      kg (AOR 2.6, CI: 1.5-4.7), co-morbidity during pregnancy (AOR 2.4, CI: 1.3-4.5), 
      preterm birth (AOR 2.9, CI: 1.4-6.1) were the risk factors associated with low
      birth weight. CONCLUSION: Having the kitchen in the same living house, iron
      intake less than 180 tablets during pregnancy, maternal weight gain less than
      6.53 kg during the second and third trimester, co-morbidity during pregnancy and 
      preterm birth were the risk factors associated with low birth weight.
FAU - K C, Anil
AU  - K C A
AUID- ORCID: 0000-0001-7113-5701
AD  - Health Foundation Nepal, Patan, Nepal.
FAU - Basel, Prem Lal
AU  - Basel PL
AD  - Department of Community Medicine and Public Health, Tribhuvan University Teaching
      Hospital, Kathmandu, Nepal.
FAU - Singh, Sarswoti
AU  - Singh S
AD  - Department of Community Medicine and Public Health, Tribhuvan University Teaching
      Hospital, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200622
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Air Pollution, Indoor/*adverse effects
MH  - Case-Control Studies
MH  - Female
MH  - *Gestational Weight Gain
MH  - Health Facilities
MH  - Humans
MH  - *Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - *Iron Deficiencies
MH  - Mothers
MH  - Nepal
MH  - Nutritional Status
MH  - Pregnancy
MH  - Pregnancy Complications
MH  - Premature Birth/*epidemiology
MH  - Risk Factors
MH  - Young Adult
PMC - PMC7307746
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/06/23 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/06/23 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - 10.1371/journal.pone.0234907 [doi]
AID - PONE-D-19-31435 [pii]
PST - epublish
SO  - PLoS One. 2020 Jun 22;15(6):e0234907. doi: 10.1371/journal.pone.0234907.
      eCollection 2020.


PMID- 32569221
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Herbal medicine for the management of idiopathic trigeminal neuralgia: A protocol
      for a systematic review of controlled trials.
PG  - e20779
LID - 10.1097/MD.0000000000020779 [doi]
AB  - BACKGROUND: Trigeminal neuralgia is an oral facial pain that is limited to one or
      more parts of the trigeminal nerve. As it becomes chronic, it can seriously
      affect the quality of life of most patients, and it is expected to increase in
      incidence in modern aging society. The objective of this systematic review
      protocol is to provide methods for evaluating the effectiveness and safety of
      herbal medicines for idiopathic trigeminal neuralgia (ITN). METHODS: A total of
      14 databases will be searched for studies uploaded from inception to the present 
      date that investigated the treatment of ITN. These databases are MEDLINE, EMBASE,
      AMED, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane
      Library, PsycARTICLES, four Korean databases, two Chinese databases, and two
      Japanese databases. We will include randomized controlled trials (RCTs) assessing
      herbal medicine decoctions used to treat any type of ITN. All RCTs of decoctions 
      or modified decoctions with any type of form of herbal medicine will be eligible 
      for inclusion. The methodological quality of randomized controlled trials will be
      analyzed using the Cochrane Collaboration tool to assess risk of bias, and the
      confidence in the cumulative evidence will be assessed using the Grading of
      Recommendations Assessment, Development and Evaluation (GRADE) instrument. ETHICS
      AND DISSEMINATION: The results of this systematic review will be published in a
      peer-reviewed journal and disseminated electronically and in print. To inform and
      guide healthcare practices, the review will be updated. TRIAL REGISTRATION
      NUMBER: PROSPERO CRD42020129667.
FAU - Hwang, Ji Hye
AU  - Hwang JH
AUID- ORCID: 0000-0002-6304-1972
AD  - Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine,
      Gachon University, Seongnam.
FAU - Ku, Jaseung
AU  - Ku J
AUID- ORCID: 0000-0003-4365-5587
AD  - Bogwang Korean Medical Clinic, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Phytotherapy/*methods
MH  - Trigeminal Neuralgia/*drug therapy
PMC - PMC7310950
EDAT- 2020/06/23 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - 10.1097/MD.0000000000020779 [doi]
AID - 00005792-202006190-00069 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20779. doi:
      10.1097/MD.0000000000020779.


PMID- 32569206
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Pelvic peritoneum reconstruction using the bladder peritoneum flap in
      laparoscopic extralevator abdominoperineal excision: A multi-center, prospective 
      single-arm cohort study (IDEAL Phase 2A).
PG  - e20712
LID - 10.1097/MD.0000000000020712 [doi]
AB  - INTRODUCTION: Extralevator abdominoperineal excision (ELAPE) may cause various
      surgical complications including disruption of perineal wound, perineal hernia
      and adhesive small-bowel obstruction. Pelvic peritoneum reconstruction (PPR)
      could prevent those complications, but it may not always be achievable,
      especially in patients with severe pelvic fibrosis after neoadjuvant
      radiotherapy. Our previous study has reported the application of the PPR using
      the bladder peritoneum flap in laparoscopic ELAPE. The aim of the study is to
      evaluate the short-term clinical, technical and safety outcomes of PPR using the 
      bladder peritoneum flap in laparoscopic ELAPE. METHODS AND ANALYSIS: This is a
      multi-center prospective single-arm cohort study and fulfill the IDEAL 2A stage
      principle. Rectal cancer patients undergoing laparoscopic ELAPE, suffering rigid 
      pelvis or huge perineal peritoneum defect, and having difficulty in primary
      perineal wound closure will be considered eligible. Main exclusion criteria are
      being complicated with urgent complications, ASA grade >3 and accompanied with
      mental illness. After informed consent, 30 patients are planned to be included in
      the study. Standard laparoscopic ELAPE with pelvic peritoneal floor
      reconstruction using bladder peritoneum flap are to be performed. The surgical
      safety is to be evaluated after one-year follow-up. Primary endpoints are the
      occurrence of intraoperative and postoperative complications of PPR using the
      bladder peritoneum flap. Second endpoints are overall complication rate within 30
      days after surgery, extent of small intestine falling down to pelvic cavity, and 
      other follow-up consequences within 1 year after surgery. ETHICS AND
      DISSEMINATION: This experiment was approved by the Biomedical Ethics Committee of
      West China Hospital of Sichuan University. TRIAL REGISTRATION: NCT04177407.
FAU - Shen, Yu
AU  - Shen Y
AD  - Department of Gastrointestinal Surgery.
FAU - Yang, Tinghan
AU  - Yang T
AD  - Department of Gastrointestinal Surgery.
FAU - Deng, Xiangbing
AU  - Deng X
AD  - Department of Gastrointestinal Surgery.
FAU - Yang, Jinliang
AU  - Yang J
AD  - State Key Lab of Biotherapy and Cancer Center, West China Hospital, Sichuan
      University, Chengdu, Sichuan, China.
FAU - Meng, Wenjian
AU  - Meng W
AD  - Department of Gastrointestinal Surgery.
FAU - Wang, Ziqiang
AU  - Wang Z
AUID- ORCID: 0000-0002-2874-1535
AD  - Department of Gastrointestinal Surgery.
LA  - eng
SI  - ClinicalTrials.gov/NCT04177407
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - Laparoscopy/*methods
MH  - Multicenter Studies as Topic
MH  - Pelvic Floor/*surgery
MH  - Perineum/*surgery
MH  - Proctectomy/*methods
MH  - Prospective Studies
MH  - Reconstructive Surgical Procedures/*methods
MH  - *Surgical Flaps
MH  - Urinary Bladder/*transplantation
PMC - PMC7310913
EDAT- 2020/06/23 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
AID - 10.1097/MD.0000000000020712 [doi]
AID - 00005792-202006190-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20712. doi:
      10.1097/MD.0000000000020712.


PMID- 32569203
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Pilot early phase II study of decitabine and carboplatin in patients with
      advanced melanoma.
PG  - e20705
LID - 10.1097/MD.0000000000020705 [doi]
AB  - INTRODUCTION: Resistance to targeted and immune checkpoint blockade treatment
      remains a major problem in patients with advanced metastatic melanoma. To
      overcome this problem, there needs to be a decrease in burden of disease as well 
      as re-establishing of immune sensitivity. The aim of this early phase 2 clinical 
      trial is to investigate a novel way of sequencing and combining decitabine and
      carboplatin to decrease methylation and increase DNA repair resulting in a
      decrease in the disease burden and to re-establish sensitivity to the immune
      response. METHODS AND ANALYSIS: This single-site early phase 2 clinical trial
      will be conducted in 30 patients with metastatic melanoma that are resistant to
      all approved therapies. Patients will receive 2 x 4-week cycles of decitabine 7
      mg/m IVI/day for 5 days (D1-D5) followed by Carboplatin AUC 5 IVI on D8; Week 3
      and Week 4 no treatment. The primary objective is to determine DNA methylation
      and DNA repair levels before, and immediately after treatment; quantify
      immune-response markers (PDL-1, PD-1, CD4/CD8, and CD68) in blood, tumor and
      microenvironment before treatment and after 2 cycles. The secondary outcome
      objective is to quantify response rate (RR) to administration of 2 cycles of
      decitabine and carboplatin cycle using response evaluation criteria in solid
      tumors (RECIST 1.1) criteria. This data will be used to calculate sample size and
      determine statistical analysis plan for larger Phase 2 study. ETHICS AND
      DISSEMINATION: Protocol version 1.1 was reviewed and approved by the Hunter New
      England Health Human Research Ethics Committee (Reference No: 15/12/16/3.08, NSW 
      HREC Reference No: HREC/15/HNE/505) and site-specific approval from the Calvary
      Mater Hospital Newcastle, NSW, Australia (NSW SSA Reference No: SSA/16/HNE/224). 
      Primary and secondary outcomes and safety data will be disseminated through
      publications. TRIAL REGISTRATION DETAILS: Australian New Zealand Clinical Trial
      Registry ACTRN12616000440426.
FAU - van der Westhuizen, Andre
AU  - van der Westhuizen A
AD  - Department of Medical Oncology, Calvary Mater Hospital, Newcastle.
AD  - Centre for Drug Repurposing and Medicines Research, School of Medicine and Public
      Health, University of Newcastle and Hunter Medical Research Institute.
FAU - Knoblauch, Naomi
AU  - Knoblauch N
AD  - Department of Medical Oncology, Calvary Mater Hospital, Newcastle.
FAU - Graves, Moira C
AU  - Graves MC
AD  - Centre for Drug Repurposing and Medicines Research, School of Medicine and Public
      Health, University of Newcastle and Hunter Medical Research Institute.
FAU - Levy, Richard
AU  - Levy R
AD  - Department of Surgical Oncology, Calvary Mater Hospital.
FAU - Vilain, Ricardo E
AU  - Vilain RE
AD  - Centre for Drug Repurposing and Medicines Research, School of Medicine and Public
      Health, University of Newcastle and Hunter Medical Research Institute.
AD  - Department of Anatomical Pathology, Pathology North, NSW Health Pathology,
      Newcastle, NSW, Australia.
FAU - Bowden, Nikola A
AU  - Bowden NA
AUID- ORCID: 0000-0002-6047-1694
AD  - Centre for Drug Repurposing and Medicines Research, School of Medicine and Public
      Health, University of Newcastle and Hunter Medical Research Institute.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 776B62CQ27 (Decitabine)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/*therapeutic use
MH  - Clinical Trials, Phase II as Topic
MH  - Decitabine/*therapeutic use
MH  - Humans
MH  - Melanoma/*drug therapy/pathology
MH  - Pilot Projects
PMC - PMC7310888
EDAT- 2020/06/23 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
AID - 10.1097/MD.0000000000020705 [doi]
AID - 00005792-202006190-00051 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20705. doi:
      10.1097/MD.0000000000020705.


PMID- 32569200
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Short and long-term efficacy of massage for functional constipation: A protocol
      for systematic review and meta analysis.
PG  - e20698
LID - 10.1097/MD.0000000000020698 [doi]
AB  - BACKGROUND: Functional constipation (FC) is one of the most common diseases
      throughout the world, which brings a bad influence on life quality as well as
      mental health. Massage has been widely used in the treatment of functional
      constipation in china. In several randomized controlled trials indicate that
      massage has a positive effect on FC. However, there remain exist controversy
      towards its effectiveness and safety. What's more, how about the short and
      long-term efficacy? We, therefore, design this systematic review to assess the
      short and long-term effects of massage for FC. METHODS: The following electronic 
      databases will be searched from their inception to May 2020, including PubMed,
      Cochrane Library, EMBASE, Web of Science, WHO International Clinical Trials
      Registry Platform, Chinese National Knowledge Infrastructure (CNKI), WanFang
      Database, Chinese Biomedical Literature Database (CBM), the Chongqing VIP Chinese
      Science, and Technology Periodical Database (VIP). RESULTS: This systematic
      review will assess the short and long-term effects of massage in the treatment of
      FC. CONCLUSION: This study will provide high-quality current evidence of short
      and long-term effects of massage for FC. ETHICS AND DISSEMINATION: Ethical
      approval is not required, for this review will not involve individuals'
      information. The results will be published in a peer-reviewed publication or
      disseminated in relevant conferences.INPLASY Registration number:
      INPLASY202050001.
FAU - Tang, Ying
AU  - Tang Y
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province,
      China.
FAU - Shi, Kejin
AU  - Shi K
FAU - He, Fengyi
AU  - He F
FAU - Li, Mao
AU  - Li M
FAU - Wen, Yong
AU  - Wen Y
FAU - Wang, Xiaomin
AU  - Wang X
FAU - Zhu, Jie
AU  - Zhu J
FAU - Jin, Zhao
AU  - Jin Z
AUID- ORCID: 0000-0002-2549-1243
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Constipation/*physiopathology/*therapy
MH  - Humans
MH  - *Massage
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7310914
EDAT- 2020/06/23 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
AID - 10.1097/MD.0000000000020698 [doi]
AID - 00005792-202006190-00048 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20698. doi:
      10.1097/MD.0000000000020698.


PMID- 32569194
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Clinical study of stent forming for symptomatic internal carotid artery stenosis.
PG  - e20637
LID - 10.1097/MD.0000000000020637 [doi]
AB  - Stroke is one of the diseases that seriously threaten the survival and health of 
      human beings. In Europe and the United States, stroke is the second leading cause
      of death after heart disease and tumors. Stroke is also one of the fatal diseases
      in Asian countries. On average, about 1.5 million new stroke patients are added
      each year in China, and the incidence of stroke is increasing year by year. About
      80% of all stroke patients are ischemic stroke, and symptomatic internal carotid 
      atherosclerotic stenosis is another important cause of ischemic stroke.
      Ipsilateral carotid stenosis >/=50% increases the incidence of transient cerebral
      ischemia and stroke in the carotid artery region by 10% to 15%, and is also
      closely related to the recurrence of acute and long-term stroke in patients.
      Therefore, the clinical application and efficacy of carotid stenting in patients 
      with symptomatic internal carotid artery stenosis are analyzed and evaluated to
      provide a basis for the selection of clinical treatment options.The clinical data
      of patients with symptomatic carotid stenosis who underwent carotid stenting and 
      the clinical data of conservative treatment of patients with symptomatic carotid 
      stenosis were retrospectively analyzed, and the carotid stenosis rate, symptoms, 
      and National Institute of Health stroke scale where compared before and after
      surgery. And activities of daily living score. Because the control group
      treatment method in this article is completely free for patients to choose, and
      belongs to a retrospective analysis, the results suggest that it can provide a
      high-quality treatment approach for the treatment of patients with symptomatic
      carotid stenosis, without causing any harm to the patient, So no ethical approval
      is needed, and no patient informed consent is required.In recent years, with the 
      continuous advancement of science and technology and new stent materials,
      intravascular interventional technology has developed rapidly. In continuous
      clinical practice and research, the safety and effectiveness of stent technology 
      have also been gradually improved. Arterial stenting has gradually become an
      important method for the treatment of atherosclerotic carotid stenosis. This
      technique can not only improve the symptoms and prognosis of patients with
      symptomatic internal carotid stenosis, but also prevent the occurrence of
      ischemic events. The promotion of this technology has the effect of reducing
      disability and mortality.The alternative therapy of drug therapy, namely arterial
      stent implantation, has become a new way to treat atherosclerotic stroke. This
      treatment technology can quickly relieve the abnormal hemodynamics of distal
      blood vessels caused by arterial stenosis, which is ischemic. Cerebrovascular
      disease provides new ideas for treatment. Carotid angioplasty and stenting for
      symptomatic internal carotid stenosis under a distal cerebral protection device
      is a safe and effective treatment.
FAU - Zhang, Yiqin
AU  - Zhang Y
AD  - The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu.
AD  - Chongming Branch, Xinhua Hospital, Shanghai Jiao Tong University School of
      Medicine, Shanghai.
FAU - Wang, Wen'an
AU  - Wang W
AD  - Chongming Branch, Xinhua Hospital, Shanghai Jiao Tong University School of
      Medicine, Shanghai.
FAU - Fang, Qi
AU  - Fang Q
AD  - The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Activities of Daily Living
MH  - Aged
MH  - Angiography
MH  - Carotid Artery, Internal
MH  - Carotid Stenosis/drug therapy/*surgery
MH  - Endovascular Procedures
MH  - Female
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - *Stents
MH  - Stroke/prevention & control
PMC - PMC7310902
EDAT- 2020/06/23 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
AID - 10.1097/MD.0000000000020637 [doi]
AID - 00005792-202006190-00042 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20637. doi:
      10.1097/MD.0000000000020637.


PMID- 32569178
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Adjuvant therapy of Chinese herbal medicine for the treatment of adenomyosis: A
      protocol for systematic review.
PG  - e20560
LID - 10.1097/MD.0000000000020560 [doi]
AB  - BACKGROUND: Adenomyosis is benign gynecologic condition with complex etiologies. 
      Common symptoms associated with adenomyosis (AM) include menorrhagia,
      dysmenorrhea, chronic pelvic pain, metrorrhagia, and dyspareunia. Although
      Chinese herbal medicine (CHM) has often been utilized for managing AM in clinical
      practice in China, evidence regarding its efficacy is lacking. This systematic
      review protocol aims to describe a systematic review to assess the effectiveness 
      and safety of CHM combined with Levonorgestrel-releasing intrauterine system for 
      AM. METHODS: The following 7 databases will be searched from the publishment to
      December 2019: the Cochrane Central Register of Controlled Trials (CENTRAL),
      PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Wanfang Digital
      Periodicals (WAN FANG), Chinese Biomedical Literature Database (CBM), Chinese
      Scientific Journal Database (VIP). The primary outcomes will be relief in pain
      and uterine bleeding. The secondary outcomes include the adverse effects, CA125
      variation in peripheral blood, reduction in uterine volume, and endometrial
      thickness. We will use RevMan V.5.3 to conduct the meta-analysis, if possible. If
      it is not allowed, a descriptive analysis will be conducted. We will use risk
      ratio with 95% confidence interval for dichotomous data and the mean difference
      for continuous data. RESULTS: This study will provide the latest analysis of the 
      currently available evidence for the efficacy of the adjuvant therapy of CHM for 
      the treatment of AM. REGISTRATION NUMBER: OSF (DOI 10.17605/OSF.IO/A2GHY) ETHICS 
      AND DISSEMINATION:: No ethical issues are required. The findings will be
      published in a peer-reviewed scientific journal.
FAU - Huang, Li
AU  - Huang L
AD  - Department of Gynecology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu.
FAU - Ji, Xiaoli
AU  - Ji X
AD  - Department of Gynecology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu.
FAU - Wang, Xia
AU  - Wang X
AD  - Department of Gynecology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu.
FAU - Wu, Yang
AU  - Wu Y
AD  - Department of Gynecology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu.
FAU - Luo, Mei
AU  - Luo M
AD  - Department of Gynecology, Hospital of Chongqing Institute of Traditional Chinese 
      Medicine, Chongqing, China.
FAU - Hao, Xiaotong
AU  - Hao X
AD  - Department of Gynecology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu.
FAU - Wei, Shaobin
AU  - Wei S
AD  - Department of Gynecology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Adenomyosis/*drug therapy
MH  - Chemotherapy, Adjuvant/methods
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Systematic Reviews as Topic
PMC - PMC7310900
EDAT- 2020/06/23 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020560 [doi]
AID - 00005792-202006190-00026 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20560. doi:
      10.1097/MD.0000000000020560.


PMID- 32569002
OWN - NLM
STAT- MEDLINE
DCOM- 20201014
LR  - 20210310
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 104
IP  - 7
DP  - 2020 Jul
TI  - Ethical Issues in the COVID Era: Doing the Right Thing Depends on Location,
      Resources, and Disease Burden.
PG  - 1316-1320
LID - 10.1097/TP.0000000000003291 [doi]
FAU - Stock, Peter G
AU  - Stock PG
AD  - University of California San Francisco, San Francisco, CA.
FAU - Wall, Anji
AU  - Wall A
AD  - Baylor University Medical Center at Dallas, Dallas, TX.
FAU - Gardner, James
AU  - Gardner J
AD  - University of California San Francisco, San Francisco, CA.
FAU - Dominguez-Gil, Beatriz
AU  - Dominguez-Gil B
AD  - Organizacion Nacional de Tranplantes (ONT), Madrid, Spain.
FAU - Chadban, Steve
AU  - Chadban S
AD  - Royal Prince Alfred Hospital, Camperdown, Australia.
FAU - Muller, Elmi
AU  - Muller E
AD  - University of Cape Town, Cape Town, South Africa.
FAU - Dittmer, Ian
AU  - Dittmer I
AD  - Auckland District Health Board (ADHB), Auckland, New Zealand.
FAU - Tullius, Stefan G
AU  - Tullius SG
AD  - Brigham and Women's Hospital, Boston, MA.
CN  - TTS Ethics Committee
LA  - eng
GR  - R01 AG064165/AG/NIA NIH HHS/United States
GR  - U01 AI132898/AI/NIAID NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
SB  - IM
MH  - Allografts/supply & distribution
MH  - Betacoronavirus/pathogenicity
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/economics/*epidemiology/prevention & control/transmission
MH  - Cost of Illness
MH  - Humans
MH  - Organ Transplantation/economics/*ethics
MH  - Pandemics/economics/prevention & control
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/economics/*epidemiology/prevention & control/transmission
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Tissue and Organ Procurement/economics/ethics/organization & administration
PMC - PMC7340125
EDAT- 2020/06/23 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1097/TP.0000000000003291 [doi]
AID - 00007890-202007000-00005 [pii]
PST - ppublish
SO  - Transplantation. 2020 Jul;104(7):1316-1320. doi: 10.1097/TP.0000000000003291.


PMID- 32568967
OWN - NLM
STAT- MEDLINE
DCOM- 20211111
LR  - 20211111
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 83
IP  - 11
DP  - 2020 Nov
TI  - The era of artificial intelligence-based individualized telemedicine is coming.
PG  - 981-983
LID - 10.1097/JCMA.0000000000000374 [doi]
AB  - Artificial intelligence (AI), Internet of Things (IoT), and telemedicine are
      deeply involved in our daily life and have also been extensively applied in the
      medical field, especially in ophthalmology. Clinical ophthalmologists are
      required to perform a vast array of image exams and analyze images containing
      complicated information, which allows them to diagnose the disease type and
      grade, make a decision on remedy, and predict treatment outcomes. AI has a great 
      potential to assist ophthalmologists in their daily routine of image analysis and
      relieve their work burden. However, in spite of these prospects, the application 
      of AI may also be controversial and associated with several legal, ethical, and
      sociological concerns. In spite of these issues, AI has indeed become an
      irresistible trend and is widely used by medical specialists in their daily
      routines in what we can call now, the era of AI. This review will encompass those
      issues and focus on recent research on the AI application in ophthalmology and
      telemedicine.
FAU - Jheng, Ying-Chun
AU  - Jheng YC
AD  - Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
AD  - Big Data Center, Taipei Veterans General Hospital Taipei, Taiwan, ROC.
AD  - Department of Physical Medicine & Rehabilitation, Taipei Veterans General
      Hospital, Taipei, Taiwan, ROC.
AD  - Department of Physical Medicine & Rehabilitation, School of Medicine, National
      Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Kao, Chung-Lan
AU  - Kao CL
AD  - Department of Physical Medicine & Rehabilitation, Taipei Veterans General
      Hospital, Taipei, Taiwan, ROC.
AD  - Department of Physical Medicine & Rehabilitation, School of Medicine, National
      Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Yarmishyn, Aliaksandr A
AU  - Yarmishyn AA
AD  - Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
FAU - Chou, Yu-Bai
AU  - Chou YB
AD  - Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
AD  - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Hsu, Chih-Chien
AU  - Hsu CC
AD  - Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
AD  - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Lin, Tai-Chi
AU  - Lin TC
AD  - Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
AD  - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Hu, Hou-Kai
AU  - Hu HK
AD  - Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
FAU - Ho, Ta-Kai
AU  - Ho TK
AD  - Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
FAU - Chen, Po-Yin
AU  - Chen PY
AD  - Department of Physical Medicine & Rehabilitation, Taipei Veterans General
      Hospital, Taipei, Taiwan, ROC.
AD  - Department of Physical Medicine & Rehabilitation, School of Medicine, National
      Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Kao, Zih-Kai
AU  - Kao ZK
AD  - Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
FAU - Chen, Shih-Jen
AU  - Chen SJ
AD  - Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
AD  - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
FAU - Hwang, De-Kuang
AU  - Hwang DK
AD  - Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan,
      ROC.
AD  - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
SB  - IM
MH  - *Artificial Intelligence
MH  - Diabetic Retinopathy/diagnosis
MH  - Glaucoma/diagnosis
MH  - Humans
MH  - Macular Degeneration/diagnosis
MH  - Neural Networks, Computer
MH  - *Ophthalmology
MH  - *Telemedicine
PMC - PMC7647420
EDAT- 2020/06/23 06:00
MHDA- 2021/11/12 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/11/12 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1097/JCMA.0000000000000374 [doi]
AID - 02118582-202011000-00003 [pii]
PST - ppublish
SO  - J Chin Med Assoc. 2020 Nov;83(11):981-983. doi: 10.1097/JCMA.0000000000000374.


PMID- 32568597
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 2328-8620 (Electronic)
IS  - 2328-8620 (Linking)
VI  - 6
IP  - 1
DP  - 2020 Jan 1
TI  - Restructuring Health Reform, Mexican Style.
PG  - 1-11
LID - 10.1080/23288604.2020.1763114 [doi]
AB  - Mexico's health system is undergoing major restructuring by the administration of
      President Andres Manuel Lopez Obrador (known as AMLO) starting in December 2018. 
      The government has eliminated the 2003 health reform (Seguro Popular) from
      national laws and government agencies and is returning Mexico to a centralized
      health system with integrated public financing and delivery and reduced private
      participation. This article looks at the political drivers of Mexico's
      restructuring reform. Three main ethical principles are identified as the
      foundation for the government's health system vision: universality, free
      services, and anti-corruption. The article then compares what existed under
      Seguro Popular with the new system under the Instituto de Salud para el Bienestar
      (INSABI), which began on 1 January 2020. The analysis uses the five policy levers
      that shape health system performance: financing, payment, organization,
      regulation, and persuasion. The article concludes with five lessons about the
      reform process in Mexico. First, undoing past reforms is much easier than
      implementing a new system. Second, the AMLO government's restructuring emerged
      more from broad ethical principles than detailed technical analyses, with limited
      plans for evaluation. Third, the overarching values of the AMLO government
      reflect a pro-statist and anti-market bias, swimming against the global flow of
      health policy trends to include the private sector in reforming health systems.
      Fourth, the experiences in Mexico show that path dependence does not always work 
      as expected in policy reform. Finally, the debate of Seguro Popular versus INSABI
      shows the influence of personality politics and polarization.
FAU - Reich, Michael R
AU  - Reich MR
AUID- ORCID: 0000-0003-3338-0612
AD  - Department of Global Health & Population, Harvard T.H. Chan School of Public
      Health , Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Health Syst Reform
JT  - Health systems and reform
JID - 101697320
SB  - IM
MH  - Health Care Reform/*methods/standards/trends
MH  - Humans
MH  - Mexico
MH  - National Health Programs/organization & administration/statistics & numerical
      data
MH  - Patient Acceptance of Health Care/statistics & numerical data
MH  - Politics
OTO - NOTNLM
OT  - * Seguro Popular
OT  - *Health reform
OT  - *INSABI
OT  - *Mexico
OT  - *health system
EDAT- 2020/06/23 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1080/23288604.2020.1763114 [doi]
PST - ppublish
SO  - Health Syst Reform. 2020 Jan 1;6(1):1-11. doi: 10.1080/23288604.2020.1763114.


PMID- 32568582
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20200826
IS  - 1546-3141 (Electronic)
IS  - 0361-803X (Linking)
VI  - 215
IP  - 1
DP  - 2020 Jul
TI  - Medicolegal-Malpractice and Ethical Issues in Radiology.
PG  - W1
LID - 10.2214/AJR.19.22687 [doi]
FAU - Berlin, Leonard
AU  - Berlin L
AD  - NorthShore University HealthSystem, Skokie Hospital, Skokie, IL.
AD  - Rush University and University of Illinois, Chicago, IL lberlin@live.com.
LA  - eng
PT  - Letter
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
SB  - IM
MH  - Guideline Adherence
MH  - Humans
MH  - Interprofessional Relations/*ethics
MH  - *Physician's Role
MH  - Radiologists/*ethics/*legislation & jurisprudence
MH  - Referral and Consultation/*ethics/*legislation & jurisprudence
MH  - United States
EDAT- 2020/06/23 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - 10.2214/AJR.19.22687 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 2020 Jul;215(1):W1. doi: 10.2214/AJR.19.22687.


PMID- 32568203
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 76
IP  - 2
DP  - 2020
TI  - Realizing the Potential of Robotics for Aged Care Through Co-Creation.
PG  - 461-466
LID - 10.3233/JAD-200214 [doi]
AB  - Socially assistive robots have the potential to improve aged care by providing
      assistance through social interaction. While some evidence suggests a positive
      impact of social robots on measures of well-being, the adoption of robotic
      technology remains slow. One approach to improve technology adoption is involving
      all stakeholders in the process of technology development using co-creation
      methods. To capture relevant stake holders' priorities and perceptions on the
      ethics of robotic companions, we conducted an interactive co-creation workshop at
      the 2019 Geriatric Services Conference in Vancouver, BC. The participants were
      presented with different portrayals of robotic companions in popular culture and 
      answered questions about perceptions, expectations, and ethical concerns about
      the implementation of robotic technology. Our results reveal that the most
      pressing ethical concerns with robotic technology, such as issues related to
      privacy, are critical potential barriers to technology adoption. We also found
      that most participants agree on the types of tasks that robots should help with, 
      such as domestic chores, communication, and medication reminders. Activities that
      robots should not help with, according to the stakeholders, included bathing,
      toileting, and managing finances. The perspectives that were captured contribute 
      to a preliminary outline of the areas of importance for geriatric care stake
      holders in the process of ethical technology design and development.
FAU - Robillard, Julie M
AU  - Robillard JM
AD  - Division of Neurology, Department of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
AD  - BC Children's and Women's Hospital, Vancouver, BC, Canada.
FAU - Kabacinska, Katarzyna
AU  - Kabacinska K
AD  - Division of Neurology, Department of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
MH  - Aged
MH  - Aging/ethics/*psychology
MH  - British Columbia
MH  - *Congresses as Topic/ethics
MH  - Education/ethics/*methods
MH  - Feasibility Studies
MH  - Humans
MH  - Pilot Projects
MH  - Robotics/ethics/*methods
MH  - *Social Interaction
OTO - NOTNLM
OT  - *Aging
OT  - *engagement
OT  - *ethics
OT  - *technology
EDAT- 2020/06/23 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - JAD200214 [pii]
AID - 10.3233/JAD-200214 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;76(2):461-466. doi: 10.3233/JAD-200214.


PMID- 32568199
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 76
IP  - 2
DP  - 2020
TI  - Addressing the Ethics of Telepresence Applications Through End-User Engagement.
PG  - 457-460
LID - 10.3233/JAD-200154 [doi]
AB  - Portacolone et al.'s Ethics Review highlights the ethical challenges associated
      with the implementation of telepresence devices and applications in the context
      of aging and dementia. In this response, we review ethical considerations as they
      relate to specific modalities of telepresence, with an emphasis on the continuum 
      of potential interaction agents, from known individuals to fully automated and
      intelligent interlocutors. We further discuss areas in need of empirical evidence
      to inform regulatory efforts in telepresence. We close with a call for meaningful
      end-user engagement at all stages of technology development.
FAU - Robillard, Julie M
AU  - Robillard JM
AD  - Division of Neurology, Department of Medicine, University of British Columbia,
      Vancouver, BC, Canada.
AD  - BC Children's & Women's Hospitals, Vancouver, BC, Canada.
FAU - Goldman, Ian P
AU  - Goldman IP
AD  - Advisor providing caregiver lived experience expertise to Neuroscience,
      Engagement and Smart Tech (NEST) Lab research team based in Vancouver, BC,
      Canada.
FAU - Prescott, Tony J
AU  - Prescott TJ
AD  - Department of Computer Science, University of Sheffield, Sheffield, UK.
FAU - Michaud, Francois
AU  - Michaud F
AD  - Department of Electrical and Computer Engineering, Universite de Sherbrooke,
      Sherbrooke, QC, Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
CON - J Alzheimers Dis. 2020;76(2):445-455. PMID: 32250295
MH  - Aged
MH  - *Cognitive Dysfunction
MH  - Friends
MH  - Humans
MH  - Intelligence
MH  - *Robotics
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *ethics
OT  - *patient engagement
OT  - *robotics
OT  - *telepresence
EDAT- 2020/06/23 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - JAD200154 [pii]
AID - 10.3233/JAD-200154 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;76(2):457-460. doi: 10.3233/JAD-200154.


PMID- 32567433
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Linking)
VI  - 48
IP  - 6
DP  - 2020 Jun
TI  - Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome:
      liraglutide compared with insulin glargine: a pilot study.
PG  - 300060520926063
LID - 10.1177/0300060520926063 [doi]
AB  - OBJECTIVE: To explore the glucagon-like peptide-1 analogue liraglutide in the
      hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute
      coronary syndrome and to evaluate the safety and efficacy and its impact on
      hospitalization and short-term glycemic variability (GV). METHODS: A 12-week,
      open-label, prospective, randomized pilot clinical study with parallel groups
      that compared liraglutide (group 1) with glargine (group 2) and its impact on
      glycemic control and GV. RESULTS: Thirteen patients were included. During
      hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in
      group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98
      (7.68) vs. 25.48 (7.19) and 34.37 (13.05) vs. 43.56 (19.53) in groups 1 and 2,
      respectively. Group 1 prandial insulin requirements during hospitalization were
      lower compared with group 2. Follow-up A1c in group 1 was 6.9% (-1.51%) and 6.5% 
      in group 2 (-1.27). GV after discharge and hypoglycemia were lower in group 1
      compared with group 2. CONCLUSIONS: Liraglutide seems to reduce GV in the acute
      phase of acute coronary syndrome, and patients achieved optimal control with a
      low incidence of hypoglycemia. These results support the need to explore
      liraglutide in a larger multicenter trial. Trial registration: The study was
      approved by the National Medical Ethics Committee of Spain. The study was
      registered at European Clinical Trials Database (EudraCT): 2014003298-40.
FAU - Del Olmo-Garcia, Maria Isabel
AU  - Del Olmo-Garcia MI
AUID- ORCID: https://orcid.org/0000-0002-4278-2624
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
AD  - Unidad Mixta Investigacion Endocrinologia, Nutricion y Dietetica, IIS La Fe,
      Valenciana, Spain.
FAU - Hervas Marin, David
AU  - Hervas Marin D
AD  - Unidad Bioestadistica, Instituto de Investigacion Sanitaria IIS La Fe (Valencia),
      Valenciana, Spain.
FAU - Caudet Esteban, Jana
AU  - Caudet Esteban J
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
AD  - Unidad Mixta Investigacion Endocrinologia, Nutricion y Dietetica, IIS La Fe,
      Valenciana, Spain.
FAU - Ballesteros Martin-Portugues, Antonio
AU  - Ballesteros Martin-Portugues A
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
FAU - Cervero Rubio, Alba
AU  - Cervero Rubio A
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
FAU - Arnau Vives, Miguel Angel
AU  - Arnau Vives MA
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
FAU - Catala Gregori, Ana
AU  - Catala Gregori A
AD  - Unidad Mixta Investigacion Endocrinologia, Nutricion y Dietetica, IIS La Fe,
      Valenciana, Spain.
FAU - Penalba Martinez, Maite
AU  - Penalba Martinez M
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
FAU - Merino-Torres, Juan Francisco
AU  - Merino-Torres JF
AD  - Hospital Universitario La Fe (Valencia), Valenciana, Spain.
AD  - Unidad Mixta Investigacion Endocrinologia, Nutricion y Dietetica, IIS La Fe,
      Valenciana, Spain.
AD  - Departamento de Medicina, Universitat de Valencia, Valenciana, Spain.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 839I73S42A (Liraglutide)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/metabolism/physiopathology
MH  - Adult
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/physiopathology
MH  - Female
MH  - Glycated Hemoglobin A/analysis
MH  - Glycemic Index/drug effects
MH  - Humans
MH  - Hypoglycemia/drug therapy
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Insulin Glargine/therapeutic use
MH  - Liraglutide/*therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Pilot Projects
MH  - Random Allocation
MH  - Spain
PMC - PMC7309403
OTO - NOTNLM
OT  - GLP-1 receptor agonist
OT  - Glycemic variability
OT  - acute coronary syndrome
OT  - hypoglycemia
OT  - liraglutide
OT  - type 2 diabetes mellitus
EDAT- 2020/06/23 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
AID - 10.1177/0300060520926063 [doi]
PST - ppublish
SO  - J Int Med Res. 2020 Jun;48(6):300060520926063. doi: 10.1177/0300060520926063.


PMID- 32567289
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1840-2445 (Electronic)
IS  - 1840-0132 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Aug 1
TI  - Epidemiology of neonatal sepsis caused by multidrug resistant pathogens in a
      neonatal intensive care unit level 3.
PG  - 375-382
LID - 10.17392/1157-20 [doi]
AB  - Aim Steady progress in intensive treatment worldwide has increased the survival
      of immature neonates, but with multiple invasive procedures, which have increased
      the risk of infection, thus the bacterial resistance to antibiotics. The aim of
      this study was to analyse the epidemiology of multidrug resistance pathogens as
      causative agents of neonatal sepsis in the neonatal intensive care unit. Methods 
      A retrospective cohort study conducted at the Intensive care unit of the
      Paediatric Clinic of Tuzla over a three-year period (2016-2018) analysed
      epidemiology of neonatal sepsis caused by multidrug resistance pathogens.
      Statistical analysis applied standard methods, and the research was approved by
      the Ethics Committee of the institution. Results Of the total of 921 treated
      neonates, multidrug resistance (MDR) pathogens among causative agents of neonatal
      sepsis were found in 22 neonates (2.38%) with no gender difference. Prematurity
      and low birth weight were confirmed as the most significant risk factors. From
      the maternal risk factors a significant difference was found in the first birth
      and in vitro fertilization. Clinically, MDR sepsis manifested frequently as late 
      onset sepsis, with longer hospital stay and higher mortality. The findings of
      leukopenia, thrombocytopenia and coagulation disorders were significant. Gram
      negative bacteria were frequently isolated, in particular Acinetobacter, which
      showed the greatest resistance to antibiotics. Conclusion Neonatal MDR sepsis is 
      a threat to life, it complicates the treatment, increases costs and mortality.
      Outcomes can be improved by preventive strategies, earlier and more accurate
      diagnosis and rational use of antibiotics.
CI  - Copyright(c) by the Medical Assotiation of Zenica-Doboj Canton.
FAU - Hadzic, Devleta
AU  - Hadzic D
AD  - Paediatric Clinic, University Clinical Centre Tuzla, Tuzla, Bosnia and
      Herzegovina.
FAU - Skokic, Fahrija
AU  - Skokic F
AD  - Paediatric Clinic, University Clinical Centre Tuzla, Tuzla, Bosnia and
      Herzegovina.
FAU - Brkic, Selmira
AU  - Brkic S
AD  - School of Medicine University of Tuzla, Tuzla, Bosnia and Herzegovina.
FAU - Saracevic, Amina
AU  - Saracevic A
AD  - Paediatric Clinic, University Clinical Centre Tuzla, Tuzla, Bosnia and
      Herzegovina.
FAU - Softic, Delila
AU  - Softic D
AD  - School of Medicine University of Tuzla, Tuzla, Bosnia and Herzegovina.
FAU - Softic, Dzenana
AU  - Softic D
AD  - Paediatric Clinic, University Clinical Centre Tuzla, Tuzla, Bosnia and
      Herzegovina.
LA  - eng
PT  - Journal Article
PL  - Bosnia and Herzegovina
TA  - Med Glas (Zenica)
JT  - Medicinski glasnik : official publication of the Medical Association of
      Zenica-Doboj Canton, Bosnia and Herzegovina
JID - 101250177
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Gram-Negative Bacteria
MH  - Humans
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal
MH  - Microbial Sensitivity Tests
MH  - *Neonatal Sepsis/drug therapy/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - antibiotic resistance
OT  - incidence
OT  - intensive care
OT  - neonatal early onset sepsis
OT  - neonatal late onset sepsis
EDAT- 2020/06/23 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.17392/1157-20 [doi]
PST - ppublish
SO  - Med Glas (Zenica). 2020 Aug 1;17(2):375-382. doi: 10.17392/1157-20.


PMID- 32567239
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20201210
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Jul
TI  - Advantages of Using Lotteries to Select Participants for High-Demand Covid-19
      Treatment Trials.
PG  - 35-40
LID - 10.1002/eahr.500061 [doi]
AB  - As hospitals have experienced a surge of Covid-19 patients, investigators of
      Covid-19 treatment trials face a difficult problem: when an institution has more 
      eligible and interested patients than trial slots, who should be enrolled?
      Defining a clear strategy for selecting participants for "high-demand" Covid-19
      treatment trials is important to avoid ad hoc and potentially biased
      decision-making by local investigators, which could inadvertently compromise a
      trial's social value, participants' interests, or fairness. In this article, we
      propose a set of ethical criteria for evaluating participant-selection strategies
      for such trials. We argue that the pandemic context-in particular, great urgency 
      to develop safe and effective treatments, uncertainty surrounding Covid-19, and
      strain on the health care system that limits the time and effort available for
      trial enrollment-favors participant-selection strategies that optimize the ease
      of enrollment and, ideally, social value. A lottery and, where possible, a
      weighted lottery have important advantages in these respects.
CI  - Published 2020. This article is a U.S. Government work and is in the public
      domain in the USA.
FAU - Iyer, Alexander A
AU  - Iyer AA
AD  - Fellow in the Department of Bioethics at the National Institutes of Health (NIH) 
      Clinical Center.
FAU - Hendriks, Saskia
AU  - Hendriks S
AD  - Bioethicist in the Department of Bioethics at the National Institutes of Health
      Clinical Center.
FAU - Rid, Annette
AU  - Rid A
AD  - Bioethicist in the Department of Bioethics at the National Institutes of Health
      Clinical Center.
LA  - eng
GR  - Intramural Research Program of the National Institutes of Health Clinical
      Center's Department of Bioethics
PT  - Journal Article
DEP - 20200622
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/drug therapy/*therapy
MH  - Humans
MH  - Pandemics
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/*therapy
MH  - Research Subjects
MH  - SARS-CoV-2
PMC - PMC7361753
OTO - NOTNLM
OT  - Covid-19
OT  - clinical trials
OT  - fair participant selection
OT  - human subjects research
OT  - lottery Iyer
OT  - research ethics
EDAT- 2020/06/23 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1002/eahr.500061 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Jul;42(4):35-40. doi: 10.1002/eahr.500061. Epub 2020 Jun 22.


PMID- 32567117
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1466-769X (Electronic)
IS  - 1466-7681 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Oct
TI  - Rethinking Carper's personal knowing for 21st century nursing.
PG  - e12307
LID - 10.1111/nup.12307 [doi]
AB  - In 1978, Barbara Carper named personal knowing as a fundamental way of knowing in
      our discipline. By that, she meant the discovery of self-and-other, arrived at
      through reflection, synthesis of perceptions and connecting with what is known.
      Along with empirics, aesthetics and ethics, personal knowing was understood as an
      essential attribute of nursing knowledge evolution, setting the context for the
      nurse to become receptively attentive to and engaged within the interpersonal
      processes of practice. Although much has been done over the 40 years since Carper
      described these ways of knowing, and we have seen enormous advances in empirics
      and ethics, and I would argue even in aesthetics (understanding the subtle craft 
      of nursing in action), personal knowing may not have attracted its fair share of 
      critical unpacking. Further, we see increasing evidence of a distortion on how
      forms of personal knowledge, including beliefs and attitudes, are being taken up 
      within segments of the profession; these include legitimizing idiosyncratic
      positionings and, most worrisome, challenges to the idea that there are and ought
      to be fundamental truths within nursing that stand as central to disciplinary
      knowledge. In this paper, the author reflects on the confusion that a continued
      uncritical deference to personal knowing may be creating and the evolving
      interests it seems to serve.
CI  - (c) 2020 The Authors. Nursing Philosophy published by John Wiley & Sons Ltd.
FAU - Thorne, Sally
AU  - Thorne S
AUID- ORCID: https://orcid.org/0000-0002-1156-9425
AD  - School of Nursing, University of British Columbia, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200621
PL  - England
TA  - Nurs Philos
JT  - Nursing philosophy : an international journal for healthcare professionals
JID - 100897394
SB  - IM
MH  - Humans
MH  - *Knowledge
MH  - *Nursing Theory
MH  - *Philosophy, Nursing
PMC - PMC7583479
OTO - NOTNLM
OT  - advocacy
OT  - evidence-based practice
OT  - nursing philosophy
OT  - social mandate
OT  - ways of knowing
EDAT- 2020/06/23 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1111/nup.12307 [doi]
PST - ppublish
SO  - Nurs Philos. 2020 Oct;21(4):e12307. doi: 10.1111/nup.12307. Epub 2020 Jun 21.


PMID- 32567082
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210120
IS  - 1099-1611 (Electronic)
IS  - 1057-9249 (Linking)
VI  - 29
IP  - 8
DP  - 2020 Aug
TI  - Decision-making in cancer care for people living with dementia.
PG  - 1347-1354
LID - 10.1002/pon.5448 [doi]
AB  - OBJECTIVE: Increasing numbers of people are expected to live with comorbid cancer
      and dementia. Cancer treatment decision-making for these individuals is complex, 
      particularly for those lacking capacity, requiring support across the cancer care
      pathway. There is little research to inform practice in this area. This
      ethnographic study reports on the cancer decision-making experiences of people
      with cancer and dementia, their families, and healthcare staff. METHODS:
      Participant observations, informal conversations, semi-structured interviews, and
      medical note review, in two NHS trusts. Seventeen people with dementia and
      cancer, 22 relatives and 19 staff members participated. RESULTS: Decision-making 
      raised complex ethical dilemmas and challenges and raised concerns for families
      and staff around whether correct decisions had been made. Whose decision it was
      and to what extent a person with dementia and cancer was able to make decisions
      was complex, requiring careful and ongoing consultation and close involvement of 
      relatives. The potential impact dementia might have on treatment understanding
      and toleration required additional consideration by clinicians when evaluating
      treatment options. CONCLUSIONS: Cancer treatment decision-making for people with 
      dementia is challenging, should be an ongoing process and has emotional impacts
      for the individual, relatives, and staff. Longer, flexible, and additional
      appointments may be required to support decision-making by people with cancer and
      dementia. Evidence-based decision-making guidance on how dementia impacts cancer 
      prognosis, treatment adherence and efficacy is required.
CI  - (c) 2020 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
FAU - Griffiths, Alys Wyn
AU  - Griffiths AW
AUID- ORCID: 0000-0001-9388-9168
AD  - Centre for Dementia Research, School of Health & Community Studies, Leeds Beckett
      University, Leeds, UK.
FAU - Ashley, Laura
AU  - Ashley L
AD  - School of Social Sciences, Leeds Beckett University, Leeds, UK.
FAU - Kelley, Rachael
AU  - Kelley R
AD  - Centre for Dementia Research, School of Health & Community Studies, Leeds Beckett
      University, Leeds, UK.
FAU - Cowdell, Fiona
AU  - Cowdell F
AD  - Faculty of Health, Education and Life Sciences, Birmingham City University,
      Birmingham, UK.
FAU - Collinson, Michelle
AU  - Collinson M
AD  - Clinical Trials Research Unit, Institute of Clinical Trials Research, University 
      of Leeds, Leeds, UK.
FAU - Mason, Ellen
AU  - Mason E
AD  - Clinical Trials Research Unit, Institute of Clinical Trials Research, University 
      of Leeds, Leeds, UK.
FAU - Farrin, Amanda
AU  - Farrin A
AD  - Clinical Trials Research Unit, Institute of Clinical Trials Research, University 
      of Leeds, Leeds, UK.
FAU - Henry, Ann
AU  - Henry A
AD  - Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
AD  - School of Medicine, University of Leeds, Leeds, UK.
FAU - Inman, Hayley
AU  - Inman H
AD  - Oncology Services, Bradford Teaching Hospitals NHS Foundation Trust, Bradford,
      UK.
FAU - Surr, Claire
AU  - Surr C
AD  - Centre for Dementia Research, School of Health & Community Studies, Leeds Beckett
      University, Leeds, UK.
LA  - eng
GR  - PB-PG-0816-20015/DH_/Department of Health/United Kingdom
GR  - PB-PG-0816-20015/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200707
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
SB  - IM
MH  - *Advance Care Planning
MH  - Aged
MH  - Aged, 80 and over
MH  - Caregivers/psychology
MH  - Cognitive Dysfunction/psychology
MH  - *Decision Making
MH  - Dementia/complications/*psychology
MH  - Humans
MH  - Male
MH  - Mental Competency/*psychology
MH  - Middle Aged
MH  - Neoplasms/complications/*psychology
MH  - Professional-Family Relations
OTO - NOTNLM
OT  - *cognitive impairment
OT  - *dementia
OT  - *ethnography
OT  - *older adults
OT  - *treatment options
EDAT- 2020/06/23 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1002/pon.5448 [doi]
PST - ppublish
SO  - Psychooncology. 2020 Aug;29(8):1347-1354. doi: 10.1002/pon.5448. Epub 2020 Jul 7.


PMID- 32566983
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Dec
TI  - Better in theory than in practise? Challenges when applying the luck egalitarian 
      ethos in health care policy.
PG  - 735-742
LID - 10.1007/s11019-020-09962-3 [doi]
AB  - Luck egalitarianism, a theory of distributive justice, holds that inequalities
      which arise due to individuals' imprudent choices must not, as a matter of
      justice, be neutralized. This article deals with the possible application of luck
      egalitarianism to the area of health care. It seeks to investigate whether the
      ethos of luck egalitarianism can be operationalized to the point of informing
      health care policy without straying from its own ideals. In the transition from
      theory to practise, luck egalitarianism encounters several difficulties. We argue
      that the charge of moral arbitrariness can, at least in part, be countered by our
      provided definition of "imprudent actions" in the health area. We discuss the
      choice for luck egalitarianism in health care between ex ante and ex post policy 
      approaches, and show how both approaches are flawed by luck egalitarianism's own 
      standards. We also examine the problem of threshold setting when luck
      egalitarianism is set to practise in health care. We argue that wherever policy
      thresholds are set, luck egalitarianism in health care risks pampering the
      imprudent, abandoning the prudent or, at worst, both. Furthermore, we claim that 
      moves to mitigate these risks in turn diminish the normative importance of the
      ethos of luck egalitarianism to policy. All in all, our conclusion is that luck
      egalitarianism cannot be consistently applied as a convincing and relevant
      normative principle in health care policy.
FAU - Bjork, Joar
AU  - Bjork J
AUID- ORCID: http://orcid.org/0000-0001-7194-4875
AD  - Stockholm Centre for Healthcare Ethics (CHE), LIME, Karolinska Institutet,
      Tomtebodavagen 18 A, 171 77, Stockholm, Sweden. joar.bjork@ki.se.
AD  - Department of Research and Development, Region Kronoberg, PO Box 1223, 351 12,
      Vaxjo, Sweden. joar.bjork@ki.se.
FAU - Helgesson, Gert
AU  - Helgesson G
AD  - Stockholm Centre for Healthcare Ethics (CHE), LIME, Karolinska Institutet,
      Tomtebodavagen 18 A, 171 77, Stockholm, Sweden.
FAU - Juth, Niklas
AU  - Juth N
AD  - Stockholm Centre for Healthcare Ethics (CHE), LIME, Karolinska Institutet,
      Tomtebodavagen 18 A, 171 77, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Choice Behavior
MH  - *Health Behavior
MH  - Health Care Rationing/ethics
MH  - *Health Policy
MH  - Humans
MH  - Morals
MH  - Philosophy, Medical
MH  - *Risk-Taking
PMC - PMC7538444
OTO - NOTNLM
OT  - Clinical ethics
OT  - Luck egalitarianism
OT  - Priority setting
OT  - Responsibility
OT  - Smoking
EDAT- 2020/06/23 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1007/s11019-020-09962-3 [doi]
AID - 10.1007/s11019-020-09962-3 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Dec;23(4):735-742. doi: 10.1007/s11019-020-09962-3.


PMID- 32566734
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 2366-5017 (Electronic)
IS  - 2366-5017 (Linking)
VI  - 37
IP  - 3
DP  - 2020
TI  - The German interprofessional attitudes scale: translation, cultural adaptation,
      and validation.
PG  - Doc32
LID - 10.3205/zma001325 [doi]
AB  - Objectives: The implementation of obstetric hybrid simulation and
      interprofessional collaboration between midwives and anesthetists in labor
      emergencies fostered the need to evaluate the impact of such a program. The
      original Interprofessional Attitude Scale (IPAS) assesses interprofessional
      attitudes among health professional students and includes the 2011 and 2016
      Interprofessional Collaborative Practice report competency domains. The purpose
      of this study was to create a German version of the IPAS (G-IPAS) to use for the 
      education of healthcare students. Methods: We performed the translation and
      validation of the IPAS in five steps: translation to German according to the
      International Society of Pharmaeconomics and Outcome Research guidelines; nine
      cognitive interviews with healthcare professionals and students;calculation of
      the Content Validity Index (CVI) by expert opinion; exploratory factor analysis
      (EFA); and internal consistency by Cronbach's alpha. All study participants gave 
      written informed consent and the cantonal ethics committee waived further ethical
      approval. Results: The cognitive interviews led to replacement of single-item
      wording. We retained 27 items for CVI analysis. The averaged overall CVI was
      0.79, with 15 items >/=0.89. 185 students (70 medicine, 51 nursing, 48
      physiotherapy, and 16 midwifery) contributed with data for the EFA and it
      produced three subscales. "Teamwork, roles, and responsibilities" with factor
      loadings >/=0.49, "Patient-centeredness" with factor loadings >/=0.31, and
      "Community-centeredness" with factor loadings >/=0.57. Two items of the total
      scale were deleted, and four items were redistributed to another subscale.
      Cronbach's alpha for the overall G-IPAS scale was 0.87. After deleting and
      redistributing items in subscales, a new Scale-CVI/Average was calculated and was
      0.82. Conclusions: Based on a rigorous validation process, the G-IPAS provides a 
      reliable tool to assess attitudes towards interprofessional education among
      different healthcare professions in German-speaking countries.
CI  - Copyright (c) 2020 Pedersen et al.
FAU - Pedersen, Tina H
AU  - Pedersen TH
AD  - University of Bern, Bern University Hospital, Inselspital, Department of
      Anesthesiology and Pain Therapy, Bern, Switzerland.
FAU - Cignacco, Eva
AU  - Cignacco E
AD  - Bern University of Applied Sciences, Health Professions, Midwifery Division,
      Bern, Switzerland.
FAU - Meuli, Jonas
AU  - Meuli J
AD  - University of Bern, Bern University Hospital, Inselspital, Department of
      Anesthesiology and Pain Therapy, Bern, Switzerland.
FAU - Habermann, Ferdinand
AU  - Habermann F
AD  - University of Bern, Bern University Hospital, Inselspital, Department of
      Anesthesiology and Pain Therapy, Bern, Switzerland.
FAU - Berger-Estilita, Joana
AU  - Berger-Estilita J
AD  - University of Bern, Bern University Hospital, Inselspital, Department of
      Anesthesiology and Pain Therapy, Bern, Switzerland.
FAU - Greif, Robert
AU  - Greif R
AD  - University of Bern, Bern University Hospital, Inselspital, Department of
      Anesthesiology and Pain Therapy, Bern, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - Germany
TA  - GMS J Med Educ
JT  - GMS journal for medical education
JID - 101676086
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Culturally Competent Care/methods
MH  - Germany
MH  - Health Personnel/*psychology/statistics & numerical data
MH  - Humans
MH  - *Interprofessional Relations
MH  - Psychometrics/instrumentation/methods/*standards
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
MH  - Translating
PMC - PMC7291384
OTO - NOTNLM
OT  - *assessment
OT  - *interprofessional attitudes
OT  - *psychometric testing
OT  - *transcultural translation
COIS- The authors declare that they have no competing interests.
EDAT- 2020/06/23 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/06/23 06:00
PHST- 2019/08/25 00:00 [received]
PHST- 2020/01/14 00:00 [revised]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
AID - 10.3205/zma001325 [doi]
AID - zma001325 [pii]
AID - Doc32 [pii]
PST - epublish
SO  - GMS J Med Educ. 2020 Apr 15;37(3):Doc32. doi: 10.3205/zma001325. eCollection
      2020.


PMID- 32566569
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2305-5839 (Print)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 10
DP  - 2020 May
TI  - Appealing for efficient, well organized clinical trials on COVID-19.
PG  - 632
LID - 10.21037/atm-20-2429 [doi]
AB  - BACKGROUND: The rapid emergence of clinical trials on COVID-19 stimulated a wave 
      of discussion in scientific community. It is important to understand the
      characteristics of the ongoing or pending interventional clinical trials on
      COVID-19. METHODS: We reviewed the characteristics of interventional trials from 
      Chinese Clinical Trial Registration (ChiCTR) and ClinicalTrials.gov. A total of
      171 COVID-19-related interventional trials were identified on Feb 22, 2020. These
      trials are classified into 4 categories based on treatment modalities, including 
      chemical drugs (CDs), biological therapies (BTs), traditional Chinese medicine
      (TCM) treatments and other therapies. RESULTS: Our analysis focused on the issues
      of stage, design, randomization, blinding, primary endpoints (PEs) definition and
      sample size of these trials. Although most trials use parallel-arm design (88.3%)
      and randomization (77.2%), blinding is applied in only 25 trials (14.6%). More
      than half of the trials planned to recruit </=100 patients, indicating a
      possibility of insufficient statistical power. About one third of trials will
      recruit severe and critically ill patients. More trials on traditional Chinese
      medical treatment use 2 or more PEs than those on CDs or biological treatments
      (57.6%, 39.4% and 40.5%, respectively). CONCLUSIONS: We found some studies with
      potential defects including unreasonable design, inappropriate PE and small
      sample size. Clinical trials on COVID-19 should be designed based on scientific
      rules, ethics and benefits for patients.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Department of Biostatistics, School of Public Health, Nanjing Medical University,
      Nanjing 210029, China.
FAU - Wei, Yongyue
AU  - Wei Y
AD  - Department of Biostatistics, School of Public Health, Nanjing Medical University,
      Nanjing 210029, China.
FAU - Shen, Sipeng
AU  - Shen S
AD  - Department of Biostatistics, School of Public Health, Nanjing Medical University,
      Nanjing 210029, China.
FAU - Zhang, Mingzhi
AU  - Zhang M
AD  - Department of Biostatistics, School of Public Health, Nanjing Medical University,
      Nanjing 210029, China.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Biostatistics, School of Public Health, Nanjing Medical University,
      Nanjing 210029, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7290614
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical trials
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/atm-20-2429). The authors have no
      conflicts of interest to declare.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
AID - 10.21037/atm-20-2429 [doi]
AID - atm-08-10-632 [pii]
PST - ppublish
SO  - Ann Transl Med. 2020 May;8(10):632. doi: 10.21037/atm-20-2429.


PMID- 32566309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2090-2840 (Print)
IS  - 2090-2840 (Linking)
VI  - 2020
DP  - 2020
TI  - Recruiting Medical Students for a First Responder Project in the Social Age:
      Direct Contact Still Outperforms Social Media.
PG  - 9438560
LID - 10.1155/2020/9438560 [doi]
AB  - INTRODUCTION: Efficient recruitment of first responders (FRs) is crucial for
      long-term success of any FR project. FRs are laypersons who are trained in
      cardiopulmonary resuscitation (CPR), medical professionals, and firemen, police
      officers, and other professions with a duty of help. As social media are widely
      used for rapid communication, we carried out a prospective observational study to
      test the hypothesis that recruitment of FRs via social media is more efficient
      than recruitment via direct face-to-face contact. METHODS: Following ethics
      committee agreement, we informed 600 medical students about becoming FRs when
      they attended a didactic lecture about the FR project or during their mandatory
      CPR-course. Furthermore, recruitment was opened to medical students through
      Facebook, which accessed approximately 1,000 medical students to see if they
      expressed interest in becoming FRs. All of the recruited students successfully
      completed the FR training. We then used an online questionnaire to ask these
      students how they had been recruited. RESULTS: Out of 63 registered student FRs, 
      59 responded to the online questionnaire. Overall, 15.3% of these FR students
      were recruited via social media. The majority (78.0%) were recruited through
      direct contact. CONCLUSIONS: Despite widespread use of social media, over
      three-quarters of these medical students were recruited to the FR project via
      direct personal contact. This suggests that the advantage of a larger reachable
      population using social media does not outweigh the impact of personal contact
      with experts.
CI  - Copyright (c) 2020 David Marx et al.
FAU - Marx, David
AU  - Marx D
AD  - Department of Anaesthesiology and Pain Medicine, Bern University Hospital and
      University of Bern, Bern, Switzerland.
FAU - Greif, Robert
AU  - Greif R
AD  - Department of Anaesthesiology and Pain Medicine, Bern University Hospital and
      University of Bern, Bern, Switzerland.
AD  - ERC ResearchNET, Bern, Switzerland.
AD  - School of Medicine, Sigmund Freud University Vienna, Vienna, Austria.
FAU - Egloff, Mike
AU  - Egloff M
AD  - Department of Anaesthesiology and Pain Medicine, Bern University Hospital and
      University of Bern, Bern, Switzerland.
FAU - Balmer, Yves
AU  - Balmer Y
AD  - Department of Anaesthesiology and Pain Medicine, Bern University Hospital and
      University of Bern, Bern, Switzerland.
FAU - Nabecker, Sabine
AU  - Nabecker S
AUID- ORCID: https://orcid.org/0000-0001-9524-0821
AD  - Department of Anaesthesiology and Pain Medicine, Bern University Hospital and
      University of Bern, Bern, Switzerland.
AD  - ERC ResearchNET, Bern, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - Egypt
TA  - Emerg Med Int
JT  - Emergency medicine international
JID - 101567070
PMC - PMC7285391
COIS- DM, ME, and YB reported that they have no conflicts of interest. RG is the
      current Board Director of Education and Training of the European Resuscitation
      Council and chair of the ILCOR Task Force on Education, Implementation, and Team.
      SN is the current Education Representative of the "Young ERC" of the European
      Resuscitation Council.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
CRDT- 2020/06/23 06:00
PHST- 2020/02/15 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
AID - 10.1155/2020/9438560 [doi]
PST - epublish
SO  - Emerg Med Int. 2020 Jun 1;2020:9438560. doi: 10.1155/2020/9438560. eCollection
      2020.


PMID- 32566249
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2056-7529 (Electronic)
IS  - 2056-7529 (Linking)
VI  - 6
DP  - 2020
TI  - Co-creating a patient and public involvement and engagement 'how to' guide for
      researchers.
PG  - 32
LID - 10.1186/s40900-020-00208-3 [doi]
AB  - PLAIN LANGUAGE SUMMARY: Research should benefit society at large. Involving
      citizens those who are affected by research may not only increase the quality,
      but can also push research towards generating greater societal benefits and
      relevant outcomes for citizens. Including citizens in research also has ethical
      implications, which necessitate structured guidance on 'how to' meaningfully
      involve them. In our project, we invited a multi-stakeholder group consisting of 
      researchers from multiple disciplines, citizen scientists, youth and patient
      advocates to co-create a guide on 'how to' meaningfully involve citizens in
      research. In five consecutive workshops, we discussed how the characteristics of 
      interactions between researchers and citizens (e.g., building trustful
      relationships and communication) and what a possible project steering structure
      enabling meaningful public involvement in research could look like. As a result
      of these workshops, the PPIE 'How to' Guide for Researchers was developed to
      support the implementation of 'Patient and Public Involvement and Engagement'
      (PPIE) activities and informed a PPIE Implementation Programme funding public
      involvement activities in Austria. ABSTRACT: Involving citizens in research is
      not widely utilised across research disciplines and countries. It requires the
      readiness of researchers and their organisations as well as guides on 'how to'
      successfully involve citizens in a meaningful way. Including the patient and
      citizen voice in research activities has been most frequently demonstrated in
      health research, however, is implemented along various degrees of involvement -
      from passively receiving information about science to actively involving the
      citizens in steering projects and research activities. In this commentary, we aim
      to report a multi-stakeholder co-creation process developing 'Patient and Public 
      Involvement and Engagement' (PPIE) activities across disciplines to provide
      guidance for researchers and the public. We use Ludwig Boltzmann Society's (LBG) 
      organisational framework as a case study, hence it consists of research
      institutes ranging from the life sciences to humanities and therefore represents 
      a well-suited research environment for this endeavour. In a co-creation approach 
      - to accomplish a shared understanding of public involvement in research among
      different stakeholders - a multi-stakeholder group comprising 11 researchers from
      natural sciences, life sciences, social sciences and humanities, and 13 citizens 
      (such as patient advocates, young people and citizen scientists) were involved.
      In five consecutive workshops, we co-developed the nature of interactions between
      citizens and researchers, as well as governance structures enabling meaningful
      involvement in research. The workshops' content was informed by an initial
      literature review. As a result of this process, the PPIE 'How to' Guide for
      Researchers was developed to support the implementation of involvement activities
      in their research projects according to the public involvement principles. These 
      principles informed assessment criteria for the newly established PPIE
      Implementation Programme at LBG. It provides funding and support for public
      involvement activities in research to embed a sustainable and meaningful
      implementation of public involvement activities in Austria.
CI  - (c) The Author(s) 2020.
FAU - Kaisler, Raphaela E
AU  - Kaisler RE
AUID- ORCID: 0000-0002-1891-3508
AD  - Ludwig Boltzmann Gesellschaft (LBG), LBG Open Innovation in Science Center,
      Nussdorferstrasse 64/2, 1090 Vienna, Austria.grid.419350.a0000 0001 0860 6806
FAU - Missbach, Benjamin
AU  - Missbach B
AD  - Ludwig Boltzmann Gesellschaft (LBG), LBG Open Innovation in Science Center,
      Nussdorferstrasse 64/2, 1090 Vienna, Austria.grid.419350.a0000 0001 0860 6806
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - England
TA  - Res Involv Engagem
JT  - Research involvement and engagement
JID - 101708164
PMC - PMC7301967
OTO - NOTNLM
OT  - Co-creation
OT  - Multidisciplinary research
OT  - Patient and public involvement
OT  - Stakeholder involvement
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
CRDT- 2020/06/23 06:00
PHST- 2020/01/06 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
AID - 10.1186/s40900-020-00208-3 [doi]
AID - 208 [pii]
PST - epublish
SO  - Res Involv Engagem. 2020 Jun 17;6:32. doi: 10.1186/s40900-020-00208-3.
      eCollection 2020.


PMID- 32565897
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1754-6605 (Print)
IS  - 1754-6605 (Linking)
VI  - 14
DP  - 2020
TI  - Multidisciplinary approach to COVID-19 and cancer: consensus from scientific
      societies in Argentina.
PG  - 1044
LID - 10.3332/ecancer.2020.1044 [doi]
AB  - INTRODUCTION: The world is living through an outbreak of an acute respiratory
      syndrome caused by a new betacoronavirus known as coronavirus 2 (SARS CoV-2),
      which has been declared an international public health emergency by the World
      Health Organisation. Cancer patients are a very special population in this
      setting since they are more susceptible to viral infections than the general
      population. Several recommendations have been made on this issue, most of them
      based on expert opinion and institutional experience. It is essential to gather
      the evidence available for decision making. OBJECTIVE: To review the evidence
      available in order to create a multi-institutional position from the perspective 
      of scientific societies in Argentina involved in the management of cancer
      patients. METHODOLOGY: The review included two phases: 1) search and systematic
      revision of the medical literature; 2) consensus and revision of the document
      drafted by national scientific societies involved in the management and care of
      cancer patients using the modified Delphi method. The final results were
      presented at a videoconference with all the participants. Also, additional
      comment and recommendations were discussed. The final document was revised and
      approved for publication by the members of the panel. RESULTS: The consensus
      panel included 18 representatives from scientific societies from Argentina who
      assessed the evidence and then made recommendations for the management of cancer 
      patients in our country. International guidelines (CDC; ASCO, NCCN and ESMO) were
      considered as a background for analysis, as well as institutional guidelines and 
      an open ad hoc survey administered to 114 healthcare professionals from the
      scientific societies involved in this study.The recommendations are grouped as
      follows: 1) general care interventions-training of the personnel, cleaning and
      disinfection of the hospital premises and patient scheduling; 2) treatment
      decisions-patient care, surgeries, immunosuppressive therapy, radiotherapy and
      screening; 3) ethical considerations-optimisation of resources, end-of-life care 
      for critically-ill patients; 4) management of hospitalised patients; and 5)
      wellbeing of the healthcare team.The general recommendation arising from the
      study is that the management of cancer patients must adapt to the exceptional
      pandemic status quo without disregarding treatment or cure options. Moreover,
      healthcare professional accompaniment of all patients should not be neglected.
      All healthcare professionals must make a significant joint effort to create
      multidisciplinary teams to discuss the most appropriate measures for each
      particular situation. CONCLUSIONS: The scientific evidence available on this
      topic worldwide is in progress. This together with the epidemiologically shifting
      scenario poses unprecedented challenges in the management of cancer amidst this
      global pandemic. Furthermore, the key role of the healthcare structural
      organisation appears evident, such as the drafting of clear guidelines for all
      the stakeholders, adaptability to constant change and an interdisciplinary shared
      vision through consensus to provide adequate care to our cancer patients in the
      light of uncertainty and fast-paced change.
CI  - (c) the authors; licensee ecancermedicalscience.
FAU - Ismael, Julia
AU  - Ismael J
AD  - Asociacion Argentina de Oncologia Clinica, Av Federico Lacroze 2252, C1426 CPU,
      Buenos Aires, Argentina.
FAU - Losco, Federico
AU  - Losco F
AD  - Asociacion Argentina de Oncologia Clinica, Av Federico Lacroze 2252, C1426 CPU,
      Buenos Aires, Argentina.
FAU - Quildrian, Sergio
AU  - Quildrian S
AD  - Asociacion Argentina de Cirugia, Marcelo T de Alvear 2415, 1122AAM, Buenos Aires,
      Argentina.
FAU - Sanchez, Pablo
AU  - Sanchez P
AD  - Asociacion Argentina de Cirugia, Marcelo T de Alvear 2415, 1122AAM, Buenos Aires,
      Argentina.
FAU - Pincemin, Isabel
AU  - Pincemin I
AD  - Asociacion Argentina de Medicina y Cuidados Paliativos, Av Rivadavia 1255 of 309 
      C1033AAC, Buenos Aires, Argentina.
FAU - Lastiri, Jose
AU  - Lastiri J
AD  - Asociacion Argentina de Oncologia Clinica, Av Federico Lacroze 2252, C1426 CPU,
      Buenos Aires, Argentina.
FAU - Bella, Santiago
AU  - Bella S
AD  - Asociacion Argentina de Oncologia Clinica, Av Federico Lacroze 2252, C1426 CPU,
      Buenos Aires, Argentina.
FAU - Chinellato, Alejandro
AU  - Chinellato A
AD  - Asociacion de Oncologia de Rosario, Sta Fe 1798, Rosario S2000AUB, Argentina.
FAU - Dellamea, Guillermo
AU  - Dellamea G
AD  - Asociacion de Oncologia del Chaco, Av Avalos 468H3500BZR, Chaco, Argentina.
FAU - Ahualli, Alejandro
AU  - Ahualli A
AD  - Asociacion de Oncologos de Cordoba, Ovidio Lagos 226, X5004 ACF, Cordoba,
      Argentina.
FAU - Rompato, Silvana
AU  - Rompato S
AD  - Asociacion Formosena de Oncologia Clinica, Padre Patino 260, P3600 KWE,
      Argentina.
FAU - Velez, Julio
AU  - Velez J
AD  - Asociacion Oncologia Clinica de Corrientes, Necochea 1050 C3400, Corrientes,
      Argentina.
FAU - Escobar, Rafael
AU  - Escobar R
AD  - Endoscopistas Digestivos de Buenos Aires, Dr Tomas Manuel de Anchorena 1357,
      1123, Caba, Argentina.
FAU - Zwenger, Ariel
AU  - Zwenger A
AD  - Fundacion Oncologica de la Patagonia, Av Francisco de Viedma 1202, R8500AYY, Rio 
      Negro, Argentina.
FAU - Rosales, Cristina
AU  - Rosales C
AD  - Red de Oncologia de CABA, Avenida Patricias Argentinas 750, C1405BWU, Argentina.
FAU - Bagnes, Claudia
AU  - Bagnes C
AD  - Red de Oncologia de CABA, Avenida Patricias Argentinas 750, C1405BWU, Argentina.
FAU - Puyol, Jorge
AU  - Puyol J
AD  - Sociedad Argentina de Cancerologia, Av Santa Fe 1171 C1059ABF, Argentina.
FAU - Niewiadomski, Dario
AU  - Niewiadomski D
AD  - Sociedad Argentina de Cancerologia, Av Santa Fe 1171 C1059ABF, Argentina.
FAU - Smecuol, Edgardo
AU  - Smecuol E
AD  - Sociedad Argentina de Gastroenterologia, Marcelo T de Alvear 1381 Piso 9,
      C1058AAU, Buenos Aires, Argentina.
FAU - Nachman, Fabio
AU  - Nachman F
AD  - Sociedad Argentina de Gastroenterologia, Marcelo T de Alvear 1381 Piso 9,
      C1058AAU, Buenos Aires, Argentina.
FAU - Gonzalez, Eduardo
AU  - Gonzalez E
AD  - Sociedad Argentina de Mastologia, Marcelo Torcuato de Alvear 1252, C1058 AAT,
      Buenos Aires, Argentina.
FAU - Ferraris, Gustavo
AU  - Ferraris G
AD  - Sociedad Argentina de Terapia Radiante, Avenida Santa Fe 1171 C1059ABF,
      Argentina.
FAU - Suppicich, Juan Ramos
AU  - Suppicich JR
AD  - Sociedad Argentina de Urologia, De la Carcova 3526, C1174, Buenos Aires,
      Argentina.
FAU - Price, Paola
AU  - Price P
AD  - Sociedad de Cancerologia de La Plata, 50 374, La Plata (1900), Buenos Aires,
      Argentina.
FAU - Medina, Luis
AU  - Medina L
AD  - Sociedad de Oncologia Clinica de Tucuman, Las Piedras 496, T4000 BRJ, Argentina.
FAU - O'Connor, Juan
AU  - O'Connor J
AD  - Asociacion Argentina de Oncologia Clinica, Av Federico Lacroze 2252, C1426 CPU,
      Buenos Aires, Argentina.
LA  - eng
PT  - Editorial
DEP - 20200513
PL  - England
TA  - Ecancermedicalscience
JT  - Ecancermedicalscience
JID - 101392236
PMC - PMC7289616
OTO - NOTNLM
OT  - COVID-19
OT  - cancer
OT  - coronavirus
OT  - guidelines
OT  - recommendation
COIS- The declaration of conflicts of interest was made by all members of the
      development group and participants in this consensus.
EDAT- 2020/06/23 06:00
MHDA- 2020/06/23 06:01
CRDT- 2020/06/23 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/23 06:01 [medline]
AID - 10.3332/ecancer.2020.1044 [doi]
AID - can-14-1044 [pii]
PST - epublish
SO  - Ecancermedicalscience. 2020 May 13;14:1044. doi: 10.3332/ecancer.2020.1044.
      eCollection 2020.


PMID- 32565750
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20220415
IS  - 1537-744X (Electronic)
IS  - 1537-744X (Linking)
VI  - 2020
DP  - 2020
TI  - The Effectiveness of Teaching Nursing Ethics via Scenarios and Group Discussion
      in Nurses' Adherence to Ethical Codes and Patients' Satisfaction with Nurses'
      Performance.
PG  - 5749687
LID - 10.1155/2020/5749687 [doi]
AB  - BACKGROUND: There are shortcomings in nurses' adherence to ethical principles in 
      practice. The present study aims to investigate the effectiveness of teaching
      nursing ethics via scenario-based learning and group discussion in nurses'
      adherence to codes of ethics and patients' satisfaction with nurses' performance.
      METHODS: Using a quasiexperimental design, the present study employed
      questionnaires which measure nurses' compliance with nursing codes of ethics and 
      patients' satisfaction with nursing care before, immediately after, and one month
      after intervention. The collected data were analyzed using the independent
      t-test, ANOVA, and chi-square test in SPSS v.22. The level of significance was
      set at p < 0.05. The nurses (n = 80) and patients (n = 160) from various units of
      two university hospitals in the south-west of Iran participated in the present
      study. RESULTS: The pretest mean scores of the intervention and control groups in
      patient rights and patients' satisfaction with nursing care were not
      significantly different (p=0.07, p=0.21). Yet, there were statistically
      significant differences between the groups' mean scores as calculated immediately
      after (p < 0.001, p < 0.001) and one month after intervention (p < 0.001, p <
      0.001). CONCLUSION: Employment of new approaches to teach nursing ethical
      principles improves compliance with nursing ethical codes and patients'
      satisfaction with nurses' performance.
CI  - Copyright (c) 2020 Fatemeh Izadi et al.
FAU - Izadi, Fatemeh
AU  - Izadi F
AUID- ORCID: https://orcid.org/0000-0002-8994-2111
AD  - Fasa University of Medical Sciences, Fasa, Iran.
FAU - Bijani, Mostafa
AU  - Bijani M
AUID- ORCID: https://orcid.org/0000-0001-7990-662X
AD  - Department of Medical Surgical Nursing, Fasa University of Medical Sciences,
      Fasa, Iran.
FAU - Fereidouni, Zhila
AU  - Fereidouni Z
AUID- ORCID: https://orcid.org/0000-0002-3345-0513
AD  - Department of Medical Surgical Nursing, Fasa University of Medical Sciences,
      Fasa, Iran.
FAU - Karimi, Shahnaz
AU  - Karimi S
AUID- ORCID: https://orcid.org/0000-0003-2438-5577
AD  - Department of Nursing, School of Nursing and Midwifery, Fasa University of
      Medical Science, Fasa, Iran.
FAU - Tehranineshat, Banafsheh
AU  - Tehranineshat B
AUID- ORCID: https://orcid.org/0000-0002-2066-5689
AD  - Department of Nursing, School of Nursing and Midwifery, Shiraz University of
      Medical Sciences, Shiraz, Iran.
FAU - Dehghan, Azizallah
AU  - Dehghan A
AD  - Department of Community Medicine, School of Medicine, Non Communicable Diseases
      Research Center, Fasa University of Medical Science, Fasa, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
SB  - IM
MH  - Adult
MH  - Aged
MH  - Attitude of Health Personnel
MH  - *Codes of Ethics
MH  - Ethics, Nursing/*education
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Staff, Hospital/psychology/*statistics & numerical data
MH  - Patient Rights/*ethics
MH  - Patient Satisfaction/*statistics & numerical data
MH  - *Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7285407
COIS- The authors declare that there are no conflicts of interest regarding the
      publication of this paper.
EDAT- 2020/06/23 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/02/08 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
AID - 10.1155/2020/5749687 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2020 Jun 1;2020:5749687. doi: 10.1155/2020/5749687.
      eCollection 2020.


PMID- 32565599
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201210
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Linking)
VI  - 52
IP  - 2
DP  - 2020 Mar-Apr
TI  - COVID-19 pandemic: A review based on current evidence.
PG  - 117-129
LID - 10.4103/ijp.IJP_310_20 [doi]
AB  - In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel
      coronavirus, initiated an outbreak of pneumonia from Wuhan in China, which
      rapidly spread worldwide. The clinical characteristics of the disease range from 
      asymptomatic cases or mild symptoms, which include nonspecific symptoms such as
      fever, cough, sore throat, headache, and nasal congestion to severe cases such as
      pneumonia, respiratory failure demanding mechanical ventilation to multi-organ
      failure, sepsis, and death. As the transmission rate is quite alarming, we
      require an effective therapeutic strategy to treat symptomatic patients and adopt
      the preventive measures in order to contain the infection and prevent community
      transmission. Coronavirus disease 2019 (COVID-19) pandemic is a public health
      emergency of international concern, hence repurposing of the drugs is an
      attractive and a feasible option because PK/PD profile, toxicity profile, and
      drug interactions are already known. This review emphasizes on the different
      aspects of COVID-19 such as the epidemiology, etiopathogenesis, diagnosis, and
      preventive measures to be adopted in order to fight this pandemic. It also
      highlights upon the ethics preparedness and challenges faced by a developing
      country like India during such an outbreak. The review focuses on the various
      approaches adopted till date for developing effective therapeutic strategies
      including combination of drugs, vaccine therapy, and convalescent plasma therapy 
      to combat this viral outbreak.
CI  - Copyright: (c) 2020 Indian Journal of Pharmacology.
FAU - Mahalmani, Vidya M
AU  - Mahalmani VM
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Mahendru, Dhruv
AU  - Mahendru D
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Semwal, Ankita
AU  - Semwal A
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Kaur, Sukhmeet
AU  - Kaur S
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Kaur, Harpinder
AU  - Kaur H
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Sarma, Phulen
AU  - Sarma P
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Prakash, Ajay
AU  - Prakash A
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
FAU - Medhi, Bikash
AU  - Medhi B
AD  - Department of Pharmacology, PGIMER, Chandigarh, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200603
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - COVID-19 Testing
MH  - COVID-19 Vaccines
MH  - *Clinical Laboratory Techniques
MH  - Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention &
      control/*therapy
MH  - Developing Countries
MH  - Disease Outbreaks
MH  - Drug Repositioning
MH  - Drug Therapy, Combination
MH  - Humans
MH  - India/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/epidemiology/*therapy
MH  - SARS-CoV-2
MH  - Viral Vaccines/administration & dosage
PMC - PMC7282680
OTO - NOTNLM
OT  - *Coronavirus disease-19
OT  - *drug repurposing
OT  - *pandemic
OT  - *severe acute respiratory syndrome-coronavirus-2
COIS- There are no conflicts of interest.
EDAT- 2020/06/23 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/23 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.4103/ijp.IJP_310_20 [doi]
AID - IJPharm-52-117 [pii]
PST - ppublish
SO  - Indian J Pharmacol. 2020 Mar-Apr;52(2):117-129. doi: 10.4103/ijp.IJP_310_20. Epub
      2020 Jun 3.


PMID- 32565483
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20220328
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II):
      protocol for an observational study using linked Scottish national data.
PG  - e039097
LID - 10.1136/bmjopen-2020-039097 [doi]
AB  - INTRODUCTION: Following the emergence of the novel severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2) in December 2019 and the ensuing COVID-19
      pandemic, population-level surveillance and rapid assessment of the effectiveness
      of existing or new therapeutic or preventive interventions are required to ensure
      that interventions are targeted to those at highest risk of serious illness or
      death from COVID-19. We aim to repurpose and expand an existing pandemic
      reporting platform to determine the attack rate of SARS-CoV-2, the uptake and
      effectiveness of any new pandemic vaccine (once available) and any protective
      effect conferred by existing or new antimicrobial drugs and other therapies.
      METHODS AND ANALYSIS: A prospective observational cohort will be used to monitor 
      daily/weekly the progress of the COVID-19 epidemic and to evaluate the
      effectiveness of therapeutic interventions in approximately 5.4 million
      individuals registered in general practices across Scotland. A national linked
      dataset of patient-level primary care data, out-of-hours, hospitalisation,
      mortality and laboratory data will be assembled. The primary outcomes will
      measure association between: (A) laboratory confirmed SARS-CoV-2 infection,
      morbidity and mortality, and demographic, socioeconomic and clinical population
      characteristics; and (B) healthcare burden of COVID-19 and demographic,
      socioeconomic and clinical population characteristics. The secondary outcomes
      will estimate: (A) the uptake (for vaccines only); (B) effectiveness; and (C)
      safety of new or existing therapies, vaccines and antimicrobials against
      SARS-CoV-2 infection. The association between population characteristics and
      primary outcomes will be assessed via multivariate logistic regression models.
      The effectiveness of therapies, vaccines and antimicrobials will be assessed from
      time-dependent Cox models or Poisson regression models. Self-controlled study
      designs will be explored to estimate the risk of therapeutic and
      prophylactic-related adverse events. ETHICS AND DISSEMINATION: We obtained
      approval from the National Research Ethics Service Committee, Southeast Scotland 
      02. The study findings will be presented at international conferences and
      published in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Simpson, Colin R
AU  - Simpson CR
AD  - Wellington School of Health, Faculty of Health, Victoria University of
      Wellington, Wellington, New Zealand.
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Robertson, Chris
AU  - Robertson C
AD  - Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
AD  - Public Health Scotland, Glasgow, UK.
FAU - Vasileiou, Eleftheria
AU  - Vasileiou E
AUID- ORCID: 0000-0001-6850-7578
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK
      eleftheria.vasileiou@ed.ac.uk.
FAU - McMenamin, Jim
AU  - McMenamin J
AD  - Public Health Scotland, Glasgow, UK.
FAU - Gunson, Rory
AU  - Gunson R
AD  - West Of Scotland Specialist Virology Centre, Glasgow, UK.
FAU - Ritchie, Lewis D
AU  - Ritchie LD
AD  - Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK.
FAU - Woolhouse, Mark
AU  - Woolhouse M
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Morrice, Lynn
AU  - Morrice L
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Kelly, Dave
AU  - Kelly D
AD  - The Centre for Health Science, Albasoft Ltd, Inverness, UK.
FAU - Stagg, Helen R
AU  - Stagg HR
AUID- ORCID: 0000-0003-4022-3447
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
FAU - Marques, Diogo
AU  - Marques D
AUID- ORCID: 0000-0002-2556-0923
AD  - Public Health Scotland, Glasgow, UK.
FAU - Murray, Josie
AU  - Murray J
AD  - Public Health Scotland, Glasgow, UK.
FAU - Sheikh, Aziz
AU  - Sheikh A
AD  - Usher Institute, The University of Edinburgh, Edinburgh, UK.
LA  - eng
GR  - MC_PC_19004/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_19075/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_20029/MRC_/Medical Research Council/United Kingdom
GR  - MR/R008345/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - *Epidemiological Monitoring
MH  - Humans
MH  - Observational Studies as Topic
MH  - Pandemics
MH  - Patient Care Planning/*organization & administration
MH  - Pneumonia, Viral/*epidemiology
MH  - Prospective Studies
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Scotland
PMC - PMC7311023
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *respiratory medicine (see thoracic medicine)
COIS- Conflicts of Interest: CRS reports grants from the UK National Institute for
      Health Research, Medical Research Council and New Zealand Health Research
      Council, and The Ministry of Business, Innovation and Employment during the
      conduct of (and related to) the study. CR reports grants from the UK Medical
      Research Council, CSO during the conduct of (and related to) the study. CR is a
      member of the Scottish Government's Chief Medical Officer's COVID-19 Advisory
      Group. He is also a member of the UK SPI-M committee and the Commission Human
      Medicines COVID-19 Vaccine Safety Working Group. The views represented in this
      article do not represent the views of the UK or Scottish Government. JM is
      Incident Director for COVID-19 at Public Health Scotland and reports no conflicts
      of interest. LDR serves on a number of Scottish Government Advisory Groups,
      including COVID-19. MW is a member of the SPI-M advisory committee for the UK
      Government and the Covid-19 Advisory Group for the Scottish Government. DK is a
      director of Albasoft Ltd and a health informatician providing technical advice
      and support to the research community. HRS reports grants from the UK Medical
      Research Council during the conduct of the study. AS is a member of the Scottish 
      Government's Chief Medical Officer's COVID-19 Advisory Group. The views
      represented in this article do not represent the views of the Scottish
      Government. EV, RG, LM, DM and JM report no conflicts of interest.
EDAT- 2020/06/23 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - bmjopen-2020-039097 [pii]
AID - 10.1136/bmjopen-2020-039097 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e039097. doi: 10.1136/bmjopen-2020-039097.


PMID- 32565482
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Health impacts of seated arm ergometry training in patients with a diabetic foot 
      ulcer: protocol for a randomised controlled trial.
PG  - e039062
LID - 10.1136/bmjopen-2020-039062 [doi]
AB  - INTRODUCTION: Once diagnosed with a diabetic foot ulcer (DFU), patients are
      advised to offload, keeping pressure off the foot in order to facilitate ulcer
      healing. An increase in offloading is often accompanied by reductions in physical
      activity which can worsen the overall health of patients.While unable to perform 
      traditional forms of upright activity, one mode of exercise that would allow
      patients to be physically active while adhering to offloading instruction is
      seated arm ergometry. The merits of tailored aerobic exercise in DFU remain
      unexplored. METHODS AND ANALYSIS: This is a prospective open-label randomised
      controlled trial. Participants will be randomised to one of two groups, an
      exercise intervention group or control. The intervention group are required to
      undertake arm ergometry training at a moderate intensity (65%-75% HRpeak), three 
      times per week for 12 weeks as individually prescribed by an exercise
      physiologist, while the control group will continue to receive standard care
      alone. Assessment of outcome measures will occur at baseline and after the
      intervention period, these will include: a seated VO2 peak test, a blood sample, 
      a short physical performance battery, a dual-energy X-ray absorptiometry scan and
      completing a range of health-based questionnaires. The above will be used to
      determine: cardiorespiratory fitness, metabolic health, physical function, body
      composition and quality of life, respectively. Ulcer area will also be measured
      as an approximate marker of ulcer healing. ETHICS AND DISSEMINATION: This trial
      has been approved by 'Yorkshire & The Humber-Leeds West Research Ethics
      Committee' (19/YH/0269). Trial results will be published in peer-reviewed
      journals and through conference presentations. TRIAL REGISTRATION NUMBER:
      ISRCTN16000053. Registered in accordance with WHO Trial Registration Data Set
      (version 1.3.1).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McCarthy, Matthew
AU  - McCarthy M
AUID- ORCID: 0000-0002-6328-5168
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK mm636@le.ac.uk.
AD  - NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester,
      UK.
FAU - Yates, Thomas
AU  - Yates T
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
AD  - NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester,
      UK.
FAU - Webb, David
AU  - Webb D
AD  - University Hospitals of Leicester NHS Trust, Leicester, UK.
FAU - Game, Frances
AU  - Game F
AD  - Department of Diabetes and Endocrinology, University Hospitals of Derby and
      Burton NHS Foundation Trust, Derby, UK.
FAU - Gray, Laura
AU  - Gray L
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
FAU - Davies, Melanie J
AU  - Davies MJ
AD  - Diabetes Research Centre, University of Leicester, Leicester, UK.
AD  - NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester,
      UK.
LA  - eng
SI  - ISRCTN/ISRCTN16000053
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Absorptiometry, Photon
MH  - Diabetic Foot/*therapy
MH  - Ergometry/*methods
MH  - Exercise Test
MH  - Humans
MH  - Oxygen Consumption
MH  - *Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Surveys and Questionnaires
PMC - PMC7311002
OTO - NOTNLM
OT  - *diabetic foot
OT  - *diabetic neuropathy
OT  - *general diabetes
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-039062 [pii]
AID - 10.1136/bmjopen-2020-039062 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e039062. doi: 10.1136/bmjopen-2020-039062.


PMID- 32565481
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - INTREPID II: protocol for a multistudy programme of research on untreated
      psychosis in India, Nigeria and Trinidad.
PG  - e039004
LID - 10.1136/bmjopen-2020-039004 [doi]
AB  - INTRODUCTION: There are few robust and directly comparable studies of the
      epidemiology of psychotic disorders in the Global South. INTREPID II is designed 
      to investigate variations in untreated psychotic disorders in the Global South in
      (1) incidence and presentation (2) 2-year course and outcome, (3) help-seeking
      and impact, and (4) physical health. METHODS: INTREPID II is a programme of
      research incorporating incidence, case-control and cohort studies of psychoses in
      contiguous urban and rural areas in India, Nigeria and Trinidad. In each country,
      the target samples are 240 untreated cases with a psychotic disorder, 240
      age-matched, sex-matched and neighbourhood-matched controls, and 240 relatives or
      caregivers. Participants will be followed, in the first instance, for 2 years. In
      each setting, we have developed and are employing comprehensive case-finding
      methods to ensure cohorts are representative of the target populations. Using
      methods developed during pilot work, extensive data are being collected at
      baseline and 2-year follow-up across several domains: clinical, social,
      help-seeking and impact, and biological. ETHICS AND DISSEMINATION: Informed
      consent is sought, and participants are free to withdraw from the study at any
      time. Participants are referred to mental health services if not already in
      contact with these and emergency treatment arranged where necessary. All data
      collected are confidential, except when a participant presents a serious risk to 
      either themselves or others. This programme has been approved by ethical review
      boards at all participating centres. Findings will be disseminated through
      international conferences, publications in international journals, and through
      local events for key stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Roberts, Tessa
AU  - Roberts T
AUID- ORCID: 0000-0001-8584-4162
AD  - Health Service & Population Research department, Institute of Psychiatry
      Psychology and Neuroscience, London, UK.
AD  - ESRC Centre for Society and Mental Health, King's College London, London, UK.
FAU - Gureje, Oye
AU  - Gureje O
AD  - WHO Collaborating Centre for Research and Training in Mental Health, Neuroscience
      and Substance Abuse, Department of Psychiatry, University of Ibadan, Ibadan, Oyo,
      Nigeria.
FAU - Thara, Rangaswamy
AU  - Thara R
AD  - Schizophrenia Research Foundation, Chennai, India.
FAU - Hutchinson, Gerard
AU  - Hutchinson G
AD  - Department of Psychiatry, The University of the West Indies at Saint Augustine
      Faculty of Medical Sciences, Saint Augustine, Tunapuna-Piarco, Trinidad and
      Tobago.
FAU - Cohen, Alex
AU  - Cohen A
AD  - Department of Epidemiology, Harvard University T H Chan School of Public Health, 
      Boston, Massachusetts, USA.
FAU - Weiss, Helen Anne
AU  - Weiss HA
AUID- ORCID: 0000-0003-3547-7936
AD  - Epidemiology and Population Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - London School of Hygiene and Tropical Medicine, London, UK.
FAU - John, Sujit
AU  - John S
AD  - Schizophrenia Research Foundation, Chennai, India.
FAU - Lee Pow, Joni
AU  - Lee Pow J
AD  - Department of Psychiatry, The University of the West Indies at Saint Augustine
      Faculty of Medical Sciences, Saint Augustine, Tunapuna-Piarco, Trinidad and
      Tobago.
FAU - Donald, Casswina
AU  - Donald C
AD  - Department of Psychiatry, The University of the West Indies at Saint Augustine
      Faculty of Medical Sciences, Saint Augustine, Tunapuna-Piarco, Trinidad and
      Tobago.
FAU - Olley, Bola
AU  - Olley B
AD  - Department of Psychiatry, University of Ibadan College of Medicine, Ibadan, Oyo, 
      Nigeria.
FAU - Miguel Esponda, Georgina
AU  - Miguel Esponda G
AD  - Health Service & Population Research department, Institute of Psychiatry
      Psychology and Neuroscience, London, UK.
AD  - ESRC Centre for Society and Mental Health, King's College London, London, UK.
FAU - Murray, Robin M
AU  - Murray RM
AD  - Department of Psychosis Studies, Institute of Psychiatry Psychology and
      Neuroscience, London, UK.
FAU - Morgan, Craig
AU  - Morgan C
AD  - Health Service & Population Research department, Institute of Psychiatry
      Psychology and Neuroscience, London, UK craig.morgan@kcl.ac.uk.
AD  - ESRC Centre for Society and Mental Health, King's College London, London, UK.
LA  - eng
GR  - WT094525/WT_/Wellcome Trust/United Kingdom
GR  - MR/P025927/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/PO25927/1/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Case-Control Studies
MH  - Follow-Up Studies
MH  - Help-Seeking Behavior
MH  - Humans
MH  - Incidence
MH  - India/epidemiology
MH  - *Mental Health Services
MH  - Nigeria/epidemiology
MH  - *Psychotic Disorders/epidemiology/therapy
MH  - *Research Design
MH  - Trinidad and Tobago/epidemiology
PMC - PMC7311008
OTO - NOTNLM
OT  - *epidemiology
OT  - *mental health
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: RMM has received payment for lectures from Janssen,
      Sunovian, Otsuka, Lundbeck, Angelini and Rekordati.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-039004 [pii]
AID - 10.1136/bmjopen-2020-039004 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e039004. doi: 10.1136/bmjopen-2020-039004.


PMID- 32565480
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Finnish study of intraoperative irrigation versus drain alone after evacuation of
      chronic subdural haematoma (FINISH): a study protocol for a multicentre
      randomised controlled trial.
PG  - e038275
LID - 10.1136/bmjopen-2020-038275 [doi]
AB  - INTRODUCTION: Chronic subdural haematomas (CSDHs) are one of the most common
      neurosurgical conditions. The goal of surgery is to alleviate symptoms and
      minimise the risk of symptomatic recurrences. In the past, reoperation rates as
      high as 20%-30% were described for CSDH recurrences. However, following the
      introduction of subdural drainage, reoperation rates dropped to approximately
      10%. The standard surgical technique includes burr-hole craniostomy, followed by 
      intraoperative irrigation and placement of subdural drainage. Yet, the role of
      intraoperative irrigation has not been established. If there is no difference in 
      recurrence rates between intraoperative irrigation and no irrigation, CSDH
      surgery could be carried out faster and more safely by omitting the step of
      irrigation. The aim of this multicentre randomised controlled trial is to study
      whether no intraoperative irrigation and subdural drainage results in
      non-inferior outcome compared with intraoperative irrigation and subdural
      drainage following burr-hole craniostomy of CSDH. METHODS AND ANALYSIS: This is a
      prospective, randomised, controlled, parallel group, non-inferiority multicentre 
      trial comparing single burr-hole evacuation of CSDH with intraoperative
      irrigation and evacuation of CSDH without irrigation. In both groups, a passive
      subdural drain is used for 48 hours as a standard of treatment. The primary
      outcome is symptomatic CSDH recurrence requiring reoperation within 6 months. The
      predefined non-inferiority margin for the primary outcome is 7.5%. To achieve a
      2.5% level of significance and 80% power, we will randomise 270 patients per
      group. Secondary outcomes include modified Rankin Scale, rate of mortality,
      duration of operation, length of hospital stay, adverse events and change in
      volume of CSDH. ETHICS AND DISSEMINATION: The study was approved by the
      institutional review board of the Helsinki and Uusimaa Hospital District
      (HUS/3035/2019 section sign238) and duly registered at ClinicalTrials.gov. We
      will disseminate the findings of this study through peer-reviewed publications
      and conference presentations. TRIAL REGISTRATION NUMBER: NCT04203550.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tommiska, Pihla
AU  - Tommiska P
AD  - Department of Neurosurgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
FAU - Raj, Rahul
AU  - Raj R
AUID- ORCID: 0000-0003-4243-9591
AD  - Department of Neurosurgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland rahul.raj@helsinki.fi.
FAU - Schwartz, Christoph
AU  - Schwartz C
AD  - Department of Neurosurgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
AD  - Department of Neurosurgery, University Hospital Salzburg, Paracelsus Medical
      University, Salzburg, Austria.
FAU - Kivisaari, Riku
AU  - Kivisaari R
AD  - Department of Neurosurgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
FAU - Luostarinen, T
AU  - Luostarinen T
AD  - Division of Anaesthesiology, Department of Anaesthesiology, Intensive Care and
      Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki,
      Uusimaa, Finland.
FAU - Satopaa, Jarno
AU  - Satopaa J
AD  - Department of Neurosurgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
FAU - Taimela, Simo
AU  - Taimela S
AUID- ORCID: 0000-0001-6755-2983
AD  - Finland and Finnish Centre for Evidence-Based Orthopedics (FICEBO), University of
      Helsinki, Helsinki, Finland.
AD  - Department of Orthopaedics and Traumatology, University of Helsinki and Helsinki 
      University Hospital, Helsinki, Uusimaa, Finland.
FAU - Jarvinen, Teppo
AU  - Jarvinen T
AUID- ORCID: 0000-0003-3713-956X
AD  - Finland and Finnish Centre for Evidence-Based Orthopedics (FICEBO), University of
      Helsinki, Helsinki, Finland.
AD  - Department of Orthopaedics and Traumatology, University of Helsinki and Helsinki 
      University Hospital, Helsinki, Uusimaa, Finland.
FAU - Ranstam, Jonas
AU  - Ranstam J
AD  - Clinical Sciences, Lunds Universitet, Lund, Sweden.
FAU - Frantzen, Janek
AU  - Frantzen J
AD  - Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain
      Centre, Turku University Hospital and University of Turku, Turku, Finland.
FAU - Posti, Jussi
AU  - Posti J
AD  - Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain
      Centre, Turku University Hospital and University of Turku, Turku, Finland.
FAU - Luoto, Teemu M
AU  - Luoto TM
AD  - Department of Neurosurgery, Tampere University Hospital and Tampere University,
      Tampere, Finland.
FAU - Leinonen, Ville
AU  - Leinonen V
AD  - Department of Neurosurgery, Kuopio University Hospital and University of Eastern 
      Finland, Kuopio, Pohjois-Savo, Finland.
FAU - Tetri, Sami
AU  - Tetri S
AD  - Unit of Clinical Neuroscience, Neurosurgery, University of Oulu and Medical
      Research Center, Oulu, Finland.
FAU - Koivisto, Timo
AU  - Koivisto T
AD  - Department of Neurosurgery, Kuopio University Hospital and University of Eastern 
      Finland, Kuopio, Pohjois-Savo, Finland.
FAU - Lonnrot, Kimmo
AU  - Lonnrot K
AUID- ORCID: 0000-0003-4361-1007
AD  - Department of Neurosurgery, University of Helsinki and Helsinki University
      Hospital, Helsinki, Uusimaa, Finland.
LA  - eng
SI  - ClinicalTrials.gov/NCT04203550
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Drainage
MH  - Finland
MH  - Hematoma, Subdural, Chronic/*therapy
MH  - Humans
MH  - Intraoperative Care
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - *Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Therapeutic Irrigation
PMC - PMC7311024
OTO - NOTNLM
OT  - *chronic subdural haematoma
OT  - *irrigation fluid
OT  - *recurrence
OT  - *surgical evacuation
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038275 [pii]
AID - 10.1136/bmjopen-2020-038275 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e038275. doi: 10.1136/bmjopen-2020-038275.


PMID- 32565478
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Association between vision impairment and mortality: protocol for a systematic
      review and meta-analysis.
PG  - e037556
LID - 10.1136/bmjopen-2020-037556 [doi]
AB  - INTRODUCTION: Due to growth and ageing of the world's population, the number of
      individuals worldwide with vision impairment (VI) and blindness is projected to
      increase rapidly over the coming decades. VI and blindness are an important cause
      of years lived with disability. However, the association of VI and blindness with
      mortality, including the risk of bias in published studies and certainty of the
      evidence, has not been adequately studied in an up-to-date systematic review and 
      meta-analysis. METHODS AND ANALYSIS: The planned systematic review and
      meta-analysis will adhere to the Preferred Reporting Items for Systematic Reviews
      and Meta-Analyses guidelines. Databases, including MEDLINE Ovid, Embase Ovid and 
      Global Health, will be searched for relevant studies. Two reviewers will then
      screen studies and review full texts to identify studies for inclusion. Data
      extraction will be performed, and for included studies, the risk of bias and
      certainty of the evidence will be assessed using the Grades of Recommendation,
      Assessment, Development and Evaluation approach. The prognostic factor in this
      study is visual function, which must have been measured using a standard
      objective ophthalmic clinical or research instrument. We will use standard
      criteria from WHO to categorise VI and blindness. All-cause mortality may be
      assessed by any method one or more years after baseline assessment of vision.
      Results from included studies will be meta-analysed according to relevant
      sections of the Meta-analysis Of Observational Studies in Epidemiology checklist.
      ETHICS AND DISSEMINATION: This review will only include published data;
      therefore, ethics approval will not be sought. The findings of this review and
      meta-analysis will be published in an open-access, peer-reviewed journal and will
      be included in the ongoing Lancet Global Health Commission on Global Eye Health.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ehrlich, Joshua R
AU  - Ehrlich JR
AUID- ORCID: 0000-0002-0607-3564
AD  - Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan,
      USA joshre@med.umich.edu.
AD  - Institute for Healthcare Policy and Innovation, University of Michigan, Ann
      Arbor, Michigan, USA.
FAU - Ramke, Jacqueline
AU  - Ramke J
AD  - School of Optometry and Vision Science, The University of Auckland, Auckland, New
      Zealand.
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Macleod, David
AU  - Macleod D
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, 
      London, UK.
FAU - Swenor, Bonnielin K
AU  - Swenor BK
AD  - Ophthalmology, Johns Hopkins University, Baltimore, Maryland, USA.
AD  - Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Burn, Helen
AU  - Burn H
AD  - Ophthalmology Department, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, 
      UK.
FAU - Lee, Chan Ning
AU  - Lee CN
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.
FAU - Waldock, William J
AU  - Waldock WJ
AD  - School of Clinical Medicine, University of Cambridge, Cambridge, Cambridgeshire, 
      UK.
FAU - Zhang, Justine H
AU  - Zhang JH
AUID- ORCID: 0000-0001-8385-2003
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Manchester Royal Eye Hospital, Manchester, UK.
FAU - Gordon, Iris
AU  - Gordon I
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
FAU - Congdon, Nathan
AU  - Congdon N
AD  - Global Eye Health, Queen's University Belfast, Belfast, UK.
AD  - Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China.
FAU - Burton, Matthew
AU  - Burton M
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
FAU - Evans, Jennifer R
AU  - Evans JR
AD  - International Centre for Eye Health, London School of Hygiene and Tropical
      Medicine, London, UK.
LA  - eng
GR  - K01 AG052640/AG/NIA NIH HHS/United States
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
GR  - K23 EY027848/EY/NEI NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Blindness
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Mortality
MH  - Research Design
MH  - *Systematic Reviews as Topic
MH  - *Vision Disorders
PMC - PMC7311038
OTO - NOTNLM
OT  - *epidemiology
OT  - *ophthalmology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037556 [pii]
AID - 10.1136/bmjopen-2020-037556 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e037556. doi: 10.1136/bmjopen-2020-037556.


PMID- 32565477
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Is virtual reality effective to teach prevention of surgical site infections in
      the operating room? study protocol for a randomised controlled multicentre trial 
      entitled VIP Room study.
PG  - e037299
LID - 10.1136/bmjopen-2020-037299 [doi]
AB  - INTRODUCTION: Some surgical site infections (SSI) could be prevented by following
      adequate infection prevention and control (IPC) measures. Poor compliance with
      IPC measures often occurs due to knowledge gaps and insufficient education of
      healthcare professionals. The education and training of SSI preventive measures
      does not usually take place in the operating room (OR), due to safety, and
      organisational and logistic issues. The proposed study aims to compare virtual
      reality (VR) as a tool for medical students to learn the SSI prevention measures 
      and adequate behaviours (eg, limit movements...) in the OR, to conventional
      teaching. METHODS AND ANALYSIS: This protocol describes a randomised controlled
      multicentre trial comparing an educational intervention based on VR simulation to
      routine education. This multicentre study will be performed in three
      universities: Grenoble Alpes University (France), Imperial College London (UK)
      and University of Heidelberg (Germany). Third-year medical students of each
      university will be randomised in two groups. The students randomised in the
      intervention group will follow VR teaching. The students randomised in the
      control group will follow a conventional education programme. Primary outcome
      will be the difference between scores obtained at the IPC exam at the end of the 
      year between the two groups. The written exam will be the same in the three
      countries. Secondary outcomes will be satisfaction and students' progression for 
      the VR group. The data will be analysed with intention-to-treat and per protocol.
      ETHICS AND DISSEMINATION: This study has been approved by the Medical Education
      Ethics Committee of the London Imperial College (MEEC1920-172), by the Ethical
      Committee for the Research of Grenoble Alpes University (CER Grenoble
      Alpes-Avis-2019-099-24-2) and by the Ethics Committee of the Medical Faculty of
      Heidelberg University (S-765/2019). Results will be published in peer-reviewed
      medical journals, communicated to participants, general public and all relevant
      stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Masson, Claire
AU  - Masson C
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
AD  - Infection control unit, Grenoble Alpes University Hospital, Grenoble, France.
FAU - Birgand, Gabriel
AU  - Birgand G
AD  - Health Protection Research Unit in Healthcare Associated Infections and
      Antimicrobial Resistance, Imperial College, London, Greater London, United
      Kingdom.
FAU - Castro-Sanchez, Enrique
AU  - Castro-Sanchez E
AUID- ORCID: 0000-0002-3351-9496
AD  - Health Protection Research Unit in Healthcare Associated Infections and
      Antimicrobial Resistance, Imperial College, London, Greater London, United
      Kingdom.
FAU - Eichel, Vanessa Maria
AU  - Eichel VM
AD  - Section for Hospital Hygiene and Environmental Health, Centre of Infectious
      Diseases, Heidelberg University Hospital, Heidelberg, Baden-Wurttemberg, Germany.
FAU - Comte, Alexa
AU  - Comte A
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
FAU - Terrisse, Hugo
AU  - Terrisse H
AUID- ORCID: 0000-0001-8239-1903
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
FAU - Rubens-Duval, Brice
AU  - Rubens-Duval B
AD  - Department of Orthopaedic Surgery and Sport Traumatology, Grenoble Alpes
      University Hospital, Grenoble, France.
FAU - Gillois, Pierre
AU  - Gillois P
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
FAU - Albaladejo, Pierre
AU  - Albaladejo P
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
AD  - Department of Anaesthesiology and Critical Care Medicine and Simulation Centre,
      Grenoble Alpes University Hospital, Grenoble, France.
FAU - Picard, Julien
AU  - Picard J
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
AD  - Department of Anaesthesiology and Critical Care Medicine and Simulation Centre,
      Grenoble Alpes University Hospital, Grenoble, France.
FAU - Bosson, Jean Luc
AU  - Bosson JL
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France.
FAU - Mutters, Nico Tom
AU  - Mutters NT
AUID- ORCID: 0000-0002-0156-9595
AD  - Section for Hospital Hygiene and Environmental Health, Centre of Infectious
      Diseases, Heidelberg University Hospital, Heidelberg, Baden-Wurttemberg, Germany.
AD  - Institute for Hygiene and Public Health, University Hospital Bonn, Bonn, Germany.
FAU - Landelle, Caroline
AU  - Landelle C
AUID- ORCID: 0000-0002-3592-1948
AD  - TIMC-IMAG, CNRS, Grenoble INP, University Grenoble Alpes, Grenoble, France
      caroline.landelle@gmail.com.
AD  - Infection control unit, Grenoble Alpes University Hospital, Grenoble, France.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Education, Medical, Graduate
MH  - Educational Measurement
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Operating Rooms
MH  - *Randomized Controlled Trials as Topic
MH  - Students, Medical
MH  - Surgical Wound Infection/*prevention & control
MH  - *Virtual Reality
PMC - PMC7311029
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *infection control
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037299 [pii]
AID - 10.1136/bmjopen-2020-037299 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e037299. doi: 10.1136/bmjopen-2020-037299.


PMID- 32565475
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Wellness and resilience for college and beyond: protocol for a quasi-experimental
      pilot study investigating a dialectical behaviour therapy skill-infused college
      course.
PG  - e036833
LID - 10.1136/bmjopen-2020-036833 [doi]
AB  - INTRODUCTION: College students' mental health problems and suicidal behaviour are
      serious, persistent and prevalent public health issues. With the need for mental 
      health support greatly exceeding the availability of on-campus treatment, a
      recent trend on college campuses is to offer courses designed to teach students
      strategies for developing mental health or resilience. While these courses are
      exceptionally popular among students, a paucity of research investigates the
      health outcomes associated with participation. The purpose of this study is to
      investigate the acceptability, appropriateness, feasibility and preliminary
      effectiveness of a college course grounded in skills from dialectical behaviour
      therapy (DBT) titled, 'Wellness and Resilience for College and Beyond'. METHODS
      AND ANALYSIS: During the spring and fall 2020 semesters, the course will be
      offered on five campuses in Southwestern Pennsylvania and West Virginia. The
      course consists of 15 weekly 2.5-hour lessons, weekly homework assignments and a 
      final examination with content drawn from DBT, acceptance and commitment therapy 
      and positive psychology. Undergraduate students aged 18-24 will self-select into 
      the course and control subjects receiving 'university as usual' will be recruited
      to serve as a comparison group. Students who receive the course will complete
      measures of course acceptability, appropriateness and feasibility. All study
      participants will complete measures of adaptive coping skills use, emotion
      dysregulation and suicidality. ETHICS AND DISSEMINATION: All of the study
      procedures were approved as an exempt protocol for evaluation of educational
      curricula by the University of Pittsburgh Human Research Protections Office
      (HRPO); the study was approved as a research study by the institutional review
      board (IRB) of the fifth study site. The University of Pittsburgh HRPO served as 
      the IRB of record for all except one study site, which required standard IRB
      review. Data from this study will be disseminated via conference presentations,
      peer-reviewed publications and via our online stakeholder learning collaborative.
      TRIAL REGISTRATION NUMBER: NCT04338256.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chugani, Carla D
AU  - Chugani CD
AUID- ORCID: 0000-0003-3993-3679
AD  - School of Medicine, Department of Pediatrics, University of Pittsburgh,
      Pittsburgh, Pennsylvania, United States carla.chugani@chp.edu.
FAU - Fuhrman, Barbara
AU  - Fuhrman B
AD  - School of Medicine, Department of Pediatrics, University of Pittsburgh,
      Pittsburgh, Pennsylvania, United States.
FAU - Abebe, Kaleab Z
AU  - Abebe KZ
AD  - School of Medicine, Division of General Internal Medicine, University of
      Pittsburgh, Pittsburgh, PA, United States.
FAU - Talis, Janine
AU  - Talis J
AD  - School of Medicine, Department of Pediatrics, University of Pittsburgh,
      Pittsburgh, Pennsylvania, United States.
FAU - Miller, Elizabeth
AU  - Miller E
AD  - School of Medicine, Department of Pediatrics, University of Pittsburgh,
      Pittsburgh, Pennsylvania, United States.
FAU - Coulter, Robert W S
AU  - Coulter RWS
AD  - School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT04338256
GR  - K01 AA027564/AA/NIAAA NIH HHS/United States
GR  - TL1 TR001858/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Adaptation, Psychological
MH  - Adolescent
MH  - Case-Control Studies
MH  - *Curriculum
MH  - *Dialectical Behavior Therapy
MH  - Humans
MH  - *Observational Studies as Topic
MH  - Pennsylvania
MH  - Pilot Projects
MH  - Research Design
MH  - *Resilience, Psychological
MH  - *Students
MH  - Universities
MH  - West Virginia
MH  - Young Adult
PMC - PMC7311003
OTO - NOTNLM
OT  - *education & training (see medical education & training)
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-036833 [pii]
AID - 10.1136/bmjopen-2020-036833 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e036833. doi: 10.1136/bmjopen-2020-036833.


PMID- 32565472
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Conceptualisation and measurement of adaptation within the Roy adaptation model
      in chronic care: a scoping review protocol.
PG  - e036546
LID - 10.1136/bmjopen-2019-036546 [doi]
AB  - INTRODUCTION: The Roy adaptation model provides a basis for developing the
      science of nursing. Its theoretical assumptions have been tested in empirical
      studies. Although several works have historically reviewed the development of
      this model, a refinement of its key concepts is needed. The proposed scoping
      review aims to describe how the concept of adaptation was defined and measured in
      nursing studies related to chronic health conditions. METHODS AND ANALYSIS: This 
      scoping review will adopt the methodology proposed by Arksey and O'Malley.
      Several databases, including MEDLINE (OVID), CINAHL, EMBASE, PsycINFO, PubMed,
      Wan Fang, China National Knowledge Infrastructure and VIP net, will be selected
      and used to mine literature published in English and Chinese languages, up to
      December 2019. Key terms related to 'Roy adaptation model' will be identified and
      used for developing tailored search strategies for each database. Articles will
      be included in the analysis if they are primary research reports explaining the
      concept of adaptation within the field of chronic care. All screening and
      extraction of literature will be independently performed and checked by two
      authors, according to the guideline of Preferred Reporting Items for Systematic
      Review and Meta-Analysis-Extension for Scoping Reviews. The findings will be
      organised and summarised into narratives in line with the construction of
      conceptual-theoretical-empirical system of knowledge for further consultation and
      translation. ETHICS AND DISSEMINATION: This scoping review does not require
      ethical approval. The findings are expected to be published in peer-reviewed
      English or Chinese journals as well as conference proceedings in the area of
      chronic care.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Xiyi
AU  - Wang X
AUID- ORCID: 0000-0002-6470-8556
AD  - Department of Nursing, Zhejiang University School of Medicine Sir Run Run Shaw
      Hospital, Hangzhou, Zhejiang, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Nursing, Zhejiang University School of Medicine Sir Run Run Shaw
      Hospital, Hangzhou, Zhejiang, China.
FAU - Shao, Jing
AU  - Shao J
AD  - Department of Nursing, Zhejiang University School of Medicine, Hangzhou,
      Zhejiang, China.
FAU - Ye, Zhihong
AU  - Ye Z
AUID- ORCID: 0000-0001-6947-3330
AD  - Department of Nursing, Zhejiang University School of Medicine Sir Run Run Shaw
      Hospital, Hangzhou, Zhejiang, China yezh@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adaptation, Psychological
MH  - Chronic Disease/*nursing
MH  - Humans
MH  - *Models, Nursing
MH  - *Models, Psychological
MH  - Research Design
MH  - *Review Literature as Topic
PMC - PMC7311031
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036546 [pii]
AID - 10.1136/bmjopen-2019-036546 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e036546. doi: 10.1136/bmjopen-2019-036546.


PMID- 32565470
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Pathways to a cancer-free future: a protocol for modelled evaluations to minimise
      the future burden of colorectal cancer in Australia.
PG  - e036475
LID - 10.1136/bmjopen-2019-036475 [doi]
AB  - INTRODUCTION: With almost 50% of cases preventable and the Australian National
      Bowel Cancer Screening Program in place, colorectal cancer (CRC) is a prime
      candidate for investment to reduce the cancer burden. The challenge is
      determining effective ways to reduce morbidity and mortality and their
      implementation through policy and practice. Pathways-Bowel is a multistage
      programme that aims to identify best-value investment in CRC control by
      integrating expert and end-user engagement; relevant evidence; modelled
      interventions to guide future investment; and policy-driven implementation of
      interventions using evidence-based methods. METHODS AND ANALYSIS: Pathways-Bowel 
      is an iterative work programme incorporating a calibrated and validated CRC
      natural history model for Australia (Policy1-Bowel) and assessing the health and 
      cost outcomes and resource use of targeted interventions. Experts help identify
      and prioritise modelled evaluations of changing trends and interventions and
      critically assess results to advise on their real-world applicability. Where
      appropriate the results are used to support public policy change and make the
      case for optimal investment in specific CRC control interventions. Fourteen
      high-priority evaluations have been modelled or planned, including evaluations of
      CRC outcomes from the changing prevalence of modifiable exposures, including
      smoking and body fatness; potential benefits of daily aspirin intake as
      chemoprevention; increasing CRC incidence in people aged <50 years; increasing
      screening participation in the general and Aboriginal and Torres Strait Islander 
      populations; alternative screening technologies and modalities; and changes to
      follow-up surveillance protocols. Pathways-Bowel is a unique, comprehensive
      approach to evaluating CRC control; no prior body of work has assessed the
      relative benefits of a variety of interventions across CRC development and
      progression to produce a list of best-value investments. ETHICS AND
      DISSEMINATION: Ethics approval was not required as human participants were not
      involved. Findings are reported in a series of papers in peer-reviewed journals
      and presented at fora to engage the community and policymakers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Feletto, Eleonora
AU  - Feletto E
AUID- ORCID: 0000-0001-6192-4694
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia eleonoraf@nswcc.org.au.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Lew, Jie-Bin
AU  - Lew JB
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Worthington, Joachim
AU  - Worthington J
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - He, Emily
AU  - He E
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Caruana, Michael
AU  - Caruana M
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Butler, Katherine
AU  - Butler K
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
FAU - Hui, Harriet
AU  - Hui H
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
FAU - Taylor, Natalie
AU  - Taylor N
AUID- ORCID: 0000-0002-0280-0883
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Banks, Emily
AU  - Banks E
AD  - ANU College of Medicine, Biology and Environment, Australian National University,
      Canberra, Australian Capital Territory, Australia.
FAU - Barclay, Karen
AU  - Barclay K
AD  - Northern Clinical School, Melbourne Medical School, The University of Melbourne, 
      Melbourne, Victoria, Australia.
FAU - Broun, Kate
AU  - Broun K
AD  - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne,
      Victoria, Australia.
FAU - Butt, Alison
AU  - Butt A
AD  - Research Strategy Office, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Carter, Rob
AU  - Carter R
AD  - Deakin Institute for Health Research, Deakin University, Melbourne, Victoria,
      Australia.
FAU - Cuff, Jeff
AU  - Cuff J
AD  - Faculty of Science Biotech and Biomolecular Science, University of New South
      Wales, Sydney, New South Wales, Australia.
AD  - Research Advocate, Sydney, New South Wales, Australia.
FAU - Dessaix, Anita
AU  - Dessaix A
AD  - Cancer Prevention and Advocacy, Cancer Council NSW, Woolloomooloo, New South
      Wales, Australia.
FAU - Ee, Hooi
AU  - Ee H
AD  - Department of Gastroenterology, Sir Charles Gairdner Hospital, Nedlands, Western 
      Australia, Australia.
FAU - Emery, Jon
AU  - Emery J
AUID- ORCID: 0000-0002-5274-6336
AD  - General Practice and Primary Care Academic Centre, University of Melbourne,
      Carlton, Victoria, Australia.
FAU - Frayling, Ian M
AU  - Frayling IM
AD  - Inherited Tumour Syndromes Research Group, Division of Cancer & Genetics, Cardiff
      University, Cardiff, UK.
FAU - Grogan, Paul
AU  - Grogan P
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Holden, Carol
AU  - Holden C
AUID- ORCID: 0000-0002-4011-6628
AD  - No Australians Dying of Bowel Cancer Initiative, South Australian Health and
      Medical Research Institute, Adelaide, South Australia, Australia.
FAU - Horn, Christopher
AU  - Horn C
AD  - Cancer Institute New South Wales, Eveleigh, New South Wales, Australia.
FAU - Jenkins, Mark A
AU  - Jenkins MA
AD  - Centre for Epidemiology and Biostatistics, The University of Melbourne,
      Parkville, Victoria, Australia.
FAU - Kench, James G
AU  - Kench JG
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
AD  - Department of Tissue Pathology & Diagnostic Oncology, Royal Prince Alfred
      Hospital, Camperdown, New South Wales, Australia.
FAU - Laaksonen, Maarit A
AU  - Laaksonen MA
AD  - Centre for Big Data Research in Health, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Leggett, Barbara
AU  - Leggett B
AD  - Conjoint Gastroenterology, QIMR Berghofer Medical Research Institute, Herston,
      Queensland, Australia.
AD  - School of Medicine, University of Queensland, Herston, Queensland, Australia.
AD  - Gastroenterology & Hepatology Department, Royal Brisbane and Women's Hospital,
      Herston, Queensland, Australia.
FAU - Mitchell, Gillian
AU  - Mitchell G
AD  - Parkville Familial Cancer Centre, Peter MacCallum Cancer Institute, Melbourne,
      Victoria, Australia.
AD  - The Sir Peter MacCallum Department of Oncology, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Morris, Susan
AU  - Morris S
AD  - Research Advocate, Sydney, New South Wales, Australia.
AD  - Lynch Syndrome Australia, Brisbane, Queensland, Australia.
FAU - Parkinson, Bonny
AU  - Parkinson B
AD  - Macquarie University Centre for the Health Economy, Macquarie University, Sydney,
      New South Wales, Australia.
FAU - St John, D James
AU  - St John DJ
AD  - Cancer Council Victoria, Melbourne, Victoria, Australia.
AD  - Department of Medicine, The Royal Melbourne Hospital, The University of
      Melbourne, Melbourne, Victoria, Australia.
FAU - Taoube, Linda
AU  - Taoube L
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Tucker, Katherine
AU  - Tucker K
AD  - Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, New South Wales,
      Australia.
AD  - Prince of Wales Clinical School, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - Wakefield, Melanie A
AU  - Wakefield MA
AD  - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne,
      Victoria, Australia.
FAU - Ward, Robyn L
AU  - Ward RL
AD  - Faculty of Medicine and Health, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Win, Aung Ko
AU  - Win AK
AD  - Centre for Epidemiology and Biostatistics, The University of Melbourne,
      Parkville, Victoria, Australia.
AD  - Precision Prevention and Early Detection, University of Melbourne Centre for
      Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, Victoria,
      Australia.
FAU - Worthley, Daniel L
AU  - Worthley DL
AD  - No Australians Dying of Bowel Cancer Initiative, South Australian Health and
      Medical Research Institute, Adelaide, South Australia, Australia.
FAU - Armstrong, Bruce K
AU  - Armstrong BK
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Macrae, Finlay A
AU  - Macrae FA
AD  - Department of Medicine, The Royal Melbourne Hospital, The University of
      Melbourne, Melbourne, Victoria, Australia.
AD  - Genetic Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia.
FAU - Canfell, Karen
AU  - Canfell K
AD  - Cancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales,
      Australia.
AD  - School of Public Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Prince of Wales Clinical School, University of New South Wales, Sydney, New South
      Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Algorithms
MH  - Australia
MH  - Colorectal Neoplasms/*prevention & control
MH  - Disease Eradication
MH  - Early Detection of Cancer
MH  - Health Behavior
MH  - Health Promotion
MH  - Humans
MH  - *Models, Theoretical
MH  - Primary Prevention
PMC - PMC7307542
OTO - NOTNLM
OT  - *colorectal cancer
OT  - *early detection
OT  - *prevention
OT  - *screening
COIS- Competing interests: KC, EF, JW, JBL, EH, MC, NT, KBu and HH receive salary
      support from CCNSW. KC is co-PI of unrelated investigator-initiated trial of
      cervical screening in Australia ('Compass') conducted by the Victorian Cytology
      Service, which has received funding contribution from Roche Molecular Systems and
      Ventana, USA.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036475 [pii]
AID - 10.1136/bmjopen-2019-036475 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e036475. doi: 10.1136/bmjopen-2019-036475.


PMID- 32565469
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Effect of early cryoprecipitate transfusion versus standard care in women who
      develop severe postpartum haemorrhage (ACROBAT) in the UK: a protocol for a pilot
      cluster randomised trial.
PG  - e036416
LID - 10.1136/bmjopen-2019-036416 [doi]
AB  - INTRODUCTION: The incidence of severe postpartum haemorrhage (PPH) that requires 
      blood transfusion is on the increase. Fibrinogen levels have been shown to drop
      early and significantly during PPH, which is associated with worse outcomes.
      Early fibrinogen replacement could potentially improve outcomes. No studies have 
      investigated the clinical impact of early cryoprecipitate transfusion in PPH.
      Prior to performing a full-scale trial, a pilot study is needed to determine
      feasibility of the intervention and recruitment. METHODS: ACROBAT is a
      cluster-randomised pilot study with a qualitative evaluation. Four large London
      maternity units are randomised to either the intervention or control group. The
      intervention group will adapt their major obstetric haemorrhage procedures to
      administer cryoprecipitate early for primary PPH. The control group will retain
      their standard of care.We include women at >24 weeks gestation who are actively
      bleeding within 24 hours of delivery and for whom transfusion of red blood cells 
      (RBCs) has been started. We exclude women who decline blood transfusions in
      advance or have inherited Factor XIII or fibrinogen deficiency. Due to the
      emergency nature of the intervention, informed consent for administering the
      intervention is waived.The primary objective is to assess the feasibility of
      administering cryoprecipitate within 90 min of RBC request, as compared with
      standard treatment where cryoprecipitate is given later or not at all. Secondary 
      objectives include the feasibility of recruitment and data collection, reasons
      for and barriers to consent, preliminary maternal clinical outcomes,
      identification of the optimal infrastructure pathways for study delivery, and
      acceptability of the intervention and outcomes. ETHICS AND DISSEMINATION: The
      trial has approvals from the London-Brighton & Sussex Research Ethics Committee
      (ref. 18/LO/2062), the Confidentiality Advisory Group (ref. 18/CAG/0199) and
      Health Research Authority (IRAS number 237959). Data analysis and publication of 
      manuscripts will start in Q3 2020. TRIAL REGISTRATION NUMBER: ISRCTN12146519.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Green, Laura
AU  - Green L
AUID- ORCID: 0000-0003-4063-9768
AD  - Blizard Institute, Queen Mary University of London, London, UK
      Laura.Green27@nhs.net.
AD  - Components, NHS Blood and Transplant, London, UK.
AD  - Department of Haematology, Barts Health NHS Trust, London, UK.
FAU - Daru, Jahnavi
AU  - Daru J
AUID- ORCID: 0000-0001-5816-2609
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Dodds, Julie
AU  - Dodds J
AUID- ORCID: 0000-0002-6041-1456
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Gonzalez Carreras, Francisco Jose
AU  - Gonzalez Carreras FJ
AUID- ORCID: 0000-0002-3043-7495
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Lanz, Doris
AU  - Lanz D
AUID- ORCID: 0000-0001-9879-3069
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Zamora, Javier
AU  - Zamora J
AUID- ORCID: 0000-0003-4901-588X
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), CIBER Epidemiology 
      and Public Health, Madrid, Spain.
FAU - Pardo Llorente, Maria Del Carmen
AU  - Pardo Llorente MDC
AUID- ORCID: 0000-0002-4623-6321
AD  - Department of Statistics and Operational Research, Complutense University of
      Madrid, Madrid, Spain.
FAU - Perez Perez, Teresa
AU  - Perez Perez T
AUID- ORCID: 0000-0003-0439-8952
AD  - Department of Statistics and Data Science, Complutense University of Madrid,
      Madrid, Spain.
FAU - Sweeney, Lorna
AU  - Sweeney L
AUID- ORCID: 0000-0002-1630-467X
AD  - Institute for Health and Human Development, University of East London, London,
      UK.
FAU - Thangaratinam, Shakila
AU  - Thangaratinam S
AUID- ORCID: 0000-0002-4254-460X
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and
      Systems Research, University of Birmingham, Birmingham, UK.
FAU - Thomas, Amy
AU  - Thomas A
AD  - Department of Women's and Neonatal Health, Royal London Hospital, Barts Health
      NHS Trust, London, UK.
FAU - Khan, Khalid Saeed
AU  - Khan KS
AUID- ORCID: 0000-0001-5084-7312
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (cryoprecipitate coagulum)
RN  - 9001-27-8 (Factor VIII)
RN  - 9001-32-5 (Fibrinogen)
SB  - IM
MH  - *Erythrocyte Transfusion
MH  - Factor VIII/*therapeutic use
MH  - Female
MH  - Fibrinogen/*therapeutic use
MH  - Humans
MH  - Pilot Projects
MH  - Postpartum Hemorrhage/*therapy
MH  - *Randomized Controlled Trials as Topic
MH  - Research Design
MH  - United Kingdom
PMC - PMC7311066
OTO - NOTNLM
OT  - *blood bank & transfusion medicine
OT  - *haematology
OT  - *maternal medicine
OT  - *obstetrics
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036416 [pii]
AID - 10.1136/bmjopen-2019-036416 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e036416. doi: 10.1136/bmjopen-2019-036416.


PMID- 32565468
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Quality of reporting for randomised clinical trials published in Latin American
      and Spanish journals: A protocol for a systematic survey of three clinical
      specialities.
PG  - e036148
LID - 10.1136/bmjopen-2019-036148 [doi]
AB  - INTRODUCTION: Quality of reporting refers to how published articles communicate
      how the research was done and what was found. Gaps and imprecisions of reporting 
      hamper the assessment of the methodological quality and internal and external
      validity. The CONsolidated Standards of Reporting Trials (CONSORT) are a set of
      evidence-based recommendations of the minimum elements to be included in the
      reporting of randomised controlled trials (RCTs) to ensure a complete and
      transparent account of what was done, how it was done and what was found. Few
      studies have been conducted on the impact of CONSORT on RCTs published in Latin
      American and Spanish journals. We aim to assess the reporting quality of RCTs of 
      three clinical specialities published in Spanish and Latin American journals, as 
      well as to assess changes over time and associations of quality with journal and 
      country indicators. METHODS AND ANALYSIS: We will conduct a systematic survey of 
      all RCTs published in Spanish-language journals in three clinical fields
      (dentistry, neurology and geriatrics) from 1990 to 2018. We will include RCTs
      from previous work that has identified all RCTs on these medical fields published
      in Spain and Latin America. We will update this work via handsearching of
      relevant journals. Assessment of quality of reporting will be conducted
      independently and in duplicate using the CONSORT 2010 Statement. We will also
      extract journal and country indicators. We will conduct descriptive statistics
      and secondary analyses considering the year, country, and journal of publication,
      among others. ETHICS AND DISSEMINATION: The Universidad de Santiago de Chile's
      ethics committee approved the protocol. We will disseminate the results of this
      work in peer-reviewed scientific journals and conference proceedings. We expect
      to raise awareness among researchers, journal editors and funders on the
      importance of training in reporting guidelines and using them from the inception 
      of RCT protocols.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bachelet, Vivienne C
AU  - Bachelet VC
AUID- ORCID: 0000-0002-5715-9755
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile vivienne.bachelet@usach.cl.
FAU - Carrasco, Victor A
AU  - Carrasco VA
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Bravo-Cordova, Fabiana
AU  - Bravo-Cordova F
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Diaz, Ruben A
AU  - Diaz RA
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Lizana, Francisca J
AU  - Lizana FJ
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Meza-Ducaud, Nicolas
AU  - Meza-Ducaud N
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Pardo-Hernandez, Hector
AU  - Pardo-Hernandez H
AUID- ORCID: 0000-0003-3714-0309
AD  - Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB Sant
      Pau) - CIBER Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
FAU - Uribe, Francisco A
AU  - Uribe FA
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Vergara, Alonso F
AU  - Vergara AF
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
FAU - Villanueva, Julio
AU  - Villanueva J
AD  - Facultad de Odontologia, Universidad de Chile, Santiago de Chile, Chile.
FAU - Navarrete, Maria S
AU  - Navarrete MS
AD  - Escuela de Medicina, Facultad de Ciencias Medicas, Universidad de Santiago de
      Chile (USACH), Santiago, Chile.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Dentistry
MH  - Geriatrics
MH  - Humans
MH  - Latin America
MH  - Neurology
MH  - *Periodicals as Topic
MH  - Randomized Controlled Trials as Topic/*standards
MH  - Research Design
MH  - Spain
MH  - *Systematic Reviews as Topic
PMC - PMC7311006
OTO - NOTNLM
OT  - *quality of reporting
OT  - *randomised controlled trials
OT  - *reporting guidelines
OT  - *spanish
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036148 [pii]
AID - 10.1136/bmjopen-2019-036148 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e036148. doi: 10.1136/bmjopen-2019-036148.


PMID- 32565467
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210316
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Getting evidence into clinical practice: protocol for evaluation of the
      implementation of a home-based cardiac rehabilitation programme for patients with
      heart failure.
PG  - e036137
LID - 10.1136/bmjopen-2019-036137 [doi]
AB  - INTRODUCTION: Cardiac rehabilitation (CR) improves health-related quality of life
      and reduces hospital admissions. However, patients with heart failure (HF) often 
      fail to attend centre-based CR programmes. Novel ways of delivering healthcare,
      such as home-based CR programmes, may improve uptake of CR. Rehabilitation
      EnAblement in CHronic Heart Failure (REACH-HF) is a new, effective and
      cost-effective home-based CR programme for people with HF. The aim of this
      prospective mixed-method implementation evaluation study is to assess the
      implementation of the REACH-HF CR programme in the UK National Health Service
      (NHS). The specific objectives are to (1) explore NHS staff perceptions of the
      barriers and facilitators to the implementation of REACH-HF, (2) assess the
      quality of delivery of the programme in real-life clinical settings, (3) consider
      the nature of any adaptation(s) made and how they might impact on intervention
      effectiveness and (4) compare real-world patient outcomes to those seen in a
      prior clinical trial. METHODS AND ANALYSIS: REACH-HF will be rolled out in four
      NHS CR centres across the UK. Three healthcare professionals from each site will 
      be trained to deliver the 12-week programme. In-depth qualitative interviews and 
      focus groups will be conducted with approximately 24 NHS professionals involved
      in delivering or commissioning the programme. Consultations for 48 patients (12
      per site) will be audio recorded and scored using an intervention fidelity
      checklist. Outcomes routinely recorded in the National Audit of Cardiac
      Rehabilitation will be analysed and compared with outcomes from a recent
      randomised controlled trial: the Minnesota Living with HF Questionnaire and
      exercise capacity (Incremental Shuttle Walk Test). Qualitative research findings 
      will be mapped onto the Normalisation Process Theory framework and presented in
      the form of a narrative synthesis. Results of the study will inform national
      roll-out of REACH-HF. ETHICS AND DISSEMINATION: The study (IRAS 261723) has
      received ethics approval from the South Central (Hampshire B) Research Ethics
      Committee (19/SC/0304). Written informed consent will be obtained from all health
      professionals and patients participating in the study. The research team will
      ensure that the study is conducted in accordance with the Declaration of
      Helsinki, the Data Protection Act 2018, General Data Protection Regulations and
      in accordance with the Research Governance Framework for Health and Social Care
      (2005). Findings will be published in scientific peer-reviewed journals and
      presented at local, national and international meetings to publicise and explain 
      the research methods and findings to key audiences to facilitate the further
      uptake of the REACH-HF intervention. TRIAL REGISTRATION: ISRCTN86234930.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Daw, Paulina
AU  - Daw P
AUID- ORCID: 0000-0002-0942-3953
AD  - School of Sport, Exercise & Rehabilitation Sciences, University of Birmingham,
      Birmingham, UK pxd891@student.bham.ac.uk.
FAU - van Beurden, Samantha B
AU  - van Beurden SB
AUID- ORCID: 0000-0001-7848-2159
AD  - Psychology, University of Exeter, Exeter, UK.
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
FAU - Greaves, Colin
AU  - Greaves C
AUID- ORCID: 0000-0003-4425-2691
AD  - School of Sport, Exercise & Rehabilitation Sciences, University of Birmingham,
      Birmingham, UK.
FAU - Veldhuijzen van Zanten, Jet J C S
AU  - Veldhuijzen van Zanten JJCS
AUID- ORCID: 0000-0001-8422-9512
AD  - School of Sport, Exercise & Rehabilitation Sciences, University of Birmingham,
      Birmingham, UK.
FAU - Harrison, Alexander
AU  - Harrison A
AUID- ORCID: 0000-0002-2257-6508
AD  - Health Sciences, University of York, York, UK.
FAU - Dalal, Hasnain
AU  - Dalal H
AUID- ORCID: 0000-0002-7316-7544
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
AD  - Royal Cornwall Hospitals NHS Trust, Cornwall, UK.
FAU - McDonagh, Sinead T J
AU  - McDonagh STJ
AUID- ORCID: 0000-0002-0283-3095
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
FAU - Doherty, Patrick J
AU  - Doherty PJ
AUID- ORCID: 0000-0002-1887-0237
AD  - Health Sciences, University of York, York, UK.
FAU - Taylor, Rod S
AU  - Taylor RS
AUID- ORCID: 0000-0002-3043-6011
AD  - College of Medicine and Health, University of Exeter, Exeter, UK.
AD  - MRC/CSO Social and Public Health Sciences Unit & Robertson Centre for
      Biostatistics, Institute of Health and Well Being, University of Glasgow,
      Glasgow, UK.
LA  - eng
SI  - ISRCTN/ISRCTN86234930
GR  - RP-PG-1210-12004/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2021 Mar 12;11(3):e036137corr1. PMID: 33712525
MH  - *Cardiac Rehabilitation
MH  - *Evaluation Studies as Topic
MH  - Exercise Tolerance
MH  - Heart Failure/*rehabilitation
MH  - *Home Care Services
MH  - Humans
MH  - Quality of Life
MH  - Research Design
MH  - United Kingdom
PMC - PMC7307528
OTO - NOTNLM
OT  - *change management
OT  - *heart failure
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036137 [pii]
AID - 10.1136/bmjopen-2019-036137 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e036137. doi: 10.1136/bmjopen-2019-036137.


PMID- 32565465
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Study protocol for the safety and efficacy of probiotic therapy on days alive and
      out of hospital in adult ICU patients: the multicentre, randomised,
      placebo-controlled Restoration Of gut microflora in Critical Illness Trial
      (ROCIT).
PG  - e035930
LID - 10.1136/bmjopen-2019-035930 [doi]
AB  - INTRODUCTION: The effect of early and sustained administration of daily probiotic
      therapy on patients admitted to the intensive care unit (ICU) remains uncertain. 
      METHODS AND ANALYSIS: The Restoration Of gut microflora in Critical Illness Trial
      (ROCIT) study is a multicentre, randomised, placebo-controlled, parallel-group,
      two-sided superiority trial that will enrol 220 patients in five ICUs. Adult
      patients who are within 48 hours of admission to an ICU and are expected to
      require intensive care beyond the next calendar day will be randomised in a 1:1
      ratio to receive early and sustained Lactobacillus plantarum 299v probiotic
      therapy in addition to usual care or placebo in addition to usual care. The
      primary endpoint is days alive and out of hospital to day 60. ETHICS AND
      DISSEMINATION: ROCIT has been approved by the South Metropolitan Health Service
      Human Research Ethics Committee (ref: RGS00000004) and the St John of God Health 
      Care Human Research Ethics Committee (ref: 1183). The trial results will be
      submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: 
      Australian and New Zealand Clinical Trials Registry (ANZCTR12617000783325);
      Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Litton, Edward
AU  - Litton E
AUID- ORCID: 0000-0002-5125-6829
AD  - Intensive Care Unit, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia ed.litton@health.wa.gov.au.
AD  - Intensive Care Unit, St John of God Hospital, Subiaco, Western Australia,
      Australia.
FAU - Anstey, Matthew
AU  - Anstey M
AD  - Intensive Care Unit, Sir Charles Gairdner Hospital, Nedlands, Western Australia, 
      Australia.
FAU - Broadhurst, David
AU  - Broadhurst D
AD  - School of Science, Edith Cowan University, Joondalup, Western Australia,
      Australia.
FAU - Chapman, Andy R
AU  - Chapman AR
AD  - Intensive Care Unit, Royal Perth Hospital, Perth, Western Australia, Australia.
FAU - Currie, Andrew
AU  - Currie A
AD  - Murdoch University, Murdoch, Western Australia, Australia.
FAU - Ferrier, Janet
AU  - Ferrier J
AD  - Intensive Care Unit, St John of God Hospital, Subiaco, Western Australia,
      Australia.
FAU - Gummer, Joel
AU  - Gummer J
AD  - Murdoch University, Murdoch, Western Australia, Australia.
FAU - Higgins, Alisa
AU  - Higgins A
AD  - Australian and New Zealand Intensive Care Research Centre, Monash University,
      Clayton, Victoria, Australia.
FAU - Lim, Jolene
AU  - Lim J
AD  - Intensive Care Unit, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia.
FAU - Manning, Laurens
AU  - Manning L
AD  - University of Western Australia, Perth, Western Australia, Australia.
FAU - Myers, Erina
AU  - Myers E
AD  - Intensive Care Unit, Sir Charles Gairdner Hospital, Nedlands, Western Australia, 
      Australia.
FAU - Orr, Katrina
AU  - Orr K
AD  - Pharmacy, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
FAU - Palermo, Anne-Marie
AU  - Palermo AM
AD  - Intensive Care Unit, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia.
FAU - Paparini, Andrew
AU  - Paparini A
AD  - Murdoch University, Murdoch, Western Australia, Australia.
FAU - Pellicano, Susan
AU  - Pellicano S
AD  - Intensive Care Unit, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia.
FAU - Raby, Edward
AU  - Raby E
AD  - Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western
      Australia, Australia.
FAU - Rammohan, Anu
AU  - Rammohan A
AD  - Department of Economics, University of Western Australia, Crawley, Western
      Australia, Australia.
FAU - Regli, Adrian
AU  - Regli A
AD  - Intensive Care Unit, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia.
AD  - Intensive Care Unit, St John of God Hospital, Murdoch, Western Australia,
      Australia.
FAU - Richter, Bernhard
AU  - Richter B
AD  - Intensive Care Unit, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia.
AD  - Division of Cardiology, Medical University of Vienna, Wien, Wien, Austria.
FAU - Salman, Sam
AU  - Salman S
AD  - University of Western Australia, Perth, Western Australia, Australia.
FAU - Strunk, Tobias
AU  - Strunk T
AD  - Neonatal Directorate, King Edward Memorial Hospital for Women Perth, Subiaco,
      Western Australia, Australia.
FAU - Waterson, Sharon
AU  - Waterson S
AD  - Intensive Care Unit, Royal Perth Hospital, Perth, Western Australia, Australia.
FAU - Wibrow, Brad
AU  - Wibrow B
AD  - Intensive Care Unit, Sir Charles Gairdner Hospital, Nedlands, Western Australia, 
      Australia.
FAU - Wood, Fiona M
AU  - Wood FM
AD  - University of Western Australia, Perth, Western Australia, Australia.
AD  - Burns Department, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Critical Care/*methods
MH  - *Critical Illness
MH  - *Equivalence Trials as Topic
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Intensive Care Units
MH  - Multicenter Studies as Topic
MH  - New Zealand
MH  - Probiotics/*therapeutic use
MH  - Research Design
PMC - PMC7311035
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *diagnostic microbiology
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035930 [pii]
AID - 10.1136/bmjopen-2019-035930 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e035930. doi: 10.1136/bmjopen-2019-035930.


PMID- 32565464
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Standardised patient encounters to improve quality of counselling for
      pre-exposure prophylaxis (PrEP) in adolescent girls and young women (AGYW) in
      Kenya: study protocol of a cluster randomised controlled trial.
PG  - e035689
LID - 10.1136/bmjopen-2019-035689 [doi]
AB  - INTRODUCTION: Adolescent girls and young women (AGYW) in sub-Saharan Africa are
      at high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) demonstration
      projects observe that AGYW uptake and adherence to PrEP during risk periods is
      suboptimal. Judgemental interactions with healthcare workers (HCW) and inadequate
      counselling can be barriers to PrEP use among AGYW. Improving HCW competency and 
      communication to support PrEP delivery to AGYW requires new strategies. METHODS
      AND ANALYSIS: PrEP Implementation for Young Women and Adolescents
      Program-standardised patient (PrIYA-SP) is a cluster randomised trial of a
      standardised patient actor (SP) training intervention designed to improve HCW
      adherence to PrEP guidelines and communication skills. We purposively selected 24
      clinics offering PrEP services under fully programmatic conditions in Kisumu
      County, Kenya. At baseline, unannounced SP 'mystery shoppers' present to clinics 
      portraying AGYW in common PrEP scenarios for a cross-sectional assessment of PrEP
      delivery. Twelve facilities will be randomised to receive a 2-day training
      intervention, consisting of lectures, role-playing with SPs and group debriefing.
      Unannounced SPs will repeat the assessment in all 24 sites following the
      intervention. The primary outcome is quality of PrEP counselling, including
      adherence to national guidelines and communication skills, scored on a checklist 
      by SPs blinded to intervention assignment. An intention-to-treat (ITT) analysis
      will evaluate whether the intervention resulted in higher scores within
      intervention compared with control facilities, adjusted for baseline SP scores
      and accounting for clustering by facility. We hypothesise that the intervention
      will improve quality of PrEP counselling compared with standard of care. Results 
      from this study will inform guidelines for PrEP delivery to AGYW in low-resource 
      settings and offer a potentially scalable strategy to improve service delivery
      for this high-risk group. ETHICS AND DISSEMINATION: The protocol was approved by 
      institutional review boards at Kenyatta National Hospital and University of
      Washington. An external advisory committee monitors social harms. Results will be
      disseminated through peer-reviewed journals and presentations. TRIAL REGISTRATION
      NUMBER: NCT03875950.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Larsen, Anna
AU  - Larsen A
AUID- ORCID: 0000-0002-0096-9386
AD  - Department of Global Health, University of Washington, Seattle, Washington, USA
      annalar@uw.edu.
AD  - Department of Epidemiology, University of Washington, Seattle, Washington, USA.
FAU - Wilson, Kate S
AU  - Wilson KS
AD  - Department of Global Health, University of Washington, Seattle, Washington, USA.
FAU - Kinuthia, John
AU  - Kinuthia J
AD  - Department of Global Health, University of Washington, Seattle, Washington, USA.
AD  - Research and Programs, Kenyatta National Hospital/University of Nairobi, Nairobi,
      Kenya.
FAU - John-Stewart, G
AU  - John-Stewart G
AD  - Department of Epidemiology, University of Washington, Seattle, Washington, USA.
AD  - Department of Medicine, University of Washington, Seattle, Washington, USA.
AD  - Department of Pediatrics, University of Washington, Seattle, WA, United States.
FAU - Richardson, B A
AU  - Richardson BA
AD  - Department of Biostatistics, University of Washington, Seattle, WA, United
      States.
FAU - Pintye, Jillian
AU  - Pintye J
AD  - Department of Global Health, University of Washington, Seattle, Washington, USA.
FAU - Abuna, Felix
AU  - Abuna F
AD  - Research and Programs, Kenyatta National Hospital/University of Nairobi, Nairobi,
      Kenya.
FAU - Lagat, Harison
AU  - Lagat H
AD  - Research and Programs, Kenyatta National Hospital/University of Nairobi, Nairobi,
      Kenya.
FAU - Owens, Tamara
AU  - Owens T
AD  - Health Sciences Simulation & Clinical Skills Center, Howard University, Seattle, 
      Washington, DC, USA.
FAU - Kohler, Pamela
AU  - Kohler P
AD  - Department of Child, Family, and Population Health Nursing, University of
      Washington, Seattle, Washington, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03875950
GR  - F31 HD101149/HD/NICHD NIH HHS/United States
GR  - R01 HD094630/HD/NICHD NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Communication
MH  - *Counseling
MH  - Female
MH  - Guideline Adherence
MH  - HIV Infections/*prevention & control
MH  - Humans
MH  - Kenya
MH  - Patient Simulation
MH  - *Pre-Exposure Prophylaxis
MH  - Quality Assurance, Health Care/*methods
MH  - *Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Young Adult
PMC - PMC7311012
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *public health
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035689 [pii]
AID - 10.1136/bmjopen-2019-035689 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e035689. doi: 10.1136/bmjopen-2019-035689.


PMID- 32565461
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Implementation of e-mental health interventions for informal caregivers of adults
      with chronic diseases: a protocol for a mixed-methods systematic review with a
      qualitative comparative analysis.
PG  - e035406
LID - 10.1136/bmjopen-2019-035406 [doi]
AB  - INTRODUCTION: Informal caregivers provide the majority of care to individuals
      with chronic health conditions, benefiting the care recipient and reducing use of
      formal care services. However, providing informal care negatively impacts the
      mental health of many caregivers. E-mental health interventions have emerged as a
      way to provide accessible mental healthcare to caregivers. Much attention has
      been given to reviewing the effectiveness and efficacy of such interventions,
      however, factors related to implementation have received less consideration.
      Therefore, this mixed-methods systematic review will aim to examine factors
      associated with the effectiveness and implementation of e-mental health
      interventions for caregivers. METHODS AND ANALYSIS: Eligible studies published
      since 1 January 2007 will be searched for in several electronic databases (CINAHL
      Plus with Full Text, the Cochrane Library, EMBASE, PsycINFO, PubMed and Web of
      Science), clinical trial registries and OpenGrey, with all screening steps
      conducted by two independent reviewers. Studies will be included if they focus on
      the implementation or effectiveness of e-mental health interventions designed for
      informal adult caregivers of adults with cancer, heart disease, stroke, diabetes,
      dementia or chronic obstructive pulmonary disease. Pragmatic randomised
      controlled trials quantitatively reporting on caregiver anxiety, depression,
      psychological distress or stress will be used for a qualitative comparative
      analysis to identify combinations of conditions that result in effective
      interventions. Qualitative and quantitative data on implementation of e-mental
      health interventions for caregivers will be integrated in a thematic synthesis to
      identify barriers and facilitators to implementation. These results will inform
      future development and implementation planning of e-mental health interventions
      for caregivers. ETHICS AND DISSEMINATION: Ethical approval is not required for
      this study as no primary data will be collected. Results will be disseminated in 
      the form of a scientific publication and presentations at academic conferences
      and plain language summaries for various stakeholders. PROSPERO REGISTRATION
      NUMBER: CRD42020155727.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Coumoundouros, Chelsea
AU  - Coumoundouros C
AUID- ORCID: 0000-0001-5539-974X
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden chelsea.coumoundouros@kbh.uu.se.
FAU - von Essen, Louise
AU  - von Essen L
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden.
FAU - Sanderman, Robbert
AU  - Sanderman R
AD  - Department of Health Psychology, University of Groningen, University Medical
      Center Groningen, Groningen, The Netherlands.
AD  - Department of Psychology, Health and Technology, University of Twente, Enschede, 
      The Netherlands.
FAU - Woodford, Joanne
AU  - Woodford J
AD  - Clinical Psychology in Healthcare, Department of Women's and Children's Health,
      Uppsala University, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Caregivers/*psychology
MH  - Chronic Disease/*therapy
MH  - Humans
MH  - *Mental Health Services
MH  - Research Design
MH  - *Systematic Reviews as Topic
MH  - *Telemedicine
PMC - PMC7307546
OTO - NOTNLM
OT  - *World Wide Web technology
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *mental health
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035406 [pii]
AID - 10.1136/bmjopen-2019-035406 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e035406. doi: 10.1136/bmjopen-2019-035406.


PMID- 32565460
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Barriers towards organ donor registration and consent among people of Indian
      origin living globally: a systematic review and integrative synthesis-protocol.
PG  - e035360
LID - 10.1136/bmjopen-2019-035360 [doi]
AB  - INTRODUCTION: The need for organs is comparatively higher among people of Indian 
      origin due to the higher prevalence of end-stage organ failure. In spite of the
      higher need, they have a lower number of organ donors. Studies have been carried 
      out among people of Indian origin living globally to understand the reasons for
      the low donation rate, but there has been no systematic review that has
      integrated all of these studies to synthesise the current literature. Therefore, 
      the purpose of this review is to examine the barriers towards organ donor
      registration and consent among Indians living globally. METHODS AND ANALYSIS: A
      systematic search will be conducted using the following relevant databases namely
      CINHAL, MEDLINE, PsycINFO, Scopus, Web of Science, PubMed Central, Global Health 
      and Grey literature. Studies from 1994 that satisfy our inclusion criteria will
      be included. Two reviewers will conduct the screening, data extraction and
      quality assessment of the studies; in event of any disagreement between the two
      reviewers at any stage, the third reviewer will reconcile any disagreements and
      consensus will be made. ETHICS AND DISSEMINATION: As this study includes only
      secondary data, ethical approval for secondary data usage has been sought. This
      study will use Preferred Reporting Items for Systematic Review and Meta-Analysis 
      guidelines to report and the study outcomes will be disseminated through a
      relevant peer-review publication, related conferences and also to various
      non-governmental organisations globally which are working with this particular
      community; following which further research can be developed based on this
      evidence and also helps in building a culturally competent strategy. PROSPERO
      REGISTRATION NUMBER: CRD42019155274.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vincent, Britzer Paul
AU  - Vincent BP
AD  - Institute for Health Research, University of Bedfordshire, Faculty of Health and 
      Social Sciences, Luton, UK.
FAU - Randhawa, Gurch
AU  - Randhawa G
AUID- ORCID: 0000-0002-2289-5859
AD  - Institute for Health Research, University of Bedfordshire, Faculty of Health and 
      Social Sciences, Luton, UK gurch.randhawa@beds.ac.uk.
FAU - Cook, Erica
AU  - Cook E
AD  - Department of Psychology, University of Bedfordshire, Luton, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - India
MH  - Informed Consent
MH  - Research Design
MH  - *Systematic Reviews as Topic
MH  - *Tissue Donors
MH  - Tissue and Organ Procurement
PMC - PMC7307552
OTO - NOTNLM
OT  - *medical ethics
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035360 [pii]
AID - 10.1136/bmjopen-2019-035360 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e035360. doi: 10.1136/bmjopen-2019-035360.


PMID- 32565458
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Study protocol for two complementary trials of non-steroidal or opioid analgesia 
      use for children aged 6 to 17 years with musculoskeletal injuries (the No OUCH
      study).
PG  - e035177
LID - 10.1136/bmjopen-2019-035177 [doi]
AB  - INTRODUCTION: Musculoskeletal (MSK) injuries are a frequent cause for emergency
      department (ED) visits in children. MSK injuries are associated with
      moderate-to-severe pain in most children, yet recent research confirms that the
      management of children's pain in the ED remains inadequate. Clinicians are
      seeking better oral analgesic options for MSK injury pain with demonstrated
      efficacy and an excellent safety profile. This study aims to determine the
      efficacy and safety of adding oral acetaminophen or oral hydromorphone to oral
      ibuprofen and interpret this information within the context of parent/caregiver
      preference. METHODS AND ANALYSIS: Using a novel preference-informed complementary
      trial design, two simultaneous trials are being conducted. Parents/caregivers of 
      children presenting to the ED with acute limb injury will be approached and they 
      will decide which trial they wish to participate in: an opioid-inclusive trial or
      a non-opioid trial. Both trials will follow randomised, double-blind,
      placebo-controlled, superiority-trial methodology and will enrol a minimum of 536
      children across six Canadian paediatric EDs. Children will be eligible if they
      are 6 to 17 years of age and if they present to the ED with an acute limb injury 
      and a self-reported verbal Numerical Rating Scale pain score >/=5. The primary
      objective is to determine the effectiveness of oral ibuprofen+oral hydromorphone 
      versus oral ibuprofen+oral acetaminophen versus oral ibuprofen alone. Recruitment
      was launched in April 2019. ETHICS AND DISSEMINATION: This study has been
      approved by the Health Research Ethics Board (University of Alberta), and by
      appropriate ethics boards at all recruiting centres. Informed consent will be
      obtained from parents/guardians of all participants, in conjunction with assent
      from the participants themselves. Study data will be submitted for publication
      regardless of results. This study is funded through a Canadian Institutes of
      Health Research grant. TRIAL REGISTRATION NUMBER: NCT03767933, first registered
      on 07 December 2018.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ali, Samina
AU  - Ali S
AUID- ORCID: 0000-0002-0595-364X
AD  - Pediatrics, University of Alberta, Edmonton, Alberta, Canada sali@ualberta.ca.
AD  - Women and Children's Health Research Institute, University of Alberta, Edmonton, 
      Alberta, Canada.
FAU - Rajagopal, Manasi
AU  - Rajagopal M
AD  - Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
FAU - Klassen, Terry
AU  - Klassen T
AD  - Children's Hospital Research Institute of Manitoba, University of Manitoba,
      Winnipeg, Manitoba, Canada.
FAU - Richer, Lawrence
AU  - Richer L
AUID- ORCID: 0000-0002-6897-8668
AD  - Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
AD  - Women and Children's Health Research Institute, University of Alberta, Edmonton, 
      Alberta, Canada.
FAU - McCabe, Christopher
AU  - McCabe C
AD  - Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada.
FAU - Willan, Andy
AU  - Willan A
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Yaskina, Maryna
AU  - Yaskina M
AD  - Women and Children's Health Research Institute, University of Alberta, Edmonton, 
      Alberta, Canada.
FAU - Heath, Anna
AU  - Heath A
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Child Health Evaluation Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
FAU - Drendel, Amy L
AU  - Drendel AL
AD  - Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
FAU - Offringa, Martin
AU  - Offringa M
AD  - Child Health Evaluation Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
FAU - Gouin, Serge
AU  - Gouin S
AD  - Pediatrics, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Stang, Antonia
AU  - Stang A
AD  - Pediatrics, University of Calgary, Calgary, Alberta, Canada.
AD  - Pediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
FAU - Sawyer, Scott
AU  - Sawyer S
AD  - Pediatrics and Emergency Medicine, University of Manitoba, Winnipeg, Manitoba,
      Canada.
FAU - Bhatt, Maala
AU  - Bhatt M
AD  - Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
AD  - Emergency Medicine, Children's Hospital of Eastern Ontario, Ottawa, Ontario,
      Canada.
FAU - Hickes, Serena
AU  - Hickes S
AD  - Parent Partner, Children's Hospital Research Institute of Manitoba, University of
      Manitoba, Winnipeg, Manitoba, Canada.
FAU - Poonai, Naveen
AU  - Poonai N
AD  - Paediatrics and Internal Medicine, Schulich School of Medicine & Dentistry,
      London Health Sciences Centre, London, Ontario, Canada.
CN  - KidsCAN PERC Innovative Pediatric Clinical Trials No OUCH Study Team
LA  - eng
SI  - ClinicalTrials.gov/NCT03767933
GR  - MYG-151207/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 362O9ITL9D (Acetaminophen)
RN  - Q812464R06 (Hydromorphone)
RN  - WK2XYI10QM (Ibuprofen)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Adolescent
MH  - Analgesics, Non-Narcotic/therapeutic use
MH  - Analgesics, Opioid/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Canada
MH  - Child
MH  - Emergency Service, Hospital
MH  - *Equivalence Trials as Topic
MH  - Extremities/injuries
MH  - Humans
MH  - Hydromorphone/therapeutic use
MH  - Ibuprofen/therapeutic use
MH  - Multicenter Studies as Topic
MH  - Musculoskeletal Pain/*drug therapy
MH  - Pain Management/methods
MH  - Research Design
PMC - PMC7311068
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *paediatric orthopaedics
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035177 [pii]
AID - 10.1136/bmjopen-2019-035177 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e035177. doi: 10.1136/bmjopen-2019-035177.


PMID- 32565455
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Acupuncture combined with medication for opioid use disorder in adults: a
      protocol for systematic review and meta-analysis.
PG  - e034554
LID - 10.1136/bmjopen-2019-034554 [doi]
AB  - INTRODUCTION: Opioid use disorder (OUD) is a worldwide health problem. Clinical
      trials indicated that acupuncture combined with medication is effective in OUD,
      however, there are different conclusions presented by previous trials. This study
      is designed to evaluate the efficacy and safety of acupuncture combined with
      medication in OUD. METHODS AND ANALYSIS: PubMed, CENTRAL, Embase, Web of Science,
      CINAHL, PsycINFO, ProQuest Dissertation and Theses, AMED, OpenGrey,
      Clinicaltrials.gov and who.int/trialsearch will be searched in September 2019
      without a language restriction. Randomised controlled trials (RCTs) and
      quasi-RCTs which included participants with OUD receiving acupuncture therapy
      combined with medication versus control group will be included in this study. Two
      reviewers will independently screen studies, extract data, assess risk of bias by
      the Cochrane risk of bias assessment tool and assess quality of evidence by
      Grading of Recommendations, Assessment, Development and Evaluation (GRADE)
      approach. Any disagreements will be arbitrated by the third reviewer. Data
      synthesis and analysis will be conducted by using RevMan V.5.3. Subgroup
      analyses, sensitivity analysis, meta-regression and reporting bias assessment
      will be conducted if necessary and appropriate. ETHICS AND DISSEMINATION: On
      account of the nature of this systematic review and meta-analysis, ethical
      approval is not required. The results will be published in a peer-reviewed
      journal. PROSPERO REGISTRATION NUMBER: CRD42019123436.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Zhihan
AU  - Chen Z
AUID- ORCID: 0000-0002-0237-7501
AD  - School of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - Wang, Rui
AU  - Wang R
AD  - School of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - Zhang, Min
AU  - Zhang M
AD  - School of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - Wang, Yitong
AU  - Wang Y
AUID- ORCID: 0000-0002-4968-4410
AD  - School of Chinese Classics, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Ren, Yulan
AU  - Ren Y
AD  - School of Chinese Classics, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China ryl@cdutcm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - Adult
MH  - Combined Modality Therapy
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Opiate Substitution Treatment
MH  - Opioid-Related Disorders/*therapy
MH  - Research Design
MH  - *Systematic Reviews as Topic
PMC - PMC7310998
OTO - NOTNLM
OT  - *acupuncture
OT  - *meta-analysis
OT  - *opioid use disorder
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034554 [pii]
AID - 10.1136/bmjopen-2019-034554 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e034554. doi: 10.1136/bmjopen-2019-034554.


PMID- 32565453
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Prevalence and risk factors of postpartum depression, general depressive
      symptoms, anxiety and stress (PODSAS) among mothers during their 4-week postnatal
      follow-up in five public health clinics in Perak: A study protocol for a
      cross-sectional study.
PG  - e034458
LID - 10.1136/bmjopen-2019-034458 [doi]
AB  - INTRODUCTION: Postpartum depression, general depressive symptoms, anxiety and
      stress (PODSAS) are often overlooked, and may cause morbidity to new mothers,
      their babies and families. This study aims to determine the point prevalence of
      depression (post partum and general), anxiety and stress among mothers in five
      public health clinics in Perak at 4 weeks postdelivery and identify their
      associated risk factors. Findings from this study will be used to identify the
      needs for early screening and detection, encourage development of interventions
      to reduce its occurrence and support mothers with PODSAS. METHODS AND ANALYSIS:
      This cross-sectional study will recruit 459 postpartum mothers during their
      4-week postnatal follow-up in five selected public health clinics in Perak from
      September 2019 to May 2020. Participants will be mothers aged 18 years and above 
      at 4 weeks postdelivery who are able to understand the English and Malay
      languages. Non-Malaysians and mothers with known diagnosis of psychotic disorders
      will be excluded from the study. Sociodemographic information and possible risk
      factors of the participants will be captured via a set of validated
      questionnaires, postpartum depression (PPD) will be measured using the Edinburgh 
      Postpartum Depression Scale questionnaire and general depressive symptoms,
      anxiety and stress will be measured using the 21-item Depression, Anxiety and
      Stress Scale. Data analysis will be conducted using SPSS V.25.0 (IBM). Besides
      descriptive statistics, multivariable regression analyses will be done to
      identify possible risk factors and their independent associations with depression
      (PPD and general depressive symptoms, combined and separately), anxiety and
      stress. ETHICS AND DISSEMINATION: The study protocol was reviewed and approved by
      the Medical Research Ethics Committee, Ministry of Health Malaysia on 7 August
      2019. Results of this study will be reported and shared with the local health
      stakeholders and disseminated through conference proceedings and journal
      publications. REGISTRATION NUMBER: This study is registered in the Malaysian
      National Medical Research Register with the ID: NMRR-19-868-47647.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mohammad Redzuan, Saidatul Akmar
AU  - Mohammad Redzuan SA
AUID- ORCID: 0000-0002-4459-2795
AD  - Gunung Rapat Health Clinic, Kinta District Health Office, Gunung Rapat, Malaysia.
FAU - Suntharalingam, Priyasini
AU  - Suntharalingam P
AD  - Buntong Health Clinic, Kinta District Health Office, Ipoh, Perak.
FAU - Palaniyappan, Thenmoli
AU  - Palaniyappan T
AD  - Pasir Pinji Health Clinic, Kinta District Health Office, Pasir Panji, Perak.
FAU - Ganasan, Venotha
AU  - Ganasan V
AD  - Gunung Rapat Health Clinic, Kinta District Health Office, Gunung Rapat, Malaysia.
FAU - Megat Abu Bakar, Puteri Normalina
AU  - Megat Abu Bakar PN
AD  - Bagan Serai Health Clinic, Kerian District Health Office, Bagan Serai, Perak.
FAU - Kaur, Paream
AU  - Kaur P
AD  - Greentown Health Clinic, Kinta District Health Office, Ipoh, Perak.
FAU - Marmuji, Lili Zuryani
AU  - Marmuji LZ
AD  - Gunung Rapat Health Clinic, Kinta District Health Office, Gunung Rapat, Malaysia.
FAU - Ambigapathy, Subashini
AU  - Ambigapathy S
AD  - Buntong Health Clinic, Kinta District Health Office, Ipoh, Perak.
FAU - Paranthaman, V
AU  - Paranthaman V
AD  - Greentown Health Clinic, Kinta District Health Office, Ipoh, Perak.
FAU - Chew, Boon How
AU  - Chew BH
AUID- ORCID: 0000-0002-8627-6248
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, UPM Serdang, Selangor chewboonhow@upm.edu.my.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Anxiety/diagnosis/epidemiology
MH  - Cross-Sectional Studies
MH  - Depression, Postpartum/*diagnosis/*epidemiology
MH  - Female
MH  - Humans
MH  - Malaysia/epidemiology
MH  - Prevalence
MH  - *Research Design
MH  - Risk Factors
MH  - Stress, Psychological/diagnosis/epidemiology
MH  - Surveys and Questionnaires
PMC - PMC7311026
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *maternal medicine
OT  - *mental health
OT  - *primary care
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034458 [pii]
AID - 10.1136/bmjopen-2019-034458 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e034458. doi: 10.1136/bmjopen-2019-034458.


PMID- 32565450
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - One-to-one befriending for people with intellectual disability and symptoms of
      depression: protocol for a pilot randomised controlled trial.
PG  - e033989
LID - 10.1136/bmjopen-2019-033989 [doi]
AB  - INTRODUCTION: People with intellectual disability (ID) are more likely to
      experience loneliness and have smaller social networks, which increases
      vulnerability to depression. Befriending may reduce depressive symptoms in other 
      populations, but randomised controlled trials (RCTs) have not been carried out in
      this population. This pilot study aims to assess the acceptability and
      feasibility of carrying out a full RCT of one-to-one befriending by volunteers
      for people with ID, compared with an active control group. METHODS AND ANALYSIS: 
      The trial aims to recruit 40 participants with ID. Participants in the
      intervention arm will receive weekly visits from a volunteer over 6 months.
      Community befriending schemes will recruit, train, supervise volunteers and match
      them to individuals with ID. Both groups will receive a booklet about local
      activities and have access to usual care. Health and social outcomes will be
      measured at the end of the intervention and 6 months' follow-up. The following
      outcomes will be assessed: (1) recruitment and retention of individuals with ID
      and volunteers in the trial, (2) adverse events related to the intervention, (3) 
      the acceptability of the intervention, (4) whether the intervention is delivered 
      as intended, (5) changes in health and social outcomes and (6) the feasibility of
      carrying out a cost-effectiveness analysis in a full trial. Qualitative data from
      participants, volunteers, staff and carers will identify barriers and
      facilitators of a future full trial. ETHICS AND DISSEMINATION: The study has been
      approved by the London City and East Research Ethics Committee (reference
      18/LO/2188). The findings will be presented at conferences and published in a
      peer-reviewed journal and in the National Institute of Health Research journals
      library. A public engagement seminar will be held at the end of the study aimed
      at key stakeholders. TRIAL REGISTRATION NUMBER: ISRCTN63779614.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ali, Afia
AU  - Ali A
AUID- ORCID: 0000-0002-0104-9370
AD  - Division of Psychiatry, University College London, London, UK afia.ali@ucl.ac.uk.
FAU - Mckenzie, Emma
AU  - Mckenzie E
AD  - Research and Development, North East London NHS Foundation Trust Goodmayes
      Hospital, Ilford, Essex, UK.
FAU - Hassiotis, Angela
AU  - Hassiotis A
AD  - Division of Psychiatry, University College London, London, UK.
FAU - Priebe, Stefan
AU  - Priebe S
AD  - Unit of Social and Community Psychiatry, Barts and the London School of Medicine 
      and Dentistry, University of London, London, UK.
FAU - Lloyd-Evans, Brynmor
AU  - Lloyd-Evans B
AD  - Division of Psychiatry, University College London, London, UK.
FAU - Omar, Rumana
AU  - Omar R
AD  - Department of Statistical Science, University College London, London, UK.
FAU - Jones, Rebecca
AU  - Jones R
AD  - Division of Psychiatry, University College London, London, UK.
FAU - Panca, Monica
AU  - Panca M
AD  - Primary Care and Population Health, University College London, London, UK.
FAU - Fernandez, Vincent
AU  - Fernandez V
AD  - Hackney Volunteer and Befriending Scheme, Outward, London, UK.
FAU - Finning, Sally
AU  - Finning S
AD  - Hackney Volunteer and Befriending Scheme, Outward, London, UK.
FAU - Moore, Shirley
AU  - Moore S
AD  - The Befriending Scheme, Sudbury, Suffolk, UK.
FAU - O'Connor, Danielle
AU  - O'Connor D
AD  - The Befriending Scheme, Sudbury, Suffolk, UK.
FAU - Roe, Christine
AU  - Roe C
AD  - The Befriending Scheme, Sudbury, Suffolk, UK.
FAU - King, Michael
AU  - King M
AD  - Division of Psychiatry, University College London, London, UK.
LA  - eng
GR  - 16/122/57/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Depression/*prevention & control
MH  - Disabled Persons
MH  - Humans
MH  - *Intellectual Disability
MH  - Loneliness
MH  - Pilot Projects
MH  - *Randomized Controlled Trials as Topic
MH  - *Social Support
MH  - Volunteers
PMC - PMC7311030
OTO - NOTNLM
OT  - *delirium & cognitive disorders
OT  - *depression & mood disorders
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033989 [pii]
AID - 10.1136/bmjopen-2019-033989 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e033989. doi: 10.1136/bmjopen-2019-033989.


PMID- 32565449
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 21
TI  - Programmes to support transitions in care for children and youth with complex
      care needs and their families: a scoping review protocol.
PG  - e033978
LID - 10.1136/bmjopen-2019-033978 [doi]
AB  - INTRODUCTION: Children and youth with complex care needs (CCNs) and their
      families experience many care transitions over their lifespan and are
      consequently vulnerable to the discontinuity or gaps in care that can occur
      during these transitions. Transitional care programmes, broadly defined as one or
      more intervention(s) or service(s) that aim to improve continuity of care, are
      increasingly being developed to address transitions in care for children and
      youth with CCNs. However, this literature has not yet been systematically
      examined at a comprehensive level. The purpose of this scoping review is to map
      the range of programmes that support transitions in care for children and youth
      with CCNs and their families during two phases of their lifespan: (1) up to the
      age of 19 years (not including their transition to adult healthcare) and (2) when
      transitioning from paediatric to adult healthcare. METHODS AND ANALYSIS: The
      Joanna Briggs Institute methodology for scoping reviews (ScR) will be used for
      the proposed scoping review. ScR are a type of knowledge synthesis that are
      useful for addressing exploratory research questions that aim to map key concepts
      and types of evidence on a topic and can be used to organise what is known about 
      the phenomena. A preliminary search of PubMed was conducted in December 2018.
      ETHICS AND DISSEMINATION: Ethical approval is not required where this study is a 
      review of the published and publicly reported literature. The research team's
      advisory council will develop a research dissemination strategy with goals,
      target audiences, expertise/leadership, resources and deadlines to maximise
      project outputs. The end-of-grant activities will be used to raise awareness,
      promote action and inform future research, policy and practice on this topic.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Doucet, Shelley
AU  - Doucet S
AUID- ORCID: 0000-0003-4420-8199
AD  - Department of Nursing and Health Sciences, University of New Brunswick, Saint
      John, New Brunswick, Canada sdoucet@unb.ca.
FAU - Curran, Janet A
AU  - Curran JA
AUID- ORCID: 0000-0001-9977-0467
AD  - School of Nursing, Faculty of Health, Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Breneol, Sydney
AU  - Breneol S
AD  - School of Nursing, Faculty of Health, Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Luke, Alison
AU  - Luke A
AUID- ORCID: 0000-0002-2800-579X
AD  - Department of Nursing and Health Sciences, University of New Brunswick, Saint
      John, New Brunswick, Canada.
FAU - Dionne, Emilie
AU  - Dionne E
AD  - St. Mary's Research Centre & Family Medicine, McGill University, Montreal,
      Quebec, Canada.
FAU - Azar, Rima
AU  - Azar R
AD  - Department of Psychology, Mount Allison University, Sackville, New Brunswick,
      Canada.
FAU - Reid, Amy E
AU  - Reid AE
AUID- ORCID: 0000-0002-7808-8247
AD  - Department of Nursing and Health Sciences, University of New Brunswick, Saint
      John, New Brunswick, Canada.
FAU - McKibbon, Shelley
AU  - McKibbon S
AD  - W.K. Kellogg Health Sciences Library, Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Horsman, Amanda R
AU  - Horsman AR
AUID- ORCID: 0000-0002-8281-2752
AD  - Interdisciplinary Studies, University of New Brunswick, Saint John, New
      Brunswick, Canada.
FAU - Binns, Krystal
AU  - Binns K
AD  - Department of Nursing and Health Sciences, University of New Brunswick, Saint
      John, New Brunswick, Canada.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200621
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - *Needs Assessment
MH  - Research Design
MH  - Review Literature as Topic
MH  - Transition to Adult Care/*organization & administration
MH  - Transitional Care/*organization & administration
PMC - PMC7307541
OTO - NOTNLM
OT  - *community child health
OT  - *complex care needs
OT  - *continuity of care
OT  - *health policy
OT  - *transitions in care
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033978 [pii]
AID - 10.1136/bmjopen-2019-033978 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 21;10(6):e033978. doi: 10.1136/bmjopen-2019-033978.


PMID- 32565427
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 6
DP  - 2020 Jun
TI  - The 6-star doctor? Physicians' communication of poor prognosis to patients and
      their families in Cape Coast, Ghana.
LID - e002334 [pii]
LID - 10.1136/bmjgh-2020-002334 [doi]
AB  - INTRODUCTION: Communication is considered a key skill for physicians globally and
      has formed a central part of medical curricula since the WHO identified it as a
      key attribute of the '5-star doctor'. Communication of poor prognosis to patients
      and caregivers is particularly challenging, yet an important example of
      physicians' clinical communication, and a priority within palliative care
      research. Knowledge is scarce regarding the different positions physicians adopt 
      during poor prognosis communication, especially in sub-Saharan countries.
      METHODS: This qualitative study took place at the Cape Coast Teaching Hospital in
      Ghana's Central Region. Physicians in the internal medicine department, with
      experience in communicating poor prognosis to patients and families on a weekly
      basis were purposively sampled. Based on the concept of information power, a
      maximum variation of participants, in terms of age, sex, seniority and experience
      was achieved after conducting 10 semistructured interviews in March 2019.
      Positioning theory was used as a theoretical lens to inform study design. The
      data were analysed through a constructivist thematic analysis approach. RESULTS: 
      Physicians adopted six positions, considered as six different themes, during
      their communication of poor prognosis: clinical expert, educator, counsellor,
      communicator, protector and mentor. Physicians' choice of position was fluid,
      guided by local context and wider health system factors. Physicians' desire to
      communicate with patients and families in a way that met their needs highlighted 
      three key challenges for communication of poor prognosis: linguistic
      difficulties, pluralistic health beliefs and the role of family. These challenges
      presented ethical complexities in relation to autonomy and non-maleficence.
      CONCLUSION: Context is key to physicians' communication of poor prognosis.
      Communication of poor prognosis is multifaceted, complex and unpredictable.
      Physicians' communication training should be developed to emphasise contextual
      circumstances and physician support, and international policy models on
      physicians' roles developed to include a greater focus on social accountability.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Caulfield, Alexandra
AU  - Caulfield A
AUID- ORCID: 0000-0002-2483-4427
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden a.caulfield1@nhs.net.
FAU - Plymoth, Amelie
AU  - Plymoth A
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institute,
      Stockholm, Stockholm County, Sweden.
FAU - Nartey, Yvonne Ayerki
AU  - Nartey YA
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institute,
      Stockholm, Stockholm County, Sweden.
FAU - Molsted-Alvesson, Helle
AU  - Molsted-Alvesson H
AD  - Department of Global Public Health, Karolinska Institute, Stockholm, Stockholm
      County, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - *Communication
MH  - Ghana
MH  - Humans
MH  - Palliative Care
MH  - *Physicians
MH  - Prognosis
PMC - PMC7311005
OTO - NOTNLM
OT  - *cancer
OT  - *health policy
OT  - *other infection, disease, disorder, or injury
OT  - *qualitative study
COIS- Competing interests: None declared.
EDAT- 2020/06/23 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-002334 [pii]
AID - 10.1136/bmjgh-2020-002334 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Jun;5(6). pii: bmjgh-2020-002334. doi:
      10.1136/bmjgh-2020-002334.


PMID- 32565387
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2468-7189 (Electronic)
IS  - 2468-7189 (Linking)
VI  - 48
IP  - 11
DP  - 2020 Nov
TI  - [Anonymity of gamete donation and genetic testing].
PG  - 820-826
LID - S2468-7189(20)30210-5 [pii]
LID - 10.1016/j.gofs.2020.06.006 [doi]
AB  - Development of genetic testing direct-to-consumer (DTC) for recreational
      purposes, although prohibited in France, is a real challenge to the current
      practice of gamete donation. Indeed, anonymity is a fundamental principle
      contributing to the ethics of donation. This principle is weakened due to the
      availability to the general public of these tests on the Internet. Several
      thousands of people are conceived by gamete donation worldwide, some of whom do
      not know how they were conceived. Gamete donors should be informed that their
      anonymity is no longer guaranteed, as they can be found by homologies of their
      DNA, or that of a parent or a child, potentially available in databases. Thus,
      adults conceived by gamete donation but not informed by their parents can
      discover their way of conception. Recipients of gamete donation should also be
      informed that their child's DNA will establish the biological discrepancy and
      they should be encouraged to disclose the conception to their child. Several
      countries now allow children conceived by donation to obtain donor's identity. In
      France, the Bioethics Law is currently being finalized and will now allow access 
      to donor's identity for people conceived by gamete donation.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Neyroud, A-S
AU  - Neyroud AS
AD  - CHU Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France;
      Univ Rennes, Inserm, EHESP, Irset (institut de recherche en sante, environnement 
      et travail) - UMR_S 1085, 35000 Rennes, France.
FAU - Roche, M
AU  - Roche M
AD  - CHU Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France.
FAU - Domin, M
AU  - Domin M
AD  - CHU Rennes, service de gynecologie, 35000 Rennes, France.
FAU - Jaillard, S
AU  - Jaillard S
AD  - Univ Rennes, Inserm, EHESP, Irset (institut de recherche en sante, environnement 
      et travail) - UMR_S 1085, 35000 Rennes, France; CHU Rennes, laboratoire de
      cytogenetique, 35000 Rennes, France.
FAU - Ravel, C
AU  - Ravel C
AD  - CHU Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France;
      Univ Rennes, Inserm, EHESP, Irset (institut de recherche en sante, environnement 
      et travail) - UMR_S 1085, 35000 Rennes, France. Electronic address:
      celia.ravel@chu-rennes.fr.
LA  - fre
PT  - Journal Article
TT  - L'anonymat du don de gametes a l'heure des tests genetiques.
DEP - 20200618
PL  - France
TA  - Gynecol Obstet Fertil Senol
JT  - Gynecologie, obstetrique, fertilite & senologie
JID - 101693805
SB  - IM
MH  - Adult
MH  - Child
MH  - France
MH  - Genetic Testing
MH  - Germ Cells
MH  - Humans
MH  - *Oocyte Donation
MH  - *Tissue Donors
OTO - NOTNLM
OT  - *Anonymat
OT  - *Anonymity
OT  - *Don de gametes
OT  - *Gamete donation
OT  - *Genetic testing
OT  - *Test genetique
EDAT- 2020/06/23 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - S2468-7189(20)30210-5 [pii]
AID - 10.1016/j.gofs.2020.06.006 [doi]
PST - ppublish
SO  - Gynecol Obstet Fertil Senol. 2020 Nov;48(11):820-826. doi:
      10.1016/j.gofs.2020.06.006. Epub 2020 Jun 18.


PMID- 32565345
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210715
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 33
DP  - 2020 Jul 14
TI  - Human papillomavirus (HPV) vaccine utilization among adults (18-29 years), BRFSS 
      2015.
PG  - 5119-5122
LID - S0264-410X(20)30701-5 [pii]
LID - 10.1016/j.vaccine.2020.05.056 [doi]
AB  - Human papillomavirus (HPV) vaccination acceptance is hampered by fears and
      conflicting attitudes about the need for and safety of vaccine. There are also
      ethical dilemmas associated with vaccinating adolescents for a sexually
      transmitted disease despite future cancer risk. The purpose of this research was 
      to determine HPV vaccination acceptance/hesitancy among young adults. Behavioral 
      Risk Factor Surveillance System 2015 data were used. During 2015, 83.1% of adults
      ages 25-29 years did not receive any HPV vaccination; the UOR was 3.47; 95% CI = 
      2.11, 5.70) compared to adults 18-24 years. There is a need to accelerate public 
      health messaging/campaigns to increase HPV vaccination rates.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Wiener, R Constance
AU  - Wiener RC
AD  - Department of Dental Practice and Rural Health, School of Dentistry, West
      Virginia University, Morgantown, WV 26506-9448 USA. Electronic address:
      rwiener2@hsc.wvu.edu.
FAU - Findley, Patricia A
AU  - Findley PA
AD  - Rutgers University, School of Social Work, 120 Albany Street, New Brunswick, NJ
      08901 USA. Electronic address: pfindley@ssw.rutgers.edu.
FAU - Shen, Chan
AU  - Shen C
AD  - Department of Surgery, Penn State, Cancer Institute, Hershey, PA 17033 USA.
      Electronic address: cshen@pennstatehealth.psu.edu.
FAU - Dwibedi, Nilanjana
AU  - Dwibedi N
AD  - Department of Pharmaceutical Systems and Policy, West Virginia University School 
      of Pharmacy, Morgantown, WV 26506-9510 USA.
FAU - Sambamoorthi, Usha
AU  - Sambamoorthi U
AD  - Department of Pharmaceutical Systems and Policy, West Virginia University School 
      of Pharmacy, Morgantown, WV 26506-9510 USA. Electronic address:
      usambamoorthi@hsc.wvu.edu.
LA  - eng
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200619
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Alphapapillomavirus
MH  - Behavioral Risk Factor Surveillance System
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Papillomavirus Infections/epidemiology/prevention & control
MH  - *Papillomavirus Vaccines
MH  - Patient Acceptance of Health Care
MH  - Vaccination
MH  - Young Adult
PMC - PMC7367495
MID - NIHMS1599671
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/06/23 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/01/18 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - S0264-410X(20)30701-5 [pii]
AID - 10.1016/j.vaccine.2020.05.056 [doi]
PST - ppublish
SO  - Vaccine. 2020 Jul 14;38(33):5119-5122. doi: 10.1016/j.vaccine.2020.05.056. Epub
      2020 Jun 19.


PMID- 32564760
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 1876-1038 (Electronic)
IS  - 1574-8871 (Linking)
VI  - 15
IP  - 3
DP  - 2020
TI  - Digitizing the Pharma Neurons - A Technological Operation in Progress!
PG  - 178-187
LID - 10.2174/1574887115666200621183459 [doi]
AB  - BACKGROUND: Digitization and automation are the buzzwords in clinical research
      and pharma companies are investigating heavily here. Right from drug discovery to
      personalized medicine, digital patients and patient engagement, there is great
      consideration of technology at each step. METHODS: The published data and online 
      information available is reviewed to give an overview of digitization in pharma, 
      across the drug development cycle, industry collaborations and innovations. The
      regulatory guidelines, innovative collaborations across industry, academics and
      thought leadership are presented. Also included are some ideas, suggestions, way 
      forwards while digitizing the pharma neurons, the regulatory stand, benefits and 
      challenges. RESULTS: The innovations range from discovering personalized medicine
      to conducting virtual clinical trials, and maximizing data collection from the
      real-world experience. To address the increasing demand for the real-world data
      and the needs of tech-savvy patients, the innovations are shaping up accordingly.
      Pharma companies are collaborating with academics and they are co-innovating the 
      technology for example Massachusetts Institute of Technology's program. This
      focuses on the modernization of clinical trials, strategic use of artificial
      intelligence and machine learning using real-world evidence, assess the
      risk-benefit ratio of deploying digital analytics in medicine, and proactively
      identifying the solutions. CONCLUSION: With unfolding data on the impact of
      science and technology amalgamation, we need shared mindset between data
      scientists and medical professionals to maximize the utility of enormous health
      and medical data. To tackle this efficiently, there is a need of
      cross-collaboration and education, and align with ethical and regulatory
      requirements. A perfect blend of industry, regulatory, and academia will ensure
      successful digitization of pharma neurons.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Bhardwaj, Payal
AU  - Bhardwaj P
AD  - Tata Consultancy Services, Noida, India.
FAU - Yadav, Raj Kumar
AU  - Yadav RK
AD  - Integral Health Clinic, Department of Physiology, All India Institute of Medical 
      Sciences, New Delhi-110029, India.
FAU - Kurian, Sojan
AU  - Kurian S
AD  - Tata Consultancy Services, New York, NY, United States.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Rev Recent Clin Trials
JT  - Reviews on recent clinical trials
JID - 101270873
SB  - IM
MH  - *Artificial Intelligence
MH  - Drug Discovery/*organization & administration
MH  - Drug Industry/*organization & administration
MH  - Humans
MH  - Precision Medicine/*methods
OTO - NOTNLM
OT  - *Artificial Intelligence
OT  - *clinical Trials
OT  - *digitization
OT  - *machine Learning
OT  - *pharmaceuticals
OT  - *technology in Medicine
EDAT- 2020/06/23 06:00
MHDA- 2021/10/02 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - RRCT-EPUB-107524 [pii]
AID - 10.2174/1574887115666200621183459 [doi]
PST - ppublish
SO  - Rev Recent Clin Trials. 2020;15(3):178-187. doi:
      10.2174/1574887115666200621183459.


PMID- 32564706
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 12
DP  - 2020 Oct
TI  - Situating Preventive Action in a Moral and Clinical Context: A Qualitative
      Synthesis on Fall Prevention.
PG  - 1913-1923
LID - 10.1177/1049732320921144 [doi]
AB  - The prevention of falls is an integral part of the safety culture of health
      institutions with mandatory fall prevention programs set within health care
      facilities. Care providers are key in identifying the risks of falls and in
      implementing strategic actions to prevent them. With the aim to better understand
      practices of fall prevention, we conducted a synthesis of qualitative evidence on
      care providers' practices to prevent older people from falling in health care
      facilities. This synthesis is part of an integrative review of the role of care
      providers in fall prevention of adults aged 65 years and above. Primary studies
      were synthesized with the emerging core category of "a complex decision" and
      described by four emerging conditions that make that decision complex: (a)
      permanent threat of a fall, (b) continuous flow of information, (c) lack of
      control, and (d) ethical dilemmas and moral issues over the course of action. The
      present synthesis shows that before implementing preventive actions, care
      providers consider the conditions in which they are immersed, in this way
      situating their preventive actions in a clinical and a moral context.
FAU - de la Cuesta-Benjumea, Carmen
AU  - de la Cuesta-Benjumea C
AUID- ORCID: 0000-0003-2160-392X
AD  - University of Alicante, Alicante, Spain.
FAU - Abad-Corpa, Eva
AU  - Abad-Corpa E
AD  - University of Murcia, Murcia, Spain.
FAU - Lidon-Cerezuela, Beatriz
AU  - Lidon-Cerezuela B
AD  - University of Murcia, Murcia, Spain.
FAU - Orts-Cortes, Isabel
AU  - Orts-Cortes I
AUID- ORCID: 0000-0002-1504-575X
AD  - University of Alicante, Alicante, Spain.
FAU - Meseguer-Liza, Cristobal
AU  - Meseguer-Liza C
AD  - University of Murcia, Murcia, Spain.
FAU - Arredondo-Gonzalez, Claudia Patricia
AU  - Arredondo-Gonzalez CP
AD  - University of Alicante, Alicante, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200620
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - *Accidental Falls/prevention & control
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Health Facilities
MH  - Humans
MH  - Morals
OTO - NOTNLM
OT  - *Asia
OT  - *Australia
OT  - *Europe
OT  - *North America
OT  - *caregivers
OT  - *falling
OT  - *falls
OT  - *nursing
OT  - *older people
OT  - *qualitative
OT  - *synthesis
EDAT- 2020/06/23 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - 10.1177/1049732320921144 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Oct;30(12):1913-1923. doi: 10.1177/1049732320921144. Epub
      2020 Jun 20.


PMID- 32564532
OWN - NLM
STAT- MEDLINE
DCOM- 20200626
LR  - 20200626
IS  - 0255-7053 (Print)
IS  - 0255-7053 (Linking)
VI  - 50
IP  - 1
DP  - 2020 Jan 28
TI  - [Human experiment study of Unit 731, Japan: take the report "The Research Report 
      on Epidemic Prevention of Army Medical School : Vol.1, No.36 " as an example].
PG  - 15-20
LID - 10.3760/cma.j.issn.0255-7053.2020.01.003 [doi]
AB  - "The Research Report on Epidemic Prevention of Army Medical School : Vol.1,
      No.36" , the report named "various symptoms and serological responses of human
      body after receiving ultrasonic cholera vaccine" is one of the declassified
      materials of Japanese biological warfare. The author is M. D. Watanabe Be.
      Through detailed analysis of its contents, such as institute of report, test
      method, test results, and so forth, conclusion is reached that Unit 731 did
      conduct scientific research based on human-subject experiment to launch
      biological warfare on human beings. The report mentioned above is one of the most
      important evidence of crime that Japan conducts biological warfare which violates
      international convention and contempt bottom line of human basic morals and
      ethics.
FAU - Li, P Y
AU  - Li PY
AD  - Department of Medical History, Harbin Medical University, Harbin 150086, China.
FAU - Zhang, Y R
AU  - Zhang YR
AD  - Department of Medical History, Harbin Medical University, Harbin 150086, China.
LA  - chi
GR  - 16KZD014/Compilation of Historical Materials of Japanese Biological Warfare
      Crimes and Establishment of the Database
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Shi Za Zhi
JT  - Zhonghua yi shi za zhi (Beijing, China : 1980)
JID - 8303081
RN  - 0 (Biological Warfare Agents)
MH  - Biological Warfare Agents/*ethics
MH  - Epidemics/*prevention & control
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - Japan
MH  - Morals
MH  - *Research Report
MH  - Schools, Medical
OTO - NOTNLM
OT  - Unit 731
OT  - Watanabe Be
OT  - human-subject experiment
OT  - ultrasonic cholera vaccine
EDAT- 2020/06/23 06:00
MHDA- 2020/06/27 06:00
CRDT- 2020/06/22 06:00
PHST- 2020/06/22 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/06/27 06:00 [medline]
AID - 10.3760/cma.j.issn.0255-7053.2020.01.003 [doi]
PST - ppublish
SO  - Zhonghua Yi Shi Za Zhi. 2020 Jan 28;50(1):15-20. doi:
      10.3760/cma.j.issn.0255-7053.2020.01.003.


PMID- 32564454
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1445-2197 (Electronic)
IS  - 1445-1433 (Linking)
VI  - 90
IP  - 7-8
DP  - 2020 Jul
TI  - Design and establishment of a cancer registry: a literature review.
PG  - 1277-1282
LID - 10.1111/ans.16084 [doi]
AB  - BACKGROUND: Establishment of a cancer registry is a complex process that requires
      substantial resources and careful planning. There are numerous resources
      available to provide guidance for this, which include guidelines and frameworks
      of varying quality. It is the authors' goal to identify evidence-based
      recommendations within the literature to help guide the process of designing a
      new registry with optimal efficiency, workability and data use. The objective of 
      this study is to examine the primary literature for evidence-based
      recommendations on how to design and establish a cancer registry, with a focus on
      literature which analyses the performance and usefulness of already established
      registries or guidelines. METHODS: An electronic search was completed in MEDLINE,
      CINAHL, EMCARE, SCOPUS and the Cochrane Database of Systematic Reviews.
      Recommendations were extracted from the identified articles and collated as
      themes. RESULTS: Nine articles of varying quality were included in the review.
      Recommendations obtained from the literature included broad themes of the
      importance of clinician involvement, establishment of clear data definitions,
      number of variables used, inbuilt strategies to improve quality and completeness 
      of data, considerations of costs, an 'opt-out' strategy for ethics and privacy
      and flexibility of the system. CONCLUSION: This review concluded that there is a 
      large gap in the primary literature for evidence-based recommendations on the
      design and establishment of cancer registries. The included articles established 
      a small scope of relevant themes, which were largely non-specific. This area of
      deficiency provides an opportunity for future research, which would further
      strengthen the quality of current or new guidelines in cancer registry
      establishment.
CI  - (c) 2020 Royal Australasian College of Surgeons.
FAU - Wormald, Jamie S
AU  - Wormald JS
AUID- ORCID: 0000-0001-7280-6482
AD  - Department of Medicine, Flinders University College of Medicine and Public
      Health, Adelaide, South Australia, Australia.
FAU - Oberai, Tarandeep
AU  - Oberai T
AD  - Discipline of Orthopaedic Surgery, Bone and Soft Tissue Tumour Unit, Flinders
      University College of Medicine and Public Health, Adelaide, South Australia,
      Australia.
FAU - Branford-White, Harriet
AU  - Branford-White H
AD  - Discipline of Orthopaedic Surgery, Bone and Soft Tissue Tumour Unit, Flinders
      University College of Medicine and Public Health, Adelaide, South Australia,
      Australia.
FAU - Johnson, Luke J
AU  - Johnson LJ
AD  - Discipline of Orthopaedic Surgery, Bone and Soft Tissue Tumour Unit, Flinders
      University College of Medicine and Public Health, Adelaide, South Australia,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200621
PL  - Australia
TA  - ANZ J Surg
JT  - ANZ journal of surgery
JID - 101086634
SB  - IM
MH  - Databases, Factual
MH  - Humans
MH  - *Neoplasms/epidemiology
MH  - Registries
MH  - Systematic Reviews as Topic
OTO - NOTNLM
OT  - *cancer
OT  - *database
OT  - *neoplasm
OT  - *registry
OT  - *review
EDAT- 2020/06/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/22 06:00
PHST- 2019/06/18 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/22 06:00 [entrez]
AID - 10.1111/ans.16084 [doi]
PST - ppublish
SO  - ANZ J Surg. 2020 Jul;90(7-8):1277-1282. doi: 10.1111/ans.16084. Epub 2020 Jun 21.


PMID- 32564367
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20211204
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 1
DP  - 2020 Jul
TI  - Opening the lines of communication: towards shared decision making and improved
      end-of-life care in the Top End.
PG  - 10-11.e1
LID - 10.5694/mja2.50656 [doi]
FAU - Spencer, Emma
AU  - Spencer E
AD  - Royal Darwin Hospital, Darwin, NT.
FAU - Waran, Eswaran
AU  - Waran E
AD  - Royal Darwin Hospital, Darwin, NT.
LA  - eng
PT  - Journal Article
DEP - 20200621
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Advance Directives
MH  - Communication
MH  - Cultural Competency
MH  - *Decision Making, Shared
MH  - Female
MH  - Health Services, Indigenous/*organization & administration
MH  - Humans
MH  - Male
MH  - *Native Hawaiian or Other Pacific Islander
MH  - Northern Territory
MH  - *Terminal Care
OTO - NOTNLM
OT  - *Advance directives
OT  - *Clinical decision-making
OT  - *Death
OT  - *Ethics
OT  - *Health services
OT  - *Health services for the aged
OT  - *Palliative medicine
OT  - *Rural health services
OT  - *Terminal care
EDAT- 2020/06/22 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/06/22 06:00
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2020/06/22 06:00 [entrez]
AID - 10.5694/mja2.50656 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Jul;213(1):10-11.e1. doi: 10.5694/mja2.50656. Epub 2020 Jun 21.


PMID- 32564093
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
VI  - 31
IP  - 11
DP  - 2020 Nov
TI  - Effects of progesterone therapy on serum sclerostin levels in healthy menopausal 
      women: a 3-month randomized, placebo-controlled clinical trial.
PG  - 2243-2250
LID - 10.1007/s00198-020-05505-x [doi]
AB  - Sclerostin, a natural hormone made in bone, suppresses bone formation. Sclerostin
      is also decreased by estrogen. Progesterone, estrogen's menstrual partner,
      stimulates bone formation. It is unclear whether progesterone influences
      sclerostin. This study showed that progesterone did not change sclerostin using
      serum remaining from a randomized progesterone hot flush therapy trial.
      INTRODUCTION: Progesterone and sclerostin are both endogenous hormones acting
      through osteoblast-origin cells and promote or suppress bone formation,
      respectively. Estradiol suppresses sclerostin, but progesterone, its menstrual
      cycle partner hormone, has unclear sclerostin relationships. We postulated that
      progesterone therapy would influence serum sclerostin levels. METHODS: We
      obtained sclerostin levels for an ethics-approved post hoc analysis. Fasting
      sclerostin was measured in all remaining sera from a previous 12-week randomized 
      controlled trial (RCT) of oral micronized progesterone (progesterone) for
      menopausal (> 1 year after last flow) vasomotor symptoms (VMS). Women in the RCT 
      took 300 mg progesterone at bedtime or placebo (1:1) in a trial showing
      progesterone significantly decreased VMS. RESULTS: Participants were healthy
      menopausal, primarily Caucasian (91.2%) community-dwelling women (+/- SD), 55.2
      +/- 4.6 years old with BMI 24.9 +/- 2.9 kg/m(2). The baseline sclerostin level in
      60 women was 28.41 +/- 10.47 pmol/L. Baseline sclerostin was not correlated with 
      the run-in VMS score (r = 0.143, P = 0.294). Paired baseline and 12-week RCT data
      for 52 women showed serum sclerostin levels did not change related to
      experimental therapy (P = 0.504). Changes in final sclerostin values adjusted for
      baseline were progesterone (- 1.07 +/- 7.96 pmol/L) and placebo (- 2.64 +/- 8.70 
      pmol/L). In observational data (n = 60), baseline sclerostin levels correlated
      with the General Framingham Cardiovascular (CVD) Risk score (r = - 0.398, P =
      0.003) and self-reported health by SF-36 quality of life instrument (QoL, r = -
      0.331, P = 0.016). CONCLUSION: Physiological oral micronized progesterone did not
      stimulate nor suppress serum sclerostin levels based on post hoc analysis of RCT 
      data. Exploratory results, however, showed sclerostin negatively correlated with 
      CVD risk and QoL. ClinicalTrials.gov #NCT0146469.
FAU - Yang, Y B
AU  - Yang YB
AD  - Department of Medicine, Division of Endocrinology, Centre for Menstrual Cycle and
      Ovulation Research (CeMCOR), University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Goshtasebi, A
AU  - Goshtasebi A
AD  - Department of Medicine, Division of Endocrinology, Centre for Menstrual Cycle and
      Ovulation Research (CeMCOR), University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - van Lierop, A H
AU  - van Lierop AH
AD  - Center for Bone Quality, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Kalidasan, D
AU  - Kalidasan D
AD  - Department of Medicine, Division of Endocrinology, Centre for Menstrual Cycle and
      Ovulation Research (CeMCOR), University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Hitchcock, C L
AU  - Hitchcock CL
AD  - Department of Medicine, Division of Endocrinology, Centre for Menstrual Cycle and
      Ovulation Research (CeMCOR), University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Prior, J C
AU  - Prior JC
AUID- ORCID: https://orcid.org/0000-0003-3232-0597
AD  - Department of Medicine, Division of Endocrinology, Centre for Menstrual Cycle and
      Ovulation Research (CeMCOR), University of British Columbia, Vancouver, British
      Columbia, Canada. Jerilynn.prior@ubc.ca.
AD  - School of Population and Public Health, University of British Columbia,
      Vancouver, Canada. Jerilynn.prior@ubc.ca.
AD  - British Columbia Women's Health Research Institute, Vancouver, Canada.
      Jerilynn.prior@ubc.ca.
AD  - Department of Medicine, Division of Endocrinology and Metabolism, University of
      British Columbia, 2775 Laurel Street, Suite 4111, Vancouver, BC, V5Z 1M9, Canada.
      Jerilynn.prior@ubc.ca.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200620
PL  - England
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation
      between the European Foundation for Osteoporosis and the National Osteoporosis
      Foundation of the USA
JID - 9100105
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (SOST protein, human)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - *Adaptor Proteins, Signal Transducing/metabolism
MH  - Estradiol
MH  - Female
MH  - Hot Flashes/drug therapy
MH  - Humans
MH  - Menopause
MH  - Middle Aged
MH  - *Progesterone/pharmacology/therapeutic use
MH  - *Quality of Life
OTO - NOTNLM
OT  - Anabolic
OT  - Hormone therapy
OT  - Progesterone
OT  - Randomized controlled clinical trial
OT  - Sclerostin
EDAT- 2020/06/22 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/22 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PHST- 2020/06/22 06:00 [entrez]
AID - 10.1007/s00198-020-05505-x [doi]
AID - 10.1007/s00198-020-05505-x [pii]
PST - ppublish
SO  - Osteoporos Int. 2020 Nov;31(11):2243-2250. doi: 10.1007/s00198-020-05505-x. Epub 
      2020 Jun 20.


PMID- 32563510
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
VI  - 65
IP  - 843-844
DP  - 2020 Mar - Apr
TI  - [Migrant children: healthcare in a transcultural setting].
PG  - 47-50
LID - S0038-0814(20)30056-6 [pii]
LID - 10.1016/S0038-0814(20)30056-6 [doi]
AB  - Children of migrants develop and grow up with two languages, that of their family
      and that learnt at school, and within the two corresponding worlds. This
      transcultural situation entails a degree of vulnerability, and these children
      need to learn to reconcile the two worlds. In the setting of care, these
      different worlds and languages should be taken into account for what they are.
      This is an ethical requirement, and also a pragmatic approach, contributing to
      the efficacy of the care of these children. In this article we analyse the
      factors to take into account for all to provide adequate care for children of
      migrants, and we explore the modes of referral to specialised transcultural
      consultations if necessary.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Rose Moro, Marie
AU  - Rose Moro M
AD  - Professeur de psychiatrie de l'enfant et de l'adolescent, universite Paris
      Descartes, chef de service de la Maison de Solenn-Maison des adolescents de
      Cochin, AP-HP, directrice de la revue transculturelle L'Autre, Maison de
      Solenn-Maison des adolescents de Cochin 97 boulevard de Port-Royal, 75014 Paris, 
      France; Professeur de psychiatrie de l'enfant et de l'adolescent, universite
      Paris Descartes, chef de service de la Maison de Solenn-Maison des adolescents de
      Cochin, AP-HP, directrice de la revue transculturelle L'Autre, Editions la pensee
      sauvage, 12 place Notre-Dame, 38000 Grenoble, France. Electronic address:
      marie-rose.moro@aphp.fr.
FAU - Radjack, Rahmeth
AU  - Radjack R
AD  - Professeur de psychiatrie de l'enfant et de l'adolescent, universite Paris
      Descartes, chef de service de la Maison de Solenn-Maison des adolescents de
      Cochin, AP-HP, directrice de la revue transculturelle L'Autre, Maison de
      Solenn-Maison des adolescents de Cochin 97 boulevard de Port-Royal, 75014 Paris, 
      France.
LA  - fre
PT  - Journal Article
TT  - L'enfant de migrants, soins en situation transculturelle.
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
MH  - Child
MH  - Delivery of Health Care/*organization & administration
MH  - Humans
MH  - *Multilingualism
MH  - *Transients and Migrants
OTO - NOTNLM
OT  - care trajectory
OT  - enfant de migrant
OT  - interpreter
OT  - interprete
OT  - langue maternelle
OT  - migrant children
OT  - native language
OT  - parcours de soins
OT  - vulnerability is transcultural setting
OT  - vulnerabilite de la situation transculturelle
EDAT- 2020/06/22 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/06/22 06:00
PHST- 2020/06/22 06:00 [entrez]
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - S0038-0814(20)30056-6 [pii]
AID - 10.1016/S0038-0814(20)30056-6 [doi]
PST - ppublish
SO  - Soins. 2020 Mar - Apr;65(843-844):47-50. doi: 10.1016/S0038-0814(20)30056-6.


PMID- 32563502
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
VI  - 65
IP  - 843-844
DP  - 2020 Mar - Apr
TI  - [Migrant health and ethical requirements].
PG  - 24-27
LID - S0038-0814(20)30048-7 [pii]
LID - 10.1016/S0038-0814(20)30048-7 [doi]
AB  - Migrants' health is a subject that is often called up for aspects that are often 
      presented as negative (insecurity, carelessness of public finances, major
      cultural replacement) in the name of which suspicion and rejection take hold.
      This vision does not survive the factual analysis of public health, social and
      economic data. Nevertheless, National Consultative Ethics Committee in its
      opinion 127 in 2017 draws up a serious, and still topical, assessment of the
      situation with regard to the health of migrants. In it, he denounced the use of
      migrant health care as an instrument for political purposes and advocated
      hospitality and fraternity.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Bernabe-Gelot, Antoinette
AU  - Bernabe-Gelot A
AD  - praticien hospitalier, affiliee au collectif Delinquants solidaires Hopital
      Armand-Trousseau AP-HP, service d'anatomie et cytologie pathologiques, 26 avenue 
      du Dr-Arnold-Netter, 75571 Paris cedex 12, France. Electronic address:
      Antoinette.gelot@aphp.fr.
LA  - fre
PT  - Journal Article
TT  - Sante des migrants et exigence ethique.
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
MH  - *Ethics
MH  - *Health Status
MH  - Humans
MH  - *Transients and Migrants
OTO - NOTNLM
OT  - citizenship
OT  - citoyennete
OT  - ethical requirement
OT  - exigence ethique
OT  - fraternity
OT  - fraternite
OT  - migrant
OT  - vulnerability
OT  - vulnerabilite
EDAT- 2020/06/22 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/06/22 06:00
PHST- 2020/06/22 06:00 [entrez]
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - S0038-0814(20)30048-7 [pii]
AID - 10.1016/S0038-0814(20)30048-7 [doi]
PST - ppublish
SO  - Soins. 2020 Mar - Apr;65(843-844):24-27. doi: 10.1016/S0038-0814(20)30048-7.


PMID- 32563294
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 2162-5514 (Electronic)
IS  - 0074-7742 (Linking)
VI  - 153
DP  - 2020
TI  - Maximizing placebo response in neurological clinical practice.
PG  - 71-101
LID - S0074-7742(20)30067-2 [pii]
LID - 10.1016/bs.irn.2020.04.003 [doi]
AB  - The placebo effect is a widely recognized phenomenon in clinical research, with a
      negative perception that it could hide the "true" drug effect. In clinical care
      its positive potential to increase known drug effects has been neglected for too 
      long. The placebo and nocebo responses have been described in many neurologic
      disorders such as Parkinson's, Huntington's and Alzheimer's diseases, restless
      leg syndrome, tics, essential tremor, dystonia, functional movement disorders,
      neuropathic pain, headaches, migraine, amyotrophic lateral sclerosis, myasthenia 
      gravis, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis and
      epilepsy. Knowledge regarding placebo mechanisms and their consequences on
      clinical outcome have greatly improved over the last two decades. This evolution 
      has led to reconsiderations of the importance of placebo response in the clinic
      and has given several clues on how to improve it in daily practice. In this
      chapter, we first illustrate "why," e.g. the reasons (relevance to clinical
      practice, help in differential diagnosis/treatment of psychogenic movements,
      clinical impact, proven neurobiological grounds, health economic potential), and 
      "how," e.g. the means (increase patients' knowledge, increase learning, improve
      patient-doctor relationship, increase Hawthorne effect, increase
      positive/decrease negative expectations (the Rosenthal effect), personalize
      placebo response), the placebo should be maximized (and nocebo avoided) in
      neurological clinical practice. Future studies regarding more specific
      neurobiological mechanisms will allow a finer tuning of placebo response in
      clinical practice. The use of placebo in clinical practice raises ethical issues,
      and a recent expert consensus regarding placebo use in the clinic is a first step
      to future guidelines necessary to this field.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Mariani, Louise-Laure
AU  - Mariani LL
AD  - Department of Neurology, Pitie-Salpetriere Hospital, Sorbonne University,
      Assistance Publique Hopitaux de Paris, Brain and Spine Institute, ICM, Inserm U
      1127, CNRS UMR 7225, Paris, France.
FAU - Corvol, Jean-Christophe
AU  - Corvol JC
AD  - Department of Neurology, Pitie-Salpetriere Hospital, Sorbonne University,
      Assistance Publique Hopitaux de Paris, Brain and Spine Institute, ICM, Inserm U
      1127, CNRS UMR 7225, Paris, France. Electronic address:
      jean-christophe.corvol@aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - United States
TA  - Int Rev Neurobiol
JT  - International review of neurobiology
JID - 0374740
RN  - 0 (Placebos)
SB  - IM
MH  - Humans
MH  - Nervous System Diseases/*therapy
MH  - Personality/*physiology
MH  - *Placebo Effect
MH  - Placebos/*therapeutic use
OTO - NOTNLM
OT  - *Clinical practice
OT  - *Neurological disease
OT  - *Placebo
EDAT- 2020/06/22 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/06/22 06:00
PHST- 2020/06/22 06:00 [entrez]
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
AID - S0074-7742(20)30067-2 [pii]
AID - 10.1016/bs.irn.2020.04.003 [doi]
PST - ppublish
SO  - Int Rev Neurobiol. 2020;153:71-101. doi: 10.1016/bs.irn.2020.04.003. Epub 2020
      Jun 9.


PMID- 32563286
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 2162-5514 (Electronic)
IS  - 0074-7742 (Linking)
VI  - 153
DP  - 2020
TI  - Deception and the ethics of placebo.
PG  - 147-163
LID - S0074-7742(20)30061-1 [pii]
LID - 10.1016/bs.irn.2020.03.030 [doi]
AB  - The placebo effect in many areas of neurological therapeutics is common and
      prominent. The importance of the response means that any new treatment must
      account for the placebo effect, but this in turn raises major challenges as to
      how to conduct scientifically meaningful research in an ethically acceptable
      fashion. Basic principles that may be in tension with one another are those of
      beneficence and respect for autonomy. It may be challenging to respect autonomy
      if the scientific design of a study depends upon the use of deception, but this
      is often mitigated by the information provided to trial participants as part of
      the informed consent process. Deception is a particular challenge if placebos are
      to be used in a clinical/therapeutic setting, outside the context of a clinical
      trial. While practice-based placebo use may on occasion be both beneficial and
      ethically acceptable, close attention must then be paid to ensuring that basic
      ethical principles are respected and that placebos are either prescribed in an
      open and honest fashion, or that any deception is authorized.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Stoessl, A Jon
AU  - Stoessl AJ
AD  - Pacific Parkinson's Research Centre and Djavad Mowafaghian Centre for Brain
      Health, University of British Columbia, Vancouver, BC, Canada. Electronic
      address: jstoessl@mail.ubc.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - United States
TA  - Int Rev Neurobiol
JT  - International review of neurobiology
JID - 0374740
RN  - 0 (Placebos)
SB  - IM
MH  - *Deception
MH  - *Ethics, Medical
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Nervous System Diseases/*therapy
MH  - *Placebo Effect
MH  - Placebos/*therapeutic use
OTO - NOTNLM
OT  - *Authorization
OT  - *Autonomy
OT  - *Beneficence
OT  - *Consent
OT  - *Deception
OT  - *Ethics
OT  - *Hope
OT  - *Justice
OT  - *Placebo
OT  - *Sham
EDAT- 2020/06/22 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/06/22 06:00
PHST- 2020/06/22 06:00 [entrez]
PHST- 2020/06/22 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
AID - S0074-7742(20)30061-1 [pii]
AID - 10.1016/bs.irn.2020.03.030 [doi]
PST - ppublish
SO  - Int Rev Neurobiol. 2020;153:147-163. doi: 10.1016/bs.irn.2020.03.030. Epub 2020
      Jun 9.

{"error":"error forwarding request","api-key":"2001:1715:9d91:5320:4458:f93:206b:14e6","type":"ip",
"status":"ok"}

PMID- 32563105
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20210110
IS  - 1876-2026 (Electronic)
IS  - 1876-2018 (Linking)
VI  - 53
DP  - 2020 Oct
TI  - Ethical standards for telemental health must be maintained during the COVID-19
      pandemic.
PG  - 102218
LID - S1876-2018(20)30330-0 [pii]
LID - 10.1016/j.ajp.2020.102218 [doi]
FAU - Liem, Andrian
AU  - Liem A
AD  - Global and Community Mental Health Research Group, Department of Psychology,
      University of Macau, Macao (SAR), PR China. Electronic address:
      andrian.liem@uq.net.au.
FAU - Sit, Hao Fong
AU  - Sit HF
AD  - Global and Community Mental Health Research Group, Department of Psychology,
      University of Macau, Macao (SAR), PR China. Electronic address:
      yb97314@um.edu.mo.
FAU - Arjadi, Retha
AU  - Arjadi R
AD  - Faculty of Psychology, Atma Jaya Catholic University of Indonesia, Jakarta,
      Indonesia. Electronic address: retha.arjadi@atmajaya.ac.id.
FAU - Patel, Anushka R
AU  - Patel AR
AD  - University of California San Francisco, Department of Psychiatry, 401 Parnassus
      Ave, San Francisco, CA, 94143, USA. Electronic address: Anushka.patel@ucsf.edu.
FAU - Elhai, Jon D
AU  - Elhai JD
AD  - Department of Psychology and Department of Psychiatry, University of Toledo,
      Toledo, Ohio, USA. Electronic address: contact@jon-elhai.com.
FAU - Hall, Brian J
AU  - Hall BJ
AD  - Global and Community Mental Health Research Group, Department of Psychology,
      University of Macau, Macao (SAR), PR China; Department of Health, Behavior and
      Society, Johns Hopkins Bloomberg School of Public Health, USA. Electronic
      address: brianhall@um.edu.mo.
LA  - eng
PT  - Letter
DEP - 20200612
PL  - Netherlands
TA  - Asian J Psychiatr
JT  - Asian journal of psychiatry
JID - 101517820
SB  - IM
MH  - *COVID-19/epidemiology/prevention & control/psychology
MH  - Confidentiality
MH  - *Ethics, Clinical
MH  - Humans
MH  - Internet-Based Intervention
MH  - *Mental Disorders/epidemiology/therapy
MH  - Mental Health Services/*standards
MH  - *Physical Distancing
MH  - Reference Standards
MH  - SARS-CoV-2
MH  - *Telemedicine/ethics/methods/standards
PMC - PMC7291973
EDAT- 2020/06/21 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/09 00:00 [revised]
PHST- 2020/06/10 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S1876-2018(20)30330-0 [pii]
AID - 10.1016/j.ajp.2020.102218 [doi]
PST - ppublish
SO  - Asian J Psychiatr. 2020 Oct;53:102218. doi: 10.1016/j.ajp.2020.102218. Epub 2020 
      Jun 12.


PMID- 32563039
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20210110
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 92
DP  - 2020 Sep
TI  - "The COVID-19 outbreak"-An empirical phenomenological study on perceptions and
      psychosocial considerations surrounding the immediate incorporation of final-year
      Spanish nursing and medical students into the health system.
PG  - 104504
LID - S0260-6917(20)30840-6 [pii]
LID - 10.1016/j.nedt.2020.104504 [doi]
AB  - The COVID-19 pandemic has caused an unprecedented health crisis worldwide, with
      the numbers of infections and deaths worldwide multiplying alarmingly in a matter
      of weeks. Accordingly, governments have been forced to take drastic actions such 
      as the confinement of the population and the suspension of face-to-face teaching.
      In Spain, due to the collapse of the health system the government has been forced
      to take a series of important measures such as requesting the voluntary
      incorporation of final-year nursing and medical students into the health system. 
      The objective of the present work is to study, using a phenomenological
      qualitative approach, the perceptions of students in this exceptional actual
      situation. A total of 62 interviews were carried out with final-year nursing and 
      medicine students from Jaime I University (Spain), with 85% reporting having
      voluntarily joined the health system for ethical and moral reasons. Results from 
      the inductive analysis of the descriptions highlighted two main categories and a 
      total of five sub-categories. The main feelings collected regarding mood were
      negative, represented by uncertainty, nervousness, and fear. This study provides 
      a description of the perceptions of final-year nursing and medical students with 
      respect to their immediate incorporation into a health system aggravated by a
      global crisis.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Collado-Boira, Eladio J
AU  - Collado-Boira EJ
AD  - Faculty of Health Sciences, Jaime I University, Castellon, Spain.
FAU - Ruiz-Palomino, Estefania
AU  - Ruiz-Palomino E
AD  - Faculty of Health Sciences, Jaime I University, Castellon, Spain.
FAU - Salas-Media, Pablo
AU  - Salas-Media P
AD  - Faculty of Health Sciences, Jaime I University, Castellon, Spain.
FAU - Folch-Ayora, Ana
AU  - Folch-Ayora A
AD  - Faculty of Health Sciences, Jaime I University, Castellon, Spain.
FAU - Muriach, Maria
AU  - Muriach M
AD  - Faculty of Health Sciences, Jaime I University, Castellon, Spain.
FAU - Balino, Pablo
AU  - Balino P
AD  - Faculty of Health Sciences, Jaime I University, Castellon, Spain. Electronic
      address: balino@uji.es.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Adult
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - Delivery of Health Care/*organization & administration
MH  - *Disease Outbreaks
MH  - Emotions
MH  - Empirical Research
MH  - Female
MH  - Humans
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*therapy
MH  - Spain/epidemiology
MH  - Students, Medical/*psychology/statistics & numerical data
MH  - Students, Nursing/*psychology/statistics & numerical data
MH  - Universities
MH  - Young Adult
PMC - PMC7289744
OTO - NOTNLM
OT  - COVID-19
OT  - Health crisis
OT  - Health sciences
OT  - Phenomenological study
OT  - Students
EDAT- 2020/06/21 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S0260-6917(20)30840-6 [pii]
AID - 10.1016/j.nedt.2020.104504 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Sep;92:104504. doi: 10.1016/j.nedt.2020.104504. Epub 2020 
      Jun 12.


PMID- 32562801
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 882
DP  - 2020 Sep 5
TI  - Reprogramming and transdifferentiation - two key processes for regenerative
      medicine.
PG  - 173202
LID - S0014-2999(20)30294-6 [pii]
LID - 10.1016/j.ejphar.2020.173202 [doi]
AB  - Regenerative medicine based on transplants obtained from donors or foetal and
      new-born mesenchymal stem cells, encounter important obstacles such as limited
      availability of organs, ethical issues and immune rejection. The growing demand
      for therapeutic methods for patients being treated after serious accidents,
      severe organ dysfunction and an increasing number of cancer surgeries, exceeds
      the possibilities of the therapies that are currently available. Reprogramming
      and transdifferentiation provide powerful bioengineering tools. Both procedures
      are based on the somatic differentiated cells, which are easily and unlimitedly
      available, like for example: fibroblasts. During the reprogramming procedure
      mature cells are converted into pluripotent cells - which are capable to
      differentiate into almost any kind of desired cells. Transdifferentiation
      directly converts differentiated cells of one type into another differentiated
      cells type. Both procedures allow to obtained patient's dedicated cells for
      therapeutic purpose in regenerative medicine. In combination with biomaterials,
      it is possible to obtain even whole anatomical structures. Those patient's
      dedicated structures may serve for them upon serious accidents with massive
      tissue damage but also upon cancer surgeries as a replacement of damaged organ.
      Detailed information about reprogramming and transdifferentiation procedures as
      well as the current state of the art are presented in our review.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Hybiak, Jolanta
AU  - Hybiak J
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
      Electronic address: jhybiak@pum.edu.pl.
FAU - Jankowska, Kornelia
AU  - Jankowska K
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Machaj, Filip
AU  - Machaj F
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Rosik, Jakub
AU  - Rosik J
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Broniarek, Izabela
AU  - Broniarek I
AD  - Department of Gene Expression, Institute of Molecular Biology and Biotechnology, 
      Adam Mickiewicz University Poznan, Poland.
FAU - Zyluk, Andrzej
AU  - Zyluk A
AD  - Department of General and Hand Surgery, Pomeranian Medical University, Szczecin, 
      Poland.
FAU - Hilderman, Gordon C
AU  - Hilderman GC
AD  - Faculty of Science, University of Manitoba, Winnipeg, Canada.
FAU - Malecki, Andrzej
AU  - Malecki A
AD  - Faculty of Physiotherapy, The Jerzy Kukuczka Academy of Physical Education in
      Katowice, Katowice, Poland.
FAU - Los, Marek J
AU  - Los MJ
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
FAU - Urasinska, Elzbieta
AU  - Urasinska E
AD  - Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200618
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
SB  - IM
MH  - Animals
MH  - *Cell Transdifferentiation
MH  - *Cellular Reprogramming
MH  - Humans
MH  - *Regenerative Medicine
OTO - NOTNLM
OT  - Metaplasia
OT  - Mogrify
OT  - Redifferentiation
OT  - Reprogramming
OT  - Transdifferentiation
EDAT- 2020/06/21 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/06/21 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S0014-2999(20)30294-6 [pii]
AID - 10.1016/j.ejphar.2020.173202 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2020 Sep 5;882:173202. doi: 10.1016/j.ejphar.2020.173202. Epub
      2020 Jun 18.


PMID- 32562594
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20220716
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Jul
TI  - Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical
      Frameworks of Inclusion in Clinical Trials.
PG  - 17-23
LID - 10.1002/eahr.500060 [doi]
AB  - Ethical issues abound during this unprecedented international public health
      crisis of Covid-19. While the trade-off between societal and individual interests
      that occurs at the intersection of public health ethics and clinical ethics
      affects all populations, this calculus has particular relevance for pregnant
      women and the question of when they will have access to new Covid-19 therapies
      and vaccines. Pregnant women are a "scientifically complex" population whose
      inclusion in clinical research must be done with consideration of the unique
      state of pregnancy. Yet research on the impact of Covid-19 on pregnant women is
      lagging. In a rush to prevent and treat SARS-CoV-2 infection, it is crucial that 
      the interests of pregnant women be prioritized to enable them to make autonomous,
      informed decisions about participating in clinical trials. The global pandemic
      calls for a revisiting of frameworks for the inclusion of pregnant women in
      research, as these women have an important stake in the prevention and treatment 
      of Covid-19.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Farrell, Ruth
AU  - Farrell R
AD  - Vice chair of research in the OB/GYN & Women's Health Institute at the Cleveland 
      Clinic.
FAU - Michie, Marsha
AU  - Michie M
AD  - Assistant professor in the Department of Bioethics at Case Western Reserve
      University School of Medicine.
FAU - Pope, Rachel
AU  - Pope R
AD  - Obstetrician-gynecologist at University Hospitals Cleveland Medical Center
      working with the Cuyahoga County Board of Health on Covid-19 management.
LA  - eng
GR  - R01 HG011480/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20200620
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/*complications/prevention & control/therapy
MH  - Female
MH  - Health Policy
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*complications/prevention & control/therapy
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/prevention & control/therapy/*virology
MH  - Research Subjects
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7323073
OTO - NOTNLM
OT  - Covid-19 clinical trials
OT  - human subjects research
OT  - inclusion of pregnant women in trials
OT  - maternal-fetal ethics
OT  - pregnant research participants
OT  - research with pregnant women
EDAT- 2020/06/21 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - 10.1002/eahr.500060 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Jul;42(4):17-23. doi: 10.1002/eahr.500060. Epub 2020 Jun 20.


PMID- 32562512
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20210110
IS  - 2044-8287 (Electronic)
IS  - 1359-107X (Linking)
VI  - 25
IP  - 4
DP  - 2020 Nov
TI  - Preferences for scarce medical resource allocation: Differences between experts
      and the general public and implications for the COVID-19 pandemic.
PG  - 889-901
LID - 10.1111/bjhp.12439 [doi]
AB  - This study concerns what lay people believe is the best way to allocate scarce
      medical resources. A sample of 515 individuals completed a short questionnaire
      asking them to rank-order eight different ethical positions with respect to the
      allocation of scarce resources. They showed a strong preference for the 'saves
      most lives' and 'sickest first' options, with 'reciprocity' and a 'lottery' being
      least favoured. There was a reasonable degree of unanimity amongst respondents
      and comparatively few correlations with individual difference factors such as
      demography. The preference results are compared to expert recommendations
      (Emanuel et al., 2020, N. Engl. J. Med., 382, 2049) made in light of the current 
      coronavirus pandemic, and differences are highlighted. Implications for scare
      medical resource allocations are discussed, and limitations of the study
      acknowledged.
CI  - (c) 2020 The British Psychological Society.
FAU - Grover, Simmy
AU  - Grover S
AUID- ORCID: 0000-0002-6726-7645
AD  - Department of Experimental Psychology, University College London, UK.
FAU - McClelland, Alastair
AU  - McClelland A
AUID- ORCID: 0000-0001-8714-9040
AD  - Department of Experimental Psychology, University College London, UK.
FAU - Furnham, Adrian
AU  - Furnham A
AUID- ORCID: 0000-0001-7545-8532
AD  - Norwegian Business School (BI), Olso, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200620
PL  - England
TA  - Br J Health Psychol
JT  - British journal of health psychology
JID - 9605409
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Health Care Rationing
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7323072
OTO - NOTNLM
OT  - *ethics
OT  - *lottery
OT  - *resource allocation
OT  - *utilitarianism
EDAT- 2020/06/21 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - 10.1111/bjhp.12439 [doi]
PST - ppublish
SO  - Br J Health Psychol. 2020 Nov;25(4):889-901. doi: 10.1111/bjhp.12439. Epub 2020
      Jun 20.


PMID- 32562478
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2213-5383 (Print)
IS  - 2213-5383 (Linking)
VI  - 25
DP  - 2020 Sep
TI  - Liability of clinical oncologists and the COVID-19 emergency: Between hopes and
      concerns.
PG  - 100234
LID - 10.1016/j.jcpo.2020.100234 [doi]
AB  - To contain COVID-19 spread, Italy is under a global lockdown since February 21,
      2020, except for health services and food supply. In this scenario, growing
      apprehension concerning legal consequences is rising among health professionals
      due to several ethical and legal questions. Even if medical ethicists may approve
      patients' prioritization protocols, hospitals and health professionals remain
      highly exposed to liability. The so-called smart-working may be very useful, but 
      it may harbor potential legal harms for health personnel and patients and safety.
      Moreover, personal umbrella policies also often exclude liability arising out of 
      the transmission of a communicable disease, especially a pandemic state, is
      declared. Under the pressure of medical associations, Italian Government
      political forces have very recently presented an amendment to the recently
      released ordinances for the COVID-19 emergency aimed to reduce medical liability.
      Presumably, similar epidemics or other wide-scale similar events may happen again
      in an unpredictable future. Therefore, more articulated legal regulations are
      strongly needed starting from lessons learned from this epidemic.
CI  - (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Gebbia, Vittorio
AU  - Gebbia V
AD  - Medical Oncology Unit, La Maddalena Clinic for Cancer, Chair of Medical Oncology,
      Department Promise, University of Palermo, Italy.
AD  - Consultant at the Labor Court, Palermo, Italy.
FAU - Bordonaro, Roberto
AU  - Bordonaro R
AD  - Medical Oncology Unit, Ospedale Garibaldi, Arnas, Catania, Italy.
FAU - Blasi, Livio
AU  - Blasi L
AD  - Medical Oncology Unit, Ospedale Civico, Arnas, Palermo, Italy.
FAU - Piazza, Dario
AU  - Piazza D
AD  - GSTU Foundation, Palermo, Italy.
FAU - Pellegrino, Alessandro
AU  - Pellegrino A
AD  - Ctl Advisory Legal Firm - Managing Partner, Milan, Italy.
FAU - Iacono, Carmelo
AU  - Iacono C
AD  - Provincial Health Service Caltanissetta, Italy.
FAU - Spada, Massimiliano
AU  - Spada M
AD  - Medical Oncology, Giglio Foundation, Cefalu, Italy.
FAU - Tralongo, Paolo
AU  - Tralongo P
AD  - Medical Oncology Siracusa Hospital, Italy.
FAU - Firenze, Alberto
AU  - Firenze A
AD  - Risk Management Unit, AOUP P. Giaccone, Palermo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200609
PL  - England
TA  - J Cancer Policy
JT  - Journal of cancer policy
JID - 101639933
PMC - PMC7282757
OTO - NOTNLM
OT  - Clinical risk management
OT  - Ethics
OT  - Healthcare professional
OT  - Legal
OT  - SARS-CoV-2
COIS- None to declare.
EDAT- 2020/06/21 06:00
MHDA- 2020/06/21 06:01
CRDT- 2020/06/21 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/21 06:00 [entrez]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/06/21 06:01 [medline]
AID - 10.1016/j.jcpo.2020.100234 [doi]
AID - S2213-5383(20)30026-6 [pii]
AID - 100234 [pii]
PST - ppublish
SO  - J Cancer Policy. 2020 Sep;25:100234. doi: 10.1016/j.jcpo.2020.100234. Epub 2020
      Jun 9.


PMID- 32562370
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 23 Suppl 1
DP  - 2020 Jun
TI  - Integrating care for non-communicable diseases into routine HIV services: key
      considerations for policy design in sub-Saharan Africa.
PG  - e25508
LID - 10.1002/jia2.25508 [doi]
AB  - INTRODUCTION: There is great interest for integrating care for non-communicable
      diseases (NCDs) into routine HIV services in sub-Saharan Africa (SSA) due to the 
      steady rise of the number of people who are ageing with HIV. Suggested health
      system approaches for intervening on these comorbidities have mostly been
      normative, with little actionable guidance on implementation, and on the
      practical, economic and ethical considerations of favouring people living with
      HIV (PLHIV) versus targeting the general population. We summarize opportunities
      and challenges related to leveraging HIV treatment platforms to address NCDs
      among PLHIV. We emphasize key considerations that can guide integrated care in
      SSA and point to possible interventions for implementation. DISCUSSION:
      Integrating care offers an opportunity for effective delivery of NCD services to 
      PLHIV, but may be viewed to unfairly ignore the larger number of NCD cases in the
      general population. Integration can also help maintain the substantial health and
      economic benefits that have been achieved by the global HIV/AIDS response.
      Implementing interventions for integrated care will require assessing the
      prevalence of common NCDs among PLHIV, which can be achieved via increased
      screening during routine HIV care. Successful integration will also necessitate
      earmarking funds for NCD interventions in national budgets. CONCLUSIONS: An
      expanded agenda for addressing HIV-NCD comorbidities in SSA may require adding
      selected NCDs to conditions that are routinely monitored in PLHIV. Attention
      should be given to mitigating potential tradeoffs in the quality of HIV services 
      that may result from the extra responsibilities borne by HIV health workers.
      Integrated care will more likely be effective in the context of concurrent health
      system reforms that address NCDs in the general population, and with synergies
      with other HIV investments that have been used to strengthen health systems.
CI  - (c) 2020 The Authors. Journal of the International AIDS Society published by John
      Wiley & Sons Ltd on behalf of the International AIDS Society.
FAU - Kintu, Alexander
AU  - Kintu A
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Sando, David
AU  - Sando D
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Okello, Samson
AU  - Okello S
AUID- ORCID: 0000-0001-7377-6094
AD  - Department of Internal Medicine, Mbarara University of Science and Technology,
      Mbarara, Uganda.
FAU - Mutungi, Gerald
AU  - Mutungi G
AD  - Department of Non-Communicable Diseases Prevention and Control, Ministry of
      Health, Kampala, Uganda.
FAU - Guwatudde, David
AU  - Guwatudde D
AD  - Department of Epidemiology and Biostatistics, School of Public Health, College of
      Health Sciences, Makerere University, Kampala, Uganda.
FAU - Menzies, Nicolas A
AU  - Menzies NA
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Danaei, Goodarz
AU  - Danaei G
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      MA, USA.
FAU - Verguet, Stephane
AU  - Verguet S
AUID- ORCID: 0000-0003-4128-0849
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
LA  - eng
GR  - T32 A1007433/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Switzerland
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - *Delivery of Health Care, Integrated
MH  - Female
MH  - HIV Infections/epidemiology/*therapy
MH  - *Health Policy
MH  - Humans
MH  - Male
MH  - Mass Screening
MH  - Noncommunicable Diseases/epidemiology/*therapy
MH  - Prevalence
PMC - PMC7305410
OTO - NOTNLM
OT  - *HIV/AIDS
OT  - *antiretroviral therapy
OT  - *integrated care
OT  - *non-communicable diseases
OT  - *sub-Saharan Africa
EDAT- 2020/06/21 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/06/21 06:00
PHST- 2019/09/28 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/06/21 06:00 [entrez]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - 10.1002/jia2.25508 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2020 Jun;23 Suppl 1:e25508. doi: 10.1002/jia2.25508.


PMID- 32561661
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20220716
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Why lockdown of the elderly is not ageist and why levelling down equality is
      wrong.
PG  - 717-721
LID - 10.1136/medethics-2020-106336 [doi]
AB  - In order to prevent the rapid spread of COVID-19, governments have placed
      significant restrictions on liberty, including preventing all non-essential
      travel. These restrictions were justified on the basis the health system may be
      overwhelmed by COVID-19 cases and in order to prevent deaths. Governments are now
      considering how they may de-escalate these restrictions. This article argues that
      an appropriate approach may be to lift the general lockdown but implement
      selective isolation of the elderly. While this discriminates against the elderly,
      there is a morally relevant difference-the elderly are far more likely to require
      hospitalisation and die than the rest of the population. If the aim is to ensure 
      the health system is not overwhelmed and to reduce the death rate, preventing the
      elderly from contracting the virus may be an effective means of achieving this.
      The alternative is to continue to keep everyone in lockdown. It is argued that
      this is levelling down equality and is unethical. It suggests that in order for
      the elderly to avoid contracting the virus, the whole population should have
      their liberty deprived, even though the same result could be achieved by only
      restricting the liberty of the elderly. Similar arguments may also be applied to 
      all groups at increased risk of COVID-19, such as men and those with
      comorbidities, the obese and people from ethnic minorities or socially deprived
      groups. This utilitarian concern must be balanced against other considerations,
      such as equality and justice, and the benefits gained from discriminating in
      these ways must be proportionately greater than the negative consequences of
      doing so. Such selective discrimination will be most justified when the liberty
      restriction to a group promotes the well-being of that group (apart from its
      wider social benefits).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Faculty of Philosophy, Uehiro Centre for Practical Ethics, University of Oxford, 
      Oxford, UK julian.savulescu@philosophy.ox.ac.uk.
AD  - Biomedical Ethics Research Group, Murdoch Childrens Research Institute,
      Parkville, Victoria, Australia.
FAU - Cameron, James
AU  - Cameron J
AD  - Biomedical Ethics Research Group, Murdoch Childrens Research Institute,
      Parkville, Victoria, Australia.
AD  - Melbourne Law School, The University of Melbourne, Carlton, Victoria, Australia.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - 203132/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200619
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Nov;46(11):724-725. PMID: 32817409
CIN - J Med Ethics. 2020 Nov;46(11):722-723. PMID: 32847943
CIN - J Med Ethics. 2020 Nov;46(11):713-714. PMID: 33115933
CIN - J Med Ethics. 2021 Sep;47(9):645-646. PMID: 33441302
MH  - Aged
MH  - *Ageism
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control/virology
MH  - Female
MH  - Freedom
MH  - *Human Rights
MH  - Humans
MH  - Male
MH  - Morals
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control/virology
MH  - Public Health/*ethics
MH  - Public Policy
MH  - *Quarantine
MH  - SARS-CoV-2
MH  - *Social Isolation
MH  - Social Justice
PMC - PMC7335694
OTO - NOTNLM
OT  - *aged
OT  - *ethics
OT  - *philosophical ethics
OT  - *public health ethics
OT  - *public policy
COIS- Competing interests: None declared.
EDAT- 2020/06/21 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - medethics-2020-106336 [pii]
AID - 10.1136/medethics-2020-106336 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):717-721. doi: 10.1136/medethics-2020-106336. Epub
      2020 Jun 19.


PMID- 32561660
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Dying individuals and suffering populations: applying a population-level
      bioethics lens to palliative care in humanitarian contexts: before, during and
      after the COVID-19 pandemic.
PG  - 514-525
LID - 10.1136/medethics-2019-105943 [doi]
AB  - BACKGROUND: Humanitarian crises and emergencies, events often marked by high
      mortality, have until recently excluded palliative care-a specialty focusing on
      supporting people with serious or terminal illness or those nearing death. In the
      COVID-19 pandemic, palliative care has received unprecedented levels of societal 
      attention. Unfortunately, this has not been enough to prevent patients dying
      alone, relatives not being able to say goodbye and palliative care being used
      instead of intensive care due to resource limitations. Yet global guidance was
      available. In 2018, the WHO released a guide on 'Integrating palliative care and 
      symptom relief into the response to humanitarian emergencies and crises'-the
      first guidance on the topic by an international body. AIMS: This paper argues
      that while a landmark document, the WHO guide took a narrowly clinical bioethics 
      perspective and missed crucial moral dilemmas. We argue for adding a
      population-level bioethics lens, which draws forth complex moral dilemmas arising
      from the fact that groups having differential innate and acquired resources in
      the context of social and historical determinants of health. We discuss dilemmas 
      concerning: limitations of material and human resources; patient prioritisation; 
      euthanasia; and legacy inequalities, discrimination and power imbalances.
      IMPLICATIONS: In parts of the world where opportunity for preparation still
      exists, and as countries emerge from COVID-19, planners must consider care for
      the dying. Immediate steps to support better resolutions to ethical dilemmas of
      the provision of palliative care in humanitarian and emergency contexts will
      require honest debate; concerted research effort; and international, national and
      local ethical guidance.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Wynne, Keona Jeane
AU  - Wynne KJ
AUID- ORCID: 0000-0002-4051-8109
AD  - Social and Behavioral Sciences, Harvard University T H Chan School of Public
      Health, Boston, Massachusetts, USA kjwynne@g.harvard.edu.
AD  - Center for Bioethics, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Petrova, Mila
AU  - Petrova M
AUID- ORCID: 0000-0001-7351-6815
AD  - Cambridge Palliative and End of Life Care Group, Primary Care Unit, Department of
      Public Health and Primary Care, University of Cambridge, Cambridge, UK.
FAU - Coghlan, Rachel
AU  - Coghlan R
AUID- ORCID: 0000-0002-3596-4630
AD  - Centre for Humanitarian Leadership, Deakin University, Burwood, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Altruism
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - Bioethics
MH  - COVID-19
MH  - Coronavirus Infections/therapy/virology
MH  - Critical Care
MH  - Decision Making/ethics
MH  - Delivery of Health Care/*ethics
MH  - *Disaster Planning
MH  - Emergencies
MH  - Ethics, Clinical
MH  - Global Health
MH  - Health Care Rationing
MH  - Health Equity
MH  - Health Resources
MH  - Humans
MH  - Palliative Care/*ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/therapy/virology
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Socioeconomic Factors
MH  - Stress, Psychological
MH  - Terminal Care/*ethics
PMC - PMC7418598
OTO - NOTNLM
OT  - *palliative care
OT  - *public health ethics
COIS- Competing interests: MP reports that she is a Steering Group member of Palliative
      Care in Humanitarian Aid Situations and Emergencies network. RC reports that she 
      is a member of the Palliative Care in Humanitarian Aid Situations and Emergencies
      network.
EDAT- 2020/06/21 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/06/21 06:00
PHST- 2019/11/05 00:00 [received]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - medethics-2019-105943 [pii]
AID - 10.1136/medethics-2019-105943 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):514-525. doi: 10.1136/medethics-2019-105943. Epub
      2020 Jun 19.


PMID- 32561520
OWN - NLM
STAT- MEDLINE
DCOM- 20200708
LR  - 20200708
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 Jun 19
TI  - Ethical decision making in a pandemic: where are the voices of vulnerable people?
PG  - m2406
LID - 10.1136/bmj.m2406 [doi]
FAU - McCullough, Melissa
AU  - McCullough M
AD  - Health and Social Care Board Northern Ireland.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
MH  - Decision Making, Organizational
MH  - Disaster Planning/organization & administration
MH  - Health Care Rationing/*ethics/legislation & jurisprudence
MH  - Hospital Administrators/ethics
MH  - Humans
MH  - Moral Obligations
MH  - *Pandemics
MH  - Resource Allocation/ethics/*organization & administration
MH  - Social Values
MH  - United Kingdom
MH  - *Vulnerable Populations
COIS- Competing interests: We have read and understood BMJ policy on declaration of
      interests and have the following interests to declare: None
EDAT- 2020/06/21 06:00
MHDA- 2020/07/09 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/06/21 06:00 [entrez]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
AID - 10.1136/bmj.m2406 [doi]
PST - epublish
SO  - BMJ. 2020 Jun 19;369:m2406. doi: 10.1136/bmj.m2406.


PMID- 32561486
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 141
DP  - 2020 Sep
TI  - Virtual Reality in Neurosurgery: "Can You See It?"-A Review of the Current
      Applications and Future Potential.
PG  - 291-298
LID - S1878-8750(20)31324-3 [pii]
LID - 10.1016/j.wneu.2020.06.066 [doi]
AB  - Virtual reality (VR) technology had its early development in the 1960s in the
      U.S. Air Force and has since evolved into a budding area of scientific research
      with many practical medical purposes. From medical education to resident training
      to the operating room, VR has provided tangible benefits to learners and trainees
      and has also improved surgery through enhanced preoperative planning and
      efficiency in the operating room. Neurosurgery is a particularly complex field of
      medicine, in which VR has blossomed into a tool with great usefulness and
      promise. In spinal surgery, VR simulation has allowed for the practice of
      innovative minimally invasive procedures. In cranial surgery, VR has excelled in 
      helping neurosurgeons design unique patient-specific approaches to particularly
      challenging tumor excisions. In neurovascular surgery, VR has helped trainees
      practice and perfect procedures requiring high levels of dexterity to minimize
      intraoperative complications and patient radiation exposure. In peripheral nerve 
      surgery, VR has allowed surgeons to gain increased practice and comfort with
      complex microsurgeries such as nerve decompression. Overall, VR continues to
      increase its potential in neurosurgery and is poised to benefit patients in a
      multitude of ways. Although cost-prohibiting, legal, and ethical challenges
      surrounding this technology must be considered, future research and more direct
      quantitative outcome comparisons between standard and VR-supplemented procedures 
      would help provide more direction regarding the feasibility of widespread
      adoption of VR technology in neurosurgery.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Fiani, Brian
AU  - Fiani B
AD  - Department of Neurosurgery, Desert Regional Medical Center, Palm Springs,
      Colorado, USA. Electronic address: bfiani@outlook.com.
FAU - De Stefano, Frank
AU  - De Stefano F
AD  - Kansas City University School of Medicine, Kansas City, Missouri, USA.
FAU - Kondilis, Athanasios
AU  - Kondilis A
AD  - Michigan State University College of Osteopathic Medicine, East Lansing,
      Michigan, USA.
FAU - Covarrubias, Claudia
AU  - Covarrubias C
AD  - Universidad Anahuac Queretaro Escuela de Medicina, Santiago de Queretaro,
      Queretaro, Mexico.
FAU - Reier, Louis
AU  - Reier L
AD  - Department of Neurosurgery, Desert Regional Medical Center, Palm Springs,
      Colorado, USA.
FAU - Sarhadi, Kasra
AU  - Sarhadi K
AD  - Miller School of Medicine, University of Miami, Miami, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200617
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
SB  - IM
MH  - Computer Simulation
MH  - Humans
MH  - *Neurosurgeons
MH  - Neurosurgery/*education
MH  - *Neurosurgical Procedures/methods
MH  - *Surgery, Computer-Assisted/methods
MH  - Virtual Reality
OTO - NOTNLM
OT  - *Augmented reality
OT  - *Mixed reality
OT  - *Neurosurgery
OT  - *Neurosurgical technology
OT  - *Virtual reality
EDAT- 2020/06/21 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/06/07 00:00 [revised]
PHST- 2020/06/07 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S1878-8750(20)31324-3 [pii]
AID - 10.1016/j.wneu.2020.06.066 [doi]
PST - ppublish
SO  - World Neurosurg. 2020 Sep;141:291-298. doi: 10.1016/j.wneu.2020.06.066. Epub 2020
      Jun 17.


PMID- 32561374
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20201218
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 83
IP  - 3
DP  - 2020 Sep
TI  - The ethics of charging patients an infection control fee in the context of
      COVID-19.
PG  - 981-982
LID - S0190-9622(20)31137-3 [pii]
LID - 10.1016/j.jaad.2020.06.040 [doi]
FAU - Muzumdar, Sonal
AU  - Muzumdar S
AD  - University of Connecticut School of Medicine, Farmington, Connecticut.
FAU - Grant-Kels, Jane M
AU  - Grant-Kels JM
AD  - Department of Dermatology, University of Connecticut Health Center, Farmington,
      Connecticut.
FAU - Feng, Hao
AU  - Feng H
AD  - Department of Dermatology, University of Connecticut Health Center, Farmington,
      Connecticut. Electronic address: haofeng625@gmail.com.
LA  - eng
PT  - Letter
DEP - 20200617
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
SB  - IM
MH  - Betacoronavirus/pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control/transmission/virology
MH  - Dermatology/*economics/ethics/standards
MH  - Health Expenditures/*ethics
MH  - Humans
MH  - Infection Control/*economics/standards
MH  - Office Visits/*economics
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control/transmission/virology
MH  - SARS-CoV-2
PMC - PMC7298476
EDAT- 2020/06/21 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/05/26 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S0190-9622(20)31137-3 [pii]
AID - 10.1016/j.jaad.2020.06.040 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2020 Sep;83(3):981-982. doi: 10.1016/j.jaad.2020.06.040. Epub
      2020 Jun 17.


PMID- 32561330
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2050-1161 (Print)
IS  - 2050-1161 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Sep
TI  - Olfactory Exposure to beta-Caryophyllene Increases Testosterone Levels in Women's
      Saliva.
PG  - 525-531
LID - S2050-1161(20)30077-5 [pii]
LID - 10.1016/j.esxm.2020.06.001 [doi]
AB  - INTRODUCTION: From previous studies, we hypothesized that olfactory exposure to
      beta-caryophyllene stimulates women's libido. However, Japan's sex culture is so 
      closed that it is difficult to test this possibility without accumulating
      scientific evidence. Therefore, it is necessary to measure the concentration of
      sex-related hormones in saliva, an experimental technique that is relatively easy
      to obtain research permission, and to obtain a scientific basis to convince
      ethics committee reviewers. AIM: The aim of this study is to investigate whether 
      beta-caryophyllene increases salivary testosterone concentrations associated with
      libido and vaginal sensation during intercourse in women. METHODS: 19 women in
      the follicular phase of the menstrual cycle participated in the study. The
      subjects then sat in front of the odor exposure device we had created. Each
      subject was exposed to dipropylene glycol for 20 minutes, followed by 3%
      beta-caryophyllene for 20 minutes. Saliva was collected 4 times: before and after
      control exposure, and before and after beta-caryophyllene exposure. MAIN OUTCOME 
      MEASURE: Salivary testosterone and estrogen concentrations were measured with a
      competition ELISA. RESULTS: beta-caryophyllene significantly increased the
      salivary concentration of testosterone (control vs beta-caryophyllene; 0.97 +/-
      0.05 vs 1.13 +/- 0.03, P = .00, 95% confidence interval of control: 0.84-1.09,
      95% confidence interval of beta-caryophyllene: 1.04-1.20) but not estrogen
      (control vs beta-caryophyllene; 1.05 +/- 0.03 vs 1.07 +/- 0.04, P = .69, 95%
      confidence interval of control: 0.96-1.12, 95% confidence interval of
      beta-caryophyllene: 0.98-1.15). STRENGTHS & LIMITATIONS: The personal preferences
      of the subjects and the order of exposure may have affected the results.
      CONCLUSION: beta-caryophyllene may be a remedy with fewer side effects for women 
      with decreased libido. We believe that beta-caryophyllene may be a remedy for
      women with decreased libido. However, this hypothesis must be tested by further
      clinical studies. Wataru Tarumi, Kazuyuki Shinohara. Olfactory Exposure to
      beta-Caryophyllene Increases Testosterone Levels in Women's Saliva. J Sex Med
      2020;8:525-531.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Tarumi, Wataru
AU  - Tarumi W
AD  - Division of Neurobiology and Behavior Department of Translational Medical
      Sciences Course of Medical and Dental Sciences Nagasaki University, Graduate
      School of Biomedical Sciences, Nagasaki, Japan.
FAU - Shinohara, Kazuyuki
AU  - Shinohara K
AD  - Division of Neurobiology and Behavior Department of Translational Medical
      Sciences Course of Medical and Dental Sciences Nagasaki University, Graduate
      School of Biomedical Sciences, Nagasaki, Japan. Electronic address:
      nagasakiphysiol2@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - United States
TA  - Sex Med
JT  - Sexual medicine
JID - 101631053
PMC - PMC7471126
OTO - NOTNLM
OT  - Aphrodisiac
OT  - Pheromone
OT  - Sexuality
OT  - Testosterone
OT  - Ylang-ylang
OT  - beta-caryophyllene
EDAT- 2020/06/21 06:00
MHDA- 2020/06/21 06:01
CRDT- 2020/06/21 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/06/21 06:01 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S2050-1161(20)30077-5 [pii]
AID - 10.1016/j.esxm.2020.06.001 [doi]
PST - ppublish
SO  - Sex Med. 2020 Sep;8(3):525-531. doi: 10.1016/j.esxm.2020.06.001. Epub 2020 Jun
      16.


PMID- 32561083
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1879-3320 (Electronic)
IS  - 0960-7404 (Linking)
VI  - 33
DP  - 2020 Jun
TI  - A safe and novel method for video-assisted thoracic surgery preoperative
      localization of small pulmonary nodules by using ZT medical glue (2-octyl
      cyanoacrylate).
PG  - 164-169
LID - S0960-7404(19)30660-7 [pii]
LID - 10.1016/j.suronc.2020.02.001 [doi]
AB  - BACKGROUND: Accurate and fast localization of small pulmonary nodules is required
      for local pulmonary resection. In this study, we introduced and assessed a novel 
      technique for the preoperative localization of small pulmonary nodules by using
      ZT medical glue (2-octyl cyanoacrylate). METHODS: 101 patients who had a combined
      total of 106 small pulmonary nodules located by ZT glue and 53patients with 53
      small pulmonary nodules located by hookwire were selected. Guided by computed
      tomography (CT), the surgeon injected certain volume ZT glue into an area
      adjacent to the small pulmonary nodule, then, the adjacent lung tissue
      infiltrated by ZT glue formed into a depressed hard nodule which can be used for 
      preoperative localization with an obvious mark on lung surface or different hand 
      touch. After localization, Wedge resection was performed via video-assisted
      thoracoscopic surgery and the specimen obtained from the procedure was
      immediately sent for pathological examination, followed by a standard surgical
      procedure. A contrast has been made between the ZT glue method and the hookwire. 
      RESULTS: 101 operations were successfully performed by using this novel
      technique, and 106 small pulmonary nodules were successfully located. Compared
      with the hookwire location, ZT glue method obviouslyextended the Time interval
      between localization and operation (P = 0.00) and a same complication rate (P =
      0.07). CONCLUSIONS: The use of ZT glue is a safe and effective method for the
      localization of small pulmonary nodules. TRIAL REGISTRATION: This study was
      approved by the ethics committee of Shaoxing People's Hospital (Number:2016-004, 
      Date:2016,2,24), and informed consent was obtained from all enrolled patients.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Wang, Bin
AU  - Wang B
AD  - Department of Cardiothoracic Surgery, Shaoxing People's Hospital (Shaoxing
      Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang Province,
      China.
FAU - Zeng, Yong
AU  - Zeng Y
AD  - Department of Cardiothoracic Surgery, Shaoxing People's Hospital (Shaoxing
      Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang Province,
      China.
FAU - Zhao, Zhenhua
AU  - Zhao Z
AD  - Department of Radiology, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang 
      University School of Medicine), Shaoxing, Zhejiang Province, China.
FAU - Wang, Ting
AU  - Wang T
AD  - Department of Radiology, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang 
      University School of Medicine), Shaoxing, Zhejiang Province, China.
FAU - Ma, Zhifeng
AU  - Ma Z
AD  - Department of Cardiothoracic Surgery, Shaoxing People's Hospital (Shaoxing
      Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang Province,
      China.
FAU - Yu, Guangmao
AU  - Yu G
AD  - Department of Cardiothoracic Surgery, Shaoxing People's Hospital (Shaoxing
      Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang Province,
      China. Electronic address: sznxxjw@163.com.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20200218
PL  - Netherlands
TA  - Surg Oncol
JT  - Surgical oncology
JID - 9208188
RN  - 0 (Cyanoacrylates)
RN  - 0 (Tissue Adhesives)
RN  - 6C655P1XVG (octyl 2-cyanoacrylate)
SB  - IM
MH  - Adenocarcinoma in Situ/diagnostic imaging/pathology/surgery
MH  - Adenocarcinoma of Lung/diagnostic imaging/pathology/surgery
MH  - Aged
MH  - Carcinoma, Squamous Cell/diagnostic imaging/pathology/surgery
MH  - *Cyanoacrylates
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/diagnostic imaging/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Multidetector Computed Tomography
MH  - Multiple Pulmonary Nodules/diagnostic imaging/pathology/*surgery
MH  - Pneumonectomy/*methods
MH  - Solitary Pulmonary Nodule/diagnostic imaging/pathology/*surgery
MH  - Surgery, Computer-Assisted
MH  - Thoracic Surgery, Video-Assisted/*methods
MH  - *Tissue Adhesives
MH  - Tumor Burden
OTO - NOTNLM
OT  - Ground glass opacity
OT  - Localization
OT  - Small pulmonary nodules
OT  - ZT medical glue (2-octyl cyanoacrylate)
COIS- Declaration of competing interest Conflicts of interest: The authors have no
      conflicts of interest to declare.
EDAT- 2020/06/21 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/06/21 06:00
PHST- 2019/12/26 00:00 [received]
PHST- 2020/01/14 00:00 [revised]
PHST- 2020/02/02 00:00 [accepted]
PHST- 2020/06/21 06:00 [entrez]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
AID - S0960-7404(19)30660-7 [pii]
AID - 10.1016/j.suronc.2020.02.001 [doi]
PST - ppublish
SO  - Surg Oncol. 2020 Jun;33:164-169. doi: 10.1016/j.suronc.2020.02.001. Epub 2020 Feb
      18.


PMID- 32560912
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20220220
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 3
DP  - 2020 Sep
TI  - An ethical algorithm for rationing life-sustaining treatment during the COVID-19 
      pandemic.
PG  - 253-258
LID - S0007-0912(20)30410-4 [pii]
LID - 10.1016/j.bja.2020.05.028 [doi]
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Wellcome Centre for Ethics and Humanities and Oxford Uehiro Centre for Practical 
      Ethics, University of Oxford, Oxford, UK; Murdoch Children's Research Institute
      and Melbourne Law School, Melbourne, Australia. Electronic address:
      julian.savulescu@philosophy.ox.ac.uk.
FAU - Vergano, Marco
AU  - Vergano M
AD  - Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care
      (SIAARTI), Italy; Department of Anesthesia and Intensive Care, San Giovanni Bosco
      Hospital, Turin, Italy.
FAU - Craxi, Lucia
AU  - Craxi L
AD  - Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of
      Palermo, Palermo, Italy.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AD  - Wellcome Centre for Ethics and Humanities and Oxford Uehiro Centre for Practical 
      Ethics, University of Oxford, Oxford, UK; John Radcliffe Hospital, University of 
      Oxford, Oxford, UK.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200602
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
MH  - *Algorithms
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/mortality/*therapy
MH  - Decision Making
MH  - Humans
MH  - Pandemics
MH  - Personal Autonomy
MH  - Pneumonia, Viral/mortality/*therapy
MH  - Quality of Life
MH  - *Resource Allocation
MH  - SARS-CoV-2
MH  - Triage
PMC - PMC7264035
OTO - NOTNLM
OT  - *COVID-19
OT  - *decision-making
OT  - *ethics
OT  - *prognosis
OT  - *resource allocation
OT  - *triage
OT  - *utilitarianism
EDAT- 2020/06/21 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S0007-0912(20)30410-4 [pii]
AID - 10.1016/j.bja.2020.05.028 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Sep;125(3):253-258. doi: 10.1016/j.bja.2020.05.028. Epub 2020 
      Jun 2.


PMID- 32560737
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20220415
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 19
TI  - The direct superior approach versus posterior approach for total hip
      arthroplasty: study protocol for a prospective double-blinded randomised control 
      trial.
PG  - 546
LID - 10.1186/s13063-020-04484-y [doi]
AB  - BACKGROUND: The direct superior approach (DSA) is a minimally invasive
      modification of the posterior approach (PA) that preserves the iliotibial band
      and short external rotators except for the piriformis or conjoint tendon during
      total hip arthroplasty (THA). The objective of this study is to compare patient
      satisfaction, functional outcomes, accuracy of implant positioning, component
      stability, gait, cost-effectiveness, and complications in the DSA versus PA for
      THA. METHODS AND ANALYSIS: This prospective double-blinded randomised control
      trial will include 80 patients with symptomatic hip osteoarthritis undergoing
      primary THA. Following informed consent, patients will be randomised to THA using
      the PA (control group) or DSA (investigation group) at a ratio of 1:1 using an
      online random number generator. Blinded observers will review patients at regular
      intervals for 2 years after surgery to record predefined study outcomes relating 
      to postoperative rehabilitation, clinical progress, functional outcomes, accuracy
      of implant positioning, gait analysis on force plate treadmill, implant migration
      with radiosteriometric analysis, cost-effectiveness, and complications. A
      superiority study design will be used to evaluate whether the DSA provides
      improved outcomes compared to the PA for THA. Evaluation of study outcomes in DSA
      and PA will be used to quantify and draw inferences on differences in the
      efficacy of treatment between the two groups. Intention-to-treat and per-protocol
      population analysis will be undertaken. The following statistical methods will be
      employed to analyse the data: descriptive statistics, independent t test, paired 
      t test, analysis of variance, Fisher exact test, chi-square test, and graphical
      displays. Ethical approval was obtained from the London-Fulham Research Ethics
      Committee, UK. The study is sponsored by University College London, UK.
      DISCUSSION: This study compares a comprehensive and robust range of clinical,
      functional, and radiological outcomes in THA performed using the PA versus DSA.
      The findings of this study will provide an improved understanding of the
      differences in the PA versus DSA for THA with respect to patient satisfaction,
      functional outcomes, implant survivorship, gait, cost-effectiveness, and
      complications. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04191993. Registered on
      10 December 2019.
FAU - Kayani, Babar
AU  - Kayani B
AUID- ORCID: http://orcid.org/0000-0001-6611-3989
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK. babar.kayani@gmail.com.
FAU - Konan, Sujith
AU  - Konan S
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Tahmassebi, Jenni
AU  - Tahmassebi J
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Ayuob, Atif
AU  - Ayuob A
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
FAU - Haddad, Fares S
AU  - Haddad FS
AD  - Department of Trauma and Orthopaedic Surgery, University College Hospital, 235
      Euston Road, Fitzrovia, London, NW1 2BU, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT04191993
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
DEP - 20200619
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Arthroplasty, Replacement, Hip/adverse effects/*methods
MH  - Double-Blind Method
MH  - Hip Joint/surgery
MH  - Humans
MH  - London
MH  - Minimally Invasive Surgical Procedures/*methods
MH  - Osteoarthritis, Hip/*surgery
MH  - Patient Satisfaction
MH  - Postoperative Complications/etiology
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Treatment Outcome
PMC - PMC7304085
EDAT- 2020/06/21 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/21 06:00 [entrez]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - 10.1186/s13063-020-04484-y [doi]
AID - 10.1186/s13063-020-04484-y [pii]
PST - epublish
SO  - Trials. 2020 Jun 19;21(1):546. doi: 10.1186/s13063-020-04484-y.


PMID- 32560591
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Informing Informed Consent for HIV Research.
PG  - 235-243
LID - 10.1177/1556264620933766 [doi]
AB  - "Respect for Persons" is an ethical principle demonstrated through the informed
      consent process. Participants at a large HIV research center were surveyed to
      identify important aspects of the consent process. Persons with and without HIV
      (n = 103) completed a short pre/post questionnaire with both open-ended and
      forced choice response options. Qualitative analysis resulted in eleven themes
      about the most important consent elements which did not differ by HIV serostatus.
      Overall, participants rated the informed consent content and presentation by
      research staff as "extremely informative" and found the consent information to be
      "extremely consistent" with their study experience. Study results support the
      value of an interactive process and can be used to inform the design of a
      standardized, digital consent process.
FAU - Campbell, Laura M
AU  - Campbell LM
AUID- ORCID: 0000-0001-9790-1603
AD  - San Diego State University/University of California San Diego Joint Doctoral
      Program in Clinical Psychology, San Diego, CA, USA.
FAU - Paolillo, Emily W
AU  - Paolillo EW
AD  - San Diego State University/University of California San Diego Joint Doctoral
      Program in Clinical Psychology, San Diego, CA, USA.
FAU - Bryan, Robert
AU  - Bryan R
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
FAU - Marquie-Beck, Jennifer
AU  - Marquie-Beck J
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
FAU - Moore, David J
AU  - Moore DJ
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
FAU - Nebeker, Camille
AU  - Nebeker C
AD  - Department of Family Medicine and Public Health, School of Medicine, University
      of California San Diego, La Jolla, CA, USA.
AD  - Center for Wireless and Population Health Systems, Qualcomm Institute, University
      of California San Diego, La Jolla, CA, USA.
FAU - Moore, Raeanne C
AU  - Moore RC
AUID- ORCID: 0000-0002-7499-041X
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.
LA  - eng
GR  - F31 AA027198/AA/NIAAA NIH HHS/United States
GR  - T32 DA031098/DA/NIDA NIH HHS/United States
GR  - K23 MH107260/MH/NIMH NIH HHS/United States
GR  - L30 MH104725/MH/NIMH NIH HHS/United States
GR  - R01 AG062387/AG/NIA NIH HHS/United States
GR  - P30 MH062512/MH/NIMH NIH HHS/United States
GR  - K23 MH105297/MH/NIMH NIH HHS/United States
GR  - R21 MH116104/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200619
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - *HIV Infections
MH  - Humans
MH  - *Informed Consent
MH  - Morals
MH  - Surveys and Questionnaires
PMC - PMC7486264
MID - NIHMS1597426
OTO - NOTNLM
OT  - *HIV/AIDS
OT  - *bioethics
OT  - *clinical research
OT  - *human subjects protection
OT  - *mental health
OT  - *research ethics
OT  - *research integrity
OT  - *vulnerable populations
EDAT- 2020/06/21 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - 10.1177/1556264620933766 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):235-243. doi:
      10.1177/1556264620933766. Epub 2020 Jun 19.


PMID- 32560334
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20201006
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 12
DP  - 2020 Jun 17
TI  - Lagging and Flagging: Air Pollution, Shale Gas Exploration and the Interaction of
      Policy, Science, Ethics and Environmental Justice in England.
LID - E4320 [pii]
LID - 10.3390/ijerph17124320 [doi]
AB  - The science on the effects of global climate change and air pollution on
      morbidity and mortality is clear and debate now centres around the scale and
      precise contributions of particular pollutants. Sufficient data existed in recent
      decades to support the adoption of precautionary public health policies relating 
      to fossil fuels including shale exploration. Yet air quality and related public
      health impacts linked to ethical and environmental justice elements are often
      marginalized or missing in planning and associated decision making. Industry and 
      government policies and practices, laws and planning regulations lagged well
      behind the science in the United Kingdom. This paper explores the reasons for
      this and what shaped some of those policies. Why did shale gas policies in
      England fail to fully address public health priorities and neglect ethical and
      environmental justice concerns. To answer this question, an interdisciplinary
      analysis is needed informed by a theoretical framework of how air pollution and
      climate change are largely discounted in the complex realpolitik of policy and
      regulation for shale gas development in England. Sources, including official
      government, regulatory and planning documents, as well as industry and scientific
      publications are examined and benchmarked against the science and ethical and
      environmental justice criteria. Further, our typology illustrates how the process
      works drawing on an analysis of official policy documents and statements on
      planning and regulatory oversight of shale exploration in England, and material
      from industry and their consultants relating to proposed shale oil and gas
      development. Currently the oil, gas and chemical industries in England continue
      to dominate and influence energy and feedstock-related policy making to the
      detriment of ethical and environmental justice decision making with significant
      consequences for public health.
FAU - Watterson, Andrew
AU  - Watterson A
AD  - Occupational and Environmental Health Research Group, Faculty of Health Sciences,
      University of Stirling, Stirling FK9 4LA, Scotland, UK.
FAU - Dinan, William
AU  - Dinan W
AUID- ORCID: 0000-0002-4259-2150
AD  - Communications, Media & Culture, Faculty of Arts & Humanities, University of
      Stirling, Stirling FK9 4LA, Scotland, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Natural Gas)
SB  - IM
MH  - *Air Pollution
MH  - England
MH  - *Environmental Policy
MH  - Ethics
MH  - *Natural Gas
MH  - Public Health
MH  - United Kingdom
PMC - PMC7344855
OTO - NOTNLM
OT  - *air pollution
OT  - *environmental justice
OT  - *ethics
OT  - *shale exploration
EDAT- 2020/06/21 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/21 06:00 [entrez]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
AID - ijerph17124320 [pii]
AID - 10.3390/ijerph17124320 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 17;17(12). pii: ijerph17124320. doi:
      10.3390/ijerph17124320.


PMID- 32559794
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20220416
IS  - 1806-9339 (Electronic)
IS  - 0100-7203 (Linking)
VI  - 42
IP  - 8
DP  - 2020 Aug
TI  - Preoperative Fasting Abbreviation and its Effects on Postoperative Nausea and
      Vomiting Incidence in Gynecological Surgery Patients.
PG  - 468-475
LID - 10.1055/s-0040-1712994 [doi]
AB  - OBJECTIVE: To investigate the effects of preoperative fasting abbreviation with a
      carbohydrate and protein-enriched solution, on postoperative nausea and vomiting 
      (PONV) incidence in gynecological surgery patients, a population naturally at
      risk for such unpleasant episodes. METHODS: The present prospective double-blind 
      randomized study was performed at The Hospital Municipal e Maternidade Dr. Odelmo
      Leao Carneiro (HMMOLC, in the Portuguese acronym), in Uberlandia, state of Minas 
      Gerais, Brazil, in partnership with the Gynecology Department of the Universidade
      Federal de Sao Paulo (UNIFESP), approved by the Human Research Ethics Committee
      of UNIFESP and the board of HMMOLC, and included in the Brazil Platform and in
      the Brazilian Clinical Trial Registry. After signing the consent form, 80 women, 
      who were submitted to gynecological surgery in the period from January to June
      2016, were randomized into 2 groups: control group (n = 42) and juice group (n = 
      38). They received, respectively, 200 mL of inert solution or liquid enriched
      with carbohydrate and protein 4 hours presurgery. The incidence, frequency and
      intensity of PONV were studied using the Visual Analogue Scale (VAS), with
      statistical analysis performed by the software IBM SPSS Statistics for Windows,
      Version 20.0 (IBM Corp, Armonk, NY, USA). RESULTS: The incidence of nausea and
      vomiting was lower than in the literature, to this population, with 18.9% (14/74)
      for the control group and 10.8% (8/74) for the juice group, respectively, with no
      statistically significant difference between the groups. CONCLUSION: The
      incidence of nausea and vomiting was lower than in the literature, but it cannot 
      be said that this is due to the abbreviation of fasting. It can provide greater
      comfort, with the possibility of PONV prevention in patients at risk for these
      episodes.
CI  - The Author(s). This is an open access article published by Thieme under the terms
      of the Creative Commons Attribution License, permitting unrestricted use,
      distribution, and reproduction so long as the original work is properly cited.
      (https://creativecommons.org/licenses/by/4.0/).
FAU - Marquini, Gisele Vissoci
AU  - Marquini GV
AUID- ORCID: 0000-0003-4573-5361
AD  - Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de
      Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Pinheiro, Francisco Edes da Silva
AU  - Pinheiro FEDS
AUID- ORCID: 0000-0003-3443-183X
AD  - Department of Gynecology, Hospital Municipal Maternidade Dr. Odelmo Leao
      Carneiro, Uberlandia, MG, Brazil.
FAU - Vieira, Alfredo Urbano da Costa
AU  - Vieira AUDC
AUID- ORCID: 0000-0002-0488-3256
AD  - Department of Gynecology, Hospital Municipal Maternidade Dr. Odelmo Leao
      Carneiro, Uberlandia, MG, Brazil.
FAU - Pinto, Rogerio Melo da Costa
AU  - Pinto RMDC
AUID- ORCID: 0000-0002-3397-5803
AD  - Faculty of Mathematics, Universidade Federal de Uberlandia, Uberlandia, MG,
      Brazil.
FAU - Uyeda, Maria Gabriela Baumgarten Kuster
AU  - Uyeda MGBK
AUID- ORCID: 0000-0003-4189-3645
AD  - Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de
      Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Girao, Manoel Joao Batista Castello
AU  - Girao MJBC
AUID- ORCID: 0000-0002-1206-9377
AD  - Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de
      Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Sartori, Marair Gracio Ferreira
AU  - Sartori MGF
AUID- ORCID: 0000-0002-3001-6076
AD  - Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de
      Sao Paulo, Sao Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Efeitos da abreviacao de jejum pre-operatorio na incidencia de nauseas e vomitos 
      em pacientes cirurgico-ginecologicas.
DEP - 20200619
PL  - Brazil
TA  - Rev Bras Ginecol Obstet
JT  - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira
      das Sociedades de Ginecologia e Obstetricia
JID - 9214757
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - *Fasting
MH  - Female
MH  - Gynecologic Surgical Procedures/*adverse effects
MH  - Humans
MH  - Postoperative Nausea and Vomiting/*epidemiology
MH  - Preoperative Care/*methods
MH  - Prospective Studies
COIS- The authors have no conflict of interests to declare.
EDAT- 2020/06/20 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1055/s-0040-1712994 [doi]
PST - ppublish
SO  - Rev Bras Ginecol Obstet. 2020 Aug;42(8):468-475. doi: 10.1055/s-0040-1712994.
      Epub 2020 Jun 19.


PMID- 32559738
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20220207
IS  - 1543-2777 (Electronic)
IS  - 0736-5829 (Linking)
VI  - 37
IP  - 3
DP  - 2020 Jul 1
TI  - Dance Programs for School-Age Individuals With Disabilities: A Systematic Review.
PG  - 349-376
LID - 10.1123/apaq.2019-0117 [doi]
LID - apaq.2019-0117 [pii]
AB  - The purpose of this systematic review was to examine published research
      literature pertaining to dance programs for school-age individuals with
      disabilities by describing study characteristics and major findings. Electronic
      database searches were conducted to identify relevant articles published between 
      January 2008 and August 2018. Sixteen articles met all inclusion criteria, and
      extracted data from the articles included major findings, study design
      characteristics (e.g., sample size), and dance program characteristics (e.g.,
      location of program). The methodological quality of each study was assessed using
      the Crowe Critical Appraisal Tool. Major findings expand on previous reviews on
      dance by including school-age individuals with disabilities. The critical
      appraisal of the articles demonstrates a gap in study design rigor between
      studies. Future research should aim to specify sampling strategies, use theories 
      to frame the impact of dance programs, and provide a thorough description of
      ethical processes and dance classes.
FAU - Prieto, Laura A
AU  - Prieto LA
AD  - University of Wisconsin-Madison.
FAU - Haegele, Justin A
AU  - Haegele JA
AD  - Old Dominion University.
FAU - Columna, Luis
AU  - Columna L
AD  - University of Wisconsin-Madison.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20200619
PL  - United States
TA  - Adapt Phys Activ Q
JT  - Adapted physical activity quarterly : APAQ
JID - 8701671
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Dance Therapy/*methods
MH  - Dancing/*psychology
MH  - Disabled Persons/psychology/*rehabilitation
MH  - Humans
MH  - Schools
OTO - NOTNLM
OT  - *children
OT  - *disability
OT  - *interventions
OT  - *youth
EDAT- 2020/06/20 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/19 00:00 [received]
PHST- 2020/01/27 00:00 [revised]
PHST- 2020/02/16 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1123/apaq.2019-0117 [doi]
AID - apaq.2019-0117 [pii]
PST - ppublish
SO  - Adapt Phys Activ Q. 2020 Jul 1;37(3):349-376. doi: 10.1123/apaq.2019-0117. Epub
      2020 Jun 19.


PMID- 32559221
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20200901
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 6
DP  - 2020
TI  - A semi-structured questionnaire survey of laboratory animal rehoming practice
      across 41 UK animal research facilities.
PG  - e0234922
LID - 10.1371/journal.pone.0234922 [doi]
AB  - If a laboratory animal survives an experiment without lasting compromised
      welfare, its future must be negotiated. Rehoming may be a consideration. This
      paper reports on research findings that provide an indication of the uptake of
      animal rehoming by UK facilities and the associated moral, ethical, practical and
      regulatory considerations that inform decisions to rehome or not. This research
      addresses a widely acknowledged gap in the literature to understand both the
      numbers, and types of animals rehomed from UK research facilities, as well as the
      main motivations for engaging in the practice, and the barriers for those
      facilities not currently rehoming. From the ~160 UK research facilities in the
      UK, 41 facilities completed the questionnaire, giving a response rate of
      approximately 25%. Results suggest rehoming occurs routinely, yet the numbers are
      small; just 2322 animals are known to have been rehomed between 2015-2017. At
      least 1 in 10 facilities are rehoming. There exists a clear preference for the
      rehoming of some species (mainly cats, dogs and horses) over others (rodents,
      agricultural animals and primates). Indeed, although 94.15% of species kept in
      laboratories are rodents, they make up under a fifth (19.14%) of all animals
      known to be rehomed between 2015-2017. The primary motivation for rehoming is to 
      boost staff morale and promote a positive ethical profile for the facility.
      Barriers include concern for the animal's welfare following rehoming, high
      scientific demand for animals that leaves few to be rehomed, and, finally,
      certain animals (mainly those genetically modified) are simply unsuited to
      rehoming. The findings of this research will support facilities choosing to
      rehome, as well as those that are not currently engaging in the practice. By
      promoting the practice, the benefits to rehoming in terms of improving laboratory
      animal's quality of life, helping facility staff to overcome the moral stress of 
      killing, and addressing public concern regarding the fate of laboratory animals, 
      can be attained. It is only once an understanding of rehoming from the
      perspective of UK research facilities has been ascertained, that appropriate
      policy and support can be provided.
FAU - Skidmore, Tess
AU  - Skidmore T
AUID- ORCID: 0000-0001-8816-4082
AD  - School of Geography and Environmental Science, University of Southampton,
      Southampton, England, United Kingdom.
FAU - Roe, Emma
AU  - Roe E
AD  - School of Geography and Environmental Science, University of Southampton,
      Southampton, England, United Kingdom.
LA  - eng
GR  - 205393/D/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200619
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animal Experimentation/ethics/standards/*statistics & numerical data
MH  - Animal Welfare/ethics/standards/*statistics & numerical data
MH  - Animals
MH  - *Animals, Laboratory
MH  - Housing, Animal/ethics/standards/*statistics & numerical data
MH  - Humans
MH  - Motivation
MH  - Practice Guidelines as Topic
MH  - *Surveys and Questionnaires
MH  - United Kingdom
PMC - PMC7304590
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/06/20 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
AID - 10.1371/journal.pone.0234922 [doi]
AID - PONE-D-20-01484 [pii]
PST - epublish
SO  - PLoS One. 2020 Jun 19;15(6):e0234922. doi: 10.1371/journal.pone.0234922.
      eCollection 2020.


PMID- 32559169
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210222
IS  - 2154-2317 (Electronic)
IS  - 2154-2287 (Linking)
VI  - 11
IP  - 3
DP  - 2020 May-Jun
TI  - Ethics in the Era of Artificial Intelligence.
PG  - 44-47
LID - 10.1109/MPULS.2020.2993667 [doi]
AB  - Ethics can be interesting and fascinatingly compelling because of the subtle
      natures of its solutions in ambiguous situations. Articles on ethical issues and 
      college courses on ethics rarely present answers to the questions that are posed.
      That is because ethical responses are highly situational and depend a lot on
      commonly accepted, but not codified, beliefs, and attitudes.
FAU - Johnson, Arthur T
AU  - Johnson AT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - IEEE Pulse
JT  - IEEE pulse
JID - 101541727
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Humans
MH  - Technology/ethics
EDAT- 2020/06/20 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - 10.1109/MPULS.2020.2993667 [doi]
PST - ppublish
SO  - IEEE Pulse. 2020 May-Jun;11(3):44-47. doi: 10.1109/MPULS.2020.2993667.


PMID- 32559015
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1440-1800 (Electronic)
IS  - 1320-7881 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Jul
TI  - 'This Is Not a Patient, This Is Property of the State': Nursing, ethics, and the 
      immigrant detention apparatus.
PG  - e12358
LID - 10.1111/nin.12358 [doi]
AB  - This paper opens with first-hand accounts of critical care medical interventions 
      in which detainees, in the custody of U.S. Immigration and Customs Enforcement
      (ICE), are brought to the emergency department for treatment. This case
      dramatizes the extent to which the provision of ethical and acceptable nursing
      care is jeopardized by federal law enforcement paradigms. Drawing on the
      scholarship of Michel Foucault and Giorgio Agamben, this paper offers a
      theoretical account of the power dynamics that inform the health care of patients
      who find themselves caught in the custodial scaffolding of a vast immigration and
      detention apparatus. It offers an analysis of the display of sovereign and
      biopolitical power over the lives (and deaths) of detainees (Foucault), as well
      as the ways these individuals are reduced to "bare life" under the political
      pretext of an emergency or "state of exception" (Agamben). Our purpose here is
      both theoretical and practical: to better understand the often hidden agency or
      impersonal "will" exercised by the immigrant detention system, but also to equip 
      clinicians in these and cognate facilities (e.g., prisons) with the critical
      tools by which they might better navigate incommensurable paradigms (i.e., care
      vs. custody) in order to deliver the best care while upholding their ethical
      duties as a care provider. This is all the more pressing because hospitals are
      not sanctuaries and given the incursion of federal law enforcement agents, nurses
      may find themselves conscripted as de facto agents of the state.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Jenkins, Danisha
AU  - Jenkins D
AD  - Sue & Bill Gross School of Nursing, University of California, Irvine, CA, USA.
FAU - Holmes, Dave
AU  - Holmes D
AUID- ORCID: 0000-0003-2751-6480
AD  - School of Nursing, University of Ottawa, Ottawa, ON, Canada.
FAU - Burton, Candace
AU  - Burton C
AD  - Sue & Bill Gross School of Nursing, University of California, Irvine, CA, USA.
FAU - Murray, Stuart J
AU  - Murray SJ
AUID- ORCID: 0000-0001-8850-5406
AD  - Department of English Language and Literature, Carleton University, Ottawa, ON,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - Australia
TA  - Nurs Inq
JT  - Nursing inquiry
JID - 9505881
MH  - Emigrants and Immigrants/*legislation & jurisprudence/psychology
MH  - *Ethics, Nursing
MH  - Humans
MH  - Jails/organization & administration/*standards
MH  - Law Enforcement/methods
MH  - Respect
OTO - NOTNLM
OT  - *critical theory
OT  - *ethics
OT  - *foucault
OT  - *politics
OT  - *professional issues
EDAT- 2020/06/20 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1111/nin.12358 [doi]
PST - ppublish
SO  - Nurs Inq. 2020 Jul;27(3):e12358. doi: 10.1111/nin.12358. Epub 2020 Jun 19.


PMID- 32558826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2056-4740 (Print)
IS  - 2056-4740 (Linking)
VI  - 17
IP  - 2
DP  - 2020 May
TI  - SKIP: emotional well-being intervention.
PG  - 47-48
LID - 10.1192/bji.2020.7 [doi]
AB  - SKIP (Students for Kids International Projects) is a student-led global health
      charity; each university branch partners with a local non-governmental
      organisation in their branch country, where they run interventions identified by 
      the local community. Research in these countries has identified an educational
      need for interventions around emotional well-being. In this article, we reflect
      on the process of creating culturally appropriate educational resources for
      children and young people in low- and middle-income countries, to be delivered by
      non-professionals. SKIP has a Research Ethics Policy. No external ethics approval
      was required.
CI  - (c) The Author 2020.
FAU - Cook, Natalie
AU  - Cook N
AUID- ORCID: https://orcid.org/0000-0003-3686-8306
AD  - Adult Mental Health, Humber NHS Foundation Trust, Willerby, UK. Email:
      natalie.cook@york.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200217
PL  - England
TA  - BJPsych Int
JT  - BJPsych international
JID - 101654173
PMC - PMC7283114
OTO - NOTNLM
OT  - Education and training
OT  - low- and middle-income countries
OT  - transcultural psychiatry
COIS- Conflicts of interest: None.
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 10.1192/bji.2020.7 [doi]
PST - ppublish
SO  - BJPsych Int. 2020 May;17(2):47-48. doi: 10.1192/bji.2020.7. Epub 2020 Feb 17.


PMID- 32558810
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1188-4169 (Print)
IS  - 1188-4169 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May 7
TI  - Summary of the NACI Seasonal Influenza Vaccine Statement for 2020-2021.
PG  - 132-137
LID - 10.14745/ccdr.v46i05a06 [doi]
AB  - BACKGROUND: Evidence on influenza vaccination is continually evolving. The
      National Advisory Committee on Immunization (NACI) provides annual
      recommendations to the Public Health Agency of Canada regarding the use of
      seasonal influenza vaccines. OBJECTIVE: To summarize NACI's recommendations
      regarding the use of seasonal influenza vaccines for the 2020-2021 influenza
      season and to highlight new and updated recommendations. METHODS: 1) To update
      wording on influenza vaccination of health care workers, NACI reassessed the
      evidence in the context of ethics and acceptability frameworks, in accordance
      with NACI's recently expanded mandate. 2) To provide recommendations on the use
      of live attenuated influenza vaccine (LAIV) in HIV-infected individuals, the
      Influenza Working Group developed a predefined search strategy to identify all
      eligible studies, then assessed the quality and summarized and analyzed the
      findings according to the NACI evidence-based process. NACI provided new
      recommendations based on assessment of the evidence. RESULTS: 1) NACI continues
      to recommend that health care workers and other care providers in facilities and 
      community settings should be vaccinated annually against influenza and that this 
      group be included among those particularly recommended to receive the influenza
      vaccine. 2) NACI concluded that LAIV is immunogenic in children with stable HIV
      infection; therefore, NACI newly recommends that LAIV may be considered as an
      option for children 2-17 years of age with stable HIV infection on highly active 
      antiretroviral therapy and with adequate immune function. CONCLUSION: NACI
      continues to recommend that an age-appropriate influenza vaccine should be
      offered annually to anyone six months of age and older who does not have
      contraindications to the vaccine, with a focus on the groups for whom influenza
      vaccination is particularly recommended.
FAU - Young, Kelsey
AU  - Young K
AD  - Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency
      of Canada, Ottawa, ON.
FAU - Gemmill, Ian
AU  - Gemmill I
AD  - NACI Influenza Working Group Chair.
AD  - Queen's University, Kingston, ON.
FAU - Harrison, Robyn
AU  - Harrison R
AD  - NACI Influenza Working Group Vice Chair.
AD  - University of Alberta; Alberta Health Services, Edmonton, AB.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - Canada
TA  - Can Commun Dis Rep
JT  - Canada communicable disease report = Releve des maladies transmissibles au Canada
JID - 9303729
PMC - PMC7279128
OTO - NOTNLM
OT  - NACI
OT  - National Advisory Committee on Immunization
OT  - guidance
OT  - influenza
OT  - influenza vaccine
COIS- Conflict of interest: None.
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 10.14745/ccdr.v46i05a06 [doi]
AID - 460506 [pii]
PST - epublish
SO  - Can Commun Dis Rep. 2020 May 7;46(5):132-137. doi: 10.14745/ccdr.v46i05a06.
      eCollection 2020 May 7.


PMID- 32558790
OWN - NLM
STAT- MEDLINE
DCOM- 20200623
LR  - 20210625
IS  - 1538-8689 (Electronic)
IS  - 0360-4039 (Linking)
VI  - 50
IP  - 7
DP  - 2020 Jul
TI  - During the COVID-19 pandemic, should nurses offer to pray with patients?
PG  - 42-46
LID - 10.1097/01.NURSE.0000668624.06487.72 [doi]
AB  - Patients hospitalized with COVID-19 are unable to visit with friends and family, 
      and religious patients cannot see personal clergy or even hospital chaplains.
      These patients may be scared, possibly mechanically ventilated, and dying. In
      these situations, should their nurse ever initiate an offer of prayer? Weighing
      the pros and cons of this issue, this discussion will argue that when offered in 
      an ethical, patient-centered manner, nurses offering prayer can be therapeutic
      for some patients.
FAU - Taylor, Elizabeth Johnston
AU  - Taylor EJ
AD  - Elizabeth Johnston Taylor is a professor at the Loma Linda University School of
      Nursing in Loma Linda, Calif.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nursing
JT  - Nursing
JID - 7600137
CIN - Nursing. 2020 Dec 1;50(12):8. PMID: 33953080
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*nursing
MH  - Humans
MH  - Nurse-Patient Relations/*ethics
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology/*nursing
MH  - *Religion
EDAT- 2020/06/20 06:00
MHDA- 2020/06/24 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
AID - 10.1097/01.NURSE.0000668624.06487.72 [doi]
AID - 00152193-202007000-00013 [pii]
PST - ppublish
SO  - Nursing. 2020 Jul;50(7):42-46. doi: 10.1097/01.NURSE.0000668624.06487.72.


PMID- 32558517
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1853-0605 (Electronic)
IS  - 0014-6722 (Linking)
VI  - 77
IP  - 2
DP  - 2020 Apr 28
TI  - [The Care as a minimum necessary change to transform the healthcare system].
PG  - 126-129
LID - 10.31053/1853.0605.v77.n2.27983 [doi]
AB  - Introduction: This article assumes a critical reflection as a personal suggestion
      to include the dimension of care in healthcare system. The discussion is
      contextualized in the epidemiological transitions of the 21st Century framework, 
      chronicity, longevity and increasing dependence. Methods: An experimental
      metaphor for manipulating the genome constituting healthcare systems, based on
      principles of universality, accessibility, solidarity, ethics, efficacy and
      efficiency, is held to achieve the minimum necessary change to transform them in 
      favour of humanization, empathy and compassion. Concepts of care and self-care
      are explored, as an attitude in relation to oneself, with others and with the
      world, undervalued dimensions of care, usually neglected or invisible. Results:
      Ten reasons are proposed to include the ethical, moral and pedagogical model of
      palliative care approach in a transversal way for the whole system and stages of 
      life, as well as the leadership to carry it out. Conclusion: this transformative 
      healthcare system model is offered, as other face of carelessness, dehumanization
      and anomie, both, to users and healthcare professionals.
CI  - Universidad Nacional de Cordoba
FAU - Tripodoro, Vilma
AU  - Tripodoro V
AD  - Instituto de Investigaciones Medicas Alfredo Lanari Universidad de Buenos Aires. 
      vilma.tripodoro@gmail.com.
LA  - spa
PT  - Journal Article
TT  - El Cuidado como cambio minimo necesario para transformar el sistema de salud.
DEP - 20200428
PL  - Argentina
TA  - Rev Fac Cien Med Univ Nac Cordoba
JT  - Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)
JID - 8303003
SB  - IM
MH  - *Health Policy
MH  - *Health Services Accessibility
MH  - *Humanism
MH  - Humans
MH  - *Palliative Care
MH  - *Universal Health Insurance
OTO - NOTNLM
OT  - *healthcare system
OT  - *palliative care
OT  - *universal health coverage
EDAT- 2020/06/20 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.31053/1853.0605.v77.n2.27983 [doi]
PST - epublish
SO  - Rev Fac Cien Med Univ Nac Cordoba. 2020 Apr 28;77(2):126-129. doi:
      10.31053/1853.0605.v77.n2.27983.


PMID- 32558058
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20201201
IS  - 1520-6505 (Electronic)
IS  - 1060-1538 (Linking)
VI  - 29
IP  - 4
DP  - 2020 Jul
TI  - Digitization of the Nissen-Riesen chimpanzee radiological growth series.
PG  - 173-179
LID - 10.1002/evan.21836 [doi]
AB  - Longitudinal morphological growth data of apes are incredibly difficult to
      obtain. Long life histories, combined with practical and ethical issues of
      obtaining such long-term data have resulted in few longitudinal data sets in
      chimpanzees of known chronological ages. One classic, long-term growth study of
      chimpanzees was that of Drs Nissen and Riesen initiated at the Yale Laboratories 
      of Primate Biology in 1939. Through that study, whole-body radiological images
      were taken on a regular basis from a "normative" group of chimpanzees from birth 
      to adulthood. Here we have digitized the known remaining radiographs from that
      growth study, many of which are deteriorating, and uploaded the data set to the
      free, online database MorphoSource. The database comprises 3,568 X-ray images of 
      15 of the 16 chimpanzee subjects in the normative group and 1 individual from an 
      experimental group. Herein, we briefly review the historical context of this
      study and specific details of the data set.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Thompson, Nathan E
AU  - Thompson NE
AUID- ORCID: https://orcid.org/0000-0002-9273-3636
AD  - Department of Anatomy, New York Institute of Technology College of Osteopathic
      Medicine, Old Westbury, New York, USA.
FAU - Ahmed, Lameesah
AU  - Ahmed L
AD  - New York Institute of Technology College of Osteopathic Medicine, Old Westbury,
      New York, USA.
FAU - Celebi, Taner B
AU  - Celebi TB
AD  - New York Institute of Technology College of Osteopathic Medicine, Old Westbury,
      New York, USA.
FAU - Coopee, Zachary S
AU  - Coopee ZS
AD  - New York Institute of Technology College of Osteopathic Medicine, Old Westbury,
      New York, USA.
FAU - Koll, Nikki
AU  - Koll N
AD  - New York Institute of Technology College of Osteopathic Medicine, Old Westbury,
      New York, USA.
FAU - Rubinstein, Danielle
AU  - Rubinstein D
AD  - New York Institute of Technology College of Osteopathic Medicine, Old Westbury,
      New York, USA.
AD  - Lancaster General Hospital Family Medicine Residency, Lancaster, Pennsylvania,
      USA.
FAU - Saunders, Megan A
AU  - Saunders MA
AD  - Department of Anthropology, University of North Carolina at Greensboro,
      Greensboro, North Carolina, USA.
FAU - Anemone, Robert L
AU  - Anemone RL
AUID- ORCID: https://orcid.org/0000-0003-2838-968X
AD  - Department of Anthropology, University of North Carolina at Greensboro,
      Greensboro, North Carolina, USA.
LA  - eng
GR  - 1719432/National Science Foundation SBE Office of Multidisciplinary Activities
GR  - Yerkes National Primate Research Center
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Evol Anthropol
JT  - Evolutionary anthropology
JID - 9306331
SB  - IM
MH  - Animals
MH  - Anthropometry/*instrumentation
MH  - Female
MH  - Florida
MH  - Male
MH  - Pan troglodytes/*growth & development
OTO - NOTNLM
OT  - X-ray
OT  - Yerkes
OT  - chimpanzee
OT  - database
OT  - growth
OT  - skeletal
EDAT- 2020/06/20 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1002/evan.21836 [doi]
PST - ppublish
SO  - Evol Anthropol. 2020 Jul;29(4):173-179. doi: 10.1002/evan.21836. Epub 2020 Jun
      18.


PMID- 32557840
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220106
IS  - 1531-8257 (Electronic)
IS  - 0885-3185 (Linking)
VI  - 35
IP  - 8
DP  - 2020 Aug
TI  - The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a
      Collaborative Project.
PG  - 1315-1322
LID - 10.1002/mds.28123 [doi]
AB  - BACKGROUND: Clinical disease registries are useful for quality improvement in
      care, benchmarking standards, and facilitating research. Collaborative networks
      established thence can enhance national and international studies by generating
      more robust samples and credible data and promote knowledge sharing and capacity 
      building. This report describes the methodology, baseline data, and prospects of 
      the Nigeria Parkinson Disease Registry. METHODS: This national registry was
      established in November 2016. Ethics approval was obtained for all sites. Basic
      anonymized data for consecutive cases fulfilling the United Kingdom Parkinson's
      Disease Brain Bank criteria (except the exclusion criterion of affected family
      members) are registered by participating neurologists via a secure registry
      website (www.parkinsonnigeria.com) using a minimal common data capture format.
      RESULTS: The registry had captured 578 participants from 5 of 6 geopolitical
      zones in Nigeria by July 2019 (72.5% men). Mean age at onset was 60.3 +/- 10.7
      years; median disease duration (interquartile range) was 36 months (18-60.5
      months). Young-onset disease (<50 years) represented 15.2%. A family history was 
      documented in 4.5% and 7.8% with age at onset <50 and >/= 50, respectively. The
      most frequent initial symptom was tremor (45.3%). At inclusion, 93.4% were on
      treatment (54.5% on levodopa monotherapy). Per-capita direct cost for the
      registry was $3.37. CONCLUSIONS: This is the first published national Parkinson's
      disease registry in sub-Saharan Africa. The registry will serve as a platform for
      development of multipronged evidence-based policies and initiatives to improve
      quality of care of Parkinson's disease and research engagement in Nigeria. (c)
      2020 International Parkinson and Movement Disorder Society.
CI  - (c) 2020 International Parkinson and Movement Disorder Society.
FAU - Ojo, Oluwadamilola O
AU  - Ojo OO
AUID- ORCID: 0000-0001-6461-2653
AD  - Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of 
      Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria.
AD  - Neurology Unit, Department of Medicine, Lagos University Teaching Hospital,
      Idi-Araba, Lagos, Nigeria.
FAU - Abubakar, Sani A
AU  - Abubakar SA
AD  - Department of Medicine, Ahmadu Bello University/ Ahmadu Bello University Teaching
      Hospital, Zaria, Kaduna State, Nigeria.
FAU - Iwuozo, Emmanuel U
AU  - Iwuozo EU
AD  - Neurology Unit, Benue State University/Benue State University Teaching Hospital, 
      Makurdi, Benue State, Nigeria.
FAU - Nwazor, Ernest O
AU  - Nwazor EO
AD  - Department of Medicine, Federal Medical Center, Owerri, Imo State, Nigeria/
      College of Medical Sciences, Madonna University, Elele, Rivers State, Nigeria.
FAU - Ekenze, Oluchi S
AU  - Ekenze OS
AD  - Neurology Unit, Department of Medicine, Faculty of Medical Sciences, University
      of Nigeria/University of Nigeria Teaching Hospital, Ituku Ozalla, Enugu State,
      Nigeria.
FAU - Farombi, Temitope H
AU  - Farombi TH
AD  - Chief Tony Anenih Geriatrics Center, University College Hospital, Ibadan, Oyo
      State, Nigeria.
FAU - Akinyemi, Rufus O
AU  - Akinyemi RO
AD  - Institute for Advanced Medical Research and Training, College of Medicine,
      University of Ibadan, Ibadan, Oyo State, Nigeria.
FAU - Williams, Uduak E
AU  - Williams UE
AD  - Department of Internal Medicine, University of Calabar/University of Calabar
      Teaching Hospital, Calabar, Cross Rivers State, Nigeria.
FAU - Bello, Abiodun H
AU  - Bello AH
AD  - University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria.
FAU - Wahab, Kolawole W
AU  - Wahab KW
AD  - Department of Medicine, University of Ilorin, Ilorin, Kwara State, Nigeria.
FAU - Iyagba, Alagoma M
AU  - Iyagba AM
AD  - University of Port Harcourt and University of Port Harcourt Teaching Hospital,
      Port Harcourt, Rivers State, Nigeria.
FAU - Arigbodi, Ohwotemu
AU  - Arigbodi O
AD  - Department of Internal Medicine, Delta State University Teaching Hospital,
      Oghara, Delta State, Nigeria.
FAU - Erameh, Cyril O
AU  - Erameh CO
AD  - Irrua Specialist Hospital, Irrua, Edo State, Nigeria.
FAU - Komolafe, Morenikeji A
AU  - Komolafe MA
AD  - Neurology Unit, Department of Medicine, Obafemi Awolowo University/ Obafemi
      Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria.
FAU - Fawale, Michael B
AU  - Fawale MB
AD  - Neurology Unit, Department of Medicine, Obafemi Awolowo University/ Obafemi
      Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria.
FAU - Onwuegbuzie, Gerald A
AU  - Onwuegbuzie GA
AD  - University of Abuja Teaching Hospital, Federal Capital Territory, Abuja, Nigeria.
FAU - Obiabo, Yahaya O
AU  - Obiabo YO
AD  - Department of Internal Medicine, Delta State University/ Delta State University
      Teaching Hospital, Oghara, Delta State, Nigeria.
FAU - Taiwo, Funlola T
AU  - Taiwo FT
AD  - Babcock University, Ilishan-Remo, Ogun State, Nigeria.
FAU - Agu, Christian E
AU  - Agu CE
AD  - Alex Ekwueme Federal Teaching Hospital, Abakaliki, Ebonyi State, Nigeria.
FAU - Ekeh, Bertha C
AU  - Ekeh BC
AD  - University of Uyo Teaching Hospital/ Ibom Specialist Hospital, Uyo, Akwa Ibom
      State, Nigeria.
FAU - Osaigbovo, Godwin O
AU  - Osaigbovo GO
AD  - Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
FAU - Achoru, Charles O
AU  - Achoru CO
AD  - Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
FAU - Arabambi, Babawale
AU  - Arabambi B
AUID- ORCID: 0000-0002-7591-9404
AD  - Lagos State University Teaching Hospital, Ikeja, Lagos State, Nigeria.
FAU - Adeniji, Olaleye
AU  - Adeniji O
AD  - Federal Medical Center, Abeokuta, Ogun State, Nigeria.
FAU - Nwani, Paul O
AU  - Nwani PO
AD  - Neurology Unit, Department of Medicine, College of Health Sciences, Nnamdi
      Azikiwe University, Awka, Anambra State, Nigeria.
FAU - Nwosu, Cosmas M
AU  - Nwosu CM
AD  - Neurology Unit, Department of Medicine, College of Health Sciences, Nnamdi
      Azikiwe University, Awka, Anambra State, Nigeria.
FAU - Ademiluyi, Babatunde A
AU  - Ademiluyi BA
AD  - Federal Medical Center, Lokoja, Kogi State, Nigeria.
FAU - Oyakhire, Shyngle I
AU  - Oyakhire SI
AD  - Department of Internal Medicine, National Hospital, Abuja, Federal Capital
      Territory, Nigeria.
FAU - Nyandaiti, Yakub
AU  - Nyandaiti Y
AD  - University of Maiduguri/ University of Maiduguri Teaching Hospital, Maiduguri,
      Borno State, Nigeria.
FAU - Rabiu, Musbahu
AU  - Rabiu M
AD  - Muritala Muhammed Specialist Hospital, Kano, Kano State, Nigeria.
FAU - Chapp-Jumbo, Emmanuel N
AU  - Chapp-Jumbo EN
AD  - Federal Medical Center, Yenagoa, Bayelsa State, Nigeria.
FAU - Balarabe, Salisu A
AU  - Balarabe SA
AD  - Department of Medicine, College of Health Sciences, Usmanu Danfodiyo
      University/Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria.
FAU - Otubogun, Folajimi M
AU  - Otubogun FM
AD  - University of Medical Sciences Teaching Hospitals Complex, Akure, Ondo State,
      Nigeria.
FAU - Obehighe, Emmanuel E
AU  - Obehighe EE
AD  - Federal Medical Center, Keffi, Nassarawa State, Nigeria.
FAU - Kehinde, Abiodun J
AU  - Kehinde AJ
AD  - Federal Medical Center, Jabi, Federal capital Territory, Abuja, Nigeria.
FAU - Ani-Osheku, Ifeyinwa
AU  - Ani-Osheku I
AD  - Asokoro District Hospital, Asokoro, Federal Capital Territory, Abuja, Nigeria.
FAU - Imarhiagbe, Frank A
AU  - Imarhiagbe FA
AD  - University of Benin/ University of Benin Teaching Hospital, Benin City, Edo
      State, Nigeria.
FAU - Dike, Franklin O
AU  - Dike FO
AD  - University of Uyo Teaching Hospital/ Ibom Specialist Hospital, Uyo, Akwa Ibom
      State, Nigeria.
FAU - Adebowale, Akintunde A
AU  - Adebowale AA
AD  - Neurology Unit, Department of Medicine, Obafemi Awolowo University/ Obafemi
      Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria.
FAU - Agabi, Osigwe P
AU  - Agabi OP
AD  - Neurology Unit, Department of Medicine, Lagos University Teaching Hospital,
      Idi-Araba, Lagos, Nigeria.
FAU - Akpekpe, John E
AU  - Akpekpe JE
AD  - Federal Medical Center, Asaba, Delta State, Nigeria.
FAU - Ali, Mohammed W
AU  - Ali MW
AD  - Federal Teaching Hospital, Gombe, Gombe State, Nigeria.
FAU - Odeniyi, Olanike A
AU  - Odeniyi OA
AD  - General Hospital, Lagos Island, Lagos State, Nigeria.
FAU - Odiase, Francis E
AU  - Odiase FE
AD  - University of Benin/ University of Benin Teaching Hospital, Benin City, Edo
      State, Nigeria.
FAU - Abiodun, Oladunni V
AU  - Abiodun OV
AD  - General Hospital, Isolo, Lagos State, Nigeria.
FAU - Olowoyo, Paul
AU  - Olowoyo P
AD  - Federal Teaching Hospital, Ido-Ekiti / Afe Babalola University Ado-Ekiti, Ekiti
      State, Nigeria.
FAU - Osemwegie, Nosakhare
AU  - Osemwegie N
AD  - University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State,
      Nigeria.
FAU - Oshinaike, Olajumoke O
AU  - Oshinaike OO
AD  - Neurology Unit, Department of Medicine, Faculty of Clinical Sciences Lagos State 
      University College of Medicine, Ikeja, Lagos State, Nigeria.
FAU - Owolabi, Lukman F
AU  - Owolabi LF
AD  - Department of Medicine, Bayero University /Aminu Kano Teaching Hospital, Kano,
      Kano State, Nigeria.
FAU - Zubair, Yusuf A
AU  - Zubair YA
AD  - Department of Internal Medicine, National Hospital, Abuja, Federal Capital
      Territory, Nigeria.
FAU - Rizig, Mie
AU  - Rizig M
AD  - Department of Molecular Neuroscience, University College London Institute of
      Neurology, Queen Square, London, United Kingdom.
FAU - Okubadejo, Njideka U
AU  - Okubadejo NU
AD  - Neurology Unit, Department of Medicine, Faculty of Clinical Sciences, College of 
      Medicine, University of Lagos, Idi-Araba, Lagos State, Nigeria.
AD  - Neurology Unit, Department of Medicine, Lagos University Teaching Hospital,
      Idi-Araba, Lagos, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200619
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
SB  - IM
CIN - Nat Rev Neurol. 2020 Oct;16(10):523-524. PMID: 32747767
MH  - Africa South of the Sahara
MH  - Female
MH  - Humans
MH  - Male
MH  - Nigeria/epidemiology
MH  - *Parkinson Disease/epidemiology
MH  - Registries
MH  - United Kingdom
OTO - NOTNLM
OT  - *Nigeria
OT  - *Parkinson's disease
OT  - *registry
OT  - *sub-Saharan Africa
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1002/mds.28123 [doi]
PST - ppublish
SO  - Mov Disord. 2020 Aug;35(8):1315-1322. doi: 10.1002/mds.28123. Epub 2020 Jun 19.


PMID- 32557729
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1098-108X (Electronic)
IS  - 0276-3478 (Linking)
VI  - 53
IP  - 8
DP  - 2020 Aug
TI  - Severe and enduring anorexia nervosa: Fertile ground for iatrogenic development.
PG  - 1318-1319
LID - 10.1002/eat.23323 [doi]
AB  - Care providers and individuals with severe and enduring anorexia nervosa (SE-AN) 
      are weathering a perfect storm in which the sickest patients receive the least
      evidence-based treatment and iatrogenic factors play a significant role.
      Examining access to treatment from an ethical perspective is one strategy for
      developing more objective protocols related to the care of individuals with
      SE-AN.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Olmsted, Marion P
AU  - Olmsted MP
AUID- ORCID: 0000-0002-0161-2426
AD  - Centre for Mental Health, University Health Network and University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200617
PL  - United States
TA  - Int J Eat Disord
JT  - The International journal of eating disorders
JID - 8111226
SB  - IM
CON - Int J Eat Disord. 2020 Aug;53(8):1303-1312. PMID: 32359125
MH  - *Anorexia Nervosa
MH  - Humans
MH  - Iatrogenic Disease
OTO - NOTNLM
OT  - *anorexia nervosa
OT  - *changing the paradigm
OT  - *eating disorders
OT  - *ethical use of resources
OT  - *iatrogenic maintaining factors
OT  - *medical ethics
OT  - *severe and enduring anorexia nervosa
EDAT- 2020/06/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1002/eat.23323 [doi]
PST - ppublish
SO  - Int J Eat Disord. 2020 Aug;53(8):1318-1319. doi: 10.1002/eat.23323. Epub 2020 Jun
      17.


PMID- 32557631
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 235
IP  - 12
DP  - 2020 Dec
TI  - Regenerative potential of Wharton's jelly-derived mesenchymal stem cells: A new
      horizon of stem cell therapy.
PG  - 9230-9240
LID - 10.1002/jcp.29810 [doi]
AB  - Umbilical cord Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have
      recently gained considerable attention in the field of regenerative medicine.
      Their high proliferation rate, differentiation ability into various cell
      lineages, easy collection procedure, immuno-privileged status, nontumorigenic
      properties along with minor ethical issues make them an ideal approach for tissue
      repair. Besides, the number of WJ-MSCs in the umbilical cord samples is high as
      compared to other sources. Because of these properties, WJ-MSCs have rapidly
      advanced into clinical trials for the treatment of a wide range of disorders.
      Therefore, this paper summarized the current preclinical and clinical studies
      performed to investigate the regenerative potential of WJ-MSCs in neural,
      myocardial, skin, liver, kidney, cartilage, bone, muscle, and other tissue
      injuries.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Abbaszadeh, Hossein
AU  - Abbaszadeh H
AUID- ORCID: 0000-0001-6284-0855
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Ghorbani, Farzaneh
AU  - Ghorbani F
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Derakhshani, Mehdi
AU  - Derakhshani M
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Movassaghpour, Ali Akbar
AU  - Movassaghpour AA
AUID- ORCID: 0000-0002-6990-9269
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences,
      Tabriz, Iran.
FAU - Yousefi, Mehdi
AU  - Yousefi M
AUID- ORCID: 0000-0003-0099-6728
AD  - Department of Immunology, Faculty of Medicine, Tabriz University of Medical
      Sciences, Tabriz, Iran.
FAU - Talebi, Mehdi
AU  - Talebi M
AUID- ORCID: 0000-0002-3633-2280
AD  - Department of Applied Cell Sciences, School of Advanced Medical Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Shamsasenjan, Karim
AU  - Shamsasenjan K
AD  - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200618
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
SB  - IM
MH  - Cell Differentiation/physiology
MH  - Cell Proliferation/physiology
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology
MH  - *Stem Cell Transplantation/methods
MH  - Umbilical Cord/*cytology
MH  - Wharton Jelly/*cytology
OTO - NOTNLM
OT  - *Wharton's jelly
OT  - *mesenchymal stem cells
OT  - *regenerative medicine
OT  - *umbilical cord
EDAT- 2020/06/20 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1002/jcp.29810 [doi]
PST - ppublish
SO  - J Cell Physiol. 2020 Dec;235(12):9230-9240. doi: 10.1002/jcp.29810. Epub 2020 Jun
      18.


PMID- 32557533
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20220720
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 8
DP  - 2020 Aug
TI  - Caring for Frail Older Adults During COVID-19: Integrating Public Health Ethics
      into Clinical Practice.
PG  - 1666-1670
LID - 10.1111/jgs.16666 [doi]
AB  - During the coronavirus disease 2019 (COVID-19) pandemic, principles from both
      clinical and public health ethics cue clinicians and healthcare administrators to
      plan alternatives for frail older adults who prefer to avoid critical care, and
      for when critical care is not available due to crisis triaging. This article will
      explore the COVID-19 Ethical Decision Making Framework, published in British
      Columbia (BC), Canada, to familiarize clinicians and policy makers with how
      ethical principles can guide systems change, in the service of frail older
      adults. In BC, the healthcare system has launched resources to support clinicians
      in proactive advance care planning discussions, and is providing enhanced
      supportive and palliative care options to residents of long-term care facilities.
      If the pandemic truly overwhelms the healthcare system, frailty, but not age
      alone, provides a fair and evidence-based means of triaging patients for critical
      care and could be included into ventilator allocation frameworks. J Am Geriatr
      Soc 68:1666-1670, 2020.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Chase, Jocelyn
AU  - Chase J
AD  - Providence Health Care, Vancouver, Canada.
AD  - Division of Geriatric Medicine, University of British Columbia, Vancouver,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200704
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Advance Care Planning/ethics
MH  - Aged
MH  - Aged, 80 and over
MH  - Betacoronavirus
MH  - British Columbia
MH  - COVID-19
MH  - Clinical Decision-Making/ethics
MH  - Coronavirus Infections/therapy
MH  - Female
MH  - *Frail Elderly
MH  - Frailty/therapy
MH  - Geriatrics/*ethics
MH  - Health Services for the Aged/*ethics
MH  - Humans
MH  - Male
MH  - Palliative Care/ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/therapy
MH  - Public Health/*ethics
MH  - SARS-CoV-2
PMC - PMC7323443
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *frailty
OT  - *older adult
OT  - *pandemic
EDAT- 2020/06/20 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1111/jgs.16666 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Aug;68(8):1666-1670. doi: 10.1111/jgs.16666. Epub 2020 Jul
      4.


PMID- 32557427
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Jun 15
TI  - Medical-ethical recommendations: preimplantation genetic testing PGT.
PG  - w20298
LID - 10.4414/smw.2020.20298 [doi]
LID - Swiss Med Wkly. 2020;150:w20298 [pii]
FAU - Swiss Academy Of Medical Sciences
AU  - Swiss Academy Of Medical Sciences
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - *Genetic Testing
MH  - Humans
EDAT- 2020/06/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.4414/smw.2020.20298 [doi]
AID - Swiss Med Wkly. 2020;150:w20298 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Jun 18;150:w20298. doi: 10.4414/smw.2020.20298. eCollection 
      2020 Jun 15.


PMID- 32557425
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 Jun 1
TI  - The well-being of Swiss general internal medicine residents.
PG  - w20255
LID - 10.4414/smw.2020.20255 [doi]
LID - Swiss Med Wkly. 2020;150:w20255 [pii]
AB  - BACKGROUND: Physician well-being has an impact on productivity and quality of
      care. Residency training is a particularly stressful period. OBJECTIVE: To assess
      the well-being of general internal medicine (GIM) residents and its association
      with personal and work-related factors. METHODS: We conducted an anonymous
      electronic survey among GIM residents from 13 Swiss teaching hospitals. We
      explored the association between a reduced well-being (&ge;5 points based on the 
      Physician Well-Being Index [PWBI]) and personal and work-related factors using
      multivariable mixed-effects logistic regression. RESULTS: The response rate was
      54% (472/880). Overall, 19% of residents had a reduced well-being, 60% felt
      burned out (emotional exhaustion), 47% were worried that their work was hardening
      them emotionally (depersonalisation), and 21% had career choice regret. Age (odds
      ratio [OR] 1.19, 95% confidence interval [CI] 1.05&ndash;1.34), working hours per
      week (OR 1.04 per hour, 95% CI 1.01&ndash;1.07) and &lt;2.5 rewarding work hours 
      per day (OR 3.73, 95% CI 2.01&ndash;6.92) were associated with reduced
      well-being. Administrative workload and satisfaction with the electronic medical 
      record were not. We found significant correlations between PWBI score and job
      satisfaction (rs = -0.54, p&lt;0.001), medical errors (rs = 0.18, p&lt;0.001),
      suicidal ideation (rs = 0.12, p = 0.009) and the intention to leave clinical
      practice (rs = 0.38, p &lt;0.001) CONCLUSIONS: Approximately 20% of Swiss GIM
      residents appear to have a reduced well-being and many show signs of distress or 
      have career choice regret. Having few hours of rewarding work and a high number
      of working hours were the most important modifiable predictors of reduced
      well-being. Healthcare organisations have an ethical responsibility to implement 
      interventions to improve physician well-being.
FAU - Zumbrunn, Brigitta
AU  - Zumbrunn B
AD  - Department of General Internal Medicine, Bern University Hospital, Inselspital,
      Bern, Switzerland.
FAU - Stalder, Odile
AU  - Stalder O
AD  - CTU Bern, and Institute of Social and Preventive Medicine (ISPM), University of
      Bern, Switzerland.
FAU - Limacher, Andreas
AU  - Limacher A
AD  - CTU Bern, and Institute of Social and Preventive Medicine (ISPM), University of
      Bern, Switzerland.
FAU - Ballmer, Peter E
AU  - Ballmer PE
AD  - Department of Internal Medicine, Kantonsspital Winterthur, Switzerland.
FAU - Bassetti, Stefano
AU  - Bassetti S
AD  - Division of Internal Medicine, University Hospital Basel, Switzerland.
FAU - Battegay, Edouard
AU  - Battegay E
AD  - Department of Internal Medicine, University Hospital Zurich, Switzerland.
FAU - Beer, Jurg Hans
AU  - Beer JH
AD  - Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland.
FAU - Brandle, Michael
AU  - Brandle M
AD  - Department of Internal Medicine, Cantonal Hospital of St Gallen, Switzerland.
FAU - Genne, Daniel
AU  - Genne D
AD  - Department of Internal Medicine, Cantonal Hospital of Biel, Switzerland.
FAU - Hayoz, Daniel
AU  - Hayoz D
AD  - Department of Internal Medicine, Cantonal Hospital of Fribourg, Switzerland.
FAU - Henzen, Christoph
AU  - Henzen C
AD  - Department of Internal Medicine, Cantonal Hospital of Lucerne, Switzerland.
FAU - Huber, Lars Chistian
AU  - Huber LC
AD  - Department of Internal Medicine, City Hospital Triemli, Zurich, Switzerland.
FAU - Petignat, Pierre-Auguste
AU  - Petignat PA
AD  - Department of Internal Medicine, Hospital of Valais, Sion, Switzerland.
FAU - Reny, Jean-Luc
AU  - Reny JL
AD  - Division of General Internal Medicine, Geneva University Hospitals, and Faculty
      of Medicine, Geneva University, Geneva, Switzerland.
FAU - Vollenweider, Peter
AU  - Vollenweider P
AD  - Department of Internal Medicine, Lausanne University Hospital, Lausanne,
      Switzerland.
FAU - Aujesky, Drahomir
AU  - Aujesky D
AD  - Department of General Internal Medicine, Bern University Hospital, Inselspital,
      Bern, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - *Burnout, Professional
MH  - Humans
MH  - Internal Medicine/education
MH  - *Internship and Residency
MH  - Job Satisfaction
MH  - Surveys and Questionnaires
MH  - Switzerland
MH  - Workload
EDAT- 2020/06/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.4414/smw.2020.20255 [doi]
AID - Swiss Med Wkly. 2020;150:w20255 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 Jun 18;150:w20255. doi: 10.4414/smw.2020.20255. eCollection 
      2020 Jun 1.


PMID- 32557297
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 2168-4804 (Electronic)
IS  - 2168-4790 (Linking)
VI  - 54
IP  - 4
DP  - 2020 Jul
TI  - A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
PG  - 749-757
LID - 10.1007/s43441-019-00008-2 [doi]
AB  - Randomized controlled clinical trials are the gold standard for evaluating the
      safety and efficacy of pharmaceutical drugs, but in many cases their costs,
      duration, limited generalizability, and ethical or technical feasibility have
      caused some to look for real-world studies as alternatives. On the other hand,
      real-world data may be much less convincing due to the lack of randomization and 
      the presence of confounding bias. In this article, we propose a statistical
      roadmap to translate real-world data (RWD) to robust real-world evidence (RWE).
      The Food and Drug Administration (FDA) is working on guidelines, with a target to
      release a draft by 2021, to harmonize RWD applications and monitor the safety and
      effectiveness of pharmaceutical drugs using RWE. The proposed roadmap aligns with
      the newly released framework for FDA's RWE Program in December 2018 and we hope
      this statistical roadmap is useful for statisticians who are eager to embark on
      their journeys in the real-world research.
FAU - Fang, Yixin
AU  - Fang Y
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
      yixin.fang@abbvie.com.
FAU - Wang, Hongwei
AU  - Wang H
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
FAU - He, Weili
AU  - He W
AD  - AbbVie, 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
LA  - eng
PT  - Journal Article
DEP - 20191206
PL  - Switzerland
TA  - Ther Innov Regul Sci
JT  - Therapeutic innovation & regulatory science
JID - 101597411
SB  - IM
MH  - Bias
MH  - Data Collection/methods
MH  - *Drug Development
MH  - Statistics as Topic
MH  - United States
MH  - United States Food and Drug Administration
OTO - NOTNLM
OT  - *Causal inference
OT  - *Clinical trials
OT  - *Confounding bias
OT  - *Real-world studies
OT  - *Statistical methods
EDAT- 2020/06/20 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/06/04 00:00 [received]
PHST- 2019/09/17 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
AID - 10.1007/s43441-019-00008-2 [doi]
AID - 10.1007/s43441-019-00008-2 [pii]
PST - ppublish
SO  - Ther Innov Regul Sci. 2020 Jul;54(4):749-757. doi: 10.1007/s43441-019-00008-2.
      Epub 2019 Dec 6.


PMID- 32557240
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200917
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Aug
TI  - Correction to: Performance of (99m)Tc-aprotinin scintigraphy for diagnosing light
      chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy.
PG  - 1154
LID - 10.1007/s12350-020-02229-7 [doi]
AB  - This prospective study was conducted according to the principles outlined within 
      the Declaration of Helsinki, and approved by the Ethics Review Board of National 
      Center for Global Health and Medicine (NCGM-G-00839-01, NCGM-G-00839-02).
FAU - Awaya, Toru
AU  - Awaya T
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan. toru0228@gmail.com.
AD  - Division of Cardiovascular Medicine, Toho University Medical Center Ohashi
      Hospital, Tokyo, Japan. toru0228@gmail.com.
FAU - Minamimoto, Ryogo
AU  - Minamimoto R
AD  - Division of Nuclear Medicine, National Center for Global Health and Medicine,
      Tokyo, Japan.
FAU - Iwama, Kentaro
AU  - Iwama K
AD  - Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
FAU - Kubota, Shuji
AU  - Kubota S
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan.
FAU - Hotta, Masatoshi
AU  - Hotta M
AD  - Division of Nuclear Medicine, National Center for Global Health and Medicine,
      Tokyo, Japan.
FAU - Hirai, Risen
AU  - Hirai R
AD  - Department of Hematology, Internal Medicine, Tokyo-Kita Medical Center, Tokyo,
      Japan.
FAU - Yamamoto, Masaya
AU  - Yamamoto M
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan.
FAU - Okazaki, Osamu
AU  - Okazaki O
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan.
FAU - Hara, Hisao
AU  - Hara H
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan.
FAU - Hiroi, Yukio
AU  - Hiroi Y
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan.
FAU - Hiroe, Michiaki
AU  - Hiroe M
AD  - Department of Cardiovascular Medicine, National Center for Global Health and
      Medicine, Tokyo, Japan.
FAU - Moroi, Masao
AU  - Moroi M
AD  - Division of Cardiovascular Medicine, Toho University Medical Center Ohashi
      Hospital, Tokyo, Japan.
LA  - eng
PT  - Published Erratum
PL  - United States
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of
      Nuclear Cardiology
JID - 9423534
SB  - IM
EFR - J Nucl Cardiol. 2020 Aug;27(4):1145-1153. PMID: 31591695
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s12350-020-02229-7 [doi]
AID - 10.1007/s12350-020-02229-7 [pii]
PST - ppublish
SO  - J Nucl Cardiol. 2020 Aug;27(4):1154. doi: 10.1007/s12350-020-02229-7.


PMID- 32557218
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - If the Price is Right: The Ethics and Efficiency of Market Solutions to the Organ
      Shortage.
PG  - 357-367
LID - 10.1007/s11673-020-09981-y [doi]
AB  - Due to the shortage of organs, it has been proposed that the ban on organ sales
      is lifted and a market-based procurement system introduced. This paper assesses
      four prominent proposals for how such a market could be arranged: unregulated
      current market, regulated current market, payment-for-consent futures market, and
      the family-reward futures market. These are assessed in terms of how applicable
      prominent concerns with organ sales are for each model. The concerns evaluated
      are that organ markets will crowd out altruistic donation, that consent to sell
      organs is invalid, that sellers will be harmed, and that commodification of
      organs will affect human relationships in a negative way. The paper concludes
      that the family-reward futures market fares best in this comparison but also that
      it provides the weakest incentive to potential buyers. There is an inverse
      relationship between how applicable prominent critiques are to organ market
      models and the increase in available organs they can be expected to provide.
FAU - Albertsen, Andreas
AU  - Albertsen A
AUID- ORCID: http://orcid.org/0000-0001-7528-2493
AD  - Department of Political Science, School of Business and Social Sciences, Aarhus
      University, Bartholins Alle 7, 8000, Aarhus C, Denmark. aba@ps.au.dk.
LA  - eng
GR  - CF14-0896/Carlsbergfondet
PT  - Journal Article
DEP - 20200615
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Altruism
MH  - Commerce
MH  - Commodification
MH  - Humans
MH  - Motivation
MH  - *Tissue and Organ Procurement/ethics
OTO - NOTNLM
OT  - Coercion
OT  - Exploitation
OT  - Future markets
OT  - Organ markets
OT  - Organ trade
EDAT- 2020/06/20 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/20 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s11673-020-09981-y [doi]
AID - 10.1007/s11673-020-09981-y [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Sep;17(3):357-367. doi: 10.1007/s11673-020-09981-y. Epub 2020 
      Jun 15.


PMID- 32557217
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - Re-examining the Ethics of Genetic Counselling in the Genomic Era.
PG  - 325-335
LID - 10.1007/s11673-020-09983-w [doi]
AB  - Respect for patient autonomy has served as the dominant ethical principle of
      genetic counselling, but as we move into a genomic era, it is time to actively
      re-examine the role that this principle plays in genetic counselling practice. In
      this paper, we argue that the field of genetic counselling should move away from 
      its emphasis on patient autonomy and toward the incorporation of a more balanced 
      set of principles that allows counsellors to offer clear guidance about how best 
      to obtain or use genetic information. We begin with a brief history of how
      respect for patient autonomy gained such emphasis in the field and how it has
      taken on various manifestations over time, including the problematic concept of
      nondirectiveness. After acknowledging the field's preliminary move away from
      nondirectiveness, we turn to a series of arguments about why the continued
      dominance of patient autonomy has become untenable given the arrival of the
      genomic era. To conclude, we describe how a more complete set of bioethical
      principles can be adapted and used by genetic counsellors to strengthen their
      practice without undermining patient autonomy.
FAU - Schupmann, Will
AU  - Schupmann W
AUID- ORCID: http://orcid.org/0000-0002-5937-8118
AD  - Department of Bioethics, Clinical Center, National Institutes of Health, 10
      Center Dr., Bldg. 10/Room 1C118, Bethesda, MD, 20892, USA. wschupmann@gmail.com.
FAU - Jamal, Leila
AU  - Jamal L
AD  - Department of Bioethics, Clinical Center, National Institutes of Health; National
      Institute of Allergy and Infectious Diseases, NIH, 10 Center Dr., Bldg. 10/Room
      1C118, Bethesda, MD, 20892, USA.
FAU - Berkman, Benjamin E
AU  - Berkman BE
AD  - Department of Bioethics, Clinical Center, National Institutes of Health;
      Bioethics Core, National Human Genome Research Institute, NIH, 10 Center Dr.,
      Bldg. 10/Room 1C118, Bethesda, MD, 20892, USA.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - *Genetic Counseling/ethics
MH  - Genomics
MH  - Humans
MH  - Morals
MH  - *Personal Autonomy
OTO - NOTNLM
OT  - Bioethics
OT  - Counselling techniques
OT  - Ethics
OT  - Genetic counselling
OT  - Nondirectiveness
OT  - Professional development
EDAT- 2020/06/20 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/28 00:00 [received]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s11673-020-09983-w [doi]
AID - 10.1007/s11673-020-09983-w [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Sep;17(3):325-335. doi: 10.1007/s11673-020-09983-w. Epub 2020 
      Jun 15.


PMID- 32557179
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1179-1942 (Electronic)
IS  - 0114-5916 (Linking)
VI  - 43
IP  - 9
DP  - 2020 Sep
TI  - Use of Social Media for Pharmacovigilance Activities: Key Findings and
      Recommendations from the Vigi4Med Project.
PG  - 835-851
LID - 10.1007/s40264-020-00951-2 [doi]
AB  - The large-scale use of social media by the population has gained the attention of
      stakeholders and researchers in various fields. In the domain of
      pharmacovigilance, this new resource was initially considered as an opportunity
      to overcome underreporting and monitor the safety of drugs in real time in close 
      connection with patients. Research is still required to overcome technical
      challenges related to data extraction, annotation, and filtering, and there is
      not yet a clear consensus concerning the systematic exploration and use of social
      media in pharmacovigilance. Although the literature has mainly considered signal 
      detection, the potential value of social media to support other pharmacovigilance
      activities should also be explored. The objective of this paper is to present the
      main findings and subsequent recommendations from the French research project
      Vigi4Med, which evaluated the use of social media, mainly web forums, for
      pharmacovigilance activities. This project included an analysis of the existing
      literature, which contributed to the recommendations presented herein. The
      recommendations are categorized into three categories: ethical (related to
      privacy, confidentiality, and follow-up), qualitative (related to the quality of 
      the information), and quantitative (related to statistical analysis). We argue
      that the progress in information technology and the societal need to consider
      patients' experiences should motivate future research on social media
      surveillance for the reinforcement of classical pharmacovigilance.
FAU - Audeh, Bissan
AU  - Audeh B
AUID- ORCID: 0000-0001-8550-8724
AD  - Laboratoire d'informatique medicale et d'ingenierie des Connaissances en e-sante,
      LIMICS, Sorbonne Universite, Inserm, Universite Paris 13, 75006, Paris, France.
      bissan.audeh@gmail.com.
FAU - Bellet, Florelle
AU  - Bellet F
AD  - Centre Regional de Pharmacovigilance, Centre Hospitalier Universitaire de
      Saint-Etienne, Hopital Nord, Saint-Etienne, France.
FAU - Beyens, Marie-Noelle
AU  - Beyens MN
AD  - Centre Regional de Pharmacovigilance, Centre Hospitalier Universitaire de
      Saint-Etienne, Hopital Nord, Saint-Etienne, France.
FAU - Lillo-Le Louet, Agnes
AU  - Lillo-Le Louet A
AD  - Centre Regional de Pharmacovigilance HEGP, AP-HP, Paris, France.
FAU - Bousquet, Cedric
AU  - Bousquet C
AD  - Laboratoire d'informatique medicale et d'ingenierie des Connaissances en e-sante,
      LIMICS, Sorbonne Universite, Inserm, Universite Paris 13, 75006, Paris, France.
AD  - SSPIM, Unit of Public Health and Medical Informatics, CHU University Hospital of 
      Saint Etienne, Saint-Etienne, France.
LA  - eng
GR  - AAP-2013-052/Agence Nationale de Securite du Medicament et des Produits de
      Sante/International
GR  - 2016S076/Agence Nationale de Securite du Medicament et des Produits de
      Sante/International
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
SB  - IM
MH  - *Adverse Drug Reaction Reporting Systems
MH  - France
MH  - Humans
MH  - *Pharmacovigilance
MH  - Research Design
MH  - *Social Media
EDAT- 2020/06/20 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s40264-020-00951-2 [doi]
AID - 10.1007/s40264-020-00951-2 [pii]
PST - ppublish
SO  - Drug Saf. 2020 Sep;43(9):835-851. doi: 10.1007/s40264-020-00951-2.


PMID- 32557007
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Danaher's Ethical Behaviourism: An Adequate Guide to Assessing the Moral Status
      of a Robot?
PG  - 2849-2866
LID - 10.1007/s11948-020-00230-4 [doi]
AB  - This paper critically assesses John Danaher's 'ethical behaviourism', a theory on
      how the moral status of robots should be determined. The basic idea of this
      theory is that a robot's moral status is determined decisively on the basis of
      its observable behaviour. If it behaves sufficiently similar to some entity that 
      has moral status, such as a human or an animal, then we should ascribe the same
      moral status to the robot as we do to this human or animal. The paper argues
      against ethical behaviourism by making four main points. First, it is argued that
      the strongest version of ethical behaviourism understands the theory as relying
      on inferences to the best explanation when inferring moral status. Second, as a
      consequence, ethical behaviourism cannot stick with merely looking at the robot's
      behaviour, while remaining neutral with regard to the difficult question of which
      property grounds moral status. Third, not only behavioural evidence ought to play
      a role in inferring a robot's moral status, but knowledge of the design process
      of the robot and of its designer's intention ought to be taken into account as
      well. Fourth, knowledge of a robot's ontology and how that relates to human
      biology often is epistemically relevant for inferring moral status as well. The
      paper closes with some concluding observations.
FAU - Smids, Jilles
AU  - Smids J
AUID- ORCID: http://orcid.org/0000-0002-1259-0883
AD  - Philosophy & Ethics, Eindhoven University of Technology, Eindhoven, The
      Netherlands. j.smids@erasmusmc.nl.
AD  - Medical Ethics, Philosophy and History of Medicine, Erasmus MC, University
      Medical Centre Rotterdam, Rotterdam, The Netherlands. j.smids@erasmusmc.nl.
LA  - eng
GR  - 10024748/NWO_/Dutch Research Council/Netherlands
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Animals
MH  - *Behaviorism
MH  - Humans
MH  - Intention
MH  - Moral Status
MH  - Morals
MH  - *Robotics
PMC - PMC7550363
OTO - NOTNLM
OT  - *Ethical behaviourism
OT  - *Inference to the best explanation
OT  - *Moral status
OT  - *Robot
OT  - *Robot ethics
EDAT- 2020/06/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s11948-020-00230-4 [doi]
AID - 10.1007/s11948-020-00230-4 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2849-2866. doi: 10.1007/s11948-020-00230-4. Epub
      2020 Jun 16.


PMID- 32556883
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210802
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 8
DP  - 2020 Aug
TI  - Truth in science: experimental design and the legacy of John D Biggers, PhD.,
      DSc.
PG  - 1789-1796
LID - 10.1007/s10815-020-01852-0 [doi]
AB  - The current article presents a brief historical perspective on Professor John D
      Biggers, PhD, DSc. who died on 7 April, 2018. His interests covered reproductive 
      physiology, embryo culture, cryobiology, sperm preservation, statistics and
      experimental design, and the history and ethics of human reproductive biology.
      Emphasis is placed on John Biggers' approach to the development of media for the 
      culture of mammalian preimplantation embryos and to correct several minor
      misconceptions that have arisen in recent years regarding some of his studies.
      Much can be learned from his detailed approach to scientific investigation and
      experimental design. His scientific accomplishments and seminal contributions are
      important, but the tapestry of his life and legacy continue to be woven through
      the many students, fellows, and collaborators with whom he worked with over many 
      years. The present article builds on a previous conversation that Michael Summers
      and Catherine Racowsky had with John Biggers that was published in 2008 [1].
FAU - Summers, Michael Charles
AU  - Summers MC
AD  - London Women's Clinic, 1-8 St Thomas Street, London Bridge, London, SE1 9RY,
      England, UK. Michael.Summers@londonwomensclinic.com.
AD  - School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, England,
      UK. Michael.Summers@londonwomensclinic.com.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
DEP - 20200618
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - *Blastocyst
MH  - Cell Culture Techniques/*history
MH  - Embryonic Development/*genetics
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Research Design
PS  - Biggers JD
FPS - Biggers, John D
PMC - PMC7468005
OTO - NOTNLM
OT  - Embryo culture
OT  - Experimental design
OT  - Simplex optimisation
EDAT- 2020/06/20 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s10815-020-01852-0 [doi]
AID - 10.1007/s10815-020-01852-0 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Aug;37(8):1789-1796. doi: 10.1007/s10815-020-01852-0.
      Epub 2020 Jun 18.


PMID- 32556826
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2110-5820 (Print)
IS  - 2110-5820 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jun 17
TI  - Ethical dilemmas due to the Covid-19 pandemic.
PG  - 84
LID - 10.1186/s13613-020-00702-7 [doi]
AB  - The devastating pandemic that has stricken the worldwide population induced an
      unprecedented influx of patients in ICUs, raising ethical concerns not only
      surrounding triage and withdrawal of life support decisions, but also regarding
      family visits and quality of end-of-life support. These ingredients are liable to
      shake up our ethical principles, sharpen our ethical dilemmas, and lead to
      situations of major caregiver sufferings. Proposals have been made to rationalize
      triage policies in conjunction with ethical justifications. However, whatever the
      angle of approach, imbalance between utilitarian and individual ethics leads to
      unsolvable discomforts that caregivers will need to overcome. With this in mind, 
      we aimed to point out some critical ethical choices with which ICU caregivers
      have been confronted during the Covid-19 pandemic and to underline their limits. 
      The formalized strategies integrating the relevant tools of ethical reflection
      were disseminated without deviating from usual practices, leaving to intensivists
      the ultimate choice of decision.
FAU - Robert, Rene
AU  - Robert R
AUID- ORCID: http://orcid.org/0000-0001-5989-5409
AD  - Universite de Poitiers, Poitiers, France. rene.robert@chu-poitiers.fr.
AD  - Inserm CIC 1402, Axe Alive, Poitiers, France. rene.robert@chu-poitiers.fr.
AD  - Service de Medecine Intensive Reanimation, CHU Poitiers, Poitiers, France.
      rene.robert@chu-poitiers.fr.
FAU - Kentish-Barnes, Nancy
AU  - Kentish-Barnes N
AD  - Service de Reanimation Medicale, APHP, CHU Saint-Louis, Paris, France.
AD  - Groupe de Recherche Famirea, Paris, France.
FAU - Boyer, Alexandre
AU  - Boyer A
AD  - Universite de Bordeaux, Bordeaux, France.
AD  - Service de Medecine Intensive Reanimation, CHU Bordeaux, Bordeaux, France.
FAU - Laurent, Alexandra
AU  - Laurent A
AD  - Laboratoire psy-DREPI, Universite de Bourgogne Franche-Comte, 7458, Dijon,
      France.
AD  - Service de Reanimation Chirurgicale, Dijon, France.
FAU - Azoulay, Elie
AU  - Azoulay E
AD  - Service de Reanimation Medicale, APHP, CHU Saint-Louis, Paris, France.
AD  - Groupe de Recherche Famirea, Paris, France.
FAU - Reignier, Jean
AU  - Reignier J
AD  - Universite de Nantes, Nantes, France.
AD  - Service de Medecine Intensive Reanimation, CHU de Nantes, Nantes, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200617
PL  - Germany
TA  - Ann Intensive Care
JT  - Annals of intensive care
JID - 101562873
PMC - PMC7298921
OTO - NOTNLM
OT  - Burnout
OT  - Covid-19
OT  - End-of-life
OT  - Ethics
OT  - Family-centered care
OT  - ICU
OT  - Pandemic
OT  - Triage
OT  - Withdrawal of life support
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 10.1186/s13613-020-00702-7 [doi]
AID - 10.1186/s13613-020-00702-7 [pii]
PST - epublish
SO  - Ann Intensive Care. 2020 Jun 17;10(1):84. doi: 10.1186/s13613-020-00702-7.


PMID- 32556748
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 41
IP  - 11
DP  - 2020 Nov
TI  - Current application of cannabidiol (CBD) in the management and treatment of
      neurological disorders.
PG  - 3085-3098
LID - 10.1007/s10072-020-04514-2 [doi]
AB  - Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant
      constituents of Cannabis, demonstrates several beneficial effects. It has been
      found to have antioxidative, anti-inflammatory, and neuroprotective effects. As
      the medicinal use of CBD is gaining popularity for treatment of various
      disorders, the recent flare-up of largely unproven and unregulated cannabis-based
      preparations on medical therapeutics may have its greatest impact in the field of
      neurology. Currently, as lot of clinical trials are underway, CBD demonstrates
      remarkable potential to become a supplemental therapy in various neurological
      conditions. It has shown promise in the treatment of neurological disorders such 
      as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors
      as well as psychiatric disorders. While recent FDA-approved prescription drugs
      have demonstrated safety, efficacy, and consistency enough for regulatory
      approval in spasticity in multiple sclerosis (MS) and in Dravet and
      Lennox-Gastaut Syndromes (LGS), many therapeutic challenges still remain. In the 
      current review, the authors have shed light on the application of CBD in the
      management and treatment of various neurological disorders.
FAU - Fiani, Brian
AU  - Fiani B
AD  - Department of Neurosurgery, Desert Regional Medical Center, Palm Springs, CA,
      USA.
FAU - Sarhadi, Kasra John
AU  - Sarhadi KJ
AD  - Miller School of Medicine, University of Miami, Miami, FL, USA.
FAU - Soula, Marisol
AU  - Soula M
AD  - New York University School of Medicine, New York, NY, USA.
FAU - Zafar, Atif
AU  - Zafar A
AD  - Department of Neurology, University of New Mexico, Albuquerque, NM, USA.
FAU - Quadri, Syed A
AU  - Quadri SA
AUID- ORCID: http://orcid.org/0000-0001-7679-1847
AD  - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA, 02114, USA. Saquadri@mgh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200616
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
RN  - 0 (Anticonvulsants)
RN  - 19GBJ60SN5 (Cannabidiol)
SB  - IM
MH  - Anticonvulsants/therapeutic use
MH  - *Cannabidiol/therapeutic use
MH  - *Cannabis
MH  - *Epilepsy/drug therapy
MH  - Humans
MH  - *Lennox Gastaut Syndrome
OTO - NOTNLM
OT  - Cannabidiol
OT  - Efficacy
OT  - Ethicality
OT  - Neurologic disorders
EDAT- 2020/06/20 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1007/s10072-020-04514-2 [doi]
AID - 10.1007/s10072-020-04514-2 [pii]
PST - ppublish
SO  - Neurol Sci. 2020 Nov;41(11):3085-3098. doi: 10.1007/s10072-020-04514-2. Epub 2020
      Jun 16.


PMID- 32555972
OWN - NLM
STAT- MEDLINE
DCOM- 20200624
LR  - 20200624
IS  - 1809-4546 (Electronic)
IS  - 0100-6991 (Linking)
VI  - 47
DP  - 2020
TI  - Surgical ethics: a framework for surgeons, patients, and society.
PG  - e20202519
LID - S0100-69912020000100701 [pii]
LID - 10.1590/0100-6991e-20202519 [doi]
AB  - The practice of surgery is based on the technical capabilities of the surgeon
      (techne), their knowledge (episteme) and their capacity of judgment (phronesis). 
      Surgeons face situations that call into question moral choices and face ethical
      difficulties in their daily practice. In fact, innovation is increasing, and as
      operations become more complex and the risks become greater, the tools necessary 
      to approach an ethically challenging surgical case become more important.
      Surgical ethics can be distinguished from other medical ethics fields because of 
      its unique characteristics and goals. Ethics lie at the core of professionalism: 
      a proficient surgeon is considered to be not only competent to perform the art
      and science of surgery as traditionally understood, but also to be ethically and 
      morally reliable. The principlism and the four-box model approaches to clinical
      ethics could serve as a guide to the surgical ethics discussion. There are five
      categories of experience and relationships that are especially important in
      surgery-rescue, proximity, ordeal, aftermath and presence. Ethical reasoning
      should help surgeons to gives answers to the questions: What should be done? Has 
      the right decision in this situation been made? The following article is
      presented with the intent of encouraging thought and dialogue about ethical
      considerations relevant to the practice of surgery. For that reason, we will
      first define the scope of surgical ethics, then we will present the main ethical 
      issues faced by surgeons and how surgeons deal with them. Finally, I will show
      the implications of the development of surgery ethics for patients, surgeons and 
      society.
FAU - Cardenas, Diana
AU  - Cardenas D
AUID- ORCID: http://orcid.org/0000-0002-0709-0307
AD  - Faculty of Medicine Universidad El Bosque, Research Institute in Nutrition,
      Genetics and Metabolism - Bogota - Colombia.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - Brazil
TA  - Rev Col Bras Cir
JT  - Revista do Colegio Brasileiro de Cirurgioes
JID - 7809515
SB  - IM
MH  - *Ethics, Medical
MH  - General Surgery/*ethics
MH  - Humans
MH  - *Physician-Patient Relations
MH  - Surgeons/*ethics
EDAT- 2020/06/20 06:00
MHDA- 2020/06/25 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/01 00:00 [received]
PHST- 2020/03/01 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
AID - S0100-69912020000100701 [pii]
AID - 10.1590/0100-6991e-20202519 [doi]
PST - epublish
SO  - Rev Col Bras Cir. 2020 Jun 15;47:e20202519. doi: 10.1590/0100-6991e-20202519.
      eCollection 2020.


PMID- 32555664
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 6
DP  - 2020
TI  - Potential research participants' use of information during the consent process: A
      qualitative pilot study of patients enrolled in a clinical trial.
PG  - e0234388
LID - 10.1371/journal.pone.0234388 [doi]
AB  - There is increasing evidence that clinical trial participants are uninformed
      about the trials in which they participate, raising ethical concerns regarding
      informed consent. The aim of this pilot study was to explore clinical trial
      participants' use of consent discussions and information sheets when considering 
      participating in clinical trials research. A qualitative, interview-based pilot
      study was designed in order to elicit, through dialogue, details of the reasons
      for participants' use of, and preferences regarding, different modes of
      information provision. Semi-structured interviews were undertaken with two
      different groups of patients who were participants in the Reinforcement of
      Closure of Stoma Site trial. The first group comprised newly-consented trial
      participants, who had been recruited up to 72 hours before our interview; the
      second group comprised patients attending a follow-up clinic 12 months after
      joining the trial. Thirteen participants were recruited in total: three
      newly-consented patients, and ten follow-up patients. The study found that
      participants' use of consent discussions to gain information about clinical
      trials was varied, and that they only minimally used information sheets after
      providing initial consent for the trial. Participants demonstrated varying
      degrees of knowledge about the trial, with some having forgotten that they were
      still involved in the trial. Participants reported a high level of trust in
      medical staff as a reason for not seeking more information about the trial. Some 
      participants reported dissatisfaction with the timing of information provision.
      Some were amenable to novel ways of receiving trial information, such as
      web-based methods. The pilot study demonstrated the feasibility of a larger study
      into the provision of information to prospective clinical trial participants. The
      results suggest that considering alternative ways of providing information and
      the appropriateness of existing information provision may be acceptable to and
      useful for potential trial participants.
FAU - Jenkins, Simon Paul
AU  - Jenkins SP
AUID- ORCID: 0000-0001-8298-0847
AD  - Division of Health Sciences, Warwick Medical School, University of Warwick,
      Coventry, West Midlands, United Kingdom.
FAU - Calvert, Melanie J
AU  - Calvert MJ
AD  - Centre for Patient Reported Outcomes Research, Institute of Applied Health
      Research, University of Birmingham, Birmingham, West Midlands, United Kingdom.
AD  - National Institute for Health Research Birmingham Biomedical Research Centre,
      University of Birmingham, Birmingham, West Midlands, United Kingdom.
AD  - National Institute for Health Research Applied Research Centre West Midlands, and
      National Institute for Health Research Surgical Reconstruction and Microbiology
      Research Centre, University of Birmingham, Birmingham, West Midlands, United
      Kingdom.
AD  - Birmingham Health Partners Centre for Regulatory Science and Innovation,
      Birmingham, West Midlands, United Kingdom.
FAU - Draper, Heather
AU  - Draper H
AUID- ORCID: 0000-0002-0020-4252
AD  - Division of Health Sciences, Warwick Medical School, University of Warwick,
      Coventry, West Midlands, United Kingdom.
LA  - eng
GR  - G0800808/MRC_/Medical Research Council/United Kingdom
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200618
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Clinical Trials as Topic/*ethics
MH  - Feasibility Studies
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Patient Education as Topic/ethics
MH  - Patient Participation
MH  - Patient Selection/ethics
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Qualitative Research
MH  - Trust
PMC - PMC7302495
COIS- Professor Calvert is a National Institute for Health Research (NIHR) Senior
      Investigator and receives funding from the National Institute for Health Research
      (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction
      and Microbiology Research Centre and NIHR ARC West Midlands at the University of 
      Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data 
      Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer
      Support, UCB Pharma. MC has received personal fees from Astellas, Takeda, Merck, 
      Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute
      (PCORI) outside the submitted work. The views expressed in this article are those
      of the author(s) and not necessarily those of the NIHR, or the Department of
      Health and Social Care. This does not alter our adherence to PLOS ONE policies on
      sharing data and materials.
EDAT- 2020/06/20 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/14 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
AID - 10.1371/journal.pone.0234388 [doi]
AID - PONE-D-19-22970 [pii]
PST - epublish
SO  - PLoS One. 2020 Jun 18;15(6):e0234388. doi: 10.1371/journal.pone.0234388.
      eCollection 2020.


PMID- 32555551
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1538-0688 (Electronic)
IS  - 0190-535X (Linking)
VI  - 47
IP  - 4
DP  - 2020 Jul 1
TI  - Ethical Challenges Encountered by Clinical Trials Nurses: A Grounded Theory
      Study.
PG  - 428-435
LID - 10.1188/20.ONF.428-435 [doi]
AB  - OBJECTIVES: To investigate the ethical challenges experienced by oncology
      clinical trials nurses (OCTNs) during the management of CTs and to examine how
      they resolve those conflicts. SAMPLE &AMP; SETTING: 12 licensed RNs who had been 
      practicing as full- or part-time OCTNs for a minimum of two years at various
      academic medical centers in the United States. METHODS &AMP; VARIABLES: Classical
      grounded theory (CGT), an inductive methodology used to explore a social process 
      in which little is known and to develop a theory grounded in the data, was used, 
      in addition to CGT data analysis strategies. RESULTS: CGT data analysis revealed 
      the OCTNs' main concern (implementing an undefined job) and the way in which the 
      OCTNs resolve this concern through the process of figuring it out. Figuring it
      out consists of learning as they go, utilizing their assets, standing their
      ground, and managing hope. IMPLICATIONS FOR NURSING: Although some nursing
      research provides examples of ethical challenges OCTNs might encounter in
      practice, there is little information regarding how nurses manage those
      encounters. A theoretical understanding of the OCTNs' experiences managing
      ethical challenges fills a gap in the nursing literature and provides a framework
      for how OCTNs manage and respond to challenges in professional practice.
FAU - Forbes, Sheryl G
AU  - Forbes SG
AUID- ORCID: 0000-0003-4335-2260
AD  - University of Texas MD Anderson Cancer Center.
FAU - Phillips, Carolyn A
AU  - Phillips CA
AD  - University of Texas Medical Branch.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncol Nurs Forum
JT  - Oncology nursing forum
JID - 7809033
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Clinical Trials as Topic/*ethics
MH  - Female
MH  - Grounded Theory
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Research/*ethics/*methods
MH  - Nursing Staff, Hospital/*ethics/*psychology
MH  - Oncology Nursing/*ethics
MH  - Qualitative Research
MH  - United States
OTO - NOTNLM
OT  - *classical grounded theory
OT  - *clinical trial
OT  - *clinical trials nurse
OT  - *ethical challenge
OT  - *ethics
EDAT- 2020/06/20 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
AID - 10.1188/20.ONF.428-435 [doi]
PST - ppublish
SO  - Oncol Nurs Forum. 2020 Jul 1;47(4):428-435. doi: 10.1188/20.ONF.428-435.


PMID- 32555420
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210618
IS  - 1759-4782 (Electronic)
IS  - 1759-4774 (Linking)
VI  - 17
IP  - 11
DP  - 2020 Nov
TI  - Personalized early detection and prevention of breast cancer: ENVISION consensus 
      statement.
PG  - 687-705
LID - 10.1038/s41571-020-0388-9 [doi]
AB  - The European Collaborative on Personalized Early Detection and Prevention of
      Breast Cancer (ENVISION) brings together several international research consortia
      working on different aspects of the personalized early detection and prevention
      of breast cancer. In a consensus conference held in 2019, the members of this
      network identified research areas requiring development to enable evidence-based 
      personalized interventions that might improve the benefits and reduce the harms
      of existing breast cancer screening and prevention programmes. The priority areas
      identified were: 1) breast cancer subtype-specific risk assessment tools
      applicable to women of all ancestries; 2) intermediate surrogate markers of
      response to preventive measures; 3) novel non-surgical preventive measures to
      reduce the incidence of breast cancer of poor prognosis; and 4) hybrid
      effectiveness-implementation research combined with modelling studies to evaluate
      the long-term population outcomes of risk-based early detection strategies. The
      implementation of such programmes would require health-care systems to be open to
      learning and adapting, the engagement of a diverse range of stakeholders and
      tailoring to societal norms and values, while also addressing the ethical and
      legal issues. In this Consensus Statement, we discuss the current state of breast
      cancer risk prediction, risk-stratified prevention and early detection
      strategies, and their implementation. Throughout, we highlight priorities for
      advancing each of these areas.
FAU - Pashayan, Nora
AU  - Pashayan N
AUID- ORCID: http://orcid.org/0000-0003-0843-2468
AD  - Department of Applied Health Research, Institute of Epidemiology and Healthcare, 
      University College London, London, UK.
FAU - Antoniou, Antonis C
AU  - Antoniou AC
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Ivanus, Urska
AU  - Ivanus U
AUID- ORCID: http://orcid.org/0000-0002-7909-522X
AD  - Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana,
      Slovenia.
FAU - Esserman, Laura J
AU  - Esserman LJ
AD  - Carol Franc Buck Breast Care Center, University of California, San Francisco, CA,
      USA.
FAU - Easton, Douglas F
AU  - Easton DF
AUID- ORCID: http://orcid.org/0000-0003-2444-3247
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - French, David
AU  - French D
AUID- ORCID: http://orcid.org/0000-0002-7663-7804
AD  - Division of Psychology & Mental Health, School of Health Sciences, University of 
      Manchester, Manchester, UK.
FAU - Sroczynski, Gaby
AU  - Sroczynski G
AD  - Department of Public Health, Health Services Research and Health Technology
      Assessment, Institute of Public Health, Medical Decision Making and Health
      Technology Assessment, UMIT-University for Health Sciences, Medical Informatics
      and Technology, Hall in Tirol, Austria.
AD  - Division of Health Technology Assessment, Oncotyrol - Center for Personalized
      Cancer Medicine, Innsbruck, Austria.
FAU - Hall, Per
AU  - Hall P
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
AD  - Department of Oncology, Sodersjukhuset, Stockholm, Sweden.
FAU - Cuzick, Jack
AU  - Cuzick J
AD  - Wolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer
      Prevention, Queen Mary University of London, London, UK.
FAU - Evans, D Gareth
AU  - Evans DG
AD  - Division of Evolution and Genomic Sciences, University of Manchester, Manchester,
      UK.
FAU - Simard, Jacques
AU  - Simard J
AUID- ORCID: http://orcid.org/0000-0001-6906-3390
AD  - Genomics Center, CHU de Quebec - Universite Laval Research Center, Quebec,
      Canada.
FAU - Garcia-Closas, Montserrat
AU  - Garcia-Closas M
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Bethesda, MD, USA.
FAU - Schmutzler, Rita
AU  - Schmutzler R
AD  - Center of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne,
      Germany.
FAU - Wegwarth, Odette
AU  - Wegwarth O
AD  - Max Planck Institute for Human Development, Center for Adaptive Rationality,
      Harding Center for Risk Literacy, Berlin, Germany.
FAU - Pharoah, Paul
AU  - Pharoah P
AUID- ORCID: http://orcid.org/0000-0001-8494-732X
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
AD  - Department of Oncology, University of Cambridge, Cambridge, UK.
FAU - Moorthie, Sowmiya
AU  - Moorthie S
AD  - PHG Foundation, Cambridge, UK.
FAU - De Montgolfier, Sandrine
AU  - De Montgolfier S
AUID- ORCID: http://orcid.org/0000-0002-4216-9379
AD  - IRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.
FAU - Baron, Camille
AU  - Baron C
AD  - Unicancer, Paris, France.
FAU - Herceg, Zdenko
AU  - Herceg Z
AUID- ORCID: http://orcid.org/0000-0003-4109-3154
AD  - Epigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, 
      France.
FAU - Turnbull, Clare
AU  - Turnbull C
AD  - Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
FAU - Balleyguier, Corinne
AU  - Balleyguier C
AD  - Department Medical Imaging, Institut Gustave Roussy, Villejuif, France.
FAU - Rossi, Paolo Giorgi
AU  - Rossi PG
AD  - Epidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.
FAU - Wesseling, Jelle
AU  - Wesseling J
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, Netherlands.
FAU - Ritchie, David
AU  - Ritchie D
AUID- ORCID: http://orcid.org/0000-0003-4816-113X
AD  - Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
FAU - Tischkowitz, Marc
AU  - Tischkowitz M
AD  - Department of Medical Genetics, National Institute for Health Research Cambridge 
      Biomedical Research Centre, University of Cambridge, Cambridge, UK.
FAU - Broeders, Mireille
AU  - Broeders M
AD  - Department for Health Evidence, Radboud University Medical Center, Nijmegen,
      Netherlands.
FAU - Reisel, Dan
AU  - Reisel D
AD  - Department of Women's Cancer, Institute for Women's Health, University College
      London, London, UK.
FAU - Metspalu, Andres
AU  - Metspalu A
AUID- ORCID: http://orcid.org/0000-0002-3718-796X
AD  - The Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu,
      Estonia.
FAU - Callender, Thomas
AU  - Callender T
AUID- ORCID: http://orcid.org/0000-0001-8440-9433
AD  - Department of Applied Health Research, Institute of Epidemiology and Healthcare, 
      University College London, London, UK.
FAU - de Koning, Harry
AU  - de Koning H
AUID- ORCID: http://orcid.org/0000-0003-4682-3646
AD  - Department of Public Health, Erasmus MC, Rotterdam, Netherlands.
FAU - Devilee, Peter
AU  - Devilee P
AD  - Department of Human Genetics, Department of Pathology, Leiden University Medical 
      Centre, Leiden, Netherlands.
FAU - Delaloge, Suzette
AU  - Delaloge S
AUID- ORCID: http://orcid.org/0000-0003-2106-9165
AD  - Breast Cancer Department, Gustave Roussy Institute, Paris, France.
FAU - Schmidt, Marjanka K
AU  - Schmidt MK
AUID- ORCID: http://orcid.org/0000-0002-2228-429X
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, Netherlands.
FAU - Widschwendter, Martin
AU  - Widschwendter M
AUID- ORCID: http://orcid.org/0000-0002-7778-8380
AD  - Department of Women's Cancer, Institute for Women's Health, University College
      London, London, UK. M.Widschwendter@ucl.ac.uk.
AD  - Universitat Innsbruck, Innsbruck, Austria. M.Widschwendter@ucl.ac.uk.
AD  - European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall
      in Tirol, Austria. M.Widschwendter@ucl.ac.uk.
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200618
PL  - England
TA  - Nat Rev Clin Oncol
JT  - Nature reviews. Clinical oncology
JID - 101500077
SB  - IM
EIN - Nat Rev Clin Oncol. 2020 Jun 29;:. PMID: 32601456
MH  - Breast Neoplasms/*diagnosis/genetics/*prevention & control
MH  - Consensus
MH  - Early Detection of Cancer
MH  - Evidence-Based Medicine
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Mass Screening
MH  - Precision Medicine
PMC - PMC7567644
EDAT- 2020/06/20 06:00
MHDA- 2021/02/11 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1038/s41571-020-0388-9 [doi]
AID - 10.1038/s41571-020-0388-9 [pii]
PST - ppublish
SO  - Nat Rev Clin Oncol. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. Epub
      2020 Jun 18.


PMID- 32555418
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220210
IS  - 1530-0366 (Electronic)
IS  - 1098-3600 (Linking)
VI  - 22
IP  - 10
DP  - 2020 Oct
TI  - Ethical conflicts in translational genetic research: lessons learned from the
      eMERGE-III experience.
PG  - 1667-1672
LID - 10.1038/s41436-020-0863-9 [doi]
AB  - PURPOSE: The Electronic Medical Records and Genomics (eMERGE) Consortium
      integrated biorepository-based research with electronic health records (EHR) to
      return results from large-scale genetic tests to participants and uploaded those 
      data into the EHR. This article explores the ethical issues investigators
      encountered in that process. METHODS: We conducted in-depth, semistructured
      interviews with study personnel of the eMERGE-III Consortium sites that returned 
      results. RESULTS: We discuss major ethical issues that arose while attempting to 
      return research results from the eMERGE Consortium to individual participants.
      These included difficulties recontacting those participants who had not
      explicitly consented to such and disclosing results to many participants with
      insufficient infrastructure and staff. Investigators reported being driven by a
      supererogatory clinical impulse. CONCLUSION: All these issues ultimately derive
      from ethical conflicts inherent to translational work being done at the interface
      of research and clinical care. A critical rethinking of this divide is important,
      but infrastructural support for such work is necessary for an ethically sound
      rollout of large-scale genetic testing.
FAU - Halverson, Colin M E
AU  - Halverson CME
AUID- ORCID: http://orcid.org/0000-0002-4205-7860
AD  - Center for Bioethics, Indiana University School of Medicine, Indianapolis, IN,
      USA. chalver@iu.edu.
AD  - Department of Anthropology, Indiana University, Indianapolis, IN, USA.
      chalver@iu.edu.
AD  - Regenstrief Institute, Indianapolis, IN, USA. chalver@iu.edu.
FAU - Bland, Sarah T
AU  - Bland ST
AD  - Department of Biomedical Informatics, Vanderbilt University Medical Center,
      Nashville, TN, USA.
FAU - Leppig, Kathleen A
AU  - Leppig KA
AD  - Genetic Services, Kaiser Permanente of Washington and Kaiser Permanente
      Washington Health Research Institute, Seattle, WA, USA.
FAU - Marasa, Maddalena
AU  - Marasa M
AD  - Division of Nephrology, Department of Medicine, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Myers, Melanie
AU  - Myers M
AD  - Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH, USA.
AD  - College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
FAU - Rasouly, Hila Milo
AU  - Rasouly HM
AD  - Division of Nephrology, Department of Medicine, Columbia University Irving
      Medical Center, New York, NY, USA.
FAU - Wynn, Julia
AU  - Wynn J
AD  - Department of Pediatrics, Columbia University Irving Medical Center, New York,
      NY, USA.
FAU - Clayton, Ellen Wright
AU  - Clayton EW
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN, USA.
AD  - Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN,
      USA.
AD  - School of Law, Vanderbilt University, Nashville, TN, USA.
LA  - eng
GR  - U01 HG008676/HG/NHGRI NIH HHS/United States
GR  - U01 HG008657/HG/NHGRI NIH HHS/United States
GR  - R01 HG010004/HG/NHGRI NIH HHS/United States
GR  - U01 HG008672/HG/NHGRI NIH HHS/United States
GR  - U01 HG008684/HG/NHGRI NIH HHS/United States
GR  - U01 HG008679/HG/NHGRI NIH HHS/United States
GR  - U01 HG008666/HG/NHGRI NIH HHS/United States
GR  - U01 HG008680/HG/NHGRI NIH HHS/United States
GR  - U01 HG008673/HG/NHGRI NIH HHS/United States
GR  - U01 HG008685/HG/NHGRI NIH HHS/United States
GR  - U01 HG006379/HG/NHGRI NIH HHS/United States
GR  - U01 HG008664/HG/NHGRI NIH HHS/United States
GR  - U01 HG008701/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200618
PL  - United States
TA  - Genet Med
JT  - Genetics in medicine : official journal of the American College of Medical
      Genetics
JID - 9815831
SB  - IM
MH  - *Electronic Health Records
MH  - Genetic Research
MH  - *Genomics
MH  - Humans
MH  - Translational Research, Biomedical
PMC - PMC7521988
OTO - NOTNLM
OT  - *electronic health records
OT  - *genomic testing
OT  - *regulation
OT  - *research ethics
OT  - *translational research
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1038/s41436-020-0863-9 [doi]
AID - S1098-3600(21)00751-6 [pii]
PST - ppublish
SO  - Genet Med. 2020 Oct;22(10):1667-1672. doi: 10.1038/s41436-020-0863-9. Epub 2020
      Jun 18.


PMID- 32554907
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20201218
IS  - 0973-7138 (Electronic)
IS  - 0250-5991 (Linking)
VI  - 45
DP  - 2020
TI  - Current global vaccine and drug efforts against COVID-19: Pros and cons of
      bypassing animal trials.
LID - 82 [pii]
AB  - COVID-19 has become one of the biggest health concern, along with huge economic
      burden. With no clear remedies to treat the disease, doctors are repurposing
      drugs like chloroquine and remdesivir to treat COVID-19 patients. In parallel,
      research institutes in collaboration with biotech companies have identified
      strategies to use viral proteins as vaccine candidates for COVID-19. Although
      this looks promising, they still need to pass the test of challenge studies in
      animal models. As various models for SARS-CoV-2 are under testing phase, biotech 
      companies have bypassed animal studies and moved to Phase I clinical trials. In
      view of the present outbreak, this looks a justified approach, but the problem is
      that in the absence of animal studies, we can never predict the outcomes in
      humans. Since animal models are critical for vaccine development and SARS-CoV-2
      has different transmission dynamics, in this review we compare different animal
      models of SARS-CoV-2 with humans for their pathogenic, immune response and
      transmission dynamics that make them ideal models for vaccine testing for
      COVID-19. Another issue of using animal model is the ethics of using animals for 
      research; thus, we also discuss the pros and cons of using animals for vaccine
      development studies.
FAU - Deb, Bijayeeta
AU  - Deb B
AD  - Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517
      507, India.
FAU - Shah, Hemal
AU  - Shah H
FAU - Goel, Suchi
AU  - Goel S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Biosci
JT  - Journal of biosciences
JID - 8100809
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - *Animal Experimentation
MH  - Animals
MH  - COVID-19
MH  - Coronavirus Infections/drug therapy/*immunology
MH  - Humans
MH  - *Models, Animal
MH  - Pandemics
MH  - Pneumonia, Viral/drug therapy/*immunology
MH  - *Viral Vaccines
PMC - PMC7291183
EDAT- 2020/06/20 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PST - ppublish
SO  - J Biosci. 2020;45.


PMID- 32554744
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Effectiveness of cervical pessary compared to cervical cerclage with or without
      vaginal progesterone for the prevention of preterm birth in women with twin
      pregnancies and a short cervix: study protocol for a two-by-two factorial
      randomised clinical trial.
PG  - e036587
LID - 10.1136/bmjopen-2019-036587 [doi]
AB  - INTRODUCTION: Women with twin pregnancies and a short cervix are at increased
      risk for preterm birth (PTB). Given the burden of prematurity and its attendant
      risks, the quest for effective interventions in twins has been an area of
      considerable research. Studies investigating the effectiveness of cervical
      cerclage, cervical pessary and vaginal progesterone in preventing PTB have
      yielded conflicting results. The aim of this study is to compare the
      effectiveness of cervical pessary and cervical cerclage with or without vaginal
      progesterone to prevent PTB in women with twin pregnancies and a cervical length 
      (CL) </= 28 mm. METHODS AND ANALYSIS: This multicentre, randomised clinical trial
      will be conducted at My Duc Hospital and My Duc Phu Nhuan Hospital, Vietnam.
      Asymptomatic women with twin pregnancies and a CL </=28 mm, measured at 16-22
      weeks' gestation, will be randomised in a 1:1:1:1 ratio to receive a cerclage,
      pessary, cerclage plus progesterone or pessary plus progesterone. Primary outcome
      will be PTB <34 weeks. Secondary outcomes will be maternal and neonatal
      complications. We preplanned a subgroup analysis according to CL from all women
      after randomisation and divided into four quartiles. Analysis will be conducted
      on an intention-to-treat basis. The rate of PTB <34 weeks' gestation in women
      with twin pregnancies and a cervix </=28 mm and treated with pessary in our
      previous study at My Duc Hospital was 24.2%. A sample size of 340 women will be
      required to show or refute that cervical cerclage decreases the rate of PTB <34
      weeks by 50% compared with pessary (from 24.2% to 12.1%, alpha level 0.05, power 
      80%, 5% lost to follow-up and protocol deviation). This study is not to be
      powered to assess interactions between interventions. ETHICS AND DISSEMINATION:
      Ethical approval was obtained from the Institutional Ethics Committee of My Duc
      Hospital and informed patient consent was obtained before study enrolment.
      Results of the study will be submitted for publication in a peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: NCT03863613 (date of registration: 4 March
      2019).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Dang, Vinh Q
AU  - Dang VQ
AUID- ORCID: 0000-0001-5205-8210
AD  - Department of Obstetrics and Gynecology, My Duc Hospital, Ho Chi Minh City, Viet 
      Nam bsvinh.dq@myduchospital.vn.
AD  - HOPE Research Center, Ho Chi Minh City, Viet Nam.
FAU - He, Yen Tn
AU  - He YT
AD  - HOPE Research Center, Ho Chi Minh City, Viet Nam.
AD  - Department of Obstetrics and Gynecology, My Duc Phu Nhuan Hospital, Ho Chi Minh
      City, Viet Nam.
FAU - Pham, Ha Nh
AU  - Pham HN
AD  - Department of Obstetrics and Gynecology, My Duc Hospital, Ho Chi Minh City, Viet 
      Nam.
FAU - Trieu, Tuyen Tt
AU  - Trieu TT
AD  - Department of Obstetrics and Gynecology, My Duc Phu Nhuan Hospital, Ho Chi Minh
      City, Viet Nam.
FAU - Bui, Trung Q
AU  - Bui TQ
AD  - Department of Obstetrics and Gynecology, My Duc Hospital, Ho Chi Minh City, Viet 
      Nam.
FAU - Vuong, Nhu T
AU  - Vuong NT
AD  - Department of Obstetrics and Gynecology, My Duc Hospital, Ho Chi Minh City, Viet 
      Nam.
FAU - Nguyen, Loc Mt
AU  - Nguyen LM
AD  - HOPE Research Center, Ho Chi Minh City, Viet Nam.
FAU - Nguyen, Diem Tn
AU  - Nguyen DT
AD  - HOPE Research Center, Ho Chi Minh City, Viet Nam.
FAU - Le, Thanh V
AU  - Le TV
AD  - Department of Obstetrics and Gynecology, My Duc Hospital, Ho Chi Minh City, Viet 
      Nam.
FAU - Li, Wentao
AU  - Li W
AD  - Department of Obstetrics and Gynecology, Monash University, Clayton, Victoria,
      Australia.
FAU - Le, Cam H
AU  - Le CH
AD  - Department of Obstetrics and Gynecology, My Duc Phu Nhuan Hospital, Ho Chi Minh
      City, Viet Nam.
FAU - Mol, Ben W
AU  - Mol BW
AD  - Department of Obstetrics and Gynecology, Monash University, Clayton, Victoria,
      Australia.
FAU - Vuong, Lan N
AU  - Vuong LN
AD  - Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at
      HCMC, Ho Chi Minh City, Viet Nam.
LA  - eng
SI  - ClinicalTrials.gov/NCT03863613
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 4G7DS2Q64Y (Progesterone)
SB  - IM
MH  - Adult
MH  - *Cerclage, Cervical
MH  - Cervix Uteri/*anatomy & histology
MH  - Female
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Pessaries
MH  - Pregnancy
MH  - *Pregnancy, Multiple
MH  - Premature Birth/*prevention & control
MH  - Progesterone/administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Vietnam
PMC - PMC7304826
OTO - NOTNLM
OT  - *fetal medicine
OT  - *maternal medicine
OT  - *ultrasonography
COIS- Competing interests: VQD has received grant from Merck Sharpe and Dohme. BWM
      reports support from a NHMRC Practitioner Fellowship (GNT1082548) and consultancy
      for ObsEva, Merck and Guerbet. LNV has received speaker and conference fees from 
      Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and
      speaker, conference and scientific board fees from Ferring.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-036587 [pii]
AID - 10.1136/bmjopen-2019-036587 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e036587. doi: 10.1136/bmjopen-2019-036587.


PMID- 32554743
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Protocol for a systematic review and meta-analysis of long-term neurocognitive
      outcomes in paediatric traumatic brain injury.
PG  - e035513
LID - 10.1136/bmjopen-2019-035513 [doi]
AB  - INTRODUCTION: Children who suffer from traumatic brain injury (TBI) are at risk
      of permanent brain damage and developmental deficits. Reports on
      neurodevelopmental outcomes in paediatric TBI suffer from small sample size and
      varying outcome definitions in the neurocognitive domains tested. This protocol
      describes a systematic review and meta-analysis of paediatric TBI in the
      following key neurocognitive domains: executive function, perceptual-motor
      function, language, learning and memory, social cognition and complex attention. 
      METHODS: A comprehensive search comprising studies from Medline, Cochrane, Embase
      and PsycINFO published from 1988 to 2019 will be conducted. We will include
      studies on children </=18 years old who suffer from mild, moderate and severe TBI
      as determined by the Glasgow Coma Scale that report neurocognitive outcomes in
      domains predetermined by the Diagnostic and Statistical Manual of Mental
      Disorders fifth edition criteria. Systematic reviews, meta-analyses, randomised
      controlled trials, case-control, cohort and cross-sectional studies will be
      included. References from systematic reviews and meta-analyses will be
      hand-searched for relevant articles. A meta-analysis will be performed and effect
      sizes will be calculated to summarise the magnitude of change in each
      neurocognitive domain compared at different timepoints and stratified by severity
      of TBI. Included studies will be pooled using pooled standardised mean
      differences with a random effects model to determine an overall effect. In the
      scenario that we are unable to pool the studies, we will perform a narrative
      analysis. ETHICS AND DISSEMINATION: Ethics approval is not required for this
      study.The authors of this study will publish and present the findings in a
      peer-reviewed journal as well as national and international conferences. The
      results of this study will provide understanding into the association between
      different severities of paediatric TBI and long-term neurocognitive outcomes.
      PROSPERO REGISTRATION NUMBER: CRD42020152680.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Looi, Dawn Shu Hui
AU  - Looi DSH
AD  - Lee Kong Chian School of Medicine, Singapore.
FAU - Goh, Mark Sen Liang
AU  - Goh MSL
AUID- ORCID: 0000-0003-1183-314X
AD  - Duke-NUS Medical School, Singapore.
FAU - Goh, Sharon Si Min
AU  - Goh SSM
AD  - Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore.
FAU - Goh, Jia Ling
AU  - Goh JL
AD  - NUS Yong Loo Lin School of Medicine, Singapore.
FAU - Sultana, Rehena
AU  - Sultana R
AD  - Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore.
FAU - Lee, Jan Hau
AU  - Lee JH
AD  - Children's Intensive Care Unit, KK Women's and Children's Hospital, Duke-NUS
      Medical School, Singapore.
FAU - Chong, Shu-Ling
AU  - Chong SL
AUID- ORCID: 0000-0003-4647-0019
AD  - Department of Emergency Medicine, KK Women's and Children's Hospital, Duke-NUS
      Medical School, Singapore chong.shu-ling@kkh.com.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brain Injuries, Traumatic/*complications/physiopathology
MH  - Child
MH  - Cognition Disorders/*etiology/physiopathology
MH  - Glasgow Coma Scale
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Prognosis
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7304810
OTO - NOTNLM
OT  - *brain injuries
OT  - *child
OT  - *cognitive disorders
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-035513 [pii]
AID - 10.1136/bmjopen-2019-035513 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e035513. doi: 10.1136/bmjopen-2019-035513.


PMID- 32554741
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Preoperative opioid use and complications following total joint replacement: a
      protocol for a systematic review and meta-analysis.
PG  - e035377
LID - 10.1136/bmjopen-2019-035377 [doi]
AB  - INTRODUCTION: Mounting evidence now indicates that preoperative opioid use is
      associated with an array of complications following total joint replacement
      (TJR). However, evidence of these risks remains fragmented. A comprehensive and
      well-integrated understanding of this body of evidence is necessary to
      appropriately inform treatment decisions, the allocation of limited healthcare
      resources, and the direction of future clinical research. The proposed systematic
      review and meta-analysis aims to identify and synthesise the available evidence
      of an association between opioid use prior to TJR and postoperative
      complications, categorised by complication type. METHODS AND ANALYSIS: We will
      search MEDLINE, EMBASE, CINAHL, PsycINFO, and Web of Science from inception to
      April 2020. Observational and experimental studies that compare preoperative
      opioid users who have undergone elective TJR to opioid naive TJR patients will be
      included. The primary outcomes will be postoperative complications, which will be
      categorised as either mortality, morbidity, or joint-related complications. The
      secondary outcomes will be persistent postoperative opioid use, readmission, and 
      length of stay. Individual study quality will be assessed using the relevant
      NIH-NHLBI study quality assessment tools. Findings will be reported in narrative 
      and tabular form, and, where possible, odds ratios (dichotomous outcomes) or
      standardised mean differences (continuous outcomes) will be reported with 95%
      confidence intervals. Where appropriate, random effect meta-analyses will be
      conducted for each outcome, and heterogeneity will be quantified using the I(2)
      statistic and Cochran's Q test. This study will be reported in accordance with
      the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
      and Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines.
      ETHICS AND DISSEMINATION: Ethics approval will not be required as no primary or
      private data are being collected. Findings will be disseminated through
      peer-reviewed publication and presentation at academic conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020153047.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shadbolt, Cade
AU  - Shadbolt C
AUID- ORCID: 0000-0002-0937-2412
AD  - Department of Surgery, The University of Melbourne, St Vincent's Hospital,
      Melbourne, Victoria, Australia.
FAU - Gould, Daniel
AU  - Gould D
AD  - Department of Surgery, The University of Melbourne, St Vincent's Hospital,
      Melbourne, Victoria, Australia.
FAU - Camacho, Ximena
AU  - Camacho X
AD  - Centre for Digital Transformation of Health, Faculty of Medicine, Dentistry and
      Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Knight, Josh
AU  - Knight J
AD  - Centre for Health Policy, Melbourne School of Population and Global Health, The
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Rele, Siddharth
AU  - Rele S
AD  - Department of Surgery, The University of Melbourne, St Vincent's Hospital,
      Melbourne, Victoria, Australia.
AD  - Melbourne Medical School, The University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Thuraisingam, Sharmala
AU  - Thuraisingam S
AD  - Department of Surgery, The University of Melbourne, St Vincent's Hospital,
      Melbourne, Victoria, Australia.
AD  - Department of General Practice, The University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Zhang, Yuting
AU  - Zhang Y
AD  - Melbourne Institute: Applied Economic & Social Research, Faculty of Business &
      Economics, The University of Melbourne, Melbourne, Victoria, Australia.
FAU - Dowsey, Michelle M
AU  - Dowsey MM
AUID- ORCID: 0000-0002-9708-5308
AD  - Department of Surgery, The University of Melbourne, St Vincent's Hospital,
      Melbourne, Victoria, Australia.
AD  - Department of Orthopaedics, St Vincent's Hospital, Melbourne, Fitzroy, Victoria, 
      Australia.
FAU - Choong, Peter Fm
AU  - Choong PF
AD  - Department of Surgery, The University of Melbourne, St Vincent's Hospital,
      Melbourne, Victoria, Australia sarcoma@bigpond.net.au.
AD  - Department of Orthopaedics, St Vincent's Hospital, Melbourne, Fitzroy, Victoria, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/adverse effects/*therapeutic use
MH  - *Arthroplasty, Replacement
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pain, Postoperative/*prevention & control
MH  - Postoperative Complications/chemically induced
MH  - Preoperative Care
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7304809
OTO - NOTNLM
OT  - *complications
OT  - *meta-analysis
OT  - *opioid
OT  - *systematic review
OT  - *total joint replacement
COIS- Competing interests: MMD reports personal fees from Pfizer and grants from
      Medacta, outside the submitted work; PFMC reports personal fees from Stryker,
      Johnson & Johnson, and Kluwer, and grants from Medacta, outside the submitted
      work. All other authors declare that the research was conducted in the absence of
      any commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-035377 [pii]
AID - 10.1136/bmjopen-2019-035377 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e035377. doi: 10.1136/bmjopen-2019-035377.


PMID- 32554740
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20220507
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Prospective evaluation of improving fluoroquinolone exposure using centralised
      therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a
      study protocol of a prospective multicentre cohort study.
PG  - e035350
LID - 10.1136/bmjopen-2019-035350 [doi]
AB  - INTRODUCTION: Global multidrug-resistant tuberculosis (MDR-TB) treatment success 
      rates remain suboptimal. Highly active WHO group A drugs moxifloxacin and
      levofloxacin show intraindividual and interindividual pharmacokinetic variability
      which can cause low drug exposure. Therefore, therapeutic drug monitoring (TDM)
      of fluoroquinolones is recommended to personalise the drug dosage, aiming to
      prevent the development of drug resistance and optimise treatment. However, TDM
      is considered laborious and expensive, and the clinical benefit in MDR-TB has not
      been extensively studied. This observational multicentre study aims to determine 
      the feasibility of centralised TDM and to investigate the impact of
      fluoroquinolone TDM on sputum conversion rates in patients with MDR-TB compared
      with historical controls. METHODS AND ANALYSIS: Patients aged 18 years or older
      with sputum smear and culture-positive pulmonary MDR-TB will be eligible for
      inclusion. Patients receiving TDM using a limited sampling strategy (t=0 and t=5 
      hours) will be matched to historical controls without TDM in a 1:2 ratio. Sample 
      analysis and dosing advice will be performed in a centralised laboratory.
      Centralised TDM will be considered feasible if >80% of the dosing recommendations
      are returned within 7 days after sampling and 100% within 14 days. The number of 
      patients who are sputum smear and culture-negative after 2 months of treatment
      will be determined in the prospective TDM group and will be compared with the
      control group without TDM to determine the impact of TDM. ETHICS AND
      DISSEMINATION: Ethical clearance was obtained by the ethical review committees of
      the 10 participating hospitals according to local procedures or is pending
      (online supplementary file 1). Patients will be included after obtaining written 
      informed consent. We aim to publish the study results in a peer-reviewed journal.
      TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03409315).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - van den Elsen, Simone Hj
AU  - van den Elsen SH
AD  - Department of Clinical Pharmacy and Pharmacology, University of Groningen,
      University Medical Center Groningen, Groningen, The Netherlands.
FAU - Sturkenboom, Marieke Gg
AU  - Sturkenboom MG
AD  - Department of Clinical Pharmacy and Pharmacology, University of Groningen,
      University Medical Center Groningen, Groningen, The Netherlands.
FAU - Akkerman, Onno
AU  - Akkerman O
AD  - Department of Pulmonary Diseases and Tuberculosis, University of Groningen,
      University Medical Center Groningen, Groningen, The Netherlands.
AD  - Tuberculosis Center Beatrixoord, University of Groningen, University Medical
      Center Groningen, Haren, The Netherlands.
FAU - Barkane, Linda
AU  - Barkane L
AD  - Department of Multidrug Resistant Tuberculosis, Riga East University Hospital TB 
      and Lung Disease Clinic, Riga, Latvia.
FAU - Bruchfeld, Judith
AU  - Bruchfeld J
AD  - Division of Infectious Diseases, Department of Medicine, Solna, Karolinska
      Institutet, Stockholm, Sweden.
AD  - Department of Infectious Diseases, Karolinska University Hospital, Stockholm,
      Sweden.
FAU - Eather, Geoffrey
AU  - Eather G
AD  - Department of Respiratory Medicine and Metro South Clinical Tuberculosis Service,
      Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
FAU - Heysell, Scott K
AU  - Heysell SK
AD  - Division of Infectious Diseases and International Health, University of Virginia,
      Charlottesville, Virginia, USA.
FAU - Hurevich, Henadz
AU  - Hurevich H
AD  - The Republican Scientific and Practical Center for Pulmonology and Tuberculosis, 
      Minsk, Belarus.
FAU - Kuksa, Liga
AU  - Kuksa L
AD  - Department of Multidrug Resistant Tuberculosis, Riga East University Hospital TB 
      and Lung Disease Clinic, Riga, Latvia.
FAU - Kunst, Heinke
AU  - Kunst H
AD  - Department of Respiratory Medicine, Blizard Institute, Queen Mary University of
      London, Barts Health NHS Trust, London, UK.
FAU - Kuhlin, Johanna
AU  - Kuhlin J
AD  - Division of Infectious Diseases, Department of Medicine, Solna, Karolinska
      Institutet, Stockholm, Sweden.
AD  - Department of Infectious Diseases, Karolinska University Hospital, Stockholm,
      Sweden.
FAU - Manika, Katerina
AU  - Manika K
AD  - Pulmonary Department, Respiratory Infections Unit, G. Papanikolaou Hospital,
      Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Moschos, Charalampos
AU  - Moschos C
AD  - Drug-Resistant Tuberculosis Unit, 'Sotiria' Hospital for Chest Diseases, Athens, 
      Greece.
FAU - Mpagama, Stellah G
AU  - Mpagama SG
AD  - Kibong'oto Infectious Diseases Hospital, Kilimanjaro, United Republic of
      Tanzania.
FAU - Munoz Torrico, Marcela
AU  - Munoz Torrico M
AD  - Clinica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, Mexico
      City, Mexico.
FAU - Skrahina, Alena
AU  - Skrahina A
AD  - The Republican Scientific and Practical Center for Pulmonology and Tuberculosis, 
      Minsk, Belarus.
FAU - Sotgiu, Giovanni
AU  - Sotgiu G
AD  - Department of Medical, Surgical and Experimental Sciences, Clinical Epidemiology 
      and Medical Statistics Unit, University of Sassari, Sassari, Italy.
FAU - Tadolini, Marina
AU  - Tadolini M
AD  - Department of Medical and Surgical Sciences, Unit of Infectious Diseases, Alma
      Mater Studiorum University of Bologna, Bologna, Italy.
FAU - Tiberi, Simon
AU  - Tiberi S
AD  - Department of Infection, Blizard Institute, Queen Mary University of London,
      Barts Health NHS Trust, London, UK.
FAU - Volpato, Francesca
AU  - Volpato F
AD  - Department of Medical and Surgical Sciences, Unit of Infectious Diseases, Alma
      Mater Studiorum University of Bologna, Bologna, Italy.
FAU - van der Werf, Tjip S
AU  - van der Werf TS
AD  - Department of Pulmonary Diseases and Tuberculosis, University of Groningen,
      University Medical Center Groningen, Groningen, The Netherlands.
AD  - Department of Internal Medicine, University of Groningen, University Medical
      Center Groningen, Groningen, The Netherlands.
FAU - Wilson, Malcolm R
AU  - Wilson MR
AD  - Department of Respiratory Medicine and Metro South Clinical Tuberculosis Service,
      Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
FAU - Zuniga, Joaquin
AU  - Zuniga J
AD  - Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades
      Respiratorias, Mexico City, Mexico.
AD  - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de Salud, Mexico City,
      Mexico.
FAU - Touw, Daan J
AU  - Touw DJ
AD  - Department of Clinical Pharmacy and Pharmacology, University of Groningen,
      University Medical Center Groningen, Groningen, The Netherlands.
FAU - Migliori, Giovanni B
AU  - Migliori GB
AD  - Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici
      Scientifici Maugeri IRCCS, Tradate, Italy.
FAU - Alffenaar, Jan-Willem
AU  - Alffenaar JW
AUID- ORCID: 0000-0001-6703-0288
AD  - Department of Clinical Pharmacy and Pharmacology, University of Groningen,
      University Medical Center Groningen, Groningen, The Netherlands
      j.w.c.alffenaar@umcg.nl.
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Sydney, New South Wales, Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT03409315
GR  - U01 AI115594/AI/NIAID NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Fluoroquinolones)
SB  - IM
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - *Drug Monitoring
MH  - Fluoroquinolones/*administration & dosage
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Observational Studies as Topic
MH  - Precision Medicine
MH  - Prospective Studies
MH  - Research Design
MH  - Sputum/microbiology
MH  - Tuberculosis, Multidrug-Resistant/*drug therapy
PMC - PMC7304807
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *infectious diseases
OT  - *organisation of health services
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-035350 [pii]
AID - 10.1136/bmjopen-2019-035350 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e035350. doi: 10.1136/bmjopen-2019-035350.


PMID- 32554737
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Individual breastfeeding support with contingent incentives for low-income
      mothers in the USA: the 'BOOST (Breastfeeding Onset & Onward with Support Tools)'
      randomised controlled trial protocol.
PG  - e034510
LID - 10.1136/bmjopen-2019-034510 [doi]
AB  - INTRODUCTION: National breastfeeding rates have improved in recent years,
      however, disparities exist by socioeconomic and psychosocial factors. Suboptimal 
      breastfeeding overburdens the society by increasing healthcare costs. Existing
      breastfeeding supports including education and peer support have not been
      sufficient in sustaining breastfeeding rates especially among low-income women.
      The preliminary outcomes of contingent incentives for breastfeeding in addition
      to existing support show promising effects in sustaining breastfeeding among
      mothers in the Special Supplemental Nutrition Programme for women, infants and
      children (WIC). METHODS AND ANALYSIS: This trial uses a parallel randomised
      controlled trial. This trial is conducted at two sites in separate states in the 
      USA. Mothers who were enrolled in WIC and initiated breastfeeding are eligible.
      Participants (n=168) are randomised into one of the two study groups: (1)
      standard care control (SC) group consisting of WIC breastfeeding services plus
      home-based individual support or (2) SC plus breastfeeding incentives (SC +BFI)
      contingent on demonstrating successful breastfeeding. All participants receive
      standard breastfeeding services from WIC, home-based individual support and
      assessments. Participants in SC receive financial compensation based on the
      number of completed monthly home visits, paid in a lump sum at the end of the
      6-month intervention period. Participants in SC +BFI receive an escalating
      magnitude of financial incentives contingent on observed breastfeeding, paid
      monthly during the intervention period, as well as bonus incentives for selecting
      full breastfeeding food packages at WIC. The primary hypothesis is that monthly
      incentives contingent on breastfeeding in SC +BFI will significantly increase
      rates of any breastfeeding compared with SC. The primary outcome is the rate of
      any breastfeeding over 12 months. Randomisation is completed in an automated
      electronic system. Staff conducting home visits for support and assessments are
      blinded to study groups. ETHICS AND DISSEMINATION: The Advarra Institutional
      Review Board has approved the study protocol (Pro00033168). Findings will be
      disseminated to our participants, scientific communities, public health officials
      and any other interested community members. TRIAL REGISTRATION NUMBER:
      NCT03964454.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Washio, Yukiko
AU  - Washio Y
AUID- ORCID: 0000-0002-3882-2953
AD  - Substance Use, Gender and Applied Research, RTI International, Research Triangle 
      Park, North Carolina, USA ywashio@rti.org.
FAU - Collins, Bradley N
AU  - Collins BN
AD  - College of Public Health, Temple University, Philadelphia, Pennsylvania, USA.
FAU - Hunt-Johnson, Alison
AU  - Hunt-Johnson A
AD  - College of Public Health, Temple University, Philadelphia, Pennsylvania, USA.
FAU - Zhang, Zugui
AU  - Zhang Z
AD  - Value Institute, Christiana Care Health System, Newark, Delaware, USA.
FAU - Herrine, Gail
AU  - Herrine G
AD  - Obstetrics and Gynecology Department, Temple University Hospital, Philadelphia,
      Pennsylvania, USA.
FAU - Hoffman, Matthew
AU  - Hoffman M
AD  - Obstetrics and Gynecology Department, Christiana Care Health System, Newark,
      Delaware, USA.
FAU - Kilby, Linda
AU  - Kilby L
AD  - N.O.R.T.H., Inc-Philadelphia WIC program, Philadelphia, Pennsylvania, USA.
FAU - Chapman, Donna
AU  - Chapman D
AD  - Department of Exercise Science and Athletic Training, Springfield College,
      Springfield, Massachusetts, USA.
FAU - Furman, Lydia M
AU  - Furman LM
AD  - Department of Pediatrics, University Hospitals Rainbow Babies and Children's
      Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio,
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03964454
GR  - R01 HD094877/HD/NICHD NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Breast Feeding/*psychology
MH  - Female
MH  - Food Assistance
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Mothers/*psychology
MH  - Motivation
MH  - Multicenter Studies as Topic
MH  - Postnatal Care/*methods
MH  - Poverty
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - United States
PMC - PMC7304794
OTO - NOTNLM
OT  - *WIC
OT  - *breastfeeding duration
OT  - *financial incentives
OT  - *home-based settings
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-034510 [pii]
AID - 10.1136/bmjopen-2019-034510 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e034510. doi: 10.1136/bmjopen-2019-034510.


PMID- 32554736
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Randomised, non-inferiority, controlled procedural outcomes TrIal comParing
      reverse T And Protrusion versus double-kissing and crush stenting: protocol of
      the TIP TAP I randomised trial.
PG  - e034264
LID - 10.1136/bmjopen-2019-034264 [doi]
AB  - INTRODUCTION: To assess the impact of 'reverse T and Protrusion' (TAP) technique 
      on the outcome after stenting of true bifurcation lesions of the left main (LM)
      or proximal epicardial vessels as compared with double kissing (DK)-crush
      technique. METHODS AND ANALYSIS: 50 consecutive patients with true coronary
      bifurcation lesion (Medina 1,1,1 or 0,1,1) of the LM or the proximal main
      vessels, requiring a two-stent technique as first-line strategy at University
      Medical Center Mainz, are randomised in a 1:1 ratio to reverse TAP or DK-crush
      stenting. As recommended by best clinical practice, final angiographic result is 
      evaluated and optical coherence tomographic (OCT) intracoronary imaging is
      performed to assess and optimise the final result. The primary end point is
      defined as the percentage of stent expansion in the side branch. Secondary end
      points consist of angiographic and procedural success (assessed until patient's
      discharge), procedural parameters (procedural time, fluoroscopy time, use of
      devices, X-ray dose) and OCT parameters expressing expansion of the stents.
      Safety parameters include all adverse events up to 6 months after discharge. A
      clinical, angiographic and intracoronary imaging control at 6 months is planned. 
      ETHICS AND DISSEMINATION: The protocol complies with good clinical practice and
      the ethical principles described in the Declaration of Helsinki and is approved
      by the local ethics committee. The results of the trial will be published as
      original article(s) in medical journals and/or as presentation at congresses.
      TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03714750).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rakhimov, Kudrat
AU  - Rakhimov K
AUID- ORCID: 0000-0003-3936-8753
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
FAU - Buono, Andrea
AU  - Buono A
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
FAU - Anadol, Remzi
AU  - Anadol R
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
AD  - DZHK, Standort Rhein-Mainz, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz,
      Germany.
FAU - Ullrich, Helen
AU  - Ullrich H
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
FAU - Knorr, Maike
AU  - Knorr M
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
FAU - Ahoopai, Majid
AU  - Ahoopai M
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
FAU - Munzel, Thomas
AU  - Munzel T
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany.
AD  - DZHK, Standort Rhein-Mainz, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz,
      Germany.
FAU - Gori, Tommaso
AU  - Gori T
AD  - Kardiologie I, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany
      tommaso.gori@unimedizin-mainz.de.
AD  - DZHK, Standort Rhein-Mainz, Universitatsmedizin Mainz, Mainz, Rheinland-Pfalz,
      Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03714750
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Angioplasty, Balloon, Coronary
MH  - Coronary Angiography
MH  - Coronary Stenosis/*diagnostic imaging/*surgery
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Stents
MH  - Tomography, Optical Coherence
PMC - PMC7304799
OTO - NOTNLM
OT  - *2-stent technique
OT  - *bifurcation lesion
OT  - *coronary artery disease
OT  - *coronary stenting
COIS- Competing interests: The trial is funded by the Kardiologie I, University Medical
      Center Mainz. No manufacturer of the drugs has been involved in this study. None 
      of the authors has conflicts of interest to declare.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-034264 [pii]
AID - 10.1136/bmjopen-2019-034264 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e034264. doi: 10.1136/bmjopen-2019-034264.


PMID- 32554735
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 16
TI  - Non-absorbable versus absorbable sutures for anterior colporrhaphy: study
      protocol for a randomised controlled trial in South Korea.
PG  - e034218
LID - 10.1136/bmjopen-2019-034218 [doi]
AB  - INTRODUCTION: The anterior vaginal wall is the segment most commonly affected by 
      prolapse. Traditionally, anterior vaginal wall prolapse is repaired via anterior 
      colporrhaphy, which is known to have a high recurrence rate. Several factors
      might affect the outcome of anterior colporrhaphy, and the use of absorbable
      sutures might also be associated with the high recurrence rate because the
      sutures might not be able to retain adequate strength until the plicated
      pubocervical fascia remodels and regains maximum tensile strength. Nonetheless,
      no comparative data exist about the relative efficacy and safety of anterior
      colporrhaphy using non-absorbable versus absorbable sutures. The objective of
      this study is to compare the surgical outcomes of anterior colporrhaphy using
      non-absorbable sutures with those of anterior colporrhaphy using absorbable
      sutures. METHODS AND ANALYSIS: This is a randomised, multicentre, superiority
      trial. Anterior colporrhaphy will be performed in a traditional manner with
      midline plication of the fibromuscular layer using either non-absorbable or
      absorbable sutures. The primary outcome is composite surgical success 1 year
      after surgery defined as the absence of all of the following: (1) anterior
      vaginal descent beyond the hymen, (2) the presence of vaginal bulge symptoms and 
      (3) retreatment for recurrent anterior vaginal wall prolapse with either surgery 
      or pessary. The secondary outcomes include the individual components of the
      composite primary end point, anatomical outcomes, condition-specific quality of
      life and adverse events related to anterior colporrhaphy. The planned number of
      participants is 192. ETHICS AND DISSEMINATION: This study was approved by the
      Institutional Review Board of Seoul National University Hospital
      (H-1810-037-977). The results of the study will be published in peer-reviewed
      journals, and the findings will be presented at scientific meetings. TRIAL
      REGISTRATION NUMBER: NCT03736811.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jeon, Myung Jae
AU  - Jeon MJ
AUID- ORCID: 0000-0001-5582-1488
AD  - Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, 
      The Republic of Korea jeonmj@snu.ac.kr.
FAU - Suh, Dong Hoon
AU  - Suh DH
AD  - Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, 
      The Republic of Korea.
FAU - Kim, Chul Hong
AU  - Kim CH
AD  - Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju,
      The Republic of Korea.
FAU - Cho, Hyun-Hee
AU  - Cho HH
AD  - Obstetrics and Gynecology, The Catholic University of Korea, Eunpyeong St. Mary's
      Hospital, Seoul, The Republic of Korea.
FAU - Shin, Jung-Ho
AU  - Shin JH
AD  - Obstetrics and Gynecology, Korea University College of Medicine, Seoul, The
      Republic of Korea.
FAU - Lee, Sa Ra
AU  - Lee SR
AD  - Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, The Republic of Korea.
FAU - Jung, Yong Wook
AU  - Jung YW
AD  - Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University College of 
      Medicine, Seoul, The Republic of Korea.
FAU - Kim, Soo Rim
AU  - Kim SR
AD  - Obstetrics and Gynecology, International St. Mary's Hospital, Catholic Kwandong
      University College of Medicine, Incheon, The Republic of Korea.
FAU - Kong, Mi Kyung
AU  - Kong MK
AD  - Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei
      University College of Medicine, Seoul, The Republic of Korea.
LA  - eng
SI  - ClinicalTrials.gov/NCT03736811
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Female
MH  - Gynecologic Surgical Procedures/*instrumentation
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Pelvic Organ Prolapse/*surgery
MH  - Randomized Controlled Trials as Topic
MH  - Republic of Korea
MH  - Research Design
MH  - *Sutures
MH  - Tensile Strength
MH  - Vagina/*surgery
PMC - PMC7304798
OTO - NOTNLM
OT  - *anterior colporrhaphy
OT  - *anterior vaginal wall prolapse
OT  - *sutures
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - bmjopen-2019-034218 [pii]
AID - 10.1136/bmjopen-2019-034218 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 16;10(6):e034218. doi: 10.1136/bmjopen-2019-034218.


PMID- 32554729
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 17
TI  - How, why, for whom and in what context, do sexual health clinics provide an
      environment for safe and supported disclosure of sexual violence: protocol for a 
      realist review.
PG  - e037599
LID - 10.1136/bmjopen-2020-037599 [doi]
AB  - INTRODUCTION: Supporting people subjected to sexual violence includes provision
      of sexual and reproductive healthcare. There is a need to ensure an environment
      for safe and supported disclosure of sexual violence in these clinical settings. 
      The purpose of this research is to gain a deeper understanding of how, why, for
      whom and in what circumstances safe and supported disclosure occurs in sexual
      health services. METHODS AND ANALYSIS: To understand how safe and supported
      disclosure of sexual violence works within sexual health services a realist
      review will be undertaken with the following steps: (1) Focussing of the review
      including a scoping literature search and guidance from an advisory group. (2)
      Developing the initial programme theories and a search strategy using
      context-mechanism-outcome (CMO) configurations. (3) Selection, data extraction
      and appraisal based on relevance and rigour. (4) Data analysis and synthesis to
      further develop and refine programme theory, CMO configurations with
      consideration of middle-range and substantive theories. DATA ANALYSIS: A realist 
      logic of analysis will be used to align data from each phase of the review, with 
      CMO configurations being developed. Programme theories will be sought from the
      review that can be further tested in the field. ETHICS AND DISSEMINATION: This
      study has been approved by the ethics committee at University of Birmingham, and 
      has Health Research Authority approval. Findings will be disseminated through
      knowledge exchange with stakeholders, publications in peer-reviewed journals,
      conference presentations and formal and informal reports. In addition, as part of
      a doctoral study, the findings will be tested in multisite case studies. PROSPERO
      REGISTRATION DETAILS: CRD4201912998. Dates of the planned realist review, from
      protocol design to completion, January 2019 to July 2020.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Caswell, Rachel J
AU  - Caswell RJ
AUID- ORCID: 0000-0002-9246-2581
AD  - Department of Sexual Health and HIV Medicine, University Hospitals Birmingham NHS
      Foundation Trust, Birmingham, UK rachelcaswell@nhs.net.
FAU - Maidment, Ian
AU  - Maidment I
AUID- ORCID: 0000-0003-4152-9704
AD  - School of Life and Health Sciences, Aston University, Birmingham, UK.
FAU - Ross, Jonathan D C
AU  - Ross JDC
AD  - Department of Sexual Health and HIV Medicine, University Hospitals Birmingham NHS
      Foundation Trust, Birmingham, UK.
FAU - Bradbury-Jones, C
AU  - Bradbury-Jones C
AD  - School of Nursing, University of Birmingham, Birmingham, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Ambulatory Care Facilities
MH  - Humans
MH  - *Patient Safety
MH  - Research Design
MH  - Review Literature as Topic
MH  - *Self Disclosure
MH  - *Sex Offenses
PMC - PMC7304828
OTO - NOTNLM
OT  - *genitourinary medicine
OT  - *quality in health care
OT  - *statistics & research methods
COIS- Competing interests: JDCR reports personal fees from GSK Pharma, Hologic
      Diagnostics, Mycovia and Janssen Pharma as well as ownership of shares in GSK
      Pharma and AstraZeneca Pharma; and is author of the UK and European Guidelines on
      Pelvic Inflammatory Disease; is a Member of the European Sexually Transmitted
      Infections Guidelines Editorial Board; is a Member of the National Institute for 
      Health Research Funding Committee (Health Technology Assessment programme). He is
      an NIHR Journals Editor and associate editor of Sexually Transmitted Infections
      journal. He is an officer of International Union against Sexually Transmitted
      Infections (treasurer), and a charity trustee of the Sexually Transmitted
      Infections Research Foundation.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037599 [pii]
AID - 10.1136/bmjopen-2020-037599 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 17;10(6):e037599. doi: 10.1136/bmjopen-2020-037599.


PMID- 32554728
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 17
TI  - Compliance of smokeless tobacco supply chain actors and products with tobacco
      control laws in Bangladesh, India and Pakistan: protocol for a multicentre
      sequential mixed-methods study.
PG  - e036468
LID - 10.1136/bmjopen-2019-036468 [doi]
AB  - INTRODUCTION: South Asia is home to more than 300 million smokeless tobacco (ST) 
      users. Bangladesh, India and Pakistan as signatories to the Framework Convention 
      for Tobacco Control (FCTC) have developed policies aimed at curbing the use of
      tobacco. The objective of this study is to assess the compliance of ST
      point-of-sale (POS) vendors and the supply chain with the articles of the FCTC
      and specifically with national tobacco control laws. We also aim to assess
      disparities in compliance with tobacco control laws between ST and smoked tobacco
      products. METHODS AND ANALYSIS: The study will be carried out at two sites each
      in Bangladesh, India and Pakistan. We will conduct a sequential mixed-methods
      study with five components: (1) mapping of ST POS, (2) analyses of ST samples
      packaging, (3) observation, (4) survey interviews of POS and (5) in-depth
      interviews with wholesale dealers/suppliers/manufacturers of ST. We aim to
      conduct at least 300 POS survey interviews and observations, and 6-10 in-depth
      interviews in each of the three countries. Data collection will be done by
      trained data collectors. The main statistical analysis will report the
      frequencies and proportions of shops that comply with the FCTC and local tobacco 
      control policies, and provide a 95% CI of these estimates. The qualitative
      in-depth interview data will be analysed using the framework approach. The
      findings will be connected, each component informing the focus and/or design of
      the next component. ETHICS AND DISSEMINATION: Ethical approvals for the study
      have been received from the Health Sciences Research Governance Committee at the 
      University of York, UK. In-country approvals were taken from the National
      Bioethics Committee in Pakistan, the Bangladesh Medical Research Council and the 
      Indian Medical Research Council. Our results will be disseminated via scientific 
      conferences, peer-reviewed research publications and press releases.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Khan, Zohaib
AU  - Khan Z
AUID- ORCID: 0000-0002-1885-8254
AD  - Office of Research, Innovation, and Commercialization, Khyber Medical University,
      Peshawar, Pakistan.
AD  - Institute of Public Health and Social Sciences, Khyber Medical University,
      Peshawar, Pakistan.
FAU - Huque, Rumana
AU  - Huque R
AD  - Department of Economics, University of Dhaka, Dhaka, Bangladesh.
AD  - Department of Research and Development, ARK Foundation, Dhaka, Bangladesh.
FAU - Sheikh, Aziz
AU  - Sheikh A
AD  - Division of Community Health Sciences, University of Edinburgh, Edinburgh, UK.
FAU - Readshaw, Anne
AU  - Readshaw A
AD  - Department of Health Sciences, University of York, York, UK
      anne.readshaw@york.ac.uk.
FAU - Eckhardt, Jappe
AU  - Eckhardt J
AD  - Department of Politics, University of York, York, UK.
FAU - Jackson, Cath
AU  - Jackson C
AD  - Department of Health Sciences, University of York, York, UK.
AD  - Vaild Research Ltd, Wetherby, UK.
FAU - Kanaan, Mona
AU  - Kanaan M
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Iqbal, Romaina
AU  - Iqbal R
AD  - Department of Community Health Sciences and Medicine, Aga Khan University,
      Karachi, Pakistan.
FAU - Akhter, Zohaib
AU  - Akhter Z
AD  - Department of Community Health Sciences and Medicine, Aga Khan University,
      Karachi, Pakistan.
FAU - Garg, Suneela
AU  - Garg S
AD  - Department of Community Medicine, Maulana Azad Medical College, New Delhi, Delhi,
      India.
FAU - Singh, Mongjam Meghachandra
AU  - Singh MM
AD  - Department of Community Medicine, Maulana Azad Medical College, New Delhi, Delhi,
      India.
FAU - Ahmad, Fayaz
AU  - Ahmad F
AD  - Institute of Public Health and Social Sciences, Khyber Medical University,
      Peshawar, Pakistan.
FAU - Abdullah, S M
AU  - Abdullah SM
AUID- ORCID: 0000-0003-2083-2253
AD  - Department of Economics, University of Dhaka, Dhaka, Bangladesh.
AD  - Department of Research and Development, ARK Foundation, Dhaka, Bangladesh.
FAU - Javaid, Arshad
AU  - Javaid A
AD  - Office of Research, Innovation, and Commercialization, Khyber Medical University,
      Peshawar, Pakistan.
FAU - A Khan, Javaid
AU  - A Khan J
AD  - Department of Pulmonary medicine, Aga Khan University, Karachi, Pakistan.
FAU - Han, Lu
AU  - Han L
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Rahman, Aziz
AU  - Rahman A
AD  - Faculty of Health, Federation University Australia, Ballarat, Victoria,
      Australia.
FAU - Siddiqi, Kamran
AU  - Siddiqi K
AUID- ORCID: 0000-0003-1529-7778
AD  - Department of Health Sciences, University of York, York, UK.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Bangladesh
MH  - Commerce/*legislation & jurisprudence
MH  - Humans
MH  - India
MH  - Multicenter Studies as Topic
MH  - Pakistan
MH  - Research Design
MH  - Tobacco, Smokeless/*legislation & jurisprudence
PMC - PMC7304837
OTO - NOTNLM
OT  - *public health
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036468 [pii]
AID - 10.1136/bmjopen-2019-036468 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 17;10(6):e036468. doi: 10.1136/bmjopen-2019-036468.


PMID- 32554726
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 17
TI  - Is dezocine effective and safe in preventing opioids-induced cough during general
      anaesthesia induction? A protocol for systematic review and meta-analysis.
PG  - e035691
LID - 10.1136/bmjopen-2019-035691 [doi]
AB  - INTRODUCTION: Cough is often observed when administrating a bolus of opioids.
      Opioid-induced cough (OIC) is mostly transient, benign and self-limiting, but
      could be associated with adverse effects. Numerous pharmacological and
      non-pharmacological interventions have been used to manage OIC with controversial
      efficacy and safety. Recent studies suggested that, pretreatment of intravenous
      dezocine (DZC) could completely suppress OIC during anaesthesia induction. To
      address this knowledge lack, we will perform a systemic review and meta-analysis 
      to evaluate the efficacy of DZC on OIC and possible complications. We provide
      here a protocol that will outline the methods and analyses planned for the
      systematic review. METHODS: PubMed, Embase, Cochrane Library, Web of Science as
      well as Chinese BioMedical Literature & Retrieval System (SinoMed), China
      National Knowledge Infrastructure, Wanfang Data and VIP Data will be searched
      from 1978 to 31 December 2019 to identify all randomised controlled trials
      comparing DZC with placebo on the incidence and severity of OIC. Primary outcomes
      of interest include the incidence and severity of OIC. Secondary outcomes of
      interest include possible complications or adverse effects of DZC. Two authors
      will independently extract relevant variables and outcome data. For continuous
      variables, treatment effects will be calculated as weighted mean difference and
      95% CI. For dichotomous data, treatment effects will be calculated as OR and 95% 
      CI. Each outcome will be tested for heterogeneity, and randomised-effects or
      fixed-effects model will be used in the presence or absence of significant
      heterogeneity. Sensitivity analyses will be done by examining the influence of
      statistical model and individual trial(s) on estimated treatment effects.
      Publication bias will be explored through visual inspection of funnel plots of
      the outcomes. Statistical significance will be defined as p<0.05. ETHICS AND
      DISSEMINATION: This study is a protocol of meta-analysis of previously published 
      literatures, ethical approval was not necessary according to the Ethical
      Committee of Fuwai Hospital. The study will be submitted to a peer-reviewed
      journal and disseminated via research presentations. PROSPERO REGISTRATION
      NUMBER: CRD42019141255.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - He, Li-Xian
AU  - He LX
AUID- ORCID: 0000-0002-6632-7335
AD  - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences,
      Beijing, China.
FAU - Shao, Ken
AU  - Shao K
AD  - Department of Anesthesiology, Jingmen No. 1 People's Hospital, Jingmen, China.
FAU - Ma, Jie
AU  - Ma J
AD  - Department of Pharmacy, Fuwai Hospital, National Center for Cardiovascular
      Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences,
      Beijing, China.
FAU - Zhao, Yuan-Yuan
AU  - Zhao YY
AD  - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences,
      Beijing, China.
FAU - Yao, Yun-Tai
AU  - Yao YT
AD  - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular 
      Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences,
      Beijing, China yuntaiyao@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Tetrahydronaphthalenes)
RN  - VHX8K5SV4X (dezocine)
SB  - IM
MH  - Analgesics, Opioid/*adverse effects/*therapeutic use
MH  - *Anesthesia, General
MH  - Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
MH  - Cough/*chemically induced/*prevention & control
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Tetrahydronaphthalenes/*therapeutic use
PMC - PMC7304830
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *anaesthetics
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035691 [pii]
AID - 10.1136/bmjopen-2019-035691 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 17;10(6):e035691. doi: 10.1136/bmjopen-2019-035691.


PMID- 32554724
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 17
TI  - Feasibility randomised controlled trial of remote symptom chemotherapy toxicity
      monitoring using the Canadian adapted Advanced Symptom Management System
      (ASyMS-Can): a study protocol.
PG  - e035648
LID - 10.1136/bmjopen-2019-035648 [doi]
AB  - INTRODUCTION: Technology is emerging as a solution to develop home-based,
      proactive 'real-time' symptom monitoring and management in cancer care. The
      Advanced Symptom Monitoring and Management System-Canada (ASyMS-Can) is a remote 
      phone-based symptom management system that enables real-time remote monitoring of
      systemic chemotherapy toxicities. METHODS AND ANALYSIS: This study is an
      open-label, prospective, mixed-method, Phase II, 2-arm parallel group assignment 
      (ASyMS-Can vs usual care) feasibility study in patients with cancer receiving
      systemic (neo-adjuvant or adjuvant) chemotherapy at Princess Margaret Cancer
      Centre. A total of 114 patients will be recruited in oncology clinics prior to
      initiation of chemotherapy. Patients in both arms will complete a demographic and
      a set of questionnaires at enrolment, mid and end of treatment. Patients in
      intervention arm will be provided with an encrypted, secure, preprogrammed ASyMS 
      phone for symptom reporting daily for the first 14 days of each chemotherapy
      treatment cycle up to sixth cycle (16 weeks). Feasibility metrics (recruitment,
      retention and protocol adherence) and outcomes to assess impact of ASyMS-Can
      include symptom severity, emotional distress, quality of life and acceptability
      to patients and clinicians. ETHICS AND DISSEMINATION: The study has received
      ethical and institutional approvals from the University Health Network.
      Dissemination will include presentations at national/international conferences,
      and publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT03335189.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Moradian, Saeed
AU  - Moradian S
AUID- ORCID: 0000-0002-5289-4806
AD  - School of Nursing, York University Faculty of Health, Toronto, Ontario, Canada.
FAU - Krzyzanowska, Monika
AU  - Krzyzanowska M
AD  - University of Toronto Institute of Health Policy Management and Evaluation,
      Toronto, Ontario, Canada.
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre,
      University Health Network, Toronto, ON, Canada.
FAU - Maguire, Roma
AU  - Maguire R
AD  - University of Strathclyde Department of Computer and Information Sciences,
      Glasgow, UK.
FAU - Kukreti, Vishal
AU  - Kukreti V
AD  - Division of Medical Oncology and Hematology, University of Toronto Faculty of
      Medicine, Toronto, Ontario, Canada.
FAU - Amir, Eitan
AU  - Amir E
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre,
      University Health Network, Toronto, Ontario, Canada.
FAU - Morita, Plinio P
AU  - Morita PP
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo, ON,
      Canada.
FAU - Liu, Geoffrey
AU  - Liu G
AD  - University Health Network and Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada.
AD  - Epidemiology Division, Dalla Lana School of Public Health, University of Toronto,
      Toronto, ON, Canada.
FAU - Howell, Doris
AU  - Howell D
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre,
      University Health Network, Toronto, Ontario, Canada doris.howell@uhn.ca.
LA  - eng
SI  - ClinicalTrials.gov/NCT03335189
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*toxicity
MH  - Drug Monitoring/*methods
MH  - Feasibility Studies
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Ontario
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Symptom Assessment
MH  - Telephone
PMC - PMC7313714
OTO - NOTNLM
OT  - *adult oncology
OT  - *telemedicine
OT  - *world wide web technology
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035648 [pii]
AID - 10.1136/bmjopen-2019-035648 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 17;10(6):e035648. doi: 10.1136/bmjopen-2019-035648.


PMID- 32554722
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 17
TI  - Creating dementia-friendly and inclusive communities for social inclusion: a
      scoping review protocol.
PG  - e035028
LID - 10.1136/bmjopen-2019-035028 [doi]
AB  - INTRODUCTION: The number of people with dementia is increasing worldwide, with
      the majority of people with dementia living at home in the community. WHO calls
      for global action on the public health response to dementia. Social exclusion is 
      commonly reported by people with dementia and their families. Dementia-friendly
      and inclusive community has emerged as an idea that holds potential to contribute
      to the mitigation of social exclusion. The objective of the scoping review is to 
      answer two questions: What social inclusion strategies that have been reported in
      the dementia-friendly and inclusive communities' literature? What strategies for 
      developing dementia-friendly and inclusive communities that have shown to improve
      social inclusion? METHODS AND ANALYSIS: This scoping review will follow the
      Joanna Briggs Institute scoping review methodology and will take place between
      April and September 2020. The proposed review will consider studies based in
      community settings with participants living at home with early to late stages of 
      dementia and their families. This includes a three-step search strategy: (1) to
      identify keywords from MEDLINE and CINAHL; (2) to conduct a second search using
      all identified keywords and index terms across selected databases (MEDLINE,
      CINAHL, AgeLine, PsycINFO, Web of Science, ProQuest and Google) and (3) to
      handsearch the reference lists of all included articles and reports for
      additional studies. Further, we will search Google for grey literature on
      published organisational reports. Two researchers will screen titles and
      abstracts independently and then assess the full text of selected citations
      against inclusion criteria. Extracted data will be presented in a narrative
      accompanied by tables that reflect the objective of the review. ETHICS AND
      DISSEMINATION: As the methodology of this study consists of collecting data from 
      publicly available articles, it does not require ethics approval. This scoping
      review provides an overview of current evidence on strategies that support
      dementia-friendly and inclusive communities for social inclusion. The findings
      will offer insights to inform strategies for education, practice, policy and
      future research. We will share the scoping review results through conference
      presentations and an open-access publication in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hung, Lillian
AU  - Hung L
AUID- ORCID: 0000-0002-7916-2939
AD  - Gerontology, Simon Fraser University, Vancouver, British Columbia, Canada
      lillian.hung@vch.ca.
AD  - Nursing, Vancouver General Hospital, Vancouver, British Columbia, Canada.
FAU - Leitch, Sharon
AU  - Leitch S
AD  - Business, Kwantlen Polytechnic University, Surrey, British Columbia, Canada.
FAU - Hung, Ryan
AU  - Hung R
AD  - Science, Simon Fraser University, Burnaby, British Columbia, Canada.
FAU - Phinney, Alison
AU  - Phinney A
AD  - Nursing, University of British Columbia, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Dementia/*psychology
MH  - Humans
MH  - Research Design
MH  - Review Literature as Topic
MH  - Social Isolation/*psychology
PMC - PMC7304818
OTO - NOTNLM
OT  - *dementia
OT  - *international health services
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035028 [pii]
AID - 10.1136/bmjopen-2019-035028 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 17;10(6):e035028. doi: 10.1136/bmjopen-2019-035028.


PMID- 32554682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210609
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 70
IP  - suppl 1
DP  - 2020 Jun
TI  - Blood tests in general practice: the use of routine data to characterise venous
      blood testing in North West London, 2016-2018.
LID - bjgp20X711605 [pii]
LID - 10.3399/bjgp20X711605 [doi]
AB  - BACKGROUND: Laboratory testing is an integral diagnostic tool, contributing to
      70% of diagnoses in the NHS today. Its use has been steadily increasing despite
      estimates that </=40% of blood tests ordered are unnecessary. Understanding
      blood-testing patterns is a fundamental step to tackling overuse. AIM: To
      characterise the volume, type, and per patient frequency (PPF) of venous blood
      testing reported in general practice in North West London, 2016-2018. METHOD:
      Following ethics clearance, aggregate data of blood tests reported in general
      practice in North West London between 2016 and 2018 were extracted from the
      Discover database. Non-venous blood test codes and codes not used within the
      designated time period were excluded. Codes reporting the same analyte were
      aggregated. Overall volume and PPF were calculated per analyte. RESULTS: Three
      hundred and thirty-six individual analytes were reported and grouped into 35
      recognised panels or groupings. Blood testing increased by 16.5% over the 3-year 
      period. Full blood count, urea and electrolytes, liver function tests, and lipid 
      profile accounted for 80.4% of all venous blood tests. Requests for HbA1c
      increased by 52.8% and non-HDL cholesterol by 148.7%, whereas glucose decreased
      by 13.3% and urea by 15.7%. The PPF remained unchanged over the 3-year period at 
      1.29 blood tests per person per year. The coagulation assay had the highest PPF
      at 3.0. CONCLUSION: Routine general practice data revealed important trends in
      blood testing. Trends uncovered can inform innovative and targeted solutions to
      reduce unnecessary blood testing.
CI  - (c) British Journal of General Practice 2020.
FAU - Bakhet, Marize
AU  - Bakhet M
AD  - Imperial College London.
FAU - Ul-Haq, Zia
AU  - Ul-Haq Z
AD  - Imperial College Health Partners.
FAU - Kamalati, Tahereh
AU  - Kamalati T
AD  - Imperial College Health Partners.
FAU - Lucas, Amanda
AU  - Lucas A
AD  - Imperial College Health Partners.
FAU - Majeed, Azeem
AU  - Majeed A
AD  - Imperial College London.
FAU - El-Osta, Austen
AU  - El-Osta A
AD  - Imperial College London.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 70/suppl_1/bjgp20X711605 [pii]
AID - 10.3399/bjgp20X711605 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2020 Jun;70(suppl 1). pii: 70/suppl_1/bjgp20X711605. doi:
      10.3399/bjgp20X711605.


PMID- 32554666
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200709
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 70
IP  - suppl 1
DP  - 2020 Jun
TI  - Time for change? A comparative analysis of GPs' opinions on appointment length.
LID - bjgp20X711413 [pii]
LID - 10.3399/bjgp20X711413 [doi]
AB  - BACKGROUND: The research on the benefits, disadvantages and factors that affect
      appointment length in general practice is fragmented. There is a need to draw the
      evidence together and who better to assess this than those on the front line.
      AIM: To investigate GPs' opinions on appointment length, including the factors
      that affect appointment length, its impact on doctors and the validity of
      increasing appointment length. METHOD: A questionnaire was sent to six general
      practices in Bristol and was completed by 30 GPs (response rate = 100%). Analysis
      of current appointment length, satisfaction and the ideal length was undertaken, 
      alongside thoughts about the advantages and disadvantages of longer appointments.
      Ethical approval was successfully sought from Student Research Ethics Committee. 
      RESULTS: Most doctors have 10-minute appointments (n = 29); however, 90% (n = 27)
      wished for 15 minutes. Appointments overrunning was described as a constant
      problem and resulting in stress. Longer appointments were due to multiple
      problems in a single consultation, mental health and multimorbidity. There did
      not appear to be any variation in viewpoints with practices, clinician experience
      and session length. The benefits of a longer appointment were a greater ability
      to deal with complex conditions, improved decision making, stress reduction and
      time to talk about interventions. However, 93.3% (n = 28) of doctors were
      concerned that there would be less appointments available if appointment lengths 
      increased. CONCLUSION: Most doctors would like longer appointments. In light of
      the concern about appointment availability, there needs to be research into
      whether this would substantiate.
CI  - (c) British Journal of General Practice 2020.
FAU - Murdoch, Katherine
AU  - Murdoch K
AD  - University of Bristol.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 70/suppl_1/bjgp20X711413 [pii]
AID - 10.3399/bjgp20X711413 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2020 Jun;70(suppl 1). pii: 70/suppl_1/bjgp20X711413. doi:
      10.3399/bjgp20X711413.


PMID- 32554651
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200709
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 70
IP  - suppl 1
DP  - 2020 Jun
TI  - Evaluating interprofessional education: initial learning from a domestic abuse
      conference.
LID - bjgp20X711233 [pii]
LID - 10.3399/bjgp20X711233 [doi]
AB  - BACKGROUND: The importance of multi-agency working to identify, prevent and
      reduce domestic abuse is widely recognised. Interprofessional learning
      opportunities can provide a supportive learning environment for multi-agency
      practitioners to explore and develop collaborative approaches to improve health
      outcomes for vulnerable children, young people and their families.Participants
      drawn from Kent GP trainees, student Health Visitors, School Nurses, Midwives,
      Social Workers, student Teachers and Special Educational Needs Coordinators
      (SENCOs), and postgraduate Police Officers attended this sixth annual conference.
      AIM: To enable participants to understand why domestic abuse is a serious public 
      health issue; identify indicators of domestic violence and abuse; identify
      opportunities for safe enquiry and know how to respond; critically reflect on
      ethical, legal, professional and interprofessional challenges for practitioners; 
      and reflect on and explore opportunities for inter-professional working. METHOD: 
      Multi-disciplinary educators delivered formal presentations and facilitated
      interprofessional workshops.Data from anonymised pre- and post- conference
      questionnaires distributed on the day, included quantitative questions using a
      Likert scale 1-5 and open and closed qualitative questions. RESULTS: In total, 75
      out of a possible 121 participants completed both questionnaires (62%). The above
      aims were all met. In all questions participants gave higher scores after the
      conference indicating increased levels of knowledge and confidence. The
      qualitative comments highlighted the learning benefits from interprofessional
      group work. 100% (average score 4.5) agreed that facilitators fostered a
      supportive learning environment. CONCLUSION: The conference provided a highly
      valued opportunity for useful interprofessional learning about domestic abuse.
      Results indicated that it increased participants' knowledge and confidence about 
      their own and others' roles and responsibilities.
CI  - (c) British Journal of General Practice 2020.
FAU - Yardley, Cheryl
AU  - Yardley C
AD  - Christchurch Canterbury University.
FAU - Hynes, Karen
AU  - Hynes K
AD  - Christchurch Canterbury University.
FAU - Charley, Andrew
AU  - Charley A
AD  - Health Education England Kent, Surrey & Sussex.
FAU - Sirkia-Weaver, Sari
AU  - Sirkia-Weaver S
AD  - Christchurch Canterbury University.
FAU - Critcher, Julie
AU  - Critcher J
AD  - Medway NHS Trust.
FAU - Hughes, Lorna
AU  - Hughes L
AD  - Christchurch Canterbury University.
FAU - Banks, Emma
AU  - Banks E
AD  - Kent Police.
FAU - Arnott, Jane
AU  - Arnott J
AD  - Christchurch Canterbury University.
FAU - Woodhouse, Tim
AU  - Woodhouse T
AD  - Kent County Council.
FAU - Lyttle, Anne
AU  - Lyttle A
AD  - Rising Sun Domestic Violence & Abuse Service.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 70/suppl_1/bjgp20X711233 [pii]
AID - 10.3399/bjgp20X711233 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2020 Jun;70(suppl 1). pii: 70/suppl_1/bjgp20X711233. doi:
      10.3399/bjgp20X711233.


PMID- 32554544
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 96
IP  - 1141
DP  - 2020 Nov
TI  - Smouldering ashes: burning questions after the outbreak of electronic cigarette
      or vaping-associated lung injury (EVALI).
PG  - 686-692
LID - 10.1136/postgradmedj-2020-137673 [doi]
AB  - In the summer of 2019, the Center for Disease Control and Prevention (CDC)
      declared an emergency of electronic cigarettes and/or vaping (vaping)-associated 
      lung injury (EVALI) in the USA. The outbreak abated by January 2020, which the
      CDC attributed to heightened public awareness, 'user actions to reduce risk' and 
      potentially the removal of vitamin E acetate (VEA) from vaping products (VEA is
      an oily chemical cutting agent, strongly associated with the disease). Even
      though the EVALI outbreak appears to be over, numerous epidemiological and
      medical questions are left still open. First, why were there practically no cases
      outside the USA, which represents nearly a quarter of the global vaping market?
      Comparative studies to map the differences in device/fluids/user habits between
      countries might be needed urgently. Second, what is the pathomechanism that
      sickens vapers irrespective of VEA exposure? VEA was only confirmed in about half
      of the cases and the presumed toxicity is yet to be determined.
      Aetiology/epidemiology focused research is needed to investigate/interpret the
      broader context to explain the outbreak. Third, could any
      socioeconomic/environmental factors have influenced the course of the outbreak?
      Finally, what should we expect in the years to come? Was EVALI a serious but
      reversible emergency medicine condition or is vaping as detrimental to long-term 
      health as smoking? Besides the complex legislative, regulatory, ethical aspects
      of EVALI, biomedical research is also difficult: in-vitro experiments have
      limited inferential value to real real-life vaping due to its complexity; user
      habits are self-reported and under-researched; there is an active black market
      pouring unknown quality counterfeit products and, in the USA, federal
      restrictions limit cannabis research. Vaping is a toxicological, multidimensional
      conundrum; therefore, stringent quality control, transparent legal/ethical
      boundaries, meticulous international research and user education are paramount to
      prevent potential future outbreaks and determine the parameters safe vaping (if
      these exist).
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Xantus, Gabor Zoltan
AU  - Xantus GZ
AUID- ORCID: http://orcid.org/0000-0003-3060-0069
AD  - Alumnus at Critical Care Department, Cardiff University, Cardiff, UK
      gabor.xantus@gmail.com.
FAU - Gyarmathy, Anna V
AU  - Gyarmathy AV
AD  - Medical Department, EpiConsult Biomedical Consulting and Medical Communications
      Agency, Dover, UK.
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Johnson, Carole Ann
AU  - Johnson CA
AD  - Urgent Care, Cayman Islands Urgent Care, George Town, Cayman Islands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200618
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
MH  - *Electronic Nicotine Delivery Systems
MH  - Emergency Medicine
MH  - Global Health/statistics & numerical data
MH  - Health Services Needs and Demand
MH  - Humans
MH  - *Lung Injury/epidemiology/etiology/prevention & control/therapy
MH  - Research/organization & administration/statistics & numerical data
MH  - United States/epidemiology
MH  - *Vaping/adverse effects/epidemiology
OTO - NOTNLM
OT  - accident & emergency medicine
OT  - epidemiology
OT  - general medicine (see internal medicine)
OT  - respiratory medicine (see thoracic medicine)
OT  - risk management
COIS- Competing interests: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - postgradmedj-2020-137673 [pii]
AID - 10.1136/postgradmedj-2020-137673 [doi]
PST - ppublish
SO  - Postgrad Med J. 2020 Nov;96(1141):686-692. doi: 10.1136/postgradmedj-2020-137673.
      Epub 2020 Jun 18.


PMID- 32554370
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 14
TI  - Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After
      Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a
      Feasibility Study.
PG  - e17976
LID - 10.2196/17976 [doi]
AB  - BACKGROUND: Nodal staging is a major concern in colorectal cancer as it is an
      important prognostic factor. Several techniques that could potentially improve
      patient treatment and prognosis have been developed to increase the accuracy of
      nodal staging. Sentinel lymph node detection has been shown to accurately reflect
      nodal status in various tumors and has become the standard procedure in nodal
      staging of breast cancer and melanoma. However, in colorectal cancer, sentinel
      lymph node detection techniques are still controversial as the sensitivity
      reported in the literature varies from one study to another. Recently,
      indocyanine green fluorescence-guided surgery has been reported to be a useful
      technique for detection of macroscopic and microscopic metastatic deposits in
      lymph nodes after intravenous administration of indocyanine green dye. However,
      no studies have focused on the potential role of sentinel lymph node detection
      after systemic administration of indocyanine green dye, so-called systemic
      sentinel lymph nodes, or on the correspondence between the identification of the 
      sentinel lymph node by standard local injection techniques and the detection of
      fluorescent lymph nodes with this new approach. OBJECTIVE: The aim of this
      protocol is to validate the concept of sentinel lymph nodes identified by
      fluorescence imaging after intravenous injection of indocyanine green dye and to 
      compare the sentinel lymph nodes identified by fluorescence imaging with sentinel
      lymph nodes detected by the standard blue dye technique. METHODS: This study
      (SeLyNoFI; Sentinel Lymph Nodes Fluorescence Imaging) is a diagnostic,
      single-arm, open-label feasibility study, including patients with colorectal
      adenocarcinoma with or without metastatic disease who are admitted for elective
      colorectal resection of the primary tumor. This study evaluates the feasibility
      of a new approach for improving the accuracy of nodal staging using fluorescence 
      imaging after intravenous administration of indocyanine green dye. Sensitivity,
      positive predictive value, and accuracy of the classical blue dye technique and
      of the investigatory fluorescence imaging technique will be calculated.
      Translational research will be proposed, if applicable. RESULTS: As of June 2020,
      this study has been registered. Submission for ethical review is planned for
      September 2020. CONCLUSIONS: The potential correlation between the two different 
      approaches to detect sentinel lymph nodes offers new strategies for improving the
      accuracy of nodal staging in colorectal cancer. This new concept of the systemic 
      sentinel lymph node and a greater understanding of the interactions between
      systemic sentinel lymph nodes and standard sentinel lymph nodes may provide
      important information regarding the underlying mechanism of primary tumor
      lymphatic drainage. The enhanced permeability and retention effect can also play 
      a role in the fluorescence of systemic sentinel lymph nodes, especially if these 
      lymph nodes are inflamed. In this case, we can even imagine that this new
      technique will highlight more instances of lymph node-positive colorectal cancer.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/17976.
CI  - (c)Gabriel Liberale, Sophie Vankerckhove, Fikri Bouazza, Maria Gomez Galdon,
      Denis Larsimont, Michel Moreau, Pierre Bourgeois, Vincent Donckier. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      14.08.2020.
FAU - Liberale, Gabriel
AU  - Liberale G
AUID- ORCID: https://orcid.org/0000-0001-8051-1588
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Vankerckhove, Sophie
AU  - Vankerckhove S
AUID- ORCID: https://orcid.org/0000-0002-1075-0249
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Bouazza, Fikri
AU  - Bouazza F
AUID- ORCID: https://orcid.org/0000-0002-1636-2888
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Gomez Galdon, Maria
AU  - Gomez Galdon M
AUID- ORCID: https://orcid.org/0000-0001-6943-0402
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Larsimont, Denis
AU  - Larsimont D
AUID- ORCID: https://orcid.org/0000-0003-2152-253X
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Moreau, Michel
AU  - Moreau M
AUID- ORCID: https://orcid.org/0000-0002-2957-5671
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Bourgeois, Pierre
AU  - Bourgeois P
AUID- ORCID: https://orcid.org/0000-0002-7349-4334
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
FAU - Donckier, Vincent
AU  - Donckier V
AUID- ORCID: https://orcid.org/0000-0003-1457-2520
AD  - Institut Jules Bordet, Belgian Comprehensive Cancer Center, Universite Libre de
      Bruxelles (ULB), BE 0257.981.101., Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200814
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7455862
OTO - NOTNLM
OT  - cancer
OT  - colorectal cancer
OT  - fluorescence imaging
OT  - indocyanine green
OT  - lymph node
OT  - nodal staging
OT  - prognosis
OT  - sentinel lymph node detection
OT  - treatment
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/01/26 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/06/04 00:00 [revised]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - v9i8e17976 [pii]
AID - 10.2196/17976 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 14;9(8):e17976. doi: 10.2196/17976.


PMID- 32554368
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 18
TI  - A Web-Based Intervention for Young Adults Whose Parents Have a Mental Illness or 
      Substance Use Concern: Protocol for a Randomized Controlled Trial.
PG  - e15626
LID - 10.2196/15626 [doi]
AB  - BACKGROUND: One in 5 young people grow up in a family where one parent has
      experienced a mental health problem or substance use concern. Compared with their
      same-aged peers, these youth are at a higher risk of academic failure and
      acquiring a substance abuse and/or mental health issue. There is a paucity of
      accessible, age-appropriate interventions that address their needs. OBJECTIVE: A 
      6-week, web-based intervention, "mental illness: supported, preventative, online,
      targeted" (mi.spot), was developed based on previous research and the competence 
      enhancement model. This paper describes the protocol for a randomized controlled 
      trial and details how the usage, safety, acceptability, and feasibility of the
      intervention will be determined. METHODS: Participants will be recruited through 
      social media and clinician referral. A total of 70 Australians, aged 18 to 25
      years, who grew up with parents with a mental illness or substance use concern
      will participate in a 2-arm parallel randomized controlled trial. The assessment 
      will consist of a baseline measurement and 2 follow-up periods, posttest and
      6-week follow-up, using the Mental Health Continuum short form; the Depression,
      Anxiety, and Stress Scale; the Coping Orientation to Problems Experienced
      inventory; the General Help Seeking Questionnaire; the Social Connectedness
      Scale; the Mental Health Literacy Scale; the General Self-Efficacy Scale; and the
      Attribution of Responsibility for Parental Mental Illness Measure. Impact will be
      examined at pre, post, and follow-up time periods using analyses of variance that
      will include a within-subjects factor (time) and a between-subjects factor
      (intervention/control). Facilitator interviews will ascertain intervention
      feasibility. Participant interviews will ascertain intervention acceptability.
      Interview data will be analyzed within a qualitative framework. Usage (data
      analytics) across site features and several indicators of clinical safety will
      also be reported. RESULTS: The impact of mi.spot will be examined at pre, post,
      and follow-up time periods using analyses of variance on each of the measures
      outlined above. There will be a within-subjects factor (time) and a
      between-subjects factor (intervention/control). Data analysis will employ the
      intention-to-treat principle by including all participants in the analyses.
      Qualitative interview data will be analyzed using interpretative phenomenological
      analysis along with respondent validation. The Monash University Human Research
      Ethics Committee (reference number: 2019-18660-30434) approved the trial on April
      17, 2019. As of October 2, 2019, 30 participants were enrolled in the control
      group and 34 participants were enrolled in the intervention group. Result are
      expected to be submitted for publication in December 2020. CONCLUSIONS: Study
      results will provide reliable evidence on a web-based intervention that has the
      potential to make a difference to the lives of many vulnerable young adults.
      Implementation guidelines are needed to embed the intervention in different
      service sectors. TRIAL REGISTRATION: Australian New Zealand Clinical Trials
      Registry ACTRN12619000335190;
      https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619000335190.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15626.
CI  - (c)Darryl Maybery, Andrea Reupert, Catherine Bartholomew, Rose Cuff, Zoe Duncan, 
      Kim Foster, Jodie Matar, Laura Pettenuzzo. Originally published in JMIR Research 
      Protocols (http://www.researchprotocols.org), 18.06.2020.
FAU - Maybery, Darryl
AU  - Maybery D
AUID- ORCID: https://orcid.org/0000-0003-1038-9374
AD  - School of Rural Health, Monash University, Warragul, Australia.
FAU - Reupert, Andrea
AU  - Reupert A
AUID- ORCID: https://orcid.org/0000-0003-1447-7769
AD  - Faculty of Education, Monash University, Clayton, Australia.
FAU - Bartholomew, Catherine
AU  - Bartholomew C
AUID- ORCID: https://orcid.org/0000-0001-7432-3679
AD  - Wellways, Melbourne, Australia.
FAU - Cuff, Rose
AU  - Cuff R
AUID- ORCID: https://orcid.org/0000-0002-3887-2256
AD  - Bouverie Centre, Melbourne, Australia.
FAU - Duncan, Zoe
AU  - Duncan Z
AUID- ORCID: https://orcid.org/0000-0003-4003-7484
AD  - School of Rural Health, Monash University, Warragul, Australia.
FAU - Foster, Kim
AU  - Foster K
AUID- ORCID: https://orcid.org/0000-0001-6931-2422
AD  - School of Nursing, Midwifery & Paramedicine, Australian Catholic University,
      Melbourne, Australia.
AD  - North Western Mental Health, Melbourne Health, Melbourne, Australia.
FAU - Matar, Jodie
AU  - Matar J
AUID- ORCID: https://orcid.org/0000-0002-9374-9154
AD  - Faculty of Education, Monash University, Clayton, Australia.
FAU - Pettenuzzo, Laura
AU  - Pettenuzzo L
AUID- ORCID: https://orcid.org/0000-0001-8588-2900
AD  - Faculty of Education, Monash University, Clayton, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7333071
OTO - NOTNLM
OT  - internet-based intervention
OT  - mental health
OT  - substance use
OT  - young adult
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2019/07/24 00:00 [received]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2019/11/11 00:00 [revised]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - v9i6e15626 [pii]
AID - 10.2196/15626 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 18;9(6):e15626. doi: 10.2196/15626.


PMID- 32554346
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20210105
IS  - 2115-7863 (Electronic)
IS  - 2115-7863 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Jun 1
TI  - [Ethics, care and ageing during the Covid-19 pandemic].
PG  - 151-156
LID - 10.1684/pnv.2020.0869 [doi]
AB  - At the beginning of the Covid-19 epidemic, National forum for ethical reflection 
      on Alzheimer's disease and neurodegenerative diseases conducted a national survey
      to identify the difficulties encountered by professionals working in the field of
      old age and autonomy, families and volunteers, and the initiatives they have
      implemented. Seven major difficulties were identified: the isolation induced by
      the prohibition of visits, the lack of protective equipment and tests, the
      difficulties of people with cognitive difficulties in understanding measures to
      avoid the spread of the epidemic, the sustainability of overwork for
      professionals, the concern of the families of residents, complex situations at
      home and difficulties in accessing care. Four initiatives are being implemented: 
      information and training for teams, compensation for interrupted visits,
      consultations and exchanges between professionals, actions to benefit people
      living at home. The Covid-19 epidemic hit the elderly sector at a very special
      moment in its history, several years of effort by the sector to reinvent itself
      around strong values. They have been a resource during this period of crisis. An 
      ambitious law on old age and autonomy therefore appears to be a necessity.
FAU - Gzil, Fabrice
AU  - Gzil F
AD  - Espace de reflexion ethique de la region Ile-de-France, France.
FAU - Clause-Verdreau, Anne-Caroline
AU  - Clause-Verdreau AC
AD  - Espace de reflexion ethique de la region Ile-de-France, France.
FAU - Brugeron, Pierre-Emmanuel
AU  - Brugeron PE
AD  - Espace de reflexion ethique de la region Ile-de-France, France.
FAU - Hirsch, Emmanuel
AU  - Hirsch E
AD  - Espace de reflexion ethique de la region Ile-de-France, France.
LA  - fre
PT  - Journal Article
TT  - Ethique, soin et grand age pendant l'epidemie de Covid-19.
PL  - France
TA  - Geriatr Psychol Neuropsychiatr Vieil
JT  - Geriatrie et psychologie neuropsychiatrie du vieillissement
JID - 101553404
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques/statistics & numerical data
MH  - Cognition Disorders/complications/psychology
MH  - Coronavirus Infections/diagnosis/epidemiology/*therapy
MH  - Family
MH  - Female
MH  - France/epidemiology
MH  - Geriatrics/*ethics/*trends
MH  - Health Services Accessibility
MH  - Humans
MH  - Male
MH  - Pandemics
MH  - Patient Education as Topic
MH  - Patient Isolation/psychology
MH  - Personal Autonomy
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *care
OT  - *elderly
OT  - *ethics
OT  - *long term care
EDAT- 2020/06/20 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - pnv.2020.0869 [pii]
AID - 10.1684/pnv.2020.0869 [doi]
PST - ppublish
SO  - Geriatr Psychol Neuropsychiatr Vieil. 2020 Jun 1;18(2):151-156. doi:
      10.1684/pnv.2020.0869.


PMID- 32553755
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201125
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
VI  - 76
IP  - 4
DP  - 2020 Oct
TI  - Social Media and Kidney Transplant Donation in the United States: Clinical and
      Ethical Considerations When Seeking a Living Donor.
PG  - 583-585
LID - S0272-6386(20)30750-2 [pii]
LID - 10.1053/j.ajkd.2020.03.027 [doi]
FAU - Henderson, Macey L
AU  - Henderson ML
AD  - Division of Transplantation, Department of Surgery, Johns Hopkins School of
      Medicine, Baltimore, MD. Electronic address: macey@jhmi.edu.
FAU - Herbst, Leyla
AU  - Herbst L
AD  - Division of Transplantation, Department of Surgery, Johns Hopkins School of
      Medicine, Baltimore, MD.
FAU - Love, Arthur D
AU  - Love AD
AD  - Division of Transplantation, Department of Surgery, Johns Hopkins School of
      Medicine, Baltimore, MD.
LA  - eng
GR  - K01 DK114388/DK/NIDDK NIH HHS/United States
GR  - R01 DK119667/DK/NIDDK NIH HHS/United States
PT  - Editorial
PT  - Research Support, N.I.H., Extramural
DEP - 20200615
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
SB  - IM
MH  - Humans
MH  - Kidney Transplantation/*ethics
MH  - Living Donors
MH  - *Social Media
MH  - Tissue and Organ Procurement/*ethics
MH  - United States
EDAT- 2020/06/20 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/10/14 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - S0272-6386(20)30750-2 [pii]
AID - 10.1053/j.ajkd.2020.03.027 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 2020 Oct;76(4):583-585. doi: 10.1053/j.ajkd.2020.03.027. Epub
      2020 Jun 15.


PMID- 32553535
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20210110
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 158
IP  - 4
DP  - 2020 Oct
TI  - Legal Immunity for Physicians During the COVID-19 Pandemic: Needs to Address
      Legal and Ethical Challenges.
PG  - 1343-1345
LID - S0012-3692(20)31671-8 [pii]
LID - 10.1016/j.chest.2020.06.007 [doi]
FAU - Klitzman, Robert L
AU  - Klitzman RL
AD  - Columbia University, New York, NY. Electronic address: rlk2@cumc.columbia.edu.
LA  - eng
PT  - Editorial
DEP - 20200615
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - *Liability, Legal
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7294282
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *law
OT  - *policy
OT  - *triage
EDAT- 2020/06/20 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/02 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - S0012-3692(20)31671-8 [pii]
AID - 10.1016/j.chest.2020.06.007 [doi]
PST - ppublish
SO  - Chest. 2020 Oct;158(4):1343-1345. doi: 10.1016/j.chest.2020.06.007. Epub 2020 Jun
      15.


PMID- 32553523
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 2213-0772 (Electronic)
IS  - 2213-0764 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Jun
TI  - Facilitating ethical quality improvement initiatives: Design and implementation
      of an initiative-specific ethics committee.
PG  - 100425
LID - S2213-0764(20)30024-5 [pii]
LID - 10.1016/j.hjdsi.2020.100425 [doi]
AB  - Like all facets of healthcare practice, quality improvement (QI) should be
      conducted in an ethically responsible manner. For methodologically complex QI,
      accountability and thoughtful ethical monitoring might be particularly important.
      Yet, access to ethical guidance for QI, as opposed to research, is often limited.
      Available mechanisms tend to be ill-equipped to accommodate the rapid cycle
      nature of QI, and monitoring standards for QI are not well defined. Providing
      appropriate ethical guidance for complex, multi-site QI initiatives can be
      especially challenging, as the body providing guidance must be familiar with QI
      methods, recognize the competing interests of stakeholder groups, respond to
      numerous requests, and understand the initiative's design. This case report
      describes our solution-an initiative-specific QI Ethics Committee that provided
      ethical guidance and consultation to a Veterans Administration QI initiative
      employing local innovations and a centralized evaluation. Enhanced by multiple
      tables, we discuss structuring and staffing the committee, the committee's role, 
      functions and activities, requests for ethics guidance, and our strategy applying
      initiative-specific ethical principles to guide recommendations. Supported by
      feedback obtained from stakeholder interviews, we share key insights regarding
      the value of: * Clarifying and marketing the committee's role to users. *
      Reconciling conflicting interests between site-based team members and cross-site 
      evaluators. * Separating ethics guidance from regulatory oversight. * Addressing 
      the ethics of evaluative design. * Adjusting the intensity of the committee's
      work over time. * Creating tangible products. Our approach shows promise in
      supporting the ethical practice of methodologically complex QI, especially in
      institutions that lack applicable ethics monitoring mechanisms. Building on this 
      approach, other complex QI initiatives can develop effective and feasible methods
      to protect participants from unintentional ethical lapses.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Bottrell, Melissa M
AU  - Bottrell MM
AD  - Ethics Quality Consulting, 814 Jones Street, Berkeley, CA, 94710, United States; 
      Sigma Health Consulting LLC, 7918 Jones Branch Dr., Suite 240, McLean, VA, 22102,
      United States. Electronic address: melissa.bottrell@gmail.com.
FAU - Simon, Alissa
AU  - Simon A
AD  - VA Center for the Study of Healthcare Innovation, Implementation and Policy
      (CSHIIP), 16111 Plummer Street, North Hills, CA, 91343, United States. Electronic
      address: alissa.simon@va.gov.
FAU - Geppert, Cynthia
AU  - Geppert C
AD  - National Center for Ethics in Health Care, U.S. Department of Veterans Affairs,
      1501 Caballo Canyon Dr. NE, Albuquerque, NM, 87112, United States. Electronic
      address: ethicdoc@comcast.net.
FAU - Chang, Evelyn T
AU  - Chang ET
AD  - VA Center for the Study of Healthcare Innovation, Implementation and Policy
      (CSHIIP), 16111 Plummer Street, North Hills, CA, 91343, United States; David
      Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte
      Ave, Los Angeles, CA, 90095, United States. Electronic address:
      Evelyn.Chang@va.gov.
FAU - Asch, Steven M
AU  - Asch SM
AD  - VA Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care
      System, 795 Willow St, Menlo Park, 94025, United States; Stanford University
      School of Medicine, 291 Campus Drive, Stanford, CA, 94305, United States.
      Electronic address: sasch@stanford.edu.
FAU - Rubenstein, Lisa
AU  - Rubenstein L
AD  - Fielding School of Public Health, University of California Los Angeles, 650
      Charles E Young Dr S, Los Angeles, CA, 90095, United States; Evidence-Based
      Practice Center, RAND Corporation, 1700 Main Street, Santa Monica, CA, 90401,
      United States. Electronic address: lisar@rand.org.
LA  - eng
PT  - Case Reports
DEP - 20200520
PL  - Netherlands
TA  - Healthc (Amst)
JT  - Healthcare (Amsterdam, Netherlands)
JID - 101622189
SB  - IM
MH  - Ethics Committees/*trends
MH  - *Ethics, Medical
MH  - Humans
MH  - *Quality Improvement
MH  - United States
MH  - United States Department of Veterans Affairs/organization & administration
OTO - NOTNLM
OT  - Ethics
OT  - Ethics committee
OT  - Ethics consultation
OT  - Quality improvement
COIS- Declaration of competing interest We wish to confirm that there are no known
      conflicts of interest associated with this publication and there has been no
      significant financial support for this work that could have influenced its
      outcome.
EDAT- 2020/06/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/08/19 00:00 [received]
PHST- 2020/02/28 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S2213-0764(20)30024-5 [pii]
AID - 10.1016/j.hjdsi.2020.100425 [doi]
PST - ppublish
SO  - Healthc (Amst). 2020 Jun;8(2):100425. doi: 10.1016/j.hjdsi.2020.100425. Epub 2020
      May 20.


PMID- 32553337
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 13
IP  - 12
DP  - 2020 Jun 22
TI  - Safety and Efficacy of Protamine Administration for Prevention of Bleeding
      Complications in Patients Undergoing TAVR.
PG  - 1471-1480
LID - S1936-8798(20)30858-X [pii]
LID - 10.1016/j.jcin.2020.03.041 [doi]
AB  - OBJECTIVES: The aim of this study was to evaluate whether protamine
      administration for heparin reversal after transcatheter aortic valve replacement 
      (TAVR) reduces bleeding complications and affects patient outcomes. BACKGROUND:
      Occurrence of major bleeding complications in patients undergoing TAVR is
      associated with increased morbidity and mortality. METHODS: This study included
      873 patients undergoing TAVR, of whom 677 received protamine for heparin
      reversal. Standard access management included the use of pre-closure devices,
      manual compression, and percutaneous transluminal angioplasty or implantation of 
      a covered stent graft, if necessary. The study complied with Good Clinical
      Practice guidelines and was approved by the local ethics committee. Written
      informed consent was obtained from all patients. RESULTS: The primary endpoint, a
      composite of 30-day all-cause mortality and life-threatening and major bleeding, 
      occurred less frequently in the protamine administration group (3.2%) compared
      with the control group (8.7%) (p = 0.003). This was driven mainly by lower rates 
      of life-threatening and major bleeding in the protamine group (0.1% vs. 2.6% [p <
      0.001] and 1.0% vs. 4.1% [p = 0.008], respectively). Furthermore, protamine
      administration resulted in a significantly shorter hospital stay (11.1 +/- 5.8
      days vs. 12.7 +/- 7.8 days; p = 0.05). In the overall cohort, stroke was observed
      in 1.9% and myocardial infarction in 0.2% of patients, with no significant
      difference between the groups (p > 0.05). Multivariate analysis revealed that
      only protamine administration (odds ratio: 0.24; 95% confidence interval: 0.10 to
      0.58; p = 0.001) and acute kidney injury (odds ratio: 5.82; 95% confidence
      interval: 2.02 to 16.77; p = 0.001) were independently associated with the
      primary endpoint. CONCLUSIONS: Protamine administration resulted in significantly
      lower rates of life-threatening and major bleeding complications compared with
      patients without heparin reversal. Occurrence of stroke and myocardial infarction
      was not increased by protamine administration.
CI  - Copyright (c) 2020 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
FAU - Al-Kassou, Baravan
AU  - Al-Kassou B
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Kandt, Julian
AU  - Kandt J
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Lohde, Luisa
AU  - Lohde L
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Shamekhi, Jasmin
AU  - Shamekhi J
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Sedaghat, Alexander
AU  - Sedaghat A
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Tabata, Noriaki
AU  - Tabata N
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Weber, Marcel
AU  - Weber M
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Sugiura, Atsushi
AU  - Sugiura A
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Fimmers, Rolf
AU  - Fimmers R
AD  - Department of Medical Biometry, Informatics, and Epidemiology, University
      Hospital Bonn, Bonn, Germany.
FAU - Werner, Nikos
AU  - Werner N
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Grube, Eberhard
AU  - Grube E
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Treede, Hendrik
AU  - Treede H
AD  - Heart Center, Department of Cardiac Surgery, University Hospital Bonn, Bonn,
      Germany.
FAU - Nickenig, Georg
AU  - Nickenig G
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
FAU - Sinning, Jan-Malte
AU  - Sinning JM
AD  - Heart Center, Department of Medicine II, University Hospital Bonn, Bonn, Germany.
      Electronic address: jan-malte.sinning@ukbonn.de.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin Antagonists)
RN  - 0 (Protamines)
RN  - 9005-49-6 (Heparin)
SB  - IM
CIN - JACC Cardiovasc Interv. 2020 Jun 22;13(12):1481-1483. PMID: 32553338
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/adverse effects
MH  - *Catheterization, Peripheral/adverse effects/mortality
MH  - Female
MH  - *Femoral Artery
MH  - Hemorrhage/etiology/mortality/*prevention & control
MH  - Heparin/*administration & dosage/adverse effects
MH  - Heparin Antagonists/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Patient Safety
MH  - Protamines/*administration & dosage/adverse effects
MH  - Punctures
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - *Transcatheter Aortic Valve Replacement/adverse effects/mortality
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *TAVR
OT  - *bleeding complication
OT  - *protamine
OT  - *vascular complication
EDAT- 2020/06/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S1936-8798(20)30858-X [pii]
AID - 10.1016/j.jcin.2020.03.041 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2020 Jun 22;13(12):1471-1480. doi:
      10.1016/j.jcin.2020.03.041.


PMID- 32553205
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1097-4199 (Electronic)
IS  - 0896-6273 (Linking)
VI  - 106
IP  - 6
DP  - 2020 Jun 17
TI  - (In)citing Action to Realize an Equitable Future.
PG  - 890-894
LID - S0896-6273(20)30357-3 [pii]
LID - 10.1016/j.neuron.2020.05.011 [doi]
AB  - Reference lists of neuroscience articles show marked gender imbalances. To
      mitigate this disparity, we discuss relevant ethical considerations and offer
      practical recommendations to scientists of all ages. We envision an equitable
      future by all scientists for all scientists.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Dworkin, Jordan
AU  - Dworkin J
AD  - Department of Biostatistics, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Zurn, Perry
AU  - Zurn P
AD  - Department of Philosophy & Religion, American University, Washington, DC, 20016, 
      USA.
FAU - Bassett, Danielle S
AU  - Bassett DS
AD  - Department of Bioengineering, School of Engineering & Applied Science, University
      of Pennsylvania, Philadelphia, PA 19104, USA; Department of Psychiatry, Perelman 
      School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA;
      Department of Neurology, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, PA 19104, USA; Department of Electrical & Systems Engineering,
      School of Engineering & Applied Science, University of Pennsylvania,
      Philadelphia, PA 19104, USA; Department of Physics & Astronomy, College of Arts &
      Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA; The Santa Fe
      Institute, Santa Fe, NM 87501, USA. Electronic address: dsb@seas.upenn.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Neuron
JT  - Neuron
JID - 8809320
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Neurosciences
MH  - *Periodicals as Topic
MH  - *Publishing
MH  - *Research
MH  - *Women
OTO - NOTNLM
OT  - *citations
OT  - *diversity
OT  - *ethics
OT  - *recommendations
OT  - *reference lists
OT  - *responsible conduct of research
COIS- Declaration of Interests D.S.B. currently serves on the Board of Scientific
      Counselors, National Institute of Mental Health.
EDAT- 2020/06/20 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
AID - S0896-6273(20)30357-3 [pii]
AID - 10.1016/j.neuron.2020.05.011 [doi]
PST - ppublish
SO  - Neuron. 2020 Jun 17;106(6):890-894. doi: 10.1016/j.neuron.2020.05.011.


PMID- 32553045
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Ethical issues in tuberculosis screening and the use of new drugs for prisoners.
PG  - 57-60
LID - 10.5588/ijtld.17.0899 [doi]
AB  - SETTING: Prisons are known to have extremely high tuberculosis (TB) and
      multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB prevalence and 
      poor treatment outcomes.OBJECTIVE: To examine the screening and M/XDR-TB
      treatment with new TB drugs in prisons from the perspective of international
      ethical and legal requirements.DESIGN: WHO recommendations on TB screening in
      prisons and M/XDR-TB treatment as well as the international human rights law on
      prisoners were analysed.RESULTS: Prisoners have a human right to access at least 
      the same level of TB care as in their communities. Screening for TB in prisons,
      which may run contrary to a given individual's choice to be tested, may be
      justified by the positive obligation to prevent other prisoners from contracting 
      a possibly deadly disease. Introduction of new TB drugs in prisons is necessary, 
      ethically sound and should start in parallel with introduction in a civilian
      sector in strict compliance with the WHO recommendations.CONCLUSION: Access to
      screening for TB, as well as effective treatment according to WHO
      recommendations, must be ensured by countries on the basis of international human
      rights conventions.
FAU - Elger, B S
AU  - Elger BS
AD  - University Center of Legal Medicine of Geneva, University of Geneva, Geneva,
      Switzerland.
FAU - Mirzayev, F
AU  - Mirzayev F
AD  - World Health Organization, Geneva, Switzerland.
FAU - Afandiyev, S
AU  - Afandiyev S
AD  - Xazar Legal Service, Baku.
FAU - Gurbanova, E
AU  - Gurbanova E
AD  - Ministry of Justice, Main Medical Department, Baku, Azerbaijan, Department of
      Pulmonary Medicine, Tartu Ulikool, Tartu, Estonia.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Antitubercular Agents)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Antitubercular Agents/therapeutic use
MH  - Humans
MH  - *Pharmaceutical Preparations
MH  - *Prisoners
MH  - Prisons
MH  - *Tuberculosis/diagnosis/drug therapy/epidemiology
MH  - *Tuberculosis, Multidrug-Resistant/diagnosis/drug therapy/epidemiology
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0899 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):57-60. doi: 10.5588/ijtld.17.0899.


PMID- 32553044
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Upholding ethical values and human rights at the frontier of TB research.
PG  - 48-56
LID - 10.5588/ijtld.17.0897 [doi]
AB  - Until recently, human rights have played a minor role in the fight against
      tuberculosis (TB), even less so in TB research. This is changing, however. The
      WHO's End TB Strategy and Ethics Guidance stress respect for human rights and
      ethical principles in every area of TB care, including research. The desired
      reductions in TB incidence and mortality are impossible without new tools and
      strategies to fight the disease. Yet, little suggests that the current state of
      TB research-including funding levels, evidence being produced, and community
      involvement-will alleviate concerns related to the availability, accessibility,
      and acceptability of TB diagnostics, drugs, and prevention in the near future. In
      this article, we consider these ethics concerns in relation to the right to enjoy
      the benefits of scientific progress and the right to health. We also reflect on
      community involvement in research and offer recommendations in the spirit of the 
      rights to health and science, such as involving affected communities in all
      aspects of research planning, execution, and dissemination. Finally, we argue
      that states have a responsibility under international law for the continued
      realization of the right to health. This realization rests, in part, on the
      realization of the right to science.
FAU - Stillo, J
AU  - Stillo J
AD  - College of Liberal Arts and Sciences, Wayne State University, Detroit, MI.
FAU - Frick, M
AU  - Frick M
AD  - Treatment Action Group, New York, NY, USA.
FAU - Cong, Y
AU  - Cong Y
AD  - Program of Medical Ethics, Peking University Health Science Center, Beijing,
      China.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - *Human Rights
MH  - Humans
MH  - *Tuberculosis/diagnosis/prevention & control
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0897 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):48-56. doi: 10.5588/ijtld.17.0897.


PMID- 32553043
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Ethics and benefits of systematic screening for active tuberculosis.
PG  - 44-47
LID - 10.5588/ijtld.17.0888 [doi]
AB  - Systematic screening for active tuberculosis (TB) provides public health benefits
      and is part of the End TB Strategy. However, two of WHO's generic principles for 
      screening for disease state that the natural history of the disease in question
      must be well understood and that there must be benefits to earlier treatment. TB 
      fulfills the first of these only in part, the other has been less well
      documented. This paper considers the ethical implications of uncertain individual
      benefits from screening and the current research gaps.
FAU - Hermanns, S
AU  - Hermanns S
AD  - Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ), Eschborn, Germany.
FAU - Bhan, A
AU  - Bhan A
AD  - Global Health, Bioethics and Health Policy, Bhopal, India.
FAU - Viney, K
AU  - Viney K
AD  - Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden,
      Research School of Population Health, Australian National University, Canberra
      ACT, Australia.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Humans
MH  - Mass Screening
MH  - Public Health
MH  - Research
MH  - *Tuberculosis/diagnosis/epidemiology
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0888 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):44-47. doi: 10.5588/ijtld.17.0888.


PMID- 32553042
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210502
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Access to experimental medicines for TB: ethical and human rights considerations.
PG  - 38-43
LID - 10.5588/ijtld.18.0885 [doi]
AB  - The revised edition of the WHO's Ethics Guidance for the Implementation of the TB
      Strategy has added a new chapter on compassionate use (CU) and expanded access
      (EA) to TB drugs. CU and EA programmes authorise access to drugs that have not
      yet received marketing approval outside of clinical trials. They are aimed at
      allowing researchers access to investigational drugs in the absence of complete
      evidence of efficacy and safety to patients with multidrug-resistant (MDR) or
      rifampicin-resistant TB (RR-TB) when no other treatment options are available. In
      doing so, the guidance acknowledged the urgent necessity to offer these patients 
      all possible treatments in respect of considerations of justice, human rights,
      human dignity, autonomy of the individual and protection of the community.
      Regulators are in general willing to accept a higher level of uncertainty in the 
      risk-benefit assessment of medicines for life-threatening diseases when there is 
      an unmet medical need. This attests to a paradigm change, which this article
      argues should also apply to allow for effective access to experimental TB
      medicines. Furthermore, in this article, we analyse the challenges connected to
      the establishment of a secure and effective regime of access to experimental
      drugs in the context of MDR/RR-TB as well as the ethical principles and human
      rights arguments in favour of the development of such programmes.
FAU - Dagron, S
AU  - Dagron S
AD  - Faculty of Law/Faculty of Medicine, University of Geneva, Geneva, Switzerland.
FAU - Chakhaia, T
AU  - Chakhaia T
AD  - National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
FAU - Gonzalez-Angulo, L
AU  - Gonzalez-Angulo L
AD  - Global TB Programme, World Health Organization, Geneva, Switzerland.
FAU - Hermanns, S
AU  - Hermanns S
AD  - Department of Politics and International Studies, University of Cambridge, UK.
FAU - Skrahina, A
AU  - Skrahina A
AD  - Republican Scientific and Practical Center for Pulmonology and TB, Minsk,
      Belarus.
FAU - Wallace, A E M
AU  - Wallace AEM
AD  - Faculty of Law/Faculty of Medicine, University of Geneva, Geneva, Switzerland.
LA  - eng
GR  - D43 TW007124/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Drugs, Investigational)
SB  - IM
MH  - *Biomedical Research
MH  - Compassionate Use Trials
MH  - Drugs, Investigational
MH  - Humans
MH  - Social Justice
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
PMC - PMC7376934
MID - NIHMS1609635
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.18.0885 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):38-43. doi: 10.5588/ijtld.18.0885.


PMID- 32553041
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - WHO ethics guidance on TB care and migration: challenges to the implementation
      process.
PG  - 32-37
LID - 10.5588/ijtld.17.0882 [doi]
AB  - We summarise the current ethical guidance on tuberculosis (TB) care and
      migration, as set out in the WHO "Ethics Guidance for the Implementation of the
      End TB Strategy." Among other aspects, the Ethics Guidance states that there
      should be firm legal principles in place that ensure the enforcement of migration
      law on the one hand and the protection of human rights, including the right to
      health, on the other are separated from one another. As a challenge to the Ethics
      Guidance and its implementation, we describe two cases, each of which typifies
      particular problems. Case one describes the experience of a migrant worker in the
      United Arab Emirates who is deported when mandatory medical exams show evidence
      of current or prior TB. Case two raises the issue of providing more than TB care,
      which may also be needed for holistic care. The paper concludes with our
      suggestions for ways in which we could make progress towards ethically optimal TB
      care for migrants.
FAU - Wild, V
AU  - Wild V
AD  - Institute of Ethics, History and Theory of Medicine,
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Frick, M
AU  - Frick M
AD  - Treatment Action Group, New York, NY, USA.
FAU - Denholm, J
AU  - Denholm J
AD  - Victorian Tuberculosis Program, Melbourne Health, Melbourne, VIC, Department of
      Microbiology and Immunology, University of Melbourne at the Peter Doherty
      Institute, Melbourne, VIC, Victorian Infectious Diseases Service, Royal Melbourne
      Hospital, Parkville, VIC, Australia.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Human Rights
MH  - Humans
MH  - *Transients and Migrants
MH  - *Tuberculosis/diagnosis/drug therapy
MH  - World Health Organization
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0882 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):32-37. doi: 10.5588/ijtld.17.0882.


PMID- 32553040
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Ethical issues surrounding childhood tuberculosis.
PG  - 27-31
LID - 10.5588/ijtld.17.0806 [doi]
AB  - Each year, at least one million children become ill with tuberculosis (TB) and
      more than 253 000 died of TB in 2016. The ethical issues surrounding childhood TB
      remain underexplored, and established or proposed management strategies are
      scarce. In this paper, we identify ethical challenges that are raised by
      childhood TB. Some of them are familiar from TB in other populations but arise
      with increased severity in children. We discuss interconnected and mutually
      reinforcing difficulties clustered around the topics of susceptibility,
      diagnosis, reporting, service provision, treatment, psychological and social
      support, and research and development (R&D) neglect. We formulate suggestions on 
      how to address these ethical issues. For developing sound research agendas and
      policies based on the WHO End TB Strategy, it is essential that diagnosis and
      reporting improve. There is a duty to care for and provide available
      interventions to children with TB even if they are not a major source of
      transmission, and therefore no major impact on public health is expected.
      Treatment should be accompanied by counselling, health education, psychological
      and material support to TB-affected children and their families. Children need to
      be included equitably and more systematically into the TB research agenda.
FAU - Hummel, P
AU  - Hummel P
AD  - Department of Philosophy, Edgecliffe, The Scores, St Andrews, UK.
FAU - Ahamed, N
AU  - Ahamed N
AD  - Global Tuberculosis Institute, Rutgers, The State University of New Jersey,
      Newark, New Jersey, USA.
FAU - Amanullah, F
AU  - Amanullah F
AD  - The Indus Hospital, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Child
MH  - Humans
MH  - Public Health
MH  - Social Support
MH  - *Tuberculosis/diagnosis/drug therapy/epidemiology
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0806 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):27-31. doi: 10.5588/ijtld.17.0806.


PMID- 32553039
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Latent tuberculosis infection and the EndTB Strategy: ethical tensions and
      imperatives.
PG  - 21-26
LID - 10.5588/ijtld.17.0756 [doi]
AB  - Latent tuberculosis infection (LTBI) is increasingly recognised as central to
      programmatic TB activity, and a critical element in global progress towards TB
      elimination. LTBI affects a much larger group of people than active disease, who 
      by definition are asymptomatic. Furthermore, while LTBI represents a state of
      risk, there remains significant uncertainty regarding which individuals will
      progress to active disease. Therefore, the development and implementation of LTBI
      management policies within the End TB Strategy requires careful ethical
      consideration. This article reviews ethical issues related to developments in
      LTBI diagnosis and management, including new tools and emerging policies and
      practice. Implications of LTBI management practices in specific settings are
      discussed, including healthcare worker infection and management of likely
      multidrug-resistant (MDR) LTBI. Better prediction of progression to active
      disease and less burdensome treatments would allow ethically appropriate
      expansion of testing programmes in future. However, even with existing tools
      there is a strong ethical imperative to provide the most effective and least
      burdensome therapy possible to those with LTBI, particularly those at highest
      risk of progression and/or poor outcomes from active disease. Greater community
      engagement is required in designing optimal LTBI management programmes, and
      ensure harms and benefits are appropriately balanced in specific settings.
FAU - Denholm, J T
AU  - Denholm JT
AD  - Victorian Tuberculosis Program, Melbourne, VIC, Australia.
FAU - Millan-Marcelo, J C
AU  - Millan-Marcelo JC
AD  - Pedro Kouri Tropical Medicine Institute, Havana, Cuba.
FAU - Fiekert, K
AU  - Fiekert K
AD  - KNCV Tuberculosis Foundation KNCV Tuberculosis Foundation, Mariahoeve, South
      Holland Province, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Humans
MH  - *Latent Tuberculosis/diagnosis/drug therapy
MH  - *Tuberculosis, Multidrug-Resistant
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0756 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):21-26. doi: 10.5588/ijtld.17.0756.


PMID- 32553038
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Ethics and human rights considerations regarding involuntary isolation of people 
      with TB.
PG  - 15-20
LID - 10.5588/ijtld.17.0879 [doi]
AB  - Involuntary isolation of people with tuberculosis is rarely medically required,
      ethically permitted or justified on the ground of human rights law. The rare
      circumstances that do call for involuntary isolation must only occur once a
      number of conditions are met. These include just procedural protections and
      ensuring that all other options have been exhausted before resorting to
      involuntary isolation. This article is intended to outline for healthcare
      workers, policy makers and advocates the ethical reasoning behind isolation and
      involuntary isolation, as well as describing the requisite human rights laws that
      impinge on the topic. Finally, we present a list of conditions that must be met
      to justify involuntary isolation on the grounds of both ethics and human rights.
FAU - Silva, D S
AU  - Silva DS
AD  - Sydney Health Ethics, Sydney School of Public Health, Marie Bashir Institute of
      Infectious Diseases, University of Sydney, Sydney, NSW, Australia.
FAU - Citro, B
AU  - Citro B
AD  - Northwestern Pritzker School of Law, Chicago, IL, USA.
FAU - Volchenkov, G
AU  - Volchenkov G
AD  - Vladimir Regional TB Control Center, Vladimir, Russia.
FAU - Gonzalez-Angulo, L
AU  - Gonzalez-Angulo L
AD  - Global TB Programme, World Health Organization, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - *Human Rights
MH  - Humans
MH  - *Tuberculosis/diagnosis
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0879 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):15-20. doi: 10.5588/ijtld.17.0879.


PMID- 32553037
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Tuberculosis surveillance and its discontents: the ethical paradox.
PG  - 9-14
LID - 10.5588/ijtld.17.0844 [doi]
AB  - In June 2017, the World Health Organization issued the Guidelines on Ethical
      Issues in Public Health Surveillance. Using the frame of public health ethics,
      the guidance declared that countries have an affirmative duty to undertake
      surveillance and that the global community had an obligation to support those
      countries whose resources limited their capacity. The centrality of TB
      surveillance has long been recognized as a matter of public health practice and
      ethics. Nevertheless, contemporary global realities make clear that TB
      surveillance falls far short of the goal of uniform notification. It is this
      reality that necessitated the paradoxical turn to research studies that require
      informed consent and human subjects' ethical review, the very burdens that
      mandated notification were designed to overcome.
FAU - Bayer, R
AU  - Bayer R
AD  - Mailman School of Public Health, Columbia University, New York, NY.
FAU - Fairchild, A L
AU  - Fairchild AL
AD  - School of Public Health, The Ohio State University, Columbus, OH, USA.
FAU - Zignol, M
AU  - Zignol M
AD  - World Health Organization, Geneva, Switzerland.
FAU - Castro, K G
AU  - Castro KG
AD  - Rollins School of Public Health, Emory University, Atlanta, GA, USA.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Humans
MH  - Informed Consent
MH  - Public Health
MH  - Public Health Surveillance
MH  - *Tuberculosis/diagnosis/epidemiology
MH  - World Health Organization
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.17.0844 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):9-14. doi: 10.5588/ijtld.17.0844.


PMID- 32553036
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - The ethical imperative to relieve suffering for people with tuberculosis by
      ensuring access to palliative care.
PG  - 3-8
LID - 10.5588/ijtld.18.0240 [doi]
AB  - Patients diagnosed with tuberculosis (TB) continue to experience clinical
      uncertainty and high mortality and to bear a high burden of symptoms and other
      concerns. Additional concerns may be family support needs and stigma,
      particularly the latter, as TB and human immunodeficiency virus (HIV) coinfection
      are common. Human rights covenants, global health policy and the End TB Strategy 
      all recommend palliative care as an essential component of care services. As
      established in the resolution adopted by the World Health Assembly (WHA) on
      "Strengthening of palliative care as a component of comprehensive care throughout
      the life course", there is a "need for palliative care across disease groups
      (non-communicable diseases, and infectious diseases, including HIV and
      multidrug-resistant tuberculosis), and across all age groups". We address the
      ethical imperative to respect the dignity and fundamental rights of people with
      TB by providing palliative care. We review the evidence for the need for
      person-centred palliative care and highlight novel models that utilise the skills
      and training functions of specialist palliative care to achieve better care. We
      outline simple recommendations for the delivery of specialist and generalist
      palliative care, offer suggestions on how to ensure optimal coverage by enabling 
      access to appropriate good-quality palliative care at all points of the health
      system, including alongside treatment. Finally, we set out the current priorities
      for research and policy to ensure that quality care is delivered to all who need 
      it irrespective of treatment outcome, to minimise distress and to optimise
      engagement in treatment and care.
FAU - Harding, R
AU  - Harding R
AD  - Department of Palliative Care, Policy & Rehabilitation, Cicely Saunders
      Institute, King's College London, London, UK.
FAU - Snyman, L
AU  - Snyman L
AD  - Medecins Sans Frontieres South Africa, Khayelitsha, South Africa.
FAU - Ostgathe, C
AU  - Ostgathe C
AD  - Department fur Physik, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Bayern,
      Germany.
FAU - Odell, S
AU  - Odell S
AD  - Palliative Medicine Unit, University of Cape Town, Cape Town, South Africa.
FAU - Gwyther, L
AU  - Gwyther L
AD  - Palliative Medicine Unit, University of Cape Town, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Clinical Decision-Making
MH  - Humans
MH  - Palliative Care
MH  - *Tuberculosis/therapy
MH  - *Tuberculosis, Multidrug-Resistant
MH  - Uncertainty
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.18.0240 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):3-8. doi: 10.5588/ijtld.18.0240.


PMID- 32553035
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 5
DP  - 2020 May 1
TI  - Ethics and human rights must drive our response to the TB epidemic.
PG  - 1-2
LID - 10.5588/ijtld.19.0765 [doi]
FAU - Jaramillo, E
AU  - Jaramillo E
AD  - World Health Organization, Global TB Programme, Geneva.
FAU - Kuesel, A C
AU  - Kuesel AC
AD  - UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in
      Tropical Diseases (TDR), Geneva.
FAU - Reis, A
AU  - Reis A
AD  - World Health Organization, Geneva, Switzerland, <email></email>, Email:
      jaramilloe@who.int.
LA  - eng
PT  - Editorial
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - *Epidemics
MH  - *Human Rights
MH  - Humans
EDAT- 2020/06/20 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.19.0765 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 May 1;24(5):1-2. doi: 10.5588/ijtld.19.0765.


PMID- 32552763
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210120
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 18
TI  - What are the benefits and harms of risk stratified screening as part of the NHS
      breast screening Programme? Study protocol for a multi-site non-randomised
      comparison of BC-predict versus usual screening (NCT04359420).
PG  - 570
LID - 10.1186/s12885-020-07054-2 [doi]
AB  - BACKGROUND: In principle, risk-stratification as a routine part of the NHS Breast
      Screening Programme (NHSBSP) should produce a better balance of benefits and
      harms. The main benefit is the offer of NICE-approved more frequent screening
      and/ or chemoprevention for women who are at increased risk, but are unaware of
      this. We have developed BC-Predict, to be offered to women when invited to NHSBSP
      which collects information on risk factors (self-reported information on family
      history and hormone-related factors via questionnaire; mammographic density; and 
      in a sub-sample, Single Nucleotide Polymorphisms). BC-Predict produces risk
      feedback letters, inviting women at high risk (>/=8% 10-year) or moderate risk
      (>/=5 to < 8% 10-year) to have discussion of prevention and early detection
      options at Family History, Risk and Prevention Clinics. Despite the promise of
      systems such as BC-Predict, there are still too many uncertainties for a
      fully-powered definitive trial to be appropriate or ethical. The present research
      aims to identify these key uncertainties regarding the feasibility of integrating
      BC-Predict into the NHSBSP. Key objectives of the present research are to
      quantify important potential benefits and harms, and identify key drivers of the 
      relative cost-effectiveness of embedding BC-Predict into NHSBSP. METHODS: A
      non-randomised fully counterbalanced study design will be used, to include
      approximately equal numbers of women offered NHSBSP (n = 18,700) and BC-Predict
      (n = 18,700) from selected screening sites (n = 7). In the initial 8-month time
      period, women eligible for NHSBSP will be offered BC-Predict in four screening
      sites. Three screening sites will offer women usual NHSBSP. In the following
      8-months the study sites offering usual NHSBSP switch to BC-Predict and vice
      versa. Key potential benefits including uptake of risk consultations,
      chemoprevention and additional screening will be obtained for both groups. Key
      potential harms such as increased anxiety will be obtained via self-report
      questionnaires, with embedded qualitative process analysis. A decision-analytic
      model-based cost-effectiveness analysis will identify the key uncertainties
      underpinning the relative cost-effectiveness of embedding BC-Predict into NHSBSP.
      DISCUSSION: We will assess the feasibility of integrating BC-Predict into the
      NHSBSP, and identify the main uncertainties for a definitive evaluation of the
      clinical and cost-effectiveness of BC-Predict. TRIAL REGISTRATION:
      Retrospectively registered with clinicaltrials.gov (NCT04359420).
FAU - French, David P
AU  - French DP
AUID- ORCID: http://orcid.org/0000-0002-7663-7804
AD  - Manchester Centre of Health Psychology, Division of Psychology and Mental Health,
      School of Health Sciences, University of Manchester, Coupland Street, Manchester,
      M13 9PL, England. david.french@manchester.ac.uk.
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England. david.french@manchester.ac.uk.
FAU - Astley, Susan
AU  - Astley S
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
AD  - Division of Informatics, Imaging and Data Sciences, School of Health Sciences,
      University of Manchester, Manchester, England.
FAU - Brentnall, Adam R
AU  - Brentnall AR
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen
      Mary University of London, London, England.
FAU - Cuzick, Jack
AU  - Cuzick J
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen
      Mary University of London, London, England.
FAU - Dobrashian, Richard
AU  - Dobrashian R
AD  - East Lancashire Hospitals NHS Trust, Royal Blackburn Hospital, Haslingden Road,
      Lancashire, BB2 3HH, England.
FAU - Duffy, Stephen W
AU  - Duffy SW
AD  - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen
      Mary University of London, London, England.
FAU - Gorman, Louise S
AU  - Gorman LS
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
AD  - NIHR Greater Manchester Patient Safety Translational Research Centre, University 
      of Manchester, Manchester, M13 9PL, England.
FAU - Harkness, Elaine F
AU  - Harkness EF
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
AD  - Division of Informatics, Imaging and Data Sciences, School of Health Sciences,
      University of Manchester, Manchester, England.
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
FAU - Harrison, Fiona
AU  - Harrison F
AD  - Patient representative, Manchester, England.
FAU - Harvie, Michelle
AU  - Harvie M
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
AD  - Manchester Breast Centre, Manchester Cancer Research Centre, University of
      Manchester, 555 Wilmslow Rd, Manchester, M20 4GJ, England.
FAU - Howell, Anthony
AU  - Howell A
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
AD  - Manchester Breast Centre, Manchester Cancer Research Centre, University of
      Manchester, 555 Wilmslow Rd, Manchester, M20 4GJ, England.
AD  - Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd,
      Manchester, M20 4BX, England.
FAU - Jerrison, Andrew
AU  - Jerrison A
AD  - Research IT, IT Services, University of Manchester, Manchester, M13 9PL, England.
FAU - Machin, Matthew
AU  - Machin M
AD  - Division of Informatics, Imaging and Data Sciences, School of Health Sciences,
      University of Manchester, Manchester, England.
FAU - Maxwell, Anthony J
AU  - Maxwell AJ
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
AD  - Division of Informatics, Imaging and Data Sciences, School of Health Sciences,
      University of Manchester, Manchester, England.
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
FAU - McWilliams, Lorna
AU  - McWilliams L
AD  - Manchester Centre of Health Psychology, Division of Psychology and Mental Health,
      School of Health Sciences, University of Manchester, Coupland Street, Manchester,
      M13 9PL, England.
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
FAU - Payne, Katherine
AU  - Payne K
AD  - Division of Population Health, Health Services Research & Primary Care, School of
      Health Sciences, University of Manchester, Manchester, M13 9PL, England.
FAU - Qureshi, Nadeem
AU  - Qureshi N
AD  - School of Medicine, University of Nottingham, University Park, Nottingham, NG7
      2RD, England.
FAU - Ruane, Helen
AU  - Ruane H
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
FAU - Sampson, Sarah
AU  - Sampson S
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
FAU - Stavrinos, Paula
AU  - Stavrinos P
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
FAU - Thorpe, Emma
AU  - Thorpe E
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
FAU - Ulph, Fiona
AU  - Ulph F
AD  - Manchester Centre of Health Psychology, Division of Psychology and Mental Health,
      School of Health Sciences, University of Manchester, Coupland Street, Manchester,
      M13 9PL, England.
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
FAU - van Staa, Tjeerd
AU  - van Staa T
AD  - Division of Informatics, Imaging and Data Sciences, School of Health Sciences,
      University of Manchester, Manchester, England.
FAU - Woof, Victoria
AU  - Woof V
AD  - Manchester Centre of Health Psychology, Division of Psychology and Mental Health,
      School of Health Sciences, University of Manchester, Coupland Street, Manchester,
      M13 9PL, England.
FAU - Evans, D Gareth
AU  - Evans DG
AD  - NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science
      Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester,
      England.
AD  - The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS
      Foundation Trust, Manchester, M23 9LT, England.
AD  - Manchester Breast Centre, Manchester Cancer Research Centre, University of
      Manchester, 555 Wilmslow Rd, Manchester, M20 4GJ, England.
AD  - Genomic Medicine, Division of Evolution and Genomic Sciences, The University of
      Manchester, St Mary's Hospital, Manchester University NHS Foundation Trust,
      Oxford Road, Manchester, M13 9WL, England.
LA  - eng
SI  - ClinicalTrials.gov/NCT04359420
GR  - GA18-001/Prevent Breast Cancer
GR  - GA15-003/Genesis Research Trust
GR  - IS-BRC-1215-20007/Manchester Biomedical Research Centre
GR  - RP-PG-1214-20016/Programme Grants for Applied Research
GR  - RP-PG-1214-20016/DH_/Department of Health/United Kingdom
GR  - 2018RP005/BBC_/Breast Cancer Now/United Kingdom
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
DEP - 20200618
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anxiety/*diagnosis/epidemiology/etiology
MH  - Breast Neoplasms/diagnosis/economics/epidemiology/*prevention & control
MH  - Child
MH  - Clinical Trials as Topic
MH  - *Cost-Benefit Analysis
MH  - Early Detection of Cancer/economics/*methods/psychology
MH  - Feasibility Studies
MH  - Female
MH  - Health Plan Implementation/economics/organization & administration
MH  - Humans
MH  - Mass Screening/economics/*methods/organization & administration/psychology
MH  - Medical History Taking
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Program Evaluation
MH  - Risk Assessment/economics/methods
MH  - Self Report/statistics & numerical data
MH  - State Medicine/economics/organization & administration
MH  - United Kingdom/epidemiology
MH  - Young Adult
PMC - PMC7302349
OTO - NOTNLM
OT  - Anxiety
OT  - Breast cancer
OT  - Chemoprevention
OT  - Early detection
OT  - High risk
OT  - Mammographic density
OT  - Psychological impact
OT  - Risk stratification
OT  - Screening
OT  - Tyrer-Cuzick
EDAT- 2020/06/20 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1186/s12885-020-07054-2 [doi]
AID - 10.1186/s12885-020-07054-2 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Jun 18;20(1):570. doi: 10.1186/s12885-020-07054-2.


PMID- 32552735
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 17
IP  - 1
DP  - 2020 Jun 18
TI  - Explaining the experience of prenatal care and investigating the association
      between psychological factors with self-care in pregnant women during COVID-19
      pandemic: a mixed method study protocol.
PG  - 98
LID - 10.1186/s12978-020-00949-0 [doi]
AB  - BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel global public health
      emergency. Prenatal care (PNC) providing institutes should identify the needs and
      demands of pregnant women by optimizing the means of PNC services during the
      COVID-19 pandemic. The present study aims to: a) explain prenatal care
      experiences; b) assess the factors affecting self-care, and c) present a prenatal
      care guideline and Strategies to improve the PNC. METHODS: This mixed-methods
      study with a sequential explanatory design consists of three phases. The first
      phase is a qualitative study exploring the prenatal care experiences among
      pregnant women. In this phase, the subjects will be selected through purposive
      sampling; moreover, in-depth individual interviewing will be used for data
      collection. Finally, the conventional content analysis approach will be employed 
      for data analysis. The second phase is quantitative and will be used as a
      cross-sectional approach for assessing the association between psychological
      factors of self-care. In this regard, a multistage cluster sampling method will
      be used to select 215 subjects who will be visited in health care centers of
      Tabriz, Iran. The third phase will be focusing on developing a prenatal care
      guideline and Strategies, using the qualitative and quantitative results of the
      previous phases, a review of the related literature, and the nominal group
      technique will be performed among experts. DISCUSSION: The present research is
      the first study to investigate the prenatal care experiences and factors
      influencing self-care among pregnant women during COVID-19 pandemic. For the
      purposes of the study, a mixed-methods approach will be used which aims to
      develop strategies for improving health care services. It is hoped that the
      strategy proposed in the current study could lead to improvements in this regard.
      ETHICAL CODE: IR.TBZMED.REC.1399.003.
FAU - Masjoudi, Marzieh
AU  - Masjoudi M
AD  - Department of Midwifery, Faculty of Nursing and Midwifery Islamic Azad
      University, Rasht branch, Rasht, Iran.
FAU - Aslani, Armin
AU  - Aslani A
AD  - Student Research Committee, Islamic Azad University, Tabriz branch, Tabriz, Iran.
FAU - Khazaeian, Somayyeh
AU  - Khazaeian S
AD  - Pregnancy Health Center, Zahedan University of Medical Sciences, Zahedan, Iran.
FAU - Fathnezhad-Kazemi, Azita
AU  - Fathnezhad-Kazemi A
AUID- ORCID: http://orcid.org/0000-0002-3601-9892
AD  - Department of Midwifery, Faculty of Nursing and Midwifery Islamic Azad
      University, Tabriz branch, Tabriz, Iran. afnkazemi@gmail.com.
LA  - eng
GR  - 990231/Islamic Azad University of Tabriz Branch
PT  - Journal Article
DEP - 20200618
PL  - England
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - Coronavirus Infections/complications/*epidemiology/virology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Iran/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/complications/*epidemiology/virology
MH  - Pregnancy
MH  - Pregnant Women/*psychology
MH  - Prenatal Care/*psychology
MH  - Qualitative Research
MH  - Research Design
MH  - SARS-CoV-2
MH  - Self Care/*psychology
MH  - Stress, Psychological/etiology/*psychology
MH  - Young Adult
PMC - PMC7301351
OTO - NOTNLM
OT  - Anxiety
OT  - COVID-19
OT  - Experiences
OT  - Fear
OT  - Perceived stress
OT  - Prenatal care
OT  - Self-care
EDAT- 2020/06/20 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1186/s12978-020-00949-0 [doi]
AID - 10.1186/s12978-020-00949-0 [pii]
PST - epublish
SO  - Reprod Health. 2020 Jun 18;17(1):98. doi: 10.1186/s12978-020-00949-0.


PMID- 32552544
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Working Through Ethics Review of Big Data Research Projects: An Investigation
      into the Experiences of Swiss and American Researchers.
PG  - 339-354
LID - 10.1177/1556264620935223 [doi]
AB  - The employment of Big Data as an increasingly used research method has introduced
      novel challenges to ethical research practices and to ethics committees (ECs)
      globally. The aim of this study is to explore the experiences of scholars with
      ECs in the ethical evaluation of Big Data projects. Thirty-five interviews were
      performed with Swiss and American researchers involved in Big Data research in
      psychology and sociology. The interviews were analyzed using thematic coding. Our
      respondents reported lack of support from ECs, absence of appropriate expertise
      among members of the boards, and lack of harmonized evaluation criteria between
      committees. To implement ECs practices we argue for updating the expertise of
      board members and the institution of a consultancy model between researchers and 
      ECs.
FAU - Favaretto, Maddalena
AU  - Favaretto M
AUID- ORCID: 0000-0003-2647-301X
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - De Clercq, Eva
AU  - De Clercq E
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Briel, Matthias
AU  - Briel M
AD  - Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital 
      Basel, Basel, Switzerland.
FAU - Elger, Bernice Simone
AU  - Elger BS
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200619
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - *Big Data
MH  - Ethical Review
MH  - Ethics Committees, Research
MH  - Ethics, Research
MH  - Humans
MH  - *Research Personnel
MH  - Switzerland
MH  - United States
OTO - NOTNLM
OT  - *Big Data
OT  - *Ethics Committee/IRB review
OT  - *ethics
OT  - *regulation
OT  - *research
EDAT- 2020/06/20 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1177/1556264620935223 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):339-354. doi:
      10.1177/1556264620935223. Epub 2020 Jun 19.


PMID- 32552455
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethics Lessons From Seattle's Early Experience With COVID-19.
PG  - 67-74
LID - 10.1080/15265161.2020.1764137 [doi]
AB  - Ethics consultants and critical care clinicians reflect on Seattle's early
      experience as the United States' first epicenter of COVID-19. We discuss
      ethically salient issues confronted at UW Medicine's hospitals and provide
      lessons for other health care institutions that may soon face what we have faced.
FAU - Dudzinski, Denise M
AU  - Dudzinski DM
AD  - University of Washington School of Medicine.
FAU - Hoisington, Benjamin Y
AU  - Hoisington BY
AD  - Harborview Medical Center.
FAU - Brown, Crystal E
AU  - Brown CE
AD  - Harborview Medical Center.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jul;20(7):103-106. PMID: 32716781
CIN - Am J Bioeth. 2020 Jul;20(7):150-152. PMID: 32716787
CIN - Am J Bioeth. 2020 Jul;20(7):92-94. PMID: 32716791
CIN - Am J Bioeth. 2020 Jul;20(7):202-204. PMID: 32716803
CIN - Am J Bioeth. 2020 Jul;20(7):133-135. PMID: 32716811
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cities
MH  - *Communicable Disease Control
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Washington/epidemiology
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethics
OT  - *SARS-CoV-2
OT  - *distributive justice
OT  - *equity
OT  - *rationing
EDAT- 2020/06/20 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1080/15265161.2020.1764137 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):67-74. doi: 10.1080/15265161.2020.1764137. Epub 2020 
      Jun 18.


PMID- 32552450
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20200713
IS  - 1053-4628 (Print)
IS  - 1053-4628 (Linking)
VI  - 44
IP  - 3
DP  - 2020
TI  - Neural Network Detection and Segmentation of Mental Foramen in Panoramic Imaging.
PG  - 168-173
LID - 10.17796/1053-4625-44.3.6 [doi]
AB  - Objective: To apply the technique of deep learning on a small dataset of
      panoramic images for the detection and segmentation of the mental foramen (MF).
      Study design: In this study we used in-house dataset created within the School of
      Dental Medicine, Tel Aviv University. The dataset contained randomly chosen and
      anonymized 112 digital panoramic X-ray images and corresponding segmentations of 
      MF. In order to solve the task of segmentation of the MF we used a single fully
      convolution neural network, that was based on U-net as well as a cascade
      architecture. 70% of the data were randomly chosen for training, 15% for
      validation and accuracy was tested on 15%. The model was trained using NVIDIA
      GeForce GTX 1080 GPU. The SPSS software, version 17.0 (Chicago, IL, USA) was used
      for the statistical analysis. The study was approved by the ethical committee of 
      Tel Aviv University. Results: The best results of the dice similarity coefficient
      ( DSC), precision, recall, MF-wise true positive rate (MFTPR) and MF-wise false
      positive rate (MFFPR) in single networks were 49.51%, 71.13%, 68.24%, 87.81% and 
      14.08%, respectively. The cascade of networks has shown better results than
      simple networks in recall and MFTPR, which were 88.83%, 93.75%, respectively,
      while DSC and precision achieved the lowest values, 31.77% and 23.92%,
      respectively. Conclusions: Currently, the U-net, one of the most used neural
      network architectures for biomedical application, was effectively used in this
      study. Methods based on deep learning are extremely important for automatic
      detection and segmentation in radiology and require further development.
FAU - Kats, Lazar
AU  - Kats L
FAU - Vered, Marilena
AU  - Vered M
FAU - Blumer, Sigalit
AU  - Blumer S
FAU - Kats, Eytan
AU  - Kats E
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - United States
TA  - J Clin Pediatr Dent
JT  - The Journal of clinical pediatric dentistry
JID - 9100079
MH  - *Image Processing, Computer-Assisted
MH  - *Mental Foramen
MH  - Neural Networks, Computer
MH  - Radiography, Dental, Digital
MH  - Radiography, Panoramic
OTO - NOTNLM
OT  - detection
OT  - mental foramen
OT  - neural network
OT  - panoramic imaging
OT  - segmentation
EDAT- 2020/06/20 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.17796/1053-4625-44.3.6 [doi]
PST - ppublish
SO  - J Clin Pediatr Dent. 2020;44(3):168-173. doi: 10.17796/1053-4625-44.3.6. Epub
      2020 Jun 17.


PMID- 32552017
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20220802
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - 8
DP  - 2020 Aug
TI  - Mandatory Bicycle Helmet Laws in the United States: Origins, Context, and
      Controversies.
PG  - 1198-1204
LID - 10.2105/AJPH.2020.305718 [doi]
AB  - This article examines the origins and context of mandatory bicycle helmet laws in
      the United States. Localities began to enact such laws in the early 1990s, having
      experimented with helmet laws for motorcycles previously. As cycling became
      increasingly popular in the 1970s and 1980s because of a variety of historical
      trends, from improved cycle technology to growing environmental consciousness,
      cycling-related injuries also increased. Bicycle safety advocates and researchers
      alike were particularly troubled by head injuries. National injury surveillance
      systems and a growing body of medical literature on bicycle-related injuries
      motivated a number of physicians, cyclists, children, and other community members
      to advocate helmet laws, which they argued would save lives. Controversy over
      these laws, particularly over whether they should apply universally or only to
      children, raised public health ethics concerns that persist in contemporary
      debates over bicycle helmet policies. (Am J Public Health. 2020;110:1198-1204.
      doi: 10.2105/AJPH.2020.305718).
FAU - Bachynski, Kathleen
AU  - Bachynski K
AD  - Kathleen Bachynski is with the Public Health Program at Muhlenberg College,
      Allentown, PA. Alison Bateman-House is with the Division of Medical Ethics and
      the Department of Population Health at New York University Grossman School of
      Medicine, New York, NY.
FAU - Bateman-House, Alison
AU  - Bateman-House A
AD  - Kathleen Bachynski is with the Public Health Program at Muhlenberg College,
      Allentown, PA. Alison Bateman-House is with the Division of Medical Ethics and
      the Department of Population Health at New York University Grossman School of
      Medicine, New York, NY.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bicycling/*injuries
MH  - Child
MH  - Craniocerebral Trauma/*epidemiology/prevention & control
MH  - Government Regulation/*history
MH  - Head Protective Devices/*history
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - United States/epidemiology
PMC - PMC7349454
EDAT- 2020/06/20 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.2105/AJPH.2020.305718 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Aug;110(8):1198-1204. doi: 10.2105/AJPH.2020.305718.
      Epub 2020 Jun 18.


PMID- 32551887
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1461-7005 (Electronic)
IS  - 1362-3613 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Oct
TI  - Person-oriented ethics for autism research: Creating best practices through
      engagement with autism and autistic communities.
PG  - 1676-1690
LID - 10.1177/1362361320918763 [doi]
AB  - LAY ABSTRACT: Research ethics means issues that concern the welfare and wellbeing
      of people who take part in research. It is important in all scientific studies.
      Ethics helps people who do research treat people who take part in research fairly
      and with respect. This article is about day-to-day ethics when autistic people
      take part in research. We present tips for researchers who want to do this type
      of study.We used two methods to create these tips. First, we wanted to know what 
      other people said about this topic. We used a literature review to find out.
      Second, we wanted to know what autistic people, parents, and professionals
      thought, and had a working group meet to discuss it. The working group provided
      advice that researchers could consider around day-to-day ethics in research. This
      article talks about these methods and advice. The advice fits into five big
      groups:Tailor the research process for the unique needs of each person.Think
      about the world in which people who take part in research live.Make it easier for
      people to make their own choices.Value what people who take part in research have
      to share and consider their needs and strengths.Think about how researchers and
      people who take part in research work together.This project shows why it is
      useful for researchers and communities to talk about research ethics together.
FAU - Cascio, M Ariel
AU  - Cascio MA
AD  - Central Michigan University, USA.
AD  - Institut de recherches cliniques de Montreal, Canada.
AD  - McGill University, Canada.
FAU - Weiss, Jonathan A
AU  - Weiss JA
AUID- ORCID: 0000-0002-5849-7334
AD  - York University, Canada.
FAU - Racine, Eric
AU  - Racine E
AUID- ORCID: 0000-0001-8306-551X
AD  - Institut de recherches cliniques de Montreal, Canada.
AD  - McGill University, Canada.
AD  - Universite de Montreal, Canada.
CN  - the Autism Research Ethics Task Force
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200618
PL  - England
TA  - Autism
JT  - Autism : the international journal of research and practice
JID - 9713494
SB  - IM
MH  - *Autism Spectrum Disorder
MH  - *Autistic Disorder/therapy
MH  - Humans
MH  - Research Personnel
MH  - Respect
OTO - NOTNLM
OT  - *advocacy
OT  - *community engagement
OT  - *ethics
OT  - *informed consent
OT  - *research ethics
EDAT- 2020/06/20 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1177/1362361320918763 [doi]
PST - ppublish
SO  - Autism. 2020 Oct;24(7):1676-1690. doi: 10.1177/1362361320918763. Epub 2020 Jun
      18.


PMID- 32551775
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20201218
IS  - 1942-969X (Electronic)
IS  - 1942-969X (Linking)
VI  - 12
IP  - S1
DP  - 2020 Aug
TI  - A model for treating COVID-19-related guilt, shame, and moral injury.
PG  - S174-S176
LID - 10.1037/tra0000742 [doi]
AB  - During the unprecedented COVID-19 pandemic, people around the world have faced a 
      myriad of heart-rending and ethically difficult scenarios (e.g., not being able
      to tend to a sick or dying loved one) that may lead to subsequent guilt, shame,
      or moral injury. Trauma-informed guilt reduction therapy is a brief intervention 
      that helps clients accurately appraise their role in a stressful event (such as
      those experienced during the COVID-19 pandemic) and find positive ways to express
      important values going forward. Future studies of trauma-informed guilt reduction
      therapy with those affected by COVID-19 will be helpful for clarifying its
      effectiveness with this population. (PsycInfo Database Record (c) 2020 APA, all
      rights reserved).
FAU - Haller, Moira
AU  - Haller M
AD  - Veterans Affairs San Diego Healthcare System.
FAU - Norman, Sonya B
AU  - Norman SB
AUID- ORCID: 0000-0002-4751-1882
AD  - Department of Psychiatry.
FAU - Davis, Brittany C
AU  - Davis BC
AD  - James A. Haley Veteran's Hospital.
FAU - Capone, Christy
AU  - Capone C
AD  - Providence Veterans Affairs Medical Center.
FAU - Browne, Kendall
AU  - Browne K
AD  - Center of Excellence in Substance Addiction Treatment and Education.
FAU - Allard, Carolyn B
AU  - Allard CB
AUID- ORCID: 0000-0002-7803-2243
AD  - Veterans Affairs San Diego Healthcare System.
LA  - eng
GR  - Congressionally Directed Medical Research Programs
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Psychol Trauma
JT  - Psychological trauma : theory, research, practice and policy
JID - 101495376
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Cognitive Behavioral Therapy/*methods
MH  - Coronavirus Infections/*psychology
MH  - *Guilt
MH  - Humans
MH  - *Morals
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - Psychological Trauma/etiology/*therapy
MH  - Psychotherapy, Brief
MH  - *Shame
EDAT- 2020/06/20 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 2020-43452-001 [pii]
AID - 10.1037/tra0000742 [doi]
PST - ppublish
SO  - Psychol Trauma. 2020 Aug;12(S1):S174-S176. doi: 10.1037/tra0000742. Epub 2020 Jun
      18.


PMID- 32551723
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1939-1536 (Electronic)
IS  - 0033-3204 (Linking)
VI  - 57
IP  - 4
DP  - 2020 Dec
TI  - Plan-compatible termination in psychotherapy: Perspectives from control-mastery
      theory.
PG  - 508-514
LID - 10.1037/pst0000300 [doi]
AB  - Termination processes in psychotherapy vary widely across patients, therapists,
      and therapies. While general guidelines on termination can inform ethical and
      responsible termination practices, termination decisions and processes are likely
      optimized using a case-specific approach. Control-mastery theory (CMT) provides a
      framework for considering the unique ways individual patients work in
      psychotherapy and can be applied to help therapists understand and facilitate
      optimal terminations. The present article provides a brief overview of CMT and
      outlines perspectives regarding the decision-making and discussion of
      psychotherapy termination, the processing of termination, and the final session
      of therapy. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
FAU - Kealy, David
AU  - Kealy D
AUID- ORCID: 0000-0002-3679-6085
AD  - Department of Psychiatry.
FAU - Gazzillo, Francesco
AU  - Gazzillo F
AUID- ORCID: 0000-0002-7955-3710
AD  - Department of Dynamic and Clinical Psychology.
FAU - Silberschatz, George
AU  - Silberschatz G
AD  - Department of Psychiatry.
FAU - Curtis, John T
AU  - Curtis JT
AUID- ORCID: 0000-0001-6306-6195
AD  - Department of Psychiatry.
LA  - eng
PT  - Journal Article
DEP - 20200618
PL  - United States
TA  - Psychotherapy (Chic)
JT  - Psychotherapy (Chicago, Ill.)
JID - 2984829R
SB  - IM
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - Patient Dropouts/*psychology
MH  - *Professional-Patient Relations
MH  - Psychotherapy/*methods
EDAT- 2020/06/20 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 2020-43091-001 [pii]
AID - 10.1037/pst0000300 [doi]
PST - ppublish
SO  - Psychotherapy (Chic). 2020 Dec;57(4):508-514. doi: 10.1037/pst0000300. Epub 2020 
      Jun 18.


PMID- 32551559
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20210428
IS  - 1936-086X (Electronic)
IS  - 1936-0851 (Linking)
VI  - 14
IP  - 7
DP  - 2020 Jul 28
TI  - Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for
      Pandemics: COVID-19.
PG  - 7783-7807
LID - 10.1021/acsnano.0c04421 [doi]
AB  - Biosensors and nanoscale analytical tools have shown huge growth in literature in
      the past 20 years, with a large number of reports on the topic of
      'ultrasensitive', 'cost-effective', and 'early detection' tools with a potential 
      of 'mass-production' cited on the web of science. Yet none of these tools are
      commercially available in the market or practically viable for mass production
      and use in pandemic diseases such as coronavirus disease 2019 (COVID-19). In this
      context, we review the technological challenges and opportunities of current
      bio/chemical sensors and analytical tools by critically analyzing the bottlenecks
      which have hindered the implementation of advanced sensing technologies in
      pandemic diseases. We also describe in brief COVID-19 by comparing it with other 
      pandemic strains such as that of severe acute respiratory syndrome (SARS) and
      Middle East respiratory syndrome (MERS) for the identification of features that
      enable biosensing. Moreover, we discuss visualization and characterization tools 
      that can potentially be used not only for sensing applications but also to assist
      in speeding up the drug discovery and vaccine development process. Furthermore,
      we discuss the emerging monitoring mechanism, namely wastewater-based
      epidemiology, for early warning of the outbreak, focusing on sensors for rapid
      and on-site analysis of SARS-CoV2 in sewage. To conclude, we provide holistic
      insights into challenges associated with the quick translation of sensing
      technologies, policies, ethical issues, technology adoption, and an overall
      outlook of the role of the sensing technologies in pandemics.
FAU - Bhalla, Nikhil
AU  - Bhalla N
AUID- ORCID: 0000-0002-4720-3679
AD  - Nanotechnology and Integrated Bioengineering Centre (NIBEC), School of
      Engineering, Ulster University, Shore Road, BT37 0QB Jordanstown, Northern
      Ireland, United Kingdom.
AD  - Healthcare Technology Hub, Ulster University, Shore Road, BT37 0QB Jordanstown,
      Northern Ireland, United Kingdom.
FAU - Pan, Yuwei
AU  - Pan Y
AD  - Cranfield Water Science Institute, Cranfield University, Cranfield, Bedfordshire 
      MK43 0AL, United Kingdom.
FAU - Yang, Zhugen
AU  - Yang Z
AUID- ORCID: 0000-0003-4183-8160
AD  - Cranfield Water Science Institute, Cranfield University, Cranfield, Bedfordshire 
      MK43 0AL, United Kingdom.
FAU - Payam, Amir Farokh
AU  - Payam AF
AD  - Nanotechnology and Integrated Bioengineering Centre (NIBEC), School of
      Engineering, Ulster University, Shore Road, BT37 0QB Jordanstown, Northern
      Ireland, United Kingdom.
AD  - Healthcare Technology Hub, Ulster University, Shore Road, BT37 0QB Jordanstown,
      Northern Ireland, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200626
PL  - United States
TA  - ACS Nano
JT  - ACS nano
JID - 101313589
SB  - IM
MH  - Betacoronavirus/*isolation & purification/pathogenicity
MH  - Biosensing Techniques/*methods
MH  - COVID-19
MH  - Contact Tracing/methods
MH  - Coronavirus Infections/diagnosis/epidemiology/*virology
MH  - Humans
MH  - Nanotechnology/*methods
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/epidemiology/*virology
MH  - SARS-CoV-2
PMC - PMC7319134
OTO - NOTNLM
OT  - *COVID-19
OT  - *X-ray diffraction
OT  - *atomic force microscopy
OT  - *electron microscopy
OT  - *microfluidics
OT  - *nanoplasmonics
OT  - *nanosensors
OT  - *pandemics
OT  - *point-of-care-technologies
OT  - *sewage sensors
EDAT- 2020/06/20 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/06/20 06:00 [entrez]
AID - 10.1021/acsnano.0c04421 [doi]
PST - ppublish
SO  - ACS Nano. 2020 Jul 28;14(7):7783-7807. doi: 10.1021/acsnano.0c04421. Epub 2020
      Jun 26.


PMID- 32551382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Jun
TI  - Owning humankind: fossils, humans and archaeological remains.
PG  - e04129
LID - 10.1016/j.heliyon.2020.e04129 [doi]
AB  - There are a myriad of laws, guidelines and unwritten agreements relating to
      human, hominid and hominin remains. Legal gaps and inadequate definitions of what
      constitutes a fossil have meant that a 'finders keepers' approach is often
      applied to the ownership and control of our ancestors' remains. Such shortcomings
      expose numerous legal and ethical conundrums. Should any one organisation,
      individual or government control access to recently-found remains, limiting
      opportunities to unlock the secrets of evolution? Given that humans can start
      fossilisation processes immediately after burial, at what point does it become
      appropriate to dig up their remains? And who should control access to them? Could
      any prehistoric Homo ever have imagined they would one day be exhumed and their
      remains laid out in cases as the centrepiece of a museum exhibit? This paper
      surveys a number of implications that arise from these foundational questions,
      and ultimately challenges the belief that human, hominin and hominid remains are 
      self-evident 'objects' capable of clear ownership: rather they constitute
      creative cultural intersections, which are deserving of greater ethical
      consideration. Protocols for respecting, protecting and conserving remains while 
      allowing a greater equity in access to information about our common ancestors are
      both desirable and urgently required.
CI  - (c) 2020 The Author(s).
FAU - Joannes-Boyau, Renaud
AU  - Joannes-Boyau R
AD  - Geoarchaeology and Archaeometry Research Group (GARG), Southern Cross GeoScience,
      Southern Cross University, Military Rd, Lismore, 2480, NSW, Australia.
AD  - Palaeo-Research Institute, University of Johannesburg, Gauteng Province, South
      Africa.
FAU - Pelizzon, Alessandro
AU  - Pelizzon A
AD  - School of Law and Justice, Southern Cross University, Military Rd, Lismore, 2480,
      NSW, Australia.
FAU - Page, John
AU  - Page J
AD  - School of Law and Justice, Southern Cross University, Military Rd, Lismore, 2480,
      NSW, Australia.
FAU - Rice, Nicole
AU  - Rice N
AD  - Office of Deputy Vice Chancellor (Research), Southern Cross University, Military 
      Rd, Lismore, 2480, NSW, Australia.
FAU - Scheffers, Anja
AU  - Scheffers A
AD  - Geoarchaeology and Archaeometry Research Group (GARG), Southern Cross GeoScience,
      Southern Cross University, Military Rd, Lismore, 2480, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7287245
OTO - NOTNLM
OT  - Archeology
OT  - Civil law
OT  - Common law
OT  - Culture heritage
OT  - Fossils
OT  - Law
OT  - Legislation
OT  - Paleoanthropology
OT  - Philosophy
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2019/01/04 00:00 [received]
PHST- 2020/02/02 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e04129 [doi]
AID - S2405-8440(20)30973-7 [pii]
AID - e04129 [pii]
PST - epublish
SO  - Heliyon. 2020 Jun 8;6(6):e04129. doi: 10.1016/j.heliyon.2020.e04129. eCollection 
      2020 Jun.


PMID- 32551303
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200622
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - Devising ethical codes for e-contents in e-learning.
PG  - 14
LID - 10.34171/mjiri.34.14 [doi]
AB  - Background: Promoting ethics is one of the goals of education, but the free flow 
      of communication and divulging unethical behaviors in e-learning make the urgent 
      need to clarify ethical values. Therefore, the aim of this study was to prepare
      ethical codes to develop and deliver e-contents. Methods: A draft of e-content
      ethical codes was prepared based on the literature review. Then, it was further
      revised by e-learning, medical education, ethics, and e-content experts. Finally,
      the draft was finalized through a 2-round Delphi process among related experts
      all over the country. Results: The final document of e-content ethical codes,
      including introduction, definitions, and 7 ethical code statements, was devised. 
      Conclusion: Considering the difference between e-content and other kinds of
      publications, this set of ethical codes can be used straightforwardly to assess
      ethical aspects of e-contents.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Mohammadi, Aeen
AU  - Mohammadi A
AD  - Department of E-learning in Medical Education, Virtual School, Center for
      Excellence in E-learning in Medical Education, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Mojtahedzadeh, Rita
AU  - Mojtahedzadeh R
AD  - Department of E-learning in Medical Education, Virtual School, Center for
      Excellence in E-learning in Medical Education, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Asadzandi, Shadi
AU  - Asadzandi S
AUID- ORCID: https://orcid.org/0000-0002-1350-9629
AD  - School of Health Management and Information Science, Iran University of Medical
      Sciences, Tehran, Iran.
AD  - Medical Library and Information Sciences, Virtual School, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Rashidi, Hamed
AU  - Rashidi H
AD  - English Language and Literature Faculty, University of Tehran, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200302
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7293808
OTO - NOTNLM
OT  - Delphi method
OT  - E-content
OT  - E-learning
OT  - Ethical codes
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2018/09/01 00:00 [received]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 10.34171/mjiri.34.14 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 Mar 2;34:14. doi: 10.34171/mjiri.34.14. eCollection 
      2020.


PMID- 32550953
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1925-8348 (Print)
IS  - 1925-8348 (Linking)
VI  - 23
IP  - 1
DP  - 2020 Mar
TI  - Age Alone is not Adequate to Determine Health-care Resource Allocation During the
      COVID-19 Pandemic.
PG  - 152-154
LID - 10.5770/cgj.23.452 [doi]
AB  - BACKGROUND: The Canadian Geriatrics Society (CGS) fosters the health and
      well-being of older Canadians and older adults worldwide. Although severe
      COVID-19 illness and significant mortality occur across the lifespan, the
      fatality rate increases with age, especially for people over 65 years of age. The
      dichotomization of COVID-19 patients by age has been proposed as a way to decide 
      who will receive intensive care admission when critical care unit beds or
      ventilators are limited. We provide perspectives and evidence why alternative
      approaches should be used. METHODS: Practitioners and researchers in geriatric
      medicine and gerontology have led in the development of alternative approaches to
      using chronological age as the sole criterion for allocating medical resources.
      Evidence and ethical based recommendations are provided. RESULTS: Age alone
      should not drive decisions for health-care resource allocation during the
      COVID-19 pandemic. Decisions on health-care resource allocation should take into 
      consideration the preferences of the patient and their goals of care, as well as 
      patient factors like the Clinical Frailty Scale score based on their status two
      weeks before the onset of symptoms. CONCLUSIONS: Age alone does not accurately
      capture the variability of functional capacities and physiological reserve seen
      in older adults. A threshold of 5 or greater on the Clinical Frailty Scale is
      recommended if this scale is utilized in helping to decide on access to limited
      health-care resources such as admission to a critical care unit and/or intubation
      during the COVID-19 pandemic.
CI  - (c) 2020 Author(s). Published by the Canadian Geriatrics Society.
FAU - Montero-Odasso, Manuel
AU  - Montero-Odasso M
AD  - Schulich School of Medicine and Dentistry, Department of Medicine and Division of
      Geriatric Medicine, The University of Western Ontario, London, ON.
AD  - Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London,
      ON.
AD  - Department of Epidemiology and Biostatistics, The University of Western Ontario, 
      London, ON.
FAU - Hogan, David B
AU  - Hogan DB
AD  - Division of Geriatric Medicine, Department of Medicine, University of Calgary,
      Calgary, AB.
FAU - Lam, Robert
AU  - Lam R
AD  - Department of Family Medicine, Toronto Western Hospital Family Practice Residency
      Program, The University of Toronto, Toronto, ON.
FAU - Madden, Kenneth
AU  - Madden K
AD  - Division of Geriatric Medicine, Department of Medicine, University of British
      Columbia, Vancouver, BC.
FAU - MacKnight, Christopher
AU  - MacKnight C
AD  - Division of Geriatric Medicine, Department of Medicine, Dalhousie University,
      Halifax, NS.
FAU - Molnar, Frank
AU  - Molnar F
AD  - Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
FAU - Rockwood, Kenneth
AU  - Rockwood K
AD  - Division of Geriatric Medicine, Department of Medicine, Dalhousie University,
      Halifax, NS.
LA  - eng
PT  - Journal Article
DEP - 20200301
PL  - Canada
TA  - Can Geriatr J
JT  - Canadian geriatrics journal : CGJ
JID - 101579189
PMC - PMC7279701
OTO - NOTNLM
OT  - COVID-19
OT  - aged
OT  - frailty
OT  - health-care resources
OT  - mechanical ventilation
COIS- CONFLICT OF INTEREST DISCLOSURES MMO is a member of the Board of directors,
      Secretary-Treasurer, and co-Chair of the COVID-19 Working Group of the Canadian
      Geriatrics Society. DBH has none to declare. FM is CGS past president and
      co-chair of the Covid-19 Working Group of the Canadian Geriatrics Society. KM is 
      editor-in-chief of the Canadian Geriatrics Journal. KR has asserted copyright of 
      the Clinical Frailty Scale; use of the scale is free for research, educational,
      and not-for-profit health-care use.
EDAT- 2020/06/20 06:00
MHDA- 2020/06/20 06:01
CRDT- 2020/06/20 06:00
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/06/20 06:01 [medline]
AID - 10.5770/cgj.23.452 [doi]
AID - cgj-23-152 [pii]
PST - epublish
SO  - Can Geriatr J. 2020 Mar 1;23(1):152-154. doi: 10.5770/cgj.23.452. eCollection
      2020 Mar.


PMID- 32550811
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1846-7482 (Electronic)
IS  - 1330-0962 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Jun 15
TI  - Copyright violation of predators in scientific publishing - Biochemia Medica's
      harmful experience and proposed solution.
PG  - 020201
LID - 10.11613/BM.2020.020201 [doi]
AB  - Biochemia Medica is an open access journal that does not charge manuscript
      processing or publishing. All editorial staff are continuously educated and
      directed to follow the highest ethical and scholarly publishing standards in all 
      steps of the manuscript processing. They are all laboratory medicine
      professionals, who apart from their regular jobs, are in charge of different
      phases in Journal processing as volunteers. The publisher of the Journal is
      scientific and professional association of laboratory medicine professionals,
      Croatian Society of Medical Biochemistry and Laboratory medicine (CSMBLM). During
      November and December 2018, without knowledge of the editorial staff, unknown
      perpetrator(s) downloaded a respectable number of articles published in Biochemia
      Medica as PDF and launched an illegal web page under the same journal name with
      downloaded articles. Although this was a very harmful experience, we have learned
      a lot from it and we would like to share this with scientific journals'
      community. Therefore, we would like to share this harmful experience, and to
      present a short workflow on how to manage situations like this if it will be
      necessary for any scientific journal in the future.
CI  - Croatian Society of Medical Biochemistry and Laboratory Medicine.
FAU - Pasalic, Daria
AU  - Pasalic D
AD  - Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Zagreb
      University School of Medicine, Zagreb, Croatia.
FAU - Supak Smolcic, Vesna
AU  - Supak Smolcic V
AD  - Clinical Department for Laboratory Diagnostics, Clinical Hospital Centre Rijeka, 
      Rijeka, Croatia.
AD  - Department of Medical Informatics, Rijeka University School of Medicine, Rijeka, 
      Croatia.
LA  - eng
PT  - Editorial
PL  - Croatia
TA  - Biochem Med (Zagreb)
JT  - Biochemia medica
JID - 9610305
SB  - IM
MH  - *Copyright
MH  - Croatia
MH  - Ethics, Research
MH  - Internet
MH  - Open Access Publishing
MH  - Peer Review, Research/*standards
MH  - Publishing/*standards
MH  - Societies, Medical
PMC - PMC7271751
OTO - NOTNLM
OT  - copyright violation
OT  - cybercriminal
OT  - predatory journal
COIS- Potential conflict of interest: None declared.
EDAT- 2020/06/20 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/06/20 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
AID - 10.11613/BM.2020.020201 [doi]
AID - bm-30-2-020201 [pii]
PST - ppublish
SO  - Biochem Med (Zagreb). 2020 Jun 15;30(2):020201. doi: 10.11613/BM.2020.020201.


PMID- 34460598
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210903
IS  - 2313-433X (Electronic)
IS  - 2313-433X (Linking)
VI  - 6
IP  - 6
DP  - 2020 Jun 20
TI  - Explainable Deep Learning Models in Medical Image Analysis.
LID - 52 [pii]
LID - 10.3390/jimaging6060052 [doi]
AB  - Deep learning methods have been very effective for a variety of medical
      diagnostic tasks and have even outperformed human experts on some of those.
      However, the black-box nature of the algorithms has restricted their clinical
      use. Recent explainability studies aim to show the features that influence the
      decision of a model the most. The majority of literature reviews of this area
      have focused on taxonomy, ethics, and the need for explanations. A review of the 
      current applications of explainable deep learning for different medical imaging
      tasks is presented here. The various approaches, challenges for clinical
      deployment, and the areas requiring further research are discussed here from a
      practical standpoint of a deep learning researcher designing a system for the
      clinical end-users.
FAU - Singh, Amitojdeep
AU  - Singh A
AUID- ORCID: 0000-0003-3874-9570
AD  - Theoretical and Experimental Epistemology Laboratory, School of Optometry and
      Vision Science, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
AD  - Department of Systems Design Engineering, University of Waterloo, Waterloo, ON
      N2L 3G1, Canada.
FAU - Sengupta, Sourya
AU  - Sengupta S
AD  - Theoretical and Experimental Epistemology Laboratory, School of Optometry and
      Vision Science, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
AD  - Department of Systems Design Engineering, University of Waterloo, Waterloo, ON
      N2L 3G1, Canada.
FAU - Lakshminarayanan, Vasudevan
AU  - Lakshminarayanan V
AUID- ORCID: 0000-0002-3473-1245
AD  - Theoretical and Experimental Epistemology Laboratory, School of Optometry and
      Vision Science, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
AD  - Department of Systems Design Engineering, University of Waterloo, Waterloo, ON
      N2L 3G1, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200620
PL  - Switzerland
TA  - J Imaging
JT  - Journal of imaging
JID - 101698819
PMC - PMC8321083
OTO - NOTNLM
OT  - XAI
OT  - deep learning
OT  - diagnosis
OT  - explainability
OT  - explainable AI
OT  - medical imaging
EDAT- 2020/06/20 00:00
MHDA- 2020/06/20 00:01
CRDT- 2021/08/30 17:17
PHST- 2020/05/28 00:00 [received]
PHST- 2020/06/16 00:00 [revised]
PHST- 2020/06/17 00:00 [accepted]
PHST- 2021/08/30 17:17 [entrez]
PHST- 2020/06/20 00:00 [pubmed]
PHST- 2020/06/20 00:01 [medline]
AID - jimaging6060052 [pii]
AID - 10.3390/jimaging6060052 [doi]
PST - epublish
SO  - J Imaging. 2020 Jun 20;6(6). pii: jimaging6060052. doi: 10.3390/jimaging6060052.


PMID- 32550676
STAT- Publisher
DA  - 20200619
ISBN- 9780309672757
ISBN- 0309672759
PB  - National Academies Press (US)
CTI - The National Academies Collection: Reports funded by National Institutes of
      Health
DP  - 2020 Feb 4
BTI - Planning for Long-Term Use of Biomedical Data: Proceedings of a Workshop
LID - 10.17226/25707 [doi]
AB  - Biomedical research data sets are becoming larger and more complex, and computing
      capabilities are expanding to enable transformative scientific results. The
      National Institutes of Health's (NIH's) National Library of Medicine (NLM) has
      the unique role of ensuring that biomedical research data are findable,
      accessible, interoperable, and reusable in an ethical manner. Tools that forecast
      the costs of long-term data preservation could be useful as the cost to curate
      and manage these data in meaningful ways continues to increase, as could
      stewardship to assess and maintain data that have future value. The National
      Academies of Sciences, Engineering, and Medicine convened a workshop on July
      11-12, 2019 to gather insight and information in order to develop and demonstrate
      a framework for forecasting long-term costs for preserving, archiving, and
      accessing biomedical data. Presenters and attendees discussed tools and practices
      that NLM could use to help researchers and funders better integrate risk
      management practices and considerations into data preservation, archiving, and
      accessing decisions; methods to encourage NIH-funded researchers to consider,
      update, and track lifetime data; and burdens on the academic researchers and
      industry staff to implement these tools, methods, and practices. This publication
      summarizes the presentations and discussion of the workshop.
CI  - Copyright 2020 by the National Academy of Sciences. All rights reserved.
CN  - National Academies of Sciences, Engineering, and Medicine; Policy and Global
      Affairs; Board on Research Data and Information; Division on Earth and Life
      Studies; Board on Life Sciences; Division on Engineering and Physical Sciences;
      Computer Science and Telecommunications Board; Committee on Applied and
      Theoretical Statistics; Board on Mathematical Sciences and Analytics
FED - Casola, Linda
ED  - Casola L
LA  - eng
GR  - HHSN263201800029I/NIH HHS/United States
PT  - Review
PT  - Book
PL  - Washington (DC)
EDAT- 2020/06/19 06:01
MHDA- 2020/06/19 06:01
CDAT- 2020/06/19 06:01
AID - NBK558227 [bookaccession]
AID - 10.17226/25707 [doi]


PMID- 32550599
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20211111
IS  - 2638-616X (Electronic)
IS  - 2638-616X (Linking)
VI  - 2
IP  - 3
DP  - 2020 May 15
TI  - CT-based Radiomic Signatures for Predicting Histopathologic Features in Head and 
      Neck Squamous Cell Carcinoma.
PG  - e190039
LID - 10.1148/rycan.2020190039 [doi]
AB  - Purpose: To determine the performance of CT-based radiomic features for
      noninvasive prediction of histopathologic features of tumor grade, extracapsular 
      spread, perineural invasion, lymphovascular invasion, and human papillomavirus
      status in head and neck squamous cell carcinoma (HNSCC). Materials and Methods:
      In this retrospective study, which was approved by the local institutional ethics
      committee, CT images and clinical data from patients with pathologically proven
      HNSCC from The Cancer Genome Atlas (n = 113) and an institutional test cohort (n 
      = 71) were analyzed. A machine learning model was trained with 2131 extracted
      radiomic features to predict tumor histopathologic characteristics. In the model,
      principal component analysis was used for dimensionality reduction, and
      regularized regression was used for classification. Results: The trained radiomic
      model demonstrated moderate capability of predicting HNSCC features. In the
      training cohort and the test cohort, the model achieved a mean area under the
      receiver operating characteristic curve (AUC) of 0.75 (95% confidence interval
      [CI]: 0.68, 0.81) and 0.66 (95% CI: 0.45, 0.84), respectively, for tumor grade; a
      mean AUC of 0.64 (95% CI: 0.55, 0.62) and 0.70 (95% CI: 0.47, 0.89),
      respectively, for perineural invasion; a mean AUC of 0.69 (95% CI: 0.56, 0.81)
      and 0.65 (95% CI: 0.38, 0.87), respectively, for lymphovascular invasion; a mean 
      AUC of 0.77 (95% CI: 0.65, 0.88) and 0.67 (95% CI: 0.15, 0.80), respectively, for
      extracapsular spread; and a mean AUC of 0.71 (95% CI: 0.29, 1.0) and 0.80 (95%
      CI: 0.65, 0.92), respectively, for human papillomavirus status. Conclusion:
      Radiomic CT models have the potential to predict characteristics typically
      identified on pathologic assessment of HNSCC.Supplemental material is available
      for this article.(c) RSNA, 2020.
CI  - 2020 by the Radiological Society of North America, Inc.
FAU - Mukherjee, Pritam
AU  - Mukherjee P
AUID- ORCID: 0000-0002-9975-9994
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Cintra, Murilo
AU  - Cintra M
AUID- ORCID: 0000-0002-9862-0392
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Huang, Chao
AU  - Huang C
AUID- ORCID: 0000-0003-4974-2649
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Zhou, Mu
AU  - Zhou M
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Zhu, Shankuan
AU  - Zhu S
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Colevas, A Dimitrios
AU  - Colevas AD
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Fischbein, Nancy
AU  - Fischbein N
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
FAU - Gevaert, Olivier
AU  - Gevaert O
AUID- ORCID: 0000-0002-9965-5466
AD  - Department of Medicine, Stanford Center for Biomedical Informatics Research
      (BMIR), Stanford, Calif (P.M., M.C., C.H., M.Z., O.G.); Department of Radiology, 
      Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil (M.C.);
      Department of Nutrition and Food Hygiene, Chronic Disease Research Institute,
      School of Public Health, School of Medicine, Zhejiang University, Zhejiang, China
      (C.H., S.Z.); Division of Oncology, Department of Medicine (A.D.C.), Department
      of Radiology (N.F.), and Department of Biomedical Data Science (O.G.), Stanford
      University, 1265 Welch Rd, Stanford, CA 94305-5479.
LA  - eng
GR  - R01 EB020527/EB/NIBIB NIH HHS/United States
GR  - R56 EB020527/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200515
PL  - United States
TA  - Radiol Imaging Cancer
JT  - Radiology. Imaging cancer
JID - 101765309
MH  - Humans
MH  - Papillomaviridae
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/*diagnostic imaging/pathology
MH  - *Tomography, X-Ray Computed
PMC - PMC7263288
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2020/01/08 00:00 [revised]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - 10.1148/rycan.2020190039 [doi]
PST - epublish
SO  - Radiol Imaging Cancer. 2020 May 15;2(3):e190039. doi: 10.1148/rycan.2020190039.


PMID- 32550595
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2590-1710 (Electronic)
IS  - 2590-1710 (Linking)
VI  - 7
DP  - 2020 Sep
TI  - The use of the dynamic weight bearing test to assess the effects of acute,
      intramuscularly administered botulinum neurotoxin type A1 in rats.
PG  - 100041
LID - 10.1016/j.toxcx.2020.100041 [doi]
AB  - Assessing the efficacy of botulinum neurotoxin (BoNT) in vivo is essential given 
      the growing number of BoNT products used in the clinic. Here, we evaluated the
      dynamic weight bearing (DWB) test for sensitivity to paralytic effects of BoNT-A 
      following intramuscular administration. The toxin was administered into the
      gastrocnemius lateralis as a single bolus or into the gastrocnemius lateralis and
      medialis as two boluses. The effects of BoNT-A in DWB were compared to those in
      the compound muscle action potential (CMAP) and the Digit Abduction Score (DAS)
      tests. Female Sprague-Dawley rats received an acute, intramuscular (i.m.)
      injection of BoNT-A1 (0.1, 1, 10 pg/rat) into the right gastrocnemius muscle,
      while the left received vehicle. The DWB and CMAP tests were performed one-two
      days after the injection in order to detect the onset of sub-maximal BoNT-A
      activity. Both tests were preceded by the DAS test. BoNT-A produced dose-related 
      reductions in both the weight-bearing and surface-bearing outcomes of up to 60%
      while showing moderate activity in the DAS. BoNT-A effects in the DWB test were
      well-aligned with those in the CMAP test, which showed dose-dependent reductions 
      in CMAP amplitude and the area under the curve (AUC; up to 100%) as well as
      increases in latency (up to 130%). The efficacy of BoNT-A in DWB and CMAP was
      more pronounced with two boluses. Thus, the DWB test can be used to assess the
      properties of BoNTs following i.m. administration. It can be used to assess the
      candidate therapies and is more ethical than the mouse lethality assay.
CI  - (c) 2020 The Authors.
FAU - Cornet, Sylvie
AU  - Cornet S
AD  - Ipsen Innovation, 5 Avenue du Canada, 91940, Les Ulis, France.
FAU - Perier, Cindy
AU  - Perier C
AD  - Ipsen Innovation, 5 Avenue du Canada, 91940, Les Ulis, France.
FAU - Wagner, Stephanie
AU  - Wagner S
AD  - Neurofit SAS, 850 Boulevard Sebastien Brant, Bioparc 1, Parc d'Innovation, 67400,
      Illkirch, France.
FAU - Andriambeloson, Emile
AU  - Andriambeloson E
AD  - Neurofit SAS, 850 Boulevard Sebastien Brant, Bioparc 1, Parc d'Innovation, 67400,
      Illkirch, France.
FAU - Pouzet, Bruno
AU  - Pouzet B
AD  - BeVivo GmbH, Christoph Merian-Ring 11, 4153, Reinach (BL), Switzerland.
FAU - Kalinichev, Mikhail
AU  - Kalinichev M
AD  - Ipsen Innovation, 5 Avenue du Canada, 91940, Les Ulis, France.
LA  - eng
PT  - Journal Article
DEP - 20200523
PL  - England
TA  - Toxicon X
JT  - Toxicon: X
JID - 101741983
PMC - PMC7286111
OTO - NOTNLM
OT  - Botulinum neurotoxin
OT  - Digit abduction
OT  - Dynamic weight bearing
OT  - In vivo
OT  - Muscle action potential
OT  - Rat
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2019/10/07 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - 10.1016/j.toxcx.2020.100041 [doi]
AID - S2590-1710(20)30019-9 [pii]
AID - 100041 [pii]
PST - epublish
SO  - Toxicon X. 2020 May 23;7:100041. doi: 10.1016/j.toxcx.2020.100041. eCollection
      2020 Sep.


PMID- 32550220
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2279-9028 (Print)
IS  - 2279-9028 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Jun 4
TI  - Corporate social responsibility and external stakeholders' health and wellbeing: 
      A viewpoint.
PG  - 1742
LID - 10.4081/jphr.2020.1742 [doi]
AB  - In recent years there has been increased interest in the role played by business 
      corporate social responsibility (CSR) strategies in promoting the health and
      wellbeing of internal and external stakeholders. However, the sparse public
      health research to date has mainly focused on the health and wellbeing of
      internal stakeholders. This viewpoint article aims to ignite discussion of how
      CSR strategies need to also target external stakeholders beyond the workplace.
      Businesses have an opportunity to help address the most important societal
      challenges, especially the social determinants of health which are the root
      causes of inequities in health. However, while advancing a new agenda for
      promoting external stakeholders' health, businesses need to take into account
      potential challenges that might arise from ethical conflicts when trying to
      balance their CSR initiatives against their business operations.
CI  - (c)Copyright: the Author(s).
FAU - Hiswals, Anne-Sofie
AU  - Hiswals AS
AD  - Department of Public Health and Sports Sciences, University of Gavle, Sweden.
FAU - Hamrin, Cornelia Wulff
AU  - Hamrin CW
AD  - Department of Public Health and Sports Sciences, University of Gavle, Sweden.
FAU - Vidman, Asa
AU  - Vidman A
AD  - Department of Social Work and Criminology, University of Gavle, Sweden.
FAU - Macassa, Gloria
AU  - Macassa G
AD  - Department of Public Health and Sports Sciences, University of Gavle, Sweden.
AD  - EPIUnit, Instituto de Saude Publica, Universidade do Porto, Porto, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - United States
TA  - J Public Health Res
JT  - Journal of public health research
JID - 101580775
PMC - PMC7282312
OTO - NOTNLM
OT  - CSR
OT  - external stakeholders
OT  - health and wellbeing
OT  - health promotion
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - 10.4081/jphr.2020.1742 [doi]
PST - epublish
SO  - J Public Health Res. 2020 Jun 4;9(1):1742. doi: 10.4081/jphr.2020.1742.
      eCollection 2020 Jun 4.


PMID- 32549880
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1650-3414 (Electronic)
IS  - 1650-3414 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Jun
TI  - Blood Lead Levels in Rag-Pickers of Kathmandu and its Association with
      Hematological and Biochemical Parameters.
PG  - 125-133
AB  - INTRODUCTION: Lead poisoning is a common health problem in Nepal and there are a 
      limited number of studies on blood lead levels in various population groups.
      Rag-pickers are those people who visit from house to house to collect the
      materials that can be recycled and thus earn their livelihood. The present study 
      was designed to evaluate blood lead level (BLL) and its relationship between
      hematological and biochemical parameters in rag-pickers working in Kathmandu.
      METHODS: An observational cross-sectional study among 50 ragpickers working in
      the selected area of Kathmandu was done in May 2019 after obtaining ethical
      approval from the Nepal health research council. Capillary and venous blood was
      drawn from each participant after written consent to measure the BLL, aspartate
      aminotransferase, alanine aminotransferase, total bilirubin, creatinine, glucose 
      and to test for a complete blood count. Whole blood was also screened for the
      presence of hemoglobin variants in cases with abnormal red blood cell indices.
      Data was analyzed using SPSS (Version 20.0). RESULT: All rag pickers were men
      with mean age of 32.56 +/- 12.51 years. The mean BLL among ragpickers was 11.6
      +/- 7.23 mug/dL. High eosinophil count was found (8.27 +/- 5.49 %) in 27 cases
      (54%) having no significant association with BLL. The mean BLL was higher (12.89 
      mug/dL) in a cohort of workers who pick and recycle electronic waste.
      Beta-Thalassemia trait was seen in four cases, all of them had high BLL. No
      significant association of BLL with the number of years worked by rag picker was 
      found. Similarly, no significant association of BLL with hematological and
      biochemical parameters was found. CONCLUSION: Rag-pickers working in Kathmandu
      are at increased risk of lead toxicity. The use of protective gloves, masks,
      shoes and clothes along with a regular medical examination of this vulnerable
      group is recommended.
CI  - Copyright (c) 2020 International Federation of Clinical Chemistry and Laboratory 
      Medicine (IFCC). All rights reserved.
FAU - Gautam, Keyoor
AU  - Gautam K
AD  - Department of Pathology, Samyak Diagnostic, Jawalakhel, Lalitpur, Nepal.
FAU - Pant, Vivek
AU  - Pant V
AD  - Department of Clinical Biochemistry, Samyak Diagnostic, Jawalakhel, Lalitpur,
      Nepal.
FAU - Pradhan, Santosh
AU  - Pradhan S
AD  - Department of Clinical Biochemistry, Samyak Diagnostic, Jawalakhel, Lalitpur,
      Nepal.
FAU - Pyakurel, Devish
AU  - Pyakurel D
AD  - Department of Pathology, Samyak Diagnostic, Jawalakhel, Lalitpur, Nepal.
FAU - Bhandari, Bijay
AU  - Bhandari B
AD  - Department of Clinical Pharmacology, Tribhuvan University Teaching Hospital,
      Nepal.
FAU - Shrestha, Abha
AU  - Shrestha A
AD  - Department of Pathology, Samyak Diagnostic, Jawalakhel, Lalitpur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - Italy
TA  - EJIFCC
JT  - EJIFCC
JID - 101092742
PMC - PMC7294816
OTO - NOTNLM
OT  - Kathmandu
OT  - blood lead level
OT  - rag pickers
COIS- Conflict of Interest: The authors declare that there is no conflict of interest
      in the publication of this manuscript.
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - ejifcc-31-125 [pii]
PST - epublish
SO  - EJIFCC. 2020 Jun 2;31(2):125-133. eCollection 2020 Jun.


PMID- 32549640
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 2
DP  - 2020 May
TI  - A Virtuous Appraisal of Heritable Genome Editing.
PG  - 223-232
LID - 10.1177/0024363920906672 [doi]
AB  - The ethics of heritable genome editing (HGE), or germline engineering, are
      currently being debated vigorously among scientists and bioethicists, and the
      Catholic Church has declared the procedure to be morally illicit. While these
      judgments are based mostly on the justice and consequences of the act, a fruitful
      approach is to consider HGE from the perspective of the virtuous Christian. This 
      article examines participation in HGE according to the virtues of charity,
      justice, hope, faith, fortitude, temperance, and prudence. HGE does not appear to
      be consonant with the virtuous life of a Christian person. SUMMARY: The article
      evaluates heritable genome editing (HGE or genetic engineering of embryos)
      according to the Christian virtues of charity, justice, hope, faith, fortitude,
      temperance, and prudence. HGE does not seem to be consonant with the virtuous
      life of a Christian person.
CI  - (c) Catholic Medical Association 2020.
FAU - Reilly, Christopher M
AU  - Reilly CM
AUID- ORCID: https://orcid.org/0000-0003-3452-2539
AD  - Holy Apostles College and Seminary, Cromwell, CT, USA.
LA  - eng
PT  - Journal Article
DEP - 20200302
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7273635
OTO - NOTNLM
OT  - Bioethics
OT  - Genetics
OT  - Moral theology
OT  - Virtue ethics
OT  - Virtue theory
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - 10.1177/0024363920906672 [doi]
AID - 10.1177_0024363920906672 [pii]
PST - ppublish
SO  - Linacre Q. 2020 May;87(2):223-232. doi: 10.1177/0024363920906672. Epub 2020 Mar
      2.


PMID- 32549633
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 2
DP  - 2020 May
TI  - Brain Death and the Dutch Organ Donation Law.
PG  - 161-170
LID - 10.1177/0024363919897441 [doi]
AB  - According to many legal systems that regulate organ donation, such as Dutch law, 
      a brain-dead patient is regarded as a mortal remains. In general, these systems
      do not take into account the fact that this definition is being heavily
      criticized and the far-reaching consequences thereof. In the case of organ
      transplantation, vital organs are procured from persons who, from a biological
      perspective, may not yet be dead. A government that values scientific data and
      wants to provide honest and reliable information to its citizens has to account
      for this critique of its policy as citizens have the right to be well-informed.
      Whoever makes the decision to donate organs performs a special act of human
      solidarity, but the readiness to donate organs in the case of brain death is not 
      inherent to the demand to love one's neighbor as one loves oneself. SUMMARY:
      According to legislation on organ donation in many countries, a brain-dead
      patient is regarded as a mortal remains. The law disregards the fact, however,
      that this definition is being heavily criticized and that it has far-reaching
      consequences. In the case of organ transplantation, vital organs are procured
      from persons who, from a biological perspective, may not yet been dead. A
      government that values scientific data and wants to provide honest and reliable
      information to its citizens has to account for this critique in its policy.
      Citizens have the right to be well-informed.
CI  - (c) Catholic Medical Association 2020.
FAU - Steensma, Douwe J
AU  - Steensma DJ
AUID- ORCID: https://orcid.org/0000-0002-4179-9256
AD  - Theological University Apeldoorn, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200106
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7273634
OTO - NOTNLM
OT  - Brain death
OT  - Determination of death
OT  - Ethics
OT  - Medical decision-making
OT  - Organ donation
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - 10.1177/0024363919897441 [doi]
AID - 10.1177_0024363919897441 [pii]
PST - ppublish
SO  - Linacre Q. 2020 May;87(2):161-170. doi: 10.1177/0024363919897441. Epub 2020 Jan
      6.


PMID- 32549629
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210502
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 2
DP  - 2020 May
TI  - Common, Difficult Questions about Providing Nutrition at End of Life: Bedside
      Application of Catholic Moral Teaching.
PG  - 122-130
LID - 10.1177/0024363919898934 [doi]
AB  - There is much confusion surrounding how to interpret provision of artificial
      nutrition and hydration (ANH) at the bedside in complicated clinical
      circumstances. The specific scenario that prompted these questions was a request 
      by a patient and her family to remove a feeding tube that had become, in the
      patient's eyes and opinion, disproportionately burdensome in her particular set
      of clinical circumstances. This clinically relevant article can be viewed as a
      bedside interpretation of Catholic bioethical teachings on provision of ANH to
      the dying patient. Please note that this article does not address specific
      ethical issues that pertain to persistent vegetative state, which is beyond the
      scope of this particular discussion.
CI  - (c) Catholic Medical Association 2020.
FAU - Raphael, John J
AU  - Raphael JJ
AD  - Saint Thomas West Hospital, Nashville, TN, USA.
FAU - Vacca, Michael A
AU  - Vacca MA
AD  - Director of Ministry Bioethics and Membership Experience for Christ Medicus
      Foundation CURO, Troy, MI, USA.
FAU - Hosie, Annmarie
AU  - Hosie A
AD  - Improving Palliative, Aged and Chronic Care through Clinical Research and
      Translation (IMPACCT), Faculty of Health, University of Technology Sydney,
      Ultimo, New South Wales, Australia.
AD  - School of Nursing Sydney, University of Notre Dame Australia, WA, Australia.
AD  - St Vincent's Health Network Sydney, Australia.
FAU - Rodden, Natalie
AU  - Rodden N
AD  - St. Anthony North Health Campus, Westminster, CO, USA.
FAU - Fernandes, Ashley K
AU  - Fernandes AK
AD  - Center for Bioethics, The Ohio State University College of Medicine, Columbus,
      OH, USA.
AD  - Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
FAU - Ely, E Wesley
AU  - Ely EW
AUID- ORCID: https://orcid.org/0000-0003-3957-2172
AD  - Veteran's Affairs TN Valley Geriatrics Research, Education and Clinical Center
      (GRECC), Nashville, TN, USA.
AD  - Department of Medicine, Division of Pulmonary and Critical Care, Vanderbilt
      University Medical Center, Nashville, TN, USA.
AD  - Center for Health Services Research, Vanderbilt University Medical Center,
      Nashville, TN, USA.
LA  - eng
PT  - Journal Article
DEP - 20200112
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7273638
OTO - NOTNLM
OT  - ANH
OT  - Artificial nutrition and hydration
OT  - End of life
OT  - Feeding tube
EDAT- 2020/06/19 06:00
MHDA- 2020/06/19 06:01
CRDT- 2020/06/19 06:00
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/06/19 06:01 [medline]
AID - 10.1177/0024363919898934 [doi]
AID - 10.1177_0024363919898934 [pii]
PST - ppublish
SO  - Linacre Q. 2020 May;87(2):122-130. doi: 10.1177/0024363919898934. Epub 2020 Jan
      12.


PMID- 32549263
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 12
DP  - 2020 Jun 15
TI  - Universities without Walls: A Blended Delivery Approach to Training the Next
      Generation of HIV Researchers in Canada.
LID - E4265 [pii]
LID - 10.3390/ijerph17124265 [doi]
AB  - (1) Background: Although HIV has not diminished in importance in Canada, the
      field of HIV research remains small, and the graduate students who decide to
      pursue careers within it feel isolated and uncertain about their professional
      skills and opportunities. Universities Without Walls (UWW) was created in 2009 to
      help redress these shortcomings. This paper presents a case study of UWW, a
      non-credit training program for emerging HIV researchers in Canada. In
      particular, we focus on the possibilities of experiential learning via online and
      blended delivery. UWW uses both online and in-person teaching modalities to teach
      engaged scholarship, interdisciplinarity, community-based research (CBR),
      intervention research, and ethics. (2) Methods: Using a case study, we elucidated
      the research question: "What are the factors that make Universities Without Walls
      a viable training environment in the contemporary HIV/AIDS field?" Focus groups
      were conducted with 13 UWW key stakeholders in 2012 during a program mid-point
      evaluation; in 2014, telephone or in-person interviews with the three directors
      were conducted by a UWW fellow (the 4th author of this paper), and in 2019 the
      authors analyzed the information and anecdotal evidence, which had been
      incorporated as thick description. In addition, fellows' self-assessments via
      portfolio and results from formal learning assessments were included. We also
      thematically analyzed 65 student self-reports (2009-2015). (3) Results and
      Discussion: Each UWW cohort lasted 9 months to one year and was comprised of: a) 
      sustained mentorship from the co-directors (e.g., phone conversations, assistance
      with grant writing, letters of reference, etc.); b) fortnightly online webinars
      that aim to develop fellows' knowledge of community-based research (CBR),
      research ethics, intervention research, and interdisciplinary research; c)
      community service learning in the form of a "field mentoring placement"; d)
      face-to-face engagement with fellows and mentors, most notably at the week-long
      culminating learning institute; e) a stipend for fellows to carry out their
      training activities. The UWW pedagogical framework features experiential
      learning, critical pedagogy, and heutagogy made manifest in the field mentoring
      placements (community service learning), mentorship mediated by technologies, and
      in-person learning institutes. Our analysis showed that experiential learning was
      imparted by UWW's a) transparency about its "implicit curriculum", the attitudes,
      values, character, and professional identity imparted in the program as well as
      the overarching programmatic elements, such as commitment to diversity, the
      inclusion of those with lived experience, the flexible admissions policies and
      procedures, interdisciplinary faculty, flexible team, administrative structure,
      and valuing of technology in conducting research, learning, and teaching; b)
      curriculum co-designing and co-teaching, and c) sustaining a community of
      practice. The main results reported in our case study included significant "soft 
      outcomes" for UWW fellows, such as developing a "social presence" as a precursor 
      to lasting professional connections; learning to experience community-based
      research, intersectionality, and interdisciplinarity by interacting online with
      persons living with HIV, leaders in the field, and a variety of stakeholders
      (including nonprofit staff and policymakers). (4) Limitations: While fellows'
      self-evaluation data were collected by an independent assessor and anonymized to 
      the extent this was possible, the co-authors inevitably bring their
      preconceptions and positive biases to UWW's assessment. As UWW was developed to
      function outside of traditional academic structures, it is unlikely that the UWW 
      program could be transferred to a post-secondary environment in its entirety. UWW
      was also built for the socio-political environment of HIV health research. (5)
      Conclusions: The experiences of those involved with UWW demonstrate that explicit
      curricular components-such as interdisciplinarity, community-based research,
      intervention research, and applied ethics-can be learned through a blended
      delivery when combined with opportunities to apply the knowledge in ways, such as
      a field mentoring placement and a learning institute. Related to this outcome,
      our case study describes that implicit curricular components in the formation of 
      a professional-the sense of self in the field as a researcher, student, and
      community member-can also be delivered through a blended model. However, the
      tools and activities need to be tailored to each student for their context, while
      pushing their disciplinarian and professional boundaries.
FAU - Ibanez-Carrasco, Francisco
AU  - Ibanez-Carrasco F
AUID- ORCID: 0000-0002-3667-6411
AD  - MAP Centre for Urban Health Solutions, St Michael's Hospital, Toronto, ON M5B
      1W8, Canada.
FAU - Worthington, Catherine
AU  - Worthington C
AD  - Public Health and Social Policy, University of Victoria, Victoria, BC V8W 2Y2,
      Canada.
FAU - Rourke, Sean
AU  - Rourke S
AD  - Li Ka Shing Knowledge Institute of St. Michael's, Toronto, ON M5B 1W8 Canada.
FAU - Hastings, Colin
AU  - Hastings C
AD  - Department of Sociology, York University, Toronto, ON M3J 1P3, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Canada
MH  - Curriculum
MH  - *HIV Infections
MH  - Humans
MH  - Research Personnel
MH  - *Universities
PMC - PMC7344852
OTO - NOTNLM
OT  - *CBPR
OT  - *CBR
OT  - *HIV
OT  - *adult education
OT  - *distance education
OT  - *eLearning
OT  - *graduate training
OT  - *online education
OT  - *research training
EDAT- 2020/06/19 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/06/19 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/19 06:00 [entrez]
PHST- 2020/06/19 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - ijerph17124265 [pii]
AID - 10.3390/ijerph17124265 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 15;17(12). pii: ijerph17124265. doi:
      10.3390/ijerph17124265.


PMID- 32549039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - Assessing Liver Function in Liver Tumors Patients: The Performance of T1 Mapping 
      and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI.
PG  - 215
LID - 10.3389/fmed.2020.00215 [doi]
AB  - Purpose: To assess the performance of T1 mapping and residual liver volume (RLV) 
      on Gd-EOBDTPA-enhanced MRI in pretreatment estimation of liver function in
      patients with liver tumors. Indocyanine green retention rate at 15 min (ICG R-15)
      was used as a reference standard. Methods: Ethical approval from the
      institutional review board and informed consent were obtained for this
      prospective study. We enrolled 155 patients with liver tumors who underwent
      pretreatment Gd-EOB-DTPA-enhanced MRI. T1 relaxation time before (T1-pre), 20 min
      after (T1-post) Gd-EOB-DTPA injection and RLV were measured. The absolute
      reduction (DeltaT1) and reduction rate (DeltaT1%) of T1 relaxation time,
      volume-assisted DeltaT1 (DeltaT1(*)RLV) and volume-assisted DeltaT1%
      (DeltaT1%(*)RLV) were calculated accordingly. The correlation of MR parameters
      with ICG R-15 was determined using Spearman's rank correlation analysis. Patients
      were classified into the normal liver function (NLF) group if their ICG R-15
      levels were <10% or otherwise into the abnormal liver function (ALF) group.
      Receiver operating characteristic (ROC) analysis was conducted to evaluate the
      performances of the MR parameters in predicting ALF. Results: T1-post (r = 0.472,
      P < 0.001), DeltaT1 (r = -0.355, P = 0.011), DeltaT1% (r = -0.482, P < 0.001),
      RLV (r = -0.336, P < 0.001), volume-assisted DeltaT1 (r = -0.458, P < 0.001) and 
      volume-assisted DeltaT1% (r = -0.522, P < 0.001) showed weak to moderate
      correlation with ICG R-15. The area under the ROC curves (AUROC) of
      volume-assisted DeltaT1 in predicting ALF was 0.777, which was significantly
      higher than the other parameters (P < 0.05 for all). Conclusions: Combined T1
      mapping and RLV on Gd-EOB-DTPA-enhanced MRI can help assess liver function with
      good diagnostic accuracy in patients with liver tumors before treatment.
CI  - Copyright (c) 2020 Duan, Jiang, Xia, Chen, Cao, Ye, Wei, Song and Lee.
FAU - Duan, Ting
AU  - Duan T
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Jiang, Hanyu
AU  - Jiang H
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Xia, Chunchao
AU  - Xia C
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Cao, Likunn
AU  - Cao L
AD  - Department of Radiology, Peking Union Medical University Hospital, Peking, China.
FAU - Ye, Zheng
AU  - Ye Z
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wei, Yi
AU  - Wei Y
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Song, Bin
AU  - Song B
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Lee, Jeong Min
AU  - Lee JM
AD  - Department of Radiology, College of Medicine, Seoul National University, Seoul,
      South Korea.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7270171
OTO - NOTNLM
OT  - Gd-EOB-DTPA
OT  - T1 relaxation time
OT  - liver function
OT  - magnetic resonance imaging
OT  - residual liver volume
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2019/10/24 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - 10.3389/fmed.2020.00215 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 May 28;7:215. doi: 10.3389/fmed.2020.00215.
      eCollection 2020.


PMID- 32549037
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1534-6617 (Electronic)
IS  - 0018-7143 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jul 9
TI  - Methodology Matters: Designing a Pilot Study Guided by Indigenous Epistemologies.
PG  - 141-151
LID - 10.13110/humanbiology.91.3.06 [doi]
AB  - Indigenous individuals and communities have experienced historic and ongoing
      negative interactions with Western health care and biomedical research. To
      rebuild trust and mitigate power structures between researchers and Indigenous
      peoples, researchers can adopt Indigenous epistemologies in methodologies, such
      as nonhierarchical approaches to relationship. This article shares models
      developed to bridge Indigenous epistemologies with Western qualitative and
      quantitative research methods and demonstrates how these epistemologies can be
      used to guide the authors' development of a pilot study on traumatic spinal cord 
      injury.
FAU - Juutilainen, Sandra A
AU  - Juutilainen SA
AD  - School of Nutrition, Ryerson University, Toronto, Ontario, Canada,
      sandra.juutilainen@ryerson.ca.
FAU - Jeffrey, Melanie
AU  - Jeffrey M
AD  - Centre for Indigenous Studies and Human Biology Program, Faculty of Arts and
      Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Stewart, Suzanne
AU  - Stewart S
AD  - Waakebiness-Bryce Institute for Indigenous Health, Dalla Lana School of Public
      Health, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Biol
JT  - Human biology
JID - 0116717
SB  - IM
MH  - Humans
MH  - *Knowledge
MH  - Pilot Projects
MH  - *Population Groups
MH  - Research
OTO - NOTNLM
OT  - *CANADA
OT  - *COMMUNITY-BASED RESEARCH
OT  - *ETHICAL INDIGENOUS RESEARCH
OT  - *FIRST NATIONS
OT  - *INDIGENOUS EPISTEMOLOGY
OT  - *INDIGENOUS METHODOLOGY
OT  - *MIXED METHODS
OT  - *ONTARIO
OT  - *SPINAL CORD INJURY
OT  - *SPINAL CORD REGISTRIES
EDAT- 2020/06/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/08/09 00:00 [received]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.13110/humanbiology.91.3.06 [doi]
PST - ppublish
SO  - Hum Biol. 2020 Jul 9;91(3):141-151. doi: 10.13110/humanbiology.91.3.06.


PMID- 32549036
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1534-6617 (Electronic)
IS  - 0018-7143 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jul 9
TI  - Momentum and Longevity for Tribally Driven Health Equity Science: Evidence from
      the Gathering for Health Project.
PG  - 153-162
LID - 10.13110/humanbiology.91.3.05 [doi]
AB  - American Indian health disparities have reached crisis levels, and there is a
      need to develop culturally congruent interventions through meaningful tribal
      involvement and ethical community-oriented approaches. Hence, it is imperative
      that researchers and university administrators better understand how research
      translation occurs for tribally driven health-equity research projects. Utilizing
      thematic analysis methods, the authors examined documents from a 12-year
      community-based participatory research partnership to elucidate factors that
      ignite momentum and support partnership longevity. The overarching finding was
      that trust and respect provide a foundation for momentum and longevity and are
      closely intertwined with other themes identified in analyses. Seven themes were
      extrapolated and classified into two domains: (1) investments, which are
      catalyzing factors that advance research, and (2) intermediate processes, which
      link investments to success. Investment themes include Indigenous scholar
      involvement, time and effort, establishing rapport, and clear and appropriate
      communication. Intermediate process themes include generative colearning, active 
      participation, and recognition and celebration. Community-based participatory
      research principles were reflected in these findings. This study also upholds
      prior published work on Indigenous research methodologies, promotes the lived
      experiences of Indigenous people, and contributes to Indigenous theory building
      and science.
FAU - Elm, Jessica H L
AU  - Elm JHL
AD  - Center for American Indian Health, Bloomberg School of Public Health, Johns
      Hopkins University, Great Lakes Hub, Duluth, Minnesota, USA, jelm@jhu.edu.
AD  - Citizen of the Oneida Nation, Descendant of the Stockbridge-Munsee Band of the
      Mohicans.
FAU - Handeland, Tina
AU  - Handeland T
AD  - Community Research Council Member, Gathering for Health study.
AD  - Citizen of the Lac du Flambeau Band of Lake Superior Chippewa Indians.
LA  - eng
GR  - R01 DK091250/DK/NIDDK NIH HHS/United States
GR  - R21 MH085852/MH/NIMH NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Hum Biol
JT  - Human biology
JID - 0116717
SB  - IM
MH  - Community-Based Participatory Research/*methods
MH  - *Health Equity
MH  - Humans
MH  - Indigenous Peoples
MH  - Longevity
MH  - Pilot Projects
MH  - Population Groups
PMC - PMC7485137
MID - NIHMS1624603
OTO - NOTNLM
OT  - *COMMUNITY-BASED PARTICIPATORY RESEARCH
OT  - *COMMUNITY-ENGAGED RESEARCH
OT  - *CULTURE
OT  - *DIABETES MELLITUS
OT  - *HISTORICAL TRAUMA
OT  - *INDIGENOUS KNOWLEDGE
OT  - *INDIGENOUS METHODOLOGIES
OT  - *INDIGENOUS PEOPLES
OT  - *STRESS PROCESS
OT  - *TRANSLATIONAL SCIENCE
OT  - *VALUES
EDAT- 2020/06/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/08/13 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.13110/humanbiology.91.3.05 [doi]
PST - ppublish
SO  - Hum Biol. 2020 Jul 9;91(3):153-162. doi: 10.13110/humanbiology.91.3.05.


PMID- 32549035
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1534-6617 (Electronic)
IS  - 0018-7143 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jul 9
TI  - Weaving the Strands of Life (Iina Bitl'ool): History of Genetic Research
      Involving Navajo People.
PG  - 189-208
LID - 10.13110/humanbiology.91.3.04 [doi]
AB  - To date, some genetic studies offer medical benefits but lack a clear pathway to 
      benefit for people from underrepresented backgrounds. Historically, Indigenous
      people, including the Dine (Navajo people), have raised concerns about the lack
      of benefits, misuse of DNA samples, lack of consultation, and ignoring of
      cultural and traditional ways of knowing. Shortly after the Navajo Nation Human
      Research Review Board was established in 1996, the Navajo Nation recognized
      growing concerns about genetic research, and in 2002 they established a
      moratorium on human genetic research studies. The moratorium effectively has
      protected their citizens from potential genetic research harms. Despite the
      placement of the moratorium, some genetic research studies have continued using
      blood and DNA samples from Navajo people. To understand the history of genetic
      research involving Navajo people, the authors conducted a literature review of
      genetic or genetics-related research publications that involved Navajo people,
      identifying 79 articles from the years 1926 to 2018. To their knowledge, no known
      literature review has comprehensively examined the history of genetic research in
      the Navajo community. This review divides the genetic research articles into the 
      following general classifications: bacteria or virus genetics, blood and human
      leukocyte antigens, complex diseases, forensics, hereditary diseases, and
      population genetics and migration. The authors evaluated the methods reported in 
      each article, described the number of Navajo individuals reported, recorded the
      academic and tribal approval statements, and noted whether the study considered
      Dine cultural values. Several studies focused on severe combined immunodeficiency
      disease, population history, neuropathy, albinism, and eye and skin disorders
      that affect Navajo people. The authors contextualize Dine ways of knowing related
      to genetics and health with Western scientific concepts to acknowledge the
      complex philosophy and belief system that guides Dine people and recognizes
      Indigenous science. They also encourage researchers to consider cultural
      perspectives and traditional knowledge that has the potential to create stronger 
      conclusions and better-informed, ethical, and respectful science.
FAU - Begay, Rene L
AU  - Begay RL
AD  - Centers for American Indian and Alaska Native Health, University of Colorado
      Anschutz Medical Campus, Aurora, Colorado, USA.
FAU - Garrison, Nanibaa' A
AU  - Garrison NA
AD  - Institute for Society and Genetics, College of Letters and Science, University of
      California, Los Angeles, Los Angeles, California, USA.
AD  - Institute for Precision Health, David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, California, USA.
AD  - Division of General Internal Medicine and Health Services Research, David Geffen 
      School of Medicine, University of California, Los Angeles, Los Angeles,
      California, USA.
AD  - Navajo Nation Human Research Review Board, Window Rock, Arizona, USA.
FAU - Sage, Franklin
AU  - Sage F
AD  - Dine Policy Institute, Navajo Nation, Tsaile, Arizona, USA.
FAU - Bauer, Mark
AU  - Bauer M
AD  - Dine College, Shiprock, New Mexico, USA.
FAU - Knoki-Wilson, Ursula
AU  - Knoki-Wilson U
AD  - Navajo Nation Human Research Review Board, Window Rock, Arizona, USA.
FAU - Begay, David H
AU  - Begay DH
AD  - Navajo Nation Human Research Review Board, Window Rock, Arizona, USA.
AD  - Dine Hataalii Association, Navajo Nation, USA.
FAU - Becenti-Pigman, Beverly
AU  - Becenti-Pigman B
AD  - Navajo Nation Human Research Review Board, Window Rock, Arizona, USA.
FAU - Claw, Katrina G
AU  - Claw KG
AD  - Division of Biomedical Informatics and Personalized Medicine, University of
      Colorado Anschutz Medical Campus, Aurora, Colorado, USA,
      katrina.claw@cuanschutz.edu.
AD  - Colorado Center for Personalized Medicine, University of Colorado Anschutz
      Medical Campus, Aurora, Colorado, USA.
LA  - eng
GR  - F32 GM119237/GM/NIGMS NIH HHS/United States
GR  - K01 HG008818/HG/NHGRI NIH HHS/United States
GR  - RM1 HG009042/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hum Biol
JT  - Human biology
JID - 0116717
SB  - IM
MH  - Genetic Research
MH  - Humans
MH  - *Indians, North American
PMC - PMC7895446
MID - NIHMS1667110
OTO - NOTNLM
OT  - *DINE
OT  - *GENETIC RESEARCH
OT  - *GENOMICS
OT  - *INDIGENOUS SCIENCE
OT  - *NAVAJO NATION
EDAT- 2020/06/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/09/04 00:00 [received]
PHST- 2020/02/18 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.13110/humanbiology.91.3.04 [doi]
PST - ppublish
SO  - Hum Biol. 2020 Jul 9;91(3):189-208. doi: 10.13110/humanbiology.91.3.04.


PMID- 32549034
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1534-6617 (Electronic)
IS  - 0018-7143 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jul 9
TI  - "Of Course, Data Can Never Fully Represent Reality": Assessing the Relationship
      between "Indigenous Data" and "Indigenous Knowledge," "Traditional Ecological
      Knowledge," and "Traditional Knowledge".
PG  - 163-178
LID - 10.13110/humanbiology.91.3.03 [doi]
AB  - Multiple terms describe Indigenous peoples' creative expressions, including
      "Indigenous knowledge" (IK), "traditional ecological knowledge" (TEK),
      "traditional knowledge" (TK), and increasingly, "Indigenous data" (ID). Variation
      in terms contributes to disciplinary divides, challenges in organizing and
      finding prior studies about Indigenous peoples' creative expressions, and
      intellectually divergent chains of reference. The authors applied a decolonial,
      digital, feminist, ethics-of-care approach to citation analysis of records about 
      Indigenous peoples knowledge and data, including network analyses of
      author-generated keywords and research areas, and content analysis of
      peer-reviewed studies about ID. Results reveal ambiguous uses of the term
      "Indigenous data"; the influence of ecology and environmental studies in research
      areas and topics associated with IK, TEK, and TK; and the influence of public
      administration and governance studies in research areas and topics associated
      with ID studies. Researchers of ID would benefit from applying a more nuanced and
      robust vocabulary, one informed by studies of IK, TEK, and TK. Researchers of TEK
      and TK would benefit from the more people-centered approaches of IK. Researchers 
      and systems designers who work with data sets can practice relational
      accountability by centering the Indigenous peoples from whom observations are
      sourced, combining narrative methodologies with computational methods to sustain 
      the holism favored by Indigenous science and the relationality of Indigenous
      peoples.
FAU - Duarte, Marisa Elena
AU  - Duarte ME
AD  - Justice and Social Inquiry, School of Social Transformation, Arizona State
      University, Tempe, Arizona, USA, Marisa.Duarte@asu.edu.
FAU - Vigil-Hayes, Morgan
AU  - Vigil-Hayes M
AD  - School of Informatics, Computing and Cyber Systems, Northern Arizona University, 
      Flagstaff, Arizona, USA.
FAU - Littletree, Sandra
AU  - Littletree S
AD  - Information School, University of Washington, Seattle, Washington, USA.
FAU - Belarde-Lewis, Miranda
AU  - Belarde-Lewis M
AD  - Information School, University of Washington, Seattle, Washington, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Biol
JT  - Human biology
JID - 0116717
SB  - IM
MH  - Ecology
MH  - Humans
MH  - Knowledge
MH  - *Population Groups
OTO - NOTNLM
OT  - *DATA SCIENCE
OT  - *INDIGENOUS DATA SOVEREIGNTY
OT  - *INDIGENOUS KNOWLEDGE
OT  - *INFORMATICS
OT  - *INFORMATION SCIENCE
OT  - *TRADITIONAL ECOLOGICAL KNOWLEDGE
OT  - *TRADITIONAL KNOWLEDGE
EDAT- 2020/06/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/08/12 00:00 [received]
PHST- 2019/12/18 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.13110/humanbiology.91.3.03 [doi]
PST - ppublish
SO  - Hum Biol. 2020 Jul 9;91(3):163-178. doi: 10.13110/humanbiology.91.3.03.


PMID- 32549032
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1534-6617 (Electronic)
IS  - 0018-7143 (Linking)
VI  - 91
IP  - 3
DP  - 2020 Jul 9
TI  - Islands as Laboratories: Indigenous Knowledge and Gene Drives in the Pacific.
PG  - 179-188
LID - 10.13110/humanbiology.91.3.01 [doi]
AB  - This article argues that the genetic engineering technology known as gene drive
      must be evaluated in the context of the historic and ongoing impacts of settler
      colonialism and military experimentation on indigenous lands and peoples. After
      defining gene drive and previewing some of the key ethical issues related to its 
      use, the author compares the language used to justify Cold War-era nuclear
      testing in the Pacific with contemporary scholarship framing islands as ideal
      test sites for gene drive-modified organisms. In both cases, perceptions of
      islands as remote and isolated are mobilized to warrant their treatment as sites 
      of experimentation for emerging technologies. Though gene drive may offer
      valuable interventions into issues affecting island communities (e.g.,
      vector-borne disease and invasive species management), proposals to conduct the
      first open trials of gene drive on islands are complicit in a long history of
      injustice that has treated islands (and their residents) as dispensable to the
      risks and unintended consequences associated with experimentation. This article
      contends that ethical gene drive research cannot be achieved without the
      inclusion of indigenous peoples as key stakeholders and provides three
      recommendations to guide community engagement involving indigenous communities:
      centering indigenous self-determination, replacing the deficit model of
      engagement with a truly participatory model, and integrating indigenous knowledge
      and values in the research and decision-making processes related to gene drive.
FAU - Taitingfong, Riley I
AU  - Taitingfong RI
AD  - Department of Communication, University of California San Diego, La Jolla,
      California, USA, rtaiting@ucsd.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Biol
JT  - Human biology
JID - 0116717
SB  - IM
MH  - Colonialism
MH  - *Gene Drive Technology
MH  - Humans
MH  - Indigenous Peoples
MH  - Islands
MH  - Laboratories
OTO - NOTNLM
OT  - *COMMUNITY ENGAGEMENT
OT  - *GENE DRIVE
OT  - *GENETIC ENGINEERING
OT  - *ISLANDS
OT  - *OCEANIA
EDAT- 2020/06/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/08/09 00:00 [received]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.13110/humanbiology.91.3.01 [doi]
PST - ppublish
SO  - Hum Biol. 2020 Jul 9;91(3):179-188. doi: 10.13110/humanbiology.91.3.01.


PMID- 32548940
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1365-2524 (Electronic)
IS  - 0966-0410 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Nov
TI  - Care navigators decision-making in prescribing Telecare for older people.
PG  - 2431-2440
LID - 10.1111/hsc.13066 [doi]
AB  - This aim of this study was to explore the decision-making process of Care
      Navigators in prescribing Telecare for older people living at home. The study
      took place in the South of England. A structured model of decision-making was
      used as the theoretical framework and a qualitative approach was employed. Care
      Navigators (n = 7), acting on behalf of the Local Authority as 'external trusted 
      assessors' were interviewed according to a semi-structured interview schedule.
      Documentary evidence of decision-making (Telecare Reasoning Forms) (n = 10), were
      also analysed and added to the interview data. The main themes identified were
      the process of decision-making, training needs, and the support of Care
      Navigators and partnership working. Care Navigators adopted a complex
      decision-making process involving information gathering, information synthesis,
      consideration of alternatives to Telecare and implementation. Decision-making has
      a strong ethical dimension, especially around funding. Training focused on the
      functioning and technical aspects of equipment. However, other training needs
      were identified in order to support decision-making, for example, assessing
      mental capacity. Peer support networks were valuable to Care Navigators and they 
      developed good relationships with social care and Telecare provider staff.
      However, professionals making referrals to the Care Navigators for Telecare often
      did not understand their role or funding eligibility. In conclusion, Care
      Navigators are well-placed to prescribe Telecare in terms of knowledge and
      decision-making skills. Comprehensive training is necessary in order to support
      decision-making. Peer support and education of professionals referring for
      Telecare is also advocated.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - MacInnes, Julie
AU  - MacInnes J
AUID- ORCID: 0000-0002-9220-1007
AD  - Centre for Health Services Studies (CHSS), University of Kent, Canterbury, UK.
LA  - eng
PT  - Journal Article
DEP - 20200617
PL  - England
TA  - Health Soc Care Community
JT  - Health & social care in the community
JID - 9306359
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Counseling
MH  - *Decision Making
MH  - England
MH  - Humans
MH  - Interviews as Topic
MH  - *Patient Navigation
MH  - Qualitative Research
MH  - Referral and Consultation/*statistics & numerical data
MH  - Telemedicine/*organization & administration
OTO - NOTNLM
OT  - *Care Navigators
OT  - *Telecare
OT  - *decision-making
OT  - *older people
EDAT- 2020/06/18 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - 10.1111/hsc.13066 [doi]
PST - ppublish
SO  - Health Soc Care Community. 2020 Nov;28(6):2431-2440. doi: 10.1111/hsc.13066. Epub
      2020 Jun 17.


PMID- 32548832
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20220218
IS  - 1573-6571 (Electronic)
IS  - 0022-4197 (Linking)
VI  - 59
IP  - 5
DP  - 2020 Oct
TI  - Religion as a Health Promoter During the 2019/2020 COVID Outbreak: View from
      Detroit.
PG  - 2243-2255
LID - 10.1007/s10943-020-01052-1 [doi]
AB  - The 2019/2020 COVID outbreak has surfaced as a global pandemic. The news has
      carried stories of the heroic efforts of medical and other health practitioners, 
      with public health officials charting the course of spread. In an urban center
      like Detroit, the generosity of everyday citizens and church organizations has
      also played an important role. This inspection of the pandemic from the view of
      Detroit will examine the epidemiology of the coronavirus, translation of
      professional practice into people's awareness of the chronic disease risk factors
      which are prevalent in Detroit, moral and ethical views on the distribution of
      resources, and three major ways that religious faith has helped to sustain
      people's health and welfare in the midst of the broad social challenges posed by 
      this novel coronavirus.
FAU - Modell, Stephen M
AU  - Modell SM
AUID- ORCID: http://orcid.org/0000-0002-0356-8545
AD  - Department of Epidemiology, University of Michigan School of Public Health,
      M5049, SPH II 1415 Washington Hts., Ann Arbor, MI, 48109-2029, USA.
      mod@umich.edu.
FAU - Kardia, Sharon L R
AU  - Kardia SLR
AD  - Department of Epidemiology, University of Michigan School of Public Health,
      M5049, SPH II 1415 Washington Hts., Ann Arbor, MI, 48109-2029, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Relig Health
JT  - Journal of religion and health
JID - 2985199R
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Disease Outbreaks
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Public Health
MH  - SARS-CoV-2
PMC - PMC7297133
OTO - NOTNLM
OT  - COVID-19
OT  - Diabetes
OT  - Ethics
OT  - Pandemics
OT  - Public health
OT  - Religion
OT  - Social environment
OT  - Urban population
EDAT- 2020/06/18 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - 10.1007/s10943-020-01052-1 [doi]
AID - 10.1007/s10943-020-01052-1 [pii]
PST - ppublish
SO  - J Relig Health. 2020 Oct;59(5):2243-2255. doi: 10.1007/s10943-020-01052-1.


PMID- 32548597
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2666-3899 (Electronic)
IS  - 2666-3899 (Linking)
VI  - 1
IP  - 3
DP  - 2020 Jun 12
TI  - Exit through the App Store?
PG  - 100054
LID - 10.1016/j.patter.2020.100054 [doi]
AB  - This Preview summarizes the Ada Lovelace Institute rapid evidence review Exit
      through the App Store?, which sets out proposals for whether, and how, the UK
      government should use technology to transition from the COVID-19 global public
      health crisis. It examines the potential development and implementation of
      technical solutions to support symptom tracking, contact tracing, and immunity
      certification. The full rapid evidence review takes into account societal,
      political, legal, and ethical perspectives and gives findings and recommendations
      for the transition and rebuild phases that follow containment, delay, and
      mitigation.
CI  - (c) 2020 The Author(s).
FAU - Kind, Carly
AU  - Kind C
AD  - Ada Lovelace Institute, 28 Bedford Square, London WC1B 3NJ, UK.
LA  - eng
PT  - News
PL  - United States
TA  - Patterns (N Y)
JT  - Patterns (New York, N.Y.)
JID - 101767765
PMC - PMC7291988
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - 10.1016/j.patter.2020.100054 [doi]
AID - S2666-3899(20)30065-9 [pii]
AID - 100054 [pii]
PST - ppublish
SO  - Patterns (N Y). 2020 Jun 12;1(3):100054. doi: 10.1016/j.patter.2020.100054.


PMID- 32547774
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for 
      the Management of Anemia in Hemodialysis Patients.
PG  - 2054358120927532
LID - 10.1177/2054358120927532 [doi]
AB  - BACKGROUND: Erythropoiesis-stimulating agents including epoetin alfa have been a 
      mainstay of anemia management in patients with chronic kidney disease. Although
      the standard practice has been to administer epoetin alfa to patients on
      hemodialysis (HD) intravenously (IV), subcutaneous (SQ) epoetin alfa is longer
      acting and achieve the same target hemoglobin level to be maintained at a reduced
      dose and cost. OBJECTIVE: The primary objective of this study was to determine
      the economic benefits of change in route of epoetin alfa administration from IV
      to SQ in HD patients. The secondary objectives were (1) to determine the
      differences in epoetin alfa doses at the pre-switch (IV) and post-switch period
      (SQ) and (2) to determine serum hemoglobin concentration, transferrin saturation,
      ferritin level, IV iron dose and cost in relationship to route of epoetin alfa
      administration. DESIGN: This retrospective observational study included patients 
      who transitioned from IV to SQ epoetin alfa. SETTING: Two HD sites in southern
      Saskatchewan (Regina General Hospital, and Wascana Dialysis Unit, Regina) and 2
      sites in northern Saskatchewan (St. Paul's [SPH] Hospital, and SPH Community
      Renal Health Center, Saskatoon). PATIENTS: The study includes 215 patients who
      transitioned from IV to SQ and were alive at the end of 12-month follow-up
      period. MEASUREMENTS: We calculated the dose and cost of different routes of
      epoetin alfa administration/patient month. Also, serum hemoglobin, markers of
      iron stores (transferrin saturation and ferritin), IV iron dose, and cost were
      determined in relation to route of epoetin alfa administration. METHODS: Data
      were gathered from 6 months prior (IV) to 12 months after switching treatment to 
      SQ. The paired t-test and Wilcoxon signed-rank test were used to compare
      variables between pre-switch (IV) and post-switch (SQ) period. RESULTS: The
      median cost (interquartile range) of epoetin alfa/patient-month decreased from
      (CAD508.3 [CAD349-CAD900.8]) pre-switch (IV) to (CAD381.2 [CAD247-CAD681])
      post-switch (SQ) (P < .001), a decrease of 25%. The median epoetin alfa
      dose/patient-month reduced from (38 500 [25 714.3-64 166.5] international unit)
      pre-switch to (26 750.3 [17 362.6-48 066] IU) post-switch (P < .001), a decrease 
      of 30.51%. The mean hemoglobin concentration (+/- standard deviation) for
      patients in both periods remained stable (103.3 +/- 9.2 vs 104.3 +/- 13.3 g/L, P 
      = .34) and within the target range. There were no significant differences in
      transferrin saturation, ferritin, and IV iron dose and cost between the 2 study
      periods. LIMITATIONS: We were unable to consistently obtain information across
      all the sites on hospitalizations, inflammatory markers, nutritional status, and 
      gastrointestinal bleeding. In addition, as our study sample was subject to
      survival bias, we cannot generalize our study results to other populations.
      CONCLUSIONS: We have shown that administering epoetin alfa SQ in HD patients led 
      to a 30.51% reduction in dose and 25% reduction in cost while achieving
      equivalent hemoglobin levels. Given the cost sparing advantages without
      compromising care while achieving comparable hemoglobin levels, HD units should
      consider converting to SQ mode of administration. TRIAL REGISTRATION: The study
      was not registered on a publicly accessible registry as it was a retrospective
      chart review and exempted from review by the Research Ethics Board of the former 
      Regina Qu'Appelle Health Region.
CI  - (c) The Author(s) 2020.
FAU - Prasad, Bhanu
AU  - Prasad B
AUID- ORCID: https://orcid.org/0000-0002-1139-4821
AD  - Section of Nephrology, Department of Medicine, Regina General Hospital,
      Saskatchewan Health Authority, Regina, Canada.
FAU - Jafari, Maryam
AU  - Jafari M
AUID- ORCID: https://orcid.org/0000-0002-7261-2191
AD  - Section of Nephrology, Department of Medicine, Regina General Hospital,
      Saskatchewan Health Authority, Regina, Canada.
FAU - Toppings, Julie
AU  - Toppings J
AD  - Department of Pharmacy, Regina General Hospital, Saskatchewan Health Authority,
      Regina, Canada.
FAU - Gross, Linda
AU  - Gross L
AD  - Department of Pharmacy, Regina General Hospital, Saskatchewan Health Authority,
      Regina, Canada.
FAU - Kappel, Joanne
AU  - Kappel J
AD  - Section of Nephrology, Department of Medicine, St Paul's Hospital, Saskatoon, SK,
      Canada.
FAU - Au, Flora
AU  - Au F
AUID- ORCID: https://orcid.org/0000-0001-5189-8488
AD  - Cumming School of Medicine, University of Calgary, AB, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7273547
OTO - NOTNLM
OT  - cost-effectiveness
OT  - economic evaluation
OT  - end-stage renal disease
OT  - epoetin alfa
OT  - hemodialysis
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/04/05 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - 10.1177/2054358120927532 [doi]
AID - 10.1177_2054358120927532 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Jun 4;7:2054358120927532. doi:
      10.1177/2054358120927532. eCollection 2020.


PMID- 32547274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1179-1594 (Print)
IS  - 1179-1594 (Linking)
VI  - 13
DP  - 2020
TI  - Retrospective Analysis of Factors Associated with Long-Stay Hospitalizations in
      an Acute Psychiatric Ward.
PG  - 433-442
LID - 10.2147/RMHP.S238741 [doi]
AB  - PURPOSE: To evaluate the longest hospitalizations in an acute psychiatric ward
      [Service of Psychiatric Diagnosis and Treatment (SPDT)] and the related
      demographic, clinical and organizational variables to understand the factors that
      contribute to long-stay (LOS) phenomenon. The term "long stay" indicates
      clinical, social and organizational problems responsible for delayed discharges. 
      In psychiatry, clinical severity, social dysfunction and/or health-care system
      organization appear relevant factors in prolonging stays. PATIENTS AND METHODS:
      We divided all the SPDT hospitalizations from 1 January 2010 to 31 December 2015 
      into two groups based on the 97.5(th) percentile of duration: </=36 day (n=3254) 
      and >36 day (n=81) stays, in order to compare the two groups for the selected
      variables. Comparisons were made using Pearson's chi-square for categorical data 
      and t-test for continuous variables, the correlation between the LOS, as a
      dependent variable, and the selected variables was analyzed in stepwise multiple 
      linear regression and in multiple logistic regression models. RESULTS: The
      longest hospitalizations were significantly related to the diagnosis of
      "schizophrenia and other psychosis" (Pearson Chi(2)=17.24; p=0.045), the presence
      of moderate and severe aggressiveness (Pearson chi(2)=29; p=0.000), compulsory
      treatment (Pearson Chi(2)=8.05; p=0.005), parenteral or other route
      administration of psycho-pharmacotherapy (Pearson Chi(2)=12.91; p=0.007),
      poli-therapy (Pearson Chi(2)=6.40; p=0.041), complex psychiatric activities
      (Pearson Chi(2)=12.26; p=0.002) and rehabilitative programs (Pearson
      Chi(2)=37.05; p=0.000) during the hospitalization and at discharge (Pearson
      Chi(2)=29.89; p=0.000). Many demographic and clinical variables were
      statistically significantly correlated to the LOS at our multiple linear and
      logistic regression model. CONCLUSION: In our sample, clinical illness severity
      and need for complex therapeutic and rehabilitative treatments were associated
      with prolonged psychiatric hospitalizations. Understanding this phenomenon can
      have not only economic but also clinical, ethical and social relevance.
CI  - (c) 2020 Di Lorenzo et al.
FAU - Di Lorenzo, Rosaria
AU  - Di Lorenzo R
AUID- ORCID: 0000-0001-9497-6837
AD  - Psychiatric Intensive Treatment Facility, Department of Mental Health and Drug
      Abuse, Az-USL Modena, Modena 41122, Italy.
FAU - Montardi, Giulia
AU  - Montardi G
AUID- ORCID: 0000-0002-7874-8778
AD  - School of Specialization in Psychiatry, University of Modena and Reggio Emilia,
      Modena 41124, Italy.
FAU - Panza, Leda
AU  - Panza L
AD  - School of Nursing, University of Modena and Reggio Emilia, Modena 41124, Italy.
FAU - Del Giovane, Cinzia
AU  - Del Giovane C
AD  - Head of Statistics and Methodology, Institute of Primary Health Care (BIHAM),
      Bern, Switzerland.
FAU - Saraceni, Serena
AU  - Saraceni S
AD  - School of Specialization in Psychiatry, University of Modena and Reggio Emilia,
      Modena 41124, Italy.
FAU - Rovesti, Sergio
AU  - Rovesti S
AUID- ORCID: 0000-0002-1499-3897
AD  - General and Applied Hygiene, Department of Biomedical, Metabolic and Neural
      Sciences, Modena 41125, Italy.
FAU - Ferri, Paola
AU  - Ferri P
AUID- ORCID: 0000-0001-7761-7226
AD  - Nursing, Department of Biomedical, Metabolic and Neural Sciences, Modena 41125,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - Risk Manag Healthc Policy
JT  - Risk management and healthcare policy
JID - 101566264
PMC - PMC7245472
OTO - NOTNLM
OT  - acute psychiatric ward
OT  - illness severity
OT  - predictors of long-stay
OT  - psychiatric long-stay
COIS- The authors report no actual or potential conflicts of interest.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - 10.2147/RMHP.S238741 [doi]
AID - 238741 [pii]
PST - epublish
SO  - Risk Manag Healthc Policy. 2020 May 19;13:433-442. doi: 10.2147/RMHP.S238741.
      eCollection 2020.


PMID- 32546979
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1177-889X (Print)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - Assessment of Quality of Care Using Information on Patient Satisfaction at Adult 
      Oncology Center of Tikur Anbessa Specialized Hospital, Ethiopia: A
      Cross-Sectional Study.
PG  - 847-858
LID - 10.2147/PPA.S253027 [doi]
AB  - BACKGROUND: Cancer is one of the leading causes of morbidity and mortality in the
      world. It results in considerable mental, physical, and emotional stress for
      patients. Because of the nature and impact of the disease, and its treatment,
      measurements of patient satisfaction are important to bring to the attention of
      health-care providers in order to improve care. OBJECTIVE: To assess patient
      satisfaction at the adult oncology center of Tikur Anbessa Specialized Hospital, 
      Ethiopia using the EORTC PATSAT-C33 tool. METHODS: A facility-based
      cross-sectional study was conducted from January 2019 to May 2019. A consecutive 
      sampling technique was employed to recruit a total of 384 study participants.
      Informed consent was obtained for each participant and data were collected using 
      an interviewer-administered questionnaire. Ethical clearance and approval of the 
      study protocol were obtained from the institutional ethics review board of the
      school of pharmacy. Descriptive statistics was used to summarize the data, while 
      multivariate linear regression analysis was employed to explore factors affecting
      patient satisfaction. P<0.05 was considered as statistically significant.
      RESULTS: Among a total of 384 study participants, the majority were female
      (65.9%) and the median age was 49 years. In most (65.9%) participants, the
      health-care service cost was covered by patients themselves; the majority of them
      were treated for gynecological malignancy (37.2%) and most received chemotherapy 
      + surgery (37.2%). The mean score for the EORTC-PATSAT33 scales for overall
      satisfaction was 44.8 out of 100. Place of residence, gender, type of cancer,
      duration since treatment started, age and source of health-care costs were
      factors associated with patient satisfaction and all together explained 83%
      (adjusted R square=0.830, P<0.0001) of variance. Of these, residence (where
      patients came from) accounted for most (78.7%) of the variance (adjusted R
      square=0.787, P<0.0001). CONCLUSION: The mean overall satisfaction of patients
      with the services provided at the outpatient adult oncology center of TASH was
      significantly lower than previously reported in the world literature, which was
      >70. Hence, a concerted effort must be made to understand and improve patient
      satisfaction in oncology health-care services in Ethiopia.
CI  - (c) 2020 Abate et al.
FAU - Abate, Dessale
AU  - Abate D
AD  - Tikur Anbessa Specialized Hospital, School of Pharmacy, College of Health
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Aman, Munir Awol
AU  - Aman MA
AUID- ORCID: 0000-0001-5889-2716
AD  - Tikur Anbessa Specialized Hospital, Adult Oncology Center, School of Medicine,
      College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Nasir, Beshir Bedru
AU  - Nasir BB
AD  - Tikur Anbessa Specialized Hospital, School of Pharmacy, College of Health
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Gebremariam, Girma Tekle
AU  - Gebremariam GT
AD  - Tikur Anbessa Specialized Hospital, School of Pharmacy, College of Health
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Fentie, Atalay Mulu
AU  - Fentie AM
AUID- ORCID: 0000-0001-6065-0695
AD  - Tikur Anbessa Specialized Hospital, School of Pharmacy, College of Health
      Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7247603
OTO - NOTNLM
OT  - EORTC PATSAT-C33
OT  - adult oncology
OT  - cancer care
OT  - patient satisfaction
COIS- All the authors declare that they have no competing interests in this work.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - 10.2147/PPA.S253027 [doi]
AID - 253027 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2020 May 20;14:847-858. doi: 10.2147/PPA.S253027.
      eCollection 2020.


PMID- 32546866
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210218
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 582
IP  - 7812
DP  - 2020 Jun
TI  - Lab-grown cells mimic crucial moment in embryo development.
PG  - 325
LID - 10.1038/d41586-020-01757-z [doi]
FAU - Cyranoski, David
AU  - Cyranoski D
LA  - eng
PT  - News
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Animals
MH  - Gastrulation/*physiology
MH  - Human Embryonic Stem Cells/*cytology
MH  - Humans
MH  - In Vitro Techniques/*methods
MH  - Mice
MH  - *Models, Biological
MH  - Mouse Embryonic Stem Cells/cytology
OTO - NOTNLM
OT  - *Developmental biology
OT  - *Diseases
OT  - *Ethics
OT  - *Evolution
EDAT- 2020/06/18 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1038/d41586-020-01757-z [doi]
AID - 10.1038/d41586-020-01757-z [pii]
PST - ppublish
SO  - Nature. 2020 Jun;582(7812):325. doi: 10.1038/d41586-020-01757-z.


PMID- 32546834
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20220417
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 123
IP  - 5
DP  - 2020 Sep
TI  - A dynamic web-based decision aid to improve informed choice in organised breast
      cancer screening. A pragmatic randomised trial in Italy.
PG  - 714-721
LID - 10.1038/s41416-020-0935-2 [doi]
AB  - BACKGROUND: Improving the quality of information and communication is a priority 
      in organised breast cancer screening and an ethical duty. Programmes must offer
      the information each woman is looking for, promoting informed decision-making.
      This study aimed to develop and evaluate a web-based dynamic decision aid (DA).
      METHODS: A pragmatic randomised trial carried out in six regional organised
      screening programmes recruited women at the first invitation receiving DA or a
      web-based standard brochure (SB). The primary outcome was informed choice
      measured on knowledge, attitudes, and intentions. Follow-up period: 7-10 days.
      Secondary outcomes included participation rate, satisfaction, decisional
      conflict, and acceptability of DA. RESULTS: Two thousand one hundred and nineteen
      women were randomised and 1001 completed the study. Respectively, 43.9% and 36.9%
      in the DA and SB reached the informed choice. The DA gave a 13-point higher
      proportion of women aware about overdiagnosis compared to SB (38.3% versus 25.2%,
      p < 0.0001). The percentage of women attending screening was the same: 84% versus
      83%. Decisional conflict was significantly lower in the DA group (14.4%) than in 
      the SB group (19.3%). CONCLUSION: DA increases informed choice. Complete
      information including the pros, cons, controversies, and
      overdiagnosis-overtreatment issues boost a woman's knowledge without reducing the
      rate of actual screening participation. CLINICAL TRIAL REGISTRATION:
      ClinicalTrials.gov number NCT03097653.
FAU - Roberto, Anna
AU  - Roberto A
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
FAU - Colombo, Cinzia
AU  - Colombo C
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
FAU - Candiani, Giulia
AU  - Candiani G
AD  - Zadig, Agenzia di Editoria Scientifica, Milano, Italy.
FAU - Satolli, Roberto
AU  - Satolli R
AD  - Zadig, Agenzia di Editoria Scientifica, Milano, Italy.
FAU - Giordano, Livia
AU  - Giordano L
AD  - SSD Epidemiologia e Screening - CPO Piemonte - AOU Citta della Salute e della
      Scienza, Torino, Italy.
FAU - Jaramillo, Lina
AU  - Jaramillo L
AD  - SSD Epidemiologia e Screening - CPO Piemonte - AOU Citta della Salute e della
      Scienza, Torino, Italy.
FAU - Castagno, Roberta
AU  - Castagno R
AD  - SSD Epidemiologia e Screening - CPO Piemonte - AOU Citta della Salute e della
      Scienza, Torino, Italy.
FAU - Mantellini, Paola
AU  - Mantellini P
AD  - SC Screening e Prevenzione Secondaria, Istituto per lo Studio, la Prevenzione e
      la Rete Oncologica - ISPRO, Firenze, Italy.
FAU - Falini, Patrizia
AU  - Falini P
AD  - SC Screening e Prevenzione Secondaria, Istituto per lo Studio, la Prevenzione e
      la Rete Oncologica - ISPRO, Firenze, Italy.
FAU - Carnesciali, Eva
AU  - Carnesciali E
AD  - SC Screening e Prevenzione Secondaria, Istituto per lo Studio, la Prevenzione e
      la Rete Oncologica - ISPRO, Firenze, Italy.
FAU - Valenza, Mario
AU  - Valenza M
AD  - UO Centro Gestionale Screening, ASP di Palermo, Palermo, Italy.
FAU - Costa, Liliana
AU  - Costa L
AD  - U.O.S. Screening Mammografico, ASP di Palermo, Palermo, Italy.
FAU - Campari, Cinzia
AU  - Campari C
AD  - S.S. Screening Oncologici - Azienda Unita Sanitaria Locale - IRCCS di Reggio
      Emilia, Reggio Emilia, Italy.
FAU - Caroli, Stefania
AU  - Caroli S
AD  - S.S. Screening Oncologici - Azienda Unita Sanitaria Locale - IRCCS di Reggio
      Emilia, Reggio Emilia, Italy.
FAU - Faggiano, Roberto Cosimo
AU  - Faggiano RC
AD  - S.S. Screening Oncologici - Azienda Unita Sanitaria Locale - IRCCS di Reggio
      Emilia, Reggio Emilia, Italy.
FAU - Orione, Lorenzo
AU  - Orione L
AD  - Centro Screening Cuneo, ASL CN1, Cuneo, Italy.
FAU - Belmessieri, Bruna
AU  - Belmessieri B
AD  - Centro Screening Cuneo, ASL CN1, Cuneo, Italy.
FAU - Marchio, Vanda
AU  - Marchio V
AD  - Centro Screening Cuneo, ASL CN1, Cuneo, Italy.
FAU - Deandrea, Silvia
AU  - Deandrea S
AD  - UOC Medicina Preventiva delle Comunita - Screening, ATS della Citta Metropolitana
      di Milano, Milano, Italy.
FAU - Silvestri, Anna
AU  - Silvestri A
AD  - UOC Medicina Preventiva delle Comunita - Screening, ATS della Citta Metropolitana
      di Milano, Milano, Italy.
FAU - Luciano, Daniela
AU  - Luciano D
AD  - UOC Medicina Preventiva delle Comunita - Screening, ATS della Citta Metropolitana
      di Milano, Milano, Italy.
FAU - Paci, Eugenio
AU  - Paci E
AD  - Lega Italiana per la Lotta contro i Tumori, Sezione Firenze, Italy.
FAU - Mosconi, Paola
AU  - Mosconi P
AD  - Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
      paola.mosconi@marionegri.it.
LA  - eng
SI  - ClinicalTrials.gov/NCT03097653
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
SB  - IM
EIN - Br J Cancer. 2021 Jul;125(1):146-147. PMID: 33976369
MH  - Breast Neoplasms/*diagnosis/diagnostic imaging
MH  - *Decision Support Techniques
MH  - Early Detection of Cancer/methods
MH  - Female
MH  - Humans
MH  - *Internet
MH  - Italy
MH  - Mammography/methods
MH  - Middle Aged
MH  - Program Evaluation
MH  - Socioeconomic Factors
PMC - PMC7462858
EDAT- 2020/06/18 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/12/24 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - 10.1038/s41416-020-0935-2 [doi]
AID - 10.1038/s41416-020-0935-2 [pii]
PST - ppublish
SO  - Br J Cancer. 2020 Sep;123(5):714-721. doi: 10.1038/s41416-020-0935-2. Epub 2020
      Jun 17.


PMID- 32546658
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210929
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - 'Healthcare Heroes': problems with media focus on heroism from healthcare workers
      during the COVID-19 pandemic.
PG  - 510-513
LID - 10.1136/medethics-2020-106398 [doi]
AB  - During the COVID-19 pandemic, the media have repeatedly praised healthcare
      workers for their 'heroic' work. Although this gratitude is undoubtedly
      appreciated by many, we must be cautious about overuse of the term 'hero' in such
      discussions. The challenges currently faced by healthcare workers are
      substantially greater than those encountered in their normal work, and it is
      understandable that the language of heroism has been evoked to praise them for
      their actions. Yet such language can have potentially negative consequences.
      Here, I examine what heroism is and why it is being applied to the healthcare
      workers currently, before outlining some of the problems associated with the
      heroism narrative currently being employed by the media. Healthcare workers have 
      a clear and limited duty to treat during the COVID-19 pandemic, which can be
      grounded in a broad social contract and is strongly associated with certain
      reciprocal duties that society has towards healthcare workers. I argue that the
      heroism narrative can be damaging, as it stifles meaningful discussion about what
      the limits of this duty to treat are. It fails to acknowledge the importance of
      reciprocity, and through its implication that all healthcare workers have to be
      heroic, it can have negative psychological effects on workers themselves. I
      conclude that rather than invoking the language of heroism to praise healthcare
      workers, we should examine, as a society, what duties healthcare workers have to 
      work in this pandemic, and how we can support them in fulfilling these.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Cox, Caitriona L
AU  - Cox CL
AUID- ORCID: 0000-0001-9416-9509
AD  - The Healthcare Improvement Studies (THIS) Institute, Cambridge CB2 0AH, UK
      caitriona.cox@nhs.net.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2021 Sep;47(9):643-644. PMID: 33328220
MH  - Attitude to Health
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communication
MH  - *Coronavirus Infections/virology
MH  - *Courage
MH  - *Delivery of Health Care
MH  - *Health Personnel
MH  - Humans
MH  - *Mass Media
MH  - Moral Obligations
MH  - *Pandemics
MH  - *Pneumonia, Viral/virology
MH  - *Public Opinion
MH  - SARS-CoV-2
MH  - Social Responsibility
PMC - PMC7316119
OTO - NOTNLM
OT  - *applied and professional ethics
OT  - *clinical ethics
OT  - *journalism/mass media
COIS- Competing interests: None declared.
EDAT- 2020/06/18 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - medethics-2020-106398 [pii]
AID - 10.1136/medethics-2020-106398 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):510-513. doi: 10.1136/medethics-2020-106398. Epub
      2020 Jun 16.


PMID- 32546657
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Triage of critical care resources in COVID-19: a stronger role for justice.
PG  - 526-530
LID - 10.1136/medethics-2020-106320 [doi]
AB  - Some ethicists assert that there is a consensus that maximising medical outcomes 
      takes precedence as a principle of resource allocation in emergency triage of
      absolutely scarce resources. But the nature of the current severe acute
      respiratory syndrome-related coronavirus 2 pandemic and the history of debate
      about balancing equity and efficiency in resource allocation do not support this 
      assertion. I distinguish a number of concerns with justice and balancing
      considerations that should play a role in critical care triage policy, focusing
      on discrimination and on fundamental egalitarian and social justice concerns.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Reid, Lynette
AU  - Reid L
AD  - Department of Bioethics, Faculty of Medicine, Dalhousie University, Halifax, Nova
      Scotia, Canada lynette.reid@dal.ca.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200616
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - N Engl J Med. 2020 May 21;382(21):2049-2055. PMID: 32202722
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Critical Care
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - *Social Justice
MH  - *Triage
PMC - PMC7316108
OTO - NOTNLM
OT  - *distributive justice
OT  - *public health ethics
OT  - *resource allocation
COIS- Competing interests: None declared.
EDAT- 2020/06/18 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - medethics-2020-106320 [pii]
AID - 10.1136/medethics-2020-106320 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):526-530. doi: 10.1136/medethics-2020-106320. Epub
      2020 Jun 16.


PMID- 32546496
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Models of maternal and child healthcare for African refugees: protocol for an
      exploratory, mixed-methods study.
PG  - e038162
LID - 10.1136/bmjopen-2020-038162 [doi]
AB  - INTRODUCTION: There is a paucity of research examining models of maternal and
      child health (MCH) care for refugees in high-income countries. Attention has
      focused on tailoring existing healthcare services to meet the needs of this
      population and ensure accessible high-quality patient-centred care. This protocol
      reports the methodology of a study designed to identify models of care for
      African refugees in New South Wales (NSW), Australia, to determine the evidence
      for these models and the improvements necessary to best meet service needs that
      can be delivered in line with available resources, organisational readiness and
      capacity to implement. METHODS AND ANALYSIS: This multiphased, participatory
      research project will employ an exploratory, mixed-methods design. Preparatory
      activities involve a situational analysis of current MCH services for African
      refugees and associated policies and guidelines in NSW. We will consult key
      health service providers and analyse Australian census and settlement data to
      identify refugee communities and their relation to healthcare services. Phase 1
      will ascertain the MCH care needs of African refugees and appropriate service
      models using: a Delphi survey with health service managers and providers, a
      nominal group process with African women refugees and; key informant interviews
      with senior health service managers. This data will be synthesised to provide
      insight into appropriate models-of-care that could be implemented. These will be 
      discussed in a stakeholder workshop. Phase 2 will comprise a readiness-to-change 
      survey with a selection of providers to explore the willingness, commitment and
      efficacy of staff members to adopt such models-of-care. ETHICS AND DISSEMINATION:
      Ethical approval was granted by NSW Health. Findings will be disseminated to all 
      stakeholders at a knowledge exchange forum to inform the development of a
      high-quality MCH service delivery model that can be feasibly implemented
      specifically for African refugee communities. PROSPERO REGISTRATION NUMBER:
      CRD42018095564.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Njue, Carolyne
AU  - Njue C
AUID- ORCID: 0000-0001-9325-3565
AD  - School of Public Health, University of Technology Sydney, Sydney, New South
      Wales, Australia Carolyne.Njue@uts.edu.au.
FAU - Hayen, Andrew
AU  - Hayen A
AD  - School of Public Health, University of Technology Sydney, Sydney, New South
      Wales, Australia.
FAU - Dawson, Angela J
AU  - Dawson AJ
AD  - School of Public Health, University of Technology Sydney, Sydney, New South
      Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa/ethnology
MH  - Child
MH  - Child Health Services/organization & administration/*statistics & numerical data
MH  - Child, Preschool
MH  - Female
MH  - Health Services Accessibility
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Maternal Health Services/organization & administration/*statistics & numerical
      data
MH  - New South Wales
MH  - *Refugees
MH  - Research Design
PMC - PMC7299034
OTO - NOTNLM
OT  - *health policy
OT  - *health services administration & management
OT  - *primary care
OT  - *public health
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/06/18 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038162 [pii]
AID - 10.1136/bmjopen-2020-038162 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e038162. doi: 10.1136/bmjopen-2020-038162.


PMID- 32546493
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Role of the intelligent exercise rehabilitation management system on adherence of
      cardiac rehabilitation in patients with coronary heart disease: a randomised
      controlled crossover study protocol.
PG  - e036720
LID - 10.1136/bmjopen-2019-036720 [doi]
AB  - INTRODUCTION: The benefits of cardiac rehabilitation (CR) on the reduction of
      cardiac and all-cause mortality are well documented. However, adherence remains
      suboptimal in China. It is clear that traditional CR does not meet the needs of
      many eligible patients and innovation is required to improve its application.
      Home-based CR (HBCR) is a cost-effective method that may be a valuable
      alternative for many individuals in China. In HBCR, it is often difficult to
      maintain an exercise intensity that is both effective and within safe limits,
      factors that are essential for patient safety. Mobile health interventions have
      the potential to overcome these obstacles and may be efficacious in improving
      adherence. The purpose of this study is to evaluate whether an Intelligent
      Exercise Rehabilitation Management System (IERMS)-based HBCR could improve
      adherence to CR and to assess the effects on exercise capacity, mental health,
      self-efficacy, quality of life and lifestyle-related risk factors. METHODS AND
      ANALYSIS: We propose a single-blinded, two-arm, randomised controlled crossover
      study of 70 patients with coronary heart disease (CHD). Participants will be
      randomly assigned in a 1:1 ratio to one of the two groups. Patients in group 1
      will receive the IERMS intervention together with usual care for the first 6
      weeks and usual care for the last 6 weeks, while patients assigned to group 2
      will receive usual care for the first 6 weeks and will use IERMS in the last 6
      weeks. The primary outcome is adherence to the programme and secondary outcomes
      include exercise capacity, psychological well-being, quality of life,
      self-efficacy and lifestyle-related risk factors. All secondary outcomes will be 
      measured at baseline, 6 weeks and 12 weeks. ETHICS AND DISSEMINATION: This study 
      has been approved by the Human Research Ethics Committee of the School of
      Nursing, Jilin University (HREC 2019120901). The results will be published in
      peer-reviewed journals and at conferences. TRIAL REGISTRATION NUMBER:
      ChiCTR1900028182; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Linqi
AU  - Xu L
AUID- ORCID: 0000-0002-4346-0547
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Xiong, Wenji
AU  - Xiong W
AD  - The First Hospital of Jilin University, Changchun, Jilin, China.
FAU - Li, Jinwei
AU  - Li J
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Shi, Hongyu
AU  - Shi H
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Shen, Meidi
AU  - Shen M
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Pang, Yue
AU  - Pang Y
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Ni, Yuanyuan
AU  - Ni Y
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Li, Yuewei
AU  - Li Y
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Guo, Lirong
AU  - Guo L
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Zhao, Lijing
AU  - Zhao L
AD  - School of Nursing, Jilin University, Changchun, Jilin, China.
FAU - Li, Feng
AU  - Li F
AUID- ORCID: 0000-0001-7423-8730
AD  - School of Nursing, Jilin University, Changchun, Jilin, China lifeng2912@163.com.
LA  - eng
SI  - ChiCTR/ChiCTR1900028182
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cardiac Rehabilitation/*methods
MH  - Coronary Disease/*rehabilitation
MH  - Cross-Over Studies
MH  - Exercise Therapy/*methods
MH  - Humans
MH  - *Patient Compliance
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7305520
OTO - NOTNLM
OT  - *coronary heart disease
OT  - *information technology
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/18 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036720 [pii]
AID - 10.1136/bmjopen-2019-036720 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e036720. doi: 10.1136/bmjopen-2019-036720.


PMID- 32546492
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210317
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Protocol for a realist review of General Practitioners' Role in Advancing
      Practice in Care Homes (GRAPE study).
PG  - e036221
LID - 10.1136/bmjopen-2019-036221 [doi]
AB  - INTRODUCTION: Older people who live in care homes have a high level of need with 
      complex health conditions. In addition to providing medical care to residents,
      general practitioners (GPs) play a role as gatekeeper for access to services, as 
      well as leadership within healthcare provision. This review will describe how GPs
      were involved in initiatives to change arrangements of healthcare services in
      order to improve quality and experience of care. METHODS AND ANALYSIS: Following 
      RAMESES quality and publication guidelines standards, we will proceed with
      realist review to develop theories of how GPs work with care home staff to bring 
      about improvements. We identify when improvement in outcomes does not occur and
      why this may be the case. The first stage will include interviews with GPs to ask
      their views on improvement in care homes. These interviews will enable
      development of initial theories and give direction for the literature searches.
      In the second stage, we will use iterative literature searches to add depth and
      context to the early theories; databases will include Medline, Embase, CINAHL,
      PsycINFO and ASSIA. In stage 3, evidence that is judged as rigorous and relevant 
      will be used to test the initial theories, and through the process, refine the
      theory statements. In the final stage, we will synthesise findings and provide
      recommendations for practice and policy-making.During the review, we will invite 
      a context expert group to reflect on our findings. This group will have expertise
      in current trends in primary care and the care home sector both in UK and
      internationally. ETHICS AND DISSEMINATION: The study was approved by University
      of Nottingham Faculty of Medicine and Health Sciences Research Ethics Committee: 
      354-1907. Findings will be shared through stakeholder networks, published in
      National Institute for Health Research journal and submitted for peer-reviewed
      journal publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Gordon, Adam L
AU  - Gordon AL
AUID- ORCID: 0000-0003-1676-9853
AD  - School of Medicine, Division of Medical Science and Graduate Entry Medicine,
      University of Nottingham, Nottingham, Nottinghamshire, UK.
AD  - NIHR Applied Research Collaboration East Midlands, University of Nottingham,
      Nottingham, Nottinghamshire, UK.
FAU - Devi, Reena
AU  - Devi R
AD  - School of Healthcare, University of Leeds, Leeds, UK.
FAU - Williams, Christopher
AU  - Williams C
AD  - Department of Health Sciences, University of Leicester, Leicester,
      Leicestershire, UK.
FAU - Goodman, Claire
AU  - Goodman C
AUID- ORCID: 0000-0002-8938-4893
AD  - Centre for Research in Public Health and Community Care, University of
      Hertfordshire, Hatfield, Hertfordshire, UK.
AD  - NIHR Applied Research Collaboration East of England, University of Hertfordshire,
      Hatfield, Hertfordshire, UK.
FAU - Sartain, Kathleen
AU  - Sartain K
AD  - Dementia and Frail Older Persons PPI Group, Division of Rehabilitation and
      Ageing, University of Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Chadborn, Neil H
AU  - Chadborn NH
AUID- ORCID: 0000-0003-1368-7983
AD  - School of Medicine, Division of Medical Science and Graduate Entry Medicine,
      University of Nottingham, Nottingham, Nottinghamshire, UK
      Neil.Chadborn@nottingham.ac.uk.
AD  - NIHR Applied Research Collaboration East Midlands, University of Nottingham,
      Nottingham, Nottinghamshire, UK.
LA  - eng
GR  - 11/1021/02/DH_/Department of Health/United Kingdom
GR  - FOP1/0115/DMT_/The Dunhill Medical Trust/United Kingdom
GR  - NIHR127257/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *General Practitioners
MH  - *Health Services for the Aged
MH  - *Homes for the Aged
MH  - Humans
MH  - *Physician's Role
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7299033
OTO - NOTNLM
OT  - *adult palliative care
OT  - *change management
OT  - *geriatric medicine
OT  - *primary care
OT  - *quality in health care
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/18 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036221 [pii]
AID - 10.1136/bmjopen-2019-036221 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e036221. doi: 10.1136/bmjopen-2019-036221.


PMID- 32546491
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Randomised controlled trial assessing the effect of a technology-assisted gait
      and balance training on mobility in older people after hip fracture: study
      protocol.
PG  - e035508
LID - 10.1136/bmjopen-2019-035508 [doi]
AB  - INTRODUCTION: Deficits in balance and walking ability are relevant risk factors
      for falls during ageing. Moreover, falls are a risk factor for future falls,
      strongly associated with adverse health outcomes, such as fear of falling or
      fractures, particularly, hip fracture. For this reason, the development of
      prevention tools and innovative rehabilitation strategies is one of the main
      objectives in geriatrics. Effective interventions to promote hip recovery after
      hip fracture are characterised by intensive and repetitive movements. One
      treatment approach is to increase the number of steps during the rehabilitation
      sessions and to improve the balance and the endurance of the patients in the use 
      of technological devices. METHODS AND ANALYSIS: This randomised controlled trial 
      aimed to evaluate an innovative rehabilitation treatment of elderly patients with
      hip fractures. A total of 195 patients with hip fractures will be recruited and
      randomly divided into three groups: traditional rehabilitation programme,
      traditional rehabilitation programme plus TYMO system and traditional
      rehabilitation programme plus Walker View. Assessments will be performed at
      baseline, at the end of treatment, at 6 months, and at 1 and 2 years after the
      end of the treatment. Only subjects hospitalised 4 weeks prior to the beginning
      of the study will be taken into consideration. Twenty treatment sessions will be 
      conducted, divided into three training sessions per week, for 7 weeks. The
      technological intervention group will carry out 30 min sessions of traditional
      therapy and 20 min of treatment with a technological device. The control group
      will perform traditional therapy sessions, each lasting 50 min. The primary
      outcomes are risk of falling, gait performance and fear of falling. ETHICS AND
      DISSEMINATION: The study was approved by the Istituto di Ricerca e Cura a
      Carattere Scientifica, Istituto Nazionale Ricovero e Cura Anziani Ethics
      Committee, with identification code number 19 014. Trial results will be
      submitted for publication in journals and conferences. TRIAL REGISTRATION NUMBER:
      NCT04095338.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Maranesi, Elvira
AU  - Maranesi E
AD  - Scientific Direction, IRCCS INRCA, Ancona, Italy.
FAU - Riccardi, Giovanni Renato
AU  - Riccardi GR
AD  - Clinical Unit of Physical Rehabilitation, IRCCS INRCA, Ancona, Italy.
FAU - Lattanzio, Fabrizia
AU  - Lattanzio F
AD  - Scientific Direction, IRCCS INRCA, Ancona, Italy.
FAU - Di Rosa, Mirko
AU  - Di Rosa M
AD  - Unit of Geriatric Pharmacoepidemiology, IRCCS INRCA, Ancona, Italy.
FAU - Luzi, Riccardo
AU  - Luzi R
AD  - Medical Direction, IRCCS INRCA, Ancona, Italy.
FAU - Casoni, Elisa
AU  - Casoni E
AD  - Clinical Unit of Physical Rehabilitation, IRCCS INRCA, Ancona, Italy.
FAU - Rinaldi, Nadia
AU  - Rinaldi N
AD  - Clinical Unit of Physical Rehabilitation, IRCCS INRCA, Fermo, Italy.
FAU - Baldoni, Renato
AU  - Baldoni R
AD  - Clinical Unit of Physical Rehabilitation, IRCCS INRCA, Ancona, Italy.
FAU - Di Donna, Valentina
AU  - Di Donna V
AD  - Clinical Unit of Physical Rehabilitation, IRCCS INRCA, Fermo, Italy.
FAU - Bevilacqua, Roberta
AU  - Bevilacqua R
AUID- ORCID: 0000-0002-3851-3552
AD  - Scientific Direction, IRCCS INRCA, Ancona, Italy r.bevilacqua@inrca.it.
LA  - eng
SI  - ClinicalTrials.gov/NCT04095338
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Female
MH  - *Gait
MH  - Hip Fractures/*physiopathology/*rehabilitation
MH  - Humans
MH  - Male
MH  - *Postural Balance
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Help Devices
PMC - PMC7299027
OTO - NOTNLM
OT  - *information technology
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/18 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035508 [pii]
AID - 10.1136/bmjopen-2019-035508 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e035508. doi: 10.1136/bmjopen-2019-035508.


PMID- 32546466
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 Mar 28
TI  - Improving global access to medical ethics education: a free self-paced online
      course on the Peoples-uni website.
PG  - 1-6
LID - 10.20529/IJME.2020.031 [doi]
AB  - In an attempt to increase global access to education about medical ethics, a free
      fully online course was developed on the Peoples-uni Open Online Courses site.
      Students came from 60 countries and were more likely to be medical practitioners,
      have come from the global North, and to have heard about the course through the
      web than other students enrolled in the Peoples-uni Open Online Courses site.
      Students scored high marks on the five quizzes. A third of the students gained a 
      certificate of completion. Course feedback was overwhelmingly positive. Students 
      stated that they learned the most from the lesson on professionalism, while other
      topics such as patient rights and autonomy, legal issues, and healthcare
      organisation and public health were also frequently mentioned. The course is an
      example of how open online courses can play a role in increasing awareness of
      medical ethics. Based on its analysis, the study identifies a need to attract
      interest in this area from low- and middle-income countries.
FAU - Worthington, Roger P
AU  - Worthington RP
AD  - Independent researcher, Lee Terrace, London SE3 9TB UK.
FAU - Madhok, Rajan
AU  - Madhok R
AD  - Chair, Board of Trustees, People's Open Access Education Initiative
      (Peoples-uni), Llanbedr DC, Wales LL151BQ.
FAU - Heller, Richard F
AU  - Heller RF
AD  - Coordinator and Trustee, People's Open Access Education Initiative (Peoples-uni),
      and Emeritus Professor, Universities of Manchester, UK, and Newcastle Australia, 
      59/96 Alfred Street, Milsons Point, NSW 2061, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200328
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.031 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 Mar 28;-(-):1-6. doi: 10.20529/IJME.2020.031.


PMID- 32546462
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 May 21
TI  - Is clinical examination for prostate cancer becoming redundant?
PG  - 1-3
LID - 10.20529/IJME.2020.061 [doi]
AB  - Prostate cancer is a paradigmatic example of the impact of technological change
      on current medical practice, because biological and radiological assessments
      appear more reliable compared to clinical examination. Thus, the prostate
      specific antigen blood-test is the key factor for patients' follow-up and for
      medical decisions. In this context, the possibility arises of medicine without
      clinical examination; and if, indeed, it would be ethical to perform clinical
      examinations such as digital rectal examination if it has no direct consequences 
      for care. However, clinical examination could have a residual value for clinical 
      practice, no more as a central factor for medical decision making, but as a key
      element in shaping the patient-physician relationship. Attention must be focused 
      on identifying the changing role of clinical examination and on discussing its
      ethical acceptability.<br><br> Keywords: Prostate cancer, screening, urooncology,
      clinical examination, digital rectal examination, care relationship.
FAU - Haaser, Thibaud
AU  - Haaser T
AD  - Service de Radiotherapie, Hopital du Haut Leveque, Avenue Magellan, 33600 Pessac,
      FRANCE, and University Hospital of Bordeaux, EA 4574, Sciences, Philosophie,
      Humanites, 33400 FRANCE.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.061 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 May 21;-(-):1-3. doi: 10.20529/IJME.2020.061.


PMID- 32546461
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 Apr 30
TI  - Clinical ethics during the Covid-19 pandemic: Missing the trees for the forest.
PG  - 1-5
LID - 10.20529/IJME.2020.053 [doi]
AB  - The SARS-CoV2 pandemic has exposed the acute vulnerability of the health systems 
      of countries worldwide. While countries are scrambling to contain the spread of
      the infection, the focus is largely on infection prevention strategies such as
      isolation, quarantine, physical distancing, hand hygiene, cough etiquette and
      country-wide lock-down. Important ethical concerns arise in the context of the
      public health interventions. However, while focusing on the forest, the
      population, attention must also be paid to the trees, the individuals who suffer 
      the illness. This article focuses on the ethical conflicts between the largely
      public health- driven focus of the Covid19 prevention and containment measures
      versus patient-centred care for those who suffer the illness and the consequent
      moral distress of healthcare providers. The key argument is for countries to
      mainstream clinical ethics considerations for care of patients with Covid-19 as
      well as "non-Covid-19" illnesses. Keywords: SARS-CoV2, Covid 19, clinical ethics,
      duty to care, allocation of scarce resources, moral distress.
FAU - Gopichandran, Vijayaprasad
AU  - Gopichandran V
AD  - Assistant Professor, Department of Community Medicine, ESIC Medical College and
      PGIMSR, KK Nagar, Chennai 600 078 INDIA.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.053 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 Apr 30;-(-):1-5. doi: 10.20529/IJME.2020.053.


PMID- 32546458
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 Jun 8
TI  - Covid-19 chemoprophylaxis: Ethics of prevention based on anecdotal evidence.
PG  - 1-6
LID - 10.20529/IJME.2020.066 [doi]
AB  - The ongoing pandemic of Covid-19 caused by the SARS-CoV-2 virus has infected more
      than 6 million all over the world and has caused more than 3.8 lakh fatalities
      till date(1) Health workers are the frontline responders and are exposed to a
      plethora of health hazards. Recently, an advisory by the Indian Council of
      Medical Research for the use of hydroxychloroquine as post-exposure prophylaxis
      was hailed as an outstanding initiative for the protection of healthcare workers 
      and high risk contacts of patients. But the evidence of effectiveness available
      is only from in vitro studies and non-randomised control trials of insufficient
      sample size. Several ongoing large scale clinical trials are focused on the same 
      research questions, the preliminary results of which are still awaited. The
      present study discusses the ethics of the introduction of therapeutic or
      preventive interventions based on limited available evidence during the ongoing
      pandemic of Covid-19.<br><br>.
FAU - Panigrahi, Sunil Kumar
AU  - Panigrahi SK
AD  - Senior Resident, Department of Community and Family Medicine, AIIMS, Raipur
      INDIA.
FAU - Majumdar, Sagarika
AU  - Majumdar S
AD  - Senior Resident, Department of Obstetrics and Gynaecology, AIIMS, Raipur INDIA.
FAU - Pal, Anjali
AU  - Pal A
AD  - Associate Professor, Department of Community and Family Medicine, AIIMS, Raipur, 
      INDIA.
FAU - Parija, Pragyan Paramita
AU  - Parija PP
AD  - Senior Resident, Centre for Community Medicine, AIIMS, New Delhi, INDIA.
FAU - Bharath, D U
AU  - Bharath DU
AD  - Consultant Psychiatrist, District Mental Health Programme, Chamarajanagar,
      Karnataka INDIA.
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.066 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 Jun 8;-(-):1-6. doi: 10.20529/IJME.2020.066.


PMID- 32546457
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 May 13
TI  - AYUSH, modern medicine and the Covid-19 pandemic.
PG  - 1-4
LID - 10.20529/IJME.2020.058 [doi]
AB  - The COVID-19 pandemic has posed several challenges to the Indian healthcare
      system. Here, we examine the situation in India considering the moral and ethical
      imperatives of decision making for public health. Currently, in the absence of
      proven therapies, empirical evidence is being used for treatment of Covid-19
      disease. We find a dual standard of practice. Currently, only modern medicine
      therapies are used on an empirical basis, however, the same principle is not
      considered for the use of AYUSH systems. Appropriate use of evidence is required.
      In the ethics context and in the interest of the larger public good, we suggest
      the inclusion of simple and safe measures from AYUSH systems in the integrative
      protocols for prophylaxis and treatment of Covid-19. Keywords: AYUSH systems,
      Covid-19, pandemic, prophylaxis, evidence, empirical evidence, priority setting, 
      public health decision making, global health emergencies,complementary medicine, 
      integrative healthcare.
FAU - Chaturvedi, Sarika
AU  - Chaturvedi S
AD  - Dr D Y Patil Vidyapeeth (DPU), Pimpri, Pune 18, INDIA.
FAU - Kumar, Nandini
AU  - Kumar N
AD  - Former Deputy Director General Sr. Grade, Indian Council of Medical Research, and
      Vice President, Forum for Ethics Review Committees in India, Padmalaya
      Apartments, Balakrishnan Road, Thiruvanmiyur, Chennai 600 041 INDIA.
FAU - Tillu, Girish
AU  - Tillu G
AD  - AYUSH Centre of Excellence, Centre for Complementary and Integrative Health,
      Interdisciplinary School of Health Sciences, Savitribai Phule Pune University,
      Pune 411 007.
FAU - Deshpande, Sharad
AU  - Deshpande S
AD  - Former Professor and Head, Department of Philosophy, University of Pune, and
      I.C.P.R. Visiting Professor, (2015-2016), IIAS, Shimla, India.
FAU - Patwardhan, Bhushan
AU  - Patwardhan B
AD  - AYUSH Centre of Excellence, Centre for Complementary and Integrative Health,
      Interdisciplinary School of Health Sciences, Savitribai Phule Pune University,
      Pune 411 007, INDIA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.058 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 May 13;-(-):1-4. doi: 10.20529/IJME.2020.058.


PMID- 32546456
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 May 27
TI  - Ethics committee meeting by video-conferencing during Covid-19.
PG  - 1-2
LID - 10.20529/IJME.2020.062 [doi]
AB  - The Covid-19 pandemic has created a situation demanding rapid ethical review of
      research on various aspects of the pandemic, while maintaining social distancing 
      norms. Research during an outbreak is important for understanding the disease and
      its management and allows scientists to study the disease <em>in situ.<br><br>.
FAU - Agrawal, Vinita
AU  - Agrawal V
AD  - Member Secretary, Institutional Ethics Committee, and Professor, Department of
      Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow,
      INDIA.
FAU - Nath, Chandishwar
AU  - Nath C
AD  - Chairperson, IEC, Sanjay Gandhi Postgraduate Institute of Medical Sciences,
      Lucknow, INDIA.
FAU - Mishra, Saroj Kanta
AU  - Mishra SK
AD  - Department of Endocrine Surgery and Faculty In charge, School of Telemedicine and
      Bioinformatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences,
      Lucknow, INDIA.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.062 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 May 27;-(-):1-2. doi: 10.20529/IJME.2020.062.


PMID- 32546455
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 May 28
TI  - Ethics for laboratory professionals during the Covid pandemic.
PG  - 1-2
LID - 10.20529/IJME.2020.063 [doi]
AB  - It is not wrong to say that ethical issues have been given limited attention by
      professionals in laboratory medicine as compared to other fields of medicine (1).
      The most ethically problematic laboratory examinations are those dealing with
      genetic testing, autopsies, prenatal and HIV examinations and now, testing
      microbial agents in epidemics or pandemics, like Covid-19.<br><br>.
FAU - Lutz, Emine Elif Vatanoglu
AU  - Lutz EEV
AD  - Associate Professor, Istanbul University Istanbul Faculty of Medicine, Department
      of Medical History and Ethics, 34093 Fatih, Istanbul, TURKEY.
FAU - Gurol, Yesim
AU  - Gurol Y
AD  - Acibadem Mehmet Ali Aydinlar University School of Medicine, Department of Medical
      Microbiology, Kayisdagi Caddesi. 34752 Atasehir-Istanbul,TURKEY.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.063 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 May 28;-(-):1-2. doi: 10.20529/IJME.2020.063.


PMID- 32546454
OWN - NLM
STAT- Publisher
LR  - 20200617
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 Jun 3
TI  - Clinical ethics during Covid-19: Plan for the whole health ecosystem.
PG  - 1-2
LID - 10.20529/IJME.2020.065 [doi]
AB  - During a pandemic, narrowing ethics into silos such as clinical and public health
      does not help the cause of ethics, which often gets neglected in desperate times.
      Our response to a recently published article in this journal, tries to take this 
      discussion forward. Keeping medical ethics at the centre of our response to the
      Covid-19 pandemic would benefit healthcare systems at all levels. This would also
      help us be prepared for future pandemics. Strengthening healthcare systems would 
      also provide an opportunity to improve non-Covid care.<br><br>.
FAU - Malik, Chetanya
AU  - Malik C
AD  - Junior Faculty, Jan Swasthya Sahyog, Village Ganiyari, Dist. Bilaspur,
      Chattisgarh INDIA.
FAU - Laux, Timothy
AU  - Laux T
AD  - Junior Faculty, Jan Swasthya Sahyog, Village Ganiyari, Dist. Bilaspur,
      Chattisgarh INDIA.
FAU - Jain, Yogesh
AU  - Jain Y
AD  - Senior Faculty, Jan Swasthya Sahyog, Village Ganiyari, Dist. Bilaspur,
      Chattisgarh INDIA.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.065 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 Jun 3;-(-):1-2. doi: 10.20529/IJME.2020.065.


PMID- 32546453
OWN - NLM
STAT- Publisher
LR  - 20220129
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - -
IP  - -
DP  - 2020 May 31
TI  - Healthcare delivery in India amid the Covid-19 pandemic: Challenges and
      opportunities.
PG  - 1-4
LID - 10.20529/IJME.2020.064 [doi]
AB  - In India, the Covid-19 pandemic has thrown open challenges on multiple fronts:
      (a) the reconfiguration of care in hospitals, in response to Covid-19, has led to
      many patients suffering non-Covid conditions having to delay their treatment, and
      (b) the lockdown which though necessary has affected people unequally, some being
      much worse-off than others. This article unpacks the impact of Covid-19 on
      healthcare systems in India by raising moral and ethical questions about the
      plight of patients with other medical conditions while accessing care. This
      article also proposes a set of actions by which healthcare systems can address
      Covid and non-Covid related healthcare needs.<br><br>.
FAU - Hebbar, Pragati B
AU  - Hebbar PB
AD  - PhD scholar and DBT/Wellcome Trust India Alliance Early Career Fellow, Institute 
      of Public Health, Krishna Rajendra Rd, Banashankari Stage II, Bengaluru,
      Karnataka 560 070 INDIA.
FAU - Sudha, Angel
AU  - Sudha A
AD  - Research Officer, Institute of Public Health, Krishna Rajendra Rd, Banashankari
      Stage II, Bengaluru, Karnataka 560 070 INDIA.
FAU - Dsouza, Vivek
AU  - Dsouza V
AD  - Research Officer, Institute of Public Health, Krishna Rajendra Rd, Banashankari
      Stage II, Bengaluru, Karnataka 560 070 INDIA.
FAU - Chilgod, Lathadevi
AU  - Chilgod L
AD  - Research Consultant, Institute of Public Health, Krishna Rajendra Rd,
      Banashankari Stage II, Bengaluru, Karnataka 560 070 INDIA.
FAU - Amin, Adhip
AU  - Amin A
AD  - Research Officer, Institute of Public Health, Krishna Rajendra Rd, Banashankari
      Stage II, Bengaluru, Karnataka 560 070 INDIA.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - IA/CPHE/17/1/503338/WTDBT_/DBT-Wellcome Trust India Alliance/India
GR  - IA/CPHI/17/1/503346/WTDBT_/DBT-Wellcome Trust India Alliance/India
PT  - Journal Article
DEP - 20200531
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
PMC - PMC7611350
MID - EMS129501
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.20529/IJME.2020.064 [doi]
PST - aheadofprint
SO  - Indian J Med Ethics. 2020 May 31;-(-):1-4. doi: 10.20529/IJME.2020.064.


PMID- 32546398
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1879-0097 (Electronic)
IS  - 0109-5641 (Linking)
VI  - 36
IP  - 8
DP  - 2020 Aug
TI  - Biomimetic in vitro test system for evaluation of dental implant materials.
PG  - 1059-1070
LID - S0109-5641(20)30129-9 [pii]
LID - 10.1016/j.dental.2020.04.020 [doi]
AB  - OBJECTIVES: Before application in dental practice, novel dental materials are
      tested in vitro and in vivo to ensure safety and functionality. However,
      transferability between preclinical and clinical results is often limited. To
      increase the predictive power of preclinical testing, a biomimetic in vitro test 
      system that mimics the wound niche after implantation was developed. METHODS:
      First, predetermined implant materials were treated with human blood plasma, M2
      macrophages and bone marrow stromal stem cells. Thereby, the three-dimensional
      wound niche was simulated. Samples were cultured for 28 days, and subsequently
      analyzed for metabolic activity and biomineralization. Second test level involved
      a cell-infiltrated bone substitute material for an osseointegration assay to
      measure mechanical bonding between dental material and bone. Standard and novel
      dental materials validated the developed test approach. RESULTS: The developed
      test system for dental implant materials allowed quantification of
      biomineralization on implant surface and assessment of the functional stability
      of mineralized biomaterial-tissue interface. Human blood plasma, M2 macrophages
      and bone marrow stromal stem cells proved to be crucial components for predictive
      assessment of implant materials in vitro. Biocompatibility was demonstrated for
      all tested materials, whereas the degree of deposited mineralized extracellular
      matrix and mechanical stability differed between the tested materials. Highest
      amount of functional biomineralization was determined to be on carbon-coated
      implant surface. SIGNIFICANCE: As an ethical alternative to animal testing, the
      established in vitro dental test system provides an economic and mid-throughput
      evaluation of novel dental implant materials or modifications thereof, by
      applying two successive readout levels: biomineralization and osseointegration.
CI  - Copyright (c) 2020 The Academy of Dental Materials. Published by Elsevier Inc.
      All rights reserved.
FAU - Ehlicke, Franziska
AU  - Ehlicke F
AD  - University Hospital Wuerzburg, Department Tissue Engineering and Regenerative
      Medicine, Roentgenring 11, 97070 Wuerzburg, Germany. Electronic address:
      franziska.ehlicke@uni-wuerzburg.de.
FAU - Berndt, Jonathan
AU  - Berndt J
AD  - Natural Dental Implants AG, Edisonstrasse 63, 12459 Berlin, Germany. Electronic
      address: jonathan.berndt@gmx.de.
FAU - Marichikj, Nina
AU  - Marichikj N
AD  - University Hospital Wuerzburg, Department Tissue Engineering and Regenerative
      Medicine, Roentgenring 11, 97070 Wuerzburg, Germany. Electronic address:
      nina.maricik@gmail.com.
FAU - Steinmuller-Nethl, Doris
AU  - Steinmuller-Nethl D
AD  - DiaCoating GmbH, c/o Werkstatte Wattens, Weisstrasse 9, 6112 Wattens, Austria.
      Electronic address: doris.steinmueller@diacoating.com.
FAU - Walles, Heike
AU  - Walles H
AD  - University Hospital Wuerzburg, Department Tissue Engineering and Regenerative
      Medicine, Roentgenring 11, 97070 Wuerzburg, Germany; Fraunhofer Institute for
      Silicate Research ISC, Translational Center Regenerative Therapies, Roentgenring 
      11, 97070 Wuerzburg, Germany. Electronic address: heike.walles@isc.fraunhofer.de.
FAU - Berndt, Ernst-Ulrich
AU  - Berndt EU
AD  - Natural Dental Implants AG, Edisonstrasse 63, 12459 Berlin, Germany. Electronic
      address: ernst-ulrich.berndt@t-online.de.
FAU - Hansmann, Jan
AU  - Hansmann J
AD  - University Hospital Wuerzburg, Department Tissue Engineering and Regenerative
      Medicine, Roentgenring 11, 97070 Wuerzburg, Germany; Fraunhofer Institute for
      Silicate Research ISC, Translational Center Regenerative Therapies, Roentgenring 
      11, 97070 Wuerzburg, Germany. Electronic address: jan.hansmann@isc.fraunhofer.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200613
PL  - England
TA  - Dent Mater
JT  - Dental materials : official publication of the Academy of Dental Materials
JID - 8508040
RN  - 0 (Dental Implants)
RN  - 0 (Dental Materials)
RN  - D1JT611TNE (Titanium)
MH  - Animals
MH  - Biomimetics
MH  - Dental Implantation, Endosseous
MH  - *Dental Implants
MH  - Dental Materials
MH  - Dental Prosthesis Design
MH  - Humans
MH  - In Vitro Techniques
MH  - Osseointegration
MH  - Surface Properties
MH  - Titanium
OTO - NOTNLM
OT  - *biomineralization
OT  - *ceramic
OT  - *dental
OT  - *human test system
OT  - *implant
OT  - *matrix remodeling
OT  - *osseointegration
OT  - *titanium
OT  - *wound healing
EDAT- 2020/06/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/08/09 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - S0109-5641(20)30129-9 [pii]
AID - 10.1016/j.dental.2020.04.020 [doi]
PST - ppublish
SO  - Dent Mater. 2020 Aug;36(8):1059-1070. doi: 10.1016/j.dental.2020.04.020. Epub
      2020 Jun 13.


PMID- 32546385
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1878-7452 (Electronic)
IS  - 1878-7452 (Linking)
VI  - 77
IP  - 6
DP  - 2020 Nov - Dec
TI  - Open Payments Reporting of Industry Compensation for Orthopedic Residents.
PG  - 1632-1637
LID - S1931-7204(20)30145-8 [pii]
LID - 10.1016/j.jsurg.2020.05.010 [doi]
AB  - OBJECTIVES: Residents receiving industry payments are not legally required to be 
      reported on the Centers for Medicare & Medicaid Services (CMS) Open Payments
      Database. The purpose of this study is to review reporting of orthopedic surgery 
      residents and identify the trends for which payments or transfers in value were
      received. DESIGN: The CMS Open Payments Database was used to search for all
      available orthopedic residents from 2014 to 2016. All data available on the CMS
      Open Payments Database was recorded. SETTING/PARTICIPANTS: This is a database
      study. Participants are residents reported in the CMS Open Payments Database.
      RESULTS: Over the 3-year period, 6832 resident "entities" were identified from
      151 programs. A total of 3217 entities (47%) were reported as receiving payments 
      from industry during this time period. This totaled $3,786,754 over the 3 year
      study period. The largest itemized categories for payment were education (32.5%) 
      and grants (30.9%) totaling more than $2.4 million. Other areas of payment
      included travel (17.0%), food (16.0%), consultation fee (1.7%), research (0.8%), 
      speaker fee (0.7%), gift (0.1%), honoraria (0.1%), and other (0.02%). CONCLUSION:
      Overall, 47% of orthopedic resident entities were reported on the CMS Open
      Payments Database. The vast majority of payments were related to education and
      grants. Residents should become familiar with how to navigate the Open Payments
      Database and be educated on maintaining appropriate relationships with industry.
CI  - Copyright (c) 2020 Association of Program Directors in Surgery. Published by
      Elsevier Inc. All rights reserved.
FAU - Almaguer, Adam M
AU  - Almaguer AM
AD  - Department of Orthopedic Surgery, University of Alabama at Birmingham Hospital,
      Birmingham, Alabama.
FAU - Wills, Bradley W
AU  - Wills BW
AD  - Department of Orthopedic Surgery, University of Alabama at Birmingham Hospital,
      Birmingham, Alabama.
FAU - Robin, Joseph X
AU  - Robin JX
AD  - University of Alabama School of Medicine, Birmingham, Alabama.
FAU - Chodaba, Yvonne
AU  - Chodaba Y
AD  - Department of Orthopedic Surgery, University of Alabama at Birmingham Hospital,
      Birmingham, Alabama.
FAU - Arguello, Alexandra M
AU  - Arguello AM
AD  - Department of Orthopedic Surgery, University of Alabama at Birmingham Hospital,
      Birmingham, Alabama.
FAU - McMichael, Benjamin J
AU  - McMichael BJ
AD  - University of Alabama School of Law, Tuscaloosa, Alabama.
FAU - McGwin, Gerald Jr
AU  - McGwin G Jr
AD  - University of Alabama School of Public Health, Birmingham, Alabama.
FAU - Ponce, Brent A
AU  - Ponce BA
AD  - Department of Orthopedic Surgery, University of Alabama at Birmingham Hospital,
      Birmingham, Alabama. Electronic address: bponce@uabmc.edu.
LA  - eng
PT  - Journal Article
DEP - 20200614
PL  - United States
TA  - J Surg Educ
JT  - Journal of surgical education
JID - 101303204
SB  - IM
MH  - Aged
MH  - Centers for Medicare and Medicaid Services, U.S.
MH  - Databases, Factual
MH  - Humans
MH  - Industry
MH  - *Medicare
MH  - *Orthopedics
MH  - United States
OTO - NOTNLM
OT  - ethics
OT  - industry
OT  - open payments database
OT  - orthopaedic surgery
OT  - sunshine act
EDAT- 2020/06/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/18 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/18 06:00 [entrez]
AID - S1931-7204(20)30145-8 [pii]
AID - 10.1016/j.jsurg.2020.05.010 [doi]
PST - ppublish
SO  - J Surg Educ. 2020 Nov - Dec;77(6):1632-1637. doi: 10.1016/j.jsurg.2020.05.010.
      Epub 2020 Jun 14.


PMID- 32546239
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20210110
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jun 17
TI  - A prospective longitudinal study on the microbiota composition in amyotrophic
      lateral sclerosis.
PG  - 153
LID - 10.1186/s12916-020-01607-9 [doi]
AB  - BACKGROUND: A connection between amyotrophic lateral sclerosis (ALS) and altered 
      gut microbiota composition has previously been reported in animal models. This
      work is the first prospective longitudinal study addressing the microbiota
      composition in ALS patients and the impact of a probiotic supplementation on the 
      gut microbiota and disease progression. METHODS: Fifty patients and 50 matched
      controls were enrolled. The microbial profile of stool samples from patients and 
      controls was analyzed via PCR-Denaturing Gradient Gel Electrophoresis, and the
      main microbial groups quantified via qPCR. The whole microbiota was then analyzed
      via next generation sequencing after amplification of the V3-V4 region of 16S
      rDNA. Patients were then randomized to receive probiotic treatment or placebo and
      followed up for 6 months with ALSFRS-R, BMI, and FVC%. RESULTS: The results
      demonstrate that the gut microbiota of ALS patients is characterized by some
      differences with respect to controls, regardless of the disability degree.
      Moreover, the gut microbiota composition changes during the course of the disease
      as demonstrated by the significant decrease in the number of observed operational
      taxonomic unit during the follow-up. Interestingly, an unbalance between
      potentially protective microbial groups, such as Bacteroidetes, and other with
      potential neurotoxic or pro-inflammatory activity, such as Cyanobacteria, has
      been shown. The 6-month probiotic treatment influenced the gut microbial
      composition; however, it did not bring the biodiversity of intestinal microbiota 
      of patients closer to that of control subjects and no influence on the
      progression of the disease measured by ALSFRS-R was demonstrated. CONCLUSIONS:
      Our study poses the bases for larger clinical studies to characterize the
      microbiota changes as a novel ALS biomarker and to test new microbial strategy to
      ameliorate the health status of the gut. TRIAL REGISTRATION: CE 107/14, approved 
      by the Ethics Committee of the "Maggiore della Carita" University Hospital,
      Italy.
FAU - Di Gioia, Diana
AU  - Di Gioia D
AD  - Department of Agricultural and Food Sciences, University of Bologna, Viale Fanin 
      42, Bologna, Italy.
FAU - Bozzi Cionci, Nicole
AU  - Bozzi Cionci N
AD  - Department of Agricultural and Food Sciences, University of Bologna, Viale Fanin 
      42, Bologna, Italy.
FAU - Baffoni, Loredana
AU  - Baffoni L
AD  - Department of Agricultural and Food Sciences, University of Bologna, Viale Fanin 
      42, Bologna, Italy.
FAU - Amoruso, Angela
AU  - Amoruso A
AD  - BIOLAB RESEARCH srl, via E. Mattei 3, 28100, Novara, Italy.
FAU - Pane, Marco
AU  - Pane M
AD  - BIOLAB RESEARCH srl, via E. Mattei 3, 28100, Novara, Italy.
FAU - Mogna, Luca
AU  - Mogna L
AD  - BIOLAB RESEARCH srl, via E. Mattei 3, 28100, Novara, Italy.
FAU - Gaggia, Francesca
AU  - Gaggia F
AD  - Department of Agricultural and Food Sciences, University of Bologna, Viale Fanin 
      42, Bologna, Italy.
FAU - Lucenti, Maria Ausiliatrice
AU  - Lucenti MA
AD  - Department of Neurology and ALS Centre, University of Piemonte Orientale,
      Maggiore della Carita Hospital, Corso Mazzini 18, 28100, Novara, Italy.
FAU - Bersano, Enrica
AU  - Bersano E
AD  - Department of Neurology and ALS Centre, University of Piemonte Orientale,
      Maggiore della Carita Hospital, Corso Mazzini 18, 28100, Novara, Italy.
FAU - Cantello, Roberto
AU  - Cantello R
AD  - Department of Neurology and ALS Centre, University of Piemonte Orientale,
      Maggiore della Carita Hospital, Corso Mazzini 18, 28100, Novara, Italy.
FAU - De Marchi, Fabiola
AU  - De Marchi F
AD  - Department of Neurology and ALS Centre, University of Piemonte Orientale,
      Maggiore della Carita Hospital, Corso Mazzini 18, 28100, Novara, Italy.
FAU - Mazzini, Letizia
AU  - Mazzini L
AD  - Department of Neurology and ALS Centre, University of Piemonte Orientale,
      Maggiore della Carita Hospital, Corso Mazzini 18, 28100, Novara, Italy.
      letizia.mazzini@uniupo.it.
LA  - eng
GR  - --/Probiotical S.p.A./International
GR  - AGING Project for Department of Excellence at the Department of Translational
      Medicine (DIMET), Universita del Piemonte Orientale, Novara, Italy/Universita
      degli Studi del Piemonte Orientale/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200617
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Amyotrophic Lateral Sclerosis/*physiopathology
MH  - Animals
MH  - Female
MH  - Gastrointestinal Microbiome/*physiology
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Young Adult
PMC - PMC7298784
OTO - NOTNLM
OT  - *Amyotrophic lateral sclerosis
OT  - *Biomarker
OT  - *Microbiota
OT  - *Neurodegeneration
EDAT- 2020/06/18 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
AID - 10.1186/s12916-020-01607-9 [doi]
AID - 10.1186/s12916-020-01607-9 [pii]
PST - epublish
SO  - BMC Med. 2020 Jun 17;18(1):153. doi: 10.1186/s12916-020-01607-9.


PMID- 32545531
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 6
DP  - 2020 Jun 12
TI  - The Relation between Red Meat and Whole-Grain Intake and the Colonic Mucosal
      Barrier: A Cross-Sectional Study.
LID - E1765 [pii]
LID - 10.3390/nu12061765 [doi]
AB  - The Colonic Mucosal Barrier (CMB) is the site of interaction between the human
      body and the colonic microbiota. The mucus is the outer part of the CMB and is
      considered as the front-line defense of the colon. It separates the host
      epithelial lining from the colonic content, and it has previously been linked to 
      health and diseases. In this study, we assessed the relationship between red meat
      and whole-grain intake and (1) the thickness of the colonic mucus (2) the
      expression of the predominant mucin gene in the human colon (MUC2). Patients
      referred to colonoscopy at the University Hospital of Southern Denmark-
      Sonderjylland were enrolled between June 2017 and December 2018, and lifestyle
      data was collected in a cross-sectional study design. Colonic biopsies, blood,
      urine, and fecal samples were collected. The colonic mucus and bacteria were
      visualized by immunostaining and fluorescence in situ hybridization techniques.
      We found a thinner mucus was associated with high red meat intake. Similarly, the
      results suggested a thinner mucus was associated with high whole-grain intake,
      albeit to a lesser extent than red meat. This is the first study assessing the
      association between red meat and whole-grain intake and the colonic mucus in
      humans. This study is approved by the Danish Ethics Committee (S-20160124) and
      the Danish Data Protecting Agency (2008-58-035). A study protocol was registered 
      at clinical trials.gov under NCT04235348.
FAU - Jawhara, Mohamad
AU  - Jawhara M
AD  - Focused Research Unit for Molecular Diagnostic and Clinical Research, Institute
      of Regional Health Research, University Hospital of Southern Denmark-
      Sonderjylland, 6200 Aabenraa, Denmark.
AD  - Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense,
      Denmark.
AD  - Department of Surgery, University Hospital of Southern Denmark-Sonderjylland,
      6200 Aabenraa, Denmark.
FAU - Sorensen, Signe Bek
AU  - Sorensen SB
AD  - Focused Research Unit for Molecular Diagnostic and Clinical Research, Institute
      of Regional Health Research, University Hospital of Southern Denmark-
      Sonderjylland, 6200 Aabenraa, Denmark.
AD  - Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense,
      Denmark.
FAU - Heitmann, Berit Lilienthal
AU  - Heitmann BL
AD  - Research Unit for Dietary Studies, the Parker Institute, Bispebjerg and
      Frederiksberg, 2000 Frederiksberg, Denmark.
AD  - Section for General Practice, Department of Public Health, University of
      Copenhagen, 2100 Copenhagen, Denmark.
AD  - The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, The
      University of Sydney, Sydney, NSW 2006, Australia.
FAU - Halldorsson, Thornorhallur Ingi
AU  - Halldorsson ThornI
AD  - Faculty of Food Science and Nutrition, School of Health Sciences, University of
      Iceland, 101 Reykjavik, Iceland.
AD  - Centre for Fetal Programming, Department of Epidemiology Research, Statens Serum 
      Institut, 2100 Copenhagen, Denmark.
FAU - Pedersen, Andreas Kristian
AU  - Pedersen AK
AD  - Laerings- og Forskningshuset, University Hospital of Southern Denmark,
      Sonderjylland, 6200 Aabenraa, Denmark.
FAU - Andersen, Vibeke
AU  - Andersen V
AD  - Focused Research Unit for Molecular Diagnostic and Clinical Research, Institute
      of Regional Health Research, University Hospital of Southern Denmark-
      Sonderjylland, 6200 Aabenraa, Denmark.
AD  - Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense,
      Denmark.
AD  - Open Patient data Explorative Network, University of Southern Jutland, 5230
      Odense, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04235348
GR  - 733100/Horizon 2020
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200612
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Mucin-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Colon/*metabolism/microbiology/pathology
MH  - Colonoscopy
MH  - Cross-Sectional Studies
MH  - Denmark
MH  - Diet/*methods
MH  - Diet Surveys
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Intestinal Mucosa/*metabolism/microbiology/pathology
MH  - Male
MH  - Microbiota
MH  - Middle Aged
MH  - Mucin-2/genetics/metabolism
MH  - Mucus/metabolism/microbiology
MH  - *Red Meat
MH  - *Whole Grains
PMC - PMC7353246
OTO - NOTNLM
OT  - MUC2
OT  - colonic mucosal barrier
OT  - human colon
OT  - large intestine
OT  - mucin
OT  - mucus
OT  - red meat
OT  - whole-grain
COIS- The authors declare no conflicts of interest. The funders had no role in the
      study design, analyses, or interpretation of data; in the writing of the
      manuscript, or in the decision to publish the results.
EDAT- 2020/06/18 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/18 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/06/07 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - nu12061765 [pii]
AID - 10.3390/nu12061765 [doi]
PST - epublish
SO  - Nutrients. 2020 Jun 12;12(6). pii: nu12061765. doi: 10.3390/nu12061765.


PMID- 32545477
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 12
TI  - Recommendations for Dental Care during COVID-19 Pandemic.
LID - E1833 [pii]
LID - 10.3390/jcm9061833 [doi]
AB  - Dental clinics were suspected to be a hotspot for nosocomial transmission of
      coronavirus disease 19 (COVID-19), yet there has been no clear recommendation
      about emergency dental care and appropriate personal protective equipment during 
      pandemics. In this paper, we aim to summarize recommendations for (i) patient
      risk assessment, (ii) patient triage, and (iii) measures to prevent infection of 
      health professionals and nosocomial transmission in dental clinics. The available
      evidence was collected by performing searches on PubMed, Embase, and Cochrane
      databases. We reviewed papers on COVID-19, severe acute respiratory syndrome
      (SARS), Middle East respiratory syndrome (MERS), influenza, and related
      respiratory viral diseases. Legal and ethical frameworks, as well as
      international (e.g., World Health Organization (WHO)) and national (e.g., public 
      health institutes, dental associations) guidelines were screened to summarize
      recommendations related to dental emergency care. To assess the patient risk, a
      questionnaire was developed to classify patients at unknown, high, and very high 
      risk. Patient triage recommendations were summarized in a flow chart that graded 
      the emergency level of treatments (i.e., urgent, as soon as possible, and
      postpone). Measures to prevent disease transmission based on current evidence
      were grouped for dental health professionals, dental clinics, and patients. The
      present recommendations may support health professionals implement preventative
      measures during the pandemic.
FAU - Gurzawska-Comis, Katarzyna
AU  - Gurzawska-Comis K
AD  - Department of Oral Surgery, University of Birmingham, 5 Mill Pool Way, Edgbaston,
      Birmingham B5 7EG, UK.
FAU - Becker, Kathrin
AU  - Becker K
AUID- ORCID: 0000-0003-1936-4683
AD  - Department of Orthodontics, Universitatsklinikum Dusseldorf, Moorenstr. 5,
      Building 18.21, 40225 Dusseldorf, Germany.
AD  - Department of Oral Surgery and Implantology, Carolinum, Goethe University,
      Theodor-Stern-Kai 7/Haus 29, 60596 Frankfurt am Main, Germany.
FAU - Brunello, Giulia
AU  - Brunello G
AUID- ORCID: 0000-0003-1436-0085
AD  - Department of Neurosciences, Dentistry Section, University of Padova, Via
      Giustiniani 2, 35128 Padova, Italy.
FAU - Gurzawska, Agata
AU  - Gurzawska A
AD  - Trilateral Research Ireland, Marine Point, Belview Port, X91 W0XW Waterford,
      Ireland.
FAU - Schwarz, Frank
AU  - Schwarz F
AD  - Department of Oral Surgery and Implantology, Carolinum, Goethe University,
      Theodor-Stern-Kai 7/Haus 29, 60596 Frankfurt am Main, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7357003
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - coronavirus
OT  - dental emergency treatment
OT  - patient questionnaire
OT  - patient triage
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2020/05/20 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - jcm9061833 [pii]
AID - 10.3390/jcm9061833 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jun 12;9(6). pii: jcm9061833. doi: 10.3390/jcm9061833.


PMID- 32545173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Jun 11
TI  - Nursing Care Ethical Implications Regarding Chronic Patients at Hospital
      Discharge.
LID - E167 [pii]
LID - 10.3390/healthcare8020167 [doi]
AB  - Mortality rates among pluripathological patients are significantly higher in the 
      hospital setting, with advanced age and dependence on certain vital functions the
      main clinical aspects. Other features involved in the care, such as the loss of
      autonomy and social problems, have important ethical implications. The aim of
      this article is to analyze the health problems and the functional and social
      situation of chronic patients after hospital admission in order to determine
      their care needs and the ethical implications these might have. For this, a
      cross-sectional descriptive study is being carried out with a sample of 111
      chronic pluripathological patients admitted to the internal medicine service and 
      discharged later. Overall, 96.6% of the patients in the sample were dependent,
      91.7% had social problems or were at social risk and 36.9% had cognitive
      impairment. Among dependent patients, 59.4% had social problems (p = 0.029),
      19.2% lived alone (p = 0.13), and in 73.3% of cases the housing was inadequate (p
      = 0.47). Among those with cognitive impairment, 79.5% of patients had social
      problems (p = 0.001), and 10.3% lived alone (p = 0.038). The results of the study
      confirm the presence of dependence and social problems at hospital discharge in a
      high proportion of chronic patients. Planning their care can lead to ethical
      conflicts related to the use of information technologies, which are destined to
      promote the patients' autonomy, and to the social problems associated with the
      illness.
FAU - Coronado-Vazquez, Valle
AU  - Coronado-Vazquez V
AD  - Department of Nursing, Catholic University of Avila, 05005 Avila, Spain.
AD  - Primary Care Research Unit, Red de Investigacion en Actividades Preventivas y
      Promocion de la Salud (RedIAPP), University of Zaragoza, 50009 Zaragoza, Spain.
FAU - Canet-Fajas, Carlota
AU  - Canet-Fajas C
AD  - Delicias Sur Community Health Center, Aragon Health Service, 50009 Zaragoza,
      Spain.
FAU - Ramirez-Duran, Maria Valle
AU  - Ramirez-Duran MV
AUID- ORCID: 0000-0001-6350-8782
AD  - Department of Nursing, Catholic University of Avila, 05005 Avila, Spain.
FAU - Gomez-Salgado, Juan
AU  - Gomez-Salgado J
AUID- ORCID: 0000-0001-9053-7730
AD  - Department of Sociology, Social Work and Public Health, Faculty of Labour
      Sciences, University of Huelva, 21007 Huelva, Spain.
AD  - Safety and Health Postgraduate Programme, Espiritu Santo University, Guayaquil
      092301, Ecuador.
FAU - Robles-Romero, Jose Miguel
AU  - Robles-Romero JM
AUID- ORCID: 0000-0001-8343-6421
AD  - Department of Nursing, Faculty of Nursing, University of Huelva, 21071 Huelva,
      Spain.
FAU - Fagundo-Rivera, Javier
AU  - Fagundo-Rivera J
AD  - Andalusian Health Service, Health Sciences Doctorate School, University of
      Huelva, 21007 Huelva, Spain.
FAU - Romero-Martin, Macarena
AU  - Romero-Martin M
AUID- ORCID: 0000-0003-3022-3339
AD  - Department of Nursing, Faculty of Nursing, University of Huelva, 21071 Huelva,
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7349255
OTO - NOTNLM
OT  - chronic patient
OT  - ethics
OT  - hospital discharge
OT  - nursing care
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
CRDT- 2020/06/18 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/06/08 00:00 [revised]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
AID - healthcare8020167 [pii]
AID - 10.3390/healthcare8020167 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Jun 11;8(2). pii: healthcare8020167. doi:
      10.3390/healthcare8020167.


PMID- 32544701
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20211002
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 111
DP  - 2020 Oct
TI  - Epilepsy through the eyes of the media: A paradox of positive reporting and
      challenges of access to advanced neurotechnology.
PG  - 107200
LID - S1525-5050(20)30379-6 [pii]
LID - 10.1016/j.yebeh.2020.107200 [doi]
AB  - OBJECTIVE: Media coverage of disorders and medical advancements can impact public
      perception regarding the riskiness, effectiveness, and accessibility of treatment
      options. We studied that coverage for epilepsy with a focus on surgical
      interventions and emerging neurotechnologies. METHODS: Epilepsy-related English
      language articles published through 2019 were retrieved from online International
      news media with a circulation of 80,000 or above. We used directed content
      analysis of news articles to code content into a priori categories both to
      identify salient themes and to characterize their valence. RESULTS: One hundred
      forty-six unique articles matched our search terms. Overall, there was a steady
      increase in epilepsy reporting over time, with a majority of articles published
      with a positive tone. Neuromodulation was the focus of over 50% of all the
      articles in the time points analyzed. Vagus nerve stimulation (VNS) and
      deep-brain stimulation (DBS) were discussed more prominently than other types of 
      neurotechnological interventions; VNS was the neurotechnological focus in 39% of 
      the pediatric articles; resective surgery was the focus in 34% of adult articles.
      Access, support, and epilepsy literacy were the central themes in the context of 
      ethical, legal, and social issues. SIGNIFICANCE: News media can influence the
      trust that the public places in science and medicine, and by extension,
      influences health policy. As innovations in neurotechnology for epilepsy emerge, 
      understanding of individual and societal values is essential to their beneficial 
      evolution and translation to care.
CI  - Crown Copyright (c) 2020. Published by Elsevier Inc. All rights reserved.
FAU - Munjal, Vrinda
AU  - Munjal V
AD  - Department of Medicine, Royal College of Surgeons in Ireland, Dublin D02 YN77,
      Ireland; Neuroethics Canada, Division of Neurology, Department of Medicine,
      University of British Columbia, Vancouver, BC V6T 2B5, Canada.
FAU - Arakelyan, Mary
AU  - Arakelyan M
AD  - Neuroethics Canada, Division of Neurology, Department of Medicine, University of 
      British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Integrated
      Sciences, University of British Columbia, Vancouver, BC V6T 1Z2, Canada.
FAU - McDonald, Patrick J
AU  - McDonald PJ
AD  - Neuroethics Canada, Division of Neurology, Department of Medicine, University of 
      British Columbia, Vancouver, BC V6T 2B5, Canada; Division of Neurosurgery,
      Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4,
      Canada.
FAU - Illes, Judy
AU  - Illes J
AD  - Neuroethics Canada, Division of Neurology, Department of Medicine, University of 
      British Columbia, Vancouver, BC V6T 2B5, Canada. Electronic address:
      jilles@mail.ubc.ca.
LA  - eng
GR  - RF1 MH117805/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200613
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
SB  - IM
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Deep Brain Stimulation/*trends
MH  - Epilepsy/epidemiology/*therapy
MH  - Female
MH  - Health Literacy/methods/*trends
MH  - Health Policy/*trends
MH  - Humans
MH  - Male
MH  - Mass Media/*trends
MH  - Vagus Nerve Stimulation/methods/*trends
PMC - PMC7541585
MID - NIHMS1598884
OTO - NOTNLM
OT  - *Ablation
OT  - *Content analysis
OT  - *Drug-resistant epilepsy
OT  - *Media
OT  - *Neuromodulation
OT  - *Neurotechnology
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/06/17 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/05/24 00:00 [revised]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - S1525-5050(20)30379-6 [pii]
AID - 10.1016/j.yebeh.2020.107200 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2020 Oct;111:107200. doi: 10.1016/j.yebeh.2020.107200. Epub 2020 
      Jun 13.


PMID- 32544539
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Linking)
VI  - 116
DP  - 2020 Sep
TI  - The efficacy, ethics, & pitfalls of stimulants for justice system involved
      individuals.
PG  - 120-129
LID - S0149-7634(20)30430-9 [pii]
LID - 10.1016/j.neubiorev.2020.06.003 [doi]
AB  - Incarceration rates in the U.S. rank among the highest in the developed world.
      Large representative studies have revealed that approximately one third of
      individuals report having been arrested, or in some other way contacted by the
      justice system, at some point in their life. A natural outgrowth of this is the
      need to consider strategies aimed at preventing further CJ contact. Complicating 
      the situation further is that incarcerated populations also report
      disproportionately high levels of both psychiatric disturbances in general, and
      ADHD symptomology in particular. Thus, much debate remains around the topic of
      preventing recidivism. We discuss the possibility of incorporating
      pharmacological interventions as adjuvant therapies directed toward preventing
      re-offending. In particular, we explore whether stimulant medications might
      provide additional return on investment on top of therapies already known to be
      effective. Given the virtual absence of evidence on this topic, we also endeavor 
      to provide specific recommendations for designing studies that could yield
      convincing evidence either for, or against, the inclusion of stimulant
      medications in the recidivism prevention toolkit.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Boutwell, Brian B
AU  - Boutwell BB
AD  - The University of Mississippi, University of Mississippi Medical Center, United
      States. Electronic address: bbboutwe@olemiss.edu.
FAU - Kavish, Nicholas
AU  - Kavish N
AD  - Sam Houston State University, United States.
FAU - Narvey, Chelsey
AU  - Narvey C
AD  - Sam Houston State University, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200613
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 0 (Central Nervous System Stimulants)
SB  - IM
MH  - *Attention Deficit Disorder with Hyperactivity/drug therapy
MH  - *Central Nervous System Stimulants/therapeutic use
MH  - Humans
OTO - NOTNLM
OT  - *ADHD
OT  - *Cognitive behavioral therapy
OT  - *Recidivism
OT  - *Stimulants
EDAT- 2020/06/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - S0149-7634(20)30430-9 [pii]
AID - 10.1016/j.neubiorev.2020.06.003 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2020 Sep;116:120-129. doi:
      10.1016/j.neubiorev.2020.06.003. Epub 2020 Jun 13.


PMID- 32544492
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20210110
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 158
IP  - 5
DP  - 2020 Nov
TI  - Lessons on Outbreak Preparedness From the Cleveland Clinic.
PG  - 2090-2096
LID - S0012-3692(20)31673-1 [pii]
LID - 10.1016/j.chest.2020.06.009 [doi]
AB  - Disasters, including infectious disease outbreaks, are inevitable. Hospitals need
      to plan in advance to ensure that their systems can adapt to a rapidly changing
      environment if necessary. This review provides an overview of 10 general
      principles that hospitals and health-care systems should consider when developing
      disaster plans. The principles are consistent with an "all-hazards" approach to
      disaster mitigation. This approach is adapted to planning for a multiplicity of
      threats but emphasizes highly relevant scenarios, such as the coronavirus disease
      2019 pandemic. We also describe specific ways these principles helped prepare our
      hospital for this pandemic. Key points include acting quickly, identifying and
      engaging key stakeholders early, providing accurate information, prioritizing
      employee safety and mental health, promoting a fully integrated clinical
      response, developing surge plans, preparing for ethical dilemmas, and having a
      cogent exit strategy for post-disaster recovery.
CI  - Copyright (c) 2020 American College of Chest Physicians. Published by Elsevier
      Inc. All rights reserved.
FAU - Orsini, Erica
AU  - Orsini E
AD  - Cleveland Clinic, Respiratory Institute, Cleveland, OH. Electronic address:
      orsinie@ccf.org.
FAU - Mireles-Cabodevila, Eduardo
AU  - Mireles-Cabodevila E
AD  - Cleveland Clinic, Respiratory Institute, Cleveland, OH.
FAU - Ashton, Rendell
AU  - Ashton R
AD  - Cleveland Clinic, Respiratory Institute, Cleveland, OH.
FAU - Khouli, Hassan
AU  - Khouli H
AD  - Cleveland Clinic, Respiratory Institute, Cleveland, OH.
FAU - Chaisson, Neal
AU  - Chaisson N
AD  - Cleveland Clinic, Respiratory Institute, Cleveland, OH.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200613
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communication
MH  - Cooperative Behavior
MH  - Coronavirus Infections/*epidemiology
MH  - Creativity
MH  - *Disaster Planning
MH  - Disease Outbreaks
MH  - *Equipment and Supplies
MH  - *Ethics
MH  - *Health Personnel
MH  - Health Services Needs and Demand
MH  - Humans
MH  - *Mental Health
MH  - *Occupational Health
MH  - Pandemics
MH  - Personal Protective Equipment/supply & distribution
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - *Stakeholder Participation
MH  - Surge Capacity
PMC - PMC7293446
OTO - NOTNLM
OT  - *review
OT  - *stress
OT  - *topics in practice management
OT  - *viral disease
EDAT- 2020/06/17 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/06/03 00:00 [revised]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - S0012-3692(20)31673-1 [pii]
AID - 10.1016/j.chest.2020.06.009 [doi]
PST - ppublish
SO  - Chest. 2020 Nov;158(5):2090-2096. doi: 10.1016/j.chest.2020.06.009. Epub 2020 Jun
      13.


PMID- 32544348
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Oct
TI  - Relationship among factors affecting research misconduct in medical sciences in
      Iran.
PG  - 417-443
LID - 10.1080/08989621.2020.1766977 [doi]
AB  - This study aims to determine the relationship among factors affecting research
      misconduct within the research system of medical sciences in Iran. Using
      phenomenography, the perceptions of individuals involved in the activities of
      macro, meso, and micro levels of the research system were investigated and 13
      affecting factors were identified. The DEMATEL method revealed complicated and
      intertwined relationships among these factors based on the experts' judgment.
      Most of the macro and meso factors were in the cause group and most of the micro 
      factors were in the effect group. The results showed that critical factors such
      as "Monitoring and dealing with research misconduct," "Transparency in research,"
      "Management of journals" and "Ethical considerations in the publication of
      research results" escalate research misconduct. The study indicated that track
      the relationship among factors in the research system can provide the opportunity
      to explain research misconduct on a transitional path from macro to micro level.
FAU - Mardani, Amirhossein
AU  - Mardani A
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences , Tehran, Iran.
AD  - Faculty of Management, University of Tehran , Tehran, Iran.
FAU - Nakhoda, Maryam
AU  - Nakhoda M
AD  - Department of Information Science & Knowledge Study, Faculty of Management,
      University of Tehran , Tehran, Iran.
FAU - Shamsi Gooshki, Ehsan
AU  - Shamsi Gooshki E
AD  - Department of Medical Ethics, Faculty of Medicine & Medical Ethics and History of
      Medicine Research Center, Tehran University of Medical Sciences , Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Biomedical Research/*ethics/standards
MH  - Guidelines as Topic
MH  - Humans
MH  - Interviews as Topic
MH  - Iran
MH  - Organizational Culture
MH  - Periodicals as Topic/standards
MH  - Policy
MH  - Qualitative Research
MH  - Research Personnel/*psychology/standards
MH  - Resource Allocation
MH  - Scientific Misconduct/*psychology
OTO - NOTNLM
OT  - *Iran
OT  - *Research misconduct
OT  - *medical research
OT  - *research system
EDAT- 2020/06/17 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1080/08989621.2020.1766977 [doi]
PST - ppublish
SO  - Account Res. 2020 Oct;27(7):417-443. doi: 10.1080/08989621.2020.1766977. Epub
      2020 Jun 16.


PMID- 32544291
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20201229
IS  - 1099-1611 (Electronic)
IS  - 1057-9249 (Linking)
VI  - 29
IP  - 10
DP  - 2020 Oct
TI  - Advanced cancer patient preferences for receiving molecular profiling results.
PG  - 1533-1539
LID - 10.1002/pon.5446 [doi]
AB  - OBJECTIVE: This study aimed to discern preferences for receiving somatic
      molecular profiling (MP) results in cancer patients who have given consent to
      undergo testing. METHODS: We conducted a mixed-methods study to explore patients'
      views on which MP results they would like to receive and why. Advanced cancer
      patients (n = 1299) completed questionnaires after giving consent to participate 
      in a parent genomics study and undergoing MP. A subset of patients (n = 20)
      participated in qualitative interviews. RESULTS: Almost all (96%) participants
      were interested in receiving results which would direct cancer treatment (ie,
      were actionable). A smaller majority wanted to access results which were not
      actionable (64%) or were variants of unknown significance (60%). Most (86%) were 
      interested in finding out about germline findings, though not as a priority.
      Themes identified in interview data were: (a) Cancer is the focus; (b) Trust in
      clinicians; and (c) Respect for a right not to know. CONCLUSIONS: The majority of
      advanced cancer patients undergoing MP prioritised results which would lead to
      treatment options. They trusted their oncologists to help them navigate the
      results return process. While there was interest in knowing about other results, 
      this was a lesser priority. Nevertheless, given high levels of interest in
      receiving all results, ethical aspects of not providing uninformative results
      requires further research, including a consideration of patient rationales for
      desiring this information and what health professionals can and should do to
      support patients in the absence of meaningful information being available.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Best, Megan
AU  - Best M
AUID- ORCID: 0000-0003-1570-8872
AD  - The University of Notre Dame, Sydney, NSW, 2007, Australia.
AD  - School of Psychology, Faculty of Science, The University of Sydney, Sydney, New
      South Wales, Australia.
FAU - Butow, Phyllis
AU  - Butow P
AUID- ORCID: 0000-0003-3562-6954
AD  - Centre for Medical Psychology & Evidence-Based Decision-Making, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Jacobs, Chris
AU  - Jacobs C
AD  - University of Technology Sydney, Sydney, New South Wales, Australia.
FAU - Juraskova, Ilona
AU  - Juraskova I
AUID- ORCID: 0000-0001-9396-4113
AD  - Centre for Medical Psychology & Evidence-Based Decision-Making, The University of
      Sydney, Sydney, New South Wales, Australia.
FAU - Savard, Jacqueline
AU  - Savard J
AUID- ORCID: 0000-0002-7965-6103
AD  - Deakin University, Geelong, Victoria, Australia.
FAU - Meiser, Bettina
AU  - Meiser B
AUID- ORCID: 0000-0002-5086-0784
AD  - University of NSW, Sydney, New South Wales, Australia.
FAU - Goldstein, David
AU  - Goldstein D
AUID- ORCID: 0000-0001-6142-3291
AD  - Department of Medical Oncology, Prince of Wales Hospital Cancer Services,
      Randwick, New South Wales, Australia.
FAU - Ballinger, Mandy
AU  - Ballinger M
AUID- ORCID: 0000-0002-9706-0514
AD  - Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
FAU - Bartley, Nicci
AU  - Bartley N
AUID- ORCID: 0000-0001-9052-1616
AD  - The University of Notre Dame, Sydney, NSW, 2007, Australia.
FAU - Napier, Christine
AU  - Napier C
AUID- ORCID: 0000-0001-8009-7735
AD  - Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
FAU - Davies, Grace
AU  - Davies G
AUID- ORCID: 0000-0001-7867-3780
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Thomas, David
AU  - Thomas D
AUID- ORCID: 0000-0002-2527-5428
AD  - Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
FAU - Tucker, Kathy
AU  - Tucker K
AD  - Hereditary Cancer Clinic, Prince of Wales Hospital and Community Health Services,
      Sydney, New South Wales, Australia.
FAU - Schlub, Timothy
AU  - Schlub T
AUID- ORCID: 0000-0001-7746-9649
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Newson, Ainsley J
AU  - Newson AJ
AUID- ORCID: 0000-0002-3460-772X
AD  - School of Public Health, University of Sydney, Sydney, New South Wales,
      Australia.
CN  - PiGeOn Project
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200811
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
SB  - IM
MH  - Adult
MH  - *Bioethics
MH  - Female
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms/*pathology
MH  - Pathology, Molecular/ethics/*statistics & numerical data
MH  - Patient Preference/*psychology
MH  - Precision Medicine
MH  - Qualitative Research
MH  - Surveys and Questionnaires
MH  - Trust
OTO - NOTNLM
OT  - *attitudes
OT  - *bioethics
OT  - *cancer
OT  - *genetic testing
OT  - *molecular profiling
OT  - *oncology
OT  - *patient preference
OT  - *personalised medicine
OT  - *qualitative research
OT  - *results
EDAT- 2020/06/17 06:00
MHDA- 2020/12/30 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1002/pon.5446 [doi]
PST - ppublish
SO  - Psychooncology. 2020 Oct;29(10):1533-1539. doi: 10.1002/pon.5446. Epub 2020 Aug
      11.


PMID- 32544150
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20201218
IS  - 0717-6384 (Electronic)
IS  - 0717-6384 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Jun 16
TI  - Ethical allocation of scarce health care resources in the context of the COVID-19
      crisis.
PG  - e7935
LID - 10.5867/medwave.2020.05.7935 [doi]
AB  - The current COVID-19 pandemic has the potential to overwhelm the capacity of
      hospitals and Intensive Care Units in Chile and Latin America. Thus local
      authorities have an ethical obligation to be prepared by implementing pertinent
      measures to prevent a situation of rationing of scarce healthcare resources, and 
      by defining ethically acceptable and socially legitimate criteria for the
      allocation of these resources. This paper responds to recent ethical guidelines
      issued by a Chilean academic institution and discusses the main moral principles 
      for the ethical foundations of criteria for rationing during the present crisis. 
      It argues that under exceptional circumstances such as the current pandemic, the 
      traditional patient-centered morality of medicine needs to be balanced with
      ethical principles formulated from a public health perspective, including the
      principles of social utility, social justice and equity, among others. The paper 
      concludes with some recommendations regarding how to reach an agreement about
      rationing criteria and about their implementation in clinical practice.
FAU - Aguilera, Bernardo
AU  - Aguilera B
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      United States; Departamento de Bioetica y Humanidades Medicas, Facultad de
      Medicina, Universidad de Chile, Santiago, Chile. Address: Department of
      Bioethics, National Institutes of Health, 10 Center Drive, Building 10, Room
      1C118, Bethesda, MD 20892-1156, United States. Email: bernardo.aguilera@nih.gov. 
      ORCID: 0000-0003-2409-8324.
LA  - spa
LA  - eng
PT  - Journal Article
TT  - Asignacion etica de recursos sanitarios escasos en el contexto de crisis por
      COVID-19.
DEP - 20200616
PL  - Chile
TA  - Medwave
JT  - Medwave
JID - 101581949
SB  - IM
MH  - COVID-19
MH  - Chile
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Guidelines as Topic
MH  - Health Care Rationing/*ethics
MH  - Hospitals/ethics/statistics & numerical data
MH  - Humans
MH  - Intensive Care Units/ethics/statistics & numerical data
MH  - Latin America
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Public Health/*ethics
MH  - Social Justice
MH  - Surge Capacity/*statistics & numerical data
OTO - NOTNLM
OT  - chile
OT  - public health
OT  - resource allocation
OT  - social justice
OT  - COVID-19
OT  - pandemics
EDAT- 2020/06/17 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - e7935 [pii]
AID - 10.5867/medwave.2020.05.7935 [doi]
PST - epublish
SO  - Medwave. 2020 Jun 16;20(5):e7935. doi: 10.5867/medwave.2020.05.7935.


PMID- 32544044
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 1195-9479 (Print)
IS  - 1195-9479 (Linking)
VI  - 27
IP  - 3
DP  - 2020 Jun
TI  - Prospective evaluation of the value of dynamic contrast enhanced (DCE) imaging
      for prostate cancer detection, with pathology correlation.
PG  - 10220-10227
AB  - INTRODUCTION: The aim of this study was to evaluate the value of dynamic contrast
      enhanced (DCE) imaging in multi-parametric prostate MRI (mpMRI) for the detection
      and staging of prostate cancer in comparison with T2W and DWI images alone in
      biparametric MRI (bpMRI) in treatment naive patients. MATERIALS AND METHODS: One 
      hundred consecutive patients who underwent a prostate MRI at our institution from
      June-August 2017, as well as a systematic ultrasound-guided prostate biopsy or
      prostatectomy, were included. Strictly following PIRADSv2, the MRI studies were
      independently interpreted by a body radiologist and a body-imaging fellow on two 
      different occasions 8-10 weeks apart. Initially, with all mpMRI sequences and
      then without the DCE sequence (bpMRI). The readers were blinded to the clinical
      information. Ethics approval was obtained. RESULTS: One hundred treatment-naive
      patients were included (median age 64, age range 48-81, mean PSA 10.3). There was
      almost perfect intra-observer agreement for mpMRI versus bpMRI for both readers
      [Cohen's Kappa (k) 0.88-0.86] and substantial inter-observer agreement (k = 0.74 
      for mpMRI and 0.76 for bpMRI). The sensitivity and specificity did not
      significantly change between multi-parametric and bi-parametric MRI (Sensitivity 
      91.7% and 90%, Specificity of 85.5% and 85% for mpMRI and bpMRI, respectively).
      CONCLUSION: Based on our findings, prostate MRI without DCE (bpMRI) is of
      comparable diagnostic accuracy to mpMRI in treatment-naive patients. Performing
      prostate MRI without DCE (bpMRI) will reduce acquisition time, decrease cost and 
      potentially improve patient safety.
FAU - Al Salmi, Ishaq
AU  - Al Salmi I
AD  - Department of Radiology, St. Joseph's Healthcare Hamilton, Hamilton, Ontario,
      Canada.
FAU - Menezes, Terence
AU  - Menezes T
FAU - El-Khodary, Mohamed
AU  - El-Khodary M
FAU - Monteiro, Sandra
AU  - Monteiro S
FAU - Haider, Ehsan A
AU  - Haider EA
FAU - Alabousi, Abdullah
AU  - Alabousi A
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Urol
JT  - The Canadian journal of urology
JID - 9515842
RN  - 0 (Contrast Media)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Contrast Media
MH  - Correlation of Data
MH  - Humans
MH  - Image-Guided Biopsy
MH  - Male
MH  - Middle Aged
MH  - Multiparametric Magnetic Resonance Imaging/*methods
MH  - Prospective Studies
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*diagnostic imaging/*pathology/surgery
EDAT- 2020/06/17 06:00
MHDA- 2021/04/23 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PST - ppublish
SO  - Can J Urol. 2020 Jun;27(3):10220-10227.


PMID- 32544036
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 1527-1315 (Electronic)
IS  - 0033-8419 (Linking)
VI  - 296
IP  - 2
DP  - 2020 Aug
TI  - Distal Femoral Cortical Irregularity at Knee MRI: Increased Prevalence in Youth
      Competitive Alpine Skiers.
PG  - 411-419
LID - 10.1148/radiol.2020192589 [doi]
AB  - Background Tumor-like cortical irregularities at the posterior distal femur are
      common incidental findings in adolescents, but the origin of these irregularities
      is debated. Purpose To compare the prevalence of distal femoral cortical
      irregularities (DFCIs) at different tendon attachment sites in youth competitive 
      alpine skiers with that in young adults. Materials and Methods In this secondary 
      analysis of a prospective trial, unenhanced 3-T knee MRI scans obtained in youth 
      competitive alpine skiers were compared with images in control participants of
      the same age from 2014 to 2019 (Cantonal Ethics Committee Zurich registry number:
      KEK-ZH-2017-01395) for presence of DFCIs at the femoral attachment of the medial 
      head of the gastrocnemius muscle (MHG) and/or lateral head of the gastrocnemius
      muscle (LHG) and adductor magnus tendon by two radiologists. DFCI size and tendon
      attachment position were measured. Tendon attachment position and associated MRI 
      findings (meniscus, cartilage, bone marrow edema, joint effusion, ligaments,
      tendons) were examined for an association with DFCI. Pearson chi(2), Student t
      test, logistic regression, and kappa statistics were applied. Results Unilateral 
      knee MRI scans obtained in 105 skiers (mean age, 14.8 years +/- 0.6 [standard
      deviation]; 66 boys) and in 105 control participants (mean age, 14.6 years +/-
      0.5; 59 boys) were evaluated. DFCIs were found in 61 of 105 skiers (58%; 95%
      confidence interval [CI]: 48.5%, 67.2%) compared with 28 of 105 control
      participants (27%; 95% CI: 18.9%, 35.7%) (P < .001). Two skiers had more than one
      DFCI. Distribution of DFCIs for skiers and control participants was 60 of 63
      (95.2%) and 26 of 28 (92.8%) at the MHG, three of 63 (4.8%) and one of 28 (3.6%) 
      at the LHG, and zero of 63 (0%) and one of 28 (3.6%) at the adductor magnus
      attachment site, respectively. Interreader agreement was almost perfect (kappa = 
      0.87; 95% CI: 0.80, 0.93). The mean size of MHG-related DFCIs in skiers (3.7 mm) 
      was not different compared to the size of those in control participants (3.4 mm) 
      (P = .32), nor was a difference found for the MHG tendon attachment position in
      knees with DFCI (63.9 mm vs 63.0 mm, P = .83) or without DFCI (63.6 mm vs 62.8
      mm, P = .86). Regarding associated MRI findings, increased signal intensity of
      the MHG tendon showed a significant association with MHG-related DFCI in both
      groups (P = .01 for both). Conclusion A distal femoral cortical irregularity at
      the attachment sites of tendons was a frequent incidental finding on knee MRI
      scans, with an increased prevalence in youth competitive alpine skiers. (c) RSNA,
      2020 Online supplemental material is available for this article.
FAU - Stern, Christoph
AU  - Stern C
AUID- ORCID: 0000-0003-2833-5753
AD  - From the Department of Radiology (C.S., J.G., R.S.), Sports Medical Research
      Group, Department of Orthopedics (S.F., L.P., J.S.), and University Centre for
      Prevention and Sports Medicine (S.F., L.P., J.S.), Balgrist University Hospital, 
      Forchstrasse 340, CH-8008, Zurich, Switzerland; and Faculty of Medicine,
      University of Zurich, Zurich, Switzerland (C.S., J.G., R.S.).
FAU - Galley, Julien
AU  - Galley J
AD  - From the Department of Radiology (C.S., J.G., R.S.), Sports Medical Research
      Group, Department of Orthopedics (S.F., L.P., J.S.), and University Centre for
      Prevention and Sports Medicine (S.F., L.P., J.S.), Balgrist University Hospital, 
      Forchstrasse 340, CH-8008, Zurich, Switzerland; and Faculty of Medicine,
      University of Zurich, Zurich, Switzerland (C.S., J.G., R.S.).
FAU - Frohlich, Stefan
AU  - Frohlich S
AUID- ORCID: 0000-0001-7187-2074
AD  - From the Department of Radiology (C.S., J.G., R.S.), Sports Medical Research
      Group, Department of Orthopedics (S.F., L.P., J.S.), and University Centre for
      Prevention and Sports Medicine (S.F., L.P., J.S.), Balgrist University Hospital, 
      Forchstrasse 340, CH-8008, Zurich, Switzerland; and Faculty of Medicine,
      University of Zurich, Zurich, Switzerland (C.S., J.G., R.S.).
FAU - Peterhans, Loris
AU  - Peterhans L
AUID- ORCID: 0000-0002-3274-0527
AD  - From the Department of Radiology (C.S., J.G., R.S.), Sports Medical Research
      Group, Department of Orthopedics (S.F., L.P., J.S.), and University Centre for
      Prevention and Sports Medicine (S.F., L.P., J.S.), Balgrist University Hospital, 
      Forchstrasse 340, CH-8008, Zurich, Switzerland; and Faculty of Medicine,
      University of Zurich, Zurich, Switzerland (C.S., J.G., R.S.).
FAU - Sporri, Jorg
AU  - Sporri J
AUID- ORCID: 0000-0002-0353-1021
AD  - From the Department of Radiology (C.S., J.G., R.S.), Sports Medical Research
      Group, Department of Orthopedics (S.F., L.P., J.S.), and University Centre for
      Prevention and Sports Medicine (S.F., L.P., J.S.), Balgrist University Hospital, 
      Forchstrasse 340, CH-8008, Zurich, Switzerland; and Faculty of Medicine,
      University of Zurich, Zurich, Switzerland (C.S., J.G., R.S.).
FAU - Sutter, Reto
AU  - Sutter R
AUID- ORCID: 0000-0001-6355-9838
AD  - From the Department of Radiology (C.S., J.G., R.S.), Sports Medical Research
      Group, Department of Orthopedics (S.F., L.P., J.S.), and University Centre for
      Prevention and Sports Medicine (S.F., L.P., J.S.), Balgrist University Hospital, 
      Forchstrasse 340, CH-8008, Zurich, Switzerland; and Faculty of Medicine,
      University of Zurich, Zurich, Switzerland (C.S., J.G., R.S.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
SB  - IM
MH  - Adolescent
MH  - Athletes
MH  - Cortical Bone/diagnostic imaging/pathology
MH  - Female
MH  - *Femur/diagnostic imaging/pathology
MH  - Humans
MH  - Knee Injuries/diagnostic imaging/pathology
MH  - *Knee Joint/diagnostic imaging/pathology
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Muscle, Skeletal/diagnostic imaging
MH  - Retrospective Studies
MH  - Skiing/*physiology
MH  - Tendons/diagnostic imaging
EDAT- 2020/06/17 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1148/radiol.2020192589 [doi]
PST - ppublish
SO  - Radiology. 2020 Aug;296(2):411-419. doi: 10.1148/radiol.2020192589. Epub 2020 Jun
      16.


PMID- 32543757
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20220716
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 33
IP  - 6
DP  - 2020 Nov
TI  - Dermatological findings in SARS-CoV-2 positive patients: An observational study
      from North India.
PG  - e13849
LID - 10.1111/dth.13849 [doi]
AB  - A novel coronavirus (severe acute respiratory syndrome corononavirus-2;
      SARS-CoV-2) has affected millions of people across the world. The coronavirus
      disease (COVID-19) resulting from SARS-CoV-2 manifests in variable clinical
      severity, featuring both respiratory and extra-respiratory symptoms.
      Dermatological manifestations of COVID-19 are sparsely reported. To study the
      various dermatological findings in SARS-CoV-2 positive patients in Indian
      population. Institutional ethical committee permission was sought and102
      SARS-CoV-2 positive patients were included in the study. A thorough clinical
      examination was done to determine the nature and frequency of various
      dermatological manifestations in these patients. Out of the 102 positive cases,
      95 were males. The mean age of the group was 39.30 years. Thirteen patients
      (12.7%) were found to have dermatological manifestations. Three (2.9%) had
      maculopapular rash, two (1.9%) had urticarial lesions and eight (7.8%) patients
      had itching without any specific cutaneous signs. Trunk was the most frequently
      affected area, followed by the extremities. No mucosal signs and symptoms were
      detected. Dermatological manifestations were seen in a small group of COVID-19
      patients. The presentation may vary in different population groups and based on
      severity of disease.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Dalal, Ashish
AU  - Dalal A
AD  - Department of Dermatology, Saheed Hasan Khan Mewati Government Medical College
      and Hospital, Nuh, India.
FAU - Jakhar, Deepak
AU  - Jakhar D
AUID- ORCID: 0000-0002-5516-8295
AD  - Department of Dermatology & STD, North Delhi Municipal Corporation Medical
      College & Hindu Rao Hospital, New Delhi, India.
FAU - Agarwal, Vishal
AU  - Agarwal V
AD  - Department of Dermatology, Saheed Hasan Khan Mewati Government Medical College
      and Hospital, Nuh, India.
FAU - Beniwal, Ravi
AU  - Beniwal R
AD  - Department of Dermatology, Saheed Hasan Khan Mewati Government Medical College
      and Hospital, Nuh, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200706
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged, 80 and over
MH  - COVID-19/*complications
MH  - Female
MH  - Humans
MH  - India
MH  - Male
MH  - Middle Aged
MH  - SARS-CoV-2/isolation & purification
MH  - Severity of Illness Index
MH  - Skin Diseases, Viral/epidemiology/*physiopathology/virology
MH  - Young Adult
PMC - PMC7323049
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *cutaneous manifestation
OT  - *dermatology
OT  - *skin
EDAT- 2020/06/17 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/03 00:00 [received]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/06/13 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1111/dth.13849 [doi]
PST - ppublish
SO  - Dermatol Ther. 2020 Nov;33(6):e13849. doi: 10.1111/dth.13849. Epub 2020 Jul 6.


PMID- 32543231
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20210813
IS  - 1473-0804 (Electronic)
IS  - 1369-7137 (Linking)
VI  - 23
IP  - 6
DP  - 2020 Dec
TI  - An extended Menopause Rating Scale II: a retrospective data analysis.
PG  - 608-613
LID - 10.1080/13697137.2020.1775808 [doi]
AB  - OBJECTIVE: This study aims to discuss a statistically reasonable inclusion of
      additional questions in the Menopause Rating Scale II (MRS II) for daily use in
      clinical practice. METHODS: Retrospective data analysis was performed (cantonal
      ethics committee No. 2016-01179). The MRS II was extended with the parameters
      'changes in weight', 'headaches', 'skin changes', 'changes in hair growth', 'hair
      loss', and whether therapy was desired. Data from 419 women seeking medical
      advice in our menopause center were collected between April 2009 and April 2017. 
      Cronbach's alpha was used to measure internal consistency of the extended
      questionnaire. RESULTS: For the conventional MRS II (N = 340 of 419, 81.1%), the 
      internal consistency measured with Cronbach's alpha increased from 0.805 to 0.820
      considering 'changes in weight' (N = 237, 56.6%), to 0.815 considering
      'headaches' (N = 247, 58.9%), and to 0.815 considering 'skin changes' (N = 236,
      56.3%) if these additional parameters were added separately. Cronbach's alpha
      increased from 0.805 to 0.835 (N = 224, 53.5%) if these parameters were added at 
      once. Desire for therapy varied between 42.1% for 'changes in hair growth' (N =
      38, 9.1%) and 60.6% for 'hair loss' (N = 33, 7.9%). CONCLUSION: We suggest
      including the items 'changes in weight', 'headaches', and 'skin changes' in the
      MRS II as our results show even higher internal consistency with these symptoms
      and as the wish for therapy was high.
FAU - Honermann, L
AU  - Honermann L
AD  - Department of Obstetrics and Gynecology, University of Bern, Bern, Switzerland.
FAU - Knabben, L
AU  - Knabben L
AD  - Department of Obstetrics and Gynecology, University of Bern, Bern, Switzerland.
FAU - Weidlinger, S
AU  - Weidlinger S
AD  - Department of Obstetrics and Gynecology, University of Bern, Bern, Switzerland.
FAU - Bitterlich, N
AU  - Bitterlich N
AD  - Medizin and Service GmbH, Chemnitz, Germany.
FAU - Stute, P
AU  - Stute P
AUID- ORCID: 0000-0002-5591-1552
AD  - Department of Obstetrics and Gynecology, University of Bern, Bern, Switzerland.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200616
PL  - England
TA  - Climacteric
JT  - Climacteric : the journal of the International Menopause Society
JID - 9810959
SB  - IM
MH  - Adult
MH  - Alopecia/diagnosis
MH  - Data Analysis
MH  - Decision Making
MH  - Estrogen Replacement Therapy/psychology
MH  - Female
MH  - Headache/diagnosis
MH  - *Health Status Indicators
MH  - Humans
MH  - *Menopause
MH  - Middle Aged
MH  - Patient Selection
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Skin Diseases/diagnosis
MH  - Surveys and Questionnaires/*standards
MH  - Symptom Assessment/methods/*standards
OTO - NOTNLM
OT  - *Menopause Rating Scale
OT  - *climacteric syndrome
OT  - *extended Menopause Rating Scale II
OT  - *menopausal hormone therapy
OT  - *menopause
EDAT- 2020/06/17 06:00
MHDA- 2021/08/14 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1080/13697137.2020.1775808 [doi]
PST - ppublish
SO  - Climacteric. 2020 Dec;23(6):608-613. doi: 10.1080/13697137.2020.1775808. Epub
      2020 Jun 16.


PMID- 32543229
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20201218
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Aug
TI  - Luxembourg's approach to research integrity during the COVID-19 pandemic.
PG  - 396-400
LID - 10.1080/08989621.2020.1778473 [doi]
AB  - The COVID-19 pandemic has accelerated the pace of research from its routine
      marathon to a sprint, and this can increase the risk of both human error
      (mistakes) as well as research misconduct. In an effort to save time, researchers
      can be tempted to "cut corners", discount ethical complexity, or use methods and 
      approaches that fall outside of good research practice. Ethically, it is vital
      that research outputs during a pandemic be robust because clinical
      decision-making may reflect on these research results. Luxembourg, while a small 
      European nation, is known for its well-ranked global research and innovation.
      Accordingly, Luxembourg's national organization for research integrity has taken 
      several proactive measures to help researchers nationally and globally, foster
      robust research. This paper reports on these measures and encourages other
      nations to similarly assist the research community.
FAU - Bramstedt, Katrina A
AU  - Bramstedt KA
AD  - Secretary General and Bioethicist, Bioethicist, Luxembourg Agency for Research
      Integrity (LARI) , Esch-sur-Alzette, Luxembourg.
AD  - Adjunct Professor, Bond University Medical Program, Gold Coast , Queensland,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200616
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics/*standards
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Luxembourg
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Reproducibility of Results
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *COVID-19
OT  - *bioethics
OT  - *pandemic
OT  - *research ethics
OT  - *research integrity
EDAT- 2020/06/17 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1080/08989621.2020.1778473 [doi]
PST - ppublish
SO  - Account Res. 2020 Aug;27(6):396-400. doi: 10.1080/08989621.2020.1778473. Epub
      2020 Jun 16.


PMID- 32542854
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 74
IP  - 8
DP  - 2020 Aug
TI  - Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms
      (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised
      controlled study.
PG  - e13530
LID - 10.1111/ijcp.13530 [doi]
AB  - INTRODUCTION & AIM: Several newer medications have emerged for the management of 
      lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). The 
      efficacy/safety of PDE-5 inhibitors (Tadalafil 5 mg) in BPH-lower urinary tract
      symptoms (LUTS) has been sparingly assessed in the published English literature
      as compared with their established role in erectile dysfunction. We aim to assess
      the efficacy/safety of tadalafil vs tamsulosin in symptomatic patients of BPH in 
      a tertiary care teaching institution. METHODS: After obtaining an informed
      written consent and institutional ethics clearance, 100 patients of BPH with an
      IPSS score of more than 7, without any complications of the disease were computer
      randomised to receive therapy with either tamsulosin 0.4 mg or tadalafil 5 mg
      once daily for a period of 2 months. They were evaluated for its efficacy (IPSS, 
      Peak flow rate, IIEF-5, quality of life index [QOL] and PVR) and safety (side
      effect profile) with monthly visit assessments for 2 months. Data were analysed
      statistically using ANOVA and unpaired t-tests.The protocol was registered with
      the CTRI/2018/03/012825. RESULTS: Patients in both groups were comparable on
      basis of their demographic data, renal function, PSA and baseline efficacy
      parameters. Significant improvements were visualised amongst/within both groups
      for IPSS, however the intergroup improvement was not significant (P = .096).
      Similar trends were seen with peak flow rate and PVR with intergroup improvement 
      differences not being significant (P = .552 and P = .131,
      respectively).Improvements in QOL index were more significant in the tamsulosin
      group (mean difference -2.3 vs -3.06 P = .010).The adverse effects were minor and
      were managed symptomatically without any drug discontinuity. CONCLUSIONS: In
      summary, therefore, we may conclude that that once daily monotherapy with
      tadalafil 5 mg or tamsulosin 0.4 mg was equally efficacious in the management of 
      moderate to severely bothersome LUTS in majority of patients as a result of BPH. 
      The role of Tadalafil monotherapy in BPH patients with predominant storage LUTS
      merits further evaluation with larger trials.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Singh, Iqbal
AU  - Singh I
AUID- ORCID: https://orcid.org/0000-0001-8743-3404
AD  - Department of Surgery (Urology), University College of Medical Sciences
      (University of Delhi) & GTB Hospital, Delhi, India.
FAU - Tk, Aravind
AU  - Tk A
AUID- ORCID: https://orcid.org/0000-0002-6501-5014
AD  - Department of Surgery (Urology), University College of Medical Sciences
      (University of Delhi) & GTB Hospital, Delhi, India.
FAU - Gupta, Sanjay
AU  - Gupta S
AD  - Department of Surgery (Urology), University College of Medical Sciences
      (University of Delhi) & GTB Hospital, Delhi, India.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200615
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
RN  - 0 (Urological Agents)
RN  - 742SXX0ICT (Tadalafil)
RN  - G3P28OML5I (Tamsulosin)
SB  - IM
MH  - Adrenergic alpha-1 Receptor Antagonists/*therapeutic use
MH  - Aged
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*drug therapy/etiology
MH  - Male
MH  - Middle Aged
MH  - Prostatic Hyperplasia/complications/*drug therapy/embryology
MH  - Quality of Life
MH  - Tadalafil/*therapeutic use
MH  - Tamsulosin/*therapeutic use
MH  - Treatment Outcome
MH  - Urological Agents/*therapeutic use
EDAT- 2020/06/17 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/02/13 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1111/ijcp.13530 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2020 Aug;74(8):e13530. doi: 10.1111/ijcp.13530. Epub 2020 Jun
      15.


PMID- 32542722
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Oct
TI  - Selecting participants fairly for controlled human infection studies.
PG  - 771-784
LID - 10.1111/bioe.12778 [doi]
AB  - Controlled human infection (CHI) studies involve the deliberate exposure of
      healthy research participants to infectious agents to study early disease
      processes and evaluate interventions under controlled conditions with high
      efficiency. Although CHI studies expose participants to the risk of infection,
      they are designed to offer investigators unique advantages for studying the
      pathogenesis of infectious diseases and testing potential vaccines or treatments 
      in humans. One of the central challenges facing investigators involves the fair
      selection of research subjects to participate in CHI studies. While there is
      widespread agreement that investigators have a duty to select research
      participants fairly, this principle also yields conflicting ethical imperatives, 
      for example requiring investigators to both exclude potential participants with
      co-morbidities since they face increased risks, but also to include them in order
      to ensure generalizability. In this paper we defend an account of fair subject
      selection that is tailored to the context of CHI studies. We identify the
      considerations of fairness that bear directly on selecting participants for CHI
      studies and provide investigators and members of IRBs and RECs with a principled 
      way to navigate the conflicting imperatives to which these considerations give
      rise.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - MacKay, Douglas
AU  - MacKay D
AUID- ORCID: 0000-0002-6465-237X
AD  - University of North Carolina, Dept. of Public Policy, Chapel Hill, North
      Carolina, USA.
FAU - Jecker, Nancy S
AU  - Jecker NS
AUID- ORCID: 0000-0002-5642-748X
AD  - University of Washington School of Medicine, Dept. of Bioethics & Humanities,
      Seattle, Washington, USA.
FAU - Pitisuttithum, Punnee
AU  - Pitisuttithum P
AUID- ORCID: 0000-0003-3215-2183
AD  - Mahidol University Faculty of Tropical Medicine, Bangkok, Thailand.
FAU - Saylor, Katherine W
AU  - Saylor KW
AUID- ORCID: 0000-0002-7092-7739
AD  - University of North Carolina, Dept. of Public Policy, Chapel Hill, North
      Carolina, USA.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Patient Selection
MH  - *Research Design
MH  - Research Personnel
MH  - Research Subjects
OTO - NOTNLM
OT  - *challenge studies
OT  - *controlled human infection studies
OT  - *fair subject selection
OT  - *research ethics
EDAT- 2020/06/17 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/11/21 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1111/bioe.12778 [doi]
PST - ppublish
SO  - Bioethics. 2020 Oct;34(8):771-784. doi: 10.1111/bioe.12778. Epub 2020 Jun 15.


PMID- 32542622
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201120
IS  - 1439-3522 (Electronic)
IS  - 0720-4299 (Linking)
VI  - 88
IP  - 11
DP  - 2020 Nov
TI  - [Biobanking in Psychiatry].
PG  - 722-729
LID - 10.1055/a-0832-8766 [doi]
AB  - Medical biobanking is concerned with establishing and maintaining large-scale
      repositories of biological specimens combined with comprehensive archives of
      clinical and biographical information on donors. This aims for controlled high
      and consistent quality of specimens for future biomedical research. One major
      objective is to assemble multiple blood components for various types of
      biochemical analysis and experimentation including different isolated cell types.
      With proper cryo-conservation, blood-derived cells can be conserved and
      revitalized after thawing and employed as in-vitro cell models carrying specific 
      biological traits of donors. Optimizing pre-analytical methods can reduce
      pre-analytical variance thereby reducing imprecision of analytical data. This is 
      particularly valuable for multivariate analyses of biological systems ("omics")
      and biomarker research. Introducing biobanking to psychiatry carries the
      challenge of making diagnostic allocation more compatible with biological
      entities than is achieved with current diagnostic categories of ICD-10 or DSM-V. 
      Diagnostic or transdiagnostic subgroups can be stratified using biologically
      anchored clinical criteria. An important ethical issue of biobanking is the need 
      for broad consent by the donors for specimen use in not yet defined future
      research projects. The organizational, logistic and financial costs of
      establishing and maintaining a biobank are considerable, but seem well warranted 
      in view of the gainable advances in biomedical research quality, translations and
      clinical applications.
CI  - Thieme. All rights reserved.
FAU - Luckhaus, Christian
AU  - Luckhaus C
FAU - Roosterman, Dirk
AU  - Roosterman D
FAU - Juckel, Georg
AU  - Juckel G
LA  - ger
PT  - Journal Article
TT  - Biobanking in der Psychiatrie.
DEP - 20200615
PL  - Germany
TA  - Fortschr Neurol Psychiatr
JT  - Fortschritte der Neurologie-Psychiatrie
JID - 8103137
SB  - IM
MH  - *Biological Specimen Banks
MH  - *Biomedical Research
MH  - Humans
MH  - *Psychiatry
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/06/17 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1055/a-0832-8766 [doi]
PST - ppublish
SO  - Fortschr Neurol Psychiatr. 2020 Nov;88(11):722-729. doi: 10.1055/a-0832-8766.
      Epub 2020 Jun 15.


PMID- 32541939
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210615
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jun 15
TI  - Risk factors and mortality of patients undergoing hip fracture surgery: a
      one-year follow-up study.
PG  - 9607
LID - 10.1038/s41598-020-66614-5 [doi]
AB  - Hip fracture (HF) remains a main issue in the elderly patient. About 1.6 million 
      patients a year worldwide are victims of a HF. Their incidence is expected to
      rise with the aging of the world's population. Identifying risk factors is
      mandatory in order to reduce mortality and morbidity. The aim of the study was to
      identify risk factors of 1-year mortality after HF surgery. We performed an
      observational, prospective, single-center study at Amiens University Hospital
      (Amiens, France). After ethical approval, we consecutively included all patients 
      with a HF who underwent surgery between June 2016 and June 2017. Perioperative
      data were collected from medical charts and by interviews. Mortality rate at 12
      months was recorded. Univariate analysis was performed and mortality risk factors
      were investigated using a Cox model. 309 patients were analyzed during this
      follow-up. Mortality at 1 year was 23.9%. Time to surgery over 48 hours involved 
      181 patients (58.6%) while 128 patients (41.4%) had surgery within the 48 hours
      following the hospital admission. Independent factors associated with 1-year
      mortality were: age (HR at 1.059 (95%CI [1.005-1.116], p = 0,032), Lee score >/= 
      3 (HR at 1,52 (95% CI [1,052-2,198], p = 0.026) and time to surgery over 48 hours
      (HR of 1.057 (95% CI [1.007-1.108], p = 0.024). Age, delayed surgical (over 48
      hours) management and medical history are important risk factors of 1-year
      mortality in this French cohort.
FAU - Huette, Pierre
AU  - Huette P
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France. huette.pierre@gmail.com.
FAU - Abou-Arab, Osama
AU  - Abou-Arab O
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
FAU - Djebara, Az-Eddine
AU  - Djebara AE
AD  - Department of orthopedic surgery. Amiens University Hospital. F- 80054, Amiens,
      France.
FAU - Terrasi, Benjamin
AU  - Terrasi B
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
FAU - Beyls, Christophe
AU  - Beyls C
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
FAU - Guinot, Pierre-Gregoire
AU  - Guinot PG
AD  - Department of Anaesthesiology and Critical Care Medicine. Dijon University
      Hospital. F- 21000, Dijon, France.
FAU - Havet, Eric
AU  - Havet E
AD  - Department of orthopedic surgery. Amiens University Hospital. F- 80054, Amiens,
      France.
FAU - Dupont, Herve
AU  - Dupont H
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
FAU - Lorne, Emmanuel
AU  - Lorne E
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
FAU - Ntouba, Alexandre
AU  - Ntouba A
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
FAU - Mahjoub, Yazine
AU  - Mahjoub Y
AD  - Department of Anaesthesiology and Critical Care Medicine. Amiens University
      Hospital. F- 80054, Amiens, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200615
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - France/epidemiology
MH  - Hip Fractures/mortality/*surgery
MH  - Humans
MH  - Male
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Risk Factors
MH  - Time-to-Treatment/statistics & numerical data
PMC - PMC7296002
EDAT- 2020/06/17 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-66614-5 [doi]
AID - 10.1038/s41598-020-66614-5 [pii]
PST - epublish
SO  - Sci Rep. 2020 Jun 15;10(1):9607. doi: 10.1038/s41598-020-66614-5.


PMID- 32541528
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Dose-response of rPMS for upper Limb hemiparesis after stroke.
PG  - e20752
LID - 10.1097/MD.0000000000020752 [doi]
AB  - INTRODUCTION: Repetitive peripheral magnetic stimulation (rPMS) therapy is an
      innovative and minimally invasive neurorehabilitative technique and has been
      shown to facilitate neural plasticity. However, there is at present no research
      that clarifies the dose-response of rPMS therapy on the recovery of upper limb
      hemiparesis after stroke. This trial aims to clarify the dose-response of rPMS
      therapy combined with intensive occupational therapy (OT) for chronic stroke
      patients with moderate to severe upper limb hemiparesis. METHODS AND ANALYSIS:
      This multicenter, prospective, assessor-blinded, randomized controlled study with
      3 parallel groups will be conducted from January 20, 2020 to September 30, 2022. 
      Fifty patients will be randomly assigned in a ratio of 1:2:2 to the control
      group, the group receiving daily 2400 pulses of rPMS, or the group receiving
      daily 4800 pulses of rPMS, respectively. From the day after admission (Day 1),
      rPMS therapy and intensive OT will be initiated. The primary outcome is the
      change in the motor function of the affected upper extremity (Fugl-Meyer
      Assessment) between the time of admission (Day 0) and the day after 2 weeks of
      treatment (Day 14). Secondary outcomes will include the changes in spasticity,
      active range of motion, motor evoked potential, and activity of daily living.
      ETHICS AND DISSEMINATION: The study was approved by the Jikei University
      Certified Review Board for all institutions (reference number: JKI19-020).
      Results of the primary and secondary outcomes will be published in a
      peer-reviewed journal and presented at international congresses. The results will
      also be disseminated to patients. TRIAL REGISTRATION NUMBER: jRCTs032190191.
FAU - Kinoshita, Shoji
AU  - Kinoshita S
AD  - Department of Rehabilitation Medicine.
FAU - Ikeda, Kumi
AU  - Ikeda K
AD  - Department of Rehabilitation Medicine.
FAU - Yasuno, Shinji
AU  - Yasuno S
AD  - Clinical Research Support Center, The Jikei University School of Medicine,
      Minato-Ku, Tokyo, Japan.
FAU - Takahashi, Sho
AU  - Takahashi S
AD  - Clinical Research Support Center, The Jikei University School of Medicine,
      Minato-Ku, Tokyo, Japan.
FAU - Yamada, Naoki
AU  - Yamada N
AD  - Department of Rehabilitation Medicine.
FAU - Okuyama, Yumi
AU  - Okuyama Y
AD  - Department of Rehabilitation Medicine.
FAU - Sasaki, Nobuyuki
AU  - Sasaki N
AD  - Department of Rehabilitation Medicine.
FAU - Hada, Takuya
AU  - Hada T
AD  - Department of Rehabilitation Medicine.
FAU - Kuriyama, Chiaki
AU  - Kuriyama C
AD  - Department of Rehabilitation Medicine.
FAU - Suzuki, Shin
AU  - Suzuki S
AD  - Department of Rehabilitation Medicine.
FAU - Hama, Midori
AU  - Hama M
AD  - Department of Rehabilitation Medicine.
FAU - Ozaki, Naoto
AU  - Ozaki N
AD  - Department of Rehabilitation Medicine.
FAU - Watanabe, Shu
AU  - Watanabe S
AD  - Department of Rehabilitation Medicine.
FAU - Abo, Masahiro
AU  - Abo M
AD  - Department of Rehabilitation Medicine.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Combined Modality Therapy
MH  - Humans
MH  - Magnetic Field Therapy/*methods
MH  - Multicenter Studies as Topic
MH  - *Occupational Therapy
MH  - Paresis/etiology/*rehabilitation
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Single-Blind Method
MH  - Stroke/complications
MH  - Stroke Rehabilitation/*methods
MH  - *Upper Extremity
PMC - PMC7302622
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020752 [doi]
AID - 00005792-202006120-00084 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20752. doi:
      10.1097/MD.0000000000020752.


PMID- 32541518
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Efficacy of intra-articular polynucleotides associated with hyaluronic acid vs
      hyaluronic acid alone in the treatment of knee osteoarthritis: A systematic
      review and meta-analysis of randomized clinical trial.
PG  - e20689
LID - 10.1097/MD.0000000000020689 [doi]
AB  - BACKGROUND: The reduced range of motion and pain are the most characteristic
      clinical features of osteoarthritis (OA). Hyaluronic acid (HA), which is one of
      the infiltrative therapies for OA treatment, and polynucleotides (PNs), which is 
      a DNA-derived macromolecule favored cell growth and collagen production, are an
      ongoing debate in clinical effectiveness. METHODS: We plan to perform a
      systematic review and meta-analysis of randomized clinical trial to evaluate
      efficacy of intra-articular polynucleotides associated with hyaluronic acid
      versus hyaluronic acid alone in the treatment of knee osteoarthritis. We will
      search PubMed, EMBASE, Cochrane Library using a comprehensive strategy. The
      related conference proceedings and reference lists of the included studies will
      also be checked to identify additional studies. Two reviewers will screen
      retrieved records, extract information and assess the risk of bias independently.
      Stata v15.1 software will be used to conduct data synthesis. RESULTS: This study 
      will be submitted to a peer-reviewed journal for publication. CONCLUSION: We hope
      it will provide a relatively comprehensive reference for clinical practice and
      future relevant clinical trials. ETHICS AND DISSEMINATION: Ethics approval and
      patient consent are not required, as this study is a systematic review and
      meta-analysis. PROSPERO REGISTRATION NUMBER: CRD42020167678.
FAU - Zhang, Lei
AU  - Zhang L
AD  - The Third Department of Articular Bone, Gansu Provincial Hospital of Traditional 
      Chinese Medicine, Lanzhou, China.
FAU - Lei, Ningbo
AU  - Lei N
FAU - Chang, Ruilong
AU  - Chang R
FAU - Yang, Chenxu
AU  - Yang C
FAU - Li, Qiang
AU  - Li Q
FAU - Zuo, Ning
AU  - Zuo N
FAU - Gu, Yubiao
AU  - Gu Y
AUID- ORCID: 0000-0003-0138-2402
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0 (Polynucleotides)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
EIN - Medicine (Baltimore). 2020 Aug 14;99(33):e21984. PMID: 32872085
MH  - Arthralgia/*drug therapy
MH  - Drug Combinations
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage
MH  - Injections, Intra-Articular
MH  - *Meta-Analysis as Topic
MH  - Osteoarthritis, Knee/*complications
MH  - Polynucleotides/*administration & dosage
MH  - Randomized Controlled Trials as Topic/*methods
MH  - *Research Design
MH  - *Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7302631
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020689 [doi]
AID - 00005792-202006120-00074 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20689. doi:
      10.1097/MD.0000000000020689.


PMID- 32541514
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Effect of acupuncture on chronic bronchitis: A protocol for systematic review and
      meta-analysis.
PG  - e20676
LID - 10.1097/MD.0000000000020676 [doi]
AB  - INTRODUCTION: Chronic bronchitis (CB) is a clinically common and recurrent
      respiratory disease. However, many trials have shown that acupuncture can
      effectively treat CB. There is currently no systematic review of this therapy.
      The plan is to evaluate the effectiveness and safety of this treatment in
      patients with CB. METHODS AND ANALYSIS: This systematic evaluation will entail an
      electronic and manual search of all acupuncture for CB from inception to December
      31, 2020, regardless of the publication status or language. Databases include
      PubMed, Embase, Springer, Web of Science, the Cochrane Library, the World Health 
      Organization International Clinical Trial Registration Platform, the Chinese
      Medicine Database, the China National Knowledge Infrastructure, the Chinese
      Biomedical Literature Database, the China Science Journal Database, and the
      Wanfang Database. Other sources of information, including bibliographies and
      meeting minutes for identified publications, will also be searched. A manual
      search for grey literature, including unpublished conference articles will be
      performed. Additionally, any clinical randomized controlled trials related to
      acupuncture for CB, regardless of the publication status and language
      limitations, will be included in the study. Study selection, data extraction, and
      research quality assessments will be conducted independently by 2 researchers.
      The main result was the Change in cystic fibrosis transmembrane conductance
      regulator function as measured by sweat chloride analysis or treatment effect.
      Secondary outcomes included Quality of life (eg, SF-36), change in
      Breathlessness, Cough, and Sputum Scale score, follow-up relapse rate, and
      adverse events. The system searches for randomized controlled trials of this
      therapy for CB. Implement the Cochrane RevMan V5.3 bias assessment tool to assess
      bias risk, data integration risk, meta-analysis risk, and subgroup analysis risk 
      (if conditions are met). Mean difference, standard mean deviation, and binary
      data will be used to represent continuous results. RESULTS: This study will
      provide a comprehensive review and evaluation of the available evidence for the
      treatment of CB using this therapy. CONCLUSION: This study will provide new
      evidence to evaluate the effectiveness and side effects of acupuncture on CB.
      Because the data are not personalized, no formal ethical approval is required.
      PROSPERO REGISTRATION NUMBER: CRD42020170287.
FAU - Mao, Dongdong
AU  - Mao D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine/Clinical Medical
      College of Chengdu University of Traditional Chinese Medicine.
FAU - Deng, Yanli
AU  - Deng Y
AD  - Sichuan Second Chinese Medicine Hospital.
FAU - Zhang, Leixiao
AU  - Zhang L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Zhao, Ying
AU  - Zhao Y
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Li, Ying
AU  - Li Y
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Wang, Fei
AU  - Wang F
AUID- ORCID: 0000-0001-6225-766
AD  - Hospital of Chengdu University of Traditional Chinese Medicine/Clinical Medical
      College of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Therapy/adverse effects
MH  - Bronchitis, Chronic/*therapy
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7302603
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020676 [doi]
AID - 00005792-202006120-00070 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20676. doi:
      10.1097/MD.0000000000020676.


PMID- 32541513
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II
      receptor blockers on insulin resistance in hypertensive patients: A protocol for 
      a systematic review and meta-analysis.
PG  - e20674
LID - 10.1097/MD.0000000000020674 [doi]
AB  - BACKGROUND: Previous studies have shown inconsistent outcomes in the efficacy of 
      angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin
      receptor blockers (ARBs) on insulin resistance (IR). Hence, we aim to compare the
      efficacy of ACE inhibitors with ARBs on IR in hypertensive patients. METHODS:
      Five electronic databases (included The Cochrane Library, MEDLINE, Embase, Web of
      Science, and Cochrane Central Register of Controlled Trials) will be searched.
      Randomized controlled trials (RCTs) will be included if they recruited
      hypertensive participants for assessing the effect of ACE inhibitors on IR versus
      ARBs. The primary outcome will be IR (using recognized methods such as
      homeostasis model assessment of insulin resistance), secondary outcomes will be
      blood pressure, fasting plasma glucose, fasting plasma insulin. Relevant
      literature search, data extraction, and quality assessment will be performed by 2
      researchers independently, and the third researcher will be involved in a
      discussion for any disagreements. All analyses will be performed based on the
      Cochrane Handbook for Systematic Reviews of Interventions. Stata 12.0 software
      will be used for statistical analysis. The effect size of dichotomous data will
      be measured using the odds ratio (OR), and the effect size of continuous data
      will be measured using the standardized mean difference. And 95% confidence
      intervals will be calculated. Heterogeneity will be tested by chi-based Cochran Q
      statistic and I statistic. Sensitivity analysis and subgroup analysis will be
      used to observe changes in the pooled effect size and heterogeneity between
      included studies, to assess the reliability and stability of the pooled results. 
      The funnel plot and Egger's and Begg's tests will be used to judge publication
      bias, and the trim and fill method will be used to correct the funnel asymmetry
      caused by publication bias. P < 0.05 will be considered to indicate a
      statistically significant result. RESULTS: This systematic review and
      meta-analysis will assess the efficacy of ACE inhibitors versus ARBs on IR in
      hypertensive patients. CONCLUSIONS: Our study will show the efficacy of ACE
      inhibitors versus ARBs on IR in hypertensive patients. And it may find a more
      beneficial therapeutic option to assist clinicians in making clinical decisions. 
      ETHICS AND DISSEMINATION: This study is a protocol for systematic review and
      meta-analysis of the efficacy of ACE inhibitors and ARBs on IR in hypertensive
      patients. This systematic review and meta-analysis will be published in a journal
      and disseminated in print by peer-review. INPLASY REGISTRATION NUMBER:
      INPLASY202050032.
FAU - Yao, Jia
AU  - Yao J
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, Sichuan Province, P.R. China.
FAU - Gong, Xiayu
AU  - Gong X
FAU - Shi, Xiaoyan
AU  - Shi X
FAU - Fan, Simin
AU  - Fan S
FAU - Chen, Junmin
AU  - Chen J
FAU - Chen, Qiu
AU  - Chen Q
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Angiotensin Receptor Antagonists/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Hypertension/*metabolism
MH  - *Insulin Resistance
MH  - *Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
PMC - PMC7302663
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020674 [doi]
AID - 00005792-202006120-00069 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20674. doi:
      10.1097/MD.0000000000020674.


PMID- 32541512
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220415
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for 
      a systematic review and meta-analysis.
PG  - e20673
LID - 10.1097/MD.0000000000020673 [doi]
AB  - BACKGROUND: Increasing evidence connects serum uric acid (sUA) with hypertension.
      Previous studies on the efficacy of febuxostat on blood pressure (BP) in
      hyperuricemic patients have provided conflicting results. Thus, we aim to perform
      a systematic review and meta-analysis to investigate the efficacy of febuxostat
      on BP. METHODS: Five electronic databases (included The Cochrane Library,
      MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled
      Trials) will be searched. Randomized controlled trials will be included if they
      recruited hyperuricemic participants for assessing the effect of febuxostat on BP
      versus control (placebo, no treatment, and other therapeutic agents). The primary
      outcome will be BP, secondary outcomes will be sUA, serum creatinine, and
      estimated glomerular filtration rate. Relevant literature search, data
      extraction, and quality assessment will be performed by 2 researchers
      independently, and the third researcher will be involved in a discussion for any 
      disagreements. All analyses will be performed based on the Cochrane Handbook for 
      Systematic Reviews of Interventions. Stata 12.0 software will be used for
      statistical analysis. The effect size of dichotomous data will be measured using 
      the odds ratio , and the effect size of continuous data will be measured using
      the standardized mean difference. And 95% confidence intervals will be
      calculated. Heterogeneity will be tested by chi-based Cochran Q statistic and I
      statistic. Sensitivity analysis and subgroup analysis will be used to observe
      changes in the pooled effect size and heterogeneity between included studies, to 
      assess the reliability and stability of the pooled results. The funnel plot and
      Egger's and Begg's tests will be used to judge publication bias, and the trim and
      fill method will be used to correct the funnel asymmetry caused by publication
      bias. P < .05 will be considered to indicate a statistically significant result. 
      RESULTS: This systematic review and meta-analysis will be to assess the efficacy 
      of febuxostat on BP. CONCLUSIONS: Our findings will show the effect of febuxostat
      on BP in hyperuricemic patients. And such a study may find a new therapeutic
      option for hypertensive patients and assist clinicians and health professionals
      make clinical decisions. ETHICS AND DISSEMINATION: This study is a protocol for
      systematic review and meta-analysis of the effect of febuxostat on BP in
      hypertensive patients. This systematic review and meta-analysis will be published
      in a journal and disseminated in print by peer-review. INPLASY REGISTRATION
      NUMBER: INPLASY202050031.
FAU - Yao, Jia
AU  - Yao J
AD  - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, Sichuan Province, P.R. China.
FAU - Shi, Xiaoyan
AU  - Shi X
FAU - Fan, Simin
AU  - Fan S
FAU - Gao, Yang
AU  - Gao Y
FAU - Hu, Hengchang
AU  - Hu H
FAU - Wang, PanPan
AU  - Wang P
FAU - Chen, Qiu
AU  - Chen Q
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 101V0R1N2E (Febuxostat)
SB  - IM
MH  - Blood Pressure/*drug effects
MH  - Febuxostat/*pharmacology/therapeutic use
MH  - Humans
MH  - Hypertension/*complications/drug therapy/*physiopathology
MH  - Hyperuricemia/*complications/*physiopathology
MH  - *Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
PMC - PMC7302651
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020673 [doi]
AID - 00005792-202006120-00068 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20673. doi:
      10.1097/MD.0000000000020673.


PMID- 32541509
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Serum vitamin D levels and type 2 diabetic erectile dysfunction: A protocol for
      systematic review and meta-analysis.
PG  - e20665
LID - 10.1097/MD.0000000000020665 [doi]
AB  - INTRODUCTION: Diabetic erectile dysfunction (DED) has gradually become a
      worldwide problem. Due to the mechanism of DED is not clear, it is impossible to 
      treat it pertinently. Recently, some studies have shown that vitamin D is
      associated with DED, type 2 diabetes mellitus (T2DM) and erectile dysfunction
      (ED), but there is no systematic review and meta-analysis on the relationship
      between vitamin D and DED. METHODS AND ANALYSIS: The databases of English
      databases (PubMed, MEDLINE, EMBASE, Web of Science, Cochrane Library) and Chinese
      databases (China National Knowledge Infrastructure, China Biology Medicine
      Database, Wanfang Database, VIP Database) will be retrieved. The search strategy 
      that will be run in the PubMed and tailored to the other database when necessary 
      is presented in . RevMan 5.3 and Stata 11.0 will be used for Systematic Review
      and Meta-analysis. This protocol reported under the Preferred Reporting ltems for
      Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement, and we will 
      report the systematic review by following the PRISMA statement.(Table is included
      in full-text article.) RESULTS:: Through a systematic review, and meta-analysis
      when necessary, we can obtain the relationship between vitamin D and DED. We will
      share our findings in the third quarter of 2021. CONCLUSION: The association
      between serum vitamin D levels and type 2 diabetic erectile dysfunction will be
      assessed. Besides, the results of this review may provide some help for
      clinicians to make decisions. ETHICS AND DISSEMINATION: Ethical approval is not
      required as the review is a secondary study based on published literature. The
      results will be published in a public issue journal to provide evidence-based
      medical evidence for urologists and andrologists to make better clinical
      decisions. PROTOCOL REGISTRATION NUMBER: INPLASY202040164.
FAU - Li, Fuhao
AU  - Li F
AUID- ORCID: 0000-0003-2909-0356
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Qiu, Xianliang
AU  - Qiu X
FAU - Yao, Hangyu
AU  - Yao H
FAU - Chang, Degui
AU  - Chang D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Diabetes Complications/*blood
MH  - Diabetes Mellitus, Type 2/*blood/complications
MH  - Erectile Dysfunction/*blood/complications
MH  - Humans
MH  - Male
MH  - *Meta-Analysis as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
MH  - Vitamin D/*blood
PMC - PMC7302604
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020665 [doi]
AID - 00005792-202006120-00065 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20665. doi:
      10.1097/MD.0000000000020665.


PMID- 32541499
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients 
      with nonalcoholic fatty liver disease: A protocol for a systematic review and
      meta-analysis.
PG  - e20624
LID - 10.1097/MD.0000000000020624 [doi]
AB  - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), especially non-alcoholic
      steatohepatitis, which is considered as the hepatic manifestation of metabolic
      syndrome, has a great prevalence all over the world. New drugs are urgently
      needed for the treatment of NAFLD. This review will be to assess the efficacy and
      safety of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on liver-related
      outcomes (liver histology and liver enzymes) in patients with NAFLD. METHODS: We 
      will search 5 databases for relative studies: Medline, the Cochrane Library,
      EMBASE, Web of Science, and ClinicalTrials.gov and identified all reports of
      randomized controlled trials published prior to July 2020. Two authors will
      independently scan the articles searched, extract the data from articles
      included, and assess the risk of bias by Cochrane tool of risk of bias.
      Disagreements will be resolved by discussion among authors. All analysis will be 
      performed based on the Cochrane Handbook for Systematic Reviews of Interventions.
      Fixed-effects model or random-effects model will be used to calculate pooled
      estimates of weighted mean difference with 95% confidence intervals. RESULTS:
      This systematic review aims to examine the effect of n-3 PUFAs on liver histology
      and liver enzymes in patients with NAFLD. CONCLUSIONS: These findings will
      provide guidance to clinicians and patients on the use of n-3 PUFAs for NAFLD.
      ETHICS AND DISSEMINATION: This study is a protocol for a systematic review of n-3
      PUFAs as a treatment of NAFLD patients. This review will be published in a
      journal and disseminated in print by peer-review. SYSTEMATIC REVIEW REGISTRATION:
      INPLASY202050008.
FAU - Shi, Xiao-Yan
AU  - Shi XY
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Fan, Si-Min
AU  - Fan SM
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Shi, Guo-Mei
AU  - Shi GM
AD  - School of Information Science and Technology, Northeast Normal University,
      Changchun, Jilin Province, P.R. China.
FAU - Yao, Jia
AU  - Yao J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Gao, Yang
AU  - Gao Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Xia, Yu-Guo
AU  - Xia YG
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
FAU - Chen, Qiu
AU  - Chen Q
AUID- ORCID: 0000-0002-9222-9261
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Fatty Acids, Omega-3)
SB  - IM
MH  - Fatty Acids, Omega-3/adverse effects/*therapeutic use
MH  - Humans
MH  - Liver/enzymology/pathology
MH  - *Meta-Analysis as Topic
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/enzymology/pathology
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - *Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7302599
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020624 [doi]
AID - 00005792-202006120-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20624. doi:
      10.1097/MD.0000000000020624.


PMID- 32541498
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - Intravenous versus topical tranexamic acid in lumbar interbody fusion: A protocol
      of randomized controlled trial.
PG  - e20619
LID - 10.1097/MD.0000000000020619 [doi]
AB  - BACKGROUND: Questions still remain about the safest and most effective route of
      administration for tranexamic acid (TXA) in lumbar interbody fusion. As such, the
      goal of this randomized clinical trial was to assess the efficacy and safety of
      topical TXA compared with intravenous TXA in lumbar interbody fusion. METHODS:
      This was a prospectively randomized trial that investigated the effectiveness and
      safety of the intravenous and topical administrations of TXA with regard to
      lumbar interbody fusion. Approval from Clinical Studies Ethical Committee in our 
      hospital was obtained. The patients were randomized to 1 of 2 treatment
      options:Patients, surgeons, anesthesiologists, nurses, and research assistants
      collecting data were blinded to group allocation. The primary outcome measures
      were perioperative calculated blood loss, total drain output at 24 hours, and
      perioperative blood transfusion rate. Secondary outcomes included an analysis of 
      complications, namely symptomatic venous thromboembolism, cerebrovascular
      accident, and arterio-occlusive events. Data were analyzed using the statistical 
      software package SPSS version 25.0 (Chicago, IL). RESULTS: There are several
      limitations to this study. We did not include a group of patients who did not
      receive TXA. Another potential limitation is that the study population contains
      heterogeneity such as varying patient diagnosis and surgical technique/approach. 
      Despite these limitations, the validity of our results should be maintained, as
      the same methodology was applied to both treatment arms. TRIAL REGISTRATION: This
      study protocol was registered in Research Registry (researchregistry5564).
FAU - Song, Fei
AU  - Song F
AD  - Department of Orthopedics, People's Hospital of Nanchuan District, Chongqing,
      China.
FAU - Zheng, Zhouhai
AU  - Zheng Z
AUID- ORCID: 0000-0002-2844-4821
LA  - eng
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
SB  - IM
MH  - Administration, Intravenous
MH  - Administration, Topical
MH  - Antifibrinolytic Agents/*administration & dosage/adverse effects
MH  - Blood Loss, Surgical/*prevention & control
MH  - Double-Blind Method
MH  - Humans
MH  - Prospective Studies
MH  - *Spinal Fusion
MH  - Tranexamic Acid/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC7302681
EDAT- 2020/06/17 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1097/MD.0000000000020619 [doi]
AID - 00005792-202006120-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20619. doi:
      10.1097/MD.0000000000020619.


PMID- 32541483
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 24
DP  - 2020 Jun 12
TI  - The maintenance effect of acupuncture on the side effects of breast cancer
      endocrine therapy: A protocol for systematic review and meta analysis.
PG  - e20567
LID - 10.1097/MD.0000000000020567 [doi]
AB  - BACKGROUND: Breast cancer is common among women throughout the world and
      endocrine therapy is an established part of its treatment. But, unfortunately,
      this has also resulted in intolerable side effects affecting the quality of life.
      Acupuncture has been widely used to treat endocrine-related side effects in
      patients with breast cancer, but how long its effect can be maintained has not
      been published. The systematic review is designed to evaluate the maintenance
      efficacy of acupuncture for related side effects after breast cancer endocrine
      therapy. METHODS AND ANALYSIS: We will search for the following databases:
      PubMed, Embase, Cochrane Library, Web of Science, including China National
      Knowledge Infrastructure (CNKI), WanFang Data, Technology Periodical Database
      (VIP), and China Biology Medicine (CBM) from inception to May 2020. Two reviewers
      will search these databases, collect all articles, and assess the quality of
      studies separately, and there will be no limitations on language. The primary
      outcomes will be assessed using acupuncture for endocrine-related hot flashes and
      joint pain duration (1 month, 3 months, 6 months). Measurement tools include the 
      Kupperman index, Brief Pain Inventory Short Form (BPI-SF), the Western Ontario
      and McMaster Universities Osteoarthritis Index (WOMAC), the Brief Pain
      Inventory-Short (BPI-SF). We will use RevMan V.5.3 for meta-analysis and employ
      the Grading of Recommendations Assessment, Development and Evaluation System to
      assess the quality of evidence. RESULTS: This systematic review will evaluate the
      maintenance efficacy of acupuncture on the side effects of breast cancer
      endocrine therapy. CONCLUSION: This study will provide high-quality current
      evidence of how long its effect can be maintained after acupuncture for related
      side effects after breast cancer endocrine therapy. ETHICS AND DISSEMINATION:
      Ethical committee approval is not required for this systematic review as patient 
      data will not be collected. This study will help to inform doctors and
      researchers on the duration of acupuncture treatment for endocrine-related hot
      flashes and joint pain. The results will be published in a peer-reviewed journal 
      and will be disseminated in relevant conferences. INPLASY REGISTRATION NUMBER:
      INPLASY202040024.
FAU - Shi, Kejin
AU  - Shi K
AD  - Chengdu university of traditional Chinese medicine, Chengdu, Sichuan province,
      China.
FAU - Tang, Ying
AU  - Tang Y
FAU - He, Fengyi
AU  - He F
FAU - Xiao, Xiao
AU  - Xiao X
FAU - Zhang, Jiayuan
AU  - Zhang J
FAU - Jin, Yuxia
AU  - Jin Y
FAU - Wang, Yunxia
AU  - Wang Y
FAU - Zhang, Qi
AU  - Zhang Q
AUID- ORCID: 0000-0002-8356-4623
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents, Hormonal)
SB  - IM
MH  - *Acupuncture Therapy
MH  - Antineoplastic Agents, Hormonal/*adverse effects
MH  - Arthralgia/chemically induced/*therapy
MH  - Breast Neoplasms/*drug therapy
MH  - Hot Flashes/chemically induced/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7302662
EDAT- 2020/06/17 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1097/MD.0000000000020567 [doi]
AID - 00005792-202006120-00039 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 12;99(24):e20567. doi:
      10.1097/MD.0000000000020567.


PMID- 32541283
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20210108
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 136
IP  - 1
DP  - 2020 Jul
TI  - Postmenopausal Pregnancy in the Era of Assisted Reproductive Technologies.
PG  - 154-160
LID - 10.1097/AOG.0000000000003877 [doi]
AB  - Assisted reproductive technologies allow women to achieve pregnancy at ages
      beyond the limits of their natural reproductive lifespans. As women seek
      pregnancy later in life, physicians are challenged with balancing their
      professional autonomy against patient autonomy. Increased parental age increases 
      risk to mother and fetus. Legal aspects of postmenopausal women desiring
      fertility services will vary by location. Ethically, the principles of
      beneficence, nonmaleficence, and justice become important factors in a
      physician's evaluation process. This article aims to highlight current guidelines
      for postmenopausal women desiring fertility services and address medical, legal, 
      and ethical concerns that may arise when assessing these patients.
FAU - Moutos, Christopher P
AU  - Moutos CP
AD  - Department of Obstetrics & Gynecology, University of Texas Medical Branch at
      Galveston, Galveston, Texas; and the Department of Obstetrics and Gynecology,
      University of Nevada Las Vegas, Las Vegas, Nevada.
FAU - Rasouli, Melody A
AU  - Rasouli MA
FAU - Phelps, John Y
AU  - Phelps JY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Humans
MH  - *Maternal Age
MH  - Middle Aged
MH  - *Postmenopause
MH  - Practice Guidelines as Topic
MH  - Pregnancy
MH  - Reproductive Techniques, Assisted/*ethics
MH  - United States
MH  - Young Adult
EDAT- 2020/06/17 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 10.1097/AOG.0000000000003877 [doi]
AID - 00006250-202007000-00025 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2020 Jul;136(1):154-160. doi: 10.1097/AOG.0000000000003877.


PMID- 32541141
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 1422-6421 (Electronic)
IS  - 1422-6405 (Linking)
VI  - 209
IP  - 1
DP  - 2020
TI  - A Biobank of Stem Cells of Human Exfoliated Deciduous Teeth: Overview of
      Applications and Developments in Brazil.
PG  - 37-42
LID - 10.1159/000506677 [doi]
AB  - A biobank is an organized collection of biological human material and its
      associated information stored for research according to regulations under
      institutional responsibility, without commercial purposes, being a mandatory and 
      strategical activity for research, regenerative medicine, and innovation. Stem
      cells have largely been employed in research and frequently stored in biobanks,
      which have been used as an essential source of biological materials. Stem cells
      of human exfoliated deciduous teeth (SHED) are stem cells which have a high
      multipotency and can be easily obtained. Besides, this extremely accessible
      tissue has advantages with respect to storage, as the SHED obtained in childhood 
      can be used in later life, which implies the necessity for the creation and
      regulation of biobanks. The proper planning for the creation of a biobank
      includes knowledge of the material types to be stored, requirements regarding
      handling and storage conditions, storage time, and room for the number of
      samples. Thus, this study aimed to establish an overview of the development of a 
      SHED biobank. Ethical and legal standardization, current applications, specific
      orientations, and challenges for the implementation of a SHED biobank were
      discussed. Through this overview, we hope to encourage further studies to use
      SHED biobanks.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Zalaf, Bianca Rapini
AU  - Zalaf BR
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil, bianca.zalaf@usp.br.
FAU - Bringel, Mayara
AU  - Bringel M
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Jorge, Paula Karine
AU  - Jorge PK
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - de Oliveira, Barbara
AU  - de Oliveira B
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Tanabe, Kim
AU  - Tanabe K
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Santos, Carlos Ferreira
AU  - Santos CF
AD  - Department of Biological Sciences, Bauru School of Dentistry, University of Sao
      Paulo, Bauru, Brazil.
FAU - Oliveira, Rodrigo Cardoso
AU  - Oliveira RC
AD  - Department of Biological Sciences, Bauru School of Dentistry, University of Sao
      Paulo, Bauru, Brazil.
FAU - Rios, Daniela
AU  - Rios D
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Cruvinel, Thiago
AU  - Cruvinel T
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Lourenco Neto, Natalino
AU  - Lourenco Neto N
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Oliveira, Thais Marchini
AU  - Oliveira TM
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
FAU - Machado, Maria Aparecida Andrade Moreira
AU  - Machado MAAM
AD  - Department of Pediatric Dentistry, Orthodontics, and Public Health, Bauru School 
      of Dentistry, University of Sao Paulo, Bauru, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200615
PL  - Switzerland
TA  - Cells Tissues Organs
JT  - Cells, tissues, organs
JID - 100883360
SB  - IM
MH  - Brazil
MH  - Cell Differentiation
MH  - Humans
MH  - Stem Cells/*metabolism
MH  - Tooth Exfoliation/*metabolism
MH  - Tooth, Deciduous/*metabolism
OTO - NOTNLM
OT  - *Biological specimen banks
OT  - *Deciduous
OT  - *Dental pulp
OT  - *Stem cells
OT  - *Tissue bank
OT  - *Tooth
EDAT- 2020/06/17 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/11/13 00:00 [received]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - 000506677 [pii]
AID - 10.1159/000506677 [doi]
PST - ppublish
SO  - Cells Tissues Organs. 2020;209(1):37-42. doi: 10.1159/000506677. Epub 2020 Jun
      15.


PMID- 32541132
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Apr-Jun
TI  - Hydrogen therapy can be used to control tumor progression and alleviate the
      adverse events of medications in patients with advanced non-small cell lung
      cancer.
PG  - 75-80
LID - 10.4103/2045-9912.285560 [doi]
AB  - Chemotherapy, targeted therapy, and immunotherapy are used against advanced
      non-small cell lung cancer. A clinically efficacious method for relieving the
      adverse events associated of such therapies is lacking. Fifty-eight adult
      patients were enrolled in our trial to relieve pulmonary symptoms or the adverse 
      events of drugs. Twenty patients who refused drug treatment were assigned equally
      and randomly to a hydrogen (H2)-only group and a control group. According to the 
      results of tumor-gene mutations and drug-sensitivity tests, 10, 18, and 10
      patients were enrolled into chemotherapy, targeted therapy, and immunotherapy
      groups in which these therapies were combined with H2-therapy, respectively.
      Patients underwent H2 inhalation for 4-5 hours per day for 5 months or stopped
      when cancer recurrence. Before study initiation, the demographics (except for
      tumor-mutation genes) and pulmonary symptoms (except for moderate cough) of the
      five groups showed no significant difference. During the first 5 months of
      treatment, the prevalence of symptoms of the control group increased gradually,
      whereas that of the four treatment groups decreased gradually. After 16 months of
      follow-up, progression-free survival of the control group was lower than that of 
      the H2-only group, and significantly lower than that of H2 + chemotherapy, H2 +
      targeted therapy, and H2 + immunotherapy groups. In the combined-therapy groups, 
      most drug-associated adverse events decreased gradually or even disappeared. H2
      inhalation was first discovered in the clinic that can be used to control tumor
      progression and alleviate the adverse events of medications for patients with
      advanced non-small cell lung cancer. This study was approved by the Ethics
      Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018
      (approval No. Fuda20181207), and was registered at ClinicalTrials.gov
      (Identifier: NCT03818347) on January 28, 2019.
FAU - Chen, Ji-Bing
AU  - Chen JB
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute,
      Guangzhou, Guangdong Province, China.
FAU - Kong, Xiao-Feng
AU  - Kong XF
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
FAU - Mu, Feng
AU  - Mu F
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
FAU - Lu, Tian-Yu
AU  - Lu TY
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute,
      Guangzhou, Guangdong Province, China.
FAU - Lu, You-Yong
AU  - Lu YY
AD  - Central Lab, Beijing Cancer Hospital, Beijing, China.
FAU - Xu, Ke-Cheng
AU  - Xu KC
AD  - Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute,
      Guangzhou, Guangdong Province, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03818347
PT  - Clinical Trial
PT  - Journal Article
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Antineoplastic Agents)
RN  - 7YNJ3PO35Z (Hydrogen)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - *Disease Progression
MH  - Female
MH  - Humans
MH  - Hydrogen/administration & dosage/*therapeutic use
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
PMC - PMC7885710
OTO - NOTNLM
OT  - *NSCLC
OT  - *PFS
OT  - *adverse event
OT  - *chemotherapy
OT  - *hydrogen
OT  - *immunotherapy
OT  - *non-small-cell lung cancer
OT  - *progression-free survival
OT  - *targeted drug
EDAT- 2020/06/17 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - MedGasRes_2020_10_2_75_285560 [pii]
AID - 10.4103/2045-9912.285560 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Apr-Jun;10(2):75-80. doi: 10.4103/2045-9912.285560.


PMID- 32541131
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Apr-Jun
TI  - Dependencies of hydrogen-water on mineral-based hardness, temperatures and the
      container materials, and effects of the oral washing and drinking.
PG  - 67-74
LID - 10.4103/2045-9912.285559 [doi]
AB  - Widely distributed electrolytic-generators for hydrogen-water are not fully
      considered for the dependencies of post-electrolytic values of the dissolved
      hydrogen concentration (DH) and the oxidation-reduction potential (ORP) on the
      properties of the pre-electrolytic water. We investigated the dependencies of DH 
      and ORP on mineral-based hardness, temperatures and the container materials, and 
      effects on the oral cavity by oral washing or drinking. Along with an increase in
      mineral-based water-hardness, DH decreased from 960 to 870 mug/L and the ORP
      unexpectedly increased from -460 to -320 mV. Purified water of almost zero
      hardness, however, caused a post-electrolytic DH as low as 80 mug/L and an ORP as
      high as +20 mV. Post-electrolytic DHs were not significantly changed (780-900
      mug/L) upon electrolysis at 1.5-30 degrees C and decreased at 40-50 degrees C.
      The diffusion of hydrogen from the inside to the outside of the container was
      extremely small even after 12 hours for an aluminum- or stainless steel-made
      container, but not for containers made of diverse plastics. The ORP of the intact
      saliva was +136 mV, and decreased to +90 mV at 20 minutes after 1-minute
      oral-cramming of hydrogen-water, but returned to +135 mV after 60-minute leaving,
      showing a transient ORP-decrease in the saliva. Drinking-pause for 4 weeks after 
      drinking hydrogen-water, however, saliva ORP, gradually but not instantly,
      increased to +60 to +80 mV, but upon drinking-resumption and 2 weeks thereafter, 
      decreased again to -100 to -110 mV, suggesting that several-week hydrogen-water
      drinking caused a certain decrease in the saliva ORP. Thus, the present study
      provided the appropriate conditions such as hardness and temperatures for
      hydrogen-water production by the electrolytic generator, and the container
      materials suitable for hydrogen-water preservation. Furthermore, we clarified ORP
      changes of human saliva, being an indicator for human oxidative stress. The study
      was approved by the Medical Ethics Committee of the NPO (Non-Profitable
      Organization)-Corporate Japanese Center for Anti-Aging Medical Sciences (approval
      No. 09S02) on May 2, 2012.
FAU - Tanaka, Yoshiharu
AU  - Tanaka Y
AD  - Osaka Prefecture University, Osaka, Japan.
FAU - Teraoka, Fumio
AU  - Teraoka F
AD  - Shin-Osaka Dental Technician College, Osaka, Japan.
FAU - Nakagawa, Masafumi
AU  - Nakagawa M
AD  - Shin-Osaka Dental Technician College, Osaka, Japan.
FAU - Miwa, Nobuhiko
AU  - Miwa N
AD  - Prefectural University of Hiroshima, Hiroshima, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
RN  - 0 (Minerals)
RN  - 059QF0KO0R (Water)
RN  - 7YNJ3PO35Z (Hydrogen)
SB  - IM
MH  - *Drinking
MH  - Hardness
MH  - Hydrogen/*chemistry
MH  - Minerals/*chemistry
MH  - Oxidation-Reduction
MH  - *Temperature
MH  - Water/*chemistry
PMC - PMC7885711
OTO - NOTNLM
OT  - *dissolved hydrogen concentration
OT  - *hydrogen-water
OT  - *hydrogen-water generator of the portable type
OT  - *oxidation-reduction potential
OT  - *oxidative stress
OT  - *saliva
OT  - *storage of hydrogen-water
OT  - *water quality
OT  - *water temperature
OT  - *water-hardness
EDAT- 2020/06/17 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - MedGasRes_2020_10_2_67_285559 [pii]
AID - 10.4103/2045-9912.285559 [doi]
PST - ppublish
SO  - Med Gas Res. 2020 Apr-Jun;10(2):67-74. doi: 10.4103/2045-9912.285559.


PMID- 32540892
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Patient-centred and family-centred care of critically ill patients who are
      potential organ donors: a qualitative study protocol of family member
      perspectives.
PG  - e037527
LID - 10.1136/bmjopen-2020-037527 [doi]
AB  - INTRODUCTION: In a patient-centred and family-centred approach to organ donation,
      compassion is paramount. Recent guidelines have called for more research,
      interventions and approaches aimed at improving and supporting the families of
      critically ill patients. The objective of this study is to help translate
      patient-centred and family-centred care into practice in deceased organ donation.
      METHODS AND ANALYSIS: This will be a national, qualitative study of family
      members of deceased organ donors in Canada. We will include family members who
      had been approached regarding an organ donation decision, including those who
      agreed and declined, at least 2 months and no later than 3 years after the
      patients' death. Data collection and analysis is ongoing and will continue until 
      September 2020 to include approximately 250 participants. Family members will be 
      identified and recruited from provincial organ donation organisation databases.
      Four experienced qualitative researchers will conduct telephone interviews in
      English or French with audio-recording for subsequent transcription. The research
      team will develop a codebook iteratively through this process using inductive
      methods, thus generating themes directly from the dataset. ETHICS AND
      DISSEMINATION: Local research ethics boards (REB) at all participating sites
      across Canada have approved this protocol. The main REB involved is the Ottawa
      Health Science Network REB. Data collection began in August 2018. Publication of 
      results is anticipated in 2021. Study findings will help improve healthcare
      provider competency in caring for potential organ donors and their families and
      improve organ donation consent rates. Findings will also help with the
      development of educational materials for a competency-based curriculum for
      critical care residents.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zheng, Katina
AU  - Zheng K
AUID- ORCID: 0000-0003-3004-156X
AD  - University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada.
FAU - Sutherland, Stephanie
AU  - Sutherland S
AD  - Department of Critical Care, Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Cardinal, Pierre
AU  - Cardinal P
AD  - Department of Critical Care, Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Meade, Maureen
AU  - Meade M
AD  - Department of Critical Care, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Landriault, Angele
AU  - Landriault A
AD  - Practice, Performance and Innovation (PPI) Unit, Royal College of Physicians and 
      Surgeons of Canada, Ottawa, Ontario, Canada.
FAU - Vanderspank-Wright, Brandi
AU  - Vanderspank-Wright B
AD  - School of Nursing, University of Ottawa Faculty of Health Sciences, Ottawa,
      Ontario, Canada.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
FAU - Valiani, Sabira
AU  - Valiani S
AD  - Department of Critical Care, Saskatchewan Health Authority, Saskatoon,
      Saskatchewan, Canada.
FAU - Shemie, Sam
AU  - Shemie S
AD  - Pediatrics, McGill University, Montreal, Quebec, Canada.
AD  - Canadian Blood Services, Ottawa, Ontario, Canada.
FAU - Appleby, Amber
AU  - Appleby A
AD  - Canadian Blood Services, Ottawa, Ontario, Canada.
FAU - Keenan, Sean
AU  - Keenan S
AD  - BC Transplant, Vancouver, British Columbia, Canada.
AD  - Division of Critical Care, UBC Department of Medicine, Vancouver, British
      Columbia, Canada.
FAU - Weiss, Matthew
AU  - Weiss M
AD  - Population Health and Optimal Health Practices Research Unit,
      Trauma-Emergency-Critical Care Medicine, CHU de Quebec-Universite Laval, Quebec
      city, Quebec, Canada.
FAU - Werestiuk, Kim
AU  - Werestiuk K
AD  - Transplant Manitoba, Winnipeg, Manitoba, Canada.
FAU - Kramer, Andreas H
AU  - Kramer AH
AD  - University of Calgary, Calgary, Alberta, Canada.
FAU - Kawchuk, Joann
AU  - Kawchuk J
AD  - Department of Critical Care, Saskatchewan Health Authority, Saskatoon,
      Saskatchewan, Canada.
FAU - Beed, Stephen
AU  - Beed S
AD  - Department of Critical Care, Dalhousie University Faculty of Medicine, Halifax,
      Nova Scotia, Canada.
FAU - Dhanani, Sonny
AU  - Dhanani S
AD  - Critical Care, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
FAU - Pagliarello, Giuseppe
AU  - Pagliarello G
AD  - Department of Critical Care, Ottawa Hospital, Ottawa, Ontario, Canada.
FAU - Chasse, Michael
AU  - Chasse M
AD  - Department of Critical Care Medicine, Centre Hospitalier de L'Universite de
      Montreal, Montreal, Quebec, Canada.
FAU - Lotherington, Ken
AU  - Lotherington K
AD  - Canadian Blood Services, Ottawa, Ontario, Canada.
FAU - Gatien, Mary
AU  - Gatien M
AD  - Horizon Health Network, Miramichi, New Brunswick, Canada.
FAU - Parsons, Kim
AU  - Parsons K
AD  - Organ Procurement and Exchange of Newfoundland and Labrador (OPEN), St. John's,
      Newfoundland and Labrador, Canada.
FAU - Chandler, Jennifer
AU  - Chandler J
AD  - University of Ottawa Faculty of Law Common Law Section, Ottawa, Ontario, Canada.
FAU - Nickerson, Peter
AU  - Nickerson P
AD  - University of Manitoba Faculty of Health Sciences, Winnipeg, Manitoba, Canada.
FAU - Kutsogiannis, Jim
AU  - Kutsogiannis J
AD  - Department of Critical Care Medicine, University of Alberta Faculty of Medicine
      and Dentistry, Edmonton, Alberta, Canada.
FAU - Sarti, Aimee J
AU  - Sarti AJ
AD  - Department of Critical Care, Ottawa Hospital, Ottawa, Ontario, Canada
      asarti@toh.ca.
AD  - Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - *Critical Illness
MH  - *Decision Making
MH  - Family/*psychology
MH  - Humans
MH  - Qualitative Research
MH  - Research Design
MH  - *Tissue Donors
PMC - PMC7299025
OTO - NOTNLM
OT  - *brain death
OT  - *cardiac death
OT  - *critical care
OT  - *deceased donation
OT  - *family surrogate
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/06/17 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037527 [pii]
AID - 10.1136/bmjopen-2020-037527 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e037527. doi: 10.1136/bmjopen-2020-037527.


PMID- 32540891
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Study protocol for a nationwide Knowledge, Attitudes and Practices (KAP) survey
      on diabetes in Singapore's general population.
PG  - e037125
LID - 10.1136/bmjopen-2020-037125 [doi]
AB  - INTRODUCTION: This study aims to establish the Knowledge, Attitudes and Practices
      (KAP) of the general population (people with and without diabetes) towards
      diabetes. The study will examine (a) recognition and understanding of causes,
      prevention and treatment strategies of diabetes; (b) identify the knowledge gaps 
      and behavioural patterns that may hamper diabetes prevention and control; (c)
      stigma towards and stigma perceived by people with diabetes and (d) awareness of 
      anti-diabetes campaigns. METHODS AND ANALYSIS: The study is a nationwide,
      cross-sectional study of Singapore's general population aged 18 years and above
      (n=3000), comprising Chinese, Malay, Indian and other ethnic groups, who can
      understand English, Chinese, Malay or Tamil language. The sample was derived
      using a disproportionate stratified sampling using age and ethnicity. The
      proportion of respondents in each ethnic group (Chinese, Malay and Indian) was
      set to approximately 30%, while the proportion of respondents in each age group
      was set around 20% in order to ensure a sufficient sample size. The respondents
      will be administered questionnaires on diabetes KAP, stigma towards diabetes,
      lifestyle, diet and awareness of local anti-diabetes campaigns. The analysis will
      include descriptive statistics and multiple logistic and linear regression
      analyses to determine the socio-demographic correlates of correct recognition of 
      diabetes, help-seeking preferences, as well as overall knowledge and attitudes
      among those with and without diabetes. We will consider a p value </=0.05 as
      significant. ETHICS AND DISSEMINATION: This study protocol has been reviewed by
      the Institutional Research Review Committee and the National Healthcare Group
      Domain Specific Review Board (NHG DSRB Ref 2018/00430). The results of the study 
      will be shared with policymakers and other stakeholders. There will be a local
      mass media briefing to disseminate the findings online, in print and on
      television and radio. The results will be published in peer-reviewed journals and
      presented in scientific meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - AshaRani, P V
AU  - AshaRani PV
AUID- ORCID: 0000-0001-8215-5214
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore
      Asharani_PEZHUMMOOTTIL_VASUDEVAN_N@imh.com.sg.
FAU - Abdin, Edimansyah
AU  - Abdin E
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Kumarasan, Roystonn
AU  - Kumarasan R
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Siva Kumar, Fiona Devi
AU  - Siva Kumar FD
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Shafie, Saleha
AU  - Shafie S
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Jeyagurunathan, Anitha
AU  - Jeyagurunathan A
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Chua, Boon Yiang
AU  - Chua BY
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Vaingankar, Janhavi Ajit
AU  - Vaingankar JA
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Fang, Sum Chee
AU  - Fang SC
AD  - Admiralty Medical Centre, Khoo Teck Puat Hospital, 676 Woodlands Drive 71,
      Singapore.
FAU - Lee, Eng Sing
AU  - Lee ES
AD  - National Healthcare Group Polyclinics, 3 Fusionopolis Link. Nexus@One-North,
      Singapore.
FAU - Van Dam, Rob
AU  - Van Dam R
AD  - Saw Swee Hock School of Public Health, National University of Singapore, 12
      Science Drive 2, Singapore.
FAU - Chong, Siow Ann
AU  - Chong SA
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
FAU - Subramaniam, Mythily
AU  - Subramaniam M
AD  - Research Division, Institute of Mental Health, 10 Buangkok View, Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Awareness
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus/*epidemiology
MH  - Diet
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Life Style
MH  - Male
MH  - Mass Media
MH  - Research Design
MH  - Singapore/epidemiology
MH  - *Social Stigma
MH  - Surveys and Questionnaires
PMC - PMC7299045
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *epidemiology
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/17 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037125 [pii]
AID - 10.1136/bmjopen-2020-037125 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e037125. doi: 10.1136/bmjopen-2020-037125.


PMID- 32540887
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Effectiveness of breathing exercises, foot reflexology and back massage (BRM) on 
      labour pain, anxiety, duration, satisfaction, stress hormones and newborn
      outcomes among primigravidae during the first stage of labour in Saudi Arabia: a 
      study protocol for a randomised controlled trial.
PG  - e033844
LID - 10.1136/bmjopen-2019-033844 [doi]
AB  - INTRODUCTION: Labour pain is among the severest pains primigravidae may
      experience during pregnancy. Failure to address labour pain and anxiety may lead 
      to abnormal labour. Despite the many complementary non-pharmacological approaches
      to coping with labour pain, the quality of evidence is low and best approaches
      are not established. This study protocol describes a proposed investigation of
      the effects of a combination of breathing exercises, foot reflexology and back
      massage (BRM) on the labour experiences of primigravidae. METHODS AND ANALYSIS:
      This randomised controlled trial will involve an intervention group receiving BRM
      and standard labour care, and a control group receiving only standard labour
      care. Primigravidae of 26-34 weeks of gestation without chronic diseases or
      pregnancy-related complications will be recruited from antenatal clinics.
      Eligible and consenting patients will be randomly allocated to the intervention
      or the control group stratified by intramuscular pethidine use. The BRM
      intervention will be delivered by a trained massage therapist. The primary
      outcomes of labour pain and anxiety will be measured during and after uterine
      contractions at baseline (cervical dilatation 6 cm) and post BRM hourly for 2
      hours. The secondary outcomes include maternal stress hormone
      (adrenocorticotropic hormone, cortisol and oxytocin) levels, maternal vital signs
      (V/S), fetal heart rate, labour duration, Apgar scores and maternal satisfaction.
      The sample size is estimated based on the between-group difference of 0.6 in
      anxiety scores, 95% power and 5% alpha error, which yields a required sample size
      of 154 (77 in each group) accounting for a 20% attrition rate. The between-group 
      and within-group outcome measures will be examined with mixed-effect regression
      models, time series analyses and paired t-test or equivalent non-parametric
      tests, respectively. ETHICS AND DISSEMINATION: Ethical approval was obtained from
      the Ethical Committee for Research Involving Human Subjects of the Ministry of
      Health in the Saudi Arabia (H-02-K-076-0319-109) on 14 April 2019, and from the
      Ethics Committee for Research Involving Human Subjects (JKEUPM) Universiti Putra 
      Malaysia on 23 October 2019, reference number: JKEUPM-2019-169. Written informed 
      consent will be obtained from all participants. Results from this trial will be
      presented at regional, national and international conferences and published in
      indexed journals. TRIAL REGISTRATION NUMBER: ISRCTN87414969, registered 3 May
      2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Baljon, Kamilya Jamel
AU  - Baljon KJ
AUID- ORCID: 0000-0003-2498-7658
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia.
AD  - Department of Nursing, Umm Al-Qura University, Makkah, Saudi Arabia.
FAU - Romli, Muhammad Hibatullah
AU  - Romli MH
AD  - Department of Nursing & Rehabilitation, Faculty of Medicine and Health Sciences, 
      Universiti Putra Malaysia, Serdang, Malaysia.
FAU - Ismail, Adibah Hanim
AU  - Ismail AH
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia.
FAU - Khuan, Lee
AU  - Khuan L
AD  - Department of Nursing & Rehabilitation, Faculty of Medicine and Health Sciences, 
      Universiti Putra Malaysia, Serdang, Malaysia.
FAU - Chew, Boon How
AU  - Chew BH
AUID- ORCID: 0000-0002-8627-6248
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia chewboonhow@upm.edu.my.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 50-56-6 (Oxytocin)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adrenocorticotropic Hormone/blood
MH  - Anxiety/prevention & control
MH  - *Breathing Exercises
MH  - Female
MH  - Gravidity
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Infant, Newborn
MH  - Labor Pain/therapy
MH  - *Massage
MH  - *Musculoskeletal Manipulations
MH  - Oxytocin/blood
MH  - Patient Satisfaction
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Randomized Controlled Trials as Topic
MH  - Saudi Arabia
MH  - *Trial of Labor
PMC - PMC7299053
OTO - NOTNLM
OT  - *breathing exercises
OT  - *labour pain
OT  - *massage
OT  - *primigravidae
OT  - *reflexology
OT  - *stress hormones
COIS- Competing interests: None declared.
EDAT- 2020/06/17 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033844 [pii]
AID - 10.1136/bmjopen-2019-033844 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e033844. doi: 10.1136/bmjopen-2019-033844.


PMID- 32540886
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Understanding implementation success: protocol for an in-depth, mixed-methods
      process evaluation of a cluster randomised controlled trial testing methods to
      improve detection of Lynch syndrome in Australian hospitals.
PG  - e033552
LID - 10.1136/bmjopen-2019-033552 [doi]
AB  - INTRODUCTION: In multisite intervention trials, implementation success often
      varies widely across settings. Process evaluations are crucial to interpreting
      trial outcomes and understanding contextual factors and causal chains necessary
      for successful implementation. Lynch syndrome is a hereditary cancer
      predisposition conferring an increased risk of colorectal, endometrial and other 
      cancer types. Despite systematic screening protocols to identify Lynch syndrome, 
      the condition remains largely underdiagnosed. The Hide and Seek Project ('HaSP') 
      is a cluster randomised controlled trial determining the effectiveness of two
      approaches to improving Lynch syndrome detection at eight Australian hospital
      networks. To enhance widespread implementation of optimal Lynch syndrome
      identification, there is a need to understand not only what works, but also why, 
      in what contexts, and at what costs. Here we describe an in-depth investigation
      of factors influencing successful implementation of procedures evaluated in the
      HaSP trial. METHODS AND ANALYSIS: A mixed-methods, theory-driven process
      evaluation will be undertaken in parallel to the HaSP trial. Data will include:
      interviews of Implementation Leads and Lynch syndrome stakeholders, pre-post
      implementation questionnaires, audio analysis of meetings and focus groups,
      observation of multidisciplinary team meetings, fidelity checklists and project
      log analysis. Results will be triangulated and coded, drawing on the Theoretical 
      Domains Framework, Consolidated Framework for Implementation Research and
      Proctor's implementation outcomes. ETHICS AND DISSEMINATION: Use of a
      theory-based process evaluation will enhance interpretation and generalisability 
      of HaSP trial findings, and contribute to the implementation research field by
      furthering understanding of the conditions necessary for implementation success. 
      Ethical approval has been granted and results will be disseminated via
      publications in peer-reviewed journals and conference presentations. At trial
      completion, key findings will be fed back to sites to enable refinement of
      intervention strategies, both in the context of Lynch syndrome and for the
      possible generalisability of intervention components in other genetic and broader
      clinical specialties. HASP TRIAL REGISTRATION NUMBER: Australian New Zealand
      Clinical Trials Registry (Identifier: ACTRN12618001072202). Registered 27 June
      2018. http://www.ANZCTR.org.au/ACTRN12618001072202.aspx.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Morrow, April
AU  - Morrow A
AUID- ORCID: 0000-0003-0714-363X
AD  - Cancer Council New South Wales, Woolloomooloo, New South Wales, Australia
      april.morrow@nswcc.org.au.
AD  - The University of Sydney, Sydney, New South Wales, Australia.
FAU - Tucker, Katherine M
AU  - Tucker KM
AD  - Hereditary Cancer Clinic, Prince of Wales Hospital and Community Health Services,
      Randwick, New South Wales, Australia.
AD  - UNSW Prince of Wales Clinical School, Randwick, New South Wales, Australia.
FAU - Shaw, Tim J
AU  - Shaw TJ
AD  - Research in Implementation Science and eHealth (RISe), Faculty of Health
      Sciences, University of Sydney, Camperdown, New South Wales, Australia.
FAU - Parkinson, Bonny
AU  - Parkinson B
AD  - The Macquarie University Centre for the Health Economy, Macquarie University,
      Macquarie, New South Wales, Australia.
FAU - Abraham, Charles
AU  - Abraham C
AD  - Melbourne School of Psychological Sciences, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Wolfenden, Luke
AU  - Wolfenden L
AD  - School of Medicine and Public Health, University of Newcastle, Newcastle, New
      South Wales, Australia.
FAU - Taylor, Natalie
AU  - Taylor N
AUID- ORCID: 0000-0002-0280-0883
AD  - Cancer Council New South Wales, Woolloomooloo, New South Wales, Australia.
AD  - The University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12618001072202
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Cluster Analysis
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/*diagnosis
MH  - Humans
MH  - *Process Assessment, Health Care
MH  - *Quality Improvement
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7299044
OTO - NOTNLM
OT  - *genetic testing
OT  - *implementation
OT  - *lynch syndrome
OT  - *process evaluation
OT  - *theoretical domains framework
COIS- Competing interests: None declared.
EDAT- 2020/06/17 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-033552 [pii]
AID - 10.1136/bmjopen-2019-033552 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e033552. doi: 10.1136/bmjopen-2019-033552.


PMID- 32540885
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 15
TI  - Effect and safety of gemtuzumab ozogamicin for the treatment of patients with
      acute myeloid leukaemia: a systematic review protocol.
PG  - e032503
LID - 10.1136/bmjopen-2019-032503 [doi]
AB  - INTRODUCTION: Acute myeloid leukaemia (AML) is a type of cancer in which the bone
      marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells
      or platelets. Gemtuzumab ozogamicin (GO) holds promise as a new agent that also
      could be efficacious in newly diagnosed AML with acceptable toxicity. This paper 
      describes the design of a protocol to conduct a systematic review of published
      studies assessing GO for the treatment of AML. METHOD AND ANALYSIS: We will
      conduct a systematic review of randomised controlled trials that investigate the 
      effect and safety of GO for the treatment of patients with AML. We will search
      for any eligible articles from selected electronic databases. We will follow the 
      Preferred Reporting Items for Systematic reviews and Meta-Analysis for study
      selection and reporting. We will use The Cochrane Handbook for Systematic Reviews
      of Interventions and Meta-Analysis as guidance to select eligible studies. All
      data will be extracted using a standardised data extraction form. ETHICS AND
      DISSEMINATION: There was no patient involved in this study, therefore no ethical 
      consideration is needed. The findings of this study will be disseminated in a
      peer-reviewed journal and any relevant conference presentation. PROSPERO
      REGISTRATION NUMBER: CRD42019123286.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Muhamad, Nor A
AU  - Muhamad NA
AUID- ORCID: 0000-0002-7772-2103
AD  - Sector for Evidence-Based, National Institutes of Health Malaysia, Shah Alam,
      Selangor, Malaysia norasiahdr@gmail.com.
AD  - Institute for Public Health, National Institutes of Health, Shah Alam, Selangor, 
      Malaysia.
FAU - Mohd Dali, Nor S
AU  - Mohd Dali NS
AD  - Institute for Medical Research, National Institutes of Health, Ministry of
      Health, Shah Alam, Selangor, Malaysia.
FAU - Mohd Yacob, Aliza
AU  - Mohd Yacob A
AD  - Institute for Medical Research, National Institutes of Health, Ministry of
      Health, Shah Alam, Selangor, Malaysia.
FAU - Kassim, Mohd S A
AU  - Kassim MSA
AD  - Institute for Public Health, National Institutes of Health, Shah Alam, Selangor, 
      Malaysia.
FAU - Lodz, Noor A
AU  - Lodz NA
AD  - Institute for Public Health, National Institutes of Health, Shah Alam, Selangor, 
      Malaysia.
FAU - Abdul Wahid, S F
AU  - Abdul Wahid SF
AD  - Cell Therapy Centre, Pusat Perubatan Universiti Kebangsaan Malaysia, Cheras,
      Kuala Lumpur, Malaysia.
FAU - Aris, Tahir
AU  - Aris T
AD  - Institute for Medical Research, National Institutes of Health, Ministry of
      Health, Shah Alam, Selangor, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 93NS566KF7 (Gemtuzumab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Gemtuzumab/*therapeutic use
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7299015
OTO - NOTNLM
OT  - *acute myeloid leukaemia
OT  - *efficacy
OT  - *gemtuzumab ozogamicin
OT  - *safety
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/06/17 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-032503 [pii]
AID - 10.1136/bmjopen-2019-032503 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 15;10(6):e032503. doi: 10.1136/bmjopen-2019-032503.


PMID- 32540846
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 7
DP  - 2020 Jul 28
TI  - Bringing Code to Data: Do Not Forget Governance.
PG  - e18087
LID - 10.2196/18087 [doi]
AB  - Developing or independently evaluating algorithms in biomedical research is
      difficult because of restrictions on access to clinical data. Access is
      restricted because of privacy concerns, the proprietary treatment of data by
      institutions (fueled in part by the cost of data hosting, curation, and
      distribution), concerns over misuse, and the complexities of applicable
      regulatory frameworks. The use of cloud technology and services can address many 
      of the barriers to data sharing. For example, researchers can access data in high
      performance, secure, and auditable cloud computing environments without the need 
      for copying or downloading. An alternative path to accessing data sets requiring 
      additional protection is the model-to-data approach. In model-to-data,
      researchers submit algorithms to run on secure data sets that remain hidden.
      Model-to-data is designed to enhance security and local control while enabling
      communities of researchers to generate new knowledge from sequestered data.
      Model-to-data has not yet been widely implemented, but pilots have demonstrated
      its utility when technical or legal constraints preclude other methods of
      sharing. We argue that model-to-data can make a valuable addition to our data
      sharing arsenal, with 2 caveats. First, model-to-data should only be adopted
      where necessary to supplement rather than replace existing data-sharing
      approaches given that it requires significant resource commitments from data
      stewards and limits scientific freedom, reproducibility, and scalability. Second,
      although model-to-data reduces concerns over data privacy and loss of local
      control when sharing clinical data, it is not an ethical panacea. Data stewards
      will remain hesitant to adopt model-to-data approaches without guidance on how to
      do so responsibly. To address this gap, we explored how commitments to open
      science, reproducibility, security, respect for data subjects, and research
      ethics oversight must be re-evaluated in a model-to-data context.
CI  - (c)Christine Suver, Adrian Thorogood, Megan Doerr, John Wilbanks, Bartha
      Knoppers. Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 28.07.2020.
FAU - Suver, Christine
AU  - Suver C
AUID- ORCID: 0000-0002-2986-385X
AD  - Sage Bionetworks, Seattle, WA, United States.
FAU - Thorogood, Adrian
AU  - Thorogood A
AUID- ORCID: 0000-0001-5078-8164
AD  - Centre of Genomics and Policy, McGill University, Montreal, QC, Canada.
FAU - Doerr, Megan
AU  - Doerr M
AUID- ORCID: 0000-0003-2383-5978
AD  - Sage Bionetworks, Seattle, WA, United States.
FAU - Wilbanks, John
AU  - Wilbanks J
AUID- ORCID: 0000-0002-4510-0385
AD  - Sage Bionetworks, Seattle, WA, United States.
FAU - Knoppers, Bartha
AU  - Knoppers B
AUID- ORCID: 0000-0001-7004-2722
AD  - Centre of Genomics and Policy, McGill University, Montreal, QC, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200728
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Biomedical Research/*methods
MH  - Cloud Computing/*standards
MH  - Humans
MH  - Information Dissemination/*methods
MH  - Reproducibility of Results
PMC - PMC7420687
OTO - NOTNLM
OT  - *data management
OT  - *data science
OT  - *ethics, research
OT  - *machine learning
OT  - *privacy
EDAT- 2020/06/17 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - v22i7e18087 [pii]
AID - 10.2196/18087 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jul 28;22(7):e18087. doi: 10.2196/18087.


PMID- 32540345
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210110
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 59
IP  - 5
DP  - 2020 Oct
TI  - Anti-SARS-CoV-2 hyperimmune plasma workflow.
PG  - 102850
LID - S1473-0502(20)30153-1 [pii]
LID - 10.1016/j.transci.2020.102850 [doi]
AB  - Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus has become a 
      Public Health Emergency of International Concern. Among the various treatment
      proposals for COVID-19 infection, passive immunotherapy using plasma from
      recovering patients - "convalescent plasma" (CP)- could be a promising option in 
      the treatment of SARS-CoV-2 infections. Immune (i.e. "convalescent") plasma
      refers to plasma that is collected from individuals, following resolution of
      infection and development of antibodies. Passive antibody administration through 
      transfusion of convalescent plasma may offer the only short-term strategy to
      confer immediate immunity to susceptible individuals. According to the World
      Health Organization (WHO), the use of plasma therapy is permitted when faced with
      <<serious diseases for which there are no effective pharmacological treatments>>.
      Several clinical trials are underway to test the effectiveness of hyperimmune
      plasma at various stages of SARS-CoV2.The Food and Drug Administration (FDA), the
      U.S. regulatory authority, has approved the use of CP for compassionate use in
      the treatment of patients with a critical COVID-19 infection. Below are the
      general indications for drawing up clinical protocols for the integral management
      of "COVID-19-convalescent plasma" for which the validation and approval of the
      Ethics Committees is still necessary.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Annamaria, Petrungaro
AU  - Annamaria P
AD  - Unit of Transfusion Medicine, Department of Services, University Hospital "G.
      Martino" Via Consolare Valeria 1, 98100, Messina, Italy. Electronic address:
      annamaria.petrungaro@polime.it.
FAU - Eugenia, Quartarone
AU  - Eugenia Q
AD  - Unit of Transfusion Medicine, Department of Services, University Hospital "G.
      Martino" Via Consolare Valeria 1, 98100, Messina, Italy. Electronic address:
      e.quartarone@virgilio.it.
FAU - Paolo, Sciarrone
AU  - Paolo S
AD  - Unit of Transfusion Medicine, Department of Services, University Hospital "G.
      Martino" Via Consolare Valeria 1, 98100, Messina, Italy. Electronic address:
      paolo.sciarrone@libero.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200610
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
RN  - COVID-19 serotherapy
MH  - COVID-19/epidemiology/*immunology/*therapy
MH  - Disease Outbreaks
MH  - Humans
MH  - Immunization, Passive
MH  - SARS-CoV-2/physiology
MH  - *Workflow
PMC - PMC7283061
OTO - NOTNLM
OT  - Covid -19
OT  - Hyperimmune plasma
OT  - Passive immunotherapy
EDAT- 2020/06/17 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/05/23 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - S1473-0502(20)30153-1 [pii]
AID - 10.1016/j.transci.2020.102850 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2020 Oct;59(5):102850. doi: 10.1016/j.transci.2020.102850.
      Epub 2020 Jun 10.


PMID- 32540271
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20220220
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 33
DP  - 2020 Jul 14
TI  - COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
PG  - 5085-5088
LID - S0264-410X(20)30768-4 [pii]
LID - 10.1016/j.vaccine.2020.06.007 [doi]
AB  - While a human challenge study holds the prospect of accelerating the development 
      of a vaccine for the coronavirus SARS-CoV-2, it may be opposed due to risks of
      harm to participants and researchers. Given the increasing number of human deaths
      and severe disruption to lives worldwide, we argue that a SARS-CoV-2 challenge
      study is ethically justifiable as its social value substantially outweighs the
      risks. Such a study should therefore be seriously considered as part of the
      global research response towards the COVID-19 pandemic. In this paper, we
      contribute to the debate by addressing the misperception that a challenge study
      for the coronavirus would lower scientific and ethical standards for vaccine
      research and development, and examine how it could be ethically conducted. We
      also set out information that needs to be disclosed to prospective participants
      to obtain their consent.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Schaefer, G Owen
AU  - Schaefer GO
AD  - Centre for Biomedical Ethics, National University of Singapore, Yong Loo Lin
      School of Medicine, Block MD11, Clinical Research Centre, #02-03, 10 Medical
      Drive, Singapore 117597, Singapore.
FAU - Tam, Clarence C
AU  - Tam CC
AD  - Saw Swee Hock School of Public Health, National University of Singapore, Tahir
      Foundation Building (MD1), 12 Science Drive 2, Singapore 117549, Singapore.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Murdoch
      Children's Research Institute, Littlegate House, St Ebbes St, Oxford OX1 1PT, UK.
FAU - Voo, Teck Chuan
AU  - Voo TC
AD  - Centre for Biomedical Ethics, National University of Singapore, Yong Loo Lin
      School of Medicine, Block MD11, Clinical Research Centre, #02-03, 10 Medical
      Drive, Singapore 117597, Singapore. Electronic address: medvtc@nus.edu.sg.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - WT104848/WT_/Wellcome Trust/United Kingdom
GR  - WT203132/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control
MH  - Humans
MH  - Informed Consent
MH  - Pandemics/ethics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Risk
MH  - SARS-CoV-2
MH  - Vaccination/*ethics
MH  - Viral Vaccines/administration & dosage/*therapeutic use
PMC - PMC7269942
OTO - NOTNLM
OT  - *Coronavirus
OT  - *Covid-19
OT  - *Ethics
OT  - *Human challenge study
OT  - *Pandemic
OT  - *Vaccine
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/06/17 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - S0264-410X(20)30768-4 [pii]
AID - 10.1016/j.vaccine.2020.06.007 [doi]
PST - ppublish
SO  - Vaccine. 2020 Jul 14;38(33):5085-5088. doi: 10.1016/j.vaccine.2020.06.007. Epub
      2020 Jun 4.


PMID- 32540095
OWN - NLM
STAT- Publisher
LR  - 20200616
IS  - 1873-5134 (Electronic)
IS  - 0738-3991 (Linking)
DP  - 2020 May 23
TI  - Predictors of medical students' ethical decision-making: A pilot study using the 
      Theory of Interpersonal Behavior.
LID - S0738-3991(20)30292-5 [pii]
LID - 10.1016/j.pec.2020.05.026 [doi]
AB  - OBJECTIVE: To understand medical students' (MS) ethical decision-making using the
      Theory of Interpersonal Behavior (TIB). METHODS: We conducted two rounds of focus
      groups to develop a TIB-based questionnaire by eliciting students' perspectives
      on an ethical dilemma they will encounter in a standardized patient (SP) station,
      in which an SP "surgeon" asked them to intubate a sedated patient whom the
      student knew had requested no student involvement. We administrated
      questionnaires to 241 third-year MS following this SP station, asking for their
      decisions in the SP station and if a surgeon made the same request in their
      clerkship. Confirmatory factor analysis (CFA) was used to test whether observed
      data fit the proposed TIB-based model. RESULTS: The CFA provided an acceptable
      fit to the a priori proposed model. Fifty-five percent of students indicated they
      would intubate in an actual situation versus 18% in the SP station (p<0.05).
      Using logistic regression, TIB domains affect and facilitating factors reported
      significant association with students' decisions in both the SP and hypothesized 
      actual situations. CONCLUSIONS: The TIB appears to be an effective theoretical
      framework for explaining students' ethical decision-making. PRACTICE
      IMPLICATIONS: The TIB may guide design and assessment of educational programs for
      professional formation.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Li, Honghe
AU  - Li H
AD  - Institute for International Health Professions Education and Research, China
      Medical University, Shenyang, China; Cambridge Health Alliance, Harvard Medical
      School, Cambridge, USA. Electronic address: hhli@cmu.edu.cn.
FAU - Novack, Dennis H
AU  - Novack DH
AD  - Office of Educational Affairs, Drexel University College of Medicine,
      Philadelphia, USA.
FAU - Duke, Pamela
AU  - Duke P
AD  - Office of Educational Affairs, Drexel University College of Medicine,
      Philadelphia, USA.
FAU - Gracely, Edward
AU  - Gracely E
AD  - Family Community and Preventive Medicine, Drexel University College of Medicine, 
      Philadelphia, USA.
FAU - Cestone, Christina
AU  - Cestone C
AD  - Office of Educational Affairs, Drexel University College of Medicine,
      Philadelphia, USA.
FAU - Davis, Tiffany
AU  - Davis T
AD  - Office of Educational Affairs, Drexel University College of Medicine,
      Philadelphia, USA.
LA  - eng
PT  - Journal Article
DEP - 20200523
PL  - Ireland
TA  - Patient Educ Couns
JT  - Patient education and counseling
JID - 8406280
OTO - NOTNLM
OT  - Education environment
OT  - Ethical decision-making
OT  - Teaching and learning
OT  - Theory of Interpersonal Behavior
COIS- Declaration of Competing Interest None.
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - S0738-3991(20)30292-5 [pii]
AID - 10.1016/j.pec.2020.05.026 [doi]
PST - aheadofprint
SO  - Patient Educ Couns. 2020 May 23. pii: S0738-3991(20)30292-5. doi:
      10.1016/j.pec.2020.05.026.


PMID- 32540036
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20210802
IS  - 1532-7361 (Electronic)
IS  - 0039-6060 (Linking)
VI  - 168
IP  - 2
DP  - 2020 Aug
TI  - Decision analysis and reinforcement learning in surgical decision-making.
PG  - 253-266
LID - S0039-6060(20)30261-0 [pii]
LID - 10.1016/j.surg.2020.04.049 [doi]
AB  - BACKGROUND: Surgical patients incur preventable harm from cognitive and judgment 
      errors made under time constraints and uncertainty regarding patients' diagnoses 
      and predicted response to treatment. Decision analysis and techniques of
      reinforcement learning theoretically can mitigate these challenges but are poorly
      understood and rarely used clinically. This review seeks to promote an
      understanding of decision analysis and reinforcement learning by describing their
      use in the context of surgical decision-making. METHODS: Cochrane, EMBASE, and
      PubMed databases were searched from their inception to June 2019. Included were
      41 articles about cognitive and diagnostic errors, decision-making, decision
      analysis, and machine-learning. The articles were assimilated into relevant
      categories according to Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses extension for Scoping Reviews guidelines. RESULTS: Requirements for
      time-consuming manual data entry and crude representations of individual patients
      and clinical context compromise many traditional decision-support tools. Decision
      analysis methods for calculating probability thresholds can inform
      population-based recommendations that jointly consider risks, benefits, costs,
      and patient values but lack precision for individual patient-centered decisions. 
      Reinforcement learning, a machine-learning method that mimics human learning, can
      use a large set of patient-specific input data to identify actions yielding the
      greatest probability of achieving a goal. This methodology follows a sequence of 
      events with uncertain conditions, offering potential advantages for personalized,
      patient-centered decision-making. Clinical application would require secure
      integration of multiple data sources and attention to ethical considerations
      regarding liability for errors and individual patient preferences. CONCLUSION:
      Traditional decision-support tools are ill-equipped to accommodate time
      constraints and uncertainty regarding diagnoses and the predicted response to
      treatment, both of which often impair surgical decision-making. Decision analysis
      and reinforcement learning have the potential to play complementary roles in
      delivering high-value surgical care through sound judgment and optimal
      decision-making.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Loftus, Tyler J
AU  - Loftus TJ
AD  - Department of Surgery, University of Florida Health, Gainesville, FL.
FAU - Filiberto, Amanda C
AU  - Filiberto AC
AD  - Department of Surgery, University of Florida Health, Gainesville, FL.
FAU - Li, Yanjun
AU  - Li Y
AD  - NSF Center for Big Learning, University of Florida, Gainesville, FL.
FAU - Balch, Jeremy
AU  - Balch J
AD  - Department of Surgery, University of Florida Health, Gainesville, FL.
FAU - Cook, Allyson C
AU  - Cook AC
AD  - Department of Medicine, University of California, San Francisco, CA.
FAU - Tighe, Patrick J
AU  - Tighe PJ
AD  - Departments of Anesthesiology, Orthopedics, and Information Systems/Operations
      Management, University of Florida Health, Gainesville, FL.
FAU - Efron, Philip A
AU  - Efron PA
AD  - Department of Surgery, University of Florida Health, Gainesville, FL.
FAU - Upchurch, Gilbert R Jr
AU  - Upchurch GR Jr
AD  - Department of Surgery, University of Florida Health, Gainesville, FL.
FAU - Rashidi, Parisa
AU  - Rashidi P
AD  - Departments of Biomedical Engineering, Computer and Information Science and
      Engineering, and Electrical and Computer Engineering, University of Florida,
      Gainesville, FL; Precision and Intelligence in Medicine, Department of Medicine, 
      University of Florida Health, Gainesville, FL.
FAU - Li, Xiaolin
AU  - Li X
AD  - NSF Center for Big Learning, University of Florida, Gainesville, FL.
FAU - Bihorac, Azra
AU  - Bihorac A
AD  - Department of Medicine, University of California, San Francisco, CA; Precision
      and Intelligence in Medicine, Department of Medicine, University of Florida
      Health, Gainesville, FL. Electronic address: abihorac@ufl.edu.
LA  - eng
GR  - R01 GM114290/GM/NIGMS NIH HHS/United States
GR  - R21 EB027344/EB/NIBIB NIH HHS/United States
GR  - T32 GM008721/GM/NIGMS NIH HHS/United States
GR  - P50 GM111152/GM/NIGMS NIH HHS/United States
GR  - R01 GM110240/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Systematic Review
DEP - 20200613
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
SB  - IM
MH  - Attitude to Health
MH  - *Clinical Decision-Making
MH  - Decision Making, Shared
MH  - *Decision Support Techniques
MH  - Decision Trees
MH  - Electronic Health Records
MH  - Humans
MH  - *Machine Learning
MH  - Numbers Needed To Treat
MH  - Patient Preference
MH  - Patient-Centered Care
MH  - *Surgical Procedures, Operative
PMC - PMC7390703
MID - NIHMS1605711
EDAT- 2020/06/17 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
AID - S0039-6060(20)30261-0 [pii]
AID - 10.1016/j.surg.2020.04.049 [doi]
PST - ppublish
SO  - Surgery. 2020 Aug;168(2):253-266. doi: 10.1016/j.surg.2020.04.049. Epub 2020 Jun 
      13.


PMID- 32539808
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 15
TI  - Cerebrospinal fluid cytokines in metastatic group 3 and 4 medulloblastoma.
PG  - 554
LID - 10.1186/s12885-020-07048-0 [doi]
AB  - BACKGROUND: Metastatic medulloblastoma (MB) portends a poor prognosis. Amongst
      the 4 molecular subtypes, Group 3 and Group 4 patients have a higher incidence of
      metastatic disease, especially involving the neuroaxis. At present, mechanisms
      underlying MB metastasis remain elusive. Separately, inflammation has been
      implicated as a key player in tumour development and metastasis. Cytokines and
      their inflammation-related partners have been demonstrated to act on autocrine
      and, or paracrine pathways within the tumour microenvironment for various
      cancers. In this study, the authors explore the involvement of cerebrospinal
      fluid (CSF) cytokines in Group 3 and 4 MB patients with disseminated disease.
      METHODS: This is an ethics approved, retrospective study of prospectively
      collected data based at a single institution. Patient clinicpathological data and
      corresponding bio-materials are collected after informed consent. All CSF samples
      are interrogated using a proteomic array. Resultant expression data of selected
      cytokines are correlated with each individual's clinical information. Statistical
      analysis is employed to determine the significance of the expression of CSF
      cytokines in Group 3 and 4 patients with metastatic MB versus non-metastatic MB. 
      RESULTS: A total of 10 patients are recruited for this study. Median age of the
      cohort is 6.6 years old. Based on Nanostring gene expression analysis, 5 patients
      have Group 3 as their molecular subtype and the remaining 5 are Group 4. There
      are 2 non-metastatic versus 3 metastatic patients within each molecular subtype. 
      Proteomic CSF analysis of all patients for both subtypes show higher expression
      of CCL2 in the metastatic group versus the non-metastatic group. Within the Group
      3 subtype, the MYC-amplified Group 3 MB patients with existing and delayed
      metastases express higher levels of CXCL1, IL6 and IL8 in their CSF specimens at 
      initial presentation. Furthermore, a longitudinal study of metastatic Group 3 MB 
      observes that selected cytokines are differentially expressed in MYC-amplified
      metastatic Group 3 MB, in comparison to the non-MYC amplified metastatic Group 3 
      MB patient. CONCLUSION: This study demonstrates higher expression of selected CSF
      cytokines, in particular CCL2, in metastatic Group 3 and 4 MB patients. Although 
      our results are preliminary, they establish a proof-of-concept basis for
      continued work in a larger cohort of patients affected by this devastating
      disease.
FAU - Low, Sharon Y Y
AU  - Low SYY
AUID- ORCID: http://orcid.org/0000-0001-7317-670X
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      Singapore, 229899, Singapore. sharon.low.y.y@singhealth.com.sg.
AD  - Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore. sharon.low.y.y@singhealth.com.sg.
AD  - SingHealth Duke-NUS Neuroscience Academic Clinical Program, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore. sharon.low.y.y@singhealth.com.sg.
AD  - VIVA-KKH Paediatric Brain and Solid Tumours Laboratory, 100 Bukit Timah Road,
      Singapore, 229899, Singapore. sharon.low.y.y@singhealth.com.sg.
FAU - Bte Syed Sulaiman, Nurfahanah
AU  - Bte Syed Sulaiman N
AD  - Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore.
AD  - VIVA-KKH Paediatric Brain and Solid Tumours Laboratory, 100 Bukit Timah Road,
      Singapore, 229899, Singapore.
FAU - Tan, Enrica E K
AU  - Tan EEK
AD  - Paediatric Haematology/Oncology Service, KK Women's and Children's Hospital, 100 
      Bukit Timah Road, Singapore, 229899, Singapore.
FAU - Ng, Lee Ping
AU  - Ng LP
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      Singapore, 229899, Singapore.
FAU - Kuick, Chik Hong
AU  - Kuick CH
AD  - Department of Pathology and Laboratory Medicine, KK Women's and Children's
      Hospital, 100 Bukit Timah Road, Singapore, 229899, Singapore.
FAU - Chang, Kenneth T E
AU  - Chang KTE
AD  - VIVA-KKH Paediatric Brain and Solid Tumours Laboratory, 100 Bukit Timah Road,
      Singapore, 229899, Singapore.
AD  - Department of Pathology and Laboratory Medicine, KK Women's and Children's
      Hospital, 100 Bukit Timah Road, Singapore, 229899, Singapore.
FAU - Tang, Phua Hwee
AU  - Tang PH
AD  - Department of Diagnostic and Interventional Imaging, KK Women's and Children's
      Hospital, 100 Bukit Timah Road, Singapore, 229899, Singapore.
FAU - Wong, Ru Xin
AU  - Wong RX
AD  - Department of Radiation Oncology, 11 Hospital Drive, Singapore, 169610,
      Singapore.
FAU - Looi, Wen Shen
AU  - Looi WS
AD  - Department of Radiation Oncology, 11 Hospital Drive, Singapore, 169610,
      Singapore.
FAU - Low, David C Y
AU  - Low DCY
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      Singapore, 229899, Singapore.
AD  - Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore.
AD  - SingHealth Duke-NUS Neuroscience Academic Clinical Program, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore.
FAU - Seow, Wan Tew
AU  - Seow WT
AD  - Neurosurgical Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 
      Singapore, 229899, Singapore.
AD  - Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore.
AD  - SingHealth Duke-NUS Neuroscience Academic Clinical Program, 11 Jalan Tan Tock
      Seng, Singapore, 308433, Singapore.
LA  - eng
GR  - Not applicable/VIVA-KKH Paediatric Brain and Solid Tumour Programme.
PT  - Journal Article
PT  - Observational Study
DEP - 20200615
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cytokines)
SB  - IM
MH  - Biomarkers, Tumor/*cerebrospinal fluid/immunology
MH  - Brain/diagnostic imaging
MH  - Cerebellar Neoplasms/cerebrospinal fluid/immunology/*pathology/surgery
MH  - Child
MH  - Child, Preschool
MH  - Cytokines/*cerebrospinal fluid/immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Profiling
MH  - Humans
MH  - Longitudinal Studies
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Medulloblastoma/cerebrospinal fluid/*diagnosis/secondary/surgery
MH  - Proof of Concept Study
MH  - Prospective Studies
MH  - Proteomics
MH  - Retrospective Studies
PMC - PMC7296667
OTO - NOTNLM
OT  - Cerebrospinal fluid
OT  - Cytokines
OT  - Medulloblastoma
OT  - Metastasis
EDAT- 2020/06/17 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/10/08 00:00 [received]
PHST- 2020/06/06 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1186/s12885-020-07048-0 [doi]
AID - 10.1186/s12885-020-07048-0 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Jun 15;20(1):554. doi: 10.1186/s12885-020-07048-0.


PMID- 32539786
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 2047-2994 (Electronic)
IS  - 2047-2994 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Jun 15
TI  - Prevention of severe infectious complications after colorectal surgery using oral
      non-absorbable antimicrobial prophylaxis: results of a multicenter randomized
      placebo-controlled clinical trial.
PG  - 84
LID - 10.1186/s13756-020-00745-2 [doi]
AB  - BACKGROUND: Surgical site infections (SSIs) are common complications after
      colorectal surgery. Oral non-absorbable antibiotic prophylaxis (OAP) can be
      administered preoperatively to reduce the risk of SSIs. Its efficacy without
      simultaneous mechanical cleaning is unknown. METHODS: The Precaution trial was a 
      double-blind, placebo-controlled randomized clinical trial conducted in six Dutch
      hospitals. Adult patients who underwent elective colorectal surgery were
      randomized to receive either a three-day course of preoperative OAP with
      tobramycin and colistin or placebo. The primary composite endpoint was the
      incidence of deep SSI or mortality within 30 days after surgery. Secondary
      endpoints included both infectious and non-infectious complications at 30 days
      and six months after surgery. RESULTS: The study was prematurely ended due to the
      loss of clinical equipoise. At that time, 39 patients had been randomized to
      active OAP and 39 to placebo, which reflected 8.1% of the initially pursued
      sample size. Nine (11.5%) patients developed the primary outcome, of whom four
      had been randomized to OAP (4/39; 10.3%) and five to placebo (5/39; 12.8%). This 
      corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95%
      confidence interval (CI) 0.23-2.78). In the per-protocol analysis, the relative
      risk was 0.64 (95% CI 0.12-3.46). CONCLUSIONS: Observational data emerging during
      the study provided new evidence for the effectiveness of OAP that changed both
      the clinical and medical ethical landscape for infection prevention in colorectal
      surgery. We therefore consider it unethical to continue randomizing patients to
      placebo. We recommend the implementation of OAP in clinical practice and
      continuing monitoring of infection rates and antibiotic susceptibilities. TRIAL
      REGISTRATION: The PreCaution trial is registered in the Netherlands Trial
      Register under NL5932 (previously: NTR6113) as well as in the EudraCT register
      under 2015-005736-17.
FAU - Mulder, Tessa
AU  - Mulder T
AUID- ORCID: 0000-0003-4556-0338
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
FAU - Kluytmans-van den Bergh, Marjolein
AU  - Kluytmans-van den Bergh M
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
AD  - Amphia Academy Infectious Disease Foundation, Amphia Hospital, Breda, The
      Netherlands.
AD  - Department of Infection Control, Amphia Hospital, Breda, The Netherlands.
FAU - Vlaminckx, Bart
AU  - Vlaminckx B
AD  - Department of Medical Microbiology, St. Antonius Hospital, Nieuwegein, the
      Netherlands.
FAU - Roos, Daphne
AU  - Roos D
AD  - Department of Surgery, Reinier de Graaf Gasthuis, Delft, The Netherlands.
FAU - de Smet, Anne Marie
AU  - de Smet AM
AD  - Department of Intensive Care Medicine, University Medical Center Groningen,
      University of Groningen, Groningen, The Netherlands.
FAU - de Vos Tot Nederveen Cappel, Robert
AU  - de Vos Tot Nederveen Cappel R
AD  - Department of Surgery, Admiraal de Ruyter Hospital, Goes, The Netherlands.
FAU - Verheijen, Paul
AU  - Verheijen P
AD  - Department of Surgery, Meander Medical Center, Amersfoort, The Netherlands.
FAU - Brandt, Alexandra
AU  - Brandt A
AD  - Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Smits, Anke
AU  - Smits A
AD  - Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
FAU - van der Vorm, Eric
AU  - van der Vorm E
AD  - Department of Medical Microbiology, Reinier de Graaf Gasthuis, Delft, The
      Netherlands.
FAU - Bathoorn, Erik
AU  - Bathoorn E
AD  - Department of Medical Microbiology, University Medical Center Groningen,
      University of Groningen, Groningen, The Netherlands.
FAU - van Etten, Boudewijn
AU  - van Etten B
AD  - Department of Surgery, University Medical Center Groningen, Groningen, The
      Netherlands.
FAU - Veenemans, Jacobien
AU  - Veenemans J
AD  - Department of Medical Microbiology, Admiraal de Ruyter Hospital, Goes, the
      Netherlands.
FAU - Weersink, Annemarie
AU  - Weersink A
AD  - Department of Medical Microbiology, Meander Medical Center, Amersfoort, The
      Netherlands.
FAU - Vos, Margreet
AU  - Vos M
AD  - Department of Microbiology and Infectious Diseases, Erasmus Medical Center,
      Rotterdam, The Netherlands.
FAU - van 't Veer, Nils
AU  - van 't Veer N
AD  - Department of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands.
FAU - Nikolakopoulos, Stavros
AU  - Nikolakopoulos S
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
FAU - Bonten, Marc
AU  - Bonten M
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands.
AD  - Department of Medical Microbiology, Utrecht University Medical Center, Utrecht
      University, Utrecht, The Netherlands.
FAU - Kluytmans, Jan
AU  - Kluytmans J
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht University, Utrecht, The Netherlands. jankluytmans@gmail.com.
AD  - Department of Infection Control, Amphia Hospital, Breda, The Netherlands.
      jankluytmans@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - Antimicrob Resist Infect Control
JT  - Antimicrobial resistance and infection control
JID - 101585411
RN  - VZ8RRZ51VK (Tobramycin)
RN  - Z67X93HJG1 (Colistin)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antibiotic Prophylaxis
MH  - Colistin/*administration & dosage/pharmacology
MH  - Colorectal Surgery/*adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Surgical Wound Infection/epidemiology/*prevention & control
MH  - Therapeutic Equipoise
MH  - Tobramycin/*administration & dosage/pharmacology
PMC - PMC7294517
OTO - NOTNLM
OT  - *Colorectal surgery
OT  - *Infection control
OT  - *Preoperative oral antibiotic prophylaxis
OT  - *Surgical site infection
EDAT- 2020/06/17 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/06/17 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
AID - 10.1186/s13756-020-00745-2 [doi]
AID - 10.1186/s13756-020-00745-2 [pii]
PST - epublish
SO  - Antimicrob Resist Infect Control. 2020 Jun 15;9(1):84. doi:
      10.1186/s13756-020-00745-2.


PMID- 32539718
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20211204
IS  - 1471-2288 (Electronic)
IS  - 1471-2288 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 15
TI  - Including 'seldom heard' views in research: opportunities, challenges and
      recommendations from focus groups with British South Asian people with type 2
      diabetes.
PG  - 157
LID - 10.1186/s12874-020-01045-4 [doi]
AB  - BACKGROUND: The inclusion of 'seldom heard' groups in health and social care
      research is increasingly seen as important on scientific, policy and ethical
      grounds. British South Asians, the largest minority ethnic group in the United
      Kingdom (UK), are under-represented in health research yet over-represented in
      the incidence of certain conditions such as type 2 diabetes. With the growing
      requirement of patient involvement in research and the inclusion of diverse
      populations, methodological guidance on how to include, engage and conduct
      research with UK South Asian populations is essential if services and
      interventions are to be relevant and impactful. However, such guidance for
      researchers is limited. METHODS: The aim of the paper is to reflect on our
      experiences of conducting focus groups with UK South Asian communities with type 
      2 diabetes, which involved experienced community partners and researchers working
      closely together. We discuss the factors that aided the successful delivery of
      the project, the challenges that we encountered, how we dealt with these, and
      recommendations. RESULTS: Our study suggests ways to involve and conduct focus
      groups with UK South Asian populations. Key considerations are categorised under 
      four headings: co-working with community partners; linguistic competency;
      cultural competency and awareness; and reflexivity, power and acknowledgement.
      Having an experienced team of researchers and community experts - with the
      relevant linguistic and cultural competencies and different kinds of knowledge
      and skills - was key to the successful delivery of the study. Working
      collaboratively enabled us to recruit a diverse sample, to navigate the
      challenges of recruitment, to be present at every discussion which helped
      contribute to data richness, and to reflect on our own roles in the research
      process. CONCLUSIONS: Focus groups with UK South Asian communities can be a
      useful way of exploring new topics and involving seldom heard views. While a
      useful method, focus groups are only one way of exploring a research topic and
      provide an insight into context-specific attitudes and views. Future research
      should explore British South Asian participants' views on how they would like to 
      be involved in research, including new methods of collecting data and coproducing
      research.
FAU - Prinjha, Suman
AU  - Prinjha S
AUID- ORCID: 0000-0001-8299-6646
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
      suman.prinjha@phc.ox.ac.uk.
FAU - Miah, Nasima
AU  - Miah N
AD  - Centre for BME Health, Diabetes Research Centre, University of Leicester,
      Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW, UK.
FAU - Ali, Ebrahim
AU  - Ali E
AD  - Bangladesh Youth & Cultural Shomiti (BYCS), 30-32 Biddulph Street, Leicester, LE2
      1BF, UK.
FAU - Farmer, Andrew
AU  - Farmer A
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
LA  - eng
GR  - RP-PG-1214-20003/DH_/Department of Health/United Kingdom
GR  - RP-PG-1214-20003/Programme Grants for Applied Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - England
TA  - BMC Med Res Methodol
JT  - BMC medical research methodology
JID - 100968545
SB  - IM
MH  - Asians
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - *Ethnicity
MH  - Focus Groups
MH  - Humans
MH  - United Kingdom
PMC - PMC7296709
OTO - NOTNLM
OT  - *Diabetes
OT  - *Focus groups
OT  - *Patient and public involvement
OT  - *Qualitative methods
OT  - *Reflexivity
OT  - *Seldom heard
OT  - *South Asian
EDAT- 2020/06/17 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/06/17 06:00
PHST- 2019/02/28 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s12874-020-01045-4 [doi]
AID - 10.1186/s12874-020-01045-4 [pii]
PST - epublish
SO  - BMC Med Res Methodol. 2020 Jun 15;20(1):157. doi: 10.1186/s12874-020-01045-4.


PMID- 32539026
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2042-8189 (Electronic)
IS  - 1478-2715 (Linking)
VI  - 50
IP  - 1
DP  - 2020 Mar
TI  - Publication misconducts related to copyright: tread carefully to avoid falling.
PG  - 3-5
LID - 10.4997/JRCPE.2020.101 [doi]
FAU - Misra, Durga Prasanna
AU  - Misra DP
AD  - Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of
      Medical Sciences (SGPGIMS), Lucknow, India.
FAU - Ravindran, Vinod
AU  - Ravindran V
AD  - Centre for Rheumatology, Calicut, Kerala India, Email: drvinod12@gmail.com.
LA  - eng
PT  - Editorial
PL  - England
TA  - J R Coll Physicians Edinb
JT  - The journal of the Royal College of Physicians of Edinburgh
JID - 101144324
SB  - IM
MH  - *Accidental Falls
MH  - *Copyright
MH  - Humans
MH  - Plagiarism
MH  - Publishing
OTO - NOTNLM
OT  - *duplicate publication
OT  - *ethics
OT  - *medical writing
OT  - *plagiarism
OT  - *research
COIS- DPM is Associate Editor of the Journal of the Royal College of Physicians of
      Edinburgh (JRCPE), and serves as editor/editorial board member/ reviewer for
      several other international journals. VR is the Editor-in-Chief of the JRCPE and 
      serves as editor/editorial board member/reviewer for several other international 
      journals. This paper has undergone peer review in accordance with JRCPE's
      policies.
EDAT- 2020/06/17 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.4997/JRCPE.2020.101 [doi]
PST - ppublish
SO  - J R Coll Physicians Edinb. 2020 Mar;50(1):3-5. doi: 10.4997/JRCPE.2020.101.


PMID- 32538929
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Thyroid Dysfunction in Patients with Abnormal Uterine Bleeding in a Tertiary Care
      Hospital: A Descriptive Cross-sectional Study.
PG  - 333-337
LID - 10.31729/jnma.5033 [doi]
AB  - INTRODUCTION: Abnormal uterine bleeding is a common gynecological presentation,
      accounting for at least 20% of all new outpatient visits. It has been recognized 
      that thyroid dysfunction may have profound effects on the female reproductive
      system. Both hypothyroidism and hyperthyroidism are associated with a variety of 
      changes, including delayed onset of puberty, anovulatory cycles, and abnormally
      high fetal wastage. Hence, this study was conducted to know the thyroid status of
      the patient with abnormal uterine bleeding. METHODS: A descriptive
      cross-sectional study was conducted in all the patients with abnormal uterine
      bleeding in a tertiary care hospital from 2 August 2019 to 2 February 2020.
      Ethical clearance was received from the institutional review committee of KIST
      Medical College. Convenient sampling was done. Data was collected using a
      questionnaire which includes patients profile, the pattern of abnormal uterine
      bleeding, and thyroid profile. Statistical analysis was done using Statistical
      Package for the Social Sciences version 23. RESULTS: Out of 79 patients, it was
      found that 67 (84.8%) were euthyroid, 11 (13.9%) were hypothyroid,and 1 (1.2%)
      was hyperthyroidism. The most common type of abnormal uterine bleeding
      wasmenorrhagia 34 (43%), followed by polymenorrhoea 23 (29%), oligomenorrhoea 13 
      (16.5%), menometrorrhagia 6 (7.6%), metrorrhagia 2 (2.5%), and hypomenorrhea 1
      (1.3%). The maximum number of patients was between 20-25 years with the mean age 
      of 31 years. Among hypothyroid, 7(8.8%) had subclinical hypothyroidism and 4 (5%)
      had frank hypothyroidism. CONCLUSIONS: Most females with abnormal uterine
      bleeding were euthyroid. Menorrhagia was the most common pattern of abnormal
      uterine bleeding.
FAU - Thakur, Minaxi
AU  - Thakur M
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
FAU - Maharjan, Meenu
AU  - Maharjan M
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
FAU - Tuladhar, Heera
AU  - Tuladhar H
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
FAU - Dwa, Yam
AU  - Dwa Y
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
FAU - Bhandari, Sunita
AU  - Bhandari S
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
FAU - Maskey, Smrity
AU  - Maskey S
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
FAU - Bajracharya, Manisha
AU  - Bajracharya M
AD  - Department of Obstetrics and Gynecology, KIST Medical College, Imadol, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Hyperthyroidism/*epidemiology
MH  - Hypothyroidism/*epidemiology
MH  - Metrorrhagia/*epidemiology
MH  - Middle Aged
MH  - Tertiary Care Centers
MH  - Thyroid Diseases/*epidemiology
MH  - Young Adult
PMC - PMC7654461
OTO - NOTNLM
OT  - hyperthyroidism; hypothyroidism; thyroid; uterine bleeding.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.5033 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):333-337. doi: 10.31729/jnma.5033.


PMID- 32538928
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Self-medication Practice of Antibiotics among Medical and Dental Undergraduate
      Students in a Medical College in Eastern Nepal: A Descriptive Cross-sectional
      Study.
PG  - 328-332
LID - 10.31729/jnma.4914 [doi]
AB  - INTRODUCTION: Self-medication plays significant role in the development of
      adverse drug reactions, antibiotic resistance, and masking of underlying
      diseases. Medical students have some knowledge about the use of antibiotics and
      have a higher chance of irrational and injudicious use. This study aims to find
      the prevalence of self-medication practice of antibiotics among medical and
      dental undergraduate students. METHODS: A descriptive cross-sectional study was
      done among medical and dental undergraduate students from the first year to the
      fifth year at BP Koirala Institute of Health Sciences from 1st June 2018 to 30th 
      August 2018. Ethical approval was obtained from the Institutional Review
      Committee (IRC/1210/018). Whole sampling was done. Data was collected using a
      self-responding, semistructured questionnaire and analyzed using Statistical
      Package for the Social Sciences version 11.5. RESULTS: In total 558 students, the
      prevalence of self-medication practice of different antibiotics was 285 (51.1%)
      within the past year. Among self-medicated students, 152 (53.3%) were males. The 
      common drug self-medicated was Azithromycin 80 (28.1%) and the common medical
      condition to use non-prescription antibiotics was for treatment of sore throat
      with runny nose 129 (45.3%). The main source for obtaining non-prescription
      antibiotics were retail pharmacies 157 (55.1%). CONCLUSIONS: Self-medication with
      antibiotics was at increasing rate with each succeeding years of the medical
      courses. Medical students should be made aware of the rational use of antibiotics
      by incorporating appropriate courses in their academic curriculum for more
      refined practice on antibiotics rather than advancement of theoretical knowledge 
      alone.
FAU - Mandal, Namita Kumari
AU  - Mandal NK
AD  - Department of Pharmacology, BP Koirala Institute of Health Sciences, Dharan,
      Nepal.
FAU - Rauniyar, Gajendra Prasad
AU  - Rauniyar GP
AD  - Department of Pharmacology, BP Koirala Institute of Health Sciences, Dharan,
      Nepal.
FAU - Rai, Dilli Sher
AU  - Rai DS
AD  - Department of Pharmacology, BP Koirala Institute of Health Sciences, Dharan,
      Nepal.
FAU - Panday, Dipesh Raj
AU  - Panday DR
AD  - Department of Pharmacology, BP Koirala Institute of Health Sciences, Dharan,
      Nepal.
FAU - Kushwaha, Ramayan
AU  - Kushwaha R
AD  - Department of Pharmacology, BP Koirala Institute of Health Sciences, Dharan,
      Nepal.
FAU - Agrawal, Santosh Kumari
AU  - Agrawal SK
AD  - Department of Public Health Dentistry, College of Dental Surgery, BP Koirala
      Institute of Health Sciences, Dharan, Nepal.
FAU - Regmee, Pragya
AU  - Regmee P
AD  - Department of Oral Medicine and Radiology, BP Koirala Institute of Health
      Sciences, Dharan, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - *Anti-Bacterial Agents/therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Nepal
MH  - *Self Medication
MH  - *Students, Medical
PMC - PMC7654467
OTO - NOTNLM
OT  - antibiotics; drugs; medical students; prescription; self medication.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4914 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):328-332. doi: 10.31729/jnma.4914.


PMID- 32538927
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Study of Arteriovenous Fistula Cases in a Tertiary Care Hospital: A Descriptive
      Cross-sectional Study.
PG  - 324-327
LID - 10.31729/jnma.4957 [doi]
AB  - INTRODUCTION: Arteriovenous fistulas are a preferred choice for hemodialysis
      access in chronic kidney disease patients. There is increased adoption of
      arteriovenous fistula creation in Nepal. Our objective is to study various
      arteriovenous fistulas that have been created in our center. METHODS: This is a
      descriptive cross-sectional study conducted in a tertiary care hospital including
      all cases of arteriovenous fistula creation from January 2018 to December 2019.
      We obtained the ethical clearance from the institutional review committee of
      Kathmandu University School of Medical sciences. Convenient sampling method was
      used. Detailed vascular mapping and color doppler ultrasonography was done in the
      bilateral upper limb as preoperative preparation and to choose a site for
      arteriovenous fistula creation. Data were entered into the Statistical Package
      for the Social Sciences version 20 for analysis. RESULTS: Among 50 patients, the 
      most common location was brachiobasilic 20 (40%) patients followed by
      brachiocephalic 18 (36%), radiocephalic 11 (22%), and arteriovenous graft between
      the brachial artery and axillary vein 1 (2%). The mean duration of hospital stay 
      was 1.44 days. Three (6%) patients required re-intervention, all within 24 hours.
      Two (4%) patients had a failure of arteriovenous fistula requiring the creation
      of a new arteriovenous fistula. CONCLUSIONS: Brachiobasilic was the most common
      location for arteriovenous fistula creation. Reintervention was not common.
FAU - Karmacharya, Robin Man
AU  - Karmacharya RM
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Vaidya, Satish
AU  - Vaidya S
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Singh, Amit Kumar
AU  - Singh AK
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Dahal, Sushil
AU  - Dahal S
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Dhakal, Prasesh
AU  - Dhakal P
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Bhandari, Niroj
AU  - Bhandari N
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Bade, Sohail
AU  - Bade S
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Shrestha, Prabha
AU  - Shrestha P
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
FAU - Thapa, Pratima
AU  - Thapa P
AD  - Department of Surgery, Kathmandu University Teaching Hospital, Dhulikhel,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Arteriovenous Fistula/epidemiology
MH  - *Arteriovenous Shunt, Surgical
MH  - Brachial Artery
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Nepal/epidemiology
MH  - Renal Dialysis
MH  - Retrospective Studies
MH  - Tertiary Care Centers
MH  - Treatment Outcome
MH  - Vascular Patency
PMC - PMC7654469
OTO - NOTNLM
OT  - arteriovenous fistula; chronic kidney disease; Nepal.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4957 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):324-327. doi: 10.31729/jnma.4957.


PMID- 32538926
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Psychiatric Morbidities of Elderly Out-patients Attending Various Outreach
      Clinics in Gandaki Province of Nepal: A Descriptive Cross-sectional Study.
PG  - 318-323
LID - 10.31729/jnma.4996 [doi]
AB  - INTRODUCTION: Dramatic growth of the aging population resulted in an increased
      number of mental disorders and such data are limited in Nepal. The objective is
      to find out the psychiatric morbidities of elderly out-patients attending
      Baglung, Kusma, Walling, and Dumre out-reach clinics in Gandaki Province of
      Nepal. METHODS: This was a descriptive cross-sectional study conducted in 392
      patients attending out-reach clinics of Baglung, Kusma, Walling, and Dumre of
      Gandaki Province for one year with the convenient sampling method. Ethical
      approval was taken from the Institutional Review Committee of Manipal College of 
      Medical Sciences, Pokhara. The diagnosis was done according to the International 
      Classification of Disease-10 guidelines. Epi-info 7 was used and point estimate
      at 95% Confidence Interval was calculated along with frequency and proportion for
      binary data and the analysis was done. RESULTS: The prevalence of neurotic,
      stress-related, and somatoform disorders 145 (37.0%) was maximum followed by mood
      disorders 111 (28.3%). Maximum cases were in between 66 and 75 years, Brahmin and
      Chhetri caste, females, married, and from an extended nuclear family. There is
      more prevalence of female gender in all psychiatric diagnoses except in mental
      and behavioral disorders due to psychoactive substance use. There is more
      prevalence of age groups of patients less than or equal to 75 years in all the
      psychiatric diagnosis. CONCLUSIONS: Neurotic, stress-related, and somatoform
      disorders were the most common diagnosis. The risk of development of certain
      disorders based on gender and age group of the patients would be helpful for case
      identification.
FAU - Khattri, Jai Bahadur
AU  - Khattri JB
AD  - Department of Psychiatry, Manipal College of Medical Sciences, Pokhara, Nepal.
FAU - Godar, Srijana Thapa
AU  - Godar ST
AD  - Department of Ophthalmology, Manipal College of Medical Sciences, Pokhara, Nepal.
FAU - Subedi, Anil
AU  - Subedi A
AD  - Department of Psychiatry, Manipal College of Medical Sciences, Pokhara, Nepal.
FAU - Tirkey, Shweta
AU  - Tirkey S
AD  - Department of Psychiatry, Manipal College of Medical Sciences, Pokhara, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Aged/*psychology
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Disorders/*epidemiology
MH  - Morbidity
MH  - Nepal/epidemiology
MH  - *Outpatients
MH  - Prevalence
MH  - Tertiary Care Centers
PMC - PMC7654465
OTO - NOTNLM
OT  - aging; cross-sectional studies; Nepal; prevalence.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4996 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):318-323. doi: 10.31729/jnma.4996.


PMID- 32538925
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Prevalence of Type 2 Diabetes Mellitus among People Attending Medical Camp in a
      Community Hospital.
PG  - 314-317
LID - 10.31729/jnma.4953 [doi]
AB  - INTRODUCTION: Diabetes is a health problem on the rise in developing countries
      like Nepal. Often in the suburban and rural areas, patients are diagnosed in the 
      late stages with complications. The aim of this study is to find out the
      prevalence of diabetes type 2 in a community hospital of Nepal. METHODS: This is 
      a descriptive cross-sectional study done in a community hospital from January to 
      March of 2019 after ethical clearance (Registration number: 150320192) from the
      institutional review committee of Kathmandu Medical College. Convenient sampling 
      technique was used. Glucometer using glucose sticks is used to measure random
      blood sugar level and relevant questions were asked in a short interview. The
      data were analyzed using the Statistical Package for the Social Sciences 20
      version. RESULTS: Out of a total of 114 people, the prevalence of type 2 diabetes
      mellitus was 5 (4.38%). Among those 5 (4.385%) people with type 2 diabetes
      mellitus, 2 (1.75%) were female and 3 (2.63%) were male. The minimum age of the
      patient was 17 years and the maximum age was 92 years. Five out of 95 patients
      with mild physical activity had random blood sugar more than 200 mg/dl and five
      out of 46 alcoholic patients had random blood sugar levels more than 200 mg/dl.
      Only 1 out of 26 smokers had a random blood sugar level of more than 200 mg/dl.
      CONCLUSIONS: Prevalence of diabetes mellitus type 2 in our study population is
      quite high. Early detection of diabetes mellitus type 2 can be a good screening
      tool for early treatment and prevention of complications.
FAU - Kushwaha, Anu
AU  - Kushwaha A
AD  - Department of Emergency Medicine and General Practice, Kathmandu Medical College 
      Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Kadel, Anuj Raj
AU  - Kadel AR
AD  - Kathmandu Medical College Teaching Hospital, Duwakot, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alcoholism
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Female
MH  - Hospitals, Community
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - Young Adult
PMC - PMC7654473
OTO - NOTNLM
OT  - diabetes mellitus; prevalence; screening.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4953 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):314-317. doi: 10.31729/jnma.4953.


PMID- 32538924
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Prevalence of Congenital Malformations among Babies Delivered at a Tertiary Care 
      Hospital.
PG  - 310-313
LID - 10.31729/jnma.4985 [doi]
AB  - INTRODUCTION: Congenital malformations have emerged as a major cause of
      stillbirths and neonatal mortality. It is a common cause of morbidity and
      mortality not only in the newborn but also in childhood and beyond. The objective
      of this study was to find the prevalence of congenital malformation at birth.
      METHODS: The descriptive cross-sectional study was conducted among 2456 live
      births in Kathmandu Medical College and Teaching Hospital from April 2017 to
      March 2018 after obtaining ethical approval from the institutional review
      committee (Ref no. 08052017). A convenient sampling method was applied. All the
      live-born babies delivered in this hospital during the study period were
      clinically examined for the presence of congenital anomalies. All malformations
      were classified according to the International Classification of Diseases-10
      classification. The mothers of the newborns with congenital malformations were
      interviewed in a predesigned proforma. Statistical analysis was done using
      statistical package for the social sciences version 20. RESULTS: Out of 2456
      examined live births, congenital malformations were observed in 66 cases. The
      prevalence of congenital malformation was 66 (2.6%) at 95% confidence interval
      (4.19-1.98) of total live births. The genitourinary system was the most common
      system involved with congenital malformations being 16 (24.2%), followed by
      musculoskeletal system 14 (21.2%), and cardiovascular system 12 (18.2%).
      CONCLUSIONS: Congenital malformation plays a major role in the mortality and
      morbidity of neonates as well as children. The genitourinary system was the most 
      common system involved.
FAU - Shrestha, Sabina
AU  - Shrestha S
AD  - Department of Pediatrics, Kathmandu Medical College and Teaching Hospital,
      Kathmandu, Nepal.
FAU - Shrestha, Anup
AU  - Shrestha A
AD  - Department of Pediatrics, Kathmandu Medical College and Teaching Hospital,
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Congenital Abnormalities/*epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Infant Mortality
MH  - Infant, Newborn
MH  - Male
MH  - Nepal/epidemiology
MH  - Pregnancy
MH  - Prevalence
MH  - *Stillbirth/epidemiology
MH  - Tertiary Care Centers
PMC - PMC7654475
OTO - NOTNLM
OT  - congenital malformations; live births; Nepal; prevalence.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4985 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):310-313. doi: 10.31729/jnma.4985.


PMID- 32538923
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Academic Stress among High School Students in a Rural Area of Nepal: A
      Descriptive Cross-sectional Study.
PG  - 306-309
LID - 10.31729/jnma.4978 [doi]
AB  - INTRODUCTION: The period of adolescence undergoes many physical and mental
      changes. Changing emotional and physical status along with increasing social,
      family, and academic pressure lead to various impairments in the mental health of
      adolescents. Academic failure leads to the suicide rate in adolescents,
      predominantly high during the declaration of exam results which is significantly 
      high in a rural area in comparison with urban. The study examined the prevalence 
      of academic stress among high school students in a rural area of Rolpa, Nepal.
      METHODS: A descriptive cross-sectional study was conducted in 6 schools in Rolpa 
      from July to October 2019. The sample size calculated was 521. A convenient
      sampling technique was used for this study. The target population was adolescents
      enrolled in high schools of Rolpa. Ethical approval was taken before data
      collection. The scale for assessing academic stress was used to find out the
      prevalence. A questionnaire was translated in local language and pre-testing was 
      done in Nepal Police School,Sanga among 10% of the calculated sample size. Data
      entry was done in Statistical Package for the Social Sciences version 18.
      Descriptive statistical analysis was done for prevalence calculation. RESULTS:
      Out of a total of 521 students, the prevalence of academic stress was seen among 
      138 (26.5%)students at a 95% confidence interval (22.72-30.28). CONCLUSIONS: The 
      prevalence of academic stress in our study was high and was consistent with other
      South Asian studies. Understanding academic stress and providing help and support
      to the students would help ease the burden for them.
FAU - Gurung, Minani
AU  - Gurung M
AD  - Faculty of Public Health, Mahidol University, Bangkok, Thailand.
FAU - Chansatitporn, Natkamol
AU  - Chansatitporn N
AD  - Department of Biostatistics, Faculty of Public Health, Mahidol University,
      Bangkok, Thailand.
FAU - Chamroonsawasdi, Kanittha
AU  - Chamroonsawasdi K
AD  - Department of Family Health, Faculty of Public Health, Mahidol University,
      Bangkok, Thailand.
FAU - Lapvongwatana, Punyarat
AU  - Lapvongwatana P
AD  - Department of Public Health Nursing, Faculty of Public Health, Mahidol
      University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - *Academic Success
MH  - Adolescent
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - *Rural Population
MH  - Schools
MH  - Stress, Psychological/*epidemiology
MH  - Students/*psychology
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7654462
OTO - NOTNLM
OT  - academic stress; adolescents; Nepal.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4978 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):306-309. doi: 10.31729/jnma.4978.


PMID- 32538922
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Patient Satisfaction in Out-patient Services at a Tertiary Care Center: A
      Descriptive Cross-sectional Study.
PG  - 301-305
LID - 10.31729/jnma.4917 [doi]
AB  - INTRODUCTION: Patient satisfaction is an important and commonly used valid
      indicator for the measurement of service quality. Patient responses to healthcare
      services are one of the best ways to obtain information about patient views
      regarding the quality of healthcare. The main aim of the study was to find out
      the patient's satisfaction level in the tertiary care center. METHODS: A
      descriptive cross-sectional study was conducted among 94 outpatients at a
      tertiary care center. Data were collected after obtaining ethical clearance from 
      the institutional review committee. Patients were selected conveniently who
      visited any four of the major department. We collected demographic data and the
      patient satisfaction towards outpatient clinic experience was studied. We used
      the Patient Satisfaction Questionnaire-18 to assess patient satisfaction. Data
      were entered and analyzed in Statistical Package for the Social Sciences version 
      23. The mean score and the standard deviation were calculated. RESULTS: Overall
      satisfaction was 74.78% with a mean value of 3.7394+/-0.40128. The highest
      satisfaction score was found in regards to the interpersonal manner of health
      personnel (4.2872+/-0.61561) followed by communication (3.9628+/-0.40982) and the
      lowest was seen in accessibility and convenience (3.2394+/-0.81478). CONCLUSIONS:
      The mean score and percentage of patient satisfaction were high in the hospital. 
      However, the accessibility and availability of medical personnel were only a
      matter of concern.
FAU - Poudel, Lisasha
AU  - Poudel L
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Baskota, Swechhya
AU  - Baskota S
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Mali, Prajita
AU  - Mali P
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Pradhananga, Priza
AU  - Pradhananga P
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Malla, Nabina
AU  - Malla N
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Rajbhandari, Bibek
AU  - Rajbhandari B
AD  - Department of Emergency, Nepal Police Hospital, Kathmandu, Nepal.
FAU - Nepal, Susmita
AU  - Nepal S
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Communication
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Outpatients
MH  - *Patient Satisfaction
MH  - Professional-Patient Relations
MH  - *Tertiary Care Centers
MH  - Young Adult
PMC - PMC7654474
OTO - NOTNLM
OT  - Nepal; patient satisfaction; tertiary care center.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4917 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):301-305. doi: 10.31729/jnma.4917.


PMID- 32538921
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Prevalence of Polycystic Ovarian Syndrome among Medical Students of a Tertiary
      Care Hospital.
PG  - 297-300
LID - 10.31729/jnma.4885 [doi]
AB  - INTRODUCTION: Polycystic ovarian syndrome is considered to be one of the most
      common endocrine disorders among women of reproductive age. Characterized by a
      triad of androgen excess, anovulation, infertility, and obesity the disease can
      lead to several complications like infertility, endometrial carcinoma. This study
      aims to find out its prevalence among female medical undergraduates. METHODS: A
      descriptive cross-sectional study was conducted among female undergraduate
      medical students in a tertiary care hospital from 1st to 7th February 2018.
      Ethical approval was taken from the Institutional Review Committee (reference
      number 10012018). The sample size was calculated. Systematic random sampling was 
      done. Statistical Package for the Social Sciences version 20.0 was used. Point
      estimate at 95% Confidence Interval was calculated along with frequency and
      proportion for binary data. RESULTS: Out of 381 participants, the prevalence of
      polycystic ovarian syndrome was found to be 35 (9.18%) at 95% Confidence Interval
      (6.28-12.08). Eighty (20.99%) participants were reported to have prolonged
      menses, 28 (7.34%) tended to grow dark, coarse hair, 79 (20.73%) reported being
      obese or overweight, and milky discharge from nipple was present in 4 (1.049%).
      CONCLUSIONS: The prevalence of polycystic ovarian syndrome was found to be
      similar to other studies conducted in similar settings. But still, it is a
      growing endocrinological problem in the females of the reproductive age group.
      Early screening is necessary to prevent lifelong complications.
FAU - Kc, Shreeyanta
AU  - Kc S
AD  - Dirghayu Guru Hospital, Chabahil, Kathmandu, Nepal.
FAU - Shah, Rakesh Kumar
AU  - Shah RK
AD  - Gajuri Primary Health Centre, Dhading, Nepal.
FAU - Singh, Avilasha
AU  - Singh A
AD  - Kathmandu Medical College, Sinamangal, Kathmandu, Nepal.
FAU - Prasai, Astha
AU  - Prasai A
AD  - Deurali Primary Health Centre, Nuwakot, Nepal.
FAU - Bhandari, Birat
AU  - Bhandari B
AD  - Kathmandu Medical College, Sinamangal, Kathmandu, Nepal.
FAU - Aryal, Saman
AU  - Aryal S
AD  - Om Hospital and Research Centre, Chabahil, Kathmandu, Nepal.
FAU - Khatri, Asmita
AU  - Khatri A
AD  - Ministry of Social Development, Hetauda, Makwanpur, Nepal.
FAU - Thapa, Meena
AU  - Thapa M
AD  - Department of Obstetrics and Gynaecology, Kathmandu Medical College, Sinamangal, 
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Nepal/epidemiology
MH  - *Polycystic Ovary Syndrome/epidemiology
MH  - Prevalence
MH  - *Students, Medical
MH  - Tertiary Care Centers
PMC - PMC7654459
OTO - NOTNLM
OT  - polycystic ovarian syndrome; medical students; Nepal.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4885 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):297-300. doi: 10.31729/jnma.4885.


PMID- 32538920
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 225
DP  - 2020 May 30
TI  - Prevalence of Intestinal Parasitic Infestation among Public School Children of a 
      Community.
PG  - 293-296
LID - 10.31729/jnma.4892 [doi]
AB  - INTRODUCTION: Intestinal parasitic infestation is one of the major health
      problems in developing countries like Nepal. This study was done to determine the
      prevalence rate of intestinal parasitic infestation among school children in
      Duwakot VDC, Bhaktapur, Nepal. METHODS: A descriptive cross-sectional study was
      done in 194 public school children of Duwakot village development committee from 
      August to October, 2019. Ethical clearance was obtained from the Institutional
      Review Committee (reference no. 1207201915). Simple random sampling was done. One
      hundred and ninety-four public school children individuals of 6 to 14 years of
      age were enrolled. Collected stools were examined for the presence of parasites
      macroscopically and microscopically. Microscopic examination was carried out by
      direct wet mount using normal saline (0.9%) and Lugol's iodine (0.5%) mount. The 
      data obtained were computed and analyzed using Statistical Package for the Social
      Sciences version 16.0. RESULTS: A total of 194 stool samples were collected from 
      school children and examined. The prevalence of intestinal parasitosis was 26
      (13.40%). The commonest organism was Giardia lamblia in 22 (11.34%) cases. Among 
      helminthic infection, 2 (1.03%) cases each were infected by Hymenolepis nana and 
      Hookworm respectively. CONCLUSIONS: The prevalence rate of intestinal parasite
      infestation in Nepal shows considerable decline in recent years. However, more
      effort is required by public health resources to minimize the problem further.
FAU - Sharma, Manisha
AU  - Sharma M
AD  - Department of Microbiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Sapkota, Jyotshna
AU  - Sapkota J
AD  - Department of Microbiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Jha, Beena
AU  - Jha B
AD  - Department of Microbiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Mishra, Bhavesh
AU  - Mishra B
AD  - Department of Microbiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Bhatt, Chandra Prakash
AU  - Bhatt CP
AD  - Department of Microbiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Ancylostomatoidea/isolation & purification
MH  - Animals
MH  - Child
MH  - Cross-Sectional Studies
MH  - Feces/parasitology
MH  - Giardia/isolation & purification
MH  - Humans
MH  - Hymenolepis nana/isolation & purification
MH  - *Intestinal Diseases, Parasitic/diagnosis/epidemiology
MH  - Nepal/epidemiology
MH  - *Parasites
MH  - Prevalence
MH  - Schools
PMC - PMC7654468
OTO - NOTNLM
OT  - intestinal diseases; parasitic; prevalence; schools.
EDAT- 2020/06/17 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4892 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 May 30;58(225):293-296. doi: 10.31729/jnma.4892.


PMID- 32538498
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1521-4036 (Electronic)
IS  - 0323-3847 (Linking)
VI  - 62
IP  - 7
DP  - 2020 Nov
TI  - Compound optimal allocations for survival clinical trials.
PG  - 1730-1746
LID - 10.1002/bimj.201900232 [doi]
AB  - The aim of the present paper is to provide optimal allocations for comparative
      clinical trials with survival outcomes. The suggested targets are derived
      adopting a compound optimization strategy based on a subjective weighting of the 
      relative importance of inferential demands and ethical concerns. The ensuing
      compound optimal targets are continuous functions of the treatment effects, so we
      provide the conditions under which they can be approached by standard
      response-adaptive randomization procedures, also guaranteeing the applicability
      of the classical asymptotic inference. The operating characteristics of the
      suggested methodology are verified both theoretically and by simulation,
      including the robustness to model misspecification. With respect to the other
      available proposals, our strategy always assigns more patients to the best
      treatment without compromising inference, taking into account estimation
      efficiency and power as well. We illustrate our procedure by redesigning two real
      oncological trials.
CI  - (c) 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Baldi Antognini, Alessandro
AU  - Baldi Antognini A
AUID- ORCID: 0000-0002-7426-8208
AD  - Department of Statistical Sciences, University of Bologna, Bologna, Italy.
FAU - Novelli, Marco
AU  - Novelli M
AD  - Department of Statistical Sciences, University of Bologna, Bologna, Italy.
FAU - Zagoraiou, Maroussa
AU  - Zagoraiou M
AD  - Department of Statistical Sciences, University of Bologna, Bologna, Italy.
FAU - Vagheggini, Alessandro
AU  - Vagheggini A
AD  - Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo 
      Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.
LA  - eng
GR  - 20154X8K23/Ministero dell'Istruzione, dell'Universita e della
      Ricerca/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - Germany
TA  - Biom J
JT  - Biometrical journal. Biometrische Zeitschrift
JID - 7708048
SB  - IM
MH  - *Clinical Trials as Topic
MH  - Computer Simulation
MH  - Humans
MH  - Random Allocation
MH  - Research Design
MH  - *Survival Analysis
OTO - NOTNLM
OT  - *censoring
OT  - *ethics
OT  - *hypothesis testing
OT  - *oncological trials
OT  - *response-adaptive randomization
EDAT- 2020/06/17 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/06/16 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2020/06/16 06:00 [entrez]
AID - 10.1002/bimj.201900232 [doi]
PST - ppublish
SO  - Biom J. 2020 Nov;62(7):1730-1746. doi: 10.1002/bimj.201900232. Epub 2020 Jun 15.


PMID- 32538458
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1687-1634 (Electronic)
IS  - 1020-3397 (Linking)
VI  - 26
IP  - 5
DP  - 2020 May 21
TI  - Second Eastern Mediterranean/Arab States regional summit of national ethics and
      bioethics committees.
PG  - 620-621
LID - 10.26719/2020.26.5.620 [doi]
LA  - eng
PT  - News
DEP - 20200521
PL  - Egypt
TA  - East Mediterr Health J
JT  - Eastern Mediterranean health journal = La revue de sante de la Mediterranee
      orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
JID - 9608387
SB  - IM
MH  - Arabs
MH  - *Bioethics
MH  - *Ethics
MH  - Health Policy
MH  - Humans
MH  - Middle East
EDAT- 2020/06/17 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 10.26719/2020.26.5.620 [doi]
PST - epublish
SO  - East Mediterr Health J. 2020 May 21;26(5):620-621. doi: 10.26719/2020.26.5.620.


PMID- 32538446
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20220415
IS  - 1687-1634 (Electronic)
IS  - 1020-3397 (Linking)
VI  - 26
IP  - 5
DP  - 2020 May 21
TI  - Priority setting for research in the field of medical ethics in the Islamic
      Republic of Iran: a Delphi study.
PG  - 531-538
LID - 10.26719/emhj.19.085 [doi]
AB  - BACKGROUND: Priority-setting is one way to develop research in a particular
      field. AIMS: We aimed to identify and prioritize the most important medical
      ethics issues for research in the Islamic Republic of Iran. METHODS: A 3-round
      Delphi survey was conducted using a questionnaire covering 77 medical ethics
      topics in 10 categories and subcategories (extracted from literature review);
      this was emailed to 40 experts in medical ethics. The participants rated
      categories and subcategories for importance on a 5-point Likert scale and ranked 
      the topics based on their research priorities. The highest Likert score showed
      the most important issue and the lowest priority score indicated the first
      priority. RESULTS: After consensus, the panel identified 6 categories as the
      highest priority and most important areas: professionalism [priority score =
      2.66, standard deviation (SD) 2.63, importance score = 4.45, SD 0.72], education 
      (priority score=3.12, SD 1.89, importance score = 4.25, SD 0.84), end of life
      (priority score = 3.79, SD 1.91, importance score = 4.47, SD 0.66), beginning of 
      life (priority = 4.62, SD 1.68, importance score= 4.26, SD 0.61), public health
      (priority score = 5.20, SD 2.39, importance score = 4.29, SD 0.75), and ethics in
      research (priority score = 5.33, SD 1.97, importance score = 4.34, SD 0.64).
      CONCLUSION: The rankings for priority and importance was not the same. Our
      results highlight a lack of applicable knowledge in the areas of professionalism 
      and end of life. This study could be used as a foundation for developing further 
      investigations by ensuring the most appropriate use of limited resources.
CI  - Copyright (c) World Health Organization (WHO) 2020. Open Access. Some rights
      reserved. This work is available under the CC BY-NC-SA 3.0 IGO license
      (https://creativecommons.org/licenses/by-nc-sa/3.0/igo).
FAU - Noroozi, Mahshad
AU  - Noroozi M
AD  - Medical Ethics and History of Medicine Research Center.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Medical Ethics and History of Medicine Research Center.
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism
      Clinical Sciences Institute.
FAU - Nedjat, Saharnaz
AU  - Nedjat S
AD  - Department of Epidemiology and Biostatistics, Tehran University of Medical
      Sciences, Tehran, Islamic Republic of Iran.
FAU - Aramesh, Kiarash
AU  - Aramesh K
AD  - The James F. Drane Bioethics Institute, Edinboro University of Pennsylvania,
      United States of America.
AD  - Department of Biology and Health Sciences, College of Science and Health
      Professions, Edinboro University of Pennsylvania, United States of America.
FAU - Salari, Pooneh
AU  - Salari P
AD  - Medical Ethics and History of Medicine Research Center.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - Egypt
TA  - East Mediterr Health J
JT  - Eastern Mediterranean health journal = La revue de sante de la Mediterranee
      orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
JID - 9608387
SB  - IM
MH  - *Biomedical Research/ethics
MH  - Delphi Technique
MH  - *Ethics, Medical/education
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - Professionalism/ethics
MH  - Public Health/ethics
MH  - Research
MH  - Surveys and Questionnaires
MH  - Terminal Care/ethics
OTO - NOTNLM
OT  - Islamic Republic of Iran
OT  - medical ethics
OT  - priority setting
OT  - research
EDAT- 2020/06/17 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/06/16 06:00
PHST- 2017/12/26 00:00 [received]
PHST- 2018/08/23 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
AID - 10.26719/emhj.19.085 [doi]
PST - epublish
SO  - East Mediterr Health J. 2020 May 21;26(5):531-538. doi: 10.26719/emhj.19.085.


PMID- 32538436
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1460-2237 (Electronic)
IS  - 0268-1080 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Jul 1
TI  - The moral perils of conditional cash transfer programmes and their significance
      for policy: a meta-ethnography of the ethical debate.
PG  - 718-734
LID - 10.1093/heapol/czaa014 [doi]
AB  - Conditional cash transfer (CCT) is a compelling policy alternative for reducing
      poverty and improving health, and its effectiveness is promising. CCT programmes 
      have been widely deployed across geographical, economic and political contexts,
      but not without contestation. Critics argue that CCTs may result in infringements
      on freedom and dignity, gender discrimination and disempowerment and power
      imbalances between programme providers and beneficiaries. In this analysis, we
      aim to identify the ethical concepts applicable to CCTs and to contextualize
      these by mapping the tensions of the debate, allowing us to understand the
      separate contributions as parts of a larger whole. We searched a range of
      databases for records on public health CCT. Strategies were last run in January
      2017. We included 31 dialectical articles deliberating the ethics of CCTs and
      applied a meta-ethnographic approach. We identified 22 distinct ethical concepts.
      By analysing and mapping the tensions in the discourse, the following four
      strands of debate emerged: (1) responsibility for poverty and health: personal vs
      public duty, (2) power balance: autonomy vs paternalism, (3) social justice:
      empowerment vs oppression and (4) marketization of human behaviour and health:
      'fair trade' vs moral corruption. The debate shed light on the ethical ideals,
      principles and doctrines underpinning CCT. These were consistent with a
      market-oriented liberal welfare regime ideal: privatization of public
      responsibilities; a selective rather than a universal approach; empowerment by
      individual entrepreneurship; marketization of health with a conception of human
      beings as utility maximizing creatures; and limited acknowledgement of the role
      of structural injustices in poverty and health. Identification of key tensions in
      the public health ethics debate may expose underpinning ideological logics of
      health and social programmes that may be at odds with public values and
      contemporary political priorities. Decisions about CCTs should therefore not be
      considered a technical exercise, but a context-dependent process requiring
      transparent, informed and deliberative decision-making.
CI  - (c) The Author(s) 2020. Published by Oxford University Press in association with 
      The London School of Hygiene and Tropical Medicine. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Scheel, Inger B
AU  - Scheel IB
AD  - Department of Global Health, Norwegian Institute of Public Health, PO Box 4404,
      Nydalen, N-0403 Oslo, Norway.
FAU - Scheel, Andrea E
AU  - Scheel AE
AD  - Department of Global Health, Norwegian Institute of Public Health, PO Box 4404,
      Nydalen, N-0403 Oslo, Norway.
FAU - Fretheim, Atle
AU  - Fretheim A
AD  - Division for Health Services, Norwegian Institute of Public Health, PO Box 4404, 
      Nydalen, N-0403 Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - England
TA  - Health Policy Plan
JT  - Health policy and planning
JID - 8610614
MH  - Anthropology, Cultural
MH  - Financing, Government/*ethics/organization & administration
MH  - Health Promotion/economics/*ethics
MH  - Humans
MH  - Motivation/ethics
MH  - *Poverty
MH  - Risk Reduction Behavior
MH  - Social Justice
OTO - NOTNLM
OT  - Conditional cash transfer
OT  - ethical discourse
OT  - incentives
OT  - meta-ethnography
OT  - policy
OT  - public health ethics
EDAT- 2020/06/17 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/02/13 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
AID - 5828348 [pii]
AID - 10.1093/heapol/czaa014 [doi]
PST - ppublish
SO  - Health Policy Plan. 2020 Jul 1;35(6):718-734. doi: 10.1093/heapol/czaa014.


PMID- 32538030
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 2210-6014 (Electronic)
IS  - 2210-6006 (Linking)
VI  - 10
IP  - 2
DP  - 2020 Jun
TI  - Top Ethical Issues Concerning Healthcare Providers Working in Saudi Arabia.
PG  - 143-152
LID - 10.2991/jegh.k.191211.001 [doi]
AB  - BACKGROUND: Healthcare providers working in Saudi Arabia come from various
      nationalities, cultures, and training backgrounds. This study aimed to assess the
      perceptions of healthcare providers working in Riyadh hospitals about ethical
      dilemmas and solutions. METHODS: This is a cross-sectional study among physicians
      working in Riyadh's private and governmental hospitals between June and December 
      2017. The study collected information on demographics, knowledge about medical
      ethics, the sources of such knowledge, and common ethical issues in general and
      the top ethical issues and dilemmas encountered in their daily practice. RESULTS:
      A total of 455 physicians from government and private hospitals were enrolled in 
      the study. The mean age of the participants was 34.29 +/- 10.5 years, females
      were 29.7% and mean years of practice was 13.0 +/- 11.5. The top ethical issues
      identified by the participants were "disagreement with the patients' relatives
      about treatment" (91%), patient disagreement with decisions made by professionals
      (84%), treating the incompetent patient (79%), conflict with administration
      policy and procedures (77%), scarcity of resources (72%), and making decision
      about do-not-resuscitate or life-sustaining treatment (68%). There were
      significant differences in dealing with ethical issues in relation to gender,
      confidence about ethical knowledge, nationality, seniority, training site, and
      private or government hospitals academic and nonacademic. CONCLUSION: Healthcare 
      providers in Riyadh hospitals face multiple ethical challenges. In addition to
      improvement in ethics knowledge through educational program among healthcare
      professional, there is a valid need for healthcare professionals and other
      sectors within society to engage in serious and continuous dialogue to address
      these issues and propose recommendations.
CI  - (c) 2020 Atlantis Press International B.V.
FAU - Almoallem, Amar Mansour
AU  - Almoallem AM
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
FAU - Almudayfir, Mohammed Abdulaziz
AU  - Almudayfir MA
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
FAU - Al-Jahdail, Yassar H
AU  - Al-Jahdail YH
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
FAU - Ahmed, Anwar E
AU  - Ahmed AE
AD  - College of Public Health and Health Informatics, King Saud bin Abdulaziz
      University for Health Sciences, Riyadh.
AD  - College of Medicine, King Abdullah International Medical Research Center
      (KAIMRC), Riyadh.
FAU - Al-Shaikh, Adnan
AU  - Al-Shaikh A
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
AD  - Department of Pediatrics, College of Medicine, King Saud bin Abdulaziz University
      for Health Sciences, Jeddah.
AD  - College of Medicine, King Abdullah International Medical Research Center
      (KAIMRC), Riyadh.
FAU - Baharoon, Salim
AU  - Baharoon S
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
AD  - Department of Medicine, King Abulaziz Medical City, King Saud bin Abdulaziz
      University for Health Sciences, Riyadh.
AD  - College of Medicine, King Abdullah International Medical Research Center
      (KAIMRC), Riyadh.
FAU - AlHarbi, Abdullah
AU  - AlHarbi A
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
AD  - Department of Medicine, King Abulaziz Medical City, King Saud bin Abdulaziz
      University for Health Sciences, Riyadh.
AD  - College of Medicine, King Abdullah International Medical Research Center
      (KAIMRC), Riyadh.
FAU - Al-Jahdali, Hamdan
AU  - Al-Jahdali H
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences,
      Riyadh.
AD  - Department of Medicine, King Abulaziz Medical City, King Saud bin Abdulaziz
      University for Health Sciences, Riyadh.
AD  - College of Medicine, King Abdullah International Medical Research Center
      (KAIMRC), Riyadh.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - J Epidemiol Glob Health
JT  - Journal of epidemiology and global health
JID - 101592084
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - *Ethics, Medical
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - *Physicians/psychology/statistics & numerical data
MH  - Saudi Arabia
MH  - Young Adult
PMC - PMC7310778
OTO - NOTNLM
OT  - *Ethics
OT  - *Saudi Arabia
OT  - *bioethics
OT  - *ethical dilemma
OT  - *ethical issues
OT  - *health care
OT  - *health care professionals
COIS- The authors declare they have no conflicts of interest.
EDAT- 2020/06/17 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/06/16 06:00
PHST- 2019/05/30 00:00 [received]
PHST- 2019/10/20 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
AID - j10/2/143 [pii]
AID - 10.2991/jegh.k.191211.001 [doi]
PST - ppublish
SO  - J Epidemiol Glob Health. 2020 Jun;10(2):143-152. doi: 10.2991/jegh.k.191211.001.


PMID- 32537962
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 2046-2344 (Electronic)
IS  - 2046-2336 (Linking)
VI  - 32
IP  - 4
DP  - 2020 Jul 14
TI  - Use of subcutaneous fluids in palliative care with children: a case study.
PG  - 26-30
LID - 10.7748/ncyp.2020.e1277 [doi]
AB  - Quality of life is a major consideration in children's palliative care,
      particularly at the end of life. Optimal symptom management is crucial in
      maintaining quality of life, with the aim being to ensure the child is as
      comfortable as possible. Ensuring adequate hydration will often be part of
      symptom management but may be associated with several practical and ethical
      challenges. Subcutaneous fluid administration in children's palliative care is
      relatively uncommon, so there is a lack of evidence on the topic. This article
      demonstrates that it is feasible to use subcutaneous fluid therapy in the
      children's hospice setting to address patients' hydration needs and manage their 
      symptoms. It presents a case study of a child who received subcutaneous fluids in
      a children's hospice for dehydration and myoclonus. It uses the case study to
      discuss subcutaneous fluid therapy in the children's palliative care setting,
      including its indications and contraindications, administration, complications
      and important factors to consider.
CI  - (c)2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Smith, Adrian
AU  - Smith A
AD  - Ty Hafan Children's Hospice, Sully, Vale of Glamorgan, Wales.
FAU - Jane Brimble, Mandy
AU  - Jane Brimble M
AD  - School of Healthcare Sciences, Cardiff University, Cardiff, Wales.
LA  - eng
PT  - Journal Article
DEP - 20200615
PL  - England
TA  - Nurs Child Young People
JT  - Nursing children and young people
JID - 101554473
MH  - Humans
MH  - Hypodermoclysis/*methods/standards
MH  - Palliative Care/*methods/standards
MH  - Patient Comfort/standards
MH  - Pediatrics/instrumentation/*methods
MH  - Quality of Life/psychology
OTO - NOTNLM
OT  - artificial hydration
OT  - child health
OT  - clinical
OT  - end of life care
OT  - ethical issues
OT  - fluid management
OT  - hospices
OT  - hydration
OT  - nutrition
OT  - palliative care
OT  - parents
OT  - professional
OT  - terminal care
COIS- None declared
EDAT- 2020/06/17 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/01/03 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/06/16 06:00 [entrez]
AID - 10.7748/ncyp.2020.e1277 [doi]
AID - e1277 [pii]
PST - ppublish
SO  - Nurs Child Young People. 2020 Jul 14;32(4):26-30. doi: 10.7748/ncyp.2020.e1277.
      Epub 2020 Jun 15.


PMID- 32537918
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 6
DP  - 2020 Jun
TI  - A major new alliance in Australian healthcare: the Australian consensus framework
      for ethical collaboration in the healthcare sector.
PG  - 679-684
LID - 10.1111/imj.14861 [doi]
AB  - The 'Australian Consensus Framework for Ethical Collaboration in the Healthcare
      Sector' (ACF) is an Australian initiative aimed at countering dysfunction and
      growing mistrust in the health sector through the development of a cross-sectoral
      consensus framework. The development of this framework arose from Australia's
      involvement in the Asia Pacific Economic Cooperative (APEC) and has since become 
      the largest of its kind internationally, with over 70 signatories representing
      professional bodies, industry organisations, hospital and health services
      associations, regulators and patient and advocacy groups. In this article, we
      describe and critique the framework and outline its implementation.
CI  - (c) 2020 Royal Australasian College of Physicians.
FAU - Lipworth, Wendy
AU  - Lipworth W
AUID- ORCID: 0000-0002-0234-657X
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia.
FAU - Fitzpatrick, Jane
AU  - Fitzpatrick J
AD  - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Australasian College of Sport and Exercise Physicians, Melbourne, Victoria,
      Australia.
FAU - Cosenza, Adrian
AU  - Cosenza A
AD  - Australian Orthopaedic Association, Sydney, New South Wales, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia.
FAU - Subramanian, Peter
AU  - Subramanian P
AD  - Royal Adelaide Hospital, Adelaide, South Australia, Australia.
FAU - Verhoeven, Alison
AU  - Verhoeven A
AD  - Australian Healthcare and Hospitals Association, Deakin, Australian Capital
      Territory, Australia.
FAU - Wells, Leanne
AU  - Wells L
AD  - Consumers Health Forum of Australia, Deakin, Australian Capital Territory,
      Australia.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
MH  - Australia
MH  - Consensus
MH  - *Delivery of Health Care
MH  - *Health Care Sector
MH  - Humans
OTO - NOTNLM
OT  - *Australian consensus framework
OT  - *ethical code
OT  - *ethical framework
OT  - *organisational ethics
EDAT- 2020/06/17 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/01/19 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1111/imj.14861 [doi]
PST - ppublish
SO  - Intern Med J. 2020 Jun;50(6):679-684. doi: 10.1111/imj.14861.


PMID- 32537329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2169-7574 (Print)
IS  - 2169-7574 (Linking)
VI  - 8
IP  - 3
DP  - 2020 Mar
TI  - Additional Relaxing Suturing Using Absorbable Symmetric Barbed Sutures to Help
      Close Scalp Defects.
PG  - e2658
LID - 10.1097/GOX.0000000000002658 [doi]
AB  - Closing a scalp wound with skin defects is challenging because the scalp skin
      lacks extensibility and closing it tends to result in a remarkable, widespread,
      hairless scar. Absorbable symmetric barbed suture device (Stratafix Symmetric;
      Ethicon, USA) allows wound closure using a pulling motion alone and provides a
      strong and secure closure for the high-tension area. We used this device to close
      wide scalp defects easily without tension and with minimized sequential scalp
      alopecia. The aim of this study was to show our experiences with using this
      technique. From January 2017 to March 2019, our relaxing suture technique was
      performed in 7 pediatric patients with scalp alopecia due to various lesions that
      ranged 23.0 +/- 6.5 mm. After resecting the lesions, the galea was sutured using 
      the 3-0 absorbable symmetric barbed suture via a running subcutaneous suture
      technique. The widespread wound edges were approximated by pulling the suture
      device. Wound closure was completed with galeal suturing and a superficial
      suture. We evaluated the width of the postoperative hairless scar at the final
      follow-up. In all 7 patients, we could approximate the widespread wound edges by 
      pulling alone. Subsequently, the wounds could be closed without tension or
      difficulty. The mean width of the postoperative hairless scar was 3.3 +/- 0.8 mm 
      (range: 1.9-4.3 mm), and no complication was detected during the follow-up
      period. Our new relaxing suture technique using an absorbable barbed suture with 
      symmetric anchors is a supportive and additional way to help close scalp defects.
CI  - Copyright (c) 2020 The Authors. Published by Wolters Kluwer Health, Inc. on
      behalf of The American Society of Plastic Surgeons.
FAU - Hosomi, Kento
AU  - Hosomi K
AD  - Department of Plastic and Reconstructive Surgery, Shinshu University School of
      Medicine, Nagano, Japan.
FAU - Yuzuriha, Shunsuke
AU  - Yuzuriha S
AD  - Department of Plastic and Reconstructive Surgery, Shinshu University School of
      Medicine, Nagano, Japan.
FAU - Nagai, Fumio
AU  - Nagai F
AD  - Department of Plastic and Reconstructive Surgery, Shinshu University School of
      Medicine, Nagano, Japan.
FAU - Yanagisawa, Daisuke
AU  - Yanagisawa D
AD  - Department of Plastic and Reconstructive Surgery, Shinshu University School of
      Medicine, Nagano, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - United States
TA  - Plast Reconstr Surg Glob Open
JT  - Plastic and reconstructive surgery. Global open
JID - 101622231
PMC - PMC7253276
COIS- Disclosure: The authors have no financial interest to declare in relation to the 
      content of this article.
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2019/08/15 00:00 [received]
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.1097/GOX.0000000000002658 [doi]
PST - epublish
SO  - Plast Reconstr Surg Glob Open. 2020 Mar 20;8(3):e2658. doi:
      10.1097/GOX.0000000000002658. eCollection 2020 Mar.


PMID- 32537245
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2057-0082 (Electronic)
IS  - 2057-0082 (Linking)
VI  - 10
DP  - 2020
TI  - Context matters: the psychoneurobiological determinants of placebo, nocebo and
      context-related effects in physiotherapy.
PG  - 11
LID - 10.1186/s40945-020-00082-y [doi]
AB  - BACKGROUND: Placebo and nocebo effects embody psychoneurobiological phenomena
      where behavioural, neurophysiological, perceptive and cognitive changes occur
      during the therapeutic encounter in the healthcare context. Placebo effects are
      produced by a positive healthcare context; while nocebo effects are consequences 
      of negative healthcare context. Historically, placebo, nocebo and context-related
      effects were considered as confounding elements for clinicians and researchers.
      In the last two decades this attitude started to change, and the understanding of
      the value of these effects has increased. Despite the growing interest, the
      knowledge and the awareness of using the healthcare context to trigger placebo
      and nocebo effects is currently limited and heterogeneous among physiotherapists,
      reducing their translational value in the physiotherapy field. OBJECTIVES: To
      introduce the placebo, nocebo and context-related effects by: (1) presenting
      their psychological models; (2) describing their neurophysiological mechanisms;
      (3) underlining their impact for the physiotherapy profession; and (4) tracing
      lines for future researches. CONCLUSION: Several psychological mechanisms are
      involved in placebo, nocebo and context-related effects; including expectation,
      learning processes (classical conditioning and observational learning),
      reinforced expectations, mindset and personality traits. The neurophysiological
      mechanisms mainly include the endogenous opioid, the endocannabinoid and the
      dopaminergic systems. Neuroimaging studies have identified different brain
      regions involved such as the dorsolateral prefrontal cortex, the rostral anterior
      cingulate cortex, the periaqueductal gray and the dorsal horn of spine. From a
      clinical perspective, the manipulation of the healthcare context with the best
      evidence-based therapy represents an opportunity to trigger placebo effects and
      to avoid nocebo effects respecting the ethical code of conduct. From a managerial
      perspective, stakeholders, organizations and governments should encourage the
      assessment of the healthcare context aimed to improve the quality of
      physiotherapy services. From an educational perspective, placebo and nocebo
      effects are professional topics that should be integrated in the university
      program of health and medical professions. From a research perspective, the
      control of placebo, nocebo and context-related effects offers to the scientific
      community the chance to better measure the impact of physiotherapy on different
      outcomes and in different conditions through primary studies.
CI  - (c) The Author(s) 2020.
FAU - Rossettini, Giacomo
AU  - Rossettini G
AUID- ORCID: 0000-0002-1623-7681
AD  - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and 
      Child Health, University of Genova, Campus Universitario di Savona, via Magliotto
      2, 17100 Savona, Italy.grid.5606.50000 0001 2151 3065
FAU - Camerone, Eleonora Maria
AU  - Camerone EM
AD  - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and 
      Child Health, University of Genova, Campus Universitario di Savona, via Magliotto
      2, 17100 Savona, Italy.grid.5606.50000 0001 2151 3065
AD  - Department of Neuroscience, University of Turin Medical School, Turin,
      Italy.grid.7605.40000 0001 2336 6580
FAU - Carlino, Elisa
AU  - Carlino E
AD  - Department of Neuroscience, University of Turin Medical School, Turin,
      Italy.grid.7605.40000 0001 2336 6580
FAU - Benedetti, Fabrizio
AU  - Benedetti F
AD  - Department of Neuroscience, University of Turin Medical School, Turin,
      Italy.grid.7605.40000 0001 2336 6580
AD  - Plateau Rosa Laboratories, Plateau Rosa Laboratories, Zermatt, Switzerland.
FAU - Testa, Marco
AU  - Testa M
AD  - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and 
      Child Health, University of Genova, Campus Universitario di Savona, via Magliotto
      2, 17100 Savona, Italy.grid.5606.50000 0001 2151 3065
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200611
PL  - England
TA  - Arch Physiother
JT  - Archives of physiotherapy
JID - 101688712
PMC - PMC7288522
OTO - NOTNLM
OT  - Conditioning
OT  - Contextual factors
OT  - Expectation
OT  - Learning
OT  - Nocebo effect
OT  - Pain
OT  - Physical therapy modalities
OT  - Placebo effect
OT  - Rehabilitation
OT  - Therapeutic outcome
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.1186/s40945-020-00082-y [doi]
AID - 82 [pii]
PST - epublish
SO  - Arch Physiother. 2020 Jun 11;10:11. doi: 10.1186/s40945-020-00082-y. eCollection 
      2020.


PMID- 32537182
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2054-2577 (Print)
IS  - 2054-2577 (Linking)
VI  - 7
IP  - 3
DP  - 2020 Jun
TI  - Considerations for a surgical RCT for diffuse low-grade glioma: a survey.
PG  - 338-343
LID - 10.1093/nop/npz058 [doi]
AB  - BACKGROUND: Diffuse low-grade gliomas (DLGGs) are heterogeneous tumors that
      inevitably differentiate into malignant entities, leading to disability and
      death. Recently, a shift toward up-front maximal safe resection of DLGGs has been
      favored. However, this transition is not supported by randomized controlled trial
      (RCT) data. Here, we sought to survey the neuro-oncology community on
      considerations for a surgical RCT for DLGGs. METHODS: A 21-question survey
      focusing on a surgical RCT for DLGGs was developed and validated by 2
      neurosurgeons. A sample case of a patient for whom management might be debatable 
      was presented to gather additional insight. The survey was disseminated to
      members of the Society for Neuro-Oncology (SNO) and responses were collected from
      March 16 to July 10, 2018. RESULTS: A total of 131 responses were collected.
      Sixty-three of 117 (54%) respondents thought an RCT would not be ethical, 39 of
      117 (33%) would consider participating, and 56 of 117 (48%) believed an RCT would
      be valuable for determining the differing roles of biopsy, surgery, and
      observation. This was exemplified by an evenly distributed selection of the
      latter management options for our sample case. Eighty-three of 120 (69.2%)
      respondents did not believe in equipoise for DLGG patients. Quality of life and
      overall survival were deemed equally important end points for a putative RCT.
      CONCLUSIONS: Based on our survey, it is evident that management of certain DLGG
      patients is not well defined and an RCT may be justified. As with any surgical
      RCT, logistic challenges are anticipated. Robust patient-relevant end points and 
      standardization of perioperative adjuncts are necessary if a surgical RCT is
      undertaken.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology and the European Association of Neuro-Oncology. All
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Mansouri, Alireza
AU  - Mansouri A
AD  - Department of Neurosurgery, Penn State College of Medicine, Hershey,
      Pennsylvania, USA.
FAU - Brar, Karanbir
AU  - Brar K
AUID- ORCID: 0000-0001-9604-7492
AD  - Faculty of Medicine, University of Toronto, Ontario, Canada.
FAU - Cusimano, Michael D
AU  - Cusimano MD
AD  - Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20191112
PL  - England
TA  - Neurooncol Pract
JT  - Neuro-oncology practice
JID - 101640528
PMC - PMC7274180
OTO - NOTNLM
OT  - glioma
OT  - low-grade glioma
OT  - randomized controlled trial
OT  - surgery
OT  - survey
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.1093/nop/npz058 [doi]
AID - npz058 [pii]
PST - ppublish
SO  - Neurooncol Pract. 2020 Jun;7(3):338-343. doi: 10.1093/nop/npz058. Epub 2019 Nov
      12.


PMID- 32537140
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 55
DP  - 2020 Jul
TI  - Ethics for surgeons during the COVID-19 pandemic, review article.
PG  - 316-319
LID - 10.1016/j.amsu.2020.06.003 [doi]
AB  - The Covid-19 pandemic is a devastating global healthcare emergency with seismic
      impact on how modern surgical services function. Surgeons worry, that whilst
      healthcare-resources are directed against the pandemic, double effect may predict
      these benevolent public health efforts will cause unintended maleficent effects
      through delays to surgical treatment. Surgeons will make many challenging ethical
      judgements during this pandemic, here we conduct a narrative review of how
      medical ethics may help us make the best available choices. A narrative review of
      all the relevant papers known to the author was conducted. We discuss the key
      aspects of medical ethics, and how they have applied to surgeons during the
      Covid-19 pandemic. The four fundamental principles of medical ethics include:
      Beneficence, Nonmaleficence, Autonomy and Justice. Surgeons will face many
      decisions which shall challenge those ethical principles during the pandemic, and
      wisdom from medical ethics can guide surgeons, to do the right thing, make best
      available choices, and get the best available outcome for patients during the
      Covid-19 pandemic. The practice of surgery is distinguished by good judgement in 
      the face of uncertainty, we must strive to do the right thing, advocate for our
      patients, and be honest in the face of uncertainty. Medical Ethics can guide us
      to make the best available choices for our patients during the Covid-19 pandemic,
      afterwards, we must emerge wiser having learnt lessons and rebuilding trust in
      surgical care.
CI  - (c) 2020 The Author.
FAU - Harkin, Denis W
AU  - Harkin DW
AD  - Royal Victoria Hospital, Belfast Health & Social Care Trust, Northern Ireland,
      UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200608
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7278633
OTO - NOTNLM
OT  - Covid-19
OT  - Ethics
OT  - Pandemic
OT  - Professionalism
OT  - Surgeons
OT  - Surgery
COIS- I have read and understood the policy on declaration of interests and have no
      relevant interests to declare. The responsibility for the content lies with the
      author and the views stated herein should not be taken to represent those of any 
      organisations or groups with and for which he works.
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/05/23 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.1016/j.amsu.2020.06.003 [doi]
AID - S2049-0801(20)30139-4 [pii]
PST - ppublish
SO  - Ann Med Surg (Lond). 2020 Jul;55:316-319. doi: 10.1016/j.amsu.2020.06.003. Epub
      2020 Jun 8.


PMID- 32537090
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20220415
IS  - 1937-8688 (Electronic)
VI  - 35
DP  - 2020
TI  - Assessment of minor psychiatric morbidity, stressors, and barriers of seeking
      help among medical students at the University of Khartoum, Khartoum, Sudan.
PG  - 87
LID - 10.11604/pamj.2020.35.87.17512 [doi]
AB  - INTRODUCTION: Medical education can be stressful and a source of psychiatric
      morbidity for medical students with the potential of causing serious professional
      and personal negative consequences. With the limited studies investigating this
      issue in Sudan, this study aimed at assessing psychiatric morbidity, determine
      stressors, evaluate mental health care seeking behavior and barriers to seeking
      help among medical students in Khartoum, Sudan. METHODS: This was a
      cross-sectional study with data collection for a period of one month, during the 
      survey. Following ethical clearance and administrative approval, 644 students who
      gave consent were selected randomly from the university of Khartoum's faculty of 
      medicine. The "12-General Health Questionnaire (GHQ12)" was used as a tool to
      assess prevalence of psychiatric morbidity, determine stressors and evaluate
      barriers to seeking mental health care among students for a period of a month.
      RESULTS: The overall prevalence of psychiatric morbidity was 56% (n = 356). The
      mean score of the GHQ12 was 6.7. There was a statistically significant
      association between GHQ12-score and level of study (in medical school), age,
      student's income (student financial allowance). Stressors mostly experienced by
      students were fear of academic failure, dissatisfaction with academic performance
      and examination stress. The most frequent barriers to seeking mental health care 
      elicited by participants were fear of stigmatization 63% (n = 401), preference
      for dealing with the problem alone 60% (n = 379), fear of the unknown 59% (n =
      365) and failure to recognize symptoms 58% (n = 366). CONCLUSION: Psychiatric
      morbidity is commonly experienced by students in medical school as can be seen
      from the high prevalence (56%). The reported high figures of psychiatric
      morbidity among medical school students points to the urgency for interventions
      to address this problem with potential for negative sequelae (personal and
      professional). Our findings suggest that interventions to improve the social and 
      economic conditions of students in medical school as well as addressing stigma
      related to mental health and educating students to recognize signs and symptoms
      of psychiatric morbidity while making help accessible might go a long way to
      address this challenge.
CI  - (c) Muwada Bashir Awad Bashir et al.
FAU - Bashir, Muwada Bashir Awad
AU  - Bashir MBA
AD  - Discipline of Medicine and Surgery, Faculty of Medicine, University of Khartoum, 
      Khartoum, Sudan.
FAU - Mohamed, Sara Omer Abdelazim
AU  - Mohamed SOA
AD  - Discipline of Medicine and Surgery, Faculty of Medicine, University of Khartoum, 
      Khartoum, Sudan.
FAU - Nkfusai, Claude Ngwayu
AU  - Nkfusai CN
AD  - Cameroon Baptist Convention Health Services (CBCHS), Yaounde, Cameroon.
FAU - Bede, Fala
AU  - Bede F
AD  - Goergetown University's Center for Global Health Practice and Impact (CGHPI),
      TIDE-Cameroon Program, Bertoua, Cameroon.
FAU - Oladimeji, Olanrewaju
AU  - Oladimeji O
AD  - Center for Community Healthcare, Research and Development, Abuja, Nigeria.
AD  - Department of Public Health, Walter Sisulu University, Eastern Cape, South
      Africa.
AD  - Faculty of Health Sciences, Durban University of Technology, Durban, South
      Africa.
FAU - Tsoka-Gwegweni, Joyce Mahlako
AU  - Tsoka-Gwegweni JM
AD  - Office of the Dean, Faculty of Health Sciences, University of the Free State,
      Bloemfontein, South Africa.
FAU - Cumber, Samuel Nambile
AU  - Cumber SN
AD  - Office of the Dean, Faculty of Health Sciences, University of the Free State,
      Bloemfontein, South Africa.
AD  - Centre for Health Systems Research and Development, University of the Free State,
      Bloemfontein, South Africa.
AD  - School of Health Systems and Public Health, Faculty of Health Sciences,
      University of Pretoria, Pretoria, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200324
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Adolescent
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Mental Disorders/*epidemiology/psychology
MH  - Patient Acceptance of Health Care/*psychology
MH  - Schools, Medical
MH  - Social Stigma
MH  - Stress, Psychological/*epidemiology
MH  - Students, Medical/*psychology/statistics & numerical data
MH  - Sudan
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7250227
OTO - NOTNLM
OT  - Medical students
OT  - barriers
OT  - psychological morbidity
OT  - stressors
COIS- The authors declare no competing interests.
EDAT- 2020/06/17 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/06/16 06:00
PHST- 2018/10/27 00:00 [received]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.11604/pamj.2020.35.87.17512 [doi]
AID - PAMJ-35-87 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Mar 24;35:87. doi: 10.11604/pamj.2020.35.87.17512.
      eCollection 2020.


PMID- 32537083
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20201224
IS  - 1937-8688 (Electronic)
VI  - 35
DP  - 2020
TI  - Mandatory pre-abortion counseling is a barrier to accessing safe abortion
      services.
PG  - 80
LID - 10.11604/pamj.2020.35.80.22043 [doi]
AB  - Empirical research showcases that pre-abortion counseling scarcely reverses the
      woman's decision either to terminate a pregnancy or not. Growing evidence
      regarding the high levels of decisional certainty among women seeking abortions
      renders a careful rethink of the place of mandatory pre-abortion counseling
      packages. Mandatory counseling packages, when inscribed in the laws, at times
      contain false information that can deter women from going in for safe abortions. 
      Mandatory waiting times indirectly label opting for an abortion as not being the 
      right thing to do. In areas where abortion stigma from health care providers and 
      communities remains highly prevalent, women are forced to incur extra expenses by
      travelling to other countries. I argue that pre-abortion counseling on opting-in 
      grounds is ethically sound (enhances the woman's reproductive autonomy), since
      most clients in need of abortions are certain on their decisions before the
      abortion care provider and do not regret these decisions after the process.
      Regrets are prone to be more prevalent in areas with high unsafe abortion
      practices, generally due to complications from excessive bleeding, pain, and post
      abortion infections. Allowing systematic mandatory pre-abortion counseling
      practice as the rule in a competent adult is unjustified ethically and
      empirically, is time consuming and presents the legality of abortions in most
      settings an oxymoron.
CI  - (c) Luchuo Engelbert Bain et al.
FAU - Bain, Luchuo Engelbert
AU  - Bain LE
AD  - Centre for Population Studies and Health Promotion, Yaounde, Cameroon.
AD  - Athena Institute for Research on Innovation and Communication in the Health and
      Life Sciences, Vrije Universiteit, Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
MH  - Abortion Applicants/*legislation & jurisprudence/psychology
MH  - Abortion, Induced/*legislation & jurisprudence/psychology
MH  - Abortion, Legal/*legislation & jurisprudence/psychology
MH  - Counseling/*legislation & jurisprudence
MH  - Family Planning Services/legislation & jurisprudence
MH  - Female
MH  - Health Services Accessibility
MH  - Humans
MH  - Pregnancy
MH  - Time Factors
PMC - PMC7250210
OTO - NOTNLM
OT  - Abortion
OT  - access
OT  - counseling
OT  - legal
OT  - mandatory
OT  - pre-abortion
COIS- Luchuo Engelbert Bain conceived the study, carried out the literature searches
      and wrote the initial draft of the paper.
EDAT- 2020/06/17 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.11604/pamj.2020.35.80.22043 [doi]
AID - PAMJ-35-80 [pii]
PST - epublish
SO  - Pan Afr Med J. 2020 Mar 19;35:80. doi: 10.11604/pamj.2020.35.80.22043.
      eCollection 2020.


PMID- 32536896
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Compassionate Conservation Clashes With Conservation Biology: Should Empathy,
      Compassion, and Deontological Moral Principles Drive Conservation Practice?
PG  - 1139
LID - 10.3389/fpsyg.2020.01139 [doi]
AB  - "Compassionate Conservation" is an emerging movement within conservation science 
      that is gaining attention through its promotion of "ethical" conservation
      practices that place empathy and compassion and the moral principles of "first,
      do no harm" and "individuals matter" at the forefront of conservation practice.
      We have articulated elsewhere how Compassionate Conservation, if adopted, could
      be more harmful for native biodiversity than any other conservation action
      implemented thus far, while also causing more net harm to individuals than it
      aims to stop. Here, we examine whether empathy, compassion and inflexible
      adherence to moral principles form a solid basis upon which to meet the goals of 
      conservation biology as specified by pioneers in the discipline. Specifically, we
      examine a large empirical literature demonstrating that empathy is subject to
      significant biases and that inflexible adherence to moral rules can result in a
      "do nothing" approach. In light of this literature, we argue that our emotional
      systems have not evolved to provide a reliable basis for making decisions as to
      how best to ensure the long-term persistence of our planet. Consequently, in its 
      most radical form, the Compassionate Conservation philosophy should not be
      enshrined as a legalized guiding principle for conservation action.
CI  - Copyright (c) 2020 Griffin, Callen, Klop-Toker, Scanlon and Hayward.
FAU - Griffin, Andrea S
AU  - Griffin AS
AD  - Animal Behaviour and Cognition Lab, School of Psychology, University of
      Newcastle, Callaghan, NSW, Australia.
AD  - Conservation Biology Research Group, School of Environmental and Life Sciences,
      University of Newcastle, Callaghan, NSW, Australia.
FAU - Callen, Alex
AU  - Callen A
AD  - Conservation Biology Research Group, School of Environmental and Life Sciences,
      University of Newcastle, Callaghan, NSW, Australia.
FAU - Klop-Toker, Kaya
AU  - Klop-Toker K
AD  - Conservation Biology Research Group, School of Environmental and Life Sciences,
      University of Newcastle, Callaghan, NSW, Australia.
FAU - Scanlon, Robert J
AU  - Scanlon RJ
AD  - Conservation Biology Research Group, School of Environmental and Life Sciences,
      University of Newcastle, Callaghan, NSW, Australia.
FAU - Hayward, Matt W
AU  - Hayward MW
AD  - Conservation Biology Research Group, School of Environmental and Life Sciences,
      University of Newcastle, Callaghan, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7269110
OTO - NOTNLM
OT  - compassion
OT  - compassionate conservation
OT  - conservation decision making
OT  - empathy
OT  - ethical bias
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.3389/fpsyg.2020.01139 [doi]
PST - epublish
SO  - Front Psychol. 2020 May 27;11:1139. doi: 10.3389/fpsyg.2020.01139. eCollection
      2020.


PMID- 32536882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Digital Phenotyping: Ethical Issues, Opportunities, and Threats.
PG  - 473
LID - 10.3389/fpsyt.2020.00473 [doi]
AB  - This paper explores the potential threats of digital phenotyping and the ways it 
      may redesign our body experience and conceptualization. We argue that technology 
      in digital medicine, and in psychiatry in particular, is not merely an extrinsic 
      device to achieve improvements in knowledge, diagnosis, and treatment of
      diseases; rather, it intrinsically and unavoidably implies potential effects on
      what it is to be a human person, namely the embodiment and relatedness in human
      affairs, and not only in the clinical setting. Last but not least, digital
      phenotyping may improve prediction of abnormal behaviour, but not improve its
      causal explanation or psychological understanding.
CI  - Copyright (c) 2020 Stanghellini and Leoni.
FAU - Stanghellini, Giovanni
AU  - Stanghellini G
AD  - Department of Psychological, Territorial and Health Sciences, "G. d'Annunzio"
      University, Chieti, Italy.
AD  - Center for Studies on Phenomenology and Psychiatry Medical Faculty, "D. Portales"
      University, Santiago, Chile.
FAU - Leoni, Federico
AU  - Leoni F
AD  - Department of Human Sciences, Verona University, Verona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7267063
OTO - NOTNLM
OT  - cause-effect relations
OT  - covariance
OT  - digital phenotyping
OT  - ethics
OT  - philosophy of psychiatry
OT  - prediction
OT  - technology
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.3389/fpsyt.2020.00473 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 May 27;11:473. doi: 10.3389/fpsyt.2020.00473. eCollection 
      2020.


PMID- 32536881
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Aims to Reduce Coercive Measures in Forensic Inpatient Treatment: A 9-Year
      Observational Study.
PG  - 465
LID - 10.3389/fpsyt.2020.00465 [doi]
AB  - Protecting the human rights is particularly important within the forensic context
      because patients in forensic psychiatry are not admitted voluntarily and so the
      treatment itself is of a coercive nature. Coercive measures (i.e., actions
      against the will of the patient such as forced medication, seclusion or
      restraint) form an additional incision of personal rights. Although the use of
      coercion within forensic psychiatric institutions remains controversial, little
      empirical research has been conducted on the use of coercive measures within
      forensic settings. The study presented here can contribute to close this research
      gap by informing about rates of coercive measures within the present institution.
      National and international organizations on the prevention of torture or inhuman 
      or degrading treatment have emphasized the need to keep the incidents of coercive
      measures to a minimum. Criticisms by such organizations on high rates of
      seclusion, restraint, and compulsory medication have led to organizational
      changes within the present institution which is Switzerland's largest forensic
      clinic with an average of 124 patients per year. After a first visit of such a
      committee, e.g., the detailed documentation of coercive measures became
      obligatory and part of special reports. Changes in the use of coercive measures
      are presented here. Data on coercive measures was analyzed for years 2010 to
      2018. With respect to the most invasive coercive measurement, restraint, a
      minimum of four patients in 2017 and a maximum of 14 patients in 2010 have been
      subject to this form of coercive measurement. A minimum of sixteen patients in
      2012 and a maximum of 40 patients in 2010 were secluded. Though total number and 
      duration show a trend towards a reduction in severity of coercive measures on
      average, a few patients are not responsive to deescalating interventions.
      Preventive mechanisms, documentation standards, and efforts to ensure humane and 
      adequate treatment are discussed under ethical considerations of coercive
      measures within court mandated treatment.
CI  - Copyright (c) 2020 Lau, Brackmann, Mokros and Habermeyer.
FAU - Lau, Steffen
AU  - Lau S
AD  - Department of Forensic Psychiatry, University Hospital of Psychiatry Zurich,
      Zurich, Switzerland.
FAU - Brackmann, Nathalie
AU  - Brackmann N
AD  - Department of Forensic Psychiatry, University Hospital of Psychiatry Zurich,
      Zurich, Switzerland.
FAU - Mokros, Andreas
AU  - Mokros A
AD  - Department of Psychology, Fern Universitat in Hagen, Hagen, Germany.
FAU - Habermeyer, Elmar
AU  - Habermeyer E
AD  - Department of Forensic Psychiatry, University Hospital of Psychiatry Zurich,
      Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7267051
OTO - NOTNLM
OT  - forensic psychiatry
OT  - prevention of torture
OT  - restraint
OT  - schizophrenia
OT  - seclusion
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.3389/fpsyt.2020.00465 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 May 27;11:465. doi: 10.3389/fpsyt.2020.00465. eCollection 
      2020.


PMID- 32536804
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1434-6222 (Print)
IS  - 1434-6222 (Linking)
VI  - 23
IP  - 4
DP  - 2020
TI  - [Ethics of resuscitation and end-of-life decisions].
PG  - 263-267
LID - 10.1007/s10049-020-00724-5 [doi]
FAU - Van de Voorde, P
AU  - Van de Voorde P
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Bossaert, L
AU  - Bossaert L
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Mentzelopoulos, S
AU  - Mentzelopoulos S
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Blom, M T
AU  - Blom MT
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Couper, K
AU  - Couper K
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Djakow, J
AU  - Djakow J
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Druwe, P
AU  - Druwe P
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Lilja, G
AU  - Lilja G
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Lulic, I
AU  - Lulic I
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Raffay, V
AU  - Raffay V
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Perkins, G D
AU  - Perkins GD
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
FAU - Monsieurs, K G
AU  - Monsieurs KG
AD  - European Resuscitation Council VZW, Emile Vanderveldelaan 35, 2845 Niel,
      Belgien.grid.494129.30000 0004 6009 4889
LA  - ger
PT  - Journal Article
TT  - Ethik der Reanimation und Entscheidungen am Lebensende: COVID-19-Leitlinien des
      European Resuscitation Council.
DEP - 20200610
PL  - Germany
TA  - Notf Rett Med
JT  - Notfall & rettungsmedizin
JID - 9812553
PMC - PMC7284670
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.1007/s10049-020-00724-5 [doi]
AID - 724 [pii]
PST - ppublish
SO  - Notf Rett Med. 2020;23(4):263-267. doi: 10.1007/s10049-020-00724-5. Epub 2020 Jun
      10.


PMID- 32536736
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200615
IS  - 0148-2963 (Print)
IS  - 0148-2963 (Linking)
VI  - 117
DP  - 2020 Sep
TI  - Effects of COVID-19 on business and research.
PG  - 284-289
LID - 10.1016/j.jbusres.2020.06.008 [doi]
AB  - The COVID-19 outbreak is a sharp reminder that pandemics, like other rarely
      occurring catastrophes, have happened in the past and will continue to happen in 
      the future. Even if we cannot prevent dangerous viruses from emerging, we should 
      prepare to dampen their effects on society. The current outbreak has had severe
      economic consequences across the globe, and it does not look like any country
      will be unaffected. This not only has consequences for the economy; all of
      society is affected, which has led to dramatic changes in how businesses act and 
      consumers behave. This special issue is a global effort to address some of the
      pandemic-related issues affecting society. In total, there are 13 papers that
      cover different industry sectors (e.g., tourism, retail, higher education),
      changes in consumer behavior and businesses, ethical issues, and aspects related 
      to employees and leadership.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Donthu, Naveen
AU  - Donthu N
AD  - Georgia State University, United States.
FAU - Gustafsson, Anders
AU  - Gustafsson A
AD  - BI Norwegian Business School, Norway.
LA  - eng
PT  - Editorial
DEP - 20200609
PL  - United States
TA  - J Bus Res
JT  - Journal of business research
JID - 101087747
PMC - PMC7280091
EDAT- 2020/06/17 06:00
MHDA- 2020/06/17 06:01
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/06/17 06:01 [medline]
AID - 10.1016/j.jbusres.2020.06.008 [doi]
AID - S0148-2963(20)30383-0 [pii]
PST - ppublish
SO  - J Bus Res. 2020 Sep;117:284-289. doi: 10.1016/j.jbusres.2020.06.008. Epub 2020
      Jun 9.


PMID- 32536443
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20210110
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 3
DP  - 2020 Sep
TI  - Supporting more than one patient with a single mechanical ventilator: useful last
      resort or unjustifiable risk?
PG  - 247-250
LID - S0007-0912(20)30411-6 [pii]
LID - 10.1016/j.bja.2020.05.029 [doi]
FAU - Laffey, John G
AU  - Laffey JG
AD  - Anaesthesia and Intensive Care Medicine, School of Medicine, and Regenerative
      Medicine Institute at the CURAM Centre for Medical Devices, National University
      of Ireland, Galway, Ireland.
FAU - Chikhani, Marc
AU  - Chikhani M
AD  - Nottingham University Hospitals NHS Trust, Nottingham, UK; Division of Clinical
      Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK.
FAU - Bates, Declan G
AU  - Bates DG
AD  - School of Engineering, University of Warwick, UK.
FAU - Hardman, Jonathan G
AU  - Hardman JG
AD  - Nottingham University Hospitals NHS Trust, Nottingham, UK; Division of Clinical
      Neuroscience, School of Medicine, University of Nottingham, Nottingham, UK.
      Electronic address: j.hardman@nottingham.ac.uk.
LA  - eng
PT  - Editorial
DEP - 20200601
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - *Ventilators, Mechanical/adverse effects
PMC - PMC7262535
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *mechanical ventilation
OT  - *resource allocation
OT  - *shared ventilation
OT  - *ventilator
EDAT- 2020/06/17 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/06/16 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2020/06/16 06:00 [entrez]
AID - S0007-0912(20)30411-6 [pii]
AID - 10.1016/j.bja.2020.05.029 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Sep;125(3):247-250. doi: 10.1016/j.bja.2020.05.029. Epub 2020 
      Jun 1.


PMID- 32535945
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20211108
IS  - 1526-4610 (Electronic)
IS  - 0017-8748 (Linking)
VI  - 60
IP  - 8
DP  - 2020 Sep
TI  - Cross-Cultural Headache Care Within the United States: Speaking the Unspoken.
PG  - 1832-1836
LID - 10.1111/head.13878 [doi]
FAU - Charleston, Larry 4th
AU  - Charleston L 4th
AD  - Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
LA  - eng
GR  - Brown
PT  - Journal Article
DEP - 20200613
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
SB  - IM
MH  - *Culturally Competent Care
MH  - *Ethics, Medical
MH  - *Headache
MH  - *Headache Disorders
MH  - *Health Communication
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - United States
OTO - NOTNLM
OT  - *cross-cultural communication
OT  - *cultural competency (cultural sensitivity)
OT  - *headache care disparities
OT  - *headache education
OT  - *medical ethics
OT  - *patient outcomes
EDAT- 2020/06/15 06:00
MHDA- 2021/11/09 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1111/head.13878 [doi]
PST - ppublish
SO  - Headache. 2020 Sep;60(8):1832-1836. doi: 10.1111/head.13878. Epub 2020 Jun 13.


PMID- 32535874
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20220218
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Autonomy in HIV testing: a call for a rethink of personal autonomy in the HIV
      response in sub-Saharan Africa.
PG  - 519-536
LID - 10.1007/s11019-020-09959-y [doi]
AB  - The author reviews various conceptions of autonomy to show that humans are
      actually not autonomous, strictly speaking. He argues for a need to rethink the
      personal autonomy approaches to HIV testing in sub-Saharan Africa (SSA)
      countries. HIV/AIDS has remained a leading cause of disease burden in SSA. It is 
      important to bring this disease burden under control, especially given the
      availability of current effective antiretroviral regimens in low- and
      middle-income countries. In most SSA countries the ethic or value of personal
      autonomy or self-determination is promoted as primary in HIV testing
      decision-making. SSA policymakers have an ontological and moral duty to adopt HIV
      testing policies that reflect human and medical realities, relationships, local
      contexts, and respect human rights for both individuals and others who are
      affected by HIV in society. Without rethinking the value of autonomy in HIV
      testing decision-making, the article cautions that attainment of the Sustainable 
      Development Goal (SDG) 3 and the UNAIDS fast-track strategy that explicitly call 
      to end the epidemic by 2030 will not be feasible for SSA.
FAU - Kasoka, Kasoka
AU  - Kasoka K
AUID- ORCID: http://orcid.org/0000-0003-3135-2095
AD  - School of Law, Birkbeck, University of London, London, UK.
      Kasoka_k@protonmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Africa South of the Sahara/epidemiology
MH  - HIV Infections/*diagnosis/epidemiology
MH  - Human Rights
MH  - Humans
MH  - Mass Screening/*ethics/*psychology
MH  - *Personal Autonomy
MH  - Philosophy, Medical
PMC - PMC7292930
OTO - NOTNLM
OT  - AIDS
OT  - Common good
OT  - HIV response
OT  - Personal autonomy
OT  - Rethinking autonomy
OT  - Sub-saharan africa
EDAT- 2020/06/15 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/06/15 06:00
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1007/s11019-020-09959-y [doi]
AID - 10.1007/s11019-020-09959-y [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):519-536. doi: 10.1007/s11019-020-09959-y.


PMID- 32535870
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20210409
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 27
IP  - 8
DP  - 2020 Aug
TI  - Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients
      Effectively through Turbulence and Change.
PG  - 2600-2613
LID - 10.1245/s10434-020-08673-6 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has posed extraordinary demands from patients, 
      providers, and health care systems. Despite this, surgical oncologists must
      maintain focus on providing high-quality, empathetic care for the almost 2
      million patients nationally who will be diagnosed with operable cancer this year.
      The focus of hospitals is transitioning from initial COVID-19 preparedness
      activities to a more sustained approach to cancer care. METHODS: Editorial Board 
      members provided observations of the implications of the pandemic on providing
      care to surgical oncology patients. RESULTS: Strategies are presented that have
      allowed institutions to successfully prepare for cancer care during COVID-19, as 
      well as other strategies that will help hospitals and surgical oncologists manage
      anticipated challenges in the near term. Perspectives are provided on: (1)
      maintaining a safe environment for surgical oncology care; (2) redirecting the
      multidisciplinary model to guide surgical decisions; (3) harnessing telemedicine 
      to accommodate requisite physical distancing; (4) understanding interactions
      between SARS CoV-2 and cancer therapy; (5) considering the ethical impact of
      professional guidelines for surgery prioritization; and (6) advocating for our
      patients who require oncologic surgery in the midst of the COVID-19 pandemic.
      CONCLUSIONS: Until an effective vaccine becomes available for widespread use, it 
      is imperative that surgical oncologists remain focused on providing optimal care 
      for our cancer patients while managing the demands that the COVID-19 pandemic
      will continue to impose on all of us.
FAU - Hwang, E Shelley
AU  - Hwang ES
AD  - Department of Surgery, Duke University and Duke Cancer Institute, Durham, NC,
      USA.
FAU - Balch, Charles M
AU  - Balch CM
AD  - Division of Surgical Oncology, University of Texas MD Anderson Cancer Center,
      Houston, TX, USA.
FAU - Balch, Glen C
AU  - Balch GC
AD  - Department of Surgery, Emory University, Atlanta, GA, USA.
FAU - Feldman, Sheldon M
AU  - Feldman SM
AD  - Department of Surgery, Montefiore Einstein Center for Cancer Care, Bronx, NY,
      USA.
FAU - Golshan, Mehra
AU  - Golshan M
AD  - Department of Surgery, Brigham and Women's Hospital, Dana Farber Cancer
      Institute, Boston, MA, USA.
FAU - Grobmyer, Stephen R
AU  - Grobmyer SR
AD  - Oncology Institute, and Pulmonary and Critical Care Medicine Institutes,
      Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
FAU - Libutti, Steven K
AU  - Libutti SK
AD  - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
FAU - Margenthaler, Julie A
AU  - Margenthaler JA
AD  - Department of Surgery, Washington University School of Medicine, St. Louis, MO,
      USA.
FAU - Sasidhar, Madhu
AU  - Sasidhar M
AD  - Oncology Institute, and Pulmonary and Critical Care Medicine Institutes,
      Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
FAU - Turaga, Kiran K
AU  - Turaga KK
AD  - Department of Surgery, University of Chicago Pritzker School of Medicine,
      Chicago, IL, USA.
FAU - Wong, Sandra L
AU  - Wong SL
AD  - Department of Surgery, Geisel School of Medicine, Dartmouth, NH, USA.
FAU - McMasters, Kelly M
AU  - McMasters KM
AD  - Department of Surgery, University of Louisville School of Medicine, Louisville,
      KY, USA.
FAU - Tanabe, Kenneth K
AU  - Tanabe KK
AD  - Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
      ktanabe@partners.org.
LA  - eng
GR  - P30 CA023108/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200614
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
SB  - IM
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/*complications/virology
MH  - Humans
MH  - Infection Control
MH  - Neoplasms/complications/epidemiology/*surgery
MH  - Pandemics
MH  - Patient Education as Topic
MH  - Pneumonia, Viral/*complications/virology
MH  - Population Health
MH  - Practice Guidelines as Topic/*standards
MH  - SARS-CoV-2
MH  - Surgical Oncology/*standards
PMC - PMC7293588
EDAT- 2020/06/15 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/06/15 06:00
PHST- 2020/05/17 00:00 [received]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1245/s10434-020-08673-6 [doi]
AID - 10.1245/s10434-020-08673-6 [pii]
PST - ppublish
SO  - Ann Surg Oncol. 2020 Aug;27(8):2600-2613. doi: 10.1245/s10434-020-08673-6. Epub
      2020 Jun 14.


PMID- 32535715
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
VI  - 179
IP  - 8
DP  - 2020 Aug
TI  - Low-risk trials for children and pregnant women threatened by unnecessary strict 
      regulations. Does the coming EU Clinical Trial Regulation offer a solution?
PG  - 1205-1211
LID - 10.1007/s00431-020-03715-3 [doi]
AB  - Investigator-initiated clinical trials are crucial for improving quality of care 
      for children and pregnant women as they are often excluded from
      industry-initiated trials. However, trials have become increasingly
      time-consuming and costly since the EU Clinical Trial Directive entered into
      force in 2001. This directive made compliance with ICH-Good Clinical Practice
      Guidelines (ethical and quality standard for conducting human subject research)
      mandatory for all clinical trials, regardless of its risk-classification. By
      discussing two investigator-initiated, 'low-risk' drug trials, we aim to
      illustrate that compliance with all GCP requirements makes trials very laborious 
      and expensive, while a clear rationale is missing. This discourages clinical
      researchers to start and carry out investigator-initiated research. However, the 
      forthcoming EU Clinical Trial Regulation (No 536/2014) seems to provide a
      solution as it allows for less stringent rules for low-risk trials. We want to
      raise awareness for these developments in both the clinical research community
      and the European and national regulatory authorities. Implementation of this
      forthcoming Regulation regulatory policies should be done in such a way that
      investigator-initiated trials evaluating standard care interventions will become 
      more feasible. This will allow us to obtain evidence on optimal and safe
      treatments, especially for groups that are underrepresented in medical research. 
      What is Known * Investigator-initiated trials are indispensable for improving
      care for children and pregnant women as they are often excluded from
      industry-initiated trials * Trials have become increasingly time-consuming and
      costly because of mandatory compliance with ICH-GCP guidelines What is New * The 
      forthcoming EU Clinical Trial Regulation allows less stringent rules for low-risk
      trials * The national legislator and regulatory authorities should recognize the 
      importance of this opportunity and implement the Regulation in such a way that
      investigator-initiated trials will become more feasible.
FAU - Knaapen, Max
AU  - Knaapen M
AUID- ORCID: http://orcid.org/0000-0002-0780-6395
AD  - Department of Paediatric Surgery, Emma Children's Hospital, Amsterdam UMC,
      University of Amsterdam & Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands. m.knaapen@amc.uva.nl.
FAU - Ploem, Martine Corrette
AU  - Ploem MC
AD  - Department of Social Medicine, Section Health Law, Amsterdam UMC, University of
      Amsterdam, Amsterdam, The Netherlands.
FAU - Kruijt, Maya
AU  - Kruijt M
AD  - Department of Reproductive Medicine, Amsterdam Reproduction and Development
      Research Institute, Amsterdam UMC, University of Amsterdam and Stichting
      Zorgevaluatie Nederland, Amsterdam, The Netherlands.
FAU - Oudijk, Martijn A
AU  - Oudijk MA
AD  - Department of Obstetrics, Amsterdam Reproduction and Development Research
      Institute, Amsterdam UMC, University of Amsterdam and Dutch Consortium for
      Healthcare Evaluation and Research in Obstetrics and Gynaecology, Amsterdam, The 
      Netherlands.
FAU - van der Graaf, Rieke
AU  - van der Graaf R
AD  - Department of Medical Humanities, Julius Center for Health Sciences and Primary
      Care, University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Bet, Pierre M
AU  - Bet PM
AD  - Department of Clinical Pharmacology and Pharmacy, VU University Medical Centre,
      Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
FAU - Bakx, Roel
AU  - Bakx R
AD  - Department of Paediatric Surgery, Emma Children's Hospital, Amsterdam UMC,
      University of Amsterdam & Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - van Heurn, L W Ernst
AU  - van Heurn LWE
AD  - Department of Paediatric Surgery, Emma Children's Hospital, Amsterdam UMC,
      University of Amsterdam & Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - Gorter, Ramon R
AU  - Gorter RR
AD  - Department of Paediatric Surgery, Emma Children's Hospital, Amsterdam UMC,
      University of Amsterdam & Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands.
FAU - van der Lee, Johanna H
AU  - van der Lee JH
AD  - Paediatric Clinical Research Office, Emma Children's Hospital, Amsterdam UMC,
      University of Amsterdam, Amsterdam, The Netherlands.
AD  - Knowledge Institute of the Dutch Association of Medical Specialists, Utrecht, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200613
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
SB  - IM
MH  - Child
MH  - Clinical Trials as Topic/ethics/*legislation & jurisprudence/standards
MH  - *European Union
MH  - Female
MH  - *Government Regulation
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Pregnancy
MH  - Research Design/*legislation & jurisprudence/standards
MH  - Research Personnel/ethics/*legislation & jurisprudence/standards
MH  - Risk
MH  - Therapeutic Human Experimentation/ethics/*legislation & jurisprudence
PMC - PMC7351802
OTO - NOTNLM
OT  - Clinical trial regulation
OT  - ICH-GCP guideline
OT  - Investigator initiated research
OT  - Pragmatic clinical trials
OT  - Risk-based trial regulation
EDAT- 2020/06/15 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/06/15 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
PHST- 2020/06/15 06:00 [entrez]
AID - 10.1007/s00431-020-03715-3 [doi]
AID - 10.1007/s00431-020-03715-3 [pii]
PST - ppublish
SO  - Eur J Pediatr. 2020 Aug;179(8):1205-1211. doi: 10.1007/s00431-020-03715-3. Epub
      2020 Jun 13.


PMID- 32534658
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 1532-6578 (Electronic)
IS  - 1062-0303 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Jun
TI  - Association of poor sleep quality with risk factors after coronary artery bypass 
      graft surgery-A prospective cohort study.
PG  - 83-92
LID - S1062-0303(20)30006-6 [pii]
LID - 10.1016/j.jvn.2020.02.001 [doi]
AB  - Fragmented sleep is a daunting experience and a common health problem with high
      prevalence among patients 3 months after coronary artery bypass grafting (CABG). 
      However, the potential predictors on poor seep quality remains unexplored. The
      main purpose of this study was to determine the predictors of poor sleep quality 
      among patients 3 months after CABG. A prospective cohort study is a part of the
      randomized controlled trial between 2012 and 2013 in which 400 adult patients
      undergoing elective CABG were being randomly sampled as per the inclusion
      criteria followed up at 3 months after CABG surgery in the cardiovascular
      outpatient clinic of a tertiary-care hospital. The study was conducted according 
      to the Declaration of Helsinki and was approved by the institutional ethical
      committee. All participants gave written informed consent on having received
      detailed information on the study. Demographic and clinical data were obtained
      from medical records at the time of CABG. The data on sleep quality were
      collected by using the Pittsburgh Sleep Quality Index and state anxiety was
      evaluated utilizing state-trait anxiety inventory (STAI-YI fo3rm). Multivariable 
      logistic regression examined the association between the postoperative poor sleep
      quality and clinical, preoperative state anxiety, and angina. The significant
      variables are chosen based on the P-value associated with the significant level
      of model that lies on alpha = 0.05. Logit determination and the correlation
      between the variables are also discussed for further analysis. A total of 187
      patients (mean age 55.6 +/- 12.05 years) completed the questionnaire. Most
      patients (78%) reported poor sleep quality (4.23 +/- 1.24) (PQSI score of less
      than 5). There was a strong relationship between PQSI and state anxiety. The
      higher state anxiety among 68% of patients with the mean score (53.51 +/- 9.55)
      had 6.42 (95% CI 3.04-9.61) times the odds of being classified as high risk for
      sleep disturbance. There are 3 factors that most significant of the 8 factors
      tested were identified as having influence significantly on the poor sleep
      quality. These factors are diabetes (OR 1.186, 95% CI 1.016-1.097, P > .01), body
      mass index > 30 kg/m(2) (OR 2.36, 95% CI 1.041-1.172, P > .05), sedentary
      lifestyle (OR 1.091, 95% CI 1.016-1.159, P > .01), and preoperative state anxiety
      (OR 1.186, 95% CI 1.074-1.115, P > .01). Even though the body mass index>30
      kg/m(2), sedentary lifestyle, and diabetes were significantly associated with
      sleep quality, the only factor with more significantly related to poor sleep
      quality was preoperative state anxiety which is the strong predictor of poor
      sleep quality. Hence, early recognition of predictors and careful management of
      poor sleep quality is warranted.
CI  - Copyright (c) 2020 Society for Vascular Nursing. Published by Elsevier Inc. All
      rights reserved.
FAU - Muthukrishnan, Akila
AU  - Muthukrishnan A
AD  - Assistant Professor, School of Nursing, College of Pharmacy and Nursing,
      University of Nizwa, Sultanate of Oman. Electronic address: akila@unizwa.edu.om.
FAU - Muralidharan, Thoddi Ramamurthy
AU  - Muralidharan TR
AD  - Professor & Head, Department of Cardiology, Sri Ramachandra Institute of Higher
      Education & Research (Deemed to be University), Chennai, Tamil Nadu, India.
FAU - Subash, Jeyagowri
AU  - Subash J
AD  - Principal, Rani Meyyammai College of Nursing, Annamalai University, Chidambaram, 
      Tamil Nadu, India.
FAU - Lathamangeswari, Chinnasamy
AU  - Lathamangeswari C
AD  - Principal, Jothi College of Management Science & Technology, Bareilly,
      Uttarpradesh, India.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200324
PL  - United States
TA  - J Vasc Nurs
JT  - Journal of vascular nursing : official publication of the Society for Peripheral 
      Vascular Nursing
JID - 9014475
MH  - Anxiety/*psychology
MH  - Coronary Artery Bypass/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Period
MH  - Prospective Studies
MH  - Sleep/*physiology
MH  - Surveys and Questionnaires
EDAT- 2020/06/15 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/11/02 00:00 [received]
PHST- 2020/01/22 00:00 [revised]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/06/15 06:00 [entrez]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - S1062-0303(20)30006-6 [pii]
AID - 10.1016/j.jvn.2020.02.001 [doi]
PST - ppublish
SO  - J Vasc Nurs. 2020 Jun;38(2):83-92. doi: 10.1016/j.jvn.2020.02.001. Epub 2020 Mar 
      24.


PMID- 32534651
OWN - NLM
STAT- MEDLINE
DCOM- 20200623
LR  - 20200623
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10240
DP  - 2020 Jun 13
TI  - Major burns: debt recovery or ethics?
PG  - e103-e104
LID - S0140-6736(20)30173-2 [pii]
LID - 10.1016/S0140-6736(20)30173-2 [doi]
FAU - Arkoulis, Nikolaos
AU  - Arkoulis N
AD  - Burns Intensive Care Unit, St Andrew's Burns Service, Broomfield Hospital,
      Chelmsford, CM1 7ET, UK. Electronic address: narkoulis@nhs.net.
FAU - Martin, Niall
AU  - Martin N
AD  - Burns Intensive Care Unit, St Andrew's Burns Service, Broomfield Hospital,
      Chelmsford, CM1 7ET, UK.
LA  - eng
PT  - Letter
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - IM
MH  - Burn Units/*economics/*ethics
MH  - Burns/*therapy
MH  - *Cost of Illness
MH  - *Health Care Costs
MH  - Humans
MH  - Insurance Coverage
MH  - National Health Programs/*economics/*ethics
MH  - United Kingdom
EDAT- 2020/06/15 06:00
MHDA- 2020/06/24 06:00
CRDT- 2020/06/15 06:00
PHST- 2019/12/11 00:00 [received]
PHST- 2020/01/17 00:00 [accepted]
PHST- 2020/06/15 06:00 [entrez]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
AID - S0140-6736(20)30173-2 [pii]
AID - 10.1016/S0140-6736(20)30173-2 [doi]
PST - ppublish
SO  - Lancet. 2020 Jun 13;395(10240):e103-e104. doi: 10.1016/S0140-6736(20)30173-2.


PMID- 32534507
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20211204
IS  - 1735-5249 (Electronic)
IS  - 1735-1502 (Linking)
VI  - 19
IP  - S1
DP  - 2020 May 17
TI  - Forty Years of Research and Treatment in Immunology and Allergy: In Honor of
      Professor Reza Farid Hosseini.
PG  - 18-26
LID - 10.18502/ijaai.v19i(s1.r1).2851 [doi]
AB  - In light of various supports of prodigious figures in the field of immunology and
      allergy, the subject area has been faced a great leap during the last century.
      The current state of the discipline owes an abundant appreciation for the
      scholars motivated in escalating the true nature of the science, who left no
      stone unturned in improving the general common sense and understanding of the
      human knowledge in general, and immunology and allergy in particular. Professor
      Reza Farid Hosseini is among the dignitaries who invested his life and energy on 
      weaving the tapestry of the immunology and allergy. He delivered a great deal of 
      influence on the field by his ethical devotion to science and was a significant
      contributor in the realms of the human immune system. His presence drastically
      rehabilitated the place of the Immunology in Iran, and the current paper seeks to
      review the personal and academic life of Professor Reza Farid Hosseini in honor
      and appreciation for his in-depth involvement in the field. The paper summarizes 
      Professor Farid's childhood, school, and higher education, compilations, and
      translation of books, his contribution to the research both inside and outside of
      Iran, and scientific activities of Dr. Farid Hosseini.
FAU - Jafari, Reza
AU  - Jafari R
AD  - Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia
      University of Medical Sciences, Urmia, Iran AND Department of Immunology and
      Genetics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. 
      rezajaafary@yahoo.com.
FAU - Moin, Mostafa
AU  - Moin M
AD  - Immunology, Asthma, and Allergy Research Institute, Children's Medical Center
      Hospital, Tehran University of Medical Sciences, Tehran, Iran. mmoin@tums.ac.ir.
FAU - Kashanchi, Fatah
AU  - Kashanchi F
AD  - School of Systems Biology, Laboratory of Molecular Virology, George Mason
      University, Manassas, VA, U.S.A. fkashanc@gmu.edu.
FAU - Rajbar, Alireza
AU  - Rajbar A
AD  - School of Systems Biology, Laboratory of Molecular Virology, George Mason
      University, Manassas, VA, USA 5 Institute of Interventional Allergology and
      Immunology, Bonn/Cologne, Bonn, Germany AND International Prof. Dr. Alireza Yalda
      Foundation in Medical Sciences, Bonn/Cologne, Bonn, Germany.
      alireza.ranjbar@web.de.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
DEP - 20200517
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
SB  - IM
MH  - Allergy and Immunology/ethics/*history
MH  - Autoimmune Diseases/*immunology
MH  - Desensitization, Immunologic
MH  - HTLV-I Infections/*immunology
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Human T-lymphotropic virus 1/*physiology
MH  - Humans
MH  - Immune System
MH  - Iran
MH  - Male
MH  - Translational Research, Biomedical
PS  - Farid Hosseini R
FPS - Farid Hosseini, Reza
OTO - NOTNLM
OT  - Allergy
OT  - Ethical devotion
OT  - Honor
OT  - Immunology
EDAT- 2020/06/15 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/06/15 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/06/15 06:00 [entrez]
PHST- 2020/06/15 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.18502/ijaai.v19i(s1.r1).2851 [doi]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):18-26. doi:
      10.18502/ijaai.v19i(s1.r1).2851.


PMID- 32533888
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1460-9592 (Electronic)
IS  - 1155-5645 (Linking)
VI  - 30
IP  - 8
DP  - 2020 Aug
TI  - Impact of clear fluid fasting on pulmonary aspiration in children undergoing
      general anesthesia: Results of the German prospective multicenter observational
      (NiKs) study.
PG  - 892-899
LID - 10.1111/pan.13948 [doi]
AB  - BACKGROUND: A preliminary national audit of real fasting times including 3324
      children showed that the fasting times for clear fluids and light meals were
      frequently shorter than recommended in current guidelines, but the sample size
      was too small for subgroup analyses. AIMS: Therefore, the primary aim of this
      extended study with more participating centers and a larger sample size was to
      determine whether shortened fasting times for clear fluids or light meals have an
      impact on the incidence of regurgitation or pulmonary aspiration during general
      anesthesia in children. The secondary aim was to evaluate the impact of age,
      emergent status, ASA classification, induction method, airway management or
      surgical procedure. METHODS: After the Ethics Committee's approval, at least more
      than 10 000 children in total were planned to be enrolled for this analysis.
      Patient demographics, real fasting times, anesthetic and surgical procedures, and
      occurrence of target adverse events defined as regurgitation or pulmonary
      aspiration were documented using a standardized case report form. RESULTS: At
      fifteen pediatric centers, 12 093 children scheduled for surgery or
      interventional procedures were included between October 2018 and December 2019.
      Fasting times were shorter than recommended in current guidelines for large meals
      in 2.5%, for light meals in 22.4%, for formula milk in 5.3%, for breastmilk in
      10.9%, and for clear fluids in 39.2%. Thirty-one cases (0.26%) of regurgitation, 
      ten cases (0.08%) of suspected pulmonary aspiration, and four cases (0.03%) of
      confirmed pulmonary aspiration were reported, and all of them recovered quickly
      without any consequences. Fasting times for clear fluids shortened from 2 hours
      to 1 hour did not affect the incidence of adverse events (upper limit 95% CI
      0.08%). The sample size of the cohort with fasting times for light meals shorter 
      than 6 hours was too small for a subgroup analysis. An age between one and 3
      years (odds ratio 2.7,95% CI 1.3 to 5.8%; P < .01) and emergent procedures (odds 
      ratio 2.8,95% CI 1.4 to 5.7;P < .01) increased the incidence of adverse events,
      whereas ASA classification, induction method, or surgical procedure had no
      influence. The clear fluid fasting times were shortest under 6/4/0 as compared to
      6/4/1 and 6/4/2 fasting regimens, all with an incidence of 0.3% for adverse
      events. CONCLUSION: This study shows that a clear fluid fasting time shortened
      from 2 hours to 1 hour does not affect the incidence of regurgitation or
      pulmonary aspiration, that an age between one and 3 years and emergent status
      increase the incidence of regurgitation or pulmonary aspiration, and that
      pulmonary aspiration followed by postoperative respiratory distress is rare and
      usually shows a quick recovery.
CI  - (c) 2020 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd.
FAU - Beck, Christiane E
AU  - Beck CE
AUID- ORCID: 0000-0002-7179-0084
AD  - Clinic of Anesthesiology and Intensive Care Medicine, Hannover Medical School,
      Hannover, Germany.
FAU - Rudolph, Diana
AU  - Rudolph D
AD  - Department of Anesthesia, Pediatric Intensive Care and Emergency Medicine, Auf
      der Bult Children's Hospital, Hannover, Germany.
FAU - Mahn, Christoph
AU  - Mahn C
AD  - Department of Anesthesia, Catholic Children's Hospital Wilhelmstift, Hamburg,
      Germany.
FAU - Etspuler, Alexander
AU  - Etspuler A
AD  - Department of Anesthesia, Altona Children's Hospital, Hamburg, Germany.
FAU - Korf, Michael
AU  - Korf M
AD  - Anesthesia practice, Luthke&Korf, Hamburg, Germany.
FAU - Luthke, Matthias
AU  - Luthke M
AD  - Anesthesia practice, Luthke&Korf, Hamburg, Germany.
FAU - Schindler, Ehrenfried
AU  - Schindler E
AUID- ORCID: 0000-0002-2377-3327
AD  - Section Pediatric Anesthesiology, Department of Anesthesiology, University
      Hospital Bonn, Bonn, Germany.
AD  - Department of Anesthesia, Asklepios Children's Hospital, St. Augustin, Germany.
FAU - Paukert, Susanne
AU  - Paukert S
AD  - Department of Anesthesia, Asklepios Children's Hospital, St. Augustin, Germany.
FAU - Trapp, Almut
AU  - Trapp A
AD  - Department of Anesthesia, Intensive Care Medicine, Pain Medicine and Palliative
      Care Medicine, Sana Clinic Leipziger Land, Borna, Germany.
FAU - Megens, Johanna H A M
AU  - Megens JHAM
AD  - Department of Anesthesia, Wilhelmina Children's Hospital, University Medical
      Center, Utrecht, The Netherlands.
FAU - Oppitz, Francesca
AU  - Oppitz F
AD  - Department of Anesthesia, Wilhelmina Children's Hospital, University Medical
      Center, Utrecht, The Netherlands.
FAU - Badelt, Gregor
AU  - Badelt G
AD  - Department of Anesthesiology and Pediatric Anesthesiology, Clinic St. Hedwig,
      Barmherzige Bruder Hospital Regensburg, Regensburg, Germany.
FAU - Roher, Katharina
AU  - Roher K
AUID- ORCID: 0000-0001-5161-6858
AD  - Department of Anesthesiology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Genahr, Arka
AU  - Genahr A
AD  - Department of Anesthesia, Intensive Care Medicine, Emergency Medicine and Pain
      Medicine Vivantes Hospital Neukolln, Berlin, Germany.
FAU - Fink, Gordon
AU  - Fink G
AD  - Department of Anesthesia, Intensive Care Medicine, Emergency Medicine and Pain
      Medicine, Vivantes Hospital im Friedrichshain, Berlin, Germany.
FAU - Muller-Lobeck, Lutz
AU  - Muller-Lobeck L
AUID- ORCID: 0000-0001-5669-9218
AD  - Clinic of Anesthesiology and Intensive Care Medicine, Lippe Hospital, Detmold,
      Germany.
FAU - Becke-Jakob, Karin
AU  - Becke-Jakob K
AD  - Department of Anesthesia, Cnopf'sches Children's Hospital, Nurnberg, Germany.
FAU - Wermelt, Julius Z
AU  - Wermelt JZ
AD  - Department of Anesthesia and Pediatric Anesthesia, Burgerhospital and Clementinen
      Children's Hospital, Frankfurt, Germany.
FAU - Boethig, Dietmar
AU  - Boethig D
AD  - Department for Paediatric Cardiology and Intensive Care, Hannover Medical School,
      Germany.
FAU - Eich, Christoph
AU  - Eich C
AD  - Department of Anesthesia, Pediatric Intensive Care and Emergency Medicine, Auf
      der Bult Children's Hospital, Hannover, Germany.
FAU - Sumpelmann, Robert
AU  - Sumpelmann R
AUID- ORCID: 0000-0001-5850-7443
AD  - Clinic of Anesthesiology and Intensive Care Medicine, Hannover Medical School,
      Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20200717
PL  - France
TA  - Paediatr Anaesth
JT  - Paediatric anaesthesia
JID - 9206575
SB  - IM
MH  - *Anesthesia, General/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - *Fasting
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Vomiting
OTO - NOTNLM
OT  - *adverse events
OT  - *children
OT  - *clear fluids
OT  - *fasting policy
OT  - *general anesthesia
OT  - *infants
OT  - *liberal fasting times
OT  - *perioperative fasting
OT  - *perioperative pulmonary aspiration
EDAT- 2020/06/14 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/06/02 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 10.1111/pan.13948 [doi]
PST - ppublish
SO  - Paediatr Anaesth. 2020 Aug;30(8):892-899. doi: 10.1111/pan.13948. Epub 2020 Jul
      17.


PMID- 32533700
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
VI  - 45
IP  - 4-5
DP  - 2020 Jul 29
TI  - Never Solo: Gratitude for My Academic Journey.
PG  - 410-416
LID - 10.1093/jmp/jhaa012 [doi]
AB  - Tom Beauchamp and I were asked by the editors of The Journal of Medicine and
      Philosophy to prepare "intellectual autobiographies," with particular attention
      to sources and influences on our work, including but not limited to Principles of
      Biomedical Ethics. Of course, it is artificial and even impossible to try fully
      to separate the "intellectual" from other aspects of our lives. So, while
      emphasizing the "intellectual" aspects of my autobiography, I have attended to
      other aspects, too. The huge debts of gratitude I owe also mix the "intellectual"
      and other aspects of life.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Childress, James F
AU  - Childress JF
AD  - University of Virginia, Charlottesville, Virginia, USA.
LA  - eng
PT  - Autobiography
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
CIN - J Med Philos. 2020 Jul 29;45(4-5):560-579. PMID: 32726810
MH  - *Bioethics
MH  - *Career Choice
MH  - *Ethical Theory
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Male
MH  - Morals
MH  - *Philosophy, Medical
PS  - Childress J
FPS - Childress, James
OTO - NOTNLM
OT  - *Beauchamp and Childress
OT  - *bioethics
OT  - *principlism
EDAT- 2020/06/14 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 5857044 [pii]
AID - 10.1093/jmp/jhaa012 [doi]
PST - ppublish
SO  - J Med Philos. 2020 Jul 29;45(4-5):410-416. doi: 10.1093/jmp/jhaa012.


PMID- 32533665
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20210303
IS  - 2171-8695 (Electronic)
IS  - 1130-6343 (Linking)
VI  - 44
IP  - 7
DP  - 2020 Jun 12
TI  - Hospital pharmacist challenges in evaluation of scientific evidence and its
      incorporation to pharmacotherapeutic protocols through therapeutic committees in 
      COVID-19 times.
PG  - 24-27
LID - 10.7399/fh.11487 [doi]
AB  - Type 2 coronavirus pandemics that is plaguing almost all the world has caused
      qualitative and quantitative strains in health systems that have had to be
      responded to. The lack of known vaccines and effective treatments has generated
      the need to use drugs with very little evidence for their incorporation into
      pharmacotherapeutic protocols agreed by the clinical team. The hospital
      pharmacist, within the multidisciplinary team, has been responsible for
      critically evaluating the alternatives and positioning them in these protocols.
      Finally, some ethical and legal questions that should be considered in this
      scenario are analyzed in this article.
CI  - Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights
      reserved.
FAU - Fernandez-Llamazares, Cecilia M
AU  - Fernandez-Llamazares CM
AD  - Servicio de Farmacia, Hospital General Universitario Gregorio Maranon, Madrid.
      Espana. Secretaria de la Sociedad Espanola de Farmacia Hospitalaria, Madrid.
      Espana. eduardo.lopezbriz@gmail.com.
FAU - Lopez-Briz, Eduardo
AU  - Lopez-Briz E
AD  - Servicio de Farmacia, Hospital Universitario y Politecnico La Fe, Valencia.
      Espana. eduardo.lopezbriz@gmail.com.
LA  - eng
PT  - Journal Article
TT  - Retos del farmaceutico de hospital en la evaluacion de la evidencia cientifica y 
      su incorporacion a los protocolos farmacoterapeuticos a traves de las comisiones 
      en tiempos de COVID-19.
DEP - 20200612
PL  - Spain
TA  - Farm Hosp
JT  - Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad
      Espanola de Farmacia Hospitalaria
JID - 9440679
RN  - COVID-19 drug treatment
SB  - IM
EIN - Farm Hosp. 2020 Jul 01;44(4):184. PMID: 32646351
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Protocols
MH  - *Coronavirus Infections/drug therapy
MH  - Drug Therapy/standards
MH  - *Evidence-Based Medicine
MH  - Humans
MH  - Interdisciplinary Communication
MH  - Off-Label Use/ethics/legislation & jurisprudence
MH  - *Pandemics
MH  - Patient Care Team
MH  - *Pharmacists
MH  - Pharmacy Service, Hospital/legislation & jurisprudence/*organization &
      administration
MH  - Pharmacy and Therapeutics Committee/*organization & administration
MH  - *Pneumonia, Viral/drug therapy
MH  - Practice Guidelines as Topic
MH  - Propaganda
MH  - Role
MH  - SARS-CoV-2
EDAT- 2020/06/14 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.7399/fh.11487 [doi]
PST - epublish
SO  - Farm Hosp. 2020 Jun 12;44(7):24-27. doi: 10.7399/fh.11487.


PMID- 32533548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 8
DP  - 2020 Aug
TI  - The Effectiveness of Acceptance and Commitment Therapy on Pain Acceptance and
      Pain Perception in Patients with Painful Diabetic Neuropathy: A Randomized
      Controlled Trial.
PG  - 1695-1708
LID - 10.1007/s13300-020-00851-9 [doi]
AB  - INTRODUCTION: Neuropathic pain is a complex phenomenon in patients with diabetes.
      These patients have many problems, such as psychological problems, high-level
      pain perception, and pain acceptance. This study aimed to evaluate the
      effectiveness of acceptance and commitment therapy on pain acceptance and pain
      perception in patients with painful diabetic neuropathy. METHODS: This study was 
      performed according to the clinical trial method. The sample size was 50
      participants. In this study, participants were divided into interventional and
      control groups. According to the diagnosis of neurologists, all participants
      received conventional medications to manage neuropathic pain. The intervention
      group received acceptance and commitment therapy for eight sessions. The results 
      in the three phases of pre-test, post-test, and follow-up were evaluated. After
      completing the study, to comply with ethical standards, the control group
      received psycho-education. The tools used were the McGill Pain Questionnaire
      (MPQ) and the Chronic Pain Acceptance Questionnaire (CPAQ). Statistical analysis 
      includes mean, standard deviation, and repeated-measures (ANOVA) conducted by
      SPSS software version 22. RESULTS: The results demonstrated that in the post-test
      and follow-up phases, acceptance and commitment therapy could improve pain
      acceptance and reduce pain perception in the intervention group compared to the
      control group (P < 0.01). CONCLUSION: The results indicated that acceptance and
      commitment therapy could be used as a psychological intervention besides
      pharmacotherapy to improve pain acceptance and reduce pain perception in patients
      with painful diabetic neuropathy. CLINICAL TRAIL REGISTRATION: This study was
      registered at the Iranian Registry of Clinical Trials (IRCT20180205038630N4).
FAU - Taheri, Amir Abbas
AU  - Taheri AA
AD  - Department of Clinical Psychology, Kermanshah University of Medical Sciences,
      Kermanshah, Iran.
FAU - Foroughi, Ali Akbar
AU  - Foroughi AA
AD  - Department of Clinical Psychology, Kermanshah University of Medical Sciences,
      Kermanshah, Iran. aliakbar.Foroughi@kums.ac.ir.
FAU - Mohammadian, Youkhabeh
AU  - Mohammadian Y
AD  - Department of Clinical Psychology, Kermanshah University of Medical Sciences,
      Kermanshah, Iran.
FAU - Ahmadi, Seyed Mojtaba
AU  - Ahmadi SM
AD  - Department of Clinical Psychology, Kermanshah University of Medical Sciences,
      Kermanshah, Iran.
FAU - Heshmati, Khatereh
AU  - Heshmati K
AD  - Department of Clinical Psychology, Kermanshah University of Medical Sciences,
      Kermanshah, Iran.
FAU - Hezarkhani, Leila Afshar
AU  - Hezarkhani LA
AD  - Department of Neurology, Kermanshah University of Medical Sciences, Kermanshah,
      Iran.
FAU - Parvizifard, Ali Akbar
AU  - Parvizifard AA
AD  - Department of Clinical Psychology, Kermanshah University of Medical Sciences,
      Kermanshah, Iran.
LA  - eng
SI  - IRCT/IRCT20180205038630N4
PT  - Journal Article
DEP - 20200612
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
PMC - PMC7376796
OTO - NOTNLM
OT  - Acceptance and commitment therapy
OT  - Pain acceptance
OT  - Pain perception
OT  - Painful diabetic neuropathy
EDAT- 2020/06/14 06:00
MHDA- 2020/06/14 06:01
CRDT- 2020/06/14 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/06/14 06:01 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 10.1007/s13300-020-00851-9 [doi]
AID - 10.1007/s13300-020-00851-9 [pii]
PST - ppublish
SO  - Diabetes Ther. 2020 Aug;11(8):1695-1708. doi: 10.1007/s13300-020-00851-9. Epub
      2020 Jun 12.


PMID- 32533448
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Exploring Ethical Pharmacy Practice in Jordan.
PG  - 2809-2834
LID - 10.1007/s11948-020-00231-3 [doi]
AB  - Patient-centered pharmacy practice involves increased pharmacist engagement in
      patient care. This increased involvement can sometimes require diverse
      decision-making when handling various situations, ranging from simple matters to 
      major ethical dilemmas. There is literature about pharmacy ethics in developed
      Western countries. However, little is known about pharmacists' practices in many 
      developing countries. For example, there is a paucity of research conducted in
      the area of pharmacy ethics in Jordan. This study aimed to explore the manner in 
      which ethical dilemmas were handled by Jordanian pharmacists, the resources used 
      and their attitudes towards them. Semi-structured, face to face interviews were
      carried out with 30 Jordanian registered pharmacists. The transcribed interviews 
      were thematically analysed for emerging themes. Four major themes were
      identified: legal practice; familiarity with the code of ethics; personal
      judgement, cultural and religious values; and Experience. Findings showed that
      ethical decision-making in pharmacy practice in Jordan was decisively influenced 
      by pharmacists' personal moral values, legal requirements and managed by
      exercising common sense and experience. This pointed to gaps in Jordanian
      pharmacists' understanding and application of basic principles of pharmacy ethics
      and highlighted the need for professional ethics training, incorporating pharmacy
      ethics courses in pharmacy undergraduate curricula, as well as professional
      development courses. This study highlighted that paternalism, personal values and
      legal obligations were major drivers influencing decision-making processes of
      Jordanian pharmacists. Findings also highlighted an inclination towards lack of
      respect for patient autonomy. This illuminated the need for increasing
      pharmacists' literacy in professional ethics.
FAU - Fino, Leen B
AU  - Fino LB
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia.
AD  - Faculty of Pharmacy, Applied Science Private University, Amman, 11931, Jordan.
FAU - Basheti, Iman A
AU  - Basheti IA
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia.
AD  - Faculty of Pharmacy, Applied Science Private University, Amman, 11931, Jordan.
FAU - Chaar, Betty B
AU  - Chaar BB
AUID- ORCID: http://orcid.org/0000-0001-8757-9403
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia. betty.chaar@sydney.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Attitude of Health Personnel
MH  - *Community Pharmacy Services
MH  - Ethics, Pharmacy
MH  - Humans
MH  - Jordan
MH  - Morals
MH  - *Pharmacies
MH  - Pharmacists
MH  - *Pharmacy
MH  - Professional Role
OTO - NOTNLM
OT  - Ethical dilemmas
OT  - Jordan
OT  - Pharmacy ethics
OT  - Pharmacy practice
EDAT- 2020/06/14 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 10.1007/s11948-020-00231-3 [doi]
AID - 10.1007/s11948-020-00231-3 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2809-2834. doi: 10.1007/s11948-020-00231-3. Epub
      2020 Jun 12.


PMID- 32533446
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Citizen Neuroscience: Brain-Computer Interface Researcher Perspectives on
      Do-It-Yourself Brain Research.
PG  - 2769-2790
LID - 10.1007/s11948-020-00227-z [doi]
AB  - Devices that record from and stimulate the brain are currently available for
      consumer use. The increasing sophistication and resolution of these devices
      provide consumers with the opportunity to engage in do-it-yourself brain research
      and contribute to neuroscience knowledge. The rise of do-it-yourself (DIY)
      neuroscience may provide an enriched fund of neural data for researchers, but
      also raises difficult questions about data quality, standards, and the boundaries
      of scientific practice. We administered an online survey to brain-computer
      interface (BCI) researchers to gather their perspectives on DIY brain research.
      While BCI researcher concerns about data quality and reproducibility were high,
      the possibility of expert validation of data generated by citizen neuroscientists
      mitigated concerns. We discuss survey results in the context of an established
      ethical framework for citizen science, and describe the potential of constructive
      collaboration between citizens and researchers to both increase data collection
      and advance understanding of how the brain operates outside the confines of the
      lab.
FAU - Naufel, Stephanie
AU  - Naufel S
AUID- ORCID: http://orcid.org/0000-0001-5682-9000
AD  - Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA.
      steph.n.thacker@gmail.com.
FAU - Klein, Eran
AU  - Klein E
AUID- ORCID: http://orcid.org/0000-0002-0132-5777
AD  - Center for Sensorimotor Neural Engineering and Department of Philosophy,
      University of Washington, Seattle, WA, USA.
AD  - Department of Neurology, Oregon Health and Science University, Portland, OR, USA.
LA  - eng
GR  - EEC#1028725./National Science Foundation (US)/International
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200612
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Brain
MH  - *Brain-Computer Interfaces
MH  - Humans
MH  - *Neurosciences
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Brain-computer interface
OT  - *Brain-machine interface
OT  - *Citizen neuroscience
OT  - *Citizen science
OT  - *EEG
OT  - *TDCS
EDAT- 2020/06/14 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/14 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 10.1007/s11948-020-00227-z [doi]
AID - 10.1007/s11948-020-00227-z [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2769-2790. doi: 10.1007/s11948-020-00227-z. Epub
      2020 Jun 12.


PMID- 32533445
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - The Ethical Interest of Frankenstein; Or, the Modern Prometheus: A Literature
      Review 200 Years After Its Publication.
PG  - 2791-2808
LID - 10.1007/s11948-020-00229-x [doi]
AB  - Two hundred years after it was first published, Mary Shelley's Frankenstein; or, 
      the modern Prometheus remains relevant. This novel has endured because of its
      literary merits and because its themes lend themselves to analysis from multiple 
      viewpoints. Scholars from many disciplines have examined this work in relation to
      controversial scientific research. In this paper, we review the academic
      literature where Frankenstein is used to discuss ethics, bioethics, science,
      technology and medicine. We searched the academic literature and carried out a
      content analysis of articles discussing the novel and films derived from it,
      analyzing the findings qualitatively and quantitatively. We recorded the
      following variables: year and language of publication, whether it referred to the
      novel or to a film, the academic discipline in which it was published, and the
      topics addressed in the analysis. Our findings indicate that the scientific
      literature on Frankenstein focuses mainly on science and the personality of the
      scientist rather than on the creature the scientist created or ethical aspects of
      his research. The scientist's responsibility is central to the ethical interest
      of Frankenstein; this issue entails both the motivation underlying the
      scientist's acts and the consequences of these acts.
FAU - Cambra-Badii, Irene
AU  - Cambra-Badii I
AUID- ORCID: http://orcid.org/0000-0003-1233-3243
AD  - Department of Experimental and Health Sciences, Universitat Pompeu Fabra,
      Barcelona, Spain.
AD  - Bioethics Chair, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.
FAU - Guardiola, Elena
AU  - Guardiola E
AUID- ORCID: http://orcid.org/0000-0001-8002-1415
AD  - School of Medicine, Universitat de Vic-Universitat Central de Catalunya, Casa de 
      Convalescencia, Dr. Junyent 1, 08500, Vic, Spain.
FAU - Banos, Josep-E
AU  - Banos JE
AUID- ORCID: http://orcid.org/0000-0001-8202-6893
AD  - Department of Experimental and Health Sciences, Universitat Pompeu Fabra,
      Barcelona, Spain. josepeladi.banos@uvic.cat.
AD  - School of Medicine, Universitat de Vic-Universitat Central de Catalunya, Casa de 
      Convalescencia, Dr. Junyent 1, 08500, Vic, Spain. josepeladi.banos@uvic.cat.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200612
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humans
MH  - *Literature, Modern
MH  - *Medicine in Literature
MH  - Morals
MH  - Technology
OTO - NOTNLM
OT  - Ethics
OT  - Feature films
OT  - Frankenstein
OT  - Literature analysis
OT  - Science
OT  - Scientist
EDAT- 2020/06/14 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/14 06:00
PHST- 2019/10/14 00:00 [received]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 10.1007/s11948-020-00229-x [doi]
AID - 10.1007/s11948-020-00229-x [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2791-2808. doi: 10.1007/s11948-020-00229-x. Epub
      2020 Jun 12.


PMID- 32533126
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20210612
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jun 12
TI  - Survival impact of the time gap between surgery and chemo-radiotherapy in
      Glioblastoma patients.
PG  - 9595
LID - 10.1038/s41598-020-66608-3 [doi]
AB  - Glioblastoma treatment protocol includes chemo-radiation (CRT) after maximal safe
      resection. However, the recommended time-gap between surgery and CRT is unclear, 
      most trials protocol required an interval of less than 6 weeks. In the current
      study we evaluated the association of the time-gap between surgery and CRT to
      overall survival (OS) and progression free survival (PFS) in a tertiary center.
      After ethics committee approval, a retrospective study was conducted. Data was
      collected from the medical records of consecutive glioblastoma patients treated
      between 2005-2014. Parameters of interest included: background characteristics of
      patients, treatment dates and type of treatment, treatment interruptions and
      survival. Only patients who were diagnosed with WHO IV, underwent surgical
      resection (any type), and treated with postoperative CRT were included. For the
      analysis, patients were divided into 3 groups according to the time gap from
      surgery to CRT: <4 weeks, 4-6 weeks and >6 weeks. Overall survival and PFS were
      investigated using the Kaplan-Meier method and Cox proportional hazard model. Out
      of 465 patients, 204 were included. Median age was 60 years (range: 23-79 years) 
      and 61.7% male vs. 38.3% female. There was a significant difference in OS (HR =
      0.49, p-value = 0.002, 95% CI: 0.32-0.78) and PFS (HR = 0.51, p-value = 0.003,
      95% CI: 0.33-0.79) in the group who was treated with CRT 6 weeks or more after
      surgery, compared with the other two groups tested. In our study, 6 weeks or more
      time-gap (median of 8 weeks) between surgery and CRT was associated with better
      OS and PFS among newly diagnosed glioblastoma patients. Our results are probably 
      subjected to unaccounted biases of a retrospective study, and that CRT in this
      patient population is an effective therapy that overcomes the potential harm of
      initiating therapy later than 6 weeks. Our current approach is to initiate CRT
      within 6 weeks after surgery, similar to what is recommended in the literature,
      but the data from this study provide us with information that no major harms was 
      done in patients who were delayed.
FAU - Zur, Inbar
AU  - Zur I
AD  - Oncology Institute, Rambam Medical Center, Haifa, Israel.
FAU - Tzuk-Shina, Tzahala
AU  - Tzuk-Shina T
AD  - Oncology Institute, Rambam Medical Center, Haifa, Israel.
AD  - Neuro-oncology unit, Rambam Medical Center, Haifa, Israel.
FAU - Guriel, Marina
AU  - Guriel M
AD  - Oncology Institute, Rambam Medical Center, Haifa, Israel.
AD  - Neuro-oncology unit, Rambam Medical Center, Haifa, Israel.
FAU - Eran, Ayelet
AU  - Eran A
AUID- ORCID: http://orcid.org/0000-0003-1439-7881
AD  - Neuro-Radiology unit, Rambam Medical Center, Haifa, Israel.
FAU - Kaidar-Person, Orit
AU  - Kaidar-Person O
AUID- ORCID: http://orcid.org/0000-0003-4023-1869
AD  - Oncology Institute, Rambam Medical Center, Haifa, Israel.
      Orit.kaidarperson@sheba.health.gov.il.
AD  - Neuro-oncology unit, Rambam Medical Center, Haifa, Israel.
      Orit.kaidarperson@sheba.health.gov.il.
AD  - Radiation Oncology unit, Rambam Medical Center, Haifa, Israel.
      Orit.kaidarperson@sheba.health.gov.il.
AD  - Radiation Oncology, Sheba Tel Hashomer, Ramat Gan, Israel.
      Orit.kaidarperson@sheba.health.gov.il.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Adult
MH  - Brain Neoplasms/*mortality/pathology/therapy
MH  - Chemoradiotherapy/*mortality
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Glioblastoma/*mortality/pathology/therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurosurgical Procedures/*mortality
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Time-to-Treatment/*statistics & numerical data
PMC - PMC7293292
EDAT- 2020/06/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-66608-3 [doi]
AID - 10.1038/s41598-020-66608-3 [pii]
PST - epublish
SO  - Sci Rep. 2020 Jun 12;10(1):9595. doi: 10.1038/s41598-020-66608-3.


PMID- 32532843
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 187
IP  - 8
DP  - 2020 Oct 17
TI  - Advancing animal welfare and ethics in veterinary practice through a national pet
      wellbeing task force, practice-based champions and clinical audit.
PG  - 316
LID - 10.1136/vr.105484 [doi]
AB  - BACKGROUND: Veterinary animal welfare advocacy can be undertaken at individual,
      community, national and international levels. The People's Dispensary for Sick
      Animals (PDSA), a veterinary charity with 48 Pet Hospitals UK-wide, created a
      consultative staff network to put an explicit organisational focus on animal
      welfare-focused veterinary practice. METHODS: PDSA created a national internal
      committee-a Pet Wellbeing Task Force-composed of veterinary staff
      representatives. Together with recruited hospital-based Champions who serve as a 
      focus for animal welfare and ethics within their clinical teams, the resulting
      staff network has described a vision of animal welfare and ethics within
      companion animal veterinary practice, with accompanying practice-level actions.
      These actions have formed the basis for national clinical audit, repeated three
      times since 2013. RESULTS: The audit, alongside targeted interventions, has
      driven organisational change (eg, new policies), led to measurable improvements
      in pet wellbeing (eg, improved pain assessment and management) and stimulated
      collaborative practice-based research with universities. CONCLUSION: A dedicated 
      staff network has facilitated organisation-wide communication on animal welfare
      and ethics; offered a safe space to raise and discuss animal welfare and ethical 
      issues; and fostered leadership, by working towards model veterinary practice
      with respect to animal welfare and ethics, with benefits for pet patients, staff 
      and the wider veterinary and veterinary nursing professions.
CI  - (c) British Veterinary Association 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. Published by BMJ.
FAU - Wensley, Sean
AU  - Wensley S
AUID- ORCID: 0000-0003-2183-8446
AD  - Veterinary Department, People's Dispensary for Sick Animals (PDSA), Telford, UK
      wensley.sean@pdsa.org.uk.
FAU - Betton, Vicki
AU  - Betton V
AD  - Veterinary Department, People's Dispensary for Sick Animals (PDSA), Telford, UK.
FAU - Martin, Nicola
AU  - Martin N
AD  - Canine Partners Midlands Centre, Loughborough, UK.
FAU - Tipton, Emma
AU  - Tipton E
AD  - Veterinary Department, People's Dispensary for Sick Animals (PDSA), Telford, UK.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
SB  - IM
MH  - Advisory Committees
MH  - Animal Welfare/*ethics/*standards
MH  - Animals
MH  - Clinical Audit
MH  - Humans
MH  - Pets
MH  - United Kingdom
MH  - Veterinary Medicine/*organization & administration
PMC - PMC7606500
OTO - NOTNLM
OT  - *clinical practice
OT  - *companion animals
OT  - *ethics
OT  - *pain
OT  - *preventive medicine
OT  - *welfare
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/06/14 06:00
PHST- 2019/04/02 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/04/05 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - vr.105484 [pii]
AID - 10.1136/vr.105484 [doi]
PST - ppublish
SO  - Vet Rec. 2020 Oct 17;187(8):316. doi: 10.1136/vr.105484. Epub 2020 Jun 12.


PMID- 32532826
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Multivalue ethical framework for fair global allocation of a COVID-19 vaccine.
PG  - 499-501
LID - 10.1136/medethics-2020-106516 [doi]
AB  - The urgent drive for vaccine development in the midst of the current COVID-19
      pandemic has prompted public and private organisations to invest heavily in
      research and development of a COVID-19 vaccine. Organisations globally have
      affirmed the commitment of fair global access, but the means by which a
      successful vaccine can be mass produced and equitably distributed remains notably
      unanswered. Barriers for low-income countries include the inability to afford
      vaccines as well as inadequate resources to vaccinate, barriers that are
      exacerbated during a pandemic. Fair distribution of a pandemic vaccine is
      unlikely without a solid ethical framework for allocation. This piece analyses
      four allocation paradigms: ability to develop or purchase; reciprocity; ability
      to implement; and distributive justice, and synthesises their ethical
      considerations to develop an allocation model to fit the COVID-19 pandemic.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Liu, Yangzi
AU  - Liu Y
AUID- ORCID: 0000-0002-4524-2623
AD  - School of Medicine, Vanderbilt University, Nashville, Tennessee, USA
      yangzi.liu@vanderbilt.edu.
FAU - Salwi, Sanjana
AU  - Salwi S
AD  - School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
FAU - Drolet, Brian C
AU  - Drolet BC
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control/virology
MH  - Developing Countries
MH  - Ethical Analysis
MH  - *Global Health
MH  - Health Care Rationing/*ethics
MH  - Health Equity/*ethics
MH  - Health Resources
MH  - Humans
MH  - International Cooperation
MH  - Models, Theoretical
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/*prevention & control/virology
MH  - Poverty
MH  - SARS-CoV-2
MH  - *Social Justice
MH  - Social Values
MH  - Vaccination Coverage/ethics
MH  - *Viral Vaccines
PMC - PMC7316117
OTO - NOTNLM
OT  - *clinical ethics
OT  - *distributive justice
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - medethics-2020-106516 [pii]
AID - 10.1136/medethics-2020-106516 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):499-501. doi: 10.1136/medethics-2020-106516. Epub
      2020 Jun 12.


PMID- 32532825
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Surgery during COVID-19 crisis conditions: can we protect our ethical integrity
      against the odds?
PG  - 505-507
LID - 10.1136/medethics-2020-106446 [doi]
AB  - COVID-19 is reducing the ability to perform surgical procedures worldwide, giving
      rise to a multitude of ethical, practical and medical dilemmas. Adapting to
      crisis conditions requires a rethink of traditional best practices in surgical
      management, delving into an area of unknown risk profiles. Key challenging areas 
      include cancelling elective operations, modifying procedures to adapt local
      services and updating the consenting process. We aim to provide an ethical
      rationale to support change in practice and guide future decision-making. Using
      the four principles approach as a structure, Medline was searched for existing
      ethical frameworks aimed at resolving conflicting moral duties. Where
      insufficient data were available, best guidance was sought from educational
      institutions: National Health Service England and The Royal College of Surgeons. 
      Multiple papers presenting high-quality, reasoned, ethical theory and practice
      guidance were collected. Using this as a basis to assess current practice,
      multiple requirements were generated to ensure preservation of ethical integrity 
      when making management decisions. Careful consideration of ethical principles
      must guide production of local guidance ensuring consistent patient selection
      thus preserving equality as well as quality of clinical services. A critical
      issue is balancing the benefit of surgery against the unknown risk of developing 
      COVID-19 and its associated complications. As such, the need for surgery must be 
      sufficiently pressing to proceed with conventional or non-conventional operative 
      management; otherwise, delaying intervention is justified. For delayed
      operations, it is our duty to quantify the long-term impact on patients' outcome 
      within the constraints of pandemic management and its long-term outlook.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Macleod, Jack
AU  - Macleod J
AD  - Cardiothoracic Surgery, Manchester Royal Infirmary, Manchester, UK
      jack.macleod@nhs.net.
FAU - Mezher, Sermed
AU  - Mezher S
AD  - Cardiothoracic Surgery, Manchester Royal Infirmary, Manchester, UK.
FAU - Hasan, Ragheb
AU  - Hasan R
AD  - Cardiothoracic Surgery, Manchester Royal Infirmary, Manchester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/virology
MH  - Cost-Benefit Analysis
MH  - Decision Making/*ethics
MH  - England
MH  - Ethical Analysis
MH  - Ethical Theory
MH  - *Ethics, Medical
MH  - General Surgery/*ethics
MH  - Health Equity/*ethics
MH  - Humans
MH  - Informed Consent/ethics
MH  - Moral Obligations
MH  - Pandemics/*ethics
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/*complications/virology
MH  - Practice Guidelines as Topic
MH  - Principle-Based Ethics
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - State Medicine
MH  - Surgeons
MH  - Surgical Procedures, Operative
PMC - PMC7316104
OTO - NOTNLM
OT  - *ethics
OT  - *public health ethics
OT  - *right to healthcare
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - medethics-2020-106446 [pii]
AID - 10.1136/medethics-2020-106446 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):505-507. doi: 10.1136/medethics-2020-106446. Epub
      2020 Jun 12.


PMID- 32532785
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Neurocognitive impairment after neonatal sepsis: protocol for a systematic review
      and meta-analysis.
PG  - e038816
LID - 10.1136/bmjopen-2020-038816 [doi]
AB  - INTRODUCTION: The effect of neonatal sepsis on the developing brain is not well
      documented. We aim to perform evidence synthesis to determine the outcome of
      neurodevelopmental impairment and intellectual disability among survivors of
      neonatal sepsis. The data gathered will inform on the long-term neurocognitive
      outcomes of neonates with sepsis and the measures used to document their
      developmental disability. METHODS AND ANALYSIS: We will perform a search based on
      the following parameters: neonates and infants less than 90 days old diagnosed
      with sepsis who had neurocognitive outcomes or measures of developmental
      disability reported. We will search PubMed, Cochrane Central, Embase and Web of
      Science for articles in English language published between January 2010 and
      December 2019. Clinical trials and observational studies will be included. Two
      independent reviewers will screen studies for eligibility. Data extraction will
      then be performed using a standardised form. The quality of evidence and risk of 
      bias will be assessed using Cochrane Collaboration's tool and Risk of Bias in
      Non-randomised Studies of Intervention (ROBINS-I). The results will be
      synthesised qualitatively and pooled for meta-analysis. ETHICS AND DISSEMINATION:
      No formal ethical approval is required as there is no collection of primary data.
      This systematic review and meta-analysis will be disseminated through conference 
      meetings and peer-reviewed publications. PROSPERO REGISTRATION NUMBER:
      Registration submitted CRD42020164334.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pek, Jen Heng
AU  - Pek JH
AUID- ORCID: 0000-0002-8356-7410
AD  - Department of Emergency Medicine, Sengkang General Hospital, Singapore.
FAU - Yap, Bei Jun
AU  - Yap BJ
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Gan, Ming Ying
AU  - Gan MY
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Seethor, Shu Ting Tammie
AU  - Seethor STT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Greenberg, Rachel
AU  - Greenberg R
AD  - Department of Pediatrics, Duke University School of Medicine, Durham, North
      Carolina, USA.
FAU - Hornik, Christoph Paul Vincent
AU  - Hornik CPV
AD  - Division of Quantitative Sciences, Department of Pediatrics, Duke University
      School of Medicine, Durham, North Carolina, USA.
FAU - Tan, Bobby
AU  - Tan B
AD  - Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore.
FAU - Lee, Jan Hau
AU  - Lee JH
AD  - Children's Intensive Care Unit, KK Women's and Children's Hospital, Duke-NUS
      Medical School, Singapore.
FAU - Chong, Shu-Ling
AU  - Chong SL
AUID- ORCID: 0000-0003-4647-0019
AD  - Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore
      chong.shu-ling@kkh.com.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Neonatal Sepsis/*complications
MH  - Neurocognitive Disorders/*etiology
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7295426
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *epidemiology
OT  - *infectious diseases
OT  - *neonatology
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038816 [pii]
AID - 10.1136/bmjopen-2020-038816 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e038816. doi: 10.1136/bmjopen-2020-038816.


PMID- 32532782
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Implementation of colorectal cancer screening interventions in low-income and
      middle-income countries: a scoping review protocol.
PG  - e037520
LID - 10.1136/bmjopen-2020-037520 [doi]
AB  - INTRODUCTION: Colorectal cancer (CRC) imposes a significant global burden of
      disease. CRC survival rates are much lower in low-income and middle-income
      countries (LMICs). Screening tends to lead to an improvement in cancer detection 
      and the uptake of available treatments and, in turn, to better chances of cancer 
      survival. Most evidence on CRC screening interventions comes from high-income
      countries. The objective of this scoping review is to map the available
      literature on the implementation of CRC screening interventions in LMICs. METHODS
      AND ANALYSIS: We will conduct a scoping review according to the framework
      proposed by Arksey and O'Malley (2005). We will search MEDLINE, EMBASE, Web of
      Science and Google Scholar using a combination of terms such as "colorectal
      cancer", "screening" and "low-middle-income countries". Studies of CRC screening 
      interventions/programmes conducted in the general adult population in LMICs as
      well as policy reviews (of interventions in LMICs) and commentaries on challenges
      and opportunities of delivering CRC screening in LMICs, published in the English 
      language before February 2020 will be included in this review. The title and
      abstract screen will be conducted by one reviewer and two reviewers will screen
      full-texts and extract data from included papers, independently, into a data
      charting template that will include criteria from an adapted template for
      intervention description and replication checklist and implementation
      considerations. The presentation of the scoping review will be reported according
      to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
      extension for Scoping Reviews guidance. ETHICS AND DISSEMINATION: There are no
      ethical concerns. The results will be used to inform colorectal screening
      interventions in LMICs. We will publish the findings in a peer-reviewed journal
      and present them at relevant conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Schliemann, Desiree
AU  - Schliemann D
AUID- ORCID: 0000-0002-8746-3002
AD  - Centre for Public Health and UKCRC Centre of Excellence for Public Health,
      Queen's University Belfast, Belfast, UK D.Schliemann@qub.ac.uk.
FAU - Matovu, Nicholas
AU  - Matovu N
AD  - Centre for Public Health and UKCRC Centre of Excellence for Public Health,
      Queen's University Belfast, Belfast, UK.
FAU - Ramanathan, Kogila
AU  - Ramanathan K
AD  - South East Asia Community Observatory (SEACO), Jeffrey Cheah School of Medicine
      and Health Sciences, Monash University Malaysia, Subang Jaya, Malaysia.
FAU - Munoz-Aguirre, Paloma
AU  - Munoz-Aguirre P
AD  - Centre for Research and Population Health, Instituto Nacional de Salud Publica,
      Cuernavaca, Morelos, Mexico.
FAU - O'Neill, Ciaran
AU  - O'Neill C
AD  - Centre for Public Health and UKCRC Centre of Excellence for Public Health,
      Queen's University Belfast, Belfast, UK.
FAU - Kee, Frank
AU  - Kee F
AD  - Centre for Public Health and UKCRC Centre of Excellence for Public Health,
      Queen's University Belfast, Belfast, UK.
FAU - Su, Tin Tin
AU  - Su TT
AD  - South East Asia Community Observatory (SEACO), Jeffrey Cheah School of Medicine
      and Health Sciences, Monash University Malaysia, Subang Jaya, Malaysia.
FAU - Donnelly, Michael
AU  - Donnelly M
AD  - Centre for Public Health and UKCRC Centre of Excellence for Public Health,
      Queen's University Belfast, Belfast, UK.
LA  - eng
GR  - MR/K023241/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/P013910/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S014349/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Colorectal Neoplasms/*diagnosis
MH  - *Developing Countries
MH  - Early Detection of Cancer
MH  - Humans
MH  - *Mass Screening
MH  - Poverty
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7295404
OTO - NOTNLM
OT  - *International health services
OT  - *adult oncology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037520 [pii]
AID - 10.1136/bmjopen-2020-037520 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e037520. doi: 10.1136/bmjopen-2020-037520.


PMID- 32532781
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Protocol for a two-cohort randomized cluster clinical trial of a motor skills
      intervention: The Promoting Activity and Trajectories of Health (PATH) Study.
PG  - e037497
LID - 10.1136/bmjopen-2020-037497 [doi]
AB  - INTRODUCTION: Data supports that motor skills are an underlying mechanism that
      influence physical activity along with perceived motor and physical competence,
      but the relationship between motor skills and physical activity during the early 
      years is unclear. The goal of this study, Promoting Activity and Trajectories of 
      Health (PATH) for Children, is to examine and compare the immediate (pre-test to 
      post-test) and sustained (3-year follow-up) effect of an intervention on motor
      performance, physical activity and perceived physical competence to a control
      condition (ie, standard practice) in preschool-age children. METHODS AND
      ANALYSIS: The PATH study is a two-cohort, randomised cluster clinical trial. 300 
      children between the ages of >3.5 to 5 years of age will be randomised to the
      motor skill intervention (n=153) or control (n=147) condition. Each assessment
      involves a measure of motor skill performance; product and process, seven
      consecutive days of physical activity monitoring and perceived physical
      competence. These measures will be assessed before and after the intervention
      (pre-test to post-test) and then each academic year across 3 years, grades
      kindergarten, first grade and second grade (3-year follow-up). To assess the
      clustered longitudinal effect of the intervention on outcome measures,
      random-effects models (eg, mixed model regression, growth curve modelling and
      structural equation modelling) will be used. The PATH study addresses gaps in
      paediatric exercise science research. Findings hold the potential to help shape
      public health and educational policies and interventions that support healthy
      development and active living during the early years. ETHICS AND DISSEMINATION:
      Ethical approval for this study was obtained through the Health Sciences and
      Behavioral Sciences Institutional Review Board, University of Michigan
      (HUM00133319). The PATH study is funded by the National Institutes of Health.
      Findings will be disseminated via print, online media, dissemination events and
      practitioner and/or research journals. TRIAL REGISTRATION NUMBER: NHLBI
      ClinicalTrials.gov Identifier, NCT03189862. Registered 17 August 2017,
      https://clinicaltrials.gov/ct2/show/NCT03189862.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Robinson, Leah E
AU  - Robinson LE
AUID- ORCID: 0000-0002-9016-648X
AD  - School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA
      lerobin@umich.edu.
AD  - Center for Human Growth and Development, University of Michigan, Ann Arbor,
      Michigan, USA.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Colabianchi, Natalie
AU  - Colabianchi N
AD  - School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
AD  - Institute for Social Research, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Stodden, David F
AU  - Stodden DF
AD  - Department of Physical Education, University of South Carolina, Columbia, South
      Carolina, USA.
FAU - Ulrich, Dale
AU  - Ulrich D
AD  - School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03189862
GR  - R01 HL132979/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Child, Preschool
MH  - Cluster Analysis
MH  - *Exercise
MH  - Health Promotion/*methods
MH  - Humans
MH  - *Motor Skills
MH  - Pediatric Obesity/*rehabilitation
MH  - Randomized Controlled Trials as Topic
MH  - Research
PMC - PMC7295413
OTO - NOTNLM
OT  - *community child health
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037497 [pii]
AID - 10.1136/bmjopen-2020-037497 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e037497. doi: 10.1136/bmjopen-2020-037497.


PMID- 32532779
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Improving gender equity in critical care medicine: a protocol to establish
      priorities and strategies for implementation.
PG  - e037090
LID - 10.1136/bmjopen-2020-037090 [doi]
AB  - INTRODUCTION: While the number of women entering medical school now equals or
      surpasses the number of men, gender equity in medicine has not been achieved.
      Women continue to be under-represented in leadership roles (eg, deans, medical
      chairs) and senior faculty positions. In addition, women do not enter medical
      specialties as often as men, which can have important implications for work
      environment, reimbursement and the delivery of patient care. Compared with other 
      medical specialties (eg, anaesthesiology, dermatology, etc), critical care
      medicine is a medical specialty with some of the lowest representation of women. 
      While strategies to improve gender equity in critical care medicine exist in the 
      published literature, efforts to comprehensively synthesise, prioritise and
      implement solutions have been limited.The objective of this programme of work is 
      to establish priorities for the development and implementation of key strategies 
      to improve the outcomes, well-being and experiences of women in critical care in 
      Canada. METHODS AND ANALYSIS: Three phases encompass this programme of work. In
      phase I, we will catalogue published strategies focused on improving gender
      inequity across medical specialties through a scoping review. In phase II, we
      will conduct a modified Delphi consensus process with decision-makers, physicians
      and researchers to identify key strategies (identified in phase I and proposed by
      participants in phase II) for improving gender inequity in the specialty of
      critical care medicine. Finally, in phase III, we will conduct a 1-day
      stakeholder meeting that engages participants from phase II to build capacity for
      the development and implementation of top ranked strategies. Data analyses from
      this programme of work will be both quantitative and qualitative. ETHICS AND
      DISSEMINATION: The proposed programme of work is a foundational step towards
      establishing targeted strategies to improve gender inequity in the medical
      specialty of critical care medicine. Strategies will be prioritised by
      stakeholders, mapped to preidentified drivers of gender equity in the specialty
      and be scalable to institutional needs. A final report of our results including
      the list of top prioritised strategies and implementation objectives will be
      disseminated to panel participants, critical care leadership teams and major
      critical care societies who are partners in this work, around the country to
      facilitate uptake at the local level.The University of Calgary Conjoint Health
      Research Ethics Board has approved this study (REB16-0890).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Parsons Leigh, Jeanna
AU  - Parsons Leigh J
AUID- ORCID: 0000-0002-8408-674X
AD  - School of Health Administration, Dalhousie University, Halifax, Nova Scotia,
      Canada j.parsonsleigh@dal.ca.
AD  - Department of Critical Care Medicine, University of Calgary, Calgary, Alberta,
      Canada.
FAU - de Grood, Chloe
AU  - de Grood C
AD  - Department of Critical Care Medicine, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Ahmed, Sofia
AU  - Ahmed S
AD  - Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
FAU - Bosma, Karen
AU  - Bosma K
AD  - Division of Critical Care Medicine, London Health Sciences Centre, London,
      Ontario, Canada.
AD  - Department of Medicine, Western University Schulich School of Medicine and
      Dentistry, London, Ontario, Canada.
FAU - Burns, Karen E A
AU  - Burns KEA
AD  - Critical Care, St. Michael's Hospital, Toronto, Ontario, Canada.
AD  - Interdepartmental Division of Critical Care Medicine, Department of Medicine,
      University of Toronto, Toronto, Ontario, Canada.
FAU - Fowler, Robert
AU  - Fowler R
AD  - Interdepartmental Division of Critical Care Medicine, Department of Medicine,
      University of Toronto, Toronto, Ontario, Canada.
AD  - Sunnybrook Research Institute, Toronto, Ontario, Canada.
FAU - Fox-Robichaud, Alison
AU  - Fox-Robichaud A
AUID- ORCID: 0000-0001-9912-3606
AD  - Department of Medicine, Division of Critical Care Medicine, McMaster University, 
      Hamilton, Ontario, Canada.
FAU - Mehta, Sangeeta
AU  - Mehta S
AD  - Interdepartmental Division of Critical Care Medicine, Department of Medicine,
      University of Toronto, Toronto, Ontario, Canada.
FAU - Mele, Tina
AU  - Mele T
AUID- ORCID: 0000-0002-6617-9790
AD  - Division of Critical Care Medicine, London Health Sciences Centre, London,
      Ontario, Canada.
AD  - Department of Medicine, Western University, London, Ontario, Canada.
FAU - Straus, Sharon E
AU  - Straus SE
AD  - Interdepartmental Division of Critical Care Medicine, Department of Medicine,
      University of Toronto, Toronto, Ontario, Canada.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
FAU - Zepeda, Nubia
AU  - Zepeda N
AD  - Department of Critical Care Medicine, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Kemp, Laryssa
AU  - Kemp L
AD  - Department of Critical Care Medicine, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Fiest, Kirsten
AU  - Fiest K
AUID- ORCID: 0000-0002-7299-6594
AD  - Departments of Critical Care Medicine, Department of Psychiatry & Hotchkiss Brain
      Institute and Department of Community Health Sciences, University of Calgary
      Cumming School of Medicine, Calgary, Alberta, Canada.
AD  - O'Brien Institute for Public Health, Calgary, Alberta, Canada.
FAU - Stelfox, Henry Thomas
AU  - Stelfox HT
AD  - O'Brien Institute for Public Health, Calgary, Alberta, Canada.
AD  - Department of Critical Care Medicine, Department of Community Health Sciences,
      University of Calgary, Calgary, Alberta, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - *Critical Care
MH  - Female
MH  - *Gender Equity
MH  - Humans
MH  - Physicians, Women/*supply & distribution
MH  - Research Design
PMC - PMC7295422
OTO - NOTNLM
OT  - *general medicine (see internal medicine)
OT  - *health services administration & management
OT  - *intensive & critical care
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037090 [pii]
AID - 10.1136/bmjopen-2020-037090 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e037090. doi: 10.1136/bmjopen-2020-037090.


PMID- 32532778
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Epidemiology of major lower limb amputation using routinely collected electronic 
      health data in the UK: a systematic review protocol.
PG  - e037053
LID - 10.1136/bmjopen-2020-037053 [doi]
AB  - INTRODUCTION: It is estimated that peripheral arterial disease occurs in one in
      five people aged over 60 years in the UK. Major lower limb amputation is a
      debilitating and life-changing potential outcome of peripheral arterial disease. 
      A number of risk factors are involved in the development of the disease including
      smoking and diabetes. There is debate over the prevalence of major lower limb
      amputation in the UK with regional variations unexplained. The choice of data
      source can affect the epidemiological calculations and sources can also differ in
      the ability to explain variation. This study will aim to estimate the
      prevalence/incidence/number of major lower limb amputation in the UK. It will
      also identify sources of routinely collected electronic health data which report 
      the epidemiology of major lower limb amputation in the UK. METHODS AND ANALYSIS: 
      A systematic search of peer-reviewed journals will be conducted in Medline,
      Excerpta Medica database, Cumulative Index of Nursing and Allied Health
      Literature, Allied and Complementary Medicine Database, The Cochrane Library and 
      Scopus. A grey literature search for government and parliament publications,
      conference abstracts, theses and unpublished articles will be performed. Articles
      will be screened against the inclusion/exclusion criteria and data extracted
      using a pretested extraction form by two independent reviewers. Prevalence,
      incidence or number of cases (depending on data reported) will be extracted.
      Disagreements will be resolved by discussion. Data synthesis will be performed
      either as a narrative summary or by meta-analysis. Heterogeneity will be assessed
      using the I(2) statistic. If heterogeneity is low-moderate, pooled estimates will
      be calculated using random-effects models. If possible, meta-regression for time 
      trends in the incidence of major lower limb amputation will be performed along
      with subgroup analysis, primarily in regional variation. ETHICS AND
      DISSEMINATION: Ethics approval is not required for this study as study data are
      anonymised and available in the public domain. Dissemination will be by
      publication in a peer reviewed journal and by appropriate conference
      presentation.PROSPERO registration numberCRD42020165592.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Meffen, Anna
AU  - Meffen A
AUID- ORCID: 0000-0002-9491-6110
AD  - Department of Health Sciences, University of Leicester, Leicester, UK
      am1173@le.ac.uk.
FAU - Pepper, Coral J
AU  - Pepper CJ
AUID- ORCID: 0000-0003-1149-8150
AD  - Library and Information Services, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
FAU - Sayers, Robert D
AU  - Sayers RD
AD  - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
FAU - Gray, Laura J
AU  - Gray LJ
AD  - Department of Health Sciences, University of Leicester, Leicester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - *Amputation
MH  - *Electronic Health Records
MH  - Humans
MH  - Incidence
MH  - Lower Extremity/*surgery
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/*epidemiology/*surgery
MH  - Prevalence
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - United Kingdom/epidemiology
PMC - PMC7295407
OTO - NOTNLM
OT  - *diabetes
OT  - *lower-extremity amputation
OT  - *peripheral artery disease
OT  - *real world evidence
OT  - *routinely collected health data
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037053 [pii]
AID - 10.1136/bmjopen-2020-037053 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e037053. doi: 10.1136/bmjopen-2020-037053.


PMID- 32532774
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Study protocol for an exploratory interventional study investigating the
      feasibility of video-based non-contact physiological monitoring in healthy
      volunteers by Mapping Of Lower Limb skIn pErfusion (MOLLIE).
PG  - e036235
LID - 10.1136/bmjopen-2019-036235 [doi]
AB  - INTRODUCTION: Skin perfusion varies in response to changes in the circulatory
      status. Blood flow to skin is reduced during haemodynamic collapse secondary to
      peripheral vasoconstriction, whereas increased skin perfusion is frequently
      observed when haemodynamics improve with resuscitation. These changes in
      perfusion may be monitored using non-contact image-based methods. Previous
      camera-derived physiological measurements have focused on accurate vital signs
      monitoring and extraction of physiological signals from environmental noise. One 
      of the biggest challenges of camera-derived monitoring is artefacts from motion, 
      which limits our understanding of what parameters may be derived from skin. In
      this study, we use phenylephrine and glyceryl trinitrate (GTN) to cause
      vasoconstriction and vasodilation in stationary healthy volunteers to describe
      directional changes in skin perfusion pattern. METHODS AND ANALYSIS: We aim to
      recruit 30 healthy volunteers who will undergo protocolised infusions of
      phenylephrine and GTN, followed by the monitored and timed release of a thigh
      tourniquet. The experimental timeline will be identical for all participants.
      Measurements of traditionally used haemodynamic markers (heart rate, blood
      pressure and stroke volume) and camera-derived measurements will be taken
      concurrently throughout the experimental period. The parameters of interest from 
      the image data are skin colour and pattern, skin surface temperature, pulsatile
      signal detected at the skin surface and skin perfusion index. ETHICS AND
      DISSEMINATION: This study was reviewed and approved by the Oxford University
      Research and Ethics Committee and Clinical Trials and Research Governance teams
      (R63796/RE001). The results of this study will be presented at scientific
      conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      ISRCTN10417167.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Harford, Mirae
AU  - Harford M
AUID- ORCID: 0000-0003-2851-1577
AD  - Critical Care Research Group, Nuffield Department of Clinical Neurosciences,
      University of Oxford, Oxford, UK mirae.harford@ndcn.ox.ac.uk.
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Areia, Carlos
AU  - Areia C
AUID- ORCID: 0000-0002-4668-7069
AD  - Critical Care Research Group, Nuffield Department of Clinical Neurosciences,
      University of Oxford, Oxford, UK.
FAU - Villarroel, Mauricio
AU  - Villarroel M
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Jorge, Joao
AU  - Jorge J
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Finnegan, Eoin
AU  - Finnegan E
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Davidson, Shaun
AU  - Davidson S
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Mahdi, Adam
AU  - Mahdi A
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Young, Duncan
AU  - Young D
AD  - Critical Care Research Group, Nuffield Department of Clinical Neurosciences,
      University of Oxford, Oxford, UK.
FAU - Tarassenko, Lionel
AU  - Tarassenko L
AD  - Department of Engineering Science, Institute of Biomedical Engineering,
      University of Oxford, Oxford, UK.
FAU - Watkinson, Peter J
AU  - Watkinson PJ
AUID- ORCID: 0000-0003-1023-3927
AD  - Critical Care Research Group, Nuffield Department of Clinical Neurosciences,
      University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 1WS297W6MV (Phenylephrine)
RN  - G59M7S0WS3 (Nitroglycerin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Artifacts
MH  - Feasibility Studies
MH  - Female
MH  - *Healthy Volunteers
MH  - Hemodynamics
MH  - Humans
MH  - Lower Extremity/*blood supply
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/*methods
MH  - Nitroglycerin
MH  - Phenylephrine
MH  - Research Design
MH  - Skin/*blood supply
MH  - *Video Recording
PMC - PMC7295406
OTO - NOTNLM
OT  - *anatomy
OT  - *clinical pharmacology
OT  - *clinical physiology
COIS- Competing interests: PJW is Chief Medical Officer for Sensyne Health and holds
      share options in the company. His organisation has received research funding from
      Sensyne Health not associated with this work. LT is a non-executive Director of
      Sensyne Health and holds share options in the company. LT is a non-executive
      Director of Oxehealth and holds shares in the company.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036235 [pii]
AID - 10.1136/bmjopen-2019-036235 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e036235. doi: 10.1136/bmjopen-2019-036235.


PMID- 32532770
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Protocol for the development and validation of a measure of persistent
      psychological and emotional distress in cardiac patients: the Cardiac Distress
      Inventory.
PG  - e034946
LID - 10.1136/bmjopen-2019-034946 [doi]
AB  - INTRODUCTION: Distress is experienced by the majority of cardiac patients, yet no
      cardiac-specific measure of distress exists. The aim of this project is to
      develop and validate the Cardiac Distress Inventory (CDI). Using the CDI, health 
      professionals will be able to identify key clusters of psychological, emotional
      and social concern to address with patients, postcardiac event. METHODS AND
      ANALYSIS: An item pool will be generated through: identification of items by a
      multidisciplinary group of clinician researchers; review of generic and
      condition-specific distress measures; focus group testing with cardiac
      rehabilitation professionals; feedback from patients. The COSMIN (COnsensus-based
      Standards for the selection of health Measurement INstruments) criteria will be
      used to inform the development of the methodology for determining the CDI's
      psychometric properties. The item pool will be tested with 400 cardiac patients
      and responses subjected to exploratory factor analysis, Rasch analysis, construct
      validity testing and latent class analysis. Receiver operating characteristic
      analysis will be used to identify the optimal CDI cut-off score for
      distinguishing whether a person experiences clinically significant distress.
      ETHICS AND DISSEMINATION: Approved by the Monash Health Human Research Ethics
      Committee (approval number-RES-19-0000631L-559790). The CDI will be made
      available to clinicians and researchers without charge. The CDI will be
      translated for use internationally. Study findings will be shared with cardiac
      patient support groups; academic and medical communities via publications and
      presentations; in the training of cardiac secondary prevention professionals; and
      in reports to funders. Authorship for publications will follow the uniform
      requirements for manuscripts submitted to biomedical journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jackson, Alun
AU  - Jackson A
AUID- ORCID: 0000-0001-9565-1399
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia
      alun.jackson@australianhearthealth.org.au.
AD  - Deakin University Faculty of Health, Burwood, Victoria, Australia.
FAU - Rogerson, Michelle
AU  - Rogerson M
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
FAU - Le Grande, Michael
AU  - Le Grande M
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
AD  - Centre for Behaviour Change, Melbourne School of Psychological Sciences,
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Thompson, David
AU  - Thompson D
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
AD  - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
FAU - Ski, Chantal
AU  - Ski C
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
AD  - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
FAU - Alvarenga, Marlies
AU  - Alvarenga M
AD  - School of Health and Life Sciences, Federation University Australia - Berwick
      Campus, Berwick, Victoria, Australia.
AD  - Monash Cardiovascular Research Centre, MonashHeart, Melbourne, Victoria,
      Australia.
FAU - Amerena, John
AU  - Amerena J
AD  - Cardiac Services, Barwon Health, Geelong, Victoria, Australia.
AD  - Deakin School of Medicine, Geelong, Victoria, Australia.
FAU - Higgins, Rosemary
AU  - Higgins R
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
AD  - Deakin University Faculty of Health, Burwood, Victoria, Australia.
FAU - Raciti, Michela
AU  - Raciti M
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
FAU - Murphy, Barbara M
AU  - Murphy BM
AD  - Australian Centre for Heart Health, North Melbourne, Victoria, Australia.
AD  - Deakin University Faculty of Health, Burwood, Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cardiovascular Diseases/*psychology
MH  - Consensus
MH  - Emotions
MH  - Humans
MH  - *Psychological Distress
MH  - Psychometrics/*instrumentation
MH  - Research Design
MH  - Validation Studies as Topic
PMC - PMC7295398
OTO - NOTNLM
OT  - *adult cardiology
OT  - *cardiology
OT  - *mental health
OT  - *protocols & guidelines
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034946 [pii]
AID - 10.1136/bmjopen-2019-034946 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e034946. doi: 10.1136/bmjopen-2019-034946.


PMID- 32532768
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 11
TI  - Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based
      health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
PG  - e034683
LID - 10.1136/bmjopen-2019-034683 [doi]
AB  - INTRODUCTION: Norway is one of several European countries that lacks a national
      value set and scoring algorithm for the EuroQol five dimensions (EQ-5D). Recent
      studies have found differences between countries in terms of health values or
      preferences for health states described by instruments such as the EQ-5D. The
      project aims to model a national value set for the five level version of the
      EQ-5D based on values elicited from a representative sample of the Norwegian
      adult general population in terms of region, age, sex and level of education.
      Using a sampling strategy supporting the collection of values for both
      hypothetical and experienced health states, the study will have the additional
      aim of assessing the feasibility of collecting experience-based values in
      accordance with the latest EQ-5D valuation study protocol, and comparing values
      with those given for hypothetical health states. METHODS AND ANALYSIS: Multistage
      random sampling and quota-sampling will contribute to representativeness. To
      increase the number of valuations of experienced health states, those with less
      than perfect health will be oversampled, increasing the total number of
      interviews from 1000 to 1300-1500. The most recent EQ-5D valuation protocol will 
      be followed which includes computer assisted face-to-face, one-to-one interviews 
      and use of composite time trade-off and discrete choice experiments. ETHICS AND
      DISSEMINATION: The study has been reviewed and found to be outside of the scope
      of the ethics committee and thus not in need of ethical approval. The study
      findings will be disseminated through peer-reviewed publications, conference
      presentations and summaries for key stakeholders and partners in the field. The
      scoring algorithms will be available for widely used statistical software.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hansen, Tonya Moen
AU  - Hansen TM
AUID- ORCID: 0000-0003-3150-4765
AD  - Health Services Research, Norwegian Institute of Public Health, Oslo, Norway
      TonyaMoen.Hansen@fhi.no.
FAU - Helland, Ylva
AU  - Helland Y
AD  - Health Services Research, Norwegian Institute of Public Health, Oslo, Norway.
FAU - Augestad, Liv Ariane
AU  - Augestad LA
AD  - Health Management and Health Economics, University of Oslo Faculty of Medicine,
      Oslo, Norway.
FAU - Rand, Kim
AU  - Rand K
AD  - Health Services Research Unit, Akershus University Hospital, Lorenskog, Norway.
FAU - Stavem, Knut
AU  - Stavem K
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
AD  - Pulmonary Medicine, Akershus University Hospital, Lorenskog, Norway.
FAU - Garratt, Andrew
AU  - Garratt A
AD  - Health Services Research, Norwegian Institute of Public Health, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Catchment Area, Health
MH  - Female
MH  - *Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norway
MH  - *Quality of Life
MH  - *Surveys and Questionnaires
PMC - PMC7295408
OTO - NOTNLM
OT  - *health economics
OT  - *health policy
COIS- Competing interests: None declared.
EDAT- 2020/06/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034683 [pii]
AID - 10.1136/bmjopen-2019-034683 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 11;10(6):e034683. doi: 10.1136/bmjopen-2019-034683.


PMID- 32532544
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 38
IP  - 36
DP  - 2020 Aug 10
TI  - A framework for the systematic consideration of ethics, equity, feasibility, and 
      acceptability in vaccine program recommendations.
PG  - 5861-5876
LID - S0264-410X(20)30696-4 [pii]
LID - 10.1016/j.vaccine.2020.05.051 [doi]
AB  - For the successful implementation of population-level recommendations, it is
      critical to consider the full spectrum of public health science, including
      clinical and programmatic factors. Current frameworks may identify various
      factors that should be examined when making evidence-informed vaccine-related
      recommendations. However, while most immunization guidelines systematically
      assess clinical factors, such as efficacy and safety of vaccines, there is no
      published framework outlining how to systematically assess programmatic factors, 
      such as the ethics, equity, feasibility, and acceptability of recommendations. We
      have addressed this gap with the development of the EEFA (Ethics, Equity
      Feasibility, Acceptability) Framework, supported by evidence-informed tools,
      including Ethics Integrated Filters, Equity Matrix, Feasibility Matrix, and an
      Acceptability Matrix. The Framework and tools are based on five years of
      environmental scans, systematic reviews and surveys, and refined by expert and
      stakeholder consultations and feedback. For each programmatic factor, the EEFA
      Framework summarizes the minimum threshold for consideration and when further
      in-depth analysis may be required, which aspects of the factor should be
      considered, how to assess the factor using the supporting evidence-informed
      tools, and who should be consulted to complete the assessment. Research,
      particularly in the fields of vaccine acceptability and equity, has validated the
      utility and comprehensiveness of the tools. The Framework has been successfully
      used in Canada for clear, timely, transparent vaccine guidance with positive
      stakeholder feedback on its comprehensiveness, relevance and appropriateness.
      Applying the EEFA Framework allows for the systematic consideration of the
      spectrum of public health science without a delay in recommendations,
      complementing existing decision-making frameworks. This Framework will therefore 
      be useful for advisory groups worldwide to integrate critical factors that could 
      impact the successful and timely implementation of comprehensive, transparent
      recommendations, and will further the global objective of developing practical
      and evidence-informed immunization policies.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Ismail, Shainoor J
AU  - Ismail SJ
AD  - Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency
      of Canada, Ottawa, Canada; Metro City Medical Clinic, Edmonton, Canada.
      Electronic address: Shainoor.Ismail@canada.ca.
FAU - Hardy, Kendra
AU  - Hardy K
AD  - Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency
      of Canada, Ottawa, Canada.
FAU - Tunis, Matthew C
AU  - Tunis MC
AD  - Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency
      of Canada, Ottawa, Canada.
FAU - Young, Kelsey
AU  - Young K
AD  - Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency
      of Canada, Ottawa, Canada.
FAU - Sicard, Nadine
AU  - Sicard N
AD  - National Advisory Committee on Immunization, Centre for Immunization and
      Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada.
FAU - Quach, Caroline
AU  - Quach C
AD  - National Advisory Committee on Immunization, Centre for Immunization and
      Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada; 
      Department of Microbiology, Infectious Diseases & Immunology, Faculty of
      Medicine, University of Montreal, Montreal, Canada; Infection Prevention and
      Control, Department of Clinical Laboratory Medicine, CHU Sainte-Justine,
      Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Vaccines)
SB  - IM
MH  - Canada
MH  - Feasibility Studies
MH  - *Immunization Programs
MH  - Public Health
MH  - *Vaccines/adverse effects
PMC - PMC7283073
OTO - NOTNLM
OT  - *Acceptability
OT  - *Equity
OT  - *Ethics
OT  - *Feasibility
OT  - *Framework
OT  - *Vaccine Program
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/06/14 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - S0264-410X(20)30696-4 [pii]
AID - 10.1016/j.vaccine.2020.05.051 [doi]
PST - ppublish
SO  - Vaccine. 2020 Aug 10;38(36):5861-5876. doi: 10.1016/j.vaccine.2020.05.051. Epub
      2020 Jun 10.


PMID- 32532436
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20200630
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 259
DP  - 2020 Mar
TI  - [Pain and support for palliative care teams].
PG  - 23-25
LID - S1293-8505(20)30054-3 [pii]
LID - 10.1016/j.revinf.2020.02.009 [doi]
AB  - Because of all the multiple forms of pain, its management is of variable
      geometry. The evaluation, its repercussion, the treatment, the assessment of the 
      benefit and the side effects are each time a singular model.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Picard, Stephane
AU  - Picard S
AD  - Groupe hospitalier Diaconesses Croix Saint-Simon, 12-18, rue du Sergent-Bauchat, 
      75012 Paris, France. Electronic address: spicard@hopital-dcss.org.
LA  - fre
PT  - Journal Article
TT  - Douleur et accompagnement des equipes de soins palliatifs.
DEP - 20200302
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - Humans
MH  - *Pain
MH  - *Pain Management
MH  - *Palliative Care
OTO - NOTNLM
OT  - accompagnement
OT  - care
OT  - douleur
OT  - ethics
OT  - pain
OT  - prise en charge
OT  - support
OT  - traitement
OT  - treatment
OT  - ethique
EDAT- 2020/06/14 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - S1293-8505(20)30054-3 [pii]
AID - 10.1016/j.revinf.2020.02.009 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Mar;69(259):23-25. doi: 10.1016/j.revinf.2020.02.009. Epub 2020 
      Mar 2.


PMID- 32532366
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20210110
IS  - 1873-2585 (Electronic)
IS  - 1047-2797 (Linking)
VI  - 46
DP  - 2020 Jun
TI  - Ensuring ethical data access: the Sierra Leone Ebola Database (SLED) model.
PG  - 1-4
LID - S1047-2797(20)30146-0 [pii]
LID - 10.1016/j.annepidem.2020.04.001 [doi]
AB  - PURPOSE: Organizations responding to the 2014-2016 Ebola epidemic in Sierra Leone
      collected information from multiple sources and kept it in separate databases,
      including distinct data systems for Ebola hot line calls, patient information
      collected by field surveillance officers, laboratory testing results, clinical
      information from Ebola treatment and isolation facilities, and burial team
      records. METHODS: After the conclusion of the epidemic, the Sierra Leone Ministry
      of Health and Sanitation and the U.S. Centers for Disease Control and Prevention 
      partnered to collect these disparate records and consolidate them in the Sierra
      Leone Ebola Database. RESULTS: The Sierra Leone Ebola Database data are providing
      a lasting resource for postepidemic data analysis and epidemiologic research,
      including identifying best strategies in outbreak response, and are used to help 
      families locate the graves of family members who died during the epidemic.
      CONCLUSION: This report describes the Ministry of Health and Sanitation and
      Centers for Disease Control and Prevention processes to safeguard Ebola records
      while making the data available for public health research.
CI  - Published by Elsevier Inc.
FAU - Gorina, Yelena
AU  - Gorina Y
AD  - National Center for Health Statistics, Division of Analysis and Epidemiology,
      Hyattsville, MD. Electronic address: yag9@cdc.gov.
FAU - Redd, John T
AU  - Redd JT
AD  - The Department of Health and Human Services, Office of the Assistant Secretary
      for Preparedness and Response, Washington, DC.
FAU - Hersey, Sara
AU  - Hersey S
AD  - World Bank, Washington, DC.
FAU - Jambai, Amara
AU  - Jambai A
AD  - Sierra Leone Ministry of Health and Sanitation, Freetown, Sierra Leone.
FAU - Meyer, Peter
AU  - Meyer P
AD  - NORC at The University of Chicago, Bethesda, MD.
FAU - Kamara, Ansumana S
AU  - Kamara AS
AD  - African Field Epidemiology Network (AFENET), Freetown, Sierra Leone.
FAU - Kamara, Alimamy
AU  - Kamara A
AD  - Centers for Disease Control and Prevention, Center for Global Health, Division of
      Global Health Protection, Freetown, Sierra Leone.
FAU - Harding, Jadnah D
AU  - Harding JD
AD  - Columbia Mailman School of Public Health, ICAP, Sierra Leone Ebola Database
      (SLED) Data Team, Freetown, Sierra Leone.
FAU - Bangura, Brima
AU  - Bangura B
AD  - Columbia Mailman School of Public Health, ICAP, Sierra Leone Ebola Database
      (SLED) Data Team, Freetown, Sierra Leone.
FAU - Kamara, Mohamed A M
AU  - Kamara MAM
AD  - Columbia Mailman School of Public Health, ICAP, Sierra Leone Ebola Database
      (SLED) Data Team, Freetown, Sierra Leone.
LA  - eng
GR  - CC999999/ImCDC/Intramural CDC HHS/United States
PT  - Journal Article
DEP - 20200410
PL  - United States
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
SB  - IM
MH  - Data Management/*ethics
MH  - Disease Outbreaks/*prevention & control
MH  - Epidemics
MH  - Hemorrhagic Fever, Ebola/*epidemiology
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - Information Storage and Retrieval/*ethics
MH  - Privacy
MH  - Public Health
MH  - Sierra Leone/epidemiology
PMC - PMC7443172
MID - NIHMS1616918
OTO - NOTNLM
OT  - *Data access
OT  - *Data ownership
OT  - *Data sharing
OT  - *Ebola virus disease
OT  - *Ethics
OT  - *Privacy
OT  - *SLED
OT  - *Sierra Leone Ebola database
EDAT- 2020/06/14 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/06/14 06:00
PHST- 2019/08/20 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - S1047-2797(20)30146-0 [pii]
AID - 10.1016/j.annepidem.2020.04.001 [doi]
PST - ppublish
SO  - Ann Epidemiol. 2020 Jun;46:1-4. doi: 10.1016/j.annepidem.2020.04.001. Epub 2020
      Apr 10.


PMID- 32532354
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20200831
IS  - 2050-7283 (Electronic)
IS  - 2050-7283 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Jun 12
TI  - Autism Spectrum Social Stories In Schools Trial 2 (ASSSIST2): study protocol for 
      a randomised controlled trial analysing clinical and cost-effectiveness of Social
      Stories in primary schools.
PG  - 60
LID - 10.1186/s40359-020-00427-z [doi]
AB  - BACKGROUND: Interventions designed to support children with a diagnosis of Autism
      Spectrum Conditions (ASC) can be time consuming, needing involvement of outside
      experts. Social Stories are a highly personalised intervention aiming to give
      children with ASC social information or describing an otherwise difficult
      situation or skill. This can be delivered daily by staff in education settings.
      Studies examining Social Story use have yielded mostly positive results but have 
      largely been single case studies with a lack of randomised controlled trials
      (RCTs). Despite this numerous schools are utilising Social Stories, and a fully
      powered RCT is timely. METHODS: A multi-site pragmatic cluster RCT comparing care
      as usual with Social Stories and care as usual. This study will recruit 278
      participants (aged 4-11) with a clinical diagnosis of ASC, currently attending
      primary school in the North of England. Approximately 278 school based staff will
      be recruited to provide school based information about participating children
      with approximately 140 recruited to deliver the intervention. The study will be
      cluster randomised by school. Potential participants will be screened for
      eligibility prior to giving informed consent. Follow up data will be collected at
      6 weeks and 6 months post randomisation and will assess changes in participants' 
      social responsiveness, goal based outcomes, social and emotional health. The
      primary outcome measure is the Social Responsiveness Scale Second Edition (SRS-2)
      completed by school based staff at 6 months. Approvals have been obtained from
      the University of York's Research Governance Committee, Research Ethics Committee
      and the Health Research Authority. Study results will be submitted for
      publication in peer-reviewed journals and disseminated to participating families,
      educational staff, local authority representatives, community groups and Patient 
      and Participant Involvement representatives. Suggestions will be made to NICE
      about treatment evidence dependent on findings. DISCUSSION: This study addresses 
      a much used but currently under researched intervention and results will inform
      school based support for primary school children with a diagnosis of ASC. TRIAL
      REGISTRATION: The trial is registered on the ISRCTN registry (registration
      number: ISRCTN11634810). The trial was retrospectively registered on 23rd April
      2019.
FAU - Wright, B
AU  - Wright B
AD  - Child Oriented Mental Health Intervention Centre, Leeds and York Partnership NHS 
      Foundation Trust, York, UK. barry.wright1@nhs.net.
AD  - Hull York Medical School, University of York, York, UK. barry.wright1@nhs.net.
AD  - COMIC, IT Centre, Innovation Way, Heslington, York, YO10 5NP, UK.
      barry.wright1@nhs.net.
FAU - Teige, C
AU  - Teige C
AD  - Child Oriented Mental Health Intervention Centre, Leeds and York Partnership NHS 
      Foundation Trust, York, UK.
FAU - Watson, J
AU  - Watson J
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Hodkinson, R
AU  - Hodkinson R
AD  - Child Oriented Mental Health Intervention Centre, Leeds and York Partnership NHS 
      Foundation Trust, York, UK.
FAU - Marshall, D
AU  - Marshall D
AD  - Centre for Reviews and Dissemination, University of York, York, UK.
FAU - Varley, D
AU  - Varley D
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Allgar, V
AU  - Allgar V
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Mandefield, L
AU  - Mandefield L
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Parrott, S
AU  - Parrott S
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Kingsley, E
AU  - Kingsley E
AD  - Child Oriented Mental Health Intervention Centre, Leeds and York Partnership NHS 
      Foundation Trust, York, UK.
FAU - Hargate, R
AU  - Hargate R
AD  - Child Oriented Mental Health Intervention Centre, Leeds and York Partnership NHS 
      Foundation Trust, York, UK.
FAU - Mitchell, N
AU  - Mitchell N
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
FAU - Ali, S
AU  - Ali S
AD  - Department of Health Sciences, University of York, York, UK.
AD  - Department of Epidemiology and Biostatistics, Schulich School of Medicine,
      Western University, London, Ontario, Canada.
FAU - McMillan, D
AU  - McMillan D
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Wang, H
AU  - Wang H
AD  - Department of Health Sciences, University of York, York, UK.
FAU - Hewitt, C
AU  - Hewitt C
AD  - York Trials Unit, Department of Health Sciences, University of York, York, UK.
LA  - eng
GR  - 16/111/91/NIHR HTA (National Institute of Health Research Health Technology
      Assessment)
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - BMC Psychol
JT  - BMC psychology
JID - 101627676
SB  - IM
MH  - Autism Spectrum Disorder/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Cost-Benefit Analysis
MH  - Emotions
MH  - England
MH  - Female
MH  - Humans
MH  - Male
MH  - *Narrative Medicine/economics
MH  - Psychotherapy/economics/*methods
MH  - Schools
PMC - PMC7291714
OTO - NOTNLM
OT  - Autism Spectrum conditions
OT  - Child mental health
OT  - Education
OT  - School based interventions
OT  - Social stories
EDAT- 2020/06/14 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 10.1186/s40359-020-00427-z [doi]
AID - 10.1186/s40359-020-00427-z [pii]
PST - epublish
SO  - BMC Psychol. 2020 Jun 12;8(1):60. doi: 10.1186/s40359-020-00427-z.


PMID- 32532349
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1750-1172 (Electronic)
IS  - 1750-1172 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Jun 12
TI  - Effects of nusinersen after one year of treatment in 123 children with SMA type 1
      or 2: a French real-life observational study.
PG  - 148
LID - 10.1186/s13023-020-01414-8 [doi]
AB  - BACKGROUND: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular
      disorder characterized by degeneration of the anterior horn cells of the spinal
      cord. Nusinersen has been covered by public healthcare in France since May 2017. 
      The aim of this article is to report results after 1 year of treatment with
      intrathecal nusinersen in children with SMA types 1 and 2 in France. Comparisons 
      between treatment onset (T0) and after 1 year of treatment (Y1) were made in
      terms of motor function and need for nutritional and ventilatory support. Motor
      development milestone achievements were evaluated using the modified Hammersmith 
      Infant Neurologic Examination-Part 2 (HINE-2) for patients under 2 years of age
      and Motor Function Measure (MFM) scores for patients over 2 years of age.
      RESULTS: Data on 204 SMA patients (type 1 or 2) were retrospectively collected
      from the 23 French centers for neuromuscular diseases. One hundred and twenty
      three patients had been treated for at least 1 year and were included, 34 of whom
      were classified as type 1 (10 as type 1a/b and 24 as type 1c) and 89 as type 2.
      Survival motor Neuron 2 (SMN2) copy numbers were available for all but 6
      patients. Patients under 2 years of age (n = 30), had significantly higher HINE-2
      scores at year 1 than at treatment onset but used more nutritional and
      ventilatory support. The 68 patients over 2 years of age evaluated with the Motor
      Function Measure test had significantly higher overall scores after 1 year,
      indicating that their motor function had improved. The scores were higher in the 
      axial and proximal motor function (D2) and distal motor function (D3) parts of
      the MFM scale, but there was no significant difference for standing and transfer 
      scores (D1). No child in either of the two groups achieved walking. CONCLUSION:
      Nusinersen offers life-changing benefits for children with SMA, particularly
      those with more severe forms of the disorder. Caregiver assessments are positive.
      Nevertheless, patients remain severely disabled and still require intensive
      support care. This new treatment raises new ethical challenges.
FAU - Audic, Frederique
AU  - Audic F
AUID- ORCID: 0000-0001-6055-9007
AD  - Centre de Reference des Maladies Neuromusculaires de l'enfant PACARARE, Service
      de Neuropediatrie, Hopital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille
      Cedex 5, France. frederique.audic@ap-hm.fr.
FAU - de la Banda, Marta Gomez Garcia
AU  - de la Banda MGG
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Hopital
      Raymond Poincare, APHP, Garches, France.
FAU - Bernoux, Delphine
AU  - Bernoux D
AD  - Centre de Reference des Maladies Neuromusculaires de l'enfant PACARARE, Service
      de Neuropediatrie, Hopital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille
      Cedex 5, France.
FAU - Ramirez-Garcia, Paola
AU  - Ramirez-Garcia P
AD  - Centre de Reference des Maladies Neuromusculaires de l'enfant PACARARE, Service
      de Neuropediatrie, Hopital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille
      Cedex 5, France.
FAU - Durigneux, Julien
AU  - Durigneux J
AD  - Centre de Reference des Maladies Neuromusculaires AOC, CHU d'Angers, Angers,
      France.
FAU - Barnerias, Christine
AU  - Barnerias C
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Service
      de Neurologie pediatrique, Hopital Necker-Enfants Malades, APHP, Paris, France.
FAU - Isapof, Arnaud
AU  - Isapof A
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Service
      de Neuropediatrie, Hopital Trousseau, APHP, Paris, France.
FAU - Cuisset, Jean-Marie
AU  - Cuisset JM
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Service
      de Neuropediatrie, Hopital Salengro CHU Lille, Lille, France.
FAU - Cances, Claude
AU  - Cances C
AD  - Centre de Reference des Maladies Neuromusculaires AOC, Unite de Neurologie
      Pediatrique, Hopital des Enfants CHU Toulouse, Toulouse, France.
FAU - Richelme, Christian
AU  - Richelme C
AD  - Centre de Reference des Maladies Neuromusculaires PACARARE, Hopitaux Pediatriques
      de Nice CHU - Lenval, Nice, France.
FAU - Vuillerot, Carole
AU  - Vuillerot C
AD  - Centre de Reference des Maladies Neuromusculaires de l'enfant PACARARE, Service
      de MPR pediatrique L'Escale Hopital Femme Mere Enfant, Hospices Civils de Lyon,
      Bron, France.
FAU - Laugel, Vincent
AU  - Laugel V
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est,
      Pediatrie medico-chirurgicale, CHU de Strasbourg - Hopital de Hautepierre,
      Strasbourg, France.
FAU - Ropars, Juliette
AU  - Ropars J
AD  - Centre de Reference des Maladies Neuromusculaires AOC, Service de Pediatrie, CHRU
      de Brest, Brest, France.
FAU - Altuzarra, Cecilia
AU  - Altuzarra C
AD  - Centre de competences des Maladies Neuromusculaires Nord/Ile de France/Est, Unite
      de Neuropediatrie et medecine pediatrique, Hopital Minjoz, CHU de Besancon,
      Besancon, France.
FAU - Espil-Taris, Caroline
AU  - Espil-Taris C
AD  - Centre de Reference des Maladies Neuromusculaires AOC, Unite de Neurologie
      pediatrique, CHU Pellegrin, Bordeaux, France.
FAU - Walther-Louvier, Ulrike
AU  - Walther-Louvier U
AD  - Centre de Reference des Maladies Neuromusculaires AOC, Service de Neuropediatrie 
      CHU Montpellier, Montpellier, France.
FAU - Sabouraud, Pascal
AU  - Sabouraud P
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Site
      Reims enfant AMH, CHU Reims, Reims, France.
FAU - Chouchane, Mondher
AU  - Chouchane M
AD  - Centre de Competence des Maladies Neuromusculaires Nord/Ile de France/Est,
      Service de pediatrie 1, Hopital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
FAU - Vanhulle, Catherine
AU  - Vanhulle C
AD  - Centre de Competence des Maladies Neuromusculaires Nord/Ile de France/Est, CHU de
      Rouen Charles Nicolle, Rouen, France.
FAU - Trommsdorff, Valerie
AU  - Trommsdorff V
AD  - Centre de Reference des Maladies Neuromusculaires PACARARE, Service de Pediatrie,
      CHU La Reunion, Saint-Pierre, France.
FAU - Perville, Anne
AU  - Perville A
AD  - Centre de Competence des Maladies Neuromusculaires PACARARE, Service de
      Pediatrie, CHU La Reunion, Saint-Denis, France.
FAU - Testard, Herve
AU  - Testard H
AD  - Centre de Competence des Maladies Neuromusculaires PACARARE, Neuropediatrie,
      Clinique Universitaire Pediatrique, Hopital Couple Enfant - CHU Grenoble,
      Grenoble, France.
FAU - Lagrue, Emmanuelle
AU  - Lagrue E
AD  - Centre de Competence des Maladies Neuromusculaires AOC, Hopital Clocheville,
      Service << Neuropediatrie et Handicaps >>, Tours, France.
FAU - Sarret, Catherine
AU  - Sarret C
AD  - Centre de Reference des Maladies Neuromusculaires PACARARE, Centre
      hospitalo-universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
FAU - Avice, Anne-Laude
AU  - Avice AL
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Nancy, 
      Hopital de Brabois, Vandoeuvre-Les, Nancy, France.
FAU - Beze-Beyrie, Pierre
AU  - Beze-Beyrie P
AD  - Service de Pediatrie, Centre Hospitalier de Pau, Pau, France.
FAU - Pauly, Vanessa
AU  - Pauly V
AD  - Centre d'etudes et de recherche sur les services de sante et la qualite de vie
      (CEReSS) EA 3279, Faculte de Medecine, Aix-Marseille Universite, Marseille,
      France.
FAU - Quijano-Roy, Susana
AU  - Quijano-Roy S
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Hopital
      Raymond Poincare, APHP, Garches, France.
FAU - Chabrol, Brigitte
AU  - Chabrol B
AD  - Centre de Reference des Maladies Neuromusculaires de l'enfant PACARARE, Service
      de Neuropediatrie, Hopital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille
      Cedex 5, France.
FAU - Desguerre, Isabelle
AU  - Desguerre I
AD  - Centre de Reference des Maladies Neuromusculaires Nord/Ile de France/Est, Service
      de Neurologie pediatrique, Hopital Necker-Enfants Malades, APHP, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200612
PL  - England
TA  - Orphanet J Rare Dis
JT  - Orphanet journal of rare diseases
JID - 101266602
RN  - 0 (Oligonucleotides)
RN  - 5Z9SP3X666 (nusinersen)
SB  - IM
MH  - Child
MH  - France
MH  - Humans
MH  - Infant
MH  - *Muscular Atrophy, Spinal
MH  - Oligonucleotides
MH  - Retrospective Studies
MH  - *Spinal Muscular Atrophies of Childhood/drug therapy
PMC - PMC7291731
OTO - NOTNLM
OT  - *MFM
OT  - *Motor function measure
OT  - *Nusinersen
OT  - *Spinal muscular atrophy type I
OT  - *Spinal muscular atrophy type II
EDAT- 2020/06/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/14 06:00
PHST- 2019/10/04 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13023-020-01414-8 [doi]
AID - 10.1186/s13023-020-01414-8 [pii]
PST - epublish
SO  - Orphanet J Rare Dis. 2020 Jun 12;15(1):148. doi: 10.1186/s13023-020-01414-8.


PMID- 32532264
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 12
TI  - Embedding international medical student electives within a 30-year partnership:
      the Ghana-Michigan collaboration.
PG  - 189
LID - 10.1186/s12909-020-02093-6 [doi]
AB  - BACKGROUND: Global health experiences are an increasingly popular component of
      medical student curricula. There is little research on the impact of
      international medical electives embedded within long-standing, sustainable
      partnerships. Our research explores the University of Michigan medical student
      elective experience in Ghana within the context of the Ghana-Michigan
      collaborative. METHODS: Study participants are University of Michigan medical
      students who completed an international elective in Ghana between March 2006 and 
      June 2017. Post-elective reports were completed by students, including a
      description of the experience, highlights, disappointments, and the impact of the
      experience on interest in future international work and future practice of
      medicine. A retrospective thematic analysis of reports was carried out using
      NVivo 12 (QSR International, Melbourne, Australia). RESULTS: A total of 57
      reports were analyzed. Benefits of the elective experience included building
      cross-cultural relationships, exposure to different healthcare environments,
      hands-on clinical and surgical experience, and exposure to different patient
      populations. Ninety-five percent of students planned to engage in additional
      international work in the future. Students felt that the long-standing
      bidirectional exchange allowed them to build cross-cultural relationships and be 
      incorporated as a trusted part of the local clinical team. The partnership
      modeled collaboration, and many students found inspiration for the direction of
      their own careers. CONCLUSIONS: Embedding clinical rotations within a
      well-established, sustained partnerships provides valuable experiences for
      trainees by modeling reciprocity, program management by local physicians, and
      cultural humility-all of which can help prepare learners to ethically engage in
      balanced, long-term partnerships in the future.
FAU - Lawrence, Emma R
AU  - Lawrence ER
AD  - Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical 
      Center Dr, Ann Arbor, MI, 48109, USA. emmarl@med.umich.edu.
FAU - Moyer, Cheryl
AU  - Moyer C
AD  - Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical 
      Center Dr, Ann Arbor, MI, 48109, USA.
AD  - Learning Health Sciences, University of Michigan, 1111 E. Catherine St, Ann
      Arbor, MI, 48109, USA.
FAU - Ashton, Carrie
AU  - Ashton C
AD  - Global REACH, University of Michigan, 1111 E. Catherine St, Ann Arbor, MI, 48109,
      USA.
FAU - Ibine, Bolade A R
AU  - Ibine BAR
AD  - Department of Obstetrics and Gynecology, Family Health University College, PO,
      Box TS 669 Teshie, Accra, Ghana.
FAU - Abedini, Nauzley C
AU  - Abedini NC
AD  - Division of Palliative Medicine, University of California, San Francisco, 533
      Parnassus Ave, San Francisco, CA, 94143, USA.
FAU - Spraggins, Yaera
AU  - Spraggins Y
AD  - College of Literature, Science and Arts, University of Michigan, 500 S. State St,
      Ann Arbor, MI, 48109, USA.
FAU - Kolars, Joseph C
AU  - Kolars JC
AD  - Department of Internal Medicine, University of Michigan, 1500 E. Medical Center
      Dr, Ann Arbor, MI, 48109, USA.
FAU - Johnson, Timothy R B
AU  - Johnson TRB
AD  - Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical 
      Center Dr, Ann Arbor, MI, 48109, USA.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Cultural Competency/*education
MH  - Education, Medical, Undergraduate/*methods
MH  - Ghana
MH  - Global Health/*education
MH  - Humans
MH  - *International Educational Exchange
MH  - Michigan
MH  - Surveys and Questionnaires
PMC - PMC7291437
OTO - NOTNLM
OT  - Bidirectional exchange
OT  - Global education partnership
OT  - International medical student electives
EDAT- 2020/06/14 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - 10.1186/s12909-020-02093-6 [doi]
AID - 10.1186/s12909-020-02093-6 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Jun 12;20(1):189. doi: 10.1186/s12909-020-02093-6.


PMID- 32532174
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Research Integrity Among PhD Students at the Faculty of Medicine: A Comparison of
      Three Scandinavian Universities.
PG  - 320-329
LID - 10.1177/1556264620929230 [doi]
AB  - This study investigates research integrity among PhD students in health sciences 
      at three universities in Scandinavia (Stockholm, Oslo, Odense). A questionnaire
      with questions on knowledge, attitudes, experiences, and behavior was distributed
      to PhD students and obtained a response rate of 77.7%. About 10% of the
      respondents agreed that research misconduct strictly defined (such as
      fabrication, falsification, and plagiarism, FFP) is common in their area of
      research, while slightly more agreed that other forms of misconduct is common. A 
      nonnegligible segment of the respondents was willing to fabricate, falsify, or
      omit contradicting data if they believe that they are right in their overall
      conclusions. Up to one third reported to have added one or more authors
      unmerited. Results showed a negative correlation between "good attitudes" and
      self-reported misconduct and a positive correlation between how frequent
      respondents thought that misconduct occurs and whether they reported misconduct
      themselves. This reveals that existing educational and research systems partly
      fail to foster research integrity.
FAU - Hofmann, Bjorn
AU  - Hofmann B
AUID- ORCID: 0000-0001-6709-4265
AD  - Norwegian University of Science and Technology, Gjovik, Norway.
AD  - University of Oslo, Norway.
FAU - Bredahl Jensen, Lone
AU  - Bredahl Jensen L
AUID- ORCID: 0000-0003-4633-9838
AD  - University Library of Southern Denmark, Odense, Denmark.
FAU - Eriksen, Mette Brandt
AU  - Eriksen MB
AD  - University Library of Southern Denmark, Odense, Denmark.
FAU - Helgesson, Gert
AU  - Helgesson G
AD  - Karolinska Institutet, Stockholm, Sweden.
FAU - Juth, Niklas
AU  - Juth N
AD  - Karolinska Institutet, Stockholm, Sweden.
FAU - Holm, Soren
AU  - Holm S
AD  - Norwegian University of Science and Technology, Gjovik, Norway.
AD  - University of Manchester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - Faculty
MH  - Humans
MH  - Plagiarism
MH  - *Scientific Misconduct
MH  - Students
MH  - *Universities
PMC - PMC7488824
OTO - NOTNLM
OT  - *attitudes
OT  - *doctoral students
OT  - *integrity
OT  - *knowledge
OT  - *misconduct
OT  - *practice
OT  - *science ethics
EDAT- 2020/06/14 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/06/14 06:00
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/06/14 06:00 [entrez]
AID - 10.1177/1556264620929230 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):320-329. doi:
      10.1177/1556264620929230. Epub 2020 Jun 12.


PMID- 32531727
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 110
DP  - 2020 Sep
TI  - Dental health in persons with disability.
PG  - 107174
LID - S1525-5050(20)30353-X [pii]
LID - 10.1016/j.yebeh.2020.107174 [doi]
AB  - Systemic and structural barriers limit dental health for individuals with special
      healthcare needs (SHCN), who have poorer dental hygiene, higher rates of dental
      disorders, and less access to oral care. We aimed to understand these barriers
      directly from the patient and caregiver population as well as review the
      literature on oral health of individuals with SHCN. We reviewed the literature on
      individuals and caregivers of those with SHCN to identify barriers to dental
      healthcare faced by these individuals. We focused on clinical and educational
      interventions to support clinicians treating this population. For the literature 
      review, PubMed, Google, and Google Scholar were searched. We also relied upon the
      knowledge gained during the course of routine clinical care and patient advocacy 
      activities. Published manuscripts were searched for the following Medical Subject
      Heading (MeSH) term: "Dental Care for Disabled" and the following subheading:
      pharmacology, adverse effects, ethics, methods, standards, and therapy.
      Relatively few dentists have formal training on caring for those with SHCN.
      Barriers faced by these individuals include accessibility, comorbidities,
      communication challenges, and barriers to home oral hygiene. Strong care
      coordination and communication between dentists, caregivers, and other providers 
      is essential for positive outcomes. Our current dental healthcare system has
      failed to meet the needs of those with SHCN. The comfort and dignity of the
      patient are of paramount importance.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Devinsky, Orrin
AU  - Devinsky O
AD  - Comprehensive Epilepsy Center, Department of Neurology, NYU Langone School of
      Medicine, New York, NY 10010, United States of America. Electronic address:
      od4@nyu.edu.
FAU - Boyce, Danielle
AU  - Boyce D
AD  - Johns Hopkins School of Medicine, 1830 E. Monument Street, Baltimore, MD 21205,
      United States of America. Electronic address: dboyce3@jhu.edu.
FAU - Robbins, Miriam
AU  - Robbins M
AD  - Oral and Maxillofacial Pathology, Radiology and Medicine, NYU College of
      Dentistry, Room 1B Dental Center, 345 First Avenue, New York, NY 10010, United
      States of America. Electronic address: miriam.robbins@nyu.edu.
FAU - Pressler, Mariel
AU  - Pressler M
AD  - Department of Neurology, NYU Langone School of Medicine, New York, NY 10010,
      United States of America.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
SB  - IM
MH  - Appointments and Schedules
MH  - Caregivers/psychology
MH  - *Dental Health Services
MH  - Disabled Persons/*psychology
MH  - Epilepsy/*psychology/therapy
MH  - *Health Services Accessibility
MH  - Humans
MH  - Oral Hygiene/methods/*psychology
MH  - Patient Advocacy/psychology
OTO - NOTNLM
OT  - *Dental care
OT  - *Developmental delay
OT  - *Epilepsy
OT  - *Oral health
OT  - *Special needs
COIS- Declaration of competing interest This research did not receive any specific
      grant from funding agencies in the public, commercial, or not-for-profit sectors.
      Orrin Devinsky has financial interests (stock options, investment, advisory board
      positions, and/or consulting arrangements) with the following business entities: 
      Privateer Holdings, Tilray, Inc., Empatica, Tevard, Engage, Receptor Life
      Sciences, Egg Rock/Papa & Barkley, RETTCO, PAIRNOMIX, Greenwich Biosciences, and 
      Zogenix. He is a noncompensated scientific advisory board member of the following
      groups: Sudden Unexplained Death in Children Foundation, KBG Foundation, Tuberous
      Sclerosis Alliance, Dup15 Alliance, Epilepsy Foundation SUDEP Institute, CDKL5
      Program of Excellence, KCNQ2 Cure Alliance, CURE DHPS, HNRNPU Foundation, KBG
      Foundation, and Finding A Cure for Epilepsy and Seizures. Danielle Boyce has no
      current financial conflicts of interest but previously worked as a consultant for
      Lundbeck Pharmaceuticals and Eton Pharmaceuticals. She currently serves as an
      unpaid scientific advisor and data analyst to the Gould Syndrome Foundation and
      COPD Foundation. The other authors have no competing interests to report.
EDAT- 2020/06/13 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - S1525-5050(20)30353-X [pii]
AID - 10.1016/j.yebeh.2020.107174 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2020 Sep;110:107174. doi: 10.1016/j.yebeh.2020.107174. Epub 2020 
      Jun 9.


PMID- 32531156
OWN - NLM
STAT- MEDLINE
DCOM- 20201228
LR  - 20201228
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 63
IP  - 21
DP  - 2020 Nov 12
TI  - Synthetic Access to Cannabidiol and Analogs as Active Pharmaceutical Ingredients.
PG  - 12131-12136
LID - 10.1021/acs.jmedchem.0c00095 [doi]
AB  - Cannabinoids have surely been one of the most widely self-administered drugs
      other than caffeine. The U.S. FDA recently approved one cannabinoid-based drug
      whose active pharmaceutical ingredient (API) is cannabidiol (CBD). The long
      history of individual use of cannabis for a wide range of conditions has sparked 
      great interest in other uses of CBD, in ethical drugs and botanical supplements
      as well as in foods and nonprescription wellness products. CBD may be sourced
      from cannabis plants but can also be prepared synthetically, the topic of this
      review.
FAU - Pirrung, Michael C
AU  - Pirrung MC
AUID- ORCID: 0000-0003-4585-8353
AD  - Department of Chemistry, University of California, Riverside, California 92521,
      United States.
AD  - Department of Pharmaceutical Sciences, University of California, Irvine,
      California 92697, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200713
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Cannabinoids)
RN  - 0 (Terpenes)
RN  - 19GBJ60SN5 (Cannabidiol)
SB  - IM
MH  - Cannabidiol/*analogs & derivatives/chemical synthesis/metabolism
MH  - Cannabinoids/chemistry
MH  - Cannabis/chemistry/metabolism
MH  - Plant Roots/chemistry/metabolism
MH  - Stereoisomerism
MH  - Terpenes/chemistry
MH  - Yeasts/chemistry/metabolism
EDAT- 2020/06/13 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1021/acs.jmedchem.0c00095 [doi]
PST - ppublish
SO  - J Med Chem. 2020 Nov 12;63(21):12131-12136. doi: 10.1021/acs.jmedchem.0c00095.
      Epub 2020 Jul 13.


PMID- 32530737
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 2150-5608 (Electronic)
IS  - 2150-5594 (Linking)
VI  - 11
IP  - 1
DP  - 2020 Dec
TI  - A novel biosafety level 2 compliant tuberculosis infection model using a
      DeltaleuDDeltapanCD double auxotroph of Mycobacterium tuberculosis H37Rv and
      Galleria mellonella.
PG  - 811-824
LID - 10.1080/21505594.2020.1781486 [doi]
AB  - Mammalian infection models have contributed significantly to our understanding of
      the host-mycobacterial interaction, revealing potential mechanisms and targets
      for novel antimycobacterial therapeutics. However, the use of conventional
      mammalian models such as mice, are typically expensive, high maintenance, require
      specialized animal housing, and are ethically regulated. Furthermore, research
      using Mycobacterium tuberculosis (MTB), is inherently difficult as work needs to 
      be carried out at biosafety level 3 (BSL3). The insect larvae of Galleria
      mellonella (greater wax moth), have become increasingly popular as an infection
      model, and we previously demonstrated its potential as a mycobacterial infection 
      model using Mycobacterium bovis BCG. Here we present a novel BSL2 complaint MTB
      infection model using G. mellonella in combination with a bioluminescent
      DeltaleuDDeltapanCD double auxotrophic mutant of MTB H37Rv (SAMTB lux) which
      offers safety and practical advantages over working with wild type MTB. Our
      results show a SAMTB lux dose dependent survival of G. mellonella larvae and
      demonstrate proliferation and persistence of SAMTB lux bioluminescence over a 1
      week infection time course. Histopathological analysis of G. mellonella,
      highlight the formation of early granuloma-like structures which matured over
      time. We additionally demonstrate the drug efficacy of first (isoniazid,
      rifampicin, and ethambutol) and second line (moxifloxacin) antimycobacterial
      drugs. Our findings demonstrate the broad potential of this insect model to study
      MTB infection under BSL2 conditions. We anticipate that the successful adaptation
      and implementation of this model will remove the inherent limitations of MTB
      research at BSL3 and increase tuberculosis research output.
FAU - Asai, Masanori
AU  - Asai M
AD  - Section of Paediatric Infectious Disease, Department of Infectious Disease,
      Imperial College London , London, UK.
FAU - Li, Yanwen
AU  - Li Y
AD  - Section of Paediatric Infectious Disease, Department of Infectious Disease,
      Imperial College London , London, UK.
FAU - Spiropoulos, John
AU  - Spiropoulos J
AUID- ORCID: 0000-0003-0119-8920
AD  - Department of Pathology, Animal and Plant Health Agency , Addlestone, UK.
FAU - Cooley, William
AU  - Cooley W
AD  - Department of Pathology, Animal and Plant Health Agency , Addlestone, UK.
FAU - Everest, David
AU  - Everest D
AD  - Department of Pathology, Animal and Plant Health Agency , Addlestone, UK.
FAU - Robertson, Brian D
AU  - Robertson BD
AUID- ORCID: 0000-0001-5785-5307
AD  - MRC Centre for Molecular Bacteriology and Infection, Department of Infectious
      Disease, Imperial College London , London, UK.
FAU - Langford, Paul R
AU  - Langford PR
AD  - Section of Paediatric Infectious Disease, Department of Infectious Disease,
      Imperial College London , London, UK.
FAU - Newton, Sandra M
AU  - Newton SM
AUID- ORCID: 0000-0001-6545-9558
AD  - Section of Paediatric Infectious Disease, Department of Infectious Disease,
      Imperial College London , London, UK.
LA  - eng
GR  - MR/P028225/1/MRC_/Medical Research Council/United Kingdom
GR  - NC/R001596/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction
      of Animals in Research/United Kingdom
GR  - BB/P001262/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Virulence
JT  - Virulence
JID - 101531386
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/isolation & purification
MH  - *Containment of Biohazards
MH  - *Disease Models, Animal
MH  - Drug Evaluation, Preclinical/methods
MH  - Larva/microbiology
MH  - Luminescent Measurements
MH  - Moths/*microbiology
MH  - Mycobacterium tuberculosis/*genetics/metabolism/pathogenicity
MH  - Tuberculosis/drug therapy/*microbiology
PMC - PMC7550006
OTO - NOTNLM
OT  - * Galleria mellonella
OT  - * Mycobacterium tuberculosis complex
OT  - *antimycobacterial agents
OT  - *auxotrophic
OT  - *drug screening
OT  - *infection model
OT  - *mycobacteria
OT  - *tuberculosis
EDAT- 2020/06/13 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1080/21505594.2020.1781486 [doi]
PST - ppublish
SO  - Virulence. 2020 Dec;11(1):811-824. doi: 10.1080/21505594.2020.1781486.


PMID- 32529754
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1557-0681 (Electronic)
IS  - 1478-2189 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Dec
TI  - Self-management approaches to reduce the ill-health burden associated with
      musculoskeletal foot and ankle problems: A scoping review protocol.
PG  - 541-545
LID - 10.1002/msc.1479 [doi]
AB  - INTRODUCTION: The high ill-health burden associated with musculoskeletal (MSK)
      disease has been widely reported, and various treatment approaches proposed.
      Increasingly, treatments have sought to reflect personalised care and incorporate
      self-management (SM). However, the range of SM approaches proposed for foot and
      ankle MSK problems, and their relative clinical or cost-effectiveness, has not
      been reviewed. A scoping review is required to understand the
      need/appropriateness of a systematic review on this topic. METHODS AND ANALYSIS: 
      The scoping review will be conducted in line with the PRISMA-ScR framework. We
      will perform an initial search across two databases to confirm search syntax. We 
      will then complete a full search across three databases (Embase [Ovid], CINAHL
      [EBSCO], and Medline [EBSCO]) and grey literature (Cochrane Library, The British 
      Library, The Canadian Agency for Drugs and Technologies in Health [CADTH], The
      Health Foundation, The Kings Fund, and MedNar). We will use a snowballing
      strategy to review the reference list of retrieved texts, as per inclusion
      criteria, to identify previously unretrieved texts of potential relevance. In an 
      iterative process, the protocol outlined above will be refined and repeated as
      new key terms come to light. ETHICS AND DISSEMINATION: The scoping review will
      synthesise what is known and not known about SM approaches for MSK foot and ankle
      problems. The review will form the first step in outlining future research
      recommendations and areas of potentially unmet clinical need. The findings will
      be submitted for publication and shared in written form with stakeholder groups
      involved in the design of future research.
CI  - (c) 2020 The Authors. Musculoskeletal Care published by John Wiley & Sons Ltd.
FAU - Cherry, Lindsey
AU  - Cherry L
AUID- ORCID: 0000-0002-3165-1004
AD  - School of Health Sciences, University of Southampton, Southampton, UK.
AD  - Solent NHS Trust, Southampton, UK.
FAU - Gates, Lucy
AU  - Gates L
AD  - School of Health Sciences, University of Southampton, Southampton, UK.
FAU - McCormick, Keith
AU  - McCormick K
AD  - School of Health Sciences, University of Southampton, Southampton, UK.
FAU - Culliford, David
AU  - Culliford D
AD  - NIHR Applied Research Collaboration Wessex, School of Health Sciences, University
      of Southampton, Southampton, UK.
FAU - Portillo, Mari Carmen
AU  - Portillo MC
AD  - NIHR Applied Research Collaboration Wessex, School of Health Sciences, University
      of Southampton, Southampton, UK.
FAU - Walker-Bone, Karen
AU  - Walker-Bone K
AD  - Medical Research Council (MRC) Lifecourse Epidemiology, University of
      Southampton, Southampton, UK.
LA  - eng
GR  - MC_U147585823/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12011/5/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200611
PL  - England
TA  - Musculoskeletal Care
JT  - Musculoskeletal care
JID - 101181344
SB  - IM
MH  - Ankle
MH  - Canada
MH  - Humans
MH  - Research Design
MH  - *Self-Management
MH  - Systematic Reviews as Topic
OTO - NOTNLM
OT  - *ankle
OT  - *burden
OT  - *foot
OT  - *protocol
OT  - *review
OT  - *self-management
EDAT- 2020/06/13 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1002/msc.1479 [doi]
PST - ppublish
SO  - Musculoskeletal Care. 2020 Dec;18(4):541-545. doi: 10.1002/msc.1479. Epub 2020
      Jun 11.


PMID- 32529710
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jul
TI  - Rethinking parenthood within assisted reproductive technology: The need for
      regulation in Nigeria.
PG  - 578-584
LID - 10.1111/bioe.12759 [doi]
AB  - In Nigeria, reproduction is highly valued, with many people desiring to produce a
      child 'in their own image and likeness'. Previously, aspiring parents often
      resorted to adoption. Today, the availability of assisted reproductive
      technologies (ARTs) has provided options other than adoption for those desiring
      to procreate. Through ARTs, aspirations for a family may be attained through an
      exchange of reproductive goods and services, and not necessarily through
      traditional heterosexual relationships. ARTs have altered the perception of
      parenthood as it exists in Nigeria, and courts face a difficult task in defining 
      parenthood within Nigerian jurisprudence, as they can only adjudicate based on
      extant law. Although ARTs provide greater individual choices for fulfilling the
      desire to procreate, they raise a number of ethical and legal issues that
      evolving legal systems, such as that in Nigeria, are ill-equipped to manage. This
      paper describes the traditional assignment of parenthood under indigenous laws
      and other sources of law within the Nigerian jurisprudence. We carried out an
      in-depth study of the Nigerian legislative framework and found that there are no 
      laws directly regulating parenthood, procreation and ARTs in Nigeria. We also
      found that the extant laws are only tangentially related and do not answer the
      relevant questions sufficiently well, especially concerning succession,
      nationality and assignment of responsibility in collaborative reproduction. We
      conclude by highlighting the need for and recommending a regulatory framework on 
      ARTs with a particular focus on providing a definition for parenthood achieved
      through ARTs in Nigeria.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Egbokhare, Olohikhuae O
AU  - Egbokhare OO
AD  - University of Ibadan, Ibadan, Nigeria.
FAU - Akintola, Simisola O
AU  - Akintola SO
AD  - University of Ibadan, Ibadan, Nigeria.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Adult
MH  - Child
MH  - Culture
MH  - Female
MH  - Humans
MH  - *Jurisprudence
MH  - Male
MH  - Nigeria/ethnology
MH  - Parent-Child Relations/ethnology/legislation & jurisprudence
MH  - *Parents
MH  - Religion
MH  - Reproductive Techniques, Assisted/*legislation & jurisprudence
OTO - NOTNLM
OT  - *Nigeria
OT  - *assisted reproductive technologies
OT  - *bioethics
OT  - *infertility
OT  - *parenthood
OT  - *regulation
EDAT- 2020/06/13 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/02/28 00:00 [received]
PHST- 2020/01/17 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1111/bioe.12759 [doi]
PST - ppublish
SO  - Bioethics. 2020 Jul;34(6):578-584. doi: 10.1111/bioe.12759.


PMID- 32529686
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1539-6924 (Electronic)
IS  - 0272-4332 (Linking)
VI  - 40
IP  - 9
DP  - 2020 Sep
TI  - Efficient or Fair? Operationalizing Ethical Principles in Flood Risk Management: 
      A Case Study on the Dutch-German Rhine.
PG  - 1844-1862
LID - 10.1111/risa.13527 [doi]
AB  - Flood risk management decisions in many countries are based on decision-support
      frameworks which rely on cost-benefit analyses. Such frameworks are seldom
      informative about the geographical distribution of risk, raising questions on the
      fairness of the proposed policies. In the present work, we propose a new decision
      criterion that accounts for the distribution of risk reduction and apply it to
      support flood risk management decisions on a transboundary stretch of the Rhine
      River. Three types of interventions are considered: embankment heightening,
      making Room for the River, and changing the discharge distribution of the river
      branches. The analysis involves solving a flood risk management problem according
      to four alternative formulations, based on different ethical principles.
      Formulations based on cost optimization lead to very poor performances in some
      areas for the sake of reducing the overall aggregated costs. Formulations that
      also include equity criteria have different results depending on how these are
      defined. When risk reduction is distributed equally, very poor economic
      performance is achieved. When risk is distributed equally, results are in line
      with formulations based on cost optimization, while a fairer risk distribution is
      achieved. Risk reduction measures also differ, with the cost optimization
      approach strongly favoring the leverage of changing the discharge distribution
      and the alternative formulations spending more on embankment heightening and Room
      for the River, to rebalance inequalities in risk levels. The proposed method
      advances risk-based decision-making by allowing to consider risk distribution
      aspects and their impacts on the choice of risk reduction measures.
CI  - (c) 2020 The Authors. Risk Analysis published by Wiley Periodicals LLC on behalf 
      of Society for Risk Analysis.
FAU - Ciullo, Alessio
AU  - Ciullo A
AUID- ORCID: 0000-0001-9032-3169
AD  - Institute of Geography, University of Bern, Bern, Switzerland.
AD  - Oeschger Centre for Climate Change Research, University of Bern, Bern,
      Switzerland.
AD  - Faculty of Technology, Policy and Management, Delft University of Technology,
      Delft, The Netherlands.
AD  - Deltares, Delft, The Netherlands.
FAU - Kwakkel, Jan H
AU  - Kwakkel JH
AD  - Faculty of Technology, Policy and Management, Delft University of Technology,
      Delft, The Netherlands.
FAU - De Bruijn, Karin M
AU  - De Bruijn KM
AD  - Deltares, Delft, The Netherlands.
FAU - Doorn, Neelke
AU  - Doorn N
AD  - Faculty of Technology, Policy and Management, Delft University of Technology,
      Delft, The Netherlands.
FAU - Klijn, Frans
AU  - Klijn F
AD  - Faculty of Technology, Policy and Management, Delft University of Technology,
      Delft, The Netherlands.
AD  - Deltares, Delft, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - United States
TA  - Risk Anal
JT  - Risk analysis : an official publication of the Society for Risk Analysis
JID - 8109978
SB  - IM
PMC - PMC7540719
OTO - NOTNLM
OT  - *Equity
OT  - *flood risk management
OT  - *large-scale systems analysis
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2019/02/13 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1111/risa.13527 [doi]
PST - ppublish
SO  - Risk Anal. 2020 Sep;40(9):1844-1862. doi: 10.1111/risa.13527. Epub 2020 Jun 11.


PMID- 32529662
OWN - NLM
STAT- MEDLINE
DCOM- 20201016
LR  - 20210131
IS  - 1531-8257 (Electronic)
IS  - 0885-3185 (Linking)
VI  - 35
IP  - 8
DP  - 2020 Aug
TI  - Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to
      Parkinson's Disease.
PG  - 1312-1314
LID - 10.1002/mds.28187 [doi]
FAU - Jankovic, Joseph
AU  - Jankovic J
AD  - Parkinson's Disease Center and Movement Disorders Clinic, Department of
      Neurology, Baylor College of Medicine, Houston, Texas, USA.
FAU - Okun, Michael S
AU  - Okun MS
AD  - Norman Fixel Institute for Neurological Diseases, Department of Neurology,
      University of Florida Health, Gainesville, Florida, USA.
FAU - Kordower, Jeffrey H
AU  - Kordower JH
AD  - Department of Neurological Sciences, Rush University Medical Center, Chicago,
      Illinois, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200707
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
CON - N Engl J Med. 2020 May 14;382(20):1926-1932. PMID: 32402162
CIN - Mov Disord. 2020 Nov;35(11):2120-2121. PMID: 33463751
CIN - Mov Disord. 2020 Nov;35(11):2119-2120. PMID: 33463754
MH  - Dopamine
MH  - Humans
MH  - *Induced Pluripotent Stem Cells
MH  - *Parkinson Disease
EDAT- 2020/06/13 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/06/05 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1002/mds.28187 [doi]
PST - ppublish
SO  - Mov Disord. 2020 Aug;35(8):1312-1314. doi: 10.1002/mds.28187. Epub 2020 Jul 7.


PMID- 32529243
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 12
DP  - 2020 Nov 13
TI  - Human Immunodeficiency Virus Phylogenetics in the United States-and Elsewhere.
PG  - 1939-1940
LID - 10.1093/infdis/jiaa108 [doi]
FAU - Lapointe, Hope R
AU  - Lapointe HR
AD  - Division of AIDS Department of Medicine, Vancouver, British Columbia, Canada.
FAU - Harrigan, P Richard
AU  - Harrigan PR
AD  - Division of AIDS Department of Medicine, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
SB  - IM
CON - J Infect Dis. 2020 Nov 13;222(12):1997-2006. PMID: 32525980
MH  - *Acquired Immunodeficiency Syndrome
MH  - Diagnostic Tests, Routine
MH  - HIV/genetics
MH  - *HIV Infections/epidemiology
MH  - Humans
MH  - Phylogeny
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *ethics
OT  - *international
OT  - *phylogenetics
EDAT- 2020/06/13 06:00
MHDA- 2021/03/20 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 5856321 [pii]
AID - 10.1093/infdis/jiaa108 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Nov 13;222(12):1939-1940. doi: 10.1093/infdis/jiaa108.


PMID- 32529102
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2421-4248 (Electronic)
IS  - 1121-2233 (Linking)
VI  - 61
IP  - 1 Suppl 1
DP  - 2020 Mar
TI  - Social determinants, ethical issues and future challenge of tuberculosis in a
      pluralistic society: the example of Israel.
PG  - E24-E27
LID - 10.15167/2421-4248/jpmh2020.61.1s1.1443 [doi]
AB  - Tuberculosis is a very serious respiratory infectious disease, caused by the
      bacillus Mycobacterium tuberculosis, which generates a relevant societal and
      clinical burden. It has always represented a permanent concern and a public
      health challenge over the course of human history, because of its severe
      epidemiological, and economic-financial implications. The present review aims at 
      over-viewing the impact of tuberculosis on the Israeli healthcare system, its
      temporal trend and evolution, stratified according to ethnicities and minorities,
      the need of establishing new facilities and implementing screening techniques,
      public health strategies and diagnostic tests, following massive immigration
      waves from countries characterized by a high incidence rate of tuberculosis
      during the fifties-sixties until the nineties, and the policies implemented by
      the Israeli government in the control, management and treatment of tuberculosis, 
      as well as the role played by Israeli prominent scientists in discovering new
      druggable targets and finding bioactive compounds and bio-molecules in the fight 
      against tuberculosis. Israel represents a unique, living laboratory in which
      features of developed and developing countries mix together. This country as a
      case-study of immigrant, pluralistic society underlines the importance of
      adopting a culturally-sensitive community intervention approach. The
      understanding of the subtle interplay between race/ethnic host and pathogen
      factors, including the role of gene variations and polymorphisms can pave the way
      for a personalized treatment and management of tuberculosis patients,
      contributing to the development of new tools for targeted tuberculosis
      therapeutics, immunodiagnostics and vaccination products.
CI  - (c)2020 Pacini Editore SRL, Pisa, Italy.
FAU - Bragazzi, N L
AU  - Bragazzi NL
AD  - Department of Mathematics and Statistics, York University, Toronto, Canada.
FAU - Martini, M
AU  - Martini M
AD  - Department of Health Sciences, University of Genoa, Italy.
FAU - Mahroum, N
AU  - Mahroum N
AD  - The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center,
      Tel-Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200430
PL  - Italy
TA  - J Prev Med Hyg
JT  - Journal of preventive medicine and hygiene
JID - 9214440
SB  - IM
MH  - Age Factors
MH  - *Cultural Diversity
MH  - *Culturally Competent Care
MH  - Emigrants and Immigrants
MH  - Ethics, Medical
MH  - *Health Policy
MH  - Healthcare Disparities/ethnology
MH  - Humans
MH  - Israel/epidemiology
MH  - *Social Determinants of Health
MH  - Tuberculosis/drug therapy/epidemiology/ethnology
MH  - Tuberculosis, Pulmonary/drug therapy/*epidemiology/ethnology
MH  - Universal Health Insurance
PMC - PMC7263062
OTO - NOTNLM
OT  - Ethical issues
OT  - Globalization
OT  - Health policy
OT  - Immigrant society
OT  - Israel
OT  - Multi-cultural
OT  - Tuberculosis
EDAT- 2020/06/13 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/12/01 00:00 [received]
PHST- 2019/12/23 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.15167/2421-4248/jpmh2020.61.1s1.1443 [doi]
PST - epublish
SO  - J Prev Med Hyg. 2020 Apr 30;61(1 Suppl 1):E24-E27. doi:
      10.15167/2421-4248/jpmh2020.61.1s1.1443. eCollection 2020 Mar.


PMID- 32529100
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2421-4248 (Electronic)
IS  - 1121-2233 (Linking)
VI  - 61
IP  - 1 Suppl 1
DP  - 2020 Mar
TI  - Tuberculosis: an ancient disease that remains a medical, social, economical and
      ethical issue.
PG  - E16-E18
LID - 10.15167/2421-4248/jpmh2020.61.1s1.1475 [doi]
FAU - Martini, M
AU  - Martini M
AD  - Department of Health Sciences, University of Genoa, Italy.
AD  - UNESCO Chair "Anthropology of Health - Biosphere and Healing System", University 
      of Genoa, Italy.
AD  - StopTB Italia Onlus, Milan, Italy.
FAU - Riccardi, N
AU  - Riccardi N
AD  - StopTB Italia Onlus, Milan, Italy.
AD  - Department of Infectious - Tropical Diseases and Microbiology, IRCCS Sacro Cuore 
      Don Calabria Hospital, Negrar, Verona, Italy.
FAU - Giacomelli, A
AU  - Giacomelli A
AD  - III Infectious Disease Unit, ASST-FBF-Sacco, Milan, Italy.
AD  - Department of Biomedical and Clinical Sciences, L. Sacco, University of Milan,
      Italy.
FAU - Gazzaniga, V
AU  - Gazzaniga V
AD  - Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University
      of Rome, Rome, Italy.
AD  - President of Italian Society of Human Sciences in Medicine (SISUMed), Rome Italy.
FAU - Besozzi, G
AU  - Besozzi G
AD  - StopTB Italia Onlus, Milan, Italy.
AD  - Villa Marelli Insitute, Niguarda Ca' Granda Hospital, Milan, Italy.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200430
PL  - Italy
TA  - J Prev Med Hyg
JT  - Journal of preventive medicine and hygiene
JID - 9214440
RN  - 0 (BCG Vaccine)
RN  - 0 (Tuberculosis Vaccines)
SB  - IM
MH  - BCG Vaccine/therapeutic use
MH  - History, 15th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Hygiene
MH  - *Malnutrition
MH  - *Population Density
MH  - *Poverty
MH  - Risk Factors
MH  - *Social Determinants of Health
MH  - Tuberculosis/epidemiology/*history/prevention & control
MH  - Tuberculosis Vaccines/therapeutic use
MH  - Urbanization
PMC - PMC7263063
OTO - NOTNLM
OT  - Disease of poverty
OT  - Ethics
OT  - History
OT  - Tuberculosis
EDAT- 2020/06/13 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.15167/2421-4248/jpmh2020.61.1s1.1475 [doi]
PST - epublish
SO  - J Prev Med Hyg. 2020 Apr 30;61(1 Suppl 1):E16-E18. doi:
      10.15167/2421-4248/jpmh2020.61.1s1.1475. eCollection 2020 Mar.


PMID- 32529047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2399-3529 (Electronic)
IS  - 2399-3529 (Linking)
VI  - 2020
IP  - 3
DP  - 2020
TI  - Fertility preservation in boys: recent developments and new insights (dagger).
PG  - hoaa016
LID - 10.1093/hropen/hoaa016 [doi]
AB  - BACKGROUND: Infertility is an important side effect of treatments used for cancer
      and other non-malignant conditions in males. This may be due to the loss of
      spermatogonial stem cells (SSCs) and/or altered functionality of testicular
      somatic cells (e.g. Sertoli cells, Leydig cells). Whereas sperm cryopreservation 
      is the first-line procedure to preserve fertility in post-pubertal males, this
      option does not exist for prepubertal boys. For patients unable to produce sperm 
      and at high risk of losing their fertility, testicular tissue freezing is now
      proposed as an alternative experimental option to safeguard their fertility.
      OBJECTIVE AND RATIONALE: With this review, we aim to provide an update on
      clinical practices and experimental methods, as well as to describe patient
      management inclusion strategies used to preserve and restore the fertility of
      prepubertal boys at high risk of fertility loss. SEARCH METHODS: Based on the
      expertise of the participating centres and a literature search of the progress in
      clinical practices, patient management strategies and experimental methods used
      to preserve and restore the fertility of prepubertal boys at high risk of
      fertility loss were identified. In addition, a survey was conducted amongst
      European and North American centres/networks that have published papers on their 
      testicular tissue banking activity. OUTCOMES: Since the first publication on
      murine SSC transplantation in 1994, remarkable progress has been made towards
      clinical application: cryopreservation protocols for testicular tissue have been 
      developed in animal models and are now offered to patients in clinics as a still 
      experimental procedure. Transplantation methods have been adapted for human
      testis, and the efficiency and safety of the technique are being evaluated in
      mouse and primate models. However, important practical, medical and ethical
      issues must be resolved before fertility restoration can be applied in the
      clinic.Since the previous survey conducted in 2012, the implementation of
      testicular tissue cryopreservation as a means to preserve the fertility of
      prepubertal boys has increased. Data have been collected from 24 co-ordinating
      centres worldwide, which are actively offering testis tissue cryobanking to
      safeguard the future fertility of boys. More than 1033 young patients (age range 
      3 months to 18 years) have already undergone testicular tissue retrieval and
      storage for fertility preservation. LIMITATIONS REASONS FOR CAUTION: The review
      does not include the data of all reproductive centres worldwide. Other centres
      might be offering testicular tissue cryopreservation. Therefore, the numbers
      might be not representative for the entire field in reproductive medicine and
      biology worldwide. The key ethical issue regarding fertility preservation in
      prepubertal boys remains the experimental nature of the intervention. WIDER
      IMPLICATIONS: The revised procedures can be implemented by the multi-disciplinary
      teams offering and/or developing treatment strategies to preserve the fertility
      of prepubertal boys who have a high risk of fertility loss. STUDY
      FUNDING/COMPETING INTERESTS: The work was funded by ESHRE. None of the authors
      has a conflict of interest.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      European Society of Human Reproduction and Embryology.
FAU - Goossens, E
AU  - Goossens E
AUID- ORCID: 0000-0001-7601-9689
AD  - Biology of the Testis, Research Laboratory for Reproduction, Genetics and
      Regenerative Medicine, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium.
FAU - Jahnukainen, K
AU  - Jahnukainen K
AD  - NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of 
      Women's and Children's Health, Karolinska Institutet and Karolinska University
      Hospital, Solna, Sweden.
AD  - Division of Haematology-Oncology and Stem Cell Transplantation, New Children's
      Hospital, Pediatric Research Center, University of Helsinki and Helsinki
      University Hospital, Helsinki, Finland.
FAU - Mitchell, R T
AU  - Mitchell RT
AD  - MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The
      University of Edinburgh; and the Edinburgh Royal Hospital for Sick Children,
      Edinburgh, UK.
FAU - van Pelt, Amm
AU  - van Pelt A
AD  - Center for Reproductive Medicine, Amsterdam UMC, Amsterdam Reproduction and
      Development Research Institute, University of Amsterdam, 1105 AZ Amsterdam, The
      Netherlands.
FAU - Pennings, G
AU  - Pennings G
AD  - Bioethics Institute Ghent, Ghent University, 9000 Ghent, Belgium.
FAU - Rives, N
AU  - Rives N
AD  - Normandie Univ, UNIROUEN, EA 4308 "Gametogenesis and Gamete Quality", Rouen
      University Hospital, Biology of Reproduction-CECOS Laboratory, F 76000, Rouen,
      France.
FAU - Poels, J
AU  - Poels J
AD  - Department of Gynecology and Andrology, Cliniques Universitaires Saint-Luc,
      Universite Catholique de Louvain, Brussels, Belgium.
FAU - Wyns, C
AU  - Wyns C
AD  - Department of Gynecology and Andrology, Cliniques Universitaires Saint-Luc,
      Universite Catholique de Louvain, Brussels, Belgium.
FAU - Lane, S
AU  - Lane S
AD  - Department of Paediatric Oncology and Haematology, Children's Hospital Oxford,
      Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
FAU - Rodriguez-Wallberg, K A
AU  - Rodriguez-Wallberg KA
AD  - Department of Oncology Pathology, Karolinska Institutet, Solna, Sweden.
AD  - Section of Reproductive Medicine, Division of Gynecology and Reproduction,
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Rives, A
AU  - Rives A
AD  - Normandie Univ, UNIROUEN, EA 4308 "Gametogenesis and Gamete Quality", Rouen
      University Hospital, Biology of Reproduction-CECOS Laboratory, F 76000, Rouen,
      France.
FAU - Valli-Pulaski, H
AU  - Valli-Pulaski H
AD  - Magee-Womens Research Institute, University of Pittsburgh School of Medicine,
      Pittsburgh, PA 15213, USA.
FAU - Steimer, S
AU  - Steimer S
AD  - Magee-Womens Research Institute, University of Pittsburgh School of Medicine,
      Pittsburgh, PA 15213, USA.
FAU - Kliesch, S
AU  - Kliesch S
AD  - Centre of Reproductive Medicine and Andrology, Institute of Reproductive and
      Regenerative Biology, University of Munster, Munster, Germany.
FAU - Braye, A
AU  - Braye A
AD  - Biology of the Testis, Research Laboratory for Reproduction, Genetics and
      Regenerative Medicine, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium.
FAU - Andres, M M
AU  - Andres MM
AD  - Reproductive Medicine Unit, Hospital Universitario y Politecnico La Fe, Valencia,
      Spain.
FAU - Medrano, J
AU  - Medrano J
AD  - Reproductive Medicine Unit, Hospital Universitario y Politecnico La Fe, Valencia,
      Spain.
FAU - Ramos, L
AU  - Ramos L
AD  - Departement of Obstetrics and Gynacology, Division Reproductive Medicine, Radboud
      University Medical Center, Nijmegen, The Netherlands.
FAU - Kristensen, S G
AU  - Kristensen SG
AD  - Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children 
      and Reproduction, University Hospital of Copenhagen, Denmark.
FAU - Andersen, C Y
AU  - Andersen CY
AD  - Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children 
      and Reproduction, University Hospital of Copenhagen, Denmark.
FAU - Bjarnason, R
AU  - Bjarnason R
AD  - Children's Medical Center, Landspitali University Hospital, Reykjavik, Iceland
      and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
FAU - Orwig, K E
AU  - Orwig KE
AD  - Magee-Womens Research Institute, University of Pittsburgh School of Medicine,
      Pittsburgh, PA 15213, USA.
FAU - Neuhaus, N
AU  - Neuhaus N
AD  - Centre of Reproductive Medicine and Andrology, Institute of Reproductive and
      Regenerative Biology, University of Munster, Munster, Germany.
FAU - Stukenborg, J B
AU  - Stukenborg JB
AD  - NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of 
      Women's and Children's Health, Karolinska Institutet and Karolinska University
      Hospital, Solna, Sweden.
LA  - eng
GR  - MR/N022556/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200606
PL  - England
TA  - Hum Reprod Open
JT  - Human reproduction open
JID - 101722764
PMC - PMC7275639
OTO - NOTNLM
OT  - cryopreservation
OT  - fertility preservation
OT  - fertility restoration
OT  - in vitro spermatogenesis
OT  - prepubertal boys
OT  - spermatogonial stem cell
OT  - testicular tissue freezing
OT  - testis
OT  - transplantation
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/01/22 00:00 [revised]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.1093/hropen/hoaa016 [doi]
AID - hoaa016 [pii]
PST - epublish
SO  - Hum Reprod Open. 2020 Jun 6;2020(3):hoaa016. doi: 10.1093/hropen/hoaa016.
      eCollection 2020.


PMID- 32529043
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Sex and gender differences and biases in artificial intelligence for biomedicine 
      and healthcare.
PG  - 81
LID - 10.1038/s41746-020-0288-5 [doi]
AB  - Precision Medicine implies a deep understanding of inter-individual differences
      in health and disease that are due to genetic and environmental factors. To
      acquire such understanding there is a need for the implementation of different
      types of technologies based on artificial intelligence (AI) that enable the
      identification of biomedically relevant patterns, facilitating progress towards
      individually tailored preventative and therapeutic interventions. Despite the
      significant scientific advances achieved so far, most of the currently used
      biomedical AI technologies do not account for bias detection. Furthermore, the
      design of the majority of algorithms ignore the sex and gender dimension and its 
      contribution to health and disease differences among individuals. Failure in
      accounting for these differences will generate sub-optimal results and produce
      mistakes as well as discriminatory outcomes. In this review we examine the
      current sex and gender gaps in a subset of biomedical technologies used in
      relation to Precision Medicine. In addition, we provide recommendations to
      optimize their utilization to improve the global health and disease landscape and
      decrease inequalities.
CI  - (c) The Author(s) 2020.
FAU - Cirillo, Davide
AU  - Cirillo D
AUID- ORCID: 0000-0003-4982-4716
AD  - Barcelona Supercomputing Center (BSC), C/ Jordi Girona, 29, 08034 Barcelona,
      Spain.0000 0004 0387 1602grid.10097.3f
FAU - Catuara-Solarz, Silvina
AU  - Catuara-Solarz S
AD  - Telefonica Innovation Alpha Health, Torre Telefonica, Placa d'Ernest Lluch i
      Martin, 5, 08019 Barcelona, Spain.
AD  - The Women's Brain Project (WBP), Guntershausen, Switzerland.
FAU - Morey, Czuee
AU  - Morey C
AD  - The Women's Brain Project (WBP), Guntershausen, Switzerland.
AD  - Wega Informatik AG, Aeschengraben 20, CH-4051 Basel, Switzerland.
FAU - Guney, Emre
AU  - Guney E
AUID- ORCID: 0000-0002-3466-6535
AD  - Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Research
      Institute and Pompeu Fabra University, Dr. Aiguader, 88, 08003 Barcelona,
      Spain.0000 0001 2172 2676grid.5612.0
FAU - Subirats, Laia
AU  - Subirats L
AUID- ORCID: 0000-0001-8646-5463
AD  - Eurecat - Centre Tecnologic de Catalunya, C/ Bilbao, 72, Edifici A, 08005
      Barcelona, Spain.
AD  - eHealth Center, Universitat Oberta de Catalunya, Rambla del Poblenou, 156, 08018 
      Barcelona, Spain.0000 0001 2171 6620grid.36083.3e
FAU - Mellino, Simona
AU  - Mellino S
AD  - The Women's Brain Project (WBP), Guntershausen, Switzerland.
FAU - Gigante, Annalisa
AU  - Gigante A
AD  - The Women's Brain Project (WBP), Guntershausen, Switzerland.
FAU - Valencia, Alfonso
AU  - Valencia A
AD  - Barcelona Supercomputing Center (BSC), C/ Jordi Girona, 29, 08034 Barcelona,
      Spain.0000 0004 0387 1602grid.10097.3f
AD  - ICREA, Pg. Lluis Companys 23, 08010 Barcelona, Spain.0000 0000 9601
      989Xgrid.425902.8
FAU - Rementeria, Maria Jose
AU  - Rementeria MJ
AD  - Barcelona Supercomputing Center (BSC), C/ Jordi Girona, 29, 08034 Barcelona,
      Spain.0000 0004 0387 1602grid.10097.3f
FAU - Chadha, Antonella Santuccione
AU  - Chadha AS
AD  - The Women's Brain Project (WBP), Guntershausen, Switzerland.
FAU - Mavridis, Nikolaos
AU  - Mavridis N
AD  - The Women's Brain Project (WBP), Guntershausen, Switzerland.
AD  - Interactive Robots and Media Laboratory (IRML), Abu Dhabi, United Arab Emirates.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200601
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7264169
OTO - NOTNLM
OT  - Biomarkers
OT  - Computational models
OT  - Medical ethics
OT  - Risk factors
COIS- Competing interestsThe authors declare no competing interests.
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.1038/s41746-020-0288-5 [doi]
AID - 288 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Jun 1;3:81. doi: 10.1038/s41746-020-0288-5. eCollection 2020.


PMID- 32529002
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2333-3936 (Electronic)
IS  - 2333-3936 (Linking)
VI  - 7
DP  - 2020 Jan-Dec
TI  - Ethics of Finitude: Nursing and the Palliative Approach in Geriatric and Forensic
      Psychiatry.
PG  - 2333393620913269
LID - 10.1177/2333393620913269 [doi]
AB  - There is a called-for shift to an upstream provision of palliative care as an
      overall care approach within a health equity perspective. Our research explored
      how nurses in psychiatry engage with aging patients and mortality to discern
      enactment of ethical dimensions of care. Drawing from tenets of interpretative
      phenomenological analysis, forensic and geriatric psychiatry registered nurses
      working at a mental health facility in eastern Ontario completed interviews for
      analysis. Nurses engaged with mortality through a process of recognition and
      through the affirmation of their values. The affirmed values are aligned with the
      palliative care approach and within an ethics of finitude lens in that their
      enactment is partly premised on the recognition of patients' accumulated losses
      related to human facticities (social, temporal, mortal). This research
      underscores preliminary insights on a process identifying care practices aligned 
      with the palliative approach and possibilities for expanding upon an ethics of
      finitude lens.
CI  - (c) The Author(s) 2020.
FAU - Skinner, Elise
AU  - Skinner E
AUID- ORCID: https://orcid.org/0000-0002-8013-6148
AD  - University of Ottawa, Ottawa, Ontario, Canada.
FAU - Jacob, Jean Daniel
AU  - Jacob JD
AD  - University of Ottawa, Ottawa, Ontario, Canada.
FAU - Vanderspank-Wright, Brandi
AU  - Vanderspank-Wright B
AD  - University of Ottawa, Ottawa, Ontario, Canada.
FAU - Wright, David Kenneth
AU  - Wright DK
AD  - University of Ottawa, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - Glob Qual Nurs Res
JT  - Global qualitative nursing research
JID - 101666563
PMC - PMC7262974
OTO - NOTNLM
OT  - caregivers
OT  - caretaking
OT  - death
OT  - dying
OT  - end-of-life issues
OT  - ethics
OT  - geriatrics
OT  - moral perspectives
OT  - nursing
OT  - palliative care
OT  - psychiatry
COIS- Declaration of Conflicting Interests: The authors declared no potential conflicts
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2019/10/27 00:00 [received]
PHST- 2020/01/31 00:00 [revised]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.1177/2333393620913269 [doi]
AID - 10.1177_2333393620913269 [pii]
PST - epublish
SO  - Glob Qual Nurs Res. 2020 May 28;7:2333393620913269. doi:
      10.1177/2333393620913269. eCollection 2020 Jan-Dec.


PMID- 32528940
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Toward Cardiac Regeneration: Combination of Pluripotent Stem Cell-Based Therapies
      and Bioengineering Strategies.
PG  - 455
LID - 10.3389/fbioe.2020.00455 [doi]
AB  - Cardiovascular diseases represent the major cause of morbidity and mortality
      worldwide. Multiple studies have been conducted so far in order to develop
      treatments able to prevent the progression of these pathologies. Despite progress
      made in the last decade, current therapies are still hampered by poor translation
      into actual clinical applications. The major drawback of such strategies is
      represented by the limited regenerative capacity of the cardiac tissue. Indeed,
      after an ischaemic insult, the formation of fibrotic scar takes place,
      interfering with mechanical and electrical functions of the heart. Hence, the
      ability of the heart to recover after ischaemic injury depends on several
      molecular and cellular pathways, and the imbalance between them results into
      adverse remodeling, culminating in heart failure. In this complex scenario, a new
      chapter of regenerative medicine has been opened over the past 20 years with the 
      discovery of induced pluripotent stem cells (iPSCs). These cells share the same
      characteristic of embryonic stem cells (ESCs), but are generated from
      patient-specific somatic cells, overcoming the ethical limitations related to ESC
      use and providing an autologous source of human cells. Similarly to ESCs, iPSCs
      are able to efficiently differentiate into cardiomyocytes (CMs), and thus hold a 
      real regenerative potential for future clinical applications. However, cell-based
      therapies are subjected to poor grafting and may cause adverse effects in the
      failing heart. Thus, over the last years, bioengineering technologies focused
      their attention on the improvement of both survival and functionality of
      iPSC-derived CMs. The combination of these two fields of study has burst the
      development of cell-based three-dimensional (3D) structures and organoids which
      mimic, more realistically, the in vivo cell behavior. Toward the same path, the
      possibility to directly induce conversion of fibroblasts into CMs has recently
      emerged as a promising area for in situ cardiac regeneration. In this review we
      provide an up-to-date overview of the latest advancements in the application of
      pluripotent stem cells and tissue-engineering for therapeutically relevant
      cardiac regenerative approaches, aiming to highlight outcomes, limitations and
      future perspectives for their clinical translation.
CI  - Copyright (c) 2020 Mazzola and Di Pasquale.
FAU - Mazzola, Marta
AU  - Mazzola M
AD  - Stem Cell Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
FAU - Di Pasquale, Elisa
AU  - Di Pasquale E
AD  - Stem Cell Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
AD  - Institute of Genetic and Biomedical Research (IRGB) - UOS of Milan, National
      Research Council (CNR), Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200527
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7266938
OTO - NOTNLM
OT  - 3D-culture system
OT  - bioengineering
OT  - cardiac regeneration
OT  - cardiomyocytes
OT  - cell therapy
OT  - induced pluripotent stem cells (iPSCs)
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.3389/fbioe.2020.00455 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 May 27;8:455. doi: 10.3389/fbioe.2020.00455.
      eCollection 2020.


PMID- 32528920
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Emerging Issues of Intelligent Assistive Technology Use Among People With
      Dementia and Their Caregivers: A U.S. Perspective.
PG  - 191
LID - 10.3389/fpubh.2020.00191 [doi]
AB  - The increasing number of older adults with cognitive deficits, including
      dementia, poses a major challenge for public health in the United States. At the 
      same time, the limited number of informal and professional caregivers available
      to support this rapidly growing population is of mounting concern. Not only does 
      population aging limit the number of potential caregivers, but extant caregivers 
      often lack skills to provide quality care. The integration of intelligent
      assistive technologies (IAT), including devices, robotics and sensors in many
      forms, into eldercare, may offer opportunities to reduce caregiver burden and
      enhance healthcare services while improving the quality of life among older
      adults with mild to severe cognitive deficits. However, many caregivers and their
      care recipients lack access to these technologies. The reasons for this reduced
      access are multifactorial, including the digital divide, sociocultural factors,
      and technological literacy. This mini review investigates the emerging use of IAT
      available to caregivers and older adults with cognitive deficits and explores the
      challenges in socioeconomic status and technological literacy as well as ethical 
      and legal implications that should be considered in the design and development of
      IAT for older adults with cognitive deficits. Drawing from existing literature,
      it will suggest frameworks for design and adoption aimed at increased and
      equitable access for this vulnerable population.
CI  - Copyright (c) 2020 Vollmer Dahlke and Ory.
FAU - Vollmer Dahlke, Deborah
AU  - Vollmer Dahlke D
AD  - DVD Associates LLC, Austin, TX, United States.
AD  - TX A&M Center for Population Health and Aging, College Station, TX, United
      States.
FAU - Ory, Marcia G
AU  - Ory MG
AD  - TX A&M Center for Population Health and Aging, College Station, TX, United
      States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200521
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Aged
MH  - Caregivers
MH  - *Cognitive Dysfunction/epidemiology
MH  - *Dementia/therapy
MH  - Humans
MH  - Quality of Life
MH  - *Self-Help Devices
MH  - United States
PMC - PMC7254691
OTO - NOTNLM
OT  - *agile design
OT  - *artificial intelligence
OT  - *cognitive deficits
OT  - *compassionate design
OT  - *digital divide
OT  - *intelligent assistive technologies
OT  - *robotics
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2019/10/20 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.3389/fpubh.2020.00191 [doi]
PST - epublish
SO  - Front Public Health. 2020 May 21;8:191. doi: 10.3389/fpubh.2020.00191.
      eCollection 2020.


PMID- 32528796
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2192-5682 (Print)
IS  - 2192-5682 (Linking)
VI  - 10
IP  - 2 Suppl
DP  - 2020 Apr
TI  - Teaching Training and Surgical Education in Minimally Invasive Surgery (MIS) of
      the Spine: What Are the Best Teaching and Learning Strategies for MIS? Do We Have
      Any Experience and Data?
PG  - 126S-129S
LID - 10.1177/2192568219875087 [doi]
AB  - STUDY DESIGN: Literature review and transversal study. OBJECTIVE: Advances in new
      technologies give the surgeons confidence to manage complex spine conditions with
      a lower morbidity rate. This has changed the expectations of patients and medical
      payers and foreshadows the shift now underway: the use of minimally invasive
      techniques. The ethical considerations of learning directly on patients require a
      change in the education and training programs. METHODS: The education paradigm
      has changed, and surgical training on minimally invasive surgery of the spine
      (MISS) techniques should follow a "curriculum." The assessment of skill
      proficiency while learning the MISS techniques must be measurable to objectively 
      show the performance gained over time and the changes that should be performed
      during training. Different strategies include "ex vivo" and "in vivo" training.
      RESULTS: We have worked on a curriculum in which the participants can perceive
      the growth in their knowledge through the different educational opportunities.
      There are 3 levels: basic, advanced, and masters. CONCLUSIONS: We developed an
      educational curriculum for MISS rationale and techniques, that showed to be
      effective and interesting in our region.
CI  - (c) The Author(s) 2019.
FAU - Falavigna, Asdrubal
AU  - Falavigna A
AD  - Caxias do Sul University, Caxias do Sul, Brazil.
FAU - Guiroy, Alfredo
AU  - Guiroy A
AUID- ORCID: https://orcid.org/0000-0001-9162-6508
AD  - Spanish Hospital, Mendoza, Argentina.
FAU - Taboada, Nestor
AU  - Taboada N
AD  - Clinica Portoazul, Barranquilla, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - Global Spine J
JT  - Global spine journal
JID - 101596156
PMC - PMC7263330
OTO - NOTNLM
OT  - minimally invasive spine surgery education
OT  - spine navigation
OT  - spine simulators
OT  - spine surgical education
OT  - spine virtual reality
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.1177/2192568219875087 [doi]
AID - 10.1177_2192568219875087 [pii]
PST - ppublish
SO  - Global Spine J. 2020 Apr;10(2 Suppl):126S-129S. doi: 10.1177/2192568219875087.
      Epub 2020 May 28.


PMID- 32528674
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 55
DP  - 2020 Jul
TI  - Changes in the disease-specific quality of life following Dor fundoplication. A
      multicentre cross-sectional study.
PG  - 252-255
LID - 10.1016/j.amsu.2020.05.018 [doi]
AB  - BACKGROUND: Gastrooesophageal reflux disease (GERD) is a spectrum of symptoms
      arising from the laxity of the cardio-oesophageal junction. Anti-reflux surgery
      is reserved for patients with refractory GERD. Anterior partial fundoplication
      (Dor) is a regularly performed anti-reflux surgery in Malaysia. We intend to
      determine the improvement in disease-specific quality of life in our patients
      after surgery. METHODS: A multicentre cross-sectional study was conducted to
      assess patients' improvement in disease-specific quality of life after Dor
      fundoplication. Ethics approval was obtained from our institutional review board.
      Patients between the ages of 18 and 65 years who underwent Dor fundoplication
      within the past five years were assessed using the GERD HRQL as well as the
      VISICK score via telephone interview. We excluded cases of revision surgery.
      RESULTS: Out of 129 patients screened, 55 patients were included. We found a
      significant improvement in patients' GERD HRQL score with the pre-operative mean 
      score of 28.3 +/- 9.39 and 6.55 +/- 8.52 post-operatively, p < 0.01.50.9% of
      patients reported a VISICK score of 1. However, we noticed a deterioration in the
      GERD HRQL and VISICK score in patients followed up four years after surgery. This
      consisted of 25.5% of total patients. CONCLUSION: Dor Fundoplication improves the
      overall disease-specific quality of life in patients with refractory GERD in the 
      short term period. Recurrence of symptoms causing a deterioration in the quality 
      of life is seen in patients followed up beyond four years of index surgery.
CI  - (c) 2020 The Authors.
FAU - Loo, Guo Hou
AU  - Loo GH
AD  - Surgical Trainee, Department of General Surgery, Faculty of Medicine, Universiti 
      Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, 56000,
      Kuala Lumpur, Malaysia.
FAU - Rajan, Reynu
AU  - Rajan R
AD  - Consultant Bariatric Surgeon Department of Surgery, Faculty of Medicine,
      Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, Bandar Tun
      Razak, 56000, Kuala Lumpur, Malaysia.
FAU - Deva Tata, Mahadevan
AU  - Deva Tata M
AD  - Consultant Upper Gastrointestinal & Bariatric SurgeonDepartment of Surgery,
      Tuanku Ja'afar Hospital Jalan Rasah, Bukit Rasah, Seremban, 70300, Negeri
      Sembilan, Malaysia.
FAU - Ritza Kosai, Nik
AU  - Ritza Kosai N
AD  - Consultant Upper Gastrointestinal & Bariatric Surgeon, Head of Unit of Upper
      Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Faculty
      of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, 
      Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7281361
OTO - NOTNLM
OT  - Anti-reflux surgery
OT  - Asian population
OT  - GERD HRQL questionnaire
OT  - Refractory GERD
OT  - VISICK Score
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.1016/j.amsu.2020.05.018 [doi]
AID - S2049-0801(20)30106-0 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 May 28;55:252-255. doi: 10.1016/j.amsu.2020.05.018.
      eCollection 2020 Jul.


PMID- 32528657
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20200729
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 9
DP  - 2020
TI  - Good news on the active management of pregnant cancer patients.
LID - F1000 Faculty Rev-487 [pii]
LID - 10.12688/f1000research.22472.1 [doi]
AB  - Cancer occurs in approximately 1/1000 to 1/2000 pregnancies and presents complex 
      medical and ethical dilemmas for patients and providers. The most common cancers 
      diagnosed in the gestational period include breast, cervical, melanoma, and
      lymphomas. The majority of existing evidence regarding the treatment of cancer
      during pregnancy is derived from experiences with breast cancer. Other cancers
      often pose unique challenges given the location of the tumors and their
      traditional mode of treatment with pelvic surgery and radiation. Additionally,
      many emerging therapies for cancer target mechanisms that are necessary for fetal
      development, such as angiogenesis, and are contraindicated in pregnant women.
      Although limitations on the treatment of cancer during pregnancy currently exist,
      increasing evidence shows that many surgical and systemic therapies can be
      effective for a mother's oncologic outcomes without significant detriment to the 
      developing fetus. Traditional perspectives of cancer during gestation may sway
      providers to encourage pregnancy termination, delays in therapy, or early
      delivery. However, recent studies and reviews discourage such practices. Although
      every cancer diagnosis in pregnancy requires an individualized approach and
      should use the multidisciplinary perspectives of maternal-fetal medicine
      specialists as well as medical and surgical oncologists, providers should feel
      empowered to safely employ systemic, surgical, and even reserved cases of
      radiation therapies for their pregnant patients with cancer. The aim of this
      review is to highlight some of the recent advances in cancer therapies for common
      cancer subtypes and encourage providers to use this growing body of evidence to
      employ treatments with curative intent while continuing to evaluate the long-term
      effects of these therapies on mothers and their children.
CI  - Copyright: (c) 2020 Folsom SM and Woodruff TK.
FAU - Folsom, Susan M
AU  - Folsom SM
AUID- ORCID: 0000-0002-0159-1282
AD  - Department of Obstetrics and Gynecology, Northwestern University, 250 East
      Superior Street, Suite 03-2303, Chicago, IL, 60611, USA.
FAU - Woodruff, Teresa K
AU  - Woodruff TK
AUID- ORCID: 0000-0002-1197-3399
AD  - Department of Obstetrics and Gynecology, Northwestern University, 250 East
      Superior Street, Suite 03-2303, Chicago, IL, 60611, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200601
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
SB  - IM
MH  - Breast Neoplasms
MH  - Female
MH  - Fetus
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Neoplastic/*therapy
PMC - PMC7265588
OTO - NOTNLM
OT  - *Cancer
OT  - *Chemotherapy
OT  - *Pregnancy
OT  - *Radiation
OT  - *Surgery
COIS- No competing interests were disclosed.No competing interests were disclosed.No
      competing interests were disclosed.No competing interests were disclosed.
EDAT- 2020/06/13 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
AID - 10.12688/f1000research.22472.1 [doi]
PST - epublish
SO  - F1000Res. 2020 Jun 1;9. doi: 10.12688/f1000research.22472.1. eCollection 2020.


PMID- 32528267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Linking)
VI  - 14
DP  - 2020
TI  - Characterizing Motor Control of Mastication With Soft Actor-Critic.
PG  - 188
LID - 10.3389/fnhum.2020.00188 [doi]
AB  - The human masticatory system is a complex functional unit characterized by a
      multitude of skeletal components, muscles, soft tissues, and teeth. Muscle
      activation dynamics cannot be directly measured on live human subjects due to
      ethical, safety, and accessibility limitations. Therefore, estimation of muscle
      activations and their resultant forces is a longstanding and active area of
      research. Reinforcement learning (RL) is an adaptive learning strategy which is
      inspired by the behavioral psychology and enables an agent to learn the dynamics 
      of an unknown system via policy-driven explorations. The RL framework is a
      well-formulated closed-loop system where high capacity neural networks are
      trained with the feedback mechanism of rewards to learn relatively complex
      actuation patterns. In this work, we are building on a deep RL algorithm, known
      as the Soft Actor-Critic, to learn the inverse dynamics of a simulated
      masticatory system, i.e., learn the activation patterns that drive the jaw to its
      desired location. The outcome of the proposed training procedure is a parametric 
      neural model which acts as the brain of the biomechanical system. We demonstrate 
      the model's ability to navigate the feasible three-dimensional (3D) envelope of
      motion with sub-millimeter accuracies. We also introduce a performance analysis
      platform consisting of a set of quantitative metrics to assess the
      functionalities of a given simulated masticatory system. This platform assesses
      the range of motion, metabolic efficiency, the agility of motion, the symmetry of
      activations, and the accuracy of reaching the desired target positions. We
      demonstrate how the model learns more metabolically efficient policies by
      integrating a force regularization term in the RL reward. We also demonstrate the
      inverse correlation between the metabolic efficiency of the models and their
      agility and range of motion. The presented masticatory model and the proposed RL 
      training mechanism are valuable tools for the analysis of mastication and other
      biomechanical systems. We see this framework's potential in facilitating the
      functional analyses aspects of surgical treatment planning and predicting the
      rehabilitation performance in post-operative subjects.
CI  - Copyright (c) 2020 Abdi, Sagl, Srungarapu, Stavness, Prisman, Abolmaesumi and
      Fels.
FAU - Abdi, Amir H
AU  - Abdi AH
AD  - Electrical and Computer Engineering Department, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Sagl, Benedikt
AU  - Sagl B
AD  - Department of Prosthodontics, University Clinic of Dentistry, Medical University 
      of Vienna, Vienna, Austria.
FAU - Srungarapu, Venkata P
AU  - Srungarapu VP
AD  - Electrical and Computer Engineering Department, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Stavness, Ian
AU  - Stavness I
AD  - Department of Computer Science, University of Saskatchewan, Saskatoon, SK,
      Canada.
FAU - Prisman, Eitan
AU  - Prisman E
AD  - Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
FAU - Abolmaesumi, Purang
AU  - Abolmaesumi P
AD  - Electrical and Computer Engineering Department, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Fels, Sidney
AU  - Fels S
AD  - Electrical and Computer Engineering Department, University of British Columbia,
      Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC7264096
OTO - NOTNLM
OT  - computational biomechanics
OT  - inverse dynamics
OT  - jaw
OT  - mastication modeling
OT  - motor control
OT  - musculoskeletal modeling
OT  - reinforcement learning
OT  - soft actor-critic
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2020/01/01 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - 10.3389/fnhum.2020.00188 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2020 May 26;14:188. doi: 10.3389/fnhum.2020.00188.
      eCollection 2020.


PMID- 32528178
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20210218
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 582
IP  - 7812
DP  - 2020 Jun
TI  - An in vitro model of early anteroposterior organization during human development.
PG  - 410-415
LID - 10.1038/s41586-020-2383-9 [doi]
AB  - The body plan of the mammalian embryo is shaped through the process of
      gastrulation, an early developmental event that transforms an isotropic group of 
      cells into an ensemble of tissues that is ordered with reference to three
      orthogonal axes(1). Although model organisms have provided much insight into this
      process, we know very little about gastrulation in humans, owing to the
      difficulty of obtaining embryos at such early stages of development and the
      ethical and technical restrictions that limit the feasibility of observing
      gastrulation ex vivo(2). Here we show that human embryonic stem cells can be used
      to generate gastruloids-three-dimensional multicellular aggregates that
      differentiate to form derivatives of the three germ layers organized
      spatiotemporally, without additional extra-embryonic tissues. Human gastruloids
      undergo elongation along an anteroposterior axis, and we use spatial
      transcriptomics to show that they exhibit patterned gene expression. This
      includes a signature of somitogenesis that suggests that 72-h human gastruloids
      show some features of Carnegie-stage-9 embryos(3). Our study represents an
      experimentally tractable model system to reveal and examine human-specific
      regulatory processes that occur during axial organization in early development.
FAU - Moris, Naomi
AU  - Moris N
AUID- ORCID: http://orcid.org/0000-0003-1910-5454
AD  - Department of Genetics, University of Cambridge, Cambridge, UK. nem33@cam.ac.uk.
FAU - Anlas, Kerim
AU  - Anlas K
AD  - Department of Genetics, University of Cambridge, Cambridge, UK.
AD  - European Molecular Biology Laboratory (EMBL) Barcelona, Barcelona, Spain.
FAU - van den Brink, Susanne C
AU  - van den Brink SC
AUID- ORCID: http://orcid.org/0000-0003-3683-7737
AD  - Oncode Institute, Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and 
      Sciences) and University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Alemany, Anna
AU  - Alemany A
AUID- ORCID: http://orcid.org/0000-0002-0795-0290
AD  - Oncode Institute, Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and 
      Sciences) and University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Schroder, Julia
AU  - Schroder J
AD  - Department of Genetics, University of Cambridge, Cambridge, UK.
AD  - Heidelberg University, Heidelberg, Germany.
FAU - Ghimire, Sabitri
AU  - Ghimire S
AD  - Department of Genetics, University of Cambridge, Cambridge, UK.
FAU - Balayo, Tina
AU  - Balayo T
AD  - Department of Genetics, University of Cambridge, Cambridge, UK.
AD  - Universidad de las Palmas de Gran Canaria (ULPGC), Las Palmas, Spain.
FAU - van Oudenaarden, Alexander
AU  - van Oudenaarden A
AUID- ORCID: http://orcid.org/0000-0002-9442-3551
AD  - Oncode Institute, Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and 
      Sciences) and University Medical Center Utrecht, Utrecht, The Netherlands.
      a.vanoudenaarden@hubrecht.eu.
FAU - Martinez Arias, Alfonso
AU  - Martinez Arias A
AUID- ORCID: http://orcid.org/0000-0002-1781-564X
AD  - Department of Genetics, University of Cambridge, Cambridge, UK.
      ama11@hermes.cam.ac.uk.
LA  - eng
GR  - MR/R017190/1/MRC_/Medical Research Council/United Kingdom
GR  - ERC_/European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200611
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - *Body Patterning/genetics
MH  - Gastrula/*cytology/embryology/metabolism
MH  - Gene Expression Regulation, Developmental
MH  - Human Embryonic Stem Cells/*cytology
MH  - Humans
MH  - In Vitro Techniques
MH  - Organoids/*cytology/*embryology/metabolism
MH  - Signal Transduction
MH  - Somites/*cytology/*embryology/metabolism
MH  - Transcriptome
EDAT- 2020/06/13 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/06/13 06:00
PHST- 2018/12/14 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1038/s41586-020-2383-9 [doi]
AID - 10.1038/s41586-020-2383-9 [pii]
PST - ppublish
SO  - Nature. 2020 Jun;582(7812):410-415. doi: 10.1038/s41586-020-2383-9. Epub 2020 Jun
      11.


PMID- 32527993
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20201218
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 Jun 12
TI  - [Influence of physical activity during outbreak on psychological states in adults
      in the Covid-19 pandemic: a study protocol.]
LID - e202006063 [pii]
AB  - This coronavirus pandemic has placed unprecedented restrictions on people's
      physical activity and routines. Prolonged home stays may lead to fear, panic,
      anxiety, and depression states, which in turn, can drive to a reduction of active
      lifestyles. Hence, determining the psychological response in the general
      population, and the influence level of home-based physical activity development
      could be relevant during this exceptional Covid-19 disease quarantine period. A
      multicenter, cross-sectional, and observational study design will be conducted in
      12 Iberoamerican countries expecting to enroll 3,096 participants, through a
      snowball sampling technique. The study started on March 15th, 2020, and it is
      expected to be completed in August 2020 through online survey that will include
      demographic data, health status, psychological impact of the Covid-19 outbreak,
      mental health status, and level of physical activity. This study will be
      conducted following the principles established by the protocol, the Declaration
      of Helsinki, and the Ethical Guidelines for Clinical Research. Data from the
      study will be disseminated in manuscripts for submission to peer-reviewed
      journals as well as in abstracts for submission to relevant conferences. Trial
      registration number: NCT04352517, pre-results.
FAU - Camacho-Cardenosa, Alba
AU  - Camacho-Cardenosa A
AD  - Facultad de Ciencias del Deporte. Universidad de Extremadura. Caceres. Espana.
FAU - Camacho-Cardenosa, Marta
AU  - Camacho-Cardenosa M
AD  - Facultad de Ciencias del Deporte. Universidad de Extremadura. Caceres. Espana.
FAU - Merellano-Navarro, Eugenio
AU  - Merellano-Navarro E
AD  - Facultad de Educacion. Universidad Autonoma de Chile. Talca. Chile.
FAU - Trape, Atila A
AU  - Trape AA
AD  - School of Physical Education and Sport of Ribeirao Preto. University of Sao
      Paulo. Riberao Preto. Brasil.
FAU - Brazo-Sayavera, Javier
AU  - Brazo-Sayavera J
AD  - Centro Universitario Regional Noreste. Universidad de la Republica. Rivera.
      Uruguay.
LA  - spa
SI  - ClinicalTrials.gov/NCT04352517
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
TT  - Influencia de la actividad fisica realizada durante el confinamiento en la
      pandemia del Covid-19 sobre el estado psicologico de adultos: un protocolo de
      estudio.
DEP - 20200612
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Protocols
MH  - Coronavirus Infections/epidemiology/*psychology
MH  - Cross-Sectional Studies
MH  - *Disease Outbreaks
MH  - Exercise/*psychology
MH  - Female
MH  - *Health Behavior
MH  - Health Status
MH  - Health Surveys
MH  - Humans
MH  - Latin America/epidemiology
MH  - Male
MH  - *Mental Health
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*psychology
MH  - Portugal/epidemiology
MH  - Quarantine/*psychology
MH  - SARS-CoV-2
MH  - Spain/epidemiology
OTO - NOTNLM
OT  - Coronavirus infection
OT  - Exercise
OT  - Mental Health
OT  - Methodology
OT  - Pandemics
OT  - Spain
EDAT- 2020/06/13 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 Jun 12;94.


PMID- 32527658
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20200915
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 3
DP  - 2020 Sep
TI  - Causal inference in perioperative medicine observational research: part 2,
      advanced methods.
PG  - 398-405
LID - S0007-0912(20)30302-0 [pii]
LID - 10.1016/j.bja.2020.03.032 [doi]
AB  - Although RCTs represent the gold standard in clinical research, most clinical
      questions cannot be answered using this technique, because of ethical
      considerations, time, and cost. The goal of observational research in clinical
      medicine is to gain insight into the relationship between a clinical exposure and
      patient outcome, in the absence of evidence from RCTs. Observational research
      offers additional benefit when compared with data from RCTs: the conclusions are 
      often more generalisable to a heterogenous population, which may be of greater
      value to everyday clinical practice. In Part 2 of this methods series, we will
      introduce the reader to several advanced methods for supporting the case for
      causality between an exposure and outcome, including: mediation analysis, natural
      experiments, and joint effects methods.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Krishnamoorthy, Vijay
AU  - Krishnamoorthy V
AD  - Critical Care and Perioperative Epidemiologic Research (CAPER) Unit, Department
      of Anesthesiology, Duke University Hospital, Durham, NC, USA. Electronic address:
      vijay.krishnamoorthy@duke.edu.
FAU - McLean, Duncan
AU  - McLean D
AD  - Department of Anesthesiology, University of North Carolina at Chapel Hill, Chapel
      Hill, NC, USA.
FAU - Ohnuma, Tetsu
AU  - Ohnuma T
AD  - Critical Care and Perioperative Epidemiologic Research (CAPER) Unit, Department
      of Anesthesiology, Duke University Hospital, Durham, NC, USA.
FAU - Harris, Steve K
AU  - Harris SK
AD  - Critical Care, University College London Hospitals NHS Foundation Trust, London, 
      UK.
FAU - Wong, Danny J N
AU  - Wong DJN
AD  - Department of Anaesthesia, Guy's and Saint Thomas' NHS Foundation Trust, London, 
      UK.
FAU - Wilson, Matt
AU  - Wilson M
AD  - Critical Care, University College London Hospitals NHS Foundation Trust, London, 
      UK.
FAU - Moonesinghe, Ramani
AU  - Moonesinghe R
AD  - Critical Care, University College London Hospitals NHS Foundation Trust, London, 
      UK.
FAU - Raghunathan, Karthik
AU  - Raghunathan K
AD  - Critical Care and Perioperative Epidemiologic Research (CAPER) Unit, Department
      of Anesthesiology, Duke University Hospital, Durham, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200503
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
MH  - Biomedical Research/*methods
MH  - Humans
MH  - Observational Studies as Topic/*methods
MH  - Perioperative Medicine/*methods
OTO - NOTNLM
OT  - *causal inference
OT  - *confounding
OT  - *epidemiology
OT  - *joint effects
OT  - *mediation analysis
OT  - *natural experiment
OT  - *observational research
EDAT- 2020/06/13 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2020/02/28 00:00 [revised]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - S0007-0912(20)30302-0 [pii]
AID - 10.1016/j.bja.2020.03.032 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Sep;125(3):398-405. doi: 10.1016/j.bja.2020.03.032. Epub 2020 
      May 3.


PMID- 32527633
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1532-8481 (Electronic)
IS  - 8755-7223 (Linking)
VI  - 36
IP  - 3
DP  - 2020 May - Jun
TI  - Using complex adaptive systems theory to guide the transition to DNP nurse
      anesthesia education.
PG  - 123-127
LID - S8755-7223(19)30171-1 [pii]
LID - 10.1016/j.profnurs.2019.10.004 [doi]
AB  - The opportunities and challenges when transitioning from a master's to DNP in
      nurse anesthesia education are complemented by using a complex adaptive system
      (CAS) theory to guide the curricula modifications. Major functional changes
      included reorganizing the curriculum to incorporate AACN DNP Essentials, COA
      competencies and integrating the scholarly work of a DNP improvement project.
      These changes were infused while balancing the intensive clinical requirements of
      a nurse anesthesia curriculum. Highlights in the DNP curriculum included the
      driving theory of complex systems, ethical values, leadership development,
      evidence-based practice and adaptation to emergent situations found in nurse
      anesthesia practice. Goals were to produce a DNP graduate that is more reliant on
      strategy and vision rather than only tasks or operations. Using the CAS framework
      enabled our program to transition and prepare DNP graduates to contribute to
      improved organizational effectiveness and understand the importance of leading
      change to positively impact patient outcomes.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Starnes-Ott, Kristen
AU  - Starnes-Ott K
AD  - University of South Carolina, College of Nursing, 1601 Greene St, Suite 214,
      Columbia, SC 29208, United States of America. Electronic address:
      Starnes2@mailbox.sc.edu.
FAU - Arnaud, Myron
AU  - Arnaud M
AD  - University of Texas Health Science Center at Houston, School of Nursing, 6901
      Bertner Ave. SON 664, Houston, TX 77030, United States of America. Electronic
      address: Myron.H.Arnaud@uth.tmc.edu.
FAU - Rooney, Laura
AU  - Rooney L
AD  - Independent education consultant.
FAU - Lewis, Matthew
AU  - Lewis M
AD  - University of Texas Health Science Center at Houston, School of Nursing, 6901
      Bertner Ave. SON 647, Houston, TX 77030, United States of America. Electronic
      address: Matthew.M.Lewis@uth.tmc.edu.
LA  - eng
PT  - Journal Article
DEP - 20191031
PL  - United States
TA  - J Prof Nurs
JT  - Journal of professional nursing : official journal of the American Association of
      Colleges of Nursing
JID - 8511298
SB  - IM
MH  - Anesthesia/*standards
MH  - Curriculum/*standards
MH  - Education, Nursing, Graduate/*organization & administration
MH  - Efficiency, Organizational
MH  - Evidence-Based Practice
MH  - Humans
MH  - Leadership
MH  - Nurse Practitioners/*education
MH  - Nursing Theory
MH  - *Systems Theory
EDAT- 2020/06/13 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/03/17 00:00 [received]
PHST- 2019/10/10 00:00 [revised]
PHST- 2019/10/25 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - S8755-7223(19)30171-1 [pii]
AID - 10.1016/j.profnurs.2019.10.004 [doi]
PST - ppublish
SO  - J Prof Nurs. 2020 May - Jun;36(3):123-127. doi: 10.1016/j.profnurs.2019.10.004.
      Epub 2019 Oct 31.


PMID- 32527473
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20201020
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 5
DP  - 2020 Jun
TI  - The Family Attitudes of Patients With End-Stage Renal Disease Toward Living
      Kidney Donation in China.
PG  - 1360-1364
LID - S0041-1345(19)31616-1 [pii]
LID - 10.1016/j.transproceed.2020.03.025 [doi]
AB  - BACKGROUND: Organ shortages limit the progress of organ transplantation. The
      family attitudes of patients with end-stage renal disease (ESRD) play an
      important role in advocating organ transplantation and donation. The purpose of
      this study was to analyze the family attitudes of patients with ESRD toward
      living kidney donation in China. Ethical approval was obtained from the ethics
      committee of Linyi People's Hospital. This study was performed in compliance with
      the Declaration of Helsinki. MATERIALS AND METHODS: This research was performed
      at 5 third-level hospitals with hemodialysis and nephrology departments, and a
      small section comes from urology departments. The participants were surveyed from
      January to November 2018. Attitudes were evaluated using a validated
      questionnaire concerning the psychosocial aspects of organ donation. The
      self-administered questionnaire was completed anonymously. Statistical analyses
      employed t tests and the chi(2) test. RESULTS: Regarding living kidney donation, 
      69.1% (n = 428) of patient families favored it; however, only 30.9% (n = 192) did
      not support it. A favorable attitude toward living donation was mainly associated
      with the following variables: 1. the recipient is not more than 50 years old; 2. 
      the recipient is a member of the immediate family; 3. the living donation is from
      the recipient's family member; 4. the family has previous personal experience
      with organ transplantation and donation; and 5. the family has a concern about
      the possibility of needing a transplant within the family unit (P < .05).
      CONCLUSIONS: Economic burden and mental stress from long-term dialysis influenced
      the attitudes and behavioral intentions of the families of patients with ESRD on 
      advocating organ donation. Repeated education and constant advocacy are advised
      to increase the participation of families of patients with ESRD in organ
      donation. The results showed favorable attitudes toward living kidney donation
      among the families of patients with ESRD.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Zhang, Zhen
AU  - Zhang Z
AD  - Department of Blood Purification &Transplantation, Qilu Hospital, Shandong
      University, Jinan, Shandong, China; Department of Urology, The People's Hospital 
      of Linyi, Linyi, Shandong, China.
FAU - Yuan, Xuemin
AU  - Yuan X
AD  - Department of Gastroenterology, The People's Hospital of Linyi, Linyi, Shandong, 
      China.
FAU - Wu, Yijin
AU  - Wu Y
AD  - School of Translation Studies, Center for Medical Humanities in the Developing
      World, Qufu Normal University, Rizhao, China.
FAU - Guo, Fengfu
AU  - Guo F
AD  - Department of Urology, The People's Hospital of Linyi, Linyi, Shandong, China.
FAU - Tian, Jun
AU  - Tian J
AD  - Department of Blood Purification &Transplantation, Qilu Hospital, Shandong
      University, Jinan, Shandong, China. Electronic address: juntianqlyy@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Adult
MH  - China
MH  - Family/*psychology
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Kidney Failure, Chronic
MH  - Kidney Transplantation/*psychology
MH  - Living Donors/*psychology
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - *Tissue and Organ Procurement
EDAT- 2020/06/13 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2019/12/29 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - S0041-1345(19)31616-1 [pii]
AID - 10.1016/j.transproceed.2020.03.025 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Jun;52(5):1360-1364. doi:
      10.1016/j.transproceed.2020.03.025. Epub 2020 Jun 8.


PMID- 32527400
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20210212
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 75
IP  - 23
DP  - 2020 Jun 16
TI  - The 4 Dimensions of Heart Allocation in an Increasingly Complex Universe.
PG  - 2917-2920
LID - S0735-1097(20)35162-7 [pii]
LID - 10.1016/j.jacc.2020.04.061 [doi]
FAU - Shah, Ashish S
AU  - Shah AS
AD  - Department of Cardiac Surgery and Division of Cardiology, Advanced Heart Disease,
      Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. Electronic
      address: Ashish.shah@vumc.org.
FAU - Stevenson, Lynne Warner
AU  - Stevenson LW
AD  - Department of Cardiac Surgery and Division of Cardiology, Advanced Heart Disease,
      Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. Electronic
      address: Lynne.w.stevenson@vumc.org.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
SB  - IM
CON - J Am Coll Cardiol. 2020 Jun 16;75(23):2892-2905. PMID: 32527398
CON - J Am Coll Cardiol. 2020 Jun 16;75(23):2906-2916. PMID: 32527399
CIN - J Am Coll Cardiol. 2020 Nov 24;76(21):2575-2576. PMID: 33213738
MH  - *Heart Transplantation
MH  - *Heart-Assist Devices
MH  - Humans
OTO - NOTNLM
OT  - *ethics
OT  - *heart failure
OT  - *heart transplantation
OT  - *mechanical circulatory support
EDAT- 2020/06/13 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - S0735-1097(20)35162-7 [pii]
AID - 10.1016/j.jacc.2020.04.061 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2020 Jun 16;75(23):2917-2920. doi: 10.1016/j.jacc.2020.04.061.


PMID- 32527399
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210617
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 75
IP  - 23
DP  - 2020 Jun 16
TI  - Practice Changes at U.S. Transplant Centers After the New Adult Heart Allocation 
      Policy.
PG  - 2906-2916
LID - S0735-1097(20)35025-7 [pii]
LID - 10.1016/j.jacc.2020.01.066 [doi]
AB  - BACKGROUND: In October 2018, the U.S. heart allocation system expanded the number
      of priority "status" tiers from 3 to 6 and added cardiogenic shock requirements
      for some heart transplant candidates listed with specific types of treatments.
      OBJECTIVES: This study sought to determine the impact of the new policy on the
      treatment practices of transplant centers. METHODS: Initial listing data on all
      adult heart candidates listed from December 1, 2017 to April 30, 2019 were
      collected from the Scientific Registry of Transplant Recipients. The
      status-qualifying treatments (or exception requests) and hemodynamic values at
      listing of a post-policy cohort (December 2018 to April 2019) were compared with 
      a seasonally matched pre-policy cohort (December 2017 to April 2018). Candidates 
      in the pre-policy cohort were reclassified into the new priority system statuses 
      by using treatment, diagnosis, and hemodynamics. RESULTS: Comparing the
      post-policy cohort (N = 1,567) with the pre-policy cohort (N = 1,606), there were
      significant increases in listings with extracorporeal membrane oxygenation
      (+1.2%), intra-aortic balloon pumps (+ 4 %), and exceptions (+ 12%). Listings
      with low-dose inotropes (-18%) and high-dose inotropes (-3%) significantly
      decreased. The new priority status distribution had more status 2 (+14%)
      candidates than expected and fewer status 3 (-5%), status 4 (- 4%) and status 6
      (-8%) candidates than expected (p values <0.01 for all comparisons). CONCLUSIONS:
      After implementation of the new heart allocation policy, transplant centers
      listed more candidates with extracorporeal membrane oxygenation, intra-aortic
      balloon pumps, and exception requests and fewer candidates with inotrope therapy 
      than expected, thus leading to significantly more high-priority status listings
      than anticipated. If these early trends persist, the new allocation system may
      not function as intended.
CI  - Copyright (c) 2020 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
FAU - Parker, William F
AU  - Parker WF
AD  - Department of Medicine, University of Chicago, Chicago, Illinois; MacLean Center 
      for Clinical Medical Ethics, University of Chicago, Chicago, Illinois. Electronic
      address: william.parker@uchospitals.edu.
FAU - Chung, Kevin
AU  - Chung K
AD  - Pritzker School of Medicine, University of Chicago, Chicago, Illinois.
FAU - Anderson, Allen S
AU  - Anderson AS
AD  - Department of Medicine, Northwestern University, Chicago Illinois.
FAU - Siegler, Mark
AU  - Siegler M
AD  - MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago,
      Illinois.
FAU - Huang, Elbert S
AU  - Huang ES
AD  - Department of Medicine, University of Chicago, Chicago, Illinois; MacLean Center 
      for Clinical Medical Ethics, University of Chicago, Chicago, Illinois.
FAU - Churpek, Matthew M
AU  - Churpek MM
AD  - Department of Medicine, Wisconsin University, Madison, Wisconsin.
LA  - eng
GR  - K08 HL150291/HL/NHLBI NIH HHS/United States
GR  - K24 DK105340/DK/NIDDK NIH HHS/United States
GR  - K24 AG069080/AG/NIA NIH HHS/United States
GR  - P30 DK092949/DK/NIDDK NIH HHS/United States
GR  - R01 GM123193/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Cardiotonic Agents)
SB  - IM
CIN - J Am Coll Cardiol. 2020 Jun 16;75(23):2917-2920. PMID: 32527400
MH  - Adult
MH  - Cardiotonic Agents/therapeutic use
MH  - Extracorporeal Membrane Oxygenation
MH  - Female
MH  - Heart Failure/*therapy
MH  - *Heart Transplantation
MH  - Humans
MH  - Intra-Aortic Balloon Pumping
MH  - Male
MH  - Middle Aged
MH  - *Registries
MH  - *Tissue and Organ Procurement
MH  - *Waiting Lists
PMC - PMC7304520
MID - NIHMS1586009
OTO - NOTNLM
OT  - *allocation
OT  - *ethics
OT  - *heart transplantation
EDAT- 2020/06/13 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/01/23 00:00 [revised]
PHST- 2020/01/27 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
AID - S0735-1097(20)35025-7 [pii]
AID - 10.1016/j.jacc.2020.01.066 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2020 Jun 16;75(23):2906-2916. doi: 10.1016/j.jacc.2020.01.066.


PMID- 32527259
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 2045-709X (Electronic)
IS  - 2045-709X (Linking)
VI  - 28
IP  - 1
DP  - 2020 Jun 11
TI  - Vitalism in contemporary chiropractic: a help or a hinderance?
PG  - 35
LID - 10.1186/s12998-020-00307-8 [doi]
AB  - BACKGROUND: Chiropractic emerged in 1895 and was promoted as a viable health care
      substitute in direct competition with the medical profession. This was an era
      when there was a belief that one cause and one cure for all disease would be
      discovered. The chiropractic version was a theory that most diseases were caused 
      by subluxated (slightly displaced) vertebrae interfering with "nerve vibrations" 
      (a supernatural, vital force) and could be cured by adjusting (repositioning)
      vertebrae, thereby removing the interference with the body's inherent capacity to
      heal. DD Palmer, the originator of chiropractic, established chiropractic based
      on vitalistic principles. Anecdotally, the authors have observed that many
      chiropractors who overtly claim to be "vitalists" cannot define the term.
      Therefore, we sought the origins of vitalism and to examine its effects on
      chiropractic today. DISCUSSION: Vitalism arose out of human curiosity around the 
      biggest questions: Where do we come from? What is life? For some, life was
      derived from an unknown and unknowable vital force. For others, a vital force was
      a placeholder, a piece of knowledge not yet grasped but attainable. Developments 
      in science have demonstrated there is no longer a need to invoke vitalistic
      entities as either explanations or hypotheses for biological phenomena.
      Nevertheless, vitalism remains within chiropractic. In this examination of
      vitalism within chiropractic we explore the history of vitalism, vitalism within 
      chiropractic and whether a vitalistic ideology is compatible with the legal and
      ethical requirements for registered health care professionals such as
      chiropractors. CONCLUSION: Vitalism has had many meanings throughout the
      centuries of recorded history. Though only vaguely defined by chiropractors,
      vitalism, as a representation of supernatural force and therefore an untestable
      hypothesis, sits at the heart of the divisions within chiropractic and acts as an
      impediment to chiropractic legitimacy, cultural authority and integration into
      mainstream health care.
FAU - Simpson, J Keith
AU  - Simpson JK
AD  - College of Science, Health, Engineering and Education, Murdoch University, Perth,
      Western Australia.
FAU - Young, Kenneth J
AU  - Young KJ
AD  - School of Sport and Health Sciences, University of Central Lancashire, Preston,
      PR1 2HE, UK. kjyoung1@uclan.ac.uk.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200611
PL  - England
TA  - Chiropr Man Therap
JT  - Chiropractic & manual therapies
JID - 101551481
SB  - IM
MH  - Chiropractic/*history
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Terminology as Topic
MH  - Vitalism/*history
PMC - PMC7291741
OTO - NOTNLM
OT  - *Chiropractic
OT  - *Cultural authority
OT  - *Fiduciary duties
OT  - *Legitimacy
OT  - *Social contract
OT  - *Vitalism
EDAT- 2020/06/13 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/06/13 06:00
PHST- 2019/06/28 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1186/s12998-020-00307-8 [doi]
AID - 10.1186/s12998-020-00307-8 [pii]
PST - epublish
SO  - Chiropr Man Therap. 2020 Jun 11;28(1):35. doi: 10.1186/s12998-020-00307-8.


PMID- 32527255
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20201218
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 11
TI  - Predictors of fatality including radiographic findings in adults with COVID-19.
PG  - 146
LID - 10.1186/s12931-020-01411-2 [doi]
AB  - BACKGROUND: Older age and elevated d-dimer are reported risk factors for
      coronavirus disease 2019 (COVID-19). However, whether early radiographic change
      is a predictor of fatality remains unknown. METHODS: We retrospectively reviewed 
      records of all laboratory-confirmed patients admitted to a quarantine unit at
      Tongji Hospital, a large regional hospital in Wuhan, China, between January 31
      and March 5, 2020. Confirmed cases were defined by positive RT-PCR detection of
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in throat-swab
      specimens. Chest CT images were reviewed independently by two radiologists. The
      Tongji Hospital ethics committee approved this study. RESULTS: A total of 102
      patients were confirmed to have SARS-CoV-2 infection. As of March 25, 85
      confirmed patients were discharged, 15 died, and 2 remained hospitalized. When
      compared with survivors, non-survivors were older (median age, 69 [interquartile 
      range, 58-77] vs. 55 [44-66], p = 0.003), and more likely to have decreased
      lymphocyte count (0.5 vs. 0.9 x 10(9)/L, p = 0.006), elevated lactate
      dehydrogenase (LDH) (569.0 vs. 272.0 U/L, p < 0.001), elevated d-dimer (> 1
      mug/mL, 86% vs. 37%, p = 0.002) on admission. Older age and elevated LDH were
      independent risk factors for fatality in a multivariate regression model included
      the above variables. In a subset of patients with CT images within the first
      week, higher total severity score, and more involved lung lobes (5 involved
      lobes) in CT images within the first week were significantly associated with
      fatality. Moreover, in this subset of patients, higher total severity score was
      the only independent risk factor in a multivariate analysis incorporating the
      above mentioned variables. CONCLUSIONS: Older age, elevated LDH on admission, and
      higher severity score of CT images within the first week are potential predictors
      of fatality in adults with COVID-19. These predictors may help clinicians
      identify patients with a poor prognosis at an early stage.
FAU - Li, Kaiyan
AU  - Li K
AD  - Division of Respiratory and Critical Care Medicine, Department of Internal
      Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science
      and Technology, Wuhan, 430030, China.
AD  - Key Laboratory of Respiratory Diseases, National Health Commission of People's
      Republic of China, Wuhan, China.
FAU - Chen, Dian
AU  - Chen D
AD  - Division of Respiratory and Critical Care Medicine, Department of Internal
      Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science
      and Technology, Wuhan, 430030, China.
AD  - Key Laboratory of Respiratory Diseases, National Health Commission of People's
      Republic of China, Wuhan, China.
FAU - Chen, Shengchong
AU  - Chen S
AD  - Division of Respiratory and Critical Care Medicine, Department of Internal
      Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science
      and Technology, Wuhan, 430030, China.
AD  - Key Laboratory of Respiratory Diseases, National Health Commission of People's
      Republic of China, Wuhan, China.
FAU - Feng, Yuchen
AU  - Feng Y
AD  - Division of Respiratory and Critical Care Medicine, Department of Internal
      Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science
      and Technology, Wuhan, 430030, China.
AD  - Key Laboratory of Respiratory Diseases, National Health Commission of People's
      Republic of China, Wuhan, China.
FAU - Chang, Chenli
AU  - Chang C
AD  - Division of Respiratory and Critical Care Medicine, Department of Internal
      Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science
      and Technology, Wuhan, 430030, China.
AD  - Key Laboratory of Respiratory Diseases, National Health Commission of People's
      Republic of China, Wuhan, China.
FAU - Wang, Zi
AU  - Wang Z
AD  - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan, 430030, China.
FAU - Wang, Nan
AU  - Wang N
AD  - Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan, 430030, China.
FAU - Zhen, Guohua
AU  - Zhen G
AD  - Division of Respiratory and Critical Care Medicine, Department of Internal
      Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science
      and Technology, Wuhan, 430030, China. ghzhen@tjh.tjmu.edu.cn.
AD  - Key Laboratory of Respiratory Diseases, National Health Commission of People's
      Republic of China, Wuhan, China. ghzhen@tjh.tjmu.edu.cn.
LA  - eng
GR  - 81670019, 91742108/National Natural Science Foundation of China
GR  - 2016YFC1304400/National Key Research and Development Program of China
PT  - Comparative Study
PT  - Journal Article
DEP - 20200611
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - COVID-19
MH  - COVID-19 Testing
MH  - China
MH  - Clinical Laboratory Techniques/*methods
MH  - Coronavirus Infections/diagnosis/*diagnostic imaging/*mortality/prevention &
      control/therapy
MH  - Databases, Factual
MH  - Disease Progression
MH  - Female
MH  - Hospital Mortality/*trends
MH  - Hospitalization/statistics & numerical data
MH  - Hospitals, Public
MH  - Humans
MH  - Intensive Care Units
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Pneumonia, Viral/*diagnostic imaging/*mortality/prevention & control/therapy
MH  - Predictive Value of Tests
MH  - Radiography, Thoracic/*methods
MH  - Real-Time Polymerase Chain Reaction/methods
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Survival Analysis
PMC - PMC7289230
OTO - NOTNLM
OT  - COVID-19
OT  - Fatality
OT  - Predictor
OT  - Radiographic findings
EDAT- 2020/06/13 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - 10.1186/s12931-020-01411-2 [doi]
AID - 10.1186/s12931-020-01411-2 [pii]
PST - epublish
SO  - Respir Res. 2020 Jun 11;21(1):146. doi: 10.1186/s12931-020-01411-2.


PMID- 32527224
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 11
TI  - Patients' preferences in selecting family physician in primary health centers: a 
      qualitative-quantitative approach.
PG  - 107
LID - 10.1186/s12875-020-01181-2 [doi]
AB  - BACKGROUND: The role of family physicians (FPs) in the metropolitan area is
      critical in identifying risk factors for disease prevention/control and health
      promotion in various age groups. Understanding patients' preferences and
      interests in choosing a FP can be an effective and fundamental step in the
      success of this program. In this study factors affecting the FP selection by
      Iranian patients referred to health centers in the most populous areas in the
      south of Tehran were assessed and ranked. METHODS: A sequential mixed-method
      (qualitative-quantitative) triangulation approach was designed with three subject
      groups of patients, physicians, and health officials. The Framework method was
      used to analyze interviews transcribed verbatim. After implementing an iterative 
      thematic process, a 26-item quantitative questionnaire with high validity and
      reliability was drafted to evaluate the different factors. A convenient sampling 
      method was used to select 400 subjects on a population-based scale to
      quantitatively rank the most critical selection factors as a mean score of items.
      RESULTS: The selection factors were divided into six centralized codes, including
      FPs' ethics, individual, professional and performance factors; patients'
      underlying disease and individual health, and disease-related factors, office's
      location and management factors, democracy factors, economic factors, and social 
      factors. After filling out the questionnaires, the most important factors in
      selecting FP were a specialist degree in family medicine (FM) (4.49 +/- 0.70),
      performing accurate examinations with receiving a detailed medical history (4.43 
      +/- 0.68), and spending enough time to visit patients (4.28 +/- 0.75),
      respectively. However, the parameters such as being a fellow-citizen, being the
      same gender, and physician's appearance were of the least importance. CONCLUSION:
      There is a possibility to screen the most important factors affecting the FP
      choice through the combination of qualitative and quantitative studies. The first
      and last patients' priority was physicians' specialty in FM and being a
      fellow-citizen with them, respectively. The clinical and administrative
      healthcare systems should schedule the entire implementation process to oversee
      the doctor's professional commitment and setting the visit times of FP.
FAU - Khatami, Farnaz
AU  - Khatami F
AD  - Department of Community Medicine, Tehran University of Medical Sciences, Tehran, 
      Iran.
AD  - Department of Family Medicine, Ziaeian Hospital, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Shariati, Mohammad
AU  - Shariati M
AD  - Department of Community Medicine, Tehran University of Medical Sciences, Tehran, 
      Iran.
AD  - Department of Family Medicine, Ziaeian Hospital, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Khedmat, Leila
AU  - Khedmat L
AD  - Health Management Research Center, Baqiyatallah University of Medical Sciences,
      Tehran, Iran.
FAU - Bahmani, Maryam
AU  - Bahmani M
AUID- ORCID: 0000-0001-5775-1006
AD  - Department of Family Medicine, Ziaeian Hospital, Tehran University of Medical
      Sciences, Tehran, Iran. maryambah98@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
SB  - IM
MH  - Adult
MH  - *Ambulatory Care/psychology/statistics & numerical data
MH  - Choice Behavior
MH  - Clinical Competence/*standards
MH  - Continuity of Patient Care
MH  - *Family Practice/standards/statistics & numerical data
MH  - Female
MH  - Health Promotion/methods
MH  - Humans
MH  - Iran
MH  - Male
MH  - *Patient Acceptance of Health Care/psychology/statistics & numerical data
MH  - *Patient Preference/psychology/statistics & numerical data
MH  - Physician-Patient Relations/*ethics
MH  - *Physicians, Family/psychology/standards
MH  - Preventive Health Services/methods
MH  - Professional Practice Location
PMC - PMC7291526
OTO - NOTNLM
OT  - *Continuity of care
OT  - *Family physician
OT  - *Health seeking behavior
OT  - *Patient satisfaction
OT  - *Primary care
EDAT- 2020/06/13 06:00
MHDA- 2021/07/10 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
AID - 10.1186/s12875-020-01181-2 [doi]
AID - 10.1186/s12875-020-01181-2 [pii]
PST - epublish
SO  - BMC Fam Pract. 2020 Jun 11;21(1):107. doi: 10.1186/s12875-020-01181-2.


PMID- 32527204
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 2042-1834 (Electronic)
IS  - 0025-8172 (Linking)
VI  - 88
IP  - 1_suppl
DP  - 2020 Nov
TI  - Will medically-assisted suicide mean the rebirth of (clinical) ethics committees 
      in Italy?
PG  - 26-30
LID - 10.1177/0025817220923650 [doi]
AB  - The Italian Constitutional Court has held that, in certain specific
      circumstances, prosecution for assisted suicide, regulated by Article 580 of the 
      Criminal Code, is not compatible with the Constitution. The circumstances in
      question relate to individuals who are being kept alive by life-sustaining
      treatments, who are fully capable of taking free, informed decisions and are
      suffering from irreversible conditions that are a source of intolerable physical 
      or mental suffering. The Court has held that the Ethics Committees must assess a 
      request for assisted suicide made by an individual meeting these conditions. The 
      decision requires the identification of the Ethics Committee authorised to issue 
      authorisation in such cases and a guarantee that these Ethics Committees are able
      to deal with this type of issue. The Court's decision is an important opportunity
      to establish and promote clinical Ethics Committees, which are not nationally
      regulated in Italy and exist in very small numbers in only a few parts of the
      country.
FAU - Petrini, Carlo
AU  - Petrini C
AD  - Istituto Superiore di Sanita (Italian National Institute of Health), Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - Med Leg J
JT  - The Medico-legal journal
JID - 0412004
SB  - IM
MH  - Ethics Committees/*legislation & jurisprudence/*organization & administration
MH  - *Ethics Committees, Clinical
MH  - Humans
MH  - Italy
MH  - Suicide, Assisted/*ethics/*legislation & jurisprudence
OTO - NOTNLM
OT  - Ethics committees
OT  - legislation
OT  - medically-assisted suicide
EDAT- 2020/06/13 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/06/13 06:00
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2020/06/13 06:00 [entrez]
AID - 10.1177/0025817220923650 [doi]
PST - ppublish
SO  - Med Leg J. 2020 Nov;88(1_suppl):26-30. doi: 10.1177/0025817220923650. Epub 2020
      Jun 12.


PMID- 32526900
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 9
TI  - Legal and Ethical Aspects of 'Best Interests' Decision-Making for Medical
      Treatment of Companion Animals in the UK.
LID - E1009 [pii]
LID - 10.3390/ani10061009 [doi]
AB  - Medical decisions for young children are made by those with parental
      responsibility, with legal involvement only if the decision is potentially
      detrimental to the child's welfare. While legally classified as property, some
      argue that animals are in a similar position to children; treatment decisions are
      made by their owners, posing a legal challenge only if the proposed treatment has
      the potential to cause harm or unnecessary suffering, as defined by animal
      protection legislation. This paper formulates the approach to a 'best interests' 
      calculation, utilising the factors included in the United Nations Convention on
      the Rights of the Child and relying on exchange of information between the human 
      parties involved. Although this form of decision-making must primarily protect
      the animal from unnecessary suffering, it recognises that the information
      provided by the owner is critical in articulating the animal's non-medical
      interests, and hence in formulating what is in the animal's best overall welfare 
      interests. While statute law does not mandate consideration of 'best interests'
      for animals, this approach might reasonably be expected as a professional
      imperative for veterinary surgeons. Importantly, this version of a 'best
      interests' calculation can be incorporated into existing ethical frameworks for
      medical decision-making and the humane treatment of animals.
FAU - Gray, Carol
AU  - Gray C
AUID- ORCID: 0000-0002-1800-4574
AD  - School of Law and Social Justice, University of Liverpool, Liverpool L69 7ZR, UK.
FAU - Fordyce, Peter
AU  - Fordyce P
AD  - Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES,
      UK.
LA  - eng
GR  - ES/T009136/1/Economic and Social Research Council
PT  - Journal Article
DEP - 20200609
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7341271
OTO - NOTNLM
OT  - best interests
OT  - companion animals
OT  - veterinary treatment
EDAT- 2020/06/13 06:00
MHDA- 2020/06/13 06:01
CRDT- 2020/06/13 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/06/01 00:00 [revised]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/13 06:01 [medline]
AID - ani10061009 [pii]
AID - 10.3390/ani10061009 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Jun 9;10(6). pii: ani10061009. doi: 10.3390/ani10061009.


PMID- 32526281
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Linking)
VI  - 95
DP  - 2020 Aug
TI  - Advances and challenges in conducting ethical trials involving populations
      lacking capacity to consent: A decade in review.
PG  - 106054
LID - S1551-7144(20)30132-4 [pii]
LID - 10.1016/j.cct.2020.106054 [doi]
AB  - Informed consent is an essential requirement prior to clinical trial
      participation, however some 'vulnerable' groups, such as people with cognitive
      impairments and those in medical emergency situations, may lack decisional
      capacity to consent. This raises ethical and practical challenges when designing 
      and conducting clinical trials involving these populations, who are frequently
      excluded as a result. Despite recent advances in improving informed consent
      processes, there has been far less attention paid to the enrolment of adults
      lacking capacity. Exclusion criteria are an important determinant of the external
      validity of clinical trial results. The exclusion of these populations, and
      consent-based recruitment biases which arise from the challenges of identifying
      and involving surrogate decision-makers, leads to trials which are not
      representative of the clinical population. This article discusses the involvement
      of adults who lack decisional capacity to consent in clinical trials and presents
      the advances over the previous decade and the remaining ethical challenges for
      the inclusion of this under-represented population in research.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Shepherd, Victoria
AU  - Shepherd V
AD  - Centre for Trials Research, 4th floor Neuadd Meirionnydd, Heath Park, Cardiff
      CF14 4YS, UK. Electronic address: ShepherdVL1@cardiff.ac.uk.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200608
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
SB  - IM
MH  - Adult
MH  - Bias
MH  - *Decision Making
MH  - Humans
MH  - *Informed Consent
PMC - PMC7832147
OTO - NOTNLM
OT  - *Clinical trials
OT  - *Ethics
OT  - *Informed consent
OT  - *Surrogate decision-making
EDAT- 2020/06/12 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - S1551-7144(20)30132-4 [pii]
AID - 10.1016/j.cct.2020.106054 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2020 Aug;95:106054. doi: 10.1016/j.cct.2020.106054. Epub
      2020 Jun 8.


PMID- 32526004
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1559-7776 (Electronic)
IS  - 1559-7768 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Jun 15
TI  - Widening the Ethical Lens in Critical Care Settings.
PG  - 210-220
LID - 10.4037/aacnacc2020265 [doi]
FAU - Meyer, Elaine C
AU  - Meyer EC
AD  - Elaine C. Meyer is Faculty Associate, Center for Bioethics, and Associate
      Professor of Psychology, Harvard Medical School, 641 Huntington Ave, Boston, MA
      02115 (elainecmeyer@gmail.com).
FAU - Carnevale, Franco A
AU  - Carnevale FA
AD  - Franco A. Carnevale is Full Professor, Ingram School of Nursing; Associate
      Member, Faculty of Medicine (Pediatrics); Adjunct Professor, Counselling
      Psychology; and Affiliate Member, Biomedical Ethics Unit, McGill University,
      Montreal, Canada.
FAU - Lillehei, Craig
AU  - Lillehei C
AD  - Craig Lillehei is Chair of Surgical Education, Boston Children's Hospital,
      Boston, Massachusetts.
FAU - Uveges, Melissa Kurtz
AU  - Uveges MK
AD  - Melissa Kurtz Uveges is Postdoctoral Research Fellow, Center for Bioethics,
      Harvard Medical School, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AACN Adv Crit Care
JT  - AACN advanced critical care
JID - 101269322
MH  - Adult
MH  - Critical Care/*ethics
MH  - *Curriculum
MH  - Education, Nursing, Continuing
MH  - Ethics, Medical/*education
MH  - Female
MH  - Health Personnel/*education
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Morals
MH  - United States
EDAT- 2020/06/12 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 31036 [pii]
AID - 10.4037/aacnacc2020265 [doi]
PST - ppublish
SO  - AACN Adv Crit Care. 2020 Jun 15;31(2):210-220. doi: 10.4037/aacnacc2020265.


PMID- 32525995
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1559-7776 (Electronic)
IS  - 1559-7768 (Linking)
VI  - 31
IP  - 2
DP  - 2020 Jun 15
TI  - Systems to Address Burnout and Support Well-being: Implications for Intensive
      Care Unit Nurses.
PG  - 141-145
LID - 10.4037/aacnacc2020771 [doi]
AB  - Burnout, a syndrome resulting from chronic job-related stress in the workplace,
      is an extensive problem among clinicians working in health care organizations.
      The 3 dimensions of burnout include emotional exhaustion, depersonalization, and 
      loss of a sense of professional efficacy. Approximately 35% of all nurses
      experience symptoms of burnout. Critical care nurses are at risk for chronic job 
      stress because of the complexity and pace of the critical care environment.
      Addressing the individual and systems-related factors that stem from the work
      environment is essential in order to achieve well-being among all clinicians.
      Strategies aimed at fostering individual resilience and well-being must be
      coupled with systemic solutions that create a work environment that removes
      impediments to ethically grounded practice, restores fulfillment achieved in
      clinical practice, and fosters resilience and well-being.
CI  - (c)2020 American Association of Critical-Care Nurses.
FAU - Rushton, Cynda Hylton
AU  - Rushton CH
AD  - Cynda Hylton Rushton is Anne and George L. Bunting Professor of Clinical Ethics, 
      Johns Hopkins University School of Nursing and Berman Institute of Bioethics, 525
      N Wolfe St, Box 420, Baltimore, MD 21205 (crushto1@jhu.edu).
FAU - Pappas, Sharon
AU  - Pappas S
AD  - Sharon Pappas is Chief Nurse Executive, Emory Healthcare, Atlanta, Georgia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AACN Adv Crit Care
JT  - AACN advanced critical care
JID - 101269322
MH  - Adult
MH  - Burnout, Professional/*prevention & control
MH  - Critical Care Nursing/*standards
MH  - Female
MH  - *Guidelines as Topic
MH  - Health Promotion/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stress, Psychological/*prevention & control
MH  - United States
OTO - NOTNLM
OT  - burnout
OT  - critical care
OT  - healthy work environments
OT  - system approaches
OT  - well-being
EDAT- 2020/06/12 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
AID - 31027 [pii]
AID - 10.4037/aacnacc2020771 [doi]
PST - ppublish
SO  - AACN Adv Crit Care. 2020 Jun 15;31(2):141-145. doi: 10.4037/aacnacc2020771.


PMID- 32525980
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210612
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 12
DP  - 2020 Nov 13
TI  - Addressing Ethical Challenges in US-Based HIV Phylogenetic Research.
PG  - 1997-2006
LID - 10.1093/infdis/jiaa107 [doi]
AB  - In recent years, phylogenetic analysis of HIV sequence data has been used in
      research studies to investigate transmission patterns between individuals and
      groups, including analysis of data from HIV prevention clinical trials, in
      molecular epidemiology, and in public health surveillance programs. Phylogenetic 
      analysis can provide valuable information to inform HIV prevention efforts, but
      it also has risks, including stigma and marginalization of groups, or potential
      identification of HIV transmission between individuals. In response to these
      concerns, an interdisciplinary working group was assembled to address ethical
      challenges in US-based HIV phylogenetic research. The working group developed
      recommendations regarding (1) study design; (2) data security, access, and
      sharing; (3) legal issues; (4) community engagement; and (5) communication and
      dissemination. The working group also identified areas for future research and
      scholarship to promote ethical conduct of HIV phylogenetic research.
CI  - Published by Oxford University Press for the Infectious Diseases Society of
      America 2020.
FAU - Dawson, Liza
AU  - Dawson L
AD  - Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
FAU - Benbow, Nanette
AU  - Benbow N
AD  - Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
FAU - Fletcher, Faith E
AU  - Fletcher FE
AD  - School of Public Health, University of Alabama at Birmingham, Birmingham,
      Alabama, USA.
FAU - Kassaye, Seble
AU  - Kassaye S
AD  - Georgetown University Medical Center, Washington, District of Columbia, USA.
FAU - Killelea, Amy
AU  - Killelea A
AD  - National Alliance of State and Territorial AIDS Directors, Washington, District
      of Columbia, USA.
FAU - Latham, Stephen R
AU  - Latham SR
AD  - Yale Interdisciplinary Center for Bioethics, New Haven, Connecticut, USA.
FAU - Lee, Lisa M
AU  - Lee LM
AD  - Virginia Tech, Blacksburg, Virginia, USA.
FAU - Leitner, Thomas
AU  - Leitner T
AD  - Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
FAU - Little, Susan J
AU  - Little SJ
AD  - University of California at San Diego, San Diego, California, USA.
FAU - Mehta, Sanjay R
AU  - Mehta SR
AD  - University of California at San Diego, San Diego, California, USA.
FAU - Martinez, Omar
AU  - Martinez O
AD  - Temple University, Philadelphia, Pennsylvania, USA.
FAU - Minalga, Brian
AU  - Minalga B
AD  - Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
FAU - Poon, Art
AU  - Poon A
AD  - University of Western Ontario, London, Ontario, Canada.
FAU - Rennie, Stuart
AU  - Rennie S
AD  - University of North Carolina, Chapel Hill, North Carolina, USA.
FAU - Sugarman, Jeremy
AU  - Sugarman J
AD  - Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Sweeney, Patricia
AU  - Sweeney P
AD  - Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
FAU - Torian, Lucia V
AU  - Torian LV
AD  - New York City Department of Health, New York, New York, USA.
FAU - Wertheim, Joel O
AU  - Wertheim JO
AD  - University of California at San Diego, San Diego, California, USA.
LA  - eng
GR  - P30 AI036214/AI/NIAID NIH HHS/United States
GR  - R01 AI087520/AI/NIAID NIH HHS/United States
GR  - R01 AI135946/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
SB  - IM
CIN - J Infect Dis. 2020 Nov 13;222(12):1939-1940. PMID: 32529243
MH  - Advisory Committees
MH  - Biomedical Research/*ethics
MH  - Community Participation
MH  - Computer Security/standards
MH  - Confidentiality/ethics/legislation & jurisprudence
MH  - HIV/*genetics
MH  - HIV Infections/*prevention & control/transmission
MH  - Humans
MH  - Information Dissemination/ethics/legislation & jurisprudence
MH  - National Institutes of Health (U.S.)
MH  - *Phylogeny
MH  - Public Health Surveillance
MH  - Research Design
MH  - United States/epidemiology
PMC - PMC7661760
OTO - NOTNLM
OT  - *HIV/AIDS
OT  - *ethics
OT  - *phylogenetics
OT  - *public health
EDAT- 2020/06/12 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/06/12 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 5856131 [pii]
AID - 10.1093/infdis/jiaa107 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Nov 13;222(12):1997-2006. doi: 10.1093/infdis/jiaa107.


PMID- 32525764
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 1347-6947 (Electronic)
IS  - 0916-8451 (Linking)
VI  - 84
IP  - 9
DP  - 2020 Sep
TI  - Elucidation of colon-protective efficacy of diosgenin in experimental
      TNBS-induced colitis: inhibition of NF-kappaB/IkB-alpha and Bax/Caspase-1
      signaling pathways.
PG  - 1903-1912
LID - 10.1080/09168451.2020.1776590 [doi]
AB  - The aim of present investigation was to elucidate the unrevealed beneficial role 
      of diosgenin against an experimental model of TNBS (2,4,6-trinitrobenzenesufonic 
      acid)-induced ulcerative colitis (UC). Colitis was induced in Sprague-Dawley rats
      by intrarectal administration of TNBS (in 50% ethanol). Then animals were treated
      with diosgenin (50, 100, and 200 mg/kg) for 14 days. Various biochemical,
      behavioral, molecular, and histological analysis was performed. Diosgenin
      significantly decreased (p < 0.05) TNBS-induced elevated colonic
      oxido-nitrosative damage, myeloperoxidase, hydroxyproline, mRNA expressions of
      proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, and IFN-gamma) and
      inflammatory markers (iNOs and COX-2) induced by TNBS. Western blot analysis
      relevated that TNBS-induced up-regulated protein expressions of NF-kappaB,
      IkappaBalpha, Bax, and Caspase-1 were markedly decreased (p < 0.05) by diosgenin 
      treatment. It also markedly ameliorated the histological insults induced in the
      colon by TNBS. In conclusion, diosgenin exerts its colon-protective efficacy
      probably through the inhibition of NF-kappaB/IkB-alpha and Bax/Caspase-1
      signaling pathways to experimental TNBS-induced ulcerative colitis.
      ABBREVIATIONS: ANOVA: Analysis of variance; 5-ASA: 5-aminosalicylic acid; Bax:
      Bcl-2-associated X protein; COX-2: Cyclooxygenase-2; DAI: Disease Activity Index;
      DMSO: Dimethyl sulfoxide; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; GSH:
      Glutathione; HP: Hydroxyproline; IAEC: International Animal Ethics Committee;
      IBD: Inflammatory Bowel Disease; IBS: Inflammatory Bowel Syndrome; IL's:
      Interleukin's; IFN-gamma: Interferon-gamma; IkappaBalpha: nuclear factor of kappa
      light polypeptide gene enhancer in B-cells inhibitor-alpha; iNOs: Inducible
      nitric oxide synthase; LTB4: Leukotriene B4; MDA: Malondialdehyde; MPO:
      Myeloperoxidase; NO: Nitric Oxide; NF-kappaB: Nuclear Factor-kappaB; ROS:
      Reactive Oxygen Species; SOD: Superoxide Dismutase; TNBS: Trinitrobenzene
      Sulfonic Acid; TNF-alpha: Tumor necrosis factor-alpha.
FAU - Tang, Xiaobo
AU  - Tang X
AD  - Gastroenterology Department, Nanchong Central Hospital, The Second Clinical
      Medical College, North Sichuan Medical , Nanchong, Sichuan, China.
FAU - Huang, Gengzhen
AU  - Huang G
AD  - Gastroenterology Department, Nanchong Central Hospital, The Second Clinical
      Medical College, North Sichuan Medical , Nanchong, Sichuan, China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Gastroenterology Department, Nanchong Central Hospital, The Second Clinical
      Medical College, North Sichuan Medical , Nanchong, Sichuan, China.
FAU - Li, Shiqing
AU  - Li S
AUID- ORCID: https://orcid.org/0000-0002-3462-1230
AD  - Gastroenterology Department, Nanchong Central Hospital, The Second Clinical
      Medical College, North Sichuan Medical , Nanchong, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - England
TA  - Biosci Biotechnol Biochem
JT  - Bioscience, biotechnology, and biochemistry
JID - 9205717
RN  - 0 (Biomarkers)
RN  - 0 (NF-kappa B)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - 8T3HQG2ZC4 (Trinitrobenzenesulfonic Acid)
RN  - EC 3.4.22.36 (Caspase 1)
RN  - K49P2K8WLX (Diosgenin)
SB  - IM
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Caspase 1/metabolism
MH  - Colitis/chemically induced/metabolism/*pathology
MH  - Colon/*drug effects/metabolism/*pathology
MH  - Cytoprotection/*drug effects
MH  - Diosgenin/*pharmacology
MH  - Disease Models, Animal
MH  - Male
MH  - NF-KappaB Inhibitor alpha/metabolism
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction/*drug effects
MH  - Trinitrobenzenesulfonic Acid/*adverse effects
MH  - bcl-2-Associated X Protein/metabolism
OTO - NOTNLM
OT  - Bax
OT  - NF-kappaB
OT  - TNBS
OT  - diosgenin
OT  - ulcerative colitis
EDAT- 2020/06/12 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1080/09168451.2020.1776590 [doi]
PST - ppublish
SO  - Biosci Biotechnol Biochem. 2020 Sep;84(9):1903-1912. doi:
      10.1080/09168451.2020.1776590. Epub 2020 Jun 11.


PMID- 32525721
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
VI  - 19
IP  - 3
DP  - 2020 Sep
TI  - Do's and Don'ts for a Good Reviewer of Scientific Papers: A Beginner's Brief
      Decalogue.
PG  - 227-229
LID - 10.1177/1534734620924349 [doi]
AB  - Peer review has been the principal way of evaluating scientific articles,
      ensuring that publications meet standards of methodology, integrity, and ethics. 
      Occasionally, however, reviews are suboptimal, especially those by inexperienced 
      reviewers. Therefore, this article offers suggestions on how to review a
      scientific article. Some of the most important suggestions include submitting the
      review in a timely fashion without undue delay, not breeching confidentiality,
      focusing mainly on the methodology, following specific format, and avoiding
      embarrassing comments to the authors.
FAU - Lazarides, Miltos K
AU  - Lazarides MK
AUID- ORCID: https://orcid.org/0000-0003-3458-7412
AD  - Democritus University Medical School, Alexandroupolis, Greece.
FAU - Georgiadis, George S
AU  - Georgiadis GS
AD  - Democritus University Medical School, Alexandroupolis, Greece.
FAU - Papanas, Nikolaos
AU  - Papanas N
AUID- ORCID: https://orcid.org/0000-0002-7320-785X
AD  - Democritus University Medical School, Alexandroupolis, Greece.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - United States
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
SB  - IM
MH  - Humans
MH  - *Medical Writing
MH  - Peer Review, Research/ethics/*methods/standards
MH  - *Publications/ethics/standards
MH  - Publishing
OTO - NOTNLM
OT  - medical writing
OT  - paper
OT  - recommendations
OT  - reviewer
EDAT- 2020/06/12 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1177/1534734620924349 [doi]
PST - ppublish
SO  - Int J Low Extrem Wounds. 2020 Sep;19(3):227-229. doi: 10.1177/1534734620924349.
      Epub 2020 Jun 11.


PMID- 32525355
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1939-0602 (Electronic)
IS  - 1091-7527 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Jun
TI  - Collaborative patient- and family-centered care for hospitalized individuals:
      Best practices for hospitalist care teams.
PG  - 200-208
LID - 10.1037/fsh0000479 [doi]
AB  - Traditionally, hospital medicine services have been dominated by the physician
      and hospital team, with significant barriers to patient- and family-centered
      care. This article offers principles and associated strategies to reduce those
      barriers and guide implementation of systemically informed, collaborative, and
      culturally responsive patient- and family-centered care provided by hospitalist
      care teams, especially regarding collaborative decision-making for treatment and 
      discharge planning. Such an approach is associated with reduced lengths of stay
      and hospital costs and lowered rates of medical errors and mortality. It also is 
      linked to improved patient and family cooperation and adherence; enhanced quality
      of care and clinical outcomes; and increased levels of satisfaction among health 
      care professionals, patients, and families. Such care uses resources wisely and
      is effective and ethical. We hope articulating and illustrating these principles 
      and strategies will facilitate efforts to shift the health care culture from
      being physician-centered to truly team-, patient-, and family-centered. (PsycInfo
      Database Record (c) 2020 APA, all rights reserved).
FAU - Kaslow, Nadine J
AU  - Kaslow NJ
AUID- ORCID: 0000-0003-0775-8597
AD  - Department of Psychiatry and Behavioral Sciences.
FAU - Dunn, Sarah E
AU  - Dunn SE
AD  - Department of Psychiatry and Behavioral Sciences.
FAU - Henry, Tracey
AU  - Henry T
AD  - Department of Medicine.
FAU - Partin, Clyde
AU  - Partin C
AD  - Department of Medicine.
FAU - Newsome, Janice
AU  - Newsome J
AD  - Department of Radiology.
FAU - O'Donnell, Christopher
AU  - O'Donnell C
AD  - Department of Medicine.
FAU - Wierson, Marsha
AU  - Wierson M
AD  - Emory Healthcare.
FAU - Schwartz, Ann C
AU  - Schwartz AC
AD  - Department of Psychiatry and Behavioral Sciences.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fam Syst Health
JT  - Families, systems & health : the journal of collaborative family healthcare
JID - 9610836
SB  - IM
CIN - Fam Syst Health. 2020 Jun;38(2):209-211. PMID: 32525356
MH  - Communication
MH  - *Cooperative Behavior
MH  - Hospitalists/psychology/*standards/statistics & numerical data
MH  - Hospitalization
MH  - Humans
MH  - Patient-Centered Care/*methods/standards/statistics & numerical data
MH  - *Physician-Patient Relations
MH  - Practice Guidelines as Topic
MH  - Quality Improvement
EDAT- 2020/06/12 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
AID - 2020-40858-010 [pii]
AID - 10.1037/fsh0000479 [doi]
PST - ppublish
SO  - Fam Syst Health. 2020 Jun;38(2):200-208. doi: 10.1037/fsh0000479.


PMID- 32525287
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 23
IP  - 7
DP  - 2020 Jul
TI  - Cross-culture adaptation and validation of English version of Rheumatoid
      Arthritis Knowledge Assessment Scale (RAKAS) in patients with rheumatoid
      arthritis.
PG  - 918-927
LID - 10.1111/1756-185X.13860 [doi]
AB  - AIM: To carry out cross-culture adaptation and validation of the English version 
      of Rheumatoid Arthritis Knowledge Assessment Scale (RAKAS) in patients with
      rheumatoid arthritis (RA). METHODS: A cross-sectional study was conducted for 2
      months in 2 tertiary care hospitals in Karachi, Pakistan. Sample size was
      calculated based on item-subject ratio. The translation was carried out using
      standard procedures for translation and cross-culture adaptation. The validation 
      process included estimation of discrimination power, item difficulty index,
      factorial, convergent, construct and known group validities and reliability.
      Reliability of the scale was estimated using Kuder-Richardson Formula 20 and a
      value of sigma(2) >/= 0.6 was acceptable. SPSS v23, Remark Classic OMR v6
      software and MedCalc Statistical Software v16.4.3, were used to analyze the data.
      The study was approved by the relevant ethics committee (IRB#NOV:15). RESULTS:
      The mean score was 7.68 +/- 2.52 (95% CI: 7.31-8.05) for 177 patients. The
      sigma(2) = 0.601, that is, >0.6, test-retest reliability rho = .753, P < .05. The
      average discrimination power = 47.27, average Item Difficulty Index = 0.557. The 
      fit indices were acceptable in a range that established its factorial validity
      and average factor loading was >/=0.7 which established convergent validity. A
      significant association (chi(2) = 33.074, P < .01) between score interpretation
      and previous counseling by pharmacists established its construct validity. A
      significant association (chi(2) = 19.113, P < .05) between score interpretation
      and patient occupation established known group validity. CONCLUSION: The English 
      version of RAKAS was deemed a reliable and validated tool to measure knowledge
      about disease in Pakistani patients with RA.
CI  - (c) 2020 Asia Pacific League of Associations for Rheumatology and John Wiley &
      Sons Australia, Ltd.
FAU - Naqvi, Atta Abbas
AU  - Naqvi AA
AUID- ORCID: https://orcid.org/0000-0003-4848-6807
AD  - Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman
      Bin Faisal University, Dammam, Saudi Arabia.
FAU - Hassali, Mohamed Azmi
AU  - Hassali MA
AD  - Discipline of Social and Administrative Pharmacy, School of Pharmaceutical
      Sciences, Universiti Sains Malaysia, Penang, Malaysia.
FAU - Iffat, Wajiha
AU  - Iffat W
AD  - Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Shakeel, Sadia
AU  - Shakeel S
AD  - Discipline of Social and Administrative Pharmacy, School of Pharmaceutical
      Sciences, Universiti Sains Malaysia, Penang, Malaysia.
AD  - Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
FAU - Zia, Madiha
AU  - Zia M
AD  - Institute of Physical Medicine and Rehabilitation, Dow University of Health
      Sciences, Karachi, Pakistan.
FAU - Fatima, Mustajab
AU  - Fatima M
AD  - Institute of Physical Medicine and Rehabilitation, Dow University of Health
      Sciences, Karachi, Pakistan.
FAU - Iqbal, Muhammad Shahid
AU  - Iqbal MS
AD  - Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz
      University, Al-Kharj, Saudi Arabia.
FAU - Iqbal, Muhammad Zahid
AU  - Iqbal MZ
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, AIMST
      University, Bedong, Malaysia.
FAU - Imam, Mohammad Tarique
AU  - Imam MT
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Hossain, Mohammad Akbar
AU  - Hossain MA
AD  - Department of Pharmacology and Toxicology, College of Medicine, Umm Al Qura
      University, Makkah, Saudi Arabia.
FAU - Ali, Majid
AU  - Ali M
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
FAU - Haseeb, Abdul
AU  - Haseeb A
AD  - Department of Clinical Pharmacy, College of Pharmacy, Umm Al Qura University,
      Makkah, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20200611
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
SB  - IM
MH  - Aged
MH  - *Arthritis, Rheumatoid/diagnosis/ethnology/physiopathology/therapy
MH  - Cross-Sectional Studies
MH  - *Cultural Characteristics
MH  - Female
MH  - Health Knowledge, Attitudes, Practice/*ethnology
MH  - *Health Literacy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pakistan/epidemiology
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - Risk Factors
MH  - *Surveys and Questionnaires
MH  - *Translating
OTO - NOTNLM
OT  - arthritis
OT  - disease knowledge
OT  - patient knowledge
OT  - rheumatoid
OT  - validation
EDAT- 2020/06/12 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1111/1756-185X.13860 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2020 Jul;23(7):918-927. doi: 10.1111/1756-185X.13860. Epub 2020 
      Jun 11.


PMID- 32525280
OWN - NLM
STAT- MEDLINE
DCOM- 20210915
LR  - 20210915
IS  - 2474-9842 (Electronic)
IS  - 2474-9842 (Linking)
VI  - 4
IP  - 5
DP  - 2020 Oct
TI  - Meta-analysis of the impact of postoperative infective complications on
      oncological outcomes in colorectal cancer surgery.
PG  - 737-747
LID - 10.1002/bjs5.50302 [doi]
AB  - BACKGROUND: Cancer outcomes are complex, involving prevention, early detection
      and optimal multidisciplinary care. Postoperative infection and surgical
      site-infection (SSI) are not only uncomfortable for patients and costly, but may 
      also be associated with poor oncological outcomes. A meta-analysis was undertaken
      to assess the oncological effects of SSI in patients with colorectal cancer.
      METHODS: An ethically approved PROSPERO-registered meta-analysis was conducted
      following PRISMA guidelines. PubMed and Scopus databases were searched for
      studies published between 2007 and 2017 reporting the effects of postoperative
      infective complications on oncological survival in colorectal cancer. Results
      were separated into those for SSI and those concerning anastomotic leakage.
      Articles with a Methodological Index for Non-Randomized Studies score of at least
      18 were included. Hazard ratios (HRs) with 95 per cent confidence intervals were 
      computed for risk factors using an observed to expected and variance fixed-effect
      model. RESULTS: Of 5027 articles were reviewed, 43 met the inclusion criteria,
      with a total of 154 981 patients. Infective complications had significant
      negative effects on overall survival (HR 1.37, 95 per cent c.i. 1.28 to 1.46) and
      cancer-specific survival (HR 2.58, 2.15 to 3.10). Anastomotic leakage occurred in
      7.4 per cent and had a significant negative impact on disease-free survival (HR
      1.14, 1.09 to 1.20), overall survival (HR 1.34, 1.28 to 1.39), cancer-specific
      survival (HR 1.43, 1.31 to 1.55), local recurrence (HR 1.18, 1.06 to 1.32) and
      overall recurrence (HR 1.46, 1.27 to 1.68). CONCLUSION: This meta-analysis
      identified a significant negative impact of postoperative infective complications
      on overall and cancer-specific survival in patients undergoing colorectal
      surgery.
CI  - (c) 2020 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of
      British Journal of Surgery Society.
FAU - Lawler, J
AU  - Lawler J
AUID- ORCID: 0000-0001-5831-0982
AD  - Department of Surgery, Letterkenny University Hospital and Donegal Clinical
      Research Academy, Donegal, Ireland.
FAU - Choynowski, M
AU  - Choynowski M
AD  - Department of Surgery, Letterkenny University Hospital and Donegal Clinical
      Research Academy, Donegal, Ireland.
FAU - Bailey, K
AU  - Bailey K
AUID- ORCID: 0000-0002-8086-7872
AD  - Department of Surgery, Letterkenny University Hospital and Donegal Clinical
      Research Academy, Donegal, Ireland.
FAU - Bucholc, M
AU  - Bucholc M
AD  - EU INTERREG Centre for Personalized Medicine, Intelligent Systems Research
      Centre, School of Computing, Engineering and Intelligent Systems, Ulster
      University, Magee Campus, Derry, /Londonderry, UK.
FAU - Johnston, A
AU  - Johnston A
AD  - Department of Surgery, Letterkenny University Hospital and Donegal Clinical
      Research Academy, Donegal, Ireland.
FAU - Sugrue, M
AU  - Sugrue M
AD  - Department of Surgery, Letterkenny University Hospital and Donegal Clinical
      Research Academy, Donegal, Ireland.
AD  - EU INTERREG Centre for Personalized Medicine, Intelligent Systems Research
      Centre, School of Computing, Engineering and Intelligent Systems, Ulster
      University, Magee Campus, Derry, /Londonderry, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200611
PL  - England
TA  - BJS Open
JT  - BJS open
JID - 101722685
SB  - IM
MH  - Anastomotic Leak/etiology/*mortality
MH  - Colorectal Neoplasms/microbiology/*mortality/surgery
MH  - Colorectal Surgery/*adverse effects
MH  - Disease-Free Survival
MH  - Humans
MH  - *Postoperative Complications
MH  - Surgical Wound Infection/etiology
PMC - PMC7528523
EDAT- 2020/06/12 06:00
MHDA- 2021/09/16 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/01/09 00:00 [received]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/09/16 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1002/bjs5.50302 [doi]
PST - ppublish
SO  - BJS Open. 2020 Oct;4(5):737-747. doi: 10.1002/bjs5.50302. Epub 2020 Jun 11.


PMID- 32524796
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20211231
IS  - 2047-9018 (Electronic)
IS  - 0029-6570 (Linking)
VI  - 35
IP  - 7
DP  - 2020 Jul 8
TI  - Understanding pharmacogenomic testing and its role in medicine prescribing.
PG  - 55-60
LID - 10.7748/ns.2020.e11543 [doi]
AB  - When making prescribing decisions, it is important for healthcare professionals
      to remember that individual patients may respond differently to medicines. For
      example, some patients may experience a therapeutic benefit while others may
      experience an adverse drug reaction. The aim of personalised medicine is to
      tailor treatment based not only on a patient's clinical factors, but also on
      their genetic profile. Pharmacogenomics is a branch of personalised medicine that
      is concerned with how differences in people's genomes affect their response to
      medicines. Pharmacogenomic testing, which recently has become less expensive and 
      increasingly available, can inform nurses' prescribing decisions and improve
      patient outcomes. This article discusses personalised medicine and
      pharmacogenomics, including how pharmacogenomic testing can optimise medicine
      prescribing, and explains the role of nurses in the process.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Youssef, Essra
AU  - Youssef E
AD  - School of Pharmacy, University of East Anglia, Norwich, England.
FAU - Buck, Jackie
AU  - Buck J
AD  - School of Health Sciences, University of East Anglia, Norwich, England.
FAU - Wright, David John
AU  - Wright DJ
AD  - School of Pharmacy, University of East Anglia, Norwich, England.
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - England
TA  - Nurs Stand
JT  - Nursing standard (Royal College of Nursing (Great Britain) : 1987)
JID - 9012906
MH  - Drug Prescriptions
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - *Pharmacogenomic Testing
MH  - Precision Medicine
OTO - NOTNLM
OT  - *adverse reactions
OT  - *clinical
OT  - *ethical issues
OT  - *genetic testing
OT  - *genetics
OT  - *genomics
OT  - *medicines
OT  - *nurse prescribing
OT  - *pharmacists
OT  - *pharmacology
OT  - *prescribing
OT  - *professional
COIS- David John Wright and Essra Youssef are engaged in a research collaboration with 
      MyDNA Life Australia Limited, but have no financial interests in the company.
      Jackie Buck has no conflict of interest.
EDAT- 2020/06/12 06:00
MHDA- 2022/01/01 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.7748/ns.2020.e11543 [doi]
AID - e11543 [pii]
PST - ppublish
SO  - Nurs Stand. 2020 Jul 8;35(7):55-60. doi: 10.7748/ns.2020.e11543. Epub 2020 Jun
      11.


PMID- 32524427
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Social Robotics, Education, and Religion in the Islamic World: An Iranian
      Perspective.
PG  - 2709-2734
LID - 10.1007/s11948-020-00225-1 [doi]
AB  - The social impact of robotics applied to domains such as education, religion,
      nursing, and therapy across the world depends on the level of technology as well 
      as the culture in which it is used. By studying how robots are used in Iran, a
      technologically-savvy country with a long history and a rich culture, we explore 
      their possible impact on interrelated areas of religious and ethical features in 
      education in an Islamic society. To accomplish this task, a preliminary
      exploratory study was conducted using two social robots as teaching assistants in
      Islamic religion classes for 42 elementary students. More than 90% of the
      participants in the study absolutely preferred the robot-assisted religion class 
      over one taught by a human. Building on the results from the students' viewpoints
      and exam scores, the acceptability and potential of using social robots in the
      education of Islamic religious concepts in Iran are further discussed in this
      paper.
FAU - Alemi, Minoo
AU  - Alemi M
AD  - Department of Humanities, Islamic Azad University-West Tehran Branch, Tehran,
      Iran. alemi@sharif.edu.
AD  - Social & Cognitive Robotics Laboratory, Sharif University of Technology, Tehran, 
      Iran. alemi@sharif.edu.
FAU - Taheri, Alireza
AU  - Taheri A
AD  - Social & Cognitive Robotics Laboratory, Sharif University of Technology, Tehran, 
      Iran.
FAU - Shariati, Azadeh
AU  - Shariati A
AD  - Department of Mechanical Engineering, University College London, London, UK.
FAU - Meghdari, Ali
AU  - Meghdari A
AUID- ORCID: http://orcid.org/0000-0001-6009-3825
AD  - Social & Cognitive Robotics Laboratory, Sharif University of Technology, Tehran, 
      Iran. meghdari@sharif.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200610
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Child
MH  - Humans
MH  - Iran
MH  - Islam
MH  - Religion
MH  - *Robotics
OTO - NOTNLM
OT  - *Ethics
OT  - *Human-robot interaction
OT  - *Iran
OT  - *Islam
OT  - *Religion
OT  - *Robots
OT  - *Social robotics
OT  - *Technology
EDAT- 2020/06/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/12 06:00
PHST- 2019/02/04 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1007/s11948-020-00225-1 [doi]
AID - 10.1007/s11948-020-00225-1 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2709-2734. doi: 10.1007/s11948-020-00225-1. Epub
      2020 Jun 10.


PMID- 32524426
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Back to Basics: Application of the Principles of Bioethics to Heritable Genome
      Interventions.
PG  - 2735-2748
LID - 10.1007/s11948-020-00226-0 [doi]
AB  - Prior to their announcement of the birth of gene-edited twins in China, Dr. He
      Jiankui and colleagues published a set of draft ethical principles for discussing
      the legal, social, and ethical aspects of heritable genome interventions. Within 
      this document, He and colleagues made it clear that their goal with these
      principles was to "clarify for the public the clinical future of early-in-life
      genetic surgeries" or heritable genome editing. In light of He's widely
      criticized gene editing experiments it is of interest to place these draft
      principles in the larger ethical debate surrounding heritable genome editing.
      Here we examine the principles proposed by He and colleagues through the lens of 
      Beauchamp and Childress' Principles of Biomedical Ethics. We also analyze the
      stated goal that the "clinical future" of heritable genome editing was clarified 
      by He and colleagues' proposed principles. Finally, we highlight what might be
      done to help prevent individual actors from pushing forward ahead of broad
      societal consensus on heritable genome editing.
FAU - Getz, Landon J
AU  - Getz LJ
AUID- ORCID: http://orcid.org/0000-0002-3841-1062
AD  - Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie
      University, PO Box 15000, Halifax, NS, B3H 4R2, Canada.
FAU - Dellaire, Graham
AU  - Dellaire G
AUID- ORCID: http://orcid.org/0000-0002-3466-6316
AD  - Department of Pathology, Faculty of Medicine, Dalhousie University, PO BOX 15000,
      Halifax, NS, B3H 4R2, Canada. dellaire@dal.ca.
AD  - Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie 
      University, Halifax, NS, Canada. dellaire@dal.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200610
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Bioethics
MH  - China
MH  - Gene Editing
MH  - Humans
MH  - Male
MH  - Moral Obligations
MH  - Morals
OTO - NOTNLM
OT  - *Autonomy
OT  - *Beneficence and non-maleficence
OT  - *CRISPR/Cas9
OT  - *Heritable genome editing
OT  - *Justice
EDAT- 2020/06/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/12 06:00
PHST- 2019/07/31 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1007/s11948-020-00226-0 [doi]
AID - 10.1007/s11948-020-00226-0 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2735-2748. doi: 10.1007/s11948-020-00226-0. Epub
      2020 Jun 10.


PMID- 32524425
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20220218
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - In AI We Trust: Ethics, Artificial Intelligence, and Reliability.
PG  - 2749-2767
LID - 10.1007/s11948-020-00228-y [doi]
AB  - One of the main difficulties in assessing artificial intelligence (AI) is the
      tendency for people to anthropomorphise it. This becomes particularly problematic
      when we attach human moral activities to AI. For example, the European
      Commission's High-level Expert Group on AI (HLEG) have adopted the position that 
      we should establish a relationship of trust with AI and should cultivate
      trustworthy AI (HLEG AI Ethics guidelines for trustworthy AI, 2019, p. 35). Trust
      is one of the most important and defining activities in human relationships, so
      proposing that AI should be trusted, is a very serious claim. This paper will
      show that AI cannot be something that has the capacity to be trusted according to
      the most prevalent definitions of trust because it does not possess emotive
      states or can be held responsible for their actions-requirements of the affective
      and normative accounts of trust. While AI meets all of the requirements of the
      rational account of trust, it will be shown that this is not actually a type of
      trust at all, but is instead, a form of reliance. Ultimately, even complex
      machines such as AI should not be viewed as trustworthy as this undermines the
      value of interpersonal trust, anthropomorphises AI, and diverts responsibility
      from those developing and using them.
FAU - Ryan, Mark
AU  - Ryan M
AUID- ORCID: http://orcid.org/0000-0003-4850-0111
AD  - The Division of Philosophy, KTH Royal Institute of Technology, Stockholm, Sweden.
      mryan@kth.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200610
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - Morals
MH  - Reproducibility of Results
MH  - *Trust
PMC - PMC7550313
OTO - NOTNLM
OT  - *Artificial intelligence ethics
OT  - *European commission high-level expert group
OT  - *Philosophy of trust
OT  - *Reliability
OT  - *Trustworthy AI
EDAT- 2020/06/12 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/12 06:00
PHST- 2019/12/16 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1007/s11948-020-00228-y [doi]
AID - 10.1007/s11948-020-00228-y [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2749-2767. doi: 10.1007/s11948-020-00228-y. Epub
      2020 Jun 10.


PMID- 32524142
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1464-3790 (Electronic)
IS  - 0967-0742 (Linking)
VI  - 28
IP  - 2
DP  - 2020 May 1
TI  - Bioethics and Universal Vulnerability: Exploring the Ethics and Practices of
      Research Participation.
PG  - 293-316
LID - 10.1093/medlaw/fwz026 [doi]
AB  - In this article, we advocate the adoption of universal vulnerability as a core
      value in bioethics. We argue that understanding vulnerability as the universal
      human condition-and rejecting the labelling of particular individuals or groups
      as vulnerable-would benefit bioethics and the research it governs. Bioethics
      first engaged with vulnerability in the context of participation in research and 
      this continues to define how the value is typically understood. Thus,
      vulnerability is generally deployed to describe individuals (or populations),
      where real or perceived deficiencies limit the ability to function and to protect
      themselves from risks. Revisiting this initial context and the participation in
      research of people living with dementia, we note that the bioethical position of 
      excluding the 'vulnerable' from research has led to major gaps in evidence and
      knowledge to inform care and support. Turning to universal vulnerability, we
      consider the research design and practices that the approach would mandate. We
      emphasise the importance of inclusive design and mechanisms of institutional
      support that enable participation. We argue that these positively impact on the
      scientific value of research and address social justice concerns around social
      inclusion. Our aim is to provoke a fundamental reassessment of how vulnerability 
      is conceived of in bioethics.
CI  - (c) The Author(s) 2019. Published by Oxford University Press; All rights
      reserved. For permissions, please email: journals.permissions@oup.com.
FAU - Ries, Nola M
AU  - Ries NM
AD  - Faculty of Law, University of Technology Sydney, Sydney, Australia, 2007.
FAU - Thomson, Michael
AU  - Thomson M
AD  - Faculty of Law, University of Technology Sydney, Sydney, Australia, 2007.
AD  - Centre for Law & Social Justice, School of Law, University of Leeds, Leeds, LS2
      9JT, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Med Law Rev
JT  - Medical law review
JID - 9308945
SB  - IM
MH  - *Bioethics
MH  - Biomedical Research/*ethics
MH  - Dementia/*psychology
MH  - Humans
MH  - *Research Design
MH  - Research Subjects/*psychology
MH  - *Universal Design
MH  - *Vulnerable Populations
OTO - NOTNLM
OT  - Bioethics
OT  - Capacity
OT  - Dementia
OT  - Research ethics
OT  - Universal design
OT  - Vulnerability
EDAT- 2020/06/12 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - 5571045 [pii]
AID - 10.1093/medlaw/fwz026 [doi]
PST - ppublish
SO  - Med Law Rev. 2020 May 1;28(2):293-316. doi: 10.1093/medlaw/fwz026.


PMID- 32523709
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Canadian Society of Nephrology COVID-19 Rapid Response Team Home Dialysis
      Recommendations.
PG  - 2054358120928153
LID - 10.1177/2054358120928153 [doi]
AB  - PURPOSE OF PROGRAM: This paper will provide guidance on how to best manage
      patients with end-stage kidney disease who will be or are being treated with home
      dialysis during the COVID-19 pandemic. SOURCES OF INFORMATION: Program-specific
      documents, pre-existing, and related to COVID-19; documents from national and
      international kidney agencies; national and international webinars, including
      webinars that we hosted for input and feedback; with additional information from 
      formal and informal review of published academic literature. METHODS: Members of 
      the Canadian Society of Nephrology (CSN) Board of Directors solicited a team of
      clinicians and administrators with expertise in home dialysis. Specific
      COVID-19-related themes in home dialysis were determined by the Canadian senior
      renal leaders community of practice, a group compromising medical and
      administrative leaders of provincial and health authority renal programs. We then
      developed consensus-based recommendations virtually by the CSN work-group with
      input from ethicists with nephrology training. The recommendations were further
      reviewed by community nephrologists and over a CSN-sponsored webinar, attended by
      225 kidney health care professionals, for further peer input. The final consensus
      recommendations also incorporated review by the editors at the Canadian Journal
      of Kidney Health and Disease (CJKHD). KEY FINDINGS: We identified 7 broad areas
      of home dialysis practice management that may be affected by the COVID-19
      pandemic: (1) peritoneal dialysis catheter placement, (2) home dialysis training,
      (3) home dialysis management, (4) personal protective equipment, (5) product
      delivery, (6) minimizing direct health care provider and patient contact, and (7)
      assisted peritoneal dialysis in the community. We make specific suggestions and
      recommendations for each of these areas. LIMITATIONS: This suggestions and
      recommendations in this paper are expert opinion, and subject to the biases
      associated with this level of evidence. To expedite the publication of this work,
      a parallel review process was created that may not be as robust as standard arms'
      length peer-review processes. IMPLICATIONS: These recommendations are intended to
      provide the best care possible during a time of altered priorities and reduced
      resources.
CI  - (c) The Author(s) 2020.
CN  - Home Dialysis Workgroup Members
FAU - Copland, Michael
AU  - Copland M
AD  - The University of British Columbia, Vancouver, BC, Canada.
FAU - Hemmett, Juliya
AU  - Hemmett J
AUID- ORCID: https://orcid.org/0000-0003-3167-844X
AD  - University of Calgary, Calgary, AB, Canada.
FAU - MacRae, Jennifer M
AU  - MacRae JM
AD  - University of Calgary, Calgary, AB, Canada.
FAU - McCormick, Brendan
AU  - McCormick B
AD  - University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada.
FAU - McCormick, Michael
AU  - McCormick M
AD  - St. Michael's Hospital, Toronto, ON, Canada.
FAU - Qirjazi, Elena
AU  - Qirjazi E
AD  - University of Calgary, Calgary, AB, Canada.
FAU - Singh, Rajinder S
AU  - Singh RS
AD  - The University of British Columbia, Vancouver, BC, Canada.
FAU - Zimmerman, Deborah
AU  - Zimmerman D
AUID- ORCID: https://orcid.org/0000-0003-0000-8806
AD  - University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada.
CN  - CSN COVID-19 RRT
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7262737
OTO - NOTNLM
OT  - COVID-19
OT  - home dialysis
OT  - recommendations
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
IR  - Antonsen J
FIR - Antonsen, John
IR  - Banks C
FIR - Banks, Cheryl
IR  - Clark D
FIR - Clark, David
IR  - Clark E
FIR - Clark, Edward
IR  - Davison SN
FIR - Davison, Sara N
IR  - Goldberg A
FIR - Goldberg, Aviva
IR  - Hiremath S
FIR - Hiremath, Swapnil
IR  - Kappel J
FIR - Kappel, Joanne
IR  - Mac-Way F
FIR - Mac-Way, Fabrice
IR  - Mathew A
FIR - Mathew, Anna
IR  - Moist L
FIR - Moist, Louise
IR  - Moran S
FIR - Moran, Sarah
IR  - Pandeya S
FIR - Pandeya, Sanjay
IR  - Ryz K
FIR - Ryz, Krista
IR  - Singh S
FIR - Singh, Suneet
IR  - Soroka S
FIR - Soroka, Steven
IR  - Suri R
FIR - Suri, Rita
IR  - Tennankore K
FIR - Tennankore, Karthik
IR  - Thanabalasingam S
FIR - Thanabalasingam, Susan
IR  - Wald R
FIR - Wald, Ron
IR  - Weir M
FIR - Weir, Matthew
IR  - White C
FIR - White, Christine
IR  - Levin A
FIR - Levin, Adeera
IR  - Mustafa RA
FIR - Mustafa, Reem A
IR  - Nesrallah G
FIR - Nesrallah, Gihad
EDAT- 2020/06/12 06:00
MHDA- 2020/06/12 06:01
CRDT- 2020/06/12 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2020/06/12 06:01 [medline]
AID - 10.1177/2054358120928153 [doi]
AID - 10.1177_2054358120928153 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 May 29;7:2054358120928153. doi:
      10.1177/2054358120928153. eCollection 2020.


PMID- 32523073
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20220531
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 582
IP  - 7812
DP  - 2020 Jun
TI  - Coronavirus R number hides raised risk for minority ethnic groups.
PG  - 341
LID - 10.1038/d41586-020-01740-8 [doi]
FAU - Uzoigwe, Chika
AU  - Uzoigwe C
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Nat Med. 2018 Dec;24(12):1779. PMID: 30523324
CON - JAMA. 2020 May 11;:null. PMID: 32391864
CIN - Nature. 2020 Jun;582(7813):488. PMID: 32577000
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Ethnicity
MH  - Humans
MH  - Minority Groups
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *SARS Virus
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Ethics
OT  - *SARS-CoV-2
EDAT- 2020/06/12 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1038/d41586-020-01740-8 [doi]
AID - 10.1038/d41586-020-01740-8 [pii]
PST - ppublish
SO  - Nature. 2020 Jun;582(7812):341. doi: 10.1038/d41586-020-01740-8.


PMID- 32522814
OWN - NLM
STAT- Publisher
LR  - 20200722
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 10
TI  - The good, the bad and the ugly: pandemic priority decisions and triage.
LID - medethics-2020-106489 [pii]
LID - 10.1136/medethics-2020-106489 [doi]
AB  - In this analysis we discuss the change in criteria for triage of patients during 
      three different phases of a pandemic like COVID-19, seen from the critical care
      point of view. Availability of critical care beds has become a hot topic, and in 
      many countries, we have seen a huge increase in the provision of temporary
      intensive care bed capacity. However, there is a limit where the hospitals may
      run out of resources to provide critical care, which is heavily dependent on
      trained staff, just-in-time supply chains for clinical consumables and drugs and 
      advanced equipment. In the first (good) phase, we can still do clinical
      prioritisation and decision-making as usual, based on the need for intensive care
      and prognostication: what are the odds for a good result with regard to survival 
      and quality of life. In the next (bad phase), the resources are mostly available,
      but the system is stressed by many patients arriving over a short time period and
      auxiliary beds in different places in the hospital being used. We may have to
      abandon admittance of patients with doubtful prognosis. In the last (ugly) phase,
      usual medical triage and priority setting may not be sufficient to decrease
      inflow and there may not be enough intensive care unit beds available. In this
      phase different criteria must be applied using a utilitarian approach for triage.
      We argue that this is an important transition where society, and not physicians, 
      must provide guidance to support triage that is no longer based on medical
      priorities alone.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Flaatten, Hans
AU  - Flaatten H
AD  - Department of Anaesthesia, Haukeland Universitetssjukehus, Bergen, Norway
      hans.flaatten@uib.no.
AD  - Intensive Care and Department of Clinical Medicine, Haukeland
      Universitetssjukehus, Bergen, Norway.
FAU - Van Heerden, Vernon
AU  - Van Heerden V
AD  - General Intensive Care Unit, Hadassah Medical Center, Jerusalem, Jerusalem,
      Israel.
FAU - Jung, Christian
AU  - Jung C
AD  - Division of Cardiology, Pulmonology and Vascular Medicine,
      Heinrich-Heine-University, Dusseldorf, Germany.
FAU - Beil, Michael
AU  - Beil M
AD  - General Intensive Care Unit, Hadassah Medical Center, Jerusalem, Jerusalem,
      Israel.
FAU - Leaver, Susannah
AU  - Leaver S
AD  - Intensive Care and Respiratory Medicine, St George's University Hospitals NHS
      Foundation Trust, London, London, UK.
FAU - Rhodes, Andrew
AU  - Rhodes A
AD  - St George's University Hospitals NHS Foundation Trust, London, London, UK.
FAU - Guidet, Bertrand
AU  - Guidet B
AD  - Assistance Publique, Hopitaux de Paris, Hopital SaintAntoine, Service de
      Reanimation Medicale, Paris 75012, France.
FAU - deLange, Dylan W
AU  - deLange DW
AD  - Department of Intensive Care Medicine, University Medical Center, University of
      Utrecht, Utrecht, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7299641
OTO - NOTNLM
OT  - allocation of health care resources
OT  - anaesthetics / anesthesiology
OT  - clinical ethics
OT  - epidemiology
OT  - health care for specific diseases/groups
COIS- Competing interests: None declared.
EDAT- 2020/06/12 06:00
MHDA- 2020/06/12 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/05/22 00:00 [received]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
AID - medethics-2020-106489 [pii]
AID - 10.1136/medethics-2020-106489 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 10. pii: medethics-2020-106489. doi:
      10.1136/medethics-2020-106489.


PMID- 32522813
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Relational ethical approaches to the COVID-19 pandemic.
PG  - 495-498
LID - 10.1136/medethics-2020-106264 [doi]
AB  - Key ethical challenges for healthcare workers arising from the COVID-19 pandemic 
      are identified: isolation and social distancing, duty of care and fair access to 
      treatment. The paper argues for a relational approach to ethics which includes
      solidarity, relational autonomy, duty, equity, trust and reciprocity as core
      values. The needs of the poor and socially disadvantaged are highlighted.
      Relational autonomy and solidarity are explored in relation to isolation and
      social distancing. Reciprocity is discussed with reference to healthcare workers'
      duty of care and its limits. Priority setting and access to treatment raise
      ethical issues of utility and equity. Difficult ethical dilemmas around triage,
      do not resuscitate decisions, and withholding and withdrawing treatment are
      discussed in the light of recently published guidelines. The paper concludes with
      the hope for a wider discussion of relational ethics and a glimpse of a future
      after the pandemic has subsided.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Jeffrey, David Ian
AU  - Jeffrey DI
AD  - Edinburgh Palliative and Supportive Care Group, University of Edinburgh Western
      General Hospital, Edinburgh EH4 2XU, UK dijeffrey@btinternet.com.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/virology
MH  - Decision Making/*ethics
MH  - Disaster Planning
MH  - *Ethics, Clinical
MH  - Health Care Rationing/*ethics
MH  - Health Equity/*ethics
MH  - Health Personnel/*ethics
MH  - Humans
MH  - Moral Obligations
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/virology
MH  - Poverty
MH  - Practice Guidelines as Topic
MH  - Professional-Patient Relations
MH  - Resuscitation Orders
MH  - SARS-CoV-2
MH  - Social Values
MH  - Triage/ethics
MH  - Vulnerable Populations
MH  - Withholding Treatment/ethics
PMC - PMC7316115
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *autonomy
OT  - *clinical ethics
OT  - *decision-making
COIS- Competing interests: None declared.
EDAT- 2020/06/12 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - medethics-2020-106264 [pii]
AID - 10.1136/medethics-2020-106264 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):495-498. doi: 10.1136/medethics-2020-106264. Epub
      2020 Jun 10.


PMID- 32522676
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 316
DP  - 2020 Oct 1
TI  - Rational and design of the China Pulmonary Thromboembolism Registry Study
      (CURES): A prospective multicenter registry.
PG  - 242-248
LID - S0167-5273(20)30725-7 [pii]
LID - 10.1016/j.ijcard.2020.05.087 [doi]
AB  - BACKGROUND: Epidemiological data on pulmonary embolism (PE) in China needs to be 
      updated and reported. The China Pulmonary Thromboembolism Registry Study (CURES) 
      is designed to provide the cross-sectional spectrum and chronological trends of
      PE in China, as well as to reveal the intrinsic etiology and pathogenesis of the 
      disease. METHODS AND DESIGN: The CURES is an ongoing large prospective
      multicenter registry, which was originally initiated in January 2009 via
      enrolling suspected or confirmed PE or PE with DVT (deep venous thrombosis)
      patients and assessed their in-hospital outcomes. As of July 2011, in order to
      determine the PE-relevant short-term outcomes, enrolled participants were
      followed-up for at least three months in a longitudinal manner. Since August
      2016, with the launch and development of precision medicine research scheme in
      China, the main principle investigators of CURES decided to collect enrolled
      patients' blood samples with regular follow-ups every three or six months for at 
      least two years (for long-term outcomes). Up to 31 December 2019, the CURES has
      enrolled 14,937 eligible patients and collected 1500 blood samples of patients
      from 100 medical centers in the China PE-DVT network. The study protocol has been
      approved by the China-Japan Friendship Hospital ethics committee, and all
      collaborating centers received approvals from their local ethics committee. All
      patients provided written or verbal informed consent to their participation.
      CONCLUSIONS: Findings of the CURES will be valuable for revealing the natural
      history of PE, and facilitating better disease management in China. Registration 
      Number inClinicalTrials.gov:NCT02943343.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Lei, Jieping
AU  - Lei J
AD  - Data and Project Management Unit, Institute of Clinical Medical Sciences,
      China-Japan Friendship Hospital, Beijing, PR China; Department of Pulmonary and
      Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship
      Hospital, Beijing, PR China; Institute of Respiratory Medicine, Chinese Academy
      of Medical Sciences, Beijing, PR China; National Clinical Research Center for
      Respiratory Disease, Beijing, PR China.
FAU - Xu, Xiaomao
AU  - Xu X
AD  - Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing, PR
      China.
FAU - Ji, Yingqun
AU  - Ji Y
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital
      of Dalian Medical University, Dalian, PR China.
FAU - Yang, Yuanhua
AU  - Yang Y
AD  - Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital,
      Capital Medical University, Beijing, PR China.
FAU - Yi, Qun
AU  - Yi Q
AD  - Department of Pulmonary and Critical Care Medicine, West China Hospital, West
      China School of Medicine, Sichuan University, Chengdu, PR China.
FAU - Chen, Hong
AU  - Chen H
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital
      of Chongqing Medical University, Chongqing, PR China.
FAU - Hu, Xiaoyun
AU  - Hu X
AD  - Department of Pulmonary and Critical Care Medicine, First Hospital of Shanxi
      Medical University, Taiyuan, PR China.
FAU - Liu, Zhihong
AU  - Liu Z
AD  - Fuwai Hospital, Chinese Academy of Medical Science, National Center for
      Cardiovascular Diseases, Beijing, PR China.
FAU - Mao, Yimin
AU  - Mao Y
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital
      of Henan University of Science and Technology, Luoyang, PR China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Pulmonary and Critical Care Medicine, The Second Hospital of Jilin 
      University, Beijing, PR China.
FAU - Shi, Juhong
AU  - Shi J
AD  - Department of Pulmonary and Critical Care Medicine, Peking Union Medical College 
      Hospital, Beijing, PR China.
FAU - Wang, Dingyi
AU  - Wang D
AD  - Data and Project Management Unit, Institute of Clinical Medical Sciences,
      China-Japan Friendship Hospital, Beijing, PR China; Department of Pulmonary and
      Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship
      Hospital, Beijing, PR China; Institute of Respiratory Medicine, Chinese Academy
      of Medical Sciences, Beijing, PR China; National Clinical Research Center for
      Respiratory Disease, Beijing, PR China.
FAU - Zhang, Shuai
AU  - Zhang S
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Zhang, Zhu
AU  - Zhang Z
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China;
      Graduate School of Peking Union Medical College, Chinese Academy of Medical
      Sciences, Peking Union Medical College, Beijing, PR China.
FAU - Wu, Sinan
AU  - Wu S
AD  - Data and Project Management Unit, Institute of Clinical Medical Sciences,
      China-Japan Friendship Hospital, Beijing, PR China; Institute of Respiratory
      Medicine, Chinese Academy of Medical Sciences, Beijing, PR China; National
      Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Gao, Qian
AU  - Gao Q
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Tao, Xincao
AU  - Tao X
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Xie, Wanmu
AU  - Xie W
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Wan, Jun
AU  - Wan J
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Zhang, Yunxia
AU  - Zhang Y
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China;
      Department of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital,
      Capital Medical University, Beijing, PR China.
FAU - Shao, Xiang
AU  - Shao X
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China;
      Beijing University of Chinese Medicine, Beijing, PR China.
FAU - Zhang, Zhonghe
AU  - Zhang Z
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital
      of Dalian Medical University, Dalian, PR China.
FAU - Fang, Baomin
AU  - Fang B
AD  - Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing, PR
      China.
FAU - Zhai, Zhenguo
AU  - Zhai Z
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China.
      Electronic address: zhaizhenguo2011@126.com.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Pulmonary and Critical Care Medicine, Center of Respiratory
      Medicine, China-Japan Friendship Hospital, Beijing, PR China; Institute of
      Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, PR China;
      National Clinical Research Center for Respiratory Disease, Beijing, PR China;
      Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR
      China; Department of Respiratory Medicine, Capital Medical University, Beijing,
      PR China. Electronic address: wangchen@pumc.edu.cn.
CN  - China pUlmonary Thromboembolism REgistry Study (CURES) investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02943343
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200606
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Anticoagulants
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Japan
MH  - Prospective Studies
MH  - *Pulmonary Embolism/diagnosis/epidemiology/therapy
MH  - Registries
MH  - Risk Factors
MH  - *Venous Thromboembolism
OTO - NOTNLM
OT  - *Deep venous thrombosis
OT  - *Protocol
OT  - *Pulmonary embolism
OT  - *Real-world study
OT  - *Registry
COIS- Declaration of Competing Interest We declare that all authors meet the criteria
      for authorship and all authors have read and approved the manuscript to be
      published. There are no financial conflicts of interest in this work.
      Additionally, we state that the original work of this manuscript has not been
      previously published in any substantial part, also has not been under
      consideration of publication elsewhere.
EDAT- 2020/06/12 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - S0167-5273(20)30725-7 [pii]
AID - 10.1016/j.ijcard.2020.05.087 [doi]
PST - ppublish
SO  - Int J Cardiol. 2020 Oct 1;316:242-248. doi: 10.1016/j.ijcard.2020.05.087. Epub
      2020 Jun 6.


PMID- 32522463
OWN - NLM
STAT- MEDLINE
DCOM- 20211019
LR  - 20211019
IS  - 1873-5010 (Electronic)
IS  - 1569-1993 (Linking)
VI  - 19
IP  - 5
DP  - 2020 Sep
TI  - Building global development strategies for cf therapeutics during a transitional 
      cftr modulator era.
PG  - 677-687
LID - S1569-1993(20)30161-2 [pii]
LID - 10.1016/j.jcf.2020.05.011 [doi]
AB  - As CFTR modulator therapy transforms the landscape of cystic fibrosis (CF) care, 
      its lack of uniform access across the globe combined with the shift towards a new
      standard of care creates unique challenges for the development of future CF
      therapies. The advancement of a full and promising CF therapeutics pipeline
      remains a necessary priority to ensure maximal clinical benefits for all people
      with CF. It is through collaboration across the global CF community that we can
      optimize the evaluation and approval process of new therapies. To this end, we
      must identify areas for which harmonization is lacking and for which efficiencies
      can be gained to promote ethical, feasible, and credible study designs amidst the
      changing CF care landscape. This article summarizes the counsel from core
      advisors across multiple international regions and clinical trial networks,
      developed during a one-day workshop in October 2019. The goal of the workshop was
      to identify, in consideration of the highly transitional era of CFTR modulator
      availability, the drug development areas for which global alignment is currently 
      uncertain, and paths forward that will enable advancement of CF therapeutic
      development.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Mayer-Hamblett, N
AU  - Mayer-Hamblett N
AD  - University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA. 
      Electronic address: nicole.hamblett@seattlechildrens.org.
FAU - van Koningsbruggen-Rietschel, S
AU  - van Koningsbruggen-Rietschel S
AD  - Cystic Fibrosis Center, Children's Hospital, University of Cologne; Faculty of
      Medicine and University Hospital Cologne, Cologne Germany.
FAU - Nichols, D P
AU  - Nichols DP
AD  - University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA.
FAU - VanDevanter, D R
AU  - VanDevanter DR
AD  - Case Western Reserve University School of Medicine, Cleveland, OH.
FAU - Davies, J C
AU  - Davies JC
AD  - National Heart & Lung Institute, Imperial College London, London, UK; Royal
      Brompton & Harefield NHS Foundation Trust, London, UK.
FAU - Lee, T
AU  - Lee T
AD  - Leeds Regional Paediatric Cystic Fibrosis Centre, Leeds, UK.
FAU - Durmowicz, A G
AU  - Durmowicz AG
AD  - Cystic Fibrosis Foundation, Bethesda, MD.
FAU - Ratjen, F
AU  - Ratjen F
AD  - University of Toronto, Toronto, Canada.
FAU - Konstan, M W
AU  - Konstan MW
AD  - Case Western Reserve University School of Medicine, Cleveland, OH; Rainbow Babies
      and Children's Hospital, Cleveland, OH.
FAU - Pearson, K
AU  - Pearson K
AD  - Seattle Children's Hospital, Seattle, WA.
FAU - Bell, S C
AU  - Bell SC
AD  - Children's Health Research Centre, The University of Queensland, Brisbane,
      Australia.
FAU - Clancy, J P
AU  - Clancy JP
AD  - Cystic Fibrosis Foundation, Bethesda, MD.
FAU - Taylor-Cousar, J L
AU  - Taylor-Cousar JL
AD  - National Jewish Health, Denver, CO.
FAU - De Boeck, K
AU  - De Boeck K
AD  - University of Leuven, Leuven, Belgium.
FAU - Donaldson, S H
AU  - Donaldson SH
AD  - University of North Carolina at Chapel Hill, Chapel Hill, NC.
FAU - Downey, D G
AU  - Downey DG
AD  - Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern
      Ireland.
FAU - Flume, P A
AU  - Flume PA
AD  - Medical University of South Carolina, Charleston, SC.
FAU - Drevinek, P
AU  - Drevinek P
AD  - Charles University, Prague, Czechia, Motol University Hospital, Prague, Czechia.
FAU - Goss, C H
AU  - Goss CH
AD  - University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA.
FAU - Fajac, I
AU  - Fajac I
AD  - Universite de Paris, Paris, France.
FAU - Magaret, A S
AU  - Magaret AS
AD  - University of Washington, Seattle, WA; Seattle Children's Hospital, Seattle, WA.
FAU - Quon, B S
AU  - Quon BS
AD  - University of British Columbia, Vancouver, British Columbia.
FAU - Singleton, S M
AU  - Singleton SM
AD  - Cystic Fibrosis Foundation, Bethesda, MD.
FAU - VanDalfsen, J M
AU  - VanDalfsen JM
AD  - Seattle Children's Hospital, Seattle, WA.
FAU - Retsch-Bogart, G Z
AU  - Retsch-Bogart GZ
AD  - University of North Carolina at Chapel Hill, Chapel Hill, NC.
LA  - eng
GR  - UL1 TR002548/TR/NCATS NIH HHS/United States
GR  - P30 DK089507/DK/NIDDK NIH HHS/United States
GR  - UL1 TR002489/TR/NCATS NIH HHS/United States
GR  - UL1 TR000062/TR/NCATS NIH HHS/United States
GR  - UL1 TR002319/TR/NCATS NIH HHS/United States
GR  - P01 HL128192/HL/NHLBI NIH HHS/United States
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200607
PL  - Netherlands
TA  - J Cyst Fibros
JT  - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis
      Society
JID - 101128966
RN  - 0 (CFTR protein, human)
RN  - 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator)
SB  - IM
CIN - J Cyst Fibros. 2020 Sep;19(5):669-670. PMID: 32792265
MH  - Cystic Fibrosis/*drug therapy/genetics
MH  - Cystic Fibrosis Transmembrane Conductance Regulator/*drug effects
MH  - Drug Development/*organization & administration
MH  - Humans
MH  - *International Cooperation
PMC - PMC7492419
MID - NIHMS1601950
OTO - NOTNLM
OT  - *CFTR modulators
OT  - *Clinical trials
OT  - *Drug development
OT  - *Global perspective
COIS- Declaration of Competing Interest NMH serves as a consultant through her
      institution in her role as Executive Director of the CF Therapeutics Development 
      Network Coordinating Center (CF TDNCC) and has received personal consulting fees 
      from Kala Pharmaceuticals and Calithera. She has received grant funding from the 
      Cystic Fibrosis Foundation (CFF) and National Institutes of Health (NIH). SvKR
      has received personal consulting fees from Antabio, Proteostasis Therapeutics
      (PTI), and Vertex Pharmaceuticals (VRTX). She has received grant support to her
      institution for her participation in the European Union HORIZON 2020 work. DPN
      serves as a consultant through his institution in his role as Medical Director of
      CF TDNCC. He has received grant support to his Institution from the CFF and
      Gilead Sciences. DRV has received personal consulting fees from AbbVie,
      Albumedix, AN2, Aradigm, Armata, Arrevus, Calithera, Chiesi USA, Cipla, Corbus,
      CFF, Eloxx, Enbiotix, Eveo, Galephar, Horizon, IBF, ICON clinical sciences,
      Ionis, Kala, Merck, Microbion, NDA, Protalix, PTC, Pulmocide, Recida, Savara,
      Vast, and VRTX. JCD has received other support from Aligipharma AS, Bayer AG, BI,
      Galapagos NV, ImevaX GmbH, Nivalis Therapeutics, ProQR Therapeutics, PTI, Raptor 
      Pharamceuticals, VRTX, Enterprise, Novartis, Pulmocide, Flately and Teva for
      advisory board and educational activities. She has received grant support from
      the CF Trust. TL has received personal fees from Alan Boyd Consultants, Ltd for
      his participation in DSMB activities. FAR has received personal consulting fees
      from Novartis, Bayer, Roche, and Genentech for participation in CF related
      consulting activities. He has received grant support to his institution from VRTX
      for his participation as site PI in multicenter trials which they have funded as 
      well as personal consulting fees. MWK has received personal consulting fees for
      advisory board participation, grant support to his institution for clinical trial
      participation, and non-financial support from VRTX, Savara, Laurent, Corbus
      Pharmaceuticals, PTC, and AzurRx. He has received personal consulting fees and
      non-financial support from Chiesi, Celtaxsys, Merck, and Kala. Personal
      consulting fees were received from Albumedix, Paranta, Protalix, Santhera, pH
      Pharma, Novartis, Ionis, the Italian Cystic Fibrosis Foundation, and the Food and
      Drug Administration. Grant support was provided to his Institution by NIH. Grant 
      support was provided to his Institution by Anthera as well as personal consulting
      fees. SCB has received support from VRTX, Galapagos, and AbbVie for his
      participation in advisory boards and as site PI in multicenter trials which they 
      have funded. JLTC has received personal consulting fees from Gilead Sciences,
      Protalix, and Santhera for participation in advisory board activities. She has
      received grant support to her institution from PTI, Celtaxsys, and VRTX as well
      as personal consulting fees for advisory activities. Grant support to her
      institution for her participation as site PI in a multicenter trial which they
      have funded from Eloxx. KDB has received consulting fees from
      Boehringer-Ingelheim (BI), Protalix Biotherapeutics, Raptor Pharmaceuticals,
      Novabiotics, Eloxx Pharmaceutics, Galapagos, and Chiesi. She has received speaker
      fees from Teva Pharmaceutical Industries and serves on the Steering Committee and
      Advisory Board for VRTX. DGD has received consulting fees from VRTX and
      consulting fees as well as grant support from PTI and Chiesi. PAF has received
      personal consulting fees from the Food and Drug Administration, Polyphor, and
      Santhera. He has received personal consulting fees and grant support from CFF,
      PTI, Savara, and VRTX. He has received grant support from NIH, Novartis,
      Novoteris, and Sound Pharmaceuticals. PD has received personal consulting fees
      from VRTX, PTI, and Actelion Pharmaceuticals. He has also received support for
      his participation as site PI in multicenter trials funded by Corbus
      Pharmaceuticals and VRTX. CHG has received grant funding from CFF, NIH, the
      European Commission and the Food and Drug Administration. He has also received
      honoraria from Gilead Sciences for grant reviews, honoraria from VRTX and Mylan
      for invited talks, and BI for participation as a PI in a multicenter trial in CF 
      that they have funded. IF has received consulting fees and support from PTI, VRTX
      and BI for her participation in advisory boards as well as site PI in multicenter
      trials which they have funded. She has received support from Corbus
      Pharmaceuticals for participation as site PI in multicenter trials which they
      have funded ASM has received grant support to her Institution from CFF. BSQ has
      received grant support to his institution from the Cystic Fibrosis Canada, CFF,
      Michael Smith Foundation for Health Research, BC Lung Association, and Gilead
      Sciences. GZRB's institution has received support from the CFF, NIH and VRTX. for
      his participation as site PI in multicenter trials which they have funded. AGD,
      KP, JPC, SHD, SMS, and JMVD have nothing to disclose.
EDAT- 2020/06/12 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - S1569-1993(20)30161-2 [pii]
AID - 10.1016/j.jcf.2020.05.011 [doi]
PST - ppublish
SO  - J Cyst Fibros. 2020 Sep;19(5):677-687. doi: 10.1016/j.jcf.2020.05.011. Epub 2020 
      Jun 7.


PMID- 32522347
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210920
IS  - 1879-3592 (Electronic)
IS  - 1383-5718 (Linking)
VI  - 853
DP  - 2020 May
TI  - Experimental investigations of carcinogen-induced mutation spectra: Innovation,
      challenges and future directions.
PG  - 503195
LID - S1383-5718(20)30065-6 [pii]
LID - 10.1016/j.mrgentox.2020.503195 [doi]
AB  - Recent years have witnessed an expansion of mutagenesis research focusing on
      experimentally modeled genome-scale mutational signatures of carcinogens and of
      endogenous processes. Experimental mutational signatures can explain etiologic
      links to patterns found in human tumors that may be linked to same exposures, and
      can serve as biomarkers of exposure history and may even provide insights on
      causality. A number of innovative exposure models have been employed and
      reported, based on cells cultured in monolayers or in 3-D, on organoids, induced 
      pluripotent stem cells, non-mammalian organisms, microorganisms and rodent
      bioassays. Here we discuss some of the latest developments and pros and cons of
      these experimental systems used in mutational signature analysis. Integrative
      designs that bring together multiple exposure systems (in vitro, in vivo and in
      silico pan-cancer data mining) started emerging as powerful tools to identify
      robust mutational signatures of the tested cancer risk agents. We further propose
      that devising a new generation of cell-based models is warranted to streamline
      systematic testing of carcinogen effects on the cell genomes, while seeking to
      increasingly supplant animal with non-animal systems to address relevant ethical 
      issues and accentuate the 3R principles. We conclude that the knowledge
      accumulating from the growing body of signature modelling investigations has
      considerable power to advance cancer etiology studies and to support cancer
      prevention efforts through streamlined characterization of cancer-causing agents 
      and the recognition of their specific effects.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Melki, Pamela N
AU  - Melki PN
AD  - Molecular Mechanisms and Biomarkers Group, International Agency for Research on
      Cancer, World Health Organization, 69008 Lyon, France.
FAU - Korenjak, Michael
AU  - Korenjak M
AD  - Molecular Mechanisms and Biomarkers Group, International Agency for Research on
      Cancer, World Health Organization, 69008 Lyon, France.
FAU - Zavadil, Jiri
AU  - Zavadil J
AD  - Molecular Mechanisms and Biomarkers Group, International Agency for Research on
      Cancer, World Health Organization, 69008 Lyon, France. Electronic address:
      ZavadilJ@iarc.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200424
PL  - Netherlands
TA  - Mutat Res Genet Toxicol Environ Mutagen
JT  - Mutation research. Genetic toxicology and environmental mutagenesis
JID - 101632149
RN  - 0 (Carcinogens)
SB  - IM
MH  - Animals
MH  - Carcinogens/*toxicity
MH  - DNA Mutational Analysis/methods
MH  - Genome, Human/drug effects/genetics
MH  - Humans
MH  - Mutagenesis/*drug effects/genetics
MH  - Mutation/*drug effects/genetics
MH  - Neoplasms/*chemically induced
OTO - NOTNLM
OT  - *Animal bioassays
OT  - *Cancer prevention
OT  - *Experimental mutagenesis
OT  - *In vitro models
OT  - *Mutagenic carcinogens
OT  - *Mutational signatures
EDAT- 2020/06/12 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/03/30 00:00 [revised]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - S1383-5718(20)30065-6 [pii]
AID - 10.1016/j.mrgentox.2020.503195 [doi]
PST - ppublish
SO  - Mutat Res Genet Toxicol Environ Mutagen. 2020 May;853:503195. doi:
      10.1016/j.mrgentox.2020.503195. Epub 2020 Apr 24.


PMID- 32522252
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 10
TI  - Drowning our sorrows: clinical and ethical considerations of termination in
      alcohol-affected pregnancy.
PG  - 356
LID - 10.1186/s12884-020-03012-9 [doi]
FAU - Martin, Roger
AU  - Martin R
AUID- ORCID: 0000-0001-7564-9216
AD  - Redcliffe Hospital, Anzac Avenue, Redcliffe, Queensland, 4020, Australia.
AD  - Department of Obstetrics & Gynaecology, Redcliffe Hospital, Anzac Avenue,
      Redcliffe, Queensland, 4020, Australia.
FAU - Bruxner, George
AU  - Bruxner G
AUID- ORCID: 0000-0002-6961-0902
AD  - Redcliffe Hospital, Anzac Avenue, Redcliffe, Queensland, 4020, Australia.
AD  - Metro North Mental Health Service, Herston, 4029, Queensland, Australia.
AD  - Faculty of Medicine, The University of Queensland, St Lucia, 4067, Queensland,
      Australia.
FAU - Ng, Gary
AU  - Ng G
AUID- ORCID: 0000-0002-1822-0621
AD  - Redcliffe Hospital, Anzac Avenue, Redcliffe, Queensland, 4020, Australia.
AD  - Department of Obstetrics & Gynaecology, Redcliffe Hospital, Anzac Avenue,
      Redcliffe, Queensland, 4020, Australia.
FAU - Brewster, Catherine
AU  - Brewster C
AD  - Redcliffe Hospital, Anzac Avenue, Redcliffe, Queensland, 4020, Australia.
AD  - Department of Alcohol & Other Drugs, Redcliffe Hospital, Redcliffe, 4020,
      Queensland, Australia.
FAU - Kothari, Alka
AU  - Kothari A
AUID- ORCID: 0000-0002-9816-3734
AD  - Redcliffe Hospital, Anzac Avenue, Redcliffe, Queensland, 4020, Australia.
      alka.kothari@uq.edu.au.
AD  - Department of Obstetrics & Gynaecology, Redcliffe Hospital, Anzac Avenue,
      Redcliffe, Queensland, 4020, Australia. alka.kothari@uq.edu.au.
AD  - Faculty of Medicine, The University of Queensland, St Lucia, 4067, Queensland,
      Australia. alka.kothari@uq.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Abortion, Induced/*ethics
MH  - Adult
MH  - Alcohol Drinking/*adverse effects
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Queensland
PMC - PMC7288674
OTO - NOTNLM
OT  - *Alcohol drinking
OT  - *Health behaviour
OT  - *Medical ethics
OT  - *Pregnancy
OT  - *Termination of pregnancy
OT  - *Women's health
EDAT- 2020/06/12 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/06/12 06:00
PHST- 2019/04/18 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 10.1186/s12884-020-03012-9 [doi]
AID - 10.1186/s12884-020-03012-9 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 Jun 10;20(1):356. doi: 10.1186/s12884-020-03012-9.


PMID- 32522217
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1757-1146 (Electronic)
IS  - 1757-1146 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Jun 10
TI  - Tendon morphological changes after a prolonged ski race can be detected by
      ultrasound echo intensity.
PG  - 34
LID - 10.1186/s13047-020-00398-9 [doi]
AB  - BACKGROUND: Ultrasound imaging techniques have been used to assess the
      characteristics of skeletal muscles and tendons. Such techniques (gray scale
      analysis) allow qualitative evaluation and have been used recently to assess the 
      internal structure of muscles and tendons by computer-aided gray scale analysis. 
      We hypothesized that changes in the internal structure of the Achilles and
      patellar tendons after a ski mountaineering race competition could be detected
      with ultrasound. METHODS: Twenty athletes were recruited during the 19th Millet
      Tour du Rutor extreme, a three-day ski mountaineering competition. Ultrasound
      measurements of the Achilles and patellar tendons were carried out before the
      first race and immediately after each of the three competition days. Tendon
      thickness, cross-sectional area (CSA), and ultrasound gray scale analysis were
      calculated. RESULTS: Significant differences (p < 0.05) were observed between the
      pre- and post-race measurements for the Achilles tendon thickness and CSA, while 
      no significant differences were noted for the patellar tendon thickness and CSA. 
      However, gray scale analysis of both the Achilles and patellar tendons showed
      significantly higher post-race values, than the pre-race values (p < 0.05).
      CONCLUSIONS: Achilles and patellar tendons of healthy athletes are highly
      responsive to an acute increase in mechanical load. Those changes can be detected
      from classical (thickness and CSA) and innovative (gray scale) ultrasound-based
      parameters. TRIAL REGISTRATION: This study was approved by the Azienda USL Valle 
      d'Aosta Ethics Committee (protocol no. 23/03/2018.0026243.I).
FAU - Schneebeli, Alessandro
AU  - Schneebeli A
AUID- ORCID: http://orcid.org/0000-0002-8411-2012
AD  - Rehabilitation Research Laboratory 2rLab, Department of Business Economics,
      Health and Social Care, University of Applied Sciences and Arts of Southern
      Switzerland, Manno/Landquart, Switzerland. alessandro.schneebeli@supsi.ch.
FAU - Visconti, Lorenzo
AU  - Visconti L
AD  - Studi fisioterapici di Montagna, Aosta, Italy.
FAU - Cescon, Corrado
AU  - Cescon C
AD  - Rehabilitation Research Laboratory 2rLab, Department of Business Economics,
      Health and Social Care, University of Applied Sciences and Arts of Southern
      Switzerland, Manno/Landquart, Switzerland.
FAU - Clijsen, Ron
AU  - Clijsen R
AD  - Rehabilitation Research Laboratory 2rLab, Department of Business Economics,
      Health and Social Care, University of Applied Sciences and Arts of Southern
      Switzerland, Manno/Landquart, Switzerland.
AD  - International university of applied sciences THIM, Thim van der Laan AG,
      Landquart, Switzerland.
AD  - Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel,
      Brussels, Belgium.
FAU - Giardini, Guido
AU  - Giardini G
AD  - SC Neurologia Centro Medicina di Montagna, Ospedale U.Parini, Aosta, Italy.
FAU - Arizzio, Maria Elisabetta
AU  - Arizzio ME
AD  - FCA group, Torino, Italy.
FAU - Barbero, Marco
AU  - Barbero M
AD  - Rehabilitation Research Laboratory 2rLab, Department of Business Economics,
      Health and Social Care, University of Applied Sciences and Arts of Southern
      Switzerland, Manno/Landquart, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - England
TA  - J Foot Ankle Res
JT  - Journal of foot and ankle research
JID - 101471610
SB  - IM
MH  - Achilles Tendon/*diagnostic imaging
MH  - Adult
MH  - Athletes
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/*methods
MH  - Patellar Ligament/*diagnostic imaging
MH  - Skiing/*physiology
MH  - Tendinopathy/diagnostic imaging
MH  - Ultrasonography/*methods
PMC - PMC7288471
OTO - NOTNLM
OT  - Achilles tendon
OT  - Gray scale analysis
OT  - Patellar tendon
EDAT- 2020/06/12 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1186/s13047-020-00398-9 [doi]
AID - 10.1186/s13047-020-00398-9 [pii]
PST - epublish
SO  - J Foot Ankle Res. 2020 Jun 10;13(1):34. doi: 10.1186/s13047-020-00398-9.


PMID- 32522132
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210903
IS  - 1557-7740 (Electronic)
IS  - 1557-7740 (Linking)
VI  - 23
IP  - 9
DP  - 2020 Sep
TI  - Outpatient Palliative Care in Heart Failure: An Integrative Review.
PG  - 1257-1269
LID - 10.1089/jpm.2020.0031 [doi]
AB  - Background: Early integration of palliative care (PC) for patients with heart
      failure (HF) improves patient outcomes and decreases health care utilization. PC 
      provided outside of an acute hospitalization is not well understood. Objective:
      To synthesize the literature of outpatient PC in HF to identify the current
      landscape, the impact on patient health outcomes, key stakeholders' perspectives,
      and future implications for research and practice. Design: A systematic search of
      PubMed, Embase, CINAHL, Cochrane, and Web of Science was conducted from inception
      to February 2019 for studies of outpatient PC in adults with HF. Each study was
      analyzed to describe study characteristics, location of PC, types of providers
      involved, participant characteristics, and main findings, and to characterize
      domains of PC addressed. Results: Most studies (N = 19) employed a quantitative
      design and were conducted in the United States. The most common locations of PC
      were the home or PC clinic and providers were mainly PC specialists. Outpatient
      PC improved quality of life, alleviated symptoms, and decreased
      rehospitalizations for patients with HF. No study addressed all eight domains of 
      PC. The structural, physical, and psychological domains were commonly addressed, 
      whereas, least commonly addressed domains were the cultural and ethical/legal
      domain. Women and ethnic minorities were underrepresented in the majority of
      samples. Conclusions: This integrative review highlights the need to promote
      primary PC and future PC research focusing on a holistic, integrated, team-based 
      approach addressing all domains of PC in representative samples.
FAU - DeGroot, Lyndsay
AU  - DeGroot L
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
FAU - Koirala, Binu
AU  - Koirala B
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
FAU - Pavlovic, Noelle
AU  - Pavlovic N
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
FAU - Nelson, Katie
AU  - Nelson K
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
FAU - Allen, Jerilyn
AU  - Allen J
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
FAU - Davidson, Patricia
AU  - Davidson P
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
FAU - Abshire, Martha
AU  - Abshire M
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
LA  - eng
GR  - T32 NR012704/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200609
PL  - United States
TA  - J Palliat Med
JT  - Journal of palliative medicine
JID - 9808462
SB  - IM
MH  - Adult
MH  - Female
MH  - *Heart Failure/therapy
MH  - *Hospice and Palliative Care Nursing
MH  - Humans
MH  - Outpatients
MH  - Palliative Care
MH  - Quality of Life
PMC - PMC7469696
OTO - NOTNLM
OT  - *health equity
OT  - *heart failure
OT  - *integrative review
OT  - *outpatient
OT  - *palliative care
EDAT- 2020/06/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1089/jpm.2020.0031 [doi]
PST - ppublish
SO  - J Palliat Med. 2020 Sep;23(9):1257-1269. doi: 10.1089/jpm.2020.0031. Epub 2020
      Jun 9.


PMID- 32522058
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20211104
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Sep
TI  - Medical cannabis in the UK: From principle to practice.
PG  - 931-937
LID - 10.1177/0269881120926677 [doi]
AB  - BACKGROUND: In the UK, medical cannabis was approved in November 2018, leading
      many patients to believe that the medicine would now be available on the NHS.
      Yet, to date, there have been only 12 NHS prescriptions and less than 60
      prescriptions in total. In marked contrast, a recent patient survey by the Centre
      for Medical Cannabis (Couch, 2020) found 1.4 m people are using illicit cannabis 
      for medical problems. AIMS: Such a mismatch between demand and supply is rare in 
      medicine. This article outlines some of the current controversies about medical
      cannabis that underpin this disparity, beginning by contrasting current medical
      evidence from research studies with patient-reported outcomes. OUTCOMES: Although
      definite scientific evidence is scarce for most conditions, there is significant 
      patient demand for access to medical cannabis. This disparity poses a challenge
      for prescribers, and there are many concerns of physicians when deciding if, and 
      how, to prescribe medical cannabis which still need to be addressed. Potential
      solutions are outlined as to how the medical profession and regulators could
      respond to the strong demand from patients and families for access to medical
      cannabis to treat chronic illnesses when there is often a limited scientific
      evidence base on whether and how to use it in many of these conditions.
      CONCLUSIONS: There is a need to maximise both clinical research and patient
      benefit, in a safe, cautious and ethical manner, so that those patients for whom 
      cannabis is shown to be effective can access it. We hope our discussion and
      outlines for future progress offer a contribution to this process.
FAU - Schlag, Anne Katrin
AU  - Schlag AK
AUID- ORCID: 0000-0003-2074-1917
AD  - Drug Science, London, UK.
AD  - King's College London, London, UK.
FAU - Baldwin, David S
AU  - Baldwin DS
AD  - Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
AD  - University of Cape Town, Cape Town, South Africa.
FAU - Barnes, Michael
AU  - Barnes M
AD  - University of Newcastle, Newcastle upon Tyne, UK.
FAU - Bazire, Steve
AU  - Bazire S
AD  - School of Pharmacy, University of East Anglia, Norwich, UK.
FAU - Coathup, Rachel
AU  - Coathup R
AD  - University of Manchester, Manchester, UK.
FAU - Curran, H Valerie
AU  - Curran HV
AD  - Clinical, Education and Health Psychology, University College London, London, UK.
FAU - McShane, Rupert
AU  - McShane R
AD  - Interventional Psychiatry Service, Oxford Health NHS Foundation Trust, Oxford,
      UK.
FAU - Phillips, Lawrence D
AU  - Phillips LD
AD  - Department of Management, London School of Economics & Political Science, London,
      UK.
FAU - Singh, Ilina
AU  - Singh I
AD  - Department of Psychiatry, University of Oxford, Oxford, UK.
FAU - Nutt, David J
AU  - Nutt DJ
AD  - Department of Brain Sciences, Imperial College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200610
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Cannabinoids)
RN  - 0 (Medical Marijuana)
SB  - IM
MH  - *Cannabinoids/economics/pharmacology/supply & distribution/therapeutic use
MH  - *Drug Prescriptions/economics/standards/statistics & numerical data
MH  - Humans
MH  - *Medical Marijuana/economics/pharmacology/supply & distribution/therapeutic use
MH  - *Practice Guidelines as Topic/standards
MH  - United Kingdom
PMC - PMC7436434
OTO - NOTNLM
OT  - *Cannabis
OT  - *cannabidiol
OT  - *d9 Tetrahydrocannabinol (d9THC)
OT  - *medical cannabis
OT  - *patient access
EDAT- 2020/06/12 06:00
MHDA- 2021/11/05 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1177/0269881120926677 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2020 Sep;34(9):931-937. doi: 10.1177/0269881120926677. Epub
      2020 Jun 10.


PMID- 32522024
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20220716
IS  - 1740-7753 (Electronic)
IS  - 1740-7745 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Aug
TI  - The APPROACH trial: Assessing pain, patient-reported outcomes, and complementary 
      and integrative health.
PG  - 351-359
LID - 10.1177/1740774520928399 [doi]
AB  - Electronic health record data can be used in multiple ways to facilitate
      real-world pragmatic studies. Electronic health record data can provide detailed 
      information about utilization of treatment options to help identify appropriate
      comparison groups, access historical clinical characteristics of participants,
      and facilitate measuring longitudinal outcomes for the treatments being studied. 
      An additional novel use of electronic health record data is to assess and
      understand referral pathways and other business practices that encourage or
      discourage patients from using different types of care. We describe an ongoing
      study utilizing access to real-time electronic health record data about changing 
      patterns of complementary and integrative health services to demonstrate how
      electronic health record data can provide the foundation for a pragmatic study
      when randomization is not feasible. Conducting explanatory trials of the value of
      emerging therapies within a healthcare system poses ethical and pragmatic
      challenges, such as withholding access to specific services that are becoming
      widely available to patients. We describe how prospective examination of
      real-time electronic health record data can be used to construct and understand
      business practices as potential surrogates for direct randomization through an
      instrumental variables analytic approach. In this context, an example of a
      business practice is the internal hiring of acupuncturists who also provide yoga 
      or Tai Chi classes and can offer these classes without additional cost compared
      to community acupuncturists. Here, the business practice of hiring internal
      acupuncturists is likely to encourage much higher rates of combined complementary
      and integrative health use compared to community referrals. We highlight the
      tradeoff in efficiency of this pragmatic approach and describe use of simulations
      to estimate the potential sample sizes needed for a variety of instrument
      strengths. While real-time monitoring of business practices from electronic
      health records provides insights into the validity of key independence
      assumptions associated with the instrumental variable approaches, we note that
      there may be some residual confounding by indication or selection bias and
      describe how alternative sources of electronic health record data can be used to 
      assess the robustness of instrumental variable assumptions to address these
      challenges. Finally, we also highlight that while some clinical outcomes can be
      obtained directly from the electronic health record, such as longitudinal opioid 
      utilization and pain intensity levels for the study of the value of complementary
      and integrative health, it is often critical to supplement clinical electronic
      health record-based measures with patient-reported outcomes. The experience of
      this example in evaluating complementary and integrative health demonstrates the 
      use of electronic health record data in several novel ways that may be of use for
      designing future pragmatic trials.
FAU - Zeliadt, Steven B
AU  - Zeliadt SB
AUID- ORCID: 0000-0003-3900-743X
AD  - Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Health 
      Administration, VA Puget Sound Health Care System, Seattle, WA, USA.
AD  - Department of Health Services, School of Public Health, University of Washington,
      Seattle, WA, USA.
FAU - Coggeshall, Scott
AU  - Coggeshall S
AD  - Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Health 
      Administration, VA Puget Sound Health Care System, Seattle, WA, USA.
FAU - Thomas, Eva
AU  - Thomas E
AD  - Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Health 
      Administration, VA Puget Sound Health Care System, Seattle, WA, USA.
FAU - Gelman, Hannah
AU  - Gelman H
AD  - Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Health 
      Administration, VA Puget Sound Health Care System, Seattle, WA, USA.
FAU - Taylor, Stephanie L
AU  - Taylor SL
AD  - Center for the Study of Healthcare Innovation, Implementation and Policy,
      Veterans Health Administration, VA Greater Los Angeles Healthcare System, Los
      Angeles, CA, USA.
AD  - Department of Health Policy and Management, UCLA School of Public Health, Los
      Angeles, CA, USA.
LA  - eng
GR  - IU1 HX002607/HX/HSRD VA/United States
PT  - Journal Article
DEP - 20200610
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
SB  - IM
MH  - Complementary Therapies/*methods
MH  - Computer Simulation
MH  - *Electronic Health Records
MH  - Humans
MH  - Integrative Medicine
MH  - Pain
MH  - *Pain Management
MH  - Pain Measurement
MH  - *Patient Reported Outcome Measures
MH  - Pragmatic Clinical Trials as Topic/*methods
MH  - Prospective Studies
MH  - Referral and Consultation
MH  - Research Design
MH  - Sample Size
MH  - Self Care
OTO - NOTNLM
OT  - *Confounding bias
OT  - *complementary and integrative health
OT  - *instrumental variables
OT  - *pain
OT  - *pragmatic trial
OT  - *self-management
EDAT- 2020/06/12 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
PHST- 2020/06/12 06:00 [entrez]
AID - 10.1177/1740774520928399 [doi]
PST - ppublish
SO  - Clin Trials. 2020 Aug;17(4):351-359. doi: 10.1177/1740774520928399. Epub 2020 Jun
      10.


PMID- 32521974
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1671-0274 (Print)
IS  - 1671-0274 (Linking)
VI  - 23
IP  - 6
DP  - 2020 Jun 25
TI  - [Integration of production-university-research based on artificial intelligence
      for technological innovation and transformation in gastrointestinal surgery].
PG  - 557-561
LID - 10.3760/cma.j.cn.441530-20200305-00118 [doi]
AB  - Medical artificial intelligence is a deeply integrated field of
      production-university-research. The collaborative innovation system of "industry,
      education and research" has broken down the barriers between various disciplines 
      and has shown great impetus in scientific and technological innovation and
      achievement transformation. The Affiliated Hospital of Qingdao University where
      the authors work, relying on Shandong Key Laboratory of Digital Medicine and
      Computer-Assisted Surgery and Institute of Digital Medicine and Computer-Assisted
      Surgery of Qingdao University, has jointly established a close
      "industry-university-research" cooperation mechanism with the State Key
      Laboratory of Virtual Reality Technology and Systems of Beijing University of
      Aeronautics and Astronautics and Qingdao Hisense Medical Equipment Co., Ltd.,
      which lasted for 10 years and carried out a series of useful explorations in
      scientific and technological innovation and achievement transformation in the
      field of gastrointestinal surgery of artificial intelligence with fruitful
      results. It mainly comprises of the following: (1) The research and development
      (R&D) of Hisense computer-assisted surgery (CAS) system has important clinical
      significance for laparoscopic gastrointestinal surgery guided by surrounding
      blood vessels that grasps globally the movement and variation of blood vessels in
      order to accurately select surgical strategies. (2) R&D of an automatic
      identification system for gastrointestinal diseases (namely image-assisted
      diagnosis system of artificial intelligence) initially applies deep neural
      network of artificial intelligence to the identification of lymph node metastases
      in rectal cancer, which has achieved accurate clinical diagnosis. (3) The virtual
      endoscopy platform for the gastrointestinal tract developed can successfully
      provide a new virtual endoscopy view of the intestinal wall eversion and realize 
      the one-way navigation of the intestinal wall. (4) A localized platform of
      laparoscopic surgery simulation training is established with completely
      independent intellectual property rights. We realize that clinical requirement is
      the source of research and development, clinical practice is the source of
      innovation, and clinicians are practitioners of transformation of achievements.
      The establishment of artificial intelligence models often requires the support of
      massive and high-quality clinical data. Therefore, the effectiveness of its
      promotion and application can only be ensured by adopting a multi-center research
      approach. In the whole process of scientific and technological innovation and
      achievement transformation, the issues of medical ethics and intellectual
      property rights cannot be ignored.
FAU - Liu, G W
AU  - Liu GW
AD  - Department of Gastrointestinal Surgery, The Affiliated Hospital, Qingdao
      University, Qingdao, Shandong 266003, China; Shandong Key Laboratory of Digital
      Medicine and Computer Assisted Surgery, Qingdao, Shandong 266003, China;
      Institute for Digital Medicine and Computer-Assisted Surgery of Qingdao
      University, Qingdao, Shandong 266000, China.
FAU - Li, S
AU  - Li S
AD  - State Key Laboratory of Virtual Reality Technology and System of Beijing
      University of Aeronautics and Astronautics, Beijing 100000, China; Qingdao
      Research Institute of Beijing University of Aeronautics and Astronautics,
      Qingdao, Shandong 266100, China.
FAU - Chen, Y J
AU  - Chen YJ
AD  - Shandong Key Laboratory of Digital Medicine and Computer Assisted Surgery,
      Qingdao, Shandong 266003, China; Institute for Digital Medicine and
      Computer-Assisted Surgery of Qingdao University, Qingdao, Shandong 266000, China;
      Qingdao Hisense Medical Equipment Co.LTD, Qingdao, Shandong 266100, China.
FAU - Lu, Y
AU  - Lu Y
AD  - Department of Gastrointestinal Surgery, The Affiliated Hospital, Qingdao
      University, Qingdao, Shandong 266003, China; Shandong Key Laboratory of Digital
      Medicine and Computer Assisted Surgery, Qingdao, Shandong 266003, China;
      Institute for Digital Medicine and Computer-Assisted Surgery of Qingdao
      University, Qingdao, Shandong 266000, China.
LA  - chi
GR  - 81802888/National Natural Science Foundation of China
GR  - ZR2019PF017/Shandong Natural Science Foundation
GR  - 2018GSF118088/the Key Research and Development Project of Shandong Province
PT  - Journal Article
PL  - China
TA  - Zhonghua Wei Chang Wai Ke Za Zhi
JT  - Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
JID - 101177990
SB  - IM
MH  - *Artificial Intelligence
MH  - Biomedical Research
MH  - Biomedical Technology
MH  - Digestive System Surgical Procedures/*trends
MH  - Humans
MH  - *Inventions
MH  - Technology Transfer
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Gastrointestinal surgery
OT  - Production-university-research
EDAT- 2020/06/12 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 10.3760/cma.j.cn.441530-20200305-00118 [doi]
PST - ppublish
SO  - Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Jun 25;23(6):557-561. doi:
      10.3760/cma.j.cn.441530-20200305-00118.


PMID- 32521917
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 2
DP  - 2020 Mar-Apr
TI  - What is the optimal high-dose treatment following autologous stem cell
      transplantation in relapsed or refractory germ cell cancer: a retrospective
      comparison of high-dose ICE and high-dose CE.
PG  - 1136-1140
AB  - PURPOSE: Testicular cancer is the most commonly diagnosed solid organ malignancy 
      in 15 to 35 year-old men with 1% incidence among all malignancies. Sixty percent 
      of patients with mild and poor-risk factors need additional treatments. Starting 
      in 1980s, high dose chemotherapy regimens (HDCT) that were not applicable before 
      due to hematological toxicity have been brought into use, and survival and cure
      possibility have increased. To date, no randomized trial has been conducted to
      demonstrate superiority of high-dose chemotherapy protocols used for autologous
      stem cell transplantation (ASCT). Our study aims to compare two commonly used
      HDCT regimens for a long period, with real-life data. METHODS: Approval for thiss
      retrospective study was obtained from the ethics committee of Gulhane Training
      and Research Hospital. Fifty refractory testicular cancer patients above 18 years
      were treated with HDCT and ASCT at Gulhane Training and Research Hospital
      (January 2011-July 2018). RESULTS: Fifty metastatic, refractory testicular
      carcinoma patients with a median age of 34 were included in the study. Ninety per
      cent of the cases had stage III disease at diagnosis. Except for 8 patients (16%)
      at mild risk group, all the other patients were at high risk. CE was used as
      salvage treatment for half of the patients and ICE was used for the other half.
      Four patients responded completely and 30 responded partially to ASCT. Post
      transplantation median progression-free survival (PFS) was 22 months. Median
      overall survival (OS) in the general population was 223.4 months (76.1-370.7).
      Although there was a difference in OS between chemotherapy groups, the difference
      was not statistically significant. The mean duration of engraftment in patients
      treated with CE was 11.2 +/- 2.3 days, while in patients receiving ICE it was
      15.5 +/- 2.1 days. This difference between chemotherapy groups was statistically 
      significant (p<0.001).
FAU - Yildiz, Birol
AU  - Yildiz B
AD  - Health Sciences University, Gulhane Training and Research Hospital, Department of
      Medical Oncology, Ankara, Turkey.
FAU - Pinar Aral, Ipek
AU  - Pinar Aral I
FAU - Balyemez, Ugurcan
AU  - Balyemez U
FAU - Esin, Ece
AU  - Esin E
FAU - Erturk, Ismail
AU  - Erturk I
FAU - Acar, Ramazan
AU  - Acar R
FAU - Karadurmus, Nuri
AU  - Karadurmus N
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - Testicular Germ Cell Tumor
SB  - IM
MH  - Adult
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local
MH  - Neoplasms, Germ Cell and Embryonal/*drug therapy/pathology/*therapy
MH  - Retrospective Studies
MH  - Testicular Neoplasms/*drug therapy/pathology/*therapy
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Autologous/*methods
EDAT- 2020/06/12 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Mar-Apr;25(2):1136-1140.


PMID- 32521838
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 2
DP  - 2020 Mar-Apr
TI  - The arbitrary magic of p<0.05: Beyond statistics.
PG  - 588-593
AB  - Modern research and scientific conclusions are widely regarded as valid when the 
      study design and analysis are interpreted correctly. P-value is considered to be 
      the most commonly used method to provide a dichotomy between true and false data 
      in evidence-based medicine. However, many authors, reviewers and editors may be
      unfamiliar with the true definition and correct interpretation of this number.
      This article intends to point out how misunderstanding or misuse of this value
      can have an impact in both the scientific community as well as the society we
      live in. The foundation of the medical education system rewards the abundance of 
      scientific papers rather than the careful search of the truth. Appropriate
      research ethics should be practised in all stages of the publication process.
FAU - E Alifieris, Constantinos
AU  - E Alifieris C
AD  - Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, USA.
FAU - Souferi Chronopoulou, Eleni
AU  - Souferi Chronopoulou E
FAU - T Trafalis, Dimitrios
AU  - T Trafalis D
FAU - Arvelakis, Antonios
AU  - Arvelakis A
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
SB  - IM
MH  - Biostatistics/*methods
MH  - Humans
MH  - Peer Review/methods/standards
MH  - Publications/standards
EDAT- 2020/06/12 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/06/12 06:00
PHST- 2020/06/12 06:00 [entrez]
PHST- 2020/06/12 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Mar-Apr;25(2):588-593.


PMID- 35514562
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 10
IP  - 38
DP  - 2020 Jun 10
TI  - The development of novel bioactive porous titanium as a bone reconstruction
      material.
PG  - 22684-22690
LID - 10.1039/d0ra03202f [doi]
AB  - Porous titanium fabricated by the resin-impregnated titanium substitute technique
      has good mechanical strength and osteoconduction. The alkali treatment of the
      titanium surface creates a bioactive surface. Alkali-treated porous titanium is
      expected to accelerate bone formation. The purpose of this study was to evaluate 
      the bone reconstruction ability of alkali-treated porous titanium. Porous
      titanium (85% porosity) was treated with an alkali solution (5 N NaOH, 24 h). To 
      assess material properties, we analyzed the surface structure by scanning
      electron microscopy (SEM) and mechanical strength testing. To assess bioactivity,
      each sample was soaked in a simulated body fluid (Hank's solution) for 7 days.
      Surface observations, weight change ratio measurement (after/before being soaked 
      in Hank's solution) and surface elemental analysis were performed. We also
      designed an in vivo study with rabbit femurs. After 2 and 3 weeks of
      implantation, histological observations and histomorphometric bone formation
      ratio analysis were performed. All data were statistically analyzed using a
      Student's t-test (P < 0.05) (this study was approved by the Hiroshima University 
      animal experiment ethics committee: A11-5-5). Non-treated porous titanium
      (control) appeared to have a smooth surface and the alkali-treated porous
      titanium (ATPT) had a nano-sized needle-like rough surface. ATPT had similar
      mechanical strength to that of the control. After soaking into the Hank's
      solution, we observed apatite-like crystals in the SEM image, weight gain, and
      high Ca and P contents in ATPT. There was significant bone formation at an early 
      stage in ATPT compared with that in control. It was suggested that the
      alkali-treated porous titanium had a bioactive surface and induced bone
      reconstruction effectively. This novel bioactive porous titanium can be expected 
      to be a good bone reconstruction material.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Doi, Kazuya
AU  - Doi K
AUID- ORCID: https://orcid.org/0000-0001-9452-4750
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
FAU - Kobatake, Reiko
AU  - Kobatake R
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
FAU - Makihara, Yusuke
AU  - Makihara Y
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
FAU - Oki, Yoshifumi
AU  - Oki Y
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
FAU - Umehara, Hanako
AU  - Umehara H
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
FAU - Kubo, Takayasu
AU  - Kubo T
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
FAU - Tsuga, Kazuhiro
AU  - Tsuga K
AD  - Department of Advanced Prosthodontics, Hiroshima University Graduate School of
      Biomedical and Health Sciences 1-2-3, Kasumi, Minami-ku Hiroshima 734-8553 Japan 
      kazuya17@hiroshima-u.ac.jp +81 82 257 5679 +81 82 257 5677.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9054584
COIS- There are no conflicts to declare.
EDAT- 2020/06/12 00:00
MHDA- 2020/06/12 00:01
CRDT- 2022/05/06 05:28
PHST- 2020/04/09 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2022/05/06 05:28 [entrez]
PHST- 2020/06/12 00:00 [pubmed]
PHST- 2020/06/12 00:01 [medline]
AID - 10.1039/d0ra03202f [doi]
AID - d0ra03202f [pii]
PST - epublish
SO  - RSC Adv. 2020 Jun 12;10(38):22684-22690. doi: 10.1039/d0ra03202f. eCollection
      2020 Jun 10.


PMID- 32521581
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2233-8233 (Print)
IS  - 2093-8896 (Linking)
VI  - 47
IP  - 2
DP  - 2020 Jun
TI  - Advantages of the outgrowth model for evaluating the implantation competence of
      blastocysts.
PG  - 85-93
LID - 10.5653/cerm.2019.03216 [doi]
AB  - The implantation process is highly complex and difficult to mimic in vitro, and a
      reliable experimental model of implantation has yet to be established. Many
      researchers have used embryo transfer (ET) to assess implantation potential;
      however, ET with pseudopregnant mice requires expert surgical skills and numerous
      sacrificial animals. To overcome those economic and ethical problems, several
      researchers have tried to use outgrowth models to evaluate the implantation
      potential of embryos. Many previous studies, as well as our experiments, have
      found significant correlations between blastocyst outgrowth in vitro and
      implantation in utero by ET. This review proposes the blastocyst outgrowth model 
      as a possible alternative to animal experimentation involving ET in utero. In
      particular, the outgrowth model might be a cost- and time-effective alternative
      method to ET for evaluating the effectiveness of culture conditions or
      treatments. An advanced outgrowth model and further culture of outgrowth embryos 
      could provide a subtle research model of peri- and postimplantation development, 
      excluding maternal effects, and thereby could facilitate progress in assisted
      reproductive technologies. Recently, we found that outgrowth embryos secreted
      extracellular vesicles containing specific microRNAs. The function of microRNAs
      from outgrowth embryos should be elucidated in further researches.
FAU - Kim, Jihyun
AU  - Kim J
AD  - Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Korea.
FAU - Lee, Jaewang
AU  - Lee J
AD  - Department of Biomedical Laboratory Science, College of Health Science, Eulji
      University, Seongnam, Korea.
FAU - Jun, Jin Hyun
AU  - Jun JH
AD  - Department of Biomedical Laboratory Science, College of Health Science, Eulji
      University, Seongnam, Korea.
AD  - Department of Senior Healthcare, BK21 Plus Program, Graduate School, Eulji
      University, Seongnam, Korea.
AD  - Eulji Medi-Bio Research Institute (EMBRI), Eulji University, Daejeon, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200507
PL  - Korea (South)
TA  - Clin Exp Reprod Med
JT  - Clinical and experimental reproductive medicine
JID - 101563916
PMC - PMC7315857
OTO - NOTNLM
OT  - Blastocysts
OT  - Extracellular vesicles
OT  - Implantation
OT  - MicroRNAs
OT  - Outgrowth
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2019/08/01 00:00 [received]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
AID - cerm.2019.03216 [pii]
AID - 10.5653/cerm.2019.03216 [doi]
PST - ppublish
SO  - Clin Exp Reprod Med. 2020 Jun;47(2):85-93. doi: 10.5653/cerm.2019.03216. Epub
      2020 May 7.


PMID- 32521489
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1877-783X (Electronic)
IS  - 1877-7821 (Linking)
VI  - 67
DP  - 2020 Aug
TI  - The tobacco epidemic curve in Brazil: Where are we going?
PG  - 101736
LID - S1877-7821(20)30070-9 [pii]
LID - 10.1016/j.canep.2020.101736 [doi]
AB  - BACKGROUND: Brazil experienced a robust decline in smoking prevalence rates as a 
      consequence of public policies. Since lung cancer is strongly associated with
      smoking, trends in lung cancer mortality rates may be used as a delayed
      effectiveness indicator of smoking prevention interventions. OBJECTIVES: The aim 
      of this study was to estimate lung cancer mortality trends from 1980 through 2017
      and to predict temporal trends in lung cancer mortality rates, in Brazil from
      2016 through 2040. METHODS: Time trends in lung cancer mortality rates were
      evaluated using data from available public databases. Crude and age-standardized 
      mortality rates were calculated for each year sex-specific mortality predictions 
      were made for each five-year period from 2016 to 2020 through 2036-2040 using an 
      age-period-cohort (APC) model. Sex ratios were estimated using age-standardized
      lung cancer mortality rates. RESULTS: A decline in age-standardized lung cancer
      mortality rates has been observed for males since 2005 and for all predicted
      periods. It is expected that females aged 55 or younger will experience a
      reduction in lung cancer mortality from 2021 to 2026 onwards, but for those aged 
      75 or over rates are predicted to continue increasing through 2036-2040.
      CONCLUSION: Smoking prevention and cessation policies are essential, and it is
      important to commit to an ethical framework whereby equity in tobacco control
      activities between genders is achieved. This will avert many premature and
      preventable smoking-related deaths in the next decades.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Carvalho de Souza, Mirian
AU  - Carvalho de Souza M
AD  - National Cancer Institute, Brazil. Electronic address: miriancs@inca.gov.br.
FAU - Giunta, Diego H
AU  - Giunta DH
AD  - National Cancer Institute, Brazil; Hospital Italiano de Buenos Aires. Electronic 
      address: diego.giunta@hiba.org.ar.
FAU - Szklo, Andre S
AU  - Szklo AS
AD  - National Cancer Institute, Brazil. Electronic address: aszklo@inca.gov.br.
FAU - Almeida, Liz Maria de
AU  - Almeida LM
AD  - National Cancer Institute, Brazil. Electronic address: lalmeida@inca.gov.br.
FAU - Szklo, Moyses
AU  - Szklo M
AD  - National Cancer Institute, Brazil; The Johns Hopkins University. Electronic
      address: mszklo1@jhu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200607
PL  - Netherlands
TA  - Cancer Epidemiol
JT  - Cancer epidemiology
JID - 101508793
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brazil/epidemiology
MH  - Databases, Factual
MH  - Epidemics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/epidemiology/etiology/*mortality
MH  - Male
MH  - Middle Aged
MH  - Mortality/*trends
MH  - Prevalence
MH  - Smoking/*adverse effects
OTO - NOTNLM
OT  - *Forecast
OT  - *Logistic models
OT  - *Lung neoplasms
OT  - *Mortality trends
OT  - *Tobacco use disorder
EDAT- 2020/06/11 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/06/11 06:00
PHST- 2019/10/23 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - S1877-7821(20)30070-9 [pii]
AID - 10.1016/j.canep.2020.101736 [doi]
PST - ppublish
SO  - Cancer Epidemiol. 2020 Aug;67:101736. doi: 10.1016/j.canep.2020.101736. Epub 2020
      Jun 7.


PMID- 32521423
OWN - NLM
STAT- Publisher
LR  - 20200616
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 91
DP  - 2020 May 8
TI  - Interrupting the cycle of bullying witnessed or experienced by nursing students: 
      An ethical and relational action framework.
PG  - 104458
LID - S0260-6917(19)31043-3 [pii]
LID - 10.1016/j.nedt.2020.104458 [doi]
AB  - BACKGROUND: The prevalence of bullying experienced by nursing students continues 
      to be a substantial concern for the profession, especially for nurse educators.
      It is also an issue in other health care professional programs. OBJECTIVES: To
      explore how educational institutions address bullying experienced by nursing and 
      other health care professional students, with the goal of creating a set of
      procedures for reporting bullying if students witness or experience it during
      their education. DESIGN: Qualitative Description. Our central question was "What 
      processes and resources do faculty members use when students disclose an
      experience related to bullying?" SETTINGS: Educational institutions in Western
      Canada. PARTICIPANTS: Nine faculty members and one staff member with a student
      service role from nursing and other health care profession programs. METHODS:
      Semi-structured interviews. RESULTS: We found significant variation in
      interviewees' conceptions of bullying and the policies, processes, and resources 
      for addressing bullying within programs. We adopted an existing definition of
      bullying; designed a set of procedures focused on reporting mechanisms; and
      developed a guiding framework entitled Addressing Bullying in Nursing Education: 
      An Ethical and Relational Action Framework. CONCLUSIONS: Nursing and other health
      care professional programs should ensure they have 1) clear and transparent
      procedures to report bullying 2) education about bullying for students and
      faculty.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - O'Flynn-Magee, Kathy
AU  - O'Flynn-Magee K
AD  - University of British Columbia, School of Nursing, Vancouver, Canada. Electronic 
      address: kathy.oflynnmagee@ubc.ca.
FAU - Rodney, Patricia
AU  - Rodney P
AD  - University of British Columbia, School of Nursing, Vancouver, Canada. Electronic 
      address: paddy.rodney@ubc.ca.
FAU - Pearson, Marion
AU  - Pearson M
AD  - University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver,
      Canada. Electronic address: marion.pearson@ubc.ca.
FAU - Afonso Burnay, Marta
AU  - Afonso Burnay M
AD  - University of British Columbia, School of Nursing, Vancouver, Canada. Electronic 
      address: marta.afonso.burnay@gmail.com.
FAU - Daly, Zachary
AU  - Daly Z
AD  - University of British Columbia, School of Nursing, Vancouver, Canada. Electronic 
      address: Zachary.daly@ubc.ca.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
OTO - NOTNLM
OT  - Bullying
OT  - Educational policy
OT  - Ethical & relational action framework
OT  - Interprofessional
OT  - Learning environment
OT  - Nursing education
COIS- Declaration of competing interest Not applicable.
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/06/11 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2020/02/13 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - S0260-6917(19)31043-3 [pii]
AID - 10.1016/j.nedt.2020.104458 [doi]
PST - aheadofprint
SO  - Nurse Educ Today. 2020 May 8;91:104458. doi: 10.1016/j.nedt.2020.104458.


PMID- 32521416
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220716
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 258
DP  - 2020 Aug
TI  - Stigma in African genomics research: Gendered blame, polygamy, ancestry and
      disease causal beliefs impact on the risk of harm.
PG  - 113091
LID - S0277-9536(20)30310-5 [pii]
LID - 10.1016/j.socscimed.2020.113091 [doi]
AB  - A recurring concern in genomics research is the possibility that it could lead to
      stigma for participants, their families and the population groups they belong to.
      Little evidence exists to explain how and when this ought to be a concern in
      genomics research in Africa whilst there is growing international evidence
      drawing into question the direct link between stigma and genetics. In this paper,
      we interrogate practical instances from African genomics research where stigma
      was identified as a concern in an attempt to nuance and refine accounts of when
      stigma should be considered as an ethical issue. The paper describes examples
      involving gendered blame, polygamy, beliefs in supernatural disease causation and
      sensitive information about group lineage. We propose that the concern may not be
      about stigma so much as broader research-related harm, including for instance
      reputational harm to population groups. Furthermore, we propose to shift the
      analytical gaze from establishing causal relationships to exploring the
      intersection of genomics with pre-existing stigma. Finally, we emphasize the
      importance of ensuring genomics researchers are culturally competent, meaning
      able to recognise when cultural factors impact on the possibility that genomics
      research could cause harm.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - de Vries, Jantina
AU  - de Vries J
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town,
      South Africa. Electronic address: jantina.devries@uct.ac.za.
FAU - Landoure, Guida
AU  - Landoure G
AD  - Faculte de Medecine et d'Odontostomatologie, USTTB, Bamako, Mali; Service de
      Neurologie, CHU du Point "G", Bamako, Mali.
FAU - Wonkam, Ambroise
AU  - Wonkam A
AD  - Department of Medicine, Faculty of Health Sciences, University of Cape Town,
      South Africa; Institute of Infectious Diseases and Molecular Medicine, Faculty of
      Health Sciences, University of Cape Town, South Africa; Department of Pathology, 
      Faculty of Health Sciences, University of Cape Town, South Africa.
LA  - eng
GR  - U01 HG007044/HG/NHGRI NIH HHS/United States
GR  - U01 HG008226/HG/NHGRI NIH HHS/United States
GR  - U24 HL135600/HL/NHLBI NIH HHS/United States
GR  - U54 HG009790/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Africa
MH  - *Genomics
MH  - Humans
MH  - *Marriage
MH  - Research Personnel
MH  - Social Stigma
PMC - PMC7396479
MID - NIHMS1612574
OTO - NOTNLM
OT  - *Africa
OT  - *Ancestry
OT  - *Gendered blame
OT  - *Genetic attribution
OT  - *Genomics
OT  - *Polygamy
OT  - *Stigma
EDAT- 2020/06/11 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - S0277-9536(20)30310-5 [pii]
AID - 10.1016/j.socscimed.2020.113091 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Aug;258:113091. doi: 10.1016/j.socscimed.2020.113091. Epub 2020
      May 30.


PMID- 32521358
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20210414
IS  - 1879-1360 (Electronic)
IS  - 0022-3999 (Linking)
VI  - 135
DP  - 2020 Aug
TI  - Protocol for a partially nested randomised controlled trial to evaluate the
      effectiveness of the scleroderma patient-centered intervention network COVID-19
      home-isolation activities together (SPIN-CHAT) program to reduce anxiety among
      at-risk scleroderma patients.
PG  - 110132
LID - S0022-3999(20)30400-1 [pii]
LID - 10.1016/j.jpsychores.2020.110132 [doi]
AB  - OBJECTIVE: Contagious disease outbreaks and related restrictions can lead to
      negative psychological outcomes, particularly in vulnerable populations at risk
      due to pre-existing medical conditions. No randomised controlled trials (RCTs)
      have tested interventions to reduce mental health consequences of contagious
      disease outbreaks. The primary objective of the Scleroderma Patient-centered
      Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT)
      Trial is to evaluate the effect of a videoconference-based program on symptoms of
      anxiety. Secondary objectives include evaluating effects on symptoms of
      depression, stress, loneliness, boredom, physical activity, and social
      interaction. METHODS: The SPIN-CHAT Trial is a pragmatic RCT that will be
      conducted using the SPIN-COVID-19 Cohort, a sub-cohort of the SPIN Cohort.
      Eligible participants will be SPIN-COVID-19 Cohort participants without a
      positive COVID-19 test, with at least mild anxiety (PROMIS Anxiety 4a v1.0
      T-score>/=55), not working from home, and not receiving current counselling or
      psychotherapy. We will randomly assign 162 participants to intervention groups of
      7 to 10 participants each or waitlist control. We will use a partially nested RCT
      design to reflect dependence between individuals in training groups but not in
      the waitlist control. The SPIN-CHAT Program includes activity engagement,
      education on strategies to support mental health, and mutual participant support.
      Intervention participants will receive the 4-week (3 sessions per week) SPIN-CHAT
      Program via videoconference. The primary outcome is PROMIS Anxiety 4a score
      immediately post-intervention. ETHICS AND DISSEMINATION: The SPIN-CHAT Trial will
      test whether a brief videoconference-based intervention will improve mental
      health outcomes among at-risk individuals during contagious disease outbreak.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Thombs, Brett D
AU  - Thombs BD
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec,
      Canada; Department of Epidemiology, Biostatistics, and Occupational Health,
      McGill University, Montreal, Quebec, Canada; Department of Medicine, McGill
      University, Montreal, Quebec, Canada; Department of Psychology, McGill
      University, Montreal, Quebec, Canada; Department of Educational and Counselling
      Psychology, McGill University, Montreal, Quebec, Canada; Biomedical Ethics Unit, 
      McGill University, Montreal, Quebec, Canada. Electronic address:
      brett.thombs@mcgill.ca.
FAU - Kwakkenbos, Linda
AU  - Kwakkenbos L
AD  - Department of Clinical Psychology, Behavioural Science Institute, Radboud
      University, Nijmegen, the Netherlands.
FAU - Carrier, Marie-Eve
AU  - Carrier ME
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Bourgeault, Angelica
AU  - Bourgeault A
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Tao, Lydia
AU  - Tao L
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Harb, Sami
AU  - Harb S
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec,
      Canada.
FAU - Gagarine, Maria
AU  - Gagarine M
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational
      Health, McGill University, Montreal, Quebec, Canada.
FAU - Rice, Danielle
AU  - Rice D
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Psychology, McGill University, Montreal, Quebec,
      Canada.
FAU - Bustamante, Laura
AU  - Bustamante L
AD  - Department of Applied Human Sciences, Concordia University, Montreal, Quebec,
      Canada.
FAU - Ellis, Kelsey
AU  - Ellis K
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
FAU - Duchek, Delaney
AU  - Duchek D
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
FAU - Wu, Yin
AU  - Wu Y
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec,
      Canada.
FAU - Bhandari, Parash Mani
AU  - Bhandari PM
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational
      Health, McGill University, Montreal, Quebec, Canada.
FAU - Neupane, Dipika
AU  - Neupane D
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational
      Health, McGill University, Montreal, Quebec, Canada.
FAU - Carboni-Jimenez, Andrea
AU  - Carboni-Jimenez A
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec,
      Canada.
FAU - Henry, Richard S
AU  - Henry RS
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec,
      Canada.
FAU - Krishnan, Ankur
AU  - Krishnan A
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Sun, Ying
AU  - Sun Y
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Levis, Brooke
AU  - Levis B
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational
      Health, McGill University, Montreal, Quebec, Canada; Centre for Prognosis
      Research, School of Primary, Community and Social Care, Keele University,
      Staffordshire, UK.
FAU - He, Chen
AU  - He C
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Turner, Kimberly A
AU  - Turner KA
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
FAU - Benedetti, Andrea
AU  - Benedetti A
AD  - Department of Epidemiology, Biostatistics, and Occupational Health, McGill
      University, Montreal, Quebec, Canada; Department of Medicine, McGill University, 
      Montreal, Quebec, Canada; Respiratory Epidemiology and Clinical Research Unit,
      McGill University Health Centre, Montreal, Quebec, Canada.
FAU - Culos-Reed, Nicole
AU  - Culos-Reed N
AD  - Department of Applied Human Sciences, Concordia University, Montreal, Quebec,
      Canada; Department of Oncology, Cumming School of Medicine, Calgary, Canada;
      Department of Psychosocial Resources, Tom Baker Cancer Centre, Alberta Health
      Services, Calgary, Alberta, Canada.
FAU - El-Baalbaki, Ghassan
AU  - El-Baalbaki G
AD  - Department of Psychology, Universite du Quebec a Montreal, Montreal, Quebec,
      Canada.
FAU - Hebblethwaite, Shannon
AU  - Hebblethwaite S
AD  - Department of Applied Human Sciences, Concordia University, Montreal, Quebec,
      Canada.
FAU - Bartlett, Susan J
AU  - Bartlett SJ
AD  - Department of Medicine, McGill University, Montreal, Quebec, Canada; Research
      Institute, McGill University Health Centre, Montreal, Quebec, Canada.
FAU - Dyas, Laura
AU  - Dyas L
AD  - Scleroderma Foundation Michigan Chapter, Southfield, MI, USA.
FAU - Patten, Scott
AU  - Patten S
AD  - Department of Community Health Sciences, University of Calgary, Calgary, Alberta,
      Canada; Hotchkiss Brain Institute and O'Brien Institute for Public Health,
      University of Calgary, Calgary, Alberta, Canada.
FAU - Varga, John
AU  - Varga J
AD  - Northwestern Scleroderma Program, Feinberg School of Medicine, Northwestern
      University, Chicago, IL, USA.
CN  - Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Patient
      Advisory Team
CN  - SPIN Investigators
LA  - eng
GR  - KL2 TR003168/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200514
PL  - England
TA  - J Psychosom Res
JT  - Journal of psychosomatic research
JID - 0376333
SB  - IM
MH  - Anxiety/*prevention & control
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/prevention & control/*psychology
MH  - Health Promotion/*methods
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Patient-Centered Care
MH  - Pneumonia, Viral/epidemiology/prevention & control/*psychology
MH  - Program Evaluation
MH  - Research Design
MH  - Risk Assessment
MH  - Scleroderma, Systemic/*therapy
MH  - Social Isolation/psychology
MH  - Videoconferencing
PMC - PMC7224675
OTO - NOTNLM
OT  - *Anxiety
OT  - *COVID-19
OT  - *Coronavirus
OT  - *Mental health
OT  - *RCT
OT  - *Scleroderma
OT  - *Systemic sclerosis
OT  - *Trial
COIS- Declaration of Competing Interest All authors have completed the ICMJE uniform
      disclosure form at www.icmje.org/coi_disclosure.pdf and declare that they have no
      competing interests.
IR  - Fortune C
FIR - Fortune, Catherine
IRAD- Ottawa Scleroderma Support Group, Ottawa, Ontario, Canada.
IR  - Gietzen A
FIR - Gietzen, Amy
IRAD- Scleroderma Foundation, Danvers, Massachusetts, USA.
IR  - Guillot G
FIR - Guillot, Genevieve
IRAD- Sclerodermie Quebec, Longueuil, Quebec, Canada.
IR  - Lewis N
FIR - Lewis, Nancy
IRAD- Toronto, Ontario, Canada.
IR  - Nielsen K
FIR - Nielsen, Karen
IRAD- Scleroderma Society of Ontario, Hamilton, Ontario, Canada.
IR  - Richard M
FIR - Richard, Michelle
IRAD- Past-president of Scleroderma Canada, Halifax, Nova Scotia, Canada.
IR  - Sauve M
FIR - Sauve, Maureen
IRAD- Scleroderma Society of Ontario and Scleroderma Canada, Hamilton, Ontario, Canada.
IR  - Welling J
FIR - Welling, Joep
IRAD- NVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, The
      Netherlands.
IR  - Baron M
FIR - Baron, Murray
IRAD- McGill University, Montreal, Quebec, Canada.
IR  - Furst DE
FIR - Furst, Daniel E
IRAD- Division of Rheumatology, Geffen School of Medicine, University of California,
      Los Angeles, CA, USA.
IR  - Gottesman K
FIR - Gottesman, Karen
IRAD- Scleroderma Foundation, Los Angeles, CA, USA.
IR  - Malcarne V
FIR - Malcarne, Vanessa
IRAD- San Diego State University, San Diego, CA, USA.
IR  - Mayes MD
FIR - Mayes, Maureen D
IRAD- University of Texas McGovern School of Medicine, Houston, TX, USA.
IR  - Mouthon L
FIR - Mouthon, Luc
IRAD- Universite Paris Descartes, Paris, France.
IR  - Nielson WR
FIR - Nielson, Warren R
IRAD- St. Joseph's Health Care, London, Ontario, Canada.
IR  - Riggs R
FIR - Riggs, Robert
IRAD- Scleroderma Foundation, Danvers, MA, USA.
IR  - Wigley F
FIR - Wigley, Fredrick
IRAD- Johns Hopkins University School of Medicine, Baltimore, MD, USA.
IR  - Assassi S
FIR - Assassi, Shervin
IRAD- University of Texas McGovern School of Medicine, Houston, TX, USA.
IR  - Boutron I
FIR - Boutron, Isabelle
IRAD- Universite Paris Descartes, Hopitaux de Paris, Paris, France.
IR  - Ells C
FIR - Ells, Carolyn
IRAD- McGill University, Montreal, Quebec, Canada.
IR  - van den Ende C
FIR - van den Ende, Cornelia
IRAD- Sint Maartenskliniek, Nijmegen, The Netherlands.
IR  - Fligelstone K
FIR - Fligelstone, Kim
IRAD- Scleroderma & Raynaud's UK, London, UK.
IR  - Frech T
FIR - Frech, Tracy
IRAD- University of Utah, Salt Lake City, UT, USA.
IR  - Godard D
FIR - Godard, Dominique
IRAD- Association des Sclerodermiques de France, Sorel-Moussel, France.
IR  - Harel D
FIR - Harel, Daphna
IRAD- New York University, New York, NY, USA.
IR  - Hinchcliff M
FIR - Hinchcliff, Monique
IRAD- Yale School of Medicine, New Haven, CT, USA.
IR  - Hudson M
FIR - Hudson, Marie
IRAD- McGill University, Montreal, Quebec, Canada.
IR  - Johnson SR
FIR - Johnson, Sindhu R
IRAD- Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital,
      University of Toronto, Toronto, Ontario, Canada.
IR  - Larche M
FIR - Larche, Maggie
IRAD- McMaster University, Hamilton, Ontario, Canada.
IR  - Leite C
FIR - Leite, Catarina
IRAD- University of Minho, Braga, Portugal.
IR  - Nguyen C
FIR - Nguyen, Christelle
IRAD- Universite Paris Descartes, Hopitaux de Paris, Paris, France.
IR  - Pope J
FIR - Pope, Janet
IRAD- University of Western Ontario, London, Ontario, Canada.
IR  - Portales A
FIR - Portales, Alexandra
IRAD- Asociacion Espanola de Esclerodermia, Madrid, Spain.
IR  - Rannou F
FIR - Rannou, Francois
IRAD- Universite Paris Descartes, Hopitaux de Paris, Paris, France.
IR  - Reyna TSR
FIR - Reyna, Tatiana Sofia Rodriguez
IRAD- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City,
      Mexico.
IR  - Schouffoer AA
FIR - Schouffoer, Anne A
IRAD- Leiden University Medical Center, Leiden, The Netherlands.
IR  - Suarez-Almazor ME
FIR - Suarez-Almazor, Maria E
IRAD- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IR  - Agard C
FIR - Agard, Christian
IRAD- Centre Hospitalier Universitaire, Hotel-Dieu de Nantes, Nantes, France.
IR  - Albert A
FIR - Albert, Alexandra
IRAD- Universite Laval, Quebec, Quebec, Canada.
IR  - Andre M
FIR - Andre, Marc
IRAD- Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
IR  - Arsenault G
FIR - Arsenault, Guylaine
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Benzidia I
FIR - Benzidia, Ilham
IRAD- Hopitaux de Paris, Hopital St-Louis, Paris, France.
IR  - Bernstein EJ
FIR - Bernstein, Elana J
IRAD- Columbia University, New York, NY, USA.
IR  - Berthier S
FIR - Berthier, Sabine
IRAD- Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.
IR  - Bissonnette L
FIR - Bissonnette, Lyne
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Boire G
FIR - Boire, Gilles
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Bruns A
FIR - Bruns, Alessandra
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Carreira P
FIR - Carreira, Patricia
IRAD- Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
IR  - Casadevall M
FIR - Casadevall, Marion
IRAD- Hopitaux de Paris, Hopital Cochin, Paris, France.
IR  - Chaigne B
FIR - Chaigne, Benjamin
IRAD- Hopitaux de Paris, Hopital Cochin, Paris, France.
IR  - Chung L
FIR - Chung, Lorinda
IRAD- Stanford University, Stanford, CA, USA.
IR  - Cohen P
FIR - Cohen, Pascal
IRAD- Hopitaux de Paris, Hopital Cochin, Paris, France.
IR  - Correia C
FIR - Correia, Chase
IRAD- Northwestern University, Chicago, IL, USA.
IR  - Dagenais P
FIR - Dagenais, Pierre
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Denton C
FIR - Denton, Christopher
IRAD- Royal Free London Hospital, London, UK.
IR  - Domsic R
FIR - Domsic, Robyn
IRAD- University of Pittsburgh, Pittsburgh, PA, USA.
IR  - Dubois S
FIR - Dubois, Sandrine
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Dunne JV
FIR - Dunne, James V
IRAD- St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia,
      Canada.
IR  - Dunogue B
FIR - Dunogue, Bertrand
IRAD- Hopitaux de Paris, Hopital Cochin, Paris, France.
IR  - Fare R
FIR - Fare, Regina
IRAD- Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
IR  - Farge-Bancel D
FIR - Farge-Bancel, Dominique
IRAD- Hopitaux de Paris, Hopital St-Louis, Paris, France.
IR  - Fortin PR
FIR - Fortin, Paul R
IRAD- CHU de Quebec, Universite Laval, Quebec, Quebec, Canada.
IR  - Gill A
FIR - Gill, Anna
IRAD- Royal Free London Hospital, London, UK.
IR  - Gordon J
FIR - Gordon, Jessica
IRAD- Hospital for Special Surgery, New York City, NY, USA.
IR  - Granel-Rey B
FIR - Granel-Rey, Brigitte
IRAD- Aix Marseille Universite, Hopitaux de Marseille, Hopital Nord, Marseille, France.
IR  - Gyger G
FIR - Gyger, Genevieve
IRAD- Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
IR  - Hachulla E
FIR - Hachulla, Eric
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Hatron PY
FIR - Hatron, Pierre-Yves
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Herrick AL
FIR - Herrick, Ariane L
IRAD- University of Manchester, Salford Royal NHS Foundation Trust, Manchester, UK.
IR  - Hij A
FIR - Hij, Adrian
IRAD- Hopitaux de Paris, Hopital St-Louis, Paris, France.
IR  - Hoa S
FIR - Hoa, Sabrina
IRAD- Centre hospitalier de l'universite de Montreal - CHUM, Montreal, Quebec, Canada.
IR  - Ikic A
FIR - Ikic, Alena
IRAD- Universite Laval, Quebec, Quebec, Canada.
IR  - Jones N
FIR - Jones, Niall
IRAD- University of Alberta, Edmonton, Alberta, Canada.
IR  - de B Fernandes AJ
FIR - de B Fernandes, Artur Jose
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Kafaja S
FIR - Kafaja, Suzanne
IRAD- University of California, Los Angeles, CA, USA.
IR  - Khalidi N
FIR - Khalidi, Nader
IRAD- McMaster University, Hamilton, Ontario, Canada.
IR  - Lambert M
FIR - Lambert, Marc
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Launay D
FIR - Launay, David
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Liang P
FIR - Liang, Patrick
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Maillard H
FIR - Maillard, Helene
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Maltez N
FIR - Maltez, Nancy
IRAD- University of Ottawa, Ottawa, Ontario, Canada.
IR  - Manning J
FIR - Manning, Joanne
IRAD- Salford Royal NHS Foundation Trust, Salford, UK.
IR  - Marie I
FIR - Marie, Isabelle
IRAD- CHU Rouen, Hopital de Bois-Guillaume, Rouen, France.
IR  - Martin M
FIR - Martin, Maria
IRAD- Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
IR  - Martin T
FIR - Martin, Thierry
IRAD- Les Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg,
      France.
IR  - Masetto A
FIR - Masetto, Ariel
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Maurier F
FIR - Maurier, Francois
IRAD- Hopitaux Prives de Metz, Hopital Belle-Isle, Metz, France.
IR  - Mekinian A
FIR - Mekinian, Arsene
IRAD- Hopitaux de Paris, Hopital St-Antoine, Paris, France.
IR  - Melchor S
FIR - Melchor, Sheila
IRAD- Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
IR  - Nikpour M
FIR - Nikpour, Mandana
IRAD- St Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
IR  - Olagne L
FIR - Olagne, Louis
IRAD- Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
IR  - Poindron V
FIR - Poindron, Vincent
IRAD- Les Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg,
      France.
IR  - Proudman S
FIR - Proudman, Susanna
IRAD- Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia,
      Australia.
IR  - Regent A
FIR - Regent, Alexis
IRAD- Hopitaux de Paris, Hopital Cochin, Paris, France.
IR  - Riviere S
FIR - Riviere, Sebastien
IRAD- Hopitaux de Paris, Hopital St-Antoine, Paris, France.
IR  - Robinson D
FIR - Robinson, David
IRAD- University of Manitoba, Winnipeg, Manitoba, Canada.
IR  - Rodriguez E
FIR - Rodriguez, Esther
IRAD- Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain.
IR  - Roux S
FIR - Roux, Sophie
IRAD- Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
IR  - Smets P
FIR - Smets, Perrine
IRAD- Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France.
IR  - Smith D
FIR - Smith, Doug
IRAD- University of Ottawa, Ottawa, Ontario, Canada.
IR  - Sobanski V
FIR - Sobanski, Vincent
IRAD- Centre Hospitalier Regional Universitaire de Lille, Hopital Claude Huriez, Lille,
      France.
IR  - Spiera R
FIR - Spiera, Robert
IRAD- Hospital for Special Surgery, New York City, NY, USA.
IR  - Steen V
FIR - Steen, Virginia
IRAD- Georgetown University, Washington, DC, USA.
IR  - Stevens W
FIR - Stevens, Wendy
IRAD- St Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
IR  - Sutton E
FIR - Sutton, Evelyn
IRAD- Dalhousie University, Halifax, Nova Scotia, Canada.
IR  - Terrier B
FIR - Terrier, Benjamin
IRAD- Hopitaux de Paris, Hopital Cochin, Paris, France.
IR  - Thorne C
FIR - Thorne, Carter
IRAD- Southlake Regional Health Centre, Newmarket, Ontario, Canada.
IR  - Varga J
FIR - Varga, John
IRAD- Northwestern University, Chicago, IL, USA.
IR  - Wilcox P
FIR - Wilcox, Pearce
IRAD- St. Paul's Hospital and University of British Columbia, Vancouver, British
      Columbia, Canada.
IR  - Ayala MC
FIR - Ayala, Mara Canedo
IRAD- Jewish General Hospital, Montreal, Quebec, Canada.
IR  - Ostbo N
FIR - Ostbo, Nora
IRAD- Jewish General Hospital, Montreal, Quebec, Canada.
EDAT- 2020/06/11 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/04/04 00:00 [received]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - S0022-3999(20)30400-1 [pii]
AID - 10.1016/j.jpsychores.2020.110132 [doi]
PST - ppublish
SO  - J Psychosom Res. 2020 Aug;135:110132. doi: 10.1016/j.jpsychores.2020.110132. Epub
      2020 May 14.


PMID- 32521190
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1362-3095 (Electronic)
IS  - 0955-3002 (Linking)
VI  - 96
IP  - 11
DP  - 2020 Nov
TI  - Consequences of a large-scale nuclear accident and guidelines for evacuation: a
      cost-effectiveness analysis.
PG  - 1382-1389
LID - 10.1080/09553002.2020.1779962 [doi]
AB  - PURPOSE: We aimed for a quantitative evaluation that justifies guidelines for
      evacuation which take into consideration both the human and economic costs. To
      the best of our knowledge, such an evaluation has not been performed yet. The
      present guidelines published by the International Atomic Energy Agency (IAEA) are
      probably based on averting radiation risk only; IAEA did not cite any
      quantitative estimation of the human cost of evacuation. MATERIALS AND METHODS:
      Quantitative estimation of the human and monetary costs of evacuation and,
      alternatively, the human and monetary costs of radiation exposure
      (non-evacuation). Associating human life with monetary value is psychologically
      difficult and somewhat challenging ethically; however, there is no escape from
      such an association (cost-effectiveness analysis) when making decisions regarding
      public health and safety, since extraneous public expenditures lead to a
      statistical life shortening. Estimating worst-case health consequences of
      irradiation, we used the conservative linear no-threshold (LNT) model because
      this model is widely used in spite of its controversy. In our estimation of the
      human cost of evacuation, we considered three factors: (a) direct loss of life
      (after Fukushima, 1% of the evacuees died within 2 years due to causes directly
      related to their evacuation), (b) loss of quality of life, and (c) loss of wealth
      leading to loss of life. The connection of economic loss with loss of life was
      performed according to the median cost-effectiveness threshold of 50-100 thousand
      USD per quality-adjusted life year. RESULTS: Even according to mortality
      calculations based on LNT, the overall loss of life due to evacuation is higher
      than the loss of life due to irradiation if the population-averaged first-year
      radiation dose is 500 mSv or less. CONCLUSIONS: Based on the performed analysis, 
      we suggest avoiding evacuation if the projected first-year dose is below 500 mSv.
      This suggested action level is about five-fold higher than the action level
      presently recommended by the IAEA (100 mSv per year).
FAU - Yanovskiy, Moshe
AU  - Yanovskiy M
AD  - Department of Electrical and Electronics Engineering, Jerusalem College of
      Technology, Jerusalem, Israel.
FAU - Levi, Ori Nissim
AU  - Levi ON
AD  - Department of Electrical and Electronics Engineering, Jerusalem College of
      Technology, Jerusalem, Israel.
FAU - Shaki, Yair Y
AU  - Shaki YY
AD  - Department of Electrical and Electronics Engineering, Jerusalem College of
      Technology, Jerusalem, Israel.
FAU - Socol, Yehoshua
AU  - Socol Y
AUID- ORCID: 0000-0003-4167-248X
AD  - Department of Electrical and Electronics Engineering, Jerusalem College of
      Technology, Jerusalem, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - England
TA  - Int J Radiat Biol
JT  - International journal of radiation biology
JID - 8809243
SB  - IM
MH  - *Cost-Benefit Analysis
MH  - Emergency Shelter/economics
MH  - *Guidelines as Topic
MH  - Humans
MH  - Radiation Exposure/adverse effects
MH  - *Radioactive Hazard Release
OTO - NOTNLM
OT  - *LNT
OT  - *Radiation protection
OT  - *cost-benefit
OT  - *disaster management
OT  - *health effects
EDAT- 2020/06/11 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1080/09553002.2020.1779962 [doi]
PST - ppublish
SO  - Int J Radiat Biol. 2020 Nov;96(11):1382-1389. doi: 10.1080/09553002.2020.1779962.
      Epub 2020 Jun 30.


PMID- 32521172
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20220416
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 21
IP  - 13
DP  - 2020 Sep
TI  - Pharmacotherapeutic considerations in women with multiple sclerosis.
PG  - 1591-1602
LID - 10.1080/14656566.2020.1774554 [doi]
AB  - INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the
      central nervous system. The relapsing form of the disease predominantly affects
      women with onset between the ages 20 to 40 years. Therefore, timing, choice, and 
      treatment options should take pregnancy planning into consideration to
      accommodate both the needs and safety of the mother and health of the fetus.
      AREAS COVERED: In this review, the authors discuss and summarize the recent
      evidence of different pharmacotherapeutic possibilities in the treatment of women
      with MS. EXPERT OPINION: There is evidence that disease modifying therapy reduces
      the risk of relapses and diminishes disability progression in people with
      relapsing MS. The disease is often diagnosed in the childbearing years, and thus 
      pregnancy planning can possibly be a part of the pharmacotherapeutic
      considerations. The management of women planning pregnancy requires a balancing
      of risks. The clinician must consider the risks related to treatment
      discontinuation versus the risk of exposing the developing fetus to drugs that
      are potential fetotoxic. Randomized controlled trials of medication safety - if
      used during pregnancy, are prohibited for ethical reasons; hence, the evidence is
      continuously gathered from observational data, post-authorization studies and
      pregnancy registries.
FAU - Andersen, Johanna B
AU  - Andersen JB
AD  - Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen
      University Hospital , Copenhagen, Denmark.
FAU - Magyari, Melinda
AU  - Magyari M
AUID- ORCID: https://orcid.org/0000-0002-0972-5222
AD  - Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen
      University Hospital , Copenhagen, Denmark.
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University 
      Hospital , Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200610
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Fertility/drug effects
MH  - Humans
MH  - Immunologic Factors/*therapeutic use
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy/immunology
MH  - Pregnancy Outcome
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Pharmacotherapeutic considerations
OT  - disease modifying therapy
OT  - multiple sclerosis
OT  - pregnancy
OT  - women
EDAT- 2020/06/11 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1080/14656566.2020.1774554 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2020 Sep;21(13):1591-1602. doi:
      10.1080/14656566.2020.1774554. Epub 2020 Jun 10.


PMID- 32521110
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 18
IP  - 8
DP  - 2020 Aug
TI  - Strengths and limitations of high-throughput sequencing for the diagnosis of
      inherited bleeding and platelet disorders.
PG  - 1839-1845
LID - 10.1111/jth.14945 [doi]
AB  - Inherited bleeding and platelet disorders (BPD) are highly heterogeneous and
      their diagnosis involves a combination of clinical investigations, laboratory
      tests, and genetic screening. This review will outline some of the challenges
      that geneticists and experts in clinical hemostasis face when implementing
      high-throughput sequencing (HTS) for patient care. We will provide an overview of
      the strengths and limitations of the different HTS techniques that can be used to
      diagnose BPD. An HTS test is cost-efficient and expected to increase the
      diagnostic rate with a possibility to detect unexpected diagnoses and decrease
      the turnaround time to diagnose patients. On the other hand, technical
      shortcomings, variant interpretation difficulties, and ethical issues related to 
      HTS for BPD will also be documented. Delivering a genetic diagnosis to patients
      is highly desirable to improve clinical management and allow family counseling,
      but making incorrect assumptions about variants and providing insufficient
      information to patients before initiating the test could be harmful. Data-sharing
      and improved HTS guidelines are essential to limit these major drawbacks of HTS.
CI  - (c) 2020 International Society on Thrombosis and Haemostasis.
FAU - Ver Donck, Fabienne
AU  - Ver Donck F
AUID- ORCID: 0000-0002-8645-8789
AD  - Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology,
      University of Leuven, Leuven, Belgium.
FAU - Downes, Kate
AU  - Downes K
AD  - East Midlands and East of England Genomics Laboratory Hub, Cambridge University
      Hospitals NHS Foundation Trust, Cambridge, UK.
AD  - Department of Haematology, University of Cambridge, Cambridge, UK.
FAU - Freson, Kathleen
AU  - Freson K
AUID- ORCID: 0000-0002-4381-2442
AD  - Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology,
      University of Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
SB  - IM
MH  - *Blood Coagulation Disorders, Inherited/diagnosis/genetics
MH  - *Blood Platelet Disorders/diagnosis/genetics
MH  - Blood Platelets
MH  - Genetic Testing
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
OTO - NOTNLM
OT  - *blood platelets
OT  - *high-throughput nucleotide sequencing
OT  - *inherited blood coagulation disorders
OT  - *molecular diagnostic techniques
OT  - *thrombosis
EDAT- 2020/06/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/05/31 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1111/jth.14945 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2020 Aug;18(8):1839-1845. doi: 10.1111/jth.14945.


PMID- 32521049
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220418
IS  - 2473-4209 (Electronic)
IS  - 0094-2405 (Linking)
VI  - 47
IP  - 11
DP  - 2020 Nov
TI  - FAIR-compliant clinical, radiomics and DICOM metadata of RIDER, interobserver,
      Lung1 and head-Neck1 TCIA collections.
PG  - 5931-5940
LID - 10.1002/mp.14322 [doi]
AB  - PURPOSE: One of the most frequently cited radiomics investigations showed that
      features automatically extracted from routine clinical images could be used in
      prognostic modeling. These images have been made publicly accessible via The
      Cancer Imaging Archive (TCIA). There have been numerous requests for additional
      explanatory metadata on the following datasets - RIDER, Interobserver, Lung1, and
      Head-Neck1. To support repeatability, reproducibility, generalizability, and
      transparency in radiomics research, we publish the subjects' clinical data,
      extracted radiomics features, and digital imaging and communications in medicine 
      (DICOM) headers of these four datasets with descriptive metadata, in order to be 
      more compliant with findable, accessible, interoperable, and reusable (FAIR) data
      management principles. ACQUISITION AND VALIDATION METHODS: Overall survival time 
      intervals were updated using a national citizens registry after internal ethics
      board approval. Spatial offsets of the primary gross tumor volume (GTV) regions
      of interest (ROIs) associated with the Lung1 CT series were improved on the TCIA.
      GTV radiomics features were extracted using the open-source Ontology-Guided
      Radiomics Analysis Workflow (O-RAW). We reshaped the output of O-RAW to map
      features and extraction settings to the latest version of Radiomics Ontology, so 
      as to be consistent with the Image Biomarker Standardization Initiative (IBSI).
      Digital imaging and communications in medicine metadata was extracted using a
      research version of Semantic DICOM (SOHARD, GmbH, Fuerth; Germany). Subjects'
      clinical data were described with metadata using the Radiation Oncology Ontology.
      All of the above were published in Resource Descriptor Format (RDF), that is,
      triples. Example SPARQL queries are shared with the reader to use on the online
      triples archive, which are intended to illustrate how to exploit this data
      submission. DATA FORMAT: The accumulated RDF data are publicly accessible through
      a SPARQL endpoint where the triples are archived. The endpoint is remotely
      queried through a graph database web application at http://sparql.cancerdata.org.
      SPARQL queries are intrinsically federated, such that we can efficiently
      cross-reference clinical, DICOM, and radiomics data within a single query, while 
      being agnostic to the original data format and coding system. The federated
      queries work in the same way even if the RDF data were partitioned across
      multiple servers and dispersed physical locations. POTENTIAL APPLICATIONS: The
      public availability of these data resources is intended to support radiomics
      features replication, repeatability, and reproducibility studies by the academic 
      community. The example SPARQL queries may be freely used and modified by readers 
      depending on their research question. Data interoperability and reusability are
      supported by referencing existing public ontologies. The RDF data are readily
      findable and accessible through the aforementioned link. Scripts used to create
      the RDF are made available at a code repository linked to this submission:
      https://gitlab.com/UM-CDS/FAIR-compliant_clinical_radiomics_and_DICOM_metadata.
CI  - (c) 2020 The Authors. Medical Physics published by Wiley Periodicals LLC on
      behalf of American Association of Physicists in Medicine.
FAU - Kalendralis, Petros
AU  - Kalendralis P
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Shi, Zhenwei
AU  - Shi Z
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Traverso, Alberto
AU  - Traverso A
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Choudhury, Ananya
AU  - Choudhury A
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Sloep, Matthijs
AU  - Sloep M
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Zhovannik, Ivan
AU  - Zhovannik I
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
AD  - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen,
      6525 GC, The Netherlands.
FAU - Starmans, Martijn P A
AU  - Starmans MPA
AD  - Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, 
      3015 GD, The Netherlands.
AD  - Department of Medical Informatics, Erasmus Medical Center, Rotterdam, 3015 GD,
      The Netherlands.
FAU - Grittner, Detlef
AU  - Grittner D
AD  - SOHARD Software GmbH, Fuerth, 90766, Germany.
FAU - Feltens, Peter
AU  - Feltens P
AD  - SOHARD Software GmbH, Fuerth, 90766, Germany.
FAU - Monshouwer, Rene
AU  - Monshouwer R
AD  - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen,
      6525 GC, The Netherlands.
FAU - Klein, Stefan
AU  - Klein S
AD  - Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, 
      3015 GD, The Netherlands.
AD  - Department of Medical Informatics, Erasmus Medical Center, Rotterdam, 3015 GD,
      The Netherlands.
FAU - Fijten, Rianne
AU  - Fijten R
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Aerts, Hugo
AU  - Aerts H
AD  - Artificial Intelligence in Medicine (AIM) Program, Brigham and Women's Hospital, 
      Harvard Medical School, Boston, MA, 02115, United States.
AD  - Radiology and Nuclear Medicine, CARIM & GROW School for Oncology, Maastricht
      University, Maastricht, 6211 LK, The Netherlands.
FAU - Dekker, Andre
AU  - Dekker A
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - van Soest, Johan
AU  - van Soest J
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
FAU - Wee, Leonard
AU  - Wee L
AD  - Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht 
      University Medical Centre+, Maastricht, 6229 ET, The Netherlands.
LA  - eng
GR  - 14929/NWO | Stichting voor de Technische Wetenschappen (STW)
PT  - Journal Article
DEP - 20200627
PL  - United States
TA  - Med Phys
JT  - Medical physics
JID - 0425746
SB  - IM
MH  - Databases, Factual
MH  - Germany
MH  - Humans
MH  - *Metadata
MH  - Reproducibility of Results
MH  - Workflow
PMC - PMC7754296
OTO - NOTNLM
OT  - FAIR
OT  - datasets
OT  - radiomics
OT  - repeatability
OT  - reproducibility
EDAT- 2020/06/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/05/19 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1002/mp.14322 [doi]
PST - ppublish
SO  - Med Phys. 2020 Nov;47(11):5931-5940. doi: 10.1002/mp.14322. Epub 2020 Jun 27.


PMID- 32521040
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20210813
IS  - 1399-6576 (Electronic)
IS  - 0001-5172 (Linking)
VI  - 64
IP  - 8
DP  - 2020 Sep
TI  - Limiting treatment in pre-hospital care: A prospective, observational multicentre
      study.
PG  - 1194-1201
LID - 10.1111/aas.13649 [doi]
AB  - BACKGROUND: Data are scarce on the withdrawal of life-sustaining therapies and
      limitation of care orders (LCOs) during physician-staffed Helicopter Emergency
      Medical Service (HEMS) missions. We investigated LCOs and the quality of
      information available when physicians made treatment decisions in pre-hospital
      care. METHODS: A prospective, nationwide, multicentre study including all Finnish
      physician-staffed HEMS bases during a 6-month study period. All HEMS missions
      where a patient had pre-existing LCOs and/or a new LCO were included. RESULTS:
      There were 335 missions with LCOs, which represented 5.7% of all HEMS missions (n
      = 5895). There were 181 missions with pre-existing LCOs, and a total of 170 new
      LCOs were issued. Usually, the pre-existing LCO was a do not attempt
      cardiopulmonary resuscitation order only (n = 133, 74%). The most frequent new
      LCO was 'termination of cardiopulmonary resuscitation' only (n = 61, 36%), while 
      'no intensive care' combined with some other LCO was almost as common (n = 54,
      32%). When issuing a new LCO for patients who did not have any preceding LCOs (n 
      = 153), in every other (49%) case the physicians thought that the patient should 
      have already had an LCO. When the physician made treatment decisions, patients'
      background information from on-scene paramedics was available in 260 (78%) of the
      LCO missions, while patients' medical records were available in 67 (20%) of the
      missions. CONCLUSION: Making LCOs or treating patients with pre-existing LCOs is 
      an integral part of HEMS physicians' work, with every twentieth mission involving
      LCO patients. The new LCOs mostly concerned withholding or withdrawal of
      cardiopulmonary resuscitation and intensive care.
CI  - (c) 2020 The Acta Anaesthesiologica Scandinavica Foundation. Published by John
      Wiley & Sons Ltd.
FAU - Kangasniemi, Heidi
AU  - Kangasniemi H
AUID- ORCID: 0000-0002-6335-5269
AD  - Research and Development Unit, FinnHEMS Ltd, WTC Helsinki Airport, Vantaa,
      Finland.
AD  - Emergency Medical Services, Tampere University Hospital, Tampere, Finland.
AD  - Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
FAU - Setala, Piritta
AU  - Setala P
AUID- ORCID: 0000-0003-0850-8485
AD  - Emergency Medical Services, Tampere University Hospital, Tampere, Finland.
FAU - Olkinuora, Anna
AU  - Olkinuora A
AD  - Research and Development Unit, FinnHEMS Ltd, WTC Helsinki Airport, Vantaa,
      Finland.
FAU - Huhtala, Heini
AU  - Huhtala H
AD  - Faculty of Social Sciences, Tampere University, Tampere, Finland.
FAU - Tirkkonen, Joonas
AU  - Tirkkonen J
AD  - Department of Intensive Care Medicine and Department of Emergency, Anaesthesia
      and Pain Medicine, Tampere University Hospital, Tampere, Finland.
AD  - Intensive Care Unit, Liverpool Hospital, Sydney, Australia.
FAU - Kamarainen, Antti
AU  - Kamarainen A
AD  - Emergency Medical Services, Tampere University Hospital, Tampere, Finland.
AD  - Department of Emergency Medicine, Department of Anaesthesia, Hyvinkaa District
      Hospital, Hyvinkaa, Finland.
FAU - Virkkunen, Ilkka
AU  - Virkkunen I
AD  - Research and Development Unit, FinnHEMS Ltd, WTC Helsinki Airport, Vantaa,
      Finland.
AD  - Emergency Medical Services, Tampere University Hospital, Tampere, Finland.
FAU - Yli-Hankala, Arvi
AU  - Yli-Hankala A
AD  - Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
AD  - Department of Anaesthesia, Tampere University Hospital, Tampere, Finland.
FAU - Jamsen, Esa
AU  - Jamsen E
AD  - Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
AD  - Centre of Geriatrics, Tampere University Hospital, Tampere, Finland.
FAU - Hoppu, Sanna
AU  - Hoppu S
AD  - Emergency Medical Services, Tampere University Hospital, Tampere, Finland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200709
PL  - England
TA  - Acta Anaesthesiol Scand
JT  - Acta anaesthesiologica Scandinavica
JID - 0370270
SB  - IM
MH  - Aged
MH  - *Air Ambulances
MH  - Emergency Medical Services/*statistics & numerical data
MH  - Female
MH  - Finland
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Resuscitation Orders
MH  - Withholding Treatment/*statistics & numerical data
OTO - NOTNLM
OT  - *DNAR
OT  - *EMS
OT  - *HEMS
OT  - *decision-making
OT  - *end-of-life
OT  - *ethics
OT  - *termination of cardiopulmonary resuscitation
EDAT- 2020/06/11 06:00
MHDA- 2021/08/14 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1111/aas.13649 [doi]
PST - ppublish
SO  - Acta Anaesthesiol Scand. 2020 Sep;64(8):1194-1201. doi: 10.1111/aas.13649. Epub
      2020 Jul 9.


PMID- 32520741
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20210506
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 4
DP  - 2020 Oct
TI  - Surprise Billing in Surgical Care Episodes - Overview, Ethical Concerns, and
      Policy Solutions in Light of COVID-19.
PG  - e264-e265
LID - 10.1097/SLA.0000000000004152 [doi]
FAU - Sheckter, Clifford C
AU  - Sheckter CC
AD  - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford
      University, Stanford, California.
FAU - Singh, Puneet
AU  - Singh P
AD  - Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer
      Center, Houston, Texas.
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery and MacLean Center for Clinical Medical Ethics, The
      University of Chicago, Chicago, Illinois.
FAU - Offodile, Anaeze C 2nd
AU  - Offodile AC 2nd
AD  - Department of Plastic Surgery, University of Texas MD Anderson Cancer Center,
      Houston, Texas.
AD  - Institute for Cancer Care Innovation, University of Texas MD Anderson Cancer
      Center, Houston, Texas.
AD  - Baker Institute for Public Policy, Rice University, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*economics/epidemiology
MH  - *Episode of Care
MH  - Fee-for-Service Plans/*economics/ethics
MH  - Female
MH  - Health Policy
MH  - Hospital Costs/*ethics
MH  - Humans
MH  - Insurance Coverage/*economics/organization & administration
MH  - Male
MH  - Pandemics/*economics
MH  - Pneumonia, Viral/*economics/epidemiology
MH  - Policy Making
MH  - Reimbursement Mechanisms/legislation & jurisprudence
MH  - Surgical Procedures, Operative/*economics
MH  - United States
PMC - PMC7299102
EDAT- 2020/06/11 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1097/SLA.0000000000004152 [doi]
AID - 00000658-202010000-00034 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Oct;272(4):e264-e265. doi: 10.1097/SLA.0000000000004152.


PMID- 32520706
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201121
IS  - 1911-6470 (Print)
IS  - 1911-6470 (Linking)
VI  - 14
IP  - 11
DP  - 2020 Nov
TI  - Current status of wet lab and cadaveric simulation in urological training: A
      systematic review.
PG  - E594-E600
LID - 10.5489/cuaj.6520 [doi]
AB  - INTRODUCTION: We undertook a systematic review of the use of wet lab (animal and 
      cadaveric) simulation models in urological training, with an aim to establishing 
      a level of evidence (LoE) for studies and level of recommendation (LoR) for
      models, as well as evaluating types of validation. METHODS: Medline, EMBASE, and 
      Cochrane databases were searched for English-language studies using search terms 
      including a combination of "surgery," "surgical training," and "medical
      education." These results were combined with "wet lab," "animal model,"
      "cadaveric," and "in-vivo." Studies were then assigned a LoE and LoR if
      appropriate as per the education-modified Oxford Centre for Evidence-Based
      Medicine classification. RESULTS: A total of 43 articles met the inclusion
      criteria. There was a mean of 23.1 (+/-19.2) participants per study with a median
      of 20. Overall, the studies were largely of low quality, with 90.7% of studies
      being lower than LoE 2a (n=26 for LoE 2b and n=13 for LoE 3). The majority
      (72.1%, n=31) of studies were in animal models and 27.9% (n=12) were in cadaveric
      models. CONCLUSIONS: Simulation in urological education is becoming more
      prevalent in the literature, however, there is a focus on animal rather than
      cadaveric simulation, possibly due to cost and ethical considerations. Studies
      are also predominately of a low LoE; higher LoEs, especially randomized
      controlled studies, are needed.
FAU - Al-Jabir, Ahmed
AU  - Al-Jabir A
AD  - GKT School of Medical Education, King's College London, London, United Kingdom.
FAU - Aydin, Abdullatif
AU  - Aydin A
AD  - MRC Centre for Transplantation, Guy's Hospital, King's College London, London,
      United Kingdom.
FAU - Al-Jabir, Hussain
AU  - Al-Jabir H
AD  - William Harvey Research Institute, Barts and The London School of Medicine School
      of Medicine and Dentistry, London, United Kingdom.
FAU - Khan, M Shamim
AU  - Khan MS
AD  - MRC Centre for Transplantation, Guy's Hospital, King's College London, London,
      United Kingdom.
AD  - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United
      Kingdom.
FAU - Dasgupta, Prokar
AU  - Dasgupta P
AD  - MRC Centre for Transplantation, Guy's Hospital, King's College London, London,
      United Kingdom.
AD  - Department of Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United
      Kingdom.
FAU - Ahmed, Kamran
AU  - Ahmed K
AD  - MRC Centre for Transplantation, Guy's Hospital, King's College London, London,
      United Kingdom.
AD  - Department of Urology, King's College Hospital NHS Foundation Trust, London,
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Can Urol Assoc J
JT  - Canadian Urological Association journal = Journal de l'Association des urologues 
      du Canada
JID - 101312644
PMC - PMC7673832
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - cuaj.6520 [pii]
AID - 10.5489/cuaj.6520 [doi]
PST - ppublish
SO  - Can Urol Assoc J. 2020 Nov;14(11):E594-E600. doi: 10.5489/cuaj.6520.


PMID- 32520293
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20201218
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 25
IP  - suppl 1
DP  - 2020 Jun
TI  - Personal data usage and privacy considerations in the COVID-19 global pandemic.
PG  - 2487-2492
LID - S1413-81232020006702487 [pii]
LID - 10.1590/1413-81232020256.1.11792020 [doi]
AB  - Data has become increasingly important and valuable for both scientists and
      health authorities searching for answers to the COVID-19 crisis. Due to
      difficulties in diagnosing this infection in populations around the world,
      initiatives supported by digital technologies are being developed by governments 
      and private companies to enable the tracking of the public's symptoms, contacts
      and movements. Considering the current scenario, initiatives designed to support 
      infection surveillance and monitoring are essential and necessary. Nonetheless,
      ethical, legal and technical questions abound regarding the amount and types of
      personal data being collected, processed, shared and used in the name of public
      health, as well as the concomitant or posterior use of this data. These
      challenges demonstrate the need for new models of responsible and transparent
      data and technology governance in efforts to control SARS-COV2, as well as in
      future public health emergencies.
FAU - Almeida, Bethania de Araujo
AU  - Almeida BA
AUID- ORCID: http://orcid.org/0000-0001-8918-2661
AD  - Centro de Integracao de Dados e Conhecimentos para Saude, Fiocruz Bahia. R.
      Mundo, Trobogy. 41745-715 Salvador BA Brasil. baraujo2010@gmail.com.
FAU - Doneda, Danilo
AU  - Doneda D
AUID- ORCID: http://orcid.org/0000-0001-9535-3586
AD  - Instituto Brasiliense de Direito Publico. Brasilia DF Brasil.
FAU - Ichihara, Maria Yury
AU  - Ichihara MY
AUID- ORCID: http://orcid.org/0000-0001-8590-6212
AD  - Centro de Integracao de Dados e Conhecimentos para Saude, Fiocruz Bahia. R.
      Mundo, Trobogy. 41745-715 Salvador BA Brasil. baraujo2010@gmail.com.
FAU - Barral-Netto, Manoel
AU  - Barral-Netto M
AUID- ORCID: http://orcid.org/0000-0002-5823-7903
AD  - Centro de Integracao de Dados e Conhecimentos para Saude, Fiocruz Bahia. R.
      Mundo, Trobogy. 41745-715 Salvador BA Brasil. baraujo2010@gmail.com.
FAU - Matta, Gustavo Correa
AU  - Matta GC
AUID- ORCID: http://orcid.org/0000-0002-5422-2798
AD  - Escola Nacional de Saude Publica Sergio Arouca, Fiocruz. Rio de Janeiro RJ
      Brasil.
FAU - Rabello, Elaine Teixeira
AU  - Rabello ET
AUID- ORCID: http://orcid.org/0000-0002-8324-1453
AD  - Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro. Rio de
      Janeiro RJ Brasil.
FAU - Gouveia, Fabio Castro
AU  - Gouveia FC
AUID- ORCID: http://orcid.org/0000-0002-0082-2392
AD  - Casa Oswaldo Cruz, Fiocruz. Rio de Janeiro RJ Brasil.
FAU - Barreto, Mauricio
AU  - Barreto M
AUID- ORCID: http://orcid.org/0000-0002-0215-4930
AD  - Centro de Integracao de Dados e Conhecimentos para Saude, Fiocruz Bahia. R.
      Mundo, Trobogy. 41745-715 Salvador BA Brasil. baraujo2010@gmail.com.
LA  - por
LA  - eng
PT  - Journal Article
TT  - Preservacao da privacidade no enfrentamento da COVID-19: dados pessoais e a
      pandemia global.
DEP - 20200501
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Confidentiality
MH  - Contact Tracing/methods
MH  - Coronavirus Infections/*epidemiology
MH  - Data Anonymization
MH  - *Global Health
MH  - *Health Records, Personal
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Population Surveillance/*methods
MH  - *Privacy
MH  - SARS-CoV-2
MH  - Social Media
EDAT- 2020/06/11 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - S1413-81232020006702487 [pii]
AID - 10.1590/1413-81232020256.1.11792020 [doi]
PST - ppublish
SO  - Cien Saude Colet. 2020 Jun;25(suppl 1):2487-2492. doi:
      10.1590/1413-81232020256.1.11792020. Epub 2020 May 1.


PMID- 32520275
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Jun
TI  - [This elusive unknown quantity: reflections on the prescription of psychotropic
      drugs in early childhood].
PG  - 2305-2314
LID - S1413-81232020000602305 [pii]
LID - 10.1590/1413-81232020256.12862018 [doi]
AB  - The scope of this article is to study aspects related to prescription habits and 
      the use of psychoactive drugs in early childhood. It takes as a starting point
      the bibliographical survey carried out on the BVS and Scielo databases on
      epidemiological and clinical research in Brazil regarding the use of psychotropic
      drugs in children under six years of age. Based on international literature, it
      highlights the increase in the number of children diagnosed with mental and
      behavioral disorders, as well as the respective prescription of psychotropic
      drugs. It discusses the predominantly off-label character of psychoactive drugs
      for children under six years of age, the heterogeneous use of prescriptions and
      polypharmacology, pointing to an ethical paradox regarding clinical research in
      this age group. It concludes that the use of psychotropic drugs in early
      childhood is as yet not well known in Brazil, and epidemiological studies are
      urgently needed in this area.
FAU - Pande, Mariana Nogueira Rangel
AU  - Pande MNR
AUID- ORCID: http://orcid.org/0000-0001-9709-4426
AD  - Laboratorio Estudos e Pesquisas em Saude Mental e Atencao Psicossocial, Escola
      Nacional de Saude Publica Sergio Arouca (ENSP), Fundacao Oswaldo Cruz (Fiocruz). 
      Av. Brasil 4036, Manguinhos. 21040-361, Rio de Janeiro, RJ, Brasil.
      nogueirarangel@gmail.com.
FAU - Amarante, Paulo Duarte de Carvalho
AU  - Amarante PDC
AUID- ORCID: http://orcid.org/0000-0001-6778-2834
AD  - Laboratorio Estudos e Pesquisas em Saude Mental e Atencao Psicossocial, Escola
      Nacional de Saude Publica Sergio Arouca (ENSP), Fundacao Oswaldo Cruz (Fiocruz). 
      Av. Brasil 4036, Manguinhos. 21040-361, Rio de Janeiro, RJ, Brasil.
      nogueirarangel@gmail.com.
FAU - Baptista, Tatiana Wargas de Faria
AU  - Baptista TWF
AUID- ORCID: http://orcid.org/0000-0002-3445-2027
AD  - Departamento de Administracao e Planejamento em Saude, ENSP, Fiocruz. Rio de
      Janeiro, RJ, Brasil.
LA  - por
PT  - Journal Article
TT  - Este ilustre desconhecido: consideracoes sobre a prescricao de psicofarmacos na
      primeira infancia.
DEP - 20180927
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Brazil
MH  - Child
MH  - Child, Preschool
MH  - Drug Prescriptions
MH  - Humans
MH  - *Mental Disorders/drug therapy
MH  - *Psychotropic Drugs/therapeutic use
EDAT- 2020/06/11 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/11 06:00
PHST- 2017/09/29 00:00 [received]
PHST- 2018/09/25 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - S1413-81232020000602305 [pii]
AID - 10.1590/1413-81232020256.12862018 [doi]
PST - ppublish
SO  - Cien Saude Colet. 2020 Jun;25(6):2305-2314. doi:
      10.1590/1413-81232020256.12862018. Epub 2018 Sep 27.


PMID- 32519272
OWN - NLM
STAT- MEDLINE
DCOM- 20210528
LR  - 20210528
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 34
IP  - 10
DP  - 2020 Oct
TI  - Anterior approach for pure laparoscopic donor right hepatectomy.
PG  - 4677-4678
LID - 10.1007/s00464-020-07649-7 [doi]
AB  - BACKGROUND: Pure laparoscopic donor hepatectomy (PLDH) is being increasingly
      performed at centers with experienced surgeons [1-6]. This procedure is still
      developing and is associated with several challenges owing to its technical
      difficulty [7-9]. Conversely, the anterior approach is sometimes applied to both 
      laparoscopic and open right hepatectomy for management of tumors in the liver
      [10, 11]. However, there are no reports regarding the use of the anterior
      approach for PLDH. We found this method to be useful; therefore, we aimed to
      introduce the novel procedure using a video clip. METHODS: The donor was placed
      in the supine position. First, the right side of the inferior vena cava was
      dissected instead of performing the liver hanging maneuver. The right Glissonean 
      pedicle was encircled and controlled, and the liver parenchyma was completely
      transected. Thereafter, the ligaments around the liver were dissected, and the
      graft was mobilized. The hilar vessels were respectively separated. Finally, the 
      right hepatic duct, right hepatic artery, right portal vein, and right hepatic
      vein were divided, and the graft liver was retrieved. This study was approved by 
      institutional ethics board (MH2019-119), and informed consent was taken from the 
      patient. RESULTS: The overall surgical time was 400 min, the volume of blood loss
      was 31 mL, the warm ischemic time was 7 min, and no complications were seen.
      CONCLUSION: The advantages of the anterior approach for right-sided PLDH might be
      attribute to reduction of compression injury and incidence of subcapsular
      hematoma, as liver mobilization is easily performed because of increased liver
      mobility. However, PLDH is a highly-skilled procedure, and indications for PLDH
      should be extended in a step-wise manner. Further, the procedure should be
      performed only by highly proficient surgeons having extensive experience in both 
      laparoscopic liver resection and living donor liver transplantation.
FAU - Hasegawa, Yasushi
AU  - Hasegawa Y
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan.
FAU - Nitta, Hiroyuki
AU  - Nitta H
AUID- ORCID: 0000-0003-1606-4773
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan. hnitta@iwate-med.ac.jp.
FAU - Takahara, Takeshi
AU  - Takahara T
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan.
FAU - Katagiri, Hirokatsu
AU  - Katagiri H
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan.
FAU - Kanno, Shoji
AU  - Kanno S
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan.
FAU - Umemura, Akira
AU  - Umemura A
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan.
FAU - Sasaki, Akira
AU  - Sasaki A
AD  - Department of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa,
      028-3695, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
SB  - IM
MH  - Female
MH  - Hepatectomy/*methods
MH  - Humans
MH  - Laparoscopy/*methods
MH  - Liver/*surgery
MH  - Living Donors/*statistics & numerical data
MH  - Male
OTO - NOTNLM
OT  - *Anterior approach
OT  - *Donor
OT  - *Hepatectomy
OT  - *Laparoscopy
OT  - *Liver transplantation
EDAT- 2020/06/11 06:00
MHDA- 2021/05/29 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/01/25 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/05/29 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1007/s00464-020-07649-7 [doi]
AID - 10.1007/s00464-020-07649-7 [pii]
PST - ppublish
SO  - Surg Endosc. 2020 Oct;34(10):4677-4678. doi: 10.1007/s00464-020-07649-7. Epub
      2020 Jun 9.


PMID- 32518844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Fast I(n)dentification of Pathogens in Neonates (FINDPATH-N): protocol for a
      prospective pilot cohort study of next-generation sequencing for pathogen
      identification in neonates with suspected sepsis.
PG  - e000651
LID - 10.1136/bmjpo-2020-000651 [doi]
AB  - INTRODUCTION: Sepsis is a major source of morbidity and mortality in neonates;
      however, identification of the causative pathogens is challenging. Many neonates 
      have negative blood cultures despite clinical evidence of sepsis. Next-generation
      sequencing (NGS) is a high-throughput, parallel sequencing technique for DNA.
      Pathogen-targeted enrichment followed by NGS has the potential to be more
      sensitive and faster than current gold-standard blood culture. In this pilot
      study, we will test the feasibility and pathogen detection patterns of
      pathogen-targeted NGS in neonates with suspected sepsis. Additionally, the
      distribution and diagnostic accuracy of biomarkers cell-free DNA and protein C
      levels at two time points will be explored. METHODS AND ANALYSIS: We will conduct
      a prospective, pilot observational study. Neonates over 1 kg with suspected
      sepsis from a single tertiary care children's hospital will be recruited for the 
      study. Recruitment will be censored at 200 events or 6 months' duration. Two
      blood study samples will be taken: the first simultaneous to the blood culture
      (time=0 hour, for NGS and biomarkers) via an exception to consent (deferred
      consent) and another 24 hours later after prospective consent (biomarkers only). 
      Neonates will be adjudicated into those with clinical sepsis, culture-proven
      sepsis and without sepsis based on clinical criteria. Feasibility parameters (eg,
      recruitment) and NGS process time will be reported.For analysis, NGS results will
      be described in aggregate, compared with the simultaneous blood culture
      (sensitivity and specificity) and reviewed via expert panel for plausibility.
      Pilot data for biomarker distribution and diagnostic accuracy (sensitivity and
      specificity) for distinguishing between septic and non-septic neonates will be
      reported. ETHICS AND DISSEMINATION: Ethics approval has been granted by the
      Hamilton Integrated Research Ethics Board. We will seek publication of study
      results in peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Klowak, Jennifer Ann
AU  - Klowak JA
AUID- ORCID: 0000-0001-9917-8789
AD  - Pediatrics, McMaster University, Hamilton, Ontario, Canada.
AD  - Pediatrics, McMaster Children's Hospital, Hamilton, Ontario, Canada.
FAU - El Helou, Salhab
AU  - El Helou S
AD  - Pediatrics, McMaster University, Hamilton, Ontario, Canada.
AD  - Pediatrics, McMaster Children's Hospital, Hamilton, Ontario, Canada.
FAU - Pernica, Jeffrey M
AU  - Pernica JM
AUID- ORCID: 0000-0002-4380-5402
AD  - Pediatrics, McMaster University, Hamilton, Ontario, Canada.
AD  - Pediatrics, McMaster Children's Hospital, Hamilton, Ontario, Canada.
FAU - Parker, Melissa J
AU  - Parker MJ
AD  - Pediatrics, McMaster University, Hamilton, Ontario, Canada.
AD  - Pediatrics, McMaster Children's Hospital, Hamilton, Ontario, Canada.
FAU - Surette, Michael
AU  - Surette M
AD  - Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Poinar, Hendrik
AU  - Poinar H
AD  - Anthropology, McMaster University, Hamilton, Ontario, Canada.
FAU - Fox-Robichaud, Alison E
AU  - Fox-Robichaud AE
AD  - Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
CN  - Canadian Critical Care Translational Biology Group
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7254136
OTO - NOTNLM
OT  - infectious diseases
OT  - intensive care
OT  - molecular biology
OT  - neonatology
OT  - paediatric practice
COIS- Competing interests: None declared.
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
AID - 10.1136/bmjpo-2020-000651 [doi]
AID - bmjpo-2020-000651 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Apr 6;4(1):e000651. doi: 10.1136/bmjpo-2020-000651.
      eCollection 2020.


PMID- 32518765
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2235-0640 (Print)
IS  - 2235-0640 (Linking)
VI  - 9
IP  - 3
DP  - 2020 May
TI  - Overdiagnosis of Juvenile Thyroid Cancer.
PG  - 124-131
LID - 10.1159/000503323 [doi]
AB  - Overdiagnosis is the detection of a disease that does not do any harm to the
      patient throughout the lifetime. Thyroid cancer in children is a rare disease;
      however, since 2011, many children in Fukushima, Japan, have been diagnosed with 
      it, and the number has shown a steady increase to over 200 cases at present. Some
      experts have stated that this phenomenon is due to overdiagnosis caused by
      thyroid ultrasound (US)-based thyroid screening detecting self-limiting thyroid
      cancer, which will not lead to clinical symptoms in the future. Harm caused by
      overdiagnosis of thyroid cancer is more serious in the young, since it is
      difficult to perform active surveillance and children diagnosed with cancer are
      likely to suffer from stigma. Thus, overdiagnosis of thyroid cancer in the young 
      is not only a health problem but also a problem of human rights. Conflicts of
      interest among people related to screening programs and some experts with
      incomplete knowledge on overdiagnosis help to spread misleading opinions together
      with fear of radiation exposure among residents, which has led to their erroneous
      understanding of the nature of US-based thyroid screening. Scientific and honest 
      discussions among experts to enhance education of residents and consideration of 
      medical ethics are crucial to prevent the expansion of overdiagnosis.
CI  - Copyright (c) 2019 by S. Karger AG, Basel.
FAU - Takano, Toru
AU  - Takano T
AD  - Rinku General Medical Center, Izumisano, Japan.
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine,
      Suita, Japan.
AD  - Department of Laboratory Medicine, Osaka University Graduate School of Medicine, 
      Suita, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191016
PL  - England
TA  - Eur Thyroid J
JT  - European thyroid journal
JID - 101604579
PMC - PMC7265730
OTO - NOTNLM
OT  - Lethal cancer
OT  - Overdiagnosis
OT  - Self-limiting cancer
OT  - Thyroid
OT  - Ultrasonography
COIS- The author has no conflicts of interest to declare.
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2019/07/20 00:00 [received]
PHST- 2019/09/12 00:00 [revised]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
AID - 10.1159/000503323 [doi]
AID - etj-0009-0124 [pii]
PST - ppublish
SO  - Eur Thyroid J. 2020 May;9(3):124-131. doi: 10.1159/000503323. Epub 2019 Oct 16.


PMID- 32518554
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1663-2699 (Print)
IS  - 1663-2699 (Linking)
VI  - 11
IP  - 2
DP  - 2020 May-Aug
TI  - Autologous Corneal Transplant from an Enucleated Fellow Eye for Choroidal
      Melanoma: A Case Report.
PG  - 181-188
LID - 10.1159/000507776 [doi]
AB  - BACKGROUND: To report a case of autologous corneal transplant in a patient with
      corneal leukoma and choroidal melanoma in the fellow eye. CASE PRESENTATION: A
      56-year-old woman was complaining about decrease in vision in her left eye. The
      patient was on the waiting list for a corneal transplant on her right eye due to 
      corneal leucoma after a previous herpes infection. The patient was diagnosed with
      choroidal melanoma in her left eye. Due to the tumor size (longitudinal diameter 
      >10 mm; anterior-posterior diameter >16 mm) the patient decided to undergo
      enucleation, after being informed about different treatment options
      (brachytherapy and enucleation). The patient showed her willingness to use the
      cornea of the left eye as a transplant for her right eye. After discussion with
      the ethical committee and its approval, and signing informed consent, the patient
      underwent enucleation of her left eye. The sample was examined by a pathologist
      and found to be free of melanoma cells in the corneolimbal tissue. Afterwards,
      trepanation of the donor cornea button was performed and transplanted to the left
      eye. CONCLUSION: Autologous corneal transplantation is a safe and feasible
      procedure in selected cases.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Iglicki, Matias
AU  - Iglicki M
AD  - Private Retina Office, University of Buenos Aires, Buenos Aires, Argentina.
FAU - Loewenstein, Anat
AU  - Loewenstein A
AD  - Ophthalmology Division, Tel Aviv Medical Center affiliated to the Sackler Faculty
      of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Manera, Manuel
AU  - Manera M
AD  - Diagnostic Ophthalmology Center, Buenos Aires, Argentina.
FAU - Castro, Claudia
AU  - Castro C
AD  - Diagnostic Ophthalmology Center, Buenos Aires, Argentina.
FAU - Busch, Catharina
AU  - Busch C
AD  - University Hospital Leipzig Department of Ophthalmology, Leipzig, Germany.
FAU - Zur, Dinah
AU  - Zur D
AD  - Ophthalmology Division, Tel Aviv Medical Center affiliated to the Sackler Faculty
      of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Negri, Hermino Pablo
AU  - Negri HP
AD  - Diagnostic Ophthalmology Center, Buenos Aires, Argentina.
LA  - eng
PT  - Case Reports
DEP - 20200514
PL  - Switzerland
TA  - Case Rep Ophthalmol
JT  - Case reports in ophthalmology
JID - 101532006
PMC - PMC7265731
OTO - NOTNLM
OT  - Choroidal melanoma
OT  - Enucleation
OT  - Homonymous corneal graft
COIS- The authors declare that they have no competing interests.
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
AID - 10.1159/000507776 [doi]
AID - cop-0011-0181 [pii]
PST - epublish
SO  - Case Rep Ophthalmol. 2020 May 14;11(2):181-188. doi: 10.1159/000507776.
      eCollection 2020 May-Aug.


PMID- 32518347
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220613
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 582
IP  - 7811
DP  - 2020 Jun
TI  - Systemic racism: science must listen, learn and change.
PG  - 147
LID - 10.1038/d41586-020-01678-x [doi]
LA  - eng
PT  - Editorial
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CIN - Nature. 2020 Jun;582(7813):488. PMID: 32546812
CIN - Nature. 2020 Jul;583(7814):30. PMID: 32606467
CIN - Nature. 2022 Jun;606(7913):225-227. PMID: 35676434
MH  - African Americans/psychology/*statistics & numerical data
MH  - Health Status
MH  - Humans
MH  - Internationality
MH  - Minority Groups/psychology/statistics & numerical data
MH  - Periodicals as Topic/ethics
MH  - Racism/*prevention & control/psychology/statistics & numerical data
MH  - *Research/statistics & numerical data/trends
MH  - Research Personnel/psychology/statistics & numerical data/supply & distribution
MH  - United States
MH  - Whites/psychology/statistics & numerical data
OTO - NOTNLM
OT  - *Education
OT  - *Ethics
OT  - *History
OT  - *Research management
OT  - *Society
EDAT- 2020/06/11 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
AID - 10.1038/d41586-020-01678-x [doi]
AID - 10.1038/d41586-020-01678-x [pii]
PST - ppublish
SO  - Nature. 2020 Jun;582(7811):147. doi: 10.1038/d41586-020-01678-x.


PMID- 32518210
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220716
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 8
TI  - Impact of a work-based feedback intervention on student performance during
      clinical placements in acute-care healthcare settings: a quasi-experimental
      protocol for the REMARK programme.
PG  - e034945
LID - 10.1136/bmjopen-2019-034945 [doi]
AB  - INTRODUCTION: Current perspectives present feedback as a dynamic, dialogic
      process. It is widely accepted that feedback can have an impact on workplace
      performance, however, how dialogic feedback is enacted with the learner in
      authentic healthcare settings is less apparent. This paper seeks to describe the 
      design and development of an implementation study to promote the learner voice in
      the feedback process and improve feedback encounters between learners and
      learning partners in healthcare settings. METHODS AND ANALYSIS: A
      quasi-experimental study design will be used to evaluate whether implementation
      of a work-based intervention to improve feedback impacts student performance
      during clinical placements in healthcare settings. Student performance will be
      measured at three time points: baseline (pre), mid-placement (post-test 1) and
      end-placement (post-test 2) in keeping with standard assessment processes of the 
      participating university. The intervention is underpinned by Normalisation
      Process Theory and involves a layered design that targets learners and learning
      partners using best-practice education strategies. Data regarding participants'
      engagement with feedback during clinical placements and participants' level of
      adoption of the intervention will be collected at the completion of the clinical 
      placement period. ETHICS AND DISSEMINATION: This study has ethics approval from
      both Griffith University and Metro South Health Human Research and Ethics
      committees. Dissemination of results will be local, national and international
      through forums, seminars, conferences and publications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ossenberg, Christine
AU  - Ossenberg C
AUID- ORCID: 0000-0001-8383-5043
AD  - School of Nursing and Midwifery, Griffith University, Nathan, Queensland,
      Australia christine.ossenberg@griffithuni.edu.au.
AD  - Nursing Practice Development Unit, Princess Alexandra Hospital, Woolloongabba,
      Queensland, Australia.
FAU - Mitchell, Marion
AU  - Mitchell M
AD  - School of Nursing and Midwifery, Griffith University, Nathan, Queensland,
      Australia.
AD  - Intensive Care, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
FAU - Henderson, Amanda
AU  - Henderson A
AD  - Nursing Practice Development Unit, Princess Alexandra Hospital, Woolloongabba,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200608
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Clinical Competence
MH  - Critical Care Nursing/education
MH  - Education, Nursing/*methods
MH  - *Formative Feedback
MH  - Humans
MH  - Students, Nursing
PMC - PMC7282324
OTO - NOTNLM
OT  - *education
OT  - *formative feedback
OT  - *protocol
OT  - *social theory
OT  - *students
COIS- Competing interests: None declared.
EDAT- 2020/06/11 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034945 [pii]
AID - 10.1136/bmjopen-2019-034945 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 8;10(6):e034945. doi: 10.1136/bmjopen-2019-034945.


PMID- 32518209
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 8
TI  - Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to
      treat solid tumours and haematological malignancies: a meta-analysis protocol for
      two systematic reviews.
PG  - e034714
LID - 10.1136/bmjopen-2019-034714 [doi]
AB  - INTRODUCTION: Autologous cancer cell vaccines are promising personalised
      immunotherapeutic options for solid and haematological malignancies that uses the
      patient's own cells to arm an immune response. Evidence suggests that among
      patients receiving these vaccines, those who mount an immune response against
      their own tumour cells have better prognosis, and a myriad of preclinical studies
      have demonstrated the same. Recently, two autologous cell vaccines Vigil and
      OncoVAX have made it to phase III clinical trials. Here, we outline a protocol to
      be used for two separate systematic reviews using a parallel approach for
      inclusion criteria, data extraction and analysis for autologous cell vaccines in 
      (1) solid and (2) haematological malignancies. We aim to review evidence from
      controlled and uncontrolled interventional studies of autologous cell vaccines
      administered to patients with cancer to determine their historical efficacy (with
      or without associated adjuvants or modifications) with clinical response rates
      and safety outcomes being of particular importance. METHODS AND ANALYSIS: We will
      search MEDLINE (OVID interface, including In-Process and Epub Ahead of Print),
      Embase (OVID interface) and the Cochrane Central Register of Controlled Trials
      (Wiley interface) for articles published from 1947 until 30 July 2018 (date
      search was performed). Studies will be screened first by title and abstract, then
      by full-text in duplicate. Interventional trials that report the use of an
      autologous cell vaccine to patients with cancer of any age will be included. The 
      primary outcomes of interest in this review are clinical response (complete or
      overall/objective response) and safety outcomes (adverse events). Secondary
      outcomes include immune response, disease-free survival and overall survival. The
      risk of bias within studies will be assessed using the appropriate Cochrane Risk 
      of Bias tool. If appropriate, a random effects meta-analysis will be performed to
      synthesise the data and report summary estimates of effect. Statistical
      heterogeneity will be assessed using the I(2) statistic. ETHICS AND
      DISSEMINATION: Ethics approval is not required for this systematic review
      protocol as the review will solely use published literature. Results will be
      submitted to peer-reviewed journals for publication and presented to relevant
      stakeholders and scientific meetings. PROSPERO REGISTRATION NUMBER:
      CRD42019140187.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Khan, Sarwat T
AU  - Khan ST
AUID- ORCID: 0000-0002-6578-8471
AD  - Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, 
      Canada.
FAU - Montroy, Joshua
AU  - Montroy J
AUID- ORCID: 0000-0002-6611-0056
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Forbes, Nicole
AU  - Forbes N
AUID- ORCID: 0000-0002-2645-695X
AD  - Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, 
      Canada.
FAU - Bastin, Donald
AU  - Bastin D
AD  - Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, 
      Canada.
FAU - Kennedy, Michael A
AU  - Kennedy MA
AUID- ORCID: 0000-0002-1071-3624
AD  - Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, 
      Canada.
FAU - Diallo, Jean-Simon
AU  - Diallo JS
AD  - Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, 
      Canada.
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine,
      University of Ottawa, Ottawa, Ontario, Canada.
FAU - Kekre, Natasha
AU  - Kekre N
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - Blood and Marrow Transplant Program, Ottawa Hospital General Campus, Ottawa,
      Ontario, Canada.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Lalu, Manoj
AU  - Lalu M
AUID- ORCID: 0000-0002-0322-382X
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - Department of Anaesthesiology and Pain Medicine, Faculty of Medicine, University 
      of Ottawa, Ottawa, Ontario, Canada.
FAU - Auer, Rebecca C
AU  - Auer RC
AD  - Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ottawa, Ontario, 
      Canada rauer@ohri.ca.
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine,
      University of Ottawa, Ottawa, Ontario, Canada.
AD  - Department of Surgery, Ottawa Hospital General Campus, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200608
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/adverse effects/*therapeutic use
MH  - Hematologic Neoplasms/*therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neoplasms/*therapy
PMC - PMC7282323
OTO - NOTNLM
OT  - *autologous cell vaccines
OT  - *cellular immunotherapy
OT  - *whole cell vaccines
COIS- Competing interests: None declared.
EDAT- 2020/06/11 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034714 [pii]
AID - 10.1136/bmjopen-2019-034714 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 8;10(6):e034714. doi: 10.1136/bmjopen-2019-034714.


PMID- 32518060
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201022
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 24
TI  - Guided Self-Help Behavioral Activation Intervention for Geriatric Depression:
      Protocol for Pilot Randomized Controlled Trial.
PG  - e18259
LID - 10.2196/18259 [doi]
AB  - BACKGROUND: Aging is a social concern. The increased incidence of depression in
      older populations in China poses a challenge to the health care system. Older
      adults who are depressed often suffer from a lack of motivation. Behavioral
      activation treatment, an evidence-based guided self-help treatment, is effective 
      in reducing anhedonia and amotivation in depression; however, the efficacy of
      guided self-help behavioral activation in older adults with depression is not yet
      known. OBJECTIVE: The aim of this study is to pilot a self-help guided
      intervention for the treatment of depression in older adults. METHODS: This study
      has been designed as a pilot randomized controlled trial with inpatients (n=60;
      to be randomly allocated 1:1) between the ages of 60 and 70 and who have major
      depressive disorder. Patients attending clinical psychological clinics at the
      Mental Health Center of Chongqing will be randomized to either receive guided
      self-help behavioral activation (intervention) or to be on a 6-week waiting list 
      (control). Participants in the treatment group will receive 6 sessions of guided 
      self-help behavioral activation delivered over the telephone. The waiting list
      control group will receive the intervention after a period of 6 weeks. Exclusion 
      criteria will be individuals who are at significant risk of harming themselves or
      others, who have a primary mental health disorder other than depression, or who
      have an intellectual disability that would hamper their ability to participate in
      the intervention. Effects of the treatment will be observed using outcomes in 3
      domains: (1) clinical outcomes (symptom severity, recovery rate), (2) process
      variables (patient satisfaction, attendance, dropout), and (3) economic outcomes 
      (cost and resource use). We will also examine mediators of outcomes in terms of
      patient variables (behavioral activation or inhibition motivation). We
      hypothesize that guided self-help behavioral activation will have a beneficial
      effect. RESULTS: The study was approved by the research ethics committee of the
      Mental Health Center of Chongqing in November 2019. As of July 2020, recruitment 
      had not yet begun. Data collection is expected to be completed by December 2020. 
      Data analysis is expected to be completed by June 2021. Results will then be
      disseminated to patients, to the public, to clinicians, and to researchers
      through publications in journals and presentations at conferences. CONCLUSIONS:
      This will be the first study in China to investigate guided self-help
      interventions for patients who are older adults and who are depressed, a group
      which is currently underrepresented in mental health research. The intervention
      is modular and adapted from an empirically supported behavioral activation
      treatment for depression. The generalizability and broad inclusion criteria are
      strengths. TRIAL REGISTRATION: Chinese Clinical Trial Register ChiCTR1900026066; 
      http://www.chictr.org.cn/showprojen.aspx?proj=43548. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): PRR1-10.2196/18259.
CI  - (c)Xiaoxia Wang, Xiaoyan Zhou, Hui Yang. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 24.09.2020.
FAU - Wang, Xiaoxia
AU  - Wang X
AUID- ORCID: https://orcid.org/0000-0001-7707-5607
AD  - Department of Basic Psychology, College of Psychology, Army Medical University,
      Chongqing, China.
FAU - Zhou, Xiaoyan
AU  - Zhou X
AUID- ORCID: https://orcid.org/0000-0002-9087-382X
AD  - Department of Clinical Psychology, Mental Health Center of Chongqing, Chongqing, 
      China.
FAU - Yang, Hui
AU  - Yang H
AUID- ORCID: https://orcid.org/0000-0001-8127-9274
AD  - Department of Clinical Psychology, Mental Health Center of Chongqing, Chongqing, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200924
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7545326
OTO - NOTNLM
OT  - behavior activation
OT  - behavior inhibition
OT  - behavior treatment
OT  - clinical
OT  - geriatric depression
OT  - guided self-help
OT  - psychiatry
OT  - psychology
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2020/02/15 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - v9i9e18259 [pii]
AID - 10.2196/18259 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Sep 24;9(9):e18259. doi: 10.2196/18259.


PMID- 32517776
OWN - NLM
STAT- MEDLINE
DCOM- 20200612
LR  - 20201218
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Jun 9
TI  - Should we deny ICU admission to the elderly? Ethical considerations in times of
      COVID-19.
PG  - 321
LID - 10.1186/s13054-020-03050-x [doi]
FAU - Haas, Lenneke E M
AU  - Haas LEM
AUID- ORCID: 0000-0002-3120-6891
AD  - Department of Intensive Care, Diakonessenhuis, PO box 80250, 3508 TG, Utrecht,
      the Netherlands. lvlelyveld@diakhuis.nl.
FAU - de Lange, Dylan W
AU  - de Lange DW
AUID- ORCID: 0000-0002-0191-7270
AD  - Department of Intensive Care Medicine and Dutch Poisons Information Center,
      University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the
      Netherlands.
FAU - van Dijk, Diederik
AU  - van Dijk D
AUID- ORCID: 0000-0002-3592-4671
AD  - Department of Intensive Care Medicine, University Medical Center Utrecht,
      Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.
FAU - van Delden, Johannes J M
AU  - van Delden JJM
AUID- ORCID: 0000-0002-5530-7275
AD  - Department of Medical Humanities, University Medical Center, University Utrecht, 
      Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.
LA  - eng
PT  - Letter
DEP - 20200609
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
SB  - IM
MH  - Aged
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Care/*ethics
MH  - Humans
MH  - *Intensive Care Units
MH  - Pandemics
MH  - *Patient Admission
MH  - Pneumonia, Viral/*epidemiology
MH  - Refusal to Treat/*ethics
PMC - PMC7282209
OTO - NOTNLM
OT  - *Age
OT  - *COVID-19
OT  - *Critical care
OT  - *Elderly
OT  - *Ethics
OT  - *ICU
OT  - *Triage
EDAT- 2020/06/11 06:00
MHDA- 2020/06/13 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/05/23 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/13 06:00 [medline]
AID - 10.1186/s13054-020-03050-x [doi]
AID - 10.1186/s13054-020-03050-x [pii]
PST - epublish
SO  - Crit Care. 2020 Jun 9;24(1):321. doi: 10.1186/s13054-020-03050-x.


PMID- 32517722
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 9
TI  - A cross-sectional study on caregivers' perspective of the quality of life and
      adherence of paediatric HIV patients to highly active antiretroviral therapy.
PG  - 286
LID - 10.1186/s12887-020-02194-7 [doi]
AB  - BACKGROUND: Poor compliance to highly active antiretroviral therapy (HAART) can
      result in the poor quality of life in children living with Human immunodeficiency
      virus/Acquired immunodeficiency syndrome (HIV/AIDS) because of low plasma drug
      concentration and the possibility of drug resistance. This study evaluates the
      response of caregivers for determination of adherence and the four quality of
      life domains in children (aged 14 years and under) on HAART. METHODS: We
      conducted a cross-sectional study of 188 children, each accompanied by their
      caregivers at Ola During Children's Hospital and Makeni Government Hospital
      between September and November 2016. Adherence to HAART and Quality of life was
      assessed using the WHO Quality of life summary questionnaire (WHOQOL-BREF). We
      obtained ethical approval from the Sierra Leone Ethics and Scientific Review
      Committee. RESULTS: The study revealed 5.9% adherence amongst paediatric
      patients, and a strong association of adherent patients(p = 0.019*) to the
      physical health domain (mean = 64.61 SD = 8.1). Caregiver HIV status showed a
      strong association with the physical (mean = 58.3, SD = 11.7 and p = 0.024*), and
      psychological health domains (mean = 68.2, SD = 14.7 and p = 0.001). Caregiver
      type (mother/father/sibling) accompanying child to hospital also showed strong
      associated with the physical (mean = 58.0, SD = 10.6, p < 0.001), psychological
      (mean 68.2 SD = 14.81 p < 0.001) and environmental health domains (mean = 59.7,
      SD = 13.47, p < 0.001). Further regression analysis showed a strong association
      with physical health domain for HIV positive caregivers (p = 0.014) and adherent 
      paediatric patients (p = 0.005). Nuclear family also showed a strong association 
      with psychological (p < 0.001) and environmental (p = 0.001) health domains.
      CONCLUSION: This study showed a strong association between the quality of life
      domains and the involvement of nuclear family caregiver, HIV-positive caregiver
      and adherence to HAART. Our study suggests that the involvement of any member of 
      the nuclear family, HIV positive parents and patient adherence to therapy can
      improve the quality of life of paediatric HIV/AIDS patients on highly active
      antiretroviral therapy in the two hospitals.
FAU - Lahai, Michael
AU  - Lahai M
AUID- ORCID: 0000-0002-8605-3407
AD  - Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health
      Sciences, University of Sierra Leone, Freetown, 00232, Sierra Leone.
      miclahisaac@gmail.com.
FAU - James, Peter Bai
AU  - James PB
AD  - Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health
      Sciences, University of Sierra Leone, Freetown, 00232, Sierra Leone.
FAU - Wannang, Noel Nen'man
AU  - Wannang NN
AD  - Department of Pharmacology and Toxicology, University of Jos, Jos, Nigeria.
FAU - Wurie, Haja Ramatulai
AU  - Wurie HR
AD  - Faculty of Basic Medical Sciences, College of Medicine and Allied Health
      Sciences, University of Sierra Leone, Freetown, Sierra Leone.
FAU - Conteh, Sorie
AU  - Conteh S
AD  - Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences,
      University of Sierra Leone, Freetown, Sierra Leone.
FAU - Bah, Abdulai Jawo
AU  - Bah AJ
AD  - Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health
      Sciences, University of Sierra Leone, Freetown, 00232, Sierra Leone.
FAU - Samai, Mohamed
AU  - Samai M
AD  - Faculty of Basic Medical Sciences, College of Medicine and Allied Health
      Sciences, University of Sierra Leone, Freetown, Sierra Leone.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200609
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
SB  - IM
MH  - Adolescent
MH  - Antiretroviral Therapy, Highly Active
MH  - *Caregivers
MH  - Child
MH  - Cross-Sectional Studies
MH  - *HIV Infections/drug therapy
MH  - Humans
MH  - Medication Adherence
MH  - Quality of Life
MH  - Sierra Leone
MH  - Surveys and Questionnaires
PMC - PMC7282047
OTO - NOTNLM
OT  - *Awareness, stigma
OT  - *Caregiver
OT  - *Disclosure
OT  - *Discrimination
OT  - *Nuclear family
EDAT- 2020/06/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12887-020-02194-7 [doi]
AID - 10.1186/s12887-020-02194-7 [pii]
PST - epublish
SO  - BMC Pediatr. 2020 Jun 9;20(1):286. doi: 10.1186/s12887-020-02194-7.


PMID- 32517663
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 9
TI  - Adjuvant VACcination against HPV in surgical treatment of Cervical
      Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised
      controlled trial.
PG  - 539
LID - 10.1186/s12885-020-07025-7 [doi]
AB  - BACKGROUND: Cervical cancer is caused by Human Papilloma viruses (HPV) and is
      preceded by precursor stages: Cervical Intraepithelial Neoplasia (CIN). CIN is
      mostly found in women in their reproductive age and treated with a Loop
      Electrosurgical Excision Procedure (LEEP). The recurrence or residual disease
      rate after treatment is up to 17%. These women have a lifelong increased risk of 
      recurrent CIN, cervical cancer and other HPV related malignancies. Furthermore,
      LEEP treatments are associated with complications such as premature birth.
      Limited data show that prophylactic HPV vaccination at the time of LEEP reduces
      recurrence rates, therefore leading to a reduction in repeated surgical
      interventions and side effect like preterm birth. The primary study objective is 
      to evaluate the efficacy of the nonavalent HPV vaccination in women with a CIN
      II-III (high-grade squamous intraepithelial lesion (HSIL) lesion who will undergo
      a LEEP in preventing recurrent CIN II-III after 24 months. METHODS: This study is
      a randomised, double blinded, placebo controlled trial in 750 patients without
      prior HPV vaccination or prior treatment for CIN and with histologically proven
      CIN II-III (independent of their hrHPV status) for whom a LEEP is planned.
      Included patients will be randomised to receive either three injections with
      nonavalent (9 HPV types) HPV vaccine or placebo injections (NaCL 0.9%) as a
      comparator. Treatment and follow-up will be according the current Dutch
      guidelines. Primary outcome is recurrence of a CIN II or CIN III lesion at 24
      months. A normal PAP smear with negative hrHPV test serves as surrogate for
      absence of CIN. At the start and throughout the study HPV typing, quality of life
      and cost effectiveness will be tested. DISCUSSION: Although prophylactic HPV
      vaccines are highly effective, little is known about the effectivity of HPV
      vaccines on women with CIN. Multiple LEEP treatments are associated with
      complications. We would like to evaluate the efficacy of HPV vaccination in
      addition to LEEP treatment to prevent residual or recurrent cervical dysplasia
      and decrease risks of repeated surgical treatment. TRIAL REGISTRATION: Medical
      Ethical Committee approval number: NL66775.078.18. Affiliation: Erasmus Medical
      Centre. Dutch trial register: NL 7938. Date of registration 2019-08-05.
FAU - van de Laar, R L O
AU  - van de Laar RLO
AD  - Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University
      Medical Centre Rotterdam, PO Box: 2040, 3000 CA, Rotterdam, The Netherlands.
      r.vandelaar@erasmusmc.nl.
FAU - Hofhuis, W
AU  - Hofhuis W
AD  - Department of Obstetrics and Gynaecology, Franciscus Gasthuis, PO Box: 10900,
      3004 BA, Rotterdam, The Netherlands.
FAU - Duijnhoven, R G
AU  - Duijnhoven RG
AD  - Clinical trials unit of the Dutch Society for Obstetrics and Gynecology,
      Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam,
      Netherlands.
FAU - Polinder, S
AU  - Polinder S
AD  - Department of Public Health, Center for Medical Decision Sciences, Erasmus MC-
      University Medical Centre Rotterdam, Rotterdam, The Netherlands.
FAU - Melchers, W J G
AU  - Melchers WJG
AD  - Department of Medical Microbiology, Radboud University Medical Centre, PO Box
      9101, 6500 HB, Nijmegen, the Netherlands.
FAU - van Kemenade, F J
AU  - van Kemenade FJ
AD  - Department of Pathology, Erasmus MC, University Medical Centre Rotterdam,
      Rotterdam, 3000 CA, The Netherlands.
FAU - Bekkers, R L M
AU  - Bekkers RLM
AD  - Department of Obstetrics and Gynecology, Catharina Hospital, PO Box 1350, 5602
      ZA, Eindhoven, the Netherlands.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University,
      Eindhoven, the Netherlands.
FAU - Van Beekhuizen, H J
AU  - Van Beekhuizen HJ
AD  - Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University
      Medical Centre Rotterdam, PO Box: 2040, 3000 CA, Rotterdam, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200609
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Alphapapillomavirus/immunology
MH  - Cervical Intraepithelial Neoplasia/pathology/*surgery/virology
MH  - Double-Blind Method
MH  - Electrosurgery/*methods
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Papillomavirus Infections/complications/*prevention & control
MH  - Papillomavirus Vaccines/*administration & dosage
MH  - *Randomized Controlled Trials as Topic
MH  - Sample Size
MH  - Uterine Cervical Neoplasms/pathology/*surgery/virology
MH  - Young Adult
PMC - PMC7285539
OTO - NOTNLM
OT  - Cervical intraepithelial neoplasia (CIN)
OT  - HPV-vaccination
OT  - HSIL
OT  - Human papillomavirus (HPV)
OT  - Loop electrosurgical excision procedure (LEEP)
OT  - Persistence
OT  - Recurrence
EDAT- 2020/06/11 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
AID - 10.1186/s12885-020-07025-7 [doi]
AID - 10.1186/s12885-020-07025-7 [pii]
PST - epublish
SO  - BMC Cancer. 2020 Jun 9;20(1):539. doi: 10.1186/s12885-020-07025-7.


PMID- 32517524
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1753-8564 (Electronic)
IS  - 0073-2753 (Linking)
VI  - 58
IP  - 4
DP  - 2020 Dec
TI  - Making matters of fraud: Sociomaterial technology in the case of Hwang and
      Schatten.
PG  - 393-416
LID - 10.1177/0073275320921687 [doi]
AB  - This paper revisits the "Hwang case," which shook Korean society and the world of
      stem cell research in 2005 with the fraudulent claim of creating patient-specific
      embryonic stem cells. My goal is to overcome a human-centered, Korea-oriented
      narrative, by illustrating how materials can have an integral role in the
      construction and judgment of fraud. To this end, I pay attention to Woo Suk
      Hwang's lab at Seoul National University as a whole, including human and nonhuman
      agents, that functioned as what I call sociomaterial technology, and Gerald P.
      Schatten at the University of Pittsburgh, Hwang's collaborator, who played a
      crucial role in demonstrating the potency of this technology to the members of
      the scientific community. By recasting the whole event as the "case of Hwang and 
      Schatten," I argue that fraud is, like all knowledge claims, a sociotechnical
      construct, and that matters of fraud are locally judged. Fraud leaves its mark on
      materials, but I show that material evidence alone never tells the whole story
      and instead can be used to limit the range of responsibility.
FAU - Park, Buhm Soon
AU  - Park BS
AUID- ORCID: 0000-0001-8263-5744
AD  - Graduate School of Science, Technology, and Policy, Korea Advanced Institute of
      Science and Technology (KAIST), Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200609
PL  - United States
TA  - Hist Sci
JT  - History of science
JID - 17340520R
PMC - PMC7731643
OTO - NOTNLM
OT  - *Gerald Schatten
OT  - *Scientific fraud
OT  - *Woo Suk Hwang
OT  - *ethics
OT  - *materiality
OT  - *research integrity
OT  - *sociomaterial technology
OT  - *stem cell
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1177/0073275320921687 [doi]
PST - ppublish
SO  - Hist Sci. 2020 Dec;58(4):393-416. doi: 10.1177/0073275320921687. Epub 2020 Jun 9.


PMID- 32517522
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1552-6127 (Electronic)
IS  - 1090-1981 (Linking)
VI  - 47
IP  - 5
DP  - 2020 Oct
TI  - Nudging in Public Health Lifestyle Interventions: A Systematic Literature Review 
      and Metasynthesis.
PG  - 749-764
LID - 10.1177/1090198120931788 [doi]
AB  - Nudging is increasingly used in public health interventions in Western societies 
      to produced health-promoting behavior changes; however, there is lack of clarity 
      as to what constitutes a nudge, scant knowledge of the effectiveness of nudging
      techniques in public health lifestyle interventions and a number of ethical and
      value-based concerns. The aim of this review is to address these research lacunae
      and identify the characteristics of nudges in empirical research on public health
      interventions intended to induce healthy lifestyle changes, including whether
      they are effective. We conducted systematic searches for relevant articles
      published between January 2008 and April 2019 in three databases, PubMed, CINAHL 
      and PsycINFO, and combined this with a metasynthesis to construct interpretative 
      explanations. A total of 66 original studies met the inclusion criteria. The
      findings of the systematic review showed that most nudging interventions involved
      diet/nutrition, most were carried out as single experiments, and the majority had
      the intended effects. Specific nudging techniques were identified with respect to
      the broader nudging categories of accessibility, presentation, using messages and
      pictures, technology-supported information, financial incentives, affecting the
      senses, and cognitive loading; several studies included more than one nudging
      technique. Although many nudging techniques had the intended effects, it is
      unclear whether they would work outside the study setting. The synthesis revealed
      that the studies lacked critical reflection on the assumptions about health that 
      were implicit in nudging interventions, the cultural acceptability of nudges, the
      context-free assumptions of nudging theory, and the implications of these aspects
      for the public health context.
FAU - Ledderer, Loni
AU  - Ledderer L
AUID- ORCID: 0000-0002-2685-4579
AD  - Aarhus University, Aarhus C, Denmark.
FAU - Kjaer, Marianne
AU  - Kjaer M
AD  - Aarhus University, Aarhus C, Denmark.
FAU - Madsen, Emilie Kirstine
AU  - Madsen EK
AD  - Aarhus University, Aarhus C, Denmark.
FAU - Busch, Jacob
AU  - Busch J
AD  - Aarhus University, Aarhus C, Denmark.
FAU - Fage-Butler, Antoinette
AU  - Fage-Butler A
AD  - Aarhus University, Aarhus C, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200609
PL  - United States
TA  - Health Educ Behav
JT  - Health education & behavior : the official publication of the Society for Public 
      Health Education
JID - 9704962
SB  - IM
MH  - *Healthy Lifestyle
MH  - Humans
MH  - Life Style
MH  - Motivation
MH  - *Public Health
OTO - NOTNLM
OT  - *general terms
OT  - *health behavior
OT  - *health communications
OT  - *health promotion
OT  - *literature review
EDAT- 2020/06/11 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.1177/1090198120931788 [doi]
PST - ppublish
SO  - Health Educ Behav. 2020 Oct;47(5):749-764. doi: 10.1177/1090198120931788. Epub
      2020 Jun 9.


PMID- 32517057
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 11
DP  - 2020 Jun 5
TI  - Caregivers of Patients with Hematological Malignancies within Home Care: A
      Phenomenological Study.
LID - E4036 [pii]
LID - 10.3390/ijerph17114036 [doi]
AB  - The role of caregivers in homecare settings is relevant to the patient's
      wellbeing and quality of life. This phenomenon is well described in the
      literature for the oncological setting but not specifically for that of
      hematological malignancies. The aim of this study was to explore the experience
      of primary caregivers of patients with hematological malignancies within home
      care. We conducted a phenomenological study based on interviews with 17 primary
      caregivers of hematological patients. Analysis of the contents led to the
      identification of five main themes. Perhaps, the innovative aspects of this study
      can be summarized in three points: This service was demonstrated to fulfil the
      ethical aspects of providing the patient with a dignified accompaniment to the
      end of life. Secondly, the efficiency of the service and the benefit are directly
      dependent on the caregivers' wellbeing, so knowledge of the dynamics and emotions
      involved can lead to the development and implementation of programs for
      hematological malignancies. Lastly, a collaborative caregivers-professionals
      relationship can improve a sense of accomplishment for all parties involved,
      lessening the family's frustration related to not having done their best. Home
      care brings significant benefits for both the patient and the caregivers and
      fulfils the ethical obligation of providing the patient dignified end-of-life
      care.
FAU - Capodanno, Isabella
AU  - Capodanno I
AD  - Department of Hematology, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento,
      80-42123 Reggio Emilia, Italy.
FAU - Rocchi, Mirta
AU  - Rocchi M
AD  - Hospice "Casa Madonna dell'Uliveto" Via Oliveto, 34-42020 Albinea, Reggio Emilia,
      Italy.
FAU - Prandi, Rossella
AU  - Prandi R
AD  - Servizio Infermieristico Domiciliare, Azienda USL di Modena, piazzale dei
      Donatori di Sangue, 3-41012 Carpi, Italy.
FAU - Pedroni, Cristina
AU  - Pedroni C
AUID- ORCID: 0000-0001-9065-3635
AD  - Direzione delle Professioni Sanitarie Azienda USL-IRCCS di Reggio Emilia Viale
      Amendola, 2-42122 Reggio Emilia, Italy.
FAU - Tamagnini, Enrica
AU  - Tamagnini E
AD  - Department of Primary Care, Azienda USL-IRCCS di Reggio Emilia Viale Amendola,
      2-42122 Reggio Emilia, Italy.
FAU - Alfieri, Pierluigi
AU  - Alfieri P
AD  - Department of Hematology, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento,
      80-42123 Reggio Emilia, Italy.
FAU - Merli, Francesco
AU  - Merli F
AD  - Department of Hematology, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento,
      80-42123 Reggio Emilia, Italy.
FAU - Ghirotto, Luca
AU  - Ghirotto L
AUID- ORCID: 0000-0001-7632-1271
AD  - Qualitative Research Unit, Azienda USL-IRCCS di Reggio Emilia Viale Umberto I,
      50-42123 Reggio Emilia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Aged
MH  - Caregivers
MH  - Child
MH  - *Hematologic Neoplasms
MH  - *Home Care Services
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Terminal Care
PMC - PMC7312962
OTO - NOTNLM
OT  - *caregivers
OT  - *hematologic neoplasms
OT  - *home care services
OT  - *palliative care
OT  - *qualitative research
EDAT- 2020/06/11 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/05/31 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - ijerph17114036 [pii]
AID - 10.3390/ijerph17114036 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 5;17(11). pii: ijerph17114036. doi:
      10.3390/ijerph17114036.


PMID- 32516948
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Jun 5
TI  - Genome Editing in Cereals: Approaches, Applications and Challenges.
LID - E4040 [pii]
LID - 10.3390/ijms21114040 [doi]
AB  - Over the past decades, numerous efforts were made towards the improvement of
      cereal crops mostly employing traditional or molecular breeding approaches. The
      current scenario made it possible to efficiently explore molecular understanding 
      by targeting different genes to achieve desirable plants. To provide guaranteed
      food security for the rising world population particularly under vulnerable
      climatic condition, development of high yielding stress tolerant crops is needed.
      In this regard, technologies upgradation in the field of genome editing looks
      promising. Clustered regularly interspaced short palindromic repeats
      (CRISPR)/Cas9 is a rapidly growing genome editing technique being effectively
      applied in different organisms, that includes both model and crop plants. In
      recent times CRISPR/Cas9 is being considered as a technology which revolutionized
      fundamental as well as applied research in plant breeding. Genome editing using
      CRISPR/Cas9 system has been successfully demonstrated in many cereal crops
      including rice, wheat, maize, and barley. Availability of whole genome sequence
      information for number of crops along with the advancement in genome-editing
      techniques provides several possibilities to achieve desirable traits. In this
      review, the options available for crop improvement by implementing CRISPR/Cas9
      based genome-editing techniques with special emphasis on cereal crops have been
      summarized. Recent advances providing opportunities to simultaneously edit many
      target genes were also discussed. The review also addressed recent advancements
      enabling precise base editing and gene expression modifications. In addition, the
      article also highlighted limitations such as transformation efficiency, specific 
      promoters and most importantly the ethical and regulatory issues related to
      commercial release of novel crop varieties developed through genome editing.
FAU - Ansari, Waquar A
AU  - Ansari WA
AUID- ORCID: 0000-0003-1212-2614
AD  - Department of Botany, Savitribai Phule Pune University, Pune 411007, India.
FAU - Chandanshive, Sonali U
AU  - Chandanshive SU
AD  - Department of Botany, Savitribai Phule Pune University, Pune 411007, India.
FAU - Bhatt, Vacha
AU  - Bhatt V
AD  - Department of Botany, Savitribai Phule Pune University, Pune 411007, India.
FAU - Nadaf, Altafhusain B
AU  - Nadaf AB
AD  - Department of Botany, Savitribai Phule Pune University, Pune 411007, India.
FAU - Vats, Sanskriti
AU  - Vats S
AD  - Agri-Biotechnology Division, National Agri-Food Biotechnology Institute (NABI),
      Mohali 140306, India.
FAU - Katara, Jawahar L
AU  - Katara JL
AD  - ICAR-National Rice Research Institute, Cuttack 753006, India.
FAU - Sonah, Humira
AU  - Sonah H
AUID- ORCID: 0000-0003-4796-6120
AD  - Agri-Biotechnology Division, National Agri-Food Biotechnology Institute (NABI),
      Mohali 140306, India.
FAU - Deshmukh, Rupesh
AU  - Deshmukh R
AUID- ORCID: 0000-0003-4167-6552
AD  - Agri-Biotechnology Division, National Agri-Food Biotechnology Institute (NABI),
      Mohali 140306, India.
LA  - eng
GR  - BL/17-18/0577/University Grants Commission
GR  - 2017/Department of Biotechnology , Ministry of Science and Technology
PT  - Journal Article
PT  - Review
DEP - 20200605
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - CRISPR-Cas Systems
MH  - Crops, Agricultural/genetics
MH  - Edible Grain/*genetics
MH  - *Gene Editing
MH  - *Genome, Plant
MH  - *Genomics/methods
MH  - Plants, Genetically Modified
MH  - Stress, Physiological
MH  - Transformation, Genetic
PMC - PMC7312557
OTO - NOTNLM
OT  - Biotic/abiotic stress
OT  - CRISPR/Cas9
OT  - cereals
OT  - genome editing
OT  - non-GMO
EDAT- 2020/06/11 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/11 06:00
PHST- 2019/11/08 00:00 [received]
PHST- 2019/12/18 00:00 [revised]
PHST- 2019/12/19 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - ijms21114040 [pii]
AID - 10.3390/ijms21114040 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Jun 5;21(11). pii: ijms21114040. doi: 10.3390/ijms21114040.


PMID- 32516867
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201210
IS  - 1606-7916 (Electronic)
IS  - 0036-3634 (Linking)
VI  - 62
IP  - 5
DP  - 2020 Sep-Oct
TI  - Allocating medical resources fairly:the CSG bioethics guide.
PG  - 590-592
LID - 10.21149/11486 [doi]
AB  - On April 12, 2020, a bioethics guide for allocating scarce hospital resources
      during the current Covid-19 pandemic was posted on the website of the Consejo de 
      Salubridad General(CSG) of the Government of Mexico. The guide, entitled Guia
      bioetica para asignacion de recursos limitados de medicina critica en situacion
      de emergencia, was intended as a preliminary document, but the website posting
      did not describe it as a first step in the process. The publicity resulted in a
      wide array of comments and criticisms. That first version posted on the CSG
      website contained an age-based criterion for breaking a tie between two or more
      medically eligible patients who needed of a ventilator: younger patients would
      have prefer-ence over older ones. The final version of the guide eliminated that 
      criterion and instead, relied on the leading public health principle, "save the
      most lives", without regard to personal characteristics other than the
      possibility of benefitting from the scarce medical resources.
FAU - Macklin, Ruth
AU  - Macklin R
AD  - Albert Einstein College of Medicine. Bronx, New York, USA.
LA  - eng
PT  - Journal Article
TT  - Asignacion justa de recursos medicos:guia bioetica del CSG.
DEP - 20200603
PL  - Mexico
TA  - Salud Publica Mex
JT  - Salud publica de Mexico
JID - 0404371
RN  - COVID-19 drug treatment
SB  - IM
MH  - Ageism
MH  - Betacoronavirus
MH  - Bioethical Issues/*standards
MH  - COVID-19
MH  - *Coronavirus Infections/drug therapy/epidemiology/therapy
MH  - Decision Making
MH  - Dissent and Disputes
MH  - Health Resources/*supply & distribution
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Life Expectancy
MH  - Mexico
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - *Practice Guidelines as Topic
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Social Justice
MH  - Triage/*ethics/standards
MH  - Value of Life
MH  - Ventilators, Mechanical/supply & distribution
MH  - Withholding Treatment/ethics/standards
OTO - NOTNLM
OT  - ethics
OT  - pandemic
OT  - social justice
COIS- Declaration of conflict of interests. The authors declare that they have no
      conflict of interests.
EDAT- 2020/06/11 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2020/06/11 06:00 [entrez]
AID - 10.21149/11486 [doi]
PST - ppublish
SO  - Salud Publica Mex. 2020 Sep-Oct;62(5):590-592. doi: 10.21149/11486. Epub 2020 Jun
      3.


PMID- 34457766
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2156-8650 (Electronic)
IS  - 2156-8650 (Linking)
VI  - 30
IP  - 3
DP  - 2020 Sep
TI  - Surgical Competencies Required in Newly Commencing Colorectal Surgeons: an
      Educational and Training Spectrum.
PG  - 1043-1047
LID - 10.1007/s40670-020-01005-z [doi]
AB  - PURPOSE: Surgical training models have changed from master-apprentice to
      competency-based training. We aimed to determine the relative importance and peak
      periods of acquiring these competencies in newly commencing colorectal surgeons. 
      METHODS: A mailed questionnaire to all current Colorectal Surgical Society of
      Australia and New Zealand (CSSANZ) members was conducted between October and
      December 2016 assessing the relative importance of each competency and the period
      or activity of learning or training contributing most to achieving that
      competency. RESULTS: The response rate was 43% (90/208) with 87% (n = 75) agreed 
      or strongly agreed to the relevance and applicability of the nine RACS
      competencies. Competencies varied in perceived importance (strongly agreed:
      judgment-clinical decision-making (JU) 63%, collaboration/teamwork (CT) 53%,
      technical expertise (TE) 47%, communication (CO) 44%, medical expertise (ME) 34%,
      scholarship/teaching (ST) 33%, professionalism (PR) 33%/ethics (ET) 24%, health
      advocacy (HA) 18%, management (MX) 13%/leadership (LE) 17%), and the peak period 
      for acquiring them (registrar: CO 39%, ST 30%; fellow: TE 62%, CT 44%, ME 40%, JU
      38%; consultant: MX/LE 52%, HA 48%, PR/ET 33%). CONCLUSION: Surgical competencies
      for colorectal surgeons are accumulated and acquired at varying degrees and
      periods across a spectrum of continuing registrar, fellow, and consultant
      education and training. These findings serve as a baseline for further refinement
      of current and continuing educational and training programs.
CI  - (c) International Association of Medical Science Educators 2020.
FAU - Zahid, Assad
AU  - Zahid A
AUID- ORCID: 0000-0002-4401-416X
AD  - Institute of Academic Surgery, Royal Prince Alfred Hospital, University of
      Sydney, Sydney, NSW Australia.grid.1013.30000 0004 1936 834X
AD  - Discipline of Surgery, University of Sydney, Sydney, NSW
      Australia.grid.1013.30000 0004 1936 834X
FAU - Rajan, Vasant
AU  - Rajan V
AD  - Institute of Academic Surgery, Royal Prince Alfred Hospital, University of
      Sydney, Sydney, NSW Australia.grid.1013.30000 0004 1936 834X
AD  - Discipline of Surgery, University of Sydney, Sydney, NSW
      Australia.grid.1013.30000 0004 1936 834X
FAU - Hong, Jonathan
AU  - Hong J
AD  - Institute of Academic Surgery, Royal Prince Alfred Hospital, University of
      Sydney, Sydney, NSW Australia.grid.1013.30000 0004 1936 834X
AD  - Department of Colorectal Surgery, Royal Prince Alfred Hospital, University of
      Sydney, Missenden Rd, Camperdown, Sydney, NSW 2050 Australia.grid.1013.30000 0004
      1936 834X
FAU - Young, Christopher J
AU  - Young CJ
AD  - Institute of Academic Surgery, Royal Prince Alfred Hospital, University of
      Sydney, Sydney, NSW Australia.grid.1013.30000 0004 1936 834X
AD  - Discipline of Surgery, University of Sydney, Sydney, NSW
      Australia.grid.1013.30000 0004 1936 834X
AD  - Department of Colorectal Surgery, Royal Prince Alfred Hospital, University of
      Sydney, Missenden Rd, Camperdown, Sydney, NSW 2050 Australia.grid.1013.30000 0004
      1936 834X
LA  - eng
PT  - Journal Article
DEP - 20200611
PL  - United States
TA  - Med Sci Educ
JT  - Medical science educator
JID - 101625548
PMC - PMC8368516
OTO - NOTNLM
OT  - Colorectal
OT  - Competency
OT  - Surgery
OT  - Training
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/06/11 00:00
MHDA- 2020/06/11 00:01
CRDT- 2021/08/30 05:57
PHST- 2021/08/30 05:57 [entrez]
PHST- 2020/06/11 00:00 [pubmed]
PHST- 2020/06/11 00:01 [medline]
AID - 10.1007/s40670-020-01005-z [doi]
AID - 1005 [pii]
PST - epublish
SO  - Med Sci Educ. 2020 Jun 11;30(3):1043-1047. doi: 10.1007/s40670-020-01005-z.
      eCollection 2020 Sep.


PMID- 32516789
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210610
IS  - 1662-8063 (Electronic)
IS  - 1662-4246 (Linking)
VI  - 23
IP  - 3-4
DP  - 2020
TI  - The Ethics of Precision Rationing: Human Genetics and the Need for Debate on
      Stratifying Access to Medication.
PG  - 149-154
LID - 10.1159/000508141 [doi]
AB  - Rising prices for new, transformative therapies are challenging health systems
      around the world, leading many payers and providers to begin rationing access to 
      treatments, even in the countries that have been most resistant to doing so. This
      is the case for direct-acting antivirals (DAAs) for the treatment of hepatitis C 
      virus (HCV). However, little attention has been paid to the increasing role that 
      human genetics might play in rationing decisions. Researchers have already
      proposed that genetic markers associated with spontaneous HCV clearance could be 
      used to restrict DAA access for some patients, although treatment would be
      medically beneficial for those patients. Would such forms of rationing present a 
      form of genetic discrimination? And what of the public health implications of
      these approaches? Here we present an ethical analysis of such proposals for
      "precision rationing" and raise 4 key areas of concern. We argue that ethical
      issues arising in this area are not substantively different from the pressing
      ethical issues regarding rationing and discrimination more broadly, but provide
      important impetus for motivating broad public debate to find ethically sound ways
      of managing genomics and new expensive medications.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Walker, Alexis
AU  - Walker A
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland,
      USA, awalker@jhu.edu.
FAU - Boyce, Angie
AU  - Boyce A
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland,
      USA.
FAU - Duggal, Priya
AU  - Duggal P
AD  - Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore,
      Maryland, USA.
FAU - Thio, Chloe L
AU  - Thio CL
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Geller, Gail
AU  - Geller G
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland,
      USA.
LA  - eng
GR  - RM1 HG009038/HG/NHGRI NIH HHS/United States
PT  - News
PT  - Research Support, N.I.H., Extramural
DEP - 20200609
PL  - Switzerland
TA  - Public Health Genomics
JT  - Public health genomics
JID - 101474167
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/economics/therapeutic use
MH  - *Genetic Phenomena
MH  - Genetic Testing/methods
MH  - Health Care Rationing/ethics/methods
MH  - Health Services Accessibility
MH  - *Hepatitis C/drug therapy/economics/genetics
MH  - *Human Genetics/methods/trends
MH  - Humans
MH  - *Patient Selection
PMC - PMC7508798
MID - NIHMS1589090
OTO - NOTNLM
OT  - *Ethics
OT  - *Genetics
OT  - *Genomics
OT  - *Hepatitis C
OT  - *Rationing
EDAT- 2020/06/10 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 000508141 [pii]
AID - 10.1159/000508141 [doi]
PST - ppublish
SO  - Public Health Genomics. 2020;23(3-4):149-154. doi: 10.1159/000508141. Epub 2020
      Jun 9.


PMID- 32516495
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1475-357X (Print)
IS  - 1475-357X (Linking)
VI  - 25
IP  - 3
DP  - 2020 Sep
TI  - A cross-cultural qualitative study of the ethical aspects in the transition from 
      child mental health services to adult mental health services.
PG  - 143-149
LID - 10.1111/camh.12377 [doi]
AB  - BACKGROUND: Transitioning from Child and Adolescent Mental Health Services
      (CAMHS) to Adult Mental Health Services (AMHS) raises novel ethical aspects for
      healthcare professionals, as well as for young people, their parents and carers. 
      METHOD: Focus groups were conducted in Croatia, Ireland and the United Kingdom
      with youth mental health groups and youth representatives with no mental health
      (MH) remit. One hundred and eleven participants, aged from 16 to 60 years,
      contributed to discussions. RESULTS: Perpetuation of stigma, autonomy and
      decision-making were central themes as both enablers and deterrents of successful
      transition. The tension between professional (and at times parental) paternalism 
      and young persons' growing autonomy was well captured in the themes; (a) desired 
      practice, (b) who should decide, (c) the process of decision-making and (d)
      potential harm(s). CONCLUSIONS: This study provides insight into the ethical
      values, particularly autonomy and collaboratively working, which people expect to
      underpin the transition between CAMHS and AMHS. KEY PRACTITIONER MESSAGE:
      Engaging young people early in making decisions about their future care can
      enhance trust between practitioner and the young person. In addition to
      diagnosis, a number of factors (such as moving home; waiting lists and stigma)
      may need to be taken into account when considering the direction of future health
      care. When possible, alternatives to AMHS should be considered if considered by
      the young person to be a less-stigmatising treatment option.
CI  - (c) 2020 Association for Child and Adolescent Mental Health.
FAU - O'Hara, Lesley
AU  - O'Hara L
AUID- ORCID: 0000-0001-5544-0917
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
FAU - Holme, Ingrid
AU  - Holme I
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
FAU - Tah, Priya
AU  - Tah P
AD  - Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, 
      Coventry, UK.
FAU - Franic, Tomislav
AU  - Franic T
AD  - Department of Psychiatry, University Hospital Split, Split, Croatia.
FAU - Vrljicak Davidovic, Nikolina
AU  - Vrljicak Davidovic N
AUID- ORCID: 0000-0002-3547-9408
AD  - Department of Psychiatry, Clinical Hospital Center Split, Split, Croatia.
FAU - Paul, Moli
AU  - Paul M
AUID- ORCID: 0000-0003-2398-4308
AD  - Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, 
      Coventry, UK.
AD  - Stratford Healthcare CAMHS, Coventry and Warwickshire Partnership NHS Trust,
      Stratford-upon-Avon, UK.
FAU - Singh, Swaran Preet
AU  - Singh SP
AD  - Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, 
      Coventry, UK.
FAU - Street, Cathy
AU  - Street C
AD  - Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, 
      Coventry, UK.
FAU - Tuomainen, Helena
AU  - Tuomainen H
AD  - Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, 
      Coventry, UK.
FAU - Schulze, Ulrike
AU  - Schulze U
AD  - Department of Child and Adolescent Psychiatry/Psychotherapy, University of Ulm,
      Ulm, Germany.
FAU - McNicholas, Fiona
AU  - McNicholas F
AD  - School of Medicine, University College Dublin, Dublin, Ireland.
CN  - MILESTONE Consortium
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200323
PL  - England
TA  - Child Adolesc Ment Health
JT  - Child and adolescent mental health
JID - 101142157
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - *Child Health Services
MH  - Clinical Decision-Making
MH  - Croatia
MH  - Cross-Cultural Comparison
MH  - Female
MH  - Humans
MH  - Ireland
MH  - Male
MH  - *Mental Health Services
MH  - Middle Aged
MH  - Qualitative Research
MH  - *Transition to Adult Care
MH  - United Kingdom
MH  - Young Adult
OTO - NOTNLM
OT  - *Transition
OT  - *adult mental health services
OT  - *child and adolescent mental health services
OT  - *decision-making
OT  - *ethics
OT  - *qualitative research
IR  - Madan J
FIR - Madan, Jason
IR  - Wolke D
FIR - Wolke, Dieter
IR  - Warwick J
FIR - Warwick, Jane
IR  - Canaway A
FIR - Canaway, Alastair
IR  - Griffin J
FIR - Griffin, James
IR  - Appleton R
FIR - Appleton, Rebecca
IR  - Tuffrey A
FIR - Tuffrey, Amanda
IR  - Wilson A
FIR - Wilson, Anna
IR  - Gatherer C
FIR - Gatherer, Charlotte
IR  - Walker L
FIR - Walker, Leanne
IR  - de Girolamo G
FIR - de Girolamo, Giovanni
IR  - Signorini G
FIR - Signorini, Giulia
IR  - Ferrari A
FIR - Ferrari, Alessandro
IR  - Gheza E
FIR - Gheza, Elisa
IR  - Ferrari C
FIR - Ferrari, Cecilia
IR  - Rivolta L
FIR - Rivolta, Laura
IR  - Levi F
FIR - Levi, Flavia
IR  - Cataldo M
FIR - Cataldo, Maria
IR  - Manenti L
FIR - Manenti, Lidia
IR  - Morini G
FIR - Morini, Giorgia
IR  - Pastore A
FIR - Pastore, Adriana
IR  - Toselli C
FIR - Toselli, Cecilia
IR  - Varvara P
FIR - Varvara, Pamela
IR  - Santosh P
FIR - Santosh, Paramala
IR  - Sagar-Ouriaghli I
FIR - Sagar-Ouriaghli, Ilyas
IR  - Heaney N
FIR - Heaney, Natalie
IR  - Singh J
FIR - Singh, Jatinder
IR  - Purper-Ouakil D
FIR - Purper-Ouakil, Diane
IR  - Russet F
FIR - Russet, Frederick
IR  - Maurice V
FIR - Maurice, Virginie
IR  - Humbertclaude V
FIR - Humbertclaude, Veronique
IR  - Maras A
FIR - Maras, Athanasios
IR  - van Bodegom L
FIR - van Bodegom, Larissa
IR  - Overbeek M
FIR - Overbeek, Mathilde
IR  - Fegert JM
FIR - Fegert, Jorg M
IR  - Plener P
FIR - Plener, Paul
IR  - Saam M
FIR - Saam, Melanie
IR  - Breuninger U
FIR - Breuninger, Ulrike
IR  - Schepker R
FIR - Schepker, Renate
IR  - Noterdaeme M
FIR - Noterdaeme, Michele
IR  - Tremmery S
FIR - Tremmery, Sabine
IR  - Hendrickx G
FIR - Hendrickx, Gaelle
IR  - Gronostaj A
FIR - Gronostaj, Aleksandra
IR  - McKenna R
FIR - McKenna, Rachael
IR  - Lievesley K
FIR - Lievesley, Kate
IR  - Fiori F
FIR - Fiori, Federico
IR  - Verhulst F
FIR - Verhulst, Frank
IR  - Dieleman GC
FIR - Dieleman, Gwen C
IR  - Gerritsen S
FIR - Gerritsen, Suzanne
IR  - Wohner A
FIR - Wohner, Andrea
EDAT- 2020/06/10 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/07/12 00:00 [received]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1111/camh.12377 [doi]
PST - ppublish
SO  - Child Adolesc Ment Health. 2020 Sep;25(3):143-149. doi: 10.1111/camh.12377. Epub 
      2020 Mar 23.


PMID- 32516217
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Sep
TI  - Convolutional Neural Networks for Immediate Surgical Needle Automatic Detection
      in Craniofacial X-Ray Images.
PG  - 1647-1650
LID - 10.1097/SCS.0000000000006594 [doi]
AB  - PURPOSE: Immediate X-ray examination is necessary while the surgical needle falls
      off during operation. In this study, one convolutional neural network (CNN) model
      was introduced for automatically surgical needle detection in craniofacial X-ray 
      images. MATERIALS AND METHODS: The craniofacial surgical needle (5-0, ETHICON,
      USA) was localized in 8 different anatomic regions of 2 pig heads for bilateral
      X-ray examination separately. Thirty-two images were obtained finally which were 
      cropped into fragmented images and divided into the training dataset and the test
      dataset. Then, one immediate needle detection CNN model was developed and
      trained. Its performance was quantitatively evaluated using the precision rate,
      the recall rate, and the f2-score. One 8-fold cross-validation experiment was
      performed. The detection rate and the time it took were calculated to quantify
      the degree of difference between the automatic detection and the manual detection
      by 3 experienced clinicians. RESULTS: The precision rate, the recall rate, and
      the f2-score of the CNN model on fragmented images were 98.99%, 92.67%, and
      93.85% respectively. For the 8-fold cross-validation experiments, 26 cases of all
      the 32 X-ray images were automatically marked the right position of the needle
      (detection rate of 81.25%). The average time of automatically detecting one image
      was 5.8 seconds. For the 3 clinicians, 65 images of all the 32x 3 images were
      checked right (detection rate of 67.7%) with the average time-consuming of 33
      seconds. CONCLUSION: In summary, after training with a large dataset, the CNN
      model showed potential for immediate surgical needle automatic detection in
      craniofacial X-ray images with better detection accuracy and efficiency than the 
      conventional manual method.
FAU - Liang, Zhuangzhuang
AU  - Liang Z
AD  - School of Optical-Electrical and Computer Engineering, University of Shanghai for
      Science and Technology.
FAU - Liao, Qian
AU  - Liao Q
AD  - Department of Oral and Cranio-maxillofacial Surgery.
FAU - Chen, Sheng
AU  - Chen S
AD  - School of Optical-Electrical and Computer Engineering, University of Shanghai for
      Science and Technology.
FAU - Qian, Qingyu
AU  - Qian Q
AD  - Department of Radiology, Shanghai Ninth People's Hospital, College of
      Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical 
      Research Center for Oral Diseases. Shanghai, China.
FAU - Zhu, Lin
AU  - Zhu L
AD  - Department of Radiology, Shanghai Ninth People's Hospital, College of
      Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical 
      Research Center for Oral Diseases. Shanghai, China.
FAU - Yang, Hui
AU  - Yang H
AD  - School of Optical-Electrical and Computer Engineering, University of Shanghai for
      Science and Technology.
FAU - Gui, Haijun
AU  - Gui H
AD  - Department of Oral and Cranio-maxillofacial Surgery.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
MH  - Animals
MH  - *Needles
MH  - Neural Networks, Computer
MH  - Swine
MH  - X-Rays
EDAT- 2020/06/10 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1097/SCS.0000000000006594 [doi]
AID - 00001665-202009000-00035 [pii]
PST - ppublish
SO  - J Craniofac Surg. 2020 Sep;31(6):1647-1650. doi: 10.1097/SCS.0000000000006594.


PMID- 32516178
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210207
IS  - 1365-2346 (Electronic)
IS  - 0265-0215 (Linking)
VI  - 37
IP  - 7
DP  - 2020 Jul
TI  - Hydroxyethyl starch and fluid challenge: Ethical concerns in haemodynamic and
      fluid responsiveness research.
PG  - 611
LID - 10.1097/EJA.0000000000001147 [doi]
FAU - Giordano, Giovanni
AU  - Giordano G
AD  - From the Department of Anaesthesia and Intensive Care, University La Sapienza,
      Rome, Italy (GG, FP, FB).
FAU - Pugliese, Francesco
AU  - Pugliese F
FAU - Bilotta, Federico
AU  - Bilotta F
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Eur J Anaesthesiol
JT  - European journal of anaesthesiology
JID - 8411711
RN  - 0 (Hydroxyethyl Starch Derivatives)
RN  - 0 (Plasma Substitutes)
SB  - IM
CON - Eur J Anaesthesiol. 2019 Sep;36(9):667-675. PMID: 31261168
MH  - Hemodynamics/drug effects
MH  - *Hydroxyethyl Starch Derivatives
MH  - Liver
MH  - *Plasma Substitutes
EDAT- 2020/06/10 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 10.1097/EJA.0000000000001147 [doi]
AID - 00003643-202007000-00002 [pii]
PST - ppublish
SO  - Eur J Anaesthesiol. 2020 Jul;37(7):611. doi: 10.1097/EJA.0000000000001147.


PMID- 32516112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 2076-9172 (Print)
IS  - 2076-9172 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct 14
TI  - The Ethics of Error in Medicine.
LID - 10.5041/RMMJ.10406 [doi]
AB  - The practice of medicine forces medical practitioners to make difficult and
      challenging choices on a daily basis. On the one hand we are obligated to cure
      with every resource available, while on the other hand we put the patient at risk
      because our treatments are flawed. To understand the ethics of error in medicine,
      its moral value, and the effects, error must first be defined. However,
      definition of error remains elusive, and its incidence has been extraordinarily
      difficult to quantify. Yet, a health care system that acknowledges error as a
      consequence of normative ethical practice must create systems to minimize error. 
      Error reduction, in turn, should attempt to decrease patient harm and improve the
      entire health care system. We discuss a number of ethical and moral
      considerations that arise from practicing medicine despite anticipated error.
FAU - Grossman, Shamai A
AU  - Grossman SA
AD  - Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard
      Medical School, Boston, MA, USA.
FAU - Gurley, Kiersten L
AU  - Gurley KL
AD  - Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard
      Medical School, Boston, MA, USA.
FAU - Wolfe, Richard E
AU  - Wolfe RE
AD  - Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard
      Medical School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201014
PL  - Israel
TA  - Rambam Maimonides Med J
JT  - Rambam Maimonides medical journal
JID - 101538065
PMC - PMC7571429
EDAT- 2020/06/10 06:00
MHDA- 2020/06/10 06:01
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/06/10 06:01 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - RMMJ.10406 [pii]
AID - 10.5041/RMMJ.10406 [doi]
PST - epublish
SO  - Rambam Maimonides Med J. 2020 Oct 14;11(4). pii: RMMJ.10406. doi:
      10.5041/RMMJ.10406.


PMID- 32516056
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - "I Want to Do It, But I Want to Make Sure That I Do It Right." Views of Patients 
      with Parkinson's Disease Regarding Early Stem Cell Clinical Trial Participation.
PG  - 160-171
LID - 10.1080/23294515.2020.1775721 [doi]
AB  - Background: First-in-human clinical trials with stem cells for Parkinson's
      disease (PD) are on the horizon. Their epistemic success depends on ensuring the 
      participation of a sufficient number and appropriately diverse group of patients 
      with PD. Their ethical soundness requires that the research community ensures
      that subjects' decisions about whether to participate or not are consistent with 
      participants' values, motivations, and goals. We sought to identify PD patients' 
      knowledge, concerns, and expectations regarding early-phase stem cell research in
      PD. Methods: We conducted five semi-structured focus groups with patients with
      PD. Group discussions were recorded, transcribed, and coded to identify
      participants' knowledge, concerns, and expectations regarding participation in
      early stem cell clinical research in PD. Results: Four themes were generated from
      our data analysis: (1) participants' skepticism about the potential benefits of
      these trials; (2) their desire to obtain information about various aspects
      related to this research; (3) a recognition that accessing available knowledge
      was often difficult; and (4) the relevance of trusting relationships with various
      stakeholders. Conclusions: Participants expressed skepticism about the immediate 
      impact of stem cell research. Nonetheless, such skepticism often reflected an
      appropriate consideration of the risks and potential benefits of participating in
      high-risk clinical trials. Despite their skepticism, participants were eager to
      learn more about stem cell research and clinical trials processes. They
      identified consistently trusted avenues of knowledge on these topics, but they
      often found it difficult to access relevant information or to determine its
      value.
FAU - de Melo-Martin, Inmaculada
AU  - de Melo-Martin I
AUID- ORCID: 0000-0001-8656-8497
AD  - Division of Medical Ethics, Weill Cornell Medical College, New York, New York,
      USA.
FAU - Holtzman, Michael
AU  - Holtzman M
AUID- ORCID: 0000-0001-9855-8210
AD  - Department of Psychology, The New School for Social Research, New York, New York,
      USA.
FAU - Hacker, Katrina S
AU  - Hacker KS
AUID- ORCID: 0000-0002-0335-8935
AD  - Department of Psychology, The New School for Social Research, New York, New York,
      USA.
LA  - eng
GR  - UL1 TR002384/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200609
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Access to Information
MH  - Aged
MH  - Biomedical Research/*ethics
MH  - Ethics, Research
MH  - Female
MH  - Goals
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Informed Consent
MH  - Male
MH  - Motivation
MH  - Parkinson Disease/*therapy
MH  - Patient Selection
MH  - Qualitative Research
MH  - *Research Subjects
MH  - *Stem Cells
MH  - Surveys and Questionnaires
MH  - Trust
PMC - PMC8212889
MID - NIHMS1708321
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *Stem cell clinical trials
OT  - *autonomy
OT  - *focus groups
OT  - *recruitment of subjects
OT  - *trust
EDAT- 2020/06/10 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1080/23294515.2020.1775721 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Jul-Sep;11(3):160-171. doi:
      10.1080/23294515.2020.1775721. Epub 2020 Jun 9.


PMID- 32515886
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1469-185X (Electronic)
IS  - 0006-3231 (Linking)
VI  - 95
IP  - 5
DP  - 2020 Oct
TI  - A review of the critics of invasion biology.
PG  - 1467-1478
LID - 10.1111/brv.12624 [doi]
AB  - Herein, I review existing criticisms of the field of invasion biology. Firstly, I
      identifiy problems of conceptual weaknesses, including disagreements regarding:
      (i) definitions of invasive, impact, and pristine conditions, and (ii) ecological
      assumptions such as species equilibrium, niche saturation, and climax
      communities. Secondly, I discuss methodological problems include the misuse of
      correlations, biases in impact reviews and risk assessment, and difficulties in
      predicting the effects of species introductions or eradications. Finally, I
      analyse the social conflict regarding invasive species management and differences
      in moral and philosophical foundations. I discuss the recent emergence of
      alternatives to traditional invasion biology approaches, including the concept of
      novel ecosystems, conciliation biology, and compassionate conservation.
      Understanding different value systems will be the first step to reconciling the
      different perspectives related to this controversial topic.
CI  - (c) 2020 Cambridge Philosophical Society.
FAU - Cassini, Marcelo H
AU  - Cassini MH
AUID- ORCID: 0000-0001-8434-4350
AD  - Laboratorio de Biologia del Comportamiento, IBYME, CONICET, Obligado, Buenos
      Aires, 2490, Argentina.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - England
TA  - Biol Rev Camb Philos Soc
JT  - Biological reviews of the Cambridge Philosophical Society
JID - 0414576
SB  - IM
MH  - Biology
MH  - *Ecosystem
MH  - *Introduced Species
OTO - NOTNLM
OT  - *biological introductions
OT  - *conservation biology
OT  - *ethics
OT  - *exotic species
OT  - *native species
EDAT- 2020/06/10 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/05/16 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1111/brv.12624 [doi]
PST - ppublish
SO  - Biol Rev Camb Philos Soc. 2020 Oct;95(5):1467-1478. doi: 10.1111/brv.12624. Epub 
      2020 Jun 9.


PMID- 32515646
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20211104
IS  - 1708-8283 (Electronic)
IS  - 0883-0738 (Linking)
VI  - 35
IP  - 11
DP  - 2020 Oct
TI  - Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With
      Nusinersen and Onasemnogene Abeparvovec.
PG  - 717-723
LID - 10.1177/0883073820928784 [doi]
AB  - Spinal muscular atrophy type 0 is the most severe phenotype of the disease, with 
      patients presenting with contractures, weakness, and respiratory failure at
      birth, and is typically fatal within weeks. We describe the case of a patient
      with spinal muscular atrophy type 0 who was treated with both nusinersen and
      onasemnogene abeparvovec. She has made modest motor improvements since treatment 
      initiation with a 30-point improvement in CHOP-INTEND score, and continues to
      make motor gains at age 13 months without regression of function, although she
      remains profoundly weak. Although she has had motor improvements, she has also
      had continued systemic complications from her spinal muscular atrophy, including 
      chronic respiratory failure, dysphagia, congenital heart malformation, digit
      necrosis, and diffuse macular rash. This case highlights the challenges in
      treating those with more severe disease phenotypes and raises questions of how
      some systemic complications may respond to current SMN replacement therapies.
FAU - Matesanz, Susan E
AU  - Matesanz SE
AUID- ORCID: 0000-0003-1556-395X
AD  - Division of Neurology, 367873Children's Hospital of Philadelphia, Philadelphia,
      PA, USA.
FAU - Curry, Candace
AU  - Curry C
AD  - Neurology, 381778Mission Children's Specialists, Asheville, NC, USA.
FAU - Gross, Brianna
AU  - Gross B
AD  - Division of Neurology, 367873Children's Hospital of Philadelphia, Philadelphia,
      PA, USA.
FAU - Rubin, Adam I
AU  - Rubin AI
AD  - Pathology and Laboratory Medicine, 14640University of Pennsylvania Perelman
      School of Medicine, Philadelphia, PA, USA.
AD  - Dermatology, 14640University of Pennsylvania Perelman School of Medicine and
      Children's Hospital of Philadelphia, Philadelphia, PA, USA.
FAU - Linn, Rebecca
AU  - Linn R
AD  - Pathology and Laboratory Medicine, 14640University of Pennsylvania Perelman
      School of Medicine, Philadelphia, PA, USA.
AD  - Department of Pathology, 367873Children's Hospital of Philadelphia, Philadelphia,
      PA, USA.
FAU - Yum, Sabrina W
AU  - Yum SW
AD  - Division of Neurology, 367873Children's Hospital of Philadelphia, Philadelphia,
      PA, USA.
AD  - Division of Neurology, 14640University of Pennsylvania Perelman School of
      Medicine, Philadelphia, PA, USA.
FAU - Kichula, Elizabeth A
AU  - Kichula EA
AD  - Division of Neurology, 367873Children's Hospital of Philadelphia, Philadelphia,
      PA, USA.
AD  - Division of Neurology, 14640University of Pennsylvania Perelman School of
      Medicine, Philadelphia, PA, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200609
PL  - United States
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
RN  - 0 (Biological Products)
RN  - 0 (Oligonucleotides)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Zolgensma)
RN  - 5Z9SP3X666 (nusinersen)
SB  - IM
MH  - Biological Products/*therapeutic use
MH  - Female
MH  - Heart Diseases/etiology/pathology
MH  - Humans
MH  - Infant, Newborn
MH  - Nervous System Diseases/etiology/pathology
MH  - Nutritional Support
MH  - Oligonucleotides/*therapeutic use
MH  - Osteomyelitis/etiology/pathology
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Respiration Disorders/etiology/pathology
MH  - Skin Diseases/etiology/pathology
MH  - Spinal Muscular Atrophies of Childhood/complications/*drug therapy/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *ethics
OT  - *infant
OT  - *neuropathy
OT  - *outcome
OT  - *treatment
EDAT- 2020/06/10 06:00
MHDA- 2021/11/05 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1177/0883073820928784 [doi]
PST - ppublish
SO  - J Child Neurol. 2020 Oct;35(11):717-723. doi: 10.1177/0883073820928784. Epub 2020
      Jun 9.


PMID- 32515398
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20201218
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70(Suppl 3)
IP  - 5
DP  - 2020 May
TI  - Ethical dilemmas in clinical care during COVID-19 pandemic.
PG  - S145-S148
LID - 10.5455/JPMA.35 [doi]
AB  - In a short span of a few weeks, the COVID-19 pandemic has affected the entire
      world like no other event in modern history. Healthcare institutions and
      providers have been at the forefront of containing the ravages of this disease,
      and are experiencing unprecedented challenges. Medical decision making has become
      all the more complex because of the moral weight of difficult decisions that need
      to be made. This paper discusses three areas where ethical decision making is
      extremely important: dealing with those patients with COVID-19 who no longer have
      access to their doctors; following ethical criteria for assigning risky duties to
      healthcare professionals; and in making life and death decisions while allocating
      scarce resources. This paper describes a national level guidance document for the
      COVID-19 pandemic that is designed to facilitate ethical decision-making.
FAU - Jafarey, Aamir
AU  - Jafarey A
AD  - Centre of Biomedical Ethics and Culture, SIUT, Karachi.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Delivery of Health Care/ethics
MH  - Humans
MH  - Pakistan
MH  - *Pandemics/ethics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Withholding Treatment/ethics
OTO - NOTNLM
OT  - Allocation, Scarce resources, Ethical decision-making, Pandemics, Ethical
      dilemmas.
EDAT- 2020/06/10 06:00
MHDA- 2020/06/19 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
AID - 10.5455/JPMA.35 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S145-S148. doi: 10.5455/JPMA.35.


PMID- 32515394
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20201218
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70(Suppl 3)
IP  - 5
DP  - 2020 May
TI  - Mental health in the aftermath of COVID-19: A new normal.
PG  - S141-S144
LID - 10.5455/JPMA.30 [doi]
AB  - The COVID-19 pandemic with its subsequent mental health consequences has
      challenged the word view of most people. A genome typically of 26,000-32,000
      bases long RNA has shut down the wheel of man made progress. The social isolation
      after the lock-down has not only led to economic difficulties but also adverse
      psychological reactions. The most common reaction is stress, anxiety and
      depression when faced with life-threatening circumstances. People have to deal
      with the imminent issue of death which is anxiety provoking in itself. This calls
      for dealing with the immediate mental health consequences with the aide of
      technological advancements as discussed in this write-up. A new inter-personal
      ethics need to emerge which is scientifically correct and in-line with age old
      values.
FAU - Naqvi, Haider A
AU  - Naqvi HA
AD  - Department of Psyhciatry, Dow University of Health Sciences, Karachi.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Anxiety/etiology/psychology
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/complications/epidemiology/psychology
MH  - Depression/etiology/psychology
MH  - Humans
MH  - Mental Health
MH  - *Pandemics
MH  - Patient Isolation/psychology
MH  - *Pneumonia, Viral/complications/epidemiology/psychology
MH  - Quarantine/psychology
MH  - SARS-CoV-2
MH  - Socioeconomic Factors
MH  - *Stress, Psychological/etiology/psychology
OTO - NOTNLM
OT  - COVID-19, Mental Health, Stress, Anxiety, Synchronicity.
EDAT- 2020/06/10 06:00
MHDA- 2020/06/19 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
AID - 10.5455/JPMA.30 [doi]
PST - ppublish
SO  - J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S141-S144. doi: 10.5455/JPMA.30.


PMID- 32515356
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 0973-7138 (Electronic)
IS  - 0250-5991 (Linking)
VI  - 45
DP  - 2020
TI  - Evaluation of memory in persons with mesial temporal lobe sclerosis: A combined
      fMRI and VBM study.
LID - 74 [pii]
AB  - Persons with drug refractory TLE have the option of being managed by surgery.
      They may develop memory impairment with specific etiology of mesial temporal
      sclerosis and anterior temporal lobe resection (ATLR). The study evaluated the
      semantic verbal memory outcomes in pre- and post-surgery temporal lobe epilepsy
      (TLE) patients using functional MRI and voxel morphometric methods. Twenty
      consecutive persons with drug-resistant epilepsy (DRE) and 20 healthy controls
      were recruited after obtaining the institute ethics approval. The fMRI scans were
      performed on a 1.5 T MR Scanner using standardized semantic verbal memory tasks
      using a native Hindi paradigm, before and after an anterior temporal lobectomy
      (in cases). A task-based functional connectivity (FC) was estimated using a conn 
      toolbox. Data analysis was carried out using the statistical parametric imaging
      (SPM12) and CAT12 toolbox. Post-surgery TLE group showed increased robust FC in
      the right middle and posterior temporal regions as compared to pre-surgery
      session. A significant reduction in grey matter volume was observed in the left
      temporal lobe post-operatively as compared to presurgery and healthy control
      groups. In the post-surgery TLE group, neuropsychological scores were reduced in 
      specific PGI domains such as visuospatial, working memory, and executive
      functioning. Our results may help in understanding of memory reorganization in
      TLE post-operatively.
FAU - Chaudhary, Kapil
AU  - Chaudhary K
AD  - Department of Nuclear Magnetic Resonance, All India Institute of Medical
      Sciences, New Delhi, India.
FAU - Tripathi, Manjari
AU  - Tripathi M
FAU - Chandra, Sarat P
AU  - Chandra SP
FAU - Nehra, Ashima
AU  - Nehra A
FAU - Kumaran, Senthil S
AU  - Kumaran SS
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Biosci
JT  - Journal of biosciences
JID - 8100809
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Drug Resistant Epilepsy/pathology
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Memory/*physiology
MH  - Temporal Lobe/*diagnostic imaging/pathology
MH  - Tuberous Sclerosis/*diagnostic imaging
MH  - Young Adult
EDAT- 2020/06/10 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PST - ppublish
SO  - J Biosci. 2020;45.


PMID- 32515231
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20201218
IS  - 1547-8181 (Electronic)
IS  - 0018-7208 (Linking)
VI  - 62
IP  - 5
DP  - 2020 Aug
TI  - An Integrative Total Worker Health Framework for Keeping Workers Safe and Healthy
      During the COVID-19 Pandemic.
PG  - 689-696
LID - 10.1177/0018720820932699 [doi]
AB  - OBJECTIVE: The aim was to recommend an integrated Total Worker Health (TWH)
      approach which embraces core human factors and ergonomic principles, supporting
      worker safety, health, and well-being during the COVID-19 pandemic. BACKGROUND:
      COVID-19 has resulted in unprecedented challenges to workplace safety and health 
      for workers and managers in essential businesses, including healthcare workers,
      grocery stores, delivery services, warehouses, and distribution centers.
      Essential workers need protection, accurate information, and a supportive work
      environment with an unwavering focus on effective infection control. METHOD: The 
      investigators reviewed emerging workplace recommendations for reducing workers'
      exposures to the novel coronavirus and the challenges to workers in protecting
      their health. Using a theoretical framework and guidelines for integrating safety
      and health management systems into an organization for TWH, the investigators
      adapted the framework's key characteristics to meet the specific worker safety
      and health issues for effective infection control, providing supports for
      increasing psychological demands while ensuring a safe work environment. RESULTS:
      The recommended approach includes six key characteristics: focusing on working
      conditions for infection control and supportive environments for increased
      psychological demands; utilizing participatory approaches involving workers in
      identifying daily challenges and unique solutions; employing comprehensive and
      collaborative efforts to increase system efficiencies; committing as leaders to
      supporting workers through action and communications; adhering to ethical and
      legal standards; and using data to guide actions and evaluate progress.
      CONCLUSION: Applying an integrative TWH approach for worker safety, health, and
      well-being provides a framework to help managers systematically organize and
      protect themselves, essential workers, and the public during the COVID-19
      pandemic. APPLICATION: By using the systems approach provided by the six
      implementation characteristics, employers of essential workers can organize their
      own efforts to improve system performance and worker well-being during these
      unprecedented times.
FAU - Dennerlein, Jack T
AU  - Dennerlein JT
AUID- ORCID: 0000-0001-7703-643X
AD  - 1848 Northeastern University, Boston, MA, USA.
FAU - Burke, Lisa
AU  - Burke L
AD  - 1855 Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Sabbath, Erika L
AU  - Sabbath EL
AD  - 205730 Boston College, Chestnut Hill, MA, USA.
FAU - Williams, Jessica A R
AU  - Williams JAR
AD  - 21638 University of Kansas Medical Center, Kansas City, KS, USA.
FAU - Peters, Susan E
AU  - Peters SE
AD  - 1857 Harvard T.H. Chan School of Public Health, Boston, MA, USA.
FAU - Wallace, Lorraine
AU  - Wallace L
AD  - 1855 Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Karapanos, Melissa
AU  - Karapanos M
AD  - 1855 Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - Sorensen, Glorian
AU  - Sorensen G
AD  - 1855 Dana-Farber Cancer Institute, Boston, MA, USA.
AD  - 1857 Harvard T.H. Chan School of Public Health, Boston, MA, USA.
LA  - eng
GR  - U19 OH008861/OH/NIOSH CDC HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20200609
PL  - United States
TA  - Hum Factors
JT  - Human factors
JID - 0374660
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/*organization & administration
MH  - Coronavirus Infections/epidemiology/*prevention & control/transmission
MH  - *Ergonomics
MH  - Humans
MH  - *Occupational Health
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control/transmission
MH  - SARS-CoV-2
MH  - Workplace/organization & administration
PMC - PMC7346710
OTO - NOTNLM
OT  - *Total Worker Health
OT  - *coronavirus
OT  - *human factors and ergonomics
OT  - *safety management systems
EDAT- 2020/06/10 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1177/0018720820932699 [doi]
PST - ppublish
SO  - Hum Factors. 2020 Aug;62(5):689-696. doi: 10.1177/0018720820932699. Epub 2020 Jun
      9.


PMID- 32515174
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 2047-8984 (Electronic)
IS  - 1354-5752 (Linking)
VI  - 28
IP  - 4
DP  - 2020 Jul 14
TI  - Meeting the needs of homeless people attending the emergency department.
PG  - 31-39
LID - 10.7748/en.2020.e2025 [doi]
AB  - Homelessness is on the rise in the UK and, over the past few years, there has
      been a significant increase in the number of emergency department (ED)
      attendances and admissions by homeless people. Those attending the ED will often 
      have multiple unmet health, housing and social care needs. While it is not
      possible to meet all these needs in the ED, emergency nurses should be equipped
      with the knowledge and skills required to communicate with, refer and signpost
      patients who are homeless. Under the Homelessness Reduction Act 2017, ED staff
      have a duty to refer homeless people, with their consent, to local authorities
      for assistance. This article details the barriers that homeless people may
      experience when accessing healthcare services and explains how these can be
      addressed. It also outlines the actions that emergency nurses can take to improve
      the care of homeless people in the ED at an individual and a systems level.
CI  - (c)2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Dorney-Smith, Samantha
AU  - Dorney-Smith S
AD  - Pathway, London, England.
FAU - Schneller, Kendra
AU  - Schneller K
AD  - Guy's and St Thomas' NHS Foundation Trust, London, England.
FAU - Swift, Anna
AU  - Swift A
AD  - University College London NHS Foundation Trust, London, England.
FAU - Phelan, Helen
AU  - Phelan H
AD  - Outreach services, Bevan Healthcare, Bradford, England.
FAU - Khan, Zana
AU  - Khan Z
AD  - National Institute for Health Research fellow, South London and Maudsley NHS
      Foundation Trust, Beckenham, England.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - England
TA  - Emerg Nurse
JT  - Emergency nurse : the journal of the RCN Accident and Emergency Nursing
      Association
JID - 9208913
MH  - *Emergency Nursing
MH  - *Emergency Service, Hospital
MH  - *Health Services Needs and Demand
MH  - *Homeless Persons
MH  - Humans
MH  - Referral and Consultation
OTO - NOTNLM
OT  - emergency care
OT  - emergency services
OT  - ethical issues
OT  - health inequalities
OT  - homelessness
OT  - mental capacity
OT  - mental health
OT  - professional
OT  - public health
OT  - substance misuse
COIS- None declared
EDAT- 2020/06/10 06:00
MHDA- 2021/03/20 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.7748/en.2020.e2025 [doi]
AID - e2025 [pii]
PST - ppublish
SO  - Emerg Nurse. 2020 Jul 14;28(4):31-39. doi: 10.7748/en.2020.e2025. Epub 2020 Jun
      9.


PMID- 32514316
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1758-3764 (Electronic)
IS  - 1758-3756 (Linking)
VI  - 15
DP  - 2020 Feb
TI  - Ethical Issues in Decision-making Regarding the Elderly Affected by Coronavirus
      Disease 2019: An Expert Opinion.
PG  - e48
LID - 10.15420/ecr.2020.14 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic is resulting in ethical
      decisions regarding resource allocation. Prioritisation reflects established
      practices that regulate the distribution of finite resources when demand exceeds 
      supply. However, discrimination based on sex, race or age has no role in
      prioritisation unless clearly justified. The risk posed by COVID-19 is higher for
      elderly people than for younger people, so older adults should be prioritised in 
      preventive measures. In the case of people who already have COVID-19, healthcare 
      professionals might prioritise those most likely to survive. Making decisions
      based on chronological age alone is not justified; in addition to age, other
      aspects that determine theoretical life expectancy must be taken into account.
      Individualised correct prioritisation in the allocation of scarce resources is
      essential to good clinical practice.
CI  - Copyright (c) 2020, Radcliffe Cardiology.
FAU - Martinez-Selles, David
AU  - Martinez-Selles D
AD  - School of Medicine, Autonomous University of Barcelona Barcelona, Spain.
FAU - Martinez-Selles, Helena
AU  - Martinez-Selles H
AD  - School of Medicine, Complutense University of Madrid Madrid, Spain.
FAU - Martinez-Selles, Manuel
AU  - Martinez-Selles M
AD  - School of Medicine, Complutense University of Madrid Madrid, Spain.
AD  - Cardiology Department, Gregorio Maranon University Hospital, CIBERCV, European
      University of Madrid Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200518
PL  - England
TA  - Eur Cardiol
JT  - European cardiology
JID - 101574780
PMC - PMC7265102
OTO - NOTNLM
OT  - COVID-19
OT  - age
OT  - elderly
OT  - ethics
OT  - life expectancy
OT  - prioritisation
OT  - resources
COIS- Disclosure: The authors have no conflicts of interest to declare.
EDAT- 2020/06/10 06:00
MHDA- 2020/06/10 06:01
CRDT- 2020/06/10 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/06/10 06:01 [medline]
AID - 10.15420/ecr.2020.14 [doi]
PST - epublish
SO  - Eur Cardiol. 2020 May 18;15:e48. doi: 10.15420/ecr.2020.14. eCollection 2020 Feb.


PMID- 32514305
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1752-4458 (Print)
IS  - 1752-4458 (Linking)
VI  - 14
DP  - 2020
TI  - Experiences, opinions and current policies on users' choice and change of the
      allocated primary mental health professional: a survey among directors of
      community mental health centers in the Emilia-Romagna region, Italy.
PG  - 41
LID - 10.1186/s13033-020-00373-8 [doi]
AB  - BACKGROUND: The subject of how the initial allocation of the primary mental
      health professional (PMHP) in community mental health services is made and the
      frequency and management of users' requests to choose and/or change their
      allocated PMHPs has been scarcely investigated. The present paper is aimed at
      exploring the experiences and opinions of directors of community mental health
      centers (CMHC) on this topic. METHODS: A cross-sectional survey was conducted.
      Electronic ad hoc questionnaires with both multiple choice and open-ended
      questions were e-mailed to the institutional addresses of CMHC directors in the
      Emilia-Romagna Region (Northern Italy) with the consent of their heads of
      department and the Ethical Committee. Quantitative data were analysed by means of
      Microsoft Excel software and STATA 14.2 (College Station, TX), while the
      qualitative analysis was performed using the Nvivo12 software. RESULTS:
      Twenty-eight questionnaires were collected (response rate: 71.8%) that were
      equally distributed between males and females. For the initial PMHP allocation,
      casual allocation by "fixed-rota" was commonly performed (39.3%). Moreover, hope 
      for a change of prescription by a different psychiatrist was the most frequent
      reason for users' requests to change their PMHP. In two mental health departments
      only (Parma and Bologna), written guidelines to manage users' requests of change 
      of PMHP were available. In this context, most participants classified the
      explored topics as relevant and believed that written policies, especially if
      shared with users, could be useful. CONCLUSIONS: In Emilia-Romagna CMHCs, neither
      users nor professionals were generally involved in the initial choice of the
      PMHP. Further national-level studies should be conducted in order to confirm this
      finding. Additionally, written and shared guidelines for managing users' request 
      to choose/change their PHMP may be useful.
CI  - (c) The Author(s) 2020.
FAU - Rioli, G
AU  - Rioli G
AD  - Department of Biomedical, Metabolic and Neural Sciences, University of Modena &
      Reggio Emilia, Via Giuseppe Campi, 287, 41125 Modena,
      Italy.grid.7548.e0000000121697570
AD  - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio
      Emilia, Via Giuseppe Campi, 287, 41125 Modena, Italy.grid.7548.e0000000121697570
AD  - Department of Mental Health and Drug Abuse, AUSL Reggio Emilia, viale Amendola 2,
      42122 Reggio Emilia, Italy.grid.458453.b
FAU - Ferrari, S
AU  - Ferrari S
AD  - Department of Biomedical, Metabolic and Neural Sciences, University of Modena &
      Reggio Emilia, Via Giuseppe Campi, 287, 41125 Modena,
      Italy.grid.7548.e0000000121697570
AD  - Centre for Neuroscience and Neurotechnology, University of Modena & Reggio
      Emilia, Via Giuseppe Campi, 287, 41125 Modena, Italy.grid.7548.e0000000121697570
FAU - Henderson, C
AU  - Henderson C
AD  - Health Service and Population Research Department, King's College London,
      Institute of Psychiatry, Psychology and Neuroscience, London, SE5 8AF
      UK.grid.13097.3c0000 0001 2322 6764
FAU - Galeazzi, G M
AU  - Galeazzi GM
AUID- ORCID: 0000-0003-2706-3362
AD  - Department of Biomedical, Metabolic and Neural Sciences, University of Modena &
      Reggio Emilia, Via Giuseppe Campi, 287, 41125 Modena,
      Italy.grid.7548.e0000000121697570
AD  - Centre for Neuroscience and Neurotechnology, University of Modena & Reggio
      Emilia, Via Giuseppe Campi, 287, 41125 Modena, Italy.grid.7548.e0000000121697570
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - England
TA  - Int J Ment Health Syst
JT  - International journal of mental health systems
JID - 101294224
PMC - PMC7260837
OTO - NOTNLM
OT  - Choice
OT  - Community mental health center
OT  - Emilia-Romagna
OT  - Primary mental health professional
OT  - Quality of care
OT  - Recovery
OT  - Service users
OT  - Social psychiatry
COIS- Competing interestsThe authors declare no potential conflicts of interest with
      respect to the research, authorship, and/or publication of this article.
EDAT- 2020/06/10 06:00
MHDA- 2020/06/10 06:01
CRDT- 2020/06/10 06:00
PHST- 2019/08/26 00:00 [received]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/06/10 06:01 [medline]
AID - 10.1186/s13033-020-00373-8 [doi]
AID - 373 [pii]
PST - epublish
SO  - Int J Ment Health Syst. 2020 May 30;14:41. doi: 10.1186/s13033-020-00373-8.
      eCollection 2020.


PMID- 32514208
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 6
DP  - 2020 Jun 1
TI  - Ethical considerations for mystery shopper studies of pharmaceutical sales.
PG  - 375-375A
LID - 10.2471/BLT.20.250878 [doi]
FAU - Collins, Jack C
AU  - Collins JC
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Science Rd, Camperdown, NSW 2006, Australia.
FAU - Moles, Rebekah J
AU  - Moles RJ
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Science Rd, Camperdown, NSW 2006, Australia.
FAU - Penm, Jonathan
AU  - Penm J
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Science Rd, Camperdown, NSW 2006, Australia.
FAU - Schneider, Carl R
AU  - Schneider CR
AD  - Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney,
      Science Rd, Camperdown, NSW 2006, Australia.
LA  - eng
PT  - Editorial
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
RN  - 0 (Prescription Drugs)
SB  - IM
MH  - Anthropology, Cultural
MH  - Commerce/*statistics & numerical data
MH  - *Ethics, Research
MH  - Humans
MH  - Medication Errors/*statistics & numerical data
MH  - *Patient Simulation
MH  - Practice Patterns, Physicians'
MH  - *Prescription Drugs
MH  - Research Design
MH  - United States
PMC - PMC7265934
EDAT- 2020/06/10 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.2471/BLT.20.250878 [doi]
AID - BLT.20.250878 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Jun 1;98(6):375-375A. doi: 10.2471/BLT.20.250878.


PMID- 32513883
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 7
TI  - Youth Mental Health Tracker: protocol to establish a longitudinal cohort and
      research database for young people attending Australian mental health services.
PG  - e035379
LID - 10.1136/bmjopen-2019-035379 [doi]
AB  - INTRODUCTION: Mental disorders are a leading cause of long-term disability
      worldwide. Much of the burden of mental ill-health is mediated by early onset,
      comorbidities with physical health conditions and chronicity of the illnesses.
      This study aims to track the early period of mental disorders among young people 
      presenting to Australian mental health services to facilitate more streamlined
      transdiagnostic processes, highly personalised and measurement-based care,
      secondary prevention and enhanced long-term outcomes. METHODS AND ANALYSIS:
      Recruitment to this large-scale, multisite, prospective, transdiagnostic,
      longitudinal clinical cohort study ('Youth Mental Health Tracker') will be
      offered to all young people between the ages of 12 and 30 years presenting to
      participating services with proficiency in English and no history of intellectual
      disability. Young people will be tracked over 3 years with standardised
      assessments at baseline and 3, 6, 12, 24 and 36 months. Assessments will include 
      self-report and clinician-administered measures, covering five key domains
      including: (1) social and occupational function; (2) self-harm, suicidal thoughts
      and behaviour; (3) alcohol or other substance misuse; (4) physical health; and
      (5) illness type, clinical stage and trajectory. Data collection will be
      facilitated by the use of health information technology. The data will be used
      to: (1) determine prospectively the course of multidimensional functional
      outcomes, based on the differential impact of demographics, medication,
      psychological interventions and other key potentially modifiable moderator
      variables and (2) map pathophysiological mechanisms and clinical illness
      trajectories to determine transition rates of young people to more severe illness
      forms. ETHICS AND DISSEMINATION: The study has been reviewed and approved by the 
      Human Research Ethics Committee of the Sydney Local Health District
      (2019/ETH00469). All data will be non-identifiable, and research findings will be
      disseminated through peer-reviewed journals and scientific conference
      presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rohleder, Cathrin
AU  - Rohleder C
AUID- ORCID: 0000-0002-3559-1846
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia
      cathrin.rohleder@sydney.edu.au.
FAU - Song, Yun Ju Christine
AU  - Song YJC
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Crouse, Jacob J
AU  - Crouse JJ
AUID- ORCID: 0000-0002-3805-2936
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Davenport, Tracey A
AU  - Davenport TA
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Iorfino, Frank
AU  - Iorfino F
AUID- ORCID: 0000-0003-1109-0972
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Hamilton, Blake
AU  - Hamilton B
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Zmicerevska, Natalia
AU  - Zmicerevska N
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Nichles, Alissa
AU  - Nichles A
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Carpenter, Joanne S
AU  - Carpenter JS
AUID- ORCID: 0000-0002-9766-6700
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Tickell, Ashleigh M
AU  - Tickell AM
AUID- ORCID: 0000-0002-8000-7864
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Wilson, Chloe
AU  - Wilson C
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Cross, Shane P
AU  - Cross SP
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Guastella, Adam J
AU  - Guastella AJ
AUID- ORCID: 0000-0001-8178-4625
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Koethe, Dagmar
AU  - Koethe D
AUID- ORCID: 0000-0002-8324-6756
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Leweke, F Markus
AU  - Leweke FM
AUID- ORCID: 0000-0002-8163-195X
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Scott, Elizabeth M
AU  - Scott EM
AUID- ORCID: 0000-0003-3907-0324
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
FAU - Hickie, Ian B
AU  - Hickie IB
AUID- ORCID: 0000-0001-8832-9895
AD  - Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200607
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adolescent Health Services
MH  - Adult
MH  - Australia
MH  - Child
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Mental Disorders/*psychology
MH  - Mental Health Services
MH  - *Patient Acceptance of Health Care
MH  - Prospective Studies
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7282334
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *child & adolescent psychiatry
OT  - *depression & mood disorders
OT  - *mental health
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: Professor Ian Hickie was an inaugural Commissioner on
      Australia's National Mental Health Commission (2012-18). He is the Co-Director,
      Health and Policy at the Brain and Mind Centre (BMC) University of Sydney. The
      BMC operates an early-intervention youth services at Camperdown under contract to
      headspace. He is the Chief Scientific Advisor to, and a 5% equity shareholder in,
      InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity)
      and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded
      Project Synergy (2017-20; a three-year program for the transformation of mental
      health services) and to lead transformation of mental health services
      internationally through the use of innovative technologies.
EDAT- 2020/06/10 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035379 [pii]
AID - 10.1136/bmjopen-2019-035379 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 7;10(6):e035379. doi: 10.1136/bmjopen-2019-035379.


PMID- 32513881
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 7
TI  - Evaluation of the For Our Children's Sake intervention, parental support in
      prison to influence positive parenting: study protocol for a controlled trial.
PG  - e034834
LID - 10.1136/bmjopen-2019-034834 [doi]
AB  - INTRODUCTION: Children of incarcerated parents comprise a greatly disadvantaged
      group in society and positive parenting constitutes an important factor for
      children's healthy development. Internationally developed parenting interventions
      for incarcerated parents suggest an impact on parenting outcomes, but no such
      evaluation has been undertaken in Sweden.This study aims to investigate the
      effects of the parenting programme currently offered in prisons in Sweden, For
      Our Children's Sake (FOCS), through a controlled trial with a parallel
      implementation process evaluation. METHODS AND ANALYSIS: The effectiveness trial 
      is carried out as a non-blinded controlled trial with a parallel investigation of
      the implementation process using mixed methods. Participants comprise
      incarcerated parents (men and women) in Swedish prisons with a target sample size
      of 76 parents. Eligible parents have a child aged 0 to 18 years, no prohibition
      to contact or committed a crime against the child, or a violent crime against the
      other parent. The FOCS intervention is carried out in group format over 10 weeks.
      The primary outcome is closeness in parent-child relationship measured with the
      Child Parent Relationship Scale. Secondary outcomes comprise parent-child
      contact, parental criminal attitude and interest in other treatment programmes.
      Mediators comprise attitude to parenting, and self-efficacy. Outcome data are
      self-reported and collected over four time points: baseline (September to
      December 2019), mid and after intervention, and at 3 months follow-up.
      Implementation data is collected during and after intervention. Intervention
      fidelity is monitored through audio recordings, dose is registered per
      participant, reach comprise included versus eligible number of parents and
      acceptability is investigated through semi-structured interviews. Factors
      influencing implementation will be investigated using a questionnaire. ETHICS AND
      DISSEMINATION: Ethical permission has been obtained by the Swedish Ethical Review
      Authority 2019-04227. Findings will be published in peer-reviewed journals,
      presented at scientific conferences and presented to participants in writing.
      TRIAL REGISTRATION NUMBER: NCT04101799; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Norman, Asa
AU  - Norman A
AUID- ORCID: 0000-0002-0313-3066
AD  - Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Stockholm
      County, Sweden asa.norman@ki.se.
FAU - Enebrink, Pia
AU  - Enebrink P
AD  - Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Stockholm
      County, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT04101799
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200607
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Child
MH  - Humans
MH  - *Parent-Child Relations
MH  - *Parenting
MH  - *Prisoners
MH  - Randomized Controlled Trials as Topic
MH  - *Social Support
MH  - Sweden
PMC - PMC7282319
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *child protection
OT  - *community child health
OT  - *forensic psychiatry
OT  - *preventive medicine
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/10 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034834 [pii]
AID - 10.1136/bmjopen-2019-034834 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 7;10(6):e034834. doi: 10.1136/bmjopen-2019-034834.


PMID- 32513879
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 7
TI  - Mapping the global evidence on nutrition transition: a scoping review protocol.
PG  - e034730
LID - 10.1136/bmjopen-2019-034730 [doi]
AB  - INTRODUCTION: Nutrition transition has emerged as an important concept in health 
      research used to describe shifts in dietary consumption and energy expenditure
      that coincide with economic, demographic and epidemiological changes at a
      population level. Better understanding of the shifts in dietary patterns across
      populations and their drivers could possibly hold the key to prevention of
      diet-related disease risk. An increasing number of studies have reported on
      nutrition transition in populations around the world, however, global evidence
      has not been summarised. OBJECTIVE: This scoping review is aimed to identify,
      explore and map the literature on nutrition transition with a specific focus on
      dietary changes in populations across the world. The review would allow better
      clarification around the concept of nutrition transition, classification of
      published studies and provide a framework for further research. METHODS AND
      ANALYSIS: The scoping review will be designed based on the methodology by Arksey 
      and O'Malley, refined by Levac et al. and developed in conjunction with guidance 
      on conducting systematic scoping reviews by Peters et al. The main research
      question addressed by the scoping review will be: 'What is the evidence on
      nutrition transition defined based on dietary changes reported in general adult
      population across the world?' Electronic databases (PubMed, ScienceDirect and Web
      of Science), grey literature sources and the reference lists of key studies will 
      be searched to identify studies appropriate for inclusion in the review. Two
      reviewers will independently screen all abstracts and full-text studies for
      inclusion. Data will be abstracted into tables and logically organised according 
      to items addressed in the specific research questions. ETHICS AND DISSEMINATION: 
      Dissemination of results will be sought through a peer-reviewed publication,
      conference presentations and stakeholder meetings. The data used are from
      publicly available secondary sources, so no ethical review would be required for 
      this study.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Singh, Jessica Emily
AU  - Singh JE
AD  - Senior Scientist Group Nutrition, Immunity and Metabolism, Department of
      Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbrucke,
      Nuthetal, Potsdam-Rehbrucke, Germany.
AD  - Department of Dietetics, Nutrition and Sport, La Trobe University, Melbourne,
      Victoria, Australia.
FAU - Illner, Anne-Kathrin
AU  - Illner AK
AD  - College of Health Sciences, UniLaSalle, Beauvais, France.
FAU - Dokova, Klara
AU  - Dokova K
AD  - Faculty of Public Health, Medical University of Varna, Varna, Bulgaria.
FAU - Usheva, Natalya
AU  - Usheva N
AD  - Department of Social Medicine and Health Care Organization, Medical University of
      Varna, Varna, Bulgaria.
FAU - Kostadinova, Todorka
AU  - Kostadinova T
AD  - Department of Health Economics and Management, Medical University of Varna,
      Varna, Bulgaria.
FAU - Aleksandrova, Krasimira
AU  - Aleksandrova K
AUID- ORCID: 0000-0002-1275-1827
AD  - Senior Scientist Group Nutrition, Immunity and Metabolism, Department of
      Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbrucke,
      Nuthetal, Potsdam-Rehbrucke, Germany krasimira.aleksandrova@dife.de.
AD  - Institute of Nutritional Science, University of Potsdam, Potsdam, Germany.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200607
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Global Health
MH  - Humans
MH  - *Nutritional Requirements
MH  - Systematic Reviews as Topic
PMC - PMC7282322
OTO - NOTNLM
OT  - *cardiology
OT  - *coronary heart disease
OT  - *diabetes and endocrinology
OT  - *general diabetes
OT  - *hypertension
OT  - *nutrition and dietetics
COIS- Competing interests: None declared.
EDAT- 2020/06/10 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034730 [pii]
AID - 10.1136/bmjopen-2019-034730 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 7;10(6):e034730. doi: 10.1136/bmjopen-2019-034730.


PMID- 32513878
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 7
TI  - Study protocol of OncoTolk: an observational study on communication problems in
      language-mediated consultations with migrant oncology patients in Flanders
      (Belgium).
PG  - e034426
LID - 10.1136/bmjopen-2019-034426 [doi]
AB  - INTRODUCTION: Effective doctor-patient communication in oncology settings can be 
      challenging due to the complexity of the cancer disease trajectory. The
      challenges can become greater when doctors and patients do not share a common
      language and need to rely on language mediators. The aim of this study is to
      provide evidence-based recommendations for healthcare professionals, patients and
      language mediators on how to interact with each other during language-mediated
      consultations in oncology settings. METHODS AND ANALYSIS: A systematic review of 
      the literature on communication problems in monolingual and multilingual oncology
      settings will be conducted. Thirty language-mediated consultations with
      Turkish-speaking or Arabic-speaking cancer patients, language mediators and
      Dutch-speaking oncologists/haematologists will be video-recorded in three urban
      hospitals in Flanders, Belgium. All participants will be interviewed immediately 
      after the consultation and 2 weeks after it by means of video-stimulated recall. 
      Multimodal interaction analysis will be combined with qualitative content
      analysis to allow for the identification of communication practices when
      communication problems occur. ETHICS AND DISSEMINATION: The study has been
      approved by the following ethics committees: Ghent University Hospital, Antwerp
      University Hospital, Antwerp Hospitals Network (ZNA). Results will be published
      via (inter)national peer-reviewed journals and the findings of the study will be 
      communicated using a comprehensive dissemination strategy aimed at healthcare
      professionals, patients and language mediators.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Krystallidou, Demi
AU  - Krystallidou D
AUID- ORCID: 0000-0002-4821-6383
AD  - Faculty of Arts, Sint Andries Campus, KU Leuven, Antwerp, Belgium
      demi.krystallidou@kuleuven.be peter.pype@ugent.be.
FAU - Vaes, Lena
AU  - Vaes L
AUID- ORCID: 0000-0003-4590-150X
AD  - Faculty of Arts, Sint Andries Campus, KU Leuven, Antwerp, Belgium.
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
FAU - Devisch, Ignaas
AU  - Devisch I
AUID- ORCID: 0000-0002-8520-4832
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
FAU - Wens, Johan
AU  - Wens J
AUID- ORCID: 0000-0002-0229-9064
AD  - Department of Primary and Interdisciplinary Care, University of Antwerp, Antwerp,
      Belgium.
FAU - Pype, Peter
AU  - Pype P
AUID- ORCID: 0000-0003-2273-0250
AD  - Department of Public Health and Primary Care, Ghent University, Ghent, Belgium
      demi.krystallidou@kuleuven.be peter.pype@ugent.be.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200607
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Belgium
MH  - *Communication Barriers
MH  - *Emigrants and Immigrants
MH  - Humans
MH  - *Language
MH  - *Neoplasms
MH  - *Referral and Consultation
PMC - PMC7282320
OTO - NOTNLM
OT  - *communication
OT  - *language barriers
OT  - *oncology
OT  - *protocols & guidelines
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/06/10 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034426 [pii]
AID - 10.1136/bmjopen-2019-034426 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 7;10(6):e034426. doi: 10.1136/bmjopen-2019-034426.


PMID- 32513876
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 7
TI  - Clinical outcomes among individuals with a first episode psychosis attending
      Butabika National Mental Referral Hospital in Uganda: a longitudinal cohort
      study. A study protocol for a longitudinal cohort study.
PG  - e034367
LID - 10.1136/bmjopen-2019-034367 [doi]
AB  - INTRODUCTION: Psychotic disorders significantly contribute to high morbidity and 
      mortality. In high-income countries, the predictors of mortality, relapse and
      barriers to care among patients with first episode psychoses (FEP) have been
      studied as a means of tailoring interventions to improve patient outcomes.
      However, little has been done to document relapse rates and their predictors in
      patients with FEP in low resourced, high disease burdened sub-Saharan Africa.
      OBJECTIVE: We shall estimate the rates of relapse of psychotic symptoms and the
      factors that predict them in patients with FEP over 4 years. METHODS AND
      ANALYSIS: We will assemble a cohort of patients with an FEP seen at the Butabika 
      National Mental Referral Hospital in Kampala over a 4-year period. Participants
      will be adults (>/=18 years old), who have received a diagnosis of a psychosis
      according to the Mini International Neuropsychiatric Instrument (M.I.N.I.), with 
      a demonstrable resolution of active symptoms following the use of antipsychotic
      medications, and deemed clinically stable for a discharge by the healthcare
      practitioner. All participants will be required to provide written informed
      consent. Trained research assistants will collect Demographic and clinical
      parameters, age of onset of symptoms, diagnostic data using the M.I.N.I.,
      physical examination data, symptom severity, level of social and occupational
      functioning and household income, during the 4-year study period. We will conduct
      a verbal audit in the event of loss of life. We shall perform survival analysis
      using the Aalen-Johansen estimator, and describe the population characteristics
      by demographics, social and economic strata using simple proportions. ETHICS AND 
      DISSEMINATION: All participants will provide written informed consent. Ethical
      approvals for the study have been obtained from the Makerere University School of
      Medicine Research and Ethics Committee and the Uganda National Council for
      Science and Technology. Findings will be published in peer reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Akena, Dickens
AU  - Akena D
AUID- ORCID: 0000-0002-8886-4553
AD  - Psychiatry, Makerere University, Kampala, Uganda akenadickens@yahoo.co.uk.
FAU - Semeere, Aggrey
AU  - Semeere A
AD  - Research Department of the Infectious Disease Institute, Infectious Diseases
      Institute Makerere University, Kampala, Uganda.
FAU - Kadama, Philippa
AU  - Kadama P
AD  - Research Department of the Infectious Disease Institute, Infectious Diseases
      Institute Makerere University, Kampala, Uganda.
FAU - Mwesiga, Emanuel
AU  - Mwesiga E
AD  - Department of Psychiatry, Makerere University College of Sciences, Kampala,
      Uganda.
FAU - Basangwa, David
AU  - Basangwa D
AD  - Research Department of Butabika Hospital, Butabika National Referral Hospital,
      Kampala, Uganda.
FAU - Nakku, Juliet
AU  - Nakku J
AD  - Psychiatry, Butabika National Referral and Teaching Mental Hospital, Kampala,
      Uganda.
FAU - Nakasujja, Noeline
AU  - Nakasujja N
AD  - Department of Psychiatry, Makerere University College of Sciences, Kampala,
      Uganda.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Observational Study
DEP - 20200607
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cohort Studies
MH  - Hospitals, Psychiatric
MH  - Humans
MH  - Longitudinal Studies
MH  - Psychotic Disorders/*psychology
MH  - *Referral and Consultation
MH  - Uganda
PMC - PMC7282297
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *mental health
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/06/10 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034367 [pii]
AID - 10.1136/bmjopen-2019-034367 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 7;10(6):e034367. doi: 10.1136/bmjopen-2019-034367.


PMID- 32513612
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 2529-9840 (Electronic)
IS  - 2529-9840 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Oct - Dec
TI  - Perspective of health personnel on end-of-life care in Intensive Care Units.
PG  - 170-183
LID - S1130-2399(20)30029-8 [pii]
LID - 10.1016/j.enfi.2019.12.003 [doi]
AB  - OBJECTIVE: To understand for what care of the patient at the end of life and
      their relatives means to ICU health professionals. METHODS: Qualitative study
      with a Research-Action (AI) design, in two intensive care units of the city of
      Bogota. Groups were formed in each unit and each group included at least six
      health professionals, the data collection techniques were: 4 participative
      assemblies and 6 clinical narratives, the data analysis was done through the
      preparation of the data, discovery of topics, coding and interpretation of data, 
      relativisation and rigour of the data. RESULTS: 20 ICU workers participated, the 
      analysis of the data revealed four thematic categories: Multidisciplinary team of
      the ICU facing the end-of-life process, Management of critical patients and their
      families at the end of life in the ICU, Communication process between the
      patient, family and multidisciplinary team at the end of life, Ethical aspects at
      the end of life in the ICU CONCLUSIONS: The professionals consider preserving
      quality of life during the patient's stay in the ICU a therapeutic objective. The
      development of evidence-based guidelines that facilitate multidisciplinary
      management at the end of life, customisation of care, effective communication,
      fulfilling the physical, emotional and spiritual needs of the person and their
      family and favouring the patient's right of autonomy in decision making.
CI  - Copyright (c) 2020 Sociedad Espanola de Enfermeria Intensiva y Unidades
      Coronarias (SEEIUC). Publicado por Elsevier Espana, S.L.U. All rights reserved.
FAU - Hernandez-Zambrano, S M
AU  - Hernandez-Zambrano SM
AD  - Facultad de Enfermeria. Grupo Perspectivas del Cuidado. Fundacion Universitaria
      de Ciencias de la Salud, Bogota, Colombia. Electronic address:
      smhernandez3@fucsalud.edu.co.
FAU - Carrillo-Algarra, A J
AU  - Carrillo-Algarra AJ
AD  - Facultad de Enfermeria. Grupo Perspectivas del Cuidado. Fundacion Universitaria
      de Ciencias de la Salud, Bogota, Colombia.
FAU - Augusto-Torres, C
AU  - Augusto-Torres C
AD  - Facultad de Enfermeria, programa de Enfermeria en cuidado critico del adulto.
      Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia.
FAU - Katherine-Marroquin, I
AU  - Katherine-Marroquin I
AD  - Facultad de Enfermeria, programa de Enfermeria en cuidado critico del adulto.
      Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia.
FAU - Enciso-Olivera, C O
AU  - Enciso-Olivera CO
AD  - Servicio de Medicina Critica y Cuidado Intensivo. Centro de Investigacion en
      Medicina Critica y Aguda. Fundacion Universitaria de Ciencias de la Salud
      FUCS-Hospital de San Jose, Hospital Infantil de San Jose, Bogota, Colombia.
FAU - Gomez-Duque, M
AU  - Gomez-Duque M
AD  - Servicio de Medicina Critica y Cuidado Intensivo. Centro de Investigacion en
      Medicina Critica y Aguda. Fundacion Universitaria de Ciencias de la Salud
      FUCS-Hospital de San Jose, Hospital Infantil de San Jose, Bogota, Colombia.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Perspectiva de los profesionales de la salud sobre cuidados al final de la vida
      en unidades de cuidados intensivos.
DEP - 20200606
PL  - Spain
TA  - Enferm Intensiva (Engl Ed)
JT  - Enfermeria intensiva
JID - 101778566
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Female
MH  - Humans
MH  - *Intensive Care Units
MH  - Male
MH  - Qualitative Research
MH  - *Terminal Care
OTO - NOTNLM
OT  - Advance Care Planning
OT  - Comunicacion interdisciplinaria
OT  - Cuidado Terminal
OT  - Derecho a Morir
OT  - Intensive Care Units
OT  - Interdisciplinary Communication
OT  - Investigacion Cualitativa
OT  - Planificacion anticipada de la atencion
OT  - Qualitative Research
OT  - Right to Die
OT  - Terminal Care
OT  - Unidad de Cuidado Intensivo
EDAT- 2020/06/10 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/06/20 00:00 [received]
PHST- 2019/11/02 00:00 [revised]
PHST- 2019/12/08 00:00 [accepted]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - S1130-2399(20)30029-8 [pii]
AID - 10.1016/j.enfi.2019.12.003 [doi]
PST - ppublish
SO  - Enferm Intensiva (Engl Ed). 2020 Oct - Dec;31(4):170-183. doi:
      10.1016/j.enfi.2019.12.003. Epub 2020 Jun 6.


PMID- 32513473
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210602
IS  - 1532-8228 (Electronic)
IS  - 0883-9417 (Linking)
VI  - 34
IP  - 3
DP  - 2020 Jun
TI  - Incidental findings: A practical protocol for reporting elevated depressive
      symptoms in behavioral health research.
PG  - 96-99
LID - S0883-9417(20)30175-8 [pii]
LID - 10.1016/j.apnu.2020.04.005 [doi]
AB  - Intervention studies conducted in caregivers often focus on improving mental
      health. Consequently, researchers may discover incidental findings like elevated 
      depressive symptoms. Researchers have an ethical obligation to report incidental 
      findings to participants, but no protocols exist for reporting behavioral health 
      symptoms. The purpose of this paper was to describe a protocol for reporting
      elevated depressive symptoms to participants, based on the protocol used in a
      national randomized clinical trial of stress-reduction methods for 348
      grandmothers raising grandchildren. Each questionnaire included the CES-D scale, 
      and was scored immediately after completion. We established a cut-off score of 30
      based on previous research. A registered nurse on the research team called
      participants with scores over 30 and ascertained whether the participant 1) was
      aware of the problem and 2) had sought help, and then offered additional
      resources. Overall, 94 (27%) participants had a CES-D score > 30. The majority
      (91%) were aware of the problem. About a third of the participants were on
      medication for their symptoms, and a third were seeing a therapist. Nine
      participants were not aware they had depressive symptoms. This paper outlines the
      ethical premise for developing our protocol, details of protocol development, and
      discussion for how research teams can apply this protocol to their work.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Wallace, McKenzie K
AU  - Wallace MK
AD  - Case Western Reserve University, Frances Payne Bolton School of Nursing, 10900
      Euclid Ave, Cleveland, OH 44106-4409, United States of America. Electronic
      address: Mkw47@case.edu.
FAU - Jeanblanc, Alexandra B
AU  - Jeanblanc AB
AD  - Case Western Reserve University, Frances Payne Bolton School of Nursing, 10900
      Euclid Ave, Cleveland, OH 44106-4409, United States of America.
FAU - Musil, Carol M
AU  - Musil CM
AD  - Case Western Reserve University, Frances Payne Bolton School of Nursing, 10900
      Euclid Ave, Cleveland, OH 44106-4409, United States of America.
LA  - eng
GR  - R01 NR015999/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20200413
PL  - United States
TA  - Arch Psychiatr Nurs
JT  - Archives of psychiatric nursing
JID - 8708534
SB  - IM
MH  - Caregivers/*psychology
MH  - Depression/*diagnosis/psychology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales/*statistics & numerical data
MH  - Referral and Consultation
PMC - PMC7323861
MID - NIHMS1586730
OTO - NOTNLM
OT  - *Depression
OT  - *Depressive symptoms
OT  - *Incidental findings
OT  - *Reporting
COIS- Declaration of competing interest The authors have no conflicts of interest to
      declare
EDAT- 2020/06/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - S0883-9417(20)30175-8 [pii]
AID - 10.1016/j.apnu.2020.04.005 [doi]
PST - ppublish
SO  - Arch Psychiatr Nurs. 2020 Jun;34(3):96-99. doi: 10.1016/j.apnu.2020.04.005. Epub 
      2020 Apr 13.


PMID- 32513364
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1681-7168 (Electronic)
IS  - 1022-386X (Linking)
VI  - 30
IP  - 4
DP  - 2020 Apr
TI  - Postoperative Cognitive Dysfunction following General Anaesthesia in Patients
      Undergoing Elective Non-cardiac Surgery.
PG  - 417-419
LID - 10.29271/jcpsp.2020.04.417 [doi]
AB  - OBJECTIVE: To determine frequency of early postoperative cognitive dysfunction
      (POCD) in patients aged 40 to 60 years, following general anaesthesia in patients
      undergoing elective, non-cardiac surgery. STUDY DESIGN: Descriptive study. PLACE 
      AND DURATION OF STUDY: Department of Anaesthesiology, The Aga Khan University
      Hospital (AKUH), Karachi, from December 2015 to May 2016. METHODOLOGY: After
      obtaining approval from Ethical Review Committee of AKUH and informed consent,
      ASA I and II patients, aged between 40 to 60 years of either gender, undergoing
      general anaesthesia for elective non-cardiac surgical procedures, were recruited.
      Patients were assessed preoperatively by using mini-mental state examination
      (MMSE); and patients having a score equal to or greater than 23 (maximum 30) were
      included in the study. All patients were reassessed at 24 hours postoperatively
      by MMSE. Both the MMSE evaluations were performed by primary investigator on
      predesigned data collection form. RESULTS: A total of 150 patients were enrolled 
      in the study. Preoperative MMSE score ranged from 24 to 30 while postoperative
      MMSE score (at 24 hours) was between 25 and 30. Thus, no patient developed POCD
      following general anaesthesia for elective, non-cardiac surgery in this study.
      CONCLUSION: Early POCD was not found in the presently studied population of
      middle aged patients having elective non-cardiac surgery under general
      anaesthesia. Key Words: Postoperative cognitive dysfunction (POCD), General
      anaesthesia, Non-cardiac surgery, Mini- mental state examination.
FAU - Yousuf, Muhammad Saad
AU  - Yousuf MS
AD  - Department of Anaesthesiology, The Aga Khan University Hospital, Karachi,
      Pakistan.
FAU - Samad, Khalid
AU  - Samad K
AD  - Department of Anaesthesiology, The Aga Khan University Hospital, Karachi,
      Pakistan.
FAU - Ullah, Hameed
AU  - Ullah H
AD  - Department of Anaesthesiology, The Aga Khan University Hospital, Karachi,
      Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Coll Physicians Surg Pak
JT  - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
JID - 9606447
SB  - IM
MH  - Adult
MH  - Anesthesia, General/adverse effects
MH  - *Cognition Disorders/epidemiology/etiology
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Middle Aged
MH  - *Postoperative Cognitive Complications
MH  - Postoperative Complications/epidemiology
EDAT- 2020/06/10 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2019/09/16 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 040579197 [pii]
AID - 10.29271/jcpsp.2020.04.417 [doi]
PST - ppublish
SO  - J Coll Physicians Surg Pak. 2020 Apr;30(4):417-419. doi:
      10.29271/jcpsp.2020.04.417.


PMID- 32513289
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20220414
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 8
TI  - The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the
      Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe
      COVID-19 patients in the first 48 hours after symptoms onset: A structured
      summary of a study protocol for a randomized control pilot trial.
PG  - 498
LID - 10.1186/s13063-020-04421-z [doi]
AB  - OBJECTIVES: The primary objective is to determine the efficacy of a single dose
      of ivermectin, administered to low risk, non-severe COVID-19 patients in the
      first 48 hours after symptom onset to reduce the proportion of patients with
      detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from
      nasopharyngeal swab at day 7 post-treatment. The secondary objectives are: 1.To
      assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the
      nasopharyngeal swab at day 7 post treatment.2.To assess the efficacy of
      ivermectin to improve symptom progression in treated patients.3.To assess the
      proportion of seroconversions in treated patients at day 21.4.To assess the
      safety of ivermectin at the proposed dose.5.To determine the magnitude of immune 
      response against SARS-CoV-2.6.To assess the early kinetics of immunity against
      SARS-CoV-2. TRIAL DESIGN: SAINT is a single centre, double-blind, randomized,
      placebo-controlled, superiority trial with two parallel arms. Participants will
      be randomized to receive a single dose of 400 mug/kg ivermectin or placebo, and
      the number of patients in the treatment and placebo groups will be the same (1:1 
      ratio). PARTICIPANTS: The population for the study will be patients with a
      positive nasopharyngeal swab PCR test for SARS-CoV-2, with non-severe COVID-19
      disease, and no risk factors for progression to severity. Vulnerable populations 
      such as pregnant women, minors (i.e.; under 18 years old), and seniors (i.e.;
      over 60 years old) will be excluded. Inclusion criteria 1. Patients diagnosed
      with COVID-19 in the emergency room of the Clinica Universidad de Navarra (CUN)
      with a positive SARS-CoV-2 PCR. 2. Residents of the Pamplona basin ("Cuenca de
      Pamplona"). 3. The patient must be between the ages of 18 and 60 years of age. 4.
      Negative pregnancy test for women of child bearing age*. 5. The patient or
      his/her representative, has given informed consent to participate in the study.
      6. The patient should, in the PI's opinion, be able to comply with all the
      requirements of the clinical trial (including home follow up during isolation).
      Exclusion criteria 1. Known history of ivermectin allergy. 2. Hypersensitivity to
      any component of ivermectin. 3. COVID-19 pneumonia. Diagnosed by the attending
      physician.Identified in a chest X-ray. 4. Fever or cough present for more than 48
      hours. 5. Positive IgG against SARS-CoV-2 by rapid diagnostic test. 6. Age under 
      18 or over 60 years. 7. The following co-morbidities (or any other disease that
      might interfere with the study in the eyes of the PI): Immunosuppression.Chronic 
      Obstructive Pulmonary Disease.Diabetes.Hypertension.Obesity.Acute or chronic
      renal failure.History of coronary disease.History of cerebrovascular
      disease.Current neoplasm. 8. Recent travel history to countries that are endemic 
      for Loa loa (Angola, Cameroon, Central African Republic, Chad, Democratic
      Republic of Congo, Ethiopia, Equatorial, Guinea, Gabon, Republic of Congo,
      Nigeria and Sudan). 9. Current use of CYP 3A4 or P-gp inhibitor drugs such as
      quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin,
      erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir,
      ritonavir or cobicistat. Use of critical CYP3A4 substrate drugs such as warfarin.
      *Women of child bearing age may participate if they use a safe contraceptive
      method for the entire period of the study and at least one month afterwards. A
      woman is considered to not have childbearing capacity if she is post-menopausal
      (minimum of 2 years without menstruation) or has undergone surgical sterilization
      (at least one month before the study). The trial is currently planned at a single
      center, Clinica Universidad de Navarra, in Navarra (Spain), and the immunology
      samples will be analyzed at the Barcelona Institute for Global Health (ISGlobal),
      in Barcelona (Spain). Participants will be recruited by the investigators at the 
      emergency room and/or COVID-19 area of the CUN. They will remain in the trial for
      a period of 28 days at their homes since they will be patients with mild disease.
      In the interest of public health and to contain transmission of infection,
      follow-up visits will be conducted in the participant's home by a clinical trial 
      team comprising nursing and medical members. Home visits will assess clinical and
      laboratory parameters of the patients. INTERVENTION AND COMPARATOR: Ivermectin
      will be administered to the treatment group at a 400mug/Kg dose (included in the 
      EU approved label of Stromectol and Scabioral). The control group will receive
      placebo. There is no current data on the efficacy of ivermectin against the virus
      in vivo, therefore the use of placebo in the control group is ethically
      justified. MAIN OUTCOMES: Primary Proportion of patients with a positive
      SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment. Secondary
      1.Mean viral load as determined by PCR cycle threshold (Ct) at baseline and on
      days 4, 7, 14, and 21.2.Proportion of patients with fever and cough at days 4, 7,
      14, and 21 as well as proportion of patients progressing to severe disease or
      death during the trial.3.Proportion of patients with seroconversion at day
      21.4.Proportion of drug-related adverse events during the trial.5.Median levels
      of IgG, IgM, IgA measured by Luminex, frequencies of innate and
      SARS-CoV-2-specific T cells assessed by flow cytometry, median levels of
      inflammatory and activation markers measured by Luminex and
      transcriptomics.6.Median kinetics of IgG, IgM, IgA levels during the trial, until
      day 28. RANDOMISATION: Eligible patients will be allocated in a 1:1 ratio using a
      randomization list generated by the trial statistician using blocks of four to
      ensure balance between the groups. A study identification code with the format
      "SAINT-##" (##: from 01 to 24) will be generated using a sequence of random
      numbers so that the randomization number does not match the subject identifier.
      The sequence and code used will be kept in an encrypted file accessible only to
      the trial statistician. A physical copy will be kept in a locked cabinet at the
      CUN, accessible only to the person administering the drug who will not enrol or
      attend to patient care. A separate set of 24 envelopes for emergency unblinding
      will be kept in the study file. BLINDING (MASKING): The clinical trial team and
      the patients will be blinded. The placebo will not be visibly identical, but it
      will be administered by staff not involved in the clinical care or participant
      follow up. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The sample size is 24
      patients: 12 participants will be randomised to the treatment group and 12
      participants to the control group. TRIAL STATUS: Current protocol version: 1.0
      dated 16 of April 2020. Recruitment is envisioned to begin by May 14th and end by
      June 14th. TRIAL REGISTRATION: EudraCT number: 2020-001474-29, registered April
      1(st). Clinicaltrials.gov: submitted, pending number FULL PROTOCOL: The full
      protocol is attached as an additional file, accessible from the Trials website
      (Additional file 1). In the interest in expediting dissemination of this
      material, the familiar formatting has been eliminated; this Letter serves as a
      summary of the key elements of the full protocol.
FAU - Chaccour, Carlos
AU  - Chaccour C
AUID- ORCID: http://orcid.org/0000-0001-9812-050X
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
      carlos.chaccour@isglobal.org.
FAU - Ruiz-Castillo, Paula
AU  - Ruiz-Castillo P
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Richardson, Mary-Ann
AU  - Richardson MA
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Moncunill, Gemma
AU  - Moncunill G
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Casellas, Aina
AU  - Casellas A
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Carmona-Torre, Francisco
AU  - Carmona-Torre F
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Giraldez, Miriam
AU  - Giraldez M
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Mota, Juana Schwartz
AU  - Mota JS
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Yuste, Jose Ramon
AU  - Yuste JR
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Azanza, Jose Ramon
AU  - Azanza JR
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Fernandez, Miriam
AU  - Fernandez M
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Reina, Gabriel
AU  - Reina G
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Dobano, Carlota
AU  - Dobano C
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Brew, Joe
AU  - Brew J
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Sadaba, Belen
AU  - Sadaba B
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Hammann, Felix
AU  - Hammann F
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
FAU - Rabinovich, Regina
AU  - Rabinovich R
AD  - Instituto de Salud Global de Barcelona, Barcelona, Spain.
LA  - eng
GR  - In kind placebo/Idifarma
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20200608
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 70288-86-7 (Ivermectin)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/prevention & control/virology
MH  - Double-Blind Method
MH  - Evaluation Studies as Topic
MH  - Female
MH  - Humans
MH  - Ivermectin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pandemics/prevention & control
MH  - Pilot Projects
MH  - Pneumonia, Viral/*drug therapy/prevention & control/virology
MH  - *Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Time Factors
MH  - Viral Load
MH  - Young Adult
PMC - PMC7276958
OTO - NOTNLM
OT  - COVID-19
OT  - PCR
OT  - Randomised controlled trial
OT  - SARS-CoV-2
OT  - antiviral
OT  - early treatment
OT  - immunomodulatory
OT  - ivermectin
OT  - protocol
OT  - transmission-blocking
EDAT- 2020/06/10 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1186/s13063-020-04421-z [doi]
AID - 10.1186/s13063-020-04421-z [pii]
PST - epublish
SO  - Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.


PMID- 32513273
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Jun 8
TI  - The effect of transtheoretical model-lead intervention for knee osteoarthritis in
      older adults: a cluster randomized trial.
PG  - 134
LID - 10.1186/s13075-020-02222-y [doi]
AB  - BACKGROUND: Knee osteoarthritis (KOA) is a common joint disease in people over 60
      years old. Exercise therapy is one of the most effective non-pharmacological
      treatments for KOA, but low exercise adherence needs to be improved. The present 
      study aimed to evaluate the effect of the transtheoretical model-lead home
      exercise intervention (TTM-HEI) program on exercise adherence, KOA symptoms, and 
      knee function in older adults with KOA. METHODS: A two-arm, superiority,
      assessor-blinded, cluster randomized trial was conducted. Community-dwelling
      older adults with KOA were recruited from 14 community centers in Beijing, China,
      via print and social media advertisements from April to October 2018. The present
      study lasted 48 weeks, with an intervention duration of 0-24 weeks and follow-up 
      time of 24-48 weeks. The intervention was a two-stage and 24-week TTM-based
      exercise program, and the control group underwent a same-length exercise program 
      guidance without any exercise adherence interventions. The primary outcome was
      exercise adherence to the prescribed home exercise program and was measured using
      an 11-point numerical (0 = not at all through and 10 = completely as instructed) 
      self-rating scale at weeks 4, 12, 24, 36, and 48 after the program started. KOA
      symptoms (pain intensity and joint stiffness) were measured using the Western
      Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and knee function
      (lower limb muscle strength and balance) was measured using the
      Five-Times-Sit-to-Stand Test (FTSST) and the Timed Up and Go Test (TUG) at
      baseline, week 24, and week 48. Latent growth model (GLM), repeated measures
      ANOVA, and independent t test were the main statistical tests used. RESULTS: A
      total of 189 older adults (intervention group: n = 103, control group: n = 86)
      were enrolled. Differences of any outcome measures at baseline were not
      significant between groups. The growth rate of exercise adherence in the
      intervention group increased 2.175 units compared with that in the control group 
      (unstandardized coefficient of slope on group B2 = 2.175, p < 0.001), and the
      intervention program maintained participants' exercise adherence with 5.56 (SD = 
      1.00) compared with 3.16 (SD = 1.31) in the control group at week 48. In
      addition, the TTM-HEI program showed significant effects on relieving KOA
      symptoms and improving knee function. CONCLUSION: Over time, TTM-HEI could
      improve participants' exercise adherence, KOA symptoms, and knee function. TRIAL 
      REGISTRATION: This study was approved by the ethics committee (IRB00001052-17066)
      in July 2017 and was registered at the Chinese Clinical Trial Registry (website: 
      www.chictr.org.cn, registry number: ChiCTR1800015458).
FAU - Wang, Limin
AU  - Wang L
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Chen, Hongbo
AU  - Chen H
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Lu, Han
AU  - Lu H
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Wang, Yunlin
AU  - Wang Y
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Liu, Congying
AU  - Liu C
AD  - Department of Cardiology, Peking University Third Hospital, Beijing, China.
FAU - Dong, Xu
AU  - Dong X
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Chen, Jieru
AU  - Chen J
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Liu, Nan
AU  - Liu N
AD  - Department of Recovery, Peking University Third Hospital, Beijing, China.
FAU - Yu, Fang
AU  - Yu F
AD  - School of Nursing, University of Minnesota, Minneapolis, USA.
FAU - Wan, Qiaoqin
AU  - Wan Q
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China.
FAU - Shang, Shaomei
AU  - Shang S
AD  - School of Nursing, Peking University, 38 Xueyuan Road, Hai Dian District,
      Beijing, China. shangshaomei@126.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200608
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
SB  - IM
MH  - Aged
MH  - China
MH  - Exercise Therapy
MH  - Humans
MH  - Middle Aged
MH  - *Osteoarthritis, Knee/therapy
MH  - Postural Balance
MH  - Time and Motion Studies
MH  - Transtheoretical Model
MH  - Treatment Outcome
PMC - PMC7278156
OTO - NOTNLM
OT  - *Exercise adherence
OT  - *Intervention
OT  - *Knee function
OT  - *Knee osteoarthritis
OT  - *Latent growth model
OT  - *Symptom
EDAT- 2020/06/10 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13075-020-02222-y [doi]
AID - 10.1186/s13075-020-02222-y [pii]
PST - epublish
SO  - Arthritis Res Ther. 2020 Jun 8;22(1):134. doi: 10.1186/s13075-020-02222-y.


PMID- 32513252
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 8
TI  - Elbow hemiarthroplasty versus open reduction and internal fixation for AO/OTA
      type 13 C2 and C3 fractures of distal humerus in patients aged 50 years or above:
      a randomized controlled trial.
PG  - 497
LID - 10.1186/s13063-020-04418-8 [doi]
AB  - BACKGROUND: Intraarticular distal humeral fractures of AO/OTA type 13 C2 and C3
      pose a surgical challenge despite the evolution of surgical implants and
      techniques. Open reduction and internal fixation (ORIF) is often preferred as the
      first choice of treatment, but the results vary and are sometimes disappointing. 
      Total elbow arthroplasty (TEA) has been widely used for fractures that are not
      amenable to ORIF in elderly patients, but the mechanical complications remain a
      challenge, especially in active patients. Elbow hemiarthroplasty (EHA) provides a
      modern alternative that might avoid the mechanical complications and weight
      bearing restrictions related to the linked articulation in semi-constrained TEA. 
      No studies have compared the results of EHA to that of ORIF, but case series have
      reported promising results. METHODS/DESIGN: This is a study protocol describing
      an investigator-initiated, non-blinded randomized controlled trial comparing the 
      outcome of EHA with ORIF for AO/OTA type 13 C2 and C3 fractures of the distal
      humerus in patients who are 50 years or older. Forty-four patients with AO/OTA
      type 13 C2 and C3 fractures of distal humerus will be randomized to either EHA or
      ORIF. The Oxford Elbow Score (OES) will be used as primary outcome. Mayo Elbow
      Performance Score (MEPS), pain severity score (VAS), range of motion, and patient
      satisfaction will be used as secondary outcomes. Reoperations, complications, and
      the length of sick leave will be recorded. The patients will be examined after
      the operation and at 3 months and 1, 2, 5, and 10 years. DISCUSSION: The main
      objective of this study is to investigate the best treatment option for AO/OTA
      type 13 C2 and C3 fractures of distal humerus in patients aged 50 years or above.
      We hypothesize that EHA results in fewer complications and superior functional
      outcome compared with ORIF and that the mechanical complications related to the
      linked articulation of TEA can be avoided. TRIAL REGISTRATION:
      ClinicalTrials.gov, PRS, NCT04163172. Registered November 13, 2019.
      https://clinicaltrials.gov/ct2/results?cond=&term=evori&cntry=&state=&city=&dist=
      (Table 2). The protocol has been approved by The Scientific Ethics Committee of
      the Capital Region of Denmark (Jr. no.: H(- 19,035,590)). The processing of
      personal data has been approved by the Danish Data Protection Agency (Jr. no.
      P-2019-246). Inclusion started on February 1, 2020.
FAU - Al-Hamdani, Ali
AU  - Al-Hamdani A
AUID- ORCID: http://orcid.org/0000-0001-5562-2737
AD  - Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, University of
      Copenhagen, Copenhagen, Denmark. akhamdani@hotmail.com.
FAU - Rasmussen, Jeppe V
AU  - Rasmussen JV
AD  - Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, University of
      Copenhagen, Copenhagen, Denmark.
FAU - Holtz, Kenneth
AU  - Holtz K
AD  - Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, University of
      Copenhagen, Copenhagen, Denmark.
FAU - Olsen, Bo S
AU  - Olsen BS
AD  - Department of Orthopaedic Surgery, Herlev and Gentofte Hospital, University of
      Copenhagen, Copenhagen, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04163172
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
DEP - 20200608
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Denmark
MH  - Elbow Joint/*injuries/surgery
MH  - Fracture Fixation, Internal/*methods
MH  - Hemiarthroplasty/*methods
MH  - Humans
MH  - Humeral Fractures/*surgery
MH  - Intra-Articular Fractures/*surgery
MH  - Middle Aged
MH  - Open Fracture Reduction
MH  - Postoperative Complications
MH  - Randomized Controlled Trials as Topic
MH  - Range of Motion, Articular
MH  - Reoperation
MH  - Treatment Outcome
PMC - PMC7278155
OTO - NOTNLM
OT  - Complication
OT  - Elbow
OT  - Fracture
OT  - Hemiarthroplasty
OT  - Humerus
OT  - Osteosynthesis
OT  - Outcome
OT  - Randomized
OT  - Reoperation
EDAT- 2020/06/10 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - 10.1186/s13063-020-04418-8 [doi]
AID - 10.1186/s13063-020-04418-8 [pii]
PST - epublish
SO  - Trials. 2020 Jun 8;21(1):497. doi: 10.1186/s13063-020-04418-8.


PMID- 32513204
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1757-7241 (Electronic)
IS  - 1757-7241 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Jun 8
TI  - Barriers and challenges in the process of including critically ill patients in
      clinical studies.
PG  - 51
LID - 10.1186/s13049-020-00732-x [doi]
AB  - BACKGROUND: Clinical research in severely ill or injured patients is required to 
      improve healthcare but may be challenging to perform in practice. The aim of this
      study was to analyse barriers and challenges in the process of including
      critically ill patients in clinical studies. METHODS: Data from critically ill
      patients considered for inclusion in an observational study of venous
      thromboembolism in Norway were analysed. This included quantitative and
      qualitative information from the screening log, consent forms and research notes.
      RESULTS: Among 279 eligible critically ill patients, 204 (73%) were omitted from 
      the study due to challenges and barriers in the inclusion process. Reasons for
      omission were categorised as practical in 133 (65%), medical in 31 (15%), and
      legal or ethical in 40 (20%) of the patients. Among 70 included patients, 29
      (41%) consents were from patients and 41 (59%) from their next of kin. Several
      challenges were described herein; these included whether patients were competent 
      to give consent, and which next of kin that should represent the patient.
      Furthermore, some included patients were unable to recall what they have
      consented, and some appeared unable to separate research from treatment.
      CONCLUSIONS: Barriers and challenges in the inclusion process led to the omission
      of near three out of four eligible patients. This analysis provided information
      about where the problem resides and may be solved. The majority of challenges
      among included patients were related to issues of autonomy and validity of
      consent. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03405766).
FAU - Dahlberg, Jorgen
AU  - Dahlberg J
AUID- ORCID: http://orcid.org/0000-0001-9602-2105
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, P.O.Box 1072 Blindern, 
      0316, Oslo, Norway. jorgen.dahlberg@medisin.uio.no.
AD  - Department of Anaesthesiology, Akershus University Hospital, Lorenskog, Norway.
      jorgen.dahlberg@medisin.uio.no.
FAU - Eriksen, Camilla
AU  - Eriksen C
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, P.O.Box 1072 Blindern, 
      0316, Oslo, Norway.
FAU - Robertsen, Annette
AU  - Robertsen A
AD  - Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
AD  - Department of Research, Innovation and Education, Oslo University Hospital, Oslo,
      Norway.
FAU - Beitland, Sigrid
AU  - Beitland S
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, P.O.Box 1072 Blindern, 
      0316, Oslo, Norway.
AD  - Department of Research, Innovation and Education, Oslo University Hospital, Oslo,
      Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT03405766
PT  - Journal Article
PT  - Observational Study
DEP - 20200608
PL  - England
TA  - Scand J Trauma Resusc Emerg Med
JT  - Scandinavian journal of trauma, resuscitation and emergency medicine
JID - 101477511
RN  - 0 (Fibrinolytic Agents)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adult
MH  - Critical Illness/*therapy
MH  - Dalteparin/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Informed Consent/*ethics/*legislation & jurisprudence
MH  - Male
MH  - Norway
MH  - Patient Selection/*ethics
PMC - PMC7276963
OTO - NOTNLM
OT  - Critical care
OT  - Informed consent
OT  - Intensive care
OT  - Mental capacity
OT  - Recruitment
OT  - Research ethics
EDAT- 2020/06/10 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 10.1186/s13049-020-00732-x [doi]
AID - 10.1186/s13049-020-00732-x [pii]
PST - epublish
SO  - Scand J Trauma Resusc Emerg Med. 2020 Jun 8;28(1):51. doi:
      10.1186/s13049-020-00732-x.


PMID- 32513178
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 8
TI  - Prognostic value of myocardial fibrosis in severe aortic stenosis: study protocol
      for a prospective observational multi-center study (FIB-AS).
PG  - 275
LID - 10.1186/s12872-020-01552-8 [doi]
AB  - BACKGROUND: Adverse cardiac remodeling with a myocardial fibrosis as a key
      pathophysiologic component may be associated to worse survival in aortic stenosis
      (AS) patients. Therefore, with the application of advanced cardiac imaging we aim
      to investigate left ventricular myocardial fibrosis in severe AS patients
      undergoing aortic valve replacement (AVR) and determine its impact with
      post-intervention clinical outcomes. METHODS: In a prospective, observational,
      cohort study patients with severe AS scheduled either for surgical or
      transcatheter AVR will be recruited from two tertiary heart centers in Denmark
      and Lithuania. All patients will receive standard of care in accordance with the 
      current guidelines and will undergo additional imaging testing before and after
      AVR: echocardiography with deformation analysis and cardiovascular magnetic
      resonance (CMR) with T1 parametric mapping. Those undergoing surgical AVR will
      also have a myocardial biopsy sampled at the time of a surgery for histological
      validation. Patients will be recruited over a 2-year period and followed up to 2 
      years to ascertain clinical outcomes. Follow-up CMR will be performed 12 months
      following AVR, and echocardiography with deformation analysis will be performed
      3, 12, and 24 months following AVR. The study primary outcome is a composite of
      all-cause mortality and major adverse cardiovascular events. DISCUSSION: Despite 
      continuous effort of research community there is still a lack of early predictors
      of left ventricular decompensation in AS, which could improve patient risk
      stratification and guide the optimal timing for aortic valve intervention, before
      irreversible left ventricular damage occurs. Advanced cardiac imaging and CMR
      derived markers of diffuse myocardial fibrosis could be utilized for this
      purpose. FIB-AS study is intended to invasively and non-invasively assess diffuse
      myocardial fibrosis in AS patients and investigate its prognostic significance in
      post-interventional outcomes. The results of the study will expand the current
      knowledge of cardiac remodeling in AS and will bring additional data on
      myocardial fibrosis and its clinical implications following AVR.
      ETHICS/DISSEMINATION: The study has full ethical approval and is actively
      recruiting patients. The results will be disseminated through scientific journals
      and conference presentations. TRIAL REGISTRATION: ClinicalTrials.govNCT03585933. 
      Registered on 02 July 2018.
FAU - Balciunaite, Giedre
AU  - Balciunaite G
AUID- ORCID: 0000-0001-7447-3001
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
      dr.giedre.balciunaite@gmail.com.
FAU - Palionis, Darius
AU  - Palionis D
AD  - Department of Radiology, Nuclear Medicine and Medical Physics, Institute of
      Biomedical Sciences, Vilnius University Faculty of Medicine, Santariskiu str. 2, 
      LT-08661, Vilnius, Lithuania.
FAU - Zurauskas, Edvardas
AU  - Zurauskas E
AD  - Department of Pathology, Forensic Medicine and Pharmacology, Institute of
      Biomedical Sciences, Vilnius University Faculty of Medicine, P. Baublio str. 5,
      LT-08406, Vilnius, Lithuania.
FAU - Skorniakov, Viktor
AU  - Skorniakov V
AD  - Institute of Applied Mathematics, Vilnius University Faculty of Mathematics and
      Informatics, Naugarduko str. 24, LT-03225, Vilnius, Lithuania.
FAU - Janusauskas, Vilius
AU  - Janusauskas V
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
FAU - Zorinas, Aleksejus
AU  - Zorinas A
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
FAU - Zaremba, Tomas
AU  - Zaremba T
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
AD  - Aalborg University Hospital, Clinical Institute of Aalborg University, Hobrovej
      18-22, 9100, Aalborg, Denmark.
FAU - Valeviciene, Nomeda
AU  - Valeviciene N
AD  - Department of Radiology, Nuclear Medicine and Medical Physics, Institute of
      Biomedical Sciences, Vilnius University Faculty of Medicine, Santariskiu str. 2, 
      LT-08661, Vilnius, Lithuania.
FAU - Aidietis, Audrius
AU  - Aidietis A
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
FAU - Serpytis, Pranas
AU  - Serpytis P
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
FAU - Rucinskas, Kestutis
AU  - Rucinskas K
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
FAU - Sogaard, Peter
AU  - Sogaard P
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
AD  - Aalborg University Hospital, Clinical Institute of Aalborg University, Hobrovej
      18-22, 9100, Aalborg, Denmark.
FAU - Glaveckaite, Sigita
AU  - Glaveckaite S
AD  - Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius 
      University Faculty of Medicine, Santariskiu str. 2, LT-08661, Vilnius, Lithuania.
LA  - eng
SI  - ClinicalTrials.gov/NCT03585933
GR  - 09.3.3-LMT-K-712-01-0105/Lietuvos Mokslo Taryba/International
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200608
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
SB  - IM
MH  - Aortic Valve Stenosis/*diagnostic imaging/pathology/physiopathology/surgery
MH  - Biopsy
MH  - Denmark
MH  - *Echocardiography
MH  - Female
MH  - Fibrosis
MH  - Heart Valve Prosthesis Implantation
MH  - Humans
MH  - Lithuania
MH  - *Magnetic Resonance Imaging, Cine
MH  - Male
MH  - Myocardium/*pathology
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Research Design
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
MH  - *Ventricular Remodeling
PMC - PMC7278169
OTO - NOTNLM
OT  - *Aortic valve replacement
OT  - *Aortic valve stenosis
OT  - *Magnetic resonance imaging
OT  - *Myocardial fibrosis
OT  - *Prognosis
EDAT- 2020/06/10 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/24 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1186/s12872-020-01552-8 [doi]
AID - 10.1186/s12872-020-01552-8 [pii]
PST - epublish
SO  - BMC Cardiovasc Disord. 2020 Jun 8;20(1):275. doi: 10.1186/s12872-020-01552-8.


PMID- 32513168
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1471-2156 (Electronic)
IS  - 1471-2156 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 8
TI  - Genomic background and genetic relationships between boar taint and fertility
      traits in German Landrace and Large White.
PG  - 61
LID - 10.1186/s12863-020-00865-z [doi]
AB  - BACKGROUND: Due to ethical reasons, surgical castration of young male piglets in 
      their first week of life without anesthesia will be banned in Germany from 2021. 
      Breeding against boar taint is already implemented in sire breeds of breeding
      organizations but in recent years a low demand made this trait economically less 
      important. The objective of this study was to estimate heritabilities and genetic
      relationships between boar taint compounds androstenone and skatole and
      maternal/paternal reproduction traits in 4'924 Landrace (LR) and 4'299 Large
      White (LW) animals from nucleus populations. Additionally, genome wide
      association analysis (GWAS) was performed per trait and breed to detect SNP
      marker with possible pleiotropic effects that are associated with boar taint and 
      fertility. RESULTS: Estimated heritabilities (h(2)) were 0.48 (+/-0.08) for LR
      (0.39 +/- 0.07 for LW) for androstenone and 0.52 (+/-0.08) for LR (0.32 +/- 0.07 
      for LW) for skatole. Heritabilities for reproduction did not differ between
      breeds except age at first insemination (LR: h(2) = 0.27 (+/-0.05), LW: h(2) =
      0.34 (+/-0.05)). Estimates of genetic correlation (rg) between boar taint and
      fertility were different in LR and LW breeds. In LR an unfavorable rg of 0.31
      (+/-0.15) was observed between androstenone and number of piglets born alive,
      whereas this rg in LW (- 0.15 (+/-0.16)) had an opposite sign. A similar
      breed-specific difference is observed between skatole and sperm count. Within LR,
      the rg of 0.08 (+/-0.13) indicates no relationship between the traits, whereas
      the rg of - 0.37 (+/-0.14) in LW points to an unfavorable relationship. In LR
      GWAS identified QTL regions on SSC5 (21.1-22.3 Mb) for androstenone and on SSC6
      (5.5-7.5 Mb) and SSC14 (141.1-141.6 Mb) for skatole. For LW, one marker was found
      on SSC17 at 48.1 Mb for androstenone and one QTL on SSC14 between 140.5 Mb and
      141.6 Mb for skatole. CONCLUSION: Knowledge about such genetic correlations could
      help to balance conventional breeding programs with boar taint in maternal
      breeds. QTL regions with unfavorable pleiotropic effects on boar taint and
      fertility could have deleterious consequences in genomic selection programs.
      Constraining the weighting of these QTL in the genomic selection formulae may be 
      a useful strategy to avoid physiological imbalances.
FAU - Brinke, Ines
AU  - Brinke I
AD  - Institute of Animal Science, University of Bonn, 53115, Bonn, Germany.
FAU - Grosse-Brinkhaus, Christine
AU  - Grosse-Brinkhaus C
AUID- ORCID: 0000-0002-6190-4463
AD  - Institute of Animal Science, University of Bonn, 53115, Bonn, Germany.
      cgro@itw.uni-bonn.de.
FAU - Roth, Katharina
AU  - Roth K
AD  - Institute of Animal Science, University of Bonn, 53115, Bonn, Germany.
FAU - Proll-Cornelissen, Maren J
AU  - Proll-Cornelissen MJ
AD  - Institute of Animal Science, University of Bonn, 53115, Bonn, Germany.
AD  - Association for Bioeconomy Research (FBF e.V.), Adenauerallee 174, 53113, Bonn,
      Germany.
FAU - Henne, Hubert
AU  - Henne H
AD  - BHZP GmbH, An der Wassermuhle 8, 21368 Dahlenburg-Ellringen, Germany.
FAU - Schellander, Karl
AU  - Schellander K
AD  - Institute of Animal Science, University of Bonn, 53115, Bonn, Germany.
FAU - Tholen, Ernst
AU  - Tholen E
AD  - Institute of Animal Science, University of Bonn, 53115, Bonn, Germany.
LA  - eng
GR  - 2817904115/Bundesministerium fur Ernahrung und Landwirtschaft/International
GR  - 2817904115/Bundesministerium fur Ernahrung und Landwirtschaft/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200608
PL  - England
TA  - BMC Genet
JT  - BMC genetics
JID - 100966978
RN  - 0 (Androstenes)
RN  - 18339-16-7 (androst-16-en-3-one)
RN  - 9W945B5H7R (Skatole)
SB  - IM
MH  - Androstenes/analysis
MH  - Animals
MH  - *Breeding
MH  - Fertility/*genetics
MH  - Genetic Association Studies/veterinary
MH  - Genotype
MH  - Germany
MH  - Male
MH  - Phenotype
MH  - Pork Meat/*analysis
MH  - Quantitative Trait Loci
MH  - Skatole/analysis
MH  - Swine/*genetics
PMC - PMC7282179
OTO - NOTNLM
OT  - *Androstenone
OT  - *Boar taint
OT  - *Genome wide association analysis
OT  - *Pigs
OT  - *Reproduction
OT  - *Skatole
EDAT- 2020/06/10 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/12/05 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 10.1186/s12863-020-00865-z [doi]
AID - 10.1186/s12863-020-00865-z [pii]
PST - epublish
SO  - BMC Genet. 2020 Jun 8;21(1):61. doi: 10.1186/s12863-020-00865-z.


PMID- 32513167
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 8
TI  - The current status of pharmaceutical care provision in tertiary hospitals:
      results of a cross-sectional survey in China.
PG  - 518
LID - 10.1186/s12913-020-05371-7 [doi]
AB  - BACKGROUND: Pharmaceutical care is attached with increasing importance around the
      world due to its clinical and economical effects. Tertiary hospitals are equipped
      with the richest healthcare resources and pioneer in the implementation of
      pharmaceutical care. Understanding current status of pharmaceutical care
      provision in tertiary hospitals not only helps to improve the practice in
      tertiary hospitals but also guide the development of pharmaceutical care in
      secondary and primary health institutions. METHOD: Data of a cross-sectional
      survey were used. The cross-sectional survey was conducted from July 2015 to June
      2016, involving 520 hospital directors, 740 clinical pharmacists, 1298
      physicians, 778 dispensing pharmacists and 3096 patients from 292 hospitals of 23
      provinces, 4 municipalities in mainland China. The survey aimed to
      comprehensively investigate the current status of pharmaceutical care and health 
      care professional's understanding of clinical pharmacist system in tertiary
      hospitals. This study reports results pertaining to current status of
      pharmaceutical care, including pharmacy department practice rules, guidelines and
      records, application of rational drug use software, staffing and working
      arrangement of clinical pharmacists and physicians, patients' satisfaction toward
      pharmaceutical care. RESULTS: A majority of the tertiary hospitals established
      clinical pharmacist system (84.2%), clinical pharmacist management rules (89%),
      clinical pharmacists' working ethics (89%) and applied clinical rational drug use
      software (93.8%). However, a number of hospitals did not establish a performance 
      evaluation system (37%) and payment rules for pharmaceutical care (81.9%). Most
      of the clinical pharmacists met the educational background set by the government.
      Averagely there were 8.3 clinical pharmacists per hospital and 90.7% of the
      tertiary hospitals had at least five full-time clinical pharmacists.
      Pharmaceutical care services provided include checking prescriptions, making
      treatment plans and joining clinical rounds and etc. Both physicians and patients
      were generally satisfied with pharmaceutical care services provided. CONCLUSION: 
      China has made progress in pharmaceutical care provision, but problems such as
      lack of rules for pharmaceutical care payment and a performance evaluation
      system, a monotonous variety of pharmaceutical care activities remain unsolved.
      Policy makers and hospitals directors are suggested to pay more attention to
      these problems.
FAU - Guo, Xiaobo
AU  - Guo X
AD  - National Development Research Center of Licensed Pharmacist, China Pharmaceutical
      University, Nanjing, China.
FAU - Yao, Dongning
AU  - Yao D
AD  - Institute of Chinese Medical Sciences, University of Macau, Macao SAR, Macao,
      China.
FAU - Liu, Jie
AU  - Liu J
AD  - National Development Research Center of Licensed Pharmacist, China Pharmaceutical
      University, Nanjing, China.
FAU - Huang, Yuankai
AU  - Huang Y
AD  - National Development Research Center of Licensed Pharmacist, China Pharmaceutical
      University, Nanjing, China.
FAU - Wang, Yitao
AU  - Wang Y
AD  - Institute of Chinese Medical Sciences, University of Macau, Macao SAR, Macao,
      China.
FAU - Yao, Wenbing
AU  - Yao W
AUID- ORCID: http://orcid.org/0000-0003-0125-6123
AD  - National Development Research Center of Licensed Pharmacist, China Pharmaceutical
      University, Nanjing, China. yaowenbing_001@163.com.
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Adult
MH  - China
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Care Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pharmacy Service, Hospital/*organization & administration
MH  - Tertiary Care Centers/*organization & administration
MH  - Young Adult
PMC - PMC7282101
OTO - NOTNLM
OT  - China
OT  - Cross-sectional survey
OT  - Current status
OT  - Pharmaceutical care
OT  - Tertiary hospitals
EDAT- 2020/06/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/10 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12913-020-05371-7 [doi]
AID - 10.1186/s12913-020-05371-7 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Jun 8;20(1):518. doi: 10.1186/s12913-020-05371-7.


PMID- 32513064
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201218
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 4
DP  - 2020 Oct
TI  - The Pandemic Effect: Raising the Bar for Ethics, Empathy, and Professional
      Collegiality.
PG  - 621-622
LID - 10.1177/0194599820933179 [doi]
AB  - The widespread, tragic loss of life and the dedication of health care
      professionals have characterized the severe acute respiratory syndrome
      coronavirus 2 pandemic. While we mourn the loss of so many Americans to this
      novel virus, we also much acknowledge the positive effects to our profession,
      which are not insignificant. We have witnessed our larger community of
      otolaryngologist-head and neck surgeons pulling together in a manner not
      heretofore observed by this author. From the local level of practitioners to our 
      national societies, there has been an amazing effort of collegial unity to
      develop the most clinically relevant guidelines for providing patient care with
      maximal safety, in the face of little scientific knowledge or experience with
      this virus. In addition, we as a specialty and individual otolaryngologists have,
      through our shared experiences, raised the bar for empathy, ethics, and
      professional interaction during these difficult times. We must reflect upon our
      professional growth and capture this renewal of altruism that lives at the heart 
      of our calling.
FAU - Holt, G Richard
AU  - Holt GR
AD  - Department of Otolaryngology-Head and Neck Surgery, The University of Texas
      Health Science Center at San Antonio, San Antonio, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - *Empathy
MH  - Health Personnel/*ethics
MH  - Humans
MH  - *Pandemics
MH  - Patient Care/*ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *collegiality
OT  - *empathy
OT  - *medical ethics
OT  - *pandemic
OT  - *professionalism
EDAT- 2020/06/10 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1177/0194599820933179 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Oct;163(4):621-622. doi:
      10.1177/0194599820933179. Epub 2020 Jun 9.


PMID- 32513061
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 6
DP  - 2020 Dec
TI  - Artificial Intelligence Applications in Otology: A State of the Art Review.
PG  - 1123-1133
LID - 10.1177/0194599820931804 [doi]
AB  - OBJECTIVE: Recent advances in artificial intelligence (AI) are driving innovative
      new health care solutions. We aim to review the state of the art of AI in otology
      and provide a discussion of work underway, current limitations, and future
      directions. DATA SOURCES: Two comprehensive databases, MEDLINE and EMBASE, were
      mined using a directed search strategy to identify all articles that applied AI
      to otology. REVIEW METHODS: An initial abstract and title screening was
      completed. Exclusion criteria included nonavailable abstract and full text,
      language, and nonrelevance. References of included studies and relevant review
      articles were cross-checked to identify additional studies. CONCLUSION: The
      database search identified 1374 articles. Abstract and title screening resulted
      in full-text retrieval of 96 articles. A total of N = 38 articles were retained. 
      Applications of AI technologies involved the optimization of hearing aid
      technology (n = 5; 13% of all articles), speech enhancement technologies (n = 4; 
      11%), diagnosis and management of vestibular disorders (n = 11; 29%), prediction 
      of sensorineural hearing loss outcomes (n = 9; 24%), interpretation of automatic 
      brainstem responses (n = 5; 13%), and imaging modalities and image-processing
      techniques (n = 4; 10%). Publication counts of the included articles from each
      decade demonstrated a marked increase in interest in AI in recent years.
      IMPLICATIONS FOR PRACTICE: This review highlights several applications of AI that
      otologists and otolaryngologists alike should be aware of given the possibility
      of implementation in mainstream clinical practice. Although there remain
      significant ethical and regulatory challenges, AI powered systems offer great
      potential to shape how healthcare systems of the future operate and clinicians
      are key stakeholders in this process.
FAU - You, Eunice
AU  - You E
AD  - McGill University, Faculty of Medicine, Montreal, Canada.
FAU - Lin, Vincent
AU  - Lin V
AD  - Department of Otolaryngology-Head & Neck Surgery, Sunnybrook Health Sciences
      Center, University of Toronto, Toronto, Canada.
FAU - Mijovic, Tamara
AU  - Mijovic T
AD  - Department of Otolaryngology Head & Neck Surgery, McGill University Health
      Center, University of McGill, Montreal, Canada.
FAU - Eskander, Antoine
AU  - Eskander A
AD  - Department of Otolaryngology-Head & Neck Surgery, Sunnybrook Health Sciences
      Center, University of Toronto, Toronto, Canada.
FAU - Crowson, Matthew G
AU  - Crowson MG
AD  - Department of Otolaryngology-Head & Neck Surgery, Sunnybrook Health Sciences
      Center, University of Toronto, Toronto, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - *Artificial Intelligence
MH  - Forecasting
MH  - Humans
MH  - *Otolaryngology
OTO - NOTNLM
OT  - artificial intelligence
OT  - machine learning
OT  - otology
EDAT- 2020/06/10 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
PHST- 2020/06/10 06:00 [entrez]
AID - 10.1177/0194599820931804 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Dec;163(6):1123-1133. doi:
      10.1177/0194599820931804. Epub 2020 Jun 9.


PMID- 32512829
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Jun 4
TI  - Concordance between Thioacetamide-Induced Liver Injury in Rat and Human In Vitro 
      Gene Expression Data.
LID - E4017 [pii]
LID - 10.3390/ijms21114017 [doi]
AB  - The immense resources required and the ethical concerns for animal-based
      toxicological studies have driven the development of in vitro and in silico
      approaches. Recently, we validated our approach in which the expression of a set 
      of genes is uniquely associated with an organ-injury phenotype (injury module),
      by using thioacetamide, a known liver toxicant. Here, we sought to explore
      whether RNA-seq data obtained from human cells (in vitro) treated with
      thioacetamide-S-oxide (a toxic intermediate metabolite) would correlate across
      species with the injury responses found in rat cells (in vitro) after exposure to
      this metabolite as well as in rats exposed to thioacetamide (in vivo). We treated
      two human cell types with thioacetamide-S-oxide (primary hepatocytes with 0
      (vehicle), 0.125 (low dose), or 0.25 (high dose) mM, and renal tubular epithelial
      cells with 0 (vehicle), 0.25 (low dose), or 1.00 (high dose) mM) and collected
      RNA-seq data 9 or 24 h after treatment. We found that the liver-injury modules
      significantly altered in human hepatocytes 24 h after high-dose treatment
      involved cellular infiltration and bile duct proliferation, which are linked to
      fibrosis. For high-dose treatments, our modular approach predicted the rat in
      vivo and in vitro results from human in vitro RNA-seq data with Pearson
      correlation coefficients of 0.60 and 0.63, respectively, which was not observed
      for individual genes or KEGG pathways.
FAU - Schyman, Patric
AU  - Schyman P
AUID- ORCID: 0000-0002-5739-3891
AD  - DoD Biotechnology High Performance Computing Software Applications Institute,
      Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research 
      and Development Command, Fort Detrick, MD 21702, USA.
AD  - The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
      (HJF), Bethesda, MD 20817, USA.
FAU - Printz, Richard L
AU  - Printz RL
AD  - Department of Molecular Physiology and Biophysics, Vanderbilt University School
      of Medicine, Nashville, TN 37232, USA.
FAU - Estes, Shanea K
AU  - Estes SK
AD  - Department of Molecular Physiology and Biophysics, Vanderbilt University School
      of Medicine, Nashville, TN 37232, USA.
FAU - O'Brien, Tracy P
AU  - O'Brien TP
AD  - Department of Molecular Physiology and Biophysics, Vanderbilt University School
      of Medicine, Nashville, TN 37232, USA.
FAU - Shiota, Masakazu
AU  - Shiota M
AD  - Department of Molecular Physiology and Biophysics, Vanderbilt University School
      of Medicine, Nashville, TN 37232, USA.
FAU - Wallqvist, Anders
AU  - Wallqvist A
AUID- ORCID: 0000-0002-9775-7469
AD  - DoD Biotechnology High Performance Computing Software Applications Institute,
      Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research 
      and Development Command, Fort Detrick, MD 21702, USA.
LA  - eng
GR  - CBCall14-CBS-05-2-0007/Defense Threat Reduction Agency
PT  - Journal Article
DEP - 20200604
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Biomarkers)
RN  - 075T165X8M (Thioacetamide)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - Cells, Cultured
MH  - Chemical and Drug Induced Liver Injury, Chronic/*etiology/*metabolism/pathology
MH  - Computational Biology
MH  - Gene Expression Profiling
MH  - Hepatocytes/drug effects/metabolism
MH  - Humans
MH  - Organ Specificity/drug effects
MH  - Rats
MH  - Thioacetamide/administration & dosage/*adverse effects
MH  - Transcriptome
PMC - PMC7312807
OTO - NOTNLM
OT  - RNA-seq
OT  - fibrosis
OT  - in vitro-in vivo correlations
OT  - interspecies correlation
OT  - predictive toxicology
OT  - thioacetamide
OT  - toxicogenomics
EDAT- 2020/06/10 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/10 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - ijms21114017 [pii]
AID - 10.3390/ijms21114017 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Jun 4;21(11). pii: ijms21114017. doi: 10.3390/ijms21114017.


PMID- 32512807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 4
TI  - A Silkworm Infection Model for In Vivo Study of Glycopeptide Antibiotics.
LID - E300 [pii]
LID - 10.3390/antibiotics9060300 [doi]
AB  - Glycopeptide antibiotics (GPAs) are drugs of last resort for treating infections 
      by Gram-positive bacteria. They inhibit bacterial cell wall assembly by binding
      to the d-Ala-d-Ala terminus of peptidoglycan precursors, leading to cell lysis.
      Vancomycin and teicoplanin are first generation GPAs, while dalbavancin is one of
      the few, recently approved, second generation GPAs. In this paper, we developed
      an in vivo insect model to compare, for the first time, the efficacy of these
      three GPAs in curing Staphylococcus aureus infection. Differently from previous
      reports, Bombyx mori larvae were reared at 37 degrees C, and the course of
      infection was monitored, following not only larval survival, but also bacterial
      load in the insect body, hemocyte activity, phenoloxidase activity, and
      antimicrobial peptide expression. We demonstrated that the injection of S. aureus
      into the hemolymph of B. mori larvae led to a marked reduction of their survival 
      rate within 24-48 hours. GPAs were not toxic to the larvae and cured S. aureus
      infection. Dalbavancin was more effective than first generation GPAs. Due to its 
      great advantages (i.e., easy and safe handling, low rearing costs, low antibiotic
      amount needed for the tests, no restrictions imposed by ethical and regulatory
      issues), this silkworm infection model could be introduced in preclinical
      phases-prior to the use of mice-accelerating the discovery/development rate of
      novel GPAs.
FAU - Montali, Aurora
AU  - Montali A
AD  - Department of Biotechnology and Life Sciences, University of Insubria, 21100
      Varese, Italy.
FAU - Berini, Francesca
AU  - Berini F
AD  - Department of Biotechnology and Life Sciences, University of Insubria, 21100
      Varese, Italy.
FAU - Brivio, Maurizio Francesco
AU  - Brivio MF
AD  - Department of Theoretical and Applied Sciences, University of Insubria, 21100
      Varese, Italy.
FAU - Mastore, Maristella
AU  - Mastore M
AD  - Department of Theoretical and Applied Sciences, University of Insubria, 21100
      Varese, Italy.
FAU - Saviane, Alessio
AU  - Saviane A
AD  - Council for Agricultural Research and Economics, Research Centre for Agriculture 
      and Environment (CREA-AA), 35143 Padova, Italy.
FAU - Cappellozza, Silvia
AU  - Cappellozza S
AD  - Council for Agricultural Research and Economics, Research Centre for Agriculture 
      and Environment (CREA-AA), 35143 Padova, Italy.
FAU - Marinelli, Flavia
AU  - Marinelli F
AD  - Department of Biotechnology and Life Sciences, University of Insubria, 21100
      Varese, Italy.
FAU - Tettamanti, Gianluca
AU  - Tettamanti G
AD  - Department of Biotechnology and Life Sciences, University of Insubria, 21100
      Varese, Italy.
AD  - Interuniversity Center for Studies on Bioinspired Agro-environmental Technology
      (BAT Center), University of Napoli Federico II, 80055 Portici, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC7344559
OTO - NOTNLM
OT  - Bombyx mori
OT  - dalbavancin
OT  - glycopeptide antibiotics
OT  - insect infection model
OT  - insect innate immunity.
OT  - teicoplanin
OT  - vancomycin
COIS- The authors declare no conflict of interest.
EDAT- 2020/06/10 06:00
MHDA- 2020/06/10 06:01
CRDT- 2020/06/10 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/05/30 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/10 06:00 [entrez]
PHST- 2020/06/10 06:00 [pubmed]
PHST- 2020/06/10 06:01 [medline]
AID - antibiotics9060300 [pii]
AID - 10.3390/antibiotics9060300 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2020 Jun 4;9(6). pii: antibiotics9060300. doi:
      10.3390/antibiotics9060300.


PMID- 32512544
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1741-2552 (Electronic)
IS  - 1741-2552 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Jul 10
TI  - Stability of flexible thin-film metallization stimulation electrodes: analysis of
      explants after first-in-human study and improvement of in vivo performance.
PG  - 046006
LID - 10.1088/1741-2552/ab9a9a [doi]
AB  - OBJECTIVE: Micro-fabricated neural interfaces based on polyimide (PI) are
      achieving increasing importance in translational research. The ability to produce
      well-defined micro-structures with properties that include chemical inertness,
      mechanical flexibility and low water uptake are key advantages for these devices.
      APPROACH: This paper reports the development of the transverse intrafascicular
      multichannel electrode (TIME) used to deliver intraneural sensory feedback to an 
      upper-limb amputee in combination with a sensorized hand prosthesis. A failure
      mode analysis on the explanted devices was performed after a first-in-human study
      limited to 30 d. MAIN RESULTS: About 90% of the stimulation contact sites of the 
      TIMEs maintained electrical functionality and stability during the full implant
      period. However, optical analysis post-explantation revealed that 62.5% of the
      stimulation contacts showed signs of delamination at the metallization-PI
      interface. Such damage likely occurred due to handling during explantation and
      subsequent analysis, since a significant change in impedance was not observed in 
      vivo. Nevertheless, whereas device integrity is mandatory for long-term
      functionality in chronic implantation, measures to increase the bonding strength 
      of the metallization-PI interface deserve further investigation. We report here
      that silicon carbide (SiC) is an effective adhesion-promoting layer resisting
      heavy electrical stimulation conditions within a rodent animal trial. Optical
      analysis of the new electrodes revealed that the metallization remained unaltered
      after delivering over 14 million pulses in vivo without signs of delamination at 
      the metallization-PI interface. SIGNIFICANCE: Failure mode analysis guided
      implant stability optimization. Reliable adhesion of thin-film metallization to
      substrate has been proven using SiC, improving the potential transfer of
      micro-fabricated neural electrodes for chronic clinical applications. (Document
      number of Ethical Committee: P/905/CE/2012; Date of approval: 2012-10-04).
FAU - Cvancara, Paul
AU  - Cvancara P
AD  - Laboratory for Biomedical Microtechnology, Department of Microsystems Engineering
      - IMTEK, Albert-Ludwig-University Freiburg, Freiburg, Germany. Author to whom any
      correspondence should be addressed.
FAU - Boretius, Tim
AU  - Boretius T
FAU - Lopez-Alvarez, Victor M
AU  - Lopez-Alvarez VM
FAU - Maciejasz, Pawel
AU  - Maciejasz P
FAU - Andreu, David
AU  - Andreu D
FAU - Raspopovic, Stanisa
AU  - Raspopovic S
FAU - Petrini, Francesco
AU  - Petrini F
FAU - Micera, Silvestro
AU  - Micera S
FAU - Granata, Giuseppe
AU  - Granata G
FAU - Fernandez, Eduardo
AU  - Fernandez E
FAU - Rossini, Paolo M
AU  - Rossini PM
FAU - Yoshida, Ken
AU  - Yoshida K
FAU - Jensen, Winnie
AU  - Jensen W
FAU - Divoux, Jean-Louis
AU  - Divoux JL
FAU - Guiraud, David
AU  - Guiraud D
FAU - Navarro, Xavier
AU  - Navarro X
FAU - Stieglitz, Thomas
AU  - Stieglitz T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200710
PL  - England
TA  - J Neural Eng
JT  - Journal of neural engineering
JID - 101217933
SB  - IM
MH  - *Amputees
MH  - Animals
MH  - Electric Impedance
MH  - Electric Stimulation
MH  - Electrodes
MH  - Electrodes, Implanted
MH  - Humans
MH  - Microelectrodes
MH  - *Prostheses and Implants
EDAT- 2020/06/09 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1088/1741-2552/ab9a9a [doi]
PST - epublish
SO  - J Neural Eng. 2020 Jul 10;17(4):046006. doi: 10.1088/1741-2552/ab9a9a.


PMID- 32511832
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20211204
IS  - 1471-8847 (Electronic)
IS  - 1471-8731 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Dec
TI  - Articulating the sources for an African normative framework of healthcare: Ghana 
      as a case study.
PG  - 216-227
LID - 10.1111/dewb.12265 [doi]
AB  - Bioethics is gradually becoming an important part of the drive to increase
      quality healthcare delivery in sub-Saharan African countries. Yet many healthcare
      service-users in Africa are familiar with incidences of questionable health
      policies and poor healthcare delivery, leading to severe consequences for
      patients. We argue that the overarching rights-based ethical administrative
      framework recently employed by healthcare authorities contributes to the poor
      uptake and enforcement of current normative tools. Taking Ghana as a case study, 
      we focus on the cultural ethical context and we tease out the concepts of the
      good and the ethical among the Akan and Bulsa ethnic groups. We point out three
      tenets towards building a normative framework that can resonate with
      service-users and practitioners: ontological communitarianism; empathic humanism;
      and virtuous character. Finally, we indicate how these core tenets can be
      dovetailed into building an effective normative framework and into the training
      of healthcare providers.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Atuire, Caesar A
AU  - Atuire CA
AUID- ORCID: 0000-0001-6825-6916
FAU - Kong, Camillia
AU  - Kong C
AUID- ORCID: 0000-0002-0551-0689
FAU - Dunn, Michael
AU  - Dunn M
AUID- ORCID: 0000-0002-5603-6200
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - England
TA  - Dev World Bioeth
JT  - Developing world bioethics
JID - 101120122
SB  - IM
MH  - Bioethics
MH  - Comprehension
MH  - *Culture
MH  - Delivery of Health Care/*ethics
MH  - Empathy
MH  - *Ethnicity
MH  - Ghana
MH  - *Health Personnel/psychology
MH  - *Health Policy
MH  - Human Rights
MH  - Humanism
MH  - Humans
MH  - Motivation
MH  - *Social Norms
MH  - Social Responsibility
MH  - *Social Values
MH  - Virtues
OTO - NOTNLM
OT  - *Africa
OT  - *Ghana
OT  - *Indigenous Frameworks
OT  - *bioethics
OT  - *clinical
OT  - *health care
EDAT- 2020/06/09 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/06/09 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1111/dewb.12265 [doi]
PST - ppublish
SO  - Dev World Bioeth. 2020 Dec;20(4):216-227. doi: 10.1111/dewb.12265. Epub 2020 Jun 
      8.


PMID- 32511780
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 1523-4681 (Electronic)
IS  - 0884-0431 (Linking)
VI  - 35
IP  - 10
DP  - 2020 Oct
TI  - Gene-Metabolite Network Linked to Inhibited Bioenergetics in Association With
      Spaceflight-Induced Loss of Male Mouse Quadriceps Muscle.
PG  - 2049-2057
LID - 10.1002/jbmr.4102 [doi]
AB  - Prolonged residence of mice in spaceflight is a scientifically robust and
      ethically ratified model of muscle atrophy caused by continued unloading. Under
      the Rodent Research Program of the National Aeronautics and Space Administration 
      (NASA), we assayed the large-scale mRNA and metabolomic perturbations in the
      quadriceps of C57BL/6j male mice that lived in spaceflight (FLT) or on the ground
      (control or CTR) for approximately 4 weeks. The wet weights of the quadriceps
      were significantly reduced in FLT mice. Next-generation sequencing and untargeted
      mass spectroscopic assays interrogated the gene-metabolite landscape of the
      quadriceps. A majority of top-ranked differentially suppressed genes in FLT
      encoded proteins from the myosin or troponin families, suggesting sarcomere
      alterations in space. Significantly enriched gene-metabolite networks were found 
      linked to sarcomeric integrity, immune fitness, and oxidative stress response;
      all inhibited in space as per in silico prediction. A significant loss of
      mitochondrial DNA copy numbers in FLT mice underlined the energy deprivation
      associated with spaceflight-induced stress. This hypothesis was reinforced by the
      transcriptomic sequencing-metabolomics integrative analysis that showed inhibited
      networks related to protein, lipid, and carbohydrate metabolism, and adenosine
      triphosphate (ATP) synthesis and hydrolysis. Finally, we discovered important
      upstream regulators, which could be targeted for next-generation therapeutic
      intervention for chronic disuse of the musculoskeletal system. (c) 2020 The
      Authors. Journal of Bone and Mineral Research published by American Society for
      Bone and Mineral Research.
CI  - (c) 2020 The Authors. Journal of Bone and Mineral Research published by American 
      Society for Bone and Mineral Research.
FAU - Chakraborty, Nabarun
AU  - Chakraborty N
AUID- ORCID: 0000-0002-7883-2013
AD  - The Geneva Foundation, Walter Reed Army Institute of Research, Silver Spring, MD,
      USA.
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
FAU - Waning, David L
AU  - Waning DL
AUID- ORCID: 0000-0002-3858-7623
AD  - Penn State College of Medicine, Hershey, PA, USA.
FAU - Gautam, Aarti
AU  - Gautam A
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
FAU - Hoke, Allison
AU  - Hoke A
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
AD  - Oak Ridge Institute for Science and Education (ORISE), Walter Reed Army Institute
      of Research, Silver Spring, MD, USA.
FAU - Sowe, Bintu
AU  - Sowe B
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
AD  - Oak Ridge Institute for Science and Education (ORISE), Walter Reed Army Institute
      of Research, Silver Spring, MD, USA.
FAU - Youssef, Dana
AU  - Youssef D
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
AD  - Oak Ridge Institute for Science and Education (ORISE), Walter Reed Army Institute
      of Research, Silver Spring, MD, USA.
FAU - Butler, Stephan
AU  - Butler S
AD  - The Geneva Foundation, Walter Reed Army Institute of Research, Silver Spring, MD,
      USA.
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
FAU - Savaglio, Michael
AU  - Savaglio M
AD  - Department of Orthopaedic Surgery, Indiana University School of Medicine,
      Indianapolis, IN, USA.
FAU - Childress, Paul J
AU  - Childress PJ
AD  - Department of Orthopaedic Surgery, Indiana University School of Medicine,
      Indianapolis, IN, USA.
FAU - Kumar, Raina
AU  - Kumar R
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
FAU - Moyler, Candace
AU  - Moyler C
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
AD  - Oak Ridge Institute for Science and Education (ORISE), Walter Reed Army Institute
      of Research, Silver Spring, MD, USA.
FAU - Dimitrov, George
AU  - Dimitrov G
AD  - The Geneva Foundation, Walter Reed Army Institute of Research, Silver Spring, MD,
      USA.
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
FAU - Kacena, Melissa A
AU  - Kacena MA
AUID- ORCID: 0000-0001-7293-0088
AD  - Department of Orthopaedic Surgery, Indiana University School of Medicine,
      Indianapolis, IN, USA.
AD  - Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA.
FAU - Hammamieh, Rasha
AU  - Hammamieh R
AUID- ORCID: 0000-0001-8643-6232
AD  - Medical Readiness Systems Biology, Walter Reed Army Institute of Research, Silver
      Spring, MD, USA.
LA  - eng
GR  - I01 BX003751/BX/BLRD VA/United States
GR  - T32 DK007519/NH/NIH HHS/United States
GR  - R01 AR060863/AR/NIAMS NIH HHS/United States
GR  - T32 DK007519/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200730
PL  - United States
TA  - J Bone Miner Res
JT  - Journal of bone and mineral research : the official journal of the American
      Society for Bone and Mineral Research
JID - 8610640
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Animals
MH  - Male
MH  - Metabolome
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - *Muscular Atrophy
MH  - Quadriceps Muscle/*pathology
MH  - RNA, Messenger
MH  - *Space Flight
MH  - *Weightlessness/adverse effects
PMC - PMC7689867
OTO - NOTNLM
OT  - *ANIMAL MODEL
OT  - *METABOLISM
OT  - *SKELETAL MUSCLE
OT  - *SYSTEMS BIOLOGY
OT  - *TISSUE SIGNALING
EDAT- 2020/06/09 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/03/21 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1002/jbmr.4102 [doi]
PST - ppublish
SO  - J Bone Miner Res. 2020 Oct;35(10):2049-2057. doi: 10.1002/jbmr.4102. Epub 2020
      Jul 30.


PMID- 32511555
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220114
DP  - 2020 Jun 8
TI  - Early Impact of COVID-19 on Individuals with Eating Disorders: A survey of ~1000 
      Individuals in the United States and the Netherlands.
LID - 2020.05.28.20116301 [pii]
LID - 10.1101/2020.05.28.20116301 [doi]
AB  - We received rapid ethical permission to evaluate the early impact of COVID-19 on 
      people with eating disorders. Participants in the United States (US, N=511) and
      the Netherlands (NL, N=510), recruited through ongoing studies and social media, 
      completed an online baseline survey that included both quantitative measures and 
      free-text responses assessing the impact of COVID-19 on situational
      circumstances, eating disorder symptoms, eating disorder treatment, and general
      well-being. Results revealed strong and wide-ranging effects on eating disorder
      concerns and illness behaviors that were consistent with diagnoses. Participants 
      with anorexia nervosa (US 62% of sample; NL 69%) reported increased restriction
      and fears about being able to find foods consistent with their meal plan.
      Individuals with bulimia nervosa and binge-eating disorder (US 30% of sample; NL 
      15%) reported increases in their binge-eating episodes and urges to binge.
      Respondents noted marked increases in anxiety since 2019 and reported greater
      concerns about the impact of COVID-19 on their mental health than physical
      health. Although many participants acknowledged and appreciated the transition to
      telehealth, limitations of this treatment modality for this population were
      raised. Individuals with past histories of eating disorders noted concerns about 
      relapse related to COVID-19 circumstances. Encouragingly, respondents also noted 
      positive effects including greater connection with family, more time for
      self-care, and motivation to recover.
FAU - Termorshuizen, Jet D
AU  - Termorshuizen JD
FAU - Watson, Hunna J
AU  - Watson HJ
FAU - Thornton, Laura M
AU  - Thornton LM
FAU - Borg, Stina
AU  - Borg S
FAU - Flatt, Rachael E
AU  - Flatt RE
FAU - MacDermod, Casey M
AU  - MacDermod CM
FAU - Harper, Lauren E
AU  - Harper LE
FAU - van Furth, Eric F
AU  - van Furth EF
FAU - Peat, Christine M
AU  - Peat CM
FAU - Bulik, Cynthia M
AU  - Bulik CM
AUID- ORCID: 0000-0001-7772-3264
LA  - eng
PT  - Preprint
DEP - 20200608
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Int J Eat Disord. 2020 Nov;53(11):1780-1790. PMID: 32720399
PMC - PMC7274236
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1101/2020.05.28.20116301 [doi]
PST - epublish
SO  - medRxiv. 2020 Jun 8. doi: 10.1101/2020.05.28.20116301.


PMID- 32511544
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210211
DP  - 2020 May 6
TI  - Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious
      Disease Outbreaks.
LID - 2020.05.01.20087429 [pii]
LID - 10.1101/2020.05.01.20087429 [doi]
AB  - Randomized controlled trials are crucial for the evaluation of interventions such
      as vaccinations, but the design and analysis of these studies during infectious
      disease outbreaks is complicated by statistical, ethical, and logistical factors.
      Attempts to resolve these complexities have led to the proposal of a variety of
      trial designs, including individual randomization and several types of cluster
      randomization designs: parallel-arm, ring vaccination, and stepped wedge designs.
      Because of the strong time trends present in infectious disease incidence,
      however, methods generally used to analyze stepped wedge trials may not perform
      well in these settings. Using simulated outbreaks, we evaluate various designs
      and analysis methods, including recently proposed methods for analyzing stepped
      wedge trials, to determine the statistical properties of these methods. While new
      methods for analyzing stepped wedge trials can provide some improvement over
      previous methods, we find that they still lag behind parallel-arm
      cluster-randomized trials and individually-randomized trials in achieving
      adequate power to detect intervention effects. We also find that these methods
      are highly sensitive to the weighting of effect estimates across time periods.
      Despite the value of new methods, stepped wedge trials still have statistical
      disadvantages compared to other trial designs in epidemic settings.
FAU - Kennedy-Shaffer, Lee
AU  - Kennedy-Shaffer L
AUID- ORCID: 0000-0001-7604-3638
FAU - Lipsitch, Marc
AU  - Lipsitch M
AUID- ORCID: 0000-0003-1504-9213
LA  - eng
GR  - T32 AI007358/AI/NIAID NIH HHS/United States
PT  - Preprint
DEP - 20200506
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
UIN - Am J Epidemiol. 2020 Jul 10;:. PMID: 32648891
PMC - PMC7274225
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.1101/2020.05.01.20087429 [doi]
PST - epublish
SO  - medRxiv. 2020 May 6. doi: 10.1101/2020.05.01.20087429.


PMID- 32511534
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
DP  - 2020 Mar 13
TI  - Protocol of a randomized controlled trial testing inhaled Nitric Oxide in
      mechanically ventilated patients with severe acute respiratory syndrome in
      COVID-19 (SARS-CoV-2).
LID - 2020.03.09.20033530 [pii]
LID - 10.1101/2020.03.09.20033530 [doi]
AB  - INTRODUCTION: Severe acute respiratory syndrome due to novel Coronavirus
      (SARS-CoV-2) related infection (COVID-19) is characterized by severe ventilation 
      perfusion mismatch leading to refractory hypoxemia. To date, there is no specific
      treatment available for 2019-nCoV. Nitric oxide is a selective pulmonary
      vasodilator gas used as a rescue therapy in refractory hypoxemia due to acute
      respiratory distress syndrome (ARDS). In has also shown in-vitro and clinical
      evidence that inhaled nitric oxide gas (iNO) has antiviral activity against other
      strains of coronavirus. The primary aim of this study is to determine whether
      inhaled NO improves oxygenation in patients with hypoxic COVID-19. This is a
      multicenter randomized controlled trial with 1:1 individual allocation. Patients 
      will be blinded to the treatment. Methods and analysis. Intubated patients
      admitted to the intensive care unit with confirmed SARS-CoV-2 infection and
      severe hypoxemia will be randomized to receive inhalation of NO (treatment group)
      or not (control group). Treatment will be stopped when patients are free from
      hypoxemia for more than 24 hours. The primary outcome evaluates levels of
      oxygenation between the two groups at 48 hours. Secondary outcomes include rate
      of survival rate at 28 and 90 days in the two groups, time to resolution of
      severe hypoxemia, time to achieve negativity of SARS-CoV-2 RT-PCR tests. Ethics
      and dissemination. The study protocol has been approved by the Investigational
      Review Board of Xijing Hospital (Xian, China) and by the Partners Human Research 
      Committee (Boston, USA). Recruitment will start after approval of both IRBs and
      local IRBs at other enrolling centers. Results of this study will be published in
      scientific journals, presented at scientific meetings, reported through flyers
      and posters, and published on related website or media in combating against this 
      widespread contagious diseases. TRIAL REGISTRATION: Clinicaltrials.gov.
      NCT04306393.
FAU - Lei, Chong
AU  - Lei C
FAU - Su, Binxiao
AU  - Su B
FAU - Dong, Hailong
AU  - Dong H
FAU - Bellavia, Andrea
AU  - Bellavia A
AUID- ORCID: 0000-0003-4988-4532
FAU - Di Fenza, Raffaele
AU  - Di Fenza R
AUID- ORCID: 0000-0002-5675-7139
FAU - Safaee Fakhr, Bijan
AU  - Safaee Fakhr B
AUID- ORCID: 0000-0002-2841-1413
FAU - Gianni, Stefano
AU  - Gianni S
FAU - Grassi, Luigi Giuseppe
AU  - Grassi LG
FAU - Kacmarek, Robert
AU  - Kacmarek R
AUID- ORCID: 0000-0002-3833-380X
FAU - Araujo Morais, Caio Cesar
AU  - Araujo Morais CC
FAU - Pinciroli, Riccardo
AU  - Pinciroli R
FAU - Vassena, Emanuele
AU  - Vassena E
FAU - Berra, Lorenzo
AU  - Berra L
AUID- ORCID: 0000-0003-2702-2093
LA  - eng
SI  - ClinicalTrials.gov/NCT04306393
PT  - Preprint
DEP - 20200313
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
PMC - PMC7273302
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.1101/2020.03.09.20033530 [doi]
PST - epublish
SO  - medRxiv. 2020 Mar 13. doi: 10.1101/2020.03.09.20033530.


PMID- 32511450
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
DP  - 2020 Mar 13
TI  - Protocol for a randomized controlled trial testing inhaled nitric oxide therapy
      in spontaneously breathing patients with COVID-19.
LID - 2020.03.10.20033522 [pii]
LID - 10.1101/2020.03.10.20033522 [doi]
AB  - INTRODUCTION: the current worldwide outbreak of Coronavirus disease 2019
      (COVID-19) due to a novel coronavirus (SARS-CoV-2) is seriously threatening the
      public health. The number of infected patients is continuously increasing and the
      need for Intensive Care Unit admission ranges from 5 to 26%. The mortality is
      reported to be around 3.4% with higher values for the elderly and in patients
      with comorbidities. Moreover, this condition is challenging the healthcare system
      where the outbreak reached its highest value. To date there is still no available
      treatment for SARS-CoV-2. Clinical and preclinical evidence suggests that nitric 
      oxide (NO) has a beneficial effect on the coronavirus-mediated acute respiratory 
      syndrome, and this can be related to its viricidal effect. The time from the
      symptoms' onset to the development of severe respiratory distress is relatively
      long. We hypothesize that high concentrations of inhaled NO administered during
      early phases of COVID-19 infection can prevent the progression of the disease.
      METHODS AND ANALYSIS: This is a multicenter randomized controlled trial.
      Spontaneous breathing patients admitted to the hospital for symptomatic COVID-19 
      infection will be eligible to enter the study. Patients in the treatment group
      will receive inhaled NO at high doses (140-180 parts per million) for 30 minutes,
      2 sessions every day for 14 days in addition to the hospital care. Patient in the
      control group will receive only hospital care. The primary outcome is the
      percentage of patients requiring endotracheal intubation due to the progression
      of the disease in the first 28 days from enrollment in the study. Secondary
      outcomes include mortality at 28 days, proportion of negative test for SARS-CoV-2
      at 7 days and time to clinical recovery. ETHICS AND DISSEMINATION: The trial
      protocol has been approved at the Investigation Review Boards of Xijing Hospital 
      (Xi'an, China) and The Partners Human Research Committee of Massachusetts General
      Hospital (Boston, USA) is pending. Recruitment is expected to start in March
      2020. Results of this study will be published in scientific journals, presented
      at scientific meetings, and on related website or media in fighting this
      widespread contagious disease.
FAU - Lei, Chong
AU  - Lei C
AD  - Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, the
      Fourth Military Medical University. Xi'an, Shaanxi, China.
FAU - Su, Binxiao
AU  - Su B
AD  - Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, the
      Fourth Military Medical University. Xi'an, Shaanxi, China.
AD  - Intensive Care Unit, Department of Anesthesiology and Perioperative Medicine,
      Xijing Hospital, the Fourth Military Medical University. Xi'an, Shaanxi, China.
FAU - Dong, Hailong
AU  - Dong H
AD  - Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, the
      Fourth Military Medical University. Xi'an, Shaanxi, China.
FAU - Fakhr, Bijan Safaee
AU  - Fakhr BS
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Grassi, Luigi Giuseppe
AU  - Grassi LG
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Di Fenza, Raffaele
AU  - Di Fenza R
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Gianni, Stefano
AU  - Gianni S
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Pinciroli, Riccardo
AU  - Pinciroli R
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Vassena, Emanuele
AU  - Vassena E
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Morais, Caio Cesar Araujo
AU  - Morais CCA
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Bellavia, Andrea
AU  - Bellavia A
AD  - Department of Environmental Health, Harvard T.H. Chan School of Public Health,
      Boston, Massachusetts, USA.
FAU - Spina, Stefano
AU  - Spina S
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Kacmarek, Robert
AU  - Kacmarek R
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
FAU - Berra, Lorenzo
AU  - Berra L
AD  - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General 
      Hospital, Boston, Massachusetts, USA.
LA  - eng
PT  - Preprint
DEP - 20200313
PL  - United States
TA  - medRxiv
JT  - medRxiv : the preprint server for health sciences
JID - 101767986
PMC - PMC7239076
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.1101/2020.03.10.20033522 [doi]
PST - epublish
SO  - medRxiv. 2020 Mar 13. doi: 10.1101/2020.03.10.20033522.


PMID- 32511171
OWN - NLM
STAT- MEDLINE
DCOM- 20200709
LR  - 20210406
IS  - 1539-0705 (Electronic)
IS  - 1522-2179 (Linking)
VI  - 22
IP  - 4
DP  - 2020 Aug
TI  - Recommendations to Leverage the Palliative Nursing Role During COVID-19 and
      Future Public Health Crises.
PG  - 260-269
LID - 10.1097/NJH.0000000000000665 [doi]
AB  - With the daily number of confirmed COVID-19 cases and associated deaths rising
      exponentially, social fabrics on a global scale are being worn by panic,
      uncertainty, fear, and other consequences of the health care crisis. Comprising
      more than half of the global health care workforce and the highest proportion of 
      direct patient care time than any other health professional, nurses are at the
      forefront of this crisis. Throughout the evolving COVID-19 pandemic, palliative
      nurses will increasingly exercise their expertise in symptom management, ethics, 
      communication, and end-of-life care, among other crucial skills. The literature
      addressing the palliative care response to COVID-19 has surged, and yet, there is
      a critical gap regarding the unique contributions of palliative nurses and their 
      essential role in mitigating the sequelae of this crisis. Thus, the primary aim
      herein is to provide recommendations for palliative nurses and other health care 
      stakeholders to ensure their optimal value is realized and to promote their
      well-being and resilience during COVID-19 and, by extension, in anticipation of
      future public health crises.
FAU - Rosa, William E
AU  - Rosa WE
AD  - William E. Rosa, PhD, MBE, ACHPN, FAANP, FAAN, is Robert Wood Johnson Foundation 
      Future of Nursing Scholar, University of Pennsylvania School of Nursing,
      Philadelphia. Tamryn F. Gray, PhD, RN, is research fellow, Department of
      Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Harvard 
      Medical School, Boston, Massachusetts. Kimberly Chow, RN, ANP-BC, ACHPN, is nurse
      practitioner, Supportive Care Service, Memorial Sloan Kettering Cancer Center,
      New York. Patricia M. Davidson, PhD, RN, FAAN, is dean and professor, Johns
      Hopkins University School of Nursing, Baltimore, Maryland. J. Nicholas
      Dionne-Odom, PhD, MSN, MA, ACHPN, FPCN, is assistant professor, University of
      Alabama at Birmingham School of Nursing; and codirector, Caregiver and
      Bereavement Support Services, UAB Center for Palliative and Supportive Care.
      Viola Karanja, BSN, RN, is deputy executive director, Partners in Health Liberia,
      Harper. Judy Khanyola, MSc, RCHN, is Chair, Nursing and Midwifery, University of 
      Global Health Equity, Butaro, Rwanda. Julius D. N. Kpoeh, ASN, RN, is senior
      clinical mentor, Partners in Health Liberia, Harper. Joseph Lusaka, BSc HM, DCM, 
      PA, is clinical manager, Pleebo Health Centre, Liberia. Samuel T. Matula, PhD,
      RN, PCNS-BC, is lecturer, University of Botswana, Gaborone. Polly Mazanec, PhD,
      AOCN, ACHPN, FPCN, FAAN, is research associate professor, Frances Payne Bolton
      School of Nursing, Case Western Reserve University, Cleveland, Ohio. Patricia J. 
      Moreland, PhD, CPNP, FAAN, is assistant clinical professor, Nell Hodgson Woodruff
      School of Nursing, Emory University, Atlanta, Georgia. Shila Pandey, MSN,
      AGPCNP-BC, ACHPN, is nurse practitioner, Supportive Care Service, Memorial Sloan 
      Kettering Cancer Center, New York. Amisha Parekh de Campos, PhD, MPH, CHPN,
      Robert Wood Johnson Foundation Future of Nursing Scholar, University of
      Connecticut, Storrs; quality and education coordinator, Hospice Program,
      Middlesex Health, Connecticut. Salimah H. Meghani, PhD, MBE, RN, FAAN, is
      professor and term chair of Palliative Care, University of Pennsylvania School of
      Nursing, Philadelphia.
FAU - Gray, Tamryn F
AU  - Gray TF
FAU - Chow, Kimberly
AU  - Chow K
FAU - Davidson, Patricia M
AU  - Davidson PM
FAU - Dionne-Odom, J Nicholas
AU  - Dionne-Odom JN
FAU - Karanja, Viola
AU  - Karanja V
FAU - Khanyola, Judy
AU  - Khanyola J
FAU - Kpoeh, Julius D N
AU  - Kpoeh JDN
FAU - Lusaka, Joseph
AU  - Lusaka J
FAU - Matula, Samuel T
AU  - Matula ST
FAU - Mazanec, Polly
AU  - Mazanec P
FAU - Moreland, Patricia J
AU  - Moreland PJ
FAU - Pandey, Shila
AU  - Pandey S
FAU - de Campos, Amisha Parekh
AU  - de Campos AP
FAU - Meghani, Salimah H
AU  - Meghani SH
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - T32 CA009461/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Hosp Palliat Nurs
JT  - Journal of hospice and palliative nursing : JHPN : the official journal of the
      Hospice and Palliative Nurses Association
JID - 100887419
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*nursing
MH  - Forecasting
MH  - Hospice and Palliative Care Nursing/*organization & administration
MH  - Humans
MH  - *Nurse's Role
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology/*nursing
PMC - PMC8018720
MID - NIHMS1685288
EDAT- 2020/06/09 06:00
MHDA- 2020/07/10 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/07/10 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1097/NJH.0000000000000665 [doi]
PST - ppublish
SO  - J Hosp Palliat Nurs. 2020 Aug;22(4):260-269. doi: 10.1097/NJH.0000000000000665.


PMID- 32511078
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical Challenges Arising in the COVID-19 Pandemic: An Overview from the
      Association of Bioethics Program Directors (ABPD) Task Force.
PG  - 15-27
LID - 10.1080/15265161.2020.1764138 [doi]
AB  - The COVID-19 pandemic has raised a host of ethical challenges, but key among
      these has been the possibility that health care systems might need to ration
      scarce critical care resources. Rationing policies for pandemics differ by
      institution, health system, and applicable law. Most seem to agree that a
      patient's ability to benefit from treatment and to survive are first-order
      considerations. However, there is debate about what clinical measures should be
      used to make that determination and about other factors that might be ethically
      appropriate to consider. In this paper, we discuss resource allocation and
      several related ethical challenges to the healthcare system and society,
      including how to define benefit, how to handle informed consent, the special
      needs of pediatric patients, how to engage communities in these difficult
      decisions, and how to mitigate concerns of discrimination and the effects of
      structural inequities.
FAU - McGuire, Amy L
AU  - McGuire AL
AUID- ORCID: 0000-0002-7819-519X
AD  - Baylor College of Medicine.
FAU - Aulisio, Mark P
AU  - Aulisio MP
AUID- ORCID: 0000-0002-6423-8523
AD  - Case Western Reserve University School of Medicine.
FAU - Davis, F Daniel
AU  - Davis FD
AUID- ORCID: 0000-0002-5637-7806
AD  - Center for Translational Bioethics and Health Care Policy.
FAU - Erwin, Cheryl
AU  - Erwin C
AUID- ORCID: 0000-0003-4223-457X
AD  - Texas Tech University Health Sciences Center.
FAU - Harter, Thomas D
AU  - Harter TD
AD  - Gundersen Health System.
FAU - Jagsi, Reshma
AU  - Jagsi R
AUID- ORCID: 0000-0001-6562-1228
AD  - University of Michigan.
FAU - Klitzman, Robert
AU  - Klitzman R
AUID- ORCID: 0000-0002-1632-0397
AD  - Columbia University.
FAU - Macauley, Robert
AU  - Macauley R
AD  - Oregon Health and Science University.
FAU - Racine, Eric
AU  - Racine E
AD  - Institut de recherches cliniques de Montreal, Universite de Montreal, McGill
      University.
AD  - McGill University.
FAU - Wolf, Susan M
AU  - Wolf SM
AUID- ORCID: 0000-0001-9547-2200
AD  - University of Minnesota.
FAU - Wynia, Matthew
AU  - Wynia M
AD  - University of Colorado.
FAU - Wolpe, Paul Root
AU  - Wolpe PR
AD  - Emory University.
CN  - COVID-19 Task Force of the Association of Bioethics Program Directors (ABPD)
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jul;20(7):117-120. PMID: 32407245
CIN - Am J Bioeth. 2020 Jul;20(7):207-209. PMID: 32716764
CIN - Am J Bioeth. 2020 Jul;20(7):106-109. PMID: 32716774
CIN - Am J Bioeth. 2020 Jul;20(7):190-192. PMID: 32716778
CIN - Am J Bioeth. 2020 Jul;20(7):103-106. PMID: 32716781
CIN - Am J Bioeth. 2020 Jul;20(7):196-198. PMID: 32716782
CIN - Am J Bioeth. 2020 Jul;20(7):160-162. PMID: 32716783
CIN - Am J Bioeth. 2020 Jul;20(7):77-80. PMID: 32716786
CIN - Am J Bioeth. 2020 Jul;20(7):199-201. PMID: 32716788
CIN - Am J Bioeth. 2020 Jul;20(7):92-94. PMID: 32716791
CIN - Am J Bioeth. 2020 Jul;20(7):204-207. PMID: 32716798
CIN - Am J Bioeth. 2020 Jul;20(7):145-147. PMID: 32716800
CIN - Am J Bioeth. 2020 Jul;20(7):193-195. PMID: 32716801
CIN - Am J Bioeth. 2020 Jul;20(7):202-204. PMID: 32716803
CIN - Am J Bioeth. 2020 Jul;20(7):163-166. PMID: 32716807
CIN - Am J Bioeth. 2020 Jul;20(7):95-97. PMID: 32716808
CIN - Am J Bioeth. 2020 Jul;20(7):133-135. PMID: 32716811
CIN - Am J Bioeth. 2020 Jul;20(7):112-114. PMID: 32716812
MH  - *Advisory Committees
MH  - *Betacoronavirus
MH  - Bioethics
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *Decision making
OT  - *end-of-life issues
OT  - *health care delivery
OT  - *health policy
OT  - *public health
OT  - *rationing/resource allocation
EDAT- 2020/06/09 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1080/15265161.2020.1764138 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):15-27. doi: 10.1080/15265161.2020.1764138. Epub 2020 
      Jun 8.


PMID- 32511039
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20220415
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 14
IP  - 7
DP  - 2020 Jul
TI  - Liver transplant for alcoholic hepatitis: a current clinical overview.
PG  - 591-600
LID - 10.1080/17474124.2020.1775579 [doi]
AB  - INTRODUCTION: Current management of severe alcoholic hepatitis is based on
      corticosteroid therapy and abstinence from alcohol. As liver transplantation is
      lifesaving in alcoholic hepatitis patients at high risk of early death,
      refractory alcoholic hepatitis has become a new indication for liver
      transplantation in highly selected non-responders to corticosteroids. AREAS
      COVERED: This review summarizes the conditions under which liver transplantation 
      may be considered, the available data on liver transplantation for refractory
      alcoholic hepatitis and explores the ethical considerations surrounding the use
      of liver transplantation in these patients. EXPERT OPINION: Selection of
      candidates should be made according to available scientific results on post-liver
      transplantation outcomes and the risk of alcohol relapse. Currently, a strict
      selection process based on a good psychosocial profile, including social
      stability, no previous treatments for alcohol dependence, no current drug use,
      and no co-existing severe mental disorder, seems to be the best way to manage
      these issues. Well-defined selection criteria for candidate selection and
      accurate tools to predict alcohol relapse after liver transplantation are still
      needed.
FAU - Marot, Astrid
AU  - Marot A
AD  - Department of Gastroenterology and Hepatology CHU UCL Namur, Universite
      Catholique De Louvain , Yvoir, Belgium.
FAU - Moreno, Christophe
AU  - Moreno C
AD  - Department of Gastroenterology Hepatopancreatology, and Digestive Oncology,
      C.U.B. Hopital Erasme, Universite Libre De Bruxelles , Brussels, Belgium.
FAU - Deltenre, Pierre
AU  - Deltenre P
AD  - Department of Gastroenterology Hepatopancreatology, and Digestive Oncology,
      C.U.B. Hopital Erasme, Universite Libre De Bruxelles , Brussels, Belgium.
AD  - Department of Gastroenterology and Hepatology, Clinique St Luc , Bouge, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200608
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Glucocorticoids/therapeutic use
MH  - Hepatitis, Alcoholic/drug therapy/etiology/*surgery
MH  - Humans
MH  - *Liver Transplantation/ethics
MH  - Patient Selection
MH  - Risk Factors
OTO - NOTNLM
OT  - Abstinence
OT  - alcohol relapse
OT  - alcoholic hepatitis
OT  - liver transplantation
OT  - prognosis
EDAT- 2020/06/09 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1080/17474124.2020.1775579 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):591-600. doi:
      10.1080/17474124.2020.1775579. Epub 2020 Jun 8.


PMID- 32509963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2397-3269 (Electronic)
IS  - 2397-3269 (Linking)
VI  - 5
IP  - 1
DP  - 2020
TI  - Selective laser trabeculoplasty (SLT) performed by optometrists for patients with
      glaucoma and ocular hypertension: a scoping review protocol.
PG  - e000438
LID - 10.1136/bmjophth-2020-000438 [doi]
AB  - INTRODUCTION: In the UK, the National Institute for Health and Clinical
      Excellence are amending guidelines to support use of selective laser
      trabeculoplasty (SLT) as a first-line treatment for patients with glaucoma and
      ocular hypertension. The procedure is quick, effective in lowering intraocular
      pressure, cost-effective for the National Health Service and offers an equivalent
      safety profile to other therapies. The procedure is typically performed by an
      ophthalmologist; however, there is potential for suitably trained non-medical
      professionals to deliver the therapy. This scoping review will identify service
      delivery models where SLT is delivered by non-medical professionals worldwide,
      with a focus on optometrists. METHODS AND ANALYSIS: A systematic search of the
      following databases will be conducted: CINAHL; MEDLINE Complete; Embase; HMIC and
      Ovid Emcare. For inclusion, studies must examine healthcare models of SLT
      delivery by optometrists and describe one of the following outcomes: training
      procedures; clinical effectiveness; safety and cost-effectiveness. A search of
      grey literature will be conducted via professional societies; national health
      departments; medicine regulatory bodies; charities and conference proceedings.
      Two reviewers will independently screen titles, abstracts and full-texts
      articles, followed by charting of data. This evidence synthesis will summarise
      findings narratively, supplemented with tables and descriptive statistics. ETHICS
      AND DISSEMINATION: The review focuses on published articles and therefore ethical
      approval is not required. The findings will be relevant to key stakeholders
      including health service managers, policymakers, clinicians and patients. The
      findings of this review will be disseminated through peer-reviewed publications, 
      conference presentations and summary reports for key stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jones, Lee
AU  - Jones L
AUID- ORCID: 0000-0002-8030-1211
AD  - Moorfields Eye Hospital NHS Foundation Trust, London, UK.
AD  - Institute of Ophthalmology, University College London, London, UK.
FAU - Konstantakopoulou, Evgenia
AU  - Konstantakopoulou E
AD  - Moorfields Eye Hospital NHS Foundation Trust, London, UK.
AD  - Institute of Ophthalmology, University College London, London, UK.
AD  - Division of Optics and Optometry, University of West Attica, Attica, Greece.
FAU - Gazzard, Gus
AU  - Gazzard G
AD  - Moorfields Eye Hospital NHS Foundation Trust, London, UK.
AD  - Institute of Ophthalmology, University College London, London, UK.
LA  - eng
GR  - 09/104/40/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200525
PL  - England
TA  - BMJ Open Ophthalmol
JT  - BMJ open ophthalmology
JID - 101714806
PMC - PMC7252989
OTO - NOTNLM
OT  - glaucoma
OT  - intraocular pressure
OT  - treatment lasers
COIS- Competing interests: None declared.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/04/02 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.1136/bmjophth-2020-000438 [doi]
AID - bmjophth-2020-000438 [pii]
PST - epublish
SO  - BMJ Open Ophthalmol. 2020 May 25;5(1):e000438. doi: 10.1136/bmjophth-2020-000438.
      eCollection 2020.


PMID- 32509649
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar
TI  - Awareness and perception regarding tuberculosis among patients and their
      relatives attending a tertiary care hospital in Uttarakhand: A hospital-based
      exploratory survey.
PG  - 1555-1561
LID - 10.4103/jfmpc.jfmpc_932_19 [doi]
AB  - BACKGROUND: Awareness about disease among tuberculosis (TB) patients plays a
      crucial role toward successfully achieving targets for control, prevention, and
      their relatives treatment adherence and is not well studied or documented. This
      study sought to explore the awareness and perceptions of TB patients in a
      tertiary care centre in northern India. METHODS: This was an exploratory study
      conducted between January and December 2016 among 1,000 pulmonary TB patients and
      their relatives. Structured and validated interview schedule was used to assess
      participants knowledge and perception regarding TB, which comprised of 41
      questions. Ethical clearance was taken and written informed consent was obtained 
      from each study participants. Data analysis was done using SPSS 22.0 version.
      RESULTS: A total of 1,000 study participants (mean age 40.2 +/- 9.6 years,
      females 51%) were enrolled. More than two-third of the study participants were
      from Uttarakhand. Study participants had highest knowledge score (61.85%)
      regarding sign and symptoms, followed by scores in the aspect of prevention and
      treatment of TB (52.7%). However, a lower proportion (51.5%) knew about its
      causation. Overall knowledge score was 54.8%. Around half of the subjects (49.7%)
      disagreed that TB is a major health problem. CONCLUSIONS: Regardless of
      non-satisfactory knowledge of participants, their perception regarding TB was
      better. As to the associated factors, we found that participants' knowledge had
      significant association with religion, educational status, occupation, family
      income per month, type of family, and source of health information. Although
      there was insignificant difference between family monthly incomes, source of
      health information and perception regarding TB.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Sharma, Suresh K
AU  - Sharma SK
AD  - College of Nursing, All India Institute of Medical Sciences, Rishikesh,
      Uttarakhand, India.
FAU - Jelly, Prasuna
AU  - Jelly P
AD  - College of Nursing, All India Institute of Medical Sciences, Rishikesh,
      Uttarakhand, India.
FAU - Bhadoria, Ajeet S
AU  - Bhadoria AS
AD  - Department of Community and Family Medicine, All India Institute of Medical
      Sciences, Rishikesh, Uttarakhand, India.
FAU - Thakur, Kalpana
AU  - Thakur K
AD  - College of Nursing, All India Institute of Medical Sciences, Rishikesh,
      Uttarakhand, India.
FAU - Gawande, Kanchan
AU  - Gawande K
AD  - Department of Community and Family Medicine, All India Institute of Medical
      Sciences, Rishikesh, Uttarakhand, India.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7266229
OTO - NOTNLM
OT  - Awareness and perception of tuberculosis
OT  - knowledge
OT  - tuberculosis
COIS- There are no conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/02/20 00:00 [revised]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_932_19 [doi]
AID - JFMPC-9-1555 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Mar 26;9(3):1555-1561. doi:
      10.4103/jfmpc.jfmpc_932_19. eCollection 2020 Mar.


PMID- 32509641
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar
TI  - Sleep Quality and its various correlates: A community-based study among geriatric
      population in a community development block of Purba Bardhaman district, West
      Bengal.
PG  - 1510-1516
LID - 10.4103/jfmpc.jfmpc_1021_19 [doi]
AB  - BACKGROUND: In the elderly population, sleep problems are prevalent and have
      known to be associated with many factors. There are many adverse consequences of 
      decreased sleep such as heart disease, diabetes, depression, accidents, impaired 
      cognition, and poor quality of life. Correlates of poor sleep quality have not
      been well explored in Indian research. OBJECTIVES: The present study aimed to
      measure prevalence of poor sleep quality among elderly and its association with
      different factors. METHODS: A cross-sectional study was conducted during
      June-November 2018 in a randomly selected block of Purba Bardhaman district.
      Cluster random sampling was applied to select required sample of 180 elderly
      people (>/=60 years) from 30 villages. Study tools used were Pittsburgh Sleep
      Quality Index (PSQI), 5-Item Geriatric Depression Scale (GDS), Generalized
      Anxiety Disorder 7-item scale (GAD-7), Global Physical Activity Questionnaire
      (GPAQ), and a pretested schedule for sociodemographic and other variables. The
      study had approval from Institutional Ethics Committee. Chi-square tests and
      multivariable logistic regression were performed using SPSS V16. RESULTS:
      Prevalence of poor sleep quality (GPSQI >/=5) was 68.89%. Median Global PSQI
      (GPSQI) score was 7.00 (4.00-11.00). Multivariable logistic regression revealed
      that marital status, vital events in past one month, anxiety status, and
      depression were significantly associated with sleep quality. Those who were
      unmarried/widowed, having vital events in past one month in the family, and
      severe anxiety and depression were having significantly higher odds of developing
      poor sleep quality. CONCLUSION: Poor sleep quality is high among elderly and
      measures toward the significant correlates are thus emphasized.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Das, Soumyaneel
AU  - Das S
AD  - Department of Community Medicine, Burdwan Medical College, Burdwan, Purba
      Barddhaman, West Bengal, India.
FAU - Roy, Rabindra Nath
AU  - Roy RN
AD  - Department of Community Medicine, Burdwan Medical College, Burdwan, Purba
      Barddhaman, West Bengal, India.
FAU - Das, Dilip Kumar
AU  - Das DK
AD  - Department of Community Medicine, Burdwan Medical College, Burdwan, Purba
      Barddhaman, West Bengal, India.
FAU - Chakraborty, Amitava
AU  - Chakraborty A
AD  - Department of Community Medicine, Burdwan Medical College, Burdwan, Purba
      Barddhaman, West Bengal, India.
FAU - Mondal, Raston
AU  - Mondal R
AD  - Department of Community Medicine, Burdwan Medical College, Burdwan, Purba
      Barddhaman, West Bengal, India.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7266224
OTO - NOTNLM
OT  - Geriatric
OT  - physical activity
OT  - sleep quality
COIS- There are no conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/11/16 00:00 [received]
PHST- 2020/02/11 00:00 [revised]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_1021_19 [doi]
AID - JFMPC-9-1510 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Mar 26;9(3):1510-1516. doi:
      10.4103/jfmpc.jfmpc_1021_19. eCollection 2020 Mar.


PMID- 32509631
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar
TI  - Knowledge about and determinants for diagnosing hidradenitis suppurativa by
      ministry of health primary healthcare physicians in Jeddah city 2019: An
      analytical cross-sectional study.
PG  - 1448-1452
LID - 10.4103/jfmpc.jfmpc_1151_19 [doi]
AB  - CONTEXT: Hidradenitis suppurativa is a noncontagious, inflammatory, chronic and
      recurrent disease. The prevalence of HS is estimated to be between less than 1
      and 4%. It is more common in females than males at a 2:1 ratio. Many cases of HS 
      are either misdiagnosed or remain undiagnosed. AIMS: To assess knowledge of
      diagnosing hidradenitis suppurativa by Ministry of Health primary health care
      physicians in Jeddah city, 2019 and to identify the determinants and knowledge of
      diagnosing hidradenitis suppurativa. SETTINGS AND DESIGN: An analytical
      cross-sectional study conducted in Jeddah city, 2019, among primary health care
      physicians of the MOH. METHODS AND MATERIAL: Estimated sample size was 114. The
      required primary health care centers were 38 centers. The centers were chosen by 
      a simple random sampling technique. A reliable self-administered questionnaire
      was used. Ethical approval was obtained. STATISTICAL ANALYSIS USED: Descriptive
      statistics consisted of means, standard deviations, frequency tables, cross
      tabulation and charts). Categorical variables were compared using the chi-square 
      test to determine significant relationships between variables. RESULTS: 65.4%
      (68) diagnosed the disease correctly. Most of their knowledge came from clinical 
      practice (39.4%). There was a significant relationship with current job title and
      medical degree (P-value < 0.0005). CONCLUSION: The present study showed good
      knowledge about and ability to diagnose HS. A more advanced medical degree and
      more years of clinical experience was positively associated with the ability to
      diagnose HS.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Alhawsawi, Ebtisam M F
AU  - Alhawsawi EMF
AD  - Department of Family Medicine, King Abdulaziz University Hospital, Jeddah, Saudi 
      Arabia.
FAU - Hariri, Ghufran A
AU  - Hariri GA
AD  - Department of Family Medicine, King Abdulaziz University Hospital, Jeddah, Saudi 
      Arabia.
FAU - Alzuhayri, Randa J
AU  - Alzuhayri RJ
AD  - Department of Family Medicine, Ministry of Health, Jeddah, Saudi Arabia.
FAU - Makhdoom, Yahya
AU  - Makhdoom Y
AD  - Department of Family Medicine, Ministry of Health, Jeddah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7266209
OTO - NOTNLM
OT  - Hidradenitis suppurativa
OT  - nodules
OT  - primary health care
OT  - pustules
OT  - skin lesions
COIS- There are no conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/01/30 00:00 [revised]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_1151_19 [doi]
AID - JFMPC-9-1448 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Mar 26;9(3):1448-1452. doi:
      10.4103/jfmpc.jfmpc_1151_19. eCollection 2020 Mar.


PMID- 32509627
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar
TI  - Perception and practice of placebo use among physicians in Mangalore.
PG  - 1424-1430
LID - 10.4103/jfmpc.jfmpc_1052_19 [doi]
AB  - BACKGROUND: Placebo use falls under two contexts: clinical care and research. In 
      today's pharmacological era where treatment is available for almost all
      illnesses, there exists a lot of questions about the perceived efficacy and usage
      of placebos. This study focuses on assessing the knowledge, attitude, and
      practice of placebo use in clinical medicine. This study also aimed to pay
      attention to the ethical dimensions of using a placebo in clinical practice.
      SUBJECTS AND METHODS: A cross-sectional study was conducted among 86 physicians
      in five hospitals and various private clinics in Mangalore, India, using a
      self-administered questionnaire. RESULTS: About 72% of physicians were found to
      be prescribing placebos. Vitamins were the most commonly prescribed placebos.
      Pure placebos were prescribed by 69.4% and impure placebos by 83.9% of
      physicians. Pure placebos were deemed acceptable by 70.9% of physicians if used
      for their psychological effect, but only 46.5% said the same for impure placebos.
      Placebos were most commonly prescribed to conform to the patients' requests for
      some sort of medicine. Among our physicians, 54.8% and 62.8% of placebo
      prescribers felt that many or some patients would be disappointed if they were to
      find out that they had been treated with pure or impure placebos, respectively.
      CONCLUSION: Physicians agreed that placebos were acceptable in some circumstances
      in clinical practice. Physicians think that the information and training about
      placebos during their medical studies was insufficient. Perhaps, more time should
      be put into teaching about placebos during medical studies and proper guidelines 
      should be laid down about placebo usage.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Aujla, Ravinder Singh
AU  - Aujla RS
AD  - Department of Medicine, Chandra Laxmi Hospital, Ghaziabad, Uttar Pradesh, India.
FAU - Agarwal, Ritika
AU  - Agarwal R
AD  - Department of Medicine, Chandra Laxmi Hospital, Ghaziabad, Uttar Pradesh, India.
FAU - Sinha, Smriti
AU  - Sinha S
AD  - Department of Anesthesia, Srinivas Institute of Medical Science and Research
      Centre, Mangalore, Karnataka, India.
FAU - Kumar, Avinash
AU  - Kumar A
AD  - Department of Community Medicine, Kasturba Medical College, Mangalore, Karnataka,
      India.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7266198
OTO - NOTNLM
OT  - Clinical pharmacology
OT  - ethics
OT  - general medicine
OT  - general practice
OT  - placebo use
COIS- There are no conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/11/23 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_1052_19 [doi]
AID - JFMPC-9-1424 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Mar 26;9(3):1424-1430. doi:
      10.4103/jfmpc.jfmpc_1052_19. eCollection 2020 Mar.


PMID- 32509620
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar
TI  - Cheiloscopy in gender determination: A study on 2112 individuals.
PG  - 1386-1390
LID - 10.4103/jfmpc.jfmpc_1046_19 [doi]
AB  - BACKGROUND: Lip prints are seen to remain the same for an individual throughout
      his/her life. Cheiloscopy can be used as an effective tool in the identification 
      of the persons from pieces of evidence that may be left behind from lip prints.
      AIM AND OBJECTIVES: The aim of the current research was to evaluate the
      predominant lip groove pattern among Calicut population, Kerala. MATERIALS AND
      METHODS: The study involved 2112 individuals (1056 males and 1056 females) in the
      Department of Oral Medicine and Radiology, KMCT Dental College, Calicut, Kerala. 
      Lipstick was used to record the lip groove patterns and the patterns were
      visualized by magnifying lens after the institutional ethical clearance and
      informed consent from the individual. Statistical analysis was done using SPSS
      software 22.0. RESULTS: Among the study population, Type 1', Type 1, Type 4, and 
      Type 5 were found to be common lip groove patterns. Males showed predominance on 
      Type 1' and Type 1 lip groove patterns, whereas females showed predominance on
      Type 4 and Type 5 lip groove patterns. The results were similar when analyzed on 
      upper and lower lips separately on males and females. CONCLUSION: Cheiloscopy is 
      a reliable tool in personal identification and gender determination of an
      individual. The geographical prevalence of lip groove patterns was reported in
      the current research and is added to the database of the anthropological data.
      Studies in different geographical regions will add lip groove patterns on the
      database in the future and henceforth the potential of cheiloscopy could be
      further utilized.
CI  - Copyright: (c) 2020 Journal of Family Medicine and Primary Care.
FAU - Thermadam, Tim Peter
AU  - Thermadam TP
AD  - Associate Professor, Department of Oral Medicine and Radiology, KMCT Dental
      College, Calicut, Kerala, India.
FAU - Chatra, Laxmikanth
AU  - Chatra L
AD  - Professor and Head of the Department, Department of Oral Medicine and Radiology, 
      Yenepoya Dental College, Mangalore, Karnataka, India.
FAU - Ahsan, Auswaf
AU  - Ahsan A
AD  - Professor and Head of the Department, Department of Oral Medicine and Radiology, 
      KMCT Dental College, Calicut, Kerala, India.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7266203
OTO - NOTNLM
OT  - Cheiloscopy
OT  - gender determination
OT  - lip print
OT  - personal identification
COIS- There are no conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/02/05 00:00 [revised]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_1046_19 [doi]
AID - JFMPC-9-1386 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Mar 26;9(3):1386-1390. doi:
      10.4103/jfmpc.jfmpc_1046_19. eCollection 2020 Mar.


PMID- 32509414
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 26
DP  - 2020 Jun
TI  - Mercury Exposure Among Artisanal and Small-Scale Gold Miners in Four Regions in
      Uganda.
PG  - 200613
LID - 10.5696/2156-9614-10.26.200613 [doi]
AB  - BACKGROUND: Artisanal and small-scale gold mining is a human health concern,
      especially in low-income countries like Uganda due to the use of mercury (Hg) in 
      the mining process. OBJECTIVE: The aim of the present study was to assess Hg
      exposure among artisanal and small-scale gold miners in Uganda through biologic
      monitoring parameters and Hg-related clinical manifestations. METHODS: A
      cross-sectional study was conducted from June to July 2018 among 183 miners from 
      Ibanda (Western region), Mubende (Central region), Amudat (Karamoja region) and
      Busia (Eastern region) in Uganda. An interviewer-administered questionnaire and
      health assessment were used to collect socio-demographic, exposure and
      self-reported Hg poisoning symptoms. In addition, 41 urine, 41 blood and 26
      environment samples were assessed. Descriptive statistics, Kruskal-Wallis test
      and Wilcoxon signed-rank test for comparison of Hg levels in urine and blood
      among miners were performed while logistic regression was used to assess
      associations between exposure and Hg poisoning-related symptoms. RESULTS: The
      miners ranged from 15 to 65 years old and were primarily male (72.6%). The
      majority (73.3%) had worked directly with Hg for an average duration of 5.3
      years. Symptoms associated with working directly with Hg included chest pain
      (odds ratio (OR)=9.0, confidence interval (CI)=3.3 to 24.6), numbness (OR=8.5,
      CI=2.1 to 34.4), back pain (OR=6.2, CI= 2.2 to 17.5), fatigue and stress (OR=5.4,
      2.0 to CI=14.9), headache (OR=4.7, CI=1.9 to 11.3), dizziness (OR=3.8, CI=1.5 to 
      9.7) joint pain (OR=3.2, CI=1.3 to 8.3) and respiratory problems (3.2, 1.0 to
      10.1). Statistically significant differences in Hg levels with p-values less than
      0.05 were observed across district, gender and type of work. Mubende had the
      highest blood and urine levels (136 mug/l and 105.5 mug/l) in comparison with
      Busia (60 mug/l and 70.6 mug/l) and Ibanda (43 mug/l and 58 mug/l). Females (84.7
      mug/l), panners (109 mug/l) and those with knowledge of occupational health and
      safety measures (95.6 mug/l) reported higher levels of Hg in urine. The average
      levels of Hg in water and soil samples were 23.79 mug/l and 0.21 mug/l,
      respectively. CONCLUSIONS: Variation in Hg levels were attributed to varied
      duration of exposure across geographical sites. There was considerable exposure
      to Hg as indicated by both clinical manifestations and biologic parameters among 
      miners in Uganda with Hg in urine exceeding the recommended thresholds.
      PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: Ethical approval was obtained
      from the Makerere University School of Health Science Institutional Review Board 
      (reference number SHSREC REF 2018-2019) and Uganda National Council for Science
      and Technology (reference number SS 4577). COMPETING INTERESTS: The authors
      declare no competing financial interests.
CI  - (c) Pure Earth 2020.
FAU - Wanyana, Mercy Wendy
AU  - Wanyana MW
AD  - Uganda National Association of Community and Occupational Health, Kampala,
      Uganda.
FAU - Agaba, Friday E
AU  - Agaba FE
AD  - Uganda National Association of Community and Occupational Health, Kampala,
      Uganda.
FAU - Sekimpi, Deogratias K
AU  - Sekimpi DK
AD  - Uganda National Association of Community and Occupational Health, Kampala,
      Uganda.
FAU - Mukasa, Victoria N
AU  - Mukasa VN
AD  - Uganda National Association of Community and Occupational Health, Kampala,
      Uganda.
FAU - Kamese, Geoffrey N
AU  - Kamese GN
AD  - Uganda National Association of Community and Occupational Health, Kampala,
      Uganda.
FAU - Douglas, Nkonge
AU  - Douglas N
AD  - Ministry of Gender Labour and Social Development, Kampala, Uganda.
FAU - Ssempebwa, John C
AU  - Ssempebwa JC
AUID- ORCID: 0000-0002-8289-2844
AD  - Department of Disease Control and Environmental Health, School of Public Health, 
      College of Health Sciences, Makerere University, Kampala, Uganda.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7269329
OTO - NOTNLM
OT  - artisanal and small-scale gold miners
OT  - blood and urine mercury
OT  - mercury exposure mercury poisoning related symptoms
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.5696/2156-9614-10.26.200613 [doi]
PST - epublish
SO  - J Health Pollut. 2020 May 28;10(26):200613. doi: 10.5696/2156-9614-10.26.200613. 
      eCollection 2020 Jun.


PMID- 32509412
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 26
DP  - 2020 Jun
TI  - Impact of Abandoned Mining Facility Wastes on the Aquatic Ecosystem of the Mogpog
      River, Marinduque, Philippines.
PG  - 200611
LID - 10.5696/2156-9614-10.26.200611 [doi]
AB  - BACKGROUND: Mine waste from abandoned mining sites can cause environmental
      degradation and ecological imbalance to receiving water bodies. Heavy metal
      pollution affects local communities and may pose health risks to the general
      public. An abandoned mining facility in Marinduque, Philippines, situated on the 
      of Mogpog River, continuously deposits mine wastes, which may affect the river
      and the health of local communities. OBJECTIVES: The aim of the present study was
      to examine the presence and extent of heavy metal contamination from mine wastes 
      in the aquatic ecosystem of the Mogpog River by determining the level of heavy
      metal concentration in the water, sediments and biota. METHODS: Four sampling
      sites were monitored for heavy metals (copper (Cu), arsenic (As), chromium (Cr)
      and sulfur (S)) pollution. Several analyses were conducted to determine the heavy
      metals present in the water, sediment and biota. Atomic absorption
      spectrophotometry was used for the analysis of Cu concentrations in water. X-ray 
      fluorescence was used for the analysis of total heavy metals in the sediments and
      biota. RESULTS: An inverse relationship with water and sediment from upstream to 
      downstream of the river were observed. This trend shows deposition of Cu in the
      sediments as factored by pH. Flora gathered from the riverbanks recorded
      concentrations of Cu in their leaves and fruits. CONCLUSIONS: It has been
      difficult for the Mogpog River to regain water quality after years of mine waste 
      deposition. Acid mine drainage occurred upstream of the river which affects the
      speciation of heavy metals. The potential risk of heavy metal exposure to local
      communities was observed due to the communities' river utilization. PARTICIPANT
      CONSENT: Obtained. ETHICS APPROVAL: The Office of Vice Chancellor for Research
      and Extension of University of the Philippines Los Banos approved the study.
      COMPETING INTERESTS: The authors declare no competing financial interests.
CI  - (c) Pure Earth 2020.
FAU - Gigantone, Catherine B
AU  - Gigantone CB
AUID- ORCID: https://orcid.org/0000-0003-1864-9193
AD  - School of Environmental Sciences and Management, University of the Philippines
      Los Banos, College, Laguna, Philippines.
FAU - Sobremisana, Marisa J
AU  - Sobremisana MJ
AD  - School of Environmental Sciences and Management, University of the Philippines
      Los Banos, College, Laguna, Philippines.
FAU - Trinidad, Lorele C
AU  - Trinidad LC
AD  - National Institute of Molecular Biology and Biotechnology, University of the
      Philippines Los Banos, College, Laguna, Philippines.
FAU - Migo, Veronica P
AU  - Migo VP
AD  - Department of Chemical Engineering, College of Engineering and Agro Industrial
      Technology, University of the Philippines Los Banos, College, Laguna,
      Philippines.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7269319
OTO - NOTNLM
OT  - Marinduque
OT  - acid mine drainage
OT  - heavy metals contamination
OT  - mine waste pollution
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/12/01 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.5696/2156-9614-10.26.200611 [doi]
PST - epublish
SO  - J Health Pollut. 2020 May 28;10(26):200611. doi: 10.5696/2156-9614-10.26.200611. 
      eCollection 2020 Jun.


PMID- 32509408
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 26
DP  - 2020 Jun
TI  - Prevalence of Chronic Bronchitis and Respiratory Health Profile of a Population
      Exposed to Wood Smoke in Nicaragua.
PG  - 200607
LID - 10.5696/2156-9614-10.26.200607 [doi]
AB  - BACKGROUND: Household air pollution (HAP) is one of the most important
      environmental risk factors worldwide associated with chronic respiratory
      diseases. OBJECTIVES: The present study focused on respiratory health in a
      population with high wood smoke exposure in Nicaragua. METHODS: We employed a
      cross-sectional study with 213 participants. Data on the prevalence of chronic
      bronchitis (chronic bronchitis), chronic obstructive pulmonary disease (COPD) and
      asthma, including respiratory scores and pulmonary function tests, were
      documented. The role of risk factors for chronic bronchitis was analyzed.
      RESULTS: We found a high prevalence of chronic airway diseases in the population 
      exposed to wood smoke. A higher prevalence of chronic bronchitis was found in
      persons serving as primary cooks in households. Further confounding factors for
      chronic bronchitis included age, a prior diagnosis of asthma, inhalational
      allergies and lower socioeconomic status. Respiratory scores were elevated in
      individuals with chronic bronchitis. CONCLUSIONS: This is one of the first
      studies in a wood smoke-exposed population in Nicaragua showing a high prevalence
      of chronic bronchitis and COPD with an emphasis on the analysis of personal and
      environmental risk factors. Further studies are needed to address which
      combination of interventions is most efficient for ameliorating respiratory
      health hazards. PARTICIPANT CONSENT: Obtained. ETHICS APPROVAL: The study
      protocol was approved by the Ethics Committee of the University of Luebeck,
      Germany (reference number 12-214), and by the Ethics Committee of the Department 
      of Medical Sciences at National Autonomous University of Nicaragua, Managua,
      Nicaragua. COMPETING INTERESTS: The authors declare no competing financial
      interests.
CI  - (c) Pure Earth 2020.
FAU - Maas, Annika
AU  - Maas A
AUID- ORCID: https://orcid.org/0000-0003-4413-0336
AD  - University of Luebeck, Luebeck, Germany.
FAU - Kothe, Henning
AU  - Kothe H
AD  - University of Luebeck, Luebeck, Germany.
FAU - Centeno, Ivette Pilarte
AU  - Centeno IP
AUID- ORCID: https://orcid.org/0000-0001-7209-6345
AD  - Faculty of Medical Sciences, National Autonomous University of Nicaragua (UNAN), 
      Managua, Nicaragua.
FAU - Gutierrez Leiva, Mauricio Jose
AU  - Gutierrez Leiva MJ
AD  - Faculty of Medical Sciences, National Autonomous University of Nicaragua (UNAN), 
      Managua, Nicaragua.
FAU - Dalhoff, Klaus
AU  - Dalhoff K
AD  - University of Luebeck, Luebeck, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7269325
OTO - NOTNLM
OT  - COPD
OT  - HAP
OT  - Nicaragua
OT  - chronic bronchitis
OT  - household air pollution
OT  - lung function
OT  - respiratory health
OT  - wood smoke exposure
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/01/12 00:00 [received]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.5696/2156-9614-10.26.200607 [doi]
PST - epublish
SO  - J Health Pollut. 2020 May 26;10(26):200607. doi: 10.5696/2156-9614-10.26.200607. 
      eCollection 2020 Jun.


PMID- 32509407
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 26
DP  - 2020 Jun
TI  - Lead Toxicoses in Free-Range Chickens in Artisanal Gold-Mining Communities,
      Zamfara, Nigeria.
PG  - 200606
LID - 10.5696/2156-9614-10.26.200606 [doi]
AB  - BACKGROUND: In early 2010, outbreaks of lead poisoning due to artisanal gold
      mining in villages in the northwest Nigerian state of Zamfara have resulted in
      the death of hundreds of children < 5 years old. There have also been unconfirmed
      reports of high mortality of geese within these villages. OBJECTIVES: To report a
      case of lead poisoning in three domestic free-range chickens found in one of the 
      affected communities where illegal small-scale gold mining activities take place.
      METHODS: Three free-range domestic chickens were presented during a field
      investigation in one of the villages. The birds were observed to be emaciated,
      weak, showing nervous manifestations and moribund. RESULTS: Tissue extracts of
      liver, spleen and intestines were negative for Newcastle viral antigens, while
      cultures of liver and spleen biopsy were positive for Escherichia coli.
      Histopathological lesions were observed in the kidney, proventriculus and brain. 
      Concentrations of lead in the tissues ranged between 7.5 mg/kg and 120.5 mg/kg
      wet weight, and the potential daily intake of lead in the tissues were estimated 
      at 34.06-200.15 mug/day/kg body weight with an average of 118.37 mug/day/kg body 
      weight. CONCLUSIONS: The results of the present study suggest probable risk to
      human health due to the consumption of chicken contaminated by lead in the
      affected villages. Poisoning in animal populations may serve as a sentinel to
      assess the extent of environmental contamination and human health problems
      related to lead. ETHICS APPROVAL: Protocols were approved and performed in
      accordance with relevant local guidelines and regulations as set by the Animal
      Care and Use Committee of the National Veterinary Research Institute, Vom,
      Nigeria. COMPETING INTERESTS: The authors declare no competing financial
      interests.
CI  - (c) Pure Earth 2020.
FAU - Oladipo, Olusola O
AU  - Oladipo OO
AUID- ORCID: https://orcid.org/0000-0001-9498-1492
AD  - Biochemistry Division, National Veterinary Research Institute, Vom, Nigeria.
AD  - Department of Veterinary Physiology, Biochemistry and Pharmacology, University of
      Jos, Jos, Nigeria.
FAU - Akanbi, Olatunde B
AU  - Akanbi OB
AUID- ORCID: https://orcid.org/0000-0002-9583-5742
AD  - Department of Veterinary Pathology, University of Ilorin, Ilorin, Nigeria.
FAU - Ekong, Pius S
AU  - Ekong PS
AUID- ORCID: https://orcid.org/0000-0003-1936-9425
AD  - Central Diagnostics Division, National Veterinary Research Institute, Vom,
      Nigeria.
FAU - Uchendu, Chidiebere
AU  - Uchendu C
AUID- ORCID: https://orcid.org/0000-0002-8124-1118
AD  - Department of Veterinary Physiology, Biochemistry and Pharmacology, University of
      Jos, Jos, Nigeria.
FAU - Ajani, Oyetunji
AU  - Ajani O
AD  - Department of Veterinary and Pest Control Services, Federal Ministry of
      Agriculture & Rural Development, Abuja, Nigeria.
LA  - eng
PT  - Case Reports
DEP - 20200526
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7269320
OTO - NOTNLM
OT  - Nigeria
OT  - Zamfara
OT  - chickens
OT  - gold mining
OT  - lead
OT  - mining
OT  - toxicity
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.5696/2156-9614-10.26.200606 [doi]
PST - epublish
SO  - J Health Pollut. 2020 May 26;10(26):200606. doi: 10.5696/2156-9614-10.26.200606. 
      eCollection 2020 Jun.


PMID- 32509405
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2156-9614 (Electronic)
IS  - 2156-9614 (Linking)
VI  - 10
IP  - 26
DP  - 2020 Jun
TI  - Survey of Methylmercury Exposures and Risk Factors Among Indigenous Communities
      in Guyana, South America.
PG  - 200604
LID - 10.5696/2156-9614-10.26.200604 [doi]
AB  - BACKGROUND: Gold mining activities in forested areas across Guyana have been a
      common practice for more than a century. The intensification of artisanal and
      small-scale gold mining (ASGM) in recent decades caused by global market demand
      is contributing to the mobilization of mercury into aquatic systems. Indigenous
      populations who consume high levels of locally sourced fish are greater at risk
      for methylmercury poisoning from ingestion of contaminated fish. OBJECTIVES: The 
      aim of the present study was to investigate the levels of mercury contamination
      and identify the risk factors associated with hair mercury levels in four
      indigenous communities in Guyana. METHODS: Concentrations of total mercury were
      measured in hair samples from 99 participants from four indigenous communities in
      the south Rupununi region in Guyana. The findings of this study were compared
      with those of previous studies to assess the prevalence of mercury contamination 
      in indigenous communities across Guyana. RESULTS: Hair mercury levels were found 
      to be above the World Health Organization (WHO) reference value for residents who
      live close to ASGM activities and who consume high quantities of locally sourced 
      fish. Our results are not only consistent with those obtained in previous
      studies, but also evidence that mercury poisoning has become a generalized
      problem for indigenous communities in Guyana. CONCLUSIONS: Fish is the main
      source of protein for many riverine communities and consumption of
      mercury-contaminated fish poses a serious health hazard for these vulnerable
      populations. The situation is especially dire for community members of Parabara
      with 100% of participants showing elevated (>15 mug*g(-1)) hair mercury levels.
      It is therefore crucial that Parabara residents be evaluated by relevant health
      agencies for clinical symptoms related to mercury toxicity. PARTICIPANT CONSENT: 
      Obtained. ETHICS APPROVAL: The study protocol was approved by the Institutional
      Review Board of the Ministry of Public Health, Guyana. COMPETING INTERESTS: The
      authors declare no competing financial interests.
CI  - (c) Pure Earth 2020.
FAU - Watson, L Cynthia
AU  - Watson LC
AUID- ORCID: https://orcid.org/0000-0001-6189-1781
AD  - Watershed Hydrology and Ecology Research Division, Environment and Climate Change
      Canada, Burlington, Ontario, Canada.
FAU - Hurtado-Gonzales, Jorge L
AU  - Hurtado-Gonzales JL
AUID- ORCID: https://orcid.org/0000-0002-6486-2553
AD  - Sustainable Environments and Social Solutions, Ontario, Canada.
FAU - Chin, Christopher J
AU  - Chin CJ
AD  - Sustainable Environments and Social Solutions, Ontario, Canada.
FAU - Persaud, Juliana
AU  - Persaud J
AD  - World Wildlife Fund, Guianas, Guyana Office, Georgetown, Guyana.
LA  - eng
PT  - Journal Article
DEP - 20200504
PL  - United States
TA  - J Health Pollut
JT  - Journal of health & pollution
JID - 101690849
PMC - PMC7269323
OTO - NOTNLM
OT  - 2020
OT  - South America
OT  - artisanal and small-scale gold mining
OT  - indigenous people
OT  - toxicity
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.5696/2156-9614-10.26.200604 [doi]
PST - epublish
SO  - J Health Pollut. 2020 May 4;10(26):200604. doi: 10.5696/2156-9614-10.26.200604.
      eCollection 2020 Jun.


PMID- 32509322
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
DP  - 2020
TI  - A guided participation nursing intervention to theraupeutic positioning and care 
      (GP_Posit) for mothers of preterm infants: protocol of a pilot randomized
      controlled trial.
PG  - 77
LID - 10.1186/s40814-020-00601-5 [doi]
AB  - BACKGROUND: In the NICU, interventions intended to enhance maternal sensitivity
      are indicated in order to optimize preterm infant development and long-term
      mother-infant attachment. A novel nursing intervention was developed following a 
      theory-oriented methodology and is based upon the guided participation theory for
      mothers to participate in their preterm infant's therapeutic POSITioning and care
      (GP_Posit). The primary objective of this study is to evaluate the feasibility
      and acceptability of (i) the study design; and (ii) the experimental GP_Posit
      nursing intervention during NICU hospitalization. The secondary objective is to
      estimate the preliminary effects of GP_Posit on maternal and preterm infant
      outcomes. METHODS: A pilot parallel-group randomized clinical trial (RCT) was
      designed where mother-preterm infant dyads are being recruited and randomized to 
      a control group (usual care) or experimental group (GP_Posit intervention). Data 
      collection includes feasibility and acceptability data as well as preliminary
      effects on maternal sensitivity and infant neurodevelopment. Ethical approval
      from the University Hospital ethical board was obtained in January 2018
      (2017-1540). DISCUSSION: Data collection for this pilot study is expected to end 
      in 2020. Results of this pilot study will inform about the feasibility and
      acceptability of the study design and GP_Posit intervention, a nursing
      intervention having the potential to favor maternal sensitivity and infant
      neurodevelopment in the NICU and guide the elaboration of a large-scale RCT.
      TRIAL REGISTRATION: clinicaltrial.gov, NCT03677752. Registered 19 September 2018.
CI  - (c) The Author(s) 2020.
FAU - Lavallee, Andreane
AU  - Lavallee A
AD  - Faculty of Nursing, Universite de Montreal, Montreal, Canada.grid.14848.310000
      0001 2292 3357
AD  - CHU Sainte-Justine Research Centre, Montreal, Canada.grid.411418.90000 0001 2173 
      6322
FAU - Aita, Marilyn
AU  - Aita M
AD  - Faculty of Nursing, Universite de Montreal, Montreal, Canada.grid.14848.310000
      0001 2292 3357
AD  - CHU Sainte-Justine Research Centre, Montreal, Canada.grid.411418.90000 0001 2173 
      6322
AD  - Quebec Network on Nursing Intervention Research (RRISIQ), Quebec, Canada.
FAU - Cote, Jose
AU  - Cote J
AD  - Faculty of Nursing, Universite de Montreal, Montreal, Canada.grid.14848.310000
      0001 2292 3357
AD  - Quebec Network on Nursing Intervention Research (RRISIQ), Quebec, Canada.
AD  - Montreal University Health Center (CHUM) Research Center, Montreal,
      Canada.grid.14848.310000 0001 2292 3357
FAU - Bell, Linda
AU  - Bell L
AD  - Quebec Network on Nursing Intervention Research (RRISIQ), Quebec, Canada.
AD  - School of Nursing, Faculty of Medicine and Health Sciences, Univertise de
      Sherbrooke, Sherbrooke, Canada.grid.86715.3d0000 0000 9064 6198
FAU - Luu, Thuy Mai
AU  - Luu TM
AD  - CHU Sainte-Justine Research Centre, Montreal, Canada.grid.411418.90000 0001 2173 
      6322
AD  - Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada.grid.411418.90000 
      0001 2173 6322
AD  - Department of Pediatrics, Universite de Montreal, Montreal,
      Canada.grid.14848.310000 0001 2292 3357
LA  - eng
SI  - ClinicalTrials.gov/NCT03677752
PT  - Journal Article
DEP - 20200526
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
PMC - PMC7251724
OTO - NOTNLM
OT  - Guided participation
OT  - Maternal sensitivity
OT  - Neonatal intensive care unit
OT  - Neurodevelopment
OT  - Preterm
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.1186/s40814-020-00601-5 [doi]
AID - 601 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 May 26;6:77. doi: 10.1186/s40814-020-00601-5.
      eCollection 2020.


PMID- 32509282
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2047-2986 (Electronic)
IS  - 2047-2978 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jun
TI  - Seven pillars for ethics in digital diagnostic assistance among clinicians:
      Take-homes from a multi-stakeholder and multi-country workshop.
PG  - 010326
LID - 10.7189/jogh.10.010326 [doi]
FAU - Laflamme, Lucie
AU  - Laflamme L
AD  - Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
AD  - University of South Africa, Institute for Social and Health Sciences,
      Johannesburg, South Africa.
FAU - Wallis, Lee Alan
AU  - Wallis LA
AD  - Division of Emergency Medicine, Faculty of Medicine and Health Sciences,
      Stellenbosch University, Bellville, South Africa.
AD  - Division of Emergency Medicine, Faculty of Health Sciences, University of Cape
      Town, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - J Glob Health
JT  - Journal of global health
JID - 101578780
SB  - IM
MH  - Africa South of the Sahara
MH  - *Decision Support Systems, Clinical/ethics/standards
MH  - *Global Health
MH  - Health Personnel/standards
MH  - Humans
MH  - Internationality
MH  - *Inventions
MH  - Privacy
MH  - *Stakeholder Participation
PMC - PMC7244932
COIS- Competing interests: The authors completed the Unified Competing Interest form at
      www.icmje.org/coi_disclo-sure.pdf (available upon request from the corresponding 
      author), and declare no conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - 10.7189/jogh.10.010326 [doi]
AID - jogh-10-010326 [pii]
PST - ppublish
SO  - J Glob Health. 2020 Jun;10(1):010326. doi: 10.7189/jogh.10.010326.


PMID- 32508696
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - How CEO Ethical Leadership Influences Top Management Team Creativity: Evidence
      From China.
PG  - 748
LID - 10.3389/fpsyg.2020.00748 [doi]
AB  - The creative thinking and ability of top management team (TMT) members is
      important in coping with rapid changes in the external environment and improving 
      the competitive advantage of an organization. This research focuses on the
      CEO-TMT interface to explain how CEOs influence TMT characteristics, which in
      turn affects TMT outcomes. Based on social learning theory, this study examines
      the associations among CEO ethical leadership, TMT cohesion, and TMT creativity
      in a Chinese context using a total of 91 TMTs. To verify the reliability and
      validity of the constructs, a series of confirmatory factor analyses (CFAs) were 
      run. The results showed that the hypothetical model captured distinct constructs 
      and fits the data well. A multistep regression method was used to test
      hypotheses. The results indicated that: (a) CEO ethical leadership has a positive
      effect on TMT creativity; (b) TMT cohesion plays a mediating role in the
      relationship between CEO ethical leadership and TMT creativity; and (c) power
      distance plays a moderating role in the relationship between CEO ethical
      leadership and TMT creativity. The greater the power distance, the weaker the
      positive relationship between CEO ethical leadership and TMT creativity. This
      study demonstrates the value of CEO ethical leadership and advocates the
      importance of establishing team cohesion and building a psychologically safe
      environment to motivate top managers within an organization to share information 
      and knowledge to improve creativity.
CI  - Copyright (c) 2020 Zhao, Sun, Zhang and Zhu.
FAU - Zhao, Jinguo
AU  - Zhao J
AD  - School of Management, Qilu University of Technology (Shandong Academy of
      Sciences), Jinan, China.
FAU - Sun, Wei
AU  - Sun W
AD  - School of Management, Shandong University, Jinan, China.
FAU - Zhang, Shujie
AU  - Zhang S
AD  - School of Management, Shandong University, Jinan, China.
FAU - Zhu, Xiaohong
AU  - Zhu X
AD  - School of Management, Qilu University of Technology (Shandong Academy of
      Sciences), Jinan, China.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7253678
OTO - NOTNLM
OT  - CEO ethical leadership
OT  - TMT cohesion
OT  - TMT creativity
OT  - power distance
OT  - top management team
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.3389/fpsyg.2020.00748 [doi]
PST - epublish
SO  - Front Psychol. 2020 May 21;11:748. doi: 10.3389/fpsyg.2020.00748. eCollection
      2020.


PMID- 32508660
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - The High "Cost" of Experimental Drugs Obtained Through Health Litigation in
      Brazil.
PG  - 752
LID - 10.3389/fphar.2020.00752 [doi]
AB  - BACKGROUND: Brazilian patients have legal right to access unlicensed medicines
      undergoing clinical research, if there is evidence of efficacy and safety. This
      study investigated the occurrence of serious adverse events related to very
      high-cost medicines from clinical studies, expanded access and compassionate use 
      programs, obtained by patients though health litigation. METHODS: A descriptive
      study using secondary data investigated unlicensed medicines obtained through
      lawsuits from 2010 to 2017, costing more than 1 million Brazilian reais (BRL),
      adjusted by the Brazilian Consumer Index to July 2017. Data sources were the
      Brazilian Health Surveillance Agency Registry (DATAVISA) and Adverse Events in
      Clinical Studies (NotivisaEC) Databases. Medicines were categorized by the
      Anatomical Therapeutic Chemical classification to level 03 and events by the WHO 
      Adverse Drug Reaction Terminology. The study received ethical approval by the
      University of Brasilia Institutional Research Board. RESULTS: In the period, 812 
      drugs were obtained through litigation, and of these, 78 exceeded cost of 1
      million BRL; 44 of them presented reports of 1,248 serious adverse events. Total 
      Brazilian Government expenditure with these drugs was 3.2 billion BRL. Class L04A
      (n=7) showed greater expenditures (over 1.8 billion BRL). One hundred ninety-six 
      deaths occurred and L01X was the most involved category (49.5%). Most other
      serious events (n=419) and sequelae (n=10) were related to L01X. CONCLUSION: Very
      high-cost drugs paid for by the government and obtained through health litigation
      presented deaths and serious adverse events in expanded access and compassionate 
      use programs in Brazil.
CI  - Copyright (c) 2020 Silva, Lima, Novaes and Osorio-de-Castro.
FAU - da Silva, Ricardo Eccard
AU  - da Silva RE
AD  - Office of Clinical Trials, Brazilian Health Regulatory Agency (Anvisa), Brasilia,
      Brazil.
FAU - Lima, Elisangela da Costa
AU  - Lima EDC
AD  - School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Novaes, Maria Rita C G
AU  - Novaes MRCG
AD  - Faculty of Health Sciences, University of Brasilia, Brasilia, Brazil.
AD  - School of Medicine, Health Sciences Education and Research Foundation, Brasilia, 
      Brazil.
FAU - Osorio-de-Castro, Claudia G S
AU  - Osorio-de-Castro CGS
AD  - Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de
      Janeiro, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7248274
OTO - NOTNLM
OT  - adverse drug event
OT  - clinical trials
OT  - compassionate use
OT  - expanded access
OT  - litigation
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2020/01/28 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.3389/fphar.2020.00752 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 May 19;11:752. doi: 10.3389/fphar.2020.00752. eCollection
      2020.


PMID- 32508404
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 0971-7196 (Print)
IS  - 0971-7196 (Linking)
VI  - 44
IP  - 2
DP  - 2020 Jun
TI  - Comparison of camel, dog and the laboratory animals' sera with the fetal calf
      serum (FCS) for cultivation of Leishmania major.
PG  - 299-304
LID - 10.1007/s12639-020-01203-x [doi]
AB  - The best-known serum for Leishmania spp. cultivation is the fetal calf serum
      (FCS), which is very expensive with ethical concerns. This study was conducted to
      compare various laboratory (BALB/c mice, rat, rabbit, hamster and guinea pig) and
      non-laboratory (dog and camel) animals' sera as a substitute for FCS in L. major 
      culture. L. major, MRHO/IR/75/ER strain, was cultivated in RPMI-1640 medium
      enriched with different percentages of mentioned animal's sera. Parasite growth
      was checked constantly. The rate of growth and survival of parasites were
      compared with a control medium enriched with FCS. As well, biochemical (albumin, 
      globulin AST, ALT, ALP, Bil, BUN, Crea, Ca, P, Na, K, Fe, TIBC, Mg, zinc, Chol,
      HDL, LDL, TG, BS, uric acid, LDH, CPK) analysis of all sera was performed and
      compared with FCS. The most promastigote growth rate is considered in 10% BALB/c,
      guinea pig and hamster sera on the 6th day of cultivation. Also, on the 8th day, 
      parasites showed viability in all animal sera. The promastigote growth in culture
      media enriched with the camel and the dog sera in comparison with laboratory
      animals was considered very low. Differences between 10% FCS and 10% cocktail
      serum were not significant (p > 0.05) but with other sera were significant (p <
      0.05). Also, differences between BALB/c with hamster and guinea pig sera were not
      significant, respectively (p = 0.07 and p = 0.09). According to the biochemical
      analysis of all sera, the higher content of iron was detected in the hamster,
      guinea pig, BALB/c and fetal calf sera. The magnesium and zinc content of guinea 
      pig and BALB/c serum was found to be more than the others and comparable with
      FCS. The promastigote growth decreased by camel, dog and rat sera orderly. In
      this study, a rapid increase in parasite growth in media supplemented with
      hamster, BALB/c and guinea pig sera was considered. It could be suggested to use 
      these sera as a suitable alternative for FCS in molecular biology researches.
CI  - (c) Indian Society for Parasitology 2020.
FAU - Esfandiari, Frideh
AU  - Esfandiari F
AD  - Department of Parasitology and Mycology, School of Medicine, Shiraz University of
      Medical Sciences, Shiraz, Iran.grid.412571.40000 0000 8819 4698
FAU - Derakhshanfar, Amin
AU  - Derakhshanfar A
AD  - Diagnostic Laboratory Sciences and Technology Research Center, School of
      Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz,
      Iran.grid.412571.40000 0000 8819 4698
AD  - Center of Comparative and Experimental Medicine, Shiraz University of Medical
      Sciences, Shiraz, Iran.grid.412571.40000 0000 8819 4698
FAU - Goudarzi, Fatemeh
AU  - Goudarzi F
AD  - Department of Parasitology and Mycology, School of Medicine, Shiraz University of
      Medical Sciences, Shiraz, Iran.grid.412571.40000 0000 8819 4698
FAU - Hatam, Gholamreza
AU  - Hatam G
AD  - Basic Sciences in Infectious Diseases Research Center, Shiraz University of
      Medical Sciences, Shiraz, Iran.grid.412571.40000 0000 8819 4698
LA  - eng
PT  - Journal Article
DEP - 20200208
PL  - India
TA  - J Parasit Dis
JT  - Journal of parasitic diseases : official organ of the Indian Society for
      Parasitology
JID - 9713059
PMC - PMC7244685
OTO - NOTNLM
OT  - Fetal calf serum
OT  - Laboratory animals
OT  - Leishmania major
COIS- Conflict of interestThe authors declared that there is no any conflict of
      interest.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/09 06:00
PHST- 2019/05/11 00:00 [received]
PHST- 2020/01/30 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - 10.1007/s12639-020-01203-x [doi]
AID - 1203 [pii]
PST - ppublish
SO  - J Parasit Dis. 2020 Jun;44(2):299-304. doi: 10.1007/s12639-020-01203-x. Epub 2020
      Feb 8.


PMID- 32508089
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
VI  - 92
IP  - 12
DP  - 2020 Jun 16
TI  - Cognitive and Human Factors in Expert Decision Making: Six Fallacies and the
      Eight Sources of Bias.
PG  - 7998-8004
LID - 10.1021/acs.analchem.0c00704 [doi]
AB  - Fallacies about the nature of biases have shadowed a proper cognitive
      understanding of biases and their sources, which in turn lead to ways that
      minimize their impact. Six such fallacies are presented: it is an ethical issue, 
      only applies to "bad apples", experts are impartial and immune, technology
      eliminates bias, blind spot, and the illusion of control. Then, eight sources of 
      bias are discussed and conceptualized within three categories: (A) factors that
      relate to the specific case and analysis, which include the data, reference
      materials, and contextual information, (B) factors that relate to the specific
      person doing the analysis, which include past experience base rates,
      organizational factors, education and training, and personal factors, and lastly,
      (C) cognitive architecture and human nature that impacts all of us. These factors
      can impact what the data are (e.g., how data are sampled and collected, or what
      is considered as noise and therefore disregarded), the actual results (e.g.,
      decisions on testing strategies, how analysis is conducted, and when to stop
      testing), and the conclusions (e.g., interpretation of the results). The paper
      concludes with specific measures that can minimize these biases.
FAU - Dror, Itiel E
AU  - Dror IE
AUID- ORCID: 0000-0003-4866-209X
AD  - University College London (UCL), London WC1H 9EZ, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200608
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
SB  - IM
CIN - Anal Chem. 2020 Sep 15;92(18):12727-12728. PMID: 32790272
CIN - Anal Chem. 2020 Sep 15;92(18):12725-12726. PMID: 32790279
MH  - Bias
MH  - Cognition
MH  - *Decision Making
MH  - Humans
EDAT- 2020/06/09 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1021/acs.analchem.0c00704 [doi]
PST - ppublish
SO  - Anal Chem. 2020 Jun 16;92(12):7998-8004. doi: 10.1021/acs.analchem.0c00704. Epub 
      2020 Jun 8.


PMID- 32507592
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20210806
IS  - 1933-2874 (Print)
IS  - 1876-4789 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Jul - Aug
TI  - Genetic testing in dyslipidemia: A scientific statement from the National Lipid
      Association.
PG  - 398-413
LID - S1933-2874(20)30081-7 [pii]
LID - 10.1016/j.jacl.2020.04.011 [doi]
AB  - The genetic basis for more than 2 dozen monogenic dyslipidemias has largely been 
      defined. Genetic technologies, such as DNA sequencing, can detect both rare and
      common DNA variants underlying dyslipidemias, and these methods are increasingly 
      available. Although patients with extreme abnormalities in low-density
      lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol
      may be considered for genetic testing, it is only in a minority of patients that 
      the results will alter treatment or outcomes. Currently, there is potential
      clinical utility of genetic testing for familial hypercholesterolemia, familial
      chylomicronemia syndrome, sitosterolemia, lysosomal acid lipase deficiency, and a
      few other rare disorders, and this will increase the demand for reliable genetic 
      diagnostic methods at lower cost. Clinical indications for genetic testing for
      most dyslipidemias are not clearly established and currently no guidelines exist.
      A shared decision-making model between the patient and the provider is essential 
      as patient values and preferences play a very strong role. Potential benefits of 
      genetic testing include providing a firm diagnosis in many cases, guiding optimal
      management and prevention strategies, advancing care strategies beyond currently 
      available treatments, and contributing to overall scientific progress.
      Understanding the limitations and risks of genetic testing techniques is also
      important, as is careful interpretation of genetic test results to achieve the
      greatest benefit. Here we review laboratory methods, as well as technical,
      biological, clinical, and ethical implications and applications of genetic
      testing in dyslipidemias.
CI  - Copyright (c) 2020 National Lipid Association. Published by Elsevier Inc. All
      rights reserved.
FAU - Brown, Emily E
AU  - Brown EE
AD  - Genetic Counselor, Center for Inherited Heart Disease, Johns Hopkins University, 
      Baltimore, MD, USA.
FAU - Sturm, Amy C
AU  - Sturm AC
AD  - Professor, Genomic Medicine Institute, Geisinger, Danville, PA, USA.
FAU - Cuchel, Marina
AU  - Cuchel M
AD  - Research Associate Professor of Medicine, Division of Translational Medicine and 
      Human Genetics, Department of Medicine, Perelman School of Medicine, University
      of Pennsylvania, Philadelphia, PA, USA.
FAU - Braun, Lynne T
AU  - Braun LT
AD  - Professor Emerita, Department of Adult Health and Gerentologic Nursing, College
      of Nursing, Rush University, Chicago, IL, USA.
FAU - Duell, P Barton
AU  - Duell PB
AD  - Professor of Medicine, Director, Lipid-Atherosclerosis Laboratory and Sterol
      Analysis Laboratory Department of Medicine, Knight Cardiovascular Institute and
      Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and
      Science University, Portland, OR, USA.
FAU - Underberg, James A
AU  - Underberg JA
AD  - Clinical Assistant Professor of Medicine, NYU School of Medicine, New York, NY,
      USA.
FAU - Jacobson, Terry A
AU  - Jacobson TA
AD  - Director, Lipid Clinic and Cardiovascular Risk Reduction Program, Emory
      University, Atlanta, GA, USA.
FAU - Hegele, Robert A
AU  - Hegele RA
AD  - Professor of Medicine and Biochemistry, Department of Medicine and Robarts
      Research Institute, Schulich School of Medicine and Dentistry, Western
      University, London, Ontario, Canada. Electronic address: hegele@robarts.ca.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - United States
TA  - J Clin Lipidol
JT  - Journal of clinical lipidology
JID - 101300157
SB  - IM
MH  - Decision Making
MH  - Dyslipidemias/*diagnosis/*genetics
MH  - *Genetic Testing
MH  - Humans
MH  - Risk
MH  - *Societies, Scientific
OTO - NOTNLM
OT  - *DNA sequencing
OT  - *Genetic counseling
OT  - *Hyperlipidemia
OT  - *Hypolipidemia
OT  - *Monogenic
OT  - *Polygenic
EDAT- 2020/06/09 06:00
MHDA- 2021/08/07 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - S1933-2874(20)30081-7 [pii]
AID - 10.1016/j.jacl.2020.04.011 [doi]
PST - ppublish
SO  - J Clin Lipidol. 2020 Jul - Aug;14(4):398-413. doi: 10.1016/j.jacl.2020.04.011.
      Epub 2020 May 7.


PMID- 32507382
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 59
IP  - 4
DP  - 2020 Aug
TI  - (Thewithdrawal of consent to haematopoietic stem cells (HSC) donation: The
      complicated balance between donor's rights and patient's protection).
PG  - 102813
LID - S1473-0502(20)30108-7 [pii]
LID - 10.1016/j.transci.2020.102813 [doi]
AB  - Hematopoietic stem cells donation is an essential prerequisite of allogeneic
      transplantation. Both family donors and matched unrelated donors should have a
      conscious involvement in every phase of the overall path, from selection to HSC
      collection. Donors also should be informed about the right to withdraw at any
      time as well as the extreme risk for recipient's life coming from the decision of
      interrupting, if the donation is not carried out once the patient's preparative
      regimen has commenced. We report our challenging experience about a donor who
      withdraws her consent to HSC donation after 3 days of mobilization with G-CSF.
      The possibility of withdrawal protects the donor but it also puts at risk both a 
      chance for a transplant and the patient's life if preparative regimen has
      started. Can the donor really be free to withdraw the consent to HSC donation at 
      any time even when this endangers the life of a recipient? Is this ethical?
      However, if the donor decides to withdraw, would we really be ready to manage
      promptly all the consequences coming from the consent revocation? At the moment
      there is not a well-defined "plan B" in case of impossibility to proceed with the
      transplant when conditioning has already started or has even been completed. In
      our opinion, because of this hard balance and such a high risk, it would be
      necessary to plan every time an alternative strategy which may be different
      according to different circumstances.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Iuliani, O
AU  - Iuliani O
AD  - Blood Transfusion Service, Spirito Santo Hospital, via Fonte Romana 8 - 65125,
      Pescara, Italy. Electronic address: ornella.iuliani@ausl.pe.it.
FAU - Passeri, C
AU  - Passeri C
AD  - Blood Transfusion Service, Spirito Santo Hospital, via Fonte Romana 8 - 65125,
      Pescara, Italy.
FAU - Papola, F
AU  - Papola F
AD  - Regional Centre of Immunohaematology and Tissue Typing, S.Salvatore Hospital of
      L'Aquila, L'Aquila, Italy.
FAU - Accorsi, P
AU  - Accorsi P
AD  - Blood Transfusion Service, Spirito Santo Hospital, via Fonte Romana 8 - 65125,
      Pescara, Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200516
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
MH  - Adult
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*ethics
MH  - Humans
MH  - Informed Consent/ethics
MH  - Tissue Donors/*ethics
MH  - Transplantation Conditioning/*ethics
MH  - Young Adult
OTO - NOTNLM
OT  - Consent to HSC donation
OT  - HSC donation
OT  - Hematopoietic stem cells
OT  - Withdrawal of consent
EDAT- 2020/06/09 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - S1473-0502(20)30108-7 [pii]
AID - 10.1016/j.transci.2020.102813 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2020 Aug;59(4):102813. doi: 10.1016/j.transci.2020.102813.
      Epub 2020 May 16.


PMID- 32507108
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2054-9369 (Electronic)
IS  - 2054-9369 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jun 7
TI  - Incidence and risk factors associated with injuries during static line parachute 
      training in Royal Thai Army.
PG  - 27
LID - 10.1186/s40779-020-00252-w [doi]
AB  - BACKGROUND: Incidence and risk factors of parachute injuries has been studied in 
      developed countries, but not in trainees of the airborne forces in the Royal
      Thailand Army. METHODS: A prospective cohort study was conducted among 992
      military personnel who attended the basic airborne training program from February
      to July 2018. Information sheets were used to collect data about (a) personal
      demographics; (b) environmental conditions surrounding the parachute practice;
      and (c) parachute-related injuries. The incidence rate of injury was then
      calculated. Risk factors were examined using multilevel Poisson regression
      analysis and presented as incidence rate ratio (IRR) and 95% confidence interval 
      (95% CI). RESULTS: A total of 166 parachute-related injuries occurred in 4677
      jumps. The incidence rate of injury was 35.50 per 1000 jumps (95%CI:
      30.04-41.21). Factors significantly related to parachute injury included: jumping
      with equipment versus without equipment [adjusted IRR (95% CI): 1.28
      (0.88-1.87)], higher wind speed [1.54 (1.27-1.87) per knot], airplane versus
      helicopter exit [1.75(0.68-4.55)], side versus rear exit [2.13 (1.43-3.23)],
      night versus day jumping [2.19 (0.81-5.90)], and presence of motion sickness
      [3.43 (1.93-6.92)]. CONCLUSIONS: To prevent military static line parachute
      injuries, the following factors should be taken into consideration: type of
      aircraft, aircraft exit, time of the day, equipment, motion sickness and wind
      speed. TRIAL REGISTRATION: The project was certified by the Research Ethics
      Committee, Faculty of Medicine, Chulalongkorn University (IRB No. 697/60).
FAU - Maneechaeye, Watcharaphat
AU  - Maneechaeye W
AUID- ORCID: 0000-0002-5811-7020
AD  - Armed Forces Research Institute of Medical Sciences, Royal Thai Army Medical
      Department, Bangkok, 10400, Thailand. watcharaphat89@gmail.com.
FAU - Deepreecha, Kathawoot
AU  - Deepreecha K
AD  - Health Promotion and Preventive Medicine Division, Royal Thai Army Medical
      Department, Bangkok, 10400, Thailand.
FAU - Jiamjarasrangsi, Wiroj
AU  - Jiamjarasrangsi W
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Chulalongkorn 
      University, Bangkok, 10330, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20200607
PL  - England
TA  - Mil Med Res
JT  - Military Medical Research
JID - 101643181
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aviation/methods/*standards/statistics & numerical data
MH  - Cohort Studies
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Military Personnel/education/*statistics & numerical data
MH  - Prospective Studies
MH  - Risk Factors
MH  - Teaching/statistics & numerical data
MH  - Thailand/epidemiology
MH  - Wounds and Injuries/epidemiology/*etiology
PMC - PMC7278130
OTO - NOTNLM
OT  - *Injuries
OT  - *Parachute
OT  - *Paratroopers
EDAT- 2020/06/09 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/06/09 06:00
PHST- 2019/07/09 00:00 [received]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - 10.1186/s40779-020-00252-w [doi]
AID - 10.1186/s40779-020-00252-w [pii]
PST - epublish
SO  - Mil Med Res. 2020 Jun 7;7(1):27. doi: 10.1186/s40779-020-00252-w.


PMID- 32506970
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Aug
TI  - Awareness of predatory publishing for Peruvian university professors and
      lecturers doing research.
PG  - 390-395
LID - 10.1080/08989621.2020.1775592 [doi]
AB  - Predatory open access journals and predatory conferences' main purpose is to make
      profit rather than promoting good science. In Peru, the University Law 30220 asks
      that professors and lecturers undertake research duties at universities. Hence,
      nowadays part of this academic staff is required to write scientific articles.
      However, not all of them are experienced on how to write a scholarly paper. Thus,
      in the rush to comply with the publication requirements that their individual
      institutions demand from them, a great number of these professors and lecturers
      are likely to fall prey of predatory publishing, which already is happening in
      other developing nations. This publishing method is not only unethical because it
      produces low-quality articles but also is an egregious mismanagement of the
      resources that universities allocate to fund research. Moreover, the time and
      effort that the academic staff put to the production of low-quality papers also
      completely go to waste. Professors and lecturers who follow these bad practices
      should be penalized; this also avoids the emergence of fraudulent research
      authorities. Thus, vice-rectorates for research in Peruvian universities should
      take corrective or preventive measures to promote the production of high-quality 
      papers by part of their academic staff.
FAU - Sotomayor-Beltran, Carlos
AU  - Sotomayor-Beltran C
AUID- ORCID: 0000-0001-6096-9225
AD  - Facultad de Ciencias e Ingenieria, Universidad de Ciencias y Humanidades , Lima, 
      Peru.
LA  - eng
PT  - Journal Article
DEP - 20200606
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Authorship/standards
MH  - Faculty/*psychology/standards
MH  - Humans
MH  - Peer Review, Research/*standards
MH  - Peru
MH  - Publishing/*organization & administration/standards
MH  - Scientific Misconduct/*psychology
MH  - Universities/*organization & administration/standards
OTO - NOTNLM
OT  - *Predatory publishing
OT  - *fraudulent researchers
OT  - *low quality papers
OT  - *measures
OT  - *professors and lecturers
OT  - *research ethics
EDAT- 2020/06/09 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 10.1080/08989621.2020.1775592 [doi]
PST - ppublish
SO  - Account Res. 2020 Aug;27(6):390-395. doi: 10.1080/08989621.2020.1775592. Epub
      2020 Jun 6.


PMID- 32506618
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 12
DP  - 2020 Dec
TI  - Impact of the elimination of the donation service area on United States lung
      transplant practices and outcomes at high and low competition centers.
PG  - 3631-3638
LID - 10.1111/ajt.16098 [doi]
AB  - In November 2017, the donation service area (DSA) was removed as the primary unit
      of US donor lung allocation. Our primary objective was to evaluate the effect of 
      this change on recipient characteristics, the use of pretransplant extracorporeal
      membrane oxygenation (ECMO), and on index hospitalization length of stay (LOS)
      and early posttransplant complications. We also assessed whether these outcomes
      differed in high and low competition centers, as defined by the
      Herfindahl-Hirschman Index. Following DSA removal, there was a 9-day decrease in 
      median waitlist time (P = .001) and an increase in median lung allocation score
      (40 vs 42, P < .0001) but no difference in the need for pretransplant ECMO
      (incidence rate ratio = 1.16, P = .12). Median LOS increased from 17 to 19 days
      in the post-DSA era (P = .01). There was no difference in posttransplant
      outcomes, including prolonged ventilation, new dialysis, or early survival, in
      the general cohort or between competition groups. High competition centers saw an
      18.5-minute increase in ischemic time compared to low competition centers (P =
      .04) but did not differentially increase single lung transplants or pretransplant
      ECMO utilization. Overall, DSA elimination was associated with increased
      posttransplant LOS but no significant differences in pretransplant ECMO or other 
      posttransplant outcomes. Effects were largely similar at low and high competition
      centers.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Drolen, Claire
AU  - Drolen C
AUID- ORCID: 0000-0002-8813-7751
AD  - Division of Pulmonary and Critical Care, Hospital of the University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Cantu, Edward
AU  - Cantu E
AD  - Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania,
      USA.
FAU - Goldberg, Hilary J
AU  - Goldberg HJ
AD  - Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boson,
      Massachusetts, USA.
FAU - Diamond, Joshua M
AU  - Diamond JM
AD  - Division of Pulmonary and Critical Care, Hospital of the University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Courtwright, Andrew
AU  - Courtwright A
AUID- ORCID: 0000-0001-9511-5975
AD  - Division of Pulmonary and Critical Care, Hospital of the University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20200628
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - Length of Stay
MH  - *Lung Transplantation
MH  - Retrospective Studies
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
MH  - United States
MH  - Waiting Lists
OTO - NOTNLM
OT  - *Organ Procurement and Transplantation Network (OPTN)
OT  - *Scientific Registry for Transplant Recipients (SRTR)
OT  - *clinical research/practice
OT  - *disparities
OT  - *ethics and public policy
OT  - *lung disease
OT  - *lung transplantation/pulmonology
OT  - *organ allocation
OT  - *organ procurement and allocation
EDAT- 2020/06/09 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - 10.1111/ajt.16098 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Dec;20(12):3631-3638. doi: 10.1111/ajt.16098. Epub 2020 Jun
      28.


PMID- 32506548
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20220716
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 33
IP  - 4
DP  - 2020 Jul
TI  - Teledermatology during COVID-19 pandemic: Ethical and legal considerations about 
      the principles of treatment prescription and privacy.
PG  - e13781
LID - 10.1111/dth.13781 [doi]
FAU - Elmas, Omer Faruk
AU  - Elmas OF
AD  - Department of Dermatology, Kirsehir Ahi Evran University, Kirsehir, Turkey.
FAU - Demirbas, Abdullah
AU  - Demirbas A
AUID- ORCID: https://orcid.org/0000-0002-3419-9084
AD  - Department of Dermatology, Konya Numune Hospital, Konya, Turkey.
FAU - Atasoy, Mustafa
AU  - Atasoy M
AD  - Department of Dermatology, Health Science University, Kayseri City Hospital,
      Kayseri, Turkey.
FAU - Tursen, Umit
AU  - Tursen U
AUID- ORCID: https://orcid.org/0000-0002-5807-6759
AD  - Department of Dermatology, Mersin University, Mersin, Turkey.
FAU - Lotti, Torello
AU  - Lotti T
AUID- ORCID: https://orcid.org/0000-0003-0840-1936
AD  - Department of Dermatology, Guglielmo Marconi University, Rome, Italy.
LA  - eng
PT  - Letter
DEP - 20200702
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - Coronavirus Infections/*epidemiology
MH  - Dermatology/*legislation & jurisprudence
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Privacy/*legislation & jurisprudence
MH  - SARS-CoV-2
MH  - Skin Diseases/*epidemiology
MH  - Telemedicine/*ethics
PMC - PMC7300501
EDAT- 2020/06/09 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - 10.1111/dth.13781 [doi]
PST - ppublish
SO  - Dermatol Ther. 2020 Jul;33(4):e13781. doi: 10.1111/dth.13781. Epub 2020 Jul 2.


PMID- 32506437
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20220716
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 50
IP  - 7
DP  - 2020 Jul
TI  - The changing face of family medicine in the COVID and post-COVID era.
PG  - e13303
LID - 10.1111/eci.13303 [doi]
AB  - This article describes the prospective changes and the fundamental values of the 
      relationships between family doctors, patients and community according to an
      ethical-social concept of medicine. New aspects of the organization of the
      activity and of the roles of family doctors are reported in order to build
      hypotheses pointing to a modern and efficient management of patients in the
      coming the post-COVID era.
CI  - (c) 2020 Stichting European Society for Clinical Investigation Journal
      Foundation.
FAU - Grattagliano, Ignazio
AU  - Grattagliano I
AUID- ORCID: https://orcid.org/0000-0002-8991-4313
AD  - Italian College of General Practitioners and Primary Care, Florence, Italy.
AD  - Family Medicine, English Medical Curriculum, University of Bari, Bari, Italy.
FAU - Rossi, Alessandro
AU  - Rossi A
AD  - Italian College of General Practitioners and Primary Care, Florence, Italy.
FAU - Cricelli, Iacopo
AU  - Cricelli I
AD  - Health Search, Italian College of General Practitioners and Primary Care,
      Florence, Italy.
FAU - Cricelli, Claudio
AU  - Cricelli C
AD  - Italian College of General Practitioners and Primary Care, Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
SB  - IM
MH  - COVID-19
MH  - *Community-Institutional Relations
MH  - Delivery of Health Care
MH  - Family Practice/methods/*organization & administration
MH  - Humans
MH  - Italy
MH  - *Physician's Role
MH  - *Physician-Patient Relations
MH  - SARS-CoV-2
MH  - Therapies, Investigational
PMC - PMC7300567
OTO - NOTNLM
OT  - COVID
OT  - family medicine
EDAT- 2020/06/09 06:00
MHDA- 2021/09/03 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/24 00:00 [revised]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - 10.1111/eci.13303 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2020 Jul;50(7):e13303. doi: 10.1111/eci.13303. Epub 2020 Jul
      7.


PMID- 32505982
OWN - NLM
STAT- MEDLINE
DCOM- 20210812
LR  - 20210812
IS  - 1873-7811 (Electronic)
IS  - 0272-7358 (Linking)
VI  - 79
DP  - 2020 Jul
TI  - Moderators of psychological and psychoeducational interventions for the
      prevention of depression: A systematic review.
PG  - 101859
LID - S0272-7358(20)30047-7 [pii]
LID - 10.1016/j.cpr.2020.101859 [doi]
AB  - Psychological and psychoeducational interventions have proven to be effective in 
      preventing depression. However, the identification of the patients that benefit
      the most from each type of intervention has not yet been established. A
      systematic review was performed of the literature on moderators of preventive
      psychological and psychoeducational interventions for depression in all types of 
      population. A search was performed on PubMed, PsycINFO, Web of Science, Embase,
      Cochrane Central Register of Controlled Trials and OpenGrey up to July 2019.
      Fulfillment of eligibility criteria, data collection, and study quality
      assessment were assessed by two independent researchers. Outcomes were moderators
      of the reduction of depressive symptoms or the incidence of depression.
      Twenty-seven moderator effect studies performed in 19 randomized controlled
      trials were included. Thirty-four potential sociodemographic, clinical,
      interpersonal, personality and life-event moderators were evaluated. Baseline
      depressive symptoms, gender, age, baseline parental depression and social support
      were the most frequently studied potential moderators. In interventions for
      children and adolescents, the moderator for which evidence was strongest was
      having parents free of depression at baseline. Psychological and
      psychoeducational interventions seem to be more effective in children and
      adolescents who exhibit a lower use of substances and whose parents do not have
      symptoms of depression at baseline. In adults, a lower age was associated with
      greater effects of preventive interventions. ETHICS: As this systematic review is
      based on published data, approval from the local ethics committee was not
      required.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Conejo-Ceron, Sonia
AU  - Conejo-Ceron S
AD  - Biomedical Research Institute of Malaga (IBIMA), C/ Sevilla 23, 29009 Malaga,
      Spain; Prevention and Health Promotion Research Network (redIAPP), ISCIII, Gran
      Via de les Corts Catalanes, 587, 08007 Barcelona, Spain. Electronic address:
      soniafundacionimabis@hotmail.com.
FAU - Bellon, Juan Angel
AU  - Bellon JA
AD  - Biomedical Research Institute of Malaga (IBIMA), C/ Sevilla 23, 29009 Malaga,
      Spain; Prevention and Health Promotion Research Network (redIAPP), ISCIII, Gran
      Via de les Corts Catalanes, 587, 08007 Barcelona, Spain; 'El Palo' Health Centre,
      Health District of Primary Care Malaga-Guadalhorce, SAS, Av. Salvador Allende,
      159, 29018 Malaga, Spain; Department of Public Health and Psychiatry, University 
      of Malaga, Bulevar Louis Pasteur, 32, 29010 Malaga, Spain.
FAU - Motrico, Emma
AU  - Motrico E
AD  - Department of Psychology, University Loyola Andalucia, Seville, Spain.
FAU - Campos-Paino, Henar
AU  - Campos-Paino H
AD  - Biomedical Research Institute of Malaga (IBIMA), C/ Sevilla 23, 29009 Malaga,
      Spain; Prevention and Health Promotion Research Network (redIAPP), ISCIII, Gran
      Via de les Corts Catalanes, 587, 08007 Barcelona, Spain.
FAU - Martin-Gomez, Carmen
AU  - Martin-Gomez C
AD  - Department of Psychology, University Loyola Andalucia, Seville, Spain.
FAU - Ebert, David D
AU  - Ebert DD
AD  - Department of Clinical Psychology and Psychotherapy, Friedrich-Alexander
      University Erlangen Nuremberg, Erlangen, Germany.
FAU - Buntrock, Claudia
AU  - Buntrock C
AD  - Department of Clinical Psychology and Psychotherapy, Friedrich-Alexander
      University Erlangen Nuremberg, Erlangen, Germany.
FAU - Gili, Margalida
AU  - Gili M
AD  - Institut Universitari d'Investigacio en Ciencies de la Salut (IUNICS-IDISPA),
      University of Balearic Islands, Carretera de Valldemossa, 07122 Palma, Illes
      Balears, Spain; Prevention and Health Promotion Research Network (redIAPP),
      ISCIII, Gran Via de les Corts Catalanes, 587, 08007 Barcelona, Spain.
FAU - Moreno-Peral, Patricia
AU  - Moreno-Peral P
AD  - Biomedical Research Institute of Malaga (IBIMA), C/ Sevilla 23, 29009 Malaga,
      Spain; Prevention and Health Promotion Research Network (redIAPP), ISCIII, Gran
      Via de les Corts Catalanes, 587, 08007 Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200511
PL  - United States
TA  - Clin Psychol Rev
JT  - Clinical psychology review
JID - 8111117
SB  - IM
MH  - Depressive Disorder/*prevention & control
MH  - Effect Modifier, Epidemiologic
MH  - Humans
MH  - *Outcome Assessment, Health Care/statistics & numerical data
MH  - *Psychotherapy/statistics & numerical data
OTO - NOTNLM
OT  - *Depression
OT  - *Moderator
OT  - *Prevention
OT  - *Systematic review
COIS- Declaration of Competing Interest The authors all declare that they have no
      conflicts of interest.
EDAT- 2020/06/09 06:00
MHDA- 2021/08/13 06:00
CRDT- 2020/06/08 06:00
PHST- 2019/08/29 00:00 [received]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/08/13 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - S0272-7358(20)30047-7 [pii]
AID - 10.1016/j.cpr.2020.101859 [doi]
PST - ppublish
SO  - Clin Psychol Rev. 2020 Jul;79:101859. doi: 10.1016/j.cpr.2020.101859. Epub 2020
      May 11.


PMID- 32505633
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20210110
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 36
IP  - 8
DP  - 2020 Aug
TI  - Guiding Cardiac Care During the COVID-19 Pandemic: How Ethics Shapes Our Health
      System Response.
PG  - 1313-1316
LID - S0828-282X(20)30520-1 [pii]
LID - 10.1016/j.cjca.2020.06.002 [doi]
AB  - The COVID-19 pandemic has raised ethical questions for the cardiovascular leader 
      and practitioner. Attention has been redirected from a system that focuses on
      individual patient benefit toward one that focuses on protecting society as a
      whole. Challenging resource allocation questions highlight the need for a clearly
      articulated ethics framework that integrates principled decision making into how 
      different cardiovascular care services are prioritized. A practical application
      of the principles of harm minimisation, fairness, proportionality, respect,
      reciprocity, flexibility, and procedural justice is provided, and a model for
      prioritisation of the restoration of cardiovascular services is outlined. The
      prioritisation model may be used to determine how and when cardiovascular
      services should be continued or restored. There should be a focus on an iterative
      and responsive approach to broader health care system needs, such as other
      disease groups and local outbreaks.
CI  - Copyright (c) 2020 Canadian Cardiovascular Society. Published by Elsevier Inc.
      All rights reserved.
FAU - Virani, Alice
AU  - Virani A
AD  - Department of Medical Genetics, University of British Columbia, British Columbia,
      Canada. Electronic address: alice.virani@phsa.ca.
FAU - Singh, Gurmeet
AU  - Singh G
AD  - Mazankowski Alberta Hearth Institute, Division of Cardiac Surgery, Departments of
      Critical Care Medicine and Surgery, University of Alberta, Edmonton, Alberta,
      Canada.
FAU - Bewick, David
AU  - Bewick D
AD  - New Brunswick Heart Centre, Saint John, New Brunswick, Canada.
FAU - Chow, Chi-Ming
AU  - Chow CM
AD  - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Clarke, Brian
AU  - Clarke B
AD  - Libin Cardiovascular Institute, Department of Cardiac Sciences, University of
      Calgary, Calgary, Alberta, Canada.
FAU - Cowan, Simone
AU  - Cowan S
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Fordyce, Christopher B
AU  - Fordyce CB
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Fournier, Anne
AU  - Fournier A
AD  - Centre Hospitalier Universitaire Sainte-Justine, Universite de Montreal,
      Montreal, Quebec, Canada.
FAU - Gin, Kenneth
AU  - Gin K
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Gupta, Anil
AU  - Gupta A
AD  - Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.
FAU - Hardiman, Sean
AU  - Hardiman S
AD  - Cardiac Services BC, Provincial Health Services Authority, Vancouver, British
      Columbia, Canada.
FAU - Jackson, Simon
AU  - Jackson S
AD  - QEII Health Sciences Center, Division of Cardiology, Dalhousie University
      Halifax, Halifax, Nova Scotia, Canada.
FAU - Lamarche, Yoan
AU  - Lamarche Y
AD  - Department of Surgery, Montreal Heart Institute, Universite de Montreal,
      Montreal, Quebec, Canada.
FAU - Lau, Benny
AU  - Lau B
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Legare, Jean-Francois
AU  - Legare JF
AD  - New Brunswick Heart Centre, Saint John, New Brunswick, Canada.
FAU - Leong-Poi, Howard
AU  - Leong-Poi H
AD  - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Mansour, Samer
AU  - Mansour S
AD  - Department of Medicine, Centre Hospitalier de l'Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Marelli, Ariane
AU  - Marelli A
AD  - Department of Medicine, McGill University Health Center, McGill University,
      Montreal, Quebec, Canada.
FAU - Quraishi, Ata
AU  - Quraishi A
AD  - QEII Health Sciences Center, Division of Cardiology, Dalhousie University
      Halifax, Halifax, Nova Scotia, Canada.
FAU - Roifman, Idan
AU  - Roifman I
AD  - Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario,
      Canada.
FAU - Ruel, Marc
AU  - Ruel M
AD  - University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
FAU - John Sapp
AU  - John Sapp
AD  - QEII Health Sciences Center, Division of Cardiology, Dalhousie University
      Halifax, Halifax, Nova Scotia, Canada.
FAU - Small, Gary
AU  - Small G
AD  - University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
FAU - Turgeon, Ricky
AU  - Turgeon R
AD  - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver,
      British Columbia, Canada.
FAU - Wood, David A
AU  - Wood DA
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Zieroth, Shelley
AU  - Zieroth S
AD  - University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Virani, Sean
AU  - Virani S
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
FAU - Krahn, Andrew D
AU  - Krahn AD
AD  - Centre for Cardiovascular Innovation, Division of Cardiology, University of
      British Columbia, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Canada/epidemiology
MH  - *Cardiology Service, Hospital/organization & administration/trends
MH  - *Cardiovascular Diseases/epidemiology/therapy
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - *Ethics, Institutional
MH  - Humans
MH  - Infection Control/*methods
MH  - Models, Organizational
MH  - Organizational Innovation
MH  - *Pandemics/prevention & control
MH  - *Patient Care Management/ethics/methods/standards
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - SARS-CoV-2
PMC - PMC7270812
EDAT- 2020/06/09 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - S0828-282X(20)30520-1 [pii]
AID - 10.1016/j.cjca.2020.06.002 [doi]
PST - ppublish
SO  - Can J Cardiol. 2020 Aug;36(8):1313-1316. doi: 10.1016/j.cjca.2020.06.002. Epub
      2020 Jun 4.


PMID- 32505512
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1095-8320 (Electronic)
IS  - 1045-1056 (Linking)
VI  - 66
DP  - 2020 Jul
TI  - Third human challenge trial conference, Oxford, United Kingdom, February 6-7,
      2020, a meeting report.
PG  - 41-52
LID - S1045-1056(20)30044-0 [pii]
LID - 10.1016/j.biologicals.2020.04.004 [doi]
AB  - The third Human Challenge Trial Meeting brought together a broad range of
      international stakeholders, including academia, regulators, funders and industry,
      with a considerable delegation from Low- and Middle-Income Countries. Controlled 
      human infection models (CHIMs) can be helpful to study pathogenesis and for the
      development of vaccines. As challenge agents are used to infect healthy
      volunteers, ethical considerations include that the challenge studies need to be 
      safe and results should be meaningful. The meeting provided a state-of-the-art
      overview on a wide range of CHIMs, including viral, bacterial and parasitic
      challenge agents. Recommendations included globally aligned guidance documents
      for CHIM studies; further definition of a CHIM, based on the challenge agent
      used; standardization of methodology and study endpoints; capacity building in
      Low- and Middle-Income Countries, in performance as well as regulation of CHIM
      studies; guidance on compensation for participation in CHIM studies; and
      preparation of CHIM studies, with strong engagement with stakeholders.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Pollard, Andrew J
AU  - Pollard AJ
AD  - Department of Paediatrics, University of Oxford, United Kingdom. Electronic
      address: andrew.pollard@paediatrics.ox.ac.uk.
FAU - Sauerwein, Robert
AU  - Sauerwein R
AD  - Radboud University Medical Center, the Netherlands. Electronic address:
      robert.sauerwein@radboudumc.nl.
FAU - Baay, Marc
AU  - Baay M
AD  - P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address:
      marc.baay@p-95.com.
FAU - Neels, Pieter
AU  - Neels P
AD  - International Alliance for Biological Standardization, Belgium. Electronic
      address: pieter.neels@vaccine-advice.be.
CN  - HCT3 speakers and session chairs
LA  - eng
GR  - MC_PC_17220/MRC_/Medical Research Council/United Kingdom
GR  - MR/R005982/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S016570/1/MRC_/Medical Research Council/United Kingdom
PT  - Congress
DEP - 20200604
PL  - England
TA  - Biologicals
JT  - Biologicals : journal of the International Association of Biological
      Standardization
JID - 9004494
RN  - 0 (Vaccines)
SB  - IM
MH  - Cholera
MH  - Drug Development
MH  - Dysentery, Bacillary
MH  - *Ethics, Research
MH  - *Human Experimentation
MH  - Humans
MH  - Infections/*physiopathology
MH  - Leishmaniasis
MH  - Paratyphoid Fever
MH  - Respiratory Syncytial Virus Infections
MH  - Scarlet Fever
MH  - Streptococcal Infections
MH  - Typhoid Fever
MH  - United Kingdom
MH  - *Vaccines
COIS- Declaration of competing interest The authors have no competing interests to
      declare.
IR  - Balasingam S
FIR - Balasingam, Shobana
IRAD- Wellcome Trust, United Kingdom. Electronic address: S.Balasingam@wellcome.ac.uk.
IR  - Bejon P
FIR - Bejon, Philippe
IRAD- KEMRI-Wellcome, Kilifi County Hospital, Kenya. Electronic address:
      pbejon@kemri-wellcome.org.
IR  - Berthels N
FIR - Berthels, Nele
IRAD- Federal Agency for Medicines and Health Products (FAMHP), Belgium. Electronic
      address: nele.berthels@fagg-afmps.be.
IR  - Bull S
FIR - Bull, Susan
IRAD- University of Oxford, United Kingdom. Electronic address:
      susan.bull@ethox.ox.ac.uk.
IR  - Catchpole A
FIR - Catchpole, Andrew
IRAD- hVIVO, United Kingdom. Electronic address: a.catchpole@hvivo.com.
IR  - Chi P
FIR - Chi, Primus
IRAD- KEMRI-Wellcome Trust Research Programme, Kenya. Electronic address:
      pchi@kemri-wellcome.org.
IR  - Chilengi R
FIR - Chilengi, Roma
IRAD- Centre for Infectious Disease Research in Zambia, Roma, Zambia. Electronic
      address: chilengi@cidrz.org.
IR  - Cox R
FIR - Cox, Rebecca
IRAD- University of Bergen, Norway. Electronic address: rebecca.cox@uib.no.
IR  - Davies H
FIR - Davies, Hugh
IRAD- University of Oxford, United Kingdom. Electronic address: hughtdavies@gmail.com.
IR  - Durbin A
FIR - Durbin, Anna
IRAD- Johns Hopkins Bloomberg School of Public Health, USA. Electronic address:
      adurbin1@jhu.edu.
IR  - Emary K
FIR - Emary, Kate
IRAD- University of Oxford, United Kingdom. Electronic address:
      kate.emary@paediatrics.ox.ac.uk.
IR  - Emerson C
FIR - Emerson, Claudia
IRAD- McMaster University, Canada. Electronic address: emerson@mcmaster.ca.
IR  - Frenck R
FIR - Frenck, Robert
IRAD- University of Cincinnati, USA. Electronic address: robert.frenck@cchmc.org.
IR  - Grimwade O
FIR - Grimwade, Olivia
IRAD- Monash University, Australia. Electronic address: orgri1@student.monash.edu.
IR  - Hobbs M
FIR - Hobbs, Marcia
IRAD- University of North Carolina, USA. Electronic address: mmhobbs@med.unc.edu.
IR  - Kang G
FIR - Kang, Gagandeep
IRAD- Christian Medical College, Vellore, India. Electronic address:
      gkang@cmcvellore.ac.in.
IR  - Kaye P
FIR - Kaye, Paul
IRAD- University of York, United Kingdom. Electronic address: paul.kaye@york.ac.uk.
IR  - Le Doare K
FIR - Le Doare, Kirsty
IRAD- St. George's, University of London, United Kingdom and mrc/uvri @lshtm, Uganda.
      Electronic address: kiledoar@sgul.ac.uk.
IR  - Levine M
FIR - Levine, Mike
IRAD- University of Maryland School of Medicine, USA. Electronic address:
      mlevine@som.umaryland.edu.
IR  - McShane H
FIR - McShane, Helen
IRAD- University of Oxford, United Kingdom. Electronic address:
      helen.mcshane@ndm.ox.ac.uk.
IR  - Oguti B
FIR - Oguti, Blanche
IRAD- University of Oxford, United Kingdom. Electronic address:
      blanche.oguti@paediatrics.ox.ac.uk.
IR  - Openshaw P
FIR - Openshaw, Peter
IRAD- Imperial College, United Kingdom. Electronic address: p.openshaw@imperial.ac.uk.
IR  - Osowicki J
FIR - Osowicki, Joshua
IRAD- Murdoch Children's Research Institute (MCRI), Australia. Electronic address:
      joshua.osowicki@rch.org.au.
IR  - Parker M
FIR - Parker, Michael
IRAD- University of Oxford, United Kingdom. Electronic address:
      michael.parker@ethox.ox.ac.uk.
IR  - Ploin D
FIR - Ploin, Dominique
IRAD- Hospices Civils de Lyon, France. Electronic address: dominique.ploin@chu-lyon.fr.
IR  - Porter C
FIR - Porter, Chad
IRAD- Naval Medical Research Center, USA. Electronic address:
      chad.k.porter2.civ@mail.mil.
IR  - Roestenberg M
FIR - Roestenberg, Meta
IRAD- Leiden University Medical Center, the Netherlands. Electronic address:
      m.roestenberg@lumc.nl.
IR  - Selgelid MJ
FIR - Selgelid, Michael J
IRAD- Monash University, Australia. Electronic address: michael.selgelid@monash.edu.
IR  - Wildfire A
FIR - Wildfire, Adrian
IRAD- SGS LIfe Sciences, Belgium. Electronic address: adrian.wildfire@sgs.com.
EDAT- 2020/06/09 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - S1045-1056(20)30044-0 [pii]
AID - 10.1016/j.biologicals.2020.04.004 [doi]
PST - ppublish
SO  - Biologicals. 2020 Jul;66:41-52. doi: 10.1016/j.biologicals.2020.04.004. Epub 2020
      Jun 4.


PMID- 32505492
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20210110
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 39
IP  - 7
DP  - 2020 Jul
TI  - Ethical considerations regarding heart and lung transplantation and mechanical
      circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force
      statement.
PG  - 619-626
LID - S1053-2498(20)31531-X [pii]
LID - 10.1016/j.healun.2020.04.019 [doi]
AB  - To understand the challenges for thoracic transplantation and mechanical
      circulatory support during the current coronavirus disease 2019 pandemic, we
      propose separating the effects of the pandemic into 5 distinct stages from a
      healthcare system perspective. We discuss how the classical ethical principles of
      utility, justice, and efficiency may need to be adapted, and we give specific
      recommendations for thoracic transplantation and mechanical circulatory support
      centers to balance their clinical decisions and strategies for advanced heart and
      lung disease during the current pandemic.
CI  - Copyright (c) 2020 International Society for Heart and Lung Transplantation.
      Published by Elsevier Inc. All rights reserved.
FAU - Holm, Are M
AU  - Holm AM
AD  - Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway;
      Faculty of Medicine, University of Oslo, Oslo, Norway.
FAU - Mehra, Mandeep R
AU  - Mehra MR
AD  - Center for Advanced Heart Disease, Brigham and Women's Hospital, Harvard Medical 
      School, Boston, Massachusetts.
FAU - Courtwright, Andrew
AU  - Courtwright A
AD  - Division of Pulmonary and Critical Care Medicine, Hospital of the University of
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Teuteberg, Jeffrey
AU  - Teuteberg J
AD  - Division of Cardiovascular Medicine, Stanford University Medical Center,
      Stanford, California.
FAU - Sweet, Stuart
AU  - Sweet S
AD  - Division of Allergy and Pulmonary Medicine, Washington University School of
      Medicine, St. Louis, Missouri.
FAU - Potena, Luciano
AU  - Potena L
AD  - Cardiovascular Department, Bologna University Hospital, Bologna, Italy.
FAU - Singer, Lianne G
AU  - Singer LG
AD  - Department of Medicine, University Health Network, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Farrero, Marta
AU  - Farrero M
AD  - Advanced Heart Failure Unit, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Shullo, Michael A
AU  - Shullo MA
AD  - West Virginia University Hospitals, Morgantown, West Virginia.
FAU - Benza, Raymond
AU  - Benza R
AD  - Division of Cardiovascular Diseases, Ohio State University, Columbus, Ohio.
FAU - Ensminger, Stephan
AU  - Ensminger S
AD  - Department of Cardiac and Thoracic Vascular Surgery, University Medical Center
      Schleswig-Holstein, Campus Lubeck, Germany.
FAU - Aslam, Saima
AU  - Aslam S
AD  - Division of Infectious Diseases and Global Public Health, University of
      California, San Diego, San Diego, California. Electronic address:
      saslam@health.ucsd.edu.
LA  - eng
PT  - Editorial
DEP - 20200425
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the
      International Society for Heart Transplantation
JID - 9102703
SB  - IM
CIN - J Heart Lung Transplant. 2020 Aug;39(8):852-853. PMID: 32576419
MH  - Assisted Circulation/*ethics
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Services Accessibility/*ethics
MH  - Heart Transplantation/*ethics
MH  - Humans
MH  - Lung Transplantation/*ethics
MH  - Pandemics
MH  - Patient Selection/ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7195343
OTO - NOTNLM
OT  - *COVID-19
OT  - *MCS
OT  - *SARS-CoV-2
OT  - *ethics
OT  - *thoracic transplant
EDAT- 2020/06/09 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - S1053-2498(20)31531-X [pii]
AID - 10.1016/j.healun.2020.04.019 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2020 Jul;39(7):619-626. doi:
      10.1016/j.healun.2020.04.019. Epub 2020 Apr 25.


PMID- 32505244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200611
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10239
DP  - 2020 Jun 6
TI  - Offline: COVID-19 and the ethics of memory.
PG  - 1750
LID - S0140-6736(20)31279-4 [pii]
LID - 10.1016/S0140-6736(20)31279-4 [doi]
FAU - Horton, Richard
AU  - Horton R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - IM
PMC - PMC7272144
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
CRDT- 2020/06/08 06:00
PHST- 2020/06/01 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/06/08 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
AID - S0140-6736(20)31279-4 [pii]
AID - 10.1016/S0140-6736(20)31279-4 [doi]
PST - ppublish
SO  - Lancet. 2020 Jun 6;395(10239):1750. doi: 10.1016/S0140-6736(20)31279-4.


PMID- 32504447
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2212-277X (Electronic)
IS  - 2212-2761 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Aug
TI  - Mindful medical practice: An innovative core course to prepare medical students
      for clerkship.
PG  - 256-259
LID - 10.1007/s40037-020-00591-3 [doi]
AB  - BACKGROUND: Medical students show a decline in empathy and ethical reasoning
      during medical school that is most marked during clerkship. We believe that part 
      of the problem is that students do not have the skills and ways of being and
      relating necessary to deal effectively with the overwhelming clinical experience 
      of clerkship. APPROACH: At McGill University in Montreal, starting in January
      2015, we have taught a course on mindful medical practice that combines a
      clinical focus on the combination of mindfulness and congruent relating that is
      aimed at giving students the skills and ways of being to function effectively in 
      clerkship. The course is taught to all medical students in groups of 20, weekly
      for 7 weeks, in the 6 months immediately prior to clerkship, a time when students
      are very open to learning the skills they need to take effective care of
      patients. EVALUATION: The course has been well accepted by students as evidenced 
      by their engagement, their evaluations, and their comments in the essays that
      they write at the end of the course. In a follow-up session at the simulation
      centre one year later students remember clearly and enact what they were taught
      in the course. REFLECTION: The next steps will be to conduct a formal evaluation 
      of the effect of our teaching that will involve a combination of qualitative
      methods to clarify the nature of the impact on our students and a quantitative
      assessment of the difference the course makes to students' experience and
      performance in clerkship.
FAU - Hutchinson, Tom A
AU  - Hutchinson TA
AUID- ORCID: 0000-0002-3231-6953
AD  - Department of Medicine, Faculty of Medicine, Programs in Whole Person Care,
      McGill University, Montreal, Quebec, Canada. tom.hutchinson@mcgill.ca.
FAU - Liben, Stephen
AU  - Liben S
AD  - Department of Pediatrics, Faculty of Medicine, Programs in Whole Person Care,
      McGill University, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Perspect Med Educ
JT  - Perspectives on medical education
JID - 101590643
SB  - IM
CIN - Perspect Med Educ. 2020 Aug;9(4):197-198. PMID: 32632668
MH  - Clinical Clerkship/*methods
MH  - Curriculum/standards/trends
MH  - Education, Medical, Undergraduate/methods
MH  - Humans
MH  - Mindfulness/*education/methods
MH  - Professional Competence/standards
MH  - Schools, Medical/organization & administration/trends
MH  - Students, Medical/*psychology
PMC - PMC7459040
OTO - NOTNLM
OT  - *Congruence
OT  - *Experiential learning
OT  - *Mindful medical practice
OT  - *Whole person care
EDAT- 2020/06/07 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - 10.1007/s40037-020-00591-3 [doi]
AID - 10.1007/s40037-020-00591-3 [pii]
PST - ppublish
SO  - Perspect Med Educ. 2020 Aug;9(4):256-259. doi: 10.1007/s40037-020-00591-3.


PMID- 32504401
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 2168-4804 (Electronic)
IS  - 2168-4790 (Linking)
VI  - 54
IP  - 6
DP  - 2020 Nov
TI  - The Current Status of European and National Financial Sources for Clinical
      Research and Their Impact on Paediatric Non-commercial Clinical Trials: A Case
      Study of the Czech Republic.
PG  - 1461-1472
LID - 10.1007/s43441-020-00173-9 [doi]
AB  - INTRODUCTION: Paediatric non-commercial interventional clinical trials (NICTs)
      are crucial for healthcare provision. In spite of the fact that current
      regulations and initiatives try to enhance the quantity and quality of paediatric
      NICTs, there are still shortcomings that need to be addressed in order to
      accelerate the conduct of relevant clinical trials in children. To improve the
      current landscape of paediatric clinical research, it is necessary to identify
      and analyse the main trends and shortcomings, along with their impact on national
      performance in paediatric NICTs and this is the aim of this work. METHOD: A
      retrospective systematic search of paediatric NICTs was performed on four
      international clinical trials registries. Entries were filtered by date from
      01/01/2004 to 31/12/2017. Each identified paediatric NICT was screened and
      analysed for sponsors, funders, type of intervention, therapeutic area, design
      characteristics and associated publications. RESULTS: The search identified 439
      unique NICTs. When stratifying the trials by enrolment ages, 86 trials were found
      involving the paediatric population. Most trials investigated the use of
      medicinal products and were focused on cancer or cardiovascular diseases. The
      most common sources of the funding were non-profit organizations. Furthermore,
      from the total number of completed trials, only half of them already published
      their results. CONCLUSION: The main shortcomings-specifically, ethical,
      methodological and, in particular, economic obstacles were identified. There is a
      continual need for greater support and collaboration between all major
      stakeholders including health policymakers, grant agencies, research
      institutions, pharmaceutical industries and healthcare providers at the national 
      and international level.
FAU - Horavova, L
AU  - Horavova L
AUID- ORCID: 0000-0002-5899-7742
AD  - Department of Applied Pharmacy, Faculty of Pharmacy, University of Veterinary and
      Pharmaceutical Sciences Brno, Brno, Czech Republic. lhoravova@cvbf.net.
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice
      753/5, 625 00, Brno, Czech Republic. lhoravova@cvbf.net.
FAU - Nebeska, K
AU  - Nebeska K
AD  - European Clinical Research Infrastructure Network (ECRIN), Paris, France.
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice
      753/5, 625 00, Brno, Czech Republic.
FAU - Souckova, L
AU  - Souckova L
AD  - European Clinical Research Infrastructure Network (ECRIN), Paris, France.
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice
      753/5, 625 00, Brno, Czech Republic.
AD  - University Hospital St. Anne's Brno - International Clinical Research Center,
      Brno, Czech Republic.
FAU - Demlova, R
AU  - Demlova R
AD  - European Clinical Research Infrastructure Network (ECRIN), Paris, France.
AD  - Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice
      753/5, 625 00, Brno, Czech Republic.
AD  - University Hospital St. Anne's Brno - International Clinical Research Center,
      Brno, Czech Republic.
AD  - Department of Clinical Trials, Masaryk Memorial Cancer Institute Brno, Brno,
      Czech Republic.
FAU - Babula, P
AU  - Babula P
AD  - Department of Applied Pharmacy, Faculty of Pharmacy, University of Veterinary and
      Pharmaceutical Sciences Brno, Brno, Czech Republic.
AD  - Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech
      Republic.
LA  - eng
GR  - CZECRIN (Identification code LM2015090)/Ministerstvo Skolstvi, Mladeze a
      Telovychovy
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200605
PL  - Switzerland
TA  - Ther Innov Regul Sci
JT  - Therapeutic innovation & regulatory science
JID - 101597411
SB  - IM
MH  - Adolescent
MH  - Aged, 80 and over
MH  - Child
MH  - *Clinical Trials as Topic
MH  - Czech Republic
MH  - Drug Industry
MH  - *Health Personnel
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Neoplasms
MH  - Retrospective Studies
PMC - PMC7704485
OTO - NOTNLM
OT  - *Financial sources
OT  - *Infrastructure
OT  - *International Clinical Trials Registries
OT  - *Non-commercial Clinical Trials
OT  - *Paediatric clinical research
EDAT- 2020/06/07 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - 10.1007/s43441-020-00173-9 [doi]
AID - 10.1007/s43441-020-00173-9 [pii]
PST - ppublish
SO  - Ther Innov Regul Sci. 2020 Nov;54(6):1461-1472. doi: 10.1007/s43441-020-00173-9. 
      Epub 2020 Jun 5.


PMID- 32503928
OWN - NLM
STAT- Publisher
LR  - 20210724
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 5
TI  - Strengthening the impairment argument against abortion.
LID - medethics-2020-106153 [pii]
LID - 10.1136/medethics-2020-106153 [doi]
AB  - Perry Hendricks' impairment argument for the immorality of abortion is based on
      two premises: first, impairing a fetus with fetal alcohol syndrome (FAS) is
      immoral, and second, if impairing an organism to some degree is immoral, then
      ceteris paribus, impairing it to a higher degree is also immoral. He calls this
      the impairment principle (TIP). Since abortion impairs a fetus to a higher degree
      than FAS, it follows from these two premises that abortion is immoral. Critics
      have focussed on the ceteris paribus clause of TIP, which requires that the
      relevant details surrounding each impairment be sufficiently similar. In this
      article, we show that the ceteris paribus clause is superfluous, and by replacing
      it with a more restrictive condition, the impairment argument is considerably
      strengthened.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Blackshaw, Bruce Philip
AU  - Blackshaw BP
AUID- ORCID: http://orcid.org/0000-0002-9115-582X
AD  - Philosophy, University of Birmingham, Birmingham, UK bblackshaw@gmail.com.
FAU - Hendricks, Perry
AU  - Hendricks P
AUID- ORCID: http://orcid.org/0000-0002-9753-6914
AD  - Purdue University Department of Philosophy, West Lafayette, Indiana, USA.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8257548
OTO - NOTNLM
OT  - abortion
OT  - embryos and fetuses
OT  - ethics
OT  - moral status
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2020/06/07 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/07 06:00 [medline]
AID - medethics-2020-106153 [pii]
AID - 10.1136/medethics-2020-106153 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 5. pii: medethics-2020-106153. doi:
      10.1136/medethics-2020-106153.


PMID- 32503927
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210324
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Use of cadavers to train surgeons: closing comment.
PG  - 477
LID - 10.1136/medethics-2020-106191 [doi]
FAU - James, Hannah
AU  - James H
AUID- ORCID: 0000-0002-0535-3062
AD  - Clinical Trials Unit, University of Warwick, Coventry, UK
      h.smith.1@warwick.ac.uk.
AD  - Trauma & Orthopaedic Surgery, University Hospitals Coventry and Warwickshire NHS 
      Trust, Coventry, UK.
LA  - eng
GR  - 20485/VAC_/Versus Arthritis/United Kingdom
PT  - Journal Article
PT  - Comment
DEP - 20200605
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Jul;46(7):470-471. PMID: 31852744
CON - J Med Ethics. 2020 Jul;46(7):472-473. PMID: 32029543
CON - J Med Ethics. 2020 Jul;46(7):474-475. PMID: 32054773
CON - J Med Ethics. 2020 Jul;46(7):476. PMID: 32102836
MH  - Cadaver
MH  - Humans
MH  - *Surgeons
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - medethics-2020-106191 [pii]
AID - 10.1136/medethics-2020-106191 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):477. doi: 10.1136/medethics-2020-106191. Epub 2020
      Jun 5.


PMID- 32503926
OWN - NLM
STAT- Publisher
LR  - 20200606
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 5
TI  - Accessing medical biobanks to solve crimes: ethical considerations.
LID - medethics-2020-106133 [pii]
LID - 10.1136/medethics-2020-106133 [doi]
AB  - Millions of human biological samples are stored worldwide for medical research or
      treatment purposes. These biospecimens are of enormous potential value to law
      enforcement as DNA profiles can be obtained from these samples. However, forensic
      use of such biospecimens raises a number of ethical questions. This article aims 
      to explore ethical issues of using human bodily material in medical biobanks for 
      crime investigation and prosecution purposes. Concerns about confidentiality,
      trust, autonomy and justice will be discussed. We explore how to balance these
      concerns against the importance of crime solving. Relevant case examples of
      forensic use of medical biobanks show that requests by law enforcement to access 
      biobanks are handled in disparate ways. We identify some core ethical issues and 
      conclude that further research on these issues is needed to provide ethical
      guidance.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - de Groot, Nina F
AU  - de Groot NF
AD  - Department of Philosophy, Faculty of Humanities, VU University Amsterdam,
      Amsterdam, The Netherlands n.f.de.groot@vu.nl.
FAU - van Beers, Britta C
AU  - van Beers BC
AD  - Department of Legal Theory and Legal History, Faculty of Law, VU University
      Amsterdam, Amsterdam, The Netherlands.
FAU - Decock, Lieven
AU  - Decock L
AD  - Department of Philosophy, Faculty of Humanities, VU University Amsterdam,
      Amsterdam, The Netherlands.
FAU - Meynen, Gerben
AU  - Meynen G
AD  - Department of Philosophy, Faculty of Humanities, VU University Amsterdam,
      Amsterdam, The Netherlands.
AD  - Willem Pompe Institute for Criminal Law and Criminology, Utrecht University,
      Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - confidentiality/privacy
OT  - ethics
OT  - genetic information
OT  - informed consent
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2020/06/07 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/07 06:00 [medline]
AID - medethics-2020-106133 [pii]
AID - 10.1136/medethics-2020-106133 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 5. pii: medethics-2020-106133. doi:
      10.1136/medethics-2020-106133.


PMID- 32503925
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 5
TI  - Is informed consent required for the diagnosis of brain death regardless of
      consent for organ donation?
LID - medethics-2020-106240 [pii]
LID - 10.1136/medethics-2020-106240 [doi]
AB  - In the half-century history of clinical practice of diagnosing brain death,
      informed consent has seldom been considered until very recently. Like many other 
      medical diagnoses and ordinary death pronouncements, it has been taken for
      granted for decades that brain death is diagnosed and death is declared without
      consideration of the patient's advance directives or family's wishes. This essay 
      examines the pros and cons of using informed consent before the diagnosis of
      brain death from an ethical point of view. As shared decision-making in clinical 
      practice became increasingly indispensable, respect for the patients' autonomous 
      wishes regarding how to end their lives has a significant role in deciding how
      death is diagnosed. Brain death, as a fully technologically controlled death, may
      require a different ethical framework from the old one for traditional cardiac
      death. With emerging and proliferating options in end-of-life care for those who 
      suffer from catastrophic brain injury, the traditional reasoning that 'death
      gives no choice, hence no consent' requires another examination. Patients facing 
      imminent brain death now have options other than undergoing the diagnostic workup
      for brain death, such as donation after circulatory death and withdrawal of
      life-sustaining treatment with maximum comfort measures for death with dignity.
      Nevertheless, just as in the debate over opt-in versus opt-out organ donation
      policies, informed consent before the diagnosis of brain death faces fierce
      opposition from consequentialists urging the expansion of the donor pool. This
      essay examines these objections and provides constructive replies along with a
      proposal to accommodate this morally required consent.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Muramoto, Osamu
AU  - Muramoto O
AUID- ORCID: http://orcid.org/0000-0003-0617-2631
AD  - Center for Ethics in Health Care, Oregon Health and Science University, Portland,
      OR 97239, USA muramoto@ohsu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639902
OTO - NOTNLM
OT  - brain death
OT  - diagnosis
OT  - informed consent
OT  - organ procurement
OT  - presumed consent
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2020/06/07 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/07 06:00 [medline]
AID - medethics-2020-106240 [pii]
AID - 10.1136/medethics-2020-106240 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 5. pii: medethics-2020-106240. doi:
      10.1136/medethics-2020-106240.


PMID- 32503924
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Children of COVID-19: pawns, pathfinders or partners?
PG  - 508-509
LID - 10.1136/medethics-2020-106465 [doi]
AB  - Countries throughout the world are counting the health and socioeconomic costs of
      the COVID-19 pandemic, including the strategies necessary to contain it. Profound
      consequences from social isolation are beginning to emerge, and there is an
      urgency about charting a path to recovery, albeit to a 'new normal' that
      mitigates them. Children have not suffered as much from the direct effects of
      COVID-19 infection as older adults. Still, there is mounting evidence that their 
      health and welfare are being adversely affected. Closure of schools has been a
      critical component of social isolation but has a far broader impact than the
      diminution of educational opportunities, as important as these are. Reopening of 
      schools is therefore essential to recovery, with some countries already
      tentatively implementing it. Children's interests are vital considerations in any
      recovery plan, but the question remains as to how to address them within the
      context of how society views children; should they be regarded as pawns,
      pathfinders or partners in this enterprise?
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Larcher, Victor
AU  - Larcher V
AD  - Paediatric Bioethics Centre, University College London Great Ormond Street
      Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research 
      Centre, London, UK.
FAU - Brierley, Joe
AU  - Brierley J
AUID- ORCID: 0000-0003-0919-6882
AD  - Paediatric Bioethics Centre, University College London Great Ormond Street
      Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research 
      Centre, London, UK joe.brierley@gosh.nhs.uk.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Adult
MH  - Adverse Childhood Experiences
MH  - Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - Child
MH  - Child Health
MH  - *Child Welfare
MH  - Coronavirus Infections/*complications/virology
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - *Pandemics/ethics
MH  - Pneumonia, Viral/*complications/virology
MH  - Public Health
MH  - Public Opinion
MH  - *Quarantine
MH  - SARS-CoV-2
MH  - *Schools
MH  - Social Change
MH  - *Social Isolation
PMC - PMC7316102
OTO - NOTNLM
OT  - *children
OT  - *ethics
OT  - *public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - medethics-2020-106465 [pii]
AID - 10.1136/medethics-2020-106465 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):508-509. doi: 10.1136/medethics-2020-106465. Epub
      2020 Jun 5.


PMID- 32503891
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20210329
IS  - 1470-2738 (Electronic)
IS  - 0143-005X (Linking)
VI  - 74
IP  - 8
DP  - 2020 Aug
TI  - Paradox of success and public perspective: COVID-19 and the perennial problem of 
      prevention.
PG  - 679
LID - 10.1136/jech-2020-214518 [doi]
FAU - Messinger Cayetano, Shari
AU  - Messinger Cayetano S
AUID- ORCID: 0000-0003-1182-2280
AD  - Public Health Sciences, University of Miami Miller School of Medicine, Miami,
      Florida, USA smessinger@biostat.med.miami.edu.
AD  - University of Miami.
FAU - Crandall, Lee
AU  - Crandall L
AD  - Public Health Sciences, Clemson University, Clemson, South Carolina, USA.
LA  - eng
GR  - UL1 TR002736/TR/NCATS NIH HHS/United States
PT  - Letter
DEP - 20200605
PL  - England
TA  - J Epidemiol Community Health
JT  - Journal of epidemiology and community health
JID - 7909766
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Preventive Medicine
MH  - Public Health
MH  - SARS-CoV-2
PMC - PMC7298205
OTO - NOTNLM
OT  - *ACCESS TO HLTH CARE
OT  - *ADDICTIVE BEHAVIOUR/ADDICTION
OT  - *ALCOHOL
OT  - *DISABILITY
OT  - *ETHICS
OT  - *PREVENTION
OT  - *PREVENTIVE MEDICINE
OT  - *PUBLIC HEALTH
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - jech-2020-214518 [pii]
AID - 10.1136/jech-2020-214518 [doi]
PST - ppublish
SO  - J Epidemiol Community Health. 2020 Aug;74(8):679. doi: 10.1136/jech-2020-214518. 
      Epub 2020 Jun 5.


PMID- 32503884
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 91
IP  - 8
DP  - 2020 Aug
TI  - Great expectations: virus-mediated gene therapy in neurological disorders.
PG  - 849-860
LID - 10.1136/jnnp-2019-322327 [doi]
AB  - Gene therapy (GT) has tremendous potential for the treatment of neurological
      disorders to transform patient care. The successful application of virus-mediated
      GT to treat spinal muscular atrophy is a significant milestone, serving to
      accelerate similar progress in a spectrum of neurological conditions, with more
      than 50 clinical trials currently underway, across neurodevelopmental,
      neurodegenerative, muscular dystrophy, epilepsy, chronic pain and neoplastic
      diseases. This review provides an overview of the key features of virus-mediated 
      GT, paradigms of delivery and dosing, potential risks and highlights ongoing
      research to optimise safe and effective delivery of vectors into the nervous
      system. Examples of the application of GT in various neurological diseases
      alongside clinical development challenges will be presented. As the development
      and translation of GTs gain pace, success can only ultimately be realised for
      patients following implementation in the health system. The challenges and
      controversies of daunting costs, ethics, early diagnosis and health system
      readiness will require innovative pricing schemes, regulatory policies, education
      and organisation of a skilled workforce to deliver of high-quality care in
      clinical practice as we prepare for advanced therapeutics in neurology.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kariyawasam, Didu
AU  - Kariyawasam D
AD  - Neurology, Sydney Children's Hospital Randwick, Randwick, New South Wales,
      Australia.
AD  - School of Women's and Children's Health, UNSW Medicine, University of New South
      Wales, Sydney, New South Wales, Australia.
FAU - Alexander, Ian E
AU  - Alexander IE
AD  - Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of
      Medicine and Health, The University of Sydney, Sydney, New South Wales,
      Australia.
AD  - Gene Therapy Unit, Children's Medical Research Institute, Westmead, New South
      Wales, Australia.
FAU - Kurian, Manju
AU  - Kurian M
AD  - Neurosciences Unit, Institute of Child Health, University College London, London,
      UK.
AD  - Neurology, Great Ormond Street Hospital for Children, London, UK.
FAU - Farrar, Michelle Anne
AU  - Farrar MA
AUID- ORCID: 0000-0002-4472-0902
AD  - Neurology, Sydney Children's Hospital Randwick, Randwick, New South Wales,
      Australia m.farrar@unsw.edu.au.
AD  - School of Women's and Children's Health, UNSW Medicine, University of New South
      Wales, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200605
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
SB  - IM
MH  - Gene Editing
MH  - Gene Silencing
MH  - Genetic Therapy/*methods
MH  - Genetic Vectors/*therapeutic use
MH  - Humans
MH  - Nervous System Diseases/*therapy
MH  - Viruses/genetics
OTO - NOTNLM
OT  - *clinical neurology
OT  - *neurogenetics
OT  - *neuromuscular
OT  - *virology
COIS- Competing interests: MF has received compensation as a member of the scientific
      advisory board for Biogen, Roche and AveXis. DK has received reimbursement for
      attending symposia, sponsored by Biogen. IA has received compensation for the
      cost of participation on a Novartis advisory panel.These funding bodies had no
      role in the manuscript design, preparation of the manuscript or decision to
      publish.
EDAT- 2020/06/07 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - jnnp-2019-322327 [pii]
AID - 10.1136/jnnp-2019-322327 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):849-860. doi:
      10.1136/jnnp-2019-322327. Epub 2020 Jun 5.


PMID- 32503874
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20201218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 4
TI  - Efficacy of remdesivir in patients with COVID-19: a protocol for systematic
      review and meta-analysis of randomised controlled trials.
PG  - e039159
LID - 10.1136/bmjopen-2020-039159 [doi]
AB  - BACKGROUND: Despite global containment measures to fight the coronavirus disease 
      2019 (COVID-19), the pandemic continued to rise, rapidly spread across the world,
      and resulting in 2.6 million confirmed cases and 185 061 deaths worldwide as of
      23 April 2020. Yet, there are no approved vaccines or drugs to make the disease
      less deadly, while efforts are underway. Remdesivir, a nucleotide-analogue
      antiviral drug developed for Ebola, is determined to prevent and stop infections 
      with COVID-19, while results are yet controversial. Here, we aim to conduct a
      systematic review and meta-analysis of randomised controlled trials (RCTs) to
      evaluate the efficacy of remdesivir in patients with COVID-19. METHOD AND
      ANALYSIS: We will search MEDLINE-PubMed, Embase, Cochrane Library,
      ClinicalTrials.gov and Google scholar databases for articles published as of 30
      June 2020 and we will complete the study on 30 August 2020. We will follow the
      Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
      (PRISMA-P) 2015 guidelines for the design and reporting of the results. We will
      include RCTs that assessed the efficacy of remdesivir versus placebo or standard 
      of care. The primary endpoint will be time to clinical recovery. The secondary
      endpoints will be proportion of participants relieved from clinical symptoms
      defined at the time (in hours) from initiation of the study treatment, all-cause 
      mortality, discharged date, frequency of respiratory progression and
      treatment-emergent adverse events. RevMan V.5.3 software will be used for
      statistical analysis. Random effects model will be carried out to calculate mean 
      differences for continuous outcome data and risk ratio for dichotomous outcome
      data between remdesivir and placebo or standard of care. ETHICS AND
      DISSEMINATION: There are no ethical considerations associated with this study as 
      we will use publicly available data from previously published studies. We plan to
      publish results in open-access peer-reviewed journals and present at
      international and national conferences. PROSPERO REGISTRATION NUMBER:
      CRD42020177953.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gebrie, Desye
AU  - Gebrie D
AUID- ORCID: 0000-0002-5137-6791
AD  - School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle,
      Ethiopia desye.gebrie@mu.edu.et.
AD  - Addis Ababa University, College of Health Sciences, Center for Innovative Drug
      Development and Therapeutic Trials for Africa, Addis Ababa, Ethiopia.
FAU - Getnet, Desalegn
AU  - Getnet D
AD  - Pharmacology and Toxicology Course and Research Team, Department of Pharmacy,
      College of Health Sciences, Adigrat University, Adigrat, Ethiopia.
FAU - Manyazewal, Tsegahun
AU  - Manyazewal T
AUID- ORCID: 0000-0002-8360-7574
AD  - Addis Ababa University, College of Health Sciences, Center for Innovative Drug
      Development and Therapeutic Trials for Africa, Addis Ababa, Ethiopia.
LA  - eng
GR  - D43 TW009127/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antiviral Agents)
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adenosine Monophosphate/administration & dosage/adverse effects/*analogs &
      derivatives
MH  - Alanine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Antiviral Agents/administration & dosage/adverse effects
MH  - *Betacoronavirus/drug effects/isolation & purification
MH  - COVID-19
MH  - *Coronavirus Infections/drug therapy/epidemiology
MH  - Humans
MH  - Infection Control/*methods
MH  - Meta-Analysis as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral/drug therapy/epidemiology
MH  - *Research Design
MH  - SARS-CoV-2
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7298683
OTO - NOTNLM
OT  - *clinical trials
OT  - *infection control
OT  - *respiratory infections
OT  - *virology
COIS- Competing interests: All review authors declare that they have no competing
      interests. The funder has no role in the design, syntheses and report of the
      study.
EDAT- 2020/06/07 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - bmjopen-2020-039159 [pii]
AID - 10.1136/bmjopen-2020-039159 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 4;10(6):e039159. doi: 10.1136/bmjopen-2020-039159.


PMID- 32503872
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 4
TI  - Study protocol of validating a numerical model to assess the blood flow in the
      circle of Willis.
PG  - e036404
LID - 10.1136/bmjopen-2019-036404 [doi]
AB  - INTRODUCTION: We developed a zero-dimensional (0D) model to assess the
      patient-specific haemodynamics in the circle of Willis (CoW). Similar numerical
      models for simulating the cerebral blood flow (CBF) had only been validated
      qualitatively in healthy volunteers by magnetic resonance (MR) angiography and
      transcranial Doppler (TCD). This study aims to validate whether a numerical model
      can simulate patient-specific blood flow in the CoW under pathological
      conditions. METHODS AND ANALYSIS: This study is a diagnostic accuracy study. We
      aim to collect data from a previously performed prospective study that involved
      patients with aneurysmal subarachnoid haemorrhage (aSAH) receiving both TCD and
      brain Computerd Tomography angiography (CTA) at the same day. The cerebral flow
      velocities are calculated by the 0D model, based on the vessel diameters measured
      on the CTA of each patient. In this study, TCD is considered the gold standard
      for measuring flow velocity in the CoW. The agreement will be analysed using
      Pearson correlation coefficients. ETHICS AND DISSEMINATION: This study protocol
      has been approved by the Medical Ethics Review Board of the University Medical
      Center Groningen: METc2019/103. The results will be submitted to an international
      scientific journal for peer-reviewed publication. TRIAL REGISTRATION NUMBER:
      NL8114.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Shen, Yuanyuan
AU  - Shen Y
AUID- ORCID: 0000-0003-0426-5295
AD  - Department of Neurosurgery, University Medical Center Groningen, Groningen, The
      Netherlands y.shen@umcg.nl.
FAU - Wei, Yanji
AU  - Wei Y
AD  - Engineering and Technology Institute Groningen, Faculty of Science & Engineering,
      University of Groningen, Groningen, The Netherlands.
FAU - Bokkers, Reinoud P H
AU  - Bokkers RPH
AD  - Department of Radiology, Medical Imaging Center, University Medical Center
      Groningen, Groningen, The Netherlands.
FAU - Uyttenboogaart, Maarten
AU  - Uyttenboogaart M
AD  - Department of Radiology, Medical Imaging Center, University Medical Center
      Groningen, Groningen, The Netherlands.
AD  - Department of Neurology, University Medical Center Groningen, Groningen, The
      Netherlands.
FAU - van Dijk, J Marc C
AU  - van Dijk JMC
AUID- ORCID: 0000-0002-0814-5680
AD  - Department of Neurosurgery, University Medical Center Groningen, Groningen, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Blood Flow Velocity/physiology
MH  - Carotid Arteries/diagnostic imaging/physiology
MH  - Circle of Willis/diagnostic imaging/*physiology
MH  - Clinical Protocols
MH  - Computed Tomography Angiography
MH  - Humans
MH  - Models, Statistical
MH  - Regional Blood Flow/*physiology
MH  - Reproducibility of Results
MH  - Subarachnoid Hemorrhage/diagnostic imaging/physiopathology
MH  - Ultrasonography, Doppler, Transcranial
PMC - PMC7279649
OTO - NOTNLM
OT  - *neuroradiology
OT  - *neurosurgery
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036404 [pii]
AID - 10.1136/bmjopen-2019-036404 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 4;10(6):e036404. doi: 10.1136/bmjopen-2019-036404.


PMID- 32503870
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 4
TI  - Assessment of visually guided reaching in prodromal Alzheimer's disease: a
      cross-sectional study protocol.
PG  - e035021
LID - 10.1136/bmjopen-2019-035021 [doi]
AB  - INTRODUCTION: Recent evidence has implicated the precuneus of the medial parietal
      lobe as one of the first brain areas to show pathological changes in Alzheimer's 
      disease (AD). Damage to the precuneus through focal brain injury is associated
      with impaired visually guided reaching, particularly for objects in peripheral
      vision. This raises the hypothesis that peripheral misreaching may be detectable 
      in patients with prodromal AD. The aim of this study is to assess the frequency
      and severity of peripheral misreaching in patients with mild cognitive impairment
      (MCI) and AD. METHODS AND ANALYSIS: Patients presenting with amnestic MCI,
      mild-to-moderate AD and healthy older-adult controls will be tested (target N=24 
      per group). Peripheral misreaching will be assessed using two set-ups: a
      tablet-based task of lateral reaching and motion-tracked radial reaching (in
      depth). There are two versions of each task, one where participants can look
      directly at targets (free reaching), another wheren they must maintain central
      fixation (peripheral reaching). All tasks will be conducted first on their
      dominant, and then their non-dominant side. For each combination of task and
      side, a Peripheral Misreaching Index (PMI) will be calculated as the increase in 
      absolute reaching error between free and peripheral reaching. Each patient will
      be classified as showing peripheral misreaching if their PMI is significantly
      abnormal, by comparison to control performance, on either side of space. We will 
      then test whether the frequency of peripheral misreaching exceeds the chance
      level in each patient group and compare the overall severity of misreaching
      between groups. ETHICS AND DISSEMINATION: Ethical approval was provided by the
      National Health Service (NHS) East of England, Cambridge Central Research Ethics 
      Committee (REC 19/EE/0170). The results of this study will be published in a
      peer-reviewed journal and presented at academic conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Mitchell, Alexandra G
AU  - Mitchell AG
AUID- ORCID: 0000-0001-8521-1891
AD  - School of Psychology, Philosophy & Language Sciences, The University of
      Edinburgh, Edinburgh, UK alexandra.mitchell@ed.ac.uk.
FAU - McIntosh, Robert D
AU  - McIntosh RD
AD  - School of Psychology, Philosophy & Language Sciences, The University of
      Edinburgh, Edinburgh, UK.
FAU - Rossit, Stephanie
AU  - Rossit S
AD  - School of Psychology, University of East Anglia, Norwich, Norfolk, UK.
FAU - Hornberger, Michael
AU  - Hornberger M
AD  - School of Medicine, University of East Anglia, Norwich, UK.
FAU - Pal, Suvankar
AU  - Pal S
AD  - Anne Rowling Regenerative Neurology Clinic, Centre for Clinical Brain Sciences,
      The University of Edinburgh, Edinburgh, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*diagnosis/physiopathology
MH  - Case-Control Studies
MH  - Clinical Protocols
MH  - Cognitive Dysfunction/physiopathology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prodromal Symptoms
MH  - *Psychomotor Performance
PMC - PMC7279656
OTO - NOTNLM
OT  - *adult neurology
OT  - *dementia
OT  - *neurology
OT  - *neuropathology
OT  - *neurophysiology
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035021 [pii]
AID - 10.1136/bmjopen-2019-035021 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 4;10(6):e035021. doi: 10.1136/bmjopen-2019-035021.


PMID- 32503867
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 4
TI  - Study protocol for an international, multicentre stepped-wedge cluster randomised
      trial to evaluate the impact of a digital antimicrobial stewardship smartphone
      application.
PG  - e033640
LID - 10.1136/bmjopen-2019-033640 [doi]
AB  - INTRODUCTION: With the widespread use of electronic health records and handheld
      electronic devices in hospitals, informatics-based antimicrobial stewardship
      interventions hold great promise as tools to promote appropriate antimicrobial
      drug prescribing. However, more research is needed to evaluate their optimal
      design and impact on quantity and quality of antimicrobial prescribing. METHODS
      AND ANALYSIS: Use of smartphone-based digital stewardship applications (apps)
      with local guideline directed empirical antimicrobial use by physicians will be
      compared with antimicrobial prescription as per usual as primary outcome in three
      hospitals in the Netherlands, Sweden and Switzerland. Secondary outcomes will
      include antimicrobial use metrics, clinical and process outcomes. A multicentre
      stepped-wedge cluster randomised trial will randomise entities defined as wards
      or specialty regarding time of introduction of the intervention. We will include 
      36 hospital entities with seven measurement periods in which the primary outcome 
      will be measured in 15 participating patients per time period per cluster. At
      participating wards, patients of at least 18 years of age using antimicrobials
      will be included. After a baseline period of 2-week measurements, six periods of 
      4 weeks will follow in which the intervention is introduced in 6 wards (in three 
      hospitals) until all 36 wards have implemented the intervention. Thereafter, we
      allow use of the app by everyone, and evaluate the sustainability of the app use 
      6 months later. ETHICS AND DISSEMINATION: This protocol has been approved by the 
      institutional review board of each participating centre. Results will be
      disseminated via media, to healthcare professionals via professional training and
      meetings and to researchers via conferences and publications. TRIAL REGISTRATION 
      NUMBER: ClinicalTrials.gov registry (NCT03793946). Stage; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Helou, R I
AU  - Helou RI
AUID- ORCID: 0000-0002-0448-6349
AD  - Department of Medical Microbiology and Infectious Diseases, Erasmus Medical
      Center, Rotterdam, The Netherlands.
FAU - Catho, Gaud
AU  - Catho G
AD  - Department of Infectious Diseases, Hopitaux Universitaires de Geneve, Geneva,
      Switzerland.
FAU - Peyravi Latif, Annabel
AU  - Peyravi Latif A
AD  - Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden.
FAU - Mouton, Johan
AU  - Mouton J
AD  - Department of Medical Microbiology and Infectious Diseases, Erasmus Medical
      Center, Rotterdam, The Netherlands.
FAU - Hulscher, M
AU  - Hulscher M
AD  - Scientific Center for Quality of Healthcare (IQ Healthcare), Radboud Institute
      for Health Sciences, Radboud University Medical Center, Nijmegen, The
      Netherlands.
FAU - Teerenstra, Steven
AU  - Teerenstra S
AD  - Department for Health Evidence, Radboud Institute for Health Sciences, Radboud
      University Medical Center, Nijmegen, The Netherlands.
FAU - Conly, John
AU  - Conly J
AD  - Department of Medicine, University of Calgary and Alberta Health Services,
      Calgary, Alberta, Canada.
FAU - Huttner, Benedikt D
AU  - Huttner BD
AUID- ORCID: 0000-0002-1749-9464
AD  - Department of Infectious Diseases, Hopitaux Universitaires de Geneve, Geneva,
      Switzerland.
FAU - Tangden, Thomas
AU  - Tangden T
AD  - Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden.
FAU - Verbon, Annelies
AU  - Verbon A
AD  - Department of Medical Microbiology and Infectious Diseases, Erasmus Medical
      Center, Rotterdam, The Netherlands a.verbon@erasmusmc.nl.
LA  - eng
SI  - ClinicalTrials.gov/NCT03793946
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Antimicrobial Stewardship
MH  - Cluster Analysis
MH  - Humans
MH  - *Mobile Applications
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Smartphone
MH  - Sweden
MH  - Switzerland
PMC - PMC7279644
OTO - NOTNLM
OT  - *infectious diseases
OT  - *information technology
OT  - *microbiology
OT  - *protocols & guidelines
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-033640 [pii]
AID - 10.1136/bmjopen-2019-033640 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 4;10(6):e033640. doi: 10.1136/bmjopen-2019-033640.


PMID- 32503866
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 4
TI  - Telephone health coaching with exercise monitoring using wearable activity
      trackers (TeGeCoach) for improving walking impairment in peripheral artery
      disease: study protocol for a randomised controlled trial and economic
      evaluation.
PG  - e032146
LID - 10.1136/bmjopen-2019-032146 [doi]
AB  - INTRODUCTION: Peripheral artery disease (PAD) is the third most prevalent
      cardiovascular disease worldwide, with smoking and diabetes being the strongest
      risk factors. The most prominent symptom is leg pain while walking, known as
      intermittent claudication. To improve mobility, first-line treatment for
      intermittent claudication is supervised exercise programmes, but these remain
      largely unavailable and economically impractical, which has led to the
      development of structured home-based exercise programmes. This trial aims to
      determine the effectiveness and cost advantage of TeGeCoach, a 12-month long
      home-based exercise programme, compared with usual care of PAD. It is
      hypothesised that TeGeCoach improves walking impairment and lowers the need of
      health care resources that are spent on patients with PAD. METHODS AND ANALYSIS: 
      The investigators conduct a prospective, pragmatic randomised controlled clinical
      trial in a health insurance setting. 1760 patients diagnosed with PAD at Fontaine
      stage II are randomly assigned to either TeGeCoach or care-as-usual. TeGeCoach
      consists of telemonitored intermittent walking exercise with medical supervision 
      by a physician and telephone health coaching. Participants allocated to the usual
      care group receive information leaflets and can access supervised exercise
      programmes, physical therapy and a variety of programmes for promoting a healthy 
      lifestyle. The primary outcome is patient reported walking ability based on the
      Walking Impairment Questionnaire. Secondary outcome measures include quality of
      life, health literacy and health behaviour. Claims data are used to collect total
      health care costs, healthcare resource use and (severe) adverse events. Outcomes 
      are measured at baseline, 12 and 24 months. ETHICS AND DISSEMINATION: Ethical
      approval has been obtained from the Medical Association Hamburg. Findings are
      disseminated through peer-reviewed journals, reports to the funding body,
      conference presentations and media press releases. Data from this trial are made 
      available to the public and researchers upon reasonable request.NCT03496948
      (www.clinicaltrials.gov), Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rezvani, Farhad
AU  - Rezvani F
AUID- ORCID: 0000-0002-2284-4410
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Hamburg, Germany f.rezvani@uke.de.
FAU - Heider, Dirk
AU  - Heider D
AD  - Department of Health Economics and Health Services Research, University Medical
      Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany.
FAU - Harter, Martin
AU  - Harter M
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Hamburg, Germany.
FAU - Konig, Hans-Helmut
AU  - Konig HH
AD  - Department of Health Economics and Health Services Research, University Medical
      Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany.
FAU - Bienert, Frank
AU  - Bienert F
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Brinkmann, Julia
AU  - Brinkmann J
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Herbarth, Lutz
AU  - Herbarth L
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Kramer, Edith
AU  - Kramer E
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Steinisch, Patrick
AU  - Steinisch P
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Freudenstein, Frank
AU  - Freudenstein F
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Terhalle, Rene
AU  - Terhalle R
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Grosse, Yvonne
AU  - Grosse Y
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Bock, Susanne
AU  - Bock S
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Posselt, Jacqueline
AU  - Posselt J
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Beutel, Corinna
AU  - Beutel C
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Reif, Franziska
AU  - Reif F
AD  - Kaufmannische Krankenkasse, Hannover, Niedersachsen, Germany.
FAU - Kirchhoff, Florian
AU  - Kirchhoff F
AD  - mhplus Krankenkasse, Nurnberg, Bayern, Germany.
FAU - Neuschwander, Carolin
AU  - Neuschwander C
AD  - mhplus Krankenkasse, Nurnberg, Bayern, Germany.
FAU - Loffler, Franziska
AU  - Loffler F
AD  - mhplus Krankenkasse, Nurnberg, Bayern, Germany.
FAU - Brunner, Lisa
AU  - Brunner L
AD  - mhplus Krankenkasse, Nurnberg, Bayern, Germany.
FAU - Dickmeis, Patrick
AU  - Dickmeis P
AD  - IEM GmbH, Stolberg, Nordrhein-Westfalen, Germany.
FAU - Heidenthal, Thomas
AU  - Heidenthal T
AD  - IEM GmbH, Stolberg, Nordrhein-Westfalen, Germany.
FAU - Schmitz, Lara
AU  - Schmitz L
AD  - Philips Germany GmbH, Hamburg, Hamburg, Germany.
FAU - Chase, Daniela Patricia
AU  - Chase DP
AD  - Philips Germany GmbH, Hamburg, Hamburg, Germany.
FAU - Seelenmeyer, Claudia
AU  - Seelenmeyer C
AD  - Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart,
      Baden-Wurttemberg, Germany.
FAU - Alscher, Mark Dominik
AU  - Alscher MD
AD  - Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart,
      Baden-Wurttemberg, Germany.
FAU - Tegtbur, Uwe
AU  - Tegtbur U
AD  - Department of Sports Medicine, Hannover Medical School, Hannover, Niedersachsen, 
      Germany.
FAU - Dirmaier, Jorg
AU  - Dirmaier J
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Hamburg, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03496948
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Exercise Therapy/*economics/*methods
MH  - *Fitness Trackers
MH  - Humans
MH  - *Mentoring
MH  - Peripheral Arterial Disease/*physiopathology/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - *Telephone
MH  - *Walking
PMC - PMC7279623
OTO - NOTNLM
OT  - *VASCULAR MEDICINE
OT  - *clinical trials
OT  - *health economics
OT  - *health services administration & management
OT  - *peripheral artery disease
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-032146 [pii]
AID - 10.1136/bmjopen-2019-032146 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 4;10(6):e032146. doi: 10.1136/bmjopen-2019-032146.


PMID- 32503865
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 4
TI  - Contextualised strategies to increase childhood and adolescent vaccination
      coverage in South Africa: a mixed-methods study.
PG  - e028476
LID - 10.1136/bmjopen-2018-028476 [doi]
AB  - INTRODUCTION: Despite the unparalleled success of immunisation in the control of 
      vaccine preventable diseases, immunisation coverage in South Africa remains
      suboptimal. While many evidence-based interventions have successfully improved
      vaccination coverage in other countries, they are not necessarily appropriate to 
      the immunisation needs, barriers and facilitators of South Africa. The aim of
      this research is to investigate barriers and facilitators to optimal vaccination 
      uptake, and develop contextualised strategies and implementation plans to
      increase childhood and adolescent vaccination coverage in South Africa. METHODS: 
      The study will employ a mixed-methods research design. It will be conducted over 
      three iterative phases and use the Adopt, Contextualise or Adapt (ACA) model as
      an overarching conceptual framework. Phase 1 will identify, and develop a
      sampling frame of, immunisation stakeholders involved in the design, planning and
      implementation of childhood and human papillomavirus immunisation programmes in
      South Africa. Phase 2 will identify the main barriers and facilitators to, and
      solutions for, increasing vaccination coverage. This phase will comprise
      exploratory qualitative research with stakeholders and a review of existing
      systematic reviews on interventions for improving vaccination coverage. Using the
      findings from Phase 2 and the ACA model, Phase 3 will develop a set of proposed
      interventions and implementation action plans for improving immunisation coverage
      in South Africa. These plans will be discussed, revised and finalised through a
      series of participatory stakeholder workshops and an online questionnaire,
      conducted as part of Phase 3. ETHICS: Ethical approval was obtained from the
      South African Medical Research Council (EC018-11/2018). No risks to participants 
      are expected. Various steps will be taken to ensure the anonymity and
      confidentiality of participants. DISSEMINATION: The study findings will be shared
      at stakeholder workshops, the website of Cochrane South Africa and academic
      publications and conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wiysonge, Charles Shey
AU  - Wiysonge CS
AUID- ORCID: 0000-0002-1273-4779
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
FAU - Mahasha, Phetole Walter
AU  - Mahasha PW
AUID- ORCID: 0000-0002-5750-3595
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
FAU - Ndwandwe, Duduzile Edith
AU  - Ndwandwe DE
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa.
FAU - Ngcobo, Ntombenhle
AU  - Ngcobo N
AD  - Independent Consultant, Pretoria, South Africa.
FAU - Grimmer, Karen
AU  - Grimmer K
AD  - Department of Physiotherapy, Stellenbosch University, Cape Town, South Africa.
FAU - Dizon, Janine
AU  - Dizon J
AD  - International Centre for Allied Health Evidence, University of South Australia - 
      City East Campus, Adelaide, South Australia, Australia.
FAU - Burnett, Rosemary J
AU  - Burnett RJ
AD  - South African Vaccination and Immunisation Centre, Department of Virology, Sefako
      Makgatho Health Sciences University, Pretoria, UK.
FAU - Cooper, Sara
AU  - Cooper S
AUID- ORCID: 0000-0001-9894-236X
AD  - Cochrane South Africa, South African Medical Research Council, Cape Town, South
      Africa sara.cooper@mrc.ac.za.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child Health Services/*trends
MH  - Female
MH  - Humans
MH  - Immunization Programs/*trends
MH  - Male
MH  - Program Development
MH  - Research Design
MH  - South Africa
MH  - Vaccination Coverage/*trends
PMC - PMC7279621
OTO - NOTNLM
OT  - *paediatric infectious disease & immunisation
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/06/07 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2018-028476 [pii]
AID - 10.1136/bmjopen-2018-028476 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 4;10(6):e028476. doi: 10.1136/bmjopen-2018-028476.


PMID- 32503729
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20210110
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 39
IP  - 6
DP  - 2020 Jun
TI  - COVID-19 and transplant research from China: An ethical dilemma.
PG  - 614-615
LID - S1053-2498(20)31521-7 [pii]
LID - 10.1016/j.healun.2020.04.014 [doi]
FAU - Rogers, Wendy A
AU  - Rogers WA
AD  - Department of Philosophy, Macquarie University, Sydney, New South Wales,
      Australia; Department of Clinical Medicine, Macquarie University, Sydney, New
      South Wales, Australia. Electronic address: Wendy.rogers@mq.edu.au.
FAU - Lavee, Jacob
AU  - Lavee J
AD  - Heart Transplantation Unit, Sheba Medical Center, Ramat Gan, Israel; Tel Aviv
      University Faculty of Medicine, Tel Aviv, Israel.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200419
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the
      International Society for Heart Transplantation
JID - 9102703
SB  - IM
CON - BMC Med Ethics. 2019 Nov 14;20(1):79. PMID: 31722695
MH  - *Betacoronavirus
MH  - COVID-19
MH  - China
MH  - Coronavirus Infections
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Tissue and Organ Procurement
PMC - PMC7167293
EDAT- 2020/06/07 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - S1053-2498(20)31521-7 [pii]
AID - 10.1016/j.healun.2020.04.014 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2020 Jun;39(6):614-615. doi:
      10.1016/j.healun.2020.04.014. Epub 2020 Apr 19.


PMID- 32503723
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1558-1926 (Electronic)
IS  - 1064-7406 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Aug
TI  - Approaches to Reducing Risk in Rhytidectomy Surgery.
PG  - 419-427
LID - S1064-7406(20)30034-1 [pii]
LID - 10.1016/j.fsc.2020.03.008 [doi]
AB  - Please verify edit, "complications could". All operations have sequelae. These
      are to be expected and must be told to patients. With surgery, the risk of
      complications is ever-present albeit infrequent. Facelift surgeons have ethical
      and intellectual duties to fully inform patients of these risks. Surgeons also
      must have strategies to reduce the risks, knowledge in how to manage each
      potential risk, and ability to help patients understand how complications could
      have occurred and how to cope with them. This article discusses facelift
      complications, the causes thereof, and how to assess a problem, manage each
      complication, and comfort a distraught patient.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Truswell, William H
AU  - Truswell WH
AD  - Division of Otolaryngology-Head and Neck Surgery, University of Connecticut
      School of Medicine, Farmington, CT, USA; American Board of Facial Plastic and
      Reconstructive Surgery; American Academy of Facial Plastic and Reconstructive
      Surgery; Private Practice, Easthampton, MA, USA. Electronic address:
      bill.truswell@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200506
PL  - United States
TA  - Facial Plast Surg Clin North Am
JT  - Facial plastic surgery clinics of North America
JID - 9414907
SB  - IM
MH  - Cicatrix/etiology/prevention & control
MH  - Cranial Nerve Injuries/etiology/*prevention & control
MH  - Hematoma/etiology/*prevention & control
MH  - Humans
MH  - Necrosis/etiology/prevention & control
MH  - Patient Satisfaction
MH  - Postoperative Complications/etiology/*prevention & control
MH  - Rhytidoplasty/*adverse effects
MH  - Skin/pathology
MH  - Surgical Wound Infection/etiology/prevention & control
OTO - NOTNLM
OT  - Hair loss
OT  - Hematoma
OT  - Infection
OT  - Nerve damage
OT  - Scar formation
OT  - Skin necrosis
OT  - The unhappy patient
COIS- Disclosure The author had nothing to disclose.
EDAT- 2020/06/07 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - S1064-7406(20)30034-1 [pii]
AID - 10.1016/j.fsc.2020.03.008 [doi]
PST - ppublish
SO  - Facial Plast Surg Clin North Am. 2020 Aug;28(3):419-427. doi:
      10.1016/j.fsc.2020.03.008. Epub 2020 May 6.


PMID- 32503707
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20201218
IS  - 1097-6795 (Electronic)
IS  - 0894-7317 (Linking)
VI  - 33
IP  - 6
DP  - 2020 Jun
TI  - Echocardiography in Pandemic: Front-Line Perspective, Expanding Role of
      Ultrasound, and Ethics of Resource Allocation.
PG  - 683-689
LID - S0894-7317(20)30218-2 [pii]
LID - 10.1016/j.echo.2020.04.007 [doi]
AB  - The grave clinical context of the coronavirus disease 2019 (COVID-19) pandemic
      must be understood. Italy is immersed in the COVID-19 pandemic. Most of the world
      will soon follow. The United States currently has the most documented cases of
      COVID-19 of any nation. Severe acute respiratory syndrome coronavirus-2
      (SARS-CoV-2)-associated acute cardiomyopathy is common in critical care patients 
      and is associated with a high mortality rate. Patients with COVID-19 frequently
      require mechanical support for adequate oxygenation. A severe shortfall of
      ventilators is predicted. Of equal concern is the projected shortage of trained
      professionals required to care for patients on mechanical ventilation.
      Ultrasonography is proving to be a valuable tool for identifying the pulmonary
      manifestations and progression of COVID-19. Lung ultrasound also facilitates
      successful weaning from mechanical ventilation. Ultrasonography of the lung,
      pleura, and diaphragm are easily mastered by experienced echocardiographers.
      Echocardiography has an established role for optimal fluid management and
      recognition of cardiac disease, including SARS-CoV-2-associated acute
      cardiomyopathy. Cardiologists, anesthesiologists, sonographers, and all providers
      should be prepared to commit their full spectrum of skills to mitigate the
      consequences of the pandemic. We should also be prepared to collaborate and
      cross-train to expand professional services as necessary. During a declared
      health care crisis, providers must be familiar with the ethical principles,
      organizational structure, practical application, and gravity of limited resource 
      allocation.
CI  - Copyright (c) 2020 American Society of Echocardiography. Published by Elsevier
      Inc. All rights reserved.
FAU - Drake, Daniel H
AU  - Drake DH
AD  - Munson Medical Center, Traverse City, Michigan. Electronic address:
      daniel.h.drake@gmail.com.
FAU - De Bonis, Michele
AU  - De Bonis M
AD  - Vita-Salute San Raffaele University, San Raffaele University Hospital, Milan,
      Italy.
FAU - Covella, Michele
AU  - Covella M
AD  - U Parini Hospital, Aosta, Italy.
FAU - Agricola, Eustachio
AU  - Agricola E
AD  - Vita-Salute San Raffaele University, San Raffaele University Hospital, Milan,
      Italy.
FAU - Zangrillo, Alberto
AU  - Zangrillo A
AD  - Vita-Salute San Raffaele University, San Raffaele University Hospital, Milan,
      Italy.
FAU - Zimmerman, Karen G
AU  - Zimmerman KG
AD  - Henry Ford Health System, Detroit, Michigan.
FAU - Cobey, Frederick C
AU  - Cobey FC
AD  - Tufts University Medical Center, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200410
PL  - United States
TA  - J Am Soc Echocardiogr
JT  - Journal of the American Society of Echocardiography : official publication of the
      American Society of Echocardiography
JID - 8801388
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiovascular Diseases/complications/*diagnosis
MH  - Coronavirus Infections/*complications
MH  - Echocardiography/*methods
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*complications
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
PMC - PMC7151341
OTO - NOTNLM
OT  - Echocardiography
OT  - Mechanical
OT  - Pandemics
OT  - Resource allocation
OT  - Ultrasonography
OT  - Ventilators
EDAT- 2020/06/07 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/03/29 00:00 [received]
PHST- 2020/04/04 00:00 [revised]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - S0894-7317(20)30218-2 [pii]
AID - 10.1016/j.echo.2020.04.007 [doi]
PST - ppublish
SO  - J Am Soc Echocardiogr. 2020 Jun;33(6):683-689. doi: 10.1016/j.echo.2020.04.007.
      Epub 2020 Apr 10.


PMID- 32503609
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1472-6947 (Electronic)
IS  - 1472-6947 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 5
TI  - 360-degree Delphi: addressing sociotechnical challenges of healthcare IT.
PG  - 101
LID - 10.1186/s12911-020-1071-x [doi]
AB  - BACKGROUND: IT systems in the healthcare field can have a marked sociotechnical
      impact: they modify communication habits, alter clinical processes and may have
      serious ethical implications. The introduction of such systems involves very
      different groups of stakeholders because of the inherent multi-professionalism in
      medicine and the role of patients and their relatives that are often
      underrepresented. Each group contributes distinct perspectives and particular
      needs, which create specific requirements for IT systems and may strongly
      influence their acceptance and success. In the past, needs analysis, challenges
      and requirements for medical IT systems have often been addressed using consensus
      techniques such as the Delphi technique. Facing the heterogeneous spectrum of
      stakeholders there is a need to develop these techniques further to control the
      (strong) influence of the composition of the expert panel on the outcome and to
      deal systematically with potentially incompatible needs of stakeholder groups.
      This approach uses the strong advantages a Delphi study has, identifies the
      disadvantages of traditional Delphi techniques and aims to introduce and evaluate
      a modified approach called 360-Degree Delphi. Key aspects of 360-Degree Delphi
      are tested by applying the approach to the needs and requirements analysis of a
      system for managing patients' advance directives and living wills. METHODS:
      360-Degree Delphi (short 360 degrees D), as a modified Delphi process, is
      specified as a structured workflow with the optional use of stakeholder groups.
      The approach redefines the composition of the expert panel by setting up groups
      of different stakeholders. Consensus is created within individual stakeholder
      groups, but is also communicated between groups, while the iterative structure of
      the Delphi process remains unchanged. We hypothesize that (1) 360-Degree Delphi
      yields complementary statements from different stakeholders, which would be lost 
      in classical Delphi; while (2) the variation of statements within individual
      stakeholder groups is lower than within the total collective. A user study is
      performed that addresses five stakeholder groups (patients, relatives, medical
      doctors, nurses and software developers) on the topic of living will
      communication in an emergency context. Qualitative open questions are used in a
      Delphi round 0. Answer texts are coded by independent raters who carry out
      systematic bottom-up qualitative text analysis. Inter-rater reliability is
      calculated and the resulting codes are used to test the hypotheses. Qualitative
      results are transferred into quantitative questions and then surveyed in round 1.
      The study took place in Germany. RESULTS: About 25% of the invited experts
      (stakeholders) agreed to take part in the Delphi round 0 (three patients, two
      relatives, three medical doctors, two qualified nurses and three developers),
      forming a structured panel of the five stakeholder groups. Two raters created a
      bottom-up coding, and 238 thematic codes were identified by the qualitative text 
      analysis. The inter-rater reliability showed that 44.95% of the codes were
      semantically similar and coded for the same parts of the raw textual replies.
      Based on a consented coding list, a quantitative online-questionnaire was
      developed and send to different stakeholder groups. With respect to the
      hypotheses, Delphi round 0 had the following results: (1) doctors had a
      completely different focus from all the other stakeholder groups on possible
      channels of communications with the patient; (2) the dispersion of codes within
      individual stakeholder groups and within the total collective - visualized by box
      plots - was approximately 28% higher in the total collective than in the
      sub-collectives, but without a marked effect size. With respect to the
      hypotheses, Delphi round 1 had the following results: different stakeholder
      groups had highly diverging opinions with respect to central questions on
      IT-development. For example, when asked to rate the importance of access control 
      against high availability of data (likert scale, 1 meaning restrictive data
      access, 6 easy access to all data), patients (mean 4.862, Stdev +/- 1.866) and
      caregivers (mean 5.667, Stdev: +/- 0.816) highly favored data availability, while
      relatives would restrict data access (mean 2.778, stdev +/- 1.093). In
      comparison, the total group would not be representative of either of these
      individual stakeholder needs (mean 4.344, stdev +/- 1.870). CONCLUSION:
      360-Degree Delphi is feasible and allows different stakeholder groups within an
      expert panel to reach agreement individually. Thus, it generates a more detailed 
      consensus which pays more tribute to individual stakeholders needs. This has the 
      potential to improve the time to consensus as well as to produce a more
      representative and precise needs and requirements analysis. However, the method
      may create new challenges for the IT development process, which will have to deal
      with complementary or even contradictory statements from different stakeholder
      groups.
FAU - Waldmuller, Heiko
AU  - Waldmuller H
AUID- ORCID: 0000-0002-1745-3060
AD  - Department of Medical Informatics, Uniklinik RWTH Aachen, Aachen, Germany.
      heiko.waldmueller@stud-mail.uni-wuerzburg.de.
AD  - Faculty of Medicine, University of Wuerzburg, Wurzburg, Germany.
      heiko.waldmueller@stud-mail.uni-wuerzburg.de.
FAU - Spreckelsen, Cord
AU  - Spreckelsen C
AD  - Institute of Medical Statistics, Computer and Data Sciences, Jena University
      Hospital, Jena, Germany.
FAU - Rudat, Hannah
AU  - Rudat H
AD  - Department of Medical Informatics, Uniklinik RWTH Aachen, Aachen, Germany.
FAU - Krumm, Norbert
AU  - Krumm N
AD  - Department of Palliative Medicine, Medical Faculty RWTH Aachen University,
      Aachen, Germany.
FAU - Rolke, Roman
AU  - Rolke R
AD  - Department of Palliative Medicine, Medical Faculty RWTH Aachen University,
      Aachen, Germany.
FAU - Jonas, Stephan Michael
AU  - Jonas SM
AD  - Department of Informatics, Technical University of Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - BMC Med Inform Decis Mak
JT  - BMC medical informatics and decision making
JID - 101088682
SB  - IM
MH  - *Biomedical Technology
MH  - Consensus
MH  - *Delphi Technique
MH  - Germany
MH  - Humans
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
PMC - PMC7275570
OTO - NOTNLM
OT  - *360-degree Delphi
OT  - *Consensus
OT  - *Delphi technique
OT  - *Feedback
OT  - *Group processes
OT  - *Health information management
OT  - *Medical informatics
OT  - *Project planning
OT  - *Qualitative research
OT  - *Quality improvement
OT  - *Stakeholder
EDAT- 2020/06/07 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/06/07 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1186/s12911-020-1071-x [doi]
AID - 10.1186/s12911-020-1071-x [pii]
PST - epublish
SO  - BMC Med Inform Decis Mak. 2020 Jun 5;20(1):101. doi: 10.1186/s12911-020-1071-x.


PMID- 32503386
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 8
DP  - 2020 Aug
TI  - Academic excellence in Latin America: Social accountability of medical schools.
PG  - 929-936
LID - 10.1080/0142159X.2020.1770712 [doi]
AB  - Context: Social accountability of medical schools has emerged as a standard of
      excellence in medical education during the last decade. However, the lack of
      valid and reliable instruments to estimate social accountability has limited the 
      possibility of measuring the impact that medical schools have in society. Our aim
      was to develop an instrument and validate its use for assessing social
      accountability in Latin American countries.Methods: We used a three-phase mixed
      methods research design to develop, validate and estimate social accountability
      in a diverse convenient sample of 49 medical schools from 16 Latin American
      countries. We used a qualitative framework approach and a Delphi consensus method
      to design an instrument with high content validity. Finally, we assessed the
      psychometric properties of the instrument.Results: The Social Accountability
      Instrument for Latin America (SAIL) contained 21 items in four domains: mission
      and quality improvement, public policy, community engagement, and professional
      integrity. Its reliability index, estimated using Cronbach's alpha, was very high
      (0.96). Most of the medical schools that had ranked over the 80th percentile on
      traditional national academic estimates did not reach the 80th percentile using
      SAIL.Conclusions: There are validity arguments (content and reliability) to
      support the measurement of social accountability using the SAIL instrument. Its
      application showed that it provides a complementary dimension to that
      traditionally obtained when estimating quality in medical schools.
FAU - Puschel, Klaus
AU  - Puschel K
AD  - Department of Family Medicine, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Riquelme, Arnoldo
AU  - Riquelme A
AD  - Department of Gastroenterology, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
AD  - Department of Health Sciences, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Sapag, Jaime
AU  - Sapag J
AD  - Department of Family Medicine, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Moore, Philippa
AU  - Moore P
AUID- ORCID: 0000-0002-3578-7240
AD  - Department of Family Medicine, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Diaz, Luis A
AU  - Diaz LA
AUID- ORCID: 0000-0002-8540-4930
AD  - Department of Gastroenterology, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Fuentes-Lopez, Eduardo
AU  - Fuentes-Lopez E
AD  - Department of Health Sciences, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Burdick, William
AU  - Burdick W
AD  - Foundation for Advancement of International Medical Education and Research
      (FAIMER), Philadelphia, PA, USA.
AD  - Department of Emergency Medicine, Drexel University College of Medicine,
      Philadelphia, PA, USA.
FAU - Norcini, John
AU  - Norcini J
AD  - Foundation for Advancement of International Medical Education and Research
      (FAIMER), Philadelphia, PA, USA.
FAU - Jimenez de la Jara, Jorge
AU  - Jimenez de la Jara J
AD  - Department of Public Health, Pontificia Universidad Catolica de Chile, Santiago, 
      Chile.
FAU - Campos, Henry
AU  - Campos H
AD  - Rector, Universidade Federal do Ceara, Fortaleza, Brazil.
FAU - Valdez, Jorge E
AU  - Valdez JE
AD  - School of Medicine, Tecnologico de Monterrey, Monterrey Nuevo Leon, Mexico.
FAU - Llosa, Maria Paola
AU  - Llosa MP
AD  - School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
FAU - Lamus-Lemus, Francisco
AU  - Lamus-Lemus F
AD  - Department of Medical Education, Universidad de La Sabana, Cundinamarca,
      Colombia.
FAU - Yulitta, Horacio
AU  - Yulitta H
AD  - Evaluation Professional Board, Argentinean Paediatrics Society, Buenos Aires,
      Argentina.
FAU - Grez, Marcela
AU  - Grez M
AD  - Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
LA  - eng
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - *Education, Medical
MH  - Humans
MH  - Latin America
MH  - Reproducibility of Results
MH  - *Schools, Medical
MH  - Social Responsibility
OTO - NOTNLM
OT  - *Ethics/attitudes
OT  - *general
OT  - *institutional accreditation
OT  - *postgraduate
OT  - *undergraduate
EDAT- 2020/06/07 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/06/07 06:00 [entrez]
AID - 10.1080/0142159X.2020.1770712 [doi]
PST - ppublish
SO  - Med Teach. 2020 Aug;42(8):929-936. doi: 10.1080/0142159X.2020.1770712. Epub 2020 
      Jun 5.


PMID- 32503260
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-3425 (Print)
IS  - 2076-3425 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Selected Ionotropic Receptors and Voltage-Gated Ion Channels: More Functional
      Competence for Human Induced Pluripotent Stem Cell (iPSC)-Derived Nociceptors.
LID - E344 [pii]
LID - 10.3390/brainsci10060344 [doi]
AB  - Preclinical research using different rodent model systems has largely contributed
      to the scientific progress in the pain field, however, it suffers from
      interspecies differences, limited access to human models, and ethical concerns.
      Human induced pluripotent stem cells (iPSCs) offer major advantages over animal
      models, i.e., they retain the genome of the donor (patient), and thus allow
      donor-specific and cell-type specific research. Consequently, human iPSC-derived 
      nociceptors (iDNs) offer intriguingly new possibilities for patient-specific,
      animal-free research. In the present study, we characterized iDNs based on the
      expression of well described nociceptive markers and ion channels, and we
      conducted a side-by-side comparison of iDNs with mouse sensory neurons.
      Specifically, immunofluorescence (IF) analyses with selected markers including
      early somatosensory transcription factors (BRN3A/ISL1/RUNX1), the low-affinity
      nerve growth factor receptor (p75), hyperpolarization-activated cyclic
      nucleotide-gated channels (HCN), as well as high voltage-gated calcium channels
      (VGCC) of the CaV2 type, calcium permeable TRPV1 channels, and ionotropic GABAA
      receptors, were used to address the characteristics of the iDN phenotype. We
      further combined IF analyses with microfluorimetric Ca(2+) measurements to
      address the functionality of these ion channels in iDNs. Thus, we provide a
      detailed morphological and functional characterization of iDNs, thereby,
      underpinning their enormous potential as an animal-free alternative for human
      specific research in the pain field for unveiling pathophysiological mechanisms
      and for unbiased, disease-specific personalized drug development.
FAU - Schoepf, Clemens L
AU  - Schoepf CL
AUID- ORCID: 0000-0001-5817-1572
FAU - Zeidler, Maximilian
AU  - Zeidler M
FAU - Spiecker, Lisa
AU  - Spiecker L
AD  - Institute of Physiology, Medical University of Innsbruck, 6020 Innsbruck,
      Austria.
FAU - Kern, Georg
AU  - Kern G
AD  - Institute of Physiology, Medical University of Innsbruck, 6020 Innsbruck,
      Austria.
FAU - Lechner, Judith
AU  - Lechner J
AD  - Institute of Physiology, Medical University of Innsbruck, 6020 Innsbruck,
      Austria.
FAU - Kummer, Kai K
AU  - Kummer KK
AD  - Institute of Physiology, Medical University of Innsbruck, 6020 Innsbruck,
      Austria.
FAU - Kress, Michaela
AU  - Kress M
AUID- ORCID: 0000-0002-8921-7470
AD  - Institute of Physiology, Medical University of Innsbruck, 6020 Innsbruck,
      Austria.
LA  - eng
GR  - DK-SPIN W1206/Austrian Science Fund
PT  - Journal Article
DEP - 20200603
PL  - Switzerland
TA  - Brain Sci
JT  - Brain sciences
JID - 101598646
PMC - PMC7348931
OTO - NOTNLM
OT  - HCN channel
OT  - KCC3
OT  - TRPV1
OT  - analgesic
OT  - p75
OT  - pain
OT  - sensory neuron
OT  - synaptic varicosity
OT  - voltage-gated calcium channel
EDAT- 2020/06/07 06:00
MHDA- 2020/06/07 06:01
CRDT- 2020/06/07 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/06/07 06:01 [medline]
AID - brainsci10060344 [pii]
AID - 10.3390/brainsci10060344 [doi]
PST - epublish
SO  - Brain Sci. 2020 Jun 3;10(6). pii: brainsci10060344. doi:
      10.3390/brainsci10060344.


PMID- 32503223
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 11
DP  - 2020 Jun 3
TI  - Current Guidelines for Protecting Health Workers from Occupational Tuberculosis
      Are Necessary, but Not Sufficient: Towards a Comprehensive Occupational Health
      Approach.
LID - E3957 [pii]
LID - 10.3390/ijerph17113957 [doi]
AB  - Health workers globally are at elevated occupational risk of tuberculosis
      infection and disease. While a raft of guidelines have been published over the
      past 25 years on infection prevention and control (IPC) in healthcare, studies in
      different settings continue to show inadequate implementation and persistence of 
      risk. The aim of this commentary is to argue, based on the literature and our own
      research, that a comprehensive occupational health approach is an essential
      complement to IPC guidelines. Such an approach includes a health system framework
      focusing on upstream or mediating components, such as a statutory regulation,
      leadership, an information system, and staff trained in protective disciplines.
      Within the classical prevention framework, primary prevention needs to be
      complemented by occupational health services (secondary prevention) and worker's 
      compensation (tertiary prevention). A worker-centric approach recognises the
      ethical implications of screening health workers, as well as the stigma perceived
      by those diagnosed with tuberculosis. It also provides for the voiced experience 
      of health workers and their participation in decision-making. We argue that such 
      a comprehensive approach will contribute to both the prevention of occupational
      tuberculosis and to the ability of a health system to withstand other crises of
      infectious hazards to its workforce.
FAU - Ehrlich, Rodney
AU  - Ehrlich R
AD  - Division of Occupational Medicine, School of Public Health and Family Medicine,
      University of Cape Town, Observatory, Cape Town 8001, South Africa.
FAU - Spiegel, Jerry M
AU  - Spiegel JM
AD  - School of Population and Public Health, University of British Columbia, 2206 East
      Mall, Vancouver, BC V6T 1Z3, Canada.
FAU - Adu, Prince
AU  - Adu P
AD  - School of Population and Public Health, University of British Columbia, 2206 East
      Mall, Vancouver, BC V6T 1Z3, Canada.
FAU - Yassi, Annalee
AU  - Yassi A
AD  - School of Population and Public Health, University of British Columbia, 2206 East
      Mall, Vancouver, BC V6T 1Z3, Canada.
LA  - eng
GR  - ROH-115212/Canadian Institute of Health Research (CIHR)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Health Personnel
MH  - Humans
MH  - Infection Control
MH  - *Occupational Diseases
MH  - *Occupational Health
MH  - *Tuberculosis
MH  - Workers' Compensation
PMC - PMC7313452
OTO - NOTNLM
OT  - *health system
OT  - *health workers
OT  - *infection prevention and control
OT  - *occupational health
OT  - *tuberculosis
COIS- The authors declare no conflict of interest.
EDAT- 2020/06/07 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/06/07 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/07 06:00 [entrez]
PHST- 2020/06/07 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - ijerph17113957 [pii]
AID - 10.3390/ijerph17113957 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 3;17(11). pii: ijerph17113957. doi:
      10.3390/ijerph17113957.


PMID- 32503059
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20200923
IS  - 1439-7803 (Electronic)
IS  - 0044-2771 (Linking)
VI  - 58
IP  - 9
DP  - 2020 Sep
TI  - [Best supportive care in a young patient with locally advanced MSI-high colon
      cancer?]
PG  - 872-876
LID - 10.1055/a-1174-0732 [doi]
AB  - Molecular diagnostics are increasingly important to guide treatment decisions in 
      oncologic patients. For instance, the presence of high-grade
      microsatellite-instability (MSI-high) is considered to be one of the major
      positive predictors of therapy response to immune-checkpoint inhibitors in
      patients with solid tumors. Based on impressive results from several
      immune-oncology trials, the American Food and Drug Administration (FDA) granted
      approval to immunotherapy in any previously treated, MSI-high solid cancer in
      2017. Here, we report the clinical case of a young patient with MSI-high
      colorectal cancer. The case illustrates, that insurance companies in Germany are 
      still reluctant to cover the cost of immunotherapy in this specific patient
      subgroup, which, in our opinion, results in an ethically problematic therapeutic 
      dilemma.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Welland, Sabrina
AU  - Welland S
AD  - Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische
      Hochschule Hannover.
FAU - De Castro, Tiago
AU  - De Castro T
AD  - Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische
      Hochschule Hannover.
FAU - Wirth, Thomas
AU  - Wirth T
AD  - Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische
      Hochschule Hannover.
FAU - Kleine, Moritz
AU  - Kleine M
AD  - Klinik fur Allgemeine, Viszeral- und Transplantationschirurgie, Medizinische
      Hochschule Hannover.
FAU - Ringe, Kristina Imeen
AU  - Ringe KI
AD  - Institut fur Diagnostische und Interventionelle Radiologie, Medizinische
      Hochschule Hannover.
FAU - Saborowski, Anna
AU  - Saborowski A
AD  - Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische
      Hochschule Hannover.
FAU - Vogel, Arndt
AU  - Vogel A
AD  - Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische
      Hochschule Hannover.
LA  - ger
PT  - Case Reports
PT  - Journal Article
TT  - Best supportive care bei einer jungen Patientin mit lokal fortgeschrittenem
      MSI-high-Kolonkarzinom?
DEP - 20200605
PL  - Germany
TA  - Z Gastroenterol
JT  - Zeitschrift fur Gastroenterologie
JID - 0033370
SB  - IM
MH  - Colonic Neoplasms/therapy
MH  - Colorectal Neoplasms/genetics/*immunology/therapy
MH  - Germany
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Microsatellite Instability
MH  - Treatment Outcome
COIS- AV hat Honorare von Roche, BMS, MSD, AstraZeneca und Merck erhalten.
EDAT- 2020/06/06 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 10.1055/a-1174-0732 [doi]
PST - ppublish
SO  - Z Gastroenterol. 2020 Sep;58(9):872-876. doi: 10.1055/a-1174-0732. Epub 2020 Jun 
      5.


PMID- 32502525
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 223
DP  - 2020 Sep 1
TI  - Industry challenges and approaches to food waste.
PG  - 112993
LID - S0031-9384(20)30307-3 [pii]
LID - 10.1016/j.physbeh.2020.112993 [doi]
AB  - Industry attention to the issue of food waste, simplistically defined as inedible
      byproducts of food production practices, is on the rise due to economic,
      social/ethical and environmental factors related to management of these
      materials. Long considered an unavoidable cost of doing business, many industry
      players are increasingly seeing food waste as a key sustainability issue and as
      an under-utilized resource. Conversely, wasted food, simplistically defined as
      uneaten edible food, is largely generated at the consumer level either at or away
      from home. Given the complex social context related to food preferences, customs 
      and the degree of awareness at the consumer level, reducing waste in home may be 
      difficult without technology and industry intervention. From that perspective,
      companies already serve this role through food storage, preservation and
      processing techniques as well as advancements in packaging technologies. Beyond
      product design elements, industry can support technology that can help reduce
      wasted food at the consumer level through advancements in "connected homes" that 
      use mobile apps, smart appliances and e-commerce platforms to help with planning,
      inventory management and cooking techniques. This is an opinion paper based on
      direct practical experience and collaboration with other companies in retail,
      restaurant and manufacturing sectors.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Tavill, Gail
AU  - Tavill G
AD  - Packaging & Food Systems Sustainability Consulting, LLC, United States.
      Electronic address: gailgogreen90@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
MH  - Attitude
MH  - Commerce
MH  - *Food
MH  - Food Preferences
MH  - *Refuse Disposal
OTO - NOTNLM
OT  - *Byproducts
OT  - *Food scraps
OT  - *Food waste
OT  - *Inedible
OT  - *Wasted food
COIS- Declaration of Competing Interest None.
EDAT- 2020/06/06 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - S0031-9384(20)30307-3 [pii]
AID - 10.1016/j.physbeh.2020.112993 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Sep 1;223:112993. doi: 10.1016/j.physbeh.2020.112993. Epub
      2020 Jun 2.


PMID- 32502313
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20210624
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Nov
TI  - Emerging evidence to support not always "just saying no" to SARS-CoV-2 positive
      donors.
PG  - 3261-3262
LID - 10.1111/ajt.16119 [doi]
FAU - Kates, Olivia S
AU  - Kates OS
AUID- ORCID: 0000-0003-4381-0049
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
FAU - Fisher, Cynthia E
AU  - Fisher CE
AUID- ORCID: 0000-0001-6661-9162
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
FAU - Rakita, Robert M
AU  - Rakita RM
AUID- ORCID: 0000-0001-8105-8455
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
FAU - Reyes, Jorge D
AU  - Reyes JD
AUID- ORCID: 0000-0003-3065-8674
AD  - Division of Transplant Surgery, University of Washington, Seattle, Washington,
      USA.
FAU - Limaye, Ajit P
AU  - Limaye AP
AUID- ORCID: 0000-0002-5350-9025
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
LA  - eng
GR  - K23 HL143050/HL/NHLBI NIH HHS/United States
GR  - T32 AI118690/AI/NIAID NIH HHS/United States
PT  - Letter
DEP - 20200618
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
RN  - 0 (DNA, Viral)
SB  - IM
MH  - COVID-19/epidemiology/*transmission
MH  - DNA, Viral/*analysis
MH  - Disease Transmission, Infectious/*prevention & control
MH  - Humans
MH  - Organ Transplantation/*methods
MH  - Pandemics
MH  - SARS-CoV-2/*genetics
MH  - *Tissue Donors
MH  - Tissue and Organ Procurement/*methods
PMC - PMC7300931
OTO - NOTNLM
OT  - *donors and donation: donor evaluation
OT  - *editorial/personal viewpoint
OT  - *ethics
OT  - *ethics and public policy
OT  - *infection and infectious agents - viral
OT  - *infectious disease
OT  - *liver transplantation: living donor
OT  - *organ procurement and allocation
OT  - *organ transplantation in general
EDAT- 2020/06/06 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/05/27 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 10.1111/ajt.16119 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Nov;20(11):3261-3262. doi: 10.1111/ajt.16119. Epub 2020 Jun
      18.


PMID- 32502144
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 6
DP  - 2020
TI  - Clinical presentation and outcomes of pre-eclampsia and eclampsia at a national
      hospital, Kenya: A retrospective cohort study.
PG  - e0233323
LID - 10.1371/journal.pone.0233323 [doi]
AB  - BACKGROUND: Hypertensive disorders in pregnancy including pre-eclampsia are
      associated with maternal and newborn mortality and morbidity. Early detection is 
      vital for effective treatment and management of pre-eclampsia. This study
      examines and compares the clinical presentation and outcomes between early- and
      late-onset pre-eclampsia over a two year period. METHODS: A retrospective cohort 
      study design which examines socio-demographic characteristics, treatment,
      outcomes, and fetal and maternal complications among women with early onset of
      pre-eclampsia (EO-PE) and late onset of pre-eclampsia (LO-PE). De-identified
      records of women who attended antenatal, intrapartum and postnatal care services 
      and experienced pre-eclampsia at Kenyatta National teaching and referral hospital
      were reviewed. We used chi square, t-test, and calculated odds ratio to determine
      any significant differences between the EO-PE and LO-PE cohorts. RESULTS: Out of 
      620 pre-eclamptic and eclamptic patients' records analyzed; 44 percent (n = 273) 
      exhibited EO-PE, while 56 percent had late onset. Women with EO-PE compared to
      LO-PE had greater odds of adverse maternal and perinatal outcomes including
      hemolysis elevated liver enzymes and low platelets (HELLP) syndrome (OR: 4.3; CI 
      2.0-10.2; p<0.001), renal dysfunction (OR; 1.7; CI 0.7-4.1; p = 0.192),
      stillbirth (OR = 4.9; CI 3.1-8.1; p<0.001), and neonatal death (OR: 8.5; CI
      3.8-21.3; p<0.001). EO-PE was also associated with higher odds of prolonged
      maternal hospitalization, beyond seven days (OR = 5.8; CI 3.9-8.4; p<0.001), and 
      antepartum hemorrhage (OR = 5.8; CI 1.1-56.4; p<0.001). Neonates born after early
      onset of pre-eclampsia had increased odds of respiratory distress (OR = 17.0; CI 
      9.0-32.3, p<0.001) and birth asphyxia (OR: 1.9; CI 0.7-4.8; p = 0.142).
      CONCLUSIONS: The profiles and outcomes of women with EO-PE (compared to late
      onset) suggest that seriousness of morbidity increases with earlier onset. To
      reduce adverse neonatal and maternal outcomes, it is critical to identify,
      manage, referral and closely follow-up pregnant women with pre-eclampsia
      throughout the pregnancy continuum. ETHICAL APPROVAL: This study protocol was
      approved by Population Council's research ethics Institutional Review Board,
      Protocol 813, and KNH-UoN Ethics and Research Committee, Protocol 293/06/2017.
FAU - Ndwiga, Charity
AU  - Ndwiga C
AUID- ORCID: 0000-0001-9926-1486
AD  - Population Council, Nairobi, Kenya.
FAU - Odwe, George
AU  - Odwe G
AUID- ORCID: 0000-0002-5330-2366
AD  - Population Council, Nairobi, Kenya.
FAU - Pooja, Sripad
AU  - Pooja S
AD  - Population Council, Washington, DC, United States of America.
FAU - Ogutu, Omondi
AU  - Ogutu O
AD  - OBGyn Department, University of Nairobi, Nairobi, Kenya.
FAU - Osoti, Alfred
AU  - Osoti A
AD  - OBGyn Department, University of Nairobi, Nairobi, Kenya.
FAU - E Warren, Charlotte
AU  - E Warren C
AD  - Population Council, Washington, DC, United States of America.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Eclampsia/*epidemiology/physiopathology
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Hypertension/physiopathology
MH  - Infant, Newborn
MH  - Kenya/epidemiology
MH  - Middle Aged
MH  - Perinatal Death
MH  - Pre-Eclampsia/*epidemiology/physiopathology
MH  - Pregnancy
MH  - Pregnancy Outcome/*epidemiology
MH  - Prenatal Care/methods
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC7274433
COIS- The authors declare no competing interests.
EDAT- 2020/06/06 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
AID - 10.1371/journal.pone.0233323 [doi]
AID - PONE-D-20-01091 [pii]
PST - epublish
SO  - PLoS One. 2020 Jun 5;15(6):e0233323. doi: 10.1371/journal.pone.0233323.
      eCollection 2020.


PMID- 32502040
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - The research of Tuna Huichun Gong on pulmonary function, exercise tolerance, and 
      quality of life in patients with chronic obstructive pulmonary disease based on
      the concept of early pulmonary rehabilitation.
PG  - e20625
LID - 10.1097/MD.0000000000020625 [doi]
AB  - INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a common
      high-burden and highly disabling lung disease. The quality of life and exercise
      endurance of patients with COPD is often low because of atrophy of the
      respiratory and skeletal muscles. Although recommended by the global initiative
      for chronic obstructive lung disease guidelines, pulmonary rehabilitation (PR)
      has not been used widely because of its inherent limitations. Tuna-Hui-Chun-Gong 
      (TNHCG) is a popular traditional exercise used to treat COPD in China. We aim to 
      evaluate the safety and efficacy of TNHCG for PR of COPD. METHODS: The provided
      protocol is for a single-blind randomized controlled trial in which 120 COPD
      patients will be randomly and equally divided into the experimental or control
      group. The control group will be treated with standard COPD drugs while the
      experimental group will perform TNHCG exercises apart from standard drug
      treatment. The duration of treatment will be 24 weeks and a follow-up for 48
      weeks. The primary outcome will be the 6-Minute Walk Test. The secondary outcomes
      will include the pulmonary function test, St George's respiratory questionnaire, 
      COPD assessment test, modified medical research council dyspnea scale, Hospital
      Anxiety and Depression Scale, and exacerbation frequency. A safety assessment
      will also be performed during the trial. DISCUSSION: Our study will provide
      evidence to support TNHCG exercise as an additional measure for PR of COPD. TRIAL
      REGISTRATION: ChiCTR1900028332, Registered December 29, 2019. ETHICS AND
      DISSEMINATION: Ethics approval has been granted by the Sichuan Traditional
      Chinese Medicine Regional Ethics Review Committee (No. 2019KL-050).
FAU - Yu, Wei
AU  - Yu W
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Su, Peiyuan
AU  - Su P
AD  - Department of Cardiothoracic Surgery, Hospital of Chengdu University of
      Traditional Chinese Medicine.
FAU - Wang, Jiaojiao
AU  - Wang J
AD  - Clinical Medical School, Chengdu University of Traditional Chinese Medicine.
FAU - Zhou, Pengcheng
AU  - Zhou P
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Chen, Keling
AU  - Chen K
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional
      Chinese Medicine.
FAU - Xia, Qianming
AU  - Xia Q
AD  - Department of Respiratory Medicine, AVIC 363 Hospital, Chengdu, Sichuan Province,
      PR China.
FAU - Chen, Yuewei
AU  - Chen Y
AD  - Department of Cardiothoracic Surgery, Hospital of Chengdu University of
      Traditional Chinese Medicine.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Exercise
MH  - *Exercise Tolerance
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Pulmonary Disease, Chronic Obstructive/*rehabilitation
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - Treatment Outcome
MH  - Walk Test
PMC - PMC7306344
EDAT- 2020/06/06 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.1097/MD.0000000000020625 [doi]
AID - 00005792-202006050-00078 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20625. doi: 10.1097/MD.0000000000020625.


PMID- 32502039
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Effect of Chinese medicine prescription on nephrotic syndrome: A protocol for
      systematic review and meta-analysis.
PG  - e20622
LID - 10.1097/MD.0000000000020622 [doi]
AB  - BACKGROUND: Nephrotic syndrome (NS) is a common chronic recurrent kidney disease.
      Many trials have shown that Chinese medicine prescription (CMP) can effectively
      treat NS. The program aims to evaluate the efficacy and safety of CMP for NS.
      METHODS: This systematic evaluation will entail an electronic and manual search
      of all CMP for NS from inception to February, 2020, regardless of the publication
      status or language. Databases include PubMed, Embase, Springer, Web of Science,
      the Cochrane Library, the World Health Organization International Clinical Trial 
      Registration Platform, the Chinese Medicine Database, the China National
      Knowledge Infrastructure, the Chinese Biomedical Literature Database, the China
      Science Journal Database, and the Wanfang Database. Other sources of information,
      including bibliographies and meeting minutes for identified publications, will
      also be searched. A manual search for grey literature, including unpublished
      conference articles will be performed. Additionally, any clinical randomized
      controlled trials related to CMP for NS, regardless of the publication status and
      language limitations, will be included in the study. Study selection, data
      extraction, and research quality assessments will be conducted independently by 2
      researchers. The main result was the total clinical efficacy rate or other
      validated scales after at least 2 weeks of treatment. Secondary outcomes included
      24-hour urine protein quantification, blood urea nitrogen, serum creatinine,
      C-reactive protein, tumor necrosis factor-alpha, and interleukin 6, recurrence
      rates and adverse events during follow-up. Implement the Cochrane RevMan V5.3
      bias assessment tool to assess bias risk, data integration risk, meta-analysis
      risk, and subgroup analysis risk (if conditions are met). Mean difference,
      standard mean deviation and binary data will be used to represent continuous
      results. RESULTS: This study will provide a comprehensive review and evaluation
      of CMP for the treatment of NS. CONCLUSION: This study will provide new evidence 
      for evaluating the effectiveness and side effects of CMP on NS. Since the data is
      not personalized, formal ethical approval is not required. INPLASY REGISTRATION
      NUMBER: INPLASY202040181.
FAU - Deng, Yanli
AU  - Deng Y
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Zhang, Leixiao
AU  - Zhang L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan, China.
FAU - Wen, Aiwei
AU  - Wen A
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Xu, Dongxian
AU  - Xu D
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Wang, Wenping
AU  - Wang W
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Hou, Yuhao
AU  - Hou Y
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Liu, Zhen
AU  - Liu Z
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Yang, Lin
AU  - Yang L
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Shen, Tao
AU  - Shen T
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Luo, Qin
AU  - Luo Q
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Wu, Wei
AU  - Wu W
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
FAU - Ou, Yuanshu
AU  - Ou Y
AD  - Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Medicine, Chinese Traditional/methods
MH  - Meta-Analysis as Topic
MH  - Nephrotic Syndrome/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7306324
EDAT- 2020/06/06 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.1097/MD.0000000000020622 [doi]
AID - 00005792-202006050-00077 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20622. doi: 10.1097/MD.0000000000020622.


PMID- 32502038
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Effects of vitamin D supplementation on serum lipid profile in women with
      polycystic ovary syndrome: A protocol for a systematic review and meta-analysis.
PG  - e20621
LID - 10.1097/MD.0000000000020621 [doi]
AB  - BACKGROUND: Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder 
      in reproductive-aged women. In addition to the reproductive consequences, PCOS is
      also characterized by a metabolic disorder, which may play a part in the etiology
      of anovulation and has important implications for long-term health as well.
      Vitamin D deficiency is prevalent in PCOS and there is a close relationship
      between metabolic dysfunction and vitamin D status in women with PCOS. The
      purpose of this systematic analysis is to evaluate the effect of vitamin D
      supplementation on serum lipid profiles in patients with PCOS. METHODS: We will
      search five databases for relative studies: Medline, the Cochrane Library,
      EMBASE, Web of Science, and ClinicalTrials.gov and identified all reports of
      randomized controlled trials published prior to July 2020. Two authors will
      independently scan the articles searched, extract the data from articles
      included, and assess the risk of bias by Cochrane tool of risk of bias.
      Disagreements will be resolved by discussion among authors. All analysis will be 
      performed based on the Cochrane Handbook for Systematic Reviews of Interventions.
      Fixed-effects model or random-effects model was used to calculate pooled
      estimates of weighted mean difference (WMD) with 95% confidence intervals.
      RESULTS: This review will be to assess the effect of vitamin D supplementation on
      serum lipid profiles in patients with PCOS. The results of the study will be
      published in a scientific journal after peer-review. CONCLUSIONS: These findings 
      will provide guidance to clinicians and patients on the use of vitamin D for PCOS
      with dyslipidemia. ETHICS AND DISSEMINATION: This study is a protocol for a
      systematic review of vitamin D as a treatment of dyslipidemia in PCOS patients.
      SYSTEMATIC REVIEW REGISTRATION: INPLASY202050007.
FAU - Shi, Xiao-Yan
AU  - Shi XY
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, P.R. China.
FAU - Yao, Jia
AU  - Yao J
FAU - Fan, Si-Min
AU  - Fan SM
FAU - Hong, Pei-Pei
AU  - Hong PP
FAU - Xia, Yu-Guo
AU  - Xia YG
FAU - Chen, Qiu
AU  - Chen Q
AUID- ORCID: 0000-0002-9222-9261
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Vitamins)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Dyslipidemias/blood/complications/*drug therapy
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Polycystic Ovary Syndrome/blood/*complications
MH  - Systematic Reviews as Topic
MH  - Vitamin D/*administration & dosage/blood
MH  - Vitamin D Deficiency/complications/drug therapy
MH  - Vitamins/*administration & dosage
PMC - PMC7306319
EDAT- 2020/06/06 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.1097/MD.0000000000020621 [doi]
AID - 00005792-202006050-00076 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20621. doi: 10.1097/MD.0000000000020621.


PMID- 32502036
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Gelomyrtol for acute or chronic sinusitis: A protocol for systematic review and
      meta-analysis.
PG  - e20611
LID - 10.1097/MD.0000000000020611 [doi]
AB  - BACKGROUND: Sinusitis is a common condition worldwide, significantly affecting
      the quality of life of patients. Due to the limitations of conventional
      medicines, such as serious side effects and low efficacies, Gelomyrtol may be a
      promising treatment for sinusitis. As no related systematic review has been
      published, the purpose of this study will be to evaluate the safety and efficacy 
      of Gelomyrtol for acute or chronic sinusitis. METHODS: PubMed, EMBASE, the
      Cochrane Library, the Web of Science, the Chinese National Knowledge
      Infrastructure Database, the Chinese Biomedical Literature Database, the Wan Fang
      Database, and the Chongqing VIP Chinese Science, and Technology Periodical
      Database will be searched from their commencement until July 2020. Randomized
      controlled trials of Gelomyrtol for acute or chronic sinusitis will be selected
      in any language. Primary outcomes will include the Sino-Nasal Outcome Test-22
      (SNOT-22) score, quality of life score as measured by SF-36, and the change in
      computed tomography (CT) score. Study selection, data extraction, and deviation
      risk assessment will be carried out by 2 investigators independently. RevMan
      V.5.3 software will be used to analyze the study data. RESULTS: The study will
      provide high-quality evidence for estimating the efficacy and safety of
      Gelomyrtol in the treatment of acute or chronic sinusitis. CONCLUSIONS: This
      systematic review will explore whether Gelomyrtol is an effective and safe
      intervention in the treatment of acute or chronic sinusitis. ETHICS AND
      DISSEMINATION: As no patient data will be used in this study, ethical approval
      will not be required. The review will be published as an article or a conference 
      presentation in a peer-reviewed journal. REGISTRATION: OSF registration number:
      DOI 10.17605/OSF.IO/MTEU2.
FAU - Wu, Yongcan
AU  - Wu Y
AD  - Department of Respiratory Medicine.
FAU - Wang, Xiaomin
AU  - Wang X
AD  - Department of Respiratory Medicine.
FAU - Huang, Demei
AU  - Huang D
AD  - Department of Geriatrics.
FAU - Pei, Caixia
AU  - Pei C
AD  - Department of Geriatrics.
FAU - Li, Shuiqin
AU  - Li S
AD  - Department of Gastroenterology, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu 610072, Sichuan Province, People's Republic of China.
FAU - Wang, Zhenxing
AU  - Wang Z
AUID- ORCID: 0000-0001-6832-9652
AD  - Department of Respiratory Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0 (gelomyrtol)
RN  - 1490-04-6 (Menthol)
SB  - IM
MH  - Acute Disease/therapy
MH  - Chronic Disease/drug therapy
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Male
MH  - Menthol/*analogs & derivatives/therapeutic use
MH  - Meta-Analysis as Topic
MH  - Sinusitis/*drug therapy
MH  - Systematic Reviews as Topic
PMC - PMC7306384
EDAT- 2020/06/06 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.1097/MD.0000000000020611 [doi]
AID - 00005792-202006050-00074 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20611. doi: 10.1097/MD.0000000000020611.


PMID- 32502029
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Urban-rural differences in parenting style in China: A protocol for systematic
      review and meta analysis.
PG  - e20592
LID - 10.1097/MD.0000000000020592 [doi]
AB  - BACKGROUND: Existing literature shows several discrepancies in parenting style
      between urban and rural China, but conclusions are confusing. Therefore, the aim 
      of this meta-analysis is to consider these inconsistencies and explore the
      influences of several moderator variables. METHODS: Literature search will be
      conducted on PubMed, OVID, the Web of Knowledge, China National Knowledge
      Infrastructure, Wan fang and Chongqing VIP database without language/date/type of
      document restrictions. The Software Comprehensive Meta-Analysis 3.0 will be used 
      to compare all the selected articles. Moreover, study quality was assessed with a
      checklist. METHOD AND ANALYSIS: Literature search will be conducted on PubMed,
      OVID, the Web of Knowledge, China National Knowledge Infrastructure, Wan fang and
      Chongqing VIP database without language/date/type of document restrictions. We
      will use Comprehensive Meta-Analysis Software to conduct main meta-analysis. The 
      primary outcomes are scores/subscores measured by the Chinese version of Egna
      Minnen Betraffande Uppfostran, Parental Bonding Instrument, and any other
      questionnaires including parenting style. ETHICS AND DISSEMINATION: Not needed
      because no data will be collected. TRIALS REGISTRATION NUMBER: INPLASY202050010.
FAU - Zhang, Junhua
AU  - Zhang J
AUID- ORCID: 0000-0002-9937-6301
AD  - School of Psychology, Nanjing Normal University, Nanjing.
AD  - School of Education, Jiangsu Key Laboratory for Big Data of Psychology and
      Cognitive Science, Yancheng Teachers University, Yancheng, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - School of Education, Jiangsu Key Laboratory for Big Data of Psychology and
      Cognitive Science, Yancheng Teachers University, Yancheng, China.
FAU - Xu, Fang
AU  - Xu F
AD  - School of Education, Jiangsu Key Laboratory for Big Data of Psychology and
      Cognitive Science, Yancheng Teachers University, Yancheng, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - *Parenting
MH  - *Rural Population
MH  - Systematic Reviews as Topic
MH  - *Urban Population
PMC - PMC7306374
EDAT- 2020/06/06 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
AID - 10.1097/MD.0000000000020592 [doi]
AID - 00005792-202006050-00067 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20592. doi: 10.1097/MD.0000000000020592.


PMID- 32502022
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Autologous blood or autologous serum acupoint injection therapy for psoriasis
      vulgaris: A protocol for a systematic review and meta-analysis.
PG  - e20555
LID - 10.1097/MD.0000000000020555 [doi]
AB  - BACKGROUND: Psoriasis vulgaris (PV) is a refractory and relapsing skin disease
      that affects the physical and mental health of patients and leads to poor quality
      of life. Current conventional systemic therapy shows a large side effect, which
      can not be used for a long time, easy to relapse after drug withdrawal, long-term
      efficacy is poor. At present, traditional Chinese medicine treatment of psoriasis
      vulgaris effective, can alleviate symptoms, improve the quality of life,
      stabilize the condition, prolong the remission period. Whereas, there is no
      related systematic review and meta-analysis. Thus, we intend to conduct a
      systematic review and meta-analysis to testify autologous blood or autologous
      serum acupoint injection therapy for Psoriasis Vulgaris. METHODS: Our systematic 
      review will search all randomized controlled trials for autologous blood therapy 
      of PV, electronically and manually, regardless of publication status and
      language, until March 19, 2020. Databases include PubMed, EMBASE, Web of Science,
      Cochrane Controlled Trials Register, China National Knowledge Infrastructure,
      China Biomedical Literature Database, Chinese Science Journal Database, and
      Wanfang database. Other sources, including reference lists of identified
      publications and meeting minutes, will also be searched. Manually search for grey
      literature, including unpublished conference articles. RESULT: The main outcomes 
      contain the variation of Psoriasis area and severity index, dermatology life
      quality index, itching score, the effective rate and adverse events from baseline
      to the end of studies. This study will provide a comprehensive review of the
      available evidence for the treatment of PV with this therapy. CONCLUSION: We will
      summarize sufficient evidence to confirm the therapeutic effect and safety of
      autologous blood or autologous serum acupoint injection therapy for PV. Due to
      the data is not individualized, formal ethical approval is not required. INPLASY 
      REGISTRATION NUMBER: INPLASY202040052.
FAU - Wang, Qiuyue
AU  - Wang Q
AUID- ORCID: 0000-0002-7500-4300
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Li, Mao
AU  - Li M
FAU - Hu, Xingxin
AU  - Hu X
FAU - Luo, Qian
AU  - Luo Q
FAU - Hao, Pingsheng
AU  - Hao P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Acupuncture Points
MH  - *Blood Transfusion, Autologous
MH  - Humans
MH  - Injections
MH  - *Medicine, Chinese Traditional
MH  - Meta-Analysis as Topic
MH  - Psoriasis/*therapy
MH  - Quality of Life
MH  - Research Design
MH  - *Serum
MH  - Severity of Illness Index
MH  - Systematic Reviews as Topic
PMC - PMC7306372
EDAT- 2020/06/06 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
AID - 10.1097/MD.0000000000020555 [doi]
AID - 00005792-202006050-00060 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20555. doi: 10.1097/MD.0000000000020555.


PMID- 32502001
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Silver acupuncture for myofascitis: A protocol for systematic review and
      meta-analysis.
PG  - e20519
LID - 10.1097/MD.0000000000020519 [doi]
AB  - BACKGROUND: This systematic review aims to evaluate the effectiveness and safety 
      of silver acupuncture in treatment of myofascitis. METHODS: Electronic databases 
      of all silver acupuncture for myofascitis will be searched at PubMed, Cochrane
      Library, Springer, Embase, China National Knowledge Infrastructure, Wanfang, and 
      Chinese Biological Medical disc from inception to March 31, 2020, with language
      restricted in Chinese and English. The primary outcome is visual analog scale, a 
      short pain scale with sensitivity and comparability. Secondary outcomes included 
      Clinical Assessment Scale for Cervical Spondylosis, Japanese Orthopaedic
      Association Scores, Oswestry dysfunction index, American Orthopaedic Foot and
      Ankle Society-Ankle Hindfoot scale, Foot and Ankle Ability Measure, The
      Cumberland ankle instability tool, Pittsburgh sleep quality index, self-rating
      anxiety scale, self-depression rating scale, and follow-up relapse rate. The
      systematic review and searches for randomized controlled trials of this therapy
      for myofascitis. The Cochrane RevMan V5.3 bias assessment tool is implemented to 
      assess bias risk, data integration risk, meta-analysis risk, and subgroup
      analysis risk (if conditions are met). Mean difference, standard mean deviation, 
      and binary data will be used to represent continuous results. RESULTS: This study
      will provide a comprehensive review and evaluation of the available evidence for 
      the treatment of myofascitis with this therapy. CONCLUSION: This study will
      provide new evidence to evaluate the effectiveness and side effects of silver
      acupuncture for myofascitis. Due to the data are not personalized, no formal
      ethical approval is required. ETHICS AND DISSEMINATION: There is no requirement
      of ethical approval and it will be in print or disseminated by electronic copies.
      PROSPERO REGISTRATION NUMBER: CRD42020151476.
FAU - Zhang, Guilong
AU  - Zhang G
AUID- ORCID: 0000-0001-7812-8096
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Lin, Yanming
AU  - Lin Y
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zhou, Qun
AU  - Zhou Q
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
FAU - Gao, Liang
AU  - Gao L
AD  - Boai Hospital Affiliated to China Rehabilitation Research Center, Beijing.
FAU - Zhang, Leixiao
AU  - Zhang L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine.
FAU - Yu, Yang
AU  - Yu Y
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Shen, Yuquan
AU  - Shen Y
AD  - The First People's Hospital of Long quanyi District, Chengdu, Sichuan, China.
FAU - Huang, Yong
AU  - Huang Y
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 3M4G523W1G (Silver)
SB  - IM
MH  - Acupuncture Therapy/methods/*standards
MH  - Clinical Protocols
MH  - Fasciitis/*drug therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pain Measurement/methods
MH  - Research Design
MH  - Silver/*standards/therapeutic use
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Visual Analog Scale
PMC - PMC7306356
EDAT- 2020/06/06 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1097/MD.0000000000020519 [doi]
AID - 00005792-202006050-00039 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20519. doi: 10.1097/MD.0000000000020519.


PMID- 32501897
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 2162-0989 (Electronic)
IS  - 2162-0989 (Linking)
VI  - 9
IP  - 3
DP  - 2020 May-Jun
TI  - Future Vision 2020 and Beyond-5 Critical Trends in Eye Research.
PG  - 180-185
LID - 10.1097/APO.0000000000000299 [doi]
AB  - Ophthalmology has been at the forefront of many innovations in basic science and 
      clinical research. The randomized prospective multicenter clinical trial,
      comparative clinical trials, the bench to beside development of diagnostic and
      therapeutic devices, the powerful combination of biostatistics and epidemiology, 
      gene therapy, cell-based therapy, stem cell therapy, regenerative medicine,
      artificial intelligence, and the development of personalized molecular medicine
      continue to propel us forward. This article summarizes several critical trends in
      eye research.Innovative translational research continues to bring new solutions
      to blinding retinal diseases. The discovery of the genetic code presaged a day
      when the development of molecular tools and understanding of the basis of disease
      would lead not only to disease management but potentially lifelong cure. After
      decades of investigation, gene therapy is now a reality for a single autosomal
      recessive bi-allelic disease, Lebers Congenital Amaurosis. Its success has paved 
      the way for a myriad of conditions once thought to be untreatable. In parallel,
      the progress to utilize pluripotential stem cells, immunomodulation,
      computational biology, and continued investigation into the fundamental
      mechanisms of cell and molecular biology is breathtaking in its rapidity. The
      next decade is likely to be the most exciting in the history of medicine. It will
      be essential that research progresses in a meticulously thoughtful, ethical, and 
      collaborative process that safeguards the trust of our work and that of the
      society we serve.Presented as the International Award Lecture, Asia-Pacific
      Vitreoretinal Society meeting, November 2019, Shanghai China.
FAU - Huang, Suber S
AU  - Huang SS
AD  - Retina Center of Ohio, Cleveland, OH.
AD  - National Eye Health Education Program Steering Committee, National Eye Institute,
      National Institutes of Health, USA.
AD  - Bascom Palmer Eye Institute, University of Miami, Miami, FL .
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Asia Pac J Ophthalmol (Phila)
JT  - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
JID - 101583622
SB  - IM
MH  - *Artificial Intelligence
MH  - Biomedical Research/*trends
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - *Ophthalmology
MH  - Retinal Diseases/genetics/*therapy
PMC - PMC7299218
EDAT- 2020/06/06 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 10.1097/APO.0000000000000299 [doi]
AID - 01599573-202006000-00003 [pii]
PST - ppublish
SO  - Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):180-185. doi:
      10.1097/APO.0000000000000299.


PMID- 32501846
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 34
IP  - 8
DP  - 2020 Jul 1
TI  - Generation of HIV-1-infected patients' gene-edited induced pluripotent stem cells
      using feeder-free culture conditions.
PG  - 1127-1139
LID - 10.1097/QAD.0000000000002535 [doi]
AB  - OBJECTIVES: The discovery of induced pluripotent stem cells (iPSC) has brought
      promise to regenerative medicine as it breaks the ethical barrier of using
      embryonic stem cells. Such cell culture-derived patient-specific autologous stem 
      cells are needed for transplantation. Here we report deriving HIV-1-infected
      patients' iPSC lines under transgene-free methods and under feeder-free and
      xeno-free culture conditions to meet the requirement for clinical application.
      METHODS AND RESULTS: We have reprogrammed patients' peripheral blood mononuclear 
      cells with EBNA1/OriP episomal vectors, or a defective and persistent Sendai
      virus vector (SeVdp) to ensure a nonintegrating iPSC generation. Both single
      picked and pooled iPSC lines demonstrated high pluripotency and were able to
      differentiate into various lineage cells in vivo. The established cell lines
      could be modified by genetic editing using the TALENs or CRISPR/Cas 9 technology 
      to have a bi-allelic CCR5Delta32 mutations seamlessly. All generated iPSC lines
      and modified cell lines had no evidence of HIV integration and maintained normal 
      karyotype after expansion. CONCLUSIONS: This study provides a reproducible simple
      procedure for generating therapeutic grade iPSCs from HIV-infected patients and
      for engineering these cells to possess a naturally occurring genotype for
      resistance to HIV-1 infection when differentiated into immune cells.
FAU - Ye, Lin
AU  - Ye L
AD  - Institute of Human Genetics.
FAU - Wang, Jiaming
AU  - Wang J
AD  - Institute of Human Genetics.
FAU - Teque, Fernando
AU  - Teque F
AD  - Division of Hematology/Oncology.
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
FAU - Xie, Fei
AU  - Xie F
AD  - Institute of Human Genetics.
FAU - Tan, Yuting
AU  - Tan Y
AD  - Institute of Human Genetics.
FAU - Kan, Yuet Wei
AU  - Kan YW
AD  - Institute of Human Genetics.
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
FAU - Levy, Jay A
AU  - Levy JA
AD  - Division of Hematology/Oncology.
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
LA  - eng
GR  - P01 DK088760/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
SB  - IM
MH  - Cell Differentiation/genetics/physiology
MH  - Family Characteristics
MH  - Gene Editing
MH  - Genetic Vectors/genetics/*metabolism
MH  - HIV Infections/diagnosis
MH  - HIV-1/*genetics
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*physiology
MH  - Leukocytes, Mononuclear/*cytology/metabolism
EDAT- 2020/06/06 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - 10.1097/QAD.0000000000002535 [doi]
AID - 00002030-202007010-00004 [pii]
PST - ppublish
SO  - AIDS. 2020 Jul 1;34(8):1127-1139. doi: 10.1097/QAD.0000000000002535.


PMID- 32501804
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 6
DP  - 2020 Jun 16
TI  - Digital Health Strategies to Fight COVID-19 Worldwide: Challenges,
      Recommendations, and a Call for Papers.
PG  - e19284
LID - 10.2196/19284 [doi]
AB  - The coronavirus disease (COVID-19) pandemic has created an urgent need for
      coordinated mechanisms to respond to the outbreak across health sectors, and
      digital health solutions have been identified as promising approaches to address 
      this challenge. This editorial discusses the current situation regarding digital 
      health solutions to fight COVID-19 as well as the challenges and ethical hurdles 
      to broad and long-term implementation of these solutions. To decrease the risk of
      infection, telemedicine has been used as a successful health care model in both
      emergency and primary care. Official communication plans should promote facile
      and diverse channels to inform people about the pandemic and to avoid rumors and 
      reduce threats to public health. Social media platforms such as Twitter and
      Google Trends analyses are highly beneficial to model pandemic trends as well as 
      to monitor the evolution of patients' symptoms or public reaction to the pandemic
      over time. However, acceptability of digital solutions may face challenges due to
      potential conflicts with users' cultural, moral, and religious backgrounds.
      Digital tools can provide collective public health benefits; however, they may be
      intrusive and can erode individual freedoms or leave vulnerable populations
      behind. The COVID-19 pandemic has demonstrated the strong potential of various
      digital health solutions that have been tested during the crisis. More concerted 
      measures should be implemented to ensure that future digital health initiatives
      will have a greater impact on the epidemic and meet the most strategic needs to
      ease the life of people who are at the forefront of the crisis.
CI  - (c)Guy Fagherazzi, Catherine Goetzinger, Mohammed Ally Rashid, Gloria A Aguayo,
      Laetitia Huiart. Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 16.06.2020.
FAU - Fagherazzi, Guy
AU  - Fagherazzi G
AUID- ORCID: 0000-0001-5033-5966
AD  - Luxembourg Institute of Health, Strassen, Luxembourg.
FAU - Goetzinger, Catherine
AU  - Goetzinger C
AUID- ORCID: 0000-0002-6377-1078
AD  - Luxembourg Institute of Health, Strassen, Luxembourg.
FAU - Rashid, Mohammed Ally
AU  - Rashid MA
AUID- ORCID: 0000-0002-3863-3212
AD  - Luxembourg Institute of Health, Strassen, Luxembourg.
FAU - Aguayo, Gloria A
AU  - Aguayo GA
AUID- ORCID: 0000-0002-5625-1664
AD  - Luxembourg Institute of Health, Strassen, Luxembourg.
FAU - Huiart, Laetitia
AU  - Huiart L
AUID- ORCID: 0000-0002-5401-1958
AD  - Luxembourg Institute of Health, Strassen, Luxembourg.
LA  - eng
PT  - Editorial
DEP - 20200616
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques
MH  - Coronavirus Infections/diagnosis/prevention & control/*therapy/transmission
MH  - Global Health
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/diagnosis/prevention & control/*therapy/transmission
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - *Social Media
MH  - Telemedicine/*methods
PMC - PMC7298971
OTO - NOTNLM
OT  - *COVID-19
OT  - *communication
OT  - *coronavirus
OT  - *digital health
OT  - *digital technology
OT  - *eHealth
OT  - *epidemiology
OT  - *health care
OT  - *infodemiology
OT  - *public health
OT  - *review
OT  - *surveillance
EDAT- 2020/06/06 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/06/04 00:00 [accepted]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - v22i6e19284 [pii]
AID - 10.2196/19284 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jun 16;22(6):e19284. doi: 10.2196/19284.


PMID- 32501036
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 2078-6204 (Electronic)
IS  - 2078-6190 (Linking)
VI  - 62
IP  - 1
DP  - 2020 May 19
TI  - Circumcised men's perceptions, understanding and experiences of voluntary medical
      male circumcision in KwaZulu-Natal, South Africa.
PG  - e1-e8
LID - 10.4102/safp.v62i1.5083 [doi]
AB  - BACKGROUND: KwaZulu-Natal, South Africa, has rolled out voluntary medical male
      circumcision (VMMC) in response to recommendations that regions with a high human
      immunodeficiency virus (HIV) prevalence adopt VMMC as an additional HIV
      prevention strategy. There is a paucity of South African data on the motivators, 
      barriers and experiences of adult male candidates regarding VMMC. This study was 
      conducted to analyse circumcised men's perceptions, understanding and experiences
      of VMMC in KwaZulu-Natal, South Africa. METHODS: A qualitative phenomenographic
      design was used. Ethical clearance was obtained from the Biomedical Research
      Ethics Committee of the University of KwaZulu-Natal (BE 627/18). Data were
      collected from 12 circumcised male candidates. Individual interviews were
      conducted and recorded by using an audiotape. Data were transcribed verbatim and 
      analysed manually. RESULTS: Participants' perceptions regarding VMMC are health
      related and appear to be the motivators for the uptake of medical circumcision.
      Circumcised men in this study appeared to misunderstand VMMC in terms of healing 
      and performance time and the nature of the procedure. Negative experiences in
      terms of quality of care received were reported. CONCLUSION: The study findings
      imply that practice interventions to promote demand generation for VMMC in
      KwaZulu-Natal, South Africa, should incorporate the perceptions and experiences
      of male candidates regarding the procedure. Tailored messaging to address
      misunderstanding related to the nature of VMMC should also be provided. Regular
      in-service training on standardised VMMC implementation practices should be
      provided to ensure the delivery of optimum quality VMMC services.
FAU - Nxumalo, Celenkosini T
AU  - Nxumalo CT
AD  - Department of Nursing, School of Nursing and Public Health, University of
      KwaZulu-Natal, Durban. thembz92@gmail.com.
FAU - Mchunu, Gugu G
AU  - Mchunu GG
LA  - eng
GR  - D43 TW010131/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200519
PL  - South Africa
TA  - S Afr Fam Pract (2004)
JT  - South African family practice : official journal of the South African Academy of 
      Family Practice/Primary Care
JID - 9701104
SB  - IM
MH  - Adult
MH  - Blacks
MH  - *Circumcision, Male
MH  - *HIV Infections/epidemiology
MH  - Humans
MH  - Male
MH  - Men
MH  - South Africa/epidemiology
PMC - PMC8378007
OTO - NOTNLM
OT  - *HIV prevention
OT  - *barriers
OT  - *circumcised male candidates
OT  - *experiences
OT  - *motivators
OT  - *perceptions
OT  - *uptake
OT  - *voluntary medical male circumcision
EDAT- 2020/06/06 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/06/06 06:00
PHST- 2019/12/31 00:00 [received]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2020/02/06 00:00 [revised]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 10.4102/safp.v62i1.5083 [doi]
PST - epublish
SO  - S Afr Fam Pract (2004). 2020 May 19;62(1):e1-e8. doi: 10.4102/safp.v62i1.5083.


PMID- 32500610
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 2324-9269 (Electronic)
IS  - 2324-9269 (Linking)
VI  - 8
IP  - 8
DP  - 2020 Aug
TI  - Germline whole genome sequencing in pediatric oncology in Denmark-Practitioner
      perspectives.
PG  - e1276
LID - 10.1002/mgg3.1276 [doi]
AB  - BACKGROUND: With the implementation of a research project providing whole genome 
      sequencing (WGS) to all pediatric cancer patients in Denmark (2016-2019), we
      sought to investigate healthcare professionals' views on WGS as it was actively
      being implemented in pediatric oncology. METHODS: Semistructured interviews were 
      carried out with pediatric oncologists, clinical geneticists, and research
      coordinating nurses (N = 17), followed by content analysis of transcribed
      interviews. Interviews were supplemented by ethnographic observations on Danish
      pediatric oncology wards. Additionally, questionnaires were distributed to
      healthcare professionals concerning when they found it appropriate to approach
      families regarding WGS. The response rate was 74%. RESULTS: Healthcare
      professionals see imbalances in doctor-patient relationship, especially the
      double role doctors have as clinicians and researchers. Some were concerned that 
      it might not be possible to obtain meaningful informed consent from all families 
      following diagnosis. Still, 94% of respondents found it acceptable to approach
      families during the first 4 weeks from the child's diagnosis. Views on the
      utility of WGS, treatment adaptation, and surveillance differed among
      interviewees. CONCLUSION: Overall, healthcare professionals see dilemmas arising 
      from WGS in the pediatric oncology clinic, and some advocate for further
      educational sessions with families and healthcare professionals. Despite
      concerns, healthcare professionals overwhelmingly supported early approach of
      families regarding WGS. Interviewees disagree on the benefits of surveillance
      based on genetic findings.
CI  - (c) 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley
      Periodicals LLC.
FAU - Byrjalsen, Anna
AU  - Byrjalsen A
AUID- ORCID: 0000-0002-3470-5995
AD  - Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet,
      Copenhagen, Denmark.
AD  - Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital
      Rigshospitalet, Copenhagen, Denmark.
FAU - Stoltze, Ulrik K
AU  - Stoltze UK
AD  - Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital
      Rigshospitalet, Copenhagen, Denmark.
FAU - Castor, Anders
AU  - Castor A
AD  - Department of Paediatrics, Skaane University Hospital, Lund, Sweden.
FAU - Wahlberg, Ayo
AU  - Wahlberg A
AD  - Department of Anthropology, University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - United States
TA  - Mol Genet Genomic Med
JT  - Molecular genetics & genomic medicine
JID - 101603758
SB  - IM
MH  - Adult
MH  - Denmark
MH  - Female
MH  - Genetic Counseling/psychology
MH  - *Genetic Testing
MH  - Germ-Line Mutation
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*diagnosis/genetics
MH  - Oncologists/*psychology
MH  - Pediatricians/*psychology
MH  - Surveys and Questionnaires
MH  - *Whole Genome Sequencing
PMC - PMC7434747
OTO - NOTNLM
OT  - *clinical genetics
OT  - *ethics
OT  - *pediatric oncology
OT  - *practitioner perspectives
OT  - *whole genome sequencing
EDAT- 2020/06/06 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/06/06 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 10.1002/mgg3.1276 [doi]
PST - ppublish
SO  - Mol Genet Genomic Med. 2020 Aug;8(8):e1276. doi: 10.1002/mgg3.1276. Epub 2020 Jun
      4.


PMID- 32500471
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1573-3688 (Electronic)
IS  - 1053-0487 (Linking)
VI  - 30
IP  - 3
DP  - 2020 Sep
TI  - Ethical Considerations of Using Machine Learning for Decision Support in
      Occupational Health: An Example Involving Periodic Workers' Health Assessments.
PG  - 343-353
LID - 10.1007/s10926-020-09895-x [doi]
AB  - Purpose Computer algorithms and Machine Learning (ML) will be integrated into
      clinical decision support within occupational health care. This will change the
      interaction between health care professionals and their clients, with unknown
      consequences. The aim of this study was to explore ethical considerations and
      potential consequences of using ML based decision support tools (DSTs) in the
      context of occupational health. Methods We conducted an ethical deliberation.
      This was supported by a narrative literature review of publications about ML and 
      DSTs in occupational health and by an assessment of the potential impact of
      ML-DSTs according to frameworks from medical ethics and philosophy of technology.
      We introduce a hypothetical clinical scenario from a workers' health assessment
      to reflect on biomedical ethical principles: respect for autonomy, beneficence,
      non-maleficence and justice. Results Respect for autonomy is affected by
      uncertainty about what future consequences the worker is consenting to as a
      result of the fluctuating nature of ML-DSTs and validity evidence used to inform 
      the worker. A beneficent advisory process is influenced because the three
      elements of evidence based practice are affected through use of a ML-DST. The
      principle of non-maleficence is challenged by the balance between group-level
      benefits and individual harm, the vulnerability of the worker in the occupational
      context, and the possibility of function creep. Justice might be empowered when
      the ML-DST is valid, but profiling and discrimination are potential risks.
      Conclusions Implications of ethical considerations have been described for the
      socially responsible design of ML-DSTs. Three recommendations were provided to
      minimize undesirable adverse effects of the development and implementation of
      ML-DSTs.
FAU - Six Dijkstra, Marianne W M C
AU  - Six Dijkstra MWMC
AUID- ORCID: 0000-0001-5074-2422
AD  - School of Health, Saxion University of Applied Sciences/AGZ, M.H. Tromplaan 28,
      7500 KB, Enschede, The Netherlands. w.m.c.sixdijkstra@saxion.nl.
AD  - Department of Rehabilitation Medicine, University Medical Center Groningen,
      University of Groningen, Groningen, The Netherlands. w.m.c.sixdijkstra@saxion.nl.
AD  - University of Groningen, Groningen, The Netherlands. w.m.c.sixdijkstra@saxion.nl.
FAU - Siebrand, Egbert
AU  - Siebrand E
AD  - Research Group Ethics & Technology, Saxion University of Applied Sciences,
      Enschede, The Netherlands.
FAU - Dorrestijn, Steven
AU  - Dorrestijn S
AD  - Research Group Ethics & Technology, Saxion University of Applied Sciences,
      Enschede, The Netherlands.
FAU - Salomons, Etto L
AU  - Salomons EL
AD  - School of Ambient Intelligence, Saxion University of Applied Sciences, Enschede, 
      The Netherlands.
FAU - Reneman, Michiel F
AU  - Reneman MF
AD  - Department of Rehabilitation Medicine, University Medical Center Groningen,
      University of Groningen, Groningen, The Netherlands.
FAU - Oosterveld, Frits G J
AU  - Oosterveld FGJ
AD  - School of Health, Saxion University of Applied Sciences/AGZ, M.H. Tromplaan 28,
      7500 KB, Enschede, The Netherlands.
FAU - Soer, Remko
AU  - Soer R
AD  - School of Health, Saxion University of Applied Sciences/AGZ, M.H. Tromplaan 28,
      7500 KB, Enschede, The Netherlands.
AD  - University Medical Center Groningen, Pain Centre, University of Groningen,
      Groningen, The Netherlands.
FAU - Gross, Douglas P
AU  - Gross DP
AD  - Department of Physical Therapy, University of Alberta, Edmonton, Canada.
FAU - Bieleman, Hendrik J
AU  - Bieleman HJ
AD  - School of Health, Saxion University of Applied Sciences/AGZ, M.H. Tromplaan 28,
      7500 KB, Enschede, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Occup Rehabil
JT  - Journal of occupational rehabilitation
JID - 9202814
SB  - IM
MH  - Decision Support Techniques
MH  - Humans
MH  - Machine Learning
MH  - Male
MH  - *Occupational Health
PMC - PMC7406529
OTO - NOTNLM
OT  - *Clinical decision support system
OT  - *Ethics
OT  - *Evidence based practice
OT  - *Machine learning
OT  - *Morals
OT  - *Occupational health
EDAT- 2020/06/06 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 10.1007/s10926-020-09895-x [doi]
AID - 10.1007/s10926-020-09895-x [pii]
PST - ppublish
SO  - J Occup Rehabil. 2020 Sep;30(3):343-353. doi: 10.1007/s10926-020-09895-x.


PMID- 32500235
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2509-9280 (Electronic)
IS  - 2509-9280 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Jun 5
TI  - Initial damage produced by a single 15-Gy x-ray irradiation to the rat calvaria
      skin.
PG  - 32
LID - 10.1186/s41747-020-00155-4 [doi]
AB  - BACKGROUND: Calvaria skin has a reduced thickness, and its initial damage
      produced by irradiation was scarcely reported. We aimed to identify the initial
      effects of x-ray irradiation in the rat calvaria skin. METHODS: After approval by
      the Animal Ethical Committee, calvaria skin sections of five Wistar rats per time
      point were evaluated on days 4, 9, 14, and 25 following a single 15-Gy x-ray
      irradiation of the head. The control group was composed of five rats and
      evaluated on day 4. Sections were assessed using hematoxylin-eosin and Masson's
      trichrome staining for morphology, inflammation, and fibrosis. Fibrosis was also 
      evaluated by the collagen maturation index from Picrosirius red staining and by
      cell proliferation using the immunohistochemistry, after 5-bromo-2-deoxyuridine
      intraperitoneal injection. RESULTS: In irradiated rats, we observed a reduction
      in epithelial cell proliferation (p = 0.004) and in matrix metalloproteinase-9
      expression (p < 0.001), an increase in the maturation index, and with a
      predominance in the type I collagen fibers, on days 9 and 14 (1.19 and 1.17,
      respectively). A progressive disorganization in the morphology of the collagen
      fibers at all time points and changes in morphology of the sebaceous gland cells 
      and hair follicle were present until day 14. CONCLUSIONS: The initial damage
      produced by a single 15-Gy x-ray irradiation to the rat calvaria skin was a
      change in the normal morphology of collagen fibers to an amorphous aspect, a
      temporary absence of the sebaceous gland and hair follicles, and without a
      visible inflammatory process, cell proliferation, or fibrosis process in the
      dermis.
FAU - da Silva Santin, Matheus
AU  - da Silva Santin M
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
FAU - Koehler, Jose
AU  - Koehler J
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
AD  - Southern Parana Oncology Institute (ISPON), Cel. Francisco Ribas, 638 - Ponta
      Grossa, Parana, Brazil.
FAU - Rocha, Danilo Massuia
AU  - Rocha DM
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
FAU - Dos Reis, Camila Audrey
AU  - Dos Reis CA
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
FAU - Omar, Nadia Fayez
AU  - Omar NF
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
FAU - Fidler, Yasmin
AU  - Fidler Y
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
FAU - de Miranda Soares, Maria Albertina
AU  - de Miranda Soares MA
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil.
FAU - Gomes, Jose Rosa
AU  - Gomes JR
AD  - Universidade Estadual de Ponta Grossa, DEBIOGEM, Carlos Cavalcanti, Campus
      Uvaranas, Ponta Grossa, Parana, 84040060, Brazil. 1967jrgomes@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200605
PL  - England
TA  - Eur Radiol Exp
JT  - European radiology experimental
JID - 101721752
SB  - IM
MH  - Animals
MH  - Cell Proliferation
MH  - Male
MH  - Radiation Injuries/*pathology
MH  - Rats
MH  - Rats, Wistar
MH  - Skin/*radiation effects
MH  - Skull/radiation effects
MH  - Staining and Labeling
MH  - X-Rays
PMC - PMC7272528
OTO - NOTNLM
OT  - *Collagen
OT  - *Radiobiology
OT  - *Rats
OT  - *Skin
OT  - *X-rays
EDAT- 2020/06/06 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/01/19 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 10.1186/s41747-020-00155-4 [doi]
AID - 10.1186/s41747-020-00155-4 [pii]
PST - epublish
SO  - Eur Radiol Exp. 2020 Jun 5;4(1):32. doi: 10.1186/s41747-020-00155-4.


PMID- 32500214
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1433-0385 (Electronic)
IS  - 0009-4722 (Linking)
VI  - 91
IP  - 7
DP  - 2020 Jul
TI  - [Innovations in surgery-How can new technologies be safely implemented in the
      clinical practice?]
PG  - 553-560
LID - 10.1007/s00104-020-01195-7 [doi]
AB  - Modern surgery is currently undergoing a significant change in the sense of the
      introduction of modern technologies and innovative techniques. Robotic-assisted
      surgery and modern techniques of visualization confront surgery with
      unprecedented challenges with respect to possible and meaningful areas of
      application for these innovations. If an innovation is not to remain only an
      interesting singularity as proof of feasibility and a sign of unchecked progress 
      but is to have a fixed place within the framework of standardized treatment
      processes, firm regulations are required which flank the path from innovation to 
      introduction into clinical practice. This overview article critically examines
      the deficits of the currently practiced models of introducing new technologies
      into the clinical practice and discusses new aspects that can improve the
      introduction of innovations with particular respect to patient safety.
FAU - Bahra, M
AU  - Bahra M
AD  - Chirurgische Klinik, Campus Charite Mitte/Campus Virchow-Klinikum, Charite -
      Universitatsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.
      marcus.bahra@charite.de.
FAU - Pratschke, J
AU  - Pratschke J
AD  - Chirurgische Klinik, Charite - Universitatsmedizin Berlin, Berlin, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Innovationen in der Chirurgie - wie konnen neue Technologien sicher in die Klinik
      eingefuhrt werden?
PL  - Germany
TA  - Chirurg
JT  - Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
JID - 16140410R
SB  - IM
MH  - Humans
MH  - Patient Safety
MH  - *Robotic Surgical Procedures
OTO - NOTNLM
OT  - Ethics
OT  - Evaluation
OT  - Evidence
OT  - Long-term results
OT  - Patient safety
EDAT- 2020/06/06 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 10.1007/s00104-020-01195-7 [doi]
AID - 10.1007/s00104-020-01195-7 [pii]
PST - ppublish
SO  - Chirurg. 2020 Jul;91(7):553-560. doi: 10.1007/s00104-020-01195-7.


PMID- 32500019
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2228-5482 (Print)
IS  - 2228-5482 (Linking)
VI  - 21
IP  - 2
DP  - 2020 Apr-Jun
TI  - Abdominal Wall Leiomyoma: A Case Report.
PG  - 151-154
AB  - BACKGROUND: Fibroma or leiomyoma is the most common benign tumor of the female
      reproductive system, which is usually found in the uterus, but may also occur in 
      other places, such as the ovary, the broad ligament, and in rare cases in the
      abdominal wall. The formation of the abdominal wall leiomyoma may result from the
      implantation of myometrium tissue following surgical removal of the uterine
      leiomyoma, but sometimes these masses occur in a person who has no history of
      myomectomy. CASE PRESENTATION: This case was a patient who became a candidate for
      laparoscopy due to abnormal uterine bleeding and pain in the right upper quadrant
      of the abdomen and ovarian mass. The patient underwent laparotomy due to the
      inability of surgeons to insert the veress needle because of the presence of mass
      in the abdominal wall. The pathologic report of the abdominal mass was leiomyoma.
      This article has been approved by the Ethics Committee of the University
      (6562276). CONCLUSION: The formation of myoma on the abdominal wall is rare but
      given the fact that leiomyoma can be created at each part of the body with smooth
      muscles, including the anterior abdominal wall, this diagnosis should be
      considered for the differential diagnosis of abdominal masses.
CI  - Copyright(c) 2020, Avicenna Research Institute.
FAU - Hafizi, Leili
AU  - Hafizi L
AD  - - Department of Obstetrics and Gynecology, School of Medicine, Mashhad University
      of Medical Sciences, Mashhad, Iran.
AD  - - Imam Reza hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Pourhoseini, Seyedeh Azam
AU  - Pourhoseini SA
AD  - - Department of Obstetrics and Gynecology, School of Medicine, Mashhad University
      of Medical Sciences, Mashhad, Iran.
AD  - - Imam Reza hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Case Reports
PL  - Iran
TA  - J Reprod Infertil
JT  - Journal of reproduction & infertility
JID - 101535586
PMC - PMC7253935
OTO - NOTNLM
OT  - Abdominal wall
OT  - Leiomyoma
OT  - Mass
OT  - Smooth muscle tumor
COIS- Conflict of Interest The authors declare no conflict of interest. Funding: The
      study was funded by the Research Deputy of Mashhad University of Medical
      Sciences.
EDAT- 2020/06/06 06:00
MHDA- 2020/06/06 06:01
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/06 06:01 [medline]
PST - ppublish
SO  - J Reprod Infertil. 2020 Apr-Jun;21(2):151-154.


PMID- 32500009
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2228-5482 (Print)
IS  - 2228-5482 (Linking)
VI  - 21
IP  - 2
DP  - 2020 Apr-Jun
TI  - How Can the Implementation of Ethical Norms Be Guaranteed in Biomedical Studies?
PG  - 69-70
FAU - Sadeghi, Mohammad Reza
AU  - Sadeghi MR
LA  - eng
PT  - Editorial
PL  - Iran
TA  - J Reprod Infertil
JT  - Journal of reproduction & infertility
JID - 101535586
PMC - PMC7253938
EDAT- 2020/06/06 06:00
MHDA- 2020/06/06 06:01
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/06 06:01 [medline]
PST - ppublish
SO  - J Reprod Infertil. 2020 Apr-Jun;21(2):69-70.


PMID- 32499910
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1828-695X (Print)
IS  - 1828-695X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Jan 28
TI  - SARS-CoV-2 pandemic in Italy: ethical and organizational considerations.
PG  - 672
LID - 10.4081/mrm.2020.672 [doi]
AB  - The current SARS-CoV-2 pandemic is still raging in Italy. The country is
      currently plagued by a huge burden of virusrelated cases and deaths. So far, the 
      disease has highlighted a number of problems, some in common with other Countries
      and others peculiar to Italy which has suffered from a mortality rate higher than
      that observed in China and in most Countries in the world. The causes must be
      sought not only in the average age of the population (one of the oldest in the
      world), but also in the inconsistencies of the regional health systems (into
      which the National Health System is divided) and their delayed response, at least
      in some areas. Ethical issues emerged from the beginning, ranging from
      restrictions on freedom of movements and restrictions on personal privacy due to 
      the lockdown, further to the dilemma for healthcare professionals to select
      people for ICU hospitalization in a shortage of beds in Intensive Care Unit
      (ICU). Organizational problems also emerged, although an official 2007 document
      from the Ministry of Health had planned not only what measures had to be taken
      during an epidemic caused by respiratory viruses, but also what had to be done in
      the inter-epidemic period (including the establishment of DPIs stocks and
      ventilators), vast areas of Italy were totally unprepared to cope with the
      disease, as a line of that document was not implemented. Since organizational
      problems can worsen (and even cause) ethical dilemmas, every effort should be
      made in the near future to prepare the health system to respond to a similar
      emergency in a joint, coherent, and homogeneous way across the Country, as
      planned in the 2007 document. In this perspective, Pulmonary Units and
      specialists can play a fundamental role in coping with the disease not only in
      hospitals, as intermediate care units, but also at a territorial level in an
      integrated network with GPs.
CI  - (c)Copyright: the Author(s).
FAU - Nardini, Stefano
AU  - Nardini S
AD  - Italian Respiratory Society Research Centre, Milan, Italy.
FAU - Sanguinetti, Claudio M
AU  - Sanguinetti CM
AD  - Italian Respiratory Society Research Centre, Milan, Italy.
FAU - De Benedetto, Fernando
AU  - De Benedetto F
AD  - Italian Respiratory Society Research Centre, Milan, Italy.
FAU - Baccarani, Claudio
AU  - Baccarani C
AD  - Business Management, University of Verona, Italy.
FAU - Del Donno, Mario
AU  - Del Donno M
AD  - Italian Respiratory Society Research Centre, Milan, Italy.
AD  - Pneumology Unit, A.O.R.N. "San Pio" - P.O. "G. Rummo", Benevento, Italy.
FAU - Polverino, Mario
AU  - Polverino M
AD  - Italian Respiratory Society Research Centre, Milan, Italy.
AD  - Endoscopic Unit, Pulmonary Division, Hospital M. Scarlato, Scafati (SA), Italy.
FAU - Annesi-Maesano, Isabella
AU  - Annesi-Maesano I
AD  - INSERM and Epidemiology of Allergic and Respiratory Diseases Department, Sorbonne
      University, IPLESP, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - Italy
TA  - Multidiscip Respir Med
JT  - Multidisciplinary respiratory medicine
JID - 101477642
PMC - PMC7256627
OTO - NOTNLM
OT  - ICU beds
OT  - SARS-CoV-2
OT  - ethical and organizational issues
OT  - intermediate respiratory care
OT  - mortality rate
COIS- Conflict of interest: The Authors declare no conflict of interest for this paper.
      CMS is Editor-in-Chief of Multidisciplinary Respiratory Medicine.
EDAT- 2020/06/06 06:00
MHDA- 2020/06/06 06:01
CRDT- 2020/06/06 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/06 06:01 [medline]
AID - 10.4081/mrm.2020.672 [doi]
PST - epublish
SO  - Multidiscip Respir Med. 2020 May 25;15(1):672. doi: 10.4081/mrm.2020.672.
      eCollection 2020 Jan 28.


PMID- 32499778
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20220325
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Dysregulated Mucosal Immunity and Associated Pathogeneses in Preterm Neonates.
PG  - 899
LID - 10.3389/fimmu.2020.00899 [doi]
AB  - Many functions of the immune system are impaired in neonates, allowing
      vulnerability to serious bacterial, viral and fungal infections which would
      otherwise not be pathogenic to mature individuals. This vulnerability is
      exacerbated in compromised newborns such as premature neonates and those who have
      undergone surgery or who require care in an intensive care unit. Higher
      susceptibility of preterm neonates to infections is associated with delayed
      immune system maturation, with deficiencies present in both the innate and
      adaptive immune components. Here, we review recent insights into early life
      immunity, and highlight features associated with compromised newborns, given the 
      challenges of studying neonatal immunity in compromised neonates due to the
      transient nature of this period of life, and logistical and ethical obstacles
      posed by undertaking studies newborns and infants. Finally, we highlight how the 
      unique immunological characteristics of the premature host play key roles in the 
      pathogenesis of diseases that are unique to this population, including
      necrotizing enterocolitis and the associated sequalae of lung and brain injury.
CI  - Copyright (c) 2020 Sampah and Hackam.
FAU - Sampah, Maame Efua S
AU  - Sampah MES
AD  - Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University
      School of Medicine, Baltimore, MD, United States.
FAU - Hackam, David J
AU  - Hackam DJ
AD  - Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University
      School of Medicine, Baltimore, MD, United States.
LA  - eng
GR  - R01 GM078238/GM/NIGMS NIH HHS/United States
GR  - T32 DK007713/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200515
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Enterocolitis, Necrotizing/etiology
MH  - Humans
MH  - *Immunity, Mucosal
MH  - Infant, Newborn
MH  - Infant, Premature/*immunology
PMC - PMC7243348
OTO - NOTNLM
OT  - *intestinal epithelial barrier
OT  - *lymphocytes
OT  - *necrotizing enterocolitis
OT  - *neonatal immunity
OT  - *regulatory lymphocytes
OT  - *sepsis
OT  - *toll like receptors
EDAT- 2020/06/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.3389/fimmu.2020.00899 [doi]
PST - epublish
SO  - Front Immunol. 2020 May 15;11:899. doi: 10.3389/fimmu.2020.00899. eCollection
      2020.


PMID- 32499267
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Risk and protective factors of dementia among adults with post-traumatic stress
      disorder: a systematic review protocol.
PG  - e035517
LID - 10.1136/bmjopen-2019-035517 [doi]
AB  - INTRODUCTION: Post-traumatic stress disorder (PTSD) is associated with an
      increased risk of dementia. Individual epidemiological studies have controlled
      for several confounders of the relationship between PTSD and increased dementia
      risk, yet particular risk factors underlying this relationship have not been
      determined. This systematic review protocol aims to identify risk and protective 
      factors of dementia among adults with PTSD. METHODS AND ANALYSIS: We will conduct
      an electronic search of the databases: PubMed, CINAHL, PsychINFO, The Cochrane
      Library, Scopus and ProQuest Dissertation and Theses Global. After screening the 
      studies, quantitative synthesis will be performed, if possible. Otherwise, a
      narrative synthesis will be performed. We will include randomised controlled
      trials and other types of research evidence including longitudinal cohort
      studies. Strength of evidence will be assessed using the Grading of
      Recommendations, Assessment, Development and Evaluations method. Examples of
      variables that will be extracted are: year of PTSD diagnosis, comorbid
      conditions, health behaviours, pharmacological treatments and year of mild
      cognitive impairment or dementia diagnosis. We developed this systematic review
      protocol according to the Preferred Reporting Items for Systematic Review and
      Meta-Analysis Protocols 2015 statement. ETHICS AND DISSEMINATION: The proposed
      study will not collect individual-level data and, therefore, does not require
      ethical approval. Results of this study will provide current evidence on risk and
      protective factors of dementia in adults with PTSD. Findings will be disseminated
      in peer-reviewed publications and conference presentations. PROSPERO REGISTRATION
      NUMBER: CRD42019128553.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lawrence, Karen A
AU  - Lawrence KA
AUID- ORCID: 0000-0002-7235-5594
AD  - College of Social Work, University of Kentucky, Lexington, Kentucky, USA
      karen.lawrence@uky.edu.
FAU - Pachner, Theresia M
AU  - Pachner TM
AD  - College of Social Work, University of Kentucky, Lexington, Kentucky, USA.
FAU - Long, Molly M
AU  - Long MM
AUID- ORCID: 0000-0001-5302-6659
AD  - College of Social Work, University of Kentucky, Lexington, Kentucky, USA.
FAU - Henderson, Stephanie
AU  - Henderson S
AD  - Medical Center Library, University of Kentucky, Lexington, Kentucky, USA.
FAU - Schuman, Donna L
AU  - Schuman DL
AD  - College of Social Work, University of Kentucky, Lexington, Kentucky, USA.
FAU - Plassman, Brenda L
AU  - Plassman BL
AD  - Department of Neurology, Duke University School of Medicine, Durham, North
      Carolina, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Dementia/*diagnosis/epidemiology
MH  - Humans
MH  - Longitudinal Studies
MH  - Protective Factors
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Stress Disorders, Post-Traumatic/*diagnosis/epidemiology
PMC - PMC7282332
OTO - NOTNLM
OT  - *delirium & cognitive disorders
OT  - *dementia
OT  - *mental health
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-035517 [pii]
AID - 10.1136/bmjopen-2019-035517 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e035517. doi: 10.1136/bmjopen-2019-035517.


PMID- 32499265
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS):
      multicentre validation cohort study.
PG  - e034897
LID - 10.1136/bmjopen-2019-034897 [doi]
AB  - INTRODUCTION: Surgery is the primary curative treatment for oesophageal cancer,
      with considerable recent improvements in long-term survival. However, surgery has
      a long-lasting impact on patient's health-related quality of life (HRQOL).
      Through a multicentre European study, our research group was able to identify key
      symptoms that affect patient's HRQOL. These symptoms were combined to produce a
      tool to identify poor HRQOL following oesophagectomy (LAsting Symptoms after
      Oesophageal Resection (LASOR) tool). The objective of this multicentre study is
      to validate a six-symptom clinical tool to identify patients with poor HRQOL for 
      use in everyday clinical practice. METHODS AND ANALYSIS: Included patients will: 
      (1) be aged 18 years or older, (2) have undergone an oesophagectomy for cancer
      between 2015 and 2019, and (3) be at least 12 months after the completion of
      adjuvant oncological treatments. Patients will be given the previously created
      LASOR questionnaire. Each symptom from the LASOR questionnaire will be graded
      according to impact on quality of life and frequency of the symptom, with a
      composite score from 0 to 5. The previously developed LASOR symptom tool will be 
      validated against HRQOL as measured by the European Organisation for Research and
      Treatment of Cancer QLQC30 and OG25. SAMPLE SIZE: With a predicted prevalence of 
      poor HRQOL of 45%, based on the previously generated LASOR clinical symptom tool,
      to validate this tool with a sensitivity and specificity of 80%, respectively, a 
      minimum of 640 patients will need to be recruited to the study. ETHICS AND
      DISSEMINATION: NHS Health Research Authority (North East-York Research Ethics
      Committee) approval was gained 8 November 2019 (REC reference 19/NE/0352).
      Multiple platforms will be used for the dissemination of the research data,
      including international clinical and patient group presentations and publication 
      of research outputs in a high impact clinical journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Markar, Sheraz Rehan
AU  - Markar SR
AUID- ORCID: 0000-0001-8650-2017
AD  - Department of Surgery & Cancer, Imperial College London, London, UK
      s.markar@imperial.ac.uk.
FAU - Griffiths, Ewen A
AU  - Griffiths EA
AD  - Department of Upper GI Surgery, University Hospitals Birmingham NHS Foundation
      Trust, Birmingham, UK.
FAU - Behrens, Paul
AU  - Behrens P
AD  - Edinburgh Law School, University of Edinburgh, Edinburgh, UK.
FAU - Singh, Pritam
AU  - Singh P
AD  - Department of Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK.
FAU - Vohra, Ravi S
AU  - Vohra RS
AD  - Department of Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK.
FAU - Gossage, James
AU  - Gossage J
AD  - Department of Surgery, St. Thomas' Hospital, London, UK.
FAU - Underwood, Tim
AU  - Underwood T
AD  - Division of Surgery, University Hospital Southampton NHS Foundation Trust,
      Southampton, Hampshire, UK.
FAU - Hanna, George B
AU  - Hanna GB
AD  - Faculty of Medicine, Department of Surgery & Cancer, Imperial College, London,
      UK.
CN  - LASORS study group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Esophageal Neoplasms/*surgery
MH  - *Esophagectomy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Postoperative Complications/*diagnosis
MH  - Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC7279661
OTO - NOTNLM
OT  - *oesophageal disease
OT  - *oncology
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034897 [pii]
AID - 10.1136/bmjopen-2019-034897 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e034897. doi: 10.1136/bmjopen-2019-034897.


PMID- 32499264
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil
      porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study
      protocol for a single-armed and single-centred clinical trial.
PG  - e034685
LID - 10.1136/bmjopen-2019-034685 [doi]
AB  - INTRODUCTION: Anlotinib hydrochloride is a multi-targeted receptor tyrosine
      kinase inhibitor that targets angiogenesis-related kinases and has already showed
      good safety and efficacy in some solid tumours. However, evidence on the safety
      and feasibility of anlotinib in patients with stage IV gastric cancer is scarce. 
      METHODS AND ANALYSIS: This study is a single-armed and single-centred clinical
      study being designed to include 150 patients of stage IV gastric cancer. The
      patients' demographics, pathological characteristics, test results of blood,
      biochemistry and tumour markers before and after medication, disease-free
      survival and overall survival will be collected and analysed. The primary and
      main efficacy outcomes are objective response rate, progression-free survival,
      disease control rate and overall survival. The secondary efficacy outcome is
      safety indicator including the incidence of adverse drug reactions and adverse
      events after administration. ETHICS AND DISSEMINATION: Ethics approval has been
      obtained from the Ethics Committee at the First Affiliated Hospital (Xijing
      Hospital) of Fourth Military Medical University (KY20192111-F-1). The results of 
      this study will be disseminated at several research conferences and as published 
      articles in peer-reviewed journals. TRIAL REGISTRATION NUMBER: ChiCTR1900026291
      (registration date: 29 September 2019).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Digestive Surgery, Xi Jing Hospital, Fourth Military Medical
      University, Xi'an, Shaanxi, China.
FAU - Wu, Dong Xue
AU  - Wu DX
AD  - Medical Department, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang,
      Jiangsu, China.
FAU - Meng, Lu
AU  - Meng L
AD  - Medical Department, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang,
      Jiangsu, China.
FAU - Ji, Gang
AU  - Ji G
AUID- ORCID: 0000-0001-7500-7192
AD  - Department of Digestive Surgery, Xi Jing Hospital, Fourth Military Medical
      University, Xi'an, Shaanxi, China jigangfmmu@163.com.
LA  - eng
SI  - ChiCTR/ChiCTR1900026291
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pyridines)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - UA8SE1325T (gimeracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Oxaliplatin/*administration & dosage/adverse effects
MH  - Oxonic Acid/*administration & dosage/adverse effects
MH  - Progression-Free Survival
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Stomach Neoplasms/*drug therapy/mortality/pathology
MH  - Tegafur/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC7279648
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *gastrointestinal tumours
OT  - *oncology
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034685 [pii]
AID - 10.1136/bmjopen-2019-034685 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e034685. doi: 10.1136/bmjopen-2019-034685.


PMID- 32499263
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Monitoring patients with acute dyspnoea with a serial focused ultrasound of the
      heart and the lungs (MODUS): a protocol for a multicentre, randomised,
      open-label, pragmatic and controlled trial.
PG  - e034373
LID - 10.1136/bmjopen-2019-034373 [doi]
AB  - INTRODUCTION: Among patients admitted to an emergency department, dyspnoea is one
      of the most common symptoms. Patients with dyspnoea have high mortality and
      morbidity. Therefore, novel methods to monitor the patients are warranted. The
      aim is to investigate whether therapy guided by monitoring patients with acute
      dyspnoea with serial ultrasound examinations of the heart and the lungs together 
      with standard care can change the severity of dyspnoea compared with treatment
      guided by standard monitoring alone. METHODS AND ANALYSIS: The study will be
      conducted as a multicentre, randomised, pragmatic, open-label and controlled
      trial where patients admitted with acute dyspnoea to an emergency ward will be
      randomised into a standard care group and a serial ultrasound group with 103
      patients in each. All patients will be examined with an ultrasound of the heart
      and the lungs upfront. In addition, the patients in the serial ultrasound group
      will be examined with an ultrasound of the heart and lungs two more times to
      guide further therapy during the admittance. The primary outcome is a change in
      dyspnoea on a verbal scale. After discharge, the patients are followed for 1 year
      to assess the number of readmissions, death and length of hospital stay. ETHICS
      AND DISSEMINATION: The trial is conducted in accordance with the Declaration of
      Helsinki and approved by The Regional Committee on Health Research Ethics for
      Region Zealand, Denmark (identifier SJ-744). Data handling agreement with
      participating centres has been made (identifier REG-056-2019). The General Data
      Protection Regulation and the Danish Data Protection Act will be respected. The
      results of the trial will be reported in peer-reviewed scientific journals
      regardless of the outcomes. TRIAL REGISTRATION NUMBER: NCT04091334.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arvig, Michael D
AU  - Arvig MD
AUID- ORCID: 0000-0001-5853-1953
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark 
      doktorarvig@gmail.com.
AD  - Department of Emergency Medicine, Slagelse Hospital, Slagelse, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
AD  - OPEN, Open Patient data Explorative Network, Odense University Hospital, Odense, 
      Denmark.
FAU - Lassen, Annmarie T
AU  - Lassen AT
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
AD  - Department of Emergency Medicine, Odense University Hospital, Odense, Denmark.
FAU - Gaede, Peter H
AU  - Gaede PH
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
AD  - Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark.
FAU - Laursen, Christian B
AU  - Laursen CB
AD  - Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
AD  - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT04091334
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Pragmatic Clinical Trial
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acute Disease
MH  - Dyspnea/*diagnostic imaging
MH  - Emergency Service, Hospital
MH  - Heart/*diagnostic imaging
MH  - Humans
MH  - Lung/*diagnostic imaging
MH  - *Monitoring, Physiologic
MH  - *Ultrasonography
PMC - PMC7279664
OTO - NOTNLM
OT  - *dyspnoea
OT  - *focused cardiac ultrasound
OT  - *inferior vena cava
OT  - *lung ultrasound
OT  - *monitoring
OT  - *serial
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034373 [pii]
AID - 10.1136/bmjopen-2019-034373 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e034373. doi: 10.1136/bmjopen-2019-034373.


PMID- 32499262
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Early Psychosis Intervention-Spreading Evidence-based Treatment (EPI-SET):
      protocol for an effectiveness-implementation study of a structured model of care 
      for psychosis in youth and emerging adults.
PG  - e034280
LID - 10.1136/bmjopen-2019-034280 [doi]
AB  - INTRODUCTION: While early psychosis intervention (EPI) has proliferated in recent
      years amid evidence of its effectiveness, programmes often struggle to deliver
      consistent, recovery-based care. NAVIGATE is a manualised model of EPI with
      demonstrated effectiveness consisting of four components: individualised
      medication management, individual resiliency training, supported employment and
      education and family education. We aim to implement NAVIGATE in geographically
      diverse EPI programmes in Ontario, Canada, evaluating implementation and its
      effect on fidelity to the EPI model, as well as individual-level outcomes
      (patient/family member-reported and interviewer-rated), system-level outcomes
      (captured in provincial administrative databases) and engagement of participants 
      with lived experience. METHODS AND ANALYSIS: This is a multisite, non-randomised 
      pragmatic hybrid effectiveness-implementation type III mixed methods study
      coordinated at the Centre for Addiction and Mental Health (CAMH) in Toronto.
      Implementation is supported by the Provincial System Support Program, a
      CAMH-based programme with provincial offices across Ontario, and Extension of
      Community Healthcare Outcomes Ontario Mental Health at CAMH and the University of
      Toronto. The primary outcome is fidelity to the EPI model as measured using the
      First Episode Psychosis Services-Fidelity Scale. Four hundred participants in the
      EPI programmes will be recruited and followed using both individual-level
      assessments and health administrative data for 2 years following NAVIGATE
      initiation. People with lived experience will be engaged in all aspects of the
      project, including through youth and family advisory committees. ETHICS AND
      DISSEMINATION: Research ethics board approval has been obtained from CAMH and
      institutions overseeing the local EPI programmes. Study findings will be reported
      in scientific journal articles and shared with key stakeholders including youth, 
      family members, programme staff and policymakers. TRIAL REGISTRATION NUMBER:
      NCT03919760; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kozloff, Nicole
AU  - Kozloff N
AUID- ORCID: 0000-0003-1389-1351
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada n.kozloff@mail.utoronto.ca
      aristotle.voineskos@camh.ca.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Foussias, George
AU  - Foussias G
AUID- ORCID: 0000-0001-6220-519X
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
FAU - Durbin, Janet
AU  - Durbin J
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Provincial System Support Program, Centre for Addiction and Mental Health,
      Toronto, Ontario, Canada.
FAU - Sockalingam, Sanjeev
AU  - Sockalingam S
AUID- ORCID: 0000-0002-9626-1509
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Education, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Addington, Jean
AU  - Addington J
AD  - Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
FAU - Addington, Donald
AU  - Addington D
AUID- ORCID: 0000-0002-0527-0275
AD  - Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
FAU - Ampofo, Augustina
AU  - Ampofo A
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Anderson, Kelly K
AU  - Anderson KK
AUID- ORCID: 0000-0001-9843-404X
AD  - Epidemiology & Biostatistics, Western University, London, Ontario, Canada.
FAU - Barwick, Melanie
AU  - Barwick M
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, 
      Canada.
FAU - Bromley, Sarah
AU  - Bromley S
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Cunningham, Jasmyn E A
AU  - Cunningham JEA
AUID- ORCID: 0000-0002-7067-8832
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario,
      Canada.
FAU - Dahrouge, Simone
AU  - Dahrouge S
AUID- ORCID: 0000-0001-6488-8086
AD  - C.T. Lamont Primary Health Care Research Centre, Bruyere Research Institute,
      Ottawa, Ontario, Canada.
AD  - Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Duda, Lillian
AU  - Duda L
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Ford, Catherine
AU  - Ford C
AD  - Ontario Ministry of Health, Toronto, Ontario, Canada.
FAU - Gallagher, Sheila
AU  - Gallagher S
AD  - Durham Amaze Early Psychosis Intervention Program, Lakeridge Health, Whitby,
      Ontario, Canada.
FAU - Haltigan, John D
AU  - Haltigan JD
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Child and Youth Psychiatry, Centre for Addiction and Mental Health, Toronto,
      Ontario, Canada.
FAU - Henderson, Joanna
AU  - Henderson J
AUID- ORCID: 0000-0002-9387-5193
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Margaret and Wallace McCain Centre for Child, Youth and Family Mental Health,
      Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Jaouich, Alexia
AU  - Jaouich A
AD  - Provincial System Support Program, Centre for Addiction and Mental Health,
      Toronto, Ontario, Canada.
FAU - Miranda, Dielle
AU  - Miranda D
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Mitchell, Patrick
AU  - Mitchell P
AD  - Ontario Ministry of Health, Toronto, Ontario, Canada.
FAU - Morin, Josette
AU  - Morin J
AD  - Regional Early Intervention in Psychosis Service, North Bay Regional Health
      Centre, North Bay, Ontario, Canada.
FAU - de Oliveira, Claire
AU  - de Oliveira C
AUID- ORCID: 0000-0003-3961-6008
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Primeau, Valerie
AU  - Primeau V
AD  - Regional Early Intervention in Psychosis Service, North Bay Regional Health
      Centre, North Bay, Ontario, Canada.
FAU - Serhal, Eva
AU  - Serhal E
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Telepsychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Soklaridis, Sophie
AU  - Soklaridis S
AUID- ORCID: 0000-0001-5119-8473
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Education, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
FAU - Urajnik, Diana
AU  - Urajnik D
AD  - Human Sciences, Social and Population Health, Northern Ontario School of
      Medicine, Sudbury, Ontario, Canada.
AD  - Centre for Rural and Northern Health Research, Laurentian University, Sudbury,
      Ontario, Canada.
FAU - Whittard, Krista
AU  - Whittard K
AD  - Early Psychosis Intervention, Niagara Region Public Health, Thorold, Ontario,
      Canada.
FAU - Zaheer, Juveria
AU  - Zaheer J
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Kurdyak, Paul
AU  - Kurdyak P
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute for Mental Health Policy Research, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada.
FAU - Voineskos, Aristotle N
AU  - Voineskos AN
AUID- ORCID: 0000-0003-0156-0395
AD  - Slaight Family Centre for Youth in Transition, Centre for Addiction and Mental
      Health, Toronto, Ontario, Canada n.kozloff@mail.utoronto.ca
      aristotle.voineskos@camh.ca.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03919760
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Multicenter Study
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - *Early Medical Intervention
MH  - *Evidence-Based Practice
MH  - Follow-Up Studies
MH  - Humans
MH  - *Models, Structural
MH  - Models, Theoretical
MH  - Psychotic Disorders/*therapy
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7282307
OTO - NOTNLM
OT  - *mental health
OT  - *patient engagement
OT  - *quality in health care
OT  - *schizophrenia and psychotic disorders
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-034280 [pii]
AID - 10.1136/bmjopen-2019-034280 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e034280. doi: 10.1136/bmjopen-2019-034280.


PMID- 32499258
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Interventions to promote access to eye care for non-Indigenous, non-dominant
      ethnic groups in high-income countries: a scoping review protocol.
PG  - e033775
LID - 10.1136/bmjopen-2019-033775 [doi]
AB  - INTRODUCTION: For many people, settling in a new country is associated with a new
      identity as an 'ethnic minority', one that can remain through future generations.
      People who are culturally distinct from the dominant population group may
      experience a variety of barriers to accessing healthcare, including linguistic
      and cultural barriers in communication, navigation of an unfamiliar health system
      and unconscious or overt discrimination. Here, we outline the protocol of a
      scoping review to identify, describe and summarise interventions aimed at
      improving access to eye care for non-Indigenous, non-dominant ethnic groups
      residing in high-income countries. METHODS AND ANALYSIS: We will search MEDLINE, 
      Embase and Global Health from their inception to July 2019. We will include
      studies of any design that describe an intervention to promote access to eye care
      for non-Indigenous, non-dominant ethnic groups. Two authors will independently
      review titles, abstracts and full-text articles for inclusion. Reference lists
      from all included articles will also be searched. In cases of disagreement
      between initial reviewers, a third author will help resolve the conflict. For
      each included article, we will extract data about the target population, details 
      of the intervention delivered and the effectiveness of or feedback from the
      intervention. Overall findings will be summarised with descriptive statistics and
      thematic analysis. ETHICS AND DISSEMINATION: This review will summarise existing 
      literature and as such ethics approval is not required. We will publish the
      review in an open-access, peer-reviewed journal, and draft appropriate summaries 
      for dissemination to the wider community. This wider community could include
      clinicians, policymakers, health service managers and organisations that work
      with non-dominant ethnic groups. Our findings will also feed into the ongoing
      Lancet Global Health Commission on Global Eye Health.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Hamm, Lisa Marie
AU  - Hamm LM
AUID- ORCID: 0000-0003-2777-7146
AD  - School of Optometry and Vision Science, The University of Auckland, Auckland, New
      Zealand.
FAU - Black, Joanna
AU  - Black J
AUID- ORCID: 0000-0002-5100-8796
AD  - School of Optometry and Vision Science, The University of Auckland, Auckland, New
      Zealand.
FAU - Burn, Helen
AU  - Burn H
AUID- ORCID: 0000-0002-1469-8169
AD  - International Centre for Eye Health, Faculty of Infectious and Tropical Diseases,
      London School of Hygiene and Tropical Medicine, London, UK.
FAU - Grey, Corina
AU  - Grey C
AUID- ORCID: 0000-0003-1751-1934
AD  - School of Population Health, The University of Auckland, Auckland, New Zealand.
FAU - Harwood, Matire
AU  - Harwood M
AUID- ORCID: 0000-0003-1240-5139
AD  - School of Population Health, The University of Auckland, Auckland, New Zealand.
FAU - Peiris-John, Roshini
AU  - Peiris-John R
AUID- ORCID: 0000-0001-7812-2268
AD  - School of Population Health, The University of Auckland, Auckland, New Zealand.
FAU - Gordon, Iris
AU  - Gordon I
AUID- ORCID: 0000-0001-8143-8132
AD  - International Centre for Eye Health, Faculty of Infectious and Tropical Diseases,
      London School of Hygiene and Tropical Medicine, London, UK.
FAU - Burton, Matthew J
AU  - Burton MJ
AUID- ORCID: 0000-0003-1872-9169
AD  - International Centre for Eye Health, Faculty of Infectious and Tropical Diseases,
      London School of Hygiene and Tropical Medicine, London, UK.
AD  - Moorfields Eye Hospital, London, UK.
FAU - Evans, Jennifer R
AU  - Evans JR
AUID- ORCID: 0000-0002-6137-2030
AD  - International Centre for Eye Health, Faculty of Infectious and Tropical Diseases,
      London School of Hygiene and Tropical Medicine, London, UK.
FAU - Ramke, Jacqueline
AU  - Ramke J
AUID- ORCID: 0000-0002-5764-1306
AD  - School of Optometry and Vision Science, The University of Auckland, Auckland, New
      Zealand jacqueline.ramke@lshtm.ac.uk.
AD  - International Centre for Eye Health, Faculty of Infectious and Tropical Diseases,
      London School of Hygiene and Tropical Medicine, London, UK.
LA  - eng
GR  - 207472/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Emigrants and Immigrants/*psychology
MH  - Eye Diseases/*diagnosis/psychology/*therapy
MH  - Health Knowledge, Attitudes, Practice
MH  - *Health Promotion
MH  - *Health Services Accessibility
MH  - Health Services Needs and Demand
MH  - Healthcare Disparities
MH  - Humans
MH  - *Minority Groups/psychology
MH  - Optometry
MH  - Patient Acceptance of Health Care/psychology
MH  - Resilience, Psychological
MH  - *Socioeconomic Factors
PMC - PMC7279662
OTO - NOTNLM
OT  - *ethnic disparity
OT  - *ethnic minority
OT  - *eye care
OT  - *immigrants
OT  - *optometry
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-033775 [pii]
AID - 10.1136/bmjopen-2019-033775 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e033775. doi: 10.1136/bmjopen-2019-033775.


PMID- 32499256
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Point-of-care tests for urinary tract infections: protocol for a systematic
      review and meta-analysis of diagnostic test accuracy.
PG  - e033424
LID - 10.1136/bmjopen-2019-033424 [doi]
AB  - INTRODUCTION: Urinary tract infections (UTIs) are the second most common type of 
      infection worldwide, accounting for a large number of primary care consultations 
      and antibiotic prescribing. Current diagnosis is based on an empirical approach, 
      relying on symptoms and occasional use of urine dipsticks. The diagnostic
      reference standard is still urine culture, although it is not routinely
      recommended for uncomplicated UTIs in the community, due to time to diagnosis (48
      hours). Faster point-of-care tests have been developed, but their diagnostic
      accuracy has not been compared. Our objective is to systematically review and
      meta-analyse the diagnostic accuracy of currently available point-of-care tests
      for UTIs. METHODS AND ANALYSIS: Studies evaluating the diagnostic accuracy of
      point-of-care tests for UTIs will be included. PubMed, Web of Science, Embase and
      Cochrane Database of Systematic Reviews were searched from inception to 1 June
      2019. Data extraction and risk-of-bias assessment will be assessed using the
      Quality Assessment of Diagnostic Accuracy Studies tool. Meta-analysis will be
      performed depending on data availability and heterogeneity. ETHICS AND
      DISSEMINATION: This is a systematic review protocol and therefore formal ethical 
      approval is not required, as no primary, identifiable, personal data will be
      collected. Patients or the public were not involved in the design of our
      research. However, the findings from this review will be shared with key
      stakeholders, including patient groups, clinicians and guideline developers, and 
      will also be presented and national and international conferences. PROSPERO
      REGISTRATION NUMBER: CRD42018112019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fraile Navarro, David
AU  - Fraile Navarro D
AUID- ORCID: 0000-0002-1108-7071
AD  - Division of Population and Behavioural Sciences, School of Medicine, University
      of Saint Andrews, Saint Andrews, UK.
FAU - Sullivan, Frank
AU  - Sullivan F
AD  - Division of Population and Behavioural Sciences, School of Medicine, University
      of Saint Andrews, Saint Andrews, UK.
AD  - Department of Family and Community Medicine, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Azcoaga-Lorenzo, Amaya
AU  - Azcoaga-Lorenzo A
AD  - Division of Population and Behavioural Sciences, School of Medicine, University
      of Saint Andrews, Saint Andrews, UK.
FAU - Hernandez Santiago, Virginia
AU  - Hernandez Santiago V
AUID- ORCID: 0000-0002-8544-1483
AD  - Division of Population and Behavioural Sciences, School of Medicine, University
      of Saint Andrews, Saint Andrews, UK vhs2@st-andrews.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Diagnostic Tests, Routine
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Point-of-Care Testing
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Urinary Tract Infections/*diagnosis
PMC - PMC7282288
OTO - NOTNLM
OT  - *diagnostic microbiology
OT  - *epidemiology
OT  - *molecular diagnostics
OT  - *urinary tract infections
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-033424 [pii]
AID - 10.1136/bmjopen-2019-033424 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e033424. doi: 10.1136/bmjopen-2019-033424.


PMID- 32499254
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - The KOMPACT-P study: Knee Osteoarthritis Management with Physiotherapy informed
      by Acceptance and Commitment Therapy-Pilot study protocol.
PG  - e032675
LID - 10.1136/bmjopen-2019-032675 [doi]
AB  - INTRODUCTION: Incidence of total knee arthroplasty (TKA) is projected to rise
      276% in 2030, and psychological distress affects up to 42% of people with knee
      osteoarthritis undergoing TKA, with demonstrated detrimental effects on
      postoperative outcomes. Few studies have assessed psychological treatment in
      people awaiting TKA, and these have been psychologist-delivered treatments. No
      evidence exists regarding psychologically-informed interventions delivered by
      health professionals currently embedded in TKA clinical pathways. The primary aim
      of this pilot study is to explore the safety, acceptability and feasibility of
      the Knee Osteoarthritis Management with Physiotherapy informed by Acceptance and 
      Commitment Therapy (KOMPACT) approach in people awaiting TKA. METHODS AND
      ANALYSIS: 51 community-dwelling adults scheduled for a primary TKA at two
      hospitals will be recruited to this pilot, mixed-methods, prospective randomised 
      controlled trial with assessor blinding. Participants will be randomised in a 1:2
      ratio to either usual care (education class) or usual care plus KOMPACT (2 hours 
      20 min of preoperative physiotherapy informed by Acceptance and Commitment
      Therapy). Our primary outcome measures are safety (length of stay, complications 
      and psychological health after KOMPACT), acceptability (treatment credibility and
      qualitative data) and feasibility (recruitment, retention and intervention
      fidelity) of the KOMPACT approach. Secondary outcomes include health service
      outcomes, patient-reported physical and psychological outcomes, and physical
      performance measures. Quantitative data collection was conducted at baseline, 1-2
      weeks before TKA, 6 weeks after TKA and 6 months after TKA. Qualitative data
      collection is 1-2 weeks before TKA. Data analysis will take a quantitative-led
      approach with triangulation after thematic analysis of the qualitative data.
      ETHICS AND DISSEMINATION: This study has full ethics approval
      (HREC/18/WMEAD/440). Results from this study will be published in peer-reviewed
      journals and presented at local and international conferences. TRIAL REGISTRATION
      NUMBER: Australia New Zealand Clinical Trials Registry (ACTRN12618001867280p).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - March, Marie K
AU  - March MK
AUID- ORCID: 0000-0003-3444-0795
AD  - Physiotherapy Department, Blacktown Mt Druitt Hospital, Western Sydney Local
      Health District, Blacktown, New South Wales, Australia
      Marie.March@health.nsw.gov.au.
AD  - Discipline of Physiotherapy, Sydney School of Health Sciences, Faculty of
      Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
FAU - Harmer, Alison
AU  - Harmer A
AD  - Discipline of Physiotherapy, Sydney School of Health Sciences, Faculty of
      Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
FAU - Godfrey, Emma
AU  - Godfrey E
AD  - Department of Health Psychology, Institute of Psychiatry, Psychology &
      Neuroscience (IoPPN), King's College London, London, United Kingdom.
AD  - Department of Population Health Sciences, School of Population Health &
      Environmental Sciences, Faculty of Life Sciences & Medicine, King's College
      London, London, United Kingdom.
FAU - Venkatesh, Shruti
AU  - Venkatesh S
AD  - Renal Supportive Care, Nepean Blue Mountains Local Health District, Penrith, New 
      South Wales, Australia.
FAU - Thomas, Bijoy
AU  - Thomas B
AD  - Orthopaedic Department, Blacktown Mt Druitt Hospital, Western Sydney Local Health
      District, Blacktown, New South Wales, Australia.
FAU - Dennis, Sarah
AU  - Dennis S
AD  - Discipline of Physiotherapy, Sydney School of Health Sciences, Faculty of
      Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
AD  - South Western Sydney Local Health District, Liverpool, New South Wales,
      Australia.
AD  - Ingham Institute of Applied Medical Research, Liverpool, New South Wales,
      Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - Adult
MH  - Arthroplasty, Replacement, Knee
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Independent Living
MH  - Male
MH  - Multicenter Studies as Topic
MH  - Osteoarthritis, Knee/surgery/*therapy
MH  - *Physical Therapy Modalities
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7279646
OTO - NOTNLM
OT  - *knee
OT  - *mental health
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-032675 [pii]
AID - 10.1136/bmjopen-2019-032675 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e032675. doi: 10.1136/bmjopen-2019-032675.


PMID- 32499253
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 3
TI  - Protocol for a systematic review of reviews evaluating effectiveness of mass
      media interventions for prevention and control of non-communicable diseases.
PG  - e032611
LID - 10.1136/bmjopen-2019-032611 [doi]
AB  - INTRODUCTION: Timely interventions are required in order to change unhealthy
      lifestyles because if continued for a prolonged period of time, these become risk
      factors for non-communicable diseases (NCDs). Education through mass media is an 
      important factor in bringing out the behavioural change which may get missed in
      community-based interventions due to their limited reach. Many countries engage
      in mass media interventions, however, the nature of interventions and their
      effectiveness differs. We, therefore, describe the protocol of a systematic
      review to evaluate the effectiveness of the mass media interventions to reduce
      the risk of NCDs in the general population and compare the differences in
      effectiveness estimates across low/middle-income countries and developed
      countries. METHODS AND ANALYSIS: We will search The Cochrane Library, Database of
      Abstracts of Reviews of Effectiveness, PubMed, Excerpta Medica Database limited
      to publications since 2000 to October 2019. Specific terms for the search
      strategy will be piloted as database-controlled vocabulary in the databases
      searched. The searches will include variations of the following terms: mass
      media, mass communication, campaign, publicity and terms for types of media, that
      is, print media, mobile, digital media, social media and broadcast. Study designs
      to be included will be systematic reviews followed by grey literature and other
      good quality reviews identified. The primary outcome of effectiveness will be the
      percentage change in population having different behavioural risk factors. In
      addition, mean overall change in levels of several physical or biochemical
      parameters will be studied as secondary outcomes. ETHICS AND DISSEMINATION: The
      review is being done under the doctoral research which has been approved by the
      Institute Ethics Committee of the Post Graduate Institute of Medical Education
      and Research Dissemination will be done by submitting scientific articles to
      academic peer-reviewed journals. We will present the results at relevant
      conferences and meetings. PROSPERO REGISTRATION NUMBER: CRD42016048013.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jeet, Gursimer
AU  - Jeet G
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, India.
FAU - Thakur, J S
AU  - Thakur JS
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, India
      jsthakur64@gmail.com.
FAU - Prinja, Shankar
AU  - Prinja S
AUID- ORCID: 0000-0001-7396-1273
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, India.
FAU - Singh, Meenu
AU  - Singh M
AD  - Advanced Paediatric Center, Post Graduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Nangia, Ria
AU  - Nangia R
AUID- ORCID: 0000-0001-7648-3473
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, India.
FAU - Sharma, Deepti
AU  - Sharma D
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, India.
FAU - Dhadwal, Priya
AU  - Dhadwal P
AD  - Department of Community Medicine and School of Public Health, Post Graduate
      Institute of Medical Education and Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Health Promotion/*methods
MH  - Humans
MH  - *Mass Media
MH  - Noncommunicable Diseases/*prevention & control
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7282296
OTO - NOTNLM
OT  - *communication
OT  - *mass media
OT  - *non-communicable diseases
OT  - *prevention
OT  - *reviews
OT  - *risk factors
COIS- Competing interests: None declared.
EDAT- 2020/06/06 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-032611 [pii]
AID - 10.1136/bmjopen-2019-032611 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 3;10(6):e032611. doi: 10.1136/bmjopen-2019-032611.


PMID- 32499195
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 2341-2879 (Electronic)
IS  - 2341-2879 (Linking)
VI  - 93
IP  - 4
DP  - 2020 Oct
TI  - [Participant-funded clinical trials on rare diseases].
PG  - 267.e1-267.e9
LID - S1695-4033(20)30153-3 [pii]
LID - 10.1016/j.anpedi.2020.03.019 [doi]
AB  - The development of medicines for certain rare diseases can be frustrated by lack 
      of funding. In certain cases the patients themselves, or their relatives,
      occasionally fund the clinical trial in which they will be treated with the
      investigational medicine. There are 3models of self-funded research: 2of them,
      "pay to try" and "pay to participate", have already been put into practice. The
      third, the "plutocratic" proposal, which has been recently put forward is still a
      theoretical model. In this work the scientific, social and ethical benefits and
      risks of the 2clinical research models, "pay to participate" and the
      "plutocratic" proposal, are reviewed. Patient-funded clinical trials are
      frequently performed through crowdfunding. The most controversial aspects of this
      funding modality are also addressed in this article from several perspectives.
      Finally, a future scenario that would allow the launching of self-funded clinical
      trials in Spain by the "plutocratic" proposal is proposed.
CI  - Copyright (c) 2020 Asociacion Espanola de Pediatria. Publicado por Elsevier
      Espana, S.L.U. All rights reserved.
FAU - Dal-Re, Rafael
AU  - Dal-Re R
AD  - Unidad de Epidemiologia, Instituto de Investigacion Sanitaria, Hospital
      Universitario Fundacion Jimenez Diaz, IIS-UAM, Universidad Autonoma de Madrid,
      Madrid, Espana. Electronic address: Rafael.dalre@quironsalud.es.
FAU - Palau, Francesc
AU  - Palau F
AD  - Servicio de Medicina Genetica y Molecular, Instituto Pediatrico de Enfermedades
      Raras (IPER), Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu,
      Esplugues de Llobregat, Barcelona, Espana; Institut Clinic de Medicina i
      Dermatologia, Hospital Clinic, Barcelona, Espana; Unidad de Pediatria, Facultat
      de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Espana; 
      CIBER de Enfermedades Raras (CIBERER), ISCIII, Madrid, Espana.
FAU - Guillen-Navarro, Encarna
AU  - Guillen-Navarro E
AD  - CIBER de Enfermedades Raras (CIBERER), ISCIII, Madrid, Espana; Seccion de
      Genetica Medica, Servicio de Pediatria, Hospital Clinico Universitario Virgen de 
      la Arrixaca, Instituto Murciano de Investigacion Biosanitaria (IMIB-Arrixaca),
      Facultad de Medicina, Universidad de Murcia, Murcia, Espana.
FAU - Ayuso, Carmen
AU  - Ayuso C
AD  - CIBER de Enfermedades Raras (CIBERER), ISCIII, Madrid, Espana; Departamento de
      Genetica y Genomica, Instituto de Investigacion Sanitaria, Hospital Universitario
      Fundacion Jimenez Diaz, IIS-UAM, Universidad Autonoma de Madrid, Madrid, Espana.
LA  - spa
PT  - Journal Article
TT  - Ensayos clinicos en enfermedades raras financiados por los participantes.
DEP - 20200601
PL  - Spain
TA  - An Pediatr (Engl Ed)
JT  - Anales de pediatria
JID - 101765626
SB  - IM
MH  - Clinical Trials as Topic/*economics/ethics/organization & administration
MH  - Crowdsourcing/economics/ethics
MH  - Health Services Accessibility/economics/ethics
MH  - Humans
MH  - Orphan Drug Production/*economics/ethics
MH  - *Patient Selection/ethics
MH  - Rare Diseases/*drug therapy/economics
MH  - Research Support as Topic/ethics/*methods
MH  - Spain
MH  - United States
OTO - NOTNLM
OT  - Autofinanciacion
OT  - Clinical trials
OT  - Crowdfunding
OT  - Enfermedades raras
OT  - Ensayos clinicos
OT  - Medicamentos huerfanos
OT  - Microfinanciacion
OT  - Micromecenazgo
OT  - Orphan drugs
OT  - Patient-funded
OT  - Rare diseases
OT  - Self-funded
EDAT- 2020/06/06 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - S1695-4033(20)30153-3 [pii]
AID - 10.1016/j.anpedi.2020.03.019 [doi]
PST - ppublish
SO  - An Pediatr (Engl Ed). 2020 Oct;93(4):267.e1-267.e9. doi:
      10.1016/j.anpedi.2020.03.019. Epub 2020 Jun 1.


PMID- 32499188
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20200625
IS  - 1769-6658 (Electronic)
IS  - 1278-3218 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Jul
TI  - [Research ethics: French regulations and applications in radiation oncology].
PG  - 306-315
LID - S1278-3218(20)30121-9 [pii]
LID - 10.1016/j.canrad.2020.02.012 [doi]
AB  - French regulations about research ethics are based on the so-called Jarde law,
      which defines researches involving human beings. Researches involving human
      beings require the submission of research protocols to a committee for protection
      of persons with a precise list of documents to submit for a favourable opinion.
      This law describes different categories of researches and determines the ethical 
      procedures to apply before setting up a research protocol. This issue of
      categorisation is central and must be taken into account by researchers from the 
      beginning of the research process. Researches considered as not involving human
      beings also require a set of ethical precautions focused on patients' information
      and the collection of their non-opposition (due to the application of the General
      Data Protection Regulation adopted by the European Parliament). Thus, many
      regulations exist and they require a real work for researchers to meet these
      requirements in research ethics. This article aims to summarise French
      regulations. Selected examples are specifically taken into the field of radiation
      oncology research.
CI  - Copyright (c) 2020 Societe francaise de radiotherapie oncologique (SFRO).
      Published by Elsevier Masson SAS. All rights reserved.
FAU - Haaser, T
AU  - Haaser T
AD  - Service d'oncologie radiotherapie, hopital Haut-Leveque, centre hospitalier
      universitaire de Bordeaux, avenue Magellan, 33600 Pessac, France; EA 4574 <<
      Sciences, philosophie, humanites >>, universite de Bordeaux-universite
      Bordeaux-Montaigne, domaine universitaire, 33607 Pessac, France; Service de
      pharmacologie medicale, comite de protection des personnes Sud-Ouest et outre-mer
      III, hopital Pellegrin, centre hospitalier universitaire de Bordeaux, 33076
      Bordeaux, France. Electronic address: thibaud.haaser@chu-bordeaux.fr.
FAU - Berdai, D
AU  - Berdai D
AD  - Service de pharmacologie medicale, comite de protection des personnes Sud-Ouest
      et outre-mer III, hopital Pellegrin, centre hospitalier universitaire de
      Bordeaux, 33076 Bordeaux, France; Faculte de pharmacie, universite de Bordeaux,
      146, rue Leo-Saignat, 33076 Bordeaux, France.
FAU - Trouette, R
AU  - Trouette R
AD  - Service d'oncologie radiotherapie, hopital Haut-Leveque, centre hospitalier
      universitaire de Bordeaux, avenue Magellan, 33600 Pessac, France.
FAU - Dupin, C
AU  - Dupin C
AD  - Service d'oncologie radiotherapie, hopital Haut-Leveque, centre hospitalier
      universitaire de Bordeaux, avenue Magellan, 33600 Pessac, France.
FAU - Marty, S
AU  - Marty S
AD  - Centre de coordination de cancerologie, hopital Saint-Andre, centre hospitalier
      universitaire de Bordeaux, 1, rue Jean-Burguet, 33000 Bordeaux, France; Unite de 
      recherche en soins et en sciences humaines, hopital Pellegrin, centre hospitalier
      universitaire de Bordeaux, 33076 Bordeaux, France.
FAU - L'Azou, B
AU  - L'Azou B
AD  - Faculte de pharmacie, universite de Bordeaux, 146, rue Leo-Saignat, 33076
      Bordeaux, France.
FAU - Berger, V
AU  - Berger V
AD  - Unite de recherche en soins et en sciences humaines, hopital Pellegrin, centre
      hospitalier universitaire de Bordeaux, 33076 Bordeaux, France.
FAU - Saux, M-C
AU  - Saux MC
AD  - Service de pharmacologie medicale, comite de protection des personnes Sud-Ouest
      et outre-mer III, hopital Pellegrin, centre hospitalier universitaire de
      Bordeaux, 33076 Bordeaux, France; Faculte de pharmacie, universite de Bordeaux,
      146, rue Leo-Saignat, 33076 Bordeaux, France.
LA  - fre
PT  - Journal Article
TT  - Ethique de la recherche : reglementations francaises et applications en oncologie
      radiotherapie.
DEP - 20200601
PL  - France
TA  - Cancer Radiother
JT  - Cancer radiotherapie : journal de la Societe francaise de radiotherapie
      oncologique
JID - 9711272
SB  - IM
MH  - Biomedical Research/ethics/legislation & jurisprudence
MH  - *Ethics, Research
MH  - France
MH  - *Government Regulation
MH  - Humans
MH  - Patient Safety/legislation & jurisprudence
MH  - Radiation Oncology/*ethics/legislation & jurisprudence
MH  - Research Subjects/legislation & jurisprudence
OTO - NOTNLM
OT  - Comite de protection des personnes
OT  - Committee for Protection of Persons
OT  - Ethics
OT  - Human beings
OT  - Oncologie radiotherapie
OT  - Personne humaine
OT  - Radiation oncology
OT  - Recherche
OT  - Research
OT  - Ethique
EDAT- 2020/06/06 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/01/31 00:00 [revised]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - S1278-3218(20)30121-9 [pii]
AID - 10.1016/j.canrad.2020.02.012 [doi]
PST - ppublish
SO  - Cancer Radiother. 2020 Jul;24(4):306-315. doi: 10.1016/j.canrad.2020.02.012. Epub
      2020 Jun 1.


PMID- 32498697
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 5
TI  - Cluster randomised trials of prescribing policy: an ethical approach to
      generating drug safety evidence? A discussion of the ethical application of a new
      research method.
PG  - 477
LID - 10.1186/s13063-020-04357-4 [doi]
AB  - For most chronic medical conditions, multiple medications are available and
      prescribers often have limited evidence about which therapy is likely to be the
      most effective and safe for an individual patient. As many patients are exposed
      every day to medicines that may be less effective than available alternatives,
      this is of public health importance. Cluster randomised trials of prescribing
      policy offer an opportunity to rapidly obtain evidence of comparative
      effectiveness and safety. These trials can pose a low risk to patients and cause 
      minimal disruption to usual care. Despite the potential scientific value of this 
      approach, there remain valid concerns about consent, medication switching and the
      use of routinely collected data in research. We discuss these concerns with
      reference to an ongoing pilot study (Evaluating Diuretics in Normal Care
      (EVIDENCE) - a cluster randomised evaluation of hypertension prescribing policy, 
      ISRCTN 46635087, registered 11 August 2017).
FAU - Rogers, Amy
AU  - Rogers A
AUID- ORCID: http://orcid.org/0000-0001-5207-7032
AD  - MEMO Research, School of Medicine, University of Dundee, Ninewells Hospital,
      Dundee, DD1 9SY, UK. arogers@dundee.ac.uk.
FAU - Craig, Gillian
AU  - Craig G
AD  - Health and Clinical Services, School of Medicine, University of Dundee, Ninewells
      Hospital, Dundee, DD1 9SY, UK.
AD  - Department of Physics, University of Strathclyde, 107 Rottenrow East, Glasgow, G4
      0NG, UK.
FAU - Flynn, Angela
AU  - Flynn A
AD  - MEMO Research, School of Medicine, University of Dundee, Ninewells Hospital,
      Dundee, DD1 9SY, UK.
FAU - Mackenzie, Isla
AU  - Mackenzie I
AD  - MEMO Research, School of Medicine, University of Dundee, Ninewells Hospital,
      Dundee, DD1 9SY, UK.
FAU - MacDonald, Thomas
AU  - MacDonald T
AD  - MEMO Research, School of Medicine, University of Dundee, Ninewells Hospital,
      Dundee, DD1 9SY, UK.
FAU - Doney, Alexander
AU  - Doney A
AD  - MEMO Research, School of Medicine, University of Dundee, Ninewells Hospital,
      Dundee, DD1 9SY, UK.
LA  - eng
GR  - CGA/18/36/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
DEP - 20200605
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Data Collection/*standards
MH  - Drug Prescriptions/*standards
MH  - Ethics, Research
MH  - Humans
MH  - Informed Consent/*standards
MH  - Randomized Controlled Trials as Topic/*ethics
MH  - Research Design
PMC - PMC7273660
OTO - NOTNLM
OT  - Clinical trials
OT  - Cluster randomization
OT  - Comparative effectiveness
OT  - Ethics
EDAT- 2020/06/06 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/06/06 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 10.1186/s13063-020-04357-4 [doi]
AID - 10.1186/s13063-020-04357-4 [pii]
PST - epublish
SO  - Trials. 2020 Jun 5;21(1):477. doi: 10.1186/s13063-020-04357-4.


PMID- 32498126
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 29
IP  - 17-18
DP  - 2020 Sep
TI  - Beyond the fear: Nurses' experiences caring for patients with Middle East
      respiratory syndrome: A phenomenological study.
PG  - 3349-3362
LID - 10.1111/jocn.15366 [doi]
AB  - AIM AND OBJECTIVES: To explore the experiences of Korean nurses who had directly 
      cared for patients with Middle East respiratory syndrome (MERS) and to derive the
      structure and meaning of these experiences. BACKGROUND: In 2015, the MERS
      epidemic struck Korea, and ill-prepared nurses had to care for patients with
      MERS. Nurses experienced conflict between their fear of the disease and their
      work and professional ethic. DESIGN: We employed a phenomenological qualitative
      approach. METHODS: Inductive, qualitative, in-depth interviews were performed
      with 17 nurses. The study process followed the Consolidated Criteria for
      Reporting Qualitative Research (COREQ) checklist. RESULTS: The qualitative
      inductive content analysis generated seven theme clusters and 18 themes. The
      theme clusters were "Fear of Uncertainty," "Beyond Hesitation," "A Scene Like a
      Battlefield," "Chaotic Nursing Identity," "Buttresses for Sustainability,"
      "Lingering Trauma" and "Expanded Horizon of Nursing." The final analysis revealed
      that the core theme was "Beyond the fear of uncertainty." CONCLUSIONS: This study
      contrives a more in-depth, holistic understanding by describing the experiences
      of nurses who directly cared for patients with MERS-the first large-scale
      infectious disease in Korea. Although nurses saw themselves as vital caregivers, 
      they were frightened of the disease, had to work in a harsh environment,
      experienced various internal conflicts and had to deal with varying forms of
      uncertainty. RELEVANCE TO CLINICAL PRACTICE: This study sheds light on the
      nursing situation during crises involving serious infectious diseases; to combat 
      these, more medical facilities are needed, and staff should be proactively guided
      on how to care for patients. It can serve as part of a good foundation for
      further study of medical staff during recurring epidemics.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Lee, Jin Young
AU  - Lee JY
AUID- ORCID: https://orcid.org/0000-0003-1454-4845
AD  - College of Nursing, Ewha Womans University, Seoul, South Korea.
FAU - Hong, Jeong Hee
AU  - Hong JH
AUID- ORCID: https://orcid.org/0000-0001-9192-6519
AD  - Nursing Administrative Support Team, Samsung Medical Center, Graduate School of
      Clinical Nursing Science, Sungkyunkwan University, Seoul, South Korea.
FAU - Park, Eun Young
AU  - Park EY
AUID- ORCID: https://orcid.org/0000-0003-1356-6487
AD  - College of Nursing, Gachon University, Incheon, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
MH  - Adult
MH  - Coronavirus Infections/*nursing
MH  - Disease Outbreaks
MH  - Fear/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Staff, Hospital/*psychology
MH  - Qualitative Research
MH  - Republic of Korea
MH  - Uncertainty
OTO - NOTNLM
OT  - MERS
OT  - coronavirus
OT  - critical care
OT  - infectious diseases nursing
OT  - lived experience
OT  - nurses
OT  - phenomenology
OT  - qualitative study
EDAT- 2020/06/05 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/05/24 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1111/jocn.15366 [doi]
PST - ppublish
SO  - J Clin Nurs. 2020 Sep;29(17-18):3349-3362. doi: 10.1111/jocn.15366. Epub 2020 Jun
      23.


PMID- 32497806
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20210110
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 96
DP  - 2020 Jul
TI  - Continuous physiological monitoring using wearable technology to inform
      individual management of infectious diseases, public health and outbreak
      responses.
PG  - 648-654
LID - S1201-9712(20)30393-3 [pii]
LID - 10.1016/j.ijid.2020.05.086 [doi]
AB  - Optimal management of infectious diseases is guided by up-to-date information at 
      the individual and public health levels. For infections of global importance,
      including emerging pandemics such as COVID-19 or prevalent endemic diseases such 
      as dengue, identifying patients at risk of severe disease and clinical
      deterioration can be challenging, considering that the majority present with a
      mild illness. In our article, we describe the use of wearable technology for
      continuous physiological monitoring in healthcare settings. Deployment of
      wearables in hospital settings for the management of infectious diseases, or in
      the community to support syndromic surveillance during outbreaks, could provide
      significant, cost-effective advantages and improve healthcare delivery. We
      highlight a range of promising technologies employed by wearable devices and
      discuss the technical and ethical issues relating to implementation in the
      clinic, focusing on low- and middle- income countries. Finally, we propose a set 
      of essential criteria for the rollout of wearable technology for clinical use.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Ming, Damien K
AU  - Ming DK
AD  - NIHR-Health Protection Research Unit in Healthcare Associated Infections and
      Antimicrobial Resistance, Imperial College London, UK; Centre for Antimicrobial
      Optimisation (CAMO), Imperial College London, UK. Electronic address:
      d.ming@imperial.ac.uk.
FAU - Sangkaew, Sorawat
AU  - Sangkaew S
AD  - NIHR-Health Protection Research Unit in Healthcare Associated Infections and
      Antimicrobial Resistance, Imperial College London, UK; Department of Family
      Medicine, Hat Yai Regional Hospital, Thailand.
FAU - Chanh, Ho Q
AU  - Chanh HQ
AD  - Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Viet Nam.
FAU - Nhat, Phung T H
AU  - Nhat PTH
AD  - Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Viet Nam.
FAU - Yacoub, Sophie
AU  - Yacoub S
AD  - Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Viet Nam;
      Centre for Tropical Medicine and Global Health, University of Oxford, UK.
FAU - Georgiou, Pantelis
AU  - Georgiou P
AD  - Department of Electrical Engineering, Imperial College London, UK.
FAU - Holmes, Alison H
AU  - Holmes AH
AD  - NIHR-Health Protection Research Unit in Healthcare Associated Infections and
      Antimicrobial Resistance, Imperial College London, UK; Centre for Antimicrobial
      Optimisation (CAMO), Imperial College London, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200601
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/*instrumentation
MH  - Coronavirus Infections
MH  - *Delivery of Health Care
MH  - Hospitals
MH  - Humans
MH  - Longitudinal Studies
MH  - Monitoring, Physiologic/*instrumentation
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Wearable Electronic Devices
PMC - PMC7263257
COIS- Declaration of Competing Interest We declare no conflict of interest.
EDAT- 2020/06/05 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/04/04 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - S1201-9712(20)30393-3 [pii]
AID - 10.1016/j.ijid.2020.05.086 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2020 Jul;96:648-654. doi: 10.1016/j.ijid.2020.05.086. Epub 2020
      Jun 1.


PMID- 32497313
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20201116
IS  - 1365-3024 (Electronic)
IS  - 0141-9838 (Linking)
VI  - 42
IP  - 9
DP  - 2020 Sep
TI  - CRISPR/Cas9 gene drive technology to control transmission of vector-borne
      parasitic infections.
PG  - e12762
LID - 10.1111/pim.12762 [doi]
AB  - Gene drive is the process of copying of an endonuclease-containing cassette that 
      leads to increased frequency of inheritance of the desired traits in a targeted
      population. CRISPR/Cas9 technology is advancing genetic manipulation of insects
      in the field of gene drive experiments. The CRISPR/Cas9 drive could be engineered
      for genetic manipulation of parasites and/or vectors for disease control. A
      number of promising CRISPR/Cas9-based gene drive strategies that interfere with
      parasite development or impairs the reproductive capability of the insect vector 
      have been proposed in the laboratory for blocking transmission of malaria and
      leishmaniasis. Still several technical and ethical challenges remain to be
      addressed, and none appear insuperable in this field.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Nateghi Rostami, Mahmoud
AU  - Nateghi Rostami M
AUID- ORCID: 0000-0003-4317-7271
AD  - Laboratory of Biology of Host-Parasite Interactions, Department of Parasitology, 
      Pasteur Institute of Iran, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200712
PL  - England
TA  - Parasite Immunol
JT  - Parasite immunology
JID - 7910948
SB  - IM
MH  - Animals
MH  - *CRISPR-Cas Systems
MH  - *Gene Drive Technology
MH  - Humans
MH  - *Insect Vectors
MH  - Malaria/*prevention & control/transmission
OTO - NOTNLM
OT  - *CRISPR/Cas9
OT  - *Gene drive
OT  - *Leishmaniasis
OT  - *malaria
OT  - *vector-borne diseases
EDAT- 2020/06/05 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1111/pim.12762 [doi]
PST - ppublish
SO  - Parasite Immunol. 2020 Sep;42(9):e12762. doi: 10.1111/pim.12762. Epub 2020 Jul
      12.


PMID- 32497232
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1938-2421 (Electronic)
IS  - 0148-4834 (Linking)
VI  - 59
IP  - 6
DP  - 2020 Jun 1
TI  - From Cultural Competence to Cultural Respect: A Critical Review of Six Models.
PG  - 311-318
LID - 10.3928/01484834-20200520-03 [doi]
AB  - BACKGROUND: Despite the development of cultural competence models in response to 
      the increase in cultural diversity in the United States, health disparities based
      on ethnicity and cross-cultural mismatches in health care practices still exist. 
      METHOD: This article critically reviews six noteworthy conceptual models of
      cultural competence and enlists multilayered definitions of culture from cultural
      anthropology, critical multicultural education, and critical literary theory, as 
      well as critical discourse analytical tools to deconstruct these frameworks.
      RESULTS: Although these models assist providers to become more culturally
      sensitive, they can essentialize and oversimplify patients' cultural experience, 
      as well as mask the dynamism and complexities of their communities and power
      relations. CONCLUSION: Competence implies that practitioners can master diverse
      cultural experiences. Building on some of the promising practices of these six
      models and the practices of cultural humility and relational ethics, processes
      and practices are proposed for practitioners to reconstruct their ongoing
      cross-cultural work in nursing. [J Nurs Educ. 2020;59(6):311-318.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Botelho, Maria Jose
AU  - Botelho MJ
FAU - Lima, Christina A
AU  - Lima CA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Nurs Educ
JT  - The Journal of nursing education
JID - 7705432
SB  - IM
MH  - Cultural Competency/*education
MH  - *Cultural Diversity
MH  - Education, Nursing, Baccalaureate/*organization & administration
MH  - Education, Nursing, Graduate/organization & administration
MH  - Humans
MH  - Schools, Nursing/*organization & administration
MH  - Students, Nursing/statistics & numerical data
MH  - United States
EDAT- 2020/06/05 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/08/05 00:00 [received]
PHST- 2020/01/17 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 10.3928/01484834-20200520-03 [doi]
PST - ppublish
SO  - J Nurs Educ. 2020 Jun 1;59(6):311-318. doi: 10.3928/01484834-20200520-03.


PMID- 32497205
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 2332-4260 (Electronic)
IS  - 2332-4252 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Sep 15
TI  - Excision of a Retrochiasmatic Craniopharyngioma by Transcallosal, Interforniceal 
      Approach With Exoscope Assistance: 2-Dimensional Operative Video.
PG  - E411
LID - 10.1093/ons/opaa130 [doi]
AB  - Retrochiasmatic craniopharyngiomas are difficult to treat due to their close
      proximity to critical neurovascular structures. Several surgical approaches with 
      distinct advantages and limitations have been described to access these tumors,
      including extended transnasal endoscopic approach (ETEA), subtemporal,
      translamina terminalis, and transpetrosal approach.1-3 We present a 51-yr-old
      male with a large retrochiasmatic craniopharyngioma extending into the third
      ventricle, causing obstructive hydrocephalus. Preoperative magnetic resonance
      imaging (MRI) showed a tumor cyst abutting the fornices expanding the space
      between two internal cerebral veins (ICV). After surgical consent, we decided to 
      take advantage of this corridor to approach the tumor in its long axis. Surgical 
      goal was to achieve cyst decompression with "safe maximal" resection of the solid
      component at last to preserve the pituitary function. Though the long axis of the
      tumor could be approached using ETEA, we preferred this approach in view of cyst 
      decompression early in the surgery while completely avoiding risks such as
      cerebrospinal fluid (CSF) rhinorrhea, internal carotid artery (ICA) injury, and
      sinonasal complications. We utilized a 3-dimensional 4 K exoscope, which provides
      an excellent ergonomic position, and a high-resolution immersive view compared to
      a microscope or endoscope. Cyst decompression and near-total resection of the
      solid component was achieved. Postoperatively, his headaches improved and he was 
      neurologically intact with intact neuroendocrine function. Approach-related risks
      may include but not limited to hemorrhage due to the rupture of venous sinuses or
      ICV, stalk or hypothalamus injury, and memory disturbances due to forniceal
      injury. To conclude, the transcallosal, interforniceal approach to
      retrochiasmatic craniopharyngiomas may provide a safe surgical corridor in select
      cases. Patient consented to the proposed procedure. All radiological images have 
      been anonymized. IRB/ethics committee approval was not required.
CI  - Published by Oxford University Press on behalf of Congress of Neurological
      Surgeons 2020.
FAU - Khatri, Deepak
AU  - Khatri D
AD  - Department of Neurosurgery, Lenox Hill Hospital, New York, New York.
FAU - Wagner, Katherine
AU  - Wagner K
AD  - Department of Neurosurgery, Lenox Hill Hospital, New York, New York.
FAU - Ligas, Barbara
AU  - Ligas B
AD  - Department of Neurosurgery, Lenox Hill Hospital, New York, New York.
FAU - Higbie, Catherine
AU  - Higbie C
AD  - Department of Neurosurgery, Lenox Hill Hospital, New York, New York.
FAU - Langer, David
AU  - Langer D
AD  - Department of Neurosurgery, Lenox Hill Hospital, New York, New York.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
PL  - United States
TA  - Oper Neurosurg (Hagerstown)
JT  - Operative neurosurgery (Hagerstown, Md.)
JID - 101635417
SB  - IM
MH  - *Craniopharyngioma/diagnostic imaging/surgery
MH  - Endoscopy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pituitary Gland
MH  - *Pituitary Neoplasms/diagnostic imaging/surgery
MH  - *Third Ventricle
OTO - NOTNLM
OT  - Craniopharyngioma
OT  - Exoscope
OT  - Interhemispheric approach
OT  - Retroinfundibular
EDAT- 2020/06/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/09/09 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 5851463 [pii]
AID - 10.1093/ons/opaa130 [doi]
PST - ppublish
SO  - Oper Neurosurg (Hagerstown). 2020 Sep 15;19(4):E411. doi: 10.1093/ons/opaa130.


PMID- 32497016
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 17
TI  - Development and Evaluation of an HIV-Testing Intervention for Primary Care:
      Protocol for a Mixed Methods Study.
PG  - e16486
LID - 10.2196/16486 [doi]
AB  - BACKGROUND: Late diagnosis of HIV fosters HIV transmission and may lead to hidden
      HIV epidemics. In Belgium, mathematical modeling indicates a high prevalence of
      undiagnosed HIV infections among men who have sex with men of non-Belgian origin 
      and among sub-Saharan African migrants. Promotion of HIV testing facilitates
      early diagnosis, but diagnostic opportunities are missed in primary care.
      OBJECTIVE: The intervention study aims to enhance provider-initiated HIV testing 
      by GPs. This protocol presents the conceptual development, implementation, and
      evaluation of an HIV-testing intervention for Flemish general practitioners
      (GPs). METHODS: A mixed methods evaluation design is used. Guided by a simplified
      intervention mapping approach, an evidence-based intervention was developed in
      collaboration, guided by an interdisciplinary advisory board. The intervention
      consisted of an evidence-based tool (ie, "HIV-testing advice for primary care")
      to support GPs in provider-initiated HIV testing. A modified stepped-wedge design
      compare two different intervention levels: (1) online dissemination of the
      HIV-testing advice and (2) dissemination with additional group-level training.
      Both conditions were compared against a control condition with no intervention.
      The effect of the intervention was measured using Poisson regression for national
      surveillance data. The primary outcome was the number of HIV diagnoses made by
      GPs. Secondary outcomes were HIV diagnoses among groups at risk for undiagnosed
      HIV, distribution of new diagnoses by CD4 cell count, number of HIV tests
      prescribed by GPs, and rate of new diagnoses by tests. To evaluate the
      intervention's implementation, the GPs' fidelity to the intervention and the
      intervention's feasibility and acceptability by GPs were assessed through
      (web-based) surveys and in-depth telephone interviews. RESULTS: The study was
      funded in 2016 and ethically approved in January 2017. The implementation of the 
      intervention started in January 2017 and ended in December 2018. Data was
      completed in October 2019 and was the starting point for the ongoing data
      analysis. The results are expected to be published in the second half of 2020.
      CONCLUSIONS: Results of the intervention study will provide useful information on
      the intervention's effectiveness among Flemish GPs and can inform further
      development of official testing guidelines. Limitations of this real-life
      intervention approach are potential spill-over effects, delay in access to
      surveillance data, and little detailed information on HIV-testing practices among
      GPs. TRIAL REGISTRATION: ClinicalTrials.gov NCT04056156;
      https://clinicaltrials.gov/ct2/show/NCT04056156. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/16486.
CI  - (c)Hanne Apers, Bea Vuylsteke, Jasna Loos, Tom Smekens, Jessika Deblonde,
      Dominique Van Beckhoven, Christiana Nostlinger. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 17.08.2020.
FAU - Apers, Hanne
AU  - Apers H
AUID- ORCID: https://orcid.org/0000-0001-6371-2425
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
AD  - Centre for Migration and Intercultural Studies, University of Antwerp, Antwerp,
      Belgium.
FAU - Vuylsteke, Bea
AU  - Vuylsteke B
AUID- ORCID: https://orcid.org/0000-0003-0514-4372
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
FAU - Loos, Jasna
AU  - Loos J
AUID- ORCID: https://orcid.org/0000-0002-3081-5409
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
AD  - Domus Medica, Antwerp, Belgium.
AD  - Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
FAU - Smekens, Tom
AU  - Smekens T
AUID- ORCID: https://orcid.org/0000-0002-3599-1719
AD  - Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
FAU - Deblonde, Jessika
AU  - Deblonde J
AUID- ORCID: https://orcid.org/0000-0002-8989-0091
AD  - Epidemiology of Infectious Diseases Unit, Department of Public Health and
      Surveillance, Belgian Scientific Institute of Public Health (Sciensano),
      Brussels, Belgium.
FAU - Van Beckhoven, Dominique
AU  - Van Beckhoven D
AUID- ORCID: https://orcid.org/0000-0003-0821-2756
AD  - Epidemiology of Infectious Diseases Unit, Department of Public Health and
      Surveillance, Belgian Scientific Institute of Public Health (Sciensano),
      Brussels, Belgium.
FAU - Nostlinger, Christiana
AU  - Nostlinger C
AUID- ORCID: https://orcid.org/0000-0001-9031-8503
AD  - Epidemiology of Infectious Diseases Unit, Department of Public Health and
      Surveillance, Belgian Scientific Institute of Public Health (Sciensano),
      Brussels, Belgium.
LA  - eng
SI  - ClinicalTrials.gov/NCT04056156
PT  - Journal Article
DEP - 20200817
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7459432
OTO - NOTNLM
OT  - Belgium
OT  - HIV testing
OT  - general practitioners
OT  - intervention
OT  - primary care
OT  - public health
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
CRDT- 2020/06/05 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2019/12/10 00:00 [accepted]
PHST- 2019/12/09 00:00 [revised]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - v9i8e16486 [pii]
AID - 10.2196/16486 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 17;9(8):e16486. doi: 10.2196/16486.


PMID- 32496949
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2167-776X (Electronic)
IS  - 1542-3050 (Linking)
VI  - 74
IP  - 2
DP  - 2020 Jun
TI  - Improving Long-Term Care through Abuse Prevention and Ethics Training.
PG  - 147-149
LID - 10.1177/1542305020925412 [doi]
AB  - This article presents a solution for a critical issue, that is, elder abuse, and 
      is focused on prevention through education and training for staff. Pastoral care 
      and mental health professionals can benefit by using this film and curriculum for
      professional development when providing counseling, or when caring for elder
      clients on a long-term basis.
FAU - Menio, Diane A
AU  - Menio DA
AUID- ORCID: https://orcid.org/0000-0002-5649-4164
AD  - Center for Advocacy for the Rights and Interests of the Elderly, Philadelphia,
      USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pastoral Care Counsel
JT  - The journal of pastoral care & counseling : JPCC
JID - 101144384
OTO - NOTNLM
OT  - Elder abuse
OT  - dementia
OT  - ethics
OT  - life story
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
AID - 10.1177/1542305020925412 [doi]
PST - ppublish
SO  - J Pastoral Care Counsel. 2020 Jun;74(2):147-149. doi: 10.1177/1542305020925412.


PMID- 32496918
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210924
IS  - 1524-4571 (Electronic)
IS  - 0009-7330 (Linking)
VI  - 126
IP  - 12
DP  - 2020 Jun 5
TI  - Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations.
PG  - 1816-1840
LID - 10.1161/CIRCRESAHA.120.315893 [doi]
AB  - Genome-wide association studies have revolutionized our understanding of the
      genetic underpinnings of cardiometabolic disease. Yet, the inadequate
      representation of individuals of diverse ancestral backgrounds in these studies
      may undercut their ultimate potential for both public health and precision
      medicine. The goal of this review is to describe the imperativeness of studying
      the populations who are most affected by cardiometabolic disease, to the aim of
      better understanding the genetic underpinnings of the disease. We support this
      premise by describing the current variation in the global burden of
      cardiometabolic disease and emphasize the importance of building a globally and
      ancestrally representative genetics evidence base for the identification of
      population-specific variants, fine-mapping, and polygenic risk score estimation. 
      We discuss the important ethical, legal, and social implications of increasing
      ancestral diversity in genetic studies of cardiometabolic disease and the
      challenges that arise from the (1) lack of diversity in current reference
      populations and available analytic samples and the (2) unequal generation of
      health-associated genomic data and their prediction accuracies. Despite these
      challenges, we conclude that additional, unprecedented opportunities lie ahead
      for public health genomics and the realization of precision medicine, provided
      that the gap in diversity can be systematically addressed. Achieving this goal
      will require concerted efforts by social, academic, professional and regulatory
      stakeholders and communities, and these efforts must be based on principles of
      equity and social justice.
FAU - Fernandez-Rhodes, Lindsay
AU  - Fernandez-Rhodes L
AD  - From the Department of Biobehavioral Health, College of Health and Human
      Development, Pennsylvania State University, University Park (L.F.-R.).
FAU - Young, Kristin L
AU  - Young KL
AD  - Department of Epidemiology, Gillings School of Global Public Health (K.L.Y,
      H.M.H., C.A., S.-A.M.L., M.G., K.D., K.E.N.), University of North Carolina at
      Chapel Hill.
FAU - Lilly, Adam G
AU  - Lilly AG
AD  - Department of Sociology (A.G.L.), University of North Carolina at Chapel Hill.
AD  - Carolina Population Center (A.G.L.), University of North Carolina at Chapel Hill.
FAU - Raffield, Laura M
AU  - Raffield LM
AD  - Department of Genetics (L.M.R.), University of North Carolina at Chapel Hill.
FAU - Highland, Heather M
AU  - Highland HM
AD  - Department of Epidemiology, Gillings School of Global Public Health (K.L.Y,
      H.M.H., C.A., S.-A.M.L., M.G., K.D., K.E.N.), University of North Carolina at
      Chapel Hill.
FAU - Wojcik, Genevieve L
AU  - Wojcik GL
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD (G.L.W.).
FAU - Agler, Cary
AU  - Agler C
AD  - Department of Epidemiology, Gillings School of Global Public Health (K.L.Y,
      H.M.H., C.A., S.-A.M.L., M.G., K.D., K.E.N.), University of North Carolina at
      Chapel Hill.
AD  - Department of Pediatric and Public Health, Adams School of Dentistry (C.A.,
      K.D.), University of North Carolina at Chapel Hill.
FAU - Love, Shelly-Ann M
AU  - Love SM
AD  - Department of Epidemiology, Gillings School of Global Public Health (K.L.Y,
      H.M.H., C.A., S.-A.M.L., M.G., K.D., K.E.N.), University of North Carolina at
      Chapel Hill.
FAU - Okello, Samson
AU  - Okello S
AD  - Department of Internal Medicine, Mbarara University of Science and Technology,
      Uganda (S.O.).
AD  - University of Virginia, Charlottesville (S.O.).
AD  - Harvard TH Chan School of Public Health, Boston, MA (S.O.).
FAU - Petty, Lauren E
AU  - Petty LE
AD  - Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville,
      TN (L.E.P., J.E.B.).
AD  - Department of Genetic Medicine, Vanderbilt University, Nashville, TN (L.E.P.,
      J.E.B.).
FAU - Graff, Mariaelisa
AU  - Graff M
AD  - Department of Epidemiology, Gillings School of Global Public Health (K.L.Y,
      H.M.H., C.A., S.-A.M.L., M.G., K.D., K.E.N.), University of North Carolina at
      Chapel Hill.
FAU - Below, Jennifer E
AU  - Below JE
AD  - Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville,
      TN (L.E.P., J.E.B.).
AD  - Department of Genetic Medicine, Vanderbilt University, Nashville, TN (L.E.P.,
      J.E.B.).
FAU - Divaris, Kimon
AU  - Divaris K
AD  - Department of Pediatric and Public Health, Adams School of Dentistry (C.A.,
      K.D.), University of North Carolina at Chapel Hill.
FAU - North, Kari E
AU  - North KE
AD  - Department of Epidemiology, Gillings School of Global Public Health (K.L.Y,
      H.M.H., C.A., S.-A.M.L., M.G., K.D., K.E.N.), University of North Carolina at
      Chapel Hill.
AD  - Carolina Center for Genome Sciences, Chapel Hill, NC (K.E.N.).
LA  - eng
GR  - P30 ES010126/ES/NIEHS NIH HHS/United States
GR  - T32 HL129982/HL/NHLBI NIH HHS/United States
GR  - R01 HL142825/HL/NHLBI NIH HHS/United States
GR  - U01 DE025046/DE/NIDCR NIH HHS/United States
GR  - R21 HL140419/HL/NHLBI NIH HHS/United States
GR  - R01 HL149683/HL/NHLBI NIH HHS/United States
GR  - R01 HL142302/HL/NHLBI NIH HHS/United States
GR  - L30 HG009840/HG/NHGRI NIH HHS/United States
GR  - T32 HD091058/HD/NICHD NIH HHS/United States
GR  - R01 HD057194/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200604
PL  - United States
TA  - Circ Res
JT  - Circulation research
JID - 0047103
SB  - IM
MH  - Gene Frequency
MH  - Genome-Wide Association Study/*methods/standards
MH  - Humans
MH  - Metabolic Syndrome/epidemiology/*genetics
MH  - Polymorphism, Genetic
PMC - PMC7285892
MID - NIHMS1583666
OTO - NOTNLM
OT  - *cardiovascular diseases
OT  - *genomics
OT  - *global burden of disease
OT  - *metabolic diseases
OT  - *minority health
OT  - *precision medicine
OT  - *social justice
EDAT- 2020/06/05 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
AID - 10.1161/CIRCRESAHA.120.315893 [doi]
PST - ppublish
SO  - Circ Res. 2020 Jun 5;126(12):1816-1840. doi: 10.1161/CIRCRESAHA.120.315893. Epub 
      2020 Jun 4.


PMID- 32496864
OWN - NLM
STAT- MEDLINE
DCOM- 20200820
LR  - 20210113
IS  - 1544-5208 (Electronic)
IS  - 0278-2715 (Linking)
VI  - 39
IP  - 8
DP  - 2020 Aug
TI  - Incarceration And Its Disseminations: COVID-19 Pandemic Lessons From Chicago's
      Cook County Jail.
PG  - 1412-1418
LID - 10.1377/hlthaff.2020.00652 [doi]
AB  - Jails and prisons are major sites of novel coronavirus (SARS-CoV-2) infection.
      Many jurisdictions in the United States have therefore accelerated the release of
      low-risk offenders. Early release, however, does not address how arrest and
      pretrial detention practices may be contributing to disease spread. Using data
      from Cook County Jail-one of the largest known nodes of SARS-CoV-2 spread in the 
      United States-in Chicago, Illinois, we analyzed the relationship between jailing 
      practices and community infections at the ZIP code level. We found that
      jail-community cycling was a significant predictor of cases of coronavirus
      disease 2019 (COVID-19), accounting for 55 percent of the variance in case rates 
      across ZIP codes in Chicago and 37 percent of the variance in all of Illinois.
      Jail-community cycling far exceeds race, poverty, public transit use, and
      population density as a predictor of variance. The data suggest that cycling
      people through Cook County Jail alone is associated with 15.7 percent of all
      documented COVID-19 cases in Illinois and 15.9 percent of all documented cases in
      Chicago as of April 19, 2020. Our findings support arguments for reduced reliance
      on incarceration and for related justice reforms both as emergency measures
      during the present pandemic and as sustained structural changes vital for future 
      pandemic preparedness and public health.
FAU - Reinhart, Eric
AU  - Reinhart E
AD  - Eric Reinhart (reinhar@fas.harvard.edu) is a PhD candidate in the Department of
      Anthropology, Harvard University, in Cambridge, Massachusetts, and an MD
      candidate at the University of Chicago Pritzker School of Medicine, in Chicago,
      Illinois. He is also a candidate in adult psychoanalysis at the Chicago Center
      for Psychoanalysis.
FAU - Chen, Daniel L
AU  - Chen DL
AD  - Daniel L. Chen is a director of research at the Centre National de la Recherche
      Scientifique (CNRS), in Paris, France; a professor at the Toulouse School of
      Economics and Universite de Toulouse Faculty of Law, in Toulouse, France; and
      lead principal investigator of the DE JURE (Data and Evidence for Justice Reform)
      Program at the World Bank in Washington, D.C.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200604
PL  - United States
TA  - Health Aff (Millwood)
JT  - Health affairs (Project Hope)
JID - 8303128
SB  - IM
CIN - Health Aff (Millwood). 2021 Jan;40(1):177. PMID: 33400568
MH  - COVID-19
MH  - Chicago
MH  - Communicable Disease Control/*organization & administration
MH  - Coronavirus Infections/*epidemiology
MH  - Female
MH  - Humans
MH  - Illinois
MH  - Infectious Disease Transmission, Vertical/prevention & control/*statistics &
      numerical data
MH  - Male
MH  - Pandemics/statistics & numerical data
MH  - Pneumonia, Viral/*epidemiology
MH  - Prisoners/*statistics & numerical data
MH  - Prisons/*organization & administration
MH  - *Public Health
MH  - Vulnerable Populations
OTO - NOTNLM
OT  - *Access and use
OT  - *Bundled charges
OT  - *Coronavirus
OT  - *Covid-19
OT  - *Diseases
OT  - *Ethics
OT  - *Health policy
OT  - *Jail-involved population
OT  - *Pandemics
OT  - *Public health
OT  - *Social determinants of health
OT  - *Socioeconomic determinants of health
OT  - *health disparities
OT  - *prison health care
EDAT- 2020/06/05 06:00
MHDA- 2020/08/21 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/08/21 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1377/hlthaff.2020.00652 [doi]
PST - ppublish
SO  - Health Aff (Millwood). 2020 Aug;39(8):1412-1418. doi: 10.1377/hlthaff.2020.00652.
      Epub 2020 Jun 4.


PMID- 32496861
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1440-1665 (Electronic)
IS  - 1039-8562 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Oct
TI  - The struggle for gender diversity.
PG  - 539-541
LID - 10.1177/1039856220930676 [doi]
AB  - INTRODUCTION: Contradictory social policies and attitudes about gender diversity 
      raise questions about how we should understand the current status of the
      historical 'heterosexual' gender regime. CONCLUSION: Drawing on the work of the
      feminist philosopher and psychoanalyst Luce Irigaray, this essay argues that
      sexual difference is the irreducible starting point for all meaning, sense,
      morality and affect.
FAU - Gardner, Sally M
AU  - Gardner SM
AD  - Deakin University, Australia.
AD  - Monash University, Australia.
FAU - Komesaroff, Paul A
AU  - Komesaroff PA
AUID- ORCID: 0000-0002-1360-3375
AD  - Monash University, Australia.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200604
PL  - England
TA  - Australas Psychiatry
JT  - Australasian psychiatry : bulletin of Royal Australian and New Zealand College of
      Psychiatrists
JID - 9613603
SB  - IM
MH  - Feminism
MH  - History, 20th Century
MH  - Humans
MH  - *Psychoanalytic Theory
MH  - *Sexuality
MH  - *Women's Rights
OTO - NOTNLM
OT  - *Irigaray
OT  - *ethics
OT  - *gender diversity
OT  - *sexuality
EDAT- 2020/06/05 06:00
MHDA- 2021/07/10 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1177/1039856220930676 [doi]
PST - ppublish
SO  - Australas Psychiatry. 2020 Oct;28(5):539-541. doi: 10.1177/1039856220930676. Epub
      2020 Jun 4.


PMID- 32496745
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210201
IS  - 1535-1386 (Electronic)
IS  - 0021-9355 (Linking)
VI  - 102
IP  - 11
DP  - 2020 Jun 3
TI  - The Corporate Practice of Medicine: Ethical Implications of Orthopaedic Surgery
      Practice Ownership by Non-Physicians.
PG  - e53
LID - 10.2106/JBJS.19.01404 [doi]
AB  - There has been an upsurge in the number of practices owned by non-physicians.
      With orthopaedic surgery as the next frontier in this market, orthopaedists need 
      to consider the ethical consequences of such acquisitions. The history and trends
      of practice ownership are reviewed alongside how laws shifted to reflect a
      changing health-care climate. The 4 tenets of bioethics (beneficence,
      nonmaleficence, autonomy, and justice) are explored with regard to practice
      acquisition by non-physician entities. Although non-physician-owned corporations 
      and private equity firms provide liquidity to the health-care sector, there are
      ethical concerns that may ultimately impact patient care. Orthopaedic surgeons
      must be cautious when engaging in acquisitions with non-physician-owned entities,
      as the goals of each party may not align. This may yield situations that infringe
      on the basic principles of bioethics for both physician and patient.
FAU - Moses, Michael J
AU  - Moses MJ
AUID- ORCID: 0000-0002-8990-7391
AD  - Department of Orthopedic Surgery, New York University Langone Orthopedic
      Hospital, New York, NY.
FAU - Weiser, Lori G
AU  - Weiser LG
AUID- ORCID: 0000-0003-3038-2786
FAU - Bosco, Joseph A 3rd
AU  - Bosco JA 3rd
AUID- ORCID: 0000-0002-4371-4105
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
SB  - IM
MH  - Humans
MH  - Orthopedics/*ethics
MH  - Ownership/*ethics
MH  - Practice Management, Medical/*ethics
MH  - Professional Corporations/*ethics
EDAT- 2020/06/05 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.2106/JBJS.19.01404 [doi]
AID - 00004623-202006030-00017 [pii]
PST - ppublish
SO  - J Bone Joint Surg Am. 2020 Jun 3;102(11):e53. doi: 10.2106/JBJS.19.01404.


PMID- 32496653
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1099-1050 (Electronic)
IS  - 1057-9230 (Linking)
VI  - 29 Suppl 1
DP  - 2020 Oct
TI  - The strange case of less C-sections: Hospital ownership, market concentration,
      and DRG-tariff regulation.
PG  - 30-46
LID - 10.1002/hec.4110 [doi]
AB  - We evaluate the relationship between hospital ownership and responses to a policy
      providing large financial incentives for vaginal deliveries and financial
      disincentives for C-sections. We compare for-profit, nonprofit, and public
      hospitals operating in a public health care system organized according to the
      quasi-market model. We first theoretically show that hospital ownership matters
      insofar different hospitals are characterized by different ethical preferences.
      We also show that competition makes ownership less important. We then consider
      the case study of Lombardy in Italy. We exploit spatial variation in hospital
      ownership and in market concentration at the local level to evaluate the
      relationship between ownership and the probability of C-section. According to
      theory, empirical results strongly suggest that competitive pressures from
      alternative providers tend to homogenize behaviors. However, in local monopolies,
      in presence of a strong monetary incentive toward vaginal deliveries, we do
      observe less C-section from private for-profit hospitals than from public and
      private nonprofit hospitals, especially when C-sections are medically
      appropriate.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Berta, Paolo
AU  - Berta P
AUID- ORCID: 0000-0003-0984-4288
AD  - Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 
      Milan, Italy.
FAU - Martini, Gianmaria
AU  - Martini G
AUID- ORCID: 0000-0001-9503-4999
AD  - Department of Management Engineering, University of Bergamo, Bergamo, Italy.
FAU - Piacenza, Massimiliano
AU  - Piacenza M
AUID- ORCID: 0000-0003-2437-8254
AD  - Department of Economics and Business (DISEI), University of Piemonte Orientale,
      Novara, Italy.
FAU - Turati, Gilberto
AU  - Turati G
AUID- ORCID: 0000-0002-2146-7887
AD  - Department of Economics and Finance, Universita Cattolica del Sacro Cuore, Rome, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - England
TA  - Health Econ
JT  - Health economics
JID - 9306780
SB  - IM
MH  - Delivery of Health Care
MH  - Female
MH  - Hospitals, Private
MH  - *Hospitals, Proprietary
MH  - Hospitals, Public
MH  - Humans
MH  - *Ownership
MH  - United States
OTO - NOTNLM
OT  - *C-sections
OT  - *and nonprofit hospitals
OT  - *for-profit
OT  - *market for birth deliveries
OT  - *public
OT  - *tariff regulation
EDAT- 2020/06/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/02/22 00:00 [revised]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1002/hec.4110 [doi]
PST - ppublish
SO  - Health Econ. 2020 Oct;29 Suppl 1:30-46. doi: 10.1002/hec.4110. Epub 2020 Jun 4.


PMID- 32496536
OWN - NLM
STAT- MEDLINE
DCOM- 20200709
LR  - 20210210
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 3
DP  - 2020 Jul 6
TI  - Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too
      Risky, Too Soon.
PG  - 514-516
LID - 10.1093/infdis/jiaa314 [doi]
FAU - Dawson, Liza
AU  - Dawson L
AD  - Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
FAU - Earl, Jake
AU  - Earl J
AD  - Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
FAU - Livezey, Jeffrey
AU  - Livezey J
AD  - Department of Pediatrics, Uniformed Services University of the Health Sciences.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CON - J Infect Dis. 2020 May 11;221(11):1752-1756. PMID: 32232474
CIN - J Infect Dis. 2020 Jul 6;222(3):516-517. PMID: 32495823
MH  - *Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Viral Vaccines
PMC - PMC7313940
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *coronavirus
OT  - *ethics
OT  - *human challenge studies
OT  - *public trust
OT  - *risk-taking
OT  - *vaccines
EDAT- 2020/06/05 06:00
MHDA- 2020/07/10 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/07/10 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 5851328 [pii]
AID - 10.1093/infdis/jiaa314 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Jul 6;222(3):514-516. doi: 10.1093/infdis/jiaa314.


PMID- 32496267
OWN - NLM
STAT- MEDLINE
DCOM- 20200611
LR  - 20201218
IS  - 0019-557X (Print)
IS  - 0019-557X (Linking)
VI  - 64
IP  - Supplement
DP  - 2020 Jun
TI  - Telepsychiatry during COVID-19: Some clinical, public health, and ethical
      dilemmas.
PG  - S245-S246
LID - 10.4103/ijph.IJPH_511_20 [doi]
FAU - Sousa, Avinash De
AU  - Sousa A
AD  - Research Associate and Consultant Psychiatrist, Lokmanya Tilak Municipal Medical 
      College and General Hospital, Mumbai, Maharashtra, India.
FAU - Karia, Sagar
AU  - Karia S
AD  - Assistant Professor, Department of Psychiatry, Lokmanya Tilak Municipal Medical
      College and General Hospital, Mumbai, Maharashtra, India.
LA  - eng
PT  - Letter
PL  - India
TA  - Indian J Public Health
JT  - Indian journal of public health
JID - 0400673
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*psychology
MH  - Humans
MH  - India
MH  - Mental Disorders/*therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - Public Health
MH  - SARS-CoV-2
MH  - Telemedicine/*organization & administration
COIS- None
EDAT- 2020/06/05 06:00
MHDA- 2020/06/12 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
AID - IndianJPublicHealth_2020_64_6_245_285627 [pii]
AID - 10.4103/ijph.IJPH_511_20 [doi]
PST - ppublish
SO  - Indian J Public Health. 2020 Jun;64(Supplement):S245-S246. doi:
      10.4103/ijph.IJPH_511_20.


PMID- 32496252
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20220414
IS  - 0019-557X (Print)
IS  - 0019-557X (Linking)
VI  - 64
IP  - Supplement
DP  - 2020 Jun
TI  - An epidemiological study of laboratory confirmed COVID-19 cases admitted in a
      tertiary care hospital of Pune, Maharashtra.
PG  - S183-S187
LID - 10.4103/ijph.IJPH_522_20 [doi]
AB  - BACKGROUND: India has reported more than 70,000 cases and 2000 deaths. Pune is
      the second city in the Maharashtra state after Mumbai to breach the 1000 cases.
      Total deaths reported from Pune were 158 with a mortality of 5.7%. To plan health
      services, it is important to learn lessons from early stage of the outbreak on
      course of the disease in a hospital setting. OBJECTIVES: To describe the
      epidemiological characteristics of the outbreak of COVID-19 in India from a
      tertiary care hospital. METHODS: This was a hospital-based cross-sectional study 
      which included all admitted laboratory confirmed COVID19 cases from March 31, to 
      April 24, 2020. The information was collected in a predesigned pro forma which
      included sociodemographic data, duration of stay, family background, outcome,
      etc., by trained staff after ethics approval. Epi Info7 was used for data
      analysis. RESULTS: Out of the total 197 cases, majority cases were between the
      ages of 31-60 years with slight male preponderance. Majority of these cases were 
      from the slums. Breathlessness was the main presenting symptom followed by fever 
      and cough. More than 1/5(th) of patients were asymptomatic from exposure to
      admission. The case fatality rate among the admitted cases was 29.4%. Comorbidity
      was one of the significant risk factors for the progression of disease and death 
      (odds ratio [OR] = 16.8, 95% confidence interval [CI] = 7.0 - 40.1, P < 0.0001). 
      CONCLUSION: Mortality was higher than the national average of 3.2%; comorbidity
      was associated with bad prognosis.
FAU - Tambe, Muralidhar Parashuram
AU  - Tambe MP
AD  - Dean and Professor and Head, B.J. Govt. Medical College, Pune, Maharashtra,
      India.
FAU - Parande, Malangori A
AU  - Parande MA
AD  - Associate Professor, B.J. Govt. Medical College, Pune, Maharashtra, India.
FAU - Tapare, Vinay S
AU  - Tapare VS
AD  - Associate Professor, B.J. Govt. Medical College, Pune, Maharashtra, India.
FAU - Borle, Pradip S
AU  - Borle PS
AD  - Statistician-cum-Assistant Professor, Department of Community Medicine, B.J.
      Govt. Medical College, Pune, Maharashtra, India.
FAU - Lakde, Rajesh N
AU  - Lakde RN
AD  - Associate Professor, B.J. Govt. Medical College, Pune, Maharashtra, India.
FAU - Shelke, Sangita C
AU  - Shelke SC
AD  - Associate Professor, B.J. Govt. Medical College, Pune, Maharashtra, India.
CN  - BJMC COVID Epidemiology group
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Public Health
JT  - Indian journal of public health
JID - 0400673
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - Coronavirus Infections/*epidemiology/mortality/physiopathology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - India/epidemiology
MH  - Length of Stay
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/mortality/physiopathology
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Socioeconomic Factors
MH  - Spatial Analysis
MH  - Tertiary Care Centers/*statistics & numerical data
MH  - Young Adult
OTO - NOTNLM
OT  - COVID-19
OT  - epidemiology
OT  - tertiary care hospital
COIS- None
EDAT- 2020/06/05 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - IndianJPublicHealth_2020_64_6_183_285630 [pii]
AID - 10.4103/ijph.IJPH_522_20 [doi]
PST - ppublish
SO  - Indian J Public Health. 2020 Jun;64(Supplement):S183-S187. doi:
      10.4103/ijph.IJPH_522_20.


PMID- 32496202
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2291-5222 (Electronic)
IS  - 2291-5222 (Linking)
VI  - 8
IP  - 6
DP  - 2020 Jun 4
TI  - Factors Influencing Acceptance of Personal Health Record Apps for Workplace
      Health Promotion: Cross-Sectional Questionnaire Study.
PG  - e16723
LID - 10.2196/16723 [doi]
AB  - BACKGROUND: Health care technologies can help improve workers' health and
      productivity by supporting workplace health promotion. A personal health record
      app is used to manage medical data such as results from medical checkups, which
      facilitates decision making for medical personnel. However, an analysis of users'
      technology acceptance is required to provide appropriate services based on
      personal health record apps. OBJECTIVE: The purpose of this study was to analyze 
      the factors influencing the behavioral intention of health experts and workers to
      use an app in workers' health centers and to examine differences in their
      perception of the main variables. METHODS: The study involved health experts and 
      workers who visited 21 workers' health centers in Korea to verify a research
      model in which perceived risk was added to the unified theory of acceptance and
      use of technology, a representative theory of information technology acceptance. 
      After receiving ethical approval from the Korea National Institute for Bioethics 
      Policy, 1050 questionnaires were distributed over 7 weeks with cooperation of the
      Korea Occupational Safety and Health Agency. A multiple linear regression
      analysis and multigroup path analysis were performed to verify the hypotheses,
      and independent samples t tests were performed to analyze differences between
      workers' and health experts' perception of the main variables. RESULTS: The
      analysis included data from 866 respondents (687 workers and 179 health experts).
      Effort expectancy (beta=.08, P=.03), social influence (beta=.43, P<.001),
      performance expectancy (beta=.07, P=.008), and facilitating conditions (beta=.13,
      P<.001) exerted significant positive effects on behavioral intention, whereas
      perceived risk (beta=-.29, P<.001) exerted a significant negative effect on
      behavioral intention. Performance expectancy had a significant effect on path
      differences depending on gender (critical ratio=-3.38) and age (critical
      ratio=1.97). Workers' mean scores for the main variables were higher relative to 
      those of health experts for all remaining variables except perceived risk, and
      significant differences were observed for all remaining variables except
      facilitating condition. CONCLUSIONS: Social influence exerted the strongest
      effect on behavioral intention to use the personal health record app.
      Consequently, it is necessary to coordinate health promotion activities in the
      workplace as well as the operational direction of community institutions such as 
      in workers' health centers to allow workers to manage their own health via
      continuous use of the app. In addition, the app should be developed based on a
      requirement analysis of the balance between both interest groups in consideration
      of differences in perspective between consumers and service providers.
CI  - (c)Hyun Sang Park, Kwang Il Kim, Jae Young Soh, Young Ho Hyun, Sae Kyun Jang, Sol
      Lee, Ga Young Hwang, Hwa Sun Kim. Originally published in JMIR mHealth and
      uHealth (http://mhealth.jmir.org), 04.06.2020.
FAU - Park, Hyun Sang
AU  - Park HS
AUID- ORCID: 0000-0002-0949-1120
AD  - Digital Healthcare Department, BIT Computer Co Ltd, Seoul, Republic of Korea.
AD  - Department of Medical Informatics, Kyungpook National University, Daegu, Republic
      of Korea.
FAU - Kim, Kwang Il
AU  - Kim KI
AUID- ORCID: 0000-0002-4746-3008
AD  - Finance Programs Department, Korea Occupational Safety & Health Agency, Ulsan,
      Republic of Korea.
FAU - Soh, Jae Young
AU  - Soh JY
AUID- ORCID: 0000-0001-7454-8288
AD  - Digital Healthcare Department, BIT Computer Co Ltd, Seoul, Republic of Korea.
FAU - Hyun, Young Ho
AU  - Hyun YH
AUID- ORCID: 0000-0002-0520-9474
AD  - Digital Healthcare Department, BIT Computer Co Ltd, Seoul, Republic of Korea.
FAU - Jang, Sae Kyun
AU  - Jang SK
AUID- ORCID: 0000-0002-0860-8761
AD  - Research Institute, HealthConnect Co Ltd, Seoul, Republic of Korea.
FAU - Lee, Sol
AU  - Lee S
AUID- ORCID: 0000-0002-2011-8335
AD  - Research Institute, HealthConnect Co Ltd, Seoul, Republic of Korea.
FAU - Hwang, Ga Young
AU  - Hwang GY
AUID- ORCID: 0000-0002-5405-2856
AD  - Research Institute, HealthConnect Co Ltd, Seoul, Republic of Korea.
FAU - Kim, Hwa Sun
AU  - Kim HS
AUID- ORCID: 0000-0003-3657-4551
AD  - Elecmarvels Co Ltd, Daegu, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - Canada
TA  - JMIR Mhealth Uhealth
JT  - JMIR mHealth and uHealth
JID - 101624439
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Health Promotion
MH  - *Health Records, Personal
MH  - Humans
MH  - Male
MH  - Republic of Korea
MH  - Surveys and Questionnaires
MH  - *Workplace
PMC - PMC7303838
OTO - NOTNLM
OT  - *perceived risk
OT  - *personal health record app
OT  - *unified theory of acceptance and use of technology
OT  - *workplace health promotion
EDAT- 2020/06/05 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
AID - v8i6e16723 [pii]
AID - 10.2196/16723 [doi]
PST - epublish
SO  - JMIR Mhealth Uhealth. 2020 Jun 4;8(6):e16723. doi: 10.2196/16723.


PMID- 32495742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 4
TI  - Simulation-Based Education for Staff Managing Aggression and Externalizing
      Behaviors in Children With Autism Spectrum Disorder in the Hospital Setting:
      Pilot and Feasibility Study Protocol for a Cluster Randomized Controlled Trial.
PG  - e18105
LID - 10.2196/18105 [doi]
AB  - BACKGROUND: Children with autism spectrum disorder (ASD) frequently demonstrate
      aggression and externalizing behaviors in the acute care hospital environment.
      Pediatric acute care nursing staff are often not trained in managing aggression
      and, in particular, lack confidence in preventing and managing externalizing
      behaviors in children with ASD. High-fidelity simulation exercises will be used
      in this study to provide deliberate practice for acute care pediatric nursing
      staff in the management of aggressive and externalizing behaviors. OBJECTIVE: The
      purpose of this study is to conduct a pilot and feasibility cluster randomized
      controlled trial (RCT) to evaluate the effectiveness of simulation-based
      education for staff in managing aggression and externalizing behaviors of
      children with ASD in the hospital setting. METHODS: This study has a mixed
      design, with between-group and within-participant comparisons to explore the
      acceptability and feasibility of delivering a large-scale cluster RCT. The trial 
      process, including recruitment, completion rates, contamination, and completion
      of outcome measures, will be assessed and reported as percentages. This study
      will assess the acceptability of the simulation-based training format for two
      scenarios involving an adolescent with autism, with or without intellectual
      disability, who displays aggressive and externalizing behaviors and the resulting
      change in confidence in managing clinical aggression. Two pediatric wards of
      similar size and patient complexity will be selected to participate in the study;
      they will be randomized to receive either simulation-based education plus
      web-based educational materials or the web-based educational materials only.
      Change in confidence will be assessed using pre- and posttraining surveys for
      bedside nursing staff exposed to the training and the control group who will
      receive the web-based training materials. Knowledge retention 3 months
      posttraining, as well as continued confidence and exposure to clinical
      aggression, will be assessed via surveys. Changes in confidence and competence
      will be compared statistically with the chi-square test using before-and-after
      data to compare the proportion of those who have high confidence between the two 
      arms at baseline and at follow-up. The simulation-based education will be
      recorded with trained assessors reviewing participants' abilities to de-escalate 
      aggressive behaviors using a validated tool. This data will be analyzed using
      mean values and SDs to understand the variation in performance of individuals who
      undertake the training. Data from each participating ward will be collected
      during each shift for the duration of the study to assess the number of
      aggressive incidents and successful de-escalation for patients with ASD. Total
      change in Code Grey activations will also be assessed, with both datasets
      analyzed using descriptive statistics. RESULTS: This study gained ethical
      approval from The Royal Children's Hospital Melbourne Human Research Ethics
      Committee (HREC) on November 1, 2019 (HREC reference number: 56684). Data
      collection was completed in February 2020. Data analysis is due to commence with 
      results anticipated by August 2020. CONCLUSIONS: We hypothesize that this study
      is feasible to be conducted as a cluster RCT and that simulation-based training
      will be acceptable for acute care pediatric nurses. We anticipate that the
      intervention ward will have increased confidence in managing clinical aggression 
      in children with ASD immediately and up to 3 months posttraining. TRIAL
      REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR)
      ACTRN12620000139976; http://www.ANZCTR.org.au/ACTRN12620000139976.aspx.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18105.
CI  - (c)Marijke Jane Mitchell, Fiona Helen Newall, Jennifer Sokol, Katrina Jane
      Williams. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 04.06.2020.
FAU - Mitchell, Marijke Jane
AU  - Mitchell MJ
AUID- ORCID: https://orcid.org/0000-0002-1863-8016
AD  - Department of Neurodevelopment and Disability, Royal Children's Hospital,
      Melbourne, Australia.
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
AD  - Murdoch Children's Research Institute, Melbourne, Australia.
FAU - Newall, Fiona Helen
AU  - Newall FH
AUID- ORCID: https://orcid.org/0000-0003-2072-6450
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
AD  - Murdoch Children's Research Institute, Melbourne, Australia.
AD  - Department of Nursing Research, Royal Children's Hospital, Melbourne, Australia.
AD  - Department of Nursing Education, Royal Children's Hospital, Melbourne, Australia.
AD  - Department of Nursing, The University of Melbourne, Melbourne, Australia.
FAU - Sokol, Jennifer
AU  - Sokol J
AUID- ORCID: https://orcid.org/0000-0002-0455-2799
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
AD  - Simulation Program, Department of Medical Education, Royal Children's Hospital,
      Melbourne, Australia.
FAU - Williams, Katrina Jane
AU  - Williams KJ
AUID- ORCID: https://orcid.org/0000-0002-1686-4458
AD  - Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
AD  - Murdoch Children's Research Institute, Melbourne, Australia.
AD  - Department of Paediatrics, Education and Research, Monash University, Melbourne, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7303837
OTO - NOTNLM
OT  - adolescent
OT  - aggression
OT  - autism spectrum disorder
OT  - child
OT  - feasibility studies
OT  - high-fidelity simulation training
OT  - intellectual disability
OT  - pediatric nursing
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
CRDT- 2020/06/05 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
AID - v9i6e18105 [pii]
AID - 10.2196/18105 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 4;9(6):e18105. doi: 10.2196/18105.


PMID- 32495718
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Health and social care educators' ethical competence.
PG  - 1115-1126
LID - 10.1177/0969733019871678 [doi]
AB  - BACKGROUND AND PURPOSE: Educators' ethical competence is of crucial importance
      for developing students' ethical thinking. Previous studies describe educators'
      ethical codes and principles. This article aims to widen the understanding of
      health- and social care educators' ethical competence in relation to core values 
      and ethos. THEORETICAL BACKGROUND AND KEY CONCEPTS: The study is based on the
      didactics of caring science and theoretically links the concepts ethos and
      competence. METHODS: Data material was collected from nine educational units for 
      healthcare and social service in Finland. In total 16 semi-structured focus group
      interviews with 48 participants were conducted. The interviews were analysed with
      a thematic analysis according to Braun and Clarke. ETHICAL CONSIDERATIONS: The
      study is approved by the Declaration of Helsinki, the legislation regarding
      personal data and the General Data Protection Regulation. The study received
      ethical permission from the University of Jyvaskyla. Informed consent was
      obtained from all the educational units and participants in the study. FINDINGS: 
      The findings are presented based on three general patterns, an ethical basic
      motive, an ethical bearing and ethical actions. Subthemes are Humane view of
      students as unique individuals with individual learning, Bearing of tactfulness
      and firmness, Bearing of perceptiveness and accessibility, Bearing of
      satisfaction and joy over student learning, Valuing bearing towards each oneself 
      and colleagues, Ability to interact and flexibility, Collegiality and a
      supportive work community and Educators as role models and inspirators.
      CONCLUSION: Educators' personal and professional ethos is crucial to student
      learning, personal growth and ethical reasoning. Therefore, it is important to
      further develop educators' training regarding ethical competence.
FAU - Koskinen, Camilla
AU  - Koskinen C
AUID- ORCID: https://orcid.org/0000-0002-8165-2857
AD  - Abo Akademi University, Finland.
FAU - Koskinen, Monika
AU  - Koskinen M
AD  - Abo Akademi University, Finland.
FAU - Koivula, Meeri
AU  - Koivula M
AD  - University of Tampere, Finland.
FAU - Korpi, Hilkka
AU  - Korpi H
AD  - University of Jyvaskyla, Finland.
FAU - Koskimaki, Minna
AU  - Koskimaki M
AD  - University of Tampere, Finland.
FAU - Lahteenmaki, Marja-Leena
AU  - Lahteenmaki ML
AD  - Tampere University of Applied Sciences, Finland.
FAU - Mikkonen, Kristina
AU  - Mikkonen K
AD  - University of Oulu, Finland.
FAU - Saaranen, Terhi
AU  - Saaranen T
AD  - University of Eastern Finland, Finland.
FAU - Salminen, Leena
AU  - Salminen L
AD  - University of Turku, Finland.
FAU - Sjogren, Tuulikki
AU  - Sjogren T
AD  - University of Jyvaskyla, Finland.
FAU - Sormunen, Marjorita
AU  - Sormunen M
AD  - University of Eastern Finland, Finland.
FAU - Wallin, Outi
AU  - Wallin O
AD  - Tampere University of Applied Sciences, Finland.
FAU - Kaariainen, Maria
AU  - Kaariainen M
AD  - University of Oulu, Finland.
LA  - eng
PT  - Journal Article
DEP - 20190905
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - *Ethics, Professional
MH  - Finland
MH  - Focus Groups
MH  - Health Educators/*ethics
MH  - Humans
MH  - *Professional Competence
MH  - Role
MH  - Social Work/*education
MH  - Teaching/*ethics
OTO - NOTNLM
OT  - Ethical competence
OT  - caring science
OT  - educators
OT  - health and social care
OT  - qualitative study
EDAT- 2020/06/05 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - 10.1177/0969733019871678 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):1115-1126. doi: 10.1177/0969733019871678. Epub 2019
      Sep 5.


PMID- 32495716
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - The state of nursing, ethics and the role of the International Council of Nurses.
PG  - 906-907
LID - 10.1177/0969733020926375 [doi]
FAU - Gallagher, Ann
AU  - Gallagher A
AD  - University of Surrey, UK.
LA  - eng
PT  - Editorial
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Female
MH  - Global Health/ethics
MH  - Humans
MH  - *International Council of Nurses
MH  - Leadership
MH  - Male
MH  - *Research Report
EDAT- 2020/06/05 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1177/0969733020926375 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):906-907. doi: 10.1177/0969733020926375.


PMID- 32495649
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 1545-1569 (Electronic)
IS  - 1055-6656 (Linking)
VI  - 57
IP  - 9
DP  - 2020 Sep
TI  - Pregnancy Termination in the Case of an Orofacial Cleft: An Investigation of the 
      Concept of Reproductive Autonomy.
PG  - 1134-1139
LID - 10.1177/1055665620929775 [doi]
AB  - OBJECTIVE: To describe ethical approaches to the issue of pregnancy termination
      after prenatal detection of cleft lip +/- palate. RESULTS: Gynecologists and
      cleft surgeons are sometimes confronted with the demand for a pregnancy
      termination after ultrasound detection of an isolated cleft lip/cleft palate. In 
      this article, we discuss different ethical theories and principles that can be
      applied to the dilemma at hand. We formulate recommendations that will respect
      the right to autonomy of the pregnant woman and at the same time acknowledge that
      a termination of pregnancy for a cleft lip may in most cases not be the best
      option. CONCLUSION: The recognition of each person's right to reproductive
      autonomy also entails that clinicians should make sure that prospective parents
      are provided with up-to-date and relevant clinical information.
FAU - Hens, Kristien
AU  - Hens K
AUID- ORCID: 0000-0003-1062-7918
AD  - Department of Philosophy, University of Antwerp, Antwerpen, Belgium.
AD  - Institute of Philosophy, KU Leuven, Leuven, Belgium.
FAU - Hens, Greet
AU  - Hens G
AD  - Department of Neurosciences, KU Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - United States
TA  - Cleft Palate Craniofac J
JT  - The Cleft palate-craniofacial journal : official publication of the American
      Cleft Palate-Craniofacial Association
JID - 9102566
SB  - IM
MH  - *Abortion, Induced
MH  - *Cleft Lip/diagnostic imaging
MH  - *Cleft Palate/diagnostic imaging
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Prospective Studies
MH  - Ultrasonography
MH  - Ultrasonography, Prenatal
OTO - NOTNLM
OT  - *ethics
OT  - *pregnancy termination
OT  - *prenatal diagnosis
EDAT- 2020/06/05 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1177/1055665620929775 [doi]
PST - ppublish
SO  - Cleft Palate Craniofac J. 2020 Sep;57(9):1134-1139. doi:
      10.1177/1055665620929775. Epub 2020 Jun 4.


PMID- 32495581
OWN - NLM
STAT- MEDLINE
DCOM- 20200608
LR  - 20201218
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 45
IP  - 10
DP  - 2020 May
TI  - [Ethical review of clinical study on intervention with traditional Chinese
      medicine in new public health emergencies].
PG  - 2287-2290
LID - 10.19540/j.cnki.cjcmm.20200318.502 [doi]
AB  - High-quality clinical study on traditional Chinese medicine is of great
      significance to effectively control new public health emergencies represented by 
      outbreaks of infectious diseases and ensure people's health and safety, but it
      still faces a series of ethical issues. Based on the seven core values of equity,
      good deeds, effectiveness, respect for individuals, freedom, reciprocity, and
      solida-rity proposed in the Guidelines for Management of Ethical Issues in
      Outbreaks of Infectious Diseases, this article emphasizes the characteristics and
      laws of clinical studies on traditional Chinese medicine. Main points of ethical 
      review of traditional Chinese medicine were summarized in the aspects of overall 
      concept, syndrome differentiation and treatment, prevention before disease onset,
      cultural value, and clinical basis. Based on the outbreak of coronavirus disease 
      2019(COVID-19), we collected relevant registered Chinese medicine clinical
      studies, summarized the core issues of the ethics review for COVID-19, and
      further improved the traditional Chinese medicine ethics review system and
      resources, so as to better serve ethical review and scientific studies in public 
      health emergencies.
FAU - Gu, Hao
AU  - Gu H
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese
      Medical Sciences Beijing 100700, China.
FAU - Wang, Zhi-Fei
AU  - Wang ZF
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese
      Medical Sciences Beijing 100700, China.
FAU - Xie, Yan-Ming
AU  - Xie YM
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese
      Medical Sciences Beijing 100700, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese
      materia medica
JID - 8913656
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Emergencies
MH  - *Ethical Review
MH  - Humans
MH  - *Medicine, Chinese Traditional
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Public Health
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - clinical research
OT  - coronavirus disease 2019(COVID-19)
OT  - ethical review
OT  - new public health emergencies
OT  - traditional Chinese medicine
EDAT- 2020/06/05 06:00
MHDA- 2020/06/09 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20200318.502 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2020 May;45(10):2287-2290. doi:
      10.19540/j.cnki.cjcmm.20200318.502.


PMID- 32495373
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1365-2834 (Electronic)
IS  - 0966-0429 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Jul
TI  - Dealing with ethical issues in rehabilitation medicine: The relationship between 
      managerial support and emotional exhaustion is mediated by moral distress and
      enhanced by positive affectivity and resilience.
PG  - 1114-1125
LID - 10.1111/jonm.13059 [doi]
AB  - AIMS: To analyse whether managerial support and ethical vision of patient care
      would be related to emotional exhaustion directly or through moral distress and
      whether these relationships would be conditional on individual levels of positive
      affectivity and resilience. BACKGROUND: Although some studies described the
      effects of ethical climate, moral distress, resilience and positive affectivity
      on emotional exhaustion, there are no attempts of explicative models containing
      these variables. METHODS: A total of 222 Italian professionals employed in
      neuro-rehabilitation medicine units participated in this cross-sectional study.
      Descriptive statistics, mediation and moderated mediation analyses were conducted
      using SPSS. RESULTS: Managerial support and ethical vision of patient care were
      negatively related to emotional exhaustion, directly and through moral distress. 
      Professionals high in resilience and positive affectivity benefited more from the
      protective effect of managerial support on emotional exhaustion through moral
      distress. CONCLUSION: Ethical climate represents a protective factor against
      moral distress and emotional exhaustion. Moreover, individual levels of positive 
      affectivity and resilience may increase the beneficial effects deriving from
      managerial support in dealing with ethical issues. IMPLICATION FOR NURSING
      MANAGEMENT: Health organisations may consider developing strategies to improve
      ethical climate, enhance managers' ability to support team in dealing with
      ethical issues and foster employees' positive affectivity and resilience.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Maffoni, Marina
AU  - Maffoni M
AUID- ORCID: https://orcid.org/0000-0002-3360-7293
AD  - Department of Brain and Behavioural Sciences, Unit of Applied Psychology,
      University of Pavia, Pavia, Italy.
AD  - Psychology Unit of Montescano Institute, Istituti Clinici Scientifici Maugeri
      IRCCS, Pavia, Italy.
FAU - Sommovigo, Valentina
AU  - Sommovigo V
AUID- ORCID: https://orcid.org/0000-0001-9273-5706
AD  - Department of Brain and Behavioural Sciences, Unit of Applied Psychology,
      University of Pavia, Pavia, Italy.
FAU - Giardini, Anna
AU  - Giardini A
AUID- ORCID: https://orcid.org/0000-0002-2845-347X
AD  - Psychology Unit of Montescano Institute, Istituti Clinici Scientifici Maugeri
      IRCCS, Pavia, Italy.
FAU - Paolucci, Stefano
AU  - Paolucci S
AUID- ORCID: https://orcid.org/0000-0002-3105-1148
AD  - Fondazione Santa Lucia - IRCCS, Rome, Italy.
FAU - Setti, Ilaria
AU  - Setti I
AUID- ORCID: https://orcid.org/0000-0001-7901-4226
AD  - Department of Brain and Behavioural Sciences, Unit of Applied Psychology,
      University of Pavia, Pavia, Italy.
LA  - eng
GR  - Ricerca Corrente
PT  - Journal Article
DEP - 20200623
PL  - England
TA  - J Nurs Manag
JT  - Journal of nursing management
JID - 9306050
MH  - *Adaptation, Psychological
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Italy
MH  - Job Satisfaction
MH  - Male
MH  - Organizational Culture
MH  - *Psychological Distress
MH  - Rehabilitation Nursing/*ethics
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - affectivity
OT  - emotional exhaustion
OT  - ethical climate
OT  - moral distress
OT  - rehabilitation
OT  - resilience
EDAT- 2020/06/05 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/03/21 00:00 [received]
PHST- 2020/05/20 00:00 [revised]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1111/jonm.13059 [doi]
PST - ppublish
SO  - J Nurs Manag. 2020 Jul;28(5):1114-1125. doi: 10.1111/jonm.13059. Epub 2020 Jun
      23.


PMID- 32495339
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1466-7657 (Electronic)
IS  - 0020-8132 (Linking)
VI  - 67
IP  - 2
DP  - 2020 Jun
TI  - Coronavirus disease 2019 (COVID-19): strengthening our resolve to achieve
      universal palliative care.
PG  - 160-163
LID - 10.1111/inr.12592 [doi]
AB  - In this paper, we strongly advocate for universal palliative care access during
      the COVID-19 pandemic. The delivery of universal palliative care services has
      been called for by leading global health organizations and experts. Nurses are
      critical to realizing this goal. COVID-19 diagnoses and fatalities continue to
      rise, underscoring the importance of palliative care, particularly in the context
      of scant resources. To inform the writing of this paper, we undertook a review of
      the COVID-19 and palliative care literature and drew on our experiences. It is
      very clear that investment in nurses is needed to ensure appropriate palliative
      care services now and into the future. Avoiding futile interventions and
      alleviating suffering is an ethical imperative for nurses regardless of the
      setting. Multi-level practices and policies to foster the delivery of safe,
      high-quality palliative care for all are urgently needed.
CI  - (c) 2020 International Council of Nurses.
FAU - Rosa, William E
AU  - Rosa WE
AD  - Robert Wood Johnson Foundation Future of Nursing Scholar, University of
      Pennsylvania School of Nursing, Philadelphia, Pennsylvania, USA.
FAU - Davidson, Patricia M
AU  - Davidson PM
AD  - Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200604
PL  - England
TA  - Int Nurs Rev
JT  - International nursing review
JID - 7808754
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Health Services Accessibility/*organization & administration
MH  - Humans
MH  - Palliative Care/*organization & administration
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - Qualitative Research
MH  - SARS-CoV-2
MH  - Social Support
MH  - Universal Health Insurance/*organization & administration
PMC - PMC7300863
OTO - NOTNLM
OT  - COVID-19
OT  - Global Palliative Care
OT  - Health Policy
OT  - Nursing Policy
OT  - Palliative Care
OT  - Palliative Nursing
OT  - Primary Palliative Care
OT  - Universal Health Coverage
EDAT- 2020/06/05 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1111/inr.12592 [doi]
PST - ppublish
SO  - Int Nurs Rev. 2020 Jun;67(2):160-163. doi: 10.1111/inr.12592. Epub 2020 Jun 4.


PMID- 32494538
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 2
TI  - Benefits of Outcomes of the Microscopic Examination of Anastomotic Donuts After
      Colorectal Resection for Oncological Purposes: A Medical Record-Based Study.
PG  - e7932
LID - 10.7759/cureus.7932 [doi]
AB  - Objective The objective of the study is to investigate the benefits of
      pathological assessment of donuts removed during coloanal anastomosis after
      anterior resection. Methodology During three years, 220 patients underwent
      circular stapled anastomosis. It is a retrospective study with convenient
      sampling. Involvement of donuts, the involvement of margins, length of donuts,
      and margins were primarily recorded. Ethical review approval was taken from the
      Institutional Review Board. Hospital electronic system was used to retrieve the
      data. Results Two hundred and twenty patients underwent circular end to end
      anastomosis (CEEA) stapled gun anastomosis. All had adenocarcinoma. Most of the
      patients had T3 disease (n=113). Low anterior resection was the most common
      procedure followed by anterior resection and sigmoid colectomy, respectively. We 
      performed all rectal cancers anastomosis with a circular stapling gun. On
      histological analyses among 220 patients, only two patients were found to have a 
      positive distal donut. No proximal donuts were positive. Both patients were also 
      found to have positive distal margins. The mean length of the proximal donut was 
      1.79+/-0.45 cm. The mean length of the distal donut was 1.68+/-0.48 cm. Two
      distal margins and none of the proximal margins were positive for cancer. The
      mean length of the proximal margin was 8.69+/-4.48 cm. The mean length of the
      distal margin was 4.9+/-5.98 cm. Both patients had already received six months of
      pre-operative chemoradiotherapy and were not offered any additional treatment.
      Both patients were kept on close surveillance. Conclusion Routine analyses of the
      donuts after anterior resection has no impact on the management and outcome of
      the disease.
CI  - Copyright (c) 2020, Haq et al.
FAU - Haq, Ihtisham
AU  - Haq I
AD  - Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center,
      Lahore, PAK.
FAU - Shakeel, Osama
AU  - Shakeel O
AD  - Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,
      Lahore, PAK.
FAU - Amjad, Awais
AU  - Amjad A
AD  - Surgery, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore,
      PAK.
FAU - Ullah, Faizan
AU  - Ullah F
AD  - Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center,
      Karachi, PAK.
FAU - Ali, Hannan
AU  - Ali H
AD  - Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,
      Lahore, PAK.
FAU - Jamal, Aun
AU  - Jamal A
AD  - Surgical Oncology, Shaukat Khanum Memoiral Cancer Hospital and Research Centre,
      Lahore, PAK.
FAU - Khattak, Shahid
AU  - Khattak S
AD  - Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,
      Lahore, PAK.
FAU - Syed, Aamir Ali
AU  - Syed AA
AD  - Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre,
      Lahore, PAK.
LA  - eng
PT  - Journal Article
DEP - 20200502
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7265751
OTO - NOTNLM
OT  - anterior resection
OT  - coloanal anastamosis
OT  - colorectal cancer
OT  - donuts
OT  - margins
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
AID - 10.7759/cureus.7932 [doi]
PST - epublish
SO  - Cureus. 2020 May 2;12(5):e7932. doi: 10.7759/cureus.7932.


PMID- 32494270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 4
DP  - 2020 May-Jun
TI  - Frequency of pap smear among doctors: A pilot study.
PG  - 761-764
LID - 10.12669/pjms.36.4.1651 [doi]
AB  - BACKGROUND AND OBJECTIVE: Carcinoma of the cervix is one of the three leading
      causes of deaths among females worldwide. Pap smear is a simple and very
      cost-effective method to detect carcinoma of the cervix. The objective of our
      study was to determine the frequency of papsmear among doctors, so the alarming
      situation of sloppiness in the screening program can be highlighted. METHODS: The
      interview-based survey was conducted; multiple questions were asked from the
      participants. It was a pilot study. Sixty doctors who were married (working in a 
      teaching hospital) were recruited from Rashid Latif Medical College, Lahore from 
      June 2018 - November 2018 and associated tertiary care teaching hospitals for the
      study. Ethical consideration was taken into account and secrecy of participants
      were maintained. RESULTS: All data was entered in SPSS 21 and statistical
      analysis was done in terms of frequencies. Only 25% of doctors have a pap smear
      once in their life. Majority 75% of the doctors never have papsmear in their
      lifetime, few reasons were a shortage of time (27%) and shyness (5%). Regarding
      HPV vaccination 89% of the participants were willing to have HPV vaccination for 
      their daughters. CONCLUSION: This study shows the poor implementation of the
      cancer screening programme in Pakistan. The general public should be informed
      about the benefits of HPV vaccination.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Yusuf, Lamia
AU  - Yusuf L
AD  - Dr. Lamia Yusuf, FCPS, MHPE. Associate Professor, Department of Gynaecology &
      Obstetrics, Rashid Latif Medical College, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7260935
OTO - NOTNLM
OT  - Doctors
OT  - HPV Vaccination
OT  - PAP Smear
OT  - Prevalence
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
AID - 10.12669/pjms.36.4.1651 [doi]
AID - PJMS-36-761 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 May-Jun;36(4):761-764. doi: 10.12669/pjms.36.4.1651.


PMID- 32494172
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Linking)
VI  - 13
DP  - 2020
TI  - Colonization by Pseudomonas aeruginosa and Staphylococcus aureus of Antral Biopsy
      Specimens from Gastritis Patients Uninfected with Helicobacter Pylori.
PG  - 1411-1417
LID - 10.2147/IDR.S254967 [doi]
AB  - PURPOSE: Roles and incidence of some microorganisms that transiently or
      permanently colonize the human stomach are still unknown despite advances in
      gastroenterology. We aimed to examine the incidence of four microorganisms,
      Helicobacter pylori, Pseudomonas aeruginosa, Staphylococcus aureus, and
      Staphylococcus epidermidis, in the antral biopsy specimens of patients with
      gastroduodenal conditions. PATIENTS AND METHODS: Patients (67 females, 33 males; 
      mean age = 49.5 years) were initially examined and diagnosed by a
      gastroenterologist at the Mehrad Hospital, Tehran, Iran. We enrolled those who
      underwent the upper gastrointestinal endoscopy because of gastroduodenal
      conditions. Two antral biopsy samples were taken by endoscopy; the first sample
      was used for the "rapid urease test" to confirm H. pylori. The second was used
      for DNA extraction and PCR analyses with specific, corresponding primer sets to
      establish the presence of the four microorganisms. Our study was approved by the 
      Ethics Committee at the Tarbiat Modares University, Tehran. RESULTS: Based on
      pathology and endoscopy findings, we divided the patients into three groups: 62
      presented with gastritis, 18 with duodenal ulcer, and 20 gastric ulcer. The
      number of patients with P. aeruginosa but without H. pylori significantly
      differed from the number of those co-infected with both microorganisms (P =
      0.03). Additionally, a similar significance was found between the incidence of S.
      aureus in patients without H. pylori and those with both infections (P = 0.04).
      Our results indicated that a significant number of patients with gastritis were
      colonized with P. aeruginosa or S. aureus without being co-infected with H.
      pylori (P < 0.001). Interestingly, the incidence of colonization by P. aeruginosa
      of patients without H. pylori (45/49, 91.8%) was higher than that by S. aureus
      (28/49, 57%). CONCLUSION: The number of patients without H. pylori but with P.
      aeruginosa or with S. aureus infection significantly differed from that with both
      infections, respectively. Our study thus shows that patients without H. pylori
      infection are prone to be colonized by P. aeruginosa or S. aureus, indicating
      that targeted antibiotic regimens are necessary for clinically treating them.
CI  - (c) 2020 Kachuei et al.
FAU - Kachuei, Vida
AU  - Kachuei V
AD  - Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares
      University, Tehran, Iran.
FAU - Talebi Bezmin Abadi, Amin
AU  - Talebi Bezmin Abadi A
AUID- ORCID: 0000-0001-5209-6436
AD  - Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares
      University, Tehran, Iran.
FAU - Rahimi, Farid
AU  - Rahimi F
AUID- ORCID: 0000-0002-0920-8188
AD  - Research School of Biology, The Australian National University, Canberra,
      Australia.
FAU - Forootan, Mojgan
AU  - Forootan M
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
PMC - PMC7231751
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - PCR
OT  - Pseudomonas aeruginosa
OT  - Staphylococcus aureus
OT  - gastritis
OT  - microbiota
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
CRDT- 2020/06/05 06:00
PHST- 2020/03/22 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
AID - 10.2147/IDR.S254967 [doi]
AID - 254967 [pii]
PST - epublish
SO  - Infect Drug Resist. 2020 May 13;13:1411-1417. doi: 10.2147/IDR.S254967.
      eCollection 2020.


PMID- 32493737
OWN - NLM
STAT- Publisher
LR  - 20200604
IS  - 1939-2869 (Electronic)
IS  - 0891-1150 (Linking)
DP  - 2020 Jun 3
TI  - Ethical considerations during the COVID-19 pandemic.
LID - 10.3949/ccjm.87a.ccc038 [doi]
AB  - The care of patients during the COVID-19 pandemic has added many layers of
      complexity to ethical issues. Our response emphasizes the importance of having an
      ethically sound framework to inform our decisions, requiring caregivers to
      consider what is ethically optimal and feasible for the patient. It is
      increasingly important to understand the ethical principles and to appropriately 
      apply them to both patient management decisions and guide scarce resource
      allocation. If we are to be prepared to face the many challenges of this
      pandemic, we must prioritize the ethical demands to our treatment and management 
      concerns.
CI  - Copyright (c) 2020 The Cleveland Clinic Foundation. All Rights Reserved.
FAU - Sese, Denise
AU  - Sese D
AD  - Education Institute, Cleveland Clinic.
FAU - Ahmad, Mahwish U
AU  - Ahmad MU
AD  - Center for Bioethics, Community Care Institute, Cleveland Clinic.
FAU - Rajendram, Prabalini
AU  - Rajendram P
AD  - Critical Care Medicine, Emergency Services Instititute, Cleveland Clinic.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
SB  - IM
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:00 [medline]
AID - ccjm.87a.ccc038 [pii]
AID - 10.3949/ccjm.87a.ccc038 [doi]
PST - aheadofprint
SO  - Cleve Clin J Med. 2020 Jun 3. pii: ccjm.87a.ccc038. doi: 10.3949/ccjm.87a.ccc038.


PMID- 32493712
OWN - NLM
STAT- Publisher
LR  - 20200722
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Jun 3
TI  - The right to know: ethical implications of antibody testing for healthcare
      workers and overlooked societal implications.
LID - medethics-2020-106467 [pii]
LID - 10.1136/medethics-2020-106467 [doi]
AB  - After the initial surge in cases of coronavirus (COVID-19), the outbreak has been
      managed differently in different countries. In the USA, it has been managed in
      many different ways between states, cities and even counties. This disparity is
      slowly becoming more and more pronounced with the advent of antibody testing.
      Although many argue over the potential merits of antibody testing as an immunity 
      passport to allow the economy to restart, there are other implications that stand
      at the heart of the bioethical debate that are often overlooked. Particularly
      with COVID-19, there are many uncertainties and the discourse alone of antibodies
      presumes misinformation that may outweigh the epidemiological benefits of
      antibody testing. Although this paper does not seek to eliminate antibody
      testing, it does highlight the need for appropriate counselling both on a
      personal level with each patient but on a more global level. This moral standard 
      of appropriate education is key to allowing the continued autonomy needed during 
      this pandemic.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Vakharia, Kunal
AU  - Vakharia K
AUID- ORCID: http://orcid.org/0000-0001-8222-8874
AD  - Neurosurgery, University at Buffalo - The State University of New York, Buffalo, 
      NY 14260-1660, USA kunalvakharia5@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC7316109
OTO - NOTNLM
OT  - distributive justice
OT  - ethics
COIS- Competing interests: None declared.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/05/17 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:00 [medline]
AID - medethics-2020-106467 [pii]
AID - 10.1136/medethics-2020-106467 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Jun 3. pii: medethics-2020-106467. doi:
      10.1136/medethics-2020-106467.


PMID- 32493579
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 29
IP  - 11
DP  - 2020 Nov
TI  - Operative Results of Mitral Valve Repair and Replacement in Chronic Ischaemic
      Mitral Valve Regurgitation.
PG  - 1713-1724
LID - S1443-9506(20)30103-7 [pii]
LID - 10.1016/j.hlc.2020.03.007 [doi]
AB  - BACKGROUND: Ischaemic mitral regurgitation (IMR) carries significant morbidity
      and mortality. Surgical management includes coronary artery bypass surgery alone 
      or concomitant with mitral valve repair or replacement. There is ongoing debate
      regarding the appropriate approach to the mitral valve in relation to long-term
      outcomes. This review examines our early and late follow-up, with operative and
      echocardiographic outcomes for mitral valve repair and mitral replacement for
      chronic IMR. METHODS: A retrospective review was performed on prospectively
      collected data of 119 consecutive patients who either underwent mitral repair
      (n=101) or mitral replacement (n=18) for chronic IMR at Prince Henry and The
      Prince of Wales hospitals in Sydney between 1999-2016. All patients had pre and
      postoperative transthoracic echocardiograms. Follow-up echocardiographic data was
      obtained from the most recent clinical appointment. Follow-up mortality outcomes 
      were obtained with ethics approval from the Australian National Death Index
      (NDI). RESULTS: There was no statistical difference between cardiopulmonary
      bypass (CPB) time, cross-clamp time, time spent in intensive care unit (ICU) and 
      time to discharge between cohorts. The replacement cohort was noted to have
      higher preoperative pulmonary artery (PA) pressures and a higher severity of IMR.
      Seven (7) deaths were in the mitral valve (MV) repair group within 30 days (6.9%)
      and three deaths in the MV replacement group within 30 days (16.7%).
      Echocardiographic follow-up was complete in 78% of the MV repair cohort at an
      average of 4.06+/-2.66 years, and 73% complete in the MV replacement cohort at an
      average of 6.09+/-4.3 years. Three (3) patients had prior MV repair before MV
      replacement early at days zero and 17, and late at 8 years respectively.
      Follow-up echocardiography showed mitral regurgitation (MR) in the mitral valve
      repair cohort as </= mild in 83.5% and </= trivial in 35.6%. In the MV
      replacement cohort MR </= mild in 100% and </= trivial in 82% with no moderate or
      severe MR. Preoperative tricuspid regurgitation (TR) and a flexible annuloplasty 
      were predictive of an MR grade > mild in the repair cohort at discharge.
      Five-year (5-year) survival for the repair cohort was 85% with a mean follow-up
      time of 7.1+/-3.83 years. For the replacement cohort, five-year survival was
      77.8% with a mean follow-up time of 5.35+/-1.54 years. CONCLUSIONS: Mitral valve 
      repair and replacement for chronic IMR has acceptable mortality, reintervention
      rates and excellent postoperative echocardiographic degrees of IMR in this
      cohort. Further evaluation is required into quality of life post intervention for
      IMR and of preoperative predictive factors of significant MR postoperatively to
      help guide the appropriate choice of treatment. The presence of preoperative
      tricuspid regurgitation of moderate grade or higher, and the use of a flexible
      annuloplasty may indicate patients more likely to have a higher grade of MR at
      follow-up following mitral valve repair in patients with IMR.
CI  - Copyright (c) 2020 Australian and New Zealand Society of Cardiac and Thoracic
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Gimpel, Damian
AU  - Gimpel D
AD  - School of Medicine Sydney, University of Notre Dame Australia, Sydney, NSW,
      Australia; Department of Cardiothoracic Surgery, The Prince of Wales Hospital,
      Sydney, NSW, Australia. Electronic address: gimpeldamian@gmail.com.
FAU - Cheung, Michael
AU  - Cheung M
AD  - School of Medicine Sydney, University of Notre Dame Australia, Sydney, NSW,
      Australia.
FAU - Bassin, Levi
AU  - Bassin L
AD  - Department of Cardiothoracic Surgery, The Prince of Wales Hospital, Sydney, NSW, 
      Australia.
FAU - Jennings, Scott
AU  - Jennings S
AD  - Department of Cardiothoracic Surgery, The Prince of Wales Hospital, Sydney, NSW, 
      Australia.
FAU - Weiss, Beatrix
AU  - Weiss B
AD  - School of Medicine Sydney, University of Notre Dame Australia, Sydney, NSW,
      Australia; Department of Cardiothoracic Surgery, The Prince of Wales Hospital,
      Sydney, NSW, Australia.
FAU - Akhunji, Zakir
AU  - Akhunji Z
AD  - Department of Cardiothoracic Surgery, The Prince of Wales Hospital, Sydney, NSW, 
      Australia.
FAU - Grant, Peter
AU  - Grant P
AD  - Department of Cardiothoracic Surgery, The Prince of Wales Hospital, Sydney, NSW, 
      Australia.
FAU - Wolfenden, Hugh
AU  - Wolfenden H
AD  - Department of Cardiothoracic Surgery, The Prince of Wales Hospital, Sydney, NSW, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
SB  - IM
MH  - Aged
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Mitral Valve/*diagnostic imaging/surgery
MH  - Mitral Valve Annuloplasty/*methods
MH  - Mitral Valve Insufficiency/diagnosis/etiology/*surgery
MH  - Myocardial Ischemia/*complications/diagnosis
MH  - *Quality of Life
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cardiothoracic surgery
OT  - Ischaemic mitral regurgitation
OT  - Mitral valve
OT  - Mitral valve repair
OT  - Mitral valve replacement
EDAT- 2020/06/05 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2020/01/10 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - S1443-9506(20)30103-7 [pii]
AID - 10.1016/j.hlc.2020.03.007 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2020 Nov;29(11):1713-1724. doi: 10.1016/j.hlc.2020.03.007. Epub 
      2020 Apr 9.


PMID- 32493494
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20220414
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 3
TI  - Controlled, double-blind, randomized trial to assess the efficacy and safety of
      hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare
      personnel in the hospital setting: A structured summary of a study protocol for a
      randomised controlled trial.
PG  - 472
LID - 10.1186/s13063-020-04400-4 [doi]
AB  - BACKGROUND: SARS-CoV-2 infection presents a high transmission in the group of
      health professionals in Spain (12-15% infected). Currently there is no accepted
      chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhibit the coronavirus
      in vitro. Our hypothesis is that oral administration of hydroxychloroquine to
      healthcare professionals can reduce the incidence and prevalence of infection as 
      well as its severity in this group. METHODS: Design: Prospective, single center, 
      double blind, randomised, controlled trial (RCT). PARTICIPANTS: Adult health-care
      professionals (18-65 years) working in areas of high exposure and high risk of
      transmission of SARS-COV-2 (COVID areas, Intensive Care Unit -ICUs-, Emergency,
      Anesthesia and all those performing aerosol-generating procedures) will be
      included. Exclusion criteria include previous infection with SARS CoV2 (positive 
      SARS-CoV-2 PCR or IgG serology), pregnancy or lactation, any contraindication to 
      hydroxychloroquine or evidence of unstable or clinically significant systemic
      disease. INTERVENTIONS: Patients will be randomized (1:1) to receive once-daily
      oral Hydroxychloroquine 200mg for two months (HC group) or placebo (P group) in
      addition to the protective measures appropriate to the level of exposure
      established by the hospital. A serological evaluation will be carried out every
      15 days with PCR in case of seroconversion, symptoms or risk exposure. Primary
      outcome is the percentage of subjects presenting infection (seroconversion and/or
      PCR +ve) by the SARS-Cov-2 virus during the observation period. Additionally,
      both the percentage of subjects in each group presenting Pneumonia with severity 
      criteria (Curb 65 >/=2) and that of subjects requiring admission to ICU will be
      determined. DISCUSSION: While awaiting a vaccine, hygiene measures, social
      distancing and personal protective equipment are the only primary prophylaxis
      measures against SARS-CoV-2, but they have not been sufficient to protect our
      healthcare professionals. Some evidence of the in vitro efficacy of
      hydroxychloroquine against this virus is known, along with some clinical data
      that would support the study of this drug in the chemoprophylaxis of infection.
      However, there are still no data from controlled clinical trials in this regard. 
      If our hypothesis is confirmed, hydroxychloroquine can help professionals fight
      this infection with more guarantees. PARTICIPANTS: This is a single-center study 
      that will be carried out at the Marques de Valdecilla University Hospital. 450
      health professionals working at the Hospital Universitario Marques de Valdecilla 
      in areas of high exposure and high risk of transmission of SARS COV2 (COVID
      hospital areas, Intensive Care Unit, Emergency, Anesthesia and all those
      performing aerosol-generating procedures) will be included. INCLUSION CRITERIA:
      1) Health professionals aged between 18 and 65 years (inclusive) at the time of
      the first screening visit; 2) They must provide signed written informed consent
      and agree to comply with the study protocol; 3) Active work in high exposure
      areas during the last two weeks and during the following weeks. EXCLUSION
      CRITERIA: 1) Previous infection with SARS CoV2 (positive coronavirus PCR or
      positive serology with SARS Cov2 negative PCR and absence of symptoms); 2)
      Current treatment with hydroxychloroquine or chloroquine; 3) Hypersensitivity,
      allergy or any contraindication for taking hydroxychloroquine, in the technical
      sheet; 4) Previous or current treatment with tamoxifen or raloxifene; 5) Previous
      eye disease, especially maculopathy; 6) Known heart failure (Grade III to IV of
      the New York Heart Association classification) or prolonged QTc; 7) Any type of
      cancer (except basal cell) in the last 5 years; 6) Refusal to give informed
      consent; 8) Evidence of any other unstable or clinically significant untreated
      immune, endocrine, hematological, gastrointestinal, neurological, neoplastic or
      psychiatric illness; 9) Antibodies positive for the human immunodeficiency virus;
      10) Significant kidney or liver disease; 11) Pregnancy or lactation. INTERVENTION
      AND COMPARATOR: Two groups will be analyzed with a 1: 1 randomization rate.
      1)Intervention: (n = 225): One 200 mg hydroxychloroquine sulfate coated tablet
      once daily for two months.2)Comparator (control group) (n = 225): One
      hydroxychloroquine placebo tablet (identical to that of the drug) once daily for 
      two months MAIN OUTCOMES: The primary outcome of this study will be to evaluate: 
      number and percentage of healthcare personnel presenting symptomatic and
      asymptomatic infection (see "Diagnosis of SARS CoV2 infection" below) by the
      SARS-Cov2 virus during the study observation period (8 weeks) in both treatment
      arms;number and percentage of healthcare personnel in each group presenting with 
      Pneumonia with severity criteria (Curb 65 >/=2) and number and percentage of
      healthcare personnel requiring admission to the Intensive Care Unit (ICU) in both
      treatment arms. DIAGNOSIS OF SARS COV2 INFECTION: Determination of IgA, IgM and
      IgG type antibodies against SARS-CoV-2 using the Anti-SARS-CoV-2 ELISA kit
      (EUROIMMUN Medizinische Labordiagnostika AG, Germany) every two weeks. In cases
      of seroconversion, a SARS-CoV-2 PCR will be performed to rule out / confirm an
      active infection (RT-PCR in One Step: RT performed with mastermix (Takara) and
      IDT probes, following protocol published and validated by the CDC Evaluation of
      COVID-19 in case of SARS-CoV-2 infection RANDOMISATION: Participants will be
      allocated to intervention and comparator groups according to a balanced
      randomization scheme (1: 1). The assignment will be made through a
      computer-generated numeric sequence for all participants BLINDING (MASKING): Both
      participants and investigators responsible for recruiting and monitoring
      participants will be blind to the assigned arm. NUMBERS TO BE RANDOMISED (SAMPLE 
      SIZE): Taking into account the current high prevalence of infection in healthcare
      personnel in Spain (up to 15%), to detect a difference equal to or greater than
      8% in the percentage estimates through a two-tailed 95% CI, with a statistical
      power of 80% and a dropout rate of 5%, a total of 450 participants will need to
      be included (250 in each arm). TRIAL STATUS: The protocol approved by the health 
      authorities in Spain (Spanish Agency for Medicines and Health Products "AEMPS")
      and the Ethics and Research Committee of Cantabria (CEIm Cantabria) corresponds
      to version 1.1 of April 2, 2020. Currently, recruitment has not yet started, with
      the start scheduled for the second week of May 2020. TRIAL REGISTRATION: Eudra CT
      number: 2020-001704-42 (Registered on 29 March 2020) FULL PROTOCOL: The full
      protocol is attached as an additional file, accessible from the Trials website
      (Additional file 1). In the interest in expediting dissemination of this
      material, the familiar formatting has been eliminated; this Letter serves as a
      summary of the key elements of the full protocol. The study protocol has been
      reported in accordance with the Standard Protocol Items: Recommendations for
      Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
FAU - Cuadrado-Lavin, Antonio
AU  - Cuadrado-Lavin A
AD  - Department of Gastroenterology and Hepatology, Marques de Valdecilla University
      Hospital, School of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008,
      Santander, Cantabria, Spain.
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
FAU - Olmos, Jose Manuel
AU  - Olmos JM
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Internal Medicine Department, Marques de Valdecilla University Hospital, School
      of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander,
      Cantabria, Spain.
FAU - Cifrian, Jose Manuel
AU  - Cifrian JM
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Service of Pneumology, Marques de Valdecilla University Hospital, School of
      Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander,
      Cantabria, Spain.
FAU - Gimenez, Teresa
AU  - Gimenez T
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Pharmacy Department, Marques de Valdecilla University Hospital, School of
      Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander,
      Cantabria, Spain.
FAU - Gandarillas, Marco Antonio
AU  - Gandarillas MA
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Department of Prevention and Risks, Work Medicine, Marques de Valdecilla
      University Hospital, School of Medicine, University of Cantabria, Av. Valdecilla,
      25, 39008, Santander, Cantabria, Spain.
FAU - Garcia-Saiz, Mar
AU  - Garcia-Saiz M
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Department of Clinical Pharmacology, Marques de Valdecilla University Hospital,
      School of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008,
      Santander, Cantabria, Spain.
FAU - Rebollo, Maria Henar
AU  - Rebollo MH
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Department of Preventive Medicine, Marques de Valdecilla University Hospital,
      School of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008,
      Santander, Cantabria, Spain.
FAU - Martinez-Taboada, Victor
AU  - Martinez-Taboada V
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Department of Rheumatology, Marques de Valdecilla University Hospital, School of 
      Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander,
      Cantabria, Spain.
FAU - Lopez-Hoyos, Marcos
AU  - Lopez-Hoyos M
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Department of Immunology, Marques de Valdecilla University Hospital, School of
      Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander,
      Cantabria, Spain.
FAU - Farinas, Maria Carmen
AU  - Farinas MC
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain.
AD  - Infectious diseases Service, Marques de Valdecilla University Hospital, School of
      Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander,
      Cantabria, Spain.
FAU - Crespo, Javier
AU  - Crespo J
AD  - Department of Gastroenterology and Hepatology, Marques de Valdecilla University
      Hospital, School of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008,
      Santander, Cantabria, Spain. javiercrespo1991@gmail.com.
AD  - Marques de Valdecilla Research Institute (IDIVAL), s/n, Calle Cardenal Herrera
      Oria, 39011, Santander, Cantabria, Spain. javiercrespo1991@gmail.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20200603
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Antiviral Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*administration & dosage/adverse effects
MH  - Betacoronavirus/*drug effects/pathogenicity
MH  - COVID-19
MH  - Chemoprevention
MH  - Coronavirus Infections/diagnosis/*prevention & control/virology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/*administration & dosage/adverse effects
MH  - Infectious Disease Transmission, Patient-to-Professional/*prevention & control
MH  - Male
MH  - Middle Aged
MH  - Occupational Exposure/*adverse effects
MH  - *Occupational Health
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/diagnosis/*prevention & control/virology
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Spain
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7268173
OTO - NOTNLM
OT  - COVID-19
OT  - Chemoprophylaxis
OT  - Healthcare professionals
OT  - Hydroxychloroquine
OT  - Protocol
OT  - Randomised controlled trial
EDAT- 2020/06/05 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/05/09 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1186/s13063-020-04400-4 [doi]
AID - 10.1186/s13063-020-04400-4 [pii]
PST - epublish
SO  - Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.


PMID- 32493473
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20220415
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 3
TI  - Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in
      COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a
      randomised, controlled trial.
PG  - 462
LID - 10.1186/s13063-020-04416-w [doi]
AB  - OBJECTIVES: The primary objective of the study is to assess the safety of a
      single intravenous infusion of Mesenchymal Stromal Cells (MSCs) in patients with 
      Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. Secondary objectives 
      are to determine the effects of MSCs on important clinical outcomes, as described
      below. TRIAL DESIGN: REALIST COVID 19 is a randomised, placebo-controlled, triple
      blinded trial. PARTICIPANTS: The study will be conducted in Intensive Care Units 
      in hospitals across the United Kingdom. Patients with moderate to severe ARDS as 
      defined by the Berlin definition, receiving invasive mechanical ventilation and
      with a diagnosis of COVID-19 based on clinical diagnosis or PCR test will be
      eligible. Patients will be excluded for the following reasons: more than 72 hours
      from the onset of ARDS; age < 16 years; patient known to be pregnant; major
      trauma in previous 5 days; presence of any active malignancy (other than
      non-melanoma skin cancer); WHO Class III or IV pulmonary hypertension; venous
      thromboembolism currently receiving anti-coagulation or within the past 3 months;
      patient receiving extracorporeal life support; severe chronic liver disease
      (Child-Pugh > 12); Do Not Attempt Resuscitation order in place; treatment
      withdrawal imminent within 24 hours; prisoners; declined consent; non-English
      speaking patients or those who do not adequately understand verbal or written
      information unless an interpreter is available; previously enrolled in the
      REALIST trial. INTERVENTION AND COMPARATOR: Intervention: Allogeneic donor CD362 
      enriched human umbilical cord derived mesenchymal stromal cells (REALIST
      ORBCEL-C) supplied as sterile, single-use cryopreserved cell suspension of a
      fixed dose of 400 x10(6) cells in 40ml volume, to be diluted in Plasma-Lyte 148
      to a total volume of 200mls for administration. Comparator (placebo): Plasma-Lyte
      148 Solution for Infusion (200mls). The cellular product (REALIST ORBCEL-C) was
      developed and patented by Orbsen Therapeutics. MAIN OUTCOMES: The primary safety 
      outcome is the incidence of serious adverse events. The primary efficacy outcome 
      is Oxygenation Index (OI) at day 7. Secondary outcomes include: OI at days 4 and 
      14; respiratory compliance, driving pressure and PaO2/FiO2 ratio (PF ratio) at
      days 4, 7 and 14; Sequential Organ Failure Assessment (SOFA) score at days 4, 7
      and 14; extubation and reintubation; ventilation free days at day 28; duration of
      mechanical ventilation; length of ICU and hospital stay; 28-day and 90-day
      mortality. RANDOMISATION: After obtaining informed consent, patients will be
      randomised via a centralised automated 24-hour telephone or web-based
      randomisation system (CHaRT, Centre for Healthcare Randomised Trials, University 
      of Aberdeen). Randomisation will be stratified by recruitment centre and by
      vasopressor use and patients will be allocated to REALIST ORBCEL-C or placebo
      control in a 1:1 ratio. BLINDING (MASKING): The investigator, treating physician,
      other members of the site research team and participants will be blinded. The
      cell therapy facility and clinical trials pharmacist will be unblinded to
      facilitate intervention and placebo preparation. The unblinded individuals will
      keep the treatment information confidential. The infusion bag will be masked at
      the time of preparation and will be administered via a masked infusion set.
      NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A sample size of 60 patients with 30
      patients randomised to the intervention and 30 to the control group. If possible,
      recruitment will continue beyond 60 patients to provide more accurate and
      definitive trial results. The total number of patients recruited will depend on
      the pandemic and be guided by the data monitoring and ethics committee (DMEC).
      TRIAL STATUS: REALIST Phase 1 completed in January 2020 prior to the COVID-19
      pandemic. This was an open label dose escalation study of REALIST ORBCEL-C in
      patients with ARDS. The COVID-19 pandemic emerged as REALIST Phase 2 was planned 
      to commence and the investigator team decided to repurpose the Phase 2 trial as a
      COVID-19 specific trial. This decision was discussed and approved by the Trial
      Steering Committee (TSC) and DMEC. Submissions were made to the Research Ethics
      Committee (REC) and MHRA to amend the protocol to a COVID-19 specific patient
      population and the protocol amendment was accepted by the REC on 27(th) March
      2020 and MHRA on 30(th) March 2020 respectively. Other protocol changes in this
      amendment included an increase in the time of onset of ARDS from 48 to 72 hours, 
      inclusion of clinical outcomes as secondary outcomes, the provision of an option 
      for telephone consent, an indicative sample size and provision to continue
      recruitment beyond this indicative sample size. The current protocol in use is
      version 4.0 23.03.2020 (Additional file 1). Urgent Public Health status was
      awarded by the NIHR on 2 April 2020 and the trial opened to recruitment and
      recruited the first participant the same day. At the time of publication the
      trial was open to recruitment at 5 sites across the UK (Belfast Health and Social
      Care Trust, King's College London, Guys and St Thomas' Hospital London,
      Birmingham Heartlands Hospital and the Queen Elizabeth Hospital Birmingham) and
      12 patients have been recruited across these sites. Additional sites are planned 
      to open and appropriate approvals for these are being obtained. It is estimated
      recruitment will continue for 6 months. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT03042143 (Registered 3 Feb 2017). EudraCT 2017-000585-33 (Registered 28 Nov
      2017). FULL PROTOCOL: The full protocol (version 4.0 23.03.2020) is attached as
      an additional file, accessible from the Trials website (Additional file 1). In
      the interest of expediting dissemination of this material, the familiar
      formatting has been eliminated; this Letter serves as a summary of the key
      elements of the full protocol. The study protocol has been reported in accordance
      with the Standard Protocol Items: Recommendations for Clinical Interventional
      Trials (SPIRIT) guidelines (Additional file 2).
FAU - Gorman, Ellen
AU  - Gorman E
AUID- ORCID: http://orcid.org/0000-0002-6020-1985
AD  - Wellcome Wolfson Institute for Experimental Medicine, School of Medicine,
      Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK.
FAU - Shankar-Hari, Manu
AU  - Shankar-Hari M
AD  - Guy's and St Thomas' NHS Foundation Trust London and School of Immunology and
      Microbial Sciences, King's College London, London, UK.
FAU - Hopkins, Phil
AU  - Hopkins P
AD  - Research and Development lead in Critical Care, Kings Trauma Centre, King's
      College London, London, UK.
FAU - Tunnicliffe, William S
AU  - Tunnicliffe WS
AD  - Queen Elizabeth Hospital, Birmingham, UK.
FAU - Perkins, Gavin D
AU  - Perkins GD
AD  - University of Warwick, Coventry, UK.
FAU - Silversides, Jonathan
AU  - Silversides J
AD  - Belfast Health and Social Care Trust, Belfast, UK.
FAU - McGuigan, Peter
AU  - McGuigan P
AD  - Royal Victoria Hospital, Belfast, UK.
FAU - Jackson, Colette
AU  - Jackson C
AD  - Northern Ireland Clinical Trials Unit, Belfast, UK.
FAU - Boyle, Roisin
AU  - Boyle R
AD  - Northern Ireland Clinical Trials Unit, Belfast, UK.
FAU - McFerran, Jamie
AU  - McFerran J
AD  - Northern Ireland Clinical Trials Unit, Belfast, UK.
FAU - McDowell, Cliona
AU  - McDowell C
AD  - Northern Ireland Clinical Trials Unit, Belfast, UK.
FAU - Campbell, Christina
AU  - Campbell C
AD  - Northern Ireland Clinical Trials Unit, Belfast, UK.
FAU - McFarland, Margaret
AU  - McFarland M
AD  - Belfast Health and Social Care Trust, Belfast, UK.
FAU - Smythe, Jon
AU  - Smythe J
AD  - NHS Blood and Transplant, Birmingham, UK.
FAU - Thompson, Jacqui
AU  - Thompson J
AD  - NHS Blood and Transplant, Birmingham, UK.
FAU - Williams, Barry
AU  - Williams B
AD  - Independent Public and Patient Representative, Sherborne, UK.
FAU - Curley, Gerard
AU  - Curley G
AD  - Royal College of Surgeons in Ireland, Dublin, Ireland.
FAU - Laffey, John G
AU  - Laffey JG
AD  - National University of Ireland, Galway, Ireland.
FAU - Clarke, Mike
AU  - Clarke M
AD  - School of Medicine, Dentistry and Biomedical Sciences, Queen's University
      Belfast, Belfast, UK.
FAU - O'Kane, Cecilia
AU  - O'Kane C
AD  - Wellcome Wolfson Institute for Experimental Medicine, School of Medicine,
      Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK.
FAU - McAuley, Daniel F
AU  - McAuley DF
AD  - Wellcome Wolfson Institute for Experimental Medicine, School of Medicine,
      Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK.
      d.f.mcauley@qub.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT03042143
GR  - WT_/Wellcome Trust/United Kingdom
GR  - G0901530/MRC_/Medical Research Council/United Kingdom
GR  - MR/M009149/1/MRC_/Medical Research Council/United Kingdom
GR  - 106939/Z/15/Z/WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial Protocol
PT  - Letter
DEP - 20200603
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/physiopathology/*surgery/virology
MH  - Humans
MH  - Lung/physiopathology/*virology
MH  - *Mesenchymal Stem Cell Transplantation/adverse effects
MH  - Multicenter Studies as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/physiopathology/*surgery/virology
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Respiration, Artificial
MH  - SARS-CoV-2
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - United Kingdom
PMC - PMC7267756
OTO - NOTNLM
OT  - ARDS
OT  - Acute Respiratory Distress Syndrome
OT  - COVID-19
OT  - MSCs
OT  - Mesenchymal Stem Cells
OT  - Mesenchymal Stromal Cells
OT  - Randomised controlled trial
OT  - protocol
EDAT- 2020/06/05 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/05/12 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1186/s13063-020-04416-w [doi]
AID - 10.1186/s13063-020-04416-w [pii]
PST - epublish
SO  - Trials. 2020 Jun 3;21(1):462. doi: 10.1186/s13063-020-04416-w.


PMID- 32493425
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1747-597X (Electronic)
IS  - 1747-597X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Jun 3
TI  - "It's business as usual": adolescents perspectives on the ban of alcohol sachets 
      towards reduction in under age alcohol use in Malawi.
PG  - 38
LID - 10.1186/s13011-020-00280-8 [doi]
AB  - BACKGROUND: Alcohol contributes to poor health, social and economic outcomes
      among adolescents. In Malawi, alcohol consumption among young people
      significantly increased after the introduction of alcohol sachets. A government
      ban on the sale of alcohol sachets affected in 2012 aimed to reduce prevalence of
      alcohol among users. We explored adolescents perceptions regarding the
      effectiveness of the ban towards reducing alcohol consumption among the under
      aged in the country. METHODS: Using a descriptive phenomenological school-based
      approach, we recruited 44 school-going adolescents, 15-17 year olds using snow
      ball sampling and conducted 12 individual semi-structured interviews and four
      group discussions differentiated by sex. We sought a waiver from College of
      Medicine Ethics Committee (COMREC) to obtain verbal consent from adolescents. All
      interviews and discussions were digitally recorded and simultaneously transcribed
      and translated verbatim into English. Data management and analysis was done
      manually using thematic approach. RESULTS: Aggressive packaging, and marketing
      tendencies and lack of restrictive measures in Malawi have rendered the ban
      ineffective through increased affordability and availability to different income 
      population groups and the underage. Results indicate that even though adolescents
      perceive the ban as a significant step towards reducing under age alcohol use,
      personality and drinking motives precede any interventions. Adolescents
      emphasized on strong personality as a significant factor for reduced alcohol
      intake or abstinence. CONCLUSIONS: We recommend strict alcohol policy and
      enforcement regarding packaging, pricing, positive role modelling by parents and 
      enhanced adolescent personality development through schools and families.
FAU - Salimu, Sangwani
AU  - Salimu S
AUID- ORCID: 0000-0002-7543-8512
AD  - Department of Public Health, School of Public Health and Family Medicine, College
      of Medicine, Blantyre, Malawi. ssalimu@mlw.mw.
AD  - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine,
      University of Malawi, Blantyre, Malawi. ssalimu@mlw.mw.
FAU - Nyondo-Mipando, Alinane Linda
AU  - Nyondo-Mipando AL
AD  - Department of Health Systems and Policy, School of Public Health and Family
      Medicine, College of Medicine, Private Bag 360, Blantyre, Malawi.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200603
PL  - England
TA  - Subst Abuse Treat Prev Policy
JT  - Substance abuse treatment, prevention, and policy
JID - 101258060
SB  - IM
MH  - Adolescent
MH  - Adolescent Behavior
MH  - Alcoholic Beverages/*legislation & jurisprudence
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Malawi
MH  - Male
MH  - Marketing/statistics & numerical data
MH  - Motivation
MH  - Personality
MH  - Product Packaging/statistics & numerical data
MH  - Sex Factors
MH  - Underage Drinking/*prevention & control/psychology/*statistics & numerical data
PMC - PMC7271476
OTO - NOTNLM
OT  - *Accessibility
OT  - *Adolescents
OT  - *Alcohol policy
OT  - *Alcohol sachets
OT  - *Availability
OT  - *Role modelling
OT  - *Snow ball sampling
EDAT- 2020/06/05 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
AID - 10.1186/s13011-020-00280-8 [doi]
AID - 10.1186/s13011-020-00280-8 [pii]
PST - epublish
SO  - Subst Abuse Treat Prev Policy. 2020 Jun 3;15(1):38. doi:
      10.1186/s13011-020-00280-8.


PMID- 32493391
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jun 3
TI  - Post-incident reviews-a gift to the Ward or just another procedure? Care
      providers' experiences and considerations regarding post-incident reviews after
      restraint in mental health services. A qualitative study.
PG  - 499
LID - 10.1186/s12913-020-05370-8 [doi]
AB  - Public guidelines in many western countries recommend post-incident reviews
      (PIRs) with patients after restraint use in mental health care. PIRs are one of
      several elements of seclusion and restraint reduction in internationally used
      programmes. PIRs may improve restraint prevention, patients' recovery processes
      and care providers' ethical mindfulness. The knowledge base on PIRs is, however, 
      vague. This qualitative study explores professional care providers' experiences
      and considerations regarding PIRs that included patients after restraint use in a
      Norwegian context. METHODS: Within a phenomenological hermeneutical framework, 19
      multidisciplinary care providers were interviewed about their experiences and
      views regarding PIRs that included patients after restraint events. The
      interviews were performed over the period 2015-2016. Data analysis followed a
      data-driven stepwise approach in line with thematic content analysis. A group of 
      two patient consultants in mental health services, and one patient's next of kin,
      contributed with input regarding the interview guide and analysis process.
      RESULTS: Care providers experienced PIRs as having the potential to improve the
      quality of care through a) knowledge of other perspectives and solutions; b)
      increased ethical and professional awareness; and c) emotional and relational
      processing. However, the care providers considered that PIRs' potential could be 
      further exploited as they struggled to get hold on the patients' voices in the
      encounter. The care providers considered that issue to be attributable to the
      patients' conditions, the care providers' safety and skills and the
      characteristics of institutional and cultural conditions. CONCLUSION: Human care 
      philosophies and a framework of care ethics seem to be preconditions for
      promoting patients' active participation in PIRs after restraints. Patients'
      voices strengthen PIRs' potential to improve care and may also contribute to
      restraint prevention. To minimise the power imbalance in PIRs, patients'
      vulnerability, dependency and perceived dignity must be recognised. Patients'
      individual needs and preferences should be assessed and mapped when planning
      PIRs, particularly regarding location, time and preferred participants. Care
      providers must receive training to strengthen their confidence in conducting PIRs
      in the best possible way. Patients' experiences with PIRs should be explored,
      especially if participation by trusted family members, peers or advocates may
      support the patients in PIRs.
FAU - Hammervold, Unn Elisabeth
AU  - Hammervold UE
AUID- ORCID: http://orcid.org/0000-0002-5622-1713
AD  - Department of Public Health, Faculty of Health Sciences, University of Stavanger,
      4036, Stavanger, Norway. unn.hammervold@uis.no.
FAU - Norvoll, Reidun
AU  - Norvoll R
AD  - Work Research Institute, Oslo Metropolitan University, Oslo, Norway.
FAU - Vevatne, Kari
AU  - Vevatne K
AD  - Department of care and ethics, Faculty of Health Sciences, University of
      Stavanger, Stavanger, Norway.
FAU - Sagvaag, Hildegunn
AU  - Sagvaag H
AD  - Department of Public Health, Faculty of Health Sciences, University of Stavanger,
      4036, Stavanger, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Female
MH  - Health Personnel/*psychology/statistics & numerical data
MH  - Hospital Units
MH  - Hospitals, University
MH  - Humans
MH  - Male
MH  - *Mental Health Services
MH  - Norway
MH  - Qualitative Research
MH  - Restraint, Physical/*adverse effects
MH  - *Risk Management
PMC - PMC7268524
OTO - NOTNLM
OT  - Care ethics
OT  - Care philosophy
OT  - Debriefing
OT  - Mental health
OT  - Participation
OT  - Post-incident reviews
OT  - Restraint
OT  - Staff experiences
EDAT- 2020/06/05 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12913-020-05370-8 [doi]
AID - 10.1186/s12913-020-05370-8 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 Jun 3;20(1):499. doi: 10.1186/s12913-020-05370-8.


PMID- 32493383
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220414
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 3
TI  - MOdified DIagnostic strateGy to safely ruLe-out pulmonary embolism In the
      emergency depArtment: study protocol for the Non-Inferiority MODIGLIANI cluster
      cross-over randomized trial.
PG  - 458
LID - 10.1186/s13063-020-04379-y [doi]
AB  - INTRODUCTION: In the work-up strategy for pulmonary embolism (PE) in the ED, the 
      recently introduced YEARS rule allows the raising of the D-dimer threshold to
      1000 ng/ml in patients with no signs of deep venous thrombosis and no hemoptysis 
      and in whom PE is not the most likely diagnosis. However, this decision rule has 
      never been prospectively compared to the usual strategy. Furthermore, it is
      unclear if the YEARS rule can be used on top of the Pulmonary Embolism Rule-out
      Criteria (PERC). We aim to assess the non-inferiority of YEARS compared to
      current guidelines to rule out PE among PERC-positive ED patients with suspicion 
      of PE. METHODS/DESIGN: The MODIGLIANI study is a multicenter, European,
      non-inferiority, cluster-randomized, two periods cross-over, controlled trial.
      Each center will be randomized for the sequence of two 4-month periods:
      intervention (MOdified Diagnostic Strategy: MODS) followed by control (usual
      care), or control followed by intervention with 1 month of "wash-out" between the
      two periods. In the control period, the threshold will be as usual (500 ng/ml for
      patients aged 50 years or younger and age x 10 for older patients). In the MODS
      period, the threshold of D-dimers to rule out PE will be raised to 1000 ng/ml if 
      no item of the YEARS score is present or will remain unchanged otherwise.
      Patients will be included if they have a suspicion of PE, defined as chest pain, 
      dyspnea, or syncope. Non-inclusion criteria comprise a high clinical probability 
      of PE or PERC-negative patients with low clinical probability. ETHICS AND
      DISSEMINATION: The study has received the following approvals: Comite de
      protection des personnes Ile de France XI (France) and Comite de Etica de la
      Investigacion con medicamentos del Hospital Clinic de Barcelona (Spain). Results 
      will be made available to all included participants and other researchers. TRIAL 
      REGISTRATION: ClinicalTrials.gov, NCT04032769. Registered on 24 July 2019.
FAU - Philippon, Anne-Laure
AU  - Philippon AL
AD  - Emergency department, Hopital Pitie-Salpetriere, Assistance Publique - Hopitaux
      de Paris, APHP, Sorbonne Universite, Paris, France.
FAU - Dumont, Margaux
AU  - Dumont M
AD  - Emergency department, Hopital Pitie-Salpetriere, Assistance Publique - Hopitaux
      de Paris, APHP, Sorbonne Universite, Paris, France.
FAU - Jimenez, Sonia
AU  - Jimenez S
AD  - Emergency Department, Hospital Clinic, Barcelona, Spain.
FAU - Salhi, Sarah
AU  - Salhi S
AD  - Department of clinical pharmacology and Clinical Research Platform of East of
      Paris (URCEST-CRC-CRB), APHP.Sorbonne Universite, hopital Saint Antoine, Paris,
      France.
FAU - Cachanado, Marine
AU  - Cachanado M
AD  - Department of clinical pharmacology and Clinical Research Platform of East of
      Paris (URCEST-CRC-CRB), APHP.Sorbonne Universite, hopital Saint Antoine, Paris,
      France.
FAU - Durand-Zaleski, Isabelle
AU  - Durand-Zaleski I
AD  - Sorbonne Universite, Paris, France.
AD  - Health economics research unit, Hopital de l'Hotel Dieu APHP, Paris, France.
FAU - Simon, Tabassome
AU  - Simon T
AD  - Department of clinical pharmacology and Clinical Research Platform of East of
      Paris (URCEST-CRC-CRB), APHP.Sorbonne Universite, hopital Saint Antoine, Paris,
      France.
AD  - Sorbonne Universite, Paris, France.
FAU - Freund, Yonathan
AU  - Freund Y
AD  - Emergency department, Hopital Pitie-Salpetriere, Assistance Publique - Hopitaux
      de Paris, APHP, Sorbonne Universite, Paris, France. yonathanfreund@gmail.com.
AD  - Sorbonne Universite, Paris, France. yonathanfreund@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04032769
GR  - PHRCN-18-0311/Ministere de l'Enseignement Superieur, de la Recherche Scientifique
      et des Technologies de l'Information et de la Communication
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (fibrin fragment D)
SB  - IM
MH  - Cross-Over Studies
MH  - *Decision Support Techniques
MH  - *Emergency Service, Hospital
MH  - Equivalence Trials as Topic
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - France
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Pulmonary Embolism/*diagnosis
MH  - Risk
MH  - Spain
PMC - PMC7268276
OTO - NOTNLM
OT  - D-dimers
OT  - Emergency department
OT  - Pulmonary embolism
EDAT- 2020/06/05 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - 10.1186/s13063-020-04379-y [doi]
AID - 10.1186/s13063-020-04379-y [pii]
PST - epublish
SO  - Trials. 2020 Jun 3;21(1):458. doi: 10.1186/s13063-020-04379-y.


PMID- 32493374
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 3
TI  - Ethical arguments against coercing provider participation in MAiD (medical
      assistance in dying) in Ontario, Canada.
PG  - 46
LID - 10.1186/s12910-020-00486-2 [doi]
AB  - It has historically been a crime in Canada to provide assistance to someone in
      ending their own life, however, this paradigm was inverted in 2015 when the
      Supreme Court of Canada (SCC) ruled that restrictions on this practice, within
      certain defined parameters, violated the right to life, liberty, and security of 
      the person. Subsequently, recent legal and policy decisions have highlighted the 
      issue of how to balance the rights of individuals to access MAiD with the rights 
      of care providers to exercise conscience-based objections to participation in
      this process. We argue that there is significant harm and ethical hazard in
      disregarding individual and institutional rights to conscientious objection and
      since measures less coercive than the threat of regulatory or economic sanctions 
      do exist, there should be no justification for such threats in Canada's health
      care systems.
FAU - Carpenter, Travis
AU  - Carpenter T
AUID- ORCID: 0000-0002-0916-2714
AD  - Unity Health Toronto, Toronto, Ontario, Canada.
      travis@carpentermedicalcorporation.com.
AD  - Department of Medicine, University of Toronto, 30 The Queensway, Toronto,
      Ontario, M6R 1B5, Canada. travis@carpentermedicalcorporation.com.
FAU - Vivas, Lucas
AU  - Vivas L
AD  - William Osler Health System, Brampton, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Canada
MH  - Conscience
MH  - Dissent and Disputes
MH  - Humans
MH  - Medical Assistance
MH  - Ontario
MH  - *Suicide, Assisted
PMC - PMC7271423
OTO - NOTNLM
OT  - *Assisted dying
OT  - *Conscience rights
OT  - *Conscientious objection
OT  - *Euthanasia
OT  - *Medical assistance in dying
OT  - *Right to die
EDAT- 2020/06/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00486-2 [doi]
AID - 10.1186/s12910-020-00486-2 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jun 3;21(1):46. doi: 10.1186/s12910-020-00486-2.


PMID- 32493373
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 3
TI  - Exploring the evolution of a dental code of ethics: a critical discourse
      analysis.
PG  - 45
LID - 10.1186/s12910-020-00485-3 [doi]
AB  - BACKGROUND: What can the analysis of the evolution of a code of ethics tell us
      about the dental profession and the association that develops it? The
      establishment of codes of ethics are foundational events in the social history of
      a profession. Within these documents it is possible to find statements of values 
      and culture that serve a variety of purposes. Codes of ethics in dentistry have
      not frequently presented as the subjects of analyses despite containing rich
      information about the priorities and anxieties within the profession's membership
      at the time that the code was written. MAIN TEXT: This essay uses critical
      discourse analysis to explore the 2012 and 2018 versions of the Code of Ethics
      produced by the New South Wales Branch of the Australian Dental Association. This
      method of discourse analysis examines contradictions between the discourses
      within the codes and how these relate to broader social realties that surround
      the dental profession in New South Wales. By analysing the 2012 and 2018 codes
      together, it is possible to understand how the dental profession views its
      commitments to society as established through the social contract. Through this
      assessment, it will be demonstrated that both codes suffer due to their failure
      to consider the public as a key stakeholder in the creation and curation of the
      Code of Ethics and how this this relates intimately with the social contract
      between the profession and the public. CONCLUSION: Without the public being the
      central consideration, both codes amount to declarations of professional
      privilege and dominance. Although the more recent 2018 Code of Ethics
      demonstrates insight into the changes in public trust placed in the professions, 
      this analysis shows that that the current code of ethics is still reluctant to
      recognise and engage with the public as an equal stakeholder in the planning and 
      provision of oral health care and the development of the profession's values and 
      cultural trajectory.
FAU - Holden, Alexander C L
AU  - Holden ACL
AUID- ORCID: 0000-0002-5698-8973
AD  - Faculty of Medicine and Health, The University of Sydney School of Dentistry,
      2-18 Chalmers Street, Surry Hills, NSW, 2010, Australia.
      alexander.holden@sydney.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Australia
MH  - *Codes of Ethics
MH  - *Ethics, Dental
MH  - Humans
MH  - New South Wales
PMC - PMC7268522
OTO - NOTNLM
OT  - *Code of ethics
OT  - *Critical discourse analysis
OT  - *Dentistry
OT  - *Professionalism
OT  - *Sociology
EDAT- 2020/06/05 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/09/24 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00485-3 [doi]
AID - 10.1186/s12910-020-00485-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Jun 3;21(1):45. doi: 10.1186/s12910-020-00485-3.


PMID- 32492861
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20201110
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 11
DP  - 2020 Jun 1
TI  - A Study on the Current Status and Improvement of the Digital Divide among Older
      People in Korea.
LID - E3917 [pii]
LID - 10.3390/ijerph17113917 [doi]
AB  - In today's knowledge- and information-based society, information literacy and
      information utilization skills are indicators of one's competitiveness, and play 
      a very important role in various fields (e.g., in one's career, hobbies, as well 
      as in daily life). In particular, information literacy and information
      utilization skills in older people are becoming essential for them to lead
      affluent lives. Moreover, information and communication technology is essential
      form of technology that can allow the elderly to ask for help in cases of
      emergency, as well as in daily life. Meanwhile, according to a recent Korean
      national statistical index, the digital divide among older people is more serious
      than that of the general public. The purpose of this paper is to statistically
      show that the digital divide among older people is more serious than other
      information-weak groups, as well as the general public. In addition, the purpose 
      of this study is to identify the priorities that affect the digital divide among 
      the three elements of the digital divide (digital access, digital capacity, and
      digital utilization) for older people. Based on that, we propose a variety of
      ways to solve the digital divide for older people. This study is expected to be
      widely used in future research and policies as a basis for solving the digital
      divide among older people.
FAU - Jun, Woochun
AU  - Jun W
AD  - Dept. of Computer Education, Seoul National University of Education, Seoul 06639,
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Aged
MH  - Communication
MH  - *Digital Divide
MH  - Humans
MH  - Republic of Korea
PMC - PMC7312514
OTO - NOTNLM
OT  - *digital divide
OT  - *disabled people
OT  - *farmers and fishermen
OT  - *information ethics
OT  - *information literacy
OT  - *information utilization skills
OT  - *low-income people
OT  - *older people
COIS- The author declares no conflict of interest.
EDAT- 2020/06/05 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/05 06:00
PHST- 2020/03/29 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/05/23 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - ijerph17113917 [pii]
AID - 10.3390/ijerph17113917 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Jun 1;17(11). pii: ijerph17113917. doi:
      10.3390/ijerph17113917.


PMID- 32492759
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20220707
IS  - 1941-2452 (Electronic)
IS  - 0884-5336 (Linking)
VI  - 35
IP  - 4
DP  - 2020 Aug
TI  - Ethical Framework for Nutrition Support Resource Allocation During Shortages:
      Lessons From COVID-19.
PG  - 599-605
LID - 10.1002/ncp.10500 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has impacted all aspects of our 
      population. The "Troubling Trichotomy" of what can be done technologically, what 
      should be done ethically, and what must be done legally is a reality during these
      unusual circumstances. Recent ethical considerations regarding allocation of
      scarce resources, such as mechanical ventilators, have been proposed. These can
      apply to other disciplines such as nutrition support, although decisions
      regarding nutrition support have a diminished potential for devastating outcomes.
      The principal values and goals leading to an ethical framework for a uniform,
      fair, and objective approach are reviewed in this article, with a focus on
      nutrition support. Some historical aspects of shortages in nutrition supplies and
      products during normal circumstances, as well as others during national crises,
      are outlined. The development and implementation of protocols using a scoring
      system seems best addressed by multidisciplinary ethics and triage committees
      with synergistic but disparate functions. Triage committees should alleviate the 
      burdens of unilateral decisions by the healthcare team caring for patients. The
      treating team should make every attempt to have patients and the public at large 
      update or execute/develop advance directives. Legal considerations, as the third 
      component of the Troubling Trichotomy, are of some concern when rationing care.
      The likelihood that criminal or civil charges could be brought against individual
      healthcare professionals or institutions can be minimized, if fair protocols are 
      uniformly applied and deliberations well documented.
CI  - (c) 2020 American Society for Parenteral and Enteral Nutrition.
FAU - Barrocas, Albert
AU  - Barrocas A
AUID- ORCID: https://orcid.org/0000-0001-8506-7244
AD  - Tulane University School of Medicine, New Orleans, Louisiana, USA.
FAU - Schwartz, Denise Baird
AU  - Schwartz DB
AUID- ORCID: https://orcid.org/0000-0001-9895-9073
AD  - Bioethics Committee, Providence Saint Joseph Medical Center, Burbank, California,
      USA.
FAU - Hasse, Jeanette M
AU  - Hasse JM
AUID- ORCID: https://orcid.org/0000-0003-0008-0576
AD  - Baylor University Medical Center, Baylor Simmons Transplant Institute, Dallas,
      Texas, USA.
FAU - Seres, David S
AU  - Seres DS
AUID- ORCID: https://orcid.org/0000-0001-7492-0836
AD  - Department of Medicine, Columbia University Medical Center, New York, New York,
      USA.
FAU - Mueller, Charles M
AU  - Mueller CM
AD  - Didactic Program in Dietetics, Department of Nutrition Food Studies, New York
      University/Steinhardt, New York, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - United States
TA  - Nutr Clin Pract
JT  - Nutrition in clinical practice : official publication of the American Society for
      Parenteral and Enteral Nutrition
JID - 8606733
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Nutritional Support/*ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Triage/*ethics
PMC - PMC7300651
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - coronavirus
OT  - enteral nutrition
OT  - ethics
OT  - nutrition support
OT  - parenteral nutrition
OT  - resource allocation
EDAT- 2020/06/04 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 10.1002/ncp.10500 [doi]
PST - ppublish
SO  - Nutr Clin Pract. 2020 Aug;35(4):599-605. doi: 10.1002/ncp.10500. Epub 2020 Jun 3.


PMID- 32492144
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20210110
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 3
DP  - 2020 Jul 6
TI  - The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials.
PG  - 351-355
LID - 10.1093/infdis/jiaa303 [doi]
AB  - In response to provocative comments by 2 European clinicians and scientists, the 
      World Health Organization Director General has declared that Africa will not host
      COVID-19 vaccine trials. Such a stance risks stigmatizing COVID-19 vaccine trials
      in Africa and depriving Africa of critical research. To the contrary, there is a 
      critical need for Africa to host COVID-19 vaccine trials on public health,
      scientific, and ethics grounds.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Singh, Jerome Amir
AU  - Singh JA
AD  - Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Africa/epidemiology
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - *Clinical Trials as Topic/ethics
MH  - Coronavirus Infections/epidemiology/ethnology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/ethnology/*prevention & control
MH  - Prevalence
MH  - Public Health
MH  - *Viral Vaccines
MH  - World Health Organization
PMC - PMC7313920
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *global health
OT  - *public health
OT  - *vaccine trials
EDAT- 2020/06/04 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 5850913 [pii]
AID - 10.1093/infdis/jiaa303 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Jul 6;222(3):351-355. doi: 10.1093/infdis/jiaa303.


PMID- 32491973
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20220415
IS  - 1552-5732 (Electronic)
IS  - 0890-3344 (Linking)
VI  - 36
IP  - 3
DP  - 2020 Aug
TI  - Implementation of the Reimbursement Cost of Human-Milk-Based Neonatal Therapy in 
      Polish Health Care Service : Practical and Ethical Background.
PG  - 426-435
LID - 10.1177/0890334420909815 [doi]
AB  - BACKGROUND: A human-milk-based diet is the best option for nutritional therapy
      for preterm and/or sick newborns. RESEARCH AIM: The study aims were to
      restructure the reimbursement rates to hospitals in Poland for infants' tube
      feedings to favor the use of donor human milk over formula for newborns who
      required supplementation of expressed mother's milk and evaluate the results of
      the financing change during the first year of implementation (2018). METHODS:
      Financial data from hospitals were collected (2015-2016) by the Human Milk Bank
      Foundation using a data sheet designed by the Agency for Health Technology
      Assessment and Tariff System. We used data to restructure the reimbursement rates
      to hospitals for infants' tube feedings and implemented the changes in late 2017.
      The National Health Fund was requested to share reported data in 2018 concerning 
      tube feeding services. RESULTS: More than half (61%) of NICUs introduced human
      milk tube feeding for newborns. It was provided to participants (N = 5,530), most
      frequently to seriously ill preterm infants (66.6%). Of these infants, 2,323 were
      fed donor human milk. Only 1,925 newborns received formula tube feeding. However,
      there were large differences in frequency of services reported among various
      parts of the country. CONCLUSIONS: Based on our knowledge, Poland is the only
      European country where the reimbursement cost for human-milk-based nutritional
      therapy has been implemented in a manner intended to increase the quality of
      health care services for preterm newborns. Equal reimbursement for expressed
      mother's milk and donor milk did not appear to cause overuse of donor milk based 
      on our analysis of the 2018 data.
FAU - Wesolowska, Aleksandra
AU  - Wesolowska A
AUID- ORCID: https://orcid.org/0000-0002-7270-5910
AD  - 37803 Laboratory of Human Milk and Lactation Research at Regional Human Milk Bank
      in Holy Family Hospital, Medical University of Warsaw, Department of Medical
      Biology, Warsaw, Poland.
AD  - Human Milk Bank Foundation, Warsaw, Poland.
FAU - Bernatowicz-Lojko, Urszula
AU  - Bernatowicz-Lojko U
AD  - Human Milk Bank Foundation, Warsaw, Poland.
AD  - 4960449770 Human Milk Bank, Ludwik Rydygier' Provincial Polyclinical Hospital in 
      Torun, Poland.
AD  - Department of Midwifery, Centre of Postgraduate Medical Education, Warsaw,
      Poland.
FAU - Sinkiewicz-Darol, Elena
AU  - Sinkiewicz-Darol E
AUID- ORCID: https://orcid.org/0000-0002-4123-866X
AD  - 4960449770 Human Milk Bank, Ludwik Rydygier' Provincial Polyclinical Hospital in 
      Torun, Poland.
FAU - Pawlus, Beata
AU  - Pawlus B
AD  - Human Milk Bank Foundation, Warsaw, Poland.
AD  - 111473 Regional Human Milk Bank, Neonatal Unit, Holy Family Specialist Hospital, 
      Warsaw, Poland.
FAU - Golicki, Dominik
AU  - Golicki D
AD  - Department of Experimental and Clinical Pharmacology, Medical University of
      Warsaw, Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - United States
TA  - J Hum Lact
JT  - Journal of human lactation : official journal of International Lactation
      Consultant Association
JID - 8709498
MH  - Delivery of Health Care/methods/trends
MH  - Female
MH  - Health Care Costs/*standards/statistics & numerical data
MH  - Humans
MH  - Infant
MH  - Infant Food/adverse effects/*economics/statistics & numerical data
MH  - Infant Nutritional Physiological Phenomena
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal
MH  - Male
MH  - Milk Banks/economics/trends
MH  - *Milk, Human
MH  - Poland
MH  - Reimbursement Mechanisms/*economics/trends
OTO - NOTNLM
OT  - breastfeeding
OT  - health service research
OT  - human milk
OT  - infant nutrition
OT  - milk bank
OT  - prematurity
EDAT- 2020/06/04 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 10.1177/0890334420909815 [doi]
PST - ppublish
SO  - J Hum Lact. 2020 Aug;36(3):426-435. doi: 10.1177/0890334420909815. Epub 2020 Jun 
      3.


PMID- 32491963
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20201218
IS  - 1545-0821 (Electronic)
IS  - 0895-9420 (Linking)
VI  - 32
IP  - 4-5
DP  - 2020 Jul-Oct
TI  - Six Propositions against Ageism in the COVID-19 Pandemic.
PG  - 515-525
LID - 10.1080/08959420.2020.1770032 [doi]
AB  - The risk of developing severe illness from COVID-19 and of dying from it
      increases with age. This statistical association has led to numerous highly
      problematic policy suggestions and comments revealing underlying ageist attitudes
      and promoting age discrimination. Such attitudes are based on negative
      stereotypes on the health and functioning of older adults. As a result, the lives
      of older people are disvalued, including in possible triage situations and in the
      potential limitation of some measures against the spread of the pandemic to older
      adults. These outcomes are unjustified and unethical. We develop six propositions
      against the ageism underlying these suggestions to spur a more adequate response 
      to the current pandemic in which the needs and dignity of older people are
      respected.
FAU - Ehni, Hans-Joerg
AU  - Ehni HJ
AD  - Professor, Institute for Ethics and the History of Medicine, University of
      Tuebingen , Tuebingen, Germany.
FAU - Wahl, Hans-Werner
AU  - Wahl HW
AD  - Professor, Network of Aging Research, Heidelberg University , Heidelberg,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - England
TA  - J Aging Soc Policy
JT  - Journal of aging & social policy
JID - 8914669
MH  - Ageism/*psychology
MH  - Aging
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communication
MH  - Computers
MH  - Coronavirus Infections/*epidemiology
MH  - Health Status
MH  - Health Status Disparities
MH  - Healthcare Disparities/ethics
MH  - Humans
MH  - Pandemics
MH  - Paternalism/ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - Policy
MH  - SARS-CoV-2
MH  - Stereotyping
MH  - User-Computer Interface
OTO - NOTNLM
OT  - COVID-19
OT  - ageism
OT  - digitalization
OT  - ethics of aging
OT  - social distancing
OT  - triage
EDAT- 2020/06/04 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 10.1080/08959420.2020.1770032 [doi]
PST - ppublish
SO  - J Aging Soc Policy. 2020 Jul-Oct;32(4-5):515-525. doi:
      10.1080/08959420.2020.1770032. Epub 2020 Jun 3.


PMID- 32491125
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Linking)
VI  - 28
DP  - 2020
TI  - Interobserver analysis of safety practices and behaviors adopted by elderly
      people to prevent falls.
PG  - e3268
LID - S0104-11692020000100332 [pii]
LID - 10.1590/1518-8345.3209.3268 [doi]
AB  - OBJECTIVE: determine the psychometric properties of the safety practices and
      behaviors dimension of the Scale of Practices and Behaviors of Institutionalized 
      Elderly People to Prevent Falls in a sample of elderly people with cognitive
      decline. METHOD: methodological study, with a quantitative approach, to assess
      the psychometric properties of the mentioned scale in a sample with 102 elderly
      people with cognitive decline who lived in two long-term care institutions for
      the public in this age group. Internal consistency evaluation was carried out by 
      calculating the Cronbach's alpha coefficient; interobserver reliability was
      expressed by Cohen's kappa coefficient; and temporal stability, by obtaining
      Spearman correlation. Compliance with all ethical procedures was observed.
      RESULTS: the dimension of safety practices and behaviors showed alpha = 0.895 for
      its 11 items. Seven out of the 11 items reached good to excellent agreement among
      the experts for interobserver reliability. Kappa index values indicated that the 
      instrument is valid and reliable. Safety practices and behaviors were influenced 
      by institutionalization time, being at least 85 years old, and gait skills.
      CONCLUSION: the results pointed out that the instrument has good reproducibility 
      and is valid and reliable, which allows its use in clinical practice in elderly
      people with cognitive decline as well as in research.
FAU - Baixinho, Cristina Rosa Soares Lavareda
AU  - Baixinho CRSL
AD  - Fundamentos de Enfermagem, Escola Superior de Enfermagem de Lisboa, Lisboa, Lx,
      Portugal.
FAU - Dixe, Maria Dos Anjos Coelho Rodrigues
AU  - Dixe MDACR
AD  - Escola Superior de Saude, Instituto Politecnico de Leiria, Leiria, Lr, Portugal.
FAU - Madeira, Carla
AU  - Madeira C
AD  - Medicina, Hospital de VIla Franca de Xira, Vila Franca de Xira, VFX, Portugal.
FAU - Alves, Silvia
AU  - Alves S
AD  - Unidade de Cuidados Intensivos, Hospital de VIla Franca de Xira, Vila Franca de
      Xira, VFX, Portugal.
FAU - Henriques, Maria Adriana
AU  - Henriques MA
AD  - Enfermagem Comunitaria, Escola Superior de Enfermagem de Lisboa, Lisboa, LX,
      Portugal.
LA  - por
LA  - spa
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20200601
PL  - Brazil
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Accidental Falls/*prevention & control
MH  - Aged
MH  - Aged, 80 and over
MH  - Behavior
MH  - Female
MH  - *Geriatric Assessment
MH  - Geriatric Psychiatry
MH  - Humans
MH  - Institutionalization
MH  - Male
MH  - Observer Variation
MH  - Psychiatric Status Rating Scales/*standards
MH  - Psychometrics/methods
MH  - Reproducibility of Results
PMC - PMC7266635
EDAT- 2020/06/04 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/04 06:00
PHST- 2018/11/23 00:00 [received]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - S0104-11692020000100332 [pii]
AID - 10.1590/1518-8345.3209.3268 [doi]
PST - ppublish
SO  - Rev Lat Am Enfermagem. 2020;28:e3268. doi: 10.1590/1518-8345.3209.3268. Epub 2020
      Jun 1.


PMID- 32490632
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 120
IP  - 4
DP  - 2020
TI  - [Ethics and medicine].
PG  - 145-149
LID - 10.17116/jnevro2020120041145 [doi]
AB  - The article deals with the problem of ethical constituent both in medical and
      teaching practice. As to the medical practice, its ethical component is treated
      as an obligatory one, no matter what physician specialty is. That is why, the
      importance of ethical aspects in medicine increases greatly now. Neurology is one
      of the quickly developing disciplines, new data being obtained on etiology,
      pathogenesis, diagnostics and treatment of diseases previously considered
      incurable. Clinical tests of new drugs demand patients Informed Consent, this
      being one of the important ethical aspects of medical practice. The importance of
      the problem is illustrated by the examples of ethically unacceptable experiments 
      on human beings in the United States after the Second World War and The Nuremberg
      Tribunal. Ethical issues that arise in the teaching process are considered.
      Ethical problems arising from the use of electronic technique of medical
      information storage are also analyzed. As to the teaching practice in higher
      medical institutions, its main ethical constituent concerns moral aspects of
      medical students training.
FAU - Damulin, I V
AU  - Damulin IV
AUID- ORCID: 0000-0003-4826-5537
AD  - RUDN University, Moscow, Russia.
AD  - Sechenov First Moscow State Medical University (Sechenov University), Moscow,
      Russia.
FAU - Strutzenko, A A
AU  - Strutzenko AA
AUID- ORCID: 0000-0002-9758-8087
AD  - RUDN University, Moscow, Russia.
FAU - Konotop, A V
AU  - Konotop AV
AUID- ORCID: 0000-0003-4139-8417
AD  - Strategic Missile Troops Military Academy, Moscow, Russia.
LA  - rus
PT  - Journal Article
TT  - Etika i meditsina.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
SB  - IM
MH  - Ethics, Medical
MH  - Humans
MH  - Informed Consent
MH  - *Neurology
MH  - *Students, Medical
OTO - NOTNLM
OT  - ethic in neurology
OT  - humanistic traditions
OT  - pedagogical component
OT  - system of values
EDAT- 2020/06/04 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.17116/jnevro2020120041145 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(4):145-149. doi:
      10.17116/jnevro2020120041145.


PMID- 32490277
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2421-4248 (Electronic)
IS  - 1121-2233 (Linking)
VI  - 61
IP  - 1
DP  - 2020 Mar
TI  - The barriers to the full implementation of strategic purchasing and the role of
      health policy and decision-makers: past, current status, ethical aspects and
      future challenges.
PG  - E119-E124
LID - 10.15167/2421-4248/jpmh2020.61.1.1439 [doi]
AB  - Healthcare systems are complex, multi-level, highly integrated organizations,
      comprising of different professional figures, institutions, and resources. Such
      breadth and complexity reflect the multi-dimensionality of the concept of health,
      which implies the adoption of a holistic approach. Health, rather than merely
      being the absence of disorders or infirmity, is a highly dynamic state, which
      represents the abilities of an individual to cope with adverse social, physical
      and emotional/psychological events and conditions, continuously adapting to them.
      Ensuring an adequate health state is one of the most important concerns, and the 
      healthcare systems are called to renew themselves in order to meet with the new
      challenges and health needs. Throughout the last decades, due to demographic
      shifts and transitions, epidemiological and societal changes, technological
      achievements and scientific advancements, healthcare systems have undergone an
      extensive series of reform plans. Therefore, health policy- and decision-makers
      have made efforts to develop and implement initiatives for preserving the quality
      of the healthcare provisions. Strategic purchasing is an approach of purchasing
      that takes into account several health-related issues such as a proper,
      comprehensive planning of service delivery, the design and selection of the best 
      packages of services and provisions, the appropriate selection of providers and
      the allocation of economical and financial incentives to provide better services 
      and to motivate managers to adopt appropriate policies to implement strategic
      purchasing. Here, we intend to consider the various dimensions and aspects that
      can be effective in strategic purchasing, as well as the main barriers and
      obstacles that hinder its full implementation.
CI  - (c)2020 Pacini Editore SRL, Pisa, Italy.
FAU - Behzadifar, M
AU  - Behzadifar M
AD  - Social Determinants of Health Research Center, Lorestan University of Medical
      Sciences, Khorramabad, Iran.
FAU - Martini, M
AU  - Martini M
AD  - Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
AD  - UNESCO Chair, "Health Anthropology Biosphere and Healing Systems," University of 
      Genoa, Italy.
FAU - Behzadifar, M
AU  - Behzadifar M
AD  - Health Management and Economics Research Center, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Bakhtiari, A
AU  - Bakhtiari A
AD  - Department of Health Management and Economics, School of Public Health, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Bragazzi, N L
AU  - Bragazzi NL
AD  - UNESCO Chair, "Health Anthropology Biosphere and Healing Systems," University of 
      Genoa, Italy.
AD  - Department of Mathematics and Statistics, York University, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200402
PL  - Italy
TA  - J Prev Med Hyg
JT  - Journal of preventive medicine and hygiene
JID - 9214440
SB  - IM
MH  - *Administrative Personnel
MH  - *Contract Services
MH  - Cost-Benefit Analysis
MH  - Delivery of Health Care/*economics/ethics
MH  - Health Policy/*economics
MH  - Humans
MH  - *Implementation Science
MH  - *Negotiating
MH  - *Quality of Health Care
PMC - PMC7225644
OTO - NOTNLM
OT  - Contracting and strategic purchasing
OT  - Cost-effectiveness
OT  - Healthcare services and provisions
OT  - Healthcare systems and organizations
OT  - Scientific evidence
EDAT- 2020/06/04 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2019/12/23 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - 10.15167/2421-4248/jpmh2020.61.1.1439 [doi]
PST - epublish
SO  - J Prev Med Hyg. 2020 Apr 2;61(1):E119-E124. doi:
      10.15167/2421-4248/jpmh2020.61.1.1439. eCollection 2020 Mar.


PMID- 32490276
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20220414
IS  - 2421-4248 (Electronic)
IS  - 1121-2233 (Linking)
VI  - 61
IP  - 1
DP  - 2020 Mar
TI  - The hepatitis C virus in Iran: health policy, historical, ethical issues and
      future challenges.
PG  - E109-E118
LID - 10.15167/2421-4248/jpmh2020.61.1.1438 [doi]
AB  - BACKGROUND: Hepatitis C infection (HCV) can have a harmful effect on the health
      of people and can impose relevant healthcare costs. The World Health Organization
      has identified the elimination of Hepatitis C by 2030 as an important goal for
      all countries. This study aimed to identify the HCV-related policies in Iran.
      METHODS: A qualitative approach was used for this study. Data was collected
      through a comprehensive search of documents and interviews with different
      stakeholders related to the HCV program. Data was analyzed and validated using
      content analysis based on the policy triangle framework. RESULTS: Our findings
      highlighted that certain social and cultural issues related to stigma can impact 
      on awareness-raising processes. It is also necessary to consider HCV directly in 
      the context of government policies. All relevant stakeholders should be included.
      Continued talks and interactions need to be made between them for the active
      participation of all actors. CONCLUSION: The findings of this study can provide
      useful information for improving, supporting and developing policy processes.
      Healthcare providers should address all aspects of the disease by 2030 in order
      to achieve the goal of HCV elimination. Evidence-based planning, support for
      up-to-date policies and resource mobilization are needed to achieve this
      ambitious goal.
CI  - (c)2020 Pacini Editore SRL, Pisa, Italy.
FAU - Behzadifar, M
AU  - Behzadifar M
AD  - Social Determinants of Health Research Center, Lorestan University of Medical
      Sciences, Khorramabad, Iran.
FAU - Azari, S
AU  - Azari S
AD  - Health Management and Economics Research Center, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Gorji, H A
AU  - Gorji HA
AD  - Department of Health Services Management, School of Health Management and
      Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
FAU - Martini, M
AU  - Martini M
AD  - Department of Health Sciences (DISSAL), University of Genoa, Italy.
AD  - UNESCO CHAIR "Anthropology of Health - Biosphere and Healing System", University 
      of Genoa, Italy.
FAU - Bragazzi, N L
AU  - Bragazzi NL
AD  - Department of Health Sciences (DISSAL), University of Genoa, Italy.
AD  - UNESCO CHAIR "Anthropology of Health - Biosphere and Healing System", University 
      of Genoa, Italy.
AD  - York University, Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - Italy
TA  - J Prev Med Hyg
JT  - Journal of preventive medicine and hygiene
JID - 9214440
SB  - IM
MH  - Adult
MH  - Attitude to Health
MH  - Disease Eradication
MH  - Female
MH  - Government Agencies
MH  - *Health Policy
MH  - Hepacivirus
MH  - Hepatitis C/diagnosis/drug therapy/*prevention & control
MH  - Humans
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Morals
MH  - Policy Making
MH  - Qualitative Research
MH  - *Social Stigma
MH  - *Stakeholder Participation
PMC - PMC7225642
OTO - NOTNLM
OT  - Ethical features
OT  - Hepatitis C virus
OT  - Policy analysis
OT  - Policy triangle framework
OT  - Stigma
EDAT- 2020/06/04 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2019/12/24 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - 10.15167/2421-4248/jpmh2020.61.1.1438 [doi]
PST - epublish
SO  - J Prev Med Hyg. 2020 Apr 2;61(1):E109-E118. doi:
      10.15167/2421-4248/jpmh2020.61.1.1438. eCollection 2020 Mar.


PMID- 32490097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-3409 (Electronic)
IS  - 2352-3409 (Linking)
VI  - 31
DP  - 2020 Aug
TI  - Ethical issues in poultry production - Datasets from a German consumer survey.
PG  - 105748
LID - 10.1016/j.dib.2020.105748 [doi]
AB  - The killing of day-old chicks is controversially discussed in poultry keeping,
      science, politics, and society. The present survey data contributes to understand
      consumers attitudes towards ethical issues in chicken production, especially the 
      killing practice and dual purpose chickens as alternative to avoid such killing. 
      Information on the various topics is provided: Consumer purchase pattern of eggs 
      and chicken meat, perception of animal welfare and protection issues, knowledge
      and perception of killing day-old chicks, attitudes towards dual purpose chickens
      as an alternative to killing day-old chicks, and socio-demographic data. The data
      set contains standardized responds of 1000 telephone interviews. These interviews
      were conducted with German consumers in spring 2016. The survey data were in part
      analysed with cluster analysis to categorize consumers according to their
      purchasing criteria for dual chicken products, and assessing which socio-economic
      variables best described each of the consumer categories. The survey raw data, a 
      file with the questionnaire and the codes, the analysed data, and additional
      files for understanding the cluster analysis are hosted in the public repository 
      Open Research Data https://www.doi.org/10.4228/ZALF.DK.106.
CI  - (c) 2020 The Authors.
FAU - Busse, Maria
AU  - Busse M
AD  - Leibniz Centre for Agricultural Landscape Research (ZALF), Eberswalder Strasse
      84, 15374 Muencheberg, Germany.
FAU - Kernecker, Maria Lee
AU  - Kernecker ML
AD  - Leibniz Centre for Agricultural Landscape Research (ZALF), Eberswalder Strasse
      84, 15374 Muencheberg, Germany.
FAU - Siebert, Rosemarie
AU  - Siebert R
AD  - Leibniz Centre for Agricultural Landscape Research (ZALF), Eberswalder Strasse
      84, 15374 Muencheberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Netherlands
TA  - Data Brief
JT  - Data in brief
JID - 101654995
PMC - PMC7256461
OTO - NOTNLM
OT  - Agriculture
OT  - Chicken husbandry
OT  - Consumer attitudes
OT  - Consumer clusters
OT  - Dual purpose chickens
OT  - Killing of day-old chicks
COIS- The authors declare that they have no known competing financial interests or
      personal relationships which have, or could be perceived to have, influenced the 
      work reported in this article.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.1016/j.dib.2020.105748 [doi]
AID - S2352-3409(20)30642-9 [pii]
AID - 105748 [pii]
PST - epublish
SO  - Data Brief. 2020 May 20;31:105748. doi: 10.1016/j.dib.2020.105748. eCollection
      2020 Aug.


PMID- 32490012
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - The use of physical restraints- knowledge and attitude of nurses of a tertiary
      care institute, Uttarakhand, India.
PG  - 77
LID - 10.4103/jehp.jehp_451_19 [doi]
AB  - BACKGROUND: The use of physical restraint in health-care settings is common and
      complex practice as it has physical, psychological, judicial, ethical, and moral 
      issues. Nurses are the key persons regarding physical restraint use in hospitals 
      as they are managing the whole process beginning with decision-making,
      application, caring the restrained patients. Lack of understanding and negative
      attitude of nurses in the use of physical restraints will hamper patient safety. 
      MATERIALS AND METHODS: A descriptive cross-sectional survey was carried out among
      110 rando mly selected nurses working in various departments at a tertiary care
      center Uttarakhand, India, in 2019. The data were collected using self-reported
      questionnaires consisting of three parts: demographic information, knowledge
      assessment questionnaire, and attitude rating scale regarding the use of
      restraints. Data were analyzed using the SPSS version 23 descriptive (frequency, 
      percentage, mean, mean percentage, and standard deviation) and inferential
      statistics (Mann-Whitney and independent t-test). RESULTS: The findings indicated
      that the mean knowledge and attitude of the nurses for physical restraints were
      13.9 +/- 1.9 (0-20 points), 35.2 +/- 4.7 (28-55 points), respectively. The study 
      revealed that there was no relationship found between knowledge and attitude of
      nurses regarding the use of physical restraints (r = 0.084). CONCLUSION: The
      knowledge and attitude regarding the use of restraints among nurses were found to
      be moderate. In-service training is highly recommended for nurses to improve the 
      knowledge and practices related to the use of physical restraint.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Mehrok, Sukhman
AU  - Mehrok S
AD  - Nursing Officer, Trauma Center, All India Institute of Medical Sciences,
      Rishikesh, Uttarakhand, India.
FAU - Belsiyal, C Xavier
AU  - Belsiyal CX
AD  - Assistant Professor, College of Nursing, All India Institute of Medical Sciences,
      Rishikesh, Uttarakhand, India.
FAU - Kamboj, Parveen
AU  - Kamboj P
AD  - Nursing Officer, Psychiatry Ward, All India Institute of Medical Sciences,
      Rishikesh, Uttarakhand, India.
FAU - Mery, Amali
AU  - Mery A
AD  - Tutor, College of Nursing, All India Institute of Medical Sciences, Rishikesh,
      Uttarakhand, India.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7255578
OTO - NOTNLM
OT  - Attitudes
OT  - health knowledge
OT  - nurses
OT  - physical
OT  - restraints
COIS- There are no conflicts of interest.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2019/08/03 00:00 [received]
PHST- 2019/12/28 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.4103/jehp.jehp_451_19 [doi]
AID - JEHP-9-77 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Mar 31;9:77. doi: 10.4103/jehp.jehp_451_19.
      eCollection 2020.


PMID- 32489987
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Spirituality and effective factors in education: A qualitative study.
PG  - 52
LID - 10.4103/jehp.jehp_430_19 [doi]
AB  - BACKGROUND AND AIM: Spirituality in education, as a necessity in improving the
      quality of teaching and learning, is affected by various personal, social,
      religious, and cultural factors. Since the identification of these factors can
      empower the faculties and facilitate the transfer of spiritual concepts through
      teaching, the aim of this study is explanation of the factors affecting the
      spirituality transfer in education process. MATERIALS AND METHODS: This
      qualitative content analysis approach study included 22 faculty members of
      medical universities, 25 faculty members of seminary, and 19 medical students
      interested in participating in the study. They were studied according to
      purposive sampling method. Data collection was done by interviewing a
      semi-structured questionnaire. Data were analyzed using conventional content
      analysis method. RESULTS: The factors influencing the spiritual transfer in
      teaching process were classified into two main forms of teacher-related factors
      and peripheral-related factors. Teacher-related factors include the teacher's
      insight and worldview, adherence to religious principles, belief in ethical
      virtues, the positive and constructive interaction of the teacher with the
      student, and the mastery of teaching skills. The peripheral-related factors
      include the highly skilled classrooms and the talented learners. CONCLUSION: The 
      intensification of the insight, religious worldview and the basic of beliefs,
      consolidating ethics and empowering faculty members in teaching skills along with
      building a positive and constructive relationship with the students, as well as
      institutionalizing spirituality as the inseparable teaching element can
      facilitate the transfer of spirituality concepts. More studies are needed in this
      regard.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Nasrollahi, Zahra
AU  - Nasrollahi Z
AD  - Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran.
FAU - Eskandari, Narges
AU  - Eskandari N
AD  - Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran.
FAU - Adaryani, Mohsen Rezaei
AU  - Adaryani MR
AD  - Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran.
FAU - Tasuji, Mohammad Hasan Haji Rahimian
AU  - Tasuji MHHR
AD  - Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7255563
OTO - NOTNLM
OT  - Medical students
OT  - qualitative research
OT  - spiritual content
OT  - spirituality in teaching
OT  - teachers
OT  - teaching
COIS- There are no conflicts of interest.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2019/09/12 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.4103/jehp.jehp_430_19 [doi]
AID - JEHP-9-52 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Mar 31;9:52. doi: 10.4103/jehp.jehp_430_19.
      eCollection 2020.


PMID- 32489918
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2223-4292 (Print)
IS  - 2223-4306 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May
TI  - Assessment of myocardial extracellular volume on body computed tomography in
      breast cancer patients treated with anthracyclines.
PG  - 934-944
LID - 10.21037/qims.2020.04.05 [doi]
AB  - BACKGROUND: Cancer treatment with anthracyclines may lead to an increased
      incidence of cardiac disease due to cardiotoxicity, as they may cause
      irreversible myocardial fibrosis. So far, the proposed methods for screening
      patients for cardiotoxicity have led to only limited success, while the analysis 
      of myocardial extracellular volume (mECV) at cardiac magnetic resonance (CMR) has
      shown promising results, albeit requiring a dedicated exam. Recent studies have
      found strong correlations between mECV values obtained through computed
      tomography (CT), and those derived from CMR. Thus, our purpose was to evaluate
      the feasibility of estimating mECV on thoracic contrast-enhanced CT performed for
      staging or follow-up in breast cancer patients treated with anthracyclines, and, 
      if feasible, to assess if a rise in mECV is associated with chemotherapy, and
      persistent over time. METHODS: After ethics committee approval, female patients
      with breast cancer who had undergone at least 2 staging or follow-up CT
      examinations at our institution, one before and one shortly after the end of
      chemotherapy including anthracyclines were retrospectively evaluated. Patients
      without available haematocrit, with artefacts in CT images, or who had undergone 
      radiation therapy of the left breast were excluded. Follow-up CT examinations at 
      longer time intervals were also analysed, when available. mECV was calculated on 
      scans obtained at 1, and 7 min after contrast injection. RESULTS: Thirty-two
      female patients (aged 57+/-13 years) with pre-treatment haematocrit 38%+/-4%, and
      ejection fraction 64%+/-6% were analysed. Pre-treatment mECV was 27.0%+/-2.9% at 
      1 min, and 26.4%+/-3.8% at 7 min, similar to values reported for normal subjects 
      in the literature. Post-treatment mECV (median interval: 89 days after treatment)
      was 31.1%+/-4.9%, and 30.0%+/-5.1%, respectively, values significantly higher
      than pre-treatment values at all times (P<0.005). mECV at follow-up (median
      interval: 135 days after post-treatment CT) was 31.0%+/-4.5%, and 27.7%+/-3.7%,
      respectively, without significant differences (P>0.548) when compared to
      post-treatment values. CONCLUSIONS: mECV values from contrast-enhanced CT scans
      could play a role in the assessment of myocardial condition in breast cancer
      patients undergoing anthracycline-based chemotherapy. CT-derived ECV could be an 
      imaging biomarker for the monitoring of therapy-related cardiotoxicity, allowing 
      for potential secondary prevention of cardiac damage, using data derived from an 
      examination that could be already part of patients' clinical workflow.
CI  - 2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.
FAU - Monti, Caterina Beatrice
AU  - Monti CB
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milan, Italy.
FAU - Zanardo, Moreno
AU  - Zanardo M
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milan, Italy.
FAU - Bosetti, Tommaso
AU  - Bosetti T
AD  - Medicine and Surgery School, Universita degli Studi di Milano, Via Festa del
      Perdono 7, 20122 Milan, Italy.
FAU - Ali, Marco
AU  - Ali M
AD  - Unit of Diagnostic Imaging and Stereotactic Radiosurgery, CDI Centro Diagnostico 
      Italiano S.p.A., Via Saint Bon 20, 20147 Milan, Italy.
AD  - Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato
      Milanese, Italy.
FAU - De Benedictis, Elena
AU  - De Benedictis E
AD  - Unit of Oncology I, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San
      Donato Milanese, Italy.
FAU - Luporini, Alberto
AU  - Luporini A
AD  - Unit of Oncology II, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San
      Donato Milanese, Italy.
FAU - Secchi, Francesco
AU  - Secchi F
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milan, Italy.
AD  - Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato
      Milanese, Italy.
FAU - Sardanelli, Francesco
AU  - Sardanelli F
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133 Milan, Italy.
AD  - Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato
      Milanese, Italy.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Quant Imaging Med Surg
JT  - Quantitative imaging in medicine and surgery
JID - 101577942
PMC - PMC7242290
OTO - NOTNLM
OT  - Extracellular space
OT  - anthracyclines
OT  - cardiotoxicity
OT  - myocardium
OT  - tomography, X-ray computed
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/qims.2020.04.05). FS reports he has
      received research grants from and he is member of the speakers' bureau for
      General Electric, Bayer, and Bracco; he is also member of the Bracco Advisory
      Group. The other authors have no conflicts of interest to declare.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.21037/qims.2020.04.05 [doi]
AID - qims-10-05-934 [pii]
PST - ppublish
SO  - Quant Imaging Med Surg. 2020 May;10(5):934-944. doi: 10.21037/qims.2020.04.05.


PMID- 32489755
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2189-7948 (Electronic)
IS  - 2189-7948 (Linking)
VI  - 21
IP  - 3
DP  - 2020 May
TI  - Ethical considerations of gene editing and genetic selection.
PG  - 37-47
LID - 10.1002/jgf2.321 [doi]
AB  - For thousands of years, humans have felt the need to understand the world around 
      them-and ultimately manipulate it to best serve their needs. There are always
      ethical questions to address, especially when the manipulation involves the human
      genome. There is currently an urgent need to actively pursue those conversations 
      as commercial gene sequencing and editing technologies have become more
      accessible and affordable. This paper explores the ethical considerations of gene
      editing (specifically germline) and genetic selection-including the hurdles
      researchers will face in trying to develop new technologies into viable
      therapeutic options.
CI  - (c) 2020 The Authors. Journal of General and Family Medicine published by John
      Wiley & Sons Australia, Ltd on behalf of Japan.
FAU - Rothschild, Jodie
AU  - Rothschild J
AUID- ORCID: https://orcid.org/0000-0002-1596-5409
AD  - Rothschild Biomedical Communications Seattle WA USA.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Japan
TA  - J Gen Fam Med
JT  - Journal of general and family medicine
JID - 101689875
PMC - PMC7260159
OTO - NOTNLM
OT  - ethical
OT  - ethics
OT  - gene editing
OT  - genetic selection
COIS- The authors have stated explicitly that there are no conflicts of interest in
      connection with this article.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.1002/jgf2.321 [doi]
AID - JGF2321 [pii]
PST - epublish
SO  - J Gen Fam Med. 2020 May 29;21(3):37-47. doi: 10.1002/jgf2.321. eCollection 2020
      May.


PMID- 32489418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - A systematic literature review of the ethics of conducting research in the
      humanitarian setting.
PG  - 27
LID - 10.1186/s13031-020-00282-0 [doi]
AB  - BACKGROUND: Research around humanitarian crises, aid delivery, and the impact of 
      these crises on health and well-being has expanded dramatically. Ethical issues
      around these topics have recently received more attention. We conducted a
      systematic literature review to synthesize the lessons learned regarding the
      ethics of research in humanitarian crises. METHODS: We conducted a systematic
      review using the Preferred Reporting Items for Systematic Reviews and
      Meta-analysis (PRISMA) guidelines to identify articles regarding the ethics of
      research in humanitarian contexts between January 1, 1997 and September 1, 2019. 
      We analyzed the articles to extract key themes and develop an agenda for future
      research. RESULTS: We identified 52 articles that matched our inclusion criteria.
      We categorized the article data into five categories of analysis: 32 were expert 
      statements, 18 were case studies, 11 contained original research, eight were
      literature reviews and three were book chapters. All included articles were
      published in English. Using a step-wise qualitative analysis, we identified 10
      major themes that encompassed these concepts and points. These major themes were:
      ethics review process (21 articles, [40.38%]); community engagement (15 articles 
      [28.85%]); the dual imperative, or necessity that research be both academically
      sound and policy driven, clinical trials in the humanitarian setting (13 articles
      for each, [25.0%)]; informed consent (10 articles [19.23%]); cultural
      considerations (6 articles, [11.54%]); risks to researchers (5 articles,
      [9.62%]); child participation (4 articles [7.69%]); and finally mental health,
      and data ownership (2 articles for each [3.85%]). CONCLUSIONS: Interest in the
      ethics of studying humanitarian crises has been dramatically increasing in recent
      years. While key concepts within all research settings such as beneficence,
      justice and respect for persons are crucially relevant, there are considerations 
      unique to the humanitarian context. The particular vulnerabilities of
      conflict-affected populations, the contextual challenges of working in
      humanitarian settings, and the need for ensuring strong community engagement at
      all levels make this area of research particularly challenging. Humanitarian
      crises are prevalent throughout the globe, and studying them with the utmost
      ethical forethought is critical to maintaining sound research principles and
      ethical standards.
CI  - (c) The Author(s) 2020.
FAU - Bruno, William
AU  - Bruno W
AUID- ORCID: 0000-0001-9429-6874
AD  - Department of Emergency Medicine, University of Southern California, Keck School 
      of Medicine, Los Angeles, USA.grid.42505.360000 0001 2156 6853
FAU - Haar, Rohini J
AU  - Haar RJ
AD  - Division of Epidemiology and Biostatistics, School of Public Health, Research
      Fellow, Human Rights Center, School of Law, University of California at Berkeley,
      Berkeley, USA.grid.47840.3f0000 0001 2181 7878
LA  - eng
PT  - Journal Article
DEP - 20200524
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7245798
OTO - NOTNLM
OT  - Aid
OT  - Conflict
OT  - Disasters
OT  - Ethics
OT  - Humanitarian crisis
OT  - Research
OT  - War
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.1186/s13031-020-00282-0 [doi]
AID - 282 [pii]
PST - epublish
SO  - Confl Health. 2020 May 24;14:27. doi: 10.1186/s13031-020-00282-0. eCollection
      2020.


PMID- 32489415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1751-1437 (Print)
IS  - 1751-1437 (Linking)
VI  - 21
IP  - 2
DP  - 2020 May
TI  - Family overrule of registered refusal to donate organs.
PG  - 179-182
LID - 10.1177/1751143719846416 [doi]
AB  - It is well known that families frequently overrule the wishes of dying patients
      who had previously expressed a wish to donate their organs. Various strategies
      have been suggested to reduce the frequency of these 'family overrules'. However,
      the possibility of families overruling a patient's registered decision not to
      donate has not been discussed in the medical literature, although it is legally
      possible in some countries. In this article, we provide an ethical analysis of
      family overrule of a relative's refusal to donate, using the different
      jurisdictions of the UK, Switzerland, Germany and the Netherlands to provide some
      context. Despite some asymmetries between overruling consent and overruling
      refusal, there are some cases in which donation should proceed despite a recorded
      refusal to do so.
CI  - (c) The Intensive Care Society 2019.
FAU - Shaw, David
AU  - Shaw D
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
AD  - CAPHRI Research Institute, Maastricht University, Maastricht, the Netherlands.
FAU - Lewis, Penney
AU  - Lewis P
AUID- ORCID: https://orcid.org/0000-0002-7217-5884
AD  - Dickson Poon School of Law, Kings College London, London, UK.
FAU - Jansen, Nichon
AU  - Jansen N
AD  - Dutch Transplant Foundation, the Netherlands.
FAU - Samuel, Undine
AU  - Samuel U
AD  - Eurotransplant International Foundation, Leiden, the Netherlands.
FAU - Wind, Tineke
AU  - Wind T
AD  - Maastricht University Medical Centre, Maastricht, the Netherlands.
FAU - Georgieva, Denie
AU  - Georgieva D
AD  - Dutch Transplant Foundation, the Netherlands.
FAU - Haase, Bernadette
AU  - Haase B
AD  - Dutch Transplant Foundation, the Netherlands.
FAU - Ploeg, Rutger
AU  - Ploeg R
AD  - Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre,
      University of Oxford, Oxford, UK.
FAU - Gardiner, Dale
AU  - Gardiner D
AD  - Nottingham University Hospitals NHS Trust, Nottingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20190507
PL  - England
TA  - J Intensive Care Soc
JT  - Journal of the Intensive Care Society
JID - 101538668
PMC - PMC7238478
OTO - NOTNLM
OT  - Ethics
OT  - deceased donation
OT  - family overrule
OT  - law
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.1177/1751143719846416 [doi]
AID - 10.1177_1751143719846416 [pii]
PST - ppublish
SO  - J Intensive Care Soc. 2020 May;21(2):179-182. doi: 10.1177/1751143719846416. Epub
      2019 May 7.


PMID- 32489315
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Moral courage and psychological empowerment among nurses.
PG  - 43
LID - 10.1186/s12912-020-00435-9 [doi]
AB  - BACKGROUND: Moral courage is one of the fundamental values of nursing profession 
      and a powerful method of coping with ethical problems. Psychological empowerment 
      is a suitable method of enabling individuals to coping mental pressures of the
      work environment. This study determined the correlation between moral courage and
      psychological empowerment of nurses. METHODS: This was a descriptive
      cross-sectional study. A total of 180 nurses employed in different wards were
      selected randomly. Data were collected by Demographics Questionnaire, Sekerka's
      Moral Courage Scale, and Spreitzer's psychological empowerment Scale and analyzed
      with SPSS16 using descriptive and inferential statistics. FINDINGS: The results
      indicated that the mean score of moral courage was 21.11 +/- 69.90 and the
      greatest amount of moral courage was in the dimension of "going beyond
      compliance". The mean score of "psychological empowerment" was 30.9 +/- 73.58 and
      the greatest mean belonged to "competence". There was a positive significant
      correlation between "psychological empowerment" and "moral courage and its
      dimensions" (P < 0.05). CONCLUSION: The findings suggested a correlation between 
      moral courage and psychological empowerment. Thus, nurses' moral courage could be
      enhanced by reinforcing their psychological empowerment leading to increased
      patient satisfaction and quality care.
CI  - (c) The Author(s) 2020.
FAU - Khoshmehr, Zahra
AU  - Khoshmehr Z
AD  - Department of Nursing, School of Medical Sciences, Yazd Branch, Islamic Azad
      University, Shohadaye Gomnam Blvd., Safaiyeh, Yazd, Postal code: 8916871967
      Iran.grid.466829.7
FAU - Barkhordari-Sharifabad, Maasoumeh
AU  - Barkhordari-Sharifabad M
AUID- ORCID: https://orcid.org/0000-0002-9832-2280
AD  - Department of Nursing, School of Medical Sciences, Yazd Branch, Islamic Azad
      University, Shohadaye Gomnam Blvd., Safaiyeh, Yazd, Postal code: 8916871967
      Iran.grid.466829.7
FAU - Nasiriani, Khadijeh
AU  - Nasiriani K
AUID- ORCID: https://orcid.org/0000-0003-3600-9456
AD  - Department of Nursing, Nursing and Midwifery Research Center, Research Center for
      Neonate & Mother, Shahid Sadoughi University of Medical Sciences and Health
      Services, Yazd, Iran.grid.412505.70000 0004 0612 5912
FAU - Fallahzadeh, Hossein
AU  - Fallahzadeh H
AUID- ORCID: https://orcid.org/0000-0001-6518-366X
AD  - Department of Biostatistics and Epidemiology, Faculty of Health, Shahid Sadoughi 
      University of Medical Sciences and Health Services, Yazd, Iran.grid.412505.70000 
      0004 0612 5912
LA  - eng
PT  - Journal Article
DEP - 20200524
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7247179
OTO - NOTNLM
OT  - Ethics
OT  - Moral action
OT  - Moral courage
OT  - Nurse
OT  - Psychological empowerment
COIS- Competing interestsThe authors declared no conflicts of interest with respect to 
      the research, authorship, and/or publication of this article.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2020/03/28 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.1186/s12912-020-00435-9 [doi]
AID - 435 [pii]
PST - epublish
SO  - BMC Nurs. 2020 May 24;19:43. doi: 10.1186/s12912-020-00435-9. eCollection 2020.


PMID- 32489207
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 4
DP  - 2020 Apr
TI  - Comparison of perioperative patient comfort with 'enhanced recovery after surgery
      (ERAS) approach' versus 'traditional approach' for elective laparoscopic
      cholecystectomy.
PG  - 316-321
LID - 10.4103/ija.IJA_782_19 [doi]
AB  - BACKGROUND: Perioperative anxiety, hunger, thirst, fatigue, pain along with
      nausea and vomiting can influence a patient's recovery after surgery. We aimed to
      compare 'enhanced recovery after surgery' (ERAS) protocol with a traditional
      perioperative approach to evaluate a patient's recovery after elective
      laparoscopic cholecystectomy. METHODS: A prospective randomised controlled study 
      was conducted after institutional ethical clearance on 50 patients undergoing
      elective laparoscopic cholecystectomy, and divided equally into two groups. In
      group 1 (traditional); standard fasting guidelines and routine perioperative
      management was implemented. In group 2 (ERAS); patients received appropriate
      multimedia information about surgery and anaesthesia besidecarbohydrate loading
      with tender coconut water on the previous night and on the morning of surgery.
      Standard guidelines of fasting for solids were followed. Intraoperatively,
      goal-directed fluid therapy and an inspired oxygen concentration of 60% were
      administered. Postoperatively, early diet and mobilisation were initiated. The
      primary outcome was the assessment of perioperative anxiety. Hunger, thirst,
      fatigue, pain, nausea, vomiting and overall perioperative experience were also
      evaluated. RESULTS: ERAS group had reduced anxiety prior to surgery: median
      (interquartile range) 3 (3-4) vs 2 (2-3) (P = 0.003), and at 6 h postoperatively:
      4 (3-6) vs 3 (1-4) (P = 0.001). Hunger, thirst and fatigue (P < 0.01) were also
      decreased with better overall perioperative experience (5 [4-5] vs 6 [5-7], P =
      0.004). Pain, nausea, vomiting and blood glucose were similar between the groups.
      CONCLUSION: 'ERAS approach reduces anxiety in addition to hunger, thirst and
      fatigue with enhanced overall perioperative comfort in patients undergoing
      laparoscopic cholecystectomy.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Udayasankar, Madhumita
AU  - Udayasankar M
AD  - Department of Anaesthesiology, Kasturba Medical College and Hospital, Manipal,
      Manipal Academy of Higher Education, Manipal, Karnataka, India.
FAU - Udupi, Sandesh
AU  - Udupi S
AD  - Department of Anaesthesiology, Kasturba Medical College and Hospital, Manipal,
      Manipal Academy of Higher Education, Manipal, Karnataka, India.
FAU - Shenoy, Anitha
AU  - Shenoy A
AD  - Department of Anaesthesiology, Kasturba Medical College and Hospital, Manipal,
      Manipal Academy of Higher Education, Manipal, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20200328
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7259410
OTO - NOTNLM
OT  - Cholecystectomy
OT  - enhanced recovery after surgery
OT  - laparoscopy
OT  - perioperative care
COIS- There are no conflicts of interest.
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2019/11/05 00:00 [received]
PHST- 2019/11/22 00:00 [revised]
PHST- 2020/02/22 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - 10.4103/ija.IJA_782_19 [doi]
AID - IJA-64-316 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Apr;64(4):316-321. doi: 10.4103/ija.IJA_782_19. Epub 2020 
      Mar 28.


PMID- 32488827
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20220216
IS  - 1573-6571 (Electronic)
IS  - 0022-4197 (Linking)
VI  - 59
IP  - 5
DP  - 2020 Oct
TI  - The Faith Community and the SARS-CoV-2 Outbreak: Part of the Problem or Part of
      the Solution?
PG  - 2215-2228
LID - 10.1007/s10943-020-01048-x [doi]
AB  - The current outbreak of the SARS-CoV-2 virus is a critical moment in time for
      institutional religion in the USA and throughout the world. Individual clergy and
      congregations, across faith traditions, have been sources of misinformation and
      disinformation, promoting messages and actions that engender fear, animosity
      toward others, and unnecessary risk-taking. But there is a positive role for
      religion and faith-based institutions here, and many examples of leaders and
      organizations stepping up to contribute to the collective recovery. Personal
      faith and spirituality may be a source of host resistance and resilience.
      Religiously sponsored medical care institutions are vital to health care response
      efforts. Ministries and faith-based organizations are source of religious health 
      assets that can help to meet community-wide needs. There is a pastoral role for
      clergy and laypeople who are instrumental in providing comfort and strength to
      the suffering and fearful in our midst. The outbreak presents an ethical
      challenge to all of us to step outside of our own preoccupations and to be
      present and of service for others. This includes having the courage to represent 
      the highest values of our faith in speaking out against religiously motivated
      foolishness and hatred and in calling for political and public health leaders to 
      be truthful and transparent in their messages to us.
FAU - Levin, Jeff
AU  - Levin J
AD  - Institute for Studies of Religion, Baylor University, One Bear Place # 97236,
      Waco, TX, 76798, USA. jeff_levin@baylor.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Relig Health
JT  - Journal of religion and health
JID - 2985199R
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clergy
MH  - *Coronavirus Infections
MH  - Disease Outbreaks
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Population Health
MH  - SARS-CoV-2
PMC - PMC7265665
OTO - NOTNLM
OT  - COVID-19
OT  - Faith-based
OT  - Religion
OT  - SARS-CoV-2
EDAT- 2020/06/04 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 10.1007/s10943-020-01048-x [doi]
AID - 10.1007/s10943-020-01048-x [pii]
PST - ppublish
SO  - J Relig Health. 2020 Oct;59(5):2215-2228. doi: 10.1007/s10943-020-01048-x.


PMID- 32488502
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1546-9549 (Electronic)
IS  - 1546-9530 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Aug
TI  - Ethical Challenges in Care of Patients on Mechanical Circulatory Support at
      End-of-Life.
PG  - 153-160
LID - 10.1007/s11897-020-00460-4 [doi]
AB  - PURPOSE OF REVIEW: Although the utilization of mechanical circulatory support
      (MCS) devices is increasing, ethical dilemmas regarding device deactivation and
      dying process persist, potentially complicating delivery of optimal and
      compassionate care at end-of-life (EOL). This review aims to study EOL
      challenges, left ventricular assist devices (LVADs) as a nuanced life support
      treatment, legal history in the US impacting EOL care, and suggestions to improve
      EOL care for patients on MCS support. RECENT FINDINGS: Recent studies have
      demonstrated challenging aspects of EOL care for patients on LVAD support: low
      use of advanced directives, high rates of surrogate decision-making due to lack
      of patient capacity, difficult decision-making involving LVAD deactivation even
      with cooperating patients, and high rates of death in the hospital and ICU
      settings. Recent studies also suggest lack of consensus even among clinicians in 
      approaching LVAD deactivation as beliefs equating LVAD deactivation with
      physician-assisted suicide and/or euthanasia remain. Optimal care at EOL will
      likely require collaborative efforts among multiple specialties, caregivers, and 
      patients. In light of the complex medical, logistical, and ethical challenges in 
      EOL care for LVAD patients, there is room for improvement by multidisciplinary
      efforts to reach consensus about LVAD deactivation and best practices for EOL
      care, development and implementation of LVAD-specific advance planning, and
      protocols for LVAD deactivation. Programmatic involvement of hospice and
      palliative care in the continuum of care of LVAD patients has the potential to
      increase and improve advance care planning, support surrogate decision-making,
      improve EOL compassionate care, and to support caregivers.
FAU - Pak, Esther S
AU  - Pak ES
AD  - Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia,
      PA, 19104, USA. Esther.Pak@pennmedicine.upenn.edu.
FAU - Jones, Christopher A
AU  - Jones CA
AD  - University of Pennsylvania, Hospice & Palliative Care Medicine, Philadelphia, PA,
      19104, USA.
FAU - Mather, Paul J
AU  - Mather PJ
AD  - Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia,
      PA, 19104, USA. Paul.Mather@pennmedicine.upenn.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Heart Fail Rep
JT  - Current heart failure reports
JID - 101196487
SB  - IM
MH  - Heart Failure/*therapy
MH  - Heart-Assist Devices/*ethics
MH  - Humans
MH  - Palliative Care/*ethics
MH  - Terminal Care/*ethics
OTO - NOTNLM
OT  - *End-of-life care
OT  - *Hospice
OT  - *Life support treatment
OT  - *Mechanical circulatory support
OT  - *Palliative care
EDAT- 2020/06/04 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 10.1007/s11897-020-00460-4 [doi]
AID - 10.1007/s11897-020-00460-4 [pii]
PST - ppublish
SO  - Curr Heart Fail Rep. 2020 Aug;17(4):153-160. doi: 10.1007/s11897-020-00460-4.


PMID- 32487730
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 24
DP  - 2020 Jun 16
TI  - P-hacking in clinical trials and how incentives shape the distribution of results
      across phases.
PG  - 13386-13392
LID - 10.1073/pnas.1919906117 [doi]
AB  - Clinical research should conform to high standards of ethical and scientific
      integrity, given that human lives are at stake. However, economic incentives can 
      generate conflicts of interest for investigators, who may be inclined to withhold
      unfavorable results or even tamper with data in order to achieve desired
      outcomes. To shed light on the integrity of clinical trial results, this paper
      systematically analyzes the distribution of P values of primary outcomes for
      phase II and phase III drug trials reported to the ClinicalTrials.gov registry.
      First, we detect no bunching of results just above the classical 5% threshold for
      statistical significance. Second, a density-discontinuity test reveals an upward 
      jump at the 5% threshold for phase III results by small industry sponsors. Third,
      we document a larger fraction of significant results in phase III compared to
      phase II. Linking trials across phases, we find that early favorable results
      increase the likelihood of continuing into the next phase. Once we take into
      account this selective continuation, we can explain almost completely the excess 
      of significant results in phase III for trials conducted by large industry
      sponsors. For small industry sponsors, instead, part of the excess remains
      unexplained.
CI  - Copyright (c) 2020 the Author(s). Published by PNAS.
FAU - Adda, Jerome
AU  - Adda J
AUID- ORCID: 0000-0002-7035-1565
AD  - Department of Economics, Bocconi University, 20136 Milan, Italy.
AD  - Bocconi Institute for Data Science and Analytics, Bocconi University, 20136
      Milan, Italy.
AD  - Innocenzo Gasparini Institute for Economic Research, Bocconi University, 20136
      Milan, Italy.
FAU - Decker, Christian
AU  - Decker C
AUID- ORCID: 0000-0002-4444-5541
AD  - Department of Economics, University of Zurich, 8001 Zurich, Switzerland.
AD  - UBS Center for Economics in Society, University of Zurich, 8001 Zurich,
      Switzerland.
FAU - Ottaviani, Marco
AU  - Ottaviani M
AUID- ORCID: 0000-0002-0943-162X
AD  - Department of Economics, Bocconi University, 20136 Milan, Italy;
      marco.ottaviani@unibocconi.it.
AD  - Bocconi Institute for Data Science and Analytics, Bocconi University, 20136
      Milan, Italy.
AD  - Innocenzo Gasparini Institute for Economic Research, Bocconi University, 20136
      Milan, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200602
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - Biomedical Research/economics
MH  - Clinical Trials as Topic/*economics/*standards/statistics & numerical data
MH  - Drug Development/economics/organization & administration
MH  - Drug Industry/economics
MH  - Humans
MH  - Registries
MH  - Research Report/*standards
MH  - Research Support as Topic
PMC - PMC7306753
OTO - NOTNLM
OT  - *clinical trials
OT  - *drug development
OT  - *economic incentives in research
OT  - *p-hacking
OT  - *selective reporting
COIS- The authors declare no competing interest.
EDAT- 2020/06/04 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - 1919906117 [pii]
AID - 10.1073/pnas.1919906117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13386-13392. doi:
      10.1073/pnas.1919906117. Epub 2020 Jun 2.


PMID- 32487584
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 1
TI  - Protocol for a mixed-method analysis of implementation of case management in
      primary care for frequent users of healthcare services with chronic diseases and 
      complex care needs.
PG  - e038241
LID - 10.1136/bmjopen-2020-038241 [doi]
AB  - INTRODUCTION: Case management (CM) in a primary care setting is a promising
      approach to integrating and improving healthcare services and outcomes for
      patients with chronic conditions and complex care needs who frequently use
      healthcare services. Despite evidence supporting CM and interest in implementing 
      it in Canada, little is known about how to do this. This research aims to
      identify the barriers and facilitators to the implementation of a CM intervention
      in different primary care contexts (objective 1) and to explain the influence of 
      the clinical context on the degree of implementation (objective 2) and on the
      outcomes of the intervention (objective 3). METHODS AND ANALYSIS: A multiple-case
      embedded mixed-methods study will be conducted on CM implemented in ten primary
      care clinics across five Canadian provinces. Each clinic will represent a subunit
      of analysis, detailed through a case history. Cases will be compared and
      contrasted using multiple analytical approaches. Qualitative data (objectives 1
      and 2) from individual semistructured interviews (n=130), focus group discussions
      (n=20) and participant observation of each clinic (36 hours) will be compared and
      integrated with quantitative (objective 3) clinical data on services use (n=300) 
      and patient questionnaires (n=300). An evaluation of intervention fidelity will
      be integrated into the data analysis. ETHICS AND DISSEMINATION: This project
      received approval from the CIUSSS de l'Estrie - CHUS Research Ethic Board
      (project number MP-31-2019-2830). Results will provide the opportunity to refine 
      the CM intervention and to facilitate effective evaluation, replication and
      scale-up. This research provides knowledge on how to resp ond to the needs of
      individuals with chronic conditions and complex care needs in a cost-effective
      way that improves patient-reported outcomes and healthcare use, while ensuring
      care team well-being. Dissemination of results is planned and executed based on
      the needs of various stakeholders involved in the research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Danish, Alya
AU  - Danish A
AUID- ORCID: 0000-0002-7988-9804
AD  - Department of Family Medicine and Emergency Medicine, Universite de Sherbrooke,
      Sherbrooke, Quebec, Canada alya.danish@usherbrooke.ca.
FAU - Chouinard, Maud-Christine
AU  - Chouinard MC
AD  - Department of Health Sciences, Universite du Quebec a Chicoutimi, Chicoutimi,
      Quebec, Canada.
FAU - Aubrey-Bassler, Kris
AU  - Aubrey-Bassler K
AD  - Primary Healthcare Research Unit, Memorial University, St-John's, Newfoundland
      and Labrador, Canada.
FAU - Burge, Fred
AU  - Burge F
AD  - Department of Family Medicine, Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Doucet, Shelley
AU  - Doucet S
AUID- ORCID: 0000-0003-4420-8199
AD  - Department of Nursing and Health Sciences, University of New Brunswick,
      Fredericton, New Brunswick, Canada.
FAU - Ramsden, Vivian R
AU  - Ramsden VR
AD  - Department of Academic Family Medicine, University of Saskatchewan, Saskatoon,
      Saskatchewan, Canada.
FAU - Bisson, Mathieu
AU  - Bisson M
AD  - Department of Family Medicine and Emergency Medicine, Universite de Sherbrooke,
      Sherbrooke, Quebec, Canada.
FAU - Cassidy, Monique
AU  - Cassidy M
AD  - Department of Nursing and Health Sciences, University of New Brunswick,
      Fredericton, New Brunswick, Canada.
FAU - Condran, Brian
AU  - Condran B
AD  - Department of Family Medicine, Dalhousie University, Halifax, Nova Scotia,
      Canada.
FAU - Lambert, Mireille
AU  - Lambert M
AD  - Centre integre universitaire de sante et de services sociaux du
      Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada.
FAU - Penney, Carla
AU  - Penney C
AD  - Primary Healthcare Research Unit, Memorial University, St-John's, Newfoundland
      and Labrador, Canada.
FAU - Sabourin, Veronique
AU  - Sabourin V
AD  - Quebec-SPOR Support Unit, Quebec, Quebec, Canada.
FAU - Warren, Mike
AU  - Warren M
AD  - NL-SPOR Suppport Unit, St-John's, Newfoundland and Labrador, Canada.
FAU - Hudon, Catherine
AU  - Hudon C
AD  - Department of Family Medicine and Emergency Medicine, Universite de Sherbrooke,
      Sherbrooke, Quebec, Canada.
AD  - Centre hospitalier universitaire de Sherbrooke Research Centre, Sherbrooke,
      Quebec, Canada.
LA  - eng
GR  - 397896/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - *Case Management
MH  - Chronic Disease
MH  - Delivery of Health Care
MH  - Humans
MH  - *Primary Health Care
MH  - Qualitative Research
PMC - PMC7265033
OTO - NOTNLM
OT  - *organisation of health services
OT  - *primary care
OT  - *protocols and guidelines
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/06/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038241 [pii]
AID - 10.1136/bmjopen-2020-038241 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 1;10(6):e038241. doi: 10.1136/bmjopen-2020-038241.


PMID- 32487581
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 1
TI  - Assessment of the association of plant-based diets with cardiovascular disease
      risk profile in Africa: a systematic review and meta-analysis protocol.
PG  - e036792
LID - 10.1136/bmjopen-2020-036792 [doi]
AB  - INTRODUCTION: Cardiovascular disease (CVD) is currently the leading cause of
      death worldwide. In Africa where infectious diseases are still the leading cause 
      of death, the contribution of non-communicable diseases led by CVDs has
      significantly increased in recent years. The rise of CVDs in Africa is attributed
      at least in part to the adoption of sedentary behaviours and unhealthy eating
      habits, which are linked with urbanisation and westernisation of cultures.
      Dietary attributes associated with CVD risk have been less investigated in
      Africa. However, evidence from developed nations has reported a protective effect
      of healthy dietary patterns such as plant-based diets (PBDs) on cardiometabolic
      health. The current protocol is for a review aiming to assess existing evidence
      on the association of PBDs with CVD risk profile in African populations. METHODS 
      AND ANALYSIS: This protocol was developed following the 2015 guidelines of the
      Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. We
      will conduct a comprehensive search of the literature for published studies on
      PBDs in relation to CVD risk profile in African populations. Observational
      studies published between January 1990 and December 2019 will be screened. A
      search strategy using keywords and medical subject headings terms will be applied
      across multiple scientific databases including PubMed-Medline, Scopus and
      EBSCOhost and the African Journals Online platform. Manual searches of reference 
      lists from relevant articles will be performed. Citations will be traced using
      the ISI Web of Science to further identify eligible studies. Grey literature will
      also be screened for relevant abstracts from conference proceedings, and experts 
      in the field will be contacted where appropriate. Two investigators will
      independently screen all the titles and abstracts to determine which records are 
      eligible for full-text review. Subsequently, two investigators will review the
      eligible full text using the selection criteria. A third investigator will be
      consulted to resolve any discrepancies. Data will be extracted from studies that 
      are eligible for the review. Meta-analysis will be performed for studies with
      similar or comparable methods and reported outcome measures. This will be
      performed overall, and by major study-level characteristics. Heterogeneity in the
      estimates across studies will be assessed and quantified with the use of Cochrane
      Q and I(2) statistics, respectively. Publication biases will be investigated
      through funnel plots and Egger test of bias. Relevant sensitivity analyses will
      be performed to confirm the robustness of the findings. ETHICS AND DISSEMINATION:
      The review will analyse data from published studies; therefore, it does not
      require ethical approval. The findings of the review will be submitted as part of
      a PhD thesis at Stellenbosch University, South Africa. Additionally, the findings
      will be presented at conferences and published in a peer-reviewed journal.
      PROSPERO REGISTRATION NUMBER: CRD42020159862.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lopes, Tatum
AU  - Lopes T
AUID- ORCID: 0000-0002-6998-1818
AD  - Non-Communicable Diseases Research Unit, South African Medical Research Council, 
      Cape Town, Tygerberg, South Africa tatum.lopes@mrc.ac.za.
AD  - Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and 
      Health Sciences, University of Stellenbosch, Cape Town, Western Cape, South
      Africa.
FAU - Zemlin, Annalise E
AU  - Zemlin AE
AD  - Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and 
      Health Sciences, University of Stellenbosch, Cape Town, Western Cape, South
      Africa.
AD  - National Health Laboratory Service (NHLS), Tygerberg Hospital, University of
      Stellenbosch, Cape Town, Western Cape, South Africa.
FAU - Erasmus, Rajiv T
AU  - Erasmus RT
AD  - Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and 
      Health Sciences, University of Stellenbosch, Cape Town, Western Cape, South
      Africa.
FAU - Faber, Mieke
AU  - Faber M
AD  - Non-Communicable Diseases Research Unit, South African Medical Research Council, 
      Cape Town, Tygerberg, South Africa.
FAU - Kengne, Andre P
AU  - Kengne AP
AD  - Non-Communicable Diseases Research Unit, South African Medical Research Council, 
      Cape Town, Tygerberg, South Africa.
AD  - Department of Medicine, University of Cape Town, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiovascular Diseases/epidemiology
MH  - Diet, Vegetarian
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - South Africa
MH  - Systematic Reviews as Topic
PMC - PMC7265011
OTO - NOTNLM
OT  - *cardiac epidemiology
OT  - *epidemiology
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036792 [pii]
AID - 10.1136/bmjopen-2020-036792 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 1;10(6):e036792. doi: 10.1136/bmjopen-2020-036792.


PMID- 32487576
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 1
TI  - Gender differences in the accuracy of dietary assessment methods to measure
      energy intake in adults: protocol for a systematic review and meta-analysis.
PG  - e035611
LID - 10.1136/bmjopen-2019-035611 [doi]
AB  - INTRODUCTION: Diet is an important modifiable risk factor for many chronic
      diseases. Measurement of dietary intake usually relies on self-report, subject to
      multiple biases. There is a need to understand gender differences in the
      self-report of dietary intake and the implications of any differences in
      targeting nutrition interventions. Literature in this area is limited and it is
      currently unknown whether self-report dietary assessment methods are equally
      accurate for women and men. The aim of this systematic review is to determine
      whether there are differences by gender in reporting energy intake compared with 
      a reference measure of total energy expenditure. METHODS AND ANALYSIS: A
      comprehensive search of published original research studies will be performed in 
      MEDLINE, Scopus, Web of Science, EMBASE, CINAHL and Cochrane library. Original
      research studies will be included if they were conducted in
      free-living/unhospitalised adults and included a measure for both women and men
      of (a) self-reported energy intake and (b) total energy expenditure by doubly
      labelled water. One author will conduct the electronic database searches, two
      authors will independently screen studies, conduct a quality appraisal of the
      included studies using standardised tools and extract data. If further
      information is needed, then study authors will be contacted. If appropriate, a
      random-effects meta-analysis will be conducted, with inverse probability
      weighting, to quantify differences in the mean difference in agreement between
      reported energy intake and measured energy expenditure between women and men, by 
      self-report assessment method. Subgroup analyses will be conducted by participant
      factors, geographical factors and study quality. ETHICS AND DISSEMINATION: All
      data used will be from published primary research studies or deidentified results
      provided at the discretion of any study authors that we contact. We will submit
      our findings to a peer-reviewed scientific journal and will disseminate results
      through presentations at international scientific conferences. PROSPERO
      REGISTRATION NUMBER: CRD42019131715.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - McKenzie, Briar L
AU  - McKenzie BL
AUID- ORCID: 0000-0001-6972-6617
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia bmckenzie@georgeinstitute.org.au.
FAU - Coyle, Daisy H
AU  - Coyle DH
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Burrows, Tracy
AU  - Burrows T
AD  - School of Health Sciences, Faculty of Health and Medicine, The University of
      Newcastle, Callaghan, New South Wales, Australia.
FAU - Rosewarne, Emalie
AU  - Rosewarne E
AUID- ORCID: 0000-0001-5748-3953
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Peters, Sanne A E
AU  - Peters SAE
AD  - The George Institute for Global Health, University of Oxford, Oxford,
      Oxfordshire, UK.
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Carcel, Cheryl
AU  - Carcel C
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
FAU - Collins, Clare E
AU  - Collins CE
AD  - School of Health Sciences, Faculty of Health and Medicine, The University of
      Newcastle, Callaghan, New South Wales, Australia.
FAU - Norton, Robyn
AU  - Norton R
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
AD  - The George Institute for Global Health, University of Oxford, Oxford,
      Oxfordshire, UK.
FAU - Woodward, Mark
AU  - Woodward M
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
AD  - The George Institute for Global Health, University of Oxford, Oxford,
      Oxfordshire, UK.
AD  - Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Jaacks, Lindsay M
AU  - Jaacks LM
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, Massachusetts, USA.
FAU - Webster, Jacqui
AU  - Webster J
AD  - The George Institute for Global Health, University of New South Wales, Sydney,
      New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Eating
MH  - Energy Intake
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - *Nutrition Assessment
MH  - Risk Factors
MH  - *Sex Characteristics
MH  - Systematic Reviews as Topic
PMC - PMC7265006
OTO - NOTNLM
OT  - *epidemiology
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/06/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035611 [pii]
AID - 10.1136/bmjopen-2019-035611 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 1;10(6):e035611. doi: 10.1136/bmjopen-2019-035611.


PMID- 32487574
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 1
TI  - Health-related quality Of Life In patients with advanced Soft TIssue sarcomas
      treated with Chemotherapy (The HOLISTIC study): protocol for an international
      observational cohort study.
PG  - e035171
LID - 10.1136/bmjopen-2019-035171 [doi]
AB  - INTRODUCTION: Chemotherapy is the mainstay of treatment for patients with
      advanced soft tissue sarcomas (STS). Treatment intent is usually palliative,
      aiming to improve symptoms, stabilise or reduce tumour burden and extend life.
      Clinical trials have traditionally used radiological response, time to
      progression and survival as measures of treatment efficacy. Health-related
      quality of life (HRQoL) is at least equally important or more important than
      survival for many patients with advanced cancer. Systematically collecting HRQoL 
      data during chemotherapy can provide greater insight into treatment efficacy from
      the patient perspective.The primary aims of this study are to evaluate HRQoL in
      patients with advanced STS treated with chemotherapy over time, explore the
      decision-making process and patient reflection post-treatment. METHODS AND
      ANALYSIS: This is an observational, international cohort study for 132 patients
      aged >/=18 years with advanced STS treated at eight centres (three in the UK,
      five in the Netherlands). Patients will be recruited prior to starting first-line
      or third-line chemotherapy and invited to complete questionnaires using the
      Patient-Reported Outcomes Following Initial treatment and Long-term Evaluation of
      Survivorship registry (PROFILES); an established international registry for
      collection of cancer patient-reported outcomes. Online (or paper) questionnaires 
      will be completed at baseline, each cycle of chemotherapy and 2-3 monthly during 
      follow-up. The questionnaire package includes the Decisional Conflict Scale,
      Control Preferences Scale, Quality-Quantity Questionnaire, treatment
      expectations, European Organisation for the Research and Treatment of Cancer
      Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30), EORTC financial toxicity
      items, Work Ability Index, Functional Assessment of Cancer Therapy-General
      (FACT-G) items and Decisional Regret Scale. Clinical data will be extracted from 
      patient records and linked with questionnaire responses. The primary outcome
      measure is the change in global HRQoL from baseline to after cycle 4 of
      first-line chemotherapy (based on published data showing that patients with
      advanced STS complete a median number of four cycles of first-line chemotherapy).
      ETHICS AND DISSEMINATION: Heath Research Authority and Research Ethics Committee 
      (REC 17/NI/0197). Results from the Health-related quality Of Life In patients
      with advanced Soft TIssue sarcomas treated with Chemotherapy (HOLISTIC) study
      will be published in peer-reviewed journals and disseminated at local, national
      and international conferences. We will also present our findings at any
      appropriate patient meetings and involve patients in study-related publications. 
      TRIAL REGISTRATION NUMBER: NCT03621332.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Younger, Eugenie
AU  - Younger E
AUID- ORCID: 0000-0002-2088-3328
AD  - Sarcoma Unit, Royal Marsden Hospital NHS Trust, London, UK.
AD  - Medical Oncology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
FAU - Jones, Robin L
AU  - Jones RL
AUID- ORCID: 0000-0003-4173-3844
AD  - Sarcoma Unit, Royal Marsden Hospital NHS Trust, London, UK.
AD  - Division of Clinical Studies, Institute of Cancer Research, London, UK.
FAU - Desar, Ingrid M E
AU  - Desar IME
AD  - Medical Oncology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
FAU - Peckitt, Clare
AU  - Peckitt C
AD  - Sarcoma Unit, Royal Marsden Hospital NHS Trust, London, UK.
FAU - van der Graaf, Winette T A
AU  - van der Graaf WTA
AD  - Sarcoma Unit, Royal Marsden Hospital NHS Trust, London, UK.
AD  - Medical Oncology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
AD  - Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam,
      Netherlands.
FAU - Husson, Olga
AU  - Husson O
AD  - Division of Clinical Studies, Institute of Cancer Research, London, UK
      olga.husson@icr.ac.uk.
AD  - Department of Psychosocial Research and Epidemiology, Netherlands Cancer
      Institute, Amsterdam, Noord-Holland, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03621332
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Jun 25;10(6):e035171corr1. PMID: 32586916
MH  - Adolescent
MH  - Adult
MH  - Cohort Studies
MH  - Humans
MH  - Netherlands
MH  - Observational Studies as Topic
MH  - Quality of Life
MH  - *Sarcoma/drug therapy
MH  - *Soft Tissue Neoplasms/drug therapy
MH  - Surveys and Questionnaires
PMC - PMC7265010
OTO - NOTNLM
OT  - *adult oncology
OT  - *chemotherapy
OT  - *sarcoma
COIS- Competing interests: RLJ is a consultant for: Adaptimmune, Blueprint, Clinigen,
      Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck, Pharmamar. WTAvDG
      has received research grants from Novartis and has been on advisory board from
      Bayer. The other authors declare that they have no competing interests.
EDAT- 2020/06/04 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035171 [pii]
AID - 10.1136/bmjopen-2019-035171 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 1;10(6):e035171. doi: 10.1136/bmjopen-2019-035171.


PMID- 32487442
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1872-6054 (Electronic)
IS  - 0168-8510 (Linking)
VI  - 124
IP  - 7
DP  - 2020 Jul
TI  - 2017-19 governmental decisions to allow home use of misoprostol for early medical
      abortion in the UK.
PG  - 679-683
LID - S0168-8510(20)30099-3 [pii]
LID - 10.1016/j.healthpol.2020.04.014 [doi]
AB  - Home use of misoprostol for early medical abortion has long been an established
      practice in several countries. It is a safe, effective, and dignified means of
      obtaining a legal abortion, with a low risk of complications. In the UK, however,
      the practice has only recently been permitted. Prior to the change, women were
      required to attend a clinic to be observed taking the drug, before being
      discharged to go home and see through the process. The requirement to attend a
      clinic was a result of political rather than medical reasoning; a desire not to
      provoke pro-life groups. It also highlighted an inconsistency whereby misoprostol
      was prescribed for home use to women who had suffered an incomplete miscarriage. 
      Failure to permit home use of misoprostol for early medical abortion has caused
      women to suffer trauma when experiencing the effects of the drug when returning
      home from clinics, in addition to acting as an obstacle to access for women
      living in remote areas with no nearby clinic. Through an overview of recent
      developments in UK abortion policy, I demonstrate the lack of good, medical
      reasons for the delayed change. Further, I suggest appropriate future steps to be
      taken by policymakers.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Parsons, Jordan A
AU  - Parsons JA
AD  - Centre for Ethics in Medicine, Bristol Medical School, University of Bristol,
      Oakfield House, Oakfield Grove, BS8 2BN, United Kingdom. Electronic address:
      jordan.parsons@bristol.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200523
PL  - Ireland
TA  - Health Policy
JT  - Health policy (Amsterdam, Netherlands)
JID - 8409431
RN  - 0 (Abortifacient Agents, Steroidal)
RN  - 0E43V0BB57 (Misoprostol)
RN  - 320T6RNW1F (Mifepristone)
MH  - *Abortifacient Agents, Steroidal
MH  - *Abortion, Induced
MH  - *Abortion, Spontaneous
MH  - Female
MH  - Humans
MH  - Mifepristone
MH  - *Misoprostol
MH  - Pregnancy
MH  - United Kingdom
OTO - NOTNLM
OT  - *Abortion
OT  - *Ethics
OT  - *Home use
OT  - *Misoprostol
OT  - *Policy development
COIS- Declaration of Competing Interest None.
EDAT- 2020/06/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/08/17 00:00 [received]
PHST- 2020/02/21 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - S0168-8510(20)30099-3 [pii]
AID - 10.1016/j.healthpol.2020.04.014 [doi]
PST - ppublish
SO  - Health Policy. 2020 Jul;124(7):679-683. doi: 10.1016/j.healthpol.2020.04.014.
      Epub 2020 May 23.


PMID- 32487426
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20210110
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 231
IP  - 2
DP  - 2020 Aug
TI  - Challenges and Ethical Considerations for Trainees and Attending Physicians
      During the COVID-19 Pandemic.
PG  - 301-302
LID - S1072-7515(20)30402-6 [pii]
LID - 10.1016/j.jamcollsurg.2020.05.009 [doi]
FAU - Hai, Shaikh
AU  - Hai S
AD  - Miami, FL.
FAU - Baroutjian, Amanda
AU  - Baroutjian A
AD  - Miami, FL.
FAU - Elkbuli, Adel
AU  - Elkbuli A
AD  - Miami, FL.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200530
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
CON - J Am Coll Surg. 2020 Jun;230(6):1114-1118. PMID: 32278728
CIN - J Am Coll Surg. 2020 Aug;231(2):302-303. PMID: 32487425
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7261091
EDAT- 2020/06/04 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - S1072-7515(20)30402-6 [pii]
AID - 10.1016/j.jamcollsurg.2020.05.009 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Aug;231(2):301-302. doi: 10.1016/j.jamcollsurg.2020.05.009. 
      Epub 2020 May 30.


PMID- 32487425
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20220531
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 231
IP  - 2
DP  - 2020 Aug
TI  - Ethics in the Time of Coronavirus: Engaging the Conversation: In Reply to Hai and
      Colleagues.
PG  - 302-303
LID - S1072-7515(20)30401-4 [pii]
LID - 10.1016/j.jamcollsurg.2020.05.008 [doi]
FAU - Kramer, Jessica B
AU  - Kramer JB
AD  - St Louis, MO.
FAU - Brown, Douglas E
AU  - Brown DE
AD  - St Louis, MO.
FAU - Kopar, Piroska K
AU  - Kopar PK
AD  - St Louis, MO.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200530
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
CON - J Am Coll Surg. 2020 Aug;231(2):301-302. PMID: 32487426
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections/transmission
MH  - Education, Medical
MH  - Humans
MH  - *Pandemics
MH  - Physicians/*ethics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7261227
EDAT- 2020/06/04 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
AID - S1072-7515(20)30401-4 [pii]
AID - 10.1016/j.jamcollsurg.2020.05.008 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Aug;231(2):302-303. doi: 10.1016/j.jamcollsurg.2020.05.008. 
      Epub 2020 May 30.


PMID- 32487338
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 1879-193X (Electronic)
IS  - 0890-4065 (Linking)
VI  - 53
DP  - 2020 Jun
TI  - A relational ethic of rural home support on two Gulf Island communities,
      1978-2018.
PG  - 100847
LID - S0890-4065(20)30017-7 [pii]
LID - 10.1016/j.jaging.2020.100847 [doi]
AB  - Since their widespread establishment in the 1970s, home support services across
      Canada have been subject to shifting state logics, policies, and funding models. 
      The impacts and responses of local actors differ across historical,
      socio-cultural, and geographical settings. This paper traces the development and 
      evolution of a small home support society on two rural islands off the coast of
      British Columbia, Canada. Using historical and current data sources, we
      demonstrate that local actors have consistently engaged a relational ethic that
      challenges neo-liberal discourses and practices. Our central thesis is that the
      islands' distinct social, cultural, and rural features set the context for
      particular constructions of relational care. We identify three themes central to 
      a relational ethic of home support on two rural islands: the strength of
      intergenerational connections, community-embedded relationships, and care as
      compassionate civic engagement. Within each theme, we consider how shifting
      policy structures inform changes over time in the nature and delivery of home
      support. To conclude, we elaborate on the conditions that allow for relational
      care to flourish in a particular rural context, and on the potential relevance to
      other settings.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Barken, Rachel
AU  - Barken R
AD  - York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada. Electronic address:
      rachelbarken@gmail.com.
FAU - Davies, Megan J
AU  - Davies MJ
AD  - Health & Society Program, Department of Social Science, York University, 704A
      Ross Building South, 4700 Keele St., Toronto, ON M3J 1P3, Canada. Electronic
      address: daviesmj@yorku.ca.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - England
TA  - J Aging Stud
JT  - Journal of aging studies
JID - 8916517
SB  - IM
MH  - British Columbia
MH  - *Feminism
MH  - *Home Care Services
MH  - Humans
MH  - *Intergenerational Relations
MH  - *Islands
MH  - Qualitative Research
MH  - *Rural Population
MH  - Volunteers
OTO - NOTNLM
OT  - Care work
OT  - Ethics of care
OT  - Home support
OT  - Neo-liberalism
OT  - Rural aging
EDAT- 2020/06/04 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/03/03 00:00 [revised]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - S0890-4065(20)30017-7 [pii]
AID - 10.1016/j.jaging.2020.100847 [doi]
PST - ppublish
SO  - J Aging Stud. 2020 Jun;53:100847. doi: 10.1016/j.jaging.2020.100847. Epub 2020
      May 7.


PMID- 32487213
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jun 1
TI  - The value of post-operative antibiotic therapy after laparoscopic appendectomy
      for complicated acute appendicitis: a prospective, randomized, double-blinded,
      placebo-controlled phase III study (ABAP study).
PG  - 451
LID - 10.1186/s13063-020-04411-1 [doi]
AB  - BACKGROUND: Approximately 30% of appendectomies are for complicated acute
      appendicitis (CAA). With laparoscopy, the main post-operative complication is
      deep abscesses (12% of cases of CAA, versus 4% for open surgery). A recent cohort
      study compared short and long courses of postoperative antibiotic therapy in
      patients with CAA. There was no significant intergroup difference in the
      post-operative complication rate (12% of organ/space surgical site infection
      (SSI)). Moreover, antibiotic therapy is increasingly less indicated for other
      situations (non-complicated appendicitis, post-operative course of cholecystitis,
      perianal abscess), calling into question whether post-operative antibiotic
      therapy is required after laparoscopic appendectomy for CAA. METHODS/DESIGN: This
      study is a prospective, multicenter, parallel-group, randomized (1:1),
      double-blinded, placebo-controlled, phase III non-inferiority study with blind
      evaluation of the primary efficacy criterion. The primary objective is to
      evaluate the impact of the absence of post-operative antibiotic therapy on the
      organ/space surgical site infection (SSI) rate in patients presenting with CAA
      (other than in cases of generalized peritonitis). Patients in the experimental
      group will receive at least one dose of preoperative and perioperative antibiotic
      therapy (2 g ceftriaxone by intravenous injection every 24 h up to the operation)
      and metronidazole (500 mg by intravenous injection every 8 h up to the operation)
      and, in the post-operative period, a placebo for ceftriaxone (2 g/24 h in one
      intravenous injection) and a placebo for metronidazole (1500 mg/24 h in three
      intravenous injections, for 3 days). In the control group, patients will receive 
      at least one dose of preoperative and perioperative antibiotic therapy (2 g
      ceftriaxone by intravenous injection every 24 h up to the operation) and
      metronidazole (500 mg by intravenous injection every 8 h up to the operation)
      and, in the post-operative period, antibiotic therapy (ceftriaxone 2 g/24 h and
      metronidazole 1500 mg/24 h for 3 days). In the event of allergy to ceftriaxone,
      it will be replaced by levofloxacin (500 mg/24 h in one intravenous injection,
      for 3 days). The expected organ space SSI rate is 12% in the population of
      patients with CAA operated on by laparoscopy. With a non-inferiority margin of
      5%, a two-sided alpha risk of 5%, a beta risk of 20%, and a loss-to-follow-up
      rate of 10%, the calculated sample size is 1476 included patients, i.e., 738 per 
      group. Due to three interim analyses at 10%, 25%, and 50% of the planned sample
      size, the total sample size increases to 1494 patients (747 per arm). TRIAL
      REGISTRATION: Ethical authorization by the Comite de Protection des Personnes and
      the Agence Nationale de Securite du Medicament: ID-RCB 2017-00334-59. Registered 
      on ClinicalTrials.gov (NCT03688295) on 28 September 2018.
FAU - Sabbagh, C
AU  - Sabbagh C
AD  - Department of Digestive Surgery, Amiens University Hospital, Amiens University
      Medical Center, Avenue Laennec, F-80054, Amiens cedex 01, France.
AD  - Jules Verne University of Picardie, Amiens, France.
AD  - SSPC (Simplifications des Soins Patients Chirurgicaux Complexes) Research Unit,
      University of Picardie Jules Verne, Amiens, France.
FAU - Siembida, N
AU  - Siembida N
AD  - Department of Digestive Surgery, Amiens University Hospital, Amiens University
      Medical Center, Avenue Laennec, F-80054, Amiens cedex 01, France.
AD  - SSPC (Simplifications des Soins Patients Chirurgicaux Complexes) Research Unit,
      University of Picardie Jules Verne, Amiens, France.
FAU - Dupont, H
AU  - Dupont H
AD  - Jules Verne University of Picardie, Amiens, France.
AD  - SSPC (Simplifications des Soins Patients Chirurgicaux Complexes) Research Unit,
      University of Picardie Jules Verne, Amiens, France.
AD  - Intensive Care Unit, Amiens University Medical Center, Amiens, France.
FAU - Diouf, M
AU  - Diouf M
AD  - Department of Methodology, Biostatistics, Direction of Clinical Research, Amiens 
      University Medical Center, Amiens, France.
FAU - Schmit, J L
AU  - Schmit JL
AD  - Jules Verne University of Picardie, Amiens, France.
AD  - Department of Infectious Diseases, Amiens University Medical Center, Amiens,
      France.
FAU - Boddaert, S
AU  - Boddaert S
AD  - Department of Pharmacology, Amiens University Medical Center, Amiens, France.
FAU - Regimbeau, J M
AU  - Regimbeau JM
AD  - Department of Digestive Surgery, Amiens University Hospital, Amiens University
      Medical Center, Avenue Laennec, F-80054, Amiens cedex 01, France.
      regimbeau.jean-marc@chu-amiens.fr.
AD  - Jules Verne University of Picardie, Amiens, France.
      regimbeau.jean-marc@chu-amiens.fr.
AD  - SSPC (Simplifications des Soins Patients Chirurgicaux Complexes) Research Unit,
      University of Picardie Jules Verne, Amiens, France.
      regimbeau.jean-marc@chu-amiens.fr.
LA  - eng
SI  - ClinicalTrials.gov/NCT03688295
GR  - PI2017-843-0002/PHRC national (French national ground)
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200601
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Abdominal Abscess/epidemiology/*prevention & control
MH  - Administration, Intravenous
MH  - Anti-Bacterial Agents/*administration & dosage/adverse effects
MH  - Appendectomy/*adverse effects
MH  - Appendicitis/*surgery
MH  - Clinical Trials, Phase III as Topic
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Surgical Wound Infection/epidemiology/*prevention & control
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7268648
OTO - NOTNLM
OT  - Antibiotic therapy
OT  - Complicated appendicitis
EDAT- 2020/06/04 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/11/24 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 10.1186/s13063-020-04411-1 [doi]
AID - 10.1186/s13063-020-04411-1 [pii]
PST - epublish
SO  - Trials. 2020 Jun 1;21(1):451. doi: 10.1186/s13063-020-04411-1.


PMID- 32487176
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20211204
IS  - 1478-4505 (Electronic)
IS  - 1478-4505 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Jun 1
TI  - Capacity building for implementation research: a methodology for advancing health
      research and practice.
PG  - 53
LID - 10.1186/s12961-020-00568-y [doi]
AB  - BACKGROUND: Implementation research is increasingly being recognised as an
      important discipline seeking to maximise the benefits of evidence-based
      interventions. Although capacity-building efforts are ongoing, there has been
      limited attention on the contextual and health system peculiarities in low- and
      middle-income countries. Moreover, given the challenges encountered during the
      implementation of health interventions, the field of implementation research
      requires a creative attempt to build expertise for health researchers and
      practitioners simultaneously. With support from the Special Programme for
      Research and Training in Tropical Diseases, we have developed an implementation
      research short course that targets both researchers and practitioners. This paper
      seeks to explain the course development processes and report on training
      evaluations, highlighting its relevance for inter-institutional and
      inter-regional capacity strengthening. METHODS: The development of the
      implementation research course curriculum was categorised into four phases,
      namely the formation of a core curriculum development team, course content
      development, internal reviews and pilot, and external reviews and evaluations.
      Five modules were developed covering Introduction to implementation research,
      Methods in implementation research, Ethics and quality management in
      implementation research, Community and stakeholder engagement, and Dissemination 
      in implementation research. Course evaluations were conducted using developed
      tools measuring participants' reactions and learning. RESULTS: From 2016 to 2018,
      the IR curriculum has been used to train a total of 165 researchers and
      practitioners predominantly from African countries, the majority of whom are
      males (57%) and researchers/academics (79.4%). Participants generally gave
      positive ratings (e.g. integration of concepts) for their reactions to the
      training. Under 'learnings', participants indicated improvement in their
      knowledge in areas such as identification of implementation research problems and
      questions. CONCLUSION: The approach for training both researchers and
      practitioners offers a dynamic opportunity for the acquisition and sharing of
      knowledge for both categories of learners. This approach was crucial in
      demonstrating a key characteristic of implementation research (e.g.
      multidisciplinary) practically evident during the training sessions. Using such a
      model to effectively train participants from various low- and middle-income
      countries shows the opportunities this training curriculum offers as a
      capacity-building tool.
FAU - Dako-Gyeke, Phyllis
AU  - Dako-Gyeke P
AD  - Department of Social and Behavioural Sciences, School of Public Health,
      University of Ghana, Geneva, Switzerland.
FAU - Asampong, Emmanuel
AU  - Asampong E
AUID- ORCID: http://orcid.org/0000-0002-1926-1118
AD  - Department of Social and Behavioural Sciences, School of Public Health,
      University of Ghana, Geneva, Switzerland. easampong@ug.edu.gh.
FAU - Afari, Edwin
AU  - Afari E
AD  - Department of Epidemiology and Disease Control, School of Public Health,
      University of Ghana, World Health Organization, Geneva, Switzerland.
FAU - Launois, Pascal
AU  - Launois P
AD  - World Health Organization, Geneva, Switzerland.
FAU - Ackumey, Mercy
AU  - Ackumey M
AD  - Department of Social and Behavioural Sciences, School of Public Health,
      University of Ghana, Geneva, Switzerland.
FAU - Opoku-Mensah, Kwabena
AU  - Opoku-Mensah K
AD  - Department of Social and Behavioural Sciences, School of Public Health,
      University of Ghana, Geneva, Switzerland.
FAU - Dery, Samuel
AU  - Dery S
AD  - Department of Biostatistics and Health Informatics, School of Public Health,
      University of Ghana, Accra, Ghana.
FAU - Akweongo, Patricia
AU  - Akweongo P
AD  - Department of Health Policy, Planning and Management, School of Public Health,
      University of Ghana, Accra, Ghana.
FAU - Nonvignon, Justice
AU  - Nonvignon J
AD  - Department of Health Policy, Planning and Management, School of Public Health,
      University of Ghana, Accra, Ghana.
FAU - Aikins, Moses
AU  - Aikins M
AD  - Department of Health Policy, Planning and Management, School of Public Health,
      University of Ghana, Accra, Ghana.
LA  - eng
GR  - RE 48/WHO_/World Health Organization/International
PT  - Journal Article
DEP - 20200601
PL  - England
TA  - Health Res Policy Syst
JT  - Health research policy and systems
JID - 101170481
SB  - IM
MH  - Africa
MH  - *Capacity Building
MH  - *Curriculum
MH  - Delivery of Health Care
MH  - Developing Countries
MH  - Ethics, Research
MH  - Female
MH  - Health Personnel/*education
MH  - Health Services Research
MH  - Humans
MH  - Information Dissemination
MH  - Learning
MH  - Male
MH  - Personal Satisfaction
MH  - Research/*education
MH  - Research Design
MH  - Research Personnel/*education
MH  - *Stakeholder Participation
MH  - Translational Research, Biomedical
PMC - PMC7268492
OTO - NOTNLM
OT  - Africa
OT  - Implementation research
OT  - LMICs
OT  - capacity-building
OT  - practitioners
EDAT- 2020/06/04 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/06/04 06:00
PHST- 2019/09/27 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.1186/s12961-020-00568-y [doi]
AID - 10.1186/s12961-020-00568-y [pii]
PST - epublish
SO  - Health Res Policy Syst. 2020 Jun 1;18(1):53. doi: 10.1186/s12961-020-00568-y.


PMID- 32486621
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 2005-7288 (Electronic)
IS  - 2005-727X (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - Faculty development in medical education: an environmental scan in countries
      within the Asia pacific region.
PG  - 119-130
LID - 10.3946/kjme.2020.160 [doi]
AB  - PURPOSE: In recent years, faculty development (FD) research is more noticeable
      within an inter-professional context and in allied health education. However,
      there is a paucity of published literature on FD medical education programs in
      Asia. With the formation of the Asia Pacific Medical Education Network (APME-Net)
      in 2015, a scoping review of an environmental scan of FD medical education
      programs in main institutions in South East Asia and Australia in 2018 was
      conducted. METHODS: A survey was developed to collect data on FD in medical
      education after several rounds of discussion with APME-Net members. The
      representatives from nine countries in Asia and Australia were invited to partner
      in this research project. They sent the questionnaire to the Dean of all
      different medical schools after ethical clearance. The data collected was
      analyzed using descriptive statistics. RESULTS: Only institutions in four
      countries responded to the questionnaire. The medical/health professions
      education center/department/unit has been established in most educational
      institutions in these countries. These centers/departments/units mostly carry out
      FD programs to improve the teaching and learning skills of trained participants, 
      particularly clinical teachers via workshops and seminars. Staffing issues and
      participant buy-in are the current key priorities of the center/department/unit
      in terms of FD. Lastly, research related FD program has not been well-supported
      in these countries, hence, the lack of publication in this area. CONCLUSION:
      Collaboration between countries to address key areas of interest and develop more
      standardized and productive FD medical education is required especially in
      research.
FAU - Samarasekera, Dujeepa D
AU  - Samarasekera DD
AD  - Centre for Medical Education, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Lee, Shuh Shing
AU  - Lee SS
AD  - Centre for Medical Education, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Findyartini, Ardi
AU  - Findyartini A
AD  - Department of Medical Education, Faculty of Medicine, Universitas Indonesia,
      Jakarta, Indonesia.
FAU - Mustika, Rita
AU  - Mustika R
AD  - Department of Medical Education, Faculty of Medicine, Universitas Indonesia,
      Jakarta, Indonesia.
FAU - Nishigori, Hiroshi
AU  - Nishigori H
AD  - Center for Medical Education, Graduate School of Medicine, Nagoya University,
      Nagoya, Japan.
FAU - Kimura, Shunsuke
AU  - Kimura S
AD  - Medical Education Center, Kyoto University, Kyoto, Japan.
FAU - Lee, Young-Mee
AU  - Lee YM
AD  - Department of Medical Education, Korea University College of Medicine, Seoul,
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - Korea (South)
TA  - Korean J Med Educ
JT  - Korean journal of medical education
JID - 101503071
SB  - IM
MH  - Asia
MH  - Australia
MH  - *Education, Medical
MH  - *Faculty, Medical
MH  - Humans
MH  - *Schools, Medical
MH  - *Staff Development
MH  - Surveys and Questionnaires
PMC - PMC7272377
OTO - NOTNLM
OT  - Medical education
OT  - Multicenter study
OT  - Staff development
OT  - Teacher training
EDAT- 2020/06/04 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
AID - kjme.2020.160 [pii]
AID - 10.3946/kjme.2020.160 [doi]
PST - ppublish
SO  - Korean J Med Educ. 2020 Jun;32(2):119-130. doi: 10.3946/kjme.2020.160. Epub 2020 
      May 28.


PMID- 32485887
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 11
DP  - 2020 May 29
TI  - Animal Models Used in Hepatitis C Virus Research.
LID - E3869 [pii]
LID - 10.3390/ijms21113869 [doi]
AB  - The narrow range of species permissive to infection by hepatitis C virus (HCV)
      presents a unique challenge to the development of useful animal models for
      studying HCV, as well as host immune responses and development of chronic
      infection and disease. Following earlier studies in chimpanzees, several unique
      approaches have been pursued to develop useful animal models for research while
      avoiding the important ethical concerns and costs inherent in research with
      chimpanzees. Genetically related hepatotropic viruses that infect animals are
      being used as surrogates for HCV in research studies; chimeras of these surrogate
      viruses harboring specific regions of the HCV genome are being developed to
      improve their utility for vaccine testing. Concurrently, genetically humanized
      mice are being developed and continually advanced using human factors known to be
      involved in virus entry and replication. Further, xenotransplantation of human
      hepatocytes into mice allows for the direct study of HCV infection in human liver
      tissue in a small animal model. The current advances in each of these approaches 
      are discussed in the present review.
FAU - Berggren, Keith A
AU  - Berggren KA
AUID- ORCID: 0000-0002-6849-8015
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08540, USA.
FAU - Suzuki, Saori
AU  - Suzuki S
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08540, USA.
FAU - Ploss, Alexander
AU  - Ploss A
AD  - Department of Molecular Biology, Princeton University, Princeton, NJ 08540, USA.
LA  - eng
GR  - 101539/Burroughs Wellcome Fund
GR  - R01 AI138797/AI/NIAID NIH HHS/United States
GR  - R01 AI153236/AI/NIAID NIH HHS/United States
GR  - W81XWH1810237/U.S. Department of Defense
GR  - T32GM007388/GM/NIGMS NIH HHS/United States
GR  - T32 GM007388/GM/NIGMS NIH HHS/United States
GR  - R01AI153236/National Institute of Allergy and Infectious Diseases
GR  - RSG-15-048-01-MPC/American Cancer Society
GR  - R01AI107301/National Institute of Allergy and Infectious Diseases
GR  - R01 AI107301/AI/NIAID NIH HHS/United States
GR  - R01 AI146917/AI/NIAID NIH HHS/United States
GR  - R01AI146917/National Institute of Allergy and Infectious Diseases
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - *Disease Models, Animal
MH  - Hepacivirus/genetics/pathogenicity/*physiology
MH  - Hepatitis C/genetics/pathology/*virology
MH  - Host-Pathogen Interactions
MH  - Humans
MH  - Mice
MH  - Primates
PMC - PMC7312079
OTO - NOTNLM
OT  - animal model
OT  - hepatitis C
OT  - hepatitis C virus
OT  - host tropism
OT  - humanized mice
EDAT- 2020/06/04 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/06/04 06:00
PHST- 2020/05/18 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - ijms21113869 [pii]
AID - 10.3390/ijms21113869 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 May 29;21(11). pii: ijms21113869. doi: 10.3390/ijms21113869.


PMID- 32485865
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-328X (Print)
IS  - 2076-328X (Linking)
VI  - 10
IP  - 6
DP  - 2020 May 29
TI  - Teachers' Constructivist and Ethical Beliefs.
LID - E96 [pii]
LID - 10.3390/bs10060096 [doi]
AB  - Teachers' approaches and beliefs are key determinants of teachers' practice. This
      study was designed to examine whether two aspects of Irish primary teacher
      beliefs are associated, their views on constructivist practices and their views
      on two ethical dimensions (idealism and relativism). The views of a sample of 35 
      teachers were assessed using the Constructivist Learning Environment Survey
      (CLES) and the Ethical Position Questionnaire (EPQ). Significant relationships
      were found between ethical position and scores on dimensions on the CLES. For
      example, idealistic teachers valued uncertainty and student negotiation more than
      teachers with high relativist scores. The results are discussed in the context of
      continuing professional development and future research.
FAU - Sharkey, Marie
AU  - Sharkey M
AD  - English Department, British International School, Ajman PO Box 8811, UAE.
FAU - Gash, Hugh
AU  - Gash H
AUID- ORCID: 0000-0002-9502-7067
AD  - Institute of Education, Dublin City University, D09 Y18 Dublin, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Switzerland
TA  - Behav Sci (Basel)
JT  - Behavioral sciences (Basel, Switzerland)
JID - 101576826
PMC - PMC7349369
OTO - NOTNLM
OT  - beliefs
OT  - constructivism
OT  - ethics
OT  - idealism
OT  - relativism
OT  - teachers
EDAT- 2020/06/04 06:00
MHDA- 2020/06/04 06:01
CRDT- 2020/06/04 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2020/06/04 06:01 [medline]
AID - bs10060096 [pii]
AID - 10.3390/bs10060096 [doi]
PST - epublish
SO  - Behav Sci (Basel). 2020 May 29;10(6). pii: bs10060096. doi: 10.3390/bs10060096.


PMID- 34713016
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211030
IS  - 2673-253X (Electronic)
IS  - 2673-253X (Linking)
VI  - 2
DP  - 2020
TI  - Using Self-Study and Peer-to-Peer Support to Change "Sick" Care to "Health" Care:
      The Patient Perspective.
PG  - 2
LID - 10.3389/fdgth.2020.00002 [doi]
AB  - Background: Access to digital health technologies is contributing to a paradigm
      shift where sickcare may become authentic healthcare. Individuals can now access 
      personal health data through wearable sensors, affordable lab screenings, genetic
      and genomic sequencing, and real-time health tracking apps. Personal health data 
      access creates opportunities to study health indicators 24/7 and in real time.
      This is especially useful for patients with hard-to-diagnose or treat diseases,
      which led to a self-formed patient group called Project Apollo. Project Apollo is
      composed of highly motivated patients with common experiences of undiagnosed
      conditions, a lack of clear treatment options, and shared frustrations with
      navigating the U.S. healthcare system. These experiences have led the Apollo
      cohort to supplement their health knowledge through self-study research.
      Objective: To qualify the experience and expectations of patients affiliated with
      Project Apollo. Methods: A qualitative approach involved record review and
      semi-structured interviews. One-hour semi-structured interviews were conducted to
      solicit motivations, expectations, and potential barriers and facilitators to
      self-study followed by a brief survey on digital tool use. Interviews were
      digitally recorded, transcribed, and analyzed to identify themes and patterns.
      Results: Participants included six females and three males ranging in age from 30
      to 70+ years. Responses were organized under five key themes including:
      frustration with healthcare system; community support; self-study/N-of-1
      research; access to experts; moving from sick to healthcare. Facilitators include
      motivation, albeit stemming from frustration, a safe community where patients
      derive support, and access to experts for guidance. Increasing awareness of
      clinicians about the potential value of partnering with patients who are
      advancing health knowledge through self-study is critical. Conclusions: N-of-1
      self-study research, coupled with community support and digital health tools,
      appears to be one plausible pathway to shifting the paradigm from sickcare toward
      patient-partnered healthcare.
CI  - Copyright (c) 2020 Nebeker, Weisberg, Hekler and Kurisu.
FAU - Nebeker, Camille
AU  - Nebeker C
AD  - Department of Family Medicine and Public Health, School of Medicine, University
      of California, San Diego, La Jolla, CA, United States.
AD  - Center for Wireless and Population Health Systems, UC San Diego, La Jolla, CA,
      United States.
AD  - The Design Lab, UC San Diego, La Jolla, CA, United States.
FAU - Weisberg, Bethany
AU  - Weisberg B
AD  - Department of Family Medicine and Public Health, School of Medicine, University
      of California, San Diego, La Jolla, CA, United States.
FAU - Hekler, Eric
AU  - Hekler E
AD  - Department of Family Medicine and Public Health, School of Medicine, University
      of California, San Diego, La Jolla, CA, United States.
AD  - Center for Wireless and Population Health Systems, UC San Diego, La Jolla, CA,
      United States.
AD  - The Design Lab, UC San Diego, La Jolla, CA, United States.
FAU - Kurisu, Michael
AU  - Kurisu M
AD  - Department of Family Medicine and Public Health, School of Medicine, University
      of California, San Diego, La Jolla, CA, United States.
AD  - Center for Wireless and Population Health Systems, UC San Diego, La Jolla, CA,
      United States.
AD  - The Design Lab, UC San Diego, La Jolla, CA, United States.
LA  - eng
PT  - Journal Article
DEP - 20200604
PL  - Switzerland
TA  - Front Digit Health
JT  - Frontiers in digital health
JID - 101771889
PMC - PMC8522003
OTO - NOTNLM
OT  - N-of-1
OT  - Research Ethics
OT  - citizen science
OT  - digital health
OT  - participant-led research
OT  - peer-to-peer support
OT  - self-tracking
EDAT- 2020/06/04 00:00
MHDA- 2020/06/04 00:01
CRDT- 2021/10/29 06:34
PHST- 2019/12/01 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2021/10/29 06:34 [entrez]
PHST- 2020/06/04 00:00 [pubmed]
PHST- 2020/06/04 00:01 [medline]
AID - 10.3389/fdgth.2020.00002 [doi]
PST - epublish
SO  - Front Digit Health. 2020 Jun 4;2:2. doi: 10.3389/fdgth.2020.00002. eCollection
      2020.


PMID- 32485440
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1557-8615 (Electronic)
IS  - 0883-9441 (Linking)
VI  - 59
DP  - 2020 Oct
TI  - Informed consent procedures in patients with an acute inability to provide
      informed consent: Policy and practice in the CENTER-TBI study.
PG  - 6-15
LID - S0883-9441(20)30563-3 [pii]
LID - 10.1016/j.jcrc.2020.05.004 [doi]
AB  - PURPOSE: Enrolling traumatic brain injury (TBI) patients with an inability to
      provide informed consent in research is challenging. Alternatives to patient
      consent are not sufficiently embedded in European and national legislation, which
      allows procedural variation and bias. We aimed to quantify variations in informed
      consent policy and practice. METHODS: Variation was explored in the CENTER-TBI
      study. Policies were reported by using a questionnaire and national legislation. 
      Data on used informed consent procedures were available for 4498 patients from 57
      centres across 17 European countries. RESULTS: Variation in the use of informed
      consent procedures was found between and within EU member states. Proxy informed 
      consent (N=1377;64%) was the most frequently used type of consent in the ICU,
      followed by patient informed consent (N=426;20%) and deferred consent
      (N=334;16%). Deferred consent was only actively used in 15 centres (26%),
      although it was considered valid in 47 centres (82%). CONCLUSIONS: Alternatives
      to patient consent are essential for TBI research. While there seems to be
      concordance amongst national legislations, there is regional variability in
      institutional practices with respect to the use of different informed consent
      procedures. Variation could be caused by several reasons, including
      inconsistencies in clear legislation or knowledge of such legislation amongst
      researchers.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - van Wijk, Roel P J
AU  - van Wijk RPJ
AD  - University Neurosurgical Center Holland, LUMC, HMC & HAGA, Leiden & The Hague,
      the Netherlands.
FAU - van Dijck, Jeroen T J M
AU  - van Dijck JTJM
AD  - University Neurosurgical Center Holland, LUMC, HMC & HAGA, Leiden & The Hague,
      the Netherlands.
FAU - Timmers, Marjolein
AU  - Timmers M
AD  - Department of Intensive Care, Erasmus MC - University Medical Centre Rotterdam,
      Rotterdam, the Netherlands.
FAU - van Veen, Ernest
AU  - van Veen E
AD  - Department of Intensive Care, Erasmus MC - University Medical Centre Rotterdam,
      Rotterdam, the Netherlands; Centre for Medical Decision Making, Department of
      Public Health, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the
      Netherlands.
FAU - Citerio, Giuseppe
AU  - Citerio G
AD  - School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; San
      Gerardo Hospital, ASST, Monza, Italy.
FAU - Lingsma, Hester F
AU  - Lingsma HF
AD  - Centre for Medical Decision Making, Department of Public Health, Erasmus MC -
      University Medical Centre Rotterdam, Rotterdam, the Netherlands.
FAU - Maas, Andrew I R
AU  - Maas AIR
AD  - Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium;
      University of Antwerp, Antwerp, Belgium.
FAU - Menon, David K
AU  - Menon DK
AD  - Department of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.
FAU - Peul, Wilco C
AU  - Peul WC
AD  - University Neurosurgical Center Holland, LUMC, HMC & HAGA, Leiden & The Hague,
      the Netherlands.
FAU - Stocchetti, Nino
AU  - Stocchetti N
AD  - Department of Physiopathology and Transplantation, Milan University, Milan,
      Italy; Neuro ICU Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milano,
      Milan, Italy.
FAU - Kompanje, Erwin J O
AU  - Kompanje EJO
AD  - Department of Intensive Care, Erasmus MC - University Medical Centre Rotterdam,
      Rotterdam, the Netherlands; Department of Medical Ethics and Philosophy of
      Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, the
      Netherlands. Electronic address: e.j.o.kompanje@erasmusmc.nl.
CN  - CENTER-TBI investigators and participants
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - United States
TA  - J Crit Care
JT  - Journal of critical care
JID - 8610642
SB  - IM
MH  - Brain Injuries, Traumatic/blood/epidemiology/*psychology
MH  - Europe/epidemiology
MH  - Follow-Up Studies
MH  - Human Experimentation/*legislation & jurisprudence
MH  - Humans
MH  - Informed Consent/*legislation & jurisprudence
MH  - Intensive Care Units
MH  - Israel/epidemiology
MH  - Patient Admission
MH  - *Policy
MH  - Prospective Studies
MH  - Proxy/*legislation & jurisprudence
MH  - Research Personnel/psychology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Ethics
OT  - *European Union
OT  - *Informed consent
OT  - *Traumatic brain injury
COIS- Declaration of Competing Interest The authors declare that they have no competing
      interests.
IR  - Akerlund C
FIR - Akerlund, Cecilia
IRAD- Department of Physiology and Pharmacology, Section of Perioperative Medicine and 
      Intensive Care, Karolinska Institutet, Stockholm, Sweden.
IR  - Amrein K
FIR - Amrein, Krisztina
IRAD- Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
IR  - Andelic N
FIR - Andelic, Nada
IRAD- Division of Surgery and Clinical Neuroscience, Department of Physical Medicine
      and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo,
      Norway.
IR  - Andreassen L
FIR - Andreassen, Lasse
IRAD- Department of Neurosurgery, University Hospital Northern Norway, Tromso, Norway.
IR  - Anke A
FIR - Anke, Audny
IRAD- Department of Physical Medicine and Rehabilitation, University Hospital Northern 
      Norway, Tromso, Norway.
IR  - Antoni A
FIR - Antoni, Anna
IRAD- Trauma Surgery, Medical University Vienna, Vienna, Austria.
IR  - Audibert G
FIR - Audibert, Gerard
IRAD- Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, 
      France.
IR  - Azouvi P
FIR - Azouvi, Philippe
IRAD- Raymond Poincare hospital, Hopitaux de Paris, Paris, France.
IR  - Azzolini ML
FIR - Azzolini, Maria Luisa
IRAD- Department of Anesthesiology & Intensive Care, S Raffaele University Hospital,
      Milan, Italy.
IR  - Bartels R
FIR - Bartels, Ronald
IRAD- Department of Neurosurgery, Radboud University Medical Center, Nijmegen, the
      Netherlands.
IR  - Barzo P
FIR - Barzo, Pal
IRAD- Department of Neurosurgery, University of Szeged, Szeged, Hungary.
IR  - Beauvais R
FIR - Beauvais, Romuald
IRAD- International Projects Management, ARTTIC, Munchen, Germany.
IR  - Beer R
FIR - Beer, Ronny
IRAD- Department of Neurology, Neurological Intensive Care Unit, Medical University of 
      Innsbruck, Innsbruck, Austria.
IR  - Bellander BM
FIR - Bellander, Bo-Michael
IRAD- Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska
      University Hospital, Stockholm, Sweden.
IR  - Belli A
FIR - Belli, Antonio
IRAD- NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK.
IR  - Benali H
FIR - Benali, Habib
IRAD- Anesthesie-Reanimation, Hopitaux de Paris, Paris, France.
IR  - Berardino M
FIR - Berardino, Maurizio
IRAD- Department of Anesthesia & ICU, AOU Citta della Salute e della Scienza di Torino 
      - Orthopedic and Trauma Center, Torino, Italy.
IR  - Beretta L
FIR - Beretta, Luigi
IRAD- Department of Anesthesiology & Intensive Care, S Raffaele University Hospital,
      Milan, Italy.
IR  - Blaabjerg M
FIR - Blaabjerg, Morten
IRAD- Department of Neurology, Odense University Hospital, Odense, Denmark.
IR  - Bragge P
FIR - Bragge, Peter
IRAD- BehaviourWorks Australia, Monash Sustainability Institute, Monash University,
      Victoria, Australia.
IR  - Brazinova A
FIR - Brazinova, Alexandra
IRAD- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava
      University, Trnava, Slovakia.
IR  - Brinck V
FIR - Brinck, Vibeke
IRAD- Quesgen Systems Inc, Burlingame, CA, USA.
IR  - Brooker J
FIR - Brooker, Joanne
IRAD- Australian & New Zealand Intensive Care Research Centre, Department of
      Epidemiology and Preventive Medicine, School of Public Health and Preventive
      Medicine, Monash University, Melbourne, Australia.
IR  - Brorsson C
FIR - Brorsson, Camilla
IRAD- Department of Surgery and Perioperative Science, Umea University, Umea, Sweden.
IR  - Buki A
FIR - Buki, Andras
IRAD- Department of Neurosurgery, Medical School, Hungary and Neurotrauma Research
      Group, Janos Szentagothai Research Centre, University of Pecs, Hungary.
IR  - Bullinger M
FIR - Bullinger, Monika
IRAD- Department of Medical Psychology, Universitatsklinikum Hamburg-Eppendorf,
      Hamburg, Germany.
IR  - Cabeleira M
FIR - Cabeleira, Manuel
IRAD- Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences,
      University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
IR  - Caccioppola A
FIR - Caccioppola, Alessio
IRAD- Neuro ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan,
      Italy.
IR  - Calappi E
FIR - Calappi, Emiliana
IRAD- Neuro ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan,
      Italy.
IR  - Calvi MR
FIR - Calvi, Maria Rosa
IRAD- Department of Anesthesiology & Intensive Care, S Raffaele University Hospital,
      Milan, Italy.
IR  - Cameron P
FIR - Cameron, Peter
IRAD- ANZIC Research Centre, Monash University, Department of Epidemiology and
      Preventive Medicine, Melbourne, Victoria, Australia.
IR  - Lozano GC
FIR - Lozano, Guillermo Carbayo
IRAD- Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain.
IR  - Carbonara M
FIR - Carbonara, Marco
IRAD- Neuro ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan,
      Italy.
IR  - Cavallo S
FIR - Cavallo, Simona
IRAD- Department of Anesthesia & ICU, AOU Citta della Salute e della Scienza di Torino 
      - Orthopedic and Trauma Center, Torino, Italy.
IR  - Chevallard G
FIR - Chevallard, Giorgio
IRAD- NeuroIntensive Care, Niguarda Hospital, Milan, Italy.
IR  - Chieregato A
FIR - Chieregato, Arturo
IRAD- NeuroIntensive Care, Niguarda Hospital, Milan, Italy.
IR  - Citerio G
FIR - Citerio, Giuseppe
IRAD- School of Medicine and Surgery, Universita Milano Bicocca, Milano, Italy;
      NeuroIntensive Care, ASST di Monza, Monza, Italy.
IR  - Ceyisakar I
FIR - Ceyisakar, Iris
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Coburn M
FIR - Coburn, Mark
IRAD- Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany.
IR  - Coles J
FIR - Coles, Jonathan
IRAD- Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS
      Foundation Trust, Cambridge, UK.
IR  - Cooper JD
FIR - Cooper, Jamie D
IRAD- School of Public Health & PM, Monash University and The Alfred Hospital,
      Melbourne, Victoria, Australia.
IR  - Correia M
FIR - Correia, Marta
IRAD- Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK.
IR  - Covic A
FIR - Covic, Amra
IRAD- Institute of Medical Psychology and Medical Sociology, Universitatsmedizin
      Gottingen, Gottingen, Germany.
IR  - Curry N
FIR - Curry, Nicola
IRAD- Oxford University Hospitals NHS Trust, Oxford, UK.
IR  - Czeiter E
FIR - Czeiter, Endre
IRAD- Department of Neurosurgery, Medical School, Hungary and Neurotrauma Research
      Group, Janos Szentagothai Research Centre, University of Pecs, Hungary.
IR  - Czosnyka M
FIR - Czosnyka, Marek
IRAD- Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences,
      University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
IR  - Dahyot-Fizelier C
FIR - Dahyot-Fizelier, Claire
IRAD- Intensive Care Unit, CHU Poitiers, Potiers, France.
IR  - Dark P
FIR - Dark, Paul
IRAD- University of Manchester NIHR Biomedical Research Centre, Critical Care
      Directorate, Salford Royal Hospital NHS Foundation Trust, Salford, UK.
IR  - Dawes H
FIR - Dawes, Helen
IRAD- Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
      University, Oxford, UK.
IR  - De Keyser V
FIR - De Keyser, Veronique
IRAD- Department of Neurosurgery, Antwerp University Hospital and University of
      Antwerp, Edegem, Belgium.
IR  - Degos V
FIR - Degos, Vincent
IRAD- Anesthesie-Reanimation, Hopitaux de Paris, Paris, France.
IR  - Corte FD
FIR - Corte, Francesco Della
IRAD- Department of Anesthesia & Intensive Care, Maggiore Della Carita Hospital,
      Novara, Italy.
IR  - den Boogert H
FIR - den Boogert, Hugo
IRAD- Department of Neurosurgery, Radboud University Medical Center, Nijmegen, the
      Netherlands.
IR  - Depreitere B
FIR - Depreitere, Bart
IRAD- Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium.
IR  - Dilvesi D
FIR - Dilvesi, Dula
IRAD- Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,
      University of Novi Sad, Novi Sad, Serbia.
IR  - Dixit A
FIR - Dixit, Abhishek
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Donoghue E
FIR - Donoghue, Emma
IRAD- Australian & New Zealand Intensive Care Research Centre, Department of
      Epidemiology and Preventive Medicine, School of Public Health and Preventive
      Medicine, Monash University, Melbourne, Australia.
IR  - Dreier J
FIR - Dreier, Jens
IRAD- Center for Stroke Research Berlin, Charite, Universitatsmedizin Berlin, Freie
      Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin Institute of Health,
      Berlin, Germany.
IR  - Duliere GL
FIR - Duliere, Guy-Loup
IRAD- Intensive Care Unit, CHR Citadelle, Liege, Belgium.
IR  - Ercole A
FIR - Ercole, Ari
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Esser P
FIR - Esser, Patrick
IRAD- Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
      University, Oxford, UK.
IR  - Ezer E
FIR - Ezer, Erzsebet
IRAD- Department of Anaesthesiology and Intensive Therapy, University of Pecs, Pecs,
      Hungary.
IR  - Fabricius M
FIR - Fabricius, Martin
IRAD- Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology,
      Region Hovedstaden Rigshospitalet, Copenhagen, Denmark.
IR  - Feigin VL
FIR - Feigin, Valery L
IRAD- National Institute for Stroke and Applied Neurosciences, Faculty of Health and
      Environmental Studies, Auckland University of Technology, Auckland, New Zealand.
IR  - Foks K
FIR - Foks, Kelly
IRAD- Department of Neurology, Erasmus MC, Rotterdam, the Netherlands.
IR  - Frisvold S
FIR - Frisvold, Shirin
IRAD- Department of Anesthesiology and Intensive care, University Hospital Northern
      Norway, Tromso, Norway.
IR  - Furmanov A
FIR - Furmanov, Alex
IRAD- Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem,
      Israel.
IR  - Gagliardo P
FIR - Gagliardo, Pablo
IRAD- Fundacion Instituto Valenciano de Neurorrehabilitacion (FIVAN), Valencia, Spain.
IR  - Galanaud D
FIR - Galanaud, Damien
IRAD- Anesthesie-Reanimation, Hopitaux de Paris, Paris, France.
IR  - Gantner D
FIR - Gantner, Dashiell
IRAD- ANZIC Research Centre, Monash University, Department of Epidemiology and
      Preventive Medicine, Melbourne, Victoria, Australia.
IR  - Gao G
FIR - Gao, Guoyi
IRAD- Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong
      University/school of medicine, Shanghai, China.
IR  - George P
FIR - George, Pradeep
IRAD- Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility,
      Stockholm, Sweden.
IR  - Ghuysen A
FIR - Ghuysen, Alexandre
IRAD- Emergency Department, CHU, Liege, Belgium.
IR  - Giga L
FIR - Giga, Lelde
IRAD- Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia.
IR  - Glocker B
FIR - Glocker, Ben
IRAD- Department of Computing, Imperial College London, London, UK.
IR  - Golubovic J
FIR - Golubovic, Jagos
IRAD- Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,
      University of Novi Sad, Novi Sad, Serbia.
IR  - Gomez PA
FIR - Gomez, Pedro A
IRAD- Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain.
IR  - Gratz J
FIR - Gratz, Johannes
IRAD- Department of Anesthesia, Critical Care and Pain Medicine, Medical University of 
      Vienna, Austria.
IR  - Gravesteijn B
FIR - Gravesteijn, Benjamin
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Grossi F
FIR - Grossi, Francesca
IRAD- Department of Anesthesia & Intensive Care, Maggiore Della Carita Hospital,
      Novara, Italy.
IR  - Gruen RL
FIR - Gruen, Russell L
IRAD- College of Health and Medicine, Australian National University, Canberra,
      Australia.
IR  - Gupta D
FIR - Gupta, Deepak
IRAD- Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All
      India Institute of Medical Sciences, New Delhi 110029, India.
IR  - Haagsma JA
FIR - Haagsma, Juanita A
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Haitsma I
FIR - Haitsma, Iain
IRAD- Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands.
IR  - Helbok R
FIR - Helbok, Raimund
IRAD- Department of Neurology, Neurological Intensive Care Unit, Medical University of 
      Innsbruck, Innsbruck, Austria.
IR  - Helseth E
FIR - Helseth, Eirik
IRAD- Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.
IR  - Horton L
FIR - Horton, Lindsay
IRAD- Division of Psychology, University of Stirling, Stirling, UK.
IR  - Huijben J
FIR - Huijben, Jilske
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Hutchinson PJ
FIR - Hutchinson, Peter J
IRAD- Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital & University of Cambridge, Cambridge, UK.
IR  - Jacobs B
FIR - Jacobs, Bram
IRAD- Department of Neurology, University of Groningen, University Medical Center
      Groningen, Groningen, the Netherlands.
IR  - Jankowski S
FIR - Jankowski, Stefan
IRAD- Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
IR  - Jarrett M
FIR - Jarrett, Mike
IRAD- Quesgen Systems Inc, Burlingame, CA, USA.
IR  - Jiang JY
FIR - Jiang, Ji-Yao
IRAD- Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong
      University/school of medicine, Shanghai, China.
IR  - Johnson F
FIR - Johnson, Faye
IRAD- Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team,
      Salford, UK.
IR  - Jones K
FIR - Jones, Kelly
IRAD- National Institute for Stroke and Applied Neurosciences, Faculty of Health and
      Environmental Studies, Auckland University of Technology, Auckland, New Zealand.
IR  - Karan M
FIR - Karan, Mladen
IRAD- Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,
      University of Novi Sad, Novi Sad, Serbia.
IR  - Kolias AG
FIR - Kolias, Angelos G
IRAD- Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
      Hospital & University of Cambridge, Cambridge, UK.
IR  - Kompanje E
FIR - Kompanje, Erwin
IRAD- Department of Intensive Care, Department of Ethics and Philosophy of Medicine,
      Erasmus Medical Center, Rotterdam, the Netherlands.
IR  - Kondziella D
FIR - Kondziella, Daniel
IRAD- Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology,
      Region Hovedstaden Rigshospitalet, Copenhagen, Denmark.
IR  - Koraropoulos E
FIR - Koraropoulos, Evgenios
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Koskinen LO
FIR - Koskinen, Lars-Owe
IRAD- Department of Clinical Neuroscience, Neurosurgery, Umea University, Umea, Sweden.
IR  - Kovacs N
FIR - Kovacs, Noemi
IRAD- Hungarian Brain Research Program - Grant No. KTIA_13_NAP-A-II/8, University of
      Pecs, Pecs, Hungary.
IR  - Kowark A
FIR - Kowark, Ana
IRAD- Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany.
IR  - Lagares A
FIR - Lagares, Alfonso
IRAD- Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain.
IR  - Lanyon L
FIR - Lanyon, Linda
IRAD- Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility,
      Stockholm, Sweden.
IR  - Laureys S
FIR - Laureys, Steven
IRAD- Cyclotron Research Center, University of Liege, Liege, Belgium.
IR  - Lecky F
FIR - Lecky, Fiona
IRAD- Centre for Urgent and Emergency Care Research (CURE), Health Services Research
      Section, School of Health and Related Research (ScHARR), University of Sheffield,
      Sheffield, UK; Emergency Department, Salford Royal Hospital, Salford, UK.
IR  - Ledoux D
FIR - Ledoux, Didier
IRAD- Cyclotron Research Center, University of Liege, Liege, Belgium.
IR  - Lefering R
FIR - Lefering, Rolf
IRAD- Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University,
      Cologne, Germany.
IR  - Legrand V
FIR - Legrand, Valerie
IRAD- VP Global Project Management CNS, ICON, Paris, France.
IR  - Lejeune A
FIR - Lejeune, Aurelie
IRAD- Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille,
      France.
IR  - Levi L
FIR - Levi, Leon
IRAD- Department of Neurosurgery, Rambam Medical Center, Haifa, Israel.
IR  - Lightfoot R
FIR - Lightfoot, Roger
IRAD- Department of Anesthesiology & Intensive Care, University Hospitals Southhampton 
      NHS Trust, Southhampton, UK.
IR  - Lingsma H
FIR - Lingsma, Hester
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Maas AIR
FIR - Maas, Andrew I R
IRAD- Department of Neurosurgery, Antwerp University Hospital and University of
      Antwerp, Edegem, Belgium.
IR  - Castano-Leon AM
FIR - Castano-Leon, Ana M
IRAD- Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain.
IR  - Maegele M
FIR - Maegele, Marc
IRAD- Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic
      Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany.
IR  - Majdan M
FIR - Majdan, Marek
IRAD- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava
      University, Trnava, Slovakia.
IR  - Manara A
FIR - Manara, Alex
IRAD- Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK.
IR  - Manley G
FIR - Manley, Geoffrey
IRAD- Department of Neurological Surgery, University of California, San Francisco, CA, 
      USA.
IR  - Martino C
FIR - Martino, Costanza
IRAD- Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy.
IR  - Marechal H
FIR - Marechal, Hugues
IRAD- Intensive Care Unit, CHR Citadelle, Liege, Belgium.
IR  - Mattern J
FIR - Mattern, Julia
IRAD- Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
IR  - McMahon C
FIR - McMahon, Catherine
IRAD- Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool,
      UK.
IR  - Melegh B
FIR - Melegh, Bela
IRAD- Department of Medical Genetics, University of Pecs, Pecs, Hungary.
IR  - Menon D
FIR - Menon, David
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Menovsky T
FIR - Menovsky, Tomas
IRAD- Department of Neurosurgery, Antwerp University Hospital and University of
      Antwerp, Edegem, Belgium.
IR  - Misset B
FIR - Misset, Benoit
IRAD- Cyclotron Research Center, University of Liege, Liege, Belgium.
IR  - Mulazzi D
FIR - Mulazzi, Davide
IRAD- Neuro ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan,
      Italy.
IR  - Muraleedharan V
FIR - Muraleedharan, Visakh
IRAD- Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility,
      Stockholm, Sweden.
IR  - Murray L
FIR - Murray, Lynnette
IRAD- ANZIC Research Centre, Monash University, Department of Epidemiology and
      Preventive Medicine, Melbourne, Victoria, Australia.
IR  - Negru A
FIR - Negru, Ancuta
IRAD- Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,
      Romania.
IR  - Nelson D
FIR - Nelson, David
IRAD- Department of Physiology and Pharmacology, Section of Perioperative Medicine and 
      Intensive Care, Karolinska Institutet, Stockholm, Sweden.
IR  - Newcombe V
FIR - Newcombe, Virginia
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Nieboer D
FIR - Nieboer, Daan
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Nyiradi J
FIR - Nyiradi, Jozsef
IRAD- Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
IR  - Olubukola O
FIR - Olubukola, Otesile
IRAD- Centre for Urgent and Emergency Care Research (CURE), Health Services Research
      Section, School of Health and Related Research (ScHARR), University of Sheffield,
      Sheffield, UK.
IR  - Oresic M
FIR - Oresic, Matej
IRAD- School of Medical Sciences, Orebro University, Orebro, Sweden.
IR  - Ortolano F
FIR - Ortolano, Fabrizio
IRAD- Neuro ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan,
      Italy.
IR  - Palotie A
FIR - Palotie, Aarno
IRAD- Institute for Molecular Medicine Finland, University of Helsinki, Helsinki,
      Finland; Analytic and Translational Genetics Unit, Department of Medicine;
      Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry,
      Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Program
      in Medical and Population Genetics, The Stanley Center for Psychiatric Research, 
      The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
IR  - Parizel PM
FIR - Parizel, Paul M
IRAD- Department of Radiology, University of Antwerp, Edegem, Belgium.
IR  - Payen JF
FIR - Payen, Jean-Francois
IRAD- Department of Anesthesiology & Intensive Care, University Hospital of Grenoble,
      Grenoble, France.
IR  - Perera N
FIR - Perera, Natascha
IRAD- International Projects Management, ARTTIC, Munchen, Germany.
IR  - Perlbarg V
FIR - Perlbarg, Vincent
IRAD- Anesthesie-Reanimation, Hopitaux de Paris, Paris, France.
IR  - Persona P
FIR - Persona, Paolo
IRAD- Department of Anesthesia & Intensive Care, Azienda Ospedaliera Universita di
      Padova, Padova, Italy.
IR  - Peul W
FIR - Peul, Wilco
IRAD- Dept. of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands;
      Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, the Netherlands.
IR  - Piippo-Karjalainen A
FIR - Piippo-Karjalainen, Anna
IRAD- Department of Neurosurgery, Helsinki University Central Hospital, Finland.
IR  - Pirinen M
FIR - Pirinen, Matti
IRAD- Institute for Molecular Medicine Finland, University of Helsinki, Helsinki,
      Finland.
IR  - Ples H
FIR - Ples, Horia
IRAD- Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,
      Romania.
IR  - Polinder S
FIR - Polinder, Suzanne
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Pomposo I
FIR - Pomposo, Inigo
IRAD- Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain.
IR  - Posti JP
FIR - Posti, Jussi P
IRAD- Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain
      Injury Centre, Turku University Hospital and University of Turku, Turku, Finland.
IR  - Puybasset L
FIR - Puybasset, Louis
IRAD- Department of Anesthesiology and Critical Care, Pitie -Salpetriere Teaching
      Hospital, Hopitaux de Paris and University Pierre et Marie Curie, Paris, France.
IR  - Radoi A
FIR - Radoi, Andreea
IRAD- Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research 
      Institute, Barcelona, Spain.
IR  - Ragauskas A
FIR - Ragauskas, Arminas
IRAD- Department of Neurosurgery, Kaunas University of technology and Vilnius
      University, Vilnius, Lithuania.
IR  - Raj R
FIR - Raj, Rahul
IRAD- Department of Neurosurgery, Helsinki University Central Hospital, Finland.
IR  - Rambadagalla M
FIR - Rambadagalla, Malinka
IRAD- Department of Neurosurgery, Rezekne Hospital, Latvia.
IR  - Rhodes J
FIR - Rhodes, Jonathan
IRAD- Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian, University 
      of Edinburg, Edinburgh, UK.
IR  - Richardson S
FIR - Richardson, Sylvia
IRAD- MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK.
IR  - Richter S
FIR - Richter, Sophie
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Ripatti S
FIR - Ripatti, Samuli
IRAD- Institute for Molecular Medicine Finland, University of Helsinki, Helsinki,
      Finland.
IR  - Rocka S
FIR - Rocka, Saulius
IRAD- Department of Neurosurgery, Kaunas University of technology and Vilnius
      University, Vilnius, Lithuania.
IR  - Roe C
FIR - Roe, Cecilie
IRAD- Department of Physical Medicine and Rehabilitation, Oslo University
      Hospital/University of Oslo, Oslo, Norway.
IR  - Roise O
FIR - Roise, Olav
IRAD- Division of Orthopedics, Oslo University Hospital, Oslo, Norway; Institue of
      Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
IR  - Rosand J
FIR - Rosand, Jonathan
IRAD- Broad Institute, Cambridge MA, Harvard Medical School, Boston MA, Massachusetts
      General Hospital, Boston, MA, USA.
IR  - Rosenfeld JV
FIR - Rosenfeld, Jeffrey V
IRAD- National Trauma Research Institute, The Alfred Hospital, Monash University,
      Melbourne, Victoria, Australia.
IR  - Rosenlund C
FIR - Rosenlund, Christina
IRAD- Department of Neurosurgery, Odense University Hospital, Odense, Denmark.
IR  - Rosenthal G
FIR - Rosenthal, Guy
IRAD- Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem,
      Israel.
IR  - Rossaint R
FIR - Rossaint, Rolf
IRAD- Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany.
IR  - Rossi S
FIR - Rossi, Sandra
IRAD- Department of Anesthesia & Intensive Care, Azienda Ospedaliera Universita di
      Padova, Padova, Italy.
IR  - Rueckert D
FIR - Rueckert, Daniel
IRAD- Department of Computing, Imperial College London, London, UK.
IR  - Rusnak M
FIR - Rusnak, Martin
IRAD- International Neurotrauma Research Organisation, Vienna, Austria.
IR  - Sahuquillo J
FIR - Sahuquillo, Juan
IRAD- Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research 
      Institute, Barcelona, Spain.
IR  - Sakowitz O
FIR - Sakowitz, Oliver
IRAD- Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; 
      Klinik fur Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany.
IR  - Sanchez-Porras R
FIR - Sanchez-Porras, Renan
IRAD- Klinik fur Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany.
IR  - Sandor J
FIR - Sandor, Janos
IRAD- Division of Biostatistics and Epidemiology, Department of Preventive Medicine,
      University of Debrecen, Debrecen, Hungary.
IR  - Schafer N
FIR - Schafer, Nadine
IRAD- Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University,
      Cologne, Germany.
IR  - Schmidt S
FIR - Schmidt, Silke
IRAD- Department Health and Prevention, University Greifswald, Greifswald, Germany.
IR  - Schoechl H
FIR - Schoechl, Herbert
IRAD- Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg,
      Austria.
IR  - Schoonman G
FIR - Schoonman, Guus
IRAD- Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the
      Netherlands.
IR  - Schou RF
FIR - Schou, Rico Frederik
IRAD- Department of Neuroanesthesia and Neurointensive Care, Odense University
      Hospital, Odense, Denmark.
IR  - Schwendenwein E
FIR - Schwendenwein, Elisabeth
IRAD- Trauma Surgery, Medical University Vienna, Vienna, Austria.
IR  - Sewalt C
FIR - Sewalt, Charlie
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Skandsen T
FIR - Skandsen, Toril
IRAD- Department of Neuromedicine and Movement Science, Norwegian University of Science
      and Technology, NTNU, Trondheim, Norway; Department of Physical Medicine and
      Rehabilitation, St.Olavs Hospital, Trondheim University Hospital, Trondheim,
      Norway.
IR  - Smielewski P
FIR - Smielewski, Peter
IRAD- Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences,
      University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
IR  - Sorinola A
FIR - Sorinola, Abayomi
IRAD- Department of Neurosurgery, University of Pecs, Pecs, Hungary.
IR  - Stamatakis E
FIR - Stamatakis, Emmanuel
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Stanworth S
FIR - Stanworth, Simon
IRAD- Oxford University Hospitals NHS Trust, Oxford, UK.
IR  - Stevens R
FIR - Stevens, Robert
IRAD- Division of Neuroscience Critical Care, John Hopkins University School of
      Medicine, Baltimore, USA.
IR  - Stewart W
FIR - Stewart, William
IRAD- Department of Neuropathology, Queen Elizabeth University Hospital, University of 
      Glasgow, Glasgow, UK.
IR  - Steyerberg EW
FIR - Steyerberg, Ewout W
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands; Dept. of Department of Biomedical Data Sciences,
      Leiden University Medical Center, Leiden, the Netherlands.
IR  - Stocchetti N
FIR - Stocchetti, Nino
IRAD- Department of Pathophysiology and Transplantation, Milan University, Neuroscience
      ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy.
IR  - Sundstrom N
FIR - Sundstrom, Nina
IRAD- Department of Radiation Sciences, Biomedical Engineering, Umea University, Umea, 
      Sweden.
IR  - Synnot A
FIR - Synnot, Anneliese
IRAD- Australian & New Zealand Intensive Care Research Centre, Department of
      Epidemiology and Preventive Medicine, School of Public Health and Preventive
      Medicine, Monash University, Melbourne, Australia; Cochrane Consumers and
      Communication Review Group, Centre for Health Communication and Participation,
      School of Psychology and Public Health, La Trobe University, Melbourne,
      Australia.
IR  - Takala R
FIR - Takala, Riikka
IRAD- Perioperative Services, Intensive Care Medicine and Pain Management, Turku
      University Hospital and University of Turku, Turku, Finland.
IR  - Tamas V
FIR - Tamas, Viktoria
IRAD- Department of Neurosurgery, University of Pecs, Pecs, Hungary.
IR  - Tamosuitis T
FIR - Tamosuitis, Tomas
IRAD- Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas,
      Lithuania.
IR  - Taylor MS
FIR - Taylor, Mark Steven
IRAD- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava
      University, Trnava, Slovakia.
IR  - Ao BT
FIR - Ao, Braden Te
IRAD- National Institute for Stroke and Applied Neurosciences, Faculty of Health and
      Environmental Studies, Auckland University of Technology, Auckland, New Zealand.
IR  - Tenovuo O
FIR - Tenovuo, Olli
IRAD- Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain
      Injury Centre, Turku University Hospital and University of Turku, Turku, Finland.
IR  - Theadom A
FIR - Theadom, Alice
IRAD- National Institute for Stroke and Applied Neurosciences, Faculty of Health and
      Environmental Studies, Auckland University of Technology, Auckland, New Zealand.
IR  - Thomas M
FIR - Thomas, Matt
IRAD- Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK.
IR  - Tibboel D
FIR - Tibboel, Dick
IRAD- Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center,
      Sophia Children's Hospital, Rotterdam, the Netherlands.
IR  - Timmers M
FIR - Timmers, Marjolein
IRAD- Department of Intensive Care, Department of Ethics and Philosophy of Medicine,
      Erasmus Medical Center, Rotterdam, the Netherlands.
IR  - Tolias C
FIR - Tolias, Christos
IRAD- Department of Neurosurgery, Kings college London, London, UK.
IR  - Trapani T
FIR - Trapani, Tony
IRAD- ANZIC Research Centre, Monash University, Department of Epidemiology and
      Preventive Medicine, Melbourne, Victoria, Australia.
IR  - Tudora CM
FIR - Tudora, Cristina Maria
IRAD- Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,
      Romania.
IR  - Vajkoczy P
FIR - Vajkoczy, Peter
IRAD- Neurologie, Neurochirurgie und Psychiatrie, Charite - Universitatsmedizin Berlin,
      Berlin, Germany.
IR  - Vallance S
FIR - Vallance, Shirley
IRAD- ANZIC Research Centre, Monash University, Department of Epidemiology and
      Preventive Medicine, Melbourne, Victoria, Australia.
IR  - Valeinis E
FIR - Valeinis, Egils
IRAD- Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia.
IR  - Vamos Z
FIR - Vamos, Zoltan
IRAD- Department of Anaesthesiology and Intensive Therapy, University of Pecs, Pecs,
      Hungary.
IR  - Van der Steen G
FIR - Van der Steen, Gregory
IRAD- Department of Neurosurgery, Antwerp University Hospital and University of
      Antwerp, Edegem, Belgium.
IR  - van der Naalt J
FIR - van der Naalt, Joukje
IRAD- Department of Neurology, University of Groningen, University Medical Center
      Groningen, Groningen, the Netherlands.
IR  - van Dijck JTJM
FIR - van Dijck, Jeroen T J M
IRAD- Dept. of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands;
      Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, the Netherlands.
IR  - van Essen TA
FIR - van Essen, Thomas A
IRAD- Dept. of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands;
      Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, the Netherlands.
IR  - Van Hecke W
FIR - Van Hecke, Wim
IRAD- icoMetrix NV, Leuven, Belgium.
IR  - van Heugten C
FIR - van Heugten, Caroline
IRAD- Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
      University, Oxford, UK.
IR  - Van Praag D
FIR - Van Praag, Dominique
IRAD- Psychology Department, Antwerp University Hospital, Edegem, Belgium.
IR  - Vyvere TV
FIR - Vyvere, Thijs Vande
IRAD- icoMetrix NV, Leuven, Belgium.
IR  - van Wijk RPJ
FIR - van Wijk, Roel P J
IRAD- Dept. of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands;
      Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, the Netherlands.
IR  - Vargiolu A
FIR - Vargiolu, Alessia
IRAD- NeuroIntensive Care, ASST di Monza, Monza, Italy.
IR  - Vega E
FIR - Vega, Emmanuel
IRAD- Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille,
      France.
IR  - Velt K
FIR - Velt, Kimberley
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Verheyden J
FIR - Verheyden, Jan
IRAD- icoMetrix NV, Leuven, Belgium.
IR  - Vespa PM
FIR - Vespa, Paul M
IRAD- Director of Neurocritical Care, University of California, Los Angeles, USA.
IR  - Vik A
FIR - Vik, Anne
IRAD- Department of Neuroanesthesia and Neurointensive Care, Odense University
      Hospital, Odense, Denmark; Department of Neurosurgery, St.Olavs Hospital,
      Trondheim University Hospital, Trondheim, Norway.
IR  - Vilcinis R
FIR - Vilcinis, Rimantas
IRAD- Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas,
      Lithuania.
IR  - Volovici V
FIR - Volovici, Victor
IRAD- Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands.
IR  - von Steinbuchel N
FIR - von Steinbuchel, Nicole
IRAD- Institute of Medical Psychology and Medical Sociology, Universitatsmedizin
      Gottingen, Gottingen, Germany.
IR  - Voormolen D
FIR - Voormolen, Daphne
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Vulekovic P
FIR - Vulekovic, Petar
IRAD- Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,
      University of Novi Sad, Novi Sad, Serbia.
IR  - Wang KKW
FIR - Wang, Kevin K W
IRAD- Department of Emergency Medicine, University of Florida, Gainesville, FL, USA.
IR  - Wiegers E
FIR - Wiegers, Eveline
IRAD- Department of Public Health, Erasmus Medical Center, University Medical Center,
      Rotterdam, the Netherlands.
IR  - Williams G
FIR - Williams, Guy
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Wilson L
FIR - Wilson, Lindsay
IRAD- Division of Psychology, University of Stirling, Stirling, UK.
IR  - Winzeck S
FIR - Winzeck, Stefan
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK.
IR  - Wolf S
FIR - Wolf, Stefan
IRAD- Department of Neurosurgery, Universitatsmedizin Berlin, Freie Universitat Berlin,
      Humboldt-Universitat zu Berlin, Berlin Institute of Health, Berlin, Germany.
IR  - Yang Z
FIR - Yang, Zhihui
IRAD- Department of Emergency Medicine, University of Florida, Gainesville, FL, USA.
IR  - Ylen P
FIR - Ylen, Peter
IRAD- VTT Technical Research Centre, Tampere, Finland.
IR  - Younsi A
FIR - Younsi, Alexander
IRAD- Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
IR  - Zeiler FA
FIR - Zeiler, Frederick A
IRAD- Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital,
      Cambridge, UK; Section of Neurosurgery, Department of Surgery, Rady Faculty of
      Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
IR  - Zelinkova V
FIR - Zelinkova, Veronika
IRAD- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava
      University, Trnava, Slovakia.
IR  - Ziverte A
FIR - Ziverte, Agate
IRAD- Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia.
IR  - Zoerle T
FIR - Zoerle, Tommaso
IRAD- Neuro ICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan,
      Italy.
EDAT- 2020/06/03 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/06/03 06:00
PHST- 2019/12/11 00:00 [received]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S0883-9441(20)30563-3 [pii]
AID - 10.1016/j.jcrc.2020.05.004 [doi]
PST - ppublish
SO  - J Crit Care. 2020 Oct;59:6-15. doi: 10.1016/j.jcrc.2020.05.004. Epub 2020 May 25.


PMID- 32485303
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
VI  - 262
DP  - 2020 Nov 15
TI  - Anti-convulsant effects of cultures bear bile powder in febrile seizure via
      regulation of neurotransmission and inhibition of neuroinflammation.
PG  - 112998
LID - S0378-8741(20)30715-7 [pii]
LID - 10.1016/j.jep.2020.112998 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Natural bear bile powder (NBBP) has been used to 
      treat seizures for thousands of years, but its application is greatly restricted 
      due to ethical reasons. Cultured bear bile powder (CBBP), which is produced by
      biotransformation, may be an appropriate substitute for NBBP. However, the
      anti-convulsant effects of CBBP and its mechanisms remain unclear. AIM OF THE
      STUDY: This study aimed to investigate the anti-convulsant effects and possible
      mechanisms of CBBP in a febrile seizure (FS) rat model. MATERIALS AND METHODS: FS
      was induced by placing the rats in a warm water bath (45.5 degrees C). The
      incidence rate and latency of FS, and hematoxylin-eosin staining (HE) were
      conducted for neurological damage. The levels of 4 bile acids and 8 main
      neurotransmitters in vivo were measured by liquid chromatography-tandem mass
      spectrometry (LC-MS/MS). The expression of bile acid related transports,
      neurotransmitter receptors, inflammatory factors, neurotrophic factors and glial 
      fibrillary acidic protein (GFAP) in hippocampal tissues were detected by
      real-time PCR, western blotting, and immunohistochemistry. RESULTS:
      Pre-treatments with CBBP and similarly, NBBP, significantly reduced the incidence
      rate and prolonged the latency of FS. Additionally, CBBP alleviated the
      histological injury induced by FS in the rat hippocampus tissue. LC-MS/MS
      analyses revealed that CBBP markedly increased the levels of tauroursodeoxycholic
      acid (TUDCA), taurochenodeoxycholic acid (TCDCA), ursodeoxycholic acid (UDCA),
      and chenodeoxycholic acid (CDCA) in FS rats. Furthermore, the content of
      gamma-aminobutyric acid (GABA) was up-regulated in rats pre-treated with CBBP
      whereas GFAP was down-regulated. CBBP also significantly suppressed the
      expression of interleukin -1beta (IL-1beta), tumor necrosis factor alpha
      (TNF-alpha), nuclear factor kappa B (NF-kappaB), and brain-derived neurotrophic
      factor (BDNF) and its TrkB receptors, and improved the expression of GABA type A 
      receptors (GABAAR) and farnesoid X receptors (FXR). CONCLUSIONS: The present
      study demonstrated that CBBP had anti-convulsant effects in a FS rat model. CBBP 
      may protect rats against FS, probably by up-regulating FXR, which was activated
      by increasing brain bile acids, up-regulating GABAergic transmission by
      inhibiting BDNF-TrkB signaling, and suppressing neuroinflammation by inhibiting
      the NF-kappaB pathway.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Sun, Xiaoshu
AU  - Sun X
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      1342819211@qq.com.
FAU - Xue, Haoyu
AU  - Xue H
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      2578832526@qq.com.
FAU - Zan, Bin
AU  - Zan B
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      zanbin007@163.com.
FAU - Zhao, Yining
AU  - Zhao Y
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      zhaoyatning@163.com.
FAU - Li, Yuanyuan
AU  - Li Y
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      yuanyuan60107@163.com.
FAU - Wang, Tianming
AU  - Wang T
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      wtmtcm@126.com.
FAU - Wu, Jiasheng
AU  - Wu J
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      wujiasheng@shutcm.edu.cn.
FAU - Liu, Shaoyong
AU  - Liu S
AD  - Shanghai Kai Bao Pharmaceutical CO. Ltd., Shanghai, 201401, China. Electronic
      address: 13601809248@163.com.
FAU - Wang, Zhengtao
AU  - Wang Z
AD  - Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese
      Medicine, Shanghai, 201203, China. Electronic address: ztwang@shutcm.edu.cn.
FAU - Shi, Rong
AU  - Shi R
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
      rongshi56@126.com.
FAU - Yang, Li
AU  - Yang L
AD  - Centre for Traditional Chinese Medicine of Complexity Systems, Shanghai
      University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic
      address: yl7@shutcm.edu.cn.
FAU - Ma, Yueming
AU  - Ma Y
AD  - Department of Pharmacology, School of Pharmacy, Shanghai University of
      Traditional Chinese Medicine, Shanghai, 201203, China; Shanghai Key Laboratory of
      Compound Chinese Medicines, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, 201203, China. Electronic address: mayueming_117@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - Ireland
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
RN  - 0 (Anticonvulsants)
RN  - 0 (Biological Factors)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Powders)
SB  - IM
MH  - Animals
MH  - Anticonvulsants/isolation & purification/pharmacology/*therapeutic use
MH  - Bile
MH  - Biological Factors/isolation & purification/pharmacology/*therapeutic use
MH  - Brain/*drug effects/metabolism
MH  - Inflammation Mediators/*antagonists & inhibitors/metabolism
MH  - Male
MH  - Powders
MH  - Random Allocation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Seizures, Febrile/*drug therapy/metabolism
MH  - Synaptic Transmission/*drug effects/physiology
MH  - Ursidae
OTO - NOTNLM
OT  - Cultures bear bile powder
OT  - Farnesoid X receptors
OT  - Febrile seizure
OT  - Gamma-aminobutyric acid
OT  - Neuroinflammation
EDAT- 2020/06/03 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S0378-8741(20)30715-7 [pii]
AID - 10.1016/j.jep.2020.112998 [doi]
PST - ppublish
SO  - J Ethnopharmacol. 2020 Nov 15;262:112998. doi: 10.1016/j.jep.2020.112998. Epub
      2020 May 30.


PMID- 32485131
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Positive Public Health Ethics: Toward Flourishing and Resilient Communities and
      Individuals.
PG  - 44-54
LID - 10.1080/15265161.2020.1764145 [doi]
AB  - The COVID-19 pandemic is a global contagion of unprecedented proportions and
      health, economic, and social consequences. As with many health problems, its
      impact is uneven. This article argues the COVID-19 pandemic is a global health
      injustice due to moral failures of national governments and international
      organizations to prepare for, prevent and control it. Global and national health 
      communities had a moral obligation to act in accordance with the current state of
      knowledge of pandemic preparedness. This obligation-a positive duty to develop
      and implement systems to reduce threats to and safeguard individuals' and,
      communities' abilities to flourish-stems from theories of global health justice
      and governance. The COVID-19 pandemic revealed and amplified the fragility and
      deficiencies in our global and domestic health institutions and systems. Moving
      forward, positive public health ethics is needed to set ethical standards for
      building and operating robust public health systems for resilient individuals and
      communities.
FAU - Prah Ruger, Jennifer
AU  - Prah Ruger J
AUID- ORCID: 0000-0003-0269-8935
AD  - University of Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jul;20(7):212-214. PMID: 32716777
CIN - Am J Bioeth. 2020 Jul;20(7):103-106. PMID: 32716781
CIN - Am J Bioeth. 2020 Jul;20(7):172-174. PMID: 32716785
CIN - Am J Bioeth. 2020 Jul;20(7):150-152. PMID: 32716787
CIN - Am J Bioeth. 2020 Jul;20(7):142-144. PMID: 32716802
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Global Health
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Public Health/*ethics
MH  - SARS-CoV-2
MH  - *Social Responsibility
OTO - NOTNLM
OT  - * risk/benefit analysis
OT  - *Health economics
OT  - *health policy
OT  - *international/global health
OT  - *public health
EDAT- 2020/06/03 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1080/15265161.2020.1764145 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):44-54. doi: 10.1080/15265161.2020.1764145. Epub 2020 
      Jun 2.


PMID- 32485043
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1460-9592 (Electronic)
IS  - 1155-5645 (Linking)
VI  - 30
IP  - 8
DP  - 2020 Aug
TI  - How should we approach parental refusals of opioids on behalf of children in the 
      perioperative setting? A practical approach based on ethical theory.
PG  - 852-858
LID - 10.1111/pan.13941 [doi]
AB  - In the midst of the current opioid epidemic, we have encountered more parents who
      are concerned about the use of opioids in the perioperative setting. Some parents
      have completely refused the use of opioids on behalf of their children. How
      should we approach this treatment refusal? This article describes ethical theory 
      related to the refusal of treatment by parents on behalf of their children, and
      when it is justified to override parental decisions. We propose a decision-making
      framework that focuses on improving communication and considering alternatives.
      Assessment of harm to the child from avoiding opioids, as well as potential harms
      from overriding parental autonomy must be undertaken prior to considering
      overriding parents.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Moreno-Galvan, Anna
AU  - Moreno-Galvan A
AD  - Rady Children's Hospital, San Diego, California, USA.
AD  - Part of this work was completed while employed at Boston Children's Hospital,
      Boston, Massachusetts, USA.
FAU - Marron, Jonathan Michael
AU  - Marron JM
AUID- ORCID: 0000-0001-8935-8524
AD  - Dana Farber Cancer Institute, Boston, Massachusetts, USA.
AD  - Center for Bioethics, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Marsiglio, Angela Maree
AU  - Marsiglio AM
AUID- ORCID: 0000-0003-0943-6380
AD  - Part of this work was completed while employed at Boston Children's Hospital,
      Boston, Massachusetts, USA.
AD  - UCSF Benioff Children's Hospital, San Francisco, California, USA.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - France
TA  - Paediatr Anaesth
JT  - Paediatric anaesthesia
JID - 9206575
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - *Analgesics, Opioid
MH  - Child
MH  - Decision Making
MH  - *Ethical Theory
MH  - Humans
MH  - Parents
MH  - Treatment Refusal
OTO - NOTNLM
OT  - *ethics
OT  - *opioids
OT  - *pain management
OT  - *pediatric anesthesia
OT  - *pediatrics
OT  - *refusal of treatment
EDAT- 2020/06/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/03 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1111/pan.13941 [doi]
PST - ppublish
SO  - Paediatr Anaesth. 2020 Aug;30(8):852-858. doi: 10.1111/pan.13941. Epub 2020 Jun
      25.


PMID- 32484911
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1467-6494 (Electronic)
IS  - 0022-3506 (Linking)
VI  - 88
IP  - 6
DP  - 2020 Dec
TI  - Intellectual humility and perceptions of political opponents.
PG  - 1196-1216
LID - 10.1111/jopy.12566 [doi]
AB  - OBJECTIVE: Intellectual humility (IH) refers to the recognition that personal
      beliefs might be wrong. We investigate possible interpersonal implications of IH 
      for how people perceive the intellectual capabilities and moral character of
      their sociopolitical opponents and for their willingness to associate with those 
      opponents. METHOD: In four initial studies (N = 1,926, Mage = 38, 880 females,
      1,035 males), we measured IH, intellectual and moral derogation of opponents, and
      willingness to befriend opponents. In two additional studies (N = 568, Mage = 40,
      252 females, 314 males), we presented participants with a specific opponent on
      certain sociopolitical issues and several social media posts from that opponent
      in which he expressed his views on the issue. We then measured IH, intellectual, 
      and moral derogation of the opponent, participants' willingness to befriend the
      opponent, participants' willingness to "friend" the opponent on social media, and
      participants' willingness to "follow" the opponent on social media. RESULTS:
      Low-IH relative to high-IH participants were more likely to derogate the
      intellectual capabilities and moral character of their opponents, less willing to
      befriend their opponents, and less willing to "friend" and "follow" an opponent
      on social media. CONCLUSIONS: IH may have important interpersonal implications
      for person perception, and for understanding social extremism and polarization.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Stanley, Matthew L
AU  - Stanley ML
AUID- ORCID: 0000-0002-2551-576X
AD  - Department of Psychology and Neuroscience, Center for Cognitive Neuroscience,
      Duke University, Durham, NC, USA.
FAU - Sinclair, Alyssa H
AU  - Sinclair AH
AD  - Department of Psychology and Neuroscience, Center for Cognitive Neuroscience,
      Duke University, Durham, NC, USA.
FAU - Seli, Paul
AU  - Seli P
AD  - Department of Psychology and Neuroscience, Center for Cognitive Neuroscience,
      Duke University, Durham, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200618
PL  - United States
TA  - J Pers
JT  - Journal of personality
JID - 2985194R
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - *Morals
MH  - Perception
MH  - *Social Media
OTO - NOTNLM
OT  - *ethics
OT  - *intellectual humility
OT  - *person perception
OT  - *polarization
OT  - *politics
EDAT- 2020/06/03 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/06/03 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1111/jopy.12566 [doi]
PST - ppublish
SO  - J Pers. 2020 Dec;88(6):1196-1216. doi: 10.1111/jopy.12566. Epub 2020 Jun 18.


PMID- 32484782
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20201218
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 3
DP  - 2020 Jul 2
TI  - The Oxford Royal College of General Practitioners Clinical Informatics Digital
      Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms.
PG  - e19773
LID - 10.2196/19773 [doi]
AB  - BACKGROUND: Routinely recorded primary care data have been used for many years by
      sentinel networks for surveillance. More recently, real world data have been used
      for a wider range of research projects to support rapid, inexpensive clinical
      trials. Because the partial national lockdown in the United Kingdom due to the
      coronavirus disease (COVID-19) pandemic has resulted in decreasing community
      disease incidence, much larger numbers of general practices are needed to deliver
      effective COVID-19 surveillance and contribute to in-pandemic clinical trials.
      OBJECTIVE: The aim of this protocol is to describe the rapid design and
      development of the Oxford Royal College of General Practitioners Clinical
      Informatics Digital Hub (ORCHID) and its first two platforms. The Surveillance
      Platform will provide extended primary care surveillance, while the Trials
      Platform is a streamlined clinical trials platform that will be integrated into
      routine primary care practice. METHODS: We will apply the FAIR (Findable,
      Accessible, Interoperable, and Reusable) metadata principles to a new, integrated
      digital health hub that will extract routinely collected general practice
      electronic health data for use in clinical trials and provide enhanced
      communicable disease surveillance. The hub will be findable through membership in
      Health Data Research UK and European metadata repositories. Accessibility through
      an online application system will provide access to study-ready data sets or
      developed custom data sets. Interoperability will be facilitated by fixed linkage
      to other key sources such as Hospital Episodes Statistics and the Office of
      National Statistics using pseudonymized data. All semantic descriptors (ie,
      ontologies) and code used for analysis will be made available to accelerate
      analyses. We will also make data available using common data models, starting
      with the US Food and Drug Administration Sentinel and Observational Medical
      Outcomes Partnership approaches, to facilitate international studies. The
      Surveillance Platform will provide access to data for health protection and
      promotion work as authorized through agreements between Oxford, the Royal College
      of General Practitioners, and Public Health England. All studies using the Trials
      Platform will go through appropriate ethical and other regulatory approval
      processes. RESULTS: The hub will be a bottom-up, professionally led network that 
      will provide benefits for member practices, our health service, and the
      population served. Data will only be used for SQUIRE (surveillance, quality
      improvement, research, and education) purposes. We have already received positive
      responses from practices, and the number of practices in the network has doubled 
      to over 1150 since February 2020. COVID-19 surveillance has resulted in tripling 
      of the number of virology sites to 293 (target 300), which has aided the
      collection of the largest ever weekly total of surveillance swabs in the United
      Kingdom as well as over 3000 severe acute respiratory syndrome coronavirus 2
      (SARS-CoV-2) serology samples. Practices are recruiting to the PRINCIPLE
      (Platform Randomised trial of INterventions against COVID-19 In older PeopLE)
      trial, and these participants will be followed up through ORCHID. These initial
      outputs demonstrate the feasibility of ORCHID to provide an extended national
      digital health hub. CONCLUSIONS: ORCHID will provide equitable and innovative use
      of big data through a professionally led national primary care network and the
      application of FAIR principles. The secure data hub will host routinely collected
      general practice data linked to other key health care repositories for clinical
      trials and support enhanced in situ surveillance without always requiring large
      volume data extracts. ORCHID will support rapid data extraction, analysis, and
      dissemination with the aim of improving future research and development in
      general practice to positively impact patient care. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/19773.
CI  - (c)Simon de Lusignan, Nicholas Jones, Jienchi Dorward, Rachel Byford, Harshana
      Liyanage, John Briggs, Filipa Ferreira, Oluwafunmi Akinyemi, Gayatri
      Amirthalingam, Chris Bates, Jamie Lopez Bernal, Gavin Dabrera, Alex Eavis, Alex J
      Elliot, Michael Feher, Else Krajenbrink, Uy Hoang, Gary Howsam, Jonathan Leach,
      Cecilia Okusi, Brian Nicholson, Philip Nieri, Julian Sherlock, Gillian Smith,
      Mark Thomas, Nicholas Thomas, Manasa Tripathy, William Victor, John Williams, Ian
      Wood, Maria Zambon, John Parry, Shaun O'Hanlon, Mark Joy, Chris Butler, Martin
      Marshall, FD Richard Hobbs. Originally published in JMIR Public Health and
      Surveillance (http://publichealth.jmir.org), 02.07.2020.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AUID- ORCID: 0000-0002-8553-2641
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Jones, Nicholas
AU  - Jones N
AUID- ORCID: 0000-0002-0352-3785
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Dorward, Jienchi
AU  - Dorward J
AUID- ORCID: 0000-0001-6072-1430
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Byford, Rachel
AU  - Byford R
AUID- ORCID: 0000-0002-4792-8995
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Liyanage, Harshana
AU  - Liyanage H
AUID- ORCID: 0000-0001-9738-6349
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Briggs, John
AU  - Briggs J
AUID- ORCID: 0000-0002-9832-5430
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Ferreira, Filipa
AU  - Ferreira F
AUID- ORCID: 0000-0002-7717-8486
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Akinyemi, Oluwafunmi
AU  - Akinyemi O
AUID- ORCID: 0000-0003-0401-0145
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Amirthalingam, Gayatri
AU  - Amirthalingam G
AUID- ORCID: 0000-0003-2078-0975
AD  - Public Health England, London, United Kingdom.
FAU - Bates, Chris
AU  - Bates C
AUID- ORCID: 0000-0003-0113-2593
AD  - TPP SystmOne, Leeds, United Kingdom.
FAU - Lopez Bernal, Jamie
AU  - Lopez Bernal J
AUID- ORCID: 0000-0002-1301-5653
AD  - Public Health England, London, United Kingdom.
FAU - Dabrera, Gavin
AU  - Dabrera G
AUID- ORCID: 0000-0003-4606-5945
AD  - Public Health England, London, United Kingdom.
FAU - Eavis, Alex
AU  - Eavis A
AUID- ORCID: 0000-0003-3525-2198
AD  - EMIS Group, Leeds, United Kingdom.
FAU - Elliot, Alex J
AU  - Elliot AJ
AUID- ORCID: 0000-0002-6414-3065
AD  - Real-time Syndromic Surveillance Team, Field Service, Public Health England,
      Birmingham, United Kingdom.
FAU - Feher, Michael
AU  - Feher M
AUID- ORCID: 0000-0003-0631-6199
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Krajenbrink, Else
AU  - Krajenbrink E
AUID- ORCID: 0000-0002-6563-9441
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Hoang, Uy
AU  - Hoang U
AUID- ORCID: 0000-0002-8428-5140
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Howsam, Gary
AU  - Howsam G
AUID- ORCID: 0000-0001-6699-5504
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Leach, Jonathan
AU  - Leach J
AUID- ORCID: 0000-0001-5142-4506
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Okusi, Cecilia
AU  - Okusi C
AUID- ORCID: 0000-0002-5575-8527
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Nicholson, Brian
AU  - Nicholson B
AUID- ORCID: 0000-0003-0661-7362
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Nieri, Philip
AU  - Nieri P
AUID- ORCID: 0000-0003-0478-0190
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Sherlock, Julian
AU  - Sherlock J
AUID- ORCID: 0000-0001-7427-1936
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Smith, Gillian
AU  - Smith G
AUID- ORCID: 0000-0002-4257-0568
AD  - Real-time Syndromic Surveillance Team, Field Service, Public Health England,
      Birmingham, United Kingdom.
FAU - Thomas, Mark
AU  - Thomas M
AUID- ORCID: 0000-0002-6290-3948
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Thomas, Nicholas
AU  - Thomas N
AUID- ORCID: 0000-0003-0460-6870
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Tripathy, Manasa
AU  - Tripathy M
AUID- ORCID: 0000-0001-9840-3876
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Victor, William
AU  - Victor W
AUID- ORCID: 0000-0003-3660-6517
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Williams, John
AU  - Williams J
AUID- ORCID: 0000-0002-6118-0434
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Wood, Ian
AU  - Wood I
AUID- ORCID: 0000-0002-0080-6624
AD  - Royal College of General Practitioners, London, United Kingdom.
AD  - EMIS Group, Leeds, United Kingdom.
FAU - Zambon, Maria
AU  - Zambon M
AUID- ORCID: 0000-0002-8897-7881
AD  - Public Health England, London, United Kingdom.
FAU - Parry, John
AU  - Parry J
AUID- ORCID: 0000-0002-0190-1121
AD  - TPP SystmOne, Leeds, United Kingdom.
FAU - O'Hanlon, Shaun
AU  - O'Hanlon S
AUID- ORCID: 0000-0002-0731-5211
AD  - EMIS Group, Leeds, United Kingdom.
FAU - Joy, Mark
AU  - Joy M
AUID- ORCID: 0000-0002-4974-3724
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Butler, Chris
AU  - Butler C
AUID- ORCID: 0000-0002-0102-3453
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
FAU - Marshall, Martin
AU  - Marshall M
AUID- ORCID: 0000-0001-8575-5442
AD  - Royal College of General Practitioners, London, United Kingdom.
FAU - Hobbs, F D Richard
AU  - Hobbs FDR
AUID- ORCID: 0000-0001-7976-7172
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200702
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - COVID-19
MH  - *Clinical Trials as Topic
MH  - Coronavirus Infections/*epidemiology
MH  - General Practice/*organization & administration
MH  - Humans
MH  - *Medical Records Systems, Computerized
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Primary Health Care/organization & administration
MH  - *Public Health Surveillance
MH  - Societies, Medical
MH  - United Kingdom/epidemiology
PMC - PMC7333793
OTO - NOTNLM
OT  - *COVID-19
OT  - *adaptive clinical trials
OT  - *clinical trials as a topic
OT  - *general practice
OT  - *medical record systems, computerized
OT  - *primary health care
OT  - *public health surveillance
OT  - *sentinel surveillance
OT  - *severe acute respiratory syndrome coronavirus 2
EDAT- 2020/06/03 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/05/29 00:00 [revised]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - v6i3e19773 [pii]
AID - 10.2196/19773 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 Jul 2;6(3):e19773. doi: 10.2196/19773.


PMID- 32484735
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201218
IS  - 1440-1665 (Electronic)
IS  - 1039-8562 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Oct
TI  - Preventing prejudice by preserving the spirit of mental health legislation during
      the COVID-19 national emergency.
PG  - 500-503
LID - 10.1177/1039856220928865 [doi]
AB  - OBJECTIVE: The COVID-19 national emergency activates legislative powers that
      allow a proportional infringement upon individual liberties. We canvas the
      complex legal landscape governing mental health consumers in this climate,
      highlight ethical considerations in application of the law and offer a simple
      algorithm to navigate this space. CONCLUSION: In times of emergency, it is
      crucial that we uphold the safeguards embodied within mental health legislation
      to prevent prejudicial treatment of mental health consumers.
FAU - Ouliaris, Calina
AU  - Ouliaris C
AUID- ORCID: 0000-0002-8395-9959
AD  - Psychiatry Registrar, Northern Sydney Local Health District, NSW, Australia.
FAU - Sheahan, Linda
AU  - Sheahan L
AD  - Clinical Ethics Consultant, South East Sydney Local Health District, Australia.
AD  - Palliative Care Specialist, St George Hospital, Australia.
FAU - George, Duncan
AU  - George D
AD  - Conjoint Lecturer, School of Psychiatry, Faculty of Medicine, University of New
      South Wales, Australia.
AD  - School of Rural Health, Faculty of Medicine and Health, University of Sydney,
      Australia.
AD  - Consultation Liaison Psychiatry, Prince of Wales Hospital, Australia.
AD  - Dubbo Base Hospital, Western NSW Local Health District, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - England
TA  - Australas Psychiatry
JT  - Australasian psychiatry : bulletin of Royal Australian and New Zealand College of
      Psychiatrists
JID - 9613603
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*psychology
MH  - Humans
MH  - Mental Health/*ethics/*legislation & jurisprudence
MH  - Pandemics
MH  - Pneumonia, Viral/*psychology
MH  - *Prejudice
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *human rights
OT  - *mental health legislation
OT  - *national emergency
EDAT- 2020/06/03 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1177/1039856220928865 [doi]
PST - ppublish
SO  - Australas Psychiatry. 2020 Oct;28(5):500-503. doi: 10.1177/1039856220928865. Epub
      2020 Jun 2.


PMID- 32484432
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 2046-4924 (Electronic)
IS  - 1366-5278 (Linking)
VI  - 24
IP  - 25
DP  - 2020 May
TI  - Carer administration of as-needed subcutaneous medication for breakthrough
      symptoms in people dying at home: the CARiAD feasibility RCT.
PG  - 1-150
LID - 10.3310/hta24250 [doi]
AB  - BACKGROUND: Most people who are dying want to be cared for at home, but only half
      of them achieve this. The likelihood of a home death often depends on the
      availability of able and willing lay carers. When people who are dying are unable
      to take oral medication, injectable medication is used. When top-up medication is
      required, a health-care professional travels to the dying person's home, which
      may delay symptom relief. The administration of subcutaneous medication by lay
      carers, although not widespread UK practice, has proven to be key in achieving
      better symptom control for those dying at home in other countries. OBJECTIVES: To
      determine if carer administration of as-needed subcutaneous medication for common
      breakthrough symptoms in people dying at home is feasible and acceptable in the
      UK, and if it would be feasible to test this intervention in a future definitive 
      randomised controlled trial. DESIGN: We conducted a two-arm, parallel-group,
      individually randomised, open pilot trial of the intervention versus usual care, 
      with a 1 : 1 allocation ratio, using convergent mixed methods. SETTING:
      Home-based care without 24/7 paid care provision, in three UK sites.
      PARTICIPANTS: Participants were dyads of adult patients and carers: patients in
      the last weeks of their life who wished to die at home and lay carers who were
      willing to be trained to give subcutaneous medication. Strict risk assessment
      criteria needed to be met before approach, including known history of substance
      abuse or carer ability to be trained to competency. INTERVENTION:
      Intervention-group carers received training by local nurses using a manualised
      training package. MAIN OUTCOME MEASURES: Quantitative data were collected at
      baseline and 6-8 weeks post bereavement and via carer diaries. Interviews with
      carers and health-care professionals explored attitudes to, experiences of and
      preferences for giving subcutaneous medication and experience of trial processes.
      The main outcomes of interest were feasibility, acceptability, recruitment rates,
      attrition and selection of the most appropriate outcome measures. RESULTS: In
      total, 40 out of 101 eligible dyads were recruited (39.6%), which met the
      feasibility criterion of recruiting > 30% of eligible dyads. The expected
      recruitment target ( approximately 50 dyads) was not reached, as fewer than
      expected participants were identified. Although the overall retention rate was
      55% (22/40), this was substantially unbalanced [30% (6/20) usual care and 80%
      (16/20) intervention]. The feasibility criterion of > 40% retention was,
      therefore, considered not met. A total of 12 carers (intervention, n = 10; usual 
      care, n = 2) and 20 health-care professionals were interviewed. The intervention 
      was considered acceptable, feasible and safe in the small study population. The
      context of the feasibility study was not ideal, as district nurses were seriously
      overstretched and unfamiliar with research methods. A disparity in readiness to
      consider the intervention was demonstrated between carers and health-care
      professionals. Findings showed that there were methodological and ethics issues
      pertaining to researching last days of life care. CONCLUSION: The success of a
      future definitive trial is uncertain because of equivocal results in the
      progression criteria, particularly poor recruitment overall and a low retention
      rate in the usual-care group. Future work regarding the intervention should
      include understanding the context of UK areas where this has been adopted,
      ascertaining wider public views and exploring health-care professional views on
      burden and risk in the NHS context. There should be consideration of the need for
      national policy and of the most appropriate quantitative outcome measures to use.
      This will help to ascertain if there are unanswered questions to be studied in a 
      trial. TRIAL REGISTRATION: Current Controlled Trials ISRCTN11211024. FUNDING:
      This project was funded by the National Institute for Health Research (NIHR)
      Health Technology Assessment programme and will be published in full in Health
      Technology Assessment; Vol. 24, No. 25. See the NIHR Journals Library website for
      further project information.
FAU - Poolman, Marlise
AU  - Poolman M
AUID- ORCID: 0000-0002-2837-363X
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - Roberts, Jessica
AU  - Roberts J
AUID- ORCID: 0000-0002-3271-1814
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - Wright, Stella
AU  - Wright S
AUID- ORCID: 0000-0001-9634-6273
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - Hendry, Annie
AU  - Hendry A
AUID- ORCID: 0000-0002-2112-1368
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - Goulden, Nia
AU  - Goulden N
AUID- ORCID: 0000-0001-6511-3987
AD  - North Wales Organisation for Randomised Trials in Health, Bangor University,
      Bangor, UK.
FAU - Holmes, Emily Af
AU  - Holmes EA
AUID- ORCID: 0000-0002-0479-5336
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - Byrne, Anthony
AU  - Byrne A
AUID- ORCID: 0000-0002-1413-1496
AD  - Marie Curie Research Centre, School of Medicine, Cardiff University, Cardiff, UK.
FAU - Perkins, Paul
AU  - Perkins P
AUID- ORCID: 0000-0002-6848-967X
AD  - Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
AD  - Sue Ryder Leckhampton Court Hospice, Cheltenham, UK.
FAU - Hoare, Zoe
AU  - Hoare Z
AUID- ORCID: 0000-0003-1803-5482
AD  - North Wales Organisation for Randomised Trials in Health, Bangor University,
      Bangor, UK.
FAU - Nelson, Annmarie
AU  - Nelson A
AUID- ORCID: 0000-0002-6075-8425
AD  - Marie Curie Research Centre, School of Medicine, Cardiff University, Cardiff, UK.
FAU - Hiscock, Julia
AU  - Hiscock J
AUID- ORCID: 0000-0002-8963-2981
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - Hughes, Dyfrig
AU  - Hughes D
AUID- ORCID: 0000-0001-8247-7459
AD  - School of Health Sciences, Bangor University, Bangor, UK.
FAU - O'Connor, Julie
AU  - O'Connor J
AD  - Sue Ryder Leckhampton Court Hospice, Cheltenham, UK.
FAU - Foster, Betty
AU  - Foster B
AD  - Public Contributor, North Wales Cancer Patient Forum, North Wales Cancer
      Treatment Centre, Bodelwyddan, UK.
FAU - Reymond, Liz
AU  - Reymond L
AUID- ORCID: 0000-0001-6617-4618
AD  - Brisbane South Palliative Care Collaborative, School of Medicine, Griffith
      University, Southport, QLD, Australia.
FAU - Healy, Sue
AU  - Healy S
AUID- ORCID: 0000-0002-9021-5835
AD  - Metro South Palliative Care Service, Brisbane, QLD, Australia.
FAU - Lewis, Penney
AU  - Lewis P
AUID- ORCID: 0000-0002-7217-5884
AD  - Centre for Medical Law and Ethics, King's College London, London, UK.
FAU - Wee, Bee
AU  - Wee B
AUID- ORCID: 0000-0002-7714-0349
AD  - Harris Manchester College, University of Oxford, Oxford, UK.
FAU - Johnstone, Rosalynde
AU  - Johnstone R
AUID- ORCID: 0000-0003-1642-5356
AD  - Betsi Cadwaladr University Health Board, Bangor, UK.
FAU - Roberts, Rossela
AU  - Roberts R
AUID- ORCID: 0000-0003-1775-0986
AD  - School of Psychology, Bangor University, Bangor, UK.
FAU - Parkinson, Anne
AU  - Parkinson A
AUID- ORCID: 0000-0003-4495-5127
AD  - Sue Ryder Leckhampton Court Hospice, Cheltenham, UK.
FAU - Roberts, Sian
AU  - Roberts S
AUID- ORCID: 0000-0002-4883-4122
AD  - Betsi Cadwaladr University Health Board, Bangor, UK.
FAU - Wilkinson, Clare
AU  - Wilkinson C
AUID- ORCID: 0000-0003-0378-8078
AD  - School of Health Sciences, Bangor University, Bangor, UK.
LA  - eng
SI  - ISRCTN/ISRCTN11211024
GR  - MCCC-FCO-11-C/MCCC_/Marie Curie/United Kingdom
GR  - 15/10/37/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Health Technol Assess
JT  - Health technology assessment (Winchester, England)
JID - 9706284
SB  - IM
MH  - Adult
MH  - *Caregivers/education/psychology
MH  - Feasibility Studies
MH  - Female
MH  - *Home Care Services
MH  - Humans
MH  - Injections, Subcutaneous/*nursing
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Surveys and Questionnaires
MH  - Terminal Care
MH  - *Terminally Ill
MH  - United Kingdom
PMC - PMC7294396
OAB - Most people in the UK would prefer to die at home, but only half of them achieve 
      this. This usually depends on having able and willing lay carers (family or
      friends) to help look after them. Once swallowing is not possible, medicine is
      given continually under the skin (syringe driver). If common problems such as
      pain, vomiting or agitation break through, health-care professionals attend to
      give extra doses. The wait for a health-care professional to arrive can be
      distressing. In the UK, it is legal (but not routine) for lay carers to give
      needle-free subcutaneous injections themselves. We reworked an Australian carer
      education package for UK use. The best way to find out if this would work well is
      to do a randomised controlled trial. This is a test in which, at random, half of 
      the people taking part receive 'usual care' and the other half receive the 'new
      care' or intervention. A pilot randomised controlled trial (a 'test' trial to see
      if a larger one is worth doing) was carried out to determine if lay carer
      injections were possible in the UK. We approached 90 dyads (a dying person and a 
      key carer) and, of these, 40 were willing to take part and 22 completed the
      follow-up visit, so we could analyse their data. Of these 22 dyads, 16 were in
      the intervention group (lay carer injects) and six were in the control group
      (usual care). All carers were asked to keep a diary. Carers and health-care
      professionals were interviewed (qualitative study) and carer preferences were
      assessed. This new practice was safe, acceptable and welcomed. Carer confidence
      increased rapidly, symptom control was quicker and the interviews backed up these
      findings. Recruitment was low owing to overstretched health-care professionals.
      Only certain families were picked. Dyads in the usual-care group often wished
      they were in the intervention group. Carers found it difficult to complete some
      of the questionnaires that were used to measure the effect of the intervention.
      Therefore, uncertainty remains as to whether or not a full trial should proceed. 
      Because the practice is already legal, some areas in the UK are already
      undertaking it. We plan to study what makes this practice possible or less
      possible to achieve.
OABL- eng
OTO - NOTNLM
OT  - *CARERS
OT  - *COMMUNITY HEALTH CARE
OT  - *INJECTIONS
OT  - *PAIN, BREAKTHROUGH
OT  - *PALLIATIVE CARE MEDICINE
OT  - *SUBCUTANEOUS
OT  - *SYMPTOM ASSESSMENT
OT  - *TERMINAL CARE
COIS- Anthony Byrne reports grants from Marie Curie (London, UK), Health and Care
      Research Wales, the End of Life Board for Wales and the National Institute for
      Health Research (NIHR) Health Technology Assessment (HTA) programme outside the
      submitted work; he is also a member of the End of Life Board for Wales, which is 
      responsible to the Welsh Government for developing and implementing strategy for 
      end-of-life care in Wales. Bee Wee reports that she is National Clinical Director
      for End of Life Care, Chairperson of the National Institute for Health and Care
      Excellence Quality Standards Advisory Committee and has a NIHR-funded grant
      outside the submitted work. She has also received royalties for a book published 
      by Oxford University Press (Oxford, UK). Dyfrig Hughes reports that he was a
      member of the HTA Programme Pharmaceuticals Panel (2008-12) and member of the HTA
      Programme Clinical Evaluation and Trials Board (2010-16). Marlise Poolman was a
      member of the HTA Prioritisation Committee: Integrated Community Health and
      Social Care (A) from 2013 to 2019. Zoe Hoare reports that she is an associate
      member of NIHR Health Services and Delivery Research board. Clare Wilkinson
      reports that she was chairperson of the HTA Commissioning Panel - Primary Care,
      Community, Preventive Interventions (2013-18) and a member of the HTA Rapid and
      Add-0n Trials Board (2012-13).
EDAT- 2020/06/03 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
AID - 10.3310/hta24250 [doi]
PST - ppublish
SO  - Health Technol Assess. 2020 May;24(25):1-150. doi: 10.3310/hta24250.


PMID- 32484404
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1522-1229 (Electronic)
IS  - 1043-4046 (Linking)
VI  - 44
IP  - 3
DP  - 2020 Sep 1
TI  - Avian gut experiments: an alternative approach for teaching the properties of
      intestinal smooth muscles.
PG  - 295-304
LID - 10.1152/advan.00195.2019 [doi]
AB  - Experiments on isolated mammalian gut are essential components of the physiology 
      curriculum worldwide. Over the years, these routine experiments have been largely
      replaced by simulation modules, to reduce the euthanization of animals for
      understanding established facts and mechanisms in gut physiology. However, a
      medical undergraduate needs hands-on training to handle a living tissue to have a
      better understanding of physiology. The present sourcebook update describes the
      use of avian gut, which is usually discarded in abattoirs, as an effective
      replacement of mammalian gut to understand basic gut smooth muscle physiology.
      The avian gut can be used to study the effect of various drugs and ions as used
      in mammalian gut experiments. The experiment protocol described in the update can
      be performed by students of basic sciences and medical students using minimal
      laboratory set up and at low cost, producing results comparable to mammalian gut 
      experiments. Ethical permissions may not be necessary; however, the disposal of
      tissue waste has to follow proper guidelines.
FAU - Pant, Jayanti
AU  - Pant J
AUID- ORCID: https://orcid.org/0000-0002-0034-1951
AD  - Department of Physiology, All India Institute of Medical Sciences, Rishikesh
      (Uttarakhand), India.
FAU - Mohan, Latika
AU  - Mohan L
AD  - Department of Physiology, All India Institute of Medical Sciences, Rishikesh
      (Uttarakhand), India.
FAU - S, Srikant
AU  - S S
AD  - Department of Physiology, All India Institute of Medical Sciences, Rishikesh
      (Uttarakhand), India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Physiol Educ
JT  - Advances in physiology education
JID - 100913944
SB  - IM
MH  - Animals
MH  - Computer Simulation
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Humans
MH  - Laboratories
MH  - Muscle, Smooth
MH  - *Physiology/education
MH  - *Students, Medical
MH  - Teaching
OTO - NOTNLM
OT  - Tyrode solution
OT  - animal experiments
OT  - discarded tissue
OT  - undergraduate students
EDAT- 2020/06/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1152/advan.00195.2019 [doi]
PST - ppublish
SO  - Adv Physiol Educ. 2020 Sep 1;44(3):295-304. doi: 10.1152/advan.00195.2019.


PMID- 32484402
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1522-1229 (Electronic)
IS  - 1043-4046 (Linking)
VI  - 44
IP  - 3
DP  - 2020 Sep 1
TI  - Systematic review and meta-analysis as a structured platform for teaching
      principles of experimentation.
PG  - 276-285
LID - 10.1152/advan.00131.2019 [doi]
AB  - Access to knowledge has never been easier in the internet age, and so it is
      important that students develop skills to discriminate undependable information
      from reliably investigated research. We have created an exercise that teaches
      good research practice by exploring the history, ethics, and design of clinical
      trials. Students apply their understanding of these principles through an
      assessed systematic review and meta-analysis (SRMA) exercise. Here, a clinically 
      themed hypothesis is tested using a structured literature search in conjunction
      with an eligibility matrix to map study design, ethics, subject selection,
      randomization and blinding, methodological standards, study power, and other
      potential sources of interstudy heterogeneity. Data extracted from selected
      studies are used to produce a forest plot with an aggregated effect size,
      confidence range, and measure of interstudy heterogeneity. A funnel plot is then 
      used in conjunction with the eligibility matrix to evaluate study bias tendency, 
      and, in this way, students reflect on the factors that promote disparate
      conclusion-making among studies with a common research focus. This exercise
      produced a normally distributed grade-profile across three academic-year cohorts,
      and comparison of individual exercise grade with year-long aggregated average
      suggested students who performed less well on conventional assignments engaged
      successfully with the systematic nature of this assessment. Those opting to use
      this format for their final-year capstone project also performed above their
      grade point average from the preceding year. We suggest that SRMA offers a
      readily applied method for students to quantitatively explore how differences in 
      experimental research practices influence study dependability.
FAU - Land, Stephen C
AU  - Land SC
AD  - Biological and Biomedical Science Education, School of Life Sciences, University 
      of Dundee, Dundee, Scotland, United Kingdom.
FAU - Booth, David
AU  - Booth D
AD  - Biological and Biomedical Science Education, School of Life Sciences, University 
      of Dundee, Dundee, Scotland, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Adv Physiol Educ
JT  - Advances in physiology education
JID - 100913944
SB  - IM
MH  - *Exercise
MH  - Humans
MH  - *Students
OTO - NOTNLM
OT  - clinical trial
OT  - good research practice
OT  - literature analysis
OT  - meta-analysis
OT  - systematic review
EDAT- 2020/06/03 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1152/advan.00131.2019 [doi]
PST - ppublish
SO  - Adv Physiol Educ. 2020 Sep 1;44(3):276-285. doi: 10.1152/advan.00131.2019.


PMID- 32484144
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20220421
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - Commentary: In Search of Medical Ethics and Its Foundation with Rosamond Rhodes.
PG  - 429-436
LID - 10.1017/S0963180120000171 [doi]
AB  - In her thorough and thoughtful contribution to the Cambridge Quarterly of
      Healthcare Ethics titled "Medical Ethics: Common or Uncommon Morality" Rosamond
      Rhodes argues that contrary to American mainstream bioethics, medical ethics is
      not, and should not be, based on common morality, but rather, that the medical
      profession requires its own distinctive morality.1 She goes on to list sixteen
      duties that, according to her, form the core of medical ethics proper.
FAU - Takala, Tuija
AU  - Takala T
FAU - Hayry, Matti
AU  - Hayry M
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
CON - Camb Q Healthc Ethics. 2020 Jul;29(3):404-420. PMID: 32484137
CIN - Camb Q Healthc Ethics. 2022 Jan;31(1):144-149. PMID: 35049448
MH  - *Bioethics
MH  - *Ethics, Medical
MH  - Morals
EDAT- 2020/06/03 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1017/S0963180120000171 [doi]
AID - S0963180120000171 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):429-436. doi: 10.1017/S0963180120000171.


PMID- 32484143
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - Thinking About Difficulties: Using Poetry to Enhance Interpretative and
      Collaborative Skills in Healthcare Ethics Education.
PG  - 459-469
LID - 10.1017/S0963180120000201 [doi]
AB  - Viewing difficulty as an opportunity for learning runs counter to the common view
      of difficulty as a source of frustration and confusion. The aim of this article
      is to focus on the idea of difficulty as a stepping-off point for learning. The
      literature on difficulty in reading texts, and its impact on thinking and the
      interpretive process, serve as a foundation for the use of poetry in healthcare
      ethics education. Because of its complexity and strangeness compared to the usual
      scientific and clinical texts health science students encounter, poetry is an
      excellent means to achieve the aim of thinking through difficulties in ethics.
      Specific examples of teaching and learning strategies for turning difficulty into
      opportunities for learning are presented, including the difficulty paper and the 
      triple mark-up method. Both methods require students to examine their process of 
      working through difficulties, reflect on how they make sense of difficult texts
      and then share their process and interpretations in a collaborative manner with
      peers. The importance of framing difficulties as a public, visible, collaborative
      process rather than a personal process is emphasized. Working together to
      hypothesize reasons for difficulty and map out plans to come to terms with
      difficulty are equally relevant for reading text as they are for reading complex 
      ethical situations. Finally, I argue that transference of this kind of personal
      and collaborative learning about difficulties benefits interprofessional clinical
      practice, particularly when dealing with ethical issues.
FAU - Haddad, Amy
AU  - Haddad A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - *Bioethics
MH  - *Curriculum
MH  - Delivery of Health Care
MH  - Educational Status
MH  - Humans
MH  - Learning
OTO - NOTNLM
OT  - *difficulty
OT  - *ethics education
OT  - *health humanities
OT  - *interprofessional collaboration
OT  - *poetry
EDAT- 2020/06/03 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000201 [doi]
AID - S0963180120000201 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):459-469. doi: 10.1017/S0963180120000201.


PMID- 32484141
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - From Death to Life: Ethical Issues in Postmortem Sperm Retrieval as a Source of
      New Life.
PG  - 369-374
LID - 10.1017/S0963180120000092 [doi]
AB  - This paper examines and critiques the ethical issues in postmortem sperm
      retrieval and the use of postmortem sperm to create new life. The article was
      occasioned by the recent request of the parents of a West Point cadet who died in
      a skiing accident at the Academy to retrieve and use his sperm to honor his
      memory and perpetuate the family name. The request occasioned national media
      attention. A trial court judge in New York in a two-page order authorized both
      the retrieval and use of the postmortem sperm.
FAU - Cummings, Brian M
AU  - Cummings BM
FAU - Paris, John J
AU  - Paris JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
MH  - Humans
MH  - Male
MH  - *Sperm Retrieval
MH  - *Spermatozoa
OTO - NOTNLM
OT  - *court decision postmortem sperm retrieval
OT  - *impregnation using postmortem sperm retrieval
OT  - *parental rights over progeny's reproduction
OT  - *postmortem sperm retrieval
EDAT- 2020/06/03 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000092 [doi]
AID - S0963180120000092 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):369-374. doi: 10.1017/S0963180120000092.


PMID- 32484140
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20220421
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - Commentary: Beyond Common or Uncommon Morality.
PG  - 426-428
LID - 10.1017/S096318012000016X [doi]
AB  - In "Medical Ethics: Common or Uncommon Morality,"1 Rosamond Rhodes defends a
      specialist view of medical ethics, specifically the ethics of physicians.
      Rhodes's account is specifically about the ethics of medical professionals,
      rooted in what these professionals do. It would seem to follow that other
      healthcare professions might be subject to ethical standards that differ from
      those applicable to physicians, rooted in what these other professions do, but I 
      leave this point aside for purposes of this commentary. Rhodes's view includes
      both a negative and a positive thesis. The negative thesis is that precepts in
      medical ethics-understood as the ethics of physicians-cannot be derived from
      principles of common morality. The positive thesis is two-fold: that precepts in 
      medical ethics must be derived from an account of the special nature of what
      physicians do, and that this account is to be understood through an overlapping
      consensus of rational and reasonable medical professionals. While I agree
      emphatically with, and have learned a great deal from, Rhodes's defense of the
      negative thesis, I disagree with both claims in Rhodes's positive thesis, for
      reasons I will now explain after a brief observation about the negative thesis.
FAU - Francis, Leslie
AU  - Francis L
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
CON - Camb Q Healthc Ethics. 2020 Jul;29(3):404-420. PMID: 32484137
CIN - Camb Q Healthc Ethics. 2022 Jan;31(1):144-149. PMID: 35049448
MH  - Ethics, Medical
MH  - Humans
MH  - Moral Obligations
MH  - *Morals
MH  - *Physicians
EDAT- 2020/06/03 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1017/S096318012000016X [doi]
AID - S096318012000016X [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):426-428. doi: 10.1017/S096318012000016X.


PMID- 32484137
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220421
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - Medical Ethics: Common or Uncommon Morality?
PG  - 404-420
LID - 10.1017/S0963180120000146 [doi]
AB  - This paper challenges the long-standing and widely accepted view that medical
      ethics is nothing more than common morality applied to clinical matters. It
      argues against Tom Beauchamp and James Childress's four principles; Bernard Gert,
      K. Danner Clouser and Charles Culver's ten rules; and Albert Jonsen, Mark
      Siegler, and William Winslade's four topics approaches to medical ethics. First, 
      a negative argument shows that common morality does not provide an account of
      medical ethics and then a positive argument demonstrates why the medical
      profession requires its own distinctive ethics. The paper also provides a way to 
      distinguish roles and professions and an account of the distinctive duties of
      medical ethics. It concludes by emphasizing ways in which the uncommon morality
      approach to medical ethics is markedly different from the common morality
      approach.
FAU - Rhodes, Rosamond
AU  - Rhodes R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
CIN - Camb Q Healthc Ethics. 2020 Jul;29(3):421-425. PMID: 32484131
CIN - Camb Q Healthc Ethics. 2020 Jul;29(3):426-428. PMID: 32484140
CIN - Camb Q Healthc Ethics. 2020 Jul;29(3):429-436. PMID: 32484144
CIN - Camb Q Healthc Ethics. 2022 Jan;31(1):144-149. PMID: 35049448
MH  - *Ethics, Medical
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - *common morality
OT  - *medical ethics
OT  - *medical professionalism
OT  - *uncommon morality
EDAT- 2020/06/03 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1017/S0963180120000146 [doi]
AID - S0963180120000146 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):404-420. doi: 10.1017/S0963180120000146.


PMID- 32484133
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20201106
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - Retrieving the Moral in the Ethics of Maternal-Fetal Surgery.
PG  - 480-493
LID - 10.1017/S0963180120000225 [doi]
AB  - Open-uterine surgery to repair spina bifida, or 'fetal surgery of open neural
      tube defects,' has generated questions throughout its history-and continues to do
      so in a variety of contexts. As clinical ethics consultants who worked (Mark J.
      Bliton) and trained (Virginia L. Bartlett) at Vanderbilt University-where the
      first successful cases of open-uterine repair of spina bifida were carried out-we
      lived with these questions for nearly two decades. We worked with clinicians as
      they were developing and offering the procedure, with researchers in refining and
      studying the procedure, and with pregnant women and their partners as they
      considered whether to undergo the procedure. From this experience in the early
      studies at Vanderbilt, we learned that pregnant women and their partners approach
      the clinical uncertainty of such a risky procedure with a curious and unique
      combination of practicality, self-reflection, fear, and overwhelming hope. These 
      early experiences were a major contributing factor to the inclusion of an
      ethics-focused interview in the informed consent process for the Management of
      Myelomeningocele Study (MOMS) trial study design.
FAU - Bartlett, Virginia L
AU  - Bartlett VL
FAU - Bliton, Mark J
AU  - Bliton MJ
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
CON - Camb Q Healthc Ethics. 2019 Jul;28(3):476-487. PMID: 31298194
MH  - Female
MH  - Fetus
MH  - Humans
MH  - *Meningomyelocele/surgery
MH  - Morals
MH  - *Neural Tube Defects
MH  - Pregnancy
MH  - *Spinal Dysraphism/surgery
EDAT- 2020/06/03 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1017/S0963180120000225 [doi]
AID - S0963180120000225 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):480-493. doi: 10.1017/S0963180120000225.


PMID- 32484131
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20220421
IS  - 1469-2147 (Electronic)
IS  - 0963-1801 (Linking)
VI  - 29
IP  - 3
DP  - 2020 Jul
TI  - Commentary: Medical Ethics: A Distinctive Species of Ethics.
PG  - 421-425
LID - 10.1017/S0963180120000158 [doi]
FAU - Fleck, Leonard M
AU  - Fleck LM
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Camb Q Healthc Ethics
JT  - Cambridge quarterly of healthcare ethics : CQ : the international journal of
      healthcare ethics committees
JID - 9208482
SB  - IM
CON - Camb Q Healthc Ethics. 2020 Jul;29(3):404-420. PMID: 32484137
CIN - Camb Q Healthc Ethics. 2022 Jan;31(1):144-149. PMID: 35049448
MH  - *Ethical Theory
MH  - *Morals
EDAT- 2020/06/03 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1017/S0963180120000158 [doi]
AID - S0963180120000158 [pii]
PST - ppublish
SO  - Camb Q Healthc Ethics. 2020 Jul;29(3):421-425. doi: 10.1017/S0963180120000158.


PMID- 32484089
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1573-4056 (Electronic)
VI  - 16
IP  - 5
DP  - 2020
TI  - Recent Advances in Cone-beam CT in Oral Medicine.
PG  - 553-564
LID - 10.2174/1573405615666190114152003 [doi]
AB  - BACKGROUND: The cone-beam computed tomography (CBCT) technology has continuously 
      evolved since its appearance in oral medicine in the early 2000s. OBJECTIVES: To 
      present recent advances in CBCT in oral medicine: i) selection of recent and
      consensual evidence-based sources, ii) structured summary of the information
      based on an iterative framework and iii) compliance with ethical, public health
      and patient-centered concerns. MAIN FINDINGS: We will focus on technological
      advances, such as sensors and reconstruction algorithms used to improve the
      constant quality of the image and dosimetry. CBCT examination is now performed in
      almost all disciplines of oral medicine: currently, the main clinical disciplines
      that use CBCT acquisitions are endodontics and oral surgery, with clearly defined
      indications. Periodontology and ear, nose and throat medicine are more recent
      fields of application. For a given application and indication, the smallest
      possible field of view must be used. One of the major challenges in contemporary 
      healthcare is ensuring that technological developments do not take precedence
      over admitted standards of care. The entire volume should be reviewed in full,
      with a systematic approach. All findings are noted in the patient's record and
      explained to the patient, including incidental findings. This presupposes the
      person reviewing the images is sufficiently trained to interpret such images,
      inform the patient and organize the clinical pathway, with referrals to other
      medical or oral medicine specialties as needed. CONCLUSION: A close collaboration
      between dentists, medical physicists, radiologists, radiographers and engineers
      is critical for all aspects of CBCT technology.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Maret, Delphine
AU  - Maret D
AD  - Oral Rehabilitation Department, Dental Faculty, Paul Sabatier University,
      Toulouse University Hospital (CHU de Toulouse), Toulouse, France.
AD  - AMIS Laboratory - Laboratoire Anthropologie Moleculaire et Imagerie de Synthese, 
      Universite de Toulouse, UMR 5288 CNRS, UPS, Toulouse, France.
FAU - Vergnes, Jean-Noel
AU  - Vergnes JN
AD  - Epidemiology and Public Health Department, Dental Faculty, Paul Sabatier
      University, Toulouse University Hospital (CHU de Toulouse), Toulouse, France.
AD  - Division of Oral Health and Society, Faculty of Dentistry, McGill University,
      Montreal, Quebec, Canada.
FAU - Peters, Ove A
AU  - Peters OA
AD  - Department of Endodontics, Arthur A. Dugoni School of Dentistry, University of
      the Pacific, San Francisco, California, United States.
AD  - School of Dentistry, University of Queensland, Brisbane, Queensland, Australia.
FAU - Peters, Christine
AU  - Peters C
AD  - Department of Endodontics, Arthur A. Dugoni School of Dentistry, University of
      the Pacific, San Francisco, California, United States.
FAU - Nasr, Karim
AU  - Nasr K
AD  - Oral Rehabilitation Department, Dental Faculty, Paul Sabatier University,
      Toulouse University Hospital (CHU de Toulouse), Toulouse, France.
FAU - Monsarrat, Paul
AU  - Monsarrat P
AD  - Oral Rehabilitation Department, Dental Faculty, Paul Sabatier University,
      Toulouse University Hospital (CHU de Toulouse), Toulouse, France.
AD  - STROMALab, Universite de Toulouse, CNRS ERL 5311, EFS, ENVT, Inserm U1031, UPS,
      Toulouse, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Imaging
JT  - Current medical imaging
JID - 101762461
SB  - IM
MH  - Cone-Beam Computed Tomography/*methods
MH  - Humans
MH  - Oral Medicine/*methods
MH  - Stomatognathic Diseases/*diagnostic imaging
OTO - NOTNLM
OT  - *Cone-beam computed tomography
OT  - *incidental findings
OT  - *oral medicine
OT  - *patientcentered care
OT  - *radiology
OT  - *stomatognathic diseases.
EDAT- 2020/06/03 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/03 06:00
PHST- 2018/09/24 00:00 [received]
PHST- 2018/12/09 00:00 [revised]
PHST- 2018/12/19 00:00 [accepted]
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - CMIR-EPUB-95775 [pii]
AID - 10.2174/1573405615666190114152003 [doi]
PST - ppublish
SO  - Curr Med Imaging. 2020;16(5):553-564. doi: 10.2174/1573405615666190114152003.


PMID- 32483841
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jul
TI  - The death of dignity is greatly exaggerated: Reflections 15 years after the
      declaration of dignity as a useless concept.
PG  - 602-611
LID - 10.1111/bioe.12752 [doi]
AB  - Fifteen years ago, Ruth Macklin shook the medical community with her claim in the
      BMJ that dignity is a useless concept. Her essay provoked a storm of reactions.
      What have we learned from the debate? In this article I analyse the responses to 
      her essay and the following debate to investigate whether she was right that
      "[d]ignity is a useless concept in medical ethics and can be eliminated without
      any loss of content." While some of the commentaries misconstrued her claim and
      argue against strawmen, others forcefully maintained that the concept of dignity 
      has functions beyond "respect for persons and their autonomy." One important
      point that came out of the debate is that dignity is a generic concept that
      covers more ground than "respect for persons or their autonomy." In particular,
      dignity seems to have a wide range of protective functions as well as having
      reciprocal, relational, and social aspects. Dignity appears more attributional
      and norm-formative than respect for persons and autonomy. While the claim that
      dignity is unclear, vague, and can be used sloganistically seems highly relevant,
      it is argued that this vagueness fulfils important functions in ethics. Moreover,
      dismissing dignity because of its lack of clarity has implications for "respect
      for persons" and "autonomy," which are also used vaguely and sloganistically. No 
      doubt medical ethics should use as a clear concept as the context requires.
      Nonetheless, dignity still seems to be a widely used generic concept in ethical
      debates and doing as much ethical work as "respect for persons" or "respect for
      autonomy." Therefore, the death of dignity seems to be greatly exaggerated.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Hofmann, Bjorn
AU  - Hofmann B
AUID- ORCID: 0000-0001-6709-4265
AD  - Department of Health Sciences, the Norwegian University for Science and
      Technology, Gjovik, Norway.
AD  - Centre for Medical Ethics, University of Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Ethics, Medical
MH  - Humans
MH  - Morals
MH  - Personal Autonomy
MH  - Personhood
MH  - *Respect
OTO - NOTNLM
OT  - *autonomy
OT  - *dignity
EDAT- 2020/06/03 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/06/03 06:00
PHST- 2019/03/31 00:00 [received]
PHST- 2019/12/30 00:00 [revised]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1111/bioe.12752 [doi]
PST - ppublish
SO  - Bioethics. 2020 Jul;34(6):602-611. doi: 10.1111/bioe.12752. Epub 2020 Jun 1.


PMID- 32483804
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20220414
IS  - 1806-9339 (Electronic)
IS  - 0100-7203 (Linking)
VI  - 42
IP  - 5
DP  - 2020 May
TI  - Evaluation of High-Dose Vitamin A Treatment in Postmolar Patients with Low and
      Plateauing Serum Human Chorionic Gonadotropin Levels.
PG  - 240-247
LID - 10.1055/s-0040-1710302 [doi]
AB  - OBJECTIVE: To compare the effect of high-dose vitamin A (HD Vit-A) use during
      postmolar follow-up of patients with low and plateauing (L&P) serum human
      chorionic gonadotropin (hCG) levels, from the moment serum hCG plateaued (P-hCG) 
      to the first normal serum hCG value (< 5 IU/L). METHODS: The present
      retrospective series case study compared two nonconcurrent cohorts of patients.
      Control group (CG): 34 patients with L&P serum hCG levels who underwent expectant
      management for 6 months after uterine evacuation, from 1992 to 2010; study group 
      (SG): 32 patients in similar conditions who received 200,000 IU of Vit-A daily,
      from the identification of a P-hCG level to the first normal hCG value or the
      diagnosis of progression to gestational trophoblastic neoplasia (GTN), from 2011 
      to 2017. The present study was approved by the Ethics Committee of the
      institution where it was conducted. RESULTS: In both groups, the prevalence of
      persistent L&P serum hCG levels was < 5%. In the SG, hCG levels at plateau were
      higher (CG = 85.5 versus SG = 195 IU/L; p = 0.028), the rate of postmolar GTN was
      lower (CG = 29.4% versus SG = 6.3%, p = 0.034) and follow-up was shorter (CG = 14
      versus SG = 10 months, p < 0.001). During GTN follow-up, there were no
      differences in GTN staging or treatment aggressiveness in both groups. High-dose 
      Vit-A use did not have any relevant toxic effect. There were no GTN relapses or
      deaths. CONCLUSION: The limited use of HD Vit-A seems to have a safe and
      significant effect on the treatment of postmolar patients with L&P serum hCG
      levels and may decrease the development of postmolar GTN in this population.
CI  - Thieme Revinter Publicacoes Ltda Rio de Janeiro, Brazil.
FAU - Uberti, Elza Maria Hartmann
AU  - Uberti EMH
AUID- ORCID: 0000-0002-3087-8573
AD  - Porto Alegre Trophoblastic Disease Center, Mario Totta Maternity Ward, Hospital
      Irmandade da Santa Casa de Misericordia, Porto Alegre, RS, Brazil.
FAU - Diaz, Ruth Karina Escobar
AU  - Diaz RKE
AUID- ORCID: 0000-0002-5863-1062
AD  - Porto Alegre Trophoblastic Disease Center, Mario Totta Maternity Ward, Hospital
      Irmandade da Santa Casa de Misericordia, Porto Alegre, RS, Brazil.
FAU - Cardoso, Rodrigo Bernardes
AU  - Cardoso RB
AUID- ORCID: 0000-0001-7021-4571
AD  - Porto Alegre Trophoblastic Disease Center, Mario Totta Maternity Ward, Hospital
      Irmandade da Santa Casa de Misericordia, Porto Alegre, RS, Brazil.
FAU - Braga, Antonio
AU  - Braga A
AUID- ORCID: 0000-0002-2942-6182
AD  - Rio de Janeiro Gestational Trophoblastic Disease Reference Center, Department of 
      Obstetrics and Gynecology, Maternity School, Universidade Federal do Rio de
      Janeiro, Rio de Janeiro, RJ, Brazil.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
TT  - Avaliacao de alta dose de Vitamina A em pacientes pos-mola hidatiforme, com
      valores baixos e em plato de gonadotrofina corionica humana.
DEP - 20200529
PL  - Brazil
TA  - Rev Bras Ginecol Obstet
JT  - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira
      das Sociedades de Ginecologia e Obstetricia
JID - 9214757
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chorionic Gonadotropin)
RN  - 11103-57-4 (Vitamin A)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers, Tumor/blood
MH  - Chorionic Gonadotropin/*blood
MH  - Female
MH  - Gestational Trophoblastic Disease/prevention & control
MH  - Humans
MH  - Hydatidiform Mole/*blood
MH  - Middle Aged
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Uterine Neoplasms/*blood
MH  - Vitamin A/administration & dosage/*therapeutic use
MH  - Young Adult
COIS- The authors have no conflict of interests to declare.
EDAT- 2020/06/03 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - 10.1055/s-0040-1710302 [doi]
PST - ppublish
SO  - Rev Bras Ginecol Obstet. 2020 May;42(5):240-247. doi: 10.1055/s-0040-1710302.
      Epub 2020 May 29.


PMID- 32482844
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20201218
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 95
IP  - 6
DP  - 2020 Aug 11
TI  - Ethical decision-making for children with neuromuscular disorders in the COVID-19
      crisis.
PG  - 260-265
LID - 10.1212/WNL.0000000000009936 [doi]
AB  - The sudden appearance and proliferation of coronavirus disease 2019 has forced
      societies and governmental authorities across the world to confront the
      possibility of resource constraints when critical care facilities are overwhelmed
      by the sheer numbers of grievously ill patients. As governments and health care
      systems develop and update policies and guidelines regarding the allocation of
      resources, patients and families affected by chronic disabilities, including many
      neuromuscular disorders that affect children and young adults, have become
      alarmed at the possibility that they may be determined to have less favorable
      prognoses due to their underlying diagnoses and thus be assigned to lower
      priority groups. It is important for health care workers, policymakers, and
      government officials to be aware that the long-term prognoses for children and
      young adults with neuromuscular disorders are often more promising than
      previously believed due to a better understanding of the natural history of these
      diseases, benefits of multidisciplinary supportive care, and novel molecular
      therapies that can dramatically improve the disease course. Although the
      realities of a global pandemic have the potential to require a shift from our
      usual, highly individualistic standards of care to crisis standards of care,
      shifting priorities should nonetheless be informed by good facts. Resource
      allocation guidelines with the potential to affect children and young adults with
      neuromuscular disorders should take into account the known trajectory of acute
      respiratory illness in this population and rely primarily on contemporary
      long-term outcome data.
CI  - (c) 2020 American Academy of Neurology.
FAU - Laventhal, Naomi T
AU  - Laventhal NT
AUID- ORCID: 0000-0002-8110-7621
AD  - From the Division of Neonatal-Perinatal Medicine (N.T.L.), Department of
      Pediatrics, University of Michigan School of Medicine and C.S. Mott Children's
      Hospital; Center for Bioethics and Social Sciences in Medicine (N.T.L.),
      University of Michigan, Ann Arbor, MI; Department of Anesthesiology (R.J.G.),
      Critical Care and Pain Medicine, Boston Children's Hospital and Department of
      Anaesthesia (R.J.G.), Harvard Medical School, Boston, MA; Department of
      Pediatrics (S.A.R.), University of Florida College of Medicine; Department of
      Epidemiology (S.A.R.), University of Florida College of Medicine and College of
      Public Health and Health Professions, Gainesville, FL; Department of Neurology
      (D.K.U.), Boston Children's Hospital and Harvard Medical School, Boston, MA;
      Division of Pediatric Neurology (P.B.K.), Department of Pediatrics, University of
      Florida College of Medicine; and Department of Neurology and Department of
      Molecular Genetics and Microbiology (P.B.K.), University of Florida College of
      Medicine, Gainesville, FL.
FAU - Graham, Robert J
AU  - Graham RJ
AD  - From the Division of Neonatal-Perinatal Medicine (N.T.L.), Department of
      Pediatrics, University of Michigan School of Medicine and C.S. Mott Children's
      Hospital; Center for Bioethics and Social Sciences in Medicine (N.T.L.),
      University of Michigan, Ann Arbor, MI; Department of Anesthesiology (R.J.G.),
      Critical Care and Pain Medicine, Boston Children's Hospital and Department of
      Anaesthesia (R.J.G.), Harvard Medical School, Boston, MA; Department of
      Pediatrics (S.A.R.), University of Florida College of Medicine; Department of
      Epidemiology (S.A.R.), University of Florida College of Medicine and College of
      Public Health and Health Professions, Gainesville, FL; Department of Neurology
      (D.K.U.), Boston Children's Hospital and Harvard Medical School, Boston, MA;
      Division of Pediatric Neurology (P.B.K.), Department of Pediatrics, University of
      Florida College of Medicine; and Department of Neurology and Department of
      Molecular Genetics and Microbiology (P.B.K.), University of Florida College of
      Medicine, Gainesville, FL.
FAU - Rasmussen, Sonja A
AU  - Rasmussen SA
AD  - From the Division of Neonatal-Perinatal Medicine (N.T.L.), Department of
      Pediatrics, University of Michigan School of Medicine and C.S. Mott Children's
      Hospital; Center for Bioethics and Social Sciences in Medicine (N.T.L.),
      University of Michigan, Ann Arbor, MI; Department of Anesthesiology (R.J.G.),
      Critical Care and Pain Medicine, Boston Children's Hospital and Department of
      Anaesthesia (R.J.G.), Harvard Medical School, Boston, MA; Department of
      Pediatrics (S.A.R.), University of Florida College of Medicine; Department of
      Epidemiology (S.A.R.), University of Florida College of Medicine and College of
      Public Health and Health Professions, Gainesville, FL; Department of Neurology
      (D.K.U.), Boston Children's Hospital and Harvard Medical School, Boston, MA;
      Division of Pediatric Neurology (P.B.K.), Department of Pediatrics, University of
      Florida College of Medicine; and Department of Neurology and Department of
      Molecular Genetics and Microbiology (P.B.K.), University of Florida College of
      Medicine, Gainesville, FL.
FAU - Urion, David K
AU  - Urion DK
AD  - From the Division of Neonatal-Perinatal Medicine (N.T.L.), Department of
      Pediatrics, University of Michigan School of Medicine and C.S. Mott Children's
      Hospital; Center for Bioethics and Social Sciences in Medicine (N.T.L.),
      University of Michigan, Ann Arbor, MI; Department of Anesthesiology (R.J.G.),
      Critical Care and Pain Medicine, Boston Children's Hospital and Department of
      Anaesthesia (R.J.G.), Harvard Medical School, Boston, MA; Department of
      Pediatrics (S.A.R.), University of Florida College of Medicine; Department of
      Epidemiology (S.A.R.), University of Florida College of Medicine and College of
      Public Health and Health Professions, Gainesville, FL; Department of Neurology
      (D.K.U.), Boston Children's Hospital and Harvard Medical School, Boston, MA;
      Division of Pediatric Neurology (P.B.K.), Department of Pediatrics, University of
      Florida College of Medicine; and Department of Neurology and Department of
      Molecular Genetics and Microbiology (P.B.K.), University of Florida College of
      Medicine, Gainesville, FL.
FAU - Kang, Peter B
AU  - Kang PB
AUID- ORCID: 0000-0002-4270-7325
AD  - From the Division of Neonatal-Perinatal Medicine (N.T.L.), Department of
      Pediatrics, University of Michigan School of Medicine and C.S. Mott Children's
      Hospital; Center for Bioethics and Social Sciences in Medicine (N.T.L.),
      University of Michigan, Ann Arbor, MI; Department of Anesthesiology (R.J.G.),
      Critical Care and Pain Medicine, Boston Children's Hospital and Department of
      Anaesthesia (R.J.G.), Harvard Medical School, Boston, MA; Department of
      Pediatrics (S.A.R.), University of Florida College of Medicine; Department of
      Epidemiology (S.A.R.), University of Florida College of Medicine and College of
      Public Health and Health Professions, Gainesville, FL; Department of Neurology
      (D.K.U.), Boston Children's Hospital and Harvard Medical School, Boston, MA;
      Division of Pediatric Neurology (P.B.K.), Department of Pediatrics, University of
      Florida College of Medicine; and Department of Neurology and Department of
      Molecular Genetics and Microbiology (P.B.K.), University of Florida College of
      Medicine, Gainesville, FL. pbkang@ufl.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200601
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Clinical Decision-Making/*ethics/methods
MH  - Coronavirus Infections/*diagnosis/*epidemiology/therapy
MH  - Health Personnel/ethics
MH  - Humans
MH  - Neuromuscular Diseases/*diagnosis/*epidemiology/therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/*epidemiology/therapy
MH  - SARS-CoV-2
EDAT- 2020/06/03 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - WNL.0000000000009936 [pii]
AID - 10.1212/WNL.0000000000009936 [doi]
PST - ppublish
SO  - Neurology. 2020 Aug 11;95(6):260-265. doi: 10.1212/WNL.0000000000009936. Epub
      2020 Jun 1.


PMID- 32482669
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 1
TI  - Photobiomodulation therapy associated with supervised therapeutic exercises for
      people with knee osteoarthritis: a randomised controlled trial protocol.
PG  - e035711
LID - 10.1136/bmjopen-2019-035711 [doi]
AB  - BACKGROUND: Physical exercise, a cornerstone of the conservative management of
      knee osteoarthritis (KOA), is exhaustively recommended by important clinical
      guidelines. A strength therapeutic exercise program (STEP) relieves pain,
      improves physical function and ultimately ameliorates quality of life (QoL).
      Furthermore, photobiomodulation (PBM) has been used as an adjunct treatment for
      people with KOA; however, there are still controversial recommendations regarding
      its use on this population. Thus, we hypothesised that PBM, when associated with 
      a STEP protocol on patients with KOA, could induce better clinical outcomes than 
      a STEP protocol alone. METHODS AND ANALYSIS: The study is a 6-month triple-blind 
      placebo-controlled randomised clinical trial with intention-to-treat analysis.
      The trial will include 120 people with clinic and radiographic signs of KOA. The 
      intervention consists of a supervised STEP and PBM protocols conducted over an
      8-week intervention period. Assessments are performed at baseline, right after
      treatment, and 3-month and 6-month follow-up periods. The primary clinical
      outcome is pain intensity according to a 10 cm Visual Analogue Scale. Secondary
      outcomes are the global Western Ontario & McMaster Universities Osteoarthritis
      Index; QoL assessed by the 36-item Short-Form health survey questionnaire; and
      performance-based physical parameters assessed by the 30 s chair stand test; the 
      stair climb test; and the 40 m fast-paced walk test. ETHICS AND DISSEMINATION:
      The trial was approved by the Human Research Ethics Committee of the Federal
      University of Sao Carlos, Sao Paulo, Brazil (REC no 2.016.122). Results will be
      published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: Brazilian
      Clinical Trials Registry (U1111-1215-6510).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - S Jorge, Ana E
AU  - S Jorge AE
AUID- ORCID: 0000-0003-0427-0158
AD  - Department of Physiotherapy, Federal University of Sao Carlos, Sao Carlos, Sao
      Paulo, Brazil.
FAU - O Dantas, Lucas
AU  - O Dantas L
AUID- ORCID: 0000-0002-6188-7552
AD  - Department of Physiotherapy, Federal University of Sao Carlos, Sao Carlos, Sao
      Paulo, Brazil.
FAU - M S Serrao, Paula R
AU  - M S Serrao PR
AUID- ORCID: 0000-0002-4547-9161
AD  - Department of Physiotherapy, Federal University of Sao Carlos, Sao Carlos, Sao
      Paulo, Brazil.
FAU - Alburquerque-Sendin, Francisco
AU  - Alburquerque-Sendin F
AUID- ORCID: 0000-0002-3892-8440
AD  - Department of Sociosanitary Sciences, Radiology and Physical Medicine,
      Universidad de Cordoba, Instituto Maiomonides de Investigacion Biomedica de
      Cordoba (IMIBIC), Cordoba, Andalucia, Spain.
FAU - Salvini, Tania F
AU  - Salvini TF
AUID- ORCID: 0000-0002-6353-6393
AD  - Department of Physiotherapy, Federal University of Sao Carlos, Sao Carlos, Sao
      Paulo, Brazil tania@ufscar.br.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brazil
MH  - Exercise Therapy
MH  - Humans
MH  - Knee Joint
MH  - *Low-Level Light Therapy
MH  - Ontario
MH  - *Osteoarthritis, Knee/therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7264996
OTO - NOTNLM
OT  - *clinical trials
OT  - *knee
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/06/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035711 [pii]
AID - 10.1136/bmjopen-2019-035711 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 1;10(6):e035711. doi: 10.1136/bmjopen-2019-035711.


PMID- 32482668
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 6
DP  - 2020 Jun 1
TI  - Cryotherapy associated with tailored land-based exercises for knee
      osteoarthritis: a protocol for a double-blind sham-controlled randomised trial.
PG  - e035610
LID - 10.1136/bmjopen-2019-035610 [doi]
AB  - INTRODUCTION: There is an unmet need to develop tailored therapeutic exercise
      protocols applying different treatment parameters and modalities for individuals 
      with knee osteoarthritis (KOA). Cryotherapy is widely used in rehabilitation as
      an adjunct treatment due to its effects on pain and the inflammatory process.
      However, disagreement between KOA guidelines remains with respect to its
      recommendation status. The aim of this study is to verify the complementary
      effects of cryotherapy when associated with a tailored therapeutic exercise
      protocol for patients with KOA. METHODS AND ANALYSIS: This study is a
      sham-controlled randomised trial with concealed allocation and intention-to-treat
      analysis. Assessments will be performed at baseline and immediately following the
      intervention period. To check for residual effects of the applied interventions, 
      3-month and 6-month follow-up assessments will be performed. Participants will be
      community members living with KOA divided into three groups: (1) the experimental
      group that will receive a tailored therapeutic exercise protocol followed by a
      cryotherapy session of 20 min; (2) the sham control group that will receive the
      same regimen as the first group, but with sham packs filled with dry sand and (3)
      the active treatment control group that will receive only the therapeutic
      exercise protocol. The primary outcome will be pain intensity according to a
      Visual Analogue Scale. Secondary outcomes will be the Western Ontario & McMaster 
      Universities Osteoarthritis Index; the Short-Form Health Survey 36; the 30-s
      Chair Stand Test; the Stair Climb test; and the 40-m fast-paced walk test. ETHICS
      AND DISSEMINATION: The trial was approved by the Institutional Ethics Committee
      of Federal University of Sao Carlos, Sao Paulo, Brazil. Registration approval
      number: CAAE: 65966617.9.0000.5504. The results will be published in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT03360500.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ogura Dantas, Lucas
AU  - Ogura Dantas L
AUID- ORCID: 0000-0002-6188-7552
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos, Sao Carlos,
      Sao Paulo, Brazil.
FAU - Serafim Jorge, Ana Elisa
AU  - Serafim Jorge AE
AUID- ORCID: 0000-0003-0427-0158
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos, Sao Carlos,
      Sao Paulo, Brazil.
FAU - Regina Mendes da Silva Serrao, Paula
AU  - Regina Mendes da Silva Serrao P
AUID- ORCID: 0000-0002-4547-9161
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos, Sao Carlos,
      Sao Paulo, Brazil.
FAU - Aburquerque-Sendin, Francisco
AU  - Aburquerque-Sendin F
AUID- ORCID: 0000-0002-3892-8440
AD  - Sociosanitary Sciences, Radiology and Physical Medicine, Universidad de Cordoba, 
      Cordoba, Andalucia, Spain.
AD  - Instituto Maiomonides de Investigacion Biomedica de Cordoba (IMIBIC), Universidad
      de Cordoba, Cordoba, Andalucia, Spain.
FAU - de Fatima Salvini, Tania
AU  - de Fatima Salvini T
AUID- ORCID: 0000-0002-6353-6393
AD  - Department of Physical Therapy, Universidade Federal de Sao Carlos, Sao Carlos,
      Sao Paulo, Brazil tania@ufscar.br.
LA  - eng
SI  - ClinicalTrials.gov/NCT03360500
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Brazil
MH  - Cryotherapy
MH  - Exercise Therapy
MH  - Humans
MH  - Ontario
MH  - *Osteoarthritis, Knee/therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7265131
OTO - NOTNLM
OT  - *pain management
OT  - *public health
OT  - *rehabilitation medicine
COIS- Competing interests: None declared
EDAT- 2020/06/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035610 [pii]
AID - 10.1136/bmjopen-2019-035610 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jun 1;10(6):e035610. doi: 10.1136/bmjopen-2019-035610.


PMID- 32482562
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1558-1365 (Electronic)
IS  - 1042-3699 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Aug
TI  - Answering the Call: How to Establish a Dentoalveolar Surgery Mission in Low- and 
      Middle-Income Countries.
PG  - 457-470
LID - S1042-3699(20)30034-0 [pii]
LID - 10.1016/j.coms.2020.04.007 [doi]
AB  - Addressing access to oral health care in many low- to middle-income countries is 
      a complicated issue. Oral and maxillofacial surgeons may help engage with
      vulnerable populations through carefully planned dentoalveolar mission trips. The
      process of planning a mission includes selecting a population and identifying
      their unique needs, designing clinic layouts and workflows, team preparation,
      collection of supplies, fundraising, and advertising. During the mission, methods
      for protecting privacy, delivering treatment that is standard of care, and
      sanitation/sterilization options are reviewed. Ethical considerations include
      avoiding exploitation of vulnerable populations, offending local hosts, need for 
      data collection, and long-term mission sustainability.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Manon, Victoria A
AU  - Manon VA
AD  - Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery,
      University of Texas Health Science Center at Houston, School of Dentistry, 7500
      Cambridge Street, Suite 6510, Houston, TX 77054, USA.
FAU - Demian, Nagi
AU  - Demian N
AD  - Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery,
      University of Texas Health Science Center at Houston, School of Dentistry, 7500
      Cambridge Street, Suite 6510, Houston, TX 77054, USA.
FAU - Aziz, Shahid R
AU  - Aziz SR
AD  - Department of Oral and Maxillofacial Surgery, Rutgers School of Dental Medicine, 
      110 Bergen Street, Room B854, Newark, NJ 07101-1709, USA; Division of Plastic and
      Reconstructive Surgery, Department of Surgery, Rutgers - New Jersey Medical
      School, Newark, NJ, USA; Update Dental College, Dhaka, Bangladesh; Smile
      Bangladesh.
FAU - Marchena, Jose M
AU  - Marchena JM
AD  - Update Dental College, Dhaka, Bangladesh; Smile Bangladesh; Department of Oral
      and Maxillofacial Surgery, The University of Texas Health Science Center at
      Houston, Ben Taub Hospital, Houston, TX, USA. Electronic address:
      Jose.M.Marchena@uth.tmc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - United States
TA  - Oral Maxillofac Surg Clin North Am
JT  - Oral and maxillofacial surgery clinics of North America
JID - 9001454
SB  - IM
MH  - Developing Countries
MH  - Humans
MH  - *Medical Missions
OTO - NOTNLM
OT  - Clinical design
OT  - Clinical workflow
OT  - Dentoalveolar
OT  - Humanitarian aid
OT  - Low- and middle-income countries
OT  - Mission ethics
OT  - Mission trip
COIS- Disclosure The authors have nothing to disclose.
EDAT- 2020/06/03 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S1042-3699(20)30034-0 [pii]
AID - 10.1016/j.coms.2020.04.007 [doi]
PST - ppublish
SO  - Oral Maxillofac Surg Clin North Am. 2020 Aug;32(3):457-470. doi:
      10.1016/j.coms.2020.04.007. Epub 2020 May 29.


PMID- 32482560
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20200924
IS  - 1558-1365 (Electronic)
IS  - 1042-3699 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Aug
TI  - Formal Training of the Global Surgeon: Current Educational Paradigms and Critical
      Elements for Progression.
PG  - 447-455
LID - S1042-3699(20)30032-7 [pii]
LID - 10.1016/j.coms.2020.04.005 [doi]
AB  - To prepare global surgeons, academic institutions have created training programs 
      that provide opportunities to develop foundational clinical knowledge, pursue
      academic inquiry, build surgical infrastructure and capacity, and become
      advocates and collaborators in resource-limited settings. Academic institutions
      can create a short course in global surgery, global surgery rotation, global
      surgery fellowship, or integrated global surgery residency. Global surgery
      training programs must account for ethics of global surgery engagement, sources
      of funding, structures for professional advancement, and trainee-appropriate
      partnerships. Global surgery training must include the establishment of
      accreditation systems, development of integrated training programs, and
      institutional investment in global surgery education.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Sherif, Youmna A
AU  - Sherif YA
AD  - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor 
      Plaza MS390, Houston, TX 77030, USA. Electronic address:
      https://twitter.com/youmnasheriff.
FAU - Davis, Rachel W
AU  - Davis RW
AD  - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor 
      Plaza MS390, Houston, TX 77030, USA. Electronic address: rgwilkin@bcm.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - United States
TA  - Oral Maxillofac Surg Clin North Am
JT  - Oral and maxillofacial surgery clinics of North America
JID - 9001454
SB  - IM
MH  - Humans
MH  - *Internship and Residency
MH  - *Surgeons
OTO - NOTNLM
OT  - Global surgery
OT  - Medical education
OT  - Surgical capacity
OT  - Training
COIS- Disclosure The authors have nothing to disclose.
EDAT- 2020/06/03 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S1042-3699(20)30032-7 [pii]
AID - 10.1016/j.coms.2020.04.005 [doi]
PST - ppublish
SO  - Oral Maxillofac Surg Clin North Am. 2020 Aug;32(3):447-455. doi:
      10.1016/j.coms.2020.04.005. Epub 2020 May 29.


PMID- 32482498
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1531-6564 (Electronic)
IS  - 0363-5023 (Linking)
VI  - 45
IP  - 11
DP  - 2020 Nov
TI  - Ethics and Professionalism: The Role of Self-Regulation and Peer Review in
      Maintaining Hand Surgery's Standards.
PG  - 1065-1069
LID - S0363-5023(20)30186-6 [pii]
LID - 10.1016/j.jhsa.2020.04.004 [doi]
AB  - The practice of hand surgery is bound by the need for each of us to maintain our 
      profession's high standards by fulfilling our peers' and society's expectations
      regarding ethical and professional behavior. Our profession is self-regulated by 
      local, state, and national organizations, which provide expectations and
      standards for practice. This manuscript reviews the resources available from such
      organizations to foster standards of practice.
CI  - Copyright (c) 2020 American Society for Surgery of the Hand. Published by
      Elsevier Inc. All rights reserved.
FAU - Lifchez, Scott D
AU  - Lifchez SD
AD  - Department of Plastic Surgery and Orthopedic Surgery, Johns Hopkins Bayview
      Medical Center, Baltimore, MD. Electronic address: Slifche1@jhmi.edu.
FAU - Adams, Julie E
AU  - Adams JE
AD  - Department of Orthopaedic Surgery, University of Tennessee College of
      Medicine-Chattanooga, Erlanger Orthopaedic Institute, Chattanooga, TN.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200529
PL  - United States
TA  - J Hand Surg Am
JT  - The Journal of hand surgery
JID - 7609631
SB  - IM
MH  - Hand/surgery
MH  - Humans
MH  - Peer Review
MH  - *Professionalism
MH  - *Self-Control
OTO - NOTNLM
OT  - Board certification
OT  - ethics
OT  - hand surgery licensure
OT  - peer review
OT  - professionalism
EDAT- 2020/06/03 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/06/03 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2020/02/15 00:00 [revised]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S0363-5023(20)30186-6 [pii]
AID - 10.1016/j.jhsa.2020.04.004 [doi]
PST - ppublish
SO  - J Hand Surg Am. 2020 Nov;45(11):1065-1069. doi: 10.1016/j.jhsa.2020.04.004. Epub 
      2020 May 29.


PMID- 32482342
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20201218
IS  - 1532-7361 (Electronic)
IS  - 0039-6060 (Linking)
VI  - 168
IP  - 1
DP  - 2020 Jul
TI  - Is it ethically appropriate to continue surgical clinical trials during the
      COVID-19 pandemic?
PG  - 1-3
LID - S0039-6060(20)30211-7 [pii]
LID - 10.1016/j.surg.2020.04.024 [doi]
FAU - Milner, Ross
AU  - Milner R
AD  - Department of Surgery, The University of Chicago Medicine, Chicago, IL.
      Electronic address: rmilner@surgery.bsd.uchicago.edu.
FAU - Donington, Jessica
AU  - Donington J
AD  - Department of Surgery, The University of Chicago Medicine, Chicago, IL.
FAU - Matthews, Jeffrey B
AU  - Matthews JB
AD  - Department of Surgery, The University of Chicago Medicine, Chicago, IL.
FAU - Posner, Mitchell
AU  - Posner M
AD  - Department of Surgery, The University of Chicago Medicine, Chicago, IL.
FAU - Turaga, Kiran
AU  - Turaga K
AD  - Department of Surgery, The University of Chicago Medicine, Chicago, IL.
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery, The University of Chicago Medicine, Chicago, IL.
LA  - eng
PT  - Editorial
DEP - 20200427
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7184004
EDAT- 2020/06/03 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - S0039-6060(20)30211-7 [pii]
AID - 10.1016/j.surg.2020.04.024 [doi]
PST - ppublish
SO  - Surgery. 2020 Jul;168(1):1-3. doi: 10.1016/j.surg.2020.04.024. Epub 2020 Apr 27.


PMID- 32482306
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20210129
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 70
DP  - 2020 May - Jun
TI  - Emergency mental health legislation in response to the Covid-19 (Coronavirus)
      pandemic in Ireland: Urgency, necessity and proportionality.
PG  - 101564
LID - S0160-2527(20)30023-6 [pii]
LID - 10.1016/j.ijlp.2020.101564 [doi]
AB  - Many countries have enacted, or are in the process of enacting, emergency mental 
      health legislation in response to the global pandemic of Covid-19 (coronavirus). 
      In Ireland, the Emergency Measures in the Public Interest (Covid-19) Act, 2020
      amends the Mental Health Act 2001 to permit the Mental Health Commission to
      request an independent psychiatric report about an involuntary patient from any
      consultant psychiatrist who is not treating the patient (and not just those on
      its designated panel). This independent examination may occur 'in person', 'by
      other appropriate means', or even, 'due to the exigencies of the public health
      emergency', not occur at all, once this is explained in the resultant report. The
      2020 Act acknowledges that 'the exigencies of the public health emergency' might 
      hamper the independent psychiatrist's work and requires a written report from the
      patient's treating psychiatrist 'no earlier than the day before' the tribunal, in
      lieu of the psychiatrist physically attending a tribunal hearing, although, if
      possible, they will attend (i.e. phone in to) a tribunal held by conference call.
      The 2020 Act permits the Mental Health Commission to, if necessary, appoint
      tribunals 'consisting of one member who shall be a practising barrister or
      solicitor'. Such a tribunal shall, if possible, consult with a consultant
      psychiatrist if the reports from the independent psychiatrist and treating
      psychiatrist conflict or if it is otherwise 'necessary in the interest of the
      patient'. A tribunal can extend an involuntary order by a second period of 14
      days 'of its own motion if the tribunal, having due regard to the interest of the
      patient, is satisfied that it is necessary'. Tribunals for current involuntary
      patients will be prioritised over retrospective tribunals for discharged
      patients; a tribunal can direct a witness to provide 'a written statement' rather
      than attending; and the patient can make written representation to the tribunal
      instead of physically attending a tribunal hearing, although they may attend
      (i.e. phone in to) a tribunal held by conference call. Psycho-surgery for
      involuntary patients is banned. While it is clear that revisions are urgent and
      necessary in light of Covid-19, the proportionality of these changes will depend 
      on how, and the extent to which, they are used in practice. With good
      communication, efficient team-working and close adherence to professional codes
      of practice and ethics, it is hoped that these amendments will result in a review
      system that is as reasonable, robust and reassuring as the current, highly
      unusual circumstances permit.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kelly, Brendan D
AU  - Kelly BD
AD  - Department of Psychiatry, Trinity College Dublin, Trinity Centre for Health
      Sciences, Tallaght University Hospital, Dublin D24 NR0A, Ireland. Electronic
      address: brendan.kelly@tcd.ie.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Advisory Committees
MH  - Betacoronavirus
MH  - COVID-19
MH  - Commitment of Mentally Ill/*legislation & jurisprudence
MH  - *Coronavirus Infections
MH  - Decision Making
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Ireland
MH  - Mental Disorders/therapy
MH  - Mental Health/*legislation & jurisprudence
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Psychiatry/*legislation & jurisprudence/*methods
MH  - SARS-CoV-2
PMC - PMC7174175
OTO - NOTNLM
OT  - *Coronavirus
OT  - *Covid-19
OT  - *Human rights
OT  - *Ireland
OT  - *Mental disorder
OT  - *Mental health legislation
COIS- Declaration of Competing Interest The author was a member of the Expert Group on 
      the Review of the Mental Health Act, 2001 (2015); was consulted by various
      parties at different stages in the development of the Emergency Measures in the
      Public Interest (Covid-19) Act, 2020; and is Editor-in-Chief of the International
      Journal of Law and Psychiatry and a co-editor of this special issue, but he
      played no role in the management of this paper during the editorial process.
      There is no other interest to declare.
EDAT- 2020/06/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/04/18 00:00 [accepted]
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - S0160-2527(20)30023-6 [pii]
AID - 10.1016/j.ijlp.2020.101564 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 May - Jun;70:101564. doi: 10.1016/j.ijlp.2020.101564. 
      Epub 2020 Apr 22.


PMID- 32482244
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 113
IP  - 6
DP  - 2020 Jun
TI  - Large randomized controlled trials in infertility.
PG  - 1093-1099
LID - S0015-0282(20)30398-8 [pii]
LID - 10.1016/j.fertnstert.2020.04.037 [doi]
AB  - As the first paper in this series of Views and Reviews on randomized controlled
      trials (RCTs), we aim to provide the basics of RCTs in infertility research. In
      this paper, we discuss the need and ethical considerations of large trials in
      infertility research and important aspects to guarantee the quality of a trial,
      including protocols, registrations and monitoring, issues of study design and
      analysis, and reporting standards. Because most of the treatment effects we would
      like to study represent relatively small signal-to-noise ratios, large RCTs are
      required to provide sufficient power to answer these questions. Trial protocols, 
      registrations, and monitoring facilitate the transparency of conduct, analysis,
      and reporting of the trial. Issues of trial design and analysis, such as
      nonblinding and misuse of the denominators, are common in published trials in
      this area and could be further improved. Finally, following the current reporting
      standard facilitates complete and transparent reporting, critical appraisal, and 
      interpretation.
CI  - Copyright (c) 2020 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Wang, Rui
AU  - Wang R
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia. 
      Electronic address: r.wang@monash.edu.
FAU - Chen, Zi-Jiang
AU  - Chen ZJ
AD  - Center for Reproductive Medicine, Shandong University, Jinan, Shandong; National 
      Research Center for Assisted Reproductive Technology and Reproductive Genetics,
      Shandong University, Jinan, Shandong; Shandong Provincial Clinical Medicine
      Research Center for Reproductive Health, Shandong University, Jinan, Shandong,
      People's Republic of China.
FAU - Vuong, Lan N
AU  - Vuong LN
AD  - Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at
      Ho Chi Minh City, Ho Chi Minh City, Vietnam.
FAU - Legro, Richard S
AU  - Legro RS
AD  - Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey,
      Pennsylvania.
FAU - Mol, Ben W
AU  - Mol BW
AD  - Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia.
FAU - Wilkinson, Jack
AU  - Wilkinson J
AD  - Centre for Biostatistics, University of Manchester, Manchester Academic Health
      Science Centre, Manchester, United Kingdom.
LA  - eng
GR  - 204796/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
MH  - Data Accuracy
MH  - Evidence-Based Medicine/*ethics
MH  - Female
MH  - Fertility
MH  - Humans
MH  - Infertility/diagnosis/physiopathology/*therapy
MH  - Male
MH  - Randomized Controlled Trials as Topic/*ethics
MH  - Reproductive Medicine/*ethics
MH  - Sample Size
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Randomized controlled trials
OT  - *ethics
OT  - *infertility
OT  - *reporting
OT  - *statistical analysis
EDAT- 2020/06/03 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - S0015-0282(20)30398-8 [pii]
AID - 10.1016/j.fertnstert.2020.04.037 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 Jun;113(6):1093-1099. doi: 10.1016/j.fertnstert.2020.04.037.


PMID- 32482180
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 1469-8978 (Electronic)
IS  - 0033-2917 (Linking)
VI  - 50
IP  - 8
DP  - 2020 Jun
TI  - Should euthanasia and assisted suicide for psychiatric disorders be permitted? A 
      systematic review of reasons.
PG  - 1241-1256
LID - 10.1017/S0033291720001543 [doi]
AB  - BACKGROUND: Euthanasia and assisted suicide (EAS) based on a psychiatric disorder
      (psychiatric EAS) continue to pose ethical and policy challenges, even in
      countries where the practice has been allowed for years. We conducted a
      systematic review of reasons, a specific type of review for bioethical questions 
      designed to inform rational policy-making. Our aims were twofold: (1) to
      systematically identify all published reasons for and against the practice (2) to
      identify current gaps in the debate and areas for future research. METHODS:
      Following the PRISMA guidelines, we performed a search across seven electronic
      databases to include publications focusing on psychiatric EAS and providing
      ethical reasons. Reasons were grouped into domains by qualitative content
      analysis. RESULTS: We included 42 articles, most of which were written after
      2013. Articles in favor and against were evenly distributed. Articles in favor
      were mostly full-length pieces written by non-clinicians, with articles against
      mostly reactive, commentary-type pieces written by clinicians. Reasons were
      categorized into eight domains: (1) mental and physical illness and suffering (2)
      decisional capacity (3) irremediability (4) goals of medicine and psychiatry (5) 
      consequences for mental health care (6) psychiatric EAS and suicide (7)
      self-determination and authenticity (8) psychiatric EAS and refusal of
      life-sustaining treatment. Parity- (or discrimination-) based reasons were
      dominant across domains, mostly argued for by non-clinicians, while policy
      reasons were mostly pointed to by clinicians. CONCLUSIONS: The ethical debate
      about psychiatric EAS is relatively young, with prominent reasons of parity. More
      direct engagement is needed to address ethical and policy considerations.
FAU - Nicolini, Marie E
AU  - Nicolini ME
AUID- ORCID: 0000-0003-1111-4372
AD  - Center for Biomedical Ethics and Law, KU Leuven, Kapucijnenvoer 35 - Box 7001
      3000 Leuven, Belgium.
AD  - Department of Bioethics, National Institutes of Health, 10 Center Drive, Room
      1C118, Bethesda, Maryland20892, USA.
FAU - Kim, Scott Y H
AU  - Kim SYH
AUID- ORCID: 0000-0002-9444-4627
AD  - Department of Bioethics, National Institutes of Health, 10 Center Drive, Room
      1C118, Bethesda, Maryland20892, USA.
FAU - Churchill, Madison E
AU  - Churchill ME
AD  - Department of Bioethics, National Institutes of Health, 10 Center Drive, Room
      1C118, Bethesda, Maryland20892, USA.
FAU - Gastmans, Chris
AU  - Gastmans C
AUID- ORCID: 0000-0002-5522-0639
AD  - Center for Biomedical Ethics and Law, KU Leuven, Kapucijnenvoer 35 - Box 7001
      3000 Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Systematic Review
DEP - 20200602
PL  - England
TA  - Psychol Med
JT  - Psychological medicine
JID - 1254142
SB  - IM
MH  - Decision Making
MH  - Euthanasia/*ethics/legislation & jurisprudence
MH  - *Health Policy
MH  - Humans
MH  - Mental Competency
MH  - Mental Disorders/*therapy
MH  - Personal Autonomy
MH  - Psychiatry/*ethics/legislation & jurisprudence
MH  - Suicide, Assisted/*ethics/legislation & jurisprudence
OTO - NOTNLM
OT  - *Ethics
OT  - *euthanasia
OT  - *non-terminal illness
OT  - *physician aid-in-dying
OT  - *physician-assisted suicide
OT  - *psychiatry
OT  - *systematic review of reasons
EDAT- 2020/06/03 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1017/S0033291720001543 [doi]
AID - S0033291720001543 [pii]
PST - ppublish
SO  - Psychol Med. 2020 Jun;50(8):1241-1256. doi: 10.1017/S0033291720001543. Epub 2020 
      Jun 2.


PMID- 32482121
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 5
DP  - 2020 Nov
TI  - Consequences of Medical Hierarchy on Medical Students, Residents, and Medical
      Education in Otolaryngology.
PG  - 906-914
LID - 10.1177/0194599820926105 [doi]
AB  - OBJECTIVE: To (1) review concepts of medical hierarchy; (2) examine the role of
      medical hierarchy in medical education and resident training; (3) discuss
      potential negative impacts of dysfunctional hierarchy in medical and surgical
      training programs, focusing on otolaryngology; and (4) investigate solutions to
      these issues. DATA SOURCES: Ovid Medline, Embase, GoogleScholar, JSTOR, Google,
      and article reference lists. REVIEW METHODS: A literature search was performed to
      identify articles relating to the objectives of the study using the
      aforementioned data sources, with subsequent exclusion of articles believed to be
      outside the scope of the current work. The search was limited to the past 5
      years. CONCLUSIONS: Two types of hierarchies exist: "functional" and
      "dysfunctional." While functional medical hierarchies aim to optimize patient
      care through clinical instruction, dysfunctional hierarchies have been linked to 
      negative impacts by creating learning environments that discourage the voicing of
      concerns, legitimize trainee mistreatment, and create moral distress through
      ethical dilemmas. Such an environment endangers patient safety, undermines
      physician empathy, hampers learning, lowers training satisfaction, and amplifies 
      stress, fatigue, and burnout. On the other hand, functional hierarchies may
      improve resident education and well-being, as well as patient safety.
      IMPLICATIONS FOR PRACTICE: Otolaryngology-head and neck surgery programs ought to
      work toward creating healthy systems of hierarchy that emphasize collaboration
      and improvement of workplace climate for trainees and faculty. The goal should be
      to identify aspects of dysfunctional hierarchy in one's own environment with the 
      ambition of rebuilding a functional hierarchy where learning, personal health,
      and patient safety are optimized.
FAU - Salehi, Parsa P
AU  - Salehi PP
AD  - Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Yale
      University School of Medicine, New Haven, Connecticut, USA.
FAU - Jacobs, Daniel
AU  - Jacobs D
AD  - Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Yale
      University School of Medicine, New Haven, Connecticut, USA.
FAU - Suhail-Sindhu, Timur
AU  - Suhail-Sindhu T
AD  - Department of Psychiatry and Human Behavior, Warren Alpert Medical School of
      Brown University, Providence, Rhode Island, USA.
FAU - Judson, Benjamin L
AU  - Judson BL
AD  - Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Yale
      University School of Medicine, New Haven, Connecticut, USA.
FAU - Azizzadeh, Babak
AU  - Azizzadeh B
AD  - Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck
      Surgery, Center for Advanced Facial Plastic Surgery, Beverly Hills, California,
      USA.
AD  - Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck
      Surgery, David Geffen School of Medicine at the University of California-Los
      Angeles, Los Angeles, California, USA.
FAU - Lee, Yan Ho
AU  - Lee YH
AD  - Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Yale
      University School of Medicine, New Haven, Connecticut, USA.
LA  - eng
PT  - Journal Article
DEP - 20200602
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - Curriculum
MH  - Education, Medical/*organization & administration
MH  - *Harassment, Non-Sexual
MH  - Humans
MH  - *Internship and Residency
MH  - *Interprofessional Relations
MH  - Otolaryngology/*education
MH  - Patient Safety
MH  - Personal Autonomy
MH  - Quality of Life
MH  - Sexual Harassment
MH  - Students, Medical/*psychology
OTO - NOTNLM
OT  - ACGME
OT  - NRMP
OT  - burnout
OT  - depression
OT  - hierarchy
OT  - match
OT  - quality of life
OT  - residency
OT  - resident
OT  - stress
OT  - well-being
OT  - wellness
EDAT- 2020/06/03 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/06/03 06:00 [entrez]
AID - 10.1177/0194599820926105 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Nov;163(5):906-914. doi:
      10.1177/0194599820926105. Epub 2020 Jun 2.


PMID- 32481452
OWN - NLM
STAT- MEDLINE
DCOM- 20200624
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 22
DP  - 2020 May 29
TI  - Acupuncture PC6 for postoperative nausea and vomiting at different times: A
      protocol for systematic review and meta analysis.
PG  - e20452
LID - 10.1097/MD.0000000000020452 [doi]
AB  - BACKGROUND: Postoperative nausea and vomiting (PONV) is a condition that commonly
      following anesthesia and surgery, antiemetics can lead to some side effects in
      treating PONV. Acupuncture PC6(Neiguan) has been widely used in the prevention
      and treatment of postoperative nausea and vomiting. However, there still exists
      controversy towards its effectiveness, appropriate, and effective intervention
      time. We, therefore, design this meta-analysis to assess the effectiveness and
      confirm the optimal time of acupuncture PC6 point for PONV. METHODS: The
      following electronic databases will be searched from their inception to April
      2020, including PubMed, Cochrane Library, EMBASE, Web of Science, WHO
      International Clinical Trials Registry Platform, Chinese National Knowledge
      Infrastructure, WanFang Database, Chinese Biomedical Literature Database, the
      Chongqing VIP Chinese Science, and Technology Periodical Database. All randomized
      controlled trials in English or Chinese involving acupuncture PC6 for patients
      with PONV will be included. Two reviewers will independently responsible for the 
      data extraction, study selection, risk of bias assessment and assessment of study
      quality. The primary outcome was the number of postoperative nausea,
      postoperative vomiting and PONV during 0 to 6 hours and after 6 hours of the
      postoperatively. The secondary outcome is the number of people with side effects 
      and the use of rescue therapy. The meta-analysis will be conducted using RevMan
      V.5.3.5 statistical software. RESULTS: This systematic review will evaluate the
      efficacy and appropriateness time of acupuncture PC6 in the treatment of PONV.
      CONCLUSION: This study will provide high-quality current evidence of the
      effectiveness and optimal time of acupuncture PC6 point for the patient with
      PONV. ETHICS AND DISSEMINATION: Ethical approval is not required; this review
      will not involve individuals' information. The results will be published in a
      peer-reviewed publication or disseminated in relevant conferences. INPLASY
      REGISTRATION NUMBER: DOI 10.37766/inplasy2020.4.0012.
FAU - Shi, Kejin
AU  - Shi K
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province,
      China.
FAU - He, Fengyi
AU  - He F
FAU - Tang, Ying
AU  - Tang Y
FAU - Xiao, Xiao
AU  - Xiao X
FAU - Zhang, Jiayuan
AU  - Zhang J
FAU - Jin, Yuxia
AU  - Jin Y
FAU - Wang, Yunxia
AU  - Wang Y
FAU - Zhang, Qi
AU  - Zhang Q
AUID- ORCID: 0000-0002-8356-4623
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/*methods
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Postoperative Nausea and Vomiting/*therapy
MH  - *Systematic Reviews as Topic
MH  - Time Factors
EDAT- 2020/06/03 06:00
MHDA- 2020/06/25 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
AID - 10.1097/MD.0000000000020452 [doi]
AID - 00005792-202005290-00097 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 29;99(22):e20452. doi:
      10.1097/MD.0000000000020452.


PMID- 32481353
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - Danggui Sini decoction for treating diabetic peripheral neuropathy: A protocol of
      systematic review and meta-analysis of randomized controlled trials.
PG  - e20482
LID - 10.1097/MD.0000000000020482 [doi]
AB  - BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common
      chronic complications of diabetic patients, which seriously affects the quality
      of life of patients. At present, mainstream drugs have problems such as poor
      efficacy and side effects. Traditional Chinese medicine (TCM) has extensive
      clinical experience in the prevention and treatment of diabetes and chronic
      complications, and it also shows clear advantages in the treatment of DPN.
      Clinical studies have confirmed that Danggui Sini decoction (DSD), a TCM
      decoction, can improve the clinical symptoms and signs of DPN patients.
      Therefore, we will conduct a systematic review to clarify the effectiveness and
      safety of DSD for DPN. METHODS: We will search every database from the built-in
      to October 2020. Chinese literature comes from CNKI, Wanfang, VIP, and CBM
      databases. English literature mainly searches Cochrane Library, PubMed, Web of
      Science, and EMBASE. At the same time, we will also search for clinical
      registration tests and gray literatures. This study only screened clinical
      randomized controlled trials (RCT) for DSD for DPN. The two researchers
      independently conducted literature selection, data extraction and quality
      assessment. Dichotomous data is represented by relative risk (RR), continuous
      data is represented by mean difference (MD) or standard mean deviation (SMD), and
      the final data is fixed effect model (FEM) or random effect model (REM),
      depending on whether it exists Heterogeneity. The main result is clinical
      efficacy and nerve conduction velocity. Fasting blood glucose, 2 hours
      postprandial blood glucose, blood lipid, hemorheology, and adverse events are
      secondary results. Finally, a meta-analysis was conducted through Review Manager 
      software version 5.3. RESULTS: This study will conduct a comprehensive analysis
      based on the currently released DSD data for the treatment of DPN and provide
      high-quality evidence of clinical efficacy and safety. CONCLUSION: This
      systematic review aims to provide new options for DSD treatment of DPN in terms
      of its efficacy and safety. ETHICS AND DISSEMINATION: The review is based solely 
      on a secondary study of published literatures and does not require ethics
      committee approval. Its conclusion will be disseminated in conference papers,
      magazines, or peer-reviewed journals. INPLASY REGISTRATION NUMBER:
      INPLASY202040157.
FAU - Zhang, Xiyu
AU  - Zhang X
AUID- ORCID: 0000-0003-3244-3554
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Heting
AU  - Wang H
AD  - Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, China.
FAU - Zhang, Yuan
AU  - Zhang Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Liu, Ya
AU  - Liu Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Zhenxing
AU  - Wang Z
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Du, Quanyu
AU  - Du Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Xie, Chunguang
AU  - Xie C
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (danggui sini)
SB  - IM
MH  - Clinical Protocols
MH  - Diabetic Neuropathies/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Medicine, Chinese Traditional/methods
MH  - Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7249906
EDAT- 2020/06/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020482 [doi]
AID - 00005792-202005220-00108 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20482. doi:
      10.1097/MD.0000000000020482.


PMID- 32481348
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - Comparison between acupuncture and cognitive behavioral therapy for primary
      insomnia: A protocol for systematic review and network meta-analysis.
PG  - e20453
LID - 10.1097/MD.0000000000020453 [doi]
AB  - BACKGROUND: Primary insomnia (PI) is a common disease affecting human health. As 
      the side effects of drug therapy were revealed, people began to seek more safe
      and effective non-drug therapies. Cognitive behavioral therapy for insomnia
      (CBT-I) and acupuncture are 2 commonly used non-drug therapies. However, there
      are few comparative studies on the efficacy of these 2 therapies. Therefore, this
      study aims to compare the efficacy and safety of the 2 therapies through network 
      meta-analysis. METHODS: We will search the following electronic bibliographic
      databases: PubMed, EMBASE, The Cochrane Library, Web of Science, China National
      Knowledge Infrastructure, Chinese Biomedical Literature Database, Chongqing VIP
      database, and Wanfang database. Randomized controlled trials in which the
      intervention was acupuncture or CBT, and in which the control group was any of
      the above, western medicine or blank control, would be included. The primary
      outcome will be the changes of the Pittsburgh Sleep Quality Index, and the
      additional outcomes will include the changes in Insomnia Severity Index, quality 
      of life, clinical effective rate and adverse events. Two independent authors will
      screen the literature in the above database, extract data and cross-check.
      Heterogeneity and inconsistencies are detected before using a network
      meta-analysis method based on frequency analysis. The risk of bias will be
      assessed in accordance with the Cochrane risk of bias tool, and the strength of
      the recommendations will be assessed by the Grading of Recommendations
      Assessment, Development and Evaluation. ETHICS AND DISSEMINATION: This network
      meta-analysis will provide a reference for clinicians and PI patients to choose a
      more appropriate non-drug regimen among multiple kinds of acupuncture or CBT-I
      therapies. This review does not require ethical approval and will be reported in 
      a peer-reviewed journal. TRIAL REGISTRATION NUMBER: PROSPERO CRD42020155327.
FAU - Peng, Wei
AU  - Peng W
AD  - Acupuncture & Tuina College.
FAU - Zhao, Ying
AU  - Zhao Y
AD  - Acupuncture & Tuina College.
FAU - Wang, Yang
AU  - Wang Y
AD  - Acupuncture & Tuina College.
FAU - Wang, Jun
AU  - Wang J
AD  - Rehabilitation and Health Preservation College, Chengdu University of Traditional
      Chinese Medicine, Chengdu, Sichuan, China.
FAU - Hao, Qinghong
AU  - Hao Q
AD  - Rehabilitation and Health Preservation College, Chengdu University of Traditional
      Chinese Medicine, Chengdu, Sichuan, China.
FAU - Tu, Yang
AU  - Tu Y
AD  - Rehabilitation and Health Preservation College, Chengdu University of Traditional
      Chinese Medicine, Chengdu, Sichuan, China.
FAU - Zhu, Tianmin
AU  - Zhu T
AUID- ORCID: 0000-0002-1257-3899
AD  - Rehabilitation and Health Preservation College, Chengdu University of Traditional
      Chinese Medicine, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/methods/*standards
MH  - China
MH  - Clinical Protocols
MH  - Cognitive Behavioral Therapy/methods/*standards
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Sleep Initiation and Maintenance Disorders/psychology/*therapy
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7249967
EDAT- 2020/06/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020453 [doi]
AID - 00005792-202005220-00103 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20453. doi:
      10.1097/MD.0000000000020453.


PMID- 32481336
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - The effect of Qigong Wuqinxi for osteopenia and primary osteoporosis: A protocol 
      for systematic review and meta analysis.
PG  - e20379
LID - 10.1097/MD.0000000000020379 [doi]
AB  - INTRODUCTION: Osteoporosis (OP) and related fragility fractures are a significant
      public health problem which leads to pain, disability, loss function of
      independence, considerable complications and increased mortality. Exercise
      training is the only alternative strategy to improve multiple skeletal and fall
      risk factors simultaneously. Wuqinxi is 1 of the Chinese mind-body exercises
      using to improve physical and mental health and fight against diseases for
      thousands of years. Our study aims to systematically review the existing
      literature to further explore the efficacy and safety of Wuqinxi in the
      prevention and treatment of osteopenia and OP. METHODS AND ANALYSIS: The
      following electronic databases (PubMed, Science Citation Index, Embase (Ovid)
      database, the Cochrane Library, the China National Knowledge Infrastructure, the 
      China Biology Medicine disc, the China Science and Technology Journal Database,
      the Wan fang Database, ClinicalTrials.gov and the Chinese Clinical Trial Registry
      Platform) will be searched from the beginning to 1 June 2020. Only randomized
      controlled trials will be enrolled, in which the intervention group must include 
      a form of Wuqinxi, while the control group can involve other conventional
      treatment or no intervention. The potential outcome measures will include bone
      mineral density values, bone turnover markers, fragility fractures, quality of
      life, pain scores, and adverse events. The Cochrane risk of bias assessment tool 
      will be used to assess the risk of bias in each study. RESULTS: The current study
      is a protocol for systematic review and meta-analysis without results, and data
      analysis will be carried out after the protocol. We will share our findings in
      the third quarter of 2021. CONCLUSION: This review aims to evaluate up-to-date
      evidence of Wuqinxi for bone health in English or Chinese language studies, and
      explore whether Wuqinxi can be used as an adjuvant treatment for osteoporosis and
      osteopenia. ETHICS AND DISSEMINATION: Ethical approval is not required as the
      review is a secondary study based on published literature. The results of the
      study will be published in peer-reviewed publications and disseminated
      electronically or in print. PROTOCOL REGISTRATION NUMBER: INPLASY202040135.
FAU - Liu, Min
AU  - Liu M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Liu, Dongying
AU  - Liu D
FAU - Hong, Peipei
AU  - Hong P
FAU - Qiu, Xianliang
AU  - Qiu X
FAU - Chen, Qiu
AU  - Chen Q
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Bone Diseases, Metabolic/*drug therapy
MH  - China
MH  - Clinical Protocols
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Osteoporosis/*drug therapy
MH  - Qigong/adverse effects/methods/*standards
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7249987
EDAT- 2020/06/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020379 [doi]
AID - 00005792-202005220-00091 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20379. doi:
      10.1097/MD.0000000000020379.


PMID- 32481335
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - Acupuncture and manual therapy for rotator cuff tears: A protocol for systematic 
      review and meta analysis.
PG  - e20377
LID - 10.1097/MD.0000000000020377 [doi]
AB  - BACKGROUND: The tears of rotator cuff is caused by the tears or aseptic
      inflammation of tendon tissue such as subscapular muscle, supraspinatus muscle,
      infraspinatus muscle, teres minor muscle, and so on, which make up the rotator
      cuff. Managements of rotator cuff disease often include acupuncture and manual
      therapy, usually delivered together. The aim of this review is to assess the
      effectiveness and safety of such interventions in patients with pain and
      dysfunction caused by rotator cuff tears. METHODS: We will search the EMBASE, the
      Cochrane Library, Ovid MEDLINE, PubMed, Web of Science, Chinese Biomedical
      Literature Database, Chinese National Knowledge Infrastructure, Wanfang Database,
      the Chongqing VIP, the US National Institute of Health, the NIH clinical registry
      Clinical Trials, the International Clinical Trials Registry Platform, the
      Australian New Zealand Clinical Trials Registry and the Chinese clinical
      registry, from their inception to April 1, 2020. Randomized controlled trials
      that include patients with rotator cuff tears receiving acupuncture and manual
      therapy versus a control group will be included. The selection of studies, data
      extraction and risk of bias assessment will be conducted by 2 independent
      researchers. A third review author will resolve disagreements. The dichotomous
      data will be presented as risk ratios with 95% CIs and the continuous data will
      be presented as weighted mean differences or standardized mean differences with
      95% CIs. Evidence quality will be evaluated using the Grading of Recommendations 
      Assessment, Development and Evaluation system. DISCUSSION: This systematic review
      will provide updated evidence of various types of acupuncture and manual therapy 
      specifically focuses on its effectiveness and safety for patients' pain and
      dysfunction caused by rotator cuff tears. ETHICS AND DISSEMINATION: Ethical
      approval is not necessary as this review will not require data from individual
      patients. The results of this will be published through peer-reviewed journal
      articles or conference presentations. REGISTRATION: Open Science Framework
      Preregistration. Registration number 10.17605/OSF.IO/M3NKV.
FAU - Tang, Hongzhi
AU  - Tang H
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Luo, Fei
AU  - Luo F
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Fan, Huaying
AU  - Fan H
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine, Chengdu city, Sichuan province, China.
FAU - Huang, Li
AU  - Huang L
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Liao, Shichuan
AU  - Liao S
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Yu, Wenjing
AU  - Yu W
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Chen, Yunbei
AU  - Chen Y
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Qin, Xuefei
AU  - Qin X
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Chen, Jiao
AU  - Chen J
AUID- ORCID: 0000-0003-0830-6242
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine, Chengdu city, Sichuan province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Acupuncture Therapy/methods/*standards
MH  - China
MH  - Clinical Protocols
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Musculoskeletal Manipulations/methods/*standards
MH  - Randomized Controlled Trials as Topic
MH  - Review Literature as Topic
MH  - Rotator Cuff Injuries/*therapy
PMC - PMC7249925
EDAT- 2020/06/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020377 [doi]
AID - 00005792-202005220-00090 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20377. doi:
      10.1097/MD.0000000000020377.


PMID- 32481324
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced
      nausea and vomiting: A systematic review protocol.
PG  - e20343
LID - 10.1097/MD.0000000000020343 [doi]
AB  - INTRODUCTION: The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class
      agent has grown rapidly in the last decade due to its effects on lowering HbA1c
      and weight and the low possibility of hypoglycemia. However, GLP-1 RAs are not
      devoid of adverse effects among which nausea and vomiting rank first, which
      reduce adherence to treatment. Accumulated evidences proved that acupuncture can 
      properly treat nausea and vomiting caused by various reasons. The study aims at
      assessing the safety and effectiveness exhibited by acupuncture treatment for
      patients with nausea and vomiting induced by GLP-1 RAs. METHODS AND ANALYSIS:
      Articles that have been identified via electronically searching databases of
      MEDLINE, Nature, PubMed, the Cochrane Library, WorldSciNet, EMbase, Science
      Online, AMED, China National Knowledge Infrastructure, the Wanfang Databse and
      China Biology Medicine Disc and the Chongqing VIP Chinese Science and Technology 
      Periodical Database from their inception of to December 31, 2019 will be
      incorporated into the systematic review. The review only adopts Chinese and
      English. It will also pay attention to searching resources of qualified studies, 
      relevant conference proceedings, potential reference list, as well as related
      system reviews. Two researchers will take charge of completing the selection of
      research, the extraction of data as well as the assessment of research quality
      independently. A random- or fixed-effects model will be employed to synthesize
      data combining the heterogeneity test. The primary outcomes will be nausea and
      vomiting, seen from the objective and self-reported assessment. Data analysis
      will be performed via the RevMan 5 software, and GRADE will help to assess the
      evidence level. The heterogeneity level will determine whether the random-effects
      model or the fixed-effects model will be used. The 2 categories will adopt risk
      ratio (RR) or odds ratio (OR) and 95% confidence interval (CI). Continuous
      variables will adopt the weighted mean difference or standardized mean difference
      and 95% CI. Meta-analysis will not be conducted if no assessment, like subgroup
      analysis, is able to explain existing meaningful heterogeneity. The subgroup
      analysis shall carefully consider each subgroup in certain case. ETHICS AND
      DISSEMINATION: The systematic review does not involve the evaluation of patients'
      individual information or patients' right; thus, there is no need to gain the
      approval from ethical institution. The article will be published in journals
      reviewed by peers and present at related conference.Registration: Open Science
      Framework (OSF) Preregistration. 2020, April 8. osf.io/3fgu8.
FAU - Ding, Ning
AU  - Ding N
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Li, Linzhi
AU  - Li L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zhu, Xinyun
AU  - Zhu X
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Huang, Xiaoying
AU  - Huang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Wang, Lizhen
AU  - Wang L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Yue, Rensong
AU  - Yue R
AUID- ORCID: 0000-0002-4417-3312
AD  - Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Acupuncture/*methods
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Nausea/chemically induced/*therapy
MH  - Vomiting/chemically induced/*therapy
PMC - PMC7249859
EDAT- 2020/06/03 06:00
MHDA- 2020/06/19 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
AID - 10.1097/MD.0000000000020343 [doi]
AID - 00005792-202005220-00079 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20343. doi:
      10.1097/MD.0000000000020343.


PMID- 32481286
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - Efficacy of transcranial magnetic stimulation and fluoxetine in the treatment of 
      postpartum depression: A protocol for systematic review and meta-analysis.
PG  - e20170
LID - 10.1097/MD.0000000000020170 [doi]
AB  - BACKGROUND: Numerous studies have reported that transcranial magnetic stimulation
      (TMS) and fluoxetine is used in the treatment of postpartum depression (PPD).
      Currently, no study has systematically investigated the efficacy and safety of
      TMS and fluoxetine for the treatment of patients with PPD. Thus, this study will 
      assess the efficacy and safety of TMS and fluoxetine for treating PPD. METHODS:
      Relevant studies involving TMS and fluoxetine for the treatment of patients with 
      PPD will be comprehensively searched from the electronic databases from inception
      to the February 1, 2020: Cochrane Library, EMBASE, MEDILINE, CINAHL, AMED,
      WANGFANG, VIP, and CNKI databases. No language and publication time restrictions 
      will be applied. RevMan 5.3 software will be utilized for data pooling, data
      analysis, and risk of bias evaluation. If necessary, we will also assess
      reporting bias using funnel plot and Egger test. RESULTS: This study will
      comprehensively summarize the existing evidence to assess the efficacy and safety
      of TMS and fluoxetine for treating PPD. CONCLUSION: The findings of this study
      may help to establish a better approach to treat PPD using TMS and fluoxetine.
      DISSEMINATION AND ETHICS: This study will be disseminated through a peer-reviewed
      journal. This study does not need ethical approval as no primary patient data
      will be used. SYSTEMATIC REVIEW REGISTRATION: INPLASY202040017.
FAU - Guo, Yan-Jun
AU  - Guo YJ
AD  - School of Medicine.
FAU - Shan, Yong-Ming
AU  - Shan YM
AD  - School of Mathematics and Information Engineering, Jiaxing University, Jiaxing,
      China.
FAU - Wang, Zhi-Jian
AU  - Wang ZJ
AD  - School of Medicine.
FAU - Shen, Zhong-Fei
AU  - Shen ZF
AUID- ORCID: 0000-0002-3256-0972
AD  - School of Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
SB  - IM
MH  - Adult
MH  - Combined Modality Therapy/methods
MH  - Depression, Postpartum/epidemiology/*therapy
MH  - Female
MH  - Fluoxetine/administration & dosage/*therapeutic use
MH  - Humans
MH  - Serotonin Uptake Inhibitors/administration & dosage/*therapeutic use
MH  - Transcranial Magnetic Stimulation/*methods
MH  - Treatment Outcome
PMC - PMC7249935
EDAT- 2020/06/03 06:00
MHDA- 2020/06/19 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
AID - 10.1097/MD.0000000000020170 [doi]
AID - 00005792-202005220-00041 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20170. doi:
      10.1097/MD.0000000000020170.


PMID- 35402946
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2644-1276 (Electronic)
IS  - 2644-1276 (Linking)
VI  - 1
DP  - 2020
TI  - A Multimodal Pancreas Phantom for Computer-Assisted Surgery Training.
PG  - 166-173
LID - 10.1109/OJEMB.2020.2999786 [doi]
AB  - Training of surgical residents and the establishment of innovative surgical
      techniques require training phantoms that realistically mimic human anatomy.
      Because animal models have their limitations due to ethical aspects, costs, and
      the required efforts to set up such training, artificial phantoms are a promising
      alternative. In the field of image-guided surgery, the challenge lies in
      developing phantoms that are accurate both anatomically and in terms of imaging
      properties, while taking the cost factor into account. With respect to the
      pancreas, animal models are less suitable because their anatomy differs
      significantly from human anatomy and tissue properties rapidly degrade in the
      case of ex vivo models. Nevertheless, progress with artificial phantoms has been 
      sparse, although the need for innovative, minimally invasive therapies that
      require adequate training is steadily increasing. Methods: In the course of this 
      project, an artificial pancreas phantom that is compatible with basic
      electrosurgical techniques was developed with realistic anatomic and haptic
      properties, computed tomography, and ultrasound imaging capabilities. This
      article contains step-by-step instructions for the fabrication of a low-cost
      pancreatic phantom. The molds are also available for download in a 3D file
      format. Results: The phantom was successfully validated with regard to its
      computed tomography and ultrasound properties. As a result, the phantom could be 
      used in combination with a state-of-the-art computer-assisted navigation system. 
      The resection capabilities were positively evaluated in a preclinical study
      evaluating endoscopic resections using the navigation system. Finally, the
      durability of the phantom material was tested in a study with multiple needle
      insertions. Conclusion: The developed phantom represents an open-access and
      low-cost durable alternative to conventional animal models in the continuous
      process of surgical training and development of new techniques.
FAU - Eigl, Benjamin
AU  - Eigl B
AUID- ORCID: https://orcid.org/0000-0002-0880-7963
AD  - ARTORG Center for Biomedical Engineering ResearchUniversity of Bern Bern 3012
      Switzerland.27210
AD  - CAScination AG Bern 3008 Switzerland.
FAU - Haslebacher, Caroline
AU  - Haslebacher C
AUID- ORCID: https://orcid.org/0000-0003-0674-1216
AD  - CAScination Bern 3008 Switzerland.
AD  - Physical Institute of the University of Bern Bern 3012 Switzerland.27210
FAU - Muller, Philip C
AU  - Muller PC
AD  - Department of Visceral and Transplant SurgeryUniversity Hospital Zurich Zurich
      8091 Switzerland.27243
FAU - Andreou, Andreas
AU  - Andreou A
AD  - Department of Visceral Surgery and MedicineUniversity Hospital of Bern Bern 3012 
      Switzerland.27210
FAU - Gloor, Beat
AU  - Gloor B
AD  - Department of Visceral Surgery and MedicineUniversity Hospital of Bern Bern 3012 
      Switzerland.27210
FAU - Peterhans, Matthias
AU  - Peterhans M
AD  - CAScination AG Bern 3008 Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - United States
TA  - IEEE Open J Eng Med Biol
JT  - IEEE open journal of engineering in medicine and biology
JID - 101766631
PMC - PMC8975253
OTO - NOTNLM
OT  - Artificial
OT  - computed-tomography
OT  - pancreas
OT  - phantom
OT  - ultrasound
EDAT- 2020/06/03 00:00
MHDA- 2020/06/03 00:01
CRDT- 2022/04/11 05:33
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2022/04/11 05:33 [entrez]
PHST- 2020/06/03 00:00 [pubmed]
PHST- 2020/06/03 00:01 [medline]
AID - 10.1109/OJEMB.2020.2999786 [doi]
PST - epublish
SO  - IEEE Open J Eng Med Biol. 2020 Jun 3;1:166-173. doi: 10.1109/OJEMB.2020.2999786. 
      eCollection 2020.


PMID- 32480362
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2561-326X (Electronic)
IS  - 2561-326X (Linking)
VI  - 4
IP  - 7
DP  - 2020 Jul 21
TI  - A Digital Library for Increasing Awareness About Living Donor Kidney Transplants:
      Formative Study.
PG  - e17441
LID - 10.2196/17441 [doi]
AB  - BACKGROUND: It is not common for people to come across a living kidney donor, let
      alone consider whether they would ever donate a kidney themselves while they are 
      alive. Narrative storytelling, the sharing of first-person narratives based on
      lived experience, may be an important way to improve education about living donor
      kidney transplants (LDKTs). Developing ways to easily standardize and disseminate
      diverse living donor stories using digital technology could inspire more people
      to consider becoming living donors and reduce the kidney shortage nationally.
      OBJECTIVE: This paper aimed to describe the development of the Living Donation
      Storytelling Project, a web-based digital library of living donation narratives
      from multiple audiences using video capture technology. Specifically, we aimed to
      describe the theoretical foundation and development of the library, a protocol to
      capture diverse storytellers, the characteristics and experiences of
      participating storytellers, and the frequency with which any ethical concerns
      about the content being shared emerged. METHODS: This study invited kidney
      transplant recipients who had received LDKTs, living donors, family members, and 
      patients seeking LDKTs to record personal stories using video capture technology 
      by answering a series of guided prompts on their computer or smartphone and
      answering questions about their filming experience. The digital software
      automatically spliced responses to open-ended prompts, creating a seamless story 
      available for uploading to a web-based library and posting to social media. Each 
      story was reviewed by a transplant professional for the disclosure of protected
      health information (PHI), pressuring others to donate, and medical inaccuracies. 
      Disclosures were edited. RESULTS: This study recruited diverse storytellers
      through social media, support groups, churches, and transplant programs. Of the
      137 storytellers who completed the postsurvey, 105/137 (76.6%) were white and
      99/137 (72.2%) were female. They spent 62.5 min, on average, recording their
      story, with a final median story length of 10 min (00:46 seconds to 32:16 min). A
      total of 94.8% (130/137) of storytellers were motivated by a desire to educate
      the public; 78.1% (107/137) were motivated to help more people become living
      donors; and 75.9% (104/137) were motivated to dispel myths. The ease of using the
      technology and telling their story varied, with the fear of being on film,
      emotional difficulty talking about their experiences, and some technological
      barriers being reported. PHI, most commonly surnames and transplant center names,
      was present in 62.9% (85/135) of stories and was edited out. CONCLUSIONS: With
      appropriate sensitivity to ensure diverse recruitment, ethical review of content,
      and support for storytellers, web-based storytelling platforms may be a
      cost-effective and convenient way to further engage patients and increase the
      curiosity of the public in learning more about the possibility of becoming living
      donors.
CI  - (c)Amy D Waterman, Emily H Wood, Omesh N Ranasinghe, Amanda Faye Lipsey, Crystal 
      Anderson, Wendy Balliet, Lauren Holland-Carter, Stacey Maurer, Maria Aurora
      Posadas Salas. Originally published in JMIR Formative Research
      (http://formative.jmir.org), 21.07.2020.
FAU - Waterman, Amy D
AU  - Waterman AD
AUID- ORCID: https://orcid.org/0000-0002-7799-0060
AD  - Division of Nephrology, David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA, United States.
AD  - Terasaki Research Institute, Los Angeles, CA, United States.
FAU - Wood, Emily H
AU  - Wood EH
AUID- ORCID: https://orcid.org/0000-0002-7141-4732
AD  - Division of Nephrology, David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA, United States.
FAU - Ranasinghe, Omesh N
AU  - Ranasinghe ON
AUID- ORCID: https://orcid.org/0000-0003-2793-4359
AD  - Division of Nephrology, David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA, United States.
FAU - Faye Lipsey, Amanda
AU  - Faye Lipsey A
AUID- ORCID: https://orcid.org/0000-0003-0172-4476
AD  - Terasaki Research Institute, Los Angeles, CA, United States.
FAU - Anderson, Crystal
AU  - Anderson C
AUID- ORCID: https://orcid.org/0000-0003-3819-2098
AD  - Division of Nephrology, David Geffen School of Medicine, University of
      California, Los Angeles, Los Angeles, CA, United States.
FAU - Balliet, Wendy
AU  - Balliet W
AUID- ORCID: https://orcid.org/0000-0002-7414-3675
AD  - Medical University of South Carolina, Charleston, SC, United States.
FAU - Holland-Carter, Lauren
AU  - Holland-Carter L
AUID- ORCID: https://orcid.org/0000-0002-1448-4988
AD  - Medical University of South Carolina, Charleston, SC, United States.
FAU - Maurer, Stacey
AU  - Maurer S
AUID- ORCID: https://orcid.org/0000-0001-5501-3704
AD  - Medical University of South Carolina, Charleston, SC, United States.
FAU - Aurora Posadas Salas, Maria
AU  - Aurora Posadas Salas M
AUID- ORCID: https://orcid.org/0000-0001-7411-7154
AD  - Medical University of South Carolina, Charleston, SC, United States.
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - Canada
TA  - JMIR Form Res
JT  - JMIR formative research
JID - 101726394
PMC - PMC7404010
OTO - NOTNLM
OT  - awareness
OT  - diffusion of innovation
OT  - digital library
OT  - health education
OT  - health literacy
OT  - health technology
OT  - informed decision-making
OT  - kidney diseases
OT  - living donation
OT  - living donor kidney transplant
OT  - mobile phone
OT  - video library
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - v4i7e17441 [pii]
AID - 10.2196/17441 [doi]
PST - epublish
SO  - JMIR Form Res. 2020 Jul 21;4(7):e17441. doi: 10.2196/17441.


PMID- 32480185
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 258
DP  - 2020 Aug
TI  - Challenges to medical ethics in the context of detention and deportation:
      Insights from a French postcolonial department in the Indian Ocean.
PG  - 113073
LID - S0277-9536(20)30292-6 [pii]
LID - 10.1016/j.socscimed.2020.113073 [doi]
AB  - Owing to a growing policing of borders, healthcare professionals become
      increasingly involved in the biopolitical management of migrants' mobility. While
      their presence on sites of migration control and detention is necessary to ensure
      migrants' access to healthcare, their role risks being instrumentalized to ensure
      the sustainability of detention and swiftness of deportations. This article
      analyses the practice and ethics of midwives' medical expertise in processes of
      migration control in the French overseas department of Mayotte in the Indian
      Ocean. Midwives in this setting are required to assess the health of pregnant
      women intercepted at sea by the police in order to determine whether they can be 
      detained. The article traces how midwives come to be invested with a power to
      police patients' mobility. In the face of such unwelcome responsibilities,
      midwives resorted to emotional distancing while suspicion on both sides impeded
      the possibility of genuine relations of care. The article analyses how midwives
      framed the ethical dilemmas at hand and examines how they perceived their
      decision-making responsibility. I argue that midwives are socialized into the
      logics of border enforcement and gradually brought to implement a minimal version
      of care as a result of migration control's inroads into care. The article thus
      questions the function and meaning of biopolitics within migration control and
      aims at initiating a conversation around the necessary conditions for ensuring
      medical personnel's independence in these extraordinary care settings. The
      article draws on a three-months fieldwork completed in Mayotte between mid-April 
      and mid-July 2017 during which I conducted 40 interviews with healthcare
      professionals in perinatal health services and 15 interviews with officers from
      stakeholder organizations, from local and international NGOs to health
      institutions. This article draws in particular on interviews with the medical
      team that was required to attend to migrant women intercepted at sea by the
      police.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - Sahraoui, Nina
AU  - Sahraoui N
AD  - Paris Center for Sociological and Political Research, CRESPPA, CNRS, 59-61 rue
      Pouchet, 75849, Cedex 17, Paris, France. Electronic address:
      nina.sahraoui@cnrs.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200521
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - *Deportation
MH  - Ethics, Medical
MH  - Female
MH  - Humans
MH  - Indian Ocean
MH  - *Midwifery
MH  - Pregnancy
MH  - Pregnant Women
OTO - NOTNLM
OT  - *Detention
OT  - *France
OT  - *Mayotte
OT  - *Medical ethics
OT  - *Migration
OT  - *Pregnancy
EDAT- 2020/06/02 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S0277-9536(20)30292-6 [pii]
AID - 10.1016/j.socscimed.2020.113073 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Aug;258:113073. doi: 10.1016/j.socscimed.2020.113073. Epub 2020
      May 21.


PMID- 32480140
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1873-6750 (Electronic)
IS  - 0160-4120 (Linking)
VI  - 141
DP  - 2020 Aug
TI  - Associations of melamine and cyanuric acid exposure with markers of kidney
      function in adults: Results from NHANES 2003-2004.
PG  - 105815
LID - S0160-4120(20)31770-0 [pii]
LID - 10.1016/j.envint.2020.105815 [doi]
AB  - Higher melamine exposure may increase the risk of kidney stone formation and
      kidney injury in infants, but little is known about the potential nephrotoxic
      effects of environmental low-dose melamine and its derivative exposure on kidney 
      function of adults in the general population. Our objective was to assess
      associations between urinary concentrations of melamine and its derivative,
      cyanuric acid, and kidney function through analyzing the data from the National
      Health and Nutrition Examination Survey (NHANES) 2003-2004. Information on 298
      participants aged >/=20 years was utilized. Urinary melamine and cyanuric acid
      levels were measured using liquid chromatography-tandem mass spectrometry
      (LC-MS/MS). Estimated glomerular filtration rate (eGFR) and urinary
      albumin-to-creatinine ratio (UACR) were calculated to reflect kidney function.
      Covariate-adjusted creatinine standardization concentrations accounting for sex, 
      race, age, race/ethically, and body mass index, was employed to control potential
      confounding of kidney function. Multivariable linear regression models were
      conducted to estimate associations of covariate-adjusted creatinine
      standardization urinary melamine and cyanuric acid concentrations with eGFR and
      UACR. Log-binomial regression models were performed to estimate risks of impaired
      kidney function and hypertension associated with urinary melamine and cyanuric
      acid levels. The geometric mean values of urinary melamine and cyanuric acid
      concentrations were 1.51 mug/L [95% confidence interval (CI): 1.21 mug/L, 1.89
      mug/L] and 5.86 mug/L (95% CI: 5.34 mug/L, 6.44 mug/L), respectively. The median 
      value of estimated daily intake (EDI) for melamine was 0.06 (ranging from
      undetectable to 1.11) mug/kg body weight/day calculated by urinary concentration 
      and creatinine excretion accounting for sex and body weight. Adults in the fourth
      quartile of melamine and cyanuric acid exposure had 0.142 mL/min/1.73 m(2) (95%
      CI: -0.271, -0.014) and 0.106 mL/min/1.73 m(2) (95% CI: -0.020, 0.006) lower eGFR
      for melamine and cyanuric acid, respectively, compared to participants in the
      first quartile of exposure with adjustment for potential confounders. To our best
      knowledge, this is the first study to report associations between melamine and
      its derivative and kidney function of the U.S. adults from NHANES 2003-2004. The 
      suggestive evidence revealed that individuals with high melamine exposure had
      lower eGFR than those with low melamine exposure, although no significant
      association between melamine and cyanuric acid exposure and markers of kidney
      function was observed. These findings should be interpreted with caution
      regarding the possible reverse causality.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Guo, Jianqiu
AU  - Guo J
AD  - School of Public Health/ Key Laboratory of Public Health Safety of Ministry of
      Education/ Key Lab of Health Technology Assessment, National Health Commission of
      the People's Republic of China, Fudan University, No. 130 Dong'an Road, Shanghai 
      200032, China.
FAU - Wu, Chunhua
AU  - Wu C
AD  - School of Public Health/ Key Laboratory of Public Health Safety of Ministry of
      Education/ Key Lab of Health Technology Assessment, National Health Commission of
      the People's Republic of China, Fudan University, No. 130 Dong'an Road, Shanghai 
      200032, China. Electronic address: chwu@shmu.edu.cn.
FAU - Zhang, Jiming
AU  - Zhang J
AD  - School of Public Health/ Key Laboratory of Public Health Safety of Ministry of
      Education/ Key Lab of Health Technology Assessment, National Health Commission of
      the People's Republic of China, Fudan University, No. 130 Dong'an Road, Shanghai 
      200032, China.
FAU - Chang, Xiuli
AU  - Chang X
AD  - School of Public Health/ Key Laboratory of Public Health Safety of Ministry of
      Education/ Key Lab of Health Technology Assessment, National Health Commission of
      the People's Republic of China, Fudan University, No. 130 Dong'an Road, Shanghai 
      200032, China.
FAU - Zhang, Yubin
AU  - Zhang Y
AD  - School of Public Health/ Key Laboratory of Public Health Safety of Ministry of
      Education/ Key Lab of Health Technology Assessment, National Health Commission of
      the People's Republic of China, Fudan University, No. 130 Dong'an Road, Shanghai 
      200032, China.
FAU - Cao, Yang
AU  - Cao Y
AD  - Clinical Epidemiology and Biostatistics, School of Medical Sciences, Orebro
      University, Orebro 70182, Sweden.
FAU - Zhou, Zhijun
AU  - Zhou Z
AD  - School of Public Health/ Key Laboratory of Public Health Safety of Ministry of
      Education/ Key Lab of Health Technology Assessment, National Health Commission of
      the People's Republic of China, Fudan University, No. 130 Dong'an Road, Shanghai 
      200032, China. Electronic address: zjzhou@fudan.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Netherlands
TA  - Environ Int
JT  - Environment international
JID - 7807270
RN  - 0 (Triazines)
RN  - H497R4QKTZ (cyanuric acid)
RN  - N3GP2YSD88 (melamine)
SB  - IM
MH  - Adult
MH  - Chromatography, Liquid
MH  - Humans
MH  - Kidney
MH  - *Nutrition Surveys
MH  - *Tandem Mass Spectrometry
MH  - Triazines/toxicity
OTO - NOTNLM
OT  - *Biomonitoring
OT  - *Cyanuric acid
OT  - *Kidney function
OT  - *Melamine
OT  - *NHANES
COIS- Declaration of Competing Interest The authors declare no conflict of interest.
EDAT- 2020/06/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/06/02 06:00
PHST- 2019/12/31 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S0160-4120(20)31770-0 [pii]
AID - 10.1016/j.envint.2020.105815 [doi]
PST - ppublish
SO  - Environ Int. 2020 Aug;141:105815. doi: 10.1016/j.envint.2020.105815. Epub 2020
      May 29.


PMID- 32479913
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210919
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 140
DP  - 2020 Aug
TI  - Scoring System to Triage Patients for Spine Surgery in the Setting of Limited
      Resources: Application to the Coronavirus Disease 2019 (COVID-19) Pandemic and
      Beyond.
PG  - e373-e380
LID - S1878-8750(20)31204-3 [pii]
LID - 10.1016/j.wneu.2020.05.233 [doi]
AB  - BACKGROUND: As of May 4, 2020, the coronavirus disease 2019 (COVID-19) pandemic
      has affected >3.5 million people and touched every inhabited continent.
      Accordingly, it has stressed health systems worldwide, leading to the
      cancellation of elective surgical cases and discussions regarding health care
      resource rationing. It is expected that rationing of surgical resources will
      continue even after the pandemic peak and may recur with future pandemics,
      creating a need for a means of triaging patients for emergent and elective spine 
      surgery. METHODS: Using a modified Delphi technique, a cohort of 16
      fellowship-trained spine surgeons from 10 academic medical centers constructed a 
      scoring system for the triage and prioritization of emergent and elective spine
      surgeries. Three separate rounds of videoconferencing and written correspondence 
      were used to reach a final scoring system. Sixteen test cases were used to
      optimize the scoring system so that it could categorize cases as requiring
      emergent, urgent, high-priority elective, or low-priority elective scheduling.
      RESULTS: The devised scoring system included 8 independent components: neurologic
      status, underlying spine stability, presentation of a high-risk postoperative
      complication, patient medical comorbidities, expected hospital course, expected
      discharge disposition, facility resource limitations, and local disease burden.
      The resultant calculator was deployed as a freely available Web-based calculator 
      (https://jhuspine3.shinyapps.io/SpineUrgencyCalculator/). CONCLUSIONS: We present
      the first quantitative urgency scoring system for the triage and prioritizing of 
      spine surgery cases in resource-limited settings. We believe that our scoring
      system, although not all encompassing, has potential value as a guide for
      triaging spine surgical cases during the COVID pandemic and post-COVID period.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Sciubba, Daniel M
AU  - Sciubba DM
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA. Electronic address: dsciubb1@jhmi.edu.
FAU - Ehresman, Jeff
AU  - Ehresman J
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Pennington, Zach
AU  - Pennington Z
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Lubelski, Daniel
AU  - Lubelski D
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Feghali, James
AU  - Feghali J
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Bydon, Ali
AU  - Bydon A
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Chou, Dean
AU  - Chou D
AD  - Department of Neurological Surgery, University of California San Francisco School
      of Medicine, San Francisco, California, USA.
FAU - Elder, Benjamin D
AU  - Elder BD
AD  - Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Elsamadicy, Aladine A
AU  - Elsamadicy AA
AD  - Department of Neurosurgery, Yale University School of Medicine, New Haven,
      Connecticut, USA.
FAU - Goodwin, C Rory
AU  - Goodwin CR
AD  - Department of Neurosurgery, Duke University School of Medicine, Durham, North
      Carolina, USA.
FAU - Goodwin, Matthew L
AU  - Goodwin ML
AD  - Department of Orthopedic Surgery, Washington University School of Medicine, St.
      Louis, Missouri, USA.
FAU - Harrop, James
AU  - Harrop J
AD  - Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, 
      Philadelphia, USA.
FAU - Klineberg, Eric O
AU  - Klineberg EO
AD  - Department of Orthopedic Surgery, University of California Davis School of
      Medicine, Davis, California, USA.
FAU - Laufer, Ilya
AU  - Laufer I
AD  - Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Lo, Sheng-Fu L
AU  - Lo SL
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Neuman, Brian J
AU  - Neuman BJ
AD  - Department of Orthopedic Surgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Passias, Peter G
AU  - Passias PG
AD  - Department of Orthopedic Surgery, New York University Grossman School of
      Medicine, New York University LangoneHealth, New York, New York, USA.
FAU - Protopsaltis, Themistocles
AU  - Protopsaltis T
AD  - Department of Orthopedic Surgery, New York University Grossman School of
      Medicine, New York University LangoneHealth, New York, New York, USA.
FAU - Shin, John H
AU  - Shin JH
AD  - Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical
      School, Boston, Massachusetts, USA.
FAU - Theodore, Nicholas
AU  - Theodore N
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Witham, Timothy F
AU  - Witham TF
AD  - Department of Neurosurgery, Johns Hopkins University School of Medicine,
      Baltimore, Maryland, USA.
FAU - Benzel, Edward C
AU  - Benzel EC
AD  - Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio, USA;
      Cleveland Clinic Center for Spine Health, Cleveland Clinic, Cleveland, Ohio, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200529
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
SB  - IM
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Decision Making
MH  - *Elective Surgical Procedures/methods
MH  - *Health Care Rationing
MH  - Humans
MH  - *Pandemics
MH  - *Patient Selection
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Triage/methods
PMC - PMC7256646
OTO - NOTNLM
OT  - *COVID-19
OT  - *Medical ethics
OT  - *Pandemic
OT  - *Rationing
OT  - *Resource allocation
OT  - *Spine surgery
OT  - *Triage
EDAT- 2020/06/02 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S1878-8750(20)31204-3 [pii]
AID - 10.1016/j.wneu.2020.05.233 [doi]
PST - ppublish
SO  - World Neurosurg. 2020 Aug;140:e373-e380. doi: 10.1016/j.wneu.2020.05.233. Epub
      2020 May 29.


PMID- 32479898
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 231
IP  - 2
DP  - 2020 Aug
TI  - Reconceptualizing Ethics Through Morbidity and Mortality Rounds.
PG  - 244-248.e3
LID - S1072-7515(20)30435-X [pii]
LID - 10.1016/j.jamcollsurg.2020.04.038 [doi]
AB  - BACKGROUND: Surgeons face ethical tensions daily, yet ethics education continues 
      to prove challenging. Two possible reasons for these challenges may be the
      different conceptions of knowledge between technical training vs those that
      underpin ethical practice, and the potential devaluing of ethics as a focus for
      education given false assumptions about its inherent nature. This study
      implemented and evaluated an innovation meant to prioritize and contextualize
      ethics in surgical learning and practice. STUDY DESIGN: After implementation of
      Ethics Morbidity and Mortality (M&M) rounds as an educational intervention, a
      qualitative evaluation consisted of interviews with 12 residents and 9 faculty.
      Analysis was informed by principles of constructivist grounded theory and the
      theoretical framework of Habermas' 3 types of knowledge: technical, practical,
      and emancipatory. For comparative purposes, analysis was conducted of how
      participants described ethics and ethics education and learning in relation to
      the traditional ethics teaching model vs the M&Ms. RESULTS: In the traditional
      model, ethics teaching was seen as disconnected from real life, and not valuable.
      Within M&Ms, ethics was viewed as integral to practice, engaging, valuable, and
      relevant. In the traditional model, ethics principles were seen as acquired
      through role modeling and as a fixed part of character. Within M&Ms, ethics
      principles were seen as learnable and transformable parts of identity.
      CONCLUSIONS: Traditional teaching of surgical ethics may result in physicians
      armed with knowledge, but unable to apply it. Our findings suggest that
      incorporating ethics into M&Ms allows not only learning the tools of ethics, but 
      the knowledge that ethical principles were becoming integrated into professional 
      identity.
CI  - Copyright (c) 2020 American College of Surgeons. Published by Elsevier Inc. All
      rights reserved.
FAU - Snelgrove, Ryan
AU  - Snelgrove R
AD  - University of Alberta Hospital, Edmonton, AB, Canada; Department of Surgery,
      University of Alberta, Edmonton, AB, Canada. Electronic address:
      ryan.snelgrove@ahs.ca.
FAU - Ng, Stella L
AU  - Ng SL
AD  - Centre for Faculty Development, St. Michael's Hospital and University of Toronto,
      University of Toronto, Toronto, ON, Canada.
FAU - Devon, Karen
AU  - Devon K
AD  - Women's College Hospital and University Health Network, University of Toronto,
      Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON,
      Canada; Joint Centre for Bioethics, Dala Lanna School of Public Health,
      University of Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
MH  - Clinical Competence
MH  - Curriculum
MH  - Ethics, Medical/*education
MH  - General Surgery/*education/ethics
MH  - Humans
MH  - Internship and Residency/*methods
MH  - Ontario
MH  - Qualitative Research
MH  - Surgeons/*ethics
MH  - Teaching Rounds/*methods
EDAT- 2020/06/02 06:00
MHDA- 2021/03/19 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S1072-7515(20)30435-X [pii]
AID - 10.1016/j.jamcollsurg.2020.04.038 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Aug;231(2):244-248.e3. doi:
      10.1016/j.jamcollsurg.2020.04.038. Epub 2020 May 29.


PMID- 32479811
OWN - NLM
STAT- MEDLINE
DCOM- 20200805
LR  - 20210110
IS  - 1531-5053 (Electronic)
IS  - 0278-2391 (Linking)
VI  - 78
IP  - 8
DP  - 2020 Aug
TI  - Considerations for Oral and Maxillofacial Surgeons in COVID-19 Era: Can We
      Sustain the Solutions to Keep Our Patients and Healthcare Personnel Safe?
PG  - 1241-1256
LID - S0278-2391(20)30551-6 [pii]
LID - 10.1016/j.joms.2020.05.027 [doi]
AB  - Several uncertainties exist regarding how we will conduct our clinical, didactic,
      business, and social activities as the coronavirus disease 2019 (COVID-19) global
      pandemic abates and social distancing guidelines are relaxed. We anticipate
      changes in how we interact with our patients and other providers, how patient
      workflow is designed, the methods used to conduct our teaching sessions, and how 
      we perform procedures in different clinical settings. The objective of the
      present report is to review some of the changes to consider in the clinical and
      academic oral and maxillofacial surgery workflow and, allow for a smoother
      transition, with less risk to our patients and healthcare personnel. New
      infection control policies should be strictly enforced and monitored in all
      clinical and nonclinical settings, with an overall goal to decrease the risk of
      exposure and transmission. Screening for COVID-19 symptoms, testing when
      indicated, and establishing the epidemiologic linkage will be crucial to
      containing and preventing new COVID-19 cases until a vaccine or an alternate
      solution is available. Additionally, the shortage of essential supplies such as
      drugs and personal protective equipment, the design and ventilation of workspaces
      and waiting areas, the increase in overhead costs, and the possible absence of
      staff, if quarantine is necessary, must be considered. This shift in our workflow
      and patient care paths will likely continue in the short-term at least through
      2021 or the next 12 to 24 months. Thus, we must prioritize surgery, balancing
      patient preferences and healthcare personnel risks. We have an opportunity now to
      make changes and embrace telemedicine and other collaborative virtual platforms
      for teaching and clinical care. It is crucial that we maintain COVID-19
      awareness, proper surveillance in our microenvironments, good clinical judgment, 
      and ethical values to continue to deliver high-quality, economical, and
      accessible patient care.
CI  - Copyright (c) 2020 American Association of Oral and Maxillofacial Surgeons.
      Published by Elsevier Inc. All rights reserved.
FAU - Chigurupati, Radhika
AU  - Chigurupati R
AD  - Associate Professor, Department of Oral and Maxillofacial Surgery, Boston
      University Medical Center, and Henry M. Goldman School of Dental Medicine, Boston
      University, Boston, MA. Electronic address: rchiguru@bu.edu.
FAU - Panchal, Neeraj
AU  - Panchal N
AD  - Assistant Professor and Section Chief, Department of Oral and Maxillofacial
      Surgery, Philadelphia Veterans Affairs Medical Center, Penn Presbyterian Medical 
      Center, University of Pennsylvania School of Dental Medicine, Philadelphia, PA.
FAU - Henry, Andrew M
AU  - Henry AM
AD  - Assistant Professor, Department of Oral and Maxillofacial Surgery, Boston
      University Medical Center and Henry M. Goldman School of Dental Medicine, Boston 
      University, Boston, MA.
FAU - Batal, Hussam
AU  - Batal H
AD  - Clinical Associate Professor and Clinical and Financial Director, Department of
      Oral and Maxillofacial Surgery, Boston University and Boston Medical Center,
      Boston, MA.
FAU - Sethi, Amit
AU  - Sethi A
AD  - Clinical Assistant Professor, Department of Oral and Maxillofacial Surgery, Henry
      M. Goldman School of Dental Medicine, Boston University, Boston, MA.
FAU - D'innocenzo, Richard
AU  - D'innocenzo R
AD  - Clinical Professor and Vice Chairman, Departments of Dentistry and Oral and
      Maxillofacial Surgery, and Director, Predoctoral Education, Henry M. Goldman
      School of Dental Medicine, Boston University, Boston, MA.
FAU - Mehra, Pushkar
AU  - Mehra P
AD  - Professor, Chair, and Chief, Department of Oral and Maxillofacial Surgery, Boston
      Medical Center, and Associate Dean of Hospital Affairs, Henry M. Goldman School
      of Dental Medicine, Boston University, Boston, MA.
FAU - Krishnan, Deepak G
AU  - Krishnan DG
AD  - Associate Professor, Department of Surgery; Chief and Residency Program Director,
      Section of Oral and Maxillofacial Surgery, University of Cincinnati Medical
      Center; and Chief, Section of Oral and Maxillofacial Surgery, Cincinnati
      Children's Hospital and Medical Center, Cincinnati, OH.
FAU - Roser, Steven M
AU  - Roser SM
AD  - DeLos Hill Chair and Professor of Surgery, and Chief, Division of Oral and
      Maxillofacial Surgery, Department of Surgery, Emory University School of
      Medicine, Atlanta, GA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200524
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
SB  - IM
CIN - J Oral Maxillofac Surg. 2020 Dec;78(12):2105. PMID: 32961125
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Humans
MH  - Occupational Exposure/prevention & control
MH  - Oral and Maxillofacial Surgeons
MH  - Pandemics/prevention & control
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Surgery, Oral/*organization & administration
MH  - Workflow
PMC - PMC7246053
EDAT- 2020/06/02 06:00
MHDA- 2020/08/06 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/05/17 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/08/06 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S0278-2391(20)30551-6 [pii]
AID - 10.1016/j.joms.2020.05.027 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 2020 Aug;78(8):1241-1256. doi:
      10.1016/j.joms.2020.05.027. Epub 2020 May 24.


PMID- 32479747
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20210330
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - COVID-19 human challenge studies: ethical issues.
PG  - e198-e203
LID - S1473-3099(20)30438-2 [pii]
LID - 10.1016/S1473-3099(20)30438-2 [doi]
AB  - COVID-19 poses an extraordinary threat to global public health and an effective
      vaccine could provide a key means of overcoming this crisis. Human challenge
      studies involve the intentional infection of research participants and can
      accelerate or improve vaccine development by rapidly providing estimates of
      vaccine safety and efficacy. Human challenge studies of low virulence
      coronaviruses have been done in the past and human challenge studies with severe 
      acute respiratory syndrome coronavirus 2 have been proposed. These studies of
      coronaviruses could provide considerable benefits to public health; for instance,
      by improving and accelerating vaccine development. However, human challenge
      studies of severe acute respiratory syndrome coronavirus 2 in particular might be
      controversial, in part, for ethical reasons. The ethical issues raised by such
      studies thus warrant early consideration involving, for example, broad
      consultation with the community. This Personal View provides preliminary analyses
      of relevant ethical considerations regarding human challenge studies of severe
      acute respiratory syndrome coronavirus 2, including the potential benefits to
      public health and to participants, the risks and uncertainty for participants,
      and the third-party risks (ie, to research staff and the wider community). We
      argue that these human challenge studies can reasonably be considered ethically
      acceptable insofar as such studies are accepted internationally and by the
      communities in which they are done, can realistically be expected to accelerate
      or improve vaccine development, have considerable potential to directly benefit
      participants, are designed to limit and minimise risks to participants, and are
      done with strict infection control measures to limit and reduce third-party
      risks.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AD  - Monash Bioethics Centre and WHO Collaborating Centre for Bioethics, Monash
      University, Melbourne, VIC, Australia; Department of Medicine, Royal Melbourne
      Hospital, University of Melbourne, Melbourne, VIC, Australia. Electronic address:
      zeb.jamrozik@monash.edu.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AD  - Monash Bioethics Centre and WHO Collaborating Centre for Bioethics, Monash
      University, Melbourne, VIC, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 210551/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200529
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
RN  - 0 (Viral Vaccines)
SB  - IM
CIN - Lancet Infect Dis. 2021 Apr;21(4):e79. PMID: 32795408
MH  - Betacoronavirus/*immunology/pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Drug Development/*ethics/methods
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
MH  - Viral Vaccines/*immunology/*isolation & purification
PMC - PMC7259898
EDAT- 2020/06/02 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - S1473-3099(20)30438-2 [pii]
AID - 10.1016/S1473-3099(20)30438-2 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2020 Aug;20(8):e198-e203. doi: 10.1016/S1473-3099(20)30438-2. 
      Epub 2020 May 29.


PMID- 32478703
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 1527-3172 (Electronic)
IS  - 1527-3172 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Apr
TI  - Are we witnessing the swan song of neoliberalism?
PG  - 24-27
LID - 10.37757/MR2020.V22.N2.7 [doi]
AB  - Dr Jose Ramon Acosta-Sariego is full professor of basic and preclinical scienc-es
      at the Medical University of Havana's Victoria de Giron Institute, where he also 
      chairs the Scientifi c Research Ethics Committee. He serves as vice-chair of the 
      Board of Directors of UNESCO's Latin American and Caribbean Bioethics Net-work
      (REDBioetica) and in 2020, UNES-CO's Director-General appointed him to its
      36-member International Bioethics Committee. Dr Acosta-Sariego has been academic 
      coordinator for the bioethics master's degree program at the Univer-sity of
      Havana since its inception in 2006, is president of the Neuroethics Chapter of
      the Cuban Neurosciences Society and is a member of the Cuban National Bioeth-ics 
      Committee.
FAU - Alerm-Gonzalez, Alina
AU  - Alerm-Gonzalez A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - MEDICC Rev
JT  - MEDICC review
JID - 100964771
SB  - IM
MH  - COVID-19/epidemiology
MH  - Cuba
MH  - Ethics
MH  - Health Policy
MH  - Humans
MH  - *Politics
MH  - *Public Policy
EDAT- 2020/06/02 06:00
MHDA- 2021/11/04 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
AID - 10.37757/MR2020.V22.N2.7 [doi]
PST - ppublish
SO  - MEDICC Rev. 2020 Apr;22(2):24-27. doi: 10.37757/MR2020.V22.N2.7.


PMID- 32478557
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20201218
IS  - 1942-969X (Electronic)
IS  - 1942-969X (Linking)
VI  - 12
IP  - S1
DP  - 2020 Aug
TI  - Moral and mental health challenges faced by maternity staff during the COVID-19
      pandemic.
PG  - S141-S142
LID - 10.1037/tra0000629 [doi]
AB  - The current COVID-19 pandemic places maternity staff at risk of engaging in
      clinical practice that may be in direct contravention with evidence; professional
      recommendations; or, more profoundly, deeply held ethical or moral beliefs and
      values, as services attempt to control the risk of cross-infection. Practice
      changes in some settings include reduction in personal contacts for tests,
      treatments and antenatal and postnatal care, exclusion of birth partners for
      labor and birth, separation of mother and baby in the immediate postnatal period,
      restrictions on breastfeeding, and reduced capacity for hands-on professional
      labor support through social distancing and use of personal protective equipment.
      These enforced changes may result in increasing levels of occupational moral
      injury that need to be addressed at both an organizational and a personal level. 
      (PsycInfo Database Record (c) 2020 APA, all rights reserved).
FAU - Horsch, Antje
AU  - Horsch A
AUID- ORCID: 0000-0002-9950-9661
AD  - Institute of Higher Education and Research in Healthcare, University of Lausanne.
FAU - Lalor, Joan
AU  - Lalor J
AD  - Research School of Nursing and Midwifery, Trinity College Dublin.
FAU - Downe, Soo
AU  - Downe S
AUID- ORCID: 0000-0003-2848-2550
AD  - Faculty of Health, University of Central Lancashire.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - Psychol Trauma
JT  - Psychological trauma : theory, research, practice and policy
JID - 101495376
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Humans
MH  - *Maternal Health Services/ethics/organization & administration
MH  - *Medical Staff/ethics/psychology
MH  - Morals
MH  - *Nursing Staff/ethics/psychology
MH  - *Occupational Diseases/etiology/psychology
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - *Psychological Trauma/etiology/psychology
EDAT- 2020/06/02 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - 2020-37315-001 [pii]
AID - 10.1037/tra0000629 [doi]
PST - ppublish
SO  - Psychol Trauma. 2020 Aug;12(S1):S141-S142. doi: 10.1037/tra0000629. Epub 2020 Jun
      1.


PMID- 32478296
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2536-4553 (Electronic)
IS  - 2536-4553 (Linking)
VI  - 7
IP  - 3
DP  - 2020
TI  - The effects of hyperventilation on seizure length and cerebral oxygenation during
      electroconvulsive therapy.
PG  - 246-254
LID - 10.14744/nci.2019.70893 [doi]
AB  - OBJECTIVE: Previous studies have reported that hyperventilation prolongs seizure 
      length. However, there is no clear consensus in clinical guidelines on how to
      perform hyperventilation during Electroconvulsive Therapy (ECT). The present
      study aims to investigate the effects of hyperventilation on seizure length and
      cerebral oxygenation. METHODS: Forty patients aged 18-65 and classified as ASA
      I-II, who would have their first ECT course were included in the study. Ethics
      committee approval was obtained and all patients' consent was taken. The
      consecutive patients were randomized into two groups as follows: group H (20
      patients; target etCO2: 25-30 mmHg) and group N (20 patients; target etCO2 35-40 
      mmHg). All patients were ventilated with a facial mask for two minutes and later 
      were ventilated by a laryngeal mask (LMA) for one minute. Vital signs, peripheric
      oxygen saturation (SpO2), and regional oxygen saturation (rSO2) were measured
      before general anesthesia induction, on the 3(rd) minute of ventilation with an
      LMA (LMA3), on the 1(st) minute postictal (PI1), on the 5(th) (PI5), and 10(th)
      (PI10) minutes. The motor seizure duration, Richmond sedation-agitation scale,
      and the time needed to reach Aldrete Score 9 were also recorded. RESULTS: There
      was a significant difference between the groups when they were compared
      concerning seizure length and recovery time. However, when we compared the rSO2
      values that were measured at different times in group H, the difference between
      the measurements was statistically significant. When rSO2 values in group H were 
      compared in doubles, there were significant differences between measurements
      between the basal and LMA3, basal and PI1, and the basal and PI5. When Richmond
      agitation scores in both groups are compared, there were no significant
      differences between the groups. CONCLUSION: This study found that seizure length 
      was longer, and the recovery time was shorter in group H. There was a
      contribution of hyperventilation on cerebral oxygenation that was measured on the
      same person at different times, but cerebral oxygenation was not statistically
      different from patients that were normoventilated. More studies are required to
      form a consensus regarding how hyperventilation applies to ECT.
CI  - Copyright: (c) 2020 by Istanbul Northern Anatolian Association of Public
      Hospitals.
FAU - Gundogdu, Oguz
AU  - Gundogdu O
AD  - Department of Anesthesiology and Reanimation, Cumhuriyet University Faculty of
      Medicine, Sivas, Turkey.
FAU - Avci, Onur
AU  - Avci O
AD  - Department of Anesthesiology and Reanimation, Cumhuriyet University Faculty of
      Medicine, Sivas, Turkey.
FAU - Gursoy, Sinan
AU  - Gursoy S
AD  - Department of Anesthesiology and Reanimation, Cumhuriyet University Faculty of
      Medicine, Sivas, Turkey.
FAU - Kaygusuz, Kenan
AU  - Kaygusuz K
AD  - Department of Anesthesiology and Reanimation, Cumhuriyet University Faculty of
      Medicine, Sivas, Turkey.
FAU - Kol, Iclal Ozdemir
AU  - Kol IO
AD  - Department of Anesthesiology and Reanimation, Cumhuriyet University Faculty of
      Medicine, Sivas, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Turkey
TA  - North Clin Istanb
JT  - Northern clinics of Istanbul
JID - 101684520
PMC - PMC7251261
OTO - NOTNLM
OT  - Cerebral oxygenation
OT  - electroconvulsive therapy
OT  - hyperventilation
OT  - seizure length
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/01/15 00:00 [received]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.14744/nci.2019.70893 [doi]
AID - NCI-7-246 [pii]
PST - epublish
SO  - North Clin Istanb. 2020 Apr 15;7(3):246-254. doi: 10.14744/nci.2019.70893.
      eCollection 2020.


PMID- 32478127
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210602
IS  - 2332-7790 (Print)
IS  - 2332-7790 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Jun
TI  - Big Data Privacy in Biomedical Research.
PG  - 296-308
LID - 10.1109/TBDATA.2016.2608848 [doi]
AB  - Biomedical research often involves studying patient data that contain personal
      information. Inappropriate use of these data might lead to leakage of sensitive
      information, which can put patient privacy at risk. The problem of preserving
      patient privacy has received increasing attentions in the era of big data. Many
      privacy methods have been developed to protect against various attack models.
      This paper reviews relevant topics in the context of biomedical research. We
      discuss privacy preserving technologies related to (1) record linkage, (2)
      synthetic data generation, and (3) genomic data privacy. We also discuss the
      ethical implications of big data privacy in biomedicine and present challenges in
      future research directions for improving data privacy in biomedical research.
FAU - Wang, Shuang
AU  - Wang S
AD  - Department of Biomedical Informatics, University of California San Diego, La
      Jolla, CA 92093.
FAU - Bonomi, Luca
AU  - Bonomi L
AD  - Department of Biomedical Informatics, University of California San Diego, La
      Jolla, CA 92093.
FAU - Dai, Wenrui
AU  - Dai W
AD  - Department of Biomedical Informatics, University of California San Diego, La
      Jolla, CA 92093.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Biomedical Informatics, University of California San Diego, La
      Jolla, CA 92093.
FAU - Cheung, Cynthia
AU  - Cheung C
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA,
      92093.
FAU - Bloss, Cinnamon S
AU  - Bloss CS
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA,
      92093.
FAU - Cheng, Samuel
AU  - Cheng S
AD  - School of Electrical and Computer Engineering, University of Oklahoma, Tulsa, OK,
      74135.
FAU - Jiang, Xiaoqian
AU  - Jiang X
AD  - Department of Biomedical Informatics, University of California San Diego, La
      Jolla, CA 92093.
LA  - eng
GR  - R21 LM012060/LM/NLM NIH HHS/United States
GR  - U54 HL108460/HL/NHLBI NIH HHS/United States
GR  - R01 HG008753/HG/NHGRI NIH HHS/United States
GR  - K99 LM011392/LM/NLM NIH HHS/United States
GR  - R00 LM011392/LM/NLM NIH HHS/United States
GR  - R00 HG008175/HG/NHGRI NIH HHS/United States
GR  - R01 GM118609/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20160913
PL  - United States
TA  - IEEE Trans Big Data
JT  - IEEE transactions on big data
JID - 101698852
PMC - PMC7258042
MID - NIHMS842701
OTO - NOTNLM
OT  - Biomedical research
OT  - bioethics
OT  - data privacy
OT  - data security
OT  - genome analysis
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.1109/TBDATA.2016.2608848 [doi]
PST - ppublish
SO  - IEEE Trans Big Data. 2020 Jun;6(2):296-308. doi: 10.1109/TBDATA.2016.2608848.
      Epub 2016 Sep 13.


PMID- 32478028
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - Life Trajectories, Biomedical Evidence, and Lessons for Policies.
PG  - 160
LID - 10.3389/fpubh.2020.00160 [doi]
AB  - Here I compare two types of evidence that have recently emerged from the
      literature. This Commentary is a contribution to the Frontiers Research Topic on 
      social disparities in aging, and aims to draw attention to the novel connections 
      that link social disparities, the biological capital of individuals, and policy
      strategies. The biological capital (as defined in the paper), accrued since
      conception by individuals, in turn affects their social, cultural, and economic
      capitals, and thus creates a positive feedback loop. In a large network funded by
      the European Commission, Lifepath, we have shown that the determinants of health 
      inequalities start in early life and cumulate throughout the life-course. For
      example, exposure to adverse childhood experiences (ACEs) influences the
      likelihood of later in life health effects, including poor aging. In this paper I
      compare two types of evidence that have recently emerged from the literature. One
      addresses the role of early vs. late exposures to risk factors for aging and
      mortality, including ACEs, using e.g., microsimulation models. The second type of
      evidence, provided in a recent document of the WHO European Regional Office, is
      based on the analysis of five broad determinants of health inequalities and eight
      different macroeconomic policies to tackle such inequalities. Six of the
      policies, if enacted, have the potential to reduce inequalities in the short term
      by increasing public expenditure on housing and community amenities, increasing
      expenditure on labor market policies, reducing income inequality, increasing
      social protection expenditure, reducing unemployment, and/or reducing
      out-of-pocket payments for health. Both of these lines of evidence suggest that
      there are ample opportunities for policy interventions. I also discuss the need
      for analytical methods to bridge the two types of analyses (biomedical and
      macroeconomic), i.e., fill the gap between analyses based on individual
      determinants of health inequalities and those based on societal determinants, to 
      help create more effective policy-making. Also, I propose that before launching
      large projects to reduce health inequalities, well-designed experiments must be
      conducted to test their efficacy. These experiments, though, are challenging when
      addressing social policies, in consideration of ethical constraints and
      timescales.
CI  - Copyright (c) 2020 Vineis.
FAU - Vineis, Paolo
AU  - Vineis P
AD  - Imperial College London, London, United Kingdom.
AD  - Department of Computation & Data Science, Italian Institute of Technology, Genoa,
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200512
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - *Health Status Disparities
MH  - Humans
MH  - *Income
MH  - Policy Making
MH  - Public Policy
MH  - Unemployment
PMC - PMC7235276
OTO - NOTNLM
OT  - *biological capital
OT  - *biomarkers
OT  - *life-course
OT  - *microsimulations
OT  - *policies
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/09/24 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.3389/fpubh.2020.00160 [doi]
PST - epublish
SO  - Front Public Health. 2020 May 12;8:160. doi: 10.3389/fpubh.2020.00160.
      eCollection 2020.


PMID- 32477979
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Mar-Apr
TI  - Dermoscopic Characterization of Dermatophytosis: A Preliminary Observation.
PG  - 202-207
LID - 10.4103/idoj.IDOJ_190_19 [doi]
AB  - INTRODUCTION: Dermatophytosis has become resistant and relapsing infection in
      India. Diagnosis of dermatophytosis is easy, however, poses diagnostic challenge 
      in partial treatment, steroid abuse. Dermoscopy is noninvasive tool for diagnosis
      of many infestations and infections. Dermoscopy in dermatophytosis is not well
      documented. We evaluated dermatoscopic patterns to correlate with
      histopathological changes. MATERIALS AND METHODS: Study was conducted in tertiary
      hospital after obtaining ethical clearance and informed consent. DermLite 3
      dermoscope was used to examine the lesions. Polarized and nonpolarized modes were
      used and ultrasound gel was utilized. Potassium hydroxide mount and skin biopsy
      was done to confirm the diagnosis. RESULTS: About 30 patients with 16 males and
      14 females were present. Median duration was 3.5 months and median age was 30
      years. The most common site was waist and crural area affecting 20 (66.66%).
      Dermoscopy revealed brown to black dots, globules, and white scales in all
      patients (100.0%). Lesions of shorter duration (26.66%) demonstrated red dots,
      dotted vessels, reddish-brown dots, and globules, and brown to black dots and
      globules were noted in lesions of longer duration (73.33%). Hair changes were
      noted in five (16.66%) patients. CONCLUSION: Dermoscopy showed particular
      patterns in dermatophytosis. Patterns were consistent irrespective of age, sex,
      and site of involvement. Presence of reddish-brown and black globules with white 
      scales was found to be the most characteristic dermoscopic feature.
CI  - Copyright: (c) 2020 Indian Dermatology Online Journal.
FAU - Ankad, Balachandra S
AU  - Ankad BS
AD  - Department of Dermatology, Medical College, Bagalkot, Karnataka, India.
FAU - Mukherjee, Samipa S
AU  - Mukherjee SS
AD  - Department of Pediatric Dermatology, Cloudnine Hospital, Bengaluru, Karnataka,
      India.
FAU - Nikam, Balakrishna P
AU  - Nikam BP
AD  - Department of Dermatology, Krishna Institute of Medical Sciences, Karad,
      Maharashtra, India.
FAU - Reshme, Apoorva S
AU  - Reshme AS
AD  - Department of Dermatology, Medical College, Bagalkot, Karnataka, India.
FAU - Sakhare, Punit S
AU  - Sakhare PS
AD  - Department of Dermatology, Kaya Clinic, Thane, Maharashtra, India.
FAU - Mural, Prabhu H
AU  - Mural PH
AD  - Department of Pathology, S. Nijalingappa Medical College, Bagalkot, Karnataka,
      India.
LA  - eng
PT  - Journal Article
DEP - 20200309
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC7247619
OTO - NOTNLM
OT  - Black globules
OT  - brown globules
OT  - dermatophytosis
OT  - dermoscopy
OT  - pattern
COIS- There are no conflicts of interest.
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.4103/idoj.IDOJ_190_19 [doi]
AID - IDOJ-11-202 [pii]
PST - epublish
SO  - Indian Dermatol Online J. 2020 Mar 9;11(2):202-207. doi:
      10.4103/idoj.IDOJ_190_19. eCollection 2020 Mar-Apr.


PMID- 32477904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2220-3206 (Print)
IS  - 2220-3206 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 19
TI  - Neuroendocrine, epigenetic, and intergenerational effects of general anesthetics.
PG  - 81-94
LID - 10.5498/wjp.v10.i5.81 [doi]
AB  - The progress of modern medicine would be impossible without the use of general
      anesthetics (GAs). Despite advancements in refining anesthesia approaches, the
      effects of GAs are not fully reversible upon GA withdrawal. Neurocognitive
      deficiencies attributed to GA exposure may persist in neonates or endure for
      weeks to years in the elderly. Human studies on the mechanisms of the long-term
      adverse effects of GAs are needed to improve the safety of general anesthesia but
      they are hampered not only by ethical limitations specific to human research, but
      also by a lack of specific biological markers that can be used in human studies
      to safely and objectively study such effects. The latter can primarily be
      attributed to an insufficient understanding of the full range of the biological
      effects induced by GAs and the molecular mechanisms mediating such effects even
      in rodents, which are far more extensively studied than any other species. Our
      most recent experimental findings in rodents suggest that GAs may adversely
      affect many more people than is currently anticipated. Specifically, we have
      shown that anesthesia with the commonly used GA sevoflurane induces in exposed
      animals not only neuroendocrine abnormalities (somatic effects), but also
      epigenetic reprogramming of germ cells (germ cell effects). The latter may pass
      the neurobehavioral effects of parental sevoflurane exposure to the offspring,
      who may be affected even at levels of anesthesia that are not harmful to the
      exposed parents. The large number of patients who require general anesthesia, the
      even larger number of their future unexposed offspring whose health may be
      affected, and a growing number of neurodevelopmental disorders of unknown
      etiology underscore the translational importance of investigating the
      intergenerational effects of GAs. In this mini review, we discuss emerging
      experimental findings on neuroendocrine, epigenetic, and intergenerational
      effects of GAs.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Martynyuk, Anatoly E
AU  - Martynyuk AE
AD  - Department of Anesthesiology and the McKnight Brain Institute, University of
      Florida College of Medicine, Gainesville, FL 32610, United States.
      amartynyuk@anest.ufl.edu.
FAU - Ju, Ling-Sha
AU  - Ju LS
AD  - Department of Anesthesiology, University of Florida College of Medicine,
      Gainesville, FL 32610, United States.
FAU - Morey, Timothy E
AU  - Morey TE
AD  - Department of Anesthesiology, University of Florida College of Medicine,
      Gainesville, FL 32610, United States.
FAU - Zhang, Jia-Qiang
AU  - Zhang JQ
AD  - Department of Anesthesiology and Perioperative Medicine, Henan Provincial
      People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003,
      Henan Province, China.
LA  - eng
GR  - R01 NS091542/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200519
PL  - United States
TA  - World J Psychiatry
JT  - World journal of psychiatry
JID - 101610480
PMC - PMC7243620
OTO - NOTNLM
OT  - Brain
OT  - Corticosterone
OT  - Cortisol
OT  - Deoxyribonucleic acid methylation
OT  - Gamma aminobutyric acid
OT  - General anesthetic
OT  - Histone acetylation
OT  - Intergenerational effects
OT  - Sevoflurane
COIS- Conflict-of-interest statement: No potential conflicts of interest.
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/12/24 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.5498/wjp.v10.i5.81 [doi]
PST - epublish
SO  - World J Psychiatry. 2020 May 19;10(5):81-94. doi: 10.5498/wjp.v10.i5.81.
      eCollection 2020 May 19.


PMID- 32477626
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2153-4063 (Print)
VI  - 2020
DP  - 2020
TI  - Replacing Paper Informed Consent with Electronic Informed Consent for Research in
      Academic Medical Centers: A Scoping Review.
PG  - 80-88
AB  - Although experts have identified benefits to replacing paper with electronic
      consent (eConsent) for research, a comprehensive understanding of strategies to
      overcome barriers to adoption is unknown. To address this gap, we performed a
      scoping review of the literature describing eConsent in academic medical centers.
      Of 69 studies that met inclusion criteria, 81% (n=56) addressed ethical, legal,
      and social issues; 67% (n=46) described user interface/user experience
      considerations; 39% (n=27) compared electronic versus paper approaches; 33%
      (n=23) discussed approaches to enterprise scalability; and 25% (n=17) described
      changes to consent elections. Findings indicate a lack of a leading commercial
      eConsent vendor, as articles described a myriad of homegrown systems and
      extensions of vendor EHR patient portals. Opportunities appear to exist for
      researchers and commercial software vendors to develop eConsent approaches that
      address the five critical areas identified in this review.
CI  - (c)2020 AMIA - All rights reserved.
FAU - Chen, Cindy
AU  - Chen C
AD  - Information Technologies & Services Department, Weill Cornell Medicine, New York,
      NY.
FAU - Lee, Pou-I
AU  - Lee PI
AD  - Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY.
FAU - Pain, Kevin J
AU  - Pain KJ
AD  - Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell 
      Medicine, New York, NY.
FAU - Delgado, Diana
AU  - Delgado D
AD  - Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell 
      Medicine, New York, NY.
FAU - Cole, Curtis L
AU  - Cole CL
AD  - Information Technologies & Services Department, Weill Cornell Medicine, New York,
      NY.
AD  - Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY.
AD  - Department of Medicine, Weill Cornell Medicine, New York, NY.
FAU - Campion, Thomas R Jr
AU  - Campion TR Jr
AD  - Information Technologies & Services Department, Weill Cornell Medicine, New York,
      NY.
AD  - Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY.
AD  - Department of Pediatrics, Weill Cornell Medicine, New York, NY.
AD  - Clinical & Translational Science Center, Weill Cornell Medicine, New York, NY.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - United States
TA  - AMIA Jt Summits Transl Sci Proc
JT  - AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on
      Translational Science
JID - 101539486
PMC - PMC7233043
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
PST - epublish
SO  - AMIA Jt Summits Transl Sci Proc. 2020 May 30;2020:80-88. eCollection 2020.


PMID- 32477469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1970-5565 (Print)
IS  - 1970-5557 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Feb 18
TI  - Perceived factors to providing palliative care for patients with cancer - a
      qualitative systematic review.
PG  - 463
LID - 10.4081/oncol.2020.463 [doi]
AB  - Palliative care (PC) is one of the necessary cares given throughout a patient's
      experience with cancer. The aim of this study was to identify the perceived
      factors to providing PC for patients with cancer. Our study was a systematic
      review of qualitative literature. To this end, electronic databases, including
      CINAHL, PubMed, PsycINFO, Ovid, and Web of Science as well as Persian databases
      were searched and qualitative studies on the role of PC in patients with cancer
      published between Jan 2008 and Dec 2017 were selected. Generally, 12 studies were
      reviewed. A thematic synthesis approach was used to analyze the data. Exploring
      the selected articles, the findings on the perceived factors to providing PC for 
      patients with cancer were categorized into three themes, including organizational
      factors, ethical factors, and psychological factors. This qualitative systematic 
      review expands our knowledge about factors influencing the provision of PC for
      patients with cancer. It is necessary for health system managers and caregivers
      to pay attention to all aforesaid factors in order to improve PC for cancer
      patients.
CI  - (c)Copyright: the Author(s).
FAU - Heidari, Haydeh
AU  - Heidari H
AD  - Social Determinants of Health Research Center, Faculty of Nursing and Midwifery, 
      Shahrekord University of Medical Sciences, Shahrekord, Iran.
FAU - Mardani-Hamooleh, Marjan
AU  - Mardani-Hamooleh M
AD  - Nursing Care Research Center, Faculty of Nursing and Midwifery, Iran University
      of Medical Sciences, Tehran, Iran.
FAU - Amiri, Masoud
AU  - Amiri M
AD  - Erasmus Medical Center, Department of Epidemiology, Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - Italy
TA  - Oncol Rev
JT  - Oncology reviews
JID - 101519906
PMC - PMC7246343
OTO - NOTNLM
OT  - Cancer
OT  - palliative care
OT  - qualitative research
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/11/03 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.4081/oncol.2020.463 [doi]
PST - epublish
SO  - Oncol Rev. 2020 May 19;14(1):463. doi: 10.4081/oncol.2020.463. eCollection 2020
      Feb 18.


PMID- 32477004
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1472-6955 (Print)
IS  - 1472-6955 (Linking)
VI  - 19
DP  - 2020
TI  - Nurse's attunement to patient's meaning in life - a qualitative study of
      experiences of Dutch adults ageing in place.
PG  - 41
LID - 10.1186/s12912-020-00431-z [doi]
AB  - BACKGROUND: Meaning in life (MiL) is considered to be an important part of health
      and is associated with many positive outcomes in older adults, such as quality of
      life and longevity. As health promotors, nurses may take patients' MiL into
      account in the care process. There is a knowledge gap in terms of what
      constitutes good care in relation to older patients' MiL, and what the benefits
      may be for patients when nursing is attuned to this aspect. The purpose of this
      study was to explore the experiences of home nursing older adults in relation to 
      nurses' attunement to MiL. METHODS: Gadamerian hermeneutic phenomenological
      design with semi-structured interviews. Participants were 24 aged home nursing
      patients. A framework of care ethical evaluation was used in the analysis.
      Multiple dialogues enhanced understanding. RESULTS: Patients did not expect
      nurses' regard for their MiL. They rather expected 'normal contact' and adequate 
      physical care. Nurses showed that they were open to patients' MiL by being
      interested in the patient as a person and by being attentive to specific and
      hidden needs. Participants explained that the nurse's behaviour upon arrival set 
      the tone: they knew immediately if there was room for MiL or not. All
      participants had positive and negative experiences with nurses' behaviour in
      relation to MiL. Valued nursing care included maintaining a long, kind and
      reciprocal relationship; doing what was needed; and skilled personalised care.
      Participants mentioned 'special ones': nurses who attuned to them in a special
      way and did more than expected. Benefits of care that was attuned to patients'
      MiL were: experiencing a cheerful moment, feeling secure, feeling like a valuable
      person and having a good day. Older adults also stressed that consideration for
      MiL helps identify what is important in healthcare. CONCLUSION: Aged homecare
      patients value nurses' attunement to their MiL positively. Although patients
      regard MiL mostly as their own quest, nurses play a modest yet important role.
      Managers and educators should support nurses' investment in reciprocal
      nurse-patient relationships.
CI  - (c) The Author(s) 2020.
FAU - Hupkens, Susan
AU  - Hupkens S
AUID- ORCID: 0000-0001-7937-7158
AD  - 1Research Centre Innovations in Care, Rotterdam University of Applied Sciences,
      Rochussenstraat 198, 3015 EK Rotterdam, The Netherlands.grid.450253.50000 0001
      0688 0318
FAU - Goumans, Marleen
AU  - Goumans M
AD  - 1Research Centre Innovations in Care, Rotterdam University of Applied Sciences,
      Rochussenstraat 198, 3015 EK Rotterdam, The Netherlands.grid.450253.50000 0001
      0688 0318
FAU - Derkx, Peter
AU  - Derkx P
AD  - 2University of Humanistic Studies, Utrecht, the Netherlands.grid.449771.80000
      0004 0545 9398
FAU - Machielse, Anja
AU  - Machielse A
AD  - 2University of Humanistic Studies, Utrecht, the Netherlands.grid.449771.80000
      0004 0545 9398
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - BMC Nurs
JT  - BMC nursing
JID - 101088683
PMC - PMC7236336
OTO - NOTNLM
OT  - Ageing in place
OT  - Healthy ageing
OT  - Home nursing
OT  - Meaning in life
OT  - Nurse-patient relationship
OT  - Older adults
OT  - Patient's perspective
OT  - Positive health
OT  - Quality of care
OT  - Well-being
COIS- Competing interestsThe authors declare no competing interests.
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.1186/s12912-020-00431-z [doi]
AID - 431 [pii]
PST - epublish
SO  - BMC Nurs. 2020 May 18;19:41. doi: 10.1186/s12912-020-00431-z. eCollection 2020.


PMID- 32476767
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0971-9202 (Print)
IS  - 0975-6434 (Linking)
VI  - 70
IP  - 3
DP  - 2020 Jun
TI  - An Integrated System for Fetal Scalp Visualization, Blood Collection and
      Analysis.
PG  - 208-213
LID - 10.1007/s13224-020-01313-9 [doi]
AB  - KEY MESSAGE: The new NB scope aids in better visualization of the scalp and blood
      collection and analysis at bed side. OBJECTIVE: Caesarean section rates and
      inherent complications are on the rise all over the world. One way to avoid a
      caesarean is to measure fetal scalp blood lactate levels. The methods available
      to visualize fetal scalp, obtain the blood sample and perform the blood test are 
      separate, cumbersome and expensive, needing a certain level of expertise. We
      propose a device that incorporates all the steps of obtaining a fetal scalp blood
      lactate into one sleek, easy to use device. METHODS: The initial design, 3-D
      print and was tried on mannequin. After ethics committee approval, the prototype 
      was experimented on patients in labour with singleton live fetus in cephalic
      presentation with no evidence of distress. RESULTS: There were (n = 9) patients
      recruited. There were (n = 5) primigravida and (n = 4) multigravida all of whom
      were in active labour. Parity did not seem to influence ease of instrumentation. 
      Of the (n = 9) mothers (n = 2) had meconium-stained liquor and the rest (n = 7)
      had clear liquor, meconium-stained liquor did not affect visualization. The mean 
      time taken to collect the sample was 184.11(+/- 33.04) seconds. CONCLUSION: The
      Neeraj-Bhaskar (NB) scope is an easy to use, affordable device that can be used
      time and again to decide on cases where emergency caesarean section can be
      avoided due to fetal distress.
CI  - (c) Federation of Obstetric & Gynecological Societies of India 2020.
FAU - Kulkarni, Neeraj
AU  - Kulkarni N
AD  - 1Department of Obstetrics and Gynecology Unit 4, Christian Medical College,
      Vellore, Tamil Nadu India.grid.11586.3b0000 0004 1767 8969
FAU - Rosario, Deepti Pinto
AU  - Rosario DP
AD  - 1Department of Obstetrics and Gynecology Unit 4, Christian Medical College,
      Vellore, Tamil Nadu India.grid.11586.3b0000 0004 1767 8969
FAU - Akkal, Shruthi
AU  - Akkal S
AD  - 2Department of Sensor and Biomedical Technology, School of Electronics
      Engineering VIT Vellore, Vellore, Tamil Nadu India.grid.412813.d0000 0001 0687
      4946
FAU - Beck, Manisha Madhai
AU  - Beck MM
AD  - 1Department of Obstetrics and Gynecology Unit 4, Christian Medical College,
      Vellore, Tamil Nadu India.grid.11586.3b0000 0004 1767 8969
FAU - David, Liji Sarah
AU  - David LS
AD  - 1Department of Obstetrics and Gynecology Unit 4, Christian Medical College,
      Vellore, Tamil Nadu India.grid.11586.3b0000 0004 1767 8969
FAU - Vijayaselvi, Reeta
AU  - Vijayaselvi R
AD  - 1Department of Obstetrics and Gynecology Unit 4, Christian Medical College,
      Vellore, Tamil Nadu India.grid.11586.3b0000 0004 1767 8969
FAU - Murari, Bhaskar Mohan
AU  - Murari BM
AD  - 2Department of Sensor and Biomedical Technology, School of Electronics
      Engineering VIT Vellore, Vellore, Tamil Nadu India.grid.412813.d0000 0001 0687
      4946
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - India
TA  - J Obstet Gynaecol India
JT  - Journal of obstetrics and gynaecology of India
JID - 0374763
PMC - PMC7239983
OTO - NOTNLM
OT  - Fetal scalp blood sampling
OT  - Fetal scalp lactate
OT  - Fetal scalp visualization
OT  - NB scope
COIS- Conflict of InterestAll the authors do not have any conflict of interest. The
      manufactures also do not have any conflict of interest. Intellectual Property
      India No. 201741011937.
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.1007/s13224-020-01313-9 [doi]
AID - 1313 [pii]
PST - ppublish
SO  - J Obstet Gynaecol India. 2020 Jun;70(3):208-213. doi: 10.1007/s13224-020-01313-9.
      Epub 2020 May 6.


PMID- 32476753
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0971-3026 (Print)
IS  - 0970-2016 (Linking)
VI  - 30
IP  - 1
DP  - 2020 Jan-Mar
TI  - Insights into obtaining FRCR and beyond: Obstacles, opportunities and
      post-relocation dilemma - An Indian perspective.
PG  - 70-76
LID - 10.4103/ijri.IJRI_438_19 [doi]
AB  - Indian radiology trainees and radiologists are interested to have FRCR (Fellow of
      the Royal College of Radiologists) qualification for various reasons including
      academic career progression, subspecialty interest and other socioeconomic
      factors. The path for acquiring FRCR qualification is adventurous yet onerous and
      exhausting. Perseverance, meticulous planning and clarity in the vision are
      essential prerequisites for an Indian graduate aiming to complete FRCR
      qualification, and one may require to invest an average of 1.5-2 years even if
      there is no reattempt in this tripartite examination. Indian doctors including
      radiologists are considered amongst the finest across global medical
      fraternities. However, the Indian medical education is skewed and variably
      distributed over the subcontinent due to organisational inability to provide
      single radiology curriculum-based education to all radiology training programmes.
      Parallel educational boards and a variety of institutions such as government,
      trust-funded and private organisations provide radiology training to further
      complicate the grand picture of radiology education in India. Conversely, UK
      radiology education is uniform nationally and rigorously enforced by deaneries
      based upon state-provided guidelines. UK training opportunities are essentially
      academically rewarding experience but they require herculean efforts to gain
      access to one. One should constantly focus on building a resume at par with that 
      of a UK trainee by obtaining experience required to fulfil checklist for such
      opportunities. Alongwith addressing local (UK) competition thoughtfully, hard
      work, diligence, and high standards of work ethics are absolute musts to build a 
      great resume, to obtain training opportunity and, in turn, to satisfy the
      ultimate goal of carrier advancement.
CI  - Copyright: (c) 2020 Indian Journal of Radiology and Imaging.
FAU - Thaker, Siddharth
AU  - Thaker S
AD  - Department of Radiology, Kettering General Hospital, Kettering, Leicester, UK.
AD  - University Hospitals of Leicester NHS Trust, Leicester, UK.
FAU - Botchu, Rajesh
AU  - Botchu R
AD  - Department of Musculoskeletal Imaging, Royal Orthopaedic Hospital, Birmingham,
      UK.
FAU - Gupta, Harun
AU  - Gupta H
AD  - Department of Musculoskeletal Imaging, Leeds Teaching Hospital, Leeds, UK.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - Germany
TA  - Indian J Radiol Imaging
JT  - The Indian journal of radiology & imaging
JID - 8503873
PMC - PMC7240893
OTO - NOTNLM
OT  - Challenges
OT  - Fellow of the Royal College of Radiologists
OT  - India
OT  - UK
OT  - UK fellowships
COIS- There are no conflicts of interest.
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2019/11/03 00:00 [received]
PHST- 2019/12/05 00:00 [revised]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.4103/ijri.IJRI_438_19 [doi]
AID - IJRI-30-70 [pii]
PST - ppublish
SO  - Indian J Radiol Imaging. 2020 Jan-Mar;30(1):70-76. doi: 10.4103/ijri.IJRI_438_19.
      Epub 2020 Mar 30.


PMID- 32476433
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1555-824X (Electronic)
IS  - 1062-8606 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Dec
TI  - Is My Quality Improvement Initiative Also Research? A Primer on Making This
      Distinction and the Ethical Considerations for Graduate Trainees.
PG  - 504
LID - 10.1177/1062860620929643 [doi]
FAU - Harrison, Tyrone G
AU  - Harrison TG
AD  - University of Calgary, Calgary, Alberta, Canada.
FAU - Ahmed, Sadia
AU  - Ahmed S
FAU - Bele, Sumedh
AU  - Bele S
FAU - Cavanagh, Nicola
AU  - Cavanagh N
FAU - Hemmelgarn, Brenda R
AU  - Hemmelgarn BR
FAU - McCaughey, Deirdre
AU  - McCaughey D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200531
PL  - Netherlands
TA  - Am J Med Qual
JT  - American journal of medical quality : the official journal of the American
      College of Medical Quality
JID - 9300756
SB  - IM
MH  - Education, Medical, Graduate
MH  - Humans
MH  - *Internship and Residency
MH  - *Quality Improvement
EDAT- 2020/06/02 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - 10.1177/1062860620929643 [doi]
AID - 00008488-202011000-00011 [pii]
PST - ppublish
SO  - Am J Med Qual. 2020 Dec;35(6):504. doi: 10.1177/1062860620929643. Epub 2020 May
      31.


PMID- 32475985
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220210
IS  - 1530-0366 (Electronic)
IS  - 1098-3600 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep
TI  - The interface of genomic information with the electronic health record: a points 
      to consider statement of the American College of Medical Genetics and Genomics
      (ACMG).
PG  - 1431-1436
LID - 10.1038/s41436-020-0841-2 [doi]
FAU - Grebe, Theresa A
AU  - Grebe TA
AD  - Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, 
      AZ, USA.
FAU - Khushf, George
AU  - Khushf G
AD  - Department of Philosophy, University of South Carolina, Columbia, SC, USA.
FAU - Chen, Margaret
AU  - Chen M
AD  - GeneDx, Gaithersburg, MD, USA.
FAU - Bailey, Dawn
AU  - Bailey D
AD  - AZ State Team for Mountain States Regional Genetics Network, Chandler, AZ, USA.
FAU - Brenman, Leslie Manace
AU  - Brenman LM
AD  - Kaiser Permanente Northern California, Oakland, CA, USA.
FAU - Williams, Marc S
AU  - Williams MS
AD  - Genomic Medicine Institute, Geisinger, Danville, PA, USA.
FAU - Seaver, Laurie H
AU  - Seaver LH
AD  - Spectrum Health/Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
AD  - Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
CN  - ACMG Social, Ethical and Legal Issues Committee
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - United States
TA  - Genet Med
JT  - Genetics in medicine : official journal of the American College of Medical
      Genetics
JID - 9815831
SB  - IM
MH  - Electronic Health Records
MH  - Genetic Testing
MH  - *Genetics, Medical
MH  - Genomics
MH  - Humans
MH  - United States
MH  - Universities
OTO - NOTNLM
OT  - *autonomy
OT  - *electronic health record (EHR)
OT  - *ethics
OT  - *genetic/genomic information
OT  - *privacy
EDAT- 2020/06/02 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/05/08 00:00 [received]
PHST- 2020/05/09 00:00 [accepted]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - 10.1038/s41436-020-0841-2 [doi]
AID - S1098-3600(21)00725-5 [pii]
PST - ppublish
SO  - Genet Med. 2020 Sep;22(9):1431-1436. doi: 10.1038/s41436-020-0841-2. Epub 2020
      Jun 1.


PMID- 32475926
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20200910
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 140
IP  - 6
DP  - 2020
TI  - [Contributions of the Japanese Pharmacopoeia to the Quality of Generic
      Pharmaceuticals].
PG  - 773-776
LID - 10.1248/yakushi.19-00253-4 [doi]
AB  - The rapid increase in the use of ethical generic pharmaceutical formulations in
      Japan emphasizes the importance of measures to ensure the quality of
      pharmaceutical distribution. This short review discusses the contributions of the
      Japanese Pharmacopoeia (JP) to pharmaceutical quality control. Numerous
      monographs have defined specifications and tests for multiple active
      pharmaceutical ingredients and excipients. Standardized methods of performing
      general tests and reference standards allow efficient, reliable evaluation of
      pharmaceutical quality during development processes and commercial manufacturing.
      Some new methods of characterizing the structure and performance of nonbiological
      complex drugs have been included in recent editions. An introduction to general
      tests and general information regarding the control of impurities in accordance
      with the International Council for Harmonisation of Technical Requirements for
      Pharmaceuticals for Human Use guidelines should significantly reduce the safety
      risks of pharmaceuticals.
FAU - Izutsu, Ken-Ichi
AU  - Izutsu KI
AD  - Division of Drugs, National Institute of Health Sciences.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Drugs, Generic)
RN  - 0 (Excipients)
SB  - IM
MH  - Chemistry, Pharmaceutical/methods
MH  - *Drugs, Generic/analysis/standards
MH  - Excipients/analysis
MH  - Japan
MH  - *Pharmacopoeias as Topic
MH  - *Quality Control
OTO - NOTNLM
OT  - generic drug
OT  - monograph
OT  - pharmacopoeia
OT  - quality
OT  - test method
EDAT- 2020/06/02 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1248/yakushi.19-00253-4 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2020;140(6):773-776. doi: 10.1248/yakushi.19-00253-4.


PMID- 32475925
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20200910
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 140
IP  - 6
DP  - 2020
TI  - [Present and Future of the Japanese Pharmacopoeia in the Clinical Setting and
      Pharmacy Education].
PG  - 767-771
LID - 10.1248/yakushi.19-00253-3 [doi]
AB  - The Japanese Pharmacopoeia (JP) has played a major role in ensuring the quality
      of drugs used in Japan as the ultimate source of information on pharmaceuticals. 
      Physicians and pharmacists can reliably use drugs in the clinical setting because
      they trust the quality when medical treatment progresses smoothly. When there is 
      a problem or challenge, they can refer to the JP. For pharmacists, both the
      quality of the drug and information on its efficacy and safety are indispensable.
      Twelve years have passed since the introduction of a 6-year course in pharmacy
      education, but the weight placed upon the JP has not increased in the educational
      curriculum. A specific behavioral objective of describing the significance and
      structure of the JP is included in the revised model core curriculum for pharmacy
      education. However, fewer than 60% of pharmacy schools have courses specifically 
      focusing on the JP. Professors of physical chemistry, analytical chemistry,
      pharmaceutics, and pharmacognosy often teach the relevant sections of the JP in
      their lectures. The foundations of the Japanese manufacturing industry have been 
      questioned because data falsification and inspection fraud have been disclosed in
      numerous fields. Therefore, ethical education for those who use the JP is a
      prerequisite for ensuring the reliability of pharmaceuticals.
FAU - Yasuhara, Masato
AU  - Yasuhara M
AD  - Laboratory of Pharmaceutical Care and Community Medicine, Faculty of
      Pharma-Science, Teikyo University.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
SB  - IM
MH  - *Biopharmaceutics
MH  - Chemical Safety
MH  - Curriculum
MH  - Education, Pharmacy/*trends
MH  - Japan
MH  - *Pharmacopoeias as Topic
MH  - Quality Control
OTO - NOTNLM
OT  - Japanese Pharmacopoeia
OT  - clinical setting
OT  - pharmacy education
EDAT- 2020/06/02 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1248/yakushi.19-00253-3 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2020;140(6):767-771. doi: 10.1248/yakushi.19-00253-3.


PMID- 32475364
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2056-4724 (Print)
IS  - 2056-4724 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Jun 1
TI  - BJPsych Open fifth anniversary editorial: history, accomplishments, trajectory
      and passion.
PG  - e52
LID - 10.1192/bjo.2020.34 [doi]
AB  - BJPsych Open has come of age. This editorial celebrates the journal's fifth
      anniversary by reviewing the history of BJPsych Open, what we have accomplished, 
      where we strive to go (our planned trajectory) and the passion of being an
      Editor-in-Chief.
FAU - Kaufman, Kenneth R
AU  - Kaufman KR
AUID- ORCID: https://orcid.org/0000-0001-7924-4902
AD  - Departments of Psychiatry, Neurology and Anesthesiology, Rutgers Robert Wood
      Johnson Medical School, New Jersey, USA; and Department of Psychological
      Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College
      London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - England
TA  - BJPsych Open
JT  - BJPsych open
JID - 101667931
PMC - PMC7345524
OTO - NOTNLM
OT  - BJPsych Open
OT  - Plan S
OT  - academic publishing
OT  - anniversary
OT  - authors
OT  - editorial board
OT  - global reach
OT  - history
OT  - methodologic rigor
OT  - metrics
OT  - passion of an Editor-in-Chief
OT  - publication integrity
OT  - research ethics
OT  - reviewers
OT  - thematic issues
EDAT- 2020/06/02 06:00
MHDA- 2020/06/02 06:01
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/02 06:01 [medline]
AID - 10.1192/bjo.2020.34 [doi]
AID - S2056472420000344 [pii]
PST - epublish
SO  - BJPsych Open. 2020 Jun 1;6(4):e52. doi: 10.1192/bjo.2020.34.


PMID- 32475240
OWN - NLM
STAT- MEDLINE
DCOM- 20200611
LR  - 20200611
IS  - 2049-4408 (Electronic)
IS  - 2049-4394 (Linking)
VI  - 102-B
IP  - 6
DP  - 2020 Jun
TI  - Patient-reported outcomes in young patients with isolated fracture of the hip.
PG  - 766-771
LID - 10.1302/0301-620X.102B6.BJJ-2019-1491.R1 [doi]
AB  - AIMS: Hip fractures in patients < 60 years old currently account for only 3% to
      4% of all hip fractures in England, but this proportion is increasing. Little is 
      known about the longer-term patient-reported outcomes in this potentially more
      active population. The primary aim is to examine patient-reported outcomes
      following isolated hip fracture in patients aged < 60 years. The secondary aim is
      to determine an association between outcomes and different types of fracture
      pattern and/or treatment implants. METHODS: All hip fracture patients aged 18 to 
      60 years admitted to a single centre over a 15-year period were used to identify 
      the study group. Fracture pattern (undisplaced intracapsular, displaced
      intracapsular, and extracapsular) and type of operation (multiple cannulated hip 
      screws, angular stable fixation, hemiarthroplasty, and total hip replacement)
      were recorded. The primary outcome measures were the Oxford Hip Score (OHS), the 
      EuroQol five-dimension questionnaire (EQ-5D-3L), and EQ-visual analogue scale
      (VAS) scores. Preinjury scores were recorded by patient recall and postinjury
      scores were collected at a mean of 57 months (9 to 118) postinjury. Ethics
      approval was obtained prior to study commencement. RESULTS: A total of 72
      patients were included. There was a significant difference in pre- and
      post-injury OHS (mean 9.8 point reduction (38 to -20; p < 0.001)), EQ-5D (mean
      0.208 reduction in index (0.897 to -0.630; p < 0.001)), and VAS , and VAS (mean
      11.6 point reduction (70 to -55; p < 0.001)) Fracture pattern had a significant
      influence on OHS (p < 0.001) with extracapsular fractures showing the least
      favourable long-term outcome. Fixation type also impacted significantly on OHS (p
      = 0.011) with the worst outcomes in patients treated by hemiarthroplasty or
      angular stable fixation. CONCLUSION: There is a significant reduction in function
      and quality of life following injury, with all three patient-reported outcome
      measures used, indicating that this is a substantial injury in younger patients. 
      Treatment with hemiarthroplasty or angular stable devices in this cohort were
      associated with a less favourable hip score outcome. Cite this article: Bone
      Joint J 2020;102-B(6):766-771.
FAU - Coughlin, T A
AU  - Coughlin TA
AD  - Department of Trauma and Orthopaedic Surgery, Nottingham University Hospitals NHS
      Trust, Queen's Medical Centre, Nottingham, UK.
FAU - Nightingale, J M
AU  - Nightingale JM
AD  - Department of Trauma and Orthopaedic Surgery, Nottingham University Hospitals NHS
      Trust, Queen's Medical Centre, Nottingham, UK.
FAU - Myint, Y
AU  - Myint Y
AD  - Department of Trauma and Orthopaedic Surgery, Nottingham University Hospitals NHS
      Trust, Queen's Medical Centre, Nottingham, UK.
FAU - Forward, D P
AU  - Forward DP
AD  - Department of Trauma and Orthopaedic Surgery, Nottingham University Hospitals NHS
      Trust, Queen's Medical Centre, Nottingham, UK.
FAU - Norrish, A R
AU  - Norrish AR
AD  - School of Medicine, University of Nottingham, Nottingham, UK.
FAU - Ollivere, B J
AU  - Ollivere BJ
AD  - School of Medicine, University of Nottingham, Nottingham, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Bone Joint J
JT  - The bone & joint journal
JID - 101599229
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Hip Fractures/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Reported Outcome Measures
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Hip fracture
OT  - Young adult
EDAT- 2020/06/02 06:00
MHDA- 2020/06/12 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [entrez]
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
AID - 10.1302/0301-620X.102B6.BJJ-2019-1491.R1 [doi]
PST - ppublish
SO  - Bone Joint J. 2020 Jun;102-B(6):766-771. doi:
      10.1302/0301-620X.102B6.BJJ-2019-1491.R1.


PMID- 32475162
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 8
DP  - 2020 Nov
TI  - A qualitative study of Equal Co-First Authorship.
PG  - 496-520
LID - 10.1080/08989621.2020.1776122 [doi]
AB  - Over the past several years, there has been a significant increase in the number 
      of scientific articles with two or more authors claiming "Equal Co-First
      Authorship" (ECFA). This study provides a critical background to ECFA
      designations, discusses likely causes of its increased use, and explores
      arguments for and against the practice. Subsequently, it presents the results of 
      a qualitative study that sought the opinion of 19 authors listed among equal
      first authors of recent publications in leading scientific journals about ECFA
      designations. Results show that circumstances leading to ECFA designations vary
      significantly from each other. While the development of policies for these
      situations would not be easy, participants suggested that the lack of clear and
      consistent policies regarding the attribution and evaluation of ECFA contributes 
      to tensions amongst ECFA authors and obscures their preferred attributions of
      credit.
FAU - Hosseini, Mohammad
AU  - Hosseini M
AUID- ORCID: 0000-0002-2385-985X
AD  - Institute of Ethics, School of Theology, Philosophy, and Music, Dublin City
      University , Dublin, Ireland.
FAU - Bruton, Samuel V
AU  - Bruton SV
AUID- ORCID: 0000-0002-5455-125X
AD  - School of Humanities, The University of Southern Mississippi , Hattiesburg, MS,
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Attitude
MH  - Authorship/*standards
MH  - Humans
MH  - Interviews as Topic
MH  - Periodicals as Topic/*standards/trends
MH  - Qualitative Research
MH  - Research Personnel/*psychology/*standards/trends
OTO - NOTNLM
OT  - *Authorship
OT  - *Equal Co-First Authorship
OT  - *equal contributions
OT  - *ethics
OT  - *publications
EDAT- 2020/06/02 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - 10.1080/08989621.2020.1776122 [doi]
PST - ppublish
SO  - Account Res. 2020 Nov;27(8):496-520. doi: 10.1080/08989621.2020.1776122. Epub
      2020 Jun 4.


PMID- 32475061
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - Retrieval of germinal zone neural stem cells from the cerebrospinal fluid of
      premature infants with intraventricular hemorrhage.
PG  - 1085-1101
LID - 10.1002/sctm.19-0323 [doi]
AB  - Intraventricular hemorrhage is a common cause of morbidity and mortality in
      premature infants. The rupture of the germinal zone into the ventricles entails
      loss of neural stem cells and disturbs the normal cytoarchitecture of the region,
      compromising late neurogliogenesis. Here we demonstrate that neural stem cells
      can be easily and robustly isolated from the hemorrhagic cerebrospinal fluid
      obtained during therapeutic neuroendoscopic lavage in preterm infants with severe
      intraventricular hemorrhage. Our analyses demonstrate that these neural stem
      cells, although similar to human fetal cell lines, display distinctive hallmarks 
      related to their regional and developmental origin in the germinal zone of the
      ventral forebrain, the ganglionic eminences that give rise to interneurons and
      oligodendrocytes. These cells can be expanded, cryopreserved, and differentiated 
      in vitro and in vivo in the brain of nude mice and show no sign of tumoral
      transformation 6 months after transplantation. This novel class of neural stem
      cells poses no ethical concerns, as the fluid is usually discarded, and could be 
      useful for the development of an autologous therapy for preterm infants, aiming
      to restore late neurogliogenesis and attenuate neurocognitive deficits.
      Furthermore, these cells represent a valuable tool for the study of the final
      stages of human brain development and germinal zone biology.
CI  - (c) 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley
      Periodicals, Inc. on behalf of AlphaMed Press.
FAU - Fernandez-Munoz, Beatriz
AU  - Fernandez-Munoz B
AUID- ORCID: 0000-0003-4238-9598
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
AD  - Grupo de Neurociencia aplicada, Instituto de Biomedicina de Sevilla, Sevilla,
      Spain.
FAU - Rosell-Valle, Cristina
AU  - Rosell-Valle C
AUID- ORCID: 0000-0001-9545-0976
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
FAU - Ferrari, Daniela
AU  - Ferrari D
AD  - Department of Biotechnology and Biosciences, University Milan-Bicocca, Milan,
      Italy.
FAU - Alba-Amador, Julia
AU  - Alba-Amador J
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
FAU - Montiel, Miguel Angel
AU  - Montiel MA
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
FAU - Campos-Cuerva, Rafael
AU  - Campos-Cuerva R
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
AD  - Centro de Transfusiones, Tejidos y Celulas de Sevilla (CTTS), Sevilla, Spain.
FAU - Lopez-Navas, Luis
AU  - Lopez-Navas L
AD  - Departamento de Preclinica, Red Andaluza de Diseno y Traslacion de Terapias
      Avanzadas, Sevilla, Spain.
FAU - Munoz-Escalona, Maria
AU  - Munoz-Escalona M
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
FAU - Martin-Lopez, Maria
AU  - Martin-Lopez M
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
AD  - Grupo de Neurociencia aplicada, Instituto de Biomedicina de Sevilla, Sevilla,
      Spain.
FAU - Profico, Daniela Celeste
AU  - Profico DC
AD  - Fondazione IRCCS Casa Sollievo della Sofferenza, Production Unit of Advanced
      Therapies (UPTA), San Giovanni Rotondo, Italy.
FAU - Blanco, Manuel Francisco
AU  - Blanco MF
AD  - Unidad de Produccion y Reprogramacion Celular (UPRC), Red Andaluza para el diseno
      y traslacion de Terapias Avanzadas, Sevilla, Spain.
FAU - Giorgetti, Alessandra
AU  - Giorgetti A
AD  - Regenerative Medicine Program, Bellvitge Biomedical Research Institute (IDIBELL);
      Program for Translation of Regenerative Medicine in Catalonia (P-CMRC),
      Barcelona, Spain.
FAU - Gonzalez-Munoz, Elena
AU  - Gonzalez-Munoz E
AD  - Department of Cell Biology, Genetics and Physiology, University of Malaga,
      Malaga, Spain.
AD  - Department of Regenerative Nanomedicine, Andalusian Center for Nanomedicine and
      Biotechnology-BIONAND, Malaga, Spain.
AD  - Networking Research Center on Bioengineering, Biomaterials and Nanomedicine
      (CIBER-BBN). Carlos III Health Institute (ISCIII), Spain.
FAU - Marquez-Rivas, Javier
AU  - Marquez-Rivas J
AD  - Grupo de Neurociencia aplicada, Instituto de Biomedicina de Sevilla, Sevilla,
      Spain.
AD  - Neurosurgery Department, Hospital Virgen del Rocio, Sevilla, Spain.
FAU - Sanchez-Pernaute, Rosario
AU  - Sanchez-Pernaute R
AUID- ORCID: 0000-0003-1144-9025
AD  - Departamento de Preclinica, Red Andaluza de Diseno y Traslacion de Terapias
      Avanzadas, Sevilla, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (AC133 Antigen)
SB  - IM
MH  - AC133 Antigen/metabolism
MH  - Animals
MH  - Cerebral Hemorrhage/*cerebrospinal fluid/genetics
MH  - Endoscopy
MH  - Female
MH  - Gene Expression Regulation, Developmental
MH  - Infant, Premature/*cerebrospinal fluid
MH  - Male
MH  - Mice, Nude
MH  - Neural Stem Cells/*pathology/transplantation
PMC - PMC7445027
OTO - NOTNLM
OT  - *cerebrospinal fluid
OT  - *germinal zone
OT  - *intraventricular hemorrhage
OT  - *neural stem cell
OT  - *neurogenesis
OT  - *premature infant
EDAT- 2020/06/01 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/06/01 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/06/01 06:00 [entrez]
AID - 10.1002/sctm.19-0323 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2020 Sep;9(9):1085-1101. doi: 10.1002/sctm.19-0323. Epub
      2020 May 30.


PMID- 32474535
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 2212-554X (Electronic)
IS  - 2212-5531 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Apr-Jun
TI  - Spectrum of pulmonary fungal pathogens, associated risk factors, and anti-fungal 
      susceptibility pattern among persons with presumptive tuberculosis at Gombe,
      Nigeria.
PG  - 144-149
LID - 10.4103/ijmy.ijmy_46_20 [doi]
AB  - Background: Pulmonary mycosis (PM) poses a great diagnostic challenge due to the 
      lack of pathognomonic and radiological features, especially in the absence of
      mycology laboratory tests. This study was aimed to isolate, phenotypically
      identify, determine the prevalence of pulmonary fungal pathogens and antifungal
      susceptibility pattern of isolates of presumptive tuberculosis (PTB) patients
      attending Federal Teaching Hospital (FTH) Gombe, Nigeria. Methods: After ethical 
      approval, three consecutive early morning sputa were collected from 216
      participants with presumptive of PTB attending FTH Gombe, between May 2, 2017 and
      May 30, 2018. Samples were processed using standard mycological staining,
      microscopy, sugar biochemistry, and antifungal susceptibility test protocols.
      Sociodemographic variables and risk factors of pulmonary fungal infection were
      assessed through structured questionnaires. Pulmonary fungal infection was
      defined by the positive culture in at least two sputa. PTB was defined by
      Genexpert((R)) nested polymerase chain reaction. Results: Of the 216
      participants, 19.9% had PTB and 73.6% had pulmonary fungal pathogens. Among the
      isolated pulmonary fungal pathogens, Aspergillus fumigatus made the highest
      occurrence, while 6.5% had PTB-fungal co-infection. No significant association
      existed between the prevalence of PM with age and sex of participants (P < 0.05).
      Cigarette smoking (adjusted odds ratio [aOR] = 15.9 [95% confidence interval
      (CI): 0.9-268.8]), prolong antibiotic use (aOR = 77.9 [95% CI: 4.7-1283]) and
      possession of domestic pet (aOR = 77.9 [95% CI: 4.7-1283]) were significant risk 
      factors of PM (P < 0.05). Penicillium citrinum, Mucor spp. and Aspergillus flavus
      are more susceptible to voriconazole, and Candida albicans was found to be more
      susceptible to Nystatin. Of the 159 fungal isolates, 92.5% were resistant to
      fluconazole. Conclusion: Findings from this study revealed high level pulmonary
      fungal pathogens, especially among PTB patients. A majority of fungal isolates
      were resistant to fluconazole. It's recommended that persons should do away with 
      or minimize risk factors for pulmonary fungal pathogens identified in this study.
FAU - Sani, Fatima Muhammad
AU  - Sani FM
AD  - Department of Biological Sciences, Division of Medical Microbiology, Abubakar
      Tafawa Balewa University, Bauchi, Nigeria.
FAU - Uba, Auwalu
AU  - Uba A
AD  - Department of Microbiology, Bauchi State University, Gadau, Nigeria.
FAU - Tahir, Fatima
AU  - Tahir F
AD  - Department of Biological Sciences, National Army University, Biu, Nigeria.
FAU - Abdullahi, Idris Nasir
AU  - Abdullahi IN
AD  - Department of Medical Laboratory Science, Faculty of Allied Health Sciences,
      Ahmadu Bello University, Zaria, Nigeria.
FAU - Adekola, Hafeez Adeinsayo
AU  - Adekola HA
AD  - Department of Microbiology, Olabisi Onabanjo University, Ago Iwoye, Ogun,
      Nigeria.
FAU - Mustapha, Jelili
AU  - Mustapha J
AD  - Biological Sciences Department, Faculty of Sciences, University of Alberta,
      Edmonton, Canada.
FAU - Nwofe, Justin
AU  - Nwofe J
AD  - Department of Health System Strengthening, Family Health International 360,
      Abuja, Nigeria.
FAU - Usman, Yahaya
AU  - Usman Y
AD  - Department of Medical Laboratory Science, Faculty of Allied Health Sciences,
      Ahmadu Bello University, Zaria, Nigeria.
FAU - Daneji, Isah Muhammad
AU  - Daneji IM
AD  - Department of Medical Microbiology and Parasitology, Faculty of Clinical
      Sciences, Bayero University, Kano, Nigeria.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Int J Mycobacteriol
JT  - International journal of mycobacteriology
JID - 101615660
RN  - 0 (Antifungal Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antifungal Agents/*therapeutic use
MH  - Coinfection/epidemiology/microbiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Fungi/*classification/*drug effects/pathogenicity
MH  - Humans
MH  - Lung Diseases/drug therapy/epidemiology/*microbiology
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Mycoses/drug therapy/*epidemiology/microbiology
MH  - Nigeria/epidemiology
MH  - Prevalence
MH  - Risk Factors
MH  - Sputum/microbiology
MH  - Tuberculosis/diagnosis/*epidemiology/microbiology
MH  - Young Adult
OTO - NOTNLM
OT  - *Antifungal resistance
OT  - *fungal pathogens; pulmonary infection
OT  - *tuberculosis
COIS- None
EDAT- 2020/06/01 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
AID - IntJMycobacteriol_2020_9_2_144_285231 [pii]
AID - 10.4103/ijmy.ijmy_46_20 [doi]
PST - ppublish
SO  - Int J Mycobacteriol. 2020 Apr-Jun;9(2):144-149. doi: 10.4103/ijmy.ijmy_46_20.


PMID- 32474432
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 30
TI  - Documenting the untold histories of late-diagnosed autistic adults: a qualitative
      study protocol using oral history methodology.
PG  - e037968
LID - 10.1136/bmjopen-2020-037968 [doi]
AB  - INTRODUCTION: Receiving a diagnosis of autism in adulthood is increasingly common
      for a subset of individuals who were either misdiagnosed in childhood or missed
      out on a diagnosis altogether. This qualitative study, coproduced with autistic
      people, invites late-diagnosed autistic adults to share their life histories to
      (1) understand better the consequences of living without a diagnosis, (2)
      elucidate what precipitates an autism diagnosis in mid-to-late adulthood and (3) 
      identify the perceived impact of receiving that diagnosis. METHODS AND ANALYSIS: 
      Oral histories have been a successful way to uncover overlooked and marginalised 
      voices. We therefore adopt qualitative, oral history methodology in this study to
      understand these adults' experiences, especially of living in an era when autism 
      was not well known. We will recruit 24 participants who will (1) have been born
      before 1975, (2) have received a clinical, autism diagnosis after the age of 35, 
      (3) be English-speaking and (4) have spent most of their childhood and adulthood 
      living in Australia. Participants will take part in four sessions, including the 
      main, qualitative, oral history interview, through a range of possible formats to
      facilitate inclusion. The interview data will be analysed using reflexive
      thematic analysis. ETHICS AND DISSEMINATION: The protocol has received
      institutional research ethics approval from Macquarie University's Human Research
      Ethics Committee (Ref.: 52019556310562). This study will yield understanding of
      the life experiences of autistic adults, especially middle-aged and older
      Australians, should inform more effective diagnostic practices and provide
      insight into the key factors that might promote resilience and enhance quality of
      life in autistic people. The findings will be disseminated to academic and
      clinical audiences through journal articles and conference presentations and to
      the autistic and autism communities through accessible reports. The interviews
      will also be prepared for digital archiving, which will enable ongoing access for
      future generations and communities.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pellicano, Elizabeth
AU  - Pellicano E
AUID- ORCID: 0000-0002-7246-8003
AD  - Macquarie School of Education, Macquarie University, Sydney, New South Wales,
      Australia liz.pellicano@mq.edu.au.
AD  - Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane,
      Queensland, Australia.
FAU - Lawson, Wenn
AU  - Lawson W
AD  - Macquarie School of Education, Macquarie University, Sydney, New South Wales,
      Australia.
AD  - Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane,
      Queensland, Australia.
FAU - Hall, Gabrielle
AU  - Hall G
AD  - Macquarie School of Education, Macquarie University, Sydney, New South Wales,
      Australia.
AD  - Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane,
      Queensland, Australia.
FAU - Mahony, Joanne
AU  - Mahony J
AD  - Macquarie School of Education, Macquarie University, Sydney, New South Wales,
      Australia.
AD  - Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane,
      Queensland, Australia.
FAU - Lilley, Rozanna
AU  - Lilley R
AD  - Macquarie School of Education, Macquarie University, Sydney, New South Wales,
      Australia.
FAU - Davis, Catherine
AU  - Davis C
AD  - Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania, 
      USA.
FAU - Arnold, Samuel
AU  - Arnold S
AUID- ORCID: 0000-0003-2900-223X
AD  - Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane,
      Queensland, Australia.
AD  - Department of Developmental Disability Neuropsychiatry, University of New South
      Wales, Sydney, New South Wales, Australia.
FAU - Trollor, Julian
AU  - Trollor J
AUID- ORCID: 0000-0002-7685-2977
AD  - Cooperative Research Centre for Living with Autism (Autism CRC), Brisbane,
      Queensland, Australia.
AD  - Department of Developmental Disability Neuropsychiatry, University of New South
      Wales, Sydney, New South Wales, Australia.
FAU - Yudell, Michael
AU  - Yudell M
AD  - Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Australia/epidemiology
MH  - *Autistic Disorder/diagnosis
MH  - Humans
MH  - Longitudinal Studies
MH  - Middle Aged
MH  - Qualitative Research
MH  - Quality of Life
PMC - PMC7264831
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *mental health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/06/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037968 [pii]
AID - 10.1136/bmjopen-2020-037968 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 30;10(5):e037968. doi: 10.1136/bmjopen-2020-037968.


PMID- 32474431
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 30
TI  - Study protocol to examine the relationship between environmental exposure to lead
      and blood lead levels among children from day-care centres in Ekurhuleni
      Metropolitan Municipality.
PG  - e036687
LID - 10.1136/bmjopen-2019-036687 [doi]
AB  - INTRODUCTION: Lead exposure is toxic to all humans and is very harmful to young
      children, especially 5-year-olds. Elevated blood lead levels (BLLs) in children
      have been associated with their daily surrounding environment. This protocol
      seeks to evaluate the association between environmental lead exposure and BLLs
      among children in day-care centres, including household and other risk factors.
      METHODS AND ANALYSIS: To achieve the objectives of the study, we adopted a
      cross-sectional analytical design. A portable X-ray fluorescence analyser was
      used for environmental sampling, and BLLs were determined using the LeadCare II
      machine among preschool children. Household and other risk factors were assessed 
      using a questionnaire. Random sampling was employed to select day-care centres in
      the municipality and children in each day-care centre. Data will be analysed
      using SPSS V. 26. ETHICS AND DISSEMINATION: Ethical approval and permission were 
      obtained prior to commencement of the study. The researcher intends to publish
      the results in peer-reviewed journals and also to present a paper at a scientific
      conference. The study will generate information on environmental lead exposure
      among vulnerable children (2-5 years), and it will promote public health action
      to prevent long-term exposure in day-care centres.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cindi, Mbalenhle Desiree
AU  - Cindi MD
AD  - Department of Environmental Health, Faculty of Health Sciences, University of
      Johannesburg, Auckland Park, Gauteng, South Africa.
FAU - Mbonane, Thokozani Patrick
AU  - Mbonane TP
AUID- ORCID: 0000-0001-5802-4265
AD  - Department of Environmental Health, Faculty of Health Sciences, University of
      Johannesburg, Auckland Park, Gauteng, South Africa tmbonane@uj.ac.za.
FAU - Naicker, Nisha
AU  - Naicker N
AUID- ORCID: 0000-0001-7223-7881
AD  - Department of Environmental Health, Faculty of Health Sciences, University of
      Johannesburg, Auckland Park, Gauteng, South Africa.
AD  - Epidemiology and Surveillance Section, National Institute of Occupational Health,
      Johannesburg, Gauteng, South Africa.
AD  - School of Public Health, Faculty of Health Sciences, University of witwatersrand,
      Johannesburg, Gauteng, South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 2P299V784P (Lead)
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Cities
MH  - Cross-Sectional Studies
MH  - Environmental Exposure/adverse effects
MH  - Humans
MH  - Infant
MH  - *Lead
MH  - *Lead Poisoning/epidemiology
MH  - Risk Factors
PMC - PMC7264638
OTO - NOTNLM
OT  - *blood lead levels
OT  - *day-care centres
OT  - *environment
OT  - *environmental health
OT  - *household risk factors
OT  - *short-term lead exposure
COIS- Competing interests: None declared.
EDAT- 2020/06/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036687 [pii]
AID - 10.1136/bmjopen-2019-036687 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 30;10(5):e036687. doi: 10.1136/bmjopen-2019-036687.


PMID- 32474430
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 30
TI  - Improving quality of surgical and anaesthesia care at hospital level in
      sub-Saharan Africa: a systematic review protocol of health system strengthening
      interventions.
PG  - e036615
LID - 10.1136/bmjopen-2019-036615 [doi]
AB  - INTRODUCTION: Over 5 billion people in the world do not have access to safe,
      affordable surgical and anaesthesia care when needed. In order to improve health 
      outcomes in patients with surgical conditions, both access to care and the
      quality of care need to be improved. A recent commission on high-quality health
      systems highlighted that poor-quality care is now a bigger barrier than
      non-utilisation of the health system for reducing mortality. AIM: To carry out a 
      systematic review to provide an evidence-based summary of hospital-based
      interventions associated with improved quality of surgical and anaesthesia care
      in sub-Saharan African countries (SSACs). METHODS AND ANALYSIS: Three search
      strings (1) surgery and anaesthesia, (2) quality improvement hospital-based
      interventions and (3) SSACs will be combined. The following databases EMBASE,
      Global Health, MEDLINE, CINAHL, Web of Science and Scopus will be searched.
      Further relevant studies will be identified from national and international
      health organisations and publications and reference lists of all selected
      full-text articles. The review will include all type of original articles in
      English published between 2008 and 2019. Article screening, data extraction and
      assessment of methodological quality will be done by two reviewers independently 
      and any disputes will be resolved by a third reviewer or team consensus. Three
      types of outcomes will be collected including clinical, process and
      implementation outcomes. The primary outcome will be mortality. Secondary
      outcomes will include other clinical outcomes (major and minor complications), as
      well as process and implementation outcomes. Descriptive statistics and outcomes 
      will be summarised and discussed. For the primary outcome, the methodological
      rigour will be assessed. ETHICS AND DISSEMINATION: The results will be published 
      in a peer reviewed open access journal and presented at national and
      international conferences. As this is a review of secondary data no formal
      ethical approval is required. PROSPERO REGISTRATION NUMBER: CRD42019125570.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brima, Nataliya
AU  - Brima N
AUID- ORCID: 0000-0002-6930-5166
AD  - King's Centre for Global Health & Health Partnerships, King's College London,
      London, UK nataliya.brima@kcl.ac.uk.
FAU - Davies, Justine
AU  - Davies J
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Leather, Andrew Jm
AU  - Leather AJ
AD  - King's Centre for Global Health & Health Partnerships, King's College London,
      London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa South of the Sahara
MH  - *Anesthesia
MH  - Government Programs
MH  - Hospitals
MH  - Humans
MH  - *Medical Assistance
MH  - Systematic Reviews as Topic
PMC - PMC7264698
OTO - NOTNLM
OT  - *health system strengthening
OT  - *improving quality of care
OT  - *sub-Saharan Africa
OT  - *surgical and anaesthesia care
COIS- Competing interests: None declared.
EDAT- 2020/06/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036615 [pii]
AID - 10.1136/bmjopen-2019-036615 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 30;10(5):e036615. doi: 10.1136/bmjopen-2019-036615.


PMID- 32474427
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 30
TI  - Development and evaluation of a patient-centred program for low anterior
      resection syndrome: protocol for a randomized controlled trial.
PG  - e035587
LID - 10.1136/bmjopen-2019-035587 [doi]
AB  - INTRODUCTION: Low anterior resection syndrome (LARS) is described as disordered
      bowel function after rectal resection that leads to a detriment in quality of
      life, and affects the majority of individuals following restorative proctectomy
      for rectal cancer. The management of LARS includes personalised troubleshooting
      and effective self-management behaviours. Thus, affected individuals need to be
      well informed and appropriately engaged in their own LARS management. This
      manuscript describes the development of a LARS patient-centred programme (LPCP)
      and the study protocol for its evaluation in a randomised controlled trial.
      METHODS AND ANALYSIS: This will be a multicentre, randomised, assessor-blind,
      parallel-groups, pragmatic trial evaluating the impact of an LPCP, consisting of 
      an informational booklet, patient diaries and nurse support, on patient-reported 
      outcomes after restorative proctectomy for rectal cancer. The informational
      booklet was developed by a multidisciplinary LARS team, and was vetted in a focus
      group and semistructured interviews involving patients, caregivers, and
      healthcare professionals. The primary outcome will be global quality of life
      (QoL), as measured by the European Organisation for Research and Treatment of
      Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30), at 6 months after
      surgery. The treatment effect on global QoL will be modelled using generalised
      estimating equations. Secondary outcomes include symptom change, patient
      activation, bowel function measures, emotional distress, knowledge about LARS and
      satisfaction with the LPCP. ETHICS AND DISSEMINATION: The Research Ethics
      Committee (REC) at the Integrated Health and Social Services Network for
      West-Central Montreal (health network responsible for the Jewish General
      Hospital) is the overseeing REC for all Quebec sites. They have granted ethical
      approval (MP-05-2019-1628) for all Quebec hospitals (Jewish General Hospital,
      McGill University Health Center, CHU de Quebec) and have granted full
      authorisation to begin research at the Jewish General Hospital. Patient
      recruitment will not begin at the other Quebec sites until inter-institutional
      contracts are finalised and feasibility/authorisation for research is granted by 
      their respective REC. The results of this study will be presented at national and
      international conferences, and a manuscript with results will be submitted for
      publication in a high-impact peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      NCT03828318; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Garfinkle, Richard
AU  - Garfinkle R
AD  - Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, Quebec, 
      Canada.
FAU - Loiselle, Carmen G
AU  - Loiselle CG
AD  - Department of Oncology, McGill University, Montreal, Quebec, Canada.
AD  - Ingram School of Nursing, McGill University, Montreal, Quebec, Canada.
FAU - Park, Jason
AU  - Park J
AD  - Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada.
FAU - Fiore, Julio F Jr
AU  - Fiore JF Jr
AUID- ORCID: 0000-0002-0019-8673
AD  - Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada.
FAU - Bordeianou, Liliana G
AU  - Bordeianou LG
AD  - Section of Colon and Rectal Surgery, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Liberman, A Sender
AU  - Liberman AS
AD  - Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada.
FAU - Morin, Nancy
AU  - Morin N
AD  - Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, Quebec, 
      Canada.
FAU - Faria, Julio
AU  - Faria J
AD  - Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, Quebec, 
      Canada.
FAU - Ghitulescu, Gabriela
AU  - Ghitulescu G
AD  - Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, Quebec, 
      Canada.
FAU - Vasilevsky, Carol-Ann
AU  - Vasilevsky CA
AD  - Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, Quebec, 
      Canada.
FAU - Bhatnagar, Sahir R
AU  - Bhatnagar SR
AD  - Department of Epidemiology, Biostatistics and Occupational Health, McGill
      University, Montreal, Quebec, Canada.
FAU - Boutros, Marylise
AU  - Boutros M
AUID- ORCID: 0000-0001-8006-321X
AD  - Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, Quebec, 
      Canada maryliseboutros@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03828318
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Postoperative Complications
MH  - *Quality of Life
MH  - Quebec
MH  - Randomized Controlled Trials as Topic
MH  - *Rectal Neoplasms/surgery
MH  - Syndrome
PMC - PMC7264642
OTO - NOTNLM
OT  - *adult gastroenterology
OT  - *colorectal surgery
OT  - *epidemiology
OT  - *gastrointestinal tumours
COIS- Competing interests: ASL receives travel stipends from Merck and Servier, and is 
      on the advisory committee of Novadaq. JFFJ received a research grant from Merck
      and fees for consulting from Shionogi.
EDAT- 2020/06/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035587 [pii]
AID - 10.1136/bmjopen-2019-035587 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 30;10(5):e035587. doi: 10.1136/bmjopen-2019-035587.


PMID- 32474426
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 30
TI  - Characteristics and interpretation of subgroup analyses based on tumour
      characteristics in randomised trials testing target-specific anticancer drugs:
      design of a systematic survey.
PG  - e034565
LID - 10.1136/bmjopen-2019-034565 [doi]
AB  - BACKGROUND: Target-specific anticancer drugs are under rapid development. Little 
      is known, however, about the risk of administering target-specific drugs to
      patients who have tumours with molecular alterations or other characteristics
      that can make the drug ineffective or even harmful. An increasing number of
      randomised clinical trials (RCTs) investigating target-specific anticancer drugs 
      include subgroup analyses based on tumour characteristics. Such subgroup analyses
      have the potential to be more credible and influential than subgroup analyses
      based on traditional factors such as sex or tumour stage. In addition, they may
      more frequently lead to qualitative subgroup effects, that is, show benefit in
      one but harm in another subgroup of patients (eg, if the tumour characteristic
      makes the drug ineffective or even enhance tumour growth). If so, subgroup
      analyses based on tumour characteristics would be highly relevant for patient
      safety. The aim of this study is to systematically assess the frequency and
      characteristics of subgroup analyses based on tumour characteristics, the
      frequency of qualitative subgroup effects, their credibility, and the
      interpretations that investigators and guidelines developers report. METHODS AND 
      ANALYSIS: We will perform a systematic survey of 433 RCTs testing the effect of
      target-specific anticancer drugs. Teams of methodologically trained investigators
      and oncologists will identify eligible studies, extract relevant data and assess 
      the credibility of putative subgroup effects using a recently developed formal
      instrument. We will systematically assess how trial investigators interpret
      apparent subgroup effects based on tumour characteristics and the extent to which
      they influence subsequent practice guidelines. Our results will provide empirical
      data characterising an increasingly used type of subgroup analysis in cancer
      trials and its potential impact on precision medicine to predict benefit or harm.
      ETHICS AND DISSEMINATION: Formal ethical approval is not required for this study.
      We will disseminate the findings in a peer-reviewed and open-access journal
      publication.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Schandelmaier, Stefan
AU  - Schandelmaier S
AUID- ORCID: 0000-0002-8429-0337
AD  - Institute for Clinical Epidemiology and Biostatistics, Department of Clinical
      Research, University Hospital and University of Basel, Basel, Switzerland
      s.schandelmaier@gmail.com.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Schmitt, Andreas M
AU  - Schmitt AM
AD  - Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
FAU - Herbrand, Amanda K
AU  - Herbrand AK
AD  - Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
FAU - Glinz, Dominik
AU  - Glinz D
AD  - Institute for Clinical Epidemiology and Biostatistics, Department of Clinical
      Research, University Hospital and University of Basel, Basel, Switzerland.
FAU - Ewald, Hannah
AU  - Ewald H
AD  - University Medical Library, University of Basel, Basel, Switzerland.
FAU - Briel, Matthias
AU  - Briel M
AD  - Institute for Clinical Epidemiology and Biostatistics, Department of Clinical
      Research, University Hospital and University of Basel, Basel, Switzerland.
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Guyatt, Gordon H
AU  - Guyatt GH
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University,
      Hamilton, Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Hemkens, Lars G
AU  - Hemkens LG
AD  - Institute for Clinical Epidemiology and Biostatistics, Department of Clinical
      Research, University Hospital and University of Basel, Basel, Switzerland.
FAU - Kasenda, Benjamin
AU  - Kasenda B
AD  - Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
AD  - Research and Development, iOMEDICO AG, Freiburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - *Antineoplastic Agents
MH  - Humans
MH  - *Neoplasms/drug therapy
MH  - *Surveys and Questionnaires
PMC - PMC7264639
OTO - NOTNLM
OT  - *oncology
OT  - *precision medicine
OT  - *randomised controlled trials
OT  - *statistics & research methods
OT  - *subgroup analysis
OT  - *systematic survey of studies
COIS- Competing interests: BK reports consultant activities for Roche and Siemens,
      research Grants from Roche/AbbVie and travel support from Riemser, AbbVie and
      Amgen-all not related to the project described herein.
EDAT- 2020/06/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034565 [pii]
AID - 10.1136/bmjopen-2019-034565 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 30;10(5):e034565. doi: 10.1136/bmjopen-2019-034565.


PMID- 32474423
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 30
TI  - Population Registry of Esophageal and Stomach Tumours in Ontario (PRESTO):
      protocol for a multicentre clinical and pathological database including 25 000
      patients.
PG  - e032729
LID - 10.1136/bmjopen-2019-032729 [doi]
AB  - INTRODUCTION: Oesophagogastric cancers carry a high mortality, economic burden
      and rising incidence. There is a need to monitor and improve care for this
      disease. Pathologic information is a cornerstone of cancer diagnosis, treatment
      and prognosis. Few population-based studies combine pathology information and
      clinical outcomes. The objective of this study is to develop a clinical and
      pathological database of oesophagogastric cancers to study practice patterns,
      resource utilisation and clinical outcomes. METHODS AND ANALYSIS: The Population 
      Registry of Esophageal and Stomach Tumours in Ontario (PRESTO) will include all
      patients with oesophagogastric cancer diagnosed from 2002 onwards within the
      province of Ontario. We estimate that the sample over the first 14 years of the
      study will include 26 000 patients. Pathologic information from diagnostic
      procedures, endomucosal resection specimens and surgical resection specimens is
      being abstracted into a purpose-built database. Pathology information will be
      linked to administrative data, which capture baseline demographics,
      patient-reported symptoms, physician billings, hospital visits, hospital
      characteristics, geography and vital statistics. The registry will be updated
      prospectively. ETHICS AND DISSEMINATION: Ethics approval for this study was
      obtained from the Sunnybrook Health Sciences Centre Research Ethics Board. The
      PRESTO database will enable the study of oesophagogastric cancer in Ontario under
      six themes of inquiry: treatment, surgical outcomes, pathology, survival, health 
      system and resource utilisation and cost. This information will be a valuable
      addition to the global efforts to understand ways to optimise care for these
      diseases.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gupta, Vaibhav
AU  - Gupta V
AUID- ORCID: 0000-0003-4568-121X
AD  - Department of Surgery and Institute of Health Policy, Management, and Evaluation,
      University of Toronto, Toronto, Ontario, Canada.
FAU - Levy, Jordan
AU  - Levy J
AD  - Department of Surgery and Institute of Health Policy, Management, and Evaluation,
      University of Toronto, Toronto, Ontario, Canada.
FAU - Allen-Ayodabo, Catherine
AU  - Allen-Ayodabo C
AD  - Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, Ontario,
      Canada.
FAU - Amirazodi, Elmira
AU  - Amirazodi E
AD  - Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, Ontario,
      Canada.
FAU - Davis, Laura
AU  - Davis L
AD  - Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, Ontario,
      Canada.
FAU - Li, Qing
AU  - Li Q
AD  - Analysis, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
FAU - Mahar, Alyson
AU  - Mahar A
AD  - Community Health Sciences, University of Manitoba College of Medicine, Winnipeg, 
      Ontario, Canada.
FAU - Coburn, Natalie G
AU  - Coburn NG
AD  - Division of General Surgery, Department of Surgery and Institute of Health
      Policy, Management, and Evaluation, Odette Cancer Centre, Toronto, Ontario,
      Canada Natalie.Coburn@sunnybrook.ca.
CN  - PRESTO Study Investigators
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200530
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Databases, Factual
MH  - *Esophageal Neoplasms/epidemiology/therapy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Ontario/epidemiology
MH  - Registries
MH  - *Stomach Neoplasms/epidemiology/therapy
PMC - PMC7264637
OTO - NOTNLM
OT  - *gastrointestinal tumours
OT  - *oesophageal disease
OT  - *oncology
OT  - *pathology
OT  - *surgery
COIS- Competing interests: NGC and GED receive salary support from Ontario
      Health-Cancer Care Ontario.
EDAT- 2020/06/01 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-032729 [pii]
AID - 10.1136/bmjopen-2019-032729 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 30;10(5):e032729. doi: 10.1136/bmjopen-2019-032729.


PMID- 32474133
OWN - NLM
STAT- Publisher
LR  - 20200616
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 91
DP  - 2020 May 22
TI  - Listening to young voices: The lived experiences of adolescent simulated patients
      in health professional education.
PG  - 104476
LID - S0260-6917(19)31456-X [pii]
LID - 10.1016/j.nedt.2020.104476 [doi]
AB  - BACKGROUND: Learners should be exposed to the core principles of adolescent
      specific communication and assessment frameworks as part of health professional
      curricula. How this is done can vary considerably, but the inclusion of
      adolescents seems an ideal and realistic option. However, securing their
      participation can be challenging. A viable option to adolescent patients may be
      adolescent simulated patients. OBJECTIVE: This study describes adolescents' lived
      experiences of being simulated patients in health professional education. DESIGN 
      & SETTING: An interpretive phenomenological approach involving ten adolescent
      simulated patients from two health professional education programs in Australia. 
      METHODS: Consenting/assenting adolescents participated in semi-structured
      audio-recorded interviews. Data was transcribed verbatim and analysed using van
      Manen's phenomenological approach. RESULTS: Adolescents offered unique insights
      and intimate knowledge of their lived experiences of simulated patient work.
      Adolescents reflected upon the often positive but sometimes challenging journey
      of simulated patient work. The identification of harm, largely unrecognized by
      adolescents themselves is the most concerning finding of this study. CONCLUSIONS:
      The experiences of adolescent simulated patients can help to shape the future of 
      their involvement. However, their experiences also reveal myriad challenges. The 
      implications for ethical practice must be reviewed before inclusion of
      adolescents as simulated patients is a feasible option.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Gamble, Andree S
AU  - Gamble AS
AD  - Nursing and Midwifery, Monash University, Clayton, Victoria, Australia.
      Electronic address: Andree.gamble1@monash.edu.
FAU - Nestel, Debra
AU  - Nestel D
AD  - Monash Institute for Health and Clinical Education, Faculty of Medicine, Nursing 
      & Health Sciences, Monash University, Clayton, Victoria, Australia; Department of
      Surgery, Melbourne Medical School, Faculty of Medicine, Dentistry & Health
      Sciences, University of Melbourne, Australia.
FAU - Bearman, Margaret
AU  - Bearman M
AD  - Centre for Research in Assessment and Digital Learning (CRADLE), Deakin
      University, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
OTO - NOTNLM
OT  - Adolescents
OT  - Health professional education
OT  - Simulated patients
OT  - Simulation
COIS- Declaration of competing interest None. No extramural funding or commercial
      financial support supported this pilot study. HREC approval granted.
EDAT- 2020/06/01 06:00
MHDA- 2020/06/01 06:00
CRDT- 2020/06/01 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2020/06/01 06:00 [medline]
PHST- 2020/06/01 06:00 [entrez]
AID - S0260-6917(19)31456-X [pii]
AID - 10.1016/j.nedt.2020.104476 [doi]
PST - aheadofprint
SO  - Nurse Educ Today. 2020 May 22;91:104476. doi: 10.1016/j.nedt.2020.104476.


PMID- 32474061
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Linking)
VI  - 102
IP  - 2
DP  - 2020 Aug
TI  - "Shared risk": Reframing risk analysis in the ethics of novel male
      contraceptives.
PG  - 67-69
LID - S0010-7824(20)30162-1 [pii]
LID - 10.1016/j.contraception.2020.05.014 [doi]
FAU - Campelia, Georgina D
AU  - Campelia GD
AD  - Department of Bioethics & Humanities, United States.
FAU - Abbe, Carmen
AU  - Abbe C
AD  - Department of Medicine, University of Washington School of Medicine, Seattle, WA,
      United States.
FAU - Nickels, Logan M
AU  - Nickels LM
AD  - Male Contraceptive Initiative, Durham, NC, United States.
FAU - McElmeel, Evy
AU  - McElmeel E
AD  - Private Practice, Seattle, WA, United States.
FAU - Amory, John K
AU  - Amory JK
AD  - Department of Medicine, University of Washington School of Medicine, Seattle, WA,
      United States. Electronic address: jamory@uw.edu.
LA  - eng
GR  - K24 HD082231/HD/NICHD NIH HHS/United States
GR  - R01 HD098039/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200529
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Contraceptive Agents, Male)
SB  - IM
MH  - Contraception
MH  - *Contraceptive Agents, Male
MH  - Humans
MH  - Male
MH  - Risk Assessment
PMC - PMC8168714
MID - NIHMS1703257
OTO - NOTNLM
OT  - *Contraception
OT  - *Male contraception
OT  - *Reproductive ethics
OT  - *Reproductive rights
OT  - *Side effects
OT  - *Unintended pregnancy
EDAT- 2020/06/01 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/06/01 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2020/05/18 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/06/01 06:00 [entrez]
AID - S0010-7824(20)30162-1 [pii]
AID - 10.1016/j.contraception.2020.05.014 [doi]
PST - ppublish
SO  - Contraception. 2020 Aug;102(2):67-69. doi: 10.1016/j.contraception.2020.05.014.
      Epub 2020 May 29.


PMID- 32473810
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1532-3390 (Electronic)
IS  - 1532-3382 (Linking)
VI  - 20
IP  - 2
DP  - 2020 Jun
TI  - Incorporating Humanities in Dental Education is Essential, but Seldom Routine.
PG  - 101442
LID - S1532-3382(20)30069-5 [pii]
LID - 10.1016/j.jebdp.2020.101442 [doi]
AB  - ARTICLE TITLE AND BIBLIOGRAPHIC INFORMATION: Humanities in Predoctoral Dental
      Education: A Scoping Review. Marti KC, Mylonas AI, MacEachern M, Gruppen L. J
      Dent Educ 2019;83(10):1174-1198. SOURCE OF FUNDING: None declared. TYPE OF
      STUDY/DESIGN: A scoping review.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Holden, Alexander C L
AU  - Holden ACL
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200413
PL  - United States
TA  - J Evid Based Dent Pract
JT  - The journal of evidence-based dental practice
JID - 101083101
SB  - IM
CON - J Dent Educ. 2019 Oct;83(10):1174-1198. PMID: 31285365
MH  - *Curriculum
MH  - Education, Dental
MH  - *Humanities
MH  - Humans
OTO - NOTNLM
OT  - *Academic integrity
OT  - *Cultural competence
OT  - *Curriculum
OT  - *Dental education
OT  - *Ethics and professionalism
OT  - *Humanities
EDAT- 2020/06/01 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/06/01 06:00
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
AID - S1532-3382(20)30069-5 [pii]
AID - 10.1016/j.jebdp.2020.101442 [doi]
PST - ppublish
SO  - J Evid Based Dent Pract. 2020 Jun;20(2):101442. doi: 10.1016/j.jebdp.2020.101442.
      Epub 2020 Apr 13.


PMID- 32473654
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 30
TI  - Endometrial scratch vs no intervention in egg donation cycles: the ENDOSCRATCH
      trial protocol.
PG  - 333
LID - 10.1186/s12884-020-02958-0 [doi]
AB  - BACKGROUND: The effects of endometrial scratching (ES) on embryo implantation
      have been studied for many years. Several studies have shown better outcomes when
      performed on patients undergoing intrauterine insemination and in vitro
      fertilization (IVF) cycles, but many other reports have not been able to find
      these differences. As far as cycles with donor eggs are concerned, reported
      evidence is scarce. Our aim in this trial is to determine if ES is useful for
      those patients undergoing IVF cycles with donor eggs, in order to assure a
      greater homogeneity in embryo quality and endometrial preparation. METHODS: This 
      single centre randomized controlled trial will include patients undergoing an egg
      donation cycle, meeting the inclusion criteria and who accept to participate in
      the study. Once informed consent is signed, patients will be randomly allocated
      to the study arm (group A) and then receive ES in the luteal phase of the cycle
      prior to embryo transfer, or the control arm (group B) without any intervention. 
      All cycle data will be collected and analyzed to obtain the clinical pregnancy
      and the live birth rates in the two groups. DISCUSSION: Several studies have
      tried to determine the effectiveness of an ES in IVF cycles, but it is still
      unclear due to the heterogeneity of these reports. The aim of this study is to
      determine if there are differences in clinical pregnancy rate and live birth rate
      in egg donor cycles, when comparing an ES performed in the preceding luteal phase
      versus no intervention, given that embryo quality and endometrial preparation
      protocols will be comparable. TRIAL REGISTRATION: Ethical approval of version 2.0
      of this trial was obtained on the 13th January 2017. It was retrospectively
      registered on the 5th April 2017 as the ENDOSCRATCH Trial (NCT03108157) in
      ClinicalTrials.gov.
FAU - Izquierdo, Alexandra
AU  - Izquierdo A
AUID- ORCID: https://orcid.org/0000-0001-5079-1769
AD  - ProcreaTec Fertility Clinic, Madrid, Spain. izquierdo.alexandra@yahoo.es.
FAU - de la Fuente, Laura
AU  - de la Fuente L
AD  - Human Reproduction Unit, Department of Obstetrics and Gynecology, University
      Hospital 12 de Octubre, Madrid, Spain.
FAU - Spies, Katharina
AU  - Spies K
AD  - ProcreaTec Fertility Clinic, Madrid, Spain.
FAU - Rayward, Jennifer
AU  - Rayward J
AD  - ProcreaTec Fertility Clinic, Madrid, Spain.
FAU - Lopez, Lourdes
AU  - Lopez L
AD  - ProcreaTec Fertility Clinic, Madrid, Spain.
FAU - Lora, David
AU  - Lora D
AD  - Clinical Research Unit (imas12-CIBERESP). University Hospital 12 de Octubre,
      Madrid, Spain.
FAU - Galindo, Alberto
AU  - Galindo A
AD  - Fetal Medicine Unit - Maternal and Child Health and Development Network (Red
      SAMID-RD12/0026/0016). Department of Obstetrics and Gynecology. University
      Hospital 12 de Octubre. 12 de Octubre Research Institute (imas12), Complutense
      University of Madrid, Madrid, Spain.
LA  - eng
SI  - ClinicalTrials.gov/NCT03108157
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200530
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biopsy
MH  - *Birth Rate
MH  - *Embryo Implantation
MH  - Embryo Transfer/*methods
MH  - Endometrium/*pathology
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Follow-Up Studies
MH  - Humans
MH  - *Live Birth
MH  - *Luteal Phase
MH  - Middle Aged
MH  - Pregnancy
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Young Adult
PMC - PMC7260784
OTO - NOTNLM
OT  - Egg donation
OT  - Endometrial injury
OT  - Endometrial receptivity
OT  - Endometrial scratching
OT  - Hysteroscopy
OT  - In vitro fertilization
OT  - Recurrent implantation failure
EDAT- 2020/06/01 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/06/01 06:00
PHST- 2019/07/09 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/06/01 06:00 [entrez]
PHST- 2020/06/01 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - 10.1186/s12884-020-02958-0 [doi]
AID - 10.1186/s12884-020-02958-0 [pii]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2020 May 30;20(1):333. doi: 10.1186/s12884-020-02958-0.


PMID- 35498877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2169-4826 (Print)
IS  - 2169-4826 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Jun
TI  - Community Health Workers' Role in Supporting Pediatric Asthma Management: A
      Review.
PG  - 195-210
LID - 10.1037/cpp0000319 [doi]
AB  - Objective: Community Health Workers (CHWs) have been effective in improving
      health outcomes in vulnerable communities by providing health education and
      management services. We review CHW-led asthma education and management
      interventions for children and their families. Next, we describe the selection
      and training of CHWs in pediatric asthma management in the Rhode Island
      Integrated Response Asthma Care Implementation Program (RI-AIR). Methods: We
      queried the MEDLine, Cochrane, PubMed, and EMBASE databases with keywords
      ("community health worker", "asthma", "health worker", "lay worker", "pediatric",
      "child", and "childhood") from inception until September 2019. Criteria for study
      inclusion included: published in English, conducted in the United States,
      approved with an ethics notification, published in peer-reviewed journal, and
      involved CHWs as the interventionists. The initial search identified 216
      manuscripts. Fifteen studies met criteria for inclusion. Results: CHWs provide
      asthma management and education services, including home environmental trigger
      assessments, strategies to reduce environmental trigger exposure, resource
      linkage, and community referrals. We describe RI-AIR, and its CHW-led asthma
      education and management interventions. Conclusions: CHWs are effective and vital
      supports for positive asthma outcomes. More research is needed to guide models of
      intervention using CHWs, specifically addressing integration in interdisciplinary
      teams, training, and reimbursement for CHW services. Implications for Impact
      Statement: CHWs are effective in helping children with asthma and their families 
      learn to manage asthma. It is important to develop programs that prepare CHWs to 
      work with other medical professionals and health care models to pay for their
      services.
FAU - Coutinho, Maria Teresa
AU  - Coutinho MT
AD  - Bradley/Hasbro Children's Research Center, Warren Alpert Medical School of Brown 
      University.
FAU - Subzwari, Sumera S
AU  - Subzwari SS
AD  - Brown University.
FAU - McQuaid, Elizabeth L
AU  - McQuaid EL
AD  - Bradley/Hasbro Children's Research Center, Warren Alpert Medical School of Brown 
      University.
FAU - Koinis-Mitchell, Daphne
AU  - Koinis-Mitchell D
AD  - Bradley/Hasbro Children's Research Center, Warren Alpert Medical School of Brown 
      University.
LA  - eng
GR  - R01 MD012225/MD/NIMHD NIH HHS/United States
GR  - U01 HL138677/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Clin Pract Pediatr Psychol
JT  - Clinical practice in pediatric psychology
JID - 101607240
PMC - PMC9053383
MID - NIHMS1713299
OTO - NOTNLM
OT  - asthma management
OT  - community health workers
OT  - pediatric asthma
EDAT- 2020/06/01 00:00
MHDA- 2020/06/01 00:01
CRDT- 2022/05/02 07:15
PHST- 2022/05/02 07:15 [entrez]
PHST- 2020/06/01 00:00 [pubmed]
PHST- 2020/06/01 00:01 [medline]
AID - 10.1037/cpp0000319 [doi]
PST - ppublish
SO  - Clin Pract Pediatr Psychol. 2020 Jun;8(2):195-210. doi: 10.1037/cpp0000319.


PMID- 32473546
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1878-013X (Electronic)
IS  - 1878-013X (Linking)
VI  - 51
DP  - 2020 Jul
TI  - Accountability issues in an English emergency department: A nursing perspective.
PG  - 100881
LID - S1755-599X(20)30053-7 [pii]
LID - 10.1016/j.ienj.2020.100881 [doi]
AB  - INTRODUCTION: Nurses confront doubts about their accountability and how it
      affects their clinical practice daily in the complex environment of an emergency 
      department. Therefore, nurses' experiences can provide vital information about
      the decisions and dilemmas in clinical practice that affect both healthcare
      professionals and patients alike. AIM: The aim of this study was to explore the
      perceptions of nursing staff in an English emergency department in relation to
      their ethical, legal and professional accountability. METHODS: Ethnographic
      content analysis was used to analyse 34 semi-structured interviews from
      registered nurses working in an emergency department. RESULTS: There were five
      categories found during the coding process: nursing care, staff interactions,
      legal and professional accountability, decision-making process and ethics and
      values. CONCLUSION: Several issues related to nursing accountability were found, 
      including the effects of nursing shortages and the reasoning behind
      multidiscipinary team conflicts. Different approaches of individual and
      institutional accountability, the evolution of Benner's nursing model and nursing
      value progression was also identified as key issues. All these phenomena affect
      nursing accountability in different ways, so their comprehension is paramount to 
      understand and influence them to benefit both patients and nurses.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Rubio-Navarro, Alfonso
AU  - Rubio-Navarro A
AD  - Emergency Department, University Hospitals of Leicester NHS Trust, Leicester LE1 
      5WW, United Kingdom. Electronic address: alfonso.rubio.navarro@gmail.com.
FAU - Jose Garcia-Capilla, Diego
AU  - Jose Garcia-Capilla D
AD  - Philosophy Faculty, University of Murcia, Campus Universitario Street, 30100
      Murcia, Spain. Electronic address: djgarcia@um.es.
FAU - Jose Torralba-Madrid, Maria
AU  - Jose Torralba-Madrid M
AD  - Nursing Faculty, University of Murcia, Campus Universitario Street, 30100 Murcia,
      Spain. Electronic address: mjtorral@um.es.
FAU - Rutty, Jane
AU  - Rutty J
AD  - Faculty of Health and Life Sciences, De Montfort University, LE1 9BH Leicester,
      United Kingdom. Electronic address: jrutty@dmu.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - Int Emerg Nurs
JT  - International emergency nursing
JID - 101472191
MH  - Decision Making
MH  - *Emergency Nursing
MH  - *Emergency Service, Hospital
MH  - England
MH  - Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Motivation
MH  - Nurse-Patient Relations
MH  - *Nursing Staff, Hospital
MH  - *Social Responsibility
MH  - State Medicine
OTO - NOTNLM
OT  - *Accountability
OT  - *Decision making
OT  - *Emergency nursing
OT  - *Motivation
OT  - *Nurse-patient relationship
OT  - *Work conditions
EDAT- 2020/05/31 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/31 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - S1755-599X(20)30053-7 [pii]
AID - 10.1016/j.ienj.2020.100881 [doi]
PST - ppublish
SO  - Int Emerg Nurs. 2020 Jul;51:100881. doi: 10.1016/j.ienj.2020.100881. Epub 2020
      May 27.


PMID- 32473197
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 231
IP  - 2
DP  - 2020 Aug
TI  - Pediatric Modification of the Medically Necessary, Time-Sensitive Scoring System 
      for Operating Room Procedure Prioritization During the COVID-19 Pandemic.
PG  - 205-215
LID - S1072-7515(20)30430-0 [pii]
LID - 10.1016/j.jamcollsurg.2020.05.015 [doi]
AB  - BACKGROUND: The COVID-19 pandemic forced surgeons to reconsider concepts of
      "elective" operations. Perceptions about the time sensitivity and medical
      necessity of a procedure have taken on greater significance during the pandemic. 
      The evolving ethical and clinical environment requires reappraisal of
      perioperative factors, such as personal protective equipment conservation;
      limiting the risk of exposure to COVID-19 for patients, families, and healthcare 
      workers; preservation of hospital beds and ICU resources; and minimizing
      COVID-19-related perioperative risk to patients. STUDY DESIGN: A scaffold for the
      complex decision-making required for prioritization of medically necessary,
      time-sensitive (MeNTS) operations was developed for adult patients by colleagues 
      at the University of Chicago. Although adult MeNTS scoring can be applied across 
      adult surgical specialties, some variables were irrelevant in a pediatric
      population. Pediatric manifestations of chronic diseases and congenital anomalies
      were not accounted for. To account for the unique challenges children face, we
      modified the adult MeNTS system for use across pediatric subspecialties. RESULTS:
      This pediatric MeNTS scoring system was applied to 101 cases both performed and
      deferred between March 23 and April 19, 2020 at the University of Chicago Comer
      Children's Hospital. The pediatric MeNTS scores provide a safe, equitable,
      transparent, and ethical strategy to prioritize children's surgical procedures.
      CONCLUSIONS: This process is adaptable to individual institutions and we project 
      it will be useful during the acute phase of the pandemic (maximal limitations),
      as well as the anticipated recovery phase.
CI  - Copyright (c) 2020 American College of Surgeons. Published by Elsevier Inc. All
      rights reserved.
FAU - Slidell, Mark B
AU  - Slidell MB
AD  - Sections of Pediatric Surgery, University of Chicago Medicine and Biological
      Sciences, Chicago, IL; Department of Surgery, University of Chicago Medicine and 
      Biological Sciences, Chicago, IL. Electronic address:
      mslidell@surgery.bsd.uchicago.edu.
FAU - Kandel, Jessica J
AU  - Kandel JJ
AD  - Sections of Pediatric Surgery, University of Chicago Medicine and Biological
      Sciences, Chicago, IL; Department of Surgery, University of Chicago Medicine and 
      Biological Sciences, Chicago, IL.
FAU - Prachand, Vivek
AU  - Prachand V
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Baroody, Fuad M
AU  - Baroody FM
AD  - Otolaryngology, University of Chicago Medicine and Biological Sciences, Chicago, 
      IL; Department of Surgery, University of Chicago Medicine and Biological
      Sciences, Chicago, IL.
FAU - Gundeti, Mohan S
AU  - Gundeti MS
AD  - Urology, University of Chicago Medicine and Biological Sciences, Chicago, IL;
      Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Reid, Russell R
AU  - Reid RR
AD  - Plastic Surgery, University of Chicago Medicine and Biological Sciences, Chicago,
      IL; Department of Surgery, University of Chicago Medicine and Biological
      Sciences, Chicago, IL.
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Matthews, Jeffrey B
AU  - Matthews JB
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Mak, Grace Z
AU  - Mak GZ
AD  - Sections of Pediatric Surgery, University of Chicago Medicine and Biological
      Sciences, Chicago, IL; Department of Surgery, University of Chicago Medicine and 
      Biological Sciences, Chicago, IL.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/*epidemiology
MH  - Cross Infection/prevention & control
MH  - *Decision Making
MH  - *Elective Surgical Procedures
MH  - Humans
MH  - Infection Control/*methods
MH  - Infectious Disease Transmission, Patient-to-Professional/prevention & control
MH  - *Operating Rooms
MH  - Pandemics
MH  - *Patient Selection
MH  - Personal Protective Equipment/supply & distribution
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Surgery Department, Hospital/*organization & administration
PMC - PMC7251404
EDAT- 2020/05/31 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - S1072-7515(20)30430-0 [pii]
AID - 10.1016/j.jamcollsurg.2020.05.015 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Aug;231(2):205-215. doi: 10.1016/j.jamcollsurg.2020.05.015. 
      Epub 2020 May 27.


PMID- 32472695
OWN - NLM
STAT- MEDLINE
DCOM- 20211111
LR  - 20211111
IS  - 1526-4610 (Electronic)
IS  - 0017-8748 (Linking)
VI  - 60
IP  - 9
DP  - 2020 Oct
TI  - Practical Professional Ethics in Headache Medicine.
PG  - 2053-2058
LID - 10.1111/head.13844 [doi]
FAU - Levin, Morris
AU  - Levin M
AD  - University of California, San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200530
PL  - United States
TA  - Headache
JT  - Headache
JID - 2985091R
SB  - IM
EIN - Headache. 2020 Nov;60(10):2669. PMID: 33249590
MH  - American Medical Association
MH  - *Burnout, Professional
MH  - *Conflict of Interest
MH  - *Ethics, Medical
MH  - *Headache Disorders
MH  - Humans
MH  - *Medical Errors
MH  - *Physicians
MH  - *Practice Guidelines as Topic/standards
MH  - United States
OTO - NOTNLM
OT  - burnout
OT  - conflict of interest
OT  - ethics
OT  - professionalism
EDAT- 2020/05/31 06:00
MHDA- 2021/11/12 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/11/12 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - 10.1111/head.13844 [doi]
PST - ppublish
SO  - Headache. 2020 Oct;60(9):2053-2058. doi: 10.1111/head.13844. Epub 2020 May 30.


PMID- 32472668
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 2162-3279 (Electronic)
VI  - 10
IP  - 7
DP  - 2020 Jul
TI  - Limb-shaking transient ischemic attack with facial muscles involuntary twitch
      successfully treated with internal carotid artery stenting.
PG  - e01679
LID - 10.1002/brb3.1679 [doi]
AB  - INTRODUCTION: Limb-shaking transient ischemic attack (LS-TIA) is a clinical
      disease with severe carotid stenosis, which is characterized by unilateral
      rhythmic dance or tremor like involuntary movements of arms and/or legs, but
      facial muscles are usually unaffected. METHODS: Today, we report a 42-year-old
      man with transient ischemic attack who suffered from right limb shaking and right
      facial muscle twitching due to the obvious stenosis of left internal carotid
      artery (ICA). Written informed consent was obtained from participants according
      to the Declaration of Helsinki, and a local ethic committee approved the study.
      ICA angioplasty and stent implantation were performed as treatment attempts. A
      brain protection device was navigated through the lesion and placed at the distal
      end of the stenosis. RESULT: The patient successfully completed the
      recanalization through stent placement, and the involuntary shaking of limbs and 
      face was improved. During the 3-month follow-up, the patient's symptoms
      disappeared completely and did not attack again. CONCLUSION: This case report
      highlights the importance of accurate diagnosis and treatment, because
      treatment-related carotid artery occlusion can not only eliminate the attack, but
      also reduce the risk of future stroke.
CI  - (c) 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
FAU - Han, Yuan-Yuan
AU  - Han YY
AUID- ORCID: 0000-0002-2564-9872
AD  - Department of Neurology, Suqian First Hospital, Suqian, China.
FAU - Qi, Dong
AU  - Qi D
AD  - Department of Neurology, Suqian First Hospital, Suqian, China.
FAU - Chen, Xiao-Dong
AU  - Chen XD
AD  - Department of Neurology, Suqian First Hospital, Suqian, China.
FAU - Song, Chun-Jie
AU  - Song CJ
AD  - Department of Neurology, Suqian First Hospital, Suqian, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200530
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
SB  - IM
MH  - Adult
MH  - Carotid Artery, Internal/diagnostic imaging/surgery
MH  - *Carotid Stenosis/complications/diagnostic imaging/therapy
MH  - Facial Muscles
MH  - Humans
MH  - *Ischemic Attack, Transient/etiology/therapy
MH  - Male
MH  - Stents
MH  - Tremor/etiology/therapy
PMC - PMC7375045
OTO - NOTNLM
OT  - *angioplasty
OT  - *carotid stenosis
OT  - *internal carotid artery
OT  - *limb-shaking transient ischemic attack
EDAT- 2020/05/31 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/01/25 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - 10.1002/brb3.1679 [doi]
PST - ppublish
SO  - Brain Behav. 2020 Jul;10(7):e01679. doi: 10.1002/brb3.1679. Epub 2020 May 30.


PMID- 32472584
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210310
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 29
IP  - 23-24
DP  - 2020 Dec
TI  - "I can't stop thinking about it": Schwartz Rounds((R)) an intervention to support
      students and higher education staff with emotional, social and ethical
      experiences at work.
PG  - 4421-4424
LID - 10.1111/jocn.15354 [doi]
FAU - Jakimowicz, Samantha
AU  - Jakimowicz S
AUID- ORCID: 0000-0002-3029-4252
AD  - School of Nursing and Midwifery, Faculty of Health, University of Technology
      Sydney, Ultimo, NSW, Australia.
FAU - Maben, Jill
AU  - Maben J
AD  - Faculty of Health and Medical Sciences, School of Health Sciences, University of 
      Surrey, Surrey, UK.
AD  - University of Technology Sydney, NSW and Murdoch University, Perth, WA,
      Australia.
LA  - eng
GR  - 13/07/49/DH_/Department of Health/United Kingdom
PT  - Editorial
DEP - 20200614
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
EDAT- 2020/05/31 06:00
MHDA- 2020/05/31 06:01
CRDT- 2020/05/31 06:00
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/05/31 06:01 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - 10.1111/jocn.15354 [doi]
PST - ppublish
SO  - J Clin Nurs. 2020 Dec;29(23-24):4421-4424. doi: 10.1111/jocn.15354. Epub 2020 Jun
      14.


PMID- 32472449
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1573-6814 (Electronic)
IS  - 1389-9333 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Sep
TI  - Human bone and amniotic membrane banking in Bangladesh for grafting: the impact
      of the international atomic energy agency (IAEA) programme.
PG  - 523-533
LID - 10.1007/s10561-020-09839-y [doi]
AB  - The idea of establishing a human tissue bank in Bangladesh was started in 1985.
      However, in 2003, with the active cooperation of international atomic energy
      agency (IAEA) and Bangladesh Atomic Energy Commission, a tissue bank laboratory
      was upgraded as a unit for tissue banking and research. Due to increasing demand 
      of allograft, this unit was transformed as an independent institute "Institute of
      Tissue Banking and Biomaterial Research (ITBBR)" in 2016. This is the only human 
      tissue bank in Bangladesh, which processes human bone and amniotic membrane to
      provide safe and cost-effective allografts for transplantation. Importantly,
      banking of human cranial bone as autograft has also started at ITBBR. These
      processed grafts are sterilized using gamma radiation according to the IAEA Code 
      of Practice for the radiation sterilization of tissues allografts. The amount of 
      grafts produced by the ITBBR from 2007 to 2018 were 120,800 cc of bone chips,
      45,420 cm(2) of amniotic membranes, 277 vials of de-mineralized bone granules
      (DMB), 95 pieces of massive bones, and 134 pieces of cranial bones. Overall,
      112,748 cc of bone chips, 40,339 cm(2) of amniotic membranes, 174 vials of DMB,
      44 pieces of massive bones, and 64 pieces of cranial bones were transplanted
      successfully. Nevertheless, to cope up with the modern advanced concepts of cell 
      and tissue banking for therapeutic purpose, ITBBR is working to set up facilities
      for skin banking, stem cells banking including amniotic and cord blood derived
      stem cells and scaffold designing. To ensure the quality, safety, ethical and
      regulatory issues are sustainable in cell and tissue banking practices, ITBBR
      always works with the Government of Bangladesh for enhancing the national tissue 
      transplantation programme within the contemporary facilities.
FAU - Zahid, Hasan M
AU  - Zahid HM
AUID- ORCID: http://orcid.org/0000-0001-8619-9812
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh. zahid_bmb@baec.gov.bd.
FAU - Rahman, Md Shaifur
AU  - Rahman MS
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
AD  - Institute for Stem Cell Research and Regenerative Medicine, University Hospital
      Dusseldorf, Heinrich Heine University, 40225, Dusseldorf, Germany.
FAU - Diba, Farzana
AU  - Diba F
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
FAU - Hossain, Md Liakat
AU  - Hossain ML
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
FAU - Akhtar, Naznin
AU  - Akhtar N
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
FAU - Siddika, Ayesha
AU  - Siddika A
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
FAU - Adnan, Md Hasib
AU  - Adnan MH
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
FAU - Jorge, Morales Pedraza
AU  - Jorge MP
AD  - Morales Project Consulting, Wien, Austria.
FAU - Asaduzzaman, Sikder M
AU  - Asaduzzaman SM
AD  - Institute of Tissue Banking and Biomaterial Research, Atomic Energy Research
      Establishment, Dhaka, 1349, Bangladesh.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Netherlands
TA  - Cell Tissue Bank
JT  - Cell and tissue banking
JID - 100965121
SB  - IM
MH  - Allografts/physiology
MH  - Amnion/*transplantation
MH  - Bangladesh
MH  - *Bone Transplantation
MH  - Hospitals
MH  - Humans
MH  - *International Agencies
MH  - Nuclear Energy
MH  - Quality Control
MH  - Radiation
MH  - Sterilization
MH  - *Tissue Banks/ethics/legislation & jurisprudence
MH  - Tissue Donors
MH  - Tissue and Organ Harvesting
OTO - NOTNLM
OT  - Amniotic membrane allografts
OT  - Bangladesh
OT  - Bone allografts
OT  - Human tissue bank
OT  - IAEA
OT  - Irradiation
EDAT- 2020/05/31 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - 10.1007/s10561-020-09839-y [doi]
AID - 10.1007/s10561-020-09839-y [pii]
PST - ppublish
SO  - Cell Tissue Bank. 2020 Sep;21(3):523-533. doi: 10.1007/s10561-020-09839-y. Epub
      2020 May 29.


PMID- 32472125
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201023
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Jun 1
TI  - Erratum. Ethics beyond ethics.
PG  - 1475
LID - 10.1093/humrep/deaa059 [doi]
FAU - Lambalk, C B
AU  - Lambalk CB
FAU - Van Wely, M
AU  - Van Wely M
FAU - Kirkegaard, K
AU  - Kirkegaard K
FAU - De Geyter, C
AU  - De Geyter C
LA  - eng
PT  - Journal Article
PT  - Published Erratum
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
EFR - Hum Reprod. 2020 Jan 1;35(1):1-2. PMID: 31886856
EDAT- 2020/05/31 06:00
MHDA- 2020/05/31 06:01
CRDT- 2020/05/31 06:00
PHST- 2019/02/12 00:00 [received]
PHST- 2019/09/19 00:00 [revised]
PHST- 2019/10/23 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/05/31 06:01 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - 5846207 [pii]
AID - 10.1093/humrep/deaa059 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Jun 1;35(6):1475. doi: 10.1093/humrep/deaa059.


PMID- 32471955
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Pandemic medical ethics.
PG  - 353-354
LID - 10.1136/medethics-2020-106431 [doi]
FAU - Blumenthal-Barby, Jennifer
AU  - Blumenthal-Barby J
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas, USA.
FAU - Boyd, Kenneth
AU  - Boyd K
AD  - Biomedical Teaching Organisation, Edinburgh University, Edinburgh, UK.
FAU - Earp, Brian D
AU  - Earp BD
AD  - Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
FAU - Frith, Lucy
AU  - Frith L
AUID- ORCID: 0000-0002-8506-0699
AD  - Health Services Research, University of Liverpool, Liverpool, UK.
FAU - McDougall, Rosalind J
AU  - McDougall RJ
AUID- ORCID: 0000-0002-3809-2575
AD  - Centre for Health Equity, Melbourne School of Population and Global Health,
      University of Melbourne, Melbourne, Victoria, Australia.
AD  - Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria,
      Australia.
FAU - McMillan, John
AU  - McMillan J
AD  - Bioethics Centre, University of Otago, Dunedin, New Zealand
      john.r.mcmillan68@gmail.com.
FAU - Wall, Jesse
AU  - Wall J
AD  - Faculty of Law, University of Auckland, Auckland, New Zealand.
LA  - eng
PT  - Editorial
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Ethics, Medical
MH  - Humans
MH  - *Influenza, Human/epidemiology
MH  - *Pandemics
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/31 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - medethics-2020-106431 [pii]
AID - 10.1136/medethics-2020-106431 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):353-354. doi: 10.1136/medethics-2020-106431.


PMID- 32471954
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Navigating difficult decisions in medical care and research.
PG  - 351-352
LID - 10.1136/medethics-2020-106410 [doi]
FAU - McDougall, Rosalind J
AU  - McDougall RJ
AUID- ORCID: 0000-0002-3809-2575
AD  - Centre for Health Equity, Melbourne School of Population and Global Health,
      University of Melbourne, Melbourne, Victoria, Australia rmcdo@unimelb.edu.au.
LA  - eng
PT  - Introductory Journal Article
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Ethics Committees
MH  - *Ethics Committees, Clinical
MH  - *Ethics Consultation
MH  - Humans
OTO - NOTNLM
OT  - *ethics
OT  - *ethics committees/consultation
COIS- Competing interests: None declared.
EDAT- 2020/05/31 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - medethics-2020-106410 [pii]
AID - 10.1136/medethics-2020-106410 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):351-352. doi: 10.1136/medethics-2020-106410.


PMID- 32471920
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1532-8651 (Electronic)
IS  - 1098-7339 (Linking)
VI  - 45
IP  - 7
DP  - 2020 Jul
TI  - Daring discourse - no: cannabinoids should not be used for acute postoperative
      pain management.
PG  - 520-523
LID - 10.1136/rapm-2020-101475 [doi]
AB  - As anesthesiologists and acute pain medicine specialists, we will care for
      patients in the perioperative period who use cannabinoids for chronic pain and/or
      marijuana recreationally. We will have to address difficult questions from
      patients regarding the potential applications for cannabinoids in acute pain
      management. While we must remain compassionate and understand our patients'
      desire to find relief from suffering using available non-opioid medications, we
      are ethically bound to do no harm and provide them with treatment options
      supported by the best available evidence. Today, we cannot support cannabinoids
      in the management of acute postoperative pain.
CI  - (c) American Society of Regional Anesthesia & Pain Medicine 2020. No commercial
      re-use. See rights and permissions. Published by BMJ.
FAU - Meeker, Jennifer D
AU  - Meeker JD
AD  - Department of Anesthesiology, University of Southern California Keck School of
      Medicine, Los Angeles, California, USA.
FAU - Ayrian, Eugenia
AU  - Ayrian E
AD  - Department of Anesthesiology, University of Southern California Keck School of
      Medicine, Los Angeles, California, USA.
FAU - Mariano, Edward R
AU  - Mariano ER
AUID- ORCID: 0000-0003-2735-248X
AD  - Anesthesiology and Perioperative Care Service, VA Palo Alto Health Care System,
      Palo Alto, California, USA emariano@stanford.edu.
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Stanford
      University School of Medicine, Stanford, California, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200528
PL  - England
TA  - Reg Anesth Pain Med
JT  - Regional anesthesia and pain medicine
JID - 9804508
RN  - 0 (Analgesics)
RN  - 0 (Cannabinoids)
SB  - IM
CON - Reg Anesth Pain Med. 2020 Jul;45(7):509-519. PMID: 32471924
EIN - Reg Anesth Pain Med. 2020 Nov;45(11):e3. PMID: 33087583
MH  - *Acute Pain/diagnosis/drug therapy
MH  - Analgesics/adverse effects
MH  - *Cannabinoids/adverse effects
MH  - Humans
MH  - Pain Management
MH  - Pain, Postoperative/diagnosis/drug therapy
OTO - NOTNLM
OT  - *Pain, postoperative
OT  - *analgesia
OT  - *complementary therapies
COIS- Competing interests: None declared.
EDAT- 2020/05/31 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - rapm-2020-101475 [pii]
AID - 10.1136/rapm-2020-101475 [doi]
PST - ppublish
SO  - Reg Anesth Pain Med. 2020 Jul;45(7):520-523. doi: 10.1136/rapm-2020-101475. Epub 
      2020 May 28.


PMID- 32471893
OWN - NLM
STAT- MEDLINE
DCOM- 20200605
LR  - 20201218
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 May 29
TI  - Covid-19: the ethics of clinical research in quarantine.
PG  - m2060
LID - 10.1136/bmj.m2060 [doi]
FAU - Evans, Nicholas G
AU  - Evans NG
AD  - Department of Philosophy, University of Massachusetts Lowell, 883 Broadway
      Street, Dugan 200F, Lowell MA 01852, USA.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Ethics, Medical
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Quarantine
MH  - SARS-CoV-2
MH  - Vulnerable Populations
COIS- Competing interests: I have read and understood BMJ policy on competing interests
      and have none to declare.
EDAT- 2020/05/31 06:00
MHDA- 2020/06/06 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/06/06 06:00 [medline]
AID - 10.1136/bmj.m2060 [doi]
PST - epublish
SO  - BMJ. 2020 May 29;369:m2060. doi: 10.1136/bmj.m2060.


PMID- 32471766
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20210110
IS  - 1878-0539 (Electronic)
IS  - 1748-6815 (Linking)
VI  - 73
IP  - 7
DP  - 2020 Jul
TI  - Economic implications of the COVID-19 pandemic on the plastic surgery community.
PG  - 1357-1404
LID - S1748-6815(20)30216-3 [pii]
LID - 10.1016/j.bjps.2020.05.030 [doi]
FAU - Inglesby, Dani C
AU  - Inglesby DC
AD  - Medical University of South Carolina College of Medicine, 96 Jonathan Lucas St,
      Charleston, Charleston, SC, United States. Electronic address:
      inglesbyeras@gmail.com.
FAU - Boyd, Carter J
AU  - Boyd CJ
AD  - School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United
      States; Collat School of Business, University of Alabama at Birmingham,
      Birmingham, AL, United States.
LA  - eng
PT  - Letter
DEP - 20200523
PL  - Netherlands
TA  - J Plast Reconstr Aesthet Surg
JT  - Journal of plastic, reconstructive & aesthetic surgery : JPRAS
JID - 101264239
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*economics/epidemiology/prevention & control
MH  - Elective Surgical Procedures/*economics
MH  - Global Health
MH  - Humans
MH  - Pandemics/*economics/prevention & control
MH  - Pneumonia, Viral/*economics/epidemiology/prevention & control
MH  - Reconstructive Surgical Procedures/*economics
MH  - SARS-CoV-2
MH  - Surgery, Plastic/*economics
MH  - United States/epidemiology
PMC - PMC7244428
OTO - NOTNLM
OT  - *Business administration
OT  - *Covid-19
OT  - *Elective plastic surgery
OT  - *Plastic surgery ethics
OT  - *Social-distancing
COIS- Declaration of Competing Interest None
EDAT- 2020/05/31 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/04/19 00:00 [received]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - S1748-6815(20)30216-3 [pii]
AID - 10.1016/j.bjps.2020.05.030 [doi]
PST - ppublish
SO  - J Plast Reconstr Aesthet Surg. 2020 Jul;73(7):1357-1404. doi:
      10.1016/j.bjps.2020.05.030. Epub 2020 May 23.


PMID- 32471696
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210216
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 29
IP  - 6
DP  - 2020 Jun
TI  - Consensus guidelines for interventional cardiology services delivery during
      covid-19 pandemic in Australia and new Zealand.
PG  - e69-e77
LID - S1443-9506(20)30126-8 [pii]
LID - 10.1016/j.hlc.2020.04.002 [doi]
AB  - The global coronavirus disease (COVID-19) pandemic poses an unprecedented stress 
      on healthcare systems internationally. These Health system-wide demands call for 
      efficient utilisation of resources at this time in a fair, consistent, ethical
      and efficient manner would improve our ability to treat patients. Excellent
      co-operation between hospital units (especially intensive care unit [ICU],
      emergency department [ED] and cardiology) is critical in ensuring optimal patient
      outcomes. The purpose of this document is to provide practical guidelines for the
      effective use of interventional cardiology services in Australia and New Zealand.
      The document will be updated regularly as new evidence and knowledge is gained
      with time. Goals Considerations.
CI  - Copyright (c) 2020.
FAU - Lo, S T H
AU  - Lo STH
AD  - Department of Cardiology, Liverpool Hospital, NSW, Australia. Electronic address:
      Intervention@csanz.edu.au.
FAU - Yong, A S
AU  - Yong AS
AD  - Department of Cardiology, Concord Repatriation General Hospital, NSW, Australia; 
      University of Sydney, Australia.
FAU - Sinhal, A
AU  - Sinhal A
AD  - Flinders Medical Centre, SA, Australia.
FAU - Shetty, S
AU  - Shetty S
AD  - Department of Cardiology, Fiona Stanley Hospital, WA, Australia.
FAU - McCann, A
AU  - McCann A
AD  - Department of Cardiology, Princess Alexandra Hospital, QLD, Australia; University
      of Queensland, Australia.
FAU - Clark, D
AU  - Clark D
AD  - Department of Cardiology, Austin Hospital, VIC, Australia.
FAU - Galligan, L
AU  - Galligan L
AD  - Department of Cardiology, Royal Hobart Hospital, TAS, Australia.
FAU - El-Jack, S
AU  - El-Jack S
AD  - Department of Cardiology, North Shore Hospital, New Zealand.
FAU - Sader, M
AU  - Sader M
AD  - University of Sydney, Australia; Department of Cardiology, St George Hospital,
      NSW, Australia.
FAU - Tan, R
AU  - Tan R
AD  - Department of Cardiology, The Canberra Hospital, ACT, Australia.
FAU - Hallani, H
AU  - Hallani H
AD  - Department of Cardiology, The Canberra Hospital, ACT, Australia.
FAU - Barlis, P
AU  - Barlis P
AD  - Department of Cardiology, Nepean Hospital, NSW, Australia; Department of
      Cardiology, The Northern Hospital, VIC, Australia; Department of Cardiology, St
      Vincents' Hospital, VIC, Australia; University of Melbourne, VIC, Australia.
FAU - Sechi, R
AU  - Sechi R
AD  - Department of Nursing, Liverpool Hospital, NSW, Australia.
FAU - Dictado, E
AU  - Dictado E
AD  - Department of Nursing, Liverpool Hospital, NSW, Australia.
FAU - Walton, A
AU  - Walton A
AD  - Department of Cardiology, Alfred Hospital, VIC, Australia; Monash University,
      VIC, Australia.
FAU - Starmer, G
AU  - Starmer G
AD  - Department of Cardiology, Cairns Hospital, QLD, Australia.
FAU - Bhagwandeen, R
AU  - Bhagwandeen R
AD  - Department of Cardiology, John Hunter Hospital, NSW, Australia; Lake Macquarie
      Private Hospital, NSW, Australia.
FAU - Leung, D Y
AU  - Leung DY
AD  - Department of Cardiology, Liverpool Hospital, NSW, Australia; University of New
      South Wales, NSW, Australia.
FAU - Juergens, C P
AU  - Juergens CP
AD  - Department of Cardiology, Liverpool Hospital, NSW, Australia; University of New
      South Wales, NSW, Australia.
FAU - Bhindi, R
AU  - Bhindi R
AD  - University of Sydney, Australia; Department of Cardiology, Royal North Shore
      Hospital, NSW, Australia.
FAU - Muller, D W M
AU  - Muller DWM
AD  - University of New South Wales, NSW, Australia; St Vincent's Hospital, NSW,
      Australia.
FAU - Rajaratnum, R
AU  - Rajaratnum R
AD  - Department of Cardiology, Liverpool Hospital, NSW, Australia; University of New
      South Wales, NSW, Australia; Western Sydney University, NSW, Australia.
FAU - French, J K
AU  - French JK
AD  - Department of Cardiology, Liverpool Hospital, NSW, Australia; University of New
      South Wales, NSW, Australia; Western Sydney University, NSW, Australia.
FAU - Kritharides, L
AU  - Kritharides L
AD  - Department of Cardiology, Concord Repatriation General Hospital, NSW, Australia; 
      University of Sydney, Australia; ANZAC Medical Research Institute, Australia.
CN  - Interventional council of CSANZ and COVID-19 Interventional cardiology working
      group
LA  - eng
PT  - Letter
DEP - 20200506
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
SB  - IM
CIN - Heart Lung Circ. 2020 Aug;29(8):1260-1261. PMID: 32646639
MH  - Australia/epidemiology
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiology/standards
MH  - *Consensus
MH  - *Coronavirus Infections/epidemiology/physiopathology/therapy
MH  - *Critical Care
MH  - Humans
MH  - *Intensive Care Units
MH  - New Zealand/epidemiology
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/physiopathology/therapy
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
PMC - PMC7202321
OTO - NOTNLM
OT  - COVID-19
OT  - acute coronary syndromes
OT  - catheter laboratory
OT  - fibrinolysis
OT  - interventional cardiology
OT  - structural interventions
EDAT- 2020/05/31 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2020/05/31 06:00 [entrez]
AID - S1443-9506(20)30126-8 [pii]
AID - 10.1016/j.hlc.2020.04.002 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2020 Jun;29(6):e69-e77. doi: 10.1016/j.hlc.2020.04.002. Epub
      2020 May 6.


PMID- 32471504
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 29
TI  - Self-evaluated ethical competence of a practicing physiotherapist: a national
      study in Finland.
PG  - 43
LID - 10.1186/s12910-020-00469-3 [doi]
AB  - BACKGROUND: Patients have the right to equal, respectful treatment. Nowadays, one
      third of patient complaints concern health care staff's behavior towards
      patients. Ethically safe care requires ethical competence, which has been
      addressed as a core competence in physiotherapy. It has been defined in terms of 
      character strength, ethical awareness, moral judgment skills in decision-making, 
      and willingness to do good. The purpose of this study was to analyze the ethical 
      competence of practicing physiotherapists. METHOD: A self-evaluation instrument
      (Physiotherapist's Ethical Competence Evaluation Tool) based on an analysis of a 
      concept "ethical competence" was constructed in 2016 and physiotherapists (n =
      839), working in public health services or private practice responded to the
      questionnaire. RESULTS: Based on the results, most of the physiotherapists
      evaluated themselves highly ethically competent in all areas of ethical
      competence, subscales being Strength, Awareness, Skills and Will. Willingness to 
      do good was evaluated as highest, while character strength, including the
      strength to support ethical processes and speak on behalf of the patient, was
      evaluated the lowest. Physiotherapists most commonly consult a colleague when
      encountering an ethical problem. Other methods for problem solving are not very
      familiar, neither are the international or national ethical codes of conduct.
      CONCLUSIONS: This was the first attempt to assess all aspects of ethical
      competence empirically in a clinical environment in physiotherapy, using a novel 
      self-evaluation instrument. Even if physiotherapists evaluate themselves as
      competent in ethics, further exploration is needed for ethical awareness. Also
      the patients' viewpoints about ethically competent care should be considered, to 
      better ensure ethical safety of the patient.
FAU - Kulju, Kati
AU  - Kulju K
AUID- ORCID: 0000-0001-6874-5592
AD  - Department of Nursing Science, University of Turku, FI-20014, Turku, Finland.
      kati.kulju@utu.fi.
FAU - Suhonen, Riitta
AU  - Suhonen R
AUID- ORCID: 0000-0002-4315-5550
AD  - Department of Nursing Science/ Turku University Hospital and City of Turku,
      Welfare Division, University of Turku, Turku, Finland.
FAU - Puukka, Pauli
AU  - Puukka P
AD  - National Institute for Health and Welfare, Turku, Finland.
FAU - Tolvanen, Anna
AU  - Tolvanen A
AD  - Department of Nursing Science, University of Turku, FI-20014, Turku, Finland.
FAU - Leino-Kilpi, Helena
AU  - Leino-Kilpi H
AUID- ORCID: 0000-0003-2477-971X
AD  - Department of Nursing Science, Turku University Hospital, University of Turku,
      Turku, Finland.
LA  - eng
GR  - -/Finnish Association of Physiotherapists/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200529
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Clinical Competence
MH  - Codes of Ethics
MH  - Finland
MH  - Humans
MH  - *Physical Therapists
MH  - Surveys and Questionnaires
PMC - PMC7257238
OTO - NOTNLM
OT  - *Character strength
OT  - *Ethical awareness
OT  - *Ethical competence
OT  - *PECET
OT  - *Physiotherapy
OT  - *Self-evaluation
EDAT- 2020/05/31 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/31 06:00
PHST- 2019/09/09 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1186/s12910-020-00469-3 [doi]
AID - 10.1186/s12910-020-00469-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 29;21(1):43. doi: 10.1186/s12910-020-00469-3.


PMID- 32471488
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20220414
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 29
TI  - An under-represented and underserved population in trials: methodological,
      structural, and systemic barriers to the inclusion of adults lacking capacity to 
      consent.
PG  - 445
LID - 10.1186/s13063-020-04406-y [doi]
AB  - BACKGROUND: There is increasing international recognition that populations
      included in trials should adequately represent the population treated in clinical
      practice; however, adults who lack the capacity to provide informed consent are
      frequently excluded from trials. Addressing the under-representation of groups
      such as those with impaired capacity to consent is essential to develop effective
      interventions and provide these groups with the opportunity to benefit from
      evidence-based care. While the spotlight has been on ensuring only appropriate
      and justifiable exclusion criteria are used in trials, barriers to the inclusion 
      of adults lacking capacity are multifactorial and complex, and addressing their
      under-representation will require more than merely widening eligibility criteria.
      This commentary draws on the literature exploring the inclusion of adults lacking
      the capacity to consent in research and a number of recent studies to describe
      the methodological, structural, and systemic factors that have been identified.
      MAIN TEXT: A number of potentially modifiable factors contributing to the
      under-representation of adults lacking the capacity to consent in trials have
      been identified. In addition to restrictive eligibility criteria, methodological 
      issues include developing appropriate interventions and outcome measures for
      populations with impaired capacity. Structurally determined factors include the
      resource-intensive nature of these trials, the requirement for more appropriate
      research infrastructure, and a lack of interventions to inform and support proxy 
      decision-makers. Systemic factors include the complexities of the legal
      frameworks, the challenges of ethical review processes, and paternalistic
      attitudes towards protecting adults with incapacity from the perceived harms of
      research. CONCLUSIONS: Measures needed to address under-representation include
      greater scrutiny of exclusion criteria by those reviewing study proposals,
      providing education and training for personnel who design, conduct, and review
      research, ensuring greater consistency in the reviews undertaken by research
      ethics committees, and extending processes for advance planning to include
      prospectively appointing a proxy for research and documenting preferences about
      research participation. Negative societal and professional attitudes towards the 
      inclusion of adults with impaired capacity in research should also be addressed, 
      and the development of trials that are more person-centred should be encouraged. 
      Further work to conceptualise under-representation in trials for such populations
      may also be helpful.
FAU - Shepherd, Victoria
AU  - Shepherd V
AUID- ORCID: http://orcid.org/0000-0002-7687-0817
AD  - Centre for Trials Research, Cardiff University, Cardiff, UK.
      ShepherdVL1@cardiff.ac.uk.
LA  - eng
GR  - NIHR-FS-2016/Health and Care Research Wales
PT  - Letter
DEP - 20200529
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
MH  - Adult
MH  - Decision Making
MH  - Humans
MH  - Information Dissemination/legislation & jurisprudence
MH  - Informed Consent/*legislation & jurisprudence
MH  - Mental Competency/*legislation & jurisprudence
MH  - Randomized Controlled Trials as Topic/*legislation & jurisprudence
MH  - United Kingdom
MH  - Vulnerable Populations
PMC - PMC7257506
OTO - NOTNLM
OT  - Inclusion
OT  - Informed consent
OT  - Mental capacity
OT  - Randomised controlled trials
OT  - Underserved populations
EDAT- 2020/05/31 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/05/31 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - 10.1186/s13063-020-04406-y [doi]
AID - 10.1186/s13063-020-04406-y [pii]
PST - epublish
SO  - Trials. 2020 May 29;21(1):445. doi: 10.1186/s13063-020-04406-y.


PMID- 32471174
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2304-8158 (Print)
IS  - 2304-8158 (Linking)
VI  - 9
IP  - 6
DP  - 2020 May 27
TI  - Clotting Properties of Onopordum tauricum (Willd.) Aqueous Extract in Milk of
      Different Species.
LID - E692 [pii]
LID - 10.3390/foods9060692 [doi]
AB  - Plant proteases used in cheesemaking are easily available and could increase the 
      acceptability of cheeses, otherwise hindered by ethical issues (e.g., religions, 
      dietary habits, aversion to genetically engineered food and food ingredients).
      The milk clotting potential of Onopordum tauricum (Willd.) aqueous extract as an 
      alternative to animal rennet was assessed for the first time in milk of different
      species (ewe, goat, cow). Among the aerial anatomical parts, i.e., receptacle,
      leaves, stems, and flowers, only the latter ones showed clotting properties. A
      response surface methodology (RSM) was used to explore the effects of three
      independent variables (temperature, pH, volume of coagulant) on the milk clotting
      activity (MCA) of the flower extract. A second-order polynomial model adequately 
      described the experimental data and predicted a temperature value of 55 degrees
      C, a pH value of 4.9-5.7, and a volume of coagulant of 300-500 muL (added to 5 mL
      of milk) as optimal conditions to maximize the MCA. At a 35 degrees C temperature
      and natural milk pH of 6.7-6.8, the estimated MCA of the O. tauricum extract was 
      72-87, 69-86, and 75-151, in goat's, ewe's, and cow's milk, respectively. In
      comparison, the MCA of calf rennet was 5.4-4.9, 3.3-14.7, and 4.9-16.7 times
      higher than that of the plant extract in goat's, ewe's, and cow's milk,
      respectively.
FAU - Mozzon, Massimo
AU  - Mozzon M
AUID- ORCID: 0000-0002-5132-5070
AD  - Department of Agricultural, Food and Environmental Sciences, Universita
      Politecnica delle Marche, Via Brecce Bianche 10, 60131 Ancona, Italy.
FAU - Foligni, Roberta
AU  - Foligni R
AD  - Department of Agricultural, Food and Environmental Sciences, Universita
      Politecnica delle Marche, Via Brecce Bianche 10, 60131 Ancona, Italy.
FAU - Mannozzi, Cinzia
AU  - Mannozzi C
AUID- ORCID: 0000-0001-8200-909X
AD  - Department of Agricultural, Food and Environmental Sciences, Universita
      Politecnica delle Marche, Via Brecce Bianche 10, 60131 Ancona, Italy.
FAU - Zamporlini, Federica
AU  - Zamporlini F
AD  - Department of Agricultural, Food and Environmental Sciences, Universita
      Politecnica delle Marche, Via Brecce Bianche 10, 60131 Ancona, Italy.
FAU - Raffaelli, Nadia
AU  - Raffaelli N
AD  - Department of Agricultural, Food and Environmental Sciences, Universita
      Politecnica delle Marche, Via Brecce Bianche 10, 60131 Ancona, Italy.
FAU - Aquilanti, Lucia
AU  - Aquilanti L
AD  - Department of Agricultural, Food and Environmental Sciences, Universita
      Politecnica delle Marche, Via Brecce Bianche 10, 60131 Ancona, Italy.
LA  - eng
GR  - https://veggiemedcheeses.com//Ministero dell'Istruzione, dell'Universita e della 
      Ricerca
PT  - Journal Article
DEP - 20200527
PL  - Switzerland
TA  - Foods
JT  - Foods (Basel, Switzerland)
JID - 101670569
PMC - PMC7353650
OTO - NOTNLM
OT  - Onopordon tauricum
OT  - ewe's milk
OT  - goat's milk
OT  - milk clotting activity
OT  - plant proteases
OT  - rennet
OT  - response surface methodology
OT  - thistle crude extract
OT  - vegetable coagulant
EDAT- 2020/05/31 06:00
MHDA- 2020/05/31 06:01
CRDT- 2020/05/31 06:00
PHST- 2020/05/09 00:00 [received]
PHST- 2020/05/24 00:00 [revised]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2020/05/31 06:01 [medline]
AID - foods9060692 [pii]
AID - 10.3390/foods9060692 [doi]
PST - epublish
SO  - Foods. 2020 May 27;9(6). pii: foods9060692. doi: 10.3390/foods9060692.


PMID- 32471008
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 56
IP  - 6
DP  - 2020 Jun
TI  - Ethical considerations for paediatrics during the COVID-19 pandemic: A discussion
      paper from the Australian Paediatric Clinical Ethics Collaboration.
PG  - 847-851
LID - 10.1111/jpc.14946 [doi]
FAU - Jansen, Melanie
AU  - Jansen M
AD  - Paediatric Intensive Care Unit, Children's Hospital at Westmead, Sydney, New
      South Wales, Australia.
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
FAU - Irving, Helen
AU  - Irving H
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
AD  - Department of Oncology, Queensland Children's Hospital, Brisbane, Queensland,
      Australia.
AD  - Centre for Children's Health Ethics and Law, Children's Health Queensland,
      Brisbane, Queensland, Australia.
FAU - Gillam, Lynn
AU  - Gillam L
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
AD  - Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria,
      Australia.
FAU - Sharwood, Erin
AU  - Sharwood E
AD  - Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
AD  - Centre for Children's Health Ethics and Law, Children's Health Queensland,
      Brisbane, Queensland, Australia.
AD  - Departments of Endocrinology & Oncology, Children's Health Queensland, Brisbane, 
      Queensland, Australia.
FAU - Preisz, Anne
AU  - Preisz A
AUID- ORCID: https://orcid.org/0000-0003-4331-1434
AD  - Clinical Ethics, Sydney Children's Hospital Network, Sydney, New South Wales,
      Australia.
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia.
AD  - School of Medicine, University of Notre Dame, Notre Dame, Indiana, United States.
FAU - Basu, Shreerupa
AU  - Basu S
AD  - Paediatric Intensive Care Unit, Children's Hospital at Westmead, Sydney, New
      South Wales, Australia.
FAU - Delaney, Clare
AU  - Delaney C
AD  - Children's Bioethics Centre, Royal Children's Hospital, Melbourne, Victoria,
      Australia.
FAU - McDougall, Rosalind
AU  - McDougall R
AD  - Melbourne School of Population and Global Health, University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Johnston, Carolyn
AU  - Johnston C
AD  - Melbourne Law School, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Isaacs, David
AU  - Isaacs D
AUID- ORCID: https://orcid.org/0000-0002-9593-7378
AD  - Infectious Diseases, Children's Hospital at Westmead, Sydney, New South Wales,
      Australia.
AD  - Paediatrics and Child Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Lister, Paula
AU  - Lister P
AD  - Paediatric Critical Care, Sunshine Coast Hospital and Health Service, Sunshine
      Coast, Queensland, Australia.
AD  - School of Medicine, Griffith University, Brisbane, Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
SB  - IM
MH  - Adult
MH  - Australia
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Care/organization & administration
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - Intensive Care Units/*organization & administration
MH  - *Pandemics
MH  - Patient Admission
MH  - Pediatrics/*ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - Resource Allocation/*ethics/methods
MH  - SARS-CoV-2
PMC - PMC7300784
EDAT- 2020/05/30 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1111/jpc.14946 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2020 Jun;56(6):847-851. doi: 10.1111/jpc.14946. Epub
      2020 May 29.


PMID- 32470909
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1724-191X (Electronic)
IS  - 1120-1797 (Linking)
VI  - 74
DP  - 2020 Jun
TI  - GEANT4 Monte Carlo simulations for virtual clinical trials in breast X-ray
      imaging: Proof of concept.
PG  - 133-142
LID - S1120-1797(20)30123-X [pii]
LID - 10.1016/j.ejmp.2020.05.007 [doi]
AB  - Virtual clinical trials (VCT) are in-silico reproductions of medical
      examinations, which adopt digital models of patients and simulated devices. They 
      are intended to produce clinically equivalent outcome data avoiding long
      execution times, ethical issues related to radiation induced risks and huge costs
      related to real clinical trials with a patient population. In this work, we
      present a platform for VCT in 2D and 3D X-ray breast imaging. The VCT platform
      uses Monte Carlo simulations based on the Geant4 toolkit and patient breast
      models derived from a cohort of high resolution dedicated breast CT (BCT) volume 
      data sets. Projection images of the breast and three-dimensional glandular dose
      maps are generated for a given breast model, by simulating both 2D full-field
      digital mammography (DM) and 3D BCT examinations. Uncompressed voxelized breast
      models were derived from segmented patient images. Compressed versions of the
      digital breast phantoms for DM were generated using a previously published
      digital compression algorithm. The Monte Carlo simulation framework has the
      capability of generating and tracking ~10(5) photons/s using a server equipped
      with 16-cores and 3.0 GHz clock speed. The VCT platform will provide a framework 
      for scanner design optimization, comparison between different scanner designs and
      between different modalities or protocols on computational breast models, without
      the need for scanning actual patients as in conventional clinical trials.
CI  - Copyright (c) 2020 Associazione Italiana di Fisica Medica. Published by Elsevier 
      Ltd. All rights reserved.
FAU - di Franco, F
AU  - di Franco F
AD  - Universita di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", and
      INFN Sezione di Napoli, Napoli, Italy.
FAU - Sarno, A
AU  - Sarno A
AD  - Universita di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", and
      INFN Sezione di Napoli, Napoli, Italy. Electronic address: sarno@na.infn.it.
FAU - Mettivier, G
AU  - Mettivier G
AD  - Universita di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", and
      INFN Sezione di Napoli, Napoli, Italy.
FAU - Hernandez, A M
AU  - Hernandez AM
AD  - Department of Radiology, University of California Davis Medical Center,
      Sacramento, CA, USA.
FAU - Bliznakova, K
AU  - Bliznakova K
AD  - Department of Medical Equipment, Electronic and Information Technologies in
      Healthcare, Medical University of Varna, Varna, Bulgaria.
FAU - Boone, J M
AU  - Boone JM
AD  - Department of Radiology, University of California Davis Medical Center,
      Sacramento, CA, USA.
FAU - Russo, P
AU  - Russo P
AD  - Universita di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", and
      INFN Sezione di Napoli, Napoli, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - Italy
TA  - Phys Med
JT  - Physica medica : PM : an international journal devoted to the applications of
      physics to medicine and biology : official journal of the Italian Association of 
      Biomedical Physics (AIFB)
JID - 9302888
SB  - IM
MH  - Breast/*diagnostic imaging
MH  - *Clinical Trials as Topic
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - *Mammography
MH  - *Monte Carlo Method
OTO - NOTNLM
OT  - Monte Carlo
OT  - Patient-derived breast phantoms
OT  - Virtual clinical trials
OT  - X-ray breast imaging
EDAT- 2020/05/30 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/05/30 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - S1120-1797(20)30123-X [pii]
AID - 10.1016/j.ejmp.2020.05.007 [doi]
PST - ppublish
SO  - Phys Med. 2020 Jun;74:133-142. doi: 10.1016/j.ejmp.2020.05.007. Epub 2020 May 26.


PMID- 32470895
OWN - NLM
STAT- Publisher
LR  - 20200616
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 91
DP  - 2020 May 7
TI  - The use of inter-professional education (IPE) healthcare law and ethics scenario 
      based learning sessions amongst nursing, midwifery and law students: An
      evaluation.
PG  - 104455
LID - S0260-6917(19)31073-1 [pii]
LID - 10.1016/j.nedt.2020.104455 [doi]
AB  - BACKGROUND: Litigation and disciplinary action taken by the Nursing and Midwifery
      Council (NMC) against nurses' remains a concern with costs of claims against the 
      NHS increasing by 72% over the five years up to 2015/16 with almost pound1.5
      billion spent in one year alone. Additionally, 5476 referrals regarding
      registrants' fitness to practice were made to the NMC in 2016-2017. The aims of
      this paper are to discuss how a pair of scenario based IPE sessions focussed on
      healthcare law and ethical topics were introduced as an addition to the existing 
      nursing and midwifery curricula and to report the evaluation of these sessions.
      METHODS: Two scenario based sessions attended by nursing, midwifery and law
      students were delivered as an addition to existing nursing, midwifery and law
      curricula. The scenarios were based on real life cases and students collaborated 
      to identify means of managing legal and ethical issues arising from the
      scenarios. These sessions were facilitated by lecturers from the schools of law, 
      midwifery and nursing. FINDINGS: All attending students completed an evaluation
      questionnaire. Student evaluations indicated that the experience of working
      through the scenarios with their colleagues from other disciplines had enabled
      them to gain further knowledge and understanding around healthcare law and
      ethics. Student evaluations indicated a high level of engagement and interest in 
      the subject and also drew attention to the supportive structure of the IPE
      sessions. CONCLUSION: Nurses and midwives continue to be called to account by
      both their professional body and in law for issues related to their practice. A
      way to enable students to consider this and aid their preparation for clinical
      and professional practice is through the use of clinically and professionally
      relevant healthcare law and ethics scenarios in IPE sessions.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Nichols, Andy
AU  - Nichols A
AD  - Faculty of Health & Human Sciences, University of Plymouth, 3 Portland Villas,
      Drake Circus, Plymouth, Devon PL4 8AA, UK. Electronic address:
      andrew.nichols@plymouth.ac.uk.
FAU - Trimble, Pippa
AU  - Trimble P
AD  - Room 18, 20 Portland Villas, School of Law, Criminology and Government, Plymouth 
      University, Drake Circus, Plymouth PL4 8AA, UK.
FAU - Stebbings, Andrea
AU  - Stebbings A
AD  - Room 213, 8 Portland Villas, Plymouth University, Drake Circus, Plymouth PL4 8AA,
      UK.
LA  - eng
PT  - Editorial
DEP - 20200507
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
OTO - NOTNLM
OT  - Ethics
OT  - Inter-professional education
OT  - Law
OT  - Midwifery
OT  - Nursing
OT  - Scenarios
COIS- Declaration of competing interest None declared.
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:00
CRDT- 2020/05/30 06:00
PHST- 2019/07/12 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - S0260-6917(19)31073-1 [pii]
AID - 10.1016/j.nedt.2020.104455 [doi]
PST - aheadofprint
SO  - Nurse Educ Today. 2020 May 7;91:104455. doi: 10.1016/j.nedt.2020.104455.


PMID- 32470677
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20200723
IS  - 1090-2414 (Electronic)
IS  - 0147-6513 (Linking)
VI  - 200
DP  - 2020 Sep 1
TI  - Does dilute nitric acid improve the removal of exogenous heavy metals from
      feathers? A comparative study towards the optimization of the cleaning procedure 
      of feather samples prior to metal analysis.
PG  - 110759
LID - S0147-6513(20)30598-4 [pii]
LID - 10.1016/j.ecoenv.2020.110759 [doi]
AB  - Feather analysis has been widely used as a biomonitoring tool to assess metal
      contamination in birds, as their sampling is a non-destructive and ethically
      preferable technique. However, for feathers to be useful as a biomonitor of heavy
      metals, exogenous contamination has to be efficiently removed. Although much
      effort has been put into this, no washing procedure has yet proven able to ensure
      the total removal of the surface-associated metals. The purpose of this study was
      to propose an efficient washing procedure of feather samples prior to metal
      analysis, on the basis of comparison of various washing schemes designed
      according to previous analytical trials, and of the verification of the efficacy 
      of the optimal scheme in cleaning intentionally contaminated feathers. Our
      investigation showed that dilute nitric acid alone or in combination with a
      detergent (Extran) or acetone under mild agitation of the samples performed
      better that any other cleaning scheme applied. Thus, a multi-step procedure
      including the sequential use of all three reagents was tested against feather
      samples contaminated by adsorbed or particulate metal species. The procedure was 
      able to completely eliminate the external metal loads in all cases except for the
      partial removal of severe contamination with adsorbed Cd.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Aloupi, Maria
AU  - Aloupi M
AD  - Department of Environment, University of the Aegean, GR-81100, Mytilene, Greece. 
      Electronic address: malou@aegean.gr.
FAU - Ferentinou, Elpida
AU  - Ferentinou E
AD  - Department of Environment, University of the Aegean, GR-81100, Mytilene, Greece.
FAU - Zaharaki, Olga-Maria
AU  - Zaharaki OM
AD  - Department of Environment, University of the Aegean, GR-81100, Mytilene, Greece.
FAU - Akriotis, Triantafyllos
AU  - Akriotis T
AD  - Department of Environment, University of the Aegean, GR-81100, Mytilene, Greece.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200526
PL  - Netherlands
TA  - Ecotoxicol Environ Saf
JT  - Ecotoxicology and environmental safety
JID - 7805381
RN  - 0 (Environmental Pollutants)
RN  - 0 (Metals, Heavy)
RN  - 411VRN1TV4 (Nitric Acid)
SB  - IM
MH  - Animals
MH  - Biological Monitoring/methods
MH  - Birds
MH  - Environmental Pollutants/*analysis
MH  - Feathers/*chemistry
MH  - Metals, Heavy/*analysis
MH  - *Nitric Acid
OTO - NOTNLM
OT  - Biomonitor
OT  - Cleaning
OT  - External contamination
OT  - Feathers
OT  - Metals
OT  - Nitric acid
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/30 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - S0147-6513(20)30598-4 [pii]
AID - 10.1016/j.ecoenv.2020.110759 [doi]
PST - ppublish
SO  - Ecotoxicol Environ Saf. 2020 Sep 1;200:110759. doi: 10.1016/j.ecoenv.2020.110759.
      Epub 2020 May 26.


PMID- 32470110
OWN - NLM
STAT- MEDLINE
DCOM- 20201016
LR  - 20201218
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep 29
TI  - The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
PG  - 1399
LID - 10.1093/neuonc/noaa134 [doi]
FAU - Das, Sunit
AU  - Das S
AD  - Division of Neurosurgery and Centre for Ethics, St Michael's Hospital, University
      of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Letter
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
MH  - *Betacoronavirus
MH  - Brain Neoplasms/therapy
MH  - COVID-19
MH  - Coronavirus Infections/therapy
MH  - Humans
MH  - Medical Oncology/*ethics
MH  - Neurology/*ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/therapy
MH  - SARS-CoV-2
PMC - PMC7313874
EDAT- 2020/05/30 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 5848538 [pii]
AID - 10.1093/neuonc/noaa134 [doi]
PST - ppublish
SO  - Neuro Oncol. 2020 Sep 29;22(9):1399. doi: 10.1093/neuonc/noaa134.


PMID- 32470071
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200909
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Health care workers in conflict and post-conflict settings: Systematic mapping of
      the evidence.
PG  - e0233757
LID - 10.1371/journal.pone.0233757 [doi]
AB  - BACKGROUND: Health care workers (HCWs) are essential for the delivery of health
      care services in conflict areas and in rebuilding health systems post-conflict.
      OBJECTIVE: The aim of this study was to systematically identify and map the
      published evidence on HCWs in conflict and post-conflict settings. Our ultimate
      aim is to inform researchers and funders on research gap on this subject and
      support relevant stakeholders by providing them with a comprehensive resource of 
      evidence about HCWs in conflict and post-conflict settings on a global scale.
      METHODS: We conducted a systematic mapping of the literature. We included a wide 
      range of study designs, addressing any type of personnel providing health
      services in either conflict or post-conflict settings. We conducted a descriptive
      analysis of the general characteristics of the included papers and built two
      interactive systematic maps organized by country, study design and theme.
      RESULTS: Out of 13,863 identified citations, we included a total of 474 studies: 
      304 on conflict settings, 149 on post-conflict settings, and 21 on both conflict 
      and post-conflict settings. For conflict settings, the most studied counties were
      Iraq (15%), Syria (15%), Israel (10%), and the State of Palestine (9%). The most 
      common types of publication were opinion pieces in conflict settings (39%), and
      primary studies (33%) in post-conflict settings. In addition, most of the first
      and corresponding authors were affiliated with countries different from the
      country focus of the paper. Violence against health workers was the most tackled 
      theme of papers reporting on conflict settings, while workforce performance was
      the most addressed theme by papers reporting on post-conflict settings. The
      majority of papers in both conflict and post-conflict settings did not report
      funding sources (81% and 53%) or conflicts of interest of authors (73% and 62%), 
      and around half of primary studies did not report on ethical approvals (45% and
      41%). CONCLUSIONS: This systematic mapping provides a comprehensive database of
      evidence about HCWs in conflict and post-conflict settings on a global scale that
      is often needed to inform policies and strategies on effective workforce planning
      and management and in reducing emigration. It can also be used to identify
      evidence for policy-relevant questions, knowledge gaps to direct future primary
      research, and knowledge clusters.
FAU - Bou-Karroum, Lama
AU  - Bou-Karroum L
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
AD  - Department of Health Management and Policy, Faculty of Health Sciences, American 
      University of Beirut, Beirut, Lebanon.
FAU - El-Harakeh, Amena
AU  - El-Harakeh A
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
AD  - Clinical Research Institute (CRI), American University of Beirut Medical Center, 
      Beirut, Lebanon.
FAU - Kassamany, Inas
AU  - Kassamany I
AUID- ORCID: 0000-0003-4461-8753
AD  - Department of Health Management and Policy, Faculty of Health Sciences, American 
      University of Beirut, Beirut, Lebanon.
FAU - Ismail, Hussein
AU  - Ismail H
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - El Arnaout, Nour
AU  - El Arnaout N
AD  - Global Health Institute, American University of Beirut, Beirut, Lebanon.
FAU - Charide, Rana
AU  - Charide R
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Madi, Farah
AU  - Madi F
AD  - Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
FAU - Jamali, Sarah
AU  - Jamali S
AUID- ORCID: 0000-0001-7618-1520
AD  - Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
FAU - Martineau, Tim
AU  - Martineau T
AUID- ORCID: 0000-0003-4833-3149
AD  - Department of International Public Health, Liverpool School of Tropical Medicine,
      United Kingdom.
FAU - El-Jardali, Fadi
AU  - El-Jardali F
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
AD  - Department of Health Management and Policy, Faculty of Health Sciences, American 
      University of Beirut, Beirut, Lebanon.
AD  - Department of Health Research Methods, Evidence, and Impact (HEI), McMaster
      University, Hamilton, Ontario, Canada.
FAU - Akl, Elie A
AU  - Akl EA
AUID- ORCID: 0000-0002-3444-8618
AD  - Center for Systematic Reviews on Health Policy and Systems Research (SPARK),
      American University of Beirut, Beirut, Lebanon.
AD  - Clinical Research Institute (CRI), American University of Beirut Medical Center, 
      Beirut, Lebanon.
AD  - Department of Health Research Methods, Evidence, and Impact (HEI), McMaster
      University, Hamilton, Ontario, Canada.
AD  - Department of Internal Medicine, Faculty of Medicine, American University of
      Beirut, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200529
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Africa
MH  - Americas
MH  - Databases, Factual
MH  - Delivery of Health Care
MH  - Geographic Mapping
MH  - Government Programs/economics
MH  - *Health Personnel
MH  - *Health Workforce
MH  - Humans
MH  - Middle East
MH  - *Warfare and Armed Conflicts
PMC - PMC7259645
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/30 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/05/30 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
AID - 10.1371/journal.pone.0233757 [doi]
AID - PONE-D-19-29429 [pii]
PST - epublish
SO  - PLoS One. 2020 May 29;15(5):e0233757. doi: 10.1371/journal.pone.0233757.
      eCollection 2020.


PMID- 32469850
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 0717-6384 (Electronic)
IS  - 0717-6384 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Apr 8
TI  - General concepts in biostatistics and clinical epidemiology: Experimental studies
      with randomized clinical trial design.
PG  - e7869
LID - 10.5867/medwave.2020.02.7869 [doi]
AB  - In experimental studies, researchers apply an intervention to a group of study
      participants and analyze the effects over a future or prospective timeline. The
      prospective nature of these types of studies allows for the determination of
      causal relationships, but the interventions they are based on require rigorous
      bioethical evaluation, approval from an ethics committee, and registration of the
      study protocol prior to implementation. Experimental research includes clinical
      and preclinical testing of a novel intervention or therapy at different phases of
      development. The main objective of clinical trials is to evaluate an
      interventions efficacy and safety. Conventional clinical trials are blinded,
      randomized, and controlled, meaning that participants are randomly assigned to
      either the study intervention group or a comparator (a control group exposed to a
      placebo intervention or another non-placebo or active interventionor not exposed 
      to any intervention) to reduce selection and confounding biases, and researchers 
      are also unaware of the type of intervention being applied. Intention-to-treat
      analysis (inclusion of all originally randomized subjects) should be done to
      avoid the effects of attrition (dropout) and crossover (variance in the exposure 
      or treatment over time). A quasi-experimental design and external controls may
      also be used. Metrics used to measure the magnitude of effects include relative
      risk, absolute and relative risk reductions, and numbers needed to treat and
      harm. Confounding factors are controlled by randomization. Other types of bias to
      consider are selection, performance, detection, and reporting. This review is the
      fifth of a methodological series on general concepts in biostatistics and
      clinical epidemiology developed by the Chair of Scientific Research Methodology
      at the School of Medicine, University of Valparaiso, Chile. It describes general 
      theoretical concepts related to randomized clinical trials and other experimental
      studies in humans, including fundamental elements, historical development,
      bioethical issues, structure, design, association measures, biases, and reporting
      guidelines. Factors that should be considered in the execution and evaluation of 
      a clinical trial are also covered.
FAU - Estrada, Sebastian
AU  - Estrada S
AD  - Catedra de Metodologia de la Investigacion Cientifica, Escuela de Medicina,
      Universidad de Valparaiso, Vina del Mar, Chile.
FAU - Arancibia, Marcelo
AU  - Arancibia M
AD  - Catedra de Metodologia de la Investigacion Cientifica, Escuela de Medicina,
      Universidad de Valparaiso, Vina del Mar, Chile; Centro Interdisciplinario de
      Estudios en Salud (CIESAL), Universidad de Valparaiso, Valparaiso, Chile.
FAU - Stojanova, Jana
AU  - Stojanova J
AD  - Catedra de Metodologia de la Investigacion Cientifica, Escuela de Medicina,
      Universidad de Valparaiso, Vina del Mar, Chile; Centro Interdisciplinario de
      Estudios en Salud (CIESAL), Universidad de Valparaiso, Valparaiso, Chile.
FAU - Papuzinski, Cristian
AU  - Papuzinski C
AD  - Catedra de Metodologia de la Investigacion Cientifica, Escuela de Medicina,
      Universidad de Valparaiso, Vina del Mar, Chile; Centro Interdisciplinario de
      Estudios en Salud (CIESAL), Universidad de Valparaiso, Valparaiso, Chile.
LA  - spa
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Conceptos generales en bioestadistica y epidemiologia clinica: estudios
      experimentales con diseno de ensayo clinico aleatorizado.
DEP - 20200408
PL  - Chile
TA  - Medwave
JT  - Medwave
JID - 101581949
SB  - IM
MH  - Bias
MH  - Biostatistics/*methods
MH  - *Epidemiologic Methods
MH  - Epidemiologic Studies
MH  - Humans
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Research Design
OTO - NOTNLM
OT  - bias
OT  - biostatistics
OT  - epidemiology
OT  - relative risk
OT  - therapeutics
OT  - clinical trial
EDAT- 2020/05/30 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/02/18 00:00 [accepted]
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
AID - e7869 [pii]
AID - 10.5867/medwave.2020.02.7869 [doi]
PST - epublish
SO  - Medwave. 2020 Apr 8;20(3):e7869. doi: 10.5867/medwave.2020.02.7869.


PMID- 32469685
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Linking)
VI  - 16
IP  - 10
DP  - 2020 Oct
TI  - A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and 
      Their Preferences for How Shortages Should Be Managed.
PG  - e1098-e1111
LID - 10.1200/JOP.19.00608 [doi]
AB  - PURPOSE: Medication shortages in US hospitals are ongoing, widespread, and
      frequently involve antineoplastic and supportive medications used in cancer care.
      The ways shortages are managed and the ways provider-patient communication takes 
      place are heterogeneous, but the related preferences of oncology patients are
      undefined. This study sought to qualitatively evaluate patient preferences.
      METHODS: A cross-sectional, semi-structured interview study was conducted from
      January to June 2019. Participants were adult oncology inpatients who received
      primary cancer care at the University of Chicago, had undergone treatment within 
      2 years, and had 1 or more previous hospitalizations during that period.
      Participants (n = 54) were selected consecutively from alternating hematology and
      oncology services. The primary outcome was thematic saturation across the domains
      of awareness of medication shortages, principle preferences regarding decision
      makers, preferences regarding allocation of therapy drugs, and allocation-related
      communication. RESULTS: Thematic saturation was reached after 39 participants
      completed the study procedures (mean age, 59.6 years [standard deviation, 14.5
      years]; men made up 61.5% of the study population [mean age, 24 years]; response 
      rate, 72.0%). In all, 18% of participants were aware of institutional medication 
      shortages. Patients preferred having multiple decision makers for allocating
      medications in the event of a shortage. A majority of patients named oncologists 
      (100%), ethicists (92%), non-oncology physicians (77%), and pharmacists (64%) as 
      their preferred decision makers. Participants favored allocation of drugs based
      on their efficacy (normalized weighted average, 1.3), and they also favored
      prioritizing people who were already receiving treatment (1.8), younger patients 
      (2.0), sicker patients (3.1), and those presenting first for treatment (5.3).
      Most participants preferred preferred disclosure of supportive care medication
      shortages (74%) and antineoplastic medication shortages (79%) for equivalent
      substitutions. CONCLUSION: In a tertiary-care center with medication shortages,
      few oncologic inpatients were aware of shortages. Participants preferred having
      multiple decision makers involved in principle-driven allocation of scarce
      medications. Disclosure was preferred when their usual medications needed to be
      substituted with equivalent alternatives. These preliminary data suggest that
      preferences do not align with current management practices for medication
      shortages.
FAU - Hantel, Andrew
AU  - Hantel A
AUID- ORCID: 0000-0001-9612-3643
AD  - Division of Population Sciences and Inpatient Oncology, Dana-Farber Cancer
      Institute, Boston, MA.
FAU - Hlubocky, Fay J
AU  - Hlubocky FJ
AUID- ORCID: 0000-0002-4647-3597
AD  - Section of Hematology/Oncology, Department of Medicine, The University of
      Chicago, Chicago, IL.
AD  - The MacLean Center for Clinical Medical Ethics, The University of Chicago,
      Chicago, IL.
FAU - Siegler, Mark
AU  - Siegler M
AD  - The MacLean Center for Clinical Medical Ethics, The University of Chicago,
      Chicago, IL.
AD  - Section of General Internal Medicine, Department of Medicine, The University of
      Chicago, Chicago, IL.
FAU - Daugherty, Christopher K
AU  - Daugherty CK
AD  - Section of Hematology/Oncology, Department of Medicine, The University of
      Chicago, Chicago, IL.
AD  - The MacLean Center for Clinical Medical Ethics, The University of Chicago,
      Chicago, IL.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*supply & distribution
MH  - Cross-Sectional Studies
MH  - *Decision Making
MH  - Hospitals, University
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Neoplasms/drug therapy
MH  - Patient Care
MH  - *Patient Preference
MH  - Pharmacists
MH  - United States
MH  - Young Adult
EDAT- 2020/05/30 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1200/JOP.19.00608 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2020 Oct;16(10):e1098-e1111. doi: 10.1200/JOP.19.00608. Epub
      2020 May 29.


PMID- 32469645
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1440-1665 (Electronic)
IS  - 1039-8562 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Oct
TI  - The complexity of childhood gender dysphoria.
PG  - 530-532
LID - 10.1177/1039856220917076 [doi]
AB  - OBJECTIVE: To explore a developmental understanding of childhood gender dysphoria
      and to compare it to the prevailing paradigm, gender-affirming care. CONCLUSION: 
      Viewing gender dysphoria through a contemporary developmental frame generates a
      different understanding of the nature of the phenomenon and its treatment and
      raises ethical questions about our current gender-affirming approach.
FAU - D'Angelo, Roberto
AU  - D'Angelo R
AUID- ORCID: 0000-0003-2929-3831
AD  - Institute of Contemporary Psychoanalysis, USA.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Australas Psychiatry
JT  - Australasian psychiatry : bulletin of Royal Australian and New Zealand College of
      Psychiatrists
JID - 9613603
SB  - IM
MH  - Child
MH  - Gender Dysphoria/psychology/*therapy
MH  - Humans
MH  - Outcome Assessment, Health Care/*ethics
MH  - Psychiatry/*ethics
MH  - Psychological Theory
MH  - Sex Reassignment Procedures/*ethics
OTO - NOTNLM
OT  - *children
OT  - *ethics
OT  - *gender dysphoria
OT  - *transgender
EDAT- 2020/05/30 06:00
MHDA- 2021/07/10 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1177/1039856220917076 [doi]
PST - ppublish
SO  - Australas Psychiatry. 2020 Oct;28(5):530-532. doi: 10.1177/1039856220917076. Epub
      2020 May 29.


PMID- 32469644
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20210709
IS  - 1440-1665 (Electronic)
IS  - 1039-8562 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Oct
TI  - Informed consent and childhood gender dysphoria: emerging complexities in
      diagnosis and treatment.
PG  - 536-538
LID - 10.1177/1039856220928863 [doi]
AB  - OBJECTIVE: To explore some of the emerging complexities in the management of
      childhood gender dysphoria. CONCLUSION: The authors raise questions about the
      gender-affirmation approach and highlight concerns about informed consent and
      research ethics.
FAU - d'Abrera, Juan Carlos
AU  - d'Abrera JC
AUID- ORCID: 0000-0003-1313-3518
AD  - Northern Sydney Local Health District, Australia.
FAU - D'Angelo, Roberto
AU  - D'Angelo R
AD  - Institute of Contemporary Psychoanalysis, USA.
FAU - Halasz, George
AU  - Halasz G
AUID- ORCID: 0000-0002-6814-3062
AD  - Monash University, Australia.
FAU - Prager, Shirley
AU  - Prager S
AD  - Private Practice, Melbourne, Australia.
FAU - Morris, Philip
AU  - Morris P
AD  - Private Practice, Southport, Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Australas Psychiatry
JT  - Australasian psychiatry : bulletin of Royal Australian and New Zealand College of
      Psychiatrists
JID - 9613603
SB  - IM
MH  - Australia
MH  - Child
MH  - Gender Dysphoria/*diagnosis/*therapy
MH  - Humans
MH  - *Informed Consent
MH  - Psychiatry/*ethics
MH  - Sex Reassignment Procedures/*ethics
MH  - Societies, Medical
OTO - NOTNLM
OT  - *childhood
OT  - *dysphoria
OT  - *ethics
OT  - *gender
OT  - *treatment
EDAT- 2020/05/30 06:00
MHDA- 2021/07/10 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1177/1039856220928863 [doi]
PST - ppublish
SO  - Australas Psychiatry. 2020 Oct;28(5):536-538. doi: 10.1177/1039856220928863. Epub
      2020 May 29.


PMID- 32469283
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20201210
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 16
IP  - 21
DP  - 2020 Jul
TI  - The future of cancer research after COVID-19 pandemic: recession?
PG  - 1493-1495
LID - 10.2217/fon-2020-0397 [doi]
FAU - Kourie, Hampig Raphael
AU  - Kourie HR
AD  - Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of
      Beirut, Beirut, Lebanon.
FAU - Eid, Roland
AU  - Eid R
AUID- ORCID: https://orcid.org/0000-0003-1097-2594
AD  - Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of
      Beirut, Beirut, Lebanon.
FAU - Haddad, Fady
AU  - Haddad F
AUID- ORCID: https://orcid.org/0000-0002-9702-8485
AD  - Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of
      Beirut, Beirut, Lebanon.
FAU - Ghosn, Marwan
AU  - Ghosn M
AD  - Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of
      Beirut, Beirut, Lebanon.
FAU - Sarkis, Dolla Karam
AU  - Sarkis DK
AD  - Microbiology Department, Faculty of Pharmacy, Saint Joseph University of Beirut.
LA  - eng
PT  - Editorial
DEP - 20200529
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus
MH  - *Biomedical Research
MH  - COVID-19
MH  - Clinical Trials as Topic
MH  - Coronavirus Infections/drug therapy/*epidemiology
MH  - Drug Development
MH  - *Economic Recession
MH  - Humans
MH  - *Neoplasms
MH  - Pandemics
MH  - Pneumonia, Viral/drug therapy/*epidemiology
MH  - *Research Support as Topic
MH  - SARS-CoV-2
PMC - PMC7435350
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - cancer
OT  - ethics
OT  - funds
OT  - research
OT  - trials
EDAT- 2020/05/30 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.2217/fon-2020-0397 [doi]
PST - ppublish
SO  - Future Oncol. 2020 Jul;16(21):1493-1495. doi: 10.2217/fon-2020-0397. Epub 2020
      May 29.


PMID- 32469104
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jul
TI  - Weiqu, structural injustice and caring for sick older people in rural Chinese
      families: An empirical ethical study.
PG  - 593-601
LID - 10.1111/bioe.12753 [doi]
AB  - This paper examines caregiving for sick older family members in the context of
      socio-economic transformations in rural China, combining empirical investigation 
      with normative inquiry. The empirical part of this paper is based on a case
      study, taken from fieldwork in a rural Chinese hospital, of a son who took care
      of his hospitalized mother. This empirical study highlighted family members'
      weiqu (sense of unfairness)-a mental status from experiencing mistreatment and
      oppression in family care, yet with constrained power to explicitly protest or
      make care-related choices. Underpinning people's weiqu and constrained choice, as
      informed by the conception of structural injustice, is the impact of unjust
      social structures, organized by unfavourable norms, discriminatory social
      policies and institutions targeting rural populations. By restraining individual 
      choices and capacities in supporting health care for aging populations, these
      unjust structures create additional difficulties for and discriminations against 
      rural families and their older members. Some policy recommendations are proposed 
      to mitigate structural injustice so as to empower families and promote care for
      older people in rural settings.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Zou, Xiang
AU  - Zou X
AUID- ORCID: 0000-0002-8808-5605
AD  - Department of Medical Humanities, Southeast University, Nanjing, Jiangsu, China.
FAU - Nie, Jing-Bao
AU  - Nie JB
AUID- ORCID: 0000-0002-1570-2254
AD  - Bioethics Centre, University of Otago, Dunedin, New Zealand.
FAU - Fitzgerald, Ruth
AU  - Fitzgerald R
AD  - School of Social Sciences, University of Otago, Dunedin, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Aged
MH  - Caregivers/ethics/*psychology
MH  - China
MH  - Ethical Theory
MH  - Family/*psychology
MH  - Family Relations/*ethnology
MH  - Female
MH  - Frail Elderly/*psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Public Policy
MH  - Rural Population
MH  - Social Support
OTO - NOTNLM
OT  - * weiqu
OT  - *China
OT  - *ageing health care
OT  - *family care
OT  - *structural injustice
EDAT- 2020/05/30 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/05/30 06:00
PHST- 2019/02/28 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1111/bioe.12753 [doi]
PST - ppublish
SO  - Bioethics. 2020 Jul;34(6):593-601. doi: 10.1111/bioe.12753. Epub 2020 May 29.


PMID- 32469074
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20210110
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 222
IP  - 3
DP  - 2020 Jul 6
TI  - Paying Participants in COVID-19 Trials.
PG  - 356-361
LID - 10.1093/infdis/jiaa284 [doi]
AB  - Trials are in development and underway to examine potential interventions for
      treatment and prophylaxis of coronavirus disease 2019 (COVID-19). How should we
      think about offering payment to participants in these trials? Payment for
      research participation is ethically contentious even under ideal circumstances.
      Here, we review 3 functions of research payment-reimbursement, compensation, and 
      incentive-and identify heightened and novel ethical concerns in the context of a 
      global pandemic. We argue that COVID-19 trial participants should usually be
      offered reimbursement for research-related expenses, and compensation for their
      time and effort, as for other types of research under usual circumstances. Given 
      increased risk of undue influence against pandemic background conditions,
      incentive payment should be avoided unless essential to recruitment and retention
      in important trials whose social value outweighs this risk. Where essential,
      however, incentives can be ethically permissible, so long as reasonable efforts
      are made to minimize the possibility of undue influence.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Largent, Emily A
AU  - Largent EA
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - Leonard Davis Institute of Health Economics, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Lynch, Holly Fernandez
AU  - Lynch HF
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - Leonard Davis Institute of Health Economics, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
SB  - IM
MH  - COVID-19
MH  - Clinical Trials as Topic/*economics/ethics
MH  - Compensation and Redress/ethics
MH  - Coronavirus Infections/prevention & control/*therapy
MH  - *Healthy Volunteers
MH  - Humans
MH  - Motivation/ethics
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/prevention & control/*therapy
MH  - Research/economics
PMC - PMC7313938
OTO - NOTNLM
OT  - * research ethics
OT  - *COVID
OT  - *informed consent
OT  - *payment
OT  - *undue influence
EDAT- 2020/05/30 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 5848446 [pii]
AID - 10.1093/infdis/jiaa284 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 Jul 6;222(3):356-361. doi: 10.1093/infdis/jiaa284.


PMID- 32469009
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20211115
IS  - 1827-675X (Electronic)
IS  - 0392-100X (Linking)
VI  - 40
IP  - SUPPL. 1
DP  - 2020 Apr
TI  - Metastatic disease in head & neck oncology.
PG  - S1-S86
LID - 10.14639/0392-100X-suppl.1-40-2020 [doi]
FAU - Pisani, Paolo
AU  - Pisani P
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Airoldi, Mario
AU  - Airoldi M
AD  - Medical Oncology, Citta della Salute e della Scienza, Torino, Italy.
FAU - Allais, Anastasia
AU  - Allais A
AD  - ENT Unit, ASL TO3, Pinerolo-Rivoli (TO), Italy.
FAU - Aluffi Valletti, Paolo
AU  - Aluffi Valletti P
AD  - SCDU Otorinolaringoiatria, AOU Maggiore della Carita di Novara, Universita del
      Piemonte Orientale, Italy.
FAU - Battista, Mariapina
AU  - Battista M
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Benazzo, Marco
AU  - Benazzo M
AD  - SC Otorinolaringoiatria, Fondazione IRCCS Policlinico "S. Matteo", Universita di 
      Pavia, Italy.
FAU - Briatore, Roberto
AU  - Briatore R
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Cacciola, Salvatore
AU  - Cacciola S
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Cocuzza, Salvatore
AU  - Cocuzza S
AD  - Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia",
      University of Catania, Italy.
FAU - Colombo, Andrea
AU  - Colombo A
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Conti, Bice
AU  - Conti B
AD  - Department of Drug Sciences, University of Pavia, Italy.
AD  - Polymerix S.r.L., Pavia, Italy.
FAU - Costanzo, Alberto
AU  - Costanzo A
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Della Vecchia, Laura
AU  - Della Vecchia L
AD  - Unit of Otorhinolaryngology General Hospital "Macchi", ASST dei Settelaghi,
      Varese, Italy.
FAU - Denaro, Nerina
AU  - Denaro N
AD  - Oncology Department A.O.S. Croce & Carle, Cuneo, Italy.
FAU - Fantozzi, Cesare
AU  - Fantozzi C
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Galizia, Danilo
AU  - Galizia D
AD  - Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo,Italy.
FAU - Garzaro, Massimiliano
AU  - Garzaro M
AD  - SCDU Otorinolaringoiatria, AOU Maggiore della Carita di Novara, Universita del
      Piemonte Orientale, Italy.
FAU - Genta, Ida
AU  - Genta I
AD  - Department of Drug Sciences, University of Pavia, Italy.
AD  - Polymerix S.r.L., Pavia, Italy.
FAU - Iasi, Gabriela Alejandra
AU  - Iasi GA
AD  - Laboratory of Pathology, Ospedale "Sant'Andrea", Vercelli, Italy.
FAU - Krengli, Marco
AU  - Krengli M
AD  - Dipartimento Medico Specialistico ed Oncologico, SC Radioterapia Oncologica, AOU 
      Maggiore della Carita, Novara, Italy.
AD  - Dipartimento di Medicina Traslazionale, Universita del Piemonte Orientale,
      Novara, Italy.
FAU - Landolfo, Vincenzo
AU  - Landolfo V
AD  - ENT Unit, ASL AT, "Cardinal Massaja" Hospital, Asti, Italy.
FAU - Lanza, Giovanni Vittorio
AU  - Lanza GV
AD  - S.O.C. Chirurgia Toracica, Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e 
      Cesare Arrigo", Alessandria, Italy.
FAU - Magnano, Mauro
AU  - Magnano M
AD  - ENT Unit, ASL TO3, Pinerolo-Rivoli (TO), Italy.
FAU - Mancuso, Maurizio
AU  - Mancuso M
AD  - S.O.C. Chirurgia Toracica, Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e 
      Cesare Arrigo", Alessandria, Italy.
FAU - Maroldi, Roberto
AU  - Maroldi R
AD  - Department of Radiology, University of Brescia, ASST Spedali Civili Brescia,
      Italy.
FAU - Masini, Laura
AU  - Masini L
AD  - Dipartimento Medico Specialistico ed Oncologico, SC Radioterapia Oncologica, AOU 
      Maggiore della Carita, Novara, Italy.
FAU - Merlano, Marco Carlo
AU  - Merlano MC
AD  - Oncology Department A.O.S. Croce & Carle, Cuneo, Italy.
AD  - Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo,Italy.
FAU - Piemonte, Marco
AU  - Piemonte M
AD  - ENT Unit, University Hospital "Santa Maria della Misericordia", Udine, Italy.
FAU - Pisani, Silvia
AU  - Pisani S
AD  - Immunology and Transplantation Laboratory Fondazione IRCCS Policlinico "S.
      Matteo", Pavia, Italy.
FAU - Prina-Mello, Adriele
AU  - Prina-Mello A
AD  - LBCAM, Department of Clinical Medicine, Trinity Translational Medicine Institute,
      Trinity College Dublin, Dublin 8, Ireland.
AD  - Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), Trinity
      College Dublin, Dublin 2, Ireland.
FAU - Prioglio, Luca
AU  - Prioglio L
AD  - Department of Otorhinolaryngology, ASL 3 "Genovese", "Padre Antero Micone"
      Hospital, Genoa, Italy.
FAU - Rugiu, Maria Gabriella
AU  - Rugiu MG
AD  - ENT Unit, University Hospital "Santa Maria della Misericordia", Udine, Italy.
FAU - Scasso, Felice
AU  - Scasso F
AD  - Department of Otorhinolaryngology, ASL 3 "Genovese", "Padre Antero Micone"
      Hospital, Genoa, Italy.
FAU - Serra, Agostino
AU  - Serra A
AD  - University of Catania, Italy.
AD  - G.B. Morgagni Foundation, Catania, Italy.
FAU - Valente, Guido
AU  - Valente G
AD  - Dipartimento di Medicina Traslazionale, Universita del Piemonte Orientale,
      Novara, Italy.
FAU - Zannetti, Micol
AU  - Zannetti M
AD  - Dipartimento di Medicina Traslazionale, Universita del Piemonte Orientale,
      Novara, Italy.
FAU - Zigliani, Angelo
AU  - Zigliani A
AD  - Department of Radiology, University of Brescia, ASST Spedali Civili Brescia,
      Italy.
LA  - eng
PT  - Review
PL  - Italy
TA  - Acta Otorhinolaryngol Ital
JT  - Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di
      otorinolaringologia e chirurgia cervico-facciale
JID - 8213019
SB  - IM
MH  - Drug Therapy/methods
MH  - Epstein-Barr Virus Infections/complications
MH  - Female
MH  - Frailty
MH  - Head and Neck Neoplasms/epidemiology/pathology/*therapy
MH  - Herpesvirus 4, Human
MH  - Humans
MH  - Immunotherapy/methods
MH  - Male
MH  - Nanomedicine/methods
MH  - Neoplasms, Second Primary/epidemiology/pathology/*therapy
MH  - Papillomavirus Infections/complications
MH  - Prognosis
MH  - Radiotherapy/methods
MH  - Socioeconomic Factors
MH  - Squamous Cell Carcinoma of Head and Neck/therapy
MH  - Tumor Microenvironment
PMC - PMC7263073
OAB - The head and neck district represents one of the most frequent sites of cancer,
      and the percentage of metastases is very high in both loco-regional and distant
      areas. Prognosis refers to several factors: a) stage of disease; b) loco-regional
      relapses; c) distant metastasis. At diagnosis, distant metastases of head and
      neck cancers are present in about 10% of cases with an additional 20-30%
      developing metastases during the course of their disease. Diagnosis of distant
      metastases is associated with unfavorable prognosis, with a median survival of
      about 10 months. The aim of the present review is to provide an update on distant
      metastasis in head and neck oncology. Recent achievements in molecular profiling,
      interaction between neoplastic tissue and the tumor microenvironment,
      oligometastatic disease concepts, and the role of immunotherapy have all deeply
      changed the therapeutic approach and disease control. Firstly, we approach topics
      such as natural history, epidemiology of distant metastases and relevant
      pathological and radiological aspects. Focus is then placed on the most relevant 
      clinical aspects; particular attention is reserved to tumours with distant
      metastasis and positive for EBV and HPV, and the oligometastatic concept. A
      substantial part of the review is dedicated to different therapeutic approaches. 
      We highlight the role of immunotherapy and the potential effects of innovative
      technologies. Lastly, we present ethical and clinical perspectives related to
      frailty in oncological patients and emerging difficulties in sustainable
      socio-economical governance.
OABL- eng
OTO - NOTNLM
OT  - *chemotherapy
OT  - *distant metastasis
OT  - *head and neck oncology
OT  - *immunotherapy
OT  - *nanomedicine
OT  - *radiotherapy
EDAT- 2020/05/30 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.14639/0392-100X-suppl.1-40-2020 [doi]
PST - ppublish
SO  - Acta Otorhinolaryngol Ital. 2020 Apr;40(SUPPL. 1):S1-S86. doi:
      10.14639/0392-100X-suppl.1-40-2020.


PMID- 32468984
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 1475-2719 (Electronic)
IS  - 0029-6651 (Linking)
VI  - 79
IP  - 3
DP  - 2020 Aug
TI  - From personalised nutrition to precision medicine: the rise of consumer genomics 
      and digital health.
PG  - 300-310
LID - 10.1017/S0029665120006977 [doi]
AB  - Advances in genomics generated the concept that a better understanding of
      individual characteristics, e.g. genotype, will lead to improved tailoring of
      pharmaceutical and nutritional therapies. Subsequent developments in proteomics
      and metabolomics, in addition to wearable technologies for tracking parameters,
      such as dietary intakes, physical activity, heart rate and blood glucose, have
      further driven this idea. Alongside these innovations, there has been a rapid
      rise in companies offering direct-to-consumer genetic and/or microbiome testing, 
      in combination with the marketing of personalised nutrition services. Key
      scientific questions include how disparate datasets are integrated, how accurate 
      are current predictions and how these may be developed in the future. In this
      regard, lessons can be learned from systems biology, which aims both to integrate
      data from different levels of organisation (e.g. genomic, proteomic and
      metabolomic) and predict the emergent behaviours of biological systems or
      organisms as a whole. The present paper reviews the origins and recent
      advancement of 'big data' and systems approaches in medicine and nutrition.
      Conclusions are that systems integration of multiple technologies has generated
      mechanistic insights and informed the evolution of precision medicine and
      personalised nutrition. Pertinent ethical issues include who is entitled to
      access new technologies and how commercial companies are storing, using and/or
      re-mining consumer data. Questions about efficacy (both long-term behavioural
      change and health outcomes), cost-benefit and impacts on health inequalities
      remain to be fully addressed.
FAU - Moore, J Bernadette
AU  - Moore JB
AUID- ORCID: 0000-0003-4750-1550
AD  - School of Food Science & Nutrition, University of Leeds, Leeds, West YorkshireLS2
      9JT, UK.
LA  - eng
GR  - BB/J014451/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
GR  - BB/I008195/1/BB_/Biotechnology and Biological Sciences Research Council/United
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200529
PL  - England
TA  - Proc Nutr Soc
JT  - The Proceedings of the Nutrition Society
JID - 7505881
SB  - IM
MH  - *Biomedical Technology
MH  - Humans
MH  - *Nutrigenomics
MH  - Nutrition Therapy
MH  - *Nutritional Physiological Phenomena/genetics
MH  - *Precision Medicine
MH  - Systems Biology
MH  - Wearable Electronic Devices
OTO - NOTNLM
OT  - *Nutrigenomics
OT  - *Personalised nutrition
OT  - *Precision medicine
OT  - *Proteomics
OT  - *Systems biology
EDAT- 2020/05/30 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1017/S0029665120006977 [doi]
AID - S0029665120006977 [pii]
PST - ppublish
SO  - Proc Nutr Soc. 2020 Aug;79(3):300-310. doi: 10.1017/S0029665120006977. Epub 2020 
      May 29.


PMID- 32468890
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20201218
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Preparedness of medical education in China: Lessons from the COVID-19 outbreak.
PG  - 787-790
LID - 10.1080/0142159X.2020.1770713 [doi]
AB  - The COVID-19 outbreak can be seen as a 'big test' for China; a summative
      assessment of its preparedness on multiple fronts, including medical education.
      Being intimately involved in the coordinated response, the First Affiliated
      Hospital of Sun Yat-sen University has been a first-hand witness to the strengths
      and weaknesses of the current medical education system in China. On the one hand,
      we believe that the distinguished contributions in disease containment efforts by
      healthcare professionals indicated that our medical education system has achieved
      its intended outcomes and is socially accountable. On the other hand, we have
      also identified three major issues that need to be addressed from an educational 
      standpoint: insufficient emphasis on public health emergency preparedness;
      unsophisticated mechanisms for interdisciplinary cooperation; and inadequate
      guidance in medical ethics. Whilst these reflections might be seen in its
      summative form, we would suggest changing it to that of a formative process,
      where we learn from our assessment through observation and feedback of the gaps, 
      upon which improvement of our present situation can be made. We hope that these
      lessons may be helpful to our colleagues in the rest of China and around the
      world, who are engaged in medical educational reform.
FAU - Yang, Da-Ya
AU  - Yang DY
AD  - The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
AD  - Key Laboratory of Assisted Circulation, National Health Commission, Guangzhou,
      China.
FAU - Cheng, Shu-Yuan
AU  - Cheng SY
AD  - The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Wang, Shu-Zhen
AU  - Wang SZ
AD  - Office of Education Administration, Sun Yat-sen University, Guangzhou, China.
FAU - Wang, Jin-Song
AU  - Wang JS
AD  - The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
FAU - Kuang, Ming
AU  - Kuang M
AD  - The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
AD  - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
FAU - Wang, Ting-Huai
AU  - Wang TH
AD  - Xinhua College of Sun, Yat-sen University, Guangzhou, China.
AD  - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
FAU - Xiao, Hai-Peng
AU  - Xiao HP
AD  - The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - China/epidemiology
MH  - Communicable Disease Control/organization & administration
MH  - Coronavirus Infections/*epidemiology
MH  - Disaster Planning/organization & administration
MH  - Education, Medical/*organization & administration/standards
MH  - Ethics, Medical
MH  - Humans
MH  - Interprofessional Relations
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *COVID-19
OT  - *medical education
OT  - *medical ethics
OT  - *preparedness
OT  - *public health emergency
EDAT- 2020/05/30 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1080/0142159X.2020.1770713 [doi]
PST - ppublish
SO  - Med Teach. 2020 Jul;42(7):787-790. doi: 10.1080/0142159X.2020.1770713. Epub 2020 
      May 29.


PMID- 32468777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200713
IS  - 1819-2718 (Electronic)
IS  - 1025-9589 (Linking)
VI  - 32
IP  - 1
DP  - 2020 Jan- Mar
TI  - Public Health And Health System Reforms In Pakistan; A View Through Ethical Lens.
PG  - 147-151
FAU - Akber, Subhana
AU  - Akber S
AD  - Health Services Academy, Ministry of National Health Services, Regulations &
      Coordination, Islamabad, Pakistan.
FAU - Hamid, Saima
AU  - Hamid S
AD  - Health Services Academy, Ministry of National Health Services, Regulations &
      Coordination, Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Ayub Med Coll Abbottabad
JT  - Journal of Ayub Medical College, Abbottabad : JAMC
JID - 8910750
SB  - IM
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:01
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:01 [medline]
AID - 4861/2865 [pii]
PST - ppublish
SO  - J Ayub Med Coll Abbottabad. 2020 Jan- Mar;32(1):147-151.


PMID- 32468763
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201022
IS  - 1819-2718 (Electronic)
IS  - 1025-9589 (Linking)
VI  - 32
IP  - 1
DP  - 2020 Jan- Mar
TI  - Surgical Outcome Of Intradural Spinal Tumours.
PG  - 87-90
AB  - BACKGROUND: This study was conducted to determine the short-term outcome of
      surgical procedure in patients having spinal intradural tumours. METHODS: This
      cross-sectional study was conducted from 26 April 2016 to 25 March 2019 on 56
      patients after approval from hospitals ethical and research committee. MRI spine 
      were studied in detail for all patients to know about the site, size, shape,
      extent and nature of the tumour. History, examination, pre-operative MRI
      findings, post-operative findings were documented in patient's pro forma. Short
      term as well as long term post-operative results were documented after surgery,
      during stay at hospital and followup visits till 6 months. RESULTS: In this
      study, 56 patients with spinal intradural tumours were observed. Male to female
      ratio was 1.33:1. Age ranged from 5-65 years (32.5+/-14.6). Paraparesis,
      hypesthesia, sphincter dysfunction were the presenting symptoms in most of the
      patients. 47% (21) patients improved according to MRC Grading system 46% (20)
      patients remained static 7% (3) patients deteriorated. Wound infection was found 
      in 7 (12.5%) patients, followed by Neurological Deficit in 5 (8.9%) cases,
      Meningitis was found in 2 (3.57%), CSF leak was noted in 4 (7.14%) patients and
      mortality in 1 (1.7%) of the case. CONCLUSIONS: Surgery of the intradural spinal 
      tumours carry good neurological outcome with acceptable complication rates.
FAU - Ali, Gohar
AU  - Ali G
AD  - Department of Neurosurgery, Mardan Medical Complex Mardan.
FAU - Khan, Shahbaz Ali
AU  - Khan SA
AD  - Department of Neurosurgery, Ayub Medical Institute, Abbottaba, Pakistan.
FAU - Khan Afridi, Ehtisham Ahmed
AU  - Khan Afridi EA
AD  - Department of Neurosurgery, Ayub Medical Institute, Abbottaba, Pakistan.
FAU - Aurangzeb, Ahsan
AU  - Aurangzeb A
AD  - Department of Neurosurgery, Ayub Medical Institute, Abbottaba, Pakistan.
FAU - Asghar, Asghar
AU  - Asghar A
AD  - Department of Neurosurgery, Ayub Medical Institute, Abbottaba, Pakistan.
FAU - Khalid, Shah
AU  - Khalid S
AD  - Department of Neurosurgery, Ayub Medical Institute, Abbottaba, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - J Ayub Med Coll Abbottabad
JT  - Journal of Ayub Medical College, Abbottabad : JAMC
JID - 8910750
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Neurosurgical Procedures/adverse effects/mortality/statistics & numerical data
MH  - Postoperative Complications/epidemiology
MH  - Spinal Cord Neoplasms/*surgery
MH  - Spine/*surgery
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Neurological deficit; Wound infection; Meningitis; CSF leak
OT  - Spinal intradural tumours
EDAT- 2020/05/30 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
AID - 7241/2849 [pii]
PST - ppublish
SO  - J Ayub Med Coll Abbottabad. 2020 Jan- Mar;32(1):87-90.


PMID- 32468631
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20220716
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Vaccine Rationing and the Urgency of Social Justice in the Covid-19 Response.
PG  - 46-49
LID - 10.1002/hast.1113 [doi]
AB  - The Covid-19 pandemic needs to be considered from two perspectives
      simultaneously. First, there are questions about which policies are most
      effective and fair in the here and now, as the pandemic unfolds. These polices
      concern, for example, who should receive priority in being tested, how to
      implement contact tracing, or how to decide who should get ventilators or
      vaccines when not all can. Second, it is imperative to anticipate the medium- and
      longer-term consequences that these policies have. The case of vaccine rationing 
      is particularly instructive. Ethical, epidemiological, and economic reasons
      demand that rationing approaches give priority to groups who have been
      structurally and historically disadvantaged, even if this means that overall life
      years gained may be lower.
CI  - (c) 2020 The Hastings Center.
FAU - Schmidt, Harald
AU  - Schmidt H
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
RN  - 0 (Vaccines)
SB  - IM
MH  - Age Factors
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/organization & administration
MH  - Comorbidity
MH  - Contact Tracing/ethics/methods
MH  - Coronavirus Infections/*epidemiology/ethnology/*prevention & control
MH  - Health Care Rationing/*ethics
MH  - Health Status
MH  - Health Status Disparities
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*epidemiology/ethnology/*prevention & control
MH  - Racial Groups
MH  - SARS-CoV-2
MH  - Social Justice
MH  - Socioeconomic Factors
MH  - Vaccines/*supply & distribution
MH  - Ventilators, Mechanical/supply & distribution
PMC - PMC7283636
OTO - NOTNLM
OT  - *Covid-19
OT  - *health disparities
OT  - *public health ethics
OT  - *public health policies
OT  - *social justice
OT  - *vaccine rationing
EDAT- 2020/05/30 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1002/hast.1113 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):46-49. doi: 10.1002/hast.1113. Epub 2020 May
      28.


PMID- 32468544
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20210719
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1194
DP  - 2020
TI  - Informatics and Cognitive Assessment: A RUDAS Scale Paradigm.
PG  - 285-291
LID - 10.1007/978-3-030-32622-7_26 [doi]
AB  - BACKGROUND: Cognitive assessment is an essential element of the screening process
      of Alzheimer's disease. The prevalence of dementia is increasing and so are the
      numbers of immigrants and elderly population relocating and in need for health
      diagnosis and treatment. However, most of the psychometric tools used in
      psychological assessments are time-consuming and suffer from biases of language
      and cultural restrictions. OBJECTIVES: Our objective was to create a computerized
      version of a multicultural cognitive screening test, which would simplify
      cognitive assessment of elderly multicultural population, as routine part of
      health check-up procedures. METHODS: The application was implemented in Android
      Studio and was written in Java code with the use of a home PC and a tablet.
      Rowland Universal Dementia Assessment Scale (RUDAS) was chosen. RUDAS is a
      cognitive screening tool with good psychological characteristics, which was
      created for multicultural and bilingual populations and was free to download. The
      collaboration with an authorized psychologist was essential for the ethics of the
      psychometric science. RESULTS: The complete computerized version of RUDAS will
      include the six-item questionnaire, assessing specific cognitive domains which
      are in high correlation with Alzheimer's screening process, such as registration,
      visuospatial orientation, praxis, visuo-constructional drawing, judgment, memory 
      recall and language. CONCLUSION: The utilization of informatics in making
      cognitive assessment a user-friendly, validated, not time- or cost-consuming
      procedure would add value to psychometric tools which still are administered with
      "pen and paper", when this proceeds with respect to the ethics of the science.
FAU - Riganis, Athanasios
AU  - Riganis A
AD  - Department of Informatics, Ionian University, Corfu, Greece.
      thanasisri@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/diagnosis
MH  - *Cognition/classification
MH  - Cultural Diversity
MH  - *Dementia/diagnosis
MH  - Humans
MH  - *Neuropsychological Tests/standards
MH  - Psychometrics/standards/trends
MH  - *Software/standards
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Computerized testing
OT  - Multicultural cognitive assessment
EDAT- 2020/05/30 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - 10.1007/978-3-030-32622-7_26 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2020;1194:285-291. doi: 10.1007/978-3-030-32622-7_26.


PMID- 32468508
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20220219
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Aug
TI  - Plasma from donors recovered from the new Coronavirus 2019 as therapy for
      critical patients with COVID-19 (COVID-19 plasma study): a multicentre study
      protocol.
PG  - 819-824
LID - 10.1007/s11739-020-02384-2 [doi]
AB  - Since the end of 2019, a new coronavirus strain has been reported in the Chinese 
      province of Wuhan, indicated as 2019-nCoV or SARS-CoV-2. In February 2020, the
      first case of transmission on Italian soil was reported. On March 09, 2020, at
      the time of protocol design, the Italian Ministry of Health reported 10,149
      people who had contracted the virus; of these, 8514 were positive, of which 5038 
      were hospitalized with symptoms (59.2%) and 877 in intensive care (10.3%), while 
      the remaining 2599 were in home isolation; 631 were deceased (6.2%) and 1004
      healed (9.9%). To date there are no studies in the literature that demonstrate
      its feasibility and efficacy in the context of the worldwide SARS-CoV-2 epidemic.
      Based upon the little existing evidence, we planned to assess the efficacy of the
      infusion of hyperimmune plasma in COVID-19 patients in a one-arm proof-of-concept
      clinical trial. The primary objective of our study is to evaluate the efficacy of
      the administration of plasma taken from convalescent donors of COVID-19 to
      critically ill patients with COVID-19 in terms of their survival. Death from any 
      cause will be considered. The main limit of this study is its one-arm
      proof-of-concept design with only 43 patients enrolled. However, in the absence
      of previous evidence, larger and/or randomized trials did not appear to be
      ethically acceptable. Moreover, the results from this study, if encouraging, will
      allow us to plan further informed large clinical trials. Trial registration:
      NCT04321421 March 23, 2020.
FAU - Perotti, Cesare
AU  - Perotti C
AUID- ORCID: http://orcid.org/0000-0003-0457-8662
AD  - Immunohematology and Transfusion Service, Fondazione IRCCS Policlinico San
      Matteo, Pavia, Italy.
FAU - Del Fante, Claudia
AU  - Del Fante C
AUID- ORCID: http://orcid.org/0000-0003-0822-0342
AD  - Immunohematology and Transfusion Service, Fondazione IRCCS Policlinico San
      Matteo, Pavia, Italy. c.delfante@smatteo.pv.it.
FAU - Baldanti, Fausto
AU  - Baldanti F
AUID- ORCID: http://orcid.org/0000-0002-3358-8969
AD  - Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
AD  - Department of Clinical-SurgicalDiagnostic and Pediatric Sciences, University of
      Pavia, Pavia, Italy.
FAU - Franchini, Massimo
AU  - Franchini M
AD  - Immunohematology and Transfusion Service, Carlo Poma Hospital, Mantova, Italy.
FAU - Percivalle, Elena
AU  - Percivalle E
AUID- ORCID: http://orcid.org/0000-0002-3355-1410
AD  - Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
FAU - Vecchio Nepita, Edoardo
AU  - Vecchio Nepita E
AD  - Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
FAU - Seminari, Elena
AU  - Seminari E
AUID- ORCID: http://orcid.org/0000-0001-5246-928X
AD  - Department of Clinical-SurgicalDiagnostic and Pediatric Sciences, University of
      Pavia, Pavia, Italy.
FAU - De Silvestri, Annalisa
AU  - De Silvestri A
AUID- ORCID: http://orcid.org/0000-0003-3128-8441
AD  - Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo,
      Pavia, Italy.
FAU - Bruno, Raffele
AU  - Bruno R
AUID- ORCID: http://orcid.org/0000-0002-0235-9207
AD  - Department of Clinical-SurgicalDiagnostic and Pediatric Sciences, University of
      Pavia, Pavia, Italy.
AD  - Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
FAU - Klersy, Catherine
AU  - Klersy C
AUID- ORCID: http://orcid.org/0000-0003-0314-8548
AD  - Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo,
      Pavia, Italy.
LA  - eng
SI  - ClinicalTrials.gov/NCT04321421
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200528
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - COVID-19 serotherapy
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*immunology/*therapy
MH  - Humans
MH  - Immunization, Passive/*methods
MH  - Pandemics
MH  - Plasma/*immunology
MH  - Pneumonia, Viral/*immunology/*therapy
MH  - SARS-CoV-2
PMC - PMC8849045
OTO - NOTNLM
OT  - *COVID-19
OT  - *Hyperimmune plasma
OT  - *Plasmapheresis
EDAT- 2020/05/30 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1007/s11739-020-02384-2 [doi]
AID - 10.1007/s11739-020-02384-2 [pii]
PST - ppublish
SO  - Intern Emerg Med. 2020 Aug;15(5):819-824. doi: 10.1007/s11739-020-02384-2. Epub
      2020 May 28.


PMID- 32468475
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20200911
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1195
DP  - 2020
TI  - Gene Editing, Sexual Reproduction, and the Arts: The Present, the Future, and the
      Imagined.
PG  - 177
LID - 10.1007/978-3-030-32633-3_25 [doi]
AB  - In recent years, popular culture has been graced with countless news announcing
      novel developments in genome editing. While many experiments are still in their
      early stages, genome editing seems very promising. Often betraying a
      sensationalist and triumphant tone, news coverage focuses on the potentials that 
      these developments will have for the advancement of the human species, i.e., the 
      eradication of disease, the extension of life, the improvement of the body and
      its appearance, etc. The future looks hopeful and unproblematic according to
      these accounts. On the opposite end of the spectrum, some may wonder whether
      these developments pose a potential worsening of the human condition: Are these
      developments safe? What are the ethical implications? Who will benefit from these
      developments? Given today's social divisions and cultural conflicts, these voices
      predict a rather unpromising future and warn against the pursue of innovation at 
      any cost.
FAU - Buiani, Roberta
AU  - Buiani R
AD  - ArtSci Salon, Fields Institute, Toronto, ON, Canada. rbuiani@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - *Art
MH  - CRISPR-Cas Systems
MH  - Gene Editing/*ethics/*trends
MH  - Humans
MH  - Reproductive Techniques, Assisted/*ethics/*trends
EDAT- 2020/05/30 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1007/978-3-030-32633-3_25 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2020;1195:177. doi: 10.1007/978-3-030-32633-3_25.


PMID- 32468456
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20210108
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1195
DP  - 2020
TI  - Three-Dimensional Models for Studying Neurodegenerative and Neurodevelopmental
      Diseases.
PG  - 35-41
LID - 10.1007/978-3-030-32633-3_6 [doi]
AB  - Human brain possesses a unique anatomy and physiology. For centuries,
      methodological barriers and ethical challenges in accessing human brain tissues
      have restricted researchers into using 2-D cell culture systems and model
      organisms as a tool for investigating the mechanisms underlying neurological
      disorders in humans. However, our understanding regarding the human brain
      development and diseases has been recently extended due to the generation of 3D
      brain organoids, grown from human stem cells or induced pluripotent stem cells
      (iPSCs). This system evolved into an attractive model of brain diseases as it
      recapitulates to a great extend the cellular organization and the
      microenvironment of a human brain. This chapter focuses on the application of
      brain organoids in modelling several neurodevelopmental and neurodegenerative
      diseases.
FAU - Tsaridou, Stavroula
AU  - Tsaridou S
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
FAU - Skamnelou, Margarita
AU  - Skamnelou M
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
FAU - Iliadou, Marianna
AU  - Iliadou M
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Lokka, Georgia
AU  - Lokka G
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Parlapani, Evangelia
AU  - Parlapani E
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Mougkogianni, Maria
AU  - Mougkogianni M
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Danalatos, Rodolfos-Iosif
AU  - Danalatos RI
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Kanellou, Anastasia
AU  - Kanellou A
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece.
FAU - Chlorogiannis, Dimitris-David
AU  - Chlorogiannis DD
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
FAU - Kyrousi, Christina
AU  - Kyrousi C
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece.
AD  - Max Planck Institute of Psychiatry, Munich, Germany.
FAU - Taraviras, Stavros
AU  - Taraviras S
AD  - Biomedical Postgraduate Programme, Stem Cells and Regenerative Medicine, Medical 
      School, University of Patras, Patras, Greece. taraviras@med.upatras.gr.
AD  - Department of Physiology, School of Medicine, University of Patras, Patras,
      Greece. taraviras@med.upatras.gr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - Brain/*pathology
MH  - Humans
MH  - Induced Pluripotent Stem Cells/pathology
MH  - Neurodegenerative Diseases/*pathology
MH  - Neurodevelopmental Disorders/*pathology
MH  - Organoids/*pathology
OTO - NOTNLM
OT  - Neurodegenerative disease
OT  - Neurodevelopmental diseases
OT  - Three-dimensional models
EDAT- 2020/05/30 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1007/978-3-030-32633-3_6 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2020;1195:35-41. doi: 10.1007/978-3-030-32633-3_6.


PMID- 32468424
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 2038-3312 (Electronic)
IS  - 2038-131X (Linking)
VI  - 72
IP  - 2
DP  - 2020 Jun
TI  - The Italian National Registry for minimally invasive pancreatic surgery: an
      initiative of the Italian Group of Minimally Invasive Pancreas Surgery (IGoMIPS).
PG  - 379-385
LID - 10.1007/s13304-020-00808-4 [doi]
AB  - The value of minimally invasive pancreatic surgery (MIPS) is still uncertain,
      despite the growing number of publications, including reviews and meta-analyses, 
      and the quick diffusion of these procedures worldwide. The Italian Group of
      Minimally Invasive Pancreas Surgery (IGoMIPS) was created under the auspices of
      three Scientific Societies: Associazione Italiana Studio Pancreas (AISP),
      Associazione Italiana Chirurgia Epato-Bilio-Pancreatica (AICEP, former IT-IHPBA),
      and Societa Italiana di Chirurgia Endoscopica (SICE). The main aim of IGoMIPS is 
      to develop and implement a national registry for MIPS. IGoMIPS was founded on
      February 22, 2019 in Pisa. The IGoMIPS registry became operational in September
      2019, following approval by the Ethic Committees of founding Institutions,
      inscription into the Registry of Patient Registries (RoPR), and a wrap-up meeting
      held in Bologna during the Annual Congress of the Italian Surgical Society.
      During this meeting IGoMIPS members approved that the Italian Registry will
      provide data to the European Registry, while retaining the right to analyze and
      publish Italian data. An audience survey was also conducted to obtain information
      on perceived value and current implementation of MIPS in founding Institutions.
      MIPS is performed in 94.7% of IGoMIPS centers, including pancreaticoduodenectomy 
      in 42.1%. Robotic assistance was employed in 52.6% of Institutions. The annual
      volume of MIPS was 6-10 cases in 38.9% of the centers, 11-20 cases in 16.7%,
      21-30 cases in 22.2%, and > 30 cases in 22.2%. The registry was felt to be
      extremely important for both safety improvement and educational purposes by 94.5%
      of the centers.
FAU - Zerbi, Alessandro
AU  - Zerbi A
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan,
      Italy.
AD  - IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.
FAU - Capretti, Giovanni
AU  - Capretti G
AUID- ORCID: http://orcid.org/0000-0001-9429-3008
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan,
      Italy. giovanni.capretti@hunimed.eu.
AD  - IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.
      giovanni.capretti@hunimed.eu.
FAU - Napoli, Niccolo
AU  - Napoli N
AD  - Universita di Pisa, Pisa, Italy.
FAU - Belli, Giulio
AU  - Belli G
AD  - Ospedale Loreto Mare, Naples, Italy.
FAU - Coppola, Roberto
AU  - Coppola R
AD  - , Campus Biomedico, Rome, Italy.
FAU - Falconi, Massimo
AU  - Falconi M
AD  - Chirurgia del Pancreas, Universita Vita Salute San Raffaele, Milan, Italy.
FAU - Salvia, Roberto
AU  - Salvia R
AD  - Policlinico di Verona Borgo Roma, Verona, Italy.
FAU - Valeri, Andrea
AU  - Valeri A
AD  - Ospedale Careggi, Florence, Italy.
FAU - Alfieri, Sergio
AU  - Alfieri S
AD  - Policlinico Gemelli, Rome, Italy.
FAU - Berti, Stefano
AU  - Berti S
AD  - Ospedale Sant' Andrea, La Spezia, Italy.
FAU - Butturini, Giovanni
AU  - Butturini G
AD  - Ospedale Pederzoli, Peschiera del Garda, VR, Italy.
FAU - Conzo, Giovanni
AU  - Conzo G
AD  - Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy.
FAU - Coratti, Andrea
AU  - Coratti A
AD  - Ospedale Careggi, Florence, Italy.
FAU - Dalla Valle, Raffaele
AU  - Dalla Valle R
AD  - Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
FAU - Garulli, Gianluca
AU  - Garulli G
AD  - Ospedale Infermi, Rimini, Italy.
FAU - Ettorre, Giuseppe Maria
AU  - Ettorre GM
AD  - Ospedale San Camillo-Forlanini, Rome, Italy.
FAU - Ferrari, Giovanni
AU  - Ferrari G
AD  - Ospedale Niguarda, Milan, Italy.
FAU - Ferrero, Alessandro
AU  - Ferrero A
AD  - Ospedale Mauriziano, Turin, Italy.
FAU - Jovine, Elio
AU  - Jovine E
AD  - Ospedale Maggiore, Bologna, Italy.
FAU - Maida, Pietro
AU  - Maida P
AD  - Ospedale del Mare, Naples, Italy.
FAU - Minni, Francesco
AU  - Minni F
AD  - Ospedale Sant'Orsola, Bologna, Italy.
FAU - Molino, Carlo
AU  - Molino C
AD  - Ospedale Cardarelli, Naples, Italy.
FAU - Nardo, Bruno
AU  - Nardo B
AD  - Ospedale Annunziata, Cosenza, Italy.
FAU - De Paolis, Paolo
AU  - De Paolis P
AD  - Ospedale Molinette, Turin, Italy.
FAU - Testini, Mario
AU  - Testini M
AD  - Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, Italy.
FAU - Boggi, Ugo
AU  - Boggi U
AD  - Universita di Pisa, Pisa, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200529
PL  - Italy
TA  - Updates Surg
JT  - Updates in surgery
JID - 101539818
SB  - IM
MH  - Aged
MH  - Female
MH  - General Surgery/*organization & administration
MH  - Humans
MH  - Italy
MH  - Laparoscopy/methods/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - *Minimally Invasive Surgical Procedures/methods/statistics & numerical data
MH  - Pancreas/*surgery
MH  - Pancreatectomy/methods/statistics & numerical data
MH  - Pancreaticoduodenectomy/methods/statistics & numerical data
MH  - *Registries
MH  - Societies, Medical/*organization & administration
MH  - Societies, Scientific/*organization & administration
OTO - NOTNLM
OT  - Distal pancreatectomy
OT  - Laparoscopic
OT  - Minimally invasive
OT  - Pancreatic surgery
OT  - Pancreaticoduodenectomy
OT  - Registry
EDAT- 2020/05/30 06:00
MHDA- 2020/09/22 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1007/s13304-020-00808-4 [doi]
AID - 10.1007/s13304-020-00808-4 [pii]
PST - ppublish
SO  - Updates Surg. 2020 Jun;72(2):379-385. doi: 10.1007/s13304-020-00808-4. Epub 2020 
      May 29.


PMID- 32468421
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1935-973X (Print)
IS  - 1935-9748 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Aug
TI  - Ethical and Practical Considerations for Integrating Cellular ("Stem Cell")
      Therapy into Clinical Practice.
PG  - 525-529
LID - 10.1007/s12178-020-09647-7 [doi]
AB  - PURPOSE OF REVIEW: Cellular therapies, also known as "stem cell" interventions
      (SCI), have undergone a rapid popularization in the USA and worldwide. The
      current review aimed at outlining (1) the ethical challenges facing the
      implementation of SCI; (2) the applicability of the currently available SCI; and 
      (3) recommendations to achieve ethical, well-regulated incorporation of SCI in
      the clinical setting. RECENT FINDINGS: Concerns regarding the inadequate
      characterization, poor adverse effects disclosure, and unorthodox, often
      inappropriate, market practices have engendered a genuine concern regarding the
      SCI compliance with ethical standards. Six instances of litigation on the basis
      of misrepresentation or inappropriate informed consent were recorded between 2012
      and 2018. Such concerns have been furthered by the loopholes in the regulatory
      aspect governing the use of SCI coupled with the unclear literature-reported
      efficacy and diverse spectrum of profess indications. Similarly, the application 
      of SCI in the clinical field is yet to prove its value. The uncertain efficacy,
      coupled with obscure true-costs of utilization, impedes a value-based assessment.
      A multidisciplinary approach involving legislative and medical professional
      societies should continue to advance regulations that govern SCI. A
      well-regulated system that allows for the ethical integration of SCI with
      appositely evidenced-based described benefits and risks should be sought.
FAU - Piuzzi, Nicolas S
AU  - Piuzzi NS
AD  - Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, USA.
      piuzzin@ccf.org.
FAU - Emara, Ahmed
AU  - Emara A
AD  - Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, USA.
FAU - Chahla, Jorge
AU  - Chahla J
AD  - Department of Orthopaedic Surgery, Division of Sports Medicine, Rush University
      Medical Center, Chicago, IL, USA.
FAU - Mandelbaum, Bert R
AU  - Mandelbaum BR
AD  - Department of Orthopaedic Surgery, Cedars Sinai Kerlan Jobe Institute, Santa
      Monica, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rev Musculoskelet Med
JT  - Current reviews in musculoskeletal medicine
JID - 101317803
PMC - PMC7340700
OTO - NOTNLM
OT  - Clinical applications
OT  - Direct-to-consumer marketing
OT  - Efficacy
OT  - Ethics
OT  - Legislation
OT  - Litigation
OT  - Stem cells
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:01
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:01 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1007/s12178-020-09647-7 [doi]
AID - 10.1007/s12178-020-09647-7 [pii]
PST - ppublish
SO  - Curr Rev Musculoskelet Med. 2020 Aug;13(4):525-529. doi:
      10.1007/s12178-020-09647-7.


PMID- 32468238
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1868-310X (Print)
IS  - 1868-310X (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul
TI  - The implementation of pharmacogenomics into UK general practice: a qualitative
      study exploring barriers, challenges and opportunities.
PG  - 269-277
LID - 10.1007/s12687-020-00468-2 [doi]
AB  - Pharmacogenomics describes interpatient genetic variability in drug responses.
      Information based on whole genome sequencing will soon open up the field of
      pharmacogenomics and facilitate the use of genomic information relating to drug
      metabolism and drug responses. We undertook a qualitative study, aiming to
      explore the potential barriers, opportunities and challenges facing the
      implementation of pharmacogenomics into primary care. Semi-structured interviews 
      were undertaken with 18 clinical participants (16 GPs and 2 other clinicians).
      All interviews were recorded and transcribed verbatim. Using a thematic analysis 
      approach, data items were coded, ordered and themes constructed. Most
      participants were aged 55-60 years and worked as part-time clinical GPs with
      other clearly defined roles. The emerging themes covered several areas of
      concern, including the following: the utility of pharmacogenomics and the value
      of introducing such testing into primary care; how to educate the primary care
      workforce and 'mainstream' pharmacogenomics; the ethical, legal and social
      aspects of pharmacogenomics and its impact on patients; and potential impacts on 
      the healthcare system particularly around economics and informatics. Most
      participants had concerns about pharmacogenomics and felt that there were a
      number of barriers and challenges to its implementation into routine primary
      care. Most striking were their concerns around the cost-effectiveness of using
      pharmacogenomics in primary care. At the same time most recognised the increasing
      availability of direct-to-consumer testing, and felt that this would drive the
      need to understand the ethical and social implications of using genomic
      information in primary care. This study has raised important issues that need to 
      be considered when planning the implementation of pharmacogenomics into clinical 
      practice. Prior to the implementation of genomic testing into day-to-day practice
      in UK primary care, it is important that considerations around education,
      cost-effectiveness and informatics are addressed, as well as the impact on
      patients.
FAU - Rafi, I
AU  - Rafi I
AUID- ORCID: http://orcid.org/0000-0001-9673-9675
AD  - St George's, University of London, London, UK. irafi@sgul.ac.uk.
FAU - Crinson, I
AU  - Crinson I
AD  - St George's, University of London, London, UK.
FAU - Dawes, M
AU  - Dawes M
AD  - Department of Family Practice, University of British Columbia, Vancouver, Canada.
FAU - Rafi, D
AU  - Rafi D
AD  - University of Birmingham, Birmingham, UK.
FAU - Pirmohamed, M
AU  - Pirmohamed M
AD  - Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
FAU - Walter, F M
AU  - Walter FM
AD  - The Primary Care Unit, Department of Public Health & Primary Care, University of 
      Cambridge, Cambridge, UK.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - Germany
TA  - J Community Genet
JT  - Journal of community genetics
JID - 101551501
PMC - PMC7295877
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:01
CRDT- 2020/05/30 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:01 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1007/s12687-020-00468-2 [doi]
AID - 10.1007/s12687-020-00468-2 [pii]
PST - ppublish
SO  - J Community Genet. 2020 Jul;11(3):269-277. doi: 10.1007/s12687-020-00468-2. Epub 
      2020 May 28.


PMID- 32468195
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Compassionate use of psychedelics.
PG  - 485-496
LID - 10.1007/s11019-020-09958-z [doi]
AB  - In the present paper, we discuss the ethics of compassionate psychedelic
      psychotherapy and argue that it can be morally permissible. When talking about
      psychedelics, we mean specifically two substances: psilocybin and MDMA. When
      administered under supportive conditions and in conjunction with psychotherapy,
      therapies assisted by these substances show promising results. However, given the
      publicly controversial nature of psychedelics, compassionate psychedelic
      psychotherapy calls for ethical justification. We thus review the safety and
      efficacy of psilocybin- and MDMA-assisted therapies and claim that it can be
      rational for some patients to try psychedelic therapy. We think it can be
      rational despite the uncertainty of outcomes associated with compassionate use as
      an unproven treatment regime, as the expected value of psychedelic psychotherapy 
      can be assessed and can outweigh the expected value of routine care, palliative
      care, or no care at all. Furthermore, we respond to the objection that
      psychedelic psychotherapy is morally impermissible because it is epistemically
      harmful. We argue that given the current level of understanding of psychedelics, 
      this objection is unsubstantiated for a number of reasons, but mainly because
      there is no experimental evidence to suggest that epistemic harm actually takes
      place.
FAU - Greif, Adam
AU  - Greif A
AUID- ORCID: http://orcid.org/0000-0003-3441-1978
AD  - Department of Philosophy and History of Philosophy, Faculty of Arts, Comenius
      University, Safarikovo namestie 6, 814 99, Bratislava, Slovak Republic.
      adam.greif@uniba.sk.
FAU - Surkala, Martin
AU  - Surkala M
AD  - Slovak Psychedelic Society, Karpatske namestie 10A, 831 06, Bratislava, Slovak
      Republic.
LA  - eng
GR  - APVV-18-0178/Agentura na Podporu Vyskumu a Vyvoja
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Chronic Disease
MH  - Compassionate Use Trials/*standards
MH  - Hallucinogens/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Mental Disorders/*therapy
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/adverse
      effects/*therapeutic use
MH  - Psilocybin/administration & dosage/adverse effects/*therapeutic use
MH  - Psychotherapy/*methods
MH  - Terminal Care/methods
OTO - NOTNLM
OT  - Compassionate use
OT  - Epistemic harm
OT  - Ethics
OT  - Naturalism
OT  - Psychedelic
OT  - Uncertainty
EDAT- 2020/05/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1007/s11019-020-09958-z [doi]
AID - 10.1007/s11019-020-09958-z [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):485-496. doi: 10.1007/s11019-020-09958-z.


PMID- 32467596
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20210408
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 582
IP  - 7810
DP  - 2020 Jun
TI  - Ethical guidelines for COVID-19 tracing apps.
PG  - 29-31
LID - 10.1038/d41586-020-01578-0 [doi]
FAU - Morley, Jessica
AU  - Morley J
FAU - Cowls, Josh
AU  - Cowls J
FAU - Taddeo, Mariarosaria
AU  - Taddeo M
FAU - Floridi, Luciano
AU  - Floridi L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CIN - Nature. 2020 Jul;583(7816):360. PMID: 32665629
MH  - COVID-19
MH  - Confidentiality/*ethics
MH  - Contact Tracing/*ethics/*instrumentation
MH  - Coronavirus Infections/diagnosis/*prevention & control/*transmission
MH  - *Guidelines as Topic
MH  - Healthcare Disparities/ethics
MH  - Humans
MH  - Informed Consent
MH  - Internationality
MH  - Mobile Applications/*ethics
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/diagnosis/*prevention & control/*transmission
MH  - Privacy/legislation & jurisprudence
MH  - Time Factors
MH  - Volunteers
OTO - NOTNLM
OT  - *Policy
OT  - *Public health
OT  - *SARS-CoV-2
OT  - *Technology
EDAT- 2020/05/30 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1038/d41586-020-01578-0 [doi]
AID - 10.1038/d41586-020-01578-0 [pii]
PST - ppublish
SO  - Nature. 2020 Jun;582(7810):29-31. doi: 10.1038/d41586-020-01578-0.


PMID- 32467410
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210903
IS  - 1528-1132 (Electronic)
IS  - 0009-921X (Linking)
VI  - 478
IP  - 9
DP  - 2020 Sep
TI  - Are the Lives of Animals Well-spent in Laboratory Science Research? A Study of
      Orthopaedic Animal Studies in Turkey.
PG  - 1965-1970
LID - 10.1097/CORR.0000000000001335 [doi]
AB  - BACKGROUND: As in all fields of medicine, animal studies are widely performed in 
      orthopaedics and have increased in number over time. However, it is not clear to 
      what extent these studies provide a basis for future research or advancements in 
      clinical science. Concerns about the reliability and translational ability of
      animal studies have been reported, and major orthopaedic journals and
      organizations are encouraging the reduction of unnecessary experiments on
      animals. QUESTION/PURPOSES: (1) What proportion of animal studies conducted for
      orthopaedic research in Turkey were never published? And of those that were
      published, how long did it take to publish? (2) What proportion of those studies 
      were published in journals with an Impact Factor of 2 or more? (3) What
      proportion of those published papers were never cited or cited only once? (4)
      What was the contribution to science of an animal euthanized for orthopaedic
      research in Turkey? METHODS: We reviewed all oral and poster presentations at the
      Turkish National Congress of Orthopaedics and Traumatology from 2009 to 2017
      (retrieved from the archives of Acta Orthopaedica et Traumatologica Turcica), as 
      well as all postgraduate theses in orthopaedics from 1991 to 2017 (retrieved from
      the archives of the National Thesis Center of the Council of Higher Education) to
      identify all orthopaedic studies that involved animals. We searched the keywords 
      "animal studies," "experimental studies," and "orthopaedics" in these archives.
      We defined animal research as orthopaedic studies based on animal models. From
      this search and using that definition, 252 studies were identified. Of those, 4% 
      (9) were excluded as they were thesis studies with no abstract in the archives.
      Thus, a total of 243 animal studies performed in Turkey were included for
      analysis in this retrospective study. The abstracts of these studies were
      examined to determine the study model (such as bone fracture models, tendon
      healing models, cartilage models) and number of euthanized animals. Between 1991 
      and 2017, 9412 vertebrate animals were euthanized for these studies. We searched 
      PubMed, Google Scholar, ResearchGate, and ORCID to determine whether these papers
      were subsequently published, in which journal, and how long after the initial
      presentation publication occurred. The Web of Science 2019 database was used to
      determine the Impact Factor of the journals, the total citation count of each
      study, and the mean annual citation for each study (citations per year). For
      purposes of this analysis, we divided journals into those with an Impact Factor
      of 2 or more, 4 or more, and those with an Impact Factor below 2. The mean annual
      citation per euthanized animal (citations per animal per year) was calculated to 
      determine the contribution of a euthanized animal to science. RESULTS: A total of
      42% (101 of 243) of the animal studies in Turkey were never published. For all
      published studies, the mean time to publication was 2.2 +/- 2.6 years (95% CI 1.7
      to 2.6). The proportion of studies published in orthopaedic journals with an
      Impact Factor of 2 or more was 14% (34 of 243). Among the 142 published papers,
      38% (54) were either never cited or were cited only once, and the mean citations 
      per year was 1.1 +/- 1.7 (95% CI 0.7 to 1.3). The mean citations per animal/year 
      among the 142 published studies was 0.03 +/- 0.04 (95% CI 0.02 to 0.04).
      CONCLUSION: In the 243 theses and national congress presentations, 9412 animals
      were euthanized. Based on the low percentage of papers using animals that were
      euthanized and the very low proportion of studies published in higher-Impact
      Factor journals or garnering more than a single citation, in aggregate, little
      seems to have been gained from the loss of animal life. Future studies should try
      to replicate or refute our results in other countries. CLINICAL RELEVANCE:
      Orthopaedic researchers should try to reduce their use of unnecessary animal
      studies, for example, by reporting on the use of the "3Rs" (replacement,
      reduction, and refinement) in the development of an animal study design, as well 
      as through following universal guidelines so that a study might have a clinical
      impact. Researchers should not conduct an animal study until they are convinced
      that the expected results are quite likely to deliver substantial benefit to
      people or to advance science in a meaningful way; although this seems intuitive, 
      our results suggest that this may not be taking place. Ethics committees in
      Turkey should consider more detailed questioning before approving animal studies.
      If our results are replicated elsewhere, then a broader look at how these
      approvals are conducted should be performed.
FAU - Ozturk, Alper
AU  - Ozturk A
AD  - A. Ozturk, O. Ersan, Diskapi Yildirim Beyazit Training and Research Hospital,
      Ankara, Turkey.
FAU - Ersan, Onder
AU  - Ersan O
AD  - A. Ozturk, O. Ersan, Diskapi Yildirim Beyazit Training and Research Hospital,
      Ankara, Turkey.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
SB  - IM
CIN - Clin Orthop Relat Res. 2020 Sep;478(9):1961-1964. PMID: 32769546
CIN - Clin Orthop Relat Res. 2021 Mar 1;479(3):427-428. PMID: 33565766
MH  - Animal Experimentation/ethics/*statistics & numerical data
MH  - Animals
MH  - Biomedical Research/ethics/*statistics & numerical data
MH  - Ethics, Research
MH  - Euthanasia, Animal/ethics
MH  - Journal Impact Factor
MH  - Laboratory Animal Science/ethics/*statistics & numerical data
MH  - Orthopedics/ethics/*statistics & numerical data
MH  - Publishing/*statistics & numerical data
MH  - Turkey
PMC - PMC7431276
EDAT- 2020/05/30 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1097/CORR.0000000000001335 [doi]
AID - 00003086-202009000-00003 [pii]
PST - ppublish
SO  - Clin Orthop Relat Res. 2020 Sep;478(9):1965-1970. doi:
      10.1097/CORR.0000000000001335.


PMID- 32467305
OWN - NLM
STAT- Publisher
LR  - 20200529
IS  - 1473-4265 (Electronic)
IS  - 1468-215X (Linking)
DP  - 2020 May 28
TI  - A brief and personal history of 'what's in a name' in reproductive genetics.
LID - medhum-2019-011812 [pii]
LID - 10.1136/medhum-2019-011812 [doi]
AB  - Although Juliet's claim, 'What's in a name? That which we call a rose by any
      other name would smell as sweet', may apply to family names, 'that which we call'
      embryos and procedures in reproductive genetics often smell sweet because the
      names were created to perfume not-so-sweet-smelling practices.
      Reproductive-genetic scientists and clinicians, including myself, have used
      perfumed names to make our research smell sweet for research ethics boards,
      research grant funders, government regulators, hospital administrators and the
      general public. The sweet-smelling names in reproductive genetics explored here
      include 'pre-embryo', preimplantation genetic 'diagnosis', 'normal' embryo,
      'suitable' embryo, 'healthy' embryo, preimplantation genetic 'testing',
      'non-invasive prenatal testing', 'donation', and most recently 'mitochondrial
      replacement therapy', a sweet-smelling name for germline nuclear transfer
      prohibited in antireproductive cloning legislation in most countries. In order
      for informed choices to occur for women who come to clinicians for information
      regarding reproductive genetics, and for transparency of scrutiny by research
      ethics boards, governmental regulators and the general public, it is essential
      that we consider the real meaning of sweet-smelling names in reproductive
      genetics.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Nisker, Jeff
AU  - Nisker J
AD  - Obstetrics & Gynecology, Western University, Schulich School of Medicine &
      Dentistry, London, ON, Canada, N6A 5C1 jeff.nisker@lhsc.on.ca.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - Med Humanit
JT  - Medical humanities
JID - 100959585
SB  - IM
OTO - NOTNLM
OT  - genetics
OT  - narrative ethics
OT  - reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
AID - medhum-2019-011812 [pii]
AID - 10.1136/medhum-2019-011812 [doi]
PST - aheadofprint
SO  - Med Humanit. 2020 May 28. pii: medhum-2019-011812. doi:
      10.1136/medhum-2019-011812.


PMID- 32467290
OWN - NLM
STAT- Publisher
LR  - 20220220
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 28
TI  - Compensation and hazard pay for key workers during an epidemic: an argument from 
      analogy.
LID - medethics-2020-106389 [pii]
LID - 10.1136/medethics-2020-106389 [doi]
AB  - The COVID-19 pandemic has created unusually challenging and dangerous workplace
      conditions for key workers. This has prompted calls for key workers to receive a 
      variety of special benefits over and above their normal pay. Here, we consider
      whether two such benefits are justified: a no-fault compensation scheme for harm 
      caused by an epidemic and hazard pay for the risks and burdens of working during 
      an epidemic. Both forms of benefit are often made available to members of the
      armed forces for the harms, risks and burdens that come with military service. We
      argue from analogy that these benefits also ought to be provided to key workers
      during an epidemic because, like the military, key workers face unavoidable
      harms, risks and burdens in providing essential public good. The amount of
      compensation should be proportional to the harm suffered and the amount of hazard
      pay should be proportional to the risk and burden endured. Therefore, key workers
      should receive the same amount of compensation and hazard pay as the military
      where the harms, risks and burdens are equivalent. In the UK, a form of no-fault 
      compensation has recently been made available to the surviving families of key
      workers who suffer fatal COVID-19 infections. According to our argument, however,
      it is insufficient because it offers less to key workers than is made available
      to the families of armed services personnel killed on duty.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - McConnell, Doug
AU  - McConnell D
AUID- ORCID: http://orcid.org/0000-0001-5813-0834
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
      douglas.mcconnell@philosophy.ox.ac.uk.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: http://orcid.org/0000-0003-3958-8633
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
AD  - John Radcliffe Hospital, Oxford, UK.
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639952
OTO - NOTNLM
OT  - applied and professional ethics
OT  - ethics
OT  - health personnel
OT  - health workforce
OT  - public health ethics
COIS- Competing interests: DW works as a consultant neonatologist in the NHS.
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/01 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
AID - medethics-2020-106389 [pii]
AID - 10.1136/medethics-2020-106389 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 28. pii: medethics-2020-106389. doi:
      10.1136/medethics-2020-106389.


PMID- 32467256
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 27
TI  - The RECARDINA Study protocol: diagnostic utility of ultra-abbreviated
      echocardiographic protocol for handheld machines used by non-experts to detect
      rheumatic heart disease.
PG  - e037609
LID - 10.1136/bmjopen-2020-037609 [doi]
AB  - INTRODUCTION: Rheumatic heart disease (RHD) causes significant morbidity and
      mortality in young people from disadvantaged populations. Early detection through
      echocardiography screening can facilitate early access to treatment. Large-scale 
      implementation of screening could be feasible with the combination of inexpensive
      standalone ultrasound transducers and upskilling non-expert practitioners to
      perform abbreviated echocardiography. METHODS AND ANALYSIS: A prospective
      cross-sectional study will evaluate an abbreviated echocardiography screening
      protocol for the detection of latent (asymptomatic) RHD in high-risk populations.
      The study will evaluate the diagnostic accuracy of health worker conducted single
      parasternal long axis view with a sweep using handheld devices (SPLASH) (Philips 
      Lumify S4-1 phased array transducer). Each participant will have at least one
      reference test performed on the same day by an expert echocardiographer.
      Diagnosis of RHD will be determined by a panel of three experts, using 2012 World
      Heart Federation criteria. Sensitivity and specificity of the index test will be 
      calculated with 95% CIs, to determine diagnostic accuracy of a screen-and-refer
      approach to echocardiography screening for RHD. Remote review of SPLASH images
      obtained by health workers will facilitate evaluation of the sensitivity and
      specificity of an alternative approach, using external review of health worker
      obtained SPLASH images to decide onward referral. ETHICS AND DISSEMINATION:
      Ethics approval was obtained from the Human Research Ethics Committee of the
      Northern Territory Department of Health and Menzies School of Health Research,
      for the project to be carried out in Timor-Leste (HREC 2019-3399), and in
      Australia, following review by the Aboriginal Ethics subcommittee (HREC
      2019-334). Ethical and technical approval was granted in Timor-Leste, by the
      Institute National of Health Research Ethics and Technical Committee
      (1073-MS-INS/GDE/VII/2019). Study results will be disseminated in the communities
      involved in the study, and through peer-reviewed publications and conference
      abstracts. TRIAL REGISTRATION NUMBER: The Australia New Zealand Clinical Trials
      Registry (ACTRN12620000122954).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Francis, Joshua Reginald
AU  - Francis JR
AUID- ORCID: 0000-0001-9302-4543
AD  - Global and Tropical Health Division, Menzies School of Health Research, Charles
      Darwin University, Darwin, Northern Territory, Australia
      josh.francis@menzies.edu.au.
AD  - Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
FAU - Fairhurst, Helen
AU  - Fairhurst H
AD  - Global and Tropical Health Division, Menzies School of Health Research, Charles
      Darwin University, Darwin, Northern Territory, Australia.
FAU - Whalley, Gillian
AU  - Whalley G
AD  - Department of Medicine, University of Otago Dunedin School of Medicine, Dunedin, 
      New Zealand.
FAU - Kaethner, Alex
AU  - Kaethner A
AD  - NT Cardiac, Darwin, Northern Territory, Australia.
FAU - Ralph, Anna
AU  - Ralph A
AD  - Global and Tropical Health Division, Menzies School of Health Research, Charles
      Darwin University, Darwin, Northern Territory, Australia.
AD  - Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory,
      Australia.
FAU - Yan, Jennifer
AU  - Yan J
AD  - Global and Tropical Health Division, Menzies School of Health Research, Charles
      Darwin University, Darwin, Northern Territory, Australia.
AD  - Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
FAU - Cush, James
AU  - Cush J
AD  - Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
FAU - Wade, Vicki
AU  - Wade V
AD  - Global and Tropical Health Division, Menzies School of Health Research, Charles
      Darwin University, Darwin, Northern Territory, Australia.
FAU - Monteiro, Andre
AU  - Monteiro A
AD  - Internal Medicine, Hospital Nacional Guido Valadares, Dili, Timor-Leste.
FAU - Remenyi, Bo
AU  - Remenyi B
AD  - Global and Tropical Health Division, Menzies School of Health Research, Charles
      Darwin University, Darwin, Northern Territory, Australia.
AD  - Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12620000122954
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200527
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Cross-Sectional Studies
MH  - Echocardiography
MH  - Humans
MH  - Northern Territory
MH  - Prospective Studies
MH  - *Rheumatic Heart Disease/diagnostic imaging
MH  - Timor-Leste
PMC - PMC7259846
OTO - NOTNLM
OT  - *paediatric cardiology
OT  - *public health
OT  - *valvular heart disease
COIS- Competing interests: None declared.
EDAT- 2020/05/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037609 [pii]
AID - 10.1136/bmjopen-2020-037609 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 27;10(5):e037609. doi: 10.1136/bmjopen-2020-037609.


PMID- 32467255
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 27
TI  - Perception of modern radiotherapy learning: study protocol for a mixed-methods
      analysis of trainees and trainers at a UK cancer centre.
PG  - e037171
LID - 10.1136/bmjopen-2020-037171 [doi]
AB  - INTRODUCTION: Radiotherapy technology and postgraduate medical training have both
      evolved significantly over the last 20 years. Clinical Oncology is a recognised
      craft specialty where the apprenticeship model of clinical training is
      applicable. The challenges of learning radiotherapy in the modern radiotherapy
      department workplace have not been comprehensively described and no optimal
      method has been identified. METHODS AND ANALYSIS: Five Clinical Oncology trainers
      and five Clinical Oncology trainees at a regional cancer centre will be invited
      to undertake a semistructured interview regarding their personal accounts of
      learning radiotherapy. Both trainees and consultants will be treated as equal
      co-investors in the process of radiotherapy learning, with the common shared aim 
      of passing radiotherapy skills from trainers to trainees. Interviews will last up
      to 40 min. After transcription, an interpretative phenomenological analysis will 
      be performed. All trainees and trainers at the same centre (n=34) will then be
      invited to complete the same purpose-built questionnaire. Four trainers and three
      trainees have piloted the questionnaire, and input was sought from the national
      leads of the biennial UK Clinical Oncology training survey. Significance testing 
      will be performed on predefined questions and thematic analysis on white space
      questions. ETHICS AND DISSEMINATION: Medical education research is evolving in
      Clinical Oncology and Radiation Oncology but there are few studies
      comprehensively assessing this from the viewpoint of trainees and trainers.
      Pending the success of the proposed study, the approach detailed represents a
      novel method that could be used to identify the strengths and weaknesses of
      radiotherapy training in other centres and settings. Ethical and governance
      approvals have been granted by the University Research Ethics Committee and the
      Integrated Research Application System, respectively. This study has been funded 
      by Friends of the Cancer Centre.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Walls, Gerard
AU  - Walls G
AUID- ORCID: 0000-0003-0845-9732
AD  - Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast,
      N. Ireland g.walls@qub.ac.uk.
AD  - Cancer Centre, Belfast City Hospital, Belfast Health & Social Care Trust,
      Belfast, N. Ireland.
FAU - McAleer, James J
AU  - McAleer JJ
AD  - Cancer Centre, Belfast City Hospital, Belfast Health & Social Care Trust,
      Belfast, N. Ireland.
AD  - Centre for Medical Education, Queen's University Belfast, Belfast, UK.
FAU - Hanna, Gerard G
AU  - Hanna GG
AD  - Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast,
      N. Ireland.
AD  - Sir Peter MacCallum Department of Oncology, The University of Melbourne,
      Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200527
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Competence
MH  - Education, Medical, Graduate
MH  - Humans
MH  - Learning
MH  - *Neoplasms/radiotherapy
MH  - Perception
MH  - *Radiation Oncology
MH  - United Kingdom
PMC - PMC7259837
OTO - NOTNLM
OT  - *medical education & training
OT  - *oncology
OT  - *radiation oncology
OT  - *radiotherapy
COIS- Competing interests: None declared.
EDAT- 2020/05/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037171 [pii]
AID - 10.1136/bmjopen-2020-037171 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 27;10(5):e037171. doi: 10.1136/bmjopen-2020-037171.


PMID- 32467253
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 27
TI  - Methodological aspects of economic evaluations conducted in the palliative or end
      of life care settings: a systematic review protocol.
PG  - e035760
LID - 10.1136/bmjopen-2019-035760 [doi]
AB  - INTRODUCTION: In light of this growing palliative care and end of life care
      patient population, as well as new (expensive) drugs and treatments, quality
      research providing evidence for decision-making is required. However, common
      research guidance is lacking in this field, especially in respect to the methods 
      applied in economic evaluations. Therefore, the aim of the planned systematic
      review is to identify and summarise relevant information on methodological
      challenges, potential solutions and recommendations for conducting economic
      evaluations of interventions in adult patients, irrespective of their underlying 
      disease and gender in the palliative or end of life care settings, with no
      restrictions in regards to countries/geographical regions. The results of this
      systematic review may help to clarify the current methodological questions and
      form the basis of new, setting specific methods guidelines and support ongoing
      applied economic evaluations in the field. METHODS AND ANALYSIS: A systematic
      review will be conducted using Medline, Embase, Health Technology Assessment
      Database and NHS Economic Evaluation Database to identify the studies published
      from 1999 onwards with relevant information on methodological challenges,
      potential solutions and recommendations for conducting economic evaluations in
      the palliative or end of life care settings. Articles in English, German,
      Spanish, French or Dutch language will be considered. Two independent reviewers
      will conduct the screening of articles; any discrepancies will be resolved by
      discussion and involvement of a third reviewer. Predesigned data extraction forms
      will be applied, consequently narratively synthesised and categorised. Studies'
      methodological quality will be critically appraised. Besides existing economic
      guidelines and checklists for specific information on the palliative and end of
      life care sector will be searched. ETHICS AND DISSEMINATION: Ethical approval is 
      not required, as this is a planned systematic review of published literature. An 
      article will be disseminated in a related peer-reviewed journal, as well as
      presented at leading palliative care and health economic conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020148160.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Fischer, Claudia
AU  - Fischer C
AUID- ORCID: 0000-0001-7574-8097
AD  - Health Economics, Medical University of Vienna, Center for Public Health, Vienna,
      Austria claudia.fischer@meduniwien.ac.at.
FAU - Chwala, Eva
AU  - Chwala E
AD  - University Library, Medical University of Vienna, Vienna, Austria.
FAU - Simon, Judit
AU  - Simon J
AD  - Health Economics, Medical University of Vienna, Center for Public Health, Vienna,
      Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200527
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cost-Benefit Analysis
MH  - Humans
MH  - Palliative Care/*economics
MH  - Terminal Care/*economics
PMC - PMC7259853
OTO - NOTNLM
OT  - *adult palliative care
OT  - *health economics
OT  - *palliative care
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/05/30 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035760 [pii]
AID - 10.1136/bmjopen-2019-035760 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 27;10(5):e035760. doi: 10.1136/bmjopen-2019-035760.


PMID- 32467101
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210110
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
VI  - 10
IP  - 4
DP  - 2020 Dec
TI  - Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review
      and evidence summary.
PG  - 381-384
LID - 10.1136/bmjspcare-2020-002368 [doi]
AB  - The spread of pandemic COVID-19 has created unprecedented need for information.
      The pandemic is the cause of significant mortality and with this the need for
      rapidly disseminated information for palliative care professionals regarding the 
      prevalence of symptoms, their intensity, their resistance or susceptibility to
      symptom control and the mode of death for patients. METHODS: We undertook a
      systematic review of published evidence for symptoms in patients with COVID-19
      (with a specific emphasis on symptoms at end of life) and on modes of death.
      Inclusion: prospective or retrospective studies detailing symptom presence and/or
      cause or mode of death from COVID-19. RESULTS: 12 papers met the inclusion
      criteria and gave details of symptom burden: four of these specifically in the
      dying and two detailed the cause or mode of death. Cough, breathlessness, fatigue
      and myalgia are significant symptoms in people hospitalised with COVID-19.
      Dyspnoea is the most significant symptom in the dying. The mode of death was
      described in two papers and is predominantly through respiratory or heart
      failure. CONCLUSIONS: There remains a dearth of information regarding symptom
      burden and mode of death to inform decisions regarding end-of-life care in
      patients dying with COVID-19. Rapid data gathering on the mode of death and the
      profile of symptoms in the dying and their prevalence and severity in areas where
      COVID-19 is prevalent will provide important intelligence for clinicians. This
      should be done urgently, within ethical norms and the practicalities of a public 
      health, clinical and logistical emergency.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Keeley, Paul
AU  - Keeley P
AUID- ORCID: http://orcid.org/0000-0002-3169-8187
AD  - Palliative Care Team, Glasgow Royal Infirmary, Glasgow, UK
      paul.keeley@glasgow.ac.uk.
AD  - MVLS, University of Glasgow, Glasgow, UK.
FAU - Buchanan, Deans
AU  - Buchanan D
AD  - Palliative Medicine & Supportive Care, NHS Tayside, Dundee, UK.
FAU - Carolan, Clare
AU  - Carolan C
AD  - University of the Highlands and Islands, Inverness, Highland, UK.
FAU - Pivodic, Lara
AU  - Pivodic L
AD  - End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent
      University, Brussels, Belgium.
FAU - Tavabie, Simon
AU  - Tavabie S
AUID- ORCID: http://orcid.org/0000-0001-9420-8168
AD  - Marie Curie Hospice Hampstead, London, UK.
FAU - Noble, Simon
AU  - Noble S
AUID- ORCID: http://orcid.org/0000-0001-5425-2383
AD  - Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK.
LA  - eng
GR  - MCCC-FCO-11-C/MCCC_/Marie Curie/United Kingdom
PT  - Journal Article
PT  - Systematic Review
DEP - 20200528
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
MH  - COVID-19
MH  - *Cause of Death
MH  - *Coronavirus Infections/complications/mortality
MH  - *Dyspnea/etiology/mortality
MH  - *Fatigue/etiology/mortality
MH  - *Heart Failure/etiology/mortality
MH  - Humans
MH  - *Myalgia/etiology/mortality
MH  - *Pandemics
MH  - *Pneumonia, Viral/complications/mortality
MH  - *Respiratory Insufficiency/etiology/mortality
OTO - NOTNLM
OT  - hospital care
OT  - symptoms and symptom management
OT  - terminal care
COIS- Competing interests: None declared.
EDAT- 2020/05/30 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - bmjspcare-2020-002368 [pii]
AID - 10.1136/bmjspcare-2020-002368 [doi]
PST - ppublish
SO  - BMJ Support Palliat Care. 2020 Dec;10(4):381-384. doi:
      10.1136/bmjspcare-2020-002368. Epub 2020 May 28.


PMID- 32466957
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - An Ethics-based approach to Global Health Research Part 3: Emphasis on
      Partnership Funding.
PG  - 1588-1596
LID - S1551-7411(20)30145-5 [pii]
LID - 10.1016/j.sapharm.2020.05.004 [doi]
AB  - Acquiring funding for global health research within pharmacy can be challenging, 
      particularly for new investigators who may have a strong interest in resolving
      global dilemmas related to health. Moreover, there can be inherent imbalances and
      ethical issues when navigating the funding process for global partnerships. There
      exists a lack of literature providing ethical guidance for mitigating dilemmas
      that may arise. This commentary discusses current funding streams for
      investigators interested in global pharmacy research, as well as specific
      recommendations for the funding process. These recommendations include managing
      award funds, ethical considerations for funding research partnerships, and
      balancing power between low to middle income countries and high-income countries.
      Lastly, case examples of funding partnerships involving pharmacy are highlighted,
      emphasizing important lessons learned. This commentary addresses the critical
      need for providing global health researchers with both important considerations
      and experience-based recommendations for navigating global funding partnerships
      using an ethical approach.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Drame, Imbi
AU  - Drame I
AD  - Howard University College of Pharmacy, 2300 4th Street NW, Washington, DC, 20059,
      USA. Electronic address: imbi.drame@howard.edu.
FAU - Kahaleh, Abby
AU  - Kahaleh A
AD  - Roosevelt University College of Pharmacy, 1400 N Roosevelt Blvd Schaumburg, IL,
      60173, USA. Electronic address: AKahaleh@roosevelt.edu.
FAU - Connor, Sharon
AU  - Connor S
AD  - University of Pittsburgh School of Pharmacy, 5607 Baum Blvd, Suite 303,
      Pittsburgh, PA, 15206, USA. Electronic address: sconnor@pitt.edu.
FAU - Seo, See-Won
AU  - Seo SW
AD  - Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY,
      12208, USA. Electronic address: See-Won.Seo@acphs.edu.
FAU - Jonkman, Lauren J
AU  - Jonkman LJ
AD  - University of Pittsburgh School of Pharmacy, 5607 Baum Blvd, Suite 303,
      Pittsburgh, PA, 15206, USA. Electronic address: ljf1@pitt.edu.
FAU - Schellhase, Ellen
AU  - Schellhase E
AD  - Purdue University College of Pharmacy 575 Stadium Mall Drive West Lafayette, IN, 
      47906, USA. Electronic address: elschell@purdue.edu.
FAU - Miller, Monica L
AU  - Miller ML
AD  - Purdue University College of Pharmacy 575 Stadium Mall Drive West Lafayette, IN, 
      47906, USA. Electronic address: mille355@purdue.edu.
FAU - Ombengi, David
AU  - Ombengi D
AD  - Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226,
      USA. Electronic address: dombengi@mcw.edu.
FAU - Amugsi, James
AU  - Amugsi J
AD  - Sandema Hospital, Builsa North District, PO Box 4, Sandema, Ghana. Electronic
      address: jamugsi2@gmail.com.
FAU - Maina, Mercy
AU  - Maina M
AD  - Moi Teaching and Referral Hospital, PO Box 3-30100, Eldoret, Kenya. Electronic
      address: mwmercy@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200516
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
SB  - IM
MH  - *Global Health
MH  - Humans
MH  - *Research Personnel
OTO - NOTNLM
OT  - Career development grants
OT  - Ethical dilemmas
OT  - Funding
OT  - Global health research
OT  - Health care ethics
OT  - Program development research
EDAT- 2020/05/30 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - S1551-7411(20)30145-5 [pii]
AID - 10.1016/j.sapharm.2020.05.004 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Nov;16(11):1588-1596. doi:
      10.1016/j.sapharm.2020.05.004. Epub 2020 May 16.


PMID- 32466954
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 5
DP  - 2020 Jun
TI  - Validation of the Adapted Social Assessment Instrument for Liver Transplantation 
      Candidates.
PG  - 1303-1307
LID - S0041-1345(20)30279-7 [pii]
LID - 10.1016/j.transproceed.2020.03.011 [doi]
AB  - BACKGROUND AND AIMS: Assessment is considered a duty, as well as a part of the
      tasks of social workers; in addition, they have an ethical commitment to improve 
      their working tools. This study aimed at validating the Adapted Social Assessment
      Instrument used in a transplant center in the state of Sao Paulo, Brazil, for
      liver transplantation candidates, requiring its improvement and strengthening.
      METHODS: The methodology was based on both Marxian dialectics and the method of
      content validation. The content validation analysis was performed by 5 social
      workers from 3 Brazilian transplant centers. They evaluated the 5 domains of the 
      instrument: identification, socio-demographic profile, eligibility criteria,
      evaluation, and social interventions. Descriptive statistics of data were
      performed, and qualitative analysis was associated to the participant
      observation. RESULTS: The 5 professionals (100%) assigned the scores 3 and 4,
      which have demonstrated clarity, relevance, and feasibility, pointing out
      suggestions for improvement, some of which were considered. CONCLUSIONS: The
      instrument was evaluated with an approval percentage of above 80%; therefore, the
      instrument is a valid measure.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Batarra, Julia Moscardini
AU  - Batarra JM
AD  - Professional Improvement Program and Specialization in Social Work in Health,
      School of Medicine of Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil.
FAU - Serrano, Luzia Cristina de Almeida
AU  - Serrano LCA
AD  - Social Work in Health Care, Regional Medical School Foundation of Sao Jose do Rio
      Preto, Sao Jose do Rio Preto, Brazil.
FAU - Duca, William Jose
AU  - Duca WJ
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - Ferreira da Silva, Renato
AU  - Ferreira da Silva R
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - de Cassia Martins Alves da Silva, Rita
AU  - de Cassia Martins Alves da Silva R
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - Virches, Adriano
AU  - Virches A
AD  - Department of Psychology, School of Medicine of Sao Jose do Rio Preto, Sao Jose
      do Rio Preto, Brazil. Electronic address:
      servicosocialtransplantes@hospitaldebase.com.br.
FAU - Camarero de Felicio, Helen Catharine
AU  - Camarero de Felicio HC
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - Arroyo, Paulo Cesar Jr
AU  - Arroyo PC Jr
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - Bento, Giuliano Ancelmo
AU  - Bento GA
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - Rocha Candolo, Aline Coelho
AU  - Rocha Candolo AC
AD  - Liver and Small Intestine Transplantation Unit, Base Hospital, Sao Jose do Rio
      Preto, Brazil.
FAU - Micelli Domingos, Neide Aparecida
AU  - Micelli Domingos NA
AD  - Department of Psychology, School of Medicine of Sao Jose do Rio Preto, Sao Jose
      do Rio Preto, Brazil.
FAU - de Oliveira Santos Miyazaki, Maria Cristina
AU  - de Oliveira Santos Miyazaki MC
AD  - Department of Psychology, School of Medicine of Sao Jose do Rio Preto, Sao Jose
      do Rio Preto, Brazil.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20200525
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Adult
MH  - Brazil
MH  - Female
MH  - Humans
MH  - Liver Diseases/*psychology/surgery
MH  - Liver Transplantation/*psychology
MH  - Male
MH  - *Patient Selection
MH  - Preoperative Period
MH  - Psychological Tests/*standards
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
EDAT- 2020/05/30 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/02/20 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - S0041-1345(20)30279-7 [pii]
AID - 10.1016/j.transproceed.2020.03.011 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Jun;52(5):1303-1307. doi:
      10.1016/j.transproceed.2020.03.011. Epub 2020 May 25.


PMID- 32466899
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 1873-7145 (Electronic)
IS  - 0963-9969 (Linking)
VI  - 133
DP  - 2020 Jul
TI  - Oxygen as a key parameter in in vitro dynamic and multi-compartment models to
      improve microbiome studies of the small intestine?
PG  - 109127
LID - S0963-9969(20)30152-6 [pii]
LID - 10.1016/j.foodres.2020.109127 [doi]
AB  - In vitro digestion and fermentation models are frequently used for human and
      animal research purposes. Different dynamic and multi-compartment models exist,
      but none have been validated with representative microbiota in the distal parts
      of the small intestine. We recently developed a dynamic and multi-compartment
      piglet model introducing microbiota in an ileum bioreactor. However, it presented
      discrepancies compared to in vivo data. Recommendations are available to
      standardize studies in this field. They target the digestion model but include
      elements of a fermentation model. But no recommendation is given concerning
      control of the atmosphere. The gastrointestinal tract is generally associated
      with anaerobiosis to conduct a good fermentation process. In this study, we
      attempted to improve the ileal microbiota of the piglet model by testing
      inoculation: real intestinal content vs feces; the latter being generally used
      for ethical and economical aspects. Results showed a positive effect of using
      real intestinal content. Fusobacteriia were less abundant in the model,
      Bacteroidia were better maintained in the colon. But for the ileum, results
      showed that anoxic conditions in the ileum bioreactor conditioned the microbial
      profile probably more than the type of inoculum itself, leading to the general
      conclusion that in vitro dynamic and multi-compartment models probably have to
      get oxygenated to improve microbiome studies of the small intestine.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Dufourny, S
AU  - Dufourny S
AD  - Animal Nutrition and Sustainability Unit, Production and Sectors Department,
      Walloon Agricultural Research Centre, Rue de Liroux 8, B-5030 Gembloux, Belgium. 
      Electronic address: s.dufourny@cra.wallonie.be.
FAU - Everaert, N
AU  - Everaert N
AD  - Precision Livestock and Nutrition Unit, AgroBioChem Department, TERRA Teaching
      and Research Centre, University of Liege, Passage des Deportes 2, B-5030
      Gembloux, Belgium. Electronic address: nadia.everaert@uliege.be.
FAU - Lebrun, S
AU  - Lebrun S
AD  - Food Quality Management, Food Science Department, FARAH, University of Liege,
      Avenue de Cureghem 10, B-4000 Liege, Belgium. Electronic address:
      sarah.lebrun@uliege.be.
FAU - Didelez, M
AU  - Didelez M
AD  - Animal Nutrition and Sustainability Unit, Production and Sectors Department,
      Walloon Agricultural Research Centre, Rue de Liroux 8, B-5030 Gembloux, Belgium. 
      Electronic address: m.didelez@cra.wallonie.be.
FAU - Wavreille, J
AU  - Wavreille J
AD  - Animal Breeding, Quality Production and Welfare Unit, Production and Sectors
      Department, Walloon Agricultural Research Centre, Rue de Liroux 8, B-5030
      Gembloux, Belgium. Electronic address: j.wavreille@cra.wallonie.be.
FAU - Froidmont, E
AU  - Froidmont E
AD  - Animal Nutrition and Sustainability Unit, Production and Sectors Department,
      Walloon Agricultural Research Centre, Rue de Liroux 8, B-5030 Gembloux, Belgium. 
      Electronic address: e.froidmont@cra.wallonie.be.
FAU - Rondia, P
AU  - Rondia P
AD  - Animal Nutrition and Sustainability Unit, Production and Sectors Department,
      Walloon Agricultural Research Centre, Rue de Liroux 8, B-5030 Gembloux, Belgium. 
      Electronic address: p.rondia@cra.wallonie.be.
FAU - Delcenserie, V
AU  - Delcenserie V
AD  - Food Quality Management, Food Science Department, FARAH, University of Liege,
      Avenue de Cureghem 10, B-4000 Liege, Belgium. Electronic address:
      Veronique.Delcenserie@uliege.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200225
PL  - Canada
TA  - Food Res Int
JT  - Food research international (Ottawa, Ont.)
JID - 9210143
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Bioreactors
MH  - Colon/microbiology
MH  - Digestion
MH  - Feces/microbiology
MH  - Fermentation
MH  - *Gastrointestinal Microbiome
MH  - Gastrointestinal Tract
MH  - Humans
MH  - Ileum/microbiology
MH  - In Vitro Techniques/*methods
MH  - Intestine, Small/*microbiology
MH  - *Models, Animal
MH  - Oxygen/*administration & dosage
MH  - Swine
OTO - NOTNLM
OT  - *16S rRNA
OT  - *Ileum
OT  - *In vitro model
OT  - *Intestinal content
OT  - *Microbiota
OT  - *Multi-compartment model
OT  - *Oxygen
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/30 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/05/30 06:00
PHST- 2019/09/06 00:00 [received]
PHST- 2020/01/10 00:00 [revised]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
AID - S0963-9969(20)30152-6 [pii]
AID - 10.1016/j.foodres.2020.109127 [doi]
PST - ppublish
SO  - Food Res Int. 2020 Jul;133:109127. doi: 10.1016/j.foodres.2020.109127. Epub 2020 
      Feb 25.


PMID- 32466700
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1741-2854 (Electronic)
IS  - 0020-7640 (Linking)
VI  - 66
IP  - 6
DP  - 2020 Sep
TI  - From folk therapy to evidence-based psychiatry practice: The benefit of
      evidence-based psychiatry in treatment-naive psychotic patients.
PG  - 593-599
LID - 10.1177/0020764020924698 [doi]
AB  - BACKGROUND: As Taiwan's Mental Health Act (MHA) clearly states that the human
      rights and legal rights of psychotic patients should be respected and guaranteed;
      however, a temple asylum violates the law in the 21st century. Hundreds of
      patients were constrained in the asylum for years without consent. Because of
      outbreak of infectious diseases, patients were evacuated from the asylum by the
      official intervention. AIMS: To evaluate the outcomes of these patients from folk
      therapy to conventional treatment. METHOD: The study recruited the drug-naive
      psychotic patients constrained in an asylum for decades. Before and after the
      formal treatment, 253 patients were diagnosed with schizophrenia and other
      psychotic disorders with assessment of using the Mini Positive and Negative
      Syndrome Scale (Mini-PANSS) and Comprehensive Occupational Therapy Evaluation
      (COTE) scale. In addition, family function, self-care ability and nutritional
      status were also evaluated. RESULTS: The initial data show the improvement in
      psychotic symptoms and occupational function in these patients. Furthermore, the 
      ratio of patients who were classified as being at risk for malnutrition was
      decreased by 21.7% after treatment. There was no statistically significant
      difference in self-care ability before and after treatment. CONCLUSION: The
      psychotic symptoms and occupational function of these patients were improved
      after the formal treatment compared to the folk therapy. The care model for the
      psychotic patients in the temple asylum should be more thoroughly discussed in
      consideration of the medical ethics principles.
FAU - Wang, Hung-Yu
AU  - Wang HY
AUID- ORCID: 0000-0001-7969-783X
AD  - Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City.
FAU - Huang, Joh-Jong
AU  - Huang JJ
AD  - Department of Family Medicine, Kaohsiung Medical University Chung Ho Memorial
      Hospital, Kaohsiung City.
AD  - Department of Health, Kaohsiung City Government, Kaohsiung City.
AD  - Bureau of Social Affairs, Tainan City Government, Kaohsiung City.
FAU - Su, Shu-Fang
AU  - Su SF
AD  - Department of Health, Kaohsiung City Government, Kaohsiung City.
FAU - Hsu, Sheng-Hao
AU  - Hsu SH
AD  - Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City.
FAU - Chou, Li-Shiu
AU  - Chou LS
AD  - Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City.
FAU - Chou, Frank Huang-Chih
AU  - Chou FH
AD  - Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - England
TA  - Int J Soc Psychiatry
JT  - The International journal of social psychiatry
JID - 0374726
SB  - IM
MH  - *Evidence-Based Medicine
MH  - Hospitals, Psychiatric
MH  - Humans
MH  - Mental Health
MH  - *Psychiatry
MH  - *Psychotic Disorders
MH  - *Schizophrenia
OTO - NOTNLM
OT  - *Mental Health Act
OT  - *asylum
OT  - *folk therapy
OT  - *medical ethic principles
EDAT- 2020/05/30 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1177/0020764020924698 [doi]
PST - ppublish
SO  - Int J Soc Psychiatry. 2020 Sep;66(6):593-599. doi: 10.1177/0020764020924698. Epub
      2020 May 28.


PMID- 32464692
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1460-9592 (Electronic)
IS  - 1155-5645 (Linking)
VI  - 30
IP  - 8
DP  - 2020 Aug
TI  - Intravenous cannula placement in children for induction of general anesthesia:
      Prospective audit and identification of success factors.
PG  - 874-884
LID - 10.1111/pan.13936 [doi]
AB  - BACKGROUND: Approaches to pediatric induction of anesthesia vary widely. While
      oral sedative premedication and inhalational induction are common, total
      intravenous anesthesia is becoming increasingly popular. Total intravenous
      anesthesia without anxiolytic premedication, which is the most commonly used
      technique in our hospital, requires intravenous (IV) cannula placement in an
      awake child. AIMS: To quantify the success rate of IV cannula placement in 1 or 2
      attempts and to identify success factors and barriers. METHODS: With ethical
      approval and written informed consent from participating anesthesiologists, a
      prospective audit of IV cannulation was undertaken over a 1-month period. The
      attending anesthesiologist captured basic demographics, IV insertion
      characteristics, setting, distraction techniques, the behavior of the child,
      number of attempts, and success/failure. A logistic regression model for
      successful IV cannulation was created. Anesthesiologists and procedural suite
      nurses participated in semi-structured interviews to identify success factors,
      barriers, and teaching approaches. RESULTS: Data from 984 cases were analyzed. IV
      induction was planned in 562 cases, and IV cannulation was successful in 90% of
      these patients. Anxiolytic premedication was given in 6% of cases. Observations
      indicated that 64% of children were pain- and reaction-free, and 90% experienced 
      minimal or no reaction. Predictors for success included older child's age and
      child behavior at first encounter. Qualitative interview data from 13
      participants suggested success factors included effective distraction, preparing 
      the family for IV induction, parental presence, support of the operating room
      team, effective use of local analgesic cream, adapting the approach to the
      individual child, and the anesthesiologist's efficiency. Barriers included needle
      phobia, uncooperative child, anxious parents, ineffective use of analgesic cream,
      and unfavorable anatomy. Distraction techniques varied by age and developmental
      stage of the child. CONCLUSIONS: Cannulation for planned IV induction is feasible
      for most children, enabling increased use of total intravenous anesthesia as an
      institutional anesthetic strategy.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Hugel, Celine
AU  - Hugel C
AD  - Research Institute, BC Children's Hospital, Vancouver, BC, Canada.
AD  - Department of Biomedical Engineering, Hamburg University of Applied Sciences,
      Hamburg, Germany.
FAU - Chen, James
AU  - Chen J
AD  - Department of Pediatric Anesthesia, BC Children's Hospital, Vancouver, BC,
      Canada.
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia (UBC), Vancouver, BC, Canada.
FAU - Poznikoff, Andrew K
AU  - Poznikoff AK
AD  - Department of Pediatric Anesthesia, BC Children's Hospital, Vancouver, BC,
      Canada.
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia (UBC), Vancouver, BC, Canada.
FAU - West, Nicholas C
AU  - West NC
AUID- ORCID: 0000-0001-8382-5136
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia (UBC), Vancouver, BC, Canada.
FAU - Reimer, Eleanor
AU  - Reimer E
AD  - Research Institute, BC Children's Hospital, Vancouver, BC, Canada.
AD  - Department of Pediatric Anesthesia, BC Children's Hospital, Vancouver, BC,
      Canada.
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia (UBC), Vancouver, BC, Canada.
FAU - Gorges, Matthias
AU  - Gorges M
AUID- ORCID: 0000-0003-2193-178X
AD  - Research Institute, BC Children's Hospital, Vancouver, BC, Canada.
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia (UBC), Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200625
PL  - France
TA  - Paediatr Anaesth
JT  - Paediatric anaesthesia
JID - 9206575
RN  - 0 (Hypnotics and Sedatives)
SB  - IM
MH  - Adolescent
MH  - *Anesthesia, General
MH  - *Cannula
MH  - Catheterization
MH  - Child
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - Pain
OTO - NOTNLM
OT  - *anesthesia
OT  - *anxiety
OT  - *child
OT  - *child behavior
OT  - *inhalational
OT  - *intravenous
OT  - *preoperative care
EDAT- 2020/05/29 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/05/14 00:00 [revised]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 10.1111/pan.13936 [doi]
PST - ppublish
SO  - Paediatr Anaesth. 2020 Aug;30(8):874-884. doi: 10.1111/pan.13936. Epub 2020 Jun
      25.


PMID- 32464645
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20220227
IS  - 1460-2369 (Electronic)
IS  - 1355-4786 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Sep 1
TI  - Studying human reproductive biology through single-cell analysis and in vitro
      differentiation of stem cells into germ cell-like cells.
PG  - 670-688
LID - 10.1093/humupd/dmaa021 [doi]
AB  - BACKGROUND: Understanding the molecular and cellular mechanisms of human
      reproductive development has been limited by the scarcity of human samples and
      ethical constraints. Recently, in vitro differentiation of human pluripotent stem
      cells into germ cells and single-cell analyses have opened new avenues to
      directly study human germ cells and identify unique mechanisms in human
      reproductive development. OBJECTIVE AND RATIONALE: The goal of this review is to 
      collate novel findings and insightful discoveries with these new methodologies,
      aiming at introducing researchers and clinicians to the use of these tools to
      study human reproductive biology and develop treatments for infertility. SEARCH
      METHODS: PubMed was used to search articles and reviews with the following main
      keywords: in vitro differentiation, human stem cells, single-cell analysis,
      spermatogenesis, oogenesis, germ cells and other key terms related to these
      subjects. The search period included all publications from 2000 until now.
      OUTCOMES: Single-cell analyses of human gonads have identified many important
      gene markers at different developmental stages and in subpopulations of cells. To
      validate the functional roles of these gene markers, researchers have used the in
      vitro differentiation of human pluripotent cells into germ cells and confirmed
      that some genetic requirements are unique in human germ cells and are not
      conserved in mouse models. Moreover, transcriptional regulatory networks and the 
      interaction of germ and somatic cells in gonads were elucidated in these studies.
      WIDER IMPLICATIONS: Single-cell analyses allow researchers to identify gene
      markers and potential regulatory networks using limited clinical samples. On the 
      other hand, in vitro differentiation methods provide clinical researchers with
      tools to examine these newly identify gene markers and study the causative
      effects of mutations previously associated with infertility. Combining these two 
      methodologies, researchers can identify gene markers and networks which are
      essential and unique in human reproductive development, thereby producing more
      accurate diagnostic tools for assessing reproductive disorders and developing
      treatments for infertility.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Li, Lin
AU  - Li L
AD  - Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical
      University, Chaoyang, Beijing 100026, China.
FAU - Yang, Risako
AU  - Yang R
AD  - Department of Biology, Colgate University, Hamilton, NY 13346, USA.
FAU - Yin, Chenghong
AU  - Yin C
AD  - Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical
      University, Chaoyang, Beijing 100026, China.
FAU - Kee, Kehkooi
AU  - Kee K
AD  - Department of Basic Medical Sciences, Center for Stem Cell Biology and
      Regenerative Medicine, School of Medicine, Tsinghua University, Beijing 100084,
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Hum Reprod Update
JT  - Human reproduction update
JID - 9507614
SB  - IM
CIN - Hum Reprod Update. 2021 Feb 19;27(2):423. PMID: 33367738
MH  - Animals
MH  - Cell Culture Techniques/methods/*trends
MH  - Cell Differentiation/*physiology
MH  - Cells, Cultured
MH  - Female
MH  - Germ Cells/cytology/*physiology
MH  - Humans
MH  - Male
MH  - Mice
MH  - Oogenesis/physiology
MH  - Pluripotent Stem Cells/cytology/*physiology
MH  - Reproduction/*physiology
MH  - Reproductive Medicine/methods/*trends
MH  - *Single-Cell Analysis/methods/trends
MH  - Spermatogenesis/physiology
OTO - NOTNLM
OT  - * in vitro differentiation
OT  - *epigenetics
OT  - *folliculogenesis
OT  - *gametogenesis
OT  - *germ cell development
OT  - *germ cells
OT  - *primordial germ cells
OT  - *single-cell analysis
OT  - *spermatogenesis
OT  - *stem cells
EDAT- 2020/05/29 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/05/29 06:00
PHST- 2019/11/23 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 5848373 [pii]
AID - 10.1093/humupd/dmaa021 [doi]
PST - ppublish
SO  - Hum Reprod Update. 2020 Sep 1;26(5):670-688. doi: 10.1093/humupd/dmaa021.


PMID- 32464269
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1878-7568 (Electronic)
IS  - 1742-7061 (Linking)
VI  - 111
DP  - 2020 Jul 15
TI  - Decellularized tissues as platforms for in vitro modeling of healthy and diseased
      tissues.
PG  - 1-19
LID - S1742-7061(20)30301-9 [pii]
LID - 10.1016/j.actbio.2020.05.031 [doi]
AB  - Biomedical engineers are at the forefront of developing novel treatments to
      improve human health, however, many products fail to translate to clinical
      implementation. In vivo pre-clinical animal models, although the current best
      approximation of complex disease conditions, are limited by reproducibility,
      ethical concerns, and poor accurate prediction of human response. Hence, there is
      a need to develop physiologically relevant, low cost, scalable, and reproducible 
      in vitro platforms to provide reliable means for testing drugs, biomaterials, and
      tissue engineered products for successful clinical translation. One emerging
      approach of developing physiologically relevant in vitro models utilizes
      decellularized tissues/organs as biomaterial platforms for 2D and 3D models of
      healthy and diseased tissue. Decellularization is a process that removes cellular
      content and produces tissue-specific extracellular matrix scaffolds that can more
      accurately recapitulate an organ/tissue's native microenvironment compared to
      other natural or synthetic materials. Decellularized tissues hold enormous
      potential for in vitro modeling of various disease phenotypes and tissue
      responses to drugs or external conditions such as aging, toxin exposure, or even 
      implantation. In this review, we highlight the need for in vitro models, the
      advantages and limitations of implementing decellularized tissues, and
      considerations of the decellularization process. We discuss current research
      efforts towards applying decellularized tissues as platforms to generate in vitro
      models of healthy and diseased tissues, and where we foresee the field
      progressing. A variety of organs/tissues are discussed, including brain, heart,
      kidney, large intestine, liver, lung, skeletal muscle, skin, and tongue.
      STATEMENT OF SIGNIFICANCE: Many biomedical products fail to reach clinical
      translation due to animal model limitations. Development of physiologically
      relevant in vitro models can provide a more economic, scalable, and reproducible 
      means of testing drugs/therapeutics for successful clinical translation. The use 
      of decellularized tissues as platforms for in vitro models holds promise, as
      these scaffolds can effectively replicate native tissue complexity, but is not
      widely explored. This review discusses the need for in vitro models, the promise 
      of decellularized tissues as biomaterial substrates, and the current research
      applying decellularized tissues towards the creation of in vitro models. Further,
      this review provides insights into the current limitations and future of such in 
      vitro models.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - McCrary, Michaela W
AU  - McCrary MW
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, University of
      Florida, 1275 Center Dr. BMS J257, Gainesville, FL 32611, United States.
      Electronic address: michaelawmertz@ufl.edu.
FAU - Bousalis, Deanna
AU  - Bousalis D
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, University of
      Florida, 1275 Center Dr. BMS J257, Gainesville, FL 32611, United States.
      Electronic address: dbousalis@ufl.edu.
FAU - Mobini, Sahba
AU  - Mobini S
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, University of
      Florida, 1275 Center Dr. BMS J257, Gainesville, FL 32611, United States;
      Instituto de Micro y Nanotechnologia, IMN-CNM, CSIC (CEI UAM+CSIC), Calle Isaac
      Newton 8, 28760 Madrid, Tres Cantos, Spain; Departamento de Biologia Molecular
      and Centro de Biologia Molecular, Universidad Autonoma de Madrid, Calle Nicolas
      Cabrera, 28049 Madrid, Spain. Electronic address: sahba.mobini@csic.es.
FAU - Song, Young Hye
AU  - Song YH
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, University of
      Florida, 1275 Center Dr. BMS J257, Gainesville, FL 32611, United States;
      Department of Biomedical Engineering, University of Arkansas, 134 White Hall,
      Fayetteville, AR 72701, United States. Electronic address: yhsong@uark.edu.
FAU - Schmidt, Christine E
AU  - Schmidt CE
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, University of
      Florida, 1275 Center Dr. BMS J257, Gainesville, FL 32611, United States.
      Electronic address: schmidt@bme.ufl.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200525
PL  - England
TA  - Acta Biomater
JT  - Acta biomaterialia
JID - 101233144
RN  - 0 (Biocompatible Materials)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials
MH  - Extracellular Matrix
MH  - Humans
MH  - Reproducibility of Results
MH  - *Tissue Engineering
MH  - *Tissue Scaffolds
OTO - NOTNLM
OT  - *Decellularization
OT  - *Extracellular matrix
OT  - *Health and disease
OT  - *In vitro models
OT  - *Test beds
COIS- Declaration of Competing Interests The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - S1742-7061(20)30301-9 [pii]
AID - 10.1016/j.actbio.2020.05.031 [doi]
PST - ppublish
SO  - Acta Biomater. 2020 Jul 15;111:1-19. doi: 10.1016/j.actbio.2020.05.031. Epub 2020
      May 25.


PMID- 32464259
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1873-6513 (Electronic)
IS  - 0885-3924 (Linking)
VI  - 60
IP  - 5
DP  - 2020 Nov
TI  - Association Between "Unacceptable Condition" Expressed in Palliative Care
      Consultation Before Left Ventricular Assist Device Implantation and Care Received
      at the End of Life.
PG  - 976-983.e1
LID - S0885-3924(20)30429-2 [pii]
LID - 10.1016/j.jpainsymman.2020.05.025 [doi]
AB  - CONTEXT: Palliative care consultation before left ventricular assist device
      (LVAD) surgery (PreVAD) has been recommended, but its impact on goal-concordant
      care is unknown. OBJECTIVES: To describe the association between patients' unique
      unacceptable condition articulated during PreVAD with the actual care provided at
      the end of life. METHODS: Among 308 patients who had PreVAD between 2014 and
      2019, 72 patients died before December 31, 2019. Based on the answers to the
      question, "Is there any condition you would find unacceptable?" patients were
      divided into ARTICULATE (those who could articulate their unacceptable condition 
      clearly, n = 58) and non-ARTICULATE (those who could not, n = 14). Circumstances 
      at death and end-of-life care were compared between groups. RESULTS: Mean age at 
      death was 63.2 years (SD +/-13.1), 56 patients (77.8%) were males, and median
      duration of LVAD was 167.5 days (interquartile range 682). ARTICULATE patients
      died less frequently in the intensive care unit than non-ARTICULATE patients (33 
      patients, 57.9% vs. 13 patients, 92.9%; P = 0.014) and had ethics consultation
      less frequently (four patients, 6.9% vs. five patients, 35.7%; P = 0.011).
      Frequency of LVAD withdrawal was similar in both groups. Among ARTICULATE cohort,
      the unacceptable condition articulated in PreVAD did not seem to influence
      decisions at the end of life. CONCLUSION: Patients who articulated their
      unacceptable condition clearly before LVAD surgery had less frequent ethics
      consultations and received less intensive care at the end of life, but it did not
      seem to affect the decision of LVAD withdrawal. It may be more important to
      engage in discussions around their unacceptable conditions, rather than the
      specific condition articulated. The question of an unacceptable condition should 
      be part of any routine palliative care consultation before LVAD surgery.
CI  - Copyright (c) 2020 American Academy of Hospice and Palliative Medicine. Published
      by Elsevier Inc. All rights reserved.
FAU - Nakagawa, Shunichi
AU  - Nakagawa S
AD  - Department of Medicine, Adult Palliative Care Service, Columbia University Irving
      Medical Center, New York, New York, USA. Electronic address:
      sn2573@cumc.columbia.edu.
FAU - Takayama, Hiroo
AU  - Takayama H
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University
      Irving Medical Center, New York, New York, USA.
FAU - Takeda, Koji
AU  - Takeda K
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University
      Irving Medical Center, New York, New York, USA.
FAU - Topkara, Veli K
AU  - Topkara VK
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University
      Irving Medical Center, New York, New York, USA.
FAU - Yuill, Lauren
AU  - Yuill L
AD  - Department of Care Coordination and Social Work, Adult Palliative Care Service,
      NewYork-Presbyterian Hospital, New York, New York, USA.
FAU - Zampetti, Suzanne
AU  - Zampetti S
AD  - Department of Medicine, Adult Palliative Care Service, Columbia University Irving
      Medical Center, New York, New York, USA.
FAU - McLaughlin, Katherine
AU  - McLaughlin K
AD  - Department of Medicine, Adult Palliative Care Service, Columbia University Irving
      Medical Center, New York, New York, USA.
FAU - Yuzefpolskaya, Melana
AU  - Yuzefpolskaya M
AD  - Division of Cardiology, Department of Medicine, Columbia University Irving
      Medical Center, New York, New York, USA.
FAU - Colombo, Paolo C
AU  - Colombo PC
AD  - Division of Cardiology, Department of Medicine, Columbia University Irving
      Medical Center, New York, New York, USA.
FAU - Naka, Yoshifumi
AU  - Naka Y
AD  - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University
      Irving Medical Center, New York, New York, USA.
FAU - Uriel, Nir
AU  - Uriel N
AD  - Division of Cardiology, Department of Medicine, Columbia University Irving
      Medical Center, New York, New York, USA.
FAU - Blinderman, Craig D
AU  - Blinderman CD
AD  - Department of Medicine, Adult Palliative Care Service, Columbia University Irving
      Medical Center, New York, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - United States
TA  - J Pain Symptom Manage
JT  - Journal of pain and symptom management
JID - 8605836
SB  - IM
MH  - Death
MH  - Female
MH  - *Heart Failure/therapy
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Palliative Care
MH  - Referral and Consultation
OTO - NOTNLM
OT  - *Mechanical circulatory support
OT  - *advance care planning
OT  - *end-of-life care
OT  - *left ventricular assist devices
OT  - *palliative care
EDAT- 2020/05/29 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - S0885-3924(20)30429-2 [pii]
AID - 10.1016/j.jpainsymman.2020.05.025 [doi]
PST - ppublish
SO  - J Pain Symptom Manage. 2020 Nov;60(5):976-983.e1. doi:
      10.1016/j.jpainsymman.2020.05.025. Epub 2020 May 25.


PMID- 32463901
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1938-2472 (Electronic)
IS  - 0022-0124 (Linking)
VI  - 51
IP  - 6
DP  - 2020 Jun 1
TI  - Improving Nurse Practitioner and Physician Assistant Preceptor Knowledge,
      Self-Efficacy, and Willingness in a Hospital Medicine Practice: An Online
      Experience.
PG  - 275-279
LID - 10.3928/00220124-20200514-07 [doi]
AB  - BACKGROUND: A hospital medicine practice experienced an increased demand for
      additional nurse practitioner (NP) and physician assistant (PA) preceptors.
      METHOD: An online preceptor education course was developed that included eight
      modules: communication and feedback, expectations for assessment and evaluation, 
      pedagogy, time management and efficiency, goal setting and coaching, working with
      struggling or at-risk students, legal and ethical considerations, and teaching
      procedures. Knowledge, self-efficacy, and willingness to precept were examined in
      a precourse and postcourse format. RESULTS: Postcourse, knowledge improved from
      69.4% to 90.6%. Self-efficacy improved by 35.2%, and willingness to precept also 
      improved. Qualitative themes emerged, including excitement to precept, helpful
      course, and time constraints. CONCLUSION: An online NP and PA preceptor training 
      program increased preceptor knowledge, self-efficacy, and willingness to serve as
      a preceptor. Additional research is needed to explore the time constraints to
      serving as an NP or a PA preceptor in the inpatient environment. [J Contin Educ
      Nurs. 2020;51(6):275-279.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Heusinkvelt, Sally E
AU  - Heusinkvelt SE
FAU - Tracy, Mary
AU  - Tracy M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Contin Educ Nurs
JT  - Journal of continuing education in nursing
JID - 0262321
MH  - *Hospital Medicine
MH  - Humans
MH  - *Nurse Practitioners
MH  - *Physician Assistants
MH  - Preceptorship
MH  - Self Efficacy
EDAT- 2020/05/29 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/29 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2019/11/25 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
AID - 10.3928/00220124-20200514-07 [doi]
PST - ppublish
SO  - J Contin Educ Nurs. 2020 Jun 1;51(6):275-279. doi: 10.3928/00220124-20200514-07.


PMID- 32463709
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20210930
IS  - 1029-2330 (Electronic)
IS  - 1026-7158 (Linking)
VI  - 28
IP  - 7-8
DP  - 2020 Aug-Sep
TI  - Engineering mesenchymal stem cells: a novel therapeutic approach in breast
      cancer.
PG  - 732-741
LID - 10.1080/1061186X.2020.1775842 [doi]
AB  - Breast cancer is one of the most prevalent and deadliest cancers among women in
      the world because of its aggressive behaviour and inadequate response to
      conventional therapies. Cellular and gene therapies based on mesenchymal stem
      cells (MSCs) represent promising treatment strategies for multiple diseases, such
      as cancers. MSCs are multipotent adult stem cells with important features for
      cell therapy, such as tissue homing to injured sites, their differentiation
      potential, their capacity of secreting plenty of trophic factors, and low
      immunogenicity. The quite easy isolation of these cells from various types of
      tissues are associated with no ethical concern when dealing with foetal or
      embryonic stem cells. The MSCs exhibit both pro and anti-oncogenic properties.
      However, genetic engineering of MSCs and nanoparticles is being employed as a
      means to solve some of these problems and improve the antitumor properties of
      these cells. The tumour-homing ability of MSCs and their exosomes to tumour
      niches have made them as a promising vector for targeted delivery of therapeutic 
      agents to tumours site. The present study investigated MSCs specifications, pro- 
      and anti-oncogenic properties of MSCs in breast cancer, and reviewed targeted
      breast cancer therapy via engineered MSCs, likely as potent cellular vehicles.
FAU - Heidari, Razieh
AU  - Heidari R
AUID- ORCID: 0000-0002-8085-8386
AD  - Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord 
      University of Medical Sciences, Shahrekord, Iran.
FAU - Gholamian Dehkordi, Neda
AU  - Gholamian Dehkordi N
AUID- ORCID: 0000-0003-1033-5237
AD  - Department of Molecular Medicine, School of Advanced Technologies, Shahrekord
      University of Medical Sciences, Shahrekord, Iran.
FAU - Mohseni, Roohollah
AU  - Mohseni R
AUID- ORCID: 0000-0001-9759-0876
AD  - Clinical Biochemistry Research Center, Basic Health Sciences Institute,
      Shahrekord University of Medical Sciences, Shahrekord, Iran.
FAU - Safaei, Mohsen
AU  - Safaei M
AUID- ORCID: 0000-0003-1504-5490
AD  - Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord 
      University of Medical Sciences, Shahrekord, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200609
PL  - England
TA  - J Drug Target
JT  - Journal of drug targeting
JID - 9312476
RN  - 0 (Toll-Like Receptors)
SB  - IM
MH  - Animals
MH  - Bioengineering/*methods
MH  - Breast Neoplasms/*therapy
MH  - Cell Line, Tumor
MH  - Cell- and Tissue-Based Therapy/*methods
MH  - Drug Delivery Systems/methods
MH  - Exosomes/metabolism
MH  - Female
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology
MH  - Toll-Like Receptors/metabolism
OTO - NOTNLM
OT  - *Mesenchymal stem cells
OT  - *breast cancer
OT  - *genetic modification
OT  - *targeted drug delivery vehicle
OT  - *tumour homing
EDAT- 2020/05/29 06:00
MHDA- 2021/10/01 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 10.1080/1061186X.2020.1775842 [doi]
PST - ppublish
SO  - J Drug Target. 2020 Aug-Sep;28(7-8):732-741. doi: 10.1080/1061186X.2020.1775842. 
      Epub 2020 Jun 9.


PMID- 32463478
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20201218
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 126
IP  - 17
DP  - 2020 Sep 1
TI  - Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic 
      and transparent ethical process.
PG  - 3896-3899
LID - 10.1002/cncr.32962 [doi]
AB  - The treatment of patients with cancer who test positive for severe acute
      respiratory syndrome coronavirus 2 (SARS-CoV-2) poses unique challenges. In this 
      commentary, the authors describe the ethical rationale and implementation details
      for the creation of a novel, multidisciplinary treatment prioritization
      committee, including physicians, frontline staff, an ethicist, and an infectious 
      disease expert. Organizational obligations to health care workers also are
      discussed. The treatment prioritization committee sets a threshold of acceptable 
      harm to patients from decreased cancer control that is justified to reduce risk
      to staff. The creation of an ethical, consistent, and transparent decision-making
      process involving such frontline stakeholders is essential as departments across 
      the country are faced with decisions regarding the treatment of
      SARS-CoV-2-positive patients with cancer.
CI  - (c) 2020 American Cancer Society.
FAU - Perni, Subha
AU  - Perni S
AUID- ORCID: 0000-0003-2851-4903
AD  - Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts,
      USA.
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Milligan, Michael G
AU  - Milligan MG
AD  - Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts,
      USA.
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Saraf, Anurag
AU  - Saraf A
AD  - Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts,
      USA.
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Vivenzio, Todd
AU  - Vivenzio T
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Marques, Amy
AU  - Marques A
AD  - Division of Infectious Diseases, Department of Medicine, Brigham and Women's
      Hospital, Boston, Massachusetts, USA.
FAU - Baker, Meghan A
AU  - Baker MA
AD  - Division of Infectious Diseases, Department of Medicine, Brigham and Women's
      Hospital, Boston, Massachusetts, USA.
AD  - Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health
      Care Institute, Harvard University, Boston, Massachusetts, USA.
FAU - Kosak, Tara
AU  - Kosak T
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Bartlett, Sarah
AU  - Bartlett S
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Physic, Michelle A
AU  - Physic MA
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Batchelder, Monica R
AU  - Batchelder MR
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - McBride, Sean
AU  - McBride S
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York, USA.
FAU - Bredfeldt, Jeremy
AU  - Bredfeldt J
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Cail, Daniel W
AU  - Cail DW
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Kearney, Meghan C
AU  - Kearney MC
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Whitehouse, Colleen
AU  - Whitehouse C
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Orio, Peter
AU  - Orio P
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Walsh, Gerard
AU  - Walsh G
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Haas-Kogan, Daphne A
AU  - Haas-Kogan DA
AUID- ORCID: 0000-0002-2378-4800
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
FAU - Martin, Neil E
AU  - Martin NE
AD  - Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber
      Cancer Institute, Harvard Medical School, Harvard University, Boston,
      Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Ambulatory Care/ethics/organization & administration
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making
MH  - Coronavirus Infections/*complications/virology
MH  - Delivery of Health Care/*ethics/organization & administration
MH  - Health Personnel/*ethics/organization & administration
MH  - Humans
MH  - Neoplasms/*complications/radiotherapy
MH  - Pandemics/*ethics
MH  - Patient Safety
MH  - Pneumonia, Viral/*complications/virology
MH  - Quality of Health Care/*ethics/organization & administration
MH  - SARS-CoV-2
PMC - PMC7283895
OTO - NOTNLM
OT  - *bioethics
OT  - *coronavirus disease 2019 (COVID-19)
OT  - *patient safety
OT  - *quality improvement
OT  - *radiation oncology
EDAT- 2020/05/29 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 10.1002/cncr.32962 [doi]
PST - ppublish
SO  - Cancer. 2020 Sep 1;126(17):3896-3899. doi: 10.1002/cncr.32962. Epub 2020 May 28.


PMID- 32463372
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 5
DP  - 2020 May 28
TI  - All Our Data Will Be Health Data One Day: The Need for Universal Data Protection 
      and Comprehensive Consent.
PG  - e16879
LID - 10.2196/16879 [doi]
AB  - Tremendous growth in the types of data that are collected and their interlinkage 
      are enabling more predictions of individuals' behavior, health status, and
      diseases. Legislation in many countries treats health-related data as a special
      sensitive kind of data. Today's massive linkage of data, however, could transform
      "nonhealth" data into sensitive health data. In this paper, we argue that the
      notion of health data should be broadened and should also take into account past 
      and future health data and indirect, inferred, and invisible health data. We also
      lay out the ethical and legal implications of our model.
CI  - (c)Christophe Olivier Schneble, Bernice Simone Elger, David Martin Shaw.
      Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 28.05.2020.
FAU - Schneble, Christophe Olivier
AU  - Schneble CO
AUID- ORCID: 0000-0003-1967-7129
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Elger, Bernice Simone
AU  - Elger BS
AUID- ORCID: 0000-0002-4249-7399
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Shaw, David Martin
AU  - Shaw DM
AUID- ORCID: 0000-0001-8180-6927
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200528
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Computer Security/*standards
MH  - Humans
MH  - Informed Consent/*standards
PMC - PMC7290498
OTO - NOTNLM
OT  - *best practices
OT  - *big data
OT  - *data protection
OT  - *guidelines
OT  - *health data
OT  - *social media
EDAT- 2020/05/29 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/05/29 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/02/17 00:00 [revised]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - v22i5e16879 [pii]
AID - 10.2196/16879 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 May 28;22(5):e16879. doi: 10.2196/16879.


PMID- 32463285
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20201218
IS  - 1942-969X (Electronic)
IS  - 1942-969X (Linking)
VI  - 12
IP  - S1
DP  - 2020 Aug
TI  - Shattered social identity and moral injuries: Work-related conditions in health
      care professionals during the COVID-19 pandemic.
PG  - S156-S158
LID - 10.1037/tra0000715 [doi]
AB  - The present article assesses the effects of shattered social identity and moral
      injuries experienced by health care professionals (HCPs) due to the COVID-19
      pandemic. Professional expertise and emotional-cognitive demands as key aspects
      of HCPs' social identity are introduced, and the effects of moral injuries-in
      terms of violation of medical-ethical and social-ethical norms-on the mental
      health of HCPs are discussed. (PsycInfo Database Record (c) 2020 APA, all rights 
      reserved).
FAU - Kroger, Christoph
AU  - Kroger C
AUID- ORCID: 0000-0002-2176-6078
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - United States
TA  - Psychol Trauma
JT  - Psychological trauma : theory, research, practice and policy
JID - 101495376
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Clinical Competence
MH  - *Coronavirus Infections
MH  - *Ethics, Medical
MH  - *Health Personnel/ethics/psychology
MH  - Humans
MH  - *Morals
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - *Psychological Trauma/etiology/psychology
MH  - Self Efficacy
MH  - *Social Identification
EDAT- 2020/05/29 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 2020-37309-001 [pii]
AID - 10.1037/tra0000715 [doi]
PST - ppublish
SO  - Psychol Trauma. 2020 Aug;12(S1):S156-S158. doi: 10.1037/tra0000715. Epub 2020 May
      28.


PMID- 32463212
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20201218
IS  - 1827-1596 (Electronic)
IS  - 0375-9393 (Linking)
VI  - 86
IP  - 8
DP  - 2020 Aug
TI  - Principled decisions and virtuous care: an ethical assessment of the SIAARTI
      Guidelines for allocating intensive care resources.
PG  - 872-876
LID - 10.23736/S0375-9393.20.14691-1 [doi]
AB  - This article sets forth ethical principles for responding to extraordinary
      circumstances in which the demand for medical care threatens to overwhelm
      available resources, as in the COVID-19 pandemic. In light of these principles,
      the author then assesses the ethics of the SIAARTI guidelines for rationing ICU
      beds and ventilators under such circumstances.
FAU - Sulmasy, Daniel P
AU  - Sulmasy DP
AD  - Kennedy Institute of Ethics, Georgetown University, Washington, DC, USA -
      sulmasyd@georgetown.edu.
LA  - eng
PT  - Journal Article
DEP - 20200528
PL  - Italy
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
SB  - IM
MH  - Age Factors
MH  - Bed Conversion/statistics & numerical data
MH  - Bed Occupancy/statistics & numerical data
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Critical Care/*ethics/standards
MH  - Health Care Rationing/ethics
MH  - Health Resources/supply & distribution
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Intensive Care Units/statistics & numerical data
MH  - Italy/epidemiology
MH  - Life Expectancy
MH  - Moral Obligations
MH  - Palliative Care/ethics
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - *Practice Guidelines as Topic
MH  - Prognosis
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Triage/*ethics
MH  - Value of Life
MH  - Ventilators, Mechanical/supply & distribution
EDAT- 2020/05/29 06:00
MHDA- 2020/08/15 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - S0375-9393.20.14691-1 [pii]
AID - 10.23736/S0375-9393.20.14691-1 [doi]
PST - ppublish
SO  - Minerva Anestesiol. 2020 Aug;86(8):872-876. doi: 10.23736/S0375-9393.20.14691-1. 
      Epub 2020 May 28.


PMID- 32463143
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20211207
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 107
IP  - 7
DP  - 2020 Jun
TI  - Regenerative medicine, organ bioengineering and transplantation.
PG  - 793-800
LID - 10.1002/bjs.11686 [doi]
AB  - BACKGROUND: Organ transplantation is predicted to increase as life expectancy and
      the incidence of chronic diseases rises. Regenerative medicine-inspired
      technologies challenge the efficacy of the current allograft transplantation
      model. METHODS: A literature review was conducted using the PubMed interface of
      MEDLINE from the National Library of Medicine. Results were examined for
      relevance to innovations of organ bioengineering to inform analysis of advances
      in regenerative medicine affecting organ transplantation. Data reports from the
      Scientific Registry of Transplant Recipient and Organ Procurement Transplantation
      Network from 2008 to 2019 of kidney, pancreas, liver, heart, lung and intestine
      transplants performed, and patients currently on waiting lists for respective
      organs, were reviewed to demonstrate the shortage and need for transplantable
      organs. RESULTS: Regenerative medicine technologies aim to repair and regenerate 
      poorly functioning organs. One goal is to achieve an immunosuppression-free state
      to improve quality of life, reduce complications and toxicities, and eliminate
      the cost of lifelong antirejection therapy. Innovative strategies include
      decellularization to fabricate acellular scaffolds that will be used as a
      template for organ manufacturing, three-dimensional printing and interspecies
      blastocyst complementation. Induced pluripotent stem cells are an innovation in
      stem cell technology which mitigate both the ethical concerns associated with
      embryonic stem cells and the limitation of other progenitor cells, which lack
      pluripotency. Regenerative medicine technologies hold promise in a wide array of 
      fields and applications, such as promoting regeneration of native cell lines,
      growth of new tissue or organs, modelling of disease states, and augmenting the
      viability of existing ex vivo transplanted organs. CONCLUSION: The future of
      organ bioengineering relies on furthering understanding of organogenesis, in vivo
      regeneration, regenerative immunology and long-term monitoring of implanted
      bioengineered organs.
CI  - (c) 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.
FAU - Edgar, L
AU  - Edgar L
AD  - Department of Surgery, Section of Transplantation, Wake Forest University School 
      of Medicine, Winston Salem, North Carolina, USA.
FAU - Pu, T
AU  - Pu T
AD  - Department of Surgery, Section of Transplantation, Wake Forest University School 
      of Medicine, Winston Salem, North Carolina, USA.
FAU - Porter, B
AU  - Porter B
AD  - University of Florida College of Medicine, Gainesville, Florida, USA.
FAU - Aziz, J M
AU  - Aziz JM
AD  - Department of Surgery, Section of Transplantation, Wake Forest University School 
      of Medicine, Winston Salem, North Carolina, USA.
FAU - La Pointe, C
AU  - La Pointe C
AD  - Sherbrooke University, Sherbrooke, Quebec, Canada.
FAU - Asthana, A
AU  - Asthana A
AD  - Department of Surgery, Section of Transplantation, Wake Forest University School 
      of Medicine, Winston Salem, North Carolina, USA.
FAU - Orlando, G
AU  - Orlando G
AUID- ORCID: 0000-0002-6460-7974
AD  - Department of Surgery, Section of Transplantation, Wake Forest University School 
      of Medicine, Winston Salem, North Carolina, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - IM
CIN - Br J Surg. 2021 Nov 11;108(11):e386. PMID: 34370831
MH  - *Artificial Organs
MH  - Biomedical Engineering
MH  - Humans
MH  - *Organ Transplantation/methods
MH  - *Regenerative Medicine/methods
EDAT- 2020/05/29 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1002/bjs.11686 [doi]
PST - ppublish
SO  - Br J Surg. 2020 Jun;107(7):793-800. doi: 10.1002/bjs.11686.


PMID- 32462323
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220216
IS  - 1432-1238 (Electronic)
IS  - 0342-4642 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Focus on better care and ethics: Are medical ethics lagging behind the
      development of new medical technologies?
PG  - 1611-1613
LID - 10.1007/s00134-020-06112-4 [doi]
FAU - Einav, Sharon
AU  - Einav S
AUID- ORCID: 0000-0001-8963-9633
AD  - General Intensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
      einav_s@szmc.org.il.
AD  - Faculty of Medicine, Hebrew University, Jerusalem, Israel. einav_s@szmc.org.il.
FAU - Ranzani, Otavio T
AU  - Ranzani OT
AD  - Pulmonary Division, Heart Institute (InCor), Hospital das Clinicas HCFMUSP,
      Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
LA  - eng
PT  - Editorial
DEP - 20200527
PL  - United States
TA  - Intensive Care Med
JT  - Intensive care medicine
JID - 7704851
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
PMC - PMC7251219
EDAT- 2020/05/29 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 10.1007/s00134-020-06112-4 [doi]
AID - 10.1007/s00134-020-06112-4 [pii]
PST - ppublish
SO  - Intensive Care Med. 2020 Aug;46(8):1611-1613. doi: 10.1007/s00134-020-06112-4.
      Epub 2020 May 27.


PMID- 32461800
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Linking)
VI  - 54
DP  - 2020 Jun
TI  - Informed consent for surgery on neck of femur fractures: A multi-loop clinical
      audit.
PG  - 26-31
LID - 10.1016/j.amsu.2020.03.008 [doi]
AB  - BACKGROUND: The Montgomery case in 2015 resulted in a pivotal change in practice,
      leading to a patient-centric approach for informed consent. Neck of femur (NOF)
      fractures are associated with a high rates perioperative morbidity and mortality.
      Using guidelines highlighted by the British Orthopaedic Association we performed 
      a multi-loop audit within our department to assess the adequacy of informed
      consent for NOF fractures. METHODS: Two prior cycles had been performed utilising
      a similar framework. Prior interventions included ward posters, verbal
      dissemination of information at Junior Doctor's (JD) induction and amendments to 
      the JD handbook. For the latest audit loop, a retrospective analysis of 100
      patients was performed. Risk were classified as common, less common, rare and
      'other' non-classifiable risks. The adequacy of informed consent was evaluated by
      assessing the quality and accuracy of documentation in the signed Consent Form-1s
      for compos mentis patients. RESULTS: Infection, bleeding risks, clots and
      anaesthetic risks were documented in all patients (100%). Areas of improvement
      included documentation of neurovascular injuries (98%), pain (75%) and altered
      wound healing (69%). There was no significant change in the documentation of
      failure of surgery (83%) and neurovascular injuries (98%). Poorly documented risk
      factors included mortality (21%), prosthetic dislocation (14%) and limb length
      discrepancy (6%). CONCLUSION: Following the latest cycle, the trust has now
      approved the use of 2 consent-specific stickers (for arthroplasty or fixation),
      amendable on a patient-to-patient basis. As part of the multi-loop process, the
      cycle will be repeated every year, in line with Junior Doctor rotations. Medical 
      professionals have an ethical, moral and legal obligation to ensure they provide 
      all information regarding surgical interventions to aid patients in making an
      informed decision.
CI  - (c) 2020 The Author(s).
FAU - Shah, Rohi
AU  - Shah R
AD  - Trauma and Orthopaedics Department, Kettering General Hospital, Rothwell Road,
      Kettering, NN16 8UZ, UK.
FAU - Sambhwani, Sharan
AU  - Sambhwani S
AD  - Trauma and Orthopaedics Department, Kettering General Hospital, Rothwell Road,
      Kettering, NN16 8UZ, UK.
FAU - Al-Shahwani, Awf
AU  - Al-Shahwani A
AD  - Trauma and Orthopaedics Department, Kettering General Hospital, Rothwell Road,
      Kettering, NN16 8UZ, UK.
FAU - Plakogiannis, Christos
AU  - Plakogiannis C
AD  - Trauma and Orthopaedics Department, Kettering General Hospital, Rothwell Road,
      Kettering, NN16 8UZ, UK.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7242500
OTO - NOTNLM
OT  - Audit cycle
OT  - British orthopaedic association
OT  - Informed consent
OT  - Montgomery case
OT  - Neck of femur fractures
COIS- None of the authors have any conflicts of interest to declare.
EDAT- 2020/05/29 06:00
MHDA- 2020/05/29 06:01
CRDT- 2020/05/29 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/05/29 06:01 [medline]
AID - 10.1016/j.amsu.2020.03.008 [doi]
AID - S2049-0801(20)30035-2 [pii]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Apr 8;54:26-31. doi: 10.1016/j.amsu.2020.03.008.
      eCollection 2020 Jun.


PMID- 32461546
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 2058-6124 (Electronic)
IS  - 2058-6124 (Linking)
VI  - 6
IP  - 1
DP  - 2020 May 27
TI  - Biases in the evaluation of self-harm in patients with disability due to spinal
      cord injury.
PG  - 43
LID - 10.1038/s41394-020-0293-6 [doi]
AB  - INTRODUCTION: Suicide is a global problem and accurate assessment of risk for
      self-harm is critical. Even morally principled clinicians can manifest bias when 
      assessing self-harm in patients with physical disabilities such as spinal cord
      injury (SCI). Assessment of self-harm is an obligation for health care clinicians
      and overestimating or underestimating risk may undermine a patient's trust in
      their care, possibly leading to less engagement, increased apathy about having an
      interest in living, and less adherence to healthy treatment options. CASE
      PRESENTATION: Introduces readers to three biases that can impact decision-making 
      regarding a patient with a disability when assessing the patient's risk for
      self-harm: (1) ineffectual bias, (2) fragile friendliness bias, and (3)
      catastrophe bias. These preconceptions are derived from a mix of paternalism,
      projection, low expectations, pity, and infantilization. In this paper, we
      explain how each bias can affect clinical decision-making regarding diagnosis,
      treatment, prognosis, and prevention for patients with SCI within a common case
      scenario. Readers can employ personal reflection and potential self-application
      when they encounter individuals with SCI in and outside clinical settings.
      DISCUSSION: Unchecked biases toward the disabled and patients with SCI can
      undermine ethical caregiving. Biases are habits of mind and thoughtful clinical
      and education interventions can improve clinical practice. The literature on
      health care bias with other minority groups is instructive for investigating
      biases related to patients with disabilities, and especially for clinicians
      outside of rehabilitation medicine.
FAU - Budd, Maggi A
AU  - Budd MA
AD  - Boston VA Healthcare System, Brockton, MA, USA. margaret.budd@va.gov.
AD  - Harvard Medical School, Boston, MA, USA. margaret.budd@va.gov.
FAU - Haque, Omar Sultan
AU  - Haque OS
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Stein, Michael Ashley
AU  - Stein MA
AD  - Harvard Law School, Cambridge, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200527
PL  - England
TA  - Spinal Cord Ser Cases
JT  - Spinal cord series and cases
JID - 101680856
SB  - IM
MH  - *Clinical Decision-Making
MH  - Humans
MH  - Risk Assessment
MH  - Self-Injurious Behavior/complications/*diagnosis
MH  - Spinal Cord Injuries/complications/*psychology
PMC - PMC7253438
EDAT- 2020/05/29 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/01/10 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
AID - 10.1038/s41394-020-0293-6 [doi]
AID - 10.1038/s41394-020-0293-6 [pii]
PST - epublish
SO  - Spinal Cord Ser Cases. 2020 May 27;6(1):43. doi: 10.1038/s41394-020-0293-6.


PMID- 32461335
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Linking)
VI  - 12
IP  - 545
DP  - 2020 May 27
TI  - Ethical and societal implications of cellular health-monitoring devices.
LID - eaax6924 [pii]
LID - 10.1126/scitranslmed.aax6924 [doi]
AB  - As cell engineering is used to develop new types of implanted health-monitoring
      devices, this may raise ethical issues for individuals and society.
CI  - Copyright (c) 2020 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Deplazes-Zemp, Anna
AU  - Deplazes-Zemp A
AUID- ORCID: 0000-0002-1992-1622
AD  - Anna Deplazes-Zemp is a senior researcher at the Ethics Research Institute at the
      University of Zurich, CH-8006 Zurich, Switzerland. Email: deplazes@ethik.uzh.ch.
AD  - Martin Fussenegger is a Professor in the Department of Bio systems Science and
      Engineering, ETH Zurich and in the Faculty of Science, University of Basel,
      CH-4058 Basel, Switzerland. Email: fussenegger@bsse.ethz.ch.
AD  - Nikola Biller-Andorno is the Director of the Institute of Biomedical Ethics and
      History of Medicine at the University of Zurich, CH-8006 Zurich, Switzerland.
      Email: biller-andorno@ibme.uzh.ch.
FAU - Fussenegger, Martin
AU  - Fussenegger M
AUID- ORCID: 0000-0001-8545-667X
AD  - Anna Deplazes-Zemp is a senior researcher at the Ethics Research Institute at the
      University of Zurich, CH-8006 Zurich, Switzerland. Email: deplazes@ethik.uzh.ch.
AD  - Martin Fussenegger is a Professor in the Department of Bio systems Science and
      Engineering, ETH Zurich and in the Faculty of Science, University of Basel,
      CH-4058 Basel, Switzerland. Email: fussenegger@bsse.ethz.ch.
AD  - Nikola Biller-Andorno is the Director of the Institute of Biomedical Ethics and
      History of Medicine at the University of Zurich, CH-8006 Zurich, Switzerland.
      Email: biller-andorno@ibme.uzh.ch.
FAU - Biller-Andorno, Nikola
AU  - Biller-Andorno N
AUID- ORCID: 0000-0001-7661-1324
AD  - Anna Deplazes-Zemp is a senior researcher at the Ethics Research Institute at the
      University of Zurich, CH-8006 Zurich, Switzerland. Email: deplazes@ethik.uzh.ch.
AD  - Martin Fussenegger is a Professor in the Department of Bio systems Science and
      Engineering, ETH Zurich and in the Faculty of Science, University of Basel,
      CH-4058 Basel, Switzerland. Email: fussenegger@bsse.ethz.ch.
AD  - Nikola Biller-Andorno is the Director of the Institute of Biomedical Ethics and
      History of Medicine at the University of Zurich, CH-8006 Zurich, Switzerland.
      Email: biller-andorno@ibme.uzh.ch.
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
SB  - IM
EDAT- 2020/05/29 06:00
MHDA- 2020/05/29 06:01
CRDT- 2020/05/29 06:00
PHST- 2019/04/14 00:00 [received]
PHST- 2019/08/08 00:00 [revised]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/05/29 06:01 [medline]
AID - 12/545/eaax6924 [pii]
AID - 10.1126/scitranslmed.aax6924 [doi]
PST - ppublish
SO  - Sci Transl Med. 2020 May 27;12(545). pii: 12/545/eaax6924. doi:
      10.1126/scitranslmed.aax6924.


PMID- 32461298
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 26
TI  - Protocol for hypofractionated adaptive radiotherapy to the bladder within a
      multicentre phase II randomised trial: radiotherapy planning and delivery
      guidance.
PG  - e037134
LID - 10.1136/bmjopen-2020-037134 [doi]
AB  - INTRODUCTION: Patients with muscle invasive bladder cancer (MIBC) who are unfit
      and unsuitable for standard radical treatment with cystectomy or daily
      radiotherapy present a large unmet clinical need. Untreated, they suffer high
      cancer specific mortality and risk significant disease-related local symptoms.
      Hypofractionated radiotherapy (delivering higher doses in fewer fractions/visits)
      is a potential treatment solution but could be compromised by the mobile nature
      of the bladder, resulting in target misses in a significant proportion of
      fractions. Adaptive 'plan of the day' image-guided radiotherapy delivery may
      improve the precision and accuracy of treatment. We aim to demonstrate within a
      randomised multicentre phase II trial feasibility of plan of the day
      hypofractionated bladder radiotherapy delivery with acceptable rates of toxicity.
      METHODS AND ANALYSIS: Patients with T2-T4aN0M0 MIBC receiving 36 Gy in 6-weekly
      fractions are randomised (1:1) between treatment delivered using a
      single-standard plan or adaptive radiotherapy using a library of three plans
      (small, medium and large). A cone beam CT taken prior to each treatment is used
      to visualise the anatomy and select the most appropriate plan depending on the
      bladder shape and size. A comprehensive radiotherapy quality assurance programme 
      has been instituted to ensure standardisation of radiotherapy planning and
      delivery. The primary endpoint is to exclude >30% acute grade >3
      non-genitourinary toxicity at 3 months for adaptive radiotherapy in patients who 
      received >1 fraction (p0=0.7, p1=0.9, alpha=0.05, beta=0.2). Secondary endpoints 
      include local disease control, symptom control, late toxicity, overall survival, 
      patient-reported outcomes and proportion of fractions benefiting from adaptive
      planning. Target recruitment is 62 patients. ETHICS AND DISSEMINATION: The trial 
      is approved by the London-Surrey Borders Research Ethics Committee (13/LO/1350). 
      The results will be disseminated via peer-reviewed scientific journals,
      conference presentations and submission to regulatory authorities. TRIAL
      REGISTRATION NUMBER: NCT01810757.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Hafeez, Shaista
AU  - Hafeez S
AUID- ORCID: 0000-0002-2057-0946
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
      shaista.hafeez@icr.ac.uk.
AD  - Radiotherapy and Imaging, The Royal Marsden Hospital NHS Trust, London, UK.
FAU - Patel, Emma
AU  - Patel E
AD  - Mount Vernon Hospital, National Radiotherapy Trials Quality Assurance Group,
      Northwood, UK.
FAU - Webster, Amanda
AU  - Webster A
AD  - Mount Vernon Hospital, National Radiotherapy Trials Quality Assurance Group,
      Northwood, UK.
FAU - Warren-Oseni, Karole
AU  - Warren-Oseni K
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
AD  - Radiotherapy and Imaging, The Royal Marsden Hospital NHS Trust, London, UK.
FAU - Hansen, Vibeke
AU  - Hansen V
AD  - Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark.
FAU - McNair, Helen
AU  - McNair H
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
AD  - Radiotherapy and Imaging, The Royal Marsden Hospital NHS Trust, London, UK.
FAU - Miles, Elizabeth
AU  - Miles E
AD  - Mount Vernon Hospital, National Radiotherapy Trials Quality Assurance Group,
      Northwood, UK.
FAU - Lewis, Rebecca
AU  - Lewis R
AD  - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London,
      UK.
FAU - Hall, Emma
AU  - Hall E
AD  - Clinical Trials and Statistics Unit, The Institute of Cancer Research, London,
      UK.
FAU - Huddart, Robert
AU  - Huddart R
AD  - Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
AD  - Radiotherapy and Imaging, The Royal Marsden Hospital NHS Trust, London, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT01810757
GR  - CRUK/12/055/CRUK_/Cancer Research UK/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Clinical Trials, Phase II as Topic
MH  - Cystectomy
MH  - Humans
MH  - London
MH  - Multicenter Studies as Topic
MH  - *Radiotherapy, Image-Guided
MH  - *Radiotherapy, Intensity-Modulated/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - *Urinary Bladder Neoplasms/radiotherapy/surgery
PMC - PMC7259864
OTO - NOTNLM
OT  - *bladder disorders
OT  - *oncology
OT  - *radiation oncology
OT  - *radiotherapy
OT  - *urological tumours
COIS- Competing interests: SH reports non-financial support from Elekta (Elekta AB,
      Stockholm, Sweden), non-financial support from Merck Sharp & Dohme, personal fees
      and non-financial support from Roche outside the submitted work; EP, AW, KW-O,
      VH, HM, EM, and RL have no conflicts to disclose; EH reports grants from Cancer
      Research UK during the conduct of the study; grants from Accuray, grants from
      Varian Medical Systems, outside the submitted work; RH reports non-financial
      support from Janssen, grants and personal fees from MSD, personal fees from
      Bristol Myers Squibb, grants from CRUK, other from Nektar, personal fees and
      non-financial support from Roche, outside the submitted work.
EDAT- 2020/05/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-037134 [pii]
AID - 10.1136/bmjopen-2020-037134 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 26;10(5):e037134. doi: 10.1136/bmjopen-2020-037134.


PMID- 32461297
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 26
TI  - Lengthening adalimumab dosing interval in quiescent Crohn's disease patients:
      protocol for the pragmatic randomised non-inferiority LADI study.
PG  - e035326
LID - 10.1136/bmjopen-2019-035326 [doi]
AB  - INTRODUCTION: Adalimumab is effective for maintenance of remission in patients
      with Crohn's disease (CD) at a dose of 40 mg subcutaneously every 2 weeks.
      However, adalimumab is associated with (long-term) adverse events and is costly. 
      The aim of this study is to demonstrate non-inferiority and cost-effectiveness of
      disease activity guided adalimumab interval lengthening compared to standard
      dosing of every other week (EOW). METHODS AND ANALYSIS: The Lengthening
      Adalimumab Dosing Interval (LADI) study is a pragmatic, multicentre, open label, 
      randomised controlled non-inferiority trial. Non-inferiority is reached if the
      difference in cumulative incidence of persistent (>8 weeks) flares does not
      exceed the non-inferiority margin of 15%. 174 CD patients on adalimumab
      maintenance therapy in long-term (>9 months) clinical and biochemical remission
      will be included (C-reactive protein (CRP) <10 mg/L, faecal calprotectin (FC)
      <150 microg/g, Harvey-Bradshaw Index (HBI) <5). Patients will be randomised 2:1
      into the intervention (adalimumab interval lengthening) or control group
      (adalimumab EOW). The intervention group will lengthen the adalimumab
      administration interval to every 3 weeks, and after 24 weeks to every 4 weeks.
      Clinical and biochemical disease activity will be monitored every 12 weeks by
      physician global assessment, HBI, CRP and FC. In case of disease flare, dosing
      will be increased. A flare is defined as two of three of the following criteria; 
      FC>250 microg/g, CRP>/=10 mg/l, HBI>/=5. Secondary outcomes include cumulative
      incidence of transient flares, adverse events, predictors for successful dose
      reduction and cost-effectiveness. ETHICS AND DISSEMINATION: The study is approved
      by the Medical Ethics Committee Arnhem-Nijmegen, the Netherlands (registration
      number NL58948.091.16). Results will be published in peer-reviewed journals and
      presented at international conferences. TRIAL REGISTRATION NUMBERS: EudraCT
      registry (2016-003321-42); Clinicaltrials.gov registry (NCT03172377); Dutch trial
      registry (NTRID6417).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Smits, L J T
AU  - Smits LJT
AUID- ORCID: 0000-0002-4090-0738
AD  - Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The
      Netherlands.
FAU - Pauwels, R W M
AU  - Pauwels RWM
AUID- ORCID: 0000-0002-2118-5687
AD  - Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,
      The Netherlands.
FAU - Kievit, W
AU  - Kievit W
AD  - Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands.
FAU - de Jong, D J
AU  - de Jong DJ
AD  - Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The
      Netherlands.
FAU - de Vries, A C
AU  - de Vries AC
AD  - Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,
      The Netherlands.
FAU - Hoentjen, F
AU  - Hoentjen F
AD  - Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The
      Netherlands.
FAU - van der Woude, C J
AU  - van der Woude CJ
AD  - Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,
      The Netherlands c.vanderwoude@erasmusmc.nl.
CN  - LADI study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03172377
SI  - EudraCT/2016-003321-42
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Crohn Disease/drug therapy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - Randomized Controlled Trials as Topic
MH  - Tumor Necrosis Factor-alpha
PMC - PMC7259868
OTO - NOTNLM
OT  - *adverse events
OT  - *clinical trials
OT  - *gastroenterology
OT  - *health economics
OT  - *inflammatory bowel disease
OT  - *statistics & research methods
COIS- Competing interests: DJdJ received consulting fees from Synthon Pharma, Abbvie
      and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, Vifor
      Pharma and Cablon Medical. ACDV has participated in advisory board and/or
      received financial compensation from the following companies: Jansen, Takeda,
      Abbvie and Tramedico. FH has served on advisory boards or as speaker for Abbvie, 
      Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk, and received
      unrestricted funding from Dr Falk, Janssen-Cilag, Abbvie and Celgene. CJvdW
      received grant support from Falk Benelux and Pfizer; received speaker fees from
      AbbVie, Takeda, Ferring, Dr Falk Pharma, Hospira, Pfizer; and served as a
      consultant for AbbVie, MSD, Takeda, Celgene, Mundipharma and Janssen.
IR  - van Bodegraven AA
FIR - van Bodegraven, A A
IR  - Bodelier AGL
FIR - Bodelier, A G L
IR  - Boekema PJ
FIR - Boekema, P J
IR  - de Boer N
FIR - de Boer, N
IR  - Ter Borg PCJ
FIR - Ter Borg, P C J
IR  - den Broeder AA
FIR - den Broeder, A A
IR  - Gisbertz IAM
FIR - Gisbertz, I A M
IR  - Hoentjen F
FIR - Hoentjen, F
IR  - Jansen FM
FIR - Jansen, F M
IR  - Jansen J
FIR - Jansen, J
IR  - Jansen SV
FIR - Jansen, S V
IR  - de Jong DJ
FIR - de Jong, D J
IR  - Kievit W
FIR - Kievit, W
IR  - van Linschoten RCA
FIR - van Linschoten, R C A
IR  - Lowenberg M
FIR - Lowenberg, M
IR  - Lutgens MWMD
FIR - Lutgens, M W M D
IR  - Mallant-Hent RC
FIR - Mallant-Hent, R C
IR  - van der Meulen AE
FIR - van der Meulen, A E
IR  - Oldenburg B
FIR - Oldenburg, B
IR  - Pauwels RWM
FIR - Pauwels, R W M
IR  - Pierik M
FIR - Pierik, M
IR  - Romberg-Camps MJL
FIR - Romberg-Camps, M J L
IR  - Romkens TEH
FIR - Romkens, T E H
IR  - Russel MGVM
FIR - Russel, M G V M
IR  - Smits LJT
FIR - Smits, L J T
IR  - Tan ACITL
FIR - Tan, A C I T L
IR  - Verhulst ML
FIR - Verhulst, M L
IR  - de Vries AC
FIR - de Vries, A C
IR  - West RL
FIR - West, R L
IR  - Wolfhagen FHJ
FIR - Wolfhagen, F H J
IR  - van der Woude CJ
FIR - van der Woude, C J
EDAT- 2020/05/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035326 [pii]
AID - 10.1136/bmjopen-2019-035326 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 26;10(5):e035326. doi: 10.1136/bmjopen-2019-035326.


PMID- 32461293
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 26
TI  - Asylum seekers' and Refugees' Changing Health (ARCH) study protocol: an
      observational study in Lebanon and Denmark to assess health implications of
      long-distance migration on communicable and non-communicable diseases and mental 
      health.
PG  - e034412
LID - 10.1136/bmjopen-2019-034412 [doi]
AB  - INTRODUCTION: By end of 2018, the European Union countries hosted approximately
      2.5 million refugees and Lebanon alone hosted more than 1 million. The majority
      of refugees worldwide came from Syria. The prevailing study design in published
      studies on asylum seekers' and refugees' health leaves a number of fundamental
      research questions unanswerable. In the Asylum seekers' and Refugees' Changing
      Health (ARCH) study, we examine the health of a homogeneous group of refugees and
      asylum seekers in two very different host countries with very different migration
      histories. We aim to study the health impact of the migration process, living
      conditions, access to healthcare, gene-environment interactions and the health
      transition. METHODS AND ANALYSIS: ARCH is an international multisite study of the
      health of adult (>18 years old) Syrian refugees and asylum seekers in Lebanon and
      Denmark. Using a standardised framework, we collect information on mental and
      physical health using validated scales and biological samples. We aim to include 
      220 participants in Danish asylum centres and 1100 participants in Lebanese
      refugee camps and settlements. We will use propensity score weights to control
      for confounding and multiple imputation to handle missing data. ETHICS AND
      DISSEMINATION: Ethical approval has been obtained in Lebanon and Denmark. In the 
      short term, we will present the cross-sectional association between long-distance
      migration and the results of the throat and wound swab, blood and faeces samples 
      and mental health screenings. In the longer term, we are planning to follow the
      refugees in Denmark with collection of dried blood spots, mental health
      screenings and semistructured qualitative interviews on the participant's health 
      and access to healthcare in the time lived in Denmark. Here, we present an
      overview of the background for the ARCH study as well as a thorough description
      of the methodology.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Eiset, Andreas Halgreen
AU  - Eiset AH
AUID- ORCID: 0000-0002-5487-8359
AD  - Center for Global Health (GloHAU), Department of Public Health, Aarhus
      University, Aarhus, Denmark eiset@ph.au.dk.
AD  - Clinic for PTSD and Anxiety, Aarhus University Hospital, Aarhus, Denmark.
FAU - Aoun, Michaelangelo P
AU  - Aoun MP
AD  - Department of Psychiatry, Lebanese University, Beirut, Lebanon.
FAU - Haddad, Ramzi S
AU  - Haddad RS
AD  - Department of Psychiatry, Lebanese University, Beirut, Lebanon.
FAU - Naja, Wadih J
AU  - Naja WJ
AD  - Department of Psychiatry, Lebanese University, Beirut, Lebanon.
FAU - Fuursted, Kurt
AU  - Fuursted K
AD  - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Kobenhavn,
      Denmark.
FAU - Nielsen, Henrik Vedel
AU  - Nielsen HV
AD  - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Kobenhavn,
      Denmark.
FAU - Stensvold, Christen Rune
AU  - Stensvold CR
AD  - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Kobenhavn,
      Denmark.
FAU - Nielsen, Monica Stougaard
AU  - Nielsen MS
AD  - Clinic for PTSD and Anxiety, Aarhus University Hospital, Aarhus, Denmark.
FAU - Gottlieb, Annemarie
AU  - Gottlieb A
AD  - Clinic for PTSD and Anxiety, Aarhus University Hospital, Aarhus, Denmark.
FAU - Frydenberg, Morten
AU  - Frydenberg M
AD  - Department of Public Health, Aarhus University, Aarhus, Denmark.
FAU - Wejse, Christian
AU  - Wejse C
AD  - Center for Global Health (GloHAU), Department of Public Health, Aarhus
      University, Aarhus, Denmark.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Denmark
MH  - Humans
MH  - Lebanon
MH  - Mental Health
MH  - *Noncommunicable Diseases
MH  - Observational Studies as Topic
MH  - *Refugees
MH  - Syria
PMC - PMC7259863
OTO - NOTNLM
OT  - *communicable diseases
OT  - *epidemiology
OT  - *mental health
OT  - *noncommunicable diseases
OT  - *refugees
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034412 [pii]
AID - 10.1136/bmjopen-2019-034412 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 26;10(5):e034412. doi: 10.1136/bmjopen-2019-034412.


PMID- 32461289
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 26
TI  - Pneumoperitoneum preconditioning for the prevention of renal function after
      laparoscopic partial nephrectomy: protocol for a double-blind randomised
      controlled trial.
PG  - e032002
LID - 10.1136/bmjopen-2019-032002 [doi]
AB  - INTRODUCTION: Renal ischaemia reperfusion injury is an inevitable pathophysiology
      in different clinical situations including laparoscopic partial nephrectomy
      (LPN), which can obviously decrease the renal function after surgery.
      Pneumoperitoneum preconditioning (PP) is a promising approach that can yield a
      protective effect on kidney, which has already been demonstrated in some animal
      models. The present study is designed to assess whether the PP can yield a
      clinical renoprotective role after LPN. METHODS AND ANALYSIS: This study is a
      randomised, prospective, double-blind and parallel controlled clinical trial.
      Eligible participants will be patients with renal tumours and willing to choose
      elective LPN. Patients randomised to the treatment arm will receive PP consisted 
      of three cycles of 5 min insuf fl ation and 5 min desuf fl ation before LPN,
      while the control arm will receive a sham operation. The primary endpoints are
      glomerular filtration rate and the level of serum cystatin C within 6 months
      after desuf fl ation. The secondary endpoints are serum creatinine, estimated
      glomerular filtration rate, alanine transaminase, serum amylase, intestinal fatty
      acid binding protein, postoperative hospital stay, the incidence of adverse
      events and mortality in postoperative 6 months. ETHICS AND DISSEMINATION: This
      study has been approved by the institutional ethics committee of Nanjing First
      Hospital. The results of this study will be reported faithfully through
      scientific conferences or published articles. TRIAL REGISTRATION NUMBER:
      NCT03822338.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhou, Changcheng
AU  - Zhou C
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Xu, Luwei
AU  - Xu L
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Xu, Zheng
AU  - Xu Z
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Ge, Yuzheng
AU  - Ge Y
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Zhou, Liuhua
AU  - Zhou L
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Nuclear Medicine Center, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Liu, Jingyu
AU  - Liu J
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Pan, Gaojian
AU  - Pan G
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Yang, Tianli
AU  - Yang T
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China.
FAU - Jia, Ruipeng
AU  - Jia R
AUID- ORCID: 0000-0002-5532-5641
AD  - Department of Urology, Nanjing First Hospital, Nanjing Medical University,
      Nangjing, Jiangsu, China urojiarp@njmu.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT03822338
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - *Insufflation
MH  - *Kidney Neoplasms/surgery
MH  - *Laparoscopy
MH  - Nephrectomy/adverse effects
MH  - *Pneumoperitoneum
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7259839
OTO - NOTNLM
OT  - *laparoscopic partial nephrectomy
OT  - *pneumoperitoneum preconditioning
OT  - *protocol
OT  - *randomised controlled trial
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-032002 [pii]
AID - 10.1136/bmjopen-2019-032002 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 26;10(5):e032002. doi: 10.1136/bmjopen-2019-032002.


PMID- 32461261
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20201218
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 1
DP  - 2020 Jul
TI  - Pediatric Palliative Care in a Pandemic: Role Obligations, Moral Distress, and
      the Care You Can Give.
LID - e20201163 [pii]
LID - 10.1542/peds.2020-1163 [doi]
AB  - Many ethical issues arise concerning the care of critically ill and dying
      patients during the coronavirus disease 2019 (COVID-19) pandemic. In this issue's
      Ethics Rounds, we present 2 cases that highlight 2 different sorts of ethical
      issues. One is focused on the decisions that have to be made when the surge of
      patients with respiratory failure overwhelm ICUs. The other is focused on the
      psychological issues that arise for parents who are caring for a dying child when
      infection-control policies limit the number of visitors. Both of these situations
      raise challenges for caregivers who are trying to be honest, to deal with their
      own moral distress, and to provide compassionate palliative care.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Evans, Amanda M
AU  - Evans AM
AD  - John Hunter Children's Hospital, New Lambton Heights, New South Wales, Australia;
      amaevans@gmail.com.
FAU - Jonas, Monique
AU  - Jonas M
AD  - Department of General Practice, Faculty of Medical and Health Sciences, The
      University of Auckland, Auckland, New Zealand; and.
FAU - Lantos, John
AU  - Lantos J
AD  - Bioethics Center, Children's Mercy Hospital, Kansas City, Missouri.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200527
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Adolescent
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Female
MH  - Humans
MH  - Male
MH  - *Moral Obligations
MH  - Palliative Care/*ethics/methods
MH  - Pandemics/*ethics
MH  - *Physician's Role
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Stress, Psychological
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/05/29 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - peds.2020-1163 [pii]
AID - 10.1542/peds.2020-1163 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Jul;146(1). pii: peds.2020-1163. doi: 10.1542/peds.2020-1163.
      Epub 2020 May 27.


PMID- 32461245
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Ethical guidelines for deliberately infecting volunteers with COVID-19.
PG  - 502-504
LID - 10.1136/medethics-2020-106322 [doi]
AB  - Global fatalities related to COVID-19 are expected to be high in 2020-2021.
      Developing and delivering a vaccine may be the most likely way to end the
      pandemic. If it were possible to shorten this development time by weeks or
      months, this may have a significant effect on reducing deaths. Phase II and phase
      III trials could take less long to conduct if they used human challenge
      methods-that is, deliberately infecting participants with COVID-19 following
      inoculation. This article analyses arguments for and against such methods and
      provides suggested broad guidelines for regulators, researchers and ethics
      committees when considering these matters. It concludes that it may be possible
      to maintain current ethical standards yet still permit human challenge trials in 
      a context where delay is critical. The implications are that regulators and
      researchers need to work together now to design robust but short trials and
      streamline ethics approval processes so that they are in place when applications 
      for trials are made.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Richards, Adair D
AU  - Richards AD
AD  - Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK
      Adair.Richards@warwick.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*ethics/methods
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*prevention & control/virology
MH  - Ethical Analysis
MH  - Ethical Review
MH  - Ethics Committees, Research
MH  - Ethics, Research
MH  - *Guidelines as Topic
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - Informed Consent
MH  - Intention
MH  - Pandemics/*ethics/prevention & control
MH  - Pneumonia, Viral/*prevention & control/virology
MH  - *Research Design
MH  - Research Personnel
MH  - Research Subjects
MH  - SARS-CoV-2
MH  - Vaccination
MH  - *Viral Vaccines
MH  - Volunteers
PMC - PMC7316118
OTO - NOTNLM
OT  - *ethics committees/consultation
OT  - *informed consent
OT  - *policy guidelines/Inst
OT  - *public policy
OT  - *research ethics
OT  - *review boards/review Cttes
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/16 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - medethics-2020-106322 [pii]
AID - 10.1136/medethics-2020-106322 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):502-504. doi: 10.1136/medethics-2020-106322. Epub
      2020 May 27.


PMID- 32461244
OWN - NLM
STAT- Publisher
LR  - 20200528
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 27
TI  - Are my religious beliefs anyone's business? A framework for declarations in
      health and biomedicine.
LID - medethics-2020-106087 [pii]
LID - 10.1136/medethics-2020-106087 [doi]
AB  - Conflicts of interests (COI) are typically divided into those that are financial 
      and those that are not. While there is general agreement that financial COIs have
      a significant impact on decisions and need to be declared and managed, the status
      of non-financial COIs continues to be disputed. In a recent BMJ feature article
      it was proposed that religious beliefs should be routinely declared as an
      interest. The article generated over 41 responses from the medical community and 
      health researchers, which put forward diverse and opposing views. In this paper, 
      we analyse the discourse to shed further light on the reasons put forward for and
      against declaring religious beliefs. We argue for a middle path in which only
      material beliefs should be declared, and then only when there are no extenuating 
      circumstances. To this end, we present a framework to help evaluate the
      materiality of interests that can be used for both financial and non-financial
      interests.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Ghinea, Narcyz
AU  - Ghinea N
AD  - Faculty of Health and Medicine, School of Public Health, Sydney Health Ethics,
      The University of Sydney, Sydney, New South Wales, Australia
      narcyz.ghinea@sydney.edu.au.
FAU - Wiersma, Miriam
AU  - Wiersma M
AUID- ORCID: http://orcid.org/0000-0003-3739-3090
AD  - Faculty of Health and Medicine, School of Public Health, Sydney Health Ethics,
      The University of Sydney, Sydney, New South Wales, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Faculty of Health and Medicine, School of Public Health, Sydney Health Ethics,
      The University of Sydney, Sydney, New South Wales, Australia.
AD  - Haematology Department, Royal North Shore Hospital, Sydney, New South Wales,
      Australia.
FAU - Lipworth, Wendy
AU  - Lipworth W
AUID- ORCID: http://orcid.org/0000-0002-0234-657X
AD  - Faculty of Health and Medicine, School of Public Health, Sydney Health Ethics,
      The University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - codes of/position statements on professional ethics
OT  - interests of health personnel/institutions
OT  - religious ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2020/05/29 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
AID - medethics-2020-106087 [pii]
AID - 10.1136/medethics-2020-106087 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 27. pii: medethics-2020-106087. doi:
      10.1136/medethics-2020-106087.


PMID- 32461243
OWN - NLM
STAT- Publisher
LR  - 20200528
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 27
TI  - Potential for epistemic injustice in evidence-based healthcare policy and
      guidance.
LID - medethics-2020-106171 [pii]
LID - 10.1136/medethics-2020-106171 [doi]
AB  - The rapid development in healthcare technologies in recent years has resulted in 
      the need for health services, whether publicly funded or insurance based, to
      identify means to maximise the benefits and provide equitable distribution of
      limited resources. This has resulted in the need for rationing decisions, and
      there has been considerable debate regarding the substantive and procedural
      ethical principles that promote distributive justice when making such decisions. 
      In this paper, I argue that while the scientifically rigorous approaches of
      evidence-based healthcare are claimed as aspects of procedural justice that
      legitimise such guidance, there are biases and distortions in all aspects of the 
      process that may lead to epistemic injustices. Regardless of adherence to
      principles of distributive justice in the decision-making process, evidential
      failings may undermine the fairness and legitimacy of such decisions. In
      particular, I identify epistemic exclusion that denies certain patient and
      professional groups the opportunity to contribute to the epistemic endeavour.
      This occurs at all stages of the process, from the generation, analysis and
      reporting of the underlying evidence, through the interpretation of such
      evidence, to the decision-making that determines access to healthcare resources. 
      I further argue that this is compounded by processes which confer unwarranted
      epistemic privilege on experts in relation to explicit or implicit value
      judgements, which are not within their remit. I suggest a number of areas in
      which changes to the processes for developing, regulating, reporting and
      evaluating evidence may improve the legitimacy of such processes.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Michaels, Jonathan Anthony
AU  - Michaels JA
AUID- ORCID: http://orcid.org/0000-0002-3422-7102
AD  - Health Economics and Decision Science, The University of Sheffield School of
      Health and Related Research, Sheffield, UK j.michaels@sheffield.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - distributive justice
OT  - ethics
OT  - health economics
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2020/05/29 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/12 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
AID - medethics-2020-106171 [pii]
AID - 10.1136/medethics-2020-106171 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 27. pii: medethics-2020-106171. doi:
      10.1136/medethics-2020-106171.


PMID- 32461242
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Is there a right not to know?
PG  - 414-415
LID - 10.1136/medethics-2020-106190 [doi]
FAU - Harris, John
AU  - Harris J
AD  - University of Manchester, Manchester, United Kingdom
      john.harris@manchester.ac.uk.
AD  - Visiting Professor, Kings College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200527
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 May;46(5):300-303. PMID: 32350031
MH  - *Genetic Testing
MH  - Humans
MH  - *Personal Autonomy
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - medethics-2020-106190 [pii]
AID - 10.1136/medethics-2020-106190 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):414-415. doi: 10.1136/medethics-2020-106190. Epub
      2020 May 27.


PMID- 32461241
OWN - NLM
STAT- Publisher
LR  - 20220716
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 27
TI  - Ethics and ego dissolution: the case of psilocybin.
LID - medethics-2020-106070 [pii]
LID - 10.1136/medethics-2020-106070 [doi]
AB  - Despite the fact that psychedelics were proscribed from medical research half a
      century ago, recent, early-phase trials on psychedelics have suggested that they 
      bring novel benefits to patients in the treatment of several mental and substance
      use disorders. When beneficial, the psychedelic experience is characterized by
      features unlike those of other psychiatric and medical treatments. These include 
      senses of losing self-importance, ineffable knowledge, feelings of unity and
      connection with others and encountering 'deep' reality or God. In addition to
      symptom relief, psychedelic experiences often lead to significant changes in a
      patient's personality and worldview. Focusing on the case of psilocybin, we argue
      that the peculiar features of psychedelics pose certain novel risks, which
      warrant an enhanced informed consent process-one that is more comprehensive than 
      what may be typical for other psychiatric medications. We highlight key issues
      that should be focused on during the consent process and suggest discussion
      prompts for enhanced consent in psychedelic psychiatry. Finally, we respond to
      potential objections before concluding with a discussion of ethical
      considerations that will arise as psychedelics proceed from highly controlled
      research environments into mainstream clinical psychiatry.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Smith, William R
AU  - Smith WR
AD  - Department of Psychiatry, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA William.Smith@pennmedicine.upenn.edu.
FAU - Sisti, Dominic
AU  - Sisti D
AD  - Department of Medical Ethics and Health Policy, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
LA  - eng
GR  - R25 MH119043/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC9202314
MID - NIHMS1767097
OTO - NOTNLM
OT  - informed consent
OT  - psychiatry
OT  - psychopharmacology
OT  - psychotherapy
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2020/05/29 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
AID - medethics-2020-106070 [pii]
AID - 10.1136/medethics-2020-106070 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 27. pii: medethics-2020-106070. doi:
      10.1136/medethics-2020-106070.


PMID- 32461227
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201218
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 5
DP  - 2020 May
TI  - Universal masking for COVID-19: evidence, ethics and recommendations.
LID - e002819 [pii]
LID - 10.1136/bmjgh-2020-002819 [doi]
FAU - Chan, Tak Kwong
AU  - Chan TK
AUID- ORCID: 0000-0001-7349-4345
AD  - Pharmacology and Pharmacy, Hong Kong University, Hong Kong, Hong Kong
      theo@hku.hk.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
CON - BMJ. 2020 Apr 9;369:m1435. PMID: 32273267
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7254130
OTO - NOTNLM
OT  - *health policies and all other topics
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
AID - bmjgh-2020-002819 [pii]
AID - 10.1136/bmjgh-2020-002819 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 May;5(5). pii: bmjgh-2020-002819. doi:
      10.1136/bmjgh-2020-002819.


PMID- 32461225
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 5
DP  - 2020 May
TI  - Regulating international clinical research: an ethical framework for
      policy-makers.
LID - e002287 [pii]
LID - 10.1136/bmjgh-2020-002287 [doi]
AB  - The global distribution of clinical trials is shifting to low-income and
      middle-income countries (LMICs), and adequate regulations are essential for
      protecting the rights and interests of research participants in these countries. 
      However, policy-makers in LMICs can face an ethical trade-off: stringent
      regulatory protections for participants can lead researchers or sponsors to
      conduct their research elsewhere, potentially depriving the local population of
      the opportunity to benefit from international clinical research. In this paper,
      we propose a three-step ethical framework that helps policy-makers to navigate
      this trade-off. We use a recent set of regulatory protections in Chile to
      illustrate the practical value of our proposed framework, providing original
      ethical analysis and previously unpublished data from Chile obtained through
      freedom of information requests.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Aguilera, Bernardo
AU  - Aguilera B
AUID- ORCID: 0000-0001-9138-5003
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      Bethesda, Maryland, USA.
FAU - DeGrazia, David
AU  - DeGrazia D
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      Bethesda, Maryland, USA.
AD  - Department of Philosophy, George Washington University, Washington, DC, USA.
FAU - Rid, Annette
AU  - Rid A
AUID- ORCID: 0000-0003-1117-1975
AD  - Department of Bioethics, The Clinical Center, National Institutes of Health,
      Bethesda, Maryland, USA annette.rid@nih.gov.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Humans
MH  - *Policy
PMC - PMC7259867
OTO - NOTNLM
OT  - *clinical trial
OT  - *health policy
OT  - *health services research
COIS- Competing interests: None declared.
EDAT- 2020/05/29 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/01/02 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-002287 [pii]
AID - 10.1136/bmjgh-2020-002287 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 May;5(5). pii: bmjgh-2020-002287. doi:
      10.1136/bmjgh-2020-002287.


PMID- 32460820
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1750-1172 (Electronic)
IS  - 1750-1172 (Linking)
VI  - 15
IP  - 1
DP  - 2020 May 27
TI  - Reproductive options for families at risk of Osteogenesis Imperfecta: a review.
PG  - 128
LID - 10.1186/s13023-020-01404-w [doi]
AB  - BACKGROUND: Osteogenesis Imperfecta (OI) is a rare genetic disorder involving
      bone fragility. OI patients typically suffer from numerous fractures, skeletal
      deformities, shortness of stature and hearing loss. The disorder is characterised
      by genetic and clinical heterogeneity. Pathogenic variants in more than 20
      different genes can lead to OI, and phenotypes can range from mild to lethal
      forms. As a genetic disorder which undoubtedly affects quality of life, OI
      significantly alters the reproductive confidence of families at risk. The current
      review describes a selection of the latest reproductive approaches which may be
      suitable for prospective parents faced with a risk of OI. The aim of the review
      is to alleviate suffering in relation to family planning around OI, by enabling
      prospective parents to make informed and independent decisions. MAIN BODY: The
      current review provides a comprehensive overview of possible reproductive options
      for people with OI and for unaffected carriers of OI pathogenic genetic variants.
      The review considers reproductive options across all phases of family planning,
      including pre-pregnancy, fertilisation, pregnancy, and post-pregnancy. Special
      attention is given to the more modern techniques of assisted reproduction, such
      as preconception carrier screening, preimplantation genetic testing for monogenic
      diseases and non-invasive prenatal testing. The review outlines the methodologies
      of the different reproductive approaches available to OI families and highlights 
      their advantages and disadvantages. These are presented as a decision tree, which
      takes into account the autosomal dominant and autosomal recessive nature of the
      OI variants, and the OI-related risks of people without OI. The complex process
      of decision-making around OI reproductive options is also discussed from an
      ethical perspective. CONCLUSION: The rapid development of molecular techniques
      has led to the availability of a wide variety of reproductive options for
      prospective parents faced with a risk of OI. However, such options may raise
      ethical concerns in terms of methodologies, choice management and good clinical
      practice in reproductive care, which are yet to be fully addressed.
FAU - Zhytnik, Lidiia
AU  - Zhytnik L
AUID- ORCID: 0000-0003-4682-0402
AD  - Clinic of Traumatology and Orthopaedics, Tartu University Hospital, Tartu,
      Estonia. lidiia.zhytnik@ut.ee.
FAU - Simm, Kadri
AU  - Simm K
AD  - Institute of Philosophy and Semiotics, Faculty of Arts and Humanities, University
      of Tartu, Tartu, Estonia.
AD  - Centre of Ethics, University of Tartu, Tartu, Estonia.
FAU - Salumets, Andres
AU  - Salumets A
AD  - Competence Centre on Health Technologies, Tartu, Estonia.
AD  - Department of Obstetrics and Gynaecology, Institute of Clinical Medicine,
      University of Tartu, Tartu, Estonia.
AD  - Institute of Genomics, University of Tartu, Tartu, Estonia.
AD  - COMBIVET ERA Chair, Institute of Veterinary Medicine and Animal Sciences,
      Estonian University of Life Sciences, Tartu, Estonia.
FAU - Peters, Maire
AU  - Peters M
AD  - Competence Centre on Health Technologies, Tartu, Estonia.
AD  - Department of Obstetrics and Gynaecology, Institute of Clinical Medicine,
      University of Tartu, Tartu, Estonia.
FAU - Martson, Aare
AU  - Martson A
AD  - Clinic of Traumatology and Orthopaedics, Tartu University Hospital, Tartu,
      Estonia.
AD  - Department of Traumatology and Orthopaedics, Institute of Clinical Medicine,
      University of Tartu, Tartu, Estonia.
FAU - Maasalu, Katre
AU  - Maasalu K
AD  - Clinic of Traumatology and Orthopaedics, Tartu University Hospital, Tartu,
      Estonia.
AD  - Department of Traumatology and Orthopaedics, Institute of Clinical Medicine,
      University of Tartu, Tartu, Estonia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200527
PL  - England
TA  - Orphanet J Rare Dis
JT  - Orphanet journal of rare diseases
JID - 101266602
SB  - IM
MH  - Female
MH  - Genetic Testing
MH  - Humans
MH  - *Osteogenesis Imperfecta/genetics
MH  - Pregnancy
MH  - Prospective Studies
MH  - Quality of Life
MH  - Reproduction
PMC - PMC7251694
OTO - NOTNLM
OT  - *Bone fragility
OT  - *Ethical decision-making
OT  - *Ethics of prenatal testing
OT  - *Family planning
OT  - *Osteogenesis Imperfecta
OT  - *Preconception carrier screening
OT  - *Preimplantation genetic testing
OT  - *Prenatal diagnosis
OT  - *Reproduction
EDAT- 2020/05/29 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13023-020-01404-w [doi]
AID - 10.1186/s13023-020-01404-w [pii]
PST - epublish
SO  - Orphanet J Rare Dis. 2020 May 27;15(1):128. doi: 10.1186/s13023-020-01404-w.


PMID- 32460804
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1742-6405 (Electronic)
IS  - 1742-6405 (Linking)
VI  - 17
IP  - 1
DP  - 2020 May 27
TI  - Views among Malawian women about joining HIV prevention clinical trials when
      pregnant.
PG  - 27
LID - 10.1186/s12981-020-00271-6 [doi]
AB  - BACKGROUND: The pressing need to expand the biomedical HIV prevention evidence
      base during pregnancy is now increasingly recognized. Women's views regarding
      participation in such trials and initiating PrEP while pregnant are critical to
      inform evolving policy and best practices aimed at responsibly expanding
      evidence-based access for this population. METHODS: We conducted 35
      semi-structured interviews with reproductive-aged women in Malawi in the local
      language, Chichewa. Participants were HIV-negative and purposively sampled to
      capture a range of experience with research during pregnancy. Women's
      perspectives on enrolling in three hypothetical HIV prevention trial vignettes
      while pregnant were explored, testing: (1) oral PrEP (Truvada) (2) a vaginal ring
      (dapivirine), and (3) a randomized trial comparing the two. The vignettes were
      read aloud to participants and a simple visual was provided. Interviews were
      audio-recorded, transcribed, translated, and coded using NVivo 11. Thematic
      analysis informed the analytic approach. RESULTS: A majority of women accepted
      participation in all trials. Women's views on research participation varied
      largely based on their assessment of whether participation or nonparticipation
      would best protect their own health and that of their offspring. Women interested
      in participating described power dynamics with their partner as fueling their HIV
      exposure concerns and highlighted health benefits of participation-principally,
      HIV protection and access to testing/treatment and ancillary care, and perceived 
      potential risks of the vignettes as low. Women who were uninterested in
      participating highlighted potential maternal and fetal health risks of the trial,
      challenges of justifying prevention use to their partner, and raised some
      modality-specific concerns. Women also described ways their social networks,
      sense of altruism and adherence requirements would influence participation
      decisions. CONCLUSIONS: The majority of participants conveyed strong interest in 
      participating in biomedical HIV prevention research during pregnancy, largely
      motivated by a desire to protect themselves and their offspring. Our results are 
      consistent with other studies that found high acceptance of HIV prevention
      products during pregnancy, and support the current direction of HIV research
      policies and practices that are increasingly aimed at protecting the health of
      pregnant women and their offspring through responsible research, rather than
      defaulting to their exclusion.
FAU - Sullivan, Kristen
AU  - Sullivan K
AUID- ORCID: 0000-0002-0796-078X
AD  - Center for Bioethics and Department of Social Medicine, University of North
      Carolina at Chapel Hill, 333 S. Columbia Street, Campus Box 7240, Chapel Hill,
      NC, 27599, USA. ksullivan@med.unc.edu.
FAU - Mtande, Tiwonge
AU  - Mtande T
AD  - UNC Project Malawi, Tidziwe Centre, Private Bag A-104, Lilongwe, Malawi.
FAU - Jaffe, Elana
AU  - Jaffe E
AD  - Center for Bioethics and Department of Social Medicine, University of North
      Carolina at Chapel Hill, 333 S. Columbia Street, Campus Box 7240, Chapel Hill,
      NC, 27599, USA.
FAU - Rosenberg, Nora
AU  - Rosenberg N
AD  - Department of Health Behavior, UNC Gillings School of Global Public Health,
      University of North Carolina at Chapel Hill, 170 Rosenau Hall, 135 Dauer Drive,
      Chapel Hill, NC, 27599, USA.
FAU - Zimba, Chifundo
AU  - Zimba C
AD  - UNC Project Malawi, Tidziwe Centre, Private Bag A-104, Lilongwe, Malawi.
FAU - Hoffman, Irving
AU  - Hoffman I
AD  - Institute for Global Health and Infectious Diseases, University of North Carolina
      at Chapel Hill, Bioinformatics Building, 130 Mason Farm Road, Chapel Hill, NC,
      27599, USA.
FAU - Little, Maggie
AU  - Little M
AD  - The Kennedy Institute of Ethics, Georgetown University, 3700 O Street Northwest, 
      Washington, DC, 20057, USA.
FAU - Faden, Ruth
AU  - Faden R
AD  - Berman Institute of Bioethics, Johns Hopkins University, 1809 Ashland Avenue,
      Baltimore, MD, 21205, USA.
FAU - Lyerly, Anne Drapkin
AU  - Lyerly AD
AD  - Center for Bioethics and Department of Social Medicine, University of North
      Carolina at Chapel Hill, 333 S. Columbia Street, Campus Box 7240, Chapel Hill,
      NC, 27599, USA.
LA  - eng
GR  - R01 AI108368/AI/NIAID NIH HHS/United States
GR  - R01AI108368/National Institute of Allergy and Infectious Diseases/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200527
PL  - England
TA  - AIDS Res Ther
JT  - AIDS research and therapy
JID - 101237921
SB  - IM
MH  - Adult
MH  - *Biomedical Research
MH  - Clinical Trials as Topic/*psychology
MH  - Female
MH  - HIV Infections/*prevention & control/*psychology
MH  - Humans
MH  - Malawi
MH  - Middle Aged
MH  - *Patient Selection
MH  - *Pre-Exposure Prophylaxis
MH  - Pregnancy
MH  - Women's Health
MH  - Young Adult
PMC - PMC7251879
OTO - NOTNLM
OT  - *Clinical trials
OT  - *HIV prevention
OT  - *Pregnancy
OT  - *Qualitative methods
OT  - *Research ethics
OT  - *Women's views
EDAT- 2020/05/29 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/05/29 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/29 06:00 [entrez]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
AID - 10.1186/s12981-020-00271-6 [doi]
AID - 10.1186/s12981-020-00271-6 [pii]
PST - epublish
SO  - AIDS Res Ther. 2020 May 27;17(1):27. doi: 10.1186/s12981-020-00271-6.


PMID- 32459832
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20220531
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 71
IP  - 12
DP  - 2020 Dec 15
TI  - Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.
PG  - 3248-3249
LID - 10.1093/cid/ciaa656 [doi]
AB  - Pediatric patients are excluded from most coronavirus disease 2019 (COVID-19)
      therapeutic trials. We outline a rationale for the inclusion of children in
      COVID-19 therapeutic trials, which enabled us to include children of all ages in 
      a therapeutic COVID-19 trial at our institution.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Raabe, Vanessa N
AU  - Raabe VN
AD  - Department of Pediatrics, Division of Pediatric Infectious Diseases, New York
      University Grossman School of Medicine, New York, New York, USA.
AD  - Department of Medicine, Division of Infectious Diseases and Immunology, New York 
      University Grossman School of Medicine and NYU Langone Vaccine Center, New York, 
      New York, USA.
FAU - Lighter, Jennifer
AU  - Lighter J
AD  - Department of Pediatrics, Division of Pediatric Infectious Diseases, New York
      University Grossman School of Medicine, New York, New York, USA.
FAU - Caplan, Arthur L
AU  - Caplan AL
AD  - Department of Population Health, Division of Bioethics, New York University
      Grossman School of Medicine, New York, New York, USA.
FAU - Ratner, Adam J
AU  - Ratner AJ
AD  - Department of Pediatrics, Division of Pediatric Infectious Diseases, New York
      University Grossman School of Medicine, New York, New York, USA.
AD  - Department of Microbiology, New York University Grossman School of Medicine, New 
      York, New York, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
RN  - COVID-19 drug treatment
RN  - COVID-19 serotherapy
SB  - IM
MH  - Adolescent
MH  - *COVID-19/drug therapy/therapy
MH  - Child
MH  - *Clinical Trials as Topic
MH  - *Coronavirus Infections
MH  - Humans
MH  - Immunization, Passive
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7314177
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *clinical trial
OT  - *ethics
OT  - *pediatrics
EDAT- 2020/05/28 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/09 00:00 [received]
PHST- 2020/05/26 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 5847864 [pii]
AID - 10.1093/cid/ciaa656 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2020 Dec 15;71(12):3248-3249. doi: 10.1093/cid/ciaa656.


PMID- 32459794
OWN - NLM
STAT- MEDLINE
DCOM- 20200902
LR  - 20210505
IS  - 1529-7535 (Print)
IS  - 1529-7535 (Linking)
VI  - 21
IP  - 8
DP  - 2020 Aug
TI  - Finding the Right Ethical Framework for PICU Resource Allocation During a
      Pandemic.
PG  - 774-775
LID - 10.1097/PCC.0000000000002473 [doi]
FAU - Miller, Kathryn E
AU  - Miller KE
AD  - Division of Pediatric Critical Care, Department of Pediatrics; and The Rainbow
      Center for Pediatric Ethics, Rainbow Babies and Children's Hospital and Case
      Western Reserve University, Cleveland, OH.
FAU - Toltzis, Philip
AU  - Toltzis P
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Rainbow Babies and
      Children's Hospital and Case Western Reserve University, Cleveland, OH.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - Pediatr Crit Care Med
JT  - Pediatric critical care medicine : a journal of the Society of Critical Care
      Medicine and the World Federation of Pediatric Intensive and Critical Care
      Societies
JID - 100954653
SB  - IM
CON - Pediatr Crit Care Med. 2020 Aug;21(8):e491-e501. PMID: 32345932
MH  - Child
MH  - Critical Care
MH  - *Disasters
MH  - Humans
MH  - Intensive Care Units, Pediatric
MH  - *Pandemics
MH  - Resource Allocation
MH  - Triage
PMC - PMC7255401
EDAT- 2020/05/28 06:00
MHDA- 2020/09/04 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/09/04 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1097/PCC.0000000000002473 [doi]
AID - 00130478-202008000-00013 [pii]
PST - ppublish
SO  - Pediatr Crit Care Med. 2020 Aug;21(8):774-775. doi: 10.1097/PCC.0000000000002473.


PMID- 32459574
OWN - NLM
STAT- MEDLINE
DCOM- 20200608
LR  - 20210507
IS  - 1819-6357 (Electronic)
IS  - 1819-6357 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Dec
TI  - The world is waiting, use sequential analysis and get us the evidence-based
      treatment we need for COVID-19.
PG  - 1770518
LID - 10.1080/19932820.2020.1770518 [doi]
AB  - In spite of the relatively high morbidity and mortality, there is no approved
      medication yet for COVID-19. There are more than 200 ongoing trials on different 
      drugs or vaccines, but new medications may take until 2021 to develop. Defining
      the optimal number of patients to be included in a study is a considerable
      challenge in these interventional researches. Ethical considerations prompt
      researchers to minimize the number of patients included in a trial. This gains
      particular importance when the disease is rare or lethal which is particularly so
      in the case of COVID-19. It is of paramount importance to explore some of the
      available tools that could help accelerate the adoption of any or some of the
      many proposed modalities for the treatment of diseases. These tools should be
      effective, yet efficient, for rapid testing of such treatments. Sequential
      analysis has not been frequently used in many clinical trials where it should
      have been used. None of the authors in published literature, as far as we know,
      used sequential analysis techniques to test potential drugs for COVID-19. In
      addition to its usefulness when the results of new forms of treatment are quickly
      needed, other important benefit of sequential analysis includes the ability to
      reach a similar conclusion about the utility of a new drug without unduly
      exposing more patients to the side effect of the old drug, in particularly, for
      the treatment of a rare disease.
FAU - El Taguri, Adel
AU  - El Taguri A
AD  - National Center for Accreditation of Health Establishments- , Tripoli-Libya,
      Libya.
AD  - Community Medicine Department, Faculty of Medicine-University of Tripoli ,
      Tripoli-Libya, Libya.
FAU - Nasef, Aisha
AU  - Nasef A
AD  - Authority of Natural Science Research and Technology , Tripoli-Libya, Libya.
AD  - Scientific Council of Laboratory Medicine, Medical Specialty council ,
      Tripoli-Libya, Libya.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Libyan J Med
JT  - The Libyan journal of medicine
JID - 101299403
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Trials as Topic
MH  - Coronavirus Infections/*drug therapy/virology
MH  - *Drug Discovery
MH  - Evidence-Based Medicine
MH  - Global Health
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/virology
MH  - SARS-CoV-2
PMC - PMC7646536
OTO - NOTNLM
OT  - COVID-19
OT  - Sequential analysis
OT  - clinical trials
OT  - treatment
EDAT- 2020/05/28 06:00
MHDA- 2020/06/09 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
AID - 10.1080/19932820.2020.1770518 [doi]
PST - ppublish
SO  - Libyan J Med. 2020 Dec;15(1):1770518. doi: 10.1080/19932820.2020.1770518.


PMID- 32459421
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20210108
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 135
IP  - 6
DP  - 2020 Jun
TI  - Abortion Policies in U.S. Teaching Hospitals: Formal and Informal Parameters
      Beyond the Law.
PG  - 1296-1305
LID - 10.1097/AOG.0000000000003876 [doi]
AB  - OBJECTIVE: To evaluate the prevalence and features of policies regulating
      abortion in U.S. teaching hospitals. METHODS: In this mixed-methods study, we
      conducted a national survey of obstetrics and gynecology teaching hospitals
      (2015-2016) and qualitative interviews (2014 and 2017) with directors at
      obstetrics and gynecology residency programs. We asked participants about
      hospital regulations on abortion and their perceptions of the nature and
      enforcement of these policies. Interview analysis was conducted with a grounded
      theoretical approach and informed development of the survey. The prevalence of
      policies was described using survey data; differences in policy structures by
      region were analyzed using a series of logistic regression models. RESULTS:
      Directors from 169 of 231 eligible training programs responded to the survey
      (73%). Institutional policies limited abortion beyond state law in 57% of
      teaching hospitals, most commonly in the Midwest and South (odds ratio [OR] 4.3, 
      P<.01 for Midwest; OR 4.0, P=.001 for South vs Northeast). Policies varied in
      form (written and unwritten) and restricted abortion based on the indication for 
      the procedure and gestational age. Nonmedically indicated, or "elective"
      procedures were more commonly restricted (48% of sites reporting any policy and
      25% prohibiting these abortions altogether) than medically indicated ones (28% of
      sites reporting any policy.) Policies were created by those with institutional
      power, including hospital leadership and obstetrics and gynecology department
      chairs, and were perceived to be motivated by personal beliefs and a desire to
      avoid controversy. Rules were commonly enforced by medical specialists, hospital 
      ethics committees, and department chairs. Qualitative data highlighted the
      convoluted nuances of these policies, which often put clinicians at odds with
      their professional mandates. DISCUSSION: Reportedly driven by broader
      institutional interests, obstetrics and gynecology teaching hospital policies
      often restricted abortion beyond state law to the detriment of abortion access
      and training opportunities. Vague or unwritten abortion policies, although
      difficult to navigate, gave health care providers some agency and flexibility
      over their practices.
FAU - Zeldovich, Varvara B
AU  - Zeldovich VB
AD  - Department of Family and Community Medicine, University of California, San
      Francisco, San Francisco; Advancing New Standards in Reproductive Health (ANSIRH)
      and the Bixby Center for Global Reproductive Health, Department of Obstetrics,
      Gynecology and Reproductive Sciences, School of Medicine, University of
      California, San Francisco; and the University of California, Berkeley, School of 
      Public Health.
FAU - Rocca, Corinne H
AU  - Rocca CH
FAU - Langton, Callie
AU  - Langton C
FAU - Landy, Uta
AU  - Landy U
FAU - Ly, Elizabeth S
AU  - Ly ES
FAU - Freedman, Lori R
AU  - Freedman LR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - IM
MH  - Abortion, Induced/*education/*legislation & jurisprudence
MH  - Curriculum
MH  - Gynecology/*education
MH  - Hospitals, Teaching
MH  - Humans
MH  - *Internship and Residency
MH  - Obstetrics/*education
MH  - Organizational Policy
MH  - State Government
MH  - Surveys and Questionnaires
MH  - United States
EDAT- 2020/05/28 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1097/AOG.0000000000003876 [doi]
AID - 00006250-202006000-00010 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2020 Jun;135(6):1296-1305. doi: 10.1097/AOG.0000000000003876.


PMID- 32458828
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2038-1778 (Electronic)
IS  - 1592-5986 (Linking)
VI  - 39
IP  - 1
DP  - 2020 Jan-Mar
TI  - [Notes of method to imagine an education tailored to the future].
PG  - 31-34
LID - 10.1702/3371.33474 [doi]
AB  - . Notes of method to imagine an education tailored to the future. Health and
      social inequalities represent a problem not only from an ethical point of view
      but also from the point of view of public and social health. Unfortunately, this 
      issue remains confined to conferences and debates and is not yet the subject of a
      serious reflection on how to constructively and permanently incorporate it in the
      education of health professionals, to provide the skill to read and interpret
      data, and to make research. This contribution, in addition to providing some
      reflections, launches an initiative that aims at incorporating these contents in 
      the basic education, to make the message of Florence Nightingale real: wounds,
      suffering, dying and the absurdity of disability can be taken care of, be part of
      the care, only if you learn to recognize the causes, which are not only in the
      medical domain.
FAU - Di Giulio, Paola
AU  - Di Giulio P
FAU - Palese, Alvisa
AU  - Palese A
FAU - Saiani, Luisa
AU  - Saiani L
FAU - Tognoni, Gianni
AU  - Tognoni G
CN  - <br>per la Redazione di AIR
LA  - ita
PT  - Journal Article
TT  - Appunti di contenuto-metodo per immaginare<br>un percorso formativo a misura del 
      futuro.
PL  - Italy
TA  - Assist Inferm Ric
JT  - Assistenza infermieristica e ricerca : AIR
JID - 100901776
MH  - Clinical Competence
MH  - Education, Professional/trends
MH  - Health Personnel/*education
MH  - *Health Status Disparities
MH  - Humans
MH  - *Public Health
EDAT- 2020/05/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1702/3371.33474 [doi]
PST - ppublish
SO  - Assist Inferm Ric. 2020 Jan-Mar;39(1):31-34. doi: 10.1702/3371.33474.


PMID- 32458827
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2038-1778 (Electronic)
IS  - 1592-5986 (Linking)
VI  - 39
IP  - 1
DP  - 2020 Jan-Mar
TI  - [The contribution of voluntary associations in the process of eliminating
      mechanical restraint in hospitals].
PG  - 24-30
LID - 10.1702/3371.33473 [doi]
AB  - . The contribution of voluntary associations in the process of eliminating
      mechanical restraint in hospitals. INTRODUCTION: Eliminating the restraint use in
      fragile people at any age and pathological condition is an ethical, legal,
      deontological commitment. OBJECTIVE: To describe the attempt to eliminate
      restraint use with the involvement of voluntary associations in the Trieste
      Health Authority. METHODS: In 2016, a register of volunteers "Albo dei Volontari 
      art. 13" (Register of Volunteers art. 13) was established, and the voluntary
      service to which 45 people from 7 voluntary associations have joined, after a
      training course of 6 weeks. RESULTS: In the three-year period 2017-19 volunteers 
      served in 17 wards assisting 83 patients, with a commitment of 1108 hours. They
      were required for people with mobilisation problems, but also with problems of
      companionship, nutrition, disorientation and wandering. These are non-critical
      situations which, if not properly managed, lead to restraint measures.
      CONCLUSIONS: Volunteers can be integrated into teams, make an important
      contribution and lead to a reduction in restraint. The experience could be
      transferable to other contexts.
FAU - Bicego, Livia
AU  - Bicego L
FAU - Mislej, Maila
AU  - Mislej M
FAU - Benedetto, Lucia
AU  - Benedetto L
FAU - Guidi, Valentina
AU  - Guidi V
LA  - ita
PT  - Journal Article
TT  - Il contributo delle associazioni di volontariato<br>nel percorso di eliminazione 
      della contenzione meccanica<br>in ambito ospedaliero.
PL  - Italy
TA  - Assist Inferm Ric
JT  - Assistenza infermieristica e ricerca : AIR
JID - 100901776
MH  - *Hospitals
MH  - Humans
MH  - Italy
MH  - Restraint, Physical/*statistics & numerical data
MH  - *Volunteers
EDAT- 2020/05/28 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1702/3371.33473 [doi]
PST - ppublish
SO  - Assist Inferm Ric. 2020 Jan-Mar;39(1):24-30. doi: 10.1702/3371.33473.


PMID- 32458790
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20220316
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 3
DP  - 2020 Sep
TI  - The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical
      Research Platform to Malaria Elimination Planning in Central West Africa.
PG  - 947-954
LID - 10.4269/ajtmh.19-0966 [doi]
LID - tpmd190966 [pii]
AB  - Fifteen years of investment in malaria control on Bioko Island, Equatorial Guinea
      (EG), dramatically reduced malaria-associated morbidity and mortality, but the
      impact has plateaued. To progress toward elimination, EG is investing in the
      development of a malaria vaccine. We assessed the unique public-private
      partnership that has had such a significant impact on malaria on Bioko Island and
      now added a major effort on malaria vaccine development. As part of a $79M
      commitment, the EG government (75%) and three American energy companies (25%)
      have invested since 2012 greater than $55M in the Equatoguinean Malaria Vaccine
      Initiative (EGMVI) to support clinical development of Sanaria((R)) PfSPZ vaccines
      (Sanaria Inc., Rockville, MD). In turn, the vaccine development program is
      building human capital and physical capacity. The EGMVI established regulatory
      and ethical oversight to ensure compliance with the International Conference on
      Harmonization and Good Clinical Practices for the first importation of
      investigational product, ethical approval, and conduct of a clinical trial in
      Equatoguinean history. The EGMVI has completed three vaccine trials in EG, two
      vaccine trials in Tanzania, and a malaria incidence study, and initiated
      preparations for a 2,100-volunteer clinical trial. Personnel are training for
      advanced degrees abroad and have been trained in Good Clinical Practices and
      protocol-specific methods. A new facility has established the foundation for a
      national research institute. Biomedical research and development within this
      visionary, ambitious public-private partnership is fostering major improvements
      in EG. The EGMVI plans to use a PfSPZ Vaccine alongside standard malaria control 
      interventions to eliminate Pf malaria from Bioko, becoming a potential model for 
      elimination campaigns elsewhere.
FAU - Billingsley, Peter F
AU  - Billingsley PF
AD  - 1Sanaria Inc., Rockville, Maryland.
FAU - Maas, Carl D
AU  - Maas CD
AD  - 2Marathon Oil, Malabo Dos, Bioko Norte, Equatorial Guinea.
FAU - Olotu, Ally
AU  - Olotu A
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
AD  - 4KEMRI Wellcome Trust Research Programme, Kilifi, Kenya.
FAU - Schwabe, Christopher
AU  - Schwabe C
AD  - 5Medical Care Development International, Silver Spring, Maryland.
FAU - Garcia, Guillermo A
AU  - Garcia GA
AD  - 5Medical Care Development International, Silver Spring, Maryland.
FAU - Rivas, Matilde Riloha
AU  - Rivas MR
AD  - 6Ministry of Health and Social Welfare, Government of Equatorial Guinea, Malabo, 
      Equatorial Guinea.
FAU - Hergott, Dianna E B
AU  - Hergott DEB
AD  - 5Medical Care Development International, Silver Spring, Maryland.
FAU - Daubenberger, Claudia
AU  - Daubenberger C
AD  - 7Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - 8University of Basel, Basel, Switzerland.
FAU - Saverino, Elizabeth
AU  - Saverino E
AD  - 1Sanaria Inc., Rockville, Maryland.
FAU - Chaouch, Adel
AU  - Chaouch A
AD  - 2Marathon Oil, Malabo Dos, Bioko Norte, Equatorial Guinea.
FAU - Embon, Oscar
AU  - Embon O
AD  - 9La Paz Hospital Medical Center, Sipopo, Equatorial Guinea.
FAU - Chemba, Mwajuma
AU  - Chemba M
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
FAU - Nyakarungu, Elizabeth
AU  - Nyakarungu E
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
FAU - Hamad, Ali
AU  - Hamad A
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
FAU - Cortes, Carlos
AU  - Cortes C
AD  - 5Medical Care Development International, Silver Spring, Maryland.
FAU - Schindler, Tobias
AU  - Schindler T
AD  - 7Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - 8University of Basel, Basel, Switzerland.
FAU - Mpina, Maximillian
AU  - Mpina M
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
AD  - 7Swiss Tropical and Public Health Institute, Basel, Switzerland.
FAU - Mtoro, Ali
AU  - Mtoro A
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
FAU - Sim, B Kim Lee
AU  - Sim BKL
AD  - 1Sanaria Inc., Rockville, Maryland.
FAU - Richie, Thomas L
AU  - Richie TL
AD  - 1Sanaria Inc., Rockville, Maryland.
FAU - McGhee, Ken
AU  - McGhee K
AD  - 10Noble Energy, Malabo Dos, Equatorial Guinea.
FAU - Tanner, Marcel
AU  - Tanner M
AD  - 7Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - 8University of Basel, Basel, Switzerland.
FAU - Obiang Lima, Gabriel Mbaga
AU  - Obiang Lima GM
AD  - 11Ministry of Mines and Hydrocarbons, Government of Equatorial Guinea, Malabo
      Dos, Equatorial Guinea.
FAU - Abdulla, Salim
AU  - Abdulla S
AD  - 3Ifakara Health Institute, Bagamoyo, Tanzania.
FAU - Hoffman, Stephen L
AU  - Hoffman SL
AD  - 1Sanaria Inc., Rockville, Maryland.
FAU - Ayekaba, Mitoha Ondo'o
AU  - Ayekaba MO
AD  - 2Marathon Oil, Malabo Dos, Bioko Norte, Equatorial Guinea.
AD  - 6Ministry of Health and Social Welfare, Government of Equatorial Guinea, Malabo, 
      Equatorial Guinea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Malaria Vaccines)
SB  - IM
MH  - Adolescent
MH  - Biomedical Research/*organization & administration
MH  - Child
MH  - Child, Preschool
MH  - Disease Eradication/trends
MH  - Equatorial Guinea/epidemiology
MH  - Female
MH  - Humans
MH  - Insecticide-Treated Bednets/supply & distribution
MH  - Islands
MH  - Malaria Vaccines/*administration & dosage
MH  - Malaria, Falciparum/*epidemiology/parasitology/*prevention & control/transmission
MH  - Male
MH  - Plasmodium falciparum/pathogenicity
MH  - Public-Private Sector Partnerships/*organization & administration
PMC - PMC7470544
EDAT- 2020/05/28 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.4269/ajtmh.19-0966 [doi]
AID - tpmd190966 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Sep;103(3):947-954. doi: 10.4269/ajtmh.19-0966.


PMID- 32458753
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210401
IS  - 2641-0397 (Electronic)
IS  - 2641-0397 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Dec
TI  - Cracked open: exploring attitudes on access to egg freezing.
PG  - 1758441
LID - 10.1080/26410397.2020.1758441 [doi]
AB  - Egg freezing (EF) technology has improved significantly over the last decade,
      giving women more choice over their reproductive futures. Despite this advance,
      EF brings forth contentious ethical and regulatory issues. Policies controlling
      access to EF vary around the world and there is a lack of consensus about who
      should have access and what criteria are relevant in making these decisions. This
      study aimed to identify views of women about access to EF for both "medical" and 
      "non-medical" risks to infertility. An online survey was administered to women
      aged between 18 and 60 years in Victoria, Australia between April and May 2018. A
      total of 1,066 individuals initiated the survey. The median age of the
      participants was 28 years and 81% were <40 years old. Almost all participants
      (98%) supported access to medical EF in situations where treatments (e.g.
      chemotherapy) or illnesses threaten fertility. Support for access to EF for
      non-medical indications was lower; 75% supported EF for "lack of suitable
      partner", followed by "financial insecurity to raise a child" (72%) and
      "career/educational advancement" (65%). Older respondents (aged >/=40 years) were
      less likely than their younger counterparts to support all indications for
      non-medical EF. Our findings indicate broad support for EF. However, the
      variation in support between indications for non-medical EF suggests that
      individuals do not think about access to EF simply in terms of medical necessity.
      To reflect public views, future policy may need to consider access to EF beyond
      the medical/non-medical distinction.
FAU - Johnston, Molly
AU  - Johnston M
AUID- ORCID: https://orcid.org/0000-0002-3786-0843
AD  - PhD candidate, Department of Obstetrics and Gynaecology, Monash University,
      Clayton, Australia, 3168.
FAU - Fuscaldo, Giuliana
AU  - Fuscaldo G
AD  - Associate Professor, Eastern Health Clinical School, Monash University, Box Hill,
      Australia; University Hospital Geelong, Australia.
FAU - Richings, Nadine Maree
AU  - Richings NM
AD  - Teaching Associate, Department of Obstetrics and Gynaecology, Monash University, 
      Clayton, Australia.
FAU - Gwini, StellaMay
AU  - Gwini S
AUID- ORCID: https://orcid.org/0000-0002-0295-4575
AD  - Adjunct Lecturer, School of Public Health & Preventive Medicine, Monash
      University, Melbourne, Australia; University Hospital Geelong, Australia; Centre 
      for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT),
      School of Medicine, Deakin University, Geelong, Australia.
FAU - Catt, Sally
AU  - Catt S
AUID- ORCID: https://orcid.org/0000-0002-7604-4507
AD  - Senior Lecturer, Department of Obstetrics and Gynaecology, Monash University,
      Clayton, Australia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sex Reprod Health Matters
JT  - Sexual and reproductive health matters
JID - 101743493
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Fertility Preservation/*psychology
MH  - *Health Knowledge, Attitudes, Practice
MH  - *Health Services Accessibility
MH  - Humans
MH  - Middle Aged
MH  - Oocytes
MH  - Ovum
MH  - Reproductive Techniques, Assisted
MH  - Surveys and Questionnaires
MH  - Victoria
MH  - Young Adult
PMC - PMC7887973
OTO - NOTNLM
OT  - ART
OT  - access
OT  - egg freezing
OT  - fertility
OT  - fertility preservation
OT  - public opinion
OT  - women's health
EDAT- 2020/05/28 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - 10.1080/26410397.2020.1758441 [doi]
PST - ppublish
SO  - Sex Reprod Health Matters. 2020 Dec;28(1):1758441. doi:
      10.1080/26410397.2020.1758441.


PMID- 32458207
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Customizable Ethics Settings for Building Resilience and Narrowing the
      Responsibility Gap: Case Studies in the Socio-Ethical Engineering of Autonomous
      Systems.
PG  - 2693-2708
LID - 10.1007/s11948-020-00221-5 [doi]
AB  - Ethics settings allow for morally significant decisions made by humans to be
      programmed into autonomous machines, such as autonomous vehicles or autonomous
      weapons. Customizable ethics settings are a type of ethics setting in which the
      users of autonomous machines make such decisions. Here two arguments are provided
      in defence of customizable ethics settings. Firstly, by approaching ethics
      settings in the context of failure management, it is argued that customizable
      ethics settings are instrumentally and inherently valuable for building
      resilience into the larger socio-technical systems in which autonomous machines
      operate. Secondly, after defining the preliminary condition of responsibility
      attribution and demonstrating how ethics settings enable humans to exert control 
      over the outcomes of morally significant incidents, it is shown that ethics
      settings narrow the responsibility gap.
FAU - Soltanzadeh, Sadjad
AU  - Soltanzadeh S
AUID- ORCID: http://orcid.org/0000-0002-0629-6952
AD  - School of Engineering and Information Technology, University of New South Wales, 
      Canberra, Australia. s.soltanzadeh@unsw.edu.au.
FAU - Galliott, Jai
AU  - Galliott J
AD  - School of Engineering and Information Technology, University of New South Wales, 
      Canberra, Australia.
FAU - Jevglevskaja, Natalia
AU  - Jevglevskaja N
AD  - School of Engineering and Information Technology, University of New South Wales, 
      Canberra, Australia.
LA  - eng
GR  - FA9550-18-1-0181/Air Force Office of Scientific Research/International
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200526
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Dissent and Disputes
MH  - *Engineering
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - *Autonomous machines
OT  - *Control
OT  - *Ethics settings
OT  - *Resilience
OT  - *Responsibility gap
OT  - *User autonomy
EDAT- 2020/05/28 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/28 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1007/s11948-020-00221-5 [doi]
AID - 10.1007/s11948-020-00221-5 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2693-2708. doi: 10.1007/s11948-020-00221-5. Epub
      2020 May 26.


PMID- 32458150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2197-1153 (Print)
IS  - 2197-1153 (Linking)
VI  - 7
IP  - 1
DP  - 2020 May 27
TI  - The role of the orthopaedic surgeon in the COVID-19 era: cautions and
      perspectives.
PG  - 35
LID - 10.1186/s40634-020-00255-5 [doi]
AB  - The current coronavirus disease 2019 (COVID-19) pandemic has revolutionized
      global healthcare in an unprecedented way and with unimaginable repercussions.
      Resource reallocation, socioeconomic confinement and reorganization of production
      activities are current challenges being faced both at the national and
      international levels, in a frame of uncertainty and fear. Hospitals have been
      restructured to provide the best care to COVID-19 patients while adopting
      preventive strategies not to spread the infection among healthcare providers and 
      patients affected by other diseases. As a consequence, the concept of urgency and
      indications for elective treatments have been profoundly reshaped. In addition,
      several providers have been recruited in COVID-19 departments despite their
      original occupation, resulting in a profound rearrangement of both inpatient and 
      outpatient care. Orthopaedic daily practice has been significantly affected by
      the pandemic. Surgical indications have been reformulated, with elective cases
      being promptly postponed and urgent interventions requiring exceptional
      attention, especially in suspected or COVID-19(+) patients. This has made a
      strong impact on inpatient management, with the need of a dedicated staff,
      patient isolation and restrictive visiting hour policies. On the other hand,
      outpatient visits have been limited to reduce contacts between patients and the
      hospital personnel, with considerable consequences on post-operative quality of
      care and the human side of medical practice.In this review, we aim to analyze the
      effect of the COVID-19 pandemic on the orthopaedic practice. Particular attention
      will be dedicated to opportune surgical indication, perioperative care and safe
      management of both inpatients and outpatients, also considering repercussions of 
      the pandemic on resident education and ethical implications.
FAU - Ambrosio, Luca
AU  - Ambrosio L
AUID- ORCID: http://orcid.org/0000-0003-2424-1274
AD  - Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of
      Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy. luc.ambros@gmail.com.
FAU - Vadala, Gianluca
AU  - Vadala G
AD  - Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of
      Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.
FAU - Russo, Fabrizio
AU  - Russo F
AD  - Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of
      Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.
FAU - Papalia, Rocco
AU  - Papalia R
AD  - Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of
      Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.
FAU - Denaro, Vincenzo
AU  - Denaro V
AD  - Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of
      Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.
LA  - eng
GR  - 20-037/ON Foundation
PT  - Journal Article
PT  - Review
DEP - 20200527
PL  - Germany
TA  - J Exp Orthop
JT  - Journal of experimental orthopaedics
JID - 101653750
PMC - PMC7250587
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Education
OT  - Elective surgery
OT  - Orthopaedic surgery
OT  - PPE
OT  - SARS-CoV-2
OT  - Surgical algorithm
OT  - Surgical indication
OT  - Telemedicine
EDAT- 2020/05/28 06:00
MHDA- 2020/05/28 06:01
CRDT- 2020/05/28 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/05/28 06:01 [medline]
AID - 10.1186/s40634-020-00255-5 [doi]
AID - 10.1186/s40634-020-00255-5 [pii]
PST - epublish
SO  - J Exp Orthop. 2020 May 27;7(1):35. doi: 10.1186/s40634-020-00255-5.


PMID- 32458102
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210702
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 7
DP  - 2020 Jul
TI  - IUI and uterine lavage of in vivo-produced blastocysts for PGT purposes: is it a 
      technically and ethically reasonable perspective? Is it actually needed?
PG  - 1579-1582
LID - 10.1007/s10815-020-01813-7 [doi]
AB  - A recent study by Munne et al. portrayed a protocol to retrieve in vivo produced 
      blastocysts after IUI and uterine lavage for preimplantation genetic testing
      (PGT) purposes. The authors claimed this protocol might represent a reasonable
      future perspective for patients who do not want to undergo IVF, but still want to
      be informed about their embryos' genetic/chromosomal defects. Although the intent
      of making PGT available also to patients who cannot or do not need to undergo IVF
      is respectable, the value of this study is undermined by severe technical and
      ethical issues. Munne and colleagues' paper was discussed within the executive
      committee (i.e., president and vice-president of the society, director and
      vice-director of the scientific committee, secretariat, and counselors), the
      special interest group in reproductive genetics, the scientific committee, and
      the collegio dei probiviri of the Italian Society of Embryology, Reproduction and
      Research (SIERR). The points raised from this discussion are summarized in this
      opinion paper.
FAU - De Santis, Lucia
AU  - De Santis L
AD  - Department of Obstetrics & Gynecology, IVF Unit, San Raffaele Scientific
      Institute, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Cimadomo, Danilo
AU  - Cimadomo D
AUID- ORCID: 0000-0002-5390-9221
AD  - GENERA Center for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy.
      cimadomo@generaroma.it.
FAU - Capalbo, Antonio
AU  - Capalbo A
AD  - Igenomix, Marostica, Italy.
AD  - Department of Biomedical and Biotechnological Sciences, Section of Biology and
      Genetics "G. Sichel", University of Catania, Catania, Italy.
FAU - Di Pietro, Cinzia
AU  - Di Pietro C
AD  - DAHFMO, Unit of Histology and Medical Embryology, Sapienza, University of Rome,
      Rome, Italy.
FAU - Zuccarello, Daniela
AU  - Zuccarello D
AD  - Unit of Clinical Genetics and Epidemiology, Department of Lab Medicine,
      University Hospital of Padova, Padova, Italy.
FAU - Anastasi, Attilio
AU  - Anastasi A
AD  - Physiopathology of Human Reproduction Center, Hospital "del Delta", Lagosanto,
      Italy.
FAU - Licata, Emanuele
AU  - Licata E
AD  - Physiopathology of Reproduction and Andrology Unit, Sandro Pertini Hospital,
      Rome, Italy.
FAU - Scarica, Catello
AU  - Scarica C
AD  - Casa di Cura Villa Salaria in partnership with Institut Marques, Reproductive
      Medicine, Rome, Italy.
FAU - Fernandez, Laura Sosa
AU  - Fernandez LS
AD  - Embryos Fertility Center, Battipaglia, Italy.
FAU - Klinger, Francesca Gioia
AU  - Klinger FG
AD  - Department of Biomedicine and Prevention, Section of Histology and Embryology,
      University of Rome "Tor Vergata", Rome, Italy.
CN  - Italian Society of Embryology, Reproduction and Research (SIERR)
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200526
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
CON - Hum Reprod. 2020 Jan 1;35(1):70-80. PMID: 31886877
MH  - Blastocyst
MH  - Female
MH  - Genetic Testing
MH  - Humans
MH  - Insemination, Artificial
MH  - Pregnancy
MH  - *Preimplantation Diagnosis
MH  - Therapeutic Irrigation
PMC - PMC7376991
OTO - NOTNLM
OT  - *Blastocyst
OT  - *Ethics
OT  - *PGT
OT  - *Preimplantation development
OT  - *Uterine lavage
EDAT- 2020/05/28 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1007/s10815-020-01813-7 [doi]
AID - 10.1007/s10815-020-01813-7 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Jul;37(7):1579-1582. doi: 10.1007/s10815-020-01813-7.
      Epub 2020 May 26.


PMID- 32457804
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Causal Attributions in an Australian Aboriginal Family With Marfan Syndrome: A
      Qualitative Study.
PG  - 461
LID - 10.3389/fgene.2020.00461 [doi]
AB  - Causal attributions are important determinants of how health threats are
      processed and affect health-related behaviors. To date, there has been no
      research on causal attributions in genetic conditions in Aboriginal Australians. 
      Forty members of a large Aboriginal Australian family with Marfan syndrome (MFS) 
      were invited to participate in an ethically approved study exploring causal
      attributions, including perceived causes of phenotypic variability within the
      family. Eighteen individuals consented to conduct semi-structured qualitative
      interviews, which were recorded, transcribed verbatim and analyzed thematically. 
      Most participants knew that MFS was genetic, but there were diverse theories
      about inheritance, including beliefs that it skipped generations, was affected by
      birth order and/or gender, and that it co-occurred with inheritance of blue eyes 
      within this family. The mutation was thought to have been inherited from British 
      settlers and initially triggered by disease or diet. Factors believed to modify
      disease severity included other genes and lifestyle factors, particularly alcohol
      and substance abuse and stress. Generally, this family did not endorse "blaming" 
      chance or a higher power for phenotypic variability, though some felt that the
      spirits or a deity may have played a role. In conclusion, although participants
      knew MFS was a genetic condition, many speculated about the role of non-genetic
      causes in initiating the original mutation; and the gene-environment interaction 
      was thought to affect severity. This study demonstrates a successful approach for
      exploring causal attributions in other genetic conditions in First Australians.
CI  - Copyright (c) 2020 McInerney-Leo, West, Meiser, West, Brown and Duncan.
FAU - McInerney-Leo, Aideen M
AU  - McInerney-Leo AM
AD  - Dermatology Research Centre, The University of Queensland Diamantina Institute,
      The University of Queensland, Brisbane, QLD, Australia.
FAU - West, Jennifer
AU  - West J
AD  - Prince Charles Hospital Clinical Unit, School of Clinical Medicine, The
      University of Queensland, Brisbane, QLD, Australia.
FAU - Meiser, Bettina
AU  - Meiser B
AD  - Prince of Wales Clinical School, University of New South Wales, Sydney, NSW,
      Australia.
FAU - West, Malcolm
AU  - West M
AD  - Prince Charles Hospital Clinical Unit, School of Clinical Medicine, The
      University of Queensland, Brisbane, QLD, Australia.
FAU - Brown, Matthew A
AU  - Brown MA
AD  - Translational Genomics Group, Institute of Health and Biomedical Innovation,
      Queensland University of Technology, Brisbane, QLD, Australia.
AD  - Guy's and St Thomas' NHS Foundation Trust and King's College London NIHR
      Biomedical Research Centre, London, United Kingdom.
FAU - Duncan, Emma
AU  - Duncan E
AD  - Translational Genomics Group, Institute of Health and Biomedical Innovation,
      Queensland University of Technology, Brisbane, QLD, Australia.
AD  - Department of Endocrinology, James Mayne Building, Royal Brisbane and Women's
      Hospital, Herston, QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7221064
OTO - NOTNLM
OT  - Aboriginal Australian
OT  - Marfan syndrome
OT  - causal attribution
OT  - genetics
OT  - psychosocial
OT  - qualitative
EDAT- 2020/05/28 06:00
MHDA- 2020/05/28 06:01
CRDT- 2020/05/28 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/05/28 06:01 [medline]
AID - 10.3389/fgene.2020.00461 [doi]
PST - epublish
SO  - Front Genet. 2020 May 7;11:461. doi: 10.3389/fgene.2020.00461. eCollection 2020.


PMID- 32457803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - How Can We Not Waste Legacy Genomic Research Data?
PG  - 446
LID - 10.3389/fgene.2020.00446 [doi]
AB  - Enabling genomic and biomedical data to be shared for secondary research purposes
      is not always straightforward for existing "legacy" data sets. Researchers may
      not know whether their data meet ethical and regulatory requirements for sharing.
      As a result, these data, collected using public funds and the good will and
      efforts of the donors and investigators, may not be used beyond their original
      purpose. Single-use plastics are now being banned in many countries; single-use
      research should be avoided if possible. This paper describes a filter developed
      through the driver projects of the Global Alliance for Genomics and Health that
      can be used by researchers to help them determine the extent of sharing possible 
      for their legacy data and actions to be taken to enable further sharing.
CI  - Copyright (c) 2020 Wallace, Kirby and Knoppers.
FAU - Wallace, Susan E
AU  - Wallace SE
AD  - Department of Health Sciences, University of Leicester, Leicester, United
      Kingdom.
FAU - Kirby, Emily
AU  - Kirby E
AD  - Centre of Genomics and Policy, McGill University, Montreal, QC, Canada.
FAU - Knoppers, Bartha Maria
AU  - Knoppers BM
AD  - Centre of Genomics and Policy, McGill University, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7225345
OTO - NOTNLM
OT  - consent
OT  - data sharing
OT  - genomic research
OT  - policy
OT  - secondary research
EDAT- 2020/05/28 06:00
MHDA- 2020/05/28 06:01
CRDT- 2020/05/28 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/05/28 06:01 [medline]
AID - 10.3389/fgene.2020.00446 [doi]
PST - epublish
SO  - Front Genet. 2020 May 8;11:446. doi: 10.3389/fgene.2020.00446. eCollection 2020.


PMID- 32457658
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-042X (Print)
IS  - 1664-042X (Linking)
VI  - 11
DP  - 2020
TI  - Gravity Deprivation: Is It Ethical for Optimal Physiology?
PG  - 470
LID - 10.3389/fphys.2020.00470 [doi]
FAU - van Loon, Jack J W A
AU  - van Loon JJWA
AD  - Department Oral & Maxillofacial Surgery/Pathology, Amsterdam Movement Sciences & 
      Amsterdam Bone Center (ABC), Amsterdam University Medical Center Location VUmc & 
      Academic Center for Dentistry Amsterdam (ACTA), Amsterdam, Netherlands.
FAU - Cras, Patrick
AU  - Cras P
AD  - Faculty of Medicine & Health Sciences, Translational Neurosciences, University of
      Antwerp, Antwerp, Belgium.
AD  - Department of Neurology, Antwerp University Hospital, Edegem, Belgium.
AD  - Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
FAU - Bouwens, Willem H A C M
AU  - Bouwens WHACM
AD  - Faculty of Law, Social Law, VU University Amsterdam, Amsterdam, Netherlands.
FAU - Roozendaal, Willemijn
AU  - Roozendaal W
AD  - Faculty of Law, Social Law, VU University Amsterdam, Amsterdam, Netherlands.
FAU - Vernikos, Joan
AU  - Vernikos J
AD  - Thirdage Health, Culpeper, VA, United States.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC7227601
OTO - NOTNLM
OT  - artificial gravity
OT  - chronic accelerations
OT  - countermeasure
OT  - ethics
OT  - large diameter centrifuge
OT  - microgravity
OT  - pathology
OT  - treatment
EDAT- 2020/05/28 06:00
MHDA- 2020/05/28 06:01
CRDT- 2020/05/28 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/05/28 06:01 [medline]
AID - 10.3389/fphys.2020.00470 [doi]
PST - epublish
SO  - Front Physiol. 2020 May 8;11:470. doi: 10.3389/fphys.2020.00470. eCollection
      2020.


PMID- 32457556
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200529
IS  - 0148-2963 (Print)
IS  - 0148-2963 (Linking)
VI  - 116
DP  - 2020 Aug
TI  - The impact of Covid-19 pandemic on corporate social responsibility and marketing 
      philosophy.
PG  - 176-182
LID - 10.1016/j.jbusres.2020.05.030 [doi]
AB  - In this article, we offer some initial examination on how Covid-19 pandemic can
      influence the developments of CSR and marketing. We argue that Covid-19 pandemic 
      offers a great opportunity for businesses to shift towards more genuine and
      authentic CSR and contribute to address urgent global social and environmental
      challenges. We also discuss some potential directions of how consumer ethical
      decision making will be shifted to due to the pandemic. In our discussion of
      marketing, we outline how we believe marketing is being affected by this pandemic
      and how we think this will change, not only the context of marketing, but how
      organizations approach their strategic marketing efforts. We end the paper with a
      identifying a number of potentially fruitful research themes and directions.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - He, Hongwei
AU  - He H
AD  - Alliance Manchester Business School, The University of Manchester, Manchester,
      M15 6PB, UK.
FAU - Harris, Lloyd
AU  - Harris L
AD  - Birmingham Business School, University of Birmingham, Edgbaston, Birmingham, B15 
      2TT, UK.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - J Bus Res
JT  - Journal of business research
JID - 101087747
PMC - PMC7241379
OTO - NOTNLM
OT  - Business ethics
OT  - Consumer ethical decision making
OT  - Corporate social responsibility
OT  - Covid-19
OT  - Marketing
OT  - Marketing philosophy
EDAT- 2020/05/28 06:00
MHDA- 2020/05/28 06:01
CRDT- 2020/05/28 06:00
PHST- 2020/05/13 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/05/28 06:01 [medline]
AID - 10.1016/j.jbusres.2020.05.030 [doi]
AID - S0148-2963(20)30329-5 [pii]
PST - ppublish
SO  - J Bus Res. 2020 Aug;116:176-182. doi: 10.1016/j.jbusres.2020.05.030. Epub 2020
      May 21.


PMID- 32457204
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Research using free text data in medical records could benefit from dynamic
      consent and other tools for responsible governance.
PG  - 380-381
LID - 10.1136/medethics-2020-106189 [doi]
FAU - Morrison, Michael
AU  - Morrison M
AD  - Centre for Health, Law and Emerging Technologies (HeLEX), Faculty of Law,
      University of Oxford, Oxford OX2 7DD, UK michael.morrison@law.ox.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200526
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Jun;46(6):367-377. PMID: 32457202
CIN - J Med Ethics. 2020 Jun;46(6):384-385. PMID: 32457203
MH  - *Electronic Health Records
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Informed Consent
MH  - United Kingdom
OTO - NOTNLM
OT  - *ethics
OT  - *regulation
OT  - *social control of science/technology
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - medethics-2020-106189 [pii]
AID - 10.1136/medethics-2020-106189 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):380-381. doi: 10.1136/medethics-2020-106189. Epub
      2020 May 26.


PMID- 32457203
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Response to commentaries on 'Should free-text data in electronic medical records 
      be shared for research? A citizens' jury study in the UK'.
PG  - 384-385
LID - 10.1136/medethics-2020-106430 [doi]
FAU - Ford, Elizabeth
AU  - Ford E
AUID- ORCID: 0000-0001-5613-8509
AD  - Department of Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, UK e.m.ford@bsms.ac.uk.
FAU - Oswald, Malcolm
AU  - Oswald M
AD  - Citizens' Juries C.I.C, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200526
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Jun;46(6):382-383. PMID: 32457200
CON - J Med Ethics. 2020 Jun;46(6):378-379. PMID: 32457201
CON - J Med Ethics. 2020 Jun;46(6):367-377. PMID: 32457202
CON - J Med Ethics. 2020 Jun;46(6):380-381. PMID: 32457204
MH  - *Community Participation
MH  - *Electronic Health Records
MH  - Humans
MH  - Public Opinion
MH  - United Kingdom
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - medethics-2020-106430 [pii]
AID - 10.1136/medethics-2020-106430 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):384-385. doi: 10.1136/medethics-2020-106430. Epub
      2020 May 26.


PMID- 32457202
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Should free-text data in electronic medical records be shared for research? A
      citizens' jury study in the UK.
PG  - 367-377
LID - 10.1136/medethics-2019-105472 [doi]
AB  - BACKGROUND: Use of routinely collected patient data for research and service
      planning is an explicit policy of the UK National Health Service and UK
      government. Much clinical information is recorded in free-text letters, reports
      and notes. These text data are generally lost to research, due to the increased
      privacy risk compared with structured data. We conducted a citizens' jury which
      asked members of the public whether their medical free-text data should be shared
      for research for public benefit, to inform an ethical policy. METHODS: Eighteen
      citizens took part over 3 days. Jurors heard a range of expert presentations as
      well as arguments for and against sharing free text, and then questioned
      presenters and deliberated together. They answered a questionnaire on whether and
      how free text should be shared for research, gave reasons for and against sharing
      and suggestions for alleviating their concerns. RESULTS: Jurors were in favour of
      sharing medical data and agreed this would benefit health research, but were more
      cautious about sharing free-text than structured data. They preferred processing 
      of free text where a computer extracted information at scale. Their concerns were
      lack of transparency in uses of data, and privacy risks. They suggested keeping
      patients informed about uses of their data, and giving clear pathways to opt out 
      of data sharing. CONCLUSIONS: Informed citizens suggested a transparent culture
      of research for the public benefit, and continuous improvement of technology to
      protect patient privacy, to mitigate their concerns regarding privacy risks of
      using patient text data.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ford, Elizabeth
AU  - Ford E
AUID- ORCID: 0000-0001-5613-8509
AD  - Department of Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, UK e.m.ford@bsms.ac.uk.
FAU - Oswald, Malcolm
AU  - Oswald M
AD  - Citizens' Juries CIC, Manchester, UK.
FAU - Hassan, Lamiece
AU  - Hassan L
AD  - Division of Informatics, Imaging and Data Sciences, School of Health Sciences,
      University of Manchester, Manchester, UK.
FAU - Bozentko, Kyle
AU  - Bozentko K
AD  - Jefferson Center, Saint Paul, Minnesota, USA.
FAU - Nenadic, Goran
AU  - Nenadic G
AD  - Department of Computer Science, The University of Manchester, Manchester, United 
      Kingdom.
FAU - Cassell, Jackie
AU  - Cassell J
AD  - Department of Primary Care and Public Health, Brighton and Sussex Medical School,
      Brighton, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Jun;46(6):382-383. PMID: 32457200
CIN - J Med Ethics. 2020 Jun;46(6):378-379. PMID: 32457201
CIN - J Med Ethics. 2020 Jun;46(6):384-385. PMID: 32457203
CIN - J Med Ethics. 2020 Jun;46(6):380-381. PMID: 32457204
MH  - *Electronic Health Records
MH  - Humans
MH  - Information Dissemination
MH  - Privacy
MH  - *State Medicine
MH  - United Kingdom
PMC - PMC7279205
OTO - NOTNLM
OT  - *healthcare
OT  - *medical text
OT  - *natural language processing
OT  - *privacy
OT  - *stakeholder participation
OT  - *text mining
COIS- Competing interests: EF, LH, GN and JC are members of the UK Healthcare Text
      Analytics Network, which funded the study.
EDAT- 2020/05/28 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/28 06:00
PHST- 2019/03/22 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2020/02/06 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - medethics-2019-105472 [pii]
AID - 10.1136/medethics-2019-105472 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):367-377. doi: 10.1136/medethics-2019-105472. Epub
      2020 May 26.


PMID- 32457201
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - From preferences to policies? Considerations when incorporating empirical ethics 
      findings into research policymaking.
PG  - 378-379
LID - 10.1136/medethics-2020-106184 [doi]
FAU - Largent, Emily A
AU  - Largent EA
AD  - Medical Ethics and Health Policy, University of Pennsylvania Perelman School of
      Medicine, Philadelphia, Pennsylvania, USA elargent@pennmedicine.upenn.edu.
FAU - Morain, Stephanie R
AU  - Morain SR
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200526
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Jun;46(6):367-377. PMID: 32457202
CIN - J Med Ethics. 2020 Jun;46(6):384-385. PMID: 32457203
MH  - *Electronic Health Records
MH  - Health Policy
MH  - Humans
MH  - *Policy Making
MH  - United Kingdom
OTO - NOTNLM
OT  - *public policy
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - medethics-2020-106184 [pii]
AID - 10.1136/medethics-2020-106184 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):378-379. doi: 10.1136/medethics-2020-106184. Epub
      2020 May 26.


PMID- 32457200
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Methodological challenges in deliberative empirical ethics.
PG  - 382-383
LID - 10.1136/medethics-2020-106185 [doi]
FAU - Carter, Stacy M
AU  - Carter SM
AD  - Australian Centre for Health Engagement, Evidence and Values, School of Health
      and Society, University of Wollongong, Wollongong, NSW 2522, Australia
      stacy_carter@uow.edu.au.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200526
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Jun;46(6):367-377. PMID: 32457202
CIN - J Med Ethics. 2020 Jun;46(6):384-385. PMID: 32457203
MH  - *Confidentiality
MH  - *Electronic Health Records
MH  - Humans
MH  - Privacy
MH  - United Kingdom
OTO - NOTNLM
OT  - *confidentiality/privacy
OT  - *political science
OT  - *public policy
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - medethics-2020-106185 [pii]
AID - 10.1136/medethics-2020-106185 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):382-383. doi: 10.1136/medethics-2020-106185. Epub
      2020 May 26.


PMID- 32457083
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220310
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 25
TI  - Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic
      Resistant Organisms (FERARO): a prospective, randomised placebo-controlled
      feasibility trial.
PG  - e038847
LID - 10.1136/bmjopen-2020-038847 [doi]
AB  - INTRODUCTION: Antimicrobial resistance is rising, largely due to the
      indiscriminate use of antimicrobials. The human gut is the largest reservoir of
      antibiotic resistant bacteria (ARB). Individuals colonised with ARB have the
      potential to spread these organisms both in the community and hospital settings. 
      Infections with ARB such as extended spectrum beta-lactamase producing
      enterobacteriales (ESBL-E) and carbapenemase producing enterobacteriales (CPE)
      are more difficult to treat and are associated with an increased morbidity and
      mortality. Presently, there is no effective decolonisation strategy for these
      ARB. Faecal microbiota transplant (FMT) has emerged as a potential strategy for
      decolonisation of ARB from the human gut, however there is significant
      uncertainty about the feasibility, effectiveness and safety of using this
      approach. METHODS AND ANALYSIS: Prospective, randomised, patient-blinded,
      placebo-controlled feasibility trial of FMT to eradicate gastrointestinal
      carriage of ARB. Eighty patients with a recent history of invasive infection
      secondary to ESBL-E or CPE and persistent gastrointestinal carriage will be
      randomised 1:1 to receive encapsulated FMT or placebo. The primary outcome
      measure is consent rate (as a proportion of patients who fulfil
      inclusion/exclusion criteria); this will be used to determine if a substantive
      trial is feasible. Participants will be followed up at 1 week, 1 month, 3 months 
      and 6 months and monitored for adverse events as well as gastrointestinal
      carriage rates of ARB after intervention. ETHICS AND DISSEMINATION: Research
      ethics approval was obtained by London-City and East Research Ethics Committee
      (ref 20/LO/0117). Trial results will be published in a peer-reviewed journal and 
      presented at international conferences. TRIAL REGISTRATION NUMBER: ISRCTN
      registration number 34 467 677 and EudraCT number 2019-001618-41.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Merrick, Blair
AU  - Merrick B
AUID- ORCID: 0000-0002-6061-6064
AD  - Centre for Clinical Infection and Diagnostics Research, Guy's and Saint Thomas'
      Hospitals NHS Trust, London, UK.
AD  - Department of Infectious Diseases, School of Immunology and Microbial Sciences,
      Faculty of Life Sciences and Medicine, King's College London, London, UK.
FAU - Robinson, Emily
AU  - Robinson E
AUID- ORCID: 0000-0002-6692-5415
AD  - School of Population Health and Environmental Sciences, King's College London,
      London, UK.
FAU - Bunce, Catey
AU  - Bunce C
AUID- ORCID: 0000-0002-0935-3713
AD  - Primary Care and Public Health Sciences, King's College London, London, UK.
FAU - Allen, Liz
AU  - Allen L
AD  - Pharmacy Department, Guy's and Saint Thomas' Hospitals NHS Trust, London, UK.
AD  - Early Clinical Development Centre of Excellence, IQVIA, Reading, UK.
FAU - Bisnauthsing, Karen
AU  - Bisnauthsing K
AD  - Centre for Clinical Infection and Diagnostics Research, Guy's and Saint Thomas'
      Hospitals NHS Trust, London, UK.
FAU - Izundu, Chi Chi
AU  - Izundu CC
AD  - Care of Guy's and Saint Thomas' NHS Trust, London, UK.
FAU - Bell, Jordana
AU  - Bell J
AD  - Department of Twin Research and Genetic Epidemiology, School of Life Course
      Sciences, Faculty of Life Sciences and Medicine, King's College London, London,
      UK.
FAU - Amos, Gregory
AU  - Amos G
AD  - National Institute for Biological Standards and Control, Potters Bar, UK.
FAU - Shankar-Hari, Manu
AU  - Shankar-Hari M
AD  - Department of Infectious Diseases, School of Immunology and Microbial Sciences,
      Faculty of Life Sciences and Medicine, King's College London, London, UK.
AD  - Intensive Care Unit, Guy's and Saint Thomas' Hospitals NHS Trust, London, UK.
FAU - Goodman, Anna
AU  - Goodman A
AD  - Centre for Clinical Infection and Diagnostics Research, Guy's and Saint Thomas'
      Hospitals NHS Trust, London, UK.
AD  - Department of Infectious Diseases, School of Immunology and Microbial Sciences,
      Faculty of Life Sciences and Medicine, King's College London, London, UK.
FAU - Shawcross, Debbie L
AU  - Shawcross DL
AD  - Institute of Liver Studies, Inflammation Biology, School of Immunology and
      Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London,
      London, UK.
FAU - Goldenberg, Simon D
AU  - Goldenberg SD
AUID- ORCID: 0000-0003-0837-7382
AD  - Centre for Clinical Infection and Diagnostics Research, Guy's and Saint Thomas'
      Hospitals NHS Trust, London, UK Simon.Goldenberg@gstt.nhs.uk.
AD  - Department of Infectious Diseases, School of Immunology and Microbial Sciences,
      Faculty of Life Sciences and Medicine, King's College London, London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN34467677
SI  - EudraCT/2019-001618-41
GR  - MC_UU_12023/22/MRC_/Medical Research Council/United Kingdom
GR  - MR/N030125/1/MRC_/Medical Research Council/United Kingdom
GR  - PB-PG-0418-20007/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - *Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Feasibility Studies
MH  - Humans
MH  - London
MH  - *Microbiota
MH  - Prospective Studies
PMC - PMC7252984
OTO - NOTNLM
OT  - *bacteriology
OT  - *infection control
OT  - *microbiology
COIS- Competing interests: SDG has received personal fees from Astellas, Enterobiotix, 
      Menarini, MSD, Pfizer and Shionogi. DLS has undertaken paid consultancy for
      Norgine Ltd, Shionogi and Kaleido Biosciences and paid lectures for Falk Pharma, 
      Norgine Ltd and Alfa Sigma.All other authors report no competing interests.
EDAT- 2020/05/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038847 [pii]
AID - 10.1136/bmjopen-2020-038847 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 25;10(5):e038847. doi: 10.1136/bmjopen-2020-038847.


PMID- 32457082
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 25
TI  - Enhanced PeriOperative Care and Health protection programme for the prevention of
      surgical site infections after elective abdominal surgery (EPOCH): study protocol
      of a randomised controlled, multicentre, superiority trial.
PG  - e038196
LID - 10.1136/bmjopen-2020-038196 [doi]
AB  - INTRODUCTION: Surgical site infections (SSI) are a common postoperative
      complication. During the development of the new WHO guidelines on SSI prevention,
      also in the Netherlands was concluded that perioperative care could be optimised 
      beyond the current standard practice. We selected a limited set of readily
      available, cheap and evidence-based interventions from these new guidelines that 
      are not part of standard practice in the Netherlands and formulated an Enhanced
      PeriOperative Care and Health bundle (EPOCH). Here, we describe the protocol for 
      an open-label, randomised controlled, parallel-group, superiority trial to test
      the effect of the EPOCH bundle added to (national) standard care in comparison to
      standard care alone on the incidence of SSI. METHODS AND ANALYSIS: EPOCH consists
      of intraoperative high fractional inspired oxygen (0.80); goal-directed fluid
      therapy; active preoperative, intraoperative and postoperative warming;
      perioperative glucose control and treatment of severe hyperglycaemia (>10
      mmol(l-1)) and standardised surgical site handling. Patients scheduled for
      elective abdominal surgery with an incision larger than 5 cm are eligible for
      inclusion. Participants are randomised daily, 1:1 according to variable block
      sizes, and stratified per participating centre to either EPOCH added to standard 
      care or standard care only. The primary endpoint will be SSI incidence according 
      to the Centers for Disease Control and Prevention (CDC) definition within 30 days
      as part of routine clinical follow-up. Four additional questionnaires will be
      sent out over the course of 90 days to capture disability and costs. Other
      secondary endpoints include anastomotic leakage, incidence of incisional hernia, 
      serious adverse events, hospital readmissions, length of stay and cost
      effectiveness. Analysis of the primary endpoint will be on an intention-to-treat 
      basis. ETHICS AND DISSEMINATION: Ethics approval is granted by the Amsterdam UMC 
      Medical Ethics Committee (reference 2015_121). Results will be disseminated
      through peer-reviewed journals and summaries shared with stakeholders. This
      protocol is published before analysis of the results. TRIAL REGISTRATION NUMBER: 
      Registered in the Dutch Trial Register: NL5572.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - de Jonge, Stijn W
AU  - de Jonge SW
AD  - Department of Surgery, Amsterdam UMC - Locatie AMC, Amsterdam, Noord-Holland,
      Netherlands.
FAU - Wolfhagen, Niels
AU  - Wolfhagen N
AUID- ORCID: 0000-0003-0573-5703
AD  - Department of Surgery, Amsterdam UMC - Locatie AMC, Amsterdam, Noord-Holland,
      Netherlands.
FAU - Boldingh, Quirine Jj
AU  - Boldingh QJ
AD  - Department of Surgery, Amsterdam UMC - Locatie AMC, Amsterdam, Noord-Holland,
      Netherlands.
FAU - Bom, Wouter J
AU  - Bom WJ
AD  - Department of Surgery, Amsterdam UMC - Locatie AMC, Amsterdam, Noord-Holland,
      Netherlands.
FAU - Posthuma, Linda M
AU  - Posthuma LM
AD  - Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam,
      Noord-Holland, Netherlands.
FAU - Scheijmans, Jochem Cg
AU  - Scheijmans JC
AD  - Department of Surgery, Amsterdam UMC - Locatie AMC, Amsterdam, Noord-Holland,
      Netherlands.
FAU - van der Leeuw, Bart Mf
AU  - van der Leeuw BM
AD  - Department of Anesthesiology, Albert Schweitzer Hospital, Dordrecht,
      Noord-Holland, Netherlands.
FAU - van der Hoeven, Joost Ab
AU  - van der Hoeven JA
AD  - Department of Surgery, Albert Schweitzer Hospital, Dordrecht, Zuid-Holland,
      Netherlands.
FAU - Hering, Jens Peter
AU  - Hering JP
AD  - Anesthesiology, Dijklander Ziekenhuis, Hoorn, Noord-Holland, Netherlands.
FAU - Sonneveld, Dirk Ja
AU  - Sonneveld DJ
AD  - Department of Surgery, Dijklander Ziekenhuis, Hoorn, Noord-Holland, Netherlands.
FAU - van Geffen, Otto E
AU  - van Geffen OE
AD  - Department of Anesthesiology, Tergooiziekenhuizen, Hilversum, Noord-Holland,
      Netherlands.
FAU - Hendriks, Eduard R
AU  - Hendriks ER
AD  - Department of Surgery, Tergooiziekenhuizen, Hilversum, Noord-Holland,
      Netherlands.
FAU - Kluyver, Ewoud B
AU  - Kluyver EB
AD  - Department of Anesthesiology, Rode Kruis Ziekenhuis, Beverwijk, Noord-Holland,
      Netherlands.
FAU - Demirkiran, Ahmet
AU  - Demirkiran A
AD  - Department of Surgery, Rode Kruis Ziekenhuis, Beverwijk, Noord-Holland,
      Netherlands.
FAU - van Lonkhuijzen, Luc Rcw
AU  - van Lonkhuijzen LR
AD  - Department of Gynaecologic Oncology, Amsterdam UMC - Locatie AMC, Amsterdam,
      Noord-Holland, Netherlands.
FAU - Slotema, Thomas
AU  - Slotema T
AD  - Department of Anesthesiology, Jeroen Bosch Hospital, 's-Hertogenbosch,
      Noord-Brabant, Netherlands.
FAU - Draaisma, Werner A
AU  - Draaisma WA
AD  - Department of Surgery, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Noord-Brabant, 
      Netherlands.
FAU - Koopman, Seppe Jsha
AU  - Koopman SJ
AD  - Department of Anesthesiology, Maasstad Ziekenhuis, Rotterdam, Zuid-Holland,
      Netherlands.
FAU - van Rossem, Charles C
AU  - van Rossem CC
AD  - Department of Surgery, Maasstad Ziekenhuis, Rotterdam, Zuid-Holland, Netherlands.
FAU - Over, Linda M
AU  - Over LM
AD  - Department of Anesthesiology, Gelre Ziekenhuizen, Apeldoorn, Gelderland,
      Netherlands.
FAU - van Duijvendijk, Peter
AU  - van Duijvendijk P
AD  - Department of Surgery, Gelre Ziekenhuizen, Apeldoorn, Gelderland, Netherlands.
FAU - Dijkgraaf, Marcel Gw
AU  - Dijkgraaf MG
AD  - Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC - Locatie 
      AMC, Amsterdam, Noord-Holland, Netherlands.
FAU - Hollmann, Markus W
AU  - Hollmann MW
AD  - Department of Anesthesiology, Amsterdam UMC - Locatie AMC, Amsterdam,
      Noord-Holland, Netherlands.
FAU - Boermeester, Marja A
AU  - Boermeester MA
AD  - Department of Surgery, Amsterdam UMC - Locatie AMC, Amsterdam, Noord-Holland,
      Netherlands m.a.boermeester@amsterdamumc.nl.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Abdomen/surgery
MH  - *Elective Surgical Procedures
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Netherlands
MH  - Perioperative Care
MH  - Randomized Controlled Trials as Topic
MH  - *Surgical Wound Infection/epidemiology/prevention & control
PMC - PMC7252990
OTO - NOTNLM
OT  - *adult anaesthesia
OT  - *adult surgery
OT  - *preventive medicine
OT  - *wound management
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038196 [pii]
AID - 10.1136/bmjopen-2020-038196 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 25;10(5):e038196. doi: 10.1136/bmjopen-2020-038196.


PMID- 32457081
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 25
TI  - Helminth infections, atopy, asthma and allergic diseases: protocol for a
      systematic review of observational studies worldwide.
PG  - e038085
LID - 10.1136/bmjopen-2020-038085 [doi]
AB  - INTRODUCTION: Childhood infections, particularly those caused by helminths are
      considered to be important environmental exposures influencing the development of
      allergic diseases. However, epidemiological studies focusing on the relationship 
      between helminth infections and risk of allergic diseases, performed worldwide,
      show inconsistent findings. Previous systematic reviews of observational studies 
      published 10 or more years ago showed conflicting findings for effects of
      helminths on allergic diseases. Over the past 10 years there has been growing
      literature addressing this research area and these need to be considered in order
      to appreciate the most contemporary evidence. The objective of the current
      systematic review will be to provide an up-to-date synthesis of findings of
      observational studies investigating the influence of helminth infections on
      atopy, and allergic diseases. METHODS AND ANALYSIS: This systematic review
      protocol was registered at PROSPERO. We will search Cochrane Library, MEDLINE,
      EMBASE, CINAHL, AMED, ISI Web of Science, WHO Global Health Library, Scielo,
      IndMed, PakMediNet, KoreaMed, Ichushi for published studies from 1970 to January 
      2020. Bibliographies of all eligible studies will be reviewed to identify
      additional studies. Unpublished and ongoing research will also be searched in key
      databases. There will be no language or geographical restrictions regarding
      publications. Critical Appraisal Skills Programme quality assessment tool will be
      used to appraise methodological quality of included studies. A descriptive
      summary with data tables will be constructed, and if adequate, meta-analysis
      using random-effects will be performed. The Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses checklist will be followed for reporting of 
      the systematic review. ETHICS AND DISSEMINATION: Since this systematic review
      will be only based on published and retrievable literature, no ethics approval
      will be sought. The multidisciplinary team performing this systematic review will
      participate in relevant dissemination activities. Findings will be presented at
      scientific meetings and publish the systematic review in international,
      peer-reviewed, open-access journals. PROSPERO REGISTRATION NUMBER:
      CRD42020167249.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Arrais, Margarete
AU  - Arrais M
AUID- ORCID: 0000-0001-6611-4260
AD  - Department of Pulmonology, Military Hospital Luanda, Luanda, Angola.
AD  - CISA - Health Sciences Research Center of Angola, Caxito, Bengo, Angola.
FAU - Maricoto, Tiago
AU  - Maricoto T
AD  - ACeS Baixo Vouga, Aveiro-Aradas Family Health Unit, Aveiro, Portugal.
AD  - Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal.
FAU - Cooper, Philip
AU  - Cooper P
AD  - Institute of Infection and Immunity, St George's University of London, London,
      UK.
AD  - School of Medicine, International Univeristy of Ecuador, Quito, Ecuador.
FAU - Gama, Jorge M R
AU  - Gama JMR
AD  - Centre of Mathematics and Applications, Faculty of Sciences, University of Beira 
      Interior, Covilha, Portugal.
FAU - Nwaru, Bright I
AU  - Nwaru BI
AD  - Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University 
      of Gothenburg, Gothenburg, Sweden.
FAU - Brito, Miguel
AU  - Brito M
AD  - CISA - Health Sciences Research Center of Angola, Caxito, Bengo, Angola.
AD  - Health and Technology Research Center (H&TRC), Lisbon Higher School of Health
      Technology, Polytechnic Institute of Lisbon, Lisbon, Portugal.
FAU - Taborda-Barata, Luis
AU  - Taborda-Barata L
AUID- ORCID: 0000-0001-6649-8890
AD  - Department of Allergy & Clinical Immunology, Cova da Beira University Hospital
      Centre, Covilha, Portugal tabordabarata@fcsaude.ubi.pt.
AD  - CICS - Health Sciences Research Centre, University of Beira Interior, Covilha,
      Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Asthma/epidemiology
MH  - Child
MH  - Humans
MH  - *Hypersensitivity/epidemiology
MH  - Meta-Analysis as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7252955
OTO - NOTNLM
OT  - *allergy
OT  - *asthma
OT  - *eczema
OT  - *epidemiology
OT  - *parasitology
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038085 [pii]
AID - 10.1136/bmjopen-2020-038085 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 25;10(5):e038085. doi: 10.1136/bmjopen-2020-038085.


PMID- 32457079
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 25
TI  - Parenthood and pregnancy in Australians receiving treatment for end-stage kidney 
      disease: protocol of a national study of perinatal and parental outcomes through 
      population record linkage.
PG  - e036329
LID - 10.1136/bmjopen-2019-036329 [doi]
AB  - INTRODUCTION: Achieving parenthood is challenging in individuals receiving renal 
      replacement therapy (RRT; dialysis or kidney transplantation) for end-stage
      kidney disease. Decision-making regarding parenthood in RRT recipients should be 
      underpinned by robust data, yet there is limited data on parental factors that
      drive adverse health outcomes. Therefore, we aim to investigate the perinatal
      risks and outcomes in parents receiving RRT. METHODS AND ANALYSIS: This is a
      multijurisdictional probabilistic data linkage study of perinatal, hospital,
      birth, death and renal registers from 1991 to 2013 from New South Wales, Western 
      Australia, South Australia and the Australian Capital Territory. This study
      includes all babies born >/=20 weeks' gestation or 400 g birth weight captured
      through mandated data collection in the perinatal data sets. Through linkage with
      the Australian and New Zealand Dialysis and Transplant (ANZDATA) registry, babies
      exposed to RRT (and their parents) will be compared with babies who have not been
      exposed to RRT (and their parents) to determine obstetric and fetal outcomes,
      birth rates and fertility rates. One of the novel aspects of this study is the
      method that will be used to link fathers receiving RRT to the mothers and their
      babies within the perinatal data sets, using the birth register, enabling the
      identification of family units. The linked data set will be used to validate the 
      parenthood events directly reported to ANZDATA. ETHICS AND DISSEMINATION: Ethics 
      approval was obtained from Human Research Ethics Committees (HREC) and Aboriginal
      HREC in each jurisdiction. Findings of this study will be disseminated at
      scientific conferences and in peer-reviewed journals in tabular and aggregated
      forms. De-identified data will be presented and individual patients will not be
      identified. We will aim to present findings to relevant stakeholders (eg,
      patients, clinicians and policymakers) to maximise translational impact of
      research findings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hewawasam, Erandi
AU  - Hewawasam E
AUID- ORCID: 0000-0002-8320-3668
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute (SAHMRI), Adelaide, South
      Australia, Australia erandi.hewawasam@sahmri.com.
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - Gulyani, Aarti
AU  - Gulyani A
AD  - School of Pharmacy and Medical Science, University of South Australia, Adelaide, 
      South Australia, Australia.
FAU - Davies, Christopher E
AU  - Davies CE
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute (SAHMRI), Adelaide, South
      Australia, Australia.
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South
      Australia, Australia.
FAU - Sullivan, Elizabeth
AU  - Sullivan E
AD  - Faculty of Health and Medicine, The University of Newcastle, Callaghan, New South
      Wales, Australia.
FAU - Wark, Sally
AU  - Wark S
AD  - Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal 
      Adelaide Hospital, Adelaide, South Australia, Australia.
FAU - Clayton, Philip A
AU  - Clayton PA
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute (SAHMRI), Adelaide, South
      Australia, Australia.
AD  - Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal 
      Adelaide Hospital, Adelaide, South Australia, Australia.
FAU - McDonald, Stephen P
AU  - McDonald SP
AD  - Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South
      Australian Health and Medical Research Institute (SAHMRI), Adelaide, South
      Australia, Australia.
AD  - Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal 
      Adelaide Hospital, Adelaide, South Australia, Australia.
FAU - Jesudason, Shilpanjali
AU  - Jesudason S
AD  - Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South
      Australia, Australia.
AD  - Central and Northern Adelaide Renal and Transplantation Services (CNARTS), Royal 
      Adelaide Hospital, Adelaide, South Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Female
MH  - Humans
MH  - *Kidney Failure, Chronic/therapy
MH  - New South Wales
MH  - New Zealand/epidemiology
MH  - Pregnancy
MH  - *Renal Dialysis
MH  - South Australia
MH  - Western Australia
PMC - PMC7252957
OTO - NOTNLM
OT  - *end stage renal failure
OT  - *epidemiology
OT  - *fetal medicine
OT  - *maternal medicine
OT  - *obstetrics
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036329 [pii]
AID - 10.1136/bmjopen-2019-036329 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 25;10(5):e036329. doi: 10.1136/bmjopen-2019-036329.


PMID- 32457078
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 25
TI  - Efficacy of maternal B12 supplementation in vegetarian women for improving infant
      neurodevelopment: protocol for the MATCOBIND multicentre, double-blind,
      randomised controlled trial.
PG  - e034987
LID - 10.1136/bmjopen-2019-034987 [doi]
AB  - INTRODUCTION: Vitamin B12 deficiency is widely prevalent across many low- and
      middle-income countries, especially where the diet is low in animal sources.
      While many observational studies show associations between B12 deficiency in
      pregnancy and infant cognitive function (including memory, language and motor
      skills), evidence from clinical trials is sparse and inconclusive. METHODS AND
      ANALYSIS: This double-blind, multicentre, randomised controlled trial will enrol 
      720 vegetarian pregnant women in their first trimester from antenatal clinics at 
      two hospitals (one in India and one in Nepal). Eligible mothers who give written 
      consent will be randomised to receive either 250 mcg methylcobalamin or 50 mcg
      (quasi control), from enrolment to 6 months post-partum, given as an oral daily
      capsule. All mothers and their infants will continue to receive standard clinical
      care. The primary trial outcome is the offspring's neurodevelopment status at 9
      months of age, assessed using the Development Assessment Scale of Indian Infants.
      Secondary outcomes include the infant's biochemical B12 status at age 9 months
      and maternal biochemical B12 status in the first and third trimesters. Maternal
      biochemical B12 status will also be assessed in the first trimester. Modification
      of association by a priori identified factors will also be explored. ETHICAL
      CONSIDERATIONS AND DISSEMINATION: The study protocol has been approved by ethical
      committees at each study site (India and Nepal) and at University College London,
      UK. The study results will be disseminated to healthcare professionals and
      academics globally via conferences, presentations and publications. Researchers
      at each study site will share results with participants during their follow-up
      visits.Trial registration numberCTRI/2018/07/015048 (Clinical Trial Registry of
      India); NCT04083560 (ClinicalTrials.gov).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Nagpal, Jitender
AU  - Nagpal J
AD  - Pediatrics, Sitaram Bhartia Institute of Science and Research, New Delhi, Delhi, 
      India.
FAU - Mathur, Manu Raj
AU  - Mathur MR
AD  - Public Health Foundation of India, New Delhi, India.
FAU - Rawat, Swapnil
AU  - Rawat S
AD  - Pediatrics, Sitaram Bhartia Institute of Science and Research, New Delhi, Delhi, 
      India.
FAU - Nagrath, Deepti
AU  - Nagrath D
AUID- ORCID: 0000-0003-3854-1841
AD  - Public Health Foundation of India, New Delhi, India.
FAU - Lee, Charlotte
AU  - Lee C
AUID- ORCID: 0000-0001-8252-9538
AD  - UCL GOS Institute of Child Health, University College London, London, UK.
FAU - Singhal, Atul
AU  - Singhal A
AD  - UCL GOS Institute of Child Health, University College London, London, UK.
FAU - Heys, Michelle
AU  - Heys M
AD  - UCL GOS Institute of Child Health, University College London, London, UK.
AD  - Specialist Children's and Young People's Services, East London NHS Foundation
      Trust, London, UK.
FAU - Cortina Borja, Mario
AU  - Cortina Borja M
AD  - UCL GOS Institute of Child Health, University College London, London, UK.
FAU - Augustin, Katrin
AU  - Augustin K
AD  - UCL GOS Institute of Child Health, University College London, London, UK.
FAU - Gautam, Jageshwor
AU  - Gautam J
AD  - Obstetrics and Gynaecology, Paropakar Maternity & Women's Hospital, Kathmandu,
      Nepal.
FAU - Pant, Rajendra
AU  - Pant R
AD  - Obstetrics and Gynaecology, Paropakar Maternity & Women's Hospital, Kathmandu,
      Nepal.
FAU - Swabey, Laura
AU  - Swabey L
AUID- ORCID: 0000-0001-6677-1420
AD  - UCL GOS Institute of Child Health, University College London, London, UK.
FAU - Lakhanpaul, Monica
AU  - Lakhanpaul M
AUID- ORCID: 0000-0001-5288-3325
AD  - UCL GOS Institute of Child Health, University College London, London, UK
      m.lakhanpaul@ucl.ac.uk.
AD  - Community Paediatrics, Whittington NHS Trust, London, United Kingdom.
LA  - eng
SI  - ClinicalTrials.gov/NCT04083560
SI  - CTRI/CTRI/2018/07/015048
GR  - MR/R020396/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Micronutrients)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Adult
MH  - Avitaminosis/*epidemiology
MH  - Cognition
MH  - *Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - India/epidemiology
MH  - Infant
MH  - Infant, Newborn
MH  - Micronutrients/administration & dosage
MH  - Mothers/*statistics & numerical data
MH  - Nepal/epidemiology
MH  - Pregnancy
MH  - *Vegetarians
MH  - Vitamin B 12/*administration & dosage
PMC - PMC7252986
OTO - NOTNLM
OT  - *community child health
OT  - *developmental neurology & neurodisability
OT  - *maternal medicine
OT  - *nutrition & dietetics
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034987 [pii]
AID - 10.1136/bmjopen-2019-034987 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 25;10(5):e034987. doi: 10.1136/bmjopen-2019-034987.


PMID- 32457077
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 25
TI  - Mapping tuberculosis prevalence in Ethiopia: protocol for a geospatial
      meta-analysis.
PG  - e034704
LID - 10.1136/bmjopen-2019-034704 [doi]
AB  - INTRODUCTION: Tuberculosis (TB), a major public health concern in Ethiopia, is
      distributed heterogeneously across the country. Mapping TB prevalence at national
      and subnational levels can provide information for designing and implementing
      control strategies. Data for spatial analysis can be obtained through systematic 
      review of the literature, and spatial prediction can be done by meta-analysis of 
      published data (geospatial meta-analysis). Geospatial meta-analysis can increase 
      the power of spatial analytic models by making use of all available data. It can 
      also provide a means for spatial prediction where new survey data in a given area
      are sparse or not available. In this report, we present a protocol for a
      geospatial meta-analysis to investigate the spatial patterns of TB prevalence in 
      Ethiopia. METHODS AND ANALYSIS: To conduct this study, a national TB prevalence
      survey, supplemented with data from a systematic review of published reports,
      will be used as the source of TB prevalence data. Systematic searching will be
      conducted in PubMed, Scopus and Web of Science for studies published up to 15
      April 2020 to identify all potential publications reporting TB prevalence in
      Ethiopia. Data for covariates for multivariable analysis will be obtained from
      different, readily available sources. Extracted TB survey and covariate data will
      be georeferenced to specific locations or the centroids of small administrative
      areas. A binomial logistic regression model will be fitted to TB prevalence data 
      using both fixed covariate effects and random geostatistical effects based on the
      approach of model-based geostatistics. Markov Chain Monte Carlo simulation will
      be conducted to obtained posterior parameter estimations, including spatially
      predicted prevalence. ETHICS AND DISSEMINATION: Ethical approval will not be
      required for this study as it will be based on deidentified, aggregate published 
      data. The final report of this review will be disseminated through publication in
      a peer-reviewed scientific journal and will also be presented at relevant
      conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alene, Kefyalew Addis
AU  - Alene KA
AUID- ORCID: 0000-0002-1904-4682
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Nedlands, Western Australia, Australia kefyalew.alene@telethonkids.org.au.
AD  - Faculty of Health Sciences, Curtin University, Perth, Western Australia,
      Australia.
FAU - Wagaw, Zeleke Alebachew
AU  - Wagaw ZA
AD  - National Tuberculosis Control Programme, Ghana Health Service, Accra, Greater
      Accra, Ghana.
FAU - Clements, Archie C A
AU  - Clements ACA
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      Nedlands, Western Australia, Australia.
AD  - Faculty of Health Sciences, Curtin University, Perth, Western Australia,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ethiopia/epidemiology
MH  - *Geographic Information Systems
MH  - Humans
MH  - *Infection Control
MH  - *Meta-Analysis as Topic
MH  - Prevalence
MH  - *Public Health
MH  - *Spatial Analysis
MH  - *Systematic Reviews as Topic
MH  - Tuberculosis/*epidemiology
PMC - PMC7252965
OTO - NOTNLM
OT  - *epidemiology
OT  - *public health
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/05/28 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034704 [pii]
AID - 10.1136/bmjopen-2019-034704 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 25;10(5):e034704. doi: 10.1136/bmjopen-2019-034704.


PMID- 32457036
OWN - NLM
STAT- MEDLINE
DCOM- 20200604
LR  - 20210125
IS  - 2059-7029 (Electronic)
IS  - 2059-7029 (Linking)
VI  - 5
IP  - Suppl 3
DP  - 2020 May
TI  - ESMO management and treatment adapted recommendations in the COVID-19 era:
      colorectal cancer.
LID - e000826 [pii]
LID - 10.1136/esmoopen-2020-000826 [doi]
AB  - COVID-19 pandemic challenges health system capacities in many countries. National
      healthcare services have to manage unexpected shortage of healthcare resources
      that have to be reallocated according to the principles of fair and ethical
      prioritisation, in order to maintain the highest levels of care to all patients, 
      ensure the safety of patients and healthcare workers and save as many lives as
      possible. Beyond that, cancer care services have to pursue restructuring,
      following the same evidence-based dispositions. In this article, we propose
      guidance to the management of colorectal cancer during the pandemic, prioritised 
      according to a three-tiered framework, based on expert clinical judgement and
      magnitude of benefit expected from specific interventions. Since the availability
      of resources for diagnostic procedures, surgery and postoperative care, systemic 
      therapy and radiotherapy may differ, authors did separate prioritisation
      analyses. The impact of postponing or abrogating cancer interventions on outcomes
      according to a high, medium or low priority scale, is outlined and discussed. The
      implementation of healthcare services using telemedicine is explored: it reveals 
      itself as functional and effective for limiting patients' need to travel to
      centres and thereby has the potential to reduce diffusion of severe acute
      respiratory syndrome coronavirus 2. Colorectal cancer demands a considerable
      amount of medical resources. Therefore, the redefinition of its diagnostic and
      therapeutic algorithms with a rigorous method is crucial in order to ensure the
      highest quality of continuum of care in the broader context of the pandemic and
      the challenged healthcare systems.
CI  - (c) Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. Published by BMJ on behalf of the European Society for Medical
      Oncology.
FAU - Vecchione, Loredana
AU  - Vecchione L
AUID- ORCID: 0000-0003-3942-5498
AD  - Charite Comprehensive Cancer Center, Charite Universitatsmedizin Berlin, Berlin, 
      Germany.
AD  - Department of Hematology, Oncology and Tumor Immunology (CCM), Charite
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Stintzing, Sebastian
AU  - Stintzing S
AUID- ORCID: 0000-0002-3297-5801
AD  - Medical Department, Division of Oncology and Hematology, Charite
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Pentheroudakis, George
AU  - Pentheroudakis G
AD  - Department of Medical Oncology, University of Ioannina, Ioannina, Epirus, Greece.
FAU - Douillard, Jean-Yves
AU  - Douillard JY
AD  - European Society for Medical Oncology, Viganello, Switzerland.
FAU - Lordick, Florian
AU  - Lordick F
AUID- ORCID: 0000-0001-8591-9339
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology and Infectious 
      Diseses, Leipzig University Medical Center, Leipzig, Germany
      florian.lordick@medizin.uni-leipzig.de.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Colorectal Neoplasms/diagnosis/pathology/*therapy
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Delivery of Health Care/standards
MH  - Humans
MH  - Medical Oncology/organization & administration/*standards
MH  - *Pandemics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Telemedicine/standards
PMC - PMC7276236
OTO - NOTNLM
OT  - *CRC and COVID-19
OT  - *colorectal cancer patients during COVID19 pandemic
OT  - *colorectal cancer patients recommendetions
COIS- Competing interests: LV is a member of the GI connect group, spouse is employee
      and shareholder of Bayer AG. LV reported grants for translational research from
      Pierre Fabre und is participant in the Charite-BIH Clinician Scientist Program
      funded by the Charite Universitaetsmedizin Berlin und Berlin Institute of Health.
      SS: personal fees from Amgen, Bayer, Isofol, Lilly, Merck KGaA, MSD, Nordic
      Pharma, Pierre-Fabre, Roche, Sanofi, Sirtex, Servier, Takeda, Taiho, research
      grants from Pierre-Fabre, Merck KGaA, Roche. GP: Research grants from Amgen,
      AstraZeneca, Roche, MSD, BMS, Merck, outside of the submitted work. FL: personal 
      fees from Amgen, Astellas, AstraZeneca, Biontech, Eli Lilly, Elsevier, Excerpta
      Medica, Imedex, Infomedica, Medscape, MedUpdate, Merck Serono, Merck Sharp &
      Dohme, Oncovis, Promedicis, Springer Nature, StreamedUp!, and Zymeworks; and
      research grants and personal fees from Bristol-Myers Squibb and Iomedico, outside
      the submitted work.
EDAT- 2020/05/28 06:00
MHDA- 2020/06/05 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/06/05 06:00 [medline]
AID - S2059-7029(20)32675-2 [pii]
AID - 10.1136/esmoopen-2020-000826 [doi]
PST - ppublish
SO  - ESMO Open. 2020 May;5(Suppl 3). pii: S2059-7029(20)32675-2. doi:
      10.1136/esmoopen-2020-000826.


PMID- 32456673
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 13
IP  - 1
DP  - 2020 May 26
TI  - Managing acute pain in HIV+/AIDS patients: knowledge and practice trends among
      emergency physicians of major tertiary care centers of a developing country.
PG  - 255
LID - 10.1186/s13104-020-05095-1 [doi]
AB  - OBJECTIVE: To assess knowledge and practice trends in managing acute pain in
      patients infected with human immunodeficiency virus (HIV+) or having acquired
      immunodeficiency syndrome (AIDS) among emergency physicians of four tertiary care
      hospitals. Acute pain management in such patients is complex because of multiple 
      concomitant painful conditions related to their disease. After obtaining ethical 
      approval and written informed consent, emergency physicians were requested to
      fill out a questionnaire. RESULTS: Out of 84 physicians who participated, 49 had 
      managed HIV+/AIDS patients during the preceding year. Out of the 49, 30 (61.2%)
      physicians stated that they used a combination of analgesics for acute pain in
      these patients. Forty-two (50%) out of the 84 participants believed that routine 
      doses of opioids were adequate for pain relief, while 42 (50%) agreed that pain
      management was more complex in these patients mainly due to presence of multiple 
      coexisting problems and psychological issues. Only 26 (31%) respondents
      considered that pain was under-reported and under-treated in these patients,
      mainly because physicians were more focused on patients' other disease related
      complications and issues. Formulation of guidelines are recommended for effective
      acute pain management in these patients encompassing associated issues, including
      concomitant painful conditions, opioid dependence, psychiatric problems, etc.
FAU - Ahmed, Aliya
AU  - Ahmed A
AUID- ORCID: http://orcid.org/0000-0002-5211-6350
AD  - Department of Anaesthesiology, 2nd-Floor Private Wing, Aga Khan University,
      Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan. aliya.ahmed@aku.edu.
FAU - Afshan, Gauhar
AU  - Afshan G
AD  - Department of Anaesthesiology, 2nd-Floor Private Wing, Aga Khan University,
      Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan.
FAU - Irshad Khan, Robyna
AU  - Irshad Khan R
AD  - Department of Anaesthesiology, 2nd-Floor Private Wing, Aga Khan University,
      Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan.
FAU - Afzal, Badar
AU  - Afzal B
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Jamali, Seemin
AU  - Jamali S
AD  - Accident and Emergency Department, Jinnah Postgraduate Medical Centre, Karachi,
      Pakistan.
FAU - Farooq, Nighat
AU  - Farooq N
AD  - Accident and Emergency Department, Civil Hospital Karachi, Karachi, Pakistan.
FAU - Saleem, Sarosh
AU  - Saleem S
AD  - Paediatrics Department, Indus Hospital, Karachi, Pakistan.
FAU - Naeem, Rubaba
AU  - Naeem R
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan.
FAU - Khan, Uzma
AU  - Khan U
AD  - Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan.
LA  - eng
GR  - 2D43- TW007292/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200526
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Analgesics)
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*complications/psychology
MH  - Acute Pain/*complications/drug therapy/psychology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics/therapeutic use
MH  - Analgesics, Opioid/therapeutic use
MH  - Developing Countries
MH  - HIV Infections/*complications/psychology
MH  - Humans
MH  - Middle Aged
MH  - Pain Management/*methods
MH  - Physicians
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
PMC - PMC7249315
OTO - NOTNLM
OT  - AIDS
OT  - Acute pain
OT  - Emergency physicians
OT  - HIV
OT  - Pain management
EDAT- 2020/05/28 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/05/28 06:00
PHST- 2019/10/04 00:00 [received]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.1186/s13104-020-05095-1 [doi]
AID - 10.1186/s13104-020-05095-1 [pii]
PST - epublish
SO  - BMC Res Notes. 2020 May 26;13(1):255. doi: 10.1186/s13104-020-05095-1.


PMID- 32456653
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1750-1172 (Electronic)
IS  - 1750-1172 (Linking)
VI  - 15
IP  - 1
DP  - 2020 May 26
TI  - TRUST4RD: tool for reducing uncertainties in the evidence generation for
      specialised treatments for rare diseases.
PG  - 127
LID - 10.1186/s13023-020-01370-3 [doi]
AB  - BACKGROUND: Many treatments developed for rare diseases will have an Orphan
      Medicinal Product (OMP) designation, indicating that they are likely to deliver
      benefit in an area of high unmet need. Their approval may be based on a small or 
      uncontrolled trial, as randomised controlled trials (RCTs) of sufficient size are
      often difficult to conduct, or repeat, as a result of the rarity of the
      condition, sparsity of patients, or for ethical reasons. Furthermore, many
      products are given a conditional marketing authorisation, requiring additional
      evidence to be collected after product launch. This is even more challenging with
      the advent of advanced therapeutic medicinal products, which use novel scientific
      approaches like gene or somatic cell therapy. ISSUE: Given the high unmet need
      associated with these products, there is pressure for Health Technology
      Assessment (HTA)/reimbursement bodies to enable rapid access to effective
      treatments. However, there is often only limited evidence available for
      assessment. METHODS: TRUST4RD proposes an approach to identify uncertainties of
      most concern for decision-makers by developing an iterative and informed dialogue
      amongst stakeholders (including manufacturers, clinicians, patients, regulatory- 
      and HTA agencies and payers), so that potential approaches to resolution can be
      discussed. As evidence is generated, uncertainties are reviewed and prioritised, 
      and evidence-generation plans revised or clarified accordingly. The aim is to
      develop - both pre- and post HTA submission - a better understanding of evidence 
      requirements versus evidence-generation trade-offs as an evidence base grows and 
      the potential value of a product becomes clearer. CONCLUSION: TRUST4RD presents
      guidance on defining uncertainties and evidence gaps in the assessment of value
      and value for money of specialised treatments for rare diseases. It also provides
      guidance on the potential of Real World Evidence (RWE) to help address such
      uncertainties, including the typology of evidence uncertainties, the importance
      of different uncertainties and the data sources available to address them before 
      and after HTA submission. In making use of the guidance, authorisation and
      reimbursement discussions on such treatments can be embedded in an evidence-rich 
      context, thereby ensuring value to all parties, particularly to patients.
FAU - Annemans, Lieven
AU  - Annemans L
AD  - Dept of Public Health and Primary Care, Faculty of Medicine and Health Sciences, 
      Ghent University, C Heymanslaan 10, 9000, Ghent, Belgium.
      Lieven.Annemans@UGent.be.
FAU - Makady, Amr
AU  - Makady A
AD  - Dept of Pharmaceutical Sciences, University of Utrecht Faculty David de
      Wiedbuilding, Universiteitsweg 99, 3584, Utrecht, CG, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - England
TA  - Orphanet J Rare Dis
JT  - Orphanet journal of rare diseases
JID - 101266602
SB  - IM
MH  - Humans
MH  - *Orphan Drug Production
MH  - *Rare Diseases/drug therapy
MH  - Technology Assessment, Biomedical
PMC - PMC7251888
OTO - NOTNLM
OT  - *Evidence generation
OT  - *Health technology assessment (HTA)
OT  - *Orphan medicinal product (OMP)
OT  - *Real world evidence (RWE)
OT  - *Value for money
EDAT- 2020/05/28 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/28 06:00
PHST- 2019/04/29 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.1186/s13023-020-01370-3 [doi]
AID - 10.1186/s13023-020-01370-3 [pii]
PST - epublish
SO  - Orphanet J Rare Dis. 2020 May 26;15(1):127. doi: 10.1186/s13023-020-01370-3.


PMID- 32456569
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1557-9034 (Electronic)
IS  - 1092-6429 (Linking)
VI  - 30
IP  - 12
DP  - 2020 Dec
TI  - Factors Affecting Retrograde Intrarenal Surgery Success: 6 Years Experience of a 
      Clinic in Central Anatolia.
PG  - 1340-1343
LID - 10.1089/lap.2020.0262 [doi]
AB  - Background: Urinary system stone disease is an important health problem. It has
      been reported to have a prevalence of 14.8% in Turkey. The aim of the renal stone
      removal surgery is to clear the stones with minimal complications. Retrograde
      intrarenal surgery (RIRS) is a safe method due to the fewer and minor
      complications. As a clinic in central Anatolia, we aimed at researching the
      factors affecting RIRS success in our area. Methods: After local ethics
      committee's approval, the data of the patients who had undergone RIRS between
      2014 and 2019 were reviewed. Patients who were <18 years old, had kidney
      anomalies, and had both ureter and kidney stones were excluded from the study.
      The patients who were defined as successful were named as Group 1 and the others 
      were named as Group 2. The demographic, intraoperative, and postoperative data of
      the two groups were compared. Results: There were a total of 416 patients in our 
      study. Group 1 consisted of 332 patients, whereas Group 2 had 84 patients.
      Opacity was significantly different between the groups (P = .004). Stone size,
      stone volume, and operation time were significantly higher in Group 2. After
      logistic regression analysis, we found that stone size, opacity, and operation
      time affected the success of RIRS significantly (P < .05). There was a reverse
      relationship with stone size, operation time, and opacity. Conclusions: We
      believe that in patients who have large lower calix stones and who want effective
      treatment, percutaneous nephrolithotomy should still be an option for treatment.
FAU - Sari, Sercan
AU  - Sari S
AD  - Department of Urology, Bozok University, Yozgat, Turkey.
FAU - Caniklioglu, Mehmet
AU  - Caniklioglu M
AD  - Department of Urology, Bozok University, Yozgat, Turkey.
FAU - Oztekin, Unal
AU  - Oztekin U
AD  - Department of Urology, Bozok University, Yozgat, Turkey.
FAU - Selmi, Volkan
AU  - Selmi V
AD  - Department of Urology, Bozok University, Yozgat, Turkey.
FAU - Taspinar, Mehmet Sakir
AU  - Taspinar MS
AD  - Department of Urology, Bozok University, Yozgat, Turkey.
FAU - Isikay, Levent
AU  - Isikay L
AD  - Department of Urology, Bozok University, Yozgat, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - United States
TA  - J Laparoendosc Adv Surg Tech A
JT  - Journal of laparoendoscopic & advanced surgical techniques. Part A
JID - 9706293
SB  - IM
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Incidence
MH  - Kidney/*surgery
MH  - Kidney Calculi/epidemiology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Nephrolithotomy, Percutaneous/*methods
MH  - Operative Time
MH  - Postoperative Period
MH  - Time Factors
MH  - Treatment Outcome
MH  - Turkey/epidemiology
MH  - Ureter/*surgery
OTO - NOTNLM
OT  - Central Anatolia
OT  - RIRS
OT  - factors
OT  - success
EDAT- 2020/05/28 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1089/lap.2020.0262 [doi]
PST - ppublish
SO  - J Laparoendosc Adv Surg Tech A. 2020 Dec;30(12):1340-1343. doi:
      10.1089/lap.2020.0262. Epub 2020 May 22.


PMID- 32456556
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Jun
TI  - Restorative Commons as an Expanded Ethical Framework for Public Health and
      Environmental Sustainability.
PG  - 125-140
LID - 10.1080/20502877.2020.1767917 [doi]
AB  - Pollution is currently responsible for 16% of premature deaths worldwide and
      poses the greatest long-term threat to public health due to the effects of
      climate change. The current framework of public health cannot justify
      sustainability measures at an appropriate scale and timeframe to prevent further 
      irreversible damage to the environment. To handle the issue of environmental
      degradation and its effect on humans, a revised framework for public health that 
      gives more thought and consideration to the non-human environment is required.
      Restorative Commons theory can bridge environmental ethics and medical ethics by 
      emphasizing the mutual benefits of environmental stewardship to nature and
      humans. This reflects an expansion of the environmentalist land ethic to a new
      'global health ethic'. In light of this, medicine should engage with the
      community and the environment, in addition to treating individuals.
FAU - Gurevich, Robert
AU  - Gurevich R
AD  - John Conley Division of Medical Ethics and Humanities, SUNY Downstate Health
      Sciences University, Brooklyn, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - *Bioethics
MH  - *Climate Change
MH  - *Delivery of Health Care
MH  - Ecology
MH  - *Environment
MH  - *Environmental Health
MH  - Humans
MH  - *Public Health
OTO - NOTNLM
OT  - Sustainable healthcare
OT  - ecology
OT  - global health ethic
OT  - health policy
OT  - public health
OT  - restorative commons
EDAT- 2020/05/28 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1080/20502877.2020.1767917 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Jun;26(2):125-140. doi: 10.1080/20502877.2020.1767917. Epub 2020
      May 27.


PMID- 32456308
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 24
TI  - Epigenetic Features of Human Perinatal Stem Cells Redefine Their Stemness
      Potential.
LID - E1304 [pii]
LID - 10.3390/cells9051304 [doi]
AB  - Human perinatal stem cells (SCs) can be isolated from fetal annexes without
      ethical or safety limitations. They are generally considered multipotent;
      nevertheless, their biological characteristics are still not fully understood.
      The aim of this study was to investigate the pluripotency potential of human
      perinatal SCs as compared to human induced pluripotent stem cells (hiPSCs).
      Despite the low expression of the pluripotent factors NANOG, OCT4, SOX2, and
      C-KIT in perinatal SC, we observed minor differences in the promoters
      DNA-methylation profile of these genes with respect to hiPSCs; we also
      demonstrated that in perinatal SCs miR-145-5p had an inverse trend in comparison 
      to these stemness markers, suggesting that NANOG, OCT4, and SOX2 were regulated
      at the post-transcriptional level. The reduced expression of stemness markers was
      also associated with shorter telomere lengths and shift of the oxidative
      metabolism between hiPSCs and fetal annex-derived cells. Our findings indicate
      the differentiation ability of perinatal SCs might not be restricted to the
      mesenchymal lineage due to an epigenetic barrier, but other regulatory mechanisms
      such as telomere shortening or metabolic changes might impair their
      differentiation potential and challenge their clinical application.
FAU - Gaggi, Giulia
AU  - Gaggi G
AUID- ORCID: 0000-0002-8761-7390
AD  - Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti- 
      Pescara, 66100 Chieti, Italy.
FAU - Di Credico, Andrea
AU  - Di Credico A
AD  - Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti- 
      Pescara, 66100 Chieti, Italy.
FAU - Izzicupo, Pascal
AU  - Izzicupo P
AUID- ORCID: 0000-0001-6944-8995
AD  - Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti- 
      Pescara, 66100 Chieti, Italy.
FAU - Antonucci, Ivana
AU  - Antonucci I
AUID- ORCID: 0000-0002-6594-2272
AD  - Department of Psychological, Humanities and Territorial Sciences, "G. D'Annunzio"
      University of Chieti, Pescara, 66100 Chieti, Italy.
FAU - Crescioli, Clara
AU  - Crescioli C
AD  - Department of Movement, Human and Health Sciences, University of Rome "Foro
      Italico", 00135 Rome, Italy.
FAU - Di Giacomo, Viviana
AU  - Di Giacomo V
AUID- ORCID: 0000-0003-3332-993X
AD  - Department of Farmacy, "G. D'Annunzio" University of Chieti- Pescara, 66100
      Chieti, Italy.
FAU - Di Ruscio, Annalisa
AU  - Di Ruscio A
AUID- ORCID: 0000-0002-9705-4245
AD  - Department of Translational Medicine, University of Eastern Piedmont, 28100
      Novara, Italy.
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School Initiative for RNA
      Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Amabile, Giovanni
AU  - Amabile G
AD  - Enthera Srl, 20123 Milan, Italy.
FAU - Alviano, Francesco
AU  - Alviano F
AUID- ORCID: 0000-0002-5315-0104
AD  - Department of Experimental, Diagnostic and Specialty Medicine, Unit of Histology,
      Embryology and Applied Biology, University of Bologna, 40126 Bologna, Italy.
FAU - Di Baldassarre, Angela
AU  - Di Baldassarre A
AUID- ORCID: 0000-0002-4473-4909
AD  - Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti- 
      Pescara, 66100 Chieti, Italy.
FAU - Ghinassi, Barbara
AU  - Ghinassi B
AUID- ORCID: 0000-0002-3529-2790
AD  - Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti- 
      Pescara, 66100 Chieti, Italy.
LA  - eng
GR  - R00 CA188595/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200524
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Chromosomes, Human/metabolism
MH  - DNA Methylation/genetics
MH  - *Epigenesis, Genetic
MH  - Gene Expression Regulation
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology/metabolism
MH  - Infant, Newborn
MH  - MicroRNAs/genetics/metabolism
MH  - Promoter Regions, Genetic
MH  - Stem Cells/*cytology/*metabolism
MH  - Telomere Homeostasis
PMC - PMC7290760
OTO - NOTNLM
OT  - *DNA methylation
OT  - *NANOG
OT  - *OCT4
OT  - *SOX2
OT  - *amniotic epithelial cells
OT  - *amniotic fluid stem cells
OT  - *fetal membrane mesenchymal stromal cells
OT  - *miRNAs expression
OT  - *perinatal stem cells
OT  - *telomere length
EDAT- 2020/05/28 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
AID - cells9051304 [pii]
AID - 10.3390/cells9051304 [doi]
PST - epublish
SO  - Cells. 2020 May 24;9(5). pii: cells9051304. doi: 10.3390/cells9051304.


PMID- 32455969
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 22
TI  - The Matter of Non-Avian Reptile Sentience, and Why It "Matters" to Them: A
      Conceptual, Ethical and Scientific Review.
LID - E901 [pii]
LID - 10.3390/ani10050901 [doi]
AB  - The concept of sentience, how it is characterised and which non-human animals
      possess it have long been of contention in academic and intellectual debates.
      Many have argued that there is no way to empirically know that animals have
      conscious experiences. Yet others argue that consciousness, awareness and
      sentience in non-human animals can be quite obvious, and can indeed be measured
      empirically. Most modern declarations of animal sentience from official
      organisations and governments now include all vertebrate animals as sentient
      beings, including reptiles and fish. Some declarations also include some
      invertebrate species. This conceptual, ethical and scientific review first
      focuses on conceptual components and definitions of consciousness, awareness and 
      sentience. It then specifically discusses how cognitive, neurobiological,
      ethological and comparative psychological research in non-avian reptiles over the
      last century has evidenced many capacities that historically were denied to this 
      class of animals. Non-avian reptiles do indeed possess all of the necessary
      capacities to be declared as sentient beings, at least in the small proportion of
      reptile species that have actually been empirically investigated so far. It is
      suggested that much innovative future research will continue to uncover evidence 
      of capabilities linked to sentience within a wide range of species, including
      non-avian reptiles, fish and invertebrates.
FAU - Learmonth, Mark James
AU  - Learmonth MJ
AUID- ORCID: 0000-0002-2237-0665
AD  - Animal Welfare Science Centre, The University of Melbourne, Parkville 3010, VIC, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7278454
OTO - NOTNLM
OT  - animal ethics
OT  - awareness
OT  - consciousness
OT  - non-avian reptiles
OT  - reptile sentience
OT  - sentience
OT  - sentience review
EDAT- 2020/05/28 06:00
MHDA- 2020/05/28 06:01
CRDT- 2020/05/28 06:00
PHST- 2020/03/21 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2020/05/28 06:01 [medline]
AID - ani10050901 [pii]
AID - 10.3390/ani10050901 [doi]
PST - epublish
SO  - Animals (Basel). 2020 May 22;10(5). pii: ani10050901. doi: 10.3390/ani10050901.


PMID- 32455178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2451-9944 (Electronic)
IS  - 2451-9944 (Linking)
VI  - 8
DP  - 2020 May
TI  - Surveying sleep quality and fatigue in multiple sclerosis patients at a multiple 
      sclerosis center in Kermanshah, Iran, in 2017.
PG  - 100050
LID - 10.1016/j.nbscr.2020.100050 [doi]
AB  - BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease of the nervous
      system which appears with de-myelination of the central nervous system. Sleep
      disorder and fatigue are very common in MS patients and are part of the main
      debilitating factors in patients. The present study was conducted to survey sleep
      quality and fatigue in MS patients. METHODS: A descriptive-analytical study was
      conducted on 87 MS patients, who were referred to the Kermanshah MS Center in
      2017. Data collection tools include a demographics form, fatigue severity scale, 
      and Pittsburg sleep quality inventory. The questionnaires were self-reporting.
      The collected data was analyzed in SPSS23. RESULTS: The mean age of the
      participants was 35.50+/-9.25 years and the majority of the participants were
      married (54; 62.1%). Quality of sleep was related to family history of MS and
      history of using medications (antidepressants like tricyclics, MAOIs, SSRIs, and 
      SNRIs and anxiety drugs such as diazepam, oxazepam, and alprazolam (p < 0.05).
      Moreover, there was a significant relationship between length of sleep and
      history of using medicines (p < 0.05). Finally, the results showed that there was
      a strong statistical relationship between performance during the day and fatigue 
      (p < 0.05). CONCLUSIONS: The results recommend holding relaxation and exercise
      courses by nurses to ease fatigue in MS patients. Clinics can also play a more
      effective role by being more supportive and holding more efficient training
      programs. The program is taught by the researchers. TRIAL REGISTRATION: This
      study was carried out following the permission from Ethics Committee, Department 
      of Research and Technology, Kermanshah University of Medical Sciences (approval
      number: KUMS.REC.1395.680).
CI  - (c) 2020 The Authors.
FAU - Karimi, Saba
AU  - Karimi S
AD  - Nursing Department, Nursing and Midwifery School, Kermanshah University of
      Medical Sciences, Kermanshah, Iran.
FAU - Jalilian, Milad
AU  - Jalilian M
AD  - Nursing Department, Nursing and Midwifery School, Student Research Committee,
      Kermanshah University of Medical Sciences, Kermanshah, Iran.
FAU - Abdi, Alireza
AU  - Abdi A
AD  - Nursing Department, Nursing and Midwifery School, Kermanshah University of
      Medical Sciences, Kermanshah, Iran.
FAU - Khazaie, Habibolah
AU  - Khazaie H
AD  - Sleep Disorders Research Center, Kermanshah University of Medical Sciences,
      Kermanshah, Iran.
FAU - Sarbarzeh, Pegah Ahmadi
AU  - Sarbarzeh PA
AD  - Nursing Department, Nursing and Midwifery School, Student Research Committee,
      Kermanshah University of Medical Sciences, Kermanshah, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - United States
TA  - Neurobiol Sleep Circadian Rhythms
JT  - Neurobiology of sleep and circadian rhythms
JID - 101690253
PMC - PMC7236050
OTO - NOTNLM
OT  - Fatigue
OT  - KUMS, Kermanshah University of Medical Sciences
OT  - Kermanshah MS Society
OT  - Multiple sclerosis
OT  - SM, self-medication
OT  - Sleep quality
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/05/27 06:00
MHDA- 2020/05/27 06:01
CRDT- 2020/05/27 06:00
PHST- 2019/01/29 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/05/27 06:01 [medline]
AID - 10.1016/j.nbscr.2020.100050 [doi]
AID - S2451-9944(20)30002-X [pii]
AID - 100050 [pii]
PST - epublish
SO  - Neurobiol Sleep Circadian Rhythms. 2020 May 11;8:100050. doi:
      10.1016/j.nbscr.2020.100050. eCollection 2020 May.


PMID- 32455168
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2397-7523 (Electronic)
IS  - 2397-7523 (Linking)
VI  - 4
DP  - 2020
TI  - When predictions are used to allocate scarce health care resources: three
      considerations for models in the era of Covid-19.
PG  - 11
LID - 10.1186/s41512-020-00079-y [doi]
AB  - BACKGROUND: The need for life-saving interventions such as mechanical ventilation
      may threaten to outstrip resources during the Covid-19 pandemic. Allocation of
      these resources to those most likely to benefit can be supported by clinical
      prediction models. The ethical and practical considerations relevant to
      predictions supporting decisions about microallocation are distinct from those
      that inform shared decision-making in ways important for model design. MAIN BODY:
      We review three issues of importance for microallocation: (1) Prediction of
      benefit (or of medical futility) may be technically very challenging; (2) When
      resources are scarce, calibration is less important for microallocation than is
      ranking to prioritize patients, since capacity determines thresholds for resource
      utilization; (3) The concept of group fairness, which is not germane in shared
      decision-making, is of central importance in microallocation. Therefore, model
      transparency is important. CONCLUSION: Prediction supporting allocation of
      life-saving interventions should be explicit, data-driven, frequently updated and
      open to public scrutiny. This implies a preference for simple, easily understood 
      and easily applied prognostic models.
CI  - (c) The Author(s) 2020.
FAU - Kent, David M
AU  - Kent DM
AUID- ORCID: 0000-0002-9205-5070
AD  - 1Predictive Analytics and Comparative Effectiveness (PACE) Center, Tufts Medical 
      Center, Boston, MA USA.grid.67033.310000 0000 8934 4045
FAU - Paulus, Jessica K
AU  - Paulus JK
AD  - 1Predictive Analytics and Comparative Effectiveness (PACE) Center, Tufts Medical 
      Center, Boston, MA USA.grid.67033.310000 0000 8934 4045
FAU - Sharp, Richard R
AU  - Sharp RR
AD  - 2Biomedical Ethics Program, Mayo Clinic, Rochester, MN USA.grid.66875.3a0000 0004
      0459 167X
FAU - Hajizadeh, Negin
AU  - Hajizadeh N
AD  - 3Feinstein Institutes for Medical Research, Northwell Health, New York City, NY
      USA.grid.416477.70000 0001 2168 3646
LA  - eng
PT  - Editorial
DEP - 20200520
PL  - England
TA  - Diagn Progn Res
JT  - Diagnostic and prognostic research
JID - 101718985
PMC - PMC7238723
OTO - NOTNLM
OT  - Algorithmic fairness
OT  - Clinical prediction models
OT  - Covid-19
OT  - Healthcare rationing
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/05/27 06:00
MHDA- 2020/05/27 06:01
CRDT- 2020/05/27 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/05/27 06:01 [medline]
AID - 10.1186/s41512-020-00079-y [doi]
AID - 79 [pii]
PST - epublish
SO  - Diagn Progn Res. 2020 May 20;4:11. doi: 10.1186/s41512-020-00079-y. eCollection
      2020.


PMID- 32454882
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20211204
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Linking)
VI  - 2020
DP  - 2020
TI  - High-Biofidelity Biomodel Generated from Three-Dimensional Imaging (Cone-Beam
      Computed Tomography): A Methodological Proposal.
PG  - 4292501
LID - 10.1155/2020/4292501 [doi]
AB  - Experimental research on living beings faces several obstacles, which are more
      than ethical and moral issues. One of the proposed solutions to these situations 
      is the computational modelling of anatomical structures. The present study shows 
      a methodology for obtaining high-biofidelity biomodels, where a novel
      imagenological technique is used, which applies several CAM/CAD computer programs
      that allow a better precision for obtaining a biomodel, with highly accurate
      morphological specifications of the molar and tissues that shape the biomodel.
      The biomodel developed is the first lower molar subjected to a basic chewing
      simulation through the application of the finite element method, resulting in a
      viable model, able to be subjected to various simulations to analyse molar
      biomechanical characteristics, as well as pathological conditions to evaluate
      restorative materials and develop treatment plans. When research is focused in
      medical and dental investigation aspects, numerical analyses could allow the
      implementation of several tools commonly used by mechanical engineers to provide 
      new answers to old problems in these areas. With this methodology, it is possible
      to perform high-fidelity models no matter the size of the anatomical structure,
      nor the complexity of its structure and internal tissues. So, it can be used in
      any area of medicine.
CI  - Copyright (c) 2020 Rosa Alicia Hernandez-Vazquez et al.
FAU - Hernandez-Vazquez, Rosa Alicia
AU  - Hernandez-Vazquez RA
AUID- ORCID: https://orcid.org/0000-0002-4486-5140
AD  - Universidad Politecnica del Valle de Mexico, Av. Mexiquense s/n esquina Av.
      Universidad Politecnica, Col. Villa Esmeralda, Tultitlan 54910, Estado de Mexico,
      Mexico.
FAU - Urriolagoitia-Sosa, Guillermo
AU  - Urriolagoitia-Sosa G
AD  - Instituto Politecnico Nacional, Escuela Superior de Ingenieria Mecanica y
      Electrica, Seccion de Estudios de Posgrado e Investigacion Unidad Profesional
      Adolfo Lopez Mateos, Zacatenco Edificio 5, 2 piso Col. Lindavista, Delegacion
      Gustavo A. Madero, Mexico City 07320, Mexico.
FAU - Marquet-Rivera, Rodrigo Arturo
AU  - Marquet-Rivera RA
AUID- ORCID: https://orcid.org/0000-0002-8261-2427
AD  - Instituto Politecnico Nacional, Escuela Superior de Ingenieria Mecanica y
      Electrica, Seccion de Estudios de Posgrado e Investigacion Unidad Profesional
      Adolfo Lopez Mateos, Zacatenco Edificio 5, 2 piso Col. Lindavista, Delegacion
      Gustavo A. Madero, Mexico City 07320, Mexico.
FAU - Romero-Angeles, Beatriz
AU  - Romero-Angeles B
AD  - Instituto Politecnico Nacional, Escuela Superior de Ingenieria Mecanica y
      Electrica, Seccion de Estudios de Posgrado e Investigacion Unidad Profesional
      Adolfo Lopez Mateos, Zacatenco Edificio 5, 2 piso Col. Lindavista, Delegacion
      Gustavo A. Madero, Mexico City 07320, Mexico.
FAU - Mastache-Miranda, Octavio Alejandro
AU  - Mastache-Miranda OA
AUID- ORCID: https://orcid.org/0000-0002-5761-4527
AD  - Instituto Politecnico Nacional, Escuela Superior de Ingenieria Mecanica y
      Electrica, Seccion de Estudios de Posgrado e Investigacion Unidad Profesional
      Adolfo Lopez Mateos, Zacatenco Edificio 5, 2 piso Col. Lindavista, Delegacion
      Gustavo A. Madero, Mexico City 07320, Mexico.
FAU - Vazquez-Feijoo, Juan Alejandro
AU  - Vazquez-Feijoo JA
AD  - Instituto Politecnico Nacional, Escuela Superior de Ingenieria Mecanica y
      Electrica, Seccion de Estudios de Posgrado e Investigacion Unidad Profesional
      Adolfo Lopez Mateos, Zacatenco Edificio 5, 2 piso Col. Lindavista, Delegacion
      Gustavo A. Madero, Mexico City 07320, Mexico.
FAU - Urriolagoitia-Calderon, Guillermo
AU  - Urriolagoitia-Calderon G
AD  - Instituto Politecnico Nacional, Escuela Superior de Ingenieria Mecanica y
      Electrica, Seccion de Estudios de Posgrado e Investigacion Unidad Profesional
      Adolfo Lopez Mateos, Zacatenco Edificio 5, 2 piso Col. Lindavista, Delegacion
      Gustavo A. Madero, Mexico City 07320, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200128
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
SB  - IM
MH  - Biomechanical Phenomena
MH  - Computational Biology
MH  - Computer Simulation
MH  - Computer-Aided Design
MH  - Cone-Beam Computed Tomography/*statistics & numerical data
MH  - Humans
MH  - Imaging, Three-Dimensional/*methods/statistics & numerical data
MH  - Models, Biological
MH  - *Models, Dental
MH  - Molar/*anatomy & histology/*diagnostic imaging/physiology
MH  - Software
PMC - PMC7212316
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/05/27 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/09/12 00:00 [received]
PHST- 2020/01/04 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
AID - 10.1155/2020/4292501 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2020 Jan 28;2020:4292501. doi: 10.1155/2020/4292501.
      eCollection 2020.


PMID- 32454860
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Acupuncture for Poststroke Dysphagia: A Pilot, Nonrandomized, Self-Controlled
      Trial.
PG  - 4689296
LID - 10.1155/2020/4689296 [doi]
AB  - OBJECTIVE: To evaluate the effectiveness and safety of acupuncture treatment for 
      dysphagia as a complication of stroke. Methods and Design. This is a multicenter,
      pragmatic, nonrandomized, self-controlled clinical trial. A total of 39 patients 
      were recruited from several Chinese medicine outpatient clinics and
      hospital-affiliated speech therapy outpatient clinics in Hong Kong. 26 patients
      completed all the 24 sessions of acupuncture treatment within two months, and
      only 12 of them were used as self-control. For the self-control group, the
      retrospective clinical data was taken from the electronic patient records with
      patient consent. The descriptive swallowing function data were converted into the
      quantitative Royal Brisbane Hospital Outcome Measure for Swallowing (RBHOMS)
      scores by two registered speech therapists through a validation process. And the 
      data were validated by reaching consensus between the two speech therapists. All 
      subjects underwent a baseline assessment before commencement of treatment, and
      outcome assessments were conducted upon the completion of treatment. The primary 
      outcome measure is the RBHOMS score, which is a swallowing disability rating
      scale for monitoring difficulties in daily swallowing function. Secondary outcome
      measures include the Chinese version of the Swallow Quality-of-Life Questionnaire
      and adverse events. All the primary and secondary outcomes were assessed at
      baseline as well as at the end of acupuncture treatment (month 2). RESULTS: A
      total of 39 participants aged 46 to 89 years were enrolled in the study, and the 
      male-to-female ratio was 15 : 11. The mean baseline RBHOMS score of all 39
      participants was 5.92 +/- 2.23. The mean retrospective RBHOMS score of the 12
      subjects who were used as self-control was 5.67 +/- 1.72 before enrollment, while
      the mean RBHOMS score of the 26 participants who completed all the 24 sessions of
      treatment was 6.92 +/- 2.07. There were statistically significant differences
      between the RBHOMS score at the completion of treatment and baseline (p=0.006),
      and retrospective data (p=0.042). Moreover, a significant difference was also
      found in terms of swallow quality-of-life score before and after acupuncture
      treatment (p < 0.01). CONCLUSIONS: This pilot study provides preliminary evidence
      for the effectiveness of acupuncture for poststroke dysphagia. The findings from 
      this trial can be used as a foundation for future full-scale randomized
      controlled clinical trials to assess the efficacy and safety of acupuncture for
      poststroke dysphagia. Ethics and Dissemination. The ethical approval of the
      clinical research study was granted by the Research Ethics Committee of both New 
      Territories East and West Cluster of Hong Kong. Written informed consent was
      obtained from all participants, and the study was undertaken according to the
      ICH-GCP Guidelines. Trial Registration. This trial is registered with
      ChiCTR-TRC-12002621 and the registration date is 2012-10-26.
CI  - Copyright (c) 2020 Yu Tat Chan et al.
FAU - Chan, Yu Tat
AU  - Chan YT
AUID- ORCID: https://orcid.org/0000-0001-8635-0658
AD  - School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong
      Kong, Shatin, Hong Kong.
AD  - Torrens University Australia, Melbourne, Victoria, Australia.
FAU - Zhang, Hong Wei
AU  - Zhang HW
AUID- ORCID: https://orcid.org/0000-0002-2288-5394
AD  - School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong
      Kong, Shatin, Hong Kong.
FAU - Sun, Wai Zhu
AU  - Sun WZ
AD  - School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong
      Kong, Shatin, Hong Kong.
FAU - Hang Or, Kevin Ka
AU  - Hang Or KK
AD  - School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong
      Kong, Shatin, Hong Kong.
FAU - Guo, Yuan-Qi
AU  - Guo YQ
AUID- ORCID: https://orcid.org/0000-0002-1346-8978
AD  - Pok Oi Hospital-The Chinese University of Hong Kong Chinese Medicine Centre for
      Training & Research, Shatin, Hong Kong.
FAU - Chen, Min
AU  - Chen M
AD  - Pok Oi Hospital-The Chinese University of Hong Kong Chinese Medicine Centre for
      Training & Research, Shatin, Hong Kong.
FAU - Wu, Guan-Yi
AU  - Wu GY
AD  - Pok Oi Hospital-The Chinese University of Hong Kong Chinese Medicine Centre for
      Training & Research, Yuen Long, Hong Kong.
FAU - Xu, Guang-Yao
AU  - Xu GY
AD  - Yan Oi Tong-The Chinese University of Hong Kong Chinese Medicine Centre for
      Training and Research, Tuen Mun, Hong Kong.
FAU - Leung, Connie
AU  - Leung C
AD  - Yan Oi Tong-The Chinese University of Hong Kong Chinese Medicine Centre for
      Training and Research, Tuen Mun, Hong Kong.
FAU - Tam, Sylvia
AU  - Tam S
AD  - Yan Oi Tong-The Chinese University of Hong Kong Chinese Medicine Centre for
      Training and Research, Tuen Mun, Hong Kong.
FAU - Chun-Keung Mok, Francis
AU  - Chun-Keung Mok F
AD  - Tuen Mun Hospital, Hospital Authority, Tuen Mun, Hong Kong.
FAU - Kwan, Yiu Keung
AU  - Kwan YK
AD  - Tuen Mun Hospital, Hospital Authority, Tuen Mun, Hong Kong.
FAU - Chow, Eddie
AU  - Chow E
AD  - Tuen Mun Hospital, Hospital Authority, Tuen Mun, Hong Kong.
FAU - Wo Mak, Joshua Kam
AU  - Wo Mak JK
AD  - Tuen Mun Hospital, Hospital Authority, Tuen Mun, Hong Kong.
FAU - Chun-Kwok Chu, Angus
AU  - Chun-Kwok Chu A
AD  - Tuen Mun Hospital, Hospital Authority, Tuen Mun, Hong Kong.
FAU - Lee, Kathy
AU  - Lee K
AD  - The Institute of Human Communicative Research, Department of Otorhinolaryngology,
      Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, Hong Kong.
FAU - Law, Thomas
AU  - Law T
AD  - The Institute of Human Communicative Research, Department of Otorhinolaryngology,
      Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, Hong Kong.
FAU - Ming Wong, Rita Wai
AU  - Ming Wong RW
AD  - The Institute of Human Communicative Research, Department of Otorhinolaryngology,
      Head and Neck Surgery, Faculty of Medicine, The Chinese University of Hong Kong, 
      Shatin, Hong Kong.
FAU - Lin, Zhi-Xiu
AU  - Lin ZX
AUID- ORCID: https://orcid.org/0000-0003-2840-6179
AD  - School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong
      Kong, Shatin, Hong Kong.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7240803
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/05/27 06:00
MHDA- 2020/05/27 06:01
CRDT- 2020/05/27 06:00
PHST- 2019/08/09 00:00 [received]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/05/27 06:01 [medline]
AID - 10.1155/2020/4689296 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 May 11;2020:4689296. doi:
      10.1155/2020/4689296. eCollection 2020.


PMID- 32454242
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1532-0480 (Electronic)
IS  - 1532-0464 (Linking)
VI  - 107
DP  - 2020 Jul
TI  - Prediction of mortality in Intensive Care Units: a multivariate feature
      selection.
PG  - 103456
LID - S1532-0464(20)30084-8 [pii]
LID - 10.1016/j.jbi.2020.103456 [doi]
AB  - CONTEXT: The critical nature of patients in Intensive Care Units (ICUs) demands
      intensive monitoring of their vital signs as well as highly qualified
      professional assistance. The combination of these needs makes ICUs very
      expensive, which requires investment to be prioritized. Administrative issues
      emerge, and health institutions face dilemmas such as: "How many beds should an
      ICU provide to serve the population, at the lowest costs" and "Which is the most 
      critical body information to monitor in an ICU?". Due to financial and ethical
      implications, these judgments require technical and precise knowledge. Decisions 
      have usually relied on clinical scores, like the APACHE (Acute Physiology And
      Chronic Health Evaluation) and SOFA (Sequential Organ Failure Assessment) scores,
      which are imprecise and outdated. The popularization of machine learning
      techniques has shed some light on the topic as a way to renew score purposes. In 
      2012, the PhysioNet/Computing in Cardiology launched the Challenge - ICU
      Patients. This Challenge aimed to stimulate the development of techniques to
      predict mortality in ICUs. Based on biometric and physiological features
      collected from patients, the participants predicted the patient's death risk by
      using their classifiers. Several participants achieved results that were better
      than the results produced by the SOFA and the APACHE scores; the prediction
      levels were approximately 54%, which is weak. OBJECTIVES: Here, we investigate
      the reasons that led to these results as a means to ground our solution. Then, we
      propose alternative practices in an attempt to improve the results. Our main goal
      is to improve the prediction of mortality in ICUs by using the same data employed
      during the 2012 PhysioNet Challenge. Our specific objectives are (i) to simplify 
      the problem by reducing the dimensionality; (ii) to reduce the uncontrolled
      variance, and (iii) to make classifiers less dependent on the training set.
      METHODS: Accordingly, we propose a methodology based on extensive steps,
      including sample filter and data normalization. To select features and to reduce 
      the intra-group variance, we employ multivariate data analysis by using Principal
      Component Analysis, Factor Analysis, Spectral Clustering, and Tukey's HSD Test,
      recursively. After that, we use machine learning techniques to create classifiers
      according to different methods. We evaluate our results with the same metrics
      proposed by the 2012 PhysioNet Challenge. RESULTS: For classifiers constructed
      and tested by using independent datasets, our best classifier was a linear SVM,
      which provided results of approximately 0.73. These results were significantly
      better than the approximately 0.54 achieved in previous work at >99% confidence
      interval. Furthermore, our approach only demanded twelve features, which was
      consistently smaller than the number of features required by the previous
      approaches. CONCLUSION: Our results indicated that our approach presented: (a)
      higher performance to predict death risks (+20%); (b) smaller dependence on the
      training set; and (c) lower costs for ICU monitoring (few features). Besides the 
      better prediction power, our approach also demanded lower costs for
      implementation and a more extensive range of potential ICUs. Future studies
      should employ our proposal to investigate the possibility of including some
      physiological features that were not available for the 2012 PhysioNet Challenge.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Monteiro, Flavio
AU  - Monteiro F
AD  - Department of Computer Science and Mathematics, Faculty of Philosophy, Sciences
      and Languages at Ribeirao Preto (FFCLRP), University of Sao Paulo (USP), Av.
      Bandeirantes, 3900, Ribeirao Preto, SP 14040-901, Brazil. Electronic address:
      flavio.monteiro@usp.br.
FAU - Meloni, Fernando
AU  - Meloni F
AD  - Department of Computer Science and Mathematics, Faculty of Philosophy, Sciences
      and Languages at Ribeirao Preto (FFCLRP), University of Sao Paulo (USP), Av.
      Bandeirantes, 3900, Ribeirao Preto, SP 14040-901, Brazil; Department of Physics, 
      FFCLRP, University of Sao Paulo, Brazil. Electronic address:
      fernandomeloni@usp.br.
FAU - Baranauskas, Jose Augusto
AU  - Baranauskas JA
AD  - Department of Computer Science and Mathematics, Faculty of Philosophy, Sciences
      and Languages at Ribeirao Preto (FFCLRP), University of Sao Paulo (USP), Av.
      Bandeirantes, 3900, Ribeirao Preto, SP 14040-901, Brazil. Electronic address:
      augusto@usp.br.
FAU - Macedo, Alessandra Alaniz
AU  - Macedo AA
AD  - Department of Computer Science and Mathematics, Faculty of Philosophy, Sciences
      and Languages at Ribeirao Preto (FFCLRP), University of Sao Paulo (USP), Av.
      Bandeirantes, 3900, Ribeirao Preto, SP 14040-901, Brazil. Electronic address:
      ale.alaniz@usp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200523
PL  - United States
TA  - J Biomed Inform
JT  - Journal of biomedical informatics
JID - 100970413
SB  - IM
MH  - APACHE
MH  - Hospital Mortality
MH  - Humans
MH  - *Intensive Care Units
MH  - *Machine Learning
MH  - Vital Signs
OTO - NOTNLM
OT  - *Clinical Decision Support
OT  - *Critical care
OT  - *Intensive Care Units
OT  - *Machine learning
OT  - *Mortality prediction
OT  - *Multivariate Data Analysis
COIS- Declaration of Competing Interest None.
EDAT- 2020/05/27 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/03/01 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - S1532-0464(20)30084-8 [pii]
AID - 10.1016/j.jbi.2020.103456 [doi]
PST - ppublish
SO  - J Biomed Inform. 2020 Jul;107:103456. doi: 10.1016/j.jbi.2020.103456. Epub 2020
      May 23.


PMID- 32454041
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20210110
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
VI  - 73
IP  - 4
DP  - 2020 Oct
TI  - An international multicenter study of protocols for liver transplantation during 
      a pandemic: A case for quadripartite equipoise.
PG  - 873-881
LID - S0168-8278(20)30342-1 [pii]
LID - 10.1016/j.jhep.2020.05.023 [doi]
AB  - BACKGROUND & AIMS: The outbreak of COVID-19 has vastly increased the operational 
      burden on healthcare systems worldwide. For patients with end-stage liver
      failure, liver transplantation is the only option. However, the strain on
      intensive care facilities caused by the pandemic is a major concern. There is an 
      urgent need for ethical frameworks to balance the need for liver transplantation 
      against the availability of national resources. METHODS: We performed an
      international multicenter study of transplant centers to understand the evolution
      of policies for transplant prioritization in response to the pandemic in March
      2020. To describe the ethical tension arising in this setting, we propose a novel
      ethical framework, the quadripartite equipoise (QE) score, that is applicable to 
      liver transplantation in the context of limited national resources. RESULTS:
      Seventeen large- and medium-sized liver transplant centers from 12 countries
      across 4 continents participated. Ten centers opted to limit transplant activity 
      in response to the pandemic, favoring a "sickest-first" approach. Conversely,
      some larger centers opted to continue routine transplant activity in order to
      balance waiting list mortality. To model these and other ethical tensions, we
      computed a QE score using 4 factors - recipient outcome, donor/graft safety,
      waiting list mortality and healthcare resources - for 7 countries. The
      fluctuation of the QE score over time accurately reflects the dynamic changes in 
      the ethical tensions surrounding transplant activity in a pandemic. CONCLUSIONS: 
      This four-dimensional model of quadripartite equipoise addresses the ethical
      tensions in the current pandemic. It serves as a universally applicable framework
      to guide regulation of transplant activity in response to the increasing burden
      on healthcare systems. LAY SUMMARY: There is an urgent need for ethical
      frameworks to balance the need for liver transplantation against the availability
      of national resources during the COVID-19 pandemic. We describe a
      four-dimensional model of quadripartite equipoise that models these ethical
      tensions and can guide the regulation of transplant activity in response to the
      increasing burden on healthcare systems.
CI  - Copyright (c) 2020 European Association for the Study of the Liver. Published by 
      Elsevier B.V. All rights reserved.
FAU - Chew, Claire Alexandra
AU  - Chew CA
AD  - National University Hospital, Singapore.
FAU - Iyer, Shridhar Ganpathi
AU  - Iyer SG
AD  - National University Hospital, Singapore.
FAU - Kow, Alfred Wei Chieh
AU  - Kow AWC
AD  - National University Hospital, Singapore.
FAU - Madhavan, Krishnakumar
AU  - Madhavan K
AD  - National University Hospital, Singapore.
FAU - Wong, Andrea Sze Teng
AU  - Wong AST
AD  - Architectural Association School of Architecture, London, United Kingdom.
FAU - Halazun, Karim J
AU  - Halazun KJ
AD  - Weill Cornell Medicine, New York, United States.
FAU - Battula, Narendra
AU  - Battula N
AD  - University of Florida Health, Florida, United States.
FAU - Scalera, Irene
AU  - Scalera I
AD  - Cardarelli Hospital, Naples, Italy.
FAU - Angelico, Roberta
AU  - Angelico R
AD  - University of Rome Tor Vegata, Rome, Italy.
FAU - Farid, Shahid
AU  - Farid S
AD  - St James University Hospital, Leeds, United Kingdom.
FAU - Buchholz, Bettina M
AU  - Buchholz BM
AD  - University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Rotellar, Fernando
AU  - Rotellar F
AD  - Clinica Universidad de Navarra, Pamplona, Spain.
FAU - Chan, Albert Chi-Yan
AU  - Chan AC
AD  - Queen Mary Hospital, Hong Kong.
FAU - Kim, Jong Man
AU  - Kim JM
AD  - Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
FAU - Wang, Chih-Chi
AU  - Wang CC
AD  - Kaohsiung Chang Gung Memorial Hospital, Taiwan.
FAU - Pitchaimuthu, Maheswaran
AU  - Pitchaimuthu M
AD  - Kovai Medical Center and Hospital, Coimbatore, India.
FAU - Reddy, Mettu Srinivas
AU  - Reddy MS
AD  - Dr. Rela Institute & Medical Centre, Chennai, India.
FAU - Soin, Arvinder Singh
AU  - Soin AS
AD  - Medanta the Medicity, Gurgaon, India.
FAU - Derosas, Carlos
AU  - Derosas C
AD  - Clinica Santa Maria, Chile.
FAU - Imventarza, Oscar
AU  - Imventarza O
AD  - Hospital Argerich, Buenos Aires, Argentina; Hospital Garrahan, Buenos Aires,
      Argentina.
FAU - Isaac, John
AU  - Isaac J
AD  - University Hospitals Birmingham, Birmingham, United Kingdom.
FAU - Muiesan, Paolo
AU  - Muiesan P
AD  - University Hospitals Birmingham, Birmingham, United Kingdom.
FAU - Mirza, Darius F
AU  - Mirza DF
AD  - University Hospitals Birmingham, Birmingham, United Kingdom.
FAU - Bonney, Glenn Kunnath
AU  - Bonney GK
AD  - National University Hospital, Singapore; SurgiCAL ProtEomics Laboratory, National
      University of Singapore, Singapore. Electronic address: glenn_bonney@nuhs.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200523
PL  - Netherlands
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - *End Stage Liver Disease/mortality/surgery
MH  - Health Resources/*trends
MH  - Humans
MH  - International Cooperation
MH  - *Liver Transplantation/ethics/methods
MH  - Organizational Innovation
MH  - *Pandemics/ethics/prevention & control
MH  - Patient Selection/ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - *Tissue and Organ Procurement/ethics/organization & administration/trends
MH  - Waiting Lists/mortality
PMC - PMC7245234
OTO - NOTNLM
OT  - *COVID-19
OT  - *Equipoise
OT  - *Ethics
OT  - *Liver transplantation
COIS- Conflict of interest The authors declare no conflicts of interest that pertain to
      this work. Please refer to the accompanying ICMJE disclosure forms for further
      details.
EDAT- 2020/05/27 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/19 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - S0168-8278(20)30342-1 [pii]
AID - 10.1016/j.jhep.2020.05.023 [doi]
PST - ppublish
SO  - J Hepatol. 2020 Oct;73(4):873-881. doi: 10.1016/j.jhep.2020.05.023. Epub 2020 May
      23.


PMID- 32453062
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 1465-7309 (Electronic)
IS  - 1067-3229 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Sep/Oct
TI  - Teaching Ethics in Psychiatry: Time to Reset.
PG  - 328-333
LID - 10.1097/HRP.0000000000000258 [doi]
FAU - Scher, Stephen
AU  - Scher S
AD  - From Harvard Medical School (Dr. Scher); McLean Hospital, Belmont, MA (Dr.
      Scher); Disciplines of Psychiatry (Drs. Scher and Kozlowska) and of Child and
      Adolescent Health (Dr. Kozlowska), University of Sydney Medical School; The
      Children's Hospital at Westmead, Westmead, New South Wales (Dr. Kozlowska); Brain
      Dynamics Centre, Westmead Institute for Medical Research, Westmead, New South
      Wales (Dr. Kozlowska).
FAU - Kozlowska, Kasia
AU  - Kozlowska K
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Harv Rev Psychiatry
JT  - Harvard review of psychiatry
JID - 9312789
SB  - IM
MH  - *Ethics, Clinical
MH  - Ethics, Medical/*education
MH  - Humans
MH  - *Internship and Residency
MH  - Moral Development
MH  - Psychiatry/*education
MH  - Teaching
PMC - PMC7526563
EDAT- 2020/05/27 06:00
MHDA- 2021/10/02 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1097/HRP.0000000000000258 [doi]
PST - ppublish
SO  - Harv Rev Psychiatry. 2020 Sep/Oct;28(5):328-333. doi:
      10.1097/HRP.0000000000000258.


PMID- 32452940
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20210213
IS  - 1932-8095 (Electronic)
IS  - 1932-8087 (Linking)
VI  - 25
IP  - 5
DP  - 2020 Sep/Oct
TI  - Essential Case Management Practices Amidst the Novel Coronavirus Disease 2019
      (COVID-19) Crisis: Part 2: End-of-Life Care, Workers' Compensation Case
      Management, Legal and Ethical Obligations, Remote Practice, and Resilience.
PG  - 267-284
LID - 10.1097/NCM.0000000000000455 [doi]
AB  - OBJECTIVES: This is the second of a 2-part article that discusses essential case 
      management practices and strategies amidst the novel coronavirus disease 2019
      (COVID-19). The series showcases the potential professional case managers have in
      support of managing during a crisis such as a global pandemic. Part II continues 
      to describe reenvisioned roles and responsibilities of case managers and their
      leaders to meet the needs of patients/support systems during the crisis. It
      focuses on the increased need for end-of-life care, impact on workers'
      compensation case management practice, and the self-care needs of the
      professional case manager. PRIMARY PRACTICE SETTINGS: Applicable to the various
      case management practice settings across the continuum of health and human
      services, with special focus on acute care. FINDINGS/CONCLUSIONS: The COVID-19
      global pandemic has resulted in a crisis case managers and other health care
      professionals never faced something like it before. At the same time, it has
      provided opportunities for innovation and creativity including use of digital and
      telecommunication technology in new ways to ensure the continued delivery of
      health and human services to those who need them regardless of location. It has
      also resulted in the development of necessary and impactful partnerships within
      and across different health care organizations and diverse professional
      disciplines. Most importantly, this pandemic has required special attention to
      the increased need of patients for timely palliative and end-of-life care. In
      addition, it has prompted a focus on the safety, health, and well-being of case
      managers and other health care professionals, resulting in expanded workers'
      compensation case management practice coupled with the need for self-care and
      resilience. IMPLICATIONS FOR CASE MANAGEMENT PRACTICE: Professional case managers
      are integral members of interprofessional health care teams. Their roles and
      responsibilities are even more necessary during the uncertainty of a global
      pandemic such as COVID-19. So far, the experience of this crisis has resulted in 
      a deliberate need to ensure the safety of both, those who are the recipients of
      health care services and those who are responsible for the provision of care.
      Self-care and resilience of health care professionals and case managers,
      especially due to the complex dynamics of the COVID-19 pandemic, have advanced a 
      desirable and necessary view of remote/virtual practice and as a strategy for
      enhancing the person's health and well-being. This pandemic has forced the
      development of impactful partnerships and collaborations among the diverse
      contexts of health care organizations and support service providers. These
      contexts of care delivery have also emphasized the necessary legal and ethical
      practice of case managers and the other involved parties. Experts agree that the 
      innovative care delivery methods practiced during the pandemic will undoubtedly
      remain as desirable beyond the current crisis period.
FAU - Tahan, Hussein M
AU  - Tahan HM
AD  - Hussein M. Tahan, PhD, RN, FAAN, is a case management consultant, expert, author,
      and researcher. Dr. Tahan has nearly 30 years of experience in hospital
      management and operations and professional case management practice; is a member 
      of the editorial advisory board of Professional Case Management; author of
      multiple textbooks, including the CMSA's Core Curriculum for Case Management and 
      Case Management: A Practical Guide for Education and Practice; is the chief
      knowledge editor of the Case Management Body of Knowledge online portal sponsored
      by the Commission for Case Manager Certification; and the recipient of CMSA's
      2016 Lifetime Achievement Award for his contributions to the field of case
      management.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prof Case Manag
JT  - Professional case management
JID - 101291585
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - *Case Management
MH  - Coronavirus Infections/epidemiology/*therapy/virology
MH  - Humans
MH  - Incidence
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy/virology
MH  - *Resilience, Psychological
MH  - SARS-CoV-2
MH  - *Terminal Care/ethics
MH  - United States/epidemiology
MH  - *Workers' Compensation/ethics
PMC - PMC7297075
EDAT- 2020/05/27 06:00
MHDA- 2020/08/22 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1097/NCM.0000000000000455 [doi]
AID - 01269241-202009000-00004 [pii]
PST - ppublish
SO  - Prof Case Manag. 2020 Sep/Oct;25(5):267-284. doi: 10.1097/NCM.0000000000000455.


PMID- 32452809
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 5
DP  - 2020 May 26
TI  - Exploring the Characteristics and Behaviors of Nurses Who Have Attained
      Microcelebrity Status on Instagram: Content Analysis.
PG  - e16540
LID - 10.2196/16540 [doi]
AB  - BACKGROUND: Instagram is a social media platform that enables users to share
      images and videos worldwide. Some nurses have used Instagram to document their
      experiences as a nurse and have subsequently gained microcelebrity status-that
      is, a user who purposefully seeks to amass a substantive Web-based following and 
      has become recognized as a niche area of interest. OBJECTIVE: This study aimed to
      identify the characteristics and behaviors of microcelebrity nurses who act as
      influencers on Instagram and use their nursing profile to gain attention and
      presence on the Web. METHODS: A qualitative, exploratory, nonparticipatory
      content analysis of media and text generated by a purposeful sample of 10
      registered nurses who use Instagram and sustain a definable microcelebrity status
      was conducted. In this study, manifest and latent data were examined to gain an
      understanding of the characteristics and behaviors of nurses who have attained
      microcelebrity status on Instagram. RESULTS: Data analysis revealed 5 themes of
      Instagram posts: (1) engaging Instagram users, (2) educational opportunities and 
      insights, (3) nursing-related humor, (4) emotions experienced by nurses, and (5) 
      media and narratives including patient details or work context. Messages were
      primarily positive in nature; however, multiple potential privacy, ethical, and
      professional issues were noted throughout the posted content. CONCLUSIONS: The
      findings of this study help to expand the current knowledge related to the use of
      social media platforms such as Instagram, especially in regard to the emergence
      of nurses who use this form of technology to achieve or maintain a microcelebrity
      status. This study calls for additional research on nurses' attainment of
      microcelebrity status on social media as well as further policy development to
      adequately prepare nurses to navigate social media.
CI  - (c)Hanna Kerr, Richard Booth, Kimberley Jackson. Originally published in the
      Journal of Medical Internet Research (http://www.jmir.org), 26.05.2020.
FAU - Kerr, Hanna
AU  - Kerr H
AUID- ORCID: 0000-0001-6894-1761
AD  - Western University, London, ON, Canada.
FAU - Booth, Richard
AU  - Booth R
AUID- ORCID: 0000-0002-0300-9954
AD  - Western University, London, ON, Canada.
FAU - Jackson, Kimberley
AU  - Jackson K
AUID- ORCID: 0000-0002-6541-6213
AD  - Western University, London, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Humans
MH  - Nurses/*psychology
MH  - Social Media/*standards
PMC - PMC7284411
OTO - NOTNLM
OT  - *Instagram
OT  - *influencer
OT  - *microcelebrity
OT  - *nursing
OT  - *policy
OT  - *professionalism
OT  - *social media
EDAT- 2020/05/27 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/02/04 00:00 [revised]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
AID - v22i5e16540 [pii]
AID - 10.2196/16540 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 May 26;22(5):e16540. doi: 10.2196/16540.


PMID- 32452703
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1473-0804 (Electronic)
IS  - 1369-7137 (Linking)
VI  - 23
IP  - 5
DP  - 2020 Oct
TI  - When you are making plans to publish research, you need to plan for data sharing.
PG  - 466-467
LID - 10.1080/13697137.2020.1771302 [doi]
AB  - Open data is another step on the pathway of strengthening medical research.
      Allowing access to data facilitates testing the reproducibility of research
      findings. It also allows for the testing of new hypotheses, the incorporation of 
      individual level data into meta-analyses and the development of very large data
      sets in which to develop and test new algorithms. There are now many data
      repositories that researchers can use to share their protocols, syntax and data. 
      There are strategies both for managing what other researchers do with publically 
      available data and for rewarding researchers who share their data. There is a
      strong ethical argument for making data publically available and research
      participants are generally supportive of this approach.
FAU - Bell, R J
AU  - Bell RJ
AUID- ORCID: 0000-0003-1935-7627
AD  - Women's Health Research Program, School of Public Health and Preventive Medicine,
      Monash University, Melbourne, Victoria, Australia.
FAU - Haring, R
AU  - Haring R
AUID- ORCID: 0000-0002-8332-5016
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Victoria, Australia.
AD  - Faculty of Applied Public Health, European University of Applied Sciences,
      Rostock, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - England
TA  - Climacteric
JT  - Climacteric : the journal of the International Menopause Society
JID - 9810959
SB  - IM
MH  - Biomedical Research/*ethics
MH  - *Ethics, Research
MH  - Humans
MH  - Information Dissemination/*ethics/methods
MH  - Publishing/*ethics
OTO - NOTNLM
OT  - *Open data
OT  - *data sharing
EDAT- 2020/05/27 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1080/13697137.2020.1771302 [doi]
PST - ppublish
SO  - Climacteric. 2020 Oct;23(5):466-467. doi: 10.1080/13697137.2020.1771302. Epub
      2020 May 26.


PMID- 32452668
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2379-3694 (Electronic)
IS  - 2379-3694 (Linking)
VI  - 5
IP  - 6
DP  - 2020 Jun 26
TI  - Paper-Based Analytical Device for Real-Time Monitoring of Egg Hatching in the
      Model Nematode Caenorhabditis elegans.
PG  - 1750-1757
LID - 10.1021/acssensors.0c00412 [doi]
AB  - Caenorhabditis elegans is an in vivo model known for its easy handling and
      maintenance and lack of associated ethical issues. The release of chitinase can
      be used to monitor the egg-laying stage in C. elegans. The aim of this study was 
      to develop a simple and cost-effective device to monitor the activity of
      chitinase in embryos of C. elegans. Colloid chitin azure (CCA), a substrate for
      chitinase, was preimmobilized on the detection area of paper, forming a purple
      region, to generate a CCA paper-based analytical device (CCA-PAD). The
      degradation of CCA by chitinase could be observed as the purple color became
      faint and the filter paper eventually became colorless. Under the optimum
      conditions, the proposed device quantified the chitinase enzyme in the range of
      15.625-125 mU/mL within 48 h (R(2) = 0.993). In this work, 10 young adult-staged 
      wild-type C. elegans (Bristol N2) worms were analyzed on the CCA-PAD, which was
      supplemented with the laboratory food source E. coli OP50 on a gauze layer. The
      same strain treated with 5-fluoro-2'-deoxyuridine was used to prevent egg
      production in C. elegans. A significant difference in the color intensity was
      observed between these two groups at the end of the experiment (P = <0.001,
      independent t-test, n = 3). We successfully developed a simple and effective
      method for monitoring chitinase activity. The device may have potential
      applications in drug-screening studies as it efficiently distinguishes drugs that
      can impact egg laying.
FAU - Noiphung, Julaluk
AU  - Noiphung J
AD  - Department of Clinical Chemistry, Faculty of Allied Health Sciences,
      Chulalongkorn University, Bangkok 10330, Thailand.
AD  - Biosensors and Bioanalytical Technology for Cells and Innovative Testing Device
      Research Unit, Department of Clinical Chemistry, Faculty of Allied Health
      Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
FAU - Prasanth, Mani Iyer
AU  - Prasanth MI
AD  - Department of Clinical Chemistry, Faculty of Allied Health Sciences,
      Chulalongkorn University, Bangkok 10330, Thailand.
AD  - Age-Related Inflammation and Degeneration Research Unit, Department of Clinical
      Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok
      10330, Thailand.
FAU - Tencomnao, Tewin
AU  - Tencomnao T
AD  - Department of Clinical Chemistry, Faculty of Allied Health Sciences,
      Chulalongkorn University, Bangkok 10330, Thailand.
AD  - Age-Related Inflammation and Degeneration Research Unit, Department of Clinical
      Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok
      10330, Thailand.
FAU - Laiwattanapaisal, Wanida
AU  - Laiwattanapaisal W
AUID- ORCID: 0000-0002-8331-021X
AD  - Department of Clinical Chemistry, Faculty of Allied Health Sciences,
      Chulalongkorn University, Bangkok 10330, Thailand.
AD  - Biosensors and Bioanalytical Technology for Cells and Innovative Testing Device
      Research Unit, Department of Clinical Chemistry, Faculty of Allied Health
      Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200608
PL  - United States
TA  - ACS Sens
JT  - ACS sensors
JID - 101669031
SB  - IM
MH  - Animals
MH  - *Caenorhabditis elegans
MH  - Drug Evaluation, Preclinical
MH  - Escherichia coli
MH  - *Nematoda
OTO - NOTNLM
OT  - *C. elegans
OT  - *colloid chitin azure
OT  - *egg hatching
OT  - *gauze layer
OT  - *paper-based devices
EDAT- 2020/05/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1021/acssensors.0c00412 [doi]
PST - ppublish
SO  - ACS Sens. 2020 Jun 26;5(6):1750-1757. doi: 10.1021/acssensors.0c00412. Epub 2020 
      Jun 8.


PMID- 32452446
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1878-7487 (Electronic)
IS  - 1752-928X (Linking)
VI  - 72
DP  - 2020 May
TI  - Statement on conversion therapy.
PG  - 101930
LID - S1752-928X(20)30036-6 [pii]
LID - 10.1016/j.jflm.2020.101930 [doi]
AB  - Conversion therapy is a set of practices that aim to change or alter an
      individual's sexual orientation or gender identity. It is practiced in every
      region of the world by health professionals, religious practitioners, and
      community or family members often by or with the support of the state. Conversion
      therapy is performed despite evidence that it is ineffective and likely to cause 
      individuals significant or severe physical and mental pain and suffering with
      long-term harmful effects. The purpose of this medico-legal statement is to
      provide legal experts, adjudicators, health care professionals, and policy
      makers, among others, with an understanding of: 1) the lack of medical and
      scientific validity of conversion therapy; 2) the likely physical and
      psychological consequences of undergoing conversion therapy; and 3) whether,
      based on these effects, conversion therapy constitutes cruel, inhuman, or
      degrading treatment or torture when individuals are subjected to it forcibly or
      without their consent. This medico-legal statement also addresses the
      responsibility of states in regulating the practice, the ethical implications of 
      offering or performing it, and the role that health professionals and medical and
      mental health organisations should play with regards to it.
CI  - Copyright (c) 2020 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All
      rights reserved.
CN  - Independent Forensic Expert Group
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200219
PL  - England
TA  - J Forensic Leg Med
JT  - Journal of forensic and legal medicine
JID - 101300022
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antipsychotic Agents)
SB  - IM
MH  - Antidepressive Agents/adverse effects
MH  - Antipsychotic Agents/adverse effects
MH  - *Gender Identity
MH  - Health Personnel/ethics
MH  - *Homosexuality
MH  - Human Rights
MH  - Humans
MH  - Professional Role
MH  - Psychotherapy/*ethics
MH  - Punishment
MH  - Torture
MH  - United Nations
OTO - NOTNLM
OT  - Child abuse and neglect
OT  - Conversion therapy
OT  - Fraud
OT  - Medical ethics
OT  - Psychotherapy
OT  - Sexual orientation and gender identity
OT  - Torture and ill-treatment
COIS- Declaration of competing interest None to declare.
IR  - Alempijevic D
FIR - Alempijevic, Djordje
IR  - Beriashvili R
FIR - Beriashvili, Rusudan
IR  - Beynon J
FIR - Beynon, Jonathan
IR  - Birmanns B
FIR - Birmanns, Bettina
IR  - Brasholt M
FIR - Brasholt, Marie
IR  - Cohen J
FIR - Cohen, Juliet
IR  - Duque M
FIR - Duque, Maximo
IR  - Duterte P
FIR - Duterte, Pierre
IR  - van Es A
FIR - van Es, Adriaan
IR  - Fernando R
FIR - Fernando, Ravindra
IR  - Fincanci SK
FIR - Fincanci, Sebnem Korur
IR  - Hamzeh S
FIR - Hamzeh, Sana
IR  - Hansen SH
FIR - Hansen, Steen Holger
IR  - Hardi L
FIR - Hardi, Lilla
IR  - Heisler M
FIR - Heisler, Michele
IR  - Iacopino V
FIR - Iacopino, Vincent
IR  - Leth PM
FIR - Leth, Peter Mygind
IR  - Lin J
FIR - Lin, James
IR  - Louahlia S
FIR - Louahlia, Said
IR  - Luytkis H
FIR - Luytkis, Hege
IR  - Modvig J
FIR - Modvig, Jens
IR  - Morcillo Mendez MD
FIR - Morcillo Mendez, Maria-Dolores
IR  - Moreno A
FIR - Moreno, Alejandro
IR  - Moscoso V
FIR - Moscoso, Valeria
IR  - Oral R
FIR - Oral, Resmiye
IR  - Ozkalipci O
FIR - Ozkalipci, Onder
IR  - Payne-James J
FIR - Payne-James, Jason
IR  - Quiroga J
FIR - Quiroga, Jose
IR  - Reyes H
FIR - Reyes, Hernan
IR  - Rogde S
FIR - Rogde, Sidsel
IR  - Sajantila A
FIR - Sajantila, Antti
IR  - Schick M
FIR - Schick, Matthis
IR  - Terzidis A
FIR - Terzidis, Agis
IR  - Thomsen JL
FIR - Thomsen, Jorgen Lange
IR  - Tidball-Binz M
FIR - Tidball-Binz, Morris
IR  - Treue F
FIR - Treue, Felicitas
IR  - Vanezis P
FIR - Vanezis, Peter
IR  - Viera DN
FIR - Viera, Duarte Nuno
EDAT- 2020/05/27 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - S1752-928X(20)30036-6 [pii]
AID - 10.1016/j.jflm.2020.101930 [doi]
PST - ppublish
SO  - J Forensic Leg Med. 2020 May;72:101930. doi: 10.1016/j.jflm.2020.101930. Epub
      2020 Feb 19.


PMID- 32452294
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1477-030X (Electronic)
IS  - 0269-2163 (Linking)
VI  - 34
IP  - 7
DP  - 2020 Jul
TI  - Nursing competencies across different levels of palliative care provision: A
      systematic integrative review with thematic synthesis.
PG  - 851-870
LID - 10.1177/0269216320918798 [doi]
AB  - BACKGROUND: Palliative care exists in diverse healthcare settings. Nurses play a 
      crucial role in its provision. Different levels of palliative care provision and 
      education have been recognized in the literature. Therefore, nurses need a set of
      various competencies to provide high-quality palliative care. AIMS: To
      systematically synthesize the empirical evidence of (1) nursing competencies
      needed in palliative care and (2) whether these competencies differ across the
      level of palliative care. DESIGN: Systematic integrative review with thematic
      synthesis. Prospero: CRD42018114869. DATA SOURCES: CINAHL, PubMed, Academic
      Search Premier, Scopus and Medic databases. Studies on nursing competencies
      linked to palliative care reported in English, Swedish, Finnish, Spanish,
      Portuguese or German were considered. Search terms: 'palliative care or hospice
      care or end-of-life care', 'competency or professional competence or skills' and 
      'nursing'. Articles were independently screened and reviewed by two researchers. 
      Quality appraisal was conducted following Hawker's criteria. RESULTS: A total of 
      7454 articles were retrieved, 21 articles were included in the analysis. Six
      diverse nursing competencies dimensions, namely leadership, communication,
      collaboration, clinical, ethico-legal and psycho-social and spiritual were
      identified. The reports rarely defined the level of palliative care and covered a
      wide array of healthcare settings. CONCLUSION: Nurses need a wide range of
      competencies to provide quality palliative care. Few studies focused on which
      competencies are relevant to a specific level of palliative care. Further
      research is needed to systematize the nursing competencies and define which
      nursing competencies are central for different levels of palliative care to
      enhance palliative care development, education and practice.
FAU - Hokka, Minna
AU  - Hokka M
AUID- ORCID: 0000-0002-3343-4839
AD  - Research Unit of Nursing Science and Health Management, Medical Department, Oulu 
      University, Oulu, Finland.
AD  - School of Health, Kajaani University of Applied Sciences, Kajaani, Finland.
FAU - Martins Pereira, Sandra
AU  - Martins Pereira S
AUID- ORCID: 0000-0003-4113-8957
AD  - CEGE - Research Center in Management and Economics, Catolica Porto Business
      School, Universidade Catolica Portuguesa, Porto, Portugal.
AD  - Instituto de Bioetica, Universidade Catolica Portuguesa, Porto, Portugal.
AD  - UNESCO Chair in Bioethics, Institute of Bioethics, Universidade Catolica
      Portuguesa, Porto, Portugal.
FAU - Polkki, Tarja
AU  - Polkki T
AD  - Department of Children and Women, Oulu University Hospital, Oulu, Finland.
FAU - Kyngas, Helvi
AU  - Kyngas H
AD  - Research Unit of Nursing Science and Health Management, Medical Department, Oulu 
      University, Oulu, Finland.
FAU - Hernandez-Marrero, Pablo
AU  - Hernandez-Marrero P
AUID- ORCID: 0000-0002-8893-3491
AD  - CEGE - Research Center in Management and Economics, Catolica Porto Business
      School, Universidade Catolica Portuguesa, Porto, Portugal.
AD  - Instituto de Bioetica, Universidade Catolica Portuguesa, Porto, Portugal.
AD  - UNESCO Chair in Bioethics, Institute of Bioethics, Universidade Catolica
      Portuguesa, Porto, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200526
PL  - England
TA  - Palliat Med
JT  - Palliative medicine
JID - 8704926
SB  - IM
MH  - Clinical Competence
MH  - *Hospice Care
MH  - Humans
MH  - Leadership
MH  - Palliative Care
MH  - *Terminal Care
OTO - NOTNLM
OT  - *Palliative care
OT  - *competencies
OT  - *nursing
OT  - *professional competence
OT  - *systematic integrative review
EDAT- 2020/05/27 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1177/0269216320918798 [doi]
PST - ppublish
SO  - Palliat Med. 2020 Jul;34(7):851-870. doi: 10.1177/0269216320918798. Epub 2020 May
      26.


PMID- 32452219
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 1753-8564 (Electronic)
IS  - 0073-2753 (Linking)
VI  - 58
IP  - 4
DP  - 2020 Dec
TI  - The scientist and the advertisement: Reklamegutachten in imperial Germany.
PG  - 507-532
LID - 10.1177/0073275320916971 [doi]
AB  - In late nineteenth- and early twentieth-century Germany, the integration of
      product-evaluating certificates and reports (Gutachten) into advertisements
      triggered repeated condemnations of "advertisement-Gutachten" (Reklamegutachten),
      and scientists and science administrators introduced various restrictions to
      prevent the appearance of such documents. At the same time, the provision of
      Gutachten to private individuals and firms seemed crucial to the success of many 
      private and public laboratories. Some chemical and other professionals, moreover,
      argued that the authoring and use of Reklamegutachten could represent a
      "scientific" and, therefore, ethical practice. By examining the contested history
      of the advertisement-Gutachten, this article reveals how a previously tolerated
      knowledge service lost its legitimacy in a particular place and period of time,
      and highlights the challenges of eliminating this practice or restoring its
      legitimacy afterward. The article also explores how professional scientists'
      approaches to maintaining a reputation for integrity in the face of commercial
      and competitive pressures related to the better-known efforts of professionals in
      other fields, particularly the medical. I emphasize that, in determining whether 
      a Gutachten qualified as scientific, the nature and transparency of the
      underlying research process was only one of the criteria that were considered,
      and often not the most significant yardstick. At the same time, however, ideas
      about the personal and professional/institutional integrity of providers of
      Gutachten were inextricably connected with assessments of the honesty and
      objectivity of their research.
FAU - Mercelis, Joris
AU  - Mercelis J
AUID- ORCID: 0000-0002-1368-6086
AD  - Johns Hopkins University, USA.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - United States
TA  - Hist Sci
JT  - History of science
JID - 17340520R
OTO - NOTNLM
OT  - *Gutachten
OT  - *Rudolf Virchow
OT  - *Theobald Werner
OT  - *Verband selbstandiger offentlicher Chemiker Deutschlands
OT  - *advertising
OT  - *analytical and food chemistry
OT  - *imperial Germany
OT  - *professional ethics
OT  - *scientific ethics
OT  - *scientific integrity
EDAT- 2020/05/27 06:00
MHDA- 2020/05/27 06:01
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/05/27 06:01 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1177/0073275320916971 [doi]
PST - ppublish
SO  - Hist Sci. 2020 Dec;58(4):507-532. doi: 10.1177/0073275320916971. Epub 2020 May
      26.


PMID- 32452142
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - National survey of confirmed thromboembolism related to female hormones in Japan.
PG  - 1173-1182
LID - 10.1111/jog.14303 [doi]
AB  - AIM: The aim of this study was to determine the number of thromboembolism
      patients among Japanese users of female hormones. METHODS: A survey of confirmed 
      thromboembolism patients among Japanese users of female hormones was conducted at
      randomly selected hospitals from across Japan. The survey examined six types of
      venous thromboembolism (VTE) and arterial thromboembolism (ATE) in all users of
      female hormones, including women and men: pulmonary embolism (PE), deep vein
      thrombosis (DVT), other venous thrombosis (other VTE), cerebral infarction
      (stroke), myocardial infarction (MI) and other arterial thrombosis (other ATE).
      The survey covered 5 years from 2009 to 2013. This study was approved in an
      ethical review by the Hamamatsu University School of Medicine. RESULTS: The
      overall number of thromboembolism patients over the 5 years was estimated to be
      about 3211. They included 452 patients with PE, 795 with DVT, 157 with other VTE,
      1228 with stroke, 478 with MI and 101 with other ATE. Among the abovementioned
      conditions, detailed information was available for 750 thromboembolism patients
      (645 women and 105 men), including 63 PE, 203 DVT, 159 PE + DVT, 65 other VTE,
      189 stroke, 35 MI, 21 other ATE and 15 other cases. Thromboembolism increased
      year by year. The number of VTE was larger than that of ATE in younger people who
      used female hormones, while the number of ATE was larger than that of VTE in
      older people who used female hormones. CONCLUSION: The number and characteristics
      of thromboembolism patients among Japanese female hormone users were revealed in 
      this national survey.
CI  - (c) 2020 Japan Society of Obstetrics and Gynecology.
FAU - Sugiura, Kazuko
AU  - Sugiura K
AD  - Department of Reproductive Health Nursing/Midwifery, Nagoya City University
      Graduate School of Nursing, Nagoya, Japan.
FAU - Kobayashi, Takao
AU  - Kobayashi T
AD  - Department of Obstetrics and Gynecology, Hamamatsu Medical Center, Hamamatsu,
      Japan.
FAU - Ojima, Toshiyuki
AU  - Ojima T
AD  - Department of Community Health and Preventive Medicine, Hamamatsu University
      School of Medicine, Hamamatsu, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (Hormones)
SB  - IM
MH  - Aged
MH  - Female
MH  - Hormones
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - *Pulmonary Embolism/epidemiology
MH  - Risk Factors
MH  - *Venous Thromboembolism/epidemiology
MH  - *Venous Thrombosis
OTO - NOTNLM
OT  - arterial thromboembolism
OT  - female hormones
OT  - national survey
OT  - venous thromboembolism
EDAT- 2020/05/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1111/jog.14303 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2020 Jul;46(7):1173-1182. doi: 10.1111/jog.14303. Epub
      2020 May 25.


PMID- 32452067
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1369-7625 (Electronic)
IS  - 1369-6513 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Aug
TI  - Engagement of community stakeholders to develop a framework to guide research
      dissemination to communities.
PG  - 958-968
LID - 10.1111/hex.13076 [doi]
AB  - BACKGROUND: Dissemination of research findings to past study participants and the
      community-at-large is important. Yet, a standardized process for research
      dissemination is needed to report results to the community. OBJECTIVE: We
      developed a framework and strategies to guide community-academic partnerships in 
      community-targeted, dissemination efforts. METHODS: From 2017 to 2019, a
      community-academic partnership was formed in Nashville, Tennessee, and
      iteratively developed a framework and strategies for research dissemination using
      cognitive interviews. A deductive, constant comparative analysis was conducted on
      interview responses to examine framework and strategy content. Feedback was used 
      to finalize the framework and strategies for the evaluation. Using existing data,
      the framework's utility was evaluated in seven town hall meetings (n = 117).
      Bivariate analyses determined its effect on community members' trust and
      willingness to participate in research using pre- and post-surveys. Evaluation
      results were used to finalize the framework. RESULTS: The Community-Engaged
      Research Dissemination (CERD) framework has two phases. Phase one is a
      preliminary planning phase with two steps, and phase two is the four-step
      dissemination process. There are five standards to be upheld conducting these
      phases. We provide competencies for each component. Three feasible, culturally
      adapted strategies were developed as exemplars to disseminate research findings. 
      Using pre- and post-surveys for intervention evaluation, there was a significant 
      difference in trust in medical research and researchers (P = .006) and
      willingness to participate in research (P = .013). DISCUSSION AND CONCLUSION: The
      CERD framework can potentially standardize the process and compare the effect of 
      dissemination efforts on the community's trust and willingness to participate in 
      research.
CI  - (c) 2020 The Authors Health Expectations published by John Wiley & Sons Ltd.
FAU - Cunningham-Erves, Jennifer
AU  - Cunningham-Erves J
AUID- ORCID: 0000-0002-7780-9874
AD  - Department of Internal Medicine, Meharry Medical College, Nashville, TN, USA.
FAU - Mayo-Gamble, Tilicia
AU  - Mayo-Gamble T
AD  - Department of Health Policy and Community Health, Georgia Southern University,
      Statesboro, GA, USA.
FAU - Vaughn, Yolanda
AU  - Vaughn Y
AD  - Neighbor 2 Neighbor, Nashville, TN, USA.
FAU - Hawk, Jim
AU  - Hawk J
AD  - Neighbor 2 Neighbor, Nashville, TN, USA.
FAU - Helms, Mike
AU  - Helms M
AD  - Bridges for the Deaf and Hard of Hearing, Nashville, TN, USA.
FAU - Barajas, Claudia
AU  - Barajas C
AD  - Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
FAU - Joosten, Yvonne
AU  - Joosten Y
AD  - Vanderbilt University Medical Center, Nashville, TN, USA.
LA  - eng
GR  - U54 MD007586/MD/NIMHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200525
PL  - England
TA  - Health Expect
JT  - Health expectations : an international journal of public participation in health 
      care and health policy
JID - 9815926
SB  - IM
MH  - *Biomedical Research
MH  - Humans
MH  - *Research Personnel
MH  - Surveys and Questionnaires
MH  - Trust
PMC - PMC7495063
OTO - NOTNLM
OT  - *communication
OT  - *ethics
OT  - *evidence-based practice
OT  - *information (research) dissemination
OT  - *patient participation
OT  - *research
OT  - *stakeholder participation
EDAT- 2020/05/27 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1111/hex.13076 [doi]
PST - ppublish
SO  - Health Expect. 2020 Aug;23(4):958-968. doi: 10.1111/hex.13076. Epub 2020 May 25.


PMID- 32452052
OWN - NLM
STAT- MEDLINE
DCOM- 20210407
LR  - 20210407
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 235
IP  - 12
DP  - 2020 Dec
TI  - Mesenchymal stromal cells; a new horizon in regenerative medicine.
PG  - 9185-9210
LID - 10.1002/jcp.29803 [doi]
AB  - In recent decades, mesenchymal stromal cells (MSCs) biomedical utilizing has
      attracted worldwide growing attention. After the first report of the human MSCs
      obtaining from the bone marrow (BM) tissue, these cells were isolated from wide
      types of the other tissues, ranging from adipose tissue to dental pulp. Their
      specific characteristics, comprising self-renewality, multipotency, and
      availability accompanied by their immunomodulatory properties and little ethical 
      concern denote their importance in the context of regenerative medicine.
      Considering preclinical studies, MSCs can modify immune reactions during tissue
      repair and restoration, providing suitable milieu for tissue recovery; on the
      other hand, they can be differentiated into comprehensive types of the body
      cells, such as osteoblast, chondrocyte, hepatocyte, cardiomyocyte, fibroblast,
      and neural cells. Though a large number of studies have investigated MSCs
      capacities in regenerative medicine in varied animal models, the oncogenic
      capability of unregulated MSCs differentiation must be more assessed to enable
      their application in the clinic. In the current review, we provide a brief
      overview of MSCs sources, isolation, and expansion as well as immunomodulatory
      activities. More important, we try to collect and discuss recent preclinical and 
      clinical research and evaluate current challenges in the context of the MSC-based
      cell therapy for regenerative medicine.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Tavakoli, Shirin
AU  - Tavakoli S
AD  - Department of Toxicology and Pharmacology, Mazandaran University of Medical
      Sciences, Sari, Iran.
AD  - Department of Tissue Engineering and Applied Cell Sciences, School of Advanced
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Ghaderi Jafarbeigloo, Hamid Reza
AU  - Ghaderi Jafarbeigloo HR
AD  - Department of Basic Science, Payame Noor University, Tehran, Iran.
FAU - Shariati, Ali
AU  - Shariati A
AD  - Department of Tissue Engineering and Applied Cell Sciences, School of Advanced
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Jahangiryan, Afsaneh
AU  - Jahangiryan A
AD  - Immunology Department, Blood Transfusion Research Center, High Institute for
      Research and Education in Transfusion Medicine (IBTO), Tehran, Iran.
FAU - Jadidi, Faezeh
AU  - Jadidi F
AD  - Student Research Committee, Zarand School of Nursing, Kerman University of
      Medical Sciences, Kerman, Iran.
FAU - Jadidi Kouhbanani, Mohammd Amin
AU  - Jadidi Kouhbanani MA
AD  - Department of Medical Nanotechnology, School of Advanced Technologies in
      Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Hassanzadeh, Ali
AU  - Hassanzadeh A
AUID- ORCID: 0000-0002-7530-1145
AD  - Department of Tissue Engineering and Applied Cell Sciences, School of Advanced
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Zamani, Majid
AU  - Zamani M
AD  - Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Gonabad
      University of Medical Sciences, Gonabad, Iran.
FAU - Javidi, Kamran
AU  - Javidi K
AD  - School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
FAU - Naimi, Adel
AU  - Naimi A
AUID- ORCID: 0000-0001-6683-6845
AD  - Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, 
      Sabzevar, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200526
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/*cytology
MH  - Cell Differentiation/physiology
MH  - Cell Proliferation/physiology
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation/methods
MH  - Mesenchymal Stem Cells/*cytology
MH  - *Regenerative Medicine/methods
OTO - NOTNLM
OT  - *cell therapy
OT  - *differentiation
OT  - *mesenchymal stromal cells (MSCs)
OT  - *regenerative medicine
OT  - *sources
EDAT- 2020/05/27 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1002/jcp.29803 [doi]
PST - ppublish
SO  - J Cell Physiol. 2020 Dec;235(12):9185-9210. doi: 10.1002/jcp.29803. Epub 2020 May
      26.


PMID- 32451812
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20210602
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Linking)
VI  - 37
IP  - 6
DP  - 2020 Jun
TI  - In response to the article titled Thoughts on the Ethics of Gestational
      Surrogacy: Perspectives from Religions, Western Liberalism, and Comparisons with 
      Adoption Issue Date: January 2020.
PG  - 1507
LID - 10.1007/s10815-020-01817-3 [doi]
FAU - Shabaik, Salma
AU  - Shabaik S
AUID- ORCID: http://orcid.org/0000-0002-0241-5168
AD  - , Sacramento, CA, USA. sshabaik@gmail.com.
FAU - Nelson, Anita
AU  - Nelson A
AD  - , Sacramento, CA, USA.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200525
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
CON - J Assist Reprod Genet. 2020 Feb;37(2):269-279. PMID: 31897847
MH  - Female
MH  - Humans
MH  - *Politics
MH  - Pregnancy
MH  - Religion
MH  - *Surrogate Mothers
PMC - PMC7311611
EDAT- 2020/05/27 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1007/s10815-020-01817-3 [doi]
AID - 10.1007/s10815-020-01817-3 [pii]
PST - ppublish
SO  - J Assist Reprod Genet. 2020 Jun;37(6):1507. doi: 10.1007/s10815-020-01817-3. Epub
      2020 May 25.


PMID- 32451222
OWN - NLM
STAT- Publisher
LR  - 20200526
IS  - 1873-5134 (Electronic)
IS  - 0738-3991 (Linking)
DP  - 2020 May 15
TI  - Shared decision making and consent post-Montgomery, UK Supreme Court judgement
      supporting best practice.
LID - S0738-3991(20)30283-4 [pii]
LID - 10.1016/j.pec.2020.05.017 [doi]
AB  - The UK Supreme Court Montgomery judgement marks a decisive shift in the legal
      test of duty of care in the context of consent to treatment from the perspective 
      of the clinician (as represented by Bolam rules) to that of the patient. This has
      important implications in the surgical field worldwide, where informed consent is
      critical. This paper aims to explain the ruling and how it impacts the consent
      process. The case and ruling are outlined and summarised as pertaining to consent
      and requirements for validity; a shift from the clinician's interpretation about 
      what would be best for patients to the values of the particular patient concerned
      in the decision in question. A sample of recent commentaries is reviewed. Four
      examples illustrate some of the practical applications of the Montgomery ruling
      on consent and how the ruling can empower doctors and patients to make mutually
      beneficial shared decisions. Future consent should be obtained using a Montgomery
      compliant strategy in accordance with the principles of shared decision making.
CI  - Crown Copyright (c) 2020. Published by Elsevier B.V. All rights reserved.
FAU - Ward, Joel
AU  - Ward J
AD  - Nuffield Department of Surgical Sciences, Oxford University, Oxford OX3 9DU
      United Kingdom. Electronic address: Joel.ward@nds.ox.ac.uk.
FAU - Kalsi, Dilraj
AU  - Kalsi D
AD  - Nuffield Department of Surgical Sciences, Oxford University, Oxford OX3 9DU
      United Kingdom.
FAU - Chandrashekar, Anirudh
AU  - Chandrashekar A
AD  - Nuffield Department of Surgical Sciences, Oxford University, Oxford OX3 9DU
      United Kingdom.
FAU - Fulford, Bill
AU  - Fulford B
AD  - Collaborating Centre for Values Based Practice, St Catherine's College, Oxford
      OX1 3UJ United Kingdom.
FAU - Lee, Regent
AU  - Lee R
AD  - Nuffield Department of Surgical Sciences, Oxford University, Oxford OX3 9DU
      United Kingdom.
FAU - Herring, Jonathan
AU  - Herring J
AD  - Faculty of Law, Oxford University, United Kingdom.
FAU - Handa, Ashok
AU  - Handa A
AD  - Nuffield Department of Surgical Sciences, Oxford University, Oxford OX3 9DU
      United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - Ireland
TA  - Patient Educ Couns
JT  - Patient education and counseling
JID - 8406280
OTO - NOTNLM
OT  - Decision making
OT  - Informed consent
OT  - Medical ethics
EDAT- 2020/05/27 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/11/10 00:00 [received]
PHST- 2020/05/12 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
AID - S0738-3991(20)30283-4 [pii]
AID - 10.1016/j.pec.2020.05.017 [doi]
PST - aheadofprint
SO  - Patient Educ Couns. 2020 May 15. pii: S0738-3991(20)30283-4. doi:
      10.1016/j.pec.2020.05.017.


PMID- 32451008
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1532-8201 (Electronic)
IS  - 0897-1897 (Linking)
VI  - 53
DP  - 2020 Jun
TI  - Pressure ulcers: The challenge of monitoring in hospital context.
PG  - 151266
LID - S0897-1897(19)30819-5 [pii]
LID - 10.1016/j.apnr.2020.151266 [doi]
AB  - AIM: To describe and analyse the PUs problem based on data from hospital
      electronic health records. METHODS: A retrospective cohort descriptive study was 
      performed based on electronic health records (medical and nursing) from adult
      patients (>/=18 years) admitted to medical, surgical and orthopaedics wards
      during 2016 after implementation of National Strategy of Patient Safety
      2015-2020. Ethical approval was obtained. RESULTS: A sample of 3904 patients was 
      obtained, 66% (n = 2575) were older than 65 years, 24.6% (n = 962) at admission
      and 21.2% (n = 829) at discharge stay at high risk of develop PUs and 88.6% (n = 
      3458) has no visual skin assessment. PUs identification, categorization and
      localization are inconsistent between nurses and doctors. CONCLUSION: The
      creation of a unified minimum dataset for PUs monitoring to standardize data on
      the occurrence of PUs and assessed the effectiveness of preventive strategies in 
      patient at risk of PUs development at national level is need. Current Portuguese 
      guideline of PUs needs a review and an innovating upgrade with zero tolerance for
      PUs.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Gaspar, Susana
AU  - Gaspar S
AD  - University of Lisbon, Faculty of Human Kinetics, Aventura Social, Lisbon,
      Portugal; University of Lisbon, Faculty of Medicine, Environmental Health
      Institute (ISAMB), Lisbon, Portugal. Electronic address: smsgaspar@gmail.com.
FAU - Collier, Mark
AU  - Collier M
AD  - University of Lincoln, Lincolnshire, United Kingdom; University of Hertfordshire,
      School of Life and Medical Sciences, Hertforshire, United Kingdom.
FAU - Marques, Adilson
AU  - Marques A
AD  - University of Lisbon, Faculty of Human Kinetics, Aventura Social, Lisbon,
      Portugal; University of Lisbon, Faculty of Medicine, Environmental Health
      Institute (ISAMB), Lisbon, Portugal; University of Lisbon, Faculty of Human
      Kinetics, Interdisciplinary Center for the Study of Human Performance (CIPER),
      Lisbon, Portugal.
FAU - Ferreira, Carlos
AU  - Ferreira C
AD  - University of Lisbon, Faculty of Human Kinetics, Aventura Social, Lisbon,
      Portugal; University of Lisbon, Institute of Education, UIDEF, Lisbon, Portugal.
FAU - Gaspar de Matos, Margarida
AU  - Gaspar de Matos M
AD  - University of Lisbon, Faculty of Human Kinetics, Aventura Social, Lisbon,
      Portugal; University of Lisbon, Faculty of Medicine, Environmental Health
      Institute (ISAMB), Lisbon, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200411
PL  - United States
TA  - Appl Nurs Res
JT  - Applied nursing research : ANR
JID - 8901557
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Care/*standards
MH  - *Practice Guidelines as Topic
MH  - Pressure Ulcer/*diagnosis/*nursing/*prevention & control
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Symptom Assessment/*standards
OTO - NOTNLM
OT  - *Electronic health records
OT  - *Hospital-acquired pressure ulcers
OT  - *Patient safety
OT  - *Pressure injury identification
COIS- Declaration of competing interest All authors declare that they have no conflict 
      of interests.
EDAT- 2020/05/27 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/11/24 00:00 [received]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - S0897-1897(19)30819-5 [pii]
AID - 10.1016/j.apnr.2020.151266 [doi]
PST - ppublish
SO  - Appl Nurs Res. 2020 Jun;53:151266. doi: 10.1016/j.apnr.2020.151266. Epub 2020 Apr
      11.


PMID- 32451004
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1532-8201 (Electronic)
IS  - 0897-1897 (Linking)
VI  - 53
DP  - 2020 Jun
TI  - "A journey towards acceptance": The process of adapting to life with HIV in
      Greece. A Qualitative study.
PG  - 151249
LID - S0897-1897(19)30266-6 [pii]
LID - 10.1016/j.apnr.2020.151249 [doi]
AB  - Aim To identify the experiences related to adaptation for people living with HIV 
      in Greece and to explore different adaptation stages as well as their individual 
      reactions. BACKGROUND: Receiving an HIV positive diagnosis leads to major changes
      in an individual's life and it can trigger an array of emotions including fear,
      despair and loss of control. As the profile of the disease has changed due to its
      transition into a chronic disease and extended life expectancy, adaptation to
      life and coping with uncertain events is of paramount importance. METHOD:
      Interpretative phenomenological research design was used to guide data collection
      and analysis. A purposive sampling technique was used. Ethical procedures were
      taken into account and nine individuals who were diagnosed with HIV took part in 
      the study using semi-structured interviews. RESULTS: Data analysis revealed the
      different stages of adaptation that the participants experienced after an HIV
      positive diagnosis. A superordinate theme identified as 'a journey towards
      acceptance' while five subthemes were formed, namely, 'Communicating the bad
      news, Conscious loneliness, Getting information, Receiving Support, and Moving on
      with hope'. CONCLUSION: An HIV positive diagnosis can affect the very core of the
      individual as the essence of -self- is targeted and in need of reform. Education,
      empathy, family and social support can help the individual make small steps
      towards a greater journey, that of acceptance.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Stroumpouki, Theodora
AU  - Stroumpouki T
AD  - Acute Adult Nursing, Faculty of Health, Social Care and Education, Kingston
      University and St George's, University of London, Kingston Hill Campus, Kingston 
      upon Thames KT2 7LB, United Kingdom. Electronic address:
      t.stroumpouki@sgul.kingston.ac.uk.
FAU - Perrett, Stephanie
AU  - Perrett S
AD  - Health and Justice, Health Protection Team, Public Health Wales, 4th Floor,
      Number 2 Capital Quarter, Tyndall Way, Cardiff CF10 4BZ, United Kingdom.
      Electronic address: stephanie.perrett@wales.nhs.uk.
FAU - Kasdovasilis, Pavlos
AU  - Kasdovasilis P
AD  - Health Psychology, Business Improvement and Research Manager, Rehability UK, 25
      Hatton Place, 118 Midland Rd, Luton, LU2 0FB, United Kingdom.
FAU - Papatheodorou, Panagiotis
AU  - Papatheodorou P
AD  - Health Center of Vamos, Vamos Apokoronou, Crete, GR 73008, Greece.
FAU - Paparizos, Vasilios
AU  - Paparizos V
AD  - HIV/AIDS Unit, 'A. Syggros' Hospital, 5 I. Dragoumi Str., Kessariani 161 21,
      Athens, Greece.
FAU - Stavropoulou, Areti
AU  - Stavropoulou A
AD  - Department of Nursing, University of West Attica, Ag. Spiridonos 28, 12243
      Aegaleo, Greece. Electronic address: astavropoulou@uniwa.gr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200307
PL  - United States
TA  - Appl Nurs Res
JT  - Applied nursing research : ANR
JID - 8901557
SB  - IM
MH  - Activities of Daily Living/*psychology
MH  - *Adaptation, Psychological
MH  - Adult
MH  - *Attitude to Death
MH  - *Attitude to Health
MH  - Female
MH  - Greece
MH  - HIV Infections/*psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - Quality of Life/*psychology
MH  - Young Adult
OTO - NOTNLM
OT  - *Adaptation
OT  - *Lived experience
OT  - *People living with HIV
OT  - *Qualitative study
OT  - *Uncertainty
COIS- Declaration of competing interest None.
EDAT- 2020/05/27 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/04/15 00:00 [received]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
AID - S0897-1897(19)30266-6 [pii]
AID - 10.1016/j.apnr.2020.151249 [doi]
PST - ppublish
SO  - Appl Nurs Res. 2020 Jun;53:151249. doi: 10.1016/j.apnr.2020.151249. Epub 2020 Mar
      7.


PMID- 32450984
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20200717
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 151
IP  - 6
DP  - 2020 Jun
TI  - Ethical considerations when participating in global mission trips before dental
      school.
PG  - 464-466
LID - S0002-8177(20)30121-5 [pii]
LID - 10.1016/j.adaj.2020.02.018 [doi]
FAU - Shick, Elizabeth
AU  - Shick E
FAU - Woodmansey, Karl
AU  - Woodmansey K
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - IM
CIN - J Am Dent Assoc. 2020 Nov;151(11):806-807. PMID: 33121593
CIN - J Am Dent Assoc. 2020 Nov;151(11):808. PMID: 33121596
MH  - *Medical Missions
MH  - *Schools, Dental
EDAT- 2020/05/27 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - S0002-8177(20)30121-5 [pii]
AID - 10.1016/j.adaj.2020.02.018 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2020 Jun;151(6):464-466. doi: 10.1016/j.adaj.2020.02.018.


PMID- 32450919
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20211204
IS  - 1478-4505 (Electronic)
IS  - 1478-4505 (Linking)
VI  - 18
IP  - 1
DP  - 2020 May 25
TI  - A review of reviews on principles, strategies, outcomes and impacts of research
      partnerships approaches: a first step in synthesising the research partnership
      literature.
PG  - 51
LID - 10.1186/s12961-020-0544-9 [doi]
AB  - BACKGROUND: Conducting research in partnership with stakeholders (e.g.
      policy-makers, practitioners, organisations, patients) is a promising and popular
      approach to improving the implementation of research findings in policy and
      practice. This study aimed to identify the principles, strategies, outcomes and
      impacts reported in different types of reviews of research partnerships in order 
      to obtain a better understanding of the scope of the research partnership
      literature. METHODS: This review of reviews is part of a Coordinated Multicenter 
      Team approach to synthesise the research partnership literature with five
      conceptually linked literature reviews. The main research question was 'What
      principles, strategies, outcomes and impacts are reported in different types of
      research partnership approaches?'. We included articles describing a literature
      review of research partnerships using a systematic search strategy. We used an
      adapted version of the Revised Assessment of Multiple Systematic Reviews tool to 
      assess quality. Nine electronic databases were searched from inception to April
      2018. Principles, strategies, outcomes and impacts were extracted from the
      included reviews and analysed using direct content analysis. RESULTS: We included
      86 reviews using terms describing several research partnership approaches (e.g.
      community-based participatory research, participatory research, integrated
      knowledge translation). After the analyses, we synthesised 17 overarching
      principles and 11 overarching strategies and grouped them into one of the
      following subcategories: relationship between partners; co-production of
      knowledge; meaningful stakeholder engagement; capacity-building, support and
      resources; communication process; and ethical issues related to the collaborative
      research activities. Similarly, we synthesised 20 overarching outcomes and
      impacts on researchers, stakeholders, the community or society, and the research 
      process. CONCLUSIONS: This review of reviews is the first that presents
      overarching principles, strategies, outcomes and impacts of research
      partnerships. This review is unique in scope as we synthesised literature across 
      multiple research areas, involving different stakeholder groups. Our findings can
      be used as a first step to guide the initiation and maintenance of research
      partnerships and to create a classification system of the key domains of research
      partnerships, which may improve reporting consistency in the research partnership
      literature. TRIAL REGISTRATION: This study is registered via Open Science
      Framework: https://doi.org/10.17605/OSF.IO/GVR7Y.
FAU - Hoekstra, F
AU  - Hoekstra F
AUID- ORCID: http://orcid.org/0000-0002-0068-652X
AD  - School of Health & Exercise Sciences, University of British Columbia, Kelowna,
      Canada.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, Canada.
FAU - Mrklas, K J
AU  - Mrklas KJ
AD  - Strategic Clinical Networks, System Innovation and Programs, Alberta Health
      Services, Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, Calgary, Alberta, Canada.
FAU - Khan, M
AU  - Khan M
AD  - Department of Community Health Sciences, Max Rady College of Medicine, University
      of Manitoba, Winnipeg, Manitoba, Canada.
FAU - McKay, R C
AU  - McKay RC
AD  - School of Health & Exercise Sciences, University of British Columbia, Kelowna,
      Canada.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, Canada.
FAU - Vis-Dunbar, M
AU  - Vis-Dunbar M
AD  - Library, University of British Columbia Okanagan, Kelowna, British Columbia,
      Canada.
FAU - Sibley, K M
AU  - Sibley KM
AD  - Department of Community Health Sciences, Max Rady College of Medicine, University
      of Manitoba, Winnipeg, Manitoba, Canada.
AD  - George & Fay Yee Centre for Healthcare Innovation, University of Manitoba,
      Winnipeg, Manitoba, Canada.
FAU - Nguyen, T
AU  - Nguyen T
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
AD  - CanChild Centre for Childhood Disability Research, Faculty of Health Sciences,
      McMaster University, Hamilton, Ontario, Canada.
FAU - Graham, I D
AU  - Graham ID
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, 
      Canada.
CN  - SCI Guiding Principles Consensus Panel
FAU - Gainforth, H L
AU  - Gainforth HL
AD  - School of Health & Exercise Sciences, University of British Columbia, Kelowna,
      Canada. heather.gainforth@ubc.ca.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, Canada. heather.gainforth@ubc.ca.
LA  - eng
GR  - FDN #143237/CAPMC/ CIHR/Canada
GR  - iKT Project grant: 156372/CAPMC/ CIHR/Canada
GR  - 16910/Michael Smith Foundation for Health Research
GR  - F17-01540/International Collaboration on Repair Discoveries
PT  - Journal Article
PT  - Review
DEP - 20200525
PL  - England
TA  - Health Res Policy Syst
JT  - Health research policy and systems
JID - 101170481
SB  - IM
MH  - Administrative Personnel
MH  - Capacity Building
MH  - Communication
MH  - Community-Based Participatory Research/methods
MH  - *Cooperative Behavior
MH  - Ethics, Research
MH  - Health Personnel
MH  - Health Services Research
MH  - Humans
MH  - Organizations
MH  - Patient Participation
MH  - *Research Design
MH  - Research Personnel
MH  - *Review Literature as Topic
MH  - *Stakeholder Participation
MH  - Systematic Reviews as Topic
MH  - Translational Research, Biomedical
PMC - PMC7249434
OTO - NOTNLM
OT  - Collaborative research partnerships
OT  - Community-based participatory research
OT  - Integrated knowledge translation
OT  - Knowledge syntheses
OT  - Research outcomes and impact
OT  - Research principles and strategies
OT  - Stakeholder engagement
IR  - Anderson K
FIR - Anderson, Kim
IR  - Anton H
FIR - Anton, Hugh
IR  - Athanasopoulos P
FIR - Athanasopoulos, Peter
IR  - Chernesky J
FIR - Chernesky, John
IR  - Forwell S
FIR - Forwell, Susan
IR  - Maffin J
FIR - Maffin, Jocelyn
IR  - Martin Ginis K
FIR - Martin Ginis, Kathleen
IR  - McBride CB
FIR - McBride, Christopher B
IR  - Mortenson B
FIR - Mortenson, Ben
IR  - Willms R
FIR - Willms, Rhonda
EDAT- 2020/05/27 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/05/27 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/05/27 06:00 [entrez]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.1186/s12961-020-0544-9 [doi]
AID - 10.1186/s12961-020-0544-9 [pii]
PST - epublish
SO  - Health Res Policy Syst. 2020 May 25;18(1):51. doi: 10.1186/s12961-020-0544-9.


PMID- 32450750
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20201218
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 2
DP  - 2020 Aug
TI  - How Strong Is the Duty to Treat in a Pandemic? Ethics in Practice:
      Point-Counterpoint.
PG  - 325-327
LID - 10.1177/0194599820930246 [doi]
FAU - Redmann, Andrew J
AU  - Redmann AJ
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati,
      Cincinnati, Ohio, USA.
AD  - Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's
      Hospital Medical Center, Cincinnati, Ohio, USA.
FAU - Manning, Amy
AU  - Manning A
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati,
      Cincinnati, Ohio, USA.
AD  - Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's
      Hospital Medical Center, Cincinnati, Ohio, USA.
FAU - Kennedy, Aimee
AU  - Kennedy A
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati,
      Cincinnati, Ohio, USA.
AD  - Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's
      Hospital Medical Center, Cincinnati, Ohio, USA.
FAU - Greinwald, John H
AU  - Greinwald JH
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati,
      Cincinnati, Ohio, USA.
AD  - Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's
      Hospital Medical Center, Cincinnati, Ohio, USA.
FAU - deAlarcon, Alessandro
AU  - deAlarcon A
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati,
      Cincinnati, Ohio, USA.
AD  - Division of Pediatric Otolaryngology-Head and Neck Surgery, Cincinnati Children's
      Hospital Medical Center, Cincinnati, Ohio, USA.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - Adult
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Education, Medical, Graduate
MH  - *Ethics, Medical
MH  - Humans
MH  - *Moral Obligations
MH  - Otolaryngology/education/*ethics
MH  - Pandemics/*ethics
MH  - Pediatricians/ethics
MH  - *Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *COVID-19
OT  - *duty to treat
OT  - *ethics
EDAT- 2020/05/27 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1177/0194599820930246 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Aug;163(2):325-327. doi:
      10.1177/0194599820930246. Epub 2020 May 26.


PMID- 35372937
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 2641-7650 (Electronic)
IS  - 2641-7650 (Linking)
VI  - 1
IP  - 7
DP  - 2020 Jul 30
TI  - Attitudes to Clinical Pig Kidney Xenotransplantation among Medical Providers and 
      Patients.
PG  - 657-662
LID - 10.34067/KID.0002082020 [doi]
AB  - Background: In addition to governmental regulation and scientific advancements,
      the World Health Organization requires extensive review of local opinions before 
      initiating clinical trials of xenotransplantation (XTx). The purpose of this
      study was to assess the attitudes of health care providers and patients regarding
      XTx. Methods: An anonymous Likert-scale survey regarding attitudes toward XTx was
      distributed to pre- and post-kidney transplant patients, nephrologists,
      transplant surgeons, and nurses ("providers"). Patient and provider responses
      were described and compared. Regression analysis using patients' responses was
      performed to identify factors associated with XTx acceptance. Results: Eighty
      percent (32/40) of providers and 69% (113/163) of patients were agreeable to
      clinical XTx if the risks and results were likely to be similar to kidney
      allotransplantation (P<0.05). Kidney providers rated the influence of religious
      beliefs in medical decisions (45% versus 15%) and genetic engineering (43% versus
      25%) as being more important than did patients (P<0.05). A small proportion in
      both groups (<15%) reported concerns about (1) potential personality changes, (2)
      how others would interact, (3) a perception of being "less human," or (4) morals 
      or ethics. Logistic regression found that the odds of patients accepting XTx were
      greater if they had no religious concerns (OR, 25.10; 95% CI, 2.59 to 243.00),
      but acceptance was less likely if they were not willing to use XTx as a bridge to
      allotransplantation (OR, 0.18; 95% CI, 0.51 to 0.70). Conclusions: (1) If
      outcomes were similar to allotransplantation, XTx support was strong among both
      providers and patients; (2) providers overestimated the influence of religious
      beliefs and genetic engineering on patient medical decisions, although religious 
      beliefs are associated with XTx acceptance; (3) XTx use as a bridge to
      allotransplant was associated with XTx acceptance; and (4) psychosocial concerns 
      were low for either group. Future studies among other communities are warranted
      to assess if similar attitudes exist.
CI  - Copyright (c) 2020 by the American Society of Nephrology.
FAU - Padilla, Luz A
AU  - Padilla LA
AUID- ORCID: 0000-0003-4032-044X
AD  - Department of Surgery, School of Medicine, University of Alabama at Birmingham,
      Birmingham, Alabama.
FAU - Hurst, Daniel
AU  - Hurst D
AD  - Department of Family Medicine, Rowan University School of Osteopathic Medicine,
      Stratford, New Jersey.
FAU - Lopez, Raymond
AU  - Lopez R
AD  - Department of Surgery, School of Medicine, University of Alabama at Birmingham,
      Birmingham, Alabama.
FAU - Kumar, Vineeta
AU  - Kumar V
AD  - Division of Nephrology, Department of Medicine, University of Alabama at
      Birmingham, Birmingham, Alabama.
FAU - Cooper, David K C
AU  - Cooper DKC
AD  - Department of Surgery, School of Medicine, University of Alabama at Birmingham,
      Birmingham, Alabama.
FAU - Paris, Wayne
AU  - Paris W
AD  - Department of Social Work, Abilene Christian University, Abilene, Texas.
LA  - eng
GR  - U19 AI090959/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200527
PL  - United States
TA  - Kidney360
JT  - Kidney360
JID - 101766381
SB  - IM
MH  - Animals
MH  - *Attitude
MH  - Humans
MH  - Kidney
MH  - *Kidney Transplantation
MH  - Surveys and Questionnaires
MH  - Swine
MH  - Transplantation, Heterologous/adverse effects
PMC - PMC8815558
OTO - NOTNLM
OT  - *attitude
OT  - *genetic engineering
OT  - *heterografts
OT  - *heterologous
OT  - *kidney
OT  - *kidney transplantation
OT  - *logistic models
OT  - *patient
OT  - *personality
OT  - *provider
OT  - *religion
OT  - *surveys and questionnaires
OT  - *transplantation
OT  - *xenotransplantation
COIS- All authors have nothing to disclose.
EDAT- 2020/05/27 00:00
MHDA- 2022/04/08 06:00
CRDT- 2022/04/04 05:35
PHST- 2020/04/14 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2022/04/04 05:35 [entrez]
PHST- 2020/05/27 00:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
AID - 10.34067/KID.0002082020 [doi]
AID - K3602020000208 [pii]
PST - epublish
SO  - Kidney360. 2020 May 27;1(7):657-662. doi: 10.34067/KID.0002082020. eCollection
      2020 Jul 30.


PMID- 32450551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Linking)
VI  - 13
IP  - 9
DP  - 2020 Sep
TI  - Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular
      Profiling.
PG  - 100799
LID - S1936-5233(20)30255-2 [pii]
LID - 10.1016/j.tranon.2020.100799 [doi]
AB  - Limited research has indicated that despite their overwhelming interest in tumor 
      molecular profiling (MP),(1) cancer patients have poor knowledge about MP. The
      current study aimed to investigate demographic and psychological predictors of
      knowledge and perceived importance of MP in an advanced cancer patient cohort.
      Eligible participants had advanced solid cancers of any histological type with
      sufficient accessible tissue for MP and were enrolled in the Molecular Screening 
      and Therapeutics (MoST) Program. A questionnaire was completed by 1074
      participants (91% response rate) after consent, prior to undergoing MP. Overall, 
      participants had poor to moderate knowledge of MP, yet perceived MP to have high 
      importance. Higher education, speaking English at home, and greater satisfaction 
      with the decision to undergo MP were associated with higher knowledge scores.
      More negative attitudes towards uncertainty, greater self-efficacy to cope with
      results, and lower perceived likelihood of cancer progression were associated
      with greater perceived importance of MP. Less educated participants and those who
      do not speak English at home will need clear explanations, visual aids and ample 
      opportunity to ask questions about MP at the time of their decision-making.
      Clinicians also need to consider psychological factors relevant to patients'
      decision to pursue MP. Given the increased awareness of and demand for cancer
      genomic information and the rapidly changing nature of the actionability of MP,
      these findings will help inform an important ongoing debate on how to facilitate 
      ethical and informed consent and manage patient expectations about personalized
      treatments.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Davies, Grace
AU  - Davies G
AD  - The University of Sydney, Faculty of Science, School of Psychology,
      Psycho-Oncology Co-operative Research Group, Sydney, NSW 2006, Australia.
      Electronic address: grace.davies@sydney.edu.au.
FAU - Butow, Phyllis
AU  - Butow P
AD  - The University of Sydney, Faculty of Science, School of Psychology,
      Psycho-Oncology Co-operative Research Group, Sydney, NSW 2006, Australia.
      Electronic address: phyllis.butow@sydney.edu.au.
FAU - Napier, Christine E
AU  - Napier CE
AD  - Cancer Division, Garvan Institute of Medical Research, Sydney, NSW 2010,
      Australia. Electronic address: c.napier@garvan.org.au.
FAU - Bartley, Nicci
AU  - Bartley N
AD  - The University of Sydney, Faculty of Science, School of Psychology,
      Psycho-Oncology Co-operative Research Group, Sydney, NSW 2006, Australia.
      Electronic address: nicole.bartley@sydney.edu.au.
FAU - Juraskova, Ilona
AU  - Juraskova I
AD  - The University of Sydney, Faculty of Science, School of Psychology,
      Psycho-Oncology Co-operative Research Group, Sydney, NSW 2006, Australia.
      Electronic address: Ilona.juraskova@sydney.edu.au.
FAU - Meiser, Bettina
AU  - Meiser B
AD  - Psychosocial Research Group, Prince of Wales Clinical School, University of NSW, 
      Sydney, NSW 2032, Australia. Electronic address: b.meiser@unsw.edu.au.
FAU - Ballinger, Mandy L
AU  - Ballinger ML
AD  - Cancer Division, Garvan Institute of Medical Research, Sydney, NSW 2010,
      Australia; St Vincent's Clinical School, University of NSW, Sydney, NSW 2010,
      Australia. Electronic address: m.ballinger@garvan.org.au.
FAU - Thomas, David M
AU  - Thomas DM
AD  - Cancer Division, Garvan Institute of Medical Research, Sydney, NSW 2010,
      Australia; St Vincent's Clinical School, University of NSW, Sydney, NSW 2010,
      Australia. Electronic address: d.thomas@garvan.org.au.
FAU - Schlub, Timothy E
AU  - Schlub TE
AD  - The University of Sydney, Faculty of Medicine and Health, Sydney School of Public
      Health, Sydney, NSW 2006, Australia. Electronic address:
      tim.schlub@sydney.edu.au.
FAU - Best, Megan C
AU  - Best MC
AD  - The University of Sydney, Faculty of Science, School of Psychology,
      Psycho-Oncology Co-operative Research Group, Sydney, NSW 2006, Australia.
      Electronic address: megan.best@sydney.edu.au.
CN  - members of the PiGeOn Project
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC7256320
EDAT- 2020/05/26 06:00
MHDA- 2020/05/26 06:01
CRDT- 2020/05/26 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/05/26 06:01 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - S1936-5233(20)30255-2 [pii]
AID - 10.1016/j.tranon.2020.100799 [doi]
PST - ppublish
SO  - Transl Oncol. 2020 Sep;13(9):100799. doi: 10.1016/j.tranon.2020.100799. Epub 2020
      May 22.


PMID- 32450000
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1600-0714 (Electronic)
IS  - 0904-2512 (Linking)
VI  - 49
IP  - 9
DP  - 2020 Oct
TI  - Bayesian disease mapping and the 'High-Risk' oral cancer population in Hong Kong.
PG  - 907-913
LID - 10.1111/jop.13045 [doi]
AB  - BACKGROUND: Preventive and early diagnostic methods such as health promotion and 
      disease screening are increasingly advocated to improve detection and survival
      rates for oral cancer. These strategies are most effective when targeted at
      "high-risk" individuals and populations. Bayesian disease-mapping modelling is a 
      statistical method to quantify and explain spatial and temporal patterns for risk
      and covariate factor influence, thereby identifying "high-risk" sub-regions or
      "case clustering" for targeted intervention. Rarely applied to oral cancer
      epidemiology, this paper highlights the efficacy of disease mapping for the Hong 
      Kong population. METHODS: Following ethical approval, anonymized individual-level
      data for oral cancer diagnoses were obtained retrospectively from the Clinical
      Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority
      (HA) database for a 7-year period (January 2013 to December 2019). Data
      facilitated disease mapping and estimation of relative risks of oral cancer
      incidence and mortality. RESULTS: A total of 3,341 new oral cancer cases and
      1,506 oral cancer-related deaths were recorded during the 7-year study period.
      Five districts, located in Hong Kong Island and Kowloon, exhibited considerably
      higher relative incidence risks with 1 significant "case cluster" hotspot. Six
      districts displayed higher mortality risks than expected from territory-wide
      values, with highest risk identified for two districts of Hong Kong Island.
      CONCLUSION: Bayesian disease mapping is successful in identifying and
      characterizing "high-risk" areas for oral cancer incidence and mortality within a
      community. This should facilitate targeted preventive and interventional
      strategies. Further work is encouraged to enhance global-level data and
      comprehensive mapping of oral cancer incidence, mortality and survival.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Adeoye, John
AU  - Adeoye J
AD  - Oral & Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, 
      Hong Kong, China.
FAU - Choi, Siu-Wai
AU  - Choi SW
AD  - Oral & Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, 
      Hong Kong, China.
FAU - Thomson, Peter
AU  - Thomson P
AUID- ORCID: https://orcid.org/0000-0002-2007-7975
AD  - Oral & Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, 
      Hong Kong, China.
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - Denmark
TA  - J Oral Pathol Med
JT  - Journal of oral pathology & medicine : official publication of the International 
      Association of Oral Pathologists and the American Academy of Oral Pathology
JID - 8911934
SB  - IM
MH  - Bayes Theorem
MH  - Hong Kong/epidemiology
MH  - Humans
MH  - Incidence
MH  - *Mouth Neoplasms/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Hong Kong population study
OT  - disease mapping
OT  - oral cancer
EDAT- 2020/05/26 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1111/jop.13045 [doi]
PST - ppublish
SO  - J Oral Pathol Med. 2020 Oct;49(9):907-913. doi: 10.1111/jop.13045. Epub 2020 Jun 
      10.


PMID- 32449984
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1756-5391 (Electronic)
IS  - 1756-5391 (Linking)
VI  - 13
IP  - 2
DP  - 2020 May
TI  - Designing clinical trials for future space missions as a pathway to changing how 
      clinical trials are conducted on Earth.
PG  - 153-160
LID - 10.1111/jebm.12391 [doi]
AB  - OBJECTIVE: The project aims to build a framework for conducting clinical trials
      for long-term interplanetary missions to contribute to innovation in clinical
      trials on Earth, especially around patient involvement and ownership. METHODS: We
      conducted two workshops in which participants were immersed in the speculative
      scenario of an interplanetary mission in which health problems emerged that
      required medical trials to resolve. The workshops used virtual reality and live
      simulation to mimic a zero-gravity environment and visual perception shifts and
      were followed by group discussion. RESULTS: Some key aspects for the framework
      that emerged from the workshops included: (a) approaches to be inclusive in the
      management of the trial, (b) approaches to be inclusive in designing the research
      project (patient preference trials, n-of-1 trials, designing clinical trials to
      be part of a future prospective meta-analysis, etc), (c) balancing the research
      needs and the community needs (eg, allocation of the participants based on both
      research and community need), (d) ethics and partnerships (ethics and consent
      issues and how they relate to partnerships and relationships). CONCLUSION: In
      identifying some key areas that need to be incorporated in future planning of
      clinical trials for interplanetary missions, we also identified areas that are
      relevant to engaging patients in clinical trials on Earth. We will suggest using 
      the same methodology to facilitate more in-depth discussions on specific aspects 
      of clinical trials in aerospace medicine. The methodology can be more widely used
      in other areas to open new inclusive conversations around innovating research
      methodology.
CI  - (c) 2020 The Authors. Journal of Evidence-Based Medicine published by Chinese
      Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons 
      Australia, Ltd.
FAU - Nasser, Mona
AU  - Nasser M
AD  - Peninsula Dental School, University of Plymouth, Plymouth, England.
FAU - Peres, Nicholas
AU  - Peres N
AD  - Transtechnology Research, School of Art, Design and Architecture, University of
      Plymouth, Plymouth, England.
AD  - Torbay and South Devon NHS Foundation Trust, Torbay, UK.
FAU - Knight, Jacqui
AU  - Knight J
AD  - Transtechnology Research, School of Art, Design and Architecture, University of
      Plymouth, Plymouth, England.
AD  - Torbay and South Devon NHS Foundation Trust, Torbay, UK.
FAU - Haines, Agatha
AU  - Haines A
AD  - Transtechnology Research, School of Art, Design and Architecture, University of
      Plymouth, Plymouth, England.
FAU - Young, Charlie
AU  - Young C
AD  - TakiTaki, Exeter, UK.
FAU - Maranan, Diego
AU  - Maranan D
AD  - Faculty of Information and Communication Studies, University of the
      Philippines-Open University, Los Banos, Philippines.
FAU - Wright, Julian
AU  - Wright J
AD  - Torbay and South Devon NHS Foundation Trust, Torbay, UK.
FAU - Carvil, Philip
AU  - Carvil P
AD  - The Health Tech Cluster, Science and Technology Facilities Council-UK Research
      and Innovation, Wiltshire, UK.
FAU - Robinson, Karen
AU  - Robinson K
AD  - JHU Evidence based Practice Center, Johns Hopkins University Bloomberg School of 
      Public Health, Maryland, Baltimore.
FAU - Westmore, Matthew
AU  - Westmore M
AD  - Wessex Institute, University of Southampton, Southampton, UK.
FAU - Griffin, Joanna
AU  - Griffin J
AD  - Transtechnology Research, School of Art, Design and Architecture, University of
      Plymouth, Plymouth, England.
FAU - Halkes, Matthew
AU  - Halkes M
AD  - Torbay and South Devon NHS Foundation Trust, Torbay, UK.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - England
TA  - J Evid Based Med
JT  - Journal of evidence-based medicine
JID - 101497477
SB  - IM
MH  - Aerospace Medicine/*methods
MH  - Astronauts
MH  - Clinical Trials as Topic/ethics/*methods
MH  - Health Services Needs and Demand
MH  - Humans
MH  - *Space Flight/methods
OTO - NOTNLM
OT  - clinical trial
OT  - clinical trial methodology
OT  - evidence-based healthcare
OT  - medical simulation
OT  - research methodology
OT  - space mission
EDAT- 2020/05/26 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1111/jebm.12391 [doi]
PST - ppublish
SO  - J Evid Based Med. 2020 May;13(2):153-160. doi: 10.1111/jebm.12391. Epub 2020 May 
      25.


PMID- 32449867
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Optimizing resilience and wellbeing for healthcare professions trainees and
      healthcare professionals during public health crises - Practical tips for an
      'integrative resilience' approach.
PG  - 744-755
LID - 10.1080/0142159X.2020.1768230 [doi]
AB  - Public health crises, including pandemics, are associated with significant health
      risk and concomitant stress, fear, decreased sense of control, and uncertainty.
      Deleterious impact on both physical and mental health can result, including for
      healthcare professionals and health professions trainees. Changes in governmental
      policies and hospital protocols for healthcare professionals as well as
      disruption of educational formats and requirements for trainees can ensue.
      Difficult anxiety-provoking realities of public health crises including pandemics
      which involve caring for many seriously ill patients, moral distress including
      difficult care decisions, personal health risk, and/or potential risk to one's
      family can take a dire toll on the mental health of healthcare professionals at
      all stages of the professional lifecycle. Educational disruptions can create
      significant anxiety for trainees about completing requirements and achieving
      competencies. Within this, coping skills may be challenged and strengths may be
      elucidated as well. Such crises create an imperative for medical educators to
      support trainees' wellbeing through adaptive flexibility for curriculum
      innovation and culturally sensitive resilience and wellbeing interventions.
      Strategies ('tips') to optimize resilience and wellbeing with an integrative
      resilience approach of individual, learning environment, and organization/systems
      factors are presented.
FAU - Wald, Hedy S
AU  - Wald HS
AD  - Clinical Professor of Family Medicine, Warren Alpert Medical School of Brown
      University, Providence, RI, USA.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - *Adaptation, Psychological
MH  - Delivery of Health Care
MH  - Health Personnel/*psychology
MH  - Health Promotion
MH  - Humans
MH  - Leadership
MH  - Mentoring
MH  - *Professionalism
MH  - Public Health
MH  - *Resilience, Psychological
OTO - NOTNLM
OT  - *Health promotion
OT  - *ethics/attitudes
OT  - *leadership
OT  - *mentoring
OT  - *professionalism
EDAT- 2020/05/26 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1080/0142159X.2020.1768230 [doi]
PST - ppublish
SO  - Med Teach. 2020 Jul;42(7):744-755. doi: 10.1080/0142159X.2020.1768230. Epub 2020 
      May 25.


PMID- 32449686
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20201218
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 2
DP  - 2020 May 29
TI  - COVID-19: Putting the General Data Protection Regulation to the Test.
PG  - e19279
LID - 10.2196/19279 [doi]
AB  - The coronavirus disease (COVID-19) pandemic is very much a global health issue
      and requires collaborative, international health research efforts to address it. 
      A valuable source of information for researchers is the large amount of digital
      health data that are continuously collected by electronic health record systems
      at health care organizations. The European Union's General Data Protection
      Regulation (GDPR) will be the key legal framework with regard to using and
      sharing European digital health data for research purposes. However, concerns
      persist that the GDPR has made many organizations very risk-averse in terms of
      data sharing, even if the regulation permits such sharing. Health care
      organizations focusing on individual risk minimization threaten to undermine
      COVID-19 research efforts. In our opinion, there is an ethical obligation to use 
      the research exemption clause of the GDPR during the COVID-19 pandemic to support
      global collaborative health research efforts. Solidarity is a European value, and
      here is a chance to exemplify it by using the GDPR regulatory framework in a way 
      that does not hinder but actually fosters solidarity during the COVID-19
      pandemic.
CI  - (c)Stuart McLennan, Leo Anthony Celi, Alena Buyx. Originally published in JMIR
      Public Health and Surveillance (http://publichealth.jmir.org), 29.05.2020.
FAU - McLennan, Stuart
AU  - McLennan S
AUID- ORCID: 0000-0002-2019-6253
AD  - Institute of History and Ethics in Medicine, Technical University of Munich,
      Munich, Germany.
FAU - Celi, Leo Anthony
AU  - Celi LA
AUID- ORCID: 0000-0001-6712-6626
AD  - Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess
      Medical Center, Boston, MA, United States.
AD  - Harvard-Massachusetts Division of Health Science and Technology, Cambridge, MA,
      United States.
FAU - Buyx, Alena
AU  - Buyx A
AUID- ORCID: 0000-0002-5726-7633
AD  - Institute of History and Ethics in Medicine, Technical University of Munich,
      Munich, Germany.
LA  - eng
GR  - R01 EB017205/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200529
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - COVID-19
MH  - Computer Security/*legislation & jurisprudence
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - European Union
MH  - *Health Services Research
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/*therapy
PMC - PMC7265798
OTO - NOTNLM
OT  - *COVID-19
OT  - *EHR
OT  - *GDPR
OT  - *data sharing
OT  - *digital health
OT  - *electronic health records
OT  - *global health
OT  - *public health
OT  - *research
OT  - *research exemption
EDAT- 2020/05/26 06:00
MHDA- 2020/06/04 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/05/22 00:00 [revised]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - v6i2e19279 [pii]
AID - 10.2196/19279 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 May 29;6(2):e19279. doi: 10.2196/19279.


PMID- 32449684
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 25
TI  - Effectiveness of Group Cognitive Behavioral Therapy and Exercise in the
      Management of Major Depressive Disorder: Protocol for a Pilot Randomized
      Controlled Trial.
PG  - e14309
LID - 10.2196/14309 [doi]
AB  - BACKGROUND: Despite evidence in scientific literature indicating the
      effectiveness of both cognitive behavioral therapy (CBT) and physical exercise in
      the management of major depressive disorder (MDD), few studies have directly
      compared them. OBJECTIVE: This study aims to evaluate and compare the
      effectiveness of group CBT, physical exercise, and only wait-listing to receive
      treatment-as-usual (TAU) in the management of MDD. The investigators hypothesize 
      that participants with MDD assigned to the group CBT or exercise arms of the
      study will achieve superior outcomes compared with participants wait-listed to
      receive TAU only. METHODS: This prospective rater-blinded randomized controlled
      trial assesses the benefits of group CBT and exercise for participants with MDD. 
      A total of 120 patients with MDD referred to addiction and mental health clinics 
      in Edmonton, Canada, will be randomly assigned to one of the three equal-sized
      arms of the study to receive either weekly sessions of group CBT plus TAU, group 
      exercise three times a week plus TAU, or only TAU for 14 weeks. Participants will
      be assessed at enrollment, 3 and 6 months post enrollment, midtreatment, and upon
      treatment completion for primary (functional and symptom variables) and secondary
      outcomes (service variables and health care utilization). In addition,
      participants in the intervention groups would be evaluated weekly with one
      functional measure. The data will be analyzed using repeated measures and effect 
      size analyses, and correlational analyses will be completed between measures at
      each time point. RESULTS: The study will be conducted in accordance with the
      Declaration of Helsinki (Hong Kong amendment) and Good Clinical Practice
      (Canadian guidelines). Written informed consent will be obtained from each
      subject. The study received ethical clearance from the Health Ethics Research
      Board of the University of Alberta on September 7, 2018 (Pro 00080975) and
      operational approval from the provincial health authority (Alberta Health
      Services 43638). As of October 13, 2019, we have enrolled 32 participants. The
      results will be disseminated at several levels, including patients,
      practitioners, academics, researchers, and health care organizations.
      CONCLUSIONS: The results of the pilot trial may inform the implementation of a
      multicenter clinical trial and provide useful information for administrators and 
      clinicians who are interested in incorporating group CBT and group exercise
      interventions into existing care. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT03731728; https://clinicaltrials.gov/ct2/show/NCT03731728. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/14309.
CI  - (c)Mojtaba Yekrang Safakar, Marianne Hrabok, Liana Urichuk, Michal Juhas, Reham
      Shalaby, Devashree Parmar, Pierre Chue, Mark Snaterse, Judith Mason, Donna
      Tchida, Jill Kelland, Pamela Coulson, Daniella Sosdjan, Jason Brown, Katherine
      Hay, Deanna Lesage, Lacey Paulsen, Amy Delday, Sherianna Duiker, Shireen Surood, 
      Adam Abba-Aji, Vincent Israel Opoku Agyapong. Originally published in JMIR
      Research Protocols (http://www.researchprotocols.org), 25.05.2020.
FAU - Yekrang Safakar, Mojtaba
AU  - Yekrang Safakar M
AUID- ORCID: https://orcid.org/0000-0001-5581-1765
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
FAU - Hrabok, Marianne
AU  - Hrabok M
AUID- ORCID: https://orcid.org/0000-0002-1663-9285
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
FAU - Urichuk, Liana
AU  - Urichuk L
AUID- ORCID: https://orcid.org/0000-0003-1013-5921
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Juhas, Michal
AU  - Juhas M
AUID- ORCID: https://orcid.org/0000-0001-7071-2511
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
FAU - Shalaby, Reham
AU  - Shalaby R
AUID- ORCID: https://orcid.org/0000-0002-3717-6398
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
FAU - Parmar, Devashree
AU  - Parmar D
AUID- ORCID: https://orcid.org/0000-0003-3633-4507
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Chue, Pierre
AU  - Chue P
AUID- ORCID: https://orcid.org/0000-0002-7916-415X
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
FAU - Snaterse, Mark
AU  - Snaterse M
AUID- ORCID: https://orcid.org/0000-0003-0719-9932
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Mason, Judith
AU  - Mason J
AUID- ORCID: https://orcid.org/0000-0001-6108-4883
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Tchida, Donna
AU  - Tchida D
AUID- ORCID: https://orcid.org/0000-0003-3492-7851
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Kelland, Jill
AU  - Kelland J
AUID- ORCID: https://orcid.org/0000-0002-6665-5128
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Coulson, Pamela
AU  - Coulson P
AUID- ORCID: https://orcid.org/0000-0002-1419-2993
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Sosdjan, Daniella
AU  - Sosdjan D
AUID- ORCID: https://orcid.org/0000-0002-7918-7298
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Brown, Jason
AU  - Brown J
AUID- ORCID: https://orcid.org/0000-0001-7476-9144
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Hay, Katherine
AU  - Hay K
AUID- ORCID: https://orcid.org/0000-0002-4868-104X
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Lesage, Deanna
AU  - Lesage D
AUID- ORCID: https://orcid.org/0000-0002-6451-3337
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Paulsen, Lacey
AU  - Paulsen L
AUID- ORCID: https://orcid.org/0000-0002-0287-7469
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Delday, Amy
AU  - Delday A
AUID- ORCID: https://orcid.org/0000-0001-9445-0990
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Duiker, Sherianna
AU  - Duiker S
AUID- ORCID: https://orcid.org/0000-0002-4388-952X
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
FAU - Surood, Shireen
AU  - Surood S
AUID- ORCID: https://orcid.org/0000-0002-9776-2348
AD  - Addiction and Mental Health, Alberta Health Services, Edmonton, AB, Canada.
AD  - Faculty of Social Work, University of Calgary, Calgary, AB, Canada.
FAU - Abba-Aji, Adam
AU  - Abba-Aji A
AUID- ORCID: https://orcid.org/0000-0003-0369-4768
AD  - Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
FAU - Agyapong, Vincent Israel Opoku
AU  - Agyapong VIO
AUID- ORCID: https://orcid.org/0000-0002-2743-0372
AD  - Department of Psychiatry, Faculty of Medicine and Dentistry, University of
      Alberta, Edmonton, AB, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03731728
PT  - Journal Article
DEP - 20200525
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7281203
OTO - NOTNLM
OT  - cognitive behavioral therapy
OT  - depression
OT  - exercise
OT  - group CBT
OT  - major depressive disorder
EDAT- 2020/05/26 06:00
MHDA- 2020/05/26 06:01
CRDT- 2020/05/26 06:00
PHST- 2019/04/28 00:00 [received]
PHST- 2019/10/15 00:00 [accepted]
PHST- 2019/10/13 00:00 [revised]
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/05/26 06:01 [medline]
AID - v9i5e14309 [pii]
AID - 10.2196/14309 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 May 25;9(5):e14309. doi: 10.2196/14309.


PMID- 32449667
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - Response to "Ethics and Linguistics of 'omestic Global Health' Experience".
PG  - E462-464
LID - amajethics.2020.462 [pii]
LID - 10.1001/amajethics.2020.462 [doi]
FAU - Shah, Sural
AU  - Shah S
AD  - Assistant clinical professor at the University of California, Los Angeles David
      Geffen School of Medicine and chief of the Primary Care Division at Olive
      View-UCLA Medical Center.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
CON - AMA J Ethics. 2019 Sep 1;21(9):E778-787. PMID: 31550226
CON - AMA J Ethics. 2020 May 1;22(5):E458-461. PMID: 32449666
MH  - Academic Medical Centers
MH  - *Global Health
MH  - Humans
MH  - *Linguistics
MH  - Students
EDAT- 2020/05/26 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - amajethics.2020.462 [pii]
AID - 10.1001/amajethics.2020.462 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E462-464. doi: 10.1001/amajethics.2020.462.


PMID- 32449666
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - Response to "How Should Academic Medical Centers Administer Students' 'Domestic
      Global Health' Experiences?" Ethics and Linguistics of "Domestic Global Health"
      Experience.
PG  - E458-461
LID - amajethics.2020.458 [pii]
LID - 10.1001/amajethics.2020.458 [doi]
FAU - Rabelais, Em
AU  - Rabelais E
AD  - Academic health ethicist and assistant professor at the University of Illinois at
      Chicago College of Nursing.
FAU - Rosales, Esmeralda
AU  - Rosales E
AD  - A family medicine resident at Erie/Northwestern McGaw beginning in July 2020.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
CON - AMA J Ethics. 2019 Sep 1;21(9):E778-787. PMID: 31550226
CIN - AMA J Ethics. 2020 May 1;22(5):E462-464. PMID: 32449667
MH  - Academic Medical Centers
MH  - *Clinical Clerkship
MH  - *Global Health
MH  - Humans
MH  - Linguistics
MH  - Students
EDAT- 2020/05/26 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - amajethics.2020.458 [pii]
AID - 10.1001/amajethics.2020.458 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E458-461. doi: 10.1001/amajethics.2020.458.


PMID- 32449665
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - How Should Decision-Sharing Roles Be Considered in Adolescent Gender Surgeries?
PG  - E452-457
LID - amajethics.2020.452 [pii]
LID - 10.1001/amajethics.2020.452 [doi]
AB  - The nascent field of gender-affirming surgery (GAS) for binary and nonbinary
      transgender adolescents is growing rapidly, and the optimal use of shared
      decision making (SDM)-including who should be involved, to what extent, and for
      which parts of the decision-is still evolving. Participants include the
      adolescent (whose goals might center on aesthetics and functionality), the
      surgeon (who might focus more on minimizing complications), the referring
      clinician (whose participation is mandated by present standards of care), and the
      caregiver (whose participation is required for patients below the age of
      consent). This article argues that effective, ethical SDM in adolescent GAS care 
      requires a different conceptualization of roles than might be expected in other
      situations and should be a longitudinal experience rather than a singular event.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Grimstad, Frances
AU  - Grimstad F
AD  - Clinical instructor in pediatrics and adolescent gynecology at Harvard Medical
      School in Boston, Massachusetts.
FAU - Boskey, Elizabeth
AU  - Boskey E
AD  - Social worker and researcher at the Center for Gender Surgery at Boston
      Children's Hospital in Massachusetts.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Adolescent
MH  - Decision Making
MH  - Decision Making, Shared
MH  - Gender Identity
MH  - Humans
MH  - Patient Participation
MH  - *Transgender Persons
MH  - *Transsexualism
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.452 [pii]
AID - 10.1001/amajethics.2020.452 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E452-457. doi: 10.1001/amajethics.2020.452.


PMID- 32449664
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - Overcoming Obstacles to Shared Mental Health Decision Making.
PG  - E446-451
LID - amajethics.2020.446 [pii]
LID - 10.1001/amajethics.2020.446 [doi]
AB  - Shared decision making (SDM) is difficult to implement in mental health practice,
      but it remains an ethical ideal for motivating therapeutic capacity in
      patient-clinician relationships; this discrepancy warrants attention from
      clinical and ethical perspectives. This article explores what some clinicians see
      as obstacles to even attempting SDM with patients with psychiatric disabilities. 
      In particular, this article identifies 4 such obstacles: a patient's lack of
      decision-making capacity, a patient's poor insight, a health care professional's 
      therapeutic pessimism or personal dislike, and a patient's or health care
      professional's conflicting recovery orientations or goals of care. This article
      argues that each obstacle could be overcome in many cases and that health care
      professionals, patients, and their caregivers should remain dedicated to
      attempting SDM in mental health practice.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Guidry-Grimes, Laura
AU  - Guidry-Grimes L
AD  - Assistant professor of medical humanities and bioethics at the University of
      Arkansas for Medical Sciences in Little Rock.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Caregivers
MH  - Decision Making
MH  - *Decision Making, Shared
MH  - Humans
MH  - *Mental Health
MH  - Patient Participation
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.446 [pii]
AID - 10.1001/amajethics.2020.446 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E446-451. doi: 10.1001/amajethics.2020.446.


PMID- 32449663
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - Salvation in a Time of Plague.
PG  - E441-445
LID - amajethics.2020.441 [pii]
LID - 10.1001/amajethics.2020.441 [doi]
AB  - Health workers offer their skills and care to COVID-19 pandemic patients, just as
      St Roch offered healing to those stricken by bubonic plague during the
      Renaissance. This article interprets 3 works of art in light of Roch's story of
      illness and recovery and applies key insights of ethical, artistic, and clinical 
      relevance to the COVID-19 pandemic.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Sweeney, Ginia
AU  - Sweeney G
AD  - Assistant director of interpretation in the Department of Learning and Public
      Engagement at the Art Institute of Chicago in Illinois.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Art/history
MH  - History, 15th Century
MH  - History, Medieval
MH  - Humans
MH  - Paintings/*history
MH  - Pandemics/history
MH  - Plague/*history
EDAT- 2020/05/26 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
AID - amajethics.2020.441 [pii]
AID - 10.1001/amajethics.2020.441 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E441-445. doi: 10.1001/amajethics.2020.441.


PMID- 32449660
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - What Cy Twombly's Art Can Teach Us About Patients' Stories.
PG  - E430-436
LID - amajethics.2020.430 [pii]
LID - 10.1001/amajethics.2020.430 [doi]
AB  - Some patients' stories can be hard to tell and hard to listen to, especially in
      pressured, time-pinched clinical environments. This difficulty, however, doesn't 
      absolve clinicians from a duty to try to understand patients' stories, interpret 
      their meanings, and respond with care. Such efforts require clinical creativity, 
      full engagement, and the recognition that emotions and personal feelings leak
      into the space between storyteller and story listener. Art objects are complex
      bodies of information that can challenge clinicians and trainees to become more
      comfortable with messy narratives as well as with ethical and aesthetic
      ambiguity. By slowing down and observing art, trainees can reflect on how
      clinicians make sense of stories that contain information that appears random and
      lacks coherence-and, more importantly, how clinicians draw on these stories to
      respond to patients' needs.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Baruch, Jay
AU  - Baruch J
AD  - Associate professor of emergency medicine, Warren Alpert Medical School at Brown 
      University in Providence, Rhode Island.
FAU - Springs, Stacey
AU  - Springs S
AD  - Research associate at the Center for Evidence Synthesis in Health at the Brown
      University School of Public Health in Providence, Rhode Island.
FAU - Poterack, Alexandra
AU  - Poterack A
AD  - Associate educator of academic and public programs at the Rhode Island School of 
      Design Museum in Providence, Rhode Island.
FAU - Blythe, Sarah Ganz
AU  - Blythe SG
AD  - Deputy director for exhibitions, education, and programs at the Rhode Island
      School of Design Museum in Providence, Rhode Island.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Creativity
MH  - Emotions
MH  - Humans
MH  - *Narration
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.430 [pii]
AID - 10.1001/amajethics.2020.430 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E430-436. doi: 10.1001/amajethics.2020.430.


PMID- 32449659
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - What Does the Evolution From Informed Consent to Shared Decision Making Teach Us 
      About Authority in Health Care?
PG  - E423-429
LID - amajethics.2020.423 [pii]
LID - 10.1001/amajethics.2020.423 [doi]
AB  - This article examines the legal doctrine and ethical norm of informed consent and
      its deficiencies, particularly its concentration on physician disclosure of
      information rather than on patient understanding, which led to the development of
      shared decision making as a way to enhance informed consent. As a vague and
      imprecise rubric, shared decision making encompasses several different
      approaches. Narrower approaches presuppose an individualistic account of
      autonomy, while broader approaches view autonomy as relational and hold that
      clinician-patient relationships grounded in good communication can assist
      decision making and foster autonomous choices. Shared decision making faces
      conceptual, normative, and practical challenges, but, with its goal of
      respecting, protecting, and promoting patients' autonomous choices, it represents
      an important cultural change in medicine.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Childress, James F
AU  - Childress JF
AD  - Professor emeritus at the University of Virginia in Charlottesville.
FAU - Childress, Marcia Day
AU  - Childress MD
AD  - Associate professor of medical education (health humanities) at the University of
      Virginia School of Medicine in Charlottesville.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Decision Making
MH  - *Decision Making, Shared
MH  - Disclosure
MH  - Humans
MH  - Informed Consent
MH  - Personal Autonomy
MH  - *Physician-Patient Relations
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.423 [pii]
AID - 10.1001/amajethics.2020.423 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E423-429. doi: 10.1001/amajethics.2020.423.


PMID- 32449658
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - What's the Role of Time in Shared Decision Making?
PG  - E416-422
LID - amajethics.2020.416 [pii]
LID - 10.1001/amajethics.2020.416 [doi]
AB  - Shared decision making (SDM) is a desirable process and outcome of
      patient-clinician relationships. Ideally, patients and clinicians have sufficient
      time to engage in SDM. In reality, time is often insufficient. This article
      explores time as a barrier to SDM, alternative ways clinicians can think about
      time, and steps they can take to have fulfilling SDM interactions despite time
      constraints. Although discussions of time typically focus on time quantity,
      redirecting attention to the ethical significance of time in establishing
      patient-clinician relationships suggests the importance of also considering time 
      quality.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Yahanda, Alexander T
AU  - Yahanda AT
AD  - Dual-degree MD and master of population health sciences candidate at Washington
      University School of Medicine in St Louis, Missouri.
FAU - Mozersky, Jessica
AU  - Mozersky J
AD  - Assistant professor of medicine in the Bioethics Research Center at Washington
      University School of Medicine in St Louis, Missouri.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Decision Making
MH  - *Decision Making, Shared
MH  - Humans
MH  - *Patient Participation
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.416 [pii]
AID - 10.1001/amajethics.2020.416 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E416-422. doi: 10.1001/amajethics.2020.416.


PMID- 32449652
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - How Should Adolescent Health Decision-Making Authority Be Shared?
PG  - E372-379
LID - amajethics.2020.372 [pii]
LID - 10.1001/amajethics.2020.372 [doi]
AB  - Shared decision making (SDM) is used in adult and pediatric practice for both its
      ethical and its practical benefits. However, its use is complicated with
      adolescents whose emerging and relational autonomy is distinct from that of
      adults, who make decisions independently, and children, whose parents make
      decisions for them. This hypothetical case scenario and commentary provide
      clinicians with a practical and stepwise approach to SDM with adolescents as well
      as guidance when SDM breaks down.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Sawyer, Kimberly
AU  - Sawyer K
AD  - Acting instructor and senior clinical fellow in pediatric bioethics and
      palliative care at the University of Washington School of Medicine in Seattle.
FAU - Rosenberg, Abby R
AU  - Rosenberg AR
AD  - Associate professor in the Department of Pediatrics' Division of
      Hematology-Oncology at the University of Washington School of Medicine in
      Seattle.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health
MH  - Adult
MH  - Child
MH  - Decision Making
MH  - Decision Making, Shared
MH  - Humans
MH  - Parents
MH  - *Patient Participation
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.372 [pii]
AID - 10.1001/amajethics.2020.372 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E372-379. doi: 10.1001/amajethics.2020.372.


PMID- 32449651
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 5
DP  - 2020 May 1
TI  - Can Consent to Participate in Clinical Research Involve Shared Decision Making?
PG  - E365-371
LID - amajethics.2020.365 [pii]
LID - 10.1001/amajethics.2020.365 [doi]
AB  - Shared decision making honors patient autonomy and improves patient comprehension
      and therefore should be a part of every clinical decision a patient makes. Use of
      shared decision making in research informed consent conversations is more
      complicated due to diverse and potentially divergent investigator and patient
      interests, along with the presence of clinical equipoise. This article clarifies 
      these different interests and discusses ways in which shared decision making can 
      be applied in research. Provided there is transparency about competing interests,
      patient-centered and values-focused communication approaches embodied in shared
      decision making can support the ethical recruitment of patients for clinical
      research.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Moulton, Haley
AU  - Moulton H
AD  - Medical student at the Dartmouth College Geisel School of Medicine in Hanover,
      New Hampshire.
FAU - Moulton, Benjamin
AU  - Moulton B
AD  - Founder and chief executive officer of Informed Consulting, LLC.
FAU - Lahey, Tim
AU  - Lahey T
AD  - Director of ethics at the University of Vermont Medical Center, professor of
      medicine at the University of Vermont Larner College of Medicine in Burlington.
FAU - Elwyn, Glyn
AU  - Elwyn G
AD  - Professor at the Dartmouth Institute for Health Policy and Clinical Practice in
      Hanover, New Hampshire.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Communication
MH  - Comprehension
MH  - *Decision Making
MH  - *Decision Making, Shared
MH  - Humans
MH  - Informed Consent
MH  - Patient Participation
MH  - Physician-Patient Relations
EDAT- 2020/05/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.365 [pii]
AID - 10.1001/amajethics.2020.365 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 May 1;22(5):E365-371. doi: 10.1001/amajethics.2020.365.


PMID- 32449625
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20220429
IS  - 1931-8405 (Electronic)
IS  - 0889-2229 (Linking)
VI  - 36
IP  - 12
DP  - 2020 Dec
TI  - "My Death Will Not [Be] in Vain": Testimonials from Last Gift Rapid Research
      Autopsy Study Participants Living with HIV at the End of Life.
PG  - 1071-1082
LID - 10.1089/AID.2020.0020 [doi]
AB  - End-of-life (EOL) HIV cure-related research provides a novel approach to studying
      HIV reservoirs. The Last Gift is a rapid autopsy research study at the University
      of California San Diego that enrolls terminally ill people living with HIV
      (PLWHIV) with a desire to contribute to HIV cure-related research. We conducted
      in-depth baseline and follow-up interviews with Last Gift study participants. We 
      analyzed interview data applying conventional content analysis. Since summer
      2017, 13 participants have been enrolled (n = 11 males and 2 females; aged 45-89 
      years) and 8 participants interviewed. Terminal illnesses included cancers, heart
      diseases, and neurodegenerative illnesses. Our analysis revealed five key themes:
      (1) The Last Gift study has tremendous meaning for participants at the end of
      their life. (2) HIV-specific altruism was a primary motivator to join the Last
      Gift study, nested within the context of community, scientific advancement, and
      moral obligation. (3) Participants did not expect physical benefits yet they
      perceived emotional/psychological, financial, and societal/scientific benefits.
      (4) There were minimal participant-perceived risks and concerns. (5) Last Gift
      participants expressed immense gratitude toward study staff. The Last Gift study 
      provides a framework for ethical HIV cure-related research at EOL and highlighted
      participants' perspectives, motivations, and experiences. Knowing how PLWHIV
      understand and experience such studies will remain critical to designing ethical,
      fully informed HIV cure research protocols that are acceptable to PLWHIV.
FAU - Perry, Kelly E
AU  - Perry KE
AD  - Public Health Leadership Program, UNC Gillings School of Global Public Health,
      Chapel Hill, North Carolina, USA.
FAU - Dube, Karine
AU  - Dube K
AD  - Public Health Leadership Program, UNC Gillings School of Global Public Health,
      Chapel Hill, North Carolina, USA.
FAU - Concha-Garcia, Susanna
AU  - Concha-Garcia S
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
AD  - HIV Neurobehavioral Research Program, University of California San Diego, San
      Diego, California, USA.
FAU - Patel, Hursch
AU  - Patel H
AD  - Public Health Leadership Program, UNC Gillings School of Global Public Health,
      Chapel Hill, North Carolina, USA.
FAU - Kaytes, Andy
AU  - Kaytes A
AD  - Community Advisory Board, AntiViral Research Center, San Diego, California, USA.
FAU - Taylor, Jeff
AU  - Taylor J
AD  - Community Advisory Board, AntiViral Research Center, San Diego, California, USA.
AD  - HIV+Aging Research Project-Palm Springs (HARP-PS), Palm Springs, California, USA.
FAU - Javadi, Sogol Stephanie
AU  - Javadi SS
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
FAU - Mathur, Kushagra
AU  - Mathur K
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
FAU - Lo, Megan
AU  - Lo M
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
FAU - Brown, Brandon
AU  - Brown B
AD  - Department of Social Medicine, Population and Public Health, Center for Healthy
      Communities, University of California, Riverside, Riverside, California, USA.
FAU - Sauceda, John A
AU  - Sauceda JA
AD  - Department of Medicine, Division of Prevention Sciences, Center for AIDS
      Prevention Studies, University of California, San Francisco, San Francisco,
      California, USA.
FAU - Wohl, David A
AU  - Wohl DA
AD  - Department of Medicine, Institute of Global Health and Infectious Diseases,
      University of North Carolina, Chapel Hill, North Carolina, USA.
FAU - Little, Susan
AU  - Little S
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
AD  - Department of Medicine, Division of Infectious Diseases and Global Public Health,
      University of California San Diego, San Diego, California, USA.
FAU - Hendrickx, Steven
AU  - Hendrickx S
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
FAU - Rawlings, Stephen A
AU  - Rawlings SA
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
AD  - Department of Medicine, Division of Infectious Diseases and Global Public Health,
      University of California San Diego, San Diego, California, USA.
FAU - Smith, Davey M
AU  - Smith DM
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
AD  - Department of Medicine, Division of Infectious Diseases and Global Public Health,
      University of California San Diego, San Diego, California, USA.
FAU - Gianella, Sara
AU  - Gianella S
AD  - Department of Medicine, University of California San Diego School of Medicine,
      AntiViral Research Center, University of California San Diego, San Diego,
      California, USA.
AD  - Department of Medicine, Division of Infectious Diseases and Global Public Health,
      University of California San Diego, San Diego, California, USA.
LA  - eng
GR  - P01 AI131385/AI/NIAID NIH HHS/United States
GR  - P30 AI036214/AI/NIAID NIH HHS/United States
GR  - R21 HD094646/HD/NICHD NIH HHS/United States
GR  - U24 MH100928/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200624
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
SB  - IM
MH  - Autopsy
MH  - Cognition
MH  - Death
MH  - Female
MH  - *HIV Infections
MH  - Humans
MH  - Male
MH  - Risk
PMC - PMC7703253
OTO - NOTNLM
OT  - *HIV cure research
OT  - *Last Gift
OT  - *altruism
OT  - *end of life
OT  - *rapid research autopsy
OT  - *sociobehavioral research
EDAT- 2020/05/26 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1089/AID.2020.0020 [doi]
PST - ppublish
SO  - AIDS Res Hum Retroviruses. 2020 Dec;36(12):1071-1082. doi: 10.1089/AID.2020.0020.
      Epub 2020 Jun 24.


PMID- 32449505
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 14
TI  - The Effects of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in
      Patients with Digestive System or Lung Cancer: Protocol for a Randomized
      Controlled Trial.
PG  - e17232
LID - 10.2196/17232 [doi]
AB  - BACKGROUND: The side effects of chemotherapy, specifically chemotherapy-induced
      nausea and vomiting, are a concern for patients. To relieve these side effects,
      antiemetic drugs are recommended. However, some patients report that these drugs 
      are not sufficiently effective. Moreover, patients with chronic disease,
      including cancer, are increasingly interested in complementary and alternative
      medicines, and express the desire for nonpharmacological treatments to be used in
      hospitals. Foot reflexology is a holistic approach that is reported to
      significantly reduce the severity of chemotherapy-induced nausea and vomiting in 
      patients with breast cancer. Some of the chemotherapy treatments for patients
      with lung and digestive system cancer are moderately or highly emetic. OBJECTIVE:
      The primary objective of this study is to assess the benefits of foot
      reflexology, together with conventional treatments, on the severity and frequency
      of chemotherapy-induced nausea and vomiting in patients with lung or digestive
      system cancer. The secondary objectives to be assessed are quality of life,
      anxiety, and self-esteem. METHODS: This study is an open-label randomized
      controlled trial conducted over 22 months (18 months intervention and 4 months
      follow-up). Eligible participants are patients with a lung or digestive system
      cancer with an indication for platinum-based chemotherapy. Participants are
      randomized into two groups: conventional care with foot reflexology and
      conventional care without foot reflexology. Foot reflexology sessions (30
      minutes) are performed on an outpatient or inpatient basis. It was estimated that
      40 participants per group will be required. The benefits of foot reflexology will
      be assessed by comparing the relative change in the severity of nausea and
      vomiting, as assessed by a visual analogue scale, and the frequency of these side
      effects between the two groups. The secondary objectives will be assessed with
      the European Organization for Research and Treatment of Cancer Quality of Life
      Questionnaire; Hospital and Anxiety Depression Scale; and Body Image
      Questionnaire. RESULTS: This study was approved by the regional ethics committee 
      (Ile de France X CPP) on April 3, 2018 (No. ID RCB 2018-A00571-54). Enrollment
      started in June 2018. Data analysis will be performed during the second quarter
      of 2020 and results will be published in the last quarter of 2020. CONCLUSIONS:
      The lack of knowledge regarding the efficacy and safety of foot reflexology
      limits oncologists to recommend it for this use. This study will provide evidence
      of the benefits of foot reflexology. If efficacy is confirmed, foot reflexology
      may be a promising complement to conventional antiemetic drugs. TRIAL
      REGISTRATION: Clinicaltrials.gov NCT03508180;
      https://www.clinicaltrials.gov/ct2/show/NCT03508180. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/17232.
CI  - (c)Audrey Murat-Ringot, Pierre Jean Souquet, Marion Chauvenet, Charlotte Rentler,
      Fabien Subtil, Anne-Marie Schott, Marie Preau, Vincent Piriou. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      14.07.2020.
FAU - Murat-Ringot, Audrey
AU  - Murat-Ringot A
AUID- ORCID: https://orcid.org/0000-0002-8177-7166
AD  - Centre de Coordination en Cancerologie, Hospices Civils de Lyon, Pierre-Benite,
      France.
AD  - HESPER EA7425, Universite Lyon 1, Lyon, France.
AD  - Laboratoire GREPS EA 4163, Institut de Psychologie, Universite Lyon 2, Bron,
      France.
FAU - Souquet, Pierre Jean
AU  - Souquet PJ
AUID- ORCID: https://orcid.org/0000-0001-6886-7557
AD  - Centre de Coordination en Cancerologie, Hospices Civils de Lyon, Pierre-Benite,
      France.
FAU - Chauvenet, Marion
AU  - Chauvenet M
AUID- ORCID: https://orcid.org/0000-0001-8929-0232
AD  - Centre de Coordination en Cancerologie, Hospices Civils de Lyon, Pierre-Benite,
      France.
FAU - Rentler, Charlotte
AU  - Rentler C
AUID- ORCID: https://orcid.org/0000-0002-3918-923X
AD  - Centre de Coordination en Cancerologie, Hospices Civils de Lyon, Pierre-Benite,
      France.
FAU - Subtil, Fabien
AU  - Subtil F
AUID- ORCID: https://orcid.org/0000-0003-1955-2019
AD  - Centre de Coordination en Cancerologie, Hospices Civils de Lyon, Pierre-Benite,
      France.
AD  - Laboratoire de Biometrie et Biologie Evolutive UMR 5558, Centre National de la
      Recherche Scientifique, Universite Lyon 1, Villeurbanne, France.
FAU - Schott, Anne-Marie
AU  - Schott AM
AUID- ORCID: https://orcid.org/0000-0003-3337-4474
AD  - HESPER EA7425, Universite Lyon 1, Lyon, France.
AD  - Pole Sante Publique, Hospices Civils de Lyon, Lyon, France.
FAU - Preau, Marie
AU  - Preau M
AUID- ORCID: https://orcid.org/0000-0002-6239-1671
AD  - Laboratoire GREPS EA 4163, Institut de Psychologie, Universite Lyon 2, Bron,
      France.
FAU - Piriou, Vincent
AU  - Piriou V
AUID- ORCID: https://orcid.org/0000-0001-6900-1480
AD  - HESPER EA7425, Universite Lyon 1, Lyon, France.
AD  - Reanimation Anesthesie, Hospices Civils de Lyon, Pierre-Benite, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03508180
PT  - Journal Article
DEP - 20200714
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7388046
OTO - NOTNLM
OT  - cancer
OT  - chemotherapy
OT  - foot reflexology
OT  - nausea
OT  - randomized controlled trial
OT  - vomiting
EDAT- 2020/05/26 06:00
MHDA- 2020/05/26 06:01
CRDT- 2020/05/26 06:00
PHST- 2019/11/28 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/05/26 06:01 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - v9i7e17232 [pii]
AID - 10.2196/17232 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 14;9(7):e17232. doi: 10.2196/17232.


PMID- 32449453
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210415
IS  - 1758-1133 (Electronic)
IS  - 0049-4755 (Linking)
VI  - 50
IP  - 3
DP  - 2020 Jul
TI  - Going together: ethical considerations for trainees in global surgery.
PG  - 178-179
LID - 10.1177/0049475520922758 [doi]
FAU - Doe, Matthew
AU  - Doe M
AUID- ORCID: 0000-0001-8386-7344
AD  - Mbale Regional Referral Hospital, Mbale, Uganda.
FAU - Bua, Emmanuel
AU  - Bua E
AD  - Mbale Regional Referral Hospital, Mbale, Uganda.
LA  - eng
PT  - Editorial
DEP - 20200525
PL  - England
TA  - Trop Doct
JT  - Tropical doctor
JID - 1301706
SB  - IM
EDAT- 2020/05/26 06:00
MHDA- 2020/05/26 06:01
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/05/26 06:01 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1177/0049475520922758 [doi]
PST - ppublish
SO  - Trop Doct. 2020 Jul;50(3):178-179. doi: 10.1177/0049475520922758. Epub 2020 May
      25.


PMID- 32449322
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20200601
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 35
IP  - 20
DP  - 2020 May 25
TI  - Innovative Strategies for Peer Review.
PG  - e138
LID - 10.3346/jkms.2020.35.e138 [doi]
AB  - Peer review is a crucial part of research and publishing. However, it remains
      imperfect and suffers from bias, lack of transparency, and professional jealousy.
      It is also overburdened by an increasing quantity of complex papers against the
      stagnant pool of reviewers, causing delays in peer review. Additionally, many
      medical, nursing, and healthcare educators, peer reviewers, and authors may not
      be completely familiar with the current changes in peer review. Moreover,
      reviewer education and training have unfortunately remained lacking. This is
      especially crucial since current initiatives to improve the review process are
      now influenced by factors other than academic needs. Thus, increasing attention
      has recently focused on ways of streamlining the peer review process and
      implementing alternative peer-review methods using new technologies and open
      access models. This article aims to give an overview of the innovative strategies
      for peer review and to consider perspectives that may be helpful in introducing
      changes to peer review. Critical assessments of peer review innovations and
      incentives based on past and present experiences are indispensable. A theoretical
      appraisal must be balanced by a realistic appraisal of the ethical roles of all
      stakeholders in enhancing the peer review process. As the peer review system is
      far from being perfect, identifying and developing core competencies among
      reviewers, continuing education of researchers, reviewer education and training, 
      and professional engagement of the scientific community in various disciplines
      may help bridge gaps in an imperfect but indispensable peer review system.
CI  - (c) 2020 The Korean Academy of Medical Sciences.
FAU - Barroga, Edward
AU  - Barroga E
AUID- ORCID: https://orcid.org/0000-0002-8920-2607
AD  - Department of General Education, Graduate School of Nursing Science, St. Luke's
      International University, Tokyo, Japan. edward-barroga@slcn.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
SB  - IM
MH  - Biomedical Research
MH  - Education, Continuing
MH  - *Peer Review
PMC - PMC7246191
OTO - NOTNLM
OT  - Bias
OT  - Education
OT  - Open Access Publishing
OT  - Peer Review
OT  - Peer Reviewer
OT  - Publications
COIS- The author has no potential conflicts of interest to disclose.
EDAT- 2020/05/26 06:00
MHDA- 2020/05/28 06:00
CRDT- 2020/05/26 06:00
PHST- 2019/08/29 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
AID - 35.e138 [pii]
AID - 10.3346/jkms.2020.35.e138 [doi]
PST - epublish
SO  - J Korean Med Sci. 2020 May 25;35(20):e138. doi: 10.3346/jkms.2020.35.e138.


PMID- 32449301
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1552-4833 (Electronic)
IS  - 1552-4825 (Linking)
VI  - 182
IP  - 7
DP  - 2020 Jul
TI  - Parent perceptions, beliefs, and fears around genetic treatments and cures for
      children with Angelman syndrome.
PG  - 1716-1724
LID - 10.1002/ajmg.a.61631 [doi]
AB  - Genetic therapies have shown recent promise in alleviating some of the cognitive 
      issues associated with some genetic disorders; however, these therapies may come 
      with significant health and socio-ethical concerns, particularly when they
      involve child participants. Little is known about what parents of children with
      genetic disorders think about genetic therapies, or about their knowledge of how 
      genetic-based therapy might treat their child's symptoms. Forty-two parents of
      children with Angelman syndrome (AS) and 27 parents of a mixed etiology
      comparison group completed an online survey reporting on their perceptions of,
      and priorities for, genetic therapy. Almost all parents of children with AS (95%)
      and the comparison group (89%) agreed that treatments aiming to reduce symptoms
      associated with their child's syndrome were positive. However, significantly more
      parents of children with AS (95%) than the comparison group (56%) felt that
      genetic treatment trials aiming to "cure" their child should be a research
      priority. AS parent priorities for the focus of clinical trials were
      neurology/seizures, communication skills, and motor skills/mobility. For the
      comparison group, the priorities were IQ, immune response, and expressive speech.
      Parents of both groups did not want treatments to change their child's
      personality or their happiness. Global assumptions cannot be made about targets
      for therapy between syndromes, about parental understanding of genetics, or about
      research evidence across syndromes. This study highlights the need for true
      family and patient engagement in all stages of the research design and treatment 
      evaluation.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Adams, Dawn
AU  - Adams D
AUID- ORCID: 0000-0001-8001-0126
AD  - Autism Centre of Excellence, Griffith University, Brisbane, Queensland,
      Australia.
FAU - Roche, Laura
AU  - Roche L
AUID- ORCID: 0000-0002-0960-4973
AD  - Autism Centre of Excellence, Griffith University, Brisbane, Queensland,
      Australia.
FAU - Heussler, Helen
AU  - Heussler H
AD  - Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's
      Health Queensland, Brisbane, Queensland, Australia.
AD  - Centre for Children's Health Research, University of Queensland, Brisbane,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200525
PL  - United States
TA  - Am J Med Genet A
JT  - American journal of medical genetics. Part A
JID - 101235741
SB  - IM
MH  - Adolescent
MH  - Angelman Syndrome/epidemiology/psychology/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Communication
MH  - Family/psychology
MH  - Fear/psychology
MH  - Female
MH  - Genetic Therapy/*psychology
MH  - Humans
MH  - Male
MH  - Parents/*psychology
MH  - Perception/physiology
OTO - NOTNLM
OT  - *genetic
OT  - *intervention
OT  - *parent
OT  - *priorities
OT  - *syndrome
OT  - *treatment
EDAT- 2020/05/26 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/05/26 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2020/02/27 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/05/26 06:00 [entrez]
AID - 10.1002/ajmg.a.61631 [doi]
PST - ppublish
SO  - Am J Med Genet A. 2020 Jul;182(7):1716-1724. doi: 10.1002/ajmg.a.61631. Epub 2020
      May 25.


PMID- 32448882
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220531
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 5
DP  - 2020 May
TI  - Medical assistance in dying: just an ethical or legal issue?
PG  - 316-326
LID - 10.1701/3366.33413 [doi]
AB  - According to current vital statistics suicide appears as a growing public health 
      problem in most Western countries. However, suicide is rarely discussed in
      scientific journals, possibly because of a persisting moral stigma. As a
      consequence, the diverse bases of suicidal behavior are little understood while
      the role of Chronic-Degenerative Terminal Diseases (CDTD) has been poorly
      investigated. In the present study, the topic of suicidality was addressed in a
      clinical, holistic, perspective in an attempt to clarify how, in some chronically
      ill patients, the decision to end their own life is taken independently from
      mental disorders, being conversely, the expression of a rational psychological
      pattern which copes with the burden of chronic illnesses to become an integral
      part of their clinical spectrum. An assisted suicide (AS) request should
      therefore be considered from a clinical point of view and not only as an ethical 
      or legal issue, in fact a holistic evaluation of the patient's situation must be 
      performed, conferring the decisions making process a further in-depth line of
      thinking. In this study we first examined the relationship between suicide and
      CDTD as reported in the medical literature; then we reviewed the psychological
      theories which allegedly explain suicidal behavior; finally we discussed the
      possible role of a full-fledged palliative care in preventing suicide and in
      managing death requests by CDTD patients.
FAU - Gristina, Giuseppe R
AU  - Gristina GR
AD  - Medico anestesista-rianimatore, Roma; Comitato Etico Societa Italiana di
      Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI).
FAU - Vergano, Marco
AU  - Vergano M
AD  - Medico anestesista-rianimatore, Servizio di Anestesia e Rianimazione, Ospedale
      San Giovanni Bosco, Torino; Coordinatore del Gruppo di Studio di Bioetica Societa
      Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI).
FAU - Orsi, Luciano
AU  - Orsi L
AD  - Medico palliativista, Crema; Direttore scientifico della Rivista Italiana di Cure
      Palliative.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
CIN - Recenti Prog Med. 2020 May;111(5):281-284. PMID: 32448874
MH  - *Euthanasia
MH  - Humans
MH  - Medical Assistance
MH  - Palliative Care
MH  - *Suicide, Assisted/psychology
EDAT- 2020/05/26 06:00
MHDA- 2022/04/14 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
AID - 10.1701/3366.33413 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 May;111(5):316-326. doi: 10.1701/3366.33413.


PMID- 32448874
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220413
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 5
DP  - 2020 May
TI  - [The role of the physician in addressing suicidal ideation: an anthropological
      and legal comment.]
PG  - 281-284
LID - 10.1701/3366.33405 [doi]
AB  - This editorial discusses, from an interdisciplinary legal-anthropological
      perspective, the essay "Medical assistance in dying: just an ethical or legal
      issue?" by Gristina et al. Starting from a review of the epidemiological data,
      the authors propose to consider suicidal ideation and suicide in patients
      affected by chronic-degenerative terminal diseases (CDTD) not only as a
      consequence of a mental disorder, but as a psychological response to the burden
      of illness. Their approach, we argue, requires a rethinking of the role of the
      physician as well as of the therapeutic alliance, which should include active
      listening and a co-constructed reflection on the end of life. Moreover, the essay
      offers a change of perspective from which to consider the current debates within 
      the legal and professional fields, raising new challenges not only to medicine,
      but also to the law and to medical ethics.
FAU - Vargas, Ana Cristina
AU  - Vargas AC
FAU - Pulice, Elisabetta
AU  - Pulice E
AD  - PhD in studi giuridici comparati ed europei. Facolta di Giurisprudenza,
      Universita di Trento; Laboratorio dei Diritti Fondamentali, Torino.
LA  - ita
PT  - Journal Article
PT  - Comment
TT  - Il ruolo del medico di fronte alla scelta suicidaria: un commento
      antropologico-giuridico.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
CON - Recenti Prog Med. 2020 May;111(5):316-326. PMID: 32448882
MH  - Ethics, Medical
MH  - Humans
MH  - *Physicians
MH  - Suicidal Ideation
MH  - *Suicide/prevention & control
EDAT- 2020/05/26 06:00
MHDA- 2022/04/14 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
AID - 10.1701/3366.33405 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 May;111(5):281-284. doi: 10.1701/3366.33405.


PMID- 32448873
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220413
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 5
DP  - 2020 May
TI  - [If help with suicide knocks on the door of medicine.]
PG  - 279-280
LID - 10.1701/3366.33404 [doi]
AB  - Most codes of ethics states that physician-assisted suicide is prohibited, mainly
      because it is "fundamentally incompatible with the physician's role as healer".
      It would also be difficult to control, and would pose serious societal risks.
      Physician-assisted suicide is contrary to the Hippocratic Oath, when it states
      that no doctors will give deadly medicine to anyone if asked, nor will suggest
      any such counsel. The push towards a change of legislation, in a permissive
      sense, and some acquittal judgments have led the top of professional orders to
      decide that, under certain conditions, disciplinary sanctions should not be
      imposed on doctors who facilitate a patient's death (6th February 2020). This
      scenario poses a challenge to the medical profession. The request for death must 
      be evaluated in the framework of a "shared planning of care".
FAU - Spinsanti, Sandro
AU  - Spinsanti S
AD  - Istituto Giano, Roma.
LA  - ita
PT  - Journal Article
TT  - Se l'aiuto al suicidio bussa alla porta della medicina.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - *Ethics, Medical
MH  - Hippocratic Oath
MH  - Humans
MH  - Physician's Role
MH  - *Suicide, Assisted
EDAT- 2020/05/26 06:00
MHDA- 2022/04/14 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
AID - 10.1701/3366.33404 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 May;111(5):279-280. doi: 10.1701/3366.33404.


PMID- 32448797
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 24
TI  - Canadian clinical practice guidelines for the use of plant-based cannabis and
      cannabinoid-based products in the management of chronic non-cancer pain and
      co-occurring conditions: protocol for a systematic literature review.
PG  - e036114
LID - 10.1136/bmjopen-2019-036114 [doi]
AB  - INTRODUCTION: Chronic pain and co-occurring disorders, such as sleep disorders,
      anxiety, depression, post-traumatic stress disorder and substance use disorders, 
      are among the most common conditions for which cannabis and cannabinoid-based
      products derived from the cannabis plant (CBP) are used for therapeutic purposes.
      However, healthcare providers report that they lack sufficient information on the
      risks, benefits and appropriate use of cannabis and CBP derived from the cannabis
      plant for therapeutic purposes. METHODS AND ANALYSIS: We will conduct a
      systematic review of studies investigating the use of cannabis and CBP derived
      from the cannabis plant for the treatment of chronic pain and co-occurring
      conditions. Randomised controlled trials, meta-analyses and observational studies
      will be prioritised. We will exclude reviews of cannabinoid mechanisms of
      actions, commentary articles and narrative reviews. The primary outcome of
      interest will be efficacy in relieving chronic pain. Secondary outcomes will be
      efficacy in ameliorating conditions such as sleep disorders, anxiety, depression,
      post-traumatic stress disorder and substance use disorders. We will search
      electronic bibliographic databases including Academic Search Complete, Cochrane
      Database of Systematic Reviews, Evidence based Medicine Reviewes, OVID Medline,
      PsychINFO, PubMed, CINAHL and Web of Science. Two reviewers will conduct
      screening and data collection independently. Study level of bias will be assessed
      using the Cochrane Risk of Bias Assessment Tool for randomised controlled trials 
      and non-randomised studies. Narrative analysis will be utilised to interpret the 
      data. ETHICS AND DISSEMINATION: The results of this systematic review will inform
      guideline development for the use of cannabis and CBP derived from the cannabis
      plant in the management of chronic pain and co-occurring conditions. Areas
      requiring further study will also be highlighted. PROSPERO REGISTRATION NUMBER:
      CRD42020135886.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wright, Patrick
AU  - Wright P
AD  - Canadian AIDS Society, Ottawa, Ontario, Canada.
FAU - Walsh, Zach
AU  - Walsh Z
AD  - Department of Psychology, University of British Columbia, Kelowna, British
      Columbia, Canada.
FAU - Margolese, Shari
AU  - Margolese S
AD  - Canadian HIV Trials Network Community Advisory Board, Vancouver, British
      Columbia, Canada.
FAU - Sanchez, Tatiana
AU  - Sanchez T
AD  - Department of Psychology, University of British Columbia, Kelowna, British
      Columbia, Canada.
FAU - Arlt, Stephanie
AU  - Arlt S
AD  - Canadian Institute for Substance Use Research,University of Victoria, Victoria,
      British Columbia, Canada.
FAU - Belle-Isle, Lynne
AU  - Belle-Isle L
AD  - Canadian AIDS Society, Ottawa, Ontario, Canada.
FAU - St Pierre, Michelle
AU  - St Pierre M
AD  - Department of Psychology, University of British Columbia, Kelowna, British
      Columbia, Canada.
FAU - Bell, Alan
AU  - Bell A
AD  - Department of Family and Community Medicine, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Daeninck, Paul
AU  - Daeninck P
AD  - Department of Internal Medicine, Max Rady College of Medicine, University of
      Manitoba, Winnipeg, Manitoba, Canada.
FAU - Gagnon, Marilou
AU  - Gagnon M
AD  - Canadian Institute for Substance Use Research, University of Victoria, Victoria, 
      British Columbia, Canada.
FAU - Lacasse, Gary
AU  - Lacasse G
AD  - Canadian AIDS Society, Ottawa, Ontario, Canada gary.lacasse@cdnaids.ca.
FAU - MacCallum, Caroline
AU  - MacCallum C
AD  - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia,
      Canada.
FAU - Mandarino, Enrico
AU  - Mandarino E
AD  - Community Advisory, Canadian Institutes of Health Research Canadian HIV Trials
      Network, Vancouver, British Columbia, Canada.
AD  - MJardin Canada, Toronto, Ontario, Canada.
FAU - Yale, Janet
AU  - Yale J
AD  - Arthritis Society of Canada, Toronto, Ontario, Canada.
FAU - O'Hara, James
AU  - O'Hara J
AD  - Canadians for Fair Access to Medical Marijuana, Toronto, Ontario, Canada.
FAU - Costiniuk, Cecilia
AU  - Costiniuk C
AUID- ORCID: 0000-0002-4547-714X
AD  - Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada.
LA  - eng
GR  - Canadian Institutes for Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200524
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Cannabinoids)
SB  - IM
MH  - Analgesics, Opioid
MH  - Canada
MH  - *Cannabinoids
MH  - *Cannabis
MH  - *Chronic Pain/drug therapy
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7253000
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *pain management
OT  - *sleep medicine
OT  - *substance misuse
OT  - *therapeutics
EDAT- 2020/05/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036114 [pii]
AID - 10.1136/bmjopen-2019-036114 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 24;10(5):e036114. doi: 10.1136/bmjopen-2019-036114.


PMID- 32448796
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 24
TI  - Study protocol for the antidepressant advisor (ADeSS): a decision support system 
      for antidepressant treatment for depression in UK primary care: a feasibility
      study.
PG  - e035905
LID - 10.1136/bmjopen-2019-035905 [doi]
AB  - INTRODUCTION: The Antidepressant Advisor Study is a feasibility trial of a
      computerised decision-support tool which uses an algorithm to provide
      antidepressant treatment guidance for general practitioners (GPs) in the UK
      primary care service. The tool is the first in the UK to implement national
      guidelines on antidepressant treatment guidance into a computerised
      decision-support tool. METHODS AND ANALYSIS: The study is a parallel group,
      cluster-randomised controlled feasibility trial where participants are blind to
      treatment allocation. GPs were assigned to two treatment arms: (1)
      treatment-as-usual (TAU) and (2) computerised decision-support tool to assist
      with antidepressant choices. The study will assess recruitment and lost to
      follow-up rates, GP satisfaction with the tool and impact on health service use. 
      A meaningful long-term roll-out unit cost will be calculated for the tool, and
      service use data will be collected at baseline and follow-up to inform a full
      economic evaluation of a future trial. ETHICS AND DISSEMINATION: The study has
      received National Health Service ethical approval from the London-Camberwell St
      Giles Research Ethics Committee (ref: 17/LO/2074). The trial was pre-registered
      in the Clinical Trials.gov registry. The results of the study will be published
      in a pre-publication archive within 1 year of completion of the last follow-up
      assessment. TRIAL REGISTRATION NUMBER: NCT03628027.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Harrison, Phillippa
AU  - Harrison P
AUID- ORCID: 0000-0002-5039-7822
AD  - Centre for Affective Disorders, Department of Psychological Medicine, Institute
      of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
FAU - Carr, Ewan
AU  - Carr E
AD  - Department of Biostatistics and Health Informatics, Institute of Psychiatry,
      Psychology & Neuroscience, King's College London, London, UK.
FAU - Goldsmith, Kimberley
AU  - Goldsmith K
AD  - Department of Biostatistics and Health Informatics, Institute of Psychiatry,
      Psychology & Neuroscience, King's College London, London, UK.
FAU - Young, Allan H
AU  - Young AH
AD  - Centre for Affective Disorders, Department of Psychological Medicine, Institute
      of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
FAU - Ashworth, Mark
AU  - Ashworth M
AUID- ORCID: 0000-0001-6514-9904
AD  - Department of Population Health Sciences, King's College London, London, UK.
FAU - Fennema, Diede
AU  - Fennema D
AD  - Centre for Affective Disorders, Department of Psychological Medicine, Institute
      of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
FAU - Barrett, Barbara
AU  - Barrett B
AD  - Department of Health Services & Population Research, Institute of Psychiatry,
      Psychology & Neuroscience, King's College London, London, UK.
FAU - Zahn, Roland
AU  - Zahn R
AD  - Centre for Affective Disorders, Department of Psychological Medicine, Institute
      of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
      Roland.zahn@kcl.ac.uk.
LA  - eng
SI  - ClinicalTrials.gov/NCT03628027
GR  - CIHR/Canada
GR  - MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200524
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/*therapeutic use
MH  - Clinical Protocols/*standards
MH  - Cost-Benefit Analysis
MH  - *Decision Support Systems, Clinical
MH  - Depression/*drug therapy
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Health Care
MH  - State Medicine
MH  - United Kingdom
PMC - PMC7252992
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *depression & mood disorders
OT  - *primary care
COIS- Competing interests: AHY is employed by King's College London as an honorary
      consultant in the South London and Maudsley Trust (NHS UK) and is a consultant to
      Johnson & Johnson and Livanova. AHY has given paid lectures and sat on advisory
      boards for the following companies with drugs used in affective and related
      disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova,
      Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma. AHY has received
      honoraria for attending advisory boards and presenting talks at meetings
      organised by LivaNova. AHY is the Principal Investigator of the following
      studies: Restore-Life VNS registry study funded by LivaNova, ESKETINTRD3004: 'An 
      Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in
      Treatment-resistant Depression', 'The Effects of Psilocybin on Cognitive Function
      in Healthy Participants'and 'The Safety and Efficacy of Psilocybin in
      Participants with Treatment-Resistant Depression (P-TRD)'. AHY has received grant
      funding (past and present) from the following: NIMH (USA); CIHR (Canada); NARSAD 
      (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK);
      Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC
      (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK);
      Janssen (UK). AHY has no shareholdings in pharmaceutical companies. RZ is a
      private psychiatrist service provider at The London Depression Institute and
      co-investigator on a Livanova-funded observational study of Vagus Nerve
      Stimulation for Depression. RZ has received honorarium for talks at three medical
      symposia sponsored by Lundbeck as well as a talk funded by Janssen whom he
      collaborates with on an MRC-funded grant. KG reports grants from NIHR, Stroke
      association, National Institutes of Health (US) and Juvenile Diabetes Research
      Foundation (US) during the conduct of the study. EC reports personal fees from
      NIHR during the conduct of the study. BB reports grants from NIHR Research for
      Patient Benefit during the conduct of the study.
EDAT- 2020/05/26 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035905 [pii]
AID - 10.1136/bmjopen-2019-035905 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 24;10(5):e035905. doi: 10.1136/bmjopen-2019-035905.


PMID- 32448795
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 24
TI  - Multicentric study of cervical cancer screening with human papillomavirus testing
      and assessment of triage methods in Latin America: the ESTAMPA screening study
      protocol.
PG  - e035796
LID - 10.1136/bmjopen-2019-035796 [doi]
AB  - INTRODUCTION: Human papillomavirus (HPV) testing is replacing cytology in primary
      screening. Its limited specificity demands using a second (triage) test to better
      identify women at high-risk of cervical disease. Cytology represents the
      immediate triage but its low sensitivity might hamper HPV testing sensitivity,
      particularly in low-income and middle-income countries (LMICs), where cytology
      performance has been suboptimal. The ESTAMPA (EStudio multicentrico de TAMizaje y
      triaje de cancer de cuello uterino con pruebas del virus del PApiloma humano;
      Spanish acronym) study will: (1) evaluate the performance of different triage
      techniques to detect cervical precancer and (2) inform on how to implement
      HPV-based screening programmes in LMIC. METHODS AND ANALYSIS: Women aged 30-64
      years are screened with HPV testing and Pap across 12 study centres in Latin
      America. Screened positives have colposcopy with biopsy and treatment of lesions.
      Women with no evident disease are recalled 18 months later for another HPV test; 
      those HPV-positive undergo colposcopy with biopsy and treatment as needed.
      Biological specimens are collected in different visits for triage testing, which 
      is not used for clinical management. The study outcome is histological high-grade
      squamous intraepithelial or worse lesions (HSIL+) under the lower anogenital
      squamous terminology. About 50 000 women will be screened and 500 HSIL+ cases
      detected (at initial and 18 months screening). Performance measures (sensitivity,
      specificity and predictive values) of triage techniques to detect HSIL+ will be
      estimated and compared with adjustment by age and study centre. ETHICS AND
      DISSEMINATION: The study protocol has been approved by the Ethics Committee of
      the International Agency for Research on Cancer (IARC), of the Pan American
      Health Organisation (PAHO) and by those in each participating centre. A Data and 
      Safety Monitoring Board (DSMB) has been established to monitor progress of the
      study, assure participant safety, advice on scientific conduct and analysis and
      suggest protocol improvements. Study findings will be published in peer-reviewed 
      journals and presented at scientific meetings. TRIAL REGISTRATION NUMBER:
      NCT01881659.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Almonte, Maribel
AU  - Almonte M
AUID- ORCID: 0000-0003-1623-8323
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France almontem@iarc.fr.
FAU - Murillo, Raul
AU  - Murillo R
AD  - Pontificia Universidad Javeriana, Bogota, Colombia.
FAU - Sanchez, Gloria Ines
AU  - Sanchez GI
AD  - Grupo de Infeccion y Cancer, Universidad de Antioquia, Medellin, Colombia.
FAU - Gonzalez, Paula
AU  - Gonzalez P
AD  - Agencia Costarricense de Investigaciones Biomedicas (ACIB), Fundacion Inciensa,
      Guanacaste, Costa Rica.
FAU - Ferrera, Annabelle
AU  - Ferrera A
AD  - Instituto de Investigaciones en Microbiologia, Universidad Nacional Autonoma de
      Honduras (UNAH), Tegucigalpa, Honduras.
FAU - Picconi, Maria Alejandra
AU  - Picconi MA
AD  - Instituto Nacional de Enfermedades Infecciosas - ANLIS Malbran, Buenos Aires,
      Argentina.
FAU - Wiesner, Carolina
AU  - Wiesner C
AD  - Instituto Nacional de Cancerologia, Bogota, Colombia.
FAU - Cruz-Valdez, Aurelio
AU  - Cruz-Valdez A
AD  - Instituto de Salud Publica de Mexico, Morelos, Mexico.
FAU - Lazcano-Ponce, Eduardo
AU  - Lazcano-Ponce E
AD  - Instituto de Salud Publica de Mexico, Morelos, Mexico.
FAU - Jeronimo, Jose
AU  - Jeronimo J
AD  - Liga contra el Cancer-Peru, Lima, Peru.
FAU - Ferreccio, Catterina
AU  - Ferreccio C
AD  - Advanced Center for Chronic Diseases, ACCDiS, Facultad de Medicina, Pontificia
      Universidad Catolica de Chile, Santiago, Chile.
FAU - Kasamatsu, Elena
AU  - Kasamatsu E
AD  - Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de
      Asuncion, San Lorenzo, Paraguay.
FAU - Mendoza, Laura
AU  - Mendoza L
AD  - Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de
      Asuncion, San Lorenzo, Paraguay.
FAU - Rodriguez, Guillermo
AU  - Rodriguez G
AD  - Comision Honoraria de Lucha contra el Cancer, Montevideo, Uruguay.
FAU - Calderon, Alejandro
AU  - Calderon A
AD  - Caja Costarricense de Seguro Social (CCSS), Region Pacifico Central, San Jose,
      Costa Rica.
FAU - Venegas, Gino
AU  - Venegas G
AD  - Clinica Angloamericana, Lima, Peru.
AD  - Escuela de Medicina Humana, Universidad de Piura, Lima, Peru.
FAU - Villagra, Veronica
AU  - Villagra V
AD  - Laboratorio Central de Salud Publica, Asuncion, Paraguay.
FAU - Tatti, Silvio
AU  - Tatti S
AD  - Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina.
FAU - Fleider, Laura
AU  - Fleider L
AD  - Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina.
FAU - Teran, Carolina
AU  - Teran C
AD  - Facultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco
      Xavier de Chuquisaca, Sucre, Bolivia.
FAU - Baena, Armando
AU  - Baena A
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France.
FAU - Hernandez, Maria de la Luz
AU  - Hernandez ML
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France.
AD  - SMS-Oncology, Amsterdam, The Netherlands.
FAU - Rol, Mary Luz
AU  - Rol ML
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France.
FAU - Lucas, Eric
AU  - Lucas E
AD  - Screening Group, International Agency for Research on Cancer, Lyon, Rhone-Alpes, 
      France.
FAU - Barbier, Sylvaine
AU  - Barbier S
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France.
FAU - Ramirez, Arianis Tatiana
AU  - Ramirez AT
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France.
FAU - Arrossi, Silvina
AU  - Arrossi S
AD  - Centro de Estudios de Estado y Sociedad/Consejo Nacional de Investigaciones
      Cientificas y Tecnicas, Buenos Aires, Argentina.
FAU - Rodriguez, Maria Isabel
AU  - Rodriguez MI
AD  - Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de
      Asuncion, San Lorenzo, Paraguay.
FAU - Gonzalez, Emmanuel
AU  - Gonzalez E
AD  - Hospital Dr Enrique Baltodano Briceno, CCSS, Liberia, Costa Rica.
FAU - Celis, Marcela
AU  - Celis M
AD  - Instituto Nacional de Cancerologia, Bogota, Colombia.
FAU - Martinez, Sandra
AU  - Martinez S
AD  - Instituto Nacional de Cancerologia, Bogota, Colombia.
FAU - Salgado, Yuly
AU  - Salgado Y
AD  - Instituto Nacional de Cancerologia, Bogota, Colombia.
FAU - Ortega, Marina
AU  - Ortega M
AD  - Hospital Nacional, Ministerio de Salud Publica y Bienestar Social, Itaugua,
      Paraguay.
AD  - Instituto Nacional del Cancer, Ministerio de Salud Publica y Bienestar Social,
      Capiata, Paraguay.
FAU - Beracochea, Andrea Veronica
AU  - Beracochea AV
AD  - Centro de Salud Ciudad de la Costa, ASSE, Ciudad de la Costa, Uruguay.
AD  - Hospital Policial, DNASS, Montevideo, Uruguay.
FAU - Perez, Natalia
AU  - Perez N
AD  - Hospital de Clinicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay.
FAU - Rodriguez de la Pena, Margarita
AU  - Rodriguez de la Pena M
AD  - Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina.
FAU - Ramon, Maria
AU  - Ramon M
AD  - Patologia Oncologica SAC, Lima, Peru.
FAU - Hernandez-Nevarez, Pilar
AU  - Hernandez-Nevarez P
AD  - Instituto de Salud Publica de Mexico, Morelos, Mexico.
FAU - Arboleda-Naranjo, Margarita
AU  - Arboleda-Naranjo M
AD  - Instituto Colombiano de Medicina Tropical Antonio Roldan Betancur, Universidad
      CES, Apartado, Colombia.
FAU - Cabrera, Yessy
AU  - Cabrera Y
AD  - Instituto de Investigaciones en Microbiologia, Universidad Nacional Autonoma de
      Honduras (UNAH), Tegucigalpa, Honduras.
FAU - Salgado, Brenda
AU  - Salgado B
AD  - Secretaria de Salud, Tegucigalpa, Honduras.
FAU - Garcia, Laura
AU  - Garcia L
AD  - Laboratorio de Biologia Molecular, Departamento de Patologia Clinica, Centro
      Hospitalario Pereira Rossell, Montevideo, Uruguay.
FAU - Retana, Marco Antonio
AU  - Retana MA
AD  - Hospital Dr Rafael Angel Calderon Guardia, CCSS, San Jose, Costa Rica.
FAU - Colucci, Maria Celeste
AU  - Colucci MC
AD  - Instituto Nacional de Enfermedades Infecciosas - ANLIS Malbran, Buenos Aires,
      Argentina.
FAU - Arias-Stella, Javier
AU  - Arias-Stella J
AD  - Instituto de Patologia y Biologia Molecular, Lima, Peru.
FAU - Bellido-Fuentes, Yenny
AU  - Bellido-Fuentes Y
AD  - Liga contra el Cancer-Peru, Lima, Peru.
FAU - Bobadilla, Maria Liz
AU  - Bobadilla ML
AD  - Laboratorio Central de Salud Publica, Asuncion, Paraguay.
FAU - Olmedo, Gladys
AU  - Olmedo G
AD  - Laboratorio Central de Salud Publica, Asuncion, Paraguay.
FAU - Brito-Garcia, Ivone
AU  - Brito-Garcia I
AD  - Instituto de Salud Publica de Mexico, Morelos, Mexico.
FAU - Mendez-Herrera, Armando
AU  - Mendez-Herrera A
AD  - Instituto de Salud Publica de Mexico, Morelos, Mexico.
FAU - Cardinal, Lucia
AU  - Cardinal L
AD  - Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina.
FAU - Flores, Betsy
AU  - Flores B
AD  - Facultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco
      Xavier de Chuquisaca, Sucre, Bolivia.
FAU - Penaranda, Jhacquelin
AU  - Penaranda J
AD  - Facultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco
      Xavier de Chuquisaca, Sucre, Bolivia.
FAU - Martinez-Better, Josefina
AU  - Martinez-Better J
AD  - ESE Hospital Antonio Roldan Betancur, Apartado, Colombia.
FAU - Soilan, Ana
AU  - Soilan A
AD  - Hospital Nacional, Ministerio de Salud Publica y Bienestar Social, Itaugua,
      Paraguay.
AD  - Hospital Materno Infantil de San Lorenzo, Ministerio de Salud Publica y Bienestar
      Social, San Lorenzo, Paraguay.
FAU - Figueroa, Jacqueline
AU  - Figueroa J
AD  - Programa Nacional contra el Cancer, Tegucigalpa, Honduras.
FAU - Caserta, Benedicta
AU  - Caserta B
AD  - Departamento de Anatomia Patologica y Citologia, Hospital de la Mujer, Centro
      Hospitalario Pereira Rossell, Montevideo, Uruguay.
FAU - Sosa, Carlos
AU  - Sosa C
AD  - Hospital Monsenor Victor Manuel Sanabria Martinez, CCSS, Puntarenas, Costa Rica.
FAU - Moreno, Adrian
AU  - Moreno A
AD  - Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina.
FAU - Mural, Juan
AU  - Mural J
AD  - Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina.
FAU - Doimi, Franco
AU  - Doimi F
AD  - Patologia Oncologica SAC, Lima, Peru.
FAU - Gimenez, Diana
AU  - Gimenez D
AD  - Hospital Materno Infantil de Trinidad, Ministerio de Salud Publica y Bienestar
      Social, Asuncion, Paraguay.
FAU - Rodriguez, Hernando
AU  - Rodriguez H
AD  - Hospital Materno Infantil de Trinidad, Ministerio de Salud Publica y Bienestar
      Social, Asuncion, Paraguay.
FAU - Lora, Oscar
AU  - Lora O
AD  - Facultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco
      Xavier de Chuquisaca, Sucre, Bolivia.
AD  - Hospital Gineco-Obstetrico y Neonatal "Dr Jaime Sanchez Porcel", Sucre, Bolivia.
FAU - Luciani, Silvana
AU  - Luciani S
AD  - Pan American Health Organization (PAHO), Washington, District of Columbia, USA.
FAU - Broutet, Nathalie
AU  - Broutet N
AD  - Department of Sexual and Reproductive Health and Research, World Health
      Organization, Geneva, Switzerland.
FAU - Darragh, Teresa
AU  - Darragh T
AD  - Department of Pathology, University of California, San Francisco, California,
      USA.
FAU - Herrero, Rolando
AU  - Herrero R
AD  - Prevention and Implementation Group, International Agency for Research on Cancer,
      Lyon, Rhone-Alpes, France.
AD  - Agencia Costarricense de Investigaciones Biomedicas (ACIB), Fundacion Inciensa,
      Guanacaste, Costa Rica.
LA  - eng
SI  - ClinicalTrials.gov/NCT01881659
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200524
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Alphapapillomavirus/*isolation & purification
MH  - Cervical Intraepithelial Neoplasia/*diagnosis
MH  - Colposcopy
MH  - *Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Latin America
MH  - Middle Aged
MH  - Papillomavirus Infections/*diagnosis
MH  - *Triage
MH  - Uterine Cervical Neoplasms/diagnosis
PMC - PMC7252979
OTO - NOTNLM
OT  - *colposcopy
OT  - *gynaecological oncology
OT  - *molecular diagnostics
OT  - *preventive medicine
OT  - *public health
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/05/26 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035796 [pii]
AID - 10.1136/bmjopen-2019-035796 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 24;10(5):e035796. doi: 10.1136/bmjopen-2019-035796.


PMID- 32448790
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 24
TI  - 10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine
      (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster 
      dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in
      Australian Aboriginal children: study protocol for a randomised controlled trial.
PG  - e033511
LID - 10.1136/bmjopen-2019-033511 [doi]
AB  - INTRODUCTION: Streptococcus pneumoniae and non-typeable Haemophilus influenzae
      (NTHi) are major otitis media pathogens that densely co-colonise the nasopharynx 
      and infect the middle ear of Australian Aboriginal infants from very early in
      life. Our co-primary hypotheses are that at 18 months of age infants receiving
      10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine
      (PHiD-CV10) compared with those receiving 13-valent pneumococcal conjugate
      vaccine (PCV13) as a booster at 12 months of age will have higher antibody levels
      to Haemophilus influenzae protein D and that infants receiving PCV13 will have
      higher antibody levels to PCV13-only serotypes 3, 6A and 19A. METHODS AND
      ANALYSES: Our randomised controlled trial will enrol 270 Aboriginal children at
      12 months of age to a booster dose of either PHiD-CV10 or PCV13. Children who
      completed the three-dose primary course schedules of PHiD-CV10 at 2, 4, 6 months 
      of age; PCV13 at 2, 4, 6 months of age; or a combination schedule of PHiD-CV10 at
      1, 2, 4 months of age plus PCV13 at 6 months of age are eligible. The co-primary 
      assessor-blinded outcomes when the infants are 18 months of age are as follows:
      (a) IgG geometric mean concentration (GMC) and proportion with IgG >/=100 EU/mL
      for protein D, and (b) IgG GMC and the proportion with IgG >/=0.35 microg/mL for 
      pneumococcal serotypes 3, 6A and 19A. Secondary immunogenicity comparisons of six
      primary and booster dose schedules of 10 shared serotypes at 18 months of age,
      nasopharyngeal carriage, all forms of otitis media, hearing loss and
      developmental milestones at 18, 24, 30 and 36 months of age will be reported.
      ETHICS AND DISSEMINATION: Ethics committees of NT Department of Health, Menzies, 
      WA Department of Health and WA Aboriginal Health approved the study. Results will
      be presented to communities, at conferences and published in peer-reviewed
      journals. TRIAL REGISTRATION NUMBER: NCT01735084.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Oguoma, Victor M
AU  - Oguoma VM
AUID- ORCID: 0000-0001-9505-7197
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Wilson, Nicole
AU  - Wilson N
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Mulholland, Kim
AU  - Mulholland K
AD  - Infection and Immunity: Pneumococcal Research, Murdoch Childrens Research
      Institute, Parkville, Victoria, Australia.
FAU - Santosham, Mathuram
AU  - Santosham M
AD  - Center American Indian Health, John Hopkins School of Public Health, Baltimore,
      Maryland, USA.
FAU - Torzillo, Paul
AU  - Torzillo P
AD  - Respiratory Medicine, Prince Alfred Hospital, Sydney, New South Wales, Australia.
FAU - McIntyre, Peter
AU  - McIntyre P
AD  - Director, National Centre for Immunisation Research and Surveillance, Sydney, New
      South Wales, Australia.
FAU - Smith-Vaughan, Heidi
AU  - Smith-Vaughan H
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Balloch, Anne
AU  - Balloch A
AD  - Pneumococcal Immunology, Murdoch Childrens Research Institute, Melbourne,
      Victoria, Australia.
FAU - Chatfield, Mark
AU  - Chatfield M
AD  - Cerebral Palsy and Rehabilitation Research Centre, University of Queensland,
      Brisbane, Queensland, Australia.
FAU - Lehmann, Deborah
AU  - Lehmann D
AD  - Division of Population Sciences, Telethon Institute for Child Health Research,
      West Perth, Western Australia, Australia.
FAU - Binks, Michael J
AU  - Binks MJ
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Chang, Anne
AU  - Chang A
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Carapetis, Jonathan
AU  - Carapetis J
AD  - Director, Telethon Kids Institute, Perth, Western Australia, Australia.
FAU - Krause, Vicki
AU  - Krause V
AD  - Centre for Disease Control, Department of Health, Darwin, Northern Territory,
      Australia.
FAU - Andrews, Ross
AU  - Andrews R
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Snelling, Tom
AU  - Snelling T
AD  - Infectious Disease Implementation Research Team, Princess Margaret Hospital for
      Children, Perth, Western Australia, Australia.
AD  - Wesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute,
      West Perth, Western Australia, Australia.
FAU - Licciardi, Paul
AU  - Licciardi P
AD  - Infections and Immunity: Pneumococcal Research, Murdoch Childrens Research
      Institute, Melbourne, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
      Australia.
FAU - Morris, Peter
AU  - Morris P
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia.
FAU - Leach, Amanda Jane
AU  - Leach AJ
AD  - Child Health Division, Menzies School of Health Research and Charles Darwin
      University, Darwin, Northern Territory, Australia amanda.leach@menzies.edu.au.
LA  - eng
SI  - ClinicalTrials.gov/NCT01735084
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200524
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (13-valent pneumococcal vaccine)
RN  - 0 (Pneumococcal Vaccines)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Australia
MH  - Child
MH  - Child, Preschool
MH  - Haemophilus influenzae/immunology
MH  - *Health Services, Indigenous
MH  - Humans
MH  - Infant
MH  - Native Hawaiian or Other Pacific Islander
MH  - *Otitis Media/prevention & control
MH  - *Pneumococcal Infections/prevention & control
MH  - Pneumococcal Vaccines
MH  - Randomized Controlled Trials as Topic
MH  - Vaccines, Conjugate
PMC - PMC7252982
OTO - NOTNLM
OT  - *PCV13
OT  - *PHiD-CV10
OT  - *nasopharyngeal carriage
OT  - *otitis media
COIS- Competing interests: In the last 5 years, AJL and PM have served on an OM
      Advisory Board for GSK and have received GSK support for the clinical outreach
      training program. KM has served on Advisory Boards for GSK who provided in kind
      support for the Vietnam Pneumococcal trial, of which he is the PI. His group is
      involved in a collaborative research project with Pfizer on adult pneumonia in
      Mongolia, and they have received a small grant to support research capacity
      building in the paediatric hospitals in Ho Chi Minh City, Vietnam. MS has served 
      on the Advisory Board of GSK and Pfizer. He is also co-investigator on projects
      funded by GSK and Pfizer. ABC serves on an independent data safety monitoring
      board for two unlicensed GSK vaccines studies currently under evaluation. DL has 
      received support from Pfizer Australia to attend conferences and is an
      investigator on an investigator-initiated research grant that was funded by
      Pfizer Australia.
EDAT- 2020/05/26 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-033511 [pii]
AID - 10.1136/bmjopen-2019-033511 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 24;10(5):e033511. doi: 10.1136/bmjopen-2019-033511.


PMID- 32448444
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210227
IS  - 1878-5921 (Electronic)
IS  - 0895-4356 (Linking)
VI  - 122
DP  - 2020 Jun
TI  - The 1960s cervical screening incident at National Women's Hospital, Auckland, New
      Zealand: insights for screening research, policy making, and practice.
PG  - A8-A13
LID - S0895-4356(20)30161-X [pii]
LID - 10.1016/j.jclinepi.2020.04.008 [doi]
AB  - BACKGROUND AND OBJECTIVES: This article examines a cervical screening incident
      from the 1960s and draws lessons for screening policy. STUDY DESIGN AND SETTING: 
      Concern about harmful overtreatment of symptomless lesions prompted university
      gynecologist Herbert Green to study, between 1965 and 1970, a 'special series' of
      33 women with carcinoma in situ (CIS) who were managed with only limited punch or
      wedge biopsy. These women were carefully followed up but not treated unless they 
      showed evidence of progression to invasive cancer. This paper examines source
      documents and subsequent publications in order to ascertain lessons from this
      incident. RESULTS: In keeping with the 1964 Helsinki Declaration, written consent
      was not sought. Green published the outcomes for his patients with CIS including 
      the 'special series.' A Judicial inquiry (the Cartwright Inquiry) in 1987
      concluded that some women had suffered harm and some had died, but numbers and
      evidence were not clearly stated. Medical case review for the Inquiry identified 
      25 women with only punch or wedge biopsy; in 21 of these, there were reasons why 
      no further treatment was given; two had developed cervical cancer, and none were 
      recorded as having died. The case review found eight patients, not necessarily in
      the 'special series,' who 'in retrospect and by 1987 standards' might have
      benefited from earlier conisation or hysterectomy. CONCLUSION: Subsequent claims 
      relating to Green's practice have wrongly stated that as many as one hundred
      women or more had treatment withheld and over 30 died as a result. These claims
      are inaccurate.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Raffle, Angela E
AU  - Raffle AE
AD  - Consultant in Public Health, The NHS Screening Programmes, Honorary Senior
      Lecturer, University of Bristol School of Community and Social Medicine, Bristol,
      UK. Electronic address: angela.raffle@bristol.ac.uk.
FAU - Gray, J A Muir
AU  - Gray JAM
AD  - UK National Screening Committee 1996-2007, Founding Director, The Oxford Centre
      for Triple Value Healthcare, Oxford, UK.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Epidemiol
JT  - Journal of clinical epidemiology
JID - 8801383
SB  - IM
CIN - J Clin Epidemiol. 2020 Jun;122:A14-A20. PMID: 32448442
CIN - J Clin Epidemiol. 2020 Jun;122:A6-A7. PMID: 32448443
CIN - J Clin Epidemiol. 2020 Nov;127:220-222. PMID: 33190720
CIN - J Clin Epidemiol. 2020 Nov;127:225-227. PMID: 33190722
CIN - J Clin Epidemiol. 2020 Nov;127:228. PMID: 33190723
CIN - J Clin Epidemiol. 2020 Nov;127:231. PMID: 33190725
CIN - J Clin Epidemiol. 2020 Nov;127:232-234. PMID: 33190726
CIN - J Clin Epidemiol. 2020 Nov;127:235-236. PMID: 33190727
CIN - J Clin Epidemiol. 2020 Nov;127:237-240. PMID: 33190728
MH  - Adult
MH  - Carcinoma in Situ/*diagnosis/*history/physiopathology/therapy
MH  - Ethics, Medical
MH  - Female
MH  - Health Policy/history
MH  - History, 20th Century
MH  - Humans
MH  - Mass Screening/*history/methods/*standards
MH  - Middle Aged
MH  - New Zealand/epidemiology
MH  - Practice Guidelines as Topic
MH  - Uterine Cervical Neoplasms/*diagnosis/*history/physiopathology/therapy
MH  - Withholding Treatment/*ethics/history
PS  - Green H
FPS - Green, Herbert
OTO - NOTNLM
OT  - *Cartwright inquiry
OT  - *Cervical screening
OT  - *Ethics of research
OT  - *Ethics of screening
OT  - *Overdiagnosis
OT  - *Overtreatment
EDAT- 2020/05/26 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - S0895-4356(20)30161-X [pii]
AID - 10.1016/j.jclinepi.2020.04.008 [doi]
PST - ppublish
SO  - J Clin Epidemiol. 2020 Jun;122:A8-A13. doi: 10.1016/j.jclinepi.2020.04.008.


PMID- 32448274
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 24
TI  - The state of ethics education at medical schools in Turkey: taking stock and
      looking forward.
PG  - 162
LID - 10.1186/s12909-020-02058-9 [doi]
AB  - BACKGROUND: Ethics teaching is globally considered an essential part of medical
      education fostering professionalism. It does not only provide knowledge for good 
      clinical conduct, but also trains medical students as virtuous practitioners.
      Although Turkey has had a considerable experience in ethics education of
      healthcare professionals, the general state of ethics curricula at medical
      schools in Turkey is unknown. METHODS: The purpose of this study was to collect
      comprehensive data about the ethics education programs at medical schools in
      Turkey. To this aim, we designed a cross-sectional descriptive questionnaire
      survey which focuses on the content, teaching years, teaching, assessment and
      evaluation methodologies, workforce and infrastructure. We delivered the
      questionnaire to all medical schools in Turkey. Seventy-nine medical schools
      participated in this study (response rate: 78%). RESULTS: Although most
      institutions had an undergraduate ethics curriculum (91.1%), the findings suggest
      deficiency of teaching personnel (34.2% had no instructors). Furthermore, the
      distribution and composition of the workforce was imbalanced. The content varies 
      largely among institutions. Medical schools with an ethics department were more
      likely to diversify teaching topics. However, ethics education was largely based 
      on the four-principle approach. The content was usually conveyed to students
      theoretically. Around 90% of schools had classroom lectures. It is the only
      method used at one-third of them. Clinical ethics education was mostly lacking.
      Multiple-choice tests were widely used to assess and evaluate student attainments
      (86.1%). CONCLUSIONS: Staff qualified to teach ethics and ethics education
      integrated into the six-year medical curriculum given by a multidisciplinary team
      are urgent necessities. Considering teaching, assessment and evaluation
      methodologies used, most medical schools seem to fall short of fostering students
      to develop ethical attitudes. Endeavors aiming for modern topics should be
      encouraged. As the organization ethics education change continuously, we think
      that a platform for monitoring ethics education at medical schools in Turkey
      should be established. Such a body would help ethics instructors to network and
      find solutions to current problems and build shared wisdom.
FAU - Kavas, Mustafa Volkan
AU  - Kavas MV
AUID- ORCID: http://orcid.org/0000-0003-1252-3469
AD  - Department of History of Medicine and Ethics, Ankara University, School of
      Medicine, Morfoloji Building, 06230, Ankara, Altindag, Turkey.
      kavas@ankara.edu.tr.
FAU - Ulman, Yesim Isil
AU  - Ulman YI
AD  - Department of History of Medicine and Ethics, Acibadem University, School of
      Medicine, Kayisdagi Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
FAU - Demir, Figen
AU  - Demir F
AD  - Department of Public Health, Acibadem University, School of Medicine, Kayisdagi
      Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
FAU - Artvinli, Fatih
AU  - Artvinli F
AD  - Department of History of Medicine and Ethics, Acibadem University, School of
      Medicine, Kayisdagi Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
FAU - Sahiner, Melike
AU  - Sahiner M
AD  - Department of Medical Education, Acibadem University, School of Medicine,
      Kayisdagi Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
FAU - Demiroren, Meral
AU  - Demiroren M
AD  - Department of Medical Education and Informatics, Hacettepe University, School of 
      Medicine, 06230, Ankara, Altindag, Turkey.
FAU - Senyurek, Gamze
AU  - Senyurek G
AD  - Department of History of Medicine and Ethics, Acibadem University, School of
      Medicine, Kayisdagi Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
FAU - Pakis, Isil
AU  - Pakis I
AD  - Department of Forensic Medicine, Acibadem University, School of Medicine,
      Kayisdagi Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
FAU - Bakirci, Nadi
AU  - Bakirci N
AD  - Department of Public Health, Acibadem University, School of Medicine, Kayisdagi
      Caddesi No:32, 34752, Istanbul, Atasehir, Turkey.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200524
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Cross-Sectional Studies
MH  - Curriculum/*standards
MH  - Education, Medical, Undergraduate/*standards
MH  - Ethics, Medical/*education
MH  - Faculty, Medical/*education
MH  - Humans
MH  - Surveys and Questionnaires
MH  - Turkey
PMC - PMC7245803
OTO - NOTNLM
OT  - Inventory
OT  - Turkey
OT  - assessment and evaluation
OT  - ethics curriculum
OT  - medical schools
OT  - survey
OT  - teaching and learning
OT  - workforce
EDAT- 2020/05/26 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/05/26 06:00
PHST- 2019/05/17 00:00 [received]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.1186/s12909-020-02058-9 [doi]
AID - 10.1186/s12909-020-02058-9 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 May 24;20(1):162. doi: 10.1186/s12909-020-02058-9.


PMID- 32448187
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 24
TI  - A study protocol for a randomized controlled trial of family-partnered delirium
      prevention, detection, and management in critically ill adults: the ACTIVATE
      study.
PG  - 453
LID - 10.1186/s12913-020-05281-8 [doi]
AB  - BACKGROUND: Delirium is very common in critically ill patients admitted to the
      intensive care unit (ICU) and results in negative long-term outcomes. Family
      members are also at risk of long-term complications, including depression and
      anxiety. Family members are frequently at the bedside and want to be engaged;
      they know the patient best and may notice subtle changes prior to the care team. 
      By engaging family members in delirium care, we may be able to improve both
      patient and family outcomes by identifying delirium sooner and capacitating
      family members in care. METHODS: The primary aim of this study is to determine
      the effect of family-administered delirium prevention, detection, and management 
      in critically ill patients on family member symptoms of depression and anxiety,
      compared to usual care. One-hundred and ninety-eight patient-family dyads will be
      recruited from four medical-surgical ICUs in Calgary, Canada. Dyads will be
      randomized 1:1 to the intervention or control group. The intervention consists of
      family-partnered delirium prevention, detection, and management, while the
      control group will receive usual care. Delirium, depression, and anxiety will be 
      measured using validated tools, and participants will be followed for 1- and
      3-months post-ICU discharge. All analyses will be intention-to-treat and adjusted
      for pre-identified covariates. Ethical approval has been granted by the
      University of Calgary Conjoint Health Research Ethics Board (REB19-1000) and the 
      trial registered. The protocol adheres to the Standard Protocol Items:
      Recommendations for Interventional Trials (SPIRIT) checklist. DISCUSSION:
      Critically ill patients are frequently unable to participate in their own care,
      and partnering with their family members is particularly important for improving 
      experiences and outcomes of care for both patients and families. TRIAL
      REGISTRATION: Registered September 23, 2019 on Clinicaltrials.gov NCT04099472.
FAU - Fiest, Kirsten M
AU  - Fiest KM
AUID- ORCID: http://orcid.org/0000-0002-7299-6594
AD  - Department of Critical Care Medicine, University of Calgary & Alberta Health
      Services, Calgary, Canada. kmfiest@ucalgary.ca.
AD  - Department of Community Health Sciences & O'Brien Institute of Public Health,
      University of Calgary, Calgary, Canada. kmfiest@ucalgary.ca.
AD  - Department of Psychiatry & Hotchkiss Brain Institute, University of Calgary,
      Calgary, Canada. kmfiest@ucalgary.ca.
FAU - Krewulak, Karla D
AU  - Krewulak KD
AD  - Department of Critical Care Medicine, University of Calgary & Alberta Health
      Services, Calgary, Canada.
FAU - Sept, Bonnie G
AU  - Sept BG
AD  - Department of Critical Care Medicine, University of Calgary & Alberta Health
      Services, Calgary, Canada.
FAU - Spence, Krista L
AU  - Spence KL
AD  - Department of Critical Care Medicine, University of Calgary & Alberta Health
      Services, Calgary, Canada.
FAU - Davidson, Judy E
AU  - Davidson JE
AD  - Department of Psychiatry, UC San Diego School of Medicine, San Diego, California,
      USA.
FAU - Ely, E Wesley
AU  - Ely EW
AD  - Tennessee Valley Veteran's Affairs Geriatric Research Education Clinical Center
      (VA GRECC), Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, 
      Vanderbilt University Medical Center, Nashville, TN, USA.
FAU - Soo, Andrea
AU  - Soo A
AD  - Department of Critical Care Medicine, University of Calgary & Alberta Health
      Services, Calgary, Canada.
FAU - Stelfox, Henry T
AU  - Stelfox HT
AD  - Department of Critical Care Medicine, University of Calgary & Alberta Health
      Services, Calgary, Canada.
AD  - Department of Community Health Sciences & O'Brien Institute of Public Health,
      University of Calgary, Calgary, Canada.
AD  - Department of Psychiatry & Hotchkiss Brain Institute, University of Calgary,
      Calgary, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT04099472
GR  - TC1-165722/Canadian Institutes of Health Research (CA)
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200524
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Adult
MH  - Anxiety
MH  - Canada
MH  - Critical Illness/*psychology
MH  - Delirium/*prevention & control
MH  - Depression
MH  - Family/*psychology
MH  - Hospitalization
MH  - Humans
MH  - Intensive Care Units
MH  - Patient Discharge
MH  - Randomized Controlled Trials as Topic
PMC - PMC7245836
OTO - NOTNLM
OT  - Critical care
OT  - Delirium
OT  - Education
OT  - Family-centered care
OT  - Prevention
EDAT- 2020/05/26 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/26 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12913-020-05281-8 [doi]
AID - 10.1186/s12913-020-05281-8 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 May 24;20(1):453. doi: 10.1186/s12913-020-05281-8.


PMID- 32448172
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20211204
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 24
TI  - Factors associated with musculoskeletal symptoms and heart rate variability among
      cleaners - cross-sectional study.
PG  - 774
LID - 10.1186/s12889-020-08928-7 [doi]
AB  - BACKGROUND: The professionals who perform cleaning activity constitute a major
      economic sector in Brazil. Cleaners may develop health problems related to the
      musculoskeletal and cardiovascular systems. It is necessary to understand the
      working and health conditions of cleaners in Brazil. Thus, the aim of this study 
      was to identify factors associated with musculoskeletal symptoms and heart rate
      variability (HRV) among cleaners. METHODS: A cross-sectional study conducted at a
      public higher education institution with 45 outsourced cleaners following
      approval from the institutional ethics committee. The participants answered a
      questionnaire addressing sociodemographic, occupational and health data, the
      Nordic Musculoskeletal Questionnaire, the Physical Activity Questionnaire (work
      and leisure) and the short version of the Copenhagen Psychosocial Questionnaire. 
      Clinical data (height, body mass, waist-to-hip ratio and blood pressure) and
      heart rate variability (HRV) were also collected. Logistic and linear regression 
      models were created to identify factors associated with symptoms and HRV.
      RESULTS: The sample consisted of women (100%) predominantly older than 50 years
      of age (44%), without a conjugal life (64%), with three or more children (59%),
      low educational level (58%) and who worked less than 12 months at the company
      (87%). Systemic arterial hypertension (23%) was the most reported health problem.
      The highest frequency of musculoskeletal symptoms was identified in the lower
      limbs (ankles/feet: 31% in the previous 12 months and 24% in the previous 7 days;
      knees: 31% in the previous 12 months and 20% in the previous 7 days). Moreover,
      the workers reported not practicing physical activity during leisure time (84%). 
      Psychosocial aspects indicated health risks for the dimensions "influence at
      work" (74%), "burnout" (59%) and "stress" (52%). Associations were found between 
      ankle/foot symptoms and body mass index, shoulder symptoms and predictability,
      and knee symptoms and self-rated health and burnout. HRV indices were associated 
      with age. CONCLUSIONS: This study outlined the profile of female cleaners and
      identified risk factors. The workers exhibited musculoskeletal symptoms, which
      were associated with the body mass index and some psychosocial factors. HRV
      indices were associated with age. Thus, health promotion and prevention measures 
      should be taken to benefit this population of workers.
FAU - Sotrate Goncalves, Josiane
AU  - Sotrate Goncalves J
AD  - Physical Therapy Department, Laboratory of Preventive Physical Therapy and
      Ergonomics (LAFIPE), Physical Therapy Postgraduate Program, Federal University of
      Sao Carlos, Rodovia Washington Luis, km 235, Monjolinho, Sao Carlos, SP,
      13565-905, Brazil.
FAU - de Oliveira Sato, Tatiana
AU  - de Oliveira Sato T
AUID- ORCID: http://orcid.org/0000-0001-8797-8981
AD  - Physical Therapy Department, Laboratory of Preventive Physical Therapy and
      Ergonomics (LAFIPE), Physical Therapy Postgraduate Program, Federal University of
      Sao Carlos, Rodovia Washington Luis, km 235, Monjolinho, Sao Carlos, SP,
      13565-905, Brazil. tatisato@gmail.com.
LA  - eng
GR  - Finance Code 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
PT  - Journal Article
DEP - 20200524
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adult
MH  - Body Mass Index
MH  - Brazil
MH  - Cross-Sectional Studies
MH  - Female
MH  - Heart Rate/*physiology
MH  - *Household Work
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Musculoskeletal Diseases/epidemiology/*physiopathology
MH  - Occupational Diseases/epidemiology/*physiopathology
MH  - Risk Factors
MH  - Surveys and Questionnaires
PMC - PMC7247127
OTO - NOTNLM
OT  - Cardiac autonomic modulation
OT  - Cleaners
OT  - Ergonomics
OT  - Work-related musculoskeletal disorders
EDAT- 2020/05/26 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/05/26 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/05/26 06:00 [entrez]
PHST- 2020/05/26 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.1186/s12889-020-08928-7 [doi]
AID - 10.1186/s12889-020-08928-7 [pii]
PST - epublish
SO  - BMC Public Health. 2020 May 24;20(1):774. doi: 10.1186/s12889-020-08928-7.


PMID- 32447568
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Vampires 2.0? The ethical quandaries of young blood infusion in the quest for
      eternal life.
PG  - 421-432
LID - 10.1007/s11019-020-09952-5 [doi]
AB  - Can transfusions of blood plasma slow down ageing or even rejuvenate people?
      Recent preclinical studies and experimental tests inspired by the technique known
      as parabiosis have aroused great media attention, although for now there is no
      clear evidence of their effectiveness. This line of research and the interest it 
      is triggering testify to the prominent role played by the idea of combating the
      "natural" ageing process in the scientific and social agenda. While seeking to
      increase the duration of healthy living time may be considered a duty, it also
      raises ethical questions about how to pursue this goal. Specifically, therapies
      and techniques accessible only to a fraction of the population seem destined to
      exponentially increase social inequality and to produce undesirable consequences.
      In this article we address the issue precisely in the light of the prospected use
      of plasma for the rejuvenation of a small elite of people.
FAU - Lavazza, Andrea
AU  - Lavazza A
AD  - Centro Universitario Internazionale, via Garbasso 42, 52100, Arezzo, Italy.
      lavazza67@gmail.com.
FAU - Garasic, Mirko
AU  - Garasic M
AD  - IMT School for Advanced Studies, Lucca, Italy.
AD  - Lumsa University, Rome, Italy.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
RN  - 0 (TIMP2 protein, human)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
SB  - IM
MH  - Aging/*physiology
MH  - Blood Transfusion/*ethics/methods
MH  - Humans
MH  - Longevity/physiology
MH  - Parabiosis/ethics/methods
MH  - *Rejuvenation
MH  - Tissue Inhibitor of Metalloproteinase-2/biosynthesis
OTO - NOTNLM
OT  - Ageing
OT  - Bioethics
OT  - Blood transfusion
OT  - Equality
OT  - Immortality
OT  - Justice
EDAT- 2020/05/25 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/05/25 06:00 [entrez]
AID - 10.1007/s11019-020-09952-5 [doi]
AID - 10.1007/s11019-020-09952-5 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):421-432. doi: 10.1007/s11019-020-09952-5.


PMID- 32447538
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20201111
IS  - 1936-3567 (Electronic)
IS  - 1932-4502 (Linking)
VI  - 54
IP  - 3
DP  - 2020 Sep
TI  - A Wittgensteinian Comment on "Psychology: A Giant with Feet of Clay" A Question
      from Research on Creativity.
PG  - 651-659
LID - 10.1007/s12124-020-09544-1 [doi]
AB  - The present comment of the paper by Zagaria, Ando and Zennaro (2020) invests in
      the possible pragmatic entry of language in the problem of Psychology as a
      scientific enterprise, concerning the impossibility of consensus on its key
      constructs/concepts, and, consequently, the little cumulative capacity of the
      knowledge produced. Thus, the necessary discussion on the ambiguity, the
      cloudiness of the fundamental concepts of Psychology are reflected through the
      contributions of Wittgenstein II (2009) and the neopragmatism of Rorty (1999,
      1995). Rorty offers a contemporary landscape on the purpose of knowledge
      production through his propositions on the relationship among truth, ethics and
      science in the humanities. The psychology of creativity is placed in the
      discussion as a field that well illustrate how the diversity of language games in
      Psychology reflects ethical perspectives in dealing with the phenomena, in this
      case related to the emergence of novelty, and the Rortian ironist reading on the 
      relationship between objectivity and solidarity.
FAU - Pinheiro, Marina Assis
AU  - Pinheiro MA
AUID- ORCID: 0000-0002-4019-0502
AD  - Department of Psychology, Federal University of Pernambuco
      (UFPE-Pernambuco-Brazil), Recife, Brazil. marinaassis.pinheiro@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Integr Psychol Behav Sci
JT  - Integrative psychological & behavioral science
JID - 101319534
RN  - T1FAD4SS2M (Clay)
SB  - IM
CON - Integr Psychol Behav Sci. 2020 Sep;54(3):521-562. PMID: 32297037
MH  - Clay
MH  - *Creativity
MH  - Humans
MH  - Knowledge
MH  - *Language
MH  - Morals
OTO - NOTNLM
OT  - *Creativity
OT  - *Language Games
OT  - *Psychology
OT  - *Rorty
OT  - *Vocabulary
OT  - *Wittgenstein
EDAT- 2020/05/25 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
PHST- 2020/05/25 06:00 [entrez]
AID - 10.1007/s12124-020-09544-1 [doi]
AID - 10.1007/s12124-020-09544-1 [pii]
PST - ppublish
SO  - Integr Psychol Behav Sci. 2020 Sep;54(3):651-659. doi:
      10.1007/s12124-020-09544-1.


PMID- 32447163
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20210110
IS  - 1873-4529 (Electronic)
IS  - 0952-8180 (Linking)
VI  - 65
DP  - 2020 Oct
TI  - VV-ECMO usage in ARDS due to COVID-19: Clinical, practical and ethical
      considerations.
PG  - 109893
LID - S0952-8180(20)30682-6 [pii]
LID - 10.1016/j.jclinane.2020.109893 [doi]
FAU - Hoyler, Marguerite M
AU  - Hoyler MM
AD  - New York-Presbyterian/Weill Cornell Medical Center, Department of Anesthesiology,
      525 East 68th Street, Box 124, New York, NY 10065, USA. Electronic address:
      mam9508@nyp.org.
FAU - Kumar, Shreyajit
AU  - Kumar S
AD  - New York-Presbyterian/Weill Cornell Medical Center, Department of Anesthesiology,
      525 East 68th Street, Box 124, New York, NY 10065, USA. Electronic address:
      srk9004@med.cornell.edu.
FAU - Thalappillil, Richard
AU  - Thalappillil R
AD  - New York-Presbyterian/Weill Cornell Medical Center, Department of Anesthesiology,
      525 East 68th Street, Box 124, New York, NY 10065, USA. Electronic address:
      rit9023@med.cornell.edu.
FAU - White, Robert S
AU  - White RS
AD  - New York-Presbyterian/Weill Cornell Medical Center, Department of Anesthesiology,
      525 East 68th Street, Box 124, New York, NY 10065, USA. Electronic address:
      rsw33@cornell.edu.
FAU - Tam, Christopher W
AU  - Tam CW
AD  - New York-Presbyterian/Weill Cornell Medical Center, Department of Anesthesiology,
      525 East 68th Street, Box 124, New York, NY 10065, USA. Electronic address:
      cwt9004@med.cornell.edu.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200520
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
SB  - IM
CON - N Engl J Med. 2020 May 21;382(21):2049-2055. PMID: 32202722
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Resource Allocation
MH  - *Respiratory Distress Syndrome
MH  - SARS-CoV-2
PMC - PMC7237897
COIS- Declaration of competing interest This research did not receive any specific
      grant from funding agencies in the public, commercial, or not-for-profit sectors.
      The authors report not proprietary or commercial interest in any product
      mentioned or concept discussed in this article.
EDAT- 2020/05/25 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/05/25 06:00 [entrez]
AID - S0952-8180(20)30682-6 [pii]
AID - 10.1016/j.jclinane.2020.109893 [doi]
PST - ppublish
SO  - J Clin Anesth. 2020 Oct;65:109893. doi: 10.1016/j.jclinane.2020.109893. Epub 2020
      May 20.


PMID- 32446977
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1873-4863 (Electronic)
IS  - 0168-1656 (Linking)
VI  - 319
DP  - 2020 Aug 10
TI  - CRISPR-Cas9 system: A genome-editing tool with endless possibilities.
PG  - 36-53
LID - S0168-1656(20)30128-0 [pii]
LID - 10.1016/j.jbiotec.2020.05.008 [doi]
AB  - The discovery of CRISPR: Cas9 and its application as a powerful gene-editing tool
      has transformed the world of basic and applied science, especially the molecular 
      biology dome. Also, the smooth, quick, flexible, and very efficient nature of
      this technology has enabled the biologists to alter the genome of prokaryotes to 
      complex eukaryotic systems, including plants and animals. Using CRISPR and
      associated tools, investigation, control, and modification of significant
      biological events have been more accessible than before. These biological
      scissors are now being used to accelerate breeding programs of crop and
      livestock, engineer new antimicrobials, and control disease-carrying pathogens.
      However, like other techniques, these cutters emerged as a double-edged sword and
      put several challenges to the scientific society. Here in this review article, we
      summarized the beneficial application of the CRISPR: Cas9 system and unsafe
      perception to the society if handled carelessly. We also discussed the
      limitations and ethical issues related to CRISPR: Cas9 technology.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Tyagi, Swati
AU  - Tyagi S
AD  - Genomic Division, National Institute of Agriculture Science, Rural Development
      Administration, Jeonju, Republic of Korea.
FAU - Kumar, Robin
AU  - Kumar R
AD  - Department of Soil Science, Acharya Narendra Dev University of Agriculture and
      Technology, Ayodhya, India.
FAU - Das, Aparup
AU  - Das A
AD  - National Institute of Research in Tribal Health (ICMR-NIRTH), Jabalpur, India.
FAU - Won, So Youn
AU  - Won SY
AD  - Genomic Division, National Institute of Agriculture Science, Rural Development
      Administration, Jeonju, Republic of Korea. Electronic address:
      soyounwon@korea.kr.
FAU - Shukla, Pratyoosh
AU  - Shukla P
AD  - Enzyme Technology and Protein Bioinformatics Laboratory, Department of
      Microbiology, Maharshi Dayanand University, Rohtak, India. Electronic address:
      pratyoosh.shukla@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200522
PL  - Netherlands
TA  - J Biotechnol
JT  - Journal of biotechnology
JID - 8411927
SB  - IM
MH  - Animals
MH  - Biomedical Research
MH  - *CRISPR-Cas Systems
MH  - *Gene Editing/ethics/methods/standards
MH  - Humans
MH  - Plants, Genetically Modified
OTO - NOTNLM
OT  - Agriculture
OT  - CRISPR-Cas9
OT  - Clinical applications
OT  - Industrial
OT  - Therapeutics
EDAT- 2020/05/25 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/05/25 06:00 [entrez]
AID - S0168-1656(20)30128-0 [pii]
AID - 10.1016/j.jbiotec.2020.05.008 [doi]
PST - ppublish
SO  - J Biotechnol. 2020 Aug 10;319:36-53. doi: 10.1016/j.jbiotec.2020.05.008. Epub
      2020 May 22.


PMID- 32446631
OWN - NLM
STAT- MEDLINE
DCOM- 20210923
LR  - 20210923
IS  - 1879-3096 (Electronic)
IS  - 0167-7799 (Linking)
VI  - 38
IP  - 11
DP  - 2020 Nov
TI  - Creating Bioethics Distance Learning Through Virtual Reality.
PG  - 1187-1192
LID - S0167-7799(20)30126-8 [pii]
LID - 10.1016/j.tibtech.2020.05.005 [doi]
AB  - Bioethics education is a central element in the biotechnology curriculum.
      Re-imagining distance learning, virtual reality (VR) is taking student
      involvement to the next level of interaction, offering a real classroom
      experience and a new way to gain ethical reasoning skills. Here, we explore a new
      paradigm for bioethics education that involves VR.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Harfouche, Antoine L
AU  - Harfouche AL
AD  - Department for Innovation in Biological, Agro-food, and Forest systems,
      University of Tuscia, Via S. Camillo de Lellis, Viterbo 01100, Italy. Electronic 
      address: aharfouche@unitus.it.
FAU - Nakhle, Farid
AU  - Nakhle F
AD  - Department for Innovation in Biological, Agro-food, and Forest systems,
      University of Tuscia, Via S. Camillo de Lellis, Viterbo 01100, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - Trends Biotechnol
JT  - Trends in biotechnology
JID - 8310903
SB  - IM
MH  - *Bioethics/education
MH  - *Biotechnology/education/ethics
MH  - *Education, Distance
MH  - Humans
MH  - *Virtual Reality
PMC - PMC7211661
OTO - NOTNLM
OT  - *bioethics
OT  - *distance education
OT  - *immersive learning
OT  - *interactive presence
OT  - *virtual classroom
OT  - *virtual reality
EDAT- 2020/05/25 06:00
MHDA- 2021/09/24 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/05/02 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2021/09/24 06:00 [medline]
PHST- 2020/05/25 06:00 [entrez]
AID - S0167-7799(20)30126-8 [pii]
AID - 10.1016/j.tibtech.2020.05.005 [doi]
PST - ppublish
SO  - Trends Biotechnol. 2020 Nov;38(11):1187-1192. doi: 10.1016/j.tibtech.2020.05.005.
      Epub 2020 May 11.


PMID- 32446565
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 2212-2672 (Print)
IS  - 2212-2672 (Linking)
VI  - 120
IP  - 6
DP  - 2020 Jun
TI  - Essential Academy Resources Support Quality and Expand Practice.
PG  - 1068-1073
LID - S2212-2672(20)30212-4 [pii]
LID - 10.1016/j.jand.2020.03.003 [doi]
AB  - The Academy of Nutrition and Dietetics (Academy) develops and maintains
      foundational documents that apply to all registered dietitian nutritionists
      (RDNs) and nutrition and dietetics technicians, registered (NDTRs): Scope of
      Practice for the RDN and NDTR; Standards of Practice in Nutrition Care and
      Standards of Professional Performance for RDNs and NDTRs; and the Academy and the
      Commission on Dietetic Registration Code of Ethics for the Nutrition and
      Dietetics Profession. The Quality Management Committee of the Academy has
      developed resources that assist RDNs and NDTRs in understanding how to work to
      the fullest extent of their individual scope of practice to increase professional
      satisfaction, achieve future employment and position goals, and provide safe and 
      reliable services. These resources are the definition of terms list, practice
      tips and case studies, and scope of practice decision algorithm, which build on
      Academy foundational documents. They support quality practice by answering
      questions such as "how can I become more autonomous in my practice" and "how can 
      I use telehealth technology in my practice?" The foundational Academy documents
      and practice application resources assist all RDNs and NDTRs in recognizing their
      individual competence and practicing within their scope of practice.
CI  - Copyright (c) 2020 Academy of Nutrition and Dietetics. Published by Elsevier Inc.
      All rights reserved.
FAU - Hui, Karen
AU  - Hui K
FAU - Buelsing, Dana
AU  - Buelsing D
FAU - Gilmore, Carol J
AU  - Gilmore CJ
FAU - McCauley, Sharon M
AU  - McCauley SM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Acad Nutr Diet
JT  - Journal of the Academy of Nutrition and Dietetics
JID - 101573920
SB  - IM
MH  - *Academies and Institutes
MH  - Clinical Competence/standards
MH  - Codes of Ethics
MH  - Dietetics/*standards
MH  - Humans
MH  - Nutrition Therapy/standards
MH  - Nutritionists/standards
MH  - Standard of Care/standards
EDAT- 2020/05/25 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/05/25 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/05/25 06:00 [entrez]
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
AID - S2212-2672(20)30212-4 [pii]
AID - 10.1016/j.jand.2020.03.003 [doi]
PST - ppublish
SO  - J Acad Nutr Diet. 2020 Jun;120(6):1068-1073. doi: 10.1016/j.jand.2020.03.003.


PMID- 32446126
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 129
DP  - 2020 Aug
TI  - Can grating interferometry-based mammography discriminate benign from malignant
      microcalcifications in fresh biopsy samples?
PG  - 109077
LID - S0720-048X(20)30266-7 [pii]
LID - 10.1016/j.ejrad.2020.109077 [doi]
AB  - PURPOSE: In addition to absorption imaging, grating interferometry-based
      mammography (GIM) is capable of detecting differential-phase and scattering
      signals. In particular, the scattering signal can enable a quantifiable
      characterization of breast lesions. The purpose of this study was to determine if
      suspicious microcalcifications associated with benign or malignant lesions can be
      discriminated based on their absorption and scattering properties. MATERIALS AND 
      METHODS: In this prospective, ethically approved study, 62 patients (mean age 60 
      y, range 39-89) with suspicious microcalcifications, who underwent stereotactic
      biopsies, were included. Biopsies were measured with an experimental GIM device
      and the ratios of the scattering and absorption signal (R-value) for
      microcalcifications were calculated. The mean R-values for benign and malignant
      lesions associated with microcalcifications were compared with the final
      histopathological diagnosis using a t-test. RESULTS: Twenty of the 62
      participants had microcalcifications associated with malignancy. Comparing the
      two largest histopathological sub-groups of fibrosis (n=23) vs. ductal carcinoma 
      in situ (n=15) resulted in an average R-value of 4.08 for benign and 2.80 for
      malignant lesions; p=0.07. All microcalcifications associated with malignancy had
      an R-value below 4.71. Excluding microcalcifications with an R-value above this
      threshold would result in an 11 % reduction of false positives. CONCLUSION: The
      novel GIM modality has the potential to non-invasively characterize
      microcalcifications and might aid in the discrimination of benign from malignant 
      lesions in fresh biopsy samples.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Forte, Serafino
AU  - Forte S
AD  - Department of Radiology, Kantonsspital Baden, Im Ergel, 5404 Baden, Switzerland. 
      Electronic address: serafinoforte@yahoo.com.
FAU - Wang, Zhentian
AU  - Wang Z
AD  - Institute of Biomedical Engineering, ETH Zurich, Switzerland; Swiss Light Source,
      Paul Scherrer Institute, Villigen, Switzerland.
FAU - Arboleda, Carolina
AU  - Arboleda C
AD  - Institute of Biomedical Engineering, ETH Zurich, Switzerland; Swiss Light Source,
      Paul Scherrer Institute, Villigen, Switzerland.
FAU - Lang, Kristina
AU  - Lang K
AD  - Institute of Biomedical Engineering, ETH Zurich, Switzerland; Swiss Light Source,
      Paul Scherrer Institute, Villigen, Switzerland.
FAU - Singer, Gad
AU  - Singer G
AD  - Department of Pathology, Kantonsspital Baden, Switzerland.
FAU - Kubik-Huch, Rahel A
AU  - Kubik-Huch RA
AD  - Department of Radiology, Kantonsspital Baden, Im Ergel, 5404 Baden, Switzerland.
FAU - Stampanoni, Marco
AU  - Stampanoni M
AD  - Institute of Biomedical Engineering, ETH Zurich, Switzerland; Swiss Light Source,
      Paul Scherrer Institute, Villigen, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200516
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy/methods
MH  - Breast/diagnostic imaging/pathology
MH  - Breast Neoplasms/*diagnostic imaging/*pathology
MH  - Calcinosis/*diagnostic imaging/*pathology
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Interferometry
MH  - Mammography/*methods
MH  - Middle Aged
MH  - Prospective Studies
OTO - NOTNLM
OT  - Breast neoplasms
OT  - Calcification
OT  - Interferometry
OT  - Mammography
OT  - Scattering
COIS- Declaration of Competing Interest All authors have approved the manuscript and
      agree with submission to European Journal of Radiology. The authors have no
      conflicts of interest to declare.
EDAT- 2020/05/24 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/05/24 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/05/09 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - S0720-048X(20)30266-7 [pii]
AID - 10.1016/j.ejrad.2020.109077 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 Aug;129:109077. doi: 10.1016/j.ejrad.2020.109077. Epub 2020
      May 16.


PMID- 32445581
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20220716
IS  - 1365-2044 (Electronic)
IS  - 0003-2409 (Linking)
VI  - 75
IP  - 11
DP  - 2020 Nov
TI  - COVID-19: legal implications for critical care.
PG  - 1517-1528
LID - 10.1111/anae.15147 [doi]
AB  - The COVID-19 pandemic has caused an unprecedented challenge for the provision of 
      critical care. Anticipating an unsustainable burden on the health service, the UK
      Government introduced numerous legislative measures culminating in the
      Coronavirus Act, which interfere with existing legislation and rights. However,
      the existing standards and legal frameworks relevant to critical care clinicians 
      are not extinguished, but anticipated to adapt to a new context. This new context
      influences the standard of care that can be reasonably provided and yields many
      human rights considerations, for example, in the use of restraints, or the
      restrictions placed on patients and visitors under the Infection Prevention and
      Control guidance. The changing landscape has also highlighted previously
      unrecognised legal dilemmas. The perceived difficulties in the provision of
      personal protective equipment for employees pose a legal risk for Trusts and a
      regulatory risk for clinicians. The spectre of rationing critical care poses a
      number of legal issues. Notably, the flux between clinical decisions based on
      best interests towards decisions explicitly based on resource considerations
      should be underpinned by an authoritative public policy decision to preserve
      legitimacy and lawfulness. Such a policy should be medically coherent, legally
      robust and ethically justified. The current crisis poses numerous challenges for 
      clinicians aspiring to remain faithful to medicolegal and human rights principles
      developed over many decades, especially when such principles could easily be
      dismissed. However, it is exactly at such times that these principles are needed 
      the most and clinicians play a disproportionate role in safeguarding them for the
      most vulnerable.
CI  - (c) 2020 Association of Anaesthetists.
FAU - Coghlan, N
AU  - Coghlan N
AUID- ORCID: https://orcid.org/0000-0003-4330-6328
AD  - Lincoln's Inn, London, UK.
AD  - European University Institute, Florence, Italy.
FAU - Archard, D
AU  - Archard D
AUID- ORCID: https://orcid.org/0000-0001-7059-8907
AD  - Queen's University Belfast, Belfast, UK.
FAU - Sipanoun, P
AU  - Sipanoun P
AD  - Centre for Outcomes and Experience Research in Children's Health, Illness and
      Disability, Great Ormond Street Hospital for Children NHS Foundation Trust and
      University College London Great Ormond Street Institute of Child Health, London, 
      UK.
FAU - Hayes, T
AU  - Hayes T
AD  - Department of Vascular Surgery, Lister Hospital, Stevenage, UK.
FAU - Baharlo, B
AU  - Baharlo B
AUID- ORCID: https://orcid.org/0000-0002-6630-4520
AD  - General Intensive Care Unit, Hammersmith Hospital, Imperial College Healthcare
      NHS Trust, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200611
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
SB  - IM
CIN - Anaesthesia. 2020 Nov;75(11):1428-1431. PMID: 32926404
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Care/ethics/*legislation & jurisprudence
MH  - Humans
MH  - Informed Consent
MH  - Pandemics
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*epidemiology
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Standard of Care
PMC - PMC7283837
OTO - NOTNLM
OT  - *COVID-19
OT  - *critical care
OT  - *human rights
OT  - *law
OT  - *resource allocation
EDAT- 2020/05/24 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1111/anae.15147 [doi]
PST - ppublish
SO  - Anaesthesia. 2020 Nov;75(11):1517-1528. doi: 10.1111/anae.15147. Epub 2020 Jun
      11.


PMID- 32445290
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep
TI  - Optimized serial expansion of human induced pluripotent stem cells using
      low-density inoculation to generate clinically relevant quantities in
      vertical-wheel bioreactors.
PG  - 1036-1052
LID - 10.1002/sctm.19-0406 [doi]
AB  - Human induced pluripotent stem cells (hiPSCs) have generated a great deal of
      attention owing to their capacity for self-renewal and differentiation into the
      three germ layers of the body. Their discovery has facilitated a new era in
      biomedicine for understanding human development, drug screening, disease
      modeling, and cell therapy while reducing ethical issues and risks of immune
      rejection associated with traditional embryonic stem cells. Bioreactor-based
      processes have been the method of choice for the efficient expansion and
      differentiation of stem cells in controlled environments. Current protocols for
      the expansion of hiPSCs use horizontal impeller, paddle, or rocking wave mixing
      method bioreactors which require large static cell culture starting populations
      and achieve only moderate cell fold increases. This study focused on optimizing
      inoculation, agitation, oxygen, and nutrient availability for the culture of
      hiPSCs as aggregates in single-use, low-shear, vertical-wheel bioreactors. Under 
      optimized conditions, we achieved an expansion of more than 30-fold in 6 days
      using a small starting population of cells and minimal media resources
      throughout. Importantly, we showed that that this optimized bioreactor expansion 
      protocol could be replicated over four serial passages resulting in a cumulative 
      cell expansion of 1.06E6-fold in 28 days. Cells from the final day of the serial 
      passage were of high quality, maintaining a normal karyotype, pluripotent marker 
      staining, and the ability to form teratomas in vivo. These findings demonstrate
      that a vertical-wheel bioreactor-based bioprocess can provide optimal conditions 
      for efficient, rapid generation of high-quality hiPSCs to meet the demands for
      clinical manufacturing of therapeutic cell products.
CI  - (c) 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley
      Periodicals, Inc. on behalf of AlphaMed Press.
FAU - Borys, Breanna S
AU  - Borys BS
AD  - Pharmaceutical Production Research Facility, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
AD  - Biomedical Engineering Graduate Program, University of Calgary, Calgary, Alberta,
      Canada.
AD  - Department of Chemical and Petroleum Engineering, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
FAU - So, Tania
AU  - So T
AD  - Pharmaceutical Production Research Facility, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
AD  - Department of Chemical and Petroleum Engineering, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
FAU - Colter, James
AU  - Colter J
AD  - Pharmaceutical Production Research Facility, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
AD  - Biomedical Engineering Graduate Program, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Dang, Tiffany
AU  - Dang T
AD  - Pharmaceutical Production Research Facility, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
AD  - Department of Chemical and Petroleum Engineering, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
FAU - Roberts, Erin L
AU  - Roberts EL
AD  - Pharmaceutical Production Research Facility, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
FAU - Revay, Tamas
AU  - Revay T
AD  - Department of Medical Genetics, Alberta Health Services, Alberta Children's
      Hospital, Calgary, Alberta, Canada.
FAU - Larijani, Leila
AU  - Larijani L
AD  - Department of Medical Genetics, Cumming School of Medicine, University of
      Calgary, Calgary, Alberta, Canada.
FAU - Krawetz, Roman
AU  - Krawetz R
AD  - Department of Cell Biology and Anatomy, Cumming School of Medicine, University of
      Calgary, Calgary, Alberta, Canada.
FAU - Lewis, Ian
AU  - Lewis I
AD  - Department of Biological Sciences, University of Calgary, Calgary, Alberta,
      Canada.
FAU - Argiropoulos, Bob
AU  - Argiropoulos B
AD  - Department of Medical Genetics, Alberta Health Services, Alberta Children's
      Hospital, Calgary, Alberta, Canada.
FAU - Rancourt, Derrick E
AU  - Rancourt DE
AD  - Department of Medical Genetics, Cumming School of Medicine, University of
      Calgary, Calgary, Alberta, Canada.
FAU - Jung, Sunghoon
AU  - Jung S
AD  - PBS Biotech Inc., Camarillo, California, USA.
FAU - Hashimura, Yas
AU  - Hashimura Y
AD  - PBS Biotech Inc., Camarillo, California, USA.
FAU - Lee, Brian
AU  - Lee B
AD  - PBS Biotech Inc., Camarillo, California, USA.
FAU - Kallos, Michael S
AU  - Kallos MS
AUID- ORCID: 0000-0002-1480-8022
AD  - Pharmaceutical Production Research Facility, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
AD  - Biomedical Engineering Graduate Program, University of Calgary, Calgary, Alberta,
      Canada.
AD  - Department of Chemical and Petroleum Engineering, Schulich School of Engineering,
      University of Calgary, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200522
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (Biomarkers)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Biomarkers/metabolism
MH  - *Bioreactors
MH  - Cell Aggregation/drug effects
MH  - Cell Culture Techniques/*instrumentation/*methods
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology/drug effects/metabolism
MH  - Infant
MH  - Kinetics
MH  - Mice, SCID
MH  - Oxygen/pharmacology
MH  - Teratoma/pathology
PMC - PMC7445025
OTO - NOTNLM
OT  - *bioreactor
OT  - *expansion
OT  - *human induced pluripotent stem cells (hiPSCs)
OT  - *low-shear
OT  - *serial-passage
EDAT- 2020/05/24 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/05/24 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1002/sctm.19-0406 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2020 Sep;9(9):1036-1052. doi: 10.1002/sctm.19-0406. Epub
      2020 May 22.


PMID- 32445288
OWN - NLM
STAT- MEDLINE
DCOM- 20200609
LR  - 20201218
IS  - 1756-5391 (Electronic)
IS  - 1756-5391 (Linking)
VI  - 13
IP  - 2
DP  - 2020 May
TI  - Challenges and strategies to research ethics in conducting COVID-19 research.
PG  - 173-177
LID - 10.1111/jebm.12388 [doi]
AB  - The number of research involving human subjects on coronavirus disease 2019
      (COVID-19) is surging, bringing challenges to the ethical review committee (ERC) 
      in terms of reviewing speed and special ethical considerations under the
      pandemic. However, the existing ethical review system and regulations have their 
      limitations to meet the demand for a prompt and efficient epidemic control. Since
      the research under the public health emergency is different from that carried out
      in familiar situations to design and implementation, the strategy for a
      satisfactory ERC response should balance the duty of protecting individual
      participants as well as the special public needs derived from the disease
      control. It is suggested that the ethical review-related regulations need to be
      updated, and a unified supervision system to the overall ERC is required. ERC
      collaboration, capacity-improving and efficiency-improving measures need to be
      taken. With respect to the reviewing guidelines, it is suggested that the
      international norms should be explained with more consideration of the local
      condition and the exceptional circumstances in this public health emergency. A
      joint effort needs to be taken for better research conduction.
CI  - (c) 2020 The Authors. Journal of Evidence-Based Medicine published by Chinese
      Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons 
      Australia, Ltd.
FAU - Ma, Xitao
AU  - Ma X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - Wang, Yanqiao
AU  - Wang Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - Gao, Tian
AU  - Gao T
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - He, Qing
AU  - He Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - He, Yan
AU  - He Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - Yue, Rensong
AU  - Yue R
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - You, Fengming
AU  - You F
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
FAU - Tang, Jianyuan
AU  - Tang J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R.
      China.
LA  - eng
GR  - 2020YFS0012/TCM Community Prevention and Control
GR  - 2020YFS0013/Study on Integrated Chinese and Western Medicine Treatment
PT  - Journal Article
DEP - 20200522
PL  - England
TA  - J Evid Based Med
JT  - Journal of evidence-based medicine
JID - 101497477
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/diagnosis/therapy
MH  - Ethics Committees, Research/*organization & administration
MH  - Global Health
MH  - Humans
MH  - Informed Consent/ethics
MH  - *Pandemics
MH  - *Pneumonia, Viral/diagnosis/therapy
MH  - *Research Design
MH  - SARS-CoV-2
MH  - Therapeutic Human Experimentation/*ethics
PMC - PMC7280675
OTO - NOTNLM
OT  - COVID-19
OT  - ethical review
OT  - informed consent
OT  - public health emergency
EDAT- 2020/05/24 06:00
MHDA- 2020/06/10 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/10 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1111/jebm.12388 [doi]
PST - ppublish
SO  - J Evid Based Med. 2020 May;13(2):173-177. doi: 10.1111/jebm.12388. Epub 2020 May 
      22.


PMID- 32445206
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201121
IS  - 1095-8649 (Electronic)
IS  - 0022-1112 (Linking)
VI  - 97
IP  - 2
DP  - 2020 Aug
TI  - Inconsistent ethical regulation of larval zebrafish in research.
PG  - 324-327
LID - 10.1111/jfb.14405 [doi]
FAU - Kelly, Jeffrey R
AU  - Kelly JR
AUID- ORCID: 0000-0002-9517-6652
AD  - Department of Psychology, University of Tennessee Knoxville, Knoxville,
      Tennessee, USA.
FAU - Benson, Scott A
AU  - Benson SA
AD  - Department of Psychology, University of Tennessee Knoxville, Knoxville,
      Tennessee, USA.
LA  - eng
GR  - University of Tennessee/International
PT  - Journal Article
DEP - 20200629
PL  - England
TA  - J Fish Biol
JT  - Journal of fish biology
JID - 0214055
SB  - IM
EDAT- 2020/05/24 06:00
MHDA- 2020/05/24 06:01
CRDT- 2020/05/24 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/05/24 06:01 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1111/jfb.14405 [doi]
PST - ppublish
SO  - J Fish Biol. 2020 Aug;97(2):324-327. doi: 10.1111/jfb.14405. Epub 2020 Jun 29.


PMID- 32445105
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20220716
IS  - 1556-0961 (Electronic)
IS  - 1541-6933 (Linking)
VI  - 33
IP  - 1
DP  - 2020 Aug
TI  - Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID):
      Study Design and Rationale.
PG  - 25-34
LID - 10.1007/s12028-020-00995-3 [doi]
AB  - BACKGROUND: As the COVID-19 pandemic developed, reports of neurological
      dysfunctions spanning the central and peripheral nervous systems have emerged.
      The spectrum of acute neurological dysfunctions may implicate direct viral
      invasion, para-infectious complications, neurological manifestations of systemic 
      diseases, or co-incident neurological dysfunction in the context of high
      SARS-CoV-2 prevalence. A rapid and pragmatic approach to understanding the
      prevalence, phenotypes, pathophysiology and prognostic implications of COVID-19
      neurological syndromes is urgently needed. METHODS: The Global Consortium to
      Study Neurological dysfunction in COVID-19 (GCS-NeuroCOVID), endorsed by the
      Neurocritical Care Society (NCS), was rapidly established to address this need in
      a tiered approach. Tier-1 consists of focused, pragmatic, low-cost, observational
      common data element (CDE) collection, which can be launched immediately at many
      sites in the first phase of this pandemic and is designed for expedited ethical
      board review with waiver-of-consent. Tier 2 consists of prospective functional
      and cognitive outcomes assessments with more detailed clinical, laboratory and
      radiographic data collection that would require informed consent. Tier 3 overlays
      Tiers 1 and 2 with experimental molecular, electrophysiology, pathology and
      imaging studies with longitudinal outcomes assessment and would require centers
      with specific resources. A multicenter pediatrics core has developed and launched
      a parallel study focusing on patients ages <18 years. Study sites are eligible
      for participation if they provide clinical care to COVID-19 patients and are able
      to conduct patient-oriented research under approval of an internal or global
      ethics committee. Hospitalized pediatric and adult patients with SARS-CoV-2 and
      with acute neurological signs or symptoms are eligible to participate. The
      primary study outcome is the overall prevalence of neurological complications
      among hospitalized COVID-19 patients, which will be calculated by pooled
      estimates of each neurological finding divided by the average census of COVID-19 
      positive patients over the study period. Secondary outcomes include: in-hospital,
      30 and 90-day morality, discharge modified Rankin score, ventilator-free
      survival, ventilator days, discharge disposition, and hospital length of stay.
      RESULTS: In a one-month period (3/27/20-4/27/20) the GCS-NeuroCOVID consortium
      was able to recruit 71 adult study sites, representing 17 countries and 5
      continents and 34 pediatrics study sites. CONCLUSIONS: This is one of the first
      large-scale global research collaboratives urgently assembled to evaluate acute
      neurological events in the context of a pandemic. The innovative and pragmatic
      tiered study approach has allowed for rapid recruitment and activation of
      numerous sites across the world-an approach essential to capture real-time
      critical neurological data to inform treatment strategies in this pandemic
      crisis.
FAU - Frontera, Jennifer
AU  - Frontera J
AD  - Department of Neurology, NYU School of Medicine, New York, NY, USA.
FAU - Mainali, Shraddha
AU  - Mainali S
AD  - Division of Stroke and Neurocritical Care, Department of Neurology, The Ohio
      State University, Columbus, OH, USA.
FAU - Fink, Ericka L
AU  - Fink EL
AD  - Division of Pediatric Critical Care Medicine, UPMC Children's Hospital of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Robertson, Courtney L
AU  - Robertson CL
AD  - Departments of Anesthesiology and Critical Care Medicine, and Pediatrics, Johns
      Hopkins Children's Center, The Johns Hopkins University SOM, Baltimore, MD, USA.
FAU - Schober, Michelle
AU  - Schober M
AD  - Primary Children's Hospital, University of Utah School of Medicine, Salt Lake
      City, UT, USA.
FAU - Ziai, Wendy
AU  - Ziai W
AD  - Departments of Anesthesiology and Critical Care Medicine, Neurology, and
      Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD,
      USA.
FAU - Menon, David
AU  - Menon D
AD  - Division of Anaesthesia, Addenbrooke's Hospital, University of Cambridge,
      Cambridge, UK.
FAU - Kochanek, Patrick M
AU  - Kochanek PM
AD  - Departments of Anesthesiology, Pediatrics, Bioengineering, and Clinical and
      Translational Science, Safar Center for Resuscitation Research, University of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Suarez, Jose I
AU  - Suarez JI
AD  - Departments of Anesthesiology and Critical Care Medicine, Neurology, and
      Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD,
      USA.
FAU - Helbok, Raimund
AU  - Helbok R
AD  - Neurocritical Care Unit, Department of Neurology, Medical University of
      Innsbruck, Innsbruck, Austria.
FAU - McNett, Molly
AU  - McNett M
AD  - College of Nursing, The Ohio State University, 760 Kinnear Rd, Columbus, OH,
      43212, USA. mcnett.21@osu.edu.
FAU - Chou, Sherry H-Y
AU  - Chou SH
AD  - Departments of Critical Care Medicine, Neurology, and Neurosurgery, Safar Center 
      for Resuscitation Research, University of Pittsburgh School of Medicine,
      Pittsburgh, PA, USA.
CN  - GCS-NeuroCOVID Study
LA  - eng
GR  - R21 NS113037/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Neurocrit Care
JT  - Neurocritical care
JID - 101156086
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/epidemiology/therapy
MH  - Humans
MH  - Nervous System Diseases/*diagnosis/epidemiology/*virology
MH  - Pandemics
MH  - Pneumonia, Viral/*complications/epidemiology/therapy
MH  - Pragmatic Clinical Trials as Topic
MH  - Prevalence
MH  - Research Design
MH  - Risk Factors
MH  - SARS-CoV-2
PMC - PMC7243953
OTO - NOTNLM
OT  - *COVID-19
OT  - *Coronavirus
OT  - *Neurological manifestations
OT  - *Neurological symptoms
OT  - *SARS-CoV-2
EDAT- 2020/05/24 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1007/s12028-020-00995-3 [doi]
AID - 10.1007/s12028-020-00995-3 [pii]
PST - ppublish
SO  - Neurocrit Care. 2020 Aug;33(1):25-34. doi: 10.1007/s12028-020-00995-3.


PMID- 32444994
OWN - NLM
STAT- MEDLINE
DCOM- 20201127
LR  - 20210203
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 34
IP  - 5
DP  - 2020 Oct
TI  - "BAX602" in Preventing Surgical Adhesion after Extracorporeal Ventricular Assist 
      Device Implantation for Refractory Congestive Heart Failure: Study Protocol for a
      Multicenter Randomized Clinical Trial.
PG  - 651-657
LID - 10.1007/s10557-020-06990-2 [doi]
AB  - BACKGROUND: The high surgical risk in redo cardiac surgery is largely attributed 
      to adhesions around the epicardium and the great vessels. BAX602 is an adhesion
      prevention reagent composed of two synthetic polyethylene glycols. Spraying
      BAX602 over the epicardium and the great vessels reportedly contributes to
      adhesion prevention after pediatric cardiac surgery. The present study aims to
      evaluate the safety and effectiveness of BAX602 spray in patients undergoing
      extracorporeal ventricular assist device implantation surgery to treat refractory
      congestive heart failure. METHODS AND DESIGN: This investigator-initiated,
      multicenter, pivotal, two-arm, open-label, randomized trial will include a total 
      of 30 patients. The primary outcome measure is the severity of adhesions, which
      will be evaluated during re-sternotomy surgery performed 2-12 weeks after the
      primary extracorporeal ventricular assist device implantation surgery. The
      adhesion severity will be evaluated at five predefined sites using a four-grade
      adhesion evaluation score (0 = no adhesion; 1 = filmy and avascular adhesion; 2 =
      dense/vascular adhesion; 3 = cohesive adhesion). This measure will be summarized 
      in two ways to evaluate the effect of BAX602: (1) the total score of the severity
      of adhesions at all five sites (ranging from 0 to 15), and (2) the total number
      of sites with dense/vascular or cohesive adhesions (ranging from 0 to 5). ETHICS 
      AND DISSEMINATION: The study findings will be disseminated at regional, national,
      and international conferences and through peer-reviewed scientific journals.
      TRIAL REGISTRATION: The trial was registered in the UMIN Clinical Trials Registry
      (UMIN-CTR: UMIN000038998) on 6 January 2020.
FAU - Fukushima, Satsuki
AU  - Fukushima S
AUID- ORCID: 0000-0002-9481-8860
AD  - Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, 6-1
      Kishibeshimmachi, Suita, Osaka, 564-8565, Japan. s.fukushima@ncvc.go.jp.
FAU - Asakura, Koko
AU  - Asakura K
AD  - Department of Data Science, National Cerebral and Cardiovascular Center, Osaka,
      Japan.
FAU - Hamasaki, Toshimitsu
AU  - Hamasaki T
AD  - The Biostatistics Center and Department of Biostatistics and Bioinformatics,
      George Washington University, Washington, DC, USA.
FAU - Onda, Kaori
AU  - Onda K
AD  - Department of Data Science, National Cerebral and Cardiovascular Center, Osaka,
      Japan.
FAU - Watanabe, Takuya
AU  - Watanabe T
AD  - Department of Transplant Medicine, National Cerebral and Cardiovascular Center,
      Osaka, Japan.
FAU - Shiose, Akira
AU  - Shiose A
AD  - Department of Cardiovascular Surgery, Kyushu University Hospital, Fukuoka, Japan.
FAU - Ono, Minoru
AU  - Ono M
AD  - Department of Cardiac Surgery, The University of Tokyo, Tokyo, Japan.
FAU - Fukushima, Norihide
AU  - Fukushima N
AD  - Department of Transplant Medicine, National Cerebral and Cardiovascular Center,
      Osaka, Japan.
FAU - Yamamoto, Haruko
AU  - Yamamoto H
AD  - Department of Data Science, National Cerebral and Cardiovascular Center, Osaka,
      Japan.
FAU - Fujita, Tomoyuki
AU  - Fujita T
AD  - Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, 6-1
      Kishibeshimmachi, Suita, Osaka, 564-8565, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Aerosols)
RN  - 0 (BAX602)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aerosols
MH  - Aged
MH  - Female
MH  - Heart Diseases/etiology/pathology/*prevention & control
MH  - Heart Failure/diagnosis/physiopathology/*therapy
MH  - *Heart-Assist Devices
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Polyethylene Glycols/*administration & dosage/adverse effects/chemical synthesis
MH  - Prosthesis Implantation/adverse effects/*instrumentation
MH  - *Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Time Factors
MH  - Tissue Adhesions/prevention & control
MH  - Treatment Outcome
MH  - *Ventricular Function, Left
MH  - Young Adult
PMC - PMC7497303
OTO - NOTNLM
OT  - *Adhesion prevention device
OT  - *Cardiac surgery
OT  - *Multicenter randomized trial
OT  - *Ventricular assist device
EDAT- 2020/05/24 06:00
MHDA- 2020/11/28 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/11/28 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1007/s10557-020-06990-2 [doi]
AID - 10.1007/s10557-020-06990-2 [pii]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2020 Oct;34(5):651-657. doi: 10.1007/s10557-020-06990-2.


PMID- 32444797
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20210112
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Jun
TI  - BBMRI-ERIC's contributions to research and knowledge exchange on COVID-19.
PG  - 728-731
LID - 10.1038/s41431-020-0634-8 [doi]
AB  - During the COVID-19 pandemic, the European biobanking infrastructure is in a
      unique position to preserve valuable biological material complemented with
      detailed data for future research purposes. Biobanks can be either integrated
      into healthcare, where preservation of the biological material is a fork in
      clinical routine diagnostics and medical treatment processes or they can also
      host prospective cohorts or material related to clinical trials. The paper
      discussed objectives of BBMRI-ERIC, the European research infrastructure
      established to facilitate access to quality-defined biological materials and data
      for research purposes, with respect to the COVID-19 crisis: (a) to collect
      information on available European as well as non-European COVID-19-relevant
      biobanking resources in BBMRI-ERIC Directory and to facilitate access to these
      via BBMRI-ERIC Negotiator platform; (b) to help harmonizing guidelines on how
      data and biological material is to be collected to maximize utility for future
      research, including large-scale data processing in artificial intelligence, by
      participating in activities such as COVID-19 Host Genetics Initiative; (c) to
      minimize risks for all involved parties dealing with (potentially) infectious
      material by developing recommendations and guidelines; (d) to provide a
      European-wide platform of exchange in relation to ethical, legal, and societal
      issues (ELSI) specific to the collection of biological material and data during
      the COVID-19 pandemic.
FAU - Holub, Petr
AU  - Holub P
AUID- ORCID: http://orcid.org/0000-0002-5358-616X
AD  - BBMRI-ERIC, Neue Stiftingtalstrasse 2/B/6, 8010, Graz, Austria.
      petr.holub@bbmri-eric.eu.
AD  - Institute of Computer Science, Masaryk University, Botanicka 68a, 60200, Brno,
      Czech Republic. petr.holub@bbmri-eric.eu.
FAU - Kozera, Lukasz
AU  - Kozera L
AD  - BBMRI-ERIC, Neue Stiftingtalstrasse 2/B/6, 8010, Graz, Austria.
FAU - Florindi, Francesco
AU  - Florindi F
AD  - BBMRI-ERIC, Neue Stiftingtalstrasse 2/B/6, 8010, Graz, Austria.
FAU - van Enckevort, Esther
AU  - van Enckevort E
AUID- ORCID: http://orcid.org/0000-0002-2440-3993
AD  - Department of Genetics CB50, University Medical Center Groningen & BBMRI-NL,
      Hanzeplein 1, 9713 GZ, Groningen, Netherlands.
FAU - Swertz, Morris
AU  - Swertz M
AUID- ORCID: http://orcid.org/0000-0002-0979-3401
AD  - Department of Genetics CB50, University Medical Center Groningen & BBMRI-NL,
      Hanzeplein 1, 9713 GZ, Groningen, Netherlands.
FAU - Reihs, Robert
AU  - Reihs R
AD  - Medical University Graz & BBMRI.at, Auenbruggerpl. 2, 8036, Graz, Austria.
FAU - Wutte, Andrea
AU  - Wutte A
AD  - BBMRI-ERIC, Neue Stiftingtalstrasse 2/B/6, 8010, Graz, Austria.
FAU - Valik, Dalibor
AU  - Valik D
AD  - Masaryk Memorial Cancer Institute, Zluty kopec 543/7, 602 00, Brno, Czech
      Republic.
FAU - Mayrhofer, Michaela Th
AU  - Mayrhofer MT
AD  - BBMRI-ERIC, Neue Stiftingtalstrasse 2/B/6, 8010, Graz, Austria.
CN  - BBMRI-ERIC community
LA  - eng
GR  - 654248/EC | EU Framework Programme for Research and Innovation H2020 | H2020
      Euratom (H2020 Euratom Research and Training Programme 2014-2018)/International
GR  - 824087/EC | EU Framework Programme for Research and Innovation H2020 | H2020
      Euratom (H2020 Euratom Research and Training Programme 2014-2018)/International
GR  - LM2015089/Ministerstvo Skolstvi, Mladeze a Telovychovy (Ministry of Education,
      Youth and Sports)/International
GR  - 184.034.019/Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands 
      Organisation for Scientific Research)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200522
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Artificial Intelligence
MH  - Betacoronavirus/drug effects/genetics/*pathogenicity
MH  - Biological Specimen Banks/supply & distribution
MH  - Biomedical Research/*organization & administration
MH  - COVID-19
MH  - Clinical Trials as Topic
MH  - Coronavirus Infections/diagnosis/drug therapy/*epidemiology/genetics
MH  - Datasets as Topic
MH  - Europe/epidemiology
MH  - Humans
MH  - Information Dissemination/ethics/*methods
MH  - International Cooperation/*legislation & jurisprudence
MH  - *Pandemics
MH  - Pneumonia, Viral/diagnosis/drug therapy/*epidemiology/genetics
MH  - Practice Guidelines as Topic
MH  - Public Health/economics
MH  - SARS-CoV-2
PMC - PMC7242892
EDAT- 2020/05/24 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1038/s41431-020-0634-8 [doi]
AID - 10.1038/s41431-020-0634-8 [pii]
PST - ppublish
SO  - Eur J Hum Genet. 2020 Jun;28(6):728-731. doi: 10.1038/s41431-020-0634-8. Epub
      2020 May 22.


PMID- 32444742
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20220531
IS  - 1476-5373 (Electronic)
IS  - 0007-0610 (Linking)
VI  - 228
IP  - 10
DP  - 2020 May
TI  - PPE or not PPE - that is the question.
PG  - 753-754
LID - 10.1038/s41415-020-1639-y [doi]
AB  - The world is in the middle of the COVID-19 pandemic and healthcare workers as
      well as dentists are having to make every difficult decision about their
      responsibilities in caring for their patients. Compounding this is the shortage
      of personal protective equipment (PPE), which makes patient-centred care
      ethically more challenging. Our first response to these ethical challenges should
      be to start with ourselves to make sure we are safe before we think about the
      patients. This is not the approach we would normally adopt when treating our
      patients outside of a pandemic.
FAU - D'Cruz, Len
AU  - D'Cruz L
AD  - General Dental Practitioner, Woodford Dental Care, UK. len.dcruz@bda.org.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Dent J
JT  - British dental journal
JID - 7513219
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Dental Care
MH  - Dentists
MH  - Humans
MH  - *Infectious Disease Transmission, Patient-to-Professional/prevention & control
MH  - Pandemics
MH  - *Personal Protective Equipment
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7243221
EDAT- 2020/05/24 06:00
MHDA- 2020/05/28 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
AID - 10.1038/s41415-020-1639-y [doi]
AID - 10.1038/s41415-020-1639-y [pii]
PST - ppublish
SO  - Br Dent J. 2020 May;228(10):753-754. doi: 10.1038/s41415-020-1639-y.


PMID- 32444434
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 21
TI  - Metformin in Pregnancy Study (MiPS): protocol for a systematic review with
      individual patient data meta-analysis.
PG  - e036981
LID - 10.1136/bmjopen-2020-036981 [doi]
AB  - INTRODUCTION: Gestational diabetes mellitus (GDM) is a common disorder of
      pregnancy and contributes to adverse pregnancy outcomes. Metformin is often used 
      for the prevention and management of GDM; however, its use in pregnancy continues
      to be debated. The Metformin in Pregnancy Study aims to use individual patient
      data (IPD) meta-analysis to clarify the efficacy and safety of metformin use in
      pregnancy and to identify relevant knowledge gaps. METHODS AND ANALYSIS: MEDLINE,
      EMBASE and all Evidence-Based Medicine will be systematically searched for
      randomised controlled trials (RCT) testing the efficacy of metformin compared
      with placebo, usual care or other interventions in pregnant women. Two
      independent reviewers will assess eligibility using prespecified criteria and
      will conduct data extraction and quality appraisal of eligible studies. Authors
      of included trials will be contacted and asked to contribute IPD. Primary
      outcomes include maternal glycaemic parameters and GDM, as well as neonatal
      hypoglycaemia, anthropometry and gestational age at delivery. Other adverse
      maternal, birth and neonatal outcomes will be assessed as secondary outcomes. IPD
      from these RCTs will be harmonised and a two-step meta-analytic approach will be 
      used to determine the efficacy and safety of metformin in pregnancy, with a
      priori adjustment for covariates and subgroups to examine effect moderators of
      treatment outcomes. Sensitivity analyses will assess heterogeneity, risk of bias 
      and the impact of trials which have not provided IPD. ETHICS AND DISSEMINATION:
      All IPD will be deidentified and studies contributing IPD will have ethical
      approval from their respective local ethics committees. This study will provide
      robust evidence regarding the efficacy and safety of metformin use in pregnancy, 
      and may identify subgroups of patients who may benefit most from this treatment
      modality. Findings will be published in peer-reviewed journals and disseminated
      at scientific meetings, providing much needed evidence to inform clinical and
      public health actions in this area.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mousa, Aya
AU  - Mousa A
AUID- ORCID: 0000-0002-7356-4523
AD  - Monash Centre for Health Research and Implementation, School of Public Health and
      Preventive Medicine, Monash University, Clayton, Victoria, Australia
      aya.mousa@monash.edu.
FAU - Lovvik, Tone
AU  - Lovvik T
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, Trondheim, Norway.
FAU - Hilkka, Ijas
AU  - Hilkka I
AD  - Department of Obstetrics and Gynaecology, University of Oulu and Oulu University 
      Hospital, Medical Research Centre, PEDEGO Research Unit, Oulu, Finland.
FAU - Carlsen, Sven M
AU  - Carlsen SM
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, Trondheim, Norway.
AD  - Department of Endocrinology, St Olavs Hospital, Trondheim, Norway.
FAU - Morin-Papunen, Laure
AU  - Morin-Papunen L
AD  - Department of Obstetrics and Gynaecology, University of Oulu and Oulu University 
      Hospital, Medical Research Centre, PEDEGO Research Unit, Oulu, Finland.
FAU - Tertti, Kristiina
AU  - Tertti K
AD  - Department of Obstetrics and Gynecology, University of Turku, Turku, Finland.
AD  - Department of Obstetrics and Gynecology, Turku University Hospital, Turku,
      Finland.
FAU - Ronnemaa, Tapani
AU  - Ronnemaa T
AD  - Department of Obstetrics and Gynecology, Turku University Hospital, Turku,
      Finland.
AD  - Department of Medicine, University of Turku, Turku, Finland.
FAU - Syngelaki, Argyro
AU  - Syngelaki A
AD  - Fetal Medicine Research Unit, King's College London, London, UK.
FAU - Nicolaides, Kypros
AU  - Nicolaides K
AD  - Fetal Medicine Research Unit, King's College London, London, UK.
FAU - Shehata, Hassan
AU  - Shehata H
AD  - Department of Maternal Medicine, Epsom Hospital, Epsom and St Helier University
      Hospitals NHS Trust, Epsom, Surrey, UK.
FAU - Burden, Christy
AU  - Burden C
AD  - Faculty of Health Sciences, University of Bristol, Bristol, UK.
FAU - Norman, Jane E
AU  - Norman JE
AD  - Faculty of Health Sciences, University of Bristol, Bristol, UK.
FAU - Rowan, Janet
AU  - Rowan J
AD  - Auckland District Health Board, Auckland, New Zealand.
AD  - School of Medicine, Faculty of Medical and Health Sciences, The University of
      Auckland, Auckland, New Zealand.
FAU - Dodd, Jodie M
AU  - Dodd JM
AUID- ORCID: 0000-0002-6363-4874
AD  - Robinson Research Institute, The University of Adelaide Discipline of Obstetrics 
      and Gynaecology, Adelaide, South Australia, Australia.
AD  - Women's and Babies Division, Women's and Children's Hospital, Adelaide, North
      Adelaide, South Australia, Australia.
FAU - Hague, William
AU  - Hague W
AD  - Robinson Research Institute, The University of Adelaide Discipline of Obstetrics 
      and Gynaecology, Adelaide, South Australia, Australia.
AD  - Women's and Babies Division, Women's and Children's Hospital, Adelaide, North
      Adelaide, South Australia, Australia.
FAU - Vanky, Eszter
AU  - Vanky E
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, Trondheim, Norway.
FAU - Teede, Helena J
AU  - Teede HJ
AD  - Monash Centre for Health Research and Implementation, School of Public Health and
      Preventive Medicine, Monash University, Clayton, Victoria, Australia.
LA  - eng
GR  - MC_G1002463/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200521
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes, Gestational/drug therapy
MH  - Female
MH  - Humans
MH  - *Hypoglycemia
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - *Metformin/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
PMC - PMC7247411
OTO - NOTNLM
OT  - *diabetes in pregnancy
OT  - *obstetrics
OT  - *preventive medicine
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036981 [pii]
AID - 10.1136/bmjopen-2020-036981 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 21;10(5):e036981. doi: 10.1136/bmjopen-2020-036981.


PMID- 32444433
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 21
TI  - Protocol for a randomised controlled trial of Subacromial spacer for Tears
      Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial 
      in Surgery (START:REACTS).
PG  - e036829
LID - 10.1136/bmjopen-2020-036829 [doi]
AB  - INTRODUCTION: Shoulder pain due to irreparable rotator cuff tears can cause
      substantial disability, but treatment options are limited. A balloon spacer is a 
      relatively simple addition to a standard arthroscopic debridement procedure, but 
      it is costly and there is no current randomised trial evidence to support its
      use. This trial will evaluate the clinical and cost-effectiveness of a
      subacromial balloon spacer for individuals undergoing arthroscopic debridement
      for irreparable rotator cuff tears.New surgical procedures can provide
      substantial benefit to patients. Good quality randomised controlled trials (RCTs)
      are needed, but trials in surgery are typically long and expensive, exposing
      patients to risk and the healthcare system to substantial costs. One way to
      improve the efficiency of trials is with an adaptive sample size. Such methods
      are well established in drug trials but have rarely, if ever, been used in
      surgical trials. METHODS AND ANALYSIS: Subacromial spacer for Tears Affecting
      Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery
      (START:REACTS) is a participant and assessor blinded, adaptive, multicentre RCT
      comparing arthroscopic debridement with the InSpace balloon (Stryker, USA) to
      arthroscopic debridement alone for people with a symptomatic irreparable rotator 
      cuff tear. It uses a group sequential adaptive design where interim analyses are 
      performed using all of the 3, 6 and 12-month data that are available at each time
      point. A maximum of 221 participants will be randomised (1:1 ratio), this will
      provide 90% power (at the 5% level) for a 6 point difference in the primary
      outcome; the Oxford Shoulder Score at 12 months. A substudy will use
      deltoid-active MRI scans in 56 participants to assess the function of the
      balloon. Analysis will be on an intention-to-treat basis and reported according
      to principles established in the Consolidated Standards of Reporting Trials
      statement. ETHICS AND DISSEMINATION: NRES number 18/WM/0025. The results will be 
      disseminated via peer-reviewed publications, presentations at conferences, lay
      summaries and social media. TRIAL REGISTRATION NUMBER: ISRCTN17825590.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Metcalfe, Andrew
AU  - Metcalfe A
AUID- ORCID: 0000-0002-4515-8202
AD  - Warwick Medical School, University of Warwick, Coventry, UK
      A.Metcalfe@warwick.ac.uk.
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
FAU - Gemperle Mannion, Elke
AU  - Gemperle Mannion E
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Parsons, Helen
AU  - Parsons H
AUID- ORCID: 0000-0002-2765-3728
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Brown, Jaclyn
AU  - Brown J
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Parsons, Nicholas
AU  - Parsons N
AUID- ORCID: 0000-0001-9975-888X
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Fox, Josephine
AU  - Fox J
AD  - Patient Representative, Durham, UK.
FAU - Kearney, Rebecca
AU  - Kearney R
AUID- ORCID: 0000-0002-8010-164X
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
FAU - Lawrence, Tom
AU  - Lawrence T
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
FAU - Bush, Howard
AU  - Bush H
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
FAU - McGowan, Kerri
AU  - McGowan K
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
FAU - Khan, Iftekhar
AU  - Khan I
AUID- ORCID: 0000-0001-6041-8837
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Mason, James
AU  - Mason J
AUID- ORCID: 0000-0001-9210-4082
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Hutchinson, Charles
AU  - Hutchinson C
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Gates, Simon
AU  - Gates S
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
AD  - Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham,
      UK.
FAU - Stallard, Nigel
AU  - Stallard N
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Underwood, Martin
AU  - Underwood M
AUID- ORCID: 0000-0002-0309-1708
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Drew, Stephen
AU  - Drew S
AD  - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
LA  - eng
SI  - ISRCTN/ISRCTN17825590
GR  - 16/61/18/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200521
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Arthroscopy
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Rotator Cuff/surgery
MH  - *Rotator Cuff Injuries/surgery
MH  - Shoulder Pain/etiology
MH  - Treatment Outcome
PMC - PMC7247380
OTO - NOTNLM
OT  - *adult orthopaedics
OT  - *clinical trials
OT  - *shoulder
COIS- Competing interests: Stryker is providing 50 free InSpace balloons for the study,
      to offset some of the costs of delivery of the study in participating hospitals. 
      Contracts are in place to ensure the full independence of the trial team with
      regard to study design and delivery, analysis and reporting of results, aligning 
      to the NIHR standard agreement. The chief investigator and multiple coauthors
      (HP, EGM, JB, JF, JM, CEH and MU) are applicants on another NIHR grant with
      similar contractual relationships with Stryker to support treatment costs but not
      research costs, in which the full independence of the trial team is protected by 
      mutually agreed contracts. MU was Chair of the NICE accreditation advisory
      committee until March 2017 for which he received a fee. He is chief investigator 
      or coinvestigator on multiple previous and current research grants from the
      National Institute for Health Research. He is an NIHR Senior Investigator. He is 
      an editor of the NIHR journal series, and a member of the NIHR Journal Editors
      Group, for which he receives a fee.
EDAT- 2020/05/24 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-036829 [pii]
AID - 10.1136/bmjopen-2020-036829 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 21;10(5):e036829. doi: 10.1136/bmjopen-2020-036829.


PMID- 32444425
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - What healthcare professionals owe us: why their duty to treat during a pandemic
      is contingent on personal protective equipment (PPE).
PG  - 432-435
LID - 10.1136/medethics-2020-106278 [doi]
AB  - Healthcare professionals' capacity to protect themselves, while caring for
      infected patients during an infectious disease pandemic, depends on their ability
      to practise universal precautions. In turn, universal precautions rely on the
      availability of personal protective equipment (PPE). During the SARS-CoV2
      outbreak many healthcare workers across the globe have been reluctant to provide 
      patient care because crucial PPE components are in short supply. The lack of such
      equipment during the pandemic was not a result of careful resource allocation
      decisions in the global north, where the short supply could be explained through 
      their high cost. Instead, they were the result of democratically elected
      governments prioritising low tax regimes over an adequate resourcing of their
      healthcare delivery systems. Such decisions were made despite global health
      experts warning about the high probability of pandemics like SARS-CoV2 occurring 
      during our lifetimes. Avoidable allocation decisions by democratically elected
      political leaders resulted in a lack of sufficient PPE for healthcare
      professionals. After discussing and discounting various ethical arguments in
      support of a professional obligation to treat, even without or with suboptimal
      PPE, I conclude that these policy decisions were sufficiently grave that they
      provide a sound ethical rationale to justify healthcare workers' refusal to
      provide care to infected patients.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Schuklenk, Udo
AU  - Schuklenk U
AD  - Department of Philosophy, Queen's University, Kingston, ON K7L 3N6, Canada
      udo.schuklenk@pm.me.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (RNA, Viral)
SB  - IM
MH  - *COVID-19
MH  - Delivery of Health Care
MH  - Health Personnel
MH  - Humans
MH  - *Pandemics/prevention & control
MH  - Personal Protective Equipment
MH  - RNA, Viral
MH  - SARS-CoV-2
PMC - PMC7295850
OTO - NOTNLM
OT  - *clinical ethics
OT  - *codes of/position statements on professional ethics
OT  - *health personnel
OT  - *philosophy of the health professions
OT  - *public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/24 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - medethics-2020-106278 [pii]
AID - 10.1136/medethics-2020-106278 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):432-435. doi: 10.1136/medethics-2020-106278. Epub
      2020 May 22.


PMID- 32444147
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20210110
IS  - 2213-2961 (Electronic)
IS  - 2213-2961 (Linking)
VI  - 9
IP  - 3
DP  - 2020 May
TI  - An evaluation of prevention initiatives by 53 national anti-doping organizations:
      Achievements and limitations.
PG  - 228-239
LID - S2095-2546(19)30149-8 [pii]
LID - 10.1016/j.jshs.2019.12.002 [doi]
AB  - BACKGROUND: One main purpose of the World Anti-Doping Agency was to harmonize
      anti-doping efforts, including the provision of anti-doping education. A
      multifaceted approach to doping prevention can play a key role in preventing
      intentional and unintentional doping. This article aimed to systematically record
      and evaluate doping prevention approaches in the form of information and
      education activities of national anti-doping organizations (NADOs) and assess the
      extent to which a multifaceted doping prevention approach has been realized.
      METHODS: Data on anti-doping information and education activities of 53 NADOs
      were collected via a survey and an online search of the NADOs' websites.
      Prevention activities were classified into knowledge focused, affective focused, 
      social skills, life skills, and ethic- and value- based. The implementation of
      the prevention activities was assessed by 4 independent raters using a modified
      visual analogue scale. RESULTS: In total, 59% of the NADOs (n=38) returned the
      survey and 70% (n=45) had information available online. The data were combined
      for the visual analogue scale assessment. Overall, 58% of the NADOs (n=37)
      reported offering activities including elements of all 5 approaches. Results of
      the raters' assessments indicated that the knowledge-focused approach was best
      implemented; the implementation of the other 4 approaches was largely
      unsatisfactory. The most common barriers to implementing doping prevention
      programs reported by the NADOs were lack of resources (n=26) and difficulties in 
      collaborating with sports organizations (n=8). CONCLUSION: Results show a
      discrepancy between NADOs' self-report data and the implementation assessment.
      Even though the NADOs indicated otherwise, most of their education-based
      approaches did not address aspects of the visual analogue scale (e.g., resisting 
      peer pressure) and only a few programs were ongoing. Possible explanations might 
      be found in the reported barriers (e.g., financial). Concrete guidelines defining
      multifaceted, values-based education, and best practice examples should be
      developed to indicate how to include all 5 approaches in prevention.
CI  - Copyright (c) 2020. Production and hosting by Elsevier B.V.
FAU - Gatterer, Katharina
AU  - Gatterer K
AD  - Institute of Sports Medicine, Alpine Medicine & Health Tourism, Private
      University for Health Sciences, Medical Informatics and Technology, Hall in
      Tirol, Tyrol 6060, Austria.
FAU - Gumpenberger, Matthias
AU  - Gumpenberger M
AD  - Institute of Sports Medicine, Alpine Medicine & Health Tourism, Private
      University for Health Sciences, Medical Informatics and Technology, Hall in
      Tirol, Tyrol 6060, Austria.
FAU - Overbye, Marie
AU  - Overbye M
AD  - Faculty of Health Sciences and Sport, University of Stirling, Stirling FK94LA,
      UK.
FAU - Streicher, Bernhard
AU  - Streicher B
AD  - Institute of Psychology, Private University for Health Sciences, Medical
      Informatics and Technology, Hall in Tirol, Tyrol 6060, Austria.
FAU - Schobersberger, Wolfgang
AU  - Schobersberger W
AD  - Institute of Sports Medicine, Alpine Medicine & Health Tourism, Private
      University for Health Sciences, Medical Informatics and Technology, Hall in
      Tirol, Tyrol 6060, Austria; Tirol Clinics (Tirol-Kliniken), Innsbruck, Tyrol
      6020, Austria.
FAU - Blank, Cornelia
AU  - Blank C
AD  - Institute of Sports Medicine, Alpine Medicine & Health Tourism, Private
      University for Health Sciences, Medical Informatics and Technology, Hall in
      Tirol, Tyrol 6060, Austria. Electronic address: cornelia.blank@umit.at.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20191224
PL  - China
TA  - J Sport Health Sci
JT  - Journal of sport and health science
JID - 101606001
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Doping in Sports/*prevention & control
MH  - Financial Support
MH  - *Health Education
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Information Dissemination
MH  - International Agencies/economics/ethics/*organization & administration
MH  - Intersectoral Collaboration
MH  - Program Evaluation
MH  - Social Skills
MH  - Sports/economics/ethics
PMC - PMC7242214
OTO - NOTNLM
OT  - *Anti-doping program
OT  - *Doping prevention
OT  - *Education
OT  - *Harmonization
OT  - *NADO
COIS- Competing interests The authors declare that they have no competing interests.
EDAT- 2020/05/24 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/05/24 06:00
PHST- 2019/07/16 00:00 [received]
PHST- 2019/09/24 00:00 [revised]
PHST- 2019/11/19 00:00 [accepted]
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
AID - S2095-2546(19)30149-8 [pii]
AID - 10.1016/j.jshs.2019.12.002 [doi]
PST - ppublish
SO  - J Sport Health Sci. 2020 May;9(3):228-239. doi: 10.1016/j.jshs.2019.12.002. Epub 
      2019 Dec 24.


PMID- 32444121
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 6
DP  - 2020 Jul - Aug
TI  - Sirolimus-Induced Delayed Severe Thrombocytopenia After Liver Transplantation: A 
      Case Report.
PG  - 1950-1952
LID - S0041-1345(19)31517-9 [pii]
LID - 10.1016/j.transproceed.2020.02.125 [doi]
AB  - OBJECTIVE: Thrombocytopenia is a common condition in patients undergoing liver
      transplantation (LT). Thrombocytopenia is prevalent in early postoperative phase,
      and it gradually improves after several weeks. Delayed severe thrombocytopenia
      occurring after the initial recovery of platelets is rare. We report a case of a 
      patient with delayed severe thrombocytopenia 59 weeks after LT. CASE
      PRESENTATION: Our patient was a 61-year-old man who presented to our institution 
      59 weeks after undergoing LT. He presented for removal of a bile duct stent that 
      was inserted 3 months prior. Tacrolimus replaced sirolimus for immunosuppression 
      during the seventh week after transplantation due to sirolimus-induced
      nephrotoxicity. On admission, the patient's vital signs were normal and his
      physical examination was unremarkable. Laboratory parameters demonstrated that
      the platelet (PLT) level was significantly decreased to 18 x 10(9)/L. PLTs
      reached a nadir of 3 x 10(9)/L even after utilization of interleukin-11,
      thrombopoietin, and low-dose prednisone. Although rare, sirolimus toxicity was
      suspected. Therefore, sirolimus was gradually replaced by cyclosporin A in
      combination with low-dose prednisone. Subsequently, a normal PLT level was
      gradually recovered. This study was approved by the ethical committee of the
      First Hospital of Jilin University and was performed in accordance with the
      ethical standards of the Helsinki Congress and Istanbul Declaration. CONCLUSIONS:
      Recurrent delayed severe thrombocytopenia is rare after LT. Sirolimus toxicity
      might be a reason for its occurrence if other possible factors are excluded.
      After diagnosis, sirolimus therapy should be discontinued and patients should be 
      treated with an alternative immunosuppressive regimen.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Li, Ting
AU  - Li T
AD  - Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin
      University, Changchun, Jilin Province, China.
FAU - Sun, Xiaodong
AU  - Sun X
AD  - Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin
      University, Changchun, Jilin Province, China.
FAU - Luo, Feixiang
AU  - Luo F
AD  - Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin
      University, Changchun, Jilin Province, China.
FAU - Song, Shifei
AU  - Song S
AD  - Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin
      University, Changchun, Jilin Province, China.
FAU - Yu, Ying
AU  - Yu Y
AD  - Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin
      University, Changchun, Jilin Province, China.
FAU - Lv, Guoyue
AU  - Lv G
AD  - Department of Hepatobiliary and Pancreas Surgery, The First Hospital of Jilin
      University, Changchun, Jilin Province, China. Electronic address: lgy08@sina.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200519
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - W36ZG6FT64 (Sirolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Cyclosporine/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*adverse effects
MH  - *Liver Transplantation
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*chemically induced
MH  - Sirolimus/*adverse effects
MH  - Tacrolimus/therapeutic use
MH  - Thrombocytopenia/*chemically induced
EDAT- 2020/05/24 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/05/24 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/01/31 00:00 [revised]
PHST- 2020/02/09 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - S0041-1345(19)31517-9 [pii]
AID - 10.1016/j.transproceed.2020.02.125 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Jul - Aug;52(6):1950-1952. doi:
      10.1016/j.transproceed.2020.02.125. Epub 2020 May 19.


PMID- 32443979
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20211204
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 May 22
TI  - Implementing volunteer-navigation for older persons with advanced chronic illness
      (Nav-CARE): a knowledge to action study.
PG  - 72
LID - 10.1186/s12904-020-00578-1 [doi]
AB  - BACKGROUND: Nav-CARE is a volunteer-led intervention designed to build upon
      strategic directions in palliative care: a palliative approach to care, a public 
      health/compassionate community approach to care, and enhancing the capacity of
      volunteerism. Nav-CARE uses specially trained volunteers to provide lay
      navigation for older persons and family living at home with advanced chronic
      illness. The goal of this study was to better understand the implementation
      factors that influenced the utilization of Nav-CARE in eight diverse Canadian
      contexts. METHODS: This was a Knowledge to Action study using the planned action 
      cycle for Nav-CARE developed through previous studies. Participants were eight
      community-based hospice societies located in diverse geographic contexts and with
      diverse capacities. Implementation data was collected at baseline, midpoint, and 
      endpoint using qualitative individual and group interviews. Field notes of all
      interactions with study sites were also used as part of the data set. Data was
      analyzed using qualitative descriptive techniques. The study received ethical
      approval from three university behavioural review boards. All participants
      provided written consent. RESULTS: At baseline, stakeholders perceived Nav-CARE
      to be a good fit with the strategic directions of their organization by providing
      early palliative support, by facilitating outreach into the community and by
      changing the public perception of palliative care. The contextual factors that
      determined the ease with which Nav-CARE was implemented included the volunteer
      coordinator champion, organizational capacity and connection, the ability to
      successfully recruit older persons, and the adequacy of volunteer preparation and
      mentorship. CONCLUSIONS: This study highlighted the importance of community-based
      champions for the success of volunteer-led initiatives and the critical need for 
      support and mentorship for both volunteers and those who lead them. Further,
      although the underutilization of hospice has been widely recognized, it is vital 
      to recognize the limitations of their capacity. New initiatives such as Nav-CARE,
      which are designed to enhance their contributions to palliative care, need to be 
      accompanied by adequate resources. Finally, this study illustrated the need to
      think carefully about the language and role of hospice societies as palliative
      care moves toward a public health approach to care.
FAU - Pesut, Barbara
AU  - Pesut B
AUID- ORCID: http://orcid.org/0000-0002-1063-7190
AD  - School of Nursing, University of British Columbia Okanagan, 1147 Research Road
      Arts 3rd Floor, Kelowna, BC, V1V 1V7, Canada. Barb.pesut@ubc.ca.
FAU - Duggleby, Wendy
AU  - Duggleby W
AD  - Faculty of Nursing University of Alberta, 3-141 ECHA 11405 87th Ave, Edmonton,
      Alberta, T6G1C9, Canada.
FAU - Warner, Grace
AU  - Warner G
AD  - Dalhousie University, P.O. Box 15000, Halifax, Nova Scotia, B3H 4R2, Canada.
FAU - Kervin, Emily
AU  - Kervin E
AD  - Mount Saint Vincent University, 166 Bedford Highway, Halifax, Nova Scotia, B3M
      2J6, Canada.
FAU - Bruce, Paxton
AU  - Bruce P
AD  - University of British Columbia Okanagan, 1147 Research Road. Arts 3rd Floor,
      Kelowna, BC, V1V 1V7, Canada.
FAU - Antifeau, Elisabeth
AU  - Antifeau E
AD  - Regional Clinical Nurse Specialist, Palliative End-of-Life Care Services,
      Interior Health, c/o 2nd floor, 333 Victoria Street, Nelson, BC, V1L 4K3, Canada.
FAU - Hooper, Brenda
AU  - Hooper B
AD  - University of British Columbia Okanagan, 1147 Research Road. Arts 3rd Floor,
      Kelowna, BC, V1V 1V7, Canada.
LA  - eng
GR  - 148655/CAPMC/ CIHR/Canada
GR  - 704887/Canadian Cancer Society Research Institute
PT  - Journal Article
DEP - 20200522
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Chronic Disease/psychology/*therapy
MH  - Female
MH  - Geriatrics/methods
MH  - Humans
MH  - Male
MH  - Patient Navigation/*methods
MH  - Qualitative Research
MH  - Translational Research, Biomedical/methods
MH  - *Volunteers
PMC - PMC7245025
OTO - NOTNLM
OT  - (3-10) volunteers
OT  - Compassionate community
OT  - Hospice
OT  - Knowledge translation
OT  - Navigation
OT  - Palliative
OT  - Palliative approach
OT  - Public-health
EDAT- 2020/05/24 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1186/s12904-020-00578-1 [doi]
AID - 10.1186/s12904-020-00578-1 [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 May 22;19(1):72. doi: 10.1186/s12904-020-00578-1.


PMID- 32443952
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1552-7468 (Electronic)
IS  - 1527-1544 (Linking)
VI  - 21
IP  - 2
DP  - 2020 May
TI  - A Matter of Conscience: Examining the Law and Policy of Conscientious Objection
      in Health Care.
PG  - 120-126
LID - 10.1177/1527154420926156 [doi]
AB  - Conscientious objection refers to refusal by a health care provider (HCP) to
      provide certain treatments, including the standard of care, to a patient based
      upon the provider's personal, ethical, or religious beliefs. Federal and state
      rules regarding conscientious objection have expanded the scope of legal
      protections that HCPs and institutions can invoke in support of refusal.
      Opponents of these rules argue that allowing refusal of care deprives patients of
      care that conforms to professionally established guidelines, contradicts
      long-standing principles related to informed consent, interferes with the ability
      of health care facilities to provide safe and efficient care, and leaves the
      patient without means of redress for injury. Proponents respond that such rules
      are necessary to preserve the moral integrity of providers, including
      institutions. Although refusal rules are most often associated with abortion,
      some HCPs have cited moral concerns regarding contraception, sterilization,
      prevention/treatment of sexually transmitted infections, transition-related care 
      for transgender individuals, medication-assisted treatment of substance use
      disorders, the use of artificial reproductive technologies, and patient
      preferences for end-of-life care. Evidence suggests that the burden of
      conscientious refusal falls disproportionately on vulnerable populations, and
      legitimate concern exists that moral disagreement is merely pretext for
      discrimination. A careful balance must be struck between the defending the
      conscience rights of HCPs and the civil rights of patients.
FAU - Fry-Bowers, Eileen K
AU  - Fry-Bowers EK
AUID- ORCID: https://orcid.org/0000-0002-5689-5996
AD  - Hahn School of Nursing and Health Science, Betty and Bob Beyster Institute for
      Nursing Research, Advanced Practice and Simulation, University of San Diego.
AD  - School of Nursing, George Washington University.
LA  - eng
PT  - Journal Article
DEP - 20200522
PL  - United States
TA  - Policy Polit Nurs Pract
JT  - Policy, politics & nursing practice
JID - 100901316
SB  - IM
MH  - Adult
MH  - Conscientious Refusal to Treat/*ethics/*legislation & jurisprudence
MH  - Delivery of Health Care/*ethics/*standards
MH  - Female
MH  - Health Personnel/*legislation & jurisprudence/*psychology/*standards
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - United States
OTO - NOTNLM
OT  - conscience
OT  - informed consent
OT  - moral obligation
OT  - standard of care
EDAT- 2020/05/24 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - 10.1177/1527154420926156 [doi]
PST - ppublish
SO  - Policy Polit Nurs Pract. 2020 May;21(2):120-126. doi: 10.1177/1527154420926156.
      Epub 2020 May 22.


PMID- 32443781
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 20
TI  - Relationships between Motivations for Food Choices and Consumption of Food
      Groups: A Prospective Cross-Sectional Survey in Manufacturing Workers in Brazil.
LID - E1490 [pii]
LID - 10.3390/nu12051490 [doi]
AB  - Motivations for food choices may determine consumption, and understanding that
      relationship may help direct strategies for formulating diets. This study aimed
      to identify associations between motivations for food choices and consumption of 
      food groups. An observational cross-sectional survey was conducted in 921
      manufacturing workers from 33 companies in Brazil, based on a stratified
      two-stage probability sample. Motivations for food choices were assessed with the
      Food Choice Questionnaire, and intake of food groups was measured using 24-h
      dietary recall. Consumption was classified into 31 food groups defined according 
      to their nutritional value and the NOVA classification. Data were analyzed with
      multilevel mixed-effects regression. The results showed that sensory appeal and
      price were the most important motivations for food choices, while ethical concern
      was less important. Sensory appeal was positively associated with consumption of 
      industrialized condiments (p = 0.022), price showed a negative correlation with
      consumption of plant oils (p = 0.022), ethical concern showed positive
      correlation within consumption white meat (p = 0.065) and negative correlation
      within pasta dishes (p < 0.001). Regarding the NOVA classification, health
      correlated with an increase in consumption of unprocessed foods (p = 0.017) and
      weight control with a decrease in consumption of processed culinary ingredients
      (p = 0.057).
FAU - Souza, Anissa M
AU  - Souza AM
AD  - Postgraduate Program in Health Sciences, Centro de Ciencias da Saude,
      Universidade Federal do Rio Grande do Norte, Natal RN 59012-570, Brazil.
FAU - Bezerra, Ingrid W L
AU  - Bezerra IWL
AD  - Nutrition Department, Centro de Ciencias da Saude, Universidade Federal do Rio
      Grande do Norte, Natal RN 59078-970, Brazil.
FAU - Pereira, Gabriela S
AU  - Pereira GS
AD  - Postgraduate Program in Health Sciences, Centro de Ciencias da Saude,
      Universidade Federal do Rio Grande do Norte, Natal RN 59012-570, Brazil.
FAU - Torres, Karina G
AU  - Torres KG
AD  - Postgraduate Program in Health Sciences, Centro de Ciencias da Saude,
      Universidade Federal do Rio Grande do Norte, Natal RN 59012-570, Brazil.
FAU - Costa, Raiane M
AU  - Costa RM
AD  - Postgraduate Program in Health Sciences, Centro de Ciencias da Saude,
      Universidade Federal do Rio Grande do Norte, Natal RN 59012-570, Brazil.
FAU - Oliveira, Antonio G
AU  - Oliveira AG
AD  - Pharmacy Department, Centro de Ciencias da Saude, Universidade Federal do Rio
      Grande do Norte, Natal RN 59012-570, Brazil.
LA  - eng
GR  - 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)
PT  - Journal Article
DEP - 20200520
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
MH  - Adult
MH  - Brazil
MH  - Cross-Sectional Studies
MH  - Diet
MH  - Eating
MH  - Female
MH  - *Food Preferences
MH  - Humans
MH  - Male
MH  - *Manufacturing Industry
MH  - Middle Aged
MH  - *Motivation
MH  - Nutritive Value
MH  - Prospective Studies
MH  - Young Adult
PMC - PMC7285032
OTO - NOTNLM
OT  - food choices
OT  - food consumption
OT  - food intake
OT  - food preferences
COIS- The authors declare no conflict of interest. The funders had no role in the
      design of the study; in the collection, analyses, or interpretation of data; in
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/05/24 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - nu12051490 [pii]
AID - 10.3390/nu12051490 [doi]
PST - epublish
SO  - Nutrients. 2020 May 20;12(5). pii: nu12051490. doi: 10.3390/nu12051490.


PMID- 32443472
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Animal Welfare Centres: Are They Useful for the Improvement of Animal Welfare?
LID - E877 [pii]
LID - 10.3390/ani10050877 [doi]
AB  - Animal welfare has emerged as a scientific discipline only in the past 30 years, 
      but a significant body of scientists has developed worldwide in this time. Over
      the past quarter century, several aggregations of scientists, centres of animal
      welfare, have become established. This can bring the benefits of the recognition 
      of expertise and an opportunity to support animal industries in improving
      welfare, but it also brings the risk of scientists being influenced by these
      industries and failing to identify animal welfare problems as such. We conducted 
      a bibliometric search of the scientific literature with the purpose of comparing 
      the characteristics of publications on animal welfare that were or were not from 
      animal welfare centres in academic institutions. We found that the number of
      publications on animal welfare from centres of animal welfare increased,
      initially, in the early 2000s and again in the last decade. Significant funding
      was obtained from the livestock industries for these centres. In a second search,
      we identified that only about 8% of scientific publications on animal welfare
      came from animal welfare centres, and the rest were mainly supported by funding
      sources other than the animal industries. It is concluded that the emergence of
      significant animal welfare centres, often with significant funding from industry,
      allows clusters of scientists to develop that could advance animal welfare
      knowledge more effectively than disparate scientists in isolated institutions.
      However, industry funding risks these scientists being aligned with industry
      goals that may not include animal welfare improvement to the extent required by
      the public. Further research to identify any ethical conflicts for scientists in 
      animal welfare centres would be warranted.
FAU - Phillips, Clive J C
AU  - Phillips CJC
AD  - Centre for Animal Welfare and Ethics, School of Veterinary Science, The
      University of Queensland, Gatton, QLD 4343, Australia.
AD  - Animal Welfare Laboratory, Animal Science Department, Federal University of
      Parana, Curitiba, R. dos Funcionarios 1540, Brazil.
FAU - Molento, Carla F M
AU  - Molento CFM
AD  - Animal Welfare Laboratory, Animal Science Department, Federal University of
      Parana, Curitiba, R. dos Funcionarios 1540, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7278406
OTO - NOTNLM
OT  - animal welfare
OT  - animal welfare science
OT  - animal wellbeing
OT  - centres of animal welfare
COIS- The authors declare no conflicts of interest
EDAT- 2020/05/24 06:00
MHDA- 2020/05/24 06:01
CRDT- 2020/05/24 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/05/24 06:01 [medline]
AID - ani10050877 [pii]
AID - 10.3390/ani10050877 [doi]
PST - epublish
SO  - Animals (Basel). 2020 May 18;10(5). pii: ani10050877. doi: 10.3390/ani10050877.


PMID- 32443388
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - Cupping for psoriasis vulgaris: A protocol of systematic review and
      meta-analysis.
PG  - e20348
LID - 10.1097/MD.0000000000020348 [doi]
AB  - BACKGROUND: Psoriasis vulgaris (PV) is a chronic, immune-mediated dermatological 
      disease that significantly affects the patient's health and quality of life. At
      present, cupping has been widely used in the treatment of psoriasis. However, the
      effectiveness and safety of cupping in patients with PV are still controversial. 
      Therefore, this review aims to evaluate the efficacy and safety of cupping
      therapy on PV. METHODS: The following databases will be searched from their
      inceptions to April 2020 with a language limitation of English and Chinese:
      Pubmed, Medline, Embase, Cochrane Central Register of Controlled Trials, Chinese 
      Biomedical Literature Databas, China National Knowledge Infrastructure Database, 
      Wanfang database and Chinese Scientific Journal Database. The reference lists of 
      eligible studies and other resources will also be searched. Two researchers will 
      independently perform the selection of studies, data extraction, and data
      analysis. A fixed or random-effect model will be applied to synthesize data
      depend on the heterogeneity test. The primary outcome is the proportion of
      patients achieving at least a 60% improvement in psoriasis area and severity
      index (PASI) score from baseline (PASI 60). Secondary outcomes include the
      proportion of patients achieving at least a 90% improvement in PASI score from
      baseline (PASI 90), the mean change of PASI and dermatology life quality index
      score, the itching index, adverse events, and recurrence rate. RevMan V.5.3
      software will be used for meta-analysis. RESULTS: The study will provide a
      high-quality evidence-based review of cupping for PV. CONCLUSIONS: The study will
      be conducted to evaluate the efficacy and safety of cupping in the treatment of
      PV and supposed to provide clear evidence for the clinical application of cupping
      therapy. ETHICS AND DISSEMINATION: As the study is a protocol of systematic
      review and meta-analysis that does not involve individual data, ethical approval 
      will not be required. The results will be published in a peer-reviewed journal.
      OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/KV4CJ.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      PR China.
FAU - Yu, Qianying
AU  - Yu Q
FAU - Peng, Li
AU  - Peng L
FAU - Zhang, Feng
AU  - Zhang F
FAU - Lin, Wenxia
AU  - Lin W
FAU - Guo, Jing
AU  - Guo J
FAU - Xiao, Min
AU  - Xiao M
FAU - Chen, Mingling
AU  - Chen M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Chronic Disease
MH  - Combined Modality Therapy
MH  - Cupping Therapy/adverse effects/*methods
MH  - Humans
MH  - Psoriasis/*therapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7253533
EDAT- 2020/05/24 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020348 [doi]
AID - 00005792-202005150-00104 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20348. doi: 10.1097/MD.0000000000020348.


PMID- 32443387
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - Dietary supplements for prediabetes: A protocol for a systematic review and
      meta-analysis.
PG  - e20347
LID - 10.1097/MD.0000000000020347 [doi]
AB  - BACKGROUND: The number of prediabetic individuals is at a high level worldwide
      and they have an increased risk of developing diabetes, causing severe physical
      impairment and heavy financial burden. Recently, using various dietary
      supplements is increasingly common, and relevant trials of different diseases are
      increasing correspondingly. The effects of dietary supplements have been
      confirmed in some studies among prediabetic individuals. However, there remains
      no comprehensive systematic review to assess the efficacy and safety of dietary
      supplements intake in prediabetic individuals. METHODS: We plan to search and
      retrieve applicable randomized controlled trials of dietary supplements for
      prediabetic individuals in the following databases before June 2020: PubMed, Web 
      of Science, EMBASE, the Cochrane Library, the Cochrane Central Register of
      Controlled Trials(CENTRAL), Allied and Complementary Medicine Database(AMED),
      Chinese Biomedical Literature database, Wan Fang database, Chinese Scientific
      Journal database (VIP), Chinese National Knowledge Infrastructure database(CNKI),
      and the ClinicalTrials.gov website. Two reviewers will separately perform study
      selection, data extraction, methodological quality assessment and quality of
      evidence assessment. Data analysis and publication bias will be conducted by
      Review Manager 5.3. RESULTS AND CONCLUSIONS: This evidence-based medicine
      systematic review will prove the efficacy and safety of multifarious dietary
      supplements for prediabetes. ETHICS AND DISSEMINATION: As this systematic review 
      is based merely on already published literature, no approval of the ethics
      committee is required. We will disseminate this systematic review to a
      peer-reviewed journal. PROTOCOL REGISTRATION NUMBER: INPLASY202040057.
FAU - Liu, Dongying
AU  - Liu D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Wen, Qing
AU  - Wen Q
FAU - Liu, Min
AU  - Liu M
FAU - Gao, Yang
AU  - Gao Y
FAU - Luo, Lihong
AU  - Luo L
FAU - Zhang, Zhuo
AU  - Zhang Z
FAU - Chen, Qiu
AU  - Chen Q
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Glucose
MH  - *Dietary Supplements
MH  - Glycated Hemoglobin A
MH  - Humans
MH  - Prediabetic State/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7253655
EDAT- 2020/05/24 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020347 [doi]
AID - 00005792-202005150-00103 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20347. doi: 10.1097/MD.0000000000020347.


PMID- 32443374
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - Clinical efficacy and safety of somatostatin in the treatment of early
      postoperative inflammatory small bowel obstruction: A protocol for systematic
      review and meta analysis.
PG  - e20288
LID - 10.1097/MD.0000000000020288 [doi]
AB  - BACKGROUND: As one of the complications after abdominal operation, early
      postoperative inflammatory small bowel obstruction (EPISBO) is a great trouble
      for many patients. The use of somatostatin in treating this disease had been
      widely reported, but its efficacy and safety were controversial. Therefore, the
      present research carried out a systematic review of the clinical efficacy and
      safety of somatostatin in treating EPISBO. METHODS: Computer retrieval was
      conducted in foreign databases (including PubMed, The Cochrane Library, and
      Embase) and Chinese database (including Sino Med, CNKI, VIP, and WangFang Data), 
      supplementary search for the literatures included was performed, and manual
      retrieval was performed in abstracts, books, and non-electronic magazines related
      to the present research to ensure the recall rate. Among all republished relevant
      experimental studies in Chinese and English from January 1, 1996 to February 1,
      2020, randomized controlled trials on the curative efficacy of somatostatin for
      EPISBO were collected. The evaluation measures included patients' total effective
      rate, peristaltic sound recovery time, time of disappearance of abdominal pain,
      time of first defecation after operation, drainage of gastrointestinal
      decompression and length of stay after treatment. The literatures were selected
      by two investigators independently to extract data according to the inclusion and
      exclusion criteria, Bias Risk Assessment Tool recommended by Cochrane Review Hand
      book 5.2 was used to assess literature quality, and meta-analysis was carried out
      by using soft Stata 12.0. RESULTS: This study will scientifically and effectively
      analyze the clinical efficacy and safety of somatostatin in the treatment of
      EPISBO through systematic review and meta-analysis. ETHICS AND DISSEMINATION: The
      results of this study will be published in a peer-reviewed SCI journal to provide
      evidence-based medical evidence for the clinical treatment of early postoperative
      inflammatory bowel obstruction. PROTOCOL AND REGISTRATION: Open Science Framework
      (https://osf.io, OSF), registration number: ryd2g.
FAU - Wu, Zhongyong
AU  - Wu Z
AD  - Department of Critical Care Medicine, The Second Affiliated Hospital of Hainan
      Medical University, Longhua District, Haikou.
FAU - Wang, Suibiao
AU  - Wang S
AD  - Department of Critical Care Medicine, Tunchang County People's Hospital of Hainan
      Province, Tuncheng Town, Tunchang County, Hainan.
FAU - Yuan, Shaofei
AU  - Yuan S
AD  - Department of Pharmacy, The Second Affiliated Hospital of Baotou Medical College,
      Baotou, Inner Mongolia, China.
FAU - Lin, Ming
AU  - Lin M
AD  - Department of Critical Care Medicine, The Second Affiliated Hospital of Hainan
      Medical University, Longhua District, Haikou.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 51110-01-1 (Somatostatin)
SB  - IM
MH  - Abdominal Pain/epidemiology
MH  - Defecation
MH  - Humans
MH  - Inflammation/*drug therapy/epidemiology
MH  - Intestinal Obstruction/*drug therapy/epidemiology
MH  - Intestine, Small/*pathology
MH  - Length of Stay
MH  - Peristalsis/physiology
MH  - Postoperative Complications/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Somatostatin/*therapeutic use
MH  - Time Factors
PMC - PMC7253791
EDAT- 2020/05/24 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020288 [doi]
AID - 00005792-202005150-00090 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20288. doi: 10.1097/MD.0000000000020288.


PMID- 32443332
OWN - NLM
STAT- MEDLINE
DCOM- 20200609
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - Research "recover from illness defense complex" helper T cell immune mechanisms
      based on the "Fuxie" theory clearing away heat evil thoroughly nourishing kidney 
      treatment of recurrent blood-heat syndrome Psoriasis.
PG  - e20161
LID - 10.1097/MD.0000000000020161 [doi]
AB  - INTRODUCTION: Psoriasis vulgaris (PV) is a chronic, painful, disfiguring, and
      disabling dermatological disease, which affects the physical and mental health of
      patients and impacts their quality of life. Current conventional systemic
      therapies can be costly, present risks of side effects, have limited efficacy and
      commonly recur following treatment cessation. Some Chinese herbal medicine
      therapies have shown therapeutic benefits for psoriasis vulgaris, including
      relieving symptoms and improving quality of life, and a potential of reducing
      relapse rate. However, explicit evidence has not yet been obtained. METHODS AND
      ANALYSIS: This is a pilot randomized controlled trial with the objective of
      investigating the effect of Jia Wei Liang Xue Xiao Feng San granules on relapse
      rate of recurrent PV and the correlation between Psoriasis area severity index
      (PASI) and key psoriasis-related cytokine changes and the number of cells. A
      total of 102 participants were recruited for this study, including 72 patients
      with recurrent PV, 15 healthy volunteers and 15 patients with psoriasis vulgaris 
      who have recovered for more than 1 year. A total of 72 patients, with recurrent
      PV, will be randomized (1:1) to receive the oral Chinese herbal medicine Jia Wei 
      Liang Xue Xiao Feng San or the oral Acitretin Capsule treatments for a period of 
      8 weeks. After this period, participants whose PASI scores improvement reached
      more than 75%, will undergo a 52-week follow-up phase.The primary outcome
      measures are as follows:The secondary study outcomes will include:This trial may 
      provide a novel regimen for recurrent PV patients if the granules decrease
      recurrence rate without further adverse effects. ETHICS AND DISSEMINATION: The
      ethics approval was provided by the Sichuan Traditional Chinese medicine regional
      ethics review committee. The ethics approval number is 2018KL-055. The design and
      the results of the study will be disseminated through peer-reviewed publications 
      and conference presentations. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial
      Registry (ChiCTR1900022766).
FAU - Li, Mao
AU  - Li M
AD  - Hospital of Chengdu University of traditional Chinese Medicine, Chengdu, China.
FAU - Hu, Xia
AU  - Hu X
FAU - Hao, Ping-Sheng
AU  - Hao PS
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cytokines)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Keratolytic Agents)
RN  - 0 (kamisyoyo san)
RN  - LCH760E9T7 (Acitretin)
SB  - IM
MH  - Acitretin/administration & dosage/therapeutic use
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Cytokines/drug effects/metabolism
MH  - Drugs, Chinese Herbal/administration & dosage/therapeutic use
MH  - Female
MH  - Heat Exhaustion/*immunology
MH  - Hot Temperature/*adverse effects
MH  - Humans
MH  - Immunity, Cellular/*drug effects/physiology
MH  - Keratolytic Agents/administration & dosage/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Psoriasis/*drug therapy/psychology
MH  - Quality of Life
MH  - Recurrence
MH  - Severity of Illness Index
MH  - T-Lymphocytes, Helper-Inducer/*immunology
MH  - Young Adult
PMC - PMC7254185
EDAT- 2020/05/24 06:00
MHDA- 2020/06/10 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/10 06:00 [medline]
AID - 10.1097/MD.0000000000020161 [doi]
AID - 00005792-202005150-00048 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20161. doi: 10.1097/MD.0000000000020161.


PMID- 32443330
OWN - NLM
STAT- MEDLINE
DCOM- 20200609
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - Does butylphthalide affect on hemodynamics in patients with watershed stroke?: A 
      protocol of systematic review and meta-analysis.
PG  - e20151
LID - 10.1097/MD.0000000000020151 [doi]
AB  - BACKGROUND: This study will specifically investigate the effect of butylphthalide
      on hemodynamics in patients with watershed stroke (WS). METHODS: We will search
      the following databases from their inceptions to the March 1, 2020: Cochrane
      Library, MEDLINE, EMBASE, PsycINFO, Web of Science, Cumulative Index to Nursing
      and Allied Health Literature, and China National Knowledge Infrastructure. All
      relevant randomized controlled trials on exploring the effect of butylphthalide
      on hemodynamics in patients with WS will be considered for inclusion. No language
      limitation will be imposed to this study. All study quality will be checked using
      Cochrane risk of bias tool. RevMan 5.3 software will be utilized for data
      analysis. RESULTS: This study will summarize the latest evidence to investigate
      the effect of butylphthalide on hemodynamics in patients with WS. CONCLUSION:
      Findings from this study will provide theoretical basis of butylphthalide on
      hemodynamics in patients with WS for clinician and future research. DISSEMINATION
      AND ETHICS: This study is carried out based on the published data, thus, no
      ethical approval is required. We will submit this study to a peer-reviewed
      journal for publication. SYSTEMATIC REVIEW REGISTRATION: INPLASY 202030006.
FAU - Jia, Li-Na
AU  - Jia LN
AD  - Department of Neurology, The Central Hospital of Jia Mu Si City, Jiamusi.
FAU - Zhang, Ya-Juan
AU  - Zhang YJ
AD  - Department of Neurology, First Affiliated Hospital of Jiamusi University,
      Jiamusi, China.
FAU - Ma, Rong
AU  - Ma R
AD  - Department of Neurology, The Central Hospital of Jia Mu Si City, Jiamusi.
FAU - Song, You
AU  - Song Y
AD  - Department of Neurology, First Affiliated Hospital of Jiamusi University,
      Jiamusi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Benzofurans)
RN  - 0 (Neuroprotective Agents)
RN  - 822Q956KGM (3-n-butylphthalide)
SB  - IM
MH  - Benzofurans/administration & dosage/adverse effects/*pharmacology
MH  - China/epidemiology
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Neuroprotective Agents/administration & dosage/adverse effects/*pharmacology
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Stroke/*drug therapy/pathology/physiopathology
MH  - Treatment Outcome
PMC - PMC7254054
EDAT- 2020/05/24 06:00
MHDA- 2020/06/10 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/10 06:00 [medline]
AID - 10.1097/MD.0000000000020151 [doi]
AID - 00005792-202005150-00046 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20151. doi: 10.1097/MD.0000000000020151.


PMID- 32443318
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 20
DP  - 2020 May
TI  - Exercise or sport activities for patients with cancer: A protocol for overview of
      systematic reviews and meta-analyses.
PG  - e20084
LID - 10.1097/MD.0000000000020084 [doi]
AB  - OBJECTIVE: We plan to review all published systematic reviews (SRs) and
      meta-analyses (MAs) of exercise or sport activities for patients with cancer. The
      aim of this study is to combine and reanalyze related data and to provide more
      comprehensive and higher-level evidence. METHODS: We plan to search four English 
      databases and four Chinese databases from inception to June 2019. Patients who
      were treated by all of exercise or sport activities such as running, gymnastics, 
      taichi, and qigong, will be included. The following information will be extracted
      from each included SR: first author, year of publication, country of origin,
      number of primary study; the number of patients enrolled, participant
      characteristics, duration of cancer diagnosis, cancer types. Preferred Reporting 
      Items for Systematic Reviews and Meta-analyses (PRISMA) and A Measurements Tool
      to Assess Systematic Reviews 2 (AMSTAR-2) will be used to assess the reporting
      and methodological quality of SRs/MAs. The characteristics of included SRs/MAs
      and their quality will be descriptively summarized using systematically
      structured tables. The network MA approach and narrative synthesis will be used
      to examine data when applicable. Odds ratio and (standardized) mean difference
      with their 95% confidence intervals will be used as summary statistics. Stata
      13.0 software will be used to analyze and pool data. RESULTS: The results of the 
      overview will be submitted to a peer-reviewed journal for publication. ETHICS AND
      DISSEMINATION: The study is not a clinical study, and we will search and evaluate
      existing sources of literature. So, ethical approval is not required.
FAU - Wang, Fang-Fang
AU  - Wang FF
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou.
FAU - Yuan, Yang
AU  - Yuan Y
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou.
FAU - Song, Yu-Jun
AU  - Song YJ
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou.
FAU - Wu, Yan-Qiong
AU  - Wu YQ
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou.
FAU - He, Yun
AU  - He Y
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou.
FAU - Deng, Xiu-Xiu
AU  - Deng XX
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
FAU - Wu, Shui-Lin
AU  - Wu SL
AD  - School of Public Health, Lanzhou University, Lanzhou, China.
FAU - Dai, Ding-Mei
AU  - Dai DM
AD  - School of Public Health, Lanzhou University, Lanzhou, China.
FAU - Wang, Min
AU  - Wang M
AD  - School of Basic Medical Sciences, Lanzhou University, Lanzhou.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Exercise Therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Neoplasms/*therapy
MH  - *Review Literature as Topic
PMC - PMC7253927
EDAT- 2020/05/24 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/05/24 06:00 [entrez]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1097/MD.0000000000020084 [doi]
AID - 00005792-202005150-00034 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(20):e20084. doi: 10.1097/MD.0000000000020084.


PMID- 32442262
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20220716
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 71
IP  - 11
DP  - 2020 Dec 31
TI  - Ethical and Practical Issues Associated With the Possibility of Using Controlled 
      Human Infection Trials in Developing a Hepatitis C Virus Vaccine.
PG  - 2986-2990
LID - 10.1093/cid/ciaa640 [doi]
AB  - Despite the existence of established treatments for hepatitis C virus (HCV), more
      effective means of preventing infection, such as a vaccine, are arguably needed
      to help reduce substantial global morbidity and mortality. Given the expected
      challenges of developing such a vaccine among those at heightened risk of
      infection, controlled human infection studies seem to be a promising potential
      approach to HCV vaccine development, but they raise substantial ethical and
      practical concerns. In this article, we describe some of the challenges related
      to the possibility of using controlled human infection studies to accelerate HCV 
      vaccine development. The related ethical and practical concerns require further
      deliberation before such studies are planned and implemented.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Cox, Andrea
AU  - Cox A
AD  - School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
AD  - Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland,
      USA.
FAU - Sulkowski, Mark
AU  - Sulkowski M
AD  - School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
FAU - Sugarman, Jeremy
AU  - Sugarman J
AD  - School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
AD  - Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland,
      USA.
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland,
      USA.
LA  - eng
GR  - K24 DA034621/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
RN  - 0 (Hepatitis C Antibodies)
RN  - 0 (Viral Hepatitis Vaccines)
SB  - IM
CIN - Clin Infect Dis. 2020 Dec 31;71(11):2991-2992. PMID: 32448897
MH  - Hepacivirus
MH  - *Hepatitis C/prevention & control
MH  - Hepatitis C Antibodies
MH  - Humans
MH  - *Viral Hepatitis Vaccines
PMC - PMC7778335
OTO - NOTNLM
OT  - *challenge studies
OT  - *controlled human infection studies
OT  - *ethics
OT  - *hepatitis C virus
OT  - *vaccines
EDAT- 2020/05/23 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/05/23 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 5842210 [pii]
AID - 10.1093/cid/ciaa640 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2020 Dec 31;71(11):2986-2990. doi: 10.1093/cid/ciaa640.


PMID- 32442152
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2291-5222 (Electronic)
IS  - 2291-5222 (Linking)
VI  - 8
IP  - 6
DP  - 2020 Jun 26
TI  - Testing Suicide Risk Prediction Algorithms Using Phone Measurements With Patients
      in Acute Mental Health Settings: Feasibility Study.
PG  - e15901
LID - 10.2196/15901 [doi]
AB  - BACKGROUND: Digital phenotyping and machine learning are currently being used to 
      augment or even replace traditional analytic procedures in many domains,
      including health care. Given the heavy reliance on smartphones and mobile devices
      around the world, this readily available source of data is an important and
      highly underutilized source that has the potential to improve mental health risk 
      prediction and prevention and advance mental health globally. OBJECTIVE: This
      study aimed to apply machine learning in an acute mental health setting for
      suicide risk prediction. This study uses a nascent approach, adding to existing
      knowledge by using data collected through a smartphone in place of clinical data,
      which have typically been collected from health care records. METHODS: We created
      a smartphone app called Strength Within Me, which was linked to Fitbit, Apple
      Health kit, and Facebook, to collect salient clinical information such as sleep
      behavior and mood, step frequency and count, and engagement patterns with the
      phone from a cohort of inpatients with acute mental health (n=66). In addition,
      clinical research interviews were used to assess mood, sleep, and suicide risk.
      Multiple machine learning algorithms were tested to determine the best fit.
      RESULTS: K-nearest neighbors (KNN; k=2) with uniform weighting and the Euclidean 
      distance metric emerged as the most promising algorithm, with 68% mean accuracy
      (averaged over 10,000 simulations of splitting the training and testing data via 
      10-fold cross-validation) and an average area under the curve of 0.65. We applied
      a combined 5x2 F test to test the model performance of KNN against the baseline
      classifier that guesses training majority, random forest, support vector machine 
      and logistic regression, and achieved F statistics of 10.7 (P=.009) and 17.6
      (P=.003) for training majority and random forest, respectively, rejecting the
      null of performance being the same. Therefore, we have taken the first steps in
      prototyping a system that could continuously and accurately assess the risk of
      suicide via mobile devices. CONCLUSIONS: Predicting for suicidality is an
      underaddressed area of research to which this paper makes a useful contribution. 
      This is part of the first generation of studies to suggest that it is feasible to
      utilize smartphone-generated user input and passive sensor data to generate a
      risk algorithm among inpatients at suicide risk. The model reveals fair
      concordance between phone-derived and research-generated clinical data, and with 
      iterative development, it has the potential for accurate discriminant risk
      prediction. However, although full automation and independence of clinical
      judgment or input would be a worthy development for those individuals who are
      less likely to access specialist mental health services, and for providing a
      timely response in a crisis situation, the ethical and legal implications of such
      advances in the field of psychiatry need to be acknowledged.
CI  - (c)Alina Haines-Delmont, Gurdit Chahal, Ashley Jane Bruen, Abbie Wall, Christina 
      Tara Khan, Ramesh Sadashiv, David Fearnley. Originally published in JMIR mHealth 
      and uHealth (http://mhealth.jmir.org), 26.06.2020.
FAU - Haines-Delmont, Alina
AU  - Haines-Delmont A
AUID- ORCID: 0000-0001-6989-0943
AD  - Faculty of Health, Psychology and Social Care, Manchester Metropolitan
      University, Manchester, United Kingdom.
FAU - Chahal, Gurdit
AU  - Chahal G
AUID- ORCID: 0000-0002-2933-291X
AD  - CLARA Labs, CLARA Analytics, Santa Clara, CA, United States.
FAU - Bruen, Ashley Jane
AU  - Bruen AJ
AUID- ORCID: 0000-0002-7256-8960
AD  - University of Liverpool, Health Services Research, Liverpool, United Kingdom.
FAU - Wall, Abbie
AU  - Wall A
AUID- ORCID: 0000-0002-2812-6874
AD  - University of Liverpool, Health Services Research, Liverpool, United Kingdom.
FAU - Khan, Christina Tara
AU  - Khan CT
AUID- ORCID: 0000-0003-1042-2445
AD  - Stanford University School of Medicine, Stanford, CA, United States.
FAU - Sadashiv, Ramesh
AU  - Sadashiv R
AUID- ORCID: 0000-0002-4620-0433
AD  - CLARA Labs, CLARA Analytics, Santa Clara, CA, United States.
FAU - Fearnley, David
AU  - Fearnley D
AUID- ORCID: 0000-0002-5158-1437
AD  - Mersey Care NHS Foundation Trust, Prescot, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200626
PL  - Canada
TA  - JMIR Mhealth Uhealth
JT  - JMIR mHealth and uHealth
JID - 101624439
SB  - IM
MH  - Algorithms
MH  - Feasibility Studies
MH  - Humans
MH  - Machine Learning
MH  - *Mental Health
MH  - *Suicide/prevention & control
PMC - PMC7380988
OTO - NOTNLM
OT  - *cell phone
OT  - *digital phenotyping
OT  - *machine learning
OT  - *nearest neighbor algorithm
OT  - *smartphone
OT  - *suicidal ideation
OT  - *suicide
EDAT- 2020/05/23 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/23 06:00
PHST- 2019/08/16 00:00 [received]
PHST- 2020/02/29 00:00 [accepted]
PHST- 2020/02/21 00:00 [revised]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - v8i6e15901 [pii]
AID - 10.2196/15901 [doi]
PST - epublish
SO  - JMIR Mhealth Uhealth. 2020 Jun 26;8(6):e15901. doi: 10.2196/15901.


PMID- 32442139
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 6
TI  - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis:
      Protocol for a Pilot Randomized Controlled Trial.
PG  - e12823
LID - 10.2196/12823 [doi]
AB  - BACKGROUND: Juvenile idiopathic arthritis (JIA) is one of the most common types
      of arthritis among children. According to JIA guidelines for physical activity
      (PA), structured PA interventions led to improved health outcomes. However, many 
      PA programs, such as yoga and aerobic dance, have not been studied in this
      population despite being popular among youth. Web-based PA programs could provide
      patients with accessible and affordable interventions. OBJECTIVE: The primary
      aims of the proposed pilot randomized controlled trial (RCT) are to examine (1)
      the feasibility of conducting a full-scale RCT to evaluate the effectiveness of
      two popular types of PA: a yoga training program and an aerobic dance training
      program, in female adolescents (aged 13-18 years) with JIA compared with an
      electronic pamphlet control group; and (2) the acceptability of these
      interventions. METHODS: A three-arm prospective randomized open-label study with 
      a parallel group design will be used. A total of 25 female adolescents with JIA
      who have pain will be randomized in a ratio of 2:2:1 to one of the 3 groups: (1) 
      online yoga training program (group A: n=10); (2) online aerobic dance training
      program (group B: n=10); and (3) electronic pamphlet control group (group C:
      n=5). Participants in groups A and B will complete 3 individual 1-hour sessions
      per week using online exercise videos, as well as a 1-hour virtual group session 
      per week using a videoconferencing platform for 12 weeks. Participants from all
      groups will have access to an electronic educational pamphlet on PA for arthritis
      developed by the Arthritis Society. All participants will also take part in
      weekly online consultations with a research coordinator and discussions on
      Facebook with participants from their own group. Feasibility (ie, recruitment
      rate, self-reported adherence to the interventions, dropout rates, and percentage
      of missing data), acceptability, and usability of Facebook and the
      videoconferencing platform will be assessed at the end of the program. Pain
      intensity, participation in general PA, morning stiffness, functional status,
      fatigue, self-efficacy, patient global assessment, disease activity, and adverse 
      events will be assessed using self-administered electronic surveys at baseline
      and then weekly until the end of the 12-week program. RESULTS: This pilot RCT has
      been funded by the Arthritis Health Professions Association. This protocol was
      approved by the Children's Hospital of Eastern Ontario Research Ethics Board
      (#17/08X). As of May 11, 2020, recruitment and data collection have not started. 
      CONCLUSIONS: To our knowledge, this is the first study to evaluate the
      effectiveness of yoga and aerobic dance as pain management interventions for
      female adolescents with JIA. The use of online programs to disseminate these 2 PA
      interventions may facilitate access to alternative methods of pain management.
      This study can lead to a full-scale RCT. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): PRR1-10.2196/12823.
CI  - (c)Karine Toupin April, Jennifer Stinson, Sabrina Cavallo, Laurie Proulx, George 
      A Wells, Ciaran M Duffy, Tania ElHindi, Patricia E Longmuir, Lucie Brosseau.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 06.07.2020.
FAU - Toupin April, Karine
AU  - Toupin April K
AUID- ORCID: https://orcid.org/0000-0003-0141-7193
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
AD  - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, 
      Canada.
AD  - Faculty of Health Sciences, School of Rehabilitation Sciences, University of
      Ottawa, Ottawa, ON, Canada.
FAU - Stinson, Jennifer
AU  - Stinson J
AUID- ORCID: https://orcid.org/0000-0002-9969-8052
AD  - Child Health Evaluative Sciences, The Peter Gilgan Centre for Research and
      Learning, The Hospital for Sick Children, Toronto, ON, Canada.
AD  - Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON,
      Canada.
FAU - Cavallo, Sabrina
AU  - Cavallo S
AUID- ORCID: https://orcid.org/0000-0003-0484-1205
AD  - Ecole de Readaptation, Universite de Montreal, Montreal, QC, Canada.
FAU - Proulx, Laurie
AU  - Proulx L
AUID- ORCID: https://orcid.org/0000-0003-1656-0371
AD  - Canadian Arthritis Patient Alliance, Ottawa, ON, Canada.
FAU - Wells, George A
AU  - Wells GA
AUID- ORCID: https://orcid.org/0000-0002-2289-9139
AD  - Cardiovascular Research Methods Centre, University of Ottawa Heart Institute,
      Ottawa, ON, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
FAU - Duffy, Ciaran M
AU  - Duffy CM
AUID- ORCID: https://orcid.org/0000-0003-2481-5450
AD  - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, 
      Canada.
AD  - Division of Rheumatology, Children's Hospital of Eastern Ontario, Ottawa, ON,
      Canada.
FAU - ElHindi, Tania
AU  - ElHindi T
AUID- ORCID: https://orcid.org/0000-0002-8670-7941
AD  - Statistics Canada, Ottawa, ON, Canada.
FAU - Longmuir, Patricia E
AU  - Longmuir PE
AUID- ORCID: https://orcid.org/0000-0003-4827-0870
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
AD  - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, 
      Canada.
AD  - School of Human Kinetics, Faculty of Health Sciences, University of Ottawa,
      Ottawa, ON, Canada.
FAU - Brosseau, Lucie
AU  - Brosseau L
AUID- ORCID: https://orcid.org/0000-0002-9587-7504
AD  - Faculty of Health Sciences, School of Rehabilitation Sciences, University of
      Ottawa, Ottawa, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7381073
OTO - NOTNLM
OT  - aerobic exercise
OT  - dance
OT  - juvenile idiopathic arthritis
OT  - pain management
OT  - pilot
OT  - yoga
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:01
CRDT- 2020/05/23 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:01 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - v9i7e12823 [pii]
AID - 10.2196/12823 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jul 6;9(7):e12823. doi: 10.2196/12823.


PMID- 32442137
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 3
TI  - Nurse-Led Education and Engagement for Diabetes Care in Sub-Saharan Africa:
      Protocol for a Mixed Methods Study.
PG  - e15408
LID - 10.2196/15408 [doi]
AB  - BACKGROUND: As the impact of diabetes grows steeply in sub-Saharan Africa,
      improvement of the control and treatment of diabetes is a goal that health care
      systems in sub-Saharan Africa must achieve in the near future. Sub-Saharan Africa
      faces a number of challenges in addressing the increasing effects of diabetes.
      One important factor is the shortage of adequately trained health care workers.
      Diabetes management in sub-Saharan Africa would benefit from innovative
      approaches that are founded upon solid theoretical constructs, built upon
      existing human resources and infrastructure, and culturally tailored to the
      priorities and needs of the local population. Existing resources, such as mobile 
      phones and task-shifting strategies, may be used to assist individuals with
      glycemic self-management and to facilitate management of additional day-to-day
      clinical responsibilities. OBJECTIVE: The objective of the Nurse-Led Education
      and Engagement Study for Diabetes Care (NEEDS) mixed-methods protocol is to
      develop a practical, collaborative, effective, and sustainable program for
      diabetes prevention and management specifically for patients with type 2 diabetes
      mellitus in sub-Saharan Africa. The protocol aims to improve access to care
      through task-shifting strategies and the use of mobile health technology.
      METHODS: This study was designed using a convergent parallel mixed-methods
      approach that consisted of surveys, key informant interviews, focus group
      discussions, and focused ethnography. Novel approaches, such as task-shifting
      strategies and the use of mobile technology, were implemented for type 2 diabetes
      mellitus health care in sub-Saharan Africa-currently an under-researched area.
      RESULTS: Data collection began in February 2018, after ethics approval, at the
      Kwame Nkrumah University of Science and Technology. As of May 2020, participant
      surveys have been completed (N=100), key informant interviews (n=7) have been
      completed, and focus groups (5 focus groups; patients, n=18; caregivers, n=6;
      community leaders, n=2; and faith leaders, n=3) as well as focused ethnographic
      field observations have been completed. All audio recordings have been
      transcribed and transcripts of sessions recorded in Twi have been translated to
      English. Data analysis is currently underway and anticipated completion is in the
      spring of 2020. Following data analysis, investigators plan to publish study
      findings. CONCLUSIONS: Insights from this study will inform the preliminary
      development of a feasible and effective nurse-led education and engagement mobile
      health intervention that has the potential to reduce diabetes-related morbidity, 
      mortality, and burden in sub-Saharan Africa. INTERNATIONAL REGISTERED REPORT
      IDENTIFIER (IRRID): DERR1-10.2196/15408.
CI  - (c)Arti Singh, Michelle Nichols. Originally published in JMIR Research Protocols 
      (http://www.researchprotocols.org), 03.06.2020.
FAU - Singh, Arti
AU  - Singh A
AUID- ORCID: https://orcid.org/0000-0002-7460-0119
AD  - University Hospital, Kwame Nkrumah University of Science and Technology, Kumasi, 
      Ghana.
FAU - Nichols, Michelle
AU  - Nichols M
AUID- ORCID: https://orcid.org/0000-0002-2078-9649
AD  - College of Nursing, Medical University of South Carolina, Charleston, SC, United 
      States.
LA  - eng
PT  - Journal Article
DEP - 20200603
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7301253
OTO - NOTNLM
OT  - Ghana
OT  - diabetes
OT  - focused ethnography
OT  - global health
OT  - mixed methods
OT  - mobile health
OT  - nurses
OT  - sub-Saharan Africa
OT  - task-shifting
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:01
CRDT- 2020/05/23 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:01 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - v9i6e15408 [pii]
AID - 10.2196/15408 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 3;9(6):e15408. doi: 10.2196/15408.


PMID- 32441996
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20201218
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 142
IP  - 4
DP  - 2020 Jul 28
TI  - The COVID-19 Pandemic: Ethical and Scientific Imperatives for "Natural"
      Experiments.
PG  - 309-311
LID - 10.1161/CIRCULATIONAHA.120.048671 [doi]
FAU - Erren, Thomas C
AU  - Erren TC
AD  - Institute and Policlinic for Occupational Medicine, Environmental Medicine and
      Prevention Research, University Hospital of Cologne, Germany (T.C.E., P.L.).
FAU - Lewis, Philip
AU  - Lewis P
AD  - Institute and Policlinic for Occupational Medicine, Environmental Medicine and
      Prevention Research, University Hospital of Cologne, Germany (T.C.E., P.L.).
FAU - Shaw, David M
AU  - Shaw DM
AD  - Institute for Biomedical Ethics, University of Basel, Switzerland (D.M.S.).
AD  - Department of Health, Ethics, and Society, CAPHRI Research Institute, Maastricht 
      University, The Netherlands (D.M.S.).
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200522
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - Pandemics/*ethics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health/*ethics/methods
MH  - SARS-CoV-2
PMC - PMC7382532
OTO - NOTNLM
OT  - *COVID-19
OT  - *public health
EDAT- 2020/05/23 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1161/CIRCULATIONAHA.120.048671 [doi]
PST - ppublish
SO  - Circulation. 2020 Jul 28;142(4):309-311. doi: 10.1161/CIRCULATIONAHA.120.048671. 
      Epub 2020 May 22.


PMID- 32441894
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20220716
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Jul
TI  - Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of
      Severe Adverse Events.
PG  - 24-34
LID - 10.1002/eahr.500056 [doi]
AB  - Human challenge trials to test the efficacy of vaccine candidates against
      SARS-CoV-2, the novel coronavirus behind Covid-19, could save considerable time
      and many lives. But they may initially seem unethical because they expose healthy
      volunteers to a live virus that is killing many people and for which no cure
      exists. This article argues that this is not the correct test of their ethics.
      The correct test is comparative. And in the special circumstances of the Covid-19
      pandemic, human challenge trials meet the correct test better than standard
      efficacy testing would.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Eyal, Nir
AU  - Eyal N
AD  - Directs the Center for Population-Level Bioethics at Rutgers University and is
      the Henry Rutgers professor of bioethics in the Department of Health Behavior,
      Society and Policy at Rutgers School of Public Health and in the Department of
      Philosophy at Rutgers's School of Arts and Sciences.
LA  - eng
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
GR  - R56 AI114617/AI/NIAID NIH HHS/United States
GR  - AI114617-06/National Institute of Allergy and Infectious Diseases
PT  - Journal Article
DEP - 20200522
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus/immunology
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials as Topic/*ethics
MH  - Coronavirus Infections/immunology/*prevention & control
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Viral Vaccines/adverse effects/immunology/*therapeutic use
PMC - PMC7280638
OTO - NOTNLM
OT  - Covid-19
OT  - coronavirus
OT  - human challenge studies
OT  - randomized controlled trials
OT  - research ethics
OT  - risk taking
OT  - vaccines
EDAT- 2020/05/23 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1002/eahr.500056 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Jul;42(4):24-34. doi: 10.1002/eahr.500056. Epub 2020 May 22.


PMID- 32441610
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Myopia in Reportability of Ethical Concerns in Healthcare Ethics Consultation.
PG  - 73-75
LID - 10.1080/15265161.2020.1754510 [doi]
FAU - Fiester, A
AU  - Fiester A
AD  - University of Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):52-64. PMID: 32441594
MH  - *Bioethics
MH  - *Ethics Consultation
MH  - Humans
MH  - Morals
MH  - *Myopia
EDAT- 2020/05/23 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1080/15265161.2020.1754510 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):73-75. doi: 10.1080/15265161.2020.1754510.


PMID- 32441608
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Engaging Patients and Families in the Ethics of Involuntary Psychiatric Care.
PG  - 82-84
LID - 10.1080/15265161.2020.1754511 [doi]
FAU - Hui, Katrina
AU  - Hui K
AUID- ORCID: 0000-0002-5472-3779
AD  - University of Toronto.
FAU - Cooper, Rachel B
AU  - Cooper RB
AUID- ORCID: 0000-0001-5368-8927
AD  - Centre for Addiction and Mental Health.
FAU - Zaheer, Juveria
AU  - Zaheer J
AUID- ORCID: 0000-0001-5071-8078
AD  - University of Toronto.
AD  - Centre for Addiction and Mental Health.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):52-64. PMID: 32441594
MH  - Humans
MH  - *Mental Disorders
MH  - Morals
EDAT- 2020/05/23 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1080/15265161.2020.1754511 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):82-84. doi: 10.1080/15265161.2020.1754511.


PMID- 32441605
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Gaps in Ethics Consultation Support for Patients and Families and Practical
      Guidance for Future Research or Quality Work Involving These Stakeholders.
PG  - 75-77
LID - 10.1080/15265161.2020.1754516 [doi]
FAU - Mabel, Hilary
AU  - Mabel H
AD  - Cleveland Clinic.
FAU - Riaz, Sundus
AU  - Riaz S
AD  - Cleveland Clinic.
FAU - Augustine, Marguerite
AU  - Augustine M
AD  - Cleveland Clinic.
FAU - Jankowski, Jane
AU  - Jankowski J
AD  - Cleveland Clinic.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):52-64. PMID: 32441594
MH  - *Ethics Consultation
MH  - Ethics, Clinical
MH  - Humans
MH  - Morals
EDAT- 2020/05/23 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1080/15265161.2020.1754516 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):75-77. doi: 10.1080/15265161.2020.1754516.


PMID- 32441603
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - How to Support Patient and Family in Dealing with Ethical Issues? The Relevance
      of Moral Case Deliberation.
PG  - 70-72
LID - 10.1080/15265161.2020.1754518 [doi]
FAU - Widdershoven, Guy
AU  - Widdershoven G
AD  - Amsterdam University Medical Centers, VU University Amsterdam.
FAU - Stolper, Margreet
AU  - Stolper M
AD  - Amsterdam University Medical Centers, VU University Amsterdam.
FAU - Molewijk, Bert
AU  - Molewijk B
AD  - Amsterdam University Medical Centers, VU University Amsterdam.
FAU - Metselaar, Suzanne
AU  - Metselaar S
AD  - Amsterdam University Medical Centers, VU University Amsterdam.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):52-64. PMID: 32441594
MH  - *Ethics Consultation
MH  - Humans
MH  - *Morals
EDAT- 2020/05/23 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1080/15265161.2020.1754518 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):70-72. doi: 10.1080/15265161.2020.1754518.


PMID- 32441601
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Schrodinger's Cat and the Ethically Untenable Act of Not Looking.
PG  - 40-42
LID - 10.1080/15265161.2020.1754519 [doi]
FAU - Vercler, Christian J
AU  - Vercler CJ
AD  - University of Michigan.
FAU - Laventhal, Naomi Tricot
AU  - Laventhal NT
AD  - University of Michigan.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):4-16. PMID: 32441596
MH  - *Apnea
MH  - Brain
MH  - *Brain Death
MH  - Death
MH  - Humans
MH  - Informed Consent
EDAT- 2020/05/23 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1080/15265161.2020.1754519 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):40-42. doi: 10.1080/15265161.2020.1754519.


PMID- 32441600
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20210602
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Broadening the Scope of Health Care Ethics Consultation: A Response to Open Peer 
      Commentaries on Patient and Family Description of Ethical Concerns.
PG  - W6-W8
LID - 10.1080/15265161.2020.1764144 [doi]
FAU - Danis, Marion
AU  - Danis M
AD  - National Institutes of Health.
FAU - Povar, Gail
AU  - Povar G
AD  - George Washington University Hospital.
FAU - Cho, Hae Lin
AU  - Cho HL
AD  - National Institutes of Health.
AD  - Harvard Medical School.
FAU - Grady, Christine
AU  - Grady C
AD  - National Institutes of Health.
FAU - Tarzian, Anita
AU  - Tarzian A
AD  - University of Maryland School of Law and School of Nursing.
FAU - Mangal, Jed
AU  - Mangal J
AD  - U.S. Army, Fort Benning.
LA  - eng
GR  - Z99 CL999999/ImNIH/Intramural NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Intramural
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):52-64. PMID: 32441594
MH  - *Bioethics
MH  - *Ethics Consultation
MH  - Humans
MH  - Morals
PMC - PMC7721250
MID - NIHMS1648272
EDAT- 2020/05/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/15265161.2020.1764144 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):W6-W8. doi: 10.1080/15265161.2020.1764144.


PMID- 32441596
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Legal and Ethical Considerations for Requiring Consent for Apnea Testing in Brain
      Death Determination.
PG  - 4-16
LID - 10.1080/15265161.2020.1754501 [doi]
AB  - The past decade has witnessed escalating legal and ethical challenges to the
      diagnosis of death by neurologic criteria (DNC). The legal tactic of demanding
      consent for the apnea test, if successful, can halt the DNC. However, US law is
      currently unsettled and inconsistent in this matter. Consent has been required in
      several trial cases in Montana and Kansas but not in Virginia and Nevada. In this
      paper, we analyze and evaluate the legal and ethical bases for requiring consent 
      before apnea testing and defend such a requirement by appealing to ethical and
      legal principles of informed consent and battery and the right to refuse medical 
      treatment. We conclude by considering and rebutting two major objections to a
      consent requirement for apnea testing: (1) a justice-based objection to allocate 
      scarce resources fairly and (2) a social utility objection that halting the
      diagnosis of brain death will reduce the number of organ donors.
FAU - Berkowitz, Ivor
AU  - Berkowitz I
AD  - Charlotte Bloomberg Children's Center.
FAU - Garrett, Jeremy R
AU  - Garrett JR
AD  - Children's Mercy Bioethics Center.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jun;20(6):17-19. PMID: 32441597
CIN - Am J Bioeth. 2020 Jun;20(6):49-51. PMID: 32441598
CIN - Am J Bioeth. 2020 Jun;20(6):40-42. PMID: 32441601
CIN - Am J Bioeth. 2020 Jun;20(6):25-27. PMID: 32441602
CIN - Am J Bioeth. 2020 Jun;20(6):28-30. PMID: 32441604
CIN - Am J Bioeth. 2020 Jun;20(6):35-37. PMID: 32441606
CIN - Am J Bioeth. 2020 Jun;20(6):44-47. PMID: 32441607
CIN - Am J Bioeth. 2020 Jun;20(6):20-22. PMID: 32441609
CIN - Am J Bioeth. 2020 Jun;20(6):30-32. PMID: 32618503
CIN - Am J Bioeth. 2020 Jun;20(6):37-39. PMID: 32618504
CIN - Am J Bioeth. 2020 Jun;20(6):42-44. PMID: 32618505
CIN - Am J Bioeth. 2020 Jun;20(6):33-35. PMID: 32618506
CIN - Am J Bioeth. 2020 Jun;20(6):22-24. PMID: 32618507
CIN - Am J Bioeth. 2020 Jun;20(6):47-49. PMID: 32618509
MH  - Apnea/*diagnosis
MH  - Brain Death/*diagnosis/*legislation & jurisprudence
MH  - Diagnostic Techniques, Neurological/*ethics
MH  - Diagnostic Techniques, Respiratory System/*ethics
MH  - Humans
MH  - Jurisprudence
MH  - Third-Party Consent/*ethics/*legislation & jurisprudence
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *Apnea test
OT  - *brain death
OT  - *consent
OT  - *organ donation
EDAT- 2020/05/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/15265161.2020.1754501 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):4-16. doi: 10.1080/15265161.2020.1754501.


PMID- 32441594
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20210602
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Patient and Family Descriptions of Ethical Concerns.
PG  - 52-64
LID - 10.1080/15265161.2020.1754500 [doi]
AB  - Ethically challenging situations routinely arise in the course of illness and
      healthcare. However, very few studies have surveyed patients and family members
      about their experiences with ethically challenging situations. To address this
      gap in the literature, we surveyed patients and family members at three
      hospitals. We conducted a content analysis of their responses to open-ended
      questions about their most memorable experience with an ethical concern for them 
      or their family member. Participants (N = 196) described 219 unique ethical
      experiences that spanned many of the prevailing themes of bioethics, including
      the patient-physician relationship, end-of-life care, decision-making capacity,
      healthcare costs, and genetic testing. Participants focused on relational issues 
      in the course of experiencing illness and receiving medical care and concerns
      regarding the patient-physician encounters. Many concerns arose outside of a
      healthcare setting. These data indicate areas for improvement for healthcare
      providers but some concerns may be better addressed outside of the traditional
      healthcare setting.
FAU - Cho, Hae Lin
AU  - Cho HL
AD  - National Institutes of Health.
FAU - Grady, Christine
AU  - Grady C
AD  - National Institutes of Health.
FAU - Tarzian, Anita
AU  - Tarzian A
AD  - University of Maryland School of Law, Law and and Nursing.
FAU - Povar, Gail
AU  - Povar G
AD  - George Washington University Hospital.
FAU - Mangal, Jed
AU  - Mangal J
AD  - Walter Reed National Military Medical Center.
FAU - Danis, Marion
AU  - Danis M
AD  - National Institutes of Health.
LA  - eng
GR  - Z99 CL999999/ImNIH/Intramural NIH HHS/United States
GR  - ZIA CL010543/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jun;20(6):68-70. PMID: 32441595
CIN - Am J Bioeth. 2020 Jun;20(6):65-67. PMID: 32441599
CIN - Am J Bioeth. 2020 Jun;20(6):W6-W8. PMID: 32441600
CIN - Am J Bioeth. 2020 Jun;20(6):70-72. PMID: 32441603
CIN - Am J Bioeth. 2020 Jun;20(6):75-77. PMID: 32441605
CIN - Am J Bioeth. 2020 Jun;20(6):82-84. PMID: 32441608
CIN - Am J Bioeth. 2020 Jun;20(6):73-75. PMID: 32441610
CIN - Am J Bioeth. 2020 Jun;20(6):80-82. PMID: 32618502
CIN - Am J Bioeth. 2020 Jun;20(6):77-80. PMID: 32618508
MH  - Adult
MH  - Aged
MH  - *Bioethical Issues
MH  - Decision Making/ethics
MH  - Dissent and Disputes
MH  - Family/*psychology
MH  - Family Conflict/ethics
MH  - Female
MH  - Health Services Accessibility/ethics
MH  - Hospitals
MH  - Humans
MH  - Inpatients/*psychology
MH  - Male
MH  - Middle Aged
MH  - Professional-Patient Relations/ethics
MH  - Qualitative Research
MH  - Quality of Health Care/*ethics
MH  - Surveys and Questionnaires
MH  - Terminal Care/ethics
MH  - United States
PMC - PMC7673656
MID - NIHMS1589156
OTO - NOTNLM
OT  - *Ethics
OT  - *clinical
OT  - *family
OT  - *patients
OT  - *qualitative research
OT  - *surveys and questionnaires
EDAT- 2020/05/23 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/15265161.2020.1754500 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):52-64. doi: 10.1080/15265161.2020.1754500.


PMID- 32441593
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20200610
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Response to Open Peer Commentaries "Rethinking the Ethical, Legal, and Clinical
      Foundations of Informed Consent and Shared Decision-Making for Brain Death
      Determination".
PG  - W1-W5
LID - 10.1080/15265161.2020.1762796 [doi]
FAU - Garrett, Jeremy R
AU  - Garrett JR
AD  - Children's Mercy Hospital, Children's Mercy Bioethics Center.
FAU - Berkowitz, Ivor
AU  - Berkowitz I
AD  - Johns Hopkins School of Medicine.
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jun;20(6):25-27. PMID: 32441602
CON - Am J Bioeth. 2020 Jun;20(6):28-30. PMID: 32441604
MH  - *Apnea
MH  - *Brain Death
MH  - Death
MH  - Decision Making
MH  - Humans
MH  - Informed Consent
EDAT- 2020/05/23 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1080/15265161.2020.1762796 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(6):W1-W5. doi: 10.1080/15265161.2020.1762796.


PMID- 32441387
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 50
IP  - 8
DP  - 2020 Aug
TI  - Efficacy of combining electric-field and coronal-plane imaging to obtain
      ultrasound-ultrasound fusion images in monopolar radiofrequency ablation for
      patients with liver cancer.
PG  - 985-995
LID - 10.1111/hepr.13527 [doi]
AB  - AIM: For radiofrequency ablation to treat patients diagnosed with liver cancer,
      the ablation area cannot be envisaged beforehand, even by experts. This study
      aimed to assess the clinical feasibility of applying a combination of electric
      (E)-field and coronal (C)-plane simulations to ultrasound-ultrasound (US-US)
      fusion images. METHODS: The study protocols were approved by the institutional
      ethics committee. Between October 2017 and July 2019, 151 patients with 151
      hepatocellular carcinoma nodules (80 treated with navigation images and 71
      without navigation images) were retrospectively compared in this cross-sectional 
      study. The E-field, which is a simulated image that predicts the ablation area,
      was applied to the US-US fusion images. The C-plane is defined as a sagittal
      plane in relation to the original 2-D US images. The positions of each E-field
      area in the maximum cross-sectional area of the tumor were easily identified from
      C-plane results. The primary end-point of this study was achievement of an
      adequate safety margin (greater than 5 mm). The sphericity of the ablation volume
      was used as a secondary end-point. RESULTS: The rate of achieving a sufficient
      safety margin was significantly higher in the group treated with navigation
      images (71/80) than in the group treated without navigation images (31/71, P <
      0.001). The median sphericity was 0.55 with navigation images and 0.42 without
      navigation images (P < 0.001). CONCLUSION: Using the combination of an E-field
      and a C-plane on US-US fusion images can be a feasible method for acquiring a
      sufficient safety margin.
CI  - (c) 2020 The Japan Society of Hepatology.
FAU - Hirooka, Masashi
AU  - Hirooka M
AUID- ORCID: https://orcid.org/0000-0001-5634-5313
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
FAU - Koizumi, Yohei
AU  - Koizumi Y
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
FAU - Tanaka, Takaaki
AU  - Tanaka T
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
FAU - Nakamura, Yoshiko
AU  - Nakamura Y
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
FAU - Tokumoto, Yoshio
AU  - Tokumoto Y
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
FAU - Abe, Masanori
AU  - Abe M
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
FAU - Hiasa, Yoichi
AU  - Hiasa Y
AUID- ORCID: https://orcid.org/0000-0003-4117-339X
AD  - Department of Gastroenterology and Metabology, Ehime University Graduate School
      of Medicine Toon, Ehime, Japan.
LA  - eng
GR  - 18K07634/Japan Society for the Promotion of Science
GR  - 18K08007/Japan Society for the Promotion of Science
GR  - 18K08007/Japan Society for the Promotion of Science (JSPS) KAKENHI
GR  - 18K07634/Japan Society for the Promotion of Science (JSPS) KAKENHI
PT  - Journal Article
DEP - 20200608
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - C-plane imaging
OT  - hepatocellular carcinoma
OT  - radiofrequency ablation
OT  - safety margin
OT  - ultrasound
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:01
CRDT- 2020/05/23 06:00
PHST- 2019/12/14 00:00 [received]
PHST- 2020/05/07 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:01 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1111/hepr.13527 [doi]
PST - ppublish
SO  - Hepatol Res. 2020 Aug;50(8):985-995. doi: 10.1111/hepr.13527. Epub 2020 Jun 8.


PMID- 32441132
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20210302
IS  - 1497-0015 (Electronic)
IS  - 0706-7437 (Linking)
VI  - 65
IP  - 9
DP  - 2020 Sep
TI  - What Does "Irremediability" in Mental Illness Mean?
PG  - 604-606
LID - 10.1177/0706743720928656 [doi]
FAU - Gaind, Karandeep Sonu
AU  - Gaind KS
AUID- ORCID: 0000-0003-1786-2566
AD  - Governing Council and Department of Psychiatry, 7938University of Toronto,
      Ontario, Canada.
AD  - Mental Health and Addictions Program, Humber River Hospital, Toronto, Ontario,
      Canada.
AD  - Board, World Psychiatric Association, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200522
PL  - United States
TA  - Can J Psychiatry
JT  - Canadian journal of psychiatry. Revue canadienne de psychiatrie
JID - 7904187
SB  - IM
CON - Can J Psychiatry. 2020 Sep;65(9):593-603. PMID: 32427501
MH  - Humans
MH  - *Mental Disorders
MH  - *Physicians
MH  - *Suicide
MH  - *Suicide, Assisted
PMC - PMC7485032
OTO - NOTNLM
OT  - *ethics
OT  - *health care policy
OT  - *irremediability
OT  - *medical assistance in dying (MAiD)
OT  - *physician-assisted death
EDAT- 2020/05/23 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1177/0706743720928656 [doi]
PST - ppublish
SO  - Can J Psychiatry. 2020 Sep;65(9):604-606. doi: 10.1177/0706743720928656. Epub
      2020 May 22.


PMID- 32440984
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20210129
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Aug
TI  - Ethics in the age of COVID-19.
PG  - 889-890
LID - 10.1007/s11739-020-02368-2 [doi]
FAU - Arora, Ananya
AU  - Arora A
AUID- ORCID: http://orcid.org/0000-0002-0650-3966
AD  - University of Cambridge, Selwyn College, Grange Road, Cambridge, CB3 9DQ, UK.
FAU - Arora, Anmol
AU  - Arora A
AUID- ORCID: http://orcid.org/0000-0003-4881-8293
AD  - School of Clinical Medicine, University of Cambridge, Addenbrooke's Hospital,
      Hills Road, Cambridge, CB2 0SP, UK. aa957@cam.ac.uk.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200521
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
SB  - IM
CON - Lancet Infect Dis. 2020 Jun;20(6):630-631. PMID: 32240633
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7240805
EDAT- 2020/05/23 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1007/s11739-020-02368-2 [doi]
AID - 10.1007/s11739-020-02368-2 [pii]
PST - ppublish
SO  - Intern Emerg Med. 2020 Aug;15(5):889-890. doi: 10.1007/s11739-020-02368-2. Epub
      2020 May 21.


PMID- 32440888
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210617
IS  - 1437-1596 (Electronic)
IS  - 0937-9827 (Linking)
VI  - 134
IP  - 5
DP  - 2020 Sep
TI  - Revolution in death sciences: body farms and taphonomics blooming. A review
      investigating the advantages, ethical and legal aspects in a Swiss context.
PG  - 1875-1895
LID - 10.1007/s00414-020-02272-6 [doi]
AB  - Taphonomy is the study of decaying organisms over time and their process of
      fossilization. Taphonomy, originally a branch of palaeontology and anthropology, 
      was developed to understand the ecology of a decomposition site, how site ecology
      changes upon the introduction of plant or animal remains and, in turn, how site
      ecology affects the decomposition of these materials. In recent years, these
      goals were incorporated by forensic science to understand the decomposition of
      human cadavers, to provide a basis on which to estimate postmortem and/or
      postburial interval, to assist in the determination of cause and circumstances of
      death, and to aid in the location of clandestine graves. These goals are achieved
      through the study of the factors that influence cadaver decomposition (e.g.
      temperature, moisture, insect activity). These studies have also provided insight
      into the belowground ecology of cadaver breakdown and allowed to develop useful
      protocols for mass disaster managements in humanitarian medicine. From the
      results obtained, new scientific disciplines have arisen, gathered under the word
      "taphonomics" such as the study of microorganisms living below/on a cadaver
      (thanatogeomicrobiology), and join the more classical forensic sciences such as
      anthropology, botany or entomology. Taking into account the specificities of the 
      study object (human cadaver), primordial requirements are needed in terms of
      security (physical and environmental) as well as ethical and legal concerns which
      are studied in the Swiss context. The present review aims to present in a first
      part the concept of human forensic taphonomy facilities (HFTF, also colloquially 
      named "body farm") leading to an enrichment of forensic sciences with new
      "taphonomics". The second part is focused on the mandatory points that must be
      addressed for a HFTF approach, especially because it requires a specific place to
      undertake this research which must be performed in conformity with a country's
      human ethics and laws.
FAU - Varlet, Vincent
AU  - Varlet V
AD  - Swiss Human Institute of Forensic Taphonomy, University Center of Legal Medicine 
      Lausanne-Geneva, Chemin de la Vulliette 4, 1000, Lausanne, Switzerland.
      vincent.varlet@chuv.ch.
FAU - Joye, Charles
AU  - Joye C
AD  - , Avenue de Mon-Repos 14, 1001, Lausanne, Switzerland.
FAU - Forbes, Shari L
AU  - Forbes SL
AD  - Departement de chimie, biochimie et physique, Universite du Quebec a
      Trois-Rivieres (UQTR), 3351 boulevard des Forges, Trois-Rivieres, Quebec, Canada.
FAU - Grabherr, Silke
AU  - Grabherr S
AD  - Swiss Human Institute of Forensic Taphonomy, University Center of Legal Medicine 
      Lausanne-Geneva, Chemin de la Vulliette 4, 1000, Lausanne, Switzerland.
AD  - Forensic Medicine and Imaging Section, University Center of Legal Medicine
      Lausanne-Geneva, Chemin de la Vulliette 4, 1000, Lausanne, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200521
PL  - Germany
TA  - Int J Legal Med
JT  - International journal of legal medicine
JID - 9101456
SB  - IM
MH  - Animals
MH  - Cadaver
MH  - Forensic Sciences/*ethics/*legislation & jurisprudence/*methods/trends
MH  - Humans
MH  - Postmortem Changes
MH  - *Private Facilities
MH  - Switzerland
OTO - NOTNLM
OT  - Body farms
OT  - Forensic anthropology
OT  - Human taphonomy
OT  - Swiss ethical context
OT  - Swiss legal context
OT  - Taphonomics
EDAT- 2020/05/23 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/05/23 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1007/s00414-020-02272-6 [doi]
AID - 10.1007/s00414-020-02272-6 [pii]
PST - ppublish
SO  - Int J Legal Med. 2020 Sep;134(5):1875-1895. doi: 10.1007/s00414-020-02272-6. Epub
      2020 May 21.


PMID- 32440650
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2520-8977 (Electronic)
IS  - 2520-8969 (Linking)
VI  - 43
IP  - 1
DP  - 2020 Mar
TI  - What are Values in Clinical Behavior Analysis?
PG  - 177-188
LID - 10.1007/s40614-019-00219-w [doi]
AB  - The context of psychotherapy involves ethical, theoretical, and technical matters
      regarding limits and possibilities to clinical practice. Some of these matters
      concern values and their importance for clinical interventions. Given the central
      role that the concept of values seems to have in current behavioral therapeutic
      models, this article intends to analyze and discuss perspectives regarding this
      concept as presented by authors such as Skinner, Leigland, Plumb, Wilson, and
      Harris. It is argued that the definition of values should be described using
      low-level terms, so that it may generate basic and applied research without
      losing its relevance to the clinical setting. We propose that values are stable
      and comprehensive qualities of behaving, described by the subject in augmental
      rules that establish a positive reinforcing function for his/her own described
      behavior. Further utility of such a definition involves its precision and focus
      on aspects that are under direct influence of the client.
CI  - (c) Association for Behavior Analysis International 2019.
FAU - da Silva Ferreira, Tiago Alfredo
AU  - da Silva Ferreira TA
AUID- ORCID: 0000-0002-8715-2925
AD  - Instituto de Psicologia, Universidade Federal da Bahia, Rua Aristides Novis, 197,
      Estrada de Sao Lazaro, Salvador, Bahia CEP 40210-730 Brazil.grid.8399.b0000 0004 
      0372 8259
FAU - Simoes, Aline Souza
AU  - Simoes AS
AD  - Instituto de Psicologia, Universidade Federal da Bahia, Rua Aristides Novis, 197,
      Estrada de Sao Lazaro, Salvador, Bahia CEP 40210-730 Brazil.grid.8399.b0000 0004 
      0372 8259
FAU - Ferreira, Amanda Rana
AU  - Ferreira AR
AD  - Instituto de Psicologia, Universidade Federal da Bahia, Rua Aristides Novis, 197,
      Estrada de Sao Lazaro, Salvador, Bahia CEP 40210-730 Brazil.grid.8399.b0000 0004 
      0372 8259
FAU - Dos Santos, Bruno Oliveira Santana
AU  - Dos Santos BOS
AD  - Instituto de Psicologia, Universidade Federal da Bahia, Rua Aristides Novis, 197,
      Estrada de Sao Lazaro, Salvador, Bahia CEP 40210-730 Brazil.grid.8399.b0000 0004 
      0372 8259
LA  - eng
PT  - Journal Article
DEP - 20190711
PL  - Switzerland
TA  - Perspect Behav Sci
JT  - Perspectives on behavior science
JID - 101743058
PMC - PMC7198652
OTO - NOTNLM
OT  - Clinical behavior analysis
OT  - Clinical practice
OT  - Values
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:01
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:01 [medline]
AID - 10.1007/s40614-019-00219-w [doi]
AID - 219 [pii]
PST - epublish
SO  - Perspect Behav Sci. 2019 Jul 11;43(1):177-188. doi: 10.1007/s40614-019-00219-w.
      eCollection 2020 Mar.


PMID- 32440433
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2169-7574 (Print)
IS  - 2169-7574 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Apr
TI  - The Role of Resident-Run Clinics for Aesthetic Surgery Training in the Context of
      Competency-based Plastic Surgery Education.
PG  - e2766
LID - 10.1097/GOX.0000000000002766 [doi]
AB  - Resident-run clinics (RRCs) have been suggested as a clinical teaching tool to
      improve resident exposure in aesthetic plastic surgery education. In exchange for
      reduced cost aesthetic services, RRCs offer trainees the opportunity to assess,
      plan, execute, and follow surgical procedures in an independent yet supervised
      manner. With the transition into a competency-based medical education model
      involving a switch away from a time-based into a milestones-based model, the role
      of RRCs, within the context of the evolving plastic surgery curriculum has yet to
      be determined. To that end, the present study summarizes current models of
      aesthetic surgery training and assesses RRCs as an adjunct to aesthetics
      education within the framework of competency-based medical education. Explored
      themes include advantages and issues of RRCs including surgical autonomy,
      feasibility, exposure, learners' perception, ethics, and quality improvement. In 
      addition, attention is focused on their role in cognitive competency acquisition 
      and exposure to non-surgical techniques. RRCs are considered an effective
      educational model that provides an autonomous learning platform with reasonable
      patient satisfaction and safety profiles.
CI  - Copyright (c) 2020 The Authors. Published by Wolters Kluwer Health, Inc. on
      behalf of The American Society of Plastic Surgeons.
FAU - Al-Halabi, Becher
AU  - Al-Halabi B
AD  - Division of Plastic and Reconstructive Surgery, McGill University Health Centre, 
      Montreal, Canada.
FAU - Hazan, Jessica
AU  - Hazan J
AD  - Division of Plastic and Reconstructive Surgery, McGill University Health Centre, 
      Montreal, Canada.
FAU - Safran, Tyler
AU  - Safran T
AD  - Division of Plastic and Reconstructive Surgery, McGill University Health Centre, 
      Montreal, Canada.
FAU - Gilardino, Mirko S
AU  - Gilardino MS
AD  - Division of Plastic and Reconstructive Surgery, McGill University Health Centre, 
      Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - United States
TA  - Plast Reconstr Surg Glob Open
JT  - Plastic and reconstructive surgery. Global open
JID - 101622231
PMC - PMC7209860
COIS- Disclosure: The authors have no financial interest to declare in relation to the 
      content of this article.
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:01
CRDT- 2020/05/23 06:00
PHST- 2020/02/08 00:00 [received]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:01 [medline]
AID - 10.1097/GOX.0000000000002766 [doi]
PST - epublish
SO  - Plast Reconstr Surg Glob Open. 2020 Apr 27;8(4):e2766. doi:
      10.1097/GOX.0000000000002766. eCollection 2020 Apr.


PMID- 32440380
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr 19
TI  - Knowledge, Attitude, and Practice of Blood Donation Among Undergraduate Medical
      Students in Azad Kashmir.
PG  - e7733
LID - 10.7759/cureus.7733 [doi]
AB  - Objective To evaluate the knowledge and attitude of undergraduate medical
      students of Poonch Medical College about blood donation. Methods This
      cross-sectional study was done using a 27-item, validated,
      interviewer-administered questionnaire involving undergraduate medical students
      from March to October 2018. Informed consent and ethical clearance were secured. 
      Results A total of 318 undergraduate medical students (response rate of 63.6%)
      was included in this study. Most respondents knew the difference between whole
      blood and blood components (294; 92.5%) and they also believed that spreading
      knowledge of blood donation among the health workers is a necessity (306; 96.2%).
      There was a statistically significant correlation between knowledge and attitude 
      (p .021). Overall knowledge was higher among the female students (p = .019).
      Conclusion The study revealed an overall good level of knowledge and attitude
      among medical students. However, there are still areas of improvement such as
      blood donation and vaccination-related knowledge. The study also identified
      important facilitators and barriers to blood donation.
CI  - Copyright (c) 2020, Javaeed et al.
FAU - Javaeed, Arslaan
AU  - Javaeed A
AD  - Pathology, Poonch Medical College, Rawalakot, PAK.
FAU - Kousar, Rubina
AU  - Kousar R
AD  - Pathology, Poonch Medical College, Rawalakot, PAK.
FAU - Farooq, Aalya
AU  - Farooq A
AD  - Pathology, Poonch Medical College, Rawalakot, PAK.
FAU - Hina, Saddaf
AU  - Hina S
AD  - Pathology, Poonch Medical College, Rawalakot, PAK.
FAU - Ghauri, Sanniya Khan
AU  - Ghauri SK
AD  - Emergency Medicine, Shifa International Hospital, Islamabad, PAK.
FAU - Tabbasum, Tayyaba
AU  - Tabbasum T
AD  - Medicine, Combined Military Hospital (CMH) Rawalakot, Rawalakot, PAK.
LA  - eng
PT  - Journal Article
DEP - 20200419
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7237058
OTO - NOTNLM
OT  - azad kashmir
OT  - blood donation
OT  - blood transfusion
OT  - medical student
OT  - pakistan
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:01
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:01 [medline]
AID - 10.7759/cureus.7733 [doi]
PST - epublish
SO  - Cureus. 2020 Apr 19;12(4):e7733. doi: 10.7759/cureus.7733.


PMID- 32439751
OWN - NLM
STAT- MEDLINE
DCOM- 20200528
LR  - 20201218
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 May 21
TI  - Ethical road map through the covid-19 pandemic.
PG  - m2033
LID - 10.1136/bmj.m2033 [doi]
FAU - Fritz, Zoe
AU  - Fritz Z
FAU - Huxtable, Richard
AU  - Huxtable R
AD  - University of Bristol Centre for Ethics in Medicine, Population Health Sciences, 
      Bristol Medical School, Bristol, UK.
FAU - Ives, Jonathan
AU  - Ives J
AD  - University of Bristol Centre for Ethics in Medicine, Population Health Sciences, 
      Bristol Medical School, Bristol, UK.
FAU - Paton, Alexis
AU  - Paton A
AD  - Aston University, Birmingham, UK.
FAU - Slowther, Anne Marie
AU  - Slowther AM
AD  - University of Warwick, Warwick, UK.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AD  - University of Oxford, Oxford, UK.
LA  - eng
PT  - Editorial
DEP - 20200521
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Delivery of Health Care/*ethics
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United Kingdom
COIS- Competing interests: We have read and understood BMJ policy on declaration of
      interests. AP is chair of the committee on ethical issues in medicine for the
      Royal College of Physicians, and a trustee of the Institute of Medical Ethics
      (IME). ZF serves on the executive of the Resuscitation Council UK and, with RH,
      the research committee of the IME. RH is vice chair of the UK Clinical Ethics
      Network (UKCEN) and a member of the ethics committees of the BMA and the Royal
      College of General Practitioners (RCGP), the Bristol clinical ethics advisory
      group, and the ALSPAC ethics and law committee; he is also a member of an expert 
      review group for the Wellcome Trust. JI sits on the ethics committee of the RCGP 
      and on the grants and awards committee of the IME. AS is a member of the board of
      trustees of UKCEN and the IME, a member of the UK National Screening Committee,
      and a member of University Hospitals Coventry and Warwickshire clinical ethics
      forum. DW is co-chair of the Oxford University Hospitals NHS Foundation Trust
      clinical ethics advisory group and a member of the ethics committees of the BMA
      and the Royal College of Paediatrics and Child Health. The views expressed are
      those of the authors.
EDAT- 2020/05/23 06:00
MHDA- 2020/05/29 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
AID - 10.1136/bmj.m2033 [doi]
PST - epublish
SO  - BMJ. 2020 May 21;369:m2033. doi: 10.1136/bmj.m2033.


PMID- 32439630
OWN - NLM
STAT- Publisher
LR  - 20200522
IS  - 2045-4368 (Electronic)
IS  - 2045-435X (Linking)
DP  - 2020 May 21
TI  - Mechanical ventilation withdrawal in motor neuron disease: an evaluation of
      practice.
LID - bmjspcare-2019-002170 [pii]
LID - 10.1136/bmjspcare-2019-002170 [doi]
AB  - OBJECTIVES: Clinicians report that withdrawal of mechanical ventilation in motor 
      neuron disease is challenging. We report on the evaluation of the process and
      outcomes called for by the Association for Palliative Medicine of Great Britain
      and Ireland (APM) guidance. METHODS: Excel analysis of a core data set, defined
      in the APM guidance, and thematic analysis of free-text comments, submitted by a 
      UK clinician soon after withdrawal of mechanical ventilation in any care setting.
      RESULTS: Thirty-seven professionals submitted 46 data sets from 4 patients with
      tracheostomy ventilation (TV) and 42 with non-invasive ventilation (NIV) in 35
      months. These took place at home (43%), inpatient hospice (48%), hospital and
      care homes. Eighty-nine per cent received opioid and/or sedative medication at
      the initiation of withdrawal, majority of which were subcutaneous. A median of 2 
      doses (range 1-9) were used to manage symptoms before ventilation withdrawal.
      Subsequently 73% of patients required either none or one dose of medication. In
      addition to any background opioid, symptom management required a total parenteral
      morphine equivalent mean of 20.6 mg (range 0-60 mg) and midazolam mean of 25.8 mg
      (range 0-120 mg). The median time from first medication to removal of mechanical 
      ventilation was 45 min. Patients with TV died within 30 min of withdrawal. The
      mode (14 of 42 patients) time to death after NIV withdrawal was 15 min, but
      ranged between <15 min and 54 hours. CONCLUSIONS: Individualised, proportionate, 
      titrated opioid and sedative medications were used to provide good symptom
      management, and provided new insight into the substantial variability in what
      patients require to manage their symptoms and how long the process takes. Most
      patients required lower doses than in previous literature.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Faull, Christina
AU  - Faull C
AUID- ORCID: http://orcid.org/0000-0002-0064-8056
AD  - LOROS Hospice, Leicester, UK ChristinaFaull@loros.co.uk.
FAU - Wenzel, David
AU  - Wenzel D
AD  - University Hospitals of Leicester NHS Trust, Leicester, UK.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - England
TA  - BMJ Support Palliat Care
JT  - BMJ supportive & palliative care
JID - 101565123
SB  - IM
OTO - NOTNLM
OT  - chronic conditions
OT  - drug administration
OT  - end of life care
OT  - ethics
OT  - neurological conditions
COIS- Competing interests: CF has received other competitive grant funding from the
      Motor Neurone Disease Association.
EDAT- 2020/05/23 06:00
MHDA- 2020/05/23 06:00
CRDT- 2020/05/23 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2020/05/23 06:00 [medline]
AID - bmjspcare-2019-002170 [pii]
AID - 10.1136/bmjspcare-2019-002170 [doi]
PST - aheadofprint
SO  - BMJ Support Palliat Care. 2020 May 21. pii: bmjspcare-2019-002170. doi:
      10.1136/bmjspcare-2019-002170.


PMID- 32438516
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 213
IP  - 3
DP  - 2020 Aug
TI  - Unintended consequences of using real time prescription monitoring systems.
PG  - 142-142.e1
LID - 10.5694/mja2.50616 [doi]
FAU - Haines, Sarah
AU  - Haines S
AD  - Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC.
FAU - Savic, Michael
AU  - Savic M
AD  - Turning Point, Eastern Health and Monash University, Melbourne, VIC.
FAU - Picco, Louisa
AU  - Picco L
AD  - Monash Addiction Research Centre, Monash University, Melbourne, VIC.
FAU - Nielsen, Suzanne
AU  - Nielsen S
AD  - Monash Addiction Research Centre, Monash University, Melbourne, VIC.
FAU - Carter, Adrian
AU  - Carter A
AD  - Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC.
LA  - eng
PT  - Letter
DEP - 20200521
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/therapeutic use
MH  - *Health Services Accessibility
MH  - Humans
MH  - *Prescription Drug Monitoring Programs
MH  - Victoria
OTO - NOTNLM
OT  - *Ethics
OT  - *Policy, drugs and alcohol
OT  - *Prescribing
EDAT- 2020/05/22 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.5694/mja2.50616 [doi]
PST - ppublish
SO  - Med J Aust. 2020 Aug;213(3):142-142.e1. doi: 10.5694/mja2.50616. Epub 2020 May
      21.


PMID- 32438509
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 2211-5463 (Electronic)
IS  - 2211-5463 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul
TI  - Self-selecting peer groups formed within the laboratory environment have a
      lasting effect on individual student attainment and working practices.
PG  - 1194-1209
LID - 10.1002/2211-5463.12902 [doi]
AB  - Within the present study, we investigate the lasting effect of laboratory peer
      group interactions on the end of year attainment of Biosciences and Chemistry
      students. By asking students to identify who they primarily work with within the 
      laboratory environment and evaluating the interactions through cluster analysis, 
      we identified two main categories of laboratory peer groups: the first long-lived
      well-established pairings of two students, 'swans', who work together for all or 
      the majority of the laboratory sessions; and the second dynamic fluid groups,
      'dolphins', of between three and nine students who work with each other
      interchangeably. Statistical analysis is presented, which demonstrates that
      individuals within each laboratory peer group were likely to achieve a similar
      average mark at the end of the first year of study on the course. We identified
      the driving factors for the formation of these groups as friendship and perceived
      work ethic. There is a preference for high-achieving students to work with other 
      high-achieving students and lower-achieving to group around a shared social
      background. Targeted interventions, in which pairings were selected by the tutor 
      at the onset of the study, altered the ratio from long-lived pairs to more
      dynamic groups and increased students' willingness to work with others outside of
      their group but did not change the drivers of group formation or resulting
      pattern of achievement. We conclude with recommendations around group working
      within the laboratory environment.
CI  - (c) 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
FAU - Lacey, Melissa M
AU  - Lacey MM
AUID- ORCID: 0000-0003-0997-0217
AD  - Department of Biosciences and Chemistry, Sheffield Hallam University, UK.
FAU - Campbell, Susan G
AU  - Campbell SG
AUID- ORCID: 0000-0002-6740-1445
AD  - Department of Biosciences and Chemistry, Sheffield Hallam University, UK.
FAU - Shaw, Holly
AU  - Shaw H
AUID- ORCID: 0000-0001-6093-9392
AD  - Department of Biosciences and Chemistry, Sheffield Hallam University, UK.
FAU - Smith, David P
AU  - Smith DP
AUID- ORCID: 0000-0001-5177-8574
AD  - Department of Biosciences and Chemistry, Sheffield Hallam University, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200607
PL  - England
TA  - FEBS Open Bio
JT  - FEBS open bio
JID - 101580716
SB  - IM
MH  - *Educational Measurement
MH  - Humans
MH  - Individuality
MH  - *Laboratories
MH  - *Learning
MH  - Peer Group
MH  - Students
PMC - PMC7327925
OTO - NOTNLM
OT  - *attainment
OT  - *laboratory
OT  - *learning space
OT  - *peer effects
OT  - *peer groups
OT  - *performance
EDAT- 2020/05/22 06:00
MHDA- 2021/10/28 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1002/2211-5463.12902 [doi]
PST - ppublish
SO  - FEBS Open Bio. 2020 Jul;10(7):1194-1209. doi: 10.1002/2211-5463.12902. Epub 2020 
      Jun 7.


PMID- 32438420
OWN - NLM
STAT- MEDLINE
DCOM- 20210114
LR  - 20210114
IS  - 2193-6323 (Electronic)
IS  - 2193-6315 (Linking)
VI  - 81
IP  - 5
DP  - 2020 Sep
TI  - Use of Sham Interventions in Randomized Controlled Trials in Neurosurgery.
PG  - 456-462
LID - 10.1055/s-0040-1709161 [doi]
AB  - BACKGROUND: The use of sham interventions in randomized controlled trials (RCTs) 
      is essential to minimize bias. However, their use in surgical RCTs is rare and
      subject to ethical concerns. To date, no studies have looked at the use of sham
      interventions in RCTs in neurosurgery. METHODS: This study evaluated the
      frequency, type, and indication of sham interventions in RCTs in neurosurgery.
      RCTs using sham interventions were also characterized in terms of design and risk
      of bias. RESULTS: From a total of 1,102 identified RCTs in neurosurgery, 82
      (7.4%) used sham interventions. The most common indication for the RCT was the
      treatment of pain (67.1%), followed by the treatment of movement disorders and
      other clinical problems (18.3%) and brain injuries (12.2%). The most used sham
      interventions were saline injections into spinal structures (31.7%) and
      peripheral nerves (10.9%), followed by sham interventions in cranial surgery
      (26.8%), and spine surgery (15.8%). Insertion of probes or catheters for a sham
      lesions was performed in 14.6%.In terms of methodology, most RCTs using sham
      interventions were double blinded (76.5%), 9.9% were single blinded, and 13.6%
      did not report the type of blinding. CONCLUSION: Sham-controlled RCTs in
      neurosurgery are feasible. Most aim to minimize bias and to evaluate the efficacy
      of pain management methods, especially in spinal disorders. The greatest
      proportion of sham-controlled RCTs involves different types of substance
      administration routes, with sham surgery the less commonly performed.
CI  - Thieme. All rights reserved.
FAU - Gorayeb, Rodrigo Panico
AU  - Gorayeb RP
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina,
      Universidade de Lisboa, Portugal.
FAU - Forjaz, Maria Joao
AU  - Forjaz MJ
AD  - National School of Public Health, Institute of Health Carlos III and REDISSEC,
      Madrid, Spain.
FAU - Ferreira, Antonio Goncalves
AU  - Ferreira AG
AD  - Institute of Anatomy, Faculdade de Medicina, Universidade de Lisboa, Portugal.
FAU - Ferreira, Joaquim Jose
AU  - Ferreira JJ
AD  - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina,
      Universidade de Lisboa, Portugal.
AD  - Instituto de Medicina Molecular, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200521
PL  - Germany
TA  - J Neurol Surg A Cent Eur Neurosurg
JT  - Journal of neurological surgery. Part A, Central European neurosurgery
JID - 101580767
SB  - IM
MH  - Double-Blind Method
MH  - Humans
MH  - Movement Disorders/*surgery
MH  - Neurosurgical Procedures/*methods
MH  - Pain/*surgery
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Research Design
COIS- None declared.
EDAT- 2020/05/22 06:00
MHDA- 2021/01/15 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/01/15 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1055/s-0040-1709161 [doi]
PST - ppublish
SO  - J Neurol Surg A Cent Eur Neurosurg. 2020 Sep;81(5):456-462. doi:
      10.1055/s-0040-1709161. Epub 2020 May 21.


PMID- 32438316
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210127
IS  - 1873-5223 (Electronic)
IS  - 1471-5953 (Linking)
VI  - 45
DP  - 2020 May
TI  - Using simulation to teach undergraduate nursing and midwifery students research
      design.
PG  - 102804
LID - S1471-5953(19)30638-9 [pii]
LID - 10.1016/j.nepr.2020.102804 [doi]
AB  - Whilst it is widely accepted that the ability to critique, interpret and
      integrate research is an integral part of the evidence-based practice of nursing 
      and midwifery, teaching such skills to undergraduate students is equally
      recognised as challenging. From a student's perspective the theoretical aspects, 
      concepts and language of research design may seem far removed from the imperative
      of developing skills and gaining clinical experience. Simulation has been widely 
      demonstrated as an effective pedagogical approach to engage students in learning 
      and developing practical skills. The 'hands-on' approach provides a cognitive
      link between theory and practice that is immediately relevant to the student.
      Simulation training has also been used in other areas of healthcare such as
      communication and ethics. However, the use of simulation to demonstrate the
      theoretical and practical aspects of research design to midwifery and nursing
      students has not been explored. This paper describes a novel approach to teaching
      undergraduate students fundamental concepts of randomised controlled trial design
      through their participation in a simulated research trial. Students experienced
      aspects such as consent, randomisation, intervention, data collection, analysis
      and interpretation. Post workshop evaluations suggest that students found the
      approach engaging, increased their knowledge and understanding of research and
      evidenced-based practice.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Lee, Nigel
AU  - Lee N
AD  - Chamberlain Building University of Queensland, St Lucia, 4072, Queensland,
      Australia. Electronic address: nigel.lee@uq.edu.au.
FAU - Peacock, Ann
AU  - Peacock A
AD  - Chamberlain Building University of Queensland, St Lucia, 4072, Queensland,
      Australia. Electronic address: a.peacock2@uq.edu.au.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Scotland
TA  - Nurse Educ Pract
JT  - Nurse education in practice
JID - 101090848
SB  - IM
MH  - Education, Nursing, Baccalaureate
MH  - *Evidence-Based Nursing
MH  - Female
MH  - Humans
MH  - Midwifery/*education
MH  - Nursing Research
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
MH  - *Simulation Training
MH  - *Students, Nursing
COIS- Declaration of competing interest None.
EDAT- 2020/05/22 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - S1471-5953(19)30638-9 [pii]
AID - 10.1016/j.nepr.2020.102804 [doi]
PST - ppublish
SO  - Nurse Educ Pract. 2020 May;45:102804. doi: 10.1016/j.nepr.2020.102804. Epub 2020 
      May 12.


PMID- 32438301
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1873-1244 (Electronic)
IS  - 0899-9007 (Linking)
VI  - 77
DP  - 2020 Sep
TI  - Preoperative fasting abbreviation (Enhanced Recovery After Surgery protocol) and 
      effects on the metabolism of patients undergoing gynecological surgeries under
      spinal anesthesia: A randomized clinical trial.
PG  - 110790
LID - S0899-9007(20)30073-3 [pii]
LID - 10.1016/j.nut.2020.110790 [doi]
AB  - OBJECTIVES: Recommended perioperative nutritional interventions may contribute to
      satisfactory surgical outcomes. Each moment in the course of a surgical
      pathologic condition may be a window of opportunity for an intervention with a
      positive impact on postoperative recovery. Based on the idea of accelerating
      postoperative recovery, the objective of this study was to evaluate the
      effectiveness of a nutritional intervention with preoperative fasting
      abbreviation (Enhanced Recovery After Surgery recommendations) on the metabolism 
      of patients undergoing gynecologic surgeries under spinal anesthesia. METHODS:
      This randomized clinical trial was performed at a hospital of medium complexity. 
      After Human Research Ethics Committee approval on August 24, 2015, 80 women who
      had gynecologic surgery in the period from January to June 2016 and signed the
      consent form were randomly allocated into two groups: a control group (n = 42)
      and a juice group (n = 38). They received 200 mL of inert solution (control
      group) or liquid enriched with carbohydrate and protein (juice group) 4 h before 
      surgery. The variables studied were serum glucose, insulin, insulin resistance
      evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR),
      C-reactive protein, and albumin in the pre- and postoperative periods. The
      statistical analysis was performed with SPSS 20.0. RESULTS: There was a
      statistically significant difference in the coefficient of variation for the
      HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice
      group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative
      period. CONCLUSIONS: Preoperative fasting abbreviation with liquid containing
      carbohydrate and protein before gynecologic surgeries may provide metabolic
      stability with lower variation in insulin resistance than inert solution.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Marquini, Gisele Vissoci
AU  - Marquini GV
AD  - Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
      Electronic address: giselemarquini@gmail.com.
FAU - da Silva Pinheiro, Francisco Edes
AU  - da Silva Pinheiro FE
AD  - Hospital and Municipal Maternity Dr. Odelmo Leao Carneiro, Uberlandia, Minas
      Gerais, Brazil.
FAU - da Costa Vieira, Alfredo Urbano
AU  - da Costa Vieira AU
AD  - Hospital and Municipal Maternity Dr. Odelmo Leao Carneiro, Uberlandia, Minas
      Gerais, Brazil.
FAU - da Costa Pinto, Rogerio Melo
AU  - da Costa Pinto RM
AD  - Faculty of Maths, Nucleus of Statistical and Biometrical Studies, Federal
      University of Uberlandia, Minas Gerais, Brazil.
FAU - Kuster Uyeda, Maria Gabriela Baumgarten
AU  - Kuster Uyeda MGB
AD  - Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
FAU - Girao, Manoel Joao Batista Castello
AU  - Girao MJBC
AD  - Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
FAU - Sartori, Marair Gracio Ferreira
AU  - Sartori MGF
AD  - Department of Gynecology, Federal University of Sao Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200306
PL  - United States
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
SB  - IM
MH  - *Anesthesia, Spinal
MH  - *Enhanced Recovery After Surgery
MH  - Fasting
MH  - Female
MH  - Gynecologic Surgical Procedures
MH  - Humans
MH  - *Insulin Resistance
MH  - Preoperative Care
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - *Carbohydrates
OT  - *Controlled clinical trial
OT  - *Fasting
OT  - *Gynecologic surgical procedures
OT  - *Preoperative care
OT  - *Proteins
EDAT- 2020/05/22 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - S0899-9007(20)30073-3 [pii]
AID - 10.1016/j.nut.2020.110790 [doi]
PST - ppublish
SO  - Nutrition. 2020 Sep;77:110790. doi: 10.1016/j.nut.2020.110790. Epub 2020 Mar 6.


PMID- 32437298
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20210813
IS  - 2042-1834 (Electronic)
IS  - 0025-8172 (Linking)
VI  - 88
IP  - 4
DP  - 2020 Dec
TI  - Management of hunger strike: A medical, ethical and legal conundrum.
PG  - 215-219
LID - 10.1177/0025817220923653 [doi]
AB  - Hunger strike is a protest where an informed person refuses essential nourishment
      with the intention of accomplishing a specific goal. Hunger strikes conflict with
      medical, ethical, humanitarian and legal values. A multidisciplinary approach is 
      important when dealing with hunger strike patients. On one hand, there is the
      wish to preserve life, and on the other to respect the strikers' autonomy and
      their wishes, values and advanced directives (or living will). Most hunger
      strikes are short-lived, but in complex and prolonged circumstances, legal advice
      must be sought from health service solicitors and a doctor's medical indemnity
      organisation. There is an emergent need to have defined guidelines for the
      management of these hunger strikes to be followed.
FAU - Sharma, Raman
AU  - Sharma R
AD  - Department of Hospital Administration, PGIMER, Chandigarh, India.
FAU - Jain, Arihant
AU  - Jain A
AD  - Department of Internal Medicine, PGIMER, Chandigarh, India.
FAU - Kumar, Ashok
AU  - Kumar A
AD  - Department of Hospital Administration, PGIMER, Chandigarh, India.
FAU - Bhadada, Sanjay Kumar
AU  - Bhadada SK
AD  - Department of Endocrinology, PGIMER, Chandigarh, India.
FAU - Grover, Sandeep
AU  - Grover S
AD  - Department of Psychiatry, PGIMER, Chandigarh, India.
FAU - Puri, Govardhan Dutt
AU  - Puri GD
AD  - Department of Anaesthesia, PGIMER, Chandigarh, India.
LA  - eng
PT  - Case Reports
DEP - 20200521
PL  - England
TA  - Med Leg J
JT  - The Medico-legal journal
JID - 0412004
SB  - IM
MH  - Adult
MH  - Enteral Nutrition/ethics
MH  - *Ethics, Medical
MH  - *Fasting
MH  - Humans
MH  - India
MH  - Informed Consent/ethics
MH  - Male
MH  - *Personal Autonomy
MH  - *Physician's Role
MH  - Starvation/*therapy
OTO - NOTNLM
OT  - Ethics
OT  - force feeding
OT  - hunger strike
OT  - mental competence
EDAT- 2020/05/22 06:00
MHDA- 2021/08/14 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1177/0025817220923653 [doi]
PST - ppublish
SO  - Med Leg J. 2020 Dec;88(4):215-219. doi: 10.1177/0025817220923653. Epub 2020 May
      21.


PMID- 32437180
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1935-990X (Electronic)
IS  - 0003-066X (Linking)
VI  - 75
IP  - 5
DP  - 2020 Jul-Aug
TI  - Ethical considerations for psychologists in the time of COVID-19.
PG  - 644-654
LID - 10.1037/amp0000661 [doi]
AB  - Psychologists are in a position to respond to the COVID-19 pandemic through
      research, practice, education, and advocacy. However, concerns exist about the
      ethical implications associated with transitioning from face-to-face to online or
      virtual formats as necessitated by stay-at-home orders designed to enforce the
      social distancing required to flatten the curve of new COVID-19 cases. The
      purpose of this article is to review potential ethical issues and to provide
      guidance to psychologists for ethical conduct in the midst of the current crisis 
      and its aftermath. In addition to contextualizing relevant ethical considerations
      according to the principles and standards of the current American Psychological
      Association's ethics code, vignettes are presented to exemplify the ethical
      dilemmas psychologists in various roles may face when responding to COVID-19 and 
      to offer suggestions and resources for resolving potential conflicts. (PsycInfo
      Database Record (c) 2020 APA, all rights reserved).
FAU - Chenneville, Tiffany
AU  - Chenneville T
AUID- ORCID: 0000-0001-5598-9387
AD  - Department of Psychology, University of South Florida, St. Petersburg.
FAU - Schwartz-Mette, Rebecca
AU  - Schwartz-Mette R
AUID- ORCID: 0000-0002-6708-0389
AD  - Department of Psychology, University of Maine.
LA  - eng
GR  - MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Am Psychol
JT  - The American psychologist
JID - 0370521
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Competence
MH  - *Codes of Ethics
MH  - Confidentiality/ethics
MH  - *Coronavirus Infections
MH  - Documentation/ethics
MH  - Ethics, Research
MH  - Guidelines as Topic
MH  - Humans
MH  - Informed Consent/ethics
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Psychology/*ethics
MH  - Publishing/ethics
MH  - Research
MH  - SARS-CoV-2
MH  - Societies, Scientific
MH  - Telemedicine/*ethics
EDAT- 2020/05/22 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 2020-35285-001 [pii]
AID - 10.1037/amp0000661 [doi]
PST - ppublish
SO  - Am Psychol. 2020 Jul-Aug;75(5):644-654. doi: 10.1037/amp0000661. Epub 2020 May
      21.


PMID- 32437032
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20201218
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Care in the time of coronavirus: Ethical considerations in head and neck
      oncology.
PG  - 1519-1525
LID - 10.1002/hed.26272 [doi]
AB  - As COVID-19 continues to challenge the practice of head and neck oncology,
      clinicians are forced to make new decisions in the setting of the pandemic that
      impact the safety of their patients, their institutions, and themselves. The
      difficulty inherent in these decisions is compounded by potentially serious
      ramifications to the welfare of patients and health-care staff, amid a scarcity
      of data on which to base informed choices. This paper explores the risks of
      COVID-19 incurred while striving to uphold the standard of care in head and neck 
      oncology. The ethical problems are assessed from the perspective of the patient
      with cancer, health-care provider, and other patients within the health-care
      system. While no single management algorithm for head and neck cancer can be
      universally implemented, a detailed examination of these issues is necessary to
      formulate ethically sound treatment strategies.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Gordin, Eli A
AU  - Gordin EA
AUID- ORCID: https://orcid.org/0000-0002-4178-8557
AD  - Otolaryngology-Head and Neck Surgery, University of Texas-Southwestern Medical
      Center, Dallas, TX, USA.
FAU - Day, Andrew
AU  - Day A
AD  - Otolaryngology-Head and Neck Surgery, University of Texas-Southwestern Medical
      Center, Dallas, TX, USA.
FAU - Stankova, Lenka
AU  - Stankova L
AD  - Otolaryngology-Head and Neck Surgery, University of Texas-Southwestern Medical
      Center, VA North Texas Health Care System, Dallas, Texas, USA.
FAU - Heitman, Elizabeth
AU  - Heitman E
AD  - Psychiatry, Division of Ethics in Science and Medicine, University of
      Texas-Southwestern Medical Center, Dallas, Texas, USA.
FAU - Sadler, John
AU  - Sadler J
AD  - Psychiatry, Division of Ethics in Science and Medicine, University of
      Texas-Southwestern Medical Center, Dallas, Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Clinical Decision-Making/ethics
MH  - Coronavirus Infections/*prevention & control/transmission
MH  - Disease Transmission, Infectious/prevention & control
MH  - Head and Neck Neoplasms/*therapy
MH  - Humans
MH  - Infection Control
MH  - Infectious Disease Transmission, Patient-to-Professional/prevention & control
MH  - Medical Oncology/*ethics
MH  - Occupational Health/ethics
MH  - Pandemics/*prevention & control
MH  - Patient Care Planning
MH  - Patient Safety
MH  - Personal Protective Equipment
MH  - Physician's Role
MH  - Pneumonia, Viral/*prevention & control/transmission
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Standard of Care
MH  - Uncertainty
PMC - PMC7280596
OTO - NOTNLM
OT  - COVID-19
OT  - cancer
OT  - ethics
OT  - head and neck
OT  - oncology
EDAT- 2020/05/22 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1002/hed.26272 [doi]
PST - ppublish
SO  - Head Neck. 2020 Jul;42(7):1519-1525. doi: 10.1002/hed.26272. Epub 2020 May 21.


PMID- 32436848
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 5
DP  - 2020 May 21
TI  - Ethical, Legal, and Social Issues Related to the Inclusion of Individuals With
      Intellectual Disabilities in Electronic Health Record Research: Scoping Review.
PG  - e16734
LID - 10.2196/16734 [doi]
AB  - BACKGROUND: Data from electronic health records (EHRs) are increasingly used in
      the field of genetic research to further precision medicine initiatives. However,
      many of these efforts exclude individuals with intellectual disabilities, which
      often stem from genetic conditions. To include this important subpopulation in
      EHR research, important ethical, legal, and social issues should be considered.
      OBJECTIVE: The goal of this study was to review prior research to better
      understand what ethical, legal, and social issues may need further investigation 
      when considering the research use of EHRs for individuals with genetic conditions
      that may result in intellectual disability. This information will be valuable in 
      developing methods and best practices for involving this group in research given 
      they are considered a vulnerable population that may need special research
      protections. METHODS: We conducted a scoping review to examine issues related to 
      the use of EHRs for research purposes and those more broadly associated with
      genetic research. The initial search yielded a total of 460 unique citations. We 
      used an evaluative coding process to determine relevancy for inclusion. RESULTS: 
      This approach resulted in 59 articles in the following areas: informed consent,
      privacy and security, return of results, and vulnerable populations. The review
      included several models of garnering informed consent in EHR or genetic research,
      including tiered or categorical, blanket or general, open, and opt-out models.
      Second, studies reported on patients' concerns regarding the privacy and security
      of EHR or genetic data, such as who has access, type of data use in research,
      identifiability, and risks associated with privacy breach. The literature on
      return of research results using biospecimens examined the dissension in the
      field, particularly when sharing individualized genetic results. Finally, work
      involving vulnerable populations highlighted special considerations when
      conducting EHR or genetic research. CONCLUSIONS: The results frame important
      questions for researchers to consider when designing EHR studies, which include
      individuals with intellectual disabilities, including appropriate safeguards and 
      protections.
CI  - (c)Melissa Raspa, Rebecca Moultrie, Laura Wagner, Anne Edwards, Sara Andrews,
      Mary Katherine Frisch, Lauren Turner-Brown, Anne Wheeler. Originally published in
      the Journal of Medical Internet Research (http://www.jmir.org), 21.05.2020.
FAU - Raspa, Melissa
AU  - Raspa M
AUID- ORCID: 0000-0003-3791-3367
AD  - RTI International, Research Triangle Park, NC, United States.
FAU - Moultrie, Rebecca
AU  - Moultrie R
AUID- ORCID: 0000-0003-2102-2287
AD  - RTI International, Research Triangle Park, NC, United States.
FAU - Wagner, Laura
AU  - Wagner L
AUID- ORCID: 0000-0002-1041-2573
AD  - RTI International, Research Triangle Park, NC, United States.
FAU - Edwards, Anne
AU  - Edwards A
AUID- ORCID: 0000-0001-6014-1655
AD  - RTI International, Research Triangle Park, NC, United States.
FAU - Andrews, Sara
AU  - Andrews S
AUID- ORCID: 0000-0003-0218-0976
AD  - RTI International, Research Triangle Park, NC, United States.
FAU - Frisch, Mary Katherine
AU  - Frisch MK
AUID- ORCID: 0000-0003-1592-9763
AD  - The University of North Carolina at Chapel Hill, TEACCH Autism Program, Chapel
      Hill, NC, United States.
FAU - Turner-Brown, Lauren
AU  - Turner-Brown L
AUID- ORCID: 0000-0001-5180-1818
AD  - The University of North Carolina at Chapel Hill, TEACCH Autism Program, Chapel
      Hill, NC, United States.
FAU - Wheeler, Anne
AU  - Wheeler A
AUID- ORCID: 0000-0003-2693-5616
AD  - RTI International, Research Triangle Park, NC, United States.
LA  - eng
GR  - R01 HD086702/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200521
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Electronic Health Records/*standards
MH  - Ethical Analysis/*methods
MH  - Humans
MH  - Intellectual Disability/*epidemiology
PMC - PMC7273235
OTO - NOTNLM
OT  - *electronic health records
OT  - *genetics
OT  - *informed consent
OT  - *intellectual disability
OT  - *privacy
EDAT- 2020/05/22 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/02/22 00:00 [accepted]
PHST- 2020/01/17 00:00 [revised]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - v22i5e16734 [pii]
AID - 10.2196/16734 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 May 21;22(5):e16734. doi: 10.2196/16734.


PMID- 32436798
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1473-0782 (Electronic)
IS  - 1362-5187 (Linking)
VI  - 25
IP  - 4
DP  - 2020 Aug
TI  - Incentivised sterilisation: lessons from India and for the future.
PG  - 314-318
LID - 10.1080/13625187.2020.1766015 [doi]
AB  - Family planning programmes in India have historically been target-driven and
      incentive-based with sterilisation seen as a key component of controlling
      population growth. This opinion paper uses India as the backcloth to examine the 
      ethics of using incentive policy measures to promote and secure sterilisations
      within communities. Whilst we acknowledge that these measures have some value in 
      reproductive health care, their use raises specific issues and wider concerns
      where the outcome is likely to be permanent and life changing for the acceptor.
FAU - Wale, Jeffrey
AU  - Wale J
AUID- ORCID: https://orcid.org/0000-0002-9210-029X
AD  - Department of Humanities & Law, Faculty of Media and Communication, Weymouth
      House, Bournemouth University, Poole, UK.
FAU - Rowlands, Sam
AU  - Rowlands S
AUID- ORCID: https://orcid.org/0000-0001-5940-9079
AD  - Department of Medical Sciences & Public Health, Faculty of Health & Social
      Sciences, Royal London House, Bournemouth University, Bournemouth, UK.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - England
TA  - Eur J Contracept Reprod Health Care
JT  - The European journal of contraception & reproductive health care : the official
      journal of the European Society of Contraception
JID - 9712127
SB  - IM
MH  - Family Planning Services/*ethics/methods
MH  - Humans
MH  - India
MH  - Motivation/*ethics
MH  - Population Control/*ethics/methods
MH  - Sterilization, Reproductive/*ethics
OTO - NOTNLM
OT  - Incentivisation
OT  - human rights
OT  - population
OT  - sterilisation
OT  - targets
EDAT- 2020/05/22 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1080/13625187.2020.1766015 [doi]
PST - ppublish
SO  - Eur J Contracept Reprod Health Care. 2020 Aug;25(4):314-318. doi:
      10.1080/13625187.2020.1766015. Epub 2020 May 21.


PMID- 32436593
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 1097-0231 (Electronic)
IS  - 0951-4198 (Linking)
VI  - 34
IP  - 16
DP  - 2020 Aug 30
TI  - Comparisons of stable isotope composition among tissues of green turtles.
PG  - e8839
LID - 10.1002/rcm.8839 [doi]
AB  - Ecologists often need to make choices about what body parts (tissues or organs)
      of an animal to sample. The decision is typically guided by the need to treat
      animals as humanely as possible, as well as the information that different body
      parts can provide. When using stable isotopes, decisions are also influenced by
      whether specimens would require preservation, and whether they have properties
      (such as high lipid concentrations) that would influence measurements. Sometimes 
      we cannot use a preferred tissue (for example, because of ethical or logistical
      constraints), and in such cases an ability to reliably predict stable isotope
      composition for one tissue from data yielded by another would be useful. METHODS:
      In this study we analysed multiple tissues (skin, whole blood, red blood cells,
      plasma and nail) from green turtles (Chelonia mydas) to evaluate variation in C:N
      ratios, and test hypotheses about the intercept and slope of regressions of
      stable carbon and nitrogen isotope compositions among tissues. RESULTS:
      Regression models revealed that linear relationships were present for most
      comparisons, except those involving the delta(13) C of skin, and the slopes
      (beta1 ) of most regressions were different from unity. The C:N ratios of skin
      were significantly higher and more variable than those of other tissues. The
      delta(13) C and delta(15) N of nail were highly correlated with those of the
      whole blood, red blood cells and plasma. Nail and red blood cells showed low
      variation in C:N. CONCLUSIONS: The patterns in slopes of regressions indicate
      that comparisons of measurements yielded by different tissues of wild animals are
      complicated by the fact that the tissues are unlikely to be in isotopic
      equilibrium with their diet. Of the tissues used in this study, nail is simple to
      collect, requires minimal disturbance to the animal and no special preservation; 
      these traits should make it attractive to turtle ecologists, but more information
      is needed on aspects such as growth rates.
CI  - (c) 2020 Commonwealth of Australia. Rapid Communications in Mass Spectrometry (c)
      2020 John Wiley & Sons Ltd.
FAU - Vanderklift, Mathew A
AU  - Vanderklift MA
AUID- ORCID: https://orcid.org/0000-0002-5170-7546
AD  - CSIRO Oceans & Atmosphere, Indian Ocean Marine Research Centre, Crawley, WA,
      6009, Australia.
FAU - Pillans, Richard D
AU  - Pillans RD
AD  - CSIRO Oceans & Atmosphere, Biosciences Precinct, St Lucia, Queensland, 4067,
      Australia.
FAU - Robson, Natalie A
AU  - Robson NA
AD  - CSIRO Oceans & Atmosphere, Indian Ocean Marine Research Centre, Crawley, WA,
      6009, Australia.
FAU - Skrzypek, Grzegorz
AU  - Skrzypek G
AUID- ORCID: https://orcid.org/0000-0002-5686-2393
AD  - School of Biological Sciences, The University of Western Australia, Crawley, WA, 
      6009, Australia.
FAU - Stubbs, Jessica L
AU  - Stubbs JL
AD  - CSIRO Oceans & Atmosphere, Indian Ocean Marine Research Centre, Crawley, WA,
      6009, Australia.
AD  - School of Biological Sciences, The University of Western Australia, Crawley, WA, 
      6009, Australia.
FAU - Tucker, Anton D
AU  - Tucker AD
AD  - Marine Science Program, Department of Biodiversity, Conservation and Attractions,
      Kensington, WA, 6151, Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Rapid Commun Mass Spectrom
JT  - Rapid communications in mass spectrometry : RCM
JID - 8802365
RN  - 0 (Carbon Isotopes)
RN  - 0 (Nitrogen Isotopes)
RN  - 0 (Nitrogen-15)
RN  - FDJ0A8596D (Carbon-13)
SB  - IM
MH  - Animal Nutritional Physiological Phenomena
MH  - Animals
MH  - Carbon Isotopes/*analysis
MH  - Female
MH  - Linear Models
MH  - Male
MH  - Nitrogen Isotopes/*analysis
MH  - Skin/chemistry
MH  - *Turtles/blood
MH  - Western Australia
EDAT- 2020/05/22 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1002/rcm.8839 [doi]
PST - ppublish
SO  - Rapid Commun Mass Spectrom. 2020 Aug 30;34(16):e8839. doi: 10.1002/rcm.8839.


PMID- 32436468
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20220309
IS  - 1475-990X (Electronic)
IS  - 1473-9879 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Jul
TI  - Defining and measuring denigration of general practice in medical education.
PG  - 205-209
LID - 10.1080/14739879.2020.1768440 [doi]
AB  - There is a workforce crisis in NHS general practice (GP). It is estimated that to
      meet future healthcare needs around 50% of current medical students will need to 
      choose a career in GP. Positive role modelling is an influential factor in
      medical students' career choice, but denigration of primary care during medical
      training may undermine the aspirations of students considering GP as a career.
      This article discusses the importance of medical schools detecting and managing
      denigration of GP in their curricula and, for the first time, suggests an
      objective approach to the measurement of denigration. Four facets which
      constitute denigration are discussed and proposed as a collective measure. These 
      are: language used about GP, proportion of curriculum time spent by students in
      GP, accurate representation of the clinical content of GP and equity of funding
      between hospital and GP placements. Furthermore, we discuss the key ethical and
      legal challenges that are faced by medical schools and, indeed, healthcare
      settings, that need to be overcome to enable proactive measurement and management
      of denigration.
FAU - Allsopp, G
AU  - Allsopp G
AD  - Primary Care Education Unit, Division of Primary Care, University of Nottingham ,
      Nottingham, UK.
FAU - Rosenthal, J
AU  - Rosenthal J
AUID- ORCID: 0000-0002-7649-2940
AD  - Department of Primary Care & Population Health, University College London ,
      London, UK.
FAU - Blythe, J
AU  - Blythe J
AD  - Barts and the London Medical School, Queen Mary University of London , London,
      UK.
FAU - Taggar, J S
AU  - Taggar JS
AUID- ORCID: 0000-0002-5031-0977
AD  - Primary Care Education Unit, Division of Primary Care, University of Nottingham ,
      Nottingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - England
TA  - Educ Prim Care
JT  - Education for primary care : an official publication of the Association of Course
      Organisers, National Association of GP Tutors, World Organisation of Family
      Doctors
JID - 101141280
SB  - IM
CIN - Educ Prim Care. 2020 Nov;31(6):387. PMID: 32544006
CIN - Educ Prim Care. 2021 Jul;32(4):253. PMID: 32856567
MH  - Attitude of Health Personnel
MH  - *Career Choice
MH  - Curriculum
MH  - General Practice/*education
MH  - Humans
MH  - Schools, Medical/organization & administration
MH  - State Medicine
MH  - Students, Medical/*psychology
MH  - United Kingdom
OTO - NOTNLM
OT  - *Denigration
OT  - *general practice
OT  - *medical education
EDAT- 2020/05/22 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1080/14739879.2020.1768440 [doi]
PST - ppublish
SO  - Educ Prim Care. 2020 Jul;31(4):205-209. doi: 10.1080/14739879.2020.1768440. Epub 
      2020 May 21.


PMID- 32436463
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - The implementation of child rights in healthcare services.
PG  - 1517-1528
LID - 10.1177/0969733020922883 [doi]
AB  - BACKGROUND: Hospitalized children have the right to "partake in practices related
      to their treatment and care." Midwives and nurses have important roles and
      responsibilities regarding the protection and enforcement of these rights, such
      as providing information and advocating for children. OBJECTIVES: This study aims
      to determine the attitudes of midwives and nurses toward their roles and
      responsibilities in the implementation of child rights in healthcare services and
      the factors affecting their attitudes. METHODS: This descriptive cross-sectional 
      study included 122 midwives and nurses in total. The data were collected through 
      a questionnaire. ETHICAL CONSIDERATIONS: Written permission was obtained from an 
      ethics committee in the center of the city where the research was conducted.
      RESULTS: The mean age of the participants was 36.70 +/- 8.03 years; 58.9% of
      midwives and nurses stated that they understood the child's consent about the
      treatment by looking at the child's facial expression; 36% of midwives and nurses
      stated that children could not participate in decisions regarding their own
      health. It was observed that obtaining the child's consent in matters related to 
      treatment does not make any difference between midwives and nurses. The rate of
      the midwives stating that they would report suspicious violence-neglect and abuse
      was found to be higher. CONCLUSION: The variables of the unit of employment, the 
      state of having children, choosing the profession and practicing in it willingly,
      and getting training on children's rights make a difference in terms of
      children's rights in healthcare services. Midwives and nurses should be reminded 
      of child rights in healthcare services through regular in-service training
      programs.
FAU - Yigitbas, Cagla
AU  - Yigitbas C
AUID- ORCID: https://orcid.org/0000-0002-3789-1156
AD  - 187438Giresun University, Turkey.
FAU - Top, Fadime Ustuner
AU  - Top FU
AD  - 187438Giresun University, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Ethics, Nursing
MH  - Female
MH  - Human Rights/*ethics/legislation & jurisprudence/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nurses/psychology
MH  - Pediatric Nursing/*ethics/methods
MH  - Surveys and Questionnaires
MH  - Turkey
OTO - NOTNLM
OT  - Attitudes
OT  - child rights
OT  - healthcare services
OT  - limitations
OT  - midwives
OT  - nurses
EDAT- 2020/05/22 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1177/0969733020922883 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1517-1528. doi: 10.1177/0969733020922883. Epub 2020
      May 21.


PMID- 32436431
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - Relational influences on experiences with assisted dying: A scoping review.
PG  - 1501-1516
LID - 10.1177/0969733020921493 [doi]
AB  - BACKGROUND: Family members and healthcare providers play an integral role in a
      person's assisted dying journey. Their own needs during the assisted dying
      journey are often, however, unrecognized and underrepresented in policies and
      guidelines. Circumstances under which people choose assisted dying, and
      relational contexts such as the sociopolitical environment, may influence the
      experiences of family members and healthcare providers. ETHICAL CONSIDERATIONS:
      Ethics approval was not required to conduct this review. AIM: This scoping review
      aims to identify the relational influences on the experiences of family members
      and healthcare providers of adults who underwent assisted dying and of those
      unable to access assisted dying due to the loss of capacity to consent. METHODS: 
      A literature search was conducted in four databases, including MEDLINE, EMBASE,
      Cumulative Index to Nursing and Allied Health Literature (CINAHL) and PsycINFO.
      The search retrieved 12,074 articles, a number narrowed down to 172 articles for 
      full-text screening. Thirty-six articles met the established inclusion criteria. 
      A feminist relational framework guided the data analysis. RESULTS: Five key
      themes on the influences of family members' and healthcare providers' experiences
      throughout the assisted dying process were synthesized from the data. They
      include (1) relationships as central to beginning the process, (2) social and
      political influences on decision making, (3) complex roles and responsibilities
      of family members and healthcare providers, (4) a unique experience of death, and
      (5) varying experiences following death. CONCLUSION: The feminist relational
      lens, used to guide analysis, shed light on the effect of the sociopolitical
      influences and the relationships among patients, families, and healthcare
      providers on each other's experiences. Addressing the needs of the family members
      and healthcare providers is vital to improving the assisted dying process.
      Including families' and healthcare providers' needs within institutional policies
      and enhancing collaboration and communication among those involved could improve 
      the overall experience.
FAU - Variath, Caroline
AU  - Variath C
AUID- ORCID: https://orcid.org/0000-0002-8149-0384
FAU - Peter, Elizabeth
AU  - Peter E
FAU - Cranley, Lisa
AU  - Cranley L
AD  - 7938University of Toronto, Canada.
FAU - Godkin, Dianne
AU  - Godkin D
FAU - Just, Danielle
AU  - Just D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200521
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Family Relations/*psychology
MH  - Humans
MH  - Personal Satisfaction
MH  - Professional-Patient Relations
MH  - Quality of Health Care/standards
MH  - Suicide, Assisted/ethics/*psychology
OTO - NOTNLM
OT  - Assisted dying
OT  - euthanasia
OT  - family
OT  - healthcare providers
OT  - relational influences
OT  - scoping review
EDAT- 2020/05/22 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1177/0969733020921493 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1501-1516. doi: 10.1177/0969733020921493. Epub 2020
      May 21.


PMID- 32436429
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov
TI  - Midwifery students' reactions to ethical dilemmas encountered in outpatient
      clinics.
PG  - 1542-1555
LID - 10.1177/0969733020922875 [doi]
AB  - BACKGROUND: Midwives are required to make ethical decisions with the support of
      respective codes of professional ethics which provide a framework for decision
      making in clinical practice. While each midwife should be ethically aware and
      sensitive to the ever-changing issues within reproduction, few empirical studies 
      have examined the views of student midwives in relation to reproductive ethical
      dilemmas. OBJECTIVE: The aim of this study was to explore midwifery students'
      reactions to a number of ethical dilemmas relating to women's experiences of
      reproductive decision making. DESIGN: A series of focus groups were conducted
      with midwifery students who were asked to discuss five culturally significant
      scenarios including issues of knowledge acquisition regarding methods of family
      planning, removal or insertion of an intrauterine device, and abortion. SETTING: 
      A University in Turkey was the setting for this study. PARTICIPANTS: Purposeful
      sampling was adopted which resulted in five focus groups with a total of 57
      midwifery students. ETHICAL CONSIDERATIONS: The study was reviewed and granted
      formal ethical approval by an ethical committee at the Faculty of Health Science 
      in Ataturk University. The head of the Faculty of Health Science approved the
      investigation. The participants received both oral and written information about 
      the study and they gave their consent. RESULTS: Five themes were identified from 
      the analysis of the focus group data related to all five scenarios. These themes 
      were 'the right to information', 'choice and protection', 'parental rights and
      welfare of the women', 'make a decision' and 'women rights and sexual abuse'.
      CONCLUSION: This study has shown that while students respected women's choice,
      they also expressed great ambivalence in some situations when personal values
      conflict with dominant societal beliefs and professional ethics. A focus on
      ethics education to include human rights is suggested as a means to enable
      students to explore their own social-value judgements, and as a means to limit
      the possible development of ethical confusion and moral distress.
FAU - Ejder Apay, Serap
AU  - Ejder Apay S
FAU - Gurol, Ayse
AU  - Gurol A
AUID- ORCID: https://orcid.org/0000-0002-7408-5428
FAU - Gur, Elif Yagmur
AU  - Gur EY
AD  - 37503Ataturk University, Turkey.
FAU - Church, Sarah
AU  - Church S
AD  - 4914London South Bank University, UK; Barts Health, UK.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Ambulatory Care Facilities/organization & administration/statistics & numerical
      data
MH  - Female
MH  - Focus Groups/methods
MH  - Humans
MH  - Male
MH  - Nurse Midwives/psychology/statistics & numerical data
MH  - Qualitative Research
MH  - Students, Nursing/*psychology/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Turkey
MH  - Young Adult
OTO - NOTNLM
OT  - Ethical dilemma
OT  - midwifery
OT  - reproduction
OT  - students
EDAT- 2020/05/22 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1177/0969733020922875 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Nov;27(7):1542-1555. doi: 10.1177/0969733020922875. Epub 2020
      May 21.


PMID- 32436251
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20220716
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 191
IP  - 3
DP  - 2020 Nov
TI  - Triage tool for the rationing of blood for massively bleeding patients during a
      severe national blood shortage: guidance from the National Blood Transfusion
      Committee.
PG  - 340-346
LID - 10.1111/bjh.16736 [doi]
AB  - The emerging COVID-19 pandemic has overwhelmed healthcare resources worldwide,
      and for transfusion services this could potentially result in rapid imbalance
      between supply and demand due to a severe shortage of blood donors. This may
      result in insufficient blood components to meet every patient's needs resulting
      in difficult decisions about which patients with major bleeding do and do not
      receive active transfusion support. This document, which was prepared on behalf
      of the National Blood Transfusion Committee in England, provides a framework and 
      triage tool to guide the allocation of blood for patients with massive
      haemorrhage during severe blood shortage. Its goal is to provide blood
      transfusions in an ethical, fair, and transparent way to ensure that the greatest
      number of life years are saved. It is based on an evidence- and ethics-based
      Canadian framework, and would become operational where demand for blood greatly
      exceeds supply, and where all measures to manage supply and demand have been
      exhausted. The guidance complements existing national shortage plans for red
      cells and platelets.
CI  - (c) 2020 The Authors. British Journal of Haematology published by British Society
      for Haematology and John Wiley & Sons Ltd.
FAU - Doughty, Heidi
AU  - Doughty H
AD  - NHS Blood & Transplant, Watford, UK.
FAU - Green, Laura
AU  - Green L
AD  - NHS Blood & Transplant, Watford, UK.
AD  - Barts Health, London, UK.
AD  - Blizard Institute, Queen Mary University of London, London, UK.
FAU - Callum, Jeannie
AU  - Callum J
AD  - Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
AD  - University of Toronto, Toronto, ON, Canada.
FAU - Murphy, Michael F
AU  - Murphy MF
AUID- ORCID: https://orcid.org/0000-0002-2375-7503
AD  - NHS Blood & Transplant, Watford, UK.
AD  - Oxford University Hospitals, Oxford, UK.
AD  - University of Oxford, Oxford, UK.
CN  - National Blood Transfusion Committee
LA  - eng
PT  - Letter
PT  - Practice Guideline
DEP - 20200520
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
SB  - IM
MH  - *Betacoronavirus
MH  - Blood Banks/*methods/standards
MH  - Blood Donors/*supply & distribution
MH  - Blood Transfusion/methods
MH  - Bloodless Medical and Surgical Procedures
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Disaster Planning
MH  - Health Care Rationing/ethics/*methods/standards
MH  - Hemorrhage/epidemiology/therapy
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Triage/ethics/*methods/standards
MH  - United Kingdom/epidemiology
PMC - PMC7280686
OTO - NOTNLM
OT  - National Blood Transfusion Committee
OT  - blood shortage
OT  - guidance
OT  - massive bleeding
OT  - triage
EDAT- 2020/05/22 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1111/bjh.16736 [doi]
PST - ppublish
SO  - Br J Haematol. 2020 Nov;191(3):340-346. doi: 10.1111/bjh.16736. Epub 2020 May 20.


PMID- 32436167
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20220531
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Why Do Firms Implement Responsible Innovation? The Case of Emerging Technologies 
      in South Korea.
PG  - 2663-2692
LID - 10.1007/s11948-020-00224-2 [doi]
AB  - With the rise of responsible innovation (RI) initiatives in firms that
      commercialize innovation in recent years, experts have argued that in order for
      RI to succeed, practical issues must be considered. Accordingly, this paper
      explores RI from the perspective of Korean emerging technology development firms.
      Although social benefits are expected from RI, which aims to reduce the side
      effects of innovations for society, the implementation of RI requires changing
      firms' existing rules and routines. Therefore, predicting benefits and costs from
      the firm's perspective can shed light on the likelihood that RI will succeed. In 
      this study, through an expert survey, the relative weights of RI-related benefit 
      criteria (technological level, economic performance, and public contribution) and
      cost criteria (anticipation, reflexivity, inclusion, and responsiveness) were
      analyzed. On this basis, trends in priorities for RI levels were evaluated from
      present and future perspectives. Unexpectedly, firms recognized that even if
      constraints such as RI impose greater costs, they will eventually bring greater
      benefits. This finding indicates that innovation induced by RI overcomes
      obstacles, offsets costs, and then finally increases firms' competitiveness, and 
      that firms are willing to do good for society through RI. In the long term, a
      firm's ethical activities may eventually result in improved performance by its
      management. Therefore, it can be concluded that, even if RI is enforced in a
      compulsory manner, it is highly likely that it can be well established and
      promoted even in firms that consider profit first.
FAU - Ko, Eunok
AU  - Ko E
AUID- ORCID: http://orcid.org/0000-0003-4516-7501
AD  - Korea Evaluation Institute of Industrial Technology (KEIT), Cheomdan-Ro 8-Gil,
      Dong-Gu, Daegu, 701-300, Republic of Korea. eunriver@snu.ac.kr.
AD  - Technology Management, Economics and Policy Program (TEMEP), College of
      Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826,
      Republic of Korea. eunriver@snu.ac.kr.
FAU - Kim, Yeonbae
AU  - Kim Y
AD  - Technology Management, Economics and Policy Program (TEMEP), College of
      Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826,
      Republic of Korea.
AD  - Graduate School of Engineering Practice, Seoul National University, 1 Gwanak-ro, 
      Gwanak-gu, Seoul, 08826, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Humans
MH  - *Inventions/ethics
MH  - Republic of Korea
MH  - Social Responsibility
OTO - NOTNLM
OT  - *Analytical hierarchy process
OT  - *Corporate social responsibility
OT  - *Emerging technology
OT  - *Ethics
OT  - *Regulation
OT  - *Responsible innovation
EDAT- 2020/05/22 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/05/09 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1007/s11948-020-00224-2 [doi]
AID - 10.1007/s11948-020-00224-2 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2663-2692. doi: 10.1007/s11948-020-00224-2. Epub
      2020 May 20.


PMID- 32435926
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1432-1084 (Electronic)
IS  - 0938-7994 (Linking)
VI  - 30
IP  - 9
DP  - 2020 Sep
TI  - Radiology reporting of osteoporotic vertebral fragility fractures on computed
      tomography studies: results of a UK national audit.
PG  - 4713-4723
LID - 10.1007/s00330-020-06845-2 [doi]
AB  - OBJECTIVES: To evaluate organisational reporting infrastructure and
      patient-related reporting data in the diagnosis of vertebral fragility fractures 
      (VFFs) as demonstrated on computed tomography (CT). METHODS: Organisational and
      patient-specific questionnaires were developed by consensus between The Royal
      College of Radiologists, the Royal College of Physicians, and the Royal
      Osteoporosis Society. The patient-specific component of the audit involved
      analysis of CT reporting data acquired from 50 consecutive non-traumatic studies 
      including the thoracolumbar spine. Ethical approval for this type of study is not
      required in the UK. All UK radiology departments with an audit lead (auditor)
      registered with The Royal College of Radiologists (RCR) were invited to
      participate in this retrospective audit. RESULTS: In total, 127 out of 202
      departments (63%) supplied data to the study, with inclusion of 6357 patients.
      Overall, 1362/6357 patients (21.4%) had a fracture present on auditor review of
      the CT imaging. There was a lack of compliance with all audit standards: 79% of
      reports commented on the vertebrae (target 100%), fracture severity was mentioned
      in 26.2% (target 100%), the recommended terminology 'vertebral fracture' was used
      in 60.1% (target 100%), and appropriate onward referral was recommended in 2.6%
      (target 100%). CONCLUSIONS: The findings from this study should be used to
      provide impetus to improve the diagnosis and care for patients with osteoporotic 
      VFFs. Solutions are multifactorial, but radiologist and local
      osteoporosis/fracture liaison service engagement is fundamental, combined with
      necessary development of electronic report notification systems and expansion of 
      supporting fracture services. KEY POINTS: * Early detection and diagnosis of
      vertebral fragility fractures (VFFs) significantly reduce patient morbidity and
      mortality. This study describes the results of a retrospective UK-wide audit
      evaluating current radiology reporting practice in the opportunistic diagnosis of
      VFFs as demonstrated on computed tomography (CT) studies including the spine. *
      Key audit standards included comment made on bone integrity in primary report
      (target 100%), comment made on severity of fractures (90%), report used
      recommended terminology 'fracture' (100%), and report made appropriate
      recommendations for referral/further assessment (100%). The audit results
      demonstrated a lack of compliance with all audit standards; lack of compliance
      was most marked in the use of recommended terminology (achieved 60.3%), in
      relation to comment on fracture severity (achieved 26.2%) and for recommendation 
      for referral/further assessment (achieved 2.6%). * Solutions are challenging and 
      multifactorial but the opportunity exists for all radiologists to examine their
      practice and directly improve patient care.
FAU - Howlett, David C
AU  - Howlett DC
AD  - Eastbourne Hospital, Eastbourne, UK.
FAU - Drinkwater, Karl J
AU  - Drinkwater KJ
AD  - The Royal College of Radiologists, 63 Lincoln's Inn Fields, London, WC2A 3JW, UK.
      karl_drinkwater@rcr.ac.uk.
FAU - Mahmood, Nadia
AU  - Mahmood N
AD  - Eastbourne Hospital, Eastbourne, UK.
FAU - Illes, Jozsef
AU  - Illes J
AD  - Dorset County Hospital, Dorchester, UK.
FAU - Griffin, Jill
AU  - Griffin J
AD  - The Royal Osteoporosis Society, Bath, UK.
FAU - Javaid, Kassim
AU  - Javaid K
AD  - The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
      Sciences, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Germany
TA  - Eur Radiol
JT  - European radiology
JID - 9114774
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Records/*standards
MH  - Osteoporotic Fractures/*diagnostic imaging
MH  - Radiography
MH  - Radiology Department, Hospital/*organization & administration
MH  - Retrospective Studies
MH  - Spinal Fractures/*diagnostic imaging
MH  - Tomography, X-Ray Computed
MH  - United Kingdom
OTO - NOTNLM
OT  - Osteoporosis
OT  - Osteoporotic fractures
OT  - Radiology
OT  - Tomography, X-ray computed
EDAT- 2020/05/22 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - 10.1007/s00330-020-06845-2 [doi]
AID - 10.1007/s00330-020-06845-2 [pii]
PST - ppublish
SO  - Eur Radiol. 2020 Sep;30(9):4713-4723. doi: 10.1007/s00330-020-06845-2. Epub 2020 
      May 20.


PMID- 32435810
OWN - NLM
STAT- Publisher
LR  - 20200521
IS  - 1744-5019 (Electronic)
IS  - 0360-5310 (Linking)
DP  - 2020 May 21
TI  - Bioethics and the Rule of Law: A Classical Liberal Theory.
LID - jhaa002 [pii]
LID - 10.1093/jmp/jhaa002 [doi]
AB  - Heated debates over healthcare policy in the United States point to the need for 
      a legal framework that can sustain both moral diversity and peaceful cooperation.
      It is argued that the classical liberal Rule of Law, with its foundation in the
      ethical principle of permission, is such a framework. The paper shows to what
      extent the current healthcare policy landscape in the United States diverges from
      the rule of law and suggests how the current framework could be modified in order
      to better approximate that ideal. Two objections are then answered. The first is 
      that the rule of law cannot be realized due to the structure of legislatures. The
      second objection is that government should guarantee both liberty and all of the 
      necessary conditions of autonomy.
CI  - (c) The Author(s) 2020. Published by Oxford University Press, on behalf of the
      Journal of Medicine and Philosophy Inc. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Brodrick, Michael
AU  - Brodrick M
AD  - Institute for Humane Studies at George Mason University, Arlington, Virginia,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200521
PL  - United States
TA  - J Med Philos
JT  - The Journal of medicine and philosophy
JID - 7610512
SB  - IM
OTO - NOTNLM
OT  - rule of law
OT  - autonomy
OT  - healthcare policy
OT  - liberty
OT  - permission
EDAT- 2020/05/22 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
AID - 5841387 [pii]
AID - 10.1093/jmp/jhaa002 [doi]
PST - aheadofprint
SO  - J Med Philos. 2020 May 21. pii: 5841387. doi: 10.1093/jmp/jhaa002.


PMID- 32435576
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2196-7865 (Print)
IS  - 2196-7865 (Linking)
VI  - 9
IP  - 2
DP  - 2020
TI  - The Role of Healthcare Robotics in Providing Support to Older Adults: a
      Socio-ecological Perspective.
PG  - 82-89
LID - 10.1007/s13670-020-00314-w [doi]
AB  - PURPOSE OF REVIEW: In this review, we provide an overview of how healthcare
      robotics can facilitate healthy aging, with an emphasis on physical, cognitive,
      and social supports. We next provide a synthesis of future challenges and
      considerations in the development and application of healthcare robots. We
      organize these considerations using a socio-ecological perspective and discuss
      considerations at the individual, care partner, community healthcare, and
      healthcare policy levels. RECENT FINDINGS: Older adults are the fastest growing
      segment of the US population. Age-related changes and challenges can present
      difficulties, for older adults want to age healthily and maintain independence.
      Technology, specifically healthcare robots, has potential to provide health
      supports to older adults. These supports span widely across the physical,
      cognitive, and social aspects of healthy aging. SUMMARY: Our review suggests that
      while healthcare robotics has potential to revolutionize the way in which older
      adults manage their health, there are many challenges such as clinical
      effectiveness, technology acceptance, health informatics, and healthcare policy
      and ethics. Addressing these challenges at all levels of the healthcare system
      will help ensure that healthcare robotics promote healthy aging and are applied
      safely, effectively, and reliably.
CI  - (c) Springer Science+Business Media, LLC, part of Springer Nature 2020.
FAU - Mois, George
AU  - Mois G
AD  - 1School of Social Work, University of Georgia, 279 Williams St, Athens, GA 30602 
      USA.grid.213876.90000 0004 1936 738X
FAU - Beer, Jenay M
AU  - Beer JM
AD  - 1School of Social Work, University of Georgia, 279 Williams St, Athens, GA 30602 
      USA.grid.213876.90000 0004 1936 738X
AD  - 2Institute of Gerontology, University of Georgia, 102 Spear Road, Athens, GA
      30606 USA.grid.213876.90000 0004 1936 738X
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200310
PL  - United States
TA  - Curr Geriatr Rep
JT  - Current geriatrics reports
JID - 101631056
PMC - PMC7223616
OTO - NOTNLM
OT  - Aging in place
OT  - Healthcare robotics
OT  - Healthy aging
OT  - Robotics
OT  - Socio-ecological model
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/05/22 06:00
MHDA- 2020/05/22 06:01
CRDT- 2020/05/22 06:00
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/05/22 06:01 [medline]
AID - 10.1007/s13670-020-00314-w [doi]
AID - 314 [pii]
PST - ppublish
SO  - Curr Geriatr Rep. 2020;9(2):82-89. doi: 10.1007/s13670-020-00314-w. Epub 2020 Mar
      10.


PMID- 32435274
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1752-1505 (Print)
IS  - 1752-1505 (Linking)
VI  - 14
DP  - 2020
TI  - Conducting operational research in humanitarian settings: is there a shared path 
      for humanitarians, national public health authorities and academics?
PG  - 25
LID - 10.1186/s13031-020-00280-2 [doi]
AB  - In humanitarian contexts, it is a difficult and multi-faceted task to enlist
      academics, humanitarian actors and health authorities in a collaborative research
      effort. The lack of research in such settings has been widely described in the
      past decade, but few have analysed the challenges in building strong and balanced
      research partnerships. The major issues include considering operational
      priorities, ethical imperatives and power differentials. This paper analyses in
      two steps a collaborative empirical endeavour to assess health service
      utilization by Syrian refugee and Lebanese women undertaken by the International 
      Committee of the Red Cross (ICRC), the Lebanese Ministry of Public Health (MoPH) 
      and the Harvard Francois-Xavier Bagnoud (FXB) Center. First, based on challenges 
      documented in the literature, we shed light on how we negotiated appropriate
      research questions, methodologies, bias analyses, resource availability,
      population specificities, security, logistics, funding, ethical issues and
      organizational cultures throughout the partnership. Second, we describe how the
      negotiations required each partner to go outside their comfort zones. For the
      academics, the drivers to engage included the intellectual value of the
      collaboration, the readiness of the operational partners to conduct an empirical 
      investigation and the possibility that such work might lead to a better
      understanding in public health terms of how the response met population needs.
      For actors responding to the humanitarian crisis (the ICRC and the MOPH),
      participating in a technical collaboration permitted methodological issues to be 
      worked through in the context of deliberations within the wider epistemic
      community. We find that when they collaborate, academics, humanitarian actors and
      health authorities deploy their respective complementarities to build a more
      comprehensive approach. Barriers such as the lack of uptake of research results
      or weak links to the existing literature were overcome by giving space to define 
      research questions and develop a longer-term collaboration involving individual
      and institutional learning. There is the need ahead of time to create balanced
      decision-making mechanisms, allow for relative financial autonomy, and define
      organizational responsibilities. Ultimately, mutual respect, trust and the
      recognition of each other's expertise formed the basis of an initiative that
      served to better understand populations affected by conflict and meet their
      needs.
CI  - (c) The Author(s) 2020.
FAU - Leresche, Enrica
AU  - Leresche E
AUID- ORCID: 0000-0003-4743-5821
AD  - International Committee of the Red Cross Delegation, Beirut, Lebanon.
FAU - Truppa, Claudia
AU  - Truppa C
AD  - International Committee of the Red Cross Delegation, Beirut, Lebanon.
FAU - Martin, Christophe
AU  - Martin C
AD  - International Committee of the Red Cross Delegation, Beirut, Lebanon.
FAU - Marnicio, Ariana
AU  - Marnicio A
AD  - 2Harvard TH Chan School of Public Health, Boston,
      USA.grid.38142.3c000000041936754X
FAU - Rossi, Rodolfo
AU  - Rossi R
AD  - 3International Committee of the Red Cross, Geneva, Switzerland.grid.482030.d0000 
      0001 2195 1479
FAU - Zmeter, Carla
AU  - Zmeter C
AD  - International Committee of the Red Cross Delegation, Beirut, Lebanon.
FAU - Harb, Hilda
AU  - Harb H
AD  - 4Lebanese Ministry of Public Health, Beirut, Lebanon.grid.490673.f
FAU - Hamadeh, Randa Sami
AU  - Hamadeh RS
AD  - 4Lebanese Ministry of Public Health, Beirut, Lebanon.grid.490673.f
FAU - Leaning, Jennifer
AU  - Leaning J
AD  - Harvard Francois Xavier Bagnoud Center for Health and Human Rights, Boston, USA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - England
TA  - Confl Health
JT  - Conflict and health
JID - 101286573
PMC - PMC7222467
OTO - NOTNLM
OT  - Co-production
OT  - Evidence-based humanitarian action
OT  - Humanitarian response
OT  - Operational research
OT  - Protracted crisis
OT  - Research partnership
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/05/22 06:00
MHDA- 2020/05/22 06:01
CRDT- 2020/05/22 06:00
PHST- 2019/11/27 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/05/22 06:01 [medline]
AID - 10.1186/s13031-020-00280-2 [doi]
AID - 280 [pii]
PST - epublish
SO  - Confl Health. 2020 May 13;14:25. doi: 10.1186/s13031-020-00280-2. eCollection
      2020.


PMID- 32435220
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Sense-Making, Meaningfulness, and Instrumental Music Education.
PG  - 837
LID - 10.3389/fpsyg.2020.00837 [doi]
AB  - The purpose of this paper is to re-examine the nature of "meaning" and
      "meaningfulness" in the context of instrumental music education. By doing so, I
      propose to expand the ways in which instrumental music educators conceive their
      mission and the ways in which we may instill meaning in people's lives.
      Traditionally, pursuits of philosophical deliberation have claimed that
      meaningfulness comes from either personal happiness (e.g., Jeremy Bentham and
      John Stuart Mill) or an impersonal sense of duty (e.g., St. Augustine, St. Thomas
      Aquinas, and Immanuel Kant). However, philosopher Wolf (2010) criticizes these
      positions in favor of a broader perspective, one that arises from understanding
      that there is a third sort of value, namely "meaningfulness." Rightly
      understanding meaningfulness may help us engage more fully with a greater sense
      and understanding of the full potentials of eudaimonia: a life of significance
      and value for oneself and one's community. Therefore, this paper links
      meaningfulness to a 4E (embodied, embedded, enacted, and extended) account of
      "sense-making" in/for instrumental music education. In doing so, I discuss the
      aims of public-school music education; aims that engage teachers and students in 
      meaningfulness-a meaningfulness that is ethical, embodied, enacted, and
      extended-in, with, and through musics and, more directly, "instrumental" music
      making.
CI  - Copyright (c) 2020 Silverman.
FAU - Silverman, Marissa
AU  - Silverman M
AD  - John J. Cali School of Music, Montclair State University, Montclair, NJ, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20200505
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7219105
OTO - NOTNLM
OT  - enaction and embodied cognition
OT  - eudaimonia (well being)
OT  - instrumental music teaching and learning
OT  - meaningfulness and motivation
OT  - sense-making
EDAT- 2020/05/22 06:00
MHDA- 2020/05/22 06:01
CRDT- 2020/05/22 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/05/22 06:01 [medline]
AID - 10.3389/fpsyg.2020.00837 [doi]
PST - epublish
SO  - Front Psychol. 2020 May 5;11:837. doi: 10.3389/fpsyg.2020.00837. eCollection
      2020.


PMID- 32434901
OWN - NLM
STAT- Publisher
LR  - 20200521
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 20
TI  - 'There is a lot of good in knowing, but there is also a lot of downs': public
      views on ethical considerations in population genomic screening.
LID - medethics-2019-105934 [pii]
LID - 10.1136/medethics-2019-105934 [doi]
AB  - Publics are key stakeholders in population genomic screening and their
      perspectives on ethical considerations are relevant to programme design and
      policy making. Using semi-structured interviews, we explored social views and
      attitudes towards possible future provision of personalised genomic risk
      information to populations to inform prevention and/or early detection of
      relevant conditions. Participants were members of the public (n=30) who had
      received information on their personal genomic risk of melanoma as part of a
      research project. The focus of the analysis presented here is participants' views
      regarding ethical considerations relevant to population genomic screening more
      generally. Data were analysed thematically and four key themes related to ethical
      considerations were identified: (i) personal responsibility for health:
      'forewarned is forearmed'; (ii) perceptions of, and responses to, genetic
      fatalism; (iii) implications for parenting and reproduction; (iv) divided views
      on choosing to receive genomic risk information. Ethical considerations
      underlying these themes include the valorisation of information and choice,
      paternalism, non-directiveness and increasing responsibilisation of individuals
      in health and healthcare. These findings arguably indicate a thin public
      conceptualisation of population genomic testing, which draws heavily on how these
      themes tend to be described in existing social discourses. Findings suggest that 
      further public engagement is required to increase complexity of debate, to
      consider (for example) the appropriate place of individual and social interests
      in population genomic testing. Further discernment of relevant ethical
      approaches, drawing on ethical frameworks from both public health and clinical
      settings, will also assist in determining the appropriate implementation of
      population genomic screening for complex conditions.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Smit, Amelia K
AU  - Smit AK
AUID- ORCID: http://orcid.org/0000-0001-5712-220X
AD  - Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health
      Ethics, The University of Sydney, Sydney, New South Wales, Australia.
AD  - Faculty of Medicine and Health, Sydney School of Public Health, Cancer
      Epidemiology and Prevention Research, The University of Sydney, Sydney, New South
      Wales, Australia.
AD  - Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Reyes-Marcelino, Gillian
AU  - Reyes-Marcelino G
AD  - Faculty of Medicine and Health, Sydney School of Public Health, Cancer
      Epidemiology and Prevention Research, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Keogh, Louise
AU  - Keogh L
AUID- ORCID: http://orcid.org/0000-0003-2963-6451
AD  - Melbourne School of Population and Global Health, The University of Melbourne,
      Melbourne, Victoria, Australia.
FAU - Cust, Anne E
AU  - Cust AE
AUID- ORCID: http://orcid.org/0000-0002-5331-6370
AD  - Faculty of Medicine and Health, Sydney School of Public Health, Cancer
      Epidemiology and Prevention Research, The University of Sydney, Sydney, New South
      Wales, Australia.
AD  - Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Newson, Ainsley J
AU  - Newson AJ
AUID- ORCID: http://orcid.org/0000-0002-3460-772X
AD  - Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health
      Ethics, The University of Sydney, Sydney, New South Wales, Australia
      AINSLEY.NEWSON@SYDNEY.EDU.AU.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - ethics
OT  - genetic screening/testing
OT  - population policy
OT  - public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/22 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/10/31 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
AID - medethics-2019-105934 [pii]
AID - 10.1136/medethics-2019-105934 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 20. pii: medethics-2019-105934. doi:
      10.1136/medethics-2019-105934.


PMID- 32434747
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210802
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 222
DP  - 2020 Aug 1
TI  - Ethical Considerations for Food and Beverage Warnings.
PG  - 112930
LID - S0031-9384(20)30244-4 [pii]
LID - 10.1016/j.physbeh.2020.112930 [doi]
AB  - Several countries have implemented warnings on unhealthy foods and beverages,
      with similar policies under consideration in the U.S. and around the world.
      Research demonstrating food warnings' effectiveness is emerging, but limited
      scholarship has evaluated the ethics of food warning policies. Using a public
      health ethics framework for evaluating obesity prevention policies, we assessed
      the ethical strengths and weaknesses of food warnings along multiple dimensions: 
      1) Health behaviors and physical health, 2) Psychosocial well-being, 3) Social
      and cultural values, 4) Informed choice, 5) Equality, 6) Attributions of
      responsibility, 7) Liberty, and 8) Privacy. Our analysis identifies both ethical 
      strengths and weaknesses of food warnings, including that: 1) warnings are likely
      to generate important benefits including increased consumer understanding and
      informed choice, healthier purchases, and potential reductions in obesity
      prevalence; 2) warnings evoke negative emotional reactions, but these reactions
      are an important mechanism through which food warnings encourage healthier
      behaviors and promote informed choice; 3) warnings appear unlikely to have
      ethically unacceptable effects on social and cultural values, attributions of
      responsibility, liberty, or privacy. Current research suggests we continue to
      pursue food warnings as a policy option for improving public health while
      simultaneously conducting additional research on the ethics of these policies.
      Future research is especially needed to clarify warnings' effects on stigma and
      to characterize the balance and distribution of costs of and benefits from
      implementing warning policies.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Grummon, Anna H
AU  - Grummon AH
AD  - Harvard Center for Population and Development Studies, Harvard TH Chan School of 
      Public Health. Address: 9 Bow Street, Room 306, Cambridge, MA, 02138, United
      States. Electronic address: agrummon@hsph.harvard.edu.
FAU - Hall, Marissa G
AU  - Hall MG
AD  - Department of Health Behavior, University of North Carolina Gillings School of
      Global Public Health, Lineberger Comprehensive Cancer Center, and UNC Center for 
      Health Promotion and Disease Prevention, University of North Carolina Chapel
      Hill. Address: 312 Rosenau Hall, 135 Dauer Drive, Chapel Hill, NC, 27599, United 
      States. Electronic address: mghall@unc.edu.
FAU - Block, Jason P
AU  - Block JP
AD  - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
      Health Care Institute. Address: 401 Park Drive, Suite 401 E, Boston, MA, 02215,
      United States. Electronic address: jblock1@partners.org.
FAU - Bleich, Sara N
AU  - Bleich SN
AD  - Department of Health Policy and Management, Harvard TH Chan School of Public
      Health, and Radcliffe Institute for Advanced Study. Address: 677 Huntington
      Avenue, Kresge 405, Boston, MA, 02115, United States. Electronic address:
      sbleich@hsph.harvard.edu.
FAU - Rimm, Eric B
AU  - Rimm EB
AD  - Department of Epidemiology and Department of Nutrition, Harvard TH Chan School of
      Public Health. Address: 655 Huntington Avenue, Building II Room 373a, Boston, MA,
      02115, United States. Electronic address: erimm@hsph.harvard.edu.
FAU - Taillie, Lindsey Smith
AU  - Taillie LS
AD  - Department of Nutrition, University of North Carolina Gillings School of Global
      Public Health, and Carolina Population Center, University of North Carolina
      Chapel Hill. Address: 123 W. Franklin St, Room 2107, Chapel Hill, NC, 27514,
      United States. Electronic address: taillie@unc.edu.
FAU - Barnhill, Anne
AU  - Barnhill A
AD  - Berman Institute of Bioethics, Johns Hopkins University, Deering Hall, 1809
      Ashland Avenue, Baltimore, MD, 21205, United States. Electronic address:
      anne.barnhill@gmail.com.
LA  - eng
GR  - K01 HL147713/HL/NHLBI NIH HHS/United States
GR  - P2C HD050924/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200511
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
MH  - *Beverages
MH  - Consumer Behavior
MH  - *Food
MH  - Humans
MH  - Obesity/prevention & control
MH  - Public Health
PMC - PMC7321920
MID - NIHMS1595320
OTO - NOTNLM
OT  - *Food and beverage warnings
OT  - *ethical considerations
OT  - *ethics
OT  - *health warnings
OT  - *obesity prevention
OT  - *warning labels
EDAT- 2020/05/22 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/22 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/22 06:00 [entrez]
AID - S0031-9384(20)30244-4 [pii]
AID - 10.1016/j.physbeh.2020.112930 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Aug 1;222:112930. doi: 10.1016/j.physbeh.2020.112930. Epub
      2020 May 11.


PMID- 32434553
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20200825
IS  - 2050-7283 (Electronic)
IS  - 2050-7283 (Linking)
VI  - 8
IP  - 1
DP  - 2020 May 20
TI  - Perceived leader integrity as a mediator between ethical leadership and ethical
      climate in a teaching context.
PG  - 52
LID - 10.1186/s40359-020-00420-6 [doi]
AB  - BACKGROUND: Scandalous incidents occurring in prominent organisations in the
      world have brought to limelight the role of leaders in shaping the ethical
      climate of their organisations. As a result, several studies across different
      organisational/occupational contexts and climes have examined and unanimously
      proven that ethical leadership was positively related to ethical climate.
      However, there is rarely any of these studies that was conducted in teaching
      context. Besides, the mechanisms involved between ethical leadership and ethical 
      climate seems not to have been addressed in literature. Thus, this paper reports 
      the findings of a study that investigated the mediating role of perceived leader 
      integrity in the ethical leadership-ethical climate relationship among teachers. 
      METHODS: Data were collected from 336 teachers (105 male and 231 female) in
      three-time periods using measures of ethical leadership, perceived leader
      integrity, ethical climate, and demographics. RESULTS: The results from OLS
      regression-based path analysis showed that: 1) ethical leadership was positively 
      related to perceived leader integrity, 2) perceived leader integrity was
      positively related to ethical climate, 3) ethical leadership was positively
      related to ethical climate, and 4) the positive relationship between ethical
      leadership and ethical climate was mediated by perceived leader integrity.
      CONCLUSIONS: The current study extends the social learning theory by identifying 
      perceived leader integrity as a mechanism underlying the relationship between
      ethical leadership and ethical climate. The findings have some implications for
      personnel selection especially in relation to selection of ethical leaders.
FAU - Enwereuzor, Ibeawuchi K
AU  - Enwereuzor IK
AUID- ORCID: http://orcid.org/0000-0003-2961-9483
AD  - Department of Psychology, University of Nigeria, Nsukka, Nsukka, 410001, Nigeria.
      ibeawuchi.enwereuzor@unn.edu.ng.
FAU - Onyishi, Ike E
AU  - Onyishi IE
AD  - Department of Psychology, University of Nigeria, Nsukka, Nsukka, 410001, Nigeria.
FAU - Albi-Oparaocha, Florence Chiji
AU  - Albi-Oparaocha FC
AD  - College of Medicine, Alex Ekwueme Federal University, Ndufu-Alike, Ikwo, P. M. B.
      1010, Abakaliki, Ebonyi State, Nigeria.
FAU - Amaeshi, Kenneth
AU  - Amaeshi K
AD  - University of Edinburgh Business School, University of Edinburgh, 29 Buccleuch
      Place, Edinburgh, EH8 9JS, UK.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - England
TA  - BMC Psychol
JT  - BMC psychology
JID - 101627676
SB  - IM
MH  - Adult
MH  - Educational Personnel/*psychology
MH  - *Ethics
MH  - Female
MH  - Humans
MH  - *Leadership
MH  - Male
MH  - Morals
MH  - *Organizational Culture
MH  - Teaching/*ethics
PMC - PMC7238651
OTO - NOTNLM
OT  - Ethical climate
OT  - Ethical leadership
OT  - Head teacher
OT  - Leader
OT  - Organisation
OT  - Perceived leader integrity
OT  - School
OT  - Teaching context
EDAT- 2020/05/22 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/05/22 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - 10.1186/s40359-020-00420-6 [doi]
AID - 10.1186/s40359-020-00420-6 [pii]
PST - epublish
SO  - BMC Psychol. 2020 May 20;8(1):52. doi: 10.1186/s40359-020-00420-6.


PMID- 34195542
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210702
IS  - 2515-4826 (Electronic)
IS  - 2515-4826 (Linking)
VI  - 3
DP  - 2020
TI  - The diagnostic and predictive accuracy of the PRISMA-7 screening tool for frailty
      in older adults: A systematic review protocol.
PG  - 26
LID - 10.12688/hrbopenres.13042.1 [doi]
AB  - Background: Older adults are at risk of adverse outcomes due to frailty. A number
      of frailty screening instruments have been developed to identify older adults at 
      increased risk of frailty. This systematic review and meta-analysis will look to 
      examine the diagnostic accuracy of the Program of Research to Integrate the
      Services for the Maintenance of Autonomy 7 (PRISMA-7). Methods and analysis: A
      systematic literature search will be conducted from 2008-February 2020 in PubMed,
      EMBASE, CINAHL, EBSCO and the Cochrane Library to identify validation studies of 
      the PRISMA-7 tool. A pre-specified PRISMA-7 score of >/=3 (maximum score 7
      points) will be used to identify frailty in older adults. Prospective or
      retrospective cohort studies, cross-sectional studies and the control arm of
      randomised controlled trials will be included that attempt to validate the
      diagnostic accuracy of the PRISMA-7 screening tool in older adults across all
      healthcare settings when compared to a reference standard. The predictive
      accuracy of the PRISMA-7 tool will also be explored. Study quality will be
      assessed by the QUADAS-2 tool. A bivariate random effects model will be used to
      generate pooled estimates of sensitivity and specificity. Statistical
      heterogeneity will be explored using validated methods. Ethics and dissemination:
      Formal ethical approval is not required as primary data will not be collected.
      The results will be disseminated through a peer-reviewed publication, conference 
      presentation and the popular press. Protocol registration: Awaiting registration 
      with the International Prospective Register for Systematic Reviews (PROSPERO).
CI  - Copyright: (c) 2020 Higginbotham O et al.
FAU - Higginbotham, Owen
AU  - Higginbotham O
AUID- ORCID: https://orcid.org/0000-0003-1414-3785
AD  - School of Allied Health, University of Limerick, Limerick, Co Limerick, V94 T9PX,
      Ireland.
FAU - O'Neill, Aoife
AU  - O'Neill A
AUID- ORCID: https://orcid.org/0000-0002-8670-6738
AD  - School of Allied Health, University of Limerick, Limerick, Co Limerick, V94 T9PX,
      Ireland.
FAU - Barry, Louise
AU  - Barry L
AUID- ORCID: https://orcid.org/0000-0001-8068-7479
AD  - School of Allied Health, University of Limerick, Limerick, Co Limerick, V94 T9PX,
      Ireland.
FAU - Leahy, Aoife
AU  - Leahy A
AUID- ORCID: https://orcid.org/0000-0003-2123-1513
AD  - School of Allied Health, University of Limerick, Limerick, Co Limerick, V94 T9PX,
      Ireland.
AD  - Department of Geriatric Medicine, University Hospital Limerick, Limerick, Co.
      Limerick, V94 F858, Ireland.
FAU - Robinson, Katie
AU  - Robinson K
AUID- ORCID: https://orcid.org/0000-0003-1008-9857
AD  - School of Allied Health, University of Limerick, Limerick, Co Limerick, V94 T9PX,
      Ireland.
FAU - O'Connor, Margaret
AU  - O'Connor M
AUID- ORCID: https://orcid.org/0000-0001-9984-9204
AD  - Department of Geriatric Medicine, University Hospital Limerick, Limerick, Co.
      Limerick, V94 F858, Ireland.
FAU - Galvin, Rose
AU  - Galvin R
AUID- ORCID: https://orcid.org/0000-0002-8171-224X
AD  - School of Allied Health, University of Limerick, Limerick, Co Limerick, V94 T9PX,
      Ireland.
LA  - eng
SI  - figshare/10.6084/m9.figshare.12229125
PT  - Journal Article
DEP - 20200522
PL  - Ireland
TA  - HRB Open Res
JT  - HRB open research
JID - 101754913
PMC - PMC8201424
OTO - NOTNLM
OT  - Frailty
OT  - PRISMA-7
OT  - diagnostic accuracy
OT  - older adults
OT  - predictive accuracy
OT  - review
OT  - sensitivity and specificity
COIS- No competing interests were disclosed.
EDAT- 2020/05/22 00:00
MHDA- 2020/05/22 00:01
CRDT- 2021/07/01 07:06
PHST- 2020/05/07 00:00 [accepted]
PHST- 2021/07/01 07:06 [entrez]
PHST- 2020/05/22 00:00 [pubmed]
PHST- 2020/05/22 00:01 [medline]
AID - 10.12688/hrbopenres.13042.1 [doi]
PST - epublish
SO  - HRB Open Res. 2020 May 22;3:26. doi: 10.12688/hrbopenres.13042.1. eCollection
      2020.


PMID- 32433782
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20220220
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jul
TI  - Utilitarianism and the pandemic.
PG  - 620-632
LID - 10.1111/bioe.12771 [doi]
AB  - There are no egalitarians in a pandemic. The scale of the challenge for health
      systems and public policy means that there is an ineluctable need to prioritize
      the needs of the many. It is impossible to treat all citizens equally, and a
      failure to carefully consider the consequences of actions could lead to massive
      preventable loss of life. In a pandemic there is a strong ethical need to
      consider how to do most good overall. Utilitarianism is an influential moral
      theory that states that the right action is the action that is expected to
      produce the greatest good. It offers clear operationalizable principles. In this 
      paper we provide a summary of how utilitarianism could inform two challenging
      questions that have been important in the early phase of the pandemic: (a)
      Triage: which patients should receive access to a ventilator if there is
      overwhelming demand outstripping supply? (b) Lockdown: how should countries
      decide when to implement stringent social restrictions, balancing preventing
      deaths from COVID-19 with causing deaths and reductions in well-being from other 
      causes? Our aim is not to argue that utilitarianism is the only relevant ethical 
      theory, or in favour of a purely utilitarian approach. However, clearly
      considering which options will do the most good overall will help societies
      identify and consider the necessary cost of other values. Societies may choose
      either to embrace or not to embrace the utilitarian course, but with a clear
      understanding of the values involved and the price they are willing to pay.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Savulescu, Julian
AU  - Savulescu J
AUID- ORCID: 0000-0003-1691-6403
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, United
      Kingdom of Great Britain and Northern Ireland.
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, United
      Kingdom of Great Britain and Northern Ireland.
AD  - Visiting Professorial Fellow in Biomedical Ethics, Biomedical Ethics Research
      Group, Murdoch Children's Research Institute, Melbourne, Australia.
AD  - Distinguished Visiting Professor in Law, Melbourne Law School, University of
      Melbourne, Melbourne, Victoria, Australia.
FAU - Persson, Ingmar
AU  - Persson I
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, United
      Kingdom of Great Britain and Northern Ireland.
AD  - Department of Philosophy, Linguistics and Theory of Science, Gothenburg
      University, Gothenburg, Sweden.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: 0000-0003-3958-8633
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, United
      Kingdom of Great Britain and Northern Ireland.
AD  - Wellcome Centre for Ethics and Humanities, University of Oxford, Oxford, United
      Kingdom of Great Britain and Northern Ireland.
AD  - John Radcliffe Hospital, Oxford, United Kingdom of Great Britain and Northern
      Ireland.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - WT203132/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Emergency Medical Services/ethics
MH  - *Ethical Theory
MH  - Humans
MH  - Pandemics/*ethics
MH  - Patient Rights/*ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - Social Justice/ethics
PMC - PMC7276855
OTO - NOTNLM
OT  - *COVID-19
OT  - *pandemic ethics
OT  - *resource allocation
OT  - *utilitarianism
EDAT- 2020/05/21 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/05/15 00:00 [revised]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1111/bioe.12771 [doi]
PST - ppublish
SO  - Bioethics. 2020 Jul;34(6):620-632. doi: 10.1111/bioe.12771.


PMID- 32433777
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20201218
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jul
TI  - Queries on the COVID-19 quick publishing ethics.
PG  - 633-634
LID - 10.1111/bioe.12772 [doi]
FAU - Agoramoorthy, Govindasamy
AU  - Agoramoorthy G
AUID- ORCID: 0000-0002-8936-6978
AD  - College of Pharmacy and Health Care, Tajen University, Yanpu, Pingtung, 907,
      Taiwan.
FAU - Hsu, Minna J
AU  - Hsu MJ
AD  - Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung,
      804, Taiwan.
FAU - Shieh, Pochuen
AU  - Shieh P
AD  - College of Pharmacy and Health Care, Tajen University, Yanpu, Pingtung, 907,
      Taiwan.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200601
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
CON - Bioethics. 2020 May;34(4):325-327. PMID: 32237085
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - Publishing
MH  - SARS-CoV-2
MH  - *Social Justice
MH  - *Triage
PMC - PMC7276831
EDAT- 2020/05/21 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1111/bioe.12772 [doi]
PST - ppublish
SO  - Bioethics. 2020 Jul;34(6):633-634. doi: 10.1111/bioe.12772. Epub 2020 Jun 1.


PMID- 32433690
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20200806
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Foodscape: A scoping review and a research agenda for food security-related
      studies.
PG  - e0233218
LID - 10.1371/journal.pone.0233218 [doi]
AB  - Since 1995, the term 'foodscape', a contraction of food and landscape, has been
      used in various research addressing social and spatial disparities in public
      health and food systems. This article presents a scoping review of the literature
      examining how this term is employed and framed. We searched publications using
      the term foodscape in the Web of Science Core Collection, MEDLINE, and Scopus
      databases. Analyzing 140 publications, we highlight four approaches to the
      foodscape: (i) Spatial approaches use statistics and spatial analysis to
      characterize the diversity of urban foodscapes and their impacts on diet and
      health, at city or neighborhood scales. (ii) Social and cultural approaches at
      the same scales show that foodscapes are socially shaped and highlight structural
      inequalities by combining qualitative case studies and quantitative surveys of
      food procurement practices. (iii) Behavioral approaches generally focus on indoor
      micro-scales, showing how consumer perceptions of foodscapes explain and
      determine food behaviors and food education. (iv) Systemic approaches contest the
      global corporate food regime and promote local, ethical, and sustainable food
      networks. Thus, although spatial analysis was the first approach to foodscapes,
      sociocultural, behavioral and systemic approaches are becoming more common. In
      the spatial approach, the term 'foodscape' is synonymous with 'food environment'.
      In the three other approaches, 'foodscape' and 'food environment' are not
      synonymous. Scholars consider that the foodscape is not an environment external
      to individuals but a landscape including, perceived, and socially shaped by
      individuals and policies. They share a systemic way of thinking, considering
      culture and experience of food as key to improving our understanding of how food 
      systems affect people. Foodscape studies principally address three issues: public
      health, social justice, and sustainability. The review concludes with a research 
      agenda, arguing that people-based and place-based approaches need to be combined 
      to tackle the complexity of the food-people-territory nexus.
FAU - Vonthron, Simon
AU  - Vonthron S
AUID- ORCID: 0000-0003-4283-3214
AD  - INNOVATION, Univ Montpellier, INRAE, CIRAD, Montpellier SupAgro, Montpellier,
      France.
FAU - Perrin, Coline
AU  - Perrin C
AUID- ORCID: 0000-0001-9914-0748
AD  - INNOVATION, Univ Montpellier, INRAE, CIRAD, Montpellier SupAgro, Montpellier,
      France.
FAU - Soulard, Christophe-Toussaint
AU  - Soulard CT
AD  - INNOVATION, Univ Montpellier, INRAE, CIRAD, Montpellier SupAgro, Montpellier,
      France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Food
MH  - *Food Supply
MH  - Humans
MH  - *Research
MH  - Urban Population
PMC - PMC7239489
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/21 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
AID - 10.1371/journal.pone.0233218 [doi]
AID - PONE-D-19-19932 [pii]
PST - epublish
SO  - PLoS One. 2020 May 20;15(5):e0233218. doi: 10.1371/journal.pone.0233218.
      eCollection 2020.


PMID- 32433384
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20210210
IS  - 1550-5022 (Electronic)
IS  - 1078-4659 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Jul/Aug
TI  - COVID-19: The Shift From Clinical to Public Health Ethics.
PG  - 306-309
LID - 10.1097/PHH.0000000000001204 [doi]
FAU - DeBruin, Debra
AU  - DeBruin D
AD  - Center for Bioethics, University of Minnesota, Minneapolis, Minnesota (Dr
      DeBruin); and Division of Health Policy and Management, University of Minnesota
      School of Public Health, Minneapolis, Minnesota (Dr Leider).
FAU - Leider, Jonathon P
AU  - Leider JP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Public Health Manag Pract
JT  - Journal of public health management and practice : JPHMP
JID - 9505213
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control/legislation & jurisprudence/methods
MH  - Coronavirus Infections/*epidemiology
MH  - Decision Making/ethics
MH  - Health Care Rationing/ethics/*organization & administration
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Public Health/*ethics/legislation & jurisprudence
MH  - SARS-CoV-2
MH  - United States
EDAT- 2020/05/21 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.1097/PHH.0000000000001204 [doi]
AID - 00124784-202007000-00003 [pii]
PST - ppublish
SO  - J Public Health Manag Pract. 2020 Jul/Aug;26(4):306-309. doi:
      10.1097/PHH.0000000000001204.


PMID- 32433136
OWN - NLM
STAT- MEDLINE
DCOM- 20201016
LR  - 20210209
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 31
IP  - 4
DP  - 2020 Jun
TI  - Three-Dimensional Bioprinting: Role in Craniomaxillary Surgery Ethics and Future.
PG  - 1114-1116
LID - 10.1097/SCS.0000000000006553 [doi]
AB  - Three-dimensional (3D) printing and bioprinting is gaining lot of momentum,
      especially in surgical specialties. These two technologies have wide array of
      applications in presurgical, surgical, and in vitro scenarios. Bioprinting can
      generate customized patient specific tissue engineered from specialized cells.
      This technology can be a gold standard in reconstructive and regenerative
      surgeries, if used in regulated and ethical environment. This communication
      focuses on basics of these technologies, their role in surgical specialties,
      ethical issues specific to these technologies, and its future.
FAU - Gupta, Nimish
AU  - Gupta N
AD  - Identity Ear Nose and Throat & Dental Center, Dehradun, India.
FAU - Agarwal, Shreya
AU  - Agarwal S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
MH  - *Bioprinting
MH  - Face/*surgery
MH  - Humans
MH  - Maxillary Diseases/*surgery
MH  - *Printing, Three-Dimensional
MH  - Reconstructive Surgical Procedures
MH  - Tissue Engineering/*ethics
EDAT- 2020/05/21 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1097/SCS.0000000000006553 [doi]
AID - 00001665-202006000-00054 [pii]
PST - ppublish
SO  - J Craniofac Surg. 2020 Jun;31(4):1114-1116. doi: 10.1097/SCS.0000000000006553.


PMID- 32433083
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 48
IP  - 6
DP  - 2020 Jun
TI  - Useful Ethics Committees: No Mandate Required.
PG  - 928-929
LID - 10.1097/CCM.0000000000004357 [doi]
FAU - Zivot, Joel B
AU  - Zivot JB
AD  - Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
SB  - IM
CON - Crit Care Med. 2020 Jun;48(6):847-853. PMID: 32317595
MH  - Ethics Committees
MH  - Ethics Committees, Research
MH  - *Ethics Consultation
MH  - Hospitals, Teaching
MH  - Policy
EDAT- 2020/05/21 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1097/CCM.0000000000004357 [doi]
AID - 00003246-202006000-00024 [pii]
PST - ppublish
SO  - Crit Care Med. 2020 Jun;48(6):928-929. doi: 10.1097/CCM.0000000000004357.


PMID- 32432992
OWN - NLM
STAT- MEDLINE
DCOM- 20210930
LR  - 20210930
IS  - 1949-0984 (Electronic)
IS  - 1949-0976 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Nov 9
TI  - An ethical investigation into the microbiome: the intersection of agriculture,
      genetics, and the obesity epidemic.
PG  - 1760712
LID - 10.1080/19490976.2020.1760712 [doi]
AB  - There is growing evidence of the interconnectivity between animals, humans, and
      the environment, which has manifested in the One Health perspective that takes
      all three into account for a more comprehensive vision of health. Over the past
      century, agriculture has become increasingly industrialized with a particular
      rise in the amount of livestock raised and meat produced. In order to fulfill
      such market demands, livestock farmers and agricultural corporations have
      artificially selected for and bred their cash animals to be more and more
      metabolically efficient via genetic and human-driven means. However, by selecting
      for more metabolically efficient animals, we may have inadvertently been
      selecting for obesogenic gut microbiota. This is further compounded by the
      potential obesogenic and microbiome-altering role antibiotics play in livestock. 
      Evidence suggests that there is the potential for interspecies gut microbe
      transmissibility. It is notable that there has been a concurrent multispecies
      obesity epidemic across the same timeframe, which raises questions about
      potential connections between these epidemics. If it is the case that humans have
      inadvertently influenced their own obesity epidemic via the artificial selection 
      of and antibiotic administration to livestock, then this holds significant
      ethical implications. This analysis considers current meat consumption trends,
      the impacts of livestock on climate change, and animal ethics. The paper
      concludes that due to the potential significant impact yet tenuous nature of the 
      evidence on this subject stemming from research silos, there is a definitive
      ethical impetus for researchers to bridge these silos to better understand the
      true nature of the issue. This case is emblematic of an overarching ethics-driven
      need for deeper collaboration between isolated but related research disciplines
      to better characterize issues of public health relevance. It also raises concerns
      regarding inherent value-driven strife that may arise between competing One
      Health domains.
FAU - Smith, Hunter Jackson
AU  - Smith HJ
AUID- ORCID: 0000-0002-3591-588X
AD  - Department of Preventive Medicine and Biostatistics, Uniformed Services
      University , Bethesda, MD, USA.
AD  - Johns Hopkins Berman Institute of Bioethics , Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - United States
TA  - Gut Microbes
JT  - Gut microbes
JID - 101495343
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Agriculture/*ethics
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology
MH  - Child
MH  - Child, Preschool
MH  - Diet
MH  - Female
MH  - *Food Preferences
MH  - Humans
MH  - Livestock/*microbiology
MH  - Male
MH  - Meat/microbiology
MH  - Middle Aged
MH  - Obesity/*microbiology/pathology
MH  - Young Adult
PMC - PMC7524164
OTO - NOTNLM
OT  - *Microbiome
OT  - *One Health
OT  - *agriculture
OT  - *antibiotics
OT  - *ethics
OT  - *livestock
OT  - *obesity
EDAT- 2020/05/21 06:00
MHDA- 2021/10/01 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/10/01 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1080/19490976.2020.1760712 [doi]
PST - ppublish
SO  - Gut Microbes. 2020 Nov 9;12(1):1760712. doi: 10.1080/19490976.2020.1760712. Epub 
      2020 May 20.


PMID- 32432406
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1552-4876 (Electronic)
IS  - 1552-4868 (Linking)
VI  - 184
IP  - 2
DP  - 2020 Jun
TI  - 41,XX(Y) * male mice: An animal model for Klinefelter syndrome.
PG  - 267-278
LID - 10.1002/ajmg.c.31796 [doi]
AB  - Klinefelter syndrome (KS, 47,XXY) is the most frequent male chromosomal
      aneuploidy resulting in a highly heterogeneous clinical phenotype associated with
      hormonal dysbalance, increased rate of co-morbidities, and reduced lifespan. Two 
      hallmarks of KS-affecting testicular functions are consistently observed:
      Hypergonadotropic hypogonadism and germ cell (GC) loss resulting in infertility. 
      Although KS is being studied for decades, the underlying mechanisms for the
      observed pathophysiology are still unclear. Due to ethical restrictions, studies 
      in humans are limited, and consequently, suitable animal models are needed to
      address the consequences of a supernumerary X chromosome. Mouse strains with
      comparable aneuploidies have been generated and yielded highly relevant insights 
      into KS. We briefly describe the establishment of the KS mouse models, summarize 
      the knowledge gained by their use, compare findings from the mouse models to
      those obtained in clinical studies, and also reflect on limitations of the
      currently used models derived from the B6Ei.Lt-Y* mouse strain, in which the Y
      chromosome is altered and its centromere position changed into a more distal
      location provoking meiotic non-disjunction. Breeding such as XY* males to XX
      females, the target 41,XX(Y) *, and 41,XXY males are generated. Here, we
      summarize features of both models but report in particular findings from our
      41,XX(Y) * mice including some novel data on Sertoli cell characteristics.
CI  - (c) 2020 The Authors. American Journal of Medical Genetics Part C: Seminars in
      Medical Genetics published by Wiley Periodicals, LLC.
FAU - Wistuba, Joachim
AU  - Wistuba J
AUID- ORCID: 0000-0001-9215-8582
AD  - Institute of Reproductive and Regenerative Biology, Centre of Reproductive
      Medicine and Andrology, University of Munster, Munster, Germany.
FAU - Beumer, Cristin
AU  - Beumer C
AD  - Institute of Reproductive and Regenerative Biology, Centre of Reproductive
      Medicine and Andrology, University of Munster, Munster, Germany.
FAU - Brehm, Ralph
AU  - Brehm R
AD  - Functional Histology and Cell Biology, Institute for Anatomy, University of
      Veterinary Medicine Hannover, Foundation, Hannover, Germany.
FAU - Gromoll, Jorg
AU  - Gromoll J
AD  - Institute of Reproductive and Regenerative Biology, Centre of Reproductive
      Medicine and Andrology, University of Munster, Munster, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200520
PL  - United States
TA  - Am J Med Genet C Semin Med Genet
JT  - American journal of medical genetics. Part C, Seminars in medical genetics
JID - 101235745
SB  - IM
MH  - *Aneuploidy
MH  - Animals
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Karyotyping
MH  - Klinefelter Syndrome/*genetics/pathology
MH  - Male
MH  - Mice
MH  - X Chromosome/*genetics
OTO - NOTNLM
OT  - *41,XXY* mouse
OT  - *Klinefelter syndrome
OT  - *Sertoli cell
OT  - *chromosomal imbalance
OT  - *germ cell loss
EDAT- 2020/05/21 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/03/21 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1002/ajmg.c.31796 [doi]
PST - ppublish
SO  - Am J Med Genet C Semin Med Genet. 2020 Jun;184(2):267-278. doi:
      10.1002/ajmg.c.31796. Epub 2020 May 20.


PMID- 32432400
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1365-3148 (Electronic)
IS  - 0958-7578 (Linking)
VI  - 30
IP  - 4
DP  - 2020 Aug
TI  - Utilising red cell antigen genotyping and serological phenotyping in sickle cell 
      disease patients to risk-stratify patients for alloimmunisation risk.
PG  - 263-274
LID - 10.1111/tme.12685 [doi]
AB  - BACKGROUND: Alloimmunisation and haemolytic transfusion reactions (HTRs) can
      occur in patients with sickle cell disease (SCD) despite providing
      phenotype-matched red blood cell (RBC) transfusions. Variant RBC antigen gene
      alleles/polymorphisms can lead to discrepancies in serological phenotyping. We
      evaluated differences between RBC antigen genotyping and phenotyping methods and 
      retrospectively assessed if partial antigen expression may lead to increased risk
      of alloimmunisation and HTRs in SCD patients at a tertiary centre in Canada.
      METHODS: RBC antigen phenotyping and genotyping were performed by a reference
      laboratory on consenting SCD patients. Patient demographic, clinical and
      transfusion-related data were obtained from a local transfusion registry and
      chart review after research ethics board approval. RESULTS: A total of 106 SCD
      patients were enrolled, and 91% (n = 96) showed additional clinically relevant
      genotyping information when compared to serological phenotyping alone. FY*02N.01 
      (FY*B GATA-1) (n = 95; 90%) and RH variant alleles (n = 52, 49%; majority
      accompanied by FY*02N.01) were common, the latter with putative partial antigen
      expression in 25 patients. Variability in genotype-phenotype antigen prediction
      occurred mostly in the Rh system, notably with the e antigen (kappa: 0.17).
      Fifteen (14.2%) patients had a history of alloimmunisation, with five having HTR 
      documented; no differences in clinical outcomes were found in patients with
      partial antigen expression. Genotype/extended-phenotype matching strategies may
      have prevented alloimmunisation events. CONCLUSION: We show a high frequency of
      variant alleles/polymorphisms in the SCD population, where genotyping may
      complement serological phenotyping. Genotyping SCD patients before transfusion
      may prevent alloimmunisation and HTRs, and knowledge of the FY*02N.01 variant
      allele increases feasibility of finding compatible blood.
CI  - (c) 2020 British Blood Transfusion Society.
FAU - Shih, Andrew W
AU  - Shih AW
AUID- ORCID: https://orcid.org/0000-0001-7107-2595
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Yan, Matthew T S
AU  - Yan MTS
AD  - Department of Pathology and Laboratory Medicine, University of British Columbia, 
      Vancouver, British Columbia, Canada.
AD  - Medical Services and Hospital Relations, Canadian Blood Services, Vancouver,
      British Columbia, Canada.
FAU - Elahie, Allahna L
AU  - Elahie AL
AD  - Hamilton Regional Laboratory Medicine Program, McMaster University, Hamilton,
      Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Barty, Rebecca L
AU  - Barty RL
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario,
      Canada.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario,
      Canada.
FAU - Berardi, Philip
AU  - Berardi P
AD  - Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa,
      Ontario, Canada.
AD  - Centre for Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
FAU - Azzam, Mona
AU  - Azzam M
AD  - Department of Pediatrics, Suez Canal University, Ismailia, Egypt.
FAU - Siddiqui, Reda
AU  - Siddiqui R
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Parvizian, Michael K
AU  - Parvizian MK
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario,
      Canada.
FAU - Mcdougall, Tara
AU  - Mcdougall T
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
FAU - Heddle, Nancy M
AU  - Heddle NM
AD  - Hamilton Regional Laboratory Medicine Program, McMaster University, Hamilton,
      Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - Centre for Innovation, Canadian Blood Services, Hamilton, Ontario, Canada.
FAU - Al-Habsi, Khalid S
AU  - Al-Habsi KS
AD  - Department of Blood Banks Services, Directorate General of Specialized Medical
      Care, Ministry of Health, Muscat, Oman.
FAU - Goldman, Mindy
AU  - Goldman M
AD  - Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa,
      Ontario, Canada.
AD  - Centre for Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
FAU - Cote, Jacqueline
AU  - Cote J
AD  - National Immunohematology Reference Laboratory, Canadian Blood Services, Ottawa, 
      Ontario, Canada.
FAU - Athale, Uma
AU  - Athale U
AD  - Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
FAU - Verhovsek, Madeleine M
AU  - Verhovsek MM
AD  - Hamilton Regional Laboratory Medicine Program, McMaster University, Hamilton,
      Ontario, Canada.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
AD  - McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario,
      Canada.
AD  - Department of Pathology and Molecular Medicine, McMaster University, Hamilton,
      Ontario, Canada.
LA  - eng
GR  - McMaster Department of Pathology and Molecular Medicine
PT  - Journal Article
DEP - 20200520
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (ACKR1 protein, human)
RN  - 0 (Duffy Blood-Group System)
RN  - 0 (Receptors, Cell Surface)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - *Anemia, Sickle Cell/immunology/therapy
MH  - *Blood Grouping and Crossmatching
MH  - Child
MH  - Child, Preschool
MH  - *Duffy Blood-Group System/genetics/immunology
MH  - *Erythrocyte Transfusion
MH  - Female
MH  - *Genotyping Techniques
MH  - Humans
MH  - Male
MH  - *Receptors, Cell Surface/genetics/immunology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Transfusion Reaction/genetics/immunology/prevention & control
OTO - NOTNLM
OT  - Rh
OT  - alloimmunisation
OT  - blood group genotyping
OT  - immunohematology
OT  - red blood cell transfusion
OT  - sickle cell disease
OT  - transfusion medicine
OT  - transfusion reactions
EDAT- 2020/05/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/02/01 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1111/tme.12685 [doi]
PST - ppublish
SO  - Transfus Med. 2020 Aug;30(4):263-274. doi: 10.1111/tme.12685. Epub 2020 May 20.


PMID- 32432057
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 10
DP  - 2020
TI  - Galleria mellonella as a Novelty in vivo Model of Host-Pathogen Interaction for
      Malassezia furfur CBS 1878 and Malassezia pachydermatis CBS 1879.
PG  - 199
LID - 10.3389/fcimb.2020.00199 [doi]
AB  - Malassezia furfur and Malassezia pachydermatis are lipophilic and lipid dependent
      yeasts, associated with the skin microbiota in humans and domestic animals,
      respectively. Although they are commensals, under specific conditions they become
      pathogens, causing skin conditions, such as pityriasis versicolor,
      dandruff/seborrheic dermatitis, folliculitis in humans, and dermatitis and otitis
      in dogs. Additionally, these species are associated with fungemia in
      immunocompromised patients and low-weight neonates in intensive care units with
      intravenous catheters or with parenteral nutrition and that are under-treatment
      of broad-spectrum antibiotics. The host-pathogen interaction mechanism in these
      yeasts is still unclear; for this reason, it is necessary to implement suitable
      new host systems, such as Galleria mellonella. This infection model has been
      widely used to assess virulence, host-pathogen interaction, and antimicrobial
      activity in bacteria and fungi. Some advantages of the G. mellonella model are:
      (1) the immune response has phagocytic cells and antimicrobial peptides that are 
      similar to those in the innate immune response of human beings; (2) no ethical
      implications; (3) low cost; and (4) easy to handle and inoculate. This study aims
      to establish G. mellonella as an in vivo infection model for M. furfur and M.
      pachydermatis. To achieve this objective, first, G. mellonella larvae were first 
      inoculated with different inoculum concentrations of these two Malassezia
      species, 1.5 x 10(6) CFU/mL, 1.5 x 10(7) CFU/mL, 1.5 x 10(8) CFU/mL, and 11.5 x
      10(9) CFU/mL, and incubated at 33 and 37 degrees C. Then, for 15 days, the
      mortality and melanization were evaluated daily. Finally, the characterization of
      hemocytes and fungal burden assessment were as carried out. It was found that at 
      33 and 37 degrees C both M. furfur and M. pachydermatis successfully established 
      a systemic infection in G. mellonella. M. pachydermatis proved to be slightly
      more virulent than M. furfur at a temperature of 37 degrees C. The results
      suggest that larvae mortality and melanization is dependent on the specie of
      Malassezia, the inoculum concentration and the temperature. According to the
      findings, G. mellonella can be used as an in vivo model of infection to conduct
      easy and reliable approaches to boost our knowledge of the Malassezia genus.
CI  - Copyright (c) 2020 Torres, Pinzon, Rey, Martinez, Parra Giraldo and Celis
      Ramirez.
FAU - Torres, Maritza
AU  - Torres M
AD  - Grupo de Investigacion Celular y Molecular de Microorganismos Patogenos (CeMoP), 
      Departamento de Ciencias Biologicas, Universidad de los Andes, Bogota, Colombia.
FAU - Pinzon, Elkin Nicolas
AU  - Pinzon EN
AD  - Grupo de Investigacion Celular y Molecular de Microorganismos Patogenos (CeMoP), 
      Departamento de Ciencias Biologicas, Universidad de los Andes, Bogota, Colombia.
FAU - Rey, Flor Maria
AU  - Rey FM
AD  - Grupo de Investigacion Celular y Molecular de Microorganismos Patogenos (CeMoP), 
      Departamento de Ciencias Biologicas, Universidad de los Andes, Bogota, Colombia.
FAU - Martinez, Heydys
AU  - Martinez H
AD  - Grupo de Investigacion Celular y Molecular de Microorganismos Patogenos (CeMoP), 
      Departamento de Ciencias Biologicas, Universidad de los Andes, Bogota, Colombia.
FAU - Parra Giraldo, Claudia Marcela
AU  - Parra Giraldo CM
AD  - Unidad de Investigacion en Proteomica y Micosis Humanas, Grupo de Enfermedades
      Infecciosas, Departamento de Microbiologia, Facultad de Ciencias, Pontificia
      Universidad Javeriana, Bogota, Colombia.
FAU - Celis Ramirez, Adriana Marcela
AU  - Celis Ramirez AM
AD  - Grupo de Investigacion Celular y Molecular de Microorganismos Patogenos (CeMoP), 
      Departamento de Ciencias Biologicas, Universidad de los Andes, Bogota, Colombia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - Malassezia pachydermatis
SB  - IM
MH  - Animals
MH  - *Dandruff
MH  - Dogs
MH  - Host-Pathogen Interactions
MH  - Humans
MH  - *Malassezia
MH  - Skin
PMC - PMC7214729
OTO - NOTNLM
OT  - *Galleria mellonella
OT  - *Malassezia furfur
OT  - *Malassezia pachydermatis
OT  - *host-pathogen interaction
OT  - *infection model
EDAT- 2020/05/21 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
AID - 10.3389/fcimb.2020.00199 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2020 May 5;10:199. doi: 10.3389/fcimb.2020.00199.
      eCollection 2020.


PMID- 32431967
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr 16
TI  - Hemodynamic Stability, Patient Acceptance and Cost of Intravenous Propofol and
      Inhalational Sevoflurane for Induction of Anaesthesia: A Prospective, Randomized 
      Comparative Study.
PG  - e7687
LID - 10.7759/cureus.7687 [doi]
AB  - Introduction The effects of an anesthetic agent on the hemodynamic stability are 
      of prime importance in patients with compromised hemodynamics. Although
      comparative studies of sevoflurane and propofol are reported, most of these are
      aimed to assess maintenance and early postoperative recovery. There are very few 
      studies on hemodynamic changes occurring with these two agents. This study
      compares the hemodynamic stability, patient acceptance, and cost of intravenous
      (IV) propofol versus inhalational (IH) sevoflurane for the induction of
      anesthesia. Methods This prospective, randomized comparative study was conducted 
      among 80 patients with American Society of Anaesthesiologists (ASA) grade-I
      requiring general anesthesia (GA) for elective surgical procedures. The study was
      approved by the institutional ethics committee and was conducted as per the
      principles of the Declaration of Helsinki and Good Clinical Practice (GCP)
      guidelines. Enrolled patients were randomized to receive either intravenous (IV) 
      propofol 2 mg/kg (n=40) or gradual inhalational (IH) induction with sevoflurane
      (n=40). All patients were maintained with sevoflurane 2% in 67% nitrous oxide
      (N2O) and O2. Hemodynamic parameters like pulse rate and mean arterial pressure
      (MAP) were monitored every minute up to five minutes. Patients' acceptance was
      assessed on a 10-item questionnaire, and the cost of anesthesia was assessed
      based on the anesthetic requirement. The hemodynamic parameters were compared
      between the two groups using two-way repeat-measures ANOVA. The incidence of
      hypotension was compared using Fischer's test. Results The two groups were
      similar at baseline with respect to the demography and other baseline
      characteristics. There was greater (p<0.05) fall in MAP with propofol induction
      (28.48%) compared to sevoflurane (14.61%). Greater reduction in pulse rate
      (p<0.05) with sevoflurane (9.18) induction was observed compared to propofol
      (5.28). Patient acceptance for both drugs was similar (p>0.05). Although
      sevoflurane was unpleasant, propofol injection was painful. Ninety percent of
      patients preferred propofol for repeat anesthesia as against 85% of patients with
      sevoflurane. Considering the quantity of anesthetic consumed and the unit cost,
      propofol was more costly as compared to sevoflurane. Conclusion Sevoflurane
      maintains better hemodynamic stability compared to propofol, and patient
      acceptance of both drugs is similar. Induction with sevoflurane was found to be
      cheaper as compared to propofol induction.
CI  - Copyright (c) 2020, Dhande et al.
FAU - Dhande, Kirtibala
AU  - Dhande K
AD  - Anesthesiology, DY Patil Hospital, Navi Mumbai, IND.
FAU - Kshirsagar, Jitendra
AU  - Kshirsagar J
AD  - Anesthesiology, Deenanath Mangeshkar Hospital, Pune, IND.
FAU - Dhande, Ashish
AU  - Dhande A
AD  - Urology, DY Patil University - School of Medicine, Navi Mumbai, IND.
FAU - Patil, Narendra
AU  - Patil N
AD  - Anesthesiology, DY Patil University - School of Medicine, Navi Mumbai, IND.
FAU - V, Parvati Jr
AU  - V P Jr
AD  - Anesthesiology, DY Patil University - School of Medicine, Navi Mumbai, IND.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7233506
OTO - NOTNLM
OT  - acceptance
OT  - hemodynamic stability
OT  - hypotension
OT  - induction
OT  - pharmacoeconomics
OT  - propofol
OT  - sevoflurane
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - 10.7759/cureus.7687 [doi]
PST - epublish
SO  - Cureus. 2020 Apr 16;12(4):e7687. doi: 10.7759/cureus.7687.


PMID- 32431492
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1177-889X (Print)
IS  - 1177-889X (Linking)
VI  - 14
DP  - 2020
TI  - Factors Driving Patient Preferences for Growth Hormone Deficiency (GHD) Injection
      Regimen and Injection Device Features: A Discrete Choice Experiment.
PG  - 781-793
LID - 10.2147/PPA.S239196 [doi]
AB  - INTRODUCTION: The daily injection burden of recombinant human growth hormone
      (r-hGH) replacement therapy to treat growth hormone deficiency (GHD) may reduce
      compliance and limit treatment benefit. Research is needed to evaluate patient
      preferences for GHD injection regimen and device features. OBJECTIVE:
      Quantitatively evaluate factors driving preferences for r-hGH injection regimen
      and device features among pediatric (3-17 years, and caregivers) and adult (>/=25
      years) patients with GHD using a discrete choice experiment (DCE) approach.
      METHODS: The DCE was part of a broader, cross-sectional observational field study
      to develop clinical outcome assessments (COAs) that assess the experience of
      patients taking r-hGH injections. Following ethics approval, discrete choice data
      were collected through an online questionnaire from consented participants
      recruited from eight sites in the United States. Participants were presented with
      20 choice tasks, each comprising different combinations of two profiles.
      Participants were then shown the same set of three hypothetical device and
      injection profiles (ie, storage, preparation, injection type device, maintenance,
      dose setting, injection schedule) and asked whether they would choose each
      profile over their current device and schedule. Choice-based conjoint analyses
      were used to estimate the marginal utilities and values for treatment attributes.
      Subject preferences were estimated at individual and aggregate levels. RESULTS:
      Two hundred and twenty-four participants completed the DCE (n=75 adults, n=79
      adolescent/caregiver dyads, n=70 child/caregiver dyads). Injection schedule was
      the strongest predictor of choice for the total sample and each patient group.
      Less frequent injection schedules were more likely to be chosen by participants. 
      A "ready to use" injection was preferred, with no preference for auto-injector
      versus needle-free device. Most participants would choose the hypothetical
      injection devices and less frequent dosing over their current daily administered 
      device schedule. CONCLUSION: Patients prefer a less frequent injection regimen
      for treating GHD. Addressing patient preferences may improve compliance,
      adherence, and ultimately, clinical outcomes.
CI  - (c) 2020 McNamara et al.
FAU - McNamara, Michelle
AU  - McNamara M
AD  - Adelphi Research, Doylestown, PA, USA.
FAU - Turner-Bowker, Diane M
AU  - Turner-Bowker DM
AUID- ORCID: 0000-0002-8491-5704
AD  - Adelphi Values, Boston, MA, USA.
FAU - Westhead, Hal
AU  - Westhead H
AUID- ORCID: 0000-0002-6500-4665
AD  - Adelphi Research, Manchester, UK.
FAU - Yaworsky, Andrew
AU  - Yaworsky A
AD  - Adelphi Values, Boston, MA, USA.
FAU - Palladino, Andrew
AU  - Palladino A
AUID- ORCID: 0000-0001-9994-1553
AD  - Pfizer, Inc., Collegeville, PA, USA.
FAU - Gross, Hillary
AU  - Gross H
AUID- ORCID: 0000-0002-2801-3167
AD  - Adelphi Research, Doylestown, PA, USA.
FAU - Pleil, Andy
AU  - Pleil A
AUID- ORCID: 0000-0003-2322-9329
AD  - Endpoints and Evidence, LLC, Surf City, NC, USA.
FAU - Loftus, Jane
AU  - Loftus J
AD  - Pfizer Ltd., Tadworth, UK.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7198440
OTO - NOTNLM
OT  - DCE
OT  - adults
OT  - attributes
OT  - children
OT  - conjoint analysis
OT  - discrete choice experiment
OT  - treatment regimen
COIS- MM and HG are employed by Adelphi Research. DTB and AY are employed by Adelphi
      Values. JL and AP are employed by and own stocks from Pfizer. HW was employed by 
      Adelphi Research at the time that the study was conducted and is now retired. A
      Pleil is an independent research and evaluation consultant who was employed by
      Pfizer at the time of the research and owns stocks from Pfizer. The authors
      report no other conflicts of interest in this work.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - 10.2147/PPA.S239196 [doi]
AID - 239196 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2020 Apr 30;14:781-793. doi: 10.2147/PPA.S239196.
      eCollection 2020.


PMID- 32431475
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0951-631X (Print)
IS  - 0951-631X (Linking)
VI  - 33
IP  - 1
DP  - 2020 Feb
TI  - 'The mothers of England object': Public Health, Privacy and Professional Ethics
      in the Early Twentieth-century Debate over the Notification of Pregnancy.
PG  - 18-40
LID - 10.1093/shm/hky035 [doi]
AB  - Amid wider efforts to improve maternal and infant health in Britain around the
      First World War, public health officials debated making pregnancy a notifiable
      condition. Although the policy never entered national legislation, a number of
      local authorities introduced 'notification of pregnancy' schemes in various
      guises, with at least one surviving until the 1950s. Resistance from private
      practitioners to infectious diseases notification in the later nineteenth century
      has been well documented. We know less about opposition to the extension of this 
      measure to maternal and infant welfare, especially from newly professionalising
      female health occupations. Conflict over notification of pregnancy drew midwives,
      in particular, into longstanding arguments over the powers of municipal
      authorities, family privacy and professional ethics. The controversy was the key 
      battleground in negotiations over the organisation of 'antenatal care' as
      occupational groups of varying degrees of authority sought to define their roles 
      and responsibilities within the emerging health services.
CI  - (c) The Author(s) 2018. Published by Oxford University Press on behalf of the
      Society for the Social History of Medicine.
FAU - Al-Gailani, Salim
AU  - Al-Gailani S
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20180531
PL  - England
TA  - Soc Hist Med
JT  - Social history of medicine : the journal of the Society for the Social History of
      Medicine
JID - 8810360
PMC - PMC7223257
OTO - NOTNLM
OT  - midwives
OT  - notification
OT  - pregnancy
OT  - privacy
OT  - public health
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - 10.1093/shm/hky035 [doi]
AID - hky035 [pii]
PST - ppublish
SO  - Soc Hist Med. 2020 Feb;33(1):18-40. doi: 10.1093/shm/hky035. Epub 2018 May 31.


PMID- 32431451
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 1
DP  - 2020 Feb
TI  - Safe Injection Sites: A Moral Reflection.
PG  - 85-93
LID - 10.1177/0024363919861590 [doi]
AB  - This article addresses the issue of safe injection sites (SIS) that
      municipalities in the United States and elsewhere in the world propose to save
      lives by curbing the instances of fatal overdoses and provide addicts with
      healthcare services and opportunities for detoxification and social
      rehabilitation. Drawing on current clinical science and the medical facts
      regarding substance abuse and addiction, widely accepted bioethical principles,
      Catholic social teaching, and the common good, it shows the administration and
      consumption of illicit recreational drugs in an SIS is not a suitable medical
      intervention and a violation of the core principles of Catholic social teaching
      and Catholic healthcare ethics. More importantly, municipal governing bodies and 
      the clinicians who staff these facilities cooperate in the evil of illegal drug
      abuse. SUMMARY: Safe injection sites are morally illicit.
CI  - (c) Catholic Medical Association 2019.
FAU - Bozza, Steven
AU  - Bozza S
AUID- ORCID: https://orcid.org/0000-0001-8476-956X
AD  - Catholic Distance University, Charles Town, WV, USA.
FAU - Berger, Jeffrey
AU  - Berger J
AD  - Guest House, Lake Orion, MI, USA.
LA  - eng
PT  - Journal Article
DEP - 20190707
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7016435
OTO - NOTNLM
OT  - Catholic healthcare ethics
OT  - Catholic social teaching
OT  - Community medicine
OT  - Cooperation in evil
OT  - Harm reduction
OT  - Safe injection sites
OT  - Social justice
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - 10.1177/0024363919861590 [doi]
AID - 10.1177_0024363919861590 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Feb;87(1):85-93. doi: 10.1177/0024363919861590. Epub 2019 Jul 7.


PMID- 32431446
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0024-3639 (Print)
IS  - 0024-3639 (Linking)
VI  - 87
IP  - 1
DP  - 2020 Feb
TI  - Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria.
PG  - 34-42
LID - 10.1177/0024363919873762 [doi]
AB  - Individuals who experience a gender identity that is discordant with biological
      sex are increasingly presenting to physicians for assistance in alleviating
      associated psychological distress. In contrast to prior efforts to identify and
      primarily address underlying psychiatric contributors to gender dysphoria,
      interventions that include uncritical social affirmation, use of
      gonadotropin-releasing hormone agonists to suppress normally timed puberty, and
      administration of cross-sex steroid hormones to induce desired secondary sex
      characteristics are now advocated by an emerging cohort of transgender medicine
      specialists. For patients with persistent gender dysphoria, surgery is offered to
      alter the appearance of breasts and genital organs. Efforts to address ethical
      concerns regarding this contentious treatment paradigm are dependent upon
      reliable evidence on immediate and long-term risks and benefits. Although strong 
      recommendations have been made for invasive and potentially irreversible
      interventions, high-quality scientific data on the effects of this approach are
      generally lacking. Limitations of the existing transgender literature include
      general lack of randomized prospective trial design, small sample size,
      recruitment bias, short study duration, high subject dropout rates, and reliance 
      on "expert" opinion. Existing data reveal significant intervention-associated
      morbidity and raise serious concern that the primary goal of suicide prevention
      is not achieved. In addition to substantial moral questions, adherence to
      established principles of evidence-based medicine necessitates a high degree of
      caution in accepting gender-affirming medical interventions as a preferred
      treatment approach. Continued consideration and rigorous investigation of
      alternate approaches to alleviating suffering in people with gender dysphoria are
      warranted. SUMMARY: This paper provides an overview of what is currently known
      about people who experience a gender identity that differs from their biological 
      sex and the associated desire to engage the medical profession in alleviating
      associated discomfort and distress. The scientific evidence used to support
      current recommendations for affirming one's preferred gender, halting normally
      timed puberty, administering cross-sex hormones, and surgically altering primary 
      and secondary sexual traits are summarized and critically evaluated. Serious
      deficits in understanding the cause of this condition, the reasons for the marked
      increase in people presenting for medical care, together with immediate and
      long-term risks relative to benefit of medical intervention are exposed.
CI  - (c) Catholic Medical Association 2019.
FAU - Hruz, Paul W
AU  - Hruz PW
AUID- ORCID: https://orcid.org/0000-0002-1478-3355
AD  - Washington University School of Medicine, St. Louis, MO, USA.
LA  - eng
PT  - Journal Article
DEP - 20190920
PL  - United States
TA  - Linacre Q
JT  - The Linacre quarterly
JID - 2985221R
PMC - PMC7016442
OTO - NOTNLM
OT  - Cross-sex hormones
OT  - Evidence-based medicine
OT  - Gender dysphoria
OT  - Gender identity
OT  - Medical research
OT  - Puberty blockade
OT  - Risk-benefit analysis
OT  - Sexuality
OT  - Suicide
OT  - Transgender operations
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - 10.1177/0024363919873762 [doi]
AID - 10.1177_0024363919873762 [pii]
PST - ppublish
SO  - Linacre Q. 2020 Feb;87(1):34-42. doi: 10.1177/0024363919873762. Epub 2019 Sep 20.


PMID- 32431312
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 84
IP  - 4
DP  - 2020 Apr
TI  - Using Photovoice to Encourage Reflection in Health Professions Students
      Completing a Short-term Experience in Global Health.
PG  - 7630
LID - 10.5688/ajpe7630 [doi]
AB  - Objective. To engage health professions students in a photo and caption sharing
      methodology to stimulate reflection and inculcate principles related to global
      health at a formative time in training. Methods. Undergraduate and graduate
      students from multiple colleges enrolled in a course that would prepare them for 
      an in-country global health experience. As part of the course, participants took 
      photos to illustrate one of three topics: global health ethics, interprofessional
      practice, or social determinants of health. The iterative and participatory
      photovoice process was used for students to analyze, discuss, and reflect on
      their work in country and upon return. Final photos with captions were displayed 
      online. Researchers analyzed photos and captions using content analysis to
      identify unifying themes. All students were required to complete the photovoice
      assignment, but only those who gave informed consent were included in the
      qualitative analysis. Results. Twenty-six students were included in the analysis.
      Two overarching themes emerged: revelation and adaptation. Revelation encompassed
      novel elements that surprised the students, including differences and
      similarities between the United States and Ecuador. Coded segments related to
      adaptation discussed participants' resourcefulness while challenging work
      environments, and how they would apply this new perspective to their future
      practice in the United States. Conclusion. This global health photovoice project 
      provided a unique medium for reflection for health care trainees. This project
      enhanced our understanding of the learners' perspectives and this new means of
      expression offered the learners a greater opportunity for deeper reflection. The 
      assignment also revealed gaps in learning related to social determinants of
      health and areas of concern related to solidarity and privilege.
CI  - (c) 2020 American Association of Colleges of Pharmacy.
FAU - Ryan, Melody
AU  - Ryan M
AD  - University of Kentucky College of Pharmacy, Lexington, Kentucky.
FAU - Feld, Hartley
AU  - Feld H
AD  - University of Kentucky College of Pharmacy, Lexington, Kentucky.
FAU - Yarrison, Rebecca
AU  - Yarrison R
AD  - University of Kentucky College of Pharmacy, Lexington, Kentucky.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
MH  - Ecuador
MH  - *Global Health
MH  - Humans
MH  - *International Educational Exchange
MH  - Interprofessional Relations
MH  - *Learning
MH  - *Narration
MH  - *Photography
MH  - Social Determinants of Health
MH  - Students, Health Occupations/*psychology
MH  - United States
MH  - *Writing
PMC - PMC7223937
OTO - NOTNLM
OT  - *education abroad
OT  - *global health
OT  - *medical mission
OT  - *photovoice
OT  - *reflection
EDAT- 2020/05/21 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - 10.5688/ajpe7630 [doi]
AID - ajpe7630 [pii]
PST - ppublish
SO  - Am J Pharm Educ. 2020 Apr;84(4):7630. doi: 10.5688/ajpe7630.


PMID- 32431307
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 84
IP  - 4
DP  - 2020 Apr
TI  - Comparing Photovoice to Traditional Reflection to Identify Student Learning on a 
      Medical Mission Trip.
PG  - 7599
LID - 10.5688/ajpe7599 [doi]
AB  - Objective. To compare the effectiveness of photovoice with traditional reflection
      as a methodology to identify student learning during an international advanced
      pharmacy practice experience (APPE). Methods. Over seven years, seven cohorts of 
      two to three pharmacy students completed an APPE in which they participated in a 
      medical mission trip to Guatemala. Cohorts were assigned to use either photovoice
      or traditional reflection techniques to identify and document their learning.
      After returning from the mission trip, a focus group was conducted with each
      cohort of students. Students' comments were audio-recorded and the audio
      recording was transcribed and the text was qualitatively analyzed. In addition,
      all students completed the Inventory for Assessing the Process of Cultural
      Competence Among Healthcare Professionals (IAPCC-SV) before and after travel.
      Results. All 18 students who participated in the mission trips, (nine in each
      group) agreed to participate in the study. Several themes were identified when
      the transcripts of the focus group sessions were reviewed. Students in both
      groups emphasized learning about the enhancement of pharmacy skills, cultural
      appreciation, and self-examination in their reflections. However, students in the
      photovoice group emphasized three additional areas that were not emphasized by
      students in the traditional reflection group: emotional impact, critical
      reflection on privilege, and ethical distribution of health resources. Students' 
      post-intervention mean scores on the IAPCC-SV increased more for the photovoice
      group (8.5 points) than the reflection group (6.8); however, this difference was 
      not significant. Conclusion. Students who used photovoice focused more on the
      connection between their learning and emotional or moral experiences than did
      students who used traditional reflection techniques. Photovoice may represent a
      promising methodology for deeper reflection into affective learning domains
      because of students' connection between visual images and their lived
      experiences.
CI  - (c) 2020 American Association of Colleges of Pharmacy.
FAU - Skoy, Elizabeth
AU  - Skoy E
AD  - North Dakota State University, Fargo, North Dakota.
FAU - Werremeyer, Amy
AU  - Werremeyer A
AD  - North Dakota State University, Fargo, North Dakota.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Clinical Competence
MH  - Culturally Competent Care
MH  - Emotions
MH  - Female
MH  - Focus Groups
MH  - Guatemala
MH  - Humans
MH  - Male
MH  - *Medical Missions
MH  - *Narration
MH  - *Photography
MH  - *Problem-Based Learning
MH  - Professional Role
MH  - Qualitative Research
MH  - Students, Pharmacy/*psychology
MH  - United States
MH  - Writing
MH  - Young Adult
PMC - PMC7223942
OTO - NOTNLM
OT  - *international health
OT  - *photovoice
OT  - *qualitative research
OT  - *reflection techniques
EDAT- 2020/05/21 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - 10.5688/ajpe7599 [doi]
AID - ajpe7599 [pii]
PST - ppublish
SO  - Am J Pharm Educ. 2020 Apr;84(4):7599. doi: 10.5688/ajpe7599.


PMID- 32431128
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20200717
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 5
DP  - 2020 May
TI  - [FORCING TREATMENT AND PREVENTING PATIENT INFORMATION].
PG  - 360-363
AB  - INTRODUCTION: An ethics committee is a quasi-judicial committee whose basis is
      its law. The Ethics Committee's actions in the area of coercive treatment and
      prevention of information from the patient have been clarified, but creative
      solutions can sometimes be used without compromising the spirit of the law,
      causing patients to receive treatment or non-treatment with a minimum of harm to 
      their values and wishes. An experienced ethics committee, with members capable of
      breaking out of the box, combined with innovative professionals, will also solve 
      complex ethical dilemmas to reach solutions agreed upon by all concerned.
FAU - Levinger, Uriel
AU  - Levinger U
LA  - heb
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - *Ethics Committees
MH  - *Ethics, Medical
MH  - Humans
MH  - Patients
EDAT- 2020/05/21 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 May;159(5):360-363.


PMID- 32431042
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 50
IP  - 5
DP  - 2020 May
TI  - Transvaginal mesh, gender and the ethics of clinical innovation.
PG  - 523-526
LID - 10.1111/imj.14833 [doi]
AB  - On 10 October 2018, Australian Health Minister Greg Hunt issued a national
      apology to the Australian women who experienced 'horrific outcomes' following
      surgery using transvaginal mesh-acknowledging the 'historic agony and pain that
      has come from mesh implantation'. This apology followed many decades of
      'innovative' use of transvaginal mesh for the treatment of pelvic organ prolapse.
      We use the case of transvaginal mesh to explore how clinical innovation may not
      only harm patients, but also entrench vulnerability and exacerbate existing
      inequities-in this case, those relating to gender.
CI  - (c) 2020 Royal Australasian College of Physicians.
FAU - Wiersma, Miriam
AU  - Wiersma M
AUID- ORCID: 0000-0003-3739-3090
AD  - The University of Sydney, Sydney Health Ethics, Faculty of Medicine and Health,
      Sydney, New South Wales, Australia.
FAU - Kerridge, Ian
AU  - Kerridge I
AD  - Professor of Bioethics and Medicine at The University of Sydney, Sydney Health
      Ethics, and Haematology Department, Royal North Shore Hospital, Sydney, New South
      Wales, Australia.
FAU - Lipworth, Wendy
AU  - Lipworth W
AD  - The University of Sydney, Sydney Health Ethics, Faculty of Medicine and Health,
      Sydney, New South Wales, Australia.
LA  - eng
GR  - APP1059732/National Health and Medical Research Council/International
GR  - APP1141943/National Health and Medical Research Council/International
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
CIN - Intern Med J. 2020 May;50(5):521-523. PMID: 32431031
CIN - Intern Med J. 2020 May;50(5):527-529. PMID: 32431034
MH  - Australia
MH  - Female
MH  - Humans
MH  - *Pelvic Organ Prolapse/surgery
MH  - Prostheses and Implants
MH  - *Surgical Mesh/adverse effects
OTO - NOTNLM
OT  - *ethics
OT  - *gender
OT  - *innovation
OT  - *patient harm
OT  - *transvaginal mesh
EDAT- 2020/05/21 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/05/18 00:00 [received]
PHST- 2019/07/29 00:00 [revised]
PHST- 2020/01/10 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.1111/imj.14833 [doi]
PST - ppublish
SO  - Intern Med J. 2020 May;50(5):523-526. doi: 10.1111/imj.14833.


PMID- 32430910
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20210224
IS  - 1365-2044 (Electronic)
IS  - 0003-2409 (Linking)
VI  - 75
IP  - 9
DP  - 2020 Sep
TI  - Optimisation of the organ donor and effects on transplanted organs: a narrative
      review on current practice and future directions.
PG  - 1191-1204
LID - 10.1111/anae.15037 [doi]
AB  - Mortality remains high for patients on the waiting list for organ
      transplantation. A marked imbalance between the number of available organs and
      recipients that need to be transplanted persists. Organs from deceased donors are
      often declined due to perceived and actual suboptimal quality. Adequate donor
      management offers an opportunity to reduce organ injury and maximise the number
      of organs than can be offered in order to respect the donor's altruistic gift.
      The cornerstones of management include: correction of hypovolaemia; maintenance
      of organ perfusion; prompt treatment of diabetes insipidus; corticosteroid
      therapy; and lung protective ventilation. The interventions used to deliver these
      goals are largely based on pathophysiological rationale or extrapolations from
      general critical care patients. There is currently insufficient high-quality
      evidence that has assessed whether any interventions in the donor after brain
      death may actually improve immediate post-transplant function and long-term graft
      survival or recipient survival after transplantation. Improvements in our
      understanding of the underlying mechanisms following brain death, in particular
      the role of immunological and metabolic changes in donors, offer promising future
      therapeutic opportunities to increase organ utilisation. Establishing a UK donor 
      management research programme involves consideration of ethical, logistical and
      legal issues that will benefit transplanted patients while respecting the wishes 
      of donors and their families.
CI  - (c) 2020 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of
      Association of Anaesthetists.
FAU - Bera, K D
AU  - Bera KD
AD  - Oxford Biomedical Research Centre and Oxford University Hospital NHS Foundation
      Trust, John Radcliffe Hospital, Oxford, UK.
FAU - Shah, A
AU  - Shah A
AD  - Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
AD  - Nuffield Department of Anaesthesia, John Radcliffe Hospital, Oxford, UK.
FAU - English, M R
AU  - English MR
AD  - University of Oxford Medical School, Oxford, UK.
FAU - Harvey, D
AU  - Harvey D
AD  - Department of Intensive Care Medicine, Nottingham University Hospitals NHS Trust,
      Nottingham, UK.
FAU - Ploeg, R J
AU  - Ploeg RJ
AD  - Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre,
      University of Oxford, UK.
LA  - eng
GR  - MR/R014132/1/MRC_/Medical Research Council/United Kingdom
GR  - DRF-2017-10-094/NIHR Doctoral Research Fellowship/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200519
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
SB  - IM
MH  - *Brain Death
MH  - Graft Survival/*physiology
MH  - Humans
MH  - Organ Transplantation/*statistics & numerical data/trends
MH  - Survival Analysis
MH  - Tissue Donors/*statistics & numerical data
MH  - Tissue and Organ Procurement/*statistics & numerical data/trends
MH  - United Kingdom
MH  - Waiting Lists
OTO - NOTNLM
OT  - *brain death pathophysiology
OT  - *organ donation: process
OT  - *organ donor and lung: management
OT  - *organ donor: treatment of diabetes insipidus
EDAT- 2020/05/21 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1111/anae.15037 [doi]
PST - ppublish
SO  - Anaesthesia. 2020 Sep;75(9):1191-1204. doi: 10.1111/anae.15037. Epub 2020 May 19.


PMID- 32430909
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20200901
IS  - 1365-2044 (Electronic)
IS  - 0003-2409 (Linking)
VI  - 75
IP  - 9
DP  - 2020 Sep
TI  - The rise of organ donation after circulatory death: a narrative review.
PG  - 1215-1222
LID - 10.1111/anae.15100 [doi]
AB  - Solid organ transplantation saves and transforms lives. The original type of
      organ donation from deceased patients was controlled donation after circulatory
      death, previously referred to as non-heart beating organ donation. The rise of
      donation after circulatory death in the UK came about through advances in
      critical care and transplant medicine and support from several key organisations 
      in developing a robust ethical, legal and professional framework. The transplant 
      waiting list reached a historic peak in 2009-2010 of 8000 patients, but fell by
      25% to 6000 in 2017-2018. There has also been a steady rise in the number of
      deceased donors and the number of donations after circulatory death. The
      contribution of donation after circulatory death to the total number of donations
      rose steadily between 2000 and 2012 and has remained about 40% since. Although
      the situation has improved for patients waiting for a transplant, deaths and long
      waits remain common. Changes to legislative, technical and peri-mortem procedures
      may greatly change future practices in donation after circulatory death in the
      UK.
CI  - (c) 2020 Association of Anaesthetists.
FAU - Gardiner, D
AU  - Gardiner D
AD  - National Clinical Lead for Organ Donation, NHS Blood and Transplant, Nottingham, 
      UK.
FAU - Charlesworth, M
AU  - Charlesworth M
AD  - Department of Cardiothoracic Anaesthesia, Critical Care and ECMO, Wythenshawe
      Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
FAU - Rubino, A
AU  - Rubino A
AD  - Department of Cardiothoracic Anaesthesia, Critical Care and ECMO, Royal Papworth 
      Hospital, Cambridge, UK.
FAU - Madden, S
AU  - Madden S
AD  - NHS Blood and Transplant, Bristol, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200519
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
SB  - IM
MH  - *Brain Death
MH  - *Heart Arrest
MH  - Humans
MH  - Tissue and Organ Procurement/*statistics & numerical data
MH  - United Kingdom
OTO - NOTNLM
OT  - *circulatory death
OT  - *donation
OT  - *ethics
OT  - *transplantation
EDAT- 2020/05/21 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1111/anae.15100 [doi]
PST - ppublish
SO  - Anaesthesia. 2020 Sep;75(9):1215-1222. doi: 10.1111/anae.15100. Epub 2020 May 19.


PMID- 32430455
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Evaluating the real-world implementation of the Family Nurse Partnership in
      England: protocol for a data linkage study.
PG  - e038530
LID - 10.1136/bmjopen-2020-038530 [doi]
AB  - INTRODUCTION: Almost 20 000 babies are born to teenage mothers each year in
      England, with poorer outcomes for mothers and babies than among older mothers. A 
      nurse home visitation programme in the USA was found to improve a wide range of
      outcomes for young mothers and their children. However, a randomised controlled
      trial in England found no effect on short-term primary outcomes, although
      cognitive development up to age 2 showed improvement. Our study will use linked
      routinely collected health, education and social care data to evaluate the
      real-world effects of the Family Nurse Partnership (FNP) on child outcomes up to 
      age 7, with a focus on identifying whether the FNP works better for particular
      groups of families, thereby informing programme targeting and resource
      allocation. METHODS AND ANALYSIS: We will construct a retrospective cohort of all
      women aged 13-24 years giving birth in English NHS hospitals between 2010 and
      2017, linking information on mothers and children from FNP programme data,
      Hospital Episodes Statistics and the National Pupil Database. To assess the
      effectiveness of FNP, we will compare outcomes for eligible mothers ever and
      never enrolled in FNP, and their children, using two analysis strategies to
      adjust for measured confounding: propensity score matching and analyses adjusting
      for maternal characteristics up to enrolment/28 weeks gestation. Outcomes of
      interest include early childhood development, childhood unplanned hospital
      admissions for injury or maltreatment-related diagnoses and children in care.
      Subgroup analyses will determine whether the effect of FNP varied according to
      maternal characteristics (eg, age and education). ETHICS AND DISSEMINATION: The
      Nottingham Research Ethics Committee approved this study. Mothers participating
      in FNP were supportive of our planned research. Results will inform policy-makers
      for targeting home visiting programmes. Methodological findings on the accuracy
      and reliability of cross-sectoral data linkage will be of interest to
      researchers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Cavallaro, Francesca L
AU  - Cavallaro FL
AUID- ORCID: 0000-0002-9641-8780
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Gilbert, Ruth
AU  - Gilbert R
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Wijlaars, Linda
AU  - Wijlaars L
AUID- ORCID: 0000-0003-1222-2922
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK.
FAU - Kennedy, Eilis
AU  - Kennedy E
AD  - Children, Young Adults and Families Directorate, Tavistock and Portman NHS
      Foundation Trust, London, UK.
FAU - Swarbrick, Ailsa
AU  - Swarbrick A
AD  - Family Nurse Partnership National Unit, Tavistock and Portman NHS Foundation
      Trust, London, UK.
FAU - van der Meulen, Jan
AU  - van der Meulen J
AD  - Department of Health Services Research and Policy, London School of Hygiene &
      Tropical Medicine, London, UK.
FAU - Harron, Katie
AU  - Harron K
AUID- ORCID: 0000-0002-3418-2856
AD  - Great Ormond Street Institute of Child Health, University College London, London,
      UK k.harron@ucl.ac.uk.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 17/99/19/DH_/Department of Health/United Kingdom
GR  - MRC_/Medical Research Council/United Kingdom
GR  - 212953/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - England
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Information Storage and Retrieval
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - *State Medicine
MH  - Young Adult
PMC - PMC7239518
OTO - NOTNLM
OT  - *child protection
OT  - *community child health
OT  - *health informatics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/05/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2020-038530 [pii]
AID - 10.1136/bmjopen-2020-038530 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 18;10(5):e038530. doi: 10.1136/bmjopen-2020-038530.


PMID- 32430452
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Protocol of a randomised controlled trial assessing the impact of physical
      activity on bone health in children with inflammatory bowel disease.
PG  - e036400
LID - 10.1136/bmjopen-2019-036400 [doi]
AB  - INTRODUCTION: Low bone mineral density (BMD) is a frequent issue in children and 
      adolescents with inflammatory bowel disease (IBD). Several studies in healthy
      populations have reported a positive impact of physical activity (PA) on bone
      health. Recently, an observational study in paediatric patients with IBD showed a
      significant positive relationship between daily PA and BMD. However, intervention
      studies investigating a causal relationship between PA and BMD are warranted to
      confirm these results. The aim of this randomised controlled trial will be to
      investigate the effect of a PA programme on BMD in paediatric patients with IBD. 
      METHODS AND ANALYSIS: This trial is a multicentre (four centres), randomised,
      controlled, blinded end-point study. Eighty children with IBD will be randomly
      assigned in a 1:1 ratio to receive a programme with adapted physical exercises
      (intervention group) or usual PA (control group) during a 9-month period. The
      primary outcome is the change from baseline at 9 months (the end of the study) in
      whole-body BMD assessed by dual-energy X-ray absorptiometry. Secondary efficacy
      outcomes include the changes from baseline at 9 months in: BMD assessed in the
      lumbar spine and trochanter; daily PA (time spent in moderate-to-vigorous PA);
      body composition (fat mass and fat-free mass); fatigue resistance; quality of
      life and activity of IBD. ETHICS AND DISSEMINATION: The study was approved by the
      Research Ethics Committee in France (Comite de Protection des Personnes,
      Sud-Ouest and Outre-Mer III, Bordeaux, France, No 2018/27). All procedures will
      be performed according to the ethical standards of the Helsinki Declaration of
      1975, as revised in 2008, and the European Union's Guidelines for Good Clinical
      Practice. Written informed consent will be obtained from the parents or legal
      guardian and from the children. Research findings will be disseminated in
      peer-reviewed journals and scientific meetings. TRIAL REGISTRATION NUMBER:
      NCT03774329.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vanhelst, Jeremy
AU  - Vanhelst J
AUID- ORCID: 0000-0002-0570-1522
AD  - Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational
      Research in Inflammation, F-59000 Lille, France, Lille, France
      jeremy.vanhelst@chru-lille.fr.
FAU - Coopman, Stephanie
AU  - Coopman S
AD  - Division of Gastroenterology, Hepatology and Nutrition, Department of
      Paediatrics, Lille University, Jeanne de Flandre Children's Hospital, Lille,
      France.
FAU - Labreuche, Julien
AU  - Labreuche J
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des technologies de sante 
      et des pratiques medicales, F-59000 Lille, France, Lille, France.
FAU - Dupont, Claire
AU  - Dupont C
AD  - Department of Paediatrics, Caen University Hospital F 14000 Caen, France and
      Normandy University, Caen, France.
FAU - Bertrand, Valerie
AU  - Bertrand V
AD  - Pediatric Unit, Le Havre Hospital, Le Havre, France.
FAU - Djeddi, Djamal
AU  - Djeddi D
AD  - Department of Paediatrics, Amiens University Hospital and University of Amiens,
      Amiens, France.
FAU - Turck, Dominique
AU  - Turck D
AD  - Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational
      Research in Inflammation, F-59000 Lille, France, Lille, France.
AD  - Division of Gastroenterology, Hepatology and Nutrition, Department of
      Paediatrics, Lille University, Jeanne de Flandre Children's Hospital, Lille,
      France.
FAU - Ley, Delphine
AU  - Ley D
AD  - Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational
      Research in Inflammation, F-59000 Lille, France, Lille, France.
AD  - Division of Gastroenterology, Hepatology and Nutrition, Department of
      Paediatrics, Lille University, Jeanne de Flandre Children's Hospital, Lille,
      France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03774329
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Bone Density
MH  - Child
MH  - Exercise
MH  - France
MH  - Humans
MH  - *Inflammatory Bowel Diseases
MH  - Multicenter Studies as Topic
MH  - Observational Studies as Topic
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7239538
OTO - NOTNLM
OT  - *paediatric gastroenterology
OT  - *paediatrics
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036400 [pii]
AID - 10.1136/bmjopen-2019-036400 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 18;10(5):e036400. doi: 10.1136/bmjopen-2019-036400.


PMID- 32430450
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC) for chronic insomnia
      disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled,
      double-blinded, proof-of-concept trial.
PG  - e034421
LID - 10.1136/bmjopen-2019-034421 [doi]
AB  - INTRODUCTION: Insomnia is a highly prevalent and costly condition that is
      associated with increased health risks and healthcare utilisation. Anecdotally,
      cannabis use is frequently reported by consumers to promote sleep. However, there
      is limited research on the effects of cannabis on sleep and daytime function in
      people with insomnia disorder using objective measures. This proof-of-concept
      study will evaluate the effects of a single dose of an oral cannabis-based
      medicine on sleep and daytime function in participants with chronic insomnia
      disorder. METHODS AND ANALYSIS: A randomised, crossover, placebo-controlled,
      single-dose study design will be used to test the safety and efficacy of an oral 
      oil solution ('ETC120') containing 10 mg Delta(9)-tetrahydrocannabinol (THC) and 
      200 mg cannabidiol (CBD) in 20 participants diagnosed with chronic insomnia
      disorder. Participants aged 35-60 years will be recruited over an 18-month period
      commencing August 2019. Each participant will receive both the active drug and
      matched placebo, in a counterbalanced order, during two overnight study
      assessment visits, with at least a 1-week washout period between each visit. The 
      primary outcomes are total sleep time and wake after sleep onset assessed via
      polysomnography. In addition, 256-channel high-density electroencephalography and
      source modelling using structural brain MRI will be used to comprehensively
      examine brain activation during sleep and wake periods on ETC120 versus placebo. 
      Next-day cognitive function, alertness and simulated driving performance will
      also be investigated. ETHICS AND DISSEMINATION: Ethics approval was received from
      Bellberry Human Research Ethics Committee (2018-04-284). The findings will be
      disseminated in a peer-reviewed open-access journal and at academic conferences. 
      TRIAL REGISTRATION NUMBER: ANZCTRN12619000714189.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Suraev, Anastasia
AU  - Suraev A
AUID- ORCID: 0000-0002-5993-2246
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Faculty of Science, School of Psychology, Sydney, New
      South Wales, Australia.
AD  - The University of Sydney, Brain and Mind Centre, Sydney, New South Wales,
      Australia.
FAU - Grunstein, Ronald R
AU  - Grunstein RR
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - RPA-Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney, New South
      Wales, Australia.
FAU - Marshall, Nathaniel S
AU  - Marshall NS
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Faculty of Medicine and Health, Susan Wakil School of
      Nursing and Midwifery, Sydney, New South Wales, Australia.
FAU - D'Rozario, Angela L
AU  - D'Rozario AL
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Faculty of Science, School of Psychology, Sydney, New
      South Wales, Australia.
FAU - Gordon, Christopher J
AU  - Gordon CJ
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Faculty of Medicine and Health, Susan Wakil School of
      Nursing and Midwifery, Sydney, New South Wales, Australia.
FAU - Bartlett, Delwyn J
AU  - Bartlett DJ
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
FAU - Wong, Keith
AU  - Wong K
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - RPA-Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney, New South
      Wales, Australia.
FAU - Yee, Brendon J
AU  - Yee BJ
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia.
AD  - RPA-Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney, New South
      Wales, Australia.
FAU - Vandrey, Ryan
AU  - Vandrey R
AD  - Behavioral Pharmacology Research Unit, Johns Hopkins University, Baltimore,
      Maryland, USA.
FAU - Irwin, Chris
AU  - Irwin C
AD  - Menzies Health Institute Queensland, School Allied Health Sciences, Griffith
      University, Gold Coast, Queensland, Australia.
FAU - Arnold, Jonathon C
AU  - Arnold JC
AD  - The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Brain and Mind Centre, Sydney, New South Wales,
      Australia.
AD  - The University of Sydney, Faculty of Medicine and Health, Discipline of
      Pharmacology, Sydney, New South Wales, Australia.
FAU - McGregor, Iain S
AU  - McGregor IS
AD  - The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics,
      Sydney, New South Wales, Australia.
AD  - The University of Sydney, Faculty of Science, School of Psychology, Sydney, New
      South Wales, Australia.
AD  - The University of Sydney, Brain and Mind Centre, Sydney, New South Wales,
      Australia.
FAU - Hoyos, Camilla M
AU  - Hoyos CM
AD  - Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology,
      Sydney, New South Wales, Australia camilla.hoyos@sydney.edu.au.
AD  - The University of Sydney, Faculty of Science, School of Psychology, Sydney, New
      South Wales, Australia.
AD  - The University of Sydney, Brain and Mind Centre, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Adult
MH  - *Cannabidiol
MH  - *Cannabis
MH  - Double-Blind Method
MH  - Dronabinol
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - *Sleep Initiation and Maintenance Disorders/drug therapy
PMC - PMC7239553
OTO - NOTNLM
OT  - *cannabinoids
OT  - *high-density EEG
OT  - *insomnia
OT  - *protocol
COIS- Competing interests: ISM is Academic Director of the Lambert Initiative for
      Cannabinoid Therapeutics. He has served as an expert witness in various
      medicolegal cases involving cannabis, has received honoraria from Janssen, is
      currently a consultant to Kinoxis Therapeutics, and has received research funding
      and fellowship support from the Lambert Initiative for Cannabinoid Therapeutics, 
      National Health and Medical Research Council (NHMRC) and Australian Research
      Council. He holds a variety of patents for cannabinoid and non-cannabinoid
      therapeutics. RV has received financial compensation from Zynerba
      Pharmaceuticals, Canopy Health Innovations and Brain Solutions. JCA is Deputy
      Academic Director of the Lambert Initiative for Cannabinoid Therapeutics. He has 
      served as an expert witness in various medicolegal cases involving cannabis and
      recently served as a temporary advisor to the WHO on their review of cannabis and
      the cannabinoids. His research is funded by the NHMRC, Canopy Growth Corporation 
      and the Lambert Initiative for Cannabinoid Therapeutics. JCA also holds several
      patents on novel cannabinoid therapies. All other authors have no conflicts of
      interest to disclose.
EDAT- 2020/05/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034421 [pii]
AID - 10.1136/bmjopen-2019-034421 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 18;10(5):e034421. doi: 10.1136/bmjopen-2019-034421.


PMID- 32430449
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Qualitative accounts from Syrian mental health professionals: shared realities in
      the context of conflict and forced displacement.
PG  - e034291
LID - 10.1136/bmjopen-2019-034291 [doi]
AB  - OBJECTIVES: To explore the impact of the provision of care of forcibly displaced 
      Syrian mental health professionals (MHPs) to Syrian clients in the community
      given shared experiences and backgrounds with clients. DESIGN: A qualitative
      study using thematic analysis of in-depth semistructured interviews to explore
      shared realities, self-disclosure and the impact of providing therapy. SETTING:
      Syrian MHPs operating in Gaziantep and Istanbul, Turkey, were interviewed.
      PARTICIPANTS: Sixteen forcibly displaced Syrian MHPs (eight male, eight female)
      aged between 24 and 54 years (M=35, SD=8.3) who provided care to the displaced
      Syrian community in Turkey. RESULTS: All workers described having a shared
      reality with their clients as helpful in therapy and a smaller proportion
      described it as a vulnerability. All described their work with Syrian clients as 
      fulfilling and most described it as distressing. Participants referred to
      self-care,supervision, peer-support and personal therapy as a means to cope.
      CONCLUSIONS: This study provides the first insight into the shared experiences of
      the ongoing trauma, loss and violations resulting from the ongoing Syrian
      conflict from the perspective of Syrian MHPs, adding to the literature of the
      professional issues and ethical duty to protect health workers in conflict
      settings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hamid, Aseel
AU  - Hamid A
AUID- ORCID: 0000-0002-9618-6510
AD  - Research Department of Clinical, Educational and Health Psychology, University
      College London, London, UK aseel.hamid@ucl.ac.uk.
FAU - Scior, Katrina
AU  - Scior K
AD  - Research Department of Clinical, Educational and Health Psychology, University
      College London, London, UK.
FAU - Williams, Amanda C de C
AU  - Williams ACC
AD  - Research Department of Clinical, Educational and Health Psychology, University
      College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Female
MH  - Health Personnel
MH  - Humans
MH  - Male
MH  - *Mental Health
MH  - *Mental Health Services
MH  - Middle Aged
MH  - Qualitative Research
MH  - Syria
MH  - Turkey
MH  - Young Adult
PMC - PMC7239525
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *medical education & training
OT  - *mental health
OT  - *qualitative research
OT  - *quality in health care
EDAT- 2020/05/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-034291 [pii]
AID - 10.1136/bmjopen-2019-034291 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 18;10(5):e034291. doi: 10.1136/bmjopen-2019-034291.


PMID- 32430448
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Developing a typology of the roles public contributors undertake to establish
      legitimacy: a longitudinal case study of patient and public involvement in a
      health network.
PG  - e033370
LID - 10.1136/bmjopen-2019-033370 [doi]
AB  - OBJECTIVE: To identify how public contributors established their legitimacy in
      the functioning of a patient and public involvement programme at a health
      network. DESIGN: A longitudinal case study with three embedded units (projects)
      involving public contributors. Interviews (n=24), observations (n=27) and
      documentary data collection occurred over 16 months. SETTING: The West of England
      Academic Health Science Network (WEAHSN), 1 of 15 regional AHSNs in England.
      PARTICIPANTS: Interviews were conducted with public contributors (n=5) and
      professionals (n=19) who were staff from the WEAHSN, its member organisations and
      its partners. RESULTS: Public contributors established their legitimacy by using 
      nine distinct roles: (1) lived experience, as a patient or carer; (2)
      occupational knowledge, offering job-related expertise; (3) occupational skills, 
      offering aptitude developed through employment; (4) patient advocate, promoting
      the interests of patients; (5) keeper of the public purse, encouraging wise
      spending; (6) intuitive public, piloting materials suitable for the general
      public; (7) fresh-eyed reviewer, critiquing materials; (8) critical friend,
      critiquing progress and proposing new initiatives and (9) boundary spanner,
      urging professionals to work across organisations. Individual public contributors
      occupied many, but not all, of the roles. CONCLUSIONS: Lived experience is only
      one of nine distinct public contributor roles. The WEAHSN provided a benign
      context for the study because in a health network public contributors are one of 
      many parties seeking to establish legitimacy through finding valuable roles. The 
      nine roles can be organised into a typology according to whether the basis for
      legitimacy lies in: the public contributor's knowledge, skills and experience;
      citizenship through the aspiration to achieve a broad public good; or being an
      outsider. The typology shows how public contributors can be involved in work
      where lived experience appears to lack relevance: strategic decision making;
      research unconnected to particular conditions; or acute service delivery.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Barker, Jacqueline
AU  - Barker J
AUID- ORCID: 0000-0002-2986-5070
AD  - Faculty of Business and Law, University of the West of England Bristol, Bristol, 
      UK jacqueline.barker@uwe.ac.uk.
FAU - Moule, Pam
AU  - Moule P
AD  - Faculty of Health and Applied Sciences, University of the West of England,
      Bristol, UK.
FAU - Evans, David
AU  - Evans D
AD  - Faculty of Health and Applied Sciences, University of the West of England,
      Bristol, UK.
FAU - Phillips, Wendy
AU  - Phillips W
AD  - Faculty of Business and Law, University of the West of England Bristol, Bristol, 
      UK.
FAU - Leggett, Nick
AU  - Leggett N
AD  - Public contributor, Bristol, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Caregivers
MH  - England
MH  - Humans
MH  - Longitudinal Studies
MH  - Surveys and Questionnaires
PMC - PMC7239550
OTO - NOTNLM
OT  - *ethics (see medical ethics)
OT  - *health services administration & management
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/05/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-033370 [pii]
AID - 10.1136/bmjopen-2019-033370 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 18;10(5):e033370. doi: 10.1136/bmjopen-2019-033370.


PMID- 32430445
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 18
TI  - Patient-centred and economic effectiveness of a decision aid for patients with
      age-related cataract in China: study protocol of a randomised controlled trial.
PG  - e032242
LID - 10.1136/bmjopen-2019-032242 [doi]
AB  - INTRODUCTION: The need for cataract surgery is on the rise due to our ageing
      population and high demands for greater visual functioning. Although the majority
      of patients want to participate in a shared decision-making process, no decision 
      aid has been available to improve the quality of decision. The present study aims
      to determine whether a decision aid increases informed decision about cataract
      surgery. METHODS AND ANALYSIS: A parallel randomised controlled trial (772
      participants) will be conducted. The decision aid will be implemented among
      patients with any age-related cataract in Yuexiu District, which is
      socioeconomically representative of a major metropolitan region in Southern
      China. Participants will be randomly assigned to receive either a patient
      decision aid or a traditional booklet, and they will complete three surveys: (1) 
      baseline assessment before the intervention (time point (T)1), 2 weeks (T2) and 1
      year (T3) after the intervention. The control group receives a traditional
      booklet with standard general information developed by the National Eye Institute
      to help patients understand cataract, whereas the intervention group receives a
      patient decision aid that includes not only the standard general information, but
      also the quantitative risk information on the possible outcomes of cataract
      surgery as well as value clarification exercise. The primary study outcome is the
      informed decision, the percentage of patients who have adequate knowledge and
      demonstrate consistency between attitudes and intentions. Secondary outcomes
      include perceived importance of cataract surgery benefits/harms, decision
      conflict and confidence, anticipated regret and booklet utilisation and
      acceptability at 2 weeks, and surgical rates and a cost-utility estimate of the
      decision aid at 1 year. ETHICS AND DISSEMINATION: Ethics approval was obtained
      from the Ethics Committee of Zhongshan Ophthalmic Center (reference number:
      2019KYPJ090). Results will be published in peer-reviewed journals and presented
      at scientific meetings for academic audiences. TRIAL REGISTRATION NUMBER:
      NCT03992807.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zheng, Yingfeng
AU  - Zheng Y
AUID- ORCID: 0000-0002-0914-7864
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China zhyfeng@mail.sysu.edu.cn.
FAU - Qu, Bo
AU  - Qu B
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
FAU - Jin, Ling
AU  - Jin L
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
FAU - Wang, Chunxiao
AU  - Wang C
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
FAU - Zhong, Yuxin
AU  - Zhong Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
FAU - He, Mingguang
AU  - He M
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Liu, Yizhi
AU  - Liu Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03992807
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cataract/therapy
MH  - China
MH  - *Decision Making, Shared
MH  - Decision Support Techniques
MH  - Humans
MH  - Pamphlets
MH  - Randomized Controlled Trials as Topic
PMC - PMC7239516
OTO - NOTNLM
OT  - *cataract
OT  - *cataract surgery
OT  - *informed choice
OT  - *patient decision aid
OT  - *shared decision making
COIS- Competing interests: None declared.
EDAT- 2020/05/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-032242 [pii]
AID - 10.1136/bmjopen-2019-032242 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 18;10(5):e032242. doi: 10.1136/bmjopen-2019-032242.


PMID- 32430441
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20210804
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 2
DP  - 2020 Aug
TI  - Benefits and Risks of Visitor Restrictions for Hospitalized Children During the
      COVID Pandemic.
LID - e2020000786 [pii]
LID - 10.1542/peds.2020-000786 [doi]
AB  - To control the spread of severe acute respiratory syndrome coronavirus 2, the
      virus responsible for coronavirus disease 2019, many hospitals have strict
      visitor restriction policies. These policies often prohibit both parents from
      visiting at the same time or having grandparents or other family members visit at
      all. We discuss cases in which such policies created ethical dilemmas and
      possibly called for compassionate exceptions from the general rules.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Virani, Alice K
AU  - Virani AK
AD  - Ethics Service, Provincial Health Services Authority, Vancouver, British
      Columbia, Canada; alice.virani@phsa.ca.
AD  - Department of Medical Genetics, University of British Columbia, Vancouver,
      British Columbia, Canada.
FAU - Puls, Henry T
AU  - Puls HT
AD  - Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri; and.
FAU - Mitsos, Rebecca
AU  - Mitsos R
AD  - Department of Child Life Services, Ann & Robert H. Lurie Children's Hospital of
      Chicago, Chicago, Illinois.
FAU - Longstaff, Holly
AU  - Longstaff H
AD  - Ethics Service, Provincial Health Services Authority, Vancouver, British
      Columbia, Canada.
FAU - Goldman, Ran D
AU  - Goldman RD
AD  - Pediatric Research in Emergency Therapeutics Program, Department of Pediatrics,
      University of British Columbia and BC Children's Hospital Research Institute,
      Vancouver, British Columbia, Canada.
FAU - Lantos, John D
AU  - Lantos JD
AD  - Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri; and.
LA  - eng
PT  - Letter
DEP - 20200519
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
CIN - Pediatrics. 2021 Aug;148(2):. PMID: 33990461
MH  - Adolescent
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Child, Hospitalized/*psychology
MH  - Coronavirus Infections/*prevention & control/psychology/transmission
MH  - Cost-Benefit Analysis
MH  - Family
MH  - Female
MH  - Health Policy
MH  - Humans
MH  - Infant, Newborn
MH  - Infection Control/*methods/standards
MH  - Male
MH  - Pandemics/*prevention & control
MH  - Patient-Centered Care/*ethics/methods/standards
MH  - Pneumonia, Viral/*prevention & control/psychology/transmission
MH  - SARS-CoV-2
MH  - Visitors to Patients/*psychology
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/05/21 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - peds.2020-000786 [pii]
AID - 10.1542/peds.2020-000786 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Aug;146(2). pii: peds.2020-000786. doi:
      10.1542/peds.2020-000786. Epub 2020 May 19.


PMID- 32430245
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 2603-6479 (Electronic)
IS  - 2603-6479 (Linking)
VI  - 35
IP  - 4
DP  - 2020 Jul - Aug
TI  - [The business case for medical informed consent as an incentive to meet in the
      clinical practice the requirements of the ethical and legal doctrine].
PG  - 267-268
LID - S2603-6479(20)30037-3 [pii]
LID - 10.1016/j.jhqr.2020.01.007 [doi]
FAU - Cruz-Valino, A B
AU  - Cruz-Valino AB
AD  - Facultade de Ciencias da Saude, Universidade da Coruna. Grupo de Investigacion
      Filosofia, Constitucion y Racionalidad, Universidade da Coruna, A Coruna, Espana.
      Electronic address: Ana.cvalino@udc.es.
LA  - spa
PT  - Letter
TT  - El argumento <<negocial>> del consentimiento informado como incentivo para
      cumplir en la practica clinica los requisitos de la doctrina etica y juridica.
DEP - 20200517
PL  - Spain
TA  - J Healthc Qual Res
JT  - Journal of healthcare quality research
JID - 101735273
SB  - IM
MH  - Humans
MH  - *Informed Consent
MH  - Morals
MH  - *Motivation
EDAT- 2020/05/21 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/12/28 00:00 [received]
PHST- 2020/01/15 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - S2603-6479(20)30037-3 [pii]
AID - 10.1016/j.jhqr.2020.01.007 [doi]
PST - ppublish
SO  - J Healthc Qual Res. 2020 Jul - Aug;35(4):267-268. doi:
      10.1016/j.jhqr.2020.01.007. Epub 2020 May 17.


PMID- 32430111
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 1545-7214 (Electronic)
IS  - 1064-7481 (Linking)
VI  - 28
IP  - 8
DP  - 2020 Aug
TI  - Achieving Safe, Effective, and Compassionate Quarantine or Isolation of Older
      Adults With Dementia in Nursing Homes.
PG  - 835-838
LID - S1064-7481(20)30326-2 [pii]
LID - 10.1016/j.jagp.2020.04.025 [doi]
AB  - Nursing homes are facing the rapid spread of COVID-19 among residents and staff
      and are at the centre of the public health emergency due to the COVID-19
      pandemic. As policy changes and interventions designed to support nursing homes
      are put into place, there are barriers to implementing a fundamental, highly
      effective element of infection control, namely the isolation of suspected or
      confirmed cases. Many nursing home residents have dementia, associated with
      impairments in memory, language, insight, and judgment that impact their ability 
      to understand and appreciate the necessity of isolation and to voluntarily comply
      with isolation procedures. While there is a clear ethical and legal basis for the
      involuntary confinement of people with dementia, the potential for unintended
      harm with these interventions is high, and there is little guidance for nursing
      homes on how to isolate safely, while maintaining the human dignity and
      personhood of the individual with dementia. In this commentary, we discuss
      strategies for effective, safe, and compassionate isolation care planning, and
      present a case vignette of a person with dementia who is placed in quarantine on 
      a dementia unit.
CI  - Copyright (c) 2020 American Association for Geriatric Psychiatry. Published by
      Elsevier Inc. All rights reserved.
FAU - Iaboni, Andrea
AU  - Iaboni A
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada; Centre for Mental Health, University Health
      Network (AL, KBR, RK, and AJF), Toronto, ON, Canada; Department of Psychiatry
      (AL, KBR, RK, and AJF), University of Toronto, Toronto, ON, Canada. Electronic
      address: andrea.iaboni@uhn.ca.
FAU - Cockburn, Amy
AU  - Cockburn A
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada.
FAU - Marcil, Meghan
AU  - Marcil M
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada.
FAU - Rodrigues, Kevin
AU  - Rodrigues K
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada; Department of Bioethics (KR), University Health
      Network, Toronto, ON, Canada.
FAU - Marshall, Cecelia
AU  - Marshall C
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada.
FAU - Garcia, Mary Anne
AU  - Garcia MA
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada.
FAU - Quirt, Hannah
AU  - Quirt H
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada.
FAU - Reynolds, Katelyn B
AU  - Reynolds KB
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada; Centre for Mental Health, University Health
      Network (AL, KBR, RK, and AJF), Toronto, ON, Canada; Department of Psychiatry
      (AL, KBR, RK, and AJF), University of Toronto, Toronto, ON, Canada.
FAU - Keren, Ron
AU  - Keren R
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada; Centre for Mental Health, University Health
      Network (AL, KBR, RK, and AJF), Toronto, ON, Canada; Department of Psychiatry
      (AL, KBR, RK, and AJF), University of Toronto, Toronto, ON, Canada.
FAU - Flint, Alastair J
AU  - Flint AJ
AD  - Toronto Rehab, University Health Network (AL, AC, MM, KR, CM, MAG, HQ, KBR, RK,
      and AJF), Toronto, ON, Canada; Centre for Mental Health, University Health
      Network (AL, KBR, RK, and AJF), Toronto, ON, Canada; Department of Psychiatry
      (AL, KBR, RK, and AJF), University of Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American
      Association for Geriatric Psychiatry
JID - 9309609
SB  - IM
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/complications/*prevention & control/*therapy/transmission
MH  - Dementia/complications/*therapy
MH  - Female
MH  - Humans
MH  - Involuntary Treatment/ethics/methods
MH  - Nursing Homes/*standards
MH  - Pandemics/*prevention & control
MH  - Patient Isolation/ethics/*methods
MH  - Pneumonia, Viral/complications/*prevention & control/*therapy/transmission
MH  - Quarantine/ethics/*methods
MH  - SARS-CoV-2
PMC - PMC7196899
OTO - NOTNLM
OT  - *COVID-19
OT  - *Dementia
OT  - *infection control
OT  - *isolation
OT  - *nursing homes
EDAT- 2020/05/21 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - S1064-7481(20)30326-2 [pii]
AID - 10.1016/j.jagp.2020.04.025 [doi]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2020 Aug;28(8):835-838. doi: 10.1016/j.jagp.2020.04.025.
      Epub 2020 May 4.


PMID- 32429963
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20201020
IS  - 1743-0003 (Electronic)
IS  - 1743-0003 (Linking)
VI  - 17
IP  - 1
DP  - 2020 May 19
TI  - Selective neural electrical stimulation restores hand and forearm movements in
      individuals with complete tetraplegia.
PG  - 66
LID - 10.1186/s12984-020-00676-4 [doi]
AB  - BACKGROUND: We hypothesized that a selective neural electrical stimulation of
      radial and median nerves enables the activation of functional movements in the
      paralyzed hand of individuals with tetraplegia. Compared to previous approaches
      for which up to 12 muscles were targeted through individual muscular
      stimulations, we focused on minimizing the number of implanted electrodes however
      providing almost all the needed and useful hand movements for subjects with
      complete tetraplegia. METHODS: We performed acute experiments during scheduled
      surgeries of the upper limb with eligible subjects. We scanned a set of
      multicontact neural stimulation cuff electrode configurations, pre-computed
      through modeling simulations. We reported the obtained isolated and functional
      movements that were considered useful for the subject (different grasping
      movements). RESULTS: In eight subjects, we demonstrated that selective
      stimulation based on multicontact cuff electrodes and optimized current spreading
      over the active contacts provided isolated, compound, functional and strong
      movements; most importantly 3 out of 4 had isolated fingers or thumb flexion, one
      patient performed a Key Grip, another one the Power and Hook Grips, and the 2
      last all the 3 Grips. Several configurations were needed to target different
      areas within the nerve to obtain all the envisioned movements. We further
      confirmed that the upper limb nerves have muscle specific fascicles, which makes 
      it possible to activate isolated movements. CONCLUSIONS: The future goal is to
      provide patients with functional restoration of object grasping and releasing
      with a minimally invasive solution: only two cuff electrodes above the elbow.
      Ethics Committee / ANSM clearance prior to the beginning of the study (inclusion 
      period 2016-2018): CPP Sud Mediterranee, #ID-RCB:2014-A01752-45, first acceptance
      10th of February 2015, amended 12th of January 2016. TRIAL REGISTRATION:
      (www.clinicaltrials.gov): #NCT03721861, Retrospectively registered on 26th of
      October 2018.
FAU - Tigra, Wafa
AU  - Tigra W
AD  - INRIA, University of Montpellier, CNRS, Montpellier, France.
AD  - MXM group, Sophia-Antipolis, France.
FAU - Dali, Melissa
AU  - Dali M
AD  - INRIA, University of Montpellier, CNRS, Montpellier, France.
FAU - William, Lucie
AU  - William L
AD  - INRIA, University of Montpellier, CNRS, Montpellier, France.
FAU - Fattal, Charles
AU  - Fattal C
AD  - La Chataigneraie Rehabilitation Center, Menucourt, France.
FAU - Gelis, Anthony
AU  - Gelis A
AD  - Propara Rehabilitation Center, Montpellier, France.
FAU - Divoux, Jean-Louis
AU  - Divoux JL
AD  - Axonic, MXM Group, Sophia-Antipolis, France.
FAU - Coulet, Bertrand
AU  - Coulet B
AD  - University Hospital of Montpellier, Montpellier, France.
FAU - Teissier, Jacques
AU  - Teissier J
AD  - Beau Soleil Clinic, Montpellier, France.
FAU - Guiraud, David
AU  - Guiraud D
AD  - INRIA, University of Montpellier, CNRS, Montpellier, France.
      david.guiraud@inria.fr.
AD  - NEURINNOV SAS, Montpellier, France. david.guiraud@inria.fr.
FAU - Azevedo Coste, Christine
AU  - Azevedo Coste C
AD  - INRIA, University of Montpellier, CNRS, Montpellier, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03721861
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200519
PL  - England
TA  - J Neuroeng Rehabil
JT  - Journal of neuroengineering and rehabilitation
JID - 101232233
SB  - IM
MH  - Adult
MH  - Electric Stimulation Therapy/*methods
MH  - Electrodes, Implanted
MH  - Forearm/physiopathology
MH  - Hand/physiopathology
MH  - Humans
MH  - Male
MH  - Median Nerve/*surgery
MH  - Middle Aged
MH  - Movement/physiology
MH  - Quadriplegia/etiology/*therapy
MH  - Radial Nerve/*surgery
MH  - Spinal Cord Injuries/complications/*therapy
MH  - Young Adult
PMC - PMC7236876
OTO - NOTNLM
OT  - *Grasping movement
OT  - *Multicontact cuff electrode
OT  - *Neural stimulation
OT  - *Selective stimulation
OT  - *Tetraplegia
EDAT- 2020/05/21 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/08/30 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1186/s12984-020-00676-4 [doi]
AID - 10.1186/s12984-020-00676-4 [pii]
PST - epublish
SO  - J Neuroeng Rehabil. 2020 May 19;17(1):66. doi: 10.1186/s12984-020-00676-4.


PMID- 32429926
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 19
TI  - Medical professionalism in ophthalmology: design and testing of a scenario based 
      survey.
PG  - 160
LID - 10.1186/s12909-020-02071-y [doi]
AB  - BACKGROUND: Professionalism is hard to quantify but essential in medical
      practice. We present a survey tool for ophthalmologists that assessed
      professionalism using case-based scenarios in central Saudi Arabia. METHODS:
      Ophthalmologists (resident, fellows and consultants) participated in a web-based 
      survey in 2015. Out of 44 attributes related to professionalism, experts selected
      32 attributes with validity indices of >/=0.80. To evaluate these attributes, 51 
      scenario-based questions were developed and included in the survey. For each
      attribute, participants were given choices of close ended responses: unacceptable
      (1), probably unacceptable (2), acceptable (3), probably acceptable (4). The
      attribute score was compared to the gold standard (responses of an expert group).
      An attribute score was generated and compared among subgroups. RESULTS: Of the
      155 ophthalmologists, responses of 147 ophthalmologists who completed more than
      50% of questions were reviewed. Their mean attribute score was 84.1 +/- 10.1
      (Median 87.1; 25% quartile 78.1; minimum 50; and maximum 100). The variation in
      attribute score among consultants, fellows and resident ophthalmologists was
      significant (P = 0.008). The variation of attribute score by groups of attributes
      was also significant (P < 0.05). The score for 'Personal characteristics' was on 
      a lower scale compared to that of other attribute groups. The variation in the
      scores for attribute groups; 'Personal characteristics attribute' group (p <
      0.01) and 'Workplace practices & relationship' group (P = 0.03) for consultants, 
      fellows and residents were significant. CONCLUSIONS: Professionalism among
      ophthalmologists and those in training was high and influenced by years of
      experience. The survey tool appeared to show differences in responses to specific
      professional attribute groups between trainees and consultants. Additional
      studies with a larger sample size might be helpful in validating the survey as a 
      tool to be used to assess professionalism in graduate medical education in
      ophthalmology.
FAU - Alkahtani, Eman
AU  - Alkahtani E
AD  - The Eye Consultant Clinic, Riyadh, Saudi Arabia. ekahtanii@gmail.com.
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia. 
      ekahtanii@gmail.com.
FAU - Assiri, Abdullah
AU  - Assiri A
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia.
AD  - Magrabi Eye Ear & Dental Hospital, Riyadh, Saudi Arabia.
FAU - Alrashaed, Saba
AU  - Alrashaed S
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia.
AD  - Dr. Sulman Alhabib Hospitals, Riyadh, Saudi Arabia.
FAU - Alharbi, Mosa
AU  - Alharbi M
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia.
AD  - The Eye Consultant Clinic, Jeddah, Saudi Arabia.
FAU - Almotowa, Saeed
AU  - Almotowa S
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia.
FAU - Khandekar, Rajiv
AU  - Khandekar R
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia.
FAU - Edward, Deepak P
AU  - Edward DP
AD  - King Khaled Eye Specialist Hospital, P.O. Box 7191, Riyadh, 11462, Saudi Arabia.
AD  - University of Illinois Eye and Ear Infirmary, Chicago, IL, USA.
AD  - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Humans
MH  - *Internship and Residency
MH  - *Ophthalmologists
MH  - *Professional Competence
MH  - *Professionalism
MH  - Saudi Arabia
MH  - Surveys and Questionnaires/*standards
PMC - PMC7236953
OTO - NOTNLM
OT  - Ethics
OT  - Medical profession
OT  - Ophthalmology
OT  - Professionalism
EDAT- 2020/05/21 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/04/26 00:00 [received]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - 10.1186/s12909-020-02071-y [doi]
AID - 10.1186/s12909-020-02071-y [pii]
PST - epublish
SO  - BMC Med Educ. 2020 May 19;20(1):160. doi: 10.1186/s12909-020-02071-y.


PMID- 32429881
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210211
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 19
TI  - Results of 198 primary total hip arthroplasties using the Delta PF-FIT system
      with ceramic-on-ceramic articulating surfaces with average seven years follow up.
PG  - 311
LID - 10.1186/s12891-020-03253-x [doi]
AB  - BACKGROUND: The lifetime implants is a key parameter that the surgeon should take
      into account at the time of the primary total hip arthroplasty (THA). The aim of 
      this study was a clinical and radiographical evaluation of the Delta PF-FIT
      (LimaCorporate, Italy) THA system with ceramic-on-ceramic articulations. We have 
      not found a clinical or radiographical assessment of this implant in available
      published literature. METHODS: A total of 197 (F = 94, M = 103) primary THAs were
      evaluated in 163 patients with a mean follow-up of 7.7 years (range 5.1-11.2
      years (SD +/- 1.5)) Harris hip Score (HHS) and the Western Ontario and McMaster
      Universities Arthritis index (WOMAC) were used for the clinical evaluation. The
      statistical evaluation was processed by standard statistical methods. The study
      was approved by Ethic Committee of the University Hospital Motol (Reference No.
      EK-73/19). RESULTS: The mean HHS score was found to be 97.59 points (61-100 range
      with a +/- 5.13 SD, preoperative HSS was 51.21, range 28-73 with a +/- 4,77 SD). 
      186 THAs were evaluated as excellent (90-100 points), 9 THAs rated as good (80-89
      points), 1 THA was rated as fair (70-79) points and 1 THA rated as poor (less
      than 70 points). The mean WOMAC score was 97.38 points (65-100 range with a +/-
      5.18 SD, preoperative was 50,12, range 27-69 with a +/- 4.85 SD). We documented
      an overall 99.49% Kaplan-Meier survival with a mean follow-up of 7.7 years with
      the FIT (LimaCorporate) stem revision and any component revision as the endpoint.
      With the Delta PF (LimaCorporate) cup revision as the endpoint, the survival was 
      100%. We have not found a previously published clinical or radiographical review 
      of this THA system, the study shows a comparison with other THA implants.
      CONCLUSION: Evaluation of the Delta-PF-FIT (LimaCorporate, Italy) THA system with
      the use of ceramic-on-ceramic BIOLOX(R)Delta articulation surfaces shows very
      good outcomes.
FAU - Fulin, Petr
AU  - Fulin P
AD  - Orthopaedic Clinic 1st Faculty of Medicine Charles University and Motol
      University Hospital, V Uvalu 84, 15006, Prague, Czech Republic.
      petrfulin@gmail.com.
FAU - Pokorny, David
AU  - Pokorny D
AD  - Orthopaedic Clinic 1st Faculty of Medicine Charles University and Motol
      University Hospital, V Uvalu 84, 15006, Prague, Czech Republic.
FAU - Hert, Jan
AU  - Hert J
AD  - Orthopaedic Clinic 1st Faculty of Medicine Charles University and Motol
      University Hospital, V Uvalu 84, 15006, Prague, Czech Republic.
FAU - Sosna, Antonin
AU  - Sosna A
AD  - Orthopaedic Clinic 1st Faculty of Medicine Charles University and Motol
      University Hospital, V Uvalu 84, 15006, Prague, Czech Republic.
LA  - eng
GR  - TH-03010354/Technologicka Agentura Ceske Republiky
GR  - 15-31269A/Agentura Pro Zdravotnicky Vyzkum Ceske Republiky
GR  - FV-30086/Ministerstvo Prumyslu a Obchodu
GR  - Q25/LF1/2/Univerzita Karlova v Praze
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Hip/*methods
MH  - *Ceramics
MH  - Female
MH  - Follow-Up Studies
MH  - *Hip Prosthesis
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Hip/*surgery
MH  - Prosthesis Design
MH  - Radiography
MH  - Reoperation
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Young Adult
PMC - PMC7236923
OTO - NOTNLM
OT  - Delta PF cup
OT  - FIT stem
OT  - HHS
OT  - LimaCorporate
OT  - Total hip arthroplasty
OT  - WOMAC
EDAT- 2020/05/21 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/02/02 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - 10.1186/s12891-020-03253-x [doi]
AID - 10.1186/s12891-020-03253-x [pii]
PST - epublish
SO  - BMC Musculoskelet Disord. 2020 May 19;21(1):311. doi: 10.1186/s12891-020-03253-x.


PMID- 32429839
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 19
TI  - Sevoflurane versus PRopofol combined with Remifentanil anesthesia Impact on
      postoperative Neurologic function in supratentorial Gliomas (SPRING): protocol
      for a randomized controlled trial.
PG  - 117
LID - 10.1186/s12871-020-01035-5 [doi]
AB  - BACKGROUND: Patients with intracranial tumors are more sensitive to anesthetics
      than the general population and are therefore more susceptible to postoperative
      neurologic and neurocognitive dysfunction. Sevoflurane or propofol combined with 
      remifentanil are widely used general anesthetic regimens for craniotomy, with
      neither regimen shown to be superior to the other in terms of neuroprotective
      efficacy and anesthesia quality. There is no evidence regarding the variable
      effects on postoperative neurologic and neurocognitive functional outcome under
      these two general anesthetic regimens. This trial will compare inhalational
      sevoflurane or intravenous propofol combined with remifentanil anesthesia in
      patients with supratentorial gliomas and test the hypothesis that postoperative
      neurologic function is equally affected between the two regimens. METHODS: This
      is a prospective, single-center, randomized parallel arm equivalent clinical
      trial, which is approved by China Ethics Committee of Registering Clinical Trials
      (ChiECRCT-20,160,051). Patients with supratentorial gliomas diagnosed by magnetic
      resonance imaging will be eligible for the trial. Written informed consent will
      be obtained before randomly assigning each subject to either the
      sevoflurane-remifentanil or propofol-remifentanil group for anesthesia
      maintenance to achieve an equal-desired depth of anesthesia. Intraoperative
      intervention and monitoring will follow a standard anesthetic management
      protocol. All of the physiological parameters and other medications administered 
      during the intervention will be recorded. The primary outcome will be neurologic 
      function change assessed by National Institute of Health Stroke Scale (NIHSS)
      within 4 h after general anesthesia when observer's assessment of
      alertness/sedation (OAA/S) reaches 4. Secondary outcomes will include NIHSS and
      modified NIHSS change 1 and 2 days after general anesthesia, hemodynamic
      stability, intraoperative brain relaxation, quality of anesthesia emergence,
      quality of anesthesia recovery, postoperative cognitive function, postoperative
      pain, postoperative neurologic complications, as well as perioperative medical
      expense. DISCUSSION: This randomized equivalency trial will primarily compare the
      impacts of sevoflurane-remifentanil and propofol-remifentanil anesthesia on
      short-term postoperative neurologic function in patients with supratentorial
      gliomas undergoing craniotomy. The exclusion criteria are strict to ensure that
      the groups are comparable in all aspects. Repeated and routine neurologic
      evaluations after operation are always important to evaluate neurosurgical
      patients' recovery and any newly presenting complications. The results of this
      trial would help specifically to interpret anesthetic residual effects on
      postoperative outcomes, and perhaps would help the anesthesiologist to select the
      optimal anesthetic regimen to minimize its impact on neurologic function in this 
      specific patient population. TRIAL REGISTRATION: The study was registered and
      approved by the Chinese Clinical Trial Registry (Chinese Clinical Trial Registry,
      ChiCTR-IOR-16009177). Principle investigator: Nan Lin (email address:
      linnan127@gmail.com) and Ruquan Han (email address: hanrq666@aliyun.com) Date of 
      Registration: September 8th, 2016. Country of recruitment: China.
FAU - Xing, Yan
AU  - Xing Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Lin, Nan
AU  - Lin N
AUID- ORCID: 0000-0002-1611-1245
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China. linnan127@gmail.com.
FAU - Han, Ruquan
AU  - Han R
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China. Hanrq666@aliyun.com.
FAU - Bebawy, John F
AU  - Bebawy JF
AD  - Departments of Anesthesiology & Neurological Surgery, Northwestern University
      Feinberg School of Medicine, 251 E. Huron St., F5-704, Chicago, IL, 60611, USA.
FAU - Peng, Yuming
AU  - Peng Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Li, Jiaxin
AU  - Li J
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Liu, Xiaoyuan
AU  - Liu X
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Dong, Jia
AU  - Dong J
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Zeng, Min
AU  - Zeng M
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Zhang, Manyu
AU  - Zhang M
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
FAU - Nie, Lanyi
AU  - Nie L
AD  - Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical
      University, No.119, West Road 4th ring South, Fengtai District, Beijing, 100070, 
      China.
LA  - eng
GR  - QML20160503/Beijing Municipal Administration of Hospitals' Youth
      Program/International
GR  - 81701038/National Natural Science Foundation of China/International
GR  - ZYLX201708/Beijing Municipal Administration of Hospitals Clinical Medicine
      Development of Special Funding Support/International
PT  - Clinical Trial Protocol
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200519
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
RN  - 38LVP0K73A (Sevoflurane)
RN  - P10582JYYK (Remifentanil)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Brain/*physiopathology
MH  - Craniotomy
MH  - Female
MH  - Glioma/physiopathology/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propofol/*administration & dosage
MH  - Prospective Studies
MH  - *Randomized Controlled Trials as Topic
MH  - Remifentanil/*administration & dosage
MH  - Sevoflurane/*administration & dosage
MH  - Supratentorial Neoplasms/physiopathology/*surgery
MH  - Young Adult
PMC - PMC7236146
OTO - NOTNLM
OT  - *(3-10): propofol
OT  - *Craniotomy
OT  - *General anesthesia
OT  - *Neurologic function
OT  - *Sevoflurane
OT  - *Supratentorial glioma
OT  - *Total intravenous anesthesia
EDAT- 2020/05/21 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/05/21 06:00
PHST- 2019/09/01 00:00 [received]
PHST- 2020/05/10 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
AID - 10.1186/s12871-020-01035-5 [doi]
AID - 10.1186/s12871-020-01035-5 [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 May 19;20(1):117. doi: 10.1186/s12871-020-01035-5.


PMID- 32429746
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 2152-4998 (Electronic)
IS  - 2152-4971 (Linking)
VI  - 22
IP  - 3
DP  - 2020 Jun
TI  - In Vitro and In Vivo Interspecies Chimera Assay Using Early Pig Embryos.
PG  - 118-133
LID - 10.1089/cell.2019.0107 [doi]
AB  - Chimeric pigs harboring organs derived from human stem cells are promising for
      patient-specific regenerative therapies. Induced pluripotent stem cells (iPSCs)
      can contribute to all cell types of the fetus, including germline after injection
      into embryos. However, ethical concerns prohibit testing human iPSCs in chimera
      assays. Here, we evaluated porcine embryos as hosts for an interspecies chimera
      assay using iPSCs from either cynomolgus monkeys (cyiPSCs) or mouse (miPSCs). To 
      establish an in vitro culture system compatible for cyiPSCs and porcine embryos, 
      we determined blastocyst development in eight different stem cell media. The
      highest developmental rates of blastocysts were achieved in Knockout Dulbecco's
      modified Eagle's medium with 20% knockout serum replacement. We found that
      cyiPSCs injected into porcine embryos survived in vitro and were mostly located
      in the trophectoderm (TE). Instead, when miPSCs were injected into porcine
      embryos, the cells rapidly proliferated. The behavior of chimeras developed in
      vitro was recapitulated in vivo; cyiPSCs were observed in the TE, but not in the 
      porcine epiblast. However, when miPSCs were injected into in vivo derived porcine
      embryos, mouse cells were found in both, the epiblast and TE. These results
      demonstrate that porcine embryos could be useful for evaluating the interspecies 
      chimera-forming ability of iPSCs from different species.
FAU - Nowak-Imialek, Monika
AU  - Nowak-Imialek M
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
AD  - REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.
FAU - Wunderlich, Stephanie
AU  - Wunderlich S
AD  - Leibniz Research Laboratories for Biotechnology and Artificial Organs-LEBAO,
      Hannover Medical School, Hannover, Germany.
FAU - Herrmann, Doris
AU  - Herrmann D
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
FAU - Breitschuh-Leibling, Svenja
AU  - Breitschuh-Leibling S
AD  - Institute of Molecular and Cell Physiology, Hannover Medical School, Hannover,
      Germany.
FAU - Gohring, Gudrun
AU  - Gohring G
AD  - Department of Human Genetics, Hannover Medical School, Hannover, Germany.
FAU - Petersen, Bjorn
AU  - Petersen B
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
FAU - Klein, Sabine
AU  - Klein S
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
FAU - Baulain, Ulrich
AU  - Baulain U
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
FAU - Lucas-Hahn, Andrea
AU  - Lucas-Hahn A
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
FAU - Martin, Ulrich
AU  - Martin U
AD  - REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.
AD  - Leibniz Research Laboratories for Biotechnology and Artificial Organs-LEBAO,
      Hannover Medical School, Hannover, Germany.
FAU - Niemann, Heiner
AU  - Niemann H
AD  - Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut, Neustadt,
      Germany.
AD  - REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200519
PL  - United States
TA  - Cell Reprogram
JT  - Cellular reprogramming
JID - 101528176
RN  - 0 (Culture Media)
SB  - IM
MH  - Animals
MH  - Blastocyst
MH  - Chimera/*embryology
MH  - Culture Media
MH  - Embryo Culture Techniques/*veterinary
MH  - Embryo, Mammalian
MH  - Embryonic Development/*physiology
MH  - Induced Pluripotent Stem Cells/*cytology
MH  - Macaca fascicularis
MH  - Mice
MH  - Species Specificity
MH  - Swine
OTO - NOTNLM
OT  - *chimera assay
OT  - *embryos
OT  - *iPSCs
OT  - *interspecies
OT  - *porcine
EDAT- 2020/05/21 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1089/cell.2019.0107 [doi]
PST - ppublish
SO  - Cell Reprogram. 2020 Jun;22(3):118-133. doi: 10.1089/cell.2019.0107. Epub 2020
      May 19.


PMID- 32429689
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20201201
IS  - 1740-7753 (Electronic)
IS  - 1740-7745 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Aug
TI  - Comment on Hemming et al.'s 'Stepped-wedge trials should be classified as
      research for the purpose of ethical review'.
PG  - 459-460
LID - 10.1177/1740774520920543 [doi]
FAU - Lilford, Richard J
AU  - Lilford RJ
AUID- ORCID: 0000-0002-0634-984X
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Watson, Samuel I
AU  - Watson SI
AD  - Warwick Medical School, The University of Warwick, Coventry, UK.
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200519
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
SB  - IM
CON - Clin Trials. 2019 Dec;16(6):580-588. PMID: 31818147
CIN - Clin Trials. 2020 Aug;17(4):461-462. PMID: 32429698
MH  - *Ethical Review
MH  - Sample Size
EDAT- 2020/05/21 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1177/1740774520920543 [doi]
PST - ppublish
SO  - Clin Trials. 2020 Aug;17(4):459-460. doi: 10.1177/1740774520920543. Epub 2020 May
      19.


PMID- 32429687
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1947-5543 (Electronic)
IS  - 1947-5543 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Aug
TI  - Best Practices for Human Biobank Ethics Review in China.
PG  - 274-282
LID - 10.1089/bio.2019.0132 [doi]
AB  - The ethical practices for human biobanks in China are intended to safeguard the
      interests of all the participants, to standardize the construction, management,
      and resource sharing of human biobanks, to promote the development of medical
      research, and to improve public health and well-being. The practices contain
      several chapters: General Principles; Ethics Review; Informed Consent; Privacy
      Protection; Benefits of Sharing; and Conflict of Interest.
FAU - Liu, Shijian
AU  - Liu S
AD  - Department of Biobank, Clinical Research Center, Shanghai Children's Medical
      Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wang, Weiye Charles
AU  - Wang WC
AD  - MOE-Shanghai Key Lab of Children's Environmental Health Xinhua Hospital, Shanghai
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Zhang, Hongxia
AU  - Zhang H
AD  - Shanghai Ethics Committee for Clinical Research, Shanghai Clinical Research
      Center, Shanghai, China.
FAU - Tong, Jianyun
AU  - Tong J
AD  - Shanghai Kangzheng Law Firm, Shanghai, China.
FAU - Zhang, Xiaoyi
AU  - Zhang X
AD  - Shanghai Ethics Committee for Clinical Research, Shanghai Clinical Research
      Center, Shanghai, China.
FAU - Chen, Pei
AU  - Chen P
AD  - Shanghai Ethics Committee for Clinical Research, Shanghai Clinical Research
      Center, Shanghai, China.
FAU - Hu, Chingli
AU  - Hu C
AD  - Shanghai Ethics Committee for Clinical Research, Shanghai Clinical Research
      Center, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - United States
TA  - Biopreserv Biobank
JT  - Biopreservation and biobanking
JID - 101507284
SB  - IM
MH  - Biological Specimen Banks/*ethics
MH  - Biomedical Research/*ethics
MH  - China
MH  - Humans
MH  - Information Dissemination/ethics
MH  - Informed Consent/ethics
MH  - Practice Guidelines as Topic/*standards
OTO - NOTNLM
OT  - best practice
OT  - biobank
OT  - ethics
OT  - review
EDAT- 2020/05/21 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
AID - 10.1089/bio.2019.0132 [doi]
PST - ppublish
SO  - Biopreserv Biobank. 2020 Aug;18(4):274-282. doi: 10.1089/bio.2019.0132. Epub 2020
      May 19.


PMID- 32429303
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 15
TI  - Functional Magnetic Resonance Imaging in the Final Stage of Creutzfeldt-Jakob
      Disease.
LID - E309 [pii]
LID - 10.3390/diagnostics10050309 [doi]
AB  - Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare fatal degenerative disease of
      the central nervous system. The clinical course is characterized by rapid
      progression of neurological and neuromuscular symptoms. The late stage with loss 
      of consciousness is not well characterized. We report a 62-year-old male patient 
      with sCJD with the clinical picture of a vegetative state/apallic syndrome, in
      whom we studied cortical responses using a vibration paradigm. The functional
      magnetic resonance imaging (fMRI) investigation demonstrated a clear response
      within the sensorimotor cortex, the cerebellum, the parietal cortex, the insular,
      and frontal inferior region. The finding of persistent cortical activity on fMRI 
      in a patient with CJD in a state of unconsciousness has implications for the
      clinical management and for ethical considerations.
FAU - Golaszewski, Stefan M
AU  - Golaszewski SM
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, 5020
      Salzburg, Austria.
AD  - Neuroscience Institute, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
FAU - Wutzl, Bettina
AU  - Wutzl B
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, 5020
      Salzburg, Austria.
AD  - Institute for Analysis and Scientific Computing, Technical University of Vienna, 
      1040 Vienna, Austria.
FAU - Unterrainer, Axel F
AU  - Unterrainer AF
AD  - Institute of Neuroanesthesiology, Christian Doppler Medical Center, Paracelsus
      Medical University, 5020 Salzburg, Austria.
FAU - Florea, Cristina
AU  - Florea C
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
FAU - Schwenker, Kerstin
AU  - Schwenker K
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, 5020
      Salzburg, Austria.
FAU - Frey, Vanessa N
AU  - Frey VN
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
FAU - Kronbichler, Martin
AU  - Kronbichler M
AD  - Neuroscience Institute, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Centre for Cognitive Neuroscience and Department of Psychology, University of
      Salzburg, 5020 Salzburg, Austria.
FAU - Rattay, Frank
AU  - Rattay F
AUID- ORCID: 0000-0002-2819-8827
AD  - Institute for Analysis and Scientific Computing, Technical University of Vienna, 
      1040 Vienna, Austria.
FAU - Nardone, Raffaele
AU  - Nardone R
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Department of Neurology, Franz-Tappeiner-Hospital, 39012 Merano, Italy.
FAU - Hauer, Larissa
AU  - Hauer L
AD  - Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Christian
      Doppler Medical Center, Paracelsus Medical University, 5020 Salzburg, Austria.
FAU - Sellner, Johann
AU  - Sellner J
AUID- ORCID: 0000-0001-8749-5533
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Department of Neurology, Landesklinikum Mistelbach-Ganserndorf, 2130 Mistelbach, 
      Austria.
AD  - Department of Neurology, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Trinka, Eugen
AU  - Trinka E
AD  - Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
AD  - Neuroscience Institute, Christian Doppler Medical Center, Paracelsus Medical
      University, 5020 Salzburg, Austria.
LA  - eng
PT  - Case Reports
DEP - 20200515
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7277986
OTO - NOTNLM
OT  - Creutzfeldt-Jakob disease
OT  - alinetic mutism
OT  - apallic syndrome
OT  - coma
OT  - functional magnetic resonance imaging
OT  - sensorimotor cortex
OT  - vibration paradigm
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - diagnostics10050309 [pii]
AID - 10.3390/diagnostics10050309 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2020 May 15;10(5). pii: diagnostics10050309. doi:
      10.3390/diagnostics10050309.


PMID- 32429230
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 10
DP  - 2020 May 15
TI  - Bioethical Decisions in Neonatal Intensive Care: Neonatologists' Self-Reported
      Practices in Greek NICUs.
LID - E3465 [pii]
LID - 10.3390/ijerph17103465 [doi]
AB  - This study presents, for the first time, empirical data on practices regarding
      bioethical decision-making in treatment of preterm and ill newborns in Greece.
      The aim of the study was to: a) record self-reported practices and involvement of
      Greek physicians in decisions of withholding and withdrawing neonatal intensive
      care, and b) explore the implication of cultural, ethical, and professional
      parameters in decision-making. Methods: 71 physicians, employed fulltime in all
      public Neonatal Intensive Care Units (NICUs) (n = 17) in Greece, completed an
      anonymous questionnaire between May 2009 and May 2011. Results: One-third of the 
      physicians in our sample admitted that they have, at least once in the past,
      decided the limitation of intensive care of a newborn close to death (37.7%)
      and/or a newborn with unfavorable neurological prognosis (30.8%). The higher the 
      physicians' support towards the value of quality of human life, the more probable
      it was that they had taken a decision to withhold or withdraw neonatal intensive 
      care (p <0.05). Conclusions: Our research shows that Greek NICU physicians report
      considerably lower levels of ethical decision-making regarding preterm and ill
      newborns compared to their counterparts in other European countries. Clinical
      practices and attitudes towards ethical decision-making appear to be influenced
      mainly by the Greek physicians' values.
FAU - Dagla, Maria
AU  - Dagla M
AD  - Department of Midwifery, University of West Attica, 122 41 Athens, Greece.
FAU - Petousi, Vasiliki
AU  - Petousi V
AD  - Department of Sociology, University of Crete, 741 00 Rethymno, Greece.
FAU - Poulios, Antonios
AU  - Poulios A
AD  - Department of Psychology, National and Kapodistrian University of Athens, 157 72 
      Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - *Decision Making/ethics
MH  - Europe
MH  - Female
MH  - Greece
MH  - Humans
MH  - Infant, Newborn
MH  - *Intensive Care Units, Neonatal
MH  - *Intensive Care, Neonatal
MH  - Male
MH  - Middle Aged
MH  - *Neonatologists/ethics
MH  - Self Report
PMC - PMC7277706
OTO - NOTNLM
OT  - *NICU
OT  - *ethical decision-making
OT  - *intensive care
OT  - *withdrawing
OT  - *withholding
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/21 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/05/21 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - ijerph17103465 [pii]
AID - 10.3390/ijerph17103465 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 May 15;17(10). pii: ijerph17103465. doi:
      10.3390/ijerph17103465.


PMID- 32429139
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 15
TI  - Navigating Uncertainties: How to Assess Welfare and Harm in Genetically Altered
      Animals Responsibly-A Practical Guideline.
LID - E857 [pii]
LID - 10.3390/ani10050857 [doi]
AB  - The use of animals in research requires careful ethical consideration of whether 
      the burden on the animals is justified. As one important part of the project
      evaluation, a harm-benefit analysis (HBA) must be carried out in order to approve
      projects in line with the EU Directive 2010/63/EU. This implies that harms and
      benefits must be assessed prospectively beforehand in order to weigh them.
      Although there are different methods of weighing, it is clear that an assessment 
      of prospective harms and benefits is a precondition for any weighing procedure.
      In this context, projects that use genetically altered (GA) lines raise new
      issues. A unique challenge when using GA lines is the significant lack of
      knowledge in this context, making it difficult and sometimes impossible to
      estimate harm prospectively with sufficient certainty, since it is not
      predictable what sort of harm-if at all-the animals are going to experience.
      Therefore, this contribution aims to deal with the challenges of harm assessment 
      in GA animals and their implications for welfare assessment and the HBA. A
      practical guideline is presented herein to serve as guidance for relevant harm
      factors and address the main challenges, particularly when dealing with
      uncertainties in the process of HBA.
FAU - Zintzsch, Anne
AU  - Zintzsch A
AD  - Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna,
      1210 Vienna ,Austria.
FAU - Noe, Elena
AU  - Noe E
AD  - Messerli Research Institute, University of Veterinary Medicine Vienna, Medical
      University Vienna, University Vienna, 1010 Vienna, Austria.
FAU - Grimm, Herwig
AU  - Grimm H
AD  - Messerli Research Institute, University of Veterinary Medicine Vienna, Medical
      University Vienna, University Vienna, 1010 Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7278426
OTO - NOTNLM
OT  - 3RsAGENT
OT  - genetically altered animals
OT  - harm-benefit analysis
OT  - severity classification
OT  - uncertainty
OT  - welfare assessment
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - ani10050857 [pii]
AID - 10.3390/ani10050857 [doi]
PST - epublish
SO  - Animals (Basel). 2020 May 15;10(5). pii: ani10050857. doi: 10.3390/ani10050857.


PMID- 32429085
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-3425 (Print)
IS  - 2076-3425 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 15
TI  - Immersive Virtual Reality in Stroke Patients as a New Approach for Reducing
      Postural Disabilities and Falls Risk: A Case Series.
LID - E296 [pii]
LID - 10.3390/brainsci10050296 [doi]
AB  - Stroke is a neurologic disorder considered the first cause of disability
      worldwide due to motor, cognitive, and sensorial sequels. Balance dysfunctions in
      stroke survivors increase the risk of falls and physiotherapeutic rehabilitation 
      is essential to reduce it. Virtual reality (VR) seems to be an alternative to
      conventional physiotherapy (CT), providing virtual environments and
      multisensorial inputs to train balance in stroke patients. The aim of this study 
      was to assess if immersive VR treatment is more effective than CT to improve
      balance after stroke. This study got the approval from the Ethics Committee of
      the University of Almeria. Three chronic ischemic stroke patients were selected. 
      One patient who received 25 sessions of immersive VR intervention for two months 
      was compared with another patient who received equivalent CT and a third patient 
      with no intervention. Balance, gait, risk of falling, and vestibular and visual
      implications in the equilibrium were assessed. After the interventions, the two
      patients receiving any of the treatments showed an improvement in balance
      compared to the untreated patient. In comparison to CT, our results suggest a
      higher effect of immersive VR in the improvement of balance and a reduction of
      falls risk due to the active upright work during the VR intervention.
FAU - Cortes-Perez, Irene
AU  - Cortes-Perez I
AD  - Department of Health Sciences, University of Jaen, Paraje Las Lagunillas s/n,
      23071 Jaen, Spain.
FAU - Nieto-Escamez, Francisco Antonio
AU  - Nieto-Escamez FA
AUID- ORCID: 0000-0001-5301-9475
AD  - Department of Psychology, University of Almeria, Ctra. Sacramento s/n, 04120
      Almeria, Spain.
AD  - Center for Neuropsychological Assessment and Rehabilitation (CERNEP), Ctra.
      Sacramento s/n, 04120 Almeria, Spain.
FAU - Obrero-Gaitan, Esteban
AU  - Obrero-Gaitan E
AUID- ORCID: 0000-0002-8430-5500
AD  - Department of Health Sciences, University of Jaen, Paraje Las Lagunillas s/n,
      23071 Jaen, Spain.
LA  - eng
GR  - FPU17/01619/Ministerio de Ciencia, Innovacion y Universidad
GR  - OTR2018/111/NeuroDigital Technologies SL
PT  - Case Reports
DEP - 20200515
PL  - Switzerland
TA  - Brain Sci
JT  - Brain sciences
JID - 101598646
PMC - PMC7287864
OTO - NOTNLM
OT  - balance
OT  - conventional physiotherapy
OT  - falls risk
OT  - gait
OT  - immersive virtual reality
OT  - stroke
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
CRDT- 2020/05/21 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
AID - brainsci10050296 [pii]
AID - 10.3390/brainsci10050296 [doi]
PST - epublish
SO  - Brain Sci. 2020 May 15;10(5). pii: brainsci10050296. doi:
      10.3390/brainsci10050296.


PMID- 32428965
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20201218
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
VI  - 37
IP  - 8
DP  - 2020 Jun
TI  - Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease
      2019 Pandemic: A Review of International Registries.
PG  - 792-799
LID - 10.1055/s-0040-1712103 [doi]
AB  - OBJECTIVE: Pregnant women have been historically excluded from clinical trials
      for nonobstetric conditions, even during prior epidemics. The objective of this
      review is to describe the current state of research for pregnant women during the
      coronavirus disease 2019 (COVID-19) pandemic. STUDY DESIGN: We conducted a search
      of international trial registries for trials relating to the novel coronavirus.
      The eligibility criteria for each trial were reviewed for inclusion/exclusion of 
      pregnant women. Relevant data were extracted and descriptive statistics were
      calculated for individual and combined data. The total number of trials from each
      registry were compared, as well as the proportions of pregnancy-related trials
      within each. RESULTS: Among 621,370 trials in the World Health Organization
      International Clinical Trials Registry, 927 (0.15%) were COVID-19 related. Of
      those, the majority (52%) explicitly excluded pregnancy or failed to address
      pregnancy at all (46%) and only 16 (1.7%) were pregnancy specific. When
      categorized by region, 688 (74.2%) of COVID-19 trials were in Asia, followed by
      128 (13.8%) in Europe, and 66 (7.2%) in North America. Of the COVID-19 trials
      which included pregnant women, only three were randomized-controlled drug trials.
      CONCLUSION: Approximately 1.7% of current COVID-19 research is pregnancy related 
      and the majority of trials either explicitly exclude or fail to address
      pregnancy. Only three interventional trials worldwide involved pregnant women.
      The knowledge gap concerning the safety and efficacy of interventions for
      COVID-19 created by the exclusion of pregnant women may ultimately harm them.
      While "ethical" concerns about fetal exposure are often cited, it is in fact
      unethical to habitually exclude pregnant women from research. KEY POINTS: .
      Pregnancy was excluded from past pandemic research.. . Pregnancy is being
      excluded from COVID-19 research.. . Exclusion of pregnant women is potentially
      harmful..
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Smith, Devin D
AU  - Smith DD
AUID- ORCID: 0000-0003-4185-6414
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The
      Ohio State University College of Medicine, Columbus, Ohio.
FAU - Pippen, Jessica L
AU  - Pippen JL
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The
      Ohio State University College of Medicine, Columbus, Ohio.
FAU - Adesomo, Adebayo A
AU  - Adesomo AA
AD  - Department of Obstetrics and Gynecology, The Ohio State University College of
      Medicine, Columbus, Ohio.
FAU - Rood, Kara M
AU  - Rood KM
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The
      Ohio State University College of Medicine, Columbus, Ohio.
FAU - Landon, Mark B
AU  - Landon MB
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The
      Ohio State University College of Medicine, Columbus, Ohio.
FAU - Costantine, Maged M
AU  - Costantine MM
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The
      Ohio State University College of Medicine, Columbus, Ohio.
LA  - eng
GR  - The Eunice Kennedy Shriver National Institute of Child Health and Human
      Development/5 UG1 HD027915-29/International
GR  - National Heart, Lung, and Blood Institute/1UG3HL140131-01/International
PT  - Journal Article
DEP - 20200519
PL  - United States
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Clinical Trials as Topic/ethics/organization & administration/standards
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Eligibility Determination/*standards
MH  - Female
MH  - Global Health
MH  - Humans
MH  - *Pandemics
MH  - Patient Selection/*ethics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/epidemiology/therapy
MH  - Registries/*statistics & numerical data
MH  - SARS-CoV-2
PMC - PMC7356075
COIS- None declared.
EDAT- 2020/05/20 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1055/s-0040-1712103 [doi]
PST - ppublish
SO  - Am J Perinatol. 2020 Jun;37(8):792-799. doi: 10.1055/s-0040-1712103. Epub 2020
      May 19.


PMID- 32428824
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1532-3099 (Electronic)
IS  - 0266-6138 (Linking)
VI  - 87
DP  - 2020 Aug
TI  - Midwives' experiences as preceptors and the development of good preceptorships in
      obstetric units.
PG  - 102718
LID - S0266-6138(20)30087-5 [pii]
LID - 10.1016/j.midw.2020.102718 [doi]
AB  - OBJECTIVE: To study midwives' experience in their role as a preceptor and their
      perception on how to best support midwifery students in obstetrics units.
      Obstetric units are an important learning area for student midwives but knowledge
      on how to become a good midwife preceptor is limited. DESIGN: This qualitative
      study explores midwife preceptors' experience of supervising midwifery students
      in three obstetric units in Sweden. Following ethical approval seventeen midwife 
      preceptors were interviewed and data were analysed thematically. FINDINGS:
      Thematic analysis of the interviews resulted in the identification of two themes 
      and five subthemes: (1) self-efficacy in the preceptor role which involves (a)
      being confident in the professional position and (b) having the support of
      management and colleagues and (2) supporting the student to attain
      self-confidence and independence which entails (a) helping the student to grow,
      (b) facilitating reflection in learning situations, and (c) "taking a step back".
      KEY CONCLUSION: Good preceptorship occurs when midwives achieve full
      self-efficacy, when they master the preceptor role, and when they have enhanced
      their abilities to help, the student reach confidence and independence.
      IMPLICATIONS FOR PRACTICE: Health care organisations needs to develop and support
      midwifery preceptorships.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - S, Zwedberg
AU  - S Z
AD  - Department for Health Promotion Science, Sophiahemmet University,
      Lindtstedtsvagen 8, Stockholm 114 86, Sweden; Karolinska University hospital,
      Solna. Children s & Women s Health Theme PA Pregnancy Care and Delivery,
      Karolinska Universitetsjukhuset Solna, Karolinska vagen, Solna 171 76, Sweden.
      Electronic address: sof.zwedberg@shh.se.
FAU - K, Forslund Frykedal
AU  - K FF
AD  - Department of Behavioral Sciences and Learning, Linkoping University, Linkoping, 
      Sweden. Electronic address: karin.forslund.frykedal@liu.se.
FAU - M, Rosander
AU  - M R
AD  - Department of Behavioral Sciences and Learning, Linkoping University, Linkoping, 
      Sweden. Electronic address: michael.rosander@liu.se.
FAU - A, Berlin
AU  - A B
AD  - The Division of Nursing Department of Neurobiology, Care Sciences and Society,
      Karolinska Institutet, Huddinge, Sweden. Electronic address: anita.berlin@ki.se.
FAU - M, Barimani
AU  - M B
AD  - The Division of Family Medicine and Primary Care, Department of Neurobiology,
      Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden; Academic
      Primary Care Centre, Region Stockholm, Solnavagen 1 E, 113 65, Stockholm, Sweden.
      Electronic address: mia.barimani@ki.se.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - Scotland
TA  - Midwifery
JT  - Midwifery
JID - 8510930
MH  - Humans
MH  - Mentors/*psychology/statistics & numerical data
MH  - Midwifery/education/standards/statistics & numerical data
MH  - Nurse Midwives/*psychology/statistics & numerical data
MH  - Nursing Staff, Hospital/*education/standards/statistics & numerical data
MH  - Obstetrics and Gynecology Department, Hospital/standards/trends
MH  - Preceptorship/methods/*standards/statistics & numerical data
MH  - Qualitative Research
MH  - Surveys and Questionnaires
MH  - Sweden
OTO - NOTNLM
OT  - Clinical placements
OT  - Midwifery
OT  - Preceptors
OT  - Student midwives
EDAT- 2020/05/20 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/11/27 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - S0266-6138(20)30087-5 [pii]
AID - 10.1016/j.midw.2020.102718 [doi]
PST - ppublish
SO  - Midwifery. 2020 Aug;87:102718. doi: 10.1016/j.midw.2020.102718. Epub 2020 May 6.


PMID- 32428795
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 195
DP  - 2020 Aug
TI  - Intracranial emergencies during pregnancy requiring urgent neurosurgical
      treatment.
PG  - 105905
LID - S0303-8467(20)30248-1 [pii]
LID - 10.1016/j.clineuro.2020.105905 [doi]
AB  - OBJECTIVE: Despite contemporary diagnostic and therapeutic techniques
      intracranial emergencies in the obstetric setting pose still a major challenge
      for the clinicians. There are limited guidelines and differing ethical views.
      Multidisciplinary teams are needed to support the pregnant woman in a way that
      she can deliver a viable and healthy child. The aim of the present study was to
      scrutinize the management of intracranial emergencies during pregnancy which
      needed urgent neurosurgical treatment. PATIENTS AND METHODS: Data of all pregnant
      women who presented with newly diagnosed intracranial pathologies and
      neurological symptoms caused by these pathologies in an emergency setting were
      collected over a 10-year period (2008-2018). Patient characteristics including
      maternal age, gestational age, and preoperative work-up of both mother and fetus 
      were recorded. Furthermore, the surgical treatment, mode of delivery, and
      neonatal and maternal outcomes were analysed. RESULTS: The mean maternal age was 
      32.7 years and most patients were in their third trimester. There was one twin
      pregnancy (total of 12 fetuses). Five out of eleven pregnant women suffered from 
      intracerebral haemorrhage (epidural haematoma (1), arteriovenous malformation
      (1), subarachnoid haemorrhage (2) and intracerebral haemorrhage (1)) and the
      other six patients had intracranial neoplasms (primary meningeal sarcoma (1),
      trigeminal schwannoma (1), anaplastic astrocytoma (2), glioblastoma (1) and
      sphenoid wing meningioma (1)).Neurosurgical procedures were performed via
      craniotomies in eight patients. A stereotactic biopsy via a frontal burr hole was
      achieved one patient. The two other patients with subarachnoid haemorrhage due to
      rupture of PICA aneurysms were treated with coil embolization. Depending on the
      gestational age and the clinical condition of the pregnant women it was decided
      to perform an emergency Caesarean section prior to further therapeutic measures
      in seven patients. Two out of 12 fetuses were unviable. Six women survived, while
      five women succumbed to the intracranial pathology. CONCLUSION: The
      individualized treatment approach in this peculiar obstetric scenario needs to
      consider various issues such as the clinical condition of the pregnant woman,
      prognosis of the disease, gestational age and the status of the pregnancy. The
      primary concern in this context must be the mother`s health and safety. Caesarean
      section is the primary mode of delivery in most cases. While contemporary care
      can insure survival for the majority of infants, maternal mortality still poses
      an extraordinary challenge. Interdisciplinary consulting of the patient and/or
      her family is necessary to develop a treatment strategy for both the expectant
      woman and her offspring.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Esmaeilzadeh, Majid
AU  - Esmaeilzadeh M
AD  - Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
      Electronic address: esmaeilzadeh_majid@mh-hannover.de.
FAU - Uksul, Nesrin
AU  - Uksul N
AD  - Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
FAU - Hong, Bujung
AU  - Hong B
AD  - Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
FAU - von Kaisenberg, Constantin
AU  - von Kaisenberg C
AD  - Department of Gynaecology & Obstetrics, Hannover Medical School, Hannover,
      Germany.
FAU - Scheinichen, Dirk
AU  - Scheinichen D
AD  - Department of Anaesthesiology, Hannover Medical School, Hannover, Germany.
FAU - Lang, Josef M
AU  - Lang JM
AD  - Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
FAU - Hermann, Elvis J
AU  - Hermann EJ
AD  - Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
FAU - Hillemanns, Peter
AU  - Hillemanns P
AD  - Department of Gynaecology & Obstetrics, Hannover Medical School, Hannover,
      Germany.
FAU - Krauss, Joachim K
AU  - Krauss JK
AD  - Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
SB  - IM
MH  - Adult
MH  - Brain Diseases/diagnostic imaging/*surgery
MH  - Brain Neoplasms/surgery
MH  - Cerebral Hemorrhage/surgery
MH  - Cesarean Section
MH  - Craniotomy
MH  - Delivery, Obstetric
MH  - *Emergencies
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Intracranial Arteriovenous Malformations/surgery
MH  - Maternal Age
MH  - Neurosurgical Procedures/*methods
MH  - Precision Medicine
MH  - Pregnancy
MH  - Pregnancy Complications, Cardiovascular/*surgery
MH  - Pregnancy Outcome
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - *Fetus
OT  - *Hemorrhage
OT  - *Intracranial bleeding
OT  - *Intracranial tumor
OT  - *Neurosurgery
OT  - *Pregnancy
OT  - *Subarachnoid
EDAT- 2020/05/20 06:00
MHDA- 2021/06/11 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/04/19 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - S0303-8467(20)30248-1 [pii]
AID - 10.1016/j.clineuro.2020.105905 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2020 Aug;195:105905. doi: 10.1016/j.clineuro.2020.105905. 
      Epub 2020 May 12.


PMID- 32428735
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210630
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 26
IP  - 9
DP  - 2020 Sep
TI  - Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in
      Patients with Multiple Myeloma.
PG  - 1589-1596
LID - S1083-8791(20)30285-8 [pii]
LID - 10.1016/j.bbmt.2020.04.030 [doi]
AB  - High-dose chemotherapy (HD-CHT) and autologous blood stem cell transplantation
      (ABSCT) represent the standard of care in multiple myeloma (MM) for
      transplantation-eligible patients. Up to 3 HD-CHT/ABSCT treatments may be
      administered during the course of disease, including during late-onset relapse.
      Transplantation centers routinely collect more than 1 peripheral blood stem cell 
      (PBSC) graft; however, subsequent HD-CHT/ABSCT treatments are often not
      performed, for various reasons. Currently, little is known about the actual
      utilization rate of stored PBSCs. The collection, storage, and disposal of PBSC
      products was analyzed in a large cohort of patients with MM (n = 1114) over a
      12-year period with a minimum follow-up of 6 years. The final dataset analysis
      was performed in March 2019, which was set as the reference date. Based on
      institution-specific charges, the costs for PBSC collection, processing, and
      storage were estimated. The median number of sufficient PBSC transplantations per
      patient was 3 (range, 0 to 6), which were stored in a median of 3 (range, 1 to
      11) cryopreserved bags (overall, n = 3644). A total of 95% of all patients (n =
      1059) underwent at least 1 HD-CHT/ABSCT treatment. However, multiple ABSCTs were 
      performed in 51% of the patients (n2/3 ABSCTs = 538), and only 14% of the
      patients underwent ABSCT 3 times (n3 ABSCTs = 149). Only a small proportion of
      collected PBSC bags (5%; n = 109) were used after being stored for longer than 5 
      years. Overall, 23% of the products (n = 830) were discarded, and 16% (n = 566)
      were kept in storage until the reference date. From a retrospective standpoint,
      the collected and discarded (definitively not used) or stored (potentially not
      used) cryostored PBSCs were associated with considerable costs for long-term
      cryostorage of approximately euro1,600,000. We identified considerable
      discrepancies between the collection/storage and utilization of PBSCs. This is
      associated with significant efforts and costs on the one hand; on the other hand,
      disposal may raise legal and ethical questions. Therefore, we implemented
      comprehensive guidelines for the systematic reevaluation of stored PBSC grafts at
      our institution.
CI  - Copyright (c) 2020 American Society for Transplantation and Cellular Therapy.
      Published by Elsevier Inc. All rights reserved.
FAU - Krummradt, Felix
AU  - Krummradt F
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany.
FAU - Sauer, Sandra
AU  - Sauer S
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany.
FAU - Pavel, Petra
AU  - Pavel P
AD  - Stem Cell Laboratory, IKTZ Heidelberg GmbH, Heidelberg, Germany.
FAU - Klein, Eva-Maria
AU  - Klein EM
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany.
FAU - Schmitt, Anita
AU  - Schmitt A
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany.
FAU - Kriegsmann, Mark
AU  - Kriegsmann M
AD  - Institute of Pathology, Heidelberg University, Heidelberg, Germany.
FAU - Jordan, Karin
AU  - Jordan K
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany.
FAU - Muller-Tidow, Carsten
AU  - Muller-Tidow C
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany; National Center of Tumor Diseases, Heidelberg, Germany.
FAU - Goldschmidt, Hartmut
AU  - Goldschmidt H
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany; National Center of Tumor Diseases, Heidelberg, Germany.
FAU - Wuchter, Patrick
AU  - Wuchter P
AD  - Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim,
      Heidelberg University, German Red Cross Blood Service Baden-Wurttemberg-Hessen,
      Mannheim, Germany.
FAU - Kriegsmann, Katharina
AU  - Kriegsmann K
AD  - Department of Hematology, Oncology and Rheumatology, Heidelberg University,
      Heidelberg, Germany. Electronic address:
      katharina.kriegsmann@med.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
DEP - 20200516
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for
      Blood and Marrow Transplantation
JID - 9600628
SB  - IM
CIN - Transplant Cell Ther. 2021 Mar;27(3):276-277. PMID: 33781542
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Hematopoietic Stem Cells
MH  - Humans
MH  - *Multiple Myeloma/therapy
MH  - Neoplasm Recurrence, Local
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Retrospective Studies
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - *Autologous transplantation
OT  - *Cost evaluation
OT  - *Cryostorage
OT  - *Hematopoietic stem cell products
OT  - *Multiple myeloma
OT  - *Peripheral blood stem cells
EDAT- 2020/05/20 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - S1083-8791(20)30285-8 [pii]
AID - 10.1016/j.bbmt.2020.04.030 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2020 Sep;26(9):1589-1596. doi:
      10.1016/j.bbmt.2020.04.030. Epub 2020 May 16.


PMID- 32428666
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 158
DP  - 2020 Aug
TI  - Regulatory oversight of cell therapy in China: Government's efforts in patient
      access and therapeutic innovation.
PG  - 104889
LID - S1043-6618(20)31197-X [pii]
LID - 10.1016/j.phrs.2020.104889 [doi]
AB  - In recent years, remarkable progress has been made in the fundamental research
      and on clinical development of cell therapy. Although China has launched a series
      of regulations to establish a proper regulatory framework that facilitates the
      development of cell therapy products, the regulatory framework has not been able 
      to meet the country's regulatory requirements. This article introduced the
      development of regulation and current regulatory pathways for cell therapy in
      China and identified the main challenges in clinical studies. China has recently 
      tightened its policy on cell therapy clinical studies after medical chaos
      occurred in the area of cell therapy over the past few years. Currently the
      regulatory jurisdiction between NMPA and NHC are not very clear, especially for
      clinical somatic cell research, further efforts are necessary to establish a
      legislative system with a clear and functional regulatory framework for cell
      therapy.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Wu, Weijia
AU  - Wu W
AD  - Department of Clinical Pharmacy and Pharmaceutical Management, School of
      Pharmacy, Fudan University, Shanghai, China; Sino-Danish Regulatory Science
      Center, Fudan University, Shanghai, China.
FAU - Wang, Yuanyuan
AU  - Wang Y
AD  - Department of Clinical Pharmacy and Pharmaceutical Management, School of
      Pharmacy, Fudan University, Shanghai, China; Sino-Danish Regulatory Science
      Center, Fudan University, Shanghai, China.
FAU - Tang, Zhijia
AU  - Tang Z
AD  - Department of Clinical Pharmacy and Pharmaceutical Management, School of
      Pharmacy, Fudan University, Shanghai, China.
FAU - Gao, Yuan
AU  - Gao Y
AD  - Department of Clinical Pharmacy and Pharmaceutical Management, School of
      Pharmacy, Fudan University, Shanghai, China; Sino-Danish Regulatory Science
      Center, Fudan University, Shanghai, China. Electronic address:
      yuan_gao@fudan.edu.cn.
FAU - Huo, Yan
AU  - Huo Y
AD  - National Institution of Food and Drug Control, National Medical Products
      Administration, Beijing, China. Electronic address: yanhuo@nifdc.org.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200517
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
SB  - IM
MH  - Cell- and Tissue-Based Therapy/ethics/*standards
MH  - China/epidemiology
MH  - Clinical Trials as Topic/ethics/legislation & jurisprudence/standards
MH  - *Government Regulation
MH  - Health Services Accessibility/ethics/*legislation & jurisprudence/*standards
MH  - Humans
MH  - Therapies, Investigational/ethics/*standards
OTO - NOTNLM
OT  - *NMPA
OT  - *cell therapy development
OT  - *ethical challenges
OT  - *regulatory framework
EDAT- 2020/05/20 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/01/11 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - S1043-6618(20)31197-X [pii]
AID - 10.1016/j.phrs.2020.104889 [doi]
PST - ppublish
SO  - Pharmacol Res. 2020 Aug;158:104889. doi: 10.1016/j.phrs.2020.104889. Epub 2020
      May 17.


PMID- 32428426
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20211204
IS  - 1552-681X (Electronic)
IS  - 0272-989X (Linking)
VI  - 40
IP  - 3
DP  - 2020 Apr
TI  - What Helps People Make Values-Congruent Medical Decisions? Eleven Strategies
      Tested across 6 Studies.
PG  - 266-278
LID - 10.1177/0272989X20904955 [doi]
AB  - Background. High-quality health decisions are often defined as those that are
      both evidence informed and values congruent. A values-congruent decision aligns
      with what matters to those most affected by the decision. Values clarification
      methods are intended to support values-congruent decisions, but their effects on 
      values congruence are rarely evaluated. Methods. We tested 11 strategies,
      including the 3 most commonly used values clarification methods, across 6
      between-subjects online randomized experiments in demographically diverse US
      populations (n1 = 1346, n2 = 456, n3 = 840, n4 = 1178, n5 = 841, n6 = 2033) in
      the same hypothetical decision. Our primary outcome was values congruence.
      Decisional conflict was a secondary outcome in studies 3 to 6. Results. Two
      commonly used values clarification methods (pros and cons, rating scales) reduced
      decisional conflict but did not encourage values-congruent decisions. Strategies 
      using mathematical models to show participants which option aligned with what
      mattered to them encouraged values-congruent decisions and reduced decisional
      conflict when assessed. Limitations. A hypothetical decision was necessary for
      ethical reasons, as we believed some strategies may harm decision quality. Later 
      studies used more outcomes and covariates. Results may not generalize outside
      US-based adults with online access. We assumed validity and stability of values
      during the brief experiments. Conclusions. Failing to explicitly support the
      process of aligning options with values leads to increased proportions of
      values-incongruent decisions. Methods representing more than half of values
      clarification methods commonly in use failed to encourage values-congruent
      decisions. Methods that use models to explicitly show people how options align
      with their values offer more promise for helping people make decisions aligned
      with what matters to them. Decisional conflict, while arguably an important
      outcome in and of itself, is not an appropriate proxy for values congruence.
FAU - Witteman, Holly O
AU  - Witteman HO
AUID- ORCID: 0000-0003-4192-0682
AD  - Universite Laval Faculte de medecine, Quebec, QC, Canada.
FAU - Julien, Anne-Sophie
AU  - Julien AS
AD  - Universite Laval Faculte des sciences et de genie, Quebec, QC, Canada.
FAU - Ndjaboue, Ruth
AU  - Ndjaboue R
AD  - Universite Laval Faculte de medecine, Quebec, QC, Canada.
FAU - Exe, Nicole L
AU  - Exe NL
AD  - University of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Kahn, Valerie C
AU  - Kahn VC
AD  - University of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Angie Fagerlin, Angela
AU  - Angie Fagerlin A
AD  - University of Utah School of Medicine, Salt Lake City, UT, USA.
FAU - Zikmund-Fisher, Brian J
AU  - Zikmund-Fisher BJ
AUID- ORCID: 0000-0002-1637-4176
AD  - University of Michigan School of Public Health, Ann Arbor, MI, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Decis Making
JT  - Medical decision making : an international journal of the Society for Medical
      Decision Making
JID - 8109073
SB  - IM
MH  - Adult
MH  - Clinical Decision-Making/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Participation/methods/psychology
MH  - Racial Groups/statistics & numerical data
MH  - *Social Values
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *interactive interfaces
OT  - *tradeoffs
OT  - *values clarification
OT  - *values concordance
OT  - *values congruence
EDAT- 2020/05/20 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
AID - 10.1177/0272989X20904955 [doi]
PST - ppublish
SO  - Med Decis Making. 2020 Apr;40(3):266-278. doi: 10.1177/0272989X20904955.


PMID- 32428060
OWN - NLM
STAT- MEDLINE
DCOM- 20200529
LR  - 20200616
IS  - 1678-7765 (Electronic)
IS  - 1678-7757 (Linking)
VI  - 28
DP  - 2020
TI  - Clinical and microbiological evaluation of non-surgical periodontal therapy in
      obese and non-obese individuals with periodontitis: a 9-month prospective
      longitudinal study.
PG  - e20190694
LID - S1678-77572020000100447 [pii]
LID - 10.1590/1678-7757-2019-0694 [doi]
AB  - Objective Obesity is a chronic disease that negatively affects an individual's
      general and oral health. The present study aimed to compare the clinical and
      microbiological effects of non-surgical periodontal therapy with the full mouth
      disinfection (FMD) protocol on obese and non-obese individuals at 9 months
      post-therapy. Methodology This clinical study was first submitted and approved by
      the Ethics Committee. Fifty-five obese patients and 39 non-obese patients with
      periodontitis were evaluated. The full-mouth periodontal clinical parameters,
      clinical attachment level (CAL), probing depth (PD), gingival index (GI), and
      plaque index (PI), were monitored at baseline, 3, 6, and 9 months after
      periodontal treatment with full mouth disinfection (FMD) protocol. The mean count
      of Tannerella forsythia , Porphyromonas gingivalis , Treponema Denticola , and
      Aggregatibacter actinomycetemcomitans was determined by quantitative polymerase
      chain reaction on subgingival biofilm samples. Demographic data were assessed by 
      Chi-square test. For clinical and microbiological parameters, two-factor
      repeated-measures ANOVA was used. Results In both groups, periodontal therapy
      using the one-stage full-mouth disinfection protocol significantly improved CAL, 
      PD, GI, and PI (p<0.05). Obese and non-obese patients equally responded to
      non-surgical periodontal therapy (p>0.05). Microbial count found no major
      differences (p>0.05) between obese and non-obese individuals who had undergone
      non-surgical periodontal therapy. Conclusions Obesity did not affect the clinical
      and microbiological outcomes of non-surgical periodontal therapy.
FAU - Peralta, Felipe da Silva
AU  - Peralta FDS
AD  - Departamento de Odontologia, Universidade de Taubate, Taubate, Sao Paulo, Brasil.
FAU - Cortelli, Sheila Cavalca
AU  - Cortelli SC
AD  - Departamento de Odontologia, Universidade de Taubate, Taubate, Sao Paulo, Brasil.
FAU - Rovai, Emanuel Silva
AU  - Rovai ES
AD  - Departamento de Odontologia, Universidade de Taubate, Taubate, Sao Paulo, Brasil.
FAU - Aquino, Davi Romeiro
AU  - Aquino DR
AD  - Departamento de Odontologia, Universidade de Taubate, Taubate, Sao Paulo, Brasil.
FAU - Miranda, Tais Browne
AU  - Miranda TB
AD  - Departamento de Odontologia, Universidade de Taubate, Taubate, Sao Paulo, Brasil.
FAU - Costa, Fernando Oliveira
AU  - Costa FO
AD  - Departamento de Periodontia, Faculdade de Odontologia, Universidade Federal de
      Minas Gerais, Belo Horizonte, Minhas Gerais, Brasil.
FAU - Cortelli, Jose Roberto
AU  - Cortelli JR
AD  - Departamento de Odontologia, Universidade de Taubate, Taubate, Sao Paulo, Brasil.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200518
PL  - Brazil
TA  - J Appl Oral Sci
JT  - Journal of applied oral science : revista FOB
JID - 101189774
SB  - IM
MH  - Adult
MH  - Aggregatibacter actinomycetemcomitans/isolation & purification
MH  - Analysis of Variance
MH  - Anthropometry
MH  - Dental Plaque Index
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Obesity/*microbiology/physiopathology
MH  - Periodontal Index
MH  - Periodontitis/*microbiology/*therapy
MH  - Porphyromonas gingivalis/isolation & purification
MH  - Prospective Studies
MH  - Risk Factors
MH  - Statistics, Nonparametric
MH  - Tannerella forsythia/isolation & purification
MH  - Time Factors
MH  - Treatment Outcome
MH  - Treponema denticola/isolation & purification
PMC - PMC7213783
EDAT- 2020/05/20 06:00
MHDA- 2020/05/30 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
AID - S1678-77572020000100447 [pii]
AID - 10.1590/1678-7757-2019-0694 [doi]
PST - ppublish
SO  - J Appl Oral Sci. 2020;28:e20190694. doi: 10.1590/1678-7757-2019-0694. Epub 2020
      May 18.


PMID- 32427995
OWN - NLM
STAT- MEDLINE
DCOM- 20200723
LR  - 20200723
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Prevalence of trachoma and associated factors in the rural area of the department
      of Vaupes, Colombia.
PG  - e0229297
LID - 10.1371/journal.pone.0229297 [doi]
AB  - OBJECTIVES: The objectives of the study were to estimate the prevalence of
      different clinical signs of trachoma and identify possible factors associated
      with TF. METHODOLOGY: Following the approval of the study protocol by the ethics 
      committee, a cross-sectional study was conducted in Vaupes, a department of the
      Colombian Amazon, between the years 2012 and 2013 in two districts. Based on the 
      records obtained from a standardized format for the clinical evaluation of the
      participants and the factors associated with follicular trachoma, an excel
      database was built and debugged, which was analyzed using IBM SPSS, Statistics
      Version 23 and Stata STATA (Version 14, 2015, StataCorp LLC, Texas, USA).
      RESULTS: The records of 13,091 individuals was collected from 216 rural
      indigenous communities, of which 12,080 were examined (92.3%); 7,274 in the
      Western and 4,806 in the Eastern districts. A prevalence of trachomatous
      inflammation-follicular (TF) of 21.7% (n = 599; 95% CI 20.2-23.3) in the Western 
      and 24.9% (n = 483; 95% CI 23.1-26.9) in the Eastern district was found in
      children aged 1 to 9 years. Regarding trachomatous trichiasis (TT), 77 cases were
      found, of which 14 belonged to the Western district (prevalence 0.3%, CI 95%
      0.2-0.5) and 63 to the Eastern district (1.8%, CI 95% 1.4-2.4). Children aged
      between 1 to 9 years were significantly more likely to have TF when there was the
      presence of secretions on the face (OR: 3.2; 95% CI: 2.6-3.9). CONCLUSIONS:
      Trachoma is a public health problem in Vaupes that requires the implementation of
      the SAFE strategy (S = Surgery, A = Antibiotics, F = Face Washing, E =
      Environment) in the Eastern and Western districts, for at least 3 consecutive
      years, in accordance with WHO recommendations.
FAU - Miller, Hollman Alfonso
AU  - Miller HA
AD  - Department of Vaupes, Vector borne and neglected infectious diseases, Mitu,
      Colombia.
FAU - Lopez de Mesa, Clara Beatriz
AU  - Lopez de Mesa CB
AD  - Escuela Superior de Oftalmologia del Instituto Barraquer de America, Bogota,
      Colombia.
FAU - Talero, Sandra Liliana
AU  - Talero SL
AD  - Escuela Superior de Oftalmologia del Instituto Barraquer de America, Bogota,
      Colombia.
FAU - Meza Cardenas, Monica
AU  - Meza Cardenas M
AD  - Subdirection of Communicable Diseases, Ministry of Health and Social Protection, 
      Bogota, Colombia.
FAU - Ramirez, Sandra Patricia
AU  - Ramirez SP
AD  - Department of Vaupes, San Antonio Hospital of Mitu, Mitu, Colombia.
FAU - Moreno-Montoya, Jose
AU  - Moreno-Montoya J
AD  - Division de Investigaciones Fundacion Santa Fe de Bogota, Bogota, Colombia.
FAU - Porras, Alexandra
AU  - Porras A
AD  - Universidad El Bosque, Bogota, Colombia.
FAU - Trujillo-Trujillo, Julian
AU  - Trujillo-Trujillo J
AUID- ORCID: 0000-0003-0739-5781
AD  - Subdirection of Communicable Diseases, Ministry of Health and Social Protection, 
      Bogota, Colombia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200519
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Censuses
MH  - Child
MH  - Child, Preschool
MH  - Chlamydia trachomatis/pathogenicity
MH  - Colombia/epidemiology
MH  - Female
MH  - *Health Surveys
MH  - Humans
MH  - Infant
MH  - Male
MH  - *Population Groups
MH  - *Public Health
MH  - Risk Factors
MH  - Rural Population
MH  - Trachoma/*epidemiology/microbiology/pathology
PMC - PMC7237033
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/20 06:00
MHDA- 2020/07/24 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/09/25 00:00 [received]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/24 06:00 [medline]
AID - 10.1371/journal.pone.0229297 [doi]
AID - PONE-D-19-25232 [pii]
PST - epublish
SO  - PLoS One. 2020 May 19;15(5):e0229297. doi: 10.1371/journal.pone.0229297.
      eCollection 2020.


PMID- 32427689
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20210505
IS  - 1529-7535 (Print)
IS  - 1529-7535 (Linking)
VI  - 21
IP  - 10
DP  - 2020 Oct
TI  - Extracorporeal Membrane Oxygenation for Pediatric Patients With Coronavirus
      Disease 2019-Related Illness.
PG  - 893-897
LID - 10.1097/PCC.0000000000002432 [doi]
AB  - OBJECTIVE: To describe current hospital guidelines and the opinions of
      extracorporeal membrane oxygenation leaders at U.S. children's hospitals
      concerning the use of extracorporeal membrane oxygenation for coronavirus disease
      2019-positive pediatric patients. DESIGN: Confidential, self-administered
      questionnaire. SETTING: One hundred twenty-seven U.S. pediatric extracorporeal
      membrane oxygenation centers. SUBJECTS: Extracorporeal membrane oxygenation
      center program directors and coordinators. INTERVENTIONS: None. MEASUREMENTS AND 
      MAIN RESULTS: In March 2020, a survey was sent to 127 pediatric extracorporeal
      membrane oxygenation centers asking them to report their current hospital
      extracorporeal membrane oxygenation guidelines for coronavirus disease
      2019-positive patients. Respondents were also asked their opinion on three
      ethical dilemmas including: prioritization of children over adults for
      extracorporeal membrane oxygenation use, institution of do-not-resuscitate
      orders, and the use of extracorporeal cardiopulmonary resuscitation for
      coronavirus disease 2019-positive patients. Forty-seven extracorporeal membrane
      oxygenation centers had enacted guidelines including 46 (100%) that offer
      venovenous-extracorporeal membrane oxygenation and 42 (89%) that offer
      venoarterial-extracorporeal membrane oxygenation for coronavirus disease
      2019-positive pediatric patients. Forty-four centers (94%) stated that the
      indications for extracorporeal membrane oxygenation candidacy in coronavirus
      disease 2019 disease were similar to those used in other viral illnesses, such as
      respiratory syncytial virus or influenza. Most program directors (98%) did not
      endorse that children hospitalized with coronavirus disease 2019 should be made
      do-not-resuscitate and had variable opinions on whether children should be given 
      higher priority over adults when rationing extracorporeal membrane oxygenation.
      Over half of program directors (60%) did not support the use of extracorporeal
      cardiopulmonary resuscitation for coronavirus disease 2019. CONCLUSIONS: The
      majority of pediatric extracorporeal membrane oxygenation centers have
      proactively established guidelines for the use of extracorporeal membrane
      oxygenation for coronavirus disease 2019-related illnesses. Further work is
      needed to help guide the fair allocation of extracorporeal membrane oxygenation
      resources and to determine the appropriateness of extracorporeal cardiopulmonary 
      resuscitation.
FAU - MacGregor, Robert M
AU  - MacGregor RM
AD  - Division of Pediatric Surgery, Department of Surgery, Washington University
      School of Medicine, St. Louis Children's Hospital, St. Louis, MO.
FAU - Antiel, Ryan M
AU  - Antiel RM
AD  - Division of Pediatric Surgery, Department of Surgery, Washington University
      School of Medicine, St. Louis Children's Hospital, St. Louis, MO.
FAU - Najaf, Tasnim
AU  - Najaf T
AD  - Division of Neonatology, Department of Pediatrics, Washington University School
      of Medicine, St. Louis Children's Hospital, St. Louis, MO.
FAU - Said, Ahmed S
AU  - Said AS
AD  - Division of Pediatric Critical Care, Department of Pediatrics, Washington
      University School of Medicine, St. Louis Children's Hospital, St. Louis, MO.
FAU - Warner, Brad W
AU  - Warner BW
AD  - Division of Pediatric Surgery, Department of Surgery, Washington University
      School of Medicine, St. Louis Children's Hospital, St. Louis, MO.
FAU - Raval, Mehul V
AU  - Raval MV
AD  - Division of Pediatric Surgery, Department of Surgery, Northwestern University
      Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of
      Chicago, Chicago, IL.
FAU - Shakhsheer, Baddr
AU  - Shakhsheer B
AD  - Division of Pediatric Surgery, Department of Surgery, Washington University
      School of Medicine, St. Louis Children's Hospital, St. Louis, MO.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Crit Care Med
JT  - Pediatric critical care medicine : a journal of the Society of Critical Care
      Medicine and the World Federation of Pediatric Intensive and Critical Care
      Societies
JID - 100954653
SB  - IM
CIN - Pediatr Crit Care Med. 2020 Oct;21(10):902-903. PMID: 33009301
MH  - Adult
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cardiopulmonary Resuscitation
MH  - Child
MH  - Coronavirus Infections/*therapy
MH  - Extracorporeal Membrane Oxygenation/legislation & jurisprudence/*methods
MH  - Female
MH  - *Hospitals, Pediatric
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pediatrics
MH  - Pneumonia, Viral/*therapy
MH  - *Practice Guidelines as Topic
MH  - Resuscitation Orders
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - United States
PMC - PMC7523473
EDAT- 2020/05/20 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1097/PCC.0000000000002432 [doi]
AID - 00130478-202010000-00005 [pii]
PST - ppublish
SO  - Pediatr Crit Care Med. 2020 Oct;21(10):893-897. doi:
      10.1097/PCC.0000000000002432.


PMID- 32427501
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1497-0015 (Electronic)
IS  - 0706-7437 (Linking)
VI  - 65
IP  - 9
DP  - 2020 Sep
TI  - Irremediable Psychiatric Suffering in the Context of Physician-assisted Death: A 
      Scoping Review of Arguments: La souffrance psychiatrique irremediable dans le
      contexte du suicide assiste : Une revue etendue des arguments.
PG  - 593-603
LID - 10.1177/0706743720923072 [doi]
AB  - OBJECTIVES: Physician-assisted death (PAD), also known as medical assistance in
      dying, of patients with a psychiatric disorder (PPD) is a global issue of debate.
      In most jurisdictions that allow PAD, irremediable suffering is a legal
      requirement, how to apply the concept of irremediability to PPD remains
      challenging. The aim of this article is to identify the main arguments concerning
      irremediability in the debate about PAD of PPD and give directions for further
      moral deliberation and empirical research. METHODS: Systematic searches in
      MEDLINE, Embase, and PsycINFO were combined with 4 additional search strategies. 
      All conceptual-ethical articles, quantitative and qualitative empirical studies, 
      guidelines, case reports, and commentaries that met the inclusion criteria were
      included, and a qualitative data synthesis was used to identify recurring themes 
      within the literature. The study protocol was preregistered at the Open Science
      Framework under registration code: thjg8. RESULTS: A total of 50 articles met the
      inclusion criteria. Three main arguments concerning irremediability were found in
      the debate about PAD of PPD: uncertainty, hope, and treatment refusal.
      CONCLUSIONS: Uncertainty about irremediability is inevitable, so which level of
      certainty is morally required should be the subject of moral deliberation.
      Whether PAD induces or resolves hopelessness is an empirical claim that deserves 
      clarification. Treatment refusal in search of PAD raises questions about
      treatment efficacy in this patient group and about decision-making in the context
      of the physician-patient relationship. Going forward, more attention should be
      given to epidemiological research and to specific challenges posed by different
      psychiatric disorders.
FAU - van Veen, Sisco M P
AU  - van Veen SMP
AUID- ORCID: 0000-0001-6660-8500
AD  - Department of Medical Humanities, University Medical Centre Amsterdam, the
      Netherlands.
AD  - Department of Psychiatry, University Medical Centre Utrecht, the Netherlands.
FAU - Ruissen, Andrea M
AU  - Ruissen AM
AD  - Department of Medical Humanities, University Medical Centre Amsterdam, the
      Netherlands.
AD  - Haaglanden MC, the Hague, the Netherlands.
FAU - Widdershoven, Guy A M
AU  - Widdershoven GAM
AD  - Department of Medical Humanities, University Medical Centre Amsterdam, the
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200519
PL  - United States
TA  - Can J Psychiatry
JT  - Canadian journal of psychiatry. Revue canadienne de psychiatrie
JID - 7904187
SB  - IM
CIN - Can J Psychiatry. 2020 Sep;65(9):604-606. PMID: 32441132
CIN - Can J Psychiatry. 2020 Sep;65(9):607-609. PMID: 32452224
CIN - Can J Psychiatry. 2020 Sep;65(9):610-611. PMID: 32551927
MH  - Humans
MH  - Physician-Patient Relations
MH  - *Physicians
MH  - Qualitative Research
MH  - *Suicide, Assisted
PMC - PMC7457463
OTO - NOTNLM
OT  - *ethics
OT  - *irremediability
OT  - *physician-assisted death
OT  - *psychiatry
OT  - *review
EDAT- 2020/05/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1177/0706743720923072 [doi]
PST - ppublish
SO  - Can J Psychiatry. 2020 Sep;65(9):593-603. doi: 10.1177/0706743720923072. Epub
      2020 May 19.


PMID- 32427187
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 2
IP  - 3
DP  - 2020 Aug
TI  - Laboring alone? Brief thoughts on ethics and practical answers during the
      coronavirus disease 2019 pandemic.
PG  - 100141
LID - 10.1016/j.ajogmf.2020.100141 [doi]
FAU - Ecker, Jeffrey L
AU  - Ecker JL
AD  - Massachusetts General Hospital, Harvard Medical School, Boston, MA.
FAU - Minkoff, Howard L
AU  - Minkoff HL
AD  - Maimonides Medical Center, SUNY Downstate Health Sciences University, Brooklyn,
      NY.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
MH  - *COVID-19/epidemiology/prevention & control/psychology
MH  - Clinical Decision-Making/*ethics
MH  - *Delivery, Obstetric/ethics/psychology/trends
MH  - Disease Transmission, Infectious/prevention & control
MH  - Humans
MH  - *Infection Control/methods/organization & administration
MH  - Occupational Exposure/prevention & control
MH  - Risk Assessment
MH  - *Risk Management/ethics/trends
MH  - SARS-CoV-2
MH  - *Visitors to Patients
PMC - PMC7228734
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2020/04/19 00:00 [received]
PHST- 2020/05/02 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1016/j.ajogmf.2020.100141 [doi]
AID - S2589-9333(20)30085-9 [pii]
AID - 100141 [pii]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2020 Aug;2(3):100141. doi: 10.1016/j.ajogmf.2020.100141.
      Epub 2020 May 15.


PMID- 32427112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 19
TI  - Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project
      for Improving Communication, Ethics, Decision Making, and Health.
PG  - e16493
LID - 10.2196/16493 [doi]
AB  - BACKGROUND: Cancer is a major burden in Ethiopia. The Oncology Department of
      Tikur Anbessa (Black Lion) Specialized Hospital in Addis Ababa is the sole
      specialist unit for cancer care in the country. With only a handful of
      oncologists, a lack of resources, and a huge patient load, the work is
      challenging, especially in terms of achieving effective and ethical patient
      consultations. Patients, usually accompanied by family members, often wait for a 
      long time to receive medical attention and frequently depart without treatment.
      Handling consultations effectively is essential to help patients as much as
      possible within such limitations. OBJECTIVE: The project has the following three 
      main aims: (1) to enhance and expand the understanding of communicative and
      associated ethical challenges in Ethiopian cancer care; (2) to enhance and expand
      the understanding of the implications and use of person- and family-centered
      solutions to address such communicative challenges in practice; and (3) to plan
      and evaluate interventions in this area. METHODS: This project develops and
      consolidates a research collaboration to better understand and mitigate the
      communicative challenges in Ethiopian cancer care, with a focus on the handling
      and sharing of decision making and ethical tension among patients, staff, and
      family. Using theoretical models from linguistics, health communication, and
      health care ethics, multiple sources of data will be analyzed. Data sources
      currently include semistructured interviews with Ethiopian staff (n= 16),
      patients (n= 54), and family caregivers (n= 22); survey data on cancer awareness 
      (n=150) and attitudes toward breaking bad news (n=450); and video recordings of
      medical consultations (n=45). In addition, we will develop clinical and
      methodological solutions to formulate educational interventions. RESULTS: The
      project was awarded funding by the Swedish Research Council in December 2017 for 
      the period 2018 to 2021. The research ethics boards in Sweden and Ethiopia
      approved the project in May 2018. The results of the studies will be published in
      2020 and 2021. CONCLUSIONS: The project is the first step toward providing unique
      and seminal knowledge for the specific context of Ethiopia in the areas of
      physician-patient communication research and ethics. It contributes to the
      understanding of the complexity of the role of family and ethical challenges in
      relation to patient involvement and decision making in Ethiopia. Improved
      knowledge in this area can provide a fundamental model for ways to improve cancer
      care in many other low-resource settings in Africa and the Middle East, which
      share central cultural prerequisites, such as a strong patriarchal family
      structure, along with strong and devout religiosity. The project will also serve 
      to develop greater understanding about the current challenges in Western health
      systems associated with greater family and patient participation in decision
      making. In addition, the project will contribute to improving the education of
      Ethiopian health professionals working in cancer care by developing a training
      program to help them better understand and respond to identified challenges
      associated with communication. INTERNATIONAL REGISTERED REPORT IDENTIFIER
      (IRRID): DERR1-10.2196/16493.
CI  - (c)Nataliya Berbyuk Lindstrom, Aynalem Abraha Woldemariam, Abebe Bekele,
      Christian Munthe, Rune Andersson, Bethlehem Girma Kebede, Barbro Linderholm,
      Wondemagegnhu Tigeneh. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 19.05.2020.
FAU - Berbyuk Lindstrom, Nataliya
AU  - Berbyuk Lindstrom N
AUID- ORCID: https://orcid.org/0000-0002-4701-7884
AD  - Department of Applied Information Technology, University of Gothenburg,
      Gothenburg, Sweden.
FAU - Woldemariam, Aynalem Abraha
AU  - Woldemariam AA
AUID- ORCID: https://orcid.org/0000-0001-5023-3011
AD  - Department of Oncology and Radiotherapy, School of Medicine, Health Science
      College, Addis Ababa University, Addis Ababa, Ethiopia.
FAU - Bekele, Abebe
AU  - Bekele A
AUID- ORCID: https://orcid.org/0000-0003-0018-9096
AD  - Department of Surgery, School of Medicine, Addis Ababa University, Addis Ababa,
      Ethiopia.
FAU - Munthe, Christian
AU  - Munthe C
AUID- ORCID: https://orcid.org/0000-0003-0761-960X
AD  - Department of Philosophy, Linguistics and Theory of Science, University of
      Gothenburg, Gothenburg, Sweden.
FAU - Andersson, Rune
AU  - Andersson R
AUID- ORCID: https://orcid.org/0000-0002-8133-1199
AD  - Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy,
      University of Gothenburg, Gothenburg, Sweden.
FAU - Girma Kebede, Bethlehem
AU  - Girma Kebede B
AUID- ORCID: https://orcid.org/0000-0002-2970-8972
AD  - Department of Applied Information Technology, University of Gothenburg,
      Gothenburg, Sweden.
FAU - Linderholm, Barbro
AU  - Linderholm B
AUID- ORCID: https://orcid.org/0000-0003-1531-630X
AD  - Department of Oncology, Institute of Clinical Sciences, University of Gothenburg 
      and Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Tigeneh, Wondemagegnhu
AU  - Tigeneh W
AUID- ORCID: https://orcid.org/0000-0003-3568-8637
AD  - Department of Oncology and Radiotherapy, School of Medicine, Health Science
      College, Addis Ababa University, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7267985
OTO - NOTNLM
OT  - Ethiopia
OT  - cancer
OT  - communication
OT  - culture
OT  - ethics
OT  - person-centered care
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2019/10/04 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - v9i5e16493 [pii]
AID - 10.2196/16493 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 May 19;9(5):e16493. doi: 10.2196/16493.


PMID- 32427007
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 1369-1627 (Electronic)
IS  - 0954-0261 (Linking)
VI  - 32
IP  - 5-6
DP  - 2020 Aug - Sep
TI  - Querulant delusion and post-traumatic embitterment disorder.
PG  - 396-402
LID - 10.1080/09540261.2020.1747410 [doi]
AB  - Injustice, breach of trust, and humiliation are social stressors which can result
      in embitterment, known to everybody and which has been described in the Bible
      (Cain and Abel) or by Aristotle in the Nicomachean Ethics. It has been discussed 
      by several authors since the early days of psychiatric classification. In the
      textbook 'Psychiatry' by E. Kraepelin a full chapter is devoted to 'querulant
      delusion', named a reactive psychosis, which can be discriminated from endogenous
      psychosis or personality disorders. Core symptoms are embitterment, negativism,
      helplessness, self blame, unspecific somatic symptoms, phobic avoidance of
      persons or situations related to the event, intrusions, phantasies of revenge and
      aggression. Another name is 'Posttraumatic Embitterment Disorder' according to
      the leading emotion. This severe mental disorder has by and large been ignored
      over the years by health professionals. In ICD-11 the term embitterment is
      mentioned for the first time in the category '6B43 adjustment disorder'.
      Embitterment can be measured with the 'Bern Embitterment Inventory (BVI)' and the
      'Post-Traumatic Embitterment Self-rating Scale (PTED scale)'. Treatment must take
      into account the special features of embitterment including often aggressive
      rejection of help. A promising treatment approach is, to refer to wisdom
      psychology and transfer this in 'wisdom psychotherapy'.
FAU - Linden, Michael
AU  - Linden M
AUID- ORCID: 0000-0002-5763-5512
AD  - Department of Psychosomatic Medicine, Charite University Medicine Berlin, Berlin,
      Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200519
PL  - England
TA  - Int Rev Psychiatry
JT  - International review of psychiatry (Abingdon, England)
JID - 8918131
SB  - IM
MH  - *Adjustment Disorders/complications
MH  - *Delusions/complications
MH  - Emotions
MH  - Humans
MH  - *Personality Disorders/complications
OTO - NOTNLM
OT  - *Embitterment
OT  - *adjustment disorder
OT  - *posttraumatic embitterment disorder
OT  - *social stressor
EDAT- 2020/05/20 06:00
MHDA- 2021/11/04 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1080/09540261.2020.1747410 [doi]
PST - ppublish
SO  - Int Rev Psychiatry. 2020 Aug - Sep;32(5-6):396-402. doi:
      10.1080/09540261.2020.1747410. Epub 2020 May 19.


PMID- 32426823
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 1930-613X (Electronic)
IS  - 0026-4075 (Linking)
VI  - 185
IP  - 9-10
DP  - 2020 Sep 18
TI  - A Comparison of Improvised and Commercially Available Point-of-Wounding
      Tourniquets in Simulated Traumatic Amputation with Catastrophic Hemorrhage.
PG  - e1536-e1541
LID - 10.1093/milmed/usaa085 [doi]
AB  - INTRODUCTION: Catastrophic hemorrhage is the leading cause of preventable trauma 
      deaths in the military and civilian populations. The use of tourniquets by first 
      responders (medical and nonmedically trained) is supported and has the potential 
      to save lives if applied correctly. AIMS: We sought to examine the use of 5
      tourniquets: 1 improvised and 4 commercially available tourniquets to investigate
      the time taken to stop simulated bleeding and to secure the device; evidence of
      rebleeding when the "blood pressure" was restored and to gain qualitative
      feedback on their application. MATERIALS AND METHODS: Four commercially available
      tourniquets (Combat Application Tourniquet [C-A-T], Special Operations Forces
      Tactical Tourniquet - Wide (SOFTT-W), stretch, wrap, and tuck tourniquet
      [SWAT-T], and the Tourni-key) and an improvised tourniquet (tie & wooden spoon)
      were tested on a complex silicone simulation model used to replicate catastrophic
      hemorrhage from a blast injury with above traumatic knee amputation (SAM 4.1
      Trauma Simulation Ltd, UK). To limit the user variability, the same investigator 
      applied each tourniquet and each was tested 3 times. No ethical approval was
      required to conduct this study. RESULTS: None of the devices took longer than 1
      minute to secure. The C-A-T and SOFTT-W were quickest to occlude and secure.
      Although the Tourni-key took longer statistically, this was unlikely to be a
      clinically important difference. Compared to the others, the SOFTT-W rebled on 2 
      out of 3 applications. The improvised tourniquet had an obvious ligature effect
      because of its narrowness, followed by the Tourni-key. This effect was least
      evident with the SWAT-T; however, particular care was needed to ensure it was
      safely secured as it was slippery when wet. CONCLUSIONS: All tourniquets tested
      were effective and swift to apply. The Tourni-key's antipinch card seems helpful 
      in reducing local pain under the windlass. Reinspection for rebleeding is
      important and should be routinely performed irrespective of the device. The width
      of the SWAT-T may be beneficial, thereby, reducing the risk of crush injury.
CI  - (c) Association of Military Surgeons of the United States 2020. All rights
      reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Hay-David, Aurelie G C
AU  - Hay-David AGC
AD  - Trauma & Orthopaedic Registrar, Queen Elizabeth University Hospital, Glasgow, UK.
FAU - Herron, Jonathan B T
AU  - Herron JBT
AD  - Medical Officer, 3 Medical Regiment.
FAU - Thurgood, Andrew
AU  - Thurgood A
AD  - Advanced Clinical Practitioner and Consultant in Prehospital Emergency Medicine, 
      Birmingham.
FAU - Whittle, Craig
AU  - Whittle C
AD  - Military Paramedic.
FAU - Mahmood, Ansar
AU  - Mahmood A
AD  - Trauma & Orthopaedic Consultant, Queen Elizabeth Hospital, Birmingham.
FAU - Bodger, Owen
AU  - Bodger O
AD  - Medical Statistician, University of Swansea, Swansea, UK.
FAU - Hodgetts, Timothy J
AU  - Hodgetts TJ
AD  - Senior Health Adviser to the British Army.
FAU - Pallister, Ian
AU  - Pallister I
AD  - Trauma & Orthopaedic Consultant, Morriston Hospital, Swansea, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
SB  - IM
EIN - Mil Med. 2021 Feb 26;186(3-4):e463. PMID: 33404604
MH  - *Amputation, Traumatic
MH  - *Emergency Responders
MH  - Hemorrhage/etiology/prevention & control/*therapy
MH  - Humans
MH  - *Military Personnel
MH  - *Tourniquets
EDAT- 2020/05/20 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/01/26 00:00 [revised]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 5839905 [pii]
AID - 10.1093/milmed/usaa085 [doi]
PST - ppublish
SO  - Mil Med. 2020 Sep 18;185(9-10):e1536-e1541. doi: 10.1093/milmed/usaa085.


PMID- 32426441
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20210110
IS  - 2352-5568 (Electronic)
IS  - 2352-5568 (Linking)
VI  - 39
IP  - 3
DP  - 2020 Jun
TI  - Prioritisation of ICU treatments for critically ill patients in a COVID-19
      pandemic with scarce resources.
PG  - 333-339
LID - S2352-5568(20)30091-6 [pii]
LID - 10.1016/j.accpm.2020.05.008 [doi]
AB  - BACKGROUND: Relying on capacity increases and patient transfers to deal with the 
      huge and continuous inflow of COVID-19 critically ill patients is a strategy
      limited by finite human and logistical resources. RATIONALE: Prioritising both
      critical care initiation and continuation is paramount to save the greatest
      number of lives. It enables to allocate scarce resources in priority to those
      with the highest probability of benefiting from them. It is fully ethical
      provided it relies on objective and widely shared criteria, thus preventing
      arbitrary decisions and guaranteeing equity. Prioritisation seeks to fairly
      allocate treatments, maximise saved lives, gain indirect life benefits from
      prioritising exposed healthcare and similar workers, give priority to those most 
      penalised as a last resort, and apply similar prioritisation schemes to all
      patients. PRIORITISATION STRATEGY: Prioritisation schemes and their criteria are 
      adjusted to the level of resource scarcity: strain (level A) or saturation (level
      B). Prioritisation yields a four level priority for initiation or continuation of
      critical care: P1-high priority, P2-intermediate priority, P3-not needed, P4-not 
      appropriate. Prioritisation schemes take into account the patient's wishes,
      clinical frailty, pre-existing chronic condition, along with severity and
      evolution of acute condition. Initial priority level must be reassessed, at least
      after 48h once missing decision elements are available, at the typical turning
      point in the disease's natural history (ICU days 7 to 10 for COVID-19), and each 
      time resource scarcity levels change. For treatments to be withheld or withdrawn,
      a collegial decision-making process and information of patient and/or next of kin
      are paramount. PERSPECTIVE: Prioritisation strategy is bound to evolve with new
      knowledge and with changes within the epidemiological situation.
CI  - Copyright (c) 2020 Societe francaise d'anesthesie et de reanimation (Sfar).
      Published by Elsevier Masson SAS. All rights reserved.
FAU - Leclerc, Thomas
AU  - Leclerc T
AD  - Percy military teaching hospital, Clamart, France; Val-de-Grace military medical 
      academy, Paris, France. Electronic address: thomas.leclerc@m4x.org.
FAU - Donat, Nicolas
AU  - Donat N
AD  - Percy military teaching hospital, Clamart, France.
FAU - Donat, Alexis
AU  - Donat A
AD  - Legouest military teaching hospital & Mercy regional hospital, Metz, France.
FAU - Pasquier, Pierre
AU  - Pasquier P
AD  - Percy military teaching hospital, Clamart, France; Val-de-Grace military medical 
      academy, Paris, France.
FAU - Libert, Nicolas
AU  - Libert N
AD  - Percy military teaching hospital, Clamart, France.
FAU - Schaeffer, Elodie
AU  - Schaeffer E
AD  - R. Picque military teaching hospital, Bordeaux, France.
FAU - D'Aranda, Erwan
AU  - D'Aranda E
AD  - Sainte Anne military teaching hospital, Toulon, France.
FAU - Cotte, Jean
AU  - Cotte J
AD  - Sainte Anne military teaching hospital, Toulon, France.
FAU - Fontaine, Bruno
AU  - Fontaine B
AD  - R. Picque military teaching hospital, Bordeaux, France; Val-de-Grace military
      medical academy, Paris, France.
FAU - Perrigault, Pierre-Francois
AU  - Perrigault PF
AD  - Gui de Chauliac hospital & Montpellier University, Montpellier, France; Ethics
      committee, French society of anaesthesia and critical care (SFAR), Paris, France.
FAU - Michel, Fabrice
AU  - Michel F
AD  - APHM, Aix Marseille Univ, UMR ADES n degrees 7268, EFS, CNRS, Marseille, France; 
      Ethics committee, French society of anaesthesia and critical care (SFAR), Paris, 
      France.
FAU - Muller, Laurent
AU  - Muller L
AD  - CHU Nimes Caremeau, Nimes, France; Ethics committee, French society of
      anaesthesia and critical care (SFAR), Paris, France.
FAU - Meaudre, Eric
AU  - Meaudre E
AD  - Sainte Anne military teaching hospital, Toulon, France; Val-de-Grace military
      medical academy, Paris, France.
FAU - Veber, Benoit
AU  - Veber B
AD  - Charles Nicolle hospital & Rouen Normandie University, Rouen, France; Ethics
      committee, French society of anaesthesia and critical care (SFAR), Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20200517
PL  - France
TA  - Anaesth Crit Care Pain Med
JT  - Anaesthesia, critical care & pain medicine
JID - 101652401
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Canada
MH  - Caregivers
MH  - Continuity of Patient Care/organization & administration
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Critical Care/ethics/*organization & administration/standards
MH  - *Critical Illness
MH  - France/epidemiology
MH  - Health Personnel
MH  - Health Priorities/ethics/*standards
MH  - Health Resources/*supply & distribution
MH  - Health Services Accessibility/ethics
MH  - Humans
MH  - Intensive Care Units/*organization & administration/supply & distribution
MH  - *Pandemics
MH  - Patient Transfer
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Practice Guidelines as Topic
MH  - Refusal to Treat/ethics
MH  - Resource Allocation/ethics
MH  - SARS-CoV-2
MH  - Social Justice
MH  - Switzerland
MH  - Triage/ethics/organization & administration/*standards
PMC - PMC7230138
OTO - NOTNLM
OT  - *COVID-19
OT  - *Critical care
OT  - *Ethics
OT  - *Pandemic
OT  - *Prioritisation
OT  - *Triage
EDAT- 2020/05/20 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1016/j.accpm.2020.05.008 [doi]
AID - S2352-5568(20)30091-6 [pii]
PST - ppublish
SO  - Anaesth Crit Care Pain Med. 2020 Jun;39(3):333-339. doi:
      10.1016/j.accpm.2020.05.008. Epub 2020 May 17.


PMID- 32426356
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-858X (Print)
IS  - 2296-858X (Linking)
VI  - 7
DP  - 2020
TI  - COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic
      CAncer): Study Protocol.
PG  - 134
LID - 10.3389/fmed.2020.00134 [doi]
AB  - Background: In many cases of pancreatic adenocarcinoma (PDAC), the diagnosis
      comes as a surprise to the patient, who often faces a disease that is already at 
      an advanced stage, with poor prognosis. The clinical visit during which the
      diagnosis is communicated together with the first information regarding the
      planned treatments is of paramount importance. We hypothesize that the clarity of
      such information can influence patients' engagement and thus their level of
      compliance. Aims: This study aims to collect (a) quantitative data on the level
      of PDAC patient engagement, (b) data on the rate of understanding of the
      information received from the doctor, and (c) data on level of compliance; the
      possible associations between these variables will be analyzed. Methods: This is 
      a single-center, observational, cross-sectional cohort study on patients
      diagnosed with PDAC, approved by the Ethics Committee of the San Raffaele
      Hospital. As no preliminary data are available on the association between PDAC
      patients' understanding rate and their level of engagement and of compliance, no 
      power calculation is possible. This is a pilot study, aimed at enrolling at least
      45 PDAC patients during a period of 3 months. Conclusion: COMMUNIcation and
      Patient Engagement at Diagnosis of PAncreatic CAncer (COMMUNI. CARE) will be the 
      first study specifically investigating whether there is a relation between PDAC
      patients' engagement, rate of understanding at the time of diagnosis, and
      compliance.
CI  - Copyright (c) 2020 Consolandi, Martini, Reni, Arcidiacono, Falconi, Graffigna and
      Capurso.
FAU - Consolandi, Monica
AU  - Consolandi M
AD  - Faculty of Philosophy, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Martini, Carlo
AU  - Martini C
AD  - Faculty of Philosophy, Vita-Salute San Raffaele University, Milan, Italy.
AD  - Centre for Philosophy of Social Science, University of Helsinki, Helsinki,
      Finland.
FAU - Reni, Michele
AU  - Reni M
AD  - Department of Medical Oncology, Pancreas Translational and Clinical Research
      Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy.
FAU - Arcidiacono, Paolo Giorgio
AU  - Arcidiacono PG
AD  - Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational
      and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan,
      Italy.
FAU - Falconi, Massimo
AU  - Falconi M
AD  - Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre,
      IRCCS San Raffaele Scientific Institute, Milan, Italy.
FAU - Graffigna, Guendalina
AU  - Graffigna G
AD  - Department of Psychology, EngageMinds Hub Consumer, Food & Health Engagement
      Research Center, Universita Cattolica del Sacro Cuore (Milano), Milan, Italy.
FAU - Capurso, Gabriele
AU  - Capurso G
AD  - Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational
      and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7203337
OTO - NOTNLM
OT  - communication
OT  - compliance
OT  - diagnosis
OT  - doctor-patient interaction
OT  - pancreatic cancer
OT  - patient engagement
OT  - therapeutic alliance
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.3389/fmed.2020.00134 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2020 Apr 30;7:134. doi: 10.3389/fmed.2020.00134.
      eCollection 2020.


PMID- 32426309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201214
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to
      Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and
      Papua New Guinea.
PG  - 197
LID - 10.3389/fped.2020.00197 [doi]
AB  - Background: Infection contributes to significant morbidity and mortality
      particularly in the very young and in low- and middle-income countries. While
      vaccines are a highly cost-effective tool against infectious disease little is
      known regarding the cellular and molecular pathways by which vaccines induce
      protection at an early age. Immunity is distinct in early life and greater
      precision is required in our understanding of mechanisms of early life protection
      to inform development of new pediatric vaccines. Methods and Analysis: We will
      apply transcriptomic, proteomic, metabolomic, multiplex cytokine/chemokine,
      adenosine deaminase, and flow cytometry immune cell phenotyping to delineate
      early cellular and molecular signatures that correspond to vaccine
      immunogenicity. This approach will be applied to a neonatal cohort in The Gambia 
      (N ~ 720) receiving at birth: (1) Hepatitis B (HepB) vaccine alone, (2) Bacille
      Calmette Guerin (BCG) vaccine alone, or (3) HepB and BCG vaccines, (4) HepB and
      BCG vaccines delayed till day 10 at the latest. Each study participant will have 
      a baseline peripheral blood sample drawn at DOL0 and a second blood sample at
      DOL1,-3, or-7 as well as late timepoints to assess HepB vaccine immunogenicity.
      Blood will be fractionated via a "small sample big data" standard operating
      procedure that enables multiple downstream systems biology assays. We will apply 
      both univariate and multivariate frameworks and multi-OMIC data integration to
      identify features associated with anti-Hepatitis B (anti-HB) titer, an
      established correlate of protection. Cord blood sample collection from a subset
      of participants will enable human in vitro modeling to test mechanistic
      hypotheses identified in silico regarding vaccine action. Maternal anti-HB titer 
      and the infant microbiome will also be correlated with our findings which will be
      validated in a smaller cohort in Papua New Guinea (N ~ 80). Ethics and
      Dissemination: The study has been approved by The Gambia Government/MRCG Joint
      Ethics Committee and The Boston Children's Hospital Institutional Review Board.
      Ethics review is ongoing with the Papua New Guinea Medical Research Advisory
      Committee. All de-identified data will be uploaded to public repositories
      following submission of study output for publication. Feedback meetings will be
      organized to disseminate output to the study communities. Clinical Trial
      Registration: Clinicaltrials.gov Registration Number: NCT03246230.
CI  - Copyright (c) 2020 Idoko, Smolen, Wariri, Imam, Shannon, Dibassey, Diray-Arce,
      Darboe, Strandmark, Ben-Othman, Odumade, McEnaney, Amenyogbe, Pomat, van Haren,
      Sanchez-Schmitz, Brinkman, Steen, Hancock, Tebbutt, Richmond, van den Biggelaar, 
      Kollmann, Levy, Ozonoff and Kampmann.
FAU - Idoko, Olubukola T
AU  - Idoko OT
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - CIH LMU Center for International Health, Medical Center of the University of
      Munich (LMU), Munich, Germany.
AD  - The Vaccine Centre, London School of Hygiene and Tropical Medicine, London,
      United Kingdom.
FAU - Smolen, Kinga K
AU  - Smolen KK
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
FAU - Wariri, Oghenebrume
AU  - Wariri O
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
FAU - Imam, Abdulazeez
AU  - Imam A
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
FAU - Shannon, Casey P
AU  - Shannon CP
AD  - PROOF Centre of Excellence, Vancouver, BC, Canada.
FAU - Dibassey, Tida
AU  - Dibassey T
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
FAU - Diray-Arce, Joann
AU  - Diray-Arce J
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
FAU - Darboe, Alansana
AU  - Darboe A
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
FAU - Strandmark, Julia
AU  - Strandmark J
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
FAU - Ben-Othman, Rym
AU  - Ben-Othman R
AD  - Department of Pediatrics, BC Children's Hospital, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Odumade, Oludare A
AU  - Odumade OA
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - The Vaccine Centre, London School of Hygiene and Tropical Medicine, London,
      United Kingdom.
AD  - Division of Medicine Critical Care, Harvard Medical School, Boston Children's
      Hospital, Boston, MA, United States.
FAU - McEnaney, Kerry
AU  - McEnaney K
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Department of Cardiology, Boston Children's Hospital, Boston, MA, United States.
FAU - Amenyogbe, Nelly
AU  - Amenyogbe N
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      University of Western Australia, Nedlands, WA, Australia.
FAU - Pomat, William S
AU  - Pomat WS
AD  - Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
FAU - van Haren, Simon
AU  - van Haren S
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
FAU - Sanchez-Schmitz, Guzman
AU  - Sanchez-Schmitz G
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
FAU - Brinkman, Ryan R
AU  - Brinkman RR
AD  - BC Cancer Agency, Vancouver, BC, Canada.
AD  - Department of Medical Genetics, University of British Columbia, Vancouver, BC,
      Canada.
FAU - Steen, Hanno
AU  - Steen H
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
AD  - Department of Pathology, Boston Children's Hospital, Boston, MA, United States.
FAU - Hancock, Robert E W
AU  - Hancock REW
AD  - Department of Microbiology & Immunology, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Tebbutt, Scott J
AU  - Tebbutt SJ
AD  - PROOF Centre of Excellence, Vancouver, BC, Canada.
AD  - Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, 
      Canada.
AD  - Division of Respiratory Medicine, Department of Medicine, UBC, Vancouver, BC,
      Canada.
FAU - Richmond, Peter C
AU  - Richmond PC
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      University of Western Australia, Nedlands, WA, Australia.
AD  - Division of Pediatrics, School of Medicine, Perth Children's Hospital, University
      of Western Australia, Nedlands, WA, Australia.
FAU - van den Biggelaar, Anita H J
AU  - van den Biggelaar AHJ
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      University of Western Australia, Nedlands, WA, Australia.
FAU - Kollmann, Tobias R
AU  - Kollmann TR
AD  - Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute,
      University of Western Australia, Nedlands, WA, Australia.
FAU - Levy, Ofer
AU  - Levy O
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
AD  - Broad Institute of MIT & Harvard, Cambridge, MA, United States.
FAU - Ozonoff, Al
AU  - Ozonoff A
AD  - Precision Vaccines Program, Division of Infectious Diseases, Boston Children's
      Hospital, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
FAU - Kampmann, Beate
AU  - Kampmann B
AD  - Vaccines and Immunity Theme, Medical Research Council Unit the Gambia at London
      School of Hygiene and Tropical Medicine, Fajara, Gambia.
AD  - The Vaccine Centre, London School of Hygiene and Tropical Medicine, London,
      United Kingdom.
LA  - eng
SI  - ClinicalTrials.gov/NCT03246230
GR  - U19 AI118608/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20200430
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
EIN - Front Pediatr. 2020 Nov 17;8:610461. PMID: 33313031
PMC - PMC7205022
OTO - NOTNLM
OT  - OMICS
OT  - immunogenicity
OT  - markers
OT  - newborn
OT  - systems biology
OT  - vaccine
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.3389/fped.2020.00197 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Apr 30;8:197. doi: 10.3389/fped.2020.00197. eCollection 2020.


PMID- 32426285
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic.
PG  - 648
LID - 10.3389/fonc.2020.00648 [doi]
AB  - Italy is the European country that was hit first and hardest by the COVID-19
      epidemic. Since February 2020, the outbreak of the epidemic disease in Italy,
      with fatal outcomes in up to 10% of cases, made it urgent to implement
      extraordinary measures to avoid a breakdown of the universal Italian national
      health system. The update for April 1, 2020, in Italy recorded 102,669 confirmed 
      COVID-19 cases, with a median patient age of 63 years. The deceased patients were
      older people (median age 80 years) and often had a cancer diagnosis (about 20%). 
      Thus, in the extraordinary epidemiological scenario of the COVID-19 pandemic in
      Italy, older persons in cancer treatment are at particularly high risk of being
      severely affected by COVID-19. These people face a health- and economics-related 
      emergency that also carries cultural and ethical implications. In accordance with
      the measures adopted by the Italian government to limit viral transmission,
      several associations of Italian oncologists have taken action to update Elderly
      Cancer Care programs. In view of the newly emerging needs, we herein outline
      practical suggestions aimed at guaranteeing the best continuity to elderly cancer
      patients.
CI  - Copyright (c) 2020 Fratino, Procopio, Di Maio, Cinieri, Leo and Beretta.
FAU - Fratino, Lucia
AU  - Fratino L
AD  - Medical Oncology Unit, National Cancer Institute, Centro di Riferimento
      Oncologico, IRCCS, Aviano, Italy.
FAU - Procopio, Giuseppe
AU  - Procopio G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,
      Milan, Italy.
FAU - Di Maio, Massimo
AU  - Di Maio M
AD  - Department of Oncology, University of Turin, at Ordine Mauriziano Hospital,
      Turin, Italy.
FAU - Cinieri, Saverio
AU  - Cinieri S
AD  - Medical Oncology Unit, Antonio Perrino Hospital, Brindisi, Italy.
FAU - Leo, Silvana
AU  - Leo S
AD  - Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy.
FAU - Beretta, Giordano
AU  - Beretta G
AD  - Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7203468
OTO - NOTNLM
OT  - COVID-19
OT  - Italy
OT  - cancer patients
OT  - elderly
OT  - pandemic
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.3389/fonc.2020.00648 [doi]
PST - epublish
SO  - Front Oncol. 2020 Apr 30;10:648. doi: 10.3389/fonc.2020.00648. eCollection 2020.


PMID- 32426222
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2213-4220 (Print)
IS  - 2213-4220 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Sep
TI  - The ethics of COVID-19 clinical trials: New considerations in a controversial
      area.
PG  - 100425
LID - 10.1016/j.imr.2020.100425 [doi]
FAU - Han, Zhenzhen
AU  - Han Z
AD  - Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin
      University of Traditional Chinese Medicine, Tianjin, China.
AD  - National Clinical Research Center for Chinese Medicine Acupuncture and
      Moxibustion, Tianjin, China.
FAU - Wang, Junting
AU  - Wang J
AD  - Department of Acupuncture and Moxibustion, Tianjin Gong An Hospital, Tianjin,
      China.
FAU - Zhang, Kai
AU  - Zhang K
AD  - Department of Acupuncture and Moxibustion, Tianjin Gong An Hospital, Tianjin,
      China.
FAU - Tang, Qilin
AU  - Tang Q
AD  - School of Basic Medical Sciences, Hebei University of Chinese Medicine, Hebei,
      China.
LA  - eng
PT  - Editorial
DEP - 20200515
PL  - Netherlands
TA  - Integr Med Res
JT  - Integrative medicine research
JID - 101612707
PMC - PMC7227522
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical trials
OT  - Ethics
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1016/j.imr.2020.100425 [doi]
AID - S2213-4220(20)30057-3 [pii]
AID - 100425 [pii]
PST - ppublish
SO  - Integr Med Res. 2020 Sep;9(3):100425. doi: 10.1016/j.imr.2020.100425. Epub 2020
      May 15.


PMID- 32426180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2164-957X (Print)
IS  - 2164-9561 (Linking)
VI  - 9
DP  - 2020
TI  - Tending the Field of Mindfulness-Based Programs: The Development of International
      Integrity Guidelines for Teachers and Teacher Training.
PG  - 2164956120923975
LID - 10.1177/2164956120923975 [doi]
AB  - Since Jon Kabat-Zinn first introduced a contemporary, secularized application of 
      mindfulness for the relief of pain and stress in physical health-care settings,
      there has been a significant and rapid expansion of the range of
      mindfulness-based programs (MBPs) designed for various health care, education,
      workplace, and other settings. As is common with developing programs, these often
      run ahead of carefully considered and researched effectiveness evaluations. This 
      raises questions of how to best train mindfulness teachers to skillfully
      facilitate such interventions while minimizing the potential for harm. In this
      article, we describe the work of an international group of senior teacher
      trainers who met to develop guidelines on the ethics and standards for teacher
      trainers and their training pathways. In this article, we will define MBPs;
      describe the process by which these international guidelines were developed; and 
      share details of the collaborative team who made up the international network
      that worked on them. We offer these guidelines as "living documents" that
      specifically set out: (1) ethical standards for mindfulness teachers and
      trainers; (2) criteria and standards for teacher trainers; and (3) criteria and
      standards for training pathways. As "living documents," these will continue to be
      commented on and refined over time. Given that MBPs offered within secular
      settings in most countries currently have limited oversight or accreditation
      processes, we hope these guidelines will provide support and clarity to the
      teachers of all established and emerging MBPs, and their trainers and
      supervisors.
CI  - (c) The Author(s) 2020.
FAU - Kenny, Maura
AU  - Kenny M
AUID- ORCID: https://orcid.org/0000-0002-9342-9417
AD  - Centre for Treatment of Anxiety and Depression, SA Health, Thebarton, Australia.
FAU - Luck, Patricia
AU  - Luck P
AD  - Division of Medical Humanities & Bioethics, University of Rochester School of
      Medicine and Dentistry, Rochester, New York.
FAU - Koerbel, Lynn
AU  - Koerbel L
AD  - MBSR Teacher Education and Curricula Development, Mindfulness Center at Brown
      University School of Public Health, Providence, Rhode Island.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - United States
TA  - Glob Adv Health Med
JT  - Global advances in health and medicine
JID - 101584936
PMC - PMC7218322
OTO - NOTNLM
OT  - ethical guidelines for mindfulness teaching
OT  - international guidelines
OT  - mindfulness
OT  - mindfulness teacher guidelines
OT  - mindfulness teacher training guidelines
OT  - mindfulness-based programs integrity
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/02/12 00:00 [revised]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.1177/2164956120923975 [doi]
AID - 10.1177_2164956120923975 [pii]
PST - epublish
SO  - Glob Adv Health Med. 2020 May 7;9:2164956120923975. doi:
      10.1177/2164956120923975. eCollection 2020.


PMID- 32426145
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Prescription Patterns in Dialysis Patients: Differences Between Hemodialysis and 
      Peritoneal Dialysis Patients and Opportunities for Deprescription.
PG  - 2054358120912652
LID - 10.1177/2054358120912652 [doi]
AB  - BACKGROUND: Patients treated with maintenance dialysis are at high risk of
      polypharmacy given their many comorbidities as well as complications from their
      disease state and treatment. The prescribing patterns and burden of polypharmacy 
      in patients treated with maintenance dialysis, and specifically the difference
      between hemodialysis (HD) and peritoneal dialysis (PD) prescribing, are not well 
      characterized. OBJECTIVES: The objectives of this study were to review the
      prescribing patterns for patients treated with maintenance dialysis, to compare
      prescribing pattern between HD and PD, and to identify opportunities for
      deprescription. DESIGN: This is a retrospective cohort study. SETTING: This study
      was conducted in all dialysis centers in British Columbia, Canada. PATIENTS:
      Patients who were receiving chronic dialysis (>120 days on the same dialysis
      modality) between June 3 and October 1, 2015, and registered in the British
      Columbia (BC) Renal Patient Records and Outcomes Management Information System.
      MEASUREMENTS: Patient demographics as well as both prescription and
      non-prescription medications were collected. Comparison of discrete and
      continuous variables was made by chi-square analysis and independent t test,
      respectively. All statistical tests were 2-sided, and a P value of <.05 was
      considered statistically significant. METHODS: Medications were classified by
      indication: (1) management of renal complications, (2) cardiovascular (CV)
      medications, (3) diabetes medications, or (4) management of symptoms, and then
      classified as to whether they were a "potentially inappropriate medication" (PIM)
      or not. Ethics approval was granted from the University of British Columbia
      Research and Ethics Board. RESULTS: In total, 3017 patients met inclusion
      criteria (2243 HD, 774 PD). The mean age was 66.2 +/- 14.8 years. The HD group
      had more patients over 80 years old (22.1% vs 12.5%) and more patients with
      diabetes and CV disease. The mean number (standard deviation [SD]) of discrete
      prescribed medications was 17.71 (5.72) overall with more medications in the HD
      group versus the PD group. The mean number of medications increased with dialysis
      vintage in both groups. HD patients were on more medications for renal
      complications and management of symptoms than PD patients. Of the total number of
      medications prescribed, 5.02 (2.78) were classified as a PIM, with the number of 
      PIMs higher in HD vs PD patients: 5.37 (2.83) versus 4.02 (2.37). LIMITATIONS: In
      BC, some of the medications are prescribed through standardized protocols and may
      not be comparable with other Canadian provinces. We report here prescribing
      patterns, not utilization patterns, as we are not able to ascertain actual
      consumption of prescribed medication. CONCLUSION: This study reviews and
      characterizes both the prescription and non-prescription medication prescribed to
      HD patients and PD patients in BC. Pill burden in both groups is high, as is the 
      prescription of PIMs. Patients receiving maintenance HD receive more overall
      medications and more PIMs. These results highlight areas of opportunities for
      future systematic and patient-informed deprescription initiatives in both patient
      groups.
CI  - (c) The Author(s) 2020.
FAU - Marin, Judith G
AU  - Marin JG
AUID- ORCID: https://orcid.org/0000-0001-9317-8809
AD  - St. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.
AD  - UBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
FAU - Beresford, Laura
AU  - Beresford L
AD  - UBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
FAU - Lo, Clifford
AU  - Lo C
AD  - UBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
FAU - Pai, Alexander
AU  - Pai A
AD  - UBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
FAU - Espino-Hernandez, Gabriela
AU  - Espino-Hernandez G
AD  - Department of Medicine, The University of British Columbia, Vancouver, Canada.
FAU - Beaulieu, Monica
AU  - Beaulieu M
AD  - St. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.
AD  - Department of Medicine, The University of British Columbia, Vancouver, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7218341
OTO - NOTNLM
OT  - deprescription
OT  - end-stage kidney disease
OT  - hemodialysis
OT  - medication safety
OT  - peritoneal dialysis
OT  - polypharmacy
OT  - potentially inappropriate medication
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2019/06/18 00:00 [received]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.1177/2054358120912652 [doi]
AID - 10.1177_2054358120912652 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 May 1;7:2054358120912652. doi:
      10.1177/2054358120912652. eCollection 2020.


PMID- 32426070
OWN - NLM
STAT- MEDLINE
DCOM- 20200805
LR  - 20210218
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 139
DP  - 2020 Jul
TI  - Challenges to Neurosurgery During the Coronavirus Disease 2019 (COVID-19)
      Pandemic.
PG  - 519-525
LID - S1878-8750(20)31079-2 [pii]
LID - 10.1016/j.wneu.2020.05.108 [doi]
AB  - The coronavirus disease 2019 pandemic has presented a massive burden to most
      health care systems across the globe. The demand for intensive care unit capacity
      in particular has increased significantly, and hospitals in most affected regions
      have struggled to cope. The focus of health care activity has shifted to the
      pandemic, with a negative impact on the management of other conditions.
      Neurosurgery, like most specialties, has been drastically affected but, arguably,
      warrants special considerations because many of the treatments required are
      time-critical. Lack or delay of appropriate intervention may lead, for an
      individual patient, to permanent neurologic injury and a significant decline in
      function and quality of life, or even death. In this report, we consider the
      challenges that neurosurgeons currently face in relation to the pandemic and are 
      likely to face in the foreseeable future. The challenges are multifaceted with
      practical, ethical, legal, and other implications. These include re-deployment of
      staff to areas outside neurosurgery, treatment priority setting, ethical
      decision-making and risk of moral injury, as well as medicolegal risks, financial
      uncertainties and implications for training, research, and global health work. As
      well as patients, these challenges will affect neurosurgeons as doctors and as
      humans. The international neurosurgical community has a moral duty to contribute 
      to the global response to the COVID-19 crisis, but also to retain a duty to care 
      for individual patients.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Tsermoulas, Georgios
AU  - Tsermoulas G
AD  - Department of Neurosurgery, Queen Elizabeth Hospital, Birmingham, United Kingdom.
      Electronic address: georgios.tsermoulas@nhs.net.
FAU - Zisakis, Athanasios
AU  - Zisakis A
AD  - Department of Neurosurgery, Queen Elizabeth Hospital, Birmingham, United Kingdom.
FAU - Flint, Graham
AU  - Flint G
AD  - Department of Neurosurgery, Queen Elizabeth Hospital, Birmingham, United Kingdom.
FAU - Belli, Antonio
AU  - Belli A
AD  - Department of Neurosurgery, Queen Elizabeth Hospital, Birmingham, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200517
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/surgery
MH  - Delivery of Health Care/methods/*trends
MH  - Humans
MH  - Neurosurgeons/*trends
MH  - Neurosurgery/methods/*trends
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/surgery
MH  - SARS-CoV-2
PMC - PMC7231488
OTO - NOTNLM
OT  - *COVID-19
OT  - *Coronavirus
OT  - *Neurosurgery
OT  - *Pandemic
EDAT- 2020/05/20 06:00
MHDA- 2020/08/06 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/05/11 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/08/06 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1016/j.wneu.2020.05.108 [doi]
AID - S1878-8750(20)31079-2 [pii]
PST - ppublish
SO  - World Neurosurg. 2020 Jul;139:519-525. doi: 10.1016/j.wneu.2020.05.108. Epub 2020
      May 17.


PMID- 32425872
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Effect of Remote Ischemic Conditioning in Patients With Takotsubo Syndrome After 
      Acute Stroke: Study Protocol for a Randomized Controlled Trial.
PG  - 286
LID - 10.3389/fneur.2020.00286 [doi]
AB  - Introduction: Takotsubo syndrome (TTS) is an acute heart failure syndrome which
      is preceded by a variety of emotional or physical triggers, with central nervous 
      system conditions being an important trigger. Remote ischemic conditioning (RIC) 
      is a promising interventional treatment based on the probability that both TTS
      and acute coronary syndrome may respond similarly to interventions. The heart
      protection effect of RIC has been repeatedly confirmed in animal models and
      observational clinical trials; however, it has never been studied in patients
      with TTS after acute stroke in randomized clinical trials with a higher level of 
      evidence. The present study will be a proof-of-concept study to determine whether
      RIC can reduce cardiac injury and eventually improve the heart function and
      clinical outcomes of TTS patients after acute stroke. Methods and Analysis: A
      single-center, outcome-assessor-blinded, randomized controlled trial (RCT) will
      be conducted to evaluate the effect of RIC in TTS patients after acute stroke.
      Major eligibility criteria include TTS patients diagnosed with acute stroke,
      which can be confirmed on computed tomography or magnetic resonance imaging;
      patients aged 18-75 years; patients admitted to a hospital within 48 h after the 
      onset of acute stroke; and patients diagnosed with Takotsubo cardiomyopathy with 
      an InterTAK diagnostic score >/=50. A total of 60 eligible patients will be
      randomly allocated into either the RIC or the control group. The primary endpoint
      is a composite of death from any cause and major adverse cardiac and
      cerebrovascular events during the in-hospital period and at the 1- and 6-month
      follow-up. Ethics and dissemination: This study has been approved by the Medical 
      Ethics Committee of Xuanwu Hospital, Capital Medical University ([2017] 072). The
      study findings will be presented at international conferences and published in a 
      peer-reviewed journal. Trial registration: This study has been prospectively
      registered in the Chinese Clinical Trial Registry on September 10, 2018
      (ChiCTR1800018290).
CI  - Copyright (c) 2020 Wang, Xu, Wang, Qi, Cheng and Qu.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Xu, Yueqiao
AU  - Xu Y
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Wang, Ning
AU  - Wang N
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Qi, Meng
AU  - Qi M
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Cheng, Weitao
AU  - Cheng W
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
FAU - Qu, Xin
AU  - Qu X
AD  - Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing,
      China.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7212382
OTO - NOTNLM
OT  - Takotsubo syndrome
OT  - randomized controlled trial
OT  - remote ischemic conditioning
OT  - stroke
OT  - study protocol
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.3389/fneur.2020.00286 [doi]
PST - epublish
SO  - Front Neurol. 2020 Apr 28;11:286. doi: 10.3389/fneur.2020.00286. eCollection
      2020.


PMID- 32425540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Indicators of Abnormal Hand Grip Strength Among Older Egyptian Adults.
PG  - 387-392
LID - 10.2147/JMDH.S240502 [doi]
AB  - BACKGROUND: Hand grip strength (HGS) is gaining the attention of researchers and 
      clinicians, including geriatricians as a readily available, inexpensive, and
      useful measure of muscle strength. OBJECTIVE: To identify the indicators of
      abnormal HGS as measured by a Jamar handheld dynamometer in community-dwelling
      Egyptian senior citizens. STUDY DESIGN: The study was approved by the relevant
      ethical committee. This cross-sectional study included 200 randomly selected
      older adults of both sexes who attended geriatric and internal medicine
      outpatient clinics. Informed consent was obtained, and comprehensive geriatric
      assessment was performed, including assessment of the health-related quality of
      life by the 12-Item Short-Form Health Survey (SF-12). MEASUREMENT: HGS was
      measured, and values of 20 kg or less in females and 30 kg or less in males were 
      considered abnormal. STATISTICAL METHODS: IBM SPSS statistics v25.0 was used for 
      data analysis. Data were expressed as the mean +/- SD for quantitative parametric
      measures and as the number and percentage for categorical data. Student's t-test,
      the chi-squared test, the diagnostic validity test, and multiple logistic
      regression analysis were performed. The ROC (receiver operating characteristic)
      curve was constructed, and the AUC (area under the curve) was also calculated.
      RESULTS: The subjects' ages ranged from 60 to 95 years with a mean age of 69 +/- 
      SD 7.1 years. The sample consisted of 117 females (58.5%) and 83 males (41.5%).
      The chi-squared test showed that abnormal findings for grip strength were
      significantly more common among females than males (67.7% vs 32.3%). Student's
      t-test showed that both height and weight were significantly lower among subjects
      with abnormal than normal HGS, while body mass index (BMI) showed a
      non-significant difference. Stepwise multiple logistic regression analysis showed
      that there was no actual relationship between sex and abnormality of HGS.
      CONCLUSION: The best indicators of abnormal HGS were found to be a general health
      score below 25 points on the SF-12 and a height of less than 178 cm. As the
      values of general health and height decrease below those cut-off points, HGS
      decreases as well, and vice versa.
CI  - (c) 2020 Elbedewy et al.
FAU - Elbedewy, Reem M S
AU  - Elbedewy RMS
AD  - Geriatric Medicine and Gerontology Department, Faculty of Medicine, Ain Shams
      University, Cairo, Egypt.
FAU - El Said, Salma M S
AU  - El Said SMS
AUID- ORCID: 0000-0001-6855-6046
AD  - Geriatric Medicine and Gerontology Department, Faculty of Medicine, Ain Shams
      University, Cairo, Egypt.
FAU - Taha, Rana M
AU  - Taha RM
AD  - Geriatric Medicine and Gerontology Department, Faculty of Medicine, Ain Shams
      University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7196203
OTO - NOTNLM
OT  - body strength
OT  - hand grip strength
OT  - muscle weakness
OT  - quality of life
OT  - senior health
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:01
CRDT- 2020/05/20 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:01 [medline]
AID - 10.2147/JMDH.S240502 [doi]
AID - 240502 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Apr 28;13:387-392. doi: 10.2147/JMDH.S240502.
      eCollection 2020.


PMID- 32425472
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210129
IS  - 1545-7214 (Electronic)
IS  - 1064-7481 (Linking)
VI  - 28
IP  - 8
DP  - 2020 Aug
TI  - Electroconvulsive Therapy for Geriatric Depression in the COVID-19 Era:
      Reflection on the Ethics.
PG  - 900-902
LID - S1064-7481(20)30336-5 [pii]
LID - 10.1016/j.jagp.2020.05.007 [doi]
FAU - Burhan, Amer M
AU  - Burhan AM
AD  - Clinical Neuropsychiatry & Therapeutic Brain Stimulation Research, Parkwood
      Institute, London, ON, Canada; Department of Psychiatry at Schulich School of
      Medicine and Dentistry, London, ON, Canada; Therapeutic Brain Stimulation Clinic 
      at Parkwood Institute-Mental Health Care Building, London, ON, Canada. Electronic
      address: amer.burhan@sjhc.london.on.ca.
FAU - Safi, Ajmal
AU  - Safi A
AD  - Clinical Neuropsychiatry & Therapeutic Brain Stimulation Research, Parkwood
      Institute, London, ON, Canada.
FAU - Blair, Mervin
AU  - Blair M
AD  - Clinical Neuropsychiatry & Therapeutic Brain Stimulation Research, Parkwood
      Institute, London, ON, Canada.
FAU - O'Reilly, Richard
AU  - O'Reilly R
AD  - Department of Psychiatry at Schulich School of Medicine and Dentistry, London,
      ON, Canada; Therapeutic Brain Stimulation Clinic at Parkwood Institute-Mental
      Health Care Building, London, ON, Canada.
LA  - eng
PT  - Letter
DEP - 20200515
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American
      Association for Geriatric Psychiatry
JID - 9309609
SB  - IM
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*prevention & control
MH  - Depression/*therapy
MH  - Electroconvulsive Therapy/*adverse effects/*ethics/methods
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*epidemiology/*prevention & control
MH  - SARS-CoV-2
PMC - PMC7227591
EDAT- 2020/05/20 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1016/j.jagp.2020.05.007 [doi]
AID - S1064-7481(20)30336-5 [pii]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2020 Aug;28(8):900-902. doi: 10.1016/j.jagp.2020.05.007.
      Epub 2020 May 15.


PMID- 32425102
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - A Scenario-Based Methodology for Analyzing the Ethical, Legal, and Social Issues 
      in Genomic Data Sharing.
PG  - 355-364
LID - 10.1177/1556264620920460 [doi]
AB  - Sharing of genomic and associated data is essential to clinical practice and
      biomedical research, and is increasingly encouraged by journals and funding
      bodies. Grappling with the range of legal and ethical issues raised by genomic
      data sharing presents a significant challenge, given the diversity of practices: 
      from defined sharing of individual patient data, to broad-scale public sharing of
      research data, to uploading of direct-to-consumer test data by community members.
      Most commentary to date has discussed these issues in broad terms, but the debate
      can only progress if we engage with more granularity, grounded in jurisdictional 
      and contextual specifics. We developed an empirical approach, creating a set of
      prototypical scenarios that capture the diversity of current genomic data sharing
      practices, which allows legal and ethical analysis of key issues at a granular
      level. The specificity of this approach provides a strong foundation for
      developing useful and relevant regulatory recommendations.
FAU - McWhirter, Rebekah
AU  - McWhirter R
AUID- ORCID: 0000-0002-9409-8074
AD  - University of Tasmania, Hobart, Australia.
FAU - Eckstein, Lisa
AU  - Eckstein L
AD  - University of Tasmania, Hobart, Australia.
FAU - Chalmers, Don
AU  - Chalmers D
AD  - University of Tasmania, Hobart, Australia.
FAU - Critchley, Christine
AU  - Critchley C
AD  - University of Tasmania, Hobart, Australia.
AD  - Swinburne University of Technology, Hawthorn, Victoria, Australia.
FAU - Nielsen, Jane
AU  - Nielsen J
AD  - University of Tasmania, Hobart, Australia.
FAU - Otlowski, Margaret
AU  - Otlowski M
AD  - University of Tasmania, Hobart, Australia.
FAU - Nicol, Dianne
AU  - Nicol D
AD  - University of Tasmania, Hobart, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200519
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - *Biomedical Research
MH  - Genomics
MH  - Humans
MH  - *Information Dissemination
MH  - Morals
OTO - NOTNLM
OT  - *ELSI
OT  - *data sharing
OT  - *ethics
OT  - *genomics
OT  - *law
EDAT- 2020/05/20 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1177/1556264620920460 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):355-364. doi:
      10.1177/1556264620920460. Epub 2020 May 19.


PMID- 32424955
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1523-1739 (Electronic)
IS  - 0888-8892 (Linking)
VI  - 34
IP  - 5
DP  - 2020 Oct
TI  - The need for ecocentrism in biodiversity conservation.
PG  - 1089-1096
LID - 10.1111/cobi.13541 [doi]
AB  - Over the past 5 decades, scientists have been documenting negative anthropogenic 
      environmental change, expressing increasing alarm, and urging dramatic
      socioecological transformation in response. A host of international meetings have
      been held, but the erosion of biological diversity continues to accelerate. Why, 
      then, has no effective political action been taken? We contend that part of the
      answer may lie in the anthropocentric ethical premises and moral rhetoric
      typically deployed in the cause of conservation. We further argue that it is
      essential to advance moral arguments for biodiversity conservation that are not
      just based on perceived human interests but on ecocentric values, namely,
      convictions that species and ecosystems have value and interests that should be
      respected regardless of whether they serve human needs and aspirations. A broader
      array of moral rationales for biodiversity conservation, we conclude, would be
      more likely to lead to effective plans, adopted and enforced by governments,
      designed to conserve biological diversity. A good place to start in this regard
      would be to explicitly incorporate ecocentric values into the recommendations
      that will be made at the conclusion of the 15th meeting of the parties to the
      Convention on Biological Diversity, scheduled to be held in October 2020.
CI  - (c) 2020 The Authors. Conservation Biology published by Wiley Periodicals LLC on 
      behalf of Society for Conservation Biology.
FAU - Taylor, Bron
AU  - Taylor B
AUID- ORCID: 0000-0002-3328-2687
AD  - University of Florida, 107 Anderson Hall, PO Box 117410, Gainesville, FL,
      32611-7410, U.S.A.
FAU - Chapron, Guillaume
AU  - Chapron G
AUID- ORCID: 0000-0002-6727-1070
AD  - Department of Ecology, Swedish University of Agricultural Sciences, Riddarhyttan,
      730 91, Sweden.
FAU - Kopnina, Helen
AU  - Kopnina H
AUID- ORCID: 0000-0001-7617-2288
AD  - International Business, The Hague University of Applied Sciences, Johanna
      Westerdijkplein 75, EN, Den Haag, 2521, the Netherlands.
FAU - Orlikowska, Ewa
AU  - Orlikowska E
AUID- ORCID: 0000-0002-2302-6102
AD  - School for Forest Management, Swedish University of Agricultural Sciences (SLU), 
      Box 43, Skinnskatteberg, 739 21, Sweden.
FAU - Gray, Joe
AU  - Gray J
AD  - Global Ecocentric Network for Implementing Ecodemocracy, Fleetville, St Albans,
      AL1, U.K.
FAU - Piccolo, John J
AU  - Piccolo JJ
AUID- ORCID: 0000-0002-2633-4178
AD  - Institution for Environmental and Life Sciences, Karlstad University,
      Universitetsgatan 3, Karlstad, 65188, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200813
PL  - United States
TA  - Conserv Biol
JT  - Conservation biology : the journal of the Society for Conservation Biology
JID - 9882301
SB  - IM
MH  - Biodiversity
MH  - *Conservation of Natural Resources
MH  - *Ecosystem
MH  - Humans
MH  - Morals
OTO - NOTNLM
OT  - *Convenio sobre la Diversidad Biologica
OT  - *Convention on Biological Diversity
OT  - *IPBES
OT  - *anthropocentrism
OT  - *antropocentrismo
OT  - *biofilia
OT  - *biophilia
OT  - *derechos de la naturaleza
OT  - *ethics
OT  - *justice
OT  - *justicia
OT  - *la naturaleza necesita la mitad
OT  - *nature
OT  - *needs half
OT  - *rights of nature
OT  - *vision del mundo
OT  - *worldviews
OT  - *etica
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
EDAT- 2020/05/20 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/05/04 00:00 [revised]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1111/cobi.13541 [doi]
PST - ppublish
SO  - Conserv Biol. 2020 Oct;34(5):1089-1096. doi: 10.1111/cobi.13541. Epub 2020 Aug
      13.


PMID- 32424724
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Refining Value Sensitive Design: A (Capability-Based) Procedural Ethics Approach 
      to Technological Design for Well-Being.
PG  - 2629-2662
LID - 10.1007/s11948-020-00223-3 [doi]
AB  - Fundamental questions in value sensitive design include whether and how high-tech
      products/artefacts could embody values and ethical ideals, and how plural and
      incommensurable values of ethical and social importance could be chosen
      rationally and objectively at a collective level. By using a humanitarian cargo
      drone study as a starting point, this paper tackles the challenges that VSD's
      lack of commitment to a specific ethical theory generates in practical
      applications. Besides, it highlights how mainstream ethical approaches usually
      related to VSD are incapable of solving main ethical dilemmas raised by
      technological design for well-being in democratic settings. Accordingly, it is
      argued that VSD's ethical-democratic import would substantially be enhanced by
      the espousal of a procedural ethics stance and the deliberative approach to value
      and welfare entailed by Amartya Sen's capability approach. Differently from rival
      ethical-political theories, its normative and meta-ethical foundations better
      handle human diversity, value-goal pluralism, conflicting vested interests as
      well as the epistemic-moral disagreements typical of contemporary complex
      democracies. Particularly, Sen's capability approach procedural-deliberative
      tenets result in an "objective-impartial" choice procedure selecting a
      "hierarchy" of plural incommensurable values and rational goals thus, suitable to
      validate an applied science such as welfare-oriented technological design in
      concrete social environments. Conclusions suggest that refining VSD with a
      capability-based procedural approach to ethics fosters the concern for democracy 
      and social justice while preserving vital scientific-technical standards. Major
      advantages are at an applied level to delivering ethically and socially
      justified, but yet highly functional technologies and high-tech
      products/artefacts.
FAU - Cenci, Alessandra
AU  - Cenci A
AUID- ORCID: http://orcid.org/0000-0001-9460-8436
AD  - Department of Philosophy, Institute for the Study of Culture, University of
      Southern Denmark, Campusvej 55, 5230, Odense M, Denmark. alessandra@sdu.dk.
FAU - Cawthorne, Dylan
AU  - Cawthorne D
AUID- ORCID: http://orcid.org/0000-0002-3068-0890
AD  - Unmanned Aerial Systems Center, Maersk Mc-Kinney Moller Institute, Technical
      Faculty, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Cultural Diversity
MH  - *Ethical Theory
MH  - Humans
MH  - Morals
MH  - *Social Justice
MH  - Technology
PMC - PMC7550296
OTO - NOTNLM
OT  - *Amartya sen's capability approach
OT  - *Democracy
OT  - *Participatory-deliberative methods
OT  - *Procedural ethics
OT  - *Technological design for well-being
OT  - *Value sensitive design (VSD)
EDAT- 2020/05/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/03/18 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1007/s11948-020-00223-3 [doi]
AID - 10.1007/s11948-020-00223-3 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2629-2662. doi: 10.1007/s11948-020-00223-3. Epub
      2020 May 18.


PMID- 32424723
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Non-safety Assessments of Genome-Edited Organisms: Should They be Included in
      Regulation?
PG  - 2601-2627
LID - 10.1007/s11948-020-00222-4 [doi]
AB  - This article presents and evaluates arguments supporting that an approval
      procedure for genome-edited organisms for food or feed should include a broad
      assessment of societal, ethical and environmental concerns; so-called non-safety 
      assessment. The core of analysis is the requirement of the Norwegian Gene
      Technology Act that the sustainability, ethical and societal impacts of a
      genetically modified organism should be assessed prior to regulatory approval of 
      the novel products. The article gives an overview how this requirement has been
      implemented in the regulatory practice, demonstrating that such assessment is
      feasible and justified. Even in situations where genome-edited organisms are
      considered comparable to non-modified organisms in terms of risk, the technology 
      may have-in addition to social benefits-negative impacts that warrant assessments
      of the kind required in the Act. The main reason is the disruptive character of
      the genome editing technologies due to their potential for novel, ground-breaking
      solutions in agriculture and aquaculture combined with the economic framework
      shaped by the patent system. Food is fundamental for a good life, biologically
      and culturally, which warrants stricter assessment procedures than what is
      required for other industries, at least in countries like Norway with a strong
      tradition for national control over agricultural markets and breeding programs.
FAU - Myskja, Bjorn Kare
AU  - Myskja BK
AUID- ORCID: http://orcid.org/0000-0002-0777-5277
AD  - Department of Philosophy and Religious Studies, Faculty of Humanities, NTNU,
      7491, Trondheim, Norway. bjorn.myskja@ntnu.no.
FAU - Myhr, Anne Ingeborg
AU  - Myhr AI
AD  - GenOk-Centre for Biosafety, SIVA Innovation Centre, PB 6418, 9294, Tromso,
      Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Agriculture
MH  - *Gene Editing
MH  - *Genome
MH  - Humans
MH  - Norway
MH  - Plants, Genetically Modified/genetics
PMC - PMC7550366
OTO - NOTNLM
OT  - *CRISPR
OT  - *Ethical impacts
OT  - *GMO
OT  - *Norwegian Gene Technology Act
OT  - *Social utility
OT  - *Sustainability
EDAT- 2020/05/20 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/03/19 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1007/s11948-020-00222-4 [doi]
AID - 10.1007/s11948-020-00222-4 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2601-2627. doi: 10.1007/s11948-020-00222-4. Epub
      2020 May 18.


PMID- 32424324
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Linking)
VI  - 28
IP  - 8
DP  - 2020 Aug
TI  - Future-proofing biobanks' governance.
PG  - 989-996
LID - 10.1038/s41431-020-0646-4 [doi]
AB  - Good biobank governance implies-at a minimum-transparency and accountability and 
      the implementation of oversight mechanisms. While the biobanking community is in 
      general committed to such principles, little is known about precisely which
      governance strategies biobanks adopt to meet those objectives. We conducted an
      exploratory analysis of governance mechanisms adopted by research biobanks,
      including genetic biobanks, located in Europe and Canada. We reviewed information
      available on the websites of 69 biobanks, and directly contacted them for
      additional information. Our study identified six types of commonly adopted
      governance strategies: communication, compliance, expert advice, external review,
      internal procedures, and partnerships. Each strategy is implemented through
      different mechanisms including, independent ethics assessment, informed consent
      processes, quality management, data access control, legal compliance, standard
      operating procedures and external certification. Such mechanisms rely on a wide
      range of bodies, committees and actors from both within and outside the biobanks 
      themselves. We found that most biobanks aim to be transparent about their
      governance mechanisms, but could do more to provide more complete and detailed
      information about them. In particular, the retrievable information, while showing
      efforts to ensure biobanks operate in a legitimate way, does not specify in
      sufficient detail how governance mechanisms support accountability, nor how they 
      ensure oversight of research operations. This state of affairs can potentially
      undermine biobanks' trustworthiness to stakeholders and the public in a long-term
      perspective. Given the ever-increasing reliance of biomedical research on large
      biological repositories and their associated databases, we recommend that
      biobanks increase their efforts to future-proof their governance.
FAU - Gille, Felix
AU  - Gille F
AUID- ORCID: http://orcid.org/0000-0002-2847-4633
AD  - ETH Zurich, Department of Health Sciences and Technology, Health Ethics and
      Policy Lab, Zurich, Switzerland. felix.gille@hest.ethz.ch.
FAU - Vayena, Effy
AU  - Vayena E
AD  - ETH Zurich, Department of Health Sciences and Technology, Health Ethics and
      Policy Lab, Zurich, Switzerland.
FAU - Blasimme, Alessandro
AU  - Blasimme A
AUID- ORCID: http://orcid.org/0000-0001-5908-2002
AD  - ETH Zurich, Department of Health Sciences and Technology, Health Ethics and
      Policy Lab, Zurich, Switzerland. alessandro.blasimme@hest.ethz.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200518
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
SB  - IM
MH  - Biological Specimen Banks/legislation & jurisprudence/*organization &
      administration/standards
MH  - Communication
MH  - Confidentiality/legislation & jurisprudence/standards
MH  - Databases, Factual/standards
MH  - *Government Regulation
MH  - Health Policy
MH  - Humans
PMC - PMC7468350
EDAT- 2020/05/20 06:00
MHDA- 2021/06/02 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/03/27 00:00 [revised]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1038/s41431-020-0646-4 [doi]
AID - 10.1038/s41431-020-0646-4 [pii]
PST - ppublish
SO  - Eur J Hum Genet. 2020 Aug;28(8):989-996. doi: 10.1038/s41431-020-0646-4. Epub
      2020 May 18.


PMID- 32424063
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Triage during the COVID-19 epidemic in Spain: better and worse ethical arguments.
PG  - 455-458
LID - 10.1136/medethics-2020-106352 [doi]
AB  - The COVID-19 pandemic has generated an imbalance between the clinical needs of
      the population and the effective availability of advanced life support (ALS)
      resources. Triage protocols have thus become necessary. Triage decisions in
      situations of scarce resources were not extraordinary in the pre-COVID-19 era;
      these protocols abounded in the context of organ transplantation. However, this
      prior experience was not considered during the COVID-19 outbreak in Spain.
      Lacking national guidance or public coordination, each hospital has been forced
      to put forth independent and autonomous triage protocols, most of which were,
      nonetheless, based on common ethical principles and clinical criteria. However,
      controversial, non-clinical criteria have also been defended by Spanish
      scientific societies and public institutions, including setting an age cut-off
      value for unilaterally withholding ALS, using 'social utility' criteria,
      prioritising healthcare professionals or using 'first come, first served'
      policies. This paper describes the most common triage criteria used in the
      Spanish context during the COVID-19 epidemic. We will highlight our missed
      opportunities by comparing these criteria to those used in organ transplantation 
      protocols. The problems posed by subjective, non-clinical criteria will also be
      discussed. We hope that this critical review might be of use to countries at
      earlier stages of the epidemic while we learn from our mistakes.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Herreros, Benjamin
AU  - Herreros B
AD  - Internal Medicine, Hospital Universitario Fundacion Alcorcon Servicio de Medicina
      Interna, Alcorcon, Comunidad de Madrid, Spain benjaminherreros@gmail.com.
AD  - Instituto de Etica Clinica Francisco Valles, Universidad Europea de Madrid Campus
      de Villaviciosa de Odon, Villaviciosa de Odon, Madrid, Spain.
FAU - Gella, Pablo
AU  - Gella P
AD  - Instituto de Etica Clinica Francisco Valles, Universidad Europea de Madrid Campus
      de Villaviciosa de Odon, Villaviciosa de Odon, Madrid, Spain.
FAU - Real de Asua, Diego
AU  - Real de Asua D
AUID- ORCID: 0000-0002-1445-5597
AD  - Department of Internal Medicine, Hospital Universitario de la Princesa, Madrid,
      Spain.
AD  - Division of Medical Ethics, Cornell University Joan and Sanford I Weill Medical
      College, New York, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Protocols/standards
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Intensive Care Units
MH  - Organ Transplantation/ethics/standards
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Spain
MH  - Triage/*ethics
PMC - PMC7242823
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *applied and professional ethics
OT  - *clinical ethics
OT  - *decision-making
OT  - *distributive justice
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - medethics-2020-106352 [pii]
AID - 10.1136/medethics-2020-106352 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):455-458. doi: 10.1136/medethics-2020-106352. Epub
      2020 May 18.


PMID- 32424062
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Can China's 'standard of care' for COVID-19 be replicated in Europe?
PG  - 451-454
LID - 10.1136/medethics-2020-106210 [doi]
AB  - The Director-General of the WHO has suggested that China's approach to the
      COVID-19 crisis could be the standard of care for global epidemics. However, as
      remarkable as the Chinese strategy might be, it cannot be replicated in other
      countries and certainly not in Europe. In Europe, there is a distribution of
      power between the European Union and its member states. In contrast, China's
      political power is concentrated in the central government. This enables it to
      take immediate measures that affect the entire country, such as massive
      quarantines or closing borders. Moreover, the Chinese legal framework includes
      restrictions on privacy and other human rights that are unknown in Europe. In
      addition, China has the technological power to easily impose such restrictions.
      In most European countries, that would be science fiction. These conditions have 
      enabled China to combat epidemics like no other country can. However, the WHO
      might have been overoptimistic. The Chinese standard of care for treating
      COVID-19 also raises problematic issues for human rights, and the real
      consequences of these actions remain to be seen.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Raposo, Vera Lucia
AU  - Raposo VL
AUID- ORCID: 0000-0001-7895-2181
AD  - Faculty of Law, University of Macau, Taipa, Macao vraposo@um.edu.mo.
AD  - Faculty of Law, Universidade de Coimbra, Coimbra, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - Europe/epidemiology
MH  - Human Rights/ethics/standards
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Privacy
MH  - SARS-CoV-2
MH  - Standard of Care/*ethics/*standards
PMC - PMC7242867
OTO - NOTNLM
OT  - *health promotion
OT  - *legal aspects
OT  - *public health ethics
OT  - *public policy
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - medethics-2020-106210 [pii]
AID - 10.1136/medethics-2020-106210 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):451-454. doi: 10.1136/medethics-2020-106210. Epub
      2020 May 18.


PMID- 32424061
OWN - NLM
STAT- Publisher
LR  - 20200519
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 18
TI  - Trust, trustworthiness and sharing patient data for research.
LID - medethics-2019-106048 [pii]
LID - 10.1136/medethics-2019-106048 [doi]
AB  - When it comes to using patient data from the National Health Service (NHS) for
      research, we are often told that it is a matter of trust: we need to trust, we
      need to build trust, we need to restore trust. Various policy papers and reports 
      articulate and develop these ideas and make very important contributions to
      public dialogue on the trustworthiness of our research institutions. But these
      documents and policies are apparently constructed with little sustained
      reflection on the nature of trust and trustworthiness, and therefore are missing 
      important features that matter for how we manage concerns related to trust. We
      suggest that what we mean by 'trust' and 'trustworthiness' matters and should
      affect the policies and guidance that govern data sharing in the NHS. We offer a 
      number of initial, general reflections on the way in which some of these features
      might affect our approach to principles, policies and strategies that are related
      to sharing patient data for research. This paper is the outcome of a 'public
      ethics' coproduction activity which involved members of the public and two
      academic ethicists. Our task was to consider collectively the accounts of trust
      developed by philosophers as they applied in the context of the NHS and to
      coproduce an argumentative position relevant to this context.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Sheehan, Mark
AU  - Sheehan M
AUID- ORCID: http://orcid.org/0000-0002-7191-901X
AD  - Ethox Centre, University of Oxford, Oxford, UK mark.sheehan@philosophy.ox.ac.uk.
FAU - Friesen, Phoebe
AU  - Friesen P
AUID- ORCID: http://orcid.org/0000-0002-1529-916X
AD  - Biomedical Ethics Unit, Social Studies of Medicine, McGill University, Montreal, 
      Quebec, Canada.
FAU - Balmer, Adrian
AU  - Balmer A
AD  - Oxford, UK.
FAU - Cheeks, Corina
AU  - Cheeks C
AD  - Oxford, UK.
FAU - Davidson, Sara
AU  - Davidson S
AD  - Oxford, UK.
FAU - Devereux, James
AU  - Devereux J
AD  - Oxford, UK.
FAU - Findlay, Douglas
AU  - Findlay D
AD  - Oxford, UK.
FAU - Keats-Rohan, Katharine
AU  - Keats-Rohan K
AD  - Oxford, UK.
FAU - Lawrence, Rob
AU  - Lawrence R
AD  - Oxford, UK.
FAU - Shafiq, Kamran
AU  - Shafiq K
AD  - London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - confidentiality/privacy
OT  - information technology
OT  - interests of health personnel/institutions
OT  - public health ethics
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2020/05/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/20 06:00 [medline]
AID - medethics-2019-106048 [pii]
AID - 10.1136/medethics-2019-106048 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 18. pii: medethics-2019-106048. doi:
      10.1136/medethics-2019-106048.


PMID- 32424060
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - The healthcare worker at risk during the COVID-19 pandemic: a Jewish ethical
      perspective.
PG  - 441-443
LID - 10.1136/medethics-2020-106294 [doi]
AB  - The current COVID-19 pandemic has raised many questions and dilemmas for modern
      day ethicists and healthcare providers. Are physicians, nurses and other
      healthcare workers morally obligated to put themselves in harm's way and treat
      patients during a pandemic, occurring a great risk to themselves, their families 
      and potentially to other patients? The issue was relevant during the 1918
      influenza epidemic and more recently severe acute respiratory syndrome epidemic
      in 2003. Since the risk to the healthcare workers was great, there was tension
      between the ethical duty and responsibility to treat and the risk to one's own
      life. This tension was further noted during the 2014 Ebola outbreak in West
      Africa that left hundreds of healthcare workers dead. The AMA Code of Ethics
      states that physicians are to 'provide urgent medical care during
      disasters...even in the face of greater than usual risk to physicians' own
      safety, health or life.'1 Classic Jewish sources have dealt with this question as
      well. There is an obligation 'to not stand by idly when your friends life is in
      danger'; however, the question arises as to whether there are limits to this
      obligation? Is one required to risk one's own life to save another's? There is a 
      consensus that one is not required but the question open to debate is whether it 
      is praiseworthy to do so. However, regarding healthcare workers, there is
      agreement for ethical, professional and societal reasons that they are required
      to put themselves in harm's way to care for their patients.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Solnica, Amy
AU  - Solnica A
AD  - Henrietta Szold School of Nursing, Faculty of Medicine, Hebrew University,
      Jerusalem, Israel amysolnica@gmail.com.
AD  - Department of Obstetrics and Gynecology, Hadassah Medical Center, Jerusalem,
      Israel.
FAU - Barski, Leonid
AU  - Barski L
AD  - Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer Sheva,
      Israel.
AD  - Department of Medicine, Soroka University Medical Center, Beer Sheva, Israel.
FAU - Jotkowitz, Alan
AU  - Jotkowitz A
AD  - Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer Sheva,
      Israel.
AD  - Department of Medicine, Soroka University Medical Center, Beer Sheva, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Nov;46(11):736-737. PMID: 32661072
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Personnel/*ethics
MH  - Humans
MH  - Jews/*psychology
MH  - Judaism/*psychology
MH  - Moral Obligations
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Risk Assessment
MH  - SARS-CoV-2
PMC - PMC7242871
OTO - NOTNLM
OT  - *codes of/position statements on professional ethics
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - medethics-2020-106294 [pii]
AID - 10.1136/medethics-2020-106294 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):441-443. doi: 10.1136/medethics-2020-106294. Epub
      2020 May 18.


PMID- 32423943
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Study protocol for a multicentre longitudinal mixed methods study to explore the 
      Outcomes of ChildrEn and fAmilies in the first year after paediatric Intensive
      Care: the OCEANIC study.
PG  - e038974
LID - 10.1136/bmjopen-2020-038974 [doi]
AB  - INTRODUCTION: Annually in the UK, 20 000 children become very ill or injured and 
      need specialist care within a paediatric intensive care unit (PICU). Most
      children survive. However, some children and their families may experience
      problems after they have left the PICU including physical, functional and/or
      emotional problems. It is unknown which children and families experience such
      problems, when these occur or what causes them. The aim of this mixed-method
      longitudinal cohort study is to understand the physical, functional, emotional
      and social impact of children surviving PICU (aged: 1 month-17 years), their
      parents and siblings, during the first year after a PICU admission. METHODS AND
      ANALYSIS: A quantitative study involving 300 child survivors of PICU; 300
      parents; and 150-300 siblings will collect data (using self-completion
      questionnaires) at baseline, PICU discharge, 1, 3, 6 and 12 months post-PICU
      discharge. Questionnaires will comprise validated and reliable instruments.
      Demographic data, PICU admission and treatment data, health-related quality of
      life, functional status, strengths and difficulties behaviour and post-traumatic 
      stress symptoms will be collected from the child. Parent and sibling data will be
      collected on the impact of paediatric health conditions on the family's
      functioning capabilities, levels of anxiety and social impact of the child's PICU
      admission. Data will be analysed using descriptive and inferential statistics.
      Concurrently, an embedded qualitative study involving semistructured interviews
      with 24 enrolled families at 3 months and 9 months post-PICU discharge will be
      undertaken. Framework analysis will be used to analyse the qualitative data.
      ETHICS AND DISSEMINATION: The study has received ethical approval from the
      National Health Services Research Ethics Committee (Ref: 19/WM/0290) and full
      governance clearance. This will be the first UK study to comprehensively
      investigate physical, functional, emotional and social consequences of PICU
      survival in the first-year postdischarge.Clinical Trials Registration Number:
      ISRCTN28072812 [Pre-results].
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Manning, Joseph C
AU  - Manning JC
AUID- ORCID: 0000-0002-6077-4169
AD  - Children and Young People Health Research, School of Health Sciences, University 
      of Nottingham, Nottingham, Nottinghamshire, UK joseph.manning@nottingham.ac.uk.
AD  - Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust,
      Nottingham, Nottinghamshire, UK.
AD  - Health Data Research UK, University of Nottingham, Nottingham, Nottinghamshire,
      UK.
FAU - Latour, Jos M
AU  - Latour JM
AD  - School of Nursing and Midwifery, University of Plymouth, Plymouth, UK.
AD  - Nursing Department, Hunan Children's Hospital, Changsha, Hunan, China.
FAU - Curley, Martha A Q
AU  - Curley MAQ
AD  - Department of Family and Community Health, School of Nursing, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - Anesthesia and Critical Care Medicine, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - The Research Institute, Children's Hospital of Philadelphia, Philadelphia, PA,
      USA.
FAU - Draper, Elizabeth S
AU  - Draper ES
AD  - Department of Health Sciences, University of Leicester, Leicester,
      Leicestershire, UK.
FAU - Jilani, Tahseen
AU  - Jilani T
AD  - Health Data Research UK, University of Nottingham, Nottingham, Nottinghamshire,
      UK.
AD  - Advanced Data Analysis Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Quinlan, Philip R
AU  - Quinlan PR
AD  - Health Data Research UK, University of Nottingham, Nottingham, Nottinghamshire,
      UK.
AD  - Advanced Data Analysis Centre, University of Nottingham, Nottingham,
      Nottinghamshire, UK.
FAU - Watson, R Scott
AU  - Watson RS
AD  - Division of Pediatric Critical Care Medicine, Department of Pediatrics,
      University of Washington, Seattle, Washington, USA.
AD  - Centre for Child Health, Behaviour, and Development, Seattle Children's Research 
      Institute, Seattle, Washington, USA.
FAU - Rennick, Janet E
AU  - Rennick JE
AD  - Ingram School of Nursing, McGill University Faculty of Medicine, Montreal,
      Quebec, Canada.
AD  - Centre for Outcomes Research & Evaluation, Research Institute of the McGill
      University Health Centre, Montreal, Quebec, Canada.
FAU - Colville, Gillian
AU  - Colville G
AD  - Paediatric Psychology Service, St Georges University Hospitals NHS Foundation
      Trust, London, UK.
AD  - Population Health Research Institute, University of London St George's, London,
      UK.
FAU - Pinto, Neethi
AU  - Pinto N
AD  - Section of Pediatric Critical Care, Department of Pediatrics, University of
      Chicago, Chicago, Illinois, USA.
FAU - Latif, Asam
AU  - Latif A
AD  - School of Health Sciences, University of Nottingham, Nottingham, Nottinghamshire,
      UK.
FAU - Popejoy, Emma
AU  - Popejoy E
AD  - Children and Young People Health Research, School of Health Sciences, University 
      of Nottingham, Nottingham, Nottinghamshire, UK.
AD  - Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust,
      Nottingham, Nottinghamshire, UK.
FAU - Coad, Jane
AU  - Coad J
AD  - Children and Young People Health Research, School of Health Sciences, University 
      of Nottingham, Nottingham, Nottinghamshire, UK.
CN  - OCEANIC Study Investigators
LA  - eng
SI  - ISRCTN/ISRCTN28072812
GR  - ICA-CL-2018-04-ST2-009/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Aftercare
MH  - Child
MH  - Critical Care
MH  - Humans
MH  - *Intensive Care Units, Pediatric
MH  - Longitudinal Studies
MH  - Multicenter Studies as Topic
MH  - Patient Discharge
MH  - *Quality of Life
PMC - PMC7239532
OTO - NOTNLM
OT  - *paediatric intensive & critical care
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-038974 [pii]
AID - 10.1136/bmjopen-2020-038974 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e038974. doi: 10.1136/bmjopen-2020-038974.


PMID- 32423941
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Internet-based cognitive-behavioural therapy for prevention of depression during 
      pregnancy and in the post partum (iPDP): a protocol for a large-scale randomised 
      controlled trial.
PG  - e036482
LID - 10.1136/bmjopen-2019-036482 [doi]
AB  - INTRODUCTION: The objective of this randomised controlled trial (RCT) is to
      examine the effects of smartphone-based cognitive-behavioural therapy (CBT) in
      preventing the onset of major depressive episodes (MDE) among pregnant women.
      METHODS AND ANALYSIS: The target study population will be pregnant women of 16-20
      weeks gestation who are currently users of 'Luna Luna Baby', the most widely used
      app for pregnant women in Japan. Those who meet the eligibility criteria will be 
      randomly allocated to the 6-module internet CBT programme that was newly
      developed for pregnant women (n=2500), or to a treatment-as-usual control group
      (n=2500). Participants in the intervention groups will be required to complete
      the programme by 32 weeks gestation. The primary outcomes are the number of new
      onsets of MDE, measured by using WHO Composite International Diagnostic Interview
      3.0 at 32 weeks gestation and 3 months post partum. Survival analysis will be
      conducted to test for the effectiveness of the intervention on the time to the
      onset of MDE. ETHICS AND DISSEMINATION: The study plan has been approved by the
      Research Ethics Review Board of the Graduate School of Medicine/Faculty of
      Medicine, the University of Tokyo (2019150NI). If the intervention programmes are
      found to produce a significant positive effect in this RCT, these programmes can 
      be made available for all users of the app in the future. TRIAL REGISTRATION
      NUMBER: UMIN000038190; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Nishi, Daisuke
AU  - Nishi D
AUID- ORCID: 0000-0001-9349-3294
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan d-nishi@m.u-tokyo.ac.jp.
FAU - Imamura, Kotaro
AU  - Imamura K
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Watanabe, Kazuhiro
AU  - Watanabe K
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Obikane, Erika
AU  - Obikane E
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Sasaki, Natsu
AU  - Sasaki N
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Yasuma, Naonori
AU  - Yasuma N
AUID- ORCID: 0000-0002-1216-7639
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Sekiya, Yuki
AU  - Sekiya Y
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Matsuyama, Yutaka
AU  - Matsuyama Y
AD  - Department of Biostatistics, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
FAU - Kawakami, Norito
AU  - Kawakami N
AUID- ORCID: 0000-0003-1080-2720
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Tokyo, Japan.
LA  - eng
SI  - UMIN-CTR/UMIN000038190
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cognitive Behavioral Therapy
MH  - *Depression/prevention & control
MH  - Female
MH  - Humans
MH  - Internet
MH  - Japan
MH  - Postpartum Period
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7239549
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *mental health
OT  - *preventive medicine
COIS- Competing interests: MTI has been involved in this study as mentioned in the
      manuscript. NK reports grants from Infocom Corp, Fujitsu, Fujitsu Software
      Technologies and TAK; personal fees from Occupational Health Foundation, Japan
      Dental Association, Sekisui Chemicals, Junpukai Health Care Center, Osaka Chamber
      of Commerce and Industry, outside the submitted work.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-036482 [pii]
AID - 10.1136/bmjopen-2019-036482 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e036482. doi: 10.1136/bmjopen-2019-036482.


PMID- 32423939
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Psychometric properties of self-reported financial toxicity measures in cancer
      survivors: a systematic review protocol using COSMIN methodology.
PG  - e036365
LID - 10.1136/bmjopen-2019-036365 [doi]
AB  - INTRODUCTION: Due to the higher costs associated with advancements in cancer
      treatment and longer duration of cancer survivorship, increasing financial
      toxicity has become a great threat to survivors, caregivers and public healthcare
      systems. Since accurate and reproducible measures are prerequisites for robust
      results, choosing an acceptable measure with strong psychometric properties to
      assess financial toxicity is essential. However, a description of the
      psychometric properties of existing measures is still lacking. The aim of this
      study is to apply COnsensus-based Standards for the selection of health
      Measurement INstruments (COSMIN) methodology to systematically review the content
      and structural validity of patient-reported outcome measures (PROMs) of financial
      toxicity for cancer survivors. METHODS AND ANALYSIS: PubMed/Medline, Medline
      (Ovid), Embase (Ovid), CINAHL (EBSCO), Web of Science, ProQuest Dissertations and
      Theses, and Cochrane Library (Wiley) will be comprehensively searched from
      database inception to 15 November 2019. Studies that report the measurement
      properties of PROMs assessing financial toxicity for cancer survivors will be
      included. The evaluation of measurement properties, data extraction and data
      synthesis will be conducted according to the COSMIN methodology. ETHICS AND
      DISSEMINATION: No individual data are involved in this systematic review. The
      results will be disseminated to a clinical audience and policy-makers though
      peer-reviewed journals and conferences and will support researchers in choosing
      the best measure to evaluate the financial toxicity of cancer survivors.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhu, Zheng
AU  - Zhu Z
AUID- ORCID: 0000-0001-9651-8311
AD  - School of Nursing, Fudan University, Shanghai, China.
AD  - Fudan University Centre for Evidence-based Nursing, A Joanna Briggs Institute
      Centre of Excellence, Shanghai, China.
FAU - Xing, Weijie
AU  - Xing W
AD  - School of Nursing, Fudan University, Shanghai, China xingweijie@fudan.edu.cn.
AD  - Fudan University Centre for Evidence-based Nursing, A Joanna Briggs Institute
      Centre of Excellence, Shanghai, China.
FAU - Lizarondo, Lucylynn
AU  - Lizarondo L
AD  - The Joanna Briggs Institute, University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Peng, Jian
AU  - Peng J
AD  - School of Nursing, Fudan University, Shanghai, China.
AD  - Fudan University Centre for Evidence-based Nursing, A Joanna Briggs Institute
      Centre of Excellence, Shanghai, China.
FAU - Hu, Yan
AU  - Hu Y
AD  - School of Nursing, Fudan University, Shanghai, China.
AD  - Fudan University Centre for Evidence-based Nursing, A Joanna Briggs Institute
      Centre of Excellence, Shanghai, China.
FAU - So, Winnie Kw
AU  - So WK
AD  - The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong,
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cancer Survivors
MH  - Humans
MH  - *Neoplasms
MH  - Patient Reported Outcome Measures
MH  - Psychometrics
MH  - Self Report
MH  - Surveys and Questionnaires
PMC - PMC7239540
OTO - NOTNLM
OT  - *health economics
OT  - *oncology
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-036365 [pii]
AID - 10.1136/bmjopen-2019-036365 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e036365. doi: 10.1136/bmjopen-2019-036365.


PMID- 32423938
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Study protocol and pilot results of an observational cohort study evaluating
      effect of red blood cell transfusion on oxygenation and mitochondrial oxygen
      tension in critically ill patients with anaemia: the INsufficient Oxygenation in 
      the Intensive Care Unit (INOX ICU-2) study.
PG  - e036351
LID - 10.1136/bmjopen-2019-036351 [doi]
AB  - INTRODUCTION: The recently developed protoporphyrin IX-triple state lifetime
      technique measures mitochondrial oxygenation tension (mitoPO2) in vivo at the
      bedside. MitoPO2might be an early indicator of oxygen disbalance in cells of
      critically ill patients and therefore may support clinical decisions regarding
      red blood cell (RBC) transfusion. We aim to investigate the effect of RBC
      transfusion and the associated changes in haemoglobin concentration on mitoPO2
      and other physiological measures of tissue oxygenation and oxygen balance in
      critically ill patients with anaemia. We present the protocol and pilot results
      for this study. METHODS AND ANALYSIS: We perform a prospective multicentre
      observational study in three mixed intensive care units in the Netherlands with
      critically ill patients with anaemia in whom an RBC transfusion is planned. The
      skin of the anterior chest wall of the patients is primed with a 5-aminolevulinic
      acid patch for 4 hours for induction of mitochondrial protoporphyrin-IX to enable
      measurements of mitoPO2, which is done with the COMET monitoring device. At
      multiple predefined moments, before and after RBC transfusion, we assess mitoPO2 
      and other physiological parameters of oxygen balance and tissue oxygenation.
      Descriptive statistics will be used to describe the data. A linear mixed-effect
      model will be used to study the association between RBC transfusion and mitoPO2
      and other traditional parameters of oxygenation, oxygen delivery and oxygen
      balance. Missing data will be imputed using multiple imputation methods. ETHICS
      AND DISSEMINATION: The institutional ethics committee of each participating
      centre approved the study (reference P16.303), which will be conducted according 
      to the 1964 Helsinki declaration and its later amendments. The results will be
      submitted for publication in peer-reviewed journals and presented at scientific
      conferences. TRIAL REGISTRATION NUMBER: NCT03092297.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Baysan, Meryem
AU  - Baysan M
AUID- ORCID: 0000-0002-8642-4802
AD  - Department of Intensive Care, LUMC, Leiden, The Netherlands.
AD  - Clinical Transfusion Research, Sanquin Research Clinical Transfusion Research,
      Leiden, Zuid-Holland, The Netherlands.
AD  - Department of Clinical Epidemiology, LUMC, Leiden, Zuid-Holland, The Netherlands.
FAU - Arbous, Mendi S
AU  - Arbous MS
AD  - Department of Intensive Care, LUMC, Leiden, The Netherlands.
AD  - Department of Clinical Epidemiology, LUMC, Leiden, Zuid-Holland, The Netherlands.
FAU - Mik, Egbert G
AU  - Mik EG
AD  - Department of Anesthesiology, Laboratory of Experimental Anesthesiology, Erasmus 
      Medical Center, Rotterdam, Zuid-Holland, The Netherlands.
FAU - Juffermans, Nicole P
AU  - Juffermans NP
AD  - Department of Intensive Care, Amsterdam UMC - Location AMC, Amsterdam, North
      Holland, The Netherlands.
FAU - van der Bom, Johanna G
AU  - van der Bom JG
AD  - Clinical Transfusion Research, Sanquin Research Clinical Transfusion Research,
      Leiden, Zuid-Holland, The Netherlands j.g.van_der_bom@lumc.nl.
AD  - Department of Clinical Epidemiology, LUMC, Leiden, Zuid-Holland, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT03092297
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 4613T5ZY7G (inosine dialdehyde)
RN  - 5A614L51CT (Inosine)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - *Anemia/therapy
MH  - Cohort Studies
MH  - *Critical Illness
MH  - Erythrocyte Transfusion
MH  - Humans
MH  - Inosine/analogs & derivatives
MH  - Intensive Care Units
MH  - Male
MH  - Netherlands
MH  - Oxygen
MH  - Prospective Studies
PMC - PMC7239524
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *anaemia
OT  - *blood bank & transfusion medicine
OT  - *clinical physiology
COIS- Competing interests: EGM is founder and shareholder of Photonics Healthcare B.V. 
      (Utrecht, The Netherlands). Photonics Healthcare develops and commercialises the 
      COMET measuring system for mitochondrial oxygen measurements. The other authors
      have no conflicts of interest to declare.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-036351 [pii]
AID - 10.1136/bmjopen-2019-036351 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e036351. doi: 10.1136/bmjopen-2019-036351.


PMID- 32423937
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Effectiveness and acceptability of metformin in preventing the onset of type 2
      diabetes after gestational diabetes in postnatal women: a protocol for a
      randomised, placebo-controlled, double-blind feasibility trial-Optimising health 
      outcomes with Metformin to prevent diAbetes After pregnancy (OMAhA).
PG  - e036198
LID - 10.1136/bmjopen-2019-036198 [doi]
AB  - INTRODUCTION: Up to half of all women diagnosed with gestational diabetes
      mellitus develop type 2 diabetes within 5 years after delivery. Metformin is
      effective in preventing type 2 diabetes in high-risk non-pregnant individuals,
      but its effect when commenced in the postnatal period is not known. We plan to
      assess the feasibility of evaluating metformin versus placebo in minimising the
      risk of dysglycaemia including type 2 diabetes after delivery in postnatal women 
      with a history of gestational diabetes through a randomised trial. METHODS AND
      ANALYSIS: Optimising health outcomes with Metformin to prevent diAbetes After
      pregnancy (OMAhA) is a multicentre placebo-controlled double-blind randomised
      feasibility trial, where we will randomly allocate 160 postnatal women with
      gestational diabetes treated with medication to either metformin (intervention)
      or placebo (control) tablets to be taken until 1 year after delivery. The primary
      outcomes are rates of recruitment, randomisation, adherence and attrition. The
      secondary outcomes are maternal dysglycaemia, cost and quality of life outcomes
      in both arms, and acceptability of the study and intervention, which will be
      evaluated through a nested qualitative study. Feasibility outcomes will be
      summarised using descriptive statistics, point estimates and 95% CIs. ETHICS AND 
      DISSEMINATION: The OMAhA study received ethics approval from the London-Brent
      Research Ethics Committee (18/LO/0505). Trial findings will be published in a
      peer-reviewed journal, disseminated at conferences, through our Patient and
      Public Involvement advisory group (Katie's Team) and through social media
      platforms. TRIAL REGISTRATION NUMBER: ISRCTN20930880.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Amaefule, Chiamaka Esther
AU  - Amaefule CE
AUID- ORCID: 0000-0003-3864-2642
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK c.e.amaefule@qmul.ac.uk.
FAU - Bolou, Angeliki
AU  - Bolou A
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Department of Family Care and Mental Health, University of Greenwich, London, UK.
FAU - Drymoussi, Zoe
AU  - Drymoussi Z
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Gonzalez Carreras, Francisco Jose
AU  - Gonzalez Carreras FJ
AUID- ORCID: 0000-0002-3043-7495
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Pardo Llorente, Maria Del Carmen
AU  - Pardo Llorente MDC
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Department of Statistics and Operational Research, Complutense University of
      Madrid, Madrid, Spain.
FAU - Lanz, Doris
AU  - Lanz D
AUID- ORCID: 0000-0001-9879-3069
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Dodds, Julie
AU  - Dodds J
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Sweeney, Lorna
AU  - Sweeney L
AD  - Institute for Health and Human Development, University of East London, London,
      UK.
FAU - Pizzo, Elena
AU  - Pizzo E
AD  - Collaborations for Leadership in Applied Health Research and Care (CLAHRC) for
      North Thames London, Department of Applied Health Research, University College
      London, London, UK.
FAU - D'Amico, Maria
AU  - D'Amico M
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Thomas, Amy
AU  - Thomas A
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Women's and Children's Health, Royal London Hospital, Barts Health NHS Trust,
      London, UK.
FAU - Heighway, James
AU  - Heighway J
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Daru, Jahnavi
AU  - Daru J
AUID- ORCID: 0000-0001-5816-2609
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Sobhy, Soha
AU  - Sobhy S
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Women's and Children's Health, Royal London Hospital, Barts Health NHS Trust,
      London, UK.
FAU - Robson, John
AU  - Robson J
AD  - Clinical Effectiveness Group, Barts and the London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
FAU - Sanghi, Anita
AU  - Sanghi A
AD  - Women's Division, Royal London Hospital, Barts Health NHS Trust, London, UK.
FAU - Zamora, Javier
AU  - Zamora J
AD  - Clinical Biostatistics Unit (IRYCIS) and CIBER Epidemiology and Public Health,
      Ramon y Cajal University Hospital, Madrid, Spain.
FAU - Harden, Angela
AU  - Harden A
AD  - Institute for Health and Human Development, University of East London, London,
      UK.
FAU - Hitman, Graham
AU  - Hitman G
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Khan, Khalid
AU  - Khan K
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
FAU - Perez, Teresa
AU  - Perez T
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Department of Statistics and Data Sciences, Complutense University of Madrid,
      Madrid, Spain.
FAU - Huda, Mohammed Sb
AU  - Huda MS
AD  - Department of Diabetes and Metabolism, Barts Health NHS Trust, Royal London
      Hospital, London, UK.
FAU - Thangaratinam, Shakila
AU  - Thangaratinam S
AD  - Barts Research Centre for Women's Health (BARC), Institute of Population Health
      Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary
      University of London, London, UK.
AD  - Institute of Metabolism and Systems Research, University of Birmingham,
      Birmingham, UK.
LA  - eng
SI  - ISRCTN/ISRCTN20930880
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - *Diabetes, Gestational/prevention & control
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - London
MH  - *Metformin/therapeutic use
MH  - Multicenter Studies as Topic
MH  - Outcome Assessment, Health Care
MH  - Pregnancy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7239519
OTO - NOTNLM
OT  - *clinical trials
OT  - *diabetes in pregnancy
OT  - *maternal medicine
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-036198 [pii]
AID - 10.1136/bmjopen-2019-036198 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e036198. doi: 10.1136/bmjopen-2019-036198.


PMID- 32423936
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Effectiveness of a self-managed digital exercise programme to prevent falls in
      older community-dwelling adults: study protocol for the Safe Step randomised
      controlled trial.
PG  - e036194
LID - 10.1136/bmjopen-2019-036194 [doi]
AB  - INTRODUCTION: Exercise interventions have a strong evidence base for falls
      prevention. However, exercise can be challenging to implement and often has
      limited reach and poor adherence. Digital technology provides opportunities for
      both increased access to the intervention and support over time. Further
      knowledge needs to be gained regarding the effectiveness of completely
      self-managed digital exercise interventions. The main objective of this study is 
      to compare the effectiveness of a self-managed digital exercise programme, Safe
      Step, in combination with monthly educational videos with educational videos
      alone, on falls over 1 year in older community-dwelling adults. METHODS AND
      ANALYSIS: A two-arm parallel randomised controlled trial will be conducted with
      at least 1400 community-living older adults (70+ years) who experience impaired
      balance. Participants will be recruited throughout Sweden with enrolment through 
      the project website. They will be randomly allocated to either the Safe Step
      exercise programme with additional monthly educational videos about healthy
      ageing and fall prevention, or the monthly education videos alone. Participants
      receiving the exercise intervention will be asked to exercise at home for at
      least 30 min, 3 times/week with support of the Safe Step application. The primary
      outcome will be rate of falls (fall per person year). Participants will keep a
      fall calendar and report falls at the end of each month through a digital
      questionnaire. Further assessments of secondary outcomes will be made through
      self-reported questionnaires and a self-test of 30 s chair stand test at baseline
      and 3, 6, 9 and 12 months after study start. Data will be analysed according to
      the intention-to-treat principle. ETHICS AND DISSEMINATION: Ethical approval was 
      obtained by The Regional Ethical Review Board in Umea (Dnr 2018/433-31). Findings
      will be disseminated through the project web-site, peer-reviewed journals,
      national and international conferences and through senior citizen organisations' 
      newsletters. TRIAL REGISTRATION NUMBER: NCT03963570.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Pettersson, Beatrice
AU  - Pettersson B
AUID- ORCID: 0000-0002-5147-9715
AD  - Department of Community Medicine and Rehabilitation, Physiotherapy, Umea
      University, Umea, Sweden beatrice.pettersson@umu.se.
FAU - Lundin-Olsson, Lillemor
AU  - Lundin-Olsson L
AD  - Department of Community Medicine and Rehabilitation, Physiotherapy, Umea
      University, Umea, Sweden.
FAU - Skelton, Dawn A
AU  - Skelton DA
AD  - School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
FAU - Liv, Per
AU  - Liv P
AD  - Department of Public Health and Clinical Medicine, Section of Sustainable Health,
      Umea University, Umea, Sweden.
FAU - Zingmark, Magnus
AU  - Zingmark M
AD  - Health and Social Care Administration, Municipality of Ostersund, Ostersund,
      Sweden.
AD  - Department of Epidemiology and Global Health, Umea University, Umea, Sweden.
FAU - Rosendahl, Erik
AU  - Rosendahl E
AD  - Department of Community Medicine and Rehabilitation, Physiotherapy, Umea
      University, Umea, Sweden.
FAU - Sandlund, Marlene
AU  - Sandlund M
AD  - Department of Community Medicine and Rehabilitation, Physiotherapy, Umea
      University, Umea, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03963570
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Accidental Falls/*prevention & control
MH  - Aged
MH  - Exercise
MH  - *Exercise Therapy
MH  - Fear
MH  - Humans
MH  - *Independent Living
MH  - Postural Balance
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Sweden
PMC - PMC7239551
OTO - NOTNLM
OT  - *geriatric medicine
OT  - *preventive medicine
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: The authors declare that they have no competing interest
      besides that DAS is a Director of Later Life Training, a not for profit training 
      company in the UK that delivers group falls prevention exercise training (Otago
      and FaME) to health and fitness professionals. The App was developed
      collaboratively and it will not be sold for profit.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-036194 [pii]
AID - 10.1136/bmjopen-2019-036194 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e036194. doi: 10.1136/bmjopen-2019-036194.


PMID- 32423935
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Innovative equipment to monitor and control salt usage when cooking at home: iMC 
      SALT research protocol for a randomised controlled trial.
PG  - e035898
LID - 10.1136/bmjopen-2019-035898 [doi]
AB  - INTRODUCTION: Excessive salt intake is a public health concern due to its
      deleterious impact on health. Most of the salt consumed come from those that are 
      added when cooking. This study will improve knowledge on the effectiveness of
      interventions to reduce salt consumption among consumers. METHODS AND ANALYSIS:
      In this randomised clinical trial, we will be evaluating the efficacy of an
      intervention-the Salt Control H, an innovative prototype equipment to monitor and
      control use of salt when cooking-among workers from a public university, with the
      aim of reducing their dietary salt intake. We will randomly select 260 workers
      who meet the eligibility criteria and who are enrolled to an occupational health 
      appointment and randomise them into one of the two arms of the study (either
      control or intervention), with matched baseline characteristics (sex and
      hypertension). The intervention will last for 8 weeks, during which the
      participants will use the equipment at home to monitor and control their use of
      salt when cooking. The main outcome will be 24-hour urinary sodium excretion at
      baseline, at fourth and eighth weeks of intervention, and at 6 months after
      intervention. ETHICS AND DISSEMINATION: Ethical approval for the study has been
      obtained from the Ethics Committee of the Centro Hospitalar Universitario Sao
      Joao. The results of the investigation will be published in peer-reviewed
      scientific papers and presented at international conferences. TRIAL REGISTRATION 
      NUMBER: NCT03974477 EQUIPMENT PROVISIONAL PATENT NUMBER: Registered at INPI:
      20191000033265.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Goncalves, Carla
AU  - Goncalves C
AUID- ORCID: 0000-0002-6113-1456
AD  - Faculdade de Ciencias da Nutricao e Alimentacao, Universidade do Porto, Porto,
      Portugal carlagoncalves.pt@gmail.com.
AD  - CITAB - Centre for the Research and Technology of Agro-Environmental and
      Biological Sciences, Universidade de Tras-os-Montes e Alto Douro, Vila Real,
      Portugal.
AD  - CIAFEL - Centro de Investigacao em Atividade Fisica, Saude e Lazer, Universidade 
      do Porto, Porto, Portugal.
FAU - Silva-Santos, Tania
AU  - Silva-Santos T
AD  - Faculdade de Ciencias da Nutricao e Alimentacao, Universidade do Porto, Porto,
      Portugal.
FAU - Abreu, Sandra
AU  - Abreu S
AD  - CIAFEL - Centro de Investigacao em Atividade Fisica, Saude e Lazer, Universidade 
      do Porto, Porto, Portugal.
AD  - ULP - Faculty of Psychology, Education and Sports, Lusofona University, Porto,
      Portugal.
FAU - Padrao, Patricia
AU  - Padrao P
AD  - Faculdade de Ciencias da Nutricao e Alimentacao, Universidade do Porto, Porto,
      Portugal.
AD  - UP EPIUnit - Institute of Public Health, Universidade do Porto, Porto, Portugal.
FAU - Graca, Pedro
AU  - Graca P
AD  - Faculdade de Ciencias da Nutricao e Alimentacao, Universidade do Porto, Porto,
      Portugal.
FAU - Oliveira, Luis
AU  - Oliveira L
AD  - INEGI - Instituto de Engenharia Mecanica e Gestao Industrial, Porto, Portugal.
FAU - Esteves, Silvia
AU  - Esteves S
AD  - INEGI - Instituto de Engenharia Mecanica e Gestao Industrial, Porto, Portugal.
FAU - Norton, Pedro
AU  - Norton P
AD  - UP EPIUnit - Institute of Public Health, Universidade do Porto, Porto, Portugal.
AD  - Departamento de Saude Ocupacional, Centro Hospitalar Universitario Sao Joao,
      Porto, Portugal.
FAU - Moreira, Pedro
AU  - Moreira P
AD  - Faculdade de Ciencias da Nutricao e Alimentacao, Universidade do Porto, Porto,
      Portugal.
AD  - CIAFEL - Centro de Investigacao em Atividade Fisica, Saude e Lazer, Universidade 
      do Porto, Porto, Portugal.
AD  - UP EPIUnit - Institute of Public Health, Universidade do Porto, Porto, Portugal.
FAU - Pinho, Olivia
AU  - Pinho O
AD  - Faculdade de Ciencias da Nutricao e Alimentacao, Universidade do Porto, Porto,
      Portugal.
AD  - LAQV/REQUIMTE - Laboratorio de Bromatologia e Hidrologia, Departamento de
      Ciencias Quimicas, Universidade do Porto, Porto, Portugal.
LA  - eng
SI  - ClinicalTrials.gov/NCT03974477
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 451W47IQ8X (Sodium Chloride)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Adult
MH  - Child
MH  - *Cooking
MH  - Feeding Behavior
MH  - Humans
MH  - *Hypertension
MH  - Occupational Health
MH  - Randomized Controlled Trials as Topic
MH  - Sodium
MH  - *Sodium Chloride
PMC - PMC7239520
OTO - NOTNLM
OT  - *cardiovascular disease prevention
OT  - *randomised controlled trial
OT  - *salt
OT  - *sodium
COIS- Competing interests: The study will use one prototype system that has been
      submitted with a provisional patent number (INPI, N masculine 20191000033265).
      CG, PG, LO, SE, PM and OP are inventors of the prototype system. The inventors
      have intellectual property rights.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035898 [pii]
AID - 10.1136/bmjopen-2019-035898 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e035898. doi: 10.1136/bmjopen-2019-035898.


PMID- 32423934
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Postpartum lifestyle interventions among women with pre-eclampsia: a scoping
      review protocol.
PG  - e035507
LID - 10.1136/bmjopen-2019-035507 [doi]
AB  - INTRODUCTION: Compared to women with normotensive pregnancies, women with a
      history of pre-eclampsia have a roughly fourfold increased risk of developing
      chronic arterial hypertension and a twofold increased risk of developing
      cardiovascular disease (CVD). Lifestyle changes, such as increased physical
      activity, weight loss, smoking cessation and healthy diet, are effective for CVD 
      prevention in the general population. However, no scoping review or systematic
      review of postpartum lifestyle interventions among women with pre-eclampsia have,
      to our best knowledge, been performed. The objective of this scoping review is to
      provide an overview of the available research literature on postpartum lifestyle 
      interventions to reduce the risk of CVD among women with pre-eclampsia. METHODS
      AND ANALYSIS: The protocol is based on the framework outlined by Arksey and
      O'Malley. Databases to be searched include: PubMed, Embase CINAHL and the JBI
      Database of Systematic Reviews and Implementation Reports. The search will be
      performed after the publication of this protocol (estimated to be 1 June 2020)
      and will be repeated 1 month prior to the submission for publication of the final
      review (estimated to be 1 January 2021). The review will consider studies that
      include women in the postpartum period (in particular, but not restricted to, the
      first 12 months after delivery), with a history of pre-eclampsia. Data will be
      extracted by two independent reviewers using a data extraction tool including
      specific details about the population, concept, context, study methods and key
      findings relevant to the review objective. Any disagreements between the
      reviewers will be resolved through discussion, or with a third reviewer. The
      extracted data will be presented in diagrammatic or tabular form that align with 
      the objective of this scoping review. A narrative summary will accompany the
      tabulated and/or charted results and will describe how the results relate to the 
      reviews objective and questions. ETHICS AND DISSEMINATION: Since all data will be
      obtained from publicly available materials, the proposed scoping review does not 
      require ethical approval. The results will be submitted for publication in an
      open-access peer-reviewed journal and presented at relevant conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Haugdahl, Hege Selnes
AU  - Haugdahl HS
AD  - Nord-Trondelag Hospital Trust, Levanger, Norway.
FAU - Sandsaeter, Heidi Linn
AU  - Sandsaeter HL
AD  - Nord-Trondelag Hospital Trust, Levanger, Norway.
FAU - Lysne, Marianne
AU  - Lysne M
AD  - Nord-Trondelag Hospital Trust, Levanger, Norway.
FAU - Bjerkeset, Ottar
AU  - Bjerkeset O
AD  - Faculty of Nursing and Health Sciences, Nord University, Levanger, Norway.
AD  - Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian
      University of Science and Technology, Trondheim, Norway.
FAU - Uhrenfeldt, Lisbeth
AU  - Uhrenfeldt L
AD  - Nord University, Bodo, Norway.
FAU - Horn, Julie
AU  - Horn J
AUID- ORCID: 0000-0003-1344-9707
AD  - HUNT Research Centre, Department of Public Health and Nursing, Norwegian
      University of Science and Technology, Levanger, Norway julie.horn@ntnu.no.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - Life Style
MH  - Peer Review
MH  - Postpartum Period
MH  - *Pre-Eclampsia/prevention & control
MH  - Pregnancy
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7239552
OTO - NOTNLM
OT  - *cardiology
OT  - *maternal medicine
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035507 [pii]
AID - 10.1136/bmjopen-2019-035507 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e035507. doi: 10.1136/bmjopen-2019-035507.


PMID- 32423932
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - The comparative effectiveness of physical exercise interventions in individuals
      with chronic non-specific neck pain: protocol for a network meta-analysis.
PG  - e034846
LID - 10.1136/bmjopen-2019-034846 [doi]
AB  - INTRODUCTION: Neck pain is a global burdensome problem, with a large proportion
      of neck pain cases becoming chronic. Although physical exercise is a commonly
      prescribed treatment, the evidence on the effectiveness of isolated exercise
      interventions remains limited. Traditional pairwise randomised controlled trials 
      (RCTs) and meta-analyses are limited in only comparing two interventions. This
      protocol describes the design of a network meta-analysis, which enables a
      comparative investigation of all physical exercise interventions for which RCTs
      are available. We aim to systematically compare the effectiveness of different
      types of physical exercise in people with chronic non-specific neck pain. METHODS
      AND ANALYSIS: Nine electronic databases (AMED, CINAHL, Cochrane Central Register 
      of Controlled Trials, Embase, MEDLINE, Physiotherapy Evidence Database, PsycINFO,
      Scopus and SPORTDiscus) were searched for RCTs from inception to 12 March 2019.
      Titles and abstract firstly, and full-text papers secondly, will be screened by
      two reviewers. Data will be extracted by two reviewers. The primary outcome
      measure is effectiveness of the intervention. Methodological quality of included 
      studies will be assessed by two reviewers using the PEDro scale. The overall
      quality of evidence will be assessed with the Grading of Recommendations
      Assessment, Development and Evaluation (GRADE) framework, which has been adapted 
      for network meta-analyses. The available evidence will be summarised using a
      network diagram. A contribution matrix will be presented to allow assessment of
      direct and indirect evidence. Forest plots will be constructed to visualise
      effects of all included exercise interventions. Pairwise effect sizes will be
      calculated by including all evidence available in the network. Effect measures
      for treatments that have not been compared in a pairwise RCT can be compared
      indirectly by contrasting effect sizes of comparisons with a common comparator.
      ETHICS AND DISSEMINATION: This work synthesises evidence from previously
      published studies and does not require ethics review or approval. A manuscript
      describing the findings will be submitted for publication in a peer-reviewed
      scientific journal. PROSPERO REGISTRATION NUMBER: CRD42019126523.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - de Zoete, Rutger Mj
AU  - de Zoete RM
AUID- ORCID: 0000-0002-0273-3377
AD  - RECOVER Injury Research Centre, NHMRC Centre of Research Excellence in Recovery
      Following Road Traffic Injuries, The University of Queensland, Brisbane,
      Queensland, Australia rutger.dezoete@adelaide.edu.au.
AD  - School of Allied Health Science and Practice, The University of Adelaide,
      Adelaide, South Australia, Australia.
FAU - McAuley, James H
AU  - McAuley JH
AD  - Neuroscience Research Australia, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - Armfield, Nigel R
AU  - Armfield NR
AD  - RECOVER Injury Research Centre, NHMRC Centre of Research Excellence in Recovery
      Following Road Traffic Injuries, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Sterling, Michele
AU  - Sterling M
AD  - RECOVER Injury Research Centre, NHMRC Centre of Research Excellence in Recovery
      Following Road Traffic Injuries, The University of Queensland, Brisbane,
      Queensland, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Chronic Pain/therapy
MH  - Exercise Therapy
MH  - Humans
MH  - *Neck Pain/therapy
MH  - *Network Meta-Analysis
MH  - Physical Therapy Modalities
PMC - PMC7239534
OTO - NOTNLM
OT  - *musculoskeletal disorders
OT  - *pain management
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034846 [pii]
AID - 10.1136/bmjopen-2019-034846 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e034846. doi: 10.1136/bmjopen-2019-034846.


PMID- 32423930
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Efficacy and safety of xuezhikang once per day versus two times per day in
      patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for
      a multicentre, prospective randomised controlled, open-label, non-inferiority
      study.
PG  - e034585
LID - 10.1136/bmjopen-2019-034585 [doi]
AB  - INTRODUCTION: Reduction in low-density lipoprotein cholesterol (LDL-C) improves
      clinical outcomes in patients with coronary artery disease. However, rates of
      lipid-lowering medication adherence are far from ideal. Reducing dosage frequency
      from multiple dosing to once-daily dosing may improve patients' medication
      adherence. Xuezhikang (XZK), an extract of Chinese red yeast rice, contains a
      family of naturally occurring statins and is traditionally prescribed as 600 mg
      two times per day. A comParative Efficacy study of XZK (APEX study) is designed
      to test the hypothesis that XZK prescribed 1200 mg once per day (OD group) is
      non-inferior to 600 mg two times per day (TD group) in patients with
      hypercholesterolaemia. METHODS AND ANALYSIS: The APEX study is a multicentre,
      prospective randomised controlled, open-label, non-inferiority study. We plan to 
      recruit 316 patients aged >/=18 years with a diagnosis of mild to moderate
      hypercholesterolaemia for primary prevention. Patients will be randomised (1:1)
      to OD group and TD group. The OD group take XZK 1200 mg once per day after dinner
      while TD group take a traditional dose of 600 mg, two times per day after meals. 
      Participants will have an 8-week medication period and be followed up at weeks 0,
      4 and 8. The primary end point is the mean percentage change from baseline to
      week 8 in serum LDL-C. Secondary end points are safety and lipid-lowering effect 
      on other lipoproteins and compliance. Data analyses will be on the
      intention-to-treat principle using non-inferiority analysis. ETHICS AND
      DISSEMINATION: The research had been approved by the Clinical Research and
      Laboratory Animal Ethics Committee of the First Affiliated Hospital, Sun Yat-sen 
      University ((2017)286). The results will be reported through peer-reviewed
      journals, seminars and conference presentations. TRIAL REGISTRATION NUMBER:
      ChiCTR-IIR-17013660.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wu, Zexuan
AU  - Wu Z
AD  - Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
AD  - NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou,
      China.
FAU - Wu, Dexi
AU  - Wu D
AD  - Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
AD  - NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou,
      China.
FAU - Jiang, Jingzhou
AU  - Jiang J
AD  - Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
AD  - NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou,
      China.
FAU - Chen, Ailan
AU  - Chen A
AD  - Department of Cardiology, The First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou, China.
FAU - Zheng, Dong-Dan
AU  - Zheng DD
AD  - Department of Cardiology, The Eastern Hospital of the First Affiliated Hospital, 
      Sun Yat-sen University, Guangzhou, China.
FAU - Li, Jianhao
AU  - Li J
AD  - Department of Cardiology, Central Hospital of Panyu District, Guangzhou, China.
FAU - Dong, Yugang
AU  - Dong Y
AD  - Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
AD  - NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou,
      China.
FAU - Chen, Yili
AU  - Chen Y
AUID- ORCID: 0000-0001-9999-9413
AD  - Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China yilichen2018@126.com.
AD  - NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou,
      China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (xuezhikang)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cholesterol, LDL
MH  - *Drugs, Chinese Herbal
MH  - Humans
MH  - *Hypercholesterolemia/drug therapy
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
PMC - PMC7239523
OTO - NOTNLM
OT  - *efficacy
OT  - *hypercholesterolaemia
OT  - *once per day
OT  - *two times per day
OT  - *xuezhikang
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034585 [pii]
AID - 10.1136/bmjopen-2019-034585 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e034585. doi: 10.1136/bmjopen-2019-034585.


PMID- 32423929
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Effectiveness of psychological, psychoeducational and psychosocial interventions 
      to prevent postpartum depression in adolescent and adult mothers: study protocol 
      for a systematic review and meta-analysis of randomised controlled trials.
PG  - e034424
LID - 10.1136/bmjopen-2019-034424 [doi]
AB  - INTRODUCTION: The prevalence of postpartum depression (PPD) is 17%, and the
      incidence is 12% worldwide. Adverse consequences for mothers and babies have been
      associated with this disease. To assess the effectiveness of psychological,
      psychoeducational and psychosocial interventions in preventing PPD, a systematic 
      review and meta-analysis (SR/MA) will be conducted. METHODS AND ANALYSIS: A SR/MA
      will be performed following the indications of the Preferred Reporting Items for 
      Systematic Reviews and Meta-Analyses guidelines. Studies will be identified
      through MEDLINE (Ovid and PubMed), PsycINFO, Web of Science, Scopus, CINAHL,
      Cochrane Central Register of Controlled Trials, OpenGrey, Australian New Zealand 
      Clinical Trial Registry, ClinicalTrials.gov and evidencebasedtherapy.org from
      inception until 31 January 2020. Bridging searches will be also conducted until
      the review is completed. The selection criteria will be as follows: (1) subjects 
      will be pregnant females or females who have given birth in the last 12 months
      and who were non-depressive at baseline; (2) psychological, psychoeducational and
      psychosocial interventions; (3) comparator will be usual care, attention control,
      waiting list or no intervention; (4) outcomes will be specific results on PPD;
      and (5) the design of the studies will be randomised controlled trials. No
      restrictions regarding the year of publication, the setting of the intervention
      or the language of publication will be considered. Pooled standardised mean
      differences and 95% CIs will be calculated. The risk of bias of the studies will 
      be assessed through the Cochrane Collaboration risk of bias tool. Heterogeneity
      between the studies will be determined by the I(2) and Cochran's Q statistics.
      Sensitivity and subgroup analyses will also be performed. Publication bias will
      be checked with funnel plots and Egger's test. Heterogeneity will be explored by 
      random-effects meta-regression analysis. ETHICS AND DISSEMINATION: The ethical
      assessment was not required. The results will be presented at conferences and
      disseminated through publications. PROSPERO REGISTRATION NUMBER: CRD42018109981.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Martin-Gomez, Carmen
AU  - Martin-Gomez C
AUID- ORCID: 0000-0003-0748-2762
AD  - Department of Psychology, Universidad Loyola Andalucia, Dos Hermanas (Sevilla),
      Spain.
FAU - Moreno-Peral, Patricia
AU  - Moreno-Peral P
AUID- ORCID: 0000-0003-4130-9090
AD  - Prevention and Health Promotion Research Network (redIAPP), ISCIII, Madrid, Spain
      predictmalaga@hotmail.com.
AD  - Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga, Spain.
FAU - Bellon, Juan A
AU  - Bellon JA
AUID- ORCID: 0000-0002-4268-4979
AD  - Prevention and Health Promotion Research Network (redIAPP), ISCIII, Madrid,
      Spain.
AD  - Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga, Spain.
AD  - El Palo Health Centre, Adalusian Health Service (SAS), Malaga, Spain.
AD  - Department of Public Health and Psychiatry, University of Malaga (UMA), Malaga,
      Spain.
FAU - Conejo Ceron, Sonia
AU  - Conejo Ceron S
AUID- ORCID: 0000-0002-1357-2281
AD  - Prevention and Health Promotion Research Network (redIAPP), ISCIII, Madrid,
      Spain.
AD  - Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga, Spain.
FAU - Campos-Paino, Henar
AU  - Campos-Paino H
AUID- ORCID: 0000-0002-0563-3080
AD  - Prevention and Health Promotion Research Network (redIAPP), ISCIII, Madrid,
      Spain.
AD  - Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga, Spain.
FAU - Gomez-Gomez, Irene
AU  - Gomez-Gomez I
AUID- ORCID: 0000-0001-8014-6955
AD  - Department of Psychology, Universidad Loyola Andalucia, Dos Hermanas (Sevilla),
      Spain.
FAU - Rigabert, Alina
AU  - Rigabert A
AUID- ORCID: 0000-0003-2121-7623
AD  - Department of Psychology, Universidad Loyola Andalucia, Dos Hermanas (Sevilla),
      Spain.
AD  - Fundacion Andaluza Beturia para la Investigacion en Salud (FABIS), Huelva, Spain.
FAU - Benitez, Isabel
AU  - Benitez I
AUID- ORCID: 0000-0002-0141-0816
AD  - Department of Psychology, Universidad Loyola Andalucia, Dos Hermanas (Sevilla),
      Spain.
FAU - Motrico, Emma
AU  - Motrico E
AUID- ORCID: 0000-0002-0720-567X
AD  - Department of Psychology, Universidad Loyola Andalucia, Dos Hermanas (Sevilla),
      Spain.
AD  - Prevention and Health Promotion Research Network (redIAPP), ISCIII, Madrid,
      Spain.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia
MH  - *Depression, Postpartum/prevention & control
MH  - Female
MH  - Humans
MH  - Mental Health
MH  - Mothers
MH  - Pregnancy
MH  - Pregnancy in Adolescence
MH  - *Psychosocial Intervention
MH  - Randomized Controlled Trials as Topic
PMC - PMC7239544
OTO - NOTNLM
OT  - *meta-analysis and study protocol
OT  - *postpartum depression
OT  - *prevention
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034424 [pii]
AID - 10.1136/bmjopen-2019-034424 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e034424. doi: 10.1136/bmjopen-2019-034424.


PMID- 32423928
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20220720
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 17
TI  - Mental health interventions for suicide prevention among indigenous adolescents: 
      a systematic review protocol.
PG  - e034055
LID - 10.1136/bmjopen-2019-034055 [doi]
AB  - INTRODUCTION: There are more than 370 million indigenous people from 5000
      cultures living in 90 countries worldwide. Although they make up 5% of the global
      population, they account for 15% of the extreme poor. Youth suicide is the second
      leading cause of mortality among 15-29 years old and disproportionately affects
      indigenous youth. This research protocol pertains to a systematic review of
      studies that use a comparator/control group to evaluate the effectiveness of
      suicide interventions targeting indigenous adolescents (aged 10-19 years).
      METHODS AND ANALYSIS: We will conduct a systematic search on MEDLINE, EMBASE,
      CINAHL, LILACS and PsycINFO from inception to September 2019 to identify articles
      that compare mental health interventions for suicide prevention among indigenous 
      adolescents. Two reviewers will independently determine the eligibility of each
      study. Studies will be assessed for methodological quality using the risk of bias
      tool to assess non-randomised studies of interventions. We will conduct a
      meta-analysis if possible and use established statistical methods to identify and
      control for heterogeneity where appropriate. ETHICS AND DISSEMINATION: This
      systematic review will use published data and does not require ethics approval.
      However, this review is in preparation of a feasibility study that will examine
      how best to support the physical and mental health of indigenous adolescents in
      Brazil. Ethics approval for the feasibility study was obtained from National
      Research Ethics Commission. Findings will be disseminated through a peer-reviewed
      publication and will be made available to key decision-makers with authority for 
      indigenous health and other relevant stakeholders. PROSPERO REGISTRATION NUMBER: 
      CRD42019141754.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Grande, Antonio Jose
AU  - Grande AJ
AD  - State University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil 
      grandeto@gmail.com.
FAU - Elia, Christelle
AU  - Elia C
AUID- ORCID: 0000-0002-8298-8440
AD  - King's College London Faculty of Life Sciences and Medicine, London, UK.
FAU - Peixoto, Clayton
AU  - Peixoto C
AD  - Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Jardim, Paulo de Tarso Coelho
AU  - Jardim PTC
AD  - State University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
FAU - Dazzan, Paola
AU  - Dazzan P
AD  - King's College London Faculty of Life Sciences and Medicine, London, UK.
FAU - Veras, Andre Barciela
AU  - Veras AB
AD  - State University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
FAU - Cruickshank, John Kennedy
AU  - Cruickshank JK
AD  - King's College London Faculty of Life Sciences and Medicine, London, UK.
FAU - Harding, Seeromanie
AU  - Harding S
AD  - King's College London Faculty of Life Sciences and Medicine, London, UK.
LA  - eng
GR  - MR/N015959/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S003444/1/MRC_/Medical Research Council/United Kingdom
GR  - MRF_C0439/MRF/MRF/United Kingdom
GR  - MR/R022739/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200517
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brazil
MH  - Child
MH  - Humans
MH  - *Mental Health
MH  - Population Groups
MH  - Research Design
MH  - Suicidal Ideation
MH  - *Suicide/prevention & control
MH  - Young Adult
PMC - PMC7239512
OTO - NOTNLM
OT  - *adolescent
OT  - *child & adolescent psychiatry
OT  - *indigenous
OT  - *mental health
OT  - *public health
OT  - *suicide & self-harm
COIS- Competing interests: None declared.
EDAT- 2020/05/20 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034055 [pii]
AID - 10.1136/bmjopen-2019-034055 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 17;10(5):e034055. doi: 10.1136/bmjopen-2019-034055.


PMID- 32423899
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20210125
IS  - 2059-7029 (Electronic)
IS  - 2059-7029 (Linking)
VI  - 5
IP  - Suppl 3
DP  - 2020 May
TI  - ESMO Management and treatment adapted recommendations in the COVID-19 era:
      Pancreatic Cancer.
LID - e000804 [pii]
LID - 10.1136/esmoopen-2020-000804 [doi]
AB  - The COVID-19 pandemic is challenging the capacities of health systems in many
      countries. National healthcare services have to manage unexpected shortages of
      healthcare resources that have to be re-allocated according to the principles of 
      fair and ethical prioritisation, in order to maintain the highest levels of care 
      to all patients, ensure the safety of patients and healthcare workers, and save
      as many lives as possible. Also, cancer care services have to pursue
      restructuring, following the same evidence-based dispositions. In this article,
      we propose a guidance to the management of pancreatic cancer during the pandemic,
      prioritised according to a three-tiered framework, and based on expert clinical
      judgement and magnitude of benefit expected from specific interventions. Since
      the availability of resources for diagnostic procedures, surgery and
      postoperative care, systemic therapy and radiotherapy may differ, the authors
      have separated the prioritisation analyses. The impact of postponing or
      abrogating cancer interventions on outcomes according to a high, medium or low
      priority scale is outlined and discussed. The implementation of healthcare
      services using telemedicine is explored; it reveals itself as functional and
      effective for limiting patients' need to travel to centres and thereby has the
      potential to reduce diffusion of SARS-CoV-2. Pancreatic cancer demands a
      considerable amount of medical resources. Therefore, the redefinition of its
      diagnostic and therapeutic algorithms with a rigorous method is crucial in order 
      to ensure the highest quality of continuum of care in the broader context of the 
      pandemic and the challenged healthcare systems.
CI  - (c) Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. Published by BMJ on behalf of the European Society for Medical
      Oncology.
FAU - Catanese, Silvia
AU  - Catanese S
AD  - Department of Medical Oncology, Azienda Ospedaliero Universitaria Pisana (AOUP), 
      University of Pisa, Pisa, Italy.
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious
      Diseases, University Cancer Center Leipzig (UCCL), Leipzig University Medical
      Center, Leipzig, Germany.
FAU - Pentheroudakis, George
AU  - Pentheroudakis G
AUID- ORCID: 0000-0002-6632-2462
AD  - Department of Medical Oncology, University of Ioannina, Ioannina, Greece.
FAU - Douillard, Jean-Yves
AU  - Douillard JY
AD  - European Society for Medical Oncology (ESMO), Lugano, Switzerland.
FAU - Lordick, Florian
AU  - Lordick F
AUID- ORCID: 0000-0001-8591-9339
AD  - Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious
      Diseases, University Cancer Center Leipzig (UCCL), Leipzig University Medical
      Center, Leipzig, Germany florian.lordick@medizin.uni-leipzig.de.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
SB  - IM
CIN - Pancreatology. 2020 Jul;20(5):1004-1005. PMID: 32418757
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Resources/supply & distribution
MH  - Humans
MH  - Medical Oncology/*organization & administration
MH  - Pancreatic Neoplasms/*diagnosis/*therapy
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Societies, Medical
MH  - Telemedicine
PMC - PMC7239531
OTO - NOTNLM
OT  - *COVID-19 pandemic
EDAT- 2020/05/20 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
AID - S2059-7029(20)32673-9 [pii]
AID - 10.1136/esmoopen-2020-000804 [doi]
PST - ppublish
SO  - ESMO Open. 2020 May;5(Suppl 3). pii: S2059-7029(20)32673-9. doi:
      10.1136/esmoopen-2020-000804.


PMID- 32423444
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 May 18
TI  - Ethical challenges in family caregivers of patients with advanced cancer - a
      qualitative study.
PG  - 70
LID - 10.1186/s12904-020-00573-6 [doi]
AB  - BACKGROUND: Caring for patients with advanced or terminal diseases can confront
      family caregivers (FC) with ethical challenges. The present study aims at tracing
      paths connected to ethical challenges among FC of advanced cancer patients by
      exploring morally troubling situations and related burden, as well as strategies 
      to handle the situation and experience of moral distress from the grieving FC's
      perspective. METHODS: Within a qualitative design, interviews with 12 grieving FC
      were conducted using a semi-structured interview guide. Data were analysed using 
      grounded theory and abductive reasoning. RESULTS: Core phenomena identified were 
      two paths connected to ethical challenges among FC. Ethical challenges occurred
      in the context of difficult decision-making (Path 1) and in the context of
      lacking decision-making options when no decision was to be made by FC (Path 2).
      We found each path to be triggered by distinct sets of morally troubling
      situations that occurred during the patient's disease trajectory. In the course
      of difficult decision-making (Path 1), detrimental external factors could add
      emotional stress, thus making the decision-making process burdensome. FC used
      various proactive strategies to overcome those detrimental factors and/or to make
      the decision. Decisions in conflict with FCs' own moral expectations and values
      led to moral distress, generating painful emotions. When no decision was to be
      made by FC (Path 2), FC felt powerless and overrun, which was associated with
      major emotionality in terms of anxiety and confusion. Either detrimental factors 
      aggravated these feelings to paralyzing shock, or internal resources enabled FC
      to accept the situation. While acceptance prevented moral distress, paralyzing
      shock often caused a sense of not meeting their their own moral expectations and 
      values, resulting in moral distress. In both paths, factors were identified that 
      helped FC finding closure and prevented moral residue. Nevertheless, some FC
      experienced residual moral distress months after the morally troubling situation 
      had occurred. CONCLUSION: Findings provide first information towards
      understanding paths leading to ethical challenges in FC and can help clinicians
      to minimize associated emotional burden and moral distress.
FAU - Ullrich, Anneke
AU  - Ullrich A
AUID- ORCID: http://orcid.org/0000-0002-1759-4461
AD  - Palliative Care Unit, Department of Oncology, Hematology and BMT, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany. a.ullrich@uke.de.
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany. a.ullrich@uke.de.
FAU - Theochari, Marianna
AU  - Theochari M
AD  - Palliative Care Unit, Department of Oncology, Hematology and BMT, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Bergelt, Corinna
AU  - Bergelt C
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Marx, Gabriella
AU  - Marx G
AD  - Department of Palliative Medicine, University Medical Center Goettingen,
      Goettingen, Germany.
AD  - Department of General Practice / Primary Care, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Woellert, Katharina
AU  - Woellert K
AD  - Department of History and Ethics of Medicine, University Medical Center
      Eppendorf, Hamburg, Germany.
FAU - Bokemeyer, Carsten
AU  - Bokemeyer C
AD  - Palliative Care Unit, Department of Oncology, Hematology and BMT, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Oechsle, Karin
AU  - Oechsle K
AD  - Palliative Care Unit, Department of Oncology, Hematology and BMT, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Caregivers/*psychology
MH  - Decision Making/ethics
MH  - *Ethics
MH  - Female
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/psychology/*therapy
MH  - Qualitative Research
PMC - PMC7236546
OTO - NOTNLM
OT  - Cancer
OT  - Caregivers
OT  - Decision
OT  - End-of-life care
OT  - Ethics
OT  - Moral distress
OT  - Palliative care
EDAT- 2020/05/20 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/07/04 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
AID - 10.1186/s12904-020-00573-6 [doi]
AID - 10.1186/s12904-020-00573-6 [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 May 18;19(1):70. doi: 10.1186/s12904-020-00573-6.


PMID- 32423438
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20210317
IS  - 1478-4505 (Electronic)
IS  - 1478-4505 (Linking)
VI  - 18
IP  - 1
DP  - 2020 May 18
TI  - Using natural experiments to improve public health evidence: a review of context 
      and utility for obesity prevention.
PG  - 48
LID - 10.1186/s12961-020-00564-2 [doi]
AB  - BACKGROUND: Natural experiments are increasingly valued as a way to assess the
      health impact of health and non-health interventions when planned controlled
      experimental research designs may be infeasible or inappropriate to implement.
      This study sought to investigate the value of natural experiments by exploring
      how they have been used in practice. The study focused on obesity prevention
      research as one complex programme area for applying natural experiment studies.
      METHODS: A literature search sought obesity prevention research from January 1997
      to December 2017 and identified 46 population health studies that self-described 
      as a natural experiment. RESULTS: The majority of studies identified were
      published in the last 5 years, illustrating a more recent adoption of such
      opportunities. The majority of studies were evaluations of the impact of policies
      (n = 19), such as assessing changes to food labelling, food advertising or
      taxation on diet and obesity outcomes, or were built environment interventions (n
      = 17), such as the impact of built infrastructure on physical activity or access 
      to healthy food. Research designs included quasi-experimental, pre-experimental
      and non-experimental methods. Few studies applied rigorous research designs to
      establish stronger causal inference, such as multiple pre/post measures, time
      series designs or comparison of change against an unexposed group. In general,
      researchers employed techniques to enhance the study utility but often were
      limited in the use of more rigorous study designs by ethical considerations
      and/or the particular context of the intervention. CONCLUSION: Greater
      recognition of the utility and versatility of natural experiments in generating
      evidence for complex health issues like obesity prevention is needed. This review
      suggests that natural experiments may be underutilised as an approach for
      providing evidence of the effects of interventions, particularly for evaluating
      health outcomes of interventions when unexpected opportunities to gather evidence
      arise.
FAU - Crane, Melanie
AU  - Crane M
AD  - The Australian Prevention Partnership Centre, Sydney School of Public Health,
      Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.
      melanie.crane@sydney.edu.au.
FAU - Bohn-Goldbaum, Erika
AU  - Bohn-Goldbaum E
AD  - The Australian Prevention Partnership Centre, Sydney School of Public Health,
      Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.
FAU - Grunseit, Anne
AU  - Grunseit A
AD  - The Australian Prevention Partnership Centre, Sydney School of Public Health,
      Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.
FAU - Bauman, Adrian
AU  - Bauman A
AD  - The Australian Prevention Partnership Centre, Sydney School of Public Health,
      Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia.
LA  - eng
GR  - GNT9100001/National Health and Medical Research Council of Australia
PT  - Journal Article
PT  - Systematic Review
DEP - 20200518
PL  - England
TA  - Health Res Policy Syst
JT  - Health research policy and systems
JID - 101170481
SB  - IM
MH  - Delivery of Health Care
MH  - Diet
MH  - Exercise
MH  - Health Policy
MH  - *Health Promotion
MH  - *Health Services Research
MH  - Humans
MH  - Obesity/*prevention & control
MH  - *Public Health
MH  - *Research Design
PMC - PMC7236508
OTO - NOTNLM
OT  - Natural experiments
OT  - evaluation methods
OT  - narrative review
OT  - nutrition
OT  - obesity prevention
OT  - physical activity
OT  - population health interventions
OT  - study design
EDAT- 2020/05/20 06:00
MHDA- 2021/03/18 06:00
CRDT- 2020/05/20 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
AID - 10.1186/s12961-020-00564-2 [doi]
AID - 10.1186/s12961-020-00564-2 [pii]
PST - epublish
SO  - Health Res Policy Syst. 2020 May 18;18(1):48. doi: 10.1186/s12961-020-00564-2.


PMID- 32423293
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20201218
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 2
DP  - 2020 Aug
TI  - Management of Adult Inpatient Otolaryngologic Consultations During the COVID-19
      Pandemic: A Proposed Tier-Based Triage System.
PG  - 330-334
LID - 10.1177/0194599820931011 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has placed tremendous strain on 
      health care systems, leading to unprecedented challenges and obstacles in the
      delivery of patient care. Otolaryngologists are frequently called on for
      inpatient consultations for an array of pathologies, ranging from chronic benign 
      conditions to acutely life-threatening processes. Professional otolaryngologic
      societies across the world have proposed limiting patient care to time-sensitive 
      and urgent matters; however, limited literature is available to describe how this
      transient change in philosophy may translate to clinical practice. Here we
      present a structured algorithm that allows for rapid triage of otolaryngologic
      consults during the ongoing pandemic, in efforts to minimize infectious spread
      and protect clinicians while preserving high-quality patient care. Considerations
      for managing these consults are presented, with a commentary on practical and
      ethical considerations.
FAU - Hussaini, Adnan S
AU  - Hussaini AS
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University
      Hospital, Washington, DC, USA.
FAU - Clark, Christine M
AU  - Clark CM
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University
      Hospital, Washington, DC, USA.
FAU - Patel, Atur A
AU  - Patel AA
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University
      Hospital, Washington, DC, USA.
FAU - Russo, Mark E
AU  - Russo ME
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University
      Hospital, Washington, DC, USA.
FAU - Chia, Stanley H
AU  - Chia SH
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Washington Hospital
      Center, Washington, DC, USA.
FAU - Davidson, Bruce J
AU  - Davidson BJ
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University
      Hospital, Washington, DC, USA.
FAU - Malekzadeh, Sonya
AU  - Malekzadeh S
AD  - Department of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University
      Hospital, Washington, DC, USA.
AD  - Department of Surgery, Washington DC Veterans Affairs Medical Center, Washington,
      DC, USA.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - Adult
MH  - *Algorithms
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/complications/diagnosis
MH  - Endoscopy
MH  - Humans
MH  - Inpatients
MH  - *Otolaryngology
MH  - *Pandemics
MH  - Personal Protective Equipment
MH  - *Pneumonia, Viral/complications/diagnosis
MH  - *Referral and Consultation
MH  - SARS-CoV-2
MH  - Telemedicine
MH  - Triage/*methods
OTO - NOTNLM
OT  - *2019
OT  - *COVID-19
OT  - *consultations
OT  - *coronavirus
OT  - *inpatient
OT  - *safety
OT  - *system
OT  - *tier
OT  - *tier-based
OT  - *triage
EDAT- 2020/05/20 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1177/0194599820931011 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Aug;163(2):330-334. doi:
      10.1177/0194599820931011. Epub 2020 May 19.


PMID- 32423292
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20210919
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 163
IP  - 1
DP  - 2020 Jul
TI  - Management of the Clinical and Academic Mission in an Urban Otolaryngology
      Department During the COVID-19 Global Crisis.
PG  - 162-169
LID - 10.1177/0194599820929613 [doi]
AB  - OBJECTIVE: The objective of this study was to assess the strategic changes
      implemented in the departmental mission to continue safe delivery of
      otolaryngology care and to support the broader institutional mission during the
      COVID-19 pandemic response. STUDY DESIGN: Retrospective assessment was performed 
      to the response and management strategy developed to transform the clinical and
      academic enterprise. SETTING: Large urban tertiary care referral center. RESULTS:
      The departmental structure was reorganized along new clinical teams to
      effectively meet the system directives for provision of otolaryngology care and
      support for inpatient cases of COVID-19. A surge deployment schedule was
      developed to assist frontline colleagues with clinical support as needed.
      Outpatient otolaryngology was consolidated across the system with conversion of
      the majority of visits to telehealth. Operative procedures were prioritized to
      ensure throughput for emergent and time-critical urgent procedures. A
      tracheostomy protocol was developed to guide management of emergent and elective 
      airways. Educational and research efforts were redirected to focus on
      otolaryngology care in the clinical context of the COVID-19 crisis. CONCLUSION:
      Emergence of the COVID-19 global health crisis has challenged delivery of
      otolaryngology care in an unparalleled manner. The concerns for preserving health
      of the workforce while ethically addressing patient career needs in a timely
      manner has created significant dilemmas. A proactive, thoughtful approach that
      reorganizes the overall departmental effort through provider and staff engagement
      can facilitate the ability to meet the needs of otolaryngology patients and to
      support the greater institutional mission to combat the pandemic.
FAU - Batra, Pete S
AU  - Batra PS
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - LoSavio, Phillip S
AU  - LoSavio PS
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Michaelides, Elias
AU  - Michaelides E
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Revenaugh, Peter C
AU  - Revenaugh PC
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Tajudeen, Bobby A
AU  - Tajudeen BA
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Al-Khudari, Samer
AU  - Al-Khudari S
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Husain, Inna
AU  - Husain I
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Papagiannopoulos, Peter
AU  - Papagiannopoulos P
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Smith, Ryan
AU  - Smith R
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Stenson, Kerstin M
AU  - Stenson KM
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
FAU - Wiet, R Mark
AU  - Wiet RM
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical 
      Center, Chicago, Illinois, USA.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/complications/*epidemiology/transmission
MH  - *Disease Management
MH  - Disease Transmission, Infectious/prevention & control
MH  - Emergencies
MH  - Humans
MH  - Otolaryngology/*methods
MH  - Otorhinolaryngologic Diseases/complications/*therapy
MH  - Pandemics
MH  - Pneumonia, Viral/complications/*epidemiology/transmission
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Telemedicine/*methods
MH  - Urban Health Services/*organization & administration
PMC - PMC7240314
OTO - NOTNLM
OT  - *COVID-19
OT  - *novel coronavirus
OT  - *otolaryngology
OT  - *pandemic
OT  - *telehealth
OT  - *tracheostomy
EDAT- 2020/05/20 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2020/05/20 06:00 [entrez]
AID - 10.1177/0194599820929613 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Jul;163(1):162-169. doi:
      10.1177/0194599820929613. Epub 2020 May 19.


PMID- 32422862
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20210209
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 14
TI  - Brazilian Vegetarian Population-Influence of Type of Diet, Motivation and
      Sociodemographic Variables on Quality of Life Measured by Specific Tool (VEGQOL).
LID - E1406 [pii]
LID - 10.3390/nu12051406 [doi]
AB  - The adoption of a vegetarian diet has been associated with positive health
      outcomes. However, few studies evaluate the effect of this eating pattern on
      quality of life. Moreover, no specific instrument for the vegetarian population
      to measure the quality of life is available worldwide. Therefore, this study
      aimed to elaborate and validate a specific questionnaire to measure the quality
      of life in vegetarians. The Specific Vegetarian Quality of Life Questionnaire
      (VEGQOL) was constructed based on other instruments and studies related to
      vegetarianism. The content and semantic validation were performed by a group of
      experts, followed by a pilot study to evaluate the questionnaire acceptability
      and reproducibility. Discriminant validation was tested using the WHOQOL as the
      gold standard measure (Pearson correlation ranging from 0.302 of the domain 3 to 
      0.392 of the domain 2). Afterward, a nationwide survey was conducted using
      VEGQOL. Content and semantic validation selected 19 of the initial 30 items.
      VEGQOL presented good reproducibility (Cohen's Kappa coefficient ranging from
      0.361 to 0.730 and intraclass correlation coefficient of 0.820) and internal
      consistency (0.708), both adequate to evaluate the quality of life in
      vegetarians. The sample size (n = 5014 individuals, error of 3% at a level of
      significance of 5%) and distribution was representative of the Brazilian
      vegetarian population. In general, the quality of life of Brazilian vegetarians
      was considered satisfactory (VEGQOL cut off points 70-80). Among different types 
      of vegetarians, the vegans showed better results with a VEGQOL mean value of 79.2
      +/- 10.7. Older individuals, the ones who adopted the diet for a longer time
      (VEGQOL mean value of 75.8 +/- 12.7) and the ones who had other vegetarians in
      their social network (VEGQOL mean value of 74.6 +/- 12.2) also had a better
      quality of life score. Individuals who adopted it for ethical or health reasons
      had a higher quality of life score. The questionnaire produced in this study is a
      useful tool for future research in this area. Results were better for vegans and 
      for the ones who adopt the diet for ethical or health reasons.
FAU - Hargreaves, Shila Minari
AU  - Hargreaves SM
AD  - Department of Nutrition, Faculty of Health Sciences, University of Brasilia
      (UnB), Campus Darcy Ribeiro, Asa Norte, Brasilia DF 70910-900, Brazil.
FAU - Nakano, Eduardo Yoshio
AU  - Nakano EY
AUID- ORCID: 0000-0002-9071-8512
AD  - Department of Statistics, University of Brasilia, Brasilia DF 70910-900, Brazil.
FAU - Zandonadi, Renata Puppin
AU  - Zandonadi RP
AUID- ORCID: 0000-0003-0370-3089
AD  - Department of Nutrition, Faculty of Health Sciences, University of Brasilia
      (UnB), Campus Darcy Ribeiro, Asa Norte, Brasilia DF 70910-900, Brazil.
LA  - eng
GR  - DPI/DIRPE/Universidade de Brasilia
PT  - Journal Article
PT  - Validation Study
DEP - 20200514
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brazil
MH  - Cross-Sectional Studies
MH  - Demography
MH  - Diet, Vegetarian/*psychology
MH  - Feeding Behavior/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Motivation
MH  - Pilot Projects
MH  - Psychological Techniques/standards
MH  - *Quality of Life
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires/*standards
MH  - Vegetarians/*psychology
MH  - Young Adult
PMC - PMC7284834
OTO - NOTNLM
OT  - motivation
OT  - quality of life
OT  - questionnaire
OT  - vegetarian diet
OT  - vegetarianism
EDAT- 2020/05/20 06:00
MHDA- 2021/02/10 06:00
CRDT- 2020/05/20 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
AID - nu12051406 [pii]
AID - 10.3390/nu12051406 [doi]
PST - epublish
SO  - Nutrients. 2020 May 14;12(5). pii: nu12051406. doi: 10.3390/nu12051406.


PMID- 32422469
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20210614
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 195
DP  - 2020 Aug
TI  - Prognosis and futility in neurosurgical emergencies: A review.
PG  - 105851
LID - S0303-8467(20)30194-3 [pii]
LID - 10.1016/j.clineuro.2020.105851 [doi]
AB  - A patient with a life-threatening intracranial insult presents a difficult
      situation to the neurosurgeon. In a few short minutes the neurosurgeon must
      assess the patient's neurologic status, imaging, and medical condition then
      confer with the patient's proxy regarding treatment. This assessment ideally
      includes recognition of situations where aggressive care is futile and therefore 
      such treatments should not be offered. The proxy discussion must involve surgical
      and nonsurgical management options and the impact of these options on survival
      and residual disability. Surgical decision-making is frequently difficult, even
      for designated proxies armed with advance directives, as these documents are
      usually vague with regard to acceptable functional outcomes. To complicate things
      further, when emergencies are off-hours, housestaff or physician extenders may
      need to represent the medical team in these discussions so that surgical
      treatment, if desired, can be arranged expeditiously. These difficulties
      sometimes lead to the performance of emergent surgical procedures in situations
      where poor outcome is certain, with deleterious effects to the patient, family,
      and healthcare system. It is clear then that neurosurgeons as well as their
      housestaff and extenders should have working knowledge of prognostic information 
      relating to intracranial insults and familiarity with the complex ethical concept
      of medical futility. In this paper we review the relevant literature and our goal
      is to juxtapose these topics so as to provide a framework for decision making in 
      that critical time.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Anderson, Emily
AU  - Anderson E
AD  - Department of Neurosurgery, Tufts Medical Center, Boston, MA, USA.
FAU - Kryzanski, James
AU  - Kryzanski J
AD  - Department of Neurosurgery, Tufts Medical Center, Boston, MA, USA. Electronic
      address: jkryzanski@tuftsmedicalcenter.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200507
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
SB  - IM
MH  - Brain Diseases/*surgery
MH  - *Clinical Decision-Making
MH  - Emergency Medical Services/*methods
MH  - Humans
MH  - *Medical Futility
MH  - *Neurosurgery
MH  - Prognosis
OTO - NOTNLM
OT  - *Futility
OT  - *Gunshot wounds
OT  - *Spontaneous intracerebral hemorrhages
OT  - *Supratentorial hemorrhage
OT  - *Traumatic brain injury
EDAT- 2020/05/19 06:00
MHDA- 2021/06/16 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/04/03 00:00 [received]
PHST- 2020/04/10 00:00 [revised]
PHST- 2020/04/11 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - S0303-8467(20)30194-3 [pii]
AID - 10.1016/j.clineuro.2020.105851 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2020 Aug;195:105851. doi: 10.1016/j.clineuro.2020.105851. 
      Epub 2020 May 7.


PMID- 32422196
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1095-6867 (Electronic)
IS  - 0018-506X (Linking)
VI  - 124
DP  - 2020 Aug
TI  - Going wild for functional genomics: RNA interference as a tool to study
      gene-behavior associations in diverse species and ecological contexts.
PG  - 104774
LID - S0018-506X(20)30100-8 [pii]
LID - 10.1016/j.yhbeh.2020.104774 [doi]
AB  - Identifying the genetic basis of behavior has remained a challenge for
      biologists. A major obstacle to this goal is the difficulty of examining gene
      function in an ecologically relevant context. New tools such as CRISPR/Cas9,
      which alter the germline of an organism, have taken center stage in functional
      genomics in non-model organisms. However, germline modifications of this nature
      cannot be ethically implemented in the wild as a part of field experiments. This 
      impediment is more than technical. Gene function is intimately tied to the
      environment in which the gene is expressed, especially for behavior. Most
      lab-based studies fail to recapitulate an organism's ecological niche, thus most 
      published functional genomics studies of gene-behavior relationships may provide 
      an incomplete or even inaccurate assessment of gene function. In this review, we 
      highlight RNA interference as an especially effective experimental method to
      deepen our understanding of the interplay between genes, behavior, and the
      environment. We highlight the utility of RNAi for researchers investigating
      behavioral genetics, noting unique attributes of RNAi including transience of
      effect and the feasibility of releasing treated animals into the wild, that make 
      it especially useful for studying the function of behavior-related genes.
      Furthermore, we provide guidelines for planning and executing an RNAi experiment 
      to study behavior, including challenges to consider. We urge behavioral
      ecologists and functional genomicists to adopt a more fully integrated approach
      which we call "ethological genomics". We advocate this approach, utilizing tools 
      such as RNAi, to study gene-behavior relationships in their natural context,
      arguing that such studies can provide a deeper understanding of how genes can
      influence behavior, as well as ecological aspects beyond the organism that houses
      them.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Walton, Alexander
AU  - Walton A
AD  - Department of Ecology, Evolution, and Organismal Biology, Iowa State University, 
      Ames, IA, USA. Electronic address: awalton@iastate.edu.
FAU - Sheehan, Michael J
AU  - Sheehan MJ
AD  - Department of Neurobiology and Behavior, Cornell University, Ithaca, NY, USA.
FAU - Toth, Amy L
AU  - Toth AL
AD  - Department of Ecology, Evolution, and Organismal Biology, Iowa State University, 
      Ames, IA, USA; Department of Entomology, Iowa State University, Ames, IA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200530
PL  - United States
TA  - Horm Behav
JT  - Hormones and behavior
JID - 0217764
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*physiology
MH  - Behavioral Research/methods/trends
MH  - Biological Evolution
MH  - Ecosystem
MH  - *Gene-Environment Interaction
MH  - *Genetic Association Studies/methods/trends/veterinary
MH  - Genomics/*methods/trends
MH  - Phenotype
MH  - RNA Interference/*physiology
MH  - Species Specificity
OTO - NOTNLM
OT  - *Behavioral ecology
OT  - *Behavioral genetics
OT  - *Ecological and evolutionary genomics
OT  - *Functional genomics
OT  - *Gene expression
OT  - *RNA interference
COIS- Declaration of competing interest The authors declare no competing interests.
EDAT- 2020/05/19 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/02/16 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - S0018-506X(20)30100-8 [pii]
AID - 10.1016/j.yhbeh.2020.104774 [doi]
PST - ppublish
SO  - Horm Behav. 2020 Aug;124:104774. doi: 10.1016/j.yhbeh.2020.104774. Epub 2020 May 
      30.


PMID- 32421949
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 3
DP  - 2020 May
TI  - IRB Policies for Obtaining Informed Consent from Non-English-Speaking People.
PG  - 21-29
LID - 10.1002/eahr.500050 [doi]
AB  - United States regulations for the protection of human research subjects prescribe
      parameters for documentation of valid informed consent, which include the
      stipulation that the process be in a "language understandable to the subject."
      While significant energy has been devoted to improving the readability of consent
      documents, supplemental educational tools, and nuanced measurements of individual
      decisional capacity, there is little guidance about how to best meet the
      informational needs of adults with decisional capacity who do not speak English. 
      This article reviews the institutional review board policies from the twenty-one 
      research centers that received the most funding from the National Institutes of
      Health in 2018 and compares their guidelines for obtaining informed consent from 
      non-English speakers. Inconsistent practices suggest the need for more assertive 
      federal direction on what parameters constitute valid consent for this
      population. These practices also indicate a reluctance to directly engage the
      ethical underpinnings of consent policies for non-English speakers.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - McMillan, Gianna
AU  - McMillan G
AD  - Program administrator and teaches research ethics at the Bioethics Institute at
      Loyola Marymount University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - *Communication Barriers
MH  - Comprehension
MH  - Consent Forms/*standards
MH  - Documentation
MH  - Ethics Committees, Research/*ethics
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Language
MH  - *Research Subjects
MH  - *Translating
OTO - NOTNLM
OT  - IRB policies
OT  - human research subjects
OT  - informed consent
OT  - non-English speaking participants
OT  - short consent form
EDAT- 2020/05/19 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1002/eahr.500050 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 May;42(3):21-29. doi: 10.1002/eahr.500050.


PMID- 32421947
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 3
DP  - 2020 May
TI  - Genomics and Infectious Diseases: Expert Perspectives on Public Health
      Considerations regarding Actionability and Privacy.
PG  - 30-40
LID - 10.1002/eahr.500051 [doi]
AB  - There is growing evidence that human genetics plays a significant role in shaping
      human responses to infectious diseases. For instance, individuals' genetic
      susceptibility or resistance to infectious disease is likely to affect disease
      transmission. Yet little attention has been paid to the ethical, legal, and
      social implications of research in genomics and infectious disease, despite the
      unique ethical issues that arise in this arena. This article presents results
      from a pilot study exploring ethics in research on human genetics and response to
      HIV and other infectious diseases and is focused on perspectives from expert
      stakeholders. Whereas chairs of institutional review boards, biobank directors,
      and researchers in genomics and infectious disease expressed similar views about 
      research privacy in the context of a public health emergency, they expressed
      different perspectives about the role that public health considerations ought to 
      play in the return of individual results to research participants. These
      perspectives highlight the need to emphasize the importance of broad dialogue for
      helping various parties navigate the ethically complex current and future
      challenges of genomics and infectious disease research.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Walker, Alexis
AU  - Walker A
AD  - Hecht-Levi postdoctoral fellow at the Berman Institute of Bioethics at Johns
      Hopkins University.
FAU - Boyce, Angie
AU  - Boyce A
AD  - Research scholar at the Berman Institute of Bioethics at Johns Hopkins
      University.
FAU - Duggal, Priya
AU  - Duggal P
AD  - Associate professor in the Department of Epidemiology at Johns Hopkins Bloomberg 
      School of Public Health.
FAU - Thio, Chloe L
AU  - Thio CL
AD  - Professor in the Department of Medicine at Johns Hopkins University School of
      Medicine.
FAU - Geller, Gail
AU  - Geller G
AD  - Professor at the Berman Institute of Bioethics at Johns Hopkins University.
LA  - eng
GR  - 5RM1HG009038-03/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Cohort Studies
MH  - Communicable Diseases/*genetics
MH  - Ethics Committees, Research/*ethics
MH  - Genomics/*ethics
MH  - Humans
MH  - Middle Aged
MH  - Pilot Projects
MH  - *Privacy
MH  - Public Health/*ethics
MH  - Research
MH  - *Stakeholder Participation
PMC - PMC7276751
OTO - NOTNLM
OT  - Certificate of Confidentiality
OT  - genetic privacy
OT  - genomic research
OT  - human research ethics
OT  - infectious diseases
OT  - return of results
EDAT- 2020/05/19 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1002/eahr.500051 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 May;42(3):30-40. doi: 10.1002/eahr.500051.


PMID- 32421870
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 1930-7837 (Electronic)
IS  - 0022-0337 (Linking)
VI  - 84
IP  - 7
DP  - 2020 Jul
TI  - Two critical thinking models-probing questions and conceptualization-adding 4
      skillsets to the teacher's armamentarium.
PG  - 733-741
LID - 10.1002/jdd.12177 [doi]
AB  - Critical thinking is ubiquitous in patient care. One track for critical thinking 
      develops skillsets emulating the thought process of the master clinician using
      probing questions and has been offered in treatment planning, literature search, 
      and critique, risk assessment in caries and geriatrics, technology
      decision-making, EBD, and IPP. This paper offers 2 additional critical thinking
      skillsets following this emulation model in social work and ethics.
      Conceptualization, another form of critical thinking, is also ubiquitous in
      health care, yet almost no literature exists to guide learning and assess
      performance on conceptualization. This paper introduces for discussion 2 examples
      of conceptualization-"How and how much does this situation differ from the
      ideal?" and "How does the student/practitioner conceptualize the outcome prior to
      the imminent procedure?" -used continually by the practitioner in patient care
      situations. The result is 4 additional critical thinking skillsets at different
      stages of development in the armamentarium for the teacher.
CI  - (c) 2020 The Authors. Journal of Dental Education published by Wiley Periodicals 
      LLC on behalf of American Dental Education Association.
FAU - Johnsen, David C
AU  - Johnsen DC
AD  - Department of Pediatric Dentistry and Dean, University of Iowa College of
      Dentistry and Dental Clinics, Iowa City, IA, USA.
FAU - Flick, Kristen
AU  - Flick K
AD  - University of Iowa College of Dentistry and Dental Clinics, Iowa City, IA, USA.
FAU - Butali, Azeez
AU  - Butali A
AD  - Department of Oral Pathology, Radiology and Medicine, University of Iowa College 
      of Dentistry and Dental Clinics, Iowa City, IA, USA.
FAU - Cunningham-Ford, Marsha A
AU  - Cunningham-Ford MA
AD  - Preventive and Community Dentistry, University of Iowa College of Dentistry and
      Dental Clinics, Iowa City, IA, USA.
FAU - Holloway, Julie A
AU  - Holloway JA
AD  - Department of Prosthodontics, University of Iowa College of Dentistry and Dental 
      Clinics, Iowa City, IA, USA.
FAU - Mahrous, Ahmed
AU  - Mahrous A
AUID- ORCID: https://orcid.org/0000-0001-5436-8247
AD  - Department of Prosthodontics, University of Iowa College of Dentistry and Dental 
      Clinics, Iowa City, IA, USA.
FAU - Marchini, Leonardo
AU  - Marchini L
AUID- ORCID: https://orcid.org/0000-0003-1291-6684
AD  - Department of Prosthodontics, University of Iowa College of Dentistry and Dental 
      Clinics, Iowa City, IA, USA.
FAU - Clancy, James M
AU  - Clancy JM
AD  - Department of Prosthodontics, University of Iowa College of Dentistry and Dental 
      Clinics, Iowa City, IA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - United States
TA  - J Dent Educ
JT  - Journal of dental education
JID - 8000150
SB  - IM
MH  - Concept Formation
MH  - Humans
MH  - *Learning
MH  - *Thinking
OTO - NOTNLM
OT  - conceptualization
OT  - critical thinking skillsets
OT  - ethics
OT  - social work
EDAT- 2020/05/19 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/03/29 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1002/jdd.12177 [doi]
PST - ppublish
SO  - J Dent Educ. 2020 Jul;84(7):733-741. doi: 10.1002/jdd.12177. Epub 2020 May 18.


PMID- 32421821
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210412
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 87
IP  - 4
DP  - 2020 Sep 15
TI  - A Primer on Human Brain Organoids for the Neurosurgeon.
PG  - 620-629
LID - 10.1093/neuros/nyaa171 [doi]
AB  - Human brain organoids emerged in 2013 as a technology that, unlike prior in Vitro
      neural models, recapitulates brain development with a high degree of spatial and 
      temporal fidelity. As the platform matured with more accurate reproduction of
      cerebral architecture, brain organoids became increasingly valuable for studying 
      both normal cortical neurogenesis and a variety of congenital human brain
      disorders. While the majority of research utilizing human brain organoids has
      been in the realm of basic science, clinical applications are forthcoming. These 
      present and future translational efforts have the potential to make a
      considerable impact on the field of neurosurgery. For example, glioma organoids
      are already being used to study tumor biology and drug responses, and adaptation 
      for the investigation of other neurosurgery-relevant diseases is underway.
      Moreover, organoids are being explored as a structured neural substrate for
      repairing brain circuitry. Thus, we believe it is important for our field to be
      aware and have an accurate understanding of this emerging technology. In this
      review, we describe the key characteristics of human brain organoids, review
      their relevant translational applications, and discuss the ethical implications
      of their use through a neurosurgical lens.
CI  - Copyright (c) 2020 by the Congress of Neurological Surgeons.
FAU - Blue, Rachel
AU  - Blue R
AD  - Department of Neurosurgery, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Miranda, Stephen P
AU  - Miranda SP
AD  - Department of Neurosurgery, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Gu, Ben Jiahe
AU  - Gu BJ
AD  - Department of Neurosurgery, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Chen, H Isaac
AU  - Chen HI
AD  - Department of Neurosurgery, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania.
AD  - Institute for Regenerative Medicine, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania.
AD  - Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia,
      Pennsylvania.
LA  - eng
GR  - IK2 RX002013/RX/RRD VA/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
SB  - IM
CIN - Neurosurgery. 2020 Sep 15;87(4):E443-E444. PMID: 32542381
MH  - Brain/pathology/*surgery
MH  - Brain Diseases/pathology/*surgery
MH  - Humans
MH  - Neurosurgeons/*education
MH  - Neurosurgical Procedures/*methods
MH  - Organoids/pathology/*surgery
OTO - NOTNLM
OT  - *Brain organoids
OT  - *Brain repair
OT  - *Disease models
OT  - *Glioblastoma
OT  - *Stem cells
EDAT- 2020/05/19 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 5838831 [pii]
AID - 10.1093/neuros/nyaa171 [doi]
PST - ppublish
SO  - Neurosurgery. 2020 Sep 15;87(4):620-629. doi: 10.1093/neuros/nyaa171.


PMID- 32421037
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0377-8401 (Print)
IS  - 0377-8401 (Linking)
VI  - 263
DP  - 2020 May
TI  - Growth and digestive enzyme activities of rohu labeo rohita fed diets containing 
      macrophytes and almond oil-cake.
PG  - 114456
LID - 10.1016/j.anifeedsci.2020.114456 [doi]
AB  - The impact of plant-based diets on the digestive physiology of rohu Labeo rohita 
      fingerlings (10.66+/-0.53g) was evaluated. A diet with all protein supplied by
      fishmeal was included as a control (F). Four test diets containing 300g/kg
      protein were formulated using the following plant ingredients and fishmeal in a
      1:1 blend: almond oil-cake Terminalia catappa (FTC), duckweed Lemna minor (FLM), 
      water fern Salvania molesta (FSM) and combination of these three ingredients
      (FTCLMSM). The final body weight and specific growth rate were significantly
      higher in rohu fed diet FLM compared to the other treatments. Significantly lower
      feed conversion ratio in rohu fed diet FLM showed that diet was utilized
      efficiently in this feeding regime compared to the other diets. The composition
      of diets also influenced the digestive enzyme activities of the fish. Thus,
      amylase, trypsin and chymotrypsin activities were significantly higher in rohu
      fed diet FLM compared to the rohu fed the other diets. Protease activity was
      significantly higher in rohu fed diets FTC and F and lipase activity was
      significantly higher in rohu fed diet FTC compared to the rohu fed the other
      diets. The inclusion of raw duckweed in feed replaced 300g/kg of dietary fishmeal
      without affecting growth.
CI  - (c) 2020 The Authors. Published by Elsevier B.V.
FAU - Goswami, R K
AU  - Goswami RK
AD  - Aqua Research Lab, Department of Zoology, University of Delhi, Delhi 110 007,
      India.
FAU - Shrivastav, A K
AU  - Shrivastav AK
AD  - Department of Biotechnology, Delhi Technological University, Bawana Road, Delhi
      110042, India.
FAU - Sharma, J G
AU  - Sharma JG
AD  - Department of Biotechnology, Delhi Technological University, Bawana Road, Delhi
      110042, India.
FAU - Tocher, D R
AU  - Tocher DR
AD  - Institute of Aquaculture, Faculty of Natural Sciences, University of Stirling,
      Stirling FK9 4LA, Scotland, United Kingdom.
FAU - Chakrabarti, R
AU  - Chakrabarti R
AD  - Aqua Research Lab, Department of Zoology, University of Delhi, Delhi 110 007,
      India.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Anim Feed Sci Technol
JT  - Animal feed science and technology
JID - 100955711
PMC - PMC7212790
OTO - NOTNLM
OT  - ANOVA, Analysis of Variance
OT  - AOAC, Association of Official Analytic Chemists
OT  - APHA, American Public Health Association
OT  - Amylase
OT  - BBSRC, Biotechnology and Biological Science Research Council
OT  - Chymotrypsin
OT  - DBT, Department of Biotechnology
OT  - DF, Dry fish
OT  - DH, Degree of hydrolysis
OT  - Duckweed
OT  - F, Fishmeal
OT  - FAO, Food and Agriculture Organization
OT  - FBW, Final body weight
OT  - FCR, Feed conversion ratio
OT  - FI, Feed Intake
OT  - FLM, Fishmeal with Lemna minor
OT  - FSM, Fishmeal with Salvinia molesta
OT  - FTC, Fishmeal with Terminalia catappa
OT  - FTCLMSM, Fishmeal with Terminalia catappa Lemna minor, Salvinia molesta
OT  - Growth
OT  - IAEC, Institutional Animal Ethics Committee
OT  - IBW, Initial body weight
OT  - LM, Lemna minor
OT  - Labeo rohita
OT  - SGR, Specific growth rate
OT  - SM, Salvinia molesta
OT  - TC, Terminalia catappa
OT  - TCLMSM, Terminalia catappa Lemna minor, Salvinia molesta
OT  - Trypsin
OT  - WG, Weight gain
COIS- The authors declare that there is no conflict of interest.
EDAT- 2020/05/19 06:00
MHDA- 2020/05/19 06:01
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/05/19 06:01 [medline]
AID - 10.1016/j.anifeedsci.2020.114456 [doi]
AID - S0377-8401(18)31609-2 [pii]
AID - 114456 [pii]
PST - ppublish
SO  - Anim Feed Sci Technol. 2020 May;263:114456. doi:
      10.1016/j.anifeedsci.2020.114456.


PMID- 32420993
OWN - NLM
STAT- MEDLINE
DCOM- 20201009
LR  - 20201009
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 159
DP  - 2020 May 1
TI  - In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular
      Crowding.
LID - 10.3791/61037 [doi]
AB  - It has been shown that in vivo tissues are highly crowded by proteins, nucleic
      acids, ribonucleoproteins, polysaccharides, etc. The following protocol applies a
      macromolecular crowding (MMC) technique to mimic this physiological crowding
      through the addition of neutral polymers (crowders) to cell cultures in vitro.
      Previous studies using Ficoll or dextran as crowders demonstrate that the
      expression of collagen I and fibronectin in WI38 and WS-1 cell lines are
      significantly enhanced using the MMC technique. However, this technique has not
      been validated in primary hypertrophic scar-derived human skin fibroblasts
      (hHSFs). As hypertrophic scarring arises from the excessive deposition of
      collagen, this protocol aims to construct a collagen-rich in vitro hypertrophic
      scar model by applying the MMC technique with hHSFs. This optimized MMC model has
      been shown to possess more similarities with in vivo scar tissue compared to
      traditional 2-dimensional (2-D) cell culture systems. In addition, it is
      cost-effective, time-efficient, and ethically desirable compared to animal
      models. Therefore, the optimized model reported here offers an advanced "in
      vivo-like" model for hypertrophic scar-related studies.
FAU - Fan, Chen
AU  - Fan C
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR); Chen.fan@sris.a-star.edu.sg.
FAU - Lim, Lay Keng Priscilla
AU  - Lim LKP
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR).
FAU - Wu, Zihao
AU  - Wu Z
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR).
FAU - Sharma, Bhavya
AU  - Sharma B
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR).
FAU - Gan, Shi Qi
AU  - Gan SQ
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR); School of Chemical and Life Sciences, Singapore Polytechnic.
FAU - Liang, Kun
AU  - Liang K
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR).
FAU - Upton, Zee
AU  - Upton Z
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR); Institute of Medical Biology, Agency for Science, Technology and
      Research (A*STAR).
FAU - Leavesley, David
AU  - Leavesley D
AD  - Skin Research Institute of Singapore, Agency for Science, Technology and Research
      (A*STAR).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Video-Audio Media
DEP - 20200501
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
RN  - 0 (Collagen Type I)
RN  - 0 (FN1 protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (Macromolecular Substances)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Cicatrix, Hypertrophic/genetics/*pathology
MH  - Collagen Type I/metabolism
MH  - Fibroblasts/metabolism/pathology
MH  - Fibronectins
MH  - Gene Expression Regulation
MH  - Humans
MH  - Macromolecular Substances/*metabolism
MH  - *Models, Biological
MH  - Skin/pathology
EDAT- 2020/05/19 06:00
MHDA- 2020/10/10 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/10/10 06:00 [medline]
AID - 10.3791/61037 [doi]
PST - epublish
SO  - J Vis Exp. 2020 May 1;(159). doi: 10.3791/61037.


PMID- 32420939
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20220716
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 2
DP  - 2020 May 11
TI  - Assessment and treatment of older individuals with COVID 19 multi-system disease:
      Clinical and ethical implications.
PG  - 150-168
LID - 10.23750/abm.v91i2.9629 [doi]
AB  - Covid-19 infection is a multisystem disease more frequent in older individuals,
      especially in those with multiple chronic diseases. This multimorbid and frail
      population requires attention and a personalized comprehensive assessment in
      order to avoid the occurrence of adverse outcomes. As other diseases, the
      COVID-19 presentation in older patients is often atypical with less severe and
      unspecific symptoms. These subjects both at home and during hospitalization
      suffer isolation and the lack of support of caregivers. The geriatric care in
      COVID-19 wards is often missing. The application of additional instruments would 
      be necessary to facilitate and personalize the clinical approach, not only based 
      on diseases but also on functional status. This narrative review starts from
      diagnostic evaluation, continues with adapted pharmacologic treatment and ends
      with the recovery phase targeting the nutrition and physical exercise. We
      developed a check-list of respiratory, gastro-intestinal and other less-specific 
      symptoms, summarized in a table and easily to be filled-up by patients, nurses
      and general practitioners. As second step, we reported the clinical phases of
      this disease. Far to be considered just viral infective and respiratory, this
      disease is also an inflammatory and thrombotic condition with frequent bacterial 
      over-infection. We finally considered timing and selection of treatment, which
      depend on the disease phase, co-administration of other drugs and require the
      monitoring of renal, liver and cardiac function. This underlines the role of age 
      not just as a limitation, but also an opportunity to increase the quality and the
      appropriateness of multidisciplinary and multidimensional intervention in this
      population.
FAU - Lauretani, Fulvio
AU  - Lauretani F
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. flauretani@ao.pr.it.
FAU - Ravazzoni, Giulia
AU  - Ravazzoni G
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. giuliaravazzoni@outlook.it.
FAU - Roberti, Maria Federica
AU  - Roberti MF
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. mariafederica90@hotmail.it.
FAU - Longobucco, Yari
AU  - Longobucco Y
AD  - SPRINTT Team, Department of Medicine and Surgery, University of Parma, Italy.
      yari.longobucco@gmail.com.
FAU - Adorni, Elisa
AU  - Adorni E
AD  - SPRINTT Team, Department of Medicine and Surgery, University of Parma, Italy.
      elisa.adorni@gmail.com.
FAU - Grossi, Margherita
AU  - Grossi M
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. margherita.grossi@studenti.unipr.it.
FAU - De Iorio, Aurelio
AU  - De Iorio A
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. aureliomaria.deiorio@gmail.com.
FAU - La Porta, Umberto
AU  - La Porta U
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. laportaumberto@gmail.com.
FAU - Fazio, Chiara
AU  - Fazio C
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. chiara.fazio@unipr.it.
FAU - Gallini, Elena
AU  - Gallini E
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. elena.gallini@unipr.it.
FAU - Federici, Raffaele
AU  - Federici R
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. raffaele.federici@unipr.it.
FAU - Salvi, Marco
AU  - Salvi M
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. marco.salvi@unipr.it.
FAU - Ciarrocchi, Erika
AU  - Ciarrocchi E
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. erika.ciarrocchi@studenti.unipr.it.
FAU - Rossi, Francesca
AU  - Rossi F
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. francirossi1991@gmail.com.
FAU - Bergamin, Marina
AU  - Bergamin M
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. marina.bergamin@gmail.com.
FAU - Bussolati, Giacomo
AU  - Bussolati G
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. dr.giacomo.bussolati@gmail.com.
FAU - Grieco, Ilaria
AU  - Grieco I
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. ilaria.grieco@studenti.unipr.it.
FAU - Broccoli, Federica
AU  - Broccoli F
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. federica.broccoli@studenti.unipr.it.
FAU - Zucchini, Irene
AU  - Zucchini I
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. irene_zucchini@libero.it.
FAU - Ielo, Giuseppe
AU  - Ielo G
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. ieloielo@hotmail.it.
FAU - Morganti, Simonetta
AU  - Morganti S
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy.
      smorganti@ao.pr.it.
FAU - Artoni, Andrea
AU  - Artoni A
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy.
      anartoni@ao.pr.it.
FAU - Arisi, Arianna
AU  - Arisi A
AD  - Postgraduate School of Geriatric Medicine, Department of Medicine and Surgery,
      University of Parma, Italy. arianna.arisi@libero.it.
FAU - Tagliaferri, Sara
AU  - Tagliaferri S
AD  - SPRINTT Team, Department of Medicine and Surgery, University of Parma, Italy.
      sara.tagliaferri@unipr.it.
FAU - Maggio, Marcello
AU  - Maggio M
AD  - Geriatric Clinic Unit, Parma University Hospital of Parma, Italy Postgraduate
      School of Geriatric Medicine, Department of Medicine and Surgery, University of
      Parma, Italy. marcellogiuseppe.maggio@unipr.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200511
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/epidemiology/*therapy
MH  - Frail Elderly
MH  - Humans
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/diagnosis/epidemiology/*therapy
MH  - Polypharmacy
MH  - SARS-CoV-2
PMC - PMC7569659
EDAT- 2020/05/19 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
AID - 10.23750/abm.v91i2.9629 [doi]
PST - epublish
SO  - Acta Biomed. 2020 May 11;91(2):150-168. doi: 10.23750/abm.v91i2.9629.


PMID- 32420828
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Ethical and Sensible Dissemination of Information During the COVID-19 Pandemic.
PG  - W4-W6
LID - 10.1080/15265161.2020.1761200 [doi]
FAU - Rahimi, Farid
AU  - Rahimi F
AD  - The Australian National University.
FAU - Talebi Bezmin Abadi, Amin
AU  - Talebi Bezmin Abadi A
AD  - Tarbiat Modares University.
LA  - eng
PT  - Letter
DEP - 20200518
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Global Health
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - Pandemics/ethics/prevention & control
MH  - *Peer Review
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
EDAT- 2020/05/19 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1080/15265161.2020.1761200 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):W4-W6. doi: 10.1080/15265161.2020.1761200. Epub 2020 
      May 18.


PMID- 32420822
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20210702
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Eliminating Categorical Exclusion Criteria in Crisis Standards of Care
      Frameworks.
PG  - 28-36
LID - 10.1080/15265161.2020.1764141 [doi]
AB  - During public health crises including the COVID-19 pandemic, resource scarcity
      and contagion risks may require health systems to shift-to some degree-from a
      usual clinical ethic, focused on the well-being of individual patients, to a
      public health ethic, focused on population health. Many triage policies exist
      that fall under the legal protections afforded by "crisis standards of care," but
      they have key differences. We critically appraise one of the most fundamental
      differences among policies, namely the use of criteria to categorically exclude
      certain patients from eligibility for otherwise standard medical services. We
      examine these categorical exclusion criteria from ethical, legal, disability, and
      implementation perspectives. Focusing our analysis on the most common type of
      exclusion criteria, which are disease-specific, we conclude that optimal policies
      for critical care resource allocation and the use of cardiopulmonary
      resuscitation (CPR) should not use categorical exclusions. We argue that the
      avoidance of categorical exclusions is often practically feasible, consistent
      with public health norms, and mitigates discrimination against persons with
      disabilities.
FAU - Auriemma, Catherine L
AU  - Auriemma CL
AUID- ORCID: 0000-0003-4803-0375
AD  - University of Pennsylvania.
FAU - Molinero, Ashli M
AU  - Molinero AM
AD  - University of Pittsburgh Medical Center.
FAU - Houtrow, Amy J
AU  - Houtrow AJ
AD  - University of Pittsburgh.
FAU - Persad, Govind
AU  - Persad G
AD  - University of Denver.
FAU - White, Douglas B
AU  - White DB
AD  - University of Pittsburgh.
FAU - Halpern, Scott D
AU  - Halpern SD
AD  - University of Pennsylvania.
LA  - eng
GR  - K24 HL143289/HL/NHLBI NIH HHS/United States
GR  - T32 HL098054/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20200518
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jul;20(7):106-109. PMID: 32716774
CIN - Am J Bioeth. 2020 Jul;20(7):109-111. PMID: 32716779
CIN - Am J Bioeth. 2020 Jul;20(7):158-160. PMID: 32716793
CIN - Am J Bioeth. 2020 Jul;20(7):156-158. PMID: 32716813
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Standard of Care/*ethics
MH  - Triage/*ethics
MH  - United States/epidemiology
PMC - PMC7387214
MID - NIHMS1602691
OTO - NOTNLM
OT  - *Allocation
OT  - *coronavirus
OT  - *disabilities
OT  - *pandemics
OT  - *rationing
OT  - *triage
EDAT- 2020/05/19 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1080/15265161.2020.1764141 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):28-36. doi: 10.1080/15265161.2020.1764141. Epub 2020 
      May 18.


PMID- 32420817
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - The Value and Ethics of Using Technology to Contain the COVID-19 Epidemic.
PG  - W7-W11
LID - 10.1080/15265161.2020.1764136 [doi]
FAU - Dubov, Alex
AU  - Dubov A
AD  - University School of Behavioral Health, Loma Linda, CA.
FAU - Shoptawb, Steven
AU  - Shoptawb S
AD  - UCLA, Los Angeles, CA, USA.
LA  - eng
GR  - P30 MH058107/MH/NIMH NIH HHS/United States
PT  - Letter
PT  - Research Support, N.I.H., Extramural
DEP - 20200518
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Contact Tracing/ethics/*instrumentation
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Global Health
MH  - Humans
MH  - Pandemics/ethics/prevention & control
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - Technology/trends
PMC - PMC7657709
MID - NIHMS1640932
EDAT- 2020/05/19 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1080/15265161.2020.1764136 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):W7-W11. doi: 10.1080/15265161.2020.1764136. Epub 2020
      May 18.


PMID- 32419711
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20201218
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10238
DP  - 2020 May 30
TI  - Health inequity during the COVID-19 pandemic: a cry for ethical global
      leadership.
PG  - 1690-1691
LID - S0140-6736(20)31145-4 [pii]
LID - 10.1016/S0140-6736(20)31145-4 [doi]
FAU - Chiriboga, David
AU  - Chiriboga D
AD  - University of Massachusetts Medical School, Worcester, MA 01655, USA. Electronic 
      address: david.chiriboga@umassmed.edu.
FAU - Garay, Juan
AU  - Garay J
AD  - National School of Public Health of Spain, Madrid, Spain.
FAU - Buss, Paulo
AU  - Buss P
AD  - The Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
FAU - Madrigal, Rocio Saenz
AU  - Madrigal RS
AD  - University of Costa Rica School of Public Health, San Jose, Costa Rica.
FAU - Rispel, Laetitia Charmaine
AU  - Rispel LC
AD  - Witwatersrand University School of Public Health, Johannesburg, South Africa.
LA  - eng
PT  - Letter
DEP - 20200515
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - IM
MH  - Advisory Committees
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Resources/*legislation & jurisprudence/supply & distribution
MH  - *Healthcare Disparities
MH  - Humans
MH  - International Cooperation
MH  - Leadership
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Resource Allocation/*ethics/*legislation & jurisprudence
MH  - SARS-CoV-2
MH  - World Health Organization
PMC - PMC7225689
EDAT- 2020/05/19 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/07 00:00 [received]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1016/S0140-6736(20)31145-4 [doi]
AID - S0140-6736(20)31145-4 [pii]
PST - ppublish
SO  - Lancet. 2020 May 30;395(10238):1690-1691. doi: 10.1016/S0140-6736(20)31145-4.
      Epub 2020 May 15.


PMID- 32419621
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Safe and competent nursing care: An argument for a minimum standard?
PG  - 1396-1407
LID - 10.1177/0969733020919137 [doi]
AB  - There is no agreed minimum standard with regard to what is considered safe,
      competent nursing care. Limited resources and organizational constraints make it 
      challenging to develop a minimum standard. As part of their everyday practice,
      nurses have to ration nursing care and prioritize what care to postpone, leave
      out, and/or omit. In developed countries where public healthcare is tax-funded, a
      minimum level of healthcare is a patient right; however, what this entails in a
      given patient's actual situation is unclear. Thus, both patients and nurses would
      benefit from the development of a minimum standard of nursing care. Clarity on
      this matter is also of ethical and legal concern. In this article, we explore the
      case for developing a minimum standard to ensure safe and competent nursing care 
      services. Any such standard must encompass knowledge of basic principles of
      clinical nursing and preservation of moral values, as well as managerial issues, 
      such as manpower planning, skill-mix, and time to care. In order for such
      standards to aid in providing safe and competent nursing care, they should be in 
      compliance with accepted evidence-based nursing knowledge, based on patients'
      needs and legal rights to healthcare and on nurses' codes of ethics. That is, a
      minimum standard must uphold a satisfactory level of quality in terms of both
      professionalism and ethics. Rather than being fixed, the minimum standard should 
      be adjusted according to patients' needs in different settings and may thus be
      different in different contexts and countries.
FAU - Tonnessen, Siri
AU  - Tonnessen S
AUID- ORCID: https://orcid.org/0000-0002-7106-5405
AD  - 7928University of South-Eastern Norway, Norway.
FAU - Scott, Anne
AU  - Scott A
AD  - 8799National University of Ireland Galway, Ireland.
FAU - Nortvedt, Per
AU  - Nortvedt P
AD  - University of Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Clinical Competence/*standards/statistics & numerical data
MH  - Humans
MH  - Norway
MH  - Nursing Care/methods/*standards/statistics & numerical data
MH  - Standard of Care/*legislation & jurisprudence/standards/*trends
PMC - PMC7543010
OTO - NOTNLM
OT  - Fundamental nursing care
OT  - human rights to nursing care
OT  - minimum standards of nursing care
OT  - missed care
OT  - rationing
OT  - safe and competent nursing care
OT  - values in nursing care
EDAT- 2020/05/19 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1177/0969733020919137 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1396-1407. doi: 10.1177/0969733020919137. Epub 2020
      May 18.


PMID- 32419394
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 35
IP  - 19
DP  - 2020 May 18
TI  - Pregnancy and Epilepsy: a Korean Tertiary Epilepsy Center Review.
PG  - e119
LID - 10.3346/jkms.2020.35.e119 [doi]
AB  - BACKGROUND: Pregnancy in women with epilepsy (WWE) is known to have a higher risk
      for fetal development complications, which may include congenital malformations. 
      Unfortunately, information pertaining to pregnancy in WWE is difficult to obtain 
      because there are considerable ethical issues preventing these studies from being
      conducted on pregnant women. Therefore, this study investigated the pregnancies
      of Korean WWE in a tertiary epilepsy center to observe data resulting from the
      outcome of the pregnancies. METHODS: This was a retrospective study of 48
      pregnant WWE who were treated at the regional tertiary epilepsy center. All
      records of hospital visits before and after the period of pregnancy were analyzed
      to obtain information about the seizures as well as pregnancy-related outcomes,
      including the status of the newborns' conditions. RESULTS: The subject group
      consisted of 31 (63.3%) with partial epilepsy, 6 (12.5%) with generalized
      epilepsy, and 11 (22.9%) with unclassified epilepsy. There were 27 subjects who
      took one antiepileptic drug (AED), and 12 who took two AEDs. The most commonly
      used drug was lamotrigine (29.8%). Of the 48 WWE involved in the study, 31
      underwent caesarian sections and 17 opted for natural birth. Thirty-nine (81.3%) 
      delivered at full-term, but 9 (18.7%) delivered at preterm. Compared to full-term
      infants, pre-mature infants showed lower birth weight, smaller head
      circumference, shorter height, and lower 1-minute Apgar scores, but seizure
      frequencies of the mothers did not differ. CONCLUSION: In WWE, epilepsy
      classification, number of AEDs taken, and frequency of seizures are not
      significantly correlated with delivery and fetal condition. This data could be
      used as a clinical reference for physicians to provide useful information to WWE 
      if they are concerned about their pregnancies.
CI  - (c) 2020 The Korean Academy of Medical Sciences.
FAU - Jeon, Ji Ye
AU  - Jeon JY
AUID- ORCID: https://orcid.org/0000-0003-1111-3521
AD  - Department of Neurology, Kyungpook National University Chilgok Hospital, School
      of Medicine, Kyungpook National University, Daegu, Korea.
FAU - Bae, Jin Gon
AU  - Bae JG
AUID- ORCID: https://orcid.org/0000-0001-6127-162X
AD  - Department of Obstetrics and Gynecology, Dongsan Medical Center, Keimyung
      University School of Medicine, Daegu, Korea.
FAU - Kim, Keun Tae
AU  - Kim KT
AUID- ORCID: https://orcid.org/0000-0002-7124-0736
AD  - Department of Neurology, Dongsan Medical Center, Keimyung University School of
      Medicine, Daegu, Korea.
FAU - Cho, Yong Won
AU  - Cho YW
AUID- ORCID: https://orcid.org/0000-0002-6127-1045
AD  - Department of Neurology, Dongsan Medical Center, Keimyung University School of
      Medicine, Daegu, Korea. neurocho@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Anticonvulsants)
RN  - U3H27498KS (Lamotrigine)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/adverse effects/*therapeutic use
MH  - Cesarean Section
MH  - Electroencephalography
MH  - Epilepsy/*drug therapy/*pathology
MH  - Female
MH  - Gestational Age
MH  - Head/physiology
MH  - Humans
MH  - Infant, Low Birth Weight
MH  - Infant, Newborn
MH  - Lamotrigine/adverse effects/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Premature Birth/etiology
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Severity of Illness Index
PMC - PMC7234856
OTO - NOTNLM
OT  - Antiepileptic Drugs
OT  - Epilepsy
OT  - Pregnancy
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2020/05/19 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/05/19 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - 35.e119 [pii]
AID - 10.3346/jkms.2020.35.e119 [doi]
PST - epublish
SO  - J Korean Med Sci. 2020 May 18;35(19):e119. doi: 10.3346/jkms.2020.35.e119.


PMID- 32419349
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1445-2197 (Electronic)
IS  - 1445-1433 (Linking)
VI  - 90
IP  - 9
DP  - 2020 Sep
TI  - Prophylactic Foley catheter insertion into defunctioning ileostomy to reduce
      obstruction after colorectal surgery: pilot randomized controlled trial.
PG  - 1637-1641
LID - 10.1111/ans.15714 [doi]
AB  - BACKGROUND: Defunctioning ileostomies provide faecal diversion in major
      colorectal surgery. This reduces the consequences of an anastomotic leak.
      However, the formation of an ileostomy carries risks including obstruction at the
      level of the fascia. Post-operative oedema at the level of the fascia may
      contribute to obstruction. We hypothesize that the prophylactic insertion of a
      Foley catheter into the afferent limb of a defunctioning loop ileostomy may help 
      decompress and improve time to low-residue diet (LRD). The objective of the study
      was to assess the feasibility of a Foley catheter, prophylactically inserted into
      the afferent limb of a defunctioning loop ileostomy, after major colorectal
      surgery. METHODS: The study was a prospective pilot-randomized controlled trial. 
      Ethical approval was obtained from Northern B Health and Disability Ethics
      Committee 15/NTB/91 ANZCTR Trial ID: ACTRN12615000691549. RESULTS: Forty-nine
      patients undergoing major elective colorectal surgery with a defunctioning
      ileostomy, between the years of 2015 and 2018 at North Shore Hospital, Auckland, 
      New Zealand were included in this study. Patients were randomly allocated to
      either the Foley catheter (n = 26) or non-Foley catheter (n = 23) group. The
      median time taken to tolerate LRD the primary outcome, was 2 days in the Foley
      group versus 2 days in the non-Foley group (P = 0.05). There were no differences 
      in the secondary outcome measures such as time to stoma output, length of stay or
      complications. CONCLUSION: This trial failed to show a statistical difference in 
      time taken to tolerate a LRD residue in the Foley catheter group. There was no
      difference in length of stay, time to flatus or stoma output.
CI  - (c) 2020 Royal Australasian College of Surgeons.
FAU - Kulasegaran, Suheelan
AU  - Kulasegaran S
AUID- ORCID: 0000-0002-4484-6687
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
FAU - Li, Ray
AU  - Li R
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
FAU - Nisbet, Sherry
AU  - Nisbet S
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
FAU - Vasey, Carolyn
AU  - Vasey C
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
FAU - Otutaha, Bacil
AU  - Otutaha B
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
FAU - Walsh, Michael
AU  - Walsh M
AD  - Planning, Funding and Outcomes, Waitemata and Auckland District Health Boards,
      Auckland, New Zealand.
FAU - Jarvis, John
AU  - Jarvis J
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
FAU - Moir, Mike H
AU  - Moir MH
AD  - Department of Surgery, North Shore Hospital, Waitemata District Health Board,
      Auckland, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200517
PL  - Australia
TA  - ANZ J Surg
JT  - ANZ journal of surgery
JID - 101086634
SB  - IM
MH  - Anastomosis, Surgical
MH  - Catheters
MH  - *Colorectal Surgery
MH  - Humans
MH  - *Ileostomy/adverse effects
MH  - New Zealand
MH  - Pilot Projects
MH  - Postoperative Complications/prevention & control
MH  - Prospective Studies
OTO - NOTNLM
OT  - *Foley catheter
OT  - *bowel obstruction
OT  - *colorectal surgery
OT  - *defunctioning loop ileostomy
OT  - *stoma
EDAT- 2020/05/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/19 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/01/06 00:00 [revised]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1111/ans.15714 [doi]
PST - ppublish
SO  - ANZ J Surg. 2020 Sep;90(9):1637-1641. doi: 10.1111/ans.15714. Epub 2020 May 17.


PMID- 32419272
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20220716
IS  - 1860-7314 (Electronic)
IS  - 1860-6768 (Linking)
VI  - 15
IP  - 6
DP  - 2020 Jun
TI  - Molecular Targets for the Testing of COVID-19.
PG  - e2000152
LID - 10.1002/biot.202000152 [doi]
AB  - The pandemic outbreaks of coronavirus disease 2019 (COVID-19), caused by severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread all over the world 
      in a short period of time. Efficient identification of the infection by
      SARS-CoV-2 has been one of the most important tasks to facilitate all the
      following counter measurements in dealing with the infectious disease. In Taiwan,
      a COVID-19 Open Science Platform adheres to the spirit of open science: sharing
      sources, data, and methods to promote progress in academic research while
      corroborating findings from various disciplines has established in mid-February
      2020, for collaborative research in support of the development of detection
      methods, therapeutics, and a vaccine for COVID-19. Research priorities include
      infection control, epidemiology, clinical characterization and management,
      detection methods (including viral RNA detection, viral antigen detection, and
      serum antibody detection), therapeutics (neutralizing antibody and small molecule
      drugs), vaccines, and SARS-CoV-2 pathogenesis. In addition, research on social
      ethics and the law are included to take full account of the impact of the
      COVID-19 virus.
CI  - (c) 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Yong, Suh Kuan
AU  - Yong SK
AD  - Department of Biological Science and Technology, National Chiao Tung University, 
      Hsinchu, 300, Taiwan.
FAU - Su, Ping-Chia
AU  - Su PC
AD  - Department of Biological Science and Technology, National Chiao Tung University, 
      Hsinchu, 300, Taiwan.
FAU - Yang, Yuh-Shyong
AU  - Yang YS
AUID- ORCID: https://orcid.org/0000-0003-0177-473X
AD  - Department of Biological Science and Technology, National Chiao Tung University, 
      Hsinchu, 300, Taiwan.
LA  - eng
GR  - 108-2218-E-009-003/Ministry of Science and Technology, Taiwan
PT  - Journal Article
DEP - 20200518
PL  - Germany
TA  - Biotechnol J
JT  - Biotechnology journal
JID - 101265833
RN  - 0 (Coronavirus Nucleocapsid Proteins)
RN  - 0 (Nucleocapsid Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (RNA, Viral)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (nucleocapsid phosphoprotein, SARS-CoV-2)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques/*methods
MH  - Coronavirus Infections/*diagnosis/virology
MH  - Coronavirus Nucleocapsid Proteins
MH  - Humans
MH  - Nucleocapsid Proteins/isolation & purification
MH  - Pandemics
MH  - Phosphoproteins
MH  - Pneumonia, Viral/*diagnosis/virology
MH  - RNA, Viral/isolation & purification
MH  - SARS-CoV-2
MH  - Sensitivity and Specificity
MH  - Spike Glycoprotein, Coronavirus/isolation & purification
PMC - PMC7267081
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - coronavirus
OT  - molecular testing
OT  - rapid-diagnostic test (RDT)
OT  - serology testing
EDAT- 2020/05/19 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1002/biot.202000152 [doi]
PST - ppublish
SO  - Biotechnol J. 2020 Jun;15(6):e2000152. doi: 10.1002/biot.202000152. Epub 2020 May
      18.


PMID- 32419110
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 3
DP  - 2020 Sep
TI  - Ensuring Risk Awareness of Vulnerable Patients in the Post-Montgomery Era:
      Treading a Fine Line.
PG  - 283-298
LID - 10.1007/s10728-020-00396-9 [doi]
AB  - The 2015 UK Supreme Court judgment in Montgomery v Lanarkshire reinforces the
      importance of informed consent to medical treatment. This paper suggests that
      Montgomery recognises the challenge faced by vulnerable individuals in choosing
      between treatment options and making decisions with appreciation of information
      about material risks. The judgment endorses a form of weak paternalism to
      safeguard such persons, which is not disrespectful of the aggregate principles of
      the Mental Capacity Act 2005. But ethical practice requires professionals to
      tread carefully between weak and hard paternalism in the context of therapeutic
      interactions with vulnerable patients, while ensuring their awareness of material
      risks.
FAU - Talukdar, Sandip
AU  - Talukdar S
AD  - School of Law, University of Manchester, Oxford Road, Manchester, UK.
      sandip.talukdar@postgrad.manchester.ac.uk.
AD  - Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Carleton Clinic,
      Cumwhinton Drive, Carlisle, CA1 3SX, UK.
      sandip.talukdar@postgrad.manchester.ac.uk.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - Humans
MH  - *Informed Consent/ethics/legislation & jurisprudence
MH  - Judgment
MH  - Mental Competency/*legislation & jurisprudence
MH  - Paternalism
MH  - *Risk Assessment
MH  - United Kingdom
MH  - Vulnerable Populations/*psychology
PMC - PMC7411513
OTO - NOTNLM
OT  - Decision-making
OT  - Informed consent
OT  - MCA 2005
OT  - Montgomery
OT  - Vulnerable patients
EDAT- 2020/05/19 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1007/s10728-020-00396-9 [doi]
AID - 10.1007/s10728-020-00396-9 [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Sep;28(3):283-298. doi: 10.1007/s10728-020-00396-9.


PMID- 32419096
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 41
IP  - 6
DP  - 2020 Aug
TI  - Pediatric Cardiology Specialist's Opinions Toward the Acceptability of Comfort
      Care for Congenital Heart Disease.
PG  - 1160-1165
LID - 10.1007/s00246-020-02367-2 [doi]
AB  - In order to evaluate physicians' willingness to seek legal action to mandate
      surgery when parents refuse surgery for various congenital heart lesions, we
      surveyed pediatric cardiologists and cardiovascular surgeons at 4 children's
      hospitals. We asked whether physicians would support parental refusal of surgery 
      for specific heart defects and, if not, whether they would seek legal action to
      mandate surgery. We then analyzed associations between physicians' willingness to
      mandate surgery and national operative mortality rates for each lesion. We
      surveyed 126 cardiologists and 9 cardiac surgeons at four tertiary referral
      centers. Overall response rate was 77%. Greater than 70% of physicians would seek
      legal action and mandate surgery for the following lesions: ventricular septal
      defect, coarctation of the aorta, complete atrioventricular canal, transposition 
      of the great arteries, tetralogy of Fallot, and unobstructed total anomalous
      pulmonary venous return. Surgery for all of these lesions has reported mortality 
      rates of < 5%. Physicians were less likely to seek legal action when parents
      refused surgery for Shone complex, any single ventricle lesion, or any congenital
      heart disease accompanied by Trisomy 13 or Trisomy 18. Among experts in pediatric
      cardiology, there is widespread agreement about the appropriate response to
      parental refusal of surgery for most congenital heart lesions, and these lesions 
      tended to be heart defects with lower surgical mortality rates. Lesions for which
      there was greater consensus among experts were those with the best outcomes.
      There was less consensus for lesions with higher mortality rates. Such surveys,
      revealing disagreement among expert professionals, can provide an operational
      definition of the current professional "gray zone" in which parental preferences 
      should determine treatment.
FAU - Swanson, Tara M
AU  - Swanson TM
AD  - Section of Cardiology, Children's Mercy Hospital, University of Missouri-Kansas
      City School of Medicine, Kansas City, MO, USA.
FAU - Patel, Angira
AU  - Patel A
AUID- ORCID: http://orcid.org/0000-0001-6760-0340
AD  - Section of Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago,
      Northwestern University Feinberg School of Medicine, 225 E. Chicago Ave.,
      Chicago, IL, 60611, USA. anpatel@luriechildrens.org.
FAU - Baxter, Austin J
AU  - Baxter AJ
AD  - Center for Ethics, Children's Mercy Hospital, University of Missouri-Kansas City 
      School of Medicine, Kansas City, MO, USA.
FAU - Morris, Shaine A
AU  - Morris SA
AD  - Section of Cardiology, Baylor College of Medicine, Texas Children's Hospital,
      Houston, TX, USA.
FAU - Maskatia, Shiraz A
AU  - Maskatia SA
AD  - Section of Cardiology, Stanford University School of Medicine, Lucile Packard
      Children's Hospital, Stanford, CA, USA.
FAU - Lantos, John D
AU  - Lantos JD
AD  - Center for Ethics, Children's Mercy Hospital, University of Missouri-Kansas City 
      School of Medicine, Kansas City, MO, USA.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Cardiology/legislation & jurisprudence/*statistics & numerical data
MH  - Child
MH  - Heart Defects, Congenital/psychology/*surgery
MH  - Humans
MH  - Palliative Care/legislation & jurisprudence/*psychology
MH  - Parents/psychology
MH  - Surveys and Questionnaires
MH  - Treatment Refusal/legislation & jurisprudence/*psychology
OTO - NOTNLM
OT  - Comfort care
OT  - Congenital heart disease
OT  - Ethics
EDAT- 2020/05/19 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1007/s00246-020-02367-2 [doi]
AID - 10.1007/s00246-020-02367-2 [pii]
PST - ppublish
SO  - Pediatr Cardiol. 2020 Aug;41(6):1160-1165. doi: 10.1007/s00246-020-02367-2. Epub 
      2020 May 18.


PMID- 32418979
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 2093-5609 (Electronic)
IS  - 1225-505X (Linking)
VI  - 29
IP  - 1
DP  - 2020 Apr
TI  - Religious Myths and their Historical Heritage: How did Saints Cosmas and Damian
      become Patron Saints of Surgery? - From the Miracle of the Black Legs to 21st
      Century Transplant Medicine - .
PG  - 165-214
LID - 10.13081/kjmh.2020.29.165 [doi]
AB  - This paper explores the heritage and the essential significance of worship of the
      twin Christian saints -St. Cosmas and St. Damian- in the history of medicine.
      These saints are well known in Western culture as one of the leading Christian
      saints to heal diseases, whose cults have spread to Europe through Byzantium,
      which have continued to spread widely to the present, starting from areas where
      Christianity had been proselytized. Although it is true that their life journeys 
      have undergone many processes of embellishment and beautification over the course
      of time, the attributes that distinctively characterize the two saints exist
      apart from such mythical fabrications. This paper categorizes the characteristics
      of the two saints as being those of "professional doctors," "ideal doctors," and 
      "holders of healing powers" as intermediaries of God, examining how these
      characteristics came to affect various medical organizations during the era when 
      Medieval medicine was gradually transitioning toward a rational approach based on
      reason. In addition, it discusses how some of the practices of ancient temple
      medicine were transplanted into the Christian culture, the process by which it
      finally arrived at human doctors through the two saints, and how it affected the 
      establishment of professional work ethics -albeit in nascent form- as their
      medical ethics came to be accepted and practiced by the Medieval guild of
      surgeons. Furthermore, the paper considers how the existence of the two saints
      has acquired symbolism in modern medicine, which has made remarkable progress in 
      organ transplantation, and in particular, how it constitutes a significant part
      of the history of organ transplantation. It is not easy to objectify and attach
      meaning to an era that was substantially influenced by myths, legends, or
      religious events. This is because it is easy to fall into the trap of simplifying
      and passing judgment on the past based on the realities of the present day,
      without making efforts to understand the unique circumstances and contexts of the
      past. This is especially the case when the distinction between "religious events"
      and "medical events" is ambiguous, or when dealing with a social culture where
      religious influence was paramount. From a broader perspective, the study of St.
      Cosmas and St. Damian is not concerned with the rights or wrongs of religious
      myths amid the advancement of medicine and its adherence to science and reason,
      but with the attempt at a deep and broad understanding of human diseases and
      human conditions of being prone to such diseases throughout life.
FAU - Soh, Jong Seok
AU  - Soh JS
AD  - HK ("Humanities Korea") Professor, Semiosis Research Center, Hankuk University of
      Foreign Studies.
LA  - eng
GR  - Ministry of Education
GR  - 2010-361-A00013/National Research Foundation of Korea
GR  - Hankuk University of Foreign Studies
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PL  - Korea (South)
TA  - Uisahak
JT  - Ui sahak
JID - 9605018
MH  - *Attitude
MH  - General Surgery/*history
MH  - History, 15th Century
MH  - History, 16th Century
MH  - History, 17th Century
MH  - History, 18th Century
MH  - History, 19th Century
MH  - History, 20th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Mythology/*history
MH  - Organ Transplantation/*psychology
MH  - Saints/*history
PS  - Saint Cosmas
FPS - Saint Cosmas
PS  - Saint Damian
FPS - Saint Damian
OTO - NOTNLM
OT  - Anargyroi
OT  - Confrerie Saint Come
OT  - Golden Legend
OT  - Guild
OT  - Miracle of the Black Leg
OT  - Transplantation medicine
OT  - Saints Cosmas and Damian
EDAT- 2020/05/19 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/05/19 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - kjmh.2020.29.165 [pii]
AID - 10.13081/kjmh.2020.29.165 [doi]
PST - ppublish
SO  - Uisahak. 2020 Apr;29(1):165-214. doi: 10.13081/kjmh.2020.29.165.


PMID- 32418880
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20210110
IS  - 1879-4076 (Electronic)
IS  - 1879-4068 (Linking)
VI  - 11
IP  - 7
DP  - 2020 Sep
TI  - The ethics (mis)used for filling the voids or harm of harm reduction ethics.
PG  - 1168-1169
LID - S1879-4068(20)30240-X [pii]
LID - 10.1016/j.jgo.2020.05.002 [doi]
FAU - Curkovic, Marko
AU  - Curkovic M
AD  - Department for Diagnostics and Intensive Care, University Psychiatric Hospital
      Vrapce, Bolnicka cesta 32, 10 090 Zagreb, Croatia; School of Medicine, University
      of Zagreb, Salata 2, 10 000 Zagreb, Croatia. Electronic address:
      marko.curkovic@bolnica-vrapce.hr.
FAU - Kosec, Andro
AU  - Kosec A
AD  - School of Medicine, University of Zagreb, Salata 2, 10 000 Zagreb, Croatia;
      Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital 
      Center Sestre milosrdnice, Vinogradska cesta 29, 10 000 Zagreb, Croatia.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Netherlands
TA  - J Geriatr Oncol
JT  - Journal of geriatric oncology
JID - 101534770
SB  - IM
MH  - Advance Care Planning
MH  - Aged
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - *Life Support Care/ethics/methods
MH  - *Pandemics/ethics
MH  - Patient Care Planning/ethics
MH  - *Pneumonia, Viral/epidemiology
MH  - Public Health/ethics
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - *Terminal Care/ethics/methods
PMC - PMC7205650
OTO - NOTNLM
OT  - *COVID-19
OT  - *Medical ethics
OT  - *Pandemic
OT  - *Resource allocation
COIS- MC has received lecture honoraria from Lundbeck, Sandoz, Janssen, Pliva (Teva)
      and Alkaloid that are not related to the content of this manuscript. AK declare
      no compeeting interests.
EDAT- 2020/05/19 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - S1879-4068(20)30240-X [pii]
AID - 10.1016/j.jgo.2020.05.002 [doi]
PST - ppublish
SO  - J Geriatr Oncol. 2020 Sep;11(7):1168-1169. doi: 10.1016/j.jgo.2020.05.002. Epub
      2020 May 8.


PMID- 32418650
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1878-7568 (Electronic)
IS  - 1742-7061 (Linking)
VI  - 110
DP  - 2020 Jul 1
TI  - Perinatal tissues and cells in tissue engineering and regenerative medicine.
PG  - 1-14
LID - S1742-7061(20)30232-4 [pii]
LID - 10.1016/j.actbio.2020.04.035 [doi]
AB  - Perinatal tissues are an abundant source of human extracellular matrix proteins, 
      growth factors and stem cells with proved potential use in a wide range of
      therapeutic applications. Due to their placental origin, these tissues possess
      unique biological properties, including being angiogenic, anti-inflammatory,
      anti-fibrotic, anti-microbial and immune privileged. Additionally, as a temporary
      organ, placenta is usually discarded as a medical waste, thus providing an easily
      available, cost effective, 'unlimited' and ethical source of raw materials.
      Although some of these tissues, such as the amniotic membrane and umbilical cord,
      have been used in clinical practices, most of them continue to be highly under
      explored. This review aims to outline the most relevant applications of perinatal
      tissues as a source of biomaterials and stem cells in the exciting fields of
      tissue engineering and regenerative medicine (TERM), as well as highlight how
      these solutions can be used to overcome the shortage of adequate scaffolds and
      cell sources that currently hampers the translation of TERM strategies towards
      clinical settings. STATEMENT OF SIGNIFICANCE: Stem cells and extracellular matrix
      derived from perinatal tissues such as placenta and umbilical cord, have drawn
      great attention for use in a wide variety of applications in the biomedical
      field. Due to their origin, these tissues possess unique biological properties,
      including being angiogenic, anti-inflammatory, anti-fibrotic, anti-microbial and 
      immune privileged. Also they are typically considered medical waste, thus
      providing an easily available, cost effective, 'unlimited' and ethical source of 
      raw materials. This work aims to present and discuss the most relevant
      applications of perinatal tissues as a source of biomaterials and stem cells in
      the exciting fields of tissue engineering and regenerative medicine (TERM).
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Deus, Ines A
AU  - Deus IA
AD  - CICECO, Department of Chemistry, University of Aveiro, Campus Universitario de
      Santiago, 3810-193 Aveiro, Portugal.
FAU - Mano, Joao F
AU  - Mano JF
AD  - CICECO, Department of Chemistry, University of Aveiro, Campus Universitario de
      Santiago, 3810-193 Aveiro, Portugal. Electronic address: jmano@ua.pt.
FAU - Custodio, Catarina A
AU  - Custodio CA
AD  - CICECO, Department of Chemistry, University of Aveiro, Campus Universitario de
      Santiago, 3810-193 Aveiro, Portugal. Electronic address: catarinacustodio@ua.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200514
PL  - England
TA  - Acta Biomater
JT  - Acta biomaterialia
JID - 101233144
SB  - IM
MH  - Amnion
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - *Regenerative Medicine
MH  - Stem Cells
MH  - *Tissue Engineering
MH  - Umbilical Cord
OTO - NOTNLM
OT  - *Amniotic membrane
OT  - *ECM
OT  - *Perinatal tissues
OT  - *Stem cells
OT  - *Tissue engineering
OT  - *Umbilical cord
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/19 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - S1742-7061(20)30232-4 [pii]
AID - 10.1016/j.actbio.2020.04.035 [doi]
PST - ppublish
SO  - Acta Biomater. 2020 Jul 1;110:1-14. doi: 10.1016/j.actbio.2020.04.035. Epub 2020 
      May 14.


PMID- 32418501
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 7
DP  - 2020 Jun
TI  - Between Choice, Necessity, and Comfort: Deciding on Tube Feeding in the Acute
      Phase After a Severe Stroke.
PG  - 1114-1124
LID - 10.1177/1049732320911370 [doi]
AB  - This is an ethnographic study of decision-making concerning tube feeding in the
      acute phase after a severe stroke. It is based on 6 months of ethnographic
      research in three stroke units in the Netherlands, where the decision-making on
      life-sustaining treatment was studied in 16 cases of severe stroke patients. Data
      were collected through participant observation and interviews. For this article, 
      the analysis was narrowed down to the decision whether or not the patient should 
      receive tube feeding. The data on tube feeding were assembled and coded according
      to different modes of dealing with this decision in clinical practice, which we
      refer to as "repertoires." We discerned three different repertoires: choice,
      necessity, and comfort. Each repertoire structures clinical practice differently:
      It implies distinctive ethical imperatives, central concerns, sources of
      information, and temporalities. We hope our findings can improve decision-making 
      by uncovering its underlying logics in clinical practice.
FAU - Frey, Isabel
AU  - Frey I
AUID- ORCID: 0000-0001-6659-6458
AD  - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
FAU - De Boer, Marike E
AU  - De Boer ME
AD  - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
FAU - Dronkert, Leonie
AU  - Dronkert L
AD  - Universiteit van Amsterdam, Amsterdam, The Netherlands.
FAU - Pols, A Jeannette
AU  - Pols AJ
AD  - Universiteit van Amsterdam, Amsterdam, The Netherlands.
FAU - Visser, Marieke C
AU  - Visser MC
AD  - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
FAU - Hertogh, Cees M P M
AU  - Hertogh CMPM
AD  - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
FAU - Depla, Marja F I A
AU  - Depla MFIA
AD  - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - Anthropology, Cultural
MH  - Decision Making
MH  - *Enteral Nutrition
MH  - Humans
MH  - Netherlands
MH  - *Stroke
PMC - PMC7322925
OTO - NOTNLM
OT  - *end-of-life decision-making
OT  - *ethnographic research
OT  - *palliative care
OT  - *qualitative research; The Netherlands
OT  - *severe stroke
OT  - *tube feeding
EDAT- 2020/05/19 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1177/1049732320911370 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Jun;30(7):1114-1124. doi: 10.1177/1049732320911370.


PMID- 32418500
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 7
DP  - 2020 Jun
TI  - The Social Construction of a Concept-Orthorexia Nervosa: Morality Narratives and 
      Psycho-Politics.
PG  - 1101-1113
LID - 10.1177/1049732320911364 [doi]
AB  - Our article explores orthorexia nervosa (ON)-an extreme fixation with healthy
      eating-from a social construction perspective. Interviews with people
      self-identified as "obsessed" with healthy eating or having ON ("Identifiers")
      and nonmedical professionals working with ON ("Professionals") were comparatively
      analyzed, along with orthorexia threads from an eating disorder website
      ("Posters"). Participants made sense of and rationalized their attitudes and
      feelings concerning healthy eating and aligned themselves according to their
      interests. Identifiers and Posters applauded "healthy eating" and regarded
      consumption of "impure" foods as leading to ill-health. Some framed their dietary
      discipline within an ethically motivated lifestyle, while others were preoccupied
      with appearance or weight management. Professionals expressed concern for, and
      disapproval of, extreme views and behaviors in clients and parental and social
      influences supporting them. Debates surrounding orthorexic practices are tangled;
      some individuals need help, yet dangers lie in over medicalizing or "troubling"
      what may be a preferred lifestyle.
FAU - Fixsen, Alison
AU  - Fixsen A
AUID- ORCID: 0000-0002-9449-2784
AD  - University of Westminster, London, United Kingdom.
FAU - Cheshire, Anna
AU  - Cheshire A
AUID- ORCID: 0000-0001-7920-6850
AD  - University of Westminster, London, United Kingdom.
FAU - Berry, Michelle
AU  - Berry M
AD  - University of Westminster, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - Diet, Healthy
MH  - Feeding Behavior
MH  - *Feeding and Eating Disorders
MH  - Health Behavior
MH  - Humans
MH  - Life Style
MH  - Morals
MH  - Politics
MH  - Surveys and Questionnaires
PMC - PMC7411527
OTO - NOTNLM
OT  - *Internet support
OT  - *UK
OT  - *USA
OT  - *eating disorders
OT  - *health and wellbeing
OT  - *orthorexia nervosa
OT  - *qualitative
OT  - *social constructionism
OT  - *triangulation
EDAT- 2020/05/19 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1177/1049732320911364 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Jun;30(7):1101-1113. doi: 10.1177/1049732320911364.


PMID- 32418472
OWN - NLM
STAT- MEDLINE
DCOM- 20210812
LR  - 20210812
IS  - 1552-5724 (Electronic)
IS  - 0898-0101 (Linking)
VI  - 38
IP  - 4
DP  - 2020 Dec
TI  - Meaning and Affecting Factors of Spirituality in Adolescents.
PG  - 362-372
LID - 10.1177/0898010120920501 [doi]
AB  - Purpose: The aim of this study was to explore the perceptions of adolescents
      about spirituality via semistructured, in-depth interviews. Method/Design: A
      qualitative research design using interviews was performed with 17 adolescents in
      a mostly Muslim region in Turkey. Interviews were conducted via five open-ended
      questions. Findings: Three main categories and eight themes emerged from the
      analysis. The "Spirituality Meaning" category included five themes, such as mind,
      emotions, mind/emotions, ethical principles, and religion. Personal practices and
      environmental factors as well as mind, emotions, ethical principles, and religion
      themes were in the "Factors That Increase Spirituality" category. The theme
      living negativity was in the "Factors That Decrease Spirituality" category. Most 
      of the adolescents (58.8%) stated that the meaning of spirituality was love,
      respect, and the ability to think, analyze, and synthesize. Conclusion: It is
      important to determine and evaluate the perceptions and experiences of children
      about spirituality in different cultures to improve the quality of care.
FAU - Kilicarslan Toruner, Ebru
AU  - Kilicarslan Toruner E
AUID- ORCID: https://orcid.org/0000-0002-3358-7616
FAU - Altay, Naime
AU  - Altay N
AD  - Gazi University.
FAU - Ceylan, Cigdem
AU  - Ceylan C
AD  - Abant Izzet Baysal University.
FAU - Arpaci, Tuba
AU  - Arpaci T
FAU - Sari, Cigdem
AU  - Sari C
AD  - Gazi University.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - United States
TA  - J Holist Nurs
JT  - Journal of holistic nursing : official journal of the American Holistic Nurses'
      Association
JID - 8506709
MH  - *Adaptation, Psychological
MH  - Adolescent
MH  - Adolescent Behavior/*psychology
MH  - Female
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Male
MH  - Qualitative Research
MH  - *Spirituality
OTO - NOTNLM
OT  - adolescent
OT  - nursing
OT  - perspective
OT  - spirituality
OT  - view
EDAT- 2020/05/19 06:00
MHDA- 2021/08/13 06:00
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/08/13 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
AID - 10.1177/0898010120920501 [doi]
PST - ppublish
SO  - J Holist Nurs. 2020 Dec;38(4):362-372. doi: 10.1177/0898010120920501. Epub 2020
      May 18.


PMID- 32418194
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20201218
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 150
DP  - 2020 May 4
TI  - Digital health and the COVID-19 epidemic: an assessment framework for apps from
      an epidemiological and legal perspective.
PG  - w20282
LID - 10.4414/smw.2020.20282 [doi]
LID - Swiss Med Wkly. 2020;150:w20282 [pii]
AB  - As COVID-19 spreads across the globe, crowdsourced digital technology harbours
      the potential to improve surveillance and epidemic control, primarily through
      increased information coverage, higher information speed, fast case tracking and 
      improved proximity tracing. Targeting those aims, COVID-19-related smartphone and
      web-based health applications are continuously emerging, leading to a multitude
      of options, raising ethical and legal challenges and potentially overwhelming end
      users. Building on an existing trustworthiness checklist for digital health
      applications, we searched the literature and developed a framework to guide the
      assessment of smartphone and web-based applications that aim to contribute to
      controlling the current epidemic or mitigating its effects. It further integrates
      epidemiological subject knowledge and a legal analysis, outlining the mechanisms 
      through which new applications can support the fight against COVID-19. The
      resulting framework includes 40 questions across 8 domains on
      &ldquo;purpose&rdquo;, &ldquo;usability&rdquo;, &ldquo;information
      accuracy&rdquo;, &ldquo;organisational attributes / reputation&rdquo;,
      &ldquo;transparency&rdquo;, &ldquo;privacy&rdquo; and &ldquo;user control /
      self-determination&rdquo;. All questions should be primarily answerable from
      publicly available data, as provided by application manufacturers. The framework 
      aims to guide end users in choosing a transparent, safe and valuable application 
      and suggests a set of information items that developers ideally make available to
      allow a balanced judgement and facilitate the trustworthiness of their products.
FAU - Vokinger, Kerstin Noelle
AU  - Vokinger KN
AD  - Faculty of Law, University of Zurich, Switzerland.
FAU - Nittas, Vasileios
AU  - Nittas V
AD  - Epidemiology, Biostatistics and Prevention Institute, University of Zurich,
      Switzerland.
FAU - Witt, Claudia M
AU  - Witt CM
AD  - Institute for Complementary and Integrative Medicine, University Hospital Zurich,
      Switzerland.
FAU - Fabrikant, Sara Irina
AU  - Fabrikant SI
AD  - Department of Geography, University of Zurich, Switzerland.
FAU - von Wyl, Viktor
AU  - von Wyl V
AD  - Epidemiology, Biostatistics and Prevention Institute, University of Zurich,
      Switzerland / Institute for Implementation Science in Health Care, University of 
      Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200517
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Checklist/*standards
MH  - Contact Tracing
MH  - *Coronavirus
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - Geographic Information Systems
MH  - Humans
MH  - Medical Informatics Applications
MH  - *Mobile Applications
MH  - Pandemics/*prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - Privacy
MH  - SARS-CoV-2
MH  - *Smartphone
MH  - *Telemedicine
EDAT- 2020/05/18 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
AID - 10.4414/smw.2020.20282 [doi]
AID - Swiss Med Wkly. 2020;150:w20282 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2020 May 17;150:w20282. doi: 10.4414/smw.2020.20282. eCollection 
      2020 May 4.


PMID- 32417870
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20201210
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 224
DP  - 2020 Apr 30
TI  - Combating COVID-19 Pandemic in Nepal: Ethical Challenges in an Outbreak.
PG  - 276-279
LID - 10.31729/jnma.4959 [doi]
AB  - Pandemic outbreak of COVID-19 is the largest of its kind of this century. All
      countries throughout the globe are trying their best to contain the disease and
      eliminate at the earliest. Efforts are continuing to improve the outcome of the
      infection in terms of minimizing the morbidity and mortality. As a public health 
      strategy every state has the responsibility of protecting the health of the
      community and such measures includes the preventive measures like social
      distancing or even lockdown of the state as a whole restricting the movement of
      the people, diagnostic measures like testing the suspects, contact tracing and
      isolation of the patients. Treatment of the infected requires decisions in
      resource constraint situation particularly ICU beds and ventilators. In the
      meantime, protecting doctors, nurses, other health workers as well as frontline
      workers need personal protective equipment which is a scarce commodity. While
      doing so there might be a compromise in the individual autonomy, privacy,
      confidentiality, and social justice for the beneficence for the larger community.
      This is an attempt to explore the ethical quandaries in relation to combating
      COVID-19 in Nepal by relating the issues with the principles of biomedical
      ethics.
FAU - Shah, Aarati
AU  - Shah A
AD  - Medical Education Commission, Sanothimi, Bhaktapur, Nepal.
FAU - Aacharya, Ramesh Prasad
AU  - Aacharya RP
AD  - Medical Education Commission, Sanothimi, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques/*ethics
MH  - *Coronavirus
MH  - *Coronavirus Infections/diagnosis/drug therapy/epidemiology/prevention &
      control/therapy
MH  - Decision Making
MH  - Delivery of Health Care/*ethics
MH  - Disaster Planning
MH  - Humans
MH  - Nepal/epidemiology
MH  - Pandemics/*ethics/prevention & control
MH  - *Pneumonia, Viral/diagnosis/epidemiology/prevention & control/therapy
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/supply & distribution
PMC - PMC7580455
OTO - NOTNLM
OT  - COVID-19; ethics; public health; strategy.
EDAT- 2020/05/18 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
AID - 10.31729/jnma.4959 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Apr 30;58(224):276-279. doi: 10.31729/jnma.4959.


PMID- 32417858
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 224
DP  - 2020 Apr 30
TI  - Utilization of Pre-Anesthetic Medications for Major Surgical Procedures at a
      Tertiary Care Center: A Descriptive Cross-sectional Study.
PG  - 223-229
LID - 10.31729/jnma.4841 [doi]
AB  - INTRODUCTION: Drug utilization research is an important tool to analyze the use
      of drugs with special emphasis on medical, social, and economic consequences in
      society. This study aims to find out the utilization of pre-anesthetic
      medications in a major surgical procedure. METHODS: A descriptive cross-sectional
      study was conducted from 15th April - 15th August 2019 in the postoperative ward 
      at Birat Medical College and Teaching Hospital. The convenience sampling method
      was used after ethical clearance from the Institutional Review Committee (IRC) of
      Birat Medical College and Teaching Hospital, Biratnagar, Nepal. About 400
      patients were studied. The collected data were entered into a statistical package
      for social science version 20 for further calculations at 95% Confidence
      Interval. RESULTS: Out of 400 patients, 215 (53.8%) of patients were underwent
      into different major surgeries. All patients received midazolam 2 mg except
      children (1 mg) and Pethidine 25 mg along with 0.2 mg glycopyrrolate 352 (88%),
      ondansetron 276 (69%) and others 58 (14.5%) as a preanesthetic agent. For general
      anesthesia propofol, 30 mg have been utilized followed by fentanyl 306 (76.5%)
      and others (halothane, isoflurane, etc) 115 (28.8%). In case of prophylactic drug
      were ceftriaxone 500 mg, 100 mg metoclopramide 387 (96.8%), dexamethasone 251
      (62.8%), tramadol 237 (59.3%), 15 mg ketorolac 368 (92%), ranitidine 163 (40.8%),
      and pantoprazole 237 (59.3%). CONCLUSIONS: The most commonly administered
      pre-anesthetic drugs were midazolam, pethidine, glycopyrrolate, and ondansetron. 
      The incidence of postoperative nausea and vomiting the patient within 24 hours
      after surgery was significantly very low.
FAU - Shah, Rekha
AU  - Shah R
AD  - Department of Pharmacology,Birat Medical College, Biratnagar, Nepal.
FAU - Pradhan, Roshan
AU  - Pradhan R
AD  - Department of Anesthesiology,Birat Medical College, Biratnagar, Nepal.
FAU - Shah, Arbindra
AU  - Shah A
AD  - Department of Radiology, Nobel Medical College, Biratnagar, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Anesthetics)
RN  - 0 (Antiemetics)
RN  - 0 (Central Nervous System Agents)
RN  - 0 (Central Nervous System Depressants)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anesthetics/administration & dosage
MH  - *Antiemetics/administration & dosage
MH  - Central Nervous System Agents/administration & dosage
MH  - Central Nervous System Depressants/administration & dosage
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal
MH  - Postoperative Nausea and Vomiting/etiology/*prevention & control
MH  - *Preanesthetic Medication
MH  - Surgical Procedures, Operative
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7580468
OTO - NOTNLM
OT  - pre-anesthetic medications; surgical procedures; utilization.
EDAT- 2020/05/18 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4841 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Apr 30;58(224):223-229. doi: 10.31729/jnma.4841.


PMID- 32417857
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 224
DP  - 2020 Apr 30
TI  - Histopathological Study of Skin Lesions in a Tertiary Care Hospital: A
      Descriptive Cross-sectional Study.
PG  - 218-222
LID - 10.31729/jnma.4799 [doi]
AB  - INTRODUCTION: Skin diseases are much common in developing countries. The spectrum
      varies according to geographic distribution, gender, age, and coexisting
      disorder. We conducted this study to find out the prevalence of different skin
      lesions and to evaluate their frequency and site of distribution. METHODS: A
      descriptive cross-sectional study was done in the pathology department of
      Kathmandu Medical college from June 2019 to November 2019 after ethical
      clearance. The skin biopsies were processed, sectioned and stained with
      Haematoxylin and eosin and evaluated. A convenience sampling method was used.
      Data was collected and entry was done in Statistical Packages for Social Services
      version 20.0, point estimate at 95% Confidence Interval was calculated along with
      frequency and proportion for binary data. RESULTS: Among 133 skin biopsies
      examined, noninfectious vesicobullous and vesicopustular disease were found in 42
      (46.6%) cases followed by microbial disease in 22 (24.5%) and noninfectious
      erythematous papular and squamous disease in 21 (23.4%) cases. Spongiotic
      dermatitis was the most common vesicobullous disease seen in 26 (28.9%) cases.
      Leprosy was the commonest microbial disease found in 7 (7.8%) cases. The
      commonest noninfectious erythematous papular and squamous disease was erythema
      dyschromicum perstans seen in 7 (7.8%) cases. The commonest neoplastic lesion was
      keratinocytic tumor seen in 12 (32.5%) cases. The commonest tumor of the skin was
      intradermal nevus seen in 6 (16.3%) cases. CONCLUSIONS: Spongiotic dermatitis is 
      a predominating non-neoplastic and overall skin lesion which was similar to the
      other studies done. Histopathological examination is the gold standard for the
      proper diagnosis as histomorphological features distinguish various skin lesions.
FAU - Chalise, Sanat
AU  - Chalise S
AD  - Department of Pathology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Dhakhwa, Ramesh
AU  - Dhakhwa R
AD  - Department of Pathology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
FAU - Pradhan, Sailesh Bahadur
AU  - Pradhan SB
AD  - Department of Pathology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Biopsy/statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Dermatitis/epidemiology/etiology/pathology
MH  - Epidermis/pathology
MH  - *Erythema/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - *Skin/pathology
MH  - Skin Diseases/*epidemiology/etiology/*pathology
MH  - Tertiary Care Centers/statistics & numerical data
PMC - PMC7580462
OTO - NOTNLM
OT  - dermatitis; papular; tumors.
EDAT- 2020/05/18 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4799 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Apr 30;58(224):218-222. doi: 10.31729/jnma.4799.


PMID- 32417856
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 224
DP  - 2020 Apr 30
TI  - Sensitivity of Sinus Radiography Compared to Computed Tomogram: A Descriptive
      Cross-sectional Study from Western Region of Nepal.
PG  - 214-217
LID - 10.31729/jnma.4824 [doi]
AB  - INTRODUCTION: Radiography of the paranasal sinuses is commonly used diagnostic
      modality. However, the trustworthiness of plain radiographic findings of
      paranasal sinuses is debatable. The intention of this study was to weigh the
      diagnostic soundness of plain radiograph of the paranasal sinuses to that of
      computed tomogram scan. METHODS: This is a descriptive cross sectional study
      carried out in 110 participants in Department of Radiology of Gandaki Medical
      College from November 2017 to April 2018. Ethical approval is obtained from
      Institution review board (Ref. No.39/074/075). Sample size was calculated taking 
      confidence level of 95%, expected prevalence of 14% and precision of 6.5% in
      population of 492098 in Province 4 of Nepal. Random sampling method was used.
      Data was enter in Statistical Package for the Social Sciences version 17 software
      and analysed. RESULTS: A total of 110 participants are included in this study of 
      which 62 (56.4%) are females and 48 (43.6%) are males with an overall mean age of
      34.5 years. The commonly involved sinus was maxillary 56 (50.9%) followed by
      ethmoid 33 (30%) sinus. The overall sensitivity and specificity of detecting
      sinusitis by sinus radiography is higher for maxillary sinus (89.7% and 87%)
      followed by ethmoid (69.7% and 96.1%) and frontal (61.5% and 96.9%) sinuses.
      CONCLUSIONS: Sinus radiography is more sensitive for detecting pathologies in
      maxillary sinuses, while it is moderate for frontal, ethmoid sinuses and least
      for sphenoid sinuses. Diagnostic accuracy of computed tomogram scan is more,
      hence should be recommended to characterize the complex pathology and anatomy of 
      the osteomeatal complex.
FAU - Shrestha, Manish Kiran
AU  - Shrestha MK
AD  - Department of Radiology, Gandaki Medical College Teaching Hospital, Pokhara,
      Nepal.
FAU - Ghartimagar, Dilasma
AU  - Ghartimagar D
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Ghosh, Arnab
AU  - Ghosh A
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
FAU - Jhunjhunwala, Adarsh Kumar
AU  - Jhunjhunwala AK
AD  - Department of Pathology, Manipal College of Medical Science, Pokhara, Nepal.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200430
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal
MH  - *Paranasal Sinuses/diagnostic imaging
MH  - Sensitivity and Specificity
MH  - *Tomography, X-Ray Computed
MH  - Young Adult
PMC - PMC7580457
OTO - NOTNLM
OT  - computed tomography; maxillary; radiography; sinusitis.
EDAT- 2020/05/18 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4824 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Apr 30;58(224):214-217. doi: 10.31729/jnma.4824.


PMID- 32417855
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 224
DP  - 2020 Apr 30
TI  - Prevalence of Self-medication Practices for Oral Health Problems among Dental
      Patients in a dental college: A Descriptive Cross-sectional Study.
PG  - 209-213
LID - 10.31729/jnma.4866 [doi]
AB  - INTRODUCTION: Self-medication means the use of medications for the treatment of
      any disease on their own, without consulting any healthcare professional. At
      times self-medication can be useful if practiced correctly by saving time and
      money, whereas disadvantages often occur due to lack of evaluation by trained
      medical professionals and delay ineffective treatment and can result in
      unnecessary expenses and drug dependence. This study was conducted to find out
      the self-medication behavior and its associated factors among patients visiting a
      dental hospital in Kathmandu. METHODS: A hospital-based, cross-sectional study
      was conducted on 265 patients in Kantipur Dental College from December 2019 to
      January 2020 among the patients attending the dental Out Patient Department.
      Ethical clearance was obtained from the Institutional Review Committee of
      Kantipur Dental College. A convenience sampling technique was used. Proformas
      were prepared in English, translated to Nepali and re-translated to English by
      the back-translation method. Data entry was done in Microsoft Excel and analysis 
      in SPSS 20. Descriptive statistics was done. RESULTS: The prevalence of
      self-medication practice was found to be 166 (62.6%). Out of total participants, 
      99 (59.6%) consumed medicines for few days only and the most common triggering
      factor was found to be toothache in 101 (60.8%) participants. The most common
      reason for selfmedication was found to be a previous experience of treating
      similar illnesses. CONCLUSIONS: The prevalence of self-medication was found to be
      low as compared to the study done in similar settings. Self-medication practice
      is a sensitive issue that hasn't been given the required consideration.
FAU - Bhattarai, Rosina
AU  - Bhattarai R
AD  - Department of Community Dentistry, College of Medical Sciences, Bharatpur,
      Chitwan, Nepal.
FAU - Khanal, Sunita
AU  - Khanal S
AD  - Department of Community Dentistry, Kantipur Dental College, Dhapasi, Kathmandu,
      Nepal.
FAU - Shrestha, Sujita
AU  - Shrestha S
AD  - Department of Community Dentistry, Kantipur Dental College, Dhapasi, Kathmandu,
      Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - *Oral Health/statistics & numerical data
MH  - Prevalence
MH  - *Self Medication/statistics & numerical data
MH  - Stomatognathic Diseases/epidemiology/therapy
MH  - Toothache/epidemiology/*therapy
MH  - Universities/statistics & numerical data
MH  - Young Adult
PMC - PMC7580453
OTO - NOTNLM
OT  - oral health; prescription drugs; self medication
EDAT- 2020/05/18 06:00
MHDA- 2021/05/14 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
AID - 10.31729/jnma.4866 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Apr 30;58(224):209-213. doi: 10.31729/jnma.4866.


PMID- 32417646
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 222
DP  - 2020 Aug 1
TI  - Policies to reduce food insecurity: An ethical imperative.
PG  - 112943
LID - S0031-9384(20)30257-2 [pii]
LID - 10.1016/j.physbeh.2020.112943 [doi]
AB  - A quarter of U.S. households receive food assistance, yet more than 11% still
      experience food insecurity annually. We argue that an expansion-oriented approach
      to food and nutrition assistance policy is an ethical imperative. Drawing on
      values from the Capability Approach and Social Empathy Model and supported by
      empirical evidence, we propose an ethical framework characterized by four
      principles that can be used to assess and inform the development of just food
      policies. We argue that policies should (1) embrace compassion, (2) create
      opportunity, (3) consider essential needs, and (4) promote knowledge and empathy.
      In an applied case, we evaluate current SNAP policy in terms of those principles 
      and offer recommendations to promote justice in the design and implementation of 
      SNAP and other food policies.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Miller, Daniel P
AU  - Miller DP
AD  - Boston University School of Social Work, 264 Bay State Road, Boston, MA 02215,
      U.S.. Electronic address: dpmiller@bu.edu.
FAU - Thomas, Margaret M C
AU  - Thomas MMC
AD  - Boston University School of Social Work, 264 Bay State Road, Boston, MA 02215,
      U.S.. Electronic address: mthomas7@bu.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200514
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
MH  - Family Characteristics
MH  - *Food Assistance
MH  - Food Insecurity
MH  - *Food Supply
MH  - Policy
PMC - PMC7255147
OTO - NOTNLM
OT  - *Capability approach
OT  - *Ethics
OT  - *Food and nutrition assistance
OT  - *Food insecurity
OT  - *SNAP
OT  - *Social work
EDAT- 2020/05/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/18 06:00
PHST- 2019/10/24 00:00 [received]
PHST- 2020/04/26 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/18 06:00 [entrez]
AID - S0031-9384(20)30257-2 [pii]
AID - 10.1016/j.physbeh.2020.112943 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Aug 1;222:112943. doi: 10.1016/j.physbeh.2020.112943. Epub
      2020 May 14.


PMID- 32417199
OWN - NLM
STAT- MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 1472-6491 (Electronic)
IS  - 1472-6483 (Linking)
VI  - 40
IP  - 6
DP  - 2020 Jun
TI  - Is cell-free DNA in spent embryo culture medium an alternative to embryo biopsy
      for preimplantation genetic testing? A systematic review.
PG  - 779-796
LID - S1472-6483(20)30088-2 [pii]
LID - 10.1016/j.rbmo.2020.02.002 [doi]
AB  - Preimplantation genetic testing (PGT) is increasingly used worldwide. It
      currently entails the use of invasive techniques, i.e. polar body, blastomere,
      trophectoderm biopsy or blastocentesis, to obtain embryonic DNA, with major
      technical limitations and ethical issues. Evidence suggests that invasive PGT can
      lead to genetic misdiagnosis in the case of embryo mosaicism, and, consequently, 
      to the selection of affected embryos for implantation or to the destruction of
      healthy embryos. Recently, spent culture medium (SCM) has been proposed as an
      alternative source of embryonic DNA. An increasing number of studies have
      reported the detection of cell-free DNA in SCM and highlighted the diagnostic
      potential of non-invasive SCM-based PGT for assessing the genetic status of
      preimplantation human embryos obtained by IVF. The reliability of this approach
      for clinical applications, however, needs to be determined. In this systematic
      review, published evidence on non-invasive SCM-based PGT is presented, and its
      current benefits and limitations compared with invasive PGT. Then, ways of
      optimizing and standardizing procedures for non-invasive SCM-based PGT to prevent
      technical biases and to improve performance in future studies are discussed.
      Finally, clinical perspectives of non-invasive PGT are presented and its future
      applications in reproductive medicine highlighted.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Brouillet, Sophie
AU  - Brouillet S
AD  - Universite Grenoble-Alpes, Inserm 1036, Commissariat a l'energie atomique et aux 
      energies alternatives (CEA), Institut de Biosciences et Biotechnologies de
      Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), Grenoble 
      38000, France; Centre Hospitalier Universitaire de Grenoble, Hopital
      Couple-Enfant, Centre Clinique et Biologique d'Assistance Medicale a la
      Procreation- Centre d'etude et de conservation des oeufs et du sperme humains
      (CECOS), La Tronche 38700, France; INSERM U1203, Equipe "Developpement
      Embryonnaire Precoce Humain et Pluripotence", Institut de Medecine Regeneratrice 
      et de Biotherapie, Hopital Saint-Eloi, Montpellier 34295, France.
FAU - Martinez, Guillaume
AU  - Martinez G
AD  - Universite Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB),
      equipe Genetique Epigenetique et Therapie de l'Infertilite (GETI), Grenoble
      38000, France; Centre Hospitalier Universitaire de Grenoble, Hopital Couple
      Enfant, Departement de Genetique et Procreation, Laboratoire de Genetique
      Chromosomique, La Tronche 38700, France.
FAU - Coutton, Charles
AU  - Coutton C
AD  - Universite Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB),
      equipe Genetique Epigenetique et Therapie de l'Infertilite (GETI), Grenoble
      38000, France; Centre Hospitalier Universitaire de Grenoble, Hopital Couple
      Enfant, Departement de Genetique et Procreation, Laboratoire de Genetique
      Chromosomique, La Tronche 38700, France.
FAU - Hamamah, Samir
AU  - Hamamah S
AD  - INSERM U1203, Equipe "Developpement Embryonnaire Precoce Humain et Pluripotence",
      Institut de Medecine Regeneratrice et de Biotherapie, Hopital Saint-Eloi,
      Montpellier 34295, France; CHU Montpellier, ART/PGD Division, Hopital Arnaud de
      Villeneuve, Montpellier, Cedex 5, Montpellier 34295, France. Electronic address: 
      s-hamamah@chu-montpellier.fr.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200220
PL  - Netherlands
TA  - Reprod Biomed Online
JT  - Reproductive biomedicine online
JID - 101122473
RN  - 0 (Cell-Free Nucleic Acids)
RN  - 0 (Culture Media)
SB  - IM
MH  - *Cell-Free Nucleic Acids
MH  - *Culture Media
MH  - Embryo Culture Techniques
MH  - Female
MH  - Genetic Testing/*methods
MH  - Humans
MH  - Pregnancy
MH  - Preimplantation Diagnosis/*methods
OTO - NOTNLM
OT  - Embryo
OT  - Non-invasive
OT  - Preimplantation genetic testing
OT  - Screening
OT  - Spent culture medium
EDAT- 2020/05/18 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/05/18 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2020/01/29 00:00 [revised]
PHST- 2020/02/02 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
PHST- 2020/05/18 06:00 [entrez]
AID - S1472-6483(20)30088-2 [pii]
AID - 10.1016/j.rbmo.2020.02.002 [doi]
PST - ppublish
SO  - Reprod Biomed Online. 2020 Jun;40(6):779-796. doi: 10.1016/j.rbmo.2020.02.002.
      Epub 2020 Feb 20.


PMID- 32416993
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20210110
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 1
DP  - 2020 Jul
TI  - Implementing shared ventilation must be scientific and ethical, or it risks harm.
PG  - e181-e183
LID - S0007-0912(20)30276-2 [pii]
LID - 10.1016/j.bja.2020.04.061 [doi]
FAU - Cook, Daniel C
AU  - Cook DC
AD  - New York, NY, USA. Electronic address: dcc2005@med.cornell.edu.
LA  - eng
PT  - Letter
PT  - Review
DEP - 20200427
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*therapy
MH  - Resource Allocation/*ethics/*methods
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/*ethics
PMC - PMC7183957
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *co-ventilation
OT  - *critical care
OT  - *medical ethics
OT  - *resource allocation
OT  - *shared ventilation
OT  - *ventilator
EDAT- 2020/05/18 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
PHST- 2020/05/18 06:00 [entrez]
AID - S0007-0912(20)30276-2 [pii]
AID - 10.1016/j.bja.2020.04.061 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Jul;125(1):e181-e183. doi: 10.1016/j.bja.2020.04.061. Epub
      2020 Apr 27.


PMID- 32416984
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20210110
IS  - 1879-1409 (Electronic)
IS  - 0305-4179 (Linking)
VI  - 46
IP  - 5
DP  - 2020 Aug
TI  - Burn center function during the COVID-19 pandemic: An international multi-center 
      report of strategy and experience.
PG  - 1021-1035
LID - S0305-4179(20)30274-6 [pii]
LID - 10.1016/j.burns.2020.04.003 [doi]
AB  - The novel coronavirus, SARS-CO V2 responsible for COVID-19 pandemic is rapidly
      escalating across the globe. Burn centers gearing for the pandemic must strike a 
      balance between contributing to the pandemic response and preserving ongoing burn
      care in a safe and ethical fashion. The authors of the present communication
      represent seven burn centers from China, Singapore, Japan, Italy, Spain, the
      United Kingdom (UK), and the United States (US). Each center is located at a
      different point along the pandemic curve and serves different patient populations
      within their healthcare systems. We review our experience with the virus to date,
      our strategic approach to burn center function under these circumstances, and
      lessons learned. The purpose of this communication is to share experiences that
      will assist with continued preparations to help burn centers advocate for optimum
      burn care and overcome challenges as this pandemic continues.
CI  - Copyright (c) 2020 Elsevier Ltd and ISBI. All rights reserved.
FAU - Barret, Juan P
AU  - Barret JP
AD  - Department of Plastic Surgery and Burns, Hospital Universitari Vall d'Hebron,
      Department of Surgery, School of Medicine, Universitat Autonoma de Barcelona,
      Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain. Electronic address: 
      jpbarret@vhebron.net.
FAU - Chong, Si Jack
AU  - Chong SJ
AD  - Department of Plastic Reconstructive and Aesthetic surgery, Singapore General
      Hospital, Academia 20 College Road, Singapore 169856, Singapore. Electronic
      address: chong_si_jack@hotmail.com.
FAU - Depetris, Nadia
AU  - Depetris N
AD  - Anaesthesia and Intensive Care, Citta della Salute di Torino, corso Bramante,
      88-10126, Torino, Italy. Electronic address: nadia.depetris@gmail.com.
FAU - Fisher, Mark D
AU  - Fisher MD
AD  - Division of Plastics and Reconstructive Surgery, Department of Surgery,
      University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52240 
      USA. Electronic address: mark-d-fisher@uiowa.edu.
FAU - Luo, Gaoxing
AU  - Luo G
AD  - Institute of Burn Research, Southwest Hospital Army (Third Military) Medical
      University, Chongqing 400038, China. Electronic address: logxw@yahoo.com.
FAU - Moiemen, Naiem
AU  - Moiemen N
AD  - University Hospitals Birmingham Foundation Trust, (Heritage Building) Queen
      Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2TH, UK. Electronic
      address: nmoiemen@aol.com.
FAU - Pham, Tam
AU  - Pham T
AD  - Harborview Medical Center, 325 Ninth Ave, Box 359796, Seattle, WA, USA.
      Electronic address: tpham94@uw.edu.
FAU - Qiao, Liang
AU  - Qiao L
AD  - Department of Burn and Plastic Surgery, Ruijin Hospital, School of Medicine,
      Shanghai Jiaotong University, 197 Ruijin Er Road, Shanghai 200025, China.
      Electronic address: ql10727@rjh.com.cn.
FAU - Wibbenmeyer, Lucy
AU  - Wibbenmeyer L
AD  - Division of Acute Care Surgery, Department of Surgery, University of Iowa
      Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, USA. Electronic address:
      lucy-wibbenmeyer@uiowa.edu.
FAU - Matsumura, Hajime
AU  - Matsumura H
AD  - Department of Plastic and Reconstructive Surgery, Tokyo Medical University, 6-7-1
      Nishishinjyuku, Shinjukuku, Tokyo, 160-0023, JAPAN. Electronic address:
      hmatsu-tki@umin.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200410
PL  - Netherlands
TA  - Burns
JT  - Burns : journal of the International Society for Burn Injuries
JID - 8913178
SB  - IM
MH  - Betacoronavirus
MH  - *Burn Units
MH  - Burns/*therapy
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Care/methods
MH  - *Delivery of Health Care
MH  - *Health Resources
MH  - Health Workforce
MH  - Humans
MH  - Infection Control/methods
MH  - Internationality
MH  - Italy/epidemiology
MH  - Japan/epidemiology
MH  - Pandemics
MH  - Personal Protective Equipment
MH  - Personnel Staffing and Scheduling/organization & administration
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Singapore/epidemiology
MH  - Spain/epidemiology
MH  - Surgical Procedures, Operative
MH  - Telemedicine/methods
MH  - United Kingdom/epidemiology
MH  - United States/epidemiology
PMC - PMC7151262
OTO - NOTNLM
OT  - *Austere conditions
OT  - *Burn surgery
OT  - *COVID-19
OT  - *Critical care
OT  - *SARS-COV2
EDAT- 2020/05/18 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/05/18 06:00 [entrez]
AID - S0305-4179(20)30274-6 [pii]
AID - 10.1016/j.burns.2020.04.003 [doi]
PST - ppublish
SO  - Burns. 2020 Aug;46(5):1021-1035. doi: 10.1016/j.burns.2020.04.003. Epub 2020 Apr 
      10.


PMID- 32416782
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20210110
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10236
DP  - 2020 May 16
TI  - Artificial intelligence and the future of global health.
PG  - 1579-1586
LID - S0140-6736(20)30226-9 [pii]
LID - 10.1016/S0140-6736(20)30226-9 [doi]
AB  - Concurrent advances in information technology infrastructure and mobile computing
      power in many low and middle-income countries (LMICs) have raised hopes that
      artificial intelligence (AI) might help to address challenges unique to the field
      of global health and accelerate achievement of the health-related sustainable
      development goals. A series of fundamental questions have been raised about
      AI-driven health interventions, and whether the tools, methods, and protections
      traditionally used to make ethical and evidence-based decisions about new
      technologies can be applied to AI. Deployment of AI has already begun for a broad
      range of health issues common to LMICs, with interventions focused primarily on
      communicable diseases, including tuberculosis and malaria. Types of AI vary, but 
      most use some form of machine learning or signal processing. Several types of
      machine learning methods are frequently used together, as is machine learning
      with other approaches, most often signal processing. AI-driven health
      interventions fit into four categories relevant to global health researchers: (1)
      diagnosis, (2) patient morbidity or mortality risk assessment, (3) disease
      outbreak prediction and surveillance, and (4) health policy and planning.
      However, much of the AI-driven intervention research in global health does not
      describe ethical, regulatory, or practical considerations required for widespread
      use or deployment at scale. Despite the field remaining nascent, AI-driven health
      interventions could lead to improved health outcomes in LMICs. Although some
      challenges of developing and deploying these interventions might not be unique to
      these settings, the global health community will need to work quickly to
      establish guidelines for development, testing, and use, and develop a user-driven
      research agenda to facilitate equitable and ethical use.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Schwalbe, Nina
AU  - Schwalbe N
AD  - Heilbrunn Department of Population and Family Health, Columbia Mailman School of 
      Public Health, New York, NY, USA; Spark Street Advisors, New York, NY, USA.
      Electronic address: nschwalbe@ssc.nyc.
FAU - Wahl, Brian
AU  - Wahl B
AD  - Spark Street Advisors, New York, NY, USA; Department of International Health,
      Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - IM
MH  - *Artificial Intelligence
MH  - Disease Outbreaks/prevention & control
MH  - Global Health/*trends
MH  - Health Policy
MH  - Humans
MH  - Risk Assessment
PMC - PMC7255280
EDAT- 2020/05/18 06:00
MHDA- 2020/05/28 06:00
CRDT- 2020/05/18 06:00
PHST- 2019/07/21 00:00 [received]
PHST- 2020/01/21 00:00 [revised]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
AID - S0140-6736(20)30226-9 [pii]
AID - 10.1016/S0140-6736(20)30226-9 [doi]
PST - ppublish
SO  - Lancet. 2020 May 16;395(10236):1579-1586. doi: 10.1016/S0140-6736(20)30226-9.


PMID- 32416751
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 1646-0758 (Electronic)
IS  - 0870-399X (Linking)
VI  - 33
IP  - 5
DP  - 2020 May 4
TI  - [Ethics Committees in Portugal: Old and New Challenges].
PG  - 295-296
LID - 10.20344/amp.13709 [doi]
FAU - Massano, Joao
AU  - Massano J
AD  - Servico de Neurologia e Unidade de Investigacao. Centro Hospitalar Universitario 
      de Sao Joao. Porto; Departamento de Neurociencias Clinicas e Saude Mental.
      Faculdade de Medicina. Universidade do Porto. Porto; Unidade de Investigacao e
      Desenvolvimento Cardiovascular (UnIC). Faculdade de Medicina. Universidade do
      Porto. Porto. Portugal.
FAU - Almeida, Filipe Nuno
AU  - Almeida FN
AD  - Comissao de Etica para a Saude. Centro Hospitalar Universitario de Sao Joao e
      Faculdade de Medicina. Universidade do Porto. Porto. Servico de Humanizacao.
      Centro Hospitalar Universitario de Sao Joao. Porto. Departamento de Ciencias de
      Saude Publica e Forenses e Educacao Medica. Faculdade de Medicina. Universidade
      do Porto. Porto. Portugal.
LA  - por
PT  - Editorial
TT  - Comissoes de Etica em Portugal: Velhos e Novos Desafios.
DEP - 20200504
PL  - Portugal
TA  - Acta Med Port
JT  - Acta medica portuguesa
JID - 7906803
SB  - IM
MH  - Betacoronavirus
MH  - Bioethical Issues/legislation & jurisprudence
MH  - Biomedical Research/ethics/*legislation & jurisprudence
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - Ethics Committees/*legislation & jurisprudence/organization &
      administration/trends
MH  - Ethics, Research
MH  - Human Experimentation/ethics/*legislation & jurisprudence
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology
MH  - Politics
MH  - Portugal
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - Bioethics
OT  - Biomedical Research
OT  - Codes of Ethics
OT  - Coronavirus
OT  - Ethics Committees
OT  - Helsinki Declaration
EDAT- 2020/05/18 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/05/18 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/05/18 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.20344/amp.13709 [doi]
PST - ppublish
SO  - Acta Med Port. 2020 May 4;33(5):295-296. doi: 10.20344/amp.13709. Epub 2020 May
      4.


PMID- 32416369
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 222
DP  - 2020 Aug 1
TI  - Eating our way through the Anthropocene.
PG  - 112929
LID - S0031-9384(20)30243-2 [pii]
LID - 10.1016/j.physbeh.2020.112929 [doi]
AB  - This paper examines the complex interactions between food systems, diets, and the
      environment. We discuss the challenges facing the food system as a result of
      environmental degradation and climate change. We review the state of current
      diets and their effects on human health outcomes. As we consider paths forward,
      we examine holistic solutions that align nutrition, health, and environmental
      goals. Finally, we identify ethical questions relevant to the changing global
      food system. We consider our moral obligations to other people - both now and in 
      the future - and the planet, and we posit that eating is an ethical act requiring
      reflection at all scales.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Fanzo, Jessica
AU  - Fanzo J
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA;
      School of Advanced International Studies, Johns Hopkins University, Washington,
      DC, USA; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, 
      MD, USA. Electronic address: Jfanzo1@jhu.edu.
FAU - Hood, Amelia
AU  - Hood A
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
FAU - Davis, Claire
AU  - Davis C
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200526
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
MH  - *Climate Change
MH  - *Diet
MH  - Humans
MH  - Nutritional Status
OTO - NOTNLM
OT  - *Climate change
OT  - *Diets
OT  - *Food choices
OT  - *Food ethics
OT  - *Food systems
EDAT- 2020/05/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/17 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - S0031-9384(20)30243-2 [pii]
AID - 10.1016/j.physbeh.2020.112929 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Aug 1;222:112929. doi: 10.1016/j.physbeh.2020.112929. Epub
      2020 May 26.


PMID- 32415822
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201209
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 8
DP  - 2020 Aug 12
TI  - Near-Infrared Cerebrovascular Reactivity for Monitoring Cerebral Autoregulation
      and Predicting Outcomes in Moderate to Severe Traumatic Brain Injury: Proposal
      for a Pilot Observational Study.
PG  - e18740
LID - 10.2196/18740 [doi]
AB  - BACKGROUND: Impaired cerebrovascular reactivity after traumatic brain injury
      (TBI) in adults is emerging as an important prognostic factor, with strong
      independent association with 6-month outcomes. To date, it is unknown if impaired
      cerebrovascular reactivity during the acute phase is associated with ongoing
      impaired continuously measured cerebrovascular reactivity in the long-term, and
      if such measures are associated with clinical phenotype at those points in time. 
      OBJECTIVE: We describe a prospective pilot study to assess the use of
      near-infrared spectroscopy (NIRS) to derive continuous measures of
      cerebrovascular reactivity during the acute and long-term phases of TBI in
      adults. METHODS: Over 2 years, we will recruit up to 80 adults with
      moderate/severe TBI admitted to the intensive care unit (ICU) with invasive
      intracranial pressure (ICP) monitoring. These patients will undergo
      high-frequency data capture of ICP, arterial blood pressure (ABP), and NIRS for
      the first 5 days of care. Patients will then have 30 minutes of noninvasive NIRS 
      and ABP monitoring in the clinic at 3, 6, and 12 months post-injury. Outcomes
      will be assessed via the Glasgow Outcome Scale and Short Form-12 questionnaires. 
      Various relationships between NIRS and ICP-derived cerebrovascular reactivity
      metrics and associated outcomes will be assessed using biomedical signal
      processing techniques and both multivariate and time-series statistical
      methodologies. RESULTS: Study recruitment began at the end of February 2020, with
      data collection ongoing and three patients enrolled at the time of writing. The
      expected duration of data collection will be from February 2020 to January 2022, 
      as per our local research ethics board approval (B2018:103). Support for this
      work has been obtained through the National Institutes of Health (NIH) through
      the National Institute of Neurological Disorders and Stroke (NINDS)
      (R03NS114335), funded in January 2020. CONCLUSIONS: With the application of NIRS 
      technology for monitoring of patients with TBI, we expect to be able to outline
      core relationships between noninvasively measured aspects of cerebral physiology 
      and invasive measures, as well as patient outcomes. Documenting these
      relationships carries the potential to revolutionize the way we monitor patients 
      with TBI, moving to more noninvasive techniques. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/18740.
CI  - (c)Alwyn Gomez, Joshua Dian, Logan Froese, Frederick Adam Zeiler. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      12.08.2020.
FAU - Gomez, Alwyn
AU  - Gomez A
AUID- ORCID: https://orcid.org/0000-0002-3737-2065
AD  - Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, 
      University of Manitoba, Winnipeg, MB, Canada.
FAU - Dian, Joshua
AU  - Dian J
AUID- ORCID: https://orcid.org/0000-0002-2193-4916
AD  - Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, 
      University of Manitoba, Winnipeg, MB, Canada.
FAU - Froese, Logan
AU  - Froese L
AUID- ORCID: https://orcid.org/0000-0002-6076-0189
AD  - Biomedical Engineering, Faculty of Engineering, University of Manitoba, Winnipeg,
      MB, Canada.
FAU - Zeiler, Frederick Adam
AU  - Zeiler FA
AUID- ORCID: https://orcid.org/0000-0003-1737-0510
AD  - Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, 
      University of Manitoba, Winnipeg, MB, Canada.
AD  - Biomedical Engineering, Faculty of Engineering, University of Manitoba, Winnipeg,
      MB, Canada.
AD  - Department of Anatomy and Cell Science, Rady Faculty of Health Sciences,
      University of Manitoba, Winnipeg, MB, Canada.
AD  - Centre on Aging, University of Mantioba, Winnipeg, MB, Canada.
AD  - Division of Anaesthesia, Department of Medicine, University of Cambridge,
      Cambridge, United Kingdom.
LA  - eng
GR  - R03 NS114335/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20200812
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7450363
OTO - NOTNLM
OT  - autoregulation
OT  - brain injury
OT  - cerebrovascular reactivity
OT  - invasive
OT  - near-infrared spectroscopy
OT  - neurology
OT  - non-invasive
OT  - outcome
OT  - protocol
OT  - trauma
EDAT- 2020/05/18 06:00
MHDA- 2020/05/18 06:01
CRDT- 2020/05/17 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/04/12 00:00 [revised]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/05/18 06:01 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - v9i8e18740 [pii]
AID - 10.2196/18740 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Aug 12;9(8):e18740. doi: 10.2196/18740.


PMID- 32414984
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20200831
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 186
IP  - 16
DP  - 2020 May 16
TI  - The ethics of culling badgers.
PG  - 538-539
LID - 10.1136/vr.m1897 [doi]
FAU - Jones, Trevor
AU  - Jones T
AD  - Nottinghamshire, UK (address supplied).
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
SB  - IM
CON - Vet Rec. 2020 Mar 21;186(11):357-358. PMID: 32198260
CIN - Vet Rec. 2020 May 16;186(16):539. PMID: 32414985
MH  - Animals
MH  - Cattle
MH  - *Cattle Diseases
MH  - *Mustelidae
MH  - *Mycobacterium bovis
MH  - *Tuberculosis, Bovine
EDAT- 2020/05/18 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - vr.m1897 [pii]
AID - 10.1136/vr.m1897 [doi]
PST - ppublish
SO  - Vet Rec. 2020 May 16;186(16):538-539. doi: 10.1136/vr.m1897.


PMID- 32414880
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20201218
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 95
IP  - 4
DP  - 2020 Jul 28
TI  - AAN position statement: The COVID-19 pandemic and the ethical duties of the
      neurologist.
PG  - 167-172
LID - 10.1212/WNL.0000000000009744 [doi]
AB  - Patients, clinicians, and hospitals have undergone monumental changes during the 
      coronavirus disease 2019 (COVID-19) pandemic. This crisis has forced us to
      consider the obligations that we neurologists have to our individual patients as 
      well as the greater community. By returning to our fundamental understanding of
      these duties, we can ensure that we are providing the most ethically appropriate 
      contingency and crisis care possible. We recommend specific adaptations to both
      the inpatient and outpatient settings, as well as changes to medical and trainee 
      education. Furthermore, we explore the daunting but potentially necessary
      implementation of scare resource allocation protocols. As the pandemic evolves,
      we will need to adapt continuously to these rapidly changing circumstances and
      consider both national and regional standards and variation.
CI  - (c) 2020 American Academy of Neurology.
FAU - Rubin, Michael A
AU  - Rubin MA
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD. Michael.Rubin@utsouthwestern.edu.
FAU - Bonnie, Richard J
AU  - Bonnie RJ
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD.
FAU - Epstein, Leon
AU  - Epstein L
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD.
FAU - Hemphill, Claude
AU  - Hemphill C
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD.
FAU - Kirschen, Matthew
AU  - Kirschen M
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD.
FAU - Lewis, Ariane
AU  - Lewis A
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD.
FAU - Suarez, Jose I
AU  - Suarez JI
AD  - From the Department of Neurology & Neurotherapeutics and Neurological Surgery
      (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Schools of
      Law, Medicine, and Public Policy (R.J.B.), University of Virginia,
      Charlottesville; Department of Pediatrics (L.E.), Northwestern University
      Feinberg School of Medicine, Chicago, IL; Departments of Neurology and
      Neurological Surgery (C.H.), University of California, San Francisco; Departments
      of Anesthesiology, Critical Care Medicine, Pediatrics and Neurology (M.K.),
      University of Pennsylvania Perelman School of Medicine, Philadelphia; Departments
      of Neurology and Neurosurgery (A.L.), New York University Langone Medical Center,
      New York; and Departments of Anesthesiology and Critical Care Medicine,
      Neurology, and Neurosurgery (J.I.S.), The Johns Hopkins University School of
      Medicine, Baltimore, MD.
CN  - Ethics, Law, and Humanities Committee, a joint committee of the American Academy 
      of Neurology, American Neurological Association, and Child Neurology Society; in 
      collaboration with the Neurocritical Care Society Ethics Committee
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/complications/*therapy
MH  - Health Resources
MH  - Humans
MH  - Nervous System Diseases/complications
MH  - Neurologists/*ethics
MH  - Neurology/education/*ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/complications/*therapy
MH  - Referral and Consultation
MH  - Societies, Medical
MH  - Telemedicine
EDAT- 2020/05/18 06:00
MHDA- 2020/08/07 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - WNL.0000000000009744 [pii]
AID - 10.1212/WNL.0000000000009744 [doi]
PST - ppublish
SO  - Neurology. 2020 Jul 28;95(4):167-172. doi: 10.1212/WNL.0000000000009744. Epub
      2020 May 15.


PMID- 32414832
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 15
TI  - Consensus on the exercise and dosage variables of an exercise training programme 
      for chronic non-specific neck pain: protocol for an international e-Delphi study.
PG  - e037656
LID - 10.1136/bmjopen-2020-037656 [doi]
AB  - INTRODUCTION: Clinical guidelines and systematic reviews recommend exercise in
      the management of chronic non-specific neck pain. Although exercise training
      programmes that consist of both motor control exercise and exercises for the
      superficial cervical muscles (segmental exercises) are effective, the exercise
      variables including dosage vary considerably across trials or are poorly
      reported. This study aims to gain expert consensus on these exercise variables so
      that they can be described clearly using intervention reporting checklists to
      inform clinical practice and future clinical trials. METHODS AND ANALYSIS: This
      protocol for an international Delphi study is informed by the Guidance on
      Conducting and REporting DElphi Studies recommendations and published to ensure
      quality, rigour and transparency. The study will consist of three rounds using
      anonymous online questionnaires. Expert exercise professionals (physiotherapists,
      strength and conditioning coaches and so on) and academics in neck pain
      management will be identified through literature searches, peer referral and
      social media calls for expression of interest. In round 1, participants will
      answer open-ended questions informed by intervention and exercise reporting
      checklists. Responses will be analysed thematically by two independent reviewers.
      In round 2, participants will rate their level of agreement with statements
      generated from round 1 and previous clinical trials using a 5-point Likert scale 
      where 1=strongly disagree and 5=strongly agree. In round 3, participants will
      re-rate their agreement with statements that achieved consensus in round 2.
      Statements reaching consensus among participants must meet progressively
      increased a priori criteria at rounds 2 and 3, measured using descriptive
      statistics: median, IQR and percentage agreement. Inferential statistics will be 
      used to evaluate measures of agreement between participants (Kendall's
      coefficient of concordance) and stability between rounds (Wilcoxon rank-sum
      test). Statements achieving consensus in round 3 will provide expert
      recommendations of the key exercise and dosage variables in the management of
      chronic non-specific neck pain. ETHICS AND DISSEMINATION: Ethical approval was
      provided by the University of Birmingham Ethics Committee (Ref:ERN_19-1857).
      Results will be disseminated through peer-reviewed publications and conference
      presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Price, Jonathan
AU  - Price J
AUID- ORCID: 0000-0002-5505-1564
AD  - Musculoskeletal Physiotherapy Services, Birmingham Community Healthcare NHS
      Foundation Trust, Birmingham, UK.
FAU - Rushton, Alison
AU  - Rushton A
AUID- ORCID: 0000-0001-8114-7669
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Tyros, Vasileios
AU  - Tyros V
AD  - Edgbaston Physiotherapy Clinic, Birmingham, UK.
FAU - Heneghan, Nicola R
AU  - Heneghan NR
AUID- ORCID: 0000-0001-7599-3674
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK
      n.heneghan@bham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200515
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Chronic Pain/therapy
MH  - Consensus
MH  - Delphi Technique
MH  - *Exercise
MH  - Humans
MH  - *Neck Pain/therapy
PMC - PMC7232615
OTO - NOTNLM
OT  - *musculoskeletal disorders
OT  - *rehabilitation medicine
OT  - *spine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/18 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2020-037656 [pii]
AID - 10.1136/bmjopen-2020-037656 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 15;10(5):e037656. doi: 10.1136/bmjopen-2020-037656.


PMID- 32414830
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 15
TI  - Men living through multiple miscarriages: protocol for a qualitative exploration 
      of experiences and support requirements.
PG  - e035967
LID - 10.1136/bmjopen-2019-035967 [doi]
AB  - INTRODUCTION: Up to 1 in 4 pregnancies and 1 in 20 subsequent pregnancies end in 
      miscarriage. Despite such prevalence the psychosocial effects are often
      unrecognised and unsupported. In the absence of any biomedical sequelae among men
      such marginalisation may be intensified. Men living through multiple miscarriages
      may also find any grief or anxiety intensified by loss of hope for future
      parenthood, but robust qualitative studies of these experiences are limited. We
      aim to rectify the deficiency. METHODS AND ANALYSIS: Our qualitative study will
      adopt the sounds of silence framework designed by Serrant-Green to hear the
      voices of populations possibly marginalised. We will listen and learn from 30 to 
      50 men with a history of two or more miscarriages. The research participants will
      be recruited from a recurrent miscarriage clinic at a large tertiary hospital in 
      England, and from advertisements to be disseminated by the project sponsor and
      miscarriage charities.Individual telephone interviews supported by a
      semistructured discussion guide will be audio-recorded, transcribed and
      anonymised. The transcriptions and any field notes will be interpreted by the
      framework method of Ritchie and Lewis embedded within the sounds of silence
      framework. Tentative findings will be presented to research participants in
      face-to-face focus group discussion, to enable member synthesis to enhance
      authenticity. The focus group discussion will be audio-recorded, transcribed,
      anonymised and similarly interpreted to contribute to our final synthesis. ETHICS
      AND DISSEMINATION: The protocol of this project received a favourable opinion
      from the West Midlands South Birmingham Research Ethics Committee (16/WM/0423).
      Results will be submitted for publication in peer-reviewed journals and at
      conferences, and disseminated via newsletters and social media of our clinical
      collaborators and miscarriage charities. Outputs are anticipated to inform future
      policy and practice in the management of multiple miscarriages. TRIAL
      REGISTRATION NUMBER: ISRCTN 21828561.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Williams, Helen Marie
AU  - Williams HM
AUID- ORCID: 0000-0003-4417-9404
AD  - Tommy's National Centre for Miscarriage Research, University of Birmingham,
      Birmingham, UK h.m.williams.1@bham.ac.uk.
AD  - Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.
FAU - Jones, Laura L
AU  - Jones LL
AUID- ORCID: 0000-0002-4018-3855
AD  - Tommy's National Centre for Miscarriage Research, University of Birmingham,
      Birmingham, UK.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Coomarasamy, Arri
AU  - Coomarasamy A
AUID- ORCID: 0000-0002-3261-9807
AD  - Tommy's National Centre for Miscarriage Research, University of Birmingham,
      Birmingham, UK.
AD  - Institute of Metabolism and Systems Research, University of Birmingham,
      Birmingham, UK.
FAU - Topping, Annie E
AU  - Topping AE
AUID- ORCID: 0000-0002-0111-2341
AD  - Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.
AD  - University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
LA  - eng
SI  - ISRCTN/ISRCTN21828561
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200515
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Anxiety
MH  - England
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - Qualitative Research
MH  - *Research Design
PMC - PMC7232625
OTO - NOTNLM
OT  - *gynaecology
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/05/18 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035967 [pii]
AID - 10.1136/bmjopen-2019-035967 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 15;10(5):e035967. doi: 10.1136/bmjopen-2019-035967.


PMID- 32414829
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 15
TI  - Assessing care models implemented in primary healthcare for persons with
      dementia: a mixed-methods study protocol.
PG  - e035916
LID - 10.1136/bmjopen-2019-035916 [doi]
AB  - INTRODUCTION: Dementia is on the rise in Canada and globally. Ensuring
      accessibility to diagnosis, treatment and management throughout the course of the
      disease is a very significant problem worldwide. In order to provide
      comprehensive care to patients and their caregivers, enhancing primary care-based
      dementia care is seen as the way forward. In many Canadian provinces various
      collaborative care models (collCMs) anchored in primary care to improve dementia 
      care have been developed and implemented. The overall objective of our research
      programme is to identify key factors for the successful implementation of
      collCMs, and to facilitate dissemination and scale-up of dementia best practices.
      METHODS AND ANALYSIS: We will use a convergent mixed-methods design. An
      observational study using chart review (2014-2016) and questionnaires (2014-2018;
      repeated in 2020) will measure application of guidelines and implementation of
      collCMs. This study will be complemented with a qualitative descriptive study
      using interviews (2017-2020) conducted in parallel. Quantitative and qualitative 
      results will be further integrated using a matrix representing sites and
      findings. An integrated knowledge exchange strategy will ensure uptake by
      principal stakeholders throughout the research. ETHICS AND DISSEMINATION: Our
      study has been approved by all relevant ethics committees. Our dissemination plan
      follows an integrated knowledge transfer strategy using provincial, national and 
      international councils. We will present the results individually to the clinical 
      sites and then to these councils. Our research will be the first provincial and
      cross jurisdictional evaluation of primary care models for patients living with
      dementia, providing evidence on the ongoing debate on the respective role of
      clinicians in primary care and specialists in caring for patients with dementia.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vedel, Isabelle
AU  - Vedel I
AUID- ORCID: 0000-0002-6873-1681
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada
      isabelle.vedel@mcgill.ca.
FAU - McAiney, Carrie
AU  - McAiney C
AUID- ORCID: 0000-0002-7864-344X
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
AD  - Schlegel-UW Research Institute for Aging, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Couturier, Yves
AU  - Couturier Y
AUID- ORCID: 0000-0001-6848-8354
AD  - Social Work, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
FAU - Pakzad, Sarah
AU  - Pakzad S
AUID- ORCID: 0000-0002-6596-5140
AD  - School of Psychology, University of Moncton, Moncton, New Brunswick, Canada.
FAU - Arsenault-Lapierre, Genevieve
AU  - Arsenault-Lapierre G
AUID- ORCID: 0000-0003-0984-6857
AD  - Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.
FAU - Godard-Sebillotte, Claire
AU  - Godard-Sebillotte C
AUID- ORCID: 0000-0003-1477-7489
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada.
FAU - Sourial, Nadia
AU  - Sourial N
AUID- ORCID: 0000-0002-5504-8680
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada.
FAU - Simmons, Rachel
AU  - Simmons R
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada.
FAU - Bergman, Howard
AU  - Bergman H
AD  - Family Medicine, McGill University, Montreal, Quebec, Canada.
CN  - Research on Organization of Healthcare Services for Alzheimers (ROSA) Team
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200515
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Caregivers
MH  - *Dementia/therapy
MH  - Humans
MH  - Observational Studies as Topic
MH  - *Primary Health Care
MH  - Qualitative Research
PMC - PMC7232631
OTO - NOTNLM
OT  - *dementia
OT  - *health policy
OT  - *primary care
COIS- Competing interests: None declared.
IR  - Aubin M
FIR - Aubin, Michele
IR  - Silva RBD
FIR - Silva, Roxane Borges da
IR  - Kroger E
FIR - Kroger, Edeltraut
IR  - St-Laurent D
FIR - St-Laurent, Danielle
IR  - Emond V
FIR - Emond, Valerie
IR  - Bourque PE
FIR - Bourque, Paul-Emile
IR  - Anderson G
FIR - Anderson, Geoff
IR  - Wilchesky M
FIR - Wilchesky, Machelle
IR  - Gagnon D
FIR - Gagnon, Dominique
IR  - Rodriguez C
FIR - Rodriguez, Charo
IR  - Lee L
FIR - Lee, Linda
IR  - Baxter P
FIR - Baxter, Pamela
IR  - Kaasalainen S
FIR - Kaasalainen, Sharon
IR  - Dupuis S
FIR - Dupuis, Sherry
IR  - Lapointe L
FIR - Lapointe, Liette
IR  - Khanassov V
FIR - Khanassov, Vladimir
IR  - Ingram J
FIR - Ingram, Jennifer
IR  - Seitz D
FIR - Seitz, Dallas
IR  - Pepin ME
FIR - Pepin, Maude-Emilie
IR  - Guillette M
FIR - Guillette, Maxime
IR  - Dame N
FIR - Dame, Nathalie
IR  - Simeon F
FIR - Simeon, Frantz
IR  - Nicol-Clavet N
FIR - Nicol-Clavet, Noemie
IR  - Hardouin M
FIR - Hardouin, Marine
IR  - Henein M
FIR - Henein, Mary
IR  - Vaillancourt L
FIR - Vaillancourt, Lucie
IR  - LeBerre M
FIR - LeBerre, Melanie
IR  - Rupp R
FIR - Rupp, Rebecca
IR  - Gueriton M
FIR - Gueriton, Muriel
IR  - Huntsbarger D
FIR - Huntsbarger, Deana
IR  - Burns S
FIR - Burns, Sheri
IR  - Bronskill S
FIR - Bronskill, Susan
IR  - Strumpf E
FIR - Strumpf, Erin
IR  - Rochon P
FIR - Rochon, Paula
IR  - Schuster T
FIR - Schuster, Tibor
IR  - Jarrett P
FIR - Jarrett, Pam
EDAT- 2020/05/18 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035916 [pii]
AID - 10.1136/bmjopen-2019-035916 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 15;10(5):e035916. doi: 10.1136/bmjopen-2019-035916.


PMID- 32414757
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20211013
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Ethical considerations for epidemic vaccine trials.
PG  - 465-469
LID - 10.1136/medethics-2020-106235 [doi]
AB  - Vaccines are a powerful measure to protect the health of individuals and to
      combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when
      one effective vaccine has been successfully developed against an epidemic disease
      and researchers seek to test the efficacy of another vaccine for the same
      pathogen in clinical trials involving human subjects. On the one hand, there are 
      compelling reasons why it would be unethical to trial a novel vaccine when an
      effective product exists already. First, it is a firm principle of medical ethics
      that an effective treatment or vaccine should not be withheld from patients if
      their life may depend on it. Second, since epidemic outbreaks often emerge in
      settings with less-resourced health systems, there is a pronounced risk that any 
      trial withholding an effective vaccine would disproportionately affect the
      vulnerable populations that historically have been exploited for biomedical
      research. Third, clinical trials for novel vaccines may be at odds with efforts
      to control active outbreaks. On the other hand, it may be justified to conduct a 
      trial for a candidate vaccine if it is expected to have certain advantages
      compared with the existing product. This essay discusses key factors for
      comparing vaccines against epidemic pathogens, including immunological,
      logistical and economic considerations. Alongside a case study of the development
      of vaccines for Ebola, the essay seeks to establish a general framework that
      should be expanded and populated by immunologists, epidemiologists, economists
      and bioethicists, and ultimately could be applied to the case of COVID-19
      vaccines.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Monrad, Joshua Teperowski
AU  - Monrad JT
AD  - Program in Ethics, Politics, and Economics, Yale University, New Haven, CT, USA
      joshua.monrad@yale.edu.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics/organization & administration
MH  - Coronavirus Infections/*epidemiology/*prevention & control
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*epidemiology/*prevention & control
MH  - SARS-CoV-2
MH  - Viral Vaccines/*administration & dosage/economics/immunology
PMC - PMC7316110
OTO - NOTNLM
OT  - *clinical trials
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/18 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - medethics-2020-106235 [pii]
AID - 10.1136/medethics-2020-106235 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):465-469. doi: 10.1136/medethics-2020-106235. Epub
      2020 May 15.


PMID- 32414724
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 20
IP  - 3
DP  - 2020 May
TI  - What do senior physicians think about AI and clinical decision support systems:
      Quantitative and qualitative analysis of data from specialty societies.
PG  - 324-328
LID - 10.7861/clinmed.2019-0317 [doi]
AB  - AIMS: The aim was to help physicians engage with NHS and other policymakers about
      the use, procurement and regulation of artificial intelligence, algorithms and
      clinical decision support systems (CDSS) in the NHS by identifying the
      professional benefits of and concerns about these systems. METHODS: We piloted a 
      three-page survey instrument with closed and open-ended questions on
      SurveyMonkey, then circulated it to specialty societies via email. Both
      quantitative and qualitative methods were used to analyse responses. RESULTS: The
      results include the current usage of CDSS; identified benefits; concerns about
      quality; concerns about regulation, professional practice, ethics and liability, 
      as well as actions being taken by the specialty societies to address these; and
      aspects of CDSS quality that need to be tested. CONCLUSION: While results confirm
      many expected benefits and concerns about CDSS, they raise new professional
      concerns and suggest further actions to explore with partners on behalf of the
      physician community.
CI  - (c) Royal College of Physicians 2020. All rights reserved.
FAU - Petkus, Haroldas
AU  - Petkus H
AD  - Lithuania.
FAU - Hoogewerf, Jan
AU  - Hoogewerf J
AD  - Faculty of Clinical Informatics, London, UK.
FAU - Wyatt, Jeremy C
AU  - Wyatt JC
AD  - University of Southampton, Southampton, UK j.c.wyatt@soton.ac.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
MH  - Algorithms
MH  - Artificial Intelligence
MH  - *Decision Support Systems, Clinical
MH  - Humans
MH  - *Physicians
MH  - Surveys and Questionnaires
PMC - PMC7354034
OTO - NOTNLM
OT  - *Professional concerns
OT  - *artificial intelligence
OT  - *decision support systems
OT  - *evaluation
OT  - *regulation
EDAT- 2020/05/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 20/3/324 [pii]
AID - 10.7861/clinmed.2019-0317 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2020 May;20(3):324-328. doi: 10.7861/clinmed.2019-0317.


PMID- 32414696
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20211204
IS  - 1878-0326 (Electronic)
IS  - 1872-4973 (Linking)
VI  - 48
DP  - 2020 Sep
TI  - Ethical publication of research on genetics and genomics of biological material: 
      guidelines and recommendations.
PG  - 102299
LID - S1872-4973(20)30072-7 [pii]
LID - 10.1016/j.fsigen.2020.102299 [doi]
AB  - Forensic Science International: Genetics and Forensic Science International:
      Reports communicate research on a variety of biological materials using genetics 
      and genomic methods. Numerous guidelines have been produced to secure
      standardization and quality of results of scientific investigations. Yet, no
      specific guidelines have been produced for the ethical acquisition of such data. 
      These guidelines summarize universally adopted principles for conducting ethical 
      research on biological materials, and provide details of the general procedures
      for conducting ethical research on materials of human, animal, plant and
      environmental origin. Finally, the minimal ethics requirements for submission of 
      research material are presented.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - D'Amato, Maria Eugenia
AU  - D'Amato ME
AD  - Forensic DNA Laboratory, Department of Biotechnology, Faculty of Natural
      Sciences, University of the Western Cape, South Africa. Electronic address:
      medamato@uwc.ac.za.
FAU - Bodner, Martin
AU  - Bodner M
AD  - Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria.
FAU - Butler, John M
AU  - Butler JM
AD  - National Institute of Standards and Technology, Gaithersburg, MD, USA.
FAU - Gusmao, Leonor
AU  - Gusmao L
AD  - DNA Diagnostic Laboratory, State University of Rio de Janeiro, Brazil.
FAU - Linacre, Adrian
AU  - Linacre A
AD  - Flinders University, College of Science & Engineering, Adelaide, Australia.
FAU - Parson, Walther
AU  - Parson W
AD  - Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria;
      Forensic Science Program, The Pennsylvania State University, University Park, PA,
      USA.
FAU - Schneider, Peter M
AU  - Schneider PM
AD  - Institute of Legal Medicine, University Clinic and Faculty of Medicine,
      University of Cologne, Cologne, Germany.
FAU - Vallone, Peter
AU  - Vallone P
AD  - National Institute of Standards and Technology, Gaithersburg, MD, USA.
FAU - Carracedo, Angel
AU  - Carracedo A
AD  - Institute of Forensic Sciences, Genomic Medicine Group-CIBERER, University of
      Santiago de Compostela, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Netherlands
TA  - Forensic Sci Int Genet
JT  - Forensic science international. Genetics
JID - 101317016
RN  - 0 (DNA, Environmental)
SB  - IM
MH  - Animal Experimentation/ethics/legislation & jurisprudence
MH  - Animals
MH  - Biological Specimen Banks/ethics/legislation & jurisprudence
MH  - DNA, Environmental
MH  - *Ethics, Research
MH  - *Genetics
MH  - *Guidelines as Topic
MH  - Humans
MH  - *Periodicals as Topic
MH  - Publishing/*ethics
OTO - NOTNLM
OT  - *Forensics
OT  - *Genetics
OT  - *Genomics
OT  - *Research ethics
EDAT- 2020/05/18 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - S1872-4973(20)30072-7 [pii]
AID - 10.1016/j.fsigen.2020.102299 [doi]
PST - ppublish
SO  - Forensic Sci Int Genet. 2020 Sep;48:102299. doi: 10.1016/j.fsigen.2020.102299.
      Epub 2020 May 12.


PMID- 32414630
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20210110
IS  - 2352-5568 (Electronic)
IS  - 2352-5568 (Linking)
VI  - 39
IP  - 3
DP  - 2020 Jun
TI  - COVID-19 and ethical considerations: Valuable decision-making tools from the
      leading medical societies in France.
PG  - 365-366
LID - S2352-5568(20)30084-9 [pii]
LID - 10.1016/j.accpm.2020.05.001 [doi]
FAU - Lamblin, Antoine
AU  - Lamblin A
AD  - Department of Civilian and Military Anaesthesia, Edouard-Herriot Hospital, Lyon
      University Hospital, 5, place d'Arsonval, 69003 Lyon, France; UMR ADeS 7268,
      Aix-Marseille University/EFS/CNRS, Espace ethique mediterraneen, University
      Hospital La Timone (adults), Marseille, France. Electronic address:
      antoine.lamblin@chu-lyon.fr.
FAU - de Montgolfier, Sandrine
AU  - de Montgolfier S
AD  - IRIS Institut de recherche interdisciplinaire sur les enjeux sociaux, UMR 8156
      CNRS - 997 Inserm - EHESS - UP13, 74, rue Marcel Cachin, 93017 Bobigny.
LA  - eng
PT  - Letter
DEP - 20200507
PL  - France
TA  - Anaesth Crit Care Pain Med
JT  - Anaesthesia, critical care & pain medicine
JID - 101652401
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Critical Care/*ethics
MH  - *Decision Making, Organizational
MH  - *Decision Support Techniques
MH  - France/epidemiology
MH  - Health Priorities/ethics
MH  - Health Resources/ethics/*supply & distribution
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Life Tables
MH  - Organ Dysfunction Scores
MH  - *Pandemics
MH  - Personal Autonomy
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Societies, Medical
MH  - Treatment Refusal/ethics
MH  - Triage/*ethics
PMC - PMC7204662
EDAT- 2020/05/18 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - S2352-5568(20)30084-9 [pii]
AID - 10.1016/j.accpm.2020.05.001 [doi]
PST - ppublish
SO  - Anaesth Crit Care Pain Med. 2020 Jun;39(3):365-366. doi:
      10.1016/j.accpm.2020.05.001. Epub 2020 May 7.


PMID- 32414333
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1471-2288 (Electronic)
IS  - 1471-2288 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 15
TI  - Developing model biobanking consent language: what matters to prospective
      participants?
PG  - 119
LID - 10.1186/s12874-020-01001-2 [doi]
AB  - BACKGROUND: Efforts to improve informed consent have led to calls for providing
      information a reasonable person would want to have, in a way that facilitates
      understanding of the reasons why one might or might not want to participate. At
      the same time, advances in large-scale genomic research have expanded both the
      opportunities and the risks for participants, families, and communities. To
      advance the use of effective consent materials that reflect this landscape, we
      used empirical data to develop model consent language, as well as brief questions
      to assist people in thinking about their own values relative to participation.
      METHODS: We conducted in-person interviews to gather preliminary input on these
      materials from a diverse sample (n = 32) of the general population in Nashville, 
      Tennessee. We asked them to highlight information they found especially
      reassuring or concerning, their hypothetical willingness to participate, and
      their opinions about the values questions. RESULTS: Consent information most
      often highlighted as reassuring included the purpose of the biobank, the
      existence and composition of a multidisciplinary oversight committee, the
      importance of participants' privacy and efforts to protect it, and controlled
      access to a scientific database. Information most often highlighted as concerning
      included the deposition of data in a publicly accessible database, the risk of
      unintended access to data, the potential for non-research use of data, and use of
      medical record information in general. Seventy-five percent of participants
      indicated initial willingness to participate in the hypothetical biobank; this
      decreased to 66% as participants more closely considered the information over the
      course of the interview. A large majority rated the values questions as helpful. 
      CONCLUSIONS: These results are consistent with other research on public
      perspectives on biobanking and genomic cohort studies, suggesting that our model 
      language effectively captures commonly expressed reasons for and against
      participation. Our study enriches this literature by connecting specific consent 
      form disclosures with qualitative data regarding what participants found
      especially reassuring or concerning and why. Interventions that facilitate
      individuals' closer engagement with consent information may result in
      participation decisions more closely aligned with their values.
FAU - Beskow, Laura M
AU  - Beskow LM
AUID- ORCID: 0000-0002-9314-1915
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      2525 West End Avenue, Suite 400, Nashville, TN, 37203, USA.
      laura.m.beskow@vanderbilt.edu.
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      2525 West End Avenue, Suite 400, Nashville, TN, 37203, USA.
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      2525 West End Avenue, Suite 400, Nashville, TN, 37203, USA.
LA  - eng
GR  - R01 HG007733/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200515
PL  - England
TA  - BMC Med Res Methodol
JT  - BMC medical research methodology
JID - 100968545
SB  - IM
MH  - *Biological Specimen Banks
MH  - Consent Forms
MH  - Humans
MH  - Informed Consent
MH  - *Language
MH  - Prospective Studies
PMC - PMC7227271
OTO - NOTNLM
OT  - *Biobanking
OT  - *Informed consent
OT  - *Patient/participant perspectives
OT  - *Precision medicine research
OT  - *Research ethics
EDAT- 2020/05/18 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/17 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s12874-020-01001-2 [doi]
AID - 10.1186/s12874-020-01001-2 [pii]
PST - epublish
SO  - BMC Med Res Methodol. 2020 May 15;20(1):119. doi: 10.1186/s12874-020-01001-2.


PMID- 32414132
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 13
TI  - Influence of In Vitro Digestion on Composition, Bioaccessibility and Antioxidant 
      Activity of Food Polyphenols-A Non-Systematic Review.
LID - E1401 [pii]
LID - 10.3390/nu12051401 [doi]
AB  - There is increased interest in following a healthy lifestyle and consuming a
      substantial portion of secondary plant metabolites, such as polyphenols, due to
      their benefits for the human body. Food products enriched with various forms of
      fruits and vegetables are sources of pro-health components. Nevertheless, in many
      cases, the level of their activities is changed in in vivo conditions. The
      changes are strictly connected with processes in the digestive system that
      transfigure the structure of the active compounds and simultaneously keep or
      modify their biological activities. Much attention has focused on their
      bioavailability, a prerequisite for further physiological functions. As human
      studies are time consuming, costly and restricted by ethical concerns, in vitro
      models for investigating the effects of digestion on these compounds have been
      developed to predict their release from the food matrix, as well as their
      bioaccessibility. Most typically, models simulate digestion in the oral cavity,
      the stomach, the small intestine and, occasionally, the large intestine. The
      presented review aims to discuss the impact of in vitro digestion on the
      composition, bioaccessibility and antioxidant activity of food polyphenols.
      Additionally, we consider the influence of pH on antioxidant changes in the
      aforementioned substances.
FAU - Wojtunik-Kulesza, Karolina
AU  - Wojtunik-Kulesza K
AD  - Department of Inorganic Chemistry, Medical University of Lublin, Chodzki 4a,
      20-093 Lublin, Poland.
FAU - Oniszczuk, Anna
AU  - Oniszczuk A
AD  - Department of Inorganic Chemistry, Medical University of Lublin, Chodzki 4a,
      20-093 Lublin, Poland.
FAU - Oniszczuk, Tomasz
AU  - Oniszczuk T
AD  - Department of Thermal Technology and Food Process Engineering, University of Life
      Sciences in Lublin, Gleboka 31, 20-612 Lublin, Poland.
FAU - Combrzynski, Maciej
AU  - Combrzynski M
AD  - Department of Thermal Technology and Food Process Engineering, University of Life
      Sciences in Lublin, Gleboka 31, 20-612 Lublin, Poland.
FAU - Nowakowska, Dominika
AU  - Nowakowska D
AD  - Department of General Ophthalmology, Medical University of Lublin, Chmielna 1,
      20-079 Lublin, Poland.
FAU - Matwijczuk, Arkadiusz
AU  - Matwijczuk A
AD  - Department of Physics, University of Life Sciences in Lublin, Akademicka 13,
      20-950 Lublin, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200513
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Antioxidants)
RN  - 0 (Plant Extracts)
RN  - 0 (Polyphenols)
SB  - IM
MH  - Antioxidants/*pharmacokinetics
MH  - Biological Availability
MH  - Body Composition/*drug effects
MH  - Digestion/*drug effects
MH  - Fruit/chemistry
MH  - Humans
MH  - Plant Extracts/*pharmacokinetics
MH  - Polyphenols/*pharmacokinetics
MH  - Vegetables/chemistry
PMC - PMC7284996
OTO - NOTNLM
OT  - antioxidants
OT  - bioaccessibility
OT  - gastrointenstinal digestion
OT  - plant metabolites
OT  - polyphenols
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/18 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - nu12051401 [pii]
AID - 10.3390/nu12051401 [doi]
PST - epublish
SO  - Nutrients. 2020 May 13;12(5). pii: nu12051401. doi: 10.3390/nu12051401.


PMID- 32414027
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20211204
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 10
DP  - 2020 May 13
TI  - The Effects of Combined Movement and Storytelling Intervention on Motor Skills in
      South Asian and White Children Aged 5-6 Years Living in the United Kingdom.
LID - E3391 [pii]
LID - 10.3390/ijerph17103391 [doi]
AB  - Early motor development has an important role in promoting physical activity (PA)
      during childhood and across the lifespan. Children from South Asian backgrounds
      are less active and have poorer motor skills, thus identifying the need for early
      motor skill instruction. This study examines the effect of a movement and
      storytelling intervention on South Asian children's motor skills. Following
      ethics approval and consent, 39 children (46% South Asian) participated in a
      12-week movement and storytelling intervention. Pre and post, seven motor skills 
      (run, jump, throw, catch, stationary dribble, roll, and kick) were assessed using
      Children's Activity and Movement in Preschool Study protocol. At baseline, South 
      Asian children had poorer performance of motor skills. Following the
      intervention, all children improved their motor skills, with a bigger improvement
      observed for South Asian children. Early intervention provided remedial benefits 
      to delays in motor skills and narrowed the motor skills gap in ethnic groups.
FAU - Eyre, Emma L J
AU  - Eyre ELJ
AUID- ORCID: 0000-0002-4040-5921
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry CF4W 
      + VG, UK.
FAU - Clark, Cain C T
AU  - Clark CCT
AUID- ORCID: 0000-0002-6610-4617
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry CF4W 
      + VG, UK.
FAU - Tallis, Jason
AU  - Tallis J
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry CF4W 
      + VG, UK.
FAU - Hodson, Danielle
AU  - Hodson D
AUID- ORCID: 0000-0001-5440-5765
AD  - School of Social and Health Sciences, Sport, Health and Physical Educatioon,
      Leeds Trinity University, Horsforth, Leeds LS18 5HD, UK.
FAU - Lowton-Smith, Sean
AU  - Lowton-Smith S
AUID- ORCID: 0000-0003-0665-1608
AD  - School of Human Sciences, University of Derby, Derby DE22 1GB, UK.
FAU - Nelson, Charlotte
AU  - Nelson C
AUID- ORCID: 0000-0002-8888-6154
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry CF4W 
      + VG, UK.
FAU - Noon, Mark
AU  - Noon M
AUID- ORCID: 0000-0002-1113-8406
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry CF4W 
      + VG, UK.
FAU - Duncan, Michael J
AU  - Duncan MJ
AUID- ORCID: 0000-0002-2016-6580
AD  - Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry CF4W 
      + VG, UK.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Asians
MH  - Child
MH  - *Child Development
MH  - Child, Preschool
MH  - Exercise
MH  - Humans
MH  - *Motor Skills
MH  - *Movement
MH  - United Kingdom
MH  - Whites
PMC - PMC7277335
OTO - NOTNLM
OT  - *disadvantaged
OT  - *ethnicity
OT  - *fundamental movement skills
OT  - *locomotor
OT  - *motor skill instruction
OT  - *object control
EDAT- 2020/05/18 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/05/17 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/17 06:00 [entrez]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
AID - ijerph17103391 [pii]
AID - 10.3390/ijerph17103391 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 May 13;17(10). pii: ijerph17103391. doi:
      10.3390/ijerph17103391.


PMID- 32413905
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
VI  - 58
IP  - 1
DP  - 2020 Jul 1
TI  - The transfiguration of the EXCEL trial: exceeding ethical and moral boundaries.
PG  - 30-34
LID - 10.1093/ejcts/ezaa121 [doi]
FAU - Gomes, Walter J
AU  - Gomes WJ
AD  - Cardiovascular Surgery Discipline, Escola Paulista de Medicina, Federal
      University of Sao Paulo, Sao Paulo, SP, Brazil.
FAU - Albuquerque, Luciano C
AU  - Albuquerque LC
AD  - Sao Lucas Hospital of the Pontifical Catholic University of Porto Alegre, Porto
      Alegre, RS, Brazil.
FAU - Jatene, Fabio B
AU  - Jatene FB
AD  - Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, SP,
      Brazil.
FAU - Leal, Joao Carlos F
AU  - Leal JCF
AD  - Faculty of Medicine of Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto, SP,
      Brazil.
FAU - Rocha, Eduardo A V
AU  - Rocha EAV
AD  - Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, MG, Brazil.
FAU - Almeida, Rui M S
AU  - Almeida RMS
AD  - Faculty of Medicine of the University Center Assis Gurgacz, Cascavel, PR, Brazil.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
SB  - IM
MH  - Coronary Artery Bypass
MH  - *Coronary Artery Disease
MH  - Humans
MH  - Morals
MH  - *Percutaneous Coronary Intervention
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Coronary artery bypass surgery
OT  - *Left main coronary artery disease
OT  - *Percutaneous coronary intervention
OT  - *Randomized controlled trials
EDAT- 2020/05/16 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 5837747 [pii]
AID - 10.1093/ejcts/ezaa121 [doi]
PST - ppublish
SO  - Eur J Cardiothorac Surg. 2020 Jul 1;58(1):30-34. doi: 10.1093/ejcts/ezaa121.


PMID- 32413707
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20210626
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 289
DP  - 2020 Jul
TI  - COVID-19 Pandemic: Impact on psychiatric care in the United States.
PG  - 113069
LID - 10.1016/j.psychres.2020.113069 [doi]
AB  - The World Health Organization declared the coronavirus outbreak a pandemic on
      March 11, 2020. Infection by the SARS-CoV2 virus leads to the COVID-19 disease
      which can be fatal, especially in older patients with medical co-morbidities. The
      impact to the US healthcare system has been disruptive, and the way healthcare
      services are provided has changed drastically. Here, we present a compilation of 
      the impact of the COVID-19 pandemic on psychiatric care in the US, in the various
      settings: outpatient, emergency room, inpatient units, consultation services, and
      the community. We further present effects seen on psychiatric physicians in the
      setting of new and constantly evolving protocols where adjustment and flexibility
      have become the norm, training of residents, leading a team of professionals with
      different expertise, conducting clinical research, and ethical considerations.
      The purpose of this paper is to provide examples of "how to" processes based on
      our current front-line experiences and research to practicing psychiatrists and
      mental health clinicians, inform practitioners about national guidelines
      affecting psychiatric care during the pandemic, and inform health care policy
      makers and health care systems about the challenges and continued needs of
      financial and administrative support for psychiatric physicians and mental health
      systems.
FAU - Bojdani, Ermal
AU  - Bojdani E
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Rajagopalan, Aishwarya
AU  - Rajagopalan A
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Chen, Anderson
AU  - Chen A
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Gearin, Priya
AU  - Gearin P
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Olcott, William
AU  - Olcott W
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Shankar, Vikram
AU  - Shankar V
AD  - Emergency Medicine Residency Program, Kern Medical, Bakersfield, CA, United
      States.
FAU - Cloutier, Alesia
AU  - Cloutier A
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Solomon, Haley
AU  - Solomon H
AD  - Harvard South Shore Psychiatry Residency Training Program, Brockton, MA, United
      States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Naqvi, Nida Z
AU  - Naqvi NZ
AD  - Department of Internal Medicine, University of Maryland Upper Chesapeake Medical 
      Center, Bel Air, MD, United States.
FAU - Batty, Nicolas
AU  - Batty N
AD  - Indiana University School of Business, Bloomington, IN, United States.
FAU - Festin, Fe Erlita D
AU  - Festin FED
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Tahera, Dil
AU  - Tahera D
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - Chang, Grace
AU  - Chang G
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - VA Boston Healthcare System, Brockton, MA, United States.
FAU - DeLisi, Lynn E
AU  - DeLisi LE
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
AD  - Cambridge Health Alliance, Cambridge Hospital, Cambridge, MA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200506
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Ambulatory Care/statistics & numerical data
MH  - Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - Coronavirus Infections/*epidemiology/psychology
MH  - Delivery of Health Care/methods/*statistics & numerical data
MH  - Emergency Service, Hospital/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Inpatients/statistics & numerical data
MH  - Male
MH  - Mental Disorders/*epidemiology/virology
MH  - Mental Health Services/*statistics & numerical data
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/psychology
MH  - SARS-CoV-2
MH  - United States/epidemiology
PMC - PMC7200362
EDAT- 2020/05/16 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/03 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 113069 [pii]
AID - S0165-1781(20)31226-9 [pii]
AID - 10.1016/j.psychres.2020.113069 [doi]
PST - ppublish
SO  - Psychiatry Res. 2020 Jul;289:113069. doi: 10.1016/j.psychres.2020.113069. Epub
      2020 May 6.


PMID- 32413344
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20210504
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 158
IP  - 3
DP  - 2020 Sep
TI  - Ventilators by Lottery: The Least Unjust Form of Allocation in the Coronavirus
      Disease 2019 Pandemic.
PG  - 890-891
LID - S0012-3692(20)31397-0 [pii]
LID - 10.1016/j.chest.2020.04.049 [doi]
FAU - Silva, Diego S
AU  - Silva DS
AD  - Sydney Health Ethics, Sydney School of Public Health, University of Sydney,
      Sydney, Australia; Marie Bashir Institute for Infectious Diseases and
      Biosecurity, University of Sydney, Sydney, Australia. Electronic address:
      diego.silva@sydney.edu.au.
LA  - eng
PT  - Editorial
DEP - 20200512
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Resource Allocation/*methods
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/*supply & distribution
PMC - PMC7217110
OTO - NOTNLM
OT  - *COVID-19, coronavirus disease 2019
OT  - *SARS-CoV-2, severe acute respiratory syndrome-coronavirus 2
OT  - *bioethics
OT  - *coronavirus
OT  - *ethics
OT  - *resource allocation
OT  - *social justice
EDAT- 2020/05/16 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - S0012-3692(20)31397-0 [pii]
AID - 10.1016/j.chest.2020.04.049 [doi]
PST - ppublish
SO  - Chest. 2020 Sep;158(3):890-891. doi: 10.1016/j.chest.2020.04.049. Epub 2020 May
      12.


PMID- 32413036
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Design of composite measure schemes for comparative severity assessment in
      animal-based neuroscience research: A case study focussed on rat epilepsy models.
PG  - e0230141
LID - 10.1371/journal.pone.0230141 [doi]
AB  - Comparative severity assessment of animal models and experimental interventions
      is of utmost relevance for harm-benefit analysis during ethical evaluation, an
      animal welfare-based model prioritization as well as the validation of refinement
      measures. Unfortunately, there is a lack of evidence-based approaches to grade an
      animal's burden in a sensitive, robust, precise, and objective manner. Particular
      challenges need to be considered in the context of animal-based neuroscientific
      research because models of neurological disorders can be characterized by
      relevant changes in the affective state of an animal. Here, we report about an
      approach for parameter selection and development of a composite measure scheme
      designed for precise analysis of the distress of animals in a specific model
      category. Data sets from the analysis of several behavioral and biochemical
      parameters in three different epilepsy models were subjected to a principal
      component analysis to select the most informative parameters. The top-ranking
      parameters included burrowing, open field locomotion, social interaction, and
      saccharin preference. These were combined to create a composite measure scheme
      (CMS). CMS data were subjected to cluster analysis enabling the allocation of
      severity levels to individual animals. The results provided information for a
      direct comparison between models indicating a comparable severity of the
      electrical and chemical post-status epilepticus models, and a lower severity of
      the kindling model. The new CMS can be directly applied for comparison of other
      rat models with seizure activity or for assessment of novel refinement approaches
      in the respective research field. The respective online tool for direct
      application of the CMS or for creating a new CMS based on other parameters from
      different models is available at https://github.com/mytalbot/cms. However, the
      robustness and generalizability needs to be further assessed in future studies.
      More importantly, our concept of parameter selection can serve as a practice
      example providing the basis for comparable approaches applicable to the
      development and validation of CMS for all kinds of disease models or
      interventions.
FAU - van Dijk, Roelof Maarten
AU  - van Dijk RM
AD  - Institute of Pharmacology, Toxicology and Pharmacy,
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Koska, Ines
AU  - Koska I
AD  - Institute of Pharmacology, Toxicology and Pharmacy,
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Bleich, Andre
AU  - Bleich A
AD  - Institute for Laboratory Animal Science and Central Animal Facility, Hannover
      Medical School, Hannover, Germany.
FAU - Tolba, Rene
AU  - Tolba R
AD  - Institute for Laboratory Animal Science and Central Animal Facility, Hannover
      Medical School, Hannover, Germany.
FAU - Seiffert, Isabel
AU  - Seiffert I
AD  - Institute of Pharmacology, Toxicology and Pharmacy,
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Moller, Christina
AU  - Moller C
AD  - Institute of Pharmacology, Toxicology and Pharmacy,
      Ludwig-Maximilians-University, Munich, Germany.
FAU - Di Liberto, Valentina
AU  - Di Liberto V
AD  - Department of Experimental Biomedicine and Clinical Neurosciences, University of 
      Palermo, Palermo, Italy.
FAU - Talbot, Steven Roger
AU  - Talbot SR
AD  - Institute for Laboratory Animal Science and Central Animal Facility, Hannover
      Medical School, Hannover, Germany.
FAU - Potschka, Heidrun
AU  - Potschka H
AUID- ORCID: 0000-0003-1506-0252
AD  - Institute of Pharmacology, Toxicology and Pharmacy,
      Ludwig-Maximilians-University, Munich, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200515
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Biological Variation, Population
MH  - *Disease Models, Animal
MH  - Epilepsy/pathology/*physiopathology
MH  - Female
MH  - Kindling, Neurologic
MH  - Locomotion
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Social Behavior
MH  - *Software
MH  - Spatial Behavior
PMC - PMC7228039
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/16 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - 10.1371/journal.pone.0230141 [doi]
AID - PONE-D-19-30119 [pii]
PST - epublish
SO  - PLoS One. 2020 May 15;15(5):e0230141. doi: 10.1371/journal.pone.0230141.
      eCollection 2020.


PMID- 32412925
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1539-0705 (Electronic)
IS  - 1522-2179 (Linking)
VI  - 22
IP  - 4
DP  - 2020 Aug
TI  - Communication and Cultural Sensitivity for Families and Children With
      Life-Limiting Diseases: An Informed Decision-Making Ethical Case in
      Community-Based Palliative Care.
PG  - 270-275
LID - 10.1097/NJH.0000000000000654 [doi]
AB  - The health care decisions of families of children who have life-limiting genetic 
      diseases are impacted by multiple factors including religious and ethical values,
      education and knowledge, emotional trauma, availability of support, and
      accessibility of care. Palliative care nurses must practice the highest standards
      by delivering nonbiased, nonjudgmental support to patients and families; however,
      nurses may experience moral distress if their personal values conflict with a
      family's decisions and needs. This case focuses on a family receiving
      community-based palliative care for a child with a genetic life-limiting disease.
      They had a family history of this disease, which had caused the deaths of
      previous children, and the mother had a current unplanned pregnancy. The care
      team overcame language barriers and cultural obstacles to establish a trusting
      relationship with the vulnerable pregnant mother. They were able to support her
      decision to terminate her pregnancy safely by helping her to navigate a complex
      health care system. Using 5 crucial pillars to assist health care members with
      the delivery of nonjudgmental family-centered palliative care is recommended: (1)
      identification of biases, (2) utilization of a culturally safe approach, (3)
      effective communication, (4) assessment and support, and (5) knowledge of
      community resources.
FAU - Koch, Amie
AU  - Koch A
AD  - Amie Koch, DNP, FNP-C, RN, ACHPN, is an assistant professor, Duke University
      School of Nursing, and a community hospice and palliative care nurse practitioner
      at Transitions LifeCare, Durham, North Carolina. Kimberlee Grier, BSN, RN, CHPPN,
      CHPN, is a hospice and palliative care nurse at Transitions LifeCare, and
      co-chair of Fostering Families, Durham, North Carolina.
FAU - Grier, Kimberlee
AU  - Grier K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Hosp Palliat Nurs
JT  - Journal of hospice and palliative nursing : JHPN : the official journal of the
      Hospice and Palliative Nurses Association
JID - 100887419
SB  - IM
MH  - Child
MH  - Communication
MH  - *Cultural Diversity
MH  - *Decision Making
MH  - Disabled Children/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mothers/psychology
MH  - Palliative Care/*methods/psychology/standards
MH  - *Professional-Patient Relations
MH  - Qualitative Research
EDAT- 2020/05/16 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1097/NJH.0000000000000654 [doi]
PST - ppublish
SO  - J Hosp Palliat Nurs. 2020 Aug;22(4):270-275. doi: 10.1097/NJH.0000000000000654.


PMID- 32412918
OWN - NLM
STAT- MEDLINE
DCOM- 20200915
LR  - 20220416
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 26
IP  - S2
DP  - 2020 Aug
TI  - COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.
PG  - 56-64
LID - AT6471 [pii]
AB  - CONTEXT: An outbreak of a novel, zoonotic coronavirus occurred in December 2019
      in the city of Wuhan, China and has now affected almost the entire world, with
      the maximum confirmed cases being 1 521 252 as of April 10, 2020. The WHO named
      this coronavirus 2019-nCoV, with COVID-19 being the name for diseases allied with
      it. OBJECTIVE: The study intended to examine the features and characteristics of 
      existing human coronaviruses and identify their resemblance to the newly
      identified 2019-nCoV. DESIGN: The research team performed a literature review,
      searching relevant literature databases. We searched four databases, PubMed,
      EMBASE, Web of Science and CNKI (Chinese Database), to identify studies reporting
      COVID-19. Articles published on or before April 10, 2020 were eligible for
      inclusion. We used the following search terms: "Coronavirus" or "2019-nCoV" or
      "COVID-19" or "SARS-CoV" or "MERS-CoV" or "Bat SARS-CoV" or "ACE2 receptor".
      SETTING: This study was take place in School of Pharmacy, Suresh Gyan Vihar
      University, Jaipur, India. RESULTS: The undistinguishable similarity of the
      genomic sequences of Severe Respiratory Syndrome (SARS)-CoV, Middle East
      Respiratory Syndrome (MERS)-CoV, and Bat SARS-CoV-bat-SL-CoVZC45 and
      bat-SL-CoVZXC21-to nCoV-2019 has facilitated the process of identifying primary
      treatment measures. Researchers are presuming the existence of
      angiotensin-converting enzyme 2 (ACE2) receptor binding in nCoV-2019, as in
      SARS-CoV. Researchers have been examining human-to-human transmission, the
      possibility of an intermediate host between bats and humans, and the existence of
      asymptomatic cases. An incubation period of 0 to 14 days has been reported, with 
      acute to chronic symptoms being cough, nasal congestion, high fever, dyspnea,
      pneumonia, invasive lesions in both lungs, respiratory failure, and even death,
      including in pediatric cases. Mechanical ventilation, extracorporeal membrane
      oxygenation, repurposing of antivirals, and plasma infusion have proven to be
      somewhat effective. Several countries have started clinical trials to evaluate
      the safety and effectiveness of some drugs, but the ability to vaccinate people
      with existing or new molecules will require time. Previously learned lessons from
      SARS and MERS have led some areas to be well equipped in terms of the ability to 
      take speedy action. CONCLUSIONS: First-level treatments include repurposing
      antivirals and antimalarials, and plasma infusion should help, but development of
      existing or new molecules into vaccines will take time. The unpredictable
      trajectory of this outbreak demands careful surveillance to monitor the
      situation, draw strategies, implement control measures, and create proper ethical
      laws and medical guidelines.
FAU - Khan, Tahseen
AU  - Khan T
FAU - Agnihotri, Kartikeya
AU  - Agnihotri K
FAU - Tripathi, Aditi
AU  - Tripathi A
FAU - Mukherjee, Suneet
AU  - Mukherjee S
FAU - Agnihotri, Namita
AU  - Agnihotri N
FAU - Gupta, Gaurav
AU  - Gupta G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
SB  - IM
MH  - Animals
MH  - Betacoronavirus/genetics
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Humans
MH  - India
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Zoonoses/*epidemiology/virology
EDAT- 2020/05/16 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - AT6471 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2020 Aug;26(S2):56-64.


PMID- 32412893
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20220414
IS  - 0969-0700 (Print)
IS  - 0969-0700 (Linking)
VI  - 29
IP  - Sup5a
DP  - 2020 May 1
TI  - Barbed and conventional sutures in spinal surgery patients: an economic and
      clinical outcomes comparison.
PG  - S9-S20
LID - 10.12968/jowc.2020.29.Sup5a.S9 [doi]
AB  - OBJECTIVE: To compare economic and clinical outcomes of barbed sutures versus
      conventional sutures alone in wound closure for patients undergoing spinal
      surgery. METHOD: A retrospective study using the Premier Healthcare Database. The
      database was searched for patients who underwent elective inpatient spinal
      surgery (fusion or laminectomy) for a spinal disorder between 1 January 2014 and 
      30 June 2018 (first=index admission). Using billing records for medical supplies 
      used during the index admission, patients were classified into mutually-exclusive
      groups: patients with any use of STRATAFIX (Ethicon, US) knotless tissue control 
      devices (barbed sutures group); or patients with use of conventional sutures
      alone (conventional sutures group). Outcomes included the index admission's
      length of stay, total and subcategories of hospital costs, non-home discharge,
      operating room time (ORT, minutes), wound complications and readmissions within
      </=90 days. Propensity score matching and generalised estimating equations were
      used to compare outcomes between the study groups. RESULTS: After matching, 3705 
      patients were allocated to each group (mean age=61.5 years [standard deviation,
      SD+/-12.9]; 54% were females). Compared with the conventional suture group, the
      barbed suture group had significantly lower mean ORT (239+/-117 minutes, versus
      263+/-79 minutes conventional sutures, p=0.015). Operating room costs were also
      siginificantly lower in the barbed suture group ($6673+/-$3976 versus
      $7100+/-$2700 conventional sutures, p=0.020). Differences were statistically
      insignificant for other outcomes (all p>0.05). Subanalysis of patients undergoing
      fusions of >/=2 vertebral joints yielded consistent results. CONCLUSION: In this 
      study, wound closure incorporating barbed sutures was associated with lower ORT
      and operating room costs, with no significant difference in wound complications
      or readmissions, when compared with conventional sutures alone.
FAU - Johnston, Stephen S
AU  - Johnston SS
AD  - PhD, Director; Medical Devices, Epidemiology, Johnson & Johnson, New Brunswick,
      NJ, US.
FAU - Chen, Brian Po-Han
AU  - Chen BP
AD  - MS, Associate Director; Health Economics and Market Access, Ethicon, Johnson &
      Johnson, Somerville, NJ, US.
FAU - Tommaselli, Giovanni A
AU  - Tommaselli GA
AD  - MD, PhD, Medical Director; Pre-Clinical & Clinical Research, Medical Affairs,
      Ethicon, Johnson & Johnson, Somerville, NJ, US.
FAU - Jain, Simran
AU  - Jain S
AD  - BS, Apprentice Leader; Mu Sigma, Bangalore, India.
FAU - Pracyk, John B
AU  - Pracyk JB
AD  - MD, PhD, MBA, Integrated Leader; Pre-Clinical & Clinical Research, Medical
      Affairs, DePuy Synthes Spine, Johnson & Johnson, Raynham, MA, US.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - J Wound Care
JT  - Journal of wound care
JID - 9417080
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Hospital Costs/*statistics & numerical data
MH  - Humans
MH  - Laminectomy/economics/*methods
MH  - Length of Stay/economics/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Operating Rooms/economics
MH  - *Operative Time
MH  - Patient Readmission/economics/statistics & numerical data
MH  - Postoperative Complications/economics/epidemiology
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Spinal Fusion/economics/*methods
MH  - Suture Techniques/economics
MH  - *Sutures
MH  - United States
MH  - Wound Closure Techniques
MH  - Young Adult
OTO - NOTNLM
OT  - barbed sutures
OT  - conventional sutures
OT  - economic outcomes
OT  - spinal surgery
OT  - wound complications
EDAT- 2020/05/16 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
AID - 10.12968/jowc.2020.29.Sup5a.S9 [doi]
PST - ppublish
SO  - J Wound Care. 2020 May 1;29(Sup5a):S9-S20. doi: 10.12968/jowc.2020.29.Sup5a.S9.


PMID- 32412853
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20210919
IS  - 1535-4970 (Electronic)
IS  - 1073-449X (Linking)
VI  - 201
IP  - 10
DP  - 2020 May 15
TI  - Making Medical Treatment Decisions for Unrepresented Patients in the ICU. An
      Official American Thoracic Society/American Geriatrics Society Policy Statement.
PG  - 1182-1192
LID - 10.1164/rccm.202003-0512ST [doi]
AB  - Background and Rationale: ICU clinicians regularly care for patients who lack
      capacity, an applicable advance directive, and an available surrogate
      decision-maker. Although there is no consensus on terminology, we refer to these 
      patients as "unrepresented." There is considerable controversy about how to make 
      treatment decisions for these patients, and there is significant variability in
      both law and clinical practice.Purpose and Objectives: This multisociety
      statement provides clinicians and hospital administrators with recommendations
      for decision-making on behalf of unrepresented patients in the critical care
      setting.Methods: An interprofessional, multidisciplinary expert committee
      developed this policy statement by using an iterative consensus process with a
      diverse working group representing critical care medicine, palliative care,
      pediatric medicine, nursing, social work, gerontology, geriatrics, patient
      advocacy, bioethics, philosophy, elder law, and health law.Main Results: The
      committee designed its policy recommendations to promote five ethical goals: 1)
      to protect highly vulnerable patients, 2) to demonstrate respect for persons, 3) 
      to provide appropriate medical care, 4) to safeguard against unacceptable
      discrimination, and 5) to avoid undue influence of competing obligations and
      conflicting interests. These recommendations also are intended to strike an
      appropriate balance between excessive and insufficient procedural safeguards. The
      committee makes the following recommendations: 1) institutions should offer
      advance care planning to prevent patients at high risk for becoming unrepresented
      from meeting this definition; 2) institutions should implement strategies to
      determine whether seemingly unrepresented patients are actually unrepresented,
      including careful capacity assessments and diligent searches for potential
      surrogates; 3) institutions should manage decision-making for unrepresented
      patients using input from a diverse interprofessional, multidisciplinary
      committee rather than ad hoc by treating clinicians; 4) institutions should use
      all available information on the patient's preferences and values to guide
      treatment decisions; 5) institutions should manage decision-making for
      unrepresented patients using a fair process that comports with procedural due
      process; 6) institutions should employ this fair process even when state law
      authorizes procedures with less oversight.Conclusions: This multisociety
      statement provides guidance for clinicians and hospital administrators on medical
      decision-making for unrepresented patients in the critical care setting.
FAU - Pope, Thaddeus M
AU  - Pope TM
AUID- ORCID: 0000-0002-7163-505X
FAU - Bennett, Joshua
AU  - Bennett J
FAU - Carson, Shannon S
AU  - Carson SS
AUID- ORCID: 0000-0001-6220-7005
FAU - Cederquist, Lynette
AU  - Cederquist L
FAU - Cohen, Andrew B
AU  - Cohen AB
FAU - DeMartino, Erin S
AU  - DeMartino ES
FAU - Godfrey, David M
AU  - Godfrey DM
FAU - Goodman-Crews, Paula
AU  - Goodman-Crews P
FAU - Kapp, Marshall B
AU  - Kapp MB
FAU - Lo, Bernard
AU  - Lo B
FAU - Magnus, David C
AU  - Magnus DC
FAU - Reinke, Lynn F
AU  - Reinke LF
FAU - Shirley, Jamie L
AU  - Shirley JL
FAU - Siegel, Mark D
AU  - Siegel MD
FAU - Stapleton, Renee D
AU  - Stapleton RD
FAU - Sudore, Rebecca L
AU  - Sudore RL
AUID- ORCID: 0000-0003-4436-2209
FAU - Tarzian, Anita J
AU  - Tarzian AJ
FAU - Thornton, J Daryl
AU  - Thornton JD
FAU - Wicclair, Mark R
AU  - Wicclair MR
FAU - Widera, Eric W
AU  - Widera EW
FAU - White, Douglas B
AU  - White DB
AUID- ORCID: 0000-0003-2269-4173
LA  - eng
GR  - K24 HL148314/HL/NHLBI NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
SB  - IM
CIN - Am J Respir Crit Care Med. 2020 Nov 15;202(10):1483-1484. PMID: 32804538
CIN - Am J Respir Crit Care Med. 2020 Nov 15;202(10):1484-1485. PMID: 32805136
MH  - Advance Care Planning
MH  - Clinical Decision-Making
MH  - Critical Care/ethics/*standards
MH  - Decision Making/*ethics
MH  - Geriatrics
MH  - Humans
MH  - *Intensive Care Units
MH  - Judgment
MH  - Patient Advocacy
MH  - Patient Care Team
MH  - Patient Preference
MH  - *Proxy
MH  - Pulmonary Medicine
MH  - Societies, Medical
PMC - PMC7233335
OTO - NOTNLM
OT  - *adult orphan
OT  - *patient without advocate
OT  - *substituted judgment
OT  - *surrogate
OT  - *unrepresented
EDAT- 2020/05/16 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
AID - 10.1164/rccm.202003-0512ST [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2020 May 15;201(10):1182-1192. doi:
      10.1164/rccm.202003-0512ST.


PMID- 32412837
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20220101
IS  - 1931-7913 (Electronic)
IS  - 1931-7913 (Linking)
VI  - 19
IP  - 2
DP  - 2020 Jun
TI  - Entering Research Learning Assessment (ERLA): Validity Evidence for an Instrument
      to Measure Undergraduate and Graduate Research Trainee Development.
PG  - ar18
LID - 10.1187/cbe.19-07-0146 [doi]
AB  - Expanding the scope of previous undergraduate research assessment tools, the
      Entering Research Learning Assessment (ERLA) measures undergraduate and graduate 
      research trainee learning gains in the seven areas of trainee development in the 
      evidence-based Entering Research conceptual framework: Research Comprehension and
      Communication Skills, Practical Research Skills, Research Ethics, Researcher
      Identity, Researcher Confidence and Independence, Equity and Inclusion Awareness 
      and Skills, and Professional and Career Development Skills. In this paper, we
      present multiple sources of validity evidence for the ERLA trainee
      self-assessment and mentor assessment of trainee learning gains. Evidence of
      internal structure of the initial scales via exploratory factor analysis
      (Ntrainees = 193; Nmentors = 130) revealed seven factors that align with the
      Entering Research conceptual framework. Validity evidence for internal structure 
      using confirmatory factor analysis, convergent validity, and evidence of internal
      consistency for the revised scale were examined with a larger sample (Ntrainees =
      489; Nmentors = 256). Evidence of internal structure and alignment for a paired
      version of the ERLA was also examined with a subset of the original sample (N =
      121 pairs). Each analysis revealed acceptable model-data fit. Guidance on using
      the ERLA instruments and interpreting their scores is presented.
FAU - Butz, Amanda R
AU  - Butz AR
AD  - Wisconsin Institute for Science Education and Community Engagement, University of
      Wisconsin-Madison, Madison, WI 53706.
FAU - Branchaw, Janet L
AU  - Branchaw JL
AD  - Wisconsin Institute for Science Education and Community Engagement, University of
      Wisconsin-Madison, Madison, WI 53706.
AD  - Department of Kinesiology, University of Wisconsin-Madison, Madison, WI 53706.
LA  - eng
GR  - U54 GM119023/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - CBE Life Sci Educ
JT  - CBE life sciences education
JID - 101269039
SB  - IM
MH  - Factor Analysis, Statistical
MH  - *Learning
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - Research
MH  - *Self-Assessment
PMC - PMC8697654
EDAT- 2020/05/16 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.1187/cbe.19-07-0146 [doi]
PST - ppublish
SO  - CBE Life Sci Educ. 2020 Jun;19(2):ar18. doi: 10.1187/cbe.19-07-0146.


PMID- 32412580
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210301
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 323
IP  - 23
DP  - 2020 Jun 16
TI  - An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in 
      the US.
PG  - 2367-2368
LID - 10.1001/jama.2020.8914 [doi]
FAU - DeJong, Colette
AU  - DeJong C
AD  - Department of Medicine, University of California, San Francisco.
FAU - Chen, Alice Hm
AU  - Chen AH
AD  - Department of Medicine, University of California, San Francisco.
FAU - Lo, Bernard
AU  - Lo B
AD  - Department of Medicine, University of California, San Francisco.
AD  - The Greenwall Foundation, New York, New York.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - COVID-19 drug treatment
SB  - IM
CIN - Hastings Cent Rep. 2021 Jan;51(1):39-46. PMID: 33630329
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy
MH  - Ethics, Medical
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Inpatients
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - Social Justice
EDAT- 2020/05/16 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 2766294 [pii]
AID - 10.1001/jama.2020.8914 [doi]
PST - ppublish
SO  - JAMA. 2020 Jun 16;323(23):2367-2368. doi: 10.1001/jama.2020.8914.


PMID- 32411831
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Growth hormone treatment in Prader-Willi syndrome patients: systematic review and
      meta-analysis.
PG  - e000630
LID - 10.1136/bmjpo-2019-000630 [doi]
AB  - BACKGROUND: Growth hormone (GH) treatment is currently recommended in
      Prader-Willi syndrome (PWS) patients. OBJECTIVES: To evaluate the impact
      (efficacy and safety) of the use of recombinant human GH (rhGH) as a treatment
      for PWS. METHOD: We performed a systematic review and, where possible,
      meta-analysis for the following outcomes: growth, body mass index, body
      composition, cognitive function, quality of life, head circumference, motor
      development/strength, behaviour and adverse effects. We included all PWS
      patients, with all types of genetic defects and with or without GH deficiency,
      who participated in rhGH studies performed in infancy, childhood and adolescence,
      that were either randomised controlled trials (RCTs) (double-blinded or not) or
      non-randomised controlled trials (NRCTs) (cohort and before and after studies).
      The databases used were MEDLINE, Embase and Cochrane Central. RESULTS: In 16 RCTs
      and 20 NRCTs selected, the treated group had an improvement in height (1.67 SD
      scores (SDS); 1.54 to 1.81); body mass index z-scores (-0.67 SDS; -0.87 to -0.47)
      and fat mass proportion (-6.5% SDS; -8.46 to -4.54) compared with the control
      group. Data about cognition could not be aggregated. Conclusion Based on high
      quality evidence, rhGH treatment favoured an improvement of stature, body
      composition and body mass index, modifying the disease's natural history; rhGH
      treatment may also be implicated in improved cognition and motor development in
      PWS patients at a young age. ETHICS AND DISSEMINATION: The current review was
      approved by the ethical committee of our institution. The results will be
      disseminated through conference presentations and publications in peer-reviewed
      journals. PROSPERO REGISTRATION NUMBER: CRD42019140295.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Passone, Caroline de Gouveia Buff
AU  - Passone CGB
AUID- ORCID: 0000-0001-7981-3335
AD  - Pediatric Endocrinology Unit, Universidade de Sao Paulo, Sao Paulo, Brazil.
AD  - Pediatric Endocrinology, Gynecology and Diabetology, Centre de Reference des
      Pathologies Gynecologiques Rares et des Maladies Endocriniennes Rares de la
      Croissance et du Developpement, Hopital Universitaire Necker Enfants Malades,
      Universite Paris Descartes, Paris, France, Paris, France.
FAU - Franco, Ruth Rocha
AU  - Franco RR
AD  - Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Ito, Simone Sakura
AU  - Ito SS
AD  - Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Trindade, Evelinda
AU  - Trindade E
AD  - Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Polak, Michel
AU  - Polak M
AD  - Pediatric Endocrinology, Gynecology and Diabetology, Centre de Reference des
      Pathologies Gynecologiques Rares et des Maladies Endocriniennes Rares de la
      Croissance et du Developpement, Hopital Universitaire Necker Enfants Malades,
      Universite Paris Descartes, Paris, France, Paris, France.
FAU - Damiani, Durval
AU  - Damiani D
AD  - Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Bernardo, Wanderley Marques
AU  - Bernardo WM
AD  - Universidade de Sao Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Systematic Review
DEP - 20200429
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7213882
OTO - NOTNLM
OT  - endocrinology
OT  - genetics
OT  - growth
OT  - obesity
OT  - syndrome
COIS- Competing interests: No, there are no competing interests.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - 10.1136/bmjpo-2019-000630 [doi]
AID - bmjpo-2019-000630 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Apr 29;4(1):e000630. doi: 10.1136/bmjpo-2019-000630.
      eCollection 2020.


PMID- 32411830
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2399-9772 (Electronic)
IS  - 2399-9772 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - Healthcare access for children and families on the move and migrants.
PG  - e000588
LID - 10.1136/bmjpo-2019-000588 [doi]
AB  - BACKGROUND: The United Kingdom (UK) National Health Service (NHS) charging
      regulations have increasingly restricted migrants' healthcare access, in the
      context of a wider national policy shift over the past few years intending to
      create a 'hostile environment' for migrants. With an estimated 144 000
      undocumented children living in the UK and increasing public concern that these
      regulations are negatively impacting migrant health and well-being, as well as
      contravening international child rights agreements, it has become imperative to
      understand their implications. METHODS: A mixed methods digital survey, covering 
      attitudes towards and understanding of UK healthcare charging, and giving space
      for relevant case submission, was disseminated through communications channels of
      the Royal College of Paediatrics and Child Health (RCPCH) to their members.
      Quantitative data were analysed on Stata, and basic proportions were calculated
      for each response proportion. Qualitative data were analysed using a framework
      analysis approach. RESULTS: There were 200 responses, from a range of healthcare 
      professional backgrounds. The majority were not confident in interpreting and
      applying the charging regulations. One-third (34%) reported examples of the
      charging regulations impacting patient care, analysis of which elicited seven key
      themes. Our survey gathered 18 cases of migrants being deterred from accessing
      healthcare, 11 cases of healthcare being delayed or denied outright, and 12 cases
      of delay in accessing care leading to worse health outcomes, including two
      intrauterine deaths. DISCUSSION: Our results describe a range of harms arising
      from the current NHS charging regulations contributing to delays in or denials of
      healthcare, due to patients' fear of charging or immigration enforcement,
      including potential deportation, and confusion around entitlements. This harm
      affects individual patients, the migrant community and the NHS - often in
      multiple simultaneous ways. Many patients eligible for NHS care, such as
      trafficking victims, are not being identified as such. We found the current
      charging regulations to be unworkable, and that harm could not be eliminated
      simply through improved awareness or implementation.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Murphy, Lisa
AU  - Murphy L
AUID- ORCID: 0000-0002-0594-9501
AD  - Medact, London, UK.
FAU - Broad, Jonathan
AU  - Broad J
AD  - Medact, London, UK.
FAU - Hopkinshaw, Bryony
AU  - Hopkinshaw B
AD  - Medact, London, UK.
FAU - Boutros, Sarah
AU  - Boutros S
AD  - Institute of child health, University College London Institute of Child Health,
      London, UK.
FAU - Russell, Neal
AU  - Russell N
AD  - Molecular and Clinical Sciences Research Institute, University of London St
      George's Molecular and Clinical Sciences Research Institute, London, UK.
FAU - Firth, Alison
AU  - Firth A
AD  - Royal College of Paediatrics and Child Health, London, UK.
FAU - McKeown, Rachael
AU  - McKeown R
AD  - Royal College of Paediatrics and Child Health, London, UK.
FAU - Steele, Alison
AU  - Steele A
AD  - Royal College of Paediatrics and Child Health, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200413
PL  - England
TA  - BMJ Paediatr Open
JT  - BMJ paediatrics open
JID - 101715309
PMC - PMC7213513
OTO - NOTNLM
OT  - children's rights
OT  - ethics
OT  - health service
OT  - paediatric practice
COIS- Competing interests: None delared.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2019/10/14 00:00 [received]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - 10.1136/bmjpo-2019-000588 [doi]
AID - bmjpo-2019-000588 [pii]
PST - epublish
SO  - BMJ Paediatr Open. 2020 Apr 13;4(1):e000588. doi: 10.1136/bmjpo-2019-000588.
      eCollection 2020.


PMID- 32411540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Linking)
VI  - 8
DP  - 2020
TI  - Multimode ultrasonic technique is recommended for the differential diagnosis of
      thyroid cancer.
PG  - e9112
LID - 10.7717/peerj.9112 [doi]
AB  - BACKGROUND: B-mode ultrasound is one of the most commonly used imaging techniques
      for evaluating thyroid nodules due to its noninvasive property and excellent
      performance in terms of discriminating between benign and malignant nodules.
      However, the accuracy of differential diagnosis strongly depends on the
      experience of ultrasonographers. In addition to B-mode ultrasound, the elastic
      mode and contrast-enhanced mode have shown complimentary value in the diagnosis
      of thyroid nodules. The combination of multiple modes in ultrasonic techniques
      may effectively undermine diagnostic subjectiveness and improve accuracy. In this
      study, we evaluated the diagnostic value of combining the three ultrasonic modes 
      for differentiating thyroid cancers. METHODS: In this retrospective study, we
      analyzed a total of 196 thyroid nodules with suspected malignancies from 185
      patients who gave informed consent. Xi'an Jiaotong University granted ethical
      approval (No. 2018200) to carry out the study within its facilities. All the
      patients received ultrasonic examinations with the B mode, elastic mode and
      contrast-enhanced mode, followed by histopathological confirmation by fine-need
      aspiration or surgery. A predictive multivariate logistic regression model was
      selected to integrate the variety of data obtained from the three modes. RESULTS:
      The combination of three ultrasonic techniques for differentiating malignant from
      benign thyroid nodules showed the highest diagnostic accuracy of 0.985 compared
      to the B mode alone (0.841) and the two-mode combination. The accuracy of the B
      mode combined with the elastic technique was 0.954, and the accuracy of the B
      mode combined with the contrast-enhanced technique was 0.960. DISCUSSION:
      Multimode ultrasonic techniques should be recommended to patients with suspected 
      malignant thyroid nodules in routine clinical practice.
CI  - (c) 2020 Wang et al.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Ultrasound, The Second Affiliated Hospital, Medical School of Xi'an
      Jiaotong University, Xi'an, China.
FAU - He, Xin
AU  - He X
AD  - Department of Ultrasound, The Second Affiliated Hospital, Medical School of Xi'an
      Jiaotong University, Xi'an, China.
FAU - Ma, Li
AU  - Ma L
AD  - Department of Pathology, The Second Affiliated Hospital, Medical School of Xi'an 
      Jiaotong University, Xi'an, China.
FAU - Li, Miao
AU  - Li M
AD  - Department of Ultrasound, The Second Affiliated Hospital, Medical School of Xi'an
      Jiaotong University, Xi'an, China.
FAU - Sun, Lei
AU  - Sun L
AD  - Department of Ultrasound, The Second Affiliated Hospital, Medical School of Xi'an
      Jiaotong University, Xi'an, China.
FAU - Jiang, Jue
AU  - Jiang J
AD  - Department of Ultrasound, The Second Affiliated Hospital, Medical School of Xi'an
      Jiaotong University, Xi'an, China.
FAU - Zhou, Qi
AU  - Zhou Q
AD  - Department of Ultrasound, The Second Affiliated Hospital, Medical School of Xi'an
      Jiaotong University, Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20200504
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC7204870
OTO - NOTNLM
OT  - B-mode ultrasound
OT  - Contrast-enhanced ultrasound
OT  - Shear wave elastography
OT  - Thyroid nodule
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - 10.7717/peerj.9112 [doi]
AID - 9112 [pii]
PST - epublish
SO  - PeerJ. 2020 May 4;8:e9112. doi: 10.7717/peerj.9112. eCollection 2020.


PMID- 32411249
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1687-8876 (Print)
IS  - 1687-8876 (Linking)
VI  - 2020
DP  - 2020
TI  - Rat Olfactory Mucosa Mesenchymal Stem/Stromal Cells (OM-MSCs): A Characterization
      Study.
PG  - 2938258
LID - 10.1155/2020/2938258 [doi]
AB  - Stem/stromal cell-based therapies are a branch of regenerative medicine and stand
      as an attractive option to promote the repair of damaged or dysfunctional tissues
      and organs. Olfactory mucosa mesenchymal stem/stromal cells have been regarded as
      a promising tool in regenerative therapies because of their several favorable
      properties such as multipotency, high proliferation rate, helpful location, and
      few associated ethical issues. These cells are easily accessible in the nasal
      cavity of most mammals, including the rat, can be easily applied in autologous
      treatments, and do not cope with most of the obstacles associated with the use of
      other stem cells. Despite this, its application in preclinical trials and in both
      human and animal patients is still limited because of the small number of studies
      performed so far and to the nonexistence of a standard and unambiguous protocol
      for collection, isolation, and therapeutic application. In the present work a
      validation of a protocol for isolation, culture, expansion, freezing, and thawing
      of olfactory mucosa mesenchymal stem/stromal cells was performed, applied to the 
      rat model, as well as a biological characterization of these cells. To
      investigate the therapeutic potential of OM-MSCs and their eventual safe
      application in preclinical trials, the main characteristics of OMSC stemness were
      addressed.
CI  - Copyright (c) 2020 Rui D. Alvites et al.
FAU - Alvites, Rui D
AU  - Alvites RD
AUID- ORCID: https://orcid.org/0000-0003-1945-6377
AD  - Departamento de Clinicas Veterinarias, Instituto de Ciencias Biomedicas de Abel
      Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n
      masculine 228, 4050-313 Porto, Portugal.
AD  - Centro de Estudos de Ciencia Animal (CECA), Instituto de Ciencias, Tecnologias e 
      Agroambiente da Universidade do Porto (ICETA), Rua D. Manuel II, Apartado 55142, 
      4051-401 Porto, Portugal.
FAU - Branquinho, Mariana V
AU  - Branquinho MV
AUID- ORCID: https://orcid.org/0000-0003-1328-464X
AD  - Departamento de Clinicas Veterinarias, Instituto de Ciencias Biomedicas de Abel
      Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n
      masculine 228, 4050-313 Porto, Portugal.
AD  - Centro de Estudos de Ciencia Animal (CECA), Instituto de Ciencias, Tecnologias e 
      Agroambiente da Universidade do Porto (ICETA), Rua D. Manuel II, Apartado 55142, 
      4051-401 Porto, Portugal.
FAU - Caseiro, Ana R
AU  - Caseiro AR
AD  - Departamento de Clinicas Veterinarias, Instituto de Ciencias Biomedicas de Abel
      Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n
      masculine 228, 4050-313 Porto, Portugal.
AD  - Centro de Estudos de Ciencia Animal (CECA), Instituto de Ciencias, Tecnologias e 
      Agroambiente da Universidade do Porto (ICETA), Rua D. Manuel II, Apartado 55142, 
      4051-401 Porto, Portugal.
AD  - REQUIMTE/LAQV - U. Porto - Porto/Portugal, Departamento de Engenharia Metalurgica
      e Materiais, Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto
      Frias, s/n, 4200-465 Porto, Portugal.
AD  - Escola Universitaria Vasco da Gama (EUVG), Avenida Jose R. Sousa Fernandes, n
      masculine 197 Lordemao, 3020-210 Coimbra, Portugal.
FAU - Amorim, Irina
AU  - Amorim I
AUID- ORCID: https://orcid.org/0000-0002-2079-216X
AD  - Departamento de Patologia e Imunologia Molecular, Instituto de Ciencias
      Biomedicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge
      Viterbo Ferreira, n masculine 228, 4050-313 Porto, Portugal.
AD  - i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto, R.
      Alfredo Allen, 4200-135 Porto, Portugal.
AD  - Institute of Molecular Pathology and Immunology of the University of Porto
      (IPATIMUP), 4200-465 Porto, Portugal.
FAU - Santos Pedrosa, Silvia
AU  - Santos Pedrosa S
AUID- ORCID: https://orcid.org/0000-0002-2055-8031
AD  - Departamento de Clinicas Veterinarias, Instituto de Ciencias Biomedicas de Abel
      Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n
      masculine 228, 4050-313 Porto, Portugal.
AD  - Centro de Estudos de Ciencia Animal (CECA), Instituto de Ciencias, Tecnologias e 
      Agroambiente da Universidade do Porto (ICETA), Rua D. Manuel II, Apartado 55142, 
      4051-401 Porto, Portugal.
FAU - Rema, Alexandra
AU  - Rema A
AUID- ORCID: https://orcid.org/0000-0003-4319-2404
AD  - Departamento de Patologia e Imunologia Molecular, Instituto de Ciencias
      Biomedicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge
      Viterbo Ferreira, n masculine 228, 4050-313 Porto, Portugal.
FAU - Faria, Fatima
AU  - Faria F
AD  - Departamento de Patologia e Imunologia Molecular, Instituto de Ciencias
      Biomedicas de Abel Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge
      Viterbo Ferreira, n masculine 228, 4050-313 Porto, Portugal.
FAU - Porto, Beatriz
AU  - Porto B
AUID- ORCID: https://orcid.org/0000-0003-4281-5438
AD  - Laboratorio de Citogenetica, Instituto de Ciencias Biomedicas de Abel Salazar
      (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n masculine
      228, 4050-313 Porto, Portugal.
FAU - Oliveira, Claudia
AU  - Oliveira C
AUID- ORCID: https://orcid.org/0000-0003-0556-406X
AD  - Laboratorio de Citogenetica, Instituto de Ciencias Biomedicas de Abel Salazar
      (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n masculine
      228, 4050-313 Porto, Portugal.
FAU - Teixeira, Paula
AU  - Teixeira P
AUID- ORCID: https://orcid.org/0000-0002-6296-5137
AD  - Universidade Catolica Portuguesa, CBQF - Centro de Biotecnologia e Quimica Fina -
      Laboratorio Associado, Escola Superior de Biotecnologia, Rua Arquiteto Lobao
      Vital 172, 4200-374 Porto, Portugal.
FAU - Magalhaes, Rui
AU  - Magalhaes R
AUID- ORCID: https://orcid.org/0000-0003-3172-440X
AD  - Universidade Catolica Portuguesa, CBQF - Centro de Biotecnologia e Quimica Fina -
      Laboratorio Associado, Escola Superior de Biotecnologia, Rua Arquiteto Lobao
      Vital 172, 4200-374 Porto, Portugal.
FAU - Geuna, Stefano
AU  - Geuna S
AUID- ORCID: https://orcid.org/0000-0002-6962-831X
AD  - Department of Clinical and Biological Sciences, and Cavalieri Ottolenghi
      Neuroscience Institute, University of Turin, Ospedale San Luigi, 10043 Orbassano,
      Turin, Italy.
FAU - Varejao, Artur S P
AU  - Varejao ASP
AUID- ORCID: https://orcid.org/0000-0002-0736-3635
AD  - Departamento de Ciencias Veterinarias, Universidade de Tras-os-Montes e Alto
      Douro (UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal.
AD  - CECAV, Centro de Ciencia Animal e Veterinaria, Universidade de Tras-os-Montes e
      Alto Douro (UTAD), Quinta de Prados, 5001-801 Vila Real, Portugal.
FAU - Mauricio, Ana C
AU  - Mauricio AC
AUID- ORCID: https://orcid.org/0000-0002-0018-9363
AD  - Departamento de Clinicas Veterinarias, Instituto de Ciencias Biomedicas de Abel
      Salazar (ICBAS), Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, n
      masculine 228, 4050-313 Porto, Portugal.
AD  - Centro de Estudos de Ciencia Animal (CECA), Instituto de Ciencias, Tecnologias e 
      Agroambiente da Universidade do Porto (ICETA), Rua D. Manuel II, Apartado 55142, 
      4051-401 Porto, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20200129
PL  - United States
TA  - Int J Cell Biol
JT  - International journal of cell biology
JID - 101517861
PMC - PMC7212324
COIS- The author(s) declare(s) that there are no conflicts of interest regarding the
      publication of this article.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2019/05/10 00:00 [received]
PHST- 2019/09/28 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - 10.1155/2020/2938258 [doi]
PST - epublish
SO  - Int J Cell Biol. 2020 Jan 29;2020:2938258. doi: 10.1155/2020/2938258. eCollection
      2020.


PMID- 32410902
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1537-2073 (Print)
IS  - 1537-2073 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Mar-Apr
TI  - The Dilemma of When to Stop Disease-Modifying Therapy in Multiple Sclerosis: A
      Narrative Review and Canadian Regional Reimbursement Policies.
PG  - 75-84
LID - 10.7224/1537-2073.2018-107 [doi]
AB  - BACKGROUND: Disease-modifying therapy (DMT) has changed the landscape of multiple
      sclerosis (MS) care. However, there is lack of consensus on the duration of
      treatment and the selection of individuals most likely to benefit from continued 
      treatment. Current evidence, practice guidelines, health policy, and ethical
      considerations presented together may further inform challenging clinical
      decision making and future directions. The objectives of this study were to
      conduct a narrative review of original research and practice guideline
      recommendations on discontinuation of DMTs in MS; to collect information
      regarding Canadian regional reimbursement policies for DMT coverage in MS; and to
      present ethical considerations applicable to such decision making. METHODS: A
      literature review was conducted of the MEDLINE/PubMed, OneFile (GALE), Scopus
      (Elsevier), and ProQuest Biological Science Collection databases. Data regarding 
      Canadian regional reimbursement policies for DMT coverage in MS were collected
      from the ministry/government websites. Ethical considerations were reviewed in
      the context of the identified evidence, guidelines, and policies. RESULTS: The
      literature lacks evidence from prospective randomized controlled trials that
      directly addresses the issue of discontinuation of DMTs in MS. Current practice
      guidelines advocate the vital role of patient choice in decision making. There
      are regional variations in Expanded Disability Status Scale criteria scores for
      continuing MS DMT coverage among Canadian provinces/territories. CONCLUSIONS: In 
      the absence of strong evidence on discontinuation of DMTs, shared decision making
      and consideration of the ethical complexities could help in the decision-making
      process.
CI  - (c) 2020 Consortium of Multiple Sclerosis Centers.
FAU - Knox, Katherine B
AU  - Knox KB
FAU - Saini, Aman
AU  - Saini A
FAU - Levin, Michael C
AU  - Levin MC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J MS Care
JT  - International journal of MS care
JID - 101132980
PMC - PMC7204360
OTO - NOTNLM
OT  - Disease-modifying therapy (DMT)
OT  - Ethics
OT  - Multiple sclerosis (MS)
OT  - Practice guidelines
OT  - Reimbursement
COIS- Dr Knox is the primary investigator for the Saskatchewan MS Drugs Research
      Program funded by the Saskatchewan Ministry of Health, is a member of the
      Saskatchewan MS Drugs review panel for the Saskatchewan Ministry of Health, and
      has received funding from the Canadian Institute for Health Information for
      participation in the former Canadian MS Monitoring System. Dr Levin has received 
      educational and/or consulting funding from Biogen, Pendopharm, and Sanofi
      Genzyme. Dr Saini declares no conflicts of interest.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - 10.7224/1537-2073.2018-107 [doi]
PST - ppublish
SO  - Int J MS Care. 2020 Mar-Apr;22(2):75-84. doi: 10.7224/1537-2073.2018-107.


PMID- 32410895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1512-7680 (Print)
IS  - 1512-7680 (Linking)
VI  - 32
IP  - 1
DP  - 2020 Mar
TI  - Spiritual Climate as is Perceived by Greek Clinical Nurses. A Validation study.
PG  - 66-70
LID - 10.5455/msm.2020.32.66-70 [doi]
AB  - INTRODUCTION: Organisational climate generally refers to issues such as
      information sharing climate, appreciation and recognition, concern for employee
      well-being, ethics and quality performance. In hospitals, it represents the
      shared beliefs and values that may affect the quality of care in health care
      groups and which could be managed to improve the quality of care. AIM: Aim of the
      study was the translation of the Spiritual climate Scale (SCS) in Greek language 
      and the validation of the scale for the Greek population. METHODS: The SCS is an 
      anonymous self-administered questionnaire that contains four, five-point Likert
      scale, closed questions. The questionnaire was translated into Greek language and
      then back translated in the English in order to be checked for any
      inconsistencies. The sample of the study was 275 nurses, working in two public
      hospital in Athens. Exploratory factor analysis, with principal components
      analysis was performed for checking the construct validity of the questionnaire. 
      The test-retest reliability and the internal consistency were also examined.
      Statistical analysis performed by the use of SPSS 25.0. Statistical significance 
      level was set at p=0.05. RESULTS: From the total 275 of the participants
      238(86.5%) were women and the mean age was 43.8+/-8.7. The final Greek version of
      the questionnaire includes all of the four questions and one factor was exported 
      from the exploratory factor analysis. The Cronbach-alpha coefficient was 0.902
      for the total questionnaire. CONCLUSIONS: The SCS is a valid and reliable
      questionnaire that can be used for assessing spiritual climate in Greek clinical 
      areas.
CI  - (c) 2020 Evangelos C. Fradelos, Foteini Tzavella.
FAU - Fradelos, Evangelos C
AU  - Fradelos EC
AD  - Internal Medicine Department, Special Infections Unit, Athens Hospital for Chest 
      Diseases "Sotiria", Athens, Greece.
FAU - Tzavella, Foteini
AU  - Tzavella F
AD  - Nursing Department, University of Peloponnese, Tripoli, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Bosnia and Herzegovina
TA  - Mater Sociomed
JT  - Materia socio-medica
JID - 101281595
PMC - PMC7219727
OTO - NOTNLM
OT  - Reliability
OT  - Validity
OT  - spiritual climate
OT  - spirituality
COIS- None declared.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - 10.5455/msm.2020.32.66-70 [doi]
AID - MSM-32-66 [pii]
PST - ppublish
SO  - Mater Sociomed. 2020 Mar;32(1):66-70. doi: 10.5455/msm.2020.32.66-70.


PMID- 32410707
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 14
TI  - Knowledge and attitudes of physicians toward research ethics and scientific
      misconduct in Lebanon.
PG  - 39
LID - 10.1186/s12910-020-00475-5 [doi]
AB  - BACKGROUND: Despite the implementation of codes and declarations of medical
      research ethics, unethical behavior is still reported among researchers. Most of 
      the medical faculties have included topics related to medical research ethics and
      developed ethical committees; yet, in some cases, unethical behaviors are still
      observed, and many obstacles are still conferring to applying these guidelines.
      METHODS: This cross-sectional questionnaire-based study was conducted by
      interviewing randomly selected 331 Lebanese physicians across Lebanon, to assess 
      their awareness, knowledge and attitudes on practice regarding international and 
      national research ethics guidelines (Lebanese decrees/Laws and CNRS chart of
      ethics) and scientific misconduct and misbehaviors. RESULTS: Our results revealed
      that although majority of participants declared familiar with ethical principles 
      governing research that involves human subjects (79.5%), the overall mean score
      achieved on their knowledge questions was 46%. Only 27.4% are aware of the
      presence of the Lebanese National Consultative Committee on Ethics (LNCCE), with 
      only half of them aware of its functions and only 25.7% know about the charter of
      ethics and guiding principles of scientific research in Lebanon. Significant
      higher levels of research ethics knowledge were recorded among Ph.D.
      degree-holding subjects, higher university positions as in professors, research
      ethics trainings-attendees, and physicians with prior research experience. A
      significant correlation was observed between knowledge of research ethics
      principles and positive attitudes toward research ethics principles. Noteworthy, 
      we found that more than one third of participants have reported witnessing
      scientific misconduct and misbehaviors at some period of their careers.
      CONCLUSIONS: The presence of low mean awareness levels regarding research ethical
      principles among the study population of physicians and high levels of perception
      of scientific misconduct raises concern on the importance of implementing proper 
      training for physicians on research ethics.
FAU - Azakir, Bilal
AU  - Azakir B
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
FAU - Mobarak, Hassan
AU  - Mobarak H
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
FAU - Al Najjar, Sami
AU  - Al Najjar S
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
FAU - El Naga, Azza Abou
AU  - El Naga AA
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
FAU - Mashaal, Najlaa
AU  - Mashaal N
AD  - Faculty of Medicine, Beirut Arab University, Beirut, Lebanon.
      najlaa.mashaal@bau.edu.lb.
LA  - eng
GR  - 12-05-18/Joint Fund between Beirut Arab University and the Lebanese National
      Counsil for Scientific Research (LNCSR)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200514
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Attitude
MH  - Child
MH  - Cross-Sectional Studies
MH  - Ethics, Research
MH  - Female
MH  - Humans
MH  - Lebanon
MH  - Male
MH  - *Physicians
MH  - *Scientific Misconduct
MH  - Surveys and Questionnaires
PMC - PMC7227247
OTO - NOTNLM
OT  - *Attitude
OT  - *Knowledge
OT  - *Lebanon
OT  - *Misconduct
OT  - *Physicians
OT  - *Research ethics
EDAT- 2020/05/16 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/08/30 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00475-5 [doi]
AID - 10.1186/s12910-020-00475-5 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 14;21(1):39. doi: 10.1186/s12910-020-00475-5.


PMID- 32410486
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Can financial rewards complement altruism to raise deceased organ donation rates?
PG  - 1436-1449
LID - 10.1177/0969733020918927 [doi]
AB  - BACKGROUND: Organ supply-demand in developing countries worldwide has continued
      to widen. Hence, using a large survey (n (1/4) 10,412), this study seeks to
      investigate whether human psychology could be used to inculcate philanthropy to
      raise deceased organ donation rates. METHODS: Three models were constructed to
      examine multidimensional relationships among the variables. Structural equation
      modeling was applied to estimate the direct and indirect influence of altruism,
      financial incentives, donation perception, and socioeconomic status
      simultaneously on willingness to donate deceased organs. ETHICAL CONSIDERATIONS: 
      The study was approved by the University of Malaya ethics committee. RESULTS: The
      results show that altruism amplifies the impact of socioeconomic status and
      donation perception on willingness to donate. Also, the results show that
      financial incentives cannot complement altruism to raise organ donation rates.
      Hence, investing in education and public awareness enhances altruism in people,
      which then increases the propensity to donate. CONCLUSION: Evidence suggests that
      governments should allocate resources to increase public awareness about organ
      donation. Awareness programs about the importance of philanthropic donations and 
      the participation of medical consultants at hospitals in the processes form the
      foundation of such a presumptive approach.
FAU - Rasiah, Rajah
AU  - Rasiah R
AD  - 37447University of Malaya, Malaysia.
FAU - Naghavi, Navaz
AU  - Naghavi N
AD  - 65214Taylor's University, Malaysia.
FAU - Mubarik, Muhammad Shujaat
AU  - Mubarik MS
AD  - Mohammad Ali Jinnah University, Pakistan.
FAU - Nia, Hamid Sharif
AU  - Nia HS
AUID- ORCID: https://orcid.org/0000-0002-5570-3710
AD  - Mazandaran University of Medical Sciences, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - *Altruism
MH  - Female
MH  - Gift Giving/*ethics
MH  - Humans
MH  - Male
MH  - Motivation
MH  - Surveys and Questionnaires
MH  - Tissue and Organ Procurement/methods/*statistics & numerical data
OTO - NOTNLM
OT  - Altruism
OT  - donation perception
OT  - financial incentives
OT  - structural equation modeling
OT  - willingness to donate
EDAT- 2020/05/16 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1177/0969733020918927 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1436-1449. doi: 10.1177/0969733020918927. Epub 2020
      May 15.


PMID- 32410225
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20220716
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Covid-19: Ethical Challenges for Nurses.
PG  - 35-39
LID - 10.1002/hast.1110 [doi]
AB  - The Covid-19 pandemic has highlighted many of the difficult ethical issues that
      health care professionals confront in caring for patients and families. The
      decisions such workers face on the front lines are fraught with uncertainty for
      all stakeholders. Our focus is on the implications for nurses, who are the
      largest global health care workforce but whose perspectives are not always fully 
      considered. This essay discusses three overarching ethical issues that create a
      myriad of concerns and will likely affect nurses globally in unique ways: the
      safety of nurses, patients, colleagues, and families; the allocation of scarce
      resources; and the changing nature of nurses' relationships with patients and
      families. We urge policy-makers to ensure that nurses' voices and perspectives
      are integrated into both local and global decision-making so as to minimize the
      structural injustices many nurses have faced to date. Finally, we urge nurses to 
      seek sources of support throughout this pandemic.
CI  - (c) 2020 The Hastings Center.
FAU - Morley, Georgina
AU  - Morley G
FAU - Grady, Christine
AU  - Grady C
FAU - McCarthy, Joan
AU  - McCarthy J
FAU - Ulrich, Connie M
AU  - Ulrich CM
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*nursing
MH  - *Ethics, Nursing
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - Morals
MH  - Nurse-Patient Relations/ethics
MH  - Pandemics
MH  - Pneumonia, Viral/*nursing
MH  - SARS-CoV-2
MH  - Safety Management/ethics
MH  - Stress, Psychological/epidemiology
PMC - PMC7272859
OTO - NOTNLM
OT  - *Covid-19 pandemic
OT  - *allocation of scarce resources
OT  - *crisis standards of care
OT  - *moral distress
OT  - *nurse-patient-family relationship
OT  - *nursing ethics
OT  - *safety of nurses
EDAT- 2020/05/16 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1002/hast.1110 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):35-39. doi: 10.1002/hast.1110. Epub 2020 May
      14.


PMID- 32410157
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20211204
IS  - 2190-3948 (Electronic)
IS  - 2190-393X (Linking)
VI  - 10
IP  - 4
DP  - 2020 Aug
TI  - Recent technological advancements in stem cell research for targeted
      therapeutics.
PG  - 1147-1169
LID - 10.1007/s13346-020-00766-9 [doi]
AB  - Stem cells have characteristic features of self-renewal, pluripotency and
      differentiation, which are responsible for replenishment of tissue or organ. Stem
      cells are potentiated as therapeutic tool in drug targeting and regenerative
      medicine-from curing various neurological diseases and malignancies to congenital
      diseases. These technological advancements have established stem cells as future 
      of medicine. However, due to ethico-social limitations, the use of embryonic stem
      cells (ESCs) has been avoided, while physiological availability of adult stem
      cells (ASCs) and induced pluripotent stem cells (iPSCs) has gained appropriate
      preference. These iPSCs are very much similar to ESCs in terms of their
      self-renewal and pluripotency. Here, we have summarized the technologies that
      have established stem cells isolation, their molecular marker and factors
      responsible for their maintenance. Different cellular (transcription factors,
      regulatory proteins, miRNA like miRNA-296, miRNA-145, etc.) and extracellular
      components transcend stem cell fate. Their identification and characterization
      involve development and efficient utilization of tools like magnetic activated
      cell sorting (MACS) and fluorescence activated cell sorting (FACS). Some of the
      technologies have been patented and spin-off's based on them have been
      commercialized. In conclusion, we present the future scope and possibilities that
      stem cell technologies behold for us. Graphical abstract Pictorial representation
      of therapeutic approaches for disease treatment using stem cell technology.
      Disease-specific adult stem cells are isolated along with niche cells by
      utilizing tools like FACS/MACS/LCM, etc. Thereafter, cells are reprogrammed
      through introduction of Yamanaka factors (Oct3/4, Sox2, c-myc, Klf4) to make
      induced pluripotent stem cell (iPSCs). The disease-specific iPSCs undergo genetic
      modification after delivery of therapeutic gene through retroviral vehicle. The
      genetically modified cells are introduced back in person with disease for
      therapeutic effects. FACS, fluorescence activated cell sorting; MACS,
      magnetic-activated cell sorting; LCM, laser capture microdissection; Oct3/4,
      octamer-binding transcription factor 3/4; Sox2, sex determining region Y-box 2;
      Klf4, Kruppel-like factor 4.
FAU - Rai, Nilesh
AU  - Rai N
AD  - Centre of Experimental Medicine and Surgery, Institute of Medical Sciences,
      Banaras Hindu University, Varanasi, 221005, India.
FAU - Singh, Anurag Kumar
AU  - Singh AK
AD  - Centre of Experimental Medicine and Surgery, Institute of Medical Sciences,
      Banaras Hindu University, Varanasi, 221005, India.
FAU - Singh, Santosh Kumar
AU  - Singh SK
AD  - Centre of Experimental Medicine and Surgery, Institute of Medical Sciences,
      Banaras Hindu University, Varanasi, 221005, India.
FAU - Gaurishankar, Bhaskar
AU  - Gaurishankar B
AD  - Department of Technology, Savitribai Phule Pune University, Ganeshkhind, Pune,
      411007, India.
FAU - Kamble, Swapnil C
AU  - Kamble SC
AD  - Department of Technology, Savitribai Phule Pune University, Ganeshkhind, Pune,
      411007, India.
FAU - Mishra, Pradeep
AU  - Mishra P
AD  - Division of Biochemistry, Department of Medical Biochemistry and Biophysics,
      Karolinska Institute, Stockholm, Sweden.
FAU - Kotiya, Deepak
AU  - Kotiya D
AD  - Department of Pharmacology and Nutritional Sciences, University of Kentucky,
      Lexington, KY, USA.
FAU - Barik, Suvakanta
AU  - Barik S
AD  - Chemical Engineering Discipline, Indian Institute of Technology Gandhinagar,
      Palaj, Gandhinagar, 382355, India.
FAU - Atri, Neelam
AU  - Atri N
AD  - Department of Botany, Mahila Maha Vidyalaya, Banaras Hindu University, Varanasi, 
      221005, India.
FAU - Gautam, Vibhav
AU  - Gautam V
AD  - Centre of Experimental Medicine and Surgery, Institute of Medical Sciences,
      Banaras Hindu University, Varanasi, 221005, India. vibhav.gautam4@bhu.ac.in.
LA  - eng
GR  - EMEQ/2019/000025/Science and Engineering Research Board/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Drug Deliv Transl Res
JT  - Drug delivery and translational research
JID - 101540061
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Humans
MH  - Kruppel-Like Factor 4
MH  - *Stem Cell Research
MH  - Stem Cell Transplantation
MH  - Stem Cells
OTO - NOTNLM
OT  - *Stem cell maintenance
OT  - *Stem cell therapy
OT  - *Stem cells
OT  - *Technological advancements
EDAT- 2020/05/16 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1007/s13346-020-00766-9 [doi]
AID - 10.1007/s13346-020-00766-9 [pii]
PST - ppublish
SO  - Drug Deliv Transl Res. 2020 Aug;10(4):1147-1169. doi: 10.1007/s13346-020-00766-9.


PMID- 32410102
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210824
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 5
DP  - 2020 Oct
TI  - Authorship Not Taught and Not Caught in Undergraduate Research Experiences at a
      Research University.
PG  - 2555-2599
LID - 10.1007/s11948-020-00220-6 [doi]
AB  - This grounded study investigated the negotiation of authorship by faculty
      members, graduate student mentors, and their undergraduate proteges in
      undergraduate research experiences at a private research university in the
      northeastern United States. Semi-structured interviews using complementary
      scripts were conducted separately with 42 participants over a 3 year period to
      probe their knowledge and understanding of responsible authorship and publication
      practices and learn how faculty and students entered into authorship
      decision-making intended to lead to the publication of peer-reviewed technical
      papers. Herein the theoretical model for the negotiation of authorship developed 
      through the analysis of these interviews is reported. The model identifies
      critical causal and intervening conditions responsible for the coping strategies 
      faculty and students employ, which, in our study, appear to often produce
      unfortunate consequences for all involved. The undergraduate student researchers 
      and their graduate student mentors interviewed in this study exhibited a limited 
      understanding of authorship and the requirements for authorship in their research
      groups. The power differential between faculty and students, the students'
      limited epistemic development, the busy-ness of the faculty, and the faculty's
      failure to prioritize authorship have been identified as key factors inhibiting
      both undergraduate and graduate students from developing a deeper understanding
      of responsible authorship and publication practices. Implications for graduate
      education and undergraduate research are discussed, and strategies for helping
      all students to develop a deeper understanding of authorship are identified.
FAU - Abbott, Lauren E
AU  - Abbott LE
AUID- ORCID: http://orcid.org/0000-0001-5957-7996
AD  - Department of Chemistry and Chemical Biology, Northeastern University, Boston,
      MA, 02115, USA.
FAU - Andes, Amy
AU  - Andes A
AUID- ORCID: http://orcid.org/0000-0002-2653-0582
AD  - Department of Chemistry and Chemical Biology, Northeastern University, Boston,
      MA, 02115, USA.
FAU - Pattani, Aneri C
AU  - Pattani AC
AUID- ORCID: http://orcid.org/0000-0002-0631-5551
AD  - Department of Chemistry and Chemical Biology, Northeastern University, Boston,
      MA, 02115, USA.
FAU - Mabrouk, Patricia Ann
AU  - Mabrouk PA
AUID- ORCID: http://orcid.org/0000-0003-4965-1448
AD  - Department of Chemistry and Chemical Biology, Northeastern University, Boston,
      MA, 02115, USA. p.mabrouk@northeastern.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200514
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Authorship
MH  - Faculty
MH  - Humans
MH  - Mentors
MH  - Students
MH  - *Universities
OTO - NOTNLM
OT  - *Authorship
OT  - *Research ethics
OT  - *Responsible conduct of research
OT  - *Undergraduate research experience
EDAT- 2020/05/16 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/01/22 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1007/s11948-020-00220-6 [doi]
AID - 10.1007/s11948-020-00220-6 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Oct;26(5):2555-2599. doi: 10.1007/s11948-020-00220-6. Epub
      2020 May 14.


PMID- 32410053
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20211014
IS  - 1437-1588 (Electronic)
IS  - 1436-9990 (Linking)
VI  - 63
IP  - 6
DP  - 2020 Jun
TI  - [Digital data for more efficient prevention: ethical and legal considerations
      regarding potentials and risks].
PG  - 741-748
LID - 10.1007/s00103-020-03147-2 [doi]
AB  - Digitization offers considerable potential for strengthening prevention in the
      healthcare system. Data from various clinical and nonclinical sources can be
      collected in a structured way and systematically processed using algorithms.
      Prevention needs can thus be identified more quickly and precisely, and
      interventions can be planned, implemented, and evaluated for specific target
      groups. At the same time, however, it is necessary that data processing not only 
      meets high technical but also ethical standards and legal data protection
      regulations in order to avoid or minimize risks.This discussion article examines 
      the potentials and risks of digital prevention first from a "data perspective,"
      which deals with the use of health-related data for the purpose of prevention,
      and second from an "algorithm perspective," which focuses on the use of
      algorithmic systems, including artificial intelligence, for the assessment of
      needs and evaluation of preventive measures, from an ethical and legal point of
      view. Finally, recommendations are formulated for framework conditions that
      should be created to strengthen the further development of prevention in the
      healthcare system.
FAU - Friele, Minou
AU  - Friele M
AD  - Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health
      (ceres), Universitat zu Koln, Koln, Deutschland. minou.friele@uk-koeln.de.
AD  - Medizinische Fakultat, Uniklinik Koln, Forschungsstelle Ethik, Universitat zu
      Koln, 50924, Koln, Deutschland. minou.friele@uk-koeln.de.
FAU - Brockerhoff, Peter
AU  - Brockerhoff P
AD  - Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health
      (ceres), Universitat zu Koln, Koln, Deutschland.
FAU - Frohlich, Wiebke
AU  - Frohlich W
AD  - Forschungsstelle Datenschutz, Institut fur Europaische Gesundheitspolitik und
      Sozialrecht (ineges), Goethe-Universitat Frankfurt a.M., Frankfurt a.M.,
      Deutschland.
FAU - Spiecker Genannt Dohmann, Indra
AU  - Spiecker Genannt Dohmann I
AD  - Forschungsstelle Datenschutz, Institut fur Europaische Gesundheitspolitik und
      Sozialrecht (ineges), Goethe-Universitat Frankfurt a.M., Frankfurt a.M.,
      Deutschland.
AD  - Lehrstuhl fur Offentliches Recht, Informationsrecht, Umweltrecht,
      Verwaltungswissenschaft, Goethe-Universitat Frankfurt a.M., Frankfurt a.M.,
      Deutschland.
FAU - Woopen, Christiane
AU  - Woopen C
AD  - Cologne Center for Ethics, Rights, Economics, and Social Sciences of Health
      (ceres), Universitat zu Koln, Koln, Deutschland.
AD  - Medizinische Fakultat, Uniklinik Koln, Forschungsstelle Ethik, Universitat zu
      Koln, 50924, Koln, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Digitale Daten fur eine effizientere Pravention: Ethische und rechtliche
      Uberlegungen zu Potenzialen und Risiken.
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
MH  - *Algorithms
MH  - *Artificial Intelligence/ethics/legislation & jurisprudence
MH  - Bioethics
MH  - Datasets as Topic/ethics
MH  - Delivery of Health Care/*ethics/methods
MH  - Electronic Health Records/*ethics
MH  - Germany
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - Algorithms
OT  - Artificial intelligence
OT  - Big data
OT  - Needs assessment
OT  - Prevention
EDAT- 2020/05/16 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1007/s00103-020-03147-2 [doi]
AID - 10.1007/s00103-020-03147-2 [pii]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020
      Jun;63(6):741-748. doi: 10.1007/s00103-020-03147-2.


PMID- 32410016
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - Medical Students' Exposure to Ethics Conflicts in Clinical Training: Implications
      for Timing UME Bioethics Education.
PG  - 85-97
LID - 10.1007/s10730-020-09412-w [doi]
AB  - While there is significant consensus that undergraduate medical education (UME)
      should include bioethics training, there is widespread debate about how to teach 
      bioethics to medical students. Educators disagree about course methods and
      approaches, the topics that should be covered, and the effectiveness and metrics 
      for UME ethics training. One issue that has received scant attention is the
      timing of bioethics education during medical training. The existing literature
      suggests that most medical ethics education occurs in the pre-clinical years.
      Follow-up studies indicate that medical students in their clinical rotations have
      little recall or ability to apply ethics concepts that were learned in their
      pre-clinical training. Trainees also report a desire for medical ethics to be
      taught in the context of practical application, which would suggest that the
      timing of pre-clinical ethics education is flawed. However, moving bioethics
      training to the clinical years should not be assumed to be the solution to the
      problems of recall and theory application. We argue that the effectiveness of
      timing bioethics education will depend on when medical students witness or
      experience particular categories of ethical dilemmas during their training. Our
      overarching hypothesis is that ethics education will be most effective when the
      bioethics training on a particular topic correlates to experiential exposure to
      that ethical issue. The purpose of our current study was to describe medical
      students exposure to particular categories of ethical conflicts, dilemmas, or
      issues. Our results may help bioethics educators better strategize about the most
      effective timing of medical ethics training in UME.
FAU - Stites, S D
AU  - Stites SD
AD  - University of Pennsylvania, 423 Guardian Dr., Blockley Hall Floor 14,
      Philadelphia, PA, 19104, USA.
FAU - Rodriguez, S
AU  - Rodriguez S
AD  - University of Pennsylvania, 423 Guardian Dr., Blockley Hall Floor 14,
      Philadelphia, PA, 19104, USA.
FAU - Dudley, C
AU  - Dudley C
AD  - University of Pennsylvania, 423 Guardian Dr., Blockley Hall Floor 14,
      Philadelphia, PA, 19104, USA.
FAU - Fiester, A
AU  - Fiester A
AD  - University of Pennsylvania, 423 Guardian Dr., Blockley Hall Floor 14,
      Philadelphia, PA, 19104, USA. fiester@upenn.edu.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Attitude of Health Personnel
MH  - Bioethics/*education
MH  - Curriculum/trends
MH  - Education, Medical, Undergraduate/methods/standards/trends
MH  - Humans
MH  - Pennsylvania
MH  - Preceptorship/*standards/trends
MH  - Students, Medical/*psychology/statistics & numerical data
OTO - NOTNLM
OT  - Clerkship
OT  - Ethical dilemmas
OT  - Ethical theory
OT  - Ethics education
OT  - Medical students
OT  - Pre-clinical training
OT  - UME
EDAT- 2020/05/16 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1007/s10730-020-09412-w [doi]
AID - 10.1007/s10730-020-09412-w [pii]
PST - ppublish
SO  - HEC Forum. 2020 Jun;32(2):85-97. doi: 10.1007/s10730-020-09412-w.


PMID- 32409857
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 1432-055X (Electronic)
IS  - 0003-2417 (Linking)
VI  - 69
IP  - 7
DP  - 2020 Jul
TI  - [Ultrasound visualization of the guidewire and positioning of the central venous 
      catheter : A prospective observational study].
PG  - 489-496
LID - 10.1007/s00101-020-00794-7 [doi]
AB  - BACKGROUND: After insertion of a central venous catheter (CVC) the catheter
      position must be controlled and a pneumothorax ruled out. OBJECTIVE: The aim was 
      to examine whether the use of two standard acoustic windows known from emergency 
      sonography examination techniques is feasible to 1) verify the correct
      intravenous localization and direction of the guidewire before final CVC
      insertion and 2) correctly predict the required CVC length for positioning of the
      catheter tip in the lower third of the superior vena cava. MATERIAL AND METHODS: 
      This single center prospective observational study included adult patients (age
      >/=18 years) with an indication for CVC insertion after institutional ethics
      approval was obtained. Puncture sites were restricted to bilateral internal
      jugular and subclavian veins and except for duplicate examinations no further
      exclusion criteria were defined. After vessel puncture and insertion of the
      guidewire, the vena cava was displayed by an additional ultrasound examiner
      (sector scanner 1.5-3.6MHz) using the transhepatic or subcostal acoustic window
      to localize the guidewire. For positioning of the CVC tip, the required catheter 
      length in relation to the cavoatrial junction was measured using the guidewire
      marks during slow retraction and consecutive disappearance of the Jshaped
      guidewire tip from each acoustic window. From the resulting insertion length of
      the guidewire 4cm was subtracted for the transhepatic and 2cm for the subcostal
      window under the assumption that this length correlates to the distance from the 
      cavoatrial junction. The CVC was finally inserted and a chest radiograph was
      performed for radiological verification of the CVC position. RESULTS: Of 100
      included patients, 94 could finally be analyzed. The guidewire could be
      identified in the vena cava in 91 patients (97%) within a time period of 2.2+/-
      1.9min. In three patients, the wire could not be visualized, although two
      catheters had the correct position, while one catheter was incorrectly positioned
      in the opposite axillary vein. In the second study part, positioning of the CVC
      was evaluated in 44 of the 94 patients. In 5 of these 44 patients, the correct
      direction and disappearance of the guidewire from the acoustic window could also 
      be reliably visualized; however, with the left subclavian vein as the puncture
      site, the respective catheters were up to 6cm too short for correct positioning. 
      Thus, these 5 patients were excluded from this analysis. In the remaining 39
      patients, the position of the CVC tip was optimally located in the lower third of
      the superior vena cava according to the chest radiograph in 20 patients (51%),
      while it was relatively too high in 5 patients (13%) and too low (entrance of the
      right atrium) in 9 patients. In the other 5 patients, disappearance of the
      guidewire from the acoustic window was not definitely detectable. CONCLUSION: The
      presented intraprocedural ultrasound-based method using two standard acoustic
      windows is reliable for verification of the correct intravenous location and
      direction of the guidewire even before dilatation of the vessel puncture site for
      insertion of the catheter. Furthermore, the method allows the clinically
      acceptable measurement of the required length for catheter positioning. A chest
      radiograph can be waived provided the ultrasound examination (identification of
      the guidewire and exclusion of puncture-related complications such as
      pneumothorax) is unambiguous.
FAU - Zick, G
AU  - Zick G
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland.
FAU - Eimer, C
AU  - Eimer C
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland.
FAU - Renner, J
AU  - Renner J
AD  - Klinik fur Anasthesiologie, Helios Kliniken Schwerin, Wismarsche Strasse 393-397,
      19049, Schwerin, Deutschland.
FAU - Becher, T
AU  - Becher T
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland.
FAU - Kott, M
AU  - Kott M
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland.
FAU - Schadler, D
AU  - Schadler D
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland.
FAU - Weiler, N
AU  - Weiler N
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland.
FAU - Elke, G
AU  - Elke G
AD  - Klinik fur Anasthesiologie und Operative Intensivmedizin, Universitatsklinikum
      Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Haus R3, 24105, Kiel,
      Deutschland. gunnar.elke@uksh.de.
LA  - ger
PT  - Journal Article
PT  - Observational Study
TT  - Sonographische Visualisierung des Fuhrungsdrahtes und Positionierung des
      zentralen Venenkatheters : Eine prospektive Beobachtungsstudie.
DEP - 20200514
PL  - Germany
TA  - Anaesthesist
JT  - Der Anaesthesist
JID - 0370525
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Catheterization, Central Venous/instrumentation/*methods
MH  - Central Venous Catheters
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Jugular Veins/diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Pneumothorax
MH  - Prospective Studies
MH  - Punctures
MH  - Subclavian Vein/diagnostic imaging
MH  - Ultrasonography, Interventional/*methods
MH  - Vena Cava, Superior/*diagnostic imaging
MH  - Young Adult
OTO - NOTNLM
OT  - *CVC
OT  - *Catheter position
OT  - *Chest xray
OT  - *Seldinger's technique
OT  - *Ultrasound
EDAT- 2020/05/16 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1007/s00101-020-00794-7 [doi]
AID - 10.1007/s00101-020-00794-7 [pii]
PST - ppublish
SO  - Anaesthesist. 2020 Jul;69(7):489-496. doi: 10.1007/s00101-020-00794-7. Epub 2020 
      May 14.


PMID- 32409778
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20220415
IS  - 1476-5624 (Electronic)
IS  - 1362-4393 (Linking)
VI  - 58
IP  - 7
DP  - 2020 Jul
TI  - A pragmatic randomized controlled trial testing the effects of the international 
      scientific SCI exercise guidelines on SCI chronic pain: protocol for the EPIC-SCI
      trial.
PG  - 746-754
LID - 10.1038/s41393-020-0478-7 [doi]
AB  - STUDY DESIGN: Protocol for a pragmatic randomized controlled trial (the Exercise 
      guideline Promotion and Implementation in Chronic SCI [EPIC-SCI] Trial). PRIMARY 
      OBJECTIVES: To test if home-/community-based exercise, prescribed according to
      the international SCI exercise guidelines, significantly reduces chronic bodily
      pain in adults with SCI. SECONDARY OBJECTIVES: To investigate: (1) the effects of
      exercise on musculoskeletal and neuropathic chronic pain; (2) if reduced
      inflammation and increased descending inhibitory control are viable pathways by
      which exercise reduces pain; (3) the effects of chronic pain reductions on
      subjective well-being; and (4) efficiency of a home-/community-based exercise
      intervention. SETTING: Exercise in home-/community-based settings; assessments in
      university-based laboratories in British Columbia, Canada. METHOD: Eighty-four
      adults with chronic SCI, reporting chronic musculoskeletal or neuropathic pain,
      and not meeting the current SCI exercise guidelines, will be recruited and
      randomized to a 6-month Exercise or Wait-List Control condition. Exercise will
      occur in home/community settings and will be supported through behavioral
      counseling. All measures will be taken at baseline, 3-months and 6-months.
      Analyses will consist of linear mixed effect models, multiple regression analyses
      and a cost-utility analysis. The economic evaluation will examine the incremental
      costs and health benefits generated by the intervention compared with usual care.
      ETHICS AND DISSEMINATION: The University of British Columbia Clinical Research
      Ethics Board approved the protocol (#H19-01650). Using an integrated knowledge
      translation approach, stakeholders will be engaged throughout the trial and will 
      co-create and disseminate evidence-based recommendations and messages regarding
      the use of exercise to manage SCI chronic pain.
FAU - Martin Ginis, Kathleen A
AU  - Martin Ginis KA
AUID- ORCID: http://orcid.org/0000-0002-7076-3594
AD  - Department of Medicine, Division of Physical Medicine and Rehabilitation,
      University of British Columbia, Vancouver, BC, Canada.
      kathleen_martin.ginis@ubc.ca.
AD  - School of Health and Exercise Sciences, University of British Columbia, Kelowna, 
      BC, Canada. kathleen_martin.ginis@ubc.ca.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada. kathleen_martin.ginis@ubc.ca.
AD  - Centre for Chronic Disease Prevention and Management, University of British
      Columbia, Kelowna, BC, Canada. kathleen_martin.ginis@ubc.ca.
FAU - van der Scheer, Jan W
AU  - van der Scheer JW
AD  - Department of Medicine, Division of Physical Medicine and Rehabilitation,
      University of British Columbia, Vancouver, BC, Canada.
AD  - School of Health and Exercise Sciences, University of British Columbia, Kelowna, 
      BC, Canada.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada.
AD  - Centre for Chronic Disease Prevention and Management, University of British
      Columbia, Kelowna, BC, Canada.
FAU - Todd, Kendra R
AU  - Todd KR
AD  - School of Health and Exercise Sciences, University of British Columbia, Kelowna, 
      BC, Canada.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada.
FAU - Davis, Jennifer C
AU  - Davis JC
AD  - Centre for Chronic Disease Prevention and Management, University of British
      Columbia, Kelowna, BC, Canada.
AD  - Social & Economic Change Laboratory, Faculty of Management; Centre for Hip Health
      and Mobility, University of British Columbia, Kelowna, BC, Canada.
FAU - Gaudet, Sonja
AU  - Gaudet S
AD  - Spinal Cord Injury British Columbia, Vancouver, BC, Canada.
AD  - The Thompson Okanagan Tourism Association; Canadian Paralympic Committee Alumni/3
      X Paralympic Gold Medalist, Vernon, BC, Canada.
FAU - Hoekstra, Femke
AU  - Hoekstra F
AUID- ORCID: http://orcid.org/0000-0002-0068-652X
AD  - School of Health and Exercise Sciences, University of British Columbia, Kelowna, 
      BC, Canada.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada.
FAU - Karim, Mohammad Ehsanul
AU  - Karim ME
AUID- ORCID: http://orcid.org/0000-0002-0346-2871
AD  - School of Population and Public Health and Centre for Health Evaluation and
      Outcome Sciences, Providence Health Care, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Kramer, John L K
AU  - Kramer JLK
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada.
AD  - School of Kinesiology, University of British Columbia, Vancouver, BC, Canada.
FAU - Little, Jonathan Peter
AU  - Little JP
AD  - School of Health and Exercise Sciences, University of British Columbia, Kelowna, 
      BC, Canada.
AD  - Centre for Chronic Disease Prevention and Management, University of British
      Columbia, Kelowna, BC, Canada.
FAU - Singer, Joel
AU  - Singer J
AD  - School of Population and Public Health, UBC; Centre for Health Evaluation and
      Outcome Sciences, Vancouver, BC, Canada.
FAU - Townson, Andrea
AU  - Townson A
AD  - Department of Medicine, Division of Physical Medicine and Rehabilitation,
      University of British Columbia, Vancouver, BC, Canada.
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada.
FAU - West, Christopher R
AU  - West CR
AD  - International Collaboration on Repair Discoveries (ICORD), University of British 
      Columbia, Vancouver, BC, Canada.
AD  - Centre for Chronic Disease Prevention and Management, University of British
      Columbia, Kelowna, BC, Canada.
AD  - Department of Cell & Physiological Sciences, Faculty of Medicine, Centre for
      Chronic Disease Prevention and Management, University of British Columbia,
      Kelowna, BC, Canada.
LA  - eng
GR  - #PJT-165903/Gouvernement du Canada | Canadian Institutes of Health Research
      (Instituts de Recherche en Sante du Canada)
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Pragmatic Clinical Trial
DEP - 20200514
PL  - England
TA  - Spinal Cord
JT  - Spinal cord
JID - 9609749
SB  - IM
CIN - Spinal Cord. 2020 Jul;58(7):731-732. PMID: 32514060
EIN - Spinal Cord. 2020 Sep;58(9):1046. PMID: 32669622
MH  - Adult
MH  - Chronic Pain/etiology/*rehabilitation
MH  - Cost-Benefit Analysis
MH  - *Exercise Therapy
MH  - Follow-Up Studies
MH  - Humans
MH  - Musculoskeletal Pain/etiology/*rehabilitation
MH  - Neuralgia/etiology/*rehabilitation
MH  - *Outcome Assessment, Health Care
MH  - Practice Guidelines as Topic/standards
MH  - Spinal Cord Injuries/complications/*rehabilitation
EDAT- 2020/05/16 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 10.1038/s41393-020-0478-7 [doi]
AID - 10.1038/s41393-020-0478-7 [pii]
PST - ppublish
SO  - Spinal Cord. 2020 Jul;58(7):746-754. doi: 10.1038/s41393-020-0478-7. Epub 2020
      May 14.


PMID- 32409628
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 2329-0358 (Electronic)
IS  - 1425-9524 (Linking)
VI  - 25
DP  - 2020 May 15
TI  - Developing an Organ Donation Curriculum for Medical Undergraduates in China Based
      on Theory of Planned Behavior: A Delphi Method Study.
PG  - e922809
LID - 10.12659/AOT.922809 [doi]
AB  - BACKGROUND Organ donation education as an important approach to improve support
      for donating, but it is inconsistent and unstructured. Therefore, the development
      of donation-related curriculum is essential, especially for medical
      undergraduates. This study aimed to define the fundamental contents for organ
      donation curriculum that could be useful for international organ donor agencies
      and educational institutions. MATERIAL AND METHODS The basic framework of the
      organ donation curriculum was constructed under the guidance of the theory of
      planned behavior in China. Then, Delphi method was used to modify and improve the
      contents by conducting 2 rounds of consultation with 22 Chinese experts from 6
      professional fields. The surveys winnowed the list and assessed the accuracy and 
      importance of each item. RESULTS Response rates for the Delphi were 100.00% for
      the first round and 95.45% for the second round. A 3-layer curriculum system was 
      developed based on 3 dimensions of the theory of planned behavior. The
      primary-layer items including the overview, cultural concepts, ethical issues,
      laws and regulations, medical knowledge, and psychological care in organ
      donation, elicited at least 85% of the experts to agree or strongly agree that
      the items were basic and core content for organ donation education. All of the 17
      second-layer and 46 third-layer items also had 80% or more expert agreement.
      CONCLUSIONS This study identified the contents of an organ donation curriculum
      for medical undergraduates in China, which would be useful for researchers and
      instructors in medical education. Determining the fundamental content of a
      donation-related curriculum is an indispensable step for implementation of organ 
      donation education and promotion of organ donation.
FAU - Lei, Lei
AU  - Lei L
AD  - School of Nursing, Third Military Medical University, Chongqing, China
      (mainland).
FAU - Lin, Li
AU  - Lin L
AD  - School of Nursing, Third Military Medical University, Chongqing, China
      (mainland).
FAU - Deng, Jing
AU  - Deng J
AD  - School of Nursing, Third Military Medical University, Chongqing, China
      (mainland).
FAU - Dong, He
AU  - Dong H
AD  - School of Nursing, Third Military Medical University, Chongqing, China
      (mainland).
FAU - Luo, Yu
AU  - Luo Y
AD  - School of Nursing, Third Military Medical University, Chongqing, China
      (mainland).
LA  - eng
PT  - Journal Article
DEP - 20200515
PL  - United States
TA  - Ann Transplant
JT  - Annals of transplantation
JID - 9802544
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - China
MH  - *Curriculum
MH  - Delphi Technique
MH  - *Education, Medical, Undergraduate
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Organ Transplantation/*education
MH  - *Theory of Mind
MH  - *Tissue and Organ Procurement
PMC - PMC7249740
EDAT- 2020/05/16 06:00
MHDA- 2021/04/24 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
AID - 922809 [pii]
AID - 10.12659/AOT.922809 [doi]
PST - epublish
SO  - Ann Transplant. 2020 May 15;25:e922809. doi: 10.12659/AOT.922809.


PMID- 32409625
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - 'Your country needs you': the ethics of allocating staff to high-risk clinical
      roles in the management of patients with COVID-19.
PG  - 436-440
LID - 10.1136/medethics-2020-106284 [doi]
AB  - As the COVID-19 pandemic impacts on health service delivery, health providers are
      modifying care pathways and staffing models in ways that require health
      professionals to be reallocated to work in critical care settings. Many of the
      roles that staff are being allocated to in the intensive care unit and emergency 
      department pose additional risks to themselves, and new policies for staff
      reallocation are causing distress and uncertainty to the professionals concerned.
      In this paper, we analyse a range of ethical issues associated with changes to
      staff allocation processes in the face of COVID-19. In line with a dominant view 
      in the medical ethics literature, we claim, first, that no individual health
      professional has a specific, positive obligation to treat a patient when doing so
      places that professional at risk of harm, and so there is a clear ethical tension
      in any reallocation process in this context. Next, we argue that the changing
      asymmetries of health needs in hospitals means that careful consideration needs
      to be given to a stepwise process for deallocating staff from their usual duties.
      We conclude by considering how a justifiable process of reallocating
      professionals to high-risk clinical roles should be configured once those who are
      'fit for reallocation' have been identified. We claim that this process needs to 
      attend to three questions that we consider in detail: (1) how the choice to make 
      reallocation decisions is made, (2) what justifiable models for reallocation
      might look like and (3) what is owed to those who are reallocated.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Dunn, Michael
AU  - Dunn M
AUID- ORCID: 0000-0002-5603-6200
AD  - The Ethox Centre and Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK michael.dunn@ethox.ox.ac.uk.
FAU - Sheehan, Mark
AU  - Sheehan M
AUID- ORCID: 0000-0002-7191-901X
AD  - The Ethox Centre and Wellcome Centre for Ethics and Humanities, University of
      Oxford, Oxford, UK.
FAU - Hordern, Joshua
AU  - Hordern J
AD  - Faculty of Theology and Religion, University of Oxford, Oxford, UK.
FAU - Turnham, Helen Lynne
AU  - Turnham HL
AUID- ORCID: 0000-0003-1011-2885
AD  - Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital,
      Oxford, UK.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: 0000-0003-3958-8633
AD  - Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital,
      Oxford, UK.
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
AD  - Murdoch Children's Research Institute, University of Melbourne, Melbourne, South 
      Australia, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200514
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - Health Care Rationing/*ethics/organization & administration
MH  - Health Personnel/*ethics/*organization & administration
MH  - Humans
MH  - Needs Assessment/ethics/organization & administration
MH  - Pandemics
MH  - Personnel Staffing and Scheduling/ethics/organization & administration
MH  - Pneumonia, Viral/*epidemiology/*therapy
MH  - Professional Role
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Volunteers
PMC - PMC7246092
OTO - NOTNLM
OT  - *clinical ethics
OT  - *health care for specific diseases/groups
OT  - *health personnel
OT  - *professional - professional relationship
COIS- Competing interests: All five authors are members of Clinical Ethics Advisory
      Groups providing support to NHS Trusts within the south-east of England. This
      includes, at the present time, providing advice on the issues discussed in this
      article.
EDAT- 2020/05/16 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - medethics-2020-106284 [pii]
AID - 10.1136/medethics-2020-106284 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):436-440. doi: 10.1136/medethics-2020-106284. Epub
      2020 May 14.


PMID- 32409622
OWN - NLM
STAT- Publisher
LR  - 20200515
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 14
TI  - Arguments on thin ice: on non-medical egg freezing and individualisation
      arguments.
LID - medethics-2020-106059 [pii]
LID - 10.1136/medethics-2020-106059 [doi]
AB  - The aim of this article is to provide a systematic reconstruction and critique of
      what is taken to be a central ethical concern against the use of non-medical egg 
      freezing (NMEF). The concern can be captured in what we can call the
      individualisation argument. The argument states, very roughly, that women should 
      not use NMEF as it is an individualistic and morally problematic solution to the 
      social problems that women face, for instance, in the labour market. Instead of
      allowing or expecting women to deal with them on an individual level, we should
      address them by challenging the patriarchal structures of the labour market-for
      example, by securing equal pay, or paid maternal leave, or 'paid paternal
      [partner] leave and sick leave and affordable child care'. It will be made clear 
      that there are several versions of this argument. The author will try to
      elaborate this claim, and it will be explained that the differences depend on the
      way in which bioethicists believe that individuals use of NMEF is morally
      problematic, compared with the alternative of securing social change for women
      in, say, the labour market. Finally, a critical discussion of three versions of
      the individualisation argument will follow, and it will be shown why all versions
      are on rather thin ice, or in other words, that they are implausible.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Petersen, Thomas Sobirk
AU  - Petersen TS
AD  - Communication and Arts, Roskilde University, Roskilde, Denmark thomassp@ruc.dk.
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - cryobanking of sperm, ova or embryos
OT  - ethics
OT  - reproductive medicine
OT  - social aspects
OT  - women
COIS- Competing interests: None declared.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:00 [medline]
AID - medethics-2020-106059 [pii]
AID - 10.1136/medethics-2020-106059 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 14. pii: medethics-2020-106059. doi:
      10.1136/medethics-2020-106059.


PMID- 32409595
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 13
IP  - 8
DP  - 2020 Aug
TI  - Population-based Genetic Testing for Precision Prevention.
PG  - 643-648
LID - 10.1158/1940-6207.CAPR-20-0002 [doi]
AB  - Global interest in genetic testing for cancer susceptibility genes (CSG) has
      surged with falling costs, increasing awareness, and celebrity endorsement.
      Current access to genetic testing is based on clinical criteria/risk model
      assessment which uses family history as a surrogate. However, this approach is
      fraught with inequality, massive underutilization, and misses 50% CSG carriers.
      This reflects huge missed opportunities for precision prevention. Early CSG
      identification enables uptake of risk-reducing strategies in unaffected
      individuals to reduce cancer risk. Population-based genetic testing (PGT) can
      overcome limitations of clinical criteria/family history-based testing. Jewish
      population studies show population-based BRCA testing is feasible, acceptable,
      has high satisfaction, does not harm psychologic well-being/quality of life, and 
      is extremely cost-effective, arguing for changing paradigm to PGT in the Jewish
      population. Innovative approaches for delivering pretest information/education
      are needed to facilitate informed decision-making for PGT. Different health
      systems will need context-specific implementation strategies and management
      pathways, while maintaining principles of population screening. Data on general
      population PGT are beginning to emerge, prompting evaluation of wider
      implementation. Sophisticated risk prediction models incorporating genetic and
      nongenetic data are being used to stratify populations for ovarian cancer and
      breast cancer risk and risk-adapted screening/prevention. PGT is potentially
      cost-effective for panel testing of breast and ovarian CSGs and for risk-adapted 
      breast cancer screening. Further research/implementation studies evaluating the
      impact, clinical efficacy, psychologic and socio-ethical consequences, and
      cost-effectiveness of PGT are needed.
CI  - (c)2020 American Association for Cancer Research.
FAU - Evans, Olivia
AU  - Evans O
AUID- ORCID: 0000-0002-8012-4964
AD  - Wolfson Institute of Preventative Medicine, Barts CRUK Cancer Centre, Queen Mary 
      University of London, Charterhouse Square, London, United Kingdom.
AD  - Department of Gynaecological Oncology, St Bartholomew's Hospital, London, United 
      Kingdom.
FAU - Manchanda, Ranjit
AU  - Manchanda R
AUID- ORCID: 0000-0003-3381-5057
AD  - Wolfson Institute of Preventative Medicine, Barts CRUK Cancer Centre, Queen Mary 
      University of London, Charterhouse Square, London, United Kingdom.
      r.manchanda@qmul.ac.uk.
AD  - Department of Gynaecological Oncology, St Bartholomew's Hospital, London, United 
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200514
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Breast Neoplasms/diagnosis/epidemiology/genetics/*prevention & control
MH  - Cost-Benefit Analysis
MH  - Counseling/economics/methods
MH  - DNA Mutational Analysis/economics/methods
MH  - Early Detection of Cancer/economics/methods
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Genetic Testing/economics/*methods
MH  - Heterozygote
MH  - Humans
MH  - Jews/genetics
MH  - Mutation
MH  - Ovarian Neoplasms/diagnosis/epidemiology/genetics/*prevention & control
MH  - Patient Education as Topic/economics/methods
MH  - Precision Medicine/economics/*methods
MH  - Prevalence
MH  - Risk Assessment/economics/methods
EDAT- 2020/05/16 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/01/01 00:00 [received]
PHST- 2020/03/22 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - 1940-6207.CAPR-20-0002 [pii]
AID - 10.1158/1940-6207.CAPR-20-0002 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2020 Aug;13(8):643-648. doi:
      10.1158/1940-6207.CAPR-20-0002. Epub 2020 May 14.


PMID- 32409490
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May
TI  - Ethics in a time of coronavirus.
PG  - 285-286
LID - 10.1136/medethics-2020-106282 [doi]
FAU - Boyd, Kenneth
AU  - Boyd K
AD  - Biomedical Teaching Organisation, Edinburgh University, Edinburgh, Scotland, UK
      K.Boyd@ed.ac.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - COVID-19
MH  - Coronavirus
MH  - Coronavirus Infections/epidemiology/*therapy/virology
MH  - Ethics, Medical
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy/virology
MH  - Triage/*ethics
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/16 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - medethics-2020-106282 [pii]
AID - 10.1136/medethics-2020-106282 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 May;46(5):285-286. doi: 10.1136/medethics-2020-106282.


PMID- 32409330
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220716
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 5
DP  - 2020 May
TI  - How to prevent and address safeguarding concerns in global health research
      programmes: practice, process and positionality in marginalised spaces.
LID - e002253 [pii]
LID - 10.1136/bmjgh-2019-002253 [doi]
AB  - Safeguarding is rapidly rising up the international development agenda, yet
      literature on safeguarding in related research is limited. This paper shares
      processes and practice relating to safeguarding within an international research 
      consortium (the ARISE hub, known as ARISE). ARISE aims to enhance accountability 
      and improve the health and well-being of marginalised people living and working
      in informal urban spaces in low-income and middle-income countries (Bangladesh,
      India, Kenya and Sierra Leone). Our manuscript is divided into three key
      sections. We start by discussing the importance of safeguarding in global health 
      research and consider how thinking about vulnerability as a relational concept
      (shaped by unequal power relations and structural violence) can help locate fluid
      and context specific safeguarding risks within broader social systems. We then
      discuss the different steps undertaken in ARISE to develop a shared approach to
      safeguarding: sharing institutional guidelines and practice; facilitating a
      participatory process to agree a working definition of safeguarding and joint
      understandings of vulnerabilities, risks and mitigation strategies and share
      experiences; developing action plans for safeguarding. This is followed by
      reflection on our key learnings including how safeguarding, ethics and health and
      safety concerns overlap; the challenges of referral and support for safeguarding 
      concerns within frequently underserved informal urban spaces; and the importance 
      of reflective practice and critical thinking about power, judgement and
      positionality and the ownership of the global narrative surrounding safeguarding.
      We finish by situating our learning within debates on decolonising science and
      argue for the importance of an iterative, ongoing learning journey that is
      critical, reflective and inclusive of vulnerable people.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Aktar, Bachera
AU  - Aktar B
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Alam, Wafa
AU  - Alam W
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Ali, Samiha
AU  - Ali S
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Awal, Abdul
AU  - Awal A
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Bayoh, Margaret
AU  - Bayoh M
AD  - Federation of Urban and Rural Poor, Freetown, Sierra Leone.
FAU - Chumo, Ivy
AU  - Chumo I
AD  - African Population and Health Research Center, Nairobi, Kenya.
FAU - Contay, Yirah
AU  - Contay Y
AD  - Federation of Urban and Rural Poor, Freetown, Sierra Leone.
FAU - Conteh, Abu
AU  - Conteh A
AD  - Sierra Leone Urban Research Centre, Njala University, Freetown, Sierra Leone.
FAU - Dean, Laura
AU  - Dean L
AUID- ORCID: 0000-0002-4910-9707
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK
      Laura.Dean@lstmed.ac.uk.
FAU - Dobson, Skye
AU  - Dobson S
AD  - Slum Dwellers International, Cape Town, South Africa.
FAU - Edstrom, Jerker
AU  - Edstrom J
AD  - Institute of Development Studies, Brighton, Brighton and Hove, UK.
FAU - Elsey, Helen
AU  - Elsey H
AUID- ORCID: 0000-0003-4724-0581
AD  - Health Sciences, University of York, York, UK.
FAU - Farnaz, Nadia
AU  - Farnaz N
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Garimella, Surekha
AU  - Garimella S
AD  - The George Institute for Global Health, New Delhi, India.
FAU - Gray, Linsay
AU  - Gray L
AD  - University of Glasgow, Glasgow, Glasgow, UK.
FAU - Gupte, Jaideep
AU  - Gupte J
AD  - Institute of Development Studies, Brighton, Brighton and Hove, UK.
FAU - Hawkins, Kate
AU  - Hawkins K
AD  - Pamoja Communications, Brighton and Hove, United Kingdom.
FAU - Hollihead, Beth
AU  - Hollihead B
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Josyula, Kunhi Lakshmi
AU  - Josyula KL
AD  - The George Institute for Global Health, New Delhi, India.
FAU - Kabaria, Caroline
AU  - Kabaria C
AD  - African Population and Health Research Center, Nairobi, Kenya.
FAU - Karuga, Robinson
AU  - Karuga R
AD  - LVCT, Nairobi, Kenya.
FAU - Kimani, Joseph
AU  - Kimani J
AD  - Slum and Shack Dwellers International Kenya, Nairobi, Kenya.
FAU - Leyland, Alastair H
AU  - Leyland AH
AD  - University of Glasgow, Glasgow, Glasgow, UK.
FAU - Te Lintelo, Dolf
AU  - Te Lintelo D
AD  - Institute of Development Studies, Brighton, Brighton and Hove, UK.
FAU - Mansaray, Bintu
AU  - Mansaray B
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone,
      Freetown, Western Area, Sierra Leone.
FAU - MacCarthy, Joseph
AU  - MacCarthy J
AD  - Sierra Leone Urban Research Centre, Njala University, Freetown, Sierra Leone.
FAU - MacGregor, Hayley
AU  - MacGregor H
AD  - Institute of Development Studies, Brighton, Brighton and Hove, UK.
FAU - Mberu, Blessing
AU  - Mberu B
AD  - African Population and Health Research Center, Nairobi, Kenya.
FAU - Muturi, Nelly
AU  - Muturi N
AD  - LVCT, Nairobi, Kenya.
FAU - Okoth, Linet
AU  - Okoth L
AD  - LVCT, Nairobi, Kenya.
FAU - Otiso, Lilian
AU  - Otiso L
AD  - LVCT, Nairobi, Kenya.
FAU - Ozano, Kim
AU  - Ozano K
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Parray, Ateeb
AU  - Parray A
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Phillips-Howard, Penny
AU  - Phillips-Howard P
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Rao, Vinodkumar
AU  - Rao V
AD  - Slum Dwellers International, Mumbai, India.
FAU - Rashid, Sabina
AU  - Rashid S
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Raven, Joanna
AU  - Raven J
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Refell, Francis
AU  - Refell F
AD  - CODOHSAPA, Freetown, Sierra Leone.
FAU - Saidu, Samuel
AU  - Saidu S
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone,
      Freetown, Western Area, Sierra Leone.
FAU - Sobhan, Shafinaz
AU  - Sobhan S
AD  - BRAC University James P Grant School of Public Health, Dhaka, Dhaka District,
      Bangladesh.
FAU - Saligram, Prasanna Subramanya
AU  - Saligram PS
AD  - The George Institute for Global Health, New Delhi, India.
FAU - Sesay, Samira
AU  - Sesay S
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone,
      Freetown, Western Area, Sierra Leone.
FAU - Theobald, Sally
AU  - Theobald S
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Tolhurst, Rachel
AU  - Tolhurst R
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Tubb, Phil
AU  - Tubb P
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Waldman, Linda
AU  - Waldman L
AD  - Institute of Development Studies, Brighton, Brighton and Hove, UK.
FAU - Wariutu, Jane
AU  - Wariutu J
AD  - Slum and Shack Dwellers International Kenya, Nairobi, Kenya.
FAU - Whittaker, Lana
AU  - Whittaker L
AD  - Liverpool School of Tropical Medicine, Liverpool, Liverpool, UK.
FAU - Wurie, Haja
AU  - Wurie H
AD  - College of Medicine and Allied Health Sciences, University of Sierra Leone,
      Freetown, Western Area, Sierra Leone.
LA  - eng
GR  - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12017/13/MRC_/Medical Research Council/United Kingdom
GR  - SPHSU17/CSO_/Chief Scientist Office/United Kingdom
GR  - SPHSU13/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Bangladesh
MH  - *Global Health
MH  - Humans
MH  - India
MH  - Kenya
MH  - *Poverty
PMC - PMC7228499
OTO - NOTNLM
OT  - *health policy
OT  - *health services research
OT  - *health systems
COIS- Competing interests: None declared.
EDAT- 2020/05/16 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/04/07 00:00 [revised]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2019-002253 [pii]
AID - 10.1136/bmjgh-2019-002253 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 May;5(5). pii: bmjgh-2019-002253. doi:
      10.1136/bmjgh-2019-002253.


PMID- 32409300
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1943-3662 (Electronic)
IS  - 1093-6793 (Linking)
VI  - 48
IP  - 3
DP  - 2020 Sep
TI  - Ethics Implications of the Use of Artificial Intelligence in Violence Risk
      Assessment.
PG  - 345-349
LID - 10.29158/JAAPL.003940-20 [doi]
AB  - Artificial intelligence is rapidly transforming the landscape of medicine.
      Specifically, algorithms powered by deep learning are already gaining
      increasingly wide adoption in fields such as radiology, pathology, and preventive
      medicine. Forensic psychiatry is a complex and intricate specialty that seeks to 
      balance the disparate approaches of psychiatric science, which strives to explain
      human behavior deterministically, and the law, which emphasizes free choice and
      moral responsibility. This balancing, a central task of the forensic
      psychiatrist, is necessarily fraught with ambiguity. Such a complex task may
      intuitively seem impenetrable to artificial intelligence. This article first aims
      to challenge this assumption and then seeks to address the unique concerns posed 
      by the adoption of artificial intelligence in violence risk assessment and
      prediction. The relevant ethics concerns are analyzed within the framework of
      traditional bioethics principles. Finally, recommendations for practitioners,
      ethicists, and others are offered as a starting point for further discussion.
CI  - (c) 2020 American Academy of Psychiatry and the Law.
FAU - Cockerill, Richard G
AU  - Cockerill RG
AD  - Dr. Cockerill is a Fellow in Forensic Psychiatry, UCLA-Semel Institute for
      Neuroscience and Behavior, Los Angeles, California. rcockerill@mednet.ucla.edu.
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - United States
TA  - J Am Acad Psychiatry Law
JT  - The journal of the American Academy of Psychiatry and the Law
JID - 9708963
SB  - IM
CIN - J Am Acad Psychiatry Law. 2021 Mar;49(1):147. PMID: 33731487
MH  - Artificial Intelligence/*ethics
MH  - Beneficence
MH  - *Forensic Psychiatry
MH  - Humans
MH  - Machine Learning/*ethics
MH  - Personal Autonomy
MH  - Risk Assessment/*methods
MH  - Social Justice
MH  - *Violence
EDAT- 2020/05/16 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - JAAPL.003940-20 [pii]
AID - 10.29158/JAAPL.003940-20 [doi]
PST - ppublish
SO  - J Am Acad Psychiatry Law. 2020 Sep;48(3):345-349. doi: 10.29158/JAAPL.003940-20. 
      Epub 2020 May 14.


PMID- 32409277
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-4898 (Electronic)
IS  - 1477-5131 (Linking)
VI  - 16
IP  - 3
DP  - 2020 Jun
TI  - Community perspectives on difference of sex development (DSD) diagnoses: A
      crowdsourced survey.
PG  - 384.e1-384.e8
LID - S1477-5131(20)30077-2 [pii]
LID - 10.1016/j.jpurol.2020.03.023 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Differences of sex development (DSD) engender
      ethical, social and psychosexual complexities that can complicate medical
      decision-making. We performed a web-based pilot study to estimate the utility
      value of a DSD diagnosis and to identify community concerns regarding DSD
      management. METHODS: A cross-sectional survey was posted on Amazon's Mechanical
      Turk, an online crowdsourcing platform. Respondents were >/=18y and were
      randomized to receive information on one of three common DSD conditions:
      Congenital Adrenal Hyperplasia (CAH), Mixed Gonadal Dysgenesis (MGD), and Partial
      Androgen Insensitivity Syndrome (PAIS). Time trade-off methodology was used to
      estimate utility values. Likert scale and statement-ranking questions were used
      to assess respondent perceptions. RESULTS: Of 1,628 respondents, median age was
      34y; most respondents were parents (59.1%), white (77.1%), and previously
      unfamiliar with DSD (60.4%). The median overall utility value was 0.70 (IQR
      0.50-0.90), similar to moderately severe chronic health conditions. Utility
      estimates varied based on the DSD scenario presented (0.80 CAH vs. 0.70 MGD vs.
      0.80 PAIS, p = 0.0006), respondent gender (p < 0.0001), race (p = 0.002),
      religion (p = 0.005), and prior knowledge of DSD (p < 0.0001). Reported concerns 
      included gender identity (23.4%), urinary function (20.5%) and surgical
      complications (17.4%). Most (67.5%) supported early surgical intervention at 6-18
      mo; 10.4% thought surgery should occur >/=18 y. COMMENT: Limitations of this
      study include that survey participants were aware of the nature of the study,
      thus some respondents may have participated to skew the results. Given the nature
      of this pilot study, the representation of families with children with DSD within
      the study is severely limited given the rarity of DSDs. This means that their
      opinions may be diluted by the large sample size. However, because utility values
      are classically estimated according to community opinions, the utility data
      presented should be taken to reflect that of the specific sample studied and is
      not reflective of that of families with a vested interest in such cases.
      CONCLUSIONS: Community-based respondents perceived that DSD conditions were
      associated with a reduction in utility values (0.70-0.80), on par with moderately
      severe chronic health conditions. Estimates varied based on respondents' gender, 
      race, religion and prior knowledge of DSD. Gender identity was the most
      concerning aspect for respondents.
CI  - Copyright (c) 2020 Journal of Pediatric Urology Company. Published by Elsevier
      Ltd. All rights reserved.
FAU - Alkazemi, M Hassan
AU  - Alkazemi MH
AD  - Duke University School of Medicine, Durham, NC, USA.
FAU - Johnston, Ashley W
AU  - Johnston AW
AD  - Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
FAU - Meglin, Diane
AU  - Meglin D
AD  - Duke University School of Medicine, Durham, NC, USA.
FAU - Adkins, Deanna
AU  - Adkins D
AD  - Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
FAU - Routh, Jonathan C
AU  - Routh JC
AD  - Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
      Electronic address: jonathan.routh@duke.edu.
LA  - eng
GR  - K08 DK100534/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20200427
PL  - England
TA  - J Pediatr Urol
JT  - Journal of pediatric urology
JID - 101233150
SB  - IM
MH  - Adult
MH  - Child
MH  - Cross-Sectional Studies
MH  - *Crowdsourcing
MH  - *Disorders of Sex Development/diagnosis
MH  - Female
MH  - Gender Identity
MH  - Humans
MH  - Male
MH  - Pilot Projects
MH  - Sexual Development
MH  - Surveys and Questionnaires
PMC - PMC7308206
MID - NIHMS1589179
OTO - NOTNLM
OT  - *Differences of sex development
OT  - *Gender
OT  - *Survey
OT  - *Utility value
EDAT- 2020/05/16 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/08/21 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - S1477-5131(20)30077-2 [pii]
AID - 10.1016/j.jpurol.2020.03.023 [doi]
PST - ppublish
SO  - J Pediatr Urol. 2020 Jun;16(3):384.e1-384.e8. doi: 10.1016/j.jpurol.2020.03.023. 
      Epub 2020 Apr 27.


PMID- 32409223
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20220416
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 7
DP  - 2020 Sep
TI  - Quality System of Kidney Donation for Transplantation From Living Donors in
      Poland.
PG  - 2033-2035
LID - S0041-1345(19)31796-8 [pii]
LID - 10.1016/j.transproceed.2020.01.115 [doi]
AB  - OBJECTIVE: The program aims to build and develop a high-quality donation system
      at the hospital and national level. Thirty coordinator posts for the
      transplantation of kidneys from living donors (LDs) were created. The
      coordinators' tasks were identified as determining or excluding the possibility
      of LD donation for kidney transplantation for every potential kidney recipient
      referred to the waiting list, qualifying potential LDs, supervising health
      monitoring for LDs and kidney recipients, and education and promotion of
      transplantation from LDs. METHODS: The coordinators' reports and verification of 
      data in the national transplant register from June 1, 2018 to November 30, 2019
      were analyzed. ETHICS: The study was conducted according to principles of the
      Declaration of Helsinki, and the Declaration of Istanbul participation was on a
      voluntary basis. RESULTS: Information on possible LDs was obtained from 707 (43%)
      of the 1630 potential recipients entered on the waiting list. In 373 cases there 
      was no potential LD; 16 recipients did not give consent for kidney
      transplantation from a LD; for 318 recipients, 340 potential LDs were identified;
      90 potential LDs were rejected at the initial stage for medical reasons; 60
      potential donors were rejected at further stages of the qualification process; 3 
      persons resigned from donation; and 23 recipients were transplanted from deceased
      donors. Kidneys from 73 LDs were qualified and transplanted. On November 30,
      2019, 91 potential donors were awaiting further qualification. As part of the
      program, 27 potential pairs for paired kidney exchange were reported to
      Poltransplant (17 pairs with positive HLA crossmatch, 10 with incompatible blood 
      groups). CONCLUSIONS: The creation of posts for coordinators for LD kidney
      transplantation in centers that qualify for LD kidney transplantation enabled
      systematic monitoring of donation potential, which led to an increase in the
      number of LD kidney transplants in 2019. Making full use of donation potential
      should significantly increase these numbers in the coming years.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Hermanowicz, M
AU  - Hermanowicz M
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland.
FAU - Borczon, S
AU  - Borczon S
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland.
FAU - Lewandowska, D
AU  - Lewandowska D
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland; Department
      of Transplantation Medicine, Nephrology and Internal Medicine, Medical University
      of Warsaw, Warsaw, Poland.
FAU - Przygoda, J
AU  - Przygoda J
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland.
FAU - Podobinska, I
AU  - Podobinska I
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland.
FAU - Danielewicz, R
AU  - Danielewicz R
AD  - Department of Surgical and Transplantation Nursing and Extracorporeal Treatment, 
      Medical University of Warsaw, Warsaw, Poland.
FAU - Malanowski, P
AU  - Malanowski P
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland.
FAU - Kaminski, A
AU  - Kaminski A
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland; Department
      of Transplantology and National Tissue and Cell Banking Center, Medical
      University of Warsaw, Warsaw, Poland.
FAU - Czerwinski, J
AU  - Czerwinski J
AD  - Polish Transplant Coordinating Center Poltransplant, Warsaw, Poland; Department
      of Emergency Medicine, Medical University of Warsaw, Warsaw, Poland. Electronic
      address: jczerwinski@poltransplant.pl.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Female
MH  - Humans
MH  - *Kidney Transplantation
MH  - Living Donors/*supply & distribution
MH  - Male
MH  - Poland
MH  - Tissue and Organ Procurement/*organization & administration
EDAT- 2020/05/16 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/12/27 00:00 [received]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - S0041-1345(19)31796-8 [pii]
AID - 10.1016/j.transproceed.2020.01.115 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Sep;52(7):2033-2035. doi:
      10.1016/j.transproceed.2020.01.115. Epub 2020 May 11.


PMID- 32409207
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1958-5578 (Electronic)
IS  - 0040-5957 (Linking)
VI  - 75
IP  - 6
DP  - 2020 Nov - Dec
TI  - [A survey on French hospital physicians'certification to the good clinical
      practices].
PG  - 537-542
LID - S0040-5957(20)30066-4 [pii]
LID - 10.1016/j.therap.2020.04.002 [doi]
AB  - Good clinical practice (GCP) is an international ethical and scientific quality
      standard for the design, conduct, performance, monitoring, auditing, recording,
      analyses and reporting of clinical trials. Before the start of a clinical trial, 
      investigators commit to perform the research in accordance with GCPs, regulatory 
      dispositions and protocol. The sponsors are responsible for investigators'
      selection and for controlling their skills. Whereas industrial sponsors
      systematically require a certificate of GCP training, academic sponsors seem to
      be less demanding. We have carried out two surveys between April and June 2018. A
      first questionnaire was sent to the 40 French academic directions of clinical
      research and innovation in order to determine their requirements about the GCP
      training of the investigators participating in their trials. The second
      questionnaire was transmitted to physicians of the "Bretagne recherche clinique
      hospitaliere network": Rennes, Saint-Malo, Saint-Brieuc, Vannes, Lorient and
      Pontivy hospitals, in order to determine the GCP certification rate, and their
      needs in terms of clinical research training. Twenty-eight (70%) directions of
      clinical research answered the first survey, among which 18 (64%) required
      systematically the investigators' GCP certification in case of category 1
      interventional studies. This rate decreased for category 2 (50%) and
      non-interventional category 3 (18%) studies. A total of 345 physicians answered
      the second survey, among which 263 (76%) had already been clinical trial
      investigators. However, only 29% of all physicians and 54% of those who had been 
      principal investigator were certified for GCP training. These results support the
      need for large campaigns of GCP training in public hospitals.
CI  - Copyright (c) 2020 Societe francaise de pharmacologie et de therapeutique.
      Published by Elsevier Masson SAS. All rights reserved.
FAU - Fougerou-Leurent, Claire
AU  - Fougerou-Leurent C
AD  - Service de pharmacologie clinique, CHU de Rennes, 35000 Rennes, France; CIC 1414,
      Inserm, centre d'investigation clinique de Rennes, 35000 Rennes, France.
      Electronic address: claire.fougerou@chu-rennes.fr.
FAU - Chesnais, Jimmy
AU  - Chesnais J
AD  - Service de pharmacologie clinique, CHU de Rennes, 35000 Rennes, France; CIC 1414,
      Inserm, centre d'investigation clinique de Rennes, 35000 Rennes, France.
FAU - Nekmouche, Sabrina
AU  - Nekmouche S
AD  - Service de pharmacologie clinique, CHU de Rennes, 35000 Rennes, France; CIC 1414,
      Inserm, centre d'investigation clinique de Rennes, 35000 Rennes, France.
FAU - Veislinger, Aurelie
AU  - Veislinger A
AD  - Service de pharmacologie clinique, CHU de Rennes, 35000 Rennes, France; CIC 1414,
      Inserm, centre d'investigation clinique de Rennes, 35000 Rennes, France.
FAU - Le Saux, Mariella
AU  - Le Saux M
AD  - Unite de recherche clinique, centre hospitalier de Lorient, 56322 Lorient,
      France.
FAU - Joumard, Celine
AU  - Joumard C
AD  - Centre de recherche clinique, centre hospitalier de Bretagne Atlantique, 56017
      Vannes, France.
FAU - Lorre, Veronique
AU  - Lorre V
AD  - Institut de formation des professionnels de sante, 56017 Vannes, France.
FAU - Bellot, Catherine
AU  - Bellot C
AD  - Unite de recherche clinique, centre hospitalier de Saint-Brieuc, 22000
      Saint-Brieuc, France.
FAU - Alleton, Nathalie
AU  - Alleton N
AD  - Unite de recherche clinique, CHSP Guillaume Regnier, 35700 Rennes, France.
FAU - Labourdette, Elodie
AU  - Labourdette E
AD  - Unite de recherche clinique, centre hospitalier de Saint-Malo, 35400 Saint-Malo, 
      France.
FAU - Marie, Carole
AU  - Marie C
AD  - Direction des affaires medicales, centre hospitalier de Centre Bretagne, 56920
      Noyal-Pontivy, France.
FAU - Fin, Loic
AU  - Fin L
AD  - Direction de la recherche clinique, CHU de Rennes, 35000 Rennes, France.
FAU - Bellissant, Eric
AU  - Bellissant E
AD  - Service de pharmacologie clinique, CHU de Rennes, 35000 Rennes, France; CIC 1414,
      Inserm, centre d'investigation clinique de Rennes, 35000 Rennes, France;
      Universite Rennes, 35000 Rennes, France.
FAU - Laviolle, Bruno
AU  - Laviolle B
AD  - Service de pharmacologie clinique, CHU de Rennes, 35000 Rennes, France; CIC 1414,
      Inserm, centre d'investigation clinique de Rennes, 35000 Rennes, France;
      Universite Rennes, 35000 Rennes, France.
LA  - fre
PT  - Journal Article
TT  - Enquete sur la certification aux bonnes pratiques cliniques en recherche
      academique.
DEP - 20200419
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
SB  - IM
MH  - Certification
MH  - Hospitals
MH  - Humans
MH  - *Physicians
MH  - *Research Personnel
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Bonnes pratiques cliniques
OT  - Certification
OT  - Clinical trial
OT  - Essais cliniques
OT  - Formation
OT  - Good clinical practices
OT  - Investigateur
OT  - Investigator
OT  - Promotion
OT  - Sponsoring
OT  - Training
EDAT- 2020/05/16 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2020/01/28 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - S0040-5957(20)30066-4 [pii]
AID - 10.1016/j.therap.2020.04.002 [doi]
PST - ppublish
SO  - Therapie. 2020 Nov - Dec;75(6):537-542. doi: 10.1016/j.therap.2020.04.002. Epub
      2020 Apr 19.


PMID- 32409192
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20201218
IS  - 1545-7214 (Electronic)
IS  - 1064-7481 (Linking)
VI  - 28
IP  - 8
DP  - 2020 Aug
TI  - Ethical and Logistical Considerations of Caring for Older Adults on Inpatient
      Psychiatry During the COVID-19 Pandemic.
PG  - 829-834
LID - S1064-7481(20)30328-6 [pii]
LID - 10.1016/j.jagp.2020.04.027 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has brought challenges to
      delivery of care for older adults on inpatient psychiatry. We describe two cases:
      patient A, a 62-year-old woman who initially refused screening for potential
      COVID-19, bringing up questions about threshold for capacity when public health
      is at risk and questions about whether screening for infection should be
      different in older adults. The other case, patient B, is that of an 83-year-old
      man who was on the unit when patient A tested positive, and brought up concerns
      for risk of dissemination in the context of wandering, spitting behaviors, and
      inability to adhere to room isolation or masking measures. We review measures
      taken to decrease risk of transmission and improve screening for infection in
      older adults.
CI  - Copyright (c) 2020 American Association for Geriatric Psychiatry. Published by
      Elsevier Inc. All rights reserved.
FAU - Fahed, Mario
AU  - Fahed M
AD  - School of Medicine (MF, GCB, DCS), University of Connecticut, Farmington, CT.
      Electronic address: fahed@uchc.edu.
FAU - Barron, Gregory C
AU  - Barron GC
AD  - School of Medicine (MF, GCB, DCS), University of Connecticut, Farmington, CT.
FAU - Steffens, David C
AU  - Steffens DC
AD  - School of Medicine (MF, GCB, DCS), University of Connecticut, Farmington, CT.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200505
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American
      Association for Geriatric Psychiatry
JID - 9309609
SB  - IM
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Female
MH  - Humans
MH  - Inpatients/*psychology
MH  - Male
MH  - Mental Health Services/*ethics/organization & administration/*standards
MH  - Middle Aged
MH  - Pandemics
MH  - Patient Care/*ethics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7198992
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *geropsychiatry
OT  - *infection
OT  - *inpatient
EDAT- 2020/05/16 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/05/16 06:00 [entrez]
AID - S1064-7481(20)30328-6 [pii]
AID - 10.1016/j.jagp.2020.04.027 [doi]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2020 Aug;28(8):829-834. doi: 10.1016/j.jagp.2020.04.027.
      Epub 2020 May 5.


PMID- 32408869
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20200910
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 14
TI  - Prioritising access to pandemic influenza vaccine: a review of the ethics
      literature.
PG  - 40
LID - 10.1186/s12910-020-00477-3 [doi]
AB  - BACKGROUND: The world is threatened by future pandemics. Vaccines can play a key 
      role in preventing harm, but there will inevitably be shortages because there is 
      no possibility of advance stockpiling. We therefore need some method of
      prioritising access. MAIN TEXT: This paper reports a critical interpretative
      review of the published literature that discusses ethical arguments used to
      justify how we could prioritise vaccine during an influenza pandemic. We found
      that the focus of the literature was often on proposing different groups as
      priorities (e.g. those with pre-existing health conditions, the young, the old,
      health care workers etc.). Different reasons were often suggested as a means of
      justifying such priority groupings (e.g. appeal to best overall outcomes,
      fairness, belonging to a vulnerable or 'at risk' group etc.). We suggest that
      much of the literature, wrongly, assumes that we are able to plan priority groups
      prior to the time of a particular pandemic and development of a particular
      vaccine. We also point out the surprising absence of various issues from the
      literature (e.g. how vaccines fit within overall pandemic planning, a lack of
      specificity about place, issues of global justice etc.). CONCLUSIONS: The
      literature proposes a wide range of ways to prioritise vaccines, focusing on
      different groups and 'principles'. Any plan to use pandemic vaccine must provide 
      justifications for its prioritisation. The focus of this review was influenza
      pandemic vaccines, but lessons can be learnt for future allocations of
      coronavirus vaccine, if one becomes available.
FAU - Williams, Jane H
AU  - Williams JH
AD  - Sydney Health Ethics, Sydney School of Public Health, University of Sydney, Level
      1, Medical Foundation Building K25, Sydney, NSW, 2006, Australia.
AD  - Marie Bashir Institute for Infectious Disease and Biosecurity, University of
      Sydney, Sydney, Australia.
FAU - Dawson, Angus
AU  - Dawson A
AD  - Sydney Health Ethics, Sydney School of Public Health, University of Sydney, Level
      1, Medical Foundation Building K25, Sydney, NSW, 2006, Australia.
      angus.dawson@sydney.edu.au.
AD  - Marie Bashir Institute for Infectious Disease and Biosecurity, University of
      Sydney, Sydney, Australia. angus.dawson@sydney.edu.au.
LA  - eng
GR  - Health/17-18/73536/Department of Health, Australian Government/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200514
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
RN  - 0 (Influenza Vaccines)
SB  - IM
CIN - Nature. 2020 Sep;585(7826):492-493. PMID: 32948865
MH  - Disease Outbreaks/*prevention & control
MH  - Health Priorities/*ethics
MH  - Health Services Accessibility/*ethics
MH  - Humans
MH  - Influenza Vaccines/*supply & distribution
MH  - Influenza, Human/*prevention & control
MH  - Pandemics
PMC - PMC7224123
OTO - NOTNLM
OT  - *Critical interpretative review
OT  - *Ethics
OT  - *Pandemic influenza
OT  - *Prioritisation
OT  - *Vaccine
EDAT- 2020/05/16 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/05/16 06:00
PHST- 2019/03/06 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - 10.1186/s12910-020-00477-3 [doi]
AID - 10.1186/s12910-020-00477-3 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 14;21(1):40. doi: 10.1186/s12910-020-00477-3.


PMID- 32408669
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20210304
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 12
TI  - Inhibition of Neuromuscular Contractions of Human and Rat Colon by Bergamot
      Essential Oil and Linalool: Evidence to Support a Therapeutic Action.
LID - E1381 [pii]
LID - 10.3390/nu12051381 [doi]
AB  - Bergamot essential oil (BEO) added to food and drink promotes a citrus flavour.
      Folklore suggests benefits on gastrointestinal functions but with little
      supporting evidence. BEO and major constituents (linalool, limonene, linalyl
      acetate) were therefore examined for any ability to influence neuromuscular
      contractions of human and rat colon. Circular muscle strips
      (macroscopically-normal human colon obtained following ethical approval at cancer
      surgery; Sprague-Dawley rats) were suspended in baths (Krebs solution; 37 degrees
      C; 5% CO2 in O2) for measurement of neuronally-mediated contractions (prevented
      by tetrodotoxin or atropine) evoked by electrical field stimulation (5 Hz, 0.5 ms
      pulse width, 10s/minute, maximally-effective voltage), or contractions evoked by 
      KCl (submaximally-effective concentrations). BEO and each constituent
      concentration dependently inhibited neuronally-mediated and KCl-induced
      contractions. In human: apparent pIC50 for BEO (volume/volume Krebs),
      respectively, 3.8 +/- 0.3 and 4.4 +/- 0.3; Imax 55.8% +/- 4.2% and 37.5% +/-
      4.2%. For the constituents, the rank order of potency differed in human (linalool
      > limonene >> linalyl-acetate) and rat colon (linalyl-acetate > limonene =
      linalool), but rank order of efficacy was similar (linalool >> (BEO) =
      linalyl-acetate >> limonene). Thus, linalool had high efficacy but greater
      potency in human colon (Imax 76.8% +/- 6.9%; pIC50 6.7 +/- 0.2; n = 4) compared
      with rat colon (Imax 75.3% +/- 1.9%; pIC50 5.8 +/- 0.1; n = 4). The ability of
      BEO and linalool to inhibit human colon neuromuscular contractility provides a
      mechanism for use as complementary treatments of intestinal disorders.
FAU - Straface, Marilisa
AU  - Straface M
AD  - Preclinical and Translational Pharmacology, Department of Pharmacy, Health
      Science and Nutrition, University of Calabria, 87036 Rende, Italy.
AD  - Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen
      Mary University of London, London E1 4NS, UK.
FAU - Makwana, Raj
AU  - Makwana R
AD  - Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen
      Mary University of London, London E1 4NS, UK.
FAU - Palmer, Alexandra
AU  - Palmer A
AD  - Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen
      Mary University of London, London E1 4NS, UK.
FAU - Rombola, Laura
AU  - Rombola L
AD  - Preclinical and Translational Pharmacology, Department of Pharmacy, Health
      Science and Nutrition, University of Calabria, 87036 Rende, Italy.
FAU - Aleong, Joanne Chin
AU  - Aleong JC
AD  - Department of Pathology, Royal London Hospital, Barts Health NHS Trust, London E1
      1BB, UK.
FAU - Morrone, Luigi Antonio
AU  - Morrone LA
AD  - Preclinical and Translational Pharmacology, Department of Pharmacy, Health
      Science and Nutrition, University of Calabria, 87036 Rende, Italy.
FAU - Sanger, Gareth J
AU  - Sanger GJ
AD  - Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen
      Mary University of London, London E1 4NS, UK.
LA  - eng
GR  - G0900805/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200512
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Acyclic Monoterpenes)
RN  - 0 (Neuromuscular Agents)
RN  - 0 (Oils, Volatile)
RN  - 0 (Plant Oils)
RN  - 39W1PKE3JI (bergamot oil)
RN  - D81QY6I88E (linalool)
SB  - IM
MH  - Acyclic Monoterpenes/*pharmacology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Colon/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Contraction/*drug effects
MH  - Neuromuscular Agents/*pharmacology
MH  - Oils, Volatile/*pharmacology
MH  - Plant Oils/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC7284490
OTO - NOTNLM
OT  - bergamot essential oil
OT  - colon
OT  - human
OT  - limonene
OT  - linalool
OT  - rat
OT  - spasmolytic
EDAT- 2020/05/16 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/05/06 00:00 [revised]
PHST- 2020/05/09 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - nu12051381 [pii]
AID - 10.3390/nu12051381 [doi]
PST - epublish
SO  - Nutrients. 2020 May 12;12(5). pii: nu12051381. doi: 10.3390/nu12051381.


PMID- 32408585
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-666X (Print)
IS  - 2072-666X (Linking)
VI  - 11
IP  - 5
DP  - 2020 May 12
TI  - Concentration Gradient Constructions Using Inertial Microfluidics for Studying
      Tumor Cell-Drug Interactions.
LID - E493 [pii]
LID - 10.3390/mi11050493 [doi]
AB  - With the continuous development of cancer therapy, conventional animal models
      have exposed a series of shortcomings such as ethical issues, being time
      consuming and having an expensive cost. As an alternative method, microfluidic
      devices have shown advantages in drug screening, which can effectively shorten
      experimental time, reduce costs, improve efficiency, and achieve a large-scale,
      high-throughput and accurate analysis. However, most of these microfluidic
      technologies are established for narrow-range drug-concentration screening based 
      on sensitive but limited flow rates. More simple, easy-to operate and
      wide-ranging concentration-gradient constructions for studying tumor cell-drug
      interactions in real-time have remained largely out of reach. Here, we proposed a
      simple and compact device that can quickly construct efficient and reliable
      drug-concentration gradients with a wide range of flow rates. The dynamic study
      of concentration-gradient formation based on successive spiral mixer regulations 
      was investigated systematically and quantitatively. Accurate, stable, and
      controllable dual drug-concentration gradients were produced to evaluate
      simultaneously the efficacy of the anticancer drug against two tumor cell lines
      (human breast adenocarcinoma cells and human cervical carcinoma cells). Results
      showed that paclitaxel had dose-dependent effects on the two tumor cell lines
      under the same conditions, respectively. We expect this device to contribute to
      the development of microfluidic chips as a portable and economical product in
      terms of the potential of concentration gradient-related biochemical research.
FAU - Shen, Shaofei
AU  - Shen S
AD  - College of Life Science, Shanxi Agricultural University, Taigu 030801, China.
FAU - Zhang, Fangjuan
AU  - Zhang F
AD  - College of Life Science, Shanxi Agricultural University, Taigu 030801, China.
FAU - Gao, Mengqi
AU  - Gao M
AD  - College of Life Science, Shanxi Agricultural University, Taigu 030801, China.
FAU - Niu, Yanbing
AU  - Niu Y
AD  - College of Life Science, Shanxi Agricultural University, Taigu 030801, China.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Switzerland
TA  - Micromachines (Basel)
JT  - Micromachines
JID - 101640903
PMC - PMC7281261
OTO - NOTNLM
OT  - concentration gradient
OT  - drug screening
OT  - inertial microfluidics
OT  - microfluidic chip
OT  - spiral mixer
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/16 06:00
MHDA- 2020/05/16 06:01
CRDT- 2020/05/16 06:00
PHST- 2020/03/28 00:00 [received]
PHST- 2020/05/03 00:00 [revised]
PHST- 2020/05/11 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2020/05/16 06:01 [medline]
AID - mi11050493 [pii]
AID - 10.3390/mi11050493 [doi]
PST - epublish
SO  - Micromachines (Basel). 2020 May 12;11(5). pii: mi11050493. doi:
      10.3390/mi11050493.


PMID- 32408481
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1999-4915 (Electronic)
IS  - 1999-4915 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 12
TI  - Usutu Virus Infection of Embryonated Chicken Eggs and a Chicken Embryo-Derived
      Primary Cell Line.
LID - E531 [pii]
LID - 10.3390/v12050531 [doi]
AB  - Usutu virus (USUV) is a mosquito-borne flavivirus, closely related to the West
      Nile virus (WNV). Similar to WNV, USUV may cause infections in humans, with
      occasional, but sometimes severe, neurological complications. Further, USUV can
      be highly pathogenic in wild and captive birds and its circulation in Europe has 
      given rise to substantial avian death. Adequate study models of this virus are
      still lacking but are critically needed to understand its pathogenesis and
      virulence spectrum. The chicken embryo is a low-cost, easy-to-manipulate and
      ethically acceptable model that closely reflects mammalian fetal development and 
      allows immune response investigations, drug screening, and high-throughput virus 
      production for vaccine development. While former studies suggested that this
      model was refractory to USUV infection, we unexpectedly found that high doses of 
      four phylogenetically distinct USUV strains caused embryonic lethality. By
      employing immunohistochemistry and quantitative reverse transcriptase-polymerase 
      chain reaction, we demonstrated that USUV was widely distributed in embryonic
      tissues, including the brain, retina, and feather follicles. We then successfully
      developed a primary cell line from the chorioallantoic membrane that was
      permissive to the virus without the need for viral adaptation. We believe the
      future use of these models would foster a significant understanding of
      USUV-induced neuropathogenesis and immune response and allow the future
      development of drugs and vaccines against USUV.
FAU - Benzarti, Emna
AU  - Benzarti E
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
FAU - Rivas, Jose
AU  - Rivas J
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
FAU - Sarlet, Michael
AU  - Sarlet M
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
FAU - Franssen, Mathieu
AU  - Franssen M
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
FAU - Moula, Nassim
AU  - Moula N
AUID- ORCID: 0000-0003-4438-8759
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
FAU - Savini, Giovanni
AU  - Savini G
AD  - OIE Reference Centre for West Nile Disease, Istituto Zooprofilattico Sperimentale
      "G. Caporale", 46100 Teramo, Italy.
FAU - Lorusso, Alessio
AU  - Lorusso A
AD  - OIE Reference Centre for West Nile Disease, Istituto Zooprofilattico Sperimentale
      "G. Caporale", 46100 Teramo, Italy.
FAU - Desmecht, Daniel
AU  - Desmecht D
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
FAU - Garigliany, Mutien-Marie
AU  - Garigliany MM
AD  - Fundamental and Applied Research for Animals & Health (FARAH), Faculty of
      Veterinary Medicine, University of Liege, Sart Tilman B43, B-4000 Liege, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - Switzerland
TA  - Viruses
JT  - Viruses
JID - 101509722
RN  - Usutu virus
SB  - IM
MH  - Animals
MH  - Brain/pathology/virology
MH  - Cell Line
MH  - Chick Embryo
MH  - Chickens
MH  - Flavivirus/genetics/*physiology
MH  - Flavivirus Infections/mortality/pathology/*veterinary/virology
MH  - Poultry Diseases/mortality/pathology/*virology
MH  - Retina/pathology/virology
PMC - PMC7291025
OTO - NOTNLM
OT  - *Usutu virus
OT  - *chicken embryo
OT  - *chorioallantoic membrane
OT  - *flavivirus
OT  - *model
OT  - *primary culture
OT  - *replication
EDAT- 2020/05/16 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/16 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/16 06:00 [entrez]
PHST- 2020/05/16 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - v12050531 [pii]
AID - 10.3390/v12050531 [doi]
PST - epublish
SO  - Viruses. 2020 May 12;12(5). pii: v12050531. doi: 10.3390/v12050531.


PMID- 32408267
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 5
DP  - 2020 May 26
TI  - A Global Digital Citizen Science Policy to Tackle Pandemics Like COVID-19.
PG  - e19357
LID - 10.2196/19357 [doi]
AB  - The coronavirus disease (COVID-19) pandemic is an extremely complex existential
      threat that requires cohesive societal effort to address health system
      inefficiencies. When our society has faced existential crises in the past, we
      have banded together by using the technology at hand to overcome them. The
      COVID-19 pandemic is one such threat that requires not only a cohesive effort,
      but also enormous trust to follow public health guidelines, maintain social
      distance, and share necessities. However, are democratic societies with civil
      liberties capable of doing this? Mobile technology has immense potential for
      addressing pandemics like COVID-19, as it gives us access to big data in terms of
      volume, velocity, veracity, and variety. These data are particularly relevant to 
      understand and mitigate the spread of pandemics such as COVID-19. In order for
      such intensive and potentially intrusive data collection measures to succeed, we 
      need a cohesive societal effort with full buy-in from citizens and their
      representatives. This article outlines an evidence-based global digital citizen
      science policy that provides the theoretical and methodological foundation for
      ethically sourcing big data from citizens to tackle pandemics such as COVID-19.
CI  - (c)Tarun R Katapally. Originally published in the Journal of Medical Internet
      Research (http://www.jmir.org), 26.05.2020.
FAU - Katapally, Tarun R
AU  - Katapally TR
AUID- ORCID: 0000-0001-5765-1435
AD  - University of Regina, Regina, SK, Canada.
LA  - eng
GR  - 153226/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Citizen Science
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Public Health
MH  - SARS-CoV-2
PMC - PMC7284491
OTO - NOTNLM
OT  - *COVID-19
OT  - *big data
OT  - *citizen science
OT  - *digital epidemiology
OT  - *eHealth
OT  - *infectious diseases
OT  - *mHealth
OT  - *pandemic
OT  - *population health
OT  - *public health
OT  - *smartphones
OT  - *virus
EDAT- 2020/05/15 06:00
MHDA- 2020/06/04 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/05/05 00:00 [revised]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - v22i5e19357 [pii]
AID - 10.2196/19357 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 May 26;22(5):e19357. doi: 10.2196/19357.


PMID- 32407829
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 223
DP  - 2020 Sep 1
TI  - Food Waste: Ethical Imperatives & Complexities.
PG  - 112927
LID - S0031-9384(20)30241-9 [pii]
LID - 10.1016/j.physbeh.2020.112927 [doi]
AB  - We identify multiple ways in which food waste matters ethically: because of its
      direct negative environmental effects, because of the environmental impacts of
      excess food production, and because of the foregone benefits that could have been
      achieved if wasted food had been consumed. The issue of food waste is complicated
      by competing views on how to define food waste; we suggest that food waste could 
      be defined as edible and nutritive plant, animal, mineral, or fungal materials
      used in ways that do not provide sufficient benefit and value. We also consider
      ways of reframing the issue of food waste, such as shifting the focus from food
      "waste" to food "conservation," allowing our emphasis to be redirected toward the
      resources that ought to be treated with greater care. Finally, we discuss ethical
      concerns with food waste-reduction efforts, which may have unintended
      consequences or may be minimally effective.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Barnhill, Anne
AU  - Barnhill A
AD  - Core Faculty, Johns Hopkins Berman Institute of Bioethics Baltimore, Maryland,
      USA. Electronic address: Anne.barnhill@gmail.com.
FAU - Civita, Nicole
AU  - Civita N
AD  - Sustainable Food Systems Specialization Lead & Instructor, Masters of the
      Environment Program, University of Colorado Boulder, Boulder, Colorado, USA.
      Electronic address: nicole.civita@colorado.edu.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
SB  - IM
MH  - Environment
MH  - *Food
MH  - *Refuse Disposal
EDAT- 2020/05/15 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - S0031-9384(20)30241-9 [pii]
AID - 10.1016/j.physbeh.2020.112927 [doi]
PST - ppublish
SO  - Physiol Behav. 2020 Sep 1;223:112927. doi: 10.1016/j.physbeh.2020.112927. Epub
      2020 May 12.


PMID- 32407772
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210110
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 76
IP  - 1
DP  - 2020 Jul 7
TI  - Scarce-Resource Allocation and Patient Triage During the COVID-19 Pandemic: JACC 
      Review Topic of the Week.
PG  - 85-92
LID - S0735-1097(20)35223-2 [pii]
LID - 10.1016/j.jacc.2020.05.006 [doi]
AB  - The COVID-19 pandemic and its sequelae have created scenarios of scarce medical
      resources, leading to the prospect that health care systems have faced or will
      face difficult decisions about triage, allocation, and reallocation. These
      decisions should be guided by ethical principles and values, should not be made
      before crisis standards have been declared by authorities, and, in most cases,
      will not be made by bedside clinicians. Do not attempt resuscitation and
      withholding and withdrawing decisions should be made according to standard
      determination of medical appropriateness and futility, but there are unique
      considerations during a pandemic. Transparent and clear communication is crucial,
      coupled with dedication to provide the best possible care to patients, including 
      palliative care. As medical knowledge about COVID-19 grows, more will be known
      about prognostic factors that can guide these difficult decisions.
CI  - Copyright (c) 2020 American College of Cardiology Foundation. All rights
      reserved.
FAU - Kirkpatrick, James N
AU  - Kirkpatrick JN
AD  - Division of Cardiology and Department of Bioethics and Humanities, University of 
      Washington, Seattle, Washington. Electronic address: kirkpatj@uw.edu.
FAU - Hull, Sarah C
AU  - Hull SC
AD  - Section of Cardiovascular Medicine, Program for Biomedical Ethics, Yale
      University, New Haven, Connecticut.
FAU - Fedson, Savitri
AU  - Fedson S
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Section 
      of Cardiology, Michael E DeBakey VA Medical Center, Houston, Texas.
FAU - Mullen, Brendan
AU  - Mullen B
AD  - American College of Cardiology, Washington, DC.
FAU - Goodlin, Sarah J
AU  - Goodlin SJ
AD  - Department of Geriatrics and Palliative Medicine, VAPORHCS, Oregon Health
      Sciences University, Patient-Centered Education and Research, Portland, Oregon.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200511
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
SB  - IM
MH  - *Advance Care Planning/ethics/organization & administration
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - *Cardiology/standards/trends
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Critical Pathways/*trends
MH  - *Health Care Rationing/methods/organization & administration/trends
MH  - Humans
MH  - Palliative Care/ethics/organization & administration
MH  - *Pandemics/ethics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Standard of Care
MH  - *Triage/methods/trends
PMC - PMC7213960
OTO - NOTNLM
OT  - COVID-19
OT  - end of life
OT  - ethics
OT  - palliative care
OT  - resource allocation
EDAT- 2020/05/15 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - S0735-1097(20)35223-2 [pii]
AID - 10.1016/j.jacc.2020.05.006 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2020 Jul 7;76(1):85-92. doi: 10.1016/j.jacc.2020.05.006. Epub 
      2020 May 11.


PMID- 32407443
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210910
IS  - 2374-2445 (Electronic)
IS  - 2374-2437 (Linking)
VI  - 6
IP  - 8
DP  - 2020 Aug 1
TI  - Clinical Application of Computational Methods in Precision Oncology: A Review.
PG  - 1282-1286
LID - 10.1001/jamaoncol.2020.1247 [doi]
AB  - Importance: There is an enormous and growing amount of data available from
      individual cancer cases, which makes the work of clinical oncologists more
      demanding. This data challenge has attracted engineers to create software that
      aims to improve cancer diagnosis or treatment. However, the move to use computers
      in the oncology clinic for diagnosis or treatment has led to instances of
      premature or inappropriate use of computational predictive systems. Objective: To
      evaluate best practices for developing and assessing the clinical utility of
      predictive computational methods in oncology. Evidence Review: The National
      Cancer Policy Forum and the Board on Mathematical Sciences and Analytics at the
      National Academies of Sciences, Engineering, and Medicine hosted a workshop to
      examine the use of multidimensional data derived from patients with cancer and
      the computational methods used to analyze these data. The workshop convened
      diverse stakeholders and experts, including computer scientists, oncology
      clinicians, statisticians, patient advocates, industry leaders, ethicists,
      leaders of health systems (academic and community based), private and public
      health insurance carriers, federal agencies, and regulatory authorities. Key
      characteristics for successful computational oncology were considered in 3
      thematic areas: (1) data quality, completeness, sharing, and privacy; (2)
      computational methods for analysis, interpretation, and use of oncology data; and
      (3) clinical infrastructure and expertise for best use of computational precision
      oncology. Findings: Quality control was found to be essential across all stages, 
      from data collection to data processing, management, and use. Collecting a
      standardized parsimonious data set at every cancer diagnosis and restaging could 
      enhance reliability and completeness of clinical data for precision oncology.
      Data completeness refers to key data elements such as information about cancer
      diagnosis, treatment, and outcomes, while data quality depends on whether
      appropriate variables have been measured in valid and reliable ways. Collecting
      data from diverse populations can reduce the risk of creating invalid and biased 
      algorithms. Computational systems that aid clinicians should be classified as
      software as a medical device and thus regulated according to the potential risk
      posed. To facilitate appropriate use of computational methods that interpret
      high-dimensional data in oncology, treating physicians need access to
      multidisciplinary teams with broad expertise and deep training among a subset of 
      clinical oncology fellows in clinical informatics. Conclusions and Relevance:
      Workshop discussions suggested best practices in demonstrating the clinical
      utility of predictive computational methods for diagnosing or treating cancer.
FAU - Panagiotou, Orestis A
AU  - Panagiotou OA
AD  - Department of Health Services, Policy and Practice, Brown University School of
      Public Health, Providence, Rhode Island.
FAU - Hogg, Lori Hoffman
AU  - Hogg LH
AD  - National Center for Health Promotion and Disease Prevention, Veterans Health
      Administration, Durham, North Carolina.
AD  - Office of Nursing Services, Veterans Health Administration, Washington, DC.
FAU - Hricak, Hedvig
AU  - Hricak H
AD  - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Khleif, Samir N
AU  - Khleif SN
AD  - Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
FAU - Levy, Mia A
AU  - Levy MA
AD  - Department of Biomedical Informatics, Vanderbilt University School of Medicine,
      Nashville, Tennessee.
AD  - Division of Hematology and Oncology, Department of Medicine, Vanderbilt
      University School of Medicine, Nashville, Tennessee.
FAU - Magnus, David
AU  - Magnus D
AD  - Center for Biomedical Ethics, Stanford University School of Medicine, Stanford,
      California.
FAU - Murphy, Martin J
AU  - Murphy MJ
AD  - CEO Roundtable on Cancer, Cary, North Carolina.
FAU - Patel, Bakul
AU  - Patel B
AD  - Center for Devices and Radiological Health, US Food and Drug Administration,
      Silver Spring, Maryland.
FAU - Winn, Robert A
AU  - Winn RA
AD  - University of Illinois at Chicago Cancer Center, University of Illinois Hospital 
      and Health Sciences System, Chicago.
FAU - Nass, Sharyl J
AU  - Nass SJ
AD  - Health and Medicine Division, National Academies of Sciences, Engineering, and
      Medicine, Washington, DC.
FAU - Gatsonis, Constantine
AU  - Gatsonis C
AD  - Department of Biostatistics, Brown University School of Public Health,
      Providence, Rhode Island.
FAU - Cogle, Christopher R
AU  - Cogle CR
AD  - Division of Hematology & Oncology, Department of Medicine, University of Florida 
      College of Medicine, Gainesville.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JAMA Oncol
JT  - JAMA oncology
JID - 101652861
SB  - IM
MH  - *Computational Biology
MH  - Data Accuracy
MH  - Humans
MH  - *Medical Oncology
MH  - Neoplasms/diagnosis/*therapy
MH  - *Precision Medicine
EDAT- 2020/05/15 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 2765757 [pii]
AID - 10.1001/jamaoncol.2020.1247 [doi]
PST - ppublish
SO  - JAMA Oncol. 2020 Aug 1;6(8):1282-1286. doi: 10.1001/jamaoncol.2020.1247.


PMID- 32407245
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Rural and Remote Communities: Unique Ethical Issues in the COVID-19 Pandemic.
PG  - 117-120
LID - 10.1080/15265161.2020.1764139 [doi]
FAU - Erwin, Cheryl
AU  - Erwin C
AD  - Texas Tech University Health Sciences Center.
FAU - Aultman, Julie
AU  - Aultman J
AD  - Northeast Ohio Medical University.
FAU - Harter, Tom
AU  - Harter T
AD  - Gundersen Health System.
FAU - Illes, Judy
AU  - Illes J
AD  - University of British Columbia.
FAU - Kogan, Rabbi Claudio J
AU  - Kogan RCJ
AD  - UTHealth Rio Grande Valley School of Medicine.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200514
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 Jul;20(7):15-27. PMID: 32511078
MH  - Betacoronavirus
MH  - *Bioethics
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
EDAT- 2020/05/15 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1080/15265161.2020.1764139 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):117-120. doi: 10.1080/15265161.2020.1764139. Epub
      2020 May 14.


PMID- 32407155
OWN - NLM
STAT- Publisher
LR  - 20220716
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
DP  - 2020 May 14
TI  - Publication Ethics During Public Health Emergencies Such as the COVID-19
      Pandemic.
PG  - e1-e2
LID - 10.2105/AJPH.2020.305686 [doi]
AB  - Public health emergencies require real-time, accurate information to guide
      effective responses. Rapid publication of information can, therefore, advance
      both the scientific validity and the social value of research conducted in these 
      contexts. Consequently, medical journals place a high priority on rapidly
      publishing reports on these emergencies, which the media often report on to the
      public. Today, the focus is on the rapid publication of research related to the
      COVID-19 outbreak. Tomorrow, it might be an influenza pandemic or a crisis
      related to a vaping-related illness. (Am J Public Health. Published online ahead 
      of print May 14, 2020: e1-e2. doi:10.2105/AJPH.2020.305686).
FAU - Smith, Maxwell J
AU  - Smith MJ
AD  - Maxwell J. Smith is with the School of Health Studies, Western University,
      London, ON. Ross E.G. Upshur is with the Dalla Lana School of Public Health,
      University of Toronto, Toronto, ON. Ezekiel J. Emanuel is with the Department of 
      Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
FAU - Upshur, Ross E G
AU  - Upshur REG
AD  - Maxwell J. Smith is with the School of Health Studies, Western University,
      London, ON. Ross E.G. Upshur is with the Dalla Lana School of Public Health,
      University of Toronto, Toronto, ON. Ezekiel J. Emanuel is with the Department of 
      Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
FAU - Emanuel, Ezekiel J
AU  - Emanuel EJ
AD  - Maxwell J. Smith is with the School of Health Studies, Western University,
      London, ON. Ross E.G. Upshur is with the Dalla Lana School of Public Health,
      University of Toronto, Toronto, ON. Ezekiel J. Emanuel is with the Department of 
      Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
LA  - eng
PT  - Editorial
DEP - 20200514
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
PMC - PMC7287521
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.2105/AJPH.2020.305686 [doi]
PST - aheadofprint
SO  - Am J Public Health. 2020 May 14:e1-e2. doi: 10.2105/AJPH.2020.305686.


PMID- 32406995
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20220104
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 96
IP  - 4
DP  - 2020 Oct 1
TI  - SCAI position statement on the performance of percutaneous coronary intervention 
      in ambulatory surgical centers.
PG  - 862-870
LID - 10.1002/ccd.28991 [doi]
AB  - The Centers for Medicare & Medicaid Services (CMS) began reimbursement for
      percutaneous coronary intervention (PCI) performed in ambulatory surgical centers
      (ASC) in January 2020. The ability to perform PCI in an ASC has been made
      possible due to the outcomes data from observational studies and randomized
      controlled trials supporting same day discharge (SDD) after PCI. In appropriately
      selected patients for outpatient PCI, clinical outcomes for SDD or routine
      overnight observation are comparable without any difference in short-term or
      long-term adverse events. Furthermore, a potential for lower cost of care without
      a compromise in clinical outcomes exists. These studies provide the framework and
      justification for performing PCI in an ASC. The Society for Cardiovascular
      Angiography and Interventions (SCAI) supported this coverage decision provided
      the quality and safety standards for PCI in an ASC were equivalent to the
      hospital setting. The current position paper is written to provide guidance for
      starting a PCI program in an ASC with an emphasis on maintaining quality
      standards. Regulatory requirements and appropriate standards for the facility,
      staff and physicians are delineated. The consensus document identified
      appropriate patients for consideration of PCI in an ASC. The key components of an
      ongoing quality assurance program are defined and the ethical issues relevant to 
      PCI in an ASC are reviewed.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Box, Lyndon C
AU  - Box LC
AD  - West Valley Specialty Clinic, Caldwell, Idaho, USA.
FAU - Blankenship, James C
AU  - Blankenship JC
AUID- ORCID: 0000-0003-4966-533X
AD  - Geisinger Health System, Danville, Pennsylvania, USA.
FAU - Henry, Timothy D
AU  - Henry TD
AUID- ORCID: 0000-0003-1123-0533
AD  - The Carl and Edyth Lindner Center for Research and Education at The Christ
      Hospital, Cincinnati, Ohio, USA.
FAU - Messenger, John C
AU  - Messenger JC
AD  - University of Colorado School of Medicine, Aurora, Colorado, USA.
FAU - Cigarroa, Joaquin E
AU  - Cigarroa JE
AUID- ORCID: 0000-0003-1567-6006
AD  - Oregon Health & Science University, Portland, Oregon, USA.
FAU - Moussa, Issam D
AU  - Moussa ID
AD  - Carle Health System, Carle Illinois College of Medicine, Champaign, Illinois,
      USA.
FAU - Snyder, Richard W
AU  - Snyder RW
AD  - Heartplace, Dallas, Texas, USA.
FAU - Duffy, Peter L
AU  - Duffy PL
AD  - Appalachian Regional Healthcare System, Boone, North Carolina, USA.
FAU - Carr, Jeffrey G
AU  - Carr JG
AD  - CardiaStream Tyler Cardiac and Endovascular Center, Tyler, Texas, USA.
FAU - Tukaye, Deepali N
AU  - Tukaye DN
AD  - Jack Stephens Heart Institute CHI St Vincent, Conway, Arkansas, USA.
FAU - Ang, Lawrence
AU  - Ang L
AUID- ORCID: 0000-0002-3206-7432
AD  - University of California, San Diego, Sulpizio Cardiovascular Center, La Jolla,
      California, USA.
FAU - Shah, Binita
AU  - Shah B
AD  - New York University School of Medicine, New York, New York, USA.
FAU - Rao, Sunil V
AU  - Rao SV
AD  - Duke University Health System, Durham, North Carolina, USA.
FAU - Mahmud, Ehtisham
AU  - Mahmud E
AD  - University of California, San Diego, Sulpizio Cardiovascular Center, La Jolla,
      California, USA.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
DEP - 20200702
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
SB  - IM
CIN - Catheter Cardiovasc Interv. 2021 Dec 1;98(7):1415. PMID: 34528367
MH  - Cardiology/*standards
MH  - Consensus
MH  - Coronary Artery Disease/diagnostic imaging/mortality/*therapy
MH  - Humans
MH  - Patient Safety/standards
MH  - Percutaneous Coronary Intervention/adverse effects/mortality/*standards
MH  - Quality Assurance, Health Care/standards
MH  - Quality Indicators, Health Care/standards
MH  - Risk Assessment
MH  - Risk Factors
MH  - Surgicenters/*standards
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *ambulatory surgery center
OT  - *angioplasty
OT  - *percutaneous coronary intervention
EDAT- 2020/05/15 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/06 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1002/ccd.28991 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2020 Oct 1;96(4):862-870. doi: 10.1002/ccd.28991.
      Epub 2020 Jul 2.


PMID- 32406990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201207
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 23
IP  - 5
DP  - 2020 May
TI  - Why ethics guidance needs to be updated for contemporary HIV prevention research.
PG  - e25500
LID - 10.1002/jia2.25500 [doi]
FAU - Brown, Brandon J
AU  - Brown BJ
AD  - Center for Healthy Communities, School of Medicine, University of California,
      Riverside, CA, USA.
FAU - Sugarman, Jeremy
AU  - Sugarman J
AUID- ORCID: 0000-0001-7022-8332
AD  - Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
SB  - IM
PMC - PMC7224307
OTO - NOTNLM
OT  - *HIV Prevention Trials Network
OT  - *HIV prevention
OT  - *guidelines
OT  - *research ethics
OT  - *stakeholders
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
CRDT- 2020/05/15 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
AID - 10.1002/jia2.25500 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2020 May;23(5):e25500. doi: 10.1002/jia2.25500.


PMID- 32406969
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20210920
IS  - 1523-1739 (Electronic)
IS  - 0888-8892 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Aug
TI  - Myths and assumptions about human-wildlife conflict and coexistence.
PG  - 811-818
LID - 10.1111/cobi.13472 [doi]
AB  - Recent extinctions often resulted from humans retaliating against wildlife that
      threatened people's interests or were perceived to threaten current or future
      interests. Today's subfield of human-wildlife conflict and coexistence (HWCC)
      grew out of an original anthropocentric concern with such real or perceived
      threats and then, starting in the mid-1990s, with protecting valued species from 
      people. Recent work in ethics and law has shifted priorities toward coexistence
      between people and wild animals. To spur scientific progress and more effective
      practice, we examined 4 widespread assumptions about HWCC that need to be tested 
      rigorously: scientists are neutral and objective about HWCC; current
      participatory, consensus-based decisions provide just and fair means to overcome 
      challenges in HWCC; wildlife threats to human interests are getting worse; and
      wildlife damage to human interests is additive to other sources of damage. The
      first 2 assumptions are clearly testable, but if they are entangled can become a 
      wicked problem and may need debunking as myths if they cannot be disentangled.
      Some assumptions have seldom or never been tested and those that have been tested
      appear dubious, yet the use of the assumptions continues in the practice and
      scholarship of HWCC. We call for tests of assumptions and debunking of myths in
      the scholarship of HWCC. Adherence to the principles of scientific integrity and 
      application of standards of evidence can help advance our call. We also call for 
      practitioners and interest groups to improve the constitutive process prior to
      decision making about wildlife. We predict these steps will hasten scientific
      progress toward evidence-based interventions and improve the fairness, ethics,
      and legality of coexistence strategies.
CI  - (c) 2020 Society for Conservation Biology.
FAU - Treves, Adrian
AU  - Treves A
AUID- ORCID: 0000-0002-3052-4708
AD  - Nelson Institute for Environmental Studies, University of Wisconsin-Madison,
      Madison, WI, 53706, U.S.A.
FAU - Santiago-Avila, Francisco J
AU  - Santiago-Avila FJ
AUID- ORCID: 0000-0003-4233-9128
AD  - Nelson Institute for Environmental Studies, University of Wisconsin-Madison,
      Madison, WI, 53706, U.S.A.
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - United States
TA  - Conserv Biol
JT  - Conservation biology : the journal of the Society for Conservation Biology
JID - 9882301
SB  - IM
CIN - Conserv Biol. 2021 Aug;35(4):1337-1340. PMID: 34324232
CIN - Conserv Biol. 2021 Aug;35(4):1334-1336. PMID: 34324233
MH  - Animals
MH  - *Animals, Wild
MH  - Consensus
MH  - *Conservation of Natural Resources
MH  - Goals
MH  - Humans
OTO - NOTNLM
OT  - *animal damage
OT  - *bias
OT  - *biodiversity conservation
OT  - *conservacion de la biodiversidad
OT  - *dano animal
OT  - *implicit value judgments
OT  - *intervenciones
OT  - *interventions
OT  - *juicios de valor implicito
OT  - *planning
OT  - *policy
OT  - *politicas de planeacion
OT  - *sesgo
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
OT  - *
EDAT- 2020/05/15 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/05/15 06:00
PHST- 2019/01/15 00:00 [received]
PHST- 2019/05/25 00:00 [revised]
PHST- 2019/06/06 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1111/cobi.13472 [doi]
PST - ppublish
SO  - Conserv Biol. 2020 Aug;34(4):811-818. doi: 10.1111/cobi.13472. Epub 2020 May 14.


PMID- 32406850
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210108
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 7
DP  - 2020 Jul 7
TI  - Artificial Intelligence and Health Technology Assessment: Anticipating a New
      Level of Complexity.
PG  - e17707
LID - 10.2196/17707 [doi]
AB  - Artificial intelligence (AI) is seen as a strategic lever to improve access,
      quality, and efficiency of care and services and to build learning and
      value-based health systems. Many studies have examined the technical performance 
      of AI within an experimental context. These studies provide limited insights into
      the issues that its use in a real-world context of care and services raises. To
      help decision makers address these issues in a systemic and holistic manner, this
      viewpoint paper relies on the health technology assessment core model to contrast
      the expectations of the health sector toward the use of AI with the risks that
      should be mitigated for its responsible deployment. The analysis adopts the
      perspective of payers (ie, health system organizations and agencies) because of
      their central role in regulating, financing, and reimbursing novel technologies. 
      This paper suggests that AI-based systems should be seen as a health system
      transformation lever, rather than a discrete set of technological devices. Their 
      use could bring significant changes and impacts at several levels: technological,
      clinical, human and cognitive (patient and clinician), professional and
      organizational, economic, legal, and ethical. The assessment of AI's value
      proposition should thus go beyond technical performance and cost logic by
      performing a holistic analysis of its value in a real-world context of care and
      services. To guide AI development, generate knowledge, and draw lessons that can 
      be translated into action, the right political, regulatory, organizational,
      clinical, and technological conditions for innovation should be created as a
      first step.
CI  - (c)Hassane Alami, Pascale Lehoux, Yannick Auclair, Michele de Guise, Marie-Pierre
      Gagnon, James Shaw, Denis Roy, Richard Fleet, Mohamed Ali Ag Ahmed, Jean-Paul
      Fortin. Originally published in the Journal of Medical Internet Research
      (http://www.jmir.org), 07.07.2020.
FAU - Alami, Hassane
AU  - Alami H
AUID- ORCID: 0000-0002-5461-7693
AD  - Public Health Research Center, Universite de Montreal, Montreal, QC, Canada.
AD  - Department of Health Management, Evaluation and Policy, Ecole de sante publique
      de l'Universite de Montreal, Montreal, QC, Canada.
AD  - Institut national d'excellence en sante et services sociaux, Montreal, QC,
      Canada.
FAU - Lehoux, Pascale
AU  - Lehoux P
AUID- ORCID: 0000-0001-9482-1800
AD  - Public Health Research Center, Universite de Montreal, Montreal, QC, Canada.
AD  - Department of Health Management, Evaluation and Policy, Ecole de sante publique
      de l'Universite de Montreal, Montreal, QC, Canada.
FAU - Auclair, Yannick
AU  - Auclair Y
AUID- ORCID: 0000-0001-8256-0148
AD  - Institut national d'excellence en sante et services sociaux, Montreal, QC,
      Canada.
FAU - de Guise, Michele
AU  - de Guise M
AUID- ORCID: 0000-0002-3597-2542
AD  - Institut national d'excellence en sante et services sociaux, Montreal, QC,
      Canada.
FAU - Gagnon, Marie-Pierre
AU  - Gagnon MP
AUID- ORCID: 0000-0002-0782-5457
AD  - Research Center on Healthcare and Services in Primary Care, Universite Laval,
      Quebec, QC, Canada.
AD  - Faculty of Nursing Science, Universite Laval, Quebec, QC, Canada.
FAU - Shaw, James
AU  - Shaw J
AUID- ORCID: 0000-0002-9522-0756
AD  - Joint Centre for Bioethics, University of Toronto, Toronto, ON, Canada.
AD  - Institute for Health System Solutions and Virtual Care, Women's College Hospital,
      Toronto, ON, Canada.
FAU - Roy, Denis
AU  - Roy D
AUID- ORCID: 0000-0001-5966-2066
AD  - Institut national d'excellence en sante et services sociaux, Montreal, QC,
      Canada.
FAU - Fleet, Richard
AU  - Fleet R
AUID- ORCID: 0000-0003-2732-7655
AD  - Research Center on Healthcare and Services in Primary Care, Universite Laval,
      Quebec, QC, Canada.
AD  - Department of Family Medicine and Emergency Medicine, Faculty of Medicine,
      Universite Laval, Quebec, QC, Canada.
AD  - Research Chair in Emergency Medicine, Universite Laval - CHAU Hotel-Dieu de
      Levis, Levis, QC, Canada.
FAU - Ag Ahmed, Mohamed Ali
AU  - Ag Ahmed MA
AUID- ORCID: 0000-0001-9374-871X
AD  - Research Chair on Chronic Diseases in Primary Care, Universite de Sherbrooke,
      Chicoutimi, QC, Canada.
FAU - Fortin, Jean-Paul
AU  - Fortin JP
AUID- ORCID: 0000-0002-4107-9937
AD  - Research Center on Healthcare and Services in Primary Care, Universite Laval,
      Quebec, QC, Canada.
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Universite
      Laval, Quebec, QC, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200707
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Artificial Intelligence/*standards
MH  - Biomedical Technology/*methods
MH  - Humans
MH  - Technology Assessment, Biomedical/*methods
PMC - PMC7380986
OTO - NOTNLM
OT  - *artificial intelligence
OT  - *eHealth
OT  - *health care
OT  - *health services
OT  - *health technology assessment
OT  - *medical device
OT  - *patient
EDAT- 2020/05/15 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/01/11 00:00 [received]
PHST- 2020/05/13 00:00 [accepted]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - v22i7e17707 [pii]
AID - 10.2196/17707 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jul 7;22(7):e17707. doi: 10.2196/17707.


PMID- 32406632
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20200826
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 3
DP  - 2020 Apr
TI  - Embryonic Regulation and Research: What Is the Status of Human Germline Genome
      Editing in Australia?
PG  - 718-740
AB  - This article considers the status of human germline genome editing in Australia. 
      Through an analysis of the current State, Territory and Commonwealth legal and
      ethical regulatory frameworks, and incorporating the capability approach to
      health justice proposed by Martha Nussbaum and Amartya Sen, the article argues
      that heritable alterations using CRISPR/Cas9 technology in a clinical context are
      inevitable in Australia, so the law needs to respond adequately to these
      scientific advances. The article concludes that human germline genome editing is 
      currently not, and should not, be lawful in Australia, except for research
      purposes.
FAU - Burbery, Rose
AU  - Burbery R
AD  - LLB (Hons) Student, Griffith Law School, Griffith University, BHSc, Griffith
      University.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Australia
MH  - *CRISPR-Cas Systems
MH  - Clustered Regularly Interspaced Short Palindromic Repeats
MH  - *Gene Editing
MH  - Germ Cells
MH  - Humans
OTO - NOTNLM
OT  - CRISPR/Cas9
OT  - capability approach
OT  - ethical regulation
OT  - gene editing
OT  - genome editing
OT  - germline
OT  - human embryo
OT  - statutory interpretation
COIS- None.
EDAT- 2020/05/15 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Apr;27(3):718-740.


PMID- 32406628
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20220531
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 3
DP  - 2020 Apr
TI  - Medical Practitioners Who Deny Young Women Sterilisation Surgery "Because They
      Will Regret It Later": Patient-centred Practice or Discrimination?
PG  - 663-678
AB  - Women in Australia routinely access medical services which, by design or
      consequence, sterilise them. There is evidence which suggests that some medical
      practitioners are not offering procedures to young women where the surgery will
      make them infertile. These decisions are often defended on the basis that women
      who lose their fertility will go on to regret the medical procedure in the
      future. This article will consider the legal and ethical implications of this
      practice. It will first critically analyse the ethics of this decision according 
      to the Beauchamp and Childress principles of justice, applying them through the
      lens of a patient-centred practice framework. It will then examine whether such
      practice may constitute discrimination under the Federal and Victorian
      discrimination frameworks, focusing on whether such decisions constitute age
      discrimination, gender discrimination, or discrimination on the basis of parental
      status. This article will draw the conclusion that such decisions are generally
      unethical and may constitute discrimination under Australian laws.
FAU - Taylor, Joshua
AU  - Taylor J
AD  - Conciliator, Victorian Equal Opportunity and Human Rights Commission Victoria.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Australia
MH  - *Emotions
MH  - Female
MH  - Humans
MH  - Morals
MH  - *Patient-Centered Care
MH  - Sterilization
MH  - *Sterilization, Reproductive
OTO - NOTNLM
OT  - discrimination
OT  - ethics
OT  - gender
OT  - hysterectomy
OT  - medical law
OT  - sterilisation
OT  - tubal ligation
OT  - young women
COIS- None.
EDAT- 2020/05/15 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Apr;27(3):663-678.


PMID- 32406623
OWN - NLM
STAT- MEDLINE
DCOM- 20200515
LR  - 20201218
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 3
DP  - 2020 Apr
TI  - COVID-19, Negligence and Occupational Health and Safety: Ethical and Legal Issues
      for Hospitals and Health Centres.
PG  - 590-600
AB  - The international incidence of health workers being infected with COVID-19 is
      deeply troubling. Until a vaccine is developed, they are the community's bulwark 
      against the pandemic. It is vital that they be protected to the maximum extent
      possible. This entails the need for implementation of effective and compassionate
      protocols to keep their workplace as safe as possible for them, their colleagues 
      and their patients in a context of much as yet not being known about the virus
      and awareness that some persons infected by it are for a time at least
      asymptomatic and that others test negative for it when they are prodromal or even
      already displaying some symptomatology. This has repercussions both for the
      liability of hospitals and multi-practitioner centres for negligence and also
      under occupational health and safety legislation. With the commencement of the
      roll out of biosecurity and disaster/emergency measures by government and
      escalating levels of anxiety in the general population, it is important to
      reflect upon the measures that most effectively can be adopted practically and
      ethically to protect the health and safety of those whose task it is to care for 
      us if we become infected by COVID-19.
FAU - Freckelton, Ian
AU  - Freckelton I
AD  - Barrister, Crockett Chambers, Melbourne; Professorial Fellow of Law and
      Psychiatry, University of Melbourne; Adjunct Professor of Forensic Medicine,
      Monash University; Adjunct Professor, John Hopkins University, United States.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - *Hospitals
MH  - Humans
MH  - *Malpractice
MH  - Occupational Health/*legislation & jurisprudence
MH  - Pandemics/*legislation & jurisprudence
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19
OT  - biosecurity
OT  - employers' responsibilities
OT  - false-negative diagnoses
OT  - infectiousness
OT  - negligence liability
OT  - occupational health and safety obligations
OT  - pandemic
COIS- None.
EDAT- 2020/05/15 06:00
MHDA- 2020/05/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/16 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Apr;27(3):590-600.


PMID- 32406618
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20200826
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 3
DP  - 2020 Apr
TI  - The Voluntary Assisted Dying Law in Victoria - A Good First Step but Many
      Problems Remain.
PG  - 535-550
AB  - In 2019, the Voluntary Assisted Dying Act 2017 (Vic) came into force. Thereupon, 
      Victoria became the first State in Australia to enact such a law since the
      Commonwealth of Australia overturned Northern Territory legislation in 1997.
      Because of the difficulties in the introduction of Victorian law, it is extremely
      conservative, with many safeguards. There are significant limitations to this law
      which will result in significant ethical difficulties for medical practitioners
      and their patients. Four problematic areas of the law are discussed: the
      prohibition on health practitioners introducing the subject, introduction of the 
      subject of voluntary assisted dying to patients; difficulties in obtaining access
      to treatment in certain populations in Victoria; the arbitrary minimum age of 18 
      to be able to access voluntary assisted dying; and the difficulties for patients 
      and practitioners in evaluating the capacity of patients with mental illness and 
      cognitive difficulties. Practical solutions to these difficulties will be
      proffered and discussed.
FAU - Savulescu, Julian
AU  - Savulescu J
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Health Personnel
MH  - Humans
MH  - *Mental Disorders
MH  - *Suicide, Assisted
MH  - Victoria
OTO - NOTNLM
OT  - Victorian Act
OT  - beneficence
OT  - capacity
OT  - children
OT  - conscientious objection
OT  - non-maleficence
OT  - psychiatric illness
OT  - subjectivity
OT  - voluntary assisted dying
COIS- None.
EDAT- 2020/05/15 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Apr;27(3):535-550.


PMID- 32406616
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20200826
IS  - 1320-159X (Print)
IS  - 1320-159X (Linking)
VI  - 27
IP  - 3
DP  - 2020 Apr
TI  - Changing to Deemed Consent for Deceased Organ Donation in the United Kingdom:
      Should Australia and New Zealand Follow?
PG  - 513-526
AB  - During 2020 new legislation in England and Scotland will come into force, which
      adopts a Welsh reform implemented in 2015, changing the law on deceased organ
      donation from an "opt-in" regime, based on the explicit consent of the deceased
      donor during their lifetime or that of their family, to a model of soft,
      "opt-out," whereby the deceased's consent to donate will be "deemed" unless they 
      have registered or made known an objection during their lifetime. This column
      examines the ethical case for both regimes and analyses the law reform and its
      implications. A key issue is whether the controversial practice in soft opt-in
      systems of the family override, even where the deceased had opted in, will
      continue under the new regime. The sole aim of the law reform is to increase the 
      supply of organs from deceased donors for transplantation to meet ever-increasing
      demand. Notwithstanding that taskforces in Australia and New Zealand have
      recently rejected introducing opt-out systems and New Zealand has not yet even
      introduced a dedicated organ donation register, evidence of increased donation
      rates following the UK reform may revive an issue which is currently off the
      reform agenda in this part of the world.
FAU - Manning, Joanna
AU  - Manning J
AD  - Professor, Faculty of Law, University of Auckland, Auckland, New Zealand.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Law Med
JT  - Journal of law and medicine
JID - 9431853
SB  - IM
MH  - Australia
MH  - England
MH  - Humans
MH  - Informed Consent
MH  - New Zealand
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
MH  - United Kingdom
OTO - NOTNLM
OT  - deceased organ donation
OT  - deemed consent
OT  - opt-in, opt-out
OT  - organ donation register
COIS- None.
EDAT- 2020/05/15 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PST - ppublish
SO  - J Law Med. 2020 Apr;27(3):513-526.


PMID- 32406543
OWN - NLM
STAT- MEDLINE
DCOM- 20200605
LR  - 20201218
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 56
IP  - 5
DP  - 2020 May
TI  - Ethical reflections on the COVID-19 pandemic: The epidemiology of panic.
PG  - 690-691
LID - 10.1111/jpc.14882 [doi]
FAU - Isaacs, David
AU  - Isaacs D
AUID- ORCID: 0000-0002-9593-7378
AD  - Department of Infectious Diseases and Microbiology and Children's Hospital at
      Westmead, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
AD  - Department of Clinical Ethics, Children's Hospital at Westmead, Sydney Children's
      Hospital Network, Sydney, New South Wales, Australia.
AD  - Discipline of Child and Adolescent Health, University of Sydney, Sydney, New
      South Wales, Australia.
FAU - Britton, Philip N
AU  - Britton PN
AD  - Department of Infectious Diseases and Microbiology and Children's Hospital at
      Westmead, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
AD  - Department of Clinical Ethics, Children's Hospital at Westmead, Sydney Children's
      Hospital Network, Sydney, New South Wales, Australia.
AD  - Discipline of Child and Adolescent Health, University of Sydney, Sydney, New
      South Wales, Australia.
FAU - Preisz, Anne
AU  - Preisz A
AUID- ORCID: 0000-0003-4331-1434
AD  - Department of Clinical Ethics, Children's Hospital at Westmead, Sydney Children's
      Hospital Network, Sydney, New South Wales, Australia.
AD  - School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
SB  - IM
CIN - J Paediatr Child Health. 2020 May;56(5):826. PMID: 32416052
MH  - Australia
MH  - COVID-19
MH  - Civil Rights/*ethics/psychology
MH  - Communicable Disease Control/*methods
MH  - Coronavirus Infections/epidemiology/prevention & control/*psychology
MH  - Decision Making/ethics
MH  - Global Health/*ethics
MH  - Humans
MH  - Pandemics/*ethics/prevention & control
MH  - *Panic
MH  - Pneumonia, Viral/epidemiology/prevention & control/*psychology
MH  - Public Health/*ethics/methods
PMC - PMC7272814
EDAT- 2020/05/15 06:00
MHDA- 2020/06/06 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/06/06 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1111/jpc.14882 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2020 May;56(5):690-691. doi: 10.1111/jpc.14882. Epub
      2020 May 14.


PMID- 32406483
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20210920
IS  - 2013-6463 (Electronic)
IS  - 1575-0620 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Jan-Apr
TI  - Involuntary outpatient treatment: the ethical implications.
PG  - 6-8
LID - S1575-06202020000100006 [pii]
LID - 10.18176/resp.0001 [doi]
FAU - Castellano Arroyo, M
AU  - Castellano Arroyo M
AD  - Professor of Legal and Forensic Medicine. Academica de numero de la Real Academia
      Nacional de Medicina. Madrid.
LA  - eng
PT  - Editorial
PL  - Spain
TA  - Rev Esp Sanid Penit
JT  - Revista espanola de sanidad penitenciaria
JID - 101284897
SB  - IM
MH  - Ambulatory Care/*ethics
MH  - Commitment of Mentally Ill/*ethics
MH  - Humans
MH  - Involuntary Commitment/*ethics
MH  - Mental Disorders/*therapy
MH  - Mental Health Services/*ethics
MH  - Physician-Patient Relations/*ethics
MH  - Treatment Refusal/*ethics
PMC - PMC7307657
EDAT- 2020/05/15 06:00
MHDA- 2021/09/21 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
AID - S1575-06202020000100006 [pii]
AID - 10.18176/resp.0001 [doi]
PST - ppublish
SO  - Rev Esp Sanid Penit. 2020 Jan-Apr;22(1):6-8. doi: 10.18176/resp.0001.


PMID- 32406393
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1745-3755 (Electronic)
IS  - 1571-0882 (Linking)
VI  - 16
IP  - 1
DP  - 2020
TI  - In the details: the micro-ethics of negotiations and in-situ judgements in
      participatory design with marginalised children.
PG  - 45-65
LID - 10.1080/15710882.2020.1722174 [doi]
AB  - Engaging marginalised children, such as disabled children, in Participatory
      Design (PD) entails particular challenges. The processes can effect social
      changes by decidedly attending to their lived experience as expertise. However,
      involving marginalised children in research also requires maintaining a delicate 
      balance between ensuring their right to participation as well as their protection
      from harm. The resulting tensions are politically charged, affected by myriads of
      power differences and create moral dilemmas. We present seven case studies,
      drawing from two participatory design research projects. They illustrate the
      in-situ judgements taken to address specific dilemmas and provide nuanced
      insights into the trade-offs required by child-led participatory design
      processes. Subsequently, we identify three challenges: positioning our work to
      the children's carers' values, protecting ourselves, and enabling the (relative) 
      risk-taking associated with participation for children. We call for this
      micro-ethical approach to be used when reporting research ethics in practice, and
      as a guidance for the training of researchers and practitioners.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Spiel, Katta
AU  - Spiel K
AUID- ORCID: 0000-0001-6094-9531
AD  - HCI Group, TU Wien, Vienna University of Technology, Vienna, Austria.
AD  - eMedia Research Lab, KU Leuven, Leuven, Belgium.
FAU - Brule, Emeline
AU  - Brule E
AUID- ORCID: 0000-0002-0110-3365
AD  - Department of Engineering and Design, University of Sussex, Brighton, UK.
FAU - Frauenberger, Christopher
AU  - Frauenberger C
AUID- ORCID: 0000-0003-0204-881X
AD  - HCI Group, TU Wien, Vienna University of Technology, Vienna, Austria.
FAU - Bailley, Gilles
AU  - Bailley G
AUID- ORCID: 0000-0001-8027-5765
AD  - ISIR Laboratory, Sorbonne Universite, CNRS, Paris, France.
FAU - Fitzpatrick, Geraldine
AU  - Fitzpatrick G
AUID- ORCID: 0000-0002-2013-2188
AD  - HCI Group, TU Wien, Vienna University of Technology, Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20200213
PL  - England
TA  - CoDesign
JT  - CoDesign : international journal of cocreation in design and the arts
JID - 101766502
PMC - PMC7194238
OTO - NOTNLM
OT  - Children
OT  - ethics
OT  - marginalisation
OT  - participatory design
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
CRDT- 2020/05/15 06:00
PHST- 2019/05/30 00:00 [received]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
AID - 10.1080/15710882.2020.1722174 [doi]
AID - 1722174 [pii]
PST - epublish
SO  - CoDesign. 2020 Feb 13;16(1):45-65. doi: 10.1080/15710882.2020.1722174.
      eCollection 2020.


PMID- 32406313
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Moral distress perspectives among interprofessional intensive care unit team
      members.
PG  - 1450-1460
LID - 10.1177/0969733020916747 [doi]
AB  - AIM: To examine interprofessional healthcare professionals' perceptions of
      triggers and root causes of moral distress. DESIGN: Qualitative description of
      open-text comments written on the Moral Distress Scale-Revised survey. METHODS: A
      subset of interprofessional providers from a parent study provided open-text
      comments that originated from four areas of the Moral Distress Scale-Revised,
      including the margins of the 21-item questionnaire, the designated open-text
      section, shared perceptions of team communication and dynamics affecting moral
      distress, and the section addressing an intent to leave a clinical position
      because of moral distress. Open-text comments were captured, coded, and divided
      into meaning units and themes using systematic text condensation. PARTICIPANTS:
      Twenty-eight of the 223 parent study participants completing the Moral Distress
      Scale-Revised shared comments on situations contributing to moral distress.
      RESULTS: All 28 participants working in the four medical center intensive care
      units reported feelings of moral distress. Feelings of moral distress were
      associated with professional anguish over patient care decisions, team, and
      system-level factors. Professional-level contributors reflected clinician
      concerns of continuing life support measures perceived not in the patient's best 
      interest. Team and unit-level factors were related to poor communication,
      bullying, and a lack of collegial collaboration. System-level factors included
      clinicians feeling unsupported by senior administration and institutional
      culpability as a result of healthcare processes and system constraints impeding
      reliable patient care delivery. ETHICAL CONSIDERATIONS: Approval was obtained
      from the Institutional Review Board (IRB) of the University of Texas Health IRB
      and the organization in which the study was conducted. CONCLUSION: Moral distress
      was associated with feelings of anguish, professional intimidation, and
      organizational factors that impacted the delivery of ethically based patient
      care. Participants expressed a sense of awareness that they may experience
      ethical dilemmas as a consequence of the changing reality of providing healthcare
      within complex healthcare systems. Strategies to combat moral distress should
      target team and system interventions designed to improve interprofessional
      collaboration and support professional ethical values and moral commitments of
      all healthcare providers.
FAU - Vincent, Heather
AU  - Vincent H
AUID- ORCID: https://orcid.org/0000-0002-6013-4372
AD  - 6614University of Pittsburgh, USA; The University of Texas Health Science Center 
      at Houston, USA.
FAU - Jones, Deborah J
AU  - Jones DJ
AD  - 12338The University of Texas Medical Branch at Galveston, USA.
FAU - Engebretson, Joan
AU  - Engebretson J
AD  - 12340The University of Texas Health Science Center at Houston, USA.
LA  - eng
GR  - T32 NR008857/NR/NINR NIH HHS/United States
PT  - Journal Article
DEP - 20200514
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Female
MH  - Humans
MH  - Intensive Care Units/organization & administration/trends
MH  - *Interprofessional Relations
MH  - Male
MH  - Psychometrics/instrumentation/methods
MH  - Qualitative Research
MH  - Stress Disorders, Post-Traumatic/etiology/*psychology
MH  - Surveys and Questionnaires
PMC - PMC8077224
MID - NIHMS1692108
OTO - NOTNLM
OT  - Futile care
OT  - intensive care
OT  - moral distress
OT  - professional ethics
OT  - professional perspectives
EDAT- 2020/05/15 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1177/0969733020916747 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1450-1460. doi: 10.1177/0969733020916747. Epub 2020
      May 14.


PMID- 32406310
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Ethical perspectives in communication in cancer care: An interpretative
      phenomenological study.
PG  - 1418-1435
LID - 10.1177/0969733020916771 [doi]
AB  - BACKGROUND: In cancer care, many clinical contexts still lack a good-quality
      patient-health professional communication about diagnosis and prognosis.
      Information transmission enables patients to make informed choices about their
      own healthcare. Nevertheless, disclosure is still an ethically challenging
      clinical problem in cancer care. High-quality care can be achieved by
      understanding the perspectives of others. The perspective of patients, their
      caregivers, physicians and nurses have seldom been simultaneously studied.
      OBJECTIVE: To investigate the phenomenon of diagnosis and prognosis-related
      communication as experienced by patients, their caregivers, and both their
      attending nurses and physicians, to enlighten meanings attached to communication 
      by the four parties. METHODS: A qualitative study using interpretative
      phenomenological analysis was performed. PARTICIPANTS AND RESEARCH CONTEXT:
      Purposive sampling of six patients, six caregivers, seven nurses and five
      physicians was performed in two oncological hospitals in Italy. ETHICAL
      CONSIDERATIONS: Local Ethics Committee approved the study. It was guided by the
      ethical principles of voluntary enrolment, anonymity, privacy and
      confidentiality. RESULTS: Three main themes were identified: (a) the infinite
      range of possibilities in knowing and willing to know, (b) communication with the
      patient as a conflicting situation and (c) the bind of implicit and explicit
      meaning of communication. CONCLUSION: The interplay of meanings attached by
      patients, their caregivers, and their attending oncologist and nurse to
      communication about diagnosis and prognosis revealed complexities and ambiguities
      not yet settled. Physicians still need to solve the ethical tensions in their
      caring relationship with patients to really allow them 'to choose with dignity
      and being aware of it'. Nurses need to develop awareness about their role in
      diagnosis and prognosis-related communication. This cognizance is essential not
      just to assure consistency of communication within the multi-disciplinary team
      but mostly because it allows and enables the moral agent to take its own
      responsibilities and be accountable for them.
FAU - Melis, Paola
AU  - Melis P
AD  - 3111University of Cagliari, Italy.
AD  - 16777Universitat Rovira i Virgili, Spain.
FAU - Galletta, Maura
AU  - Galletta M
AUID- ORCID: https://orcid.org/0000-0002-0124-4248
AD  - 3111University of Cagliari, Italy.
FAU - Gonzalez, Cesar Ivan Aviles
AU  - Gonzalez CIA
AD  - 3111University of Cagliari, Italy.
AD  - 16777Universitat Rovira i Virgili, Spain.
FAU - Contu, Paolo
AU  - Contu P
AD  - 3111University of Cagliari, Italy.
FAU - Herrera, Maria Francisca Jimenez
AU  - Herrera MFJ
AD  - 16777Universitat Rovira i Virgili, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200514
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Aged
MH  - Attitude of Health Personnel
MH  - Communication Barriers
MH  - Female
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*therapy
MH  - Professional-Patient Relations/*ethics
MH  - Qualitative Research
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Cancer
OT  - communication
OT  - diagnosis and prognosis
OT  - ethics
OT  - interpretative phenomenological analysis
OT  - meanings
OT  - multi-perspective
EDAT- 2020/05/15 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1177/0969733020916771 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1418-1435. doi: 10.1177/0969733020916771. Epub 2020
      May 14.


PMID- 32405980
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - "You took an Oath!": Engaging Medical Students About the Importance of Oaths and 
      Codes Through Film and Television.
PG  - 175-189
LID - 10.1007/s10730-020-09411-x [doi]
AB  - In this paper, we will consider the role of oaths and codes of ethics in
      undergraduate medical education. Studies of ethics syllabi suggest that ethics
      educators typically use well-known bioethics texts such as Beauchamp and
      Childress (Principles of biomedical ethics, 8th ed. Oxford University Press,
      Oxford, 2019). Yet, many issues that medical students will face (as students and 
      as physicians) are addressed by codes of ethics and oaths. We will first provide 
      a historical survey of oaths and codes and then address how these sources of
      ethical guidance can be effectively used in ethics education of medical students.
      Oaths and codes can be engagingly taught using a range of techniques including
      visual narrative. Excerpts from television and film can be used to highlight
      challenging ethical dilemmas in a variety of settings, taking the learning from
      the theoretical to the more applied while offering context.
FAU - Parsi, Kayhan
AU  - Parsi K
AD  - Neiswanger Institute for Bioethics, Loyola University Chicago Stritch School of
      Medicine, 2160 S. First Avenue, Maywood, IL, 60153, USA. kparsi@luc.edu.
FAU - Elster, Nanette
AU  - Elster N
AD  - Neiswanger Institute for Bioethics, Loyola University Chicago Stritch School of
      Medicine, 2160 S. First Avenue, Maywood, IL, 60153, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Codes of Ethics/*trends
MH  - Ethics, Medical/education
MH  - Humans
MH  - Motion Pictures/*trends
MH  - Students, Medical/*psychology/statistics & numerical data
MH  - Television/trends
OTO - NOTNLM
OT  - Codes
OT  - Ethics education
OT  - Film
OT  - Medical school
OT  - Mixed media
OT  - Movies
OT  - Oaths
OT  - Television
EDAT- 2020/05/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1007/s10730-020-09411-x [doi]
AID - 10.1007/s10730-020-09411-x [pii]
PST - ppublish
SO  - HEC Forum. 2020 Jun;32(2):175-189. doi: 10.1007/s10730-020-09411-x.


PMID- 32405966
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20220824
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 28
IP  - 9
DP  - 2020 Sep
TI  - Advances and future directions in the use of mobile health in supportive cancer
      care: proceedings of the 2019 MASCC Annual Meeting symposium.
PG  - 4059-4067
LID - 10.1007/s00520-020-05513-x [doi]
AB  - PURPOSE: The role of mobile health (mHealth) technology in cancer care has
      evolved alongside the rapid development in digital technology. Its use can come
      with significant potential benefits; however, such use may also be associated
      with risks. This paper summarizes the latest developments around mHealth use in
      cancer care presented by a panel of experts at the 2019 Annual Meeting of the
      Multinational Association of Supportive Care in Cancer. METHODS: Through
      lectures, case studies, and panel discussions, speakers and participants
      (including cancer specialist doctors, nurses, and allied health professionals)
      evaluated current and emerging mHealth methods for supportive care in cancer
      survivorship. Focus areas and special considerations were agreed upon by
      consensus. RESULTS: Three focus areas for the use of mHealth in cancer care were 
      identified: activation and support of self-management, exercise oncology, and
      enablement of survivorship care delivery. In addition to these focus areas, two
      special considerations were highlighted: technology-enhanced supportive cancer
      care for disparate populations, and ethical considerations relevant to the use of
      technology in supportive care. CONCLUSION: mHealth has the potential to
      revolutionize and transform cancer care delivery. Future research should guide
      further advances in the use of technology in supportive cancer care and carefully
      explore the safety, efficacy, cost-effectiveness, and implementation of
      interventions delivered through mHealth platforms.
FAU - Chan, Raymond J
AU  - Chan RJ
AUID- ORCID: http://orcid.org/0000-0003-0248-7046
AD  - School of Nursing and Cancer and Palliative Care Outcomes Centre, Queensland
      University of Technology, Level 3, N Block, Brisbane, 4059, Australia.
      Raymond.Chan@qut.edu.au.
AD  - Division of Cancer Services, Princess Alexandra Hospital, Metro South Hospital
      and Health Services, Brisbane, Australia. Raymond.Chan@qut.edu.au.
FAU - Howell, Doris
AU  - Howell D
AD  - Department of Supportive Care, Princess Margaret Cancer Research Center and
      Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada.
FAU - Lustberg, Maryam B
AU  - Lustberg MB
AD  - College of Medicine, The Ohio State Comprehensive Cancer Center, Columbus, OH,
      USA.
FAU - Mustian, Karen
AU  - Mustian K
AD  - Department of Surgery, Wilmot Cancer Institute, School of Medicine and Dentistry,
      University of Rochester Medical Center, Rochester, NY, USA.
FAU - Koczwara, Bogda
AU  - Koczwara B
AD  - Department of Medical Oncology, Flinders Medical Centre, Flinders University,
      Adelaide, Australia.
FAU - Ng, Chiu Chin
AU  - Ng CC
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
FAU - Kim, Yoon
AU  - Kim Y
AD  - Department of Physical Medicine and Rehabilitation, Samsung Medical Center,
      Sungkyunkwan University School of Medicine, Seoul, South Korea.
FAU - Napoles, Anna Maria
AU  - Napoles AM
AD  - Division of Intramural Research, National Institute on Minority Health and Health
      Disparities, National Institutes of Health, Bethesda, MD, USA.
FAU - Dixit, Niharika
AU  - Dixit N
AD  - Department of Medicine, Division of Hematology and Oncology, University of
      California San Francisco/Zuckerberg San Francisco General Hospital, San
      Francisco, CA, USA.
FAU - Klemanski, Dori
AU  - Klemanski D
AD  - Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
FAU - Ke, Yu
AU  - Ke Y
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
FAU - Toh, Yi Long
AU  - Toh YL
AD  - Department of Pharmacy, National University of Singapore, Singapore, Singapore.
FAU - Fitch, Margaret I
AU  - Fitch MI
AD  - Lawrence S. Bloomberg, Faculty of Nursing, University of Toronto, Toronto,
      Canada.
FAU - Crichton, Megan
AU  - Crichton M
AD  - School of Nursing and Cancer and Palliative Care Outcomes Centre, Queensland
      University of Technology, Level 3, N Block, Brisbane, 4059, Australia.
FAU - Agarawal, Sangeeta
AU  - Agarawal S
AD  - Helpsyhealth.com and University of California San Francisco, San Francisco, CA,
      USA.
FAU - Chan, Alexandre
AU  - Chan A
AD  - Department of Clinical Pharmacy Practice, Susan and Henry Samueli College of
      Health Sciences, University of California, Irvine, 101 Theory, Suite 100, Irvine,
      CA, 92697-3958, USA. a.chan@uci.edu.
LA  - eng
GR  - UG1 CA189961/CA/NCI NIH HHS/United States
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20200514
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Delivery of Health Care/*methods
MH  - History, 21st Century
MH  - Humans
MH  - Neoplasms/*therapy
MH  - Telemedicine/*methods
OTO - NOTNLM
OT  - Cancer
OT  - Mobile health
OT  - Oncology
OT  - Survivorship
OT  - Technology
OT  - mHealth
EDAT- 2020/05/15 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/02/09 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1007/s00520-020-05513-x [doi]
AID - 10.1007/s00520-020-05513-x [pii]
PST - ppublish
SO  - Support Care Cancer. 2020 Sep;28(9):4059-4067. doi: 10.1007/s00520-020-05513-x.
      Epub 2020 May 14.


PMID- 32405877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210408
IS  - 2364-1746 (Electronic)
IS  - 2364-1754 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Dec
TI  - A Review: Does Complement or the Contact System Have a Role in Protection or
      Pathogenesis of COVID-19?
PG  - 169-176
LID - 10.1007/s41030-020-00118-5 [doi]
AB  - INTRODUCTION: COVID-19 presentation may include a profound increase in cytokines 
      and associated pneumonia, rapidly progressing to acute respiratory distress
      syndrome (ARDS). This so-called cytokine storm often leads to refractory edema,
      respiratory arrest, and death. At present, anti-IL-6, antiviral therapy,
      convalescent plasma, hydroxychloroquine, and azithromycin among others are being 
      investigated as potential treatments for COVID-19. As the disease etiology and
      precise therapeutic interventions are still not definitively defined, we wanted
      to review the roles that complement and the contact system may have in either the
      treatment or pathogenesis of the disease. METHODS: We searched the recent
      literature (PubMed) on complement and coronavirus; contact system and
      coronavirus; bradykinin and coronavirus; and angiotensin receptor and
      coronavirus. The manuscript complies with ethics guidelines and was deemed exempt
      from institutional review board approval according to Human Subjects Protection
      Office guidelines. RESULTS: Mouse models are available for the study of
      coronavirus and complement. Although complement is effective in protecting
      against many viruses, it does not seem to be protective against coronavirus. C3
      knockout mice infected with SARS-CoV had less lung disease than wild-type mice,
      suggesting that complement may play a role in coronavirus pathogenesis. Some
      evidence suggests that the observed pulmonary edema may be bradykinin-induced and
      could be the reason that corticosteroids, antihistamines, and other traditional
      interventions for edema are not effective. Angiotensin-converting enzyme 2 (ACE2)
      is a co-receptor for SARS-CoV-2, and studies thus far have not concluded a
      benefit or risk associated with the use of either ACE-inhibitors or angiotensin
      receptor antagonists. Activation of complement and the contact system, through
      generation of bradykinin, may play a role in the SARS-CoV-2-induced pulmonary
      edema, and our search suggests that further work is necessary to confirm our
      suspicions.
FAU - Maglakelidze, Natella
AU  - Maglakelidze N
AD  - Penn State University College of Medicine, 500 University Drive, Hershey, PA,
      17033, USA.
FAU - Manto, Kristen M
AU  - Manto KM
AD  - Penn State University College of Medicine, 500 University Drive, Hershey, PA,
      17033, USA.
FAU - Craig, Timothy J
AU  - Craig TJ
AD  - Department of Medicine and Pediatrics, Penn State University, 500 University
      Drive, Hershey, PA, 17033, USA. tcraig@psu.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200513
PL  - United States
TA  - Pulm Ther
JT  - Pulmonary therapy
JID - 101687144
PMC - PMC7218701
OTO - NOTNLM
OT  - Angiotensin receptors
OT  - Bradykinin
OT  - COVID-19
OT  - Complement
OT  - Contact system
OT  - Coronavirus
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
CRDT- 2020/05/15 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1007/s41030-020-00118-5 [doi]
AID - 10.1007/s41030-020-00118-5 [pii]
PST - ppublish
SO  - Pulm Ther. 2020 Dec;6(2):169-176. doi: 10.1007/s41030-020-00118-5. Epub 2020 May 
      13.


PMID- 32405841
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20201218
IS  - 1613-3560 (Electronic)
IS  - 1438-3276 (Linking)
VI  - 162
IP  - 9
DP  - 2020 May
TI  - [Covid-19 pandemic. Mechanical ventilation in geriatric patients - an ethical
      dilemma?]
PG  - 40-45
LID - 10.1007/s15006-020-0475-y [doi]
FAU - Zeeh, Joachim
AU  - Zeeh J
AD  - Abteilung Hospiz- und Palliativversorgung, Sozialwerk Meiningen gGmbH,
      Ernststrasse 7, D-98617, Meiningen, Deutschland. joachim@doktor-zeeh.de.
FAU - Memm, Kristin
AU  - Memm K
AD  - Kanzlei fur Medizinrecht/Medizinethik/Digitale Medizin, Wiesenbach 11, D-99097,
      Erfurt, Deutschland.
FAU - Heppner, Hans-Jurgen
AU  - Heppner HJ
AD  - HELIOS Klinikum Schwelm, Dr.-Moeller-Strasse 15, D-58332, Schwelm, Deutschland.
FAU - Kwetkat, Anja
AU  - Kwetkat A
AD  - Universitatsklinikum Jena, Bachstrasse 18, D-07743, Jena, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Beatmung geriatrischer Patienten - ein ethisches Dilemma? : Corona-Pandemie 2020.
PL  - Germany
TA  - MMW Fortschr Med
JT  - MMW Fortschritte der Medizin
JID - 100893959
SB  - IM
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/complications/therapy
MH  - Decision Making/ethics
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral/complications/therapy
MH  - *Respiration, Artificial/ethics
MH  - SARS-CoV-2
PMC - PMC7220539
OTO - NOTNLM
OT  - *Covid-19
OT  - *Geriatric
OT  - *frailty
OT  - *mechanical ventilation
EDAT- 2020/05/15 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - 10.1007/s15006-020-0475-y [doi]
AID - 10.1007/s15006-020-0475-y [pii]
PST - ppublish
SO  - MMW Fortschr Med. 2020 May;162(9):40-45. doi: 10.1007/s15006-020-0475-y.


PMID- 32405671
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200909
IS  - 0942-0940 (Electronic)
IS  - 0001-6268 (Linking)
VI  - 162
IP  - 7
DP  - 2020 Jul
TI  - Ethical triage during the COVID-19 pandemic: a toolkit for neurosurgical resource
      allocation.
PG  - 1485-1490
LID - 10.1007/s00701-020-04375-w [doi]
AB  - BACKGROUND: The COVID-19 pandemic confronts healthcare workers, including
      neurosurgeons, with difficult choices regarding which patients to treat. METHODS:
      In order to assist ethical triage, this article gives an overview of the main
      considerations and ethical principles relevant when allocating resources in times
      of scarcity. RESULTS: We discuss a framework employing four principles:
      prioritizing the worst off, maximizing benefits, treating patients equally, and
      promoting instrumental value. We furthermore discuss the role of age and
      comorbidity in triage and highlight some principles that may seem intuitive but
      should not form a basis for triage. CONCLUSIONS: This overview is presented on
      behalf of the European Association of Neurosurgical Societies and can be used as 
      a toolkit for neurosurgeons faced with ethical dilemmas when triaging patients in
      times of scarcity.
FAU - Hulsbergen, Alexander F C
AU  - Hulsbergen AFC
AUID- ORCID: http://orcid.org/0000-0002-1869-5352
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium. a.f.c.hulsbergen@students.uu.nl.
AD  - Departments of Neurosurgery, Haaglanden Medical Center and Leiden University
      Medical Center, Lijnbaan 32, 2512, VA, The Hague, The Netherlands.
      a.f.c.hulsbergen@students.uu.nl.
FAU - Eijkholt, Marleen M
AU  - Eijkholt MM
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
AD  - Unit Ethics and Health Care, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Balak, Naci
AU  - Balak N
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Brennum, Jannick
AU  - Brennum J
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Bolger, Ciaran
AU  - Bolger C
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
AD  - Department of Clinical Neuroscience, Beaumont Hospital, Dublin, Ireland.
FAU - Bohrer, Anna-Margarete
AU  - Bohrer AM
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Feldman, Zeev
AU  - Feldman Z
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Holsgrove, Daniel
AU  - Holsgrove D
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Kitchen, Neil
AU  - Kitchen N
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Mathiesen, Tiit I
AU  - Mathiesen TI
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
AD  - Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet,
      Blegdamsvej 9, 2100, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Clinical Neuroscience, Section for Neurosurgery, Karolinska
      Intitutet, Stockholm, Sweden.
FAU - Moojen, Wouter A
AU  - Moojen WA
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
AD  - Departments of Neurosurgery, Haaglanden Medical Center and Leiden University
      Medical Center, Lijnbaan 32, 2512, VA, The Hague, The Netherlands.
FAU - Sampron, Nicolas
AU  - Sampron N
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
AD  - Department of Neurosurgery, Hospital Universitario Donostia, San Sebastian,
      Spain.
FAU - Sames, Martin
AU  - Sames M
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Sandvik, Ulrika
AU  - Sandvik U
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
AD  - Department of Clinical Neuroscience, Section for Neurosurgery, Karolinska
      Intitutet, Stockholm, Sweden.
FAU - Tisell, Magnus
AU  - Tisell M
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium.
FAU - Broekman, Marike L D
AU  - Broekman MLD
AD  - Ethics Committee of the European Association of Neurosurgical Societies,
      Brussels, Belgium. m.broekman@haaglandenmc.nl.
AD  - Departments of Neurosurgery, Haaglanden Medical Center and Leiden University
      Medical Center, Lijnbaan 32, 2512, VA, The Hague, The Netherlands.
      m.broekman@haaglandenmc.nl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200514
PL  - Austria
TA  - Acta Neurochir (Wien)
JT  - Acta neurochirurgica
JID - 0151000
SB  - IM
PMC - PMC7220806
OTO - NOTNLM
OT  - Covid-19
OT  - Ethics
OT  - Neurosurgery
OT  - SARS-CoV-2
OT  - Triage
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
CRDT- 2020/05/15 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1007/s00701-020-04375-w [doi]
AID - 10.1007/s00701-020-04375-w [pii]
PST - ppublish
SO  - Acta Neurochir (Wien). 2020 Jul;162(7):1485-1490. doi:
      10.1007/s00701-020-04375-w. Epub 2020 May 14.


PMID- 32405604
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 22
DP  - 2020
TI  - Is routine preoperative esophagogastroduodenscopy prior to bariatric surgery
      mandatory? protocol for a systematic review and meta-analysis.
PG  - 1-5
LID - 10.1016/j.isjp.2020.04.001 [doi]
AB  - INTRODUCTION: Routine preoperative esophagogastroduodenscopy (p-EGD) prior to
      bariatric surgery (BS) is currently widely undertaken, and hence an important
      issue with many clinical and financial repercussions. Yet, the true extent of why
      p-EGD is routinely undertaken for all bariatric patients remains not well
      understood. METHODS AND ANALYSIS: To address this, we will undertake a systematic
      review and meta-analysis of routine p-EGD prior to BS from around the world. This
      protocol describes the methodological approach to be adopted and outlines the
      search strategies and eligibility criteria that will be employed to identify and 
      select studies, and the way by which data from the selected studies will be
      extracted for analysis. PubMed, Cochrane Central Register of Controlled Trials
      (CENTRAL), WHO International Clinical Trials Registry Platform, Cochrane Library,
      MEDLINE, Scopus, clinicaltrials.gov and Google scholar will be searched from 01
      January 2000 to 30 April 2019 for original studies written in English that
      provided prevalence estimates of the outcomes of routine p-EGD prior to BS.
      STROBE criteria will assess the methodological quality of the selected studies.
      The use of fixed or random effects model will depend on the results of
      statistical tests for heterogeneity. Publication bias will be visually estimated 
      by assessing funnel plots. Pooled estimates will be calculated. This protocol
      conforms to the Preferred Reporting Items for Systematic reviews and
      Meta-Analysis (PRISMA) guidelines and has been submitted for registration at the 
      PROSPERO International Prospective Register of systematic reviews. No ethical
      clearance is required for this study. This review will be published in a peer-
      reviewed journal and will be presented at various national and international
      conferences.
CI  - (c) 2020 The Author(s).
FAU - El Ansari, Walid
AU  - El Ansari W
AD  - Department of Surgery, Hamad General Hospital, Hamad Medical Corporation, Doha
      3050, Qatar.
AD  - College of Medicine, Qatar University, Doha 2713, Qatar.
AD  - Schools of Health and Education, University of Skovde, 541 28 Skovde, Sweden.
FAU - El-Menyar, Ayman
AU  - El-Menyar A
AD  - Department of Surgery, Trauma and Vascular Surgery, Clinical Research, Hamad
      General Hospital, Doha 3050, Qatar.
AD  - Clinical Medicine, Weill Cornell Medical School, Doha 24144, Qatar.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7210597
OTO - NOTNLM
OT  - Bariatric
OT  - Esophagogastroduodenoscopy
OT  - Metanalysis
OT  - Preoperative
OT  - Systematic review
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
CRDT- 2020/05/15 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
AID - 10.1016/j.isjp.2020.04.001 [doi]
AID - S2468-3574(20)30014-0 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Apr 22;22:1-5. doi: 10.1016/j.isjp.2020.04.001.
      eCollection 2020.


PMID- 32405426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2055-6640 (Print)
IS  - 2055-6640 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Apr 30
TI  - Willingness to risk death endpoint in HIV cure-related research with otherwise
      healthy volunteers is misleading.
PG  - 81-84
AB  - This viewpoint article critiques two recent articles examining 'willingness to
      risk death' to advance HIV cure-related research. The 'willingness to risk death'
      endpoint sends the wrong signal to the HIV cure-related research community about 
      ongoing research in otherwise healthy volunteers living with HIV.
      Socio-behavioural scientists have examined the acceptability of a 99% risk of
      death scenario, which is unrealistic and would not be acceptable by current
      regulatory and ethical standards. We believe that the field needs robust and
      relevant socio-behavioural research reflecting ongoing biomedical HIV
      cure-related trials. These studies will need to withstand regulatory and ethical 
      scrutiny if cure or remission regimens are to proceed to the licensing stage. The
      HIV cure-related research community must continue to protect the public trust in 
      the HIV cure-related research field and sustain societal value generated by such 
      research. We call for the utmost prudence in designing biomedical HIV cure trials
      as well as in setting up socio-behavioural research experiments related to these 
      complex trials.
CI  - (c) 2020 The Authors. Journal of Virus Eradication published by Mediscript Ltd.
FAU - Dube, Karine
AU  - Dube K
AD  - Public Health Leadership Program, UNC Gillings School of Global Public Health,
      Chapel Hill, NC, USA.
FAU - Dee, Lynda
AU  - Dee L
AD  - Delaney AIDS Research Enterprise Community Advisory Board (CAB), Baltimore, MD,
      USA.
AD  - amfAR Institute for HIV Cure Research CAB, Baltimore, MD, USA.
AD  - AIDS Action Baltimore, MD, USA.
LA  - eng
PT  - Editorial
DEP - 20200430
PL  - England
TA  - J Virus Erad
JT  - Journal of virus eradication
JID - 101654142
PMC - PMC7213068
OTO - NOTNLM
OT  - HIV cure-related research
OT  - otherwise healthy volunteers
OT  - risk of death
OT  - socio-behavioural research
OT  - willingness to participate (WTP)
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
PST - epublish
SO  - J Virus Erad. 2020 Apr 30;6(2):81-84.


PMID- 32405301
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 1687-9813 (Electronic)
IS  - 1687-9805 (Linking)
VI  - 2020
DP  - 2020
TI  - Parent's Perception regarding the Delivery of Sexual and Reproductive Health
      (SRH) Education in Secondary Schools in Fiji: A Qualitative Study.
PG  - 3675684
LID - 10.1155/2020/3675684 [doi]
AB  - Background: Adolescent Sexual and Reproductive Health (SRH) remains a challenge
      globally. This study aims to gauge the perceptions of parents towards the
      delivery of SRH education in mainstream public secondary schools in Fiji.
      Methods: The qualitative study design was used to collect the data from parents
      in Suva, Fiji, from July to August 2018. A semistructured questionnaire was
      developed to run Focus Group Discussion (FGD) among parents residing in Suva who 
      had school-attending children from years 11 to 13. Parents were recruited from
      five schools with the help of students. Twenty-six parents of which 10 were
      males, aged between 38 and 65, participated in this study. Consent was obtained
      from each participant prior to the data collection stage. Data collected were
      transcribed verbatim and were analyzed thematically. Ethical approvals were
      obtained before collecting the data. Results: Seven themes emerged which included
      the provision of school-based sex education, parental involvement with
      school-based sex education, sex education at home, age-appropriate incremental
      sex education, ethnic variations regarding sex education, barriers and
      facilitators for the delivery of school-based sex education, and perceived ideal 
      version of sex education. Conclusions: Findings from this study suggest for
      policy and programs to match parents, schools, and students' expectations.
      Effective interventions need to involve and help parents to take a more active
      part to change policy, program, and advocacy for relevant SRH education.
CI  - Copyright (c) 2020 Sharan Ram et al.
FAU - Ram, Sharan
AU  - Ram S
AUID- ORCID: 0000-0003-1903-8677
AD  - School of Public Health and Primary Care, Department of Public Health, Fiji
      National University, Suva, Fiji.
FAU - Andajani, Sari
AU  - Andajani S
AD  - School of Public Health and Psychosocial Studies, Department of Public Health,
      Auckland University of Technology, Auckland, New Zealand.
FAU - Mohammadnezhad, Masoud
AU  - Mohammadnezhad M
AUID- ORCID: 0000-0002-5048-9719
AD  - School of Public Health and Primary Care, Department of Public Health, Fiji
      National University, Suva, Fiji.
LA  - eng
PT  - Journal Article
DEP - 20200109
PL  - United States
TA  - J Environ Public Health
JT  - Journal of environmental and public health
JID - 101516361
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Female
MH  - Fiji/epidemiology
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Parents/*psychology
MH  - Qualitative Research
MH  - Reproductive Health/*education
MH  - School Health Services/*statistics & numerical data
MH  - Sex Education/*methods
MH  - Sexual Health/*education
MH  - Surveys and Questionnaires
PMC - PMC7201858
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/05/15 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/05/15 06:00
PHST- 2019/04/23 00:00 [received]
PHST- 2019/09/20 00:00 [revised]
PHST- 2019/10/08 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1155/2020/3675684 [doi]
PST - epublish
SO  - J Environ Public Health. 2020 Jan 9;2020:3675684. doi: 10.1155/2020/3675684.
      eCollection 2020.


PMID- 32405101
OWN - NLM
STAT- MEDLINE
DCOM- 20200624
LR  - 20210110
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 192
DP  - 2020 Aug
TI  - Incidence of asymptomatic deep vein thrombosis in patients with COVID-19
      pneumonia and elevated D-dimer levels.
PG  - 23-26
LID - S0049-3848(20)30190-0 [pii]
LID - 10.1016/j.thromres.2020.05.018 [doi]
AB  - AIM: An increased risk of venous thromboembolism (VTE) in patients with COVID-19 
      pneumonia admitted to intensive care unit (ICU) has been reported. Whether
      COVID-19 increases the risk of VTE in non-ICU wards remains unknown. We aimed to 
      evaluate the burden of asymptomatic deep vein thrombosis (DVT) in COVID-19
      patients with elevated D-dimer levels. METHOD: In this prospective study
      consecutive patients hospitalized in non-intensive care units with diagnosis of
      COVID-19 pneumonia and D-dimer>1000ng/ml were screened for asymptomatic DVT with 
      complete compression doppler ultrasound (CCUS). The study was approved by the
      Institutional Ethics Committee. RESULTS: The study comprised 156 patients (65.4% 
      male). All but three patients received standard doses of thromboprophylaxis.
      Median days of hospitalization until CCUS was 9 (IQR 5-17). CCUS was positive for
      DVT in 23 patients (14.7%), of whom only one was proximal DVT. Seven patients
      (4.5%) had bilateral distal DVT. Patients with DVT had higher median D-dimer
      levels: 4527 (IQR 1925-9144) ng/ml vs 2050 (IQR 1428-3235) ng/ml; p<0.001.
      D-dimer levels>1570ng/ml were associated with asymptomatic DVT (OR 9.1; CI 95%
      1.1-70.1). D-dimer showed an acceptable discriminative capacity (area under the
      ROC curve 0.72, 95% CI 0.61-0.84). CONCLUSION: In patients admitted with COVID-19
      pneumonia and elevated D-dimer levels, the incidence of asymptomatic DVT is
      similar to that described in other series. Higher cut-off levels for D-dimer
      might be necessary for the diagnosis of DVT in COVID-19 patients.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Demelo-Rodriguez, P
AU  - Demelo-Rodriguez P
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain;
      Gregorio Maranon Sanitary Research Institute, Madrid, Spain.
FAU - Cervilla-Munoz, E
AU  - Cervilla-Munoz E
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Ordieres-Ortega, L
AU  - Ordieres-Ortega L
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Parra-Virto, A
AU  - Parra-Virto A
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Toledano-Macias, M
AU  - Toledano-Macias M
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Toledo-Samaniego, N
AU  - Toledo-Samaniego N
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Garcia-Garcia, A
AU  - Garcia-Garcia A
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Garcia-Fernandez-Bravo, I
AU  - Garcia-Fernandez-Bravo I
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain.
FAU - Ji, Z
AU  - Ji Z
AD  - School of Medicine, Universidad Complutense de Madrid, Spain; Respiratory
      Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain.
FAU - de-Miguel-Diez, J
AU  - de-Miguel-Diez J
AD  - School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Maranon
      Sanitary Research Institute, Madrid, Spain; Respiratory Department, Hospital
      General Universitario Gregorio Maranon, Madrid, Spain; Respiratory Diseases CIBER
      (CIBERER), Madrid, Spain.
FAU - Alvarez-Sala-Walther, L A
AU  - Alvarez-Sala-Walther LA
AD  - School of Medicine, Universidad Complutense de Madrid, Spain; Gregorio Maranon
      Sanitary Research Institute, Madrid, Spain.
FAU - Del-Toro-Cervera, J
AU  - Del-Toro-Cervera J
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain;
      Gregorio Maranon Sanitary Research Institute, Madrid, Spain.
FAU - Galeano-Valle, F
AU  - Galeano-Valle F
AD  - Venous Thromboembolism Unit, Hospital General Universitario Gregorio Maranon,
      Madrid, Spain; School of Medicine, Universidad Complutense de Madrid, Spain;
      Gregorio Maranon Sanitary Research Institute, Madrid, Spain. Electronic address: 
      paco.galeano.valle@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200513
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (fibrin fragment D)
RN  - COVID-19 drug treatment
SB  - IM
CIN - Thromb Res. 2020 Sep;193:98. PMID: 32534328
MH  - Anticoagulants/administration & dosage
MH  - Asymptomatic Diseases
MH  - Betacoronavirus/*pathogenicity
MH  - Biomarkers/blood
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques
MH  - Coronavirus Infections/diagnosis/drug therapy/*epidemiology/virology
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/*analysis
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Pandemics
MH  - Pneumonia, Viral/diagnosis/drug therapy/*epidemiology/virology
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Spain/epidemiology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Up-Regulation
MH  - Venous Thrombosis/diagnostic imaging/*epidemiology/prevention & control/virology
PMC - PMC7219400
OTO - NOTNLM
OT  - *COVID-19
OT  - *D-dimer
OT  - *Deep vein thrombosis
OT  - *Doppler ultrasound
OT  - *SARS-CoV-2 infection
OT  - *Venous thromboembolism
EDAT- 2020/05/15 06:00
MHDA- 2020/06/25 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/12 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1016/j.thromres.2020.05.018 [doi]
AID - S0049-3848(20)30190-0 [pii]
PST - ppublish
SO  - Thromb Res. 2020 Aug;192:23-26. doi: 10.1016/j.thromres.2020.05.018. Epub 2020
      May 13.


PMID- 32405083
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20210110
IS  - 0013-7006 (Print)
IS  - 0013-7006 (Linking)
VI  - 46
IP  - 3S
DP  - 2020 Jun
TI  - [Appreciating COVID-19 as a child and adolescent psychiatrist on the move].
PG  - S99-S106
LID - S0013-7006(20)30090-7 [pii]
LID - 10.1016/j.encep.2020.05.005 [doi]
AB  - COVID-19 is a multi-organ disease due to an infection with the SARS-CoV2 virus.
      It has become a pandemic in early 2020. The disease appears less devastating in
      children and adolescents. However, stress, quarantine and eventually mourning
      have major impacts on development. It is difficult to describe what this pandemic
      implies for a child psychiatrist, other than by giving a first-hand account. I
      propose to go through the main ethical questions that have arisen; to describe
      how my hospital team has reorganized itself to meet the new demands and
      questions, in particular by opening a unit dedicated to people with autism and
      challenging behaviors affected by COVID-19; and to address, in a context of
      national discussion, how the discipline has sought to understand the conditions
      of a certain well-being during quarantine. Finally, I will try to conclude with
      more speculative reflections on re-opening.
CI  - Copyright (c) 2020 L'Encephale, Paris. Published by Elsevier Masson SAS. All
      rights reserved.
FAU - Cohen, D
AU  - Cohen D
AD  - Service de psychiatrie de l'enfant et de l'adolescent, Sorbonne universite, CNRS 
      UMR 7222 << institut des systemes intelligents et robotiques >>, AP-HP, Paris,
      France. Electronic address: david.cohen@aphp.fr.
LA  - fre
PT  - Journal Article
TT  - Apprehender le COVID-19 au fil de l'eau en tant que psychiatre d'enfant et
      d'adolescent.
DEP - 20200513
PL  - France
TA  - Encephale
JT  - L'Encephale
JID - 7505643
SB  - IM
MH  - Adolescent
MH  - Adolescent Behavior
MH  - *Adolescent Psychiatry/ethics
MH  - *Attitude of Health Personnel
MH  - Autistic Disorder/complications/psychology/*therapy
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Child Behavior
MH  - *Child Psychiatry/ethics
MH  - Communicable Disease Control/methods
MH  - *Coronavirus Infections/complications/epidemiology/prevention &
      control/psychology/transmission
MH  - Cross Infection/complications/psychology/therapy
MH  - Environmental Exposure
MH  - France
MH  - Health Services Accessibility
MH  - Hospital Restructuring
MH  - Hospital Units/organization & administration
MH  - Humans
MH  - Infection Control/methods
MH  - Mental Health Services/ethics/organization & administration
MH  - Olfaction Disorders/etiology/psychology
MH  - *Pandemics/prevention & control
MH  - Patient Acceptance of Health Care
MH  - Patient Care Team
MH  - Patient Isolation/psychology
MH  - Play Therapy
MH  - *Pneumonia, Viral/complications/prevention & control/psychology/transmission
MH  - Professional Practice/ethics
MH  - Protective Devices
MH  - *Psychiatry
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Stress, Psychological/etiology
PMC - PMC7218362
OTO - NOTNLM
OT  - Adolescence
OT  - COVID-19
OT  - Childhood
OT  - Confinement
OT  - Deconfinement
OT  - Enfance
OT  - Quarantine
OT  - Re-opening
EDAT- 2020/05/15 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1016/j.encep.2020.05.005 [doi]
AID - S0013-7006(20)30090-7 [pii]
PST - ppublish
SO  - Encephale. 2020 Jun;46(3S):S99-S106. doi: 10.1016/j.encep.2020.05.005. Epub 2020 
      May 13.


PMID- 32405024
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20200615
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 581
IP  - 7807
DP  - 2020 May
TI  - Meet this super-spotter of duplicated images in science papers.
PG  - 132-136
LID - 10.1038/d41586-020-01363-z [doi]
FAU - Shen, Helen
AU  - Shen H
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - News
PT  - Portrait
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Artificial Intelligence/trends
MH  - History, 21st Century
MH  - Molecular Biology
MH  - Molecular Imaging/*standards
MH  - Photography/*standards
MH  - Plagiarism
MH  - Reproducibility of Results
MH  - Research Design/*statistics & numerical data
MH  - Research Report/*standards
MH  - Retraction of Publication as Topic
MH  - Scientific Misconduct/*statistics & numerical data
MH  - Social Media
MH  - Software
PS  - Bik E
FPS - Bik, Elisabeth
OTO - NOTNLM
OT  - *Ethics
OT  - *Peer review
OT  - *Publishing
OT  - *Software
EDAT- 2020/05/15 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
AID - 10.1038/d41586-020-01363-z [doi]
AID - 10.1038/d41586-020-01363-z [pii]
PST - ppublish
SO  - Nature. 2020 May;581(7807):132-136. doi: 10.1038/d41586-020-01363-z.


PMID- 32405023
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20201218
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 581
IP  - 7807
DP  - 2020 May
TI  - Coronavirus drugs trials must get bigger and more collaborative.
PG  - 120
LID - 10.1038/d41586-020-01391-9 [doi]
LA  - eng
PT  - Editorial
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
CON - N Engl J Med. 2020 Apr 10;:null. PMID: 32275812
MH  - Adenosine Monophosphate/analogs & derivatives
MH  - Alanine/analogs & derivatives
MH  - Betacoronavirus
MH  - COVID-19
MH  - Compassionate Use Trials
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - *Diseases
OT  - *Ethics
OT  - *SARS-CoV-2
OT  - *Vaccines
EDAT- 2020/05/15 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - 10.1038/d41586-020-01391-9 [doi]
AID - 10.1038/d41586-020-01391-9 [pii]
PST - ppublish
SO  - Nature. 2020 May;581(7807):120. doi: 10.1038/d41586-020-01391-9.


PMID- 32404670
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20210203
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 1
DP  - 2020 Jul
TI  - COVID-19, Ethics and Equity-What Is Our Role as Surgeons?
PG  - e14-e17
LID - 10.1097/SLA.0000000000003969 [doi]
FAU - Zakrison, Tanya L
AU  - Zakrison TL
AD  - MPH Section for Trauma and Acute Care Surgery, Department of Surgery, The
      University of Chicago, Chicago, IL.
FAU - Martin, Matthew
AU  - Martin M
AD  - Trauma and Emergency Surgical Service, Scripps Mercy Medical Center, San Diego,
      CA.
FAU - Seamon, Mark
AU  - Seamon M
AD  - Division of Traumatology, Surgical Critical Care and Emergency Surgery, Perelman 
      School of Medicine at the University of Pennsylvania, PA.
FAU - Matthews, Jeffrey
AU  - Matthews J
AD  - Department of Surgery, The University of Chicago, Chicago, IL.
FAU - Joseph, Bellal
AU  - Joseph B
AD  - Trauma, Critical Care, Burn and Emergency Surgery, University of Arizona College 
      of Medicine, Tuscon, AZ.
FAU - Rattan, Rishi
AU  - Rattan R
AD  - Division of Trauma and Surgical Critical Care, University of Miami Miller School 
      of Medicine, Miami, FL.
FAU - Mendoza, April
AU  - Mendoza A
AD  - Division of Trauma, Emergency Surgery, and Surgical Critical Care, Massachusetts 
      General Hospital, Boston, MA.
FAU - Bernard, Andrew
AU  - Bernard A
AD  - Acute Care Surgery, Trauma and Surgical Critical Care, University of Kentucky
      College of Medicine, Lexington, KY.
FAU - Gelbard, Rondi
AU  - Gelbard R
AD  - Acute Care Surgery, Department of Surgery, University of Alabama at Birmingham,
      Birmingham, AL.
FAU - Crandall, Marie
AU  - Crandall M
AD  - Division of Acute Care Surgery, Department of Surgery, University of Florida
      College of Medicine Jacksonville, Jacksonville, FL.
FAU - Punch, Laurie
AU  - Punch L
AD  - Department of Surgery, Washington University in St. Louis School of Medicine, St.
      Louis, MO.
FAU - Joseph, D'Andrea
AU  - Joseph D
AD  - Trauma and Acute Care Surgery, New York University Winthrop Hospital School of
      Medicine, Mineola, NY.
FAU - Bonne, Stephanie
AU  - Bonne S
AD  - Division of Trauma and Surgical Critical Care, Rutgers New Jersey Medical School,
      Newark, NJ.
FAU - Mubang, Ronnie
AU  - Mubang R
AD  - Division of Trauma and Surgical Critical Care, Department of Surgery, Vanderbilt 
      University Medical Center, Nashville, TN.
FAU - McCunn, Maureen
AU  - McCunn M
AD  - Division of Critical Care Anesthesiology, Department of Anesthesiology,
      University of Maryland School of Medicine, Baltimore, MD.
FAU - Rogers, Selwyn
AU  - Rogers S
AD  - MPH Section for Trauma and Acute Care Surgery, Department of Surgery, The
      University of Chicago, Chicago, IL.
FAU - Turner, Patricia
AU  - Turner P
AD  - American College of Surgeons, Chicago, IL.
FAU - Claridge, Jeffrey
AU  - Claridge J
AD  - Department of Surgery, MetroHealth Medical Center, Cleveland, OH.
FAU - Henry, Sharon
AU  - Henry S
AD  - R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine,
      Baltimore, MD.
FAU - de Moya, Marc
AU  - de Moya M
AD  - Division of Trauma and Acute Care Surgery, Department of Surgery, Medical College
      of Wisconsin, Milwaukee, WI.
FAU - Tseng, Esther
AU  - Tseng E
AD  - Department of Surgery, MetroHealth Medical Center, Cleveland, OH.
FAU - Goulet, Nicole
AU  - Goulet N
AD  - Department of Surgery, NYU Langone, New York University School of Medicine, New
      York, NY.
FAU - Tung, Lily
AU  - Tung L
AD  - Department of Surgery, Division of Trauma, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Kiselak, Elizabeth
AU  - Kiselak E
AD  - Department of Trauma, Surgical Critical Care and Injury Prevention, Hackensack
      University Medical Center, Hackensack University Medical Center, Hackensack, NJ.
FAU - Duncan, Thomas
AU  - Duncan T
AD  - Division of Trauma, Ventura County Medical Center, Ventura, CA.
FAU - Kaafarani, Haytham
AU  - Kaafarani H
AD  - Center for Outcomes and Patient Safety in Surgery (COMPASS), Massachusetts
      General Hospital, Boston, MA.
FAU - Ferrada, Paula
AU  - Ferrada P
AD  - Division of Acute Care Surgical Services, Virginia Commonwealth University School
      of Medicine, Richmond, VA.
FAU - Foster, Shannon
AU  - Foster S
AD  - Reading Trauma Center, Reading Hospital, Tower Health System, West Reading, PA.
FAU - Ding, Linda
AU  - Ding L
AD  - Division of Trauma and Acute Care Surgery, Department of Surgery, University of
      South Alabama, AL.
FAU - Santos, Ariel
AU  - Santos A
AD  - Trauma, Acute Care Surgery and Surgical Critical Care, Texas Tech University
      Health Sciences Center School of Medicine, Lubbock, TX.
FAU - Winfield, Robert D
AU  - Winfield RD
AD  - Division of Acute Care Surgery, Trauma, and Surgical Critical Care, University of
      Kansas Medical Center, Kansas City, KS.
FAU - Weaver, Jessica
AU  - Weaver J
AD  - Division of Trauma, Surgical Critical Care, Department of Surgery, UC San Diego
      Health, San Diego, CA.
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery and MacLean Center for Clinical Medical Ethics, The
      University of Chicago, Chicago, IL.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*therapy/transmission
MH  - Epidemics
MH  - *Health Equity
MH  - Health Personnel/psychology
MH  - Humans
MH  - Infectious Disease Transmission, Patient-to-Professional/prevention & control
MH  - Pandemics
MH  - Personal Protective Equipment
MH  - *Physician's Role
MH  - Pneumonia, Viral/*epidemiology/*therapy/transmission
MH  - Racism
MH  - SARS-CoV-2
MH  - Social Problems
MH  - Stress, Psychological
MH  - *Surgeons
MH  - United States/epidemiology
MH  - Violence
PMC - PMC7268878
EDAT- 2020/05/15 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1097/SLA.0000000000003969 [doi]
AID - 00000658-202007000-00007 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Jul;272(1):e14-e17. doi: 10.1097/SLA.0000000000003969.


PMID- 32404609
OWN - NLM
STAT- MEDLINE
DCOM- 20201230
LR  - 20210108
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 12
DP  - 2020 Dec
TI  - The Conscientious Use of Images Illustrating Diversity in Medical Education
      Marketing.
PG  - 1807-1810
LID - 10.1097/ACM.0000000000003503 [doi]
AB  - An institution's marketing materials are an important part of presenting its
      culture. In 2018, communication professionals in the Office of Faculty Affairs,
      Professional Development, and Diversity at the Indiana University School of
      Medicine recognized after reviewing the literature that using images illustrating
      diversity in marketing materials may have unintended negative consequences and
      could potentially reflect poorly on the institution. Representations of diversity
      that are discordant with the actual demographics of an institution can create
      distrust among faculty, students, and staff who discover an institution is not as
      diverse or supportive of diversity as their marketing materials suggest. If
      institutions adopt an aspirational approach to images and depict more diversity
      than actual demographics reflect, the authors of this Perspective recommend that 
      they both develop marketing materials that present a widely diverse selection of 
      images and demonstrate transparency in their communication strategies.To improve 
      their promotional materials, the authors conducted an analysis of their
      institution's strategy for selecting images for these materials, identified
      institutional goals related to the strategic use of images, created training
      materials for staff, and drafted a public-facing statement about diversity in
      images. These measures are a significant step forward in cultivating the ethical 
      use of images illustrating diversity. In the future, institutions should
      highlight their approaches to using images to portray diversity, as well as
      photograph and document a wide range of events that represent diverse topics and 
      individuals. When these images are used for marketing purposes, it is also
      important to ensure that they are used in an appropriate context and not selected
      with the single goal of presenting diversity. Future research should focus on how
      underrepresented students and faculty interpret the use of diverse images in
      marketing, as well as their preferences for the use of their own images in
      marketing materials portraying diversity.
FAU - Hernandez, Rachael
AU  - Hernandez R
AD  - R. Hernandez is a postdoctoral fellow, Department of Communication, University of
      Missouri, Columbia, Missouri; ORCID: https://orcid.org/0000-0003-4919-5753.
FAU - Hoffmann-Longtin, Krista
AU  - Hoffmann-Longtin K
AD  - K. Hoffmann-Longtin is assistant professor of communication studies, Indiana
      University-Purdue University Indianapolis, and assistant dean, Office of Faculty 
      Affairs, Professional Development, and Diversity, Indiana University School of
      Medicine, Indianapolis, Indiana; ORCID: http://orcid.org/0000-0002-5625-3977.
FAU - Patrick, Shawn
AU  - Patrick S
AD  - S. Patrick is director of faculty development, Office of Faculty Affairs,
      Professional Development, and Diversity, Indiana University School of Medicine,
      Indianapolis, Indiana; ORCID: https://orcid.org/0000-0003-2392-4954.
FAU - Tucker-Edmonds, Brownsyne
AU  - Tucker-Edmonds B
AD  - B. Tucker-Edmonds is assistant dean for diversity affairs, Indiana University
      School of Medicine, Indianapolis, Indiana; ORCID:
      https://orcid.org/0000-0003-0023-4440.
FAU - Rucker, Sydney
AU  - Rucker S
AD  - S. Rucker is director of diversity initiatives, Office of Faculty Affairs,
      Professional Development, and Diversity, Indiana University School of Medicine,
      Indianapolis, Indiana.
FAU - Livingston, Nikki
AU  - Livingston N
AD  - N. Livingston is marketing and communications specialist, Office of Faculty
      Affairs, Professional Development, and Diversity, Indiana University School of
      Medicine, Indianapolis, Indiana.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
MH  - *Cultural Diversity
MH  - *Education, Medical, Graduate
MH  - *Healthcare Disparities
MH  - Humans
MH  - *Marketing
MH  - United States
EDAT- 2020/05/15 06:00
MHDA- 2020/12/31 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/12/31 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1097/ACM.0000000000003503 [doi]
AID - 00001888-202012000-00017 [pii]
PST - ppublish
SO  - Acad Med. 2020 Dec;95(12):1807-1810. doi: 10.1097/ACM.0000000000003503.


PMID- 32404441
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
VI  - 105
IP  - 10
DP  - 2020 Oct
TI  - Umbilical cord interleukin-6 predicts outcome in very low birthweight infants in 
      a high HIV-burden setting: a prospective cohort study.
PG  - 932-937
LID - 10.1136/archdischild-2019-318665 [doi]
AB  - OBJECTIVES: South Africa has a double burden of high neonatal mortality and
      maternal HIV prevalence. Common to both is a proinflammatory in utero and
      perinatal milieu. The aim of this study was to determine cytokine profiles in HIV
      exposed (HE) and HIV unexposed (HU) very low birthweight (VLBW) infants and to
      determine whether these were associated with predischarge outcomes. DESIGN:
      Single-centre, prospective cohort study conducted from 1 June 2017 to 31 January 
      2019. PATIENTS: Inborn infants with birth weight of <1500 g were enrolled and
      cord blood was collected for interleukin (IL)-6 and tumour necrosis factor alpha 
      (TNF-alpha) assays. Participants provided informed consent and ethics approval
      was obtained. OUTCOME MEASURES: The primary outcome was umbilical cord cytokine
      levels according to maternal HIV status. Secondary outcomes included death and/or
      serious neonatal infection, necrotising enterocolitis, intraventricular
      haemorrhage, periventricular leucomalacia, chronic lung disease and
      haemodynamically significant patent ductus arteriosus before discharge. RESULTS: 
      A total of 279 cases were included with 269 cytokine assays performed on 122 HEs 
      and 147 HUs. Median IL-6 levels were 53.0 pg/mL in HEs and 21.0 pg/mL in HUs
      (p=0.07). Median TNF-alpha levels were 7.2 pg/mL in HEs and 6.5 pg/mL in HUs
      (p=0.6). There was significantly more late-onset sepsis in the HE group compared 
      with the HU group (41.2% vs 27.9%) (p=0.03). IL-6 levels were significantly
      higher for those with any adverse outcome (p=0.006) and death and/or any adverse 
      outcome (p=0.0001). TNF-alpha levels did not differ according to predischarge
      outcomes. CONCLUSION: There is no significant difference in IL-6 and TNF-alpha
      levels in cord blood of HE compared with HU VLBWs. However, IL-6 levels are
      significantly higher in VLBWs with adverse predischarge outcomes, and VLBW HEs
      are at increased risk of adverse predischarge outcomes compared with HUs,
      particularly late-onset sepsis.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Mackay, Cheryl Anne
AU  - Mackay CA
AUID- ORCID: 0000-0002-4966-4911
AD  - Paediatrics Department, Dora Nginza Hospital, Port Elizabeth, South Africa
      cmackay@mweb.co.za.
FAU - Smit, James Stephanus
AU  - Smit JS
AD  - Paediatrics Department, Dora Nginza Hospital, Port Elizabeth, Eastern Cape, South
      Africa.
FAU - Khan, Farhaad
AU  - Khan F
AD  - Paediatrics Department, Dora Nginza Hospital, Port Elizabeth, Eastern Cape, South
      Africa.
FAU - Dessai, Fazana
AU  - Dessai F
AD  - University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
FAU - Connolly, Catherine
AU  - Connolly C
AD  - University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
FAU - Masekela, Refiloe
AU  - Masekela R
AD  - Paediatrics and Child Health, University of KwaZulu-Natal College of Health
      Sciences, Durban, South Africa.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200513
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Cohort Studies
MH  - Female
MH  - Fetal Blood/*metabolism
MH  - HIV Infections/*epidemiology
MH  - Humans
MH  - Infant, Newborn
MH  - *Infant, Very Low Birth Weight
MH  - Interleukin-6/*metabolism
MH  - Neonatal Sepsis/*epidemiology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*epidemiology
MH  - South Africa/epidemiology
MH  - Tumor Necrosis Factor-alpha/blood
OTO - NOTNLM
OT  - *HIV
OT  - *mortality
OT  - *neonatology
OT  - *outcomes research
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/15 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - archdischild-2019-318665 [pii]
AID - 10.1136/archdischild-2019-318665 [doi]
PST - ppublish
SO  - Arch Dis Child. 2020 Oct;105(10):932-937. doi: 10.1136/archdischild-2019-318665. 
      Epub 2020 May 13.


PMID- 32404398
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal
      chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal
      metastases from colorectal, ovarian or gastric origin: protocol for a systematic 
      review and individual participant data (IPD) meta-analyses of effectiveness and
      cost-effectiveness.
PG  - e039314
LID - 10.1136/bmjopen-2020-039314 [doi]
AB  - INTRODUCTION: There is uncertainty about whether cytoreductive surgery
      (CRS)+hyperthermic intraoperative peritoneal chemotherapy (HIPEC) improves
      survival and/or quality of life compared with standard of care (SoC) in people
      with peritoneal metastases who can withstand major surgery. PRIMARY OBJECTIVES:
      To compare the relative benefits and harms of CRS+HIPEC versus SoC in people with
      peritoneal metastases from colorectal, ovarian or gastric cancers eligible to
      undergo CRS+HIPEC by a systematic review and individual participant data (IPD)
      meta-analysis. SECONDARY OBJECTIVES: To compare the cost-effectiveness of
      CRS+HIPEC versus SoC from a National Health Service (NHS) and personal social
      services perspective using a model-based cost-utility analysis. METHODS AND
      ANALYSIS: We will perform a systematic review of literature by updating the
      searches from MEDLINE, Embase, Cochrane library, Science Citation Index as well
      as trial registers. Two members of our team will independently screen the search 
      results and identify randomised controlled trials comparing CRS+HIPEC versus SoC 
      for inclusion based on full texts for articles shortlisted during screening. We
      will assess the risk of bias in the trials and obtain data related to baseline
      prognostic characteristics, details of intervention and control, and outcome data
      related to overall survival, disease progression, health-related quality of life,
      treatment related complications and resource utilisation data. Using IPD, we will
      perform a two-step IPD, that is, calculate the adjusted effect estimate from each
      included study and then perform a random-effects model meta-analysis. We will
      perform various subgroup analyses, meta-regression and sensitivity analyses. We
      will also perform a model-based cost-utility analysis to assess whether CRS+HIPEC
      is cost-effective in the NHS setting. ETHICS AND DISSEMINATION: This project was 
      approved by the UCL Research Ethics Committee (Ethics number: 16023/001). We aim 
      to present the findings at appropriate international meetings and publish the
      review, irrespective of the findings, in a peer-reviewed journal. PROSPERO
      REGISTRATION NUMBER: CRD42019130504.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Gurusamy, Kurinchi
AU  - Gurusamy K
AUID- ORCID: 0000-0002-0313-9134
AD  - Division of Surgery and Interventional Science, University College London,
      London, UK k.gurusamy@ucl.ac.uk.
FAU - Vale, Claire L
AU  - Vale CL
AD  - Meta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK.
FAU - Pizzo, Elena
AU  - Pizzo E
AD  - Department of Applied Health Research, University College London, London, UK.
FAU - Bhanot, R
AU  - Bhanot R
AD  - Division of Surgery and Interventional Science, University College London,
      London, UK.
FAU - Davidson, Brian R
AU  - Davidson BR
AD  - Division of Surgery and Interventional Science, University College London,
      London, UK.
AD  - Department of HPB Surgery, Royal Free London NHS Foundation Trust, London, UK.
FAU - Mould, Tim
AU  - Mould T
AD  - Gynaecological Oncology, University College London Hospitals NHS Trust, London,
      UK.
FAU - Mughal, Muntzer
AU  - Mughal M
AD  - Surgery, University College London Hospital NHS Foundation Trust, London, UK.
FAU - Saunders, Mark
AU  - Saunders M
AD  - Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust,
      Manchester, UK.
FAU - Aziz, Omer
AU  - Aziz O
AD  - Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust,
      Manchester, UK.
FAU - O'Dwyer, Sarah
AU  - O'Dwyer S
AD  - Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust,
      Manchester, UK.
LA  - eng
GR  - MC_UU_12023/25/MRC_/Medical Research Council/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Colorectal Neoplasms/complications/pathology/therapy
MH  - Combined Modality Therapy
MH  - Cost-Benefit Analysis/statistics & numerical data/trends
MH  - Cytoreduction Surgical Procedures/*methods
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Hyperthermic Intraperitoneal Chemotherapy/*methods
MH  - Male
MH  - Ovarian Neoplasms/complications/pathology/therapy
MH  - Peritoneal Neoplasms/mortality/*secondary/therapy
MH  - Prognosis
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Sensitivity and Specificity
MH  - Standard of Care/*statistics & numerical data
MH  - State Medicine/organization & administration
MH  - Stomach Neoplasms/complications/pathology/therapy
MH  - United Kingdom/epidemiology
PMC - PMC7228534
OTO - NOTNLM
OT  - *chemotherapy
OT  - *health economics
OT  - *oncology
OT  - *qualitative research
OT  - *surgery
COIS- Competing interests: The clinical practice of the clinicians in the project: TM, 
      MM, MS, OA and SO may be altered by the findings of the review.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-039314 [pii]
AID - 10.1136/bmjopen-2020-039314 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e039314. doi: 10.1136/bmjopen-2020-039314.


PMID- 32404397
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - What are the links between evidence-based medicine and shared decision-making in 
      training programs for junior doctors? A scoping review protocol.
PG  - e037225
LID - 10.1136/bmjopen-2020-037225 [doi]
AB  - INTRODUCTION: Patient-centred care is pivotal to clinical practice and medical
      education. The practice of evidence-based medicine (EBM) and shared
      decision-making (SDM) are complementary aspects of patient-centred care, but they
      are frequently taught and reported as independent entities. To effectively
      perform all steps of EBM, clinicians need to include patients in SDM
      conversations, however, the uptake of this has been slow and inconsistent. A
      solution may be the incorporation of SDM into EBM training programmes, but such
      programmes do not routinely include SDM skills development. This scoping review
      will survey the literature on the kinds of EBM and SDM educational programmes
      that exist for recently qualified doctors, programmes that incorporate the
      teaching of both EBM and SDM skills, as well as identifying research gaps in the 
      literature. METHODS AND ANALYSIS: Literature searches will be conducted in the
      databases Medline, Embase, Scopus and Cochrane Library. Bibliographies of key
      articles and their citing references will also be hand-searched and assessed for 
      inclusion. Selected grey literature will be included. Papers must be written in
      English, or provide English abstracts, and date from 1996 to the present day.Two 
      independent reviewers will screen titles and abstracts, check full texts of
      selected papers for eligibility and extract the data. Any disagreement will be
      resolved, and consensus reached, if necessary, with the assistance of a third
      reviewer. Qualitative and quantitative studies that address educational
      interventions for either EBM, SDM or both will be included. Data extraction
      tables will present bibliographic information, populations, interventions,
      context and outcomes. Data will be summarised using tables and figures and a
      description of findings. ETHICS AND DISSEMINATION: This review will synthesise
      information from publicly available publications and does not require ethics
      approval. The results will be disseminated via conference presentations and
      publications in medical journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Simons, Mary
AU  - Simons M
AUID- ORCID: 0000-0001-9627-7861
AD  - Library, Macquarie University, North Ryde, New South Wales, Australia
      mary.simons@mq.edu.au.
FAU - Rapport, Frances
AU  - Rapport F
AUID- ORCID: 0000-0002-4428-2826
AD  - Australian Institute of Health Innovation, Macquarie University, Sydney, New
      South Wales, Australia.
FAU - Zurynski, Yvonne
AU  - Zurynski Y
AUID- ORCID: 0000-0001-7744-8717
AD  - Australian Institute of Health Innovation, Macquarie University, Sydney, New
      South Wales, Australia.
FAU - Cullis, Jeremy
AU  - Cullis J
AD  - Library, Macquarie University, North Ryde, New South Wales, Australia.
FAU - Davidson, Andrew
AU  - Davidson A
AD  - Library, Macquarie University, North Ryde, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Jun 15;10(6):e037225corr1. PMID: 32540893
MH  - Clinical Competence/standards
MH  - Databases, Factual
MH  - Decision Making, Shared
MH  - Education/*methods/standards
MH  - Evaluation Studies as Topic
MH  - Evidence-Based Medicine/*methods/statistics & numerical data
MH  - Humans
MH  - Medical Staff, Hospital/*education
MH  - Patient-Centered Care/*ethics/standards
PMC - PMC7228528
OTO - NOTNLM
OT  - *internal medicine
OT  - *medical education & training
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-037225 [pii]
AID - 10.1136/bmjopen-2020-037225 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e037225. doi: 10.1136/bmjopen-2020-037225.


PMID- 32404396
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - Prediction of childhood brain outcomes in infants born preterm using neonatal MRI
      and concurrent clinical biomarkers (PREBO-6): study protocol for a prospective
      cohort study.
PG  - e036480
LID - 10.1136/bmjopen-2019-036480 [doi]
AB  - INTRODUCTION: Infants born very preterm are at risk of adverse neurodevelopmental
      outcomes, including cognitive deficits, motor impairments and cerebral palsy.
      Earlier identification enables targeted early interventions to be implemented
      with the aim of improving outcomes. METHODS AND ANALYSIS: Protocol for 6-year
      follow-up of two cohorts of infants born <31 weeks gestational age (PPREMO:
      Prediction of Preterm Motor Outcomes; PREBO: Prediction of Preterm Brain
      Outcomes) and a small term-born reference sample in Brisbane, Australia. Both
      preterm cohorts underwent very early MRI and concurrent clinical assessment at 32
      and 40 weeks postmenstrual age (PMA) and were followed up at 3, 12 and 24 months 
      corrected age (CA). This study will perform MRI and electroencephalography (EEG).
      Primary outcomes include the Movement Assessment Battery for Children second
      edition and Full-Scale IQ score from the Wechsler Intelligence Scale for Children
      fifth edition (WISC-V). Secondary outcomes include the Gross Motor Function
      Classification System for children with cerebral palsy; executive function
      (Behavior Rating Inventory of Executive Function second edition, WISC-V Digit
      Span and Picture Span, Wisconsin Card Sorting Test 64 Card Version); attention
      (Test of Everyday Attention for Children second edition); language (Clinical
      Evaluation of Language Fundamentals fifth edition), academic achievement
      (Woodcock Johnson IV Tests of Achievement); mental health and quality of life
      (Development and Well-Being Assessment, Autism Spectrum Quotient-10 Items Child
      version and Child Health Utility-9D). AIMS: Examine the ability of early neonatal
      MRI, EEG and concurrent clinical measures at 32 weeks PMA to predict motor,
      cognitive, language, academic achievement and mental health outcomes at 6 years
      CA.Determine if early brain abnormalities persist and are evident on brain MRI at
      6 years CA and the relationship to EEG and concurrent motor, cognitive, language,
      academic achievement and mental health outcomes. ETHICS AND DISSEMINATION:
      Ethical approval has been obtained from Human Research Ethics Committees at
      Children's Health Queensland (HREC/19/QCHQ/49800) and The University of
      Queensland (2019000426). Study findings will be presented at national and
      international conferences and published in peer-reviewed journals. TRIAL
      REGISTRATION NUMBER: ACTRN12619000155190p. WEB ADDRESS OF TRIAL:
      http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619000155190
      p.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - George, Joanne M
AU  - George JM
AUID- ORCID: 0000-0003-4893-6564
AD  - Child Health Research Centre, Queensland Cerebral Palsy and Rehabilitation
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia j.george2@uq.edu.au.
FAU - Pagnozzi, Alex M
AU  - Pagnozzi AM
AD  - The Australian e-Health Research Centre, Commonwealth Scientific and Industrial
      Research Organisation (CSIRO), Brisbane, Queensland, Australia.
FAU - Bora, Samudragupta
AU  - Bora S
AD  - Mothers, Babies and Women's Health Program, Mater Research Institute, Faculty of 
      Medicine, The University of Queensland, Brisbane, Queensland, Australia.
FAU - Boyd, Roslyn N
AU  - Boyd RN
AD  - Child Health Research Centre, Queensland Cerebral Palsy and Rehabilitation
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Colditz, Paul B
AU  - Colditz PB
AD  - Centre for Clinical Research, The University of Queensland, Brisbane, Queensland,
      Australia.
AD  - Perinatal Research Centre, Royal Brisbane and Women's Hospital, Brisbane,
      Queensland, Australia.
FAU - Rose, Stephen E
AU  - Rose SE
AD  - The Australian e-Health Research Centre, Commonwealth Scientific and Industrial
      Research Organisation (CSIRO), Brisbane, Queensland, Australia.
FAU - Ware, Robert S
AU  - Ware RS
AD  - Menzies Health Institute Queensland, Griffith University, Nathan, Queensland,
      Australia.
FAU - Pannek, Kerstin
AU  - Pannek K
AD  - The Australian e-Health Research Centre, Commonwealth Scientific and Industrial
      Research Organisation (CSIRO), Brisbane, Queensland, Australia.
FAU - Bursle, Jane E
AU  - Bursle JE
AD  - Department of Medical Imaging, Royal Brisbane and Women's Hospital, Brisbane,
      Queensland, Australia.
FAU - Fripp, Jurgen
AU  - Fripp J
AD  - The Australian e-Health Research Centre, Commonwealth Scientific and Industrial
      Research Organisation (CSIRO), Brisbane, Queensland, Australia.
FAU - Barlow, Karen
AU  - Barlow K
AD  - Child Health Research Centre, The University of Queensland, Brisbane, Queensland,
      Australia.
FAU - Iyer, Kartik
AU  - Iyer K
AD  - Centre for Clinical Research, The University of Queensland, Brisbane, Queensland,
      Australia.
AD  - Child Health Research Centre, The University of Queensland, Brisbane, Queensland,
      Australia.
FAU - Leishman, Shaneen J
AU  - Leishman SJ
AD  - Child Health Research Centre, Queensland Cerebral Palsy and Rehabilitation
      Research Centre, Faculty of Medicine, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Jendra, Rebecca L
AU  - Jendra RL
AD  - Consumer Representative, Brisbane, Queensland, Australia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
SB  - IM
MH  - Academic Success
MH  - Australia/epidemiology
MH  - Biomarkers/metabolism
MH  - Brain/*diagnostic imaging/physiopathology
MH  - Cerebral Palsy/diagnosis/epidemiology/physiopathology
MH  - Cognitive Dysfunction/diagnosis/epidemiology/physiopathology
MH  - Early Medical Intervention/*methods
MH  - Electroencephalography/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Language
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Mental Health/statistics & numerical data
MH  - Motor Neuron Disease/diagnosis/epidemiology/physiopathology
MH  - Neurodevelopmental Disorders/*complications/diagnosis/epidemiology
MH  - Premature Birth/*epidemiology
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC7228524
OTO - NOTNLM
OT  - *developmental neurology & neurodisability
OT  - *magnetic resonance imaging
OT  - *neonatology
OT  - *paediatric neurology
OT  - *paediatric radiology
OT  - *perinatology
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036480 [pii]
AID - 10.1136/bmjopen-2019-036480 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e036480. doi: 10.1136/bmjopen-2019-036480.


PMID- 32404395
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - FeBRILe3 Project: protocol for a prospective pragmatic, multisite observational
      study and safety evaluation assessing Fever, Blood cultures and Readiness for
      discharge in Infants Less than 3 months old.
PG  - e035992
LID - 10.1136/bmjopen-2019-035992 [doi]
AB  - INTRODUCTION: The purpose of this observational study is to assess the safety and
      impact of the introduction of a clinical practice guideline (CPG) recommending
      early discharge of infants with fever without source who are at low risk of
      serious bacterial infection (SBI). We hypothesise that implementation of this
      guideline will be associated with a rate of unplanned readmission to hospital
      (within 7 days of discharge) which is similar (ie, non-inferior) to that observed
      under previous standard practice. METHODS AND ANALYSIS: This observational study 
      is a prospective pragmatic, multisite safety assessment and impact project. It
      will evaluate the safety of a CPG which allows febrile infants fulfilling
      low-risk criteria to be discharged early from hospital if their blood cultures
      demonstrate no growth at 24 hours (compared with previous minimum 48 hours
      admission). This guideline has been implemented at two Western Australian
      metropolitan hospitals. Infants aged <3 months (chronological or corrected for
      premature birth before 37 weeks gestation) presenting with fever without source
      will be included. The primary outcome is readmission to hospital due to clinical 
      deterioration/caregiver concern within 7 days of discharge, identified through
      review of electronic admission details and study-specific caregiver surveys.
      Secondary outcomes include rates of SBI, hospital lengths of stay compared with
      previous practice, clinician guideline adherence and caregiver satisfaction with 
      the discharge process. Analysis will be within a sequential Bayesian safety
      monitoring framework, which incorporates new information and updates the evidence
      for guideline safety relative to previous practice (historical control) at
      prespecified interim analyses. Demographic and clinical information will be
      summarised. ETHICS AND DISSEMINATION: Ethics approval and waiver of consent for
      data collection has been granted by the Child and Adolescent Health Service Human
      Research Ethics Committee (RGS0000001415). Caregivers will have the option to opt
      out of survey follow-up. Results will be disseminated via peer-reviewed
      publication. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials
      Registry (ACTRN12619001010189).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mace, Ariel Olivia
AU  - Mace AO
AUID- ORCID: 0000-0002-8621-5664
AD  - Department of Paediatrics, Fiona Stanley Hospital, Murdoch, Western Australia,
      Australia ariel.mace@health.wa.gov.au.
AD  - Department of General Paediatrics, Perth Children's Hospital, Nedlands, Western
      Australia, Australia.
AD  - Wesfarmer's Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, 
      The University of Western Australia, Nedlands, Western Australia, Australia.
FAU - Martin, Andrew C
AU  - Martin AC
AD  - Department of General Paediatrics, Perth Children's Hospital, Nedlands, Western
      Australia, Australia.
AD  - School of Medicine, The University of Western Australia, Perth, Western
      Australia, Australia.
FAU - Ramsay, Jessica
AU  - Ramsay J
AD  - Wesfarmer's Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, 
      The University of Western Australia, Nedlands, Western Australia, Australia.
FAU - Totterdell, James
AU  - Totterdell J
AD  - Wesfarmer's Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, 
      The University of Western Australia, Nedlands, Western Australia, Australia.
FAU - Marsh, Julie A
AU  - Marsh JA
AD  - Wesfarmer's Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, 
      The University of Western Australia, Nedlands, Western Australia, Australia.
AD  - School of Mathematics & Statistics, The University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Snelling, Tom
AU  - Snelling T
AD  - Wesfarmer's Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, 
      The University of Western Australia, Nedlands, Western Australia, Australia.
AD  - Department of Infectious Diseases, Perth Children's Hospital, Nedlands, Western
      Australia, Australia.
AD  - Menzies School of Health Research, Charles Darwin University, Darwin, Northern
      Territory, Australia.
AD  - Curtin University, Perth, Western Australia, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001010189
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia/epidemiology
MH  - Bacterial Infections/complications/*epidemiology
MH  - Bayes Theorem
MH  - Blood Culture/*methods/statistics & numerical data
MH  - Caregivers/*psychology/statistics & numerical data
MH  - Case-Control Studies
MH  - Fever/complications/*diagnosis/etiology
MH  - Gestational Age
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Patient Discharge/*trends
MH  - Patient Readmission/trends
MH  - Personal Satisfaction
MH  - Practice Guidelines as Topic/standards
MH  - Prospective Studies
MH  - Safety
MH  - Severity of Illness Index
PMC - PMC7228564
OTO - NOTNLM
OT  - *paediatric A&E and ambulatory care
OT  - *paediatric infectious disease & immunisation
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035992 [pii]
AID - 10.1136/bmjopen-2019-035992 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e035992. doi: 10.1136/bmjopen-2019-035992.


PMID- 32404393
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - Prevalence and associated factors of preterm birth in Ethiopia: systematic review
      and meta-analysis protocol.
PG  - e035574
LID - 10.1136/bmjopen-2019-035574 [doi]
AB  - INTRODUCTION: Preterm birth (PTB) complications are the leading cause of death
      among neonates globally. The reduction in neonatal mortality is not remarkable in
      Ethiopia. Therefore, this review will assess the magnitude and associated factors
      of PTB in Ethiopia. METHODS AND ANALYSIS: The Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses guideline will be followed during the
      systematic review. We will include all observational studies published from 1
      January 2009 to 31 December 2019 that examined the level and/or associated
      factors of any type of PTB among live births in Ethiopia. Inclusion criteria will
      be all live births, PTB defined as delivery before 37 weeks gestation. The
      primary outcome will be PTB <37 weeks, and secondary outcomes including PTB <34, 
      <32 and <28 weeks will be analysed. PubMed and Science Direct databases as well
      as Google search engine and Google Scholar will be searched. The pooled
      prevalence of preterm and effect size of association for associated factors will 
      be analysed using the Stata software V.14. The heterogeneity between studies will
      be measured by I(2) statistics. A random-effects model will be used to estimate
      if heterogeneity detected. Publication bias will be assessed using a funnel plot.
      Subgroup analysis will be sought based on possible characteristics of the
      studies, specific morbidity (like pre-eclampsia, hypertension), type of PTB
      (spontaneous or iotrogenic) and quality of study (high-quality or low-risk).
      Meta-regression will be considered for major covariates (maternal age and
      maternal body mass index) related to PTB. Forest plots will be used to present
      the combined estimate with 95% CIs. The quality of evidence of the outcomes will 
      be assessed with the GRADE (Grading of Recommendations, Assessment, Development
      and Evaluations) approach. ETHICS AND DISSEMINATION: No ethical approval is
      necessary for this systematic review. The findings will be published in a
      peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42017077356.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Muchie, Kindie Fentahun
AU  - Muchie KF
AUID- ORCID: 0000-0002-9975-7948
AD  - Epidemiology and Biostatistics, Bahir Dar University, Bahir Dar, Ethiopia
      mkindief@gmail.com.
FAU - Lakew, Ayenew Molla
AU  - Lakew AM
AUID- ORCID: 0000-0003-3648-9891
AD  - Epidemiology and Biostatistics, University of Gondar College of Medicine and
      Health Sciences, Gondar, Ethiopia.
FAU - Teshome, Destaw Fetene
AU  - Teshome DF
AD  - Epidemiology and Biostatistics, University of Gondar College of Medicine and
      Health Sciences, Gondar, Ethiopia.
FAU - Yenit, Melaku Kindie
AU  - Yenit MK
AUID- ORCID: 0000-0002-8982-2814
AD  - Epidemiology and Biostatistics, University of Gondar College of Medicine and
      Health Sciences, Gondar, Ethiopia.
FAU - Sisay, Malede Mequanent
AU  - Sisay MM
AD  - Epidemiology and Biostatistics, University of Gondar College of Medicine and
      Health Sciences, Gondar, Ethiopia.
FAU - Mekonnen, Fantahun Ayenew
AU  - Mekonnen FA
AD  - Epidemiology and Biostatistics, University of Gondar College of Medicine and
      Health Sciences, Gondar, Ethiopia.
FAU - Habitu, Yohanes Ayanaw
AU  - Habitu YA
AD  - Reproductive Health, University of Gondar College of Medicine and Health
      Sciences, Gondar, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Body Mass Index
MH  - Ethiopia/epidemiology
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Infant
MH  - Infant Mortality/*trends
MH  - Infant, Newborn
MH  - Maternal Age
MH  - Observational Studies as Topic
MH  - Pre-Eclampsia/epidemiology
MH  - Pregnancy
MH  - Pregnancy Complications/*epidemiology/mortality
MH  - Premature Birth/*epidemiology/mortality
MH  - Prevalence
PMC - PMC7228533
OTO - NOTNLM
OT  - *gynaecology
OT  - *neonatology
OT  - *obstetrics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035574 [pii]
AID - 10.1136/bmjopen-2019-035574 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e035574. doi: 10.1136/bmjopen-2019-035574.


PMID- 32404392
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - Taking stock of vaccine hesitancy among migrants: a scoping review protocol.
PG  - e035225
LID - 10.1136/bmjopen-2019-035225 [doi]
AB  - INTRODUCTION: At the 72nd World Health Assembly of May 2019, WHO member states
      prioritised a global action plan to promote migrant and refugee health. Five
      months earlier, WHO had declared vaccine hesitancy-the reluctance to vaccinate
      despite the availability of vaccination services-as one of the top 10 threats to 
      global health. Although vaccination is often a requirement for immigration,
      repeated outbreaks of vaccine-preventable diseases within certain immigrant
      communities in some host nations suggest that vaccine hesitancy could be a factor
      in their susceptibility to vaccine-preventable diseases. Studies of the
      prevalence and determinants of vaccine hesitancy among migrants globally seem to 
      be lacking. This scoping review will (1) identify articles on vaccine hesitancy
      among migrants; (2) examine the extent and nature of the extant evidence; and (3)
      determine the value of undertaking a full systematic review. METHODS AND
      ANALYSIS: The framework for the scoping review proposed by the Joanna Briggs
      Institute will be used. The reporting will follow the Preferred Reporting Items
      for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist.
      Studies published in English or French between January 1999 and December 2019
      will be drawn from most or all of the following multidisciplinary databases:
      Africa-Wide Information, Allied and Complementary Medicine, Cochrane Library,
      Cumulative Index of Nursing and Allied Health Literature, Embase, Index Medicus
      for the Eastern Mediterranean Region, International Bibliography of Social
      Sciences, Literature in the Health Sciences in Latin America and the Caribbean,
      Medline, Proquest Theses/Dissertations, PsycInfo and Web of Science. The search
      will include an extensive list of keywords to capture multiple dimensions of
      confidence and hesitancy vis-a-vis vaccines among migrants. Findings will be
      reported through summary narratives, tables, flowcharts and evidence maps. ETHICS
      AND DISSEMINATION: This review is exempted from ethical approval and will be
      published in a peer-reviewed open-access journal to ensure wide dissemination.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tankwanchi, Akhenaten Siankam
AU  - Tankwanchi AS
AUID- ORCID: 0000-0002-6051-3292
AD  - Department of Health Services, University of Washington School of Public Health, 
      Seattle, WA, United States abs.tankwanchi@gmail.com.
FAU - Jaca, Anelisa
AU  - Jaca A
AUID- ORCID: 0000-0002-9814-8374
AD  - Cochrane South Africa, South African Medical Research Council, Tygerberg, Western
      Cape, South Africa.
FAU - Larson, Heidi J
AU  - Larson HJ
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
AD  - Institute of Health Metrics and Evaluation, University of Washington, Seattle,
      WA, United States.
FAU - Wiysonge, Charles S
AU  - Wiysonge CS
AUID- ORCID: 0000-0002-1273-4779
AD  - Cochrane South Africa, South African Medical Research Council, Tygerberg, Western
      Cape, South Africa.
AD  - Department of Global Health, Stellenbosch University, Cape Town, South Africa.
AD  - School of Public Health and Family Medicine, University of Cape Town, Cape Town, 
      South Africa.
FAU - Vermund, Sten H
AU  - Vermund SH
AUID- ORCID: 0000-0001-7289-8698
AD  - Office of the Dean, Yale School of Public Health, Yale University, New Haven, CT,
      United States.
LA  - eng
GR  - P30 MH062294/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vaccines)
SB  - IM
MH  - Africa/epidemiology
MH  - Caribbean Region/epidemiology
MH  - Global Health/*legislation & jurisprudence
MH  - Health Promotion/methods
MH  - Humans
MH  - Latin America/epidemiology
MH  - Mediterranean Region/epidemiology
MH  - Prevalence
MH  - Transients and Migrants/*psychology
MH  - Uncertainty
MH  - Vaccination/*legislation & jurisprudence/standards
MH  - Vaccines/*supply & distribution/therapeutic use
PMC - PMC7228513
OTO - NOTNLM
OT  - *community child health
OT  - *immunology
OT  - *paediatric infectious disease & immunisation
OT  - *public health
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035225 [pii]
AID - 10.1136/bmjopen-2019-035225 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e035225. doi: 10.1136/bmjopen-2019-035225.


PMID- 32404390
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - Effects of an automated digital brief prevention intervention targeting
      adolescents and young adults with risky alcohol and other substance use: study
      protocol for a randomised controlled trial.
PG  - e034894
LID - 10.1136/bmjopen-2019-034894 [doi]
AB  - INTRODUCTION: Adolescence and young adulthood is a period in life when
      individuals may be especially vulnerable to harmful substance use. Several
      critical developmental processes are occurring in the brain, and substance use
      poses both short-term and long-term risks with regard to mental health and social
      development. From a public health perspective, it is important to prevent or
      delay substance use to reduce individual risk and societal costs. Given the
      scarcity of effective interventions targeting substance use among adolescents and
      young adults, cost-effective and easily disseminated interventions are warranted.
      The current study will test the effectiveness of a fully automated digital brief 
      intervention aimed at reducing alcohol and other substance use in adolescents and
      young adults aged 15 to 25 years. METHODS AND ANALYSIS: A two-arm, double-blind, 
      randomised controlled trial design is applied to assess the effectiveness of the 
      intervention. Baseline assessment, as well as 3-month and 6-month follow-up, will
      be carried out. The aim is to include 800 participants with risky substance use
      based on the screening tool CRAFFT (Car,Relax, Alone, Forget, Friends, Trouble). 
      Recruitment, informed consent, randomisation, intervention and follow-up will be 
      implemented online. The primary outcome is reduction in alcohol use, measured by 
      Alcohol Use Disorders Identification Test total score. Secondary outcomes concern
      binge drinking, frequency of alcohol consumption, amount of alcohol consumed a
      typical day when alcohol is consumed, average daily drinks per typical week,
      other substance use, mental health, sexual risk behaviours and perceived peer
      pressure. Moreover, the study involves analyses of potential moderators including
      perfectionism, openness to parents, help-seeking and background variables. ETHICS
      AND DISSEMINATION: The study was approved by the Swedish Ethical Review Authority
      (no. 2019-03249). The trial is expected to expand the knowledge on digital
      preventive interventions for substance using adolescents and young adults.
      Results will be disseminated in research journals, at conferences and via the
      media. TRIAL REGISTRATION NUMBER: 24 September 2019, ISRCTN91048246; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kvillemo, Pia
AU  - Kvillemo P
AUID- ORCID: 0000-0002-9706-4902
AD  - STAD (Stockholm Prevents Alcohol and Drug Problems), Centre for Psychiatry
      Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm
      Health Care Services, Region Stockholm, Stockholm, Sweden pia.kvillemo@ki.se.
FAU - Strandberg, Anna K
AU  - Strandberg AK
AD  - STAD (Stockholm Prevents Alcohol and Drug Problems), Centre for Psychiatry
      Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm
      Health Care Services, Region Stockholm, Stockholm, Sweden.
FAU - Gripenberg, Johanna
AU  - Gripenberg J
AD  - STAD (Stockholm Prevents Alcohol and Drug Problems), Centre for Psychiatry
      Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm
      Health Care Services, Region Stockholm, Stockholm, Sweden.
FAU - Berman, Anne H
AU  - Berman AH
AD  - Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska
      Institutet, & Stockholm Health Care Services, Region Stockholm, Stockholm,
      Sweden.
AD  - Department of Psychology, Uppsala University, Uppsala, Sweden.
FAU - Skoglund, Charlotte
AU  - Skoglund C
AD  - STAD (Stockholm Prevents Alcohol and Drug Problems), Centre for Psychiatry
      Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm
      Health Care Services, Region Stockholm, Stockholm, Sweden.
AD  - Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
FAU - Elgan, Tobias H
AU  - Elgan TH
AD  - STAD (Stockholm Prevents Alcohol and Drug Problems), Centre for Psychiatry
      Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm
      Health Care Services, Region Stockholm, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alcohol Drinking/*prevention & control
MH  - Case-Control Studies
MH  - Cost-Benefit Analysis
MH  - Crisis Intervention/economics/*methods
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Mass Screening/methods
MH  - Mental Health/standards
MH  - Peer Influence
MH  - Perception
MH  - Sexual Behavior/statistics & numerical data
MH  - Substance-Related Disorders/*prevention & control
MH  - Sweden/epidemiology
MH  - Young Adult
PMC - PMC7228518
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *preventive medicine
OT  - *psychiatry
OT  - *substance misuse
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034894 [pii]
AID - 10.1136/bmjopen-2019-034894 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e034894. doi: 10.1136/bmjopen-2019-034894.


PMID- 32404385
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 12
TI  - Maternal and newborn outcomes of antenatal breastmilk expression: a scoping
      review protocol.
PG  - e033101
LID - 10.1136/bmjopen-2019-033101 [doi]
AB  - INTRODUCTION: Mothers with diabetes face unique challenges associated with
      breastfeeding initiation and maintenance. Antenatal breastmilk expression (BME)
      may be suggested to mothers, including mothers with diabetes, to improve
      breastfeeding, maternal, and infant outcomes postpartum. However, there have been
      few evaluations of the potential harms and benefits of this practice. The
      objective of our scoping review will be to broadly examine the literature
      describing maternal and infant outcomes of antenatal BME. METHODS AND ANALYSIS:
      This scoping review will address the research question: 'Among women who engaged 
      in antenatal BME, what maternal and infant outcomes have been evaluated?' A
      search of published and unpublished studies available in English will be
      conducted in February 2020 using the following databases: Medline (OVID), Embase 
      (OVID), CINAHL (EBSCOHost), and Cochrane Database of Systematic Reviews (OVID). A
      search of the British Library E-Theses Online Services (EThOS) database and
      OpenGrey will be conducted to identify relevant grey literature. This scoping
      review will use a five-step framework to guide the selection, extraction, and
      analysis of eligible studies. Clinical consultation will be included as a sixth
      step to our methodology. Literature reporting on the effect of antenatal BME on
      maternal and infant outcomes, breastfeeding initiation and duration, and the
      experiences of women who have engaged in the practice will be considered. The
      data will be summarised with attention paid to high-risk obstetrical populations 
      such as women with diabetes. Our results will be reported as outlined by the
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for 
      Scoping Reviews. ETHICS AND DISSEMINATION: Research ethics board approval will
      not be required due to the nature of the study's methodology. The results of this
      review will be disseminated through peer-reviewed publication and presentation at
      relevant conferences. TRAIL REGISTRATION NUMBER: Open Science Framework
      (osf.io/gfp2q).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Foudil-Bey, Imane
AU  - Foudil-Bey I
AD  - OMNI Research Group, Clinical Epidemiology Program, Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Murphy, Malia Sq
AU  - Murphy MS
AD  - OMNI Research Group, Clinical Epidemiology Program, Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada.
FAU - Keely, Erin J
AU  - Keely EJ
AD  - Department of Obstetrics, Gynecology and Newborn Care, University of Ottawa,
      Ottawa, Ontario, Canada.
AD  - Division of Endocrinology and Metabolism, The Ottawa Hospital, Ottawa, Ontario,
      Canada.
FAU - El-Chaar, Darine
AU  - El-Chaar D
AUID- ORCID: 0000-0002-8266-0242
AD  - OMNI Research Group, Clinical Epidemiology Program, Ottawa Hospital Research
      Institute, Ottawa, Ontario, Canada delchaar@toh.ca.
AD  - Department of Obstetrics, Gynecology and Newborn Care, University of Ottawa,
      Ottawa, Ontario, Canada.
LA  - eng
GR  - FDN 148438/ Canadian Institutes for Health Research /International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200512
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Jul 30;10(7):e033101corr1. PMID: 32737102
MH  - Breast Feeding/*methods
MH  - Breast Milk Expression/adverse effects/*methods
MH  - Diabetes, Gestational/*epidemiology
MH  - Female
MH  - Humans
MH  - Infant Health/statistics & numerical data
MH  - Infant, Newborn
MH  - Maternal Health/statistics & numerical data
MH  - Postpartum Period/*physiology
MH  - Pregnancy
MH  - Pregnancy, High-Risk/physiology
MH  - Research Design
MH  - Risk Factors
PMC - PMC7228481
OTO - NOTNLM
OT  - *antenatal breast expression
OT  - *breastfeeding
OT  - *breastmilk expression
OT  - *diabetes in pregnancy
COIS- Competing interests: None declared.
EDAT- 2020/05/15 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033101 [pii]
AID - 10.1136/bmjopen-2019-033101 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 12;10(5):e033101. doi: 10.1136/bmjopen-2019-033101.


PMID- 32404291
OWN - NLM
STAT- MEDLINE
DCOM- 20211001
LR  - 20211001
IS  - 2603-6479 (Electronic)
IS  - 2603-6479 (Linking)
VI  - 35
IP  - 3
DP  - 2020 May - Jun
TI  - [Ethical aspects of specific precautions programs in patients infected or
      colonised by multidrug-resistant microorganisms in a hospital setting].
PG  - 159-165
LID - S2603-6479(20)30040-3 [pii]
LID - 10.1016/j.jhqr.2020.03.006 [doi]
AB  - The approach to public health, patient safety and quality of care has led to
      analysing health situations or problems from a population perspective, in a wide 
      way and giving priority to factors that can normally be left in the background
      from a clinical point of view. For years, the problem of the use and abuse of
      antimicrobials, the increase and diffusion of microorganisms resistant to them,
      cross-transmission, and healthcare related infections have been prioritised both 
      nationally and internationally. To combat these problems, various strategies are 
      being developed and put into practice, from the policies of rational use and
      optimization of antimicrobials, surveillance, and control of infections related
      to health care, to training information and awareness strategies. One of the
      pillars of surveillance and control is the correct application of standard and
      specific precautions, which within the framework of these comprehensive programs 
      aim to control the transmission of microorganisms of special microbiological
      and/or epidemiological interest through a series of measures. In hospitals, the
      application of these precautions (single room, barrier measures, restrictions on 
      access to rooms, waste management...) in patients infected or colonised by these 
      microorganisms can have different repercussions, both for patients and the
      professionals that attend them, and it is considered pertinent that the protocols
      and/or programs of specific precautions explicitly include the analysis of the
      ethical aspects in their preparation, implementation, and monitoring.
CI  - Copyright (c) 2020 FECA. Publicado por Elsevier Espana, S.L.U. All rights
      reserved.
FAU - Porras-Povedano, M
AU  - Porras-Povedano M
AD  - Area de Gestion Sanitaria de Osuna, Osuna, Sevilla, Espana. Electronic address:
      miguel.porras.sspa@juntadeandalucia.es.
FAU - Santacruz-Hamer, V
AU  - Santacruz-Hamer V
AD  - Hospital Quiron Salud Cordoba, Cordoba, Espana.
FAU - Munoz-Collado, E
AU  - Munoz-Collado E
AD  - Area de Gestion Sanitaria de Osuna, Osuna, Sevilla, Espana.
FAU - Ramirez-Pulido, R
AU  - Ramirez-Pulido R
AD  - Area de Gestion Sanitaria de Osuna, Osuna, Sevilla, Espana.
LA  - spa
PT  - Journal Article
TT  - Aspectos eticos de los programas de precauciones especificas de contacto en
      pacientes infectados o colonizados por microorganismos multirresistentes en el
      ambito hospitalario.
DEP - 20200511
PL  - Spain
TA  - J Healthc Qual Res
JT  - Journal of healthcare quality research
JID - 101735273
SB  - IM
MH  - *Bioethical Issues
MH  - *Drug Resistance, Multiple
MH  - *Hospitalization
MH  - Hospitals
MH  - Humans
MH  - Infection Control/*methods
OTO - NOTNLM
OT  - Bioethics
OT  - Bioetica
OT  - Cross infection
OT  - Drug resistance, multiple
OT  - Infeccion relacionada con la asistencia sanitaria
OT  - Infection control
OT  - Microorganismos multirresistentes
OT  - Patient isolation
OT  - Precauciones especificas
OT  - Precauciones universales
OT  - Universal precautions
OT  - Vigilancia y control de la infeccion
EDAT- 2020/05/15 06:00
MHDA- 2021/10/02 06:00
CRDT- 2020/05/15 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/01/28 00:00 [revised]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/10/02 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - S2603-6479(20)30040-3 [pii]
AID - 10.1016/j.jhqr.2020.03.006 [doi]
PST - ppublish
SO  - J Healthc Qual Res. 2020 May - Jun;35(3):159-165. doi:
      10.1016/j.jhqr.2020.03.006. Epub 2020 May 11.


PMID- 32404133
OWN - NLM
STAT- MEDLINE
DCOM- 20200922
LR  - 20200922
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 13
TI  - Efficacy of a physical activity programme combining individualized aerobic
      exercise and coaching to improve physical fitness in neuromuscular diseases (I'M 
      FINE): study protocol of a randomized controlled trial.
PG  - 184
LID - 10.1186/s12883-020-01725-0 [doi]
AB  - BACKGROUND: In individuals with neuromuscular diseases (NMD), symptoms of muscle 
      weakness, fatigue and pain may limit physical activity. Inactivity leads to
      reduced physical fitness, which further complicates daily life functioning. Due
      to inconclusive evidence regarding exercise in NMD, the optimal training approach
      and strategies to preserve an active lifestyle remain to be determined. The
      physical activity programme I'M FINE, consisting of individualized aerobic
      exercise to improve physical fitness and coaching to preserve an active
      lifestyle, was therefore developed. The primary objective of this study will be
      to evaluate the efficacy of the I'M FINE programme in terms of improved physical 
      fitness in individuals with slowly progressive NMD, compared to usual care.
      METHODS: A multicentre, assessor-blinded, two armed, randomized controlled trial 
      will be conducted in a sample of 90 individuals with slowly progressive NMD.
      Participants motivated to improve their reduced physical fitness will be
      randomized (ratio 1:1) to the I'M FINE intervention or usual care. The I'M FINE
      intervention consists of a six-month physical activity programme, including
      individualized home-based aerobic exercise to improve physical fitness (i.e. peak
      oxygen uptake), and motivational interviewing coaching (e.g. goal setting,
      self-management) to adopt and preserve an active lifestyle. Measurements will be 
      performed at baseline, post-intervention, and at 12- and 18-months follow-up. The
      primary outcome is peak oxygen uptake (VO2 peak) directly post intervention. Main
      secondary outcomes are physical capacity, muscle strength, self-efficacy, daily
      activity, quality of life and markers of metabolic syndrome. The primary analysis
      compares change in VO2 peak post-intervention between the intervention and usual 
      care group, with analysis of covariance. DISCUSSION: The I'M FINE study will
      provide evidence regarding the efficacy of a physical activity intervention on
      the physical fitness and active lifestyle over the short- and long-term in
      individuals with slowly progressive NMD. These outcomes could potentially improve
      the (inter)national guidelines for efficacy of aerobic exercise programmes and
      provide insight in achieving a more active lifestyle in NMD. TRIAL REGISTRATION: 
      (5/11/2018): Netherlands Trial Register NTR7609 (retrospectively registered),
      https://www.trialregister.nl/trial/7344. However, the Ethics Review Committee of 
      the Amsterdam Medical Center (AMC) approved the study protocol on 7/11/2017. No
      adjustments were made to the approved study protocol before the first participant
      enrolment and registration. Registration was done after the second participant
      enrolment and the information in the register corresponds one on one with the
      approved study protocol.
FAU - Oorschot, Sander
AU  - Oorschot S
AD  - Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC,
      University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
      s.oorschot@amsterdamumc.nl.
FAU - Brehm, Merel A
AU  - Brehm MA
AD  - Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC,
      University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - van Groenestijn, Annerieke C
AU  - van Groenestijn AC
AD  - Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC,
      University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Koopman, Fieke S
AU  - Koopman FS
AD  - Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC,
      University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Verhamme, Camiel
AU  - Verhamme C
AD  - Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of
      Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Eftimov, Filip
AU  - Eftimov F
AD  - Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of
      Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Jelsma, Judith G M
AU  - Jelsma JGM
AD  - Department of Public and Occupational Health, Amsterdam UMC, VU University
      Medical Center, de Boelelaan 1118, Amsterdam, The Netherlands.
FAU - Jorstad, Harald T
AU  - Jorstad HT
AD  - Department of Cardiology, Amsterdam Movement Sciences, Amsterdam UMC, University 
      of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Nollet, Frans
AU  - Nollet F
AD  - Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC,
      University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
FAU - Voorn, Eric L
AU  - Voorn EL
AD  - Department of Rehabilitation, Amsterdam Movement Sciences, Amsterdam UMC,
      University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
LA  - eng
GR  - W.OK17-03/Prinses Beatrix Spierfonds
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200513
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
SB  - IM
MH  - Adult
MH  - Exercise Therapy/*methods
MH  - Female
MH  - Humans
MH  - Mentoring/methods
MH  - *Multicenter Studies as Topic
MH  - Netherlands
MH  - Neuromuscular Diseases/*rehabilitation
MH  - Physical Fitness/*physiology
MH  - *Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Treatment Outcome
PMC - PMC7218829
OTO - NOTNLM
OT  - Active lifestyle
OT  - Aerobic exercise
OT  - Coaching
OT  - Motivational interviewing
OT  - Neuromuscular diseases
OT  - Physical fitness
EDAT- 2020/05/15 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/04/12 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - 10.1186/s12883-020-01725-0 [doi]
AID - 10.1186/s12883-020-01725-0 [pii]
PST - epublish
SO  - BMC Neurol. 2020 May 13;20(1):184. doi: 10.1186/s12883-020-01725-0.


PMID- 32404098
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 13
TI  - Ethical issues and practical barriers in internet-based suicide prevention
      research: a review and investigator survey.
PG  - 37
LID - 10.1186/s12910-020-00479-1 [doi]
AB  - BACKGROUND: People who are at elevated risk of suicide stand to benefit from
      internet-based interventions; however, research in this area is likely impacted
      by a range of ethical and practical challenges. The aim of this study was to
      examine the ethical issues and practical barriers associated with clinical
      studies of internet-based interventions for suicide prevention. METHOD: This was 
      a mixed-methods study involving two phases. First, a systematic search was
      conducted to identify studies evaluating internet-based interventions for people 
      at risk of suicide, and information pertaining to safety protocols and exclusion 
      criteria was extracted. Second, investigators on the included studies were
      invited to complete an online survey comprising open-ended and forced-choice
      responses. Quantitative and qualitative methods were used to analyse the data.
      RESULTS: The literature search identified 18 eligible studies, of which three
      excluded participants based on severity of suicide risk. Half of the 15 suicide
      researchers who participated in the survey had experienced problems obtaining
      ethics approval, and none had encountered adverse events attributed to their
      intervention. Survey respondents noted the difficulty of managing risk in online 
      environments and the limitations associated with implementing safety protocols,
      although some also reported increased confidence resulting from the ethical
      review process. Respondents recommended researchers pursue a collaborative
      relationship with their research ethics committees. CONCLUSION: There is a
      balance to be achieved between the need to minimise the risk of adverse events
      whilst also ensuring interventions are being validated on populations who may be 
      most likely to use and benefit from them (i.e., those who prefer anonymity).
      Further research is required to obtain the views of research ethics committees
      and research participants on these issues. Dialogue between researchers and
      ethics committees is necessary to address the need to ensure safety while also
      advancing the timely development of effective interventions in this critical
      area.
FAU - Bailey, Eleanor
AU  - Bailey E
AUID- ORCID: 0000-0003-4918-1618
AD  - Orygen, Locked Bag 10, 35 Poplar Road, Parkville, VIC, 3052, Australia.
      eleanor.bailey@orygen.org.au.
AD  - Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road,
      Parkville, VIC, 3052, Australia. eleanor.bailey@orygen.org.au.
AD  - Centre for Mental Health, Swinburne University of Technology, John St, Hawthorn, 
      VIC, 3122, Australia. eleanor.bailey@orygen.org.au.
FAU - Muhlmann, Charlotte
AU  - Muhlmann C
AD  - Danish Research Institute for Suicide Prevention, Mental Health Centre
      Copenhagen, Gentofte Hospitalsvej 15, 4. Sal, 2900, Hellerup, Denmark.
AD  - University of Copenhagen, Norregade 10, 1165, Kobenhavn, Denmark.
FAU - Rice, Simon
AU  - Rice S
AD  - Orygen, Locked Bag 10, 35 Poplar Road, Parkville, VIC, 3052, Australia.
AD  - Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road,
      Parkville, VIC, 3052, Australia.
FAU - Nedeljkovic, Maja
AU  - Nedeljkovic M
AD  - Centre for Mental Health, Swinburne University of Technology, John St, Hawthorn, 
      VIC, 3122, Australia.
FAU - Alvarez-Jimenez, Mario
AU  - Alvarez-Jimenez M
AD  - Orygen, Locked Bag 10, 35 Poplar Road, Parkville, VIC, 3052, Australia.
AD  - Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road,
      Parkville, VIC, 3052, Australia.
FAU - Sander, Lasse
AU  - Sander L
AD  - Department of Rehabilitation Psychology and Psychotherapy,
      Albert-Ludwigs-University Freiburg, Engelbergerstr. 41, D-79085, Freiburg,
      Germany.
FAU - Calear, Alison L
AU  - Calear AL
AD  - Centre for Mental Health Research, Research School of Population Health, The
      Australian National University, Canberra, ACT, 2061, Australia.
FAU - Batterham, Philip J
AU  - Batterham PJ
AD  - Centre for Mental Health Research, Research School of Population Health, The
      Australian National University, Canberra, ACT, 2061, Australia.
FAU - Robinson, Jo
AU  - Robinson J
AD  - Orygen, Locked Bag 10, 35 Poplar Road, Parkville, VIC, 3052, Australia.
AD  - Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road,
      Parkville, VIC, 3052, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200513
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Acceptance and Commitment Therapy
MH  - Adolescent
MH  - Adult
MH  - *Alcoholism
MH  - Australia
MH  - Cohort Studies
MH  - *Depressive Disorder, Major
MH  - Ethical Review
MH  - Ethics, Research
MH  - Humans
MH  - *Internet
MH  - Pilot Projects
MH  - *Suicide/prevention & control
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7222514
OTO - NOTNLM
OT  - *Ethics
OT  - *Internet
OT  - *Research
OT  - *Suicide
EDAT- 2020/05/15 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/15 06:00
PHST- 2019/09/04 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00479-1 [doi]
AID - 10.1186/s12910-020-00479-1 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 13;21(1):37. doi: 10.1186/s12910-020-00479-1.


PMID- 32404097
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 13
TI  - Too much safety? Safeguards and equal access in the context of voluntary assisted
      dying legislation.
PG  - 38
LID - 10.1186/s12910-020-00483-5 [doi]
AB  - BACKGROUND: In June 2019, the Australian state of Victoria joined the growing
      number of jurisdictions around the world to have legalised some form of voluntary
      assisted dying. A discourse of safety was prominent during the implementation of 
      the Victorian legislation. MAIN TEXT: In this paper, we analyse the ethical
      relationship between legislative "safeguards" and equal access. Drawing primarily
      on Ruger's model of equal access to health care services, we analyse the
      Victorian approach to voluntary assisted dying in terms of four dimensions:
      horizontal equity, patient agency, high quality care, and supportive social
      norms. We argue that some provisions framed as safeguards in the legislation
      create significant barriers to equal access for eligible patients. CONCLUSIONS:
      While safety is undoubtedly ethically important, we caution against an
      overemphasis on safeguarding in voluntary assisted dying legislation given the
      implications for equal access.
FAU - McDougall, Rosalind
AU  - McDougall R
AUID- ORCID: 0000-0002-3809-2575
AD  - Centre for Health Equity, Melbourne School of Population and Global Health,
      University of Melbourne, Level 4, 207 Bouverie St, Melbourne, VIC, 3010,
      Australia. rmcdo@unimelb.edu.au.
FAU - Pratt, Bridget
AU  - Pratt B
AD  - Centre for Health Equity, Melbourne School of Population and Global Health,
      University of Melbourne, Level 4, 207 Bouverie St, Melbourne, VIC, 3010,
      Australia.
LA  - eng
GR  - DE170100414/Australian Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200513
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Australia
MH  - Humans
MH  - *Patient Safety
MH  - Quality of Health Care
MH  - *Suicide, Assisted
PMC - PMC7222560
OTO - NOTNLM
OT  - *Equal access
OT  - *Equity
OT  - *Medical assistance in dying
OT  - *Voluntary assisted dying
EDAT- 2020/05/15 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/15 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00483-5 [doi]
AID - 10.1186/s12910-020-00483-5 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 13;21(1):38. doi: 10.1186/s12910-020-00483-5.


PMID- 32402532
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20210729
IS  - 2173-5727 (Electronic)
IS  - 2173-5727 (Linking)
VI  - 44
IP  - 7
DP  - 2020 Oct
TI  - [Ethical recommendations for a difficult decision-making in intensive care units 
      due to the exceptional situation of crisis by the COVID-19 pandemia: A rapid
      review & consensus of experts].
PG  - 439-445
LID - S0210-5691(20)30110-8 [pii]
LID - 10.1016/j.medin.2020.04.006 [doi]
AB  - In view of the exceptional public health situation caused by the COVID-19
      pandemic, a consensus work has been promoted from the ethics group of the Spanish
      Society of Intensive, Critical Medicine and Coronary Units (SEMICYUC), with the
      objective of finding some answers from ethics to the crossroads between the
      increase of people with intensive care needs and the effective availability of
      means.In a very short period, the medical practice framework has been changed to 
      a 'catastrophe medicine' scenario, with the consequent change in the
      decision-making parameters. In this context, the allocation of resources or the
      prioritization of treatment become crucial elements, and it is important to have 
      an ethical reference framework to be able to make the necessary clinical
      decisions. For this, a process of narrative review of the evidence has been
      carried out, followed by a unsystematic consensus of experts, which has resulted 
      in both the publication of a position paper and recommendations from SEMICYUC
      itself, and the consensus between 18 scientific societies and 5 institutes/chairs
      of bioethics and palliative care of a framework document of reference for general
      ethical recommendations in this context of crisis.
CI  - (c) 2020 Published by Elsevier Espana, S.L.U.
FAU - Rubio, O
AU  - Rubio O
AD  - Cuidados Intensivos, Althaia, Xarxa Assistencial Universitaria de Manresa,
      Manresa, Barcelona, Espana. Electronic address: orubio@althaia.cat.
FAU - Estella, A
AU  - Estella A
AD  - Cuidados Intensivos, Hospital Universitario de Jerez, Jerez de la Frontera,
      Cadiz, Espana.
FAU - Cabre, L
AU  - Cabre L
AD  - Cuidados Intensivos, Comite de Bioetica de Cataluna, Catalunya, Espana.
FAU - Saralegui-Reta, I
AU  - Saralegui-Reta I
AD  - Cuidados Intensivos, Hospital Universitario de Araba, Osakidetza Araba,
      Vitoria-Gasteiz, Espana.
FAU - Martin, M C
AU  - Martin MC
AD  - Servicio de Medicina Intensiva, Hospital Universitario de Torrejon, Torrejon de
      Ardoz, Madrid, Espana.
FAU - Zapata, L
AU  - Zapata L
AD  - Cuidados Intensivos, Hospital de la Santa Creu i Sant Pau, Barcelona, Espana.
FAU - Esquerda, M
AU  - Esquerda M
AD  - Instituto Borja de Bioetica, Esplugues de Llobregat, Barcelona, Espana.
FAU - Ferrer, R
AU  - Ferrer R
AD  - Servicio de Medicina Intensiva, Hospital Universitario Vall de Hebron, Barcelona,
      Espana.
FAU - Castellanos, A
AU  - Castellanos A
AD  - Area de Medicina Critica, Hospital Universitario y Politecnico La Fe, Valencia,
      Espana.
FAU - Trenado, J
AU  - Trenado J
AD  - Servicio de Medicina Intensiva, Hospital Universitario Mutua de Terrassa,
      Terrassa, Barcelona, Espana.
FAU - Amblas, J
AU  - Amblas J
AD  - Geriatria y Cuidados paliativos, Hospital Universitario de la Santa Creu de Vic, 
      Central Catalonia Chronicity Research Group (C3RG), Universitat de Vic-UCC, Vic, 
      Barcelona, Espana.
LA  - spa
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Practice Guideline
PT  - Review
TT  - Recomendaciones eticas para la toma de decisiones dificiles en las unidades de
      cuidados intensivos ante la situacion excepcional de crisis por la pandemia por
      COVID-19: revision rapida y consenso de expertos.
DEP - 20200415
PL  - Spain
TA  - Med Intensiva (Engl Ed)
JT  - Medicina intensiva
JID - 101717568
SB  - IM
CIN - Med Intensiva (Engl Ed). 2021 Aug-Sep;45(6):381-382. PMID: 34294237
CIN - Med Intensiva (Engl Ed). 2021 Aug-Sep;45(6):382. PMID: 34294238
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Clinical Decision-Making
MH  - Coronavirus Infections/*epidemiology/therapy
MH  - Critical Care/*ethics/methods/psychology/standards
MH  - Ethics Committees
MH  - Health Services Needs and Demand
MH  - Hospital Bed Capacity
MH  - Humans
MH  - *Intensive Care Units
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/therapy
MH  - Precision Medicine
MH  - Resource Allocation/ethics/standards
MH  - Respiration, Artificial
MH  - SARS-CoV-2
MH  - Societies, Scientific
MH  - Spain/epidemiology
MH  - Triage/ethics/standards
PMC - PMC7158790
OTO - NOTNLM
OT  - *Catastrophe
OT  - *Crisis care
OT  - *Ethics
OT  - *ICU
OT  - *Pandemic
EDAT- 2020/05/14 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - S0210-5691(20)30110-8 [pii]
AID - 10.1016/j.medin.2020.04.006 [doi]
PST - ppublish
SO  - Med Intensiva (Engl Ed). 2020 Oct;44(7):439-445. doi:
      10.1016/j.medin.2020.04.006. Epub 2020 Apr 15.


PMID- 32402511
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20210119
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 95
IP  - 6
DP  - 2020 Jun
TI  - COVID-19 Ethics and Research.
PG  - 1119-1123
LID - S0025-6196(20)30389-X [pii]
LID - 10.1016/j.mayocp.2020.04.019 [doi]
FAU - Meagher, Karen M
AU  - Meagher KM
AD  - Division of Health Care Policy and Research, Department of Health Sciences
      Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Electronic
      address: Meagher.Karen@mayo.edu.
FAU - Cummins, Nathan W
AU  - Cummins NW
AD  - Division of Infectious Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 
      55905.
FAU - Bharucha, Adil E
AU  - Bharucha AE
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW,
      Rochester, MN 55905.
FAU - Badley, Andrew D
AU  - Badley AD
AD  - Division of Infectious Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 
      55905.
FAU - Chlan, Linda L
AU  - Chlan LL
AD  - Department of Nursing, Mayo Clinic College of Medicine and Science, Mayo Clinic, 
      200 First Street SW, Rochester, MN 55905.
FAU - Wright, R Scott
AU  - Wright RS
AD  - Department of Cardiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200424
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
SB  - IM
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - *Clinical Trials as Topic/ethics/methods/organization & administration
MH  - *Coronavirus Infections/epidemiology/prevention & control/therapy
MH  - *Ethics, Research
MH  - Global Health/ethics
MH  - Humans
MH  - Needs Assessment
MH  - Pandemics/*prevention & control
MH  - Patient Selection/ethics
MH  - *Pneumonia, Viral/epidemiology/prevention & control/therapy
MH  - *Research/organization & administration/standards
MH  - SARS-CoV-2
PMC - PMC7180345
EDAT- 2020/05/14 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - S0025-6196(20)30389-X [pii]
AID - 10.1016/j.mayocp.2020.04.019 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2020 Jun;95(6):1119-1123. doi: 10.1016/j.mayocp.2020.04.019. Epub
      2020 Apr 24.


PMID- 32402503
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1532-821X (Electronic)
IS  - 0003-9993 (Linking)
VI  - 101
IP  - 11
DP  - 2020 Nov
TI  - Retractions in Rehabilitation and Sport Sciences Journals: A Systematic Review.
PG  - 1980-1990
LID - S0003-9993(20)30208-2 [pii]
LID - 10.1016/j.apmr.2020.03.010 [doi]
AB  - OBJECTIVE: To identify the characteristics of retracted publications in
      rehabilitation and sport sciences journals. DATA SOURCES: The Web of Science,
      PubMed, and Retraction Watch databases were searched from inception to August
      2019. STUDY SELECTION: Retracted publications published in rehabilitation or
      sport sciences journals, indexed in the Science Citation Index Expanded (SCIE)
      and Social Sciences Citation Index (SSCI) were included. DATA EXTRACTION: One
      author extracted the data. Two other authors checked the data. DATA SYNTHESIS: A 
      total of 37 and 52 retracted publications and their retraction notices were
      identified for rehabilitation and sport sciences, respectively. The majority of
      retracted publications (68% of all retracted papers in rehabilitation and 54% of 
      all retracted papers in sport sciences) were published in the past decade.
      Retracted publications in rehabilitation and sport sciences were published in 21 
      and 22 different journals and originated from 18 and 21 different countries,
      respectively. The full-text of the retracted publications was available with a
      retraction watermark or note for 59% of cases in rehabilitation and 58% in sport 
      sciences. The reasons for the retractions were more often attributed to
      misconduct (79% and 61%) than to honest error (21% and 39%) in rehabilitation and
      sport sciences, respectively. However, a reason was not stated for 15% of the
      publications. The median time interval between publication and retraction was 622
      days in rehabilitation and 607 days in sport sciences publications. CONCLUSIONS: 
      The total number of retracted publications in rehabilitation and sport sciences
      journals was small. The retracted publications have been published in a variety
      of rehabilitation and sport sciences journals and came from different countries
      across the world. Several retracted publications and retraction notices failed to
      adhere to The Committee on Publication Ethics guidelines in the handling of
      full-text (retain with a watermark or note) or stating the underlying reasons for
      the retraction.
CI  - Copyright (c) 2020 American Congress of Rehabilitation Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Kardes, Sinan
AU  - Kardes S
AD  - Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine,
      Istanbul University, Istanbul, Turkey. Electronic address:
      sinan.kardes@istanbul.edu.tr.
FAU - Levack, William
AU  - Levack W
AD  - Rehabilitation Teaching and Research Unit, Department of Medicine, University of 
      Otago, Wellington, New Zealand.
FAU - Ozkuk, Kagan
AU  - Ozkuk K
AD  - Department of Medical Ecology and Hydroclimatology, Faculty of Medicine, Usak
      University, Usak, Turkey.
FAU - Atmaca Aydin, Ebru
AU  - Atmaca Aydin E
AD  - Department of Medical Ecology and Hydroclimatology, Antalya Training and Research
      Hospital, University of Health Sciences, Antalya, Turkey.
FAU - Seringec Karabulut, Serap
AU  - Seringec Karabulut S
AD  - Department of Medical Ecology and Hydroclimatology, Gaziosmanpasa Training and
      Research Hospital, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200510
PL  - United States
TA  - Arch Phys Med Rehabil
JT  - Archives of physical medicine and rehabilitation
JID - 2985158R
SB  - IM
MH  - Humans
MH  - Periodicals as Topic/*statistics & numerical data
MH  - Physical and Rehabilitation Medicine/*statistics & numerical data
MH  - *Retraction of Publication as Topic
MH  - Sports Medicine/*statistics & numerical data
OTO - NOTNLM
OT  - *Ethics
OT  - *Physical and rehabilitation medicine
OT  - *Plagiarism
OT  - *Rehabilitation
OT  - *Retracted publication
OT  - *Retraction of publication
OT  - *Scientific misconduct
OT  - *Sports medicine
EDAT- 2020/05/14 06:00
MHDA- 2021/01/14 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/09/27 00:00 [received]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - S0003-9993(20)30208-2 [pii]
AID - 10.1016/j.apmr.2020.03.010 [doi]
PST - ppublish
SO  - Arch Phys Med Rehabil. 2020 Nov;101(11):1980-1990. doi:
      10.1016/j.apmr.2020.03.010. Epub 2020 May 10.


PMID- 32402392
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1528-3968 (Electronic)
IS  - 0029-6554 (Linking)
VI  - 68
IP  - 5
DP  - 2020 Sep - Oct
TI  - The potential of digital phenotyping to advance the contributions of mobile
      health to self-management science.
PG  - 548-559
LID - S0029-6554(19)30442-7 [pii]
LID - 10.1016/j.outlook.2020.03.007 [doi]
AB  - Digital phenotyping consists of moment-by-moment quantification of behavioral
      data from individual people, typically collected passively from smartphones and
      other sensors. Within the evolving context of precision health, digital
      phenotyping can advance the use of mobile health -based self-management tools and
      interventions by enabling more accurate prediction for prevention and treatment, 
      facilitating supportive strategies, and informing the development of features to 
      motivate self-management behaviors within real-world conditions. This represents 
      an advancement in self-management science: with digital phenotyping, nurse
      scientists have opportunities to tailor interventions with increased precision.
      In this paper, we discuss the emergence of digital phenotyping, the historical
      background of ecological momentary assessment, and the current state of the
      science of digital phenotyping, with implications for research design,
      computational requirements, and ethical considerations in self-management
      science, as well as limitations.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Radhakrishnan, Kavita
AU  - Radhakrishnan K
AD  - School of Nursing, The University of Texas - Austin, Austin, TX. Electronic
      address: kradhakrishnan@mail.nur.utexas.edu.
FAU - Kim, Miyong T
AU  - Kim MT
AD  - School of Nursing, The University of Texas - Austin, Austin, TX.
FAU - Burgermaster, Marissa
AU  - Burgermaster M
AD  - Department of Population Health, The University of Texas - Austin, Austin, TX;
      Department of Nutritional Sciences, The University of Texas - Austin, Austin, TX.
FAU - Brown, Richard Allen
AU  - Brown RA
AD  - School of Nursing, The University of Texas - Austin, Austin, TX.
FAU - Xie, Bo
AU  - Xie B
AD  - School of Nursing, The University of Texas - Austin, Austin, TX; School of
      Information, The University of Texas - Austin, Austin, TX.
FAU - Bray, Molly S
AU  - Bray MS
AD  - School of Nutrition, Department of Pediatrics, The University of Texas - Austin, 
      Austin, TX.
FAU - Fournier, Catherine A
AU  - Fournier CA
AD  - School of Nursing, The University of Texas - Austin, Austin, TX.
LA  - eng
GR  - P30 NR015335/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200508
PL  - United States
TA  - Nurs Outlook
JT  - Nursing outlook
JID - 0401075
SB  - IM
MH  - Ecological Momentary Assessment
MH  - Humans
MH  - *Phenotype
MH  - *Precision Medicine
MH  - *Self-Management
MH  - *Telemedicine
MH  - Wearable Electronic Devices
OTO - NOTNLM
OT  - *Digital phenotyping
OT  - *Mhealth
OT  - *Precision medicine
OT  - *Self-management interventions
EDAT- 2020/05/14 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/07/11 00:00 [received]
PHST- 2020/03/21 00:00 [revised]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - S0029-6554(19)30442-7 [pii]
AID - 10.1016/j.outlook.2020.03.007 [doi]
PST - ppublish
SO  - Nurs Outlook. 2020 Sep - Oct;68(5):548-559. doi: 10.1016/j.outlook.2020.03.007.
      Epub 2020 May 8.


PMID- 32401892
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 1983-1447 (Electronic)
IS  - 0102-6933 (Linking)
VI  - 41
IP  - spe
DP  - 2020
TI  - Performance of nurses/nursing team in the dispensing of materials for users of
      home care services.
PG  - e20190151
LID - S1983-14472020000200416 [pii]
LID - 10.1590/1983-1447.2020.20190151 [doi]
AB  - OBJECTIVE: To contextualize the performance of nurses/nursing team in the
      dispensing of materials to assist users in home visits, in primary care. METHODS:
      Dialectical qualitative study conducted between March and April 2018 in which 24 
      nurses from primary health care units in the Gloria/Cruzeiro/Cristal District of 
      Porto Alegre, Rio Grande do Sul, completed the self-administered questionnaire,
      whose data were treated by thematic content analysis. The study was approved by
      the Research Ethics Committee. RESULTS: Two categories emerged from the empirical
      corpus: logistic chain of material management for home user assistance;
      production of services and capacity of the team. CONCLUSION: The work processes
      related to materials management for home user assistance and the resulting health
      services production require a look at specificities such as workload and
      technologies involved, as they move the performance of the nurse/nursing staff.
FAU - Freitas, Priscila de Carvalho
AU  - Freitas PC
AD  - Escola de Enfermagem, Universidade Federal do Rio Grande do Sul, Porto Alegre,
      Rio Grande do Sul, Brasil.
FAU - Galdino, Daniel Magno
AU  - Galdino DM
AD  - Escola de Enfermagem, Universidade Federal do Rio Grande do Sul, Porto Alegre,
      Rio Grande do Sul, Brasil.
FAU - Grillo, Maria de Fatima
AU  - Grillo MF
AD  - Unidade Basica de Saude Santa Cecilia, Hospital de Clinicas de Porto Alegre,
      Porto Alegre, Rio Grande do Sul, Brasil.
FAU - Duro, Carmen Lucia Mottin
AU  - Duro CLM
AD  - Escola de Enfermagem, Universidade Federal do Rio Grande do Sul, Porto Alegre,
      Rio Grande do Sul, Brasil.
FAU - Duarte, Erica Rosalba Mallmann
AU  - Duarte ERM
AD  - Escola de Enfermagem, Universidade Federal do Rio Grande do Sul, Porto Alegre,
      Rio Grande do Sul, Brasil.
FAU - Kaiser, Dagmar Elaine
AU  - Kaiser DE
AD  - Escola de Enfermagem, Universidade Federal do Rio Grande do Sul, Porto Alegre,
      Rio Grande do Sul, Brasil.
LA  - por
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Brazil
TA  - Rev Gaucha Enferm
JT  - Revista gaucha de enfermagem
JID - 8504882
MH  - Brazil
MH  - *Home Care Services
MH  - *House Calls
MH  - Humans
MH  - *Nursing, Team
MH  - *Primary Health Care
MH  - Qualitative Research
EDAT- 2020/05/14 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/04/05 00:00 [received]
PHST- 2019/06/09 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - S1983-14472020000200416 [pii]
AID - 10.1590/1983-1447.2020.20190151 [doi]
PST - ppublish
SO  - Rev Gaucha Enferm. 2020;41(spe):e20190151. doi: 10.1590/1983-1447.2020.20190151. 
      Epub 2020 Apr 30.


PMID- 32401227
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 48
IP  - 5
DP  - 2020 Jun 25
TI  - Professionally responsible counseling about birth location during the COVID-19
      pandemic.
PG  - 450-452
LID - 10.1515/jpm-2020-0183 [doi]
LID - /j/jpme.2020.48.issue-5/jpm-2020-0183/jpm-2020-0183.xml [pii]
AB  - If the worries about the coronavirus disease 2019 (COVID-19) pandemic are not
      already enough, some pregnant women have been questioning whether the hospital is
      a safe or safe enough place to deliver their babies and therefore whether they
      should deliver out-of-hospital during the pandemic. In the United States, planned
      out-of-hospital births are associated with significantly increased risks of
      neonatal morbidity and death. In addition, there are obstetric emergencies during
      out-of-hospital births that can lead to adverse outcomes, partly because of the
      delay in transporting the woman to the hospital. In other countries with
      well-integrated obstetric services and well-trained midwives, the differences in 
      outcomes of planned hospital birth and planned home birth are smaller. Women are 
      empowered to make informed decisions when the obstetrician makes ethically
      justified recommendations, which is known as directive counseling.
      Recommendations are ethically justified when the outcomes of one form of
      management is clinically superior to another. The outcomes of morbidity and
      mortality and of infection control and prevention of planned hospital birth are
      clinically superior to those of out-of-hospital birth. The obstetrician therefore
      should recommend planned hospital birth and recommend against planned
      out-of-hospital birth during the COVID-19 pandemic. The COVID-19 pandemic has
      increased stress levels for all patients and even more so for pregnant patients
      and their families. The response in this difficult time should be to mitigate
      this stress and empower women to make informed decisions by routinely providing
      counseling that is evidence-based and directive.
FAU - Grunebaum, Amos
AU  - Grunebaum A
AD  - Department of Obstetrics and Gynecology, Lenox Hill Hospital, 100 East 77St., New
      York, NY 10075, USA.
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, NY, USA.
FAU - McCullough, Laurence B
AU  - McCullough LB
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, NY, USA.
FAU - Bornstein, Eran
AU  - Bornstein E
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, NY, USA.
FAU - Klein, Risa
AU  - Klein R
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, NY, USA.
FAU - Dudenhausen, Joachim W
AU  - Dudenhausen JW
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, NY, USA.
AD  - Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, New York,
      NY, USA.
AD  - Faculty of Health Sciences Brandenburg, Potsdam, Germany.
FAU - Chervenak, Frank A
AU  - Chervenak FA
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, NY, USA.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
SB  - IM
MH  - *Betacoronavirus
MH  - *Birth Setting
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Delivery, Obstetric/ethics/methods
MH  - Directive Counseling/ethics/*methods
MH  - Evidence-Based Medicine
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Patient Participation/methods
MH  - Patient Safety
MH  - Pneumonia, Viral/*prevention & control
MH  - Pregnancy
MH  - Prenatal Care/ethics/*methods
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - birth center
OT  - birth location
OT  - counseling
OT  - home birth
OT  - professional ethics in obstetrics
OT  - professional virtue of integrity
OT  - public health emergency
EDAT- 2020/05/14 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1515/jpm-2020-0183 [doi]
AID - /j/jpme.ahead-of-print/jpm-2020-0183/jpm-2020-0183.xml [pii]
PST - ppublish
SO  - J Perinat Med. 2020 Jun 25;48(5):450-452. doi: 10.1515/jpm-2020-0183.


PMID- 32401204
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210210
IS  - 2148-3817 (Electronic)
IS  - 1308-7649 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Apr
TI  - Grading of the Position of the Mastoid Tegmen in Human Temporal Bones - A
      Surgeon's Perspective.
PG  - 63-66
LID - 10.5152/iao.2020.7748 [doi]
AB  - OBJECTIVES: To establish a new surgically relevant classification system of the
      anatomic variations of the temporal bone tegmen plate as well as to perform a
      comparative analysis, with respect to the pneumatization patterns in the
      cadaveric temporal bones. MATERIALS AND METHODS: Microdissection of the human
      cadaveric temporal bones was performed after obtaining ethical approval from the 
      Institutional Ethical Committee (F.8-522/A-522/2017/RS). The pneumatization
      pattern of the temporal bones was noted as "under-pneumatized" or
      "well-pneumatized." The tegmen mastoid (TM) was classified into two grades as per
      the position of the tegmen plate and the visibility of the superior semicircular 
      canal (SSCC) and the aditus. The latter two structures were well visualized in
      Grade A and poorly visualized in Grade B. The data were analyzed using Stata 14.0
      (Stata Corp, 4905, Lakway drive, College Station, Texas, USA). RESULTS:
      Ninety-three temporal bones were dissected under microscope. Fifty-eight bones
      were well-pneumatized and 35 were under-pneumatized. The tegmen plates were
      classified as Grade-A in 49 bones (well-pneumatized -37 and under-pneumatized
      -12), and as Grade-B in 44 bones (well-pneumatized-21, poorly-pneumatized-23).
      Grade-A classification was significantly more common in well-pneumatized temporal
      bones, while Grade-B was more common in under-pneumatized bones (p=0.0057).
      CONCLUSION: We propose a surgically relevant classification for TM positioning. A
      well-pneumatized temporal bone is associated with a significantly higher position
      of the tegmen plate (Grade-A TM).
FAU - Singh, Anup
AU  - Singh A
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute 
      of Medical Sciences, New Delhi, India.
FAU - Thakur, Rishikesh
AU  - Thakur R
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute 
      of Medical Sciences, New Delhi, India.
FAU - Kumar, Rajeev
AU  - Kumar R
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute 
      of Medical Sciences, New Delhi, India.
FAU - Verma, Hitesh
AU  - Verma H
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute 
      of Medical Sciences, New Delhi, India.
FAU - Irugu, David Victor Kumar
AU  - Irugu DVK
AD  - Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute 
      of Medical Sciences, New Delhi, India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Turkey
TA  - J Int Adv Otol
JT  - The journal of international advanced otology
JID - 101522982
SB  - IM
MH  - Anatomic Landmarks/anatomy & histology
MH  - Anatomic Variation/*physiology
MH  - Cadaver
MH  - Classification/methods
MH  - Humans
MH  - Mastoid/anatomy & histology/*surgery/ultrastructure
MH  - Microdissection/*methods
MH  - Otologic Surgical Procedures/methods
MH  - Semicircular Canals/surgery
MH  - Surgeons/education
MH  - Temporal Bone/anatomy & histology/*surgery/ultrastructure
PMC - PMC7224437
EDAT- 2020/05/14 06:00
MHDA- 2021/02/11 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
AID - 10.5152/iao.2020.7748 [doi]
PST - ppublish
SO  - J Int Adv Otol. 2020 Apr;16(1):63-66. doi: 10.5152/iao.2020.7748.


PMID- 32400943
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20201218
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Ethical framework for head and neck endocrine surgery in the COVID-19 pandemic.
PG  - 1418-1419
LID - 10.1002/hed.26240 [doi]
FAU - Chen, Amy Y
AU  - Chen AY
AUID- ORCID: https://orcid.org/0000-0003-3563-6343
AD  - Emory University, Atlanta, Georgia, USA.
FAU - Shindo, Maisie
AU  - Shindo M
AD  - Oregon Health Sciences University, Portland, Oregon, USA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
SB  - IM
MH  - COVID-19
MH  - Communicable Disease Control/methods
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Elective Surgical Procedures/*ethics/methods
MH  - Endocrine Surgical Procedures/*ethics/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Occupational Health
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Patient Safety
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Risk Assessment
MH  - Time-to-Treatment/*ethics
MH  - United States
PMC - PMC7272909
EDAT- 2020/05/14 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1002/hed.26240 [doi]
PST - ppublish
SO  - Head Neck. 2020 Jul;42(7):1418-1419. doi: 10.1002/hed.26240. Epub 2020 May 13.


PMID- 32400880
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 1930-6180 (Electronic)
IS  - 1084-2020 (Linking)
VI  - 60
IP  - 2
DP  - 2020 Oct 19
TI  - The Influence of Behavioral, Social, and Environmental Factors on Reproducibility
      and Replicability in Aquatic Animal Models.
PG  - 270-288
LID - 10.1093/ilar/ilz019 [doi]
AB  - The publication of reproducible, replicable, and translatable data in studies
      utilizing animal models is a scientific, practical, and ethical necessity. This
      requires careful planning and execution of experiments and accurate reporting of 
      results. Recognition that numerous developmental, environmental, and test-related
      factors can affect experimental outcomes is essential for a quality study design.
      Factors commonly considered when designing studies utilizing aquatic animal
      species include strain, sex, or age of the animal; water quality; temperature;
      and acoustic and light conditions. However, in the aquatic environment, it is
      equally important to consider normal species behavior, group dynamics, stocking
      density, and environmental complexity, including tank design and structural
      enrichment. Here, we will outline normal species and social behavior of 2
      commonly used aquatic species: zebrafish (Danio rerio) and Xenopus (X. laevis and
      X. tropicalis). We also provide examples as to how these behaviors and the
      complexity of the tank environment can influence research results and provide
      general recommendations to assist with improvement of reproducibility and
      replicability, particularly as it pertains to behavior and environmental
      complexity, when utilizing these popular aquatic models.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      National Academies of Sciences, Engineering, and Medicine. All rights reserved.
      For permissions, please email: journals.permissions@oup.com.
FAU - Lieggi, Christine
AU  - Lieggi C
AD  - Center of Comparative Medicine and Pathology, Memorial Sloan Kettering Cancer
      Center, Weill Cornell Medicine, and Hospital for Special Surgery, New York, New
      York.
FAU - Kalueff, Allan V
AU  - Kalueff AV
AD  - School of Pharmacy, Southwest University, Chongqing, China, and Ural Federal
      University, Ekaterinburg, Russia.
FAU - Lawrence, Christian
AU  - Lawrence C
AD  - Boston Children's Hospital, Boston, Massachusetts.
FAU - Collymore, Chereen
AU  - Collymore C
AD  - University of Ottawa, Ottawa, Ontario, Canada.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30 DK049216/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - ILAR J
JT  - ILAR journal
JID - 9516416
SB  - IM
MH  - Animal Welfare/statistics & numerical data
MH  - Animals
MH  - Behavior, Animal/physiology
MH  - Housing, Animal/statistics & numerical data
MH  - Models, Animal
MH  - Reproducibility of Results
MH  - Xenopus/physiology
MH  - Zebrafish/*physiology
PMC - PMC7743897
OTO - NOTNLM
OT  - *behavior
OT  - *enrichment
OT  - *husbandry
OT  - *neurobehavior
OT  - *replicability
OT  - *reproducibility
OT  - *xenopus; zebrafish
EDAT- 2020/05/14 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/05/14 06:00
PHST- 2018/02/28 00:00 [received]
PHST- 2019/08/08 00:00 [revised]
PHST- 2019/09/11 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 5836534 [pii]
AID - 10.1093/ilar/ilz019 [doi]
PST - ppublish
SO  - ILAR J. 2020 Oct 19;60(2):270-288. doi: 10.1093/ilar/ilz019.


PMID- 32400291
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20201218
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Should Extremely Premature Babies Get Ventilators During the COVID-19 Crisis?
PG  - 37-43
LID - 10.1080/15265161.2020.1764134 [doi]
AB  - In a crisis, societal needs take precedence over a patient's best interests.
      Triage guidelines, however, differ on whether limited resources should focus on
      maximizing lives or life-years. Choosing between these two approaches has
      implications for neonatology. Neonatal units have ventilators, some adaptable for
      adults. This raises the question of whether, in crisis conditions, guidelines for
      treating extremely premature babies should be altered to free-up ventilators.
      Some adults who need ventilators will have a survival rate higher than some
      extremely premature babies. But surviving babies will likely live longer,
      maximizing life-years. Empiric evidence demonstrates that these babies can derive
      significant survival benefits from ventilation when compared to adults. When
      "triaging" or choosing between patients, justice demands fair guidelines.
      Premature babies do not deserve special consideration; they deserve equal
      consideration. Solidarity is crucial but must consider needs specific to patient 
      populations and avoid biases against people with disabilities and extremely
      premature babies.
FAU - Haward, Marlyse F
AU  - Haward MF
AD  - Albert Einstein College of Medicine.
FAU - Janvier, Annie
AU  - Janvier A
AD  - Universite de Montreal.
AD  - CHU Sainte-Justine.
FAU - Moore, Gregory P
AU  - Moore GP
AD  - Children's Hospital of Eastern Ontario.
AD  - University of Ottawa.
FAU - Laventhal, Naomi
AU  - Laventhal N
AD  - University of Michigan.
FAU - Fry, Jessica T
AU  - Fry JT
AD  - Ann & Robert H. Lurie Children's Hospital of Chicago.
AD  - Northwestern University Feinberg School of Medicine.
FAU - Lantos, John
AU  - Lantos J
AD  - Children's Mercy Bioethics Center.
AD  - Children's Mercy Hospital.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200513
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jul;20(7):182-184. PMID: 32716766
CIN - Am J Bioeth. 2020 Jul;20(7):177-180. PMID: 32716769
CIN - Am J Bioeth. 2020 Jul;20(7):180-182. PMID: 32716773
CIN - Am J Bioeth. 2020 Jul;20(7):122-124. PMID: 32716776
CIN - Am J Bioeth. 2020 Jul;20(7):98-101. PMID: 32716792
CIN - Am J Bioeth. 2020 Jul;20(7):174-177. PMID: 32716796
CIN - Am J Bioeth. 2020 Jul;20(7):147-150. PMID: 32716804
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Female
MH  - Humans
MH  - *Infant, Extremely Premature
MH  - Infant, Newborn
MH  - Male
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/*therapy
MH  - Respiration, Artificial/*ethics
MH  - SARS-CoV-2
MH  - Triage/*ethics
OTO - NOTNLM
OT  - *COVID-19
OT  - *Health care delivery
OT  - *ethics
OT  - *justice
OT  - *neonatology
OT  - *rationing
EDAT- 2020/05/14 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1080/15265161.2020.1764134 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jul;20(7):37-43. doi: 10.1080/15265161.2020.1764134. Epub 2020 
      May 13.


PMID- 32400273
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1757-9767 (Electronic)
IS  - 1757-9759 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Dec
TI  - Developing the culture of ethics in population health intervention research in
      Canada.
PG  - 69-77
LID - 10.1177/1757975920913547 [doi]
AB  - Population health intervention research (PHIR) is a particular field of health
      research that aims to generate knowledge that contributes to the sustainable
      improvement of population health by enabling the implementation of cross-sectoral
      solutions adapted to social realities. Despite the ethical issues that
      necessarily raise its social agenda, the ethics of PHIR is still not very
      formalized. Unresolved ethical challenges may limit its focus on health equity.
      This contribution aims to highlight some of these issues and calls on researchers
      to develop a culture of ethics in PHIR. Three complementary ways are proposed: to
      build an ethical concept specific to this field, to promote a shared space for
      critical reflection on PHIR ethics, and to develop the ethical competence in PHIR
      for which a preliminary framework is proposed.
FAU - Hamelin, Anne-Marie
AU  - Hamelin AM
AUID- ORCID: 0000-0001-8662-2043
AD  - Universite McGill, Montreal, Canada.
FAU - Caux, Chantal
AU  - Caux C
AD  - Universite de Montreal, Montreal, Canada.
FAU - Desy, Michel
AU  - Desy M
AD  - Institut national de sante publique du Quebec, Montreal, Canada.
FAU - Guichard, Anne
AU  - Guichard A
AD  - Universite Laval, Quebec City, Canada.
FAU - Ouedraogo, Samiratou
AU  - Ouedraogo S
AD  - Universite McGill, Montreal, Canada.
FAU - Tremblay, Marie-Claude
AU  - Tremblay MC
AD  - Universite Laval, Quebec City, Canada.
FAU - Vissandjee, Bilkis
AU  - Vissandjee B
AD  - Universite de Montreal, Montreal, Canada.
FAU - Godard, Beatrice
AU  - Godard B
AUID- ORCID: 0000-0003-1980-7755
AD  - Universite de Montreal, Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - England
TA  - Glob Health Promot
JT  - Global health promotion
JID - 101497462
SB  - IM
MH  - Canada
MH  - Ethics, Research
MH  - Humans
MH  - *Population Health
MH  - Research Design
MH  - Research Personnel
OTO - NOTNLM
OT  - *Ethics
OT  - *competences
OT  - *equity
OT  - *population and public health
OT  - *population health intervention research
EDAT- 2020/05/14 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1177/1757975920913547 [doi]
PST - ppublish
SO  - Glob Health Promot. 2020 Dec;27(4):69-77. doi: 10.1177/1757975920913547. Epub
      2020 May 13.


PMID- 32400261
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - The inequity of conscientious objection: Refusal of emergency contraception.
PG  - 1408-1417
LID - 10.1177/0969733020918926 [doi]
AB  - In the medical field, conscientious objection is claimed by providers and
      pharmacists in an attempt to forgo administering select forms of sexual and
      reproductive healthcare services because they state it goes against their moral
      integrity. Such claim of conscientious objection may include refusing to
      administer emergency contraception to an individual with a medical need that is
      time-sensitive. Conscientious objection is first defined, and then a historical
      context is provided on the medical field's involvement with the issue. An
      explanation of emergency contraception's physiological effects is provided along 
      with historical context of the use on emergency contraception in terms of United 
      States Law. A comparison is given between the United States and other developed
      countries in regard to conscientious objection. Once an understanding of
      conscientious objection and emergency contraception is presented, arguments
      supporting and contradicting the claim are described. Opinions supporting
      conscientious objection include the support of moral integrity, religious
      diversity, and less regulation on government involvement in state law will be
      offered. Finally, arguments against the effects of conscientious objection with
      emergency contraception are explained in terms of financial implications and
      other repercussions for people in lower socioeconomic status groups, especially
      people of color. Although every clinician has the right and responsibility to
      treat according to their sense of responsibility or conscience, the ethical
      consequences of living by one's conscience are limiting and negatively impact
      underprivileged groups of people. It is the aim of this article to advocate
      against the use of provider's and pharmacist's right to claim conscientious
      objection due to the inequitable impact the practice has on people of color and
      individuals with lower incomes.
FAU - Yang, Chelsey
AU  - Yang C
AUID- ORCID: https://orcid.org/0000-0003-4777-2334
AD  - 15760Columbia University, USA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Conscientious Refusal to Treat/*ethics/legislation & jurisprudence
MH  - Contraception, Postcoital/methods/*psychology
MH  - Human Rights/standards
MH  - Humans
MH  - Religion and Medicine
OTO - NOTNLM
OT  - Conscientious objection
OT  - emergency contraception
OT  - people of color
OT  - pharmacists
OT  - refusal to treat
EDAT- 2020/05/14 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1177/0969733020918926 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1408-1417. doi: 10.1177/0969733020918926. Epub 2020
      May 13.


PMID- 32400121
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20220531
IS  - 1708-8208 (Electronic)
IS  - 1523-0899 (Linking)
VI  - 22
IP  - 4
DP  - 2020 Aug
TI  - Narrative review regarding the applicability, accuracy, and clinical outcome of
      flapless implant surgery with or without computer guidance.
PG  - 454-467
LID - 10.1111/cid.12901 [doi]
AB  - BACKGROUND: The advent of computer-guided surgery removed the need for complex
      surgical interventions such as extensive flap elevations, second stage implant
      exposure, and complications usually associated with conventional protocols.
      PURPOSE: (a) Analyze available literature reporting on applicability, accuracy,
      clinical outcome of flapless surgery with or without computer guidance. (b)
      Evaluate quality of studies, in terms of scientific level of evidence and ethical
      committee approval. MATERIALS AND METHODS: A PUBMED search was performed in July 
      2018. A first search was based on a general search string limited to "Dental
      Implants" and "flapless surgery." A second search focused on accuracy of
      computer-guided surgery using search string "Surgery, Computer-Assisted" or
      "guided surgery," and "Dental implants." The following inclusion criteria were
      applied: (a) studies in English; (b) human studies (excluding cadaver); (c)
      systematic reviews; (d) systematic reviews with meta-analysis. Reviews not
      mentioning accuracy were excluded in search 2. RESULTS: Nine reviews included in 
      total. Implant survival ranged between 89% and 100%. Early surgical and
      prosthetic complications reported in 9.1% to 36.4% of reviewed papers.
      Tooth-supported guides show more accuracy than bone or mucosa-supported guides.
      Fully guided surgery yields higher accuracy, with lower values for horizontal
      coronal, horizontal apical and angular deviation (1.00, 1.23, and 3.13 degrees
      mm, respectively) than those placed with half guided surgery (1.44, 1.91, and
      4.30 mm, respectively). Thirty-four of 71 human studies included in nine reviews,
      mentioned ethical committee approval or compliance with Declaration of Helsinki. 
      CONCLUSIONS: Guided flapless surgery is comparable to free-hand surgery in terms 
      of implant survival, marginal bone remodeling, and peri-implant variables.
      Clinicians advised to take care in all steps of the protocol, and include safety 
      margins around virtually planned implants. Regarding compliance with research
      ethics, we should question whether scientific reports of clinical trials
      performed without an ethical umbrella are trustworthy. Compliance of ethics
      standards is imperative for submitted research papers.
CI  - (c) 2020 The Authors. Clinical Implant Dentistry and Related Research Published
      by Wiley Periodicals LLC.
FAU - Naeini, Emitis Natali
AU  - Naeini EN
AUID- ORCID: https://orcid.org/0000-0003-0135-3177
AD  - Dental School, Faculty of Medicine and Health Sciences, University of Ghent,
      Department of Periodontolgy and Oral Implantology, Ghent, Belgium.
FAU - Atashkadeh, Mandana
AU  - Atashkadeh M
AD  - All Saints Green Dental Practice, Norwich, UK.
FAU - De Bruyn, Hugo
AU  - De Bruyn H
AD  - Faculty of Medicine and Health Sciences, University of Ghent, Department of
      Periodontology and Oral Implantology, Belgium.
AD  - Dental Department, Radboud University Medical Centre, Nijmegen, Gelderland, The
      Netherlands.
FAU - D'Haese, Jan
AU  - D'Haese J
AD  - Department of Periodontology and Implantology, Radboud University Medical Centre,
      Nijmegen, Gelderland, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200513
PL  - United States
TA  - Clin Implant Dent Relat Res
JT  - Clinical implant dentistry and related research
JID - 100888977
RN  - 0 (Dental Implants)
SB  - IM
MH  - Computers
MH  - Dental Implantation, Endosseous
MH  - *Dental Implants
MH  - Humans
MH  - *Surgery, Computer-Assisted
PMC - PMC7496427
OTO - NOTNLM
OT  - accuracy
OT  - complications
OT  - computer-assisted
OT  - dental implants
OT  - research ethics
EDAT- 2020/05/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/10/20 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1111/cid.12901 [doi]
PST - ppublish
SO  - Clin Implant Dent Relat Res. 2020 Aug;22(4):454-467. doi: 10.1111/cid.12901. Epub
      2020 May 13.


PMID- 32400087
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20220716
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?"
PG  - 1787-1794
LID - 10.1111/ajt.16000 [doi]
AB  - In the context of a rapidly evolving pandemic, multiple organizations have
      released guidelines stating that all organs from potential deceased donors with
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection should be 
      deferred, including from otherwise medically eligible donors found to have mild
      or asymptomatic SARS-CoV-2 discovered on routine donor screening. In this
      article, we critically examine the available data on the risk of transmission of 
      SARS-CoV-2 through organ transplantation. The isolation of SARS-CoV-2 from
      nonlung clinical specimens, the detection of SARS-CoV-2 in autopsy specimens,
      previous experience with the related coronaviruses SARS-CoV and MERS-CoV, and the
      vast experience with other common RNA respiratory viruses are all addressed.
      Taken together, these data provide little evidence to suggest the presence of
      intact transmissible SARS-CoV in organs that can potentially be transplanted,
      specifically liver and heart. Other considerations including ethical, financial, 
      societal, and logistical concerns are also addressed. We conclude that, for
      selected patients with high waitlist mortality, transplant programs should
      consider accepting heart or liver transplants from deceased donors with
      SARS-CoV-2 infection.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Kates, Olivia S
AU  - Kates OS
AUID- ORCID: https://orcid.org/0000-0003-4381-0049
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
FAU - Fisher, Cynthia E
AU  - Fisher CE
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
FAU - Rakita, Robert M
AU  - Rakita RM
AUID- ORCID: https://orcid.org/0000-0001-8105-8455
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
FAU - Reyes, Jorge D
AU  - Reyes JD
AD  - Division of Transplant Surgery, University of Washington, Seattle, Washington,
      USA.
FAU - Limaye, Ajit P
AU  - Limaye AP
AD  - Division of Allergy and Infectious Diseases, University of Washington, Seattle,
      Washington, USA.
LA  - eng
GR  - K23 HL143050/HL/NHLBI NIH HHS/United States
GR  - T32 AI118690/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20200611
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control/*transmission
MH  - Ethics, Medical
MH  - Heart/virology
MH  - Heart Transplantation/adverse effects/trends
MH  - Humans
MH  - Liver/virology
MH  - Liver Transplantation/adverse effects/trends
MH  - Lung/virology
MH  - Occupational Exposure
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control/*transmission
MH  - SARS-CoV-2
MH  - Severe Acute Respiratory Syndrome/prevention & control
MH  - *Tissue Donors
MH  - Tissue and Organ Procurement/ethics/*standards/*trends
MH  - Waiting Lists
PMC - PMC7272824
OTO - NOTNLM
OT  - donors and donation: deceased
OT  - donors and donation: donor-derived infections
OT  - editorial/personal viewpoint
OT  - ethics
OT  - ethics and public policy
OT  - infection and infectious agents - viral
OT  - infectious disease
OT  - organ acceptance
OT  - organ procurement and allocation
OT  - organ transplantation in general
EDAT- 2020/05/14 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1111/ajt.16000 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jul;20(7):1787-1794. doi: 10.1111/ajt.16000. Epub 2020 Jun 
      11.


PMID- 32399953
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - Introduction: Special Issue on Undergraduate Medical Education in Ethics and
      Professionalism.
PG  - 77-83
LID - 10.1007/s10730-020-09407-7 [doi]
FAU - Childs, Brian H
AU  - Childs BH
AD  - Mercer University School of Medicine, Savannah, GA, USA. Childs_bh@mercer.edu.
FAU - Rizvi, Nasser
AU  - Rizvi N
AD  - Mercer University School of Medicine, Savannah, GA, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Education, Medical, Undergraduate/*ethics/methods/trends
MH  - *Ethics, Medical
MH  - Humans
MH  - Professionalism/*trends
EDAT- 2020/05/14 06:00
MHDA- 2021/09/23 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1007/s10730-020-09407-7 [doi]
AID - 10.1007/s10730-020-09407-7 [pii]
PST - ppublish
SO  - HEC Forum. 2020 Jun;32(2):77-83. doi: 10.1007/s10730-020-09407-7.


PMID- 32399903
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20220716
IS  - 1420-9144 (Electronic)
IS  - 0036-6978 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Jun
TI  - [The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
PG  - 219-225
LID - 10.1007/s00048-020-00257-5 [doi]
AB  - This paper is part of Forum COVID-19: Perspectives in the Humanities and Social
      Sciences. The novel coronavirus (Sars-CoV-2) poses a huge challenge to the world 
      community. Knowledge about the virus and its properties is limited, but there is 
      a great need to base political and medical decisions on scientific knowledge.
      This situation is leading to a dynamization of research. A prominent example of
      such a development is SOLIDARITY. The epistemological dimensions of this trial,
      which is coordinated by the WHO, and the resulting ethical implications are
      discussed in this article.
FAU - Gadebusch Bondio, Mariacarla
AU  - Gadebusch Bondio M
AD  - Institute for Medical Humanities, UKB University Hospital Bonn,
      Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland. gadebusch.bondio@uni-bonn.de.
FAU - Marloth, Maria
AU  - Marloth M
AD  - University of Cologne, Faculty of Medicine and University Hospital Cologne,
      Department of Psychiatry, Germany, University of Cologne, Koln, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Die "historische Studie" SOLIDARITY als Antwort der Forschung auf die Sars-CoV-2 
      Pandemie.
PL  - Switzerland
TA  - NTM
JT  - NTM
JID - 0347631
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (lopinavir-ritonavir drug combination)
RN  - 2494G1JF75 (Lopinavir)
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 886U3H6UFF (Chloroquine)
RN  - O3J8G9O825 (Ritonavir)
RN  - OF5P57N2ZX (Alanine)
MH  - Adenosine Monophosphate/analogs & derivatives/therapeutic use
MH  - Alanine/analogs & derivatives/therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - *Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - Chloroquine/therapeutic use
MH  - *Clinical Trials as Topic/ethics/organization & administration
MH  - Coronavirus Infections/*drug therapy/*epidemiology
MH  - Drug Combinations
MH  - Editorial Policies
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - International Cooperation
MH  - Lopinavir/therapeutic use
MH  - *Pandemics
MH  - Pneumonia, Viral/*drug therapy/*epidemiology
MH  - Research Design
MH  - Ritonavir/therapeutic use
MH  - SARS-CoV-2
MH  - World Health Organization
PMC - PMC7216120
OTO - NOTNLM
OT  - *COVID-19
OT  - *Evidence-based medicine
OT  - *Research ethics
OT  - *SOLIDARITY
OT  - *WHO
EDAT- 2020/05/14 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1007/s00048-020-00257-5 [doi]
AID - 10.1007/s00048-020-00257-5 [pii]
PST - ppublish
SO  - NTM. 2020 Jun;28(2):219-225. doi: 10.1007/s00048-020-00257-5.


PMID- 32399648
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Beyond Money: Conscientious Objection in Medicine as a Conflict of Interests.
PG  - 229-243
LID - 10.1007/s11673-020-09976-9 [doi]
AB  - Conflict of interests (COIs) in medicine are typically taken to be financial in
      nature: it is often assumed that a COI occurs when a healthcare practitioner's
      financial interest conflicts with patients' interests, public health interests,
      or professional obligations more generally. Even when non-financial COIs are
      acknowledged, ethical concerns are almost exclusively reserved for financial
      COIs. However, the notion of "interests" cannot be reduced to its financial
      component. Individuals in general, and medical professionals in particular, have 
      different types of interests, many of which are non-financial in nature but can
      still conflict with professional obligations. The debate about healthcare
      delivery has largely overlooked this broader notion of interests. Here, we will
      focus on health practitioners' moral or religious values as particular types of
      personal interests involved in healthcare delivery that can generate COIs and on 
      conscientious objection in healthcare as the expression of a particular type of
      COI. We argue that, in the healthcare context, the COIs generated by interests of
      conscience can be as ethically problematic, and therefore should be treated in
      the same way, as financial COIs.
FAU - Giubilini, Alberto
AU  - Giubilini A
AD  - Wellcome Centre for Ethics and Humanities and Oxford Uehiro Centre for Practical 
      Ethics, University of Oxford, 16-17 St Ebbes Street, Littlegate House, Oxford,
      OX1 1PT, UK. alberto.giubilini@philosophy.ox.ac.uk.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Oxford Uehiro Centre for Practical Ethics and Wellcome Centre for Ethics and
      Humanities, University of Oxford, 16-17 St Ebbes Street, Littlegate House,
      Oxford, OX1 1PT, UK.
AD  - Melbourne Law School, University of Melbourne, Melbourne, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
GR  - 203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200512
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
CIN - J Bioeth Inq. 2021 Mar;18(1):177-180. PMID: 33405194
CIN - J Bioeth Inq. 2021 Mar;18(1):181-185. PMID: 33538935
MH  - *Conflict of Interest
MH  - Conscience
MH  - Female
MH  - Humans
MH  - Morals
MH  - Pharmaceutical Preparations
MH  - Pregnancy
MH  - Refusal to Treat
PMC - PMC7367904
OTO - NOTNLM
OT  - Conflicts of interests
OT  - Conscience
OT  - Conscientious objection
OT  - Professionalism
EDAT- 2020/05/14 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1007/s11673-020-09976-9 [doi]
AID - 10.1007/s11673-020-09976-9 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Jun;17(2):229-243. doi: 10.1007/s11673-020-09976-9. Epub 2020 
      May 12.


PMID- 32399328
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr 8
TI  - The Potential for Undue Patient Exposure during the Use of Telementoring
      Technology.
PG  - e7594
LID - 10.7759/cureus.7594 [doi]
AB  - Background Surgical telementoring holds great promise for safe and effective
      patient care and medical education, but recording and streaming audio and video
      introduces the potential for exposure of patient information. Physicians maintain
      an ethical responsibility to protect the privacy of patients, and privacy
      violations may carry significant legal liability. Despite the legal treatment of 
      violations as discrete, methods for quantifying and characterizing the exposure
      of patient information during procedural recordings are lacking. This study is
      the first to quantify the potential risk for violation of privacy when using a
      wearable, telementoring technology capable of video and audio recording during
      surgical procedures in various locations including the operating room,
      interventional radiology suite, and the intensive care unit. Methods A
      head-mounted recording device, Google Glass, was used to record routine
      neurosurgical and critical care procedures in a convenience sample of patients.
      Periods of maximal risk, including the beginning of procedures, were targeted.
      Recordings were manually coded for discrete instances of exposure of directly
      identifying information and indirectly identifying information. Results
      Twenty-two procedures were recorded for a total of 12 hours, during which 807
      directly identifiable exposures were found. The overall average rate of exposure 
      was 1.13 exposures per minute. Most exposures were full-face images (90%), names 
      (7%), or phone numbers (3%). Indirectly identifying exposures were found to be
      tattoos, genitals, and caretaker names. The rate of exposures was found to be
      lower in the operating room (OR) when compared to the intensive care unit (ICU)
      or interventional radiology (IR) suite (p = 0.0376). Conclusions High rates of
      potential privacy violations were discovered and found to be related the location
      of the procedure. Sterile draping of the face prior to recording, when
      appropriate, would mitigate most exposure risk, though patient names and unique
      tattoos may be an underappreciated source of potential exposure. This study
      establishes the most conservative baseline to compare techniques for preventing
      exposure of patient information on telementoring or video/audio
      recording/streaming platforms.
CI  - Copyright (c) 2020, Darrow et al.
FAU - Darrow, David P
AU  - Darrow DP
AD  - Neurosurgery, University of Minnesota, Minneapolis, USA.
FAU - Spano, Anthony
AU  - Spano A
AD  - Radiology, University of Minnesota, Minneapolis, USA.
FAU - Grande, Andrew
AU  - Grande A
AD  - Neurosurgery, University of Minnesota, Minneapolis, USA.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7212714
OTO - NOTNLM
OT  - hipaa
OT  - medical education
OT  - privacy
OT  - surgery
OT  - telementoring
OT  - video recording
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/14 06:00
MHDA- 2020/05/14 06:01
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/05/14 06:01 [medline]
AID - 10.7759/cureus.7594 [doi]
PST - epublish
SO  - Cureus. 2020 Apr 8;12(4):e7594. doi: 10.7759/cureus.7594.


PMID- 32399258
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 4
DP  - 2020
TI  - Ethical considerations in global surgery: a scoping review.
PG  - e002319
LID - 10.1136/bmjgh-2020-002319 [doi]
AB  - Introduction: An unmet burden of surgical disease exists worldwide and is
      disproportionately shouldered by low-income and middle-income countries (LMICs). 
      As the field of global surgery grows to meet this need, ethical considerations
      need to be addressed. Currently, there are no formal guidelines to help inform
      relevant stakeholders of the ethical challenges and considerations facing global 
      surgical collaborations. The aim of this scoping review is to synthesise the
      existing literature on ethics in global surgery and identify gaps in the current 
      knowledge. Methods: A scoping review of relevant databases to identify the
      literature pertaining to ethics in global surgery was performed. Eligible
      articles addressed at least one ethical consideration in global surgery. A
      grounded theory approach to content analysis was used to identify themes in the
      included literature and guide the identification of gaps in existing literature. 
      Results: Four major ethical domains were identified in the literature: clinical
      care and delivery; education and exchange of trainees; research, monitoring and
      evaluation; and engagement in collaborations and partnerships. The majority of
      published literature related to issues of clinical care and delivery of the
      individual patient. Most of the published literature was published exclusively by
      authors in high-income countries (HICs) (80%), and the majority of articles were 
      in the form of editorials or commentaries (69.1%). Only 12.7% of articles
      published were original research studies. Conclusion: The literature on ethics in
      global surgery remains sparse, with most publications coming from HICs, and
      focusing on clinical care and short-term surgical missions. Given that LMICs are 
      frequently the recipients of global surgical initiatives, the relative absence of
      literature from their perspective needs to be addressed. Furthermore, there is a 
      need for more literature focusing on the ethics surrounding sustainable
      collaborations and partnerships.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Grant, Chantalle Lauren
AU  - Grant CL
AUID- ORCID: 0000-0003-4726-8242
AD  - Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
FAU - Robinson, Tessa
AU  - Robinson T
AD  - Division of Pediatric Surgery, Department of Surgery, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Al Hinai, Alreem
AU  - Al Hinai A
AD  - Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
FAU - Mack, Cheryl
AU  - Mack C
AD  - Department of Pediatrics, University of Alberta Faculty of Medicine and
      Dentistry, Edmonton, Alberta, Canada.
AD  - Department of Anesthesiology and Pain Medicine, University of Alberta Faculty of 
      Medicine and Dentistry, Edmonton, Alberta, Canada.
FAU - Guilfoyle, Regan
AU  - Guilfoyle R
AD  - Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
AD  - Office of Global Surgery, University of Alberta, Edmonton, Alberta, Canada.
FAU - Saleh, Abdullah
AU  - Saleh A
AD  - Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
AD  - Office of Global Surgery, University of Alberta, Edmonton, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200421
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Humans
MH  - *Poverty
PMC - PMC7204923
OTO - NOTNLM
OT  - *public health
OT  - *qualitative study
OT  - *review
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/05/14 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/02 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1136/bmjgh-2020-002319 [doi]
AID - bmjgh-2020-002319 [pii]
PST - epublish
SO  - BMJ Glob Health. 2020 Apr 21;5(4):e002319. doi: 10.1136/bmjgh-2020-002319.
      eCollection 2020.


PMID- 32399251
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210407
IS  - 2053-3624 (Print)
IS  - 2053-3624 (Linking)
VI  - 7
IP  - 1
DP  - 2020
TI  - Exploring the acceptability of implantable defibrillators in patients with
      cardiac dystrophinopathy and carers.
PG  - e001230
LID - 10.1136/openhrt-2019-001230 [doi]
AB  - Objective: Unlike for patients with other forms of cardiomyopathies, those with
      severe ventricular dysfunction due to Duchenne muscular dystrophy (DMD) are not
      offered implantable cardioverter-defibrillator (ICD) therapy routinely. This
      prospective study aimed to determine the views of DMD-patients and their carers
      about discussing sudden death risk and their acceptance of ICDs. Design and
      setting: Adults with DMD (n=9) and parents/carers (n=9) participated in
      audio-recorded, 60-90 min focus group sessions (patients 2; parents/carers 2)
      conducted through either a face-to-face session at a neutral venue or a
      videoconference. Sessions were facilitated by a clinical psychologist,
      experienced in conducting focus group research. All participants understood the
      rationale for the study and the nature of ICD therapy. The same predefined themes
      were explored with each group. Recordings were transcribed, analysed thematically
      by two researchers, working independently and then agreed. Differences in
      responses between patient and carer groups were also studied and compared.
      Participants all provided informed written consent and the study had ethical
      approval. Results: Three main themes emerged: (1) access to/quality of
      information provided by professionals and patient engagement with them; (2)
      decision-making about ICDs; (3) individuals' own 'lived experience' of DMD.
      Conclusions: The main findings were: (1) patients with DMD want to have their
      risk of sudden arrhythmic death discussed, when relevant and (2) if ICD therapy
      were established as beneficial, they would welcome an individualised discussion
      about its appropriateness for them.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hiermeier, Ursula M
AU  - Hiermeier UM
AD  - Department of Clinical Health Psychology, Royal Victoria Infirmary, Newcastle
      upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
FAU - Baker, Christine
AU  - Baker C
AD  - Department of Clinical Health Psychology, Royal Victoria Infirmary, Newcastle
      upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
FAU - Bourke, John P
AU  - Bourke JP
AUID- ORCID: 0000-0001-7857-9073
AD  - Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust,
      Newcastle upon Tyne, UK.
AD  - Institute of Translational and Clinical Research, Newcastle University, Newcastle
      upon Tyne, Tyne and Wear, UK.
LA  - eng
GR  - SP/05/001/18616/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200421
PL  - England
TA  - Open Heart
JT  - Open heart
JID - 101631219
SB  - IM
MH  - Adult
MH  - Cardiomyopathies/etiology/mortality/physiopathology/*therapy
MH  - Caregivers/*psychology
MH  - Clinical Decision-Making
MH  - Death, Sudden, Cardiac/etiology/*prevention & control
MH  - *Defibrillators, Implantable
MH  - Electric Countershock/*instrumentation
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscular Dystrophy, Duchenne/*complications/mortality/physiopathology
MH  - *Patient Acceptance of Health Care
MH  - Patient Participation
MH  - Prospective Studies
MH  - Quality of Life
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ventricular Dysfunction, Left/etiology/mortality/physiopathology/*therapy
MH  - Ventricular Function, Left
MH  - Young Adult
PMC - PMC7204554
OTO - NOTNLM
OT  - *cardiomyopathy dilated
OT  - *delivery of care
OT  - *gene expression
OT  - *implantable cardioverter defibrillator (ICD)
OT  - *sudden cardiac death
COIS- Competing interests: JPB reports funding support from 'Charitable Funds', NUTH
      NHS Foundation Trust for this research and a grant from British Heart Foundation 
      for another DMD-related research study ongoing over the same time period.
EDAT- 2020/05/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1136/openhrt-2019-001230 [doi]
AID - openhrt-2019-001230 [pii]
PST - epublish
SO  - Open Heart. 2020 Apr 21;7(1):e001230. doi: 10.1136/openhrt-2019-001230.
      eCollection 2020.


PMID- 32399143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210312
IS  - 0019-5413 (Print)
IS  - 0019-5413 (Linking)
VI  - 54
IP  - 3
DP  - 2020 May
TI  - Genetics and the Elite Athlete: Our Understanding in 2020.
PG  - 256-263
LID - 10.1007/s43465-020-00056-z [doi]
AB  - Modern competitive sport has evolved so much that athletes would go to great
      extremes to develop themselves into champions; medicine has also evolved to the
      point that many genetic elements have been identified to be associated with
      specific athletic traits, and genetic alterations are also possible. The current 
      review examines the published literature and looks at three important factors:
      genetic polymorphism influencing sporting ability, gene doping and genetic
      tendency to injury. The ACTN3 gene has an influence on type II muscle fibres,
      with the R allele being advantageous to power sports like sprinting and the XX
      genotype being associated with lower muscle strength and sprinting ability. The
      ACE gene polymorphisms are associated with cardio-respiratory efficiency and
      could influence endurance athletes. Many other genes are being looked at, with
      specific focus on those that are potentially related to enhancement of athletic
      ability. Recognition of these specific gene polymorphisms brings into play the
      concept of genetic engineering in athletes, which constitutes gene doping and is 
      outlawed. This has the potential to develop into the next big threat in elite
      sports; gene doping could have dangerous and even fatal outcomes, as the
      knowledge of gene therapy is still in its infancy. Genetic predisposition to
      injury is also being identified; recent publications have increased the awareness
      of gene polymorphisms predisposing to injuries of ligaments and tendons due to
      influence on collagen structure and extracellular matrix. Ongoing work is looking
      at identifying the same genes from different races and different sexes to see if 
      there are quantitative racial or sexual differences. All of the above have led to
      serious ethical concerns; in the twenty-first century some sports associations
      and some countries are looking at genetic testing for their players.
      Unfortunately, the science is still developing, and the experience of its
      application is limited worldwide. Nevertheless, this field has caught the
      imagination of both the public and the sportsperson, and hence the concerned
      doctors should be aware of the potential problems and current issues involved in 
      understanding genetic traits and polymorphisms, genetic testing and genetic
      engineering.
CI  - (c) Indian Orthopaedics Association 2020.
FAU - John, Rakesh
AU  - John R
AD  - 1Department of Trauma and Orthopaedics, Hull University Teaching Hospital, East
      Yorkshire, Hull, HU3 2JZ UK.grid.9481.40000 0004 0412 8669
FAU - Dhillon, Mandeep Singh
AU  - Dhillon MS
AUID- ORCID: 0000-0002-2592-1362
AD  - 2Department of Orthopaedics, Post Graduate Institute of Medical Education and
      Research, Chandigarh, India 160012.grid.415131.30000 0004 1767 2903
FAU - Dhillon, Sidak
AU  - Dhillon S
AD  - FC Chennaiyan, Chennai, Tamil Nadu India.
LA  - eng
PT  - Journal Article
DEP - 20200311
PL  - Switzerland
TA  - Indian J Orthop
JT  - Indian journal of orthopaedics
JID - 0137736
PMC - PMC7205921
OTO - NOTNLM
OT  - Gene doping
OT  - Gene testing
OT  - Genetic polymorphism
OT  - Genetics
COIS- Conflict of interestThe authors declare that they have no conflict of interest.
EDAT- 2020/05/14 06:00
MHDA- 2020/05/14 06:01
CRDT- 2020/05/14 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/05/14 06:01 [medline]
AID - 10.1007/s43465-020-00056-z [doi]
AID - 56 [pii]
PST - epublish
SO  - Indian J Orthop. 2020 Mar 11;54(3):256-263. doi: 10.1007/s43465-020-00056-z.
      eCollection 2020 May.


PMID- 32398342
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Codesigning discharge communication interventions with healthcare providers,
      youth and parents for emergency practice settings: EDUCATE study protocol.
PG  - e038314
LID - 10.1136/bmjopen-2020-038314 [doi]
AB  - INTRODUCTION: Discharge communication is an important aspect of patient care but 
      frequently has shortcomings in emergency departments (EDs). In a paediatric
      context, youth or parents with young children often leave the ED with minimal
      opportunity to ask questions or to ensure comprehension of important information.
      Strategies for improving discharge communication have primarily targeted patients
      and/or parents, although neither group has been engaged in intervention design or
      implementation. Furthermore, ED healthcare providers (HCPs), important actors in 
      discharge communication practice, are rarely consulted regarding intervention
      design decisions. We will generate evidence to enhance discharge communication by
      engaging youth, parents and HCPs in the codesign of ED discharge communication
      strategies (EDUCATE) for asthma and minor head injury. METHODS AND ANALYSIS: This
      mixed methods study will take place at two academic paediatric EDs in Canada. The
      study will occur in two phases: (A) codesign and refinement of the intervention
      prototypes; and (B) usability testing of the prototypes. During the first phase, 
      two codesign teams (one for each condition) will follow a series of structured
      design meetings based on the Behavior Change Wheel to develop the EDUCATE
      interventions. Each codesign team (composed of youth, parents, HCPs and study
      researchers) will collaborate to identify priority target behaviours and
      acceptable components to include in the interventions. During the second phase,
      we will conduct usability testing in two EDs with a group of youth, parents and
      HCPs to refine the interventions. Two cycles of usability testing will be
      conducted with intervention refinement occurring at the end of each cycle. ETHICS
      AND DISSEMINATION: Informed consent will be obtained from all participants.
      Ethics approval for this study has been obtained from the Research Ethics Board, 
      IWK Health Centre. Results from this study will form the basis of a future
      effectiveness implementation trial. Key findings will be presented at national
      and international conferences and published within peer-reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Curran, Janet A
AU  - Curran JA
AUID- ORCID: 0000-0001-9977-0467
AD  - Department of Nursing, Dalhousie University, Halifax, Nova Scotia, Canada
      jacurran@dal.ca.
AD  - Department of Pediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Cassidy, Christine
AU  - Cassidy C
AD  - Department of Nursing, Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Bishop, Andrea
AU  - Bishop A
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Wozney, Lori
AU  - Wozney L
AD  - Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.
FAU - Plint, Amy C
AU  - Plint AC
AD  - Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Ritchie, Krista
AU  - Ritchie K
AD  - Faculty of Education, Mount Saint Vincent University, Halifax, Nova Scotia,
      Canada.
FAU - Straus, Sharon E
AU  - Straus SE
AD  - Li Ka Shing Knowledge Institute, Saint Mike's, Toronto, Ontario, Canada.
FAU - Wong, Helen
AU  - Wong H
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Newton, Amanda
AU  - Newton A
AD  - Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
FAU - Jabbour, Mona
AU  - Jabbour M
AD  - Division of Emergency Medicine, Children's Hospital of Eastern Ontario, Ottawa,
      Ontario, Canada.
FAU - MacPhee, Shannon
AU  - MacPhee S
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Breneol, Sydney
AU  - Breneol S
AD  - Department of Nursing, Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Burns, Emma
AU  - Burns E
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Chorney, Jill
AU  - Chorney J
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Lawton, Jennifer
AU  - Lawton J
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Doyle, Melanie
AU  - Doyle M
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - MacKay, Rebecca
AU  - MacKay R
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Zemek, Roger
AU  - Zemek R
AD  - Department of Pediatrics, CHEO, Ottawa, Ontario, Canada.
FAU - Penney, Tanya
AU  - Penney T
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Grimshaw, Jeremy
AU  - Grimshaw J
AD  - Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario,
      Canada.
CN  - Pediatric Emergency Research Canada (PERC)
LA  - eng
GR  - 399798/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Ambulatory Care
MH  - Asthma/therapy
MH  - Canada
MH  - *Communication
MH  - Consensus
MH  - Craniocerebral Trauma/therapy
MH  - *Emergency Service, Hospital
MH  - Feasibility Studies
MH  - *Health Personnel
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - *Parents
MH  - *Patient Discharge
MH  - *Patient Participation
PMC - PMC7223275
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *education & training (see medical education & training)
OT  - *paediatric A&E and ambulatory care
COIS- Competing interests: None declared.
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038314 [pii]
AID - 10.1136/bmjopen-2020-038314 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e038314. doi: 10.1136/bmjopen-2020-038314.


PMID- 32398341
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE)
      randomised clinical trial: study protocol.
PG  - e038300
LID - 10.1136/bmjopen-2020-038300 [doi]
AB  - INTRODUCTION: Bloodstream infections are a leading cause of mortality and
      morbidity; the duration of treatment for these infections is understudied.
      METHODS AND ANALYSIS: We will conduct an international, multicentre randomised
      clinical trial of shorter (7 days) versus longer (14 days) antibiotic treatment
      among hospitalised patients with bloodstream infections. The trial will include
      3626 patients across 60 hospitals and 6 countries. We will include patients with 
      blood cultures confirming a pathogenic bacterium after hospital admission.
      Exclusion criteria will include patient factors (severe immunosuppression),
      infection site factors (endocarditis, osteomyelitis, undrained abscesses,
      infected prosthetic material) and pathogen factors (Staphylococcus aureus,
      Staphylococcus lugdunensis, Candida and contaminant organisms). We will leave the
      selection of specific antibiotics, doses and route of delivery to the discretion 
      of treating physicians; no placebo control will be used given the diversity of
      pathogens and sources of bacteraemia. The intervention will be assignment of
      treatment duration to be 7 versus 14 days. We will minimise selection bias via
      central randomisation with variable block sizes, with concealed allocation until 
      day 7 of adequate antibiotic treatment. The primary outcome is 90-day survival;
      we will test whether 7 days is non-inferior to 14 days of treatment, with a
      non-inferiority margin of 4% absolute mortality. Secondary outcomes include
      hospital and intensive care unit (ICU) mortality, relapse rates of bacteraemia,
      hospital and ICU length of stay, mechanical ventilation and vasopressor duration,
      antibiotic-free days, Clostridium difficile infection, antibiotic allergy and
      adverse events and colonisation/infection with antibiotic-resistant organisms.
      ETHICS AND DISSEMINATION: The study has been approved by the ethics review board 
      at each participating site. Sunnybrook Health Sciences Centre is the central
      ethics committee. We will disseminate study results via the Canadian Critical
      Care Trials Group and other collaborating networks to set the global paradigm for
      antibiotic treatment duration for non-staphylococcal Gram-positive, Gram-negative
      and anaerobic bacteraemia, among patients admitted to hospital. TRIAL
      REGISTRATION NUMBER: The BALANCE (Bacteremia Antibiotic Length Actually Needed
      for Clinical Effectiveness) trial was registered at www.clinicaltrials.gov
      (registration number: NCT03005145).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Daneman, Nick
AU  - Daneman N
AUID- ORCID: 0000-0001-8827-3764
AD  - Division of Infectious Diseases & Clinical Epidemiology, Sunnybrook Health
      Sciences Centre, University of Toronto, Toronto, Ontario, Canada
      Nick.Daneman@sunnybrook.ca.
FAU - Rishu, Asgar H
AU  - Rishu AH
AD  - Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre,
      Toronto, Ontario, Canada.
FAU - Pinto, Ruxandra L
AU  - Pinto RL
AD  - Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada.
FAU - Arabi, Yaseen M
AU  - Arabi YM
AD  - Intensive Care Department, King Saud Bin Abdulaziz University for Health
      Sciences, Riyadh, Saudi Arabia.
FAU - Cook, Deborah J
AU  - Cook DJ
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Hall, Richard
AU  - Hall R
AD  - Departments of Critical Care Medicine and Anesthesiology, Pain Management and
      Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - McGuinness, Shay
AU  - McGuinness S
AD  - Auckland City Hospital, Auckland, New Zealand.
FAU - Muscedere, John
AU  - Muscedere J
AD  - Kingston General Hospital, Kingston, Ontario, Canada.
FAU - Parke, Rachael
AU  - Parke R
AD  - The University of Auckland, Auckland, New Zealand.
FAU - Reynolds, Steven
AU  - Reynolds S
AD  - Royal Columbian Hospital, New Westminster, British Columbia, Canada.
FAU - Rogers, Benjamin
AU  - Rogers B
AD  - Centre for Inflammatory Diseases, Monash University School of Clinical Sciences, 
      Melborne, Victoria, Australia.
FAU - Shehabi, Yahya
AU  - Shehabi Y
AD  - Critical Care and Perioperative Medicine, School of Clinical Sciences, Monash
      University and Monash Health, Melbourne, Victoria, Australia.
FAU - Fowler, Robert A
AU  - Fowler RA
AD  - Departments of Medicine and Critical Care Medicine, Sunnybrook Health Sciences
      Centre, Toronto, Ontario, Canada.
CN  - Canadian Critical Care Trials Group
LA  - eng
SI  - ClinicalTrials.gov/NCT03005145
GR  - CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/administration & dosage/*therapeutic use
MH  - Bacteremia/*drug therapy/mortality
MH  - Cross Infection/*drug therapy/mortality
MH  - Drug Administration Schedule
MH  - Humans
MH  - Recurrence
MH  - Selection Bias
MH  - Treatment Outcome
PMC - PMC7223357
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *bacteriology
OT  - *infectious diseases
COIS- Competing interests: None declared.
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038300 [pii]
AID - 10.1136/bmjopen-2020-038300 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e038300. doi: 10.1136/bmjopen-2020-038300.


PMID- 32398340
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Australian Suicide Prevention using Health-Linked Data (ASHLi): Protocol for a
      population-based case series study.
PG  - e038181
LID - 10.1136/bmjopen-2020-038181 [doi]
AB  - INTRODUCTION: In Australia, suicide is the leading cause of death for people aged
      15-44 years. Health professionals deliver most of our key suicide prevention
      strategies via health services, but other efficacious population-level strategies
      include means restriction and public awareness campaigns. Currently, we have no
      population-level data allowing us to determine which individuals, in what parts
      of Australia, are likely to use our most promising interventions delivered by
      health services. The aims of this study are to describe: (1) health service
      utilisation rates in the year prior to death by suicide, and how this varies by
      individual case characteristics; (2) prescribed medicines use in the year prior
      to death by suicide, medicines used in suicide by poisoning and how this varies
      by individual case characteristics. METHODS AND ANALYSIS: This is a
      population-based case series study of all suicide cases in Australia identified
      through the National Coronial Information System (NCIS) from 2013 to 2019. Cases 
      will be linked to administrative claims data detailing health service use and
      medicines dispensed in the year before death. We will also obtain findings from
      the coronial enquiry, including toxicology. Descriptive statistics will be
      produced to characterise health service and prescribed medicine use and how
      utilisation varies by age, sex, method of death and socioeconomic status. We will
      explore the geographical variability of health service and medicine use,
      highlighting regions in Australia associated with more limited access. ETHICS AND
      DISSEMINATION: This project involves the use of sensitive and confidential data. 
      Data will be linked using a third-party privacy-preserving protocol meaning that 
      investigators will not have access to identifiable information once the data have
      been linked. Statistical analyses will be carried out in a secure environment.
      This study has been approved by the following ethics committees: (1) the Justice 
      Department Human Research Ethics Committee (REF: CF/17/23250), (2) the Western
      Australian Coroners Court (REF: EC 14/18 M0400), (3) the Australian Institute of 
      Health and Welfare (REF: EO2017/4/366) and (4) NSW Population & Health Services
      Research Ethics Committee (REF: 2017/HRE1204). Findings will be published in
      peer-reviewed journals, presented at conferences and communicated to regulatory
      authorities, clinicians and policy-makers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chitty, Kate M
AU  - Chitty KM
AD  - Discipline of Pharmacology, Clinical Pharmacology and Toxicology Research Group, 
      Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales,
      Australia kate.chitty@sydney.edu.au.
FAU - Schumann, Jennifer L
AU  - Schumann JL
AD  - Department of Forensic Medicine, Victorian Institute of Forensic Medicine, Monash
      University, Clayton, Victoria, Australia.
FAU - Schaffer, Andrea
AU  - Schaffer A
AUID- ORCID: 0000-0002-3701-4997
AD  - Medicines Policy Research Unit, Centre for Big Data Research in Health,
      University of New South Wales, Sydney, New South Wales, Australia.
FAU - Cairns, Rose
AU  - Cairns R
AUID- ORCID: 0000-0002-8946-5079
AD  - NSW Poisons Information Centre, The Children's Hospital at Westmead, Sydney, New 
      South Wales, Australia.
AD  - Sydney Pharmacy School, University of Sydney, Sydney, New South Wales, Australia.
FAU - Gonzaga, Nicole J
AU  - Gonzaga NJ
AUID- ORCID: 0000-0002-9596-4894
AD  - Discipline of Pharmacology, Clinical Pharmacology and Toxicology Research Group, 
      Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Raubenheimer, Jacques E
AU  - Raubenheimer JE
AD  - Discipline of Pharmacology, Clinical Pharmacology and Toxicology Research Group, 
      Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Carter, Gregory
AU  - Carter G
AD  - Calvary Mater Newcastle Hospital, University of Newcastle, Newcastle, New South
      Wales, Australia.
FAU - Page, Andrew
AU  - Page A
AD  - Translational Health Research Institute, Western Sydney University, Campbelltown,
      New South Wales, Australia.
FAU - Pearson, Sallie-Anne
AU  - Pearson SA
AD  - Medicines Policy Research Unit, Centre for Big Data Research in Health,
      University of New South Wales, Sydney, New South Wales, Australia.
FAU - Buckley, Nicholas A
AU  - Buckley NA
AD  - Discipline of Pharmacology, Clinical Pharmacology and Toxicology Research Group, 
      Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Australia/epidemiology
MH  - Drug Therapy/*statistics & numerical data
MH  - Health Services Needs and Demand/*statistics & numerical data
MH  - Humans
MH  - Medical Record Linkage
MH  - Pharmaceutical Preparations
MH  - Poisoning/epidemiology
MH  - Socioeconomic Factors
MH  - Suicide/*prevention & control
MH  - Time Factors
MH  - Young Adult
PMC - PMC7223353
OTO - NOTNLM
OT  - *administrative data
OT  - *data linkage
OT  - *epidemiology
OT  - *health service utilisation
OT  - *medicines
OT  - *mental health
OT  - *retrospective
OT  - *suicides
COIS- Competing interests: None declared.
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2020-038181 [pii]
AID - 10.1136/bmjopen-2020-038181 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e038181. doi: 10.1136/bmjopen-2020-038181.


PMID- 32398338
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Protocol for assessing the determinants of preoperative test-ordering behaviour
      for low-risk surgical procedures using a theoretically driven, qualitative
      design.
PG  - e036511
LID - 10.1136/bmjopen-2019-036511 [doi]
AB  - INTRODUCTION: Current evidence suggests that preoperative tests such as chest
      X-rays, electrocardiograms and baseline laboratory studies may not be useful for 
      healthy patients undergoing low-risk surgical procedures. Routine preoperative
      testing for healthy patients having low-risk surgery is not a scientifically
      sound practice. In this study, we will interview healthcare providers working at 
      medical facilities where low-risk surgical procedures are carried out. This will 
      allow us to gain insight into the determinants of preoperative testing behaviours
      for healthy patients undergoing low-risk surgeries and their barriers and
      enablers to guideline adherence. METHODS AND ANALYSIS: We will use semistructured
      interviews with anaesthesiologists, surgeons and preadmission clinic nurses to
      assess the determinants of preoperative testing behaviours. The interview guide
      was designed around the Theoretical Domains Framework (TDF), developed
      specifically to determine the barriers and enablers to implementing
      evidence-based guidelines. Interviews will be audio-recorded, transcribed
      verbatim and coded according to the TDF. Key themes will be generated for each of
      the identified domains. ETHICS AND DISSEMINATION: We have received ethics
      approval from the Health Research Ethics Board in Newfoundland and Labrador (HREB
      #2018.190) for this study. The results of this work will be disseminated through 
      a peer-reviewed publication, presentation at a healthcare forum and
      plain-language infographic summaries. Additionally, deidentified data collected
      and analysed for this study will be available for review from the corresponding
      author on reasonable request.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pike, Andrea
AU  - Pike A
AUID- ORCID: 0000-0003-4020-2291
AD  - Primary Healthcare Research Unit, Faculty of Medicine, Memorial University of
      Newfoundland, St. John's, Newfoundland and Labrador, Canada.
FAU - Mahoney, Krista
AU  - Mahoney K
AD  - Faculty of Medicine, Memorial University of Newfoundland, St. John's,
      Newfoundland and Labrador, Canada.
FAU - Patey, Andrea M
AU  - Patey AM
AD  - Centre for Implementation Research, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Inwood, Samantha
AU  - Inwood S
AUID- ORCID: 0000-0001-8900-9017
AD  - Primary Healthcare Research Unit, Faculty of Medicine, Memorial University of
      Newfoundland, St. John's, Newfoundland and Labrador, Canada.
FAU - Mortazhejri, Sameh
AU  - Mortazhejri S
AD  - Centre for Implementation Research, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Lawrence, Rebecca
AU  - Lawrence R
AD  - Primary Healthcare Research Unit, Faculty of Medicine, Memorial University of
      Newfoundland, St. John's, Newfoundland and Labrador, Canada.
FAU - Hall, Amanda
AU  - Hall A
AD  - Primary Healthcare Research Unit, Faculty of Medicine, Memorial University of
      Newfoundland, St. John's, Newfoundland and Labrador, Canada
      amanda.hall@med.mun.ca.
CN  - De-implementing Wisely Research Group
LA  - eng
GR  - 398527/Canadian Institute of Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anesthesiologists
MH  - Clinical Protocols
MH  - *Diagnostic Tests, Routine
MH  - Guideline Adherence
MH  - Health Status
MH  - Humans
MH  - Models, Theoretical
MH  - Newfoundland and Labrador
MH  - Perioperative Nursing
MH  - *Preoperative Care
MH  - Qualitative Research
MH  - Risk
MH  - Surgeons
MH  - *Surgical Procedures, Operative
MH  - Unnecessary Procedures
PMC - PMC7223279
OTO - NOTNLM
OT  - *change management
OT  - *protocols & guidelines
OT  - *quality in health care
COIS- Competing interests: None declared.
IR  - Grimshaw J
FIR - Grimshaw, Jeremy
IR  - Levinson W
FIR - Levinson, Wendy
IR  - Kirkham K
FIR - Kirkham, Kyle
IR  - Dowling S
FIR - Dowling, Shawn
IR  - Mrklas K
FIR - Mrklas, Kelly
IR  - Presseau J
FIR - Presseau, Justin
IR  - Bhatia S
FIR - Bhatia, Sacha
IR  - Sikorski T
FIR - Sikorski, Todd
IR  - Parfrey P
FIR - Parfrey, Patrick
IR  - Jasaui Y
FIR - Jasaui, Yamile
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036511 [pii]
AID - 10.1136/bmjopen-2019-036511 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e036511. doi: 10.1136/bmjopen-2019-036511.


PMID- 32398336
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Autologous transplantation of umbilical cord blood-derived cells in extreme
      preterm infants: protocol for a safety and feasibility study.
PG  - e036065
LID - 10.1136/bmjopen-2019-036065 [doi]
AB  - INTRODUCTION: Preterm brain injury continues to be an important complication of
      preterm birth, especially in extremely premature infants. Umbilical cord
      blood-derived cells (UCBCs) are increasingly being evaluated for their
      neuroprotective and neuroreparative properties in preclinical and clinical
      studies. There remains a paucity of information on the feasibility and safety of 
      autologous UCBC transplantation in extremely premature infants. METHODS AND
      ANALYSIS: A single centre safety and feasibility study in preterm babies born
      before 28 weeks gestation. Cord blood will be collected after birth and if
      sufficient blood is obtained, UCB mononuclear cells will be harvested from the
      cord blood, characterised and stored. After excluding infants who have already
      suffered severe preterm brain injury, based on cranial ultrasounds in first week 
      of life, preterm infants will be infused with autologous UCBCs via the
      intravenous route at a dose of 25-50 million UCBCs/kg body weight of live cells, 
      with the cell number being the maximum available up to 50 million cells/kg. A
      minimum of 20 infants will be administered autologous UCBCs. Primary outcomes
      will include feasibility and safety. Feasibility will be determined by access to 
      sufficient cord blood at collection and UCBCs following processing. Safety will
      be determined by lack of adverse events directly related to autologous UCBC
      administration in the first few days after cell administration. Secondary
      outcomes studied will include neonatal and neurodevelopmental morbidities till 2 
      years of life. Additional outcomes will include cell characteristics of all
      collected cord blood, and cytokine responses to cell administration in
      transplanted infants till 36 weeks' corrected age. ETHICS AND DISSEMINATION:
      Monash Health Human Research Ethics Committee approved this study in December
      2019. Recruitment is to commence in July 2020 and is expected to take around 12
      months. The findings of this study will be disseminated via peer-reviewed
      journals and at conferences. TRIAL REGISTRATION NUMBER: ACTRN12619001637134.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Malhotra, Atul
AU  - Malhotra A
AUID- ORCID: 0000-0001-9664-4182
AD  - Department of Paediatrics, Monash University, Melbourne, Victoria, Australia
      atul.malhotra@monash.edu.
AD  - Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia.
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria,
      Australia.
FAU - Novak, Iona
AU  - Novak I
AD  - Cerebral Palsy Alliance, Sydney, New South Wales, Australia.
FAU - Miller, Suzanne Lee
AU  - Miller SL
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria,
      Australia.
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria,
      Australia.
FAU - Jenkin, Graham
AU  - Jenkin G
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria,
      Australia.
AD  - Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria,
      Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619001637134
PT  - Journal Article
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Blood Specimen Collection/methods
MH  - Brain Injuries/*prevention & control
MH  - Clinical Protocols
MH  - Cord Blood Stem Cell Transplantation/adverse effects/*methods
MH  - Feasibility Studies
MH  - Fetal Blood/*cytology
MH  - Humans
MH  - *Infant, Extremely Premature
MH  - Infant, Newborn
MH  - Infusions, Intravenous
MH  - Leukocytes, Mononuclear/*transplantation
MH  - Safety
MH  - Transplantation, Autologous/adverse effects/methods
PMC - PMC7223148
OTO - NOTNLM
OT  - *neonatal intensive & critical care
OT  - *neurological injury
OT  - *paediatric neurology
COIS- Competing interests: None declared.
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036065 [pii]
AID - 10.1136/bmjopen-2019-036065 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e036065. doi: 10.1136/bmjopen-2019-036065.


PMID- 32398334
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Reporting of drug trial funding sources and author financial conflicts of
      interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study.
PG  - e035633
LID - 10.1136/bmjopen-2019-035633 [doi]
AB  - OBJECTIVE: To (1) investigate the extent to which recently published
      meta-analyses report trial funding, author-industry financial ties and
      author-industry employment from included randomised controlled trials (RCTs),
      comparing Cochrane and non-Cochrane meta-analyses; (2) examine characteristics of
      meta-analyses independently associated with reporting funding sources of included
      RCTs; and (3) compare reporting among recently published Cochrane meta-analyses
      to Cochrane reviews published in 2010. DESIGN: Review of consecutive sample of
      recently published meta-analyses. DATA SOURCES: MEDLINE database via PubMed
      searched on 19 October 2018. ELIGIBILITY CRITERIA FOR SELECTING ARTICLES: We
      selected the 250 most recent meta-analyses listed in PubMed that included a
      documented search of at least one database, statistically combined results from
      >/=2 RCTs and evaluated the effects of a drug or class of drugs. RESULTS: 90 of
      107 (84%) Cochrane meta-analyses reported funding sources for some or all
      included trials compared with 21 of 143 (15%) non-Cochrane meta-analyses, a
      difference of 69% (95% CI 59% to 77%). Percent reporting was also higher for
      Cochrane meta-analyses compared with non-Cochrane meta-analyses for trial
      author-industry financial ties (44% versus 1%; 95% CI for difference 33% to 52%) 
      and employment (17% versus 1%; 95% CI for difference 9% to 24%). In multivariable
      analysis, compared with Cochrane meta-analyses, the odds ratio (OR) for reporting
      trial funding was </=0.11 for all other journal category and impact factor
      combinations. Compared with Cochrane reviews from 2010, reporting of funding
      sources of included RCTs among recently published Cochrane meta-analyses improved
      by 54% (95% CI 42% to 63%), and reporting of trial author-industry financial ties
      and employment improved by 37% (95% CI 26% to 47%) and 10% (95% CI 2% to 19%).
      CONCLUSIONS: Reporting of trial funding sources, trial author-industry financial 
      ties and trial author-industry employment in Cochrane meta-analyses has improved 
      since 2010 and is higher than in non-Cochrane meta-analyses.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Turner, Kimberly
AU  - Turner K
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
AD  - McGill University, Montreal, Quebec, Canada.
FAU - Carboni-Jimenez, Andrea
AU  - Carboni-Jimenez A
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
AD  - McGill University, Montreal, Quebec, Canada.
FAU - Benea, Carla
AU  - Benea C
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
AD  - McGill University, Montreal, Quebec, Canada.
FAU - Elder, Katharine
AU  - Elder K
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
AD  - McGill University, Montreal, Quebec, Canada.
FAU - Levis, Brooke
AU  - Levis B
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada.
AD  - McGill University, Montreal, Quebec, Canada.
FAU - Boruff, Jill
AU  - Boruff J
AD  - Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill
      University, Montreal, Quebec, Canada.
FAU - Roseman, Michelle
AU  - Roseman M
AD  - Kingsway Medical Centre Family Health Organization, Toronto, Ontario, Canada.
FAU - Bero, Lisa
AU  - Bero L
AD  - Charles Perkins Centre/Pharmacy, University of Sydney, Camperdown, New South
      Wales, Australia.
FAU - Lexchin, Joel
AU  - Lexchin J
AUID- ORCID: 0000-0001-5120-8029
AD  - School of Health Policy and Management, York University, Toronto, Ontario,
      Canada.
FAU - Turner, Erick H
AU  - Turner EH
AUID- ORCID: 0000-0002-3522-3357
AD  - Department of Psychiatry, Oregon Health & Science University, Portland, Oregon,
      USA.
FAU - Benedetti, Andrea
AU  - Benedetti A
AD  - Department of Epidemiology, Biostatistics and Occupational Health, McGill
      University, Montreal, Quebec, Canada.
FAU - Thombs, Brett D
AU  - Thombs BD
AUID- ORCID: 0000-0002-5644-8432
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal,
      Quebec, Canada brett.thombs@mcgill.ca.
AD  - McGill University, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Authorship
MH  - *Conflict of Interest
MH  - Cross-Sectional Studies
MH  - Drug Industry/economics/*ethics
MH  - Employment
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Odds Ratio
MH  - Randomized Controlled Trials as Topic/economics/*ethics
MH  - Research Support as Topic/*ethics
PMC - PMC7229983
OTO - NOTNLM
OT  - *epidemiology
OT  - *medical ethics
OT  - *statistics & research methods
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf. Dr. Bero disclosed that she is Senior
      Editor, Cochrane Public Health and Health Systems, for which the University of
      Sydney receives remuneration. Dr. Thombs disclosed that he is a content editor
      with the Cochrane Common Mental Disorders review group (no remuneration
      received). All other authors declared: no support from any organisation for the
      submitted work; no financial relationships with any organisations that might have
      an interest in the submitted work in the previous three years; no other
      relationships or activities that could appear to have influenced the submitted
      work.
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035633 [pii]
AID - 10.1136/bmjopen-2019-035633 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e035633. doi: 10.1136/bmjopen-2019-035633.


PMID- 32398333
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20220208
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 11
TI  - Androgens In Men Study (AIMS): protocol for meta-analyses of individual
      participant data investigating associations of androgens with health outcomes in 
      men.
PG  - e034777
LID - 10.1136/bmjopen-2019-034777 [doi]
AB  - INTRODUCTION: This study aims to clarify the role(s) of endogenous sex hormones
      to influence health outcomes in men, specifically to define the associations of
      plasma testosterone with incidence of cardiovascular events, cancer, dementia and
      mortality risk, and to identify factors predicting testosterone concentrations.
      Data will be accrued from at least three Australian, two European and four North 
      American population-based cohorts involving approximately 20 000 men. METHODS AND
      ANALYSIS: Eligible studies include prospective cohort studies with baseline
      testosterone concentrations measured using mass spectrometry and 5 years of
      follow-up data on incident cardiovascular events, mortality, cancer diagnoses or 
      deaths, new-onset dementia or decline in cognitive function recorded. Data for
      men, who were not taking androgens or drugs suppressing testosterone production, 
      metabolism or action; and had no prior orchidectomy, are eligible. Systematic
      literature searches were conducted from 14 June 2019 to 31 December 2019, with no
      date range set for searches. Aggregate level data will be sought where individual
      participant data (IPD) are not available. One-stage IPD random-effects
      meta-analyses will be performed, using linear mixed models, generalised linear
      mixed models and either stratified or frailty-augmented Cox regression models.
      Heterogeneity in estimates from different studies will be quantified and bias
      investigated using funnel plots. Effect size estimates will be presented in
      forest plots and non-negligible heterogeneity and bias investigated using
      subgroup or meta-regression analyses. ETHICS AND DISSEMINATION: Ethics approvals 
      obtained for each of the participating cohorts state that participants have
      consented to have their data collected and used for research purposes. The
      Androgens In Men Study has been assessed as exempt from ethics review by the
      Human Ethics office at the University of Western Australia (file reference number
      RA/4/20/5014). Each of the component studies had obtained ethics approvals;
      please refer to respective component studies for details. Research findings will 
      be disseminated to the scientific and broader community via the publication of
      four research articles, with each involving a separate set of IPD meta-analyses
      (articles will investigate different, distinct outcomes), at scientific
      conferences and meetings of relevant professional societies. Collaborating cohort
      studies will disseminate findings to study participants and local communities.
      PROSPERO REGISTRATION NUMBER: CRD42019139668.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Yeap, Bu Beng
AU  - Yeap BB
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia bu.yeap@uwa.edu.au.
AD  - Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western 
      Australia, Australia.
FAU - Marriott, Ross James
AU  - Marriott RJ
AUID- ORCID: 0000-0002-8805-8498
AD  - School of Population and Global Health, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Adams, Robert J
AU  - Adams RJ
AD  - Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South
      Australia, Australia.
FAU - Antonio, Leen
AU  - Antonio L
AD  - Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
AD  - Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
FAU - Bhasin, Shalender
AU  - Bhasin S
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Cawthon, Peggy M
AU  - Cawthon PM
AD  - San Francisco Coordinating Center, California Pacific Medical Center Research
      Institute, San Francisco, California, USA.
FAU - Couper, David John
AU  - Couper DJ
AD  - Gillings School of Global Public Health, University of North Carolina at Chapel
      Hill, Chapel Hill, North Carolina, USA.
FAU - Dobs, Adrian S
AU  - Dobs AS
AD  - School of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns
      Hopkins University, Baltimore, Maryland, USA.
FAU - Flicker, Leon
AU  - Flicker L
AD  - WA Centre for Health & Ageing, University of Western Australia, Perth, Western
      Australia, Australia.
FAU - Karlsson, Magnus
AU  - Karlsson M
AD  - Department of Clinical Sciences and Orthopedic Surgery, Lund University, Lund,
      Sweden.
FAU - Martin, Sean A
AU  - Martin SA
AD  - Freemasons Foundation Centre for Men's Health, The University of Adelaide,
      Adelaide, South Australia, Australia.
FAU - Matsumoto, Alvin M
AU  - Matsumoto AM
AD  - Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care
      System, Seattle, Washington, USA.
AD  - Department of Medicine, Division of Gerontology & Geriatric Medicine, University 
      of Washington School of Medicine, Seattle, Washington, USA.
FAU - Mellstrom, Dan
AU  - Mellstrom D
AD  - Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of
      Medicine, University of Gothenburg, Goteborg, Sweden.
FAU - Norman, Paul E
AU  - Norman PE
AD  - Medical School, University of Western Australia, Perth, Western Australia,
      Australia.
FAU - Ohlsson, Claes
AU  - Ohlsson C
AD  - Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of
      Medicine, University of Gothenburg, Goteborg, Sweden.
FAU - Orwoll, Eric S
AU  - Orwoll ES
AD  - Oregon Health & Science University, Portland, Oregon, USA.
FAU - O'Neill, Terence W
AU  - O'Neill TW
AD  - Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and
      Health, The University of Manchester & NIHR Manchester Biomedical Research
      Centre, Manchester, UK.
AD  - Manchester University NHS Foundation Trust, Manchester Academic Health Science
      Centre, Manchester, UK.
FAU - Shores, Molly M
AU  - Shores MM
AD  - VA Puget Sound Health Care System, Seattle, Washington, USA.
AD  - School of Medicine, Department of Psychiatry and Behavioral Sciences, University 
      of Washington, Seattle, Washington, USA.
FAU - Travison, Thomas G
AU  - Travison TG
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Institute for Aging Research, Hebrew SeniorLife, Beth Israel Deaconess Medical
      Center, Boston, Massachusetts, USA.
FAU - Vanderschueren, Dirk
AU  - Vanderschueren D
AD  - Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Laboratory of
      Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, 
      Flanders, Belgium.
FAU - Wittert, Gary A
AU  - Wittert GA
AD  - Freemasons Foundation Centre for Men's Health, The University of Adelaide,
      Adelaide, South Australia, Australia.
FAU - Wu, Frederick C W
AU  - Wu FCW
AD  - Division of Diabetes, Endocrinology and Gastroenterology, The University of
      Manchester, Manchester, UK.
FAU - Murray, Kevin
AU  - Murray K
AUID- ORCID: 0000-0002-8856-6046
AD  - School of Population and Global Health, University of Western Australia, Perth,
      Western Australia, Australia.
LA  - eng
GR  - U01 HL080295/HL/NHLBI NIH HHS/United States
GR  - U01 AG042124/AG/NIA NIH HHS/United States
GR  - N01HC85086/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700002C/HL/NHLBI NIH HHS/United States
GR  - U01 AG042140/AG/NIA NIH HHS/United States
GR  - ARC_/Arthritis Research UK/United Kingdom
GR  - N01HC85083/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700004C/HL/NHLBI NIH HHS/United States
GR  - U01 AG042139/AG/NIA NIH HHS/United States
GR  - UL1 TR000128/TR/NCATS NIH HHS/United States
GR  - U01 HL130114/HL/NHLBI NIH HHS/United States
GR  - R01 CA094143/CA/NCI NIH HHS/United States
GR  - HHSN268200800007C/HL/NHLBI NIH HHS/United States
GR  - N01HC55222/HL/NHLBI NIH HHS/United States
GR  - U01 AG042145/AG/NIA NIH HHS/United States
GR  - HHSN268201200036C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201800001C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700001I/HL/NHLBI NIH HHS/United States
GR  - U01 AG042168/AG/NIA NIH HHS/United States
GR  - HHSN268201700004I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700005C/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700001C/HL/NHLBI NIH HHS/United States
GR  - N01HC85082/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700003C/HL/NHLBI NIH HHS/United States
GR  - U01 AG027810/AG/NIA NIH HHS/United States
GR  - HHSN268201700002I/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700005I/HL/NHLBI NIH HHS/United States
GR  - N01HC85079/HL/NHLBI NIH HHS/United States
GR  - R01 AG023629/AG/NIA NIH HHS/United States
GR  - R01 HL134320/HL/NHLBI NIH HHS/United States
GR  - N01HC85080/HL/NHLBI NIH HHS/United States
GR  - HHSN268201700003I/HL/NHLBI NIH HHS/United States
GR  - 75N92019D00031/HL/NHLBI NIH HHS/United States
GR  - U01 AG042143/AG/NIA NIH HHS/United States
GR  - U01 AR066160/AR/NIAMS NIH HHS/United States
GR  - N01HC85081/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200511
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Androgens)
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Adult
MH  - Androgens/deficiency
MH  - Cardiovascular Diseases/*epidemiology/mortality
MH  - Cause of Death
MH  - Cohort Studies
MH  - Dementia/*epidemiology/mortality
MH  - Dihydrotestosterone/blood
MH  - Estradiol/blood
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Mass Spectrometry
MH  - Men's Health
MH  - Neoplasms/*epidemiology/mortality
MH  - Prospective Studies
MH  - Testosterone/*blood
PMC - PMC7239545
OTO - NOTNLM
OT  - *epidemiology
OT  - *general endocrinology
OT  - *sex steroids & HRT
COIS- Competing interests: None declared.
EDAT- 2020/05/14 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-034777 [pii]
AID - 10.1136/bmjopen-2019-034777 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 11;10(5):e034777. doi: 10.1136/bmjopen-2019-034777.


PMID- 32398225
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20201218
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 May 12
TI  - Ethics of reallocating ventilators in the covid-19 pandemic.
PG  - m1828
LID - 10.1136/bmj.m1828 [doi]
FAU - Peterson, Andrew
AU  - Peterson A
AD  - Department of Philosophy, Institute for Philosophy and Public Policy, George
      Mason University, Fairfax, VA, USA apeter31@gmu.edu.
FAU - Largent, Emily A
AU  - Largent EA
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine and
      Leonard Davis Institute of Health Economics, University of Pennsylvania,
      Philadelphia, PA, USA.
FAU - Karlawish, Jason
AU  - Karlawish J
AD  - Departments of Medicine, Medical Ethics and Health Policy, and Neurology, Penn
      Memory Center and Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Decision Making
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - *Resource Allocation/ethics
MH  - Respiration, Artificial/ethics/*instrumentation
MH  - SARS-CoV-2
COIS- Competing interests: We have read and understood BMJ policy on declaration of
      interests and declare that JK is a site principal investigator for clinical
      trials with Eli Lilly and Novartis.
EDAT- 2020/05/14 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.1136/bmj.m1828 [doi]
PST - epublish
SO  - BMJ. 2020 May 12;369:m1828. doi: 10.1136/bmj.m1828.


PMID- 32398066
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 12
TI  - How do 66 European institutional review boards approve one protocol for an
      international prospective observational study on traumatic brain injury?
      Experiences from the CENTER-TBI study.
PG  - 36
LID - 10.1186/s12910-020-00480-8 [doi]
AB  - BACKGROUND: The European Union (EU) aims to optimize patient protection and
      efficiency of health-care research by harmonizing procedures across Member
      States. Nonetheless, further improvements are required to increase multicenter
      research efficiency. We investigated IRB procedures in a large prospective
      European multicenter study on traumatic brain injury (TBI), aiming to inform and 
      stimulate initiatives to improve efficiency. METHODS: We reviewed relevant
      documents regarding IRB submission and IRB approval from European neurotrauma
      centers participating in the Collaborative European NeuroTrauma Effectiveness
      Research in Traumatic Brain Injury (CENTER-TBI). Documents included detailed
      information on IRB procedures and the duration from IRB submission until
      approval(s). They were translated and analyzed to determine the level of
      harmonization of IRB procedures within Europe. RESULTS: From 18 countries, 66
      centers provided the requested documents. The primary IRB review was conducted
      centrally (N = 11, 61%) or locally (N = 7, 39%) and primary IRB approval was
      obtained after one (N = 8, 44%), two (N = 6, 33%) or three (N = 4, 23%) review
      rounds with a median duration of respectively 50 and 98 days until primary IRB
      approval. Additional IRB approval was required in 55% of countries and could
      increase duration to 535 days. Total duration from submission until required IRB 
      approval was obtained was 114 days (IQR 75-224) and appeared to be shorter after 
      submission to local IRBs compared to central IRBs (50 vs. 138 days, p = 0.0074). 
      CONCLUSION: We found variation in IRB procedures between and within European
      countries. There were differences in submission and approval requirements, number
      of review rounds and total duration. Research collaborations could benefit from
      the implementation of more uniform legislation and regulation while acknowledging
      local cultural habits and moral values between countries.
FAU - Timmers, Marjolein
AU  - Timmers M
AD  - Department of Intensive Care, Erasmus MC - University Medical Centre Rotterdam,
      P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
FAU - van Dijck, Jeroen T J M
AU  - van Dijck JTJM
AD  - Department of Neurosurgery, University Neurosurgical Center Holland, LUMC, HMC & 
      Haga Teaching Hospital, Leiden, The Hague, The Netherlands.
FAU - van Wijk, Roel P J
AU  - van Wijk RPJ
AD  - Department of Neurosurgery, University Neurosurgical Center Holland, LUMC, HMC & 
      Haga Teaching Hospital, Leiden, The Hague, The Netherlands.
FAU - Legrand, Valerie
AU  - Legrand V
AD  - ICON plc, South County Business Park Leopardstown, Dublin 18, Ireland.
FAU - van Veen, Ernest
AU  - van Veen E
AD  - Department of Intensive Care, Erasmus MC - University Medical Centre Rotterdam,
      P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
AD  - Department of Public Health, Erasmus MC - University Medical Centre Rotterdam,
      Rotterdam, the Netherlands.
FAU - Maas, Andrew I R
AU  - Maas AIR
AD  - Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.
AD  - University of Antwerp, Antwerp, Belgium.
FAU - Menon, David K
AU  - Menon DK
AD  - Department of Anaesthesia, University of Cambridge, Cambridge, UK.
FAU - Citerio, Giuseppe
AU  - Citerio G
AD  - School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
AD  - San Gerardo Hospital, ASST-Monza, Monza, Italy.
FAU - Stocchetti, Nino
AU  - Stocchetti N
AD  - Department of Physiopathology and Transplantation, Milan University, Milan,
      Italy.
AD  - Neuro ICU Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milano, Milan,
      Italy.
FAU - Kompanje, Erwin J O
AU  - Kompanje EJO
AUID- ORCID: 0000-0002-0649-4019
AD  - Department of Intensive Care, Erasmus MC - University Medical Centre Rotterdam,
      P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands. erwinkompanje@me.com.
AD  - Department of Medical Ethics and Philosophy of Medicine, Erasmus MC - University 
      Medical Center Rotterdam, Rotterdam, the Netherlands. erwinkompanje@me.com.
CN  - CENTER-TBI investigators and participants
LA  - eng
GR  - 602150/European Commission/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Brain Injuries, Traumatic/therapy
MH  - *Ethics Committees, Research
MH  - Europe
MH  - Health Services Research
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Observational Studies as Topic
MH  - Prospective Studies
PMC - PMC7216427
OTO - NOTNLM
OT  - *CENTER-TBI
OT  - *European Union
OT  - *Harmonization
OT  - *Health-care research
OT  - *Research ethic committees
IR  - Akerlund C
FIR - Akerlund, Cecilia
IR  - Amrein K
FIR - Amrein, Krisztina
IR  - Andelic N
FIR - Andelic, Nada
IR  - Andreassen L
FIR - Andreassen, Lasse
IR  - Anke A
FIR - Anke, Audny
IR  - Antoni A
FIR - Antoni, Anna
IR  - Audibert G
FIR - Audibert, Gerard
IR  - Azouvi P
FIR - Azouvi, Philippe
IR  - Azzolini ML
FIR - Azzolini, Maria Luisa
IR  - Bartels R
FIR - Bartels, Ronald
IR  - Barzo P
FIR - Barzo, Pal
IR  - Beauvais R
FIR - Beauvais, Romuald
IR  - Beer R
FIR - Beer, Ronny
IR  - Bellander BM
FIR - Bellander, Bo-Michael
IR  - Belli A
FIR - Belli, Antonio
IR  - Benali H
FIR - Benali, Habib
IR  - Berardino M
FIR - Berardino, Maurizio
IR  - Beretta L
FIR - Beretta, Luigi
IR  - Blaabjerg M
FIR - Blaabjerg, Morten
IR  - Bragge P
FIR - Bragge, Peter
IR  - Brazinova A
FIR - Brazinova, Alexandra
IR  - Brinck V
FIR - Brinck, Vibeke
IR  - Brooker J
FIR - Brooker, Joanne
IR  - Brorsson C
FIR - Brorsson, Camilla
IR  - Buki A
FIR - Buki, Andras
IR  - Bullinger M
FIR - Bullinger, Monika
IR  - Cabeleira M
FIR - Cabeleira, Manuel
IR  - Caccioppola A
FIR - Caccioppola, Alessio
IR  - Calappi E
FIR - Calappi, Emiliana
IR  - Calvi MR
FIR - Calvi, Maria Rosa
IR  - Cameron P
FIR - Cameron, Peter
IR  - Lozano GC
FIR - Lozano, Guillermo Carbayo
IR  - Carbonara M
FIR - Carbonara, Marco
IR  - Cavallo S
FIR - Cavallo, Simona
IR  - Chevallard G
FIR - Chevallard, Giorgio
IR  - Chieregato A
FIR - Chieregato, Arturo
IR  - Citerio G
FIR - Citerio, Giuseppe
IR  - Ceyisakar I
FIR - Ceyisakar, Iris
IR  - Coburn M
FIR - Coburn, Mark
IR  - Coles J
FIR - Coles, Jonathan
IR  - Cooper JD
FIR - Cooper, Jamie D
IR  - Correia M
FIR - Correia, Marta
IR  - Covic A
FIR - Covic, Amra
IR  - Curry N
FIR - Curry, Nicola
IR  - Czeiter E
FIR - Czeiter, Endre
IR  - Czosnyka M
FIR - Czosnyka, Marek
IR  - Dahyot-Fizelier C
FIR - Dahyot-Fizelier, Claire
IR  - Dark P
FIR - Dark, Paul
IR  - Dawes H
FIR - Dawes, Helen
IR  - De Keyser V
FIR - De Keyser, Veronique
IR  - Degos V
FIR - Degos, Vincent
IR  - Corte FD
FIR - Corte, Francesco Della
IR  - den Boogert H
FIR - den Boogert, Hugo
IR  - Depreitere B
FIR - Depreitere, Bart
IR  - Dilvesi D
FIR - Dilvesi, Dula
IR  - Dixit A
FIR - Dixit, Abhishek
IR  - Donoghue E
FIR - Donoghue, Emma
IR  - Dreier J
FIR - Dreier, Jens
IR  - Duliere GL
FIR - Duliere, Guy-Loup
IR  - Ercole A
FIR - Ercole, Ari
IR  - Esser P
FIR - Esser, Patrick
IR  - Ezer E
FIR - Ezer, Erzsebet
IR  - Fabricius M
FIR - Fabricius, Martin
IR  - Feigin VL
FIR - Feigin, Valery L
IR  - Foks K
FIR - Foks, Kelly
IR  - Frisvold S
FIR - Frisvold, Shirin
IR  - Furmanov A
FIR - Furmanov, Alex
IR  - Gagliardo P
FIR - Gagliardo, Pablo
IR  - Galanaud D
FIR - Galanaud, Damien
IR  - Gantner D
FIR - Gantner, Dashiell
IR  - Gao G
FIR - Gao, Guoyi
IR  - George P
FIR - George, Pradeep
IR  - Ghuysen A
FIR - Ghuysen, Alexandre
IR  - Giga L
FIR - Giga, Lelde
IR  - Glocker B
FIR - Glocker, Ben
IR  - Golubovic J
FIR - Golubovic, Jagos
IR  - Gomez PA
FIR - Gomez, Pedro A
IR  - Gratz J
FIR - Gratz, Johannes
IR  - Gravesteijn B
FIR - Gravesteijn, Benjamin
IR  - Grossi F
FIR - Grossi, Francesca
IR  - Gruen RL
FIR - Gruen, Russell L
IR  - Gupta D
FIR - Gupta, Deepak
IR  - Haagsma JA
FIR - Haagsma, Juanita A
IR  - Haitsma I
FIR - Haitsma, Iain
IR  - Helbok R
FIR - Helbok, Raimund
IR  - Helseth E
FIR - Helseth, Eirik
IR  - Horton L
FIR - Horton, Lindsay
IR  - Huijben J
FIR - Huijben, Jilske
IR  - Hutchinson PJ
FIR - Hutchinson, Peter J
IR  - Jacobs B
FIR - Jacobs, Bram
IR  - Jankowski S
FIR - Jankowski, Stefan
IR  - Jarrett M
FIR - Jarrett, Mike
IR  - Jiang JY
FIR - Jiang, Ji-Yao
IR  - Johnson F
FIR - Johnson, Faye
IR  - Jones K
FIR - Jones, Kelly
IR  - Karan M
FIR - Karan, Mladen
IR  - Kolias AG
FIR - Kolias, Angelos G
IR  - Kompanje E
FIR - Kompanje, Erwin
IR  - Kondziella D
FIR - Kondziella, Daniel
IR  - Koraropoulos E
FIR - Koraropoulos, Evgenios
IR  - Koskinen LO
FIR - Koskinen, Lars-Owe
IR  - Kovacs N
FIR - Kovacs, Noemi
IR  - Kowark A
FIR - Kowark, Ana
IR  - Lagares A
FIR - Lagares, Alfonso
IR  - Lanyon L
FIR - Lanyon, Linda
IR  - Laureys S
FIR - Laureys, Steven
IR  - Lecky F
FIR - Lecky, Fiona
IR  - Ledoux D
FIR - Ledoux, Didier
IR  - Lefering R
FIR - Lefering, Rolf
IR  - Legrand V
FIR - Legrand, Valerie
IR  - Lejeune A
FIR - Lejeune, Aurelie
IR  - Levi L
FIR - Levi, Leon
IR  - Lightfoot R
FIR - Lightfoot, Roger
IR  - Lingsma H
FIR - Lingsma, Hester
IR  - Maas AIR
FIR - Maas, Andrew I R
IR  - Castano-Leon AM
FIR - Castano-Leon, Ana M
IR  - Maegele M
FIR - Maegele, Marc
IR  - Majdan M
FIR - Majdan, Marek
IR  - Manara A
FIR - Manara, Alex
IR  - Manley G
FIR - Manley, Geoffrey
IR  - Martino C
FIR - Martino, Costanza
IR  - Marechal H
FIR - Marechal, Hugues
IR  - Mattern J
FIR - Mattern, Julia
IR  - McMahon C
FIR - McMahon, Catherine
IR  - Melegh B
FIR - Melegh, Bela
IR  - Menon D
FIR - Menon, David
IR  - Menovsky T
FIR - Menovsky, Tomas
IR  - Misset B
FIR - Misset, Benoit
IR  - Mulazzi D
FIR - Mulazzi, Davide
IR  - Muraleedharan V
FIR - Muraleedharan, Visakh
IR  - Murray L
FIR - Murray, Lynnette
IR  - Negru A
FIR - Negru, Ancuta
IR  - Nelson D
FIR - Nelson, David
IR  - Newcombe V
FIR - Newcombe, Virginia
IR  - Nieboer D
FIR - Nieboer, Daan
IR  - Nyiradi J
FIR - Nyiradi, Jozsef
IR  - Olubukola O
FIR - Olubukola, Otesile
IR  - Oresic M
FIR - Oresic, Matej
IR  - Ortolano F
FIR - Ortolano, Fabrizio
IR  - Palotie A
FIR - Palotie, Aarno
IR  - Parizel PM
FIR - Parizel, Paul M
IR  - Payen JF
FIR - Payen, Jean-Francois
IR  - Perera N
FIR - Perera, Natascha
IR  - Perlbarg V
FIR - Perlbarg, Vincent
IR  - Persona P
FIR - Persona, Paolo
IR  - Peul W
FIR - Peul, Wilco
IR  - Piippo-Karjalainen A
FIR - Piippo-Karjalainen, Anna
IR  - Pirinen M
FIR - Pirinen, Matti
IR  - Ples H
FIR - Ples, Horia
IR  - Polinder S
FIR - Polinder, Suzanne
IR  - Pomposo I
FIR - Pomposo, Inigo
IR  - Posti JP
FIR - Posti, Jussi P
IR  - Puybasset L
FIR - Puybasset, Louis
IR  - Radoi A
FIR - Radoi, Andreea
IR  - Ragauskas A
FIR - Ragauskas, Arminas
IR  - Raj R
FIR - Raj, Rahul
IR  - Rambadagalla M
FIR - Rambadagalla, Malinka
IR  - Rhodes J
FIR - Rhodes, Jonathan
IR  - Richardson S
FIR - Richardson, Sylvia
IR  - Richter S
FIR - Richter, Sophie
IR  - Ripatti S
FIR - Ripatti, Samuli
IR  - Rocka S
FIR - Rocka, Saulius
IR  - Roe C
FIR - Roe, Cecilie
IR  - Roise O
FIR - Roise, Olav
IR  - Rosand J
FIR - Rosand, Jonathan
IR  - Rosenfeld JV
FIR - Rosenfeld, Jeffrey V
IR  - Rosenlund C
FIR - Rosenlund, Christina
IR  - Rosenthal G
FIR - Rosenthal, Guy
IR  - Rossaint R
FIR - Rossaint, Rolf
IR  - Rossi S
FIR - Rossi, Sandra
IR  - Rueckert D
FIR - Rueckert, Daniel
IR  - Rusnak M
FIR - Rusnak, Martin
IR  - Sahuquillo J
FIR - Sahuquillo, Juan
IR  - Sakowitz O
FIR - Sakowitz, Oliver
IR  - Sanchez-Porras R
FIR - Sanchez-Porras, Renan
IR  - Sandor J
FIR - Sandor, Janos
IR  - Schafer N
FIR - Schafer, Nadine
IR  - Schmidt S
FIR - Schmidt, Silke
IR  - Schoechl H
FIR - Schoechl, Herbert
IR  - Schoonman G
FIR - Schoonman, Guus
IR  - Schou RF
FIR - Schou, Rico Frederik
IR  - Schwendenwein E
FIR - Schwendenwein, Elisabeth
IR  - Sewalt C
FIR - Sewalt, Charlie
IR  - Skandsen T
FIR - Skandsen, Toril
IR  - Smielewski P
FIR - Smielewski, Peter
IR  - Sorinola A
FIR - Sorinola, Abayomi
IR  - Stamatakis E
FIR - Stamatakis, Emmanuel
IR  - Stanworth S
FIR - Stanworth, Simon
IR  - Stevens R
FIR - Stevens, Robert
IR  - Stewart W
FIR - Stewart, William
IR  - Steyerberg EW
FIR - Steyerberg, Ewout W
IR  - Stocchetti N
FIR - Stocchetti, Nino
IR  - Sundstrom N
FIR - Sundstrom, Nina
IR  - Synnot A
FIR - Synnot, Anneliese
IR  - Takala R
FIR - Takala, Riikka
IR  - Tamas V
FIR - Tamas, Viktoria
IR  - Tamosuitis T
FIR - Tamosuitis, Tomas
IR  - Taylor MS
FIR - Taylor, Mark Steven
IR  - Ao BT
FIR - Ao, Braden Te
IR  - Tenovuo O
FIR - Tenovuo, Olli
IR  - Theadom A
FIR - Theadom, Alice
IR  - Thomas M
FIR - Thomas, Matt
IR  - Tibboel D
FIR - Tibboel, Dick
IR  - Timmers M
FIR - Timmers, Marjolein
IR  - Tolias C
FIR - Tolias, Christos
IR  - Trapani T
FIR - Trapani, Tony
IR  - Tudora CM
FIR - Tudora, Cristina Maria
IR  - Vajkoczy P
FIR - Vajkoczy, Peter
IR  - Vallance S
FIR - Vallance, Shirley
IR  - Valeinis E
FIR - Valeinis, Egils
IR  - Vamos Z
FIR - Vamos, Zoltan
IR  - Van der Steen G
FIR - Van der Steen, Gregory
IR  - van der Naalt J
FIR - van der Naalt, Joukje
IR  - van Dijck JTJM
FIR - van Dijck, Jeroen T J M
IR  - van Essen TA
FIR - van Essen, Thomas A
IR  - Van Hecke W
FIR - Van Hecke, Wim
IR  - van Heugten C
FIR - van Heugten, Caroline
IR  - Van Praag D
FIR - Van Praag, Dominique
IR  - Vyvere TV
FIR - Vyvere, Thijs Vande
IR  - van Wijk RPJ
FIR - van Wijk, Roel P J
IR  - Vargiolu A
FIR - Vargiolu, Alessia
IR  - Vega E
FIR - Vega, Emmanuel
IR  - Velt K
FIR - Velt, Kimberley
IR  - Verheyden J
FIR - Verheyden, Jan
IR  - Vespa PM
FIR - Vespa, Paul M
IR  - Vik A
FIR - Vik, Anne
IR  - Vilcinis R
FIR - Vilcinis, Rimantas
IR  - Volovici V
FIR - Volovici, Victor
IR  - von Steinbuchel N
FIR - von Steinbuchel, Nicole
IR  - Voormolen D
FIR - Voormolen, Daphne
IR  - Vulekovic P
FIR - Vulekovic, Petar
IR  - Wang KKW
FIR - Wang, Kevin K W
IR  - Wiegers E
FIR - Wiegers, Eveline
IR  - Williams G
FIR - Williams, Guy
IR  - Wilson L
FIR - Wilson, Lindsay
IR  - Winzeck S
FIR - Winzeck, Stefan
IR  - Wolf S
FIR - Wolf, Stefan
IR  - Yang Z
FIR - Yang, Zhihui
IR  - Ylen P
FIR - Ylen, Peter
IR  - Younsi A
FIR - Younsi, Alexander
IR  - Zeiler FA
FIR - Zeiler, Frederick A
IR  - Zelinkova V
FIR - Zelinkova, Veronika
IR  - Ziverte A
FIR - Ziverte, Agate
IR  - Zoerle T
FIR - Zoerle, Tommaso
EDAT- 2020/05/14 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/11/09 00:00 [received]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00480-8 [doi]
AID - 10.1186/s12910-020-00480-8 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 12;21(1):36. doi: 10.1186/s12910-020-00480-8.


PMID- 32397999
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 12
TI  - Ethical challenges regarding the use of stem cells: interviews with researchers
      from Saudi Arabia.
PG  - 35
LID - 10.1186/s12910-020-00482-6 [doi]
AB  - BACKGROUND: With the huge number of patients who suffer from chronic and
      incurable diseases, medical scientists continue to search for new curative
      methods for patients in dire need of treatment. Interest in stem cells is
      growing, generating high expectations in terms of the possible benefits that
      could be derived from stem cell research and therapy. However, regardless of the 
      hope of stem cells changing and improving lives, there are many ethical,
      religious, and political challenges and controversies that affect the research,
      and mandated to establish ethical guidelines and regulations. In Saudi Arabia,
      key stakeholders play an active role in discussing the ethics of stem cell
      research and therapy. The focus of the study was to explore professionals'
      perceptions related to the ethical challenges of using stem cells in research and
      treatment in Saudi Arabia. RESULTS: A qualitative research study was conducted to
      explore and describe the perceptions of 25 professionals employed at different
      tertiary hospitals in the various regions of Saudi. A thematic analysis was
      performed to search for and identify the most significant perceptions shared by
      the participants. Four themes were generated based on the ethical challenges of
      four areas related to stem cell use, including (1) forbidden and permitted
      sources of stem cells, (2) informed consent, (3) beneficence, and (4) ethical
      regulations and guidelines. CONCLUSION: The study identified that there is a
      growing need to advance the knowledge, education, and awareness related to stem
      cell research and treatment in Saudi Arabia.
FAU - Alahmad, Ghiath
AU  - Alahmad G
AUID- ORCID: 0000-0002-3331-4378
AD  - King Abdullah International Medical Research Center (KAIMRC), King Saud Bin
      Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry
      of National Guard - Health Affairs, P.O. Box 22490, Mail Code 1515, Riyadh,
      11426, Saudi Arabia. ghiathalahmad@hotmail.com.
FAU - Aljohani, Sarah
AU  - Aljohani S
AD  - King Abdullah International Medical Research Center (KAIMRC), King Saud Bin
      Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry
      of National Guard - Health Affairs, P.O. Box 22490, Mail Code 1515, Riyadh,
      11426, Saudi Arabia.
FAU - Najjar, Muath Fahmi
AU  - Najjar MF
AD  - King Abdullah International Medical Research Center (KAIMRC), King Saud Bin
      Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry
      of National Guard - Health Affairs, P.O. Box 22490, Mail Code 1515, Riyadh,
      11426, Saudi Arabia.
LA  - eng
GR  - RC16/188/R/King Abdullah International Medical Research Center/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Physicians
MH  - Qualitative Research
MH  - *Research Personnel
MH  - Saudi Arabia
MH  - *Stem Cell Research/ethics
MH  - Stem Cells
PMC - PMC7216643
OTO - NOTNLM
OT  - *Ethics
OT  - *Informed consent
OT  - *Law
OT  - *Qualitative
OT  - *Stem cell
EDAT- 2020/05/14 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00482-6 [doi]
AID - 10.1186/s12910-020-00482-6 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 12;21(1):35. doi: 10.1186/s12910-020-00482-6.


PMID- 32397793
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 2156-535X (Electronic)
IS  - 2156-5333 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Oct
TI  - Moving Beyond the Friend-Foe Myth: A Scoping Review of the Use of Social Media in
      Adolescent and Young Adult Oncology.
PG  - 561-571
LID - 10.1089/jayao.2019.0168 [doi]
AB  - Purpose: Adolescents and young adults (AYA) with cancer present a unique
      challenge to health care institutions. Their cancer diagnosis and treatment have 
      a profound impact upon their health and well-being. Despite the various support
      services aimed at improving their quality of life, their needs and preferences
      are often underestimated or misjudged. Recent studies show that patients are
      empowered by the knowledge and support they receive online. Given the extensive
      use of social media among AYA, we aim to identify promises, challenges, and
      recommendations for integrating these platforms in AYA cancer care. Methodology: 
      We systematically searched seven databases systematically: Scopus, PubMed,
      PsycInfo, Web of Science, CINAHL, SocINDEX, and Media. We placed no restriction
      on the type of methodology used in the studies. The Preferred Reporting Items for
      Systematic Reviews and Meta-Analyses was used to frame the research. Results:
      Many studies argued that health care professionals need to integrate social media
      in their clinical practice to engage with patients' lifeworld. Social media were 
      considered important allies in optimizing cancer care at all levels of support,
      ranging from information provision, treatment adherence, diet and exercise
      interventions, to professional, peer, and psychosocial self-care. Lack of
      research on the efficacy of social media in the context of psychosocial support
      was a commonly cited problem. A small number of publications paid attention to
      the inherent risks of promoting self-care online. Conclusion: Future studies
      should continue to pursue empirical research on the efficacy of online
      psychosocial care, while not neglecting the ethical challenges of social media
      research.
FAU - De Clercq, Eva
AU  - De Clercq E
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Rost, Michael
AU  - Rost M
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
FAU - Gumy-Pause, Fabienne
AU  - Gumy-Pause F
AD  - Departement de l'Enfant et de l'Adolescent, Onco-hematologie pediatrique,
      Hopitaux Universitaires de Geneve, Geneve, Switzerland.
FAU - Diesch, Tamara
AU  - Diesch T
AD  - Onkologie/Hamatologie, Universitats-Kinderspital Basel, Basel, Switzerland.
FAU - Espelli, Vittoria
AU  - Espelli V
AD  - Oncologia medica, Istituto Oncologico della Svizzera Italiana, Bellinzona,
      Switzerland.
FAU - Elger, Bernice S
AU  - Elger BS
AD  - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200512
PL  - United States
TA  - J Adolesc Young Adult Oncol
JT  - Journal of adolescent and young adult oncology
JID - 101543508
SB  - IM
EIN - J Adolesc Young Adult Oncol. 2021 Apr;10(2):246. PMID: 33872067
MH  - Adolescent
MH  - Ethics
MH  - Humans
MH  - Neoplasms/*psychology
MH  - Social Media/*standards
MH  - Young Adult
OTO - NOTNLM
OT  - *digital natives
OT  - *ethics
OT  - *social media
OT  - *support
EDAT- 2020/05/14 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1089/jayao.2019.0168 [doi]
PST - ppublish
SO  - J Adolesc Young Adult Oncol. 2020 Oct;9(5):561-571. doi: 10.1089/jayao.2019.0168.
      Epub 2020 May 12.


PMID- 32397618
OWN - NLM
STAT- MEDLINE
DCOM- 20200922
LR  - 20200922
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 9
DP  - 2020 May 10
TI  - Access to Healthcare for Immigrant Children in Canada.
LID - E3320 [pii]
LID - 10.3390/ijerph17093320 [doi]
AB  - Immigrants experience poorer health outcomes than nonimmigrants in Canada for
      several reasons. A central contributing factor to poor health outcomes for
      immigrants is access to healthcare. Previous research on access to healthcare for
      immigrants has largely focused on the experience of immigrant adults. The purpose
      of this study was to investigate how immigrants access health services for their 
      children in Alberta, Canada. Our study involved a descriptive qualitative design.
      Upon receiving ethics approval from the University of Alberta Research Ethics
      Board, we invited immigrant parents to participate in this study. We interviewed 
      50 immigrant parents, including 17 fathers and 33 mothers. Interviews were audio 
      recorded, transcribed, and analyzed according to the themes that emerged.
      Findings reveal that systemic barriers contributed to challenges in accessing
      healthcare for immigrant children. Participants identified several of these
      barriers-namely, system barriers, language and cultural barriers, relationship
      with health professionals, and financial barriers. These barriers can be
      addressed by policymakers and service providers by strengthening the diversity of
      the workforce, addressing income as a social determinant of health, and improving
      access to language interpretation services.
FAU - Salami, Bukola
AU  - Salami B
AD  - Faculty of Nursing, University of Alberta, Edmonton, AB T6G 1C9, Canada.
FAU - Mason, Alleson
AU  - Mason A
AD  - Faculty of Nursing, University of Alberta, Edmonton, AB T6G 1C9, Canada.
FAU - Salma, Jordana
AU  - Salma J
AD  - Faculty of Nursing, University of Alberta, Edmonton, AB T6G 1C9, Canada.
FAU - Yohani, Sophie
AU  - Yohani S
AD  - Faculty of Education, University of Alberta, Edmonton, AB T6G 2G5, Canada.
FAU - Amin, Maryam
AU  - Amin M
AUID- ORCID: 0000-0003-2249-5465
AD  - Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7,
      Canada.
FAU - Okeke-Ihejirika, Philomena
AU  - Okeke-Ihejirika P
AD  - Faculty of Arts, University of Alberta, Edmonton, AB T6G 2R7, Canada.
FAU - Ladha, Tehseen
AU  - Ladha T
AD  - Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R7,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200510
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Adult
MH  - Alberta
MH  - Canada
MH  - Child
MH  - Communication Barriers
MH  - *Cultural Diversity
MH  - Emigrants and Immigrants/*statistics & numerical data
MH  - *Health Services Accessibility/statistics & numerical data
MH  - Humans
MH  - Interviews as Topic
MH  - Language
MH  - Primary Health Care/*statistics & numerical data
MH  - Qualitative Research
PMC - PMC7246832
OTO - NOTNLM
OT  - *Alberta
OT  - *Canada
OT  - *access to healthcare
OT  - *child health
OT  - *immigrant health
OT  - *immigration
OT  - *migrant health
OT  - *migration
EDAT- 2020/05/14 06:00
MHDA- 2020/09/23 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/09/23 06:00 [medline]
AID - ijerph17093320 [pii]
AID - 10.3390/ijerph17093320 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 May 10;17(9). pii: ijerph17093320. doi:
      10.3390/ijerph17093320.


PMID- 32397470
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 9
TI  - Humane Use of Cardiac Puncture for Non-Terminal Phlebotomy of Wild-Caught and
      Released Peromyscus spp.
LID - E826 [pii]
LID - 10.3390/ani10050826 [doi]
AB  - The cardiac puncture technique for obtaining relatively large volume (50-150
      microL) blood samples from sedated rodents has been used in research for nearly a
      century. Historically, its use to phlebotomize and then release live rodents was 
      more common. However, recently its use in a non-terminal capacity frequently
      imparts negative connotations in part because exsanguination of sedated animals
      via cardiac puncture is now an American Veterinary Medical Association-approved
      euthanasia technique. This association has resulted in ethical concerns by
      manuscript reviewers and in a few instances, outright refusal by some
      peer-reviewed journals to publish research that utilized the technique. To
      counter the perceived negative associations with its non-terminal use, we
      summarized nearly two decades (2001-2019) of capture and handling data throughout
      Connecticut, resulting in over 7000 cardiac punctures performed on nearly 5000
      sedated, live-captured and released Peromyscus spp. We show that our total
      handling mortality rate (3.7%) was comparable, if not lower, than similar field
      studies that utilized other phlebotomy techniques. Many public health, integrated
      tick management, and vector-borne disease ecology studies require samples from
      individual wild-caught Peromyscus spp. over time to determine intervention
      efficacy and pathogen infection monitoring, and in such field studies,
      post-operative care is not an option. Proper execution of cardiac puncture does
      not increase susceptibility of individuals to predation upon release as can
      potential ocular abnormalities or infections that can occur as the result of use 
      of other techniques. We posit that neither exsanguination nor resulting
      euthanasia are requirements of cardiac puncture and that its use is entirely
      appropriate for obtaining blood samples from live-captured and released
      Peromyscus spp. Properly performed cardiac puncture is an excellent technique to 
      obtain blood samples from sedated, individual Peromyscus spp. on multiple
      appropriately-spaced occasions over single trapping seasons while keeping animal 
      welfare a top priority.
FAU - Williams, Scott C
AU  - Williams SC
AUID- ORCID: 0000-0002-3751-7703
AD  - Department of Forestry and Horticulture, Center for Vector Biology and Zoonotic
      Diseases, The Connecticut Agricultural Experiment Station, PO Box 1106, New
      Haven, CT 06504, USA.
FAU - Linske, Megan A
AU  - Linske MA
AD  - Department of Entomology, Center for Vector Biology and Zoonotic Diseases, The
      Connecticut Agricultural Experiment Station, PO Box 1106, New Haven, CT 06504,
      USA.
FAU - Stafford, Kirby C 3rd
AU  - Stafford KC 3rd
AD  - Department of Entomology, Center for Vector Biology and Zoonotic Diseases, The
      Connecticut Agricultural Experiment Station, PO Box 1106, New Haven, CT 06504,
      USA.
LA  - eng
GR  - 1/CX/CSRD VA/United States
GR  - 2/CC/CDC HHS/United States
GR  - 3/Natural Resources Conservation Service
GR  - 4/US Biologic, Inc.
GR  - 5/Propane Education & Research Council
GR  - 6/New England Propane
GR  - 7/Long Island Sound Futures Fund
GR  - 8/The Nature Conservancy's Weed it Now Program
GR  - 9/Connecticut Chapter of the Nature Conservancy
GR  - 10/Norcross Wildlife Foundation
GR  - 11/Aquarion Water Company
GR  - 12/South Central Connecticut Regional Water Authority
GR  - 13/Town of Greenwich, CT
GR  - 14/Town of Mansfield, CT
GR  - 15/Hatch Act Funds
GR  - 16/State of Connecticut General Fund
PT  - Journal Article
DEP - 20200509
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7278385
OTO - NOTNLM
OT  - Peromyscus leucopus
OT  - Peromyscus maniculatus
OT  - blood sampling
OT  - cardiac puncture
OT  - isoflurane
EDAT- 2020/05/14 06:00
MHDA- 2020/05/14 06:01
CRDT- 2020/05/14 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/07 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/05/14 06:01 [medline]
AID - ani10050826 [pii]
AID - 10.3390/ani10050826 [doi]
PST - epublish
SO  - Animals (Basel). 2020 May 9;10(5). pii: ani10050826. doi: 10.3390/ani10050826.


PMID- 32397096
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May 8
TI  - Research Implications for Future Telemedicine Studies and Innovations in Diabetes
      and Hypertension-A Mixed Methods Study.
LID - E1340 [pii]
LID - 10.3390/nu12051340 [doi]
AB  - (1) Background: The objective of this study was to identify, categorize and
      prioritize current implications for future research in the use telemedicine for
      diabetes and hypertension in order to inform policy and practice decisions. (2)
      Methods: An iterative mixed methods design was followed, including three
      consecutive steps: An updated umbrella review of telemedicine effectiveness,
      qualitative content analysis of extracted data on current research needs and a
      quantitative survey with practitioners and health care researchers in order to
      prioritize the identified needs. (3) Results: Overall, 32 included records
      reported on future research implications. Qualitative content analysis yielded
      five categories as well as subcategories, covering a need for high quality
      studies, comprehensive technology assessments, in-depth considerations of
      patients' characteristics, ethics and safety as well as implementation
      strategies. The online survey revealed that the most pressing future research
      needs are data security, patient safety, patient satisfaction, implementation
      strategies and longer follow-ups. Chi(2) statistics and t-tests revealed
      significant differences in the priorities of participants with and without
      experience in telemedicine use, evaluation and development. A factor analysis
      revealed six over-arching factors. (4) Conclusion: These results may help
      learning from mistakes previously made and may serve as key topics of a future
      telemedicine research agenda.
FAU - Timpel, Patrick
AU  - Timpel P
AUID- ORCID: 0000-0002-5158-0178
AD  - Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav
      Carus, Technische Universitat Dresden, 01307 Dresden, Germany.
FAU - Harst, Lorenz
AU  - Harst L
AD  - Research Association Public Health Saxony/Center for Evidence-Based Healthcare,
      Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, 01307
      Dresden, Germany.
LA  - eng
GR  - 100310385/European Social Fund
PT  - Journal Article
DEP - 20200508
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
MH  - *Diabetes Mellitus
MH  - Forecasting
MH  - Humans
MH  - *Hypertension
MH  - *Qualitative Research
MH  - Telemedicine/methods/*trends
PMC - PMC7284383
OTO - NOTNLM
OT  - diabetes
OT  - factor analysis
OT  - hypertension
OT  - joint display
OT  - mixed method
OT  - qualitative content analysis
OT  - research needs
OT  - telemedicine
EDAT- 2020/05/14 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/05/01 00:00 [revised]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
AID - nu12051340 [pii]
AID - 10.3390/nu12051340 [doi]
PST - epublish
SO  - Nutrients. 2020 May 8;12(5). pii: nu12051340. doi: 10.3390/nu12051340.


PMID- 32396969
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1305-7456 (Print)
VI  - 14
IP  - 2
DP  - 2020 Mar
TI  - Knowledge and Attitude of Dentists and Patients Toward Use and Health Safety of
      Dental Amalgam in Saudi Arabia.
PG  - 233-238
LID - 10.1055/s-0040-1709829 [doi]
AB  - OBJECTIVE: The aim of this study was to assess: (1) the perceptions of dentists
      in Saudi Arabia concerning the amalgam controversy, (2) their attitude toward the
      ethical responsibility of patient information, and (3) patients' knowledge and
      attitude toward the use of dental amalgam. MATERIALS AND METHODS: A total of
      1,139 dentists were sampled on convenience by electronic survey. The
      questionnaire contained questions about the safety of dental amalgam, use of
      amalgam, case selection, alternate materials, and informing their patients about 
      risks of amalgam. Also, 425 patients were sampled on convenience and information 
      collected on their knowledge about amalgam and its acceptance in their oral
      cavities. RESULTS: A total of 201 dentists and 425 patients participated in the
      study. A total of 60% of dentists and specialists declared it safe. A total of
      32.4% (31) of general dental practitioners and 41% (43) specialists considered it
      a moral obligation to inform patients about the potential health risks associated
      with amalgam. Mercury toxicity was identified as the most common health hazard.
      About 57.3% dentists and 36.2% specialists opted for superior longevity as the
      principle advantage. Majority of patients (52.2%) in Saudi Arabia had no
      knowledge about dental amalgam. While 23.1% (98) had concern about poor color,
      8.7% (30) knew it contained silver while only 7.8% (27) patients were aware of
      its mercury content. CONCLUSION: Majority of dentists in Saudi Arabia found it
      safe to use amalgam while the patients had little knowledge about the possible
      issues with amalgam. It is recommended to improve public awareness about impact
      of mercury containing products on the environment.
FAU - Al-Nahedh, Hend N
AU  - Al-Nahedh HN
AD  - Department of Restorative Dental Sciences, College of Dentistry, King Saud
      University, Riyadh, Saudi Arabia.
FAU - El-Hejazi, Ahmed A
AU  - El-Hejazi AA
AD  - Department of Restorative Dental Sciences, College of Dentistry, King Saud
      University, Riyadh, Saudi Arabia.
FAU - Habib, Syed Rashid
AU  - Habib SR
AUID- ORCID: 0000-0002-4398-3479
AD  - Department of Prosthetic Dental Sciences, College of Dentistry, King Saud
      University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Germany
TA  - Eur J Dent
JT  - European journal of dentistry
JID - 101303672
PMC - PMC7274835
COIS- None declared.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1055/s-0040-1709829 [doi]
PST - ppublish
SO  - Eur J Dent. 2020 Mar;14(2):233-238. doi: 10.1055/s-0040-1709829. Epub 2020 May
      12.


PMID- 32396907
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1662-8063 (Electronic)
IS  - 1662-4246 (Linking)
VI  - 23
IP  - 3-4
DP  - 2020
TI  - At a Moment's Notice: Community Advisory Board Perspectives on Biobank
      Communication to Supplement Broad Consent.
PG  - 77-89
LID - 10.1159/000507057 [doi]
AB  - INTRODUCTION: To address ethical concerns about the of future research
      authorization, biobanks employing a broad model of consent can design ongoing
      communication with contributors. Notifying contributors at the time of sample
      distribution provides one form of communication to supplement broad consent.
      However, little is known about how community-informed governance might anticipate
      contributor responses and inform communication efforts. OBJECTIVE: We explored
      the attitudes of members of a three-site Community Advisory Board (CAB) network. 
      CAB members responded to a hypothetical proposal for notifying biobank
      contributors at the time of sample distribution to researchers utilizing the
      biobank. METHODS: We used regularly scheduled CAB meetings to facilitate 3
      large-group and 6 small-group discussions. Discussions were audio-recorded,
      transcribed, and analyzed for thematic content using descriptive thematic
      analysis. RESULTS: The results challenged our expectation of general support for 
      the proposed communications. While CAB members identified some advantages, they
      were concerned about several potential harms to biobank contributors and the
      biobank. The CABs understood biobank communication in terms of an ongoing
      relationship with the biobank and a personal contribution to research.
      CONCLUSION: Our findings contribute to the emerging literature on community
      engagement in biobanking. Additional communication with biobank contributors can 
      serve a variety of value-based objectives to supplement broad consent. Design of 
      communication efforts by biobanks can be improved by CAB members' anticipation of
      the unintended consequences of additional contact with contributors. CAB members'
      holistic interpretation of communication efforts suggests that biobank leadership
      considers all communication options as part of a more comprehensive
      communications strategy.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Meagher, Karen M
AU  - Meagher KM
AD  - Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA.
FAU - Curtis, Susan H
AU  - Curtis SH
AD  - Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA.
FAU - Gamm, Kylie O
AU  - Gamm KO
AD  - Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA.
FAU - Sutton, Erica J
AU  - Sutton EJ
AD  - Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA.
FAU - McCormick, Jennifer B
AU  - McCormick JB
AD  - Department of Humanities, College of Medicine, Pennsylvania State University,
      Hershey, Pennsylvania, USA.
FAU - Sharp, Richard R
AU  - Sharp RR
AD  - Mayo Clinic Biomedical Ethics Research Program, Rochester, Minnesota, USA,
      sharp.richard@mayo.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - Switzerland
TA  - Public Health Genomics
JT  - Public health genomics
JID - 101474167
SB  - IM
MH  - Access to Information
MH  - Attitude
MH  - *Biological Specimen Banks/ethics/trends
MH  - *Communication
MH  - Ethics, Research
MH  - *Governing Board/ethics/organization & administration
MH  - Humans
MH  - *Informed Consent/ethics/standards
MH  - Patient Rights
OTO - NOTNLM
OT  - *Biobank ethics
OT  - *Biorepository
OT  - *Broad consent
OT  - *Communication
OT  - *Community advisory board
OT  - *Governance
OT  - *Research ethics
EDAT- 2020/05/13 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/09/11 00:00 [received]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 000507057 [pii]
AID - 10.1159/000507057 [doi]
PST - ppublish
SO  - Public Health Genomics. 2020;23(3-4):77-89. doi: 10.1159/000507057. Epub 2020 May
      12.


PMID- 32396832
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210602
IS  - 0168-9525 (Print)
IS  - 0168-9525 (Linking)
VI  - 36
IP  - 6
DP  - 2020 Jun
TI  - Are Public Repository Requirements Exacerbating Lack of Diversity?
PG  - 390-394
LID - S0168-9525(20)30068-8 [pii]
LID - 10.1016/j.tig.2020.03.004 [doi]
AB  - Although public repository requirements are aimed at researchers and designed to 
      ensure that the utility of the limited data we have is optimized, these policies 
      also have ramifications for research participants. In this opinion article, I
      discuss how the nature of such repositories can subject participants whose data
      are 'banked' to unwitting participation in scientific projects they might find
      objectionable. In addition, concerns about the privacy of banked genomic data are
      exacerbated by recent projects that demonstrate the ability to re-identify
      genomic data, raising the specter of discriminatory or oppressive use of this
      information. These concerns are most likely to discourage participation in
      research that requires data sharing among those who have experienced these
      phenomena and are less likely to discount their likelihood.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - May, Thomas
AU  - May T
AD  - Elson S. Floyd College of Medicine, Washington State University, Vancouver, WA,
      USA; HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA. Electronic
      address: thomas.may@wsu.edu.
LA  - eng
GR  - G13 LM012445/LM/NLM NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200414
PL  - England
TA  - Trends Genet
JT  - Trends in genetics : TIG
JID - 8507085
SB  - IM
MH  - *Biological Variation, Population
MH  - Biomedical Research/*standards
MH  - Databases, Genetic/*standards
MH  - Genomics/*standards
MH  - Humans
MH  - Information Dissemination/*methods
MH  - Metadata/*standards
MH  - Patient Selection
MH  - Privacy
PMC - PMC7372716
MID - NIHMS1584914
OTO - NOTNLM
OT  - *data sharing
OT  - *ethics
EDAT- 2020/05/13 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/12/31 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
AID - S0168-9525(20)30068-8 [pii]
AID - 10.1016/j.tig.2020.03.004 [doi]
PST - ppublish
SO  - Trends Genet. 2020 Jun;36(6):390-394. doi: 10.1016/j.tig.2020.03.004. Epub 2020
      Apr 14.


PMID- 32396700
OWN - NLM
STAT- MEDLINE
DCOM- 20201230
LR  - 20210329
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 23
IP  - 5
DP  - 2020 May
TI  - Integrating oral PrEP delivery among African women in a large HIV endpoint-driven
      clinical trial.
PG  - e25491
LID - 10.1002/jia2.25491 [doi]
AB  - INTRODUCTION: Global guidelines emphasize the ethical obligation of investigators
      to help participants in HIV-endpoint trials reduce HIV risk by offering an
      optimal HIV prevention package. Oral pre-exposure prophylaxis (PrEP) has
      increasingly become part of state-of-the-art HIV prevention. Here we describe the
      process of integrating oral PrEP delivery into the HIV prevention package of the 
      Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. METHODS: ECHO
      was an open-label randomized clinical trial that compared HIV incidence among
      women randomized to one of three effective contraceptives. In total, 7830 women
      aged 16 to 35 years from 12 sites in four African countries (Eswatini, Kenya,
      South Africa and Zambia) were enrolled and followed for 12 to 18 months, from
      2015 to 2018. Part-way through the course of the trial, oral PrEP was provided to
      study participants either off-site via referral or on site via trained trial
      staff. PrEP uptake was compared between different contraceptive users using
      Chi-squared tests or t-tests. HIV seroincidence rates were compared between
      participants who never versus ever initiated PrEP using exact Poisson regression.
      RESULTS: PrEP access in ECHO began through public availability in Kenya in May
      2017 and was available at all sites by June 2018. When PrEP became available,
      3626 (46.3%) eligible women were still in follow-up in the study, and of these,
      622 (17.2%) initiated PrEP. Women initiating PrEP were slightly older; more
      likely to be unmarried, not living with their partner, having multiple partners; 
      and less likely to be earning their own income and receiving financial support
      from partners (all p < 0.05). PrEP initiation did not differ across study
      randomized groups (p = 0.7). Two-thirds of PrEP users were continuing PrEP at
      study exit. CONCLUSIONS: There is a need for improved HIV prevention services in 
      clinical trials with HIV endpoints, especially trials among African women. PrEP
      as a component of a comprehensive HIV prevention package provided to women in a
      large clinical trial is practical and feasible. Provision of PrEP within clinical
      trials with HIV outcomes should be standard of prevention.
CI  - (c) 2020 The Authors. Journal of the International AIDS Society published by John
      Wiley & Sons Ltd on behalf of the International AIDS Society.
FAU - Beesham, Ivana
AU  - Beesham I
AUID- ORCID: 0000-0003-4889-8123
AD  - MatCH Research Unit (MRU), Faculty of Health Sciences, University of the
      Witwatersrand, Durban, South Africa.
FAU - Welch, Julia D
AU  - Welch JD
AD  - FHI 360, Durham, NC, USA.
FAU - Heffron, Renee
AU  - Heffron R
AUID- ORCID: 0000-0001-6039-0352
AD  - University of Washington, Seattle, WA, USA.
FAU - Pleaner, Melanie
AU  - Pleaner M
AD  - Wits Reproductive Health and HIV Institute, Faculty of Health Sciences,
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Kidoguchi, Lara
AU  - Kidoguchi L
AD  - University of Washington, Seattle, WA, USA.
FAU - Palanee-Phillips, Thesla
AU  - Palanee-Phillips T
AD  - Wits Reproductive Health and HIV Institute, Faculty of Health Sciences,
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Ahmed, Khatija
AU  - Ahmed K
AD  - Setshaba Research Centre, Tshwane, South Africa.
FAU - Baron, Deborah
AU  - Baron D
AUID- ORCID: 0000-0001-5439-2538
AD  - Wits Reproductive Health and HIV Institute, Faculty of Health Sciences,
      University of the Witwatersrand, Johannesburg, South Africa.
FAU - Bukusi, Elizabeth A
AU  - Bukusi EA
AD  - University of Washington, Seattle, WA, USA.
AD  - Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
FAU - Louw, Cheryl
AU  - Louw C
AD  - Madibeng Centre for Research, Brits, South Africa.
AD  - Department of Family Medicine, Faculty of Health Sciences, University of
      Pretoria, Pretoria, South Africa.
FAU - Mastro, Timothy D
AU  - Mastro TD
AD  - FHI 360, Durham, NC, USA.
FAU - Smit, Jennifer
AU  - Smit J
AD  - MatCH Research Unit (MRU), Faculty of Health Sciences, University of the
      Witwatersrand, Durban, South Africa.
FAU - Batting, Joanne R
AU  - Batting JR
AD  - Effective Care Research Unit (ECRU), Fort Hare and Eastern Cape Department of
      Health, Universities of the Witwatersrand, East London, South Africa.
FAU - Malahleha, Mookho
AU  - Malahleha M
AD  - Setshaba Research Centre, Tshwane, South Africa.
FAU - Bailey, Veronique C
AU  - Bailey VC
AD  - Setshaba Research Centre, Tshwane, South Africa.
FAU - Beksinska, Mags
AU  - Beksinska M
AD  - MatCH Research Unit (MRU), Faculty of Health Sciences, University of the
      Witwatersrand, Durban, South Africa.
FAU - Donnell, Deborah
AU  - Donnell D
AD  - University of Washington, Seattle, WA, USA.
FAU - Baeten, Jared M
AU  - Baeten JM
AUID- ORCID: 0000-0001-8242-8438
AD  - University of Washington, Seattle, WA, USA.
CN  - ECHO Trial Consortium
LA  - eng
SI  - ClinicalTrials.gov/NCT02550067
GR  - UM1 AI069463/AI/NIAID NIH HHS/United States
GR  - PEPFAR/PEPFAR/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Switzerland
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Anti-HIV Agents/administration & dosage/*therapeutic use
MH  - Eswatini/epidemiology
MH  - Female
MH  - HIV Infections/drug therapy/epidemiology/*prevention & control
MH  - Humans
MH  - Incidence
MH  - Kenya/epidemiology
MH  - *Pre-Exposure Prophylaxis
MH  - Sexual Partners
MH  - South Africa/epidemiology
MH  - Young Adult
MH  - Zambia/epidemiology
PMC - PMC7217491
OTO - NOTNLM
OT  - *HIV
OT  - *clinical trials
OT  - *pre-exposure prophylaxis
OT  - *standard of care
OT  - *women
IR  - Kiarie J
FIR - Kiarie, James
IR  - Mugo NR
FIR - Mugo, Nelly R
IR  - Rees H
FIR - Rees, Helen
IR  - Justman J
FIR - Justman, Jessica
IR  - Nhlabatsi Z
FIR - Nhlabatsi, Zelda
IR  - Onono M
FIR - Onono, Maricianah
IR  - Bekker LG
FIR - Bekker, Linda-Gail
IR  - Nair G
FIR - Nair, Gonasagrie
IR  - Hofmeyr GJ
FIR - Hofmeyr, G Justus
IR  - Singata-Madliki M
FIR - Singata-Madliki, Mandisa
IR  - Smit J
FIR - Smit, Jennifer
IR  - Sibiya S
FIR - Sibiya, Sydney
IR  - Stringer J
FIR - Stringer, Jeffrey
IR  - Gichangi PB
FIR - Gichangi, Peter B
IR  - Heller KB
FIR - Heller, Kate B
IR  - Mbandazayo N
FIR - Mbandazayo, Nomthandazo
IR  - Morrison CS
FIR - Morrison, Charles S
IR  - Nanda K
FIR - Nanda, Kavita
IR  - Scoville CW
FIR - Scoville, Caitlin W
IR  - Shears K
FIR - Shears, Kathleen
IR  - Steyn PS
FIR - Steyn, Petrus S
IR  - Taylor D
FIR - Taylor, Douglas
IR  - Thomas KK
FIR - Thomas, Katherine K
IR  - Selepe RAP
FIR - Selepe, Raesibe Agnes Pearl
IR  - Phiri Kasaro M
FIR - Phiri Kasaro, Margaret
EDAT- 2020/05/13 06:00
MHDA- 2020/12/31 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/12/31 06:00 [medline]
AID - 10.1002/jia2.25491 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2020 May;23(5):e25491. doi: 10.1002/jia2.25491.


PMID- 32396396
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Oct
TI  - Is research in peril in Nepal? Publication trend and research quality from
      projects funded by the University Grants Commission-Nepal.
PG  - 444-456
LID - 10.1080/08989621.2020.1768374 [doi]
AB  - Institutions of higher learning are critical in promoting a knowledge-driven
      economy through research and training. Nepali universities receive funding from
      the University Grants Commission, Nepal (UGC-N) to support for impactful
      research. UGC-N requires grantees to publish research results as journal
      articles. We reviewed papers published through UGC-N funded research projects
      over a 10-year period (2008-2018) to assess the trends of article publication in 
      terms of frequency and quality (based on journal impact factor and SCImago
      journal ranking). At most, 17% projects (n = 325) had publications and the
      majority of articles were published in journals that had neither SJR rank (74%, n
      = 240) nor impact factor (86%, n = 279). Most importantly, 10% of articles (n =
      23) published in the non-ranked journals appeared in predatory journals. Although
      there were increasing trends of grants and research article publications in the
      last 10 years, journal-level quality metrics showed no improvements and suggested
      decreasing trends during the last half decade. The publication output varied
      among grant categories. Master research grants and PhD research grants performed 
      better than those of faculty research grants in terms of publication in quality
      journals. We call for an increased commitment from political and academic
      leadership to promote quality research in Nepal.
FAU - Paudel, Prakash K
AU  - Paudel PK
AUID- ORCID: 0000-0001-5583-7615
AD  - Center for Conservation Biology, Kathmandu Institute of Applied Sciences ,
      Kathmandu, Nepal.
FAU - Giri, Basant
AU  - Giri B
AUID- ORCID: 0000-0003-4798-3414
AD  - Center for Analytical Sciences, Kathmandu Institute of Applied Sciences ,
      Kathmandu, Nepal.
FAU - Dhakal, Shanta
AU  - Dhakal S
AUID- ORCID: 0000-0001-8041-7049
AD  - Sunita Foundation , Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200529
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Humans
MH  - Journal Impact Factor
MH  - Nepal
MH  - Research Support as Topic/*standards/*statistics & numerical data
MH  - Universities/ethics/*standards/*statistics & numerical data
OTO - NOTNLM
OT  - *Research productivity
OT  - *publication ethics
OT  - *research in developing countries
OT  - *research integrity
OT  - *science funding
OT  - *science policy
EDAT- 2020/05/13 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1080/08989621.2020.1768374 [doi]
PST - ppublish
SO  - Account Res. 2020 Oct;27(7):444-456. doi: 10.1080/08989621.2020.1768374. Epub
      2020 May 29.


PMID- 32396056
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 12
DP  - 2020 Oct
TI  - "We're Talking About You, Not to You": Methodological Reflections on Public
      Health Research With Families With Young Children.
PG  - 1888-1898
LID - 10.1177/1049732320917927 [doi]
AB  - In this article, we critically reflect upon the experience of public health
      research involving children and contribute to existing conversations about the
      methodological and ethical facets of research in this field. Drawing on two
      phases of a study that sought to explore the lived experiences of families with
      young children who have had a recent common childhood illness (gastrointestinal
      infection), we address the research process, from inception of the studies, to
      fieldwork and the resultant material obtained. We argue that when researching
      with families about a child-centered experience, it is important to look beyond
      the individual adult as "participant" and to conceptualize dependents either as, 
      or "like" participants-what we suggest as a "family-centered approach."
      Theoretically, this strategy best addresses the lived reality of relationality
      and responsibility of parent/carers for dependent children; while improving the
      ease and safety of data collection for the researcher and participants alike.
FAU - Eastham, Rachael
AU  - Eastham R
AUID- ORCID: 0000-0001-6881-7875
AD  - Lancaster University, Lancaster, United Kingdom.
FAU - Kaley, Alexandra
AU  - Kaley A
AD  - Lancaster University, Lancaster, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
EIN - Qual Health Res. 2020 Oct;30(12):1978. PMID: 32639200
MH  - Adult
MH  - Caregivers
MH  - Child
MH  - Child, Preschool
MH  - *Family
MH  - Humans
MH  - Parents
MH  - *Public Health
MH  - Qualitative Research
MH  - Research Personnel
PMC - PMC7905741
OTO - NOTNLM
OT  - *North West England
OT  - *children
OT  - *ethics
OT  - *qualitative interviews
OT  - *qualitative research
EDAT- 2020/05/13 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1177/1049732320917927 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Oct;30(12):1888-1898. doi: 10.1177/1049732320917927. Epub
      2020 May 12.


PMID- 32396036
OWN - NLM
STAT- MEDLINE
DCOM- 20210812
LR  - 20210812
IS  - 1744-1706 (Electronic)
IS  - 1744-1692 (Linking)
VI  - 15
IP  - 9
DP  - 2020 Sep
TI  - Promoting male circumcision as HIV prevention in sub-Saharan Africa: An
      evaluation of the ethical and pragmatic considerations of adopting a demand
      creation approach.
PG  - 1349-1363
LID - 10.1080/17441692.2020.1761423 [doi]
AB  - Male circumcision for HIV prevention is being promoted in 14 sub-Saharan African 
      countries. Campaigns take a demand creation approach, a strategy based on
      generating awareness of and demand for an intervention. This article analyzes
      campaign materials, making the case that a focus on demand per se, at the expense
      of quality public health information, constitutes an ethical and pragmatic
      campaign flaw. Clinical trials have demonstrated that circumcision can reduce
      transmission of HIV from women to men by 53-60%. Since circumcision does not
      approach 100% prevention efficacy for men and does not directly protect women,
      behavioural and structural interventions remain necessary, leading international 
      health bodies to position circumcision as an add-on to behavioural interventions.
      However, in practice, circumcision promotion often lacks information about
      behavioural prevention. At times, campaigns omit any HIV prevention message.
      Instead, campaigns variously favour representing circumcision as a route to
      normative masculinity, to sexual prowess, or to good citizenship, among others.
      Alongside their targeted outcomes, public health campaigns also contribute to
      public discourses around sexuality and non-HIV aspects of health, in this case
      potentially leading to confusion and mistrust. The current public health
      promotion strategy for circumcision threatens to undermine the social processes
      needed to support HIV prevention.
FAU - Rudrum, Sarah
AU  - Rudrum S
AD  - Sociology, Acadia University, Wolfville, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - Glob Public Health
JT  - Global public health
JID - 101256323
SB  - IM
MH  - Africa South of the Sahara
MH  - *Circumcision, Male
MH  - *HIV Infections/prevention & control
MH  - *Health Promotion/ethics/methods
MH  - Humans
MH  - Male
OTO - NOTNLM
OT  - *Circumcision
OT  - *HIV prevention
OT  - *VMMC
OT  - *demand creation
OT  - *sub-Saharan Africa
EDAT- 2020/05/13 06:00
MHDA- 2021/08/13 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/08/13 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1080/17441692.2020.1761423 [doi]
PST - ppublish
SO  - Glob Public Health. 2020 Sep;15(9):1349-1363. doi: 10.1080/17441692.2020.1761423.
      Epub 2020 May 12.


PMID- 32395951
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20201218
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 164
DP  - 2020 Apr 23
TI  - [Ethical principles compromised during the COVID-19 pandemic?]
LID - D5049 [pii]
AB  - In the late 1970s, the American bioethicists Tom Beauchamp and James Childress
      described the four ethical principles that should guide a physician's actions in 
      individual patient care. These principles are: (a) respect for autonomy; (b)
      doing well (beneficence); (c) not harming (non-maleficence); and (d) justice. In 
      many countries, the global outbreak of SARS-CoV-2 has led to overloaded
      healthcare systems due to large numbers of COVID-19 patients. In order to provide
      care to this high volume of patients, far-reaching measures are taken that affect
      everyone. These measures are not taken from an individual patient's perspective
      but in the interest of public health; nonetheless, they can directly affect the
      individual patient's interests. This article examines the extent to which
      Beauchamp and Childress' ethical principles may be compromised during the
      COVID-19 pandemic.
FAU - Bakker, Marleen
AU  - Bakker M
AD  - Erasmus MC, Rotterdam. Afd. Longgeneeskunde.
AD  - Contact: Marleen Bakker (m.bakker.1@erasmusmc.nl).
FAU - van de Vathorst, Suzanne
AU  - van de Vathorst S
AD  - Erasmus MC, Rotterdam.Afd. Medische ethiek, filosofie en geschiedenis.
LA  - dut
PT  - Journal Article
TT  - Ethische principes in het gedrang door COVID-19?
DEP - 20200423
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
SB  - IM
MH  - Beneficence
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Humans
MH  - Moral Obligations
MH  - Pandemics/*ethics
MH  - Personal Autonomy
MH  - Pneumonia, Viral
MH  - *Quality of Health Care
MH  - SARS-CoV-2
MH  - Social Justice
EDAT- 2020/05/13 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PST - epublish
SO  - Ned Tijdschr Geneeskd. 2020 Apr 23;164.


PMID- 32395815
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20200908
IS  - 2724-7031 (Electronic)
IS  - 0041-4131 (Linking)
VI  - 98
IP  - 3
DP  - 2020 Mar
TI  - Initial Medical Certificate: survey of post graduate students in dentistry.
PG  - 219-224
AB  - INTRODUCTION: The initial medical certificate (IMC) is the first document
      delivered to an injured person, or his or her legal representative. The objective
      of this study was to determine the knowledge and writing habits of Tunisian
      dental post-graduate students regarding the IMC. METHOD: This was a descriptive
      study conducted at the Faculty of Dentistry of Monastir (Tunisia) during the
      period from October 1, 2018 to March 31, 2019. All the post graduate students
      were included in the survey. For data collection, a questionnaire written in
      French was used. The platform "Google Forms" was used to perform the
      questionnaire and the link was sent by mail to all participants. RESULTS: For
      19.9% of respondents , the IMC was considered as an expertise and 22% of them
      declared that even non-graduates can deliver it. In addition, 22% of participants
      have already given a IMC to a third party and 12.2% have reported photos and
      X-rays to the IMC. On the other hand, 82.4% of respondents do not indicate total 
      incapacity for work (TIW) when writing the IMC. In fact, 13.7% of them do not
      know what a TIW is and 52.1% think that it will be determined during the
      expertise. Finally, 85.6% of respondents estimated that they did not have the
      necessary information about the IMC and 96.9% of them thought that an information
      support would be useful to help them in writing it. CONCLUSION: The writing of
      IMC incurs the criminal, civil and ethical responsibility of the practitioner.
FAU - Ouni, Marouen
AU  - Ouni M
FAU - Khemiss, Mehdi
AU  - Khemiss M
FAU - Frih, Nadia
AU  - Frih N
LA  - eng
PT  - Journal Article
PL  - Tunisia
TA  - Tunis Med
JT  - La Tunisie medicale
JID - 0413766
SB  - IM
MH  - Dentistry/standards/statistics & numerical data
MH  - *Education, Dental, Graduate/statistics & numerical data
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Internship and Residency/standards/statistics & numerical data
MH  - Maxillofacial Injuries/therapy
MH  - Medical Records/*standards/statistics & numerical data
MH  - *Practice Patterns, Physicians'/standards/statistics & numerical data
MH  - Students, Dental/*statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Tunisia/epidemiology
MH  - Writing/standards
EDAT- 2020/05/13 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
AID - /article-medicale-tunisie.php?article=3710 [pii]
PST - ppublish
SO  - Tunis Med. 2020 Mar;98(3):219-224.


PMID- 32395587
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-3409 (Electronic)
IS  - 2352-3409 (Linking)
VI  - 30
DP  - 2020 Jun
TI  - Panel Dataset of Ethical Commitment Disclosures in Malaysia.
PG  - 105624
LID - 10.1016/j.dib.2020.105624 [doi]
AB  - Panel dataset in this article contains information on the ethical commitment
      disclosures of Malaysian publicly listed companies. The data presented is related
      to the research article entitled "Ethical Practice Disclosure of Malaysian Public
      Listed Companies" [1]. In examining the level of ethical commitment disclosures, 
      content analysis is performed involving 1,115 annual reports for five year
      periods (2012 - 2016). The annual reports are gathered from Main Market of Bursa 
      Malaysia website. Information on ethical commitment disclosures are extracted
      from the annual reports. The data are collected using Ethical Commitment Index
      (ECI) comprising six themes; corporate ethics values, action to promote ethics,
      whistle-blowing policy, code of ethics, sustainability practices, and ethics
      committee. This dataset is useful as an indicator of the companies' ethical
      commitment reflecting ethical climate in Malaysian public listed companies.
CI  - (c) 2020 The Author(s). Published by Elsevier Inc.
FAU - Hashim, Hafiza Aishah
AU  - Hashim HA
AD  - Faculty of Business Economics and Social Development, Universiti Malaysia
      Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia.
FAU - Abidin, Ahmad Firdhauz Zainul
AU  - Abidin AFZ
AD  - Faculty of Business Economics and Social Development, Universiti Malaysia
      Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia.
FAU - Salleh, Zalailah
AU  - Salleh Z
AD  - Faculty of Business Economics and Social Development, Universiti Malaysia
      Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia.
FAU - Devi, S Susela
AU  - Devi SS
AD  - Sunway University, No. 5, Jalan Universiti, Bandar Sunway, 47500 Selangor Darul
      Ehsan, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - Netherlands
TA  - Data Brief
JT  - Data in brief
JID - 101654995
PMC - PMC7210393
OTO - NOTNLM
OT  - Code of ethics
OT  - Disclosures
OT  - Ethics
OT  - Whistleblowing
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - 10.1016/j.dib.2020.105624 [doi]
AID - S2352-3409(20)30518-7 [pii]
AID - 105624 [pii]
PST - epublish
SO  - Data Brief. 2020 Apr 28;30:105624. doi: 10.1016/j.dib.2020.105624. eCollection
      2020 Jun.


PMID- 32395494
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2305-5839 (Print)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 7
DP  - 2020 Apr
TI  - Deep learning for detecting corona virus disease 2019 (COVID-19) on
      high-resolution computed tomography: a pilot study.
PG  - 450
LID - 10.21037/atm.2020.03.132 [doi]
AB  - BACKGROUND: To evaluate the diagnostic efficacy of Densely Connected
      Convolutional Networks (DenseNet) for detection of COVID-19 features on high
      resolution computed tomography (HRCT). METHODS: The Ethic Committee of our
      institution approved the protocol of this study and waived the requirement for
      patient informed consent. Two hundreds and ninety-five patients were enrolled in 
      this study (healthy person: 149; COVID-19 patients: 146), which were divided into
      three separate non-overlapping cohorts (training set, n=135, healthy person,
      n=69, patients, n=66; validation set, n=20, healthy person, n=10, patients, n=10;
      test set, n=140, healthy person, n=70, patients, n=70). The DenseNet was trained 
      and tested to classify the images as having manifestation of COVID-19 or as
      healthy. A radiologist also blindly evaluated all the test images and rechecked
      the misdiagnosed cases by DenseNet. Receiver operating characteristic curves
      (ROC) and areas under the curve (AUCs) were used to assess the model performance.
      The sensitivity, specificity and accuracy of DenseNet model and radiologist were 
      also calculated. RESULTS: The DenseNet algorithm model yielded an AUC of 0.99
      (95% CI: 0.958-1.0) in the validation set and 0.98 (95% CI: 0.972-0.995) in the
      test set. The threshold value was selected as 0.8, while for validation and test 
      sets, the accuracies were 95% and 92%, the sensitivities were 100% and 97%, the
      specificities were 90% and 87%, and the F1 values were 95% and 93%, respectively.
      The sensitivity of radiologist was 94%, the specificity was 96%, while the
      accuracy was 95%. CONCLUSIONS: Deep learning (DL) with DenseNet can accurately
      classify COVID-19 on HRCT with an AUC of 0.98, which can reduce the miss
      diagnosis rate (combined with radiologists' evaluation) and radiologists'
      workload.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Yang, Shuyi
AU  - Yang S
AD  - Department of Radiology, Shanghai Public Health Clinical Center, Fudan
      University, Shanghai 201508, China.
FAU - Jiang, Longquan
AU  - Jiang L
AD  - School of Computer Science, Fudan University, Shanghai 200433, China.
FAU - Cao, Zhuoqun
AU  - Cao Z
AD  - School of Computer Science, Fudan University, Shanghai 200433, China.
FAU - Wang, Liya
AU  - Wang L
AD  - Department of Radiology, Affiliated Longhua People's Hospital, Southern Medical
      University, Shenzhen 518109, China.
FAU - Cao, Jiawang
AU  - Cao J
AD  - Academy of Engineering & Technology, Fudan University, Shanghai 200433, China.
FAU - Feng, Rui
AU  - Feng R
AD  - School of Computer Science, Fudan University, Shanghai 200433, China.
FAU - Zhang, Zhiyong
AU  - Zhang Z
AD  - Department of Radiology, Shanghai Public Health Clinical Center, Fudan
      University, Shanghai 201508, China.
AD  - Fudan University, Shanghai 200433, China.
FAU - Xue, Xiangyang
AU  - Xue X
AD  - School of Computer Science, Fudan University, Shanghai 200433, China.
FAU - Shi, Yuxin
AU  - Shi Y
AD  - Department of Radiology, Shanghai Public Health Clinical Center, Fudan
      University, Shanghai 201508, China.
FAU - Shan, Fei
AU  - Shan F
AD  - Department of Radiology, Shanghai Public Health Clinical Center, Fudan
      University, Shanghai 201508, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7210135
OTO - NOTNLM
OT  - COVID-19
OT  - deep learning (DL)
OT  - high resolution computed tomography (HRCT)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/atm.2020.03.132). The authors have 
      no conflicts of interest to declare.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - 10.21037/atm.2020.03.132 [doi]
AID - atm-08-07-450 [pii]
PST - ppublish
SO  - Ann Transl Med. 2020 Apr;8(7):450. doi: 10.21037/atm.2020.03.132.


PMID- 32395347
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-2867 (Print)
IS  - 2090-2867 (Linking)
VI  - 2020
DP  - 2020
TI  - Physiotherapists' Experiences Using the Ekso Bionic Exoskeleton with Patients in 
      a Neurological Rehabilitation Hospital: A Qualitative Study.
PG  - 2939573
LID - 10.1155/2020/2939573 [doi]
AB  - Use of bionic overground exoskeletons to assist with neurological rehabilitation 
      is becoming increasingly prevalent and has important implications for
      physiotherapists and their patients. Yet, there is a paucity of research about
      the impact of integrating this technology on physiotherapists' work. The purpose 
      of this study was to explore how the training and implementation of using the
      Ekso robotic exoskeleton with patients affects physiotherapists' work. An
      exploratory qualitative study of three physiotherapists working at a neurological
      rehabilitation centre in Eastern Canada was conducted using one-on-one
      semistructured interviews in July 2017. Audio recordings were transcribed
      verbatim, and data was coded and analyzed using thematic analysis. Six themes
      emerged from the data: developing organizational capacity; ethical use of
      technology; benefits of the equipment; challenges of the equipment; cognitive
      workload; and the technological environment. The results suggest that the
      adoption and integration of bionic exoskeletons into rehabilitation practice is
      not as simple as training physiotherapists and giving them the device. More
      research is needed to understand the increased cognitive demands of working with 
      patients using technologically advanced exoskeletons within a dynamic,
      technology-rich healthcare environment, while managing patient expectations and
      ethical use.
CI  - Copyright (c) 2020 Emily Read et al.
FAU - Read, Emily
AU  - Read E
AUID- ORCID: https://orcid.org/0000-0002-5023-5559
AD  - Faculty of Nursing, University of New Brunswick, Canada.
AD  - Institute of Biomedical Engineering, University of New Brunswick, Canada.
FAU - Woolsey, Cora
AU  - Woolsey C
AD  - Faculty of Nursing, University of New Brunswick, Canada.
FAU - McGibbon, Chris A
AU  - McGibbon CA
AUID- ORCID: https://orcid.org/0000-0001-7849-7895
AD  - Institute of Biomedical Engineering, University of New Brunswick, Canada.
AD  - Faculty of Kinesiology, University of New Brunswick, Canada.
FAU - O'Connell, Colleen
AU  - O'Connell C
AD  - Faculty of Kinesiology, University of New Brunswick, Canada.
AD  - Faculty of Medicine, Dalhousie University, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200108
PL  - United States
TA  - Rehabil Res Pract
JT  - Rehabilitation research and practice
JID - 101566862
PMC - PMC7199547
COIS- We declare no conflict of interest in this research.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2019/06/28 00:00 [received]
PHST- 2019/12/27 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - 10.1155/2020/2939573 [doi]
PST - epublish
SO  - Rehabil Res Pract. 2020 Jan 8;2020:2939573. doi: 10.1155/2020/2939573.
      eCollection 2020.


PMID- 32395314
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-1439 (Print)
IS  - 2072-1439 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr
TI  - The conundrum of contrast-induced acute kidney injury.
PG  - 1721-1727
LID - 10.21037/jtd.2019.12.88 [doi]
AB  - More than sixty years have elapsed since contrast induced nephropathy (CIN) was
      first described in the medical literature. This term has since been extensively
      explored, with a variety of studies conducted to investigate its incidence and
      various mechanisms examined to explain its pathophysiology. However, the topic of
      CIN remains one of controversy with a widely variable and often questionable
      incidence derived from various studies. The past two decades have seen a surge in
      reports questioning the existing of CIN altogether and if more harm is actually
      being caused to patients out of fear of this potential complication. We have
      attempted to review relevant studies regarding CIN and highlight the key points
      of its surmised understanding. The review has a higher focus on more recent
      literature and updates, in order to determine if an accurate estimate can be made
      on the incidence of CIN. While there was certainly no lack of material available,
      practically all the studies reviewed were limited by one or more significant
      drawbacks that limited the reliability of their conclusions regarding CIN. Based 
      on the information reviewed, the strengths and the flaws encountered in other
      studies can be used to design a randomized control trial that may help in
      concluding the longstanding debate on this topic. However due to time, financial,
      and perhaps even ethical constraints such a trial will be difficult to arrange,
      and so a definitive answer on CI-AKI, and whether it really exist, may continue
      to elude clinicians.
CI  - 2020 Journal of Thoracic Disease. All rights reserved.
FAU - Haq, Mohammad Faraz Ul
AU  - Haq MFU
AD  - Department of Medicine, SUNY at Buffalo, NY, USA.
FAU - Yip, Cindy S
AU  - Yip CS
AD  - Department of Medicine, SUNY at Buffalo, NY, USA.
FAU - Arora, Pradeep
AU  - Arora P
AD  - Department of Medicine, SUNY at Buffalo, NY, USA.
AD  - Division of Nephrology at VAMC, Buffalo, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC7212164
OTO - NOTNLM
OT  - Radiocontrast media
OT  - acute kidney injury (AKI)
OT  - outcomes
COIS- Conflicts of Interest: The series "Interventional Cardiology" was commissioned by
      the editorial office without any funding or sponsorship. The authors have no
      other conflicts of interest to declare.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - 10.21037/jtd.2019.12.88 [doi]
AID - jtd-12-04-1721 [pii]
PST - ppublish
SO  - J Thorac Dis. 2020 Apr;12(4):1721-1727. doi: 10.21037/jtd.2019.12.88.


PMID- 32395294
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2072-1439 (Print)
IS  - 2072-1439 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr
TI  - Spontaneous ventilation versus mechanical ventilation during video-assisted
      thoracoscopic surgery for spontaneous pneumothorax: a study protocol for
      multicenter randomized controlled trial.
PG  - 1570-1581
LID - 10.21037/jtd.2020.02.13 [doi]
AB  - BACKGROUND: With the evolution and adoption of video-assisted thoracoscopic
      surgery (VATS), options for anesthesia control have also seen major developments.
      Intubated anesthesia with single lung mechanical ventilation VATS (MV-VATS) is
      considered the standard of care in VATS. However, this type of ventilation
      strategy has been associated with several adverse effects, which can trigger
      complications and increase the overall surgical risk. In order to avoid intubated
      anesthesia related adverse effects, non-intubated spontaneous ventilation VATS
      (SV-VATS) strategies have been proposed in recent years and widely applied.
      METHODS: We established a two-arm parallel multicenter randomized controlled
      trial for comparative analysis of the outcomes of patients undergoing either
      SV-VATS or MV-VATS for spontaneous pneumothorax. Outcomes of interest include
      safety during operation, total analgesic dose, recovery time, postoperative
      complication rates, postoperative pain score, length of hospitalization,
      inflammation index, medical cost, etc. The recruitment target is 316 patients.
      Patients will be eligible if their chest CT is diagnosed with "localized lung
      bullae" and need VATS resection. Patients will be randomized into the SV-VATS
      (test group) or MV-VATS (control group) after signing informed consent and
      surgical anesthesia evaluation. DISCUSSION: This protocol has been approved by
      the Research Ethics Committee of the First Affiliated Hospital of Guangzhou
      Medical university. Results will be presented at national and international
      meetings and conferences and published in peer-reviewed journals. We will also
      disseminate the main results to all participants in a letter. Non-intubated
      SV-VATS offered a more individual choice of anesthetics and surgical method for
      spontaneous pneumothorax patients. TRIAL REGISTRATION: NCT03016858; pre-results.
CI  - 2020 Journal of Thoracic Disease. All rights reserved.
FAU - Cui, Fei
AU  - Cui F
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - Xu, Ke
AU  - Xu K
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - Liang, Hengrui
AU  - Liang H
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - Liang, Wenhua
AU  - Liang W
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - Li, Jingpei
AU  - Li J
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - Liu, Hui
AU  - Liu H
AD  - Department of Anesthesia, First Affiliated Hospital of Guangzhou Medical
      University, Guangzhou 510120, China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
FAU - He, Jianxing
AU  - He J
AD  - Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical
      University, National Respiratory Disease Clinical Research Center, Guangzhou
      510120, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03016858
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC7212161
OTO - NOTNLM
OT  - Spontaneous ventilation
OT  - randomized controlled trial
OT  - spontaneous pneumothorax
OT  - video-assisted thoracoscopic surgery (VATS)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure
      form (available at http://dx.doi.org/10.21037/jtd.2020.02.13). JH serves as an
      unpaid Editor-in-Chief of Journal of Thoracic Disease. WL serves as an unpaid
      editorial board member of Journal of Thoracic Disease from Dec 2015 to Dec 2021. 
      The other authors have no conflicts of interest to declare.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - 10.21037/jtd.2020.02.13 [doi]
AID - jtd-12-04-1570 [pii]
PST - ppublish
SO  - J Thorac Dis. 2020 Apr;12(4):1570-1581. doi: 10.21037/jtd.2020.02.13.


PMID- 32395014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0921-3449 (Print)
IS  - 0921-3449 (Linking)
VI  - 160
DP  - 2020 Sep
TI  - Differentiating ethical imperatives of the collective sustainability research
      community and the individual researcher.
PG  - 104928
LID - 10.1016/j.resconrec.2020.104928 [doi]
FAU - Chiu, A S F
AU  - Chiu ASF
AD  - Center for Engineering and Sustainable Development Research, De La Salle
      University, 2401 Taft Avenue, 0922 Manila, Philippines.
AD  - Industrial Engineering Department, De La Salle University, 2401 Taft Avenue, 0922
      Manila, Philippines.
FAU - Aviso, K B
AU  - Aviso KB
AD  - Center for Engineering and Sustainable Development Research, De La Salle
      University, 2401 Taft Avenue, 0922 Manila, Philippines.
AD  - Chemical Engineering Department, De La Salle University, 2401 Taft Avenue, 0922
      Manila, Philippines.
FAU - Tan, R R
AU  - Tan RR
AD  - Center for Engineering and Sustainable Development Research, De La Salle
      University, 2401 Taft Avenue, 0922 Manila, Philippines.
AD  - Chemical Engineering Department, De La Salle University, 2401 Taft Avenue, 0922
      Manila, Philippines.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - Netherlands
TA  - Resour Conserv Recycl
JT  - Resources, conservation, and recycling
JID - 9891750
PMC - PMC7211715
COIS- The authors declare that we have no conflict of interest.
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1016/j.resconrec.2020.104928 [doi]
AID - S0921-3449(20)30246-9 [pii]
AID - 104928 [pii]
PST - ppublish
SO  - Resour Conserv Recycl. 2020 Sep;160:104928. doi: 10.1016/j.resconrec.2020.104928.
      Epub 2020 May 11.


PMID- 32394976
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 11
DP  - 2020 Nov
TI  - Muscovite nanoparticles mitigate neuropathic pain by modulating the inflammatory 
      response and neuroglial activation in the spinal cord.
PG  - 2162-2168
LID - 10.4103/1673-5374.282260 [doi]
AB  - Despite numerous efforts to overcome neuropathic pain, various pharmacological
      drugs often fail to meet the needs and have many side effects. Muscovite is an
      aluminosilicate mineral that has been reported to have an anti-inflammatory
      effect, but the efficacy of muscovite for neuropathic pain has not been
      investigated. Here, we assessed whether muscovite nanoparticles can reduce the
      symptoms of pain by controlling the inflammatory process observed in neuropathic 
      pain. The analgesic effects of muscovite nanoparticles were explored using
      partial sciatic nerve ligation model of neuropathic pain, in which one-third to
      one-half of the nerve trifurcation of the sciatic nerve was tightly tied to the
      dorsal side. Muscovite nanoparticles (4 mg/100 muL) was given intramuscularly to 
      evaluate its effects on neuropathic pain (3 days per week for 4 weeks). The
      results showed that the muscovite nanoparticle injections significantly
      alleviated partial sciatic nerve ligation-induced mechanical and cold allodynia. 
      In the spinal cord, the muscovite nanoparticle injections exhibited inhibitory
      effects on astrocyte and microglia activation and reduced the expression of
      pro-inflammatory cytokines, such as interleukin-1beta, tumor necrosis
      factor-alpha, interleiukin-6 and monocyte chemoattractant protein-1, which were
      upregulated in the partial sciatic nerve ligation model. Moreover, the muscovite 
      nanoparticle injections resulted in a decrease in activating transcription factor
      3, a neuronal injury marker, in the sciatic nerve. These results suggest that the
      analgesic effects of muscovite nanoparticle on partial sciatic nerve
      ligation-induced neuropathic pain may result from inhibiting activation of
      astrocytes and microglia as well as pro-inflammatory cytokines. We propose that
      muscovite nanoparticle is a potential anti-nociceptive candidate for neuropathic 
      pain. All experimental protocols in this study were approved by the Institutional
      Animal Ethics Committee (IACUC) at Dongguk University, South Korea (approval No. 
      2017-022-1) on September 28, 2017.
FAU - Oh, Ju-Young
AU  - Oh JY
AD  - Acupuncture and Meridian Science Research Center, Kyung Hee University, 26
      Kyungheedae-ro, Dongdaemun-gu; Department of Korean Medical Science, Graduate
      School of Korean Medicine; BK21 PLUS Korean Medicine Science Center, College of
      Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
FAU - Hwang, Tae-Yeon
AU  - Hwang TY
AD  - Acupuncture and Meridian Science Research Center, Kyung Hee University, 26
      Kyungheedae-ro, Dongdaemun-gu; Department of Korean Medical Science, Graduate
      School of Korean Medicine; BK21 PLUS Korean Medicine Science Center, College of
      Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
FAU - Jang, Jae-Hwan
AU  - Jang JH
AD  - Acupuncture and Meridian Science Research Center, Kyung Hee University, 26
      Kyungheedae-ro, Dongdaemun-gu; Department of Korean Medical Science, Graduate
      School of Korean Medicine; BK21 PLUS Korean Medicine Science Center, College of
      Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
FAU - Park, Ji-Yeun
AU  - Park JY
AD  - Acupuncture and Meridian Science Research Center, Kyung Hee University, 26
      Kyungheedae-ro, Dongdaemun-gu, Seoul; College of Korean Medicine, Daejeon
      University, Daejeon, Republic of Korea.
FAU - Ryu, Yeonhee
AU  - Ryu Y
AD  - Korean Institute of Oriental Medicine, Daejeon, Republic of Korea.
FAU - Lee, HyeJung
AU  - Lee H
AD  - Acupuncture and Meridian Science Research Center, Kyung Hee University, 26
      Kyungheedae-ro, Dongdaemun-gu; Department of Korean Medical Science, Graduate
      School of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
FAU - Park, Hi-Joon
AU  - Park HJ
AD  - Acupuncture and Meridian Science Research Center, Kyung Hee University, 26
      Kyungheedae-ro, Dongdaemun-gu; Department of Korean Medical Science, Graduate
      School of Korean Medicine; BK21 PLUS Korean Medicine Science Center, College of
      Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7716045
OTO - NOTNLM
OT  - astrocyte
OT  - microglia
OT  - muscovite
OT  - nanoparticle
OT  - neuropathic pain
OT  - partial sciatic nerve ligation
OT  - pharmacopuncture
OT  - pro-inflammatory cytokine
OT  - spinal cord
COIS- None
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - NeuralRegenRes_2020_15_11_2162_282260 [pii]
AID - 10.4103/1673-5374.282260 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Nov;15(11):2162-2168. doi: 10.4103/1673-5374.282260.


PMID- 32394971
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 11
DP  - 2020 Nov
TI  - MicroRNA regulatory pattern in spinal cord ischemia-reperfusion injury.
PG  - 2123-2130
LID - 10.4103/1673-5374.280323 [doi]
AB  - After spinal cord injury, dysregulated miRNAs appear and can participate in
      inflammatory responses, as well as the inhibition of apoptosis and axon
      regeneration through multiple pathways. However, the functions of miRNAs in
      spinal cord ischemia-reperfusion injury progression remain unclear. miRCURY LNATM
      Arrays were used to analyze miRNA expression profiles of rats after 90 minutes of
      ischemia followed by reperfusion for 24 and 48 hours. Furthermore, subsequent
      construction of aberrantly expressed miRNA regulatory patterns involved cell
      survival, proliferation, and apoptosis. Remarkably, the mitogen-activated protein
      kinase (MAPK) signaling pathway was the most significantly enriched pathway among
      24- and 48-hour groups. Bioinformatics analysis and quantitative reverse
      transcription polymerase chain reaction confirmed the persistent overexpression
      of miR-22-3p in both groups. These results suggest that the aberrant miRNA
      regulatory network is possibly regulated MAPK signaling and continuously affects 
      the physiological and biochemical status of cells, thus participating in the
      regulation of spinal cord ischemia-reperfusion injury. As such, miR-22-3p may
      play sustained regulatory roles in spinal cord ischemia-reperfusion injury. All
      experimental procedures were approved by the Animal Ethics Committee of Jilin
      University, China [approval No. 2020 (Research) 01].
FAU - Liu, Zhi-Gang
AU  - Liu ZG
AD  - Department of Orthopedics, The Second Hospital of Jilin University, Changchun,
      Jilin Province, China.
FAU - Li, Yin
AU  - Li Y
AD  - School of Public Health, Jilin University, Changchun, Jilin Province, China.
FAU - Jiao, Jian-Hang
AU  - Jiao JH
AD  - Department of Orthopedics, The Second Hospital of Jilin University, Changchun,
      Jilin Province, China.
FAU - Long, Hao
AU  - Long H
AD  - Pain Clinic, The Sixth Affiliated Hospital of Xinjiang Medical University,
      Urumqi, Xinjiang Uygur Autonomous Region, China.
FAU - Xin, Zhuo-Yuan
AU  - Xin ZY
AD  - The Key Laboratory of Zoonosis Search, Chinese Ministry of Education, College of 
      Basic Medicine, Jilin University, Changchun, Jilin Province, China.
FAU - Yang, Xiao-Yu
AU  - Yang XY
AD  - Department of Orthopedics, The Second Hospital of Jilin University, Changchun,
      Jilin Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7716024
OTO - NOTNLM
OT  - gene regulatory networks
OT  - miR-22-3p
OT  - microRNA
OT  - microarray analysis
OT  - mitogen-activated protein kinase signaling pathway
OT  - nerve regeneration
OT  - neural regeneration
OT  - spinal cord ischemia-reperfusion injury
OT  - transcriptome
COIS- None
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - NeuralRegenRes_2020_15_11_2123_280323 [pii]
AID - 10.4103/1673-5374.280323 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Nov;15(11):2123-2130. doi: 10.4103/1673-5374.280323.


PMID- 32394970
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 11
DP  - 2020 Nov
TI  - Sequencing analysis of matrix metalloproteinase 7-induced genetic changes in
      Schwann cells.
PG  - 2116-2122
LID - 10.4103/1673-5374.282263 [doi]
AB  - Previous research revealed the positive activity of matrix metalloproteinase 7
      (MMP7) on migration and myelin regeneration of Schwann cells (SCs). However,
      understanding of the molecular changes and biological activities induced by
      increased amounts of MMP7 in SCs remains limited. To better understand the
      underlying molecular events, primary SCs were isolated from the sciatic nerve
      stump of newborn rats and cultured with 10 nM human MMP7 for 24 hours. The
      results of genetic testing were analyzed at a relatively relaxed threshold value 
      (fold change >/= 1.5 and P-value < 0.05). Upon MMP7 exposure, 149 genes were
      found to be upregulated in SCs, whereas 133 genes were downregulated. Gene
      Ontology analysis suggested that many differentially expressed molecules were
      related to cellular processes, single-organism processes, and metabolic
      processes. Kyoto Enrichment of Genes and Genomes pathway analysis further
      indicated the critical involvement of cell signaling and metabolism in
      MMP7-induced molecular regulation of SCs. Results of Ingenuity Pathway Analysis
      (IPA) also revealed that MMP7 regulates biological processes, molecular
      functions, cellular components, diseases and functions, biosynthesis, material
      metabolism, cell movement, and axon guidance. The outcomes of further analysis
      will deepen our comprehension of MMP7-induced biological changes in SCs. This
      study was approved by the Laboratory Animal Ethics Committee of Nantong
      University, China (approval No. 20190225-004) on February 27, 2019.
FAU - Lu, Pan-Jian
AU  - Lu PJ
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
FAU - Wang, Gang
AU  - Wang G
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
FAU - Cai, Xiao-Dong
AU  - Cai XD
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
FAU - Zhang, Ping
AU  - Zhang P
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
FAU - Wang, Hong-Kui
AU  - Wang HK
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7716050
OTO - NOTNLM
OT  - RNA sequencing
OT  - Schwann cells
OT  - bioinformatic analysis
OT  - ingenuity pathway analysis
OT  - matrix metalloproteinase 7
OT  - peripheral nerve regeneration
OT  - sciatic nerve injury
COIS- None
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - NeuralRegenRes_2020_15_11_2116_282263 [pii]
AID - 10.4103/1673-5374.282263 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Nov;15(11):2116-2122. doi: 10.4103/1673-5374.282263.


PMID- 32394969
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 11
DP  - 2020 Nov
TI  - Intraoperative single administration of neutrophil peptide 1 accelerates the
      early functional recovery of peripheral nerves after crush injury.
PG  - 2108-2115
LID - 10.4103/1673-5374.282270 [doi]
AB  - Neutrophil peptide 1 belongs to a family of peptides involved in innate immunity.
      Continuous intramuscular injection of neutrophil peptide 1 can promote the
      regeneration of peripheral nerves, but clinical application in this manner is not
      convenient. To this end, the effects of a single intraoperative administration of
      neutrophil peptide 1 on peripheral nerve regeneration were experimentally
      observed. A rat model of sciatic nerve crush injury was established using the
      clamp method. After model establishment, a normal saline group and a neutrophil
      peptide 1 group were injected with a single dose of normal saline or 10 mug/mL
      neutrophil peptide 1, respectively. A sham group, without sciatic nerve crush was
      also prepared as a control. Sciatic nerve function tests,
      neuroelectrophysiological tests, and hematoxylin-eosin staining showed that the
      nerve conduction velocity, sciatic functional index, and tibialis anterior muscle
      fiber cross-sectional area were better in the neutrophil peptide 1 group than in 
      the normal saline group at 4 weeks after surgery. At 4 and 8 weeks after surgery,
      there were no differences in the wet weight of the tibialis anterior muscle
      between the neutrophil peptide 1 and saline groups. Histological staining of the 
      sciatic nerve showed no significant differences in the number of myelinated nerve
      fibers or the axon cross-sectional area between the neutrophil peptide 1 and
      normal saline groups. The above data confirmed that a single dose of neutrophil
      peptide 1 during surgery can promote the recovery of neurological function 4
      weeks after sciatic nerve injury. All the experiments were approved by the
      Medical Ethics Committee of Peking University People's Hospital, China (approval 
      No. 2015-50) on December 9, 2015.
FAU - Yuan, Yu-Song
AU  - Yuan YS
AD  - Department of Trauma and Orthopedics, Peking University People's Hospital, Peking
      University; Key Laboratory of Trauma and Neural Regeneration (Peking University),
      Ministry of Education, Beijing, China.
FAU - Niu, Su-Ping
AU  - Niu SP
AD  - Office of Academic Research, Peking University People's Hospital, Beijing, China.
FAU - Yu, Fei
AU  - Yu F
AD  - Department of Trauma and Orthopedics, Peking University People's Hospital, Peking
      University, Beijing; National and Local Joint Engineering Research Center of
      Orthopaedic Biomaterials, Department of Bone & Joint Surgery, Peking University
      Shenzhen Hospital, Shenzhen, Guangdong Province, China.
FAU - Zhang, Ya-Jun
AU  - Zhang YJ
AD  - National Center for Trauma Medicine, Beijing, China.
FAU - Han, Na
AU  - Han N
AD  - Key Laboratory of Trauma and Neural Regeneration (Peking University), Ministry of
      Education; Office of Academic Research, Peking University People's Hospital,
      Beijing, China.
FAU - Lu, Hao
AU  - Lu H
AD  - Department of Trauma and Orthopedics, Peking University People's Hospital, Peking
      University; Diabetic Foot Treatment Center, Peking University People's Hospital, 
      Peking University, Beijing, China.
FAU - Yin, Xiao-Feng
AU  - Yin XF
AD  - Department of Trauma and Orthopedics, Peking University People's Hospital, Peking
      University; Key Laboratory of Trauma and Neural Regeneration (Peking University),
      Ministry of Education, Beijing, China.
FAU - Xu, Hai-Lin
AU  - Xu HL
AD  - Department of Trauma and Orthopedics, Peking University People's Hospital, Peking
      University; Diabetic Foot Treatment Center, Peking University People's Hospital, 
      Peking University, Beijing, China.
FAU - Kou, Yu-Hui
AU  - Kou YH
AD  - Department of Trauma and Orthopedics, Peking University People's Hospital, Peking
      University; Key Laboratory of Trauma and Neural Regeneration (Peking University),
      Ministry of Education, Beijing, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7716025
OTO - NOTNLM
OT  - crush injury
OT  - defensin 1
OT  - gait analysis
OT  - intraoperative administration
OT  - nerve conduction velocity
OT  - nervous system
OT  - neutrophil peptide 1
OT  - peripheral nerve injury
OT  - peripheral nerve regeneration
OT  - sciatic nerve
OT  - tibialis anterior muscle
OT  - trauma
COIS- None
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - NeuralRegenRes_2020_15_11_2108_282270 [pii]
AID - 10.4103/1673-5374.282270 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Nov;15(11):2108-2115. doi: 10.4103/1673-5374.282270.


PMID- 32394966
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 11
DP  - 2020 Nov
TI  - Effects of mild intrauterine hypoperfusion in the second trimester on memory and 
      learning function in rat offspring.
PG  - 2082-2088
LID - 10.4103/1673-5374.282268 [doi]
AB  - Mild intrauterine hypoperfusion (MIUH) is a serious pathological event that
      affects the growth and development of fetuses and offspring. MIUH can lead to
      growth restriction, low birth weight, neurodevelopmental disorders, and other
      adverse clinical outcomes. To study the effects of MIUH on learning and memory
      function in offspring, a model of MIUH was established by placing a coil (length 
      2.5 mm, diameter 0.24 mm) on the uterine artery and ovarian uterine artery of
      Sprague-Dawley rats in the second trimester of pregnancy (day 17). Next, 120
      mg/kg lithium chloride (the MIUH + Li group) or normal saline (the MIUH group)
      was injected intraperitoneally into these rats. In addition, 120 mg/kg lithium
      chloride (the Li group) or normal saline (the SHAM group) was injected
      intraperitoneally into pregnant rats without coil placement. The Morris water
      maze was used to detect changes in learning and memory ability in the offspring
      at 4 weeks after birth. In the MIUH group, the escape latency and journey length 
      before reaching the platform were both increased, and the number of times that
      the platform was crossed and the activity time in the target quadrant within 90
      seconds were both decreased compared with the SHAM group. Immunofluorescence
      double staining and western blot assays demonstrated that hippocampal nestin and 
      Ki67 (both cell-proliferation-related proteins) expression was significantly
      downregulated in the MIUH group compared with the SHAM group. Furthermore,
      western blot assays were conducted to investigate changes in related signaling
      pathway proteins in the brains of offspring rats, and revealed that glycogen
      synthase kinase 3beta (GSK3beta) expression was upregulated and beta-catenin
      expression was downregulated in the MIUH group compared with the SHAM group. In
      addition, compared with the MIUH group, the expression levels of p-GSK3beta and
      beta-catenin were upregulated in the MIUH + Li group. These results suggest that 
      MIUH may affect learning and memory function in rat offspring by regulating the
      GSK3beta signaling pathway. The experimental procedures were approved by Animal
      Ethics Committee of Shengjing Hospital of China Medical University (approval No. 
      2018PS07K) in June 2018.
FAU - Yin, Shao-Wei
AU  - Yin SW
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical
      University; Key Laboratory of Maternal-Fetal Medicine of Liaoning Province,
      Shenyang, Liaoning Province, China.
FAU - Wang, Yuan
AU  - Wang Y
AD  - Department of Anesthesiology, Shengjing Hospital of China Medical University,
      Shenyang, Liaoning Province, China.
FAU - Meng, Yi-Lin
AU  - Meng YL
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical
      University; Key Laboratory of Maternal-Fetal Medicine of Liaoning Province,
      Shenyang, Liaoning Province, China.
FAU - Liu, Cai-Xia
AU  - Liu CX
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical
      University; Key Laboratory of Maternal-Fetal Medicine of Liaoning Province,
      Shenyang, Liaoning Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7716030
OTO - NOTNLM
OT  - developmental neurobiology
OT  - glycogen synthase kinase 3
OT  - intrauterine
OT  - learning
OT  - lithium
OT  - memory
OT  - offspring
OT  - placenta diseases
OT  - signal pathways
OT  - beta-catenin
COIS- None
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - NeuralRegenRes_2020_15_11_2082_282268 [pii]
AID - 10.4103/1673-5374.282268 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Nov;15(11):2082-2088. doi: 10.4103/1673-5374.282268.


PMID- 32394964
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201211
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 11
DP  - 2020 Nov
TI  - Aquatic exercise program-modulated oxidative stress markers in patients with
      Parkinson's disease.
PG  - 2067-2072
LID - 10.4103/1673-5374.276337 [doi]
AB  - Parkinson's disease is a neurodegenerative disease. Oxidative stress, i.e., the
      imbalance between the generation of reactive oxygen species and the antioxidant
      defense capacity of the body, plays an important role in the pathogenesis of this
      disease. Physical exercise can regulate oxidative stress. The purpose of this
      study was to analyze the short- and long-term effects of an aquatic exercise
      program on oxidative stress levels in patients with Parkinson's disease. The
      aquatic exercise program was carried out during 1 month with two sessions per
      week (1 hour/session). Blood samples were collected at four different time
      points: pre-intervention, immediately, 48 hours, and 30 days after the first
      session of aquatic exercise program. Our results revealed that water-based
      programs modulated antioxidant enzyme activity, increased superoxide dismutase
      activity, reduced catalase activity, and increased the ratio of superoxide
      dismutase activity to catalase activity in patients with Parkinson's disease.
      Compared with pre-intervention and 48 hours after the first session of aquatic
      exercise program, superoxide dismutase activity was higher and catalase activity 
      was lower immediately and 30 days after the first session. Our results
      demonstrated that aquatic exercise program could modulate oxidative stress,
      mainly by the effect of antioxidant enzyme activity. These results could better
      help understand the target of oxidative stress in Parkinson's disease. This study
      was approved by the Ethics Committee of Centro Universitario Metodista IPA
      (approval No. 1.373.911) on August 9, 2019 and registered with REBEC
      (registration number: RBR-6NJ4MK).
FAU - Dani, Caroline
AU  - Dani C
AD  - Programa de Pos Graduacao em Biociencias e Reabilitacao do Centro Universitario
      Metodista-IPA, Porto Alegre; Programa de Pos Graduacao em Farmacologia e
      Terapeutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
FAU - Proenca, Isabel Teixeira
AU  - Proenca IT
AD  - Programa de Pos Graduacao em Biociencias e Reabilitacao do Centro Universitario
      Metodista-IPA, Porto Alegre, RS, Brazil.
FAU - Marinho, Jessica
AU  - Marinho J
AD  - Programa de Pos Graduacao em Biociencias e Reabilitacao do Centro Universitario
      Metodista-IPA, Porto Alegre, RS, Brazil.
FAU - Peccin, Pamela
AU  - Peccin P
AD  - Curso de Fisioterapia do Centro Universitario Metodista-IPA, Porto Alegre, RS,
      Brazil.
FAU - da Silva, Ivy Reichert Vital
AU  - da Silva IRV
AD  - Programa de Pos Graduacao em Biociencias e Reabilitacao do Centro Universitario
      Metodista-IPA, Porto Alegre, RS, Brazil.
FAU - Nique, Simone
AU  - Nique S
AD  - Curso de Fisioterapia do Centro Universitario Metodista-IPA, Porto Alegre, RS,
      Brazil.
FAU - Striebel, Vera
AU  - Striebel V
AD  - Curso de Fisioterapia do Centro Universitario Metodista-IPA, Porto Alegre, RS,
      Brazil.
FAU - Pochmann, Daniela
AU  - Pochmann D
AD  - Programa de Pos Graduacao em Biociencias e Reabilitacao do Centro Universitario
      Metodista-IPA, Porto Alegre, RS, Brazil.
FAU - Elsner, Viviane Rostirola
AU  - Elsner VR
AD  - Programa de Pos Graduacao em Biociencias e Reabilitacao do Centro Universitario
      Metodista-IPA; Curso de Fisioterapia do Centro Universitario Metodista-IPA;
      Programa de Pos Graduacao em Ciencias Biologicas: Fisiologia, Universidade
      Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7716021
OTO - NOTNLM
OT  - Parkinson's disease
OT  - antioxidant enzyme
OT  - antioxidants
OT  - aquatic exercise
OT  - exercise therapies
OT  - neurodegenerative disease
OT  - oxidative stress
COIS- None
EDAT- 2020/05/13 06:00
MHDA- 2020/05/13 06:01
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/13 06:01 [medline]
AID - NeuralRegenRes_2020_15_11_2067_276337 [pii]
AID - 10.4103/1673-5374.276337 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Nov;15(11):2067-2072. doi: 10.4103/1673-5374.276337.


PMID- 32394875
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20220316
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 1
DP  - 2020 Jul
TI  - Issues and Challenges Associated with Data-Sharing in LMICs: Perspectives of
      Researchers in Thailand.
PG  - 528-536
LID - 10.4269/ajtmh.19-0651 [doi]
LID - tpmd190651 [pii]
AB  - Data-sharing helps advance scientific research and assures the benefits of
      research data are maximized. Previous work has highlighted ethical challenges,
      especially in low- and middle-income countrie (LMIC) countries. This study
      examined the views of researchers in a middle-income country, Thailand, regarding
      the most important data-sharing challenges. The target researchers worked in
      biomedical and related research. The survey was distributed to 38 academic and
      health-science institutes, 18 university hospitals, 84 nonuniversity hospitals,
      and 22 research institutes across Thailand; 229 researchers in clinical/basic and
      social/behavioral sciences, and pubxxlic health/policy participated. Thai
      researchers were less concerned with informed consent and the feasibility of
      conducting research and sharing data, focusing on the importance of safeguards
      when handling data, including transfer to others, and possible lack of control
      over subsequent data use. The respondents felt that researchers should decide
      what types of project data are shareable and which data are likely useful to the 
      scientific community. They were more concerned with appropriate acknowledgment
      and protecting the legal rights of the primary data collectors and providers.
      Although they had concerns about data access conditions, they rated sharing
      sufficient data and metadata to reproduce the analysis of the primary outcomes as
      highly important. These results are important for future efforts of the LMIC
      countries to develop efficient data-sharing frameworks and establish
      institutional data access committees. They highlight the importance, for the
      sustainability and fairness of these efforts, to ensure that parties in LMIC
      countries receive appropriate credit and are involved in determining
      where/when/how their data may be used.
FAU - Kaewkungwal, Jaranit
AU  - Kaewkungwal J
AD  - 1Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol
      University, Bangkok, Thailand.
FAU - Adams, Pornpimon
AU  - Adams P
AD  - 2Office of Research Services, Faculty of Tropical Medicine, Mahidol University,
      Bangkok, Thailand.
FAU - Sattabongkot, Jetsumon
AU  - Sattabongkot J
AD  - 3Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University,
      Bangkok, Thailand.
FAU - Lie, Reidar K
AU  - Lie RK
AD  - 4Department of Philosophy, University of Bergen, Bergen, Norway.
FAU - Wendler, David
AU  - Wendler D
AD  - 5Department of Bioethics, National Institutes of Health Clinical Center, National
      Institutes of Health, Bethesda, Maryland.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
SB  - IM
MH  - *Attitude
MH  - *Biomedical Research
MH  - Costs and Cost Analysis
MH  - Data Accuracy
MH  - Developing Countries
MH  - Ethics, Research
MH  - Female
MH  - Health Policy
MH  - Humans
MH  - *Information Dissemination
MH  - Intellectual Property
MH  - Male
MH  - Organizational Policy
MH  - Public Health
MH  - *Research Personnel
MH  - Social Sciences
MH  - Surveys and Questionnaires
MH  - Thailand
PMC - PMC7356467
EDAT- 2020/05/13 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.4269/ajtmh.19-0651 [doi]
AID - tpmd190651 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Jul;103(1):528-536. doi: 10.4269/ajtmh.19-0651. Epub 2020
      May 7.


PMID- 32394322
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Sep
TI  - The Ethical Dilemma of Truth-Telling in Healthcare in China.
PG  - 337-344
LID - 10.1007/s11673-020-09979-6 [doi]
AB  - Truth-telling is often regarded as a challenge in Chinese medical practices given
      the amount of clinical and ethical controversies it may raise. This study sets to
      collect and synthesize relevant ethical evidence of the current situation in
      mainland China, thereby providing corresponding guidance for medical practices.
      This study looks into the ethical issues on the basis of the philosophy of
      deontology and utilitarianism and the ethical principles of veracity, autonomy,
      beneficence, and nonmaleficence. Chinese philosophy, context and culture are also
      discussed to provide some suggestions for decision-making about disclosure in a
      medical setting. This study holds that, in order to respect the basic rights to
      which critically ill patients are entitled, decisions regarding truth-telling and
      their implementation should be carried out with thorough consideration, which can
      be achieved by critical thinking, well-developed and effective communication
      skills, the consideration of cultural context, an understanding of individual
      differences, and compliance with relevant laws and regulations.
FAU - Zhang, Zanhua
AU  - Zhang Z
AD  - Department of Emergency Intensive Care Unit, The Second Affiliated Hospital and
      Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuanxi Road,
      Wenzhou, 325000, China.
FAU - Min, Xiaoyan
AU  - Min X
AD  - Department of Intensive Care Unit, The Second Affiliated Hospital and Yuying
      Children's Hospital of Wenzhou Medical University, 109 Xueyuanxi Road, Wenzhou,
      325000, China. 395566359@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - China
MH  - Ethics, Medical
MH  - Humans
MH  - Morals
MH  - *Physician-Patient Relations/ethics
MH  - *Truth Disclosure/ethics
OTO - NOTNLM
OT  - China
OT  - Ethics
OT  - Healthcare
OT  - Truth-telling
EDAT- 2020/05/13 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1007/s11673-020-09979-6 [doi]
AID - 10.1007/s11673-020-09979-6 [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Sep;17(3):337-344. doi: 10.1007/s11673-020-09979-6. Epub 2020 
      May 11.


PMID- 32394059
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1437-9813 (Electronic)
IS  - 0179-0358 (Linking)
VI  - 36
IP  - 8
DP  - 2020 Aug
TI  - Ethics of randomized trials in pediatric surgery.
PG  - 865-867
LID - 10.1007/s00383-020-04665-5 [doi]
AB  - To provide the best evidence-based treatment for children, and timely evaluation 
      of innovations, the role of the pediatric surgeon's participation in randomized
      controlled trials (RCTs) and prospective comparative studies is required. The
      ethical considerations of pediatric surgical RCTs pose unique practical
      difficulties in the design and performance of clinical trials in children. There 
      are several ethical issues unique to pediatric surgical RCTs: diseases with low
      volume, an inability to conduct Phase 1 and 2 trials, parental emotional
      involvement, difficulty with recruitment in surgical trials, volume, and modified
      study design, issues with permission vs. assent and investigator bias. This
      article reviews the ethical aspects unique to pediatric surgical RCTs and
      prospective comparative studies.Level of evidence: Level 3.
FAU - Rentea, Rebecca M
AU  - Rentea RM
AUID- ORCID: http://orcid.org/0000-0002-8689-5989
AD  - Pediatric Surgery, Comprehensive Colorectal Center, Children's Mercy Hospital,
      2401 Gillham Road, Kansas City, MO, 64108, USA. rrentea@cmh.edu.
FAU - Oyetunji, Tolulope A
AU  - Oyetunji TA
AD  - Pediatric Surgery, Comprehensive Colorectal Center, Children's Mercy Hospital,
      2401 Gillham Road, Kansas City, MO, 64108, USA.
FAU - Peter, Shawn D St
AU  - Peter SDS
AD  - Pediatric Surgery, Comprehensive Colorectal Center, Children's Mercy Hospital,
      2401 Gillham Road, Kansas City, MO, 64108, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200511
PL  - Germany
TA  - Pediatr Surg Int
JT  - Pediatric surgery international
JID - 8609169
SB  - IM
MH  - Child
MH  - Humans
MH  - Pediatrics/*ethics
MH  - Randomized Controlled Trials as Topic/*ethics
MH  - Surgical Procedures, Operative/*ethics
OTO - NOTNLM
OT  - Ethics
OT  - Pediatric surgery
OT  - Randomized control trial (RCT)
EDAT- 2020/05/13 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1007/s00383-020-04665-5 [doi]
AID - 10.1007/s00383-020-04665-5 [pii]
PST - ppublish
SO  - Pediatr Surg Int. 2020 Aug;36(8):865-867. doi: 10.1007/s00383-020-04665-5. Epub
      2020 May 11.


PMID- 32393836
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20210701
IS  - 2397-3374 (Electronic)
IS  - 2397-3374 (Linking)
VI  - 4
IP  - 6
DP  - 2020 Jun
TI  - Using genetics for social science.
PG  - 567-576
LID - 10.1038/s41562-020-0862-5 [doi]
AB  - Social science genetics is concerned with understanding whether, how and why
      genetic differences between human beings are linked to differences in behaviours 
      and socioeconomic outcomes. Our review discusses the goals, methods, challenges
      and implications of this research endeavour. We survey how the recent
      developments in genetics are beginning to provide social scientists with a
      powerful new toolbox they can use to better understand environmental effects, and
      we illustrate this with several substantive examples. Furthermore, we examine how
      medical research can benefit from genetic insights into social-scientific
      outcomes and vice versa. Finally, we discuss the ethical challenges of this work 
      and clarify several common misunderstandings and misinterpretations of genetic
      research on individual differences.
FAU - Harden, K Paige
AU  - Harden KP
AUID- ORCID: http://orcid.org/0000-0002-1557-6737
AD  - Department of Psychology, University of Texas at Austin, Austin, Texas, USA.
      harden@utexas.edu.
FAU - Koellinger, Philipp D
AU  - Koellinger PD
AUID- ORCID: http://orcid.org/0000-0001-7413-0412
AD  - Department of Economics, Vrije Universiteit Amsterdam, Amsterdam, The
      Netherlands. p.d.koellinger@vu.nl.
LA  - eng
GR  - P2C HD042849/HD/NICHD NIH HHS/United States
GR  - R01 HD083613/HD/NICHD NIH HHS/United States
GR  - R01 HD092548/HD/NICHD NIH HHS/United States
GR  - R24 HD042849/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200511
PL  - England
TA  - Nat Hum Behav
JT  - Nature human behaviour
JID - 101697750
SB  - IM
MH  - Genome-Wide Association Study
MH  - *Human Genetics/methods
MH  - Humans
MH  - Multifactorial Inheritance
MH  - Psychology, Social
MH  - Social Mobility
MH  - Social Sciences/*methods
PMC - PMC8240138
MID - NIHMS1717352
EDAT- 2020/05/13 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/01/31 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1038/s41562-020-0862-5 [doi]
AID - 10.1038/s41562-020-0862-5 [pii]
PST - ppublish
SO  - Nat Hum Behav. 2020 Jun;4(6):567-576. doi: 10.1038/s41562-020-0862-5. Epub 2020
      May 11.


PMID- 32393614
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 10
TI  - Can a teacher-led mindfulness intervention for new school entrants improve child 
      outcomes? Protocol for a school cluster randomised controlled trial.
PG  - e036523
LID - 10.1136/bmjopen-2019-036523 [doi]
AB  - INTRODUCTION: The first years of school are critical in establishing a foundation
      for positive long-term academic, social and well-being outcomes.
      Mindfulness-based interventions may help students transition well into school,
      but few robust studies have been conducted in this age group. We aim to determine
      whether compared with controls, children who receive a mindfulness intervention
      within the first years of primary school have better: (1) immediate
      attention/short-term memory at 18 months post-randomisation (primary outcome);
      (2) inhibition, working memory and cognitive flexibility at 18 months
      post-randomisation; (3) socio-emotional well-being, emotion-regulation and mental
      health-related behaviours at 6 and 18 months post-randomisation; (4) sustained
      changes in teacher practice and classroom interactions at 18 months
      post-randomisation. Furthermore, we aim to determine whether the implementation
      predicts the efficacy of the intervention, and the cost effectiveness relative to
      outcomes. METHODS AND ANALYSIS: This cluster randomised controlled trial will be 
      conducted in 22 primary schools in disadvantaged areas of Melbourne, Australia.
      826 students in the first year of primary school will be recruited to detect
      between groups differences of Cohen's d=0.25 at the 18-month follow-up. Parent,
      teacher and child-assessment measures of child attention, emotion-regulation,
      executive functioning, socio-emotional well-being, mental health-related
      behaviour and learning, parent mental well-being, teacher well-being will be
      collected 6 and 18 months post-randomisation. Implementation factors will be
      measured throughout the study. Intention-to-treat analyses, accounting for
      clustering within schools and classes, will adopt a two-level random effects
      linear regression model to examine outcomes for the intervention versus control
      students. Unadjusted and analyses adjusted for baseline scores, baseline age,
      gender and family socioeconomic status will be conducted. ETHICS AND
      DISSEMINATION: Ethics approval has been received by the Human Research Ethics
      Committee at the University of Melbourne. Findings will be reported in
      peer-review publications, national and international conference presentations and
      research snapshots directly provided to participating schools and families.
      PRE-RESULTS TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials
      Registry (ACTRN12619000326190).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Quach, Jon L
AU  - Quach JL
AUID- ORCID: 0000-0002-3055-3082
AD  - Melbourne Graduate School of Education, The University of Melbourne, Carlton,
      Victoria, Australia jon.quach@unimelb.edu.au.
AD  - Centre for Community Child Health, Murdoch Childrens Research Institute,
      Parkville, Victoria, Australia.
FAU - Deery, Ben
AU  - Deery B
AD  - Melbourne Graduate School of Education, The University of Melbourne, Carlton,
      Victoria, Australia.
FAU - Kern, Margaret
AU  - Kern M
AD  - Melbourne Graduate School of Education, The University of Melbourne, Carlton,
      Victoria, Australia.
FAU - Clinton, Janet
AU  - Clinton J
AD  - Melbourne Graduate School of Education, The University of Melbourne, Carlton,
      Victoria, Australia.
FAU - Gold, Lisa
AU  - Gold L
AD  - Deakin Health Economics, Deakin University, Burwood, Victoria, Australia.
FAU - Orsini, Francesca
AU  - Orsini F
AD  - Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research
      Institute, Melbourne, Victoria, Australia.
FAU - Sciberras, Emma
AU  - Sciberras E
AD  - Centre for Community Child Health, Murdoch Childrens Research Institute,
      Parkville, Victoria, Australia.
AD  - School of Psychology, Deakin University, Burwood, Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12619000326190
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200510
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - Child
MH  - Humans
MH  - Mental Health
MH  - *Mindfulness
MH  - Randomized Controlled Trials as Topic
MH  - School Health Services
MH  - Schools
MH  - Students
PMC - PMC7223282
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *community child health
OT  - *public health
COIS- Competing interests: BD developed the intervention but does not receive any
      commercial or non-commercial financial entitlements.
EDAT- 2020/05/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036523 [pii]
AID - 10.1136/bmjopen-2019-036523 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 10;10(5):e036523. doi: 10.1136/bmjopen-2019-036523.


PMID- 32393613
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 10
TI  - Biomarkers of exposure and early effect in three contaminated sites of southern
      Italy: protocols for etiological epidemiological studies.
PG  - e036160
LID - 10.1136/bmjopen-2019-036160 [doi]
AB  - INTRODUCTION: Environmental pollution has been progressively becoming one of the 
      main risk factors to human diseases. In particular, populations living in
      high-contaminated sites are particularly exposed to environmental toxicants, with
      consequent increased risks to human health. In Italy, there are currently ongoing
      three epidemiological etiological studies aimed at evaluating the association
      between exposure to inorganic and organic chemicals and presence of biological
      markers of early effects in population living in three National Priority
      Contaminated Sites (NPCSs). Specifically, the correlations concern preclinical
      indicators of liver disease in Priolo NPCS, thyroid diseases in Milazzo-Valle del
      Mela NPCS and cardiovascular risk and kidney damage in Crotone NPCS. METHODS AND 
      ANALYSIS: Overall, approximately 1300 subjects of both sexes will be enrolled in 
      the three NPCSs according to specific inclusion criteria. For each subject, serum
      and urine specimens are collected, on which the determination of biological
      markers of exposure and early effects for the selected outcomes are performed.
      Individual information on environmental and occupational exposure, medical
      history, diet and life habits is obtained through questionnaires provided by web 
      platform. In Milazzo-Valle del Mela and Crotone NPCSs, not invasive instrumental 
      and imaging examinations are performed in order to evaluate further risk factors 
      of thyroid carcinoma and cardiovascular disease, respectively. ETHICS AND
      DISSEMINATION: The protocol studies have been approved by the Ethics Committees
      responsible for the three involved NPCSs: the Ethics Committee 'Catania 2' for
      the NPCS of Priolo (21 July 2017, n. 500/2017/CECT2), the Ethics Committee of the
      University Hospitals of Messina for the NPCS of Milazzo-Valle del Mela (19
      February 2018, n.2/2018); the Ethics Committee of the Region of Calabria for the 
      NPCS of Crotone (20 July 2017, n. 174). Results will be disseminated among
      policy-makers, citizens, stakeholders and scientific community through the
      organisation of conferences and events, and the publication on international
      peer/reviewed journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gorini, Francesca
AU  - Gorini F
AUID- ORCID: 0000-0002-4619-6227
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy
      fgorini@ifc.cnr.it.
FAU - Bustaffa, Elisa
AU  - Bustaffa E
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy.
FAU - Bolignano, Davide
AU  - Bolignano D
AD  - National Research Council, Institute of Clinical Physiology, Reggio Calabria,
      Italy.
FAU - Cori, Liliana
AU  - Cori L
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy.
FAU - Faita, Francesco
AU  - Faita F
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy.
FAU - Gastaldelli, Amalia
AU  - Gastaldelli A
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy.
FAU - Interdonato, Monica
AU  - Interdonato M
AD  - Department of Clinical and Experimental Medicine, Section of Pharmacology,
      University of Messina, Messina, Italy.
FAU - Minichilli, Fabizio
AU  - Minichilli F
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy.
FAU - Quattrone, Giancarlo
AU  - Quattrone G
AD  - Local Health Authority of Messina, Messina, Italy.
FAU - Squadrito, Francesco
AU  - Squadrito F
AD  - Department of Clinical and Experimental Medicine, Section of Pharmacology,
      University of Messina, Messina, Italy.
FAU - Tripepi, Giovanni
AU  - Tripepi G
AD  - National Research Council, Institute of Clinical Physiology, Reggio Calabria,
      Italy.
FAU - Vassalle, Cristina
AU  - Vassalle C
AD  - Fondazione CNR-Regione Toscana G Monasterio, Laboratory Medicine Unit, Pisa,
      Italy.
FAU - Bianchi, Fabrizio
AU  - Bianchi F
AD  - National Research Council, Institute of Clinical Physiology, Pisa, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200510
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers
MH  - *Environmental Exposure/adverse effects
MH  - *Environmental Pollution
MH  - Epidemiologic Studies
MH  - Female
MH  - Humans
MH  - Italy/epidemiology
MH  - Male
PMC - PMC7223157
OTO - NOTNLM
OT  - *epidemiology
OT  - *health policy
OT  - *protocols & guidelines
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/05/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036160 [pii]
AID - 10.1136/bmjopen-2019-036160 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 10;10(5):e036160. doi: 10.1136/bmjopen-2019-036160.


PMID- 32393612
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 10
TI  - Machine learning health-related applications in low-income and middle-income
      countries: a scoping review protocol.
PG  - e035983
LID - 10.1136/bmjopen-2019-035983 [doi]
AB  - INTRODUCTION: Machine learning (ML) has been used in bio-medical research, and
      recently in clinical and public health research. However, much of the available
      evidence comes from high-income countries, where different health profiles
      challenge the application of this research to low/middle-income countries
      (LMICs). It is largely unknown what ML applications are available for LMICs that 
      can support and advance clinical medicine and public health. We aim to address
      this gap by conducting a scoping review of health-related ML applications in
      LMICs. METHODS AND ANALYSIS: This scoping review will follow the methodology
      proposed by Levac et al. The search strategy is informed by recent systematic
      reviews of ML health-related applications. We will search Embase, Medline and
      Global Health (through Ovid), Cochrane and Google Scholar; we will present the
      date of our searches in the final review. Titles and abstracts will be screened
      by two reviewers independently; selected reports will be studied by two reviewers
      independently. Reports will be included if they are primary research where data
      have been analysed, ML techniques have been used on data from LMICs and they
      aimed to improve health-related outcomes. We will synthesise the information
      following evidence mapping recommendations. ETHICS AND DISSEMINATION: The review 
      will provide a comprehensive list of health-related ML applications in LMICs. The
      results will be disseminated through scientific publications. We also plan to
      launch a website where ML models can be hosted so that researchers, policymakers 
      and the general public can readily access them.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Carrillo-Larco, Rodrigo M
AU  - Carrillo-Larco RM
AUID- ORCID: 0000-0002-2090-1856
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK r.carrillo-larco@imperial.ac.uk.
AD  - CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano
      Heredia, Lima, Peru.
FAU - Tudor Car, Lorainne
AU  - Tudor Car L
AD  - Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang
      Technological University, Singapore.
AD  - Department of Primary Care and Public Health, School of Public Health, Imperial
      College London, London, UK.
FAU - Pearson-Stuttard, Jonathan
AU  - Pearson-Stuttard J
AD  - Department of Epidemiology and Biostatistics and MRC-PHE Centre for Environment
      and Health, School of Public Health, Imperial College London, London, UK.
FAU - Panch, Trishan
AU  - Panch T
AD  - Wellframe Inc, Boston, Massachusetts, USA.
FAU - Miranda, J Jaime
AU  - Miranda JJ
AUID- ORCID: 0000-0002-4738-5468
AD  - CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano
      Heredia, Lima, Peru.
AD  - Facultad de Medicina "Alberto Hurtado", Universidad Peruana Cayetano Heredia,
      Lima, Peru.
FAU - Atun, Rifat
AU  - Atun R
AD  - Harvard T.H Chan School of Public Health and Harvard Medical School, Harvard
      University, Cambridge, Massachusetts, USA.
LA  - eng
GR  - 100693/Z/12/Z/WT_/Wellcome Trust/United Kingdom
GR  - 294834/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 214185/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200510
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Delivery of Health Care
MH  - *Developing Countries
MH  - Humans
MH  - Income
MH  - Machine Learning
MH  - *Poverty
MH  - Review Literature as Topic
PMC - PMC7223147
OTO - NOTNLM
OT  - *World Wide Web technology
OT  - *biotechnology & bioinformatics
OT  - *epidemiology
OT  - *health informatics
COIS- Competing interests: None declared.
EDAT- 2020/05/13 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035983 [pii]
AID - 10.1136/bmjopen-2019-035983 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 10;10(5):e035983. doi: 10.1136/bmjopen-2019-035983.


PMID- 32393611
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 10
TI  - Mixed methods evaluation of workshops for citizen health advocates about
      financial conflicts of interests in healthcare.
PG  - e034195
LID - 10.1136/bmjopen-2019-034195 [doi]
AB  - OBJECTIVES: To evaluate workshops delivered to citizen health advocates about
      financial conflicts of interest in healthcare, transparency databases which
      disclose industry payments in the USA and Australia and the pros and cons of
      advocacy groups accepting industry sponsorship. DESIGN: Thematic analysis of
      workshop participant recorded discussions, and pre, post and 3-month follow-up
      questionnaires on confidence and knowledge about financial conflicts of interest,
      transparency databases and the merits of advocacy organisations accepting
      industry sponsorship. PARTICIPANTS AND SETTING: 48 citizen health advocates
      participated in a half-day workshop, held in four Australian cities, which ended 
      with a 1-hour recorded discussion. Participants were recruited with assistance
      from leading state-based health advocacy organisations. RESULTS: The thematic
      analysis of the recorded discussions revealed two major themes, (i) transparency 
      and (ii) relationships with industry; and three minor themes: a lack of awareness
      about conflicts of interest and transparency, issues relating to trust and next
      steps in terms of potential reforms. In relation to transparency, participants
      felt strong support for transparency, strongly favouring the mandatory, extensive
      and accessible US Open Payments over the self-regulatory Australian model.
      Participants also noted that transparency had limitations, including the utility 
      of disclosed information. In relation to industry sponsorship of advocacy groups,
      some participants expressed an openness to and support for accepting sponsorship,
      while many expressed a caution around potential downsides. Questionnaire results 
      showed increases in both confidence and knowledge after the workshop, though only
      23 of 48 participants returned the 3-month follow-up questionnaire. CONCLUSIONS: 
      Following a half-day workshop, citizen health advocates recruited by leading
      health advocacy organisations expressed strong support for tough transparency
      rules, and mixed feelings about advocacy groups accepting sponsorship from
      industry. Study limitations include a non-representative sample and a large
      drop-out at the 3-month post-workshop follow-up.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Moynihan, Ray
AU  - Moynihan R
AUID- ORCID: 0000-0001-9283-742X
AD  - Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland,
      Australia raymoynihan@bond.edu.au.
FAU - Fabbri, Alice
AU  - Fabbri A
AD  - Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health,
      University of Sydney, Sydney, New South Wales, Australia.
FAU - Parker, Lisa
AU  - Parker L
AUID- ORCID: 0000-0001-8635-6953
AD  - Centre for Values, Ethics and the Law in Medicine, University of Sydney, Sydney, 
      New South Wales, Australia.
FAU - Bero, Lisa
AU  - Bero L
AD  - Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health,
      University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200510
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Australia
MH  - *Conflict of Interest
MH  - *Consumer Advocacy
MH  - Databases, Factual
MH  - Delivery of Health Care
MH  - Disclosure
MH  - Female
MH  - Humans
MH  - *Industry
MH  - Male
PMC - PMC7223283
OTO - NOTNLM
OT  - *ethics
OT  - *health services administration
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/05/13 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034195 [pii]
AID - 10.1136/bmjopen-2019-034195 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 10;10(5):e034195. doi: 10.1136/bmjopen-2019-034195.


PMID- 32393563
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Linking)
VI  - 18
IP  - 3
DP  - 2020 May
TI  - Physician Involvement in Promoting Gun Safety.
PG  - 262-264
LID - 10.1370/afm.2516 [doi]
AB  - Firearm-related deaths are on the rise in the United States, especially among our
      youth. Tragically, proper firearm storage and safety could have prevented a great
      number of these deaths. Professional and public health organizations have thus
      encouraged physicians to provide direct patient counseling on firearm safety.
      Yet, even with these recommendations, the majority of physicians are still not
      talking to their patients about this issue. There may be many reasons for this,
      including concerns about liability, feeling unprepared, patient discomfort, and
      lack of time during office visits. Despite these concerns, we argue that
      physicians have an ethical obligation to discuss firearm safety with their
      patients. Making these discussions a part of routine clinical care would go a
      long way in the bipartisan effort to protect public safety and improve public
      health.
CI  - (c) 2020 Annals of Family Medicine, Inc.
FAU - Tolat, Nicholas Darshan
AU  - Tolat ND
AD  - Baylor College of Medicine, Houston, Texas.
FAU - Naik-Mathuria, Bindi Jayendra
AU  - Naik-Mathuria BJ
AD  - Baylor College of Medicine, Houston, Texas.
AD  - Division of Pediatric Surgery, Texas Children's Hospital, Houston, Texas.
FAU - McGuire, Amy Lynn
AU  - McGuire AL
AD  - Baylor College of Medicine, Houston, Texas amcguire@bcm.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
SB  - IM
MH  - Counseling/*ethics/methods
MH  - Firearms/*ethics
MH  - Gun Violence/*prevention & control/psychology
MH  - Humans
MH  - Patient Safety
MH  - Physician's Role/*psychology
MH  - Physicians/ethics/*psychology
MH  - United States
PMC - PMC7213995
OTO - NOTNLM
OT  - *counseling
OT  - *ethics
OT  - *firearms
OT  - *physicians
EDAT- 2020/05/13 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2019/11/12 00:00 [revised]
PHST- 2019/11/21 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 18/3/262 [pii]
AID - 10.1370/afm.2516 [doi]
PST - ppublish
SO  - Ann Fam Med. 2020 May;18(3):262-264. doi: 10.1370/afm.2516.


PMID- 32393527
OWN - NLM
STAT- MEDLINE
DCOM- 20200612
LR  - 20201218
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 368
IP  - 6494
DP  - 2020 May 29
TI  - Ethics and governance for digital disease surveillance.
PG  - 951-954
LID - 10.1126/science.abb9045 [doi]
FAU - Mello, Michelle M
AU  - Mello MM
AD  - Center for Health Policy/Primary Care and Outcomes Research, Department of
      Medicine, Stanford University School of Medicine, Stanford, CA, USA.
      mmello@law.stanford.edu.
AD  - Stanford Law School, Stanford, CA, USA.
FAU - Wang, C Jason
AU  - Wang CJ
AD  - Center for Health Policy/Primary Care and Outcomes Research, Department of
      Medicine, Stanford University School of Medicine, Stanford, CA, USA.
AD  - Department of Pediatrics and Center for Policy, Outcomes and Prevention, Stanford
      University School of Medicine, Stanford, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - COVID-19
MH  - Confidentiality/ethics
MH  - Coronavirus Infections/*epidemiology
MH  - Datasets as Topic
MH  - *Epidemiological Monitoring
MH  - Forecasting
MH  - Humans
MH  - Machine Learning
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
EDAT- 2020/05/13 06:00
MHDA- 2020/06/13 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/06/13 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - science.abb9045 [pii]
AID - 10.1126/science.abb9045 [doi]
PST - ppublish
SO  - Science. 2020 May 29;368(6494):951-954. doi: 10.1126/science.abb9045. Epub 2020
      May 11.


PMID- 32393516
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20220531
IS  - 1943-3662 (Electronic)
IS  - 1093-6793 (Linking)
VI  - 48
IP  - 2
DP  - 2020 Jun
TI  - A Duty to Protect Our Patients from Physician Sexual Misconduct.
PG  - 176-180
LID - 10.29158/JAAPL.200014-20 [doi]
AB  - In this issue of The Journal, MacIntyre and Appel have reviewed state laws and
      medical boards' policies to ascertain which states require reporting of sexually 
      exploitive psychiatrists, specifically when the patient reveals the exploitation 
      during treatment. They highlight the competing ethics duties faced by physicians 
      who are in a position to report such conduct and provide guidance for future
      development of reporting laws to help balance the conflicting ethics principles
      at stake. In this commentary, I discuss the pros and cons of mandatory reporting 
      laws and underscore the importance of physicians' ethics duty to report the
      sexual misconduct of other physicians even in the absence of a legal mandate. In 
      light of recent high-profile cases that demonstrate a failure of medicine to
      self-regulate, I make the case for a cultural shift in our profession so that the
      subject of reporting physician sexual misconduct is viewed not from the lens of a
      duty to report, but that of a duty to protect.
CI  - (c) 2020 American Academy of Psychiatry and the Law.
FAU - Gulrajani, Chinmoy
AU  - Gulrajani C
AD  - Department of Psychiatry and Behavioral Sciences, University of Minnesota,
      Minneapolis, Minnesota. cgulraja@umn.edu.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200511
PL  - United States
TA  - J Am Acad Psychiatry Law
JT  - The journal of the American Academy of Psychiatry and the Law
JID - 9708963
SB  - IM
CON - J Am Acad Psychiatry Law. 2020 Jun;48(2):166-175. PMID: 32051200
MH  - Humans
MH  - Mandatory Reporting
MH  - *Physicians
MH  - *Professional Misconduct
MH  - *Psychiatry
MH  - Sexual Behavior
EDAT- 2020/05/13 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - JAAPL.200014-20 [pii]
AID - 10.29158/JAAPL.200014-20 [doi]
PST - ppublish
SO  - J Am Acad Psychiatry Law. 2020 Jun;48(2):176-180. doi: 10.29158/JAAPL.200014-20. 
      Epub 2020 May 11.


PMID- 32393471
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Who gets the ventilator? Important legal rights in a pandemic.
PG  - 421-426
LID - 10.1136/medethics-2020-106332 [doi]
FAU - Liddell, Kathleen
AU  - Liddell K
AD  - Faculty of Law, University of Cambridge, Cambridge, UK k.liddell@law.cam.ac.uk.
FAU - Skopek, Jeffrey M
AU  - Skopek JM
AD  - Faculty of Law, University of Cambridge, Cambridge, UK.
FAU - Palmer, Stephanie
AU  - Palmer S
AD  - Faculty of Law, University of Cambridge, Cambridge, UK.
FAU - Martin, Stevie
AU  - Martin S
AD  - Faculty of Law, University of Cambridge, Cambridge, UK.
FAU - Anderson, Jennifer
AU  - Anderson J
AD  - Faculty of Law, University of Cambridge, Cambridge, UK.
FAU - Sagar, Andrew
AU  - Sagar A
AD  - Faculty of Law, University of Cambridge, Cambridge, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Jul;46(7):419-420. PMID: 32601258
MH  - Civil Rights
MH  - Human Rights
MH  - Humans
MH  - *Pandemics/prevention & control
MH  - *Ventilators, Mechanical
PMC - PMC7316113
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/13 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - medethics-2020-106332 [pii]
AID - 10.1136/medethics-2020-106332 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):421-426. doi: 10.1136/medethics-2020-106332. Epub
      2020 May 11.


PMID- 32393461
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Minor gifts from pharmaceutical companies to doctors: A comparison between
      psychiatry and general medicine.
PG  - 116-119
LID - 10.20529/IJME.2020.03 [doi]
AB  - Pharmaceutical companies in countries that have community-oriented models of
      healthcare, unlike other countries with highly privatised healthcare systems,
      such as the United States, cannot legally advertise medications directly to
      patients. Thus, the physician is entirely responsible for choosing the right
      medication, and needs to take important professional and ethical concerns into
      consideration during this decision-making process. Pharmaceutical companies
      invest considerably in in marketing products to physicians. Often, this is in the
      form of "minor gifts" to the physician. This study examines variations in the
      number and type of such minor gifts present in the offices of psychiatrists and
      internists in various medical contexts in Israel. Our results showed that
      psychiatrists received more minor gifts than physicians in general hospitals. No 
      significant differences were found between inpatient and outpatient psychiatric
      departments. It is important to increase awareness and highlight the impact of
      exposure to minor gifts as advertising products on doctors in order to avoid bias
      and maintain objectivity in clinical judgement regarding pharmacological
      management of patients. Keywords: Pharmaceutical, gifts, ethics, physicians.
FAU - Frenkel, Ekaterina Avituv
AU  - Frenkel EA
AD  - Beer Yaakov Mental Health Center, Tel Aviv University, ISRAEL.
FAU - Israeli, David
AU  - Israeli D
AD  - Kaplan Medical Center, Tel Aviv, ISRAEL.
FAU - Gold, Azgad
AU  - Gold A
AD  - Beer Yaakov Mental Health Center, Tel Aviv University, ISRAEL.
FAU - Serfaty, David
AU  - Serfaty D
AD  - Maayenei Hayeshua Medical Center, Tel Aviv, ISRAEL.
FAU - Strous, Rael D
AU  - Strous RD
AD  - Maayenei Hayeshua Medical Center, Bnei Brak, ISRAEL, and Sackler Faculty of
      Medicine, Tel Aviv, ISRAEL.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Drug Industry
MH  - Gift Giving
MH  - Humans
MH  - Israel
MH  - Pharmaceutical Preparations
MH  - *Physicians
MH  - *Psychiatry
MH  - United States
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.03 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):116-119. doi: 10.20529/IJME.2020.03.


PMID- 32393460
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - The ethical responsibility of healthcare providers to advise patients with
      diabetes on lifestyle modifications.
PG  - 124-127
LID - 10.20529/IJME.2020.04 [doi]
AB  - There is clear evidence of a link between health and physical activity (PA). PA
      is universally prescribed as a primary treatment for most chronic diseases.
      However, studies show that not many health professionals advise patients about
      PA. The current study examines how a cost-effective tool to improve population
      health has been completely neglected in professional practice in a state with
      maximum healthcare availability. Is this malfeasance in practice or a violation
      of human rights? Are healthcare providers exempted from their responsibilities
      because they choose to neglect them? Who should be held responsible for the
      increasing disease-related deaths that are easily preventable? Keywords: physical
      activity, inactivity, advice, low- and middle-income country, health
      professionals, providers, chronic disease, diabetes, lifestyle modification,
      counselling.
FAU - Garg, Shalini
AU  - Garg S
AD  - Sr Doctoral Fellow, Achutha Menon Centre for Health Science Studies, Sree Chitra 
      Tirunal Institute for Medical Science and Technology, Thiruvananthapuram, 650
      119, INDIA.
FAU - Kutty, V Raman
AU  - Kutty VR
AD  - Professor Emeritus, Achutha Menon Centre for Health Science Studies, Sree Chitra 
      Tirunal institute for Medical Science and Technology, Thiruvananthapuram, 650 119
      INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Counseling
MH  - *Diabetes Mellitus
MH  - Exercise
MH  - *Health Personnel
MH  - Humans
MH  - Life Style
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.04 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):124-127. doi: 10.20529/IJME.2020.04.


PMID- 32393459
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Assessing completion reports for compliance with institutional ethics
      committee-approved protocols: An observational study.
PG  - 119-123
LID - 10.20529/IJME.2020.025 [doi]
AB  - BACKGROUND: Protocol non-compliance in clinical research studies is common and
      can affect both patient safety and data integrity. There are no published studies
      which actively looked for non-compliance. The present study was carried out,
      against this background, with the objective of assessing the proportion of
      protocol non-compliance and evaluating those aspects of protocol where there was 
      non-compliance. METHODS: The study completion reports that were submitted to the 
      institutional ethics committee for the period January 2017 to December 2017 were 
      compared with the approved protocol. A checklist for recording protocol
      non-compliance was developed, which was validated by five experts and consisted
      of a 12-point checklist with responses such as yes, no, not applicable, and
      insufficient information. RESULTS: Out of 193 studies, prospective observational 
      studies were n = 120 (62.17 %), retrospective studies were n = 39 (20.21%),
      interventional studies n = 28 (14.51 %), and observational studies with both
      prospective and retrospective study design were n = 6 (3.11%). The study
      objective was modified in n=18 (9.32%) studies. Only n = 14 (7.24%) satisfied the
      selection criteria. Six studies (3.10%) did not collect the data as mentioned in 
      the protocol. Fifty-eight studies (30.05%) did not achieve the calculated sample 
      size, whereas n = 78 (40.41%) did not complete the study as per the stipulated
      study duration. Contrary to 180 protocol deviations found in this study, only 14 
      protocol deviations were reported by the principal investigator. Aspects like
      blinding and randomisation, which are relevant to interventional studies (n =
      28), showed 100 % compliance. CONCLUSION: The research protocol is not adhered to
      in all aspects. Adequate training to investigators will help prevent
      non-compliance and enable us to conduct studies with higher ethical and
      scientific integrity.
FAU - Gajbhiye, Snehalata V
AU  - Gajbhiye SV
AD  - Assistant Professor, Department of Pharmacology and Therapeutics, Seth GS Medical
      College and KEM Hospital, Parel, Mumbai 400 012 INDIA.
FAU - Jalgaonkar, Sharmila V
AU  - Jalgaonkar SV
AD  - Associate Professor, Department of Pharmacology and Therapeutics, Seth GS Medical
      College and KEM Hospital, Mumbai, 400012, INDIA.
FAU - Dabba, Sarita G
AU  - Dabba SG
AD  - Senior Executive, Medical Services. SIRO Clinpharm Pvt. Ltd. Wagle Industrial
      Estate, Thane West, Thane, 400 604 INDIA.
FAU - Surve, Shweta
AU  - Surve S
AD  - Executive Assistant, Institutional Ethics Committee, Seth GS Medical College and 
      KEM Hospital, Parel, Mumbai 400 012 INDIA.
FAU - Lad, Manasi S
AU  - Lad MS
AD  - Executive Assistant, Institutional Ethics Committee, Seth GS Medical College and 
      KEM Hospital, Parel, Mumbai 400 012 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - *Ethics Committees, Research
MH  - Humans
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - *Research Design
MH  - Research Personnel
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *interventional studies non-compliance.
OT  - *sample size
OT  - *study design
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.025 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):119-123. doi: 10.20529/IJME.2020.025.


PMID- 32393458
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20201218
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Response to Covid-19: An ethical imperative to build a resilient health system in
      India.
PG  - 1-4
LID - 10.20529/IJME.2020.026 [doi]
AB  - China reported cases of a severe form of pneumonia in December 2019 from Wuhan
      city, Hubei province. The virus causing this illness was identified as the novel 
      Coronavirus 2019, which has now been christened Covid-19. The illness is
      characterised by fever, cough, body pain and in a few cases, progression to acute
      respiratory distress syndrome (ARDS) which marks very serious damage to the lungs
      (1-4). Apart from Wuhan, China, the virus has spread to 26 other countries as on 
      February 18, 2020. Of these 26 countries, the cases of Covid-19 have been
      exported directly from China in 23 of them. As on February 23, 2020, a total of
      78,811 confirmed cases, 2445 deaths have been reported globally. The World Health
      Organization declared this as a Public Health Emergency of International Concern 
      (PHEIC) on January 30, 2020 (5).
FAU - Gopichandran, Vijayaprasad
AU  - Gopichandran V
AD  - Assistant Professor, Department of Community Medicine, ESIC Medical College and
      PGIMSR, KK Nagar, Chennai 600 078 INDIA.
FAU - Subramaniam, Sudarshini
AU  - Subramaniam S
AD  - Assistant Professor, Institute of Community Medicine, Madras Medical College,
      Chennai 600 003 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
CIN - Indian J Med Ethics. 2020 Apr-Jun;V(2):169-170. PMID: 32393440
MH  - Betacoronavirus
MH  - COVID-19
MH  - Civil Defense
MH  - *Clinical Governance
MH  - *Coronavirus Infections
MH  - *Delivery of Health Care
MH  - *Health Resources
MH  - Humans
MH  - India/epidemiology
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/05/13 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.20529/IJME.2020.026 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):1-4. doi: 10.20529/IJME.2020.026.


PMID- 32393457
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - On being heckled at a National Health Technology Conference: Patient
      participation and democratic discourse.
PG  - 128-133
LID - 10.20529/IJME.2020.027 [doi]
AB  - This article uses my experience of being heckled by patient advocates at a health
      technology conference in Canada as a springboard for discussing the politics of
      health technology assessment (HTA). While HTA is widely understood and practised 
      as a scientific endeavour grounded in rigorous quantitative research methods, the
      socio-political aspects of HTA cannot be separated from the scientific.
      Integrating the social, political, and ethical dimensions of HTA into the
      practice of assessment means understanding how a technology will shift power
      relationships among actors, alter resource flows, and affect how knowledge is
      produced and circulated. I suggest these factors contributed to the hostile
      reception I received when I attempted to present a paper about the biased
      selection of patient advocates involved in Canada's main HTA agency. As India
      embarks on the challenge of establishing its own agency to support healthcare
      decision-making, and as patient advocacy groups rise in India with the support of
      the pharmaceutical industry, I offer this account as a cautionary tale to those
      shaping India's new agency.
FAU - Batt, Sharon
AU  - Batt S
AD  - Adjunct Professor, Department of Bioethics, Dalhousie University, Halifax, B3H
      4R2 CANADA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Biomedical Technology
MH  - Humans
MH  - India
MH  - *Patient Participation
MH  - Politics
MH  - *Technology Assessment, Biomedical
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.027 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):128-133. doi: 10.20529/IJME.2020.027.


PMID- 32393456
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Administering drugs to an individual in a non-pathological situation: The Caster 
      Semenya case.
PG  - 139-143
LID - 10.20529/IJME.2020.030. [doi]
AB  - The International Association of Athletics Federations (IAAF) has barred
      individuals whose circulating testosterone levels are higher than 5 nmol/L from
      competing in women's competitions in middle-distance track events. To become
      eligible, they must take anti-testosterone treatment to achieve the appropriate
      testosterone levels. The 2019 decision of the Court of Arbitration for Sport has 
      brought the spotlight back on Caster Semenya's case and on the ethics of testing 
      the testosterone levels of sports persons with or without consent, imposing
      anti-testosterone treatment in order to qualify to participate in sports
      competitions for females. This article debates all the issues concerned from
      various perspectives.
FAU - Jagadeesh, N
AU  - Jagadeesh N
AD  - Professor and Head Department of Forensic Medicine and Toxicology, Vydehi
      Institute of Medical Sciences and Research Centre, Whitefield Road, Bengaluru 560
      066 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Athletes
MH  - Female
MH  - Humans
MH  - Hyperandrogenism
MH  - Pharmaceutical Preparations
MH  - *Sports
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.030 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):139-143. doi: 10.20529/IJME.2020.030.


PMID- 32393455
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - The ethics of penal amputation.
PG  - 143-148
LID - 10.20529/IJME.2020.032 [doi]
AB  - Malaysia is a South East Asian country with a racially diverse population. Islam 
      is the state religion and about 60% of the population is Muslim, but the rights
      of other religious groups are protected by law. The Parti Islam se Malaysia,
      which has ruled the state of Kelantan since 1999, and believes that Malaysia
      should be ruled by Sharia law, recently proposed the implementation of Hudud laws
      in Kelantan. However, the federal government has ruled out its implementation.
      The suggestion stirred up a controversy among the physician community and the
      Malaysian Medical Association rejected a proposal by the state's political
      leadership to utilise the services of qualified surgeons to carry out punitive
      limb amputations. Several Islamic states such as Sudan, Saudi Arabia, and Iran
      practice Islamic penal justice, including amputations. The question therefore
      arises: how should a modern medical practitioner approach this ethical question? 
      This study focuses mainly on Malaysia, but draws upon practices in other Islamic 
      countries also.
FAU - Das, Anjan K
AU  - Das AK
AD  - Associate Professor, Taylor's University School of Medicine, Faculty of Health
      and Medical Sciences, Taylor's University, 1, Jalan Taylor's, 47500, Subang Jaya,
      Selangor, MALAYSIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
CIN - Indian J Med Ethics. 2020 Apr-Jun;V(2):151. PMID: 32393445
CIN - Indian J Med Ethics. 2020 Apr-Jun;V(2):149-151. PMID: 32393454
MH  - *Amputation
MH  - Humans
MH  - Iran
MH  - Islam
MH  - Malaysia
MH  - *Morals
MH  - Religion and Medicine
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.032 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):143-148. doi: 10.20529/IJME.2020.032.


PMID- 32393454
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - The crime of medical complicity in penal amputation.
PG  - 149-151
LID - 10.20529/IJME.2020.034 [doi]
AB  - Professor Das writes a challenging article about the ethical dilemma of the
      prohibition on inflicting of harm versus the utilisation of surgical expertise in
      carrying out penal amputations under Sharia law.
FAU - van Es, Adriaan
AU  - van Es A
AD  - Secretary, IFHHRO/ Medical Human Rights Network, Regentesselaan 32, 3818 HJ
      Amersfoort, THE NETHERLANDS.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
CON - Indian J Med Ethics. 2020 Apr-Jun;V(2):143-148. PMID: 32393455
CIN - Indian J Med Ethics. 2020 Apr-Jun;V(2):151. PMID: 32393445
MH  - Amputation
MH  - *Complicity
MH  - *Crime
MH  - Humans
MH  - India
MH  - Morals
EDAT- 2020/05/13 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.20529/IJME.2020.034 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):149-151. doi: 10.20529/IJME.2020.034.


PMID- 32393450
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Pregnancy and severe mental illness: Confounding ethical doctrines.
PG  - 133-139
LID - 10.20529/IJME.2020.037 [doi]
AB  - Pregnancy brings joy and excitement to some women, but great distress to those
      who suffer from severe mental illnesses like schizophrenia. Women with severe
      mental illnesses (SMIs) may have difficulty planning a pregnancy and deciding
      whether to continue to viability, and thence to term. Dilemmas also surround
      pharmacotherapy for this population, as (non)treatment is associated with its own
      challenges. The psychiatrist may have to make challenging decisions based on the 
      principles of autonomy, beneficence, and relational ethics. Furthermore, there
      are ethical controversies inherent to the underlying pathologies, their
      non-treatment, and the various psychosocial factors that could impact parenting
      in such mothers. In addition, limited or ineffective use of family planning,
      mental health services, and contraception often act as forerunners of these
      problems. Considering the sparse literature on this topic and the perplexing
      legal responsibilities pertaining to the recently implemented Mental Health Care 
      Act, 2017, we have attempted to highlight the various ethical dilemmas that
      confront a psychiatrist while managing a patient from this group Keywords:
      pregnancy, perinatal, severe mental illness, schizophrenia, psychosis, ethics.
FAU - Aneja, Jitender
AU  - Aneja J
AD  - Associate Professor, Department of Psychiatry, All India Institute of Medical
      Sciences, Jodhpur- Romana, Punjab 151001, INDIA.
FAU - Arora, Sonam
AU  - Arora S
AD  - Consultant Pathologist, Metropolis Healthcare Limited, Sector-11 D, Chandigarh,
      160 011 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Beneficence
MH  - Family Planning Services
MH  - Female
MH  - Humans
MH  - Parenting
MH  - Pregnancy
MH  - *Psychiatry
MH  - Schizophrenia
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.037 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):133-139. doi: 10.20529/IJME.2020.037.


PMID- 32393449
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Integrating concerns of gender, sexuality and marital status in the medical
      curriculum.
PG  - 92-94
LID - 10.20529/IJME.2020.039 [doi]
AB  - The introduction of AETCOM (attitude, ethics and communication) (1) is seen as an
      effort at incorporating Medical Humanities (MH) within the medical curriculum.
      For the first time, India's medical curriculum includes modules on the
      patient-doctor relationship, helping doctors to address ethical dilemmas that
      might arise during medical practice. Despite this progressive step, AETCOM has a 
      number of drawbacks. Gayathri Prabhu (2) has analysed AETCOM as ossified,
      instrumental, lacking in a critical sensibility and failing to borrow from a
      humanities methodology. We would like to add to her excellent critique by
      examining other areas which have been overlooked within AETCOM. Our editorial
      addresses AETCOM's lack of sensibility towards the diversity of patients in India
      by focusing specifically on questions of gender, sexuality and marital status.
      While it is also important to understand how caste, religious, tribal and ethnic 
      backgrounds of patients might be addressed within AETCOM, it is outside the scope
      of this editorial.
FAU - Govind, Nikhil
AU  - Govind N
AD  - Associate Professor and Head, Manipal Centre for Humanities, Manipal Academy of
      Higher Education, Manipal 576 104, Karnataka, INDIA.
FAU - Chowkhani, Ketaki
AU  - Chowkhani K
AD  - Postdoctoral Fellow, Manipal Centre for Humanities, Manipal Academy of Higher
      Education, Manipal 576 104, Karnataka, INDIA.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Female
MH  - Humanities
MH  - Humans
MH  - India
MH  - *Marital Status
MH  - *Sexuality
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.039 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):92-94. doi: 10.20529/IJME.2020.039.


PMID- 32393447
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20201218
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Non-communicable disease management in vulnerable patients during Covid-19.
PG  - 103-105
LID - 10.20529/IJME.2020.041 [doi]
AB  - It is now well established that non-communicable diseases (NCD), like diabetes
      mellitus, hypertension,, respiratory and heart disease, particularly among the
      elderly, increase the susceptibility to COVID-19 disease. Mortality in 60%-90% of
      the COVID-19 cases is attributed to either one or more of these comorbidities.
      However, healthcare management for control of COVID-19 involves public health and
      policy decisions that may critically undermine the existing health needs of the
      most vulnerable NCD patients. Temporary closure of outpatient health facilities
      in some secondary and tertiary care hospitals have deprived millions of NCD
      patients of their regular medication and diagnostic health needs. The lack of
      robust primary healthcare facilities in most states, and the failure to maintain 
      physical distancing norms due to inadequate infrastructure is also problematic.
      In the absence of effective public health interventions, socioeconomically
      vulnerable patients are likely to become non-adherent increasing manifold their
      risk of disease complications. In this context, the feasibility of dispensing
      longer than usual drug refills for chronic NCD conditions at functional
      government health facilities, home delivery of essential drugs, running dedicated
      NCD clinics at PHCs, and utilisation of telemedicine opportunities for care and
      support to patients warrant aggressive exploration. Keywords: Covid-19, NCDs,
      Medical ethics, epidemic, India.
FAU - Basu, Saurav
AU  - Basu S
AD  - Senior Resident, Department of Community Medicine, Maulana Azad Medical College, 
      2, Bahadur Shah Zafar Marg, New Delhi 110 002 INDIA.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - *Delivery of Health Care
MH  - *Health Services Accessibility/ethics
MH  - Health Services Needs and Demand
MH  - Humans
MH  - India/epidemiology
MH  - *Noncommunicable Diseases/therapy
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - Primary Health Care
MH  - SARS-CoV-2
MH  - Telemedicine
MH  - *Vulnerable Populations
EDAT- 2020/05/13 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.20529/IJME.2020.041 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):103-105. doi: 10.20529/IJME.2020.041.


PMID- 32393446
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20201218
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Alcohol withdrawal management during the Covid-19 lockdown in Kerala.
PG  - 105-106
LID - 10.20529/IJME.2020.042 [doi]
AB  - The lockdown declared to prevent the spread of Covid 19 in India created
      unforeseen problems, including severe alcohol withdrawal symptoms and the need to
      manage them. The state of Kerala in India saw suicide deaths by six affected
      individuals, prompting the state government to instruct government doctors to
      prescribe alcohol to addicts. The local medical association approached the courts
      against this. These events raise interesting ethical issues discussed here.
      Keywords: alcohol withdrawal, prescribing alcohol, Covid 19, ethics of alcohol
      prescription.
FAU - Varma, Ravi Prasad
AU  - Varma RP
AD  - Associate Professor, Achutha Menon Centre for Health Science Studies, Sree Chitra
      Tirunal Institute for Medical Sciences and Technology, Trivandrum.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - *Alcoholism/therapy
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Health Services Accessibility/ethics
MH  - Humans
MH  - India
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
MH  - *Substance Withdrawal Syndrome/therapy
EDAT- 2020/05/13 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.20529/IJME.2020.042 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):105-106. doi: 10.20529/IJME.2020.042.


PMID- 32393445
OWN - NLM
STAT- MEDLINE
DCOM- 20201104
LR  - 20201104
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Response to Commentary by Adriaan van Es.
PG  - 151
LID - 10.20529/IJME.2020.043 [doi]
AB  - I would like to thank Dr Adriaan Van Es for his commentary (1) on my article (2).
      To start with, let me make one thing clear: I am not sure why he thinks that I am
      condoning the practice of penal amputation. As I clearly state in my conclusion, 
      the arguments that may (or may not) justify penal amputation are abhorrent in
      liberal societies. We are on the same side here. But what of those who live in
      less secular societies where religious faith may be unquestioned? In my opinion, 
      van Es has resorted to a typical example of a tortured form of ethical logic (3),
      which researchers from countries that have different value systems and different 
      problems have deplored, albeit in a different context.
FAU - Das, Anjan K
AU  - Das AK
AD  - Associate Professor, Taylor's University School of Medicine, Faculty of Health
      and Medical Sciences, Taylor's University, 1, Jalan Taylor, 47500, Subang Jaya,
      Selangor, MALAYSIA.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
CON - Indian J Med Ethics. 2020 Apr-Jun;V(2):149-151. PMID: 32393454
CON - Indian J Med Ethics. 2020 Apr-Jun;V(2):143-148. PMID: 32393455
MH  - Amputation
MH  - *Complicity
MH  - *Crime
MH  - Humans
MH  - India
MH  - Male
MH  - Morals
EDAT- 2020/05/13 06:00
MHDA- 2020/11/05 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/11/05 06:00 [medline]
AID - 10.20529/IJME.2020.043 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):151. doi: 10.20529/IJME.2020.043.


PMID- 32393441
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20201218
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - Ethics in the Covid-19 emergency: Examining rationing decisions.
PG  - 168-169
LID - 10.20529/IJME.2020.049 [doi]
AB  - Early last month, the Italian Society of Anaesthesia was forced to publish the
      above guideline (1) for the country's hospitals. Besides the rising cases of
      infection, the doctors realised that patients required up to 15-20 days of
      intensive care as the disease progressed (2). In the face of medical resource
      scarcities, the guideline established that everyone could not be saved from the
      coronavirus. And a massive death toll ensued.
FAU - Mahurkar, Arnav
AU  - Mahurkar A
AD  - MSc Student, Health Economics, Policy and Law, Erasmus University Rotterdam, THE 
      NETHERLANDS.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - Decision Making
MH  - *Emergency Medical Services/ethics
MH  - *Health Care Rationing/ethics
MH  - Humans
MH  - India/epidemiology
MH  - Italy/epidemiology
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - Practice Guidelines as Topic
MH  - SARS-CoV-2
EDAT- 2020/05/13 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.20529/IJME.2020.049 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):168-169. doi: 10.20529/IJME.2020.049.


PMID- 32393439
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 0975-5691 (Electronic)
IS  - 0974-8466 (Linking)
VI  - V
IP  - 2
DP  - 2020 Apr-Jun
TI  - The Robin Hood dilemma: Is it ethical to use unethical means to achieve something
      good?
PG  - 170-171
LID - 10.20529/IJME.2020.051 [doi]
AB  - The website Sci-Hub (http://sci-hub.tw/) (1) offers access to medical and
      scientific research papers from all over the world to anyone horizontal line for 
      free. So, what's the catch? There isn't one, except for the fact that this is an 
      initiative by an enterprising hacker, Alexandra Asanovna Elbakyan, a Kazakhstani 
      computer programmer, who has cracked the firewalls of the websites of medical
      publishers.
FAU - Malpani, Aniruddha
AU  - Malpani A
AD  - Malpani Infertility Clinic, Jamuna Sagar, SBS Road, Colaba, Mumbai 400 005.
      INDIA.
LA  - eng
PT  - Letter
PL  - India
TA  - Indian J Med Ethics
JT  - Indian journal of medical ethics
JID - 101214913
SB  - IM
MH  - Humans
MH  - *Morals
EDAT- 2020/05/13 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - 10.20529/IJME.2020.051 [doi]
PST - ppublish
SO  - Indian J Med Ethics. 2020 Apr-Jun;V(2):170-171. doi: 10.20529/IJME.2020.051.


PMID- 32393330
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 11
TI  - Addressing ethical challenges of disclosure in dementia prediction: limitations
      of current guidelines and suggestions to proceed.
PG  - 33
LID - 10.1186/s12910-020-00476-4 [doi]
AB  - BACKGROUND: Biomarker research is gaining increasing attention focusing on the
      preclinical stages of the disease. Such interest requires special attention for
      communication and disclosure in clinical contexts. Many countries give dementia a
      high health policy priority by developing national strategies and by improving
      guidelines addressing disclosure of a diagnosis; however, risk communication is
      often neglected. MAIN TEXT: This paper aims to identify the challenges of
      disclosure in the context of dementia prediction and to find out whether existing
      clinical guidelines sufficiently address the issues of disclosing a dementia
      diagnosis and of disclosing the risk of developing dementia in asymptomatic and
      MCI stage. We will examine clinical guidelines and recommendations of three
      countries (USA, Canada and Germany) regarding predictive testing and diagnostic
      disclosure in dementia and Mild Cognitive Impairment (MCI) to show their
      potentials and limits. This will provide a background to address ethical
      implications of predictive information and to identify ways how to proceed
      further. We will start by examining the guidelines and recommendations by
      focusing on what there is already and what is missing regarding the challenges of
      disclosing dementia prediction and MCI. Then, we will highlight the novel ethical
      issues generated by the shift to identify preclinical stages of the disease by
      biomarkers. We will argue for the need to develop guidelines for disclosing a
      risk status, which requires different considerations then disclosing a diagnosis 
      of dementia. Finally, we will make some suggestions on how to address the gap and
      challenges raised by referring to German Stakeholder Conference, which presents
      us a good starting point to the applicability of involving stakeholders.
      CONCLUSIONS: This paper underlines the need to develop empirically based
      guidelines that address the ethical and social strategies for risk communication 
      of dementia prediction by genetic as well as non-genetic biomarkers. According to
      our analysis, the guidelines do not address the new developments sufficiently.
      International efforts should aim for specific guidelines on counseling,
      communicating risk and disclosing results. We argue that guidelines on (risk)
      disclosure should be developed by involving various stakeholders and should be
      informed by socio-empirical studies involving laypersons' needs and wishes
      regarding risk communication.
FAU - Alpinar-Sencan, Zumrut
AU  - Alpinar-Sencan Z
AUID- ORCID: 0000-0001-6635-3317
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Humboldtallee 36, 37073, Gottingen, Germany.
      zuemruet.alpinar-sencan@med.uni-goettingen.de.
FAU - Schicktanz, Silke
AU  - Schicktanz S
AUID- ORCID: 0000-0001-9627-752X
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Humboldtallee 36, 37073, Gottingen, Germany.
LA  - eng
GR  - G-1413-119.4/2017/German-Israeli Foundation for Scientific Research and
      Development/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200511
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Canada
MH  - *Cognitive Dysfunction/diagnosis
MH  - *Dementia/diagnosis
MH  - *Disclosure/ethics
MH  - Germany
MH  - Humans
PMC - PMC7216419
OTO - NOTNLM
OT  - *Biomarkers
OT  - *Clinical guidelines
OT  - *Communication
OT  - *Dementia prediction
OT  - *Disclosure
OT  - *Risk information
OT  - *Stakeholders
EDAT- 2020/05/13 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00476-4 [doi]
AID - 10.1186/s12910-020-00476-4 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 11;21(1):33. doi: 10.1186/s12910-020-00476-4.


PMID- 32393259
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20201125
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 11
TI  - Methodology for assessment of public health emergency preparedness and response
      synergies between institutional authorities and communities.
PG  - 411
LID - 10.1186/s12913-020-05298-z [doi]
AB  - BACKGROUND: This paper describes a participatory methodology that supports
      investigation of the synergistic collaboration between communities affected by
      infectious disease outbreak events and relevant official institutions. The core
      principle underlying the methodology is the recognition that synergistic
      relationships, characterised by mutual trust and respect, between affected
      communities and official institutions provide the most effective means of
      addressing outbreak situations. METHODS: The methodological approach and lessons 
      learned were derived from four qualitative case studies including (i) two
      tick-borne disease events (Crimean-Congo haemorrhagic fever in Spain, 2016, and
      tick-borne encephalitis in the Netherlands, 2016); and (ii) two outbreaks of
      acute gastroenteritis (norovirus in Iceland, 2017, and verocytotoxin-producing
      Escherichia coli [VTEC] in Ireland, 2018). An after-event qualitative case study 
      approach was taken using mixed methods. The studies were conducted in
      collaboration with the respective national public health authorities in the
      affected countries by the European Centre for Disease Prevention and Control
      (ECDC). The analysis focused on the specific actions undertaken by the
      participating countries' public health and other authorities in relation to
      community engagement, as well as the view from the perspective of affected
      communities. RESULTS: Lessons highlight the critical importance of collaborating 
      with ECDC National Focal Points during preparation and planning and with
      anthropological experts. Field work for each case study was conducted over one
      working week, which although limiting the number of individuals and institutions 
      involved, still allowed for rich data collection due to the close collaboration
      with local authorities. The methodology enabled efficient extraction of synergies
      between authorities and communities. Implementing the methodology required a
      reflexivity among fieldworkers that ackowledges that different versions of
      reality can co-exist in the social domain. The method allowed for potential
      generalisability across studies. Issues of extra attention included
      insider-outsider perspectives, politically sensitivity of findings, and how to
      deal with ethical and language issues. CONCLUSIONS: The overall objective of the 
      assessment is to identify synergies between institutional decision-making bodies 
      and community actors and networks before, during and after an outbreak response
      to a given public health emergency. The methodology is generic and could be
      applied to a range of public health emergencies, zoonotic or otherwise.
FAU - de Vries, Daniel H
AU  - de Vries DH
AUID- ORCID: http://orcid.org/0000-0001-7455-0628
AD  - Department of Anthropology, University of Amsterdam, Nieuwe Achtergracht 166,
      1018, WV, Amsterdam, the Netherlands. d.h.devries@uva.nl.
FAU - Kinsman, John
AU  - Kinsman J
AD  - European Centre for Disease Prevention and Control, Gustav III:s Boulevard 40,
      169 73, Solna, Sweden.
AD  - Department of Epidemiology and Global Health, Umea University, Umea, Sweden.
FAU - Takacs, Judit
AU  - Takacs J
AD  - European Centre for Disease Prevention and Control, Gustav III:s Boulevard 40,
      169 73, Solna, Sweden.
AD  - Centre for Social Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
FAU - Tsolova, Svetla
AU  - Tsolova S
AD  - European Centre for Disease Prevention and Control, Gustav III:s Boulevard 40,
      169 73, Solna, Sweden.
FAU - Ciotti, Massimo
AU  - Ciotti M
AD  - European Centre for Disease Prevention and Control, Gustav III:s Boulevard 40,
      169 73, Solna, Sweden.
LA  - eng
GR  - ECDC/2014/005/European Centre for Disease Prevention and Control
PT  - Journal Article
DEP - 20200511
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - *Community-Institutional Relations
MH  - Disease Outbreaks/*prevention & control
MH  - *Emergencies
MH  - Health Facilities
MH  - Humans
MH  - Iceland
MH  - Ireland
MH  - Netherlands
MH  - *Public Health
MH  - Qualitative Research
MH  - Spain
PMC - PMC7212582
OTO - NOTNLM
OT  - Community engagement
OT  - European Union
OT  - Methodology
OT  - Protocol
OT  - Public health emergency preparedness
OT  - Synergies
EDAT- 2020/05/13 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1186/s12913-020-05298-z [doi]
AID - 10.1186/s12913-020-05298-z [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 May 11;20(1):411. doi: 10.1186/s12913-020-05298-z.


PMID- 32393230
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 11
TI  - Partnering with patients in healthcare research: a scoping review of ethical
      issues, challenges, and recommendations for practice.
PG  - 34
LID - 10.1186/s12910-020-0460-0 [doi]
AB  - BACKGROUND: Partnering with patients in healthcare research now benefits from a
      strong rationale and is encouraged by funding agencies and research institutions.
      However, this new approach raises ethical issues for patients, researchers,
      research professionals and administrators. The main objective of this review is
      to map the literature related to the ethical issues associated with patient
      partnership in healthcare research, as well as the recommendations to address
      them. Our global aim is to help researchers, patients, research institutions and 
      research ethics boards reflecting on and dealing with these issues. METHODS: We
      conducted a scoping review of the ethical issues and recommendations associated
      with partnering with patients in healthcare research. After our search strategy, 
      31 peer reviewed articles published between 2007 and 2017 remained and were
      analyzed. RESULTS: We have identified 58 first-order ethical issues and
      challenges associated with patient partnership in research, regrouped in 18
      second-order ethical themes. Most of the issues are transversal to all phases and
      stages of the research process and a lot of them could also apply to
      patient-partnership in other spheres of health, such as governance, quality
      improvement, and education. We suggested that ethical issues and challenges of
      partnered research can be related to four ethical frameworks: 1) Research ethics;
      2) Research integrity; 3) Organizational ethics, and 4) Relational ethics.
      CONCLUSIONS: We have identified numerous ethical issues associated with the
      recent approach of patient-partnership in research. These issues are more diverse
      than the issues associated with a more traditional research approach. Indeed, the
      current discussion on how we address ethical issues in research is anchored in
      the assumption that patients, as research participants, must be protected from
      risk. However, doing research with, and not on, the patient involves changes in
      the way we reflect on the ethical issues associated with this approach to
      research. We propose to broaden the ethical discussion on partnered research to
      not only rely on a research ethics framework, but to also frame it within the
      areas of research integrity, organizational ethics and relational ethics.
FAU - Martineau, Joe T
AU  - Martineau JT
AUID- ORCID: 0000-0001-8441-3184
AD  - Department of Management, HEC Montreal, 3000 chemin de la Cote-Ste-Catherine,
      Montreal, QC, H3T2A7, Canada. joe.trempe-martineau@hec.ca.
FAU - Minyaoui, Asma
AU  - Minyaoui A
AD  - University of Montreal, Montreal, Canada.
FAU - Boivin, Antoine
AU  - Boivin A
AD  - Canada Research Chair in Patient and Public Partnership, CHUM Research Center
      (CRCHUM) and University of Montreal, Montreal, Canada.
LA  - eng
GR  - ./CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200511
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Ethics, Research
MH  - *Health Services Research
MH  - Humans
MH  - Research Personnel
PMC - PMC7216517
OTO - NOTNLM
OT  - *Ethical issues
OT  - *Healthcare research
OT  - *Patient engagement
OT  - *Patient partnership
OT  - *Scoping review
EDAT- 2020/05/13 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-0460-0 [doi]
AID - 10.1186/s12910-020-0460-0 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 11;21(1):34. doi: 10.1186/s12910-020-0460-0.


PMID- 32393185
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 11
TI  - Production of ERCP training model using a 3D printing technique (with video).
PG  - 145
LID - 10.1186/s12876-020-01295-y [doi]
AB  - BACKGROUND: ERCP training models are very different in terms of anatomical
      differences, ethical issues, storage problems, realistic tactile sensation,
      durability and portability. There is no easy way to select an optimized model for
      ERCP training. If the ERCP training model could be made as a soft silicone model 
      using 3D printing technique, it would have numerous advantages over the models
      presented so far. The purpose of this study was to develop an optimized ERCP
      training model using a 3D printing technique and to try to find ways for
      implementing various practical techniques. METHODS: All organ parts of this model
      were fabricated using silicone molding techniques with 3D printing. Especially,
      various anatomy of the ampulla of Vater and common bile duct (CBD) were
      creatively designed for different diagnostic and therapeutic procedures. In order
      to manufacture each of the designed organ parts with silicone, a negative part
      had to be newly designed to produce the molder. The negative molders were 3D
      printed and then injection molding was applied to obtain organ parts in silicone 
      material. The eight different types of ampulla and CBD were repeatedly utilized
      and replaced to the main system as a module-type. RESULTS: ERCP training silicone
      model using 3D technique was semi-permanently used to repeat various ERCP
      procedures. All ERCP procedures using this model could be observed by real-time
      fluoroscopic examination as well as endoscopic examination simultaneously. Using 
      different ampulla and CBD modules, basic biliary cannulation, difficult
      cannulation, stone extraction, mechanical lithotripsy, metal stent insertion,
      plastic stent insertion, and balloon dilation were successfully and repeatedly
      achieved. Endoscopic sphincterotomy was also performed on a specialized ampulla
      using a Vienna sausage. After repeat procedures and trainings, all parts of
      organs including the ampulla and CBD modules were not markedly damaged or
      deformed. CONCLUSIONS: We made a specialized ERCP training silicon model with 3D 
      printing technique. This model is durable, relatively cheap and easy to make, and
      thus allows the users to perform various specialized ERCP techniques, which
      increases its chances of being a good ERCP training model.
FAU - Kwon, Chang-Il
AU  - Kwon CI
AD  - Digestive Disease Center, CHA Bundang Medical Center, CHA University School of
      Medicine, Seongnam, South Korea.
AD  - Research Group for Endoscopic Instruments and Stents, Korean Society of
      Gastrointestinal Endoscopy, Seoul, Korea.
FAU - Shin, Yeonsun
AU  - Shin Y
AD  - Gluck, Seoul, South Korea.
FAU - Hong, Jaeok
AU  - Hong J
AD  - Gluck, Seoul, South Korea.
FAU - Im, Minje
AU  - Im M
AD  - Anymedi Inc., Seoul, South Korea.
FAU - Kim, Guk Bae
AU  - Kim GB
AD  - Anymedi Inc., Seoul, South Korea.
FAU - Koh, Dong Hee
AU  - Koh DH
AD  - Research Group for Endoscopic Instruments and Stents, Korean Society of
      Gastrointestinal Endoscopy, Seoul, Korea.
AD  - Division of Gastroenterology, Department of Internal Medicine, Hallym University 
      Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong,
      South Korea.
FAU - Song, Tae Jun
AU  - Song TJ
AD  - Research Group for Endoscopic Instruments and Stents, Korean Society of
      Gastrointestinal Endoscopy, Seoul, Korea.
AD  - Division of Gastroenterology, Department of Internal Medicine, Asan medical
      center, Ulsan University College of medicine, Seoul, South Korea.
FAU - Park, Won Suk
AU  - Park WS
AD  - Research Group for Endoscopic Instruments and Stents, Korean Society of
      Gastrointestinal Endoscopy, Seoul, Korea.
AD  - Division of Gastroenterology, Department of Internal Medicine, Daejeon St. Mary's
      Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South
      Korea.
FAU - Hyun, Jong Jin
AU  - Hyun JJ
AD  - Division of Gastroenterology and Hepatology, Korea University College of
      Medicine, Seoul, South Korea.
FAU - Jeong, Seok
AU  - Jeong S
AUID- ORCID: http://orcid.org/0000-0001-6178-8338
AD  - Research Group for Endoscopic Instruments and Stents, Korean Society of
      Gastrointestinal Endoscopy, Seoul, Korea. inos@inha.ac.kr.
AD  - Division of Gastroenterology, Department of Internal Medicine, Inha University
      Hospital, Inha University School of Medicine, 27 Inhang-ro, Jung-gu, Incheon,
      22332, Republic of Korea. inos@inha.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20200511
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - Z4152N8IUI (Silicon)
SB  - IM
MH  - Ampulla of Vater/surgery
MH  - Cholangiopancreatography, Endoscopic Retrograde/*methods
MH  - Common Bile Duct/surgery
MH  - Gastroenterology/*education
MH  - Humans
MH  - *Models, Anatomic
MH  - *Printing, Three-Dimensional
MH  - Silicon
PMC - PMC7216470
OTO - NOTNLM
OT  - Cholangiopancreatography, endoscopic retrograde
OT  - Endoscopy
OT  - Printing
OT  - Three-dimensional
OT  - Training model
EDAT- 2020/05/13 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/11/27 00:00 [received]
PHST- 2020/05/05 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
AID - 10.1186/s12876-020-01295-y [doi]
AID - 10.1186/s12876-020-01295-y [pii]
PST - epublish
SO  - BMC Gastroenterol. 2020 May 11;20(1):145. doi: 10.1186/s12876-020-01295-y.


PMID- 32393169
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-2253 (Electronic)
IS  - 1471-2253 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 11
TI  - Does the revised intubating laryngeal tube (ILTS-D2) perform better than the
      intubating laryngeal mask (Fastrach)? - a randomised simulation research study.
PG  - 111
LID - 10.1186/s12871-020-01029-3 [doi]
AB  - BACKGROUND: The intubating laryngeal tube (ILTS-D) and the intubating laryngeal
      mask (Fastrach) are devices that facilitate both extraglottic application and
      blind tracheal intubation. A revised model of the iLTS-D (for scientific reasons 
      called ILTS-D2) has been designed but not yet evaluated. Therefore, we compared
      the ILTS-D2 with the established Fastrach under controlled conditions in a
      prospective randomised controlled simulation research study. METHODS: After
      ethical approval, we randomised 126 medical students into two groups. Each
      participant received either Fastrach or ILTS-D2 to perform five consecutive
      ventilation attempts in a manikin. The primary endpoint was the time to
      ventilation in the last attempt of using the devices as extraglottic devices.
      Secondary endpoints were the time to tracheal intubation and the success rates.
      RESULTS: There was no relevant difference between the two devices in the time to 
      ventilation in the last of five attempts (Fastrach: median 14 s [IQR: 12-15];
      ILTS-D2: median 13 s [IQR: 12-15], p = 0.592). Secondary endpoints showed a 2 s
      faster blind tracheal intubation using the Fastrach than using the ILTS-D2
      (Fastrach: median 14 s [IQR: 13-17]; ILTS-D2: median 16 s [IQR: 15-20] p <
      0.001). For both devices, the success rates were 100% in the last attempt.
      CONCLUSIONS: Concerning extraglottic airway management, we could not detect a
      relevant difference between the revised ILTS-D2 and the Fastrach under laboratory
      conditions. We advocate for an evaluation of the ILTS-D2 in randomised controlled
      clinical trials. TRIAL REGISTRATION: Identifier at clinicaltrials.gov:
      NCT03542747. May 31, 2018.
FAU - Ott, Thomas
AU  - Ott T
AUID- ORCID: 0000-0001-7510-7679
AD  - Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg
      University, Langenbeckstr. 1, 55131, Mainz, Germany. ottth@uni-mainz.de.
FAU - Tschope, Katharina
AU  - Tschope K
AD  - Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg
      University, Langenbeckstr. 1, 55131, Mainz, Germany.
FAU - Toenges, Gerrit
AU  - Toenges G
AD  - Institute of Medical Biostatistics, Epidemiology, and Informatics, Medical Centre
      of the Johannes Gutenberg University, Mainz, Germany.
FAU - Buggenhagen, Holger
AU  - Buggenhagen H
AD  - Rudolf-Frey Lernklinik Central Education Platform, Medical Centre of the Johannes
      Gutenberg University, Mainz, Germany.
FAU - Engelhard, Kristin
AU  - Engelhard K
AD  - Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg
      University, Langenbeckstr. 1, 55131, Mainz, Germany.
FAU - Kriege, Marc
AU  - Kriege M
AD  - Department of Anaesthesiology, Medical Centre of the Johannes Gutenberg
      University, Langenbeckstr. 1, 55131, Mainz, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03542747
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200511
PL  - England
TA  - BMC Anesthesiol
JT  - BMC anesthesiology
JID - 100968535
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Intubation, Intratracheal/*instrumentation
MH  - *Laryngeal Masks
MH  - Male
MH  - Manikins
MH  - Prospective Studies
PMC - PMC7212614
OTO - NOTNLM
OT  - *Airway management [E02.041]
OT  - *Intubation [E05.497.578]
OT  - *Laryngeal masks [E05.497.578.475]
OT  - *Manikins [J01.897.280.500.545.129.400]
OT  - *[MeSH tree numbers]: simulation
EDAT- 2020/05/13 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/05/13 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/13 06:00 [entrez]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
AID - 10.1186/s12871-020-01029-3 [doi]
AID - 10.1186/s12871-020-01029-3 [pii]
PST - epublish
SO  - BMC Anesthesiol. 2020 May 11;20(1):111. doi: 10.1186/s12871-020-01029-3.


PMID- 32393112
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1552-7468 (Electronic)
IS  - 1527-1544 (Linking)
VI  - 21
IP  - 2
DP  - 2020 May
TI  - Medical Assistance in Dying: A Review of Canadian Regulatory Documents.
PG  - 56-59
LID - 10.1177/1527154420923733 [doi]
AB  - After years of heated debate about the issue, medical assistance in dying (MAiD) 
      was legalized in Canada in 2016. Canada became the first jurisdiction where MAiD 
      may be delivered by nurse practitioners as well as physicians. Experience has
      revealed significant public demand for the service, and Canadians expect nurses
      to advocate for safe, high-quality, ethical practice in this new area of care.
      Pesut et al. offer a superb analysis of the related Canadian nursing regulatory
      documents and the challenges in creating a harmonized approach that arise in a
      federation where the Criminal Code is a federal entity and the regulation of
      health care providers and delivery of care fall under provincial and territorial 
      legislation. Organizations like the Canadian Nurses Association contribute to the
      development of good legislation by working with partners to present evidence to
      help legislators consider impacts on public health, health care, and providers.
      Nursing regulators across Canada responded quickly to the unfolding policy
      landscape as the federal legislation evolved and will face that task again: In
      February 2020, the federal government tabled legislation to relax conditions
      related to MAiD requests that will force regulators and professional associations
      back to public advocacy and legislative tables. The success of the cautious
      approach exercised by nursing bodies throughout this journey should continue to
      reassure Canadians that their high trust in the profession is well placed.
FAU - Villeneuve, Michael J
AU  - Villeneuve MJ
AUID- ORCID: https://orcid.org/0000-0003-4123-3516
AD  - Canadian Nurses Association, Ottawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - United States
TA  - Policy Polit Nurs Pract
JT  - Policy, politics & nursing practice
JID - 100901316
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Attitude of Health Personnel
MH  - Canada
MH  - Euthanasia, Active, Voluntary/*ethics/*legislation & jurisprudence
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nurse Practitioners/ethics/psychology
MH  - Physicians/ethics/psychology
MH  - Public Health/*legislation & jurisprudence
MH  - Suicide, Assisted/ethics/legislation & jurisprudence
MH  - Terminal Care/*ethics/*legislation & jurisprudence
OTO - NOTNLM
OT  - Canada
OT  - Supreme Court decisions
OT  - assisted
OT  - nurse practitioners
OT  - nurses' role
OT  - suicide
EDAT- 2020/05/13 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1177/1527154420923733 [doi]
PST - ppublish
SO  - Policy Polit Nurs Pract. 2020 May;21(2):56-59. doi: 10.1177/1527154420923733.
      Epub 2020 May 11.


PMID- 32392624
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20201218
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 7
DP  - 2020 Jul
TI  - Israel Ad Hoc COVID-19 Committee: Guidelines for Care of Older Persons During a
      Pandemic.
PG  - 1370-1375
LID - 10.1111/jgs.16554 [doi]
AB  - Early on, geriatricians in Israel viewed with increasing alarm the spread of
      coronavirus disease 2019 (COVID-19). It was clear that this viral disease
      exhibited a clear predilection for and danger to older persons. Informal contacts
      began with senior officials from the country's Ministry of Health, the Israel
      Medical Association, and the country's largest health fund; this was done to plan
      an approach to the possible coming storm. A group was formed, comprising three
      senior geriatricians, a former dean, a palliative care specialist, and a
      lawyer/ethicist. The members made every effort to ensure that their
      recommendations would be practical while at the same time taking into account the
      tenets of medical ethics. The committee's main task was to think through a
      workable approach because intensive care unit/ventilator resources may be far
      outstripped by those requiring such care. Recommendations included the approach
      to older persons both in the community and in long-term care institutions, a
      triage instrument, and palliative care. Patient autonomy was emphasized, with a
      strong recommendation for people of all ages to update their advance directives
      or, if they did not have any, to quickly draw them up. Considering the value of
      distributive justice, with respect to triage, a "soft utilitarian" approach was
      advocated with the main criteria being function and comorbidity. Although
      chronological age was rejected as a sole criterion, in the case of an
      overwhelming crisis, "biological age" would enter into the triage considerations,
      but only in the case of distinguishing between people with equal non-age-related 
      deficits. The guideline emphasized that no matter what, in the spirit of
      beneficence, anyone who fell ill must receive active palliative care throughout
      the course of a COVD-19 infection but especially at the end of life. Furthermore,
      in the spirit of nonmaleficence, the frail, very old, and severely demented would
      be actively protected from dying on ventilation. J Am Geriatr Soc 68:1370-1375,
      2020.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Clarfield, A Mark
AU  - Clarfield AM
AD  - Division of Geriatrics, Israel Ministry of Health, Jerusalem, Israel.
AD  - Department of Geriatrics, Soroka University Medical Centre, Beer-sheva, Israel.
AD  - Medical School for International Health, Ben-Gurion University of the Negev,
      Beer-sheva, Israel.
FAU - Dwolatzky, Tzvi
AU  - Dwolatzky T
AUID- ORCID: https://orcid.org/0000-0002-3861-2278
AD  - Israel Geriatrics Society, Tel aviv, Israel.
AD  - Geriatrics, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel
      Institute of Technology, Haifa, Israel.
AD  - Geriatric Unit, Rambam Health Care Campus, Haifa, Israel.
FAU - Brill, Shai
AU  - Brill S
AD  - Clalit Health Care Services, Tel aviv, Israel.
FAU - Press, Yan
AU  - Press Y
AUID- ORCID: https://orcid.org/0000-0001-9245-4891
AD  - Department of Geriatrics, Soroka University Medical Center, Beer-sheva, Israel.
AD  - Geriatrics, Ben-Gurion University of the Negev, Beer-sheva, Israel.
FAU - Glick, Shimon
AU  - Glick S
AD  - Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-sheva,
      Israel.
FAU - Shvartzman, Pesach
AU  - Shvartzman P
AD  - Family Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, 
      Beer-sheva, Israel.
AD  - Israel Palliative Care Association, Tel aviv, Israel.
FAU - Doron, Israel Issi
AU  - Doron II
AUID- ORCID: https://orcid.org/0000-0003-2607-6890
AD  - Department of Gerontology, University of Haifa, Haifa, Israel.
AD  - Israel Gerontological Society, Tel aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200523
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control/*therapy
MH  - Female
MH  - Geriatrics/*standards
MH  - Health Services for the Aged/*standards
MH  - Humans
MH  - Israel
MH  - Long-Term Care/methods/standards
MH  - Male
MH  - Palliative Care/methods/standards
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control/*therapy
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Triage/methods/standards
PMC - PMC7272988
OTO - NOTNLM
OT  - COVID-19
OT  - Israel national guidelines
OT  - triage
EDAT- 2020/05/12 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/26 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 10.1111/jgs.16554 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Jul;68(7):1370-1375. doi: 10.1111/jgs.16554. Epub 2020 May
      23.


PMID- 32392516
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
VI  - 192
IP  - 12
DP  - 2020 Mar 23
TI  - Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat
      ethics.
PG  - E319-E320
LID - 10.1503/cmaj.191236 [doi]
FAU - Breiner, Ari
AU  - Breiner A
AD  - Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa
      Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner,
      Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain
      Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology
      (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.
      abreiner@toh.ca.
FAU - Zinman, Lorne
AU  - Zinman L
AD  - Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa
      Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner,
      Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain
      Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology
      (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.
FAU - Bourque, Pierre R
AU  - Bourque PR
AD  - Division of Neurology (Breiner, Bourque), Department of Medicine, The Ottawa
      Hospital and University of Ottawa; Ottawa Hospital Research Institute (Breiner,
      Bourque), Ottawa, Ont.; Sunnybrook Research Institute (Zinman), Hurvitz Brain
      Sciences Program, Sunnybrook Health Sciences Centre; Division of Neurology
      (Zinman), Department of Medicine, University of Toronto, Toronto, Ont.
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale
      canadienne
JID - 9711805
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Neuroprotective Agents)
RN  - S798V6YJRP (Edaravone)
SB  - IM
MH  - Amyotrophic Lateral Sclerosis/*drug therapy
MH  - Canada
MH  - Compassionate Use Trials
MH  - Disease Progression
MH  - Drug Costs
MH  - Edaravone/economics/*supply & distribution/*therapeutic use
MH  - Financing, Government
MH  - Free Radical Scavengers/economics/*supply & distribution/*therapeutic use
MH  - Humans
MH  - Neuroprotective Agents/economics/*supply & distribution/*therapeutic use
MH  - United States
PMC - PMC7101182
COIS- Competing interests: Ari Breiner has served as site principal investigator for
      trials for amyotrophic lateral sclerosis funded by Mallinkrodt, Cytokinetics and 
      the University of Calgary. He has also received research grant funding from
      CIDP/GBS Foundation International, Grifols and Muscular Dystropy Canada, and
      honoraria from CSL, Allergan, Pfizer and Akcea. Ari Breiner and Lorne Zinman have
      received honoraria from Mitsubishi Tanabe Pharma. Lorne Zinman has also received 
      an honorarium from Biogen. No other competing interests were declared.
EDAT- 2020/05/12 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
AID - 192/12/E319 [pii]
AID - 10.1503/cmaj.191236 [doi]
PST - ppublish
SO  - CMAJ. 2020 Mar 23;192(12):E319-E320. doi: 10.1503/cmaj.191236.


PMID- 32392334
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 71
IP  - 16
DP  - 2020 Nov 19
TI  - Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic 
      Medical Center: Approach of Michigan Medicine.
PG  - 2187-2190
LID - 10.1093/cid/ciaa560 [doi]
AB  - Clinicians, eager to offer the best care in the absence of guiding data, have
      provided patients with coronavirus disease 2019 (COVID-19) diverse clinical
      interventions. This usage has led to perceptions of efficacy of some
      interventions that, while receiving media coverage, lack robust evidence. Moving 
      forward, randomized controlled clinical trials are necessary to ensure that
      clinicians can treat patients effectively during this outbreak and the next. To
      do so, academic medical centers must address 2 key research issues: (1) how to
      effectively and efficiently determine which trials have the best chance of
      benefiting current and future patients and (2) how to establish a transparent and
      ethical process for subject recruitment while maintaining research integrity and 
      without overburdening patients or staff. We share here the current methods used
      by Michigan Medicine to address these issues.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America. All rights reserved. For permissions, e-mail:
      journals.permissions@oup.com.
FAU - Spector-Bagdady, Kayte
AU  - Spector-Bagdady K
AD  - Department of Obstetrics & Gynecology and the Center for Bioethics & Social
      Sciences in Medicine, University of Michigan Medical School, Ann Arbor, Michigan,
      USA.
FAU - Higgins, Peter D R
AU  - Higgins PDR
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology,
      University of Michigan Medical School, Ann Arbor, Michigan, USA.
FAU - Aaronson, Keith D
AU  - Aaronson KD
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan Medical School, Ann Arbor, Michigan, USA.
FAU - Birk, Judy
AU  - Birk J
AD  - Office of Research, University of Michigan Medical School, Ann Arbor, Michigan,
      USA.
FAU - Flaherty, Kevin R
AU  - Flaherty KR
AD  - Department of Internal Medicine, Division of Pulmonary and Critical Care
      Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
FAU - Gregg, Kevin S
AU  - Gregg KS
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of
      Michigan Medical School, Ann Arbor, Michigan, USA.
FAU - Hyzy, Robert C
AU  - Hyzy RC
AD  - Department of Internal Medicine, Division of Pulmonary and Critical Care
      Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
FAU - Kaul, Daniel R
AU  - Kaul DR
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of
      Michigan Medical School, Ann Arbor, Michigan, USA.
FAU - Lauring, Adam S
AU  - Lauring AS
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of
      Michigan Medical School, Ann Arbor, Michigan, USA.
AD  - Department of Microbiology and Immunology, University of Michigan Medical School,
      Ann Arbor, Michigan, USA.
FAU - Magee, John C
AU  - Magee JC
AD  - Department of Surgery, University of Michigan Medical School, Ann Arbor,
      Michigan, USA.
FAU - Meurer, William J
AU  - Meurer WJ
AD  - Department of Neurology, University of Michigan Medical School, Ann Arbor,
      Michigan, USA.
AD  - Department of Emergency Medicine, University of Michigan Medical School, Ann
      Arbor, Michigan, USA.
FAU - Park, Pauline K
AU  - Park PK
AD  - Department of Surgery, University of Michigan Medical School, Ann Arbor,
      Michigan, USA.
FAU - Scott, Phillip
AU  - Scott P
AD  - Department of Emergency Medicine, University of Michigan Medical School, Ann
      Arbor, Michigan, USA.
FAU - Lok, Anna S
AU  - Lok AS
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology,
      University of Michigan Medical School, Ann Arbor, Michigan, USA.
LA  - eng
GR  - UL1 TR002240/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
SB  - IM
MH  - *Academic Medical Centers
MH  - COVID-19/*therapy
MH  - Humans
MH  - Informed Consent
MH  - Michigan
MH  - Patient Selection/*ethics
MH  - Randomized Controlled Trials as Topic/*standards
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7239254
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *informed consent
OT  - *randomized clinical trial
OT  - *research ethics
EDAT- 2020/05/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/05/08 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 5835855 [pii]
AID - 10.1093/cid/ciaa560 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2020 Nov 19;71(16):2187-2190. doi: 10.1093/cid/ciaa560.


PMID- 32392096
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20201218
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 142
IP  - 3
DP  - 2020 Jul 21
TI  - Forced Choices: Ethical Challenges in Cardiology During the COVID-19 Pandemic.
PG  - 194-196
LID - 10.1161/CIRCULATIONAHA.120.047681 [doi]
FAU - Khazanie, Prateeti
AU  - Khazanie P
AD  - Division of Cardiology (P.K.), Department of Medicine, The University of Colorado
      School of Medicine, Aurora.
FAU - Wynia, Matthew K
AU  - Wynia MK
AD  - Center for Bioethics and Humanities (M.K.W.), Department of Medicine, The
      University of Colorado School of Medicine, Aurora.
FAU - Dickert, Neal W
AU  - Dickert NW
AD  - Division of Cardiology, Department of Medicine, Emory University School of
      Medicine, Atlanta, GA (N.W.D.).
LA  - eng
GR  - K23 HL145122/HL/NHLBI NIH HHS/United States
GR  - R01 HS026081/HS/AHRQ HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200511
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
SB  - IM
MH  - Attitude of Health Personnel
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Cardiologists/ethics
MH  - Cardiology/*ethics
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/diagnosis/epidemiology/*therapy/virology
MH  - Delivery of Health Care/*ethics
MH  - Heart Diseases/diagnosis/epidemiology/*therapy
MH  - Host Microbial Interactions
MH  - Humans
MH  - Pandemics
MH  - Patient Safety
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/diagnosis/epidemiology/*therapy/virology
MH  - Practice Patterns, Physicians'/ethics
MH  - Risk Assessment
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Triage/*ethics
PMC - PMC7365667
OTO - NOTNLM
OT  - *COVID-19
OT  - *decision making
OT  - *heart failure
OT  - *heart transplantation
OT  - *medical ethics
OT  - *pandemics
OT  - *resource allocation
EDAT- 2020/05/12 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 10.1161/CIRCULATIONAHA.120.047681 [doi]
PST - ppublish
SO  - Circulation. 2020 Jul 21;142(3):194-196. doi: 10.1161/CIRCULATIONAHA.120.047681. 
      Epub 2020 May 11.


PMID- 32392016
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1876-8784 (Electronic)
IS  - 0028-2162 (Linking)
VI  - 164
DP  - 2020 Mar 19
TI  - [Lifestyle, genetics and the risk of dementia].
LID - D4864 [pii]
AB  - An unhealthy lifestyle increases the risk of dementia. Two observational studies 
      explored whether targeted health and lifestyle interventions could attenuate or
      even offset increased genetic risk. Results from these observational studies are 
      inconclusive. However, after the age of 60, favourable lifestyle behaviours may
      have less impact in groups with high genetic risk. This might inspire researchers
      and clinicians to determine genetic risk prior to offering preventive
      interventions. However, this raises important ethical concerns and practical
      difficulties. Lifestyle interventions should take place irrespective of
      genetically determined risk of dementia.
FAU - Richard, Edo
AU  - Richard E
AD  - Radboudumc, Donders Institutefor Brain, Cognition and Behaviour, afd. Neurologie,
      Nijmegen.
AD  - Contact: Edo Richard (Edo.Richard@radboudumc.nl).
FAU - van Dalen, Jan Willem
AU  - van Dalen JW
AD  - Radboudumc, Donders Institutefor Brain, Cognition and Behaviour, afd. Neurologie,
      Nijmegen.
FAU - Moll van Charante, Eric
AU  - Moll van Charante E
AD  - Amsterdam UMC, locatie AMC, afd. Huisartsgeneeskunde/Sociale Geneeskunde,
      Amsterdam.
LA  - dut
PT  - Journal Article
TT  - Leefstijl, genetica en het risico op dementie.
DEP - 20200319
PL  - Netherlands
TA  - Ned Tijdschr Geneeskd
JT  - Nederlands tijdschrift voor geneeskunde
JID - 0400770
SB  - IM
MH  - *Dementia/genetics/prevention & control/psychology
MH  - Genetic Predisposition to Disease
MH  - Healthy Lifestyle
MH  - Humans
MH  - Life Style
MH  - *Preventive Health Services/ethics/methods
MH  - Risk Reduction Behavior
EDAT- 2020/05/12 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
PST - epublish
SO  - Ned Tijdschr Geneeskd. 2020 Mar 19;164.


PMID- 32391870
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210325
IS  - 2168-6211 (Electronic)
IS  - 2168-6203 (Linking)
VI  - 174
IP  - 9
DP  - 2020 Sep 1
TI  - Guidance for the Conduct and Reporting of Clinical Trials of Breast Milk
      Substitutes.
PG  - 874-881
LID - 10.1001/jamapediatrics.2020.0578 [doi]
AB  - Importance: Breast milk substitutes (BMS) are important nutritional products
      evaluated in clinical trials. Concerns have been raised about the risk of bias in
      BMS trials, the reliability of claims that arise from such trials, and the
      potential for BMS trials to undermine breastfeeding in trial participants.
      Existing clinical trial guidance does not fully address issues specific to BMS
      trials. Objectives: To establish new methodological criteria to guide the design,
      conduct, analysis, and reporting of BMS trials and to support clinical trialists 
      designing and undertaking BMS trials, editors and peer reviewers assessing trial 
      reports for publication, and regulators evaluating the safety, nutritional
      adequacy, and efficacy of BMS products. Design, Setting, and Participants: A
      modified Delphi method was conducted, involving 3 rounds of anonymous
      questionnaires and a face-to-face consensus meeting between January 1 and October
      24, 2018. Participants were 23 experts in BMS trials, BMS regulation, trial
      methods, breastfeeding support, infant feeding research, and medical publishing, 
      and were affiliated with institutions across Europe, North America, and
      Australasia. Guidance development was supported by an industry consultation,
      analysis of methodological issues in a sample of published BMS trials, and
      consultations with BMS trial participants and a research ethics committee.
      Results: An initial 73 criteria, derived from the literature, were sent to the
      experts. The final consensus guidance contains 54 essential criteria and 4
      recommended criteria. An 18-point checklist summarizes the criteria that are
      specific to BMS trials. Key themes emphasized in the guidance are research
      integrity and transparency of reporting, supporting breastfeeding in trial
      participants, accurate description of trial interventions, and use of valid and
      meaningful outcome measures. Conclusions and Relevance: Implementation of this
      guidance should enhance the quality and validity of BMS trials, protect BMS trial
      participants, and better inform the infant nutrition community about BMS
      products.
FAU - Jarrold, Katharine
AU  - Jarrold K
AD  - National Heart and Lung Institute, Imperial College London, London, United
      Kingdom.
FAU - Helfer, Bartosz
AU  - Helfer B
AD  - National Heart and Lung Institute, Imperial College London, London, United
      Kingdom.
FAU - Eskander, Mona
AU  - Eskander M
AD  - Bureau of Nutritional Sciences, Food Directorate, Health Canada, Ottawa, Ontario,
      Canada.
FAU - Crawley, Helen
AU  - Crawley H
AD  - First Steps Nutrition Trust, London, United Kingdom.
AD  - Scientific and Technical Advisory Group on the Inappropriate Promotion of Foods
      for Infants and Young Children, World Health Organization, Geneva, Switzerland.
FAU - Trabulsi, Jillian
AU  - Trabulsi J
AD  - Department of Behavioral Health and Nutrition, University of Delaware, Newark.
FAU - Caulfield, Laura E
AU  - Caulfield LE
AD  - Center for Human Nutrition, The Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland.
FAU - Duffy, Gillian
AU  - Duffy G
AD  - Department of Public Health Nutrition Standards, Food Standards Australia New
      Zealand, Canberra, Australia.
FAU - Garcia-Larsen, Vanessa
AU  - Garcia-Larsen V
AD  - Center for Human Nutrition, The Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland.
FAU - Hayward, Deborah
AU  - Hayward D
AD  - Bureau of Nutritional Sciences, Food Directorate, Health Canada, Ottawa, Ontario,
      Canada.
FAU - Hyde, Matthew
AU  - Hyde M
AD  - Section of Neonatal Medicine, Imperial College London, London, United Kingdom.
FAU - Jeffries, Suzan
AU  - Jeffries S
AD  - National Heart and Lung Institute, Imperial College London, London, United
      Kingdom.
AD  - International Board of Certified Lactation Consultant Examiners, Fairfax,
      Virginia.
FAU - Knip, Mikael
AU  - Knip M
AD  - Children's Hospital, Helsinki University Hospital, University of Helsinki,
      Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, Helsinki, Finland.
FAU - Leonardi-Bee, Jo
AU  - Leonardi-Bee J
AD  - Medical Statistics, University of Nottingham, Nottingham, United Kingdom.
FAU - Loder, Elizabeth
AU  - Loder E
AD  - Research, British Medical Journal , London, United Kingdom.
AD  - Department of Neurology, Harvard Medical School, Cambridge, Massachusetts.
FAU - Lodge, Caroline J
AU  - Lodge CJ
AD  - Allergy and Lung Health Unit, Melbourne School of Population and Global Health,
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - Lowe, Adrian J
AU  - Lowe AJ
AD  - Allergy and Lung Health Unit, Melbourne School of Population and Global Health,
      University of Melbourne, Melbourne, Victoria, Australia.
FAU - McGuire, William
AU  - McGuire W
AD  - Centre for Reviews and Dissemination, University of York, York, United Kingdom.
FAU - Osborn, David
AU  - Osborn D
AD  - Division of Obstetrics, Gynaecology and Neonatology, University of Sydney,
      Sydney, New South Wales, Australia.
FAU - Przyrembel, Hildegard
AU  - Przyrembel H
AD  - Department of Food Safety, Federal Institute for Risk Assessment, Berlin,
      Germany.
FAU - Renfrew, Mary J
AU  - Renfrew MJ
AD  - Mother and Infant Research Unit, University of Dundee School of Nursing and
      Health Sciences, Dundee, United Kingdom.
FAU - Trumbo, Paula
AU  - Trumbo P
AD  - Nutrition Programs, Food and Drug Administration, Silver Spring, Maryland.
FAU - Warner, John
AU  - Warner J
AD  - National Heart and Lung Institute, Imperial College London, London, United
      Kingdom.
FAU - Schneeman, Barbara
AU  - Schneeman B
AD  - Department of Nutrition, University of California, Davis, Davis.
FAU - Boyle, Robert J
AU  - Boyle RJ
AD  - National Heart and Lung Institute, Imperial College London, London, United
      Kingdom.
AD  - Centre of Evidence-Based Dermatology, University of Nottingham, Nottingham,
      United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Pediatr
JT  - JAMA pediatrics
JID - 101589544
SB  - IM
MH  - Breast Feeding/*methods
MH  - Checklist/*statistics & numerical data
MH  - Clinical Trials as Topic/*statistics & numerical data
MH  - *Consensus
MH  - Delphi Technique
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Milk Substitutes/*pharmacology
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
PMC - PMC7215627
EDAT- 2020/05/12 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 2765822 [pii]
AID - 10.1001/jamapediatrics.2020.0578 [doi]
PST - ppublish
SO  - JAMA Pediatr. 2020 Sep 1;174(9):874-881. doi: 10.1001/jamapediatrics.2020.0578.


PMID- 32391667
OWN - NLM
STAT- MEDLINE
DCOM- 20200512
LR  - 20220402
IS  - 1008-9292 (Print)
IS  - 1008-9292 (Linking)
VI  - 49
IP  - 2
DP  - 2020 May 25
TI  - [A pilot study of hydroxychloroquine in treatment of patients with moderate
      COVID-19].
PG  - 215-219
LID - 10.3785/j.issn.1008-9292.2020.03.03 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the
      treatment of patients with moderate coronavirus disease 2019 (COVID-19). METHODS:
      We prospectively enrolled 30 treatment-naive patients with confirmed COVID-19
      after informed consent at Shanghai Public Health Clinical Center. The patients
      were randomized 11 to HCQ group and the control group. Patients in HCQ group were
      given HCQ 400 mg per day for 5 days plus conventional treatments, while those in 
      the control group were given conventional treatment only. The primary endpoint
      was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal
      swab on days 7 after randomization. This study has been approved by the Ethics
      Committee of Shanghai Public Health Clinical Center and registered online
      (NCT04261517). RESULTS: One patient in HCQ group developed to severe during the
      treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%)
      cases in the HCQ group and 14 (93.3%) cases in the control group (P>0.05). The
      median duration from hospitalization to virus nucleic acid negative conservation 
      was 4 (1,9) days in HCQ group, which is comparable to that in the control group
      [2 (1,4) days, Z=1.27, P>0.05]. The median time for body temperature
      normalization in HCQ group was 1 (0,2) day after hospitalization, which was also 
      comparable to that in the control group [1 (0,3) day]. Radiological progression
      was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of
      the control group, and all patients showed improvement in follow-up examinations.
      Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had
      transient diarrhea and abnormal liver function (P>0.05). CONCLUSIONS: The
      prognosis of COVID-19 moderate patients is good. Larger sample size study are
      needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent
      research should determine better endpoint and fully consider the feasibility of
      experiments such as sample size.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Liu, Danping
AU  - Liu D
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Liu, Ping
AU  - Liu P
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Xu, Qingnian
AU  - Xu Q
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Xia, Lu
AU  - Xia L
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Ling, Yun
AU  - Ling Y
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Huang, Dan
AU  - Huang D
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Song, Shuli
AU  - Song S
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Zhang, Dandan
AU  - Zhang D
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Qian, Zhiping
AU  - Qian Z
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Li, Tao
AU  - Li T
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Shen, Yinzhong
AU  - Shen Y
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
FAU - Lu, Hongzhou
AU  - Lu H
AD  - Department of Infection and Immunity, Shanghai Public Health Clinical Center,
      Fudan University, Shanghai 201508, China.
LA  - chi
SI  - ClinicalTrials.gov/NCT04261517
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhejiang Da Xue Xue Bao Yi Xue Ban
JT  - Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical
      sciences
JID - 100927946
RN  - 0 (RNA, Viral)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - *Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - China
MH  - Coronavirus Infections/diagnostic imaging/drug therapy
MH  - Humans
MH  - *Hydroxychloroquine/therapeutic use
MH  - Pandemics
MH  - Pilot Projects
MH  - Pneumonia, Viral/diagnostic imaging/drug therapy
MH  - RNA, Viral/isolation & purification
MH  - SARS-CoV-2
MH  - Treatment Outcome
PMC - PMC8800713
EDAT- 2020/05/12 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - 10.3785/j.issn.1008-9292.2020.03.03 [doi]
PST - ppublish
SO  - Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi:
      10.3785/j.issn.1008-9292.2020.03.03.


PMID- 32391389
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Pastoral Farming Ethics and Economics-Aligning Grazing Practices and
      Expectations.
PG  - 209
LID - 10.3389/fvets.2020.00209 [doi]
FAU - Fisher, Mark W
AU  - Fisher MW
AD  - Ministry for Primary Industries, Wellington, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7189785
OTO - NOTNLM
OT  - animal welfare
OT  - body condition
OT  - community engagement
OT  - painful husbandry procedures
OT  - profitability
OT  - shelter
OT  - values
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
CRDT- 2020/05/12 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
AID - 10.3389/fvets.2020.00209 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 Apr 22;7:209. doi: 10.3389/fvets.2020.00209. eCollection
      2020.


PMID- 32391174
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2071-9736 (Electronic)
IS  - 1025-9848 (Linking)
VI  - 25
DP  - 2020
TI  - Ethical conflicts experienced by intensive care unit health professionals in a
      regional hospital, Limpopo province, South Africa.
PG  - 1183
LID - 10.4102/hsag.v25i0.1183 [doi]
AB  - BACKGROUND: Conflicts arise when healthcare providers disagree about providing
      optimal care to critically ill patients where resources and services are
      constrained. AIM: This study investigated ethical conflicts experienced by
      intensive care unit (ICU) healthcare professionals working in a regional
      hospital, Limpopo province of South Africa. SETTING: The study was conducted at a
      rural public regional hospital in Vhembe district, Limpopo Province. Communities 
      served by the hospital are poor and medically uninsured. METHODS: This study
      adopted a qualitative, exploratory and descriptive design. The target population 
      comprised Health care professionals working in an ICU of the regional hospital.
      Purposive sample was selected and 17 unstructured interviews were conducted.
      Tesch's method of data analysis was used. Ethical considerations were adhered to.
      RESULTS: Patients' care needs were compromised because of the unavailability of
      beds and high-technology equipment, such as well-functioning ventilators. Doctors
      were not having the necessary skills required in the ICU as the majority were on 
      community service/internship and nurses acted beyond their scope of practice
      because of a lack of adequately trained intensive care specialists. Infection
      control practices were overlooked and 'use once' pieces of equipment were reused.
      Conflicting values between nurses, patients and family of patients exist.
      CONCLUSION: Lack of resources compromises provision of optimal and intensive
      care. Patients were prone to infections and their safety might have been
      compromised.
CI  - (c) 2020. The Authors.
FAU - Ramathuba, Dorah U
AU  - Ramathuba DU
AUID- ORCID: https://orcid.org/0000-0002-7571-4767
AD  - Department of Advanced Nursing Science, University of Venda, Thohoyandou, South
      Africa.
FAU - Ndou, Hulisani
AU  - Ndou H
AUID- ORCID: https://orcid.org/0000-0003-2947-2442
AD  - Department of Advanced Nursing Science, University of Venda, Thohoyandou, South
      Africa.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - South Africa
TA  - Health SA
JT  - Health SA = SA Gesondheid
JID - 101213385
PMC - PMC7203238
OTO - NOTNLM
OT  - conflicts
OT  - ethical frameworks
OT  - ethics
OT  - health professionals
OT  - intensive care unit
OT  - professional bodies
COIS- The authors have declared that no competing interest exist.
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
CRDT- 2020/05/12 06:00
PHST- 2018/05/07 00:00 [received]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
AID - 10.4102/hsag.v25i0.1183 [doi]
AID - HSAG-25-1183 [pii]
PST - epublish
SO  - Health SA. 2020 Apr 16;25:1183. doi: 10.4102/hsag.v25i0.1183. eCollection 2020.


PMID- 32390903
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Inner Experience - Direct Access to Reality: A Complementarist Ontology and Dual 
      Aspect Monism Support a Broader Epistemology.
PG  - 640
LID - 10.3389/fpsyg.2020.00640 [doi]
AB  - Ontology, the ideas we have about the nature of reality, and epistemology, our
      concepts about how to gain knowledge about the world, are interdependent.
      Currently, the dominant ontology in science is a materialist model, and
      associated with it an empiricist epistemology. Historically speaking, there was a
      more comprehensive notion at the cradle of modern science in the middle ages.
      Then "experience" meant both inner, or first person, and outer, or third person, 
      experience. With the historical development, experience has come to mean only
      sense experience of outer reality. This has become associated with the ontology
      that matter is the most important substance in the universe, everything
      else-consciousness, mind, values, etc., -being derived thereof or reducible to
      it. This ontology is insufficient to explain the phenomena we are living
      with-consciousness, as a precondition of this idea, or anomalous cognitions.
      These have a robust empirical grounding, although we do not understand them
      sufficiently. The phenomenology, though, demands some sort of non-local model of 
      the world and one in which consciousness is not derivative of, but coprimary with
      matter. I propose such a complementarist dual aspect model of consciousness and
      brain, or mind and matter. This then also entails a different epistemology. For
      if consciousness is coprimary with matter, then we can also use a deeper
      exploration of consciousness as happens in contemplative practice to reach an
      understanding of the deep structure of the world, for instance in mathematical or
      theoretical intuition, and perhaps also in other areas such as in ethics. This
      would entail a kind of contemplative science that would also complement our
      current experiential mode that is exclusively directed to the outside aspect of
      our world. Such an epistemology might help us with various issues, such as good
      theoretical and other intuitions.
CI  - Copyright (c) 2020 Walach.
FAU - Walach, Harald
AU  - Walach H
AD  - Poznan University of Medical Sciences, Poznan, Poland.
AD  - Department of Psychology and Psychotherapy, University of Witten/Herdecke,
      Witten, Germany.
AD  - Department of Pediatric Gastroenterology, Health Science Institute, Berlin,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7191055
OTO - NOTNLM
OT  - complementarity
OT  - consciousness
OT  - contemplative science
OT  - dual aspect model
OT  - epistemology
OT  - introspection
OT  - materialism
OT  - ontology
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
CRDT- 2020/05/12 06:00
PHST- 2019/10/26 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
AID - 10.3389/fpsyg.2020.00640 [doi]
PST - epublish
SO  - Front Psychol. 2020 Apr 23;11:640. doi: 10.3389/fpsyg.2020.00640. eCollection
      2020.


PMID- 32390690
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0921-3449 (Print)
IS  - 0921-3449 (Linking)
VI  - 160
DP  - 2020 Sep
TI  - Sustainability science is ethics: Bridging the philosophical gap between science 
      and policy.
PG  - 104929
LID - 10.1016/j.resconrec.2020.104929 [doi]
FAU - Joaquin, Jeremiah Joven B
AU  - Joaquin JJB
AD  - Department of Philosophy, De La Salle University, 2401 Taft Avenue, Malate,
      Manila 0922, Philippines.
FAU - Biana, Hazel T
AU  - Biana HT
AD  - Department of Philosophy, De La Salle University, 2401 Taft Avenue, Malate,
      Manila 0922, Philippines.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200508
PL  - Netherlands
TA  - Resour Conserv Recycl
JT  - Resources, conservation, and recycling
JID - 9891750
PMC - PMC7205642
COIS- No funding was received for this paper. The authors declare that they have no
      known competing financial interests or personal relationships that could have
      appeared to influence the work reported in this paper.
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
CRDT- 2020/05/12 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 10.1016/j.resconrec.2020.104929 [doi]
AID - S0921-3449(20)30247-0 [pii]
AID - 104929 [pii]
PST - ppublish
SO  - Resour Conserv Recycl. 2020 Sep;160:104929. doi: 10.1016/j.resconrec.2020.104929.
      Epub 2020 May 8.


PMID- 32390591
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 11
TI  - A Smartphone App-Based Mindfulness Intervention for Cancer Survivors: Protocol
      for a Randomized Controlled Trial.
PG  - e15178
LID - 10.2196/15178 [doi]
AB  - BACKGROUND: Cancer patients transitioning to survivorship after completing cancer
      treatments need psychosocial interventions to manage stressors such as anxiety,
      depression, and fear of cancer recurrence. Mindfulness-based interventions (MBIs)
      are effective for treating these symptoms; however, cancer survivors are often
      unable to participate in face-to-face interventions because of difficulties such 
      as work and family commitments, treatment-related side-effects, scheduling
      conflicts, and geography. Smartphone app-based MBIs are an innovative way to
      deliver psychosocial cancer care and can overcome several such difficulties,
      since patients can participate at their own convenience. OBJECTIVE: The SEAMLESS 
      (Smartphone App-Based Mindfulness Intervention for Cancer Survivors) study aims
      to evaluate the efficacy of a tailored app-based mindfulness intervention for
      cancer survivors (the Am Mindfulness-Based Cancer Survivorship-MBCS-Journey) for 
      treating (1) symptoms of stress (primary outcome), as well as (2) fear of cancer 
      recurrence, anxiety, depression, fatigue, and overall physical functioning
      (secondary outcomes). This is the first Canadian efficacy trial of a tailored
      mindfulness app intervention in cancer survivors. METHODS: This is a randomized
      waitlist-controlled trial, which will evaluate the effectiveness of Am MBCS for
      impacting the primary and secondary outcomes in cancer survivors who have
      completed all their cancer treatments. Outcomes will be assessed using web-based 
      surveys with validated psychometric instruments at (1) baseline, (2)
      mid-intervention (2 weeks later), (3) immediately postintervention (4 weeks), (4)
      3 months postbaseline, (5) 6 months postbaseline, and (6) 12 months postbaseline.
      The waitlist group will complete all assessments and will cross over to the
      intervention condition after the 3-month assessment. In addition, data will be
      obtained by the smartphone app itself, which includes users' engagement with the 
      app-based intervention, their emotional state (eg, angry and elated) from a
      user-inputted digital emotion-mapping board, and psychobiometric data using
      photoplethysmography technology. RESULTS: The study received ethics approval in
      September 2018 and recruitment commenced in January 2019. Participants are being 
      recruited through a provincial cancer registry, and the majority of participants 
      currently enrolled are breast (44/83, 53%) or colorectal (17/83, 20%) cancer
      survivors, although some survivors of other cancer are also present. Data
      collection for analysis of the primary outcome time-point will be complete by
      September 2019, and the follow-up data will be collected and analyzed by
      September 2020. Data will be analyzed to determine group differences using linear
      mixed modelling statistical techniques. CONCLUSIONS: Cancer care providers are
      uncertain about the efficacy of app-based mindfulness interventions for patients,
      which are available in great supply in today's digital world. This study will
      provide rigorously evaluated efficacy data for an app-based mindfulness
      intervention for cancer survivors, which if helpful, could be made available for 
      psychosocial care at cancer centers worldwide. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT03484000; https://clinicaltrials.gov/ct2/show/NCT03484000. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15178.
CI  - (c)Utkarsh B Subnis, Norman AS Farb, Katherine-Ann Laura Piedalue, Michael Speca,
      Sasha Lupichuk, Patricia A Tang, Peter Faris, Mark Thoburn, Bechara J Saab, Linda
      E Carlson. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 11.05.2020.
FAU - Subnis, Utkarsh B
AU  - Subnis UB
AUID- ORCID: https://orcid.org/0000-0002-2313-9334
AD  - Department of Oncology, University of Calgary, Calgary, AB, Canada.
FAU - Farb, Norman As
AU  - Farb NA
AUID- ORCID: https://orcid.org/0000-0002-8407-2938
AD  - Department of Psychology, University of Toronto Mississauga, Mississauga, ON,
      Canada.
FAU - Piedalue, Katherine-Ann Laura
AU  - Piedalue KL
AUID- ORCID: https://orcid.org/0000-0002-2106-5431
AD  - Department of Oncology, University of Calgary, Calgary, AB, Canada.
FAU - Speca, Michael
AU  - Speca M
AUID- ORCID: https://orcid.org/0000-0001-8929-6351
AD  - Department of Oncology, University of Calgary, Calgary, AB, Canada.
FAU - Lupichuk, Sasha
AU  - Lupichuk S
AUID- ORCID: https://orcid.org/0000-0001-9545-0802
AD  - Department of Oncology, University of Calgary, Calgary, AB, Canada.
FAU - Tang, Patricia A
AU  - Tang PA
AUID- ORCID: https://orcid.org/0000-0003-1497-8539
AD  - Department of Oncology, University of Calgary, Calgary, AB, Canada.
FAU - Faris, Peter
AU  - Faris P
AUID- ORCID: https://orcid.org/0000-0001-5208-817X
AD  - Department of Community Health Sciences, University of Calgary, Calgary, AB,
      Canada.
FAU - Thoburn, Mark
AU  - Thoburn M
AUID- ORCID: https://orcid.org/0000-0003-3809-2724
AD  - Mobio Interactive, Toronto, ON, Canada.
FAU - Saab, Bechara J
AU  - Saab BJ
AUID- ORCID: https://orcid.org/0000-0003-1673-129X
AD  - Mobio Interactive, Toronto, ON, Canada.
FAU - Carlson, Linda E
AU  - Carlson LE
AUID- ORCID: https://orcid.org/0000-0002-4411-2085
AD  - Department of Oncology, University of Calgary, Calgary, AB, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03484000
PT  - Journal Article
DEP - 20200511
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7248798
OTO - NOTNLM
OT  - mind-body therapies
OT  - mindfulness
OT  - mobile health
OT  - psycho-oncology
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
CRDT- 2020/05/12 06:00
PHST- 2019/08/19 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2019/11/27 00:00 [revised]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
AID - v9i5e15178 [pii]
AID - 10.2196/15178 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 May 11;9(5):e15178. doi: 10.2196/15178.


PMID- 32390495
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20201218
IS  - 1724-6032 (Electronic)
IS  - 1129-7298 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Jul
TI  - Balancing the Covid-19-motivated vascular access guidelines and patient-centred
      care of pre-dialysis candidates.
PG  - 536-538
LID - 10.1177/1129729820926860 [doi]
AB  - The recommendations recently proposed by the European and American Vascular
      Societies in this new 'Covid-19' era regarding the triage of various vascular
      operations into urgent, emergent and programmed based on the nature of their
      pathology aim at reserving health care expenses and hospital staff towards
      managing the current unexpected worldwide pandemic to the highest possible
      degree. The suggestion for implementation of these changes into real-world
      practice, however, does not come without a cost. In particular, the
      recommendation for deferral of access creation in pre-dialysis patients, ethical,
      socio-economic and medico-legal issues arise which should be seriously taken into
      consideration. At the end of the day, vascular access creation is the lifeline of
      haemodialysis patients and the indication for surgery warrants patient-specific
      clinical judgement rather than 'group labelling'.
FAU - Georgiadis, George S
AU  - Georgiadis GS
AUID- ORCID: https://orcid.org/0000-0003-1274-3445
AD  - Department of Vascular Surgery, 'Democritus' University of Thrace, University
      General Hospital of Evros, Alexandroupolis, Greece.
FAU - Argyriou, Christos
AU  - Argyriou C
AD  - Department of Vascular Surgery, 'Democritus' University of Thrace, University
      General Hospital of Evros, Alexandroupolis, Greece.
FAU - Baktiroglu, Selcuk
AU  - Baktiroglu S
AD  - General Surgery Clinic, Istanbul Medical Faculty, Istanbul University, Istanbul, 
      Turkey.
FAU - Lazarides, Miltos K
AU  - Lazarides MK
AUID- ORCID: https://orcid.org/0000-0003-3458-7412
AD  - Department of Vascular Surgery, 'Democritus' University of Thrace, University
      General Hospital of Evros, Alexandroupolis, Greece.
FAU - Mallios, Alexandros
AU  - Mallios A
AUID- ORCID: https://orcid.org/0000-0003-0641-6050
AD  - Service de Chir Vasc, Institut Mutualiste Montsouris, Paris, France.
FAU - Tordoir, Jan Hm
AU  - Tordoir JH
AUID- ORCID: https://orcid.org/0000-0002-0766-282X
AD  - Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht,
      The Netherlands.
LA  - eng
PT  - Letter
DEP - 20200510
PL  - United States
TA  - J Vasc Access
JT  - The journal of vascular access
JID - 100940729
SB  - IM
MH  - *Arteriovenous Shunt, Surgical/adverse effects
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - *Catheterization, Central Venous/adverse effects
MH  - Clinical Decision-Making
MH  - Coronavirus Infections/diagnosis/*prevention & control/transmission/virology
MH  - Humans
MH  - Infectious Disease Transmission, Patient-to-Professional/*prevention & control
MH  - Infectious Disease Transmission, Professional-to-Patient/*prevention & control
MH  - Kidney Diseases/diagnosis/*therapy
MH  - Occupational Exposure/adverse effects/*prevention & control
MH  - Occupational Health
MH  - Pandemics/*prevention & control
MH  - Patient Safety
MH  - Patient Selection
MH  - Pneumonia, Viral/diagnosis/*prevention & control/transmission/virology
MH  - *Renal Dialysis/adverse effects
MH  - Risk Assessment
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Time-to-Treatment
MH  - Virulence
OTO - NOTNLM
OT  - Covid-19 vascular guidelines
OT  - arteriovenous fistula
OT  - catheters
OT  - dialysis
OT  - dialysis access
OT  - economics and health services
OT  - ethics and end-of-life issues
OT  - pre-dialysis patients
EDAT- 2020/05/12 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 10.1177/1129729820926860 [doi]
PST - ppublish
SO  - J Vasc Access. 2020 Jul;21(4):536-538. doi: 10.1177/1129729820926860. Epub 2020
      May 10.


PMID- 32390358
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20200703
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Linking)
VI  - 61
IP  - 5
DP  - 2020 May
TI  - A Review of Pre-Exposure Prophylaxis Adherence among Female Sex Workers.
PG  - 349-358
LID - 10.3349/ymj.2020.61.5.349 [doi]
AB  - Globally and in Africa specifically, female sex workers (FSWs) are at an
      extraordinarily high risk of contracting human immunodeficiency virus (HIV).
      Pre-exposure prophylaxis (PrEP) has emerged as an effective and ethical method
      with which to prevent HIV infection among FSWs. PrEP efficacy is, however,
      closely linked to adherence, and adherence to PrEP among FSWs is a complex and
      interrelated process that has been shown to be of importance to public health
      policies and HIV control and intervention programs. This comprehensive review
      categorizes barriers to and facilitators of adherence to HIV PrEP for FSWs, and
      describes five strategies for promoting PrEP adherence among FSWs. These
      strategies encompass 1) a long-term educational effort to decrease the stigma
      associated with sex work and PrEP use, 2) education on how PrEP works, 3)
      lifestyle modification, 4) research on next-generation PrEP products to address
      the inconvenience of taking daily pills, and 5) integration of PrEP into existing
      services, such as social services and routine primary care visits, to reduce the 
      economic burden of seeking the medication. Our review is expected to be useful
      for the design of future PrEP intervention programs. Multidisciplinary
      intervention should be considered to promote PrEP adherence among FSWs in order
      to help control the HIV epidemic.
CI  - (c) Copyright: Yonsei University College of Medicine 2020.
FAU - Ghayda, Ramy Abou
AU  - Ghayda RA
AUID- ORCID: https://orcid.org/0000-0002-5170-3983
AD  - Division of Urology, Brigham and Women's Hospital and Harvard Medical School,
      Boston, MA, USA.
AD  - Department of Global Health and Population, Harvard T.H. Chan School of Public
      Health, Boston, MA, USA.
FAU - Hong, Sung Hwi
AU  - Hong SH
AUID- ORCID: https://orcid.org/0000-0002-9781-4822
AD  - Division of Urology, Brigham and Women's Hospital and Harvard Medical School,
      Boston, MA, USA.
AD  - Division of Urology, Brigham and Women's Hospital and Harvard Medical School,
      Boston, MA, USA.
FAU - Yang, Jae Won
AU  - Yang JW
AUID- ORCID: https://orcid.org/0000-0001-8119-2574
AD  - Department of Internal Medicine, Yonsei University Wonju College of Medicine,
      Wonju, Korea.
FAU - Jeong, Gwang Hun
AU  - Jeong GH
AUID- ORCID: https://orcid.org/0000-0003-0009-8434
AD  - College of Medicine, Gyeongsang National University, Jinju, Korea.
FAU - Lee, Keum Hwa
AU  - Lee KH
AUID- ORCID: https://orcid.org/0000-0002-1511-9587
AD  - Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kronbichler, Andreas
AU  - Kronbichler A
AUID- ORCID: https://orcid.org/0000-0002-2945-2946
AD  - Department of Internal Medicine IV (Nephrology and Hypertension), Medical
      University Innsbruck, Innsbruck, Austria.
FAU - Solmi, Marco
AU  - Solmi M
AUID- ORCID: https://orcid.org/0000-0003-4877-7233
AD  - Department of Neuroscience, Padova Neuroscience Center (PNC), University of
      Padua, Padua, Italy.
FAU - Stubbs, Brendon
AU  - Stubbs B
AUID- ORCID: https://orcid.org/0000-0001-7387-3791
AD  - Institute of Psychiatry, Psychology and Neuroscience, King's College London, De
      Crespigny Park, London, UK.
AD  - South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK.
AD  - Faculty of Health, Social Care and Education, Anglia Ruskin University,
      Chelmsford, UK.
FAU - Koyanagi, Ai
AU  - Koyanagi A
AUID- ORCID: https://orcid.org/0000-0002-9565-5004
AD  - Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant 
      Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain.
AD  - ICREA, Pg. Lluis Companys 23, Barcelona, Spain.
FAU - Jacob, Louis
AU  - Jacob L
AUID- ORCID: https://orcid.org/0000-0003-1071-1239
AD  - Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant 
      Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain.
AD  - Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines,
      Montigny-le-Bretonneux, France.
FAU - Oh, Hans
AU  - Oh H
AUID- ORCID: https://orcid.org/0000-0002-8458-8723
AD  - School of Social Work, University of Southern California, Los Angeles, CA, USA.
FAU - Kim, Jong Yeob
AU  - Kim JY
AUID- ORCID: https://orcid.org/0000-0003-4756-9440
AD  - Yonsei University College of Medicine, Seoul, Korea.
FAU - Shin, Jae Il
AU  - Shin JI
AUID- ORCID: https://orcid.org/0000-0003-2326-1820
AD  - Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
      shinji@yuhs.ac.
FAU - Smith, Lee
AU  - Smith L
AUID- ORCID: https://orcid.org/0000-0002-5340-9833
AD  - The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,
      Cambridge, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Anti-HIV Agents/therapeutic use
MH  - Female
MH  - HIV Infections/drug therapy/epidemiology
MH  - Humans
MH  - *Medication Adherence
MH  - Observational Studies as Topic
MH  - *Pre-Exposure Prophylaxis
MH  - Risk Factors
MH  - *Sex Workers
PMC - PMC7214109
OTO - NOTNLM
OT  - Human immunodeficiency virus infection and acquired immune deficiency syndrome
      prevention
OT  - drug adherence
OT  - female sex workers
OT  - pre-exposure prophylaxis
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2020/05/12 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/03/24 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
AID - 61.349 [pii]
AID - 10.3349/ymj.2020.61.5.349 [doi]
PST - ppublish
SO  - Yonsei Med J. 2020 May;61(5):349-358. doi: 10.3349/ymj.2020.61.5.349.


PMID- 32390329
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 2366-7478 (Print)
IS  - 2366-7478 (Linking)
VI  - 4
IP  - 6
DP  - 2020 Jun
TI  - A 3D Self-Assembled In Vitro Model to Simulate Direct and Indirect Interactions
      between Adipocytes and Skeletal Muscle Cells.
PG  - e2000034
LID - 10.1002/adbi.202000034 [doi]
AB  - The molecular mechanisms of the development and progression of diabetes and
      obesity involve complex interactions between adipocytes and skeletal muscle
      cells. Although 2D in-vitro models are the gold standard for the mechanistic
      study of such behaviors, they do not recreate the complexity and dynamics of the 
      interactions between the cell types involved. Alternatively, animal models are
      used but are expensive, difficult to visualize or analyze, are not completely
      representative of human physiology or genetic background, and have associated
      ethical considerations. 3D co-culture systems can be complementary to these
      approaches. Here, using a newly developed 3D biofabrication method, adipocytes
      and myoblasts are positioned precisely either in direct physical contact or in
      close proximity such that the paracrine effects could be systematically studied. 
      Suitable protocols for growth and differentiation of both cells in the co-culture
      system is also developed. Cells show more restrained lipid and protein production
      in 3D systems compared to 2D ones and adipocytes show more lipolysis in indirect 
      contact with myoblasts as response to drug treatment. These findings emphasize
      importance of physical contact between cells that have been overlooked in
      co-culture systems using transwell inserts and can be used in studies for the
      development of anti-obesity drugs.
CI  - (c) 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Shahin-Shamsabadi, Alireza
AU  - Shahin-Shamsabadi A
AD  - School of Biomedical Engineering, McMaster University, 1280 Main Street West,
      Hamilton, Ontario, L8S 4L7, Canada.
FAU - Selvaganapathy, Ponnambalam Ravi
AU  - Selvaganapathy PR
AUID- ORCID: 0000-0003-2041-7180
AD  - School of Biomedical Engineering, McMaster University, 1280 Main Street West,
      Hamilton, Ontario, L8S 4L7, Canada.
AD  - Department of Mechanical Engineering, McMaster University, 1280 Main Street West,
      Hamilton, Ontario, L8S 4L7, Canada.
LA  - eng
GR  - Canadian Institute for Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200510
PL  - Germany
TA  - Adv Biosyst
JT  - Advanced biosystems
JID - 101711718
SB  - IM
MH  - 3T3-L1 Cells
MH  - Adipocytes/*metabolism/pathology
MH  - Animals
MH  - *Cell Communication
MH  - Coculture Techniques
MH  - Diabetes Mellitus/*metabolism/pathology
MH  - Lipolysis
MH  - Mice
MH  - *Models, Biological
MH  - Myoblasts, Skeletal/*metabolism/pathology
MH  - Obesity/*metabolism/pathology
OTO - NOTNLM
OT  - *3D in vitro models
OT  - *collagenous tissue construct
OT  - *drug assay
OT  - *muscle-fat co-culture
OT  - *self-assembly
EDAT- 2020/05/12 06:00
MHDA- 2021/08/12 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/04/07 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 10.1002/adbi.202000034 [doi]
PST - ppublish
SO  - Adv Biosyst. 2020 Jun;4(6):e2000034. doi: 10.1002/adbi.202000034. Epub 2020 May
      10.


PMID- 32390244
OWN - NLM
STAT- MEDLINE
DCOM- 20210727
LR  - 20210727
IS  - 1399-3046 (Electronic)
IS  - 1397-3142 (Linking)
VI  - 24
IP  - 5
DP  - 2020 Aug
TI  - Lower prevalence of aortic dilatation among preemptive pediatric renal transplant
      recipients - A cross-sectional cohort study.
PG  - e13716
LID - 10.1111/petr.13716 [doi]
AB  - BACKGROUND: Aortic dilatation is a cardiovascular complication in pediatric renal
      transplant recipients and may have an increased risk of aortic dissection, aortic
      rupture, and death. Studies failed to show an association between blood pressure 
      and aortic dilatation; however, 24-hours ambulatory blood pressure monitoring
      (ABPM) was not performed. There was also no comparison between preemptive
      transplantation and dialysis. METHODS: After ethics approval, a retrospective
      cross-sectional study was performed on all prevalent pediatric renal transplant
      recipients from a single tertiary care center. The presence of aortic dilatation 
      was determined using standard echocardiographic measurements, and those with
      other risk factors for aortic dilatation were excluded. Associations between
      24-hours ABPM, renal function, dialysis history, and aortic dimensions were
      determined. RESULTS: We enrolled 37 participants with the following
      characteristics: 46% female, mean age 14.5 +/- 3.7 years, 16% preemptive
      transplantation, and median end-stage renal disease (ESRD) combined vintage (time
      from ESRD onset to echocardiogram) 597 days (range 289-1290 days). We found 16/37
      patients (43%) with aortic dilatation at any level, mostly mild. There was no
      association between 24-hours ABPM measurements and aortic dilatation. None of the
      preemptively transplanted children had aortic dilatation. CONCLUSION: This study 
      confirms a high prevalence of aortic dilatation among pediatric renal transplant 
      recipients, which appears to be independent of hypertension on 24-hour ABPM.
      Patients with preemptive renal transplantation did not have aortic dilatation,
      suggesting that the effects of dialysis may contribute to the high prevalence of 
      this complication. Pediatric cardiologists need to carefully assess aortic
      dimensions in these at-risk patients.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Surak, Aimann
AU  - Surak A
AD  - Department of Paediatrics, Schulich School of Medicine & Dentistry, University of
      Western Ontario, London, ON, Canada.
FAU - Filler, Guido
AU  - Filler G
AUID- ORCID: 0000-0003-1891-6765
AD  - Department of Paediatrics, Schulich School of Medicine & Dentistry, University of
      Western Ontario, London, ON, Canada.
AD  - Department of Medicine, Schulich School of Medicine & Dentistry, University of
      Western Ontario, London, ON, Canada.
AD  - Departments of Pathology and Laboratory Medicine, Schulich School of Medicine &
      Dentistry, University of Western Ontario, London, ON, Canada.
AD  - The Lilibeth Caberto Kidney Clinical Research Unit, Western University, London,
      ON, London, ON, Canada.
FAU - Sharma, Ajay Parkash
AU  - Sharma AP
AD  - Department of Paediatrics, Schulich School of Medicine & Dentistry, University of
      Western Ontario, London, ON, Canada.
FAU - Torres Canchala, Laura Alejandra
AU  - Torres Canchala LA
AUID- ORCID: 0000-0002-2536-982X
AD  - The Lilibeth Caberto Kidney Clinical Research Unit, Western University, London,
      ON, London, ON, Canada.
AD  - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Cali, Colombia.
FAU - Grattan, Michael
AU  - Grattan M
AD  - Department of Paediatrics, Schulich School of Medicine & Dentistry, University of
      Western Ontario, London, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - Denmark
TA  - Pediatr Transplant
JT  - Pediatric transplantation
JID - 9802574
SB  - IM
MH  - Adolescent
MH  - Aortic Diseases/diagnostic imaging/epidemiology/*etiology
MH  - Blood Pressure Monitoring, Ambulatory
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Dilatation, Pathologic
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Kidney Failure, Chronic/physiopathology/*surgery/therapy
MH  - *Kidney Transplantation
MH  - Male
MH  - Postoperative Complications/diagnostic imaging/epidemiology/*etiology
MH  - Prevalence
MH  - Renal Dialysis/adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - *aortic dilation
OT  - *cardiovascular complication
OT  - *dialysis vintage
OT  - *preemptive transplantation
OT  - *renal transplantation
EDAT- 2020/05/12 06:00
MHDA- 2021/07/28 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/02/04 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2021/07/28 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - 10.1111/petr.13716 [doi]
PST - ppublish
SO  - Pediatr Transplant. 2020 Aug;24(5):e13716. doi: 10.1111/petr.13716. Epub 2020 May
      11.


PMID- 32389878
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210110
IS  - 1878-8769 (Electronic)
IS  - 1878-8750 (Linking)
VI  - 140
DP  - 2020 Aug
TI  - Early Report on the Impact of COVID-19 Outbreak in Neurosurgical Practice Among
      Members of the Latin American Federation of Neurosurgical Societies.
PG  - e195-e202
LID - S1878-8750(20)30936-0 [pii]
LID - 10.1016/j.wneu.2020.04.226 [doi]
AB  - BACKGROUND: The COVID-19 pandemic has caused severe economic consequences by
      local governmental measures to contain the outbreak. We provide insight on the
      impact that health care restriction has made on neurosurgical activity in Latin
      Iberoamerica. METHODS: We performed an internet-based survey among presidents and
      members of the societies of the Latin American Federation of Neurosurgical
      Societies (FLANC). We blindly analyzed information regarding local conditions and
      their impact on neurosurgical praxis using SPSS software. RESULTS: Information
      came from 21 countries. Sixteen society presidents reported having suspended
      regular activities and deferring local scheduled congresses, 14 reported
      mandatory isolation by government, and 4 instituted a telemedicine project.
      Four-hundred eighty-six colleagues, mean age 49 years, reported a mean 79%
      reduction in their neurosurgical praxis. Seventy-six percent of neurosurgeons
      have savings to self-support for 3-6 months if restrictions are long lasting.
      CONCLUSIONS: Stopping activities among societies of the FLANC, together with a
      drop of 79% of neurosurgical praxis, adds to deficits in provider's protection
      equipment and increasing demand for attention in the health care systems,
      representing a huge financial risk to their sustainability. Neurosurgeons should 
      be involved in local policies to protect health and economy. Telemedicine
      represents an excellent solution, avoiding another pandemic of severe diseases
      across all-specialties as nonessential care can turn essential if left untreated.
      Financial support and ethics code review is needed to battle this new disease,
      designated the occupational disease of the decade, that continues to scrag the
      health care system. Times of crisis are times of great opportunities for humanity
      to evolve.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Soriano Sanchez, Jose Antonio
AU  - Soriano Sanchez JA
AD  - Spine Clinic and Neurosurgery Department, The American-British Cowdray Medical
      Center IAP, Mexico City, Mexico. Electronic address: neurojass1@hotmail.com.
FAU - Perilla Cepeda, Tito Arcadio
AU  - Perilla Cepeda TA
AD  - Spine Surgery and Neurosurgery Department, University Children's Hospital of San 
      Jose, Bogota, Colombia.
FAU - Zenteno, Marcelo
AU  - Zenteno M
AD  - Neurosurgery Department, San Juan De Dios University Hospital, Tarija, Bolivia.
FAU - Campero, Alvaro
AU  - Campero A
AD  - Neurosurgery Department, The Padilla Hospital of Tucuman, Tucuman, Argentina.
FAU - Yampolsky, Claudio
AU  - Yampolsky C
AD  - Neurosurgery Department, Italian Hospital of Buenos Aires, Buenos Aires,
      Argentina.
FAU - Varela, Mauro Loyo
AU  - Varela ML
AD  - Neurosurgery Department, The American-British Cowdray Medical Center IAP, Mexico 
      City, Mexico.
FAU - Soto Garcia, Manuel Eduardo
AU  - Soto Garcia ME
AD  - Spine Clinic and Neurosurgery Department, The American-British Cowdray Medical
      Center IAP, Mexico City, Mexico.
FAU - Romero Rangel, Jose Alberto Israel
AU  - Romero Rangel JAI
AD  - Spine Clinic and Neurosurgery Department, The American-British Cowdray Medical
      Center IAP, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - United States
TA  - World Neurosurg
JT  - World neurosurgery
JID - 101528275
SB  - IM
MH  - Betacoronavirus/*pathogenicity
MH  - COVID-19
MH  - Coronavirus Infections/*surgery
MH  - Disease Outbreaks/prevention & control
MH  - Humans
MH  - Latin America
MH  - Middle Aged
MH  - Neurosurgery/*statistics & numerical data
MH  - Neurosurgical Procedures/statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/*surgery
MH  - SARS-CoV-2
MH  - Societies, Medical
PMC - PMC7204692
OTO - NOTNLM
OT  - *COVID-19 outbreak
OT  - *FLANC
OT  - *Financial risk
OT  - *Neurosurgeons
OT  - *Survey
OT  - *Telemedicine
EDAT- 2020/05/12 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - S1878-8750(20)30936-0 [pii]
AID - 10.1016/j.wneu.2020.04.226 [doi]
PST - ppublish
SO  - World Neurosurg. 2020 Aug;140:e195-e202. doi: 10.1016/j.wneu.2020.04.226. Epub
      2020 May 7.


PMID- 32389512
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1095-8320 (Electronic)
IS  - 1045-1056 (Linking)
VI  - 66
DP  - 2020 Jul
TI  - Human challenge trial workshop: Focus on quality requirements for challenge
      agents, Langen, Germany, October 22, 2019.
PG  - 53-61
LID - S1045-1056(20)30045-2 [pii]
LID - 10.1016/j.biologicals.2020.04.005 [doi]
AB  - Controlled human infection models can be helpful to study pathogenesis and immune
      responses as a basis for the development of vaccines. In controlled human
      infection models, human challenge agents are used to infect healthy volunteers,
      therefore, ethical considerations include that the exposure studies need to be
      safe and results should be meaningful, e.g. contribute to a better cure. Both in 
      the US and in Europe, the level of Good Manufacturing Practice required is
      related to the phase of the study ('sliding scale Good Manufacturing Practice'), 
      and, hence, is much more open to speedy drug development than anticipated.
      Recommendations included: the development of guidelines for human challenge
      agents; a focus on strain selection, in particular with regard to strain
      infectivity, stability and purity; the use of whole genome sequencing; a
      reference repository of challenge agents, the need for early exchange with
      regulators to ensure acceptability of strain selection and manufacturing for
      later drug development; sharing of models and challenge agents.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Bekeredjian-Ding, Isabelle
AU  - Bekeredjian-Ding I
AD  - Paul-Ehrlich-Institut (PEI), Langen, Germany; Institute for Medical Microbiology,
      Immunology and Parasitology, University Hospital Bonn, Bonn, Germany. Electronic 
      address: Isabelle.Bekeredjian-Ding@pei.de.
FAU - Van Molle, Wim
AU  - Van Molle W
AD  - Sciensano, Brussels, Belgium. Electronic address: Wim.VanMolle@sciensano.be.
FAU - Baay, Marc
AU  - Baay M
AD  - P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address:
      marc.baay@p-95.com.
FAU - Neels, Pieter
AU  - Neels P
AD  - International Alliance for Biological Standardization (IABS), Belgium. Electronic
      address: pieter.neels@vaccine-advice.be.
CN  - PEI speakers and session chairs
LA  - eng
PT  - Congress
DEP - 20200504
PL  - England
TA  - Biologicals
JT  - Biologicals : journal of the International Association of Biological
      Standardization
JID - 9004494
RN  - 0 (Biological Products)
RN  - 0 (Vaccines)
SB  - IM
MH  - Biological Products/*standards
MH  - *Drug Development
MH  - *Human Experimentation/ethics/legislation & jurisprudence
MH  - Humans
MH  - Vaccines
MH  - Whole Genome Sequencing
COIS- Declaration of competing interest The authors have no competing interests to
      declare.
IR  - Berthels N
FIR - Berthels, Nele
IRAD- Federal Agency for Medicines and Health Products (FAMHP), Belgium.
IR  - Conrad C
FIR - Conrad, Christoph
IRAD- Paul-Ehrlich-Institut (PEI), Langen, Germany.
IR  - van Diepen A
FIR - van Diepen, Angela
IRAD- Department of Parasitology, Leiden University Medical Center, the Netherlands.
IR  - Fortune S
FIR - Fortune, Sarah
IRAD- Harvard T.H. Chan School of Public Health, Boston, United States.
IR  - Goetz K
FIR - Goetz, Karen
IRAD- Paul-Ehrlich-Institut (PEI), Langen, Germany.
IR  - Gorringe A
FIR - Gorringe, Andrew
IRAD- Public Health England, Porton Down, United Kingdom.
IR  - Hoft D
FIR - Hoft, Daniel
IRAD- Center for Vaccine Development, Saint Louis University, MO, United States.
IR  - Johnson RA
FIR - Johnson, Robert A
IRAD- Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research
      and Development Authority (BARDA), Assistant Secretary for Preparedness and
      Response (ASPR), United States.
IR  - Kremsner P
FIR - Kremsner, Peter
IRAD- Institute of Tropical Medicine, University of Tubingen, Germany.
IR  - Krut O
FIR - Krut, Oleg
IRAD- Section Microbiological Safety, Paul-Ehrlich-Institut, Langen, Germany.
IR  - Levy Y
FIR - Levy, Yves
IRAD- French Vaccine Research Institute (VRI), Paris, France.
IR  - Metzger W
FIR - Metzger, Wolfram
IRAD- Institute of Tropical Medicine, University of Tubingen, Germany.
IR  - Oeppling V
FIR - Oeppling, Volker
IRAD- Paul-Ehrlich-Institut (PEI), Langen, Germany.
IR  - Stibitz S
FIR - Stibitz, Scott
IRAD- Food & Drug Administration (FDA), United States.
IR  - Talaat KR
FIR - Talaat, Kawsar R
IRAD- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
IR  - Thomas S
FIR - Thomas, Stephen
IRAD- Division of Infectious Diseases, SUNY Upstate Medical University, United States
      Barry Walker, Biologics and Vaccine Development Consultant, United Kingdom.
IR  - Wildfire A
FIR - Wildfire, Adrian
IRAD- SGS Life Sciences, Belgium.
IR  - Yakubu BN
FIR - Yakubu, Beno Nyam
IRAD- Nigerian National Agency for Food and Drug Administration and Control (NAFDAC),
      African Vaccine Regulatory Forum (AVAREF), Nigeria.
EDAT- 2020/05/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/12 06:00 [entrez]
AID - S1045-1056(20)30045-2 [pii]
AID - 10.1016/j.biologicals.2020.04.005 [doi]
PST - ppublish
SO  - Biologicals. 2020 Jul;66:53-61. doi: 10.1016/j.biologicals.2020.04.005. Epub 2020
      May 4.


PMID- 32389149
OWN - NLM
STAT- Publisher
LR  - 20200511
IS  - 1475-2719 (Electronic)
IS  - 0029-6651 (Linking)
DP  - 2020 May 11
TI  - Omega-3 index in 2018/19.
PG  - 1-7
LID - 10.1017/S0029665120006989 [doi]
AB  - The omega-3 index, the percentage of EPA plus DHA in erythrocytes (measured by
      standardised analysis), represents a human body's status in EPA and DHA. An
      omega-3 index is measured in many laboratories around the world; however, even
      small differences in analytical methods entail large differences in results.
      Nevertheless, results are frequently related to the target range of 8-11 %,
      defined for the original and scientifically validated method (HS-Omega-3
      Index(R)), raising ethical issues, and calling for standardisation. No human
      subject has an omega-3 index <2 %, indicating a vital minimum. Thus, the absence 
      of EPA and DHA cannot be tested against presence. Moreover, clinical events
      correlate with levels, less with the dose of EPA and DHA, and the bioavailability
      of EPA and DHA varies inter-individually. Therefore, the effects of EPA and DHA
      are difficult to demonstrate using typical drug trial methods. Recent
      epidemiologic data further support the relevance of the omega-3 index in the
      cardiovascular field, since total mortality, cardiovascular mortality,
      cardiovascular events such as myocardial infarction or stroke, or blood pressure 
      all correlate inversely with the omega-3 index. The omega-3 index directly
      correlates with complex brain functions. Compiling recent data supports the
      target range for the omega-3 index of 8-11 % in pregnancy. Many other potential
      applications have emerged. Some, but not all health issues mentioned have already
      been demonstrated to be improved by increasing intake of EPA and DHA. Increasing 
      the omega-3 index into the target range of 8-11 % with individualised doses of
      toxin-free sources for EPA and DHA is tolerable and safe.
FAU - von Schacky, Clemens
AU  - von Schacky C
AD  - Omegametrix, Martinsried, Germany and Preventive Cardiology, University of
      Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - England
TA  - Proc Nutr Soc
JT  - The Proceedings of the Nutrition Society
JID - 7505881
SB  - IM
OTO - NOTNLM
OT  - DHA
OT  - EPA
OT  - n-3 Fatty acids
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 10.1017/S0029665120006989 [doi]
AID - S0029665120006989 [pii]
PST - aheadofprint
SO  - Proc Nutr Soc. 2020 May 11:1-7. doi: 10.1017/S0029665120006989.


PMID- 32388963
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 0253-9624 (Print)
IS  - 0253-9624 (Linking)
VI  - 54
IP  - 5
DP  - 2020 May 6
TI  - [Progress on the oocyte cryopreservation technology assessment].
PG  - 577-580
LID - 10.3760/cma.j.cn112150-20190723-00592 [doi]
AB  - As a way of female fertility preservation, oocyte cryopreservation
      technology(OCT) has attracted more attention from the society. The health
      technology assessment (HTA) research progresses on OCT are important evidence
      basis for OCT clinical application promotion. Literatures on the maternal and
      offspring safety, efficacy and social ethics assessment of OCT were reviewed in
      this paper. Based on the current OCT evaluation evidence, short-term safety and
      effectiveness were confirmed, but long-term maternal and child safety should be
      testified in a large scale follow-up study. Social ethics evaluation methods of
      human assisted reproductive technology(ART) research were still in the
      exploratory stage. Therefore, it is necessary to establish the social ethics
      evaluation methods and system of human ART, including OCT, in China.
FAU - Bai, F
AU  - Bai F
AD  - National Center for Women and Children's Health, Chinese Center for Disease
      Control and Prevention, Beijing 100081, China.
FAU - Liu, C
AU  - Liu C
AD  - National Center for Women and Children's Health, Chinese Center for Disease
      Control and Prevention, Beijing 100081, China.
FAU - Zhang, Y X
AU  - Zhang YX
AD  - National Center for Women and Children's Health, Chinese Center for Disease
      Control and Prevention, Beijing 100081, China.
FAU - Ma, Y
AU  - Ma Y
AD  - National Center for Women and Children's Health, Chinese Center for Disease
      Control and Prevention, Beijing 100081, China.
FAU - Wang, D Y
AU  - Wang DY
AD  - National Center for Women and Children's Health, Chinese Center for Disease
      Control and Prevention, Beijing 100081, China.
FAU - Zhang, Y N
AU  - Zhang YN
AD  - National Center for Women and Children's Health, Chinese Center for Disease
      Control and Prevention, Beijing 100081, China.
LA  - chi
GR  - 2018YFC1002106/National Key Research and Development Program
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Yu Fang Yi Xue Za Zhi
JT  - Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
JID - 7904962
SB  - IM
MH  - China
MH  - Cryopreservation/*trends
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Oocytes
MH  - Pregnancy
MH  - *Technology Assessment, Biomedical
OTO - NOTNLM
OT  - Freezing
OT  - Oocytes
OT  - Social ethics
EDAT- 2020/05/12 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
AID - 10.3760/cma.j.cn112150-20190723-00592 [doi]
PST - ppublish
SO  - Zhonghua Yu Fang Yi Xue Za Zhi. 2020 May 6;54(5):577-580. doi:
      10.3760/cma.j.cn112150-20190723-00592.


PMID- 32388849
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 0303-7339 (Print)
IS  - 0303-7339 (Linking)
VI  - 62
IP  - 4
DP  - 2020
TI  - [Parents of suicidal young persons and transitional psychiatry: therapeutic and
      ethical challenges].
PG  - 274-282
AB  - BACKGROUND: Young people aged 15-25 with mental health problems often experience 
      discontinuity of care during the transition from child to adult mental health
      services. Furthermore, suicide is one of the most common causes of death in this 
      age category. Although it is known that parents are important in the care process
      of suicidal youth, parental participation faces various challenges.<br/> AIM: To 
      investigate the ethical, therapeutic and practical aspects regarding parents of a
      suicidal young person during the mental health care transition.<br/> METHOD: A
      literature search in the most important literature databases.<br/> RESULTS: We
      found no studies that specifically examined the role of parents of suicidal youth
      during the transition. However, there is enough scientific evidence suggesting
      that including parents during treatment of suicidal young persons has a positive 
      effect on outcome and quality of life. Regarding transition, parents are also
      important. Nevertheless, several bottlenecks impede their involvement.<br/>
      CONCLUSION: Parental participation during transitional care is hampered by
      ethical, therapeutic and practical issues. Taking these into account, parents
      should be involved as much as possible in the care for their child. Furthermore, 
      sufficient attention must be paid to the concerns and needs of the parents
      themselves.
FAU - Sabbe, M
AU  - Sabbe M
FAU - Hendrickx, G
AU  - Hendrickx G
FAU - Vanlinthout, E
AU  - Vanlinthout E
FAU - Tremmery, S
AU  - Tremmery S
LA  - dut
PT  - Journal Article
TT  - Ouders van suicidale jongeren en transitiepsychiatrie; ethische en therapeutische
      uitdagingen.
PL  - Netherlands
TA  - Tijdschr Psychiatr
JT  - Tijdschrift voor psychiatrie
JID - 0423731
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Humans
MH  - Parents
MH  - *Psychiatry
MH  - Quality of Life
MH  - Suicidal Ideation
MH  - *Transition to Adult Care
EDAT- 2020/05/11 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/05/11 06:00 [entrez]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - TVPart_12156 [pii]
PST - ppublish
SO  - Tijdschr Psychiatr. 2020;62(4):274-282.


PMID- 32388736
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20201111
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 22
IP  - 6
DP  - 2020 May 9
TI  - Medical Ethics Issues in Dementia and End of Life.
PG  - 31
LID - 10.1007/s11920-020-01150-7 [doi]
AB  - PURPOSE OF REVIEW: I review ethical and legal challenges for end of life (EOL)
      care in dementia. Is access to hospice care for dementia patients impacted by
      Medicare's terminal prognosis requirement? Are dementia-specific advance
      directives warranted? How does state legislation affect dementia patients' EOL
      options? Should dementia patients' be able to refuse orally ingested food and
      fluids by advance directive? RECENT FINDINGS: The difficulty of predicting time
      to death in dementia inhibits access to Medicare hospice benefits. Efforts have
      been made to create dementia-specific advance directives. Advance refusal of
      artificial nutrition and hydration are common, but the issue of oral ingestion of
      food and fluids by dementia patients remains controversial. Medicare's hospice
      benefit should be made more accessible to dementia patients. State advance
      directive threshold definitions should be broadened to include dementia, and
      capacitated persons who refuse in advance orally ingested food and fluids should 
      have their choices honored.
FAU - Allen, William
AU  - Allen W
AD  - Department of Community Health and Family Medicine, University of Florida College
      of Medicine, Gainesville, FL, 32610, USA. wmallen@UFL.EDU.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200509
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
SB  - IM
MH  - Advance Directives
MH  - Aged
MH  - *Dementia/therapy
MH  - Ethics, Medical
MH  - Humans
MH  - Medicare
MH  - *Terminal Care
MH  - United States
OTO - NOTNLM
OT  - *Best interest standard
OT  - *Comfort feeding only
OT  - *Definitions of terminal
OT  - *Dementia-specific advance directives
OT  - *Palliative care in dementia
OT  - *Refusal of orally ingested food and fluids
OT  - *Self-discrimination
OT  - *Voluntary stopping eating and drinking
EDAT- 2020/05/11 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/05/11 06:00 [entrez]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1007/s11920-020-01150-7 [doi]
AID - 10.1007/s11920-020-01150-7 [pii]
PST - epublish
SO  - Curr Psychiatry Rep. 2020 May 9;22(6):31. doi: 10.1007/s11920-020-01150-7.


PMID- 32388029
OWN - NLM
STAT- Publisher
LR  - 20200622
IS  - 1873-4367 (Electronic)
IS  - 0927-7765 (Linking)
VI  - 192
DP  - 2020 Apr 17
TI  - Permeation kinetics of active drugs through lanolin-based artificial membranes.
PG  - 111024
LID - S0927-7765(20)30254-X [pii]
LID - 10.1016/j.colsurfb.2020.111024 [doi]
AB  - Skin-penetration studies play an essential role in the selection of drugs for
      dermal or transdermal application. In vivo experiments in humans are not always
      possible for ethical, practical, or economic reasons, especially in the first
      part of the drug development. It is necessary to develop alternative methods
      using accessible and reproducible surrogates for in vivo human skin. The in vitro
      methodologies using biological membranes (human and animal skin) are recognized
      and well accepted as an alternative but present high inter- and intra-individual 
      variability. Therefore, the formation of synthetic membranes has been studied to 
      obtain skin- mimicking models for permeation studies. The aim of this work is to 
      create lanolin-based artificial membranes that can mimic the absorption through
      the skin of compounds applied topically. A series of synthetic membranes using
      two different types of lanolin (water-extracted (WE) and solvent-extracted (SE)) 
      were prepared. Next, the in vitro release test of three drugs (diclofenac sodium,
      ibuprofen and lidocaine) was performed on artificial membranes and on porcine
      skin placed on Franz cells. The percentage of release, flux, permeability
      coefficient, lag time, area under the curve, maximal concentration and time were 
      determined for each compound in the different types of membrane. The results
      showed that lanolin membranes presented a strong diminution of permeability
      compared to most artificial membranes, leading to a very similar permeability to 
      that of skin. The SE and WE membranes showed a diminution of transepidermal water
      loss and permeability of compounds compared with membranes alone. The results
      from WE membranes were similar to those found for the skin. The lanolin membranes
      were not capable of perfectly mimicking permeation through the skin, but they did
      have the same rank order of drug penetration as the skin. It may be deduced from 
      these tests that these systems provide more reliable results for compounds with
      low to medium lipophilicity. The results demonstrated that new lanolin-based
      artificial membranes have the potential to be exploited as screening models for
      determining the permeability of a compound destined to be topically delivered.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Alonso, Cristina
AU  - Alonso C
AD  - Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona
      18-26, 08034 Barcelona, Spain. Electronic address: cristina.alonso@iqac.csic.es.
FAU - Collini, I
AU  - Collini I
AD  - Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona
      18-26, 08034 Barcelona, Spain.
FAU - Carrer, V
AU  - Carrer V
AD  - Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona
      18-26, 08034 Barcelona, Spain.
FAU - Barba, C
AU  - Barba C
AD  - Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona
      18-26, 08034 Barcelona, Spain.
FAU - Marti, M
AU  - Marti M
AD  - Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona
      18-26, 08034 Barcelona, Spain.
FAU - Coderch, L
AU  - Coderch L
AD  - Institute of Advanced Chemical of Catalonia of CSIC, (IQAC-CSIC), Jordi Girona
      18-26, 08034 Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Netherlands
TA  - Colloids Surf B Biointerfaces
JT  - Colloids and surfaces. B, Biointerfaces
JID - 9315133
SB  - IM
OTO - NOTNLM
OT  - Franz cells
OT  - Lanolin
OT  - Permeation profile
OT  - Synthetic membranes
EDAT- 2020/05/11 06:00
MHDA- 2020/05/11 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/04/04 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/05/11 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S0927-7765(20)30254-X [pii]
AID - 10.1016/j.colsurfb.2020.111024 [doi]
PST - aheadofprint
SO  - Colloids Surf B Biointerfaces. 2020 Apr 17;192:111024. doi:
      10.1016/j.colsurfb.2020.111024.


PMID- 32388003
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20200909
IS  - 1873-4499 (Electronic)
IS  - 0899-7071 (Linking)
VI  - 64
DP  - 2020 Aug
TI  - Diagnostic utility of arterial spin labeling in identifying changes in brain
      perfusion in patients with carbon monoxide poisoning.
PG  - 92-96
LID - S0899-7071(20)30108-X [pii]
LID - 10.1016/j.clinimag.2020.04.006 [doi]
AB  - OBJECTIVE: Carbon monoxide (CO) poisoning is one of the most common poisonings
      worldwide. The affinity of hemoglobin for CO is significantly higher than that
      for oxygen, and the formation of carboxy-hemoglobin leads to a decrease in the
      capacity of blood to transport oxygen to tissues, tissue hypoxia, and early
      perfusion changes in the affected tissue. This study aimed to investigate the
      utility of arterial spin labeling perfusion imaging (ASL-PI) in revealing
      cerebral vascular hemodynamic changes in patients presenting to the emergency
      room with CO poisoning and to compare findings with those from diffusion-weighted
      imaging (DWI). METHOD: This study was conducted between November 2016 and May
      2019 and was approved by the local ethics committee. DWI and ASL-PI examinations 
      were performed in 83 patients who presented to the emergency room with CO
      poisoning. Four regions-the cerebral cortex, basal ganglia, cerebral white
      matter, and cerebellum-were evaluated for alterations in perfusion and diffusion,
      and findings from DWI and ASL-PI were compared. RESULTS: The study group included
      39 (50.6%) females and 38 (49.4%) males, with a mean (+/-SD) age of 40.08 +/-
      20.41 years (range, 7-86 years). DWI revealed restricted diffusion in 10 regions 
      in 6 (7.8%) patients, including the basal ganglia (n = 2), cerebral white matter 
      (n = 2), cerebral cortex (n = 3), and the cerebellum (n = 3). ASL-PI revealed
      hypo-perfusion in 64 regions in 36 (46.8%) patients, including the basal ganglia 
      (n = 21), cerebral white matter (n = 12), cerebral cortex (n = 23), and
      cerebellum (n = 7). CONCLUSION: ASL-PI provided additional information when used 
      to identify perfusion changes in the brains of individuals who experienced CO
      poisoning and was superior to DWI as it revealed early changes in the brain.
      Considering its limitations, ASL-PI can be routinely used with DWI in cases of CO
      poisoning.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Cebeci, Hakan
AU  - Cebeci H
AD  - Department of Radiology, Selcuk University, Medical Faculty, Konya, Turkey.
      Electronic address: hcebeci16@gmail.com.
FAU - Durmaz, Mehmet Sedat
AU  - Durmaz MS
AD  - Department of Radiology, Selcuk University, Medical Faculty, Konya, Turkey.
FAU - Arslan, Serdar
AU  - Arslan S
AD  - Departments of Radiology, Istanbul University, Cerrahpasa Medical Faculty,
      Istanbul, Turkey.
FAU - Arslan, Abdullah
AU  - Arslan A
AD  - Department of Underwater and Hyperbaric Medicine, University of Health Science,
      Konya Training and Research Hospital, Konya, Turkey.
FAU - Tekin, Ali Fuat
AU  - Tekin AF
AD  - Department of Radiology, University of Health Sciences, Konya Training and
      Research Hospital, Konya, Turkey.
FAU - Habibi, Hatice Arioz
AU  - Habibi HA
AD  - Departments of Radiology, Istanbul University, Cerrahpasa Medical Faculty,
      Istanbul, Turkey.
FAU - Koylu, Ramazan
AU  - Koylu R
AD  - Department of Emergency Medicine, University of Health Sciences, Konya Training
      and Research Hospital, Konya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - United States
TA  - Clin Imaging
JT  - Clinical imaging
JID - 8911831
RN  - 0 (Spin Labels)
SB  - IM
MH  - Adult
MH  - Arteries
MH  - Brain/*diagnostic imaging
MH  - Carbon Monoxide Poisoning/*diagnostic imaging
MH  - Cerebral Cortex
MH  - Cerebrovascular Circulation
MH  - Diffusion Magnetic Resonance Imaging/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perfusion
MH  - Perfusion Imaging/methods
MH  - Spin Labels
MH  - White Matter
OTO - NOTNLM
OT  - Arterial spin labeling
OT  - Carbon monoxide poisoning
OT  - Diffusion weighted imaging
OT  - Magnetic resonance imaging
COIS- Declaration of competing interest The authors declare that there are no financial
      or other relations that could lead to a conflict of interest.
EDAT- 2020/05/11 06:00
MHDA- 2020/09/10 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S0899-7071(20)30108-X [pii]
AID - 10.1016/j.clinimag.2020.04.006 [doi]
PST - ppublish
SO  - Clin Imaging. 2020 Aug;64:92-96. doi: 10.1016/j.clinimag.2020.04.006. Epub 2020
      Apr 11.


PMID- 32387742
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 1095-9572 (Electronic)
IS  - 1053-8119 (Linking)
VI  - 217
DP  - 2020 Aug 15
TI  - Simultaneous cortical and subcortical recordings in humans with movement
      disorders: Acute and chronic paradigms.
PG  - 116904
LID - S1053-8119(20)30390-6 [pii]
LID - 10.1016/j.neuroimage.2020.116904 [doi]
AB  - Invasive basal ganglia recordings in humans have significantly advanced our
      understanding of the neurophysiology of movement disorders. A recent technical
      advance has been the addition of electrocorticography to basal ganglia recording,
      for evaluating distributed motor networks. Here we review the rationale, results,
      and ethics of this multisite recording technique in movement disorders, as well
      as its application in chronic recording paradigms utilizing implantable neural
      interfaces that include a sensing function.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Wozny, Thomas A
AU  - Wozny TA
AD  - Department of Neurological Surgery, University of California, 505 Parnassus
      Avenue, San Francisco, CA, 94143, USA. Electronic address: thomas.wozny@ucsf.edu.
FAU - Wang, Doris D
AU  - Wang DD
AD  - Department of Neurological Surgery, University of California, 505 Parnassus
      Avenue, San Francisco, CA, 94143, USA.
FAU - Starr, Philip A
AU  - Starr PA
AD  - Department of Neurological Surgery, University of California, 505 Parnassus
      Avenue, San Francisco, CA, 94143, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200506
PL  - United States
TA  - Neuroimage
JT  - NeuroImage
JID - 9215515
SB  - IM
MH  - Acute Disease
MH  - Basal Ganglia/diagnostic imaging
MH  - Cerebral Cortex/*diagnostic imaging
MH  - Chronic Disease
MH  - Efferent Pathways/diagnostic imaging
MH  - Electrocorticography
MH  - Humans
MH  - Movement Disorders/*diagnostic imaging
EDAT- 2020/05/11 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S1053-8119(20)30390-6 [pii]
AID - 10.1016/j.neuroimage.2020.116904 [doi]
PST - ppublish
SO  - Neuroimage. 2020 Aug 15;217:116904. doi: 10.1016/j.neuroimage.2020.116904. Epub
      2020 May 6.


PMID- 32387532
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1879-3304 (Electronic)
IS  - 0039-6257 (Linking)
VI  - 65
IP  - 6
DP  - 2020 Nov - Dec
TI  - The eyes of the angel of death: Ophthalmic experiments of Josef Mengele.
PG  - 744-748
LID - S0039-6257(20)30073-4 [pii]
LID - 10.1016/j.survophthal.2020.04.007 [doi]
AB  - The infamous Schutzstaffel doctor Josef Mengele was known as the Angel of Death
      for choosing and condemning Jews, gypsies, and other prisoners to the gas
      chambers at the Auschwitz-Birkenau concentration camp. Less known was his active 
      participation in ophthalmic research with equal disregard for life and ethical
      principles. Mengele was not an ophthalmologist, but he worked in close
      collaboration and complicity with two genetic researchers at the Kaiser-Wilhelm
      Institute in Berlin, Karin Magnussen and Otmar Von Verschuer. The objective of
      the eye color protocol was to demonstrate hereditary differences in iris
      structure determined by race and ostensibly to "cure" heterochromia. Mengele sent
      heterochromous Gypsy eyes to Magnussen, extracted from the bodies of inmates who 
      died (or he killed). Mengele injected adrenaline into children's eyes in an
      attempt to change eye color and to study environmental influences. Mengele was
      undoubtedly influenced to conduct these human experiments by his great ambition
      to publish to obtain academic promotion. These ophthalmologic experiments not
      only solidify Mengele's reputation as an angel of death but also show the
      symbiosis that existed between the concentration camp physicians and others in
      the Nazi medical establishment. Ophthalmology, like all of medicine, has had its 
      share of unethical experimentation, but none with more disregard for life and
      ethical principles than that of Mengele at Auschwitz.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Halioua, Bruno
AU  - Halioua B
AD  - Universite Paris Sud-Department of Research in Ethics, Saint-Louis Hospital,
      Paris, France. Electronic address: haliouab@yahoo.fr.
FAU - Marmor, Michael F
AU  - Marmor MF
AD  - Department of Ophthalmology and Byers Eye Institute, Stanford University School
      of Medicine, Palo Alto, California, USA.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Review
DEP - 20200507
PL  - United States
TA  - Surv Ophthalmol
JT  - Survey of ophthalmology
JID - 0404551
SB  - IM
MH  - Concentration Camps/*history
MH  - Eye Diseases/*history
MH  - Germany
MH  - History, 20th Century
MH  - National Socialism/*history
MH  - Ophthalmology/*history
PS  - Mengele J
FPS - Mengele, Josef
EDAT- 2020/05/11 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/05/11 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2020/04/20 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S0039-6257(20)30073-4 [pii]
AID - 10.1016/j.survophthal.2020.04.007 [doi]
PST - ppublish
SO  - Surv Ophthalmol. 2020 Nov - Dec;65(6):744-748. doi:
      10.1016/j.survophthal.2020.04.007. Epub 2020 May 7.


PMID- 32387082
OWN - NLM
STAT- MEDLINE
DCOM- 20200611
LR  - 20220818
IS  - 1424-3911 (Electronic)
IS  - 1424-3903 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Jun
TI  - Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case
      report on three family members.
PG  - 665-667
LID - S1424-3903(20)30147-2 [pii]
LID - 10.1016/j.pan.2020.04.021 [doi]
AB  - BACKGROUND/OBJECTIVES: Abdominal pain is one of the known symptoms associated
      with coronavirus disease 2019. Little is known about the development of acute
      pancreatitis as a complication of severe acute respiratory syndrome coronavirus 2
      infection. This case report describes the presentation of acute pancreatitis in
      two of three family members with severe COVID-19 infection. METHODS: Data were
      collected from three family members admitted with COVID-19 to the intensive care 
      unit in March 2020. This study was reviewed and approved by the local data and
      ethics committee (31-1521-253). RESULTS: Two of the three family members were
      diagnosed with acute pancreatitis associated with SARS-CoV-2. Other causes of
      acute pancreatitis were excluded for both patients (including alcohol, biliary
      obstruction/gall stones, drugs, trauma, hypertriglyceridemia, hypercalcemia, and 
      hypotension). CONCLUSIONS: These cases highlight acute pancreatitis as a
      complication associated with COVID-19 and underlines the importance of measuring 
      pancreas-specific plasma amylase in patients with COVID-19 and abdominal pain.
CI  - Copyright (c) 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.
FAU - Hadi, Amer
AU  - Hadi A
AD  - Pancreatitis Centre East, Gastrounit, Copenhagen University Hospital Hvidovre,
      Hvidovre, Denmark. Electronic address: amer.hadi@regionh.dk.
FAU - Werge, Mikkel
AU  - Werge M
AD  - Pancreatitis Centre East, Gastrounit, Copenhagen University Hospital Hvidovre,
      Hvidovre, Denmark.
FAU - Kristiansen, Klaus Tjelle
AU  - Kristiansen KT
AD  - Intensive Care Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
FAU - Pedersen, Ulf Gottrup
AU  - Pedersen UG
AD  - Intensive Care Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
FAU - Karstensen, John Gasdal
AU  - Karstensen JG
AD  - Pancreatitis Centre East, Gastrounit, Copenhagen University Hospital Hvidovre,
      Hvidovre, Denmark; Department of Clinical Medicine, University of Copenhagen,
      Denmark.
FAU - Novovic, Srdan
AU  - Novovic S
AD  - Pancreatitis Centre East, Gastrounit, Copenhagen University Hospital Hvidovre,
      Hvidovre, Denmark; Department of Clinical Medicine, University of Copenhagen,
      Denmark. Electronic address: lise.lotte.gluud.01@regionh.dk.
FAU - Gluud, Lise Lotte
AU  - Gluud LL
AD  - Pancreatitis Centre East, Gastrounit, Copenhagen University Hospital Hvidovre,
      Hvidovre, Denmark; Department of Clinical Medicine, University of Copenhagen,
      Denmark.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200505
PL  - Switzerland
TA  - Pancreatology
JT  - Pancreatology : official journal of the International Association of
      Pancreatology (IAP) ... [et al.]
JID - 100966936
RN  - EC 3.2.1.- (Amylases)
SB  - IM
MH  - Abdominal Pain/etiology
MH  - Acute Disease
MH  - Aged
MH  - Amylases/blood
MH  - COVID-19
MH  - Coronavirus Infections/blood/*complications/diagnostic imaging
MH  - Critical Care
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pancreatitis/blood/diagnostic imaging/*etiology
MH  - Pandemics
MH  - Pneumonia, Viral/blood/*complications/diagnostic imaging
MH  - Radiography
MH  - Thorax/diagnostic imaging
MH  - Ultrasonography
PMC - PMC7199002
OTO - NOTNLM
OT  - Acute pancreatitis
OT  - COVID-19
OT  - SARS-CoV-2
OT  - Severe acute pancreatitis
OT  - Viral pancreatitis
COIS- Declaration of competing interest None reported.
EDAT- 2020/05/11 06:00
MHDA- 2020/06/12 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/04/25 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S1424-3903(20)30147-2 [pii]
AID - 10.1016/j.pan.2020.04.021 [doi]
PST - ppublish
SO  - Pancreatology. 2020 Jun;20(4):665-667. doi: 10.1016/j.pan.2020.04.021. Epub 2020 
      May 5.


PMID- 32387041
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20210110
IS  - 1873-5487 (Electronic)
IS  - 0188-4409 (Linking)
VI  - 51
IP  - 6
DP  - 2020 Aug
TI  - COVID-19 and Moral Imperialism in Multinational Clinical Research.
PG  - 572-573
LID - S0188-4409(20)30571-3 [pii]
LID - 10.1016/j.arcmed.2020.04.017 [doi]
AB  - A TV debate in April 2020 between two French doctors regarding the benefits of
      testing a coronavirus vaccine in Africa where there are no masks or treatments
      available has led to international criticism. This case highlights a problematic 
      ethical double standard in multinational clinical research: trials that would be 
      considered unethical in high income countries (e.g., placebo-controlled where
      there is an existing treatment) are nonetheless justified in
      low-and-middle-income countries because the existing standards of care are less
      (i.e., no access to a treatment). Underlying this ethical double standard in some
      multinational clinical trials is a moral imperialism and persistent colonialist
      thinking that must be rejected.
CI  - (c) 2020 IMSS. Published by Elsevier Inc.
FAU - Hellmann, Fernando
AU  - Hellmann F
AD  - Department of Public Health, Federal University of Santa Catarina, Campus
      Universitario Reitor Joao David Ferreira Lima, Santa Catarina, Brazil. Electronic
      address: fernando.hellmann@ufsc.br.
FAU - Williams-Jones, Bryn
AU  - Williams-Jones B
AD  - Bioethics Program, Department of Social and Preventive Medicine, School of Public
      Health, Universite de Montreal, Quebec, Canada.
FAU - Garrafa, Volnei
AU  - Garrafa V
AD  - UNESCO Chair and Post Graduate Program in Bioethics, University of Brasilia,
      Brasilia, DF, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Africa
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials as Topic/*ethics
MH  - Colonialism
MH  - Coronavirus Infections/*diagnosis/*prevention & control
MH  - Developing Countries
MH  - Ethical Relativism
MH  - *Ethics, Research
MH  - France
MH  - Human Experimentation/ethics
MH  - Humans
MH  - Moral Obligations
MH  - Pandemics/*prevention & control
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*diagnosis/*prevention & control
MH  - Research Subjects
MH  - SARS-CoV-2
MH  - Viral Vaccines/*therapeutic use
PMC - PMC7188637
OTO - NOTNLM
OT  - *COVID-19
OT  - *Clinical trials
OT  - *Colonialism
OT  - *Ethics
OT  - *Low-and-middle-income countries
OT  - *Research design
EDAT- 2020/05/11 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S0188-4409(20)30571-3 [pii]
AID - 10.1016/j.arcmed.2020.04.017 [doi]
PST - ppublish
SO  - Arch Med Res. 2020 Aug;51(6):572-573. doi: 10.1016/j.arcmed.2020.04.017. Epub
      2020 Apr 29.


PMID- 32386699
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20201030
IS  - 1556-4088 (Electronic)
IS  - 1556-407X (Linking)
VI  - 15
IP  - 2
DP  - 2020 Jun
TI  - Avoiding and Managing Oral Appliance Therapy Side Effects.
PG  - 251-260
LID - S1556-407X(20)30022-9 [pii]
LID - 10.1016/j.jsmc.2020.02.011 [doi]
AB  - There is a serious need to consider all potential side effects thoughtfully
      before commencing individual treatment with oral appliance therapy. Although many
      of these side effects are self-limiting, easily corrected, or innocuous, others
      are difficult or impossible to correct and can affect the patient in serious
      ways. As this field evolves, new information is discovered, and new products are 
      introduced at a rather rapid pace, continuing education and prudent practice are 
      critical to ethical care in the practice of dental sleep medicine.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Schell, Thomas G
AU  - Schell TG
AD  - Dr Thomas G Schell and Dr. Patrick C Noble PLLC, 31 Old Etna Road, N1 Lebanon, NH
      03770, USA; Department of Surgery, Dartmouth Geisel School of Medicine, 1 Rope
      Ferry Road, Hanover, NH 03755-1404, USA. Electronic address: tgschell@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Sleep Med Clin
JT  - Sleep medicine clinics
JID - 101271531
SB  - IM
MH  - Humans
MH  - Mandibular Advancement/*adverse effects
MH  - Sleep Apnea, Obstructive/*therapy
OTO - NOTNLM
OT  - Dental sleep medicine
OT  - Obstructive sleep apnea
OT  - Oral appliance therapy
OT  - Side effects of OAT
EDAT- 2020/05/11 06:00
MHDA- 2020/10/31 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/05/11 06:00 [entrez]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
AID - S1556-407X(20)30022-9 [pii]
AID - 10.1016/j.jsmc.2020.02.011 [doi]
PST - ppublish
SO  - Sleep Med Clin. 2020 Jun;15(2):251-260. doi: 10.1016/j.jsmc.2020.02.011.


PMID- 32386618
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210409
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 113
IP  - 5
DP  - 2020 May
TI  - Selecting the optimal gestational carrier: medical, reproductive, and ethical
      considerations.
PG  - 892-896
LID - S0015-0282(20)30300-9 [pii]
LID - 10.1016/j.fertnstert.2020.03.024 [doi]
AB  - The goals of a gestational surrogacy relationship are to have a healthy baby for 
      the intended parents while maintaining the medical and psychological well-being
      of the gestational carrier. A successful gestational surrogacy relationship will 
      result also in good psychosocial outcomes for the gestational carrier, intended
      parents, and child. Finding a gestational carrier who will achieve these goals
      would be the ideal. This article focuses on key medical, reproductive, and
      ethical considerations to optimize clinical outcomes in gestational carrier
      cycles. Recommendations from available clinical guidelines regarding gestational 
      surrogacy are reviewed, along with updates from current literature.
CI  - Copyright (c) 2020 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Kim, Helen H
AU  - Kim HH
AD  - Division of Reproductive Endocrinology and Infertility, Department of Obstetrics 
      and Gynecology, Northwestern University Feinberg School of Medicine, Chicago,
      Illinois. Electronic address: helen.kim1@northwestern.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
CIN - Fertil Steril. 2020 Aug;114(2):287. PMID: 32622658
MH  - Choice Behavior
MH  - Humans
MH  - Live Birth
MH  - Maternal Health
MH  - Policy Making
MH  - *Reproductive Medicine/ethics/legislation & jurisprudence
MH  - *Reproductive Techniques, Assisted/adverse effects/ethics/legislation &
      jurisprudence/psychology
MH  - *Surrogate Mothers/legislation & jurisprudence/psychology
OTO - NOTNLM
OT  - *Gestational carrier
OT  - *gestational carrier criteria
OT  - *gestational carrier outcome
OT  - *gestational carrier selection
OT  - *interpregnancy interval
EDAT- 2020/05/11 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/03/02 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/05/11 06:00 [entrez]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - S0015-0282(20)30300-9 [pii]
AID - 10.1016/j.fertnstert.2020.03.024 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 May;113(5):892-896. doi: 10.1016/j.fertnstert.2020.03.024.


PMID- 32386611
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210219
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - From the micro to the macro to improve health: microorganism ecology and society 
      in teaching infectious disease epidemiology.
PG  - e142-e147
LID - S1473-3099(20)30136-5 [pii]
LID - 10.1016/S1473-3099(20)30136-5 [doi]
AB  - Chronic and emerging infectious diseases and antimicrobial resistance remain a
      substantial global health threat. Microbiota are increasingly recognised to play 
      an important role in health. Infections also have a profound effect beyond
      health, especially on global and local economies. To maximise health
      improvements, the field of infectious disease epidemiology needs to derive
      learning from ecology and traditional epidemiology. New methodologies and tools
      are transforming understanding of these systems, from a better understanding of
      socioeconomic, environmental, and cultural drivers of infection, to improved
      methods to detect microorganisms, describe the immunome, and understand the role 
      of human microbiota. However, exploiting the potential of novel methods to
      improve global health remains elusive. We argue that to exploit these advances a 
      shift is required in the teaching of infectious disease epidemiology to ensure
      that students are well versed in a breadth of disciplines, while maintaining core
      epidemiological skills. We discuss the following key points using a series of
      teaching vignettes: (1) integrated training in classic and novel techniques is
      needed to develop future scientists and professionals who can work from the micro
      (interactions between pathogens, their cohabiting microbiota, and the host at a
      molecular and cellular level), with the meso (the affected communities), and to
      the macro (wider contextual drivers of disease); (2) teach students to use a
      team-science multidisciplinary approach to effectively integrate biological,
      clinical, epidemiological, and social tools into public health; and (3) develop
      the intellectual skills to critically engage with emerging technologies and
      resolve evolving ethical dilemmas. Finally, students should appreciate that the
      voices of communities affected by infection need to be kept at the heart of their
      work.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Shahmanesh, Maryam
AU  - Shahmanesh M
AD  - Institute for Global Health, University College London, London, UK; Africa Health
      Research Institute, Durban, South Africa. Electronic address:
      m.shahmanesh@ucl.ac.uk.
FAU - Harling, Guy
AU  - Harling G
AD  - Institute for Global Health, University College London, London, UK; Africa Health
      Research Institute, Durban, South Africa; MRC/Wits-Agincourt Unit, University of 
      the Witwatersrand, Johannesburg, South Africa; Harvard Centre for Population and 
      Development Studies, Harvard T H Chan School of Public Health, Boston, MA, USA.
FAU - Coltart, Cordelia E M
AU  - Coltart CEM
AD  - Institute for Global Health, University College London, London, UK.
FAU - Bailey, Heather
AU  - Bailey H
AD  - Institute for Global Health, University College London, London, UK.
FAU - King, Carina
AU  - King C
AD  - Institute for Global Health, University College London, London, UK; Department of
      Public Health Sciences, Karolinska Institutet, Solna, Sweden.
FAU - Gibbs, Jo
AU  - Gibbs J
AD  - Institute for Global Health, University College London, London, UK.
FAU - Seeley, Janet
AU  - Seeley J
AD  - Africa Health Research Institute, Durban, South Africa; London School of Hygiene 
      and Tropical Medicine, London, UK.
FAU - Phillips, Andrew
AU  - Phillips A
AD  - Institute for Global Health, University College London, London, UK.
FAU - Sabin, Caroline A
AU  - Sabin CA
AD  - Institute for Global Health, University College London, London, UK.
FAU - Aldridge, Robert W
AU  - Aldridge RW
AD  - Institute of Health Informatics, University College London, London, UK.
FAU - Sonnenberg, Pam
AU  - Sonnenberg P
AD  - Institute for Global Health, University College London, London, UK.
FAU - Hart, Graham
AU  - Hart G
AD  - Institute for Global Health, University College London, London, UK.
FAU - Rowson, Mike
AU  - Rowson M
AD  - Institute for Global Health, University College London, London, UK.
FAU - Pillay, Deenan
AU  - Pillay D
AD  - Division of infection and immunity, University College London, London, UK; Africa
      Health Research Institute, Durban, South Africa.
FAU - Johnson, Anne M
AU  - Johnson AM
AD  - Institute for Global Health, University College London, London, UK.
FAU - Abubakar, Ibrahim
AU  - Abubakar I
AD  - Institute for Global Health, University College London, London, UK.
FAU - Field, Nigel
AU  - Field N
AD  - Institute for Global Health, University College London, London, UK.
LA  - eng
GR  - 082384/Z/07/Z/WT_/Wellcome Trust/United Kingdom
GR  - R01 HL131049/HL/NHLBI NIH HHS/United States
GR  - WT_/Wellcome Trust/United Kingdom
GR  - NF-SI-0616-10037/DH_/Department of Health/United Kingdom
GR  - R01 MH114560/MH/NIMH NIH HHS/United States
GR  - 210479/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200507
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
SB  - IM
MH  - Communicable Disease Control/*methods
MH  - Communicable Diseases/*epidemiology
MH  - *Environmental Microbiology
MH  - Humans
MH  - *Microbiota
MH  - Public Health/education
PMC - PMC7252039
EDAT- 2020/05/11 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/11 06:00
PHST- 2019/06/06 00:00 [received]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/02/18 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S1473-3099(20)30136-5 [pii]
AID - 10.1016/S1473-3099(20)30136-5 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2020 Jun;20(6):e142-e147. doi: 10.1016/S1473-3099(20)30136-5. 
      Epub 2020 May 7.


PMID- 32386564
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20220213
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 395
IP  - 10238
DP  - 2020 May 30
TI  - Access to lifesaving medical resources for African countries: COVID-19 testing
      and response, ethics, and politics.
PG  - 1735-1738
LID - S0140-6736(20)31093-X [pii]
LID - 10.1016/S0140-6736(20)31093-X [doi]
FAU - Kavanagh, Matthew M
AU  - Kavanagh MM
AD  - Department of International Health, Washington DC, USA; O'Neill Institute for
      National and Global Health Law, Washington DC, USA. Electronic address:
      matthew.kavanagh@georgetown.edu.
FAU - Erondu, Ngozi A
AU  - Erondu NA
AD  - Centre for Universal Health, Chatham House, London, UK.
FAU - Tomori, Oyewale
AU  - Tomori O
AD  - Redeemer's University, Ede, Nigeria.
FAU - Dzau, Victor J
AU  - Dzau VJ
AD  - US National Academy of Medicine, Washington DC, USA.
FAU - Okiro, Emelda A
AU  - Okiro EA
AD  - KEMRI-Wellcome Trust Research Programme, Narobi, Kenya.
FAU - Maleche, Allan
AU  - Maleche A
AD  - Kenya Legal and Ethical Issues Network on HIV and AIDS, Narobi, Kenya.
FAU - Aniebo, Ifeyinwa C
AU  - Aniebo IC
AD  - Health Strategy and Delivery Foundation, Abuja, Nigeria; TH Chan School of Public
      Health, Harvard University, Boston, MA, USA.
FAU - Rugege, Umunya
AU  - Rugege U
AD  - Section 27, Johannesburg, South Africa.
FAU - Holmes, Charles B
AU  - Holmes CB
AD  - School of Medicine, Georgetown University, Washington DC, USA.
FAU - Gostin, Lawrence O
AU  - Gostin LO
AD  - O'Neill Institute for National and Global Health Law, Washington DC, USA.
LA  - eng
GR  - 201866/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200507
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Africa
MH  - Betacoronavirus
MH  - COVID-19
MH  - COVID-19 Testing
MH  - Clinical Laboratory Techniques/ethics
MH  - Coronavirus Infections/*diagnosis/*epidemiology
MH  - Health Resources/*supply & distribution
MH  - Health Services Accessibility/*ethics
MH  - Human Rights
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnosis/*epidemiology
MH  - Politics
MH  - Reagent Kits, Diagnostic/supply & distribution
MH  - SARS-CoV-2
PMC - PMC7252104
EDAT- 2020/05/11 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/05/11 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/05/01 00:00 [accepted]
PHST- 2020/05/11 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
PHST- 2020/05/11 06:00 [entrez]
AID - S0140-6736(20)31093-X [pii]
AID - 10.1016/S0140-6736(20)31093-X [doi]
PST - ppublish
SO  - Lancet. 2020 May 30;395(10238):1735-1738. doi: 10.1016/S0140-6736(20)31093-X.
      Epub 2020 May 7.


PMID- 32385829
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210110
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Dec
TI  - COVID-19 and off label use of drugs: an ethical viewpoint.
PG  - 789-793
LID - 10.1007/s40199-020-00351-y [doi]
AB  - BACKGROUND: The COVID-19 outbreak is rapidly spread over the world and kills
      infected patients. There is no proven medication for its treatment, so, all of
      the medications used for treatment are considered to be off-label. Off-label uses
      are not under regulation in the outbreak because there is no specific regulation 
      for this condition. OBJECTIVES: In this short communication we aim at describing 
      two ways of off-label use as clinical practice or investigational use. Further,
      we will describe the third way of off-label use, we named it pseudo-research and 
      then we will state the most possible ethical challenges of off-label use for
      better perceptions and responsibility. RESULTS: The WHO considers off-label uses 
      as country-specific. All international regulatory bodies consider off-label
      prescription as the physician's responsibility and legal by necessitating some
      requirements. There is no international guideline for regulating investigational 
      off-label uses as clinical practice. CONCLUSION: There are different types of
      approaches, none of them is comprehensive and conclusive. Furthermore, respecting
      the four ethical principles necessitates codification and strict regulation of
      off-label uses either as clinical practice or investigational. Besides,
      compilation of a special guideline based on ethical principles especially
      non-maleficence and autonomy for investigational off-label uses in disasters is
      highly recommended.
FAU - Shojaei, Amirahmad
AU  - Shojaei A
AD  - Department of Medical Ethics, Medical Ethics and History of Medicine Research
      Center, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Salari, Pooneh
AU  - Salari P
AUID- ORCID: http://orcid.org/0000-0001-5595-0087
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, 23# 16 Azar Ave, Keshavarz Blvd, Tehran, Iran.
      poonehsalari@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - COVID-19 drug treatment
SB  - IM
MH  - COVID-19/*drug therapy/virology
MH  - Drug and Narcotic Control/legislation & jurisprudence
MH  - *Ethics, Medical
MH  - Humans
MH  - *Off-Label Use/ethics
PMC - PMC7207985
OTO - NOTNLM
OT  - Ethical challenges
OT  - Investigational off-label uses
OT  - Off-label prescription
OT  - Off-label uses
EDAT- 2020/05/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/10 06:00 [entrez]
AID - 10.1007/s40199-020-00351-y [doi]
AID - 10.1007/s40199-020-00351-y [pii]
PST - ppublish
SO  - Daru. 2020 Dec;28(2):789-793. doi: 10.1007/s40199-020-00351-y. Epub 2020 May 8.


PMID- 32385811
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20220223
IS  - 1654-7209 (Electronic)
IS  - 0044-7447 (Linking)
VI  - 49
IP  - 12
DP  - 2020 Dec
TI  - Transitioning towards human-large carnivore coexistence in extensive grazing
      systems.
PG  - 1982-1991
LID - 10.1007/s13280-020-01340-w [doi]
AB  - In light of escalating threats to biodiversity, conflicts between humans and
      large carnivores in production landscapes must be resolved. We explore how
      interactions between humans, large carnivores, and livestock can be modified to
      promote coexistence. We identify four rationales for building coexistence
      capacities in extensive rangeland livestock production systems: (1) livestock
      production is a dominant terrestrial land use; (2) large carnivores provide
      critical contributions to ecological functions; (3) the persecution of large
      carnivores has high ethical, welfare, reputational and social costs; and (4) a
      growing body of evidence shows that lethal control can be counterproductive to
      reducing predation risk. Two key leverage points to foster human-carnivore
      coexistence are the adoption of preventive non-lethal innovations, and the
      creation of an enabling environment. Leverage points must be appropriate at the
      local landscape scale and contribute towards global efforts to conserve large
      carnivores.
FAU - Boronyak, Louise
AU  - Boronyak L
AUID- ORCID: http://orcid.org/0000-0001-9932-0394
AD  - Institute for Sustainable Futures, University of Technology Sydney, PO BOX 123,
      Ultimo, NSW, 2007, Australia. Louise.Boronyak@uts.edu.au.
FAU - Jacobs, Brent
AU  - Jacobs B
AD  - Institute for Sustainable Futures, University of Technology Sydney, PO BOX 123,
      Ultimo, NSW, 2007, Australia.
FAU - Wallach, Arian
AU  - Wallach A
AD  - School of Life Sciences and the Centre for Compassionate Conservation, University
      of Technology Sydney, PO BOX 123, Ultimo, NSW, 2007, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200508
PL  - Sweden
TA  - Ambio
JT  - Ambio
JID - 0364220
SB  - IM
MH  - Animals
MH  - Biodiversity
MH  - *Carnivora
MH  - *Conservation of Natural Resources
MH  - Humans
MH  - Livestock
MH  - Predatory Behavior
PMC - PMC7568737
OTO - NOTNLM
OT  - Human-wildlife conflict
OT  - Large carnivore conservation
OT  - Predator friendly farming
OT  - Social ecological systems
EDAT- 2020/05/10 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/04/18 00:00 [accepted]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/10 06:00 [entrez]
AID - 10.1007/s13280-020-01340-w [doi]
AID - 10.1007/s13280-020-01340-w [pii]
PST - ppublish
SO  - Ambio. 2020 Dec;49(12):1982-1991. doi: 10.1007/s13280-020-01340-w. Epub 2020 May 
      8.


PMID- 32385650
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1432-1084 (Electronic)
IS  - 0938-7994 (Linking)
VI  - 30
IP  - 10
DP  - 2020 Oct
TI  - Speed of sound ultrasound: comparison with proton density fat fraction assessed
      with Dixon MRI for fat content quantification of the lower extremity.
PG  - 5272-5280
LID - 10.1007/s00330-020-06885-8 [doi]
AB  - OBJECTIVES: To compare speed of sound (SoS) ultrasound (US) of the calves with
      Dixon magnetic resonance imaging (MRI) for fat content quantification. MATERIALS 
      AND METHODS: The study was approved by the local ethics committee. Fifty calf
      muscles of 35 women (age range 22-81 years) prospectively underwent an US and
      subsequent MRI (Dixon sequence) examination as well as body weight and impedance 
      fat measurements. SoS (in m/s) was calculated positioning a reflector on the
      opposite side of a conventional US machine probe with the calf in between.
      Fiducial nitroglycerin markers were placed on the calf at the reflector and US
      probe end positions for later registration of the US sonification volumetric
      section. An automatic segmentation algorithm separated MRI adipose tissue, muscle
      and bone regions. MRI fat fraction of the entire leg slice (total) and
      intramuscular and adipose tissue fat fraction were calculated and correlation
      analysis and correlation coefficient comparison were performed. RESULTS: Median
      SoS demonstrated a very strong (r = - 0.83 (95% CI - 0.90; - 0.72); p < 0.001)
      correlation with MRI total fat fraction, a strong (r = - 0.61 (95% CI - 0.76; -
      0.40); p < 0.001) correlation with MRI adipose tissue fat fraction and a moderate
      (r = - 0.54 (95% CI - 0.71; - 0.31); p < 0.001) correlation with MRI
      intramuscular fat fraction. Impedance body fat percentage correlated strongly
      with SoS (r = - 0.72 (95% CI - 0.85; - 0.51); p < 0.001) and MRI total fat
      fraction (r = 0.61 (95% CI 0.34; 0.78); p < 0.001). For electrical impedance,
      significantly lower correlations (p = 0.033) were found for MRI total fat
      fraction compared with SoS. CONCLUSIONS: Correlations of SoS with Dixon MRI fat
      fraction measurements were very strong to moderate. KEY POINTS: * Correlations of
      speed of sound with Dixon MRI fat fraction measurements of the same body location
      were very strong to moderate. * Speed of sound measurements showed a high
      repeatability. * Speed of sound provides a sufficient discrimination range for
      fat fraction estimates.
FAU - Ruby, Lisa
AU  - Ruby L
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland. lisa.ruby@usz.ch.
FAU - Kunut, Ahmet
AU  - Kunut A
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland.
FAU - Nakhostin, Dominik N
AU  - Nakhostin DN
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland.
FAU - Huber, Florian A
AU  - Huber FA
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland.
FAU - Finkenstaedt, Tim
AU  - Finkenstaedt T
AD  - Institute of Diagnostic and Interventional Radiology, University Hospital Zurich,
      Ramistrasse 100, 8091, Zurich, Switzerland.
FAU - Frauenfelder, Thomas
AU  - Frauenfelder T
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland.
FAU - Sanabria, Sergio J
AU  - Sanabria SJ
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland.
FAU - Rominger, Marga B
AU  - Rominger MB
AD  - Zurich Ultrasound Research and Translation (ZURT), Institute of Diagnostic and
      Interventional Radiology, University Hospital Zurich, Ramistrasse 100, 8091,
      Zurich, Switzerland.
LA  - eng
GR  - ./University Hospital of Zurich Foundation
PT  - Comparative Study
PT  - Journal Article
DEP - 20200508
PL  - Germany
TA  - Eur Radiol
JT  - European radiology
JID - 9114774
RN  - 0 (Protons)
SB  - IM
MH  - Adipose Tissue/*diagnostic imaging
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Algorithms
MH  - Animals
MH  - Cattle
MH  - Female
MH  - Humans
MH  - Lower Extremity
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*diagnostic imaging
MH  - Protons
MH  - Ultrasonography/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - Adipose tissue
OT  - Magnetic resonance imaging
OT  - Skeletal muscle
OT  - Ultrasonography
EDAT- 2020/05/10 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/05/10 06:00
PHST- 2019/12/24 00:00 [received]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/03/24 00:00 [revised]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/05/10 06:00 [entrez]
AID - 10.1007/s00330-020-06885-8 [doi]
AID - 10.1007/s00330-020-06885-8 [pii]
PST - ppublish
SO  - Eur Radiol. 2020 Oct;30(10):5272-5280. doi: 10.1007/s00330-020-06885-8. Epub 2020
      May 8.


PMID- 32385186
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20211217
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 95
IP  - 3
DP  - 2020 Jul 21
TI  - Preserving stroke care during the COVID-19 pandemic: Potential issues and
      solutions.
PG  - 124-133
LID - 10.1212/WNL.0000000000009713 [doi]
AB  - The coronavirus 2019 (COVID-19) pandemic requires drastic changes in allocation
      of resources, which can affect the delivery of stroke care, and many providers
      are seeking guidance. As caregivers, we are guided by 3 distinct principles that 
      will occasionally conflict during the pandemic: (1) we must ensure the best care 
      for those stricken with COVID-19, (2) we must provide excellent care and advocacy
      for patients with cerebrovascular disease and their families, and (3) we must
      advocate for the safety of health care personnel managing patients with stroke,
      with particular attention to those most vulnerable, including trainees. This
      descriptive review by a diverse group of experts in stroke care aims to provide
      advice by specifically addressing the potential impact of this pandemic on (1)
      the quality of the stroke care delivered, (2) ethical considerations in stroke
      care, (3) safety and logistic issues for providers of patients with stroke, and
      (4) stroke research. Our recommendations on these issues represent our best
      opinions given the available information, but are subject to revision as the
      situation related to the COVID-19 pandemic continues to evolve. We expect that
      ongoing emergent research will offer additional insights that will provide
      evidence that could prompt the modification or removal of some of these
      recommendations.
CI  - (c) 2020 American Academy of Neurology.
FAU - Leira, Enrique C
AU  - Leira EC
AUID- ORCID: 0000-0003-3695-2946
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
      enrique-leira@uiowa.edu.
FAU - Russman, Andrew N
AU  - Russman AN
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Biller, Jose
AU  - Biller J
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Brown, Devin L
AU  - Brown DL
AUID- ORCID: 0000-0002-9815-3421
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Bushnell, Cheryl D
AU  - Bushnell CD
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Caso, Valeria
AU  - Caso V
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Chamorro, Angel
AU  - Chamorro A
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Creutzfeldt, Claire J
AU  - Creutzfeldt CJ
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Cruz-Flores, Salvador
AU  - Cruz-Flores S
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Elkind, Mitchell S V
AU  - Elkind MSV
AUID- ORCID: 0000-0003-2562-1156
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Fayad, Pierre
AU  - Fayad P
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Froehler, Michael T
AU  - Froehler MT
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Goldstein, Larry B
AU  - Goldstein LB
AUID- ORCID: 0000-0001-7747-128X
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Gonzales, Nicole R
AU  - Gonzales NR
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Kaskie, Brian
AU  - Kaskie B
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Khatri, Pooja
AU  - Khatri P
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Livesay, Sarah
AU  - Livesay S
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Liebeskind, David S
AU  - Liebeskind DS
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Majersik, Jennifer J
AU  - Majersik JJ
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Moheet, Asma M
AU  - Moheet AM
AUID- ORCID: 0000-0001-9133-4660
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Romano, Jose G
AU  - Romano JG
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Sanossian, Nerses
AU  - Sanossian N
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Sansing, Lauren H
AU  - Sansing LH
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Silver, Brian
AU  - Silver B
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Simpkins, Alexis N
AU  - Simpkins AN
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Smith, Wade
AU  - Smith W
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Tirschwell, David L
AU  - Tirschwell DL
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Wang, David Z
AU  - Wang DZ
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Yavagal, Dileep R
AU  - Yavagal DR
AUID- ORCID: 0000-0003-4739-0133
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
FAU - Worrall, Bradford B
AU  - Worrall BB
AUID- ORCID: 0000-0001-9386-4091
AD  - From the Departments of Neurology, Neurosurgery & Epidemiology (E.C.L.),
      University of Iowa, Iowa City, IA; Cerebrovascular Center (A.N.R.), Cleveland
      Clinic, OH; Department of Neurology (J.B.), Loyola University Chicago, Maywood,
      IL; Department of Neurology (D.L.B.), University of Michigan, Ann Arbor, MI;
      Department of Neurology (C.D.B.), Wake Forest School of Medicine, Winston-Salem, 
      NC; Stroke Unit (V.C.), University of Perugia, Italy; Department of Neurology
      (A.C.), Hospital Clinic, Barcelona, Spain; Department of Neurology (C.J.C.,
      D.L.T.), University of Washington, Seattle, WA; Department of Neurology
      (S.C.-F.), Texas Tech University, El Paso, TX; Departments of Neurology &
      Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of
      Neurological Sciences (P.F.), University of Nebraska, Omaha, NE; Department of
      Neurology & Neurosurgery (M.T.F.), Vanderbilt University, Nashville, TN;
      Department of Neurology (L.B.G.), University of Kentucky, Lexington, KY;
      Department of Neurology (N.R.G.), McGovern Medical School at UTHealth, Houston,
      TX; Department of Health Management and Policy (B.K.), University of Iowa, Iowa
      City, IA; Department of Neurology (P.K.), University of Cincinnati, OH;
      Department of Adult Health & Gerontology Nursing (S.L.), Rush University,
      Chicago, IL; Department of Neurology (D.S.L.), UCLA; Department of Neurology
      (J.J.M.), University of Utah, Salt Lake City, UT; Neurocritical Care, OhioHealth 
      Riverside Methodist Hospital (A.M.M.), Columbus, OH; Department of Neurology
      (J.G.R.), University of Miami, FL; Department of Neurology (N.S.), University
      Southern California, Los Angeles, CA; Department of Neurology (L.H.S.), Yale
      School of Medicine, New Haven, CT; Department of Neurology (B.S.), University of 
      Massachusetts, Worcester, MA; Department of Neurology (A.N.S.), University of
      Florida, Gainesville, FL; Department of Neurology (W.S.), UCSF; Department of
      Neurology (D.Z.W.), Barrow Neurological Institute, Phoenix, AZ; Department of
      Neurology & Neurosurgery (D.R.Y.), University of Miami, FL; and Department of
      Neurology (B.B.W.), University of Virginia, Charlottesville, VA.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200508
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - *Delivery of Health Care
MH  - Ethics, Medical
MH  - Health Care Rationing/ethics
MH  - Health Resources
MH  - Health Services Accessibility
MH  - *Health Services Needs and Demand
MH  - Hospital Bed Capacity
MH  - Humans
MH  - Intensive Care Units
MH  - Neurology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - *Quality of Health Care
MH  - SARS-CoV-2
MH  - Stroke/*therapy
MH  - Telemedicine
PMC - PMC7455350
EDAT- 2020/05/10 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/05/10 06:00 [entrez]
AID - WNL.0000000000009713 [pii]
AID - 10.1212/WNL.0000000000009713 [doi]
PST - ppublish
SO  - Neurology. 2020 Jul 21;95(3):124-133. doi: 10.1212/WNL.0000000000009713. Epub
      2020 May 8.


PMID- 32385064
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 7
TI  - Nutritional Outcomes of patients Undergoing Resection for upper gastroIntestinal 
      cancer in AuStralian Hospitals (NOURISH): protocol for a multicentre point
      prevalence study.
PG  - e035824
LID - 10.1136/bmjopen-2019-035824 [doi]
AB  - INTRODUCTION: Nutritional intervention and prevention of malnutrition is
      significantly important for patients with upper gastrointestinal oesophageal,
      pancreatic and gastric cancer. However, there is limited information regarding
      nutritional status, and perioperative nutritional interventions that patients
      receive when undergoing curative surgery. METHODS AND ANALYSIS: Patients
      diagnosed with upper gastrointestinal cancer, planned for curative intent
      resection across 27 Australian hospitals will be eligible to participate in this 
      point prevalence study. The primary aim is to determine the prevalence of
      malnutrition in patients with upper gastrointestinal cancer at the time of
      surgery using subjective global assessment. Secondary aims are to determine the
      type and frequency of perioperative nutritional intervention received, the
      prevalence of clinically important weight loss and low muscle strength, and to
      investigate associations between the use of an evidence-based nutrition care
      pathway or protocol for the nutritional management of upper gastrointestinal
      surgical oncology patients and malnutrition prevalence. Data collection will be
      completed using a purpose-built data collection tool. ETHICS AND DISSEMINATION:
      Ethical approval was granted in May 2019 (LNR/51107/PMCC-2019). The design and
      reporting of this study comply with the Strengthening the Reporting of
      Observational Studies in Epidemiology checklist for reporting of observational
      cohort studies. Findings will be published in peer-reviewed scholarly journals
      and presented at relevant conferences. Results will assist in defining priority
      areas for research to improve patient outcomes.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Deftereos, Irene
AU  - Deftereos I
AUID- ORCID: 0000-0002-3822-147X
AD  - Department of Surgery Western Health, The University of Melbourne, Melbourne,
      Victoria, Australia irene.deftereos@unimelb.edu.au.
AD  - Nutrition and Dietetics, Western Health, Footscray, Victoria, Australia.
FAU - Yeung, Justin M C
AU  - Yeung JMC
AD  - Department of Surgery Western Health, The University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Department of Colorectal Surgery, Western Health, Footscray, Victoria, Australia.
AD  - Western Chronic Disease Alliance, Western Health, Melbourne, Victoria, Australia.
FAU - Carter, Vanessa M
AU  - Carter VM
AD  - Nutrition and Dietetics, Western Health, Footscray, Victoria, Australia.
FAU - Isenring, Elizabeth
AU  - Isenring E
AD  - Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland,
      Australia.
AD  - Department of Nutrition and Dietetics, Princess Alexandra Hospital, Brisbane,
      Queensland, Australia.
FAU - Kiss, Nicole K
AU  - Kiss NK
AD  - Institute for Physical Activity and Nutrition, Deakin University, Geelong,
      Victoria, Australia.
AD  - Department of Cancer Experiences Research, Peter MacCallum Cancer Centre,
      Melbourne, Victoria, Australia.
CN  - NOURISH Point Prevalence Study Group
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Australia/epidemiology
MH  - Body Mass Index
MH  - Cohort Studies
MH  - Female
MH  - Gastrointestinal Neoplasms/*surgery
MH  - Hospitals
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Malnutrition/*epidemiology
MH  - Middle Aged
MH  - Muscle Strength/physiology
MH  - *Nutrition Assessment
MH  - Nutrition Therapy
MH  - *Patients
MH  - Prevalence
MH  - Weight Loss/physiology
PMC - PMC7228529
OTO - NOTNLM
OT  - *adult surgery
OT  - *gastrointestinal tumours
OT  - *nutrition & dietetics
OT  - *nutritional support
COIS- Competing interests: None declared.
IR  - Cardamis A
FIR - Cardamis, Anna
IR  - Dorey A
FIR - Dorey, Annika
IR  - Ottaway A
FIR - Ottaway, Aurora
IR  - Maguire B
FIR - Maguire, Brook
IR  - Cleeve B
FIR - Cleeve, Brydie
IR  - Davis C
FIR - Davis, Caitlin
IR  - Choong C
FIR - Choong, Christine
IR  - Douglas C
FIR - Douglas, Claire
IR  - Nixon C
FIR - Nixon, Claire
IR  - Platt D
FIR - Platt, Daniel
IR  - Quinn E
FIR - Quinn, Eleanor
IR  - Simpson E
FIR - Simpson, Eliza
IR  - Hamdorf E
FIR - Hamdorf, Emma
IR  - McNamara E
FIR - McNamara, Emma
IR  - Whelan E
FIR - Whelan, Emma
IR  - Jegendran G
FIR - Jegendran, Gayathri
IR  - Moore G
FIR - Moore, Georgia
IR  - Lockwood G
FIR - Lockwood, Georgina
IR  - McNamara J
FIR - McNamara, Jacqueline
IR  - Corrigan J
FIR - Corrigan, Jemma
IR  - Fox K
FIR - Fox, Kate
IR  - Furness K
FIR - Furness, Kate
IR  - Cochrane KW
FIR - Cochrane, Kiah Witney
IR  - Huynh K
FIR - Huynh, Kieu
IR  - Hames N
FIR - Hames, Nadia
IR  - Hendricks N
FIR - Hendricks, Nadia
IR  - Page N
FIR - Page, Naomi
IR  - Brooks N
FIR - Brooks, Natalie
IR  - Nevin L
FIR - Nevin, Lauren
IR  - Parfrey L
FIR - Parfrey, Lindy
IR  - Putrus E
FIR - Putrus, Emma
IR  - Pons R
FIR - Pons, Rachel
IR  - Hoevenaars R
FIR - Hoevenaars, Roy
IR  - Singh S
FIR - Singh, Sheena
IR  - McCoy S
FIR - McCoy, Simone
IR  - Wallin S
FIR - Wallin, Siobhan
IR  - Mexias S
FIR - Mexias, Stella
IR  - Daniells S
FIR - Daniells, Suzie
IR  - Storr T
FIR - Storr, Tayla
IR  - Robertson T
FIR - Robertson, Tayla
IR  - Brown T
FIR - Brown, Teresa
EDAT- 2020/05/10 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/05/10 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035824 [pii]
AID - 10.1136/bmjopen-2019-035824 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 7;10(5):e035824. doi: 10.1136/bmjopen-2019-035824.


PMID- 32385063
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 7
TI  - Cow's Milk Fat Obesity pRevention Trial (CoMFORT): a primary care embedded
      randomised controlled trial protocol to determine the effect of cow's milk fat on
      child adiposity.
PG  - e035241
LID - 10.1136/bmjopen-2019-035241 [doi]
AB  - INTRODUCTION: Cow's milk is a dietary staple for children in North America.
      Though clinical guidelines suggest children transition from whole (3.25% fat)
      milk to reduced (1% or 2%) fat milk at age 2 years, recent epidemiological
      evidence supports a link between whole milk consumption and lower adiposity in
      children. The purpose of this trial is to determine which milk fat recommendation
      minimises excess adiposity and optimises child nutrition and growth. METHODS AND 
      ANALYSIS: Cow's Milk Fat Obesity pRevention Trial will be a pragmatic,
      superiority, parallel group randomised controlled trial involving children
      receiving routine healthcare aged 2 to 4-5 years who are participating in the
      TARGet Kids! practice-based research network in Toronto, Canada. Children (n=534)
      will be randomised to receive one of two interventions: (1) a recommendation to
      consume whole milk or (2) a recommendation to consume reduced (1%) fat milk. The 
      primary outcome is adiposity measured by body mass index z-score and waist
      circumference z-score; secondary outcomes will be cognitive development (using
      the Ages and Stages Questionnaire), vitamin D stores, cardiometabolic health
      (glucose, high-sensitivity C-reactive protein, non-high density lipoprotein
      (non-HDL), low density lipoprotein (LDL), triglyceride, HDL and total
      cholesterol, insulin and diastolic and systolic blood pressure), sugary beverage 
      and total energy intake (measured by 24 hours dietary recall) and cost
      effectiveness. Outcomes will be measured 24 months postrandomisation and compared
      using analysis of covariance (ANCOVA), adjusting for baseline measures. ETHICS
      AND DISSEMINATION: Ethics approval has been obtained from Unity Health Toronto
      and The Hospital for Sick Children. Results will be presented locally, nationally
      and internationally and published in a peer-reviewed journal. The findings may be
      helpful to nutrition guidelines for children in effort to reduce childhood
      obesity using a simple, inexpensive and scalable cow's milk fat intervention.
      TRIAL REGISTRATION NUMBER: NCT03914807; pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vanderhout, Shelley M
AU  - Vanderhout SM
AD  - Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
AD  - Pediatrics, St. Michael's Hospital, Toronto, Ontario, Canada.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
FAU - Aglipay, Mary
AU  - Aglipay M
AD  - Pediatrics, St. Michael's Hospital, Toronto, Ontario, Canada.
FAU - Birken, Catherine
AU  - Birken C
AD  - Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
AD  - University of Toronto Institute of Health Policy Management and Evaluation,
      Toronto, Ontario, Canada.
AD  - Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Li, Patricia
AU  - Li P
AD  - McGill University, Montreal, Quebec, Canada.
FAU - O'Connor, Deborah L
AU  - O'Connor DL
AD  - Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
FAU - Thorpe, Kevin
AU  - Thorpe K
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - University of Toronto Institute of Health Policy Management and Evaluation,
      Toronto, Ontario, Canada.
FAU - Constantin, Evelyn
AU  - Constantin E
AD  - Department of Pediatrics, Mcgill University, Montreal, Quebec, Canada.
FAU - Davis, Marie-Adele
AU  - Davis MA
AD  - Canadian Paediatric Society, Ottawa, Ontario, Canada.
FAU - Feldman, Mark
AU  - Feldman M
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
AD  - Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Ball, Geoff D C
AU  - Ball GDC
AD  - University of Alberta, Edmonton, Alberta, Canada.
FAU - Janus, Magdalena
AU  - Janus M
AUID- ORCID: 0000-0002-9500-6776
AD  - Offord Centre for Child Studies, McMaster University, Hamilton, Ontario, Canada.
FAU - Juni, Peter
AU  - Juni P
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - University of Toronto Institute of Health Policy Management and Evaluation,
      Toronto, Ontario, Canada.
FAU - Junker, Anne
AU  - Junker A
AD  - Pediatrics, The University of British Columbia, Vancouver, British Columbia,
      Canada.
FAU - Laupacis, Andreas
AU  - Laupacis A
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - University of Toronto Institute of Health Policy Management and Evaluation,
      Toronto, Ontario, Canada.
FAU - L'Abbe, Mary
AU  - L'Abbe M
AD  - Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
FAU - Manson, Heather
AU  - Manson H
AD  - Health Promotion, Chronic Disease and Injury Prevention, Public Health Ontario,
      Ottawa, Ontario, Canada.
FAU - Moretti, Myla E
AU  - Moretti ME
AD  - Clinical Trials Unit, The Hospital for Sick Children, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Persaud, Nav
AU  - Persaud N
AUID- ORCID: 0000-0003-3327-5580
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - Family and Community Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
FAU - Omand, Jessica A
AU  - Omand JA
AUID- ORCID: 0000-0003-2095-3629
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
FAU - Relton, Clare
AU  - Relton C
AD  - University of Sheffield, Sheffield, UK.
FAU - Wong, Peter
AU  - Wong P
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Ontario, Canada.
AD  - Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
FAU - Yamashiro, Hirotaka
AU  - Yamashiro H
AD  - Ontario Medical Association, Toronto, Ontario, Canada.
FAU - Tavares, Erika
AU  - Tavares E
AD  - Patient Partner, Toronto, Ontario, Canada.
FAU - Weir, Shannon
AU  - Weir S
AD  - Patient Partner, Toronto, Ontario, Canada.
FAU - Maguire, Jonathon L
AU  - Maguire JL
AUID- ORCID: 0000-0002-4083-8612
AD  - Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
      jonathon.maguire@utoronto.ca.
AD  - Pediatrics, St. Michael's Hospital, Toronto, Ontario, Canada.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario,
      Canada.
AD  - University of Toronto Institute of Health Policy Management and Evaluation,
      Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03914807
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Adiposity/*physiology
MH  - Animals
MH  - *Body Mass Index
MH  - Canada
MH  - Cardiometabolic Risk Factors
MH  - Child, Preschool
MH  - *Energy Intake
MH  - Female
MH  - Humans
MH  - Male
MH  - Milk/*metabolism
MH  - Pediatric Obesity/*prevention & control
MH  - Vitamin D/blood
PMC - PMC7228521
OTO - NOTNLM
OT  - *nutrition & dietetics
OT  - *paediatrics
OT  - *preventive medicine
OT  - *primary care
COIS- Competing interests: JLM received an unrestricted research grant for a completed 
      investigator-initiated study from the Dairy Farmers of Canada (2011-2012) and
      Ddrops provided non-financial support (vitamin D supplements) for an investigator
      initiated study on vitamin D and respiratory tract infections (2011-2015).
EDAT- 2020/05/10 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/05/10 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035241 [pii]
AID - 10.1136/bmjopen-2019-035241 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 7;10(5):e035241. doi: 10.1136/bmjopen-2019-035241.


PMID- 32385061
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 7
TI  - Effect of PIFR-based optimised inhalation therapy in patients recovering from
      acute exacerbation of chronic obstructive pulmonary disease: protocol of a
      prospective, multicentre, superiority, randomised controlled trial.
PG  - e034804
LID - 10.1136/bmjopen-2019-034804 [doi]
AB  - INTRODUCTION: Acute exacerbation (AE) is a major cause of disease progression and
      death in patients with chronic obstructive pulmonary disease (COPD), accounting
      for majority of medical expenditures. Correct inhalation therapy is effective in 
      preventing AE attacks. However, inappropriate usage of dry powder inhaler,
      partially due to the unrecovered peak inhalation flow rate (PIFR) after acute
      exacerbation of COPD (AECOPD), results in increased risk of early treatment
      failure. Therefore, we designed a multicentre, randomised clinical trial to
      determine whether PIFR-based optimised inhalation therapy and training on inhaler
      usage at discharge could effectively reduce early treatment failure events.
      METHODS AND ANALYSIS: A total of 416 hospitalised patients just recovering from
      AECOPD will be recruited and equally randomised into the PIFR group and the
      control group at a 1:1 ratio. The PIFR group will receive additive support before
      discharge, including choice of PIFR-guided inhaler and education on its usage.
      PIFR is measured by InCheck DIAL. In comparison, the control group will receive
      inhalers based on judgement of the respiratory physician. The primary outcome of 
      the study is 30-day treatment failure rate. Other endpoints include PIFR, error
      rate of inhalation device use, satisfaction with inhalation devices, 30-day
      mortality, 90-day mortality, symptoms and quality of life of patients, and
      COPD-related treatment costs. ETHICS AND DISSEMINATION: The trial has been
      approved by the Ethics Committee of Zhongshan Hospital of Fudan University
      (B2019-142). Participants will be screened and enrolled from hospitalised
      patients with AECOPD by clinicians, with no public advertisement for recruitment.
      After the trial has completed, the results will be reported to the public through
      conference presentations and peer-reviewed journals. TRIAL REGISTRATION NUMBER:
      NCT04000958.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hua, Jianlan
AU  - Hua J
AUID- ORCID: 0000-0001-5832-5893
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan
      University, Shanghai, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Biostatistics, Fudan University, Shanghai, China.
FAU - Cao, Hui-Fang
AU  - Cao HF
AD  - Department of Pulmonary, Shanghai Jing'an District Central Hospital, Shanghai,
      China, Shanghai, China.
FAU - Du, Chun-Ling
AU  - Du CL
AD  - Department of Pulmonary, Shanghai Qingpu District Central Hospital, Shanghai,
      China.
FAU - Ma, Jia-Yun
AU  - Ma JY
AD  - Department of Pulmonary, North Branch of Shanghai Ninth People's Hospital,
      Shanghai, China.
FAU - Zuo, Yi-Hui
AU  - Zuo YH
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan
      University, Shanghai, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan
      University, Shanghai, China jingatlas@hotmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT04000958
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200507
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
EIN - BMJ Open. 2020 Aug 20;10(8):e034804corr1. PMID: 32820003
MH  - Adult
MH  - Aged
MH  - *Chronic Disease
MH  - Disease Progression
MH  - *Dry Powder Inhalers
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mortality/trends
MH  - Patient Satisfaction/statistics & numerical data
MH  - Prospective Studies
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - *Respiratory Therapy
MH  - Treatment Failure
PMC - PMC7228517
OTO - NOTNLM
OT  - *chronic airways disease
OT  - *medical education & training
OT  - *respiratory medicine (see thoracic medicine)
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/05/10 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034804 [pii]
AID - 10.1136/bmjopen-2019-034804 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 7;10(5):e034804. doi: 10.1136/bmjopen-2019-034804.


PMID- 32385060
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 7
TI  - Estimation of the prevalence of depression using diagnostic instruments in the
      elderly population in India, 2000-2019: a systematic review protocol.
PG  - e034330
LID - 10.1136/bmjopen-2019-034330 [doi]
AB  - INTRODUCTION: Depression is a common mental disorder in the elderly population,
      which significantly impacts their quality of life. However, correct estimates of 
      its magnitude are not available in the elderly in India. The present systematic
      review and meta-analysis would attempt to estimate the prevalence of depression
      using diagnostic instruments among elderly persons aged 60 years and above.
      METHODS AND ANALYSIS: Searches will be performed in PubMed, Scopus, Embase, Web
      of Science, CINAHL and PsycINFO. Community-based cross-sectional and cohort
      studies (2001 to September 2019) reporting the prevalence of depression in the
      elderly, using diagnostic instruments will be included. Studies conducted among
      chronic disease patients, in-hospital patients and special groups such as with
      disaster-stricken populations, and studies reporting the only one or two
      subcategories of depression, will be excluded. Disagreements in study selection
      and data abstraction will be resolved by consensus and arbitration by a third
      reviewer. AXIS critical appraisal tool will be used for quality assessment of
      individual studies. Findings of eligible studies will be pooled using
      fixed-effects or random-effects meta-analysis whichever is appropriate.
      Heterogeneity between studies will be examined by Cochran's Q test and quantified
      by I(2) statistic. A cumulative meta-analysis will be used to detect temporal
      trends in the prevalence of depression and the effect of poor-quality studies on 
      the pooled estimate. Publication bias will be assessed by visual inspection of
      funnel plots and the Egger test. ETHICS AND DISSEMINATION: No ethical approval
      will be needed because it will be a systematic review. Data from previously
      published studies will be retrieved and analysed. Findings will be disseminated
      through a peer-reviewed publication in a scientific journal and conferences.
      PROSPERO REGISTRATION NUMBER: CRD42019138453.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Behera, Priyamadhaba
AU  - Behera P
AD  - Department of Community and Family Medicine, AIIMS, Raebareli, Uttar Pradesh,
      India.
FAU - Pilania, Manju
AU  - Pilania M
AD  - Department of Community Medicine, RUHS College of Medical Sciences, Jaipur,
      Rajasthan, India.
FAU - Yadav, Vikas
AU  - Yadav V
AD  - Department of Community Medicine, Atal Bihari Vajpayee Government Medical
      College, Vidisha, Madhya Pradesh, India.
FAU - Bairwa, Mohan
AU  - Bairwa M
AUID- ORCID: 0000-0001-7763-2530
AD  - Centre for Community Medicine, AIIMS, New Delhi, India drmohanbairwa@gmail.com.
FAU - Dabar, Deepti
AU  - Dabar D
AD  - Department of Community and Family Medicine, AIIMS, Bhopal, Madhya Pradesh,
      India.
FAU - Behera, Surama Manjari
AU  - Behera SM
AD  - RMRC-ICMR, Bhubaneswar, Odisha, India.
FAU - Poongothai, Subramani
AU  - Poongothai S
AD  - Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.
FAU - Mohan, Viswanathan
AU  - Mohan V
AD  - Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.
FAU - Gupta, Shiv Dutt
AU  - Gupta SD
AD  - IIHMR University, Jaipur, Rajasthan, India.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200507
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Depression/*epidemiology
MH  - Humans
MH  - India/epidemiology
MH  - Prevalence
MH  - *Psychiatric Status Rating Scales
MH  - *Quality of Life
PMC - PMC7228514
OTO - NOTNLM
OT  - *India
OT  - *depression
OT  - *diagnostic tool
OT  - *elderly
OT  - *prevalence
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/05/10 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-034330 [pii]
AID - 10.1136/bmjopen-2019-034330 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 7;10(5):e034330. doi: 10.1136/bmjopen-2019-034330.


PMID- 32385058
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 7
TI  - Cluster randomised controlled trial of home cook intervention to reduce salt
      intake in China: a protocol study.
PG  - e033842
LID - 10.1136/bmjopen-2019-033842 [doi]
AB  - INTRODUCTION: Salt intake in China is twice the upper limit recommended by the
      WHO, and nearly 80% of salt is added during cooking. This study will develop a
      package of salt reduction interventions targeting home cooks and evaluate its
      effectiveness and feasibility for scale-up. METHODS AND ANALYSIS: A cluster
      randomised controlled trial design is adopted in this study, which will be
      conducted in six provinces covering northern, central and southern China. For
      each province, 10 communities/villages (clusters) with 13 families (one cook and 
      one adult family member) will be selected in each cluster for evaluation. In
      total, 780 home cooks and 780 adult family members will be recruited. The home
      cooks in the intervention group will be provided with the intervention package,
      including community-based standardised offline and online health education and
      salt intake monitoring. The duration of the intervention will be 1 year. The
      primary outcome is the difference between the intervention and control group in
      change in salt intake as measured by 24 hours urinary sodium from baseline to the
      end of the trial. The secondary outcome is the difference between the two groups 
      in the change in salt-related knowledge, attitude and practice and blood pressure
      (BP). ETHICS AND DISSEMINATION: The study has been approved by The Queen Mary
      Research Ethics Committee (QMERC2018/13) and Institutional Review Board of the
      Chinese Center for Disease Control and Prevention (No. 201801). The study
      findings will be disseminated widely through conference presentations and
      peer-reviewed publications and the general media. TRIAL REGISTRATION NUMBER:
      ChiCTR1800016804.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Xiaochang
AU  - Zhang X
AD  - Chinese Center for Disease Control and Prevention, Beijing, China.
FAU - Hu, Xiao
AU  - Hu X
AUID- ORCID: 0000-0002-4790-2066
AD  - Beijing Center for Diseases Prevention and Control, Beijing, China.
FAU - Ma, Jixiang
AU  - Ma J
AD  - Chinese Center for Disease Control and Prevention, Beijing, China
      majx@chinacdc.cn zpuhong@georgeinstitute.org.cn.
FAU - Zhang, Puhong
AU  - Zhang P
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China majx@chinacdc.cn zpuhong@georgeinstitute.org.cn.
AD  - Faculty of Medicine, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Li, Yuan
AU  - Li Y
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
AD  - Faculty of Medicine, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Luo, Rong
AU  - Luo R
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
FAU - He, Feng J
AU  - He FJ
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London,
      London, UK.
FAU - MacGregor, Graham A
AU  - MacGregor GA
AD  - Wolfson Institute of Preventive Medicine, Queen Mary University of London,
      London, UK.
FAU - Wang, Jinglei
AU  - Wang J
AD  - Chinese Center for Disease Control and Prevention, Beijing, China.
FAU - Yin, Zhaoxue
AU  - Yin Z
AD  - Chinese Center for Disease Control and Prevention, Beijing, China.
LA  - eng
SI  - ChiCTR/ChiCTR1800016804
GR  - 16/136/77/DH_/Department of Health/United Kingdom
GR  - MR/J015903/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Sodium Chloride, Dietary)
SB  - IM
MH  - Adult
MH  - Blood Pressure
MH  - China
MH  - Cooking
MH  - *Feeding Behavior
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Sodium Chloride, Dietary
PMC - PMC7228508
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *public health
OT  - *salt reduction
COIS- Competing interests: FJH is a member of Consensus Action on Salt & Health (CASH) 
      and World Action on Salt & Health (WASH). Both CASH and WASH are non-profit
      charitable organisations, and FJH has not received any financial support from
      CASH or WASH. GAM is Chairman of Blood Pressure UK (BPUK), Chairman of CASH, WASH
      and Action on Sugar. BPUK, CASH, WASH and Action on Sugar are non-profit
      charitable organisations. GAM has not received receive any financial support from
      any of these organisations.
EDAT- 2020/05/10 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/05/10 06:00
PHST- 2020/05/10 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-033842 [pii]
AID - 10.1136/bmjopen-2019-033842 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 7;10(5):e033842. doi: 10.1136/bmjopen-2019-033842.


PMID- 32384569
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1438-8685 (Electronic)
IS  - 0935-8943 (Linking)
VI  - 99
IP  - S 01
DP  - 2020 Mar
TI  - Quality Management in Otolaryngology - An Assessment of the Current Situation -
      On Current View, how is the State of Quality Standards in German Hospitals and
      Practices, esp. in Otolaryngology? An Appraisal with.
PG  - S336-S428
LID - 10.1055/a-1012-9442 [doi]
AB  - To deal with medical malpractice, apart from sanctions an ethical code has been
      developed since ancient times which shapes our present expectation of a good
      physician. A century ago, industrialization and standardization initiated medical
      quality management in the USA. In the 1950s, the Japanese concept of total
      quality management arose, winning huge influence also in medicine. Every recent
      system of certification or accreditation originates from these roots.In the last 
      15 years in Germany, minimum standards in health care have been enforced by law
      with increasing sophistication. Additionally, self-governed institutions of
      physicians have been clearly contributing to the quality of care.Quality
      management has become an integral part of the German healthcare system, most
      notably in risk management and patient orientation. There are also a multitude of
      voluntary physician-driven initiatives to improve the quality of care, among
      others the guidelines of the medical societies.A survey was conducted by the
      author to evaluate the implementation of quality management in otolaryngological 
      departments and practices. The degree of implementation was predominately higher 
      than for the national peers.Currently there are substantial challenges to the
      health care system which impact the quality of care. Lack of funding, shortage of
      qualified staff, societal changes and effects of rapid scientific progress are a 
      few to name.To achieve a broad implementation of quality management in the
      future, wise political decisions and proper funding are crucial - the concept as 
      such has long been accepted.
CI  - Eigentumer und Copyright (c)Georg Thieme Verlag KG 2019.
FAU - Wallner, Frank
AU  - Wallner F
AD  - Universitats-HNO-Klinik Heidelberg.
LA  - eng
LA  - ger
PT  - Journal Article
TT  - Qualitatsmanagement in der HNO - eine Standortbestimmung.
DEP - 20200316
PL  - Germany
TA  - Laryngorhinootologie
JT  - Laryngo- rhino- otologie
JID - 8912371
SB  - IM
MH  - Delivery of Health Care
MH  - Germany
MH  - Hospitals
MH  - Humans
MH  - *Otolaryngology
MH  - Reference Standards
COIS- Der Autor gibt an, dass kein Interessenkonflikt besteht.
EDAT- 2020/05/10 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
AID - 10.1055/a-1012-9442 [doi]
PST - ppublish
SO  - Laryngorhinootologie. 2020 Mar;99(S 01):S336-S428. doi: 10.1055/a-1012-9442. Epub
      2020 Mar 16.


PMID- 32384521
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 19
DP  - 2020 May
TI  - The effect of vitamin D supplementation on the progression of fibrosis in
      patients with chronic liver disease: A protocol for a systematic review and
      meta-analysis.
PG  - e20296
LID - 10.1097/MD.0000000000020296 [doi]
AB  - BACKGROUND: Hepatic fibrosis (HF) is the common pathological basis of chronic
      liver disease (CLD). Many data indicate that serum vitamin D (VD) levels in
      patients with liver fibrosis are significantly lower than those without liver
      fibrosis, and lower level of serum 1,25(OH)2D3 is also an independent risk factor
      for patients with liver fibrosis combined with other diseases. VD has the
      functions of anti-fibrosis, regulating cell proliferation and differentiation,
      anti-inflammatory, and immune regulation, Therefore, serum 1,25(OH)2D3 level may 
      be negatively correlated with the progression of liver fibrosis. But there is
      absent convincing evidence-based medicine to confirm the efficacy of VD
      supplementation for CLD. Thus, we aimed to conduct this meta-analysis to
      summarize the efficacy of VD supplementation on the progression of fibrosis in
      patients with CLD. METHODS: The study only selects clinical randomized controlled
      trials of VD supplementation for CLD. We will search each database from the
      built-in until September 2020. The English literature mainly searches Cochrane
      Library, Pubmed, EMBASE, and Web of Science. While the Chinese literature comes
      from CNKI, CBM, VIP, and Wangfang database. Meanwhile, we will retrieve clinical 
      trial registries and gray literature. Two researchers worked independently on
      literature selection, data extraction and quality assessment. The dichotomous
      data is represented by relative risk (RR), and the continuous is expressed by
      mean difference (MD) or standard mean difference (SMD), eventually the data is
      synthesized using a fixed effect model (FEM) or a random effect model (REM)
      depending on the heterogeneity. The serum VD level, hepatic function and
      serological indexes of hepatic fibrosis were evaluated as the main outcomes.
      While several secondary outcomes were also evaluated in this study. The
      statistical analysis of this Meta-analysis was conducted by RevMan software
      version 5.3. RESULTS: This meta-analysis will further determine the beneficial
      efficacy of VD supplementation on the progression of fibrosis in patients with
      CLD. CONCLUSION: This study determines the positive efficacy of VD
      supplementation for CLD. ETHICS AND DISSEMINATION: This review is based solely on
      a secondary study of published literatures and does not require ethics committee 
      approval. Its conclusion will be disseminated in conference papers, magazines or 
      peer-reviewed journals. REGISTRATION NUMBER: INPLASY202040054.
FAU - Chen, Tiantian
AU  - Chen T
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu 610072.
FAU - Zuo, Xiaohong
AU  - Zuo X
AD  - School of basic medical sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu 611137.
FAU - Wang, Shengju
AU  - Wang S
AD  - Department of Endocrinology, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu 610072.
FAU - Yu, Penglong
AU  - Yu P
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu 610072.
FAU - Yuan, Jie
AU  - Yuan J
AD  - School of basic medical sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu 611137.
FAU - Wei, Shujun
AU  - Wei S
AD  - School of basic medical sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu 611137.
FAU - Chen, Jiayi
AU  - Chen J
AD  - Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
      Medicine, Chengdu 610072.
FAU - Sun, Yue
AU  - Sun Y
AD  - School of basic medical sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu 611137.
FAU - Gao, Yongxiang
AU  - Gao Y
AD  - College of International Education of Chengdu University of Traditional Chinese
      Medicine, PR China.
FAU - Li, Xueping
AU  - Li X
AD  - School of basic medical sciences, Chengdu University of Traditional Chinese
      Medicine, Chengdu 611137.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Chronic Disease
MH  - *Dietary Supplements
MH  - Disease Progression
MH  - Humans
MH  - Liver Cirrhosis/etiology/*prevention & control
MH  - Liver Diseases/*complications
MH  - Liver Function Tests
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Risk
MH  - Vitamin D/*administration & dosage/blood
PMC - PMC7220037
EDAT- 2020/05/10 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
AID - 10.1097/MD.0000000000020296 [doi]
AID - 00005792-202005080-00098 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(19):e20296. doi: 10.1097/MD.0000000000020296.


PMID- 32384479
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 19
DP  - 2020 May
TI  - Efficacy and safety of Chinese medicines for vitreous hemorrhage: A protocol for 
      systematic review and meta-analysis.
PG  - e20086
LID - 10.1097/MD.0000000000020086 [doi]
AB  - BACKGROUND: Vitreous hemorrhage (VH) is a common ophthalmic disease with a high
      rate of blindness, which will seriously affect the quality of life of patients
      and bring great burden to patients' families and society. The treatment for VH
      contains medical therapy, lasers, and surgery. At present, there is no recognized
      western medicine with definite curative effect and little side effect for the
      treatment of VH. In most cases, PRP is not available to treat VH; intravitreal
      injection or surgical treatment is adopted as the primary therapy. However, in
      the long-term treatment, the effect of the above-mentioned treatment is not
      satisfactory, so many patients choose oral Chinese medicines, which has been
      widely used in China to treat VH. Numerous clinical trials have demonstrated that
      Chinese medicines can promote the absorption of VH and improve the visual
      function of patients. The purpose of this review is to evaluate the efficacy and 
      safety of Chinese medicines in the treatment of VH and inform a decision aid for 
      the clinical encounter between patients and clinicians. Besides, it is beneficial
      to establish a future research agenda. METHODS: The systematic review will
      include all of the randomized controlled trials on the efficacy and safety of
      Chinese medicines for VH. Nine electronic databases, namely PubMed, Web of
      Science, EMBASE, the Cochrane Library, Google Scholar, China National Knowledge
      Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal
      database (VIP), and CBM, will be searched normatively on the basis of the rule of
      each database from the inception to August 31, 2019. We will also search
      registers of clinical trials, potential gray literature, and conference
      abstracts. There are no limits on language and publication status. The literature
      screening, data extraction, and quality assessment will be conducted by 2
      reviewers independently. The reporting quality and risk of bias will be assessed 
      by other 2 researchers. Standard of curative effect and total treatment efficacy 
      rate were assessed as the primary outcome. The secondary outcomes will include
      the curative effect of single symptom and sign, the improvement rate of single
      auxiliary examination, withdrawal and reduction of western medicines in a course 
      of treatment, maintenance of western medicines after the course of treatment,
      laboratory efficacy indexes. Meta-analysis will be performed using RevMan5.3
      software provided by the Cochrane Collaboration. RESULTS: This study will provide
      a comprehensive review based on current evidence of Chinese medicines treatment
      for VH in several aspects, including standard of curative effect, total treatment
      efficacy rate, the curative effect of single symptom and sign, the improvement
      rate of single auxiliary examination, withdrawal and reduction of western
      medicines in a course of treatment, laboratory efficacy indexes, total treatment 
      efficacy, and safety, among others. CONCLUSION: The conclusion of this study will
      provide evidence to determine whether Chinese medicines are an effective and safe
      intervention for patients with VH. ETHICS AND DISSEMINATION: It is not necessary 
      to obtain ethical approval for this study. The systematic review will be
      published in a peer-reviewed journal, presented at conferences and will be shared
      on social media platforms. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42020152321.
FAU - Han, Mengyu
AU  - Han M
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Liu, Ziqiang
AU  - Liu Z
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Nong, Luqi
AU  - Nong L
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Zi, Yingxin
AU  - Zi Y
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Meng, Huan
AU  - Meng H
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Deng, Yu
AU  - Deng Y
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Wang, Zhi-Jun
AU  - Wang ZJ
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
FAU - Jin, Ming
AU  - Jin M
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - China
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Vitreous Hemorrhage/*drug therapy
PMC - PMC7440084
EDAT- 2020/05/10 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
AID - 10.1097/MD.0000000000020086 [doi]
AID - 00005792-202005080-00056 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(19):e20086. doi: 10.1097/MD.0000000000020086.


PMID- 32384457
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 19
DP  - 2020 May
TI  - Randomized cross-over trial of demand oxygen delivery system.
PG  - e20010
LID - 10.1097/MD.0000000000020010 [doi]
AB  - INTRODUCTION: Long-term oxygen therapy is reported to improve hypoxemia and
      survival in patients with respiratory failure. The demand oxygen delivery system 
      (DODS) saves oxygen and extends the usable time of an oxygen cylinder 2- to
      3-fold. A portable oxygen concentrator with an auto-DODS has been developed to
      switch its sensitivity among 3 levels (standard, high, and extra high) and to
      supply pulsed-flow oxygen when it detects apnea. The aim of this study is to
      evaluate the efficacy of this newly developed portable oxygen concentrator with
      auto-DODS compared to the efficacy of conventional DODS in oxygenation. METHODS
      AND ANALYSIS: Twenty-six patients with chronic obstructive pulmonary disease or
      interstitial pneumonia will be randomized to use auto-DODS or conventional DODS
      at rest and during a 6-minute walk test. Primary endpoints are mean oxygen
      saturation (SpO2) at rest and during the 6-minute walk test. Secondary endpoints 
      are the ratios of the times during which the oxygen concentrator operates at each
      sensitivity mode (standard, high, and extra high) and at a constant pulse rate to
      the examination time, the ratio of the times during which SpO2 fall below 90% to 
      the examination time, the lowest value of SpO2 during the examination time, the
      mean and highest pulse rates during the examination time, 6-minute walking
      distance, recovery time, Borg scale, comfort, and reliability, which are measured
      by a numerical rating scale and a questionnaire, respectively. ETHICS AND
      DISSEMINATION: The study was conducted in accordance with the Declaration of
      Helsinki and was registered on Aug 23, 2019
      (https://jrct.niph.go.jp/en-latest-detail/jRCTs052190041). The results of the
      study will be presented at academic conferences and submitted to a peer-reviewed 
      journal. TRIAL REGISTRATION NUMBER: jRCTs052190041.
FAU - Nagano, Tatsuya
AU  - Nagano T
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Kobayashi, Kazuyuki
AU  - Kobayashi K
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Omori, Takashi
AU  - Omori T
AD  - Clinical and Translational Research Center, Kobe University Hospital, 7-5-2
      Kusunoki-cho, Chuo-ku, Kobe, Hyogo, Japan.
FAU - Otoshi, Takehiro
AU  - Otoshi T
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Umezawa, Kanoko
AU  - Umezawa K
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Katsurada, Naoko
AU  - Katsurada N
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Yamamoto, Masatsugu
AU  - Yamamoto M
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Tachihara, Motoko
AU  - Tachihara M
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
FAU - Nishimura, Yoshihiro
AU  - Nishimura Y
AD  - Department of Internal Medicine, Division of Respiratory Medicine.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Lung Diseases, Interstitial/*complications
MH  - Male
MH  - Nebulizers and Vaporizers
MH  - Oximetry/methods
MH  - *Oxygen Inhalation Therapy/instrumentation/methods
MH  - Patient Preference
MH  - Pulmonary Disease, Chronic Obstructive/*complications
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Reproducibility of Results
MH  - *Respiratory Insufficiency/etiology/metabolism/physiopathology/therapy
MH  - Walk Test/methods
PMC - PMC7220698
EDAT- 2020/05/10 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
AID - 10.1097/MD.0000000000020010 [doi]
AID - 00005792-202005080-00034 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(19):e20010. doi: 10.1097/MD.0000000000020010.


PMID- 32384454
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 19
DP  - 2020 May
TI  - Effectiveness of the integrated care model Salut+Social in patients with chronic 
      conditions: A mixed methods study protocol.
PG  - e19994
LID - 10.1097/MD.0000000000019994 [doi]
AB  - INTRODUCTION: Integrated care models aim to provide solutions to fragmentation of
      care by improving coordination. This study will evaluate the effectiveness of a
      new integrated care model (Salut + Social), which will promote the coordination
      and communication between social and healthcare services in southern Catalonia
      (Spain) to improve quality of life, adherence to treatment and access to medical 
      services for patients with chronic conditions, and also to reduce caregiver
      burden. Additionally, we will evaluate the experience of caregivers, health
      professionals and social workers with the new model implemented. METHODS AND
      ANALYSIS: A clinical trial using mixed methodology will be carried out. The
      intervention consists of improving the coordination between the social and
      healthcare sectors during a 6-month period, by means of information and
      communication technology (ICT) tools that operate as an interface for the
      integrated care model. The study subjects are primary care patients with chronic 
      health and social conditions that can benefit from a collaborative and
      coordinated approach. A sample size of 141 patients was estimated. Questionnaires
      that assess quality of life, treatment adherence, medical service and caregiver
      burden will be used at baseline and at 6, 9, and 12 months after the beginning of
      the study. The principal variable is quality of life. For statistical analysis,
      comparisons of means and proportions at different time points will be performed. 
      A discussion group and semi-structured interviews will be conducted with the aim 
      of improving the care model taking into account the opinions of professionals and
      caregivers. A thematic content analysis will be carried out. ETHICS AND
      DISSEMINATION: This study protocol has been approved by the Clinical Research
      Ethics Committee of the Fundacio Institut Universitari per a la Recerca a
      l'Atencio Primaria de Salut Jordi Gol i Gurina (code P17/100). Articles will be
      published in international, peer-reviewed scientific journals. TRIAL
      REGISTRATION: Clinical-Trials.gov: NCT04164160.
FAU - Gavalda-Espelta, Ester
AU  - Gavalda-Espelta E
AD  - Direccio d'Atencio Primaria Terres de l'Ebre, Gerencia Territorial Terres de
      l'Ebre, Institut Catala de la Salut, Tortosa.
AD  - Departament d'Infermeria, Programa de Doctorat Infermeria i Salut, Universitat
      Rovira i Virgili, Tarragona.
FAU - Del Mar Lleixa-Fortuno, Maria
AU  - Del Mar Lleixa-Fortuno M
AD  - Departament d'Infermeria, Programa de Doctorat Infermeria i Salut, Universitat
      Rovira i Virgili, Tarragona.
AD  - Direccio de Serveis Territorials de Salut a les Terres de l'Ebre, CatSalut,
      Generalitat de Catalunya, Tortosa, Spain.
FAU - Baucells-Lluis, Jordi
AU  - Baucells-Lluis J
AD  - Direccio de Sistemes d'Informacio i Comunicacio, Gerencia Territorial Terres de
      l'Ebre, Institut Catala de la Salut, Tortosa.
FAU - Ferre-Ferrate, Maria
AU  - Ferre-Ferrate M
AD  - Direccio d'Atencio Primaria Terres de l'Ebre, Gerencia Territorial Terres de
      l'Ebre, Institut Catala de la Salut, Tortosa.
FAU - Mora-Lopez, Gerard
AU  - Mora-Lopez G
AD  - Direccio d'Atencio Primaria Terres de l'Ebre, Gerencia Territorial Terres de
      l'Ebre, Institut Catala de la Salut, Tortosa.
FAU - Tomas-Navarro, Begona
AU  - Tomas-Navarro B
AD  - Equip d'Atencio Primaria Amposta, Gerencia Territorial Terres de l'Ebre, Institut
      Catala de la Salut, Tortosa.
FAU - Curto-Romeu, Claudia
AU  - Curto-Romeu C
AD  - Equip d'Atencio Primaria Amposta, Gerencia Territorial Terres de l'Ebre, Institut
      Catala de la Salut, Tortosa.
FAU - Lucas-Noll, Jorgina
AU  - Lucas-Noll J
AD  - Direccio d'Atencio Primaria Terres de l'Ebre, Gerencia Territorial Terres de
      l'Ebre, Institut Catala de la Salut, Tortosa.
AD  - Departament d'Infermeria, Programa de Doctorat Infermeria i Salut, Universitat
      Rovira i Virgili, Tarragona.
FAU - Aguilar Martin, Carina
AU  - Aguilar Martin C
AD  - Unitat d'Avaluacio, Direccio d'Atencio Primaria Terres de l'Ebre, Institut Catala
      de la Salut, Tortosa.
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, Fundacio Institut Universitari
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol),
      Tortosa.
FAU - Goncalves, Alessandra Queiroga
AU  - Goncalves AQ
AD  - Unitat de Suport a la Recerca Terres de l'Ebre, Fundacio Institut Universitari
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol),
      Tortosa.
AD  - Unitat Docent de Medicina de Familia i Comunitaria Tortosa-Terres de L'Ebre,
      Institut Catala de la Salut, Tortosa, Tarragona, Spain.
FAU - Ferre-Grau, Carmen
AU  - Ferre-Grau C
AD  - Departament d'Infermeria, Programa de Doctorat Infermeria i Salut, Universitat
      Rovira i Virgili, Tarragona.
LA  - eng
SI  - ClinicalTrials.gov/NCT04164160
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - *Chronic Disease/epidemiology/psychology/rehabilitation/therapy
MH  - *Delivery of Health Care, Integrated/methods/organization & administration
MH  - Humans
MH  - Intersectoral Collaboration
MH  - *Models, Organizational
MH  - *Patient Care Team
MH  - *Quality of Life
MH  - *Social Work
MH  - Spain
PMC - PMC7220253
EDAT- 2020/05/10 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
AID - 10.1097/MD.0000000000019994 [doi]
AID - 00005792-202005080-00031 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(19):e19994. doi: 10.1097/MD.0000000000019994.


PMID- 32384437
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20200616
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 19
DP  - 2020 May
TI  - Extracorporeal shock wave therapy versus corticosteroid injection for chronic
      plantar fasciitis: A protocol of randomized controlled trial.
PG  - e19920
LID - 10.1097/MD.0000000000019920 [doi]
AB  - BACKGROUND: The outcomes of corticosteroid injection (CSI) and extracorporeal
      shock wave therapy (ESWT) as primary treatment of plantar fasciitis have been
      debated. This study was conducted to compare and evaluate the therapeutic effects
      of ultrasound-guided CSI versus medium frequency ESWT in the treatment of plantar
      fasciitis among Chinese population. METHODS: This study was a single-center,
      randomized, and double-blinded trial. The study protocol was approved by local
      ethics committee board and subsequently registered in Research Registry. Eighty
      patients with unilateral plantar fasciitis were randomized to receive either ESWT
      (3 times once per week) (n = 40) or CSI treatment (a single 1-mL dose of
      betamethasone sodium plus 0.5 mL of prilocaine under ultrasound guidance by
      injection into the plantar fascia) (n = 40). The primary outcome measures were
      visual analog scale and Foot Function Index scores. Secondary outcome measures
      included the heel tenderness index score and plantar fascia thickness as obtained
      by ultrasound examination. All of the assessments were performed at baseline and 
      1, 3, and 6 months after treatment. RESULTS: This is a randomized controlled
      trial evaluating the efficacy of CSI versus ESWT in the treatment of plantar
      fasciitis. This study has limited inclusion and exclusion criteria and a
      well-controlled intervention. CONCLUSIONS: The results of this trial will provide
      more evidence on which method can better treat plantar fasciitis. TRIAL
      REGISTRATION: This study protocol was registered in Research Registry
      (researchregistry5428).
FAU - Zhao, Jie
AU  - Zhao J
AD  - Department of Traumatic Orthopedics, Weifang People's Hospital, Weifang,
      Shandong, 261041.
FAU - Luo, Wen Ming
AU  - Luo WM
AD  - Department of Traumatic Orthopedics, Weifang People's Hospital, Weifang,
      Shandong, 261041.
FAU - Li, Tingting
AU  - Li T
AD  - Department of Ultrasound, Weifang Maternal and Child health Hospital, Weifang,
      Shandong, 261000, China.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Adrenal Cortex Hormones)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - Extracorporeal Shockwave Therapy/adverse effects/*methods
MH  - Fasciitis, Plantar/*therapy
MH  - Female
MH  - Humans
MH  - Injections/adverse effects/*methods
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Pain, Procedural/etiology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7220254
EDAT- 2020/05/10 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
AID - 10.1097/MD.0000000000019920 [doi]
AID - 00005792-202005080-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(19):e19920. doi: 10.1097/MD.0000000000019920.


PMID- 32384328
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1536-0911 (Electronic)
IS  - 1536-0903 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Jun
TI  - Conceptually Redefining Neonatal Palliative Care.
PG  - 187-195
LID - 10.1097/ANC.0000000000000731 [doi]
AB  - BACKGROUND: First defined in 2002 by Catlin and Carter, neonatal palliative care 
      (NPC) is a relatively new model of care in neonatal pediatrics, first appearing
      in the medical literature in the early 1980s. PURPOSE: The purpose of this
      article is to suggest a conceptual definition of NPC that encompasses all the
      essential concepts as a way of moving NPC forward by having a consistent
      approach. METHODS: Following a review of the NPC literature, a thematic analysis 
      as a method for identifying, analyzing, and interpreting patterns of meaning in
      the definitions ("themes") within the literature was undertaken. FINDINGS: The
      major themes identified included philosophies of care, support, culture and
      spirituality, the team, and clinical management. IMPLICATIONS FOR RESEARCH: At
      the heart of NPC is the primacy of maintaining quality of life, while providing
      ethical and humane care that supports a "good death." The extensive elements
      presented in this article are considered essential to a comprehensive and
      conceptual definition of NPC proposed here.
FAU - Kain, Victoria J
AU  - Kain VJ
AD  - School of Nursing and Midwifery, Griffith University, Nathan, Queensland,
      Australia (Dr Kain); and Molloy College, New York City, New York (Ms Chin).
FAU - Chin, Susan D
AU  - Chin SD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Neonatal Care
JT  - Advances in neonatal care : official journal of the National Association of
      Neonatal Nurses
JID - 101125644
SB  - IM
MH  - Attitude to Death
MH  - Humans
MH  - Infant Care/*methods
MH  - Infant, Newborn
MH  - Medical Futility/ethics/psychology
MH  - Neonatology/ethics/methods/trends
MH  - *Palliative Care/ethics/methods/psychology
MH  - Patient Care Team
MH  - Patient Comfort/*methods
MH  - *Quality of Life
EDAT- 2020/05/10 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - 10.1097/ANC.0000000000000731 [doi]
AID - 00149525-202006000-00004 [pii]
PST - ppublish
SO  - Adv Neonatal Care. 2020 Jun;20(3):187-195. doi: 10.1097/ANC.0000000000000731.


PMID- 32384090
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20200731
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Assessing mentoring: A scoping review of mentoring assessment tools in internal
      medicine between 1990 and 2019.
PG  - e0232511
LID - 10.1371/journal.pone.0232511 [doi]
AB  - BACKGROUND: Mentoring's success in enhancing a mentee's professional and personal
      development, and a host organisations' reputation has been called into question, 
      amidst a lack of effective tools to evaluate mentoring relationships and guide
      oversight of mentoring programs. A scoping review is proposed to map available
      literature on mentoring assessment tools in Internal Medicine to guide design of 
      new tools. OBJECTIVE: The review aims to explore how novice mentoring is assessed
      in Internal Medicine, including the domains assessed, and the strengths and
      limitations of the assessment methods. METHODS: Guided by Levac et al.'s
      framework for scoping reviews, 12 reviewers conducted independent literature
      reviews of assessment tools in novice mentoring in PubMed, Embase, Scopus, ERIC, 
      Cochrane, GreyLit, Web of Science, Open Dissertations and British Education Index
      databases. A 'split approach' saw research members adopting either Braun and
      Clarke's approach to thematic analysis or directed content analysis to
      independently evaluate the data and improve validity and objectivity of the
      findings. RESULTS: 9662 abstracts were identified, 187 full-text articles
      reviewed, and 54 full-text articles included. There was consensus on the themes
      and categories identified through the use of the split approach, which were the
      domains assessed and methods of assessment. CONCLUSION: Most tools fail to
      contend with mentoring's evolving nature and provide mere snap shots of the
      mentoring process largely from the mentee's perspective. The lack of holistic,
      longitudinal and validated assessments propagate fears that ethical issues in
      mentoring are poorly recognized and addressed. To this end, we forward a
      framework for the design of 'fit for purpose' multi-dimensional tools. PRACTICE
      POINTS: Most tools focus on the mentee's perspective, do not consider mentoring's
      evolving nature and fail to consider mentoring holistically nor longitudinallyA
      new tool capable of addressing these gaps must also consider inputs from all
      stakeholders and take a longitudinal perspective of mentoring.
FAU - Ng, Yong Xiang
AU  - Ng YX
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Koh, Zachary Yong Keat
AU  - Koh ZYK
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Yap, Hong Wei
AU  - Yap HW
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore,
      Singapore.
FAU - Tay, Kuang Teck
AU  - Tay KT
AUID- ORCID: 0000-0002-2703-7052
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Tan, Xiu Hui
AU  - Tan XH
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Ong, Yun Ting
AU  - Ong YT
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Tan, Lorraine Hui En
AU  - Tan LHE
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Chin, Annelissa Mien Chew
AU  - Chin AMC
AD  - Medical Library, National University of Singapore Libraries, National University 
      of Singapore, Singapore, Singapore.
FAU - Toh, Ying Pin
AU  - Toh YP
AD  - Department of Family Medicine, National University Health System, Singapore,
      Singapore.
FAU - Shivananda, Sushma
AU  - Shivananda S
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
FAU - Compton, Scott
AU  - Compton S
AD  - Education Department, Duke-NUS Medical School, Singapore, Singapore.
FAU - Mason, Stephen
AU  - Mason S
AD  - Cancer Research Centre, Marie Curie Palliative Care Institute, University of
      Liverpool, Liverpool, England, United Kingdom.
FAU - Kanesvaran, Ravindran
AU  - Kanesvaran R
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Education Department, Duke-NUS Medical School, Singapore, Singapore.
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore,
      Singapore.
FAU - Krishna, Lalit
AU  - Krishna L
AUID- ORCID: 0000-0001-6995-1646
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Supportive and Palliative Care, National Cancer Centre Singapore,
      Singapore, Singapore.
AD  - Education Department, Duke-NUS Medical School, Singapore, Singapore.
AD  - Cancer Research Centre, Marie Curie Palliative Care Institute, University of
      Liverpool, Liverpool, England, United Kingdom.
AD  - Centre of Biomedical Ethics, National University of Singapore, Singapore,
      Singapore.
AD  - Division of Cancer Education, National Cancer Centre Singapore, Singapore,
      Singapore.
AD  - PalC, The Palliative Care Centre for Excellence in Research and Education,
      Singapore, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200508
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Educational Measurement/methods
MH  - Humans
MH  - Internal Medicine/*education
MH  - *Mentoring
MH  - *Mentors
PMC - PMC7209188
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/05/10 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
AID - 10.1371/journal.pone.0232511 [doi]
AID - PONE-D-20-04105 [pii]
PST - epublish
SO  - PLoS One. 2020 May 8;15(5):e0232511. doi: 10.1371/journal.pone.0232511.
      eCollection 2020.


PMID- 32383125
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20220413
IS  - 1496-8975 (Electronic)
IS  - 0832-610X (Linking)
VI  - 67
IP  - 9
DP  - 2020 Sep
TI  - Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic
      randomized-controlled trial.
PG  - 1201-1211
LID - 10.1007/s12630-020-01684-7 [doi]
AB  - BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
      emerged in December 2019 causing the coronavirus disease (COVID-19) pandemic.
      Currently, there is a lack of evidence-based therapies to prevent COVID-19
      following exposure to the virus, or to prevent worsening of symptoms following
      confirmed infection. We describe the design of a clinical trial of
      hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy
      (PET) for COVID-19. METHODS: We will conduct two nested multicentre international
      double-blind randomized placebo-controlled clinical trials of hydroxychloroquine 
      for: 1) PEP of asymptomatic household contacts or healthcare workers exposed to
      COVID-19 within the past four days, and 2) PET for symptomatic outpatients with
      COVID-19 showing symptoms for less than four days. We will recruit 1,500 patients
      each for the PEP and PET trials. Participants will be randomized 1:1 to receive
      five days of hydroxychloroquine or placebo. The primary PEP trial outcome will be
      the incidence of symptomatic COVID-19. The primary PET trial outcome will be an
      ordinal scale of disease severity (not hospitalized, hospitalized without
      intensive care, hospitalization with intensive care, or death). Participant
      screening, informed consent, and follow-up will be exclusively internet-based
      with appropriate regulatory and research ethics board approvals in Canada and the
      United States. DISCUSSION: These complementary randomized-controlled trials are
      innovatively designed and adequately powered to rapidly answer urgent questions
      regarding the effectiveness of hydroxychloroquine to reduce virus transmission
      and disease severity of COVID-19 during a pandemic. In-person participant
      follow-up will not be conducted to facilitate social distancing strategies and
      reduce risks of exposure to study personnel. Innovative trial approaches are
      needed to urgently assess therapeutic options to mitigate the global impact of
      this pandemic. TRIALS REGISTRATION: clinicaltrials.gov (NCT04308668); registered 
      16 March, 2020.
FAU - Lother, Sylvain A
AU  - Lother SA
AD  - Department of Internal Medicine, Section of Critical Care, University of
      Manitoba, Winnipeg, MB, Canada. slother@manitoba-physicians.ca.
AD  - Section of Infectious Diseases, Department of Internal Medicine, University of
      Manitoba, Winnipeg, MB, Canada. slother@manitoba-physicians.ca.
FAU - Abassi, Mahsa
AU  - Abassi M
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - Agostinis, Alyssa
AU  - Agostinis A
AD  - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and 
      Dentistry, University of Alberta, Edmonton, AB, Canada.
AD  - School of Medicine, Trinity College Dublin, Dublin, Ireland.
FAU - Bangdiwala, Ananta S
AU  - Bangdiwala AS
AD  - Division of Biostatistics, School of Public Health, University of Minnesota,
      Minneapolis, MN, USA.
FAU - Cheng, Matthew P
AU  - Cheng MP
AD  - Divisions of Infectious Diseases & Medical Microbiology, McGill University Health
      Centre, Montreal, QC, Canada.
AD  - McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, QC,
      Canada.
FAU - Drobot, Glen
AU  - Drobot G
AD  - Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
FAU - Engen, Nicole
AU  - Engen N
AD  - Division of Biostatistics, School of Public Health, University of Minnesota,
      Minneapolis, MN, USA.
FAU - Hullsiek, Kathy H
AU  - Hullsiek KH
AD  - Division of Biostatistics, School of Public Health, University of Minnesota,
      Minneapolis, MN, USA.
FAU - Kelly, Lauren E
AU  - Kelly LE
AD  - Department of Pediatrics and Child Health, Department of Pharmacology, University
      of Manitoba, Winnipeg, MB, Canada.
FAU - Lee, Todd C
AU  - Lee TC
AD  - Clinical Practice Assessment Unit, Department of Medicine, McGill University,
      Montreal, QC, Canada.
FAU - Lofgren, Sarah M
AU  - Lofgren SM
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - MacKenzie, Lauren J
AU  - MacKenzie LJ
AD  - Section of Infectious Diseases, Department of Internal Medicine, University of
      Manitoba, Winnipeg, MB, Canada.
AD  - Department of Community Health Sciences, University of Manitoba, Winnipeg, MB,
      Canada.
FAU - Marten, Nicole
AU  - Marten N
AD  - Critical Care Research, St-Boniface Hospital, Winnipeg, MB, Canada.
FAU - McDonald, Emily G
AU  - McDonald EG
AD  - Clinical Practice Assessment Unit, Department of Medicine, McGill University,
      Montreal, QC, Canada.
FAU - Okafor, Elizabeth C
AU  - Okafor EC
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - Pastick, Katelyn A
AU  - Pastick KA
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - Pullen, Matthew F
AU  - Pullen MF
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - Rajasingham, Radha
AU  - Rajasingham R
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - Schwartz, Ilan
AU  - Schwartz I
AD  - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and 
      Dentistry, University of Alberta, Edmonton, AB, Canada.
FAU - Skipper, Caleb P
AU  - Skipper CP
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
FAU - Turgeon, Alexis F
AU  - Turgeon AF
AD  - CHU de Quebec - Universite Laval Research Centre, Population Health and Optimal
      Health Practices Research Unit Trauma - Emergency - Critical Care Medicine,
      Universite Laval, Quebec, QC, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Division of Critical
      Care Medicine, Faculty of Medicine, Universite Laval, Quebec, QC, Canada.
FAU - Zarychanski, Ryan
AU  - Zarychanski R
AD  - Department of Internal Medicine, Section of Critical Care, University of
      Manitoba, Winnipeg, MB, Canada.
AD  - Department of Internal Medicine, Section of Hematology and Oncology, University
      of Manitoba, Winnipeg, MB, Canada.
AD  - Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB,
      Canada.
FAU - Boulware, David R
AU  - Boulware DR
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04308668
GR  - K23 AI138851/AI/NIAID NIH HHS/United States
GR  - K23 MH121220/MH/NIMH NIH HHS/United States
GR  - T35 AI118620/AI/NIAID NIH HHS/United States
GR  - UL1 TR002494/TR/NCATS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire
      aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude
      randomisee controlee pragmatique.
DEP - 20200507
PL  - United States
TA  - Can J Anaesth
JT  - Canadian journal of anaesthesia = Journal canadien d'anesthesie
JID - 8701709
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control/transmission
MH  - Double-Blind Method
MH  - Humans
MH  - Hydroxychloroquine/*administration & dosage
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control/transmission
MH  - Post-Exposure Prophylaxis/*methods
MH  - SARS-CoV-2
MH  - Severity of Illness Index
PMC - PMC7205369
OTO - NOTNLM
OT  - *COVID-19
OT  - *Hydroxychloroquine
OT  - *SARS-CoV-2
OT  - *clinical trials
OT  - *coronavirus
OT  - *healthcare worker
OT  - *post-exposure prophylaxis
OT  - *pre-emptive therapy
EDAT- 2020/05/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - 10.1007/s12630-020-01684-7 [doi]
AID - 10.1007/s12630-020-01684-7 [pii]
PST - ppublish
SO  - Can J Anaesth. 2020 Sep;67(9):1201-1211. doi: 10.1007/s12630-020-01684-7. Epub
      2020 May 7.


PMID- 32382792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201123
IS  - 1432-5195 (Electronic)
IS  - 0341-2695 (Linking)
VI  - 44
IP  - 10
DP  - 2020 Oct
TI  - Are negative reviews, predatory reviewers or failed peer review rewarded at
      Publons?
PG  - 2193-2194
LID - 10.1007/s00264-020-04587-w [doi]
FAU - Teixeira da Silva, Jaime A
AU  - Teixeira da Silva JA
AD  - Independent researcher, P. O. Box 7, Miki-cho post office, Ikenobe 3011-2,
      Kagawa-ken, 7610799, Japan. jaimetex@yahoo.com.
LA  - eng
PT  - Letter
DEP - 20200507
PL  - Germany
TA  - Int Orthop
JT  - International orthopaedics
JID - 7705431
SB  - IM
OTO - NOTNLM
OT  - *Confidentiality
OT  - *Ethics
OT  - *Peer reviewer
OT  - *Predatory peers
OT  - *Quality control
OT  - *Transparency
OT  - *Trust
EDAT- 2020/05/10 06:00
MHDA- 2020/05/10 06:01
CRDT- 2020/05/09 06:00
PHST- 2020/04/23 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/04/23 00:00 [revised]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/10 06:01 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - 10.1007/s00264-020-04587-w [doi]
AID - 10.1007/s00264-020-04587-w [pii]
PST - ppublish
SO  - Int Orthop. 2020 Oct;44(10):2193-2194. doi: 10.1007/s00264-020-04587-w. Epub 2020
      May 7.


PMID- 32382676
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Linking)
VI  - 6
IP  - 4
DP  - 2020 Apr
TI  - Effects of atorvastatin and metformin on development of
      pentylenetetrazole-induced seizure in mice.
PG  - e03761
LID - 10.1016/j.heliyon.2020.e03761 [doi]
AB  - Recent studies have shown that statins and Metformin may have beneficial effects 
      on seizure through different mechanisms. In the current study, we investigated
      whether Metformin, Atorvastatin, and concomitant uses of them have beneficial
      effects on pentylenetetrazole (PTZ)-induced kindling. Adult male C57BL/6 mice
      were randomly divided into four experimental groups with seven mice in each
      group. Group 1, control group; group 2, received Metformin (200 mg/kg, i.p);
      group 3, received Atorvastatin (10 mg/kg, i.p.); group 4, received Atorvastatin
      (10 mg/kg, i.p.) plus Metformin (200 mg/kg, i.p.). Twenty minutes after injection
      of the mentioned drugs, the experimented mice received 37/5 mg/kg of PTZ
      intraperitoneally on alternating days. Then the convulsive behavior signs were
      evaluated for 20 min after each PTZ injection. There were significant differences
      in the stage 2 latency parameter among group 2 (p = 0.033, F = 8.46)/group 3 (p =
      0.032, F = 10.42)/group 4 (p = 0.008, F = 24.57) as compared to the control
      group, while no significant differences were found comparing only group 2,3, and 
      4 with eachother excluding the control group. Pretreatment with Atorvastatin (p =
      0.002, F = 33), Atorvastatin + Metformin (p = 0.006, F = 20.77), and Metformin
      alone increased stage 5 latency as compared to the PTZ group, significantly.
      Also, our results have shown that pretreatment with Atorvastatin (p = 0.013, F = 
      14.48), Metformin (p = 0.015, F = 16.67), and concomitant usage of them
      significantly decreased stage 5 duration as compared to the control group. Our
      findings clearly demonstrate that concomitant use of Metformin and Atorvastatin
      has no more protective effect against the development of kindling as compare to
      these drugs alone. Thus, we concluded that, these drugs may inhibit kindling via 
      a similar mechanism and we suggested that it is probably through regulation of
      autophagy.
CI  - (c) 2020 The Authors. Published by Elsevier Ltd.
FAU - Zeyghami, Mohammad Ali
AU  - Zeyghami MA
AD  - Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan,
      Iran.
AD  - Dept. Pharmacology, Faculty of Medicine, Golestan University of Medical Sciences,
      Gorgan, Iran.
FAU - Hesam, Ebrahim
AU  - Hesam E
AD  - Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan,
      Iran.
AD  - Dept. Physiology, Faculty of Medicine, Golestan University of Medical Sciences,
      Gorgan, Iran.
FAU - Khadivar, Parand
AU  - Khadivar P
AD  - Dept. Medical Biotechnology, Faculty of Advanced Technologies in Medicine,
      Golestan University of Medical Sciences, Gorgan, Iran.
FAU - Hesam, Halimeh Khaton
AU  - Hesam HK
AD  - Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan,
      Iran.
FAU - Ahmadnia, Ali
AU  - Ahmadnia A
AD  - Dept. Molecular Medicine, Faculty of Advanced Technologies in Medicine, Golestan 
      University of Medical Sciences, Gorgan, Iran.
FAU - Amini, Abolfazl
AU  - Amini A
AD  - Laboratory Sciences Research Center, Golestan University of Medical Sciences,
      Gorgan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC7203078
OTO - NOTNLM
OT  - Atorvastatin
OT  - Biochemistry
OT  - Clinical toxicology
OT  - Medical ethics
OT  - Metformin
OT  - Pentylenetetrazole kindling
OT  - Pharmacology
OT  - Seizure
OT  - Toxicology
EDAT- 2020/05/10 06:00
MHDA- 2020/05/10 06:01
CRDT- 2020/05/09 06:00
PHST- 2019/08/19 00:00 [received]
PHST- 2019/10/21 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/10 06:01 [medline]
AID - 10.1016/j.heliyon.2020.e03761 [doi]
AID - S2405-8440(20)30606-X [pii]
AID - e03761 [pii]
PST - epublish
SO  - Heliyon. 2020 Apr 9;6(4):e03761. doi: 10.1016/j.heliyon.2020.e03761. eCollection 
      2020 Apr.


PMID- 32382530
OWN - NLM
STAT- MEDLINE
DCOM- 20210211
LR  - 20220414
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Knowledge, Awareness, and Health-Seeking Behaviour regarding Tuberculosis in a
      Rural District of Khyber Pakhtunkhwa, Pakistan.
PG  - 1850541
LID - 10.1155/2020/1850541 [doi]
AB  - BACKGROUND: Pakistan is a country with one of the highest burden of tuberculosis 
      (TB) in the world, and therefore, it is imperative to revisit the design of
      behaviour change interventions in the program. This study was designed to
      understand and assess the knowledge, awareness, perceptions, and health-seeking
      behaviour of general and specifically TB-affected population and to determine the
      presence and level of stigma and discrimination toward TB patients. METHODS: A
      mixed-method study was conducted in district Haripur of the Khyber Pakhtunkhwa
      province, comprising a household survey, whereby 526 individuals were
      interviewed, and five focus group discussions with various subgroups including TB
      patients and health workers and authorities. Study sought an ethical approval,
      and data of all respondents was kept confidential. RESULTS: Quantitative results 
      show that women were more knowledgeable on symptomatology and spread of TB, and
      with rising education, awareness on TB improves. The majority of our respondents 
      had the understanding that it is a curable disease, yet some would avoid TB
      patients. Most of the respondents (both men and women) knew that one must go to a
      government facility for treatment. Only one-third would speak to doctor first, if
      they suspect TB-like symptoms. Television was a popular source of information on 
      TB. Qualitative results captured people's perceptions that TB was related with
      poverty and was still considered a stigma in the community; hence, patients
      afflicted feared disclosing the disease. CONCLUSION: With contextual
      understanding of communities' knowledge, attitudes, health-seeking behaviour, and
      care-seeking patterns, it can be concluded that there is a need to increase the
      awareness about TB symptoms, mode of transmission, prevention, diagnosis and
      treatment, and destigmatization of the disease through health education.
CI  - Copyright (c) 2020 Adeela Khan et al.
FAU - Khan, Adeela
AU  - Khan A
AD  - Rights & Health Alliance for Integrated Development, Islamabad, Pakistan.
FAU - Shaikh, Babar Tasneem
AU  - Shaikh BT
AUID- ORCID: https://orcid.org/0000-0002-2056-4132
AD  - Health Services Academy, Islamabad, Pakistan.
FAU - Baig, Mirza Amir
AU  - Baig MA
AD  - Field Epidemiology & Laboratory Training Program, National Institute of Health,
      Islamabad, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - *Health Behavior
MH  - *Health Education
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pakistan/epidemiology
MH  - *Patient Acceptance of Health Care
MH  - *Rural Population
MH  - Tuberculosis/*epidemiology/therapy
PMC - PMC7193271
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/10 06:00
MHDA- 2021/02/12 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/02/12 06:00 [medline]
AID - 10.1155/2020/1850541 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Apr 21;2020:1850541. doi: 10.1155/2020/1850541. eCollection 
      2020.


PMID- 32382000
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20220414
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 94
DP  - 2020 May 5
TI  - [Ethical issues in the clinical records of a group of terminal patients admitted 
      into a third level hospital. Lacks and improvements.]
LID - e202005030 [pii]
AB  - OBJECTIVE: Terminal patients and their relatives must know their real situation, 
      and be treated according to the principle of autonomy, to establish therapeutic
      objectives adapted each one, according to their needs and decisions. The
      objective of this study is to identify the sufficient existence of records in the
      Medical Histories of terminal patients, which indicate their situation, such as
      the information given to the patients, or the LET, No-RCP or Z.51.5 codes, and
      the statistical relation they have with the sociodemographic and clinical
      variables. METHODS: Cross-sectional study in a third-level hospital, with
      patients admitted between January and December 2017, who died with terminal
      illness criteria. Data were collected from the medical records, and,
      fundamentally, from the nursing clinical notes. The statistical analysis was
      performed with the SPSS program, version 22. RESULTS: Participants were 140
      people, 54.3% men, of 78.51 (SD=13.5) of middle age. People up to 70 years of age
      received less information (Odds ratio (OR): 0.077, 95% Confidence interval (CI): 
      0.015-0.390) and lower sedation (OR: 0.366, 95% CI: 0.149-0.899). Proceeding from
      city reduced the probability of receiving information (OR: 0.202; IC95%:
      0.058-0.705). Presenting dyspnea reduced LTE (OR: 0.44, 95% CI: 0.20-093), No CPR
      (0.29, 95% CI: 0.12-0.68) and sedation (OR: 0.27; 95% CI: 0.12-060). Fatigue
      increased the probability of being Non-CPR (OR: 2.77, 95% CI: 1.166-6.627) and of
      receiving sedation (OR: 2.6, 95% CI: 1.065-6.331). CONCLUSIONS: Efforts to
      empower the patient in the decision of their process and the management of the
      information of their diagnosis and prognosis are still lacking. A greater and
      better clinical records facilitates knowing how actions are developed, allowing
      to identify and implement ethical and responsible interventions.
FAU - Hernandez-Bello, Estela
AU  - Hernandez-Bello E
AD  - Hospital Clinico Universitario Lozano Blesa. Zaragoza. Espana.
FAU - Gasch-Gallen, Angel
AU  - Gasch-Gallen A
AD  - Facultad de Ciencias de la Salud. Departamento de Fisiatria y Enfermeria.
      Universidad de Zaragoza. Zaragoza. Espana.
LA  - spa
PT  - Journal Article
TT  - Cuestiones eticas en los registros clinicos de un grupo de pacientes terminales
      ingresados en un hospital de tercer nivel. Carencias y mejoras.
DEP - 20200505
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Adult
MH  - Advance Directives/*ethics/statistics & numerical data
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Decision Making/ethics
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Informed Consent/ethics/standards/statistics & numerical data
MH  - Male
MH  - *Medical Records
MH  - Middle Aged
MH  - *Patient Participation/methods/statistics & numerical data
MH  - *Personal Autonomy
MH  - Quality Improvement/*ethics/statistics & numerical data
MH  - Retrospective Studies
MH  - Spain
MH  - Terminal Care/*ethics/standards/statistics & numerical data
MH  - Tertiary Care Centers/*ethics/standards/statistics & numerical data
OTO - NOTNLM
OT  - Advance directives
OT  - Bioethics
OT  - Chronic disease
OT  - Decision making
OT  - Palliative Care
OT  - Personal Autonomy
OT  - Spain
EDAT- 2020/05/10 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/05/09 06:00
PHST- 2019/06/21 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PST - epublish
SO  - Rev Esp Salud Publica. 2020 May 5;94.


PMID- 32381738
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20201107
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 21
DP  - 2020 May 26
TI  - Decisional autonomy undermines advisees' judgments of experts in medicine and in 
      life.
PG  - 11368-11378
LID - 10.1073/pnas.1910572117 [doi]
AB  - Over the past several decades, the United States medical system has increasingly 
      prioritized patient autonomy. Physicians routinely encourage patients to come to 
      their own decisions about their medical care rather than providing patients with 
      clearer yet more paternalistic advice. Although political theorists,
      bioethicists, and philosophers generally see this as a positive trend, the
      present research examines the important question of how patients and advisees in 
      general react to full decisional autonomy when making difficult decisions under
      uncertainty. Across six experiments (N = 3,867), we find that advisers who give
      advisees decisional autonomy rather than offering paternalistic advice are judged
      to be less competent and less helpful. As a result, advisees are less likely to
      return to and recommend these advisers and pay them lower wages. Importantly, we 
      also demonstrate that advisers do not anticipate these effects. We document these
      results both inside and outside the medical domain, suggesting that the
      preference for paternalism is not unique to medicine but rather is a feature of
      situations in which there are adviser-advisee asymmetries in expertise. We find
      that the preference for paternalism holds when advice is solicited or
      unsolicited, when both paternalism and autonomy are accompanied by expert
      guidance, and it persists both before and after the outcomes of paternalistic
      advice are realized. Lastly, we see that the preference for paternalism only
      occurs when decision makers perceive their decision to be difficult. These
      results challenge the benefits of recently adopted practices in medical decision 
      making that prioritize full decisional autonomy.
FAU - Kassirer, Samantha
AU  - Kassirer S
AD  - Kellogg School of Management, Northwestern University, Evanston, IL 60208;
      samantha.kassirer@kellogg.northwestern.edu.
FAU - Levine, Emma E
AU  - Levine EE
AD  - Booth School of Business, University of Chicago, Chicago, IL, 60637.
FAU - Gaertig, Celia
AU  - Gaertig C
AUID- ORCID: 0000-0002-5444-4999
AD  - Booth School of Business, University of Chicago, Chicago, IL, 60637.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - Adult
MH  - Chicago
MH  - *Decision Making
MH  - Female
MH  - Financial Management/ethics
MH  - Humans
MH  - Internet
MH  - Male
MH  - Medicine
MH  - Paternalism
MH  - *Personal Autonomy
MH  - *Physician-Patient Relations/ethics
MH  - Workplace
PMC - PMC7260954
OTO - NOTNLM
OT  - *autonomy
OT  - *ethics
OT  - *medical decision making
OT  - *paternalism
COIS- The authors declare no competing interest.
EDAT- 2020/05/10 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - 1910572117 [pii]
AID - 10.1073/pnas.1910572117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 May 26;117(21):11368-11378. doi:
      10.1073/pnas.1910572117. Epub 2020 May 7.


PMID- 32381683
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20220531
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Human infection challenge studies in endemic settings and/or low-income and
      middle-income countries: key points of ethical consensus and controversy.
PG  - 601-609
LID - 10.1136/medethics-2019-106001 [doi]
AB  - Human infection challenge studies (HCS) involve intentionally infecting research 
      participants with pathogens (or other micro-organisms). There have been recent
      calls for more HCS to be conducted in low-income and middle-income countries
      (LMICs), where many relevant diseases are endemic. HCS in general, and HCS in
      LMICs in particular, raise numerous ethical issues. This paper summarises the
      findings of a project that explored ethical and regulatory issues related to LMIC
      HCS via (i) a review of relevant literature and (ii) 45 qualitative interviews
      with scientists and ethicists. Among other areas of consensus, we found that
      there was widespread agreement that LMIC HCS can be ethically acceptable,
      provided that they have a sound scientific rationale, are accepted by local
      communities and meet usual research ethics requirements. Unresolved issues
      include those related to (i) acceptable approaches to trade-offs between the
      scientific aim to produce generalisable results and the protection of
      participants, (iii) the sharing of benefits with LMIC populations, (iii) the
      acceptable limits to risks and burdens for participants, (iv) the potential for
      third-party risk and whether the degree of acceptable third-party risk is
      different in endemic settings, (v) the conditions under which (if any) it would
      be appropriate to recruit children for disease-causing HCS, (v) appropriate
      levels of payment to participants and (vi) appropriate governance of (LMIC) HCS. 
      This paper provides preliminary analyses of these ethical considerations in order
      to (i) inform scientists and policymakers involved in the planning, conduct
      and/or governance of LMIC HCS and (ii) highlight areas warranting future
      research. Insofar as this article focuses on HCS in (endemic) settings where
      diseases are present and/or widespread, much of the analysis provided is relevant
      to HCS (in HICs or LMICs) involving pandemic diseases including COVID19.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AUID- ORCID: 0000-0001-5940-602X
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia
      zeb.jamrozik@monash.edu.
AD  - Department of General Medicine, Royal Melbourne Hospital, Melbourne, Victoria,
      Australia.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AUID- ORCID: 0000-0003-3496-2884
AD  - Monash Bioethics Centre, Monash University, Melbourne, Victoria, Australia.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 210551/Z/18/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200507
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - *COVID-19
MH  - Child
MH  - Consensus
MH  - *Developing Countries
MH  - Humans
MH  - Poverty
PMC - PMC7476299
OTO - NOTNLM
OT  - *Communicable disease
OT  - *research ethics
OT  - *research on special populations
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/09 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - medethics-2019-106001 [pii]
AID - 10.1136/medethics-2019-106001 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):601-609. doi: 10.1136/medethics-2019-106001. Epub
      2020 May 7.


PMID- 32381630
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2059-8696 (Electronic)
IS  - 2059-8696 (Linking)
VI  - 5
IP  - 4
DP  - 2020 Dec
TI  - Statin treatment for unruptured intracranial aneurysms study: a study protocol
      for a double-blind, placebo-controlled trial.
PG  - 410-415
LID - 10.1136/svn-2020-000353 [doi]
AB  - BACKGROUND AND PURPOSE: A large proportion of patients with unruptured
      intracranial aneurysm (IA) are not suitable for surgical clipping and
      endovascular treatment. For these patients, anti-inflammatory medications are
      worth exploring due to inflammation of aneurysmal wall being a major factor in
      higher risk of rupture. Statin has been proven to reduce inflammation of
      atherosclerosis and maybe a suitable candidate. This study aimed to evaluate
      whether atorvastatin will reduce in fl ammatory of the aneurysm wall measured by 
      the signal index of aneurysm wall enhancement. METHODS AND ANALYSIS: The Statin
      Treatment for UnruptureD Intracranial anEurysms Study is a single-centre, phase
      2, randomised, controlled, double-blind clinical trial. 60 patients with
      unruptured IAs with aneurysm wall enhancement will be enrolled in Beijing Tiantan
      Hospital. The patients will be randomised to receive atorvastatin 20 mg or
      placebo orally per day for 12 months. The primary outcome will be the change in
      aneurysm wall enhancement measured by the signal index during the 12 months
      treatment with atorvastatin. The secondary study outcomes will be the change in
      aneurysm wall enhancement measured by the signal index at 3 months, the changes
      in aneurysmal morphology and inflammation-related factors (C reactive protein,
      tumour necrosis factor-alpha, interleukin-1beta and interleukin-6) at 3 and 12
      months. This study is the first to explore the role of atorvastatin in reducing
      inflammation in unruptured IA, which could lay the groundwork for future phase
      III trial. ETHICS AND DISSEMINATION: Beijing Tiantan Hospital's Ethics committee 
      approved the research and written informed consents would be obtained from all
      participant or representative included in this study. TRIAL REGISTRATION NUMBER: 
      NCT04149483.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Wenqiang
AU  - Li W
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Zhang, Yisen
AU  - Zhang Y
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Tian, Zhongbin
AU  - Tian Z
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Liu, Jian
AU  - Liu J
AUID- ORCID: 0000-0002-5454-2847
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
FAU - Yang, Xinjian
AU  - Yang X
AD  - Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and 
      Beijing Tiantan Hospital, Capital Medical University, Beijing, China
      decaitian@hotmail.com yangxinjian@voiceoftiantan.org.
FAU - Tian, De-Cai
AU  - Tian DC
AUID- ORCID: 0000-0002-5153-2491
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University,
      Beijing, China decaitian@hotmail.com yangxinjian@voiceoftiantan.org.
AD  - Advanced Innovation Center for Human Brain Protection, Capital Medical
      University, Beijing, China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing,
      China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04149483
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200506
PL  - England
TA  - Stroke Vasc Neurol
JT  - Stroke and vascular neurology
JID - 101689996
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Atorvastatin/adverse effects/*therapeutic use
MH  - Beijing
MH  - Clinical Trials, Phase II as Topic
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
MH  - Intracranial Aneurysm/diagnostic imaging/*drug therapy
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC7804054
OTO - NOTNLM
OT  - *MRI
OT  - *aneurysm
OT  - *inflammation
OT  - *vessel wall
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/02/16 00:00 [received]
PHST- 2020/04/05 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - svn-2020-000353 [pii]
AID - 10.1136/svn-2020-000353 [doi]
PST - ppublish
SO  - Stroke Vasc Neurol. 2020 Dec;5(4):410-415. doi: 10.1136/svn-2020-000353. Epub
      2020 May 6.


PMID- 32381590
OWN - NLM
STAT- MEDLINE
DCOM- 20200528
LR  - 20201218
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 368
IP  - 6493
DP  - 2020 May 22
TI  - Ethics of controlled human infection to address COVID-19.
PG  - 832-834
LID - 10.1126/science.abc1076 [doi]
FAU - Shah, Seema K
AU  - Shah SK
AD  - Author affiliations are listed in the supplementary materials.
      seema.shah@northwestern.edu.
FAU - Miller, Franklin G
AU  - Miller FG
AD  - Author affiliations are listed in the supplementary materials.
FAU - Darton, Thomas C
AU  - Darton TC
AD  - Author affiliations are listed in the supplementary materials.
FAU - Duenas, Devan
AU  - Duenas D
AD  - Author affiliations are listed in the supplementary materials.
FAU - Emerson, Claudia
AU  - Emerson C
AD  - Author affiliations are listed in the supplementary materials.
FAU - Lynch, Holly Fernandez
AU  - Lynch HF
AD  - Author affiliations are listed in the supplementary materials.
FAU - Jamrozik, Euzebiusz
AU  - Jamrozik E
AD  - Author affiliations are listed in the supplementary materials.
FAU - Jecker, Nancy S
AU  - Jecker NS
AD  - Author affiliations are listed in the supplementary materials.
FAU - Kamuya, Dorcas
AU  - Kamuya D
AD  - Author affiliations are listed in the supplementary materials.
FAU - Kapulu, Melissa
AU  - Kapulu M
AD  - Author affiliations are listed in the supplementary materials.
FAU - Kimmelman, Jonathan
AU  - Kimmelman J
AD  - Author affiliations are listed in the supplementary materials.
FAU - MacKay, Douglas
AU  - MacKay D
AD  - Author affiliations are listed in the supplementary materials.
FAU - Memoli, Matthew J
AU  - Memoli MJ
AD  - Author affiliations are listed in the supplementary materials.
FAU - Murphy, Sean C
AU  - Murphy SC
AD  - Author affiliations are listed in the supplementary materials.
FAU - Palacios, Ricardo
AU  - Palacios R
AD  - Author affiliations are listed in the supplementary materials.
FAU - Richie, Thomas L
AU  - Richie TL
AD  - Author affiliations are listed in the supplementary materials.
FAU - Roestenberg, Meta
AU  - Roestenberg M
AD  - Author affiliations are listed in the supplementary materials.
FAU - Saxena, Abha
AU  - Saxena A
AD  - Author affiliations are listed in the supplementary materials.
FAU - Saylor, Katherine
AU  - Saylor K
AD  - Author affiliations are listed in the supplementary materials.
FAU - Selgelid, Michael J
AU  - Selgelid MJ
AD  - Author affiliations are listed in the supplementary materials.
FAU - Vaswani, Vina
AU  - Vaswani V
AD  - Author affiliations are listed in the supplementary materials.
FAU - Rid, Annette
AU  - Rid A
AD  - Author affiliations are listed in the supplementary materials.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Viral Vaccines)
SB  - IM
CIN - J Med Ethics. 2020 Sep;46(9):569-573. PMID: 32616623
CIN - Science. 2020 Jul 10;369(6500):150-151. PMID: 32646991
CIN - Science. 2020 Jul 10;369(6500):151. PMID: 32646992
MH  - Betacoronavirus/physiology
MH  - COVID-19
MH  - Coronavirus Infections/*immunology
MH  - Drug Development/ethics
MH  - *Human Experimentation
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*immunology
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Viral Vaccines/adverse effects/*therapeutic use
EDAT- 2020/05/10 06:00
MHDA- 2020/05/29 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - science.abc1076 [pii]
AID - 10.1126/science.abc1076 [doi]
PST - ppublish
SO  - Science. 2020 May 22;368(6493):832-834. doi: 10.1126/science.abc1076. Epub 2020
      May 7.


PMID- 32381536
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 6
TI  - Evaluation of the role of sex as a prognostic factor in critically ill adults
      with sepsis: systematic review protocol.
PG  - e035927
LID - 10.1136/bmjopen-2019-035927 [doi]
AB  - INTRODUCTION: Sepsis is a leading cause of mortality in critically ill patients. 
      Recently, it has been recognised that sex may contribute to a differential risk
      for developing sepsis and it remains uncertain if the prognosis of sepsis varies 
      between the sexes. The aim of this systematic review is to summarise the
      available evidence to assess the role of sex as a prognostic factor in patients
      with sepsis managed in the intensive care unit (ICU). METHODS AND ANALYSIS: This 
      is a systematic review protocol of prognostic studies of sex in patients with
      sepsis managed in the ICU. The primary outcomes include all-cause hospital
      mortality and all-cause hospital mortality during the first 28 days. The
      secondary outcomes include all-cause hospital mortality during the first 7 days
      and all-cause mortality at 1 year. We will conduct a search strategy based on the
      population (sepsis), the prognostic factor (sex), the outcome of interest
      (mortality) and prognostic study methods. We will search in the following
      databases up to December 2019: MEDLINE Ovid (from 1976), Embase Elsevier (from
      1974), Web of Science and two trial registries. We will impose no language
      restrictions. Two authors will independently screen titles, abstracts and
      full-text articles for eligibility of studies, and subsequently extract data. Two
      authors will independently assess the risk of bias of each study using the
      Quality in Prognostic Studies (QUIPS) tool. If possible, we will carry out a
      meta-analysis to provide a pooled prognostic effect estimate for each outcome. We
      will use the Grading of Recommendations Assessment, Development and Evaluation
      system to assess the quality of evidence. ETHICS AND DISSEMINATION: Ethical
      approval will not be required. Findings from this review will be reported in a
      peer-reviewed scientific journal. Additionally, the results will be disseminated 
      at conferences and in the mass media. PROSPERO REGISTRATION NUMBER:
      CRD42019145054.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lopez-Alcalde, Jesus
AU  - Lopez-Alcalde J
AUID- ORCID: 0000-0002-1598-8790
AD  - Faculty of Health Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcon,
      Spain.
AD  - Clinical Biostatistics Unit, Instituto Ramon y Cajal de Investigacion Sanitaria, 
      Madrid, Spain.
AD  - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), 
      Madrid, Spain.
FAU - Antequera Martin, Alba
AU  - Antequera Martin A
AUID- ORCID: 0000-0002-1670-6302
AD  - Autonomous University of Barcelona, Barcelona, Spain
      alba.antequera.martin@gmail.com.
AD  - Biomedical Research Institute Sant Pau, Hospital Santa Cruz y San Pablo,
      Barcelona, Spain.
FAU - Stallings, Elena
AU  - Stallings E
AD  - Clinical Biostatistics Unit, Instituto Ramon y Cajal de Investigacion Sanitaria, 
      Madrid, Spain.
FAU - Muriel, Alfonso
AU  - Muriel A
AUID- ORCID: 0000-0002-4805-4011
AD  - Clinical Biostatistics Unit, Instituto Ramon y Cajal de Investigacion Sanitaria, 
      Madrid, Spain.
AD  - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), 
      Madrid, Spain.
AD  - Department of Nursing and Physiotherapy, Universidad de Alcala, Madrid, Spain.
FAU - Fernandez-Felix, Borja
AU  - Fernandez-Felix B
AD  - Clinical Biostatistics Unit, Instituto Ramon y Cajal de Investigacion Sanitaria, 
      Madrid, Spain.
AD  - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), 
      Madrid, Spain.
FAU - Sola, Ivan
AU  - Sola I
AUID- ORCID: 0000-0003-0078-3706
AD  - Biomedical Research Institute Sant Pau, Hospital Santa Cruz y San Pablo,
      Barcelona, Spain.
AD  - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), 
      Barcelona, Spain.
AD  - Iberoamerican Cochrane Centre, Barcelona, Spain.
FAU - Del Campo, Rosa
AU  - Del Campo R
AUID- ORCID: 0000-0003-1147-7923
AD  - Department of Microbiology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Ponce-Alonso, Manuel
AU  - Ponce-Alonso M
AUID- ORCID: 0000-0002-3239-9373
AD  - Department of Microbiology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Gordo, Federico
AU  - Gordo F
AD  - Faculty of Health Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcon,
      Spain.
AD  - Department of Intensive Care, Hospital Universitario del Henares, Coslada,
      Madrid, Spain.
FAU - Fidalgo, Pilar
AU  - Fidalgo P
AD  - Faculty of Health Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcon,
      Spain.
AD  - Department of Internal Medicine, Hospital Universitario del Henares, Coslada,
      Madrid, Spain.
FAU - Halperin, Ana Veronica
AU  - Halperin AV
AD  - Department of Microbiology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Alvarez-Diaz, Noelia
AU  - Alvarez-Diaz N
AUID- ORCID: 0000-0002-5904-3609
AD  - Medical Library, Hospital Universitario Ramon y Cajal, Madrid, Madrid, Spain.
FAU - Madrid-Pascual, Olaya
AU  - Madrid-Pascual O
AUID- ORCID: 0000-0002-2861-0121
AD  - Arztpraxis Kalkbreite, Zurich, Switzerland.
FAU - Urrutia, Gerard
AU  - Urrutia G
AD  - Biomedical Research Institute Sant Pau, Hospital Santa Cruz y San Pablo,
      Barcelona, Spain.
AD  - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), 
      Barcelona, Spain.
AD  - Iberoamerican Cochrane Centre, Barcelona, Spain.
FAU - Zamora, Javier
AU  - Zamora J
AUID- ORCID: 0000-0003-4901-588X
AD  - Clinical Biostatistics Unit, Instituto Ramon y Cajal de Investigacion Sanitaria, 
      Madrid, Spain.
AD  - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), 
      Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200506
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Critical Illness
MH  - Humans
MH  - Intensive Care Units
MH  - Meta-Analysis as Topic
MH  - Prognosis
MH  - *Sepsis
MH  - Systematic Reviews as Topic
PMC - PMC7223151
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *epidemiology
OT  - *infectious diseases
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-035927 [pii]
AID - 10.1136/bmjopen-2019-035927 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 6;10(5):e035927. doi: 10.1136/bmjopen-2019-035927.


PMID- 32381535
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 6
TI  - Effectiveness and safety of acupuncture and moxibustion for defecation
      dysfunction after sphincter-preserving surgery for rectal cancer: protocol for
      systematic review and meta-analysis.
PG  - e034152
LID - 10.1136/bmjopen-2019-034152 [doi]
AB  - INTRODUCTION: Defecation dysfunction (DD) is one of the most common complications
      following sphincter-preserving surgery for rectal cancer. And there is no
      effective treatment of DD after sphincter-preserving surgery for rectal cancer.
      Although some studies suggested that acupuncture and moxibustion (AM) is
      effective and safe for DD after sphincter-preserving surgery for rectal cancer,
      lacking strong evidence, for instance, the relevant systematic review,
      meta-analysis and randomised controlled trial (RCT) of a large, multicentre
      sample, makes the effects and safety remain uncertain. The present protocol is
      described for a systematic review and meta-analysis to investigate the
      effectiveness and safety of AM for DD after sphincter-preserving surgery for
      rectal cancer. METHODS AND ANALYSIS: We will search nine online databases from
      inception to 1 October 2019; the language of included trials will not be
      restricted. This study will include RCTs that performed AM as the main method of 
      the experimental group for patients with DD after sphincter-preserving surgery
      for rectal cancer. Two of the researchers will independently select the studies, 
      conduct risk of bias assessment and extract the data. We will use the
      fixed-effects model or random-effects model of RevMan V.5.2 software to analyse
      data synthesis. The risk ratios with 95% CIs and weighted mean differences or
      standardised mean differences with 95% CIs will be used to present the data
      synthesis outcome of dichotomous data respectively and the continuous data.
      Evidence quality of outcome will be assessed by using the Grading of
      Recommendations Assessment, Development and Evaluation (GRADE) system. ETHICS AND
      DISSEMINATION: Ethical approval is not required in this secondary research
      evidence, and we will publish the results of this study in a journal or concerned
      conferences. TRIAL REGISTRATION NUMBER: CRD42019140097.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xu, Guixing
AU  - Xu G
AUID- ORCID: 0000-0002-8040-3656
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Xiao, Qiwei
AU  - Xiao Q
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Lei, Hanzhou
AU  - Lei H
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Fu, Yanan
AU  - Fu Y
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Kong, Jing
AU  - Kong J
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zheng, Qianhua
AU  - Zheng Q
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China.
FAU - Zhao, Ling
AU  - Zhao L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China acuresearch@126.com zhaoling@cdutcm.edu.cn.
FAU - Liang, Fanrong
AU  - Liang F
AUID- ORCID: 0000-0001-8518-9268
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, China acuresearch@126.com zhaoling@cdutcm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200506
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - Defecation
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Moxibustion
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - *Rectal Neoplasms/surgery
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7223156
OTO - NOTNLM
OT  - *acupuncture and moxibustion
OT  - *defecation dysfunction
OT  - *meta-analysis
OT  - *sphincter preserving surgery for rectal cancer
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-034152 [pii]
AID - 10.1136/bmjopen-2019-034152 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 6;10(5):e034152. doi: 10.1136/bmjopen-2019-034152.


PMID- 32381522
OWN - NLM
STAT- MEDLINE
DCOM- 20200623
LR  - 20210110
IS  - 1759-8486 (Electronic)
IS  - 1759-8478 (Linking)
VI  - 12
IP  - 7
DP  - 2020 Jul
TI  - A rationale and framework for seeking remote electronic or phone consent approval
      in endovascular stroke trials - special relevance in the COVID-19 environment and
      beyond.
PG  - 654-657
LID - 10.1136/neurintsurg-2020-016221 [doi]
AB  - BACKGROUND: Enrollment in time-sensitive endovascular stroke trials can be
      challenging because of an inability to consent a debilitated patient. Often the
      legally authorized representative is not on site. Remote consent procedures in
      the US are inconsistent with the majority of sites shunning these approaches. The
      current pandemic with visitor restrictions highlights the need for enhancing
      these options. METHODS: Remote electronic and phone consent procedures
      specifically for endovascular stroke trials from two comprehensive stroke centers
      (CSC) are presented. An overview of the genesis of informed consent procedures in
      the US is also included. RESULTS: The two CSCs identified as Institution-1 and
      Institution-2 are large tertiary systems. Institution-1 is a non-profit
      university-affiliated academic medical center in rural geography. Institution-2
      is an HCA hospital in an urban environment. Both serve patients through a
      spoke-and-hub network, have participated in multiple randomized endovascular
      stroke trials, and have successfully used these remote options for enrollment. A 
      tiered approach is employed at both institutions with an emphasis on obtaining
      informed consent in person and resorting to alternatives methods when efforts to 
      that are unsuccessful. A rationale for electronic and phone consent is included, 
      followed by step-by-step illustration of the process at each institution.
      CONCLUSION: Two examples of remote electronic or phone consent procedures from
      institutions in different geographic environments and organization structures
      demonstrate that these options can be successfully used for enrollment in stroke 
      trials. The current pandemic highlights the need to enhance these approaches
      while maintaining appropriate adherence to ethical and legal frameworks.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rai, Ansaar T
AU  - Rai AT
AUID- ORCID: http://orcid.org/0000-0001-9864-4805
AD  - Neuroradiology, Rockefeller Neurosciences Institute, West Virginia University
      Robert C Byrd Health Sciences Center, Morgantown, West Virginia, USA
      ansaar.rai@gmail.com.
FAU - Frei, Donald
AU  - Frei D
AUID- ORCID: http://orcid.org/0000-0002-7811-5030
AD  - Interventional Neuroradiology, Radiology Imaging Associates, Englewood, Colorado,
      USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200507
PL  - England
TA  - J Neurointerv Surg
JT  - Journal of neurointerventional surgery
JID - 101517079
SB  - IM
MH  - Academic Medical Centers/methods
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cell Phone
MH  - Clinical Trials as Topic/*methods
MH  - Coronavirus Infections/diagnosis/*epidemiology/therapy
MH  - Humans
MH  - *Informed Consent
MH  - Pandemics
MH  - Patient Selection
MH  - Pneumonia, Viral/diagnosis/*epidemiology/therapy
MH  - SARS-CoV-2
MH  - Stroke/diagnosis/*epidemiology/therapy
MH  - Telemedicine/*methods
PMC - PMC7246108
OTO - NOTNLM
OT  - stroke
OT  - thrombectomy
COIS- Competing interests: None declared.
EDAT- 2020/05/10 06:00
MHDA- 2020/06/24 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/06/24 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - neurintsurg-2020-016221 [pii]
AID - 10.1136/neurintsurg-2020-016221 [doi]
PST - ppublish
SO  - J Neurointerv Surg. 2020 Jul;12(7):654-657. doi: 10.1136/neurintsurg-2020-016221.
      Epub 2020 May 7.


PMID- 32381261
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20220220
IS  - 1471-6771 (Electronic)
IS  - 0007-0912 (Linking)
VI  - 125
IP  - 1
DP  - 2020 Jul
TI  - Equality or utility? Ethics and law of rationing ventilators.
PG  - 10-15
LID - S0007-0912(20)30223-3 [pii]
LID - 10.1016/j.bja.2020.04.011 [doi]
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of
      Oxford, Oxford, UK; Murdoch Children's Research Institute, Melbourne, Australia; 
      Melbourne Law School, University of Melbourne, Melbourne, Australia. Electronic
      address: julian.savulescu@philosophy.ox.ac.uk.
FAU - Cameron, James
AU  - Cameron J
AD  - Murdoch Children's Research Institute, Melbourne, Australia; Melbourne Law
      School, University of Melbourne, Melbourne, Australia.
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AD  - Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of
      Oxford, Oxford, UK; John Radcliffe Hospital, Oxford, UK.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Editorial
DEP - 20200420
PL  - England
TA  - Br J Anaesth
JT  - British journal of anaesthesia
JID - 0372541
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Delivery of Health Care/*ethics/*legislation & jurisprudence
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/*ethics
PMC - PMC7167543
OTO - NOTNLM
OT  - *COVID-19
OT  - *age
OT  - *disability
OT  - *discrimination
OT  - *egalitarianism
OT  - *ethics
OT  - *rationing
OT  - *utilitarianism
EDAT- 2020/05/10 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
PHST- 2020/05/09 06:00 [entrez]
AID - S0007-0912(20)30223-3 [pii]
AID - 10.1016/j.bja.2020.04.011 [doi]
PST - ppublish
SO  - Br J Anaesth. 2020 Jul;125(1):10-15. doi: 10.1016/j.bja.2020.04.011. Epub 2020
      Apr 20.


PMID- 32381009
OWN - NLM
STAT- MEDLINE
DCOM- 20201208
LR  - 20201214
IS  - 1475-2875 (Electronic)
IS  - 1475-2875 (Linking)
VI  - 19
IP  - 1
DP  - 2020 May 7
TI  - Evaluation of human-baited double net trap and human-odour-baited CDC light trap 
      for outdoor host-seeking malaria vector surveillance in Kenya and Ethiopia.
PG  - 174
LID - 10.1186/s12936-020-03244-2 [doi]
AB  - BACKGROUND: Surveillance of outdoor host-seeking malaria vectors is crucial to
      monitor changes in vector biting behaviour and evaluate the impact of vector
      control interventions. Human landing catch (HLC) has been considered the most
      reliable and gold standard surveillance method to estimate human-biting rates.
      However, it is labour-intensive, and its use is facing an increasing ethical
      concern due to potential risk of exposure to infectious mosquito bites. Thus,
      alternative methods are required. This study was conducted to evaluate the
      performance of human-odour-baited CDC light trap (HBLT) and human-baited double
      net trap (HDNT) for outdoor host-seeking malaria vector surveillance in Kenya and
      Ethiopia. METHODS: The sampling efficiency of HBLT and HDNT was compared with CDC
      light trap and HLC using Latin Square Design in Ahero and Iguhu sites, western
      Kenya and Bulbul site, southwestern Ethiopia between November 2015 and December
      2018. The differences in Anopheles mosquito density among the trapping methods
      were compared using generalized linear model. RESULTS: Overall, 16,963 female
      Anopheles mosquitoes comprising Anopheles gambiae sensu lato (s.l.), Anopheles
      funestus s.l., Anopheles pharoensis, Anopheles coustani and Anopheles squamosus
      were collected. PCR results (n = 552) showed that Anopheles arabiensis was the
      only member of An. gambiae s.l. in Ahero and Bulbul, while 15.7% An. arabiensis
      and 84.3% An. gambiae sensu stricto (s.s.) constituted An. gambiae s.l. in Iguhu.
      In Ahero, HBLT captured 2.23 times as many An. arabiensis and 2.11 times as many 
      An. funestus as CDC light trap. In the same site, HDNT yielded 3.43 times more
      An. arabiensis and 3.24 times more An. funestus than HBLT. In Iguhu, the density 
      of Anopheles mosquitoes did not vary between the traps (p > 0.05). In Bulbul,
      HBLT caught 2.19 times as many An. arabiensis as CDC light trap, while HDNT
      caught 6.53 times as many An. arabiensis as CDC light trap. The mean density of
      An. arabiensis did not vary between HDNT and HLC (p = 0.098), whereas the HLC
      yielded significantly higher density of An. arabiensis compared to HBLT and CDC
      light trap. There was a significant density-independent positive correlation
      between HDNT and HLC (r = 0.69). CONCLUSION: This study revealed that both HBLT
      and HDNT caught higher density of malaria vectors than conventional CDC light
      trap. Moreover, HDNT yielded a similar vector density as HLC, suggesting that it 
      could be an alternative tool to HLC for outdoor host-seeking malaria vector
      surveillance.
FAU - Degefa, Teshome
AU  - Degefa T
AUID- ORCID: http://orcid.org/0000-0002-3518-2372
AD  - School of Medical Laboratory Sciences, Faculty of Health Sciences, Jimma
      University, Jimma, Ethiopia. teshedege@gmail.com.
AD  - Centre for Global Health Research, Kenya Medical Research Institute, Kisumu,
      Kenya. teshedege@gmail.com.
FAU - Yewhalaw, Delenasaw
AU  - Yewhalaw D
AD  - School of Medical Laboratory Sciences, Faculty of Health Sciences, Jimma
      University, Jimma, Ethiopia.
AD  - Tropical and Infectious Diseases Research Center (TIDRC), Jimma University,
      Jimma, Ethiopia.
FAU - Zhou, Guofa
AU  - Zhou G
AD  - Program in Public Health, College of Health Sciences, University of California at
      Irvine, Irvine, CA, 92697, USA.
FAU - Atieli, Harrysone
AU  - Atieli H
AD  - School of Public Health and Community Development, Maseno University, Kisumu,
      Kenya.
FAU - Githeko, Andrew K
AU  - Githeko AK
AD  - Centre for Global Health Research, Kenya Medical Research Institute, Kisumu,
      Kenya.
FAU - Yan, Guiyun
AU  - Yan G
AD  - Program in Public Health, College of Health Sciences, University of California at
      Irvine, Irvine, CA, 92697, USA.
LA  - eng
GR  - R01 AI050243/AI/NIAID NIH HHS/United States
GR  - U19 AI129326/NH/NIH HHS/United States
GR  - D43 TW001505/NH/NIH HHS/United States
GR  - R01 AI050243/NH/NIH HHS/United States
GR  - U19 AI129326/AI/NIAID NIH HHS/United States
GR  - D43 TW001505/TW/FIC NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20200507
PL  - England
TA  - Malar J
JT  - Malaria journal
JID - 101139802
SB  - IM
MH  - Animals
MH  - Anopheles/*physiology
MH  - Entomology/methods
MH  - Ethiopia
MH  - Female
MH  - Humans
MH  - Kenya
MH  - Male
MH  - Mosquito Control/*methods
MH  - Mosquito Vectors/*physiology
MH  - Odorants/*analysis
PMC - PMC7206766
OTO - NOTNLM
OT  - Ethiopia
OT  - Human-baited double net trap
OT  - Human-odour-baited CDC light trap
OT  - Kenya
OT  - Malaria vectors
OT  - Outdoor host-seeking
OT  - Surveillance
EDAT- 2020/05/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12936-020-03244-2 [doi]
AID - 10.1186/s12936-020-03244-2 [pii]
PST - epublish
SO  - Malar J. 2020 May 7;19(1):174. doi: 10.1186/s12936-020-03244-2.


PMID- 32380995
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 May 8
TI  - Supporting a definition of predatory publishing.
PG  - 125
LID - 10.1186/s12916-020-01599-6 [doi]
FAU - Aromataris, Edoardo
AU  - Aromataris E
AD  - JBI, Faculty of Health and Medical Sciences, The University of Adelaide,
      Adelaide, Australia. ed.aromataris@adelaide.edu.au.
FAU - Stern, Cindy
AU  - Stern C
AD  - JBI, Faculty of Health and Medical Sciences, The University of Adelaide,
      Adelaide, Australia.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200508
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
CON - BMC Med. 2020 May 7;18(1):104. PMID: 32375818
MH  - *Checklist
MH  - Humans
MH  - Peer Review, Research
MH  - *Periodicals as Topic
MH  - Publishing
PMC - PMC7206668
OTO - NOTNLM
OT  - *Communication
OT  - *Dissemination
OT  - *Predatory journals
OT  - *Predatory publishing
OT  - *Publication ethics
EDAT- 2020/05/10 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - 10.1186/s12916-020-01599-6 [doi]
AID - 10.1186/s12916-020-01599-6 [pii]
PST - epublish
SO  - BMC Med. 2020 May 8;18(1):125. doi: 10.1186/s12916-020-01599-6.


PMID- 32380986
OWN - NLM
STAT- MEDLINE
DCOM- 20201113
LR  - 20201113
IS  - 1472-6874 (Electronic)
IS  - 1472-6874 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 7
TI  - Community stakeholders' views on reducing violence against women in Pakistan.
PG  - 98
LID - 10.1186/s12905-020-00961-3 [doi]
AB  - BACKGROUND: Nearly half of the women experience violence across their lifespan in
      all the provinces of Pakistan at an alarming rate. Despite knowing the
      prevalence, there has been meager progress in developing strategies to combat
      violence at individual, family, or community level. Many interventions suggested 
      in other countries have been pilot tested but the effects of those interventions 
      had been limited. Therefore, the aim of this study is to understand the voices of
      stakeholders to reduce Violence Against Women (VAW) and to explore the possible
      community-based strategies that could be implemented in Pakistan. METHODS: A
      total of 14 Key Informant Interviews (KIIs) and 18 Focus Group Discussions (FGDs)
      were held across all four provinces of Pakistan. Participants were purposefully
      recruited and all the interviews were audio-recorded. Transcriptions were open
      coded and content analysis was done to emerge codes, categories and themes.
      Ethical approval was obtained from Aga Khan University Ethics Review Committee.
      RESULTS: Three major themes emerged on community members and stakeholders' views 
      on VAW: a) community's perception of VAW b) the repercussions of VAW, and c)
      multiple voices regarding strategies to reduce VAW. Participants voiced the need 
      of standing against the status quo, role of awareness and education: regarding
      capacity building skills, promotion of women rights and women empowerment through
      Life Skills Based Education (LSBE) through national health works program, has
      been proposed as an innovative strategy to reduce VAW. CONCLUSIONS: The
      responsibility to bring about a substantial change in behavior and attitudes must
      begin with engaging men in all the interventions that aim to reduce violence.
      Since, VAW is very much linked with the cultural norms, so, without community
      stakeholder's involvement and participation it could never be reduced. Keeping
      the existing socio-cultural dynamics in mind, the need of time is to design and
      implement innovative interventions that are culturally and contextually
      appropriate and can be expanded across the country.
FAU - Ali, Tazeen Saeed
AU  - Ali TS
AUID- ORCID: 0000-0002-8896-8766
AD  - School of Nursing and Midwifery, Aga Khan University (SONAM AKU), Stadium Road,
      Karachi, Sindh, Pakistan. tazeen.ali@aku.edu.
FAU - Karmaliani, Rozina
AU  - Karmaliani R
AD  - School of Nursing and Midwifery, Aga Khan University (SONAM AKU), Stadium Road,
      Karachi, Sindh, Pakistan.
FAU - Khuwaja, Hussain Maqbool Ahmed
AU  - Khuwaja HMA
AD  - School of Nursing and Midwifery, Aga Khan University (SONAM AKU), Stadium Road,
      Karachi, Sindh, Pakistan.
FAU - Shah, Nasim Zahid
AU  - Shah NZ
AD  - Umeed-e-Nau Innovations Center of Excellence in Women and Child Health (COE), Aga
      Khan University (AKU), Karachi, Pakistan.
FAU - Wadani, Zahid Hyder
AU  - Wadani ZH
AD  - Umeed-e-Nau Innovations Center of Excellence in Women and Child Health (COE), Aga
      Khan University (AKU), Karachi, Pakistan.
FAU - Aijaz, Saher
AU  - Aijaz S
AD  - School of Nursing and Midwifery, Aga Khan University (SONAM AKU), Stadium Road,
      Karachi, Sindh, Pakistan.
FAU - Kulane, Asli
AU  - Kulane A
AD  - Department of Equity and Policy Development at Karolinska Institutet, Stockholm, 
      Sweden.
LA  - eng
GR  - 2015-R1-A1-A3A0-4001267/Bill and Melinda Gates Foundation/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - England
TA  - BMC Womens Health
JT  - BMC women's health
JID - 101088690
SB  - IM
MH  - Attitude
MH  - Child
MH  - *Domestic Violence
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Pakistan
MH  - Qualitative Research
MH  - Spouse Abuse/*prevention & control/psychology
MH  - Violence/*ethnology/*prevention & control/psychology
MH  - Women's Rights
PMC - PMC7206774
OTO - NOTNLM
OT  - *Interventions to reduce violence
OT  - *Violence against women
OT  - *Violence reduction
OT  - *community's perception of violence
EDAT- 2020/05/10 06:00
MHDA- 2020/11/18 06:00
CRDT- 2020/05/09 06:00
PHST- 2019/06/10 00:00 [received]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1186/s12905-020-00961-3 [doi]
AID - 10.1186/s12905-020-00961-3 [pii]
PST - epublish
SO  - BMC Womens Health. 2020 May 7;20(1):98. doi: 10.1186/s12905-020-00961-3.


PMID- 32380959
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1471-2318 (Electronic)
IS  - 1471-2318 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 7
TI  - Reducing physical restraints by older adults in home care: development of an
      evidence-based guideline.
PG  - 169
LID - 10.1186/s12877-020-1499-y [doi]
AB  - BACKGROUND: Restraint use is a complex and challenging issue in home care. Due to
      socio-demographic trends, worldwide home healthcare providers are faced with an
      increasing demand for restraint use from informal caregivers, patients and
      healthcare providers, resulting in the use of various types of restraints in home
      care. Awareness and knowledge of restraint use in home care, its implications and
      the ethical challenges surrounding it are of crucial importance to its reduction.
      This research aimed to describe the development process of an evidence-based
      practice guideline to support caregivers to optimize home care. METHOD: The
      practice guideline was developed according to the framework of the Belgian Centre
      for Evidence-Based Medicine and AGREE II. The guideline was developed over
      several stages: (1) determination of the target population and scope, (2)
      literature search, (3) drafting and (4) validation. A multidisciplinary working
      group determined the proposed purpose, target group, and six clinical questions
      for the guideline. A consensus procedure and consultation by experts were used to
      develop the guideline. RESULTS: The guideline provides an answer to six clinical 
      questions and contains ten key recommendations based on the classification of
      GRADE, with the objective of increasing healthcare providers' awareness,
      knowledge and competence to adequately deal with situations or questions related 
      to restraint use. The guideline also includes a flowchart for dealing with
      complex situations where the use of restraints is requested, already present or
      considered. CONCLUSIONS: The guideline was validated by the Belgian Centre for
      Evidence-Based Medicine. Increasing competence, awareness and knowledge related
      to restraint use are key objectives of the guideline for reducing restraint use
      in home care. A multicomponent intervention to support healthcare workers in
      implementing the guideline in clinical practice needs to be developed.
FAU - Scheepmans, Kristien
AU  - Scheepmans K
AD  - Wit-Gele Kruis van Vlaanderen, Nursing Department, Frontispiesstraat 8, bus 1.2, 
      1000, Brussels, Belgium.
AD  - Department of Public Health and Primary Care, Academic Centre for Nursing and
      Midwifery, KU Leuven, Kapucijnenvoer 35 blok d - bus 7001, B-3000, Leuven,
      Belgium.
FAU - Dierckx de Casterle, Bernadette
AU  - Dierckx de Casterle B
AD  - Department of Public Health and Primary Care, Academic Centre for Nursing and
      Midwifery, KU Leuven, Kapucijnenvoer 35 blok d - bus 7001, B-3000, Leuven,
      Belgium.
FAU - Paquay, Louis
AU  - Paquay L
AD  - Wit-Gele Kruis van Vlaanderen, Nursing Department, Frontispiesstraat 8, bus 1.2, 
      1000, Brussels, Belgium.
FAU - Van Gansbeke, Hendrik
AU  - Van Gansbeke H
AD  - Wit-Gele Kruis van Vlaanderen, Nursing Department, Frontispiesstraat 8, bus 1.2, 
      1000, Brussels, Belgium.
FAU - Milisen, Koen
AU  - Milisen K
AUID- ORCID: 0000-0001-9230-1246
AD  - Department of Public Health and Primary Care, Academic Centre for Nursing and
      Midwifery, KU Leuven, Kapucijnenvoer 35 blok d - bus 7001, B-3000, Leuven,
      Belgium. koen.milisen@kuleuven.be.
AD  - Division of Geriatric Medicine, Department of Internal Medicine, Leuven
      University Hospitals, Herestraat 49, 3000, Leuven, Belgium.
      koen.milisen@kuleuven.be.
LA  - eng
GR  - no number/Vanbreda Risk &amp; Benefits/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - England
TA  - BMC Geriatr
JT  - BMC geriatrics
JID - 100968548
SB  - IM
MH  - Aged
MH  - Belgium
MH  - Caregivers
MH  - Evidence-Based Medicine
MH  - *Home Care Services
MH  - Humans
MH  - *Restraint, Physical
PMC - PMC7204038
OTO - NOTNLM
OT  - *Evidence based
OT  - *Home care
OT  - *Nurses
OT  - *Nursing
OT  - *Physical restraints
OT  - *Practice guideline
OT  - *Reduction
EDAT- 2020/05/10 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/05/09 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12877-020-1499-y [doi]
AID - 10.1186/s12877-020-1499-y [pii]
PST - epublish
SO  - BMC Geriatr. 2020 May 7;20(1):169. doi: 10.1186/s12877-020-1499-y.


PMID- 32380932
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20210604
IS  - 1461-7471 (Electronic)
IS  - 1363-4615 (Linking)
VI  - 57
IP  - 2
DP  - 2020 Apr
TI  - Advancing Indigenous Mental Health Research: Ethical, conceptual and
      methodological challenges.
PG  - 235-249
LID - 10.1177/1363461520923151 [doi]
AB  - The articles in this issue of Transcultural Psychiatry point the way toward
      meaningful advances in mental health research pertaining to Indigenous peoples,
      illuminating the distinctive problems and predicaments that confront these
      communities as well as unrecognized or neglected sources of well-being and
      resilience. As we observe in this introductory essay, future research will
      benefit from ethical awareness, conceptual clarity, and methodological
      refinement. Such efforts will enable additional insight into that which is common
      to Indigenous mental health across settler societies, and that which is specific 
      to local histories, cultures and contexts. Research of this kind can contribute
      to nuanced understandings of developmental pathways, intergenerational effects,
      and community resilience, and inform policy and practice to better meet the needs
      of Indigenous individuals, communities and populations.
FAU - Gone, Joseph P
AU  - Gone JP
AD  - Department of Anthropology, Harvard University, Cambridge, MA, and Department of 
      Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
FAU - Kirmayer, Laurence J
AU  - Kirmayer LJ
AD  - Division of Social & Transcultural Psychiatry, McGill University, and Culture &
      Mental Health Research Unit, Institute of Community & Family Psychiatry, Jewish
      General Hospital, Montreal, Quebec, Canada.
LA  - eng
PT  - Editorial
PL  - England
TA  - Transcult Psychiatry
JT  - Transcultural psychiatry
JID - 9708119
SB  - IM
MH  - Ethnopsychology/methods
MH  - Humans
MH  - Indians, North American/*psychology
MH  - Mental Disorders/epidemiology/*etiology/*psychology
MH  - Mental Health
MH  - Morals
MH  - Prejudice
MH  - *Research
OTO - NOTNLM
OT  - *Indigenous peoples
OT  - *cultural psychiatry
OT  - *historical trauma
OT  - *mental health
OT  - *social epigenetics
EDAT- 2020/05/10 06:00
MHDA- 2021/06/05 06:00
CRDT- 2020/05/09 06:00
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
AID - 10.1177/1363461520923151 [doi]
PST - ppublish
SO  - Transcult Psychiatry. 2020 Apr;57(2):235-249. doi: 10.1177/1363461520923151.


PMID- 32380765
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Is Humane Slaughter Possible?
LID - E799 [pii]
LID - 10.3390/ani10050799 [doi]
AB  - One of the biggest ethical issues in animal agriculture is that of the welfare of
      animals at the end of their lives, during the process of slaughter. Much work in 
      animal welfare science is focussed on finding humane ways to transport and
      slaughter animals, to minimise the harm done during this process. In this paper, 
      we take a philosophical look at what it means to perform slaughter humanely,
      beyond simply reducing pain and suffering during the slaughter process. In
      particular, we will examine the issue of the harms of deprivation inflicted in
      ending life prematurely, as well as shape of life concerns and the ethical
      implications of inflicting these harms at the end of life, without the potential 
      for future offsetting through positive experiences. We will argue that though
      these considerations may mean that no slaughter is in a deep sense truly
      'humane', this should not undermine the importance of further research and
      development to ensure that while the practice continues, animal welfare harms are
      minimised as far as possible.
FAU - Browning, Heather
AU  - Browning H
AD  - School of Philosophy, Australian National University, Canberra 0200, Australia.
FAU - Veit, Walter
AU  - Veit W
AD  - School of History and Philosophy of Science, University of Sydney, Camperdown
      2006, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200505
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7278393
OTO - NOTNLM
OT  - harm
OT  - humane
OT  - shape of a life
OT  - slaughter
OT  - welfare
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/10 06:00
MHDA- 2020/05/10 06:01
CRDT- 2020/05/09 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/10 06:01 [medline]
AID - ani10050799 [pii]
AID - 10.3390/ani10050799 [doi]
PST - epublish
SO  - Animals (Basel). 2020 May 5;10(5). pii: ani10050799. doi: 10.3390/ani10050799.


PMID- 32380376
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20210312
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 79
DP  - 2020 Jul
TI  - The impact and challenges of the 2018 MHRA statement on the use of sodium
      valproate in women of childbearing age during the first year of implementation,
      in a UK epilepsy centre.
PG  - 8-13
LID - S1059-1311(20)30102-3 [pii]
LID - 10.1016/j.seizure.2020.03.015 [doi]
AB  - PURPOSE: On 24/04/2018, the United Kingdom (UK) Medicines and Healthcare Products
      Regulatory Agency (MHRA) clarified previous policies by issuing a statement, that
      the use of sodium valproate is contraindicated in women of childbearing potential
      unless the conditions of a pregnancy prevention programme are met, and only if
      other treatments are ineffective or not tolerated. We evaluated the impact of
      this over the first year of implementation in a tertiary epilepsy centre.
      METHODS: Cross-sectional study of all women under active follow up, or newly
      referred, of childbearing age (16-55 years), taking valproate for the treatment
      of epilepsy, over 12 months from 01/05/2018. RESULTS: We identified 125 cases,
      with 31 newly referred in response to MHRA regulations. 9.6% of patients did not 
      attend their appointment, 35.2% had a learning disability (LD), which in 19.2%
      was sufficiently severe that they could not consent to a sexual relationship.
      Patients with LD prescribed valproate were significantly younger, and more likely
      to have a focal or uncharacterised epilepsy than patients without LD. In 46.4% of
      patients, MHRA regulations were followed: women were already using highly active 
      contraception (HAC), HAC was started, or valproate withdrawn. In 24.8% of cases, 
      women elected to continue valproate, and were not willing to use HAC.
      CONCLUSIONS: In 53.6% of cases, MHRA regulations contraindicating the use
      valproate in women of childbearing potential could not be followed fully, due to 
      lack of patient attendance, lack of applicability in severe LD, or ethical
      concerns relating to patient choice.
CI  - Copyright (c) 2020 British Epilepsy Association. Published by Elsevier Ltd. All
      rights reserved.
FAU - Davies, Philippa
AU  - Davies P
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Reuber, Markus
AU  - Reuber M
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK; Academic Neurology Unit, University of Sheffield, Sheffield, UK.
FAU - Grunewald, Richard
AU  - Grunewald R
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Howell, Stephen
AU  - Howell S
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Dickson, Jon
AU  - Dickson J
AD  - Academic Unit of Primary Medical Care, University of Sheffield, Sheffield, UK.
FAU - Dennis, Gary
AU  - Dennis G
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Shanmugarajah, Priya
AU  - Shanmugarajah P
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Tsironis, Theocharis
AU  - Tsironis T
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Brockington, Alice
AU  - Brockington A
AD  - Neurology Department, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK. Electronic address: alice.brockington@nhs.net.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 614OI1Z5WI (Valproic Acid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/*therapeutic use
MH  - Contraception/*statistics & numerical data
MH  - *Contraindications, Drug
MH  - Cross-Sectional Studies
MH  - Epilepsy/*drug therapy/epidemiology
MH  - Female
MH  - Humans
MH  - *Learning Disabilities/epidemiology
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy Complications/*chemically induced/*prevention & control
MH  - United Kingdom/epidemiology
MH  - Valproic Acid/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Antiepileptic
OT  - Epilepsy
OT  - Pregnancy
OT  - Teratogenicity
OT  - Valproate
EDAT- 2020/05/08 06:00
MHDA- 2021/03/13 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/03/24 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - S1059-1311(20)30102-3 [pii]
AID - 10.1016/j.seizure.2020.03.015 [doi]
PST - ppublish
SO  - Seizure. 2020 Jul;79:8-13. doi: 10.1016/j.seizure.2020.03.015. Epub 2020 Apr 17.


PMID- 32380347
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210903
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 253
DP  - 2020 Sep
TI  - Implementation of a Surgical Oncology Disparities Curriculum for Preclinical
      Medical Students.
PG  - 214-223
LID - S0022-4804(20)30192-X [pii]
LID - 10.1016/j.jss.2020.03.058 [doi]
AB  - BACKGROUND: Underinsured and uninsured surgical-oncology patients are at higher
      risk of perioperative morbidity and mortality. Curricular innovation is needed to
      train medical students to work with this vulnerable population. We describe the
      implementation of and early educational outcomes from a student-initiated pilot
      program aimed at improving medical student insight into health disparities in
      surgery. MATERIALS/METHODS: First-year medical students participated in a dual
      didactic and perioperative-liaison experience over a 10-month period. Didactic
      sessions included surgical-skills training and faculty-led lectures on financial 
      toxicity and management of surgical-oncology patients. Students were partnered
      with uninsured and Medicaid patients receiving surgical-oncology care and worked 
      with these patients by providing appointment reminders, clarifying perioperative 
      instructions, and accompanying patients to surgery and clinic appointments.
      Students' interest in surgery and self-reported comfort in 15 Association of
      American Medical Colleges core competencies were assessed with preparticipation
      and postparticipation surveys using a 5-point Likert scale. RESULTS: Twenty-four 
      first-year students were paired with 14 surgical-oncology patients during the
      2017-2018 academic year. Sixteen students (66.7%) completed both preprogram and
      postprogram surveys. Five students (31.3%) became "More Interested" in surgery,
      whereas 11 (68.8%) reported "Similar Interest or No Change." Half of the students
      (n = 8) felt more prepared for their surgery clerkship after participating.
      Median self-reported comfort improved in 7/15 competencies including Oral
      Communication and Ethical Responsibility. All students reported being "Somewhat" 
      or "Extremely Satisfied" with the program. CONCLUSIONS: We demonstrate that an
      innovative program to expose preclinical medical students to challenges faced by 
      financially and socially vulnerable surgical-oncology patients is feasible and
      may increase students' clinical preparedness and interest in surgery.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Rhodin, Kristen E
AU  - Rhodin KE
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina.
FAU - Hong, Cierra S
AU  - Hong CS
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Olivere, Lindsey A
AU  - Olivere LA
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Howell, Elizabeth P
AU  - Howell EP
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Giri, Vinay K
AU  - Giri VK
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Mehta, Kurren A
AU  - Mehta KA
AD  - Duke University School of Medicine, Durham, North Carolina.
FAU - Oyekunle, Taofik
AU  - Oyekunle T
AD  - Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina.
FAU - Scheri, Randall P
AU  - Scheri RP
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina.
FAU - Tong, Betty C
AU  - Tong BC
AD  - Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke
      University School of Medicine, Durham, North Carolina.
FAU - Sosa, Julie A
AU  - Sosa JA
AD  - Department of Surgery, University of California, San Francisco (UCSF), San
      Francisco, California.
FAU - Fayanju, Oluwadamilola M
AU  - Fayanju OM
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina;
      Women's Cancer Program, Duke Cancer Institute, Durham, North Carolina; Department
      of Population Health Sciences, Duke University School of Medicine, Durham, North 
      Carolina; Duke Forge, Duke University, Durham, North Carolina; Department of
      Surgery, Durham VA Medical Center, Durham, North Carolina. Electronic address:
      lola.fayanju@duke.edu.
LA  - eng
GR  - K08 CA241390/CA/NCI NIH HHS/United States
GR  - P30 CA014236/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
SB  - IM
MH  - *Curriculum
MH  - Education, Medical, Undergraduate/methods/*organization & administration
MH  - Female
MH  - Healthcare Disparities/*economics
MH  - Humans
MH  - Male
MH  - Neoplasms/economics/*surgery
MH  - Pilot Projects
MH  - Program Development
MH  - Program Evaluation
MH  - Socioeconomic Factors
MH  - Students, Medical/statistics & numerical data
MH  - Surgical Oncology/*education
MH  - Surveys and Questionnaires/statistics & numerical data
MH  - Vulnerable Populations
PMC - PMC7384959
MID - NIHMS1583191
OTO - NOTNLM
OT  - *Health disparities
OT  - *Insurance status
OT  - *Surgical oncology
OT  - *Undergraduate medical education
EDAT- 2020/05/08 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - S0022-4804(20)30192-X [pii]
AID - 10.1016/j.jss.2020.03.058 [doi]
PST - ppublish
SO  - J Surg Res. 2020 Sep;253:214-223. doi: 10.1016/j.jss.2020.03.058. Epub 2020 May
      4.


PMID- 32380344
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20210110
IS  - 1476-5616 (Electronic)
IS  - 0033-3506 (Linking)
VI  - 183
DP  - 2020 Jun
TI  - The ethics of scare: COVID-19 and the Philippines' fear appeals.
PG  - 2-3
LID - S0033-3506(20)30122-0 [pii]
LID - 10.1016/j.puhe.2020.04.017 [doi]
FAU - Biana, H T
AU  - Biana HT
AD  - Philosophy, De La Salle University, 2401 Taft Avenue, Malate, Manila, 0922,
      Philippines. Electronic address: hazel.biana@dlsu.edu.ph.
FAU - Joaquin, J J B
AU  - Joaquin JJB
AD  - Philosophy, De La Salle University, 2401 Taft Avenue, Malate, Manila, 0922,
      Philippines. Electronic address: jeremiah.joaquin@dlsu.edu.ph.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200420
PL  - Netherlands
TA  - Public Health
JT  - Public health
JID - 0376507
SB  - IM
CON - Public Health. 2020 May;182:188-189. PMID: 32344272
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - *Fear
MH  - Humans
MH  - Pandemics
MH  - Philippines
MH  - Pneumonia, Viral
MH  - *Public Health
MH  - SARS-CoV-2
PMC - PMC7167568
EDAT- 2020/05/08 06:00
MHDA- 2020/06/23 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - S0033-3506(20)30122-0 [pii]
AID - 10.1016/j.puhe.2020.04.017 [doi]
PST - ppublish
SO  - Public Health. 2020 Jun;183:2-3. doi: 10.1016/j.puhe.2020.04.017. Epub 2020 Apr
      20.


PMID- 32380180
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1532-0480 (Electronic)
IS  - 1532-0464 (Linking)
VI  - 107
DP  - 2020 Jul
TI  - A medical treatment based scoring model to detect abusive institutions.
PG  - 103423
LID - S1532-0464(20)30051-4 [pii]
LID - 10.1016/j.jbi.2020.103423 [doi]
AB  - Medical abuse refers to a type of abnormal medical practice which is not in
      compliance with qualitative or ethical standards, such as excessive prescription 
      or overbilling of medical services. Detection of such medical abuses is crucial, 
      especially for the patients and insurance providers, because they become subject 
      to the extra payments incurred. As a result, insurance providers hire medical
      experts in order to review claims manually, yet through examination is almost
      impossible due to the volume of the claims filed. A typical approach is to select
      institutions on suspicion of abusive practices and to manually review all claims 
      involving suspect institutions. In this light, several studies have developed
      models designed to extract institution-level variables. However, since these
      variables are at an institution-level, the model cannot account for different
      types of abuse practiced by individual institutions, hence degrading the accuracy
      of the prediction model. At the same time, these variables contain information
      too simple to construct an effective scoring model. In this study, we propose a
      model that scores the degree of abuse practiced by institutions at the
      treatment-level, which is the lowest level of data that can be obtained from a
      medical claim. Our model is the first to use such fine-grained information to
      construct a model for scoring the abuse by medical institutions. The proposed
      model consists of two stages: Training a deep neural network with embedding
      layers for categorical variables, and scoring the abuse degree for each treatment
      with the model. Then, we aggregate the resulting abuse score of each treatment
      and the claim amount associated with each treatment by an institution which we
      define as the abuse score of the institution. We test our model using real-world 
      claim data submitted to the Health Insurance Review and Assessment (HIRA) in
      2016. We also compare the performance of the proposed model against the scoring
      model HIRA has been using, which computes the abuse score of an institution by
      using institution-level variables as proposed in past literature. Experiment
      results show that the proposed model represents the degree of medical abuse
      better. In addition, the results suggest that the reviewers may examine through
      the claims by at most 6.1 times more efficiently than when using the scoring
      model with institution-level variables.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Lee, Jehyuk
AU  - Lee J
AD  - Department of Industrial Engineering & Institute for Industrial Systems
      Innovation, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826,
      Republic of Korea. Electronic address: jehyuk.lee@dm.snu.ac.kr.
FAU - Shin, Hunsik
AU  - Shin H
AD  - Department of Industrial Engineering & Institute for Industrial Systems
      Innovation, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826,
      Republic of Korea. Electronic address: hunsik@dm.snu.ac.kr.
FAU - Cho, Sungzoon
AU  - Cho S
AD  - Department of Industrial Engineering & Institute for Industrial Systems
      Innovation, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826,
      Republic of Korea. Electronic address: zoon@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - United States
TA  - J Biomed Inform
JT  - Journal of biomedical informatics
JID - 100970413
SB  - IM
MH  - Humans
MH  - *Insurance, Health
OTO - NOTNLM
OT  - *Data mining
OT  - *Health insurance
OT  - *Medical abuse detection
OT  - *Medical treatment
OT  - *Neural network
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/08 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/07/17 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - S1532-0464(20)30051-4 [pii]
AID - 10.1016/j.jbi.2020.103423 [doi]
PST - ppublish
SO  - J Biomed Inform. 2020 Jul;107:103423. doi: 10.1016/j.jbi.2020.103423. Epub 2020
      May 4.


PMID- 32379986
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1548-8756 (Electronic)
IS  - 1548-8748 (Linking)
VI  - 40
DP  - 2020 Mar
TI  - Direct-to-Consumer Advertising for Cancer Centers and Institutes: Ethical
      Dilemmas and Practical Implications.
PG  - 1-11
LID - 10.1200/EDBK_279963 [doi]
AB  - In the United States, many cancer centers advertise their clinical services
      directly to the public. Although there are potential public benefits from such
      advertising, including increased patient awareness of treatment options and
      improved access to care and clinical trials, there is also potential for harm
      through misinformation, provision of false hope, inappropriate use of health care
      resources, and disruption in doctor-patient relationships. Although patient
      education through advertising is appropriate, misleading patients in the name of 
      gaining market share, boosting profits, or even boosting trial accrual is not. It
      is critical that rigorous ethical guidelines are adopted and that oversight is
      introduced to ensure that cancer center marketing supports good patient care and 
      public health interests. Patients with cancer have been identified as an
      especially vulnerable population because of fears and anxiety related to their
      diagnosis and the very real need to identify optimal sources of care. Cancer
      organizations have a fiduciary duty and a moral and legal obligation to provide
      truthful information to avoid deceptive, inaccurate claims associated with
      treatment success. In this article, actionable recommendations are provided for
      both the oncologist and the cancer center's marketing team to promote ethical
      marketing of services to patients with cancer. This tailored guidance for the
      oncology community includes explicit communication on (1) ensuring fair and
      balanced promotion of cancer services, (2) avoiding exaggeration of claims in the
      context of reputational marketing, (3) providing data and statistics to support
      direct and implied assertions of treatment success, and (4) defining eligible
      patient groups in the context of marketing for research. These recommendations
      for cancer centers are designed to promote ethical quality marketing information 
      to patients with cancer.
FAU - Hlubocky, Fay J
AU  - Hlubocky FJ
AD  - Department of Medicine, Section of Hematology/Oncology, MacLean Center for
      Clinical Medical Ethics, University of Chicago Medicine, and the Cancer Research 
      Center, Chicago, IL.
FAU - McFarland, Daniel F
AU  - McFarland DF
AD  - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer
      Center, New York, NY.
FAU - Spears, Patricia A
AU  - Spears PA
AD  - UNC Lineberger Patient Advocates for Research Council, University of North
      Carolina at Chapel Hill, Chapel Hill, NC.
FAU - Smith, Laura
AU  - Smith L
AD  - Truth in Advertising, Inc., Madison, CT.
FAU - Patten, Bonnie
AU  - Patten B
AD  - Truth in Advertising, Inc., Madison, CT.
FAU - Peppercorn, Jeffery
AU  - Peppercorn J
AD  - Division of Hematology/Oncology, Massachusetts General Hospital, Dana-Farber
      Partners/Harvard Health System, Boston, MA.
FAU - Holcombe, Randall
AU  - Holcombe R
AD  - University of Hawai'i Cancer Center, Honolulu, HI.
LA  - eng
GR  - L30 CA220778/CA/NCI NIH HHS/United States
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Am Soc Clin Oncol Educ Book
JT  - American Society of Clinical Oncology educational book. American Society of
      Clinical Oncology. Annual Meeting
JID - 101233985
SB  - IM
MH  - *Academies and Institutes/ethics/history/legislation & jurisprudence
MH  - *Cancer Care Facilities/ethics/history/legislation & jurisprudence
MH  - *Direct-to-Consumer Advertising/ethics/history/legislation & jurisprudence
MH  - Health Communication
MH  - Health Literacy
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Oncologists
MH  - Public Policy
EDAT- 2020/05/08 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1200/EDBK_279963 [doi]
PST - ppublish
SO  - Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-11. doi: 10.1200/EDBK_279963.


PMID- 32379854
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20201210
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 4
DP  - 2020 Aug 18
TI  - Biomedical Research in Times of Emergency: Lessons From History.
PG  - 297-299
LID - 10.7326/M20-2076 [doi]
AB  - Coronavirus disease 2019 (COVID-19) has sickened millions, killed hundreds of
      thousands, and utterly disrupted the daily lives of billions of people around the
      world. In an effort to ameliorate this devastation, the biomedical research
      complex has allocated billions of dollars and scientists have initiated hundreds 
      of clinical trials in an expedited effort to understand, prevent, and treat this 
      disease. National emergencies can stimulate significant investment of financial, 
      physical, and intellectual resources that catalyze impressive scientific
      accomplishments, as evident with the Manhattan Project, penicillin, and the polio
      vaccines in the 20th century. However, pressurized research has also led to false
      promises, disastrous consequences, and breaches in ethics. Antiserum in the 1918 
      flu epidemic, contaminated yellow fever vaccines in World War II, and unethical
      human experimentation with mustard gas offer just a few cautionary exemplars. It 
      is critical to continue biomedical research efforts to address this pandemic, and
      it is appropriate that they receive priority in both attention and funding. But
      history also demonstrates the importance of treating early results-such as those 
      associated with hydroxychloroquine-with caution as we only begin to understand
      the biology, epidemiology, and potential target points of COVID-19.
FAU - Doroshow, Deborah
AU  - Doroshow D
AD  - Icahn School of Medicine at Mount Sinai, New York, New York (D.D.).
FAU - Podolsky, Scott
AU  - Podolsky S
AD  - Harvard Medical School, Boston, Massachusetts (S.P.).
FAU - Barr, Justin
AU  - Barr J
AD  - Duke University Medical Center, Durham, North Carolina (J.B.).
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200507
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/*history/*standards
MH  - COVID-19
MH  - Coronavirus Infections/drug therapy/*history/*therapy
MH  - Emergencies/*history
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Human Experimentation/history
MH  - Humans
MH  - Pandemics/*history
MH  - Pneumonia, Viral/*history/*therapy
MH  - SARS-CoV-2
PMC - PMC7233188
EDAT- 2020/05/08 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 2766020 [pii]
AID - 10.7326/M20-2076 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Aug 18;173(4):297-299. doi: 10.7326/M20-2076. Epub 2020 May 
      7.


PMID- 32379145
OWN - NLM
STAT- MEDLINE
DCOM- 20201230
LR  - 20210108
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 12
DP  - 2020 Dec
TI  - Changing How Race Is Portrayed in Medical Education: Recommendations From Medical
      Students.
PG  - 1802-1806
LID - 10.1097/ACM.0000000000003496 [doi]
AB  - The medical community has been complicit in legitimizing claims of racial
      difference throughout the history of the United States. Unfortunately, a rigorous
      examination of the role medicine plays in perpetuating inequity across racial
      lines is often missing in medical school curricula due to time constraints and
      other challenges inherent to medical education. The imprecise use of race-a
      social construct-as a proxy for pathology in medical education is a vestige of
      institutionalized racism. Recent examples are presented that illustrate how
      attributing outcomes to race may contribute to bias and unequal care. This paper 
      proposes the following recommendations for guiding efforts to mitigate the
      adverse effects associated with the use of race in medical education: emphasize
      the need for incoming students to be familiar with how race can influence health 
      outcomes; provide opportunities to hold open conversations about race in medicine
      among medical school faculty, students, and staff; craft and implement protocols 
      that address and correct the inappropriate use of race in medical school classes 
      and course materials; and encourage a large cultural shift within the field of
      medicine. Adoption of an interdisciplinary approach that taps into many fields,
      including ethics, history, sociology, evolutionary genetics, and public health is
      a necessary step for cultivating more thoughtful physicians who will be better
      prepared to care for patients of all racial and ethnic backgrounds.
FAU - Nieblas-Bedolla, Edwin
AU  - Nieblas-Bedolla E
AD  - E. Nieblas-Bedolla is a second-year student, University of Washington School of
      Medicine, Seattle, Washington; ORCID: http://orcid.org/0000-0001-5879-1800.
FAU - Christophers, Briana
AU  - Christophers B
AD  - B. Christophers is a second-year MD-PhD student, Weill Cornell/Rockefeller/Sloan 
      Kettering Tri-Institutional MD-PhD Program, New York, New York; ORCID:
      http://orcid.org/0000-0001-5248-069X.
FAU - Nkinsi, Naomi T
AU  - Nkinsi NT
AD  - N.T. Nkinsi is a second-year MD-MPH student, University of Washington School of
      Medicine, Seattle, Washington; ORCID: https://orcid.org/0000-0002-0504-696X.
FAU - Schumann, Paul D
AU  - Schumann PD
AD  - P.D. Schumann is a second-year student, University of Washington School of
      Medicine, Seattle, Washington.
FAU - Stein, Elizabeth
AU  - Stein E
AD  - E. Stein is a second-year student, University of Washington School of Medicine,
      Seattle, Washington; ORCID: https://orcid.org/0000-0002-1820-3821.
LA  - eng
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
CIN - Acad Med. 2020 Dec;95(12):1781-1786. PMID: 33031120
MH  - *Education, Medical, Graduate
MH  - *Healthcare Disparities
MH  - Humans
MH  - *Racism
MH  - *Students, Medical
MH  - United States
EDAT- 2020/05/08 06:00
MHDA- 2020/12/31 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/12/31 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1097/ACM.0000000000003496 [doi]
AID - 00001888-202012000-00016 [pii]
PST - ppublish
SO  - Acad Med. 2020 Dec;95(12):1802-1806. doi: 10.1097/ACM.0000000000003496.


PMID- 32378955
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200726
IS  - 1935-990X (Electronic)
IS  - 0003-066X (Linking)
VI  - 75
IP  - 4
DP  - 2020 May-Jun
TI  - Donald T. Stuss (1941-2019).
PG  - 595
LID - 10.1037/amp0000601 [doi]
AB  - Memorializes Donald T. Stuss (1941-2019). Through his early spiritual training in
      a monastery, Don developed an interest in the highest forms of human
      consciousness, ethics, and behavior. As a teacher and coach, he became interested
      in team building and motivation. Don nurtured those interests in his research on 
      the functions of the human frontal lobes and as the founding director of two
      world-leading neuroscience institutes. In 1991, he was recruited to launch the
      Rotman Research Institute (RRI) at Baycrest Hospital in Toronto. After leaving
      the RRI in 2011, Don was recruited to lead the Ontario Brain Institute, a
      provincially funded network of integrated discovery platforms that became a model
      for data sharing in clinical neuroscience throughout the world. (PsycInfo
      Database Record (c) 2020 APA, all rights reserved).
FAU - Levine, Brian
AU  - Levine B
AUID- ORCID: 0000-0003-4343-811X
AD  - Rotman Research Institute at Baycrest.
FAU - Craik, Fergus I M
AU  - Craik FIM
AD  - Rotman Research Institute at Baycrest.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Psychol
JT  - The American psychologist
JID - 0370521
SB  - IM
EDAT- 2020/05/08 06:00
MHDA- 2020/05/08 06:01
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/08 06:01 [medline]
AID - 2020-29966-017 [pii]
AID - 10.1037/amp0000601 [doi]
PST - ppublish
SO  - Am Psychol. 2020 May-Jun;75(4):595. doi: 10.1037/amp0000601.


PMID- 32378945
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1935-990X (Electronic)
IS  - 0003-066X (Linking)
VI  - 75
IP  - 4
DP  - 2020 May-Jun
TI  - The bucket list effect: Why leisure goals are often deferred until retirement.
PG  - 499-510
LID - 10.1037/amp0000617 [doi]
AB  - The central argument of this article is that historical changes in longevity in
      Western societies, globalization, and the weakening of social expectations
      regarding the timing of developmental goals lead to a compression of the time for
      pursuing highly demanding developmental goals related to work and family in late 
      young and middle adulthood. The expectation of longevity might lead adults to
      construct a "bucket list," postponing important leisure and social goals to the
      postretirement phase. Jointly, the weakening of age-related social expectations
      and the long postretirement phase in Western societies might result in a stronger
      segregation of the life course: education in "emerging adulthood," work and
      family in later young and middle adulthood, leisure and social goals in later
      adulthood. This segregation also conforms to a Western cultural script following 
      the Protestant work ethic of delaying gratification by pursuing obligatory goals 
      first (work, family) and only then turn to "play" after retirement (leisure,
      social goals), a time with relatively few obligations and social expectations.
      The segmentation of the life course has implications for self-regulatory demands,
      such that the importance of goal selection increases in emerging adulthood, the
      importance of managing multiple goals in late young and middle adulthood, and the
      importance of self-regulation for the pursuit of ill-defined goals in old age.
      Taken together, historical changes in the increased life expectancy in Western
      countries and weakened age-related expectations represent a challenge and an
      opportunity for developmental regulation. (PsycInfo Database Record (c) 2020 APA,
      all rights reserved).
FAU - Freund, Alexandra M
AU  - Freund AM
AUID- ORCID: 0000-0001-9953-523X
AD  - University of Zurich.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Psychol
JT  - The American psychologist
JID - 0370521
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Goals
MH  - Humans
MH  - Leisure Activities/*psychology
MH  - Longevity
MH  - Male
MH  - Middle Aged
MH  - Retirement/*psychology
MH  - Young Adult
EDAT- 2020/05/08 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - 2020-29966-007 [pii]
AID - 10.1037/amp0000617 [doi]
PST - ppublish
SO  - Am Psychol. 2020 May-Jun;75(4):499-510. doi: 10.1037/amp0000617.


PMID- 32378491
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Elements of assisted bodily care: Ethical aspects.
PG  - 1377-1395
LID - 10.1177/0969733020914348 [doi]
AB  - BACKGROUND: Many frail older persons who die in Swedish nursing homes need
      assisted bodily care. They must surrender their bodies to the authority of
      assistant nurses, which may affect their autonomy and dignity of identity. While 
      assistant nurses claim to support older persons' wishes, older persons claim they
      have to adapt to assistant nurses' routines. The provider-receiver incongruence
      revealed here warrants investigation. AIM: To describe the elements of assisted
      bodily care, as performed in a nursing home. RESEARCH DESIGN: Data were collected
      through thirty-nine observations of assisted bodily care, analyzed with
      qualitative content analysis. PARTICIPANTS AND RESEARCH CONTEXT: Seventeen older 
      persons and twenty-two assistant nurses from a Swedish nursing home. ETHICAL
      CONSIDERATIONS: The research was conducted in line with the Declaration of
      Helsinki, further approved by the regional ethics committee. FINDINGS: Findings
      show that assisted bodily care consists of assistant nurses' practical work,
      performed at a high tempo. Assistant nurses still attempt to adapt this work to
      the older persons' wishes for self-determination, taking into account their
      day-to-day state of health. In spite of time pressure and occasional
      interruptions, there is room for consideration and affection in assisted bodily
      care. DISCUSSION: Assistant nurses try to promote older persons' dignity of
      identity, but sometimes fail, possibly due to lack of time. They nevertheless
      seem to know the older persons well enough to adapt the assisted bodily care
      according to their preferences and to support self-determination. This indicates 
      that openness to older persons' lifeworlds may be more important than the amount 
      of time available. CONCLUSION: Nursing home contexts might benefit from adopting 
      a person-centered palliative care perspective, highlighting the value of
      relationships and shared decision-making. If so, older persons and assisted
      nurses could agree on practices and goals in assisted bodily care beforehand.
      Such routines may be time-saving and beneficial to all.
FAU - Holmberg, Bodil
AU  - Holmberg B
AUID- ORCID: https://orcid.org/0000-0002-8912-8101
AD  - 7643Ersta Skondal Bracke University College, Sweden.
FAU - Hellstrom, Ingrid
AU  - Hellstrom I
AD  - 7643Ersta Skondal Bracke University College, Sweden; Linkoping University,
      Sweden.
FAU - Osterlind, Jane
AU  - Osterlind J
AD  - 7643Ersta Skondal Bracke University College, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - *Activities of Daily Living
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Frail Elderly/*psychology
MH  - Health Personnel/*psychology/statistics & numerical data
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Male
MH  - Middle Aged
MH  - Nursing Homes/organization & administration/statistics & numerical data
MH  - Patients/*psychology/statistics & numerical data
MH  - Qualitative Research
MH  - Sweden
OTO - NOTNLM
OT  - Assistant nurses
OT  - bodily care
OT  - dignity
OT  - ethics
OT  - nursing home
EDAT- 2020/05/08 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1177/0969733020914348 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1377-1395. doi: 10.1177/0969733020914348. Epub 2020
      May 7.


PMID- 32378395
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - Vol. 30
IP  - 4
DP  - 2020 Jan 8
PG  - 51-68
LID - 10.3917/jibes.304.0051 [doi]
AB  - Artists of the biotechnological art manipulate living matter in the laboratory
      and orient the evolutionary trajectories of organisms to produce new living
      entities in vivo and in vitro. These metacarnations, provided by contemporary
      biological techniques, reveal the worrying utopias of a living person in the
      making and heighten the fears and dangers of uncontrolled drift. From an
      ethical-political point of view, the question is whether such work can raise a
      possible critical awareness of biotechnologies or whether, on the contrary, these
      "bioartistic" behaviours reveal a moral inertia linked to artists' fascination
      with the technical reprogramming of life. In other words, in the name of art and 
      in a liberal society where artistic autonomy prevails, the question is to what
      extent should or can these artists create living entities that have until now
      been invisible and unthinkable without running the risk of losing reason and
      lucidity about our future living conditions?
FAU - Voison, Catherine
AU  - Voison C
LA  - fre
PT  - Journal Article
TT  - Chapitre 2. L'art biotechnologique : une anticipation d'un au-dela de l'humain ?
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Art
MH  - *Bioethics
MH  - Morals
MH  - Utopias
EDAT- 2020/05/08 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - 10.3917/jibes.304.0051 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Jan 8;Vol. 30(4):51-68. doi:
      10.3917/jibes.304.0051.


PMID- 32378394
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - Vol. 30
IP  - 4
DP  - 2020 Jan 8
PG  - 19-49
LID - 10.3917/jibes.304.0019 [doi]
AB  - The ever-growing ecological imprint of human activities has lead numerous and
      diverse actors to develop new environmental ethical approaches, both based on
      experimentation and theoretical elaboration. These approaches hold multiple
      philosophical roots and practical consequences: some insist on the life and value
      of each being, ecosystems or evolutional processes, other insist on the
      instrumental value of nature. As for us, we have chosen to bring together
      experimentation and theorization, in order to lead a hybrid exploration between
      contemporary art and anthropology. Since 2015, we have conducted a series of
      performances, stemming from our own body fluids, considered as feminine
      (breastmilk, menstrual blood, tears of grief), and used as offerings for
      different living environments (<< milieux de vie >>). These gestures, conceived
      as rituals, led to debate with different publics about the relation between human
      existence and biogeochimical cycles. This reflection is grounded in the analogies
      between terrestrial and female fertility, but it goes one step further. We
      propose that a new pathway could be opened, based on a renewal of physiological
      concepts in relation with the development of an ethical position for the
      protection of the biosphere. It is rooted in the intimacy of each of us, and the 
      material and symbolic continuities between human existence and the rest of the
      living word.
FAU - Legrand, Marine
AU  - Legrand M
FAU - Tondeur, Anais
AU  - Tondeur A
LA  - fre
PT  - Journal Article
TT  - Chapitre 1. Lait, sang, larmes en offrande : la manipulation des fluides
      corporels feminins comme support d'une elaboration ethique pour la biosphere.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Anthropology
MH  - Ecology/*ethics
MH  - *Ecosystem
MH  - Female
MH  - Humans
MH  - Morals
EDAT- 2020/05/08 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - 10.3917/jibes.304.0019 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Jan 8;Vol. 30(4):19-49. doi:
      10.3917/jibes.304.0019.


PMID- 32378393
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 2608-1008 (Print)
IS  - 2555-5111 (Linking)
VI  - Vol. 30
IP  - 4
DP  - 2020 Jan 8
PG  - 11-18
LID - 10.3917/jibes.304.0011 [doi]
AB  - Inspired by the most recent scientific advances in the field of biology and
      biotechnology, several artists propose, for a number of years now, singular
      artworks, at the frontier of arts and science, that transform living beings into 
      aesthetics proposals. These new artistic practices are developing under the
      appellation of "bioart" and have for effects to blur the border between arts and 
      science. These artists are taking over laboratories and manipulate the living.
      Many scientists venture themselves into those new territories or collaborate on
      creations. This field of artistic investigation inspires a number of reflections 
      from bioethics. Entitled "Art(bio)ethics", this special issue proposes an
      encounter between bioart and bioethics in order to offer a recent and varied
      sample of reflections on the relations developing between these two disciplines.
FAU - Couture, Vincent
AU  - Couture V
FAU - Noury, Mathieu
AU  - Noury M
LA  - fre
PT  - Journal Article
TT  - Art(bio)ethique : vers de nouvelles relations entre le bioart et la bioethique.
PL  - France
TA  - J Int Bioethique Ethique Sci
JT  - Journal international de bioethique et d'ethique des sciences
JID - 101714875
SB  - IM
MH  - *Art
MH  - *Bioethics
MH  - Humans
EDAT- 2020/05/08 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - 10.3917/jibes.304.0011 [doi]
PST - ppublish
SO  - J Int Bioethique Ethique Sci. 2020 Jan 8;Vol. 30(4):11-18. doi:
      10.3917/jibes.304.0011.


PMID- 32377810
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1432-1084 (Electronic)
IS  - 0938-7994 (Linking)
VI  - 30
IP  - 10
DP  - 2020 Oct
TI  - Implementation of eHealth and AI integrated diagnostics with multidisciplinary
      digitized data: are we ready from an international perspective?
PG  - 5510-5524
LID - 10.1007/s00330-020-06874-x [doi]
AB  - Digitization of medicine requires systematic handling of the increasing amount of
      health data to improve medical diagnosis. In this context, the integration of the
      versatile diagnostic information, e.g., from anamnesis, imaging, histopathology, 
      and clinical chemistry, and its comprehensive analysis by artificial intelligence
      (AI)-based tools is expected to improve diagnostic precision and the therapeutic 
      conduct. However, the complex medical environment poses a major obstacle to the
      translation of integrated diagnostics into clinical research and routine. There
      is a high need to address aspects like data privacy, data integration,
      interoperability standards, appropriate IT infrastructure, and education of
      staff. Besides this, a plethora of technical, political, and ethical challenges
      exists. This is complicated by the high diversity of approaches across Europe.
      Thus, we here provide insights into current international activities on the way
      to digital comprehensive diagnostics. This includes a technical view on
      challenges and solutions for comprehensive diagnostics in terms of data
      integration and analysis. Current data communications standards and common IT
      solutions that are in place in hospitals are reported. Furthermore, the
      international hospital digitalization scoring and the European funding situation 
      were analyzed. In addition, the regional activities in radiomics and the related 
      publication trends are discussed. Our findings show that prerequisites for
      comprehensive diagnostics have not yet been sufficiently established throughout
      Europe. The manifold activities are characterized by a heterogeneous digitization
      progress and they are driven by national efforts. This emphasizes the importance 
      of clear governance, concerted investments, and cooperation at various levels in 
      the health systems.Key Points* Europe is characterized by heterogeneity in its
      digitization progress with predominantly national efforts. Infrastructural
      prerequisites for comprehensive diagnostics are not given and not sufficiently
      funded throughout Europe, which is particularly true for data integration.* The
      clinical establishment of comprehensive diagnostics demands for a clear
      governance, significant investments, and cooperation at various levels in the
      healthcare systems.* While comprehensive diagnostics is on its way, concerted
      efforts should be taken in Europe to get consensus concerning interoperability
      and standards, security, and privacy as well as ethical and legal concerns.
FAU - Bukowski, Mark
AU  - Bukowski M
AD  - Department of Science Management, Institute of Applied Medical Engineering,
      Helmholtz Institute, University Hospital Aachen, RWTH Aachen University,
      Pauwelsstr. 20, 52074, Aachen, Germany.
FAU - Farkas, Robert
AU  - Farkas R
AD  - Department of Science Management, Institute of Applied Medical Engineering,
      Helmholtz Institute, University Hospital Aachen, RWTH Aachen University,
      Pauwelsstr. 20, 52074, Aachen, Germany. farkas@ame.rwth-aachen.de.
FAU - Beyan, Oya
AU  - Beyan O
AD  - Fraunhofer Institute for Applied Information Technology, FIT, Schloss
      Birlinghoven, 53754, Sankt Augustin, Germany.
AD  - Chair of Computer Science 5 - Information Systems & Databases, RWTH Aachen
      University, Ahornstr. 55, 52074, Aachen, Germany.
FAU - Moll, Lorna
AU  - Moll L
AD  - RWTH Centralized Biomaterial Bank (RWTH cBMB), Institute of Pathology, University
      Hospital Aachen, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany.
FAU - Hahn, Horst
AU  - Hahn H
AD  - Fraunhofer Institute for Digital Medicine, MEVIS, Am Fallturm 1, 28359, Bremen,
      Germany.
FAU - Kiessling, Fabian
AU  - Kiessling F
AD  - Fraunhofer Institute for Digital Medicine, MEVIS, Am Fallturm 1, 28359, Bremen,
      Germany. fkiessling@ukaachen.de.
AD  - Institute for Experimental Molecular Imaging, Center for Biohybrid Medical
      Systems (CBMS), University Hospital Aachen, RWTH Aachen University,
      Forckenbeckstr. 55, 52074, Aachen, Germany. fkiessling@ukaachen.de.
AD  - Comprehensive Diagnostic Center Aachen, University Hospital Aachen, Pauwelsstr.
      30, 52074, Aachen, Germany. fkiessling@ukaachen.de.
FAU - Schmitz-Rode, Thomas
AU  - Schmitz-Rode T
AD  - Institute of Applied Medical Engineering, Helmholtz Institute, University
      Hospital Aachen, RWTH Aachen University, Pauwelsstr. 20, 52074, Aachen, Germany. 
      smiro@ame.rwth-aachen.de.
LA  - eng
GR  - none/RWTH Aachen University
PT  - Journal Article
DEP - 20200506
PL  - Germany
TA  - Eur Radiol
JT  - European radiology
JID - 9114774
SB  - IM
MH  - Artificial Intelligence/*trends
MH  - Computer Systems
MH  - Data Mining
MH  - Europe
MH  - Humans
MH  - Interdisciplinary Research
MH  - Internationality
MH  - Medical Informatics/*trends
MH  - Privacy
MH  - Publishing/trends
MH  - Radiology/*trends
MH  - Software
MH  - Telemedicine/*trends
PMC - PMC7476980
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Diagnosis
OT  - Electronic health records
OT  - Europe
OT  - Information storage and retrieval
EDAT- 2020/05/08 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1007/s00330-020-06874-x [doi]
AID - 10.1007/s00330-020-06874-x [pii]
PST - ppublish
SO  - Eur Radiol. 2020 Oct;30(10):5510-5524. doi: 10.1007/s00330-020-06874-x. Epub 2020
      May 6.


PMID- 32377510
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2214-9996 (Electronic)
IS  - 2214-9996 (Linking)
VI  - 86
IP  - 1
DP  - 2020 Apr 28
TI  - Eswatini Nursing Council Regulatory Reforms: Process towards Entry to Practice
      Examination.
PG  - 45
LID - 10.5334/aogh.2800 [doi]
AB  - Objective: To identify and to measure entry level competencies (knowledge,
      skills, attitudes, judgements) for nurses to practice safely and effectively in
      the Kingdom of Eswatini. Introduction: Eswatini, formerly known as Swaziland, is 
      a small sub-Saharan country between South Africa and Mozambique. There are four
      nursing programs approved by the Eswatini Nursing Council (ENC) that provide
      nursing education in the areas of general nursing, midwifery, mental health and
      community health. The mandate of the ENC is to protect the public and to this end
      licensed nurses must be able to meet standardized entry level requirements.
      Methods: We identified gaps in expected competencies of new nurses led to
      comprehensive strategies by many stakeholders to close the gaps. Nursing
      competencies were categorized into seven learning domains with specific,
      measurable indicators included in each domain. Specific clinical skills essential
      for entry to practice were identified. Results: Provision of Quality Care;
      Information Management Systems; Emergency/Trauma/Disaster Management; Infection
      Prevention & Control; Leadership and Management; Ethics/Legal Issues/Professional
      Conduct; and Prevention/Treatment & Care of HIV, AIDS, TB are the seven
      competency domains that are measured on a newly developed standardized entry to
      practice multiple choice examination. Essential clinical skills are also assessed
      prior to obtaining licensure. Conclusion: Implementing these standards will
      ensure that nurses in Eswatini have the appropriate skill set to deliver care to 
      their patients, improve their communities' health, and enable the kingdom to make
      advances towards universal health coverage and attainment of the sustainable
      development goals.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Msibi, Glory
AU  - Msibi G
AD  - Ministry of Health, SZ.
FAU - Nkwanyana, Nkosinathi
AU  - Nkwanyana N
AD  - Eswatini Nursing Council, SZ.
FAU - Kuebel, Helen
AU  - Kuebel H
AD  - Seed Global Health, Boston, Massachusetts, US.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200428
PL  - United States
TA  - Ann Glob Health
JT  - Annals of global health
JID - 101620864
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/nursing/prevention & control
MH  - Clinical Competence/*standards
MH  - Education, Nursing
MH  - Eswatini
MH  - Ethics, Nursing
MH  - HIV Infections/nursing/prevention & control
MH  - Health Information Management
MH  - Humans
MH  - Infection Control
MH  - Leadership
MH  - Licensure/*standards
MH  - Nurses/*standards
MH  - Professional Competence/standards
MH  - Quality of Health Care
MH  - Tuberculosis/nursing/prevention & control
PMC - PMC7193753
COIS- The authors have no competing interests to declare.
EDAT- 2020/05/08 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.5334/aogh.2800 [doi]
PST - epublish
SO  - Ann Glob Health. 2020 Apr 28;86(1):45. doi: 10.5334/aogh.2800.


PMID- 32377426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-8016 (Print)
IS  - 2090-0597 (Linking)
VI  - 2020
DP  - 2020
TI  - Urine-Derived Induced Pluripotent Stem Cells in Cardiovascular Disease.
PG  - 3563519
LID - 10.1155/2020/3563519 [doi]
AB  - Recent studies have demonstrated that stem cells are equipped with the potential 
      to differentiate into various types of cells, including cardiomyocytes.
      Meanwhile, stem cells are highly promising in curing cardiovascular diseases.
      However, owing to the ethical challenges posed in stem cell acquisition and the
      complexity and invasive nature of the method, large-scale expansions and clinical
      applications in the laboratory have been limited. The current generation of
      cardiomyocytes is available from diverse sources; urine is one of the promising
      sources among them. Although advanced research was established in the generation 
      of human urine cells as cardiomyocytes, the reprogramming of urine cells to
      cardiomyocytes remains unclear. In this context, it is necessary to develop a
      minimally invasive method to create induced pluripotent stem cells (iPSCs). This 
      review focuses on the latest advances in research on urine-derived iPSCs and
      their application mechanisms in cardiovascular diseases.
CI  - Copyright (c) 2020 Ping Huang et al.
FAU - Huang, Ping
AU  - Huang P
AD  - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100, China.
AD  - Southern Medical University, Guangzhou, Guangdong 510515, China.
FAU - Li, Yibin
AU  - Li Y
AD  - The Third Affiliated Hospital of Southern Medical University, Guangzhou,
      Guangdong 510000, China.
FAU - Nasser, M I
AU  - Nasser MI
AD  - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100, China.
FAU - Guo, Huiming
AU  - Guo H
AD  - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100, China.
FAU - Huang, Huanlei
AU  - Huang H
AD  - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100, China.
FAU - Zhao, Mingyi
AU  - Zhao M
AUID- ORCID: https://orcid.org/0000-0002-2884-0736
AD  - Department of Pediatrics, The Third Xiangya Hospital of Central South University,
      Changsha, Hunan 410013, China.
FAU - Zhu, Ping
AU  - Zhu P
AUID- ORCID: https://orcid.org/0000-0002-4276-9593
AD  - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital,
      Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200110
PL  - United States
TA  - Cardiol Res Pract
JT  - Cardiology research and practice
JID - 101516542
PMC - PMC7199581
COIS- The authors declare no conflicts of interest.
EDAT- 2020/05/08 06:00
MHDA- 2020/05/08 06:01
CRDT- 2020/05/08 06:00
PHST- 2019/08/20 00:00 [received]
PHST- 2019/11/26 00:00 [revised]
PHST- 2019/12/17 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/08 06:01 [medline]
AID - 10.1155/2020/3563519 [doi]
PST - epublish
SO  - Cardiol Res Pract. 2020 Jan 10;2020:3563519. doi: 10.1155/2020/3563519.
      eCollection 2020.


PMID- 32377367
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2054-4774 (Print)
IS  - 2054-4774 (Linking)
VI  - 7
IP  - 1
DP  - 2020
TI  - Hepatitis C elimination in the Netherlands (CELINE): study protocol for
      nationwide retrieval of lost to follow-up patients with chronic hepatitis C.
PG  - e000396
LID - 10.1136/bmjgast-2020-000396 [doi]
AB  - Background: The Netherlands has a low hepatitis C virus (HCV) prevalence,
      estimated at 0.16%. Previous studies have shown that up to 30% of the diagnosed
      HCV population in the Netherlands has been lost to follow-up (LTFU). Retrieval of
      these patients could halt progression of liver disease in infected patients,
      reduce the number of infected individuals and limit HCV transmission. Several
      regional Dutch retrieval projects have already been executed, which demonstrated 
      that retrieval is feasible. Therefore, we initiated a nationwide retrieval
      project, aiming to achieve microelimination in previously diagnosed but LTFU
      patients with chronic HCV through retrieval. Methods: Laboratory records will be 
      used to identify possible patients with chronic hepatitis C, defined as either a 
      positive most recent HCV RNA or positive HCV antibodies without known RNA result.
      Reviewing patient records and obtaining current contact information from
      municipality databases will identify LTFU patients who are eligible for
      retrieval. These patients will be invited for outpatient clinic care. The primary
      outcome of the study is the total number of LTFU patients who have been
      successfully linked to care. Discussion: Hepatitis C ELimination In the
      NEtherlands (CELINE) is within the remit of WHO elimination targets and the Dutch
      National Hepatitis Plan. The methodology of CELINE is based on previously
      conducted regional retrieval projects and is designed to overcome some of their
      limitations. After ethical approval was obtained in 2018, the first centre
      initiated retrieval in 2018 and the project is expected to finish in 2021. Trial 
      registration number: NCT04208035.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Isfordink, Cas J
AU  - Isfordink CJ
AD  - Department of Gastroenterology and Hepatology, University Medical Centre Utrecht,
      Utrecht, the Netherlands.
AD  - Division of Infectious Diseases, Amsterdam Infection & Immunity Institute
      Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
FAU - Brakenhoff, Sylvia M
AU  - Brakenhoff SM
AD  - Department of Gastroenterology and Hepatology, Erasmus MC University Medical
      Centre, Rotterdam, the Netherlands.
FAU - van Dijk, Marleen
AU  - van Dijk M
AUID- ORCID: 0000-0001-9092-0481
AD  - Department of Gastroenterology and Hepatology, Radboud University Medical Centre,
      Nijmegen, the Netherlands.
FAU - van der Valk, Marc
AU  - van der Valk M
AD  - Division of Infectious Diseases, Amsterdam Infection & Immunity Institute
      Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
FAU - de Knegt, Rob J
AU  - de Knegt RJ
AD  - Department of Gastroenterology and Hepatology, Erasmus MC University Medical
      Centre, Rotterdam, the Netherlands.
FAU - Arends, Joop E
AU  - Arends JE
AD  - Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht,
      the Netherlands.
FAU - Drenth, Joost Ph
AU  - Drenth JP
AD  - Department of Gastroenterology and Hepatology, Radboud University Medical Centre,
      Nijmegen, the Netherlands.
CN  - HepNed study group
LA  - eng
SI  - ClinicalTrials.gov/NCT04208035
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200412
PL  - England
TA  - BMJ Open Gastroenterol
JT  - BMJ open gastroenterology
JID - 101660690
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Hepacivirus
MH  - *Hepatitis C/drug therapy
MH  - *Hepatitis C, Chronic/diagnosis
MH  - Humans
MH  - Lost to Follow-Up
MH  - Netherlands/epidemiology
PMC - PMC7199651
OTO - NOTNLM
OT  - *HCV
OT  - *antiviral therapy
OT  - *health service research
OT  - *hepatitis C
OT  - *infectious disease
COIS- Competing interests: CJI, SMB and MvD have no conflicts of interest. MvdV
      declares that the Amsterdam Infection & Immunity Institute Amsterdam UMC, on
      behalf of MvdV, received fees for participation in advisory boards of Abbvie,
      Gilead, Johnson & Johnson, Merck Sharp & Dohme (MSD), and ViiV and received
      independent research grants from Abbvie, Johnson & Johnson, Gilead, and MSD. RJdK
      declares that the Erasmus University Medical Centre, on behalf of RJdK, received 
      honoraria for consulting/speaking from Gilead, Janssen-Cilag, Bristol-Myers
      Squibb (BMS), Abbvie, MSD, Roche, and Norgine and received research grants from
      Gilead, Janssen-Cilag, BMS, and Roche. JEA declares that the University Medical
      Centre Utrecht, on behalf of JEA, received honoraria for participation in
      advisory boards of Gilead, Janssen-Cilag, BMS, Abbvie, MSD, and ViiV and received
      research grants from BMS, Abbvie, and ViiV. JPHD declares that the Radboudumc, on
      behalf of JPHD, received honoraria or research grants from Novartis, Ipsen,
      Otsuka, Abbvie, and Gilead. JPHD served as consultant for Gilead and Abbvie, and 
      in the last two years has been member of advisory boards of Otsuka, Norgine
      Gilead, BMS, Janssen, and Abbvie. JS participated in advisory boards of Gilead
      and received research grants from Gilead and Abbvie. SW has received honoraria
      for consulting/speaking from Gilead, Janssen-Cilag, BMS, and Roche, participated 
      in advisory boards of Gilead, BMS, and Abbvie and received research grants from
      Gilead, Janssen-Cilag BMS, Abbvie, MSD, and Roche. BvH participated in advisory
      boards of Janssen-Cilag, BMS, Abbvie, MSD, and Norgine and received a research
      grant from Zambon Pharma. DP has no conflicts of interest to declare. DB has
      received honoraria for consulting/speaking from MSD, participated in advisory
      boards of MSD and received research grants from Gilead, Janssen-Cilag, BMS, MSD, 
      and Roche. HB has participated in advisory boards of Gilead. KvE participated in 
      advisory boards of Gilead, Janssen-Cilag, BMS, Abbvie, and MSD and received
      research grants from Gilead and Janssen-Cilag.
EDAT- 2020/05/08 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 10.1136/bmjgast-2020-000396 [doi]
AID - bmjgast-2020-000396 [pii]
PST - epublish
SO  - BMJ Open Gastroenterol. 2020 Apr 12;7(1):e000396. doi:
      10.1136/bmjgast-2020-000396. eCollection 2020.


PMID- 32377031
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0308-5961 (Print)
IS  - 0308-5961 (Linking)
VI  - 44
IP  - 6
DP  - 2020 Jul
TI  - Harnessing artificial intelligence (AI) to increase wellbeing for all: The case
      for a new technology diplomacy.
PG  - 101988
LID - 10.1016/j.telpol.2020.101988 [doi]
AB  - The field of artificial intelligence (AI) is experiencing a period of intense
      progress due to the consolidation of several key technological enablers. AI is
      already deployed widely and has a high impact on work and daily life activities. 
      The continuation of this process will likely contribute to deep economic and
      social changes. To realise the tremendous benefits of AI while mitigating
      undesirable effects will require enlightened responses by many stakeholders.
      Varying national institutional, economic, political, and cultural conditions will
      influence how AI will affect convenience, efficiency, personalisation, privacy
      protection, and surveillance of citizens. Many expect that the winners of the AI 
      development race will dominate the coming decades economically and
      geopolitically, potentially exacerbating tensions between countries. Moreover,
      nations are under pressure to protect their citizens and their interests-and even
      their own political stability-in the face of possible malicious or biased uses of
      AI. On the one hand, these different stressors and emphases in AI development and
      deployment among nations risk a fragmentation between world regions that
      threatens technology evolution and collaboration. On the other hand, some level
      of differentiation will likely enrich the global AI ecosystem in ways that
      stimulate innovation and introduce competitive checks and balances through the
      decentralisation of AI development. International cooperation, typically
      orchestrated by intergovernmental and non-governmental organisations, private
      sector initiatives, and by academic researchers, has improved common welfare and 
      avoided undesirable outcomes in other technology areas. Because AI will most
      likely have more fundamental effects on our lives than other recent technologies,
      stronger forms of cooperation that address broader policy and governance
      challenges in addition to regulatory and technological issues may be needed. At a
      time of great challenges among nations, international policy coordination remains
      a necessary instrument to tackle the ethical, cultural, economic, and political
      repercussions of AI. We propose to advance the emerging concept of technology
      diplomacy to facilitate the global alignment of AI policy and governance and
      create a vibrant AI innovation system. We argue that the prevention of malicious 
      uses of AI and the enhancement of human welfare create strong common interests
      across jurisdictions that require sustained efforts to develop better, mutually
      beneficial approaches. We hope that new technology diplomacy will facilitate the 
      dialogues necessary to help all interested parties develop a shared understanding
      and coordinate efforts to utilise AI for the benefit of humanity, a task whose
      difficulty should not be underestimated.
CI  - (c) 2020 The Authors.
FAU - Feijoo, Claudio
AU  - Feijoo C
AD  - Technical University of Madrid, Spain.
AD  - Tongji University, China.
FAU - Kwon, Youngsun
AU  - Kwon Y
AD  - Korea Advanced Institute of Science and Technology, Republic of Korea.
FAU - Bauer, Johannes M
AU  - Bauer JM
AD  - Michigan State University, USA.
FAU - Bohlin, Erik
AU  - Bohlin E
AD  - Chalmers University of Technology, Sweden.
FAU - Howell, Bronwyn
AU  - Howell B
AD  - Victoria University of Wellington, New Zealand.
FAU - Jain, Rekha
AU  - Jain R
AD  - Indian Institute of Management Ahmedabad, India.
FAU - Potgieter, Petrus
AU  - Potgieter P
AD  - University of South Africa, South Africa.
FAU - Vu, Khuong
AU  - Vu K
AD  - National University of Singapore, Singapore.
FAU - Whalley, Jason
AU  - Whalley J
AD  - Northumbria University, United Kingdom.
FAU - Xia, Jun
AU  - Xia J
AD  - Beijing University of Posts and Telecommunications, China.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - England
TA  - Telecomm Policy
JT  - Telecommunications policy
JID - 9879423
PMC - PMC7200378
OTO - NOTNLM
OT  - Artificial intelligence
OT  - Decentralisation
OT  - Fragmentation
OT  - Human well-being
OT  - International collaborative governance
OT  - Protectionism
OT  - Techno-nationalism
OT  - Technology diplomacy
EDAT- 2020/05/08 06:00
MHDA- 2020/05/08 06:01
CRDT- 2020/05/08 06:00
PHST- 2020/05/04 00:00 [received]
PHST- 2020/05/04 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/08 06:01 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1016/j.telpol.2020.101988 [doi]
AID - S0308-5961(20)30080-X [pii]
AID - 101988 [pii]
PST - ppublish
SO  - Telecomm Policy. 2020 Jul;44(6):101988. doi: 10.1016/j.telpol.2020.101988. Epub
      2020 May 6.


PMID- 32376754
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Prospective, single-centre, randomised controlled trial to evaluate the efficacy 
      and safety of ischaemia-free liver transplantation (IFLT) in the treatment of
      end-stage liver disease.
PG  - e035374
LID - 10.1136/bmjopen-2019-035374 [doi]
AB  - INTRODUCTION: During conventional liver transplantation (CLT),
      ischaemia-reperfusion injury (IRI) is inevitable and is associated with
      complications such as early allograft dysfunction (EAD), primary non-function and
      ischaemic-type biliary lesions. We have established a novel procedure called
      ischaemia-free liver transplantation (IFLT). The results from a pilot study
      suggest that IFLT might prevent IRI and yield better transplant outcomes than
      CLT. The purpose of this study was to further assess the efficacy and safety of
      IFLT versus CLT in patients with end-stage liver disease. METHODS AND ANALYSIS:
      This is an investigator-initiated, open-label, phase III, prospective,
      single-centre randomised controlled trial on the effects of IFLT in patients with
      end-stage liver disease. Adult patients (aged 18-75 years) eligible for liver
      transplantation will be screened for participation in this trial and will be
      randomised between the IFLT group (n=34) and the CLT group (n=34). In the IFLT
      group, the donor liver will be procured, preserved and implanted with continuous 
      normothermic machine perfusion (NMP). In the CLT group, the donor liver will be
      procured after a fast cold flush, preserved in 0 degrees C-4 degrees C solution
      and implanted under hypothermic and hypoxic conditions. Patients in both groups
      will be managed according to the standard protocol of our centre. The primary end
      point is the incidence of EAD after liver transplantation. Intraoperative and
      postoperative parameters of donor livers and recipients will be observed and
      recorded, and postoperative liver graft function, complications and recipient and
      graft survival will be evaluated. After a 12-month follow-up of the last enrolled
      recipient, the outcomes will be analysed to evaluate the safety and efficacy of
      IFLT versus CLT in patients with end-stage liver disease. ETHICS AND
      DISSEMINATION: The protocol was reviewed and approved by the Ethics Committee of 
      The First Affiliated Hospital of Sun Yat-sen University. The findings will be
      disseminated to the public through conference presentations and peer-reviewed
      scientific journals. TRIAL REGISTRATION NUMBER: ChiCTR1900021158.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huang, Changjun
AU  - Huang C
AUID- ORCID: 0000-0002-7411-7637
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Huang, Shanzhou
AU  - Huang S
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Tang, Yunhua
AU  - Tang Y
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Zhao, Qiang
AU  - Zhao Q
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Wang, Dongping
AU  - Wang D
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Ju, Weiqiang
AU  - Ju W
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Yang, Lu
AU  - Yang L
AD  - Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, China.
FAU - Wu, Linwei
AU  - Wu L
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Chen, Maogen
AU  - Chen M
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Zhang, Zhiheng
AU  - Zhang Z
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Zhu, Zebin
AU  - Zhu Z
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Wang, Linhe
AU  - Wang L
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Zhu, Caihui
AU  - Zhu C
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Zhang, Yixi
AU  - Zhang Y
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Sun, Chengjun
AU  - Sun C
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Xiong, Wei
AU  - Xiong W
AD  - Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Shen, Yuekun
AU  - Shen Y
AD  - Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Chen, Xiaoxiang
AU  - Chen X
AD  - Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Ma, Yi
AU  - Ma Y
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Hu, Anbin
AU  - Hu A
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Zhu, Xiaofeng
AU  - Zhu X
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - Rong, Jian
AU  - Rong J
AD  - Department of Cardiopulmonary Bypass, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Cai, Changjie
AU  - Cai C
AD  - Surgical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen
      University, Guangzhou, China.
FAU - Guo, Zhiyong
AU  - Guo Z
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China gdtrc@163.com rockyucsf1981@126.com.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
FAU - He, Xiaoshun
AU  - He X
AD  - Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University,
      Guangzhou, China gdtrc@163.com rockyucsf1981@126.com.
AD  - Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, 
      Guangzhou, China.
AD  - Guangdong Provincial International Cooperation Base of Science and Technology
      (Organ Transplantation), Guangzhou, China.
LA  - eng
SI  - ChiCTR/ChiCTR1900021158
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Clinical Trials, Phase III as Topic
MH  - End Stage Liver Disease/*surgery
MH  - Female
MH  - Humans
MH  - Liver Transplantation/*methods
MH  - Male
MH  - Middle Aged
MH  - Organ Preservation/*methods
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Reperfusion Injury/*prevention & control
MH  - Research Design
PMC - PMC7223152
OTO - NOTNLM
OT  - *hepatobiliary surgery
OT  - *hepatology
OT  - *transplant surgery
COIS- Competing interests: None declared.
EDAT- 2020/05/08 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035374 [pii]
AID - 10.1136/bmjopen-2019-035374 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e035374. doi: 10.1136/bmjopen-2019-035374.


PMID- 32376751
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Understanding decision making about major surgery: protocol for a qualitative
      study of shared decision making by high-risk patients and their clinical teams.
PG  - e033703
LID - 10.1136/bmjopen-2019-033703 [doi]
AB  - INTRODUCTION: Surgical treatments are being offered to more patients than ever
      before, and increasingly to high-risk patients (typically multimorbid and over
      75). Shared decision making is seen as essential practice. However, little is
      currently known about what 'good' shared decision making involves nor how it
      applies in the context of surgery for high-risk patients. This new study aims to 
      identify how high-risk patients, their families and clinical teams negotiate
      decision making for major surgery. METHODS AND ANALYSIS: Focusing on major joint 
      replacement, colorectal and cardiac surgery, we use qualitative methods to
      explore how patients, their families and clinicians negotiate decision making
      (including interactional, communicative and informational aspects and the extent 
      to which these are perceived as shared) and reflect back on the decisions they
      made. Phase 1 involves video recording 15 decision making encounters about major 
      surgery between patients, their carers/families and clinicians; followed by up to
      90 interviews (with the same patient, carer and clinician participants)
      immediately after a decision has been made and again 3-6 months later. Phase 2
      involves focus groups with a wider group of (up to 90) patients and (up to 30)
      clinicians to test out emerging findings and inform development of shared
      decision making scenarios (3-5 summary descriptions of how decisions are made).
      ETHICS AND DISSEMINATION: The study forms the first part in a 6-year programme of
      research, Optimising Shared decision-makIng for high-RIsk major Surgery (OSIRIS).
      Ethical challenges around involving patients at a challenging time in their lives
      will be overseen by the programme steering committee, which includes strong
      patient representation and a lay chair. In addition to academic outputs, we will 
      produce a typology of decision making scenarios for major surgery to feed back to
      patients, professionals and service providers and inform subsequent work in the
      OSIRIS programme.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Shaw, Sara
AU  - Shaw S
AUID- ORCID: 0000-0002-7014-4793
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK sara.shaw@phc.ox.ac.uk.
FAU - Hughes, Gemma
AU  - Hughes G
AUID- ORCID: 0000-0003-2930-1125
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Stephens, Tim
AU  - Stephens T
AD  - School of Medicine & Dentistry, Queen Mary University of London, London, UK.
FAU - Pearse, Rupert
AU  - Pearse R
AD  - Barts and the London School of Medicine & Dentistry, Queen Mary University of
      London, London, UK.
FAU - Prowle, John
AU  - Prowle J
AD  - Barts and the London School of Medicine & Dentistry, Queen Mary University of
      London, London, UK.
FAU - Ashcroft, Richard Edmund
AU  - Ashcroft RE
AUID- ORCID: 0000-0001-6065-4717
AD  - School of Law, City University of London, London, UK.
FAU - Avagliano, Ester
AU  - Avagliano E
AD  - Department of Anaesthesia, St. George's University Hospitals Foundation Trust,
      London, UK.
FAU - Day, James
AU  - Day J
AD  - Department of Anaesthesia, John Radcliffe Hospital, Oxford, UK.
FAU - Edsell, Mark
AU  - Edsell M
AD  - Department of Anaesthesia, St. George's University Hospitals Foundation Trust,
      London, UK.
FAU - Edwards, Jennifer
AU  - Edwards J
AD  - Department of Anaesthesia, Royal Alexandra Hospital, Paisley, UK.
FAU - Everest, Leslie
AU  - Everest L
AD  - Patient Representative, Leeds, UK.
LA  - eng
GR  - RP-PG-0218-20001/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Arthroplasty, Replacement
MH  - *Cardiac Surgical Procedures
MH  - Colon/*surgery
MH  - *Decision Making, Shared
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Patient Participation
MH  - Qualitative Research
MH  - Research Design
PMC - PMC7223149
OTO - NOTNLM
OT  - *adult surgery
OT  - *communication
OT  - *high risk
OT  - *qualitative research
OT  - *shared decision making
COIS- Competing interests: RP has received research grants and/or honoraria from
      Edwards Lifesciences, Intersurgical, BBraun and GlaxoSmithkline.
EDAT- 2020/05/08 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033703 [pii]
AID - 10.1136/bmjopen-2019-033703 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e033703. doi: 10.1136/bmjopen-2019-033703.


PMID- 32376749
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Risk factors for recurrent falls in older adults: a study protocol for a
      systematic review with meta-analysis.
PG  - e033602
LID - 10.1136/bmjopen-2019-033602 [doi]
AB  - INTRODUCTION: Older adults who fall recurrently (i.e., >1 fall/year) are at risk 
      for functional decline and mortality. Key risk factors for recurrent falls in
      community-dwelling older adults are not well established due to methodological
      limitations, such as recall bias. A better understanding of the risk factors for 
      recurrent falls will aid in refining clinical practice guidelines for secondary
      fall prevention strategies. The primary objective of this systematic review with 
      meta-analysis is to examine the risk factors for recurrent falls in prospective
      studies among community-dwelling older adults. METHODS AND ANALYSIS: A
      comprehensive search for articles indexed in MEDLINE, EMBASE, PsycINFO and CINAHL
      databases as well as grey literature was conducted on April 25, 2019. We will use
      MeSH and keyword search terms around the following topics: falls, recurrence,
      fall-risk, ageing and prospective studies. Prospective studies with monthly falls
      monitoring for 12 months, investigating risk factors for recurrent falls in older
      adults will be included. One author will complete the search. Two authors will
      remove duplicates and screen the titles and abstracts for their potential
      inclusion against the eligibility criteria. Two authors will screen the full
      texts and extract the data using a piloted extraction sheet. Included studies
      will be evaluated for the risk of bias with the Joanna Briggs Institute
      Prevalence Critical Appraisal tools. The quality of reporting will be determined 
      with the Strengthening the Reporting of OBservational studies in Epidemiology.
      The data extraction will include study characteristics as well as
      sociodemographic, balance and mobility, sensory and neuromuscular, psychological,
      medical, medication and environmental factors. The results will be presented via 
      figures, summary tables, meta-analysis (when possible) and narrative summaries.
      ETHICS AND DISSEMINATION: No ethics approval will be required. Findings will be
      disseminated through publication and media. PROSPERO REGISTRATION NUMBER:
      CRD42019118888; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jehu, Deborah A
AU  - Jehu DA
AUID- ORCID: 0000-0002-9084-7445
AD  - Djavad Mowafaghian Centre for Brain Health, Vancouver Coastal Health Research
      Institute, Vancouver, British Columbia, Canada.
AD  - Centre for Hip Health and Mobility, Vancouver Coastal Health Research Institute, 
      Vancouver, British Columbia, Canada.
AD  - Aging, Mobility and Cognitive Neuroscience Laboratory, Department of Physical
      Therapy, University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Davis, Jennifer C
AU  - Davis JC
AD  - Centre for Hip Health and Mobility, Vancouver Coastal Health Research Institute, 
      Vancouver, British Columbia, Canada.
AD  - Social & Economic Change Laboratory, Faculty of Management, University of British
      Columbia - Okanagan Campus, Kelowna, British Columbia, Canada.
FAU - Liu-Ambrose, Teresa
AU  - Liu-Ambrose T
AD  - Djavad Mowafaghian Centre for Brain Health, Vancouver Coastal Health Research
      Institute, Vancouver, British Columbia, Canada teresa.ambrose@ubc.ca.
AD  - Centre for Hip Health and Mobility, Vancouver Coastal Health Research Institute, 
      Vancouver, British Columbia, Canada.
AD  - Aging, Mobility and Cognitive Neuroscience Laboratory, Department of Physical
      Therapy, University of British Columbia, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Accidental Falls/*statistics & numerical data
MH  - Aged
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Recurrence
MH  - Research Design
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7223009
OTO - NOTNLM
OT  - *meta-analysis
OT  - *older adults
OT  - *recurrent falls
OT  - *risk factors
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/05/08 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-033602 [pii]
AID - 10.1136/bmjopen-2019-033602 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e033602. doi: 10.1136/bmjopen-2019-033602.


PMID- 32376719
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Public interest in health data research: laying out the conceptual groundwork.
PG  - 610-616
LID - 10.1136/medethics-2020-106152 [doi]
AB  - The future of health research will be characterised by three continuing trends:
      rising demand for health data; increasing impracticability of obtaining specific 
      consent for secondary research; and decreasing capacity to effectively anonymise 
      data. In this context, governments, clinicians and the research community must
      demonstrate that they can be responsible stewards of health data. IRBs and RECs
      sit at heart of this process because in many jurisdictions they have the capacity
      to grant consent waivers when research is judged to be of particular value.
      However, several different terms are used to refer to this value (including
      public interest, public benefit, public good and social value), indicating a lack
      of conceptual clarity regarding the appropriate test for access to health data
      for research without consent. In this paper we do three things. First we describe
      the current confusion and instability in terminology relating to public interest 
      in the context of consent waivers. Second we argue for harmonisation of
      terminology on the grounds of clarity, transparency and consistency. Third we
      argue that the term 'public interest' best reflects the normative work required
      to justify consent waivers because it is the broadest of the competing terms.
      'Public interest' contains within its scope positive and negative implications of
      a study, as well as welfare, justice and rights considerations. In making this
      argument, we explain the normative basis for consent waivers, and provide a
      starting place for further discussion about the precise conditions in which a
      given study can be said to advance the public interest. Ipsos MORI study found
      that: ... the public would be broadly happy with administrative data linking for 
      research projects provided (1) Those projects have social value, broadly defined.
      (2) Data are de-identified. (3) Data are kept secure. (4) Businesses are not able
      to access the data for profit.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Ballantyne, Angela
AU  - Ballantyne A
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University Singapore, Singapore.
FAU - Schaefer, G Owen
AU  - Schaefer GO
AUID- ORCID: 0000-0002-6915-6148
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University Singapore, Singapore owen_schaefer@nus.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200506
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2021 Aug;47(8):580-582. PMID: 32934111
MH  - *Ethics Committees, Research
MH  - *Informed Consent
MH  - Social Justice
OTO - NOTNLM
OT  - *informed consent
OT  - *public policy
OT  - *regulation
OT  - *research ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/08 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - medethics-2020-106152 [pii]
AID - 10.1136/medethics-2020-106152 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):610-616. doi: 10.1136/medethics-2020-106152. Epub
      2020 May 6.


PMID- 32376718
OWN - NLM
STAT- Publisher
LR  - 20200520
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 6
TI  - Old problems in need of new (narrative) approaches? A young
      physician-bioethicist's search for ethical guidance in the practice of
      physician-assisted dying in the Netherlands.
LID - medethics-2019-106016 [pii]
LID - 10.1136/medethics-2019-106016 [doi]
AB  - The current empirical research and normative arguments on physician-assisted
      dying (PAD) in the Netherlands seem insufficient to provide ethical guidance to
      general practitioners in the practice of PAD, due to a gap between the evidence
      and arguments on the one hand and the uncertainties and complexities as found in 
      everyday practice on the other. This paper addresses the problems of current
      ethical arguments and empirical research and how both seem to be profoundly
      influenced by the Dutch legislative framework on PAD and a certain view on
      ethics. Furthermore, the paper elaborates on how other approaches to empirical
      research in bioethics, such as found in the broad field of narrative research,
      could supplement the empirical and ethical evaluation of PAD in the Netherlands. 
      This paper also addresses the challenging question of how empirical data-in this 
      case narratives-relate to normativity. The paper is written in the form of a
      personal narrative of the author, a young Dutch general practitioner and
      researcher in bioethics. This style is intentionally chosen, to illustrate how
      work context and professional background influence the observations one makes and
      the questions one may ask about the topic of PAD. In addition, by using this
      style, this paper not only gives a different perspective on a much-contested
      bioethical issue, but also on the challenges faced when a physician-bioethicist
      has to navigate different disciplinary fields and (moral) epistemological
      paradigms, especially since the 'empirical turn' in bioethics.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Roest, Bernadette
AU  - Roest B
AUID- ORCID: http://orcid.org/0000-0002-1178-8150
AD  - Department of Care Ethics, University of Humanistic Studies, Utrecht, The
      Netherlands bernadette.roest@phd.uvh.nl.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - end-of-life
OT  - euthanasia
COIS- Competing interests: No competing interests.
EDAT- 2020/05/08 06:00
MHDA- 2020/05/08 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/08 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - medethics-2019-106016 [pii]
AID - 10.1136/medethics-2019-106016 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 6. pii: medethics-2019-106016. doi:
      10.1136/medethics-2019-106016.


PMID- 32376717
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Best interests versus resource allocation: could COVID-19 cloud decision-making
      for the cognitively impaired?
PG  - 447-450
LID - 10.1136/medethics-2020-106323 [doi]
AB  - The COVID-19 pandemic is putting the NHS under unprecedented pressure, requiring 
      clinicians to make uncomfortable decisions they would not ordinarily face. These 
      decisions revolve primarily around intensive care and whether a patient should
      undergo invasive ventilation. Certain vulnerable populations have featured in the
      media as falling victim to an increasingly utilitarian response to the
      pandemic-primarily those of advanced years or with serious existing health
      conditions. Another vulnerable population potentially at risk is those who lack
      the capacity to make their own care decisions. Owing to the pandemic, there are
      increased practical and normative challenges to following the requirements of the
      Mental Capacity Act 2005. Both capacity assessments and best interests decisions 
      may prove more difficult in the current situation. This may create a more
      paternalistic situation in decisions about the care of the cognitively impaired
      which is at risk of taking on a utilitarian focus. We look to these issues and
      consider whether there is a risk of patients who lack capacity to make their own 
      care decisions being short-changed.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Parsons, Jordan A
AU  - Parsons JA
AUID- ORCID: 0000-0002-1050-6051
AD  - Centre for Ethics in Medicine, Bristol Medical School, University of Bristol,
      Bristol, UK jordan.parsons@bristol.ac.uk.
FAU - Johal, Harleen Kaur
AU  - Johal HK
AUID- ORCID: 0000-0002-8665-8932
AD  - Centre for Ethics in Medicine, Bristol Medical School, University of Bristol,
      Bristol, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200506
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Age Factors
MH  - Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - Cognitive Dysfunction/*epidemiology
MH  - Coronavirus Infections/*epidemiology
MH  - *Decision Making
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Mental Competency/standards
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - State Medicine/*ethics/organization & administration
MH  - United Kingdom/epidemiology
PMC - PMC7239662
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *capacity
OT  - *clinical ethics
OT  - *decision-making
COIS- Competing interests: None declared.
EDAT- 2020/05/08 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - medethics-2020-106323 [pii]
AID - 10.1136/medethics-2020-106323 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):447-450. doi: 10.1136/medethics-2020-106323. Epub
      2020 May 6.


PMID- 32376716
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - More philosophical work needed in One Health on ethical frameworks and theory.
PG  - 705-706
LID - 10.1136/medethics-2020-106243 [doi]
AB  - We thank Zohar Lederman and Benjamin Capps for engaging with our paper on One
      Health (OH) and ethical frameworks, however we want to take issue with them on
      three points. First, they appear to misunderstand the distinction we appeal to
      between ethical theory and ethical frameworks, and so misinterpret what we are
      trying to achieve in our paper. Second, in spite of what they seem to imply, we
      agree that an OH approach can obscure differences in values, and that to progress
      the field there needs to be recognition of competing values and their
      implications for OH. Finally, we are puzzled by their interest in pursuing a
      deliberative process, as this seems at odds with other positions they take in
      their paper, and also opens up many questions that need to be addressed.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Johnson, Jane
AU  - Johnson J
AUID- ORCID: 0000-0003-0682-7909
AD  - Marie Bashir Institute for Infectious Disease and Biosecurity, The University of 
      Sydney, Sydney, NSW, Australia jane.johnson@mq.edu.au.
AD  - Department of Philosophy, Macquarie University, North Ryde, NSW, Australia.
FAU - Degeling, Chris
AU  - Degeling C
AUID- ORCID: 0000-0003-4279-3443
AD  - Australian Centre for Health Engagement, Evidence and Values, University of
      Wollongong, Wollongong, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200506
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2019 Apr;45(4):239-243. PMID: 30772841
MH  - Ethical Theory
MH  - Humans
MH  - Morals
MH  - *One Health
OTO - NOTNLM
OT  - *decision-making
OT  - *public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/08 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - medethics-2020-106243 [pii]
AID - 10.1136/medethics-2020-106243 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):705-706. doi: 10.1136/medethics-2020-106243. Epub
      2020 May 6.


PMID- 32376715
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Parental manual ventilation in resource-limited settings: an ethical controversy.
PG  - 459-464
LID - 10.1136/medethics-2019-105992 [doi]
AB  - Lower respiratory tract infections are a leading cause of paediatric morbidity
      and mortality worldwide. Children in low-income countries are disproportionately 
      affected. This is in large part due to limitations in healthcare resources and
      medical technologies. Mechanical ventilation can be a life-saving therapy for
      many children with acute respiratory failure. The scarcity of functioning
      ventilators in low-income countries results in countless preventable deaths. Some
      hospitals have attempted to adapt to this scarcity by using hand-bag ventilation,
      as either a bridge to a mechanical ventilator, or until clinical improvement
      occurs rendering mechanical ventilation no longer necessary. In instances of
      hand-bag ventilation, an endotracheal tube is first placed. Family members are
      then asked to play the role of a ventilator, manually compressing a bag
      repeatedly to inflate the child's lungs. This approach is fraught with numerous
      ethical challenges. A careful examination of the data and a nuanced approach to
      the ethical considerations are imperative. Ethical arguments in support of and in
      opposition to allowing parental hand-bag ventilation are explored, including the 
      best interests of the child, the child's right to an open future, beneficence and
      parental protection, legitimising substandard care, and finally, contextual
      concerns. An algorithmic, potentially ethically permissible approach to parental 
      participation in manual ventilation is proposed.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Barsky, Emily
AU  - Barsky E
AD  - Division of Pulmonary Medicine, Department of Medicine, Boston Children's
      Hospital, Boston, Massachusetts, USA emily.barsky@childrens.harvard.edu.
AD  - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Sayeed, Sadath
AU  - Sayeed S
AD  - Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital,
      Boston, Massachusetts, USA.
AD  - Department of Global Health and Social Medicine, Harvard Medical School, Boston, 
      Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Beneficence
MH  - Child
MH  - Family
MH  - Humans
MH  - Parents
MH  - *Respiration, Artificial
MH  - *Ventilators, Mechanical
OTO - NOTNLM
OT  - *autonomy
OT  - *decision-making
OT  - *ethics
OT  - *paediatrics
OT  - *resource allocation
COIS- Competing interests: None declared.
EDAT- 2020/05/08 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/03/27 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - medethics-2019-105992 [pii]
AID - 10.1136/medethics-2019-105992 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):459-464. doi: 10.1136/medethics-2019-105992. Epub
      2020 May 6.


PMID- 32375908
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1469-8978 (Electronic)
IS  - 0033-2917 (Linking)
VI  - 50
IP  - 7
DP  - 2020 May
TI  - Knowing me, knowing you: theory of mind in AI.
PG  - 1057-1061
LID - 10.1017/S0033291720000835 [doi]
AB  - Artificial intelligence has dramatically changed the world as we know it, but is 
      yet to fully embrace 'hot' cognition, i.e., the way an intelligent being's
      thinking is affected by their emotional state. Artificial intelligence
      encompassing hot cognition will not only usher in enhanced machine-human
      interactions, but will also promote a much needed ethical approach. Theory of
      Mind, the ability of the human mind to attribute mental states to others, is a
      key component of hot cognition. To endow machines with (limited) Theory of Mind
      capabilities, computer scientists will need to work closely with psychiatrists,
      psychologists and neuroscientists. They will need to develop new models, but also
      to formally define what problems need to be solved and how the results should be 
      assessed.
FAU - Cuzzolin, F
AU  - Cuzzolin F
AD  - School of Engineering, Computing and Mathematics, Oxford Brookes University,
      Oxford, UK.
FAU - Morelli, A
AU  - Morelli A
AD  - Universita' degli Studi Suor Orsola Benincasa, Naples, Italy.
FAU - Cirstea, B
AU  - Cirstea B
AD  - School of Engineering, Computing and Mathematics, Oxford Brookes University,
      Oxford, UK.
FAU - Sahakian, B J
AU  - Sahakian BJ
AUID- ORCID: 0000-0001-7352-1745
AD  - Department of Psychiatry, University of Cambridge, Cambridge, UK.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200507
PL  - England
TA  - Psychol Med
JT  - Psychological medicine
JID - 1254142
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Humans
MH  - *Theory of Mind
PMC - PMC7253617
OTO - NOTNLM
OT  - *AI ethics
OT  - *Theory of Mind
OT  - *artificial intelligence (AI)
OT  - *hot cognition
OT  - *human-machine interaction
EDAT- 2020/05/08 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1017/S0033291720000835 [doi]
AID - S0033291720000835 [pii]
PST - ppublish
SO  - Psychol Med. 2020 May;50(7):1057-1061. doi: 10.1017/S0033291720000835. Epub 2020 
      May 7.


PMID- 32375855
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20201218
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 24
IP  - 1
DP  - 2020 May 6
TI  - Ethics guidelines on COVID-19 triage-an emerging international consensus.
PG  - 201
LID - 10.1186/s13054-020-02927-1 [doi]
FAU - Joebges, Susanne
AU  - Joebges S
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland.
FAU - Biller-Andorno, Nikola
AU  - Biller-Andorno N
AUID- ORCID: http://orcid.org/0000-0001-7661-1324
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland.
LA  - eng
PT  - Editorial
DEP - 20200506
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus/*isolation & purification
MH  - *Coronavirus Infections/diagnosis/epidemiology/therapy
MH  - *Critical Care/ethics/methods/standards
MH  - Europe
MH  - Humans
MH  - *Intensive Care Units/ethics/organization & administration/standards
MH  - *Pandemics
MH  - *Pneumonia, Viral/diagnosis/epidemiology/therapy
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Triage/*ethics/organization & administration/standards
MH  - Universal Precautions/*methods
PMC - PMC7202791
OTO - NOTNLM
OT  - COVID-19
OT  - Ethics
OT  - Pandemic
OT  - Triage
EDAT- 2020/05/08 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/04/15 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 10.1186/s13054-020-02927-1 [doi]
AID - 10.1186/s13054-020-02927-1 [pii]
PST - epublish
SO  - Crit Care. 2020 May 6;24(1):201. doi: 10.1186/s13054-020-02927-1.


PMID- 32375740
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 6
TI  - Factors and predictors of length of stay in offenders diagnosed with
      schizophrenia - a machine-learning-based approach.
PG  - 201
LID - 10.1186/s12888-020-02612-1 [doi]
AB  - BACKGROUND: Prolonged forensic psychiatric hospitalizations have raised ethical, 
      economic, and clinical concerns. Due to the confounded nature of factors
      affecting length of stay of psychiatric offender patients, prior research has
      called for the application of a new statistical methodology better accommodating 
      this data structure. The present study attempts to investigate factors
      contributing to long-term hospitalization of schizophrenic offenders referred to 
      a Swiss forensic institution, using machine learning algorithms that are better
      suited than conventional methods to detect nonlinear dependencies between
      variables. METHODS: In this retrospective file and registry study,
      multidisciplinary notes of 143 schizophrenic offenders were reviewed using a
      structured protocol on patients' characteristics, criminal and medical history
      and course of treatment. Via a forward selection procedure, the most influential 
      factors for length of stay were preselected. Machine learning algorithms then
      identified the most efficient model for predicting length-of-stay. RESULTS: Two
      factors have been identified as being particularly influential for a prolonged
      forensic hospital stay, both of which are related to aspects of the index
      offense, namely (attempted) homicide and the extent of the victim's injury. The
      results are discussed in light of previous research on this topic. CONCLUSIONS:
      In this study, length of stay was determined by legal considerations, but not by 
      factors that can be influenced therapeutically. Results emphasize that forensic
      risk assessments should be based on different evaluation criteria and not merely 
      on legal aspects.
FAU - Kirchebner, Johannes
AU  - Kirchebner J
AUID- ORCID: 0000-0002-6072-9958
AD  - University Hospital of Psychiatry Zurich, Department of Forensic Psychiatry,
      Zurich, Switzerland. johannes.kirchebner@puk.zh.ch.
FAU - Gunther, Moritz Philipp
AU  - Gunther MP
AD  - University Hospital of Psychiatry Zurich, Department of Psychiatry, Psychotherapy
      and Psychosomatics, Zurich, Switzerland.
FAU - Sonnweber, Martina
AU  - Sonnweber M
AD  - University Hospital of Psychiatry Zurich, Department of Forensic Psychiatry,
      Zurich, Switzerland.
FAU - King, Alice
AU  - King A
AD  - University Hospital of Psychiatry Zurich, Department of Forensic Psychiatry,
      Zurich, Switzerland.
FAU - Lau, Steffen
AU  - Lau S
AD  - University Hospital of Psychiatry Zurich, Department of Forensic Psychiatry,
      Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
MH  - Adult
MH  - Criminals/*psychology/*statistics & numerical data
MH  - Female
MH  - *Forensic Psychiatry
MH  - Homicide
MH  - Humans
MH  - Length of Stay/*statistics & numerical data
MH  - *Machine Learning
MH  - Male
MH  - Retrospective Studies
MH  - Schizophrenia/*diagnosis
MH  - Switzerland
PMC - PMC7201968
OTO - NOTNLM
OT  - *Forensic psychiatry
OT  - *Length of stay
OT  - *Machine learning
OT  - *Patient characteristics
OT  - *Schizophrenic offenders
EDAT- 2020/05/08 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1186/s12888-020-02612-1 [doi]
AID - 10.1186/s12888-020-02612-1 [pii]
PST - epublish
SO  - BMC Psychiatry. 2020 May 6;20(1):201. doi: 10.1186/s12888-020-02612-1.


PMID- 32375662
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 6
TI  - Screening for atrial fibrillation and other arrhythmias in primary care.
PG  - 79
LID - 10.1186/s12875-020-01151-8 [doi]
AB  - BACKGROUND: Atrial fibrillation (AF) and other arrhythmias are prevalent and
      often encountered by general practitioners (GPs). In response to the growing
      prevalence and to assist practitioners in the diagnosis and management of AF, the
      Cardiac Society of Australia & New Zealand and Heart Foundation of Australia
      published the first Australian AF Guidelines in 2018. We aimed to examine (a) the
      proportion of GPs who performed any form of AF screening and identify the methods
      they applied, (b) GPs' awareness of the AF Guidelines and approaches to
      arrhythmia screening, (c) the roles of conventional 12-lead ECG and mobile health
      devices, and (d) GPs' confidence in ECG interpretation and need for training.
      METHODS: A cross-sectional online survey titled "GPs Screen their patients for
      Atrial Fibrillation and othEr aRrhythmia (GPSAFER)" was conducted from October
      2018 to March 2019. The participants were recruited via various GP networks
      across Australia. Ethics approval was granted by The University of Sydney.
      RESULTS: A total of 463 surveys were completed. Many GPs (394/463, 85.1%, 95% CI 
      81.5-88.2%) performed some forms of AF screening and applied at least one AF
      screening method, most frequently pulse palpation (389/463, 84.0%). Some
      (299/463, 64.6%) GPs considered assessing their patients for other arrhythmias
      (237/299, 79.3% for complete heart block and 236/299, 78.9% for long-QT). Most
      GPs (424/463, 91.6%) were not using mobile ECG devices in their practice but some
      (147/463, 31.7%) were contemplating it. One third (175/463, 37.8%) of GPs were
      aware of the Australian AF Guidelines; those aware were more likely to perform AF
      screening (98.9% vs 76.7%, p < 0.001). Factors significantly and positively
      associated with AF screening were "awareness of the AF Guidelines" (p < 0.001),
      "number of years working in general practice" (p < 0.001), and "confidence in ECG
      interpretation of AF" (p = 0.003). Most GPs reported that they were very or
      extremely confident in interpreting AF (381/463, 82.3%) and complete heart block 
      (266/463, 57.5%). Many GPs (349/463, 75.4%) would like to receive online ECG
      interpretation training. CONCLUSIONS: Assessment of arrhythmias is common in
      general practice and GPs are open to further training in ECG interpretation and
      using mobile ECG devices to aid their clinical practice. Increasing awareness of 
      AF Guidelines and improving confidence in ECG interpretation may increase AF
      screening.
FAU - Wong, Kam Cheong
AU  - Wong KC
AUID- ORCID: 0000-0003-1898-7678
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Westmead Hospital, Westmead, NSW, Australia. kam.wong@sydney.edu.au.
AD  - Westmead Clinical School, Faculty of Medicine and Health, The University of
      Sydney, Westmead, NSW, Australia. kam.wong@sydney.edu.au.
AD  - Bathurst Rural Clinical School, School of Medicine, Western Sydney University,
      Bathurst, NSW, Australia. kam.wong@sydney.edu.au.
AD  - School of Rural Health, Faculty of Medicine and Health, The University of Sydney,
      Orange, NSW, Australia. kam.wong@sydney.edu.au.
FAU - Kok, Cindy
AU  - Kok C
AD  - Northern Clinical School, Faculty of Medicine and Health, The University of
      Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia.
FAU - Marschner, Simone
AU  - Marschner S
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Westmead Hospital, Westmead, NSW, Australia.
FAU - Usherwood, Tim
AU  - Usherwood T
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Westmead Hospital, Westmead, NSW, Australia.
AD  - Westmead Clinical School, Faculty of Medicine and Health, The University of
      Sydney, Westmead, NSW, Australia.
FAU - Chow, Clara K
AU  - Chow CK
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Westmead Hospital, Westmead, NSW, Australia.
AD  - Westmead Clinical School, Faculty of Medicine and Health, The University of
      Sydney, Westmead, NSW, Australia.
AD  - Department of Cardiology, Westmead Hospital, Westmead, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
SB  - IM
MH  - Arrhythmias, Cardiac/*diagnosis
MH  - Atrial Fibrillation/*diagnosis
MH  - Australia
MH  - Cross-Sectional Studies
MH  - Diagnosis, Differential
MH  - Electrocardiography
MH  - *General Practitioners
MH  - Health Care Surveys
MH  - Humans
MH  - Mass Screening
MH  - *Primary Health Care
PMC - PMC7201749
OTO - NOTNLM
OT  - *Arrhythmia
OT  - *Atrial fibrillation
OT  - *Electrocardiogram
OT  - *Electrocardiography
OT  - *Mobile health
OT  - *Screening
OT  - *eHealth
EDAT- 2020/05/08 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/05/08 06:00
PHST- 2019/10/08 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.1186/s12875-020-01151-8 [doi]
AID - 10.1186/s12875-020-01151-8 [pii]
PST - epublish
SO  - BMC Fam Pract. 2020 May 6;21(1):79. doi: 10.1186/s12875-020-01151-8.


PMID- 32375565
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 1557-8534 (Electronic)
IS  - 1547-3287 (Linking)
VI  - 29
IP  - 13
DP  - 2020 Jul 1
TI  - Monkey Embryos Cultured to 20 Days.
PG  - 807-810
LID - 10.1089/scd.2020.0006 [doi]
AB  - Gastrulation is a phase in early mammalian development when the three germ layers
      are generated and body plan is formed. Although well studied in mice, much less
      is known about gastrulation in humans. Owing to the lack of access to primary
      human tissue for study and experimental manipulation, as well as legal and
      ethical constraints surrounding the use of human embryos, a dissection of the
      molecular and cellular mechanisms that underlie this process in humans has proven
      elusive. Nonhuman primates, owing to their relatedness to human species, comprise
      a tantalizing alternative model system for understanding human biology. Two
      recent studies have established novel systems to study monkey embryos for 20
      days, demonstrating landmark events of early primate embryogenesis with possible 
      relevance to human development. Most strikingly, cells grown in the dish closely 
      resembled cells in in vivo embryos, suggesting that embryo development in a dish 
      might actually be equivalent to that which occurs in vivo. In this piece, the
      author discusses the tremendous potential of these new methods to unveil insights
      into mechanisms that mediate primate embryo development. Moreover, repurposing
      the extended monkey embryo culture methods to create human-monkey embryonic
      chimeras would aid the development of strategies to create human organs inside
      livestock species. Finally, the ethical and regulatory issues that emerge from
      reconsideration of extending time limits for human embryo culture beyond 14 days 
      or primitive streak formation are also briefly considered.
FAU - De Los Angeles, Alejandro
AU  - De Los Angeles A
AD  - Department of Psychiatry, Yale University School of Medicine, New Haven,
      Connecticut, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200602
PL  - United States
TA  - Stem Cells Dev
JT  - Stem cells and development
JID - 101197107
SB  - IM
CON - Science. 2019 Nov 15;366(6467):. PMID: 31672917
CON - Science. 2019 Nov 15;366(6467):. PMID: 31672918
MH  - Animals
MH  - *Embryo Culture Techniques
MH  - Embryo, Mammalian
MH  - Embryonic Development
MH  - *Gastrulation
MH  - Haplorhini
MH  - Mice
OTO - NOTNLM
OT  - *14 days rule
OT  - *embryo
OT  - *extended culture
OT  - *interspecies chimera
OT  - *monkey
OT  - *nonhuman primate
OT  - *pluripotent
EDAT- 2020/05/08 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1089/scd.2020.0006 [doi]
PST - ppublish
SO  - Stem Cells Dev. 2020 Jul 1;29(13):807-810. doi: 10.1089/scd.2020.0006. Epub 2020 
      Jun 2.


PMID- 32375488
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20201219
IS  - 2048-8734 (Electronic)
IS  - 2048-8726 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Apr
TI  - Respiratory management in severe acute respiratory syndrome coronavirus 2
      infection.
PG  - 229-238
LID - 10.1177/2048872620924613 [doi]
AB  - The severe acute respiratory syndrome coronavirus 2 pandemic is to date affecting
      more than a million of patients and is challenging healthcare professionals
      around the world. Coronavirus disease 2019 may present with a wide range of
      clinical spectrum and severity, including severe interstitial pneumonia with high
      prevalence of hypoxic respiratory failure requiring intensive care admission.
      There has been increasing sharing experience regarding the patient's clinical
      features over the last weeks which has underlined the need for general guidance
      on treatment strategies. We summarise the evidence existing in the literature of 
      oxygen and positive pressure treatments in patients at different stages of
      respiratory failure and over the course of the disease, including environment and
      ethical issues related to the ongoing coronavirus disease 2019 infection.
FAU - Price, Susanna
AU  - Price S
AD  - Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, UK.
AD  - Imperial College London, UK.
FAU - Singh, Suveer
AU  - Singh S
AD  - Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, UK.
AD  - Imperial College London, UK.
FAU - Ledot, Stephane
AU  - Ledot S
AD  - Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, UK.
AD  - Anaesthesia, Royal Brompton and Harefield NHS Foundation Trust, UK.
FAU - Bianchi, Paolo
AU  - Bianchi P
AD  - Adult Intensive Care, Royal Brompton and Harefield NHS Foundation Trust, UK.
AD  - Anaesthesia, Royal Brompton and Harefield NHS Foundation Trust, UK.
FAU - Hind, Matthew
AU  - Hind M
AD  - Department of Respiratory Medicine, Royal Brompton and Harefield NHS Foundation
      Trust, UK.
FAU - Tavazzi, Guido
AU  - Tavazzi G
AD  - Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of
      Pavia, Italy.
AD  - Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS, 
      Italy.
FAU - Vranckx, Pascal
AU  - Vranckx P
AD  - Department of Cardiology and Intensive Care, Jessaziekenhuis Hasselt, Belgium.
AD  - Faculty of Medicine and Life Sciences, University of Hasselt, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - England
TA  - Eur Heart J Acute Cardiovasc Care
JT  - European heart journal. Acute cardiovascular care
JID - 101591369
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - Civil Defense
MH  - Coronavirus Infections/*complications/epidemiology/mortality/virology
MH  - Critical Care/methods
MH  - Cross Infection/epidemiology/prevention & control
MH  - Disease Management
MH  - Extracorporeal Membrane Oxygenation/adverse effects/methods
MH  - Female
MH  - Humans
MH  - Hypoxia/etiology/*therapy
MH  - Ideal Body Weight/physiology
MH  - Intubation, Intratracheal/ethics/methods
MH  - Male
MH  - Oxygen/administration & dosage/therapeutic use
MH  - Pandemics
MH  - Personal Protective Equipment/*standards/supply & distribution
MH  - Pneumonia, Viral/*complications/epidemiology/mortality/virology
MH  - Positive-Pressure Respiration/methods
MH  - Respiration, Artificial/methods
MH  - Respiratory Insufficiency/etiology/*therapy
MH  - SARS-CoV-2
PMC - PMC7215090
OTO - NOTNLM
OT  - Severe acute respiratory syndrome coronavirus 2
OT  - acute respiratory distress syndrome
OT  - coronavirus disease 2019
OT  - mechanical ventilation
OT  - oxygen therapy
OT  - respiratory failure
EDAT- 2020/05/08 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/05/08 06:00 [entrez]
AID - 10.1177/2048872620924613 [doi]
PST - ppublish
SO  - Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):229-238. doi:
      10.1177/2048872620924613. Epub 2020 May 7.


PMID- 32374958
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 383
IP  - 2
DP  - 2020 Jul 9
TI  - CPR in the Covid-19 Era - An Ethical Framework.
PG  - e6
LID - 10.1056/NEJMp2010758 [doi]
FAU - Kramer, Daniel B
AU  - Kramer DB
AD  - From the Richard A. and Susan F. Smith Center for Outcomes Research in
      Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School -
      both in Boston (D.B.K.); the Greenwall Foundation, New York (B.L.); the
      University of California, San Francisco, San Francisco (B.L.); and Emory
      University School of Medicine, Atlanta (N.W.D.).
FAU - Lo, Bernard
AU  - Lo B
AD  - From the Richard A. and Susan F. Smith Center for Outcomes Research in
      Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School -
      both in Boston (D.B.K.); the Greenwall Foundation, New York (B.L.); the
      University of California, San Francisco, San Francisco (B.L.); and Emory
      University School of Medicine, Atlanta (N.W.D.).
FAU - Dickert, Neal W
AU  - Dickert NW
AD  - From the Richard A. and Susan F. Smith Center for Outcomes Research in
      Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School -
      both in Boston (D.B.K.); the Greenwall Foundation, New York (B.L.); the
      University of California, San Francisco, San Francisco (B.L.); and Emory
      University School of Medicine, Atlanta (N.W.D.).
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Cardiopulmonary Resuscitation/*ethics/*standards
MH  - Coronavirus Infections
MH  - Health Personnel
MH  - Health Resources/supply & distribution
MH  - Humans
MH  - Occupational Exposure
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral
MH  - Resuscitation Orders
MH  - SARS-CoV-2
EDAT- 2020/05/07 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1056/NEJMp2010758 [doi]
PST - ppublish
SO  - N Engl J Med. 2020 Jul 9;383(2):e6. doi: 10.1056/NEJMp2010758. Epub 2020 May 6.


PMID- 32374922
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1526-9914 (Electronic)
IS  - 1526-9914 (Linking)
VI  - 21
IP  - 6
DP  - 2020 Jun
TI  - Dosimetric impact of tracheostomy devices in head and neck cancer patients.
PG  - 26-32
LID - 10.1002/acm2.12862 [doi]
AB  - INTRODUCTION: The tracheostomy site and adjacent skin is at risk for recurrence
      in head/neck squamous cell cancer patients. The tracheostomy tube is an in situ
      device located directly over the tracheostomy site and may have clinical
      implications on the radiation dose delivered to the peristomal region. This study
      aimed to investigate this effect by comparing the prescribed treatment planning
      dose with the actual dose in vivo to the peristomal clinical target region. A
      retrospective, dosimetric study was performed with approval of the institutional 
      research ethics board. METHODS: Fifteen patients who had received high-dose
      radiotherapy to the tracheostomy region with in vivo dose measurements were
      included. The radiation dose at the skin surface underneath the tracheostomy
      device was measured using an optically stimulated luminescent dosimeter (OSLD)
      and was compared with the prescribed dose from the radiation planning system. The
      effect of the tracheostomy flange and/or soft tissue equivalent bolus on the
      peristomal dose was calculated. RESULTS AND DISCUSSION: Patients with
      tracheostomy equipment in situ were found to have a 3.7% difference between their
      prescribed and actual dose. With a tissue equivalent bolus there was a 2.0%
      difference between predicted and actual. The mean prescribed single fraction dose
      (mean = 191.8 cGy, SD = 40.18) and OSLD measured dose (mean = 194.02 cGy, SD =
      44.3) were found to have no significant difference. However, with the flange
      excluded from the planning simulation (density = air) target skin dose deviated
      from predicted by an average of 55.3% (range = 12.4-72.9, SD = 22.5) and volume
      coverage was not achieved. CONCLUSION: In summary, the tracheostomy flange acts
      like bolus with a twofold increase in the skin surface dose. Changes in the
      peristomal apparatus from simulation to treatment needs to be considered to
      ensure that the simulated dose and coverage is achieved.
CI  - (c) 2020 The Authors. Journal of Applied Clinical Medical Physics published by
      Wiley Periodicals, Inc. on behalf of American Association of Physicists in
      Medicine.
FAU - Lee, Justin
AU  - Lee J
AD  - Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health
      Sciences Centre, Toronto, ON, Canada.
AD  - Department of Radiation Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
FAU - Ramadan, Sherif
AU  - Ramadan S
AD  - Department of Health Sciences, McMaster University, Hamilton, ON, Canada.
FAU - Kim, Anthony
AU  - Kim A
AD  - Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health
      Sciences Centre, Toronto, ON, Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
FAU - Alayed, Yasir
AU  - Alayed Y
AD  - Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health
      Sciences Centre, Toronto, ON, Canada.
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
FAU - Ravi, Ananth
AU  - Ravi A
AD  - Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
AD  - Department of Medical Physics, Odette Cancer Centre, Sunnybrook Health Sciences
      Center, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - United States
TA  - J Appl Clin Med Phys
JT  - Journal of applied clinical medical physics
JID - 101089176
SB  - IM
MH  - Female
MH  - *Head and Neck Neoplasms/radiotherapy
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local
MH  - Radiotherapy Dosage
MH  - *Radiotherapy Planning, Computer-Assisted
MH  - Retrospective Studies
MH  - *Tracheostomy
PMC - PMC7324706
OTO - NOTNLM
OT  - head and neck cancer
OT  - optically stimulated luminescent dosimetry
OT  - radiation therapy
OT  - tracheostomy devices
EDAT- 2020/05/07 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/05/07 06:00
PHST- 2019/08/11 00:00 [received]
PHST- 2020/02/26 00:00 [revised]
PHST- 2020/02/29 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1002/acm2.12862 [doi]
PST - ppublish
SO  - J Appl Clin Med Phys. 2020 Jun;21(6):26-32. doi: 10.1002/acm2.12862. Epub 2020
      May 6.


PMID- 32374801
OWN - NLM
STAT- MEDLINE
DCOM- 20200512
LR  - 20201218
IS  - 2317-6385 (Electronic)
IS  - 1679-4508 (Linking)
VI  - 18
DP  - 2020 Apr 30
TI  - Fair allocation of scarce medical resources during COVID-19 pandemic: ethical
      considerations.
PG  - eAE5775
LID - S1679-45082020000100903 [pii]
LID - 10.31744/einstein_journal/2020AE5775 [doi]
FAU - Satomi, Erika
AU  - Satomi E
AUID- ORCID: 0000-0002-6641-5650
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Souza, Polianna Mara Rodrigues de
AU  - Souza PMR
AUID- ORCID: 0000-0001-8238-6135
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Thome, Beatriz da Costa
AU  - Thome BDC
AUID- ORCID: 0000-0002-3941-3756
AD  - Universidade Federal de Sao Paulo , Sao Paulo , SP , Brazil.
FAU - Reingenheim, Claudio
AU  - Reingenheim C
AUID- ORCID: 0000-0002-4412-4246
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Werebe, Eduardo
AU  - Werebe E
AUID- ORCID: 0000-0001-8763-1371
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Troster, Eduardo Juan
AU  - Troster EJ
AUID- ORCID: 0000-0002-9164-9280
AD  - Faculdade Israelita de Ciencias da Saude Albert Einstein , Hospital Israelita
      Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Scarin, Farah Christina de La Cruz
AU  - Scarin FCC
AUID- ORCID: 0000-0001-5724-6448
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Bacha, Helio Arthur
AU  - Bacha HA
AUID- ORCID: 0000-0003-4269-0065
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Grunspun, Henrique
AU  - Grunspun H
AUID- ORCID: 0000-0002-6838-873X
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Ferraz, Leonardo Jose Rolim
AU  - Ferraz LJR
AUID- ORCID: 0000-0003-1822-1568
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Bueno, Marco Aurelio Scarpinella
AU  - Bueno MAS
AUID- ORCID: 0000-0003-2736-9935
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Barros Filho, Mario Thadeu Leme de
AU  - Barros Filho MTL
AUID- ORCID: 0000-0001-7936-3813
AD  - Faculdade Israelita de Ciencias da Saude Albert Einstein , Hospital Israelita
      Albert Einstein , Sao Paulo , SP , Brazil.
FAU - Borges, Pedro Custodio de Mello
AU  - Borges PCM
AUID- ORCID: 0000-0002-7775-8659
AD  - Hospital Israelita Albert Einstein , Sao Paulo , SP , Brazil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20200430
PL  - Brazil
TA  - Einstein (Sao Paulo)
JT  - Einstein (Sao Paulo, Brazil)
JID - 101281800
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/economics/*therapy
MH  - Decision Making/*ethics
MH  - Humans
MH  - *Pandemics/economics/ethics
MH  - Pneumonia, Viral/economics/*therapy
MH  - Resource Allocation/ethics/*methods
MH  - SARS-CoV-2
MH  - Triage/ethics/*methods
PMC - PMC7186000
EDAT- 2020/05/07 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
AID - S1679-45082020000100903 [pii]
AID - 10.31744/einstein_journal/2020AE5775 [doi]
PST - epublish
SO  - Einstein (Sao Paulo). 2020 Apr 30;18:eAE5775. doi:
      10.31744/einstein_journal/2020AE5775.


PMID- 32374693
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20200813
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 110
IP  - 6
DP  - 2020 Jun
TI  - A Year With Law and Ethics: Maturing Fields and Heightened Perils.
PG  - 750
LID - 10.2105/AJPH.2020.305632 [doi]
FAU - Parmet, Wendy E
AU  - Parmet WE
AD  - Northeastern University School of Law.
LA  - eng
PT  - Editorial
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - IM
MH  - *Ethics, Medical
MH  - Humans
MH  - Public Health/*ethics/*legislation & jurisprudence
MH  - United States
PMC - PMC7204449
EDAT- 2020/05/07 06:00
MHDA- 2020/08/14 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
AID - 10.2105/AJPH.2020.305632 [doi]
PST - ppublish
SO  - Am J Public Health. 2020 Jun;110(6):750. doi: 10.2105/AJPH.2020.305632.


PMID- 32374577
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20210206
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 3
DP  - 2020 Jun
TI  - Update and breakthrough in cardiac xenotransplantation.
PG  - 261-267
LID - 10.1097/MOT.0000000000000767 [doi]
AB  - PURPOSE OF REVIEW: Considerable advancements have been made in the field of
      cardiac xenotransplantation in the recent years, achieving prolonged survival of 
      the life-supporting cardiac xenograft and paving the way toward first clinical
      implications. RECENT FINDINGS: The combination of genetic modifications and novel
      immunosuppression with costimulation blockade, as well as supporting therapy with
      antiinflammatory treatment, growth prevention, and adaptation of the heart
      procurement system to reduce myocardial ischemia and reperfusion injury improves 
      the overall cardiac xenograft function and overall survival in nonhuman primates.
      Through the newly identified xenoantigens and novel gene-editing techniques,
      further genetic modification of the porcine xenografts should be explored, to
      ensure clinical safety. SUMMARY: With continuous progress in all fields of
      cardiac xenotransplantation, first clinical use in humans seems accomplishable.
      To ensure the clinical safety and to conform to the ethical regulations, further 
      investigation of the infectious and immunological implications on humans should
      be explored prior to first clinical use. The first clinical use of cardiac
      xenotransplantation will be limited to only highly selected patients.
FAU - Brenner, Paolo
AU  - Brenner P
AD  - Department of Cardiac Surgery, LMU Munich University Hospital, Klinikum
      Grosshadern, Ludwig-Maximillians-University Munich, Munich, Germany.
FAU - Mihalj, Maks
AU  - Mihalj M
AD  - Department of Cardiovascular Surgery, Inselspital, Bern University Hospital,
      University of Bern, Bern, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Animals
MH  - Heart Transplantation/*methods
MH  - Humans
MH  - Swine
MH  - Transplantation, Heterologous/*methods
EDAT- 2020/05/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MOT.0000000000000767 [doi]
AID - 00075200-202006000-00010 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Jun;25(3):261-267. doi:
      10.1097/MOT.0000000000000767.


PMID- 32374575
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20210206
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Linking)
VI  - 25
IP  - 3
DP  - 2020 Jun
TI  - Cardiac donation after circulatory death.
PG  - 241-247
LID - 10.1097/MOT.0000000000000758 [doi]
AB  - PURPOSE OF REVIEW: Increasing number of patients with end-stage heart failure and
      those with improved survivorship from selective utilization of implantable
      mechanical circulatory support devices have added further burden and complexity
      to the transplant waitlist and on the rate-limiting availability of donor hearts 
      from the standard pathway of donation after brain death. Unlike this conventional
      route, the increasing clinical use of donation after circulatory death (DCD)
      donor hearts necessitates a closer understanding of the logistics involved in the
      DCD process as well as of the risks associated with the unique pathophysiological
      consequences in this setting. RECENT FINDINGS: Notwithstanding a higher incidence
      of delayed graft function, the clinical utilization of DCD hearts for cardiac
      transplantation over the past five years has demonstrated this to be a
      well-tolerated and strategic alternative with excellent medium-term clinical
      outcomes. SUMMARY: The uptake of DCD heart transplantation remains selective and 
      currently confined to Australia, the United Kingdom, Belgium, and more recently
      the USA. A more significant adoption will only come about through: a concerted
      effort to resolve the ethical and clinical controversies; a better understanding 
      of postconditioning strategies; continued resolve to reduce the obligatory period
      of warm ischemia; and from better extracorporeal platforms that permit functional
      viability assessment of the DCD donor heart.
FAU - Iyer, Arjun
AU  - Iyer A
AD  - Department of Cardiothoracic Surgery and Transplantation, Alfred Hospital,
      Melbourne, Victoria.
FAU - Dhital, Kumud
AU  - Dhital K
AD  - Department of Cardiothoracic Surgery and Transplantation, Alfred Hospital,
      Melbourne, Victoria.
AD  - Transplant Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst,
      NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
SB  - IM
MH  - Brain Death/*physiopathology
MH  - Female
MH  - Heart Transplantation/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tissue Donors/*statistics & numerical data
MH  - Tissue and Organ Procurement/*methods
EDAT- 2020/05/07 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - 10.1097/MOT.0000000000000758 [doi]
AID - 00075200-202006000-00007 [pii]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2020 Jun;25(3):241-247. doi:
      10.1097/MOT.0000000000000758.


PMID- 32374466
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220720
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 6
DP  - 2020 Jun
TI  - Rationing Limited Healthcare Resources in the COVID-19 Era and Beyond: Ethical
      Considerations Regarding Older Adults.
PG  - 1143-1149
LID - 10.1111/jgs.16539 [doi]
AB  - Coronavirus disease 2019 (COVID-19) continues to impact older adults
      disproportionately with respect to serious consequences ranging from severe
      illness and hospitalization to increased mortality risk. Concurrently, concerns
      about potential shortages of healthcare professionals and health supplies to
      address these issues have focused attention on how these resources are ultimately
      allocated and used. Some strategies, for example, misguidedly use age as an
      arbitrary criterion that disfavors older adults in resource allocation decisions.
      This is a companion article to the American Geriatrics Society (AGS) position
      statement, "Resource Allocation Strategies and Age-Related Considerations in the 
      COVID-19 Era and Beyond." It is intended to inform stakeholders including
      hospitals, health systems, and policymakers about ethical considerations that
      should be considered when developing strategies for allocation of scarce
      resources during an emergency involving older adults. This review presents the
      legal and ethical background for the position statement and discusses these
      issues that informed the development of the AGS positions: (1) age as a
      determining factor, (2) age as a tiebreaker, (3) criteria with a differential
      impact on older adults, (4) individual choices and advance directives, (5)
      racial/ethnic disparities and resource allocation, and (6) scoring systems and
      their impact on older adults. It also considers the role of advance directives as
      expressions of individual preferences in pandemics. J Am Geriatr Soc
      68:1143-1149, 2020.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Farrell, Timothy W
AU  - Farrell TW
AD  - Division of Geriatrics, Department of Internal Medicine, University of Utah
      School of Medicine, Salt Lake City, Utah, USA.
AD  - VA SLC Geriatric Research, Education, and Clinical Center, Salt Lake City, Utah, 
      USA.
AD  - University of Utah Health Interprofessional Education Program, Salt Lake City,
      Utah, USA.
FAU - Francis, Leslie
AU  - Francis L
AD  - University of Utah S.J. Quinney College of Law, Salt Lake City, Utah, USA.
AD  - Department of Philosophy, University of Utah, Salt Lake City, Utah, USA.
FAU - Brown, Teneille
AU  - Brown T
AD  - Center for Law and the Biomedical Sciences, University of Utah S.J. Quinney
      College of Law, Salt Lake City, Utah, USA.
AD  - Program in Medical Ethics and Humanities, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah, USA.
FAU - Ferrante, Lauren E
AU  - Ferrante LE
AD  - Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal
      Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
FAU - Widera, Eric
AU  - Widera E
AD  - Division of Geriatrics, Department of Medicine, University of California, San
      Francisco, San Francisco, California, USA.
AD  - San Francisco Veterans Affairs Health Care System, San Francisco, California,
      USA.
FAU - Rhodes, Ramona
AU  - Rhodes R
AD  - Division of Geriatric Medicine, Department of Internal Medicine, UT Southwestern 
      Medical Center, Dallas, Texas, USA.
AD  - Central Arkansas Veterans Healthcare System, Geriatric Research, Education, and
      Clinical Center, Little Rock, Arkansas, USA.
FAU - Rosen, Tony
AU  - Rosen T
AD  - Department of Emergency Medicine, Division of Geriatric Emergency Medicine, Weill
      Cornell Medicine/New York-Presbyterian Hospital, New York, New York, USA.
FAU - Hwang, Ula
AU  - Hwang U
AD  - Department of Emergency Medicine & Brookdale Department of Geriatrics and
      Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York,
      USA.
AD  - Geriatric Research, Education and Clinical Center, James J. Peters VAMC, Bronx,
      New York, USA.
FAU - Witt, Leah J
AU  - Witt LJ
AD  - Division of Geriatrics, Department of Medicine, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Division of UCSF Pulmonary, Critical Care, Allergy and Sleep Medicine, University
      of California, San Francisco, San Francisco, California, USA.
FAU - Thothala, Niranjan
AU  - Thothala N
AD  - Hospitalist Division, Department of Medicine, Good Samaritan Hospital, Vincennes,
      Indiana, USA.
AD  - Hospitalist Division, Department of Medicine, Union Hospital, Terre Haute,
      Indiana, USA.
FAU - Liu, Shan W
AU  - Liu SW
AD  - Department of Emergency Medicine, Division of Geriatric Emergency Medicine,
      Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts,
      USA.
FAU - Vitale, Caroline A
AU  - Vitale CA
AD  - Division of Geriatric and Palliative Medicine, Department of Internal Medicine,
      University of Michigan Medical School, Ann Arbor, Michigan, USA.
AD  - VA Ann Arbor Geriatric Research, Education, and Clinical Center (GRECC), Ann
      Arbor, Michigan, USA.
FAU - Braun, Ursula K
AU  - Braun UK
AD  - Section of Geriatrics and Palliative Medicine, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
AD  - Rehabilitation and Extended Care Line, Michael E. DeBakey VA Medical Center,
      Houston, Texas, USA.
FAU - Stephens, Caroline
AU  - Stephens C
AD  - University of Utah College of Nursing, Salt Lake City, Utah, USA.
FAU - Saliba, Debra
AU  - Saliba D
AD  - UCLA Borun Center for Gerontological Research, Los Angeles, California, USA.
AD  - VA Los Angeles Geriatric Research Education and Clinical Center, Los Angeles,
      California, USA.
AD  - RAND Corporation, Santa Monica, California, USA.
LA  - eng
GR  - K76 AG054862/AG/NIA NIH HHS/United States
GR  - K76 AG054866/AG/NIA NIH HHS/United States
GR  - K76 AG057023/AG/NIA NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Female
MH  - Geriatrics/*ethics
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Male
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United States/epidemiology
PMC - PMC7267288
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *older adult
OT  - *rationing
OT  - *triage
EDAT- 2020/05/07 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/jgs.16539 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Jun;68(6):1143-1149. doi: 10.1111/jgs.16539.


PMID- 32374440
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220720
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 6
DP  - 2020 Jun
TI  - AGS Position Statement: Resource Allocation Strategies and Age-Related
      Considerations in the COVID-19 Era and Beyond.
PG  - 1136-1142
LID - 10.1111/jgs.16537 [doi]
AB  - Coronavirus disease 2019 (COVID-19) continues to impact older adults
      disproportionately, from severe illness and hospitalization to increased
      mortality risk. Concurrently, concerns about potential shortages of healthcare
      professionals and health supplies to address these needs have focused attention
      on how resources are ultimately allocated and used. Some strategies misguidedly
      use age as an arbitrary criterion, inappropriately disfavoring older adults. This
      statement represents the official policy position of the American Geriatrics
      Society (AGS). It is intended to inform stakeholders including hospitals, health 
      systems, and policymakers about ethical considerations to consider when
      developing strategies for allocating scarce resources during an emergency
      involving older adults. Members of the AGS Ethics Committee collaborated with
      interprofessional experts in ethics, law, nursing, and medicine (including
      geriatrics, palliative care, emergency medicine, and pulmonology/critical care)
      to conduct a structured literature review and examine relevant reports. The
      resulting recommendations defend a particular view of distributive justice that
      maximizes relevant clinical factors and deemphasizes or eliminates factors
      placing arbitrary, disproportionate weight on advanced age. The AGS positions
      include (1) avoiding age per se as a means for excluding anyone from care; (2)
      assessing comorbidities and considering the disparate impact of social
      determinants of health; (3) encouraging decision makers to focus primarily on
      potential short-term (not long-term) outcomes; (4) avoiding ancillary criteria
      such as "life-years saved" and "long-term predicted life expectancy" that might
      disadvantage older people; (5) forming and staffing triage committees tasked with
      allocating scarce resources; (6) developing institutional resource allocation
      strategies that are transparent and applied uniformly; and (7) facilitating
      appropriate advance care planning. The statement includes recommendations that
      should be immediately implemented to address resource allocation strategies
      during COVID-19, aligning with AGS positions. The statement also includes
      recommendations for post-pandemic review. Such review would support revised
      strategies to ensure that governments and institutions have equitable emergency
      resource allocation strategies, avoid future discriminatory language and
      practice, and have appropriate guidance to develop national frameworks for
      emergent resource allocation decisions. J Am Geriatr Soc 68:1136-1142, 2020.
CI  - (c) 2020 The American Geriatrics Society.
FAU - Farrell, Timothy W
AU  - Farrell TW
AD  - Division of Geriatrics, Department of Internal Medicine, University of Utah
      School of Medicine, Salt Lake City, Utah, USA.
AD  - VA SLC Geriatric Research, Education, and Clinical Center, Salt Lake City, Utah, 
      USA.
AD  - University of Utah Health Interprofessional Education Program, Salt Lake City,
      Utah, USA.
FAU - Ferrante, Lauren E
AU  - Ferrante LE
AD  - Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal
      Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
FAU - Brown, Teneille
AU  - Brown T
AD  - Center for Law and the Biomedical Sciences, University of Utah S.J. Quinney
      College of Law, Salt Lake City, Utah, USA.
AD  - Program in Medical Ethics and Humanities, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah, USA.
FAU - Francis, Leslie
AU  - Francis L
AD  - University of Utah S.J. Quinney College of Law, Salt Lake City, Utah, USA.
AD  - Department of Philosophy, University of Utah, Salt Lake City, Utah, USA.
FAU - Widera, Eric
AU  - Widera E
AD  - Division of Geriatrics, Department of Medicine, University of California, San
      Francisco, San Francisco, California, USA.
AD  - San Francisco Veterans Affairs Health Care System, San Francisco, California,
      USA.
FAU - Rhodes, Ramona
AU  - Rhodes R
AD  - Division of Geriatric Medicine, Department of Internal Medicine, UT Southwestern 
      Medical Center, Dallas, Texas, USA.
AD  - Central Arkansas Veterans Healthcare System, Geriatric Research, Education, and
      Clinical Center, Little Rock, Arkansas, USA.
FAU - Rosen, Tony
AU  - Rosen T
AD  - Department of Emergency Medicine, Division of Geriatric Emergency Medicine, Weill
      Cornell Medicine/New York-Presbyterian Hospital, New York, New York, USA.
FAU - Hwang, Ula
AU  - Hwang U
AD  - Department of Emergency Medicine & Brookdale Department of Geriatrics and
      Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York,
      USA.
AD  - Geriatric Research, Education and Clinical Center, James J. Peters VAMC, Bronx,
      New York, USA.
FAU - Witt, Leah J
AU  - Witt LJ
AUID- ORCID: https://orcid.org/0000-0001-5665-4060
AD  - Division of Geriatrics, Department of Medicine, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Division of UCSF Pulmonary, Critical Care, Allergy and Sleep Medicine, University
      of California, San Francisco, San Francisco, California, USA.
FAU - Thothala, Niranjan
AU  - Thothala N
AD  - Hospitalist Division, Department of Medicine, Good Samaritan Hospital, Vincennes,
      Indiana, USA.
AD  - Hospitalist Division, Department of Medicine, Union Hospital, Terre Haute,
      Indiana, USA.
FAU - Liu, Shan W
AU  - Liu SW
AD  - Department of Emergency Medicine, Division of Geriatric Emergency Medicine,
      Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts,
      USA.
FAU - Vitale, Caroline A
AU  - Vitale CA
AD  - Division of Geriatric and Palliative Medicine, Department of Internal Medicine,
      University of Michigan Medical School, Ann Arbor, Michigan, USA.
AD  - VA Ann Arbor Geriatric Research, Education, and Clinical Center (GRECC), Ann
      Arbor, Michigan, USA.
FAU - Braun, Ursula K
AU  - Braun UK
AD  - Section of Geriatrics and Palliative Medicine, Department of Medicine, Baylor
      College of Medicine, Houston, Texas, USA.
AD  - Rehabilitation and Extended Care Line, Michael E. DeBakey VA Medical Center,
      Houston, Texas, USA.
FAU - Stephens, Caroline
AU  - Stephens C
AD  - University of Utah College of Nursing, Salt Lake City, Utah, USA.
FAU - Saliba, Debra
AU  - Saliba D
AD  - UCLA Borun Center for Gerontological Research, Los Angeles, California, USA.
AD  - VA Los Angeles Geriatric Research Education and Clinical Center, Los Angeles,
      California, USA.
AD  - RAND Corporation, Santa Monica, California, USA.
LA  - eng
GR  - K76 AG054862/AG/NIA NIH HHS/United States
GR  - K76 AG054866/AG/NIA NIH HHS/United States
GR  - K76 AG057023/AG/NIA NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Female
MH  - Geriatrics/*standards
MH  - Health Care Rationing/*standards
MH  - *Health Planning Guidelines
MH  - Humans
MH  - Male
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United States/epidemiology
PMC - PMC7267615
OTO - NOTNLM
OT  - COVID-19
OT  - aging
OT  - bioethics
OT  - pandemic
OT  - rationing
EDAT- 2020/05/07 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/04/30 00:00 [received]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/jgs.16537 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Jun;68(6):1136-1142. doi: 10.1111/jgs.16537.


PMID- 32374411
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 68
IP  - 7
DP  - 2020 Jul
TI  - We Need More Wisdom, Not More Paper: A Reply to Merel and Gaster.
PG  - 1609-1610
LID - 10.1111/jgs.16494 [doi]
FAU - Sulmasy, Daniel P
AU  - Sulmasy DP
AD  - Departments of Medicine and Philosophy, Georgetown University, Washington, DC,
      USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200506
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
CON - J Am Geriatr Soc. 2020 Jul;68(7):1606-1608. PMID: 32374417
MH  - *Advance Care Planning
MH  - Advance Directives
MH  - *Dementia
MH  - Humans
MH  - Patient Care
OTO - NOTNLM
OT  - *advance care planning
OT  - *dementia
OT  - *ethics
OT  - *palliative care
EDAT- 2020/05/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/jgs.16494 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2020 Jul;68(7):1609-1610. doi: 10.1111/jgs.16494. Epub 2020 May
      6.


PMID- 32374357
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201218
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 323
IP  - 22
DP  - 2020 Jun 9
TI  - The Ethics of COVID-19 Immunity-Based Licenses ("Immunity Passports").
PG  - 2241-2242
LID - 10.1001/jama.2020.8102 [doi]
FAU - Persad, Govind
AU  - Persad G
AD  - Sturm College of Law, University of Denver, Denver, Colorado.
FAU - Emanuel, Ezekiel J
AU  - Emanuel EJ
AD  - Department of Medical Ethics and Health Policy, Perelman School of Medicine,
      Department of Healthcare Management, The Wharton School, University of
      Pennsylvania, Philadelphia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - *Adaptive Immunity
MH  - Betacoronavirus/*immunology
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/*immunology/prevention & control
MH  - Documentation/*ethics
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*immunology
MH  - SARS-CoV-2
MH  - Vaccination
MH  - *Viral Vaccines
EDAT- 2020/05/07 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 2765836 [pii]
AID - 10.1001/jama.2020.8102 [doi]
PST - ppublish
SO  - JAMA. 2020 Jun 9;323(22):2241-2242. doi: 10.1001/jama.2020.8102.


PMID- 32374289
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20201218
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
VI  - 48
IP  - 5
DP  - 2020 Jun 25
TI  - Expanding the concept of the professional integrity of obstetrics during a public
      health emergency.
PG  - 435-437
LID - 10.1515/jpm-2020-0174 [doi]
LID - /j/jpme.2020.48.issue-5/jpm-2020-0174/jpm-2020-0174.xml [pii]
AB  - The coronavirus disease 2019 (COVID-19) pandemic has placed great demands on many
      hospitals to maximize their capacity to care for affected patients. The
      requirement to reassign space has created challenges for obstetric services. We
      describe the nature of that challenge for an obstetric service in New York City. 
      This experience raised an ethical challenge: whether it would be consistent with 
      professional integrity to respond to a public health emergency with a plan for
      obstetric services that would create an increased risk of rare maternal
      mortality. We answered this question using the conceptual tools of professional
      ethics in obstetrics, especially the professional virtue of integrity. A public
      health emergency requires frameshifting from an individual-patient perspective to
      a population-based perspective. We show that an individual-patient-based,
      beneficence-based deliberative clinical judgment is not an adequate basis for
      organizational policy in response to a public health emergency. Instead,
      physicians, especially those in leadership positions, must frameshift to
      population-based clinical ethical judgment that focuses on reduction of mortality
      as much as possible in the entire population of patients served by a healthcare
      organization.
FAU - Chervenak, Frank A
AU  - Chervenak FA
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
AD  - Department of Obstetrics and Gynecology, Lenox Hill Hospital, 100 East 77St., New
      York, NY 10075, USA.
FAU - Grunebaum, Amos
AU  - Grunebaum A
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Bornstein, Eran
AU  - Bornstein E
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Wasden, Shane
AU  - Wasden S
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Katz, Adi
AU  - Katz A
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - Rochelson, Burton L
AU  - Rochelson BL
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
FAU - McCullough, Laurence B
AU  - McCullough LB
AD  - Department of Obstetrics and Gynecology, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, NY, USA.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
SB  - IM
MH  - Beneficence
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/therapy
MH  - Emergencies
MH  - Female
MH  - Health Care Rationing/ethics/organization & administration
MH  - Health Services Accessibility/*ethics/organization & administration
MH  - Humans
MH  - Maternal Health Services/*ethics/organization & administration
MH  - New York City
MH  - Obstetrics/*ethics
MH  - Obstetrics and Gynecology Department, Hospital/*ethics/organization &
      administration
MH  - *Pandemics
MH  - *Pneumonia, Viral/therapy
MH  - Pregnancy
MH  - *Public Health
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - COVID-19 pandemic
OT  - frameshifting
OT  - professional ethics in obstetrics
OT  - professional virtue of integrity
OT  - public health emergency
EDAT- 2020/05/07 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/04/22 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1515/jpm-2020-0174 [doi]
AID - /j/jpme.ahead-of-print/jpm-2020-0174/jpm-2020-0174.xml [pii]
PST - ppublish
SO  - J Perinat Med. 2020 Jun 25;48(5):435-437. doi: 10.1515/jpm-2020-0174.


PMID- 32374002
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 8
DP  - 2020 Apr
TI  - Editorial - Epidemiological transition, crisis of the Italian health system:
      ethical and logical economic choices.
PG  - 4616-4622
LID - 21049 [pii]
LID - 10.26355/eurrev_202004_21049 [doi]
FAU - De Lorenzo, A
AU  - De Lorenzo A
AD  - Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and
      Prevention, University of Rome Tor Vergata, Rome, Italy. delorenzo@uniroma2.it.
FAU - Esposito, E
AU  - Esposito E
LA  - eng
PT  - Editorial
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - Humans
MH  - Italy/epidemiology
MH  - National Health Programs/*economics/*ethics/organization & administration
MH  - Risk Factors
EDAT- 2020/05/07 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 10.26355/eurrev_202004_21049 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4616-4622. doi:
      10.26355/eurrev_202004_21049.


PMID- 32373570
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2296-2565 (Print)
IS  - 2296-2565 (Linking)
VI  - 8
DP  - 2020
TI  - The Ethics of Taxing Sugar-Sweetened Beverages to Improve Public Health.
PG  - 110
LID - 10.3389/fpubh.2020.00110 [doi]
AB  - The World Health Organization highlights fiscal policies as priority
      interventions for the promotion of healthy eating in its Action Plan for the
      Prevention and Control of Non-communicable Diseases. The taxation of sugar
      sweetened beverages (SSBs) in particular is noted to be an effective measure, and
      SSBs taxes have already been implemented in several countries worldwide. However,
      although the evidence base suggests that this will be effective in helping to
      combat rising obesity rates, opponents of SSBs taxation argue that it is
      illiberal and paternalistic, and therefore should be avoided. Bioethical analysis
      may play an essential role in clarifying whether policymakers should adopt SSBs
      taxes as part of wider obesity strategy. In this article we argue that no single 
      ethical theory can account for the complexities inherent in obesity prevention
      strategy, especially the liberal theories relied upon by opponents of SSBs
      taxation. We contend that a pluralist approach to the ethics of SSBs taxation
      must be adopted as the only suitable way of accounting for the multiple
      overlapping, and sometimes, conflicting factors that are relevant to determining 
      the moral acceptability of such an intervention.
CI  - Copyright (c) 2020 Goiana-da-Silva, Cruz-e-Silva, Bartlett, Vasconcelos, Morais
      Nunes, Ashrafian, Miraldo, Machado, Araujo and Darzi.
FAU - Goiana-da-Silva, Francisco
AU  - Goiana-da-Silva F
AD  - Centre for Health Policy, Institute of Global Health Innovation, Imperial College
      London, London, United Kingdom.
AD  - Faculdade de Ciencias da Saude, Universidade da Beira Interior, Covilha,
      Portugal.
FAU - Cruz-E-Silva, David
AU  - Cruz-E-Silva D
AD  - Centre for Innovation, Technology and Policy Research, IN+, Instituto Superior
      Tecnico, Universidade de Lisboa, Lisbon, Portugal.
FAU - Bartlett, Oliver
AU  - Bartlett O
AD  - Department of Law, Maynooth University, Maynooth, Ireland.
FAU - Vasconcelos, Joana
AU  - Vasconcelos J
AD  - Centro Hospitalar Universitario Sao Joao, Servico Nacional de Saude, Oporto,
      Portugal.
FAU - Morais Nunes, Alexandre
AU  - Morais Nunes A
AD  - Centro de Administracao e Politicas Publicas, Instituto Superior de Ciencias
      Sociais e Politicas, Universidade de Lisboa, Lisbon, Portugal.
FAU - Ashrafian, Hutan
AU  - Ashrafian H
AD  - Centre for Health Policy, Institute of Global Health Innovation, Imperial College
      London, London, United Kingdom.
FAU - Miraldo, Marisa
AU  - Miraldo M
AD  - Department of Economics and Public Policy & Centre for Economics and Policy
      Innovation, Imperial College Business School, London, United Kingdom.
FAU - Machado, Maria do Ceu
AU  - Machado MDC
AD  - Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
FAU - Araujo, Fernando
AU  - Araujo F
AD  - Centro Hospitalar Universitario Sao Joao, Faculty of Medicine, Universidade do
      Porto, Oporto, Portugal.
FAU - Darzi, Ara
AU  - Darzi A
AD  - Department of Surgery and Cancer, Faculty of Medicine, Imperial College London,
      London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200416
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
MH  - Beverages/adverse effects
MH  - Humans
MH  - Obesity/prevention & control
MH  - Public Health
MH  - *Sugar-Sweetened Beverages
MH  - Taxes
PMC - PMC7179756
OTO - NOTNLM
OT  - *bioethics
OT  - *health policy
OT  - *pricing policies
OT  - *sweetened beverages
OT  - *taxation
EDAT- 2020/05/07 06:00
MHDA- 2020/05/07 06:01
CRDT- 2020/05/07 06:00
PHST- 2019/08/08 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/05/07 06:01 [medline]
AID - 10.3389/fpubh.2020.00110 [doi]
PST - epublish
SO  - Front Public Health. 2020 Apr 16;8:110. doi: 10.3389/fpubh.2020.00110.
      eCollection 2020.


PMID- 32372789
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200506
IS  - 0262-4079 (Print)
IS  - 0262-4079 (Linking)
VI  - 245
IP  - 3276
DP  - 2020 Apr 4
TI  - Who will get ventilators in a covid-19 crisis?
PG  - 12
LID - 10.1016/S0262-4079(20)30663-1 [doi]
AB  - If there is a shortage of breathing machines, doctors and ethicists say priority 
      should go to people with the best chance of recovery, reports Alice Klein.
CI  - (c) 2020.
FAU - Klein, Alice
AU  - Klein A
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - England
TA  - New Sci
JT  - New scientist (1971)
JID - 9815377
PMC - PMC7194888
EDAT- 2020/05/07 06:00
MHDA- 2020/05/07 06:01
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/05/07 06:01 [medline]
AID - 10.1016/S0262-4079(20)30663-1 [doi]
AID - S0262-4079(20)30663-1 [pii]
PST - ppublish
SO  - New Sci. 2020 Apr 4;245(3276):12. doi: 10.1016/S0262-4079(20)30663-1. Epub 2020
      Apr 3.


PMID- 32372625
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20211204
IS  - 1735-5249 (Electronic)
IS  - 1735-1502 (Linking)
VI  - 19
IP  - 2
DP  - 2020 Apr 16
TI  - Iranian Society of Asthma and Allergy Codes of Professional Ethics.
PG  - 117-131
LID - 10.18502/ijaai.v19i2.2760 [doi]
AB  - The advances in science and technology in recent decades, especially in medical
      sciences, have raised new ethical challenges. Hence, professional organizations
      in the field of medical science are trying to develop regulations in the field of
      medical ethics to help medical science professionals in making the best decisions
      in different circumstances and moral dilemmas. The organizations also try to
      monitor their performance using those regulations. On the other hand, due to the 
      specialization of medical science as well as the complexity of communication
      between these disciplines, there is a growing need for regulations to answer
      questions and resolve the challenges of each discipline. Certainly, scientific
      societies, due to benefit from relevant specialists, are the best reference for
      the development of specialized guidelines, one of which is the Iranian Society of
      Asthma and Allergy (ISAA). The aim of the current study was to develop codes of
      ethics for ISAA members, using a qualitative study. Generally, the ISAA codes of 
      professional ethics consists of general and specific sections. In order to
      compile the general section, the upstream medical documents, including the
      patients' rights charter in Iran, the research ethics guidelines approved by the 
      Ministry of Health and Medical Education (MOHME), ethical codes from the
      international societies of asthma and allergy, the general codes of professional 
      ethics of the Iran Medical Council and the Islamic jurisprudential rules and the 
      statute law of the country were used. To develop specific sections, we
      interviewed the experts in the field of Asthma and Allergy about the ethical
      challenges they had ever faced with. The ISAA codes of professional ethics
      developed in five chapters, entitled "Ethical Guidelines for the Mangers and
      Director of the Society, General Guidelines, Specific Guidelines, Ethical
      Guidelines for Research and Education, and Procedure for Supervision on the
      Professional Behavior of the ISAA Members", and approved by the board of
      directors of ISAA.
FAU - Shamsi-Gooshki, Ehsan
AU  - Shamsi-Gooshki E
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran. shamsi@tums.ac.ir.
FAU - Ahmadi Pishkuhi, Mahin
AU  - Ahmadi Pishkuhi M
AD  - Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars
      Hospital, Iran University of Medical Sciences, Tehran, Iran.
      mahin.ahmadipishkuhi@gmail.com.
FAU - Mousavi, Maryam Sadat
AU  - Mousavi MS
AD  - Medical Ethics and Professionalism Office, Shariati Hospital, Tehran University
      of Medical Sciences, Tehran, Iran. m.moosavi70@yahoo.com.
FAU - Raoofi, Azam
AU  - Raoofi A
AD  - Department of Health Economics and Management, School of Public Health, Tehran
      University of Medical Sciences, Tehran, Iran. parastooraufee@gmail.com.
FAU - Fazlollahi, Mohammad Reza
AU  - Fazlollahi MR
AD  - Immunology, Asthma and Allergy Research Institute, Children's Medical Center
      Hospital, Tehran University of Medical Sciences, Tehran, Iran.
      fazlollahi@tums.ac.ir.
FAU - Parsapour, Alireza
AU  - Parsapour A
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran. aliparsa@tums.ac.ir.
FAU - Moin, Mostafa
AU  - Moin M
AD  - Immunology, Asthma and Allergy Research Institute, Children's Medical Center
      Hospital, Tehran University of Medical Sciences, Tehran, Iran.
      mmoin@sina.tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
SB  - IM
MH  - Allergy and Immunology/*ethics
MH  - Asthma/*epidemiology
MH  - *Codes of Ethics
MH  - Humans
MH  - Hypersensitivity/*epidemiology
MH  - Iran
MH  - Patient Rights
MH  - Practice Guidelines as Topic
MH  - Societies, Medical
MH  - Translational Research, Biomedical
OTO - NOTNLM
OT  - Asthma and allergy
OT  - Codes of ethics
OT  - Guideline
EDAT- 2020/05/07 06:00
MHDA- 2021/02/10 06:00
CRDT- 2020/05/07 06:00
PHST- 2019/07/31 00:00 [received]
PHST- 2019/10/07 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
AID - 10.18502/ijaai.v19i2.2760 [doi]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2020 Apr 16;19(2):117-131. doi:
      10.18502/ijaai.v19i2.2760.


PMID- 32372519
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1523-1739 (Electronic)
IS  - 0888-8892 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Dec
TI  - Celebrating Aldo Leopold's land ethic at 70.
PG  - 1586-1588
LID - 10.1111/cobi.13526 [doi]
FAU - Piccolo, John J
AU  - Piccolo JJ
AUID- ORCID: 0000-0002-2633-4178
AD  - Institution for Environmental and Life Sciences, Karlstad University,
      Universitetsgatan 3, Karlstad, 65188, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200615
PL  - United States
TA  - Conserv Biol
JT  - Conservation biology : the journal of the Society for Conservation Biology
JID - 9882301
SB  - IM
MH  - *Conservation of Natural Resources
EDAT- 2020/05/07 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/cobi.13526 [doi]
PST - ppublish
SO  - Conserv Biol. 2020 Dec;34(6):1586-1588. doi: 10.1111/cobi.13526. Epub 2020 Jun
      15.


PMID- 32372491
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1399-3089 (Electronic)
IS  - 0908-665X (Linking)
VI  - 27
IP  - 3
DP  - 2020 May
TI  - Regulatory changes in China on xenotransplantation and related products.
PG  - e12601
LID - 10.1111/xen.12601 [doi]
AB  - BACKGROUND: Given the persistence and the worldwide shortage of organs from both 
      the deceased and living donors for clinical transplantation, pig organs or
      tissues hold immense promises for the patients on the waiting list, and
      xenotransplantation is deemed as one of the solutions to the organ shortage
      crisis. Indeed, the emerging gene editing technologies, such as CRISPR/Cas9, have
      led to tremendous progress in the generation of genetically modified pigs to
      overcome many barriers associated. METHOD: We presented a description of the
      xenotransplantation regulations in China and the related products. RESULT:
      Several groups in China have successfully generated transgenic pigs with the
      elimination of immune rejection or coagulation-related genes, and both
      pre-clinical and clinical studies have been reported. However, the pre-clinical
      evaluation and clinical application of porcine xenotransplantation raises ethical
      and regulatory considerations. Herein, in this review, we will summarize and
      discuss the progress in xenotransplantation in China and
      xenotransplantation-related products from the regulatory perspective. CONCLUSION:
      There has been remarkable progress in both the genetically modified pigs and
      pre-clinical studies in China, and China will be the first country to
      successfully fulfill the xenotransplantation from pig organ to human in the near 
      future.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Liu, Yuping
AU  - Liu Y
AD  - Center for Health Management, Sichuan Academy of Medical Science & Sichuan
      Provincial People's Hospital, Chengdu, China.
FAU - Qin, Lixia
AU  - Qin L
AD  - Medical Administration Department, Sichuan Academy of Medical Science & Sichuan
      Provincial People's Hospital, Chengdu, China.
FAU - Tong, Rongsheng
AU  - Tong R
AD  - Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial
      People's Hospital, Chengdu, China.
FAU - Liu, Ting
AU  - Liu T
AD  - School of Medicine, University of Electronic Science and Technology of China,
      Chengdu, China.
FAU - Ling, Chen
AU  - Ling C
AD  - School of Medicine, University of Electronic Science and Technology of China,
      Chengdu, China.
FAU - Lei, Tiantian
AU  - Lei T
AD  - School of Medicine, University of Electronic Science and Technology of China,
      Chengdu, China.
FAU - Zhang, Dingding
AU  - Zhang D
AD  - Medical Library, Sichuan Academy of Medical Science & Sichuan Provincial People's
      Hospital, Chengdu, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Center for Health Management, Sichuan Academy of Medical Science & Sichuan
      Provincial People's Hospital, Chengdu, China.
AD  - Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial
      People's Hospital, Chengdu, China.
AD  - Organ Transplant and Clinical Immunology Translational Medicine Key Laboratory of
      Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial
      People's Hospital, Chengdu, China.
FAU - Deng, Shaoping
AU  - Deng S
AD  - Organ Transplant and Clinical Immunology Translational Medicine Key Laboratory of
      Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial
      People's Hospital, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200505
PL  - Denmark
TA  - Xenotransplantation
JT  - Xenotransplantation
JID - 9438793
SB  - IM
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Blood Coagulation
MH  - China
MH  - *Government Regulation
MH  - Graft Rejection
MH  - Heterografts
MH  - Humans
MH  - Swine
MH  - Transplantation, Heterologous/ethics/*standards
OTO - NOTNLM
OT  - *Changsha Communique
OT  - *preclinical and clinical studies
OT  - *transgenic pigs
OT  - *xenotransplantation regulation/consensus
EDAT- 2020/05/07 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/xen.12601 [doi]
PST - ppublish
SO  - Xenotransplantation. 2020 May;27(3):e12601. doi: 10.1111/xen.12601. Epub 2020 May
      5.


PMID- 32372466
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1523-1739 (Electronic)
IS  - 0888-8892 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Aug
TI  - Misunderstandings of science and ethics in the moral panic over cats: reply to
      Crespin et al. 2020.
PG  - 1038-1040
LID - 10.1111/cobi.13527 [doi]
FAU - Lynn, William S
AU  - Lynn WS
AUID- ORCID: 0000-0003-4957-426X
AD  - George Perkins Marsh Institute, Clark University, 950 Main Street, Worcester, MA,
      01710, U.S.A.
FAU - Santiago-Avila, Francisco J
AU  - Santiago-Avila FJ
AUID- ORCID: 0000-0003-4233-9128
AD  - Carnivore Coexistence Lab, Nelson Institute for Environmental Studies, University
      of Wisconsin-Madison, 70 Science Hall, 550 North Park Street, Madison, WI, 53706,
      U.S.A.
FAU - Hadidian, John
AU  - Hadidian J
AD  - Center for Leadership in Global Sustainability, Virginia Polytechnic Institute
      and State University, 900 N. Glebe Road, Arlington, VA, 22208, U.S.A.
FAU - Wallach, Arian D
AU  - Wallach AD
AUID- ORCID: 0000-0002-6640-3887
AD  - Centre for Compassionate Conservation, Faculty of Science, University of
      Technology Sydney, Ultimo, NSW, 2007, Australia.
FAU - Lindenmayer, Joann
AU  - Lindenmayer J
AD  - One Health Commission, P.O. Box 972, Apex, NC, 27502, U.S.A.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200617
PL  - United States
TA  - Conserv Biol
JT  - Conservation biology : the journal of the Society for Conservation Biology
JID - 9882301
SB  - IM
CON - Conserv Biol. 2019 Aug;33(4):769-776. PMID: 31087701
CON - Conserv Biol. 2020 Aug;34(4):1035-1037. PMID: 32372489
MH  - Animals
MH  - Cats
MH  - *Conservation of Natural Resources
MH  - *Morals
EDAT- 2020/05/07 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/cobi.13527 [doi]
PST - ppublish
SO  - Conserv Biol. 2020 Aug;34(4):1038-1040. doi: 10.1111/cobi.13527. Epub 2020 Jun
      17.


PMID- 32372460
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210624
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Estimating the potential pool of uncontrolled DCD donors in the United States.
PG  - 2842-2846
LID - 10.1111/ajt.15981 [doi]
AB  - Organs from uncontrolled DCD donors (uDCDs) have expanded donation in Europe
      since the 1980s, but are seldom used in the United States. Cited barriers include
      lack of knowledge about the potential donor pool, lack of robust outcomes data,
      lack of standard donor eligibility criteria and preservation methods, and
      logistical and ethical challenges. To determine whether it would be appropriate
      to invest in addressing these barriers and building this practice, we sought to
      enumerate the potential pool of uDCD donors. Using data from the Nationwide
      Emergency Department Sample, the largest all-payer emergency department (ED)
      database, between 2013 and 2016, we identified patients who had refractory
      cardiac arrest in the ED. We excluded patients with contraindications to both
      deceased donation (including infection, malignancy, cardiopulmonary disease) and 
      uDCD (including hemorrhage, major polytrauma, burns, and poisoning). We
      identified 9828 (range: 9454-10 202) potential uDCDs/y; average age was 32 years,
      and all were free of major comorbidity. Of these, 91.1% had traumatic deaths,
      with major causes including nonhead blunt injuries (43.2%) and head injuries
      (40.1%). In the current era, uDCD donors represent a significant potential source
      of unused organs. Efforts to address barriers to uDCD in the United States should
      be encouraged.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Boyarsky, Brian J
AU  - Boyarsky BJ
AUID- ORCID: 0000-0001-6902-9854
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Jackson, Kyle R
AU  - Jackson KR
AUID- ORCID: 0000-0002-8135-5377
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Kernodle, Amber B
AU  - Kernodle AB
AUID- ORCID: 0000-0002-6459-5280
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Sakran, Joseph V
AU  - Sakran JV
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Garonzik-Wang, Jacqueline M
AU  - Garonzik-Wang JM
AUID- ORCID: 0000-0002-2789-7503
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Segev, Dorry L
AU  - Segev DL
AUID- ORCID: 0000-0003-3205-1024
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
      Baltimore, Maryland, USA.
FAU - Ottmann, Shane E
AU  - Ottmann SE
AD  - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
LA  - eng
GR  - F32DK113719/DK/NIDDK NIH HHS/United States
GR  - F32DK117563/DK/NIDDK NIH HHS/United States
GR  - K23DK115908/DK/NIDDK NIH HHS/United States
GR  - K24DK101828/DK/NIDDK NIH HHS/United States
GR  - T32DK007713-22/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200522
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CIN - Am J Transplant. 2021 Jun;21(6):2301-2302. PMID: 33320990
CIN - Am J Transplant. 2021 Jun;21(6):2303. PMID: 33559349
MH  - Adult
MH  - Europe
MH  - *Heart Arrest
MH  - Humans
MH  - Risk Factors
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
MH  - United States/epidemiology
OTO - NOTNLM
OT  - *clinical research/ practice
OT  - *donors and donation: deceased
OT  - *donors and donation: donation after circulatory death (DCD)
OT  - *ethics and public policy
OT  - *kidney transplantation/nephrology
OT  - *law/legislation
OT  - *organ allocation
OT  - *organ procurement
OT  - *organ procurement and allocation
EDAT- 2020/05/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/04/10 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1111/ajt.15981 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Oct;20(10):2842-2846. doi: 10.1111/ajt.15981. Epub 2020 May
      22.


PMID- 32372173
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 47
IP  - 5
DP  - 2020 May
TI  - Closing gaps, opening doors: an experimental collaboration in stem cell
      intervention.
PG  - 4105-4108
LID - 10.1007/s11033-020-05469-5 [doi]
AB  - Despite years of warnings by the academic community that for most of the stem
      cell-based therapies offered in the private arena little evidence of efficacy
      exists, these services have been increasingly offered by Canadian private
      clinics. Recently, as the culmination of years of clashes between stem cell
      researchers and therapy providers, Health Canada issued a statement prohibiting
      any type of cell therapy that is not specifically approved. In this climate of
      conflict, a small group representing both these communities as well as the
      government gathered in Vancouver to identify common values, and agree on
      principles to move forward constructively. This historic moment demonstrated that
      even in this contentious space a meeting-of-minds in between researchers,
      clinicians, ethicists, entrepreneurs and other stakeholders is possible.
FAU - Rossi, Fabio
AU  - Rossi F
AUID- ORCID: http://orcid.org/0000-0002-0368-2620
AD  - University of British Columbia, Vancouver, BC, Canada. fabio@brc.ubc.ca.
FAU - Braun, Martin
AU  - Braun M
AD  - Vancouver Laser and Skin Care Inc., Vancouver, BC, Canada.
FAU - Brock, Jonathan
AU  - Brock J
AD  - Vancouver Laser and Skin Care Inc., Vancouver, BC, Canada.
FAU - Sen-Lum, Janette
AU  - Sen-Lum J
AD  - Vancouver Laser and Skin Care Inc., Vancouver, BC, Canada.
FAU - Ellens, Sonya
AU  - Ellens S
AD  - Vancouver Laser and Skin Care Inc., Vancouver, BC, Canada.
FAU - Lander, Elliot
AU  - Lander E
AD  - Cell Surgical Network, Rancho Mirage, CA, USA.
FAU - Stoddard, Douglas
AU  - Stoddard D
AD  - SEMI, Toronto, ON, Canada.
FAU - Cross, Carolyn
AU  - Cross C
AD  - Ondine Biomedical Inc., Vancouver, BC, Canada.
FAU - Vance, Angelika
AU  - Vance A
AD  - Ondine Biomedical Inc., Vancouver, BC, Canada.
FAU - Stewart, Duncan
AU  - Stewart D
AD  - Ottawa Hospital Research Institute, Ottawa, ON, Canada.
FAU - Thebaud, Bernard
AU  - Thebaud B
AD  - Ottawa Hospital Research Institute, Ottawa, ON, Canada.
FAU - Illes, Judy
AU  - Illes J
AD  - University of British Columbia, Vancouver, BC, Canada. jilles@mail.ubc.ca.
LA  - eng
PT  - Journal Article
DEP - 20200506
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
SB  - IM
MH  - Canada
MH  - Delivery of Health Care
MH  - Health Policy/legislation & jurisprudence/*trends
MH  - Humans
MH  - Stakeholder Participation
MH  - Stem Cell Transplantation/*economics/methods/*trends
MH  - Stem Cells/metabolism
PMC - PMC7239812
OTO - NOTNLM
OT  - Clinical
OT  - Ethics
OT  - Health policy
OT  - Medicine and the law
OT  - Stem cell therapies
EDAT- 2020/05/07 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/05/07 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1007/s11033-020-05469-5 [doi]
AID - 10.1007/s11033-020-05469-5 [pii]
PST - ppublish
SO  - Mol Biol Rep. 2020 May;47(5):4105-4108. doi: 10.1007/s11033-020-05469-5. Epub
      2020 May 6.


PMID- 32371641
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20210125
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 33
IP  - 3
DP  - 2020 Jun
TI  - Preoperative considerations for Jehovah's Witness patients: a clinical guide.
PG  - 432-440
LID - 10.1097/ACO.0000000000000871 [doi]
AB  - PURPOSE OF REVIEW: Jehovah's Witnesses have religious beliefs that preclude
      transfusion of blood products and certain medical interventions. This presents a 
      unique dilemma and ethical challenge to healthcare providers, especially in a
      surgical setting. RECENT FINDINGS: The growing number of followers of this faith 
      warrants a deeper look at the ethical, legal, and clinical implications of their 
      beliefs. Advances in patient blood management now allow timely optimization
      before surgery. SUMMARY: Anticipating the challenges associated with managing and
      optimizing patients who refuse blood products allows for more favorable outcomes 
      in the preoperative period.
FAU - Chae, Christina
AU  - Chae C
AD  - Department of Anesthesiology, Northwestern University Feinberg School of
      Medicine, Chicago, Illinois, USA.
FAU - Okocha, Obianuju
AU  - Okocha O
FAU - Sweitzer, BobbieJean
AU  - Sweitzer B
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
SB  - IM
MH  - *Blood Transfusion/ethics
MH  - Humans
MH  - *Jehovah's Witnesses
MH  - Perioperative Care/ethics/*methods
MH  - Physician-Patient Relations
MH  - *Practice Guidelines as Topic
MH  - Religion and Medicine
EDAT- 2020/05/07 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1097/ACO.0000000000000871 [doi]
AID - 00001503-202006000-00027 [pii]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2020 Jun;33(3):432-440. doi:
      10.1097/ACO.0000000000000871.


PMID- 32371638
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20210125
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 33
IP  - 3
DP  - 2020 Jun
TI  - Conjoined twins in 2020 - state of the art and future directions.
PG  - 381-387
LID - 10.1097/ACO.0000000000000864 [doi]
AB  - PURPOSE OF REVIEW: A number of high profile conjoined twin separations have been 
      extensively covered by the world media. Anaesthesia for conjoined twins is a
      procedure rarely experienced by paediatric anaesthetists. The increased survival 
      of the twins has prompted discussion as to the most appropriate selection of
      patients, teams and hospitals to provide exceptional anaesthetic care. RECENT
      FINDINGS: The number of conjoined twins presenting for surgery remains low with
      many infants not surviving foetal or early neonatal life. Anaesthetic management 
      of less common conjoined infants such as craniopagus twins has highlighted the
      benefit of careful patient selection, extensive preoperative investigations and
      meticulous multidisciplinary team planning. The role of simulation of possible
      adverse perioperative events has been highlighted. Three dimensional anatomical
      models and virtual reality systems have permitted surgical planning in advance of
      actual intervention. A number of legal and ethical concerns have been reported
      especially in the setting of emergency separation where surgery is likely to
      contribute to death of one of the twins. SUMMARY: There appears to be an
      expanding role for international teams with extensive separation experience
      becoming involved in international teleconferencing to improve patient management
      in low-resource countries. Whether the perioperative outcome is better when the
      conjoined twins are transferred to major centres for surgery or teams operate in 
      the twin's country of origin remains to be seen.
FAU - Frawley, Geoff
AU  - Frawley G
AD  - Department Paediatric Anaesthesia and Pain Management, Royal Children's Hospital,
      Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
SB  - IM
MH  - *Airway Management/trends
MH  - Anesthesia/*trends
MH  - Child
MH  - *Critical Care/trends
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal
MH  - Resuscitation
MH  - Twins, Conjoined/*surgery
EDAT- 2020/05/07 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1097/ACO.0000000000000864 [doi]
AID - 00001503-202006000-00020 [pii]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2020 Jun;33(3):381-387. doi:
      10.1097/ACO.0000000000000864.


PMID- 32371521
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Role of maternal mental health disorders on stillbirth and infant mortality risk:
      a protocol for a systematic review and meta-analysis.
PG  - e036280
LID - 10.1136/bmjopen-2019-036280 [doi]
AB  - INTRODUCTION: Maternal mental health disorders such as anxiety and depression are
      major public health concerns. Evidence shows a link between maternal mental
      health disorders and preterm birth and low birth weight. However, the impacts of 
      maternal mental health disorders on stillbirth and infant mortality have been
      less investigated and inconsistent findings have been reported. Thus, using the
      available literature, we plan to examine whether prenatal maternal mental health 
      disorders impact the risk of stillbirth and infant mortality. METHODS AND
      ANALYSIS: This systematic review and meta-analysis will adhere to Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses guidelines and will be
      registered with the International Prospective Register of Systematic Reviews.
      Systematic searches will be conducted (from database inception to December 2019) 
      in Medline, Embase, PsycINFO and Scopus for studies examining the association of 
      prenatal mental health disorders and stillbirth and infant mortality. The search 
      will be limited to studies published in English language and in humans only, with
      no restriction on the year of publication. Two independent reviewers will
      evaluate records and assess the quality of individual studies. The
      Newcastle-Ottawa scales and GRADE (Grading of Recommendations, Assessment,
      Development and Evaluations) approach will be used to assess the methodological
      quality and bias of the included studies. In addition to a narrative synthesis, a
      random-effects meta-analysis will be conducted when sufficient data are
      available. I(2) statistics will be used to assess between-study heterogeneity in 
      the estimated effect size. ETHICS AND DISSEMINATION: As it will be a systematic
      review and meta-analysis based on previously published evidence, there will be no
      requirement for ethical approval. Findings will be published in a peer-reviewed
      journal and will be presented at various conferences. PROSPERO REGISTRATION
      NUMBER: 159834.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Adane, Akilew A
AU  - Adane AA
AUID- ORCID: 0000-0002-3022-5230
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia akilew.adane@telethonkids.org.au.
FAU - Bailey, Helen D
AU  - Bailey HD
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia.
FAU - Marriott, Rhonda
AU  - Marriott R
AD  - Ngangk Yira Research Centre for Aboriginal Health & Social Equity, Murdoch
      University, Murdoch, Western Australia, Australia.
FAU - Farrant, Brad M
AU  - Farrant BM
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia.
FAU - White, Scott W
AU  - White SW
AD  - Maternal Fetal Medicine Service, King Edward Memorial Hospital, Subiaco, Western 
      Australia, Australia.
AD  - Division of Obstetrics and Gynaecology, The University of Western Australia,
      Nedlands, Western Australia, Australia.
FAU - Morgan, Vera A
AU  - Morgan VA
AD  - Neuropsychiatric Epidemiology Research Unit, School of Population and Global
      Health, The University of Western Australia, Nedlands, Western Australia,
      Australia.
FAU - Shepherd, Carrington Cj
AU  - Shepherd CC
AD  - Telethon Kids Institute, The University of Western Australia, Nedlands, Western
      Australia, Australia.
AD  - Ngangk Yira Research Centre for Aboriginal Health & Social Equity, Murdoch
      University, Murdoch, Western Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Female
MH  - Humans
MH  - Infant
MH  - *Infant Mortality
MH  - *Maternal Health
MH  - *Mental Health
MH  - Meta-Analysis as Topic
MH  - Pregnancy
MH  - Research Design
MH  - Risk Factors
MH  - *Stillbirth
MH  - Systematic Reviews as Topic
PMC - PMC7228523
OTO - NOTNLM
OT  - *epidemiology
OT  - *mental health
OT  - *perinatology
COIS- Competing interests: None declared.
EDAT- 2020/05/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-036280 [pii]
AID - 10.1136/bmjopen-2019-036280 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e036280. doi: 10.1136/bmjopen-2019-036280.


PMID- 32371520
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 4
TI  - Study protocol for a randomised controlled trial evaluating an evidence-based,
      stepped and coordinated care service model for mental disorders (RECOVER).
PG  - e036021
LID - 10.1136/bmjopen-2019-036021 [doi]
AB  - INTRODUCTION: Healthcare systems around the world are looking for solutions to
      the growing problem of mental disorders. RECOVER is the synonym for an
      evidence-based, stepped and cross-sectoral coordinated care service model for
      mental disorders. RECOVER implements a cross-sectoral network with managed care, 
      comprehensive psychological, somatic and social diagnostics, crisis resolution
      and a general structure of four severity levels, each with assigned
      evidence-based therapy models (eg, assertive community treatment) and therapies
      (eg, psychotherapy). The study rationale is the investigation of the
      effectiveness and efficiency of stepped and integrated care in comparison to
      standard care. METHODS AND ANALYSIS: The trial is conducted in accordance to the 
      Standard Protocol Items: Recommendations for Interventional Trials Statement. The
      study aims to compare the RECOVER model with treatment as usual (TAU). The
      following questions are examined: Does RECOVER reduce healthcare costs compared
      with TAU? Does RECOVER improve patient-relevant outcomes? Is RECOVER
      cost-effective compared with TAU? A total sample of 890 patients with mental
      disorders will be assessed at baseline and individually randomised into RECOVER
      or TAU. Follow-up assessments are conducted after 6 and 12 months. As primary
      outcomes, cost reduction, improvement in symptoms, daily functioning and quality 
      of life as well as cost-effectiveness ratios will be measured. In addition,
      several secondary outcomes will be assessed. Primary and secondary outcomes are
      evaluated according to the intention-to-treat principle. Mixed linear or logistic
      regression models are used with the direct maximum likelihood estimation
      procedure which results in unbiassed estimators under the missing-at-random
      assumption. Costs due to healthcare utilisation and productivity losses are
      evaluated using difference-in-difference regressions. ETHICS AND DISSEMINATION:
      Ethical approval from the ethics committee of the Hamburg Medical Association has
      been obtained (PV5672). The results will be disseminated to service users and
      their families via the media, to healthcare professionals via professional
      training and meetings and to researchers via conferences and publications. TRIAL 
      REGISTRATION NUMBER AND REGISTRY NAME: ClinicalTrials.gov (NCT03459664), RECOVER 
      PROTOCOL VERSION: 19 March 2020 (V.3.0).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lambert, Martin
AU  - Lambert M
AUID- ORCID: 0000-0001-6258-3895
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany lambert@uke.de.
FAU - Karow, Anne
AU  - Karow A
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Gallinat, Jurgen
AU  - Gallinat J
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Ludecke, Daniel
AU  - Ludecke D
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Kraft, Vivien
AU  - Kraft V
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Rohenkohl, Anja
AU  - Rohenkohl A
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Schroter, Romy
AU  - Schroter R
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Finter, Constanze
AU  - Finter C
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Siem, Anna-Katharina
AU  - Siem AK
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Tlach, Lisa
AU  - Tlach L
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Werkle, Nathalie
AU  - Werkle N
AD  - Department of Psychiatry and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Bargel, Susann
AU  - Bargel S
AD  - Department of Strategic Business Development, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Ohm, Gunda
AU  - Ohm G
AD  - Department of Strategic Business Development, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Hoff, Martin
AU  - Hoff M
AD  - Department of Strategic Business Development, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Peter, Helmut
AU  - Peter H
AD  - Ambulatory Healthcare Center for Psychotherapy, Psychiatry and Psychosomatic,
      Cognitive-Behavioral Therapy Falkenried MVZ GmbH, Hamburg, Germany.
FAU - Scherer, Martin
AU  - Scherer M
AD  - Department of General Practice/Primary Care, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Mews, Claudia
AU  - Mews C
AD  - Department of General Practice/Primary Care, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Pruskil, Susanne
AU  - Pruskil S
AD  - Department of General Practice/Primary Care, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Luke, Johannes
AU  - Luke J
AD  - Department of General Practice/Primary Care, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Harter, Martin
AU  - Harter M
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Dirmaier, Jorg
AU  - Dirmaier J
AD  - Department of Medical Psychology, University Medical Center Hamburg-Eppendorf,
      Hamburg, Germany.
FAU - Schulte-Markwort, Michael
AU  - Schulte-Markwort M
AD  - Department of Child- and Youth Psychiatry, Psychotherapy and Psychosomatics,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Lowe, Bernd
AU  - Lowe B
AD  - Psychosomatic Medicine and Psychotherapy, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Briken, Peer
AU  - Briken P
AD  - Institute for Sex Research, Sexual Medicine and Forensic Psychiatry, University
      Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Peper, Heike
AU  - Peper H
AD  - Chamber for Psychotherapists Hamburg, Hamburg, Germany.
FAU - Schweiger, Michael
AU  - Schweiger M
AD  - Service Provider for vocational rehabilitation, ARINET GmbH, Hamburg, Hamburg,
      Germany.
FAU - Mosko, Mike
AU  - Mosko M
AD  - Department of Medical Psychology, Research Group on Migration and Psychosocial
      Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Bock, Thomas
AU  - Bock T
AD  - Irre Menschlich Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg,
      Hamburg, Germany.
FAU - Wittzack, Martin
AU  - Wittzack M
AD  - Regional Psychiatric Patient Association Hamburg e.V, Hamburg, Germany.
FAU - Meyer, Hans-Jochim
AU  - Meyer HJ
AD  - Regional Psychiatric Relative Association Hamburg e.V, Hamburg, Germany.
FAU - Deister, Arno
AU  - Deister A
AD  - Center for Psychosocial Medicine, Klinikum Itzehoe, Itzehoe, Schleswig-Holstein, 
      Germany.
FAU - Michels, Rolf
AU  - Michels R
AD  - Center for Psychosocial Medicine, Klinikum Itzehoe, Itzehoe, Schleswig-Holstein, 
      Germany.
FAU - Herr, Stephanie
AU  - Herr S
AD  - Center for Psychosocial Medicine, Klinikum Itzehoe, Itzehoe, Schleswig-Holstein, 
      Germany.
FAU - Konnopka, Alexander
AU  - Konnopka A
AD  - Department of Health Economics and Health Services Research, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Konig, Hannah
AU  - Konig H
AD  - Department of Health Economics and Health Services Research, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Wegscheider, Karl
AU  - Wegscheider K
AUID- ORCID: 0000-0003-2974-3142
AD  - Institute of Medical Biometry and Epidemiology, Universitatsklinikum
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Daubmann, Anne
AU  - Daubmann A
AD  - Institute of Medical Biometry and Epidemiology, Universitatsklinikum
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Zapf, Antonia
AU  - Zapf A
AD  - Institute of Medical Biometry and Epidemiology, Universitatsklinikum
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Peth, Judith
AU  - Peth J
AD  - Department of Medical Psychology, Professorship Clinical Healthcare Research,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Konig, Hans-Helmut
AU  - Konig HH
AD  - Department of Health Economics and Health Services Research, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Schulz, Holger
AU  - Schulz H
AD  - Department of Medical Psychology, Professorship Clinical Healthcare Research,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT03459664
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Mental Disorders/therapy
MH  - *Mental Health Services
MH  - Psychotherapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7223141
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *child & adolescent psychiatry
OT  - *health economics
OT  - *organisation of health services
OT  - *protocols & guidelines
COIS- Competing interests: ML: consultant or speaker fees AstraZeneca, Bristol-Myers
      Squibb, Lilly Deutschland GmbH, Janssen Cilag GmbH, Lundbeck GmbH, Otsuka Pharma 
      GmbH, Roche Deutschland Holding GmbH, Sanovi Aventis, Trommsdorff GmbH & Co KG.
      AK: consultant or speaker fees from AstraZeneca, Bristol-Myers Squibb, Lilly
      Deutschland GmbH, Janssen Cilag GmbH, Lundbeck GmbH, Otsuka Pharma GmbH, Roche
      Deutschland Holding GmbH. JG: speaker fees from Lundbeck GmbH, Otsuka Pharma
      GmbH, Janssen Cilag GmbH. DL: speaker fees Janssen Cilag GmbH.
EDAT- 2020/05/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - bmjopen-2019-036021 [pii]
AID - 10.1136/bmjopen-2019-036021 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 4;10(5):e036021. doi: 10.1136/bmjopen-2019-036021.


PMID- 32371518
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Psychiatric hospital reform in low-income and middle-income countries Structured 
      Individualised inTervention And Recovery (SITAR): a two-arm pragmatic randomised 
      controlled trial study protocol.
PG  - e035753
LID - 10.1136/bmjopen-2019-035753 [doi]
AB  - INTRODUCTION: Low-income and middle-income settings like India have large
      treatment gaps in mental healthcare. People with severe mental disorders face
      impediments to their clinical and functional recovery, and have large unmet
      needs. The infrastructure and standards of care are poor in colonial period
      psychiatric hospitals, with no clear pathways to discharge and successfully
      integrate recovered individuals into the community. Our aim is to study the
      impact of psychiatric hospital reform on individual patient outcomes in a
      psychiatric hospital in India. METHODS AND ANALYSIS: Structured Individualised
      inTervention And Recovery (SITAR) is a two-arm pragmatic randomised controlled
      trial, focusing on patients aged 18-60 years with a hospital stay of 12-120
      months and a primary diagnosis of psychosis. It tests the effectiveness of
      structural and process reform with and without an individually tailored recovery 
      plan on patient outcomes of disability (primary outcome WHO Disability Assessment
      Scale), symptom severity, social and occupational functioning and quality of
      life. A computer-generated permuted block randomisation schedule will allocate
      recruited subjects to the two study arms. We aim to recruit 100 people into each 
      trial arm. Baseline and outcome measures will be undertaken by trained
      researchers independent to the case managers providing the individual
      intervention. A health economic analysis will determine the costing of
      implementing the individually tailored recovery plan. ETHICS AND DISSEMINATION:
      The study will provide answers to important questions around the nature and
      process of reforms in institutional care that promote recovery while being
      cognizant of protecting human rights, and dignity. Ethical approval for SITAR was
      obtained from a registered ethics committee in India (Institutional Ethics
      Committee VikasAnvesh Foundation, VAF/2018-19/012 dated 6 December 2018) and the 
      University of Warwick's Biomedical and Scientific Research Ethics Committee
      (REGO-2019-2332, dated 21 March 2019), and registered on the Central Trial
      Registry of India (CTRI/2019/01/017267). Trial results will be published in
      accordance to CONSORT guidelines.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Raja, Tasneem
AU  - Raja T
AUID- ORCID: 0000-0002-5821-8673
AD  - Mental Health, Tata Trusts, Mumbai, India T.Raja@warwick.ac.uk.
AD  - Mental health and wellbeing, Warwick Medical School, University of Warwick,
      Coventry, UK.
FAU - Tuomainen, Helena
AU  - Tuomainen H
AUID- ORCID: 0000-0003-1636-8187
FAU - Madan, Jason
AU  - Madan J
AD  - Center for Health Economics, Warwick Medical School, University of Warwick,
      Coventry, UK.
FAU - Mistry, Dipesh
AU  - Mistry D
AD  - Warwick Cinical Trials Unit, University of Warwick, Coventry, UK.
FAU - Jain, Sanjeev
AU  - Jain S
AD  - Department of Psychiatry, NIMHANS, Bangalore, Karnataka, India.
FAU - Singh, Swaran
AU  - Singh S
AUID- ORCID: 0000-0003-3454-2089
AD  - Director, Centre for Mental Health and Wellbeing Research, Warwick Medical
      School, Coventry, UK.
LA  - eng
SI  - CTRI/CTRI/2019/01/017267
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Developing Countries
MH  - Female
MH  - *Health Care Reform
MH  - Hospitals, Psychiatric/*organization & administration
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychotic Disorders/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7228526
OTO - NOTNLM
OT  - *adult psychiatry
OT  - *change management
OT  - *schizophrenia & psychotic disorders
COIS- Competing interests: This trial is part of the PhD programme undertaken by the
      TR. She is an employee of the Tata Trusts and the Tata Trusts External Individual
      educational grants programme funds the PhD won on basis of merit.
EDAT- 2020/05/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035753 [pii]
AID - 10.1136/bmjopen-2019-035753 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e035753. doi: 10.1136/bmjopen-2019-035753.


PMID- 32371516
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210924
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 4
TI  - Response to physical rehabilitation and recovery trajectories following critical 
      illness: individual participant data meta-analysis protocol.
PG  - e035613
LID - 10.1136/bmjopen-2019-035613 [doi]
AB  - INTRODUCTION: The number of inconclusive physical rehabilitation randomised
      controlled trials for patients with critical illness is increasing. Evidence
      suggests critical illness patient subgroups may exist that benefit from targeted 
      physical rehabilitation interventions that could improve their recovery
      trajectory. We aim to identify critical illness patient subgroups that respond to
      physical rehabilitation and map recovery trajectories according to physical
      function and quality of life outcomes. Additionally, the utilisation of
      healthcare resources will be examined for subgroups identified. METHODS AND
      ANALYSIS: This is an individual participant data meta-analysis protocol. A
      systematic literature review was conducted for randomised controlled trials that 
      delivered additional physical rehabilitation for patients with critical illness
      during their acute hospital stay, assessed chronic disease burden, with a minimum
      follow-up period of 3 months measuring performance-based physical function and
      health-related quality of life outcomes. From 2178 records retrieved in the
      systematic literature review, four eligible trials were identified by two
      independent reviewers. Principal investigators of eligible trials were invited to
      contribute their data to this individual participant data meta-analysis. Risk of 
      bias will be assessed (Cochrane risk of bias tool for randomised trials).
      Participant and trial characteristics, interventions and outcomes data of
      included studies will be summarised. Meta-analyses will entail a one-stage model,
      which will account for the heterogeneity across and the clustering between
      studies. Multiple imputation using chained equations will be used to account for 
      the missing data. ETHICS AND DISSEMINATION: This individual participant data
      meta-analysis does not require ethical review as anonymised participant data will
      be used and no new data collected. Additionally, eligible trials were granted
      approval by institutional review boards or research ethics committees and
      informed consent was provided for participants. Data sharing agreements are in
      place permitting contribution of data. The study findings will be disseminated at
      conferences and through peer-reviewed publications. PROSPERO REGISTRATION NUMBER:
      CRD42019152526.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jones, Jennifer R A
AU  - Jones JRA
AUID- ORCID: 0000-0002-9443-3426
AD  - Physiotherapy Department, The University of Melbourne, Parkville, Victoria,
      Australia jrjones@student.unimelb.edu.au.
AD  - Physiotherapy Department, Division of Allied Health, Austin Health, Heidelberg,
      Victoria, Australia.
FAU - Berney, Sue
AU  - Berney S
AD  - Physiotherapy Department, The University of Melbourne, Parkville, Victoria,
      Australia.
AD  - Physiotherapy Department, Division of Allied Health, Austin Health, Heidelberg,
      Victoria, Australia.
FAU - Berry, Michael J
AU  - Berry MJ
AD  - Department of Health and Exercise Science, Wake Forest University, Winston-Salem,
      North Carolina, USA.
FAU - Files, D Clark
AU  - Files DC
AD  - Pulmonary, Critical Care, Allergy and Immunologic Disease, Wake Forest
      University, Winston-Salem, North Carolina, USA.
AD  - Wake Forest Critical Illness Injury and Recovery Research Center, Wake Forest
      University, Winston-Salem, North Carolina, USA.
FAU - Griffith, David M
AU  - Griffith DM
AUID- ORCID: 0000-0001-9500-241X
AD  - Anaesthesia, Critical Care and Pain, University of Edinburgh, Royal Infirmary of 
      Edinburgh, Edinburgh, UK.
FAU - McDonald, Luke A
AU  - McDonald LA
AD  - Physiotherapy Department, Division of Allied Health, Austin Health, Heidelberg,
      Victoria, Australia.
FAU - Morris, Peter E
AU  - Morris PE
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Kentucky, 
      Lexington, Kentucky, USA.
FAU - Moss, Marc
AU  - Moss M
AD  - Division of Pulmonary Sciences & Critical Care Medicine, University of Colorado
      Denver School of Medicine, Aurora, Colorado, USA.
FAU - Nordon-Craft, Amy
AU  - Nordon-Craft A
AD  - Physical Therapy Program, University of Colorado Denver School of Medicine,
      Aurora, Colorado, USA.
FAU - Walsh, Timothy
AU  - Walsh T
AD  - Anaesthesia, Critical Care and Pain, University of Edinburgh, Royal Infirmary of 
      Edinburgh, Edinburgh, UK.
FAU - Gordon, Ian
AU  - Gordon I
AD  - Statistical Consulting Centre, The University of Melbourne, Parkville, Victoria, 
      Australia.
FAU - Karahalios, Amalia
AU  - Karahalios A
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Parkville, Victoria, Australia.
FAU - Puthucheary, Zudin
AU  - Puthucheary Z
AD  - William Harvey Research Institute, Barts and The London School of Medicine &
      Dentistry, Queen Mary University of London, London, UK.
AD  - Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, 
      UK.
FAU - Denehy, Linda
AU  - Denehy L
AD  - Melbourne School of Health Sciences, The University of Melbourne, Parkville,
      Victoria, Australia.
AD  - Allied Health, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
CN  - CRITICALConnect Study Investigators
LA  - eng
GR  - CZH/4/531/CSO_/Chief Scientist Office/United Kingdom
GR  - R01 NR011051/NR/NINR NIH HHS/United States
GR  - CZH/4/531/Chief Scientist Office [UK]/International
GR  - K24 HL089223/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200504
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Critical Illness/*rehabilitation
MH  - *Exercise Therapy
MH  - Humans
MH  - *Length of Stay
MH  - Quality of Life
PMC - PMC7223158
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *intensive & critical care
OT  - *rehabilitation medicine
COIS- Competing interests: None declared.
IR  - Berney S
FIR - Berney, Sue
IR  - Berry MJ
FIR - Berry, Michael J
IR  - Denehy L
FIR - Denehy, Linda
IR  - Clark Files D
FIR - Clark Files, D
IR  - Griffith DM
FIR - Griffith, David M
IR  - Jones JRA
FIR - Jones, Jennifer R A
IR  - Morris PE
FIR - Morris, Peter E
IR  - Moss M
FIR - Moss, Marc
IR  - Nordon-Craft A
FIR - Nordon-Craft, Amy
IR  - Puthucheary Z
FIR - Puthucheary, Zudin
IR  - Walsh T
FIR - Walsh, Timothy
EDAT- 2020/05/07 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035613 [pii]
AID - 10.1136/bmjopen-2019-035613 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 4;10(5):e035613. doi: 10.1136/bmjopen-2019-035613.


PMID- 32371514
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Impact of a farmers' market nutrition coupon programme on diet quality and
      psychosocial well-being among low-income adults: protocol for a randomised
      controlled trial and a longitudinal qualitative investigation.
PG  - e035143
LID - 10.1136/bmjopen-2019-035143 [doi]
AB  - INTRODUCTION: Low-income populations have poorer diet quality and lower
      psychosocial well-being than their higher-income counterparts. These inequities
      increase the burden of chronic disease in low-income populations. Farmers' market
      subsidies may improve diet quality and psychosocial well-being among low-income
      populations. In Canada, the British Columbia (BC) Farmers' Market Nutrition
      Coupon Programme (FMNCP) aims to improve dietary patterns and health among
      low-income participants by providing coupons to purchase healthy foods from
      farmers' markets. This study will assess the impact of the BC FMNCP on the diet
      quality and psychosocial well-being of low-income adults and explore mechanisms
      of programme impacts. METHODS AND ANALYSIS: In a parallel group randomised
      controlled trial, low-income adults will be randomised to an FMNCP intervention
      (n=132) or a no-intervention control group (n=132). The FMNCP group will receive 
      16 coupon sheets valued at CAD$21/sheet over 10-15 weeks to purchase fruits,
      vegetables, dairy, meat/poultry/fish, eggs, nuts and herbs at farmers' markets
      and will be invited to participate in nutrition skill-building activities.
      Overall diet quality (primary outcome), diet quality subscores, mental
      well-being, sense of community, food insecurity and malnutrition risk (secondary 
      outcomes) will be assessed at baseline, immediately post-intervention and 16
      weeks post-intervention. Dietary intake will be assessed using the Automated
      Self-Administered 24-hour Dietary Recall. Diet quality will be calculated using
      the Healthy Eating Index-2015. Repeated measures mixed-effect regression will
      assess differences in outcomes between groups from baseline to 16 weeks
      post-intervention. Furthermore, 25-30 participants will partake in
      semi-structured interviews during and 5 weeks after programme completion to
      explore participants' experiences with and perceived outcomes from the programme.
      ETHICS AND DISSEMINATION: Ethical approval was obtained from the University of
      Calgary Conjoint Health Research Ethics Board, Rutgers University Ethics and
      Compliance, and University of Waterloo Office of Research Ethics. Findings will
      be disseminated through policy briefs, conference presentations and peer-reviewed
      publications. TRIAL REGISTRATION NUMBER: NCT03952338.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Aktary, Michelle L
AU  - Aktary ML
AUID- ORCID: 0000-0001-7425-5282
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
FAU - Caron-Roy, Stephanie
AU  - Caron-Roy S
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
FAU - Sajobi, Tolulope
AU  - Sajobi T
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - O'Hara, Heather
AU  - O'Hara H
AD  - British Columbia Association of Farmers' Markets, Vancouver, British Columbia,
      Canada.
FAU - Leblanc, Peter
AU  - Leblanc P
AD  - British Columbia Association of Farmers' Markets, Vancouver, British Columbia,
      Canada.
FAU - Dunn, Sharlette
AU  - Dunn S
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - McCormack, Gavin R
AU  - McCormack GR
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
AD  - School of Architecture, Planning and Landscape, University of Calgary, Calgary,
      Alberta, Canada.
FAU - Timmins, Dianne
AU  - Timmins D
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - Ball, Kylie
AU  - Ball K
AD  - Institute for Physical Activity and Nutrition (IPAN), Deakin University, Burwood,
      Victoria, Australia.
FAU - Downs, Shauna
AU  - Downs S
AD  - School of Public Health, Rutgers University, Newark, New Jersey, USA.
FAU - Minaker, Leia M
AU  - Minaker LM
AD  - School of Planning, University of Waterloo, Waterloo, Ontario, Canada.
FAU - Nykiforuk, Candace Ij
AU  - Nykiforuk CI
AD  - School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
FAU - Godley, Jenny
AU  - Godley J
AD  - Department of Sociology, University of Calgary, Calgary, Alberta, Canada.
FAU - Milaney, Katrina
AU  - Milaney K
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - Lashewicz, Bonnie
AU  - Lashewicz B
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
FAU - Fournier, Bonnie
AU  - Fournier B
AD  - School of Nursing, Thompson Rivers University, Kamloops, British Columbia,
      Canada.
FAU - Elliott, Charlene
AU  - Elliott C
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
AD  - Department of Communication Media and Film, University of Calgary, Calgary,
      Alberta, Canada.
FAU - Raine, Kim D
AU  - Raine KD
AD  - School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
FAU - Prowse, Rachel Jl
AU  - Prowse RJ
AD  - School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
FAU - Olstad, Dana Lee
AU  - Olstad DL
AUID- ORCID: 0000-0001-9787-9952
AD  - Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada
      dana.olstad@ucalgary.ca.
AD  - Department of Community Health Sciences, University of Calgary, Cumming School of
      Medicine, Calgary, Alberta, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03952338
GR  - 155916/CAPMC/ CIHR/Canada
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Agriculture
MH  - Commerce
MH  - *Diet
MH  - Female
MH  - *Food Supply
MH  - *Gardening
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - *Poverty
MH  - *Public Assistance
MH  - Randomized Controlled Trials as Topic
PMC - PMC7228519
OTO - NOTNLM
OT  - *health policy
OT  - *nutrition & dietetics
OT  - *public health
OT  - *qualitative research
COIS- Competing interests: HO is the Executive Director of the British Columbia
      Association of Farmers' Markets. PL is the Programme Manager for the British
      Columbia Farmers' Market Nutrition Coupon Programme. DT is employed by Abbott
      Nutrition.
EDAT- 2020/05/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-035143 [pii]
AID - 10.1136/bmjopen-2019-035143 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e035143. doi: 10.1136/bmjopen-2019-035143.


PMID- 32371513
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 4
TI  - CHI study: protocol for an observational cohort study on ageing and mental health
      in community-dwelling older adults.
PG  - e035003
LID - 10.1136/bmjopen-2019-035003 [doi]
AB  - INTRODUCTION: Ageing is associated with a multitude of healthcare issues
      including dementia, depression, frailty, morbidity associated with chronic
      disease and high healthcare utilisation. With Singapore's population projected to
      age significantly over the next two decades, it has become increasingly important
      to understand the disease burden and etiological process among older adults. The 
      Community Health and Intergenerational study aims to holistically examine ageing 
      in place by investigating the resilience and vulnerability factors of the ageing 
      process in the biological, psychological and social domains within the
      environment. METHODS AND ANALYSIS: Using a cohort multiple randomised controlled 
      trial design, comprehensive health profiles of community-dwelling older adults
      will be collected. The objective is to recruit 1000 participants (aged 60-99
      years) living in the western region of Singapore within a period of 3 years
      (2018-2020). Assessments include basic sociodemographic, physical health and
      function (cardiac, oral and blood profiles and visual function), cognitive
      functioning, daily functioning, physical fitness, emotional state, free-flowing
      speech, sleep quality, social connectedness, caregiver burden, intergenerational 
      communication, quality of life, life satisfaction, attitudes to ageing and
      gratitude and compassion. Results from the cohort will enable future studies to
      identify at-risk groups and develop interventions to improve the physical and
      mental health and quality of life of older adults. ETHICS AND DISSEMINATION:
      Approval of the cohort study by the National University of Singapore
      Institutional Review Board (NUS-IRB Reference code: H-17-047) was obtained on 12 
      October 2017. Written consent will be obtained from all participants. Findings
      from the cohort study will be disseminated by publication of peer-reviewed
      manuscripts, presentations at scientific meetings and conferences with local
      stakeholders.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lee, Rachael Zhi Yi
AU  - Lee RZY
AUID- ORCID: 0000-0001-9844-941X
AD  - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Yu, Junhong
AU  - Yu J
AD  - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Rawtaer, Iris
AU  - Rawtaer I
AD  - Department of Psychiatry, Sengkang General Hospital, Singapore.
FAU - Allen, Patrick Finbarr
AU  - Allen PF
AD  - Dean, Faculty of Dentistry, National University of Singapore, Singapore.
AD  - Centre for Oral Health, National University Health System, Singapore.
FAU - Bao, Zhiming
AU  - Bao Z
AD  - Department of English Language and Literature, Faculty of Arts and Social
      Science, National University of Singapore, Singapore.
FAU - Feng, Lei
AU  - Feng L
AD  - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Feng, Qiushi
AU  - Feng Q
AD  - Department of Sociology, National University of Singapore, Singapore.
AD  - Centre for Family and Population Research, National University of Singapore,
      Singapore.
FAU - Lee, Jeong Kyu
AU  - Lee JK
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.
FAU - Lim, Chin Tat
AU  - Lim CT
AD  - Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Ling, Lieng Hsi
AU  - Ling LH
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore.
AD  - Department of Cardiology, National University Heart Centre, Singapore.
FAU - Thang, Leng Leng
AU  - Thang LL
AD  - Centre for Family and Population Research, National University of Singapore,
      Singapore.
AD  - Department of Japanese Studies, National University of Singapore, Singapore.
FAU - Naing, Thet
AU  - Naing T
AD  - Department of Ophthalmology, National University Health System, Singapore.
FAU - Wang, D Y
AU  - Wang DY
AD  - Department of Otolaryngology, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
FAU - Yap, Kai Zhen
AU  - Yap KZ
AD  - Department of Pharmacy, Faculty of Science, National University of Singapore,
      Singapore.
FAU - Kua, E H
AU  - Kua EH
AD  - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
AD  - Department of Psychological Medicine, National University Hospital, Singapore.
FAU - Mahendran, Rathi
AU  - Mahendran R
AD  - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore pcmrathi@nus.edu.sg.
AD  - Academic Development Department, Duke-NUS Medical School, Singapore.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aging
MH  - Cognition/physiology
MH  - Cohort Studies
MH  - Depression/psychology
MH  - Female
MH  - Humans
MH  - Independent Living/*psychology
MH  - Male
MH  - *Mental Health
MH  - Middle Aged
MH  - *Physical Fitness
MH  - *Public Health
MH  - Quality of Life
MH  - Singapore
MH  - *Sleep
PMC - PMC7229981
OTO - NOTNLM
OT  - *cardiac epidemiology
OT  - *epidemiology
OT  - *geriatric medicine
OT  - *mental health
OT  - *old age psychiatry
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/05/07 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035003 [pii]
AID - 10.1136/bmjopen-2019-035003 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 4;10(5):e035003. doi: 10.1136/bmjopen-2019-035003.


PMID- 32371507
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 4
TI  - Comparison of the clinical effectiveness of treatments for aromatase
      inhibitor-induced arthralgia in breast cancer patients: a protocol for a
      systematic review and network meta-analysis.
PG  - e033461
LID - 10.1136/bmjopen-2019-033461 [doi]
AB  - INTRODUCTION: Aromatase inhibitor-induced arthralgia (AIA) is a major adverse
      event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI 
      therapy in breast cancer patients. The objective of this protocol for a
      systematic review and network meta-analysis (NMA) is to provide the methodology
      to compare the change in pain intensity between different AIA treatments and
      demonstrate the rank probabilities for different treatments by combining all
      available direct and indirect evidence. METHODS AND ANALYSIS: PubMed, the
      Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and
      ClinicalTrials.gov will be searched to identify publications in English from
      inception to November 2019. We will include randomised controlled trials (RCTs)
      assessing the effects of different treatments for AIA in postmenopausal women
      with stage 0-III hormone receptor-positive breast cancer. The primary endpoints
      will be the change in patient-reported pain intensity from baseline to
      post-treatment. The number of adverse events will be presented as a secondary
      outcome.Both pairwise meta-analysis and NMA with the Frequentist approach will be
      conducted. We will demonstrate summary estimates with forest plots in
      meta-analysis and direct and mixed evidence with a ranking of the treatments as
      the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials 
      will be used to assess the methodological quality within individual RCTs. The
      quality of evidence will be assessed. ETHICS AND DISSEMINATION: As this review
      does not involve individual patients, ethical approval is not required. The
      results of this systematic review and NMA will be published in a peer-reviewed
      journal. This review will provide valuable information on AIA therapeutic options
      for clinicians, health practitioners and breast cancer survivors. PROSPERO
      REGISTRATION NUMBER: CRD42019136967.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Bae, Kyeore
AU  - Bae K
AUID- ORCID: 0000-0002-8596-8293
AD  - Department of Integrative Medicine, Center for Immunity and Pain, Kwanghye
      Hospital, Seoul, Republic of Korea kyeorebae@gmail.com.
FAU - Song, Si Yeon
AU  - Song SY
AD  - East-West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University,
      Daejeon, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Aromatase Inhibitors)
SB  - IM
MH  - *Aromatase Inhibitors/adverse effects
MH  - *Arthralgia/chemically induced
MH  - *Breast Neoplasms/drug therapy
MH  - Female
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7223021
OTO - NOTNLM
OT  - *aromatase inhibitor
OT  - *arthralgia
OT  - *breast tumours
OT  - *network meta-analysis
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/05/07 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - bmjopen-2019-033461 [pii]
AID - 10.1136/bmjopen-2019-033461 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 4;10(5):e033461. doi: 10.1136/bmjopen-2019-033461.


PMID- 32371505
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 5
DP  - 2020 May 5
TI  - Systematic literature review of the burden and outcomes of infections due to
      multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol.
PG  - e030608
LID - 10.1136/bmjopen-2019-030608 [doi]
AB  - INTRODUCTION: Despite the increasing importance of infections due to
      multidrug-resistant organisms (MDROs), there is a lack of comprehensive
      information about the burden of disease and outcomes of key infections caused by 
      these pathogens. The aim of the ABOUT-MDRO (A systematic review on the burden and
      outcomes of infections due to multidrug resitant organisms) project is to provide
      estimations of the burden of some key infections and their outcomes caused by the
      target MDROs. METHODS AND ANALYSIS: A systematic literature search will be
      performed using MEDLINE/PubMed, Elsevier's SCOPUS, Cochrane library, Clinical
      trials and Web of Science, as well as the Surveillance Systems from Public Health
      Institutions and Scientific Societies for Antimicrobial Resistance and
      Healthcare-Associated Infections in Europe database of European surveillance
      systems, for data on prevalence/incidence, mortality and length of stay of target
      infections in hospitalised patients (including ventilator-associated pneumonia,
      hospital-acquired pneumonia, complicated intra-abdominal infections, complicated 
      urinary tract infections, skin and soft tissue infections and bloodstream
      infections) and in specific populations (children, hospital wards, neutropenic
      patients) caused by cephalosporin-resistant or carbapenem-resistant
      Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter
      spp., methicillin-resistant Staphylococcus aureus, and vancomycin-resistant
      Enterococcus spp. The information retrieved will be tabulated and pooled
      estimates and 95% CIs calculated of rates and outcomes, using random effects
      models. Relationships between rates and outcomes in randomised control trials and
      epidemiological studies, and data of proportions and incidence/prevalence rates
      will also be analysed. The information collected in this study will be useful for
      identifying gaps in our knowledge in terms of incidence/prevalence and clinical
      outcomes of infections caused by MDROs, and for informing priorities in infection
      control and the research and design of appropriate studies. ETHICS AND
      DISSEMINATION: This study will be based on published data so we did not require
      ethical approval. Formal consent is not required. The results of this review will
      be reported according to the Preferred Reporting Items for Systematic Review and 
      Meta-Analyses statement. Data will be presented at international conferences and 
      published in peer-reviewed journals. REGISTRATION DETAILS: PROSPERO
      (https://www.crd.york.ac.uk/prospero/) (CRD42019124185).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Anaya-Baz, Blanca
AU  - Anaya-Baz B
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena / Departamento de Medicina, Universidad de
      Sevilla / Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.
FAU - Maldonado, Natalia
AU  - Maldonado N
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena / Departamento de Medicina, Universidad de
      Sevilla / Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.
FAU - Palacios-Baena, Zaira R
AU  - Palacios-Baena ZR
AUID- ORCID: 0000-0002-1713-6807
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena / Departamento de Medicina, Universidad de
      Sevilla / Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.
FAU - Palomo, Virginia
AU  - Palomo V
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena / Departamento de Medicina, Universidad de
      Sevilla / Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.
FAU - Pezzani, Maria Diletta
AU  - Pezzani MD
AD  - Divisione di Malattie Infettive, Dipartimento di Diagnostica e Sanita Pubblica,
      Ospedale Policlinico Borgo Roma, Verona, Italy.
FAU - Chiesi, Sheila
AU  - Chiesi S
AUID- ORCID: 0000-0002-0108-0722
AD  - Divisione di Malattie Infettive, Dipartimento di Diagnostica e Sanita Pubblica,
      Ospedale Policlinico Borgo Roma, Verona, Italy.
FAU - Razzaboni, Elisa
AU  - Razzaboni E
AD  - Divisione di Malattie Infettive, Dipartimento di Diagnostica e Sanita Pubblica,
      Ospedale Policlinico Borgo Roma, Verona, Italy.
FAU - Compri, Monica
AU  - Compri M
AD  - Divisione di Malattie Infettive, Dipartimento di Diagnostica e Sanita Pubblica,
      Ospedale Policlinico Borgo Roma, Verona, Italy.
FAU - Tacconelli, Evelina
AU  - Tacconelli E
AD  - Divisione di Malattie Infettive, Dipartimento di Diagnostica e Sanita Pubblica,
      Ospedale Policlinico Borgo Roma, Verona, Italy.
FAU - Rodriguez-Bano, Jesus
AU  - Rodriguez-Bano J
AD  - Unidad Clinica de Enfermedades Infecciosas, Microbiologia y Medicina Preventiva, 
      Hospital Universitario Virgen Macarena / Departamento de Medicina, Universidad de
      Sevilla / Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain
      jesusrb@us.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - *Drug Resistance, Multiple, Bacterial
MH  - Europe/epidemiology
MH  - Humans
MH  - Infections/*drug therapy/*epidemiology/*microbiology
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7228488
OTO - NOTNLM
OT  - *antimicrobial resistance
OT  - *healthcare-associated infections
OT  - *incidence rates
OT  - *outcome
OT  - *surveillance
COIS- Competing interests: ZRP-B received honoraria for educational talks by Gilead.
      JR-B received honoraria for accredited educational activities funded by Merck
      through unrestricted grants. All other authors declare that they have no
      conflicts of interest.
EDAT- 2020/05/07 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-030608 [pii]
AID - 10.1136/bmjopen-2019-030608 [doi]
PST - epublish
SO  - BMJ Open. 2020 May 5;10(5):e030608. doi: 10.1136/bmjopen-2019-030608.


PMID- 32371297
OWN - NLM
STAT- Publisher
LR  - 20200527
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 90
DP  - 2020 Apr 23
TI  - A Nordic model for learning compassionate care in clinical education.
PG  - 104454
LID - S0260-6917(19)30787-7 [pii]
LID - 10.1016/j.nedt.2020.104454 [doi]
AB  - BACKGROUND: Preceptorship is one model of supporting student nurses' learning and
      development during their clinical education. However, little is known about what 
      there is in preceptorship that promotes or hinders learning. Earlier studies
      found that there were ethical dimensions to students' encounters with preceptors.
      AIM: The overall purpose of this Nordic follow-up study was to develop a model
      for learning compassionate care among student nurses during their clinical
      education - first, to deeper understand the learning of student nurses, and
      second, to investigate the phenomenon of preceptorship from the preceptors point 
      of view. METHOD: This study used a mixed methods design. Undergraduate student
      nurses (n = 139) from three universities in Finland and Sweden were shadowed for 
      a period of three years. Quantitative data were collected through a questionnaire
      and were analysed using statistical methods. To better understand the learning
      acquired by the student nurses, focus group interviews (n = 70) were conducted.
      The phenomenological-hermeneutical approach was adopted. To capture the
      preceptors' point of view, narrative interviews were held with them (n = 88) in
      western Finland and northern Sweden. A hermeneutical approach was used when
      analysing the data. FINDINGS: According to both student nurses and preceptors, a 
      caring student-preceptor relationship, imbued with commitment, reverence and
      responsibility, is fundamental and serves as the basis for students' learning and
      development more than pedagogical methods used. Three main themes emerged: a
      caring student-preceptor relationship; a caring manner of being-the conduct; and 
      a caring culture-the tone of the learning space. CONCLUSIONS: This study shows
      the importance of preceptorship on student nurses in their quest of becoming
      compassionate and caring nurses. Therefore, based on earlier findings and the
      findings in this study, there is a need to facilitate and support the students'
      transformation, that is, the process of becoming, from student to a professional 
      nurse.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Hilli, Yvonne
AU  - Hilli Y
AD  - Faculty of Nursing and Health Sciences, Nord University, Norway; Faculty of
      Caring Science, Work Life and Social Welfare, University of Boras, Sweden.
      Electronic address: yvonne.hilli@nord.no.
FAU - Sandvik, Ann-Helen
AU  - Sandvik AH
AD  - Faculty of Nursing and Health Sciences, Nord University, Norway; Faculty of
      Caring Science, Work Life and Social Welfare, University of Boras, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
COIS- Declaration of competing interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/07 06:00
MHDA- 2020/05/07 06:00
CRDT- 2020/05/07 06:00
PHST- 2019/06/03 00:00 [received]
PHST- 2020/01/21 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/05/07 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - S0260-6917(19)30787-7 [pii]
AID - 10.1016/j.nedt.2020.104454 [doi]
PST - aheadofprint
SO  - Nurse Educ Today. 2020 Apr 23;90:104454. doi: 10.1016/j.nedt.2020.104454.


PMID- 32371227
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20210110
IS  - 1876-2026 (Electronic)
IS  - 1876-2018 (Linking)
VI  - 51
DP  - 2020 Jun
TI  - Ethical dilemmas faced by health care workers during COVID-19 pandemic: Issues,
      implications and suggestions.
PG  - 102116
LID - S1876-2018(20)30227-6 [pii]
LID - 10.1016/j.ajp.2020.102116 [doi]
FAU - Menon, Vikas
AU  - Menon V
AD  - Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education 
      and Research (JIPMER), Dhanvantri Nagar P.O, Puducherry, 605006, India.
      Electronic address: drvmenon@gmail.com.
FAU - Padhy, Susanta Kumar
AU  - Padhy SK
AD  - Department of Psychiatry, All India Institute of Medical Sciences, Bhubaneswar,
      751019, India.
LA  - eng
PT  - Letter
DEP - 20200428
PL  - Netherlands
TA  - Asian J Psychiatr
JT  - Asian journal of psychiatry
JID - 101517820
SB  - IM
MH  - Adult
MH  - COVID-19
MH  - Clinical Decision-Making/*ethics
MH  - Coronavirus Infections/*therapy
MH  - Health Personnel/*ethics/*psychology
MH  - Humans
MH  - India
MH  - *Pandemics
MH  - Pneumonia, Viral/*therapy
PMC - PMC7187815
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Health personnel
OT  - Mental health
OT  - Psychiatry
COIS- Declaration of Competing Interest The authors declare no conflicts of interest
      relevant to the contents of the manuscript.
EDAT- 2020/05/07 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - S1876-2018(20)30227-6 [pii]
AID - 10.1016/j.ajp.2020.102116 [doi]
PST - ppublish
SO  - Asian J Psychiatr. 2020 Jun;51:102116. doi: 10.1016/j.ajp.2020.102116. Epub 2020 
      Apr 28.


PMID- 32371059
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 1873-5177 (Electronic)
IS  - 0091-3057 (Linking)
VI  - 194
DP  - 2020 Jul
TI  - Antipsychotic lurasidone: Behavioural and pharmacokinetic data in C57BL/6 mice.
PG  - 172933
LID - S0091-3057(20)30107-6 [pii]
LID - 10.1016/j.pbb.2020.172933 [doi]
AB  - Lurasidone is an atypical antipsychotic that has been shown to be effective in
      reversing schizophrenia-related cognitive impairment. The development of new
      preclinical models of schizophrenia is a key for improving treatments of
      cognitive symptoms. This study investigated the effects of chronic lurasidone
      treatment in C57BL/6 male mice via intraperitoneal injection (1 mg/kg daily at 5 
      p.m. for 5 weeks). A large battery of behavioural tests was performed (between 9 
      a.m. and 5 p.m.), which is currently used to assess face validity in animal
      models of psychiatric diseases. Overall, lurasidone did not interfere with
      behavioural performances, which characterises very good tolerance to such a high 
      dose. Moreover, pharmacokinetic parameters after i.p. and oral administration
      were measured. Mean transit time (MTT) values were 1.91 h (1 mg/kg acute i.p.)
      and 1.74 h (8.3 mg/kg acute oral), respectively, and relative bioavailability
      comparing these two routes of administration was of 19.8%. This last result gives
      important data to adapt oral chronic administration of lurasidone with a more
      ethical perspective in comparison with chronic i.p. injections. This study brings
      tools to improve pharmacological validity of preclinical models of psychiatric
      diseases, and to adapt dosage of antipsychotics according to the route used.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Percelay, Solenn
AU  - Percelay S
AD  - Normandie Universite, UNICAEN, INSERM, COMETE, GIP CYCERON, 14000 Caen, France.
      Electronic address: solenn.percelay@unicaen.fr.
FAU - Since, Marc
AU  - Since M
AD  - Plateforme de Recherche et d'Innovation en Spectrometrie de Masse et
      Metabolomique PRISMM, Normandie Universite, UNICAEN, Comprehensive Cancer Center 
      F. Baclesse, 14000 Caen, France; Centre d'Etudes et de Recherche sur le
      Medicament de Normandie, Normandie Universite, UNICAEN, CERMN, 14000 Caen,
      France.
FAU - Lagadu, Stephanie
AU  - Lagadu S
AD  - Plateforme de Recherche et d'Innovation en Spectrometrie de Masse et
      Metabolomique PRISMM, Normandie Universite, UNICAEN, Comprehensive Cancer Center 
      F. Baclesse, 14000 Caen, France.
FAU - Freret, Thomas
AU  - Freret T
AD  - Normandie Universite, UNICAEN, INSERM, COMETE, GIP CYCERON, 14000 Caen, France.
FAU - Bouet, Valentine
AU  - Bouet V
AD  - Normandie Universite, UNICAEN, INSERM, COMETE, GIP CYCERON, 14000 Caen, France.
FAU - Boulouard, Michel
AU  - Boulouard M
AD  - Normandie Universite, UNICAEN, INSERM, COMETE, GIP CYCERON, 14000 Caen, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200501
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Antipsychotic Agents)
RN  - O0P4I5851I (Lurasidone Hydrochloride)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Antipsychotic Agents/administration & dosage/*pharmacokinetics
MH  - Anxiety/metabolism
MH  - Behavior, Animal/*drug effects
MH  - Biological Availability
MH  - Cognitive Dysfunction/drug therapy/metabolism
MH  - Humans
MH  - Injections, Intraperitoneal
MH  - Lurasidone Hydrochloride/administration & dosage/*pharmacokinetics
MH  - Male
MH  - Memory/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Reflex, Startle/drug effects
MH  - Schizophrenia/drug therapy/metabolism
OTO - NOTNLM
OT  - *Cognitive deficits
OT  - *Lurasidone
OT  - *Mice
OT  - *Pharmacokinetic
OT  - *Schizophrenia
OT  - *Sociability
COIS- Declaration of competing interest None.
EDAT- 2020/05/07 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - S0091-3057(20)30107-6 [pii]
AID - 10.1016/j.pbb.2020.172933 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2020 Jul;194:172933. doi: 10.1016/j.pbb.2020.172933.
      Epub 2020 May 1.


PMID- 32370835
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20200910
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 95
IP  - 5
DP  - 2020 May
TI  - Artificial Intelligence in Cardiology: Present and Future.
PG  - 1015-1039
LID - S0025-6196(20)30138-5 [pii]
LID - 10.1016/j.mayocp.2020.01.038 [doi]
AB  - Artificial intelligence (AI) is a nontechnical, popular term that refers to
      machine learning of various types but most often to deep neural networks.
      Cardiology is at the forefront of AI in medicine. For this review, we searched
      PubMed and MEDLINE databases with no date restriction using search terms related 
      to AI and cardiology. Articles were selected for inclusion on the basis of
      relevance. We highlight the major achievements in recent years in nearly all
      areas of cardiology and underscore the mounting evidence suggesting how AI will
      take center stage in the field. Artificial intelligence requires a close
      collaboration among computer scientists, clinical investigators, clinicians, and 
      other users in order to identify the most relevant problems to be solved. Best
      practices in the generation and implementation of AI include the selection of
      ideal data sources, taking into account common challenges during the
      interpretation, validation, and generalizability of findings, and addressing
      safety and ethical concerns before final implementation. The future of AI in
      cardiology and in medicine in general is bright as the collaboration between
      investigators and clinicians continues to excel.
CI  - Copyright (c) 2020 Mayo Foundation for Medical Education and Research. Published 
      by Elsevier Inc. All rights reserved.
FAU - Lopez-Jimenez, Francisco
AU  - Lopez-Jimenez F
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic
      address: lopez@mayo.edu.
FAU - Attia, Zachi
AU  - Attia Z
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Arruda-Olson, Adelaide M
AU  - Arruda-Olson AM
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Carter, Rickey
AU  - Carter R
AD  - Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL.
FAU - Chareonthaitawee, Panithaya
AU  - Chareonthaitawee P
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Jouni, Hayan
AU  - Jouni H
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Kapa, Suraj
AU  - Kapa S
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Lerman, Amir
AU  - Lerman A
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Luong, Christina
AU  - Luong C
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Medina-Inojosa, Jose R
AU  - Medina-Inojosa JR
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Noseworthy, Peter A
AU  - Noseworthy PA
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Robert D. and 
      Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic,
      Rochester, MN.
FAU - Pellikka, Patricia A
AU  - Pellikka PA
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Redfield, Margaret M
AU  - Redfield MM
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Roger, Veronique L
AU  - Roger VL
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Robert D. and 
      Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic,
      Rochester, MN.
FAU - Sandhu, Gurpreet S
AU  - Sandhu GS
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Senecal, Conor
AU  - Senecal C
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
FAU - Friedman, Paul A
AU  - Friedman PA
AD  - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
LA  - eng
GR  - K01 HL124045/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
SB  - IM
CIN - Mayo Clin Proc. 2020 May;95(5):843-844. PMID: 32370846
MH  - Artificial Intelligence/*trends
MH  - Cardiology/*methods
MH  - Forecasting
MH  - *Heart Diseases/diagnosis/therapy
MH  - Humans
EDAT- 2020/05/07 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/05/07 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2020/01/30 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
AID - S0025-6196(20)30138-5 [pii]
AID - 10.1016/j.mayocp.2020.01.038 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2020 May;95(5):1015-1039. doi: 10.1016/j.mayocp.2020.01.038.


PMID- 32370186
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20211008
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 9
DP  - 2020 May 2
TI  - Nurse Manager Core Competencies: A Proposal in the Spanish Health System.
LID - E3173 [pii]
LID - 10.3390/ijerph17093173 [doi]
AB  - Nurses who are capable of developing their competencies appropriately in the
      field of management are considered fundamental to the sustainability and
      improvement of health outcomes. These core competencies are the critical
      competencies to be developed in specific areas. There are different core
      competencies for nurse managers, but none in the Spanish health system. The
      objective of this research is to identify the core competencies needed for nurse 
      managers in the Spanish health system. The research was carried out using the
      Delphi method to reach a consensus on the core competencies and a Principal
      Component Analysis (PCA) to determine construct validity, reducing the
      dimensionality of a dataset by finding the causes of variability in the set and
      organizing them by importance. A panel of 50 experts in management and healthcare
      engaged in a four-round Delphi study with Likert scored surveys. We identified
      eight core competencies from an initial list of 51: decision making, relationship
      management, communication skills, listening, Leadership, conflict management,
      ethical principles, collaboration and team management skills. PCA indicated the
      structural validity of the core competencies by saturation into three components 
      (alpha Cronbach >0.613): communication, leadership and decision making. The
      research shows that eight competencies must be developed by the nursing managers 
      in the Spanish health system. Nurse managers can use these core competencies as
      criteria to develop and plan their professional career. These core competencies
      can serve as a guideline for the design of nurse managers' development programs
      in Spain.
FAU - Garcia, Alberto Gonzalez
AU  - Garcia AG
AUID- ORCID: 0000-0001-5218-097X
AD  - Department of Nursing and Physiotherapy, Universidad de Leon, 24401 Ponferrada,
      Spain.
FAU - Pinto-Carral, Arrate
AU  - Pinto-Carral A
AUID- ORCID: 0000-0002-2168-4478
AD  - SALBIS Research Group, Department of Nursing and Physiotherapy, Universidad de
      Leon, 24001 Ponferrada, Spain.
FAU - Villorejo, Jesus Sanz
AU  - Villorejo JS
AD  - Director of the University Dental Clinic, European University of Madrid, 28670
      Madrid, Spain.
FAU - Marques-Sanchez, Pilar
AU  - Marques-Sanchez P
AUID- ORCID: 0000-0002-1304-1552
AD  - SALBIS Research Group, Department of Nursing and Physiotherapy, Universidad de
      Leon, 24001 Ponferrada, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200502
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Communication
MH  - Female
MH  - Humans
MH  - Leadership
MH  - Male
MH  - *Nurse Administrators
MH  - *Professional Competence
MH  - Spain
MH  - Surveys and Questionnaires
PMC - PMC7246551
OTO - NOTNLM
OT  - *competence
OT  - *core competencies
OT  - *governance
OT  - *leadership
OT  - *nurse manager
EDAT- 2020/05/07 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - ijerph17093173 [pii]
AID - 10.3390/ijerph17093173 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 May 2;17(9). pii: ijerph17093173. doi:
      10.3390/ijerph17093173.


PMID- 34457752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2156-8650 (Electronic)
IS  - 2156-8650 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Jun
TI  - Perceptions of patients and medical students towards each other in the setting of
      patient care-a South African perspective.
PG  - 933-942
LID - 10.1007/s40670-020-00976-3 [doi]
AB  - INTRODUCTION: South Africa urgently needs more doctors. We examined perceptions
      of patients and students to provide evidence for optimum student-patient ratios
      and substantiate solutions for this dilemma. METHODS: We interviewed 118 patients
      and invited 120 students to complete a self-administered questionnaire from four 
      specialities in an academic hospital in Johannesburg. RESULTS: The total sample
      size was 238 participants. A total of 91/118 (77%) patients and 78/120 (65%)
      students were female. Almost all the patients had some level of education, with
      most patients having received at least a secondary education (71/120). More than 
      half of the students (69/120) were final year students. A third (41/118) of the
      patients were unaware they were admitted to a teaching hospital. Half of the
      patients (60/118) thought they had the right to refuse interaction with students.
      Patients and students preferred smaller groups of between 1-3 and 4-8 students at
      a bedside tutorial (p < 0.001), although patients preferred smaller groups (1-3) 
      compared with the students (4-8). Majority of patients said they never refused
      consent to students, while a third of students reported at least up to three
      patients refusing consent to be examined. The most frequent reason cited by
      students for refusal of consent by patients was the exposure to excessive numbers
      of students and healthcare professionals. CONCLUSION: Medical schools should
      consider patient safeguards while responding to the country's need for more
      doctors. The Medical Council and medical schools need to draw up professional
      guidelines on patient-student interactions, including the role of patients in
      this setting.
CI  - (c) International Association of Medical Science Educators 2020.
FAU - Menezes, Colin Nigel
AU  - Menezes CN
AUID- ORCID: 0000-0003-3838-5359
AD  - Department of Internal Medicine, School of Clinical Medicine, Faculty of Health
      Sciences, University of the Witwatersrand, Johannesburg, South
      Africa.grid.11951.3d0000 0004 1937 1135
AD  - Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital,
      Johannesburg, South Africa.grid.414240.70000 0004 0367 6954
FAU - Dhai, Ames
AU  - Dhai A
AD  - Steve Biko Centre for Bioethics, School of Clinical Medicine, Faculty of Health
      Sciences, University of the Witwatersrand, Johannesburg, South
      Africa.grid.11951.3d0000 0004 1937 1135
FAU - Tshabalala, Nonzwakazi
AU  - Tshabalala N
AD  - Perinatal HIV Research Unit, School of Clinical Medicine, Faculty of Health
      Sciences, University of the Witwatersrand, Johannesburg, South
      Africa.grid.11951.3d0000 0004 1937 1135
FAU - Mpanya, Dineo
AU  - Mpanya D
AD  - Department of Internal Medicine, School of Clinical Medicine, Faculty of Health
      Sciences, University of the Witwatersrand, Johannesburg, South
      Africa.grid.11951.3d0000 0004 1937 1135
FAU - Dickens, Caroline
AU  - Dickens C
AD  - Department of Internal Medicine, School of Clinical Medicine, Faculty of Health
      Sciences, University of the Witwatersrand, Johannesburg, South
      Africa.grid.11951.3d0000 0004 1937 1135
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - United States
TA  - Med Sci Educ
JT  - Medical science educator
JID - 101625548
PMC - PMC8368803
OTO - NOTNLM
OT  - Ethics
OT  - Medical student numbers
OT  - Patients' rights
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/05/07 00:00
MHDA- 2020/05/07 00:01
CRDT- 2021/08/30 05:57
PHST- 2021/08/30 05:57 [entrez]
PHST- 2020/05/07 00:00 [pubmed]
PHST- 2020/05/07 00:01 [medline]
AID - 10.1007/s40670-020-00976-3 [doi]
AID - 976 [pii]
PST - epublish
SO  - Med Sci Educ. 2020 May 7;30(2):933-942. doi: 10.1007/s40670-020-00976-3.
      eCollection 2020 Jun.


PMID- 32369817
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20211204
IS  - 2504-3188 (Electronic)
IS  - 2504-3161 (Linking)
VI  - 13
IP  - 3
DP  - 2020
TI  - What Will It Take to Build an Expert Group of Nutrigenomic Practitioners?
PG  - 122-128
LID - 10.1159/000507252 [doi]
AB  - BACKGROUND: The past two decades have seen exponential growth in the number of
      genetic testing companies, but only a small percentage of these tests are being
      sold through health care professionals (HCPs). As each new genetic testing
      company appears, it is becoming more difficult for the practitioner and consumer 
      to evaluate the credibility of the claims being made and the value of the tests
      being offered. SUMMARY: HCPs appear to have minimal nutrigenomics knowledge and
      little confidence in choosing and interpreting nutrigenetic tests. To remedy
      this, HCPs need access to credible education, professional support, networking,
      career development, mentorship, and a regulated testing environment. This will
      enable them to evaluate the credibility of genetic tests and testing companies,
      provide genetic results in context, and apply appropriate clinical translation.
      Key Message: In order to establish an expert group of nutrigenomic practitioners,
      collaboration is required between educational institutions, professional
      organizations, and genetic testing companies. This will provide the necessary
      support, skills, and knowledge to ensure that the best value is extracted from
      nutrigenetic tests in an ethical and responsible manner.
CI  - (c) 2020 The Author(s) Published by S. Karger AG, Basel.
FAU - Joffe, Yael
AU  - Joffe Y
AD  - Maryland University of Integrative Health, Laurel, Maryland, USA,
      Yael@manukascience.co.za.
AD  - 3X4 Genetics, Cape Town, South Africa, Yael@manukascience.co.za.
FAU - Herholdt, Helene
AU  - Herholdt H
AD  - 3X4 Genetics, Cape Town, South Africa.
LA  - eng
PT  - Editorial
DEP - 20200505
PL  - Switzerland
TA  - Lifestyle Genom
JT  - Lifestyle genomics
JID - 101716139
SB  - IM
MH  - Commerce
MH  - Educational Status
MH  - Evidence-Based Medicine
MH  - Expert Testimony
MH  - *Genetic Testing
MH  - Genome, Human
MH  - *Health Personnel
MH  - Health Promotion
MH  - Humans
MH  - Interprofessional Relations
MH  - Life Style
MH  - Nutrigenomics/education/*standards
MH  - Nutritional Sciences/education/*standards
MH  - Research Design
MH  - Societies, Medical
MH  - Translational Research, Biomedical
MH  - United Kingdom
MH  - United States
OTO - NOTNLM
OT  - *Clinical translation
OT  - *Education
OT  - *Genetic testing
OT  - *Health care practitioner
OT  - *Nutrigenetics
OT  - *Nutrigenomics
EDAT- 2020/05/06 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/11/28 00:00 [received]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 000507252 [pii]
AID - 10.1159/000507252 [doi]
PST - ppublish
SO  - Lifestyle Genom. 2020;13(3):122-128. doi: 10.1159/000507252. Epub 2020 May 5.


PMID- 32369433
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20210702
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - "We're Not Ready, But I Don't Think You're Ever Ready." Clinician Perspectives on
      Implementation of Crisis Standards of Care.
PG  - 148-159
LID - 10.1080/23294515.2020.1759731 [doi]
AB  - Background: The COVID-19 pandemic has highlighted health care systems'
      vulnerabilities. Hospitals face increasing risk of periods of scarcity of
      life-sustaining resources such as ventilators for mechanical respiratory support,
      as has been the case in Italy as of March, 2020. The National Academy of Medicine
      has provided guidance on crisis standards of care, which call for the
      reallocation of scarce medical resources to those who will benefit most during
      extreme situations. Given that this will require a departure from the usual
      fiduciary duty of the bedside clinician, we determined and mapped potential
      barriers to the implementation of the guidelines from stakeholders using an
      implementation science framework. Methods: A protocol was created to
      operationalize national and state guidelines for triaging ventilators during
      crisis conditions. Focus groups and key informant interviews were conducted from 
      July-September 2018 with clinicians at three acute care hospitals of an urban
      academic medical center. Respiratory therapists, intensivists, nursing leadership
      and the palliative care interdisciplinary team participated in focus groups. Key 
      informant interviews were conducted with emergency management, respiratory
      therapy and emergency medicine. Subjects were presented the protocol and their
      reflections were elicited using a semi-structured interview guide. Data from
      transcripts and notes were categorized using a coding strategy based on the
      Theoretical Domains Framework. Results: Participants anticipated that
      implementing this protocol would challenge their roles and identities as
      clinicians including both their fiduciary duty to the patient and their
      decision-making autonomy. Despite this, many participants acknowledged the need
      for such a protocol to standardize care and minimize bias as well as to mitigate 
      potential consequences for individual clinicians. Participants identified the
      question of considering patient quality of life in triage decisions as an
      important and unresolved ethical issue in disaster triage. Conclusion:
      Clinicians' discomfort with shifting roles and obligations could pose
      implementation barriers for crisis standards of care.
FAU - Chuang, Elizabeth
AU  - Chuang E
AUID- ORCID: 0000-0002-2505-8159
AD  - Department of Family and Social Medicine, Albert Einstein College of Medicine,
      Montefiore Medical Center, Bronx, New York, USA.
FAU - Cuartas, Pablo A
AU  - Cuartas PA
AD  - Albert Einstein College of Medicine, New York, New York, USA.
FAU - Powell, Tia
AU  - Powell T
AD  - Montefiore-Einstein Center for Bioethics, Bronx, New York, USA.
FAU - Gong, Michelle Ng
AU  - Gong MN
AD  - Division of Critical Care Medicine, Department of Medicine, Albert Einstein
      College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
LA  - eng
GR  - KL2 TR002558/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200505
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Academic Medical Centers
MH  - *Attitude of Health Personnel
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Critical Care/ethics/*standards
MH  - Emergency Medicine/standards
MH  - Focus Groups
MH  - Humans
MH  - Interviews as Topic
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Practice Guidelines as Topic
MH  - Quality of Life
MH  - Respiration, Artificial/standards
MH  - Respiratory Therapy/standards
MH  - SARS-CoV-2
MH  - *Standard of Care/ethics
MH  - Triage/methods/standards
MH  - Withholding Treatment/*ethics
PMC - PMC7790438
MID - NIHMS1654979
OTO - NOTNLM
OT  - *COVID-19
OT  - *Disaster triage
OT  - *implementation science
OT  - *pandemic
OT  - *qualitative
EDAT- 2020/05/06 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1080/23294515.2020.1759731 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Jul-Sep;11(3):148-159. doi:
      10.1080/23294515.2020.1759731. Epub 2020 May 5.


PMID- 32369192
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Experiencing Community in a Covid Surge.
PG  - 10-11
LID - 10.1002/hast.1109 [doi]
AB  - As I organize a pile of ethics consult chart notes in New York City in mid-April 
      2020, I look at the ten cases that I have co-consulted on recently. Nine of the
      patients were found to be Covid positive. The reasons for the consults are mostly
      familiar-surrogate decision-making, informed refusal of treatment, goals of care,
      defining futility. But the context is unfamiliar and unsettling. Bioethicists are
      in pandemic mode, dusting off and revising triage plans. Patients and potential
      patients are fearful-of the disease itself and of the amplification of health
      disparities and inequities. There is much to contemplate, but as I go through my 
      cases, I worry about disability, about biases and racist stereotypes. In this
      pandemic, historically marginalized communities are at risk of further
      disenfranchisement.
CI  - (c) 2020 The Hastings Center.
FAU - Mukherjee, Debjani
AU  - Mukherjee D
LA  - eng
PT  - Journal Article
DEP - 20200505
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/ethnology
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - New York City
MH  - Pandemics
MH  - Patient Care Planning/ethics
MH  - Pneumonia, Viral/*epidemiology/ethnology
MH  - SARS-CoV-2
MH  - Triage/ethics
PMC - PMC7267420
OTO - NOTNLM
OT  - *Asian Americans
OT  - *Covid-19
OT  - *allocation of scarce resources
OT  - *bias in medicine
OT  - *disability
OT  - *novel coronavirus SARS-CoV-2
EDAT- 2020/05/06 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1002/hast.1109 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):10-11. doi: 10.1002/hast.1109. Epub 2020 May 5.


PMID- 32369167
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 6
DP  - 2020 Jun 1
TI  - Expanded carrier screening should not be mandatory for gamete donors.
PG  - 1256-1261
LID - 10.1093/humrep/deaa088 [doi]
AB  - More and more centers are imposing expanded carrier screening (ECS) on their
      gamete donors. In some clinics and gamete banks, gamete donors are not given this
      right, contrary to the freedom to decline genetic screening in the general
      population. The possible social and psychological burdens that are recognized for
      infertility patients and the general population are downplayed for gamete donors.
      The procedure of imposing ECS on gamete donors shows that the interests of the
      recipients are valued higher than those of the donors. The general ethical
      argument defended here is the principle of proportionality: the burdens imposed
      on donors have to be balanced against the potential benefits for the offspring
      and the recipients. The risk reduction of ECS is below 1% and is too small to
      outweigh the potential dangers and disadvantages for donors. The conclusion is
      that clinics may ask, but not compel, donors to submit to ECS provided that they 
      offer appropriate genetic and psychological counseling.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please email: journals.permissions@oup.com.
FAU - Pennings, Guido
AU  - Pennings G
AD  - Department of Philosophy and Moral Science, Bioethics Institute Ghent (BIG),
      Ghent University, Gent, Belgium.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Germ Cells
MH  - Humans
MH  - *Infertility
MH  - Male
MH  - *Oocyte Donation
MH  - Spermatozoa
MH  - Tissue Donors
OTO - NOTNLM
OT  - *ethics
OT  - *expanded carrier screening
OT  - *gamete donation
OT  - *genetic testing
OT  - *oocyte donor
OT  - *risk reduction
OT  - *sperm donor
OT  - *welfare of the child
EDAT- 2020/05/06 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/03/27 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 5829837 [pii]
AID - 10.1093/humrep/deaa088 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Jun 1;35(6):1256-1261. doi: 10.1093/humrep/deaa088.


PMID- 32368850
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20220716
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Utilization of deceased donors during a pandemic: argument against using
      SARS-CoV-2-positive donors.
PG  - 1795-1799
LID - 10.1111/ajt.15969 [doi]
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become
      an unprecedented pandemic that has impacted society, disrupted hospital
      functions, strained health care resources, and impacted the lives of transplant
      professionals. Despite this, organ failure and the need for transplant continues 
      throughout the United States. Considering the perpetual scarcity of deceased
      donor organs, Kates et al present a viewpoint that advocates for the utilization 
      of coronavirus disease 2019 (COVID-19)-positive donors in selected cases. We
      present a review of the current literature that details the potential negative
      consequences of COVID-19-positive donors. The factors we consider include (1) the
      risk of blood transmission of SARS-CoV-2, (2) involvement of donor organs, (3)
      lack of effective therapies, (4) exposure of health care and recovery teams, (5) 
      disease transmission and propagation, and (6) hospital resource utilization.
      While we acknowledge that transplant fulfills the mission of saving lives, it is 
      imperative to consider the consequences not only to our recipients but also to
      the community and to health care workers, particularly in the absence of
      effective preventative or curative therapies. For these reasons, we believe the
      evidence and risks show that COVID-19 infection should continue to remain a
      contraindication for donation, as has been the initial response of donation and
      transplant societies.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Shah, Malay B
AU  - Shah MB
AUID- ORCID: https://orcid.org/0000-0001-5325-2410
AD  - Department of Surgery, Division of Abdominal Transplant Surgery, University of
      Kentucky College of Medicine, Lexington, Kentucky, USA.
FAU - Lynch, Raymond J
AU  - Lynch RJ
AD  - Department of Surgery, Division of Transplantation, Emory University School of
      Medicine, Atlanta, Georgia, USA.
FAU - El-Haddad, Hanine
AU  - El-Haddad H
AD  - Department of Medicine, Division of Infectious Diseases, University of Kentucky
      College of Medicine, Lexington, Kentucky, USA.
FAU - Doby, Brianna
AU  - Doby B
AD  - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore,
      Maryland, USA.
FAU - Brockmeier, Diane
AU  - Brockmeier D
AD  - Mid-America Transplant, St. Louis, Missouri, USA.
FAU - Goldberg, David S
AU  - Goldberg DS
AUID- ORCID: https://orcid.org/0000-0002-1465-0691
AD  - Department of Medicine, Division of Hepatology, University of Miami Miller School
      of Medicine, Miami, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200609
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CIN - J Urol. 2021 Feb;205(2):618-620. PMID: 33155877
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control/*transmission
MH  - Ethics, Medical
MH  - Humans
MH  - Intensive Care Units
MH  - Occupational Exposure
MH  - Organ Transplantation/*adverse effects/*trends
MH  - Pandemics/*prevention & control
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*prevention & control/*transmission
MH  - Resource Allocation
MH  - Risk
MH  - SARS-CoV-2
MH  - *Tissue Donors
MH  - Tissue and Organ Procurement/*ethics/statistics & numerical data/*trends
MH  - United States
PMC - PMC7267604
OTO - NOTNLM
OT  - donors and donation
OT  - editorial/personal viewpoint
OT  - ethics and public policy
OT  - infection and infectious agents - viral
OT  - infectious disease
OT  - organ allocation
OT  - organ procurement
OT  - organ procurement and allocation
OT  - organ transplantation in general
EDAT- 2020/05/06 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/04/25 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1111/ajt.15969 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jul;20(7):1795-1799. doi: 10.1111/ajt.15969. Epub 2020 Jun 
      9.


PMID- 32368446
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0929-6441 (Print)
IS  - 0929-6441 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Jan-Mar
TI  - Sonographic Portal Vein Biometry in Apparently Healthy Children in Northeastern
      Nigeria.
PG  - 24-28
LID - 10.4103/JMU.JMU_89_18 [doi]
AB  - BACKGROUND: This study aimed at determining the mean portal vein diameter (PVD)
      based on age, gender, and anthropometric variables. METHODS: This was a
      cross-sectional prospective study carried out among apparently healthy children
      aged 0-18 years at the radiology department of Abubakar Tafawa Balewa University 
      Teaching Hospital (ATBUTH) Bauchi, from November 2016 to April 2017. Ethical
      clearance was obtained from the institutional committee on ethics and the head of
      radiology department in ATBUTH, Bauchi. Written and informed consent was obtained
      from all the participants, through their parents or guardians and from the head
      teachers of their schools before the study. Participants (children) were
      recruited (voluntarily) from primary and junior secondary schools within the
      vicinity of the hospital, and from parents who consented for their children to
      participate in the study. Data analysis was done using SPSS version 22.0.
      Descriptive statistics (mean, standard deviation, frequency, and percentages) and
      Pearson product-moment correlation were used for the analysis. Statistical
      significance was considered at P < 0.05. RESULTS: There were 111 (58.2%) males
      and 99 (47.14%) females. The individuals were between the ages of <1-18 years
      with mean age of 8.8 +/- 5.8. Participants' mean PVD, chest circumference, and
      body mass index (BMI) for the males were 6.96 +/- 1.86 mm, 0.60 +/- 0.08 mm, and 
      15.73 +/- 1.40, respectively, and the mean PVD, chest circumference, and BMI for 
      females were 6.60 +/- 1.68 mm, 0.58 +/- 0.09 mm, and 15.73 +/- 1.42,
      respectively. A positive relationship was found between PVD and some
      anthropometric parameters. CONCLUSION: The mean PVD in this study was 6.85 +/-
      1.18 mm, and the PVD correlates positively with some anthropometric variables
      among children in the studied population.
CI  - Copyright: (c) 2019 Journal of Medical Ultrasound.
FAU - Luntsi, Geofery
AU  - Luntsi G
AD  - Department of Medical Radiography, College of Medical Sciences, University of
      Maiduguri, Maiduguri, Borno State, Nigeria.
FAU - Umar, Ramatu Danjuma
AU  - Umar RD
AD  - Department of Medical Radiography, College of Medical Sciences, University of
      Maiduguri, Maiduguri, Borno State, Nigeria.
FAU - Ivor, Chigozie Nwobi
AU  - Ivor CN
AD  - Department of Medical Radiography, College of Medical Sciences, University of
      Maiduguri, Maiduguri, Borno State, Nigeria.
FAU - Zira, Joseph Dlama
AU  - Zira JD
AD  - Department of Radiology Abubakar Tafawa Balewa University Teaching Hospital
      Bauchi, Bauchi, Nigeria.
FAU - Ahidjo, Ahmed
AU  - Ahidjo A
AD  - Department of Radiology, University of Maiduguri, Maiduguri, Borno State,
      Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20190520
PL  - India
TA  - J Med Ultrasound
JT  - Journal of medical ultrasound
JID - 9423829
PMC - PMC7194425
OTO - NOTNLM
OT  - Anthropometric variable
OT  - apparently healthy children
OT  - biometry
OT  - portal vein
OT  - sonography
COIS- There are no conflicts of interest.
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:01
CRDT- 2020/05/06 06:00
PHST- 2018/09/03 00:00 [received]
PHST- 2019/01/20 00:00 [revised]
PHST- 2019/04/02 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:01 [medline]
AID - 10.4103/JMU.JMU_89_18 [doi]
AID - JMU-28-24 [pii]
PST - epublish
SO  - J Med Ultrasound. 2019 May 20;28(1):24-28. doi: 10.4103/JMU.JMU_89_18.
      eCollection 2020 Jan-Mar.


PMID- 32368351
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2056-7529 (Electronic)
IS  - 2056-7529 (Linking)
VI  - 6
DP  - 2020
TI  - Setting the research agenda for living with and beyond cancer with comorbid
      illness: reflections on a research prioritisation exercise.
PG  - 17
LID - 10.1186/s40900-020-00191-9 [doi]
AB  - BACKGROUND: People living with and beyond cancer are more likely to have comorbid
      conditions and poorer mental and physical health, but there is a dearth of
      in-depth research exploring the psychosocial needs of people experiencing cancer 
      and comorbid chronic conditions. A patient partnership approach to research
      prioritisation and planning can ensure outcomes meaningful to those affected and 
      can inform policy and practice accordingly, but can be challenging. METHODS: We
      aimed to inform priorities for qualitative inquiry into the experiences and
      support needs of people living with and beyond cancer with comorbid illness using
      a partnership approach. A three-step process including a patient workshop to
      develop a consultation document, online consultation with patients, and academic 
      expert consultation was carried out. The research prioritisation process was also
      appraised and reflected upon. RESULTS: Six people attended the workshop, ten
      responded online and eight academic experts commented on the consultation
      document. Five key priorities were identified for exploration in subsequent
      qualitative studies, including the diagnostic journey, the burden of symptoms,
      managing medications, addressing the needs of informal carers, and service
      provision. Limitations of patient involvement and reflections on procedural
      ethics, and the challenge of making measurable differences to patient outcomes
      were discussed. CONCLUSIONS: Findings from this research prioritisation exercise 
      will inform planned qualitative work to explore patients' experiences of living
      with and beyond cancer with comorbid illness. Including patient partners in the
      research prioritisation process adds focus and relevance, and feeds into future
      work and recommendations to improve health and social care for this group of
      patients. Reflections on the consultation process contribute to a broadening of
      understanding the field of patient involvement.
CI  - (c) The Author(s) 2020.
FAU - Cavers, D
AU  - Cavers D
AD  - 1Usher Institute, University of Edinburgh, Medical School, Rm 123, Doorway 1,
      Teviot Place, Edinburgh, EH8 9AG UK.grid.4305.20000 0004 1936 7988
FAU - Cunningham-Burley, S
AU  - Cunningham-Burley S
AD  - 1Usher Institute, University of Edinburgh, Medical School, Rm 123, Doorway 1,
      Teviot Place, Edinburgh, EH8 9AG UK.grid.4305.20000 0004 1936 7988
FAU - Watson, E
AU  - Watson E
AD  - 2Faculty of Health and Life Sciences, Oxford Brookes University, Jack Straws
      Lane, Marston, Oxford, OX3 0FL UK.grid.7628.b0000 0001 0726 8331
FAU - Banks, E
AU  - Banks E
AD  - 3c/o NCRI, 2 Redman Place, Stratford, London, E20 1JQ UK.grid.451262.60000 0004
      0578 6831
FAU - Campbell, C
AU  - Campbell C
AD  - 1Usher Institute, University of Edinburgh, Medical School, Rm 123, Doorway 1,
      Teviot Place, Edinburgh, EH8 9AG UK.grid.4305.20000 0004 1936 7988
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - Res Involv Engagem
JT  - Research involvement and engagement
JID - 101708164
PMC - PMC7191759
OTO - NOTNLM
OT  - Comorbid illness
OT  - Living with and beyond cancer
OT  - Multi-morbidity
OT  - Patient and public involvement
OT  - Qualitative
OT  - Research prioritisation
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:01
CRDT- 2020/05/06 06:00
PHST- 2019/10/13 00:00 [received]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:01 [medline]
AID - 10.1186/s40900-020-00191-9 [doi]
AID - 191 [pii]
PST - epublish
SO  - Res Involv Engagem. 2020 Apr 29;6:17. doi: 10.1186/s40900-020-00191-9.
      eCollection 2020.


PMID- 32368204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1658-3612 (Electronic)
IS  - 1658-3612 (Linking)
VI  - 15
IP  - 2
DP  - 2020 Apr
TI  - Cadaver as a first teacher: A module to learn the ethics and values of cadaveric 
      dissection.
PG  - 94-101
LID - 10.1016/j.jtumed.2020.03.002 [doi]
AB  - OBJECTIVES: The undergraduate medical students must be made aware of the ethical 
      and humanistic values of cadaveric dissection. This study therefore designed,
      implemented, and evaluated the impact of the module 'Cadaver as a Teacher'
      (CrAFT) that examines the ethical values of cadaveric dissection. METHODS: This
      prospective, multimethod study involved 447 first-year undergraduate medical
      students who had participated in all three sessions of the CrAFT module.
      Activities included interactive lectures, individual assignments, and a
      poster-making competition. Students offered a silent tribute and wrote words of
      gratitude down on a tribute wall. They also expressed their thoughts in the form 
      of essays, poems, and collages. These reflections were qualitatively analysed to 
      generate themes. At the end of the module, an online quiz was conducted to assess
      the knowledge gained by the students. Their scores were correspondingly recorded 
      and calculated. RESULTS: The major themes identified were: cadaver as a teacher, 
      acknowledgement and thanksgiving, bonding, and empathy. Out of all the test
      takers, 316 students (94.32%) scored more than a five out of ten. The students
      strongly felt that the module effectively sensitised them towards the ethical and
      humanitarian aspects of handling cadavers. CONCLUSIONS: The implementation of an 
      educational module about cadavers is a novel approach towards sensitising medical
      students. The students believed that sensitising them early on would have helped 
      them establish a practice grounded in professionalism, human values, and empathy.
CI  - (c) 2020 The Authors.
FAU - D Souza, Anne
AU  - D Souza A
AD  - Department of Anatomy, Kasturba Medical College, Manipal Academy of Higher
      Education, Manipal, India.
FAU - Kotian, Sushma R
AU  - Kotian SR
AD  - Department of Anatomy, Kasturba Medical College, Manipal Academy of Higher
      Education, Manipal, India.
FAU - Pandey, Arvind K
AU  - Pandey AK
AD  - Department of Anatomy, Kasturba Medical College, Manipal Academy of Higher
      Education, Manipal, India.
FAU - Rao, Pragna
AU  - Rao P
AD  - Biochemistry, Kasturba Medical College, Manipal Academy of Higher Education,
      Manipal, India.
FAU - Kalthur, Sneha G
AU  - Kalthur SG
AD  - Department of Anatomy, Kasturba Medical College, Manipal Academy of Higher
      Education, Manipal, India.
LA  - eng
PT  - Journal Article
DEP - 20200323
PL  - Saudi Arabia
TA  - J Taibah Univ Med Sci
JT  - Journal of Taibah University Medical Sciences
JID - 101621911
PMC - PMC7184209
OTO - NOTNLM
OT  - Ethics
OT  - Human cadaver
OT  - Humanism
OT  - Professionalism
OT  - Reflection
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:01
CRDT- 2020/05/06 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/02/28 00:00 [revised]
PHST- 2020/03/01 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:01 [medline]
AID - 10.1016/j.jtumed.2020.03.002 [doi]
AID - S1658-3612(20)30036-6 [pii]
PST - epublish
SO  - J Taibah Univ Med Sci. 2020 Mar 23;15(2):94-101. doi:
      10.1016/j.jtumed.2020.03.002. eCollection 2020 Apr.


PMID- 32367955
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0972-8988 (Print)
IS  - 0972-8988 (Linking)
VI  - 13
IP  - 3
DP  - 2020 Mar
TI  - Molecular and cellular evidence of natural Venezuelan equine encephalitis virus
      infection in frugivorous bats in Colombia.
PG  - 495-501
LID - 10.14202/vetworld.2020.495-501 [doi]
AB  - BACKGROUND AND AIM: Venezuelan equine encephalitis virus (VEEV) is an alphavirus 
      that causes encephalitis with a high impact on public health in Latin America.
      However, only in Guatemala, Trinidad and Tobago, and Mexico have found antibodies
      in VEEV in bats, using immunohistochemistry, the sensitivity and specificity are 
      improved; thus, it is better for demonstrating natural infection in bats as
      potential hosts. This study aimed to determine the presence of VEEV in tissues of
      frugivorous bats. MATERIALS AND METHODS: A prospective descriptive
      cross-sectional study with a non-probabilistic sampling was carried out in 12
      localities of Cordoba and Sucre area of the Colombian Caribbean. Two hundred and 
      eighty-six bats were captured using fog nets, and the specimens according to
      taxonomic keys were classified. According to the Ethics Committee of the
      University of Cordoba, the bats were treated with analgesics and anesthetics.
      Blood samples were taken and then euthanized to obtain tissues and organs which
      were preserved in liquid N2 at -196 degrees C. A portion of each organ was fixed 
      in 10% buffered formalin for the detection of antigens by immunohistochemistry.
      Several pathological anatomy analyses were performed to determine the
      histological characteristics of tissue lesions of frugivorous bats naturally
      infected with the VEEV. RESULTS: Of the 286 bats captured, 23 species were
      identified. In samples of the brain, spleen, and lung of two frugivorous bats
      (2/286=0.70%) Artibeus planirostris and Sturnira lilium, the presence of VEEV was
      confirmed by immunohistochemistry. CONCLUSION: A fragment of the nsP4
      non-structural protein gene corresponding to the alphavirus was amplified. Two
      samples were positive (2/286=0.70%) in frugivorous bats; A. planirostris (code
      GenBank: MG820274) and S. lilium (code GenBank: MG820275). The present study
      showed the first molecular evidence and cellular evidence (histopathology and
      immunohistochemistry) of natural VEEV infection in frugivorous bats in Colombia; 
      these bats could be a host of this zoonosis.
CI  - Copyright: (c) Guzman, et al.
FAU - Guzman, Camilo
AU  - Guzman C
AD  - Department of Pharmacy, Faculty of Health Sciences, Institute of Biological
      Research of the Tropics, University of Cordoba, Colombia.
FAU - Calderon, Alfonso
AU  - Calderon A
AD  - Faculty of Veterinary Medicine and Animal, Institute for Biological Research in
      the Tropics, University of Cordoba, Colombia.
FAU - Oviedo, Teresa
AU  - Oviedo T
AD  - University of Cordoba, Colombia.
FAU - Mattar, Salim
AU  - Mattar S
AD  - Faculty of Veterinary Medicine and Animal, Institute of Biological Research of
      the Tropics, University of Cordoba, Colombia.
FAU - Castaneda, Jose
AU  - Castaneda J
AD  - ICA Diagnostic Center - Cordoba, Colombia.
FAU - Rodriguez, Virginia
AU  - Rodriguez V
AD  - Faculty of Health Sciences, University of Cordoba, Colombia.
FAU - Moraes Figueiredo, Luiz Tadeu
AU  - Moraes Figueiredo LT
AD  - Center for Virological Research, University of Sao Paulo, Riberao Preto, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200316
PL  - India
TA  - Vet World
JT  - Veterinary world
JID - 101504872
PMC - PMC7183472
OTO - NOTNLM
OT  - Alphavirus infections
OT  - Chiroptera
OT  - pathology
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:01
CRDT- 2020/05/06 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:01 [medline]
AID - 10.14202/vetworld.2020.495-501 [doi]
AID - Vetworld-13-495 [pii]
PST - ppublish
SO  - Vet World. 2020 Mar;13(3):495-501. doi: 10.14202/vetworld.2020.495-501. Epub 2020
      Mar 16.


PMID- 32367775
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Aug
TI  - Discharge policies for homeless people and immigrants: Compromising professional 
      ethics.
PG  - 1355-1363
LID - 10.1177/0969733020912518 [doi]
AB  - Discharging a homeless patient from hospital raises ethical issues which are
      compounded when the patient is from outside the United Kingdom. This article
      begins with an extended case study of a 30-year-old homeless man from Lithuania
      describing his complex medical and social needs. It is best practice for all
      homeless patients to have their housing needs planned for prior to discharge, but
      this is made more difficult by the United Kingdom's 'hostile environment' policy 
      which creates a subclass of homeless people who are not eligible for support.
      This means healthcare professionals discharge patients back to homelessness, even
      when this is likely to adversely affect their health and dignity both directly
      and indirectly through impairing access to care for chronic conditions. Policies 
      in health and social care which compel professionals to treat some patients with 
      second-class care undermine the ethics of healthcare professions.
FAU - Hodson, Nathan
AU  - Hodson N
AUID- ORCID: https://orcid.org/0000-0001-6022-2260
AD  - Harvard T.H. Chan School of Public Health, USA.
FAU - Glennerster, Rose
AU  - Glennerster R
AD  - St Christopher's Hospice, UK.
LA  - eng
PT  - Journal Article
DEP - 20200505
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - *Emigrants and Immigrants
MH  - Ethics, Professional
MH  - *Homeless Persons
MH  - Humans
MH  - Male
MH  - Patient Discharge/*standards
MH  - Policy
MH  - United Kingdom
OTO - NOTNLM
OT  - Discharge
OT  - equity
OT  - homelessness
OT  - primary care
OT  - professional ethics
OT  - professionalism
EDAT- 2020/05/06 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1177/0969733020912518 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Aug;27(5):1355-1363. doi: 10.1177/0969733020912518. Epub 2020
      May 5.


PMID- 32367759
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20220417
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Sep
TI  - Personal values among undergraduate nursing students: A cross-sectional study.
PG  - 1461-1471
LID - 10.1177/0969733020914350 [doi]
AB  - BACKGROUND: Personal values influence nursing students' development of
      professional values, which affect professional outcomes, and how nursing students
      react to different situations. Personal values can be shaped by different
      factors, including culture, gender, and age. AIMS: To explore personal values
      held by nursing students, and to verify if and how gender and year of study
      affect nursing students' personal values. RESEARCH DESIGN: A multicenter,
      cross-sectional study was used. PARTICIPANTS AND RESEARCH CONTEXT: The whole
      population of nursing undergraduate students available at the time was recruited 
      from eight centers of two Universities, composing a sample of 947 students.
      Demographic data were collected and it was administered the Portrait Values
      Questionnaire. ETHICAL CONSIDERATIONS: Ethical approval was obtained from the
      Institutional Review Boards of the University of the participating centers.
      FINDINGS: The study sample was mainly composed of young (92.6%, n = 877), female 
      (77.3%, n = 732), Italian (95.8%, n = 907), and unmarried (98.6%, n = 934)
      nursing students. The most important value for nursing students, consistently
      through the years of nursing school, was Self-transcendence, which has the
      motivational emphasis on helping others and selflessness. Then, we found that
      male students had higher levels of Power (p < 0.001) and Achievement (p = 0.031),
      while female students outscored male students in Benevolence (p = 0.005) and
      Security (p = 0.006). Year of study showed no statistically significant
      difference. DISCUSSION: Nursing students express high levels in hetero-directed
      values. Male nursing students, although they choose a stereotypically feminine
      profession, outscored females in stereotypical masculine values such as dominance
      and success. This is the first study that describes the personal value profile of
      undergraduate nursing students, according to the Theory of Basic Human Values,
      and it is a starting point for future research. CONCLUSION: Nursing educators
      might want to consider the findings from this study while guiding students in
      developing awareness for their personal values.
FAU - Luciani, Michela
AU  - Luciani M
AUID- ORCID: https://orcid.org/0000-0001-7598-5658
FAU - Rampoldi, Giulia
AU  - Rampoldi G
AUID- ORCID: https://orcid.org/0000-0003-2908-2735
FAU - Ardenghi, Stefano
AU  - Ardenghi S
AUID- ORCID: https://orcid.org/0000-0002-7057-1269
FAU - Bani, Marco
AU  - Bani M
AD  - 9305University of Milano-Bicocca, Italy.
FAU - Merati, Sandra
AU  - Merati S
AD  - 189743ASST Monza, San Gerardo Hospital, Italy.
FAU - Ausili, Davide
AU  - Ausili D
AD  - 9305University of Milano-Bicocca, Italy.
FAU - Grazia Strepparava, Maria
AU  - Grazia Strepparava M
AUID- ORCID: https://orcid.org/0000-0001-5068-8753
AD  - 9305University of Milano-Bicocca, Italy.
AD  - 189743ASST Monza, San Gerardo Hospital, Italy.
FAU - Di Mauro, Stefania
AU  - Di Mauro S
AD  - 9305University of Milano-Bicocca, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200505
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Analysis of Variance
MH  - Cross-Sectional Studies
MH  - Education, Nursing, Baccalaureate
MH  - Female
MH  - Humans
MH  - Male
MH  - *Social Values
MH  - Students, Nursing/*psychology/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Universities/organization & administration/statistics & numerical data
OTO - NOTNLM
OT  - Basic human values
OT  - medical education
OT  - nursing education
OT  - nursing students
OT  - personal values
OT  - undergraduate student
EDAT- 2020/05/06 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1177/0969733020914350 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Sep;27(6):1461-1471. doi: 10.1177/0969733020914350. Epub 2020
      May 5.


PMID- 32367741
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1740-7753 (Electronic)
IS  - 1740-7745 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Jun
TI  - Cluster over individual randomization: are study design choices appropriately
      justified? Review of a random sample of trials.
PG  - 253-263
LID - 10.1177/1740774519896799 [doi]
AB  - BACKGROUND: Novel rationales for randomizing clusters rather than individuals
      appear to be emerging from the push for more pragmatic trials, for example, to
      facilitate trial recruitment, reduce the costs of research, and improve external 
      validity. Such rationales may be driven by a mistaken perception that choosing
      cluster randomization lessens the need for informed consent. We reviewed a random
      sample of published cluster randomized trials involving only individual-level
      health care interventions to determine (a) the prevalence of reporting a
      rationale for the choice of cluster randomization; (b) the types of explicit, or 
      if absent, apparent rationales for the use of cluster randomization; (c) the
      prevalence of reporting patient informed consent for study interventions; and (d)
      the types of justifications provided for waivers of consent. We considered
      cluster randomized trials for evaluating exclusively the individual-level health 
      care interventions to focus on clinical trials where individual randomization is 
      only theoretically possible and where there is a general expectation of informed 
      consent. METHODS: A random sample of 40 cluster randomized trials were identified
      by implementing a validated electronic search filter in two electronic databases 
      (Ovid MEDLINE and Embase), with two reviewers independently extracting
      information from each trial. Inclusion criteria were the following: primary
      report of a cluster randomized trial, evaluating exclusively an individual-level 
      health care intervention, published between 2007 and 2016, and conducted in
      Canada, the United States, European Union, Australia, or low- and middle-income
      country settings. RESULTS: Twenty-five trials (62.5%, 95% confidence interval =
      47.5%-77.5%) reported an explicit rationale for the use of cluster randomization.
      The most commonly reported rationales were those with logistical or
      administrative convenience (15 trials, 60%) and those that need to avoid
      contamination (13 trials, 52%); five trials (20%) were cited rationales related
      to the push for more pragmatic trials. Twenty-one trials (52.5%, 95% confidence
      interval = 37%-68%) reported written informed consent for the intervention, two
      (5%) reported verbal consent, and eight (20%) reported waivers of consent, while 
      in nine trials (22.5%) consent was unclear or not mentioned. Reported
      justifications for waivers of consent included that study interventions were
      already used in clinical practice, patients were not randomized individually, and
      the need to facilitate the pragmatic nature of the trial. Only one trial reported
      an explicit and appropriate justification for waiver of consent based on minimum 
      criteria in international research ethics guidelines, namely, infeasibility and
      minimal risk. CONCLUSION: Rationales for adopting cluster over individual
      randomization and for adopting consent waivers are emerging, related to the need 
      to facilitate pragmatic trials. Greater attention to clear reporting of study
      design rationales, informed consent procedures, as well as justification for
      waivers is needed to ensure that such trials meet appropriate ethical standards.
FAU - Taljaard, Monica
AU  - Taljaard M
AUID- ORCID: 0000-0002-3978-8961
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The
      Ottawa Hospital, Ottawa, ON, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
FAU - Goldstein, Cory E
AU  - Goldstein CE
AUID- ORCID: 0000-0002-0229-5039
AD  - Rotman Institute of Philosophy, Western University, London, ON, Canada.
FAU - Giraudeau, Bruno
AU  - Giraudeau B
AD  - Universite de Tours, Universite de Nantes, INSERM, SPHERE U1246, Tours, France.
AD  - INSERM CIC1415, CHRU de Tours, Tours, France.
FAU - Nicholls, Stuart G
AU  - Nicholls SG
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The
      Ottawa Hospital, Ottawa, ON, Canada.
FAU - Carroll, Kelly
AU  - Carroll K
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The
      Ottawa Hospital, Ottawa, ON, Canada.
FAU - Hey, Spencer Phillips
AU  - Hey SP
AD  - Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,
      Brigham and Women's Hospital, Boston, MA, USA.
AD  - Center for Bioethics, Harvard Medical School, Boston, MA, USA.
FAU - Brehaut, Jamie C
AU  - Brehaut JC
AUID- ORCID: 0000-0002-4213-1143
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The
      Ottawa Hospital, Ottawa, ON, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
FAU - Jairath, Vipul
AU  - Jairath V
AD  - Division of Gastroenterology, Department of Medicine, Western University, London,
      ON, Canada.
AD  - Division of Epidemiology and Biostatistics, University Hospital, Western
      University, London, ON, Canada.
FAU - London, Alex John
AU  - London AJ
AUID- ORCID: 0000-0002-6450-0309
AD  - Department of Philosophy and Center for Ethics and Policy, Carnegie Mellon
      University, Pittsburgh, PA, USA.
FAU - Eldridge, Sandra M
AU  - Eldridge SM
AD  - Centre for Primary Care and Public Health, Queen Mary University of London,
      London, UK.
FAU - Grimshaw, Jeremy M
AU  - Grimshaw JM
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The
      Ottawa Hospital, Ottawa, ON, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
AD  - Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
FAU - Fergusson, Dean A
AU  - Fergusson DA
AD  - Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The
      Ottawa Hospital, Ottawa, ON, Canada.
AD  - School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON,
      Canada.
AD  - Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
FAU - Weijer, Charles
AU  - Weijer C
AD  - Rotman Institute of Philosophy, Western University, London, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200505
PL  - England
TA  - Clin Trials
JT  - Clinical trials (London, England)
JID - 101197451
SB  - IM
MH  - Australia
MH  - Canada
MH  - Cluster Analysis
MH  - Ethics, Research
MH  - Europe
MH  - Humans
MH  - Informed Consent/*ethics/statistics & numerical data
MH  - Pragmatic Clinical Trials as Topic/ethics
MH  - Prevalence
MH  - Randomized Controlled Trials as Topic/*ethics/statistics & numerical data
MH  - *Research Design
MH  - United States
OTO - NOTNLM
OT  - *Cluster randomized trials
OT  - *informed consent
OT  - *pragmatic trials
OT  - *research ethics review
OT  - *waivers of consent
EDAT- 2020/05/06 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1177/1740774519896799 [doi]
PST - ppublish
SO  - Clin Trials. 2020 Jun;17(3):253-263. doi: 10.1177/1740774519896799. Epub 2020 May
      5.


PMID- 32367393
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210608
IS  - 1438-8359 (Electronic)
IS  - 0913-8668 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Aug
TI  - Comparison of the standard and triple airway maneuvering techniques for i-gel
      placement in patients undergoing elective surgery: a randomized controlled study.
PG  - 512-518
LID - 10.1007/s00540-020-02780-0 [doi]
AB  - PURPOSE: The i-gel is a supraglottic airway device with non-inflatable cuff which
      can suffer insertion failure if its standard placement technique is implemented. 
      The aim of this study was to compare the placement technique proposed by the
      manufacturer of i-gel with the triple airway maneuver in terms of successful
      device insertion time and first-attempt success. METHODS: After ethics committee 
      approval, 103 ASA I-III patients were randomly allocated to the standard or
      triple airway maneuver groups. In the standard Group, the i-gel was inserted in
      the sniffing position while, in the triple group, it was inserted using the
      triple airway maneuver consisting of head tilt, jaw thrust, and open mouth. The
      time taken for successful insertion, first-attempt success rate, i-gel position, 
      airway complications, and hemodynamic responses were assessed. RESULTS: Between
      the two groups patient characteristics were similar. Time for successful
      insertion was significantly shorter in the triple group (20 +/- 7 s) than with
      the standard technique (32 +/- 11 s; p < 0.001). Successful insertion at the
      first attempt was 78% and 92% for the standard and triple group, respectively (p 
      = 0.092). The i-gel position, airway complications, and hemodynamic responses
      were similar in both groups. CONCLUSION: The triple airway maneuver required less
      i-gel insertion time as compared with the standard placement technique.
      First-attempt success rates were similar with both techniques, although the
      triple airway maneuver was superior to the standard method as a rescue technique 
      in failed insertions. We therefore recommend use of the triple airway maneuver in
      i-gel insertion.
FAU - Baran Akkus, Ilkay
AU  - Baran Akkus I
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Omer Halisdemir
      Str, 06110, Diskapi- Altindag, Ankara, Turkey. ilkayb@hotmail.com.
FAU - Kavak Akelma, Fatma
AU  - Kavak Akelma F
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Omer Halisdemir
      Str, 06110, Diskapi- Altindag, Ankara, Turkey.
FAU - Emlek, Merve
AU  - Emlek M
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Omer Halisdemir
      Str, 06110, Diskapi- Altindag, Ankara, Turkey.
FAU - Ozkan, Derya
AU  - Ozkan D
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Omer Halisdemir
      Str, 06110, Diskapi- Altindag, Ankara, Turkey.
FAU - Ergil, Julide
AU  - Ergil J
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Omer Halisdemir
      Str, 06110, Diskapi- Altindag, Ankara, Turkey.
FAU - Polat, Reyhan
AU  - Polat R
AD  - Department of Anesthesiology and Reanimation, University of Health Sciences,
      Diskapi Yildirim Beyazit Trainig and Research Hospital, Sehit Omer Halisdemir
      Str, 06110, Diskapi- Altindag, Ankara, Turkey.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200504
PL  - Japan
TA  - J Anesth
JT  - Journal of anesthesia
JID - 8905667
SB  - IM
MH  - Anesthesia, General
MH  - Elective Surgical Procedures
MH  - Humans
MH  - Intubation, Intratracheal
MH  - *Laryngeal Masks
MH  - Reference Standards
OTO - NOTNLM
OT  - *I-gel
OT  - *Insertion
OT  - *Triple airway maneuver
EDAT- 2020/05/06 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1007/s00540-020-02780-0 [doi]
AID - 10.1007/s00540-020-02780-0 [pii]
PST - ppublish
SO  - J Anesth. 2020 Aug;34(4):512-518. doi: 10.1007/s00540-020-02780-0. Epub 2020 May 
      4.


PMID- 32366705
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Ethics of instantaneous contact tracing using mobile phone apps in the control of
      the COVID-19 pandemic.
PG  - 427-431
LID - 10.1136/medethics-2020-106314 [doi]
AB  - In this paper we discuss ethical implications of the use of mobile phone apps in 
      the control of the COVID-19 pandemic. Contact tracing is a well-established
      feature of public health practice during infectious disease outbreaks and
      epidemics. However, the high proportion of pre-symptomatic transmission in
      COVID-19 means that standard contact tracing methods are too slow to stop the
      progression of infection through the population. To address this problem, many
      countries around the world have deployed or are developing mobile phone apps
      capable of supporting instantaneous contact tracing. Informed by the on-going
      mapping of 'proximity events' these apps are intended both to inform public
      health policy and to provide alerts to individuals who have been in contact with 
      a person with the infection. The proposed use of mobile phone data for
      'intelligent physical distancing' in such contexts raises a number of important
      ethical questions. In our paper, we outline some ethical considerations that need
      to be addressed in any deployment of this kind of approach as part of a
      multidimensional public health response. We also, briefly, explore the
      implications for its use in future infectious disease outbreaks.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Parker, Michael J
AU  - Parker MJ
AD  - Wellcome Centre for Ethics and the Humanities and Ethox Centre,The Ethox Centre, 
      Nuffield Department of Population Health, University of Oxford, Oxford, UK
      michael.parker@ethox.ox.ac.uk.
FAU - Fraser, Christophe
AU  - Fraser C
AD  - Big Data Institute, University of Oxford, Oxford, UK.
AD  - Wellcome Centre for Human Genomics, University of Oxford, Oxford, UK.
FAU - Abeler-Dorner, Lucie
AU  - Abeler-Dorner L
AD  - Big Data Institute, University of Oxford, Oxford, UK.
FAU - Bonsall, David
AU  - Bonsall D
AD  - Big Data Institute, University of Oxford, Oxford, UK.
AD  - Oxford University NHS Trust, University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - *Cell Phone
MH  - Communicable Disease Control/methods
MH  - Contact Tracing/*ethics/*methods
MH  - Coronavirus Infections/*epidemiology
MH  - Freedom
MH  - Humans
MH  - Mobile Applications
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Privacy
MH  - SARS-CoV-2
MH  - Trust
PMC - PMC7231546
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/06 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - medethics-2020-106314 [pii]
AID - 10.1136/medethics-2020-106314 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):427-431. doi: 10.1136/medethics-2020-106314. Epub
      2020 May 4.


PMID- 32366704
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Remote monitoring of medication adherence and patient and industry
      responsibilities in a learning health system.
PG  - 386-391
LID - 10.1136/medethics-2019-105667 [doi]
AB  - A learning health system (LHS) seeks to establish a closer connection between
      clinical care and research and establishes new responsibilities for healthcare
      providers as well as patients. A new set of technological approaches in
      medication adherence monitoring can potentially yield valuable data within an
      LHS, and raises the question of the scope and limitations of patients'
      responsibilities to use them. We argue here that, in principle, it is plausible
      to suggest that patients have a prima facie obligation to use novel adherence
      monitors. However, the strength of the obligations depends considerably on the
      extent to which data that adherence monitors generate are, in fact, used to
      further the goals of LHSs. The way in which data ownership is structured in the
      USA poses a considerable challenge here, while the European Union framework
      offers a more promising alternative.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Kim, Junhewk
AU  - Kim J
AUID- ORCID: 0000-0002-9109-270X
AD  - Dental Education Research Center, College of Dentistry, Yonsei University, Seoul,
      Seodaemun-gu, Republic of Korea.
FAU - Kassels, Austin Connor
AU  - Kassels AC
AD  - Medical Ethics and Health Policy, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - School of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
FAU - Costin, Nathaniel Isaac
AU  - Costin NI
AUID- ORCID: 0000-0003-3858-1851
AD  - Medical Ethics and Health Policy, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - Hackensack Meridian School of Medicine, Seton Hall University, Nutley, New
      Jersey, USA.
FAU - Schmidt, Harald
AU  - Schmidt H
AD  - Medical Ethics and Health Policy, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA schmidth@upenn.edu.
LA  - eng
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Health Personnel
MH  - Humans
MH  - *Learning Health System
MH  - Medication Adherence
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *behaviour modification
OT  - *ethics
OT  - *health promotion
OT  - *information technology
COIS- Competing interests: None declared.
EDAT- 2020/05/06 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/06/29 00:00 [received]
PHST- 2020/02/10 00:00 [revised]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - medethics-2019-105667 [pii]
AID - 10.1136/medethics-2019-105667 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):386-391. doi: 10.1136/medethics-2019-105667. Epub
      2020 May 4.


PMID- 32366703
OWN - NLM
STAT- Publisher
LR  - 20210507
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 May 4
TI  - Blockchain, consent and prosent for medical research.
LID - medethics-2019-105963 [pii]
LID - 10.1136/medethics-2019-105963 [doi]
AB  - Recent advances in medical and information technologies, the availability of new 
      types of medical data, the requirement of increasing numbers of study
      participants, as well as difficulties in recruitment and retention, all present
      serious problems for traditional models of specific and informed consent to
      medical research. However, these advances also enable novel ways to securely
      share and analyse data. This paper introduces one of these advances-blockchain
      technologies-and argues that they can be used to share medical data in a secure
      and auditable fashion. In addition, some aspects of consent and data collection, 
      as well as data access management and analysis, can be automated using
      blockchain-based smart contracts. This paper demonstrates how blockchain
      technologies can be used to further all three of the bioethical principles
      underlying consent requirements: the autonomy of patients, by giving them much
      greater control over their data; beneficence, by greatly facilitating medical
      research efficiency and by reducing biases and opportunities for errors; and
      justice, by enabling patients with rare or under-researched conditions to
      pseudonymously aggregate their data for analysis. Finally, we coin and describe
      the novel concept of prosent, by which we mean the blockchain-enabled ability of 
      all stakeholders in the research process to pseudonymously and proactively
      consent to data release or exchange under specific conditions, such as trial
      completion.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Porsdam Mann, Sebastian
AU  - Porsdam Mann S
AD  - Department of Communication, University of Copenhagen Faculty of Humanities,
      Kobenhavn, Denmark sebastian.porsdammann@philosophy.ox.ac.uk.
AD  - Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
FAU - Savulescu, Julian
AU  - Savulescu J
AD  - Faculty of Philosophy, Oxford Uehiro Centre for Practical Ethics, Oxford, UK.
FAU - Ravaud, Philippe
AU  - Ravaud P
AD  - Mailman School of Public Health, Columbia University, New York, New York, USA.
AD  - Clinical Epidemiology, Universite Paris Descartes Faculte de Medecine, Paris,
      Ile-de-France, France.
FAU - Benchoufi, Mehdi
AU  - Benchoufi M
AD  - Clinical Epidemiology, Universite Paris Descartes Faculte de Medecine, Paris,
      Ile-de-France, France.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8053330
OTO - NOTNLM
OT  - autonomy
OT  - confidentiality/privacy
OT  - information technology
OT  - informed consent
OT  - public health ethics
COIS- Competing interests: SPM reports grants from Carlsberg Foundation, during the
      conduct of the study; and is a co-founder of A&BC Consulting, which offers
      editing and academic consulting services. JS reports grants from Wellcome Trust, 
      grants from Uehiro Foundation on Ethics and Education, grants from Murdoch
      Children's Research Institute, grants from Melbourne Law School, during the
      conduct of the study; grants from Wellcome Trust, grants from Oxford Martin
      School, personal fees and other from Various, outside the submitted work. PR has 
      nothing to disclose. MB reports non-financial support from SunnyLake, outside the
      submitted work.
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - medethics-2019-105963 [pii]
AID - 10.1136/medethics-2019-105963 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 May 4. pii: medethics-2019-105963. doi:
      10.1136/medethics-2019-105963.


PMID- 32366702
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 10
DP  - 2020 Oct
TI  - Paediatric deep brain stimulation: ethical considerations in malignant Tourette
      syndrome.
PG  - 668-673
LID - 10.1136/medethics-2020-106074 [doi]
AB  - Gilles de la Tourette syndrome (TS) is a childhood neuropsychiatric disorder
      characterised by the presence of motor and vocal tics. Patients with malignant TS
      experience severe disease sequelae; risking morbidity and mortality due to tics, 
      self-harm, psychiatric comorbidities and suicide. By definition, those cases
      termed 'malignant' are refractory to all conventional psychiatric and
      pharmacological regimens. In these instances, deep brain stimulation (DBS) may be
      efficacious. Current 2015 guidelines recommend a 6-month period absent of
      suicidal ideation before DBS is offered to patients with TS. We therefore
      wondered whether it may be ethically justifiable to offer DBS to a minor with
      malignant TS. We begin with a discussion of non-maleficence and beneficence. New 
      evidence suggests that suicide risk in young patients with TS has been
      underestimated. In turn, DBS may represent an invaluable opportunity for children
      with malignant TS to secure future safety, independence and fulfilment.
      Postponing treatment is associated with additional risks. Ultimately, we assert
      this unique risk-benefit calculus justifies offering DBS to paediatric patients
      with malignant TS. A multidisciplinary team of clinicians must determine whether 
      DBS is in the best interest of their individual patients. We conclude with a
      suggestion for future TS-DBS guidelines regarding suicidal ideation. The
      importance of informed consent and assent is underscored.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Behmer Hansen, Rosemary T
AU  - Behmer Hansen RT
AUID- ORCID: 0000-0002-6335-7627
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark,
      New Jersey, USA.
FAU - Dubey, Arjun
AU  - Dubey A
AD  - School of Medicine, The University of Notre Dame Australia, Fremantle, Western
      Australia, Australia.
FAU - Smith, Cynthia
AU  - Smith C
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark,
      New Jersey, USA.
FAU - Henry, Patrick J
AU  - Henry PJ
AUID- ORCID: 0000-0002-5690-7539
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark,
      New Jersey, USA.
FAU - Mammis, Antonios
AU  - Mammis A
AD  - Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark,
      New Jersey, USA mammisan@njms.rutgers.edu.
LA  - eng
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Child
MH  - Comorbidity
MH  - *Deep Brain Stimulation
MH  - Forecasting
MH  - Humans
MH  - Morals
MH  - *Tourette Syndrome/therapy
OTO - NOTNLM
OT  - *clinical ethics
OT  - *deep brain stimulation
OT  - *informed consent
OT  - *minors/parental consent
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/05/06 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/02/29 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - medethics-2020-106074 [pii]
AID - 10.1136/medethics-2020-106074 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Oct;46(10):668-673. doi: 10.1136/medethics-2020-106074. Epub
      2020 May 4.


PMID- 32366610
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20201218
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 146
IP  - 1
DP  - 2020 Jul
TI  - The Ethics of Creating a Resource Allocation Strategy During the COVID-19
      Pandemic.
LID - e20201243 [pii]
LID - 10.1542/peds.2020-1243 [doi]
AB  - The coronavirus disease 2019 pandemic has affected nearly every aspect of
      medicine and raises numerous moral dilemmas for clinicians. Foremost of these
      quandaries is how to delineate and implement crisis standards of care and,
      specifically, how to consider how health care resources should be distributed in 
      times of shortage. We review basic principles of disaster planning and resource
      stewardship with ethical relevance for this and future public health crises,
      explore the role of illness severity scoring systems and their limitations and
      potential contribution to health disparities, and consider the role for
      exceptionally resource-intensive interventions. We also review the philosophical 
      and practical underpinnings of crisis standards of care and describe historical
      approaches to scarce resource allocation to offer analysis and guidance for
      pediatric clinicians. Particular attention is given to the impact on children of 
      this endeavor. Although few children have required hospitalization for
      symptomatic infection, children nonetheless have the potential to be profoundly
      affected by the strain on the health care system imposed by the pandemic and
      should be considered prospectively in resource allocation frameworks.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Laventhal, Naomi
AU  - Laventhal N
AD  - Department of Pediatrics, Medical School, University of Michigan, Ann Arbor,
      Michigan; naomilav@med.umich.edu.
FAU - Basak, Ratna
AU  - Basak R
AD  - Brookdale University Hospital Medical Center, Brooklyn, New York.
FAU - Dell, Mary Lynn
AU  - Dell ML
AD  - Departments of Psychiatry and Pediatrics, College of Medicine, The Ohio State
      University, Columbus, Ohio.
FAU - Diekema, Douglas
AU  - Diekema D
AD  - Department of Pediatrics, School of Medicine, University of Washington, Seattle, 
      Washington.
FAU - Elster, Nanette
AU  - Elster N
AD  - Neiswanger Institute for Bioethics and Healthcare Leadership, Stritch School of
      Medicine, Loyola University Chicago, Chicago, Illinois.
FAU - Geis, Gina
AU  - Geis G
AD  - Bernard and Millie Duker Children's Hospital, Albany Medical College, Albany, New
      York.
FAU - Mercurio, Mark
AU  - Mercurio M
AD  - Department of Pediatrics, School of Medicine, Yale University, New Haven,
      Connecticut.
FAU - Opel, Douglas
AU  - Opel D
AD  - Department of Pediatrics, School of Medicine, University of Washington, Seattle, 
      Washington.
FAU - Shalowitz, David
AU  - Shalowitz D
AD  - Department of Obstetrics and Gynecology, School of Medicine, Wake Forest
      University, Winston-Salem, North Carolina.
FAU - Statter, Mindy
AU  - Statter M
AD  - Dpartment of Surgery, Albert Einstein College of Medicine, Bronx, New York; and.
FAU - Macauley, Robert
AU  - Macauley R
AD  - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200504
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/therapy
MH  - Delivery of Health Care/ethics/methods
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pediatrics/*ethics/methods
MH  - Pneumonia, Viral/therapy
MH  - Resource Allocation/*ethics/methods
MH  - SARS-CoV-2
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/05/06 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - peds.2020-1243 [pii]
AID - 10.1542/peds.2020-1243 [doi]
PST - ppublish
SO  - Pediatrics. 2020 Jul;146(1). pii: peds.2020-1243. doi: 10.1542/peds.2020-1243.
      Epub 2020 May 4.


PMID- 32366459
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 96
IP  - 1137
DP  - 2020 Jul
TI  - Regaining balance during 'reality vertigo': six insights gleaned from the
      front-line to manage pandemic-related anxiety.
PG  - 369-370
LID - 10.1136/postgradmedj-2020-137825 [doi]
FAU - Allespach, Heidi
AU  - Allespach H
AUID- ORCID: 0000-0003-4949-2256
AD  - Family Medicine, Medicine & Surgery, University of Miami School of Medicine,
      Miami, Florida, USA h.allespach@med.miami.edu.
FAU - Diaz, Yvonne
AU  - Diaz Y
AD  - Jackson Memorial Hospital, Miami, Florida, USA.
AD  - Medicine, University of Miami School of Medicine, Miami, Florida, USA.
FAU - St Onge, Joan E
AU  - St Onge JE
AD  - Medicine, Faculty Affairs, University of Miami School of Medicine, Miami,
      Florida, USA.
AD  - Graduate Medical Education, Jackson Memorial Hospital, Miami, Florida, USA.
LA  - eng
PT  - Editorial
DEP - 20200504
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
SB  - IM
MH  - *Anxiety/prevention & control/psychology
MH  - COVID-19/*psychology
MH  - Emotional Intelligence/*ethics
MH  - Humans
MH  - Life Change Events
MH  - *Physicians/ethics/psychology
MH  - Psychological Distress
MH  - SARS-CoV-2
MH  - Self-Control/*psychology
MH  - Social Interaction
MH  - *Uncertainty
OTO - NOTNLM
OT  - *medical education & training
OT  - *medical ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/06 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/04/05 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - postgradmedj-2020-137825 [pii]
AID - 10.1136/postgradmedj-2020-137825 [doi]
PST - ppublish
SO  - Postgrad Med J. 2020 Jul;96(1137):369-370. doi: 10.1136/postgradmedj-2020-137825.
      Epub 2020 May 4.


PMID- 32366376
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20220429
IS  - 1477-9129 (Electronic)
IS  - 0950-1991 (Linking)
VI  - 147
IP  - 9
DP  - 2020 May 4
TI  - Once upon a dish: engineering multicellular systems.
LID - dev188573 [pii]
LID - 10.1242/dev.188573 [doi]
AB  - In February 2020, the European Molecular Biology Laboratory (EMBL) and the
      Institute for Bioengineering of Catalonia (IBEC) joined forces to unite
      researchers from all over the globe to discuss emerging topics in 'Engineering
      Multicellular Systems'. As we review here, key themes that arose throughout the
      meeting included the ethics of organoids in developmental biology, bottom-up
      versus top-down models, tissue organizing principles, and the future of improving
      these systems to better mimic the natural world.
CI  - (c) 2020. Published by The Company of Biologists Ltd.
FAU - Haase, Kristina
AU  - Haase K
AUID- ORCID: 0000-0003-3321-4286
AD  - EMBL Barcelona, Carrer/Dr. Aiguader 88, Barcelona 08003, Spain
      kristina.haase@embl.es benof@uw.edu.
FAU - Freedman, Benjamin S
AU  - Freedman BS
AUID- ORCID: 0000-0003-2228-7383
AD  - Division of Nephrology, Kidney Research Institute, and Institute for Stem Cell
      and Regenerative Medicine, Department of Pathology (Adjunct), and Department of
      Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA
      kristina.haase@embl.es benof@uw.edu.
LA  - eng
GR  - UG3 TR003288/TR/NCATS NIH HHS/United States
GR  - U01 EB028892/EB/NIBIB NIH HHS/United States
GR  - R01 DK117914/DK/NIDDK NIH HHS/United States
GR  - UG3 TR002158/TR/NCATS NIH HHS/United States
GR  - U01 DK127553/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200504
PL  - England
TA  - Development
JT  - Development (Cambridge, England)
JID - 8701744
SB  - IM
MH  - Animals
MH  - Bioengineering/*methods
MH  - Developmental Biology/methods
MH  - Humans
MH  - Organoids
MH  - Synthetic Biology/*methods
MH  - Tissue Engineering/methods
OTO - NOTNLM
OT  - *Embryoids
OT  - *Morphogenesis
OT  - *Organ-on-chip
OT  - *Patterning
OT  - *Signaling
OT  - *Synthetic embryos
OT  - *Vascularization
COIS- Competing interestsDr Freedman is an inventor on patent applications related to
      kidney organoids and is an advisor for Chinook Therapeutics. The authors declare 
      no other competing or financial interests.
EDAT- 2020/05/06 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
AID - 147/9/dev188573 [pii]
AID - 10.1242/dev.188573 [doi]
PST - epublish
SO  - Development. 2020 May 4;147(9). pii: 147/9/dev188573. doi: 10.1242/dev.188573.


PMID- 32366288
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20200917
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 4
TI  - Impact of Erythropoietin in the management of Hypoxic Ischaemic Encephalopathy in
      resource-constrained settings: protocol for a randomized control trial.
PG  - 171
LID - 10.1186/s12883-020-01751-y [doi]
AB  - BACKGROUND: Perinatal asphyxia, more appropriately known as hypoxic-ischemic
      encephalopathy (HIE), is a condition characterized by clinical and laboratory
      evidence of acute or sub-acute brain injury resulting from systemic hypoxemia
      and/or reduced cerebral blood flow. HIE is a common and devastating clinical
      condition in resource-poor countries with poor treatment outcome. This paper
      describes the protocol for an ongoing study that aims to evaluate the
      neuroprotective effects of Erythropoietin (EPO) as compared to routine care in
      the management of moderate to severe HIE among term infants. METHODS: This study 
      is a double-blind randomized controlled trial that will be conducted in the
      neonatal wards of the Lagos University Teaching Hospital (LUTH), Lagos, Nigeria, 
      over a two-year period after ethical approvals and consents. One hundred and
      twenty-eight term newborns (>/= 37 weeks gestation) diagnosed with moderate/
      severe HIE at admission will be allocated by randomization to receive either EPO 
      or normal saline. All the participants will be offered standard care according to
      the unit protocol for HIE. Baseline investigations and close monitoring of the
      babies are done until discharge. Participants are followed up for 2 years to
      monitor their outcome (death or neurological development) using standard
      instruments. DISCUSSION: Previous trials had shown that EPO confers
      neuroprotective benefits and improve neurological and behavioral outcome in
      infants with HIE both singly or as an adjuvant to therapeutic hypothermia. This
      study hypothesized that administering EPO to newborns with moderate /severe HIE
      can positively influence their clinical and neurological outcomes and will
      provide evidence to either support or disprove the usefulness of Erythropoietin
      as a sole agent in the treatment of HIE, especially in resource-limited
      environment with the highest burden of the disease. TRIAL REGISTRATION: The study
      has been registered with the Pan African Clinical trials registry on the 2nd of
      December 2018, with registration number PACTR201812814507775.
FAU - Ezenwa, Beatrice
AU  - Ezenwa B
AUID- ORCID: http://orcid.org/0000-0001-7437-3211
AD  - Neonatology unit, Department of Paediatrics, College of Medicine University of
      Lagos, Lagos, Nigeria. beatriceezenwa@yahoo.com.
AD  - Department of Paediatrics, Lagos University Teaching Hospital, Lagos, Nigeria.
      beatriceezenwa@yahoo.com.
FAU - Ezeaka, Chinyere
AU  - Ezeaka C
AD  - Neonatology unit, Department of Paediatrics, College of Medicine University of
      Lagos, Lagos, Nigeria.
AD  - Department of Paediatrics, Lagos University Teaching Hospital, Lagos, Nigeria.
FAU - Fajolu, Iretiola
AU  - Fajolu I
AD  - Neonatology unit, Department of Paediatrics, College of Medicine University of
      Lagos, Lagos, Nigeria.
AD  - Department of Paediatrics, Lagos University Teaching Hospital, Lagos, Nigeria.
FAU - Ogbenna, Anne
AU  - Ogbenna A
AD  - Department of Haematology & Blood transfusion, College of Medicine University of 
      Lagos, Lagos, Nigeria.
FAU - Olowoyeye, Omodele
AU  - Olowoyeye O
AD  - Department of Radiodiagnosis, College of Medicine University of Lagos, Lagos,
      Nigeria.
FAU - Nwaiwu, Obiyo
AU  - Nwaiwu O
AD  - Department of Pharmacology, Therapeutics &Toxicology, College of Medicine
      University of Lagos, Lagos, Nigeria.
FAU - Opoola, Zainab
AU  - Opoola Z
AD  - Department of Paediatrics, Lagos University Teaching Hospital, Lagos, Nigeria.
FAU - Olorunfemi, Gbenga
AU  - Olorunfemi G
AD  - Division of Epidemiology and Biostatistics, School of Public Health, University
      of Witwatersrand, Johannesburg, South Africa.
LA  - eng
GR  - 2019/05/University of Lagos Central Research Committee grant
PT  - Clinical Trial Protocol
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (EPO protein, human)
RN  - 0 (Neuroprotective Agents)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Asphyxia Neonatorum/*drug therapy
MH  - Brain Injuries/therapy
MH  - Cerebrovascular Circulation
MH  - Double-Blind Method
MH  - Erythropoietin/*therapeutic use
MH  - Humans
MH  - Hypoxia-Ischemia, Brain/*drug therapy
MH  - Infant, Newborn
MH  - Neuroprotection
MH  - Neuroprotective Agents/therapeutic use
MH  - Nigeria
MH  - Outcome Assessment, Health Care
MH  - Randomized Controlled Trials as Topic
PMC - PMC7199320
OTO - NOTNLM
OT  - EPO and neurodevelopment
OT  - Hypoxic-ischemic encephalopathy
OT  - Perinatal asphyxia
EDAT- 2020/05/06 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - 10.1186/s12883-020-01751-y [doi]
AID - 10.1186/s12883-020-01751-y [pii]
PST - epublish
SO  - BMC Neurol. 2020 May 4;20(1):171. doi: 10.1186/s12883-020-01751-y.


PMID- 32366270
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 4
TI  - How do older adults understand and manage distress? A qualitative study.
PG  - 77
LID - 10.1186/s12875-020-01152-7 [doi]
AB  - BACKGROUND: Distress is an expected emotional response to a negative life event. 
      Experiences common in later life may trigger distress such as bereavement or loss
      of physical mobility. Distress is considered to be distinct to anxiety and/or
      depression and is not diagnostically labelled as a mental health problem. Older
      adults will often manage their own distress. Previous literature has focused on
      how younger adults self-manage mental health problems, however little research
      has explored the self-management strategies used by older people. There is a need
      to clarify the role of primary care in the context of distressed older adults who
      may consult healthcare services. This study seeks to address these gaps through
      qualitative methods. METHODS: Keele University's ethical review panel approved
      this study. We recruited older adults who self-identified as distressed from
      community groups in North Staffordshire, England. Data were generated through
      semi-structured interviews and analysed thematically using constant comparison
      methods. A patient and public involvement and engagement group contributed to
      development of the research questions and methods, and offered their perspectives
      on the findings. RESULTS: After 18 interviews data saturation was achieved. Key
      themes were: experiences of distress, actions taken, help-seeking from healthcare
      services and perceptions of treatments offered in primary care. Various forms of 
      loss contributed to participants' distress. Participants initiated their own
      self-management strategies which included: pursuing independent activities,
      seeking social support and attending community groups and church. Five
      participants reported having consulted a GP when distressed but described a lack 
      of acceptable treatments offered. CONCLUSIONS: To support older adults who are
      distressed, healthcare professionals in primary care should consider exploring
      how patients currently manage their mood problems, provide a broad range of
      information about potential management options and consider sign-posting older
      adults to community resources.
FAU - Moult, Alice
AU  - Moult A
AUID- ORCID: 0000-0002-9424-5660
AD  - Keele Medical School, Keele University, Staffordshire, ST5 5BG, UK.
      a.moult@keele.ac.uk.
FAU - Kingstone, Tom
AU  - Kingstone T
AD  - School of Primary, Community and Social Care, Keele University, Staffordshire,
      ST5 5BG, UK.
AD  - Midlands Partnership NHS Foundation Trust, Stafford, ST16 3SR, UK.
FAU - Chew-Graham, Carolyn A
AU  - Chew-Graham CA
AD  - School of Primary, Community and Social Care, Keele University, Staffordshire,
      ST5 5BG, UK.
AD  - Applied Research Collaboration (ARC) West Midlands, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200504
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
SB  - IM
MH  - Activities of Daily Living/psychology
MH  - Aged
MH  - Aged, 80 and over
MH  - Anxiety
MH  - Female
MH  - Humans
MH  - Male
MH  - *Psychological Distress
MH  - Qualitative Research
MH  - Social Isolation/psychology
MH  - *Social Support
PMC - PMC7199345
OTO - NOTNLM
OT  - *Distress
OT  - *General practitioner
OT  - *Mental health
OT  - *Older adults
OT  - *Primary care
OT  - *Self-management
EDAT- 2020/05/06 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.1186/s12875-020-01152-7 [doi]
AID - 10.1186/s12875-020-01152-7 [pii]
PST - epublish
SO  - BMC Fam Pract. 2020 May 4;21(1):77. doi: 10.1186/s12875-020-01152-7.


PMID- 32366227
OWN - NLM
STAT- MEDLINE
DCOM- 20200608
LR  - 20210401
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 4
TI  - Continuous quality monitoring in the field: an evaluation of the performance of
      the Fio Deki Reader for rapid HIV testing in South Africa.
PG  - 320
LID - 10.1186/s12879-020-4932-0 [doi]
AB  - BACKGROUND: Rapid diagnostic tests (RDTs) are a cornerstone of HIV diagnosis and 
      rely on good quality processing and interpretation, particularly in the era of
      test and treat. The Deki Reader (Fio Corporation(R), Toronto, Ontario, Canada) is
      a portable device designed specifically for analysing RDTs and was selected for
      evaluation in South Africa in the context of HIV RDT analysis. METHODS: This
      study consisted of a laboratory evaluation and two-part field evaluation of the
      Deki Reader v100, covering two RDT testing algorithms, and an evaluation of the
      continuous quality monitoring through the Fionet web portal. Based on user
      feedback from the field evaluation, the device underwent hardware and software
      redesign, and the Deki Reader v200 was evaluated in the laboratory. Ethics
      approval for this evaluation was obtained from the University of the
      Witwatersrand Human Research Ethics Committee: M150160. RESULTS: The intra- and
      inter-device laboratory precision of the Deki Reader v100 were 98.3 and 99.2%
      respectively, and 99.3 and 100% for the Deki Reader v200. The laboratory
      concordances compared to standard-of-care reporting were 99.5 and 98.0% for the
      two respective models, while sensitivity and specificity were 99.5 and 99.4% for 
      the Deki Reader V100 and 100 and 93.1% for the Deki Reader V200 respectively.
      Screening and confirmatory concordances in the field were 99.3 and 96.5% under
      algorithm 1 and 99.7 and 100% under algorithm 2. Sensitivity and specificity for 
      the field evaluation were 99.8 and 97.7%. Overall robustness of the device was
      acceptable and continuous quality monitoring through Fionet was feasible.
      CONCLUSIONS: The Deki Reader provides an option for improved and reliable quality
      assessment for rapid diagnosis of HIV using RDTs to enhance the quality of
      healthcare at the point-of-care. However, the introduction of new RDTs and
      modification of current algorithms necessitates ongoing and agile RDT reader
      adjustments, which will require cost modelling to ensure sustainability of
      devices implemented into national HIV programs.
FAU - Noble, Lara
AU  - Noble L
AUID- ORCID: http://orcid.org/0000-0002-4661-9023
AD  - Department of Molecular Medicine and Haematology, School of Pathology, Faculty of
      Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South
      Africa. lara.noble@wits.ac.za.
FAU - Scott, Lesley
AU  - Scott L
AD  - Department of Molecular Medicine and Haematology, School of Pathology, Faculty of
      Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South
      Africa.
FAU - Stewart-Isherwood, Lynsey
AU  - Stewart-Isherwood L
AD  - Department of Molecular Medicine and Haematology, School of Pathology, Faculty of
      Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South
      Africa.
AD  - National Priority Programme, National Health Laboratory Service, Johannesburg,
      Gauteng, South Africa.
AD  - BroadReach Consulting, Johannesburg, Gauteng, South Africa.
FAU - Molifi, Seponono John
AU  - Molifi SJ
AD  - National Priority Programme, National Health Laboratory Service, Johannesburg,
      Gauteng, South Africa.
AD  - Strategic Evaluation Advisory and Development Consulting, Johannesburg, Gauteng, 
      South Africa.
FAU - Sanne, Ian
AU  - Sanne I
AD  - Right to Care, Johannesburg, Gauteng, South Africa.
FAU - Da Silva, Pedro
AU  - Da Silva P
AD  - National Priority Programme, National Health Laboratory Service, Johannesburg,
      Gauteng, South Africa.
FAU - Stevens, Wendy
AU  - Stevens W
AD  - Department of Molecular Medicine and Haematology, School of Pathology, Faculty of
      Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South
      Africa.
AD  - National Priority Programme, National Health Laboratory Service, Johannesburg,
      Gauteng, South Africa.
LA  - eng
GR  - MC_PC_16021/MRC_/Medical Research Council/United Kingdom
GR  - #015NEWTON TB/South African Medical Research Council
GR  - OPP1171455/Bill and Melinda Gates Foundation
GR  - ZAC-C-NDOH/Global Fund to Fight AIDS, Tuberculosis and Malaria (CH)
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
SB  - IM
MH  - AIDS Serodiagnosis/*instrumentation/methods
MH  - Algorithms
MH  - Diagnostic Tests, Routine/*instrumentation/methods
MH  - Enzyme-Linked Immunosorbent Assay/*instrumentation/methods
MH  - HIV Infections/*diagnosis/*epidemiology/virology
MH  - HIV-1/*immunology
MH  - HIV-2/*immunology
MH  - Humans
MH  - Mass Screening/methods
MH  - Mobile Applications
MH  - Point-of-Care Systems
MH  - Prevalence
MH  - Sensitivity and Specificity
MH  - South Africa/epidemiology
PMC - PMC7199324
OTO - NOTNLM
OT  - Automated rapid strip reader
OT  - Continuous quality monitoring
OT  - Deki reader
OT  - HIV
OT  - Rapid diagnostic test
EDAT- 2020/05/06 06:00
MHDA- 2020/06/09 06:00
CRDT- 2020/05/06 06:00
PHST- 2019/04/10 00:00 [received]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
AID - 10.1186/s12879-020-4932-0 [doi]
AID - 10.1186/s12879-020-4932-0 [pii]
PST - epublish
SO  - BMC Infect Dis. 2020 May 4;20(1):320. doi: 10.1186/s12879-020-4932-0.


PMID- 32366131
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20210211
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Linking)
VI  - 18
IP  - 8
DP  - 2020 Aug
TI  - Harnessing the potential of CRISPR-based platforms to advance the field of
      hospital medicine.
PG  - 799-805
LID - 10.1080/14787210.2020.1761333 [doi]
AB  - INTRODUCTION: Clustered regularly interspaced short palindromic repeats (CRISPR) 
      are segments of nucleic acid that play a role in prokaryotic defense and form the
      basis of a genome editing technology that allows permanent alteration of genetic 
      material. This methodology, known as CRISPR-Cas9, is poised to revolutionize
      molecular biology, but no literature yet exists on how these advances will affect
      hospitalists. AREAS COVERED: These specialists in inpatient medicine care for a
      wide variety of hospitalized patients, including those with infectious disease,
      cancer, cardiovascular disease, autoimmune disease, hematologic disease, and a
      variety of other conditions that may soon be impacted by advances in
      gene-modifying technology provided by CRISPR-Cas9. A Literature search was
      performed using PubMed [1 December 2019-17 April 2020]. EXPERT OPINION: This
      paper reviews the remarkable diagnostic and therapeutic potential of the
      CRISPR-Cas9 platform and concludes with a look at ethical issues and technical
      hurdles pertaining to the implementation of permanent gene modification in the
      practice of Hospital Medicine.
FAU - McCarthy, Matthew W
AU  - McCarthy MW
AD  - Weill Cornell Medical College, Division of General Internal Medicine, New
      York-Presbyterian Hospital , New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200504
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *CRISPR-Cas Systems
MH  - Coronavirus Infections/therapy
MH  - Gene Editing/methods
MH  - Genetic Therapy/*methods
MH  - *Hospital Medicine
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/therapy
MH  - SARS-CoV-2
PMC - PMC7212535
OTO - NOTNLM
OT  - *CRISPR-Cas9
OT  - *SARS-CoV-2
OT  - *hospitalist
OT  - *nucleic acid
OT  - *resistance
EDAT- 2020/05/06 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
AID - 10.1080/14787210.2020.1761333 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2020 Aug;18(8):799-805. doi:
      10.1080/14787210.2020.1761333. Epub 2020 May 4.


PMID- 32365928
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 5
DP  - 2020 Apr 30
TI  - Effect of Research Impact on Emerging Camel Husbandry, Welfare and Social-Related
      Awareness.
LID - E780 [pii]
LID - 10.3390/ani10050780 [doi]
AB  - The lack of applied scientific research on camels, despite them being recognized 
      as production animals, compels the reorganization of emerging camel breeding
      systems with the aim of achieving successful camel welfare management strategies 
      all over the world. Relevant and properly-framed research widely impacts
      dissemination of scientific contents and drives public willingness to enhance
      ethically acceptable conditions for domestic animals. Consumer perception of this
      livestock industry will improve and high-quality products will be obtained. This 
      paper draws on bibliometric indicators as promoting factors for camel-related
      research advances, tracing historical scientific publications indexed in
      ScienceDirect directory from 1880-2019. Camel as a species did not affect Journal
      Citation Reports (JCR) impact (p > 0.05) despite the journal, author number,
      corresponding author origin, discipline and publication year affecting it (p <
      0.001). Countries with traditionally well-established camel farming are also
      responsible for the papers with the highest academic impact. However, camel
      research advances may have only locally and partially influenced welfare related 
      laws, so intentional harming acts and basic needs neglect may persist in these
      species. A sustainable camel industry requires those involved in camel research
      to influence business stakeholders and animal welfare advocacies by highlighting 
      the benefits of camel wellbeing promotion, co-innovation partnership
      establishment and urgent enhancement of policy reform.
FAU - Pastrana, Carlos Iglesias
AU  - Pastrana CI
AD  - Department of Genetics, Faculty of Veterinary Sciences, University of Cordoba,
      14014 Cordoba, Spain.
FAU - Gonzalez, Francisco Javier Navas
AU  - Gonzalez FJN
AD  - Department of Genetics, Faculty of Veterinary Sciences, University of Cordoba,
      14014 Cordoba, Spain.
FAU - Ciani, Elena
AU  - Ciani E
AD  - Department of Biosciences, Biotechnologies and Biopharmaceutics, Faculty of
      Veterinary Sciences, University of Bari 'Aldo Moro', 70121 Bari, Italy.
FAU - Capote, Cecilio Jose Barba
AU  - Capote CJB
AD  - Department of Animal Production, Faculty of Veterinary Sciences, University of
      Cordoba, 14014 Cordoba, Spain.
FAU - Bermejo, Juan Vicente Delgado
AU  - Bermejo JVD
AD  - Department of Genetics, Faculty of Veterinary Sciences, University of Cordoba,
      14014 Cordoba, Spain.
LA  - eng
GR  - APCIN-2016-00011-00-00/ARIMNet2 (Coordination of Agricultural Research in the
      Mediterranean)
PT  - Journal Article
DEP - 20200430
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7277471
OTO - NOTNLM
OT  - animal welfare
OT  - bibliometrics
OT  - camels
OT  - emerging industry
OT  - international research
OT  - law enforcement
OT  - science-society dialogue
COIS- The authors declare no con fl ict of interest. The founding sponsors had no role 
      in the design of the study; in the collection, analyses, or interpretation of
      data; in the writing of the manuscript, and in the decision to publish the
      results.
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:01
CRDT- 2020/05/06 06:00
PHST- 2020/04/10 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:01 [medline]
AID - ani10050780 [pii]
AID - 10.3390/ani10050780 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Apr 30;10(5). pii: ani10050780. doi: 10.3390/ani10050780.


PMID- 32364879
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210502
IS  - 1557-8674 (Electronic)
IS  - 1096-2964 (Linking)
VI  - 21
IP  - 4
DP  - 2020 May
TI  - Pro-Con Perspectives on Ethics in Surgical Research: Update from the 39th Annual 
      Surgical Infection Society Meeting.
PG  - 332-343
LID - 10.1089/sur.2020.098 [doi]
AB  - Background: Surgical research is potentially invasive, high-risk, and costly.
      Research that advances medical dogma must justify both its ends and its means.
      Although ethical questions do not always have simple answers, it is critically
      important for the clinician, researcher, and patient to approach these dilemmas
      and surgical research in a thoughtful, conscientious manner. Methods: We present 
      four ethical issues in surgical research and discuss the opposing viewpoints.
      These topics were presented and discussed at the 39th Annual Meeting of the
      Surgical Infection Society as pro-con debates. The presenters of each opinion
      developed a succinct summary of their respective reviews for this publication.
      Results: The key subjects for these pro-con debates were: (1) Should patients be 
      enrolled for time-sensitive surgical infection research using an opt-out or an
      opt-in strategy? (2) Should patients who are being enrolled in a randomized
      controlled trial (RCT) comparing surgery with a non-operative intervention pay
      the costs of their treatment arm? (3) Should the scientific community embrace
      open access journals as the future of scientific publishing? (4) Should the
      majority of funding go to clinical or basic science research? Important points
      were illustrated in each of the pro-con presentations and illustrated the
      difficulties that are facing the performance and payment of infection research in
      the future. Conclusions: Surgical research is ethically complex, with conflicting
      demands between individual patients, society, and healthcare economics. At
      present, there are no clear answers to these and the many other ethical issues
      facing research in the future. Answers will only come from continued robust
      dialogue among all stakeholders in surgical research.
FAU - Ho, Vanessa P
AU  - Ho VP
AD  - Department of Surgery, MetroHealth Medical Center, Cleveland, Ohio, USA.
AD  - Department of Quantitative and Population Health Sciences, Case Western Reserve
      University, Cleveland, Ohio, USA.
FAU - Truong, Evelyn I
AU  - Truong EI
AD  - Department of Surgery, MetroHealth Medical Center, Cleveland, Ohio, USA.
FAU - Nisar, Saira
AU  - Nisar S
AD  - The Burn Center, Medstar Washington Hospital Center, Department of Surgery,
      Georgetown University School of Medicine, Washington, DC, USA.
FAU - May, Addison K
AU  - May AK
AD  - Department of Surgery, Carolinas Medical Center, Atrium Health, Charlotte, North 
      Carolina, USA.
FAU - Beilman, Gregory J
AU  - Beilman GJ
AD  - Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
FAU - Fry, Donald E
AU  - Fry DE
AD  - Department of Surgery, Northwestern University, Chicago, Illinois, USA.
FAU - Barie, Philip S
AU  - Barie PS
AD  - Departments of Surgery and Public Health, Weill Cornell Medical College, New
      York, New York, USA.
FAU - Huston, Jared M
AU  - Huston JM
AD  - Departments of Surgery and Science Education, Zucker School of Medicine at
      Hofstra/Northwell, Hempstead, New York, USA.
FAU - Shupp, Jeffrey W
AU  - Shupp JW
AD  - The Burn Center, Medstar Washington Hospital Center, Department of Surgery,
      Georgetown University School of Medicine, Washington, DC, USA.
FAU - Pieracci, Fredric M
AU  - Pieracci FM
AD  - Department of Surgery, Denver Health Medical Center/University of Colorado School
      of Medicine, Denver, Colorado, USA.
LA  - eng
GR  - KL2 TR002547/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Surg Infect (Larchmt)
JT  - Surgical infections
JID - 9815642
SB  - IM
MH  - Communication
MH  - Congresses as Topic
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent/ethics/standards
MH  - Open Access Publishing/ethics
MH  - Randomized Controlled Trials as Topic/economics/ethics
MH  - Surgical Procedures, Operative/*ethics
MH  - Surgical Wound Infection/drug therapy/prevention & control
MH  - Time Factors
PMC - PMC7232654
OTO - NOTNLM
OT  - ethics
OT  - informed consent
OT  - research
OT  - research funding
OT  - surgery
EDAT- 2020/05/05 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - 10.1089/sur.2020.098 [doi]
PST - ppublish
SO  - Surg Infect (Larchmt). 2020 May;21(4):332-343. doi: 10.1089/sur.2020.098.


PMID- 32364875
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1544-5208 (Electronic)
IS  - 0278-2715 (Linking)
VI  - 39
IP  - 5
DP  - 2020 May
TI  - Held Against Our Wills: Reimagining Involuntary Commitment.
PG  - 898-901
LID - 10.1377/hlthaff.2019.00765 [doi]
AB  - Involuntary psychiatric treatment for people with serious mental illness should
      focus on returning to health instead of reducing danger.
FAU - Nussbaum, Abraham M
AU  - Nussbaum AM
AD  - Abraham M. Nussbaum ( Abraham. Nussbaum@dhha. org ) is chief education officer at
      Denver Health, in Colorado, and an associate professor of psychiatry and
      assistant dean of graduate medical education at the University of Colorado School
      of Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Health Aff (Millwood)
JT  - Health affairs (Project Hope)
JID - 8303128
SB  - IM
MH  - Commitment of Mentally Ill
MH  - Humans
MH  - *Involuntary Commitment
MH  - Living Wills
MH  - *Mental Disorders/therapy
OTO - NOTNLM
OT  - *Involuntary commitment
OT  - *Mental disorders
OT  - *Psychiatric hospitals
OT  - *Psychiatrists
OT  - *Safety net hospitals
OT  - *Schizophrenia
OT  - *Surgeons
OT  - *Surgery
OT  - *access to care
OT  - *ethics
OT  - *health policy
OT  - *mental health
EDAT- 2020/05/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1377/hlthaff.2019.00765 [doi]
PST - ppublish
SO  - Health Aff (Millwood). 2020 May;39(5):898-901. doi: 10.1377/hlthaff.2019.00765.


PMID- 32364809
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20201218
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 31
IP  - 5
DP  - 2020 Aug
TI  - Inpatient teledermatology during the COVID-19 pandemic.
PG  - 441-443
LID - 10.1080/09546634.2020.1762843 [doi]
AB  - Coronavirus Disease 2019 (COVID-19) represents a global health crisis in which
      personal protective equipment has become increasingly limited. Dermatologists are
      poised to use technology, such as teledermatology, to innovate existing workflows
      and optimize dermatologic care. The state of Ohio has emerged as a leader in the 
      United States with its response to the COVID-19 crisis. In response to the
      COVID-19 crisis, we developed a simple algorithm and strict guidelines to
      prioritize telemedicine specifically for inpatient dermatology consults. This
      algorithm was quickly accepted by our hospital leadership and adopted by other
      inpatient consultative services. In this Viewpoint, we share our experience with 
      early adoption of teledermatology in the inpatient consultative setting in light 
      of the COVID-19 crisis. We also highlight the limitations, ethical
      considerations, and areas for future research with respect to the implementation 
      of teledermatology.
FAU - Rismiller, Kyle
AU  - Rismiller K
AD  - Division of Dermatology, Department of Internal Medicine, The Ohio State
      University Wexner Medical Center, Columbus, OH, USA.
FAU - Cartron, Alexander M
AU  - Cartron AM
AD  - Department of Dermatology, University of Maryland School of Medicine, Baltimore, 
      MD, USA.
FAU - Trinidad, John C L
AU  - Trinidad JCL
AD  - Division of Dermatology, Department of Internal Medicine, The Ohio State
      University Wexner Medical Center, Columbus, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20200513
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Coding
MH  - Coronavirus Infections/*epidemiology
MH  - Delivery of Health Care
MH  - Dermatology/*methods
MH  - Hospitalization
MH  - Humans
MH  - Inpatients
MH  - *Pandemics
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*epidemiology
MH  - *Referral and Consultation
MH  - Reimbursement Mechanisms
MH  - SARS-CoV-2
MH  - Skin Diseases/diagnosis/therapy
MH  - Telemedicine/*methods
MH  - United States/epidemiology
OTO - NOTNLM
OT  - COVID-19
OT  - Teledermatology
OT  - coronavirus
OT  - inpatient dermatology
OT  - store-and-forward
OT  - telemedicine
EDAT- 2020/05/05 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1080/09546634.2020.1762843 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2020 Aug;31(5):441-443. doi: 10.1080/09546634.2020.1762843.
      Epub 2020 May 13.


PMID- 32364479
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Jun
TI  - "Living Robots": Ethical Questions About Xenobots.
PG  - W1-W3
LID - 10.1080/15265161.2020.1746102 [doi]
FAU - Coghlan, Simon
AU  - Coghlan S
AUID- ORCID: 0000-0002-6021-9878
AD  - Center for AI and Digital Ethics and School of Computing and Information Systems,
      The University of Melbourne, Melbourne, Australia.
FAU - Leins, Kobi
AU  - Leins K
AUID- ORCID: 0000-0002-9432-5724
AD  - Center for AI and Digital Ethics and School of Computing and Information Systems,
      The University of Melbourne, Melbourne, Australia.
LA  - eng
PT  - Letter
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - *Models, Biological
MH  - Robotics/*ethics
MH  - Stem Cells
MH  - Synthetic Biology/ethics
MH  - *Xenopus laevis
EDAT- 2020/05/05 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/15265161.2020.1746102 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(5):W1-W3. doi: 10.1080/15265161.2020.1746102.


PMID- 32364468
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Jun
TI  - Partnering With Patients to Bridge Gaps in Consent for Acute Care Research.
PG  - 7-17
LID - 10.1080/15265161.2020.1745931 [doi]
AB  - Clinical trials for acute conditions such as myocardial infarction and stroke
      pose challenges related to informed consent due to time limitations, stress, and 
      severe illness. Consent processes should be sensitive to the context in which
      trials are conducted and to needs of patients and surrogate decision-makers. This
      manuscript describes a collaborative effort between ethicists, researchers,
      patients, and surrogates to develop patient-driven, patient-centered approaches
      to consent for clinical trials in acute myocardial infarction and stroke.Our
      group identified important ways in which existing consent processes and forms for
      clinical trials fail to meet patients' and surrogates' needs in the acute
      context. We collaborated to create model forms and consent processes that are
      substantially shorter and, hopefully, better-matched to patients' and surrogates'
      needs and expectations from the perspective of content, structure, and tone.
      These changes, however, challenge some common conventions regarding consent.
FAU - Dickert, Neal W
AU  - Dickert NW
AD  - Emory University School of Medicine.
FAU - Bernard, Amanda Michelle
AU  - Bernard AM
AD  - Emory University Winship Cancer Institute.
FAU - Brabson, JoAnne M
AU  - Brabson JM
AD  - Emory University Winship Cancer Institute.
FAU - Hunter, Rodney J
AU  - Hunter RJ
AD  - Emory University.
FAU - McLemore, Regina
AU  - McLemore R
AD  - Emory University Winship Cancer Institute.
FAU - Mitchell, Andrea R
AU  - Mitchell AR
AD  - Emory University School of Medicine.
FAU - Palmer, Stephen
AU  - Palmer S
AD  - Emory University Winship Cancer Institute.
FAU - Reed, Barbara
AU  - Reed B
AD  - Emory University Winship Cancer Institute.
FAU - Riedford, Michele
AU  - Riedford M
AD  - Emory University Winship Cancer Institute.
FAU - Simpson, Raymond T
AU  - Simpson RT
AD  - Emory University Winship Cancer Institute.
FAU - Speight, Candace D
AU  - Speight CD
AD  - Emory University School of Medicine.
FAU - Steadman, Tracie
AU  - Steadman T
AD  - Emory University Winship Cancer Institute.
FAU - D Pentz, Rebecca
AU  - D Pentz R
AD  - Emory University Winship Cancer Institute.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jun;20(5):24-25. PMID: 32364469
CIN - Am J Bioeth. 2020 Jun;20(5):40-42. PMID: 32364470
CIN - Am J Bioeth. 2020 Jun;20(5):28-30. PMID: 32364472
CIN - Am J Bioeth. 2020 Jun;20(5):31-33. PMID: 32364474
CIN - Am J Bioeth. 2020 Jun;20(5):36-37. PMID: 32364476
CIN - Am J Bioeth. 2020 Jun;20(5):1-3. PMID: 32364478
CIN - Am J Bioeth. 2020 Jun;20(5):38-40. PMID: 32364480
CIN - Am J Bioeth. 2020 Jun;20(5):33-35. PMID: 32364484
CIN - Am J Bioeth. 2020 Jun;20(5):20-22. PMID: 32364488
CIN - Am J Bioeth. 2020 Jun;20(5):18-20. PMID: 32364489
CIN - Am J Bioeth. 2020 May;20(5):26-28. PMID: 32677867
CIN - Am J Bioeth. 2020 May;20(5):22-23. PMID: 32677869
CIN - Am J Bioeth. 2020 Aug;20(8):W12-W13. PMID: 32757920
MH  - *Acute Disease
MH  - Adult
MH  - *Advisory Committees
MH  - Aged
MH  - Clinical Trials as Topic/*ethics
MH  - *Consent Forms
MH  - Female
MH  - Humans
MH  - Informed Consent
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/prevention & control
MH  - *Research Subjects
MH  - Stroke/prevention & control
OTO - NOTNLM
OT  - *Informed consent
OT  - *acute care
OT  - *myocardial infarction
OT  - *patient-centered care
OT  - *research ethics
OT  - *stroke
EDAT- 2020/05/05 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/15265161.2020.1745931 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(5):7-17. doi: 10.1080/15265161.2020.1745931.


PMID- 32364467
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Jun
TI  - Solidarity and Community Engagement in Global Health Research.
PG  - 43-56
LID - 10.1080/15265161.2020.1745930 [doi]
AB  - Community engagement (CE) is gaining prominence in global health research. A
      number of ethical goals-spanning the instrumental, intrinsic, and
      transformative-have been ascribed to CE in global health research. This paper
      draws attention to an additional transformative value that CE is not typically
      linked to but that seems very relevant: solidarity. Both are concerned with
      building relationships and connecting parties that are distant from one another. 
      This paper first argues that furthering solidarity should be recognized as
      another ethical goal for CE in global health research. It contends that, over
      time, CE can build the bases of solidaristic relationships-moral imagination,
      recognition, understanding, empathy-between researchers and community members.
      Applying concepts from existing accounts of solidarity, the paper develops
      preliminary ideas about who should be engaged and how to advance solidarity. The 
      proposed approach is compared to current CE practice in global health research.
      Finally, the paper briefly considers how solidaristic CE could affect how global 
      health research is performed.
FAU - Pratt, Bridget
AU  - Pratt B
AD  - Centre for Health Equity, School of Population and Global Health, University of
      Melbourne, Victoria, Australia.
FAU - Cheah, Phaik Yeong
AU  - Cheah PY
AD  - Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical
      Medicine, Mahidol University, Bangkok, Thailand.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical
      Medicine, University of Oxford, Oxford, UK.
AD  - The Ethox Centre, Nuffield Department of Population Health, University of Oxford,
      Oxford, UK.
FAU - Marsh, Vicki
AU  - Marsh V
AD  - Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme,
      Nairobi, Kenya.
AD  - Centre for Tropical Medicine and Global Health, Nuffield Department of Population
      Health, University of Oxford, Oxford, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CIN - Am J Bioeth. 2020 Jun;20(5):64-66. PMID: 32364466
CIN - Am J Bioeth. 2020 Jun;20(5):69-71. PMID: 32364471
CIN - Am J Bioeth. 2020 Jun;20(5):75-77. PMID: 32364473
CIN - Am J Bioeth. 2020 Jun;20(5):80-81. PMID: 32364475
CIN - Am J Bioeth. 2020 Jun;20(5):4-6. PMID: 32364477
CIN - Am J Bioeth. 2020 Jun;20(5):77-79. PMID: 32364481
CIN - Am J Bioeth. 2020 Jun;20(5):72-74. PMID: 32364482
CIN - Am J Bioeth. 2020 Jun;20(5):67-69. PMID: 32364483
CIN - Am J Bioeth. 2020 Jun;20(5):59-62. PMID: 32364485
CIN - Am J Bioeth. 2020 Jun;20(5):62-64. PMID: 32364486
CIN - Am J Bioeth. 2020 May;20(5):57-59. PMID: 32677868
CIN - Am J Bioeth. 2020 Aug;20(8):W14-W16. PMID: 32757939
MH  - Community Participation/*methods
MH  - Community-Based Participatory Research/*ethics
MH  - *Cooperative Behavior
MH  - *Global Health
MH  - Humans
MH  - International Cooperation
OTO - NOTNLM
OT  - *Community engagement
OT  - *ethics
OT  - *global health
OT  - *research
OT  - *solidarity
EDAT- 2020/05/05 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/15265161.2020.1745930 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 Jun;20(5):43-56. doi: 10.1080/15265161.2020.1745930.


PMID- 32364338
OWN - NLM
STAT- MEDLINE
DCOM- 20200528
LR  - 20220414
IS  - 0019-1442 (Print)
IS  - 0019-1442 (Linking)
VI  - 73
IP  - 3-4
DP  - 2020 Mar 30
TI  - Cyanocobalamin and cholecalciferol synergistically improve functional and
      histopathological nerve healing in experimental rat model.
PG  - 113-120
LID - 10.18071/isz.73.0113 [doi]
AB  - BACKGROUND AND PURPOSE: Peripheral nerve injury (PNI) is a frequent problem among
      young adults. Hopefully, regeneration can occur in PNI unlike central nervous
      system. If nerve cut is complete, gold standard treatment is surgery, but
      incomplete cuts have been tried to be treated by medicines. The aim of the study 
      was to evaluate and compare clinical and histopathological outcomes of
      independent treatment of each of Vitamin B12 (B12) and Vitamin D3 (D3) and their 
      combination on sciatic nerve injury in an experimental rat model. METHODS:
      Experimental animal study was performed after the approval of BEH Ethics
      Committee No. 2015/10. 32 rats were grouped into four (n=8) according to
      treatment procedures, such as Group 1 (controls with no treatment), Group 2
      (intraperitoneal 1 mg/kg/day B12), Group 3 (oral 3500 IU/kg/week D3), Group 4
      (intraperitoneal 1 mg/kg/day B12+ oral 3500 IU/kg/week D3). Sciatic Functional
      Index (SFI) and histopathological analysis were performed. RESULTS: SFIs of Group
      2, 3, 4 were statistically significantly higher than controls. Group 2 and 3 were
      statistically not different, however Group 4 was statistically significantly
      higher than others according to SFI. Axonal degeneration (AD) in all treatment
      groups were statistically significantly lower than in Group 1. AD in Group 4 was 
      significantly lower than in Group 2 and 3; there was no significant difference
      between Group 2 and 3. There was no significant difference between Group 1,2 and 
      3 in Axonolysis (A). But A of Group 4 was significantly very much lower than all 
      others. Oedema- inflammation (OE-I) in all treatment groups were significantly
      lower than in Group 1; there was no significant difference between Group 2 and
      group 4. OE-I in Group 2 and 4 were significantly lower than in Group 3. There
      were no significant differences between Group 1, 2 and 3 in damage level scores; 
      score of Group 4 was significantly lower than of Group 1. CONCLUSION: B12 and D3 
      were found effective with no statistically significant difference. But combined
      use of B12 and D3 improve nerve healing synergistically. We recommend combined
      use of B12 and D3 after PNI as soon as possible.
FAU - Albay, Cem
AU  - Albay C
AD  - Metin Sabanci Baltalimani Bone Diseases Research and Training Hospital,
      Department of Orthopaedics and Traumatology, Istanbul.
FAU - Adanir, Oktay
AU  - Adanir O
AD  - Bagcilar Research and Training Hospital, Department of Orthopaedics and
      Traumatology, Istanbul.
FAU - Kahraman Akkalp, Asli
AU  - Kahraman Akkalp A
AD  - Izmir Katip Celebi University Ataturk Research and Training Hospital, Department 
      of Pathology, Izmir.
FAU - Dogan, Vasfiye Burcu
AU  - Dogan VB
AD  - Prof. Dr. Mazhar Osman Bakirkoy Psychiatry and Neurology Research and Training
      Hospital, Department of Neurology, Istanbul.
FAU - Gulec, Mehmet Akif
AU  - Gulec MA
AD  - Bagcilar Research and Training Hospital, Department of Orthopaedics and
      Traumatology, Istanbul.
FAU - Beytemur, Ozan
AU  - Beytemur O
AD  - Bagcilar Research and Training Hospital, Department of Orthopaedics and
      Traumatology, Istanbul.
LA  - eng
PT  - Journal Article
TT  - A cianokobalamin es a kolekalciferol szinergikusan segiti a funkcionalis es
      hisztopatologiai ideggyogyulast patkanymodellben.
PL  - Hungary
TA  - Ideggyogy Sz
JT  - Ideggyogyaszati szemle
JID - 17510500R
RN  - 0 (Neuroprotective Agents)
RN  - 1C6V77QF41 (Cholecalciferol)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Animals
MH  - Cholecalciferol/*pharmacology
MH  - Disease Models, Animal
MH  - Humans
MH  - Neuroprotective Agents/*pharmacology
MH  - Peripheral Nerve Injuries/*drug therapy
MH  - Rats
MH  - Sciatic Nerve/*drug effects
MH  - Vitamin B 12/*pharmacology
MH  - Young Adult
OTO - NOTNLM
OT  - animal model
OT  - cholecalciferol
OT  - cyanocobalamin
OT  - histopathologic investigation
OT  - peripheral nerve injury
EDAT- 2020/05/05 06:00
MHDA- 2020/05/29 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/05/29 06:00 [medline]
AID - 10.18071/isz.73.0113 [doi]
PST - ppublish
SO  - Ideggyogy Sz. 2020 Mar 30;73(3-4):113-120. doi: 10.18071/isz.73.0113.


PMID- 32364328
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1935-9780 (Electronic)
IS  - 1935-9772 (Linking)
VI  - 13
IP  - 5
DP  - 2020 Sep
TI  - A Good Death - Can the Concept Be Applied to Anatomy?
PG  - 657-663
LID - 10.1002/ase.1969 [doi]
AB  - The importance of patient-centered decisions is embedded throughout clinical
      practice. The principle that the patient is at the center of all decisions has
      helped form the contemporary approach to death and dying. The concept of a "good 
      death" will naturally mean different things to different individuals, but is
      based on the foundation of being pain free, comfortable, and able to make
      informed decisions. Potential donors are faced with many personal, ethical, and
      often spiritual considerations when they come to think about their wishes after
      death. One consideration is that of a "good death." This article explores how the
      concept of a "good death" may be applied to anatomy. Where first-person consent
      is in place, the motivating factors frequently include the wish for others to
      learn from the donation, and this notion may form part of the "good death" for
      the donor. Such motivations may impact positively on how students feel about
      dissecting and may provide comfort, assuaging feelings of discomfort, and
      allowing students to focus on anatomical learning. For donors where second-person
      consent is in place, the concept of a "good death" must depend on whether the
      individual wanted to donate their body in the first instance. The notion of a
      "bad death" may also be considered with body donation where no consent for
      donation is in place. This article proposes that there is ultimately a place for 
      the concept that a "good death" may involve an individual donating their body to 
      medical education.
CI  - (c) 2020 American Association for Anatomy.
FAU - Smith, Claire F
AU  - Smith CF
AUID- ORCID: https://orcid.org/0000-0002-4366-8591
AD  - Department of Medical Education, Brighton and Sussex Medical School, University
      of Sussex, Brighton, United Kingdom.
FAU - Alderton, Dasha L
AU  - Alderton DL
AD  - Department of Medical Education, Brighton and Sussex Medical School, University
      of Sussex, Brighton, United Kingdom.
FAU - Clifford, Katie M
AU  - Clifford KM
AD  - Department of Medical Education, Brighton and Sussex Medical School, University
      of Sussex, Brighton, United Kingdom.
FAU - Wells, Geoffrey
AU  - Wells G
AD  - Department of Medical Education, Brighton and Sussex Medical School, University
      of Sussex, Brighton, United Kingdom.
LA  - eng
PT  - Editorial
DEP - 20200527
PL  - United States
TA  - Anat Sci Educ
JT  - Anatomical sciences education
JID - 101392205
SB  - IM
MH  - *Advance Directives
MH  - Anatomy/*education
MH  - *Cadaver
MH  - *Death
MH  - Humans
MH  - Tissue Donors/*psychology
OTO - NOTNLM
OT  - altruism
OT  - body donation
OT  - consent
OT  - dissection
OT  - good death
OT  - gross anatomy education
OT  - medical education
OT  - memorial service
EDAT- 2020/05/05 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/04/26 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1002/ase.1969 [doi]
PST - ppublish
SO  - Anat Sci Educ. 2020 Sep;13(5):657-663. doi: 10.1002/ase.1969. Epub 2020 May 27.


PMID- 32364256
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20201218
IS  - 1651-2227 (Electronic)
IS  - 0803-5253 (Linking)
VI  - 109
IP  - 8
DP  - 2020 Aug
TI  - Paediatric ethical issues during the COVID-19 pandemic are not just about
      ventilator triage.
PG  - 1519-1521
LID - 10.1111/apa.15334 [doi]
FAU - Haward, Marlyse F
AU  - Haward MF
AUID- ORCID: 0000-0002-4954-168X
AD  - Division of Neonatology, Department of Pediatrics, Children's Hospital at
      Montefiore, Montefiore Medical Center, Albert Einstein College of Medicine,
      Bronx, NY, USA.
FAU - Moore, Gregory P
AU  - Moore GP
AUID- ORCID: 0000-0003-2430-7835
AD  - Division of Neonatology, Department of Pediatrics, Children's Hospital of Eastern
      Ontario, University of Ottawa, Ottawa, ON, Canada.
AD  - Division of Newborn Care, Department of Obstetrics and Gynecology, The Ottawa
      Hospital General Campus, University of Ottawa, Ottawa, ON, Canada.
FAU - Lantos, John
AU  - Lantos J
AUID- ORCID: 0000-0002-6553-3874
AD  - Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
FAU - Janvier, Annie
AU  - Janvier A
AUID- ORCID: 0000-0002-5462-9352
AD  - Department of Pediatrics, Bureau de l'Ethique Clinique, Universite de Montreal,
      Montreal, QC, Canada.
AD  - Division of Neonatology, Research Center, Clinical Ethics Unit, Palliative Care
      Unit, Unite de recherche en ethique clinique et partenariat famille, CHU
      Sainte-Justine, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Norway
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
SB  - IM
CIN - Acta Paediatr. 2020 Sep;109(9):1915. PMID: 32488896
MH  - COVID-19
MH  - Child
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - *Pandemics
MH  - Pediatrics/*ethics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Triage/ethics
MH  - Ventilators, Mechanical/supply & distribution
PMC - PMC7267437
EDAT- 2020/05/05 06:00
MHDA- 2020/07/16 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/27 00:00 [revised]
PHST- 2020/04/28 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1111/apa.15334 [doi]
PST - ppublish
SO  - Acta Paediatr. 2020 Aug;109(8):1519-1521. doi: 10.1111/apa.15334. Epub 2020 May
      20.


PMID- 32364248
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1360-0443 (Electronic)
IS  - 0965-2140 (Linking)
VI  - 115
IP  - 11
DP  - 2020 Nov
TI  - Restoring the Bacloville trial: efficacy and harms.
PG  - 2184-2186
LID - 10.1111/add.15109 [doi]
FAU - Naudet, Florian
AU  - Naudet F
AUID- ORCID: 0000-0003-3760-3801
AD  - University of Rennes, CHU Rennes, Inserm, CIC 1414 [(Centre d'Investigation
      Clinique de Rennes)], F- 35000, Rennes, France.
FAU - Braillon, Alain
AU  - Braillon A
AUID- ORCID: 0000-0001-5735-9530
AD  - Alcohol treatment unit, University Hospital, Amiens, France.
FAU - Cristea, Ioana A
AU  - Cristea IA
AUID- ORCID: 0000-0002-9854-7076
AD  - Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
FAU - Lexchin, Joel
AU  - Lexchin J
AD  - School of Health Policy and Management, York University, Toronto, Canada.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200522
PL  - England
TA  - Addiction
JT  - Addiction (Abingdon, England)
JID - 9304118
RN  - 0 (GABA-B Receptor Agonists)
RN  - H789N3FKE8 (Baclofen)
SB  - IM
CON - Addiction. 2020 Jul;115(7):1265-1276. PMID: 31833590
CIN - Addiction. 2020 Nov;115(11):2186-2187. PMID: 32364260
MH  - *Alcohol Drinking
MH  - *Baclofen
MH  - Follow-Up Studies
MH  - GABA-B Receptor Agonists
MH  - Humans
MH  - Outpatients
OTO - NOTNLM
OT  - *Alcohol
OT  - *baclofen
OT  - *bias
OT  - *conflict of interests
OT  - *ethics
OT  - *randomized controlled trial
EDAT- 2020/05/05 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1111/add.15109 [doi]
PST - ppublish
SO  - Addiction. 2020 Nov;115(11):2184-2186. doi: 10.1111/add.15109. Epub 2020 May 22.


PMID- 32364137
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1878-6847 (Electronic)
IS  - 0924-6479 (Linking)
VI  - 31
IP  - 3
DP  - 2020
TI  - Inadequate evaluation of potential side effects of sildenafil in preterm stopped 
      Dutch trial.
PG  - 145-148
LID - 10.3233/JRS-202003 [doi]
AB  - Recently a drug trial in the Netherlands in which the efficacy of oral sildenafil
      was compared to placebo in women bearing children with fetal growth restriction
      was stopped early because of very harmful side effects to the babies. There were 
      quite some unwanted and unscientific aspects related to this study and the manner
      in which the side effects were communicated to the patients and the community.
      These have not gained the attention they ought to have. We therefore made an
      analysis of the basic problems which aims to prevent that the trust in medical
      research will be weakened.
FAU - Bijl, Dick
AU  - Bijl D
AD  - Physician-Epidemiologist, Utrecht, The Netherlands.
FAU - Healy, David
AU  - Healy D
AD  - Professor of Psychiatry, Hergest Unit, Bangor, Wales, UK.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - Int J Risk Saf Med
JT  - The International journal of risk & safety in medicine
JID - 9100907
RN  - 0 (Vasodilator Agents)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Ethics Committees, Research
MH  - Female
MH  - Fetal Growth Retardation/*drug therapy
MH  - Humans
MH  - Netherlands
MH  - Pregnancy
MH  - Sildenafil Citrate/*adverse effects/therapeutic use
MH  - Ultrasonography, Doppler
MH  - Vasodilator Agents/*adverse effects/therapeutic use
OTO - NOTNLM
OT  - *Ethical Commissions
OT  - *STRIDER
OT  - *Sildenafil
OT  - *cardiovascular side effects
OT  - *death of patients
OT  - *fetal growth retardation
OT  - *inadequate patient information
EDAT- 2020/05/05 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - JRS202003 [pii]
AID - 10.3233/JRS-202003 [doi]
PST - ppublish
SO  - Int J Risk Saf Med. 2020;31(3):145-148. doi: 10.3233/JRS-202003.


PMID- 32364048
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20201218
IS  - 2050-2885 (Electronic)
IS  - 2050-2877 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Jun
TI  - The BMA COVID-19 ethical guidance: a legal analysis.
PG  - 176-189
LID - 10.1080/20502877.2020.1762027 [doi]
AB  - The paper considers the recently published British Medical Association Guidance
      on ethical issues arising in relation to rationing of treatment during the
      COVID-19 Pandemic. It considers whether it is lawful to create policies for the
      rationing and withdrawal of treatment, and goes on to consider how such policies 
      might apply in practice. Legal analysis is undertaken of certain aspects of the
      Guidance which appear to misunderstand the law in respect of withdrawing
      treatment.
FAU - Hurford, James E LLB (Hons), LLM, MA, Solicitor
AU  - Hurford JE LLB (Hons), LLM, MA, Solicitor
LA  - eng
PT  - Journal Article
DEP - 20200502
PL  - England
TA  - New Bioeth
JT  - The New bioethics : a multidisciplinary journal of biotechnology and the body
JID - 101627814
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Health Care Rationing/*ethics
MH  - *Health Policy
MH  - Humans
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/*therapy
MH  - *Practice Guidelines as Topic
MH  - SARS-CoV-2
MH  - Societies, Medical
MH  - United Kingdom
MH  - Withholding Treatment/*ethics/*legislation & jurisprudence
OTO - NOTNLM
OT  - British Medical Association
OT  - COVID-19
OT  - ethical guidance
OT  - withdrawal of treatment
EDAT- 2020/05/05 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1080/20502877.2020.1762027 [doi]
PST - ppublish
SO  - New Bioeth. 2020 Jun;26(2):176-189. doi: 10.1080/20502877.2020.1762027. Epub 2020
      May 2.


PMID- 32363984
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 5
DP  - 2020 Dec
TI  - Self-Interested and Altruistic Motivations in Volunteering for Clinical Trials: A
      More Complex Relationship.
PG  - 443-451
LID - 10.1177/1556264620914463 [doi]
AB  - Empirical studies have found that altruism and self-interest are the two primary 
      motivations for enrollment in clinical trials. Some studies have shown that in
      some cases these two motivations are contingent upon each other, which
      complicates our understanding of motivation. In this study, we interviewed 27
      people with Parkinson's disease about their willingness to enroll in a
      hypothetical clinical trial. Through inductive, grounded theory analysis of the
      interview transcripts, we find four different contingent relationships between
      altruism and self-interest. It is important for ethicists to be aware of these
      more complex motivations because some are ethically problematic and others not.
      Moreover, practitioners need to be aware of these contingent relationships so
      that they can understand the motivations of the research participants.
FAU - Olsen, Lauren
AU  - Olsen L
AD  - Temple University, Philadelphia, PA, USA.
FAU - DePalma, Lindsay
AU  - DePalma L
AD  - UC San Diego, La Jolla, CA, USA.
FAU - Evans, John H
AU  - Evans JH
AUID- ORCID: 0000-0001-7487-3216
AD  - UC San Diego, La Jolla, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200502
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - *Altruism
MH  - Humans
MH  - *Motivation
MH  - Volunteers
OTO - NOTNLM
OT  - *Parkinson's
OT  - *motivation
OT  - *therapeutic misconception
EDAT- 2020/05/05 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1177/1556264620914463 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Dec;15(5):443-451. doi:
      10.1177/1556264620914463. Epub 2020 May 2.


PMID- 32363909
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1469-2910 (Electronic)
IS  - 1364-8470 (Linking)
VI  - 27
IP  - 2
DP  - 2020 Jun
TI  - Contested legitimacy for anthropologists involved in medical humanitarian action:
      experiences from the 2014-2016 West Africa Ebola epidemic.
PG  - 125-143
LID - 10.1080/13648470.2020.1742576 [doi]
AB  - The growing involvement of anthropologists in medical humanitarian response
      efforts has laid bare the moral and ethical consequences that emerge from
      humanitarian action. Anthropologists are well placed to examine the social,
      political, cultural and economic dimensions that influence the spread of
      diseases, and the ways in which to respond to epidemics. Anthropologists are
      also, with care, able to turn a critical lens on medical humanitarian response.
      However, there remains some resistance to involving anthropologists in response
      activities in the field. Drawing on interviews with anthropologists and
      humanitarian workers involved in the 2014-2016 West African Ebola epidemic, this 
      paper reveals the complex roles taken on by anthropologists in the field and
      reveals how anthropologists faced questions of legitimacy vis-a-vis communities
      and responders in their roles in response activities, which focused on acting as 
      'firefighters' and 'cultural brokers' as well as legitimacy as academic
      researchers. Whilst these anthropologists were able to conduct research alongside
      these activities, or draw on anthropological knowledge to inform response
      activities, questions also arose about the legitimacy of these roles for
      anthropological academia. We conclude that the process of gaining legitimacy from
      all these different constituencies is particular to anthropologists and reveals
      the role of 'giving voice' to communities alongside critiquing medical
      humanitarianism. Whilst these anthropologists have strengthened the argument for 
      the involvement of anthropologists in epidemic response this anthropological
      engagement with medical humanitarianism has revealed theoretical considerations
      more broadly for the discipline, as highlighted through engagement in other
      fields, especially in human rights and global health.
FAU - Lees, Shelley
AU  - Lees S
AUID- ORCID: http://orcid.org/0000-0003-0062-7930
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, England.
FAU - Palmer, Jennifer
AU  - Palmer J
AUID- ORCID: http://orcid.org/0000-0001-7777-722X
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, England.
FAU - Procureur, Fanny
AU  - Procureur F
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, England.
FAU - Blanchet, Karl
AU  - Blanchet K
AD  - Department of Global Health and Development, London School of Hygiene and
      Tropical Medicine, London, England.
LA  - eng
PT  - Journal Article
DEP - 20200504
PL  - England
TA  - Anthropol Med
JT  - Anthropology & medicine
JID - 9709920
SB  - IM
MH  - Africa, Western
MH  - *Altruism
MH  - *Anthropology, Medical/ethics/organization & administration
MH  - Epidemics
MH  - *Health Personnel/ethics/organization & administration
MH  - *Hemorrhagic Fever, Ebola/ethnology/therapy
MH  - Humans
OTO - NOTNLM
OT  - Ebola
OT  - West Africa
OT  - anthropology
OT  - epidemics
OT  - legitimacy
EDAT- 2020/05/05 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1080/13648470.2020.1742576 [doi]
PST - ppublish
SO  - Anthropol Med. 2020 Jun;27(2):125-143. doi: 10.1080/13648470.2020.1742576. Epub
      2020 May 4.


PMID- 32363337
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 2589-9333 (Electronic)
IS  - 2589-9333 (Linking)
VI  - 2
IP  - 3
DP  - 2020 Aug
TI  - Severe acute respiratory distress syndrome in coronavirus disease 2019-infected
      pregnancy: obstetric and intensive care considerations.
PG  - 100120
LID - 10.1016/j.ajogmf.2020.100120 [doi]
AB  - Since the emergence of a novel coronavirus (severe acute respiratory syndrome
      coronavirus 2) in Wuhan, China, at the end of December 2019, coronavirus disease 
      2019 has been associated with severe morbidity and mortality and has left world
      governments, healthcare systems, and providers caring for vulnerable populations,
      such as pregnant women, wrestling with the optimal management strategy. Unique
      physiologic and ethical considerations negate a one-size-fits-all approach when
      caring for critically ill pregnant women with coronavirus disease 2019, and few
      resources exist to guide the multidisciplinary team through decisions regarding
      optimal maternal-fetal surveillance, intensive care procedures, and delivery
      timing. We present a case of rapid clinical decompensation and development of
      severe acute respiratory distress syndrome in a woman at 31 weeks' gestation to
      highlight these unique considerations and present an algorithmic approach to the 
      diagnosis and management of the disease.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Schnettler, William T
AU  - Schnettler WT
AD  - Divisions of Maternal-Fetal Medicine, TriHealth-Good Samaritan Hospital,
      Cincinnati, OH.
FAU - Al Ahwel, Yousef
AU  - Al Ahwel Y
AD  - Pulmonology and Critical Care Medicine, TriHealth-Good Samaritan Hospital,
      Cincinnati, OH.
FAU - Suhag, Anju
AU  - Suhag A
AD  - Divisions of Maternal-Fetal Medicine, TriHealth-Good Samaritan Hospital,
      Cincinnati, OH.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200414
PL  - United States
TA  - Am J Obstet Gynecol MFM
JT  - American journal of obstetrics & gynecology MFM
JID - 101746609
MH  - Adult
MH  - *COVID-19/complications/diagnosis/physiopathology/therapy
MH  - COVID-19 Testing/methods
MH  - Cesarean Section, Repeat/methods
MH  - Clinical Deterioration
MH  - Critical Care/methods
MH  - Female
MH  - Humans
MH  - Infection Control/*methods
MH  - Lung/diagnostic imaging
MH  - Patient Positioning/*methods
MH  - *Pneumonia, Viral/diagnosis/etiology/physiopathology
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/physiopathology/therapy/virology
MH  - Pregnancy Outcome
MH  - Pregnancy Trimester, Third
MH  - Respiration, Artificial/*methods
MH  - *Respiratory Distress Syndrome/diagnosis/therapy/virology
MH  - SARS-CoV-2/*isolation & purification/pathogenicity
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
MH  - Ultrasonography/methods
PMC - PMC7194528
OTO - NOTNLM
OT  - *ARDS
OT  - *COVID-19
OT  - *acute SARS-CoV-2
OT  - *coronavirus
OT  - *pneumonia
OT  - *pregnancy
OT  - *respiratory distress syndrome
EDAT- 2020/05/05 06:00
MHDA- 2020/05/05 06:01
CRDT- 2020/05/05 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/05/05 06:01 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1016/j.ajogmf.2020.100120 [doi]
AID - S2589-9333(20)30050-1 [pii]
AID - 100120 [pii]
PST - ppublish
SO  - Am J Obstet Gynecol MFM. 2020 Aug;2(3):100120. doi: 10.1016/j.ajogmf.2020.100120.
      Epub 2020 Apr 14.


PMID- 32362641
OWN - NLM
STAT- MEDLINE
DCOM- 20200917
LR  - 20220610
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 151
IP  - 2 & 3
DP  - 2020 Feb & Mar
TI  - Ethics preparedness for infectious disease outbreaks research in India: A case
      for novel coronavirus disease 2019.
PG  - 124-131
LID - 10.4103/ijmr.IJMR_463_20 [doi]
FAU - Mathur, Roli
AU  - Mathur R
AD  - ICMR Bioethics Unit, ICMR-National Centre for Disease Informatics & Research,
      Bengaluru 562 110, Karnataka, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
SB  - IM
MH  - *Betacoronavirus
MH  - *Bioethical Issues
MH  - COVID-19
MH  - Clinical Trials as Topic/ethics
MH  - Coronavirus Infections/*epidemiology
MH  - Disaster Planning/*organization & administration
MH  - Disease Outbreaks/*ethics
MH  - Humans
MH  - India/epidemiology
MH  - Interdisciplinary Communication
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Population Surveillance
MH  - Registries
MH  - SARS-CoV-2
PMC - PMC7288766
COIS- None
EDAT- 2020/05/05 06:00
MHDA- 2020/09/18 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/09/18 06:00 [medline]
AID - IndianJMedRes_2020_151_2_124_280042 [pii]
AID - 10.4103/ijmr.IJMR_463_20 [doi]
PST - ppublish
SO  - Indian J Med Res. 2020 Feb & Mar;151(2 & 3):124-131. doi:
      10.4103/ijmr.IJMR_463_20.


PMID- 32362458
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Linking)
VI  - 52
IP  - 7
DP  - 2020 Aug - Sep
TI  - [Author's reply to article: Contributions on the editorial: "Importance of
      Research Ethics Committees in Family Medicine"].
PG  - 507-508
LID - S0212-6567(19)30481-0 [pii]
LID - 10.1016/j.aprim.2019.09.005 [doi]
FAU - Parraga Martinez, Ignacio
AU  - Parraga Martinez I
AD  - Responsable de investigacion de la Junta Permanente de la semFYC. Miembro del
      CEIm de la Gerencia de Atencion Integrada de Albacete. Editor de Revista Clinica 
      de Medicina de Familia. Profesor Asociado de Medicina Preventiva y Salud Publica 
      de la Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha.
      Electronic address: iparraga@sescam.jccm.es.
FAU - Martin Alvarez, Remedios
AU  - Martin Alvarez R
AD  - Secretaria de la Junta Permanente de la semFYC. Responsable de investigacion de
      la Junta Permanente de la semFYC desde 2016 a mayo de 2019. Responsable de
      Investigacion del Grupo Comunicacion y Salud de la semFYc entre 2009 y 2016.
      Profesora Asociada Clinica de la Universidad Autonoma de Barcelona.
LA  - spa
PT  - Letter
PT  - Comment
TT  - Respuesta al articulo titulado: Aportes sobre el editorial: <<Importancia de los 
      Comites de Etica en la Investigacion en Medicina de Familia>>.
DEP - 20200430
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
SB  - IM
CON - Aten Primaria. 2019 May;51(5):263-265. PMID: 31054632
CON - Aten Primaria. 2020 Jun - Jul;52(6):440-441. PMID: 31653440
MH  - *Ethics Committees, Research
MH  - *Family Practice
PMC - PMC7393551
EDAT- 2020/05/05 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/05/05 06:00
PHST- 2019/08/01 00:00 [received]
PHST- 2019/09/20 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - S0212-6567(19)30481-0 [pii]
AID - 10.1016/j.aprim.2019.09.005 [doi]
PST - ppublish
SO  - Aten Primaria. 2020 Aug - Sep;52(7):507-508. doi: 10.1016/j.aprim.2019.09.005.
      Epub 2020 Apr 30.


PMID- 32362295
OWN - NLM
STAT- MEDLINE
DCOM- 20200804
LR  - 20210110
IS  - 1472-1465 (Electronic)
IS  - 0007-1250 (Linking)
VI  - 217
IP  - 2
DP  - 2020 Aug
TI  - Psychiatry and COVID-19: putting our best foot forward.
PG  - 410-412
LID - 10.1192/bjp.2020.90 [doi]
AB  - COVID-19 presents new challenges for psychiatry as clinical management, ethical
      dilemmas and administrative complications need to be addressed. The psychiatrist 
      should protect the needs and rights of the mentally ill while maximising
      population health and ensuring solidarity, reciprocity and community well-being
      for all.
FAU - Strous, Rael D
AU  - Strous RD
AUID- ORCID: 0000-0002-2287-1726
AD  - Mental Health Wing, Mayanei Hayeshua Medical Centre, Bnei Brak; and Sackler
      Faculty of Medicine, Tel Aviv University, Israel.
FAU - Gold, Azgad
AU  - Gold A
AD  - Ambulatory Forensic Psychiatry Unit, Yehuda Abarbanel Mental Health Centre, Bat
      Yam, Israel.
LA  - eng
PT  - Editorial
PL  - England
TA  - Br J Psychiatry
JT  - The British journal of psychiatry : the journal of mental science
JID - 0342367
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Humans
MH  - *Infection Control
MH  - *Mental Health Services/ethics/standards
MH  - *Mentally Ill Persons
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - *Psychiatry/ethics/standards
PMC - PMC7256216
OTO - NOTNLM
OT  - *Ethics
OT  - *clinical governance
OT  - *psychosocial interventions
OT  - *service users
OT  - *trauma
EDAT- 2020/05/05 06:00
MHDA- 2020/08/05 06:00
CRDT- 2020/05/05 06:00
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/08/05 06:00 [medline]
PHST- 2020/05/05 06:00 [entrez]
AID - 10.1192/bjp.2020.90 [doi]
AID - S0007125020000902 [pii]
PST - ppublish
SO  - Br J Psychiatry. 2020 Aug;217(2):410-412. doi: 10.1192/bjp.2020.90.


PMID- 34901264
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2314-6141 (Electronic)
VI  - 2020
DP  - 2020
TI  - Effect of Hydrocortisone on Intradialytic Hypotension: A Preliminary
      Investigational Study.
PG  - 4987547
LID - 10.1155/2020/4987547 [doi]
AB  - INTRODUCTION: Approximately 15 to 33% of all dialysis treatments are complicated 
      by intradialytic hypotension (IDH). In this study, we tested the hypothesis that 
      the intravenous administration of hydrocortisone prior to HD treatment could
      prevent IDH or at least decrease the drop in the blood pressure resulting from
      IDH. METHODS: This study was approved by our local ethics committee/IRB (2017/87)
      and by the Jordan Food and Drug Administration (7/clinical/18). Additionally, it 
      is registered on ClinicalTrials.gov (NCT03465007). In this preliminary
      investigational study, we screened all chronic hemodialysis patients at our
      clinic who were 18 years of age or older (n = 82) for IDH. There were 14 patients
      included in the interventional part of this study; patients were given IV
      hydrocortisone for 3 consecutive HD sessions, followed or preceded by 3
      intervention-free sessions where they were given 5 ml of saline as a placebo.
      RESULTS: The initial total sample size was 82 patients. The frequency of IDH at
      our clinic was 24.4%. Fourteen out of the 20 patients who were diagnosed with IDH
      agreed to enroll in the interventional part of our study. The mean age of the
      patients in the interventional part of our study was 53.5 years (+/-10.3). These 
      patients included 5 (35.7%) men and 9 (64.3%) women. Upon comparing the number of
      hypotensive attacks with and without the hydrocortisone administration, we found 
      a significant difference (p = 0.003) between the hydrocortisone and placebo
      treatments in which 12 (85.7%) patients had fewer IDH episodes with the
      hydrocortisone treatment than with placebo. CONCLUSION: This preliminary
      investigational study found that the administration of a stress dose of
      hydrocortisone prior to hemodialysis could be an effective measure for preventing
      or minimizing the risk of IDH episodes. Additional prospective studies on this
      subject are needed. Ruling out adrenal insufficiency in patients diagnosed with
      IDH is also crucial.
CI  - Copyright (c) 2020 Hussein H. Alhawari et al.
FAU - Alhawari, Hussein H
AU  - Alhawari HH
AUID- ORCID: https://orcid.org/0000-0002-5413-3736
AD  - Division of Nephrology, Department of Internal Medicine, School of Medicine, The 
      University of Jordan, Jordan.
FAU - Alshelleh, Sameeha
AU  - Alshelleh S
AUID- ORCID: https://orcid.org/0000-0003-4216-0662
AD  - Division of Nephrology, Department of Internal Medicine, School of Medicine, The 
      University of Jordan, Jordan.
FAU - Alhawari, Hussam H
AU  - Alhawari HH
AUID- ORCID: https://orcid.org/0000-0003-2525-9193
AD  - Division of Endocrinology, Department of Internal Medicine, School of Medicine,
      The University of Jordan, Jordan.
FAU - Alawwa, Izzat Ahmad
AU  - Alawwa IA
AUID- ORCID: https://orcid.org/0000-0001-8247-9403
AD  - Division of Nephrology, Department of Internal Medicine, School of Medicine, The 
      University of Jordan, Jordan.
FAU - AlRyalat, Saif Aldeen
AU  - AlRyalat SA
AUID- ORCID: https://orcid.org/0000-0001-5588-9458
AD  - Department of Special Surgery, School of Medicine, The University of Jordan,
      Jordan.
FAU - Mesmar, Ahmad
AU  - Mesmar A
AUID- ORCID: https://orcid.org/0000-0001-9986-8034
AD  - Department of Internal Medicine, School of Medicine, The University of Jordan,
      Jordan.
FAU - Ojjoh, Khaled
AU  - Ojjoh K
AUID- ORCID: https://orcid.org/0000-0003-2018-7522
AD  - Department of Internal Medicine, School of Medicine, The University of Jordan,
      Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AUID- ORCID: https://orcid.org/0000-0002-2808-5099
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of
      Science and Technology, Jordan.
LA  - eng
SI  - ClinicalTrials.gov/NCT03465007
PT  - Journal Article
DEP - 20200505
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
PMC - PMC8654564
COIS- All authors declare that there are no conflicts of interest.
EDAT- 2020/05/05 00:00
MHDA- 2020/05/05 00:01
CRDT- 2021/12/13 18:10
PHST- 2019/08/27 00:00 [received]
PHST- 2020/04/11 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2021/12/13 18:10 [entrez]
PHST- 2020/05/05 00:00 [pubmed]
PHST- 2020/05/05 00:01 [medline]
AID - 10.1155/2020/4987547 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 May 5;2020:4987547. doi: 10.1155/2020/4987547. eCollection
      2020.


PMID- 32361715
OWN - NLM
STAT- MEDLINE
DCOM- 20200505
LR  - 20201218
IS  - 1790-5427 (Print)
IS  - 1790-5427 (Linking)
VI  - 23
IP  - 1
DP  - 2020 Jan-Apr
TI  - Clinical trials and the COVID-19 pandemic.
PG  - 4-5
LID - 10.1967/s002449912014 [doi]
AB  - "...but why think? Why not try the experiment?..." John Hunter (1728-1793), in a 
      letter to Edward Jenner. August 2(nd), 1775. When Galen of Pergamum (2(nd) c.
      A.D.), physician, philosopher and experimentalist, sought to ascertain the
      therapeutic properties of Theriac, an antidote of repute against poisons, he
      resorted to an experiment. Theriac or Theriaca was a compound drug, containing in
      some versions used in antiquity numerous components; Galen's own composition
      included over 70 ingredients! One of its uses was as an antidote against
      snakebites, a frequent peril for the Roman armies marching on in sandals. Galen
      spent most of his life in Rome and was elevated to Imperial Physician at the
      court of Marcus Aurelius, who apparently took daily doses of Theriac, which among
      other components included opium. Describing the experiment to his friend Pison,
      Galen wrote, "as I could not possibly conduct a trial on humans, I experimented
      on roosters" For his experiment, Galen, studied two groups of roosters, but he
      doesn't tell us how many animals he included in each category. Both groups were
      exposed to poisonous snakebites. All roosters who were fed with theriac prior to 
      exposure to viper bites survived, whereas in the second group that had not
      received prophylactic Theriac, all roosters died. Not only is Galen's methodology
      remarkable, preceding the modern randomised trial by eighteen centuries, but more
      importantly, it is notable for his ethical stance at a time when sensitivities
      about human rights, prevalent in our times, were largely absent in societies of
      widespread slavery. For example, Mithridates VI (132-63 BC), the King of Pontus
      who is credited with the first use of Theriac, tested its efficacy on criminals
      and slaves. For his experiment Galen used the random allocation of treatment,
      today's prospective randomised clinical trial, implemented in the evaluation of
      novel therapies, widely used internationally, particularly in cancer research!
      This experimental method used for ascertaining the efficacy of new drugs became
      established after the second half of the 20(th) century and is now firmly
      entrenched as a research tool. On the other hand, the retrieval of information
      from observational studies or non-randomised series is considered scientifically 
      inferior and is often dismissed or ignored as irrelevant or anecdotal. Such is
      the compulsion for the randomised study that in the midst of the COVID-19
      pandemic, respected physicians and scientists appeared in the media hesitant to
      recommend the use of protective facial masks, as there was no evidence of benefit
      for their use from prospective randomised studies in the general population!
      Logic had no place in the argument! COVID-19, caused by the SARS-CoV-2 new corona
      virus, brought to the fore the randomised trial, as well as, the ethical dilemmas
      that surround the allocation of treatment at random, in the face of a devastating
      pandemic. Anthony Fauci, distinguished infectious diseases expert and an adviser 
      to the President of the USA, at a recent briefing from the Situation Room of the 
      White House, endorsed categorically and unreservedly the randomised trial for the
      evaluation of drugs potentially effective against SARS-CoV-2, in patients
      afflicted with COVID-19. A few days later on April 8(th), 2020, Professor Sotiris
      Tsiodras, scientific advisor to the Greek Government for COVID-19 and an expert
      on infectious diseases, when asked by a journalist about chloroquine, he
      responded, "Antony Fauci is correct. Nevertheless, we give the drug to everyone, 
      that is, not half of the patients will receive it, and the other half will not". 
      If we accept that the randomised trial represents the unique, impregnable method 
      of evaluating new treatments-several clinicians dispute this dogma. -the question
      arises how will treatments be allocated to patients? According to the Declaration
      of Helsinki participation of a subject in a clinical trial requires their
      explicit written consent. Will, a potentially hypoxic patient rapidly
      deteriorating, be able to understand what is being asked of them, and will that
      patient be in a position to provide consent? And if that patient refuses to be
      randomised, what are the options? Is it his/her right to request the active
      treatment that a fellow patient is receiving in the next bed? Although the
      Declaration of Helsinki allows the option of no treatment or even placebo, where 
      no known treatment is available for a certain condition, such as COVID-19, it
      also emphasizes that "while the primary purpose of medical research is to
      generate new knowledge, this goal can never take precedence over the rights and
      interests of individual research subjects". Consider now the physicians and
      nurses on the first line of the battle against the pandemic; to the enormous
      pressures and risks that they experience daily, they may have to endure the added
      psychological burden of the randomised trial, knowing that half of their patients
      are receiving the promising drug, whilst the other half are denied the chance of 
      potential benefit. When during the Medical Research Council's randomized trial of
      streptomycin, one senior physician contracted tuberculosis, the Medical Research 
      Council obtained supplies for him outside the trial. In this brief instance of
      medical history, the equipoise, the scientific imperative, all arguments and
      other justifications for providing treatment at random, were thrown out of the
      window in favour of the human factor! Why is randomization necessary? Because-it 
      is presumed-the process of randomising subjects, protects the study from the
      selective inclusion of patients with favourable characteristics, thus
      inadvertently allowing or facilitating a falsely favourable result for the drug
      or treatment under investigation. However, the process of randomising patients
      does not necessarily result in the randomisation of the characteristics of their 
      disease. Exactly because of this, at the end of a randomised study, even if the
      prognostic variables are evenly represented and balanced in the strata, further
      confirmation of the result is sought with a statistical multifactorial analysis. 
      Such multifactorial analyses can also be applied to a non-randomised group of
      patients engaged in the trial of a new drug. Since the middle of the 20(th)
      century a generation of physicians have been trained to dismiss, or are incapable
      of evaluating the validity of a treatment beyond the established etiquette of the
      randomised study. This, some have argued, constitutes intellectual indolence, it 
      is not scientific robustness. Pandits foresee that the world will be different
      after the end of this pandemic. Perhaps human ingenuity will seek new
      investigative methods that will render the randomised clinical trial obsolete,
      both, on methodological and ethical grounds. Until then and even if we have to
      accept the scientific supremacy of the randomised study in the evaluation of
      novel therapies, the ethical considerations in the unprecedented circumstances of
      a relentless pandemic demand a more humane approach, befitting the beneficent
      precepts of the Hippocratic tradition.
FAU - Retsas, Spyros
AU  - Retsas S
AD  - Former Consultant Medical Oncologist, Formerly, Lead Clinician of the Melanoma
      Unit, Imperial College at Charing Cross Hospital, London, U.K. sretsas@msn.com.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hell J Nucl Med
JT  - Hellenic journal of nuclear medicine
JID - 101257471
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - *Randomized Controlled Trials as Topic/ethics/methods
MH  - Research Design
MH  - SARS-CoV-2
MH  - Therapeutic Equipoise
EDAT- 2020/05/04 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/05/04 06:00 [entrez]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - s002449912014 [pii]
AID - 10.1967/s002449912014 [doi]
PST - ppublish
SO  - Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.


PMID- 32361690
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1473-4265 (Electronic)
IS  - 1468-215X (Linking)
VI  - 46
IP  - 4
DP  - 2020 Dec
TI  - Exploring the conceptualisation and study of freebirthing as a historical and
      social phenomenon: a meta-narrative review of diverse research traditions.
PG  - 512-524
LID - 10.1136/medhum-2019-011786 [doi]
AB  - Freebirthing is a clandestine practice whereby women intentionally give birth
      without healthcare professionals (HCPs) present in countries where there are
      medical facilities available to assist them. Women who make this decision are
      frequently subjected to stigma and condemnation, yet research on the phenomenon
      suggests that women's motivations are often complex. The aim of this review was
      to explore how freebirth has been conceptualised over time in the
      English-language academic and grey literature. The meta-narrative methodology
      employed enables a phenomenon to be understood within and between differing
      research traditions, as well as against its social and historical context. Our
      research uncovered nine research traditions (nursing, autobiographical text with 
      birthing philosophy, midwifery, activism, medicine, sociology, law and ethics,
      pregnancy and birth advice, and anthropology) originating from eight countries
      and spanning the years 1957-2018. Most of the texts were written by women, with
      the majority being non-empirical. Empirical studies on freebirth were usually
      qualitative, although there were a small number of quantitative medical and
      midwifery studies; these texts often focused on women's motivations and
      highlighted a range of reasons as to why a woman would decide to give birth
      without HCPs present. Motivations frequently related to women's previous negative
      maternity experiences and the type of maternity care available, for example
      medicalised and hospital-based. The use of the meta-narrative methodology allowed
      the origins of freebirth in 1950s America to be traced to present-day empirical
      studies of the phenomenon. This highlighted how the subject and the publication
      of literature relating to freebirth are embedded within their social and
      historical contexts. From its very inception, freebirth aligns with the
      medicalisation of childbirth, the position of women in society, the provision of 
      maternity care and the way in which women experience maternity services.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - McKenzie, Gemma
AU  - McKenzie G
AUID- ORCID: http://orcid.org/0000-0003-2639-0636
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, UK gemma.mckenzie@kcl.ac.uk.
FAU - Robert, Glenn
AU  - Robert G
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, UK.
FAU - Montgomery, Elsa
AU  - Montgomery E
AD  - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's
      College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200502
PL  - United States
TA  - Med Humanit
JT  - Medical humanities
JID - 100959585
SB  - IM
MH  - *Concept Formation
MH  - Female
MH  - Humans
MH  - Maternal Health Services
MH  - Motivation
MH  - Parturition
MH  - Pregnancy
MH  - Qualitative Research
PMC - PMC7786152
OTO - NOTNLM
OT  - history
OT  - medical humanities
OT  - obstetrics
OT  - pregnancy
OT  - sociology
COIS- Competing interests: None declared.
EDAT- 2020/05/04 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - medhum-2019-011786 [pii]
AID - 10.1136/medhum-2019-011786 [doi]
PST - ppublish
SO  - Med Humanit. 2020 Dec;46(4):512-524. doi: 10.1136/medhum-2019-011786. Epub 2020
      May 2.


PMID- 32361481
OWN - NLM
STAT- Publisher
LR  - 20200615
IS  - 1873-4162 (Electronic)
IS  - 1344-6223 (Linking)
VI  - 45
DP  - 2020 Apr 23
TI  - Genetic variants of uncertain significance: How to match scientific rigour and
      standard of proof in sudden cardiac death?
PG  - 101712
LID - S1344-6223(20)30046-8 [pii]
LID - 10.1016/j.legalmed.2020.101712 [doi]
AB  - In many SCD cases, in particular in pediatric age, autopsy can be completely
      negative and then a post-mortem genetic testing (molecular autopsy) is indicated.
      In NGS era finding new/rare variants is extremely frequent and, when only
      variants of unknown significance are found, molecular autopsy fails to find a
      cause of death. We describe the emblematic case of the sudden death of a
      7-year-old girl. We performed a full-body micro-CT analysis, an accurate autopsy,
      a serum tryptase test and toxicological tests. Since the only macroscopic
      abnormality we found was a myocardial bridging (length: 1,1 cm, thickness: 0,5
      cm) of the left anterior descending coronary artery, a molecular autopsy has been
      performed. NGS analysis on victim DNA detected rare variants in DPP6, MYH7, SCN2B
      and NOTCH1 and segregation analysis was then achieved. On the basis of ACMG/AMP
      (clinical) guidelines, all the found variants were classified as of unknown
      significance. In other words, both the macroscopic and genetic anomalies we found
      were of uncertain significance and then the autopsy failed to find the cause of
      the death. Our case raises three main discussion points: (a) economical, ethical 
      and legal limitations of genetic investigation; (b) risk that genetic testing
      does not succeed in finding a certain cause of the death; (c) absence of specific
      guidelines to face the problem of VUS in forensic cases.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Grassi, Simone
AU  - Grassi S
AD  - Institute of Public Health, Section of Legal Medicine, Catholic University, Rome,
      Italy.
FAU - Campuzano, Oscar
AU  - Campuzano O
AD  - Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain;
      Medical Science Department, School of Medicine, University of Girona, Girona,
      Spain; Centro Investigacion Biomedica Red Enfermedades Cardiovasculares, Madrid, 
      Spain; Department of Biochemistry and Molecular Genetics, Hospital Clinic,
      IDIBAPS, Barcelona, Spain.
FAU - Coll, Monica
AU  - Coll M
AD  - Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
FAU - Brion, Maria
AU  - Brion M
AD  - Genetics of Cardiovascular and Ophthalmological Diseases, Health Research
      Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain;
      Genomic Medicine, University of Santiago de Compostela, IDIS, CIBERER, Santiago
      de Compostela, Spain.
FAU - Arena, Vincenzo
AU  - Arena V
AD  - Institute of Anatomical Pathology, Catholic University, Rome, Italy.
FAU - Iglesias, Anna
AU  - Iglesias A
AD  - Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
FAU - Carracedo, Angel
AU  - Carracedo A
AD  - Genomic Medicine, University of Santiago de Compostela, IDIS, CIBERER, Santiago
      de Compostela, Spain.
FAU - Brugada, Ramon
AU  - Brugada R
AD  - Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain;
      Medical Science Department, School of Medicine, University of Girona, Girona,
      Spain; Centro Investigacion Biomedica Red Enfermedades Cardiovasculares, Madrid, 
      Spain; Cardiology Service, Hospital Josep Trueta, Girona, Spain.
FAU - Oliva, Antonio
AU  - Oliva A
AD  - Institute of Public Health, Section of Legal Medicine, Catholic University, Rome,
      Italy. Electronic address: antonio.oliva@unicatt.it.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - Ireland
TA  - Leg Med (Tokyo)
JT  - Legal medicine (Tokyo, Japan)
JID - 100889186
SB  - IM
OTO - NOTNLM
OT  - Myocardial bridging
OT  - NGS
OT  - Pathologist responsibility
OT  - Sudden cardiac death
OT  - Unknown significance variants
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/05/04 06:00
MHDA- 2020/05/04 06:00
CRDT- 2020/05/04 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2020/02/17 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2020/05/04 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S1344-6223(20)30046-8 [pii]
AID - 10.1016/j.legalmed.2020.101712 [doi]
PST - aheadofprint
SO  - Leg Med (Tokyo). 2020 Apr 23;45:101712. doi: 10.1016/j.legalmed.2020.101712.


PMID- 32360550
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1549-9642 (Electronic)
IS  - 1549-9634 (Linking)
VI  - 28
DP  - 2020 Aug
TI  - The importance of reflecting on treatment and post-treatment care when assessing 
      the social aspects of cosmetic nanomedicine and transdermal delivery system.
PG  - 102214
LID - S1549-9634(20)30068-X [pii]
LID - 10.1016/j.nano.2020.102214 [doi]
AB  - In the field of nanomedicine, the development of targeted drug delivery aims to
      design more effective delivery systems that directly target cancer cells and
      tumours. The development of transdermal delivery mechanisms is promising. At the 
      same time, these areas of research raise profound social and ethical questions
      and are tied to significant transformations in the nature of contemporary
      healthcare and personal subjectivity. Socio- political consideration of these
      issues is shaped by a wider set of debates concerning the societal dimensions of 
      nanotechnology. In this paper we report findings from an interdisciplinary
      research project uilising semi-structured interviews with key-informants engaged 
      in cancer research and health-care. We identified narrative constracts that
      shaped participants' responses to and understandings of novel nanomedicines. This
      analysis contributes to a growing body of literature on the social and ethical
      aspects of nanotechnology and nanomedicine, providing evidence for the engagement
      of publics in the early stage of technological developments.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Duche, Genevieve
AU  - Duche G
AD  - School of Chemistry, The University of New South Wales, Sydney, NSW, Australia;
      Australian Centre for Nanomedicine, and the ARC Centre of Excellence in
      Convergent Bio-Nano Science and Technology, The University of New South Wales,
      Sydney, NSW, Australia. Electronic address: gen.duche@yahoo.fr.
FAU - Thordarson, Pall
AU  - Thordarson P
AD  - School of Chemistry, The University of New South Wales, Sydney, NSW, Australia;
      Australian Centre for Nanomedicine, and the ARC Centre of Excellence in
      Convergent Bio-Nano Science and Technology, The University of New South Wales,
      Sydney, NSW, Australia.
FAU - Kearnes, Matthew
AU  - Kearnes M
AD  - Australian Centre for Nanomedicine, and the ARC Centre of Excellence in
      Convergent Bio-Nano Science and Technology, The University of New South Wales,
      Sydney, NSW, Australia; School of Humanities and Languages, The University of New
      South Wales, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200430
PL  - United States
TA  - Nanomedicine
JT  - Nanomedicine : nanotechnology, biology, and medicine
JID - 101233142
RN  - 0 (Cosmetics)
SB  - IM
MH  - Administration, Cutaneous
MH  - Cosmetics/analysis/chemistry
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Nanomedicine/*methods
MH  - Nanotechnology/*methods
OTO - NOTNLM
OT  - *Interdisciplinary
OT  - *Nanomedicine
OT  - *Social science
OT  - *Topical
EDAT- 2020/05/04 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/05/04 06:00
PHST- 2019/10/07 00:00 [received]
PHST- 2020/01/03 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S1549-9634(20)30068-X [pii]
AID - 10.1016/j.nano.2020.102214 [doi]
PST - ppublish
SO  - Nanomedicine. 2020 Aug;28:102214. doi: 10.1016/j.nano.2020.102214. Epub 2020 Apr 
      30.


PMID- 32360444
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20210110
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Linking)
VI  - 26
IP  - 7
DP  - 2020 Jul
TI  - Balancing evidence and frontline experience in the early phases of the COVID-19
      pandemic: current position of the Italian Society of Anti-infective Therapy
      (SITA) and the Italian Society of Pulmonology (SIP).
PG  - 880-894
LID - S1198-743X(20)30257-3 [pii]
LID - 10.1016/j.cmi.2020.04.031 [doi]
AB  - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
      causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become 
      epidemic in Italy and other European countries. The disease spectrum ranges from 
      asymptomatic/mildly symptomatic presentations to acute respiratory failure. At
      the present time the absolute number of severe cases requiring ventilator support
      is reaching or even surpassing the intensive care unit bed capacity in the most
      affected regions and countries. OBJECTIVES: To narratively summarize the
      available literature on the management of COVID-19 in order to combine current
      evidence and frontline opinions and to provide balanced answers to pressing
      clinical questions. SOURCES: Inductive PubMed search for publications relevant to
      the topic. CONTENT: The available literature and the authors' frontline-based
      opinion are summarized in brief narrative answers to selected clinical questions,
      with a conclusive statement provided for each answer. IMPLICATIONS: Many
      off-label antiviral and anti-inflammatory drugs are currently being administered 
      to patients with COVID-19. Physicians must be aware that, as they are not
      supported by high-level evidence, these treatments may often be ethically
      justifiable only in those worsening patients unlikely to improve only with
      supportive care, and who cannot be enrolled onto randomized clinical trials.
      Access to well-designed randomized controlled trials should be expanded as much
      as possible because it is the most secure way to change for the better our
      approach to COVID-19 patients.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Bassetti, M
AU  - Bassetti M
AD  - Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy;
      Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
      Electronic address: matteo.bassetti@unige.it.
FAU - Giacobbe, D R
AU  - Giacobbe DR
AD  - Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy;
      Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
FAU - Aliberti, S
AU  - Aliberti S
AD  - University of Milan, Department of Pathophysiology and Transplantation, Milan,
      Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal
      Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Milan,
      Italy.
FAU - Barisione, E
AU  - Barisione E
AD  - Interventional Pulmonology, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy.
FAU - Centanni, S
AU  - Centanni S
AD  - Department of Health Sciences, University of Milan, Respiratory Unit, ASST Santi 
      Paolo e Carlo, Milan, Italy.
FAU - De Rosa, F G
AU  - De Rosa FG
AD  - Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, 
      Italy.
FAU - Di Marco, F
AU  - Di Marco F
AD  - Department of Health Sciences, University of Milan, Respiratory Unit, ASST Papa
      Giovanni XXIII Hospital, Bergamo, Italy.
FAU - Gori, A
AU  - Gori A
AD  - Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore
      Policlinico, University of Milan, Milan, Italy.
FAU - Granata, G
AU  - Granata G
AD  - Clinical and Research Department for Infectious Diseases, Severe and
      Immunedepression-Associated Infections Unit, National Institute for Infectious
      Diseases L. Spallanzani, IRCCS, Rome, Italy.
FAU - Mikulska, M
AU  - Mikulska M
AD  - Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy;
      Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
FAU - Petrosillo, N
AU  - Petrosillo N
AD  - Clinical and Research Department for Infectious Diseases, Severe and
      Immunedepression-Associated Infections Unit, National Institute for Infectious
      Diseases L. Spallanzani, IRCCS, Rome, Italy.
FAU - Richeldi, L
AU  - Richeldi L
AD  - Dipartimento Scienze Gastroenterologiche, Endocrino-Metaboliche e
      Nefro-Urologiche, UOC Pneumologia, Fondazione Policlinico Universitario 'A.
      Gemelli' IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Santus, P
AU  - Santus P
AD  - Department of Biomedical and Clinical Sciences (DIBIC), University of Milan,
      Division of Respiratory Diseases, Luigi Sacco University Hospital, Milan, Italy.
FAU - Tascini, C
AU  - Tascini C
AD  - Infectious Diseases Clinic, Santa Maria Misericordia Hospital, Udine, Italy.
FAU - Vena, A
AU  - Vena A
AD  - Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy.
FAU - Viale, P
AU  - Viale P
AD  - Department of Medical and Surgical Sciences, Infectious Diseases Unit, Alma Mater
      Studiorum, University of Bologna, Bologna, Italy.
FAU - Blasi, F
AU  - Blasi F
AD  - University of Milan, Department of Pathophysiology and Transplantation, Milan,
      Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal
      Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Milan,
      Italy.
CN  - Italian Society of Anti-infective Therapy (SITA) and the Italian Society of
      Pulmonology (SIP)
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200429
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - Betacoronavirus/*drug effects
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy/epidemiology
MH  - Humans
MH  - Intensive Care Units/statistics & numerical data
MH  - Italy/epidemiology
MH  - Lung Diseases/drug therapy/pathology/virology
MH  - Off-Label Use/*ethics
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy/epidemiology
MH  - Respiration, Artificial/methods
MH  - SARS-CoV-2
PMC - PMC7195088
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Pneumonia
OT  - SARS-CoV-2
OT  - Therapy
EDAT- 2020/05/04 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S1198-743X(20)30257-3 [pii]
AID - 10.1016/j.cmi.2020.04.031 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2020 Jul;26(7):880-894. doi: 10.1016/j.cmi.2020.04.031.
      Epub 2020 Apr 29.


PMID- 32360429
OWN - NLM
STAT- MEDLINE
DCOM- 20210305
LR  - 20210305
IS  - 1879-0135 (Electronic)
IS  - 0020-7519 (Linking)
VI  - 50
IP  - 5
DP  - 2020 May
TI  - Methods to assess the effect of meat processing on viability of Toxoplasma
      gondii: towards replacement of mouse bioassay by in vitro testing.
PG  - 357-369
LID - S0020-7519(20)30092-8 [pii]
LID - 10.1016/j.ijpara.2020.04.001 [doi]
AB  - Consumption of meat containing viable tissue cysts is considered one of the main 
      sources of human infection with Toxoplasma gondii. In contrast to fresh meat, raw
      meat products usually undergo processing, including salting and mixing with other
      additives such as sodium acetate and sodium lactate, which affects the viability 
      of T. gondii. However, the experiments described in the literature are not always
      performed in line with the current processing methods applied in industry. It was
      our goal to study the effect of salting and additives according to the recipes
      used by industrial producers. Mouse or cat bioassay is the 'gold standard' to
      demonstrate the presence of viable T. gondii. However, it is costly, time
      consuming and for ethical reasons not preferred for large-scale
      studies.Therefore, we first aimed to develop an alternative for mouse bioassay
      that can be used to determine the effect of processing on the viability of T.
      gondii tissue cysts. The assays studied were (i) a cell culture method to
      determine the parasite's ability to multiply, and (ii) a propidium monoazide
      (PMA) dye-based assay to selectively detect DNA from intact parasites. Processing
      experiments were performed with minced meat incubated for 20 h with low
      concentrations of NaCl, sodium lactate and sodium acetate. NaCl appeared to be
      the most effective ingredient with only one or two out of eight mice infected
      after inoculation with pepsin-digest of portions processed with 1.0, 1.2 and 1.6%
      NaCl. Results of preliminary experiments with the PMA-based method were
      inconsistent and did not sufficiently discriminate between live and dead
      parasites. In contrast, the cell culture method showed promising results, but
      further optimization is needed before it can replace or reduce the number of
      mouse bioassays needed. In future, standardised in vitro methods are necessary to
      allow more extensive testing of product-specific processing methods, thereby
      providing a better indication of the risk of T. gondii infection for consumers.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Opsteegh, Marieke
AU  - Opsteegh M
AD  - Centre for Infectious Disease Control - Zoonoses and Environmental Microbiology, 
      National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA
      Bilthoven, The Netherlands. Electronic address: marieke.opsteegh@rivm.nl.
FAU - Dam-Deisz, Cecile
AU  - Dam-Deisz C
AD  - Centre for Infectious Disease Control - Zoonoses and Environmental Microbiology, 
      National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA
      Bilthoven, The Netherlands.
FAU - de Boer, Paulo
AU  - de Boer P
AD  - TNO (Netherlands Organisation for Applied Scientific Research), Microbiology &
      Systems Biology, 3704 HE Zeist, The Netherlands.
FAU - DeCraeye, Stephane
AU  - DeCraeye S
AD  - Sciensano, Service of Foodborne Pathogens, Rue Juliette Wytsmanstraat 14, 1050
      Brussels, Belgium.
FAU - Fare, Andrea
AU  - Fare A
AD  - Luiten Vleeswaren, Production Company of Artisanal Meat Products, Edisonstraat
      70, 2723 RR Zoetermeer, The Netherlands.
FAU - Hengeveld, Paul
AU  - Hengeveld P
AD  - Centre for Infectious Disease Control - Zoonoses and Environmental Microbiology, 
      National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA
      Bilthoven, The Netherlands.
FAU - Luiten, Ruud
AU  - Luiten R
AD  - Luiten Vleeswaren, Production Company of Artisanal Meat Products, Edisonstraat
      70, 2723 RR Zoetermeer, The Netherlands.
FAU - Schares, Gereon
AU  - Schares G
AD  - Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health,
      Institute of Epidemiology, National Reference Centre for Toxoplasmosis, Sudufer
      10, 17493 Greifswald-Insel Riems, Germany.
FAU - van Solt-Smits, Conny
AU  - van Solt-Smits C
AD  - Wageningen Bioveterinary Research, P.O. Box 65, 8200 AB Lelystad, The
      Netherlands.
FAU - Verhaegen, Bavo
AU  - Verhaegen B
AD  - Sciensano, Service of Foodborne Pathogens, Rue Juliette Wytsmanstraat 14, 1050
      Brussels, Belgium.
FAU - Verkleij, Theo
AU  - Verkleij T
AD  - TNO (Netherlands Organisation for Applied Scientific Research), Microbiology &
      Systems Biology, 3704 HE Zeist, The Netherlands; Wageningen Food & Biobased
      Research, P.O. Box 17, 6700 AA Wageningen, The Netherlands.
FAU - van der Giessen, Joke
AU  - van der Giessen J
AD  - Centre for Infectious Disease Control - Zoonoses and Environmental Microbiology, 
      National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA
      Bilthoven, The Netherlands.
FAU - Wisselink, Henk J
AU  - Wisselink HJ
AD  - Wageningen Bioveterinary Research, P.O. Box 65, 8200 AB Lelystad, The
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200428
PL  - England
TA  - Int J Parasitol
JT  - International journal for parasitology
JID - 0314024
RN  - 451W47IQ8X (Sodium Chloride)
SB  - IM
MH  - Animals
MH  - Biological Assay/*methods
MH  - Cats
MH  - Cell Culture Techniques
MH  - Food Parasitology/methods
MH  - Humans
MH  - Meat Products/*parasitology
MH  - Mice
MH  - Sodium Chloride/pharmacology
MH  - *Toxoplasma/drug effects/parasitology
MH  - Toxoplasmosis/transmission
MH  - Toxoplasmosis, Animal
OTO - NOTNLM
OT  - *Food safety
OT  - *Inactivation
OT  - *Meat
OT  - *Salting
OT  - *Toxoplasma gondii
OT  - *Viability
EDAT- 2020/05/04 06:00
MHDA- 2021/03/06 06:00
CRDT- 2020/05/04 06:00
PHST- 2019/09/23 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2021/03/06 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S0020-7519(20)30092-8 [pii]
AID - 10.1016/j.ijpara.2020.04.001 [doi]
PST - ppublish
SO  - Int J Parasitol. 2020 May;50(5):357-369. doi: 10.1016/j.ijpara.2020.04.001. Epub 
      2020 Apr 28.


PMID- 32360403
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 30
IP  - 4
DP  - 2020 Apr
TI  - Randomisation versus prioritisation in a managed access programme: Lessons from
      spinal muscular atrophy.
PG  - 267-269
LID - S0960-8966(20)30082-1 [pii]
LID - 10.1016/j.nmd.2020.03.006 [doi]
FAU - Servais, Laurent
AU  - Servais L
AD  - MDUK Oxford Neuromuscular Center, Department of Paediatrics, Oxford University,
      UK; Division of Child Neurology, Centre de References des Maladies
      Neuromusculaires, Department of Pediatrics, University Hospital Liege &
      University of Liege, Belgium. Electronic address:
      laurent.servais@paediatrics.ox.ac.uk.
FAU - Kirschner, Janbernd
AU  - Kirschner J
AD  - Department of Neuropediatrics, University Hospital Bonn, Bonn, Germany.
FAU - Muntoni, Francesco
AU  - Muntoni F
AD  - Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health 
      and Great Ormond Street Hospital, London, UK; NIHR Great Ormond Street Hospital
      Biomedical Research Centre, Great Ormond Street Institute of Child Health,
      University College London, & Great Ormond Street Hospital Trust, London, UK.
LA  - eng
PT  - Editorial
DEP - 20200417
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
SB  - IM
MH  - *Genetic Therapy
MH  - Health Services Accessibility/*ethics
MH  - Humans
MH  - Muscular Atrophy, Spinal/*therapy
MH  - *Program Development
MH  - Random Allocation
MH  - Resource Allocation
OTO - NOTNLM
OT  - *Ethics
OT  - *Gene therapy
OT  - *Managed access programme
OT  - *Spinal Muscular Atrophy
OT  - *Treatment
COIS- Declaration of Competing Interest LS has received research support from Avexis,
      Roche and Biogen, and consultancy fees/ board member of Avexis, Biogen, Roche and
      Cytokinetics. JK has received research support from Roche and Biogen, and
      consultancy fees from Avexis, Biogen, Roche and Scholar Rock. FM has received
      research support from Roche, Avexis and Biogen, and consultancy fees from Avexis,
      Biogen, Roche and Novartis.
EDAT- 2020/05/04 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S0960-8966(20)30082-1 [pii]
AID - 10.1016/j.nmd.2020.03.006 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2020 Apr;30(4):267-269. doi: 10.1016/j.nmd.2020.03.006. Epub 
      2020 Apr 17.


PMID- 32360321
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1879-176X (Electronic)
IS  - 0300-5712 (Linking)
VI  - 98
DP  - 2020 Jul
TI  - Developing a questionnaire to measure psychological disturbance associated with
      tooth loss.
PG  - 103353
LID - S0300-5712(20)30095-6 [pii]
LID - 10.1016/j.jdent.2020.103353 [doi]
AB  - OBJECTIVES: To develop and validate a self-reporting measure to assess the
      psychological disturbance in adult patients with tooth loss and dentures Methods:
      Ethical approval obtained from the Health Research Authority NHS England
      (Ref:17/NI/0098). 128 participants (100 patients - 28 clinicians) were recruited 
      to participate in the development and validation of the questionnaire. Inclusion 
      criteria included adults (age >/=18) with tooth loss/dentures. Exclusion criteria
      included patients with a history of psychotic mental illness or patients who had 
      treatment with dental implants. The development processes included: Phase 1.
      Development of questionnaire: describing the aims/target population of the
      questionnaire, generating a pool of items, defining the constructs to be
      measured, adapting psychological morbidity screening tools, Items reduction and
      producing a preliminary questionnaire. Phase 2. Validation of questionnaire:
      content validation, face validation, establishing construct validity, pilot
      testing and establishing reliability. RESULTS: Face and content validation
      indicated that the questionnaire was an appropriate tool to measure the impact of
      tooth loss and related psychological morbidities. Reliability analysis (Test
      re-test reliability/internal consistency) indicated the questionnaire has
      satisfactory reliability (correlation >0.7). Testing the theoretical hypothesis
      structure of the impact of tooth loss has also enhanced the construct validity of
      the questionnaire (domains correlated mildly (r>5 & <3) to strongly (r>5). Pilot 
      testing confirmed the scale adequacy and wording clarity (>90 % of respondents). 
      Results indicated that the developed questionnaire has adequate psychometric
      properties. CONCLUSION: A disease-specific measure that assesses the
      psychological impact of tooth loss and the effectiveness of interventions (i.e.
      dentures) has been developed and validated. CLINICAL SIGNIFICANT: A patient
      outcome measure was developed which could be used to assess the psychological
      impact of tooth loss and compare the effectiveness of various interventions like 
      dentures and implants.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kudsi, Zaki
AU  - Kudsi Z
AD  - Emerson Green NHS Treatment Center, The Brooms, Emerson Green, BS16 7FH, United
      Kingdom. Electronic address: z.kudsi@nhs.net.
FAU - Fenlon, Michael R
AU  - Fenlon MR
AD  - Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London,
      London, United Kingdom. Electronic address: michael.fenlon@kcl.ac.uk.
FAU - Hill, Kirsty
AU  - Hill K
AD  - The School of Dentistry Edgbaston Birmingham, B5 7 EG, United Kingdom. Electronic
      address: k.b.hill@bham.ac.uk.
FAU - Baysan, Aylin
AU  - Baysan A
AD  - Institute of Dentistry, Queen Mary University of London, United Kingdom.
      Electronic address: a.baysan@qmul.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - J Dent
JT  - Journal of dentistry
JID - 0354422
SB  - IM
MH  - Adult
MH  - Humans
MH  - Psychometrics
MH  - Quality of Life
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
MH  - *Tooth Loss
OTO - NOTNLM
OT  - *Anxiety
OT  - *Dentures
OT  - *Depression
OT  - *Stress
OT  - *Tooth loss
EDAT- 2020/05/04 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S0300-5712(20)30095-6 [pii]
AID - 10.1016/j.jdent.2020.103353 [doi]
PST - ppublish
SO  - J Dent. 2020 Jul;98:103353. doi: 10.1016/j.jdent.2020.103353. Epub 2020 Apr 29.


PMID- 32360015
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1878-1306 (Electronic)
IS  - 0195-5616 (Linking)
VI  - 50
IP  - 4
DP  - 2020 Jul
TI  - Integrating Science and Well-Being.
PG  - 899-904
LID - S0195-5616(20)30025-5 [pii]
LID - 10.1016/j.cvsm.2020.03.009 [doi]
AB  - Veterinary medicine has traditionally functioned as an art and a science, that
      is, as knowledge of general principles and knowledge of, and relationship with,
      the individual animal and their caregiver. With the advent of increasing
      specialization, this intimate knowledge of the individual is being lost. This has
      great ramifications for diagnosis and treatment. Knowing the particular
      personality and tendencies of the patient helps differentiate between behavioral 
      issues and fully medical issues. Excessive "scientization" in veterinary medicine
      needs to be addressed in veterinary medical education.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Rollin, Bernard E
AU  - Rollin BE
AD  - Colorado State University, Fort Collins, CO 80525, USA. Electronic address:
      Bernard.Rollin@Colostate.Edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200429
PL  - United States
TA  - Vet Clin North Am Small Anim Pract
JT  - The Veterinary clinics of North America. Small animal practice
JID - 7809942
SB  - IM
MH  - Animals
MH  - *Behavior, Animal
MH  - *Pets
MH  - *Science
MH  - *Veterinary Medicine
OTO - NOTNLM
OT  - Art and science of veterinary medicine
OT  - Ethics of specialization
OT  - Moral stress
OT  - Suicide
OT  - Veterinarians as animal advocates
OT  - Veterinarians as family members
COIS- Disclosure The author has nothing to disclose.
EDAT- 2020/05/04 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/04 06:00 [entrez]
AID - S0195-5616(20)30025-5 [pii]
AID - 10.1016/j.cvsm.2020.03.009 [doi]
PST - ppublish
SO  - Vet Clin North Am Small Anim Pract. 2020 Jul;50(4):899-904. doi:
      10.1016/j.cvsm.2020.03.009. Epub 2020 Apr 29.


PMID- 32359529
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20200928
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 31
IP  - 5
DP  - 2020 May
TI  - Research Ethics in IR: The Intersection Between Care and Progress.
PG  - 846-848
LID - S1051-0443(20)30200-1 [pii]
LID - 10.1016/j.jvir.2020.02.014 [doi]
FAU - Bozorghadad, Sayeh
AU  - Bozorghadad S
AD  - College of Medicine, Penn State University, Hershey, Pennsylvania.
FAU - Newton, Isabel G
AU  - Newton IG
AD  - Department of Radiology, Division of Vascular and Interventional Radiology,
      University of California San Diego, San Diego, California.
FAU - Perez, Andrew W
AU  - Perez AW
AD  - Department of Radiology, Division of Vascular and Interventional Radiology,
      Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Makary, Mina S
AU  - Makary MS
AD  - Department of Radiology, Division of Vascular and Interventional Radiology, The
      Ohio State University Wexner Medical Center, Columbus, Ohio.
FAU - Keller, Eric J
AU  - Keller EJ
AD  - Department of Radiology, Division of Vascular and Interventional Radiology,
      Stanford University, 300 Pasteur Drive, H3630, Stanford, CA 94305. Electronic
      address: ejkeller607@gmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
SB  - IM
MH  - Biomedical Research/*ethics
MH  - Conflict of Interest
MH  - Diffusion of Innovation
MH  - *Ethics, Research
MH  - Health Care Sector/ethics
MH  - Humans
MH  - Informed Consent/ethics
MH  - Patient Safety
MH  - Public-Private Sector Partnerships/ethics
MH  - Radiography, Interventional/adverse effects/*ethics
MH  - Radiology, Interventional/*ethics
MH  - Truth Disclosure/ethics
EDAT- 2020/05/04 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/05/04 06:00
PHST- 2019/11/21 00:00 [received]
PHST- 2020/02/08 00:00 [revised]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/05/04 06:00 [entrez]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - S1051-0443(20)30200-1 [pii]
AID - 10.1016/j.jvir.2020.02.014 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2020 May;31(5):846-848. doi: 10.1016/j.jvir.2020.02.014.


PMID- 32359503
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 1474-5488 (Electronic)
IS  - 1470-2045 (Linking)
VI  - 21
IP  - 5
DP  - 2020 May
TI  - Cancer in Syrian refugees in Jordan and Lebanon between 2015 and 2017.
PG  - e280-e291
LID - S1470-2045(20)30160-1 [pii]
LID - 10.1016/S1470-2045(20)30160-1 [doi]
AB  - Protracted conflicts in the Middle East have led to successive waves of refugees 
      crossing borders. Chronic, non-communicable diseases are now recognised as
      diseases that need to be addressed in such crises. Cancer, in particular, with
      its costly, multidisciplinary care, poses considerable financial and ethical
      challenges for policy makers. In 2014 and with funding from the United Nations
      High Commissioner for Refugees, we reported on cancer cases among Iraqi refugees 
      in Jordan (2010-12) and Syria (2009-11). In this Policy Review, we provide data
      on 733 refugees referred to the United Nations High Commissioner for Refugees in 
      Lebanon (2015-17) and Jordan (2016-17), analysed by cancer type, demographic risk
      factors, treatment coverage status, and cost. Results show the need for increased
      funding and evidence-based standard operating procedures across countries to
      ensure that patients have equitable access to care. We recommend a holistic
      response to humanitarian crises that includes education, screening, treatment,
      and palliative care for refugees and nationals and prioritises breast cancer and 
      childhood cancers.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Spiegel, Paul B
AU  - Spiegel PB
AD  - Department of International Health, Johns Hopkins University, Baltimore, MD, USA;
      Center for Humanitarian Health, Johns Hopkins University, Baltimore, MD, USA.
      Electronic address: pbspiegel@jhu.edu.
FAU - Cheaib, Joseph G
AU  - Cheaib JG
AD  - Department of International Health, Johns Hopkins University, Baltimore, MD, USA.
FAU - Aziz, Saad Abdel
AU  - Aziz SA
AD  - Department of International Health, Johns Hopkins University, Baltimore, MD, USA.
FAU - Abrahim, Orit
AU  - Abrahim O
AD  - Center for Humanitarian Health, Johns Hopkins University, Baltimore, MD, USA.
FAU - Woodman, Michael
AU  - Woodman M
AD  - Office of the United Nations High Commissioner for Refugees, Beirut, Lebanon.
FAU - Khalifa, Adam
AU  - Khalifa A
AD  - Office of the United Nations High Commissioner for Refugees, Damascus, Syria.
FAU - Jang, Minyoung
AU  - Jang M
AD  - Johns Hopkins Bloomberg School of Public Health, and Johns Hopkins University
      School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
FAU - Mateen, Farrah J
AU  - Mateen FJ
AD  - Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Harvard
      Medical School, Harvard University, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Lancet Oncol
JT  - The Lancet. Oncology
JID - 100957246
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Delivery of Health Care/economics/legislation & jurisprudence/*organization &
      administration
MH  - Female
MH  - Health Care Costs
MH  - *Health Policy/economics/legislation & jurisprudence
MH  - Humans
MH  - Jordan/epidemiology
MH  - Lebanon/epidemiology
MH  - Male
MH  - Medical Oncology/economics/legislation & jurisprudence/*organization &
      administration
MH  - Middle Aged
MH  - Neoplasms/diagnosis/economics/ethnology/*therapy
MH  - Policy Making
MH  - *Refugees/legislation & jurisprudence
MH  - Relief Work/economics/legislation & jurisprudence/*organization & administration
MH  - Syria/ethnology
MH  - Young Adult
EDAT- 2020/05/04 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/05/04 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/05/04 06:00 [entrez]
PHST- 2020/05/04 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - S1470-2045(20)30160-1 [pii]
AID - 10.1016/S1470-2045(20)30160-1 [doi]
PST - ppublish
SO  - Lancet Oncol. 2020 May;21(5):e280-e291. doi: 10.1016/S1470-2045(20)30160-1.


PMID- 32359145
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1526-4637 (Electronic)
IS  - 1526-2375 (Linking)
VI  - 21
IP  - 7
DP  - 2020 Nov 7
TI  - Ethical Considerations for Chronic Pain Care During a Pandemic.
PG  - 1327-1330
LID - 10.1093/pm/pnaa159 [doi]
FAU - Driver, Larry C
AU  - Driver LC
AD  - Section of Clinical Ethics, Department of Pain Medicine, The University of Texas 
      MD Anderson Cancer Center, Houston, Texas, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pain Med
JT  - Pain medicine (Malden, Mass.)
JID - 100894201
SB  - IM
MH  - *Chronic Pain/epidemiology
MH  - Humans
MH  - *Pandemics
EDAT- 2020/05/03 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/03 06:00 [entrez]
AID - 5828234 [pii]
AID - 10.1093/pm/pnaa159 [doi]
PST - ppublish
SO  - Pain Med. 2020 Nov 7;21(7):1327-1330. doi: 10.1093/pm/pnaa159.


PMID- 32358948
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201001
IS  - 1118-4841 (Print)
IS  - 1118-4841 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Mar
TI  - Might Reinfibulation be Medically Plausible in Carefully Screened Cases?
PG  - 165-181
LID - 10.29063/ajrh2020/v24i1.17 [doi]
AB  - In light of the relational account of autonomy and the modern (holistic and
      phenomenological) account of health, this paper examines ethical justifications
      for consensual' reinfibulation. Significant and constant discomfort in the body
      following deinfibulation might make a case for reinfibulation (considered as
      medical treatment in the traditional sense of the term). In any other case, the
      following requirements should be met for reinfibulation to be considered
      medically plausible: a) strong evidence that reinfibulation could help
      effectively improve woman's relational well-being, b) insignificant complications
      are expected, c) congruence between first-order and second-order autonomy or -in 
      the context of political liberalism- strong second-order autonomy, d) an -open
      door || for the woman to exit an oppressive context, e) rigorous scrutiny of
      woman's psychology, and f) woman's practical wisdom to organize her
      identity-related values, find a balance between her extreme emotions and realize 
      her own goal of meaningful life in accordance with her own conception of the
      good. Conclusively, in carefully screened cases and individually judged requests 
      for reinfibulation, it should not be ruled out that, after having been conducted 
      a multi-disciplinary in- depth investigation at social, psychological and medical
      level may be met conditions that make a case for reinfibulation.
FAU - Voultsos, Polychronis
AU  - Voultsos P
AD  - Department of Legal Medicine & Toxicology, School of Medicine, Faculty of Health 
      Sciences, Aristotle University of Thessaloniki, University Campus, 54124
      Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Nigeria
TA  - Afr J Reprod Health
JT  - African journal of reproductive health
JID - 9712263
SB  - IM
MH  - Circumcision, Female/*psychology/rehabilitation
MH  - Ethics, Medical
MH  - Female
MH  - Gynecologic Surgical Procedures/ethics/*psychology
MH  - Humans
MH  - *Women's Health
MH  - *Women's Rights
OTO - NOTNLM
OT  - Reinfibulation
OT  - autonomy
OT  - deinfibulation
OT  - health
OT  - sexuality
OT  - well-being
EDAT- 2020/05/03 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.29063/ajrh2020/v24i1.17 [doi]
PST - ppublish
SO  - Afr J Reprod Health. 2020 Mar;24(1):165-181. doi: 10.29063/ajrh2020/v24i1.17.


PMID- 32358768
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20210602
IS  - 1548-3576 (Electronic)
IS  - 1548-3568 (Linking)
VI  - 17
IP  - 3
DP  - 2020 Jun
TI  - Ethical Considerations in HIV eHealth Intervention Research: Implications for
      Informational Risk in Recruitment, Data Maintenance, and Consent Procedures.
PG  - 180-189
LID - 10.1007/s11904-020-00489-z [doi]
AB  - PURPOSE OF REVIEW: Along with the benefits of eHealth HIV interventions are
      challenges to participant privacy and confidentiality inherent in the use of
      online strategies. This paper reviews current guidelines and recent publications 
      to identify ethical issues and suggested solutions in recruitment, data
      management, and informed consent. RECENT FINDINGS: Across eHealth HIV research,
      recruitment, data collection, and storage efforts to protect informational risk
      highlight the tension between the investigators' ability to protect participant
      confidentiality and the evolving informational risk posed by the online platforms
      on which they are operating. Adequately addressing these challenges requires
      updating technical competencies and educating participants on their own
      responsibilities to guard against privacy violations. Additional protections are 
      required when interventions involve peer or community support, especially with
      minors. The rapid progression of technology presents challenges in solidifying
      best practices for future interventions. This article draws on published works
      describing investigator experiences to contribute to the ongoing development of
      guidance in this area.
FAU - Fisher, Celia B
AU  - Fisher CB
AD  - Center for Ethics Education and Department of Psychology, Fordham University, 117
      Dealy Hall, Rose Hill Campus, 441 E. Fordham Road, Bronx, NY, 10458, USA.
      fisher@fordham.edu.
FAU - Bragard, Elise
AU  - Bragard E
AD  - Department of Psychology, Fordham University, Bronx, NY, USA.
FAU - Bloom, Rachel
AU  - Bloom R
AD  - Department of Psychology, Fordham University, Bronx, NY, USA.
LA  - eng
GR  - R25 DA031608/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Curr HIV/AIDS Rep
JT  - Current HIV/AIDS reports
JID - 101235661
SB  - IM
MH  - Confidentiality/*ethics
MH  - HIV Infections/*prevention & control
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Patient Selection
MH  - *Privacy
MH  - Telemedicine/ethics
PMC - PMC7263316
MID - NIHMS1590242
OTO - NOTNLM
OT  - *Data privacy
OT  - *HIV
OT  - *Informed consent
OT  - *Mobile research
OT  - *Online recruitment
OT  - *Research ethics
OT  - *eHealth
EDAT- 2020/05/03 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/05/03 06:00 [entrez]
AID - 10.1007/s11904-020-00489-z [doi]
AID - 10.1007/s11904-020-00489-z [pii]
PST - ppublish
SO  - Curr HIV/AIDS Rep. 2020 Jun;17(3):180-189. doi: 10.1007/s11904-020-00489-z.


PMID- 32358614
OWN - NLM
STAT- MEDLINE
DCOM- 20200624
LR  - 20200624
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 113
IP  - 5
DP  - 2020 May
TI  - Virtue Ethics and the Physician: Aristotle's Burnout Antidote?
PG  - 211-212
LID - 10.14423/SMJ.0000000000001088 [doi]
FAU - Smith, Carolyn Ann
AU  - Smith CA
AD  - From the Loyola University Chicago, Chicago, Illinois.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
SB  - IM
MH  - *Burnout, Professional
MH  - *Ethical Theory
MH  - *Ethics, Medical
MH  - Humans
MH  - *Physicians
MH  - Principle-Based Ethics
MH  - *Virtues
EDAT- 2020/05/03 06:00
MHDA- 2020/06/25 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
AID - 10.14423/SMJ.0000000000001088 [doi]
AID - SMJ50785 [pii]
PST - ppublish
SO  - South Med J. 2020 May;113(5):211-212. doi: 10.14423/SMJ.0000000000001088.


PMID- 32358599
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 5
DP  - 2020 May 1
TI  - The mitochondrial DNA copy number of cumulus granulosa cells may be related to
      the maturity of oocyte cytoplasm.
PG  - 1120-1129
LID - 10.1093/humrep/deaa085 [doi]
AB  - STUDY QUESTION: Is the mitochondrial DNA (mtDNA) copy number of cumulus granulosa
      cells (CGCs) related to the maturation of oocyte cytoplasm? SUMMARY ANSWER:
      Compared with the mtDNA copy number of CGCs from germinal vesicles (GV), CGCs
      from Metaphase I (MI) oocytes appear to have a lower mtDNA copy number. WHAT IS
      KNOWN ALREADY: The growth and development of CGCs and oocyte are synchronised.
      The interaction between CGCs and the oocyte provides the appropriate balance of
      energy, which is necessary for mammalian oocyte development. Moreover, in the
      oocyte-cumulus complex (OCC), mature oocytes with higher mtDNA copy numbers tend 
      to have corresponding CGCs with higher mtDNA copy numbers. STUDY DESIGN, SIZE,
      DURATION: This is a prospective study of 302 OCCs obtained from 70 women
      undergoing in vitro fertilisation with intracytoplasmic sperm injection (ICSI) at
      the Reproductive and Genetic Hospital of CITIC-Xiangya, between 24 February 2018 
      and 21 December 2019. The CGCs were divided into three groups (GV, MI and MII
      stages) based on the maturation status of their corresponding oocyte. The sample 
      sizes (n = 302) of CGCs in the three stages were 63 (CGCGV), 70 (CGCMI) and 169
      (CGCMII), respectively. Some of the samples (n = 257) was used to quantify the
      mtDNA copy number, while the rest (n = 45) were used to analyse the expression
      level of mitochondrial genes. Furthermore, we retrieved 82 immature oocytes from 
      among the 257 OCCs used for mtDNA copy numbers, including 36 GV oocytes and 46 MI
      oocytes, for analysis of oocyte mtDNA. PARTICIPANTS/MATERIALS, SETTING, METHODS: 
      We selected genes with high consistency of real-time PCR results to accurately
      measure the mtDNA copy number by testing the efficacy and the reproducibility in 
      whole genome amplification (WGA) samples from a human embryonic stem cell line.
      The CGCs of each oocyte were individually isolated. The mtDNA copy number and
      gene expression of the CGCs were assessed using real-time PCR techniques.
      Mitochondrial DNA copy number of the corresponding immature oocytes was also
      evaluated. MAIN RESULTS AND THE ROLE OF CHANCE: MT-ND1, MT-CO1 and beta-globin
      genes were chosen for the assessment of mtDNA content, and mRNA expressions of
      MT-ND1, MT-CO1, PGC-1alpha and TFAM were also measured. The genome of 257 CGCs
      and 82 immature oocytes were amplified according to the multiple displacement
      amplification (MDA) protocol, and RNA was extracted from 45 CGCs. Compared with
      CGCGV, CGCMI had a significantly lower mtDNA copy number. In the MT-ND1 assay,
      the CGCGV: CGCMI was [270 +/- 302]: [134 +/- 201], P = 0.015. In the MT-CO1
      assay, CGCGV: CGCMI was [205 +/- 228]: [92 +/- 112], P = 0.026. There was no
      statistical difference in mtDNA between CGCGV and CGCMII. In the MT-ND1 assay,
      CGCGV: CGCMII was [270 +/- 302]: [175 +/- 223], P = 0.074. In the MT-CO1 assay,
      CGCGV: CGCMII was [205 +/- 228]: [119 +/- 192], P = 0.077. No statistical
      difference of mtDNA copy number was observed between CGCMI and CGCMII. In the
      MT-ND1 assay, CGCMI: CGCMII was [134 +/- 201]: [175 +/- 223], P = 0.422. In the
      MT-CO1 assay, CGCMI: CGCMII was [92 +/- 112]: [119 +/- 192], P = 0.478. To verify
      the reliability of the above results, we further analysed the mtDNA copy number
      of CGCs of 14 patients with GV, MI and MII oocytes, and the results showed that
      the mtDNA copy number of CGCMI may be lower. The mtDNA copy number of CGCGV and
      CGCMI was statistically different in the MT-ND1 assay where CGCGV: CGCMI was [249
      +/- 173]: [118 +/- 113], P = 0.016, but in the MT-CO1 assay, CGCGV: CGCMI was
      [208 +/- 199]: [83 +/- 98], P = 0.109. There was no significant difference in
      mtDNA between CGCGV and CGCMII. In the MT-ND1 assay, CGCGV: CGCMII was [249 +/-
      173]: [185 +/- 200], P = 0.096. In the MT-CO1 assay, CGCGV: CGCMII was [208 +/-
      199]: [114 +/- 139], P = 0.096. There was also no significant difference in mtDNA
      between CGCMI and CGCMII. In the MT-ND1 assay, CGCMI: CGCMII was [118 +/- 113]:
      [185 +/- 200], P = 0.198. In the MT-CO1 assay, CGCMI: CGCMII was [83 +/- 98]:
      [114 +/- 139], P = 0.470. Moreover, there were no statistical differences in the 
      expression levels of MT-ND1, MT-CO1, PGC-1alpha and TFAM between CGCGV, CGCMI and
      CGCMII (P > 0.05). LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Due
      to the ethical issues, the study did not quantify the mtDNA content of MII
      oocytes. Thus, whether the change in mtDNA copy number in CGCs is related to the 
      different developmental stages of oocytes has not been further confirmed.
      Moreover, the sample size was relatively small. WIDER IMPLICATIONS OF THE
      FINDINGS: The mtDNA copy number of CGCs decreases from the GV phase to the MI
      phase and stays steady from the MI to MII stage. At different stages of oocyte
      maturation, the mtDNA of CGCs may undergo self-degradation and replication to
      meet the energy requirements of the corresponding oocyte and the maturation of
      the oocyte cytoplasm. STUDY FUNDING/COMPETING INTEREST(S): Funding was provided
      by the National Key R&D Program of China (Grant 2018YFC1003100, to L.H.), the
      science and technology major project of the Ministry of Science and Technology of
      Hunan Province, China (grant 2017SK1030, to G.L.), the National Natural Science
      Foundation of China (grant 81873478, to L.H.), and Merck Serono China Research
      Fund for Fertility Experts (to L.H.). There is no conflict of interest.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Lan, Yueyun
AU  - Lan Y
AD  - Institute of Reproduction and Stem Cell Engineering, School of Basic Medical
      Science, Central South University, Changsha, Hunan, China.
AD  - Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
AD  - Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research
      Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi
      Zhuang Autonomous Region, Nanning, China.
FAU - Zhang, Shuoping
AU  - Zhang S
AD  - Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
AD  - Clinical Research Center For Reproduction and Genetics in Hunan Province,
      Changsha, Hunan, China.
FAU - Gong, Fei
AU  - Gong F
AD  - Institute of Reproduction and Stem Cell Engineering, School of Basic Medical
      Science, Central South University, Changsha, Hunan, China.
AD  - Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
AD  - NHC Key Laboratory of Human Stem Cell and Reproductive Engineering (Central South
      University), Changsha, Hunan, China.
AD  - Clinical Research Center For Reproduction and Genetics in Hunan Province,
      Changsha, Hunan, China.
FAU - Lu, Changfu
AU  - Lu C
AD  - Institute of Reproduction and Stem Cell Engineering, School of Basic Medical
      Science, Central South University, Changsha, Hunan, China.
AD  - Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
AD  - NHC Key Laboratory of Human Stem Cell and Reproductive Engineering (Central South
      University), Changsha, Hunan, China.
AD  - Clinical Research Center For Reproduction and Genetics in Hunan Province,
      Changsha, Hunan, China.
FAU - Lin, Ge
AU  - Lin G
AD  - Institute of Reproduction and Stem Cell Engineering, School of Basic Medical
      Science, Central South University, Changsha, Hunan, China.
AD  - Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
AD  - National Engineering and Research Center of Human Stem Cells, Changsha, Hunan,
      China.
AD  - NHC Key Laboratory of Human Stem Cell and Reproductive Engineering (Central South
      University), Changsha, Hunan, China.
AD  - Clinical Research Center For Reproduction and Genetics in Hunan Province,
      Changsha, Hunan, China.
FAU - Hu, Liang
AU  - Hu L
AD  - Institute of Reproduction and Stem Cell Engineering, School of Basic Medical
      Science, Central South University, Changsha, Hunan, China.
AD  - Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
AD  - National Engineering and Research Center of Human Stem Cells, Changsha, Hunan,
      China.
AD  - NHC Key Laboratory of Human Stem Cell and Reproductive Engineering (Central South
      University), Changsha, Hunan, China.
AD  - Clinical Research Center For Reproduction and Genetics in Hunan Province,
      Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (DNA, Mitochondrial)
SB  - IM
MH  - Animals
MH  - China
MH  - *Cumulus Cells
MH  - DNA Copy Number Variations
MH  - *DNA, Mitochondrial/genetics
MH  - Female
MH  - Humans
MH  - In Vitro Oocyte Maturation Techniques
MH  - Oocytes
MH  - Prospective Studies
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - *cumulus granulosa cells
OT  - *energy metabolism
OT  - *gene expression
OT  - *mitochondrial DNA
OT  - *oocyte cytoplasm
EDAT- 2020/05/03 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/05/03 06:00
PHST- 2019/07/14 00:00 [received]
PHST- 2020/02/20 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/05/03 06:00 [entrez]
AID - 5827225 [pii]
AID - 10.1093/humrep/deaa085 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 May 1;35(5):1120-1129. doi: 10.1093/humrep/deaa085.


PMID- 32358593
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20211102
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 16
IP  - 11
DP  - 2020 Nov
TI  - The ethics of genetic testing for kidney diseases.
PG  - 619-620
LID - 10.1038/s41581-020-0294-5 [doi]
FAU - Sabatello, Maya
AU  - Sabatello M
AUID- ORCID: http://orcid.org/0000-0003-4444-5389
AD  - Center for Research on Ethical, Legal & Social Implications of Psychiatric,
      Neurologic & Behavioral Genetics, Department of Psychiatry, Columbia University, 
      New York, NY, USA. ms4075@columbia.edu.
FAU - Milo Rasouly, Hila
AU  - Milo Rasouly H
AD  - Division of Nephrology, Department of Medicine, Columbia University, College of
      Physicians and Surgeons, New York, NY, USA.
LA  - eng
GR  - K01 HG008653/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200501
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
SB  - IM
MH  - Genetic Testing/*ethics/trends
MH  - Genomics/*ethics/trends
MH  - Humans
MH  - Kidney Diseases/*genetics
MH  - Nephrology/*ethics/trends
PMC - PMC7572470
MID - NIHMS1590110
EDAT- 2020/05/03 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/05/03 06:00 [entrez]
AID - 10.1038/s41581-020-0294-5 [doi]
AID - 10.1038/s41581-020-0294-5 [pii]
PST - ppublish
SO  - Nat Rev Nephrol. 2020 Nov;16(11):619-620. doi: 10.1038/s41581-020-0294-5. Epub
      2020 May 1.


PMID- 32358371
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 18
DP  - 2020 May
TI  - The cardiovascular risk of celecoxib for knee osteoarthritis: A protocol for
      systematic review and meta-analysis.
PG  - e19976
LID - 10.1097/MD.0000000000019976 [doi]
AB  - OBJECTIVE: The aim of this systematic review and meta-analysis is to assess the
      cardiovascular (CV) risk of celecoxib on knee osteoarthritis (KOA) patients
      compared with the risk in those prescribed other non-selective non-steroidal
      anti-inflammatory drugs (NSAIDs), no intervention or placebo-controlled patients.
      METHODS: The following databases will be searched: MEDLINE, EMBASE, the Cochrane 
      Library, Web of Science, Chinese Biomedical Literature Database, Chinese Nation
      Knowledge Infrastructure, Wanfang Database, and the Chongqing VIP from inception 
      to April 1, 2020. All randomized controlled trials (RCTs) of celecoxib that
      presented data on serious cardiovascular events among KOA patients will be
      included. Study selection, data extraction, quality assessment, and assessment of
      risk bias will be performed by 2 reviewers independently. Odds ratios and
      correlative 95% confidence intervals will be calculated to present the
      association between the celecoxib and CV risk using Review Manager version 5.3
      when there is sufficient available data. ETHICS AND DISSEMINATION: This review
      does not require ethical approval. The results of this review may be published in
      a peer-reviewed journal or disseminated at relevant conferences. PROSPERO
      REGISTRATION NUMBER: CRD42020166721.
FAU - Cheng, Shirui
AU  - Cheng S
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
FAU - Xin, Ming
AU  - Xin M
AD  - The Rehabilitation Department, Chengdu Fifth People's Hospital, Chengdu, Sichuan,
      China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
FAU - Cheng, Ying
AU  - Cheng Y
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
AD  - The Cheng Clinic Limited, London, England.
FAU - Xu, Guixing
AU  - Xu G
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
FAU - Zhou, Yuanfang
AU  - Zhou Y
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
FAU - Li, Zhengjie
AU  - Li Z
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
FAU - Liang, Fanrong
AU  - Liang F
AD  - The Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
      Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Cardiovascular Diseases/*chemically induced
MH  - Celecoxib/*adverse effects
MH  - Humans
MH  - Odds Ratio
MH  - Osteoarthritis, Knee/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Risk Factors
PMC - PMC7440337
EDAT- 2020/05/03 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
AID - 10.1097/MD.0000000000019976 [doi]
AID - 00005792-202005010-00033 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(18):e19976. doi: 10.1097/MD.0000000000019976.


PMID- 32358370
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 18
DP  - 2020 May
TI  - Bee venom acupuncture for adhesive capsulitis: A protocol for systematic review
      and meta-analysis.
PG  - e19975
LID - 10.1097/MD.0000000000019975 [doi]
AB  - BACKGROUND: Bee venom acupuncture has been used in treating patients with
      shoulder adhesive capsulitis, yet the effectiveness and safety remains unclear.
      Therefore, this systematic review will aim to assess the effectiveness and safety
      of bee venom acupuncture for shoulder adhesive capsulitis. METHODS: Electronic
      databases including EMBASE, PUBMED, the Cochrane Central Register of Controlled
      Trials, China National Knowledge Infrastructure, Chinese Scientific Journal
      Database, Wanfang Database, and Chinese Biomedical Literature Database will be
      searched for relevant randomized controlled trials from their inception to the
      search data without language and publication status. Randomized controlled trials
      involving bee venom acupuncture for treating shoulder adhesive capsulitis will be
      included. The primary outcome will be pain visual analogue scale, and secondary
      outcomes include active and passive range of motions, shoulder pain and
      disability index. Meta-analysis will be conducted using Review Manager software
      (V.5.3). The results will be presented as risk ratio for dichotomous data, and
      standardized or weighted mean difference for continuous data. RESULTS: The
      results will be disseminated through a peer-reviewed journal publication.
      CONCLUSION: These systematic review findings will provide an evidence of bee
      venom acupuncture for shoulder adhesive capsulitis, and help to inform clinical
      practitioners and policy-makers in the decision-making. ETHICS AND DISSEMINATION:
      Ethics approval and patient consent are not required as this study is a
      systematic review based on published articles.
FAU - Chen, Xiaohua
AU  - Chen X
AD  - Department of Central Transportation Center, West China Hospital, Sichuan
      University.
FAU - Fan, Huaying
AU  - Fan H
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Chen, Jiao
AU  - Chen J
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
FAU - Fan, Huayu
AU  - Fan H
AD  - Respiratory Failure Center and Lung Transplant Unit, Sicuhan Province Hospital,
      Chengdu City, Sichuan Province, China.
FAU - Wu, Ping
AU  - Wu P
AD  - College of Acupuncture and Tuina, Chengdu University of Traditional Chinese
      Medicine.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Bee Venoms)
SB  - IM
MH  - Acupuncture Therapy/adverse effects/*methods
MH  - Bee Venoms/*administration & dosage/adverse effects
MH  - Bursitis/*therapy
MH  - Disability Evaluation
MH  - Humans
MH  - Pain Measurement
MH  - Randomized Controlled Trials as Topic
MH  - Range of Motion, Articular
MH  - Research Design
PMC - PMC7440301
EDAT- 2020/05/03 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
AID - 10.1097/MD.0000000000019975 [doi]
AID - 00005792-202005010-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(18):e19975. doi: 10.1097/MD.0000000000019975.


PMID- 32358359
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 18
DP  - 2020 May
TI  - To assess hemodynamic disturbances to the ostia of the renal arteries generated
      by the implantation of EVAR with a suprarenal fixation.
PG  - e19917
LID - 10.1097/MD.0000000000019917 [doi]
AB  - INTRODUCTION: The treatment of abdominal aortic aneurysm (AAA) is increasingly
      performed via endovascular aneurysm repair (EVAR). Different types of fixation
      are possible with EVAR, i.e., below (infrarenal fixation) or above (suprarenal
      fixation) the renal arteries. Hemodynamic alterations in renal arterial flow with
      suprarenal (SR) fixation remain to be demonstrated. The IFIXEAR (Impact of
      Supra-renal Fixation of EVAR on Hemodynamics of Renal Arteries) study is designed
      to assess the hemodynamic effects at the ostia of at least 1 renal artery,
      generated immediately post-surgery by the implantation of an aortic stent with SR
      fixation. METHODS: IFIXEAR is a prospective, 2 center study. Every patient
      undergoing elective EVAR with SR fixation is eligible for inclusion. Patients
      with previous hemodynamic disturbances to the ostia of 1 of the renal arteries
      are not eligible. All patients undergo echocardiography and renal arteries duplex
      ultrasound within a month before surgery, and at 1 and 12 months after surgery.
      The primary endpoint is hemodynamic disturbance, defined as a peak systolic
      velocity greater than 120 cm/second, at the ostia of 1 of the renal arteries in
      the immediate postoperative period. ETHICS AND DISSEMINATION: The study was
      approved by the Ethics Committee "Comite de Protection des Personnes Ouest V"
      under the number 18/019-2 on April 20, 2018. All patients provide written
      informed consent before inclusion. The University Hospital of Besancon is the
      trial sponsor. Results of the study will be submitted for publication in a
      peer-reviewed international medical journal. REGISTRATION: The trial is
      registered with ClinicalTrials.gov (Identifier: NCT03594786, principal
      investigator: Dr Patricia Costa, Registered on April 24, 2018).
FAU - Salomon du Mont, Lucie
AU  - Salomon du Mont L
AD  - Vascular and Endovascular Surgery Department, University Hospital Besancon.
AD  - EA3920, Universite de Bourgogne Franche-Comte F-25000 Besancon.
FAU - Parmentier, Anne-Laure
AU  - Parmentier AL
AD  - Inserm CIC 1431, CHU Besancon, F-25000 Besancon.
AD  - Laboratoire Chrono-Environnement UMR 6249, CNRS, Universite de Bourgogne
      Franche-Comte F-25000 Besancon.
FAU - Puyraveau, Marc
AU  - Puyraveau M
AD  - Inserm CIC 1431, CHU Besancon, F-25000 Besancon.
AD  - Laboratoire Chrono-Environnement UMR 6249, CNRS, Universite de Bourgogne
      Franche-Comte F-25000 Besancon.
FAU - Mauny, Frederic
AU  - Mauny F
AD  - Inserm CIC 1431, CHU Besancon, F-25000 Besancon.
AD  - Laboratoire Chrono-Environnement UMR 6249, CNRS, Universite de Bourgogne
      Franche-Comte F-25000 Besancon.
FAU - Guillon, Benoit
AU  - Guillon B
AD  - EA3920, Universite de Bourgogne Franche-Comte F-25000 Besancon.
AD  - Department of Cardiology.
FAU - Rinckenbach, Simon
AU  - Rinckenbach S
AD  - Vascular and Endovascular Surgery Department, University Hospital Besancon.
AD  - EA3920, Universite de Bourgogne Franche-Comte F-25000 Besancon.
FAU - Costa, Patricia
AU  - Costa P
AD  - Vascular Medicine Unit, Vascular and Endovascular Surgery department, University 
      Hospital Besancon, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03594786
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Aortic Aneurysm, Abdominal/*surgery
MH  - Endovascular Procedures/*adverse effects/*methods
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Renal Artery/*physiology
PMC - PMC7440303
EDAT- 2020/05/03 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
AID - 10.1097/MD.0000000000019917 [doi]
AID - 00005792-202005010-00021 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(18):e19917. doi: 10.1097/MD.0000000000019917.


PMID- 32358339
OWN - NLM
STAT- MEDLINE
DCOM- 20200514
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 18
DP  - 2020 May
TI  - The effects of green cardamom supplementation on blood pressure and endothelium
      function in type 2 diabetic patients: A study protocol for a randomized
      controlled clinical trial.
PG  - e11005
LID - 10.1097/MD.0000000000011005 [doi]
AB  - INTRODUCTION: Cardamom possesses antioxidant, anti-inflammation, and blood
      pressure lowering properties, which might improve endothelial function in type 2 
      diabetic patients. However, no study has examined the effect of cardamom on
      diabetic patients. The present study aimed to examine the effects of 10-week
      green cardamom intake on blood pressure, concentrations of inflammatory and
      endothelial function biomarkers in type 2 diabetes mellitus patients, and its
      potential mechanisms. METHODS AND ANALYSIS DESIGN: Eighty overweight or obese
      patients with type 2 diabetes mellitus (aged 30-60 years) will be recruited into 
      the trial and will assign to receive either cardamom (3 g/day, 6 capsules) or
      placebo (rusk powder, 6 capsules) for a period of 10 weeks. Systolic blood
      pressure and diastolic blood pressure, asymmetric dimethylarginine, and nitric
      oxide will be measured. Serum inflammatory markers namely interleukin 6, tumor
      necrosis factor-alpha, high-sensitivity C-reactive protein, and factors related
      to endothelial function including intercellular adhesion molecule-1, vascular
      cell adhesion molecule 1, CD62 antigen-like family member E, and cluster of
      differentiation 163 will be measured at baseline and at the end of the trial.
      Sociodemographic, International Physical Activity Questionnaire, and three
      24-hour dietary recall questionnaires will be collected for each participant.
      ETHICS AND DISSEMINATION: The study has been approved by The Ethics Committee of 
      Tehran University of Medical Sciences (IR.TUMS.REC.1395.2700). Each participant
      will sign a written informed consent at the beginning of the study. At the end of
      the study, results will be published timely manner. TRIAL REGISTRATION NUMBER:
      (http://www.irct.ir, identifier: IRCT-2016042717254N5) Date of registration:
      2016-11-23.
FAU - Ghazi Zahedi, Shohreh
AU  - Ghazi Zahedi S
AD  - Department of Community Nutrition.
FAU - Koohdani, Fariba
AU  - Koohdani F
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences
      and Dietetics, Tehran University of Medical Sciences, Tehran.
FAU - Qorbani, Mostafa
AU  - Qorbani M
AD  - Noncommunicable Diseases Research Center, Endocrinology and Metabolism Population
      Sciences Institute, Tehran University of Medical Sciences, School of Medicine,
      Alborz University of Medical Sciences, Baghestan Boulevard, Karaj.
FAU - Siassi, Fereydoun
AU  - Siassi F
AD  - Department of Community Nutrition.
FAU - Keshavarz, Ali
AU  - Keshavarz A
AD  - Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics.
FAU - Nasli-Esfahani, Ensieh
AU  - Nasli-Esfahani E
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Aghasi, Mohadeseh
AU  - Aghasi M
AD  - Department of Community Nutrition.
FAU - Khoshamal, Hoorieh
AU  - Khoshamal H
AD  - Department of Community Nutrition.
FAU - Sotoudeh, Gity
AU  - Sotoudeh G
AD  - Department of Community Nutrition.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Blood Pressure/*drug effects
MH  - Blood Pressure Determination
MH  - Diabetes Mellitus, Type 2/etiology/physiopathology/*therapy
MH  - *Dietary Supplements
MH  - Double-Blind Method
MH  - *Elettaria
MH  - Endothelium/*drug effects
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications
MH  - Overweight/complications
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7440108
EDAT- 2020/05/03 06:00
MHDA- 2020/05/15 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/05/15 06:00 [medline]
AID - 10.1097/MD.0000000000011005 [doi]
AID - 00005792-202005010-00001 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May;99(18):e11005. doi: 10.1097/MD.0000000000011005.


PMID- 32358216
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20211216
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 95
IP  - 1
DP  - 2020 Jul 7
TI  - The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial
      in a pandemic.
PG  - 29-36
LID - 10.1212/WNL.0000000000009698 [doi]
AB  - The coronavirus disease 2019 pandemic has disrupted the lives of whole
      communities and nations. The multinational multicenter National Institute of
      Neurological Disorders and Stroke Carotid Revascularization and Medical
      Management for Asymptomatic Carotid Stenosis Trial stroke prevention trial
      rapidly experienced the effects of the pandemic and had to temporarily suspend
      new enrollments and shift patient follow-up activities from in-person clinic
      visits to telephone contacts. There is an ethical obligation to the patients to
      protect their health while taking every feasible step to ensure that the goals of
      the trial are successfully met. Here, we describe the effects of the pandemic on 
      the trial and steps that are being taken to mitigate the effects of the pandemic 
      so that trial objectives can be met.
CI  - (c) 2020 American Academy of Neurology.
FAU - Meschia, James F
AU  - Meschia JF
AUID- ORCID: 0000-0002-4475-8142
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park. meschia.james@mayo.edu.
FAU - Barrett, Kevin M
AU  - Barrett KM
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Brown, Robert D Jr
AU  - Brown RD Jr
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Turan, Tanya N
AU  - Turan TN
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Howard, Virginia J
AU  - Howard VJ
AUID- ORCID: 0000-0003-4912-9975
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Voeks, Jenifer H
AU  - Voeks JH
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Lal, Brajesh K
AU  - Lal BK
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Howard, George
AU  - Howard G
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
FAU - Brott, Thomas G
AU  - Brott TG
AUID- ORCID: 0000-0002-1266-0941
AD  - From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic,
      Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN;
      Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina,
      Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics
      (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.),
      University of Maryland, College Park.
LA  - eng
GR  - U01 NS080165/NS/NINDS NIH HHS/United States
GR  - U01 NS080168/NS/NINDS NIH HHS/United States
GR  - U01 NS086872/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200501
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin II Type 1 Receptor Blockers/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Asymptomatic Diseases
MH  - Betacoronavirus
MH  - COVID-19
MH  - Canada/epidemiology
MH  - Carotid Stenosis/epidemiology/*therapy
MH  - Communicable Disease Control/methods
MH  - Comorbidity
MH  - Coronavirus Infections/*epidemiology
MH  - Diabetes Mellitus/epidemiology
MH  - Dyslipidemias/epidemiology
MH  - Elective Surgical Procedures
MH  - Female
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Infection Control/methods
MH  - Male
MH  - Middle Aged
MH  - *Pandemics
MH  - Patient Selection
MH  - Pneumonia, Viral/*epidemiology
MH  - Randomized Controlled Trials as Topic/*methods
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Spain/epidemiology
MH  - Stroke/*prevention & control
MH  - Telemedicine
MH  - United States/epidemiology
PMC - PMC7371383
EDAT- 2020/05/03 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
PHST- 2020/05/03 06:00 [entrez]
AID - WNL.0000000000009698 [pii]
AID - 10.1212/WNL.0000000000009698 [doi]
PST - ppublish
SO  - Neurology. 2020 Jul 7;95(1):29-36. doi: 10.1212/WNL.0000000000009698. Epub 2020
      May 1.


PMID- 32357976
OWN - NLM
STAT- Publisher
LR  - 20201214
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
DP  - 2020 May 1
TI  - Evaluating the national PPE guidance for NHS healthcare workers during the
      COVID-19 pandemic.
LID - clinmed.2020-0143 [pii]
LID - 10.7861/clinmed.2020-0143 [doi]
AB  - Tragically, many of the infections and deaths recorded in the global coronavirus 
      disease 2019 (COVID-19) pandemic have occurred in healthcare workers. Some have
      attributed this to inadequate provision of personal protective equipment (PPE).
      In the UK, several organisations have voiced their concerns that the national PPE
      guidance issued by Public Health England is inadequate. Despite recent revisions 
      to these guidelines, concerns remain that they offer insufficient protection to
      frontline NHS healthcare workers. In this report, we evaluate whether these
      concerns are merited, through critical appraisal of the available evidence,
      review of international PPE guidance, and consideration of the ethical
      implications.
CI  - (c) Royal College of Physicians 2020. All rights reserved.
FAU - Thomas, John P
AU  - Thomas JP
AD  - Norfolk and Norwich University Hospital, Norwich, UK drjohnpthomas@gmail.com.
FAU - Srinivasan, Anand
AU  - Srinivasan A
AD  - Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
FAU - Wickramarachchi, Chandu S
AU  - Wickramarachchi CS
AD  - Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
FAU - Dhesi, Parveen K
AU  - Dhesi PK
AD  - Norfolk and Norwich University Hospital, Norwich, UK.
FAU - Hung, Yat Ma
AU  - Hung YM
AD  - Norfolk and Norwich University Hospital, Norwich, UK.
FAU - Kamath, Ajay V
AU  - Kamath AV
AD  - Norfolk and Norwich University Hospital, Norwich, UK.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
CIN - Clin Med (Lond). 2020 Jul;20(4):e131. PMID: 32675163
PMC - PMC7354042
OTO - NOTNLM
OT  - COVID-19
OT  - NHS
OT  - SARS-CoV-2
OT  - pandemic
OT  - personal protective equipment
EDAT- 2020/05/03 06:00
MHDA- 2020/05/03 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/05/03 06:00 [medline]
AID - clinmed.2020-0143 [pii]
AID - 10.7861/clinmed.2020-0143 [doi]
PST - aheadofprint
SO  - Clin Med (Lond). 2020 May 1. pii: clinmed.2020-0143. doi:
      10.7861/clinmed.2020-0143.


PMID- 32357889
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1472-6831 (Electronic)
IS  - 1472-6831 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 1
TI  - The effect of antimicrobial activity of Teucrium Polium on Oral Streptococcus
      Mutans: a randomized cross-over clinical trial study.
PG  - 130
LID - 10.1186/s12903-020-01116-4 [doi]
AB  - BACKGROUND: The purpose of this study is to determine the effect of a mouthwash
      containing Teucriumpolium herb on Streptococcus mutans in mouth. METHODS: This
      study was a randomized, crossover, double-blind clinical trial, where we selected
      22 volunteers (dental students) randomly and we divided them into two groups. The
      study had two phases. In each phase, one group acted as the intervention group,
      while the other one was the control group. Both the intervention and control
      groups were given the mouthwash with and without Teucriumpolium, respectively. S.
      mutans of saliva were measured before and after each phase to compare the effects
      of the mouthwashes. A three-week washout period was considered between the two
      phases. An independent two-sample t-test was utilized to compare the mean of S.
      mutans colonies. Additionally, we used a standard AB/BA crossover model to find
      the results of the treatment and the impact of carryover on the residual's
      biological effects. The significance level was considered 0.05 in this
      experiment. RESULTS: There is no significant difference observed between the two 
      groups in the number of S. mutans before using the mouthwashes. When the
      mouthwash containing Teucriumpolium was used, there was a significant decrease in
      the number of S. mutans colonies in both phases' extract (P = 0.002). CONCLUSION:
      The results of this study indicate the mouthwash containing aqueous extract of
      Teucrium polium can majorly reduce the colonization of S. mutans in human saliva.
      TRIAL REGISTRATION: Ethical issues approved by the Ethics Committee of the
      Rafsanjan University of Medical Sciences with the approval number of 937/9/31,
      IRCT code Number of IRCT2013121815842N1 and it was approved on 06/16/2014. The
      study was conducted in the period of September to November 2014.
FAU - Khoramian Tusi, Somayeh
AU  - Khoramian Tusi S
AD  - Department of Pediatric Dentistry, School of Dentistry, Alborz University of
      Medical Sciences, Alborz, Iran.
FAU - Jafari, Ahmad
AU  - Jafari A
AUID- ORCID: 0000-0001-9164-8264
AD  - Research Center for Caries Prevention, Dental Research Institute, Department of
      Community Oral Health, School of Dentistry, Tehran University of Medical
      Sciences, Tehran, Iran. ajafari@tums.ac.ir.
AD  - Department of Pediatric Dentistry, School of Dentistry, Al Hussain University,
      Karbala, Iraq. ajafari@tums.ac.ir.
FAU - Marashi, Seyed Mahmoud Amin
AU  - Marashi SMA
AD  - Department of Microbiology, Qazvin University of Medical Sciences, Qazvin, Iran.
FAU - Faramarzi Niknam, Salomeh
AU  - Faramarzi Niknam S
AD  - Department of Pediatric Dentistry, School of Dentistry, Alborz University of
      Medical Sciences, Alborz, Iran.
FAU - Farid, Malihe
AU  - Farid M
AD  - Department of Community Medicine, School of Medicine, Alborz University of
      Medical Sciences, Alborz, Iran.
FAU - Ansari, Mehdi
AU  - Ansari M
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical
      Sciences, Kerman, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200501
PL  - England
TA  - BMC Oral Health
JT  - BMC oral health
JID - 101088684
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Mouthwashes)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Anti-Infective Agents/*pharmacology
MH  - Colony Count, Microbial
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Mouthwashes/*pharmacology
MH  - Oral Hygiene
MH  - Plant Extracts/*pharmacology
MH  - Plants, Medicinal
MH  - Saliva/*microbiology
MH  - Streptococcus mutans/*drug effects/isolation & purification
MH  - Teucrium/*chemistry
MH  - Treatment Outcome
PMC - PMC7195746
OTO - NOTNLM
OT  - *Dental caries
OT  - *Herbal extract
OT  - *Medicinal plants
OT  - *Mouthwash
OT  - *Oral hygiene
OT  - *Salvia
EDAT- 2020/05/03 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/01/28 00:00 [received]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1186/s12903-020-01116-4 [doi]
AID - 10.1186/s12903-020-01116-4 [pii]
PST - epublish
SO  - BMC Oral Health. 2020 May 1;20(1):130. doi: 10.1186/s12903-020-01116-4.


PMID- 32357883
OWN - NLM
STAT- MEDLINE
DCOM- 20200506
LR  - 20201218
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 May 1
TI  - COVID-19: where is the national ethical guidance?
PG  - 32
LID - 10.1186/s12910-020-00478-2 [doi]
FAU - Huxtable, Richard
AU  - Huxtable R
AD  - Centre for Ethics in Medicine, Population Health Sciences, Bristol Medical
      School, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
      R.Huxtable@bristol.ac.uk.
LA  - eng
PT  - Editorial
DEP - 20200501
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - *Coronavirus
MH  - *Coronavirus Infections
MH  - Decision Making/*ethics
MH  - England/epidemiology
MH  - *Guidelines as Topic
MH  - *Health Resources/ethics/supply & distribution
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7193541
OTO - NOTNLM
OT  - *COVID-19
OT  - *Coronavirus
OT  - *Ethical guidance
OT  - *Professional guidance
EDAT- 2020/05/03 06:00
MHDA- 2020/05/07 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/04/20 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/05/07 06:00 [medline]
AID - 10.1186/s12910-020-00478-2 [doi]
AID - 10.1186/s12910-020-00478-2 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 May 1;21(1):32. doi: 10.1186/s12910-020-00478-2.


PMID- 32357873
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201120
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 1
TI  - Eliciting patient views on the allocation of limited healthcare resources: a
      deliberation on hepatitis C treatment in the Veterans Health Administration.
PG  - 369
LID - 10.1186/s12913-020-05211-8 [doi]
AB  - BACKGROUND: In response to the development of highly effective but expensive new 
      medications, policymakers, payors, and health systems are considering novel and
      pragmatic ways to provide these medications to patients. One approach is to
      target these treatments to those most likely to benefit. However, to maximize the
      fairness of these policies, and the acceptance of their implementation, the
      values and beliefs of patients should be considered. The provision of treatments 
      for chronic hepatitis C (CHC) in the resource-constrained context of the Veterans
      Health Administration (VHA) offered a real-world example of this situation,
      providing the opportunity to test the value of using Democratic Deliberation (DD)
      methods to solicit the informed opinions of laypeople on this complex issue.
      METHODS: We recruited Veterans (n = 30) from the VHA to attend a DD session.
      Following educational presentations from content experts, participants engaged in
      facilitated small group discussions to: 1) identify strategies to overcome CHC
      treatment barriers and 2) evaluate, vote on, and modify/improve two CHC treatment
      policies - "first come, first served" (FCFS) and "sickest first" (SF). We used
      transcripts and facilitators' notes to identify key themes from the small group
      discussions. Additionally, participants completed pre- and post-DD surveys.
      RESULTS: Most participants endorsed the SF policy over the FCFS policy,
      emphasizing the ethical and medical appropriateness of treating the sickest
      first. Concerns about SF centered on the difficulty of implementation (e.g., how 
      is "sickest" determined?) and unfairness to other Veterans. Proposed
      modifications focused on: 1) the need to consider additional health factors, 2)
      taking behavior and lifestyle into account, 3) offering education and support, 4)
      improving access, and 5) facilitating better decision-making. CONCLUSIONS: DD
      offered a robust and useful method for addressing the allocation of the scarce
      resource of CHC treatment. Participants were able to develop a modified version
      of the SF policy and offered diverse recommendations to promote fairness and
      improve quality of care for Veterans. DD is an effective approach for
      incorporating patient preferences and gaining valuable insights for critical
      healthcare policy decisions in resource-limited environments.
FAU - Waljee, Akbar K
AU  - Waljee AK
AD  - VA Ann Arbor Health Services Research and Development Center of Clinical
      Management Research, 2215 Fuller Road, Mail Stop 152, Ann Arbor, MI, 48105, USA. 
      awaljee@med.umich.edu.
AD  - Michigan Medicine, Department of Internal Medicine, Division of Gastroenterology 
      and Hepatology, 3912 Taubman Center, 1500 East Medical Center Drive, SPC 5362,
      Ann Arbor, MI, 48109-5362, USA. awaljee@med.umich.edu.
AD  - Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP),
      2800 Plymouth Road, North Campus Research Complex (NCRC), Building 16, Ann Arbor,
      MI, 48109-2800, USA. awaljee@med.umich.edu.
FAU - Ryan, Kerry A
AU  - Ryan KA
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan
      Medical School, 2800 Plymouth Road, North Campus Research Complex, Bldg. 14,
      G016, Ann Arbor, MI, 48109-2800, USA.
FAU - Krenz, Chris D
AU  - Krenz CD
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan
      Medical School, 2800 Plymouth Road, North Campus Research Complex, Bldg. 14,
      G016, Ann Arbor, MI, 48109-2800, USA.
FAU - Ioannou, George N
AU  - Ioannou GN
AD  - Veterans Affairs Puget Sound Healthcare System, 1660 South Columbian Way,
      Seattle, WA, 98108, USA.
AD  - Division of Gastroenterology, Department of Medicine, University of Washington,
      1959 NE Pacific St., Box 356424, Seattle, WA, 98195-6424, USA.
FAU - Beste, Lauren A
AU  - Beste LA
AD  - Division of Gastroenterology, Department of Medicine, University of Washington,
      1959 NE Pacific St., Box 356424, Seattle, WA, 98195-6424, USA.
AD  - Division of General Internal Medicine, University of Washington, Harborview
      Medical Center, 325 Ninth Ave, Box 359780, Seattle, WA, 98104, USA.
FAU - Tincopa, Monica A
AU  - Tincopa MA
AD  - Michigan Medicine, Department of Internal Medicine, Division of Gastroenterology 
      and Hepatology, 3912 Taubman Center, 1500 East Medical Center Drive, SPC 5362,
      Ann Arbor, MI, 48109-5362, USA.
FAU - Saini, Sameer D
AU  - Saini SD
AD  - VA Ann Arbor Health Services Research and Development Center of Clinical
      Management Research, 2215 Fuller Road, Mail Stop 152, Ann Arbor, MI, 48105, USA.
AD  - Michigan Medicine, Department of Internal Medicine, Division of Gastroenterology 
      and Hepatology, 3912 Taubman Center, 1500 East Medical Center Drive, SPC 5362,
      Ann Arbor, MI, 48109-5362, USA.
AD  - Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP),
      2800 Plymouth Road, North Campus Research Complex (NCRC), Building 16, Ann Arbor,
      MI, 48109-2800, USA.
FAU - Su, Grace L
AU  - Su GL
AD  - VA Ann Arbor Health Services Research and Development Center of Clinical
      Management Research, 2215 Fuller Road, Mail Stop 152, Ann Arbor, MI, 48105, USA.
AD  - Michigan Medicine, Department of Internal Medicine, Division of Gastroenterology 
      and Hepatology, 3912 Taubman Center, 1500 East Medical Center Drive, SPC 5362,
      Ann Arbor, MI, 48109-5362, USA.
FAU - Arasim, Maria E
AU  - Arasim ME
AD  - VA Ann Arbor Health Services Research and Development Center of Clinical
      Management Research, 2215 Fuller Road, Mail Stop 152, Ann Arbor, MI, 48105, USA.
FAU - Roman, Patti T
AU  - Roman PT
AD  - VA Ann Arbor Health Services Research and Development Center of Clinical
      Management Research, 2215 Fuller Road, Mail Stop 152, Ann Arbor, MI, 48105, USA.
FAU - Nallamothu, Brahmajee K
AU  - Nallamothu BK
AD  - VA Ann Arbor Health Services Research and Development Center of Clinical
      Management Research, 2215 Fuller Road, Mail Stop 152, Ann Arbor, MI, 48105, USA.
AD  - Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP),
      2800 Plymouth Road, North Campus Research Complex (NCRC), Building 16, Ann Arbor,
      MI, 48109-2800, USA.
AD  - Michigan Medicine, Department of Internal Medicine, Division of Cardiovascular
      Medicine, 1500 East Medical Center Drive, SPC 5856, Ann Arbor, MI, 48109-5362,
      USA.
FAU - De Vries, Raymond
AU  - De Vries R
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan
      Medical School, 2800 Plymouth Road, North Campus Research Complex, Bldg. 14,
      G016, Ann Arbor, MI, 48109-2800, USA.
LA  - eng
GR  - I01 HX002220/HX/HSRD VA/United States
PT  - Journal Article
DEP - 20200501
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
MH  - Aged
MH  - *Attitude to Health
MH  - Female
MH  - Health Care Rationing/*organization & administration
MH  - Hepatitis C, Chronic/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - United States
MH  - United States Department of Veterans Affairs/*organization & administration
MH  - Veterans/*psychology/statistics & numerical data
PMC - PMC7193376
OTO - NOTNLM
OT  - Democratic Deliberation
OT  - Health policy
OT  - Hepatitis C
OT  - Public deliberation
OT  - Qualitative research
OT  - VA
OT  - Veterans
EDAT- 2020/05/03 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/05/03 06:00
PHST- 2019/07/26 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - 10.1186/s12913-020-05211-8 [doi]
AID - 10.1186/s12913-020-05211-8 [pii]
PST - epublish
SO  - BMC Health Serv Res. 2020 May 1;20(1):369. doi: 10.1186/s12913-020-05211-8.


PMID- 32357446
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 9
DP  - 2020 Apr 26
TI  - Health Information Systems in the Digital Health Ecosystem-Problems and Solutions
      for Ethics, Trust and Privacy.
LID - E3006 [pii]
LID - 10.3390/ijerph17093006 [doi]
AB  - Digital health information systems (DHIS) are increasingly members of ecosystems,
      collecting, using and sharing a huge amount of personal health information (PHI),
      frequently without control and authorization through the data subject. From the
      data subject's perspective, there is frequently no guarantee and therefore no
      trust that PHI is processed ethically in Digital Health Ecosystems. This results 
      in new ethical, privacy and trust challenges to be solved. The authors' objective
      is to find a combination of ethical principles, privacy and trust models,
      together enabling design, implementation of DHIS acting ethically, being
      trustworthy, and supporting the user's privacy needs. Research published in
      journals, conference proceedings, and standards documents is analyzed from the
      viewpoint of ethics, privacy and trust. In that context, systems theory and
      systems engineering approaches together with heuristic analysis are deployed. The
      ethical model proposed is a combination of consequentialism, professional medical
      ethics and utilitarianism. Privacy enforcement can be facilitated by defining it 
      as health information specific contextual intellectual property right, where a
      service user can express their own privacy needs using computer-understandable
      policies. Thereby, privacy as a dynamic, indeterminate concept, and computational
      trust, deploys linguistic values and fuzzy mathematics. The proposed solution,
      combining ethical principles, privacy as intellectual property and computational 
      trust models, shows a new way to achieve ethically acceptable, trustworthy and
      privacy-enabling DHIS and Digital Health Ecosystems.
FAU - Ruotsalainen, Pekka
AU  - Ruotsalainen P
AD  - Faculty for Information Technology and Communication Sciences, Tampere
      University, 33100 Tampere, Finland.
FAU - Blobel, Bernd
AU  - Blobel B
AD  - Medical Faculty, University of Regensburg, 93053 Regensburg, Germany.
AD  - Fist Medical Faculty, Charles University Prague, 12800 Prague, Czech Republic.
AD  - eHealth Competence Center Bavaria, Deggendorf Institute of Technology, 94469
      Deggendorf, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200426
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Confidentiality
MH  - *Health Information Systems/ethics
MH  - *Health Records, Personal
MH  - Privacy
MH  - Trust
PMC - PMC7246854
OTO - NOTNLM
OT  - *computational privacy
OT  - *ethical design
OT  - *ethics
OT  - *fuzzy logic
OT  - *models
OT  - *privacy
OT  - *trust
EDAT- 2020/05/03 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/05/03 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/05/03 06:00 [entrez]
PHST- 2020/05/03 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - ijerph17093006 [pii]
AID - 10.3390/ijerph17093006 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Apr 26;17(9). pii: ijerph17093006. doi:
      10.3390/ijerph17093006.


PMID- 32357378
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20220716
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 42
IP  - 7
DP  - 2020 Jul
TI  - Ethical surgical triage of patients with head and neck cancer during the COVID-19
      pandemic.
PG  - 1423-1447
LID - 10.1002/hed.26229 [doi]
AB  - BACKGROUND: Coronavirus has serially overtaken our metropolitan hospitals. At
      peak, patients with acute respiratory distress syndrome may outnumber mechanical 
      ventilators. In our Miami Hospital System, COVID-19 cases have multiplied for 4
      weeks and elective surgery has been suspended. METHODS: An Otolaryngologic Triage
      Committee was created to appropriately allocate resources to patients. Hospital
      ethicists provided support. Our tumor conference screened patients for
      nonsurgical options. Patients were tested twice for coronavirus before performing
      urgent contaminated operations. N95 masks and protective equipment were conserved
      when possible. Patients with low-grade cancers were advised to delay surgery, and
      other difficult decisions were made. RESULTS: Hundreds of surgeries were
      canceled. Sixty-five cases screened over 3 weeks are tabulated. Physicians and
      patients expressed discomfort regarding perceived deviations from standards, but 
      risk of COVID-19 exposure tempered these discussions. CONCLUSIONS: We describe
      the use of actively managed surgical triage to fairly balance our patient's
      health with public health concerns.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Civantos, Francisco J
AU  - Civantos FJ
AUID- ORCID: https://orcid.org/0000-0002-1648-0868
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Leibowitz, Jason M
AU  - Leibowitz JM
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Arnold, David J
AU  - Arnold DJ
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Stubbs, Vanessa C
AU  - Stubbs VC
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Gross, Jennifer H
AU  - Gross JH
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Thomas, Giovana R
AU  - Thomas GR
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Sargi, Zoukaa
AU  - Sargi Z
AD  - Department of Otolaryngology and Neurosurgery, Sylvester Cancer Center/University
      of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Casiano, Roy R
AU  - Casiano RR
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Franzmann, Elizabeth J
AU  - Franzmann EJ
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Weed, Donald
AU  - Weed D
AUID- ORCID: https://orcid.org/0000-0002-8551-7142
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Perez, Cesar
AU  - Perez C
AUID- ORCID: https://orcid.org/0000-0001-5860-4921
AD  - Department of Medicine, Sylvester Cancer Center/University of Miami Miller School
      of Medicine, Miami, Florida, USA.
FAU - Samuels, Michael
AU  - Samuels M
AD  - Departments of Radiation Oncology, Sylvester Cancer Center/University of Miami
      Miller School of Medicine, Miami, Florida, USA.
FAU - Goodman, Kenneth W
AU  - Goodman KW
AD  - Department of Medicine, Institute for Bioethics and Health Policy, Sylvester
      Cancer Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
FAU - Goodwin, W Jarrard
AU  - Goodwin WJ
AD  - Department of Otolaryngology, Head and Neck Division, Sylvester Cancer
      Center/University of Miami Miller School of Medicine, Miami, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200521
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Elective Surgical Procedures/*ethics/statistics & numerical data
MH  - Female
MH  - Head and Neck Neoplasms/diagnosis/epidemiology/*surgery
MH  - Hospitals, Urban
MH  - Humans
MH  - Infection Control/methods
MH  - Male
MH  - Occupational Health
MH  - Otolaryngology/organization & administration
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Patient Safety
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Risk Assessment
MH  - Triage/*ethics
MH  - United States
PMC - PMC7267510
EDAT- 2020/05/02 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/04/21 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1002/hed.26229 [doi]
PST - ppublish
SO  - Head Neck. 2020 Jul;42(7):1423-1447. doi: 10.1002/hed.26229. Epub 2020 May 21.


PMID- 32356774
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 1
TI  - Effectiveness of a Quit Vaping Text Message Program in Promoting Abstinence Among
      Young Adult E-Cigarette Users: Protocol for a Randomized Controlled Trial.
PG  - e18327
LID - 10.2196/18327 [doi]
AB  - BACKGROUND: Millions of young adults currently vape electronic cigarettes
      (e-cigarettes), yet little research on vaping cessation interventions exists.
      Text messaging is a promising, scalable intervention strategy for delivering
      vaping cessation treatment. OBJECTIVE: This study evaluates the effectiveness of 
      a text message quit vaping program (This is Quitting) in promoting abstinence
      from e-cigarettes among young adults; examines changes in self-efficacy,
      perceived social norms, and social support for quitting as hypothesized mediators
      of effectiveness; and examines if treatment effectiveness is moderated by gender,
      race, ethnicity, or sexual minority status. METHODS: Overall, 2600 young adult
      (aged 18-24 years) e-cigarette users in the United States will be recruited via
      web advertisements to participate in the study. Participants will be randomized
      to This is Quitting or an assessment-only control condition. The primary outcome 
      measure is 30-day vaping abstinence at 7 months post enrollment. RESULTS: Study
      recruitment began on December 18, 2019, and is projected to be completed by
      spring 2020. The final 7-month follow-up is anticipated to be completed by
      fall/winter 2020. Because this is the first-ever evaluation of a quit vaping
      program, we were unable to draw on existing literature to determine the
      appropriate sample size. Therefore, we examined abstinence rates among an initial
      pilot sample of 269 participants (This is Quitting: n=148 and control: n=121) who
      completed the 1-month follow-up to determine the final sample size. The 1-month
      response rate was 79.2% (213/269), with no difference between arms. Using
      intention-to-treat analyses that counted nonresponders as still vaping, 30-day
      abstinence rates were 16.2% (24/148) among those randomized to This is Quitting
      and 8.3% (10/121) among those randomized to control. A treatment difference of
      16% vs 8% is detectable with 80% power at 2-sided alpha=.05 with 260/group (520
      total). To detect treatment differences of this magnitude in a 20% subsample (eg,
      Hispanic or sexual minority young adult e-cigarette users), we will enroll
      1300/group (2600 total). CONCLUSIONS: The scientific, clinical, and public health
      communities are desperate for cessation resources to address vaping among young
      people. This study is the first-ever comparative effectiveness trial of an
      intervention to help young people quit vaping. It focuses on evaluating the
      effectiveness of a theory-grounded, empirically informed text message
      intervention among young adults. The study is fully powered to examine
      potentially important subgroup differences among young people who are more
      vulnerable to e-cigarette use. Although potentially more challenging from a
      research ethics and pragmatic standpoint, evaluating quit vaping intervention
      approaches in teens is an important area for future research. Data from this
      trial will establish a benchmark of effectiveness for other vaping cessation
      programs and begin to create a body of evidence focused on how best to help young
      people break free from e-cigarettes. TRIAL REGISTRATION: ClinicalTrials.gov
      NCT04251273; https://clinicaltrials.gov/ct2/show/NCT04251273. INTERNATIONAL
      REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18327.
CI  - (c)Amanda L Graham, Megan A Jacobs, Michael S Amato, Sarah Cha, Mia M Bottcher,
      George D Papandonatos. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 01.05.2020.
FAU - Graham, Amanda L
AU  - Graham AL
AUID- ORCID: https://orcid.org/0000-0003-3036-9653
AD  - Innovations Center, Truth Initiative, Washington, DC, United States.
AD  - Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester,
      MN, United States.
AD  - Department of Oncology, Georgetown University Medical Center, Washington, DC,
      United States.
FAU - Jacobs, Megan A
AU  - Jacobs MA
AUID- ORCID: https://orcid.org/0000-0001-6526-964X
AD  - Innovations Center, Truth Initiative, Washington, DC, United States.
FAU - Amato, Michael S
AU  - Amato MS
AUID- ORCID: https://orcid.org/0000-0002-9769-957X
AD  - Innovations Center, Truth Initiative, Washington, DC, United States.
AD  - Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester,
      MN, United States.
FAU - Cha, Sarah
AU  - Cha S
AUID- ORCID: https://orcid.org/0000-0003-3505-3164
AD  - Innovations Center, Truth Initiative, Washington, DC, United States.
FAU - Bottcher, Mia M
AU  - Bottcher MM
AUID- ORCID: https://orcid.org/0000-0003-0057-7646
AD  - Innovations Center, Truth Initiative, Washington, DC, United States.
FAU - Papandonatos, George D
AU  - Papandonatos GD
AUID- ORCID: https://orcid.org/0000-0001-6770-932X
AD  - Center for Statistical Sciences, Brown University, Providence, RI, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT04251273
PT  - Journal Article
DEP - 20200501
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7229526
OTO - NOTNLM
OT  - e-cigarettes
OT  - telehealth
OT  - text messaging
OT  - tobacco cessation
OT  - young adults
EDAT- 2020/05/02 06:00
MHDA- 2020/05/02 06:01
CRDT- 2020/05/02 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/05/02 06:01 [medline]
AID - v9i5e18327 [pii]
AID - 10.2196/18327 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 May 1;9(5):e18327. doi: 10.2196/18327.


PMID- 32356699
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20220414
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 36
IP  - 4
DP  - 2020 Apr
TI  - [Ethics of clinical trials].
PG  - 303-307
LID - 10.1051/medsci/2020092 [doi]
FAU - Alperovitch, Annick
AU  - Alperovitch A
AD  - Directrice de recherche honoraire a l'Inserm.
FAU - Lazar, Philippe
AU  - Lazar P
AD  - Directeur de recherche honoraire a l'Inserm Ancien Directeur general de l'Inserm.
LA  - fre
PT  - Editorial
PT  - Historical Article
TT  - L'ethique des essais therapeutiques.
DEP - 20200501
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
MH  - COVID-19
MH  - Clinical Trials as Topic/*ethics/legislation & jurisprudence
MH  - Coronavirus Infections/epidemiology/therapy
MH  - Emergency Medical Services/ethics/history/legislation & jurisprudence/methods
MH  - *Ethics, Medical
MH  - History, 21st Century
MH  - Humans
MH  - Informed Consent/ethics/legislation & jurisprudence/standards
MH  - Knowledge
MH  - Legislation, Medical
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/therapy
MH  - Quality Improvement
MH  - Quality of Health Care/ethics/legislation & jurisprudence
MH  - Research Design/legislation & jurisprudence/standards
MH  - Therapies, Investigational/ethics/standards
EDAT- 2020/05/02 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1051/medsci/2020092 [doi]
AID - msc200127 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2020 Apr;36(4):303-307. doi: 10.1051/medsci/2020092. Epub 2020
      May 1.


PMID- 32356639
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 1897-9483 (Electronic)
IS  - 0032-3772 (Linking)
VI  - 130
IP  - 5
DP  - 2020 May 29
TI  - The ethical dimension of prioritization and allocation decisions within the
      context of the coronavirus disease 2019 pandemic.
PG  - 466-472
LID - 10.20452/pamw.15334 [doi]
FAU - Pawlikowski, Jakub
AU  - Pawlikowski J
AD  - Faculty of Medicine, Cardinal Stefan Wyszynski University in Warsaw, Warsaw,
      Poland; Department of Ethics and Medical Law, Medical University of Lublin,
      Lublin, Poland. jpawlikowski@wp.pl
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - Poland
TA  - Pol Arch Intern Med
JT  - Polish archives of internal medicine
JID - 101700960
SB  - IM
CIN - Pol Arch Intern Med. 2020 Aug 27;130(7-8):719. PMID: 32621667
MH  - Advance Care Planning/ethics
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Critical Pathways/*ethics
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Intersectoral Collaboration
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - Resource Allocation
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Triage/*ethics
EDAT- 2020/05/02 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.20452/pamw.15334 [doi]
PST - ppublish
SO  - Pol Arch Intern Med. 2020 May 29;130(5):466-472. doi: 10.20452/pamw.15334. Epub
      2020 May 1.


PMID- 32356347
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210129
IS  - 1365-2516 (Electronic)
IS  - 1351-8216 (Linking)
VI  - 26 Suppl 3
DP  - 2020 Apr
TI  - Requirements to participate in haemophilia clinical trials.
PG  - 22-25
LID - 10.1111/hae.13886 [doi]
AB  - INTRODUCTION: Clinical trials in haemophilia product development are expanding
      rapidly however, the number of sites and expertise in the clinical trial conduct 
      is limited. Guidance on the requirement for conducting clinical trials is
      required AIM: The aim of this paper is to outline generic requirements to
      participate in clinical trials in haemophilia MATERIALS: This paper describes
      three elements which are the requirements for success conduct of haemophilia
      clinical trials. These are the study product, study participant, and the global
      regulatory and ethics framework RESULTS AND CONCLUSION: In haemophilia clinical
      trials, requirements for participate in studies are many and include
      considerations of study product, study participant and ethical and regulatory
      framework. When these elements are in place, it is possible to conduct
      haemophilia clinical trials anywhere in the world.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Mahlangu, Johnny N
AU  - Mahlangu JN
AUID- ORCID: https://orcid.org/0000-0001-5781-7669
AD  - Department of Molecular Medicine and Haematology, Faculty of Health Sciences,
      University of the Witwatersrand and National Health Laboratory Service, Parktown,
      South Africa.
LA  - eng
GR  - University of the Witwatersrand Vice-Chancellor Academic Citizenship Award
PT  - Journal Article
PL  - England
TA  - Haemophilia
JT  - Haemophilia : the official journal of the World Federation of Hemophilia
JID - 9442916
SB  - IM
MH  - Clinical Trials as Topic
MH  - Hemophilia A/*diagnosis
MH  - Humans
MH  - Research Design
OTO - NOTNLM
OT  - clinical trials
OT  - guidance
OT  - haemophilia
OT  - novel therapies
OT  - requirements
EDAT- 2020/05/02 06:00
MHDA- 2021/01/30 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - 10.1111/hae.13886 [doi]
PST - ppublish
SO  - Haemophilia. 2020 Apr;26 Suppl 3:22-25. doi: 10.1111/hae.13886.


PMID- 32356300
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20200811
IS  - 1439-4421 (Electronic)
IS  - 0941-3790 (Linking)
VI  - 82
IP  - 5
DP  - 2020 May
TI  - [Pandemic Disaster from a Legal and Medical Point of View].
PG  - 381-385
LID - 10.1055/a-1152-4836 [doi]
AB  - The corona pandemic has caused a serious emergency also in the Federal Republic
      of Germany; shortages of medical capacities and failure of critical
      infrastructures may occur resulting in a pandemic catastrophe. German laws
      prescribe various mechanisms for disaster preparedness and disaster response.
      Nevertheless, both authorities and physicians will have to make difficult ethical
      and legal decisions. In the event of lack of resources (e. g. vaccines or
      ventilation capacity), conflict-laden selection decisions must be made. The
      regulations on pandemic preparedness need to be reviewed: preparing for the
      response to pandemics must be a clear and legally binding task and responsibility
      of all state and private agents involved. Here, among other things, planning,
      training, exercises and stockpiling are crucial elements of being prepared to
      deal with a pandemic.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Walus, Andreas
AU  - Walus A
AD  - Lehrbeauftragter fur Polizei- und Ordnungsrecht, Hochschule Wismar, Wismar.
FAU - Holbe, Fabian
AU  - Holbe F
AD  - Landkreis Nordwestmecklenburg, Leitender Notarzt, Neuburg.
LA  - ger
PT  - Journal Article
TT  - Die Pandemiekatastrophe aus katastrophenrechtlicher und -medizinischer Sicht.
DEP - 20200430
PL  - Germany
TA  - Gesundheitswesen
JT  - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes
      (Germany))
JID - 9204210
SB  - IM
MH  - *Disaster Planning
MH  - *Disasters
MH  - *Emergencies
MH  - Germany
MH  - Humans
MH  - *Pandemics
PMC - PMC7295304
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/05/02 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1055/a-1152-4836 [doi]
PST - ppublish
SO  - Gesundheitswesen. 2020 May;82(5):381-385. doi: 10.1055/a-1152-4836. Epub 2020 Apr
      30.


PMID- 32356245
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210422
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 6
DP  - 2020 Jun
TI  - The Do-It-Yourself Artificial Pancreas: A Comprehensive Review.
PG  - 1217-1235
LID - 10.1007/s13300-020-00823-z [doi]
AB  - Diabetes technology (DT) has accomplished tremendous progress in the past
      decades, aiming to convert these technologies as viable treatment options for the
      benefit of patients with diabetes (PWD). Despite the advances, PWD face multiple 
      challenges with the efficient management of type 1 diabetes. Most of the
      promising and innovative technological developments are not accessible to a
      larger proportion of PWD. The slow pace of development and commercialization,
      overpricing, and lack of peer support are few such factors leading to inequitable
      access to the innovations in DT. Highly motivated and tech-savvy members of the
      diabetes community have therefore come up with the #WeAreNotWaiting movement and 
      started developing their own do-it-yourself artificial pancreas systems (DIYAPS) 
      integrating continuous glucose monitoring (CGM), insulin pumps, and smartphone
      technology to run openly shared algorithms to achieve appreciable glycemic
      control and quality of life (QoL). These systems use tailor-made interventions to
      achieve automated insulin delivery (AID) and are not commercialized or regulated.
      Online social network megatrends such as GitHub, CGM in the Cloud, and Twitter
      have been providing platforms to share these open source technologies and user
      experiences. Observational studies, anecdotal evidence, and real-world patient
      stories revealed significant improvements in time in range (TIR), time in
      hypoglycemia (TIHypo), HbA1c levels, and QoL after the initiation of DIYAPS. But 
      this unregulated do-it-yourself (DIY) approach is perceived with great
      circumspection by healthcare professionals (HCP), regulatory bodies, and device
      manufacturers, making users the ultimate risk-bearers. The use of the regularized
      CGM and insulin pump with unauthorized algorithms makes them off-label and has
      been a matter of great concern. Besides these, lack of safety data, funding or
      insurance coverage, ethical, and legal issues are roadblocks to the unanimous
      acceptance of these systems among patients with type 1 diabetes (T1D). A
      multi-agency approach is necessary to evaluate the risks, and to delineate the
      incumbency and liability of clinicians, regulatory bodies, and manufacturers
      associated with the use of DIYAPS. Understanding the potential of DIYAPS as the
      need of the present time, many regional and international agencies have come with
      strategies to appraise its safety as well as to support education and training on
      its use. Here we provide a comprehensive description of the DIYAPS-including
      their origin, existing literature, advantages, and disadvantages that can help
      the industry leaders, clinicians, and PWD to make the best use of these systems.
FAU - Kesavadev, Jothydev
AU  - Kesavadev J
AD  - Jothydev's Diabetes Research Centre, Mudavanmugal, Thiruvananthapuram, Kerala,
      India. jothydev@gmail.com.
FAU - Srinivasan, Seshadhri
AU  - Srinivasan S
AD  - Kalasalingam Academy of Research and Education, Srivilliputtur, Tamil Nadu,
      India.
FAU - Saboo, Banshi
AU  - Saboo B
AD  - DiaCare, Ahmedabad, Gujarat, India.
FAU - Krishna B, Meera
AU  - Krishna B M
AD  - Jothydev's Diabetes Research Centre, Mudavanmugal, Thiruvananthapuram, Kerala,
      India.
FAU - Krishnan, Gopika
AU  - Krishnan G
AD  - Jothydev's Diabetes Research Centre, Mudavanmugal, Thiruvananthapuram, Kerala,
      India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200430
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
PMC - PMC7261300
OTO - NOTNLM
OT  - #WeAreNotWaiting
OT  - AndroidAPS
OT  - Closed loop
OT  - Do-it-yourself artificial pancreas
OT  - Loop
OT  - Nightscout
OT  - OpenAPS
OT  - People with diabetes
OT  - Type 1 diabetes
EDAT- 2020/05/02 06:00
MHDA- 2020/05/02 06:01
CRDT- 2020/05/02 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/05/02 06:01 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s13300-020-00823-z [doi]
AID - 10.1007/s13300-020-00823-z [pii]
PST - ppublish
SO  - Diabetes Ther. 2020 Jun;11(6):1217-1235. doi: 10.1007/s13300-020-00823-z. Epub
      2020 Apr 30.


PMID- 32356217
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - Suppl 1
DP  - 2020 Dec
TI  - Screening for multi-drug-resistant Gram-negative bacteria: what is effective and 
      justifiable?
PG  - 72-90
LID - 10.1007/s40592-020-00113-1 [doi]
AB  - Effectiveness is a key criterion in assessing the justification of antibiotic
      resistance interventions. Depending on an intervention's effectiveness, burdens
      and costs will be more or less justified, which is especially important for large
      scale population-level interventions with high running costs and pronounced risks
      to individuals in terms of wellbeing, integrity and autonomy. In this paper, we
      assess the case of routine hospital screening for multi-drug-resistant
      Gram-negative bacteria (MDRGN) from this perspective. Utilizing a comparison to
      screening programs for Methicillin-Resistant Staphylococcus aureus (MRSA) we
      argue that current screening programmes for MDRGN in low endemic settings should 
      be reconsidered, as its effectiveness is in doubt, while general downsides to
      screening programs remain. To accomplish justifiable antibiotic stewardship,
      MDRGN screening should not be viewed as a separate measure, but rather as part of
      a comprehensive approach. The program should be redesigned to focus on those at
      risk of developing symptomatic infections with MDRGN rather than merely detecting
      those colonised.
FAU - Nijsingh, Niels
AU  - Nijsingh N
AD  - Centre for Antibiotic Resistance Research (CARe), University of Gothenburg,
      Gothenburg, Sweden. nielsnijsingh@posteo.net.
AD  - Department of Philosophy, Linguistics and Theory of Science (FLoV), University of
      Gothenburg, Gothenburg, Sweden. nielsnijsingh@posteo.net.
AD  - Institute for Ethics, History and Theory of Medicine, Ludwig-Maximilians
      University, Lessingstr. 2, 80336, Munich, Germany. nielsnijsingh@posteo.net.
FAU - Munthe, Christian
AU  - Munthe C
AD  - Centre for Antibiotic Resistance Research (CARe), University of Gothenburg,
      Gothenburg, Sweden.
AD  - Department of Philosophy, Linguistics and Theory of Science (FLoV), University of
      Gothenburg, Gothenburg, Sweden.
FAU - Lindblom, Anna
AU  - Lindblom A
AD  - Centre for Antibiotic Resistance Research (CARe), University of Gothenburg,
      Gothenburg, Sweden.
AD  - Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy,
      Gothenburg, Sweden.
AD  - Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg,
      Sweden.
FAU - Ahren, Christina
AU  - Ahren C
AD  - Centre for Antibiotic Resistance Research (CARe), University of Gothenburg,
      Gothenburg, Sweden.
AD  - Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy,
      Gothenburg, Sweden.
AD  - Swedish Strategic Program Against Antimicrobial Resistance (Strama), Region
      Vastra Gotaland, Gothenburg, Sweden.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - Carrier State/*diagnosis
MH  - Diagnostic Screening Programs/*ethics/*standards
MH  - *Drug Resistance, Multiple, Bacterial
MH  - *Gram-Negative Bacteria
MH  - Humans
MH  - Methicillin-Resistant Staphylococcus aureus
PMC - PMC7749868
OTO - NOTNLM
OT  - Antibiotic resistance
OT  - Colonisation
OT  - Hospital screening
OT  - Public health ethics
OT  - Risk
OT  - Symptomatic infection
EDAT- 2020/05/02 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s40592-020-00113-1 [doi]
AID - 10.1007/s40592-020-00113-1 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(Suppl 1):72-90. doi: 10.1007/s40592-020-00113-1.


PMID- 32356183
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Linking)
VI  - 36
IP  - 8
DP  - 2020 Aug
TI  - The association of mechanical dyssynchrony and resynchronization therapy with
      survival in heart failure with a wide QRS complex: a two-world study.
PG  - 1507-1514
LID - 10.1007/s10554-020-01865-x [doi]
AB  - Setting up a randomized trial to assess the association of mechanical
      dyssynchrony (MD) and the success of cardiac resynchronization therapy (CRT) in
      heart failure with a wide QRS complex is ethically challenging. We therefore
      investigated this association in a retrospective cohort study observing different
      treatment strategies which were chosen based on the availability of health care
      resources. The survival of 500 patients from six Western European centers treated
      with CRT was compared to their 137 Eastern European counterparts not treated with
      CRT, with regard to the presence of MD. MD was visually assessed and was defined 
      as the presence of apical rocking and/or septal flash. Patients were followed for
      a mean of 26 +/- 8 months for the occurrence of death of any cause. As compared
      with medical therapy alone, CRT was associated with a more favorable survival
      (hazard ratio (HR), 0.53; 95% confidence interval (CI) 0.35-0.79; P = 0.002).
      Patients with MD treated by CRT had better survival than patients belonging to
      all other groups-they showed 72%, 66% and 56% reduction in all-cause mortality,
      respectively, compared to patients with MD not treated by CRT (HR 0.28; 95% CI
      0.17-0.44), patients without MD treated by CRT (HR 0.34; 95% CI 0.22-0.52) and
      patients without MD not treated by CRT (HR 0.44; 95% CI 0.25-0.76). Patients with
      wide QRS complex who are treated with CRT have a significantly better survival
      when MD is present.
FAU - Stankovic, Ivan
AU  - Stankovic I
AD  - Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Catholic
      University Leuven, Herestraat 49, 3000, Leuven, Belgium.
AD  - Department of Cardiology, Clinical Hospital Centre Zemun, Faculty of Medicine,
      University of Belgrade, Belgrade, Serbia.
FAU - Stefanovic, Milica
AU  - Stefanovic M
AD  - Department of Cardiology, Clinical Hospital Centre Zemun, Faculty of Medicine,
      University of Belgrade, Belgrade, Serbia.
FAU - Prinz, Christian
AU  - Prinz C
AD  - Department of Cardiology, Heart and Diabetes Centre of North-Rhine Westphalia,
      Ruhr University Bochum, Bad Oeynhausen, Germany.
AD  - Practice Steuber & Prinz, Clemens-August-Str. 15, 49751, Sogel, Germany.
FAU - Ciarka, Agnieszka
AU  - Ciarka A
AD  - Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Catholic
      University Leuven, Herestraat 49, 3000, Leuven, Belgium.
FAU - Daraban, Ana Maria
AU  - Daraban AM
AD  - Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Catholic
      University Leuven, Herestraat 49, 3000, Leuven, Belgium.
AD  - Department of Internal Medicine and Gastroenterology, Clinical Emergency
      Hospital, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
FAU - Kotrc, Martin
AU  - Kotrc M
AD  - Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
AD  - Department of Cardiology, Institute for Clinical and Experimental Medicine,
      Prague, Czech Republic.
FAU - Aarones, Marit
AU  - Aarones M
AD  - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
FAU - Szulik, Mariola
AU  - Szulik M
AD  - Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical
      University of Silesia, School of Medicine With the Division of Dentistry,
      Silesian Center for Heart Diseases, Zabrze, Poland.
AD  - WSB Academy, Dabrowa Gornicza, Poland.
FAU - Winter, Stefan
AU  - Winter S
AD  - Klinik fur Innere Medizin Und Kardiologie, St. Vinzenz Hospital, Cologne,
      Germany.
FAU - Kukulski, Tomasz
AU  - Kukulski T
AD  - Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical
      University of Silesia, School of Medicine With the Division of Dentistry,
      Silesian Center for Heart Diseases, Zabrze, Poland.
FAU - Aakhus, Svend
AU  - Aakhus S
AD  - Department of Circulation and Imaging, Faculty of Medicine and Health Science,
      NTNU, Norwegian University of Science and Technology, and Clinic of Cardiology,
      St. Olavs Hospital, Trondheim, Norway.
FAU - Willems, Rik
AU  - Willems R
AD  - Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Catholic
      University Leuven, Herestraat 49, 3000, Leuven, Belgium.
FAU - Fehske, Wolfgang
AU  - Fehske W
AD  - Klinik fur Innere Medizin Und Kardiologie, St. Vinzenz Hospital, Cologne,
      Germany.
FAU - Penicka, Martin
AU  - Penicka M
AD  - Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
FAU - Faber, Lothar
AU  - Faber L
AD  - Department of Cardiology, Heart and Diabetes Centre of North-Rhine Westphalia,
      Ruhr University Bochum, Bad Oeynhausen, Germany.
FAU - Neskovic, Aleksandar N
AU  - Neskovic AN
AD  - Department of Cardiology, Clinical Hospital Centre Zemun, Faculty of Medicine,
      University of Belgrade, Belgrade, Serbia.
FAU - Voigt, Jens-Uwe
AU  - Voigt JU
AD  - Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Catholic
      University Leuven, Herestraat 49, 3000, Leuven, Belgium.
      jens-uwe.voigt@uzleuven.be.
LA  - eng
GR  - OT/12/085/University Hospitals Leuven
GR  - 175099/Ministry of Science, Republic of Serbia
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Video-Audio Media
DEP - 20200430
PL  - United States
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
RN  - 0 (Cardiovascular Agents)
SB  - IM
MH  - Action Potentials
MH  - Aged
MH  - Aged, 80 and over
MH  - *Cardiac Resynchronization Therapy/adverse effects/mortality
MH  - Cardiovascular Agents/therapeutic use
MH  - Echocardiography
MH  - Europe
MH  - Female
MH  - Heart Failure/diagnostic imaging/mortality/physiopathology/*therapy
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - Apical rocking
OT  - Cardiac resynchronization therapy
OT  - Mechanical dyssynchrony
OT  - Septal flash
OT  - Survival
EDAT- 2020/05/02 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/01/18 00:00 [received]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s10554-020-01865-x [doi]
AID - 10.1007/s10554-020-01865-x [pii]
PST - ppublish
SO  - Int J Cardiovasc Imaging. 2020 Aug;36(8):1507-1514. doi:
      10.1007/s10554-020-01865-x. Epub 2020 Apr 30.


PMID- 32356156
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20210209
IS  - 1432-1084 (Electronic)
IS  - 0938-7994 (Linking)
VI  - 30
IP  - 10
DP  - 2020 Oct
TI  - Results of trials assessing transarterial chemoembolization for treating
      hepatocellular carcinoma are critically underreported.
PG  - 5633-5640
LID - 10.1007/s00330-020-06900-y [doi]
AB  - OBJECTIVE: We aimed to evaluate to what extent the results of registered
      randomized controlled trials (RCTs) assessing transarterial chemoembolization
      (TACE) for treating hepatocellular carcinoma (HCC) are publicly available.
      METHODS: We searched the Cochrane Central Register of Controlled Trials, the
      International Clinical Trials Registry Platform, and primary registries for RCTs 
      assessing TACE for treating HCC, registered between January 2008 and August 2018,
      that had exceeded their completion date by more than 1 year. We systematically
      searched PubMed, EMBASE, and Google Scholar for a publication as well as the
      registry for results. The main outcomes were the availability of results, and the
      time to the first availability of results (i.e., posted on the registry or
      published). Secondary outcomes were the proportion of results available at 12 and
      36 months after completion. RESULTS: Among 67 identified RCTs, including a total 
      target number to 11,599 participants, 26 had publicly available results (39%;
      i.e., 42% of total target number of participants). Results of 25 RCTs (37%) were 
      published, with only 3 having results posted on the registry and 2 with both
      published and posted results. The median (Q1-Q3) time from completion to the
      first public availability of results was 18 months (11-29). The cumulative
      percentages of RCTs with results available were 10% (95% CI, 3-17%) and 29% (95% 
      CI, 17-39%) at 12 and 36 months, respectively, after completion. CONCLUSIONS:
      Despite the ethical commitments and societal expectations for disclosure of
      results, the availability of results of RCTs on TACE for treating HCC is very
      limited. KEY POINTS: * Underreporting of trial results is a major cause of wasted
      medical research since inaccessible research results fail to help both patients
      and clinicians. * Transarterial chemoembolization (TACE) is the most common
      treatment for hepatocellular carcinoma (HCC) and has called for considerable
      research efforts. * Yet, almost two-thirds of randomized controlled trials
      assessing TACE for treating HCC did not yield any public results, either on the
      registry platform or in scientific journals.
FAU - Gregory, Jules
AU  - Gregory J
AD  - INSERM, UMR1153, Epidemiology and Biostatistics Sorbonne Paris Cite Center
      (CRESS), METHODS team, Paris, France; Centre d'Epidemiologie Clinique, AP-HP
      (Assistance Publique des Hopitaux de Paris), Hopital Hotel Dieu, Paris, France,
      F-75004, Paris, France. jules.gregory@aphp.fr.
AD  - Universite de Paris, Paris, France. jules.gregory@aphp.fr.
AD  - Department of Radiology, Paris Nord Val de Seine Hospitals, APHP, Beaujon
      Hospital, Clichy, France. jules.gregory@aphp.fr.
FAU - Crequit, Perrine
AU  - Crequit P
AD  - INSERM, UMR1153, Epidemiology and Biostatistics Sorbonne Paris Cite Center
      (CRESS), METHODS team, Paris, France; Centre d'Epidemiologie Clinique, AP-HP
      (Assistance Publique des Hopitaux de Paris), Hopital Hotel Dieu, Paris, France,
      F-75004, Paris, France.
AD  - Direction of Clinical Research, Foch Hospital, Suresnes, France.
FAU - Vilgrain, Valerie
AU  - Vilgrain V
AD  - Universite de Paris, Paris, France.
AD  - Department of Radiology, Paris Nord Val de Seine Hospitals, APHP, Beaujon
      Hospital, Clichy, France.
AD  - Laboratory of Imaging Biomarkers, INSERM U1149, Centre for Research on
      Inflammation, Paris, France.
FAU - Ronot, Maxime
AU  - Ronot M
AD  - Universite de Paris, Paris, France.
AD  - Department of Radiology, Paris Nord Val de Seine Hospitals, APHP, Beaujon
      Hospital, Clichy, France.
AD  - Laboratory of Imaging Biomarkers, INSERM U1149, Centre for Research on
      Inflammation, Paris, France.
FAU - Boutron, Isabelle
AU  - Boutron I
AD  - INSERM, UMR1153, Epidemiology and Biostatistics Sorbonne Paris Cite Center
      (CRESS), METHODS team, Paris, France; Centre d'Epidemiologie Clinique, AP-HP
      (Assistance Publique des Hopitaux de Paris), Hopital Hotel Dieu, Paris, France,
      F-75004, Paris, France.
AD  - Universite de Paris, Paris, France.
LA  - eng
GR  - DOC20180507331/Fondation ARC pour la Recherche sur le Cancer
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200430
PL  - Germany
TA  - Eur Radiol
JT  - European radiology
JID - 9114774
SB  - IM
MH  - *Bibliometrics
MH  - Carcinoma, Hepatocellular/pathology/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - Humans
MH  - Liver Neoplasms/pathology/*therapy
MH  - Probability
MH  - Randomized Controlled Trials as Topic
MH  - Registries
MH  - Treatment Outcome
MH  - Vascular Surgical Procedures
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Publication bias
OT  - Randomized controlled trial
OT  - Therapeutic embolization
EDAT- 2020/05/02 06:00
MHDA- 2021/02/10 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s00330-020-06900-y [doi]
AID - 10.1007/s00330-020-06900-y [pii]
PST - ppublish
SO  - Eur Radiol. 2020 Oct;30(10):5633-5640. doi: 10.1007/s00330-020-06900-y. Epub 2020
      Apr 30.


PMID- 32356128
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20211204
IS  - 1573-6628 (Electronic)
IS  - 1092-7875 (Linking)
VI  - 24
IP  - 7
DP  - 2020 Jul
TI  - Acceptability and Feasibility of Hair and Salivary Biomarker Collection Among
      Multiethnic School-Age Children.
PG  - 865-874
LID - 10.1007/s10995-020-02926-2 [doi]
AB  - OBJECTIVE: As noninvasive biological markers gain increasing popularity in
      pediatric research, it is critical to understand how study participants perceive 
      these measures, especially among groups underrepresented in biobehavioral
      research, like children and people of color. The purpose of this study was to
      examine acceptability and feasibility of hair and salivary biomarker collection
      in an urban community sample of ethnically diverse children (age 4 to 10 years). 
      METHODS: Ninety-seven mother-child dyads were recruited for a cross-sectional
      follow up study of the Minding the Baby(R) home visiting intervention. Children
      were Hispanic (63%), Black (34%), and multi-racial (3.1%). A conventional content
      analysis was conducted using two sources of data: (1) mothers' responses to
      open-ended interview questions on their views and suggestions regarding biomarker
      collection, and (2) field notes recorded by investigators. RESULTS: Forty-four
      percent of mothers reported biomarker-related questions or concerns, including
      questions about the purpose of biomarker testing, and concerns about cosmetic
      issues, child discomfort, and future use of biomarker data. Mothers also offered 
      positive feedback and advice for collection. Issues affecting feasibility
      included children's hair length and style, refusal to participate, and behavioral
      or developmental issues. CONCLUSIONS: Hair and salivary biomarker collection was 
      largely acceptable and feasible in this sample. Strategies for promoting ethical 
      and sensitive biomarker collection include respectful explanations and parental
      involvement, creating a comfortable and safe environment for the child, flexible 
      collection strategies, and attention to development, cultural preferences and
      perspectives.
FAU - Condon, Eileen M
AU  - Condon EM
AUID- ORCID: http://orcid.org/0000-0001-7747-5870
AD  - Yale School of Nursing, 400 West Campus Drive, Orange, CT, 06477, USA.
      Eileen.Condon@yale.edu.
FAU - Londono Tobon, Amalia
AU  - Londono Tobon A
AD  - Yale Child Study Center, 230 S Frontage Rd, New Haven, CT, 06519, USA.
FAU - Mayes, Linda C
AU  - Mayes LC
AD  - Yale Child Study Center, 230 S Frontage Rd, New Haven, CT, 06519, USA.
FAU - Sadler, Lois S
AU  - Sadler LS
AD  - Yale School of Nursing, 400 West Campus Drive, Orange, CT, 06477, USA.
AD  - Yale Child Study Center, 230 S Frontage Rd, New Haven, CT, 06519, USA.
LA  - eng
GR  - F31 NR016385/NR/NINR NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
GR  - Alpha Nu Chapter/Sigma Theta Tau International
GR  - T32 NR008346/NR/NINR NIH HHS/United States
GR  - F31NR016385/NR/NINR NIH HHS/United States
GR  - T32NR008346/NR/NINR NIH HHS/United States
GR  - K99 NR018876/NR/NINR NIH HHS/United States
GR  - T32 MH018268/MH/NIMH NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Matern Child Health J
JT  - Maternal and child health journal
JID - 9715672
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/*analysis
MH  - Chi-Square Distribution
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Ethnicity/*genetics/statistics & numerical data
MH  - Feasibility Studies
MH  - Female
MH  - *Hair
MH  - Humans
MH  - Male
MH  - *Saliva
MH  - Specimen Handling/methods
PMC - PMC7378972
MID - NIHMS1608735
OTO - NOTNLM
OT  - Child health
OT  - Health disparities
OT  - Mothers
OT  - Parent-child relations
EDAT- 2020/05/02 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s10995-020-02926-2 [doi]
AID - 10.1007/s10995-020-02926-2 [pii]
PST - ppublish
SO  - Matern Child Health J. 2020 Jul;24(7):865-874. doi: 10.1007/s10995-020-02926-2.


PMID- 32356112
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Jun
TI  - Phronesis in Medical Ethics: Courage and Motivation to Keep on the Track of
      Rightness in Decision-Making.
PG  - 158-175
LID - 10.1007/s10728-020-00398-7 [doi]
AB  - Ethical decision making in medicine has recently seen calls to move towards less 
      prescriptive- based approaches that consider the particularities of each case.
      The main alternative call from the literature is for better understanding of
      phronesis (practical wisdom) concepts applied to decision making. A well-cited
      phronesis-based approach is Kaldjian's five-stage theoretical framework: goals,
      concrete circumstances, virtues, deliberation and motivation to act. We build on 
      Kaldjian's theory after using his framework to analyse data collected from a
      three-year empirical study of phronesis and the medical community. The data are a
      set of narratives collected in response to asking a medical community (131
      doctors at various stages of their careers) what making ethically wise decisions 
      means to them. We found that Kaldjian's five concepts are present in the accounts
      to some extent but that one of the elements, motivation, is constructed as
      playing a different, though still crucial role. Rather than being an end-stage of
      the process as Kaldjian's framework suggests, motivation was constructed as
      initiating the process and maintaining the momentum of taking a phronesis-based
      approach. The implications for medical ethics decision-making education are
      significant as motivation itself is a highly complex concept. We therefore
      theorise that motivation is required for leading in, continuing and completing
      the actions of the ethical decision taken. Appreciating the central importance of
      motivation through the whole of Kaldjian's framework has implications for
      cultivating the virtues of phronesis and courage to take the right course of
      action.
FAU - Malik, Aisha
AU  - Malik A
AUID- ORCID: http://orcid.org/0000-0003-1751-2806
AD  - Health Services Management Centre, University of Birmingham, Birmingham, UK.
      aisha.malik@oxon.org.
FAU - Conroy, Mervyn
AU  - Conroy M
AD  - Health Services Management Centre, University of Birmingham, Birmingham, UK.
FAU - Turner, Chris
AU  - Turner C
AD  - Emergency Medicine, University Hospital Coventry and Warwickshire, Coventry, UK.
LA  - eng
GR  - AH/M006646/1/Arts and Humanities Research Council
PT  - Journal Article
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - *Courage
MH  - Decision Making/*ethics
MH  - *Ethics, Medical
MH  - Humans
MH  - Morals
MH  - *Motivation
MH  - Physicians
MH  - *Professionalism
MH  - Virtues
PMC - PMC7319403
OTO - NOTNLM
OT  - Decision-making
OT  - Medical ethics
OT  - Motivation
OT  - Phronesis
OT  - Practical wisdom
OT  - Virtue ethics
EDAT- 2020/05/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s10728-020-00398-7 [doi]
AID - 10.1007/s10728-020-00398-7 [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Jun;28(2):158-175. doi: 10.1007/s10728-020-00398-7.


PMID- 32356091
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Aug
TI  - Brain Recording, Mind-Reading, and Neurotechnology: Ethical Issues from Consumer 
      Devices to Brain-Based Speech Decoding.
PG  - 2295-2311
LID - 10.1007/s11948-020-00218-0 [doi]
AB  - Brain reading technologies are rapidly being developed in a number of
      neuroscience fields. These technologies can record, process, and decode neural
      signals. This has been described as 'mind reading technology' in some instances, 
      especially in popular media. Should the public at large, be concerned about this 
      kind of technology? Can it really read minds? Concerns about mind-reading might
      include the thought that, in having one's mind open to view, the possibility for 
      free deliberation, and for self-conception, are eroded where one isn't at liberty
      to privately mull things over. Themes including privacy, cognitive liberty, and
      self-conception and expression appear to be areas of vital ethical concern.
      Overall, this article explores whether brain reading technologies are really mind
      reading technologies. If they are, ethical ways to deal with them must be
      developed. If they are not, researchers and technology developers need to find
      ways to describe them more accurately, in order to dispel unwarranted concerns
      and address appropriately those that are warranted.
FAU - Rainey, Stephen
AU  - Rainey S
AD  - Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.
      Stephen.rainey@philosophy.ox.ac.uk.
FAU - Martin, Stephanie
AU  - Martin S
AD  - Department of Basic Neurosciences, Faculty of Medicine, University of Geneva,
      Geneva, Switzerland.
FAU - Christen, Andy
AU  - Christen A
AD  - Department of Basic Neurosciences, Faculty of Medicine, University of Geneva,
      Geneva, Switzerland.
FAU - Megevand, Pierre
AU  - Megevand P
AD  - Department of Basic Neurosciences, Faculty of Medicine, University of Geneva,
      Geneva, Switzerland.
FAU - Fourneret, Eric
AU  - Fourneret E
AD  - Braintech Lab (U 1205), Universite Grenoble Alpes, Grenoble, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200430
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Brain
MH  - Humans
MH  - Morals
MH  - *Neurosciences
MH  - Privacy
MH  - *Speech
MH  - *Speech Recognition Software/ethics
PMC - PMC7417394
OTO - NOTNLM
OT  - *Language
OT  - *Mind reading
OT  - *Neuroethics
OT  - *Neuroprosthetics
OT  - *Neuroscience
OT  - *Neurotechnology
OT  - *Philosophy
OT  - *Speech
EDAT- 2020/05/02 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/05/02 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1007/s11948-020-00218-0 [doi]
AID - 10.1007/s11948-020-00218-0 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Aug;26(4):2295-2311. doi: 10.1007/s11948-020-00218-0. Epub
      2020 Apr 30.


PMID- 32355806
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2305-5839 (Print)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 6
DP  - 2020 Mar
TI  - The use of algeness in the face and neck: a safe, alternative filler for
      cosmetics and reconstruction.
PG  - 362
LID - 10.21037/atm.2020.02.52 [doi]
AB  - BACKGROUND: The search for effectiveness and safety in the use of dermal fillers,
      is an ongoing challenge for aesthetic physicians, plastic surgeons and the
      science of bioengineering. Understanding the variety of characteristics,
      capabilities, advantages and disadvantages of available injectables is essential 
      to reduce complication rates and achieve satisfying aesthetic and functional
      results. METHODS: Algeness is a 100% natural, biodegradable tissue implant,
      consisting of a gel derived from agarose. This paper analyzes the use of this
      newly introduced agarose gel as an alternative filler in the face and neck for
      aesthetic and functional indications. All participants gave informed consent
      before taking part and there was no ethics approval required. As this work
      describes opinions based on clinical experienced physicians and not the results
      of a monocentric study. RESULTS: Algeness is competitive with other available
      hydrophilic biomaterials, such as hyaluronic acid, and has the advantage of its
      unique hydrocolloid nature. CONCLUSIONS: Compared to other injectables, it
      exhibits good tolerability, excellent persistence, negligible immunological
      reaction, biocompatibility and maximal safety-all properties combined with
      immediate volume restoration and predictable outcomes. "What you see (on
      injection), is what you get (as a result)". Level of evidence: Level V, opinions 
      based on clinical experience.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Karapantzou, Chrisanthi
AU  - Karapantzou C
AD  - ORL Clinic, Ludwigs-Maximilians-University Munich, Munich, Germany.
AD  - Karapantzou ENT Company, Drama, Greece.
FAU - Jakob, Mark
AU  - Jakob M
AD  - ORL Department, Ludwig-Maximilians University Munich, Munich, Germany.
FAU - Kinney, Brian
AU  - Kinney B
AD  - University of Southern California, Beverly Hills, USA.
FAU - Vandeputte, Joan
AU  - Vandeputte J
AD  - Plastische Chirurgie bvba, Oudenaarde, Belgium.
FAU - Vale, Joao Pedro
AU  - Vale JP
AD  - Plastic Surgery, Bellage Clinic Aesthetic Medicine, Lisbon, Portugal.
FAU - Canis, Martin
AU  - Canis M
AD  - ORL Department, Ludwig-Maximilians University Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7186688
OTO - NOTNLM
OT  - Agarose gel
OT  - facial reconstruction
OT  - facial rejuvenation
OT  - hydrocolloid biomaterial
OT  - natural filler
COIS- Conflicts of Interest: Dr. Kinney is a member of the Board of Directors, one of
      the developers of the product and an investor in the company. Dr. Vandeputte is
      investor in the company. The other authors have no conflicts of interest to
      declare.
EDAT- 2020/05/02 06:00
MHDA- 2020/05/02 06:01
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/05/02 06:01 [medline]
AID - 10.21037/atm.2020.02.52 [doi]
AID - atm-08-06-362 [pii]
PST - ppublish
SO  - Ann Transl Med. 2020 Mar;8(6):362. doi: 10.21037/atm.2020.02.52.


PMID- 32355344
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20201101
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 5
DP  - 2020 May
TI  - Veterinary Medical Ethics.
PG  - 463-464
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7155872
EDAT- 2020/05/02 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PST - ppublish
SO  - Can Vet J. 2020 May;61(5):463-464.


PMID- 32355342
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20201101
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 5
DP  - 2020 May
TI  - Ethical questions concern animal activists - A response.
PG  - 458
FAU - Blackwell, Tim
AU  - Blackwell T
AD  - Ontario Ministry of Agriculture, Food and Rural Affairs.
LA  - eng
PT  - Letter
PT  - Comment
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CON - Can Vet J. 2020 May;61(5):457-458. PMID: 32355340
CON - Can Vet J. 2020 May;61(5):457. PMID: 32355341
MH  - *Animal Welfare
MH  - Animals
MH  - *Morals
PMC - PMC7155887
EDAT- 2020/05/02 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PST - ppublish
SO  - Can Vet J. 2020 May;61(5):458.


PMID- 32355341
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 5
DP  - 2020 May
TI  - Ethical questions concerning animal activists - Comments.
PG  - 457
FAU - Drosdovech, Moira
AU  - Drosdovech M
AD  - Kelowna, British Columba.
FAU - Arbour, Josianne
AU  - Arbour J
AD  - Saint-Jean-sur-Richelieu, Quebec.
FAU - Kona-Boun, Jean-Jacques
AU  - Kona-Boun JJ
AD  - Montreal, Quebec.
LA  - eng
PT  - Letter
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CIN - Can Vet J. 2020 May;61(5):458. PMID: 32355342
CIN - Can Vet J. 2020 Aug;61(8):807. PMID: 32741979
CIN - Can Vet J. 2020 Aug;61(8):807-808. PMID: 32741980
CIN - Can Vet J. 2020 Aug;61(8):808. PMID: 32741981
CIN - Can Vet J. 2020 Aug;61(8):809. PMID: 32741982
CIN - Can Vet J. 2020 Aug;61(8):809. PMID: 32741983
CIN - Can Vet J. 2020 Aug;61(8):809-810. PMID: 32741984
CIN - Can Vet J. 2020 Aug;61(8):810. PMID: 32741985
CIN - Can Vet J. 2020 Aug;61(8):810-811. PMID: 32741986
MH  - *Animal Welfare/ethics
MH  - Animals
MH  - *Morals
EDAT- 2020/05/02 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/05/02 06:00
PMCR- 2020/11/01 00:00
PHST- 2020/11/01 00:00 [pmc-release]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PST - ppublish
SO  - Can Vet J. 2020 May;61(5):457.


PMID- 32355340
OWN - NLM
STAT- MEDLINE
DCOM- 20200929
LR  - 20220531
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 5
DP  - 2020 May
TI  - Ethical questions concerning animal activists - Comments.
PG  - 457-458
FAU - Kona-Boun, Jean-Jacques
AU  - Kona-Boun JJ
AD  - DMV Veterinary Center, Montreal, Quebec.
FAU - Arbour, Josianne
AU  - Arbour J
AD  - Saint-Jean-sur-Richelieu, Quebec.
FAU - Drosdovech, Moira
AU  - Drosdovech M
AD  - Kelowna, British Columbia.
LA  - eng
PT  - Letter
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
CIN - Can Vet J. 2020 May;61(5):458. PMID: 32355342
MH  - *Animal Welfare/ethics
MH  - Animals
MH  - *Morals
EDAT- 2020/05/02 06:00
MHDA- 2020/09/30 06:00
CRDT- 2020/05/02 06:00
PMCR- 2020/11/01 00:00
PHST- 2020/11/01 00:00 [pmc-release]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/09/30 06:00 [medline]
PST - ppublish
SO  - Can Vet J. 2020 May;61(5):457-458.


PMID- 32354781
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20220301
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 30
TI  - How do community advisory boards fulfil their ethical role in HIV clinical
      trials? A protocol for a systematic review of qualitative evidence.
PG  - e035368
LID - 10.1136/bmjopen-2019-035368 [doi]
AB  - INTRODUCTION: Community advisory boards (CABs) continue to gain wide use and
      acceptance in global health research including in HIV clinical trials. They
      provide means through which community concerns regarding the trial can be
      considered by the research team, and provide an important platform of
      communication between the researchers and the community about study goals.
      Therefore, this systematic review protocol will guide the review of qualitative
      evidence on the ethical roles of CABs in HIV clinical trials based on the three
      fundamental ethical principles: respect for the person, beneficence and justice. 
      METHODS AND ANALYSIS: This systematic review of qualitative evidence will involve
      searching four medical databases: PubMed, ScienceDirect, CINAHL and Cochrane
      Library. Additionally, other relevant evidence will be obtained through hand
      searching and grey literature. Searches will be limited to studies published in
      the English language from 1989 (the year that CABs were first established in HIV 
      clinical trials) to 2019. Articles searched will be screened by two independent
      authors based on inclusion and exclusion criteria. Included articles will be
      appraised for quality using the Critical Appraisal Skills Programme checklist and
      followed by qualitative data extraction. Findings will be analysed based on the
      meta-aggregative approach with the aid of EPPI-Reviewer 4 web-based software.
      ETHICS AND DISSEMINATION: Ethical approval does not apply to this review. Data
      will be disseminated through scientific conferences and peer-reviewed journals to
      inform policies and stake-holders about the ethical role of CABs. PROSPERO
      REGISTRATION NUMBER: CRD42019133787.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Pancras, Godwin
AU  - Pancras G
AUID- ORCID: 0000-0002-7802-9490
AD  - Department of Bioethics and Health Professionalism, Muhimbili University of
      Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania
      katunzip@gmail.com.
FAU - Amour, Maryam
AU  - Amour M
AD  - Department of Community Health, Muhimbili University of Health and Allied
      Sciences, Dar es Salaam, United Republic of Tanzania.
FAU - Mwakyandile, Tosi
AU  - Mwakyandile T
AD  - Department of Clinical Pharmacology, Muhimbili University of Health and Allied
      Sciences, Dar es Salaam, United Republic of Tanzania.
FAU - Morris, Baraka
AU  - Morris B
AD  - Department of Nursing Management, Muhimbili University of Health and Allied
      Sciences, Dar es Salaam, United Republic of Tanzania.
FAU - Sunguya, Bruno F
AU  - Sunguya BF
AD  - Department of Community Health, Muhimbili University of Health and Allied
      Sciences, Dar es Salaam, United Republic of Tanzania.
FAU - Mmbaga, Blandina
AU  - Mmbaga B
AD  - Department of Paediatric, Kilimanjaro Christian Medical College, Kilimanjaro,
      United Republic of Tanzania.
LA  - eng
GR  - D43 TW009573/TW/FIC NIH HHS/United States
GR  - R25 TW011227/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200430
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Advisory Committees
MH  - Clinical Trials as Topic
MH  - Community Participation
MH  - *Ethics, Research
MH  - *HIV Infections
MH  - Humans
MH  - Qualitative Research
MH  - *Stakeholder Participation
MH  - *Systematic Reviews as Topic
PMC - PMC7213848
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *clinical trials
OT  - *ethics (see medical ethics)
OT  - *qualitative research
COIS- Competing interests: None declared.
EDAT- 2020/05/02 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035368 [pii]
AID - 10.1136/bmjopen-2019-035368 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 30;10(4):e035368. doi: 10.1136/bmjopen-2019-035368.


PMID- 32354780
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 30
TI  - Study protocol for a prospective randomised double-blind placebo-controlled
      clinical trial investigating a Better Outcome with Melatonin compared to Placebo 
      Administered to normalize sleep-wake cycle and treat hypoactive ICU Delirium: the
      Basel BOMP-AID study.
PG  - e034873
LID - 10.1136/bmjopen-2019-034873 [doi]
AB  - INTRODUCTION: Delirium is frequently observed in the intensive care unit (ICU)
      population, in particular. Until today, there is no evidence for any reliable
      pharmacological intervention to treat delirium. The Basel BOMP-AID (Better
      Outcome with Melatonin compared to Placebo Administered to normalize sleep-wake
      cycle and treat hypoactive ICU Delirium) randomised trial targets improvement of 
      hypoactive delirium therapy in critically ill patients and will be conducted as a
      counterpart to the Basel ProDex Study (Study Protocol, BMJ Open, July 2017) on
      hyperactive and mixed delirium. The aim of the BOMP-AID trial is to assess the
      superiority of melatonin to placebo for the treatment of hypoactive delirium in
      the ICU. The study hypothesis is based on the assumption that melatonin
      administered at night restores a normal circadian rhythm, and that restoration of
      a normal circadian rhythm will cure delirium. METHODS AND ANALYSIS: The Basel
      BOMP-AID study is an investigator-initiated, single-centre, randomised controlled
      clinical trial for the treatment of hypoactive delirium with the once daily oral 
      administration of melatonin 4 mg versus placebo in 190 critically ill patients.
      The primary outcome measure is delirium duration in 8-hour shifts. Secondary
      outcome measures include delirium-free days and death at 28 days after study
      inclusion, number of ventilator days, length of ICU and hospital stay, and sleep 
      quality. Patients will be followed after 3 and 12 months for activities of daily 
      living and mortality assessment. Sample size was calculated to demonstrate
      superiority of melatonin compared with placebo regarding the duration of
      delirium. Results will be presented using an intention-to-treat approach. ETHICS 
      AND DISSEMINATION: This study has been approved by the Ethics Committee of
      Northwestern and Central Switzerland and will be conducted in compliance with the
      protocol, the current version of the Declaration of Helsinki, the International
      Conference on Harmonisation (ICH) of technical requirements for registration of
      pharmaceuticals for human use; Good Clinical Practice (GCP) or ISO EN 14155 (as
      far as applicable), as well as all national legal and regulatory requirements.
      Study results will be presented in international conferences and published in a
      peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT03438526. PROTOCOL VERSION: 
      Clinical Study Protocol Version 3, 10.03.2019.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hollinger, Alexa
AU  - Hollinger A
AUID- ORCID: 0000-0001-6799-1652
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland
      alexa.hollinger@usb.ch.
FAU - von Felten, Stefanie
AU  - von Felten S
AD  - Department of Clinical Research, Clinical Trial Unit, c/o University Hospital
      Basel, University of Basel, Basel, Switzerland.
AD  - Department of Biostatistics, Epidemiology, Biostatistics and Prevention
      Institute, University of Zurich, Zurich, Switzerland.
FAU - Sutter, Raoul
AU  - Sutter R
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
AD  - Department for Clinical Neurophysiology, Department of Neurology, University
      Hospital Basel, Basel, Switzerland.
AD  - Faculty of Medicine, University of Basel, Basel, BS, Switzerland.
FAU - Huber, Jan
AU  - Huber J
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
FAU - Tran, Fabian
AU  - Tran F
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
FAU - Reinhold, Simona
AU  - Reinhold S
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
FAU - Abdelhamid, Salim
AU  - Abdelhamid S
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
FAU - Todorov, Atanas
AU  - Todorov A
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
FAU - Gebhard, Caroline Eva
AU  - Gebhard CE
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
FAU - Cajochen, Christian
AU  - Cajochen C
AD  - Faculty of Medicine, University of Basel, Basel, BS, Switzerland.
AD  - Centre of Chronobiology, Psychiatric Hospital of the University of Basel, and
      Transfaculty Research Platform Molecular and Cognitive Neurosciences, University 
      of Basel, Basel, Switzerland.
FAU - Steiner, Luzius A
AU  - Steiner LA
AD  - Faculty of Medicine, University of Basel, Basel, BS, Switzerland.
AD  - Department for Anesthesia, Prehospital Emergency Medicine and Pain Therapy,
      University Hospital Basel, Basel, Switzerland.
FAU - Siegemund, Martin
AU  - Siegemund M
AD  - Intensive Care Unit, University Hospital Basel, Basel, Switzerland.
AD  - Faculty of Medicine, University of Basel, Basel, BS, Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03438526
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200430
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - JL5DK93RCL (Melatonin)
SB  - IM
MH  - Activities of Daily Living
MH  - *Delirium/drug therapy
MH  - Double-Blind Method
MH  - Humans
MH  - Intensive Care Units
MH  - *Melatonin/therapeutic use
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Sleep
MH  - Switzerland
MH  - Treatment Outcome
PMC - PMC7213885
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *adult neurology
OT  - *sleep medicine
COIS- Competing interests: MS and MD has received speaker honoraria from Fresenius
      Kabi, Switzerland. RS received research grants from the Swiss National Foundation
      (No. 320030_169379), the Research Fund of the University Basel, the Scientific
      Society Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. He received
      personal grants from UCB-pharma and holds stocks from Novartis Roche and Johnson 
      & Johnson.
EDAT- 2020/05/02 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034873 [pii]
AID - 10.1136/bmjopen-2019-034873 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 30;10(4):e034873. doi: 10.1136/bmjopen-2019-034873.


PMID- 32354732
OWN - NLM
STAT- Publisher
LR  - 20200714
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
DP  - 2020 Apr 30
TI  - UK neurology response to the COVID-19 crisis.
LID - clinmed.2020-0159 [pii]
LID - 10.7861/clinmed.2020-0159 [doi]
AB  - COVID-19 has led to seismic changes in neurological practice in a matter of
      weeks. The Association of British Neurologists has supported neurology
      specialists and patients during this rapid reorganisation and its attendant
      challenges. We have written guidance on structured service transformation,
      considering the need to sustain long term care while responding to acute
      developments; we have recognised that staff experience differs and that this, as 
      well as individual risk factors should be considered when redeployment occurs.
      Appreciating that there may be understandable anxiety when facing a working
      routine outside normal practice, we have signposted ethical and psychological
      support for individuals. We have also focused on our patients: we have
      facilitated a national alert system to register all neurological COVID cases,
      coordinating research efforts on this new disease; finally we have defined how to
      identify the most vulnerable patients under our care. When this initial wave of
      the pandemic subsides, we will have planned for return to the new 'norm', ready
      to embrace innovation where appropriate, aiming to minimise fall-out in our
      chronic disease population, and potentially having enhanced and modernised our
      services.
CI  - (c) Royal College of Physicians 2020. All rights reserved.
FAU - Mummery, Catherine J
AU  - Mummery CJ
AD  - National Hospital for Neurology and Neurosurgery, University College London
      Hospital NHS Foundation Trust and University College London, London, UK
      cath.mummery@nhs.net.
FAU - Kipps, Christopher M
AU  - Kipps CM
AD  - University Hospital Southampton NHS Foundation Trust and University of
      Southampton, Southampton, UK.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
PMC - PMC7354026
OTO - NOTNLM
OT  - COVID-19
OT  - neurology
OT  - service reconfiguration
OT  - service transformation
OT  - workforce deployment
EDAT- 2020/05/02 06:00
MHDA- 2020/05/02 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/05/02 06:00 [medline]
AID - clinmed.2020-0159 [pii]
AID - 10.7861/clinmed.2020-0159 [doi]
PST - aheadofprint
SO  - Clin Med (Lond). 2020 Apr 30. pii: clinmed.2020-0159. doi:
      10.7861/clinmed.2020-0159.


PMID- 32354535
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20201218
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
VI  - 35
IP  - 7S
DP  - 2020 Jul
TI  - The Rapid Response to the COVID-19 Pandemic by the Arthroplasty Divisions at Two 
      Academic Referral Centers.
PG  - S10-S14
LID - S0883-5403(20)30384-3 [pii]
LID - 10.1016/j.arth.2020.04.030 [doi]
AB  - The COVID-19 pandemic has created widespread changes across all of health care.
      As a result, the impacts on the delivery of orthopedic services have been
      challenged. To ensure and provide adequate health care resources in terms of
      hospital capacity and personnel and personal protective equipment, service lines 
      such as adult reconstruction and lower limb arthroplasty have stopped or
      substantially limited elective surgeries and have been forced to re-engineer care
      processes for a high volume of patients. Herein, we summarize the similar
      approaches by two arthroplasty divisions in high-volume academic referral centers
      in (1) the cessation of elective surgeries, (2) workforce restructuring, (3)
      phased delivery of outpatient and inpatient care, and (4) educational
      restructuring.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Pelt, Christopher E
AU  - Pelt CE
AD  - The University of Utah Department of Orthopaedic Surgery, University of Utah
      Health, Salt Lake City, UT.
FAU - Campbell, Kevin L
AU  - Campbell KL
AD  - The University of Utah Department of Orthopaedic Surgery, University of Utah
      Health, Salt Lake City, UT.
FAU - Gililland, Jeremy M
AU  - Gililland JM
AD  - The University of Utah Department of Orthopaedic Surgery, University of Utah
      Health, Salt Lake City, UT.
FAU - Anderson, Lucas A
AU  - Anderson LA
AD  - The University of Utah Department of Orthopaedic Surgery, University of Utah
      Health, Salt Lake City, UT.
FAU - Peters, Christopher L
AU  - Peters CL
AD  - The University of Utah Department of Orthopaedic Surgery, University of Utah
      Health, Salt Lake City, UT.
FAU - Barnes, C Lowry
AU  - Barnes CL
AD  - Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences,
      Little Rock, AR.
FAU - Edwards, Paul K
AU  - Edwards PK
AD  - Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences,
      Little Rock, AR.
FAU - Mears, Simon C
AU  - Mears SC
AD  - Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences,
      Little Rock, AR.
FAU - Stambough, Jeffrey B
AU  - Stambough JB
AD  - Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences,
      Little Rock, AR.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - United States
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
SB  - IM
MH  - *Arthroplasty
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Elective Surgical Procedures
MH  - Hospitals
MH  - Humans
MH  - Pandemics/prevention & control
MH  - Personal Protective Equipment/supply & distribution
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Referral and Consultation
MH  - SARS-CoV-2
MH  - Time Factors
PMC - PMC7172838
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - arthroplasty
OT  - ethics
OT  - pandemic
EDAT- 2020/05/02 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/04/11 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - S0883-5403(20)30384-3 [pii]
AID - 10.1016/j.arth.2020.04.030 [doi]
PST - ppublish
SO  - J Arthroplasty. 2020 Jul;35(7S):S10-S14. doi: 10.1016/j.arth.2020.04.030. Epub
      2020 Apr 21.


PMID- 32354190
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 12
IP  - 5
DP  - 2020 Apr 28
TI  - Got Mylk? The Emerging Role of Australian Plant-Based Milk Alternatives as A
      Cow's Milk Substitute.
LID - E1254 [pii]
LID - 10.3390/nu12051254 [doi]
AB  - Growing ethical, environmental and health concerns have encouraged demand for
      novel plant-based milk alternatives, yet it remains nebulous whether these
      products are nutritionally adequate as cow's milk replacements. The aim of this
      study was to conduct a cross-sectional survey of plant-based milk alternatives
      available in major Australian supermarkets and selected niche food retailers from
      November 2019 to January 2020 and assess two dietary scenarios (adolescents and
      older women) where dairy serves were substituted for plant-based alternatives
      against Australian Estimated Average Requirements (EAR). We collected
      compositional data from nutrition panels in juxtaposition with derivatives from
      the Australian Food Composition database, with a total of 115 products, including
      tree nuts and seeds (n = 48), legumes (n = 27), coconut (n = 10), grains (n = 19)
      and mixed sources (n = 10). Just over 50% of products were fortified, but only
      1/3 contained similar calcium content to cow's milk. Indiscriminate substitutions
      might reduce intakes of protein and micronutrients, particularly vitamin A, B2,
      B12, iodine and zinc, and lead to reductions >50% of the EARs for protein, zinc
      and calcium in the chosen dietary scenarios. To avoid unintended dietary
      outcomes, it is vital that consumers make pragmatic decisions regarding dietary
      replacements for cow's milk.
FAU - Zhang, Yianna Y
AU  - Zhang YY
AUID- ORCID: 0000-0001-5765-8477
AD  - School of Agriculture and Food, Faculty of Veterinary and Agricultural Sciences, 
      The University of Melbourne, Parkville, VIC 3052, Australia.
AD  - CSIRO Agriculture & Food, 671 Sneydes Road, Werribee, VIC 3030, Australia.
FAU - Hughes, Jaimee
AU  - Hughes J
AUID- ORCID: 0000-0003-2228-9880
AD  - Grains & Legumes Nutrition Council, Mount Street, North Sydney, NSW 2060,
      Australia.
FAU - Grafenauer, Sara
AU  - Grafenauer S
AUID- ORCID: 0000-0002-4286-8284
AD  - Grains & Legumes Nutrition Council, Mount Street, North Sydney, NSW 2060,
      Australia.
AD  - School of Medicine, University of Wollongong, Northfields Avenue, Wollongong, NSW
      2522, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Dietary Proteins)
RN  - 0 (Vitamins)
RN  - 9679TC07X4 (Iodine)
RN  - J41CSQ7QDS (Zinc)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Australia
MH  - Calcium/*analysis
MH  - *Cocos
MH  - Cross-Sectional Studies
MH  - Dietary Proteins/analysis
MH  - *Edible Grain
MH  - *Fabaceae
MH  - *Food Analysis
MH  - Iodine/analysis
MH  - *Milk Substitutes/chemistry
MH  - Nutrients/*analysis
MH  - *Nutritive Value
MH  - *Nuts
MH  - *Seeds
MH  - Vitamins/analysis
MH  - Zinc/analysis
PMC - PMC7281999
OTO - NOTNLM
OT  - fortification
OT  - milk
OT  - milk alternatives
OT  - nutrient composition
OT  - plant-based alternatives
OT  - vegetarian
EDAT- 2020/05/02 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - nu12051254 [pii]
AID - 10.3390/nu12051254 [doi]
PST - epublish
SO  - Nutrients. 2020 Apr 28;12(5). pii: nu12051254. doi: 10.3390/nu12051254.


PMID- 32353939
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201001
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 9
DP  - 2020 Apr 28
TI  - Supporting Innovative Person-Centred Care in Financially Constrained
      Environments: The WE CARE Exploratory Health Laboratory Evaluation Strategy.
LID - E3050 [pii]
LID - 10.3390/ijerph17093050 [doi]
AB  - The COST CARES project aims to support healthcare cost containment and improve
      healthcare quality across Europe by developing the research and development
      necessary for person-centred care (PCC) and health promotion. This paper presents
      an overview evaluation strategy for testing 'Exploratory Health Laboratories' to 
      deliver these aims. Our strategy is theory driven and evidence based, and
      developed through a multi-disciplinary and European-wide team. Specifically, we
      define the key approach and essential criteria necessary to evaluate initial
      testing, and on-going large-scale implementation with a core set of accompanying 
      methods (metrics, models, and measurements). This paper also outlines the
      enabling mechanisms that support the development of the "Health Labs" towards
      innovative models of ethically grounded and evidenced-based PCC.
FAU - Lloyd, Helen M
AU  - Lloyd HM
AD  - School of Psychology, University of Plymouth, Plymouth PL6 8BX, UK.
FAU - Ekman, Inger
AU  - Ekman I
AD  - Institute of Health and Care Sciences, Gothenburg University Centre for
      Person-Centred Care (GPCC), 405 30 Gothenburg, Sweden.
FAU - Rogers, Heather L
AU  - Rogers HL
AD  - Biocruces Bizkaia Health Research Institute, Barakaldo, 48903 Bizkaia, Spain.
AD  - IKERBASQUE, Basque Foundation for Science, Bilbao, 48013 Bizkaia, Spain.
FAU - Raposo, Vitor
AU  - Raposo V
AUID- ORCID: 0000-0002-9328-8415
AD  - Centre for Business and Economics Research (CeBER), Centre of Health Studies and 
      Research of the University of Coimbra, Faculty of Economics, University of
      Coimbra, Av. Dr. Dias da Silva 165, 3004-512 Coimbra, Portugal.
FAU - Melo, Paulo
AU  - Melo P
AUID- ORCID: 0000-0002-9166-0615
AD  - Centre for Business and Economics Research, Faculty of Economics, INESC Coimbra, 
      University of Coimbra, Av. Dr. Dias da Silva 165, 3004-512 Coimbra, Portugal.
FAU - Marinkovic, Valentina D
AU  - Marinkovic VD
AD  - Faculty of Pharmacy, Department of Social Pharmacy and Pharmaceutical
      Legislation, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia.
FAU - Buttigieg, Sandra C
AU  - Buttigieg SC
AD  - Department of Health Services Management, Faculty of Health Sciences, University 
      of Malta, MSD2080 Msida, Malta.
FAU - Srulovici, Einav
AU  - Srulovici E
AD  - Department of Nursing, University of Haifa, Haifa 3498838, Israel.
FAU - Lewandowski, Roman Andrzej
AU  - Lewandowski RA
AUID- ORCID: 0000-0002-9589-0629
AD  - Faculty of Management, University of Social Sciences, 90-113 Lodz, Poland.
FAU - Britten, Nicky
AU  - Britten N
AUID- ORCID: 0000-0002-7533-414X
AD  - Institute of Health Research, University of Exeter Medical School, St Luke's
      Campus, Exeter EX1 2LU, UK.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200428
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Europe
MH  - Health Promotion
MH  - Humans
MH  - *Patient-Centered Care
MH  - *Self Care
PMC - PMC7246834
OTO - NOTNLM
OT  - *We-CARE
OT  - *complex intervention
OT  - *cost containment
OT  - *ethically grounded
OT  - *evaluation
OT  - *evidence-based model
OT  - *patient-centred care
OT  - *person centred care
OT  - *person-centred care
OT  - *quality of care
EDAT- 2020/05/02 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/05/02 06:00 [entrez]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - ijerph17093050 [pii]
AID - 10.3390/ijerph17093050 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Apr 28;17(9). pii: ijerph17093050. doi:
      10.3390/ijerph17093050.


PMID- 32353351
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1558-349X (Electronic)
IS  - 1546-1440 (Linking)
VI  - 17
IP  - 7
DP  - 2020 Jul
TI  - Pandemic: Radiologists' Ethical and Professional Responsibilities.
PG  - 931-932
LID - S1546-1440(20)30402-6 [pii]
LID - 10.1016/j.jacr.2020.04.009 [doi]
FAU - Love, Harrison L
AU  - Love HL
AD  - Indiana University School of Medicine, Indianapolis, Indiana.
FAU - Gunderman, Richard B
AU  - Gunderman RB
AD  - Indiana University School of Medicine, Indianapolis, Indiana. Electronic address:
      rbgunder@iu.edu.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - United States
TA  - J Am Coll Radiol
JT  - Journal of the American College of Radiology : JACR
JID - 101190326
SB  - IM
MH  - Humans
MH  - Morals
MH  - *Pandemics
MH  - Radiologists
MH  - *Radiology
PMC - PMC7164854
EDAT- 2020/05/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/04/03 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - S1546-1440(20)30402-6 [pii]
AID - 10.1016/j.jacr.2020.04.009 [doi]
PST - ppublish
SO  - J Am Coll Radiol. 2020 Jul;17(7):931-932. doi: 10.1016/j.jacr.2020.04.009. Epub
      2020 Apr 17.


PMID- 32353264
OWN - NLM
STAT- MEDLINE
DCOM- 20200505
LR  - 20201218
IS  - 2215-0374 (Electronic)
IS  - 2215-0366 (Linking)
VI  - 7
IP  - 5
DP  - 2020 May
TI  - Key ethical questions for research during the COVID-19 pandemic.
PG  - 381-383
LID - S2215-0366(20)30150-4 [pii]
LID - 10.1016/S2215-0366(20)30150-4 [doi]
FAU - Townsend, Ellen
AU  - Townsend E
AD  - Self-Harm Research Group, School of Psychology, University of Nottingham,
      Nottingham NG7 2RD, UK. Electronic address: ellen.townsend@nottingham.ac.uk.
FAU - Nielsen, Emma
AU  - Nielsen E
AD  - Self-Harm Research Group, School of Psychology, University of Nottingham,
      Nottingham NG7 2RD, UK.
FAU - Allister, Rosie
AU  - Allister R
AD  - College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, 
      UK.
FAU - Cassidy, Sarah A
AU  - Cassidy SA
AD  - Self-Harm Research Group, School of Psychology, University of Nottingham,
      Nottingham NG7 2RD, UK; Mental Health in Autism Research Group, School of
      Psychology, University of Nottingham, Nottingham NG7 2RD, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet Psychiatry
JT  - The lancet. Psychiatry
JID - 101638123
SB  - IM
MH  - Betacoronavirus
MH  - Biomedical Research/trends
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/psychology
MH  - *Ethics, Research
MH  - Humans
MH  - *Mental Health
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/psychology
MH  - SARS-CoV-2
PMC - PMC7185919
EDAT- 2020/05/01 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - S2215-0366(20)30150-4 [pii]
AID - 10.1016/S2215-0366(20)30150-4 [doi]
PST - ppublish
SO  - Lancet Psychiatry. 2020 May;7(5):381-383. doi: 10.1016/S2215-0366(20)30150-4.


PMID- 32353210
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Kidney transplantation and donation in the transgender population: A
      single-institution case series.
PG  - 2899-2904
LID - 10.1111/ajt.15963 [doi]
AB  - The medical needs of the transgender population are increasingly recognized
      within the US health care system. Hormone therapy and gender-affirming surgery
      present distinct anatomic, hormonal, infectious, and psychosocial issues among
      transgender kidney transplant donors and recipients. We present the first
      reported experience with kidney transplantation and donation in transgender
      patients. A single-center case series (January 2014-December 2018) comprising 4
      transgender kidney transplant recipients and 2 transgender living donors was
      constructed and analyzed. Experts in transplant surgery, transplant psychiatry,
      transplant infectious disease, pharmacy, and endocrinology were consulted to
      discuss aspects of care for these patients. Four transgender patients identified 
      as male-to-female and 2 as female-to-male. Three of 6 had gender-affirming
      surgeries prior to transplant surgery, 1 of whom had further procedures
      posttransplant. Additionally, 4 patients were on hormone therapy. All 6 had
      psychiatric comorbidities. The 4 grafts have done well, with an average serum
      creatinine of 1.45 mg/dL at 2 years (range 1.01-1.85 mg/dL). However, patients
      encountered various postoperative complications, 1 of which was attributable to
      modified anatomy. Thus, transgender kidney transplant patients can present novel 
      challenges in regard to surgical considerations as well as pre- and
      posttransplant care. Dedicated expertise is needed to optimize outcomes for this 
      population.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Ramadan, Omar I
AU  - Ramadan OI
AUID- ORCID: 0000-0003-0194-2860
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Naji, Ali
AU  - Naji A
AUID- ORCID: 0000-0002-6926-3306
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Levine, Matthew H
AU  - Levine MH
AUID- ORCID: 0000-0003-4525-5827
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Porrett, Paige M
AU  - Porrett PM
AUID- ORCID: 0000-0002-6895-5597
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Dunn, Ty B
AU  - Dunn TB
AUID- ORCID: 0000-0002-5941-0659
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Nazarian, Susanna M
AU  - Nazarian SM
AUID- ORCID: 0000-0001-6775-8236
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Weinrieb, Robert M
AU  - Weinrieb RM
AD  - Department of Psychiatry, Hospital of the University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Kaminski, Mary
AU  - Kaminski M
AD  - Penn Transplant Institute, Hospital of the University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Johnson, David
AU  - Johnson D
AD  - Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
FAU - Trofe-Clark, Jennifer
AU  - Trofe-Clark J
AUID- ORCID: 0000-0003-4370-3796
AD  - Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
AD  - Division of Nephrology, Department of Medicine, Hospital of the University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Lorincz, Ilona S
AU  - Lorincz IS
AUID- ORCID: 0000-0003-3074-3959
AD  - Division of Endocrinology, Department of Medicine, Hospital of the University of 
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Blumberg, Emily A
AU  - Blumberg EA
AUID- ORCID: 0000-0002-5193-6170
AD  - Division of Infectious Disease, Department of Medicine, Hospital of the
      University of Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Weikert, Blair C
AU  - Weikert BC
AD  - Division of Infectious Disease, Department of Medicine, Hospital of the
      University of Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Bleicher, Melissa
AU  - Bleicher M
AD  - Division of Nephrology, Department of Medicine, Hospital of the University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Abt, Peter L
AU  - Abt PL
AD  - Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CIN - Am J Transplant. 2020 Dec;20(12):3693-3694. PMID: 32476237
CIN - Am J Transplant. 2020 Dec;20(12):3691-3692. PMID: 32476262
CIN - Am J Transplant. 2020 Dec;20(12):3695-3696. PMID: 32594653
MH  - Delivery of Health Care
MH  - Female
MH  - Humans
MH  - *Kidney Transplantation
MH  - Living Donors
MH  - Male
MH  - Referral and Consultation
MH  - *Transgender Persons
OTO - NOTNLM
OT  - *clinical decision-making
OT  - *clinical research/practice
OT  - *disparities
OT  - *endocrinology/diabetology
OT  - *ethics and public policy
OT  - *gender
OT  - *kidney transplantation/nephrology
OT  - *mental health
OT  - *sexuality
OT  - *social sciences
EDAT- 2020/05/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/01 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1111/ajt.15963 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Oct;20(10):2899-2904. doi: 10.1111/ajt.15963. Epub 2020 May
      27.


PMID- 32352415
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20211204
IS  - 2149-2271 (Electronic)
IS  - 2149-2263 (Linking)
VI  - 23
IP  - 5
DP  - 2020 Apr
TI  - Comparison of 3-year clinical outcomes between Endeavor Resolute(R) and Resolute 
      Integrity(R) zotarolimus-eluting stents in an Asian population.
PG  - 268-276
LID - 10.14744/AnatolJCardiol.2020.80845 [doi]
AB  - OBJECTIVE: There is a scarcity of comparative studies between Endeavor
      Resolute(R)-zotarolimus-eluting stent (R-ZES) and Resolute Integrity(R)-ZES
      (I-ZES) during long-term follow-up periods. Although the stent alloy and the
      polymer of these two ZESs are similar, the platform and the design of these two
      stents are different. This study was conducted to compare the efficacy and safety
      of these two different ZESs in the all-comer Korean patients who underwent
      percutaneous coronary intervention (PCI) during a 3-year follow-up period.
      METHODS: This study was performed in accordance with the ethical standards laid
      down in the 1964 Declaration of Helsinki. In this single-center, retrospective,
      and all-comer patients' cohort study, a total of 889 patients who underwent PCI
      with R-ZES (n=394) or I-ZES (n=495) were enrolled. The primary endpoint was the
      occurrence of major adverse cardiac events (MACEs) defined as all-cause death,
      nonfatal myocardial infarction (MI), any repeat revascularization including
      target lesion revascularization (TLR), target vessel revascularization (TVR), and
      non-TVR, and the secondary endpoint was stent thrombosis (ST) at 3 years.
      RESULTS: To adjust for any potential confounders, the propensity score-adjusted
      multivariable analysis was performed using the logistic regression model
      (C-statistics=0.689). The cumulative incidence rates of MACEs [adjusted hazard
      ratio (aHR), 1.341; 95% confidence interval (CI), 0.615-2.922; p=0.461],
      all-cause death, nonfatal MI, any repeat revascularization, and ST (aHR, 2.090;
      95% CI, 0.163-26.77; p=0.571) were similar between the two groups during the
      3-year follow-up period. CONCLUSION: R-ZES and I-ZES demonstrated comparable
      efficacy and safety after PCI during a 3-year follow-up period. However, these
      results can perhaps be more precisely defined by other large and long-term
      follow-up studies in the future. (Anatol J Cardiol 2020; 23: 268-76).
FAU - Kim, Yong Hoon
AU  - Kim YH
AD  - Division of Cardiology, Department of Internal Medicine, Kangwon National
      University School of Medicine; Chuncheon-South Korea.
FAU - Her, Ae-Young
AU  - Her AY
AD  - Division of Cardiology, Department of Internal Medicine, Kangwon National
      University School of Medicine; Chuncheon-South Korea.
FAU - Rha, Seung-Woon
AU  - Rha SW
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Choi, Byoung Geol
AU  - Choi BG
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Choi, Se Yeon
AU  - Choi SY
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Byun, Jae Kyeong
AU  - Byun JK
AD  - Department of Medicine, Korea University Graduate School; Seoul-South Korea.
FAU - Park, Yoonjee
AU  - Park Y
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Kang, Dong Oh
AU  - Kang DO
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Jang, Won Young
AU  - Jang WY
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Kim, Woohyeun
AU  - Kim W
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Choi, Cheol Ung
AU  - Choi CU
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
FAU - Seo, Hong Seog
AU  - Seo HS
AD  - Cardiovascular Center, Korea University Guro Hospital; Seoul-South Korea.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Turkey
TA  - Anatol J Cardiol
JT  - Anatolian journal of cardiology
JID - 101652981
RN  - H4GXR80IZE (zotarolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Asians
MH  - Coronary Artery Disease/*therapy
MH  - Coronary Restenosis/*epidemiology
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Republic of Korea/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sirolimus/administration & dosage/*analogs & derivatives
PMC - PMC7219307
EDAT- 2020/05/01 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.14744/AnatolJCardiol.2020.80845 [doi]
PST - ppublish
SO  - Anatol J Cardiol. 2020 Apr;23(5):268-276. doi:
      10.14744/AnatolJCardiol.2020.80845.


PMID- 32352218
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Philip John DiSaia, MD: Available Light & The Origin of Storms.
PG  - 959-988
LID - 10.1111/jog.14277 [doi]
AB  - During a career, which spanned nearly 60 years, Professor Philip J. DiSaia
      (1937-2018) trailblazed a path forward in academic medicine, which would become
      the standard by which Departments of Obstetrics and Gynecology and Gynecologic
      Oncology Divisions and Cancer Centers would be measured throughout the United
      States, in Europe and Japan. Following his discovery of fetal warfarin syndrome
      as a resident, DiSaia would serve in the U.S. Navy and successfully compete for
      an American Cancer Society Grant that would fund his Fellowship in Gynecologic
      Oncology under the instruction of Dr Felix N. Rutledge at the MD Anderson
      Hospital and Tumor Institute in Houston, Texas. Dr DiSaia's goal to establish a
      traditional academic department was realized at the University of California,
      Irvine, where he remained active in an unprecedented, uninterrupted 42-year run, 
      training many outstanding obstetrician-gynecologists and gynecologic oncologists,
      future Division Directors, Cancer Center Directors and Department Chairpersons.
      His dedication to the field and inexhaustible work ethic fueled his many
      successes in tumor immunology and the clinical trials of the National Cancer
      Institute's Gynecologic Oncology Group.
CI  - (c) 2020 Japan Society of Obstetrics and Gynecology.
FAU - Tewari, Krishnansu S
AU  - Tewari KS
AUID- ORCID: https://orcid.org/0000-0002-8417-7000
AD  - Division of Gynecologic Oncology, Department of Obstetrics & Gynecology,
      University of California, Irvine Medical Center, Orange, California, USA.
FAU - Monk, Bradley J
AU  - Monk BJ
AD  - Arizona Oncology (US Oncology Network), University of Arizona College of
      Medicine, Creighton University School of Medicine, Phoenix, Arizona, USA.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
SB  - IM
MH  - Female
MH  - *Gynecology
MH  - Humans
MH  - Japan
MH  - Male
MH  - *Obstetrics
MH  - Pregnancy
MH  - United States
OTO - NOTNLM
OT  - Gynecologic Oncology Group
OT  - Irvine
OT  - MD
OT  - Philip DiSaia
OT  - University of California
EDAT- 2020/05/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1111/jog.14277 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2020 Jul;46(7):959-988. doi: 10.1111/jog.14277. Epub 2020 
      Apr 30.


PMID- 32352032
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2374-8265 (Electronic)
IS  - 2374-8265 (Linking)
VI  - 16
DP  - 2020 Apr 3
TI  - Ethical Dilemmas at the Beginning and End of Life: A Needs-Based,
      Experience-Informed, Small-Group, Case-Based Curriculum for Pediatric Residents.
PG  - 10895
LID - 10.15766/mep_2374-8265.10895 [doi]
AB  - Introduction: Pediatric residents are faced with ethical dilemmas in beginning-
      and end-of-life situations throughout their training. These situations are
      innately challenging, yet despite recommendations that residents receive training
      in ethics and end-of-life domains, they continue to report the need for
      additional training. To address these concerns, we developed an interactive and
      reflective palliative care and medical ethics curriculum including sessions
      focusing on ethical dilemmas at the beginning and end of life. Methods: This
      module includes a trio of case-based, small-group discussions on artificial
      nutrition and hydration, futility, and ethical considerations in neonatology.
      Content was developed based on a needs assessment, input from local experts, and 
      previously published material. Trainees completed assessments of comfort and
      understanding before and after each session. Results: The module was attended and
      assessed by an average of 27 trainees per session, including residents and
      medical students. Knowledge of ethical considerations improved after individual
      sessions, with 86% of trainees reporting understanding ethical considerations
      involved in the decision to withdraw or withhold medically provided nutrition and
      hydration and 67% of trainees reporting understanding the use of the term
      futility. Trainee comfort in providing counseling or recommendations regarding
      specific ethical issues demonstrated a trend toward improvement but did not reach
      statistical significance. Discussion: We successfully implemented this innovative
      module, which increased trainees' comfort with end-of-life care and ethical
      conflicts. Future studies should focus on the trainees' ability to implement
      these skills in clinical practice.
CI  - Copyright (c) 2020 Herbst and deSante-Bertkau.
FAU - Herbst, Lori A
AU  - Herbst LA
AD  - Assistant Professor, Department of Pediatrics, Division of Hospital Medicine,
      Cincinnati Children's Hospital Medical Center.
AD  - Assistant Professor, Department of Pediatrics, Division of Hospital Medicine,
      University of Cincinnati College of Medicine.
AD  - Volunteer Assistant Professor, Department of General Internal Medicine,
      University of Cincinnati College of Medicine.
FAU - deSante-Bertkau, Jennifer
AU  - deSante-Bertkau J
AD  - Assistant Professor, Department of Pediatrics, Division of Hospital Medicine,
      Cincinnati Children's Hospital Medical Center.
AD  - Assistant Professor, Department of Pediatrics, Division of Hospital Medicine,
      University of Cincinnati College of Medicine.
AD  - Assistant Professor, Department of Pediatrics, Ethics Center, Cincinnati
      Children's Hospital Medical Center.
AD  - Assistant Professor, Department of Pediatrics, Ethics Center, University of
      Cincinnati College of Medicine.
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - United States
TA  - MedEdPORTAL
JT  - MedEdPORTAL : the journal of teaching and learning resources
JID - 101714390
SB  - IM
MH  - Child
MH  - *Curriculum
MH  - Death
MH  - Ethics, Medical
MH  - Humans
MH  - Needs Assessment
MH  - *Students, Medical
PMC - PMC7187913
OTO - NOTNLM
OT  - *Artificial Nutrition
OT  - *End of Life
OT  - *Ethics/Bioethics
OT  - *Futility
OT  - *Hospice
OT  - *Medical Ethics
OT  - *Neonatal-Perinatal Medicine
OT  - *Neonatology
OT  - *Palliative Care
OT  - *Palliative Medicine
OT  - *Pediatrics
OT  - *Terminal Care
COIS- None to report.
EDAT- 2020/05/01 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.15766/mep_2374-8265.10895 [doi]
PST - epublish
SO  - MedEdPORTAL. 2020 Apr 3;16:10895. doi: 10.15766/mep_2374-8265.10895.


PMID- 32351974
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2297-055X (Print)
IS  - 2297-055X (Linking)
VI  - 7
DP  - 2020
TI  - AI in Cardiac Imaging: A UK-Based Perspective on Addressing the Ethical, Social, 
      and Political Challenges.
PG  - 54
LID - 10.3389/fcvm.2020.00054 [doi]
AB  - Imaging and cardiology are the healthcare domains which have seen the greatest
      number of FDA approvals for novel data-driven technologies, such as artificial
      intelligence, in recent years. The increasing use of such data-driven
      technologies in healthcare is presenting a series of important challenges to
      healthcare practitioners, policymakers, and patients. In this paper, we review
      ten ethical, social, and political challenges raised by these technologies. These
      range from relatively pragmatic concerns about data acquisition to potentially
      more abstract issues around how these technologies will impact the relationships 
      between practitioners and their patients, and between healthcare providers
      themselves. We describe what is being done in the United Kingdom to identify the 
      principles that should guide AI development for health applications, as well as
      more recent efforts to convert adherence to these principles into more practical 
      policy. We also consider the approaches being taken by healthcare organizations
      and regulators in the European Union, the United States, and other countries.
      Finally, we discuss ways by which researchers and frontline clinicians, in
      cardiac imaging and more broadly, can ensure that these technologies are
      acceptable to their patients.
CI  - Copyright (c) 2020 Fenech and Buston.
FAU - Fenech, Matthew E
AU  - Fenech ME
AD  - Future Advocacy, London, United Kingdom.
FAU - Buston, Olly
AU  - Buston O
AD  - Future Advocacy, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200415
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC7174604
OTO - NOTNLM
OT  - artificial intelligence
OT  - ethics
OT  - policy
OT  - principles
OT  - regulation
EDAT- 2020/05/01 06:00
MHDA- 2020/05/01 06:01
CRDT- 2020/05/01 06:00
PHST- 2019/10/31 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/01 06:01 [medline]
AID - 10.3389/fcvm.2020.00054 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2020 Apr 15;7:54. doi: 10.3389/fcvm.2020.00054. eCollection
      2020.


PMID- 32351894
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type 
      and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.
PG  - 517
LID - 10.3389/fonc.2020.00517 [doi]
AB  - Background: Brain radiotherapy is the standard treatment option for multiple
      brain metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the
      absence of a driver mutation. However, the prognosis for such patients remains
      poor. Apatinib is a potent antiangiogenic compound directed at the vascular
      endothelial growth factor receptor-2 (VEGFR-2); however, to date, there are no
      investigations of apatinib concurrent with brain radiotherapy for NSCLC patients 
      with BMs. We report a case of EGFR wild-type and ALK-negative lung adenocarcinoma
      patient with multiple symptomatic BMs, who received apatinib together with brain 
      radiation therapy. A favorable oncologic outcome was achieved for both brain
      metastatic lesions and the primary pulmonary tumor. Case Presentation: A
      61-year-old female (never smoker) who initially presented with headache and
      dizziness was diagnosed with lung adenocarcinoma with multiple brain metastasis
      (cT2aN3M1b stage IV), and was negative for EGFR and ALK. The patient refused to
      receive chemotherapy and was only amenable to brain radiotherapy and targeted
      therapy. After approval from the institutional ethics committee, she underwent
      concurrent oral apatinib (500 mg/day) with whole brain radiation therapy (WBRT)
      (37.5Gy) with simultaneous in-field boost (49.5Gy) in 15 fractions with image
      guided intensity-modulated radiotherapy. Three weeks later, neurologic symptoms
      entirely ceased and a partial response (PR) for the BMs with near-complete
      resolution of peritumoral brain edema was achieved. Chest CT performed at the
      same time and showed shrinkage of the lung primary with a PR. The patient
      suffered grade III oral mucositis one week after brain radiotherapy and refused
      further apatinib. At 12 months after brain radiotherapy, the brain tumors
      remained well controlled. Conclusions: This is the first known documentation of a
      rapid clinical response of apatinib concurrent with brain radiotherapy in a lung 
      adenocarcinoma patient with symptomatic multiple BMs. Apatinib combined with
      brain radiotherapy could be an alternative treatment option for BMs from NSCLC,
      especially for those without a driver mutation. Further clinical trials are
      required to corroborate this discovery.
CI  - Copyright (c) 2020 Ying, Liu, Wang, Peng, Ruan, Verma and Han.
FAU - Ying, Xiaofang
AU  - Ying X
AD  - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Liu, Huali
AU  - Liu H
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Wang, Mingwei
AU  - Wang M
AD  - Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Peng, Min
AU  - Peng M
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Ruan, Peng
AU  - Ruan P
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Verma, Vivek
AU  - Verma V
AD  - Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA,
      United States.
FAU - Han, Guang
AU  - Han G
AD  - Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Case Reports
DEP - 20200415
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7174649
OTO - NOTNLM
OT  - ALK-negative
OT  - EGFR wild-type
OT  - apatinib
OT  - brain metastases
OT  - lung adenocarcinoma
EDAT- 2020/05/01 06:00
MHDA- 2020/05/01 06:01
CRDT- 2020/05/01 06:00
PHST- 2019/12/08 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/01 06:01 [medline]
AID - 10.3389/fonc.2020.00517 [doi]
PST - epublish
SO  - Front Oncol. 2020 Apr 15;10:517. doi: 10.3389/fonc.2020.00517. eCollection 2020.


PMID- 32351417
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Granting Leave to Patients in Bavarian Forensic-Psychiatric Hospitals: A Survey
      to Describe the Current Process and Develop Guidelines.
PG  - 287
LID - 10.3389/fpsyt.2020.00287 [doi]
AB  - Forensic-psychiatric patients reoffending or absconding during the leave granted 
      to them (hereafter referred to as "granted leave") have gained increased
      attention by researchers and the general public. The patients' right to freedom
      on the one hand and the need for protection of the general public from serious
      harm on the other hand represent broadly discussed ethical issues. Thus, demands 
      on quality regarding decisions on patients' granted leaves might be high. Despite
      such requirements, research on decision-making processes regarding granting leave
      in forensic psychiatry is very limited and focuses primarily on particular
      aspects. The present study aims at providing a first overview of the
      decision-making processes regarding granted leave in forensic psychiatry as a
      whole. Furthermore, the link between the particular steps of the process and
      absconding should be explored. In this way, the study results should contribute
      to provide a theoretical framework for the development of guidelines concerning
      granted leave in forensic psychiatry. A combination of qualitative and
      quantitative approaches will be used to collect data: information about risk
      assessment, decisions on granted leave, and documentation systems in forensic
      psychiatry will be collected via semi-structured interviews and quantified for
      further analyses using a checklist developed for this study; data on the
      implementation of risk assessment tools and documented patient information will
      be obtained via two self-constructed questionnaires; information about the
      absolute number of abscondences per hospital will be obtained from the Bavarian
      Authority for Forensic Commitment. The sample will include staff from all 13
      forensic-psychiatric hospitals in Bavaria (Germany) comprising six professional
      groups: hospital directors, security officers, complementary therapists,
      psychiatrists, psychologists, social workers, and nursing staff. In each
      hospital, at least one member of each professional group should participate in
      the study. In total, 151 interviews will be held. As the study goals are
      descriptive, there are no pre-formulated hypotheses. Developing guidelines would 
      be the first step towards further standardization of the granted leave decisional
      process in forensic psychiatry and to make it more transparent for patients,
      staff members, hospital directors, and the government.
CI  - Copyright (c) 2020 Sklenarova, Neutze, Kretschmer and Nitschke.
FAU - Sklenarova, Halina
AU  - Sklenarova H
AD  - Forensic Psychiatric Clinic, Ansbach District Hospital, Ansbach, Germany.
FAU - Neutze, Janina
AU  - Neutze J
AD  - Forensic Psychiatric Clinic, Ansbach District Hospital, Ansbach, Germany.
FAU - Kretschmer, Thomas
AU  - Kretschmer T
AD  - Forensic Psychiatric Clinic, Ansbach District Hospital, Ansbach, Germany.
FAU - Nitschke, Joachim
AU  - Nitschke J
AD  - Forensic Psychiatric Clinic, Ansbach District Hospital, Ansbach, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7175993
OTO - NOTNLM
OT  - forensic patients
OT  - forensic psychiatry
OT  - reoffending
OT  - risk assessment
OT  - standardized intervention
EDAT- 2020/05/01 06:00
MHDA- 2020/05/01 06:01
CRDT- 2020/05/01 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/01 06:01 [medline]
AID - 10.3389/fpsyt.2020.00287 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Apr 15;11:287. doi: 10.3389/fpsyt.2020.00287. eCollection 
      2020.


PMID- 32351201
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 67
IP  - 5
DP  - 2020 May 1
TI  - High incidence of chronic hypoparathyroidism secondary to total thyroidectomy.
LID - A11190647 [pii]
AB  - INTRODUCTION: Hypoparathyroidism (HypoPT) is the most common complication after
      total thyroidectomy (TT). Recent literature report incidences of HypoPT that are 
      higher than previously anticipated. This study aimed to assess the incidence of
      transient and chronic HypoPT in patients undergoing TT and to specify risk
      factors and recovery time. METHODS: This was a retrospective review of patients
      undergoing TT in the period from 2013 to 2018 due to benign thyroid disease in a 
      Danish university hospital. In total, 187 patients were eligible for inclusion.
      Data were collected from internal medical files, the Thykir database sheets and
      patient records. HypoPT was defined as SE-ionised-Ca2+ levels (Less than 1.16
      mmol/l) and inappropriately low parathyroid hormone levels. RESULTS: The
      incidence of transient and chronic HypoPT was 81 (43.3%) and 25 (13.4%),
      respectively. Younger ages and toxic indication for surgery were independent risk
      factors for transient and chronic HypoPT. Incidences in Graves' disease
      population were 70.5% and 27.3%, respectively. Resolution within the first months
      was seen in 48.2% of the patients with acute transient HypoPT. CONCLUSIONS: The
      incidence of chronic HypoPT after TT is higher than previously reported. This is 
      primarily due to a lack of consistency in the definition and follow-up time
      between studies. Younger patients and those with a toxic indication for surgery
      are at higher risk of HypoPT after TT than other patients. FUNDING: none. TRIAL
      REGISTRATION: The study was approved by the Danish Data Protection Agency
      (REG-015-2019) and The Ethical Committee of Central Denmark (No. 66792).
CI  - Articles published in the DMJ are "open access". This means that the articles are
      distributed under the terms of the Creative Commons Attribution Non-commercial
      License, which permits any non-commercial use, distribution, and reproduction in 
      any medium, provided the original author(s) and source are credited.
FAU - Jorgensen, Camilla Uhre
AU  - Jorgensen CU
AD  - cuj@regionsjaelland.dk.
FAU - Homoe, Preben
AU  - Homoe P
FAU - Dahl, Morten
AU  - Dahl M
FAU - Hitz, Mette Friberg
AU  - Hitz MF
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
MH  - Adult
MH  - Denmark/epidemiology
MH  - Female
MH  - Humans
MH  - Hypoparathyroidism/*epidemiology/etiology
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*epidemiology/etiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thyroid Diseases/surgery
MH  - Thyroidectomy/*adverse effects
EDAT- 2020/05/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - A11190647 [pii]
PST - epublish
SO  - Dan Med J. 2020 May 1;67(5). pii: A11190647.


PMID- 32351023
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1613-6829 (Electronic)
IS  - 1613-6810 (Linking)
VI  - 16
IP  - 36
DP  - 2020 Sep
TI  - Mechanistic Similarities between 3D Human Bronchial Epithelium and Mice Lung,
      Exposed to Copper Oxide Nanoparticles, Support Non-Animal Methods for Hazard
      Assessment.
PG  - e2000527
LID - 10.1002/smll.202000527 [doi]
AB  - The diversity and increasing prevalence of products derived from engineered
      nanomaterials (ENM), warrants implementation of non-animal approaches to health
      hazard assessment for ethical and practical reasons. Although non-animal
      approaches are becoming increasingly popular, there are almost no studies of
      side-by-side comparisons with traditional in vivo assays. Here, transcriptomics
      is used to investigate mechanistic similarities between healthy/asthmatic models 
      of 3D air-liquid interface (ALI) cultures of donor-derived human bronchial
      epithelia cells, and mouse lung tissue, following exposure to copper oxide ENM.
      Only 19% of mouse lung genes with human orthologues are not expressed in the
      human 3D ALI model. Despite differences in taxonomy and cellular complexity
      between the systems, a core subset of matching genes cluster mouse and human
      samples strictly based on ENM dose (exposure severity). Overlapping gene
      orthologue pairs are highly enriched for innate immune functions, suggesting an
      important and maybe underestimated role of epithelial cells. In conclusion, 3D
      ALI models based on epithelial cells, are primed to bridge the gap between
      traditional 2D in vitro assays and animal models of airway exposure, and
      transcriptomics appears to be a unifying dose metric that links in vivo and in
      vitro test systems.
CI  - (c) 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Ndika, Joseph
AU  - Ndika J
AUID- ORCID: 0000-0003-0669-1300
AD  - Human Microbiome Research Program, Faculty of Medicine, University of Helsinki,
      Helsinki, 00290, Finland.
FAU - Ilves, Marit
AU  - Ilves M
AD  - Human Microbiome Research Program, Faculty of Medicine, University of Helsinki,
      Helsinki, 00290, Finland.
FAU - Kooter, Ingeborg M
AU  - Kooter IM
AD  - The Netherlands Organization for Applied Scientific, Research TNO, P.O. Box
      80015, Utrecht, 3584 CB, The Netherlands.
FAU - Grollers-Mulderij, Mariska
AU  - Grollers-Mulderij M
AD  - The Netherlands Organization for Applied Scientific, Research TNO, P.O. Box
      80015, Utrecht, 3584 CB, The Netherlands.
FAU - Duistermaat, Evert
AU  - Duistermaat E
AD  - The Netherlands Organization for Applied Scientific, Research TNO, P.O. Box
      80015, Utrecht, 3584 CB, The Netherlands.
FAU - Tromp, Peter C
AU  - Tromp PC
AD  - The Netherlands Organization for Applied Scientific, Research TNO, P.O. Box
      80015, Utrecht, 3584 CB, The Netherlands.
FAU - Kuper, Frieke
AU  - Kuper F
AD  - The Netherlands Organization for Applied Scientific, Research TNO, P.O. Box
      80015, Utrecht, 3584 CB, The Netherlands.
FAU - Kinaret, Pia
AU  - Kinaret P
AD  - Institute of Biotechnology, Helsinki Institute of Life Science, University of
      Helsinki, Helsinki, 00790, Finland.
FAU - Greco, Dario
AU  - Greco D
AD  - Faculty of Medicine and Health Technology, Tampere University, Tampere, FI-33014,
      Finland.
FAU - Karisola, Piia
AU  - Karisola P
AD  - Human Microbiome Research Program, Faculty of Medicine, University of Helsinki,
      Helsinki, 00290, Finland.
FAU - Alenius, Harri
AU  - Alenius H
AUID- ORCID: 0000-0003-0106-8923
AD  - Human Microbiome Research Program, Faculty of Medicine, University of Helsinki,
      Helsinki, 00290, Finland.
AD  - Institute of Environmental Medicine, Karolinska Institutet, P.O. Box 210,
      Stockholm, SE-17176, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200430
PL  - Germany
TA  - Small
JT  - Small (Weinheim an der Bergstrasse, Germany)
JID - 101235338
RN  - 789U1901C5 (Copper)
RN  - V1XJQ704R4 (cupric oxide)
SB  - IM
MH  - *Animal Testing Alternatives/methods/standards
MH  - Animals
MH  - *Copper/toxicity
MH  - *Epithelial Cells/drug effects
MH  - Humans
MH  - *Lung/drug effects
MH  - *Metal Nanoparticles/toxicity
MH  - Mice
MH  - Models, Animal
MH  - *Toxicology/methods
OTO - NOTNLM
OT  - *air-liquid interface
OT  - *copper oxide nanoparticles
OT  - *mouse versus human
OT  - *nanosafety
OT  - *non-animal
OT  - *transcriptomics
EDAT- 2020/05/01 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1002/smll.202000527 [doi]
PST - ppublish
SO  - Small. 2020 Sep;16(36):e2000527. doi: 10.1002/smll.202000527. Epub 2020 Apr 30.


PMID- 32350794
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20201218
IS  - 1826-6983 (Electronic)
IS  - 0033-8362 (Linking)
VI  - 125
IP  - 5
DP  - 2020 May
TI  - Use of CT and artificial intelligence in suspected or COVID-19 positive patients:
      statement of the Italian Society of Medical and Interventional Radiology.
PG  - 505-508
LID - 10.1007/s11547-020-01197-9 [doi]
AB  - The COVID-19 pandemic started in Italy in February 2020 with an exponential
      growth that has exceeded the number of cases reported in China. Italian radiology
      departments found themselves at the forefront in the management of suspected and 
      positive COVID cases, both in diagnosis, in estimating the severity of the
      disease and in follow-up. In this context SIRM recommends chest X-ray as
      first-line imaging tool, CT as additional tool that shows typical features of
      COVID pneumonia, and ultrasound of the lungs as monitoring tool. SIRM recommends,
      as high priority, to ensure appropriate sanitation procedures on the scan
      equipment after detecting any suspected or positive COVID-19 patients. In this
      emergency situation, several expectations have been raised by the scientific
      community about the role that artificial intelligence can have in improving the
      diagnosis and treatment of coronavirus infection, and SIRM wishes to deliver
      clear statements to the radiological community, on the usefulness of artificial
      intelligence as a radiological decision support system in COVID-19 positive
      patients. (1) SIRM supports the research on the use of artificial intelligence as
      a predictive and prognostic decision support system, especially in hospitalized
      patients and those admitted to intensive care, and welcomes single center of
      multicenter studies for a clinical validation of the test. (2) SIRM does not
      support the use of CT with artificial intelligence for screening or as first-line
      test to diagnose COVID-19. (3) Chest CT with artificial intelligence cannot
      replace molecular diagnosis tests with nose-pharyngeal swab (rRT-PCR) in
      suspected for COVID-19 patients.
FAU - Neri, Emanuele
AU  - Neri E
AUID- ORCID: http://orcid.org/0000-0001-7950-4559
AD  - Department of Translational Research, Diagnostic Radiology 3, University of Pisa,
      Pisa, Italy. emanuele.neri@med.unipi.it.
FAU - Miele, Vittorio
AU  - Miele V
AD  - Department of Radiology, Careggi University Hospital, Florence, Italy.
FAU - Coppola, Francesca
AU  - Coppola F
AD  - Malpighi Radiology Unit, Department of Diagnostic and Preventive Medicine,
      Sant'Orsola Malpighi University Hospital, Bologna, Italy.
FAU - Grassi, Roberto
AU  - Grassi R
AD  - Department of Clinical and Experimental Medicine, "F. Magrassi-A. Lanzara",
      University of Campania "Luigi Vanvitelli", Naples, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - Italy
TA  - Radiol Med
JT  - La Radiologia medica
JID - 0177625
SB  - IM
MH  - *Artificial Intelligence
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*diagnostic imaging
MH  - Humans
MH  - Italy
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnostic imaging
MH  - Radiology, Interventional
MH  - SARS-CoV-2
MH  - Societies, Medical
MH  - Tomography, X-Ray Computed
PMC - PMC7189175
OTO - NOTNLM
OT  - Artificial intellingence
OT  - COVID-19
OT  - Computed tomography
OT  - Ethics
OT  - Imaging
EDAT- 2020/05/01 06:00
MHDA- 2020/05/14 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1007/s11547-020-01197-9 [doi]
AID - 10.1007/s11547-020-01197-9 [pii]
PST - ppublish
SO  - Radiol Med. 2020 May;125(5):505-508. doi: 10.1007/s11547-020-01197-9. Epub 2020
      Apr 29.


PMID- 32350758
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Aug
TI  - The Emergence and Development of Animal Research Ethics: A Review with a Focus on
      Nonhuman Primates.
PG  - 2277-2293
LID - 10.1007/s11948-020-00219-z [doi]
AB  - The ethics of using nonhuman animals in biomedical research is usually seen as a 
      subfield of animal ethics. In recent years, however, the ethics of animal
      research has increasingly become a subfield within research ethics under the term
      "animal research ethics". Consequently, ethical issues have become prominent that
      are familiar in the context of human research ethics, such as autonomy or
      self-determination, harms and benefits, justice, and vulnerability. After a brief
      overview of the development of the field and a discussion of relevant theoretical
      ethical frameworks, I consider two of these issues, namely autonomy and
      self-determination on the one hand, and harms and benefits on the other hand. My 
      concern is with philosophical and ethical issues, rather than animal research
      oversight. I focus my discussion on nonhuman primates, as the most plausible
      nonhuman candidates for this approach. I conclude that the approach, although
      promising, depends strongly on the moral status of nonhuman research subjects.
FAU - Arnason, Gardar
AU  - Arnason G
AUID- ORCID: 0000-0002-9667-7096
AD  - Institute of Ethics and History of Medicine, University of Tubingen,
      Gartenstrasse 47, 72074, Tubingen, Germany. gardar.arnason@uni-tuebingen.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200429
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Animal Experimentation/ethics
MH  - Animals
MH  - Ethics
MH  - *Ethics, Research
MH  - Personal Autonomy
MH  - Primates
MH  - Social Justice
PMC - PMC7417401
OTO - NOTNLM
OT  - *Animal research
OT  - *Animal research ethics
OT  - *Nonhuman primates
OT  - *Research ethics
EDAT- 2020/05/01 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/05/01 06:00
PHST- 2019/08/31 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1007/s11948-020-00219-z [doi]
AID - 10.1007/s11948-020-00219-z [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Aug;26(4):2277-2293. doi: 10.1007/s11948-020-00219-z. Epub
      2020 Apr 29.


PMID- 32350751
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Jun
TI  - Solidarity with Whom? The Boundary Problem and the Ethical Origins of Solidarity 
      of the Health System in Taiwan.
PG  - 176-192
LID - 10.1007/s10728-020-00397-8 [doi]
AB  - Publicly-funded health systems, including those national health services and
      social or National Health Insurances, are institutionalized solidarity in health.
      In Europe, solidarity originated from the legacies of labor movements, the
      Judeo-Christian traditions, and nationalist sentiments in the re-construction Era
      after the WWII. In middle-to-high income East Asian countries, such as Japan,
      Taiwan, Korea, the health systems were built on different grounds and do not have
      such ethical origins of solidarity. As health systems in Europe and East Asia are
      both facing sustainability crises due to aging population, stagnant economy,
      changing boundaries, and advancing medical technologies, how those systems with
      the European solidaristic ethical traditions can be revived and how those without
      the European traditions could survive become a matter of theoretical interests
      and an urgent policy problem to be addressed. Drawing on contemporary theories of
      solidarity, this essay analyzes the boundary problem and its impact on the
      sustainability of the health system in Taiwan. It then considers two plausible
      origins of solidarity in Taiwan. One is the re-emerged civic nationalism, and the
      other is an ethos of common life. It is argued that after years of
      implementation, the National Health Insurance in Taiwan might have shaped the
      social values and people's habits and formed an ethos of common life. Such ethos 
      could be an ethical origin of solidarity in non-western societies and help the
      health systems endure the prolonged sustainability crises.
FAU - Yeh, Ming-Jui
AU  - Yeh MJ
AD  - Institute of Health and Welfare Policy, National Yang-Ming University, 155 Linong
      St. Sec. 2, Taipei City, 112, Taiwan. mj.yeh@ym.edu.tw.
FAU - Chen, Chia-Ming
AU  - Chen CM
AD  - Research Center for Humanities and Social Sciences, Academia Sinica, Taipei,
      Taiwan.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - *Aging
MH  - Humans
MH  - *Morals
MH  - National Health Programs/*ethics
MH  - *Social Marginalization
MH  - Taiwan
OTO - NOTNLM
OT  - Boundary problem
OT  - Civic nationalism
OT  - Ethos of common life
OT  - National Health Insurance
OT  - Sustainability
EDAT- 2020/05/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1007/s10728-020-00397-8 [doi]
AID - 10.1007/s10728-020-00397-8 [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Jun;28(2):176-192. doi: 10.1007/s10728-020-00397-8.


PMID- 32350707
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 2
DP  - 2020 Jun
TI  - Decision-making capacity: from testing to evaluation.
PG  - 253-259
LID - 10.1007/s11019-019-09930-6 [doi]
AB  - Decision-making capacity (DMC) is the gatekeeping element for a patient's right
      to self-determination with regard to medical decisions. A DMC evaluation is not
      only conducted on descriptive grounds but is an inherently normative task
      including ethical reasoning. Therefore, it is dependent to a considerable extent 
      on the values held by the clinicians involved in the DMC evaluation. Dealing with
      the question of how to reasonably support clinicians in arriving at a DMC
      judgment, a new tool is presented that fundamentally differs from existing ones: 
      the U-Doc. By putting greater emphasis on the judgmental process rather than on
      the measurement of mental abilities, the clinician as a decision-maker is brought
      into focus, rendering the tool more of an evaluation guide than a test
      instrument. In a qualitative study, the perceived benefits of and difficulties
      with the tool have been explored. The findings show on the one hand that the
      evaluation aid provides basic orientation, supports a holistic perspective on the
      patient, sensitizes for ethical considerations and personal biases, and helps to 
      think through the decision, to argue, and to justify one's judgment. On the other
      hand, the room for interpretation due to absent operationalisations, related
      ambiguities, and the confrontation with one's own subjectivity may be experienced
      as unsettling.
FAU - Hermann, Helena
AU  - Hermann H
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland.
FAU - Feuz, Martin
AU  - Feuz M
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland.
FAU - Trachsel, Manuel
AU  - Trachsel M
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland.
FAU - Biller-Andorno, Nikola
AU  - Biller-Andorno N
AUID- ORCID: http://orcid.org/0000-0001-7661-1324
AD  - Institute of Biomedical Ethics and History of Medicine, University of Zurich,
      Winterthurerstrasse 30, 8006, Zurich, Switzerland. biller-andorno@ibme.uzh.ch.
LA  - eng
GR  - 406740_139294/Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen 
      Forschung
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - *Decision Making
MH  - *Decision Support Techniques
MH  - Humans
MH  - Judgment
MH  - Mental Competency/*psychology
MH  - Personal Autonomy
MH  - *Professional-Patient Relations
OTO - NOTNLM
OT  - Competence
OT  - Decision-making capacity
OT  - Documentation
OT  - Ethics
OT  - Evaluation
OT  - Tool
EDAT- 2020/05/01 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1007/s11019-019-09930-6 [doi]
AID - 10.1007/s11019-019-09930-6 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Jun;23(2):253-259. doi: 10.1007/s11019-019-09930-6.


PMID- 32350035
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May
TI  - Is the right not to know an instance of 'bad faith'?
PG  - 308
LID - 10.1136/medethics-2020-106145 [doi]
FAU - Deslandes, Aisha
AU  - Deslandes A
AD  - Houston, Texas, USA aishadeslandes@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200429
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 May;46(5):300-303. PMID: 32350031
CIN - J Med Ethics. 2020 May;46(5):309-310. PMID: 32350033
MH  - Humans
MH  - *Informed Consent
MH  - *Personal Autonomy
OTO - NOTNLM
OT  - *autonomy
OT  - *informed consent
OT  - *philosophical ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - medethics-2020-106145 [pii]
AID - 10.1136/medethics-2020-106145 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 May;46(5):308. doi: 10.1136/medethics-2020-106145. Epub 2020
      Apr 29.


PMID- 32350034
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May
TI  - Commentary on 'The right not to know and the obligation not to know'.
PG  - 304-305
LID - 10.1136/medethics-2020-106082 [doi]
FAU - Berkman, Benjamin
AU  - Berkman B
AUID- ORCID: 0000-0002-9098-0799
AD  - Department of Bioethics, National Institutes of Health, Bethesda, MD 20892, USA
      berkmanbe@mail.nih.gov.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Comment
DEP - 20200429
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 May;46(5):300-303. PMID: 32350031
CIN - J Med Ethics. 2020 May;46(5):309-310. PMID: 32350033
OTO - NOTNLM
OT  - *clinical ethics
OT  - *ethics
OT  - *genethics
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2020/05/01 06:01
CRDT- 2020/05/01 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/01 06:01 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - medethics-2020-106082 [pii]
AID - 10.1136/medethics-2020-106082 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 May;46(5):304-305. doi: 10.1136/medethics-2020-106082. Epub
      2020 Apr 29.


PMID- 32350033
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20220220
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May
TI  - 'The right not to know and the obligation to know', response to commentaries.
PG  - 309-310
LID - 10.1136/medethics-2020-106261 [doi]
FAU - Davies, Ben
AU  - Davies B
AUID- ORCID: 0000-0003-4612-7894
AD  - Uehiro Centre for Practical Ethics, University of Oxford, Oxford OX1 1PT, UK
      benjamin.davies@philosophy.ox.ac.uk.
LA  - eng
GR  - 104848/WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Comment
DEP - 20200429
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 May;46(5):300-303. PMID: 32350031
CON - J Med Ethics. 2020 May;46(5):306-307. PMID: 32350032
CON - J Med Ethics. 2020 May;46(5):304-305. PMID: 32350034
CON - J Med Ethics. 2020 May;46(5):308. PMID: 32350035
MH  - Humans
MH  - *Personal Autonomy
MH  - *Truth Disclosure
PMC - PMC7279182
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - medethics-2020-106261 [pii]
AID - 10.1136/medethics-2020-106261 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 May;46(5):309-310. doi: 10.1136/medethics-2020-106261. Epub
      2020 Apr 29.


PMID- 32350032
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May
TI  - Obligations and preferences in knowing and not knowing: the importance of
      context.
PG  - 306-307
LID - 10.1136/medethics-2020-106108 [doi]
FAU - Dive, Lisa
AU  - Dive L
AUID- ORCID: 0000-0001-6655-5138
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia
      lisa.dive@sydney.edu.au.
FAU - Newson, Ainsley Janelle
AU  - Newson AJ
AUID- ORCID: 0000-0002-3460-772X
AD  - Sydney Health Ethics, University of Sydney, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200429
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 May;46(5):300-303. PMID: 32350031
CIN - J Med Ethics. 2020 May;46(5):309-310. PMID: 32350033
MH  - Humans
MH  - *Moral Obligations
MH  - *Personal Autonomy
OTO - NOTNLM
OT  - *autonomy
OT  - *genetic information
OT  - *philosophical ethics
OT  - *professional - professional relationship
OT  - *rights
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/02/28 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - medethics-2020-106108 [pii]
AID - 10.1136/medethics-2020-106108 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 May;46(5):306-307. doi: 10.1136/medethics-2020-106108. Epub
      2020 Apr 29.


PMID- 32350018
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 28
TI  - End-of-life management protocol offered within emergency room (EMPOWER): study
      protocol for a multicentre study.
PG  - e036598
LID - 10.1136/bmjopen-2019-036598 [doi]
AB  - BACKGROUND: Patients at their end-of-life (EOL) phase frequently visit the
      emergency department (ED) due to their symptoms, yet the environment and
      physicians in ED are not traditionally equipped or trained to provide palliative 
      care. This multicentre study aims to measure the current quality of EOL care in
      ED to identify gaps, formulate improvements and implement the improved EOL care
      protocol. We shall also evaluate healthcare resource utilisation and its
      associated costs. METHODS AND ANALYSIS: This study employs a quasiexperimental
      interrupted time series design using both qualitative and quantitative methods,
      involving the EDs of three tertiary hospitals in Singapore, over a period of 3
      years. There are five phases in this study: (1) retrospective chart reviews of
      patients who died within 5 days of ED attendance; (2) pilot phase to validate the
      CODE questionnaire in the local context; (3) preimplementation phase; (4) focus
      group discussions (FGDs); and (5) postimplementation phase. In the prospective
      cohort, patients who are actively dying or have high likelihood of mortality this
      admission, and whose goal of care is palliation, will be eligible for inclusion. 
      At least 140 patients will be recruited for each preimplementation and
      postimplementation phase. There will be face-to-face interviews with patients'
      family members, review of medical records and self-administered staff survey to
      evaluate existing knowledge and confidence. The FGDs will involve hospital and
      community healthcare providers. Data obtained from the retrospective cohort,
      preimplementation phase and FGDs will be used to guide prospective improvement
      and protocol changes. Patient, family and staff relevant outcomes from these
      changes will be measured using time series regression. ETHICS AND DISSEMINATION: 
      The study protocol has been reviewed and ethics approval obtained from the
      National Healthcare Group Domain Specific Review Board, Singapore. The results
      from this study will be actively disseminated through manuscript publications and
      conference presentations. TRIAL REGISTRATION NUMBER: NCT03906747.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yash Pal, Rakhee
AU  - Yash Pal R
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore.
FAU - Kuan, Win Sen
AU  - Kuan WS
AUID- ORCID: 0000-0002-2134-7842
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore.
AD  - Department of Surgery, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore.
FAU - Tiah, Ling
AU  - Tiah L
AD  - Accident & Emergency Medicine, Changi General Hospital, Singapore.
FAU - Kumar, Ranjeev
AU  - Kumar R
AD  - Acute and Emergency Care Centre, Khoo Teck Puat Hospital, Singapore.
FAU - Wong, Yoko Kin Yoke
AU  - Wong YKY
AD  - Singapore Clinical Research Institute, Singapore.
FAU - Shi, Luming
AU  - Shi L
AD  - Singapore Clinical Research Institute, Singapore.
FAU - Zheng, Charles Qishi
AU  - Zheng CQ
AD  - Singapore Clinical Research Institute, Singapore.
FAU - Lin, Jingping
AU  - Lin J
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore.
FAU - Liang, Sufang
AU  - Liang S
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore.
FAU - Segara, Uma Chandra
AU  - Segara UC
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore.
FAU - Yong, Woon Chai
AU  - Yong WC
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore.
AD  - Division of Palliative Care, National University Cancer Institute, Singapore.
FAU - Chan, Noreen Guek Cheng
AU  - Chan NGC
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore.
AD  - Division of Palliative Care, National University Cancer Institute, Singapore.
FAU - Chua, Mui Teng
AU  - Chua MT
AUID- ORCID: 0000-0002-6326-4914
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore mui_teng_chua@nuhs.edu.sg.
AD  - Department of Surgery, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore.
FAU - Ibrahim, Irwani
AU  - Ibrahim I
AD  - Emergency Medicine Department, National University Hospital, National University 
      Health System, Singapore.
AD  - Department of Surgery, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore.
LA  - eng
SI  - ClinicalTrials.gov/NCT03906747
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200428
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Emergency Service, Hospital/*organization & administration
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Prospective Studies
MH  - Research Design
MH  - Retrospective Studies
MH  - Singapore
MH  - Surveys and Questionnaires
MH  - Terminal Care/*organization & administration
MH  - Tertiary Care Centers
PMC - PMC7213875
OTO - NOTNLM
OT  - *cost effectiveness
OT  - *emergency medical services
OT  - *palliative care
OT  - *terminally ill
COIS- Competing interests: The authors declare that they have no competing interests.
      This study is funded by a major government funding body (National Medical
      Research Council, Ministry of Health, Singapore), and there is no funding or
      assistance from any commercial organisation.
EDAT- 2020/05/01 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036598 [pii]
AID - 10.1136/bmjopen-2019-036598 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 28;10(4):e036598. doi: 10.1136/bmjopen-2019-036598.


PMID- 32350017
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 28
TI  - Requests for futile treatments: what mechanisms play a role? Results of a
      qualitative study among Dutch physicians.
PG  - e035675
LID - 10.1136/bmjopen-2019-035675 [doi]
AB  - OBJECTIVES: Overtreatment is increasingly seen as a challenge in clinical
      practice and can lead to unnecessary interventions, poor healthcare outcomes and 
      increasing costs. However, little is known as to what exactly causes
      overtreatment. In 2015, the Royal Dutch Medical Association (RDMA) attempted to
      address this problem and distinguished several mechanisms that were thought to
      drive overtreatment. In 14 qualitative interviews among Dutch physicians, we
      investigated which mechanisms played a role in decision-making and whether all
      mechanisms were considered equally important. DESIGN: We asked physicians to
      present a case from personal experience, in which the patient or family requested
      continuing treatment against the advice of the physician. PARTICIPANTS: Fourteen 
      physicians from five different medical areas agreed to participate. SETTING:
      Interviews were held face-to-face at the workplace of the physician. RESULTS:
      Three closely related mechanisms were mentioned most frequently as drivers of
      overtreatment, as perceived by the physician: 'death is not a common topic of
      conversation', ''never give up' is the default attitude in our society' and
      'patients' culture and outlook on life influences their perception of death'. The
      mechanism 'medical view taking priority' was mentioned to be an inhibitor of
      overtreatment. CONCLUSIONS: Of the 15 mechanisms described by the report of the
      Steering Committee of the RDMA, not all mechanisms were mentioned as driving
      overtreatment. Three mechanisms were mentioned most as being a driver of
      overtreatment ('death is not a common topic of conversation'; ''never give up' is
      the default attitude in our society'' and 'patients' culture and outlook on life 
      influences their perception of death'), some played no role at all, and others
      were considered to be inhibitors of overtreatment, especially the mechanism
      'medical view taking priority'.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - van Bruchem-Visser, Rozemarijn Lidewij
AU  - van Bruchem-Visser RL
AUID- ORCID: 0000-0002-6833-7641
AD  - Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
      r.l.visser@erasmusmc.nl.
FAU - van Dijk, Gert
AU  - van Dijk G
AD  - Medical Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam,
      Zuid-Holland, The Netherlands.
FAU - Mattace Raso, Francesco
AU  - Mattace Raso F
AD  - Section of Geriatric Medicine, Department of Internal Medicine, Erasmus MC,
      Rotterdam, Zuid-Holland, The Netherlands.
FAU - de Beaufort, Inez
AU  - de Beaufort I
AD  - Medical Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam,
      Zuid-Holland, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - Attitude to Death/ethnology
MH  - Attitude to Health
MH  - *Clinical Decision-Making
MH  - Culture
MH  - *Family
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medical Futility
MH  - *Medical Overuse
MH  - Middle Aged
MH  - Netherlands
MH  - *Patient Preference
MH  - Qualitative Research
MH  - Religion
MH  - *Terminal Care
PMC - PMC7213846
OTO - NOTNLM
OT  - *general medicine (see internal medicine)
OT  - *health policy
OT  - *medical ethics
OT  - *qualitative research
OT  - *quality in healthcare
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035675 [pii]
AID - 10.1136/bmjopen-2019-035675 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 28;10(4):e035675. doi: 10.1136/bmjopen-2019-035675.


PMID- 32350016
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 28
TI  - Clinical and cost-effectiveness of a diabetes education and behavioural weight
      management programme versus a diabetes education programme in adults with a
      recent diagnosis of type 2 diabetes: study protocol for the Glucose Lowering
      through Weight management (GLoW) randomised controlled trial.
PG  - e035020
LID - 10.1136/bmjopen-2019-035020 [doi]
AB  - INTRODUCTION: People with type 2 diabetes (T2D) can improve glycaemic control or 
      even achieve remission through weight loss and reduce their use of medication and
      risk of cardiovascular disease. The Glucose Lowering through Weight management
      (GLoW) trial will evaluate whether a tailored diabetes education and behavioural 
      weight management programme (DEW) is more effective and cost-effective than a
      diabetes education (DE) programme in helping people with overweight or obesity
      and a recent diagnosis of T2D to lower their blood glucose, lose weight and
      improve other markers of cardiovascular risk. METHODS AND ANALYSIS: This study is
      a pragmatic, randomised, single-blind, parallel group, two-arm, superiority
      trial. We will recruit 576 adults with body mass index>25 kg/m(2) and diagnosis
      of T2D in the past 3 years and randomise them to a tailored DEW or a DE
      programme. Participants will attend measurement appointments at a local general
      practitioner practice or research centre at baseline, 6 and 12 months. The
      primary outcome is 12-month change in glycated haemoglobin. The effect of the
      intervention on the primary outcome will be estimated and tested using a linear
      regression model (analysis of covariance) including randomisation group and
      adjusted for baseline value of the outcome and the randomisation stratifiers.
      Participants will be included in the group to which they were randomised, under
      the intention-to-treat principle. Secondary outcomes include 6-month and 12-month
      changes in body weight, body fat percentage, systolic and diastolic blood
      pressure and lipid profile; probability of achieving good glycaemic control;
      probability of achieving remission from diabetes; probability of losing 5% and
      10% body weight and modelled cardiovascular risk (UKPDS). An intention-to-treat
      within-trial cost-effectiveness analysis will be conducted from NHS and societal 
      perspectives using participant-level data. Qualitative interviews will be
      conducted with participants to understand why and how the programme achieved its 
      results and how participants manage their weight after the programme ends. ETHICS
      AND DISSEMINATION: Ethical approval was received from East of Scotland Research
      Ethics Service on 15 May 2018 (18/ES/0048). This protocol (V.3) was approved on
      19 June 2019. Findings will be published in peer-reviewed scientific journals and
      communicated to other stakeholders as appropriate. TRIAL REGISTRATION NUMBER:
      ISRCTN18399564.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ahern, Amy L
AU  - Ahern AL
AUID- ORCID: 0000-0001-5069-4758
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK ala34@cam.ac.uk.
FAU - Woolston, Jenny
AU  - Woolston J
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Wells, Emma
AU  - Wells E
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Sharp, Stephen J
AU  - Sharp SJ
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Islam, Nazrul
AU  - Islam N
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Lawlor, Emma Ruth
AU  - Lawlor ER
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Duschinsky, Robbie
AU  - Duschinsky R
AD  - Primary Care Unit, Institute of Public Health, University of Cambridge School of 
      Clinical Medicine, Cambridge, Cambridgeshire, UK.
FAU - Hill, Andrew J
AU  - Hill AJ
AD  - School of Medicine, University of Leeds, Leeds, West Yorkshire, UK.
FAU - Doble, Brett
AU  - Doble B
AUID- ORCID: 0000-0002-4948-8831
AD  - Programme in Health Services and Systems Research, Duke-NUS Medical School,
      Singapore.
FAU - Wilson, Ed
AU  - Wilson E
AUID- ORCID: 0000-0002-8369-1577
AD  - Norwich Medical School, University of East Anglia, Norwich, UK.
FAU - Morris, Stephen
AU  - Morris S
AD  - Primary Care Unit, Institute of Public Health, University of Cambridge School of 
      Clinical Medicine, Cambridge, Cambridgeshire, UK.
FAU - Hughes, Carly A
AU  - Hughes CA
AD  - Patient and Public Involvement Representative, Fakenham Medical Practice,
      Fakenham, Norfolk, UK.
AD  - Faculty of Medicine and Health Sciences, University of East Anglia, Norwich,
      Norfolk, UK.
FAU - Brennan, Alan
AU  - Brennan A
AD  - School of Health and Related Research, The University of Sheffield, Sheffield,
      UK.
FAU - Bostock, Jennifer
AU  - Bostock J
AD  - Patient and Public Involvement Representative, Kent, UK.
FAU - Boothby, Clare
AU  - Boothby C
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
FAU - Griffin, Simon J
AU  - Griffin SJ
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Cambridge, Cambridgeshire, UK.
AD  - Primary Care Unit, Institute of Public Health, University of Cambridge School of 
      Clinical Medicine, Cambridge, Cambridgeshire, UK.
LA  - eng
SI  - ISRCTN/ISRCTN18399564
GR  - RP-PG-0216-20010/DH_/Department of Health/United Kingdom
GR  - MC_UU_12015/4/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200428
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Cost-Benefit Analysis
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Female
MH  - Glucose
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Scotland
MH  - Single-Blind Method
MH  - *Weight Reduction Programs
PMC - PMC7213851
OTO - NOTNLM
OT  - *diabetes education
OT  - *primary care
OT  - *randomised controlled trial
OT  - *type 2 diabetes
OT  - *weight management
COIS- Competing interests: ALA is principal investigator on another publically funded
      trial where WW provided the intervention at no cost but has received no personal 
      fees. SJG reports grants from Medical Research Council, personal fees from Eli
      Lilly and personal fees from Janssen, outside this programme of research. AH
      reports personal fees from Slimming World and the College of Contemporary Health,
      outside this programme of research. CH reports informal unpaid advice to Thriva. 
      Other Investigators report no conflicts of interest.
EDAT- 2020/05/01 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035020 [pii]
AID - 10.1136/bmjopen-2019-035020 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 28;10(4):e035020. doi: 10.1136/bmjopen-2019-035020.


PMID- 32350012
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 28
TI  - Effects of moxibustion on symptoms of mild cognitive impairment: protocol of a
      systematic review and meta-analysis.
PG  - e033910
LID - 10.1136/bmjopen-2019-033910 [doi]
AB  - INTRODUCTION: Mild cognitive impairment (MCI) is considered the intermediate
      phase between normal age-related cognitive decline and dementia. Moxibustion has 
      gained increased popularity for the management of MCI in China.This study aimed
      to evaluate the effects and safety of moxibustion on symptoms of MCI. METHODS AND
      ANALYSIS: Four English databases and six Chinese databases will be searched from 
      their inception to October 2019: Embase, MEDLINE, Cochrane Central Register of
      Controlled Trials, Allied and Complementary Medicine Database, China National
      Knowledge Infrastructure, Chongqing VIP Chinese Science and Technology Periodical
      Database, Wanfang Database, SinoMed, China Doctoral Dissertations Full-text
      Database and the China Master's Theses Full-text Database. Only clinical
      randomised controlled trials and the first period in randomised cross-over trial 
      related to moxibustion for MCI will be included. The primary outcomes include the
      improvement of cognitive function, as measured by validated assessment tools. The
      secondary outcomes include changes in the activity of daily living scale,
      effective rate and the incidences of adverse events. The selection of studies,
      data extraction and risk of bias assessment will be carried out by two
      independent reviewers. Review Manager V.5.3 software will be used for statistical
      analyses. Heterogeneity test, data synthesis and subgroup analysis will be
      performed if necessary. The risk of bias of included studies will be assessed by 
      the Cochrane Handbook risk of bias tool. Evidence quality will be evaluated using
      the Grading of Recommendations Assessment, Development and Evaluation system.
      ETHICS AND DISSEMINATION: Ethics approval is not required as no private
      information from individuals are collected. The results will be published in a
      peer-reviewed journal or disseminated in relevant conferences. TRIAL REGISTRATION
      NUMBER: CRD42018112657.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhang, Tao
AU  - Zhang T
AUID- ORCID: 0000-0002-8349-9091
AD  - Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional
      Chinese Medicine, Capital Medical University, Beijing Key Laboratory of
      Acupuncture Neuromodulation, Beijing, China.
FAU - Wang, Lin-Peng
AU  - Wang LP
AD  - Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional
      Chinese Medicine, Capital Medical University, Beijing Key Laboratory of
      Acupuncture Neuromodulation, Beijing, China.
FAU - Wang, Gui-Ling
AU  - Wang GL
AD  - Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional
      Chinese Medicine, Capital Medical University, Beijing Key Laboratory of
      Acupuncture Neuromodulation, Beijing, China.
FAU - Sun, Jing-Qing
AU  - Sun JQ
AD  - Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional
      Chinese Medicine, Capital Medical University, Beijing Key Laboratory of
      Acupuncture Neuromodulation, Beijing, China.
FAU - Mao, Xue-Wen
AU  - Mao XW
AD  - Department of Acupuncture and Moxibustion, Shunyi Hospital, Beijing Traditional
      Chinese Medicine Hospital, Beijing, China.
FAU - Jiang, Hui-Li
AU  - Jiang HL
AD  - Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing
      University of Chinese Medicine, Beijing, China.
FAU - Li, Bin
AU  - Li B
AD  - Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional
      Chinese Medicine, Capital Medical University, Beijing Key Laboratory of
      Acupuncture Neuromodulation, Beijing, China lcz623780@126.com
      libin@bjzhongyi.com.
FAU - Liu, Cun-Zhi
AU  - Liu CZ
AD  - Acupuncture Research Center, School of Acupuncture-Moxibustion and Tuina, Beijing
      University of Chinese Medicine, Beijing, China lcz623780@126.com
      libin@bjzhongyi.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200428
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - China
MH  - Cognitive Dysfunction/*therapy
MH  - Humans
MH  - *Moxibustion
MH  - Randomized Controlled Trials as Topic
PMC - PMC7213842
OTO - NOTNLM
OT  - *meta-analysis
OT  - *mild cognitive impairment
OT  - *moxibustion
OT  - *protocol
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033910 [pii]
AID - 10.1136/bmjopen-2019-033910 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 28;10(4):e033910. doi: 10.1136/bmjopen-2019-033910.


PMID- 32350009
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 28
TI  - Rationale and methodology for a European pooled analysis of postmarketing
      interventional and observational studies of insulin glargine 300 U/mL in
      diabetes: protocol of REALI project.
PG  - e033659
LID - 10.1136/bmjopen-2019-033659 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a common and heterogeneous
      disease. Using advanced analytic approaches to explore real-world data may
      identify different disease characteristics, responses to treatment and
      progression patterns. Insulin glargine 300 units/mL (Gla-300) is a
      second-generation basal insulin analogue with preserved glucose-lowering efficacy
      but reduced risk of hypoglycaemia. The purpose of the REALI pooled analysis
      described in this paper is to advance the understanding of the effectiveness and 
      real-world safety of Gla-300 based on a large European patient database of
      postmarketing interventional and observational studies. METHODS AND ANALYSIS: In 
      the current round of pooling, REALI will include data from up to 10 000 subjects 
      with diabetes mellitus (mostly T2DM) from 20 European countries. Outcomes of
      interest include change from baseline to week 24 in haemoglobin A1c, fasting
      plasma glucose, self-measured plasma glucose, body weight, insulin dose,
      incidence and rate of any-time-of-the-day and nocturnal hypoglycaemia. The data
      pool is being investigated using two complementary methodologies: a conventional 
      descriptive, univariate and multivariable prognostic analysis; and a data-mining 
      approach using subgroup discovery to identify phenotypic clusters of patients who
      are highly associated with the outcome of interest. By mid-2019, deidentified
      data of 7584 patients were included in the REALI database, with a further
      expected increase in patient number in 2020 as a result of pooling additional
      studies. ETHICS AND DISSEMINATION: The proposed study does not involve collection
      of primary data. Moreover, all individual study protocols were approved by
      independent local ethics committees, and all study participants provided written 
      informed consent. Furthermore, patient data is deidentified before inclusion in
      the REALI database. Hence, there is no requirement for ethical approval. Results 
      will be disseminated via peer-reviewed publications and presentations at
      international congresses as data are analysed.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Freemantle, Nick
AU  - Freemantle N
AD  - Institute of Clinical Trials and Methodology, University College London, London, 
      UK nicholas.freemantle@ucl.ac.uk.
FAU - Bonadonna, Riccardo C
AU  - Bonadonna RC
AD  - Azienda Ospedaliero-Universitaria di Parma, Parma, Emilia-Romagna, Italy.
AD  - School of Medicine, University of Parma, Parma, Emilia-Romagna, Italy.
FAU - Gourdy, Pierre
AU  - Gourdy P
AD  - University Hospital Centre Toulouse Cardiovascular and Metabolic Medicine
      Section, Toulouse, Midi-Pyrenees, France.
AD  - INSERM, Paul Sabatier University, Toulouse, Occitanie, France.
FAU - Mauricio, Didac
AU  - Mauricio D
AUID- ORCID: 0000-0002-2868-0250
AD  - Endocrinology & Nutrition, Hospital Universitari Germans Trias i Pujol,
      Barcelona, Spain.
AD  - Hospital de la Santa Creu i Sant Pau Institut de Recerca, Barcelona, Catalunya,
      Spain.
FAU - Mueller-Wieland, Dirk
AU  - Mueller-Wieland D
AD  - University Hospital Aachen, Aachen, Nordrhein-Westfalen, Germany.
FAU - Bigot, Gregory
AU  - Bigot G
AD  - IVIDATA, Paris, France.
FAU - Ciocca, Alice
AU  - Ciocca A
AD  - Global Diabetes, Sanofi SA, Paris, Ile-de-France, France.
FAU - Mauquoi, Celine
AU  - Mauquoi C
AD  - IDDI SA, Louvain-la-Neuve, Belgium.
FAU - Rollot, Melissa
AU  - Rollot M
AD  - Quinten, Paris, France.
FAU - Bonnemaire, Mireille
AU  - Bonnemaire M
AD  - Global Diabetes, Sanofi SA, Paris, Ile-de-France, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200428
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Data Analysis
MH  - Databases, Factual/statistics & numerical data
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Disease Progression
MH  - Europe
MH  - Fasting/blood
MH  - Glycated Hemoglobin A/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Insulin Glargine/administration & dosage/*therapeutic use
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Observational Studies as Topic
MH  - Treatment Outcome
PMC - PMC7213840
OTO - NOTNLM
OT  - *Europe
OT  - *clinical practice
OT  - *insulin glargine 300 units/mL
OT  - *pooled analysis
OT  - *type 2diabetes mellitus
COIS- Competing interests: NF: research, travel or consultancy: Takeda, Pfizer, Biogen,
      Tesaro, Allergan, Ipsen, Sanofi and AstraZeneca. RCB: speakers' bureau: Sanofi,
      Merck, Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca and Janssen; Advisory
      panel: Merck, Sharp & Dohme, Eli Lilly, Sanofi and Johnson & Johnson. PG:
      research: AstraZeneca, Novo Nordisk and Sanofi; speakers' bureau and consultancy:
      Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp
      & Dohme, Novartis, Novo Nordisk, Sanofi, Servier and Takeda. DM: consultancy
      and/or speakers' bureau: Almirall, Ascensia, AstraZeneca, Boehringer Ingelheim,
      GlaxoSmithKline, Eli Lilly, Ferrer, Janssen, Menarini, Merck, Sharp & Dohme,
      Novartis, Novo Nordisk and Sanofi. DMW: speakers' bureau and consultancy/advisory
      panel: Amgen, AstraZeneca, Boehringer Ingelheim, MSD (Merck & Co.), Novartis,
      Novo Nordisk and Sanofi. GB: IVIDATA employee on behalf of Sanofi. CM: IDDI
      employee. MR: Quinten employee. AC and MB: Sanofi employees.
EDAT- 2020/05/01 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033659 [pii]
AID - 10.1136/bmjopen-2019-033659 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 28;10(4):e033659. doi: 10.1136/bmjopen-2019-033659.


PMID- 32349964
OWN - NLM
STAT- MEDLINE
DCOM- 20201029
LR  - 20201029
IS  - 1473-0480 (Electronic)
IS  - 0306-3674 (Linking)
VI  - 54
IP  - 19
DP  - 2020 Oct
TI  - The need for speed! 10 ways that WhatsApp and instant messaging can enhance
      communication (and clinical care) in sport and exercise medicine.
PG  - 1128-1129
LID - 10.1136/bjsports-2019-101707 [doi]
FAU - Ahmed, Osman Hassan
AU  - Ahmed OH
AUID- ORCID: http://orcid.org/0000-0002-1439-0076
AD  - Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, UK
      osman.hassan.ahmed@gmail.com.
AD  - The FA Centre for Disability Football Research, The Football Association,
      Burton-Upon-Trent, UK.
FAU - Carmody, Sean
AU  - Carmody S
AD  - Medical Department, Queens Park Rangers Football Club, London, UK.
FAU - Walker, Lewis J
AU  - Walker LJ
AD  - Medical Department, Queens Park Rangers Football Club, London, UK.
FAU - Ahmad, Imtiaz
AU  - Ahmad I
AD  - Medical Department, Queens Park Rangers Football Club, London, UK.
LA  - eng
PT  - Editorial
DEP - 20200429
PL  - England
TA  - Br J Sports Med
JT  - British journal of sports medicine
JID - 0432520
SB  - IM
MH  - Adult
MH  - *Communication
MH  - *Exercise
MH  - Humans
MH  - *Mobile Applications
MH  - *Sports
MH  - Telemedicine/*methods
MH  - United Kingdom
MH  - Young Adult
OTO - NOTNLM
OT  - app
OT  - ethics
OT  - social media
OT  - society
OT  - sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/05/01 06:00
MHDA- 2020/10/30 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/10/30 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - bjsports-2019-101707 [pii]
AID - 10.1136/bjsports-2019-101707 [doi]
PST - ppublish
SO  - Br J Sports Med. 2020 Oct;54(19):1128-1129. doi: 10.1136/bjsports-2019-101707.
      Epub 2020 Apr 29.


PMID- 32349817
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 1472-1465 (Electronic)
IS  - 0007-1250 (Linking)
VI  - 217
IP  - 5
DP  - 2020 Nov
TI  - Challenges to welcoming people with mental illnesses into faith communities.
PG  - 595-596
LID - 10.1192/bjp.2020.83 [doi]
AB  - Faith communities are important to the psychiatric care of people with mental
      illness. I distinguish the effects of two principles of becoming welcoming
      communities: compassion, in which the community accommodates members with mental 
      illnesses so they are fully included, and dignity, which rests on the essential
      worth of everyone.
FAU - Corrigan, Patrick W
AU  - Corrigan PW
AUID- ORCID: 0000-0001-7405-4173
AD  - Department of Psychology, Illinois Institute of Technology, Illinois, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Psychiatry
JT  - The British journal of psychiatry : the journal of mental science
JID - 0342367
SB  - IM
MH  - *Empathy
MH  - Humans
MH  - *Mental Disorders/psychology
MH  - *Religion
MH  - Religion and Psychology
MH  - *Social Stigma
MH  - *Social Support
OTO - NOTNLM
OT  - *Stigma and discrimination
OT  - *ethics
OT  - *human rights
OT  - *rehabilitation
OT  - *social deprivation
EDAT- 2020/05/01 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/05/01 06:00 [entrez]
AID - 10.1192/bjp.2020.83 [doi]
AID - S0007125020000835 [pii]
PST - ppublish
SO  - Br J Psychiatry. 2020 Nov;217(5):595-596. doi: 10.1192/bjp.2020.83.


PMID- 32349718
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 29
TI  - LncRNA WT1-AS over-expression inhibits non-small cell lung cancer cell stemness
      by down-regulating TGF-beta1.
PG  - 113
LID - 10.1186/s12890-020-1146-6 [doi]
AB  - BACKGROUND: LncRNA WT1-AS is a recently identified potential tumor suppressor in 
      gastric cancer. This study mainly explored the role of WT1-AS in non-small cell
      lung cancer (NSCLC). METHODS: WT1-AS and TGF-beta1 mRNA in two types of tissues
      of 74 NSCLC patients were detected by performing RT-qPCR experiments. WT1-AS and 
      TGF-beta1 expression vectors were established using the pcDNA3.1 vector. Protein 
      concentration was measured by BCA assay. Mean values in this study were
      calculated using the data of three biological replicates of each experiment.
      RESULTS: We found that WT1-AS was down-regulated, while TGF-beta1 was upregulated
      in NSCLC tissues. Survival analysis showed that low levels of WT1-AS expression
      predicted poor survival of NSCLC patients. WT1-AS and TGF-beta1 were inversely
      correlated in NSCLC tissues. Over-expression experiments revealed down-regulated 
      TGF-beta1 after WT1-AS over-expression, while TGF-beta1 over-expression failed to
      affect WT1-AS. WT1-AS over-expression resulted in inhibited cancer cell stemness.
      TGF-beta1 over-expression played an opposite role and attenuated the effects of
      TGF-beta1 over-expression. CONCLUSION: Therefore, WT1-AS over-expression may
      inhibit non-small cell lung cancer cell stemness by down-regulating TGF-beta1.
      TRIAL REGISTRATION: The First Affiliated Hospital of Anhui Medical University
      Ethics committee approved this study (AHMU20101009).
FAU - Jiang, Xueqin
AU  - Jiang X
AUID- ORCID: http://orcid.org/0000-0002-7116-5676
AD  - Department of Geriatric Respiratory and Critical Care, the First Affiliated
      Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei City, Anhui
      Province, 230022, People's Republic of China. itgjsoe007596614@126.com.
FAU - Wang, Jiong
AU  - Wang J
AD  - Department of Geriatric Respiratory and Critical Care, the First Affiliated
      Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei City, Anhui
      Province, 230022, People's Republic of China.
FAU - Fang, Lei
AU  - Fang L
AD  - Department of Geriatric Respiratory and Critical Care, the First Affiliated
      Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei City, Anhui
      Province, 230022, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (TGFB1 protein, human)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (WT1 Proteins)
RN  - 0 (WT1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation/genetics
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - RNA, Long Noncoding/*genetics/metabolism
MH  - Signal Transduction
MH  - Survival Analysis
MH  - Transforming Growth Factor beta1/*genetics/metabolism
MH  - WT1 Proteins/*genetics/metabolism
PMC - PMC7191710
OTO - NOTNLM
OT  - Non-small cell lung cancer
OT  - Stemness
OT  - TGF-beta1
OT  - lncRNA WT1-AS
EDAT- 2020/05/01 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/05/01 06:00
PHST- 2019/04/09 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
AID - 10.1186/s12890-020-1146-6 [doi]
AID - 10.1186/s12890-020-1146-6 [pii]
PST - epublish
SO  - BMC Pulm Med. 2020 Apr 29;20(1):113. doi: 10.1186/s12890-020-1146-6.


PMID- 32349598
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20200511
IS  - 2049-4408 (Electronic)
IS  - 2049-4394 (Linking)
VI  - 102-B
IP  - 5
DP  - 2020 May
TI  - Surgeon proficiency in robot-assisted spine surgery.
PG  - 568-572
LID - 10.1302/0301-620X.102B5.BJJ-2019-1392.R2 [doi]
AB  - Continuous technical improvement in spinal surgical procedures, with the aim of
      enhancing patient outcomes, can be assisted by the deployment of advanced
      technologies including navigation, intraoperative CT imaging, and surgical
      robots. The latest generation of robotic surgical systems allows the simultaneous
      application of a range of digital features that provide the surgeon with an
      improved view of the surgical field, often through a narrow portal. There is
      emerging evidence that procedure-related complications and intraoperative blood
      loss can be reduced if the new technologies are used by appropriately trained
      surgeons. Acceptance of the role of surgical robots has increased in recent years
      among a number of surgical specialities including general surgery, neurosurgery, 
      and orthopaedic surgeons performing major joint arthroplasty. However, ethical
      challenges have emerged with the rollout of these innovations, such as ensuring
      surgeon competence in the use of surgical robotics and avoiding financial
      conflicts of interest. Therefore, it is essential that trainees aspiring to
      become spinal surgeons as well as established spinal specialists should develop
      the necessary skills to use robotic technology safely and effectively and
      understand the ethical framework within which the technology is introduced.
      Traditional and more recently developed platforms exist to aid skill acquisition 
      and surgical training which are described. The aim of this narrative review is to
      describe the role of surgical robotics in spinal surgery, describe measures of
      proficiency, and present the range of training platforms that institutions can
      use to ensure they employ confident spine surgeons adequately prepared for the
      era of robotic spinal surgery. Cite this article: Bone Joint J
      2020;102-B(5):568-572.
FAU - McDonnell, Jake Michael
AU  - McDonnell JM
AUID- ORCID: http://orcid.org/0000-0002-8002-8024
AD  - Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, Ireland.
FAU - Ahern, Daniel P
AU  - Ahern DP
AD  - School of Medicine, Trinity College Dublin, Dublin, Ireland.
AD  - National Spinal Injuries Unit, Department of Trauma & Orthopaedic Surgery, Mater 
      Misericordiae University Hospital, Dublin, Ireland.
FAU - O Doinn, Tiarnan
AU  - O Doinn T
AD  - National Spinal Injuries Unit, Department of Trauma & Orthopaedic Surgery, Mater 
      Misericordiae University Hospital, Dublin, Ireland.
FAU - Gibbons, Denys
AU  - Gibbons D
AD  - School of Medicine, Trinity College Dublin, Dublin, Ireland, National Spinal
      Injuries Unit, Department of Trauma & Orthopaedic Surgery, Mater Misericordiae
      University Hospital, Dublin, Ireland.
FAU - Rodrigues, Katharina Nagassima
AU  - Rodrigues KN
AD  - School of Medicine, Trinity College Dublin, Dublin, Ireland.
FAU - Birch, Nick
AU  - Birch N
AD  - The Chris Moody Rehabilitation and Sports Injury Centre, Northampton, UK.
FAU - Butler, Joseph S
AU  - Butler JS
AD  - National Spinal Injuries Unit, Department of Trauma & Orthopaedic Surgery, Mater 
      Misericordiae University Hospital, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Bone Joint J
JT  - The bone & joint journal
JID - 101599229
SB  - IM
MH  - *Clinical Competence
MH  - Humans
MH  - Intraoperative Complications/prevention & control
MH  - Postoperative Complications/prevention & control
MH  - Robotic Surgical Procedures/*education/*standards
MH  - Spinal Diseases/*surgery
OTO - NOTNLM
OT  - Robotics
OT  - Spine Surgery
EDAT- 2020/05/01 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/05/01 06:00
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 10.1302/0301-620X.102B5.BJJ-2019-1392.R2 [doi]
PST - ppublish
SO  - Bone Joint J. 2020 May;102-B(5):568-572. doi:
      10.1302/0301-620X.102B5.BJJ-2019-1392.R2.


PMID- 32349176
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1432-2277 (Electronic)
IS  - 0934-0874 (Linking)
VI  - 33
IP  - 9
DP  - 2020 Sep
TI  - Global Kidney Exchange: opportunity or exploitation? An ELPAT/ESOT appraisal.
PG  - 989-998
LID - 10.1111/tri.13630 [doi]
AB  - This paper addresses ethical, legal, and psychosocial aspects of Global Kidney
      Exchange (GKE). Concerns have been raised that GKE violates the nonpayment
      principle, exploits donors in low- and middle-income countries, and detracts from
      the aim of self-sufficiency. We review the arguments for and against GKE. We
      argue that while some concerns about GKE are justified based on the available
      evidence, others are speculative and do not apply exclusively to GKE but to
      living donation more generally. We posit that concerns can be mitigated by
      implementing safeguards, by developing minimum quality criteria and by
      establishing an international committee that independently monitors and evaluates
      GKE's procedures and outcomes. Several questions remain however that warrant
      further clarification. What are the experiences and views of recipients and
      donors participating in GKE? Who manages the escrow funds that have been put in
      place for donor and recipients? What procedures and safeguards have been put in
      place to prevent corruption of these funds? What are the inclusion criteria for
      participating GKE centers? GKE provides opportunity to promote access to donation
      and transplantation but can only be conducted with the appropriate safeguards.
      Patients' and donors' voices are missing in this debate.
CI  - (c) 2020 The Authors. Transplant International published by John Wiley & Sons Ltd
      on behalf of Steunstichting ESOT.
FAU - Ambagtsheer, Frederike
AU  - Ambagtsheer F
AUID- ORCID: 0000-0002-3232-6449
AD  - Department of Internal Medicine, Nephrology & Transplantation, Erasmus MC,
      Rotterdam, The Netherlands.
FAU - Haase-Kromwijk, Bernadette
AU  - Haase-Kromwijk B
AD  - Dutch Transplant Foundation, Leiden, The Netherlands.
FAU - Dor, Frank J M F
AU  - Dor FJMF
AD  - Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, UK.
AD  - Department of Surgery and Cancer, Imperial College, London, UK.
FAU - Moorlock, Greg
AU  - Moorlock G
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Citterio, Franco
AU  - Citterio F
AD  - Renal Transplantation Unit, Fondazione Policlinico Universitario, A. Gemelli,
      Rome, Italy.
FAU - Berney, Thierry
AU  - Berney T
AUID- ORCID: 0000-0002-4230-9378
AD  - Division of Transplantation, University of Geneva Hospitals, Geneva, Switzerland.
FAU - Massey, Emma K
AU  - Massey EK
AUID- ORCID: 0000-0002-9017-1924
AD  - Department of Internal Medicine, Nephrology & Transplantation, Erasmus MC,
      Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200520
PL  - Switzerland
TA  - Transpl Int
JT  - Transplant international : official journal of the European Society for Organ
      Transplantation
JID - 8908516
SB  - IM
MH  - Humans
MH  - Kidney
MH  - *Kidney Transplantation
MH  - Living Donors
MH  - *Tissue and Organ Procurement
PMC - PMC7540591
OTO - NOTNLM
OT  - *chronic kidney disease
OT  - *kidney transplantation
OT  - *living donation
OT  - *medical ethics
OT  - *organ trafficking
EDAT- 2020/04/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/03/11 00:00 [revised]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1111/tri.13630 [doi]
PST - ppublish
SO  - Transpl Int. 2020 Sep;33(9):989-998. doi: 10.1111/tri.13630. Epub 2020 May 20.


PMID- 32349014
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20210529
IS  - 1938-808X (Electronic)
IS  - 1040-2446 (Linking)
VI  - 95
IP  - 8
DP  - 2020 Aug
TI  - Medical Students Are Not Essential Workers: Examining Institutional
      Responsibility During the COVID-19 Pandemic.
PG  - 1149-1151
LID - 10.1097/ACM.0000000000003478 [doi]
AB  - In light of the evolving COVID-19 pandemic, the Association of American Medical
      Colleges (AAMC) and Liaison Committee on Medical Education (LCME) released a
      joint statement in March 2020 recommending an immediate suspension of medical
      student participation in direct patient contact. As graduating medical students
      who will soon begin residency, the authors fully support this recommendation.
      Though paid health care workers, like residents, nurses, and environmental
      services staff, are essential to the management of COVID-19 patients, medical
      students are not. Students' continued involvement in direct patient care will
      contribute to SARS-CoV-2 exposures and transmissions and will waste already
      limited personal protective equipment. By decreasing nonessential personnel in
      health care settings, including medical students, medical schools will contribute
      to national and global efforts to "flatten the curve."The authors also assert
      that medical schools are responsible for ensuring medical student safety. Without
      the protections provided to paid health care workers, students are uniquely
      disadvantaged within the medical hierarchy; these inequalities must be addressed 
      before medical students are safely reintegrated into clinical roles. Although
      graduating medical students and institutional leadership may worry that
      suspending clinical rotations might prevent students from completing graduation
      requirements, the authors argue the ethical obligation to "flatten the curve"
      supersedes usual teaching responsibilities. Therefore, the authors request
      further guidance from the LCME and AAMC regarding curricular
      exemptions/alternatives and adjusted graduation timelines. The pool of graduating
      medical students affected by this pause in direct patient contact represents a
      powerful reserve, which may soon need to be used as the COVID-19 pandemic
      continues to challenge the U.S. health care infrastructure.
FAU - Menon, Anitha
AU  - Menon A
AD  - A. Menon is a fourth-year MD-MPH student, University of Michigan Medical School, 
      Ann Arbor, Michigan.
FAU - Klein, Edwin J
AU  - Klein EJ
AD  - E.J. Klein is a fourth-year MD-MPH student, University of Michigan Medical
      School, Ann Arbor, Michigan.
FAU - Kollars, Kate
AU  - Kollars K
AD  - K. Kollars is a fourth-year medical student, University of Michigan Medical
      School, Ann Arbor, Michigan.
FAU - Kleinhenz, Alissa L W
AU  - Kleinhenz ALW
AD  - A.L.W. Kleinhenz is a fourth-year medical student, University of Michigan Medical
      School, Ann Arbor, Michigan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Acad Med
JT  - Academic medicine : journal of the Association of American Medical Colleges
JID - 8904605
SB  - IM
CIN - Acad Med. 2021 May 1;96(5):e20-e21. PMID: 33284165
MH  - Academic Medical Centers/*organization & administration
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Education, Medical/organization & administration
MH  - Health Personnel/*classification
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - Students, Medical/*classification
MH  - United States/epidemiology
PMC - PMC7202103
EDAT- 2020/04/30 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1097/ACM.0000000000003478 [doi]
AID - 00001888-202008000-00026 [pii]
PST - ppublish
SO  - Acad Med. 2020 Aug;95(8):1149-1151. doi: 10.1097/ACM.0000000000003478.


PMID- 32348697
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1557-9034 (Electronic)
IS  - 1092-6429 (Linking)
VI  - 30
IP  - 6
DP  - 2020 Jun
TI  - End-User Input into the Design and Validation of a Synthetic Thoracoscopic
      Esophageal Atresia/Tracheo-Esophageal Fistula Simulator.
PG  - 685-691
LID - 10.1089/lap.2019.0600 [doi]
AB  - Introduction: Thoracoscopic repair of esophageal atresia and tracheo-esophageal
      fistula (EA/TEF) is challenging. We addressed this by designing a fully synthetic
      simulator of the procedure and described the design process and how its content
      validity was assessed. Methods: An iterative design and assessment of content
      validity was undertaken in three stages. Data were collected from participants
      who trialed the model and completed a survey of their experience (adapted from
      Barsness et al.). Results: The model was trialed by participants of varying
      experience. Each design refinement improved the model's fidelity and validity.
      For the last iteration of the simulator, the observed averages (out of a maximum 
      of 5) were: value as a training tool 4.8, relevance 4.6, physical attributes 4.5,
      realism of material 4.25, realism experience 4.17, and ability to perform tasks
      3.77. Conclusion: An iterative design process based on end-user feedback has led 
      to a synthetic simulator that has achieved a high level of content validity. This
      model has advantages over other EA/TEF simulators in that it is relatively
      inexpensive and does not use animal tissue, thus removing ethical and procurement
      issues. It was rated highly for its value and relevance to training.
FAU - Wells, Jonathan M
AU  - Wells JM
AD  - Department of Paediatric Surgery, Christchurch Hospital, Christchurch, New
      Zealand.
FAU - Nair, David
AU  - Nair D
AD  - Department of Surgery, University of Otago, Christchurch, New Zealand.
FAU - Cook, Nick
AU  - Cook N
AD  - Department of Medical and Women's Business Management, Christchurch Hospital,
      Christchurch, New Zealand.
FAU - Yi, Ma
AU  - Yi M
AD  - Department of Paediatric Surgery, Christchurch Hospital, Christchurch, New
      Zealand.
FAU - Moorhead, Ash
AU  - Moorhead A
AD  - Department of Medical Physics and Bioengineering, Christchurch Hospital,
      Christchurch, New Zealand.
FAU - Maoate, Kiki
AU  - Maoate K
AD  - Department of Paediatric Surgery, Christchurch Hospital, Christchurch, New
      Zealand.
AD  - Department of Surgery, University of Otago, Christchurch, New Zealand.
FAU - Beasley, Spencer W
AU  - Beasley SW
AD  - Department of Paediatric Surgery, Christchurch Hospital, Christchurch, New
      Zealand.
AD  - Department of Surgery, University of Otago, Christchurch, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - United States
TA  - J Laparoendosc Adv Surg Tech A
JT  - Journal of laparoendoscopic & advanced surgical techniques. Part A
JID - 9706293
RN  - Esophageal atresia with or without tracheoesophageal fistula
SB  - IM
MH  - *Computer Simulation
MH  - Esophageal Atresia/diagnosis/*surgery
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Surveys and Questionnaires
MH  - Thoracoscopy/*methods
MH  - Tracheoesophageal Fistula/diagnosis/*surgery
OTO - NOTNLM
OT  - esophageal atresia
OT  - simulation
OT  - thoracoscopy
OT  - validation
EDAT- 2020/04/30 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1089/lap.2019.0600 [doi]
PST - ppublish
SO  - J Laparoendosc Adv Surg Tech A. 2020 Jun;30(6):685-691. doi:
      10.1089/lap.2019.0600. Epub 2020 Apr 28.


PMID- 32348471
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 5
DP  - 2020 May 1
TI  - International consensus: ovarian tissue cryopreservation in young Turner syndrome
      patients: outcomes of an ethical Delphi study including 55 experts from 16
      different countries.
PG  - 1061-1072
LID - 10.1093/humrep/deaa007 [doi]
AB  - STUDY QUESTION: What is the standpoint of an international expert panel on
      ovarian tissue cryopreservation (OTC) in young females with Turner syndrome (TS)?
      SUMMARY ANSWER: The expert panel states that OTC should be offered to young
      females with TS, but under strict conditions only. WHAT IS KNOWN ALREADY: OTC is 
      already an option for preserving the fertility of young females at risk of
      iatrogenic primary ovarian insufficiency (POI). Offering OTC to females with a
      genetic cause of POI could be the next step. One of the most common genetic
      disorders related to POI is TS. Due to an early depletion of the ovarian reserve,
      most females with TS are confronted with infertility before reaching adulthood.
      However, before offering OTC as an experimental fertility preservation option to 
      young females with TS, medical and ethical concerns need to be addressed. STUDY
      DESIGN, SIZE, DURATION: A three-round ethical Delphi study was conducted to
      systematically discuss whether the expected benefits exceed the expected negative
      consequences of OTC in young females with TS. The aim was to reach group
      consensus and form an international standpoint based on selected key statements. 
      The study took place between February and December 2018. PARTICIPANTS/MATERIALS, 
      SETTING, METHODS: Anonymous panel selection was based on expertise in TS,
      fertility preservation or medical ethics. A mixed panel of 12 gynaecologists, 13 
      (paediatric) endocrinologists, 10 medical ethicists and 20 patient
      representatives from 16 different countries gave consent to participate in this
      international Delphi study. In the first two rounds, experts were asked to rate
      and rank 38 statements regarding OTC in females with TS. Participants were
      offered the possibility to adjust their opinions after repetitive feedback. The
      selection of key statements was based on strict inclusion criteria. MAIN RESULTS 
      AND THE ROLE OF CHANCE: A total of 46 participants completed the first Delphi
      round (response rate 84%). Based on strict selection criteria, six key statements
      were selected, and 13 statements were discarded. The remaining 19 statements and 
      two additional statements submitted by the expert panel were re-evaluated in the 
      second round by 41 participants (response rate 75%). The analysis of the second
      survey resulted in the inclusion of two additional key statements. After the
      approval of these eight key statements, the majority of the expert panel (96%)
      believed that OTC should be offered to young females with TS, but in a safe and
      controlled research setting first, with proper counselling and informed consent
      procedures, before offering this procedure in routine care. The remaining
      participants (4%) did not object but did not respond despite several reminders.
      LIMITATIONS, REASONS FOR CAUTION: The anonymous nature of this study may have led
      to lack of accountability. The selection of experts was based on their
      willingness to participate. The fact that not all panellists took part in all
      rounds may have resulted in selection bias. WIDER IMPLICATIONS OF THE FINDINGS:
      This international standpoint is the first step in the global acceptance of OTC
      in females with TS. Future collaborative research with a focus on efficacy and
      safety and long-term follow-up is urgently needed. Furthermore, we recommend an
      international register for fertility preservation procedures in females with TS. 
      STUDY FUNDING/COMPETING INTEREST(S): Unconditional funding (A16-1395) was
      received from Merck B.V., The Netherlands. The authors declare that they have no 
      conflict of interest.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      European Society of Human Reproduction and Embryology. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Schleedoorn, M J
AU  - Schleedoorn MJ
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Mulder, B H
AU  - Mulder BH
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Braat, D D M
AU  - Braat DDM
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Beerendonk, C C M
AU  - Beerendonk CCM
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Peek, R
AU  - Peek R
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Nelen, W L D M
AU  - Nelen WLDM
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Van Leeuwen, E
AU  - Van Leeuwen E
AD  - Medical Ethics, Radboud University Medical Centre, Nijmegen, The Netherlands.
FAU - Van der Velden, A A E M
AU  - Van der Velden AAEM
AD  - Paediatric Endocrinology, Radboud University Medical Centre Amalia Children's
      Hospital, Nijmegen, The Netherlands.
FAU - Fleischer, K
AU  - Fleischer K
AD  - Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The
      Netherlands.
FAU - Turner Fertility Expert Panel, On Behalf Of The
AU  - Turner Fertility Expert Panel OBOT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Adult
MH  - Child
MH  - Cryopreservation
MH  - Delphi Technique
MH  - Female
MH  - *Fertility Preservation
MH  - Humans
MH  - Netherlands
MH  - *Turner Syndrome
PMC - PMC7493129
OTO - NOTNLM
OT  - *Delphi study
OT  - *Turner syndrome
OT  - *endocrinology-disorders of sex development
OT  - *ethics
OT  - *fertility preservation
OT  - *international statement
OT  - *ovarian tissue cryopreservation
OT  - *paediatrics
OT  - *primary ovarian insufficiency
EDAT- 2020/04/30 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/08/21 00:00 [received]
PHST- 2020/01/09 00:00 [revised]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 5826726 [pii]
AID - 10.1093/humrep/deaa007 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 May 1;35(5):1061-1072. doi: 10.1093/humrep/deaa007.


PMID- 32348419
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 1983-1447 (Electronic)
IS  - 0102-6933 (Linking)
VI  - 41
DP  - 2020
TI  - Professional practice of nurses and influences on moral sensitivity.
PG  - e20190080
LID - S1983-14472020000100407 [pii]
LID - 10.1590/1983-1447.2019.20190080 [doi]
AB  - OBJECTIVE: To understand the professional practice of nurses and their influence 
      on the development of moral sensibility. METHODS: A qualitative and descriptive
      study, conducted between November 2015 and February 2016 in the hospitalization
      units of the medical clinic of two large hospitals located in Belo Horizonte,
      Minas Gerais. 14 nurses participated. Data collection was done through
      interviews, guided by semi-structured scripts. The data were submitted to content
      analysis. RESULTS: Two categories emerged: Professional practice of the nurse:
      internal and external goods and Moral sensitivity and the interface with the
      professional practice of nurses. The development of the moral sensitivity of
      nurses is influenced by factors related to professional practice, such as
      interpersonal relations, ethical education and management activities. Final
      considerations: In the professional practice, moral sensibility is an integral
      part of the ethical decision-making process in services, being essential for
      quality care.
FAU - Moreira, Danielle de Araujo
AU  - Moreira DA
AD  - Escola Tecnica Sandoval Soares de Azevedo, Ibirite, Minas Gerais, Brasil.
FAU - Ferraz, Cecilia Maria Lima Cardoso
AU  - Ferraz CMLC
AD  - Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Minas
      Gerais, Brasil.
FAU - Costa, Iluska Pinto da
AU  - Costa IPD
AD  - Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Minas
      Gerais, Brasil.
FAU - Amaral, Jessica Martins
AU  - Amaral JM
AD  - Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Minas
      Gerais, Brasil.
FAU - Lima, Thais Teixeira
AU  - Lima TT
AD  - Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Minas
      Gerais, Brasil.
FAU - Brito, Maria Jose Menezes
AU  - Brito MJM
AD  - Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Minas
      Gerais, Brasil.
LA  - por
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200427
PL  - Brazil
TA  - Rev Gaucha Enferm
JT  - Revista gaucha de enfermagem
JID - 8504882
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Decision Making/*ethics
MH  - *Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Morals
MH  - Nursing Care/*ethics
MH  - Professional Practice/*ethics
MH  - Qualitative Research
EDAT- 2020/04/30 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/03/04 00:00 [received]
PHST- 2019/09/16 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - S1983-14472020000100407 [pii]
AID - 10.1590/1983-1447.2019.20190080 [doi]
PST - ppublish
SO  - Rev Gaucha Enferm. 2020;41:e20190080. doi: 10.1590/1983-1447.2019.20190080. Epub 
      2020 Apr 27.


PMID- 32348313
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20200710
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Food transfers, electronic food vouchers and child nutritional status among
      Rohingya children living in Bangladesh.
PG  - e0230457
LID - 10.1371/journal.pone.0230457 [doi]
AB  - OBJECTIVE: To examine associations between receipt of an electronic food voucher 
      (e-voucher) compared to food rations on the nutritional status of Rohingya
      children living in refugee camps in Bangladesh. METHODS: This is an associational
      study using cross-sectional data. We measured heights and weights of 523 children
      aged between 6 and 23 months in households receiving either a food ration
      consisting of rice, pulses, vegetable oil (362 children) or an e-voucher (161
      children) that could be used to purchase 19 different foods. Data were also
      collected on the characteristics of their mothers and the households in which
      they lived, including household demographics, consumption and expenditure, coping
      strategies, livelihoods and income profiles, and access to assistance.
      Associations between measures of anthropometric status (height-for-age z scores, 
      stunting, weight-for-height z scores, wasting, weight-for-age z scores and
      mid-upper arm circumference) and household receipt of the e-voucher were
      estimated using ordinary least squares regressions. Control variables included
      child, maternal, household and locality characteristics. The study received
      ethical approval from the Institutional Review Board of the International Food
      Policy Research Institute, Washington DC. RESULTS: Household receipt of an
      e-voucher was associated with improved linear growth in children. This
      association is robust to the inclusion of maternal, household and location
      characteristics. The magnitude of the association is 0.38 SD (CI: 0.01, 0.74),
      and statistically significant at the five percent level. We cannot reject the
      null hypothesis that these associations differ by child sex. Receipt of an
      e-voucher is not associated with stunting when a full set of control variables
      are included. There is no association between receipt of e-vouchers and
      weight-for-length, weight-for-age or mid-upper arm circumference. We cannot
      reject the null hypothesis that these associations differ by child sex.
      CONCLUSIONS: In a humanitarian assistance setting, Rohingya refugee camps in
      Bangladesh, household receipt of an electronic food voucher instead of a food
      ration is associated with improvements in the linear growth of children between 6
      and 23 months but not in measures of acute undernutrition or other anthropometric
      outcomes. Our associational evidence indicates that transitioning from food
      rations to electronic food vouchers does not adversely affect child nutritional
      status.
FAU - Hoddinott, John
AU  - Hoddinott J
AUID- ORCID: 0000-0002-0590-3917
AD  - Cornell University, Ithaca, New York, United States of America.
AD  - International Food Policy Research Institute (IFPRI), Washington, DC, United
      States of America.
FAU - Dorosh, Paul
AU  - Dorosh P
AUID- ORCID: 0000-0001-6049-6018
AD  - International Food Policy Research Institute (IFPRI), Washington, DC, United
      States of America.
FAU - Filipski, Mateusz
AU  - Filipski M
AD  - International Food Policy Research Institute (IFPRI), Washington, DC, United
      States of America.
AD  - University of Georgia, Athens GA, United States of America.
FAU - Rosenbach, Gracie
AU  - Rosenbach G
AUID- ORCID: 0000-0003-3518-1465
AD  - International Food Policy Research Institute (IFPRI), Washington, DC, United
      States of America.
FAU - Tiburcio, Ernesto
AU  - Tiburcio E
AD  - International Food Policy Research Institute (IFPRI), Washington, DC, United
      States of America.
AD  - Tufts University, Medford MA, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Anthropometry
MH  - Bangladesh
MH  - Body Weight
MH  - Child
MH  - *Child Nutritional Physiological Phenomena
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Food
MH  - Humans
MH  - Infant
MH  - Male
MH  - *Nutritional Status
MH  - *Refugee Camps
PMC - PMC7190090
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/30 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/09/06 00:00 [received]
PHST- 2020/03/01 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - 10.1371/journal.pone.0230457 [doi]
AID - PONE-D-19-25181 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 29;15(4):e0230457. doi: 10.1371/journal.pone.0230457.
      eCollection 2020.


PMID- 32348293
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20210104
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 2
DP  - 2020 May 6
TI  - Agile Requirements Engineering and Software Planning for a Digital Health
      Platform to Engage the Effects of Isolation Caused by Social Distancing: Case
      Study.
PG  - e19297
LID - 10.2196/19297 [doi]
AB  - BACKGROUND: Social distancing and shielding measures have been put in place to
      reduce social interaction and slow the transmission of the coronavirus disease
      (COVID-19). For older people, self-isolation presents particular challenges for
      mental health and social relationships. As time progresses, continued social
      distancing could have a compounding impact on these concerns. OBJECTIVE: This
      project aims to provide a tool for older people and their families and peers to
      improve their well-being and health during and after regulated social distancing.
      First, we will evaluate the tool's feasibility, acceptability, and usability to
      encourage positive nutrition, enhance physical activity, and enable virtual
      interaction while social distancing. Second, we will be implementing the app to
      provide an online community to assist families and peer groups in maintaining
      contact with older people using goal setting. Anonymized data from the app will
      be aggregated with other real-world data sources to develop a machine learning
      algorithm to improve the identification of patients with COVID-19 and track for
      real time use by health systems. METHODS: Development of this project is
      occurring at the time of publication, and therefore, a case study design was
      selected to provide a systematic means of capturing software engineering in
      progress. The app development framework for software design was based on agile
      methods. The evaluation of the app's feasibility, acceptability and usability
      shall be conducted using Public Health England's guidance on evaluating digital
      health products, Bandura's model of health promotion, the Reach Effectiveness
      Adoption Implementation Maintenance (RE-AIM) framework and the Nonadoption,
      Abandonment and Challenges to the Scale-up, Spread and Suitability (NASSS)
      framework. RESULTS: Making use of a pre-existing software framework for health
      behavior change, a proof of concept was developed, and a multistage app
      development and deployment for the solution was created. Grant submissions to
      fund the project and study execution have been sought at the time of publication,
      and prediscovery iteration of the solution has begun. Ethical approval for a
      feasibility study design is being sought. CONCLUSIONS: This case study lays the
      foundations for future app development to combat mental and societal issues
      arising from social distancing measures. The app will be tested and evaluated in 
      future studies to allow continuous improvement of the app. This novel
      contribution will provide an evidence-based exemplar for future app development
      in the space of social isolation and loneliness.
CI  - (c)Edward Meinert, Madison Milne-Ives, Svitlana Surodina, Ching Lam. Originally
      published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 
      06.05.2020.
FAU - Meinert, Edward
AU  - Meinert E
AUID- ORCID: 0000-0003-2484-3347
AD  - Digitally Enabled PrevenTative Health Research Group, Department of Paediatrics, 
      University of Oxford, Oxford, United Kingdom.
AD  - Department of Primary Care and Public Health, Imperial College London, London,
      United Kingdom.
FAU - Milne-Ives, Madison
AU  - Milne-Ives M
AUID- ORCID: 0000-0001-7628-882X
AD  - Digitally Enabled PrevenTative Health Research Group, Department of Paediatrics, 
      University of Oxford, Oxford, United Kingdom.
FAU - Surodina, Svitlana
AU  - Surodina S
AUID- ORCID: 0000-0002-9444-0917
AD  - Skein Ltd, London, United Kingdom.
FAU - Lam, Ching
AU  - Lam C
AUID- ORCID: 0000-0002-9137-749X
AD  - Digitally Enabled PrevenTative Health Research Group, Department of Paediatrics, 
      University of Oxford, Oxford, United Kingdom.
AD  - Institute of Biomedical Engineering, University of Oxford, Oxford, United
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200506
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - Artificial Intelligence
MH  - Betacoronavirus
MH  - *COVID-19/prevention & control/psychology
MH  - *Coronavirus
MH  - Coronavirus Infections
MH  - Delivery of Health Care/*methods
MH  - Engineering
MH  - Humans
MH  - Pandemics
MH  - *Physical Distancing
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Software
MH  - *Technology/methods
MH  - *Telemedicine
PMC - PMC7205031
OTO - NOTNLM
OT  - *COVID-19
OT  - *aged
OT  - *agile
OT  - *app
OT  - *artificial intelligence
OT  - *cellphone
OT  - *coronavirus
OT  - *data science
OT  - *digital health
OT  - *exercise
OT  - *health care quality, access and evaluation
OT  - *information science
OT  - *mental health
OT  - *public reporting of healthcare data
OT  - *requirements engineering
OT  - *social distancing
OT  - *telemedicine
EDAT- 2020/04/30 06:00
MHDA- 2020/05/14 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - v6i2e19297 [pii]
AID - 10.2196/19297 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 May 6;6(2):e19297. doi: 10.2196/19297.


PMID- 32348268
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 6
DP  - 2020 Jun 1
TI  - A Digital Pornography Literacy Resource Co-Designed With Vulnerable Young People:
      Development of "The Gist".
PG  - e15964
LID - 10.2196/15964 [doi]
AB  - BACKGROUND: The impact of viewing pornography at a young age on the sexual health
      of subgroups of young people is an important public health issue. However, the
      topic is complex and extremely sensitive, and best practices for research and
      harm reduction are yet to be defined. Drawing on cross-disciplinary approaches,
      such as co-design, is one way to achieve a better understanding of the issue
      among vulnerable young people and to create needs-based and evidence-informed
      digital resources to promote pornography literacy. OBJECTIVE: The objective of
      this study was to co-design a relevant, usable, and acceptable digital prototype 
      to address the pornography literacy needs of vulnerable young people. METHODS: In
      total, 17 young people aged between 14 and 23 years who were engaged in youth
      services programs or alternative education programs were recruited to participate
      in 4 co-design workshops with a multidisciplinary design team. RESULTS: Although 
      the participants could identify problems with pornography and critique its
      messages, they lacked the information to understand alternative healthy attitudes
      and behaviors. A digital resource that provides detailed and practical
      information about sex, sexual ethics, and relationships may help vulnerable young
      people to identify and contrast with any problematic messages they receive from
      both pornography and society. Embedding this information with pornography
      literacy messages may be a more effective way of addressing underlying attitudes.
      Acknowledging information-seeking patterns and leveraging user interaction
      patterns from commonly used digital platforms among users may enhance engagement 
      with resources. Importantly, digital platforms are perceived among this group as 
      a source of anonymous secondary information but would not be organically accessed
      among this group without face-to-face conversations as an access point.
      CONCLUSIONS: This paper highlights the potential for pornography literacy to be
      embedded within real and practical information about having sex, navigating
      sexuality, and healthy relationships. The study findings include important
      recommendations for the conceptualization of digital pornography literacy
      programs and opportunities for cross-disciplinary co-design research to address
      complex and emerging health issues.
CI  - (c)Angela C Davis, Cassandra JC Wright, Stacey Murphy, Paul Dietze, Meredith J
      Temple-Smith, Margaret E Hellard, Megan SC Lim. Originally published in the
      Journal of Medical Internet Research (http://www.jmir.org), 01.06.2020.
FAU - Davis, Angela C
AU  - Davis AC
AUID- ORCID: 0000-0002-3564-0708
AD  - Burnet Institute, Melbourne, Australia.
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Australia.
FAU - Wright, Cassandra Jc
AU  - Wright CJ
AUID- ORCID: 0000-0001-9751-4005
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Australia.
AD  - Centre for Alcohol Policy Research, La Trobe University, Melbourne, Australia.
FAU - Murphy, Stacey
AU  - Murphy S
AUID- ORCID: 0000-0001-5161-4369
AD  - Sheda, Melbourne, Australia.
FAU - Dietze, Paul
AU  - Dietze P
AUID- ORCID: 0000-0001-7871-6234
AD  - Burnet Institute, Melbourne, Australia.
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Australia.
FAU - Temple-Smith, Meredith J
AU  - Temple-Smith MJ
AUID- ORCID: 0000-0003-1296-9591
AD  - Department of General Practice, Melbourne Medical School, University of
      Melbourne, Melbourne, Australia.
FAU - Hellard, Margaret E
AU  - Hellard ME
AUID- ORCID: 0000-0002-5055-3266
AD  - Burnet Institute, Melbourne, Australia.
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Australia.
AD  - Doherty Institute and School of Population and Global Health, University of
      Melbourne, Melbourne, Australia.
AD  - Department of Infectious Diseases, The Alfred Hospital, Melbourne, Australia.
FAU - Lim, Megan Sc
AU  - Lim MS
AUID- ORCID: 0000-0003-3136-6761
AD  - Burnet Institute, Melbourne, Australia.
AD  - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
      Australia.
AD  - Melbourne School of Population and Global Health, Department of General Practice,
      University of Melbourne, Melbourne, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200601
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Erotica/*psychology
MH  - Female
MH  - Health Resources
MH  - Humans
MH  - Male
MH  - Sexual Behavior/*psychology
MH  - Young Adult
PMC - PMC7296407
OTO - NOTNLM
OT  - *co-design
OT  - *pornography literacy
OT  - *sex education
OT  - *sexual health
EDAT- 2020/04/30 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2019/11/17 00:00 [revised]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - v22i6e15964 [pii]
AID - 10.2196/15964 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jun 1;22(6):e15964. doi: 10.2196/15964.


PMID- 32348250
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210919
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 15
TI  - A Web-Based Intervention to Reduce Decision Conflict Regarding HIV Pre-Exposure
      Prophylaxis: Protocol for a Clinical Trial.
PG  - e15080
LID - 10.2196/15080 [doi]
AB  - BACKGROUND: HIV pre-exposure prophylaxis (PrEP) is recommended for populations at
      high ongoing risk for infection. There are noted racial disparities in the
      incidence of HIV and other sexually transmitted infections (STIs) for African,
      Caribbean, and Canadian Black (ACB, black) populations in Ontario, Canada.
      Although blacks represent only 4.7% of the Ontario population, they account for
      30% of HIV prevalence and 25% of new infections in the province. The existing
      clinical public health practice toolkit has not been sufficient to optimize PrEP 
      uptake, despite the overwhelming evidence of PrEP's efficacy for reducing HIV
      transmission risk. Since its establishment as an effective HIV prevention tool,
      the major focus in behavioral research on PrEP has been on understanding and
      improving adherence. To date, there is no known formalized intervention in place 
      designed to support ACB men and women at high risk of making high-quality
      decisions regarding the adoption of PrEP as an HIV prevention practice.
      OBJECTIVE: We propose 2 aims to address these gaps in HIV prevention and
      implementation science. First, the Ottawa Decision Support Framework (ODSF) for
      use in the PrEP decisional needs of black patients was adapted. Second, the
      decision support intervention to estimate effect size compared with control
      conditions in reducing decision conflict and predicting adherence over 60 days
      was pilot tested. METHODS: In aim 1, we propose a cross-sectional qualitative
      descriptive study using data collected from key informant interviews with
      eligible PrEP patients (n=30) and surveys with health professionals (n=20)
      involved in HIV PrEP management. Data obtained from aim 1 will be used to develop
      a decision support intervention based on the ODSF. In aim 2, the adopted decision
      support intervention using a block-randomized design to estimate effect size
      compared with control conditions in reducing decision conflict and predicting
      adherence over 60 days was pilot tested. Hypothesis testing will be de-emphasized
      in favor of generating effect size estimates. RESULTS: A research award was
      funded on March 25, 2017 (Multimedia Appendix 1). Ethical approval was received
      on March 25, 2019 (with supplemental approval received on May 10, 2019). Data
      collection started on April 9, 2019. As of September 30, 2019, we enrolled 29
      patients and 24 health care providers for aim 1. We are currently analysing the
      data collected for aim 1. Aim 2 is scheduled to start in May 2020. CONCLUSIONS:
      This study will provide evidence-based information on the decisional needs of
      black patients who are at risk of HIV and have been offered PrEP. The study will 
      also test the effect of decision support intervention in reducing decision
      conflict, adoption of PrEP, and adherence to PrEP. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): PRR1-10.2196/15080.
CI  - (c)LaRon E Nelson, Wale Ajiboye, Pascal Djiadeu, Apondi J Odhiambo, Cheryl
      Pedersen, S Raquel Ramos, Aisha Lofters, Lawrence Mbuagbaw, Geoffrey Williams.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 15.06.2020.
FAU - Nelson, LaRon E
AU  - Nelson LE
AUID- ORCID: https://orcid.org/0000-0002-2630-602X
AD  - MAP Center for Urban Health Solution, St. Michael's Hospital, Toronto, ON,
      Canada.
AD  - Yale School of Nursing, Yale University, New Haven, CT, United States.
FAU - Ajiboye, Wale
AU  - Ajiboye W
AUID- ORCID: https://orcid.org/0000-0001-9526-2895
AD  - MAP Center for Urban Health Solution, St. Michael's Hospital, Toronto, ON,
      Canada.
FAU - Djiadeu, Pascal
AU  - Djiadeu P
AUID- ORCID: https://orcid.org/0000-0001-9708-6530
AD  - Department of Health Research Methods Evidence and Impact, McMaster University,
      Hamilton, ON, Canada.
FAU - Odhiambo, Apondi J
AU  - Odhiambo AJ
AUID- ORCID: https://orcid.org/0000-0002-1042-9260
AD  - MAP Center for Urban Health Solution, St. Michael's Hospital, Toronto, ON,
      Canada.
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
FAU - Pedersen, Cheryl
AU  - Pedersen C
AUID- ORCID: https://orcid.org/0000-0002-4454-9412
AD  - MAP Center for Urban Health Solution, St. Michael's Hospital, Toronto, ON,
      Canada.
FAU - Ramos, S Raquel
AU  - Ramos SR
AUID- ORCID: https://orcid.org/0000-0003-2403-7222
AD  - New York University, Rory Meyers College of Nursing, New York, NY, United States.
FAU - Lofters, Aisha
AU  - Lofters A
AUID- ORCID: https://orcid.org/0000-0002-7322-0894
AD  - MAP Center for Urban Health Solution, St. Michael's Hospital, Toronto, ON,
      Canada.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AUID- ORCID: https://orcid.org/0000-0001-5855-5461
AD  - Department of Health Research Methods Evidence and Impact, McMaster University,
      Hamilton, ON, Canada.
FAU - Williams, Geoffrey
AU  - Williams G
AUID- ORCID: https://orcid.org/0000-0003-2050-5658
AD  - University of Rochester, Rochester, NY, United States.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200615
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7324994
OTO - NOTNLM
OT  - HIV
OT  - PrEP
OT  - blacks
OT  - mobile phone
OT  - pre-exposure prophylaxis
OT  - prevention
OT  - smartphone
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
CRDT- 2020/04/30 06:00
PHST- 2019/06/18 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2019/11/29 00:00 [revised]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - v9i6e15080 [pii]
AID - 10.2196/15080 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 15;9(6):e15080. doi: 10.2196/15080.


PMID- 32347821
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 223
DP  - 2020 Mar
TI  - Medical Thoracoscopy for Undiagnosed Exudative Pleural Effusion: Experience from 
      Two Tertiary Care Hospitals of Nepal.
PG  - 158-164
AB  - INTRODUCTION: Medical thoracoscopy has recently gained renewed interest due to
      its minimal invasive nature and high yield diagnostic outcome. This study aims to
      observe diagnostic yield and safety of medical thoracoscopy in undiagnosed
      exudative pleural effusion. METHODS: This is a descriptive cross-sectional study 
      conducted in two tertiary care hospitals in Chitwan from March 2018 to May 2018. 
      Ethical approval from the Institutional Review Board was obtained. Convenient
      sampling was done that included all the patients who met criteria for undiagnosed
      exudative pleural effusion after diagnostic thoracocentesis. Patients having
      contraindication to procedure and who refused consent were excluded. Statistical 
      analysis was performed using IBM SPSS Statistics 20 and data are presented as
      mean +/-SD and frequency (percentage). RESULTS: A total of 14 patients underwent 
      rigid medical thoracoscopy. All 14 patients had unilateral pleural effusion. The 
      overall diagnostic yield was 100%. Malignancy was the most frequent
      histopathology diagnosis seen in 11 (78.57%) patients, the commonest being
      metastatic adenocarcinoma in 8 (57.1%). Pleural tuberculosis and acute-on-chronic
      pleuritis were seen in 2 (14.3%) and 1 (7.1%) patients, respectively. Pleural
      deposits and hemorrhagic pleural fluid were the two commonest findings, seen in
      10 (70.1%) and 9 (64.3%) patients, respectively. Two (14.3%) patients clinically 
      treated as tuberculous pleural effusion was re-diagnosed to have metastatic
      adenocarcinoma. Procedure related mortality and major complications were nil.
      Common procedure-related minor complications observed were mild to moderate pain 
      and mild bleeding, observed in 3 (21.4%) and 2 (14.3%) patients, respectively.
      CONCLUSIONS: Medical thoracoscopy is a safe, well-tolerated and high yield
      procedure in undiagnosed exudative pleural effusion. This art of medicine should 
      be promoted in daily medical practice.
FAU - Shrestha, Bishow Kumar
AU  - Shrestha BK
AD  - Pulmonary, Critical Care and Sleep Medicine Unit, Chitwan Medical College
      Teaching Hospital, Chitwan, Nepal.
FAU - Adhikari, Shital
AU  - Adhikari S
AD  - Pulmonary, Critical Care and Sleep Medicine Unit, Chitwan Medical College
      Teaching Hospital, Chitwan, Nepal.
FAU - Thakur, Binay Kumar
AU  - Thakur BK
AD  - Department of Thoracic Surgery, B P Koirala Memorial Cancer Hospital, Chitwan,
      Nepal.
FAU - Kadaria, Dipen
AU  - Kadaria D
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Tennessee 
      HSC, Memphis, TN, USA.
FAU - Tamrakar, Kishor Kumar
AU  - Tamrakar KK
AD  - Department of Surgery, Chitwan Medical College Teaching Hospital, Chitwan, Nepal.
FAU - Devkota, Mukti
AU  - Devkota M
AD  - Department of Thoracic Surgery, B P Koirala Memorial Cancer Hospital, Chitwan,
      Nepal.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nepal
MH  - *Pleural Effusion/diagnosis/etiology
MH  - Tertiary Care Centers
MH  - *Thoracoscopy
MH  - Tuberculosis/complications/diagnosis
PMC - PMC7580310
OTO - NOTNLM
OT  - exudative pleural effusion; tertiary care hospitals; thoracoscopy.
EDAT- 2020/04/30 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Mar;58(223):158-164.


PMID- 32347817
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 223
DP  - 2020 Mar
TI  - Study of the Head of Human Dry Radii in a Medical College of Nepal: A Descriptive
      Cross-sectional Study.
PG  - 141-143
AB  - INTRODUCTION: Radius is a lateral bone of forearm. Its proximal end forms a part 
      of elbow joint and superior radioulnar joint. Knowledge of the shape and size of 
      radial head is essential for construction of radial head prosthesis. The
      objective of this study is to study the morphology of head of human dry radii.
      METHODS: A descriptive cross-sectional study was conducted in human dry radii in 
      the dissection hall of Nepalese Army Institute of Health Sciences, Sanobharyang, 
      Kathmandu, Nepal from September to October 2019. Ethical approval was taken.
      Altogether, 68 dry bones were enrolled in the study by convenience sampling
      method. Radial head was studied in respect to anteroposterior and transverse
      diameter, height at medial and distal end and shape. Mean and standard deviations
      of the parameters were obtained by using Statistical Package for Social Sciences 
      version 20. RESULTS: Mean height of radial head at medial and lateral end was
      0.91 cm and 0.76 cm respectively. Mean anteroposterior and transverse diameter of
      radial head were 2.09 cm and 2.02 cm respectively. Most common shape of radial
      head in this study was circular in 40 (59%) radii followed by elliptical in 23
      (34%). Mean depth of the superior articular facet of the radial head was 0.19 mm.
      CONCLUSIONS: The most common shape of radial head is elliptical but it was found 
      to be circular in this study. This study will be useful for orthopedic surgeons
      in making prosthesis of radial head.
FAU - Kadel, Muna
AU  - Kadel M
AD  - Department of Anatomy, Nepalese Army Institute of Health Sciences, Sanobharyang, 
      Kathmandu, Nepal.
FAU - Thapa, Trilok Pati
AU  - Thapa TP
AD  - Department of Anatomy, Nepalese Army Institute of Health Sciences, Sanobharyang, 
      Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cadaver
MH  - Cross-Sectional Studies
MH  - Dissection
MH  - Elbow Joint
MH  - Forearm
MH  - Humans
MH  - Nepal
MH  - Radius/*anatomy & histology
PMC - PMC7580317
OTO - NOTNLM
OT  - head; neck; orthopedics; prosthesis; radius.
EDAT- 2020/04/30 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Mar;58(223):141-143.


PMID- 32347816
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 223
DP  - 2020 Mar
TI  - Prevalence of Postpartum Depression in a Tertiary Health Care.
PG  - 137-140
AB  - INTRODUCTION: Postpartum Depression is an important public health problem in
      developing country like Nepal.Although prevalence of postpartum depression is
      high in our setting, it is most neglected area of mental health. These have
      negative consequences not only to mother but also to infant. Data related to
      postpartum depression in Nepal are limited, research in this particular field
      will contribute in knowing the gravity of the situation and helps to formulate
      the factor association to upcoming researchers. This research is done in order to
      find out the prevalence of postpartum depression. METHODS: A descriptive
      cross-sectional study was carried out in Paropakar Maternity and Women's
      Hospital, among total 348 postnatal mothers who were selected through convenient 
      sampling technique. Validated Nepalese version of Edinburg Postnatal Depression
      Scale was used to screen depressive symptoms. Data was collected after receiving 
      ethical approval letter. Data entry was done using SPSS version 20. RESULTS: Out 
      of total mothers, the prevalence of Postpartum Depression (PPD) was seen among 51
      (14.7%) mothers. CONCLUSIONS: Postpartum Depression being a common yet neglected 
      area of maternal health in Nepal, should be detected in early stage. As the study
      showed that about one sixth of mothers had postpartum depression, more focus
      should be given to maternal mental health.
FAU - Pradhananga, Priza
AU  - Pradhananga P
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Mali, Prajita
AU  - Mali P
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Poudel, Lisasha
AU  - Poudel L
AD  - Department of Public Health, Om Health Campus, Kathmandu, Nepal.
FAU - Gurung, Minani
AU  - Gurung M
AD  - Nepal Institute of Development Studies, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care
MH  - *Depression, Postpartum/diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Mothers/psychology
MH  - Nepal/epidemiology
MH  - Pregnancy
MH  - Prevalence
MH  - Risk Factors
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7580319
OTO - NOTNLM
OT  - postpartum depression; prevalence; tertiary health care.
EDAT- 2020/04/30 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Mar;58(223):137-140.


PMID- 32347758
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210302
IS  - 1548-8756 (Electronic)
IS  - 1548-8748 (Linking)
VI  - 40
DP  - 2020 Mar
TI  - Medical Decision-Making in Oncology for Patients Lacking Capacity.
PG  - 1-11
LID - 10.1200/EDBK_280279 [doi]
AB  - Modern oncology practice is built upon the idea that a patient with cancer has
      the legal and ethical right to make decisions about their medical care. There are
      situations in which patients might no longer be fully able to make decisions on
      their own behalf, however, and some patients never were able to do so. In such
      cases, it is critical to be aware of how to determine if a patient has the
      ability to make medical decisions and what should be done if they do not. In this
      article, we examine the concept of decision-making capacity in oncology and
      explore situations in which patients may have altered/diminished capacity (e.g., 
      depression, cognitive impairment, delirium, brain tumor, brain metastases, etc.) 
      or never had decisional capacity (e.g., minor children or developmentally
      disabled adults). We describe fundamental principles to consider when caring for 
      a patient with cancer who lacks decisional capacity. We then introduce strategies
      for capacity assessment and discuss how clinicians might navigate scenarios in
      which their patients could lack capacity to make decisions about their cancer
      care. Finally, we explore ways in which pediatric and medical oncology can learn 
      from one another with regard to these challenging situations.
FAU - Marron, Jonathan M
AU  - Marron JM
AD  - Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood 
      Disorders Center, Boston, MA.
AD  - Harvard Medical School, Boston, MA.
AD  - Center for Bioethics, Harvard Medical School, Boston, MA.
FAU - Kyi, Kaitlin
AU  - Kyi K
AD  - Department of Medicine, University of Rochester Medical Center, Rochester, NY.
FAU - Appelbaum, Paul S
AU  - Appelbaum PS
AD  - Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia
      University, New York, NY.
FAU - Magnuson, Allison
AU  - Magnuson A
AD  - Division of Hematology/Oncology, University of Rochester Medical Center,
      Rochester, NY.
LA  - eng
GR  - K76 AG064394/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am Soc Clin Oncol Educ Book
JT  - American Society of Clinical Oncology educational book. American Society of
      Clinical Oncology. Annual Meeting
JID - 101233985
SB  - IM
MH  - Adult
MH  - Child
MH  - *Clinical Decision-Making
MH  - Humans
MH  - Medical Oncology
MH  - Neoplasms/*therapy
MH  - Pediatrics
PMC - PMC7830737
MID - NIHMS1663219
EDAT- 2020/04/30 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 10.1200/EDBK_280279 [doi]
PST - ppublish
SO  - Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-11. doi: 10.1200/EDBK_280279.


PMID- 32347745
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20201219
IS  - 2048-8734 (Electronic)
IS  - 2048-8726 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Apr
TI  - Ethical aspects of the COVID-19 crisis: How to deal with an overwhelming shortage
      of acute beds.
PG  - 248-252
LID - 10.1177/2048872620922788 [doi]
AB  - The current outbreak of SARS-CoV-2 has and continues to put huge pressure on
      intensive care units (ICUs) worldwide. Many patients with COVID-19 require some
      form of respiratory support and often have prolonged ICU stays, which results in 
      a critical shortage of ICU beds. It is therefore not always physically possible
      to treat all the patients who require intensive care, raising major ethical
      dilemmas related to which patients should benefit from the limited resources and 
      which should not. Here we consider some of the approaches to the acute shortages 
      seen during this and other epidemics, including some guidelines for triaging ICU 
      admissions and treatments.
FAU - Vincent, Jean-Louis
AU  - Vincent JL
AD  - Department of Intensive Care, Erasme University Hospital, Universite Libre de
      Bruxelles, Belgium.
FAU - Creteur, Jacques
AU  - Creteur J
AD  - Department of Intensive Care, Erasme University Hospital, Universite Libre de
      Bruxelles, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - Eur Heart J Acute Cardiovasc Care
JT  - European heart journal. Acute cardiovascular care
JID - 101591369
SB  - IM
MH  - Beds/supply & distribution
MH  - Betacoronavirus/*isolation & purification
MH  - COVID-19
MH  - Catastrophic Illness/epidemiology/nursing
MH  - Clinical Decision-Making/ethics
MH  - Communication
MH  - Coronavirus Infections/*epidemiology
MH  - Ethics, Medical/education
MH  - Health Resources/*organization & administration/supply & distribution
MH  - Humans
MH  - Intensive Care Units/*organization & administration/supply & distribution
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Resource Allocation/ethics/methods
MH  - SARS-CoV-2
MH  - Severity of Illness Index
MH  - Triage/*ethics/organization & administration
PMC - PMC7196891
OTO - NOTNLM
OT  - Triage
OT  - catastrophe
OT  - communication
OT  - distributive justice
OT  - epidemic
EDAT- 2020/04/30 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1177/2048872620922788 [doi]
PST - ppublish
SO  - Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):248-252. doi:
      10.1177/2048872620922788. Epub 2020 Apr 29.


PMID- 32347586
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20220725
IS  - 1941-2452 (Electronic)
IS  - 0884-5336 (Linking)
VI  - 35
IP  - 3
DP  - 2020 Jun
TI  - Understanding Equipoise.
PG  - 495-498
LID - 10.1002/ncp.10492 [doi]
FAU - Hoffer, L John
AU  - Hoffer LJ
AUID- ORCID: 0000-0001-6632-6802
AD  - Lady Davis Institute for Medical Research, Jewish General Hospital, McGill
      University, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200429
PL  - United States
TA  - Nutr Clin Pract
JT  - Nutrition in clinical practice : official publication of the American Society for
      Parenteral and Enteral Nutrition
JID - 8606733
SB  - IM
CON - Nutr Clin Pract. 2020 Jun;35(3):499-505. PMID: 31175689
MH  - *Critical Illness
MH  - Humans
MH  - *Therapeutic Equipoise
MH  - Uncertainty
OTO - NOTNLM
OT  - *Clinical equipoise
OT  - *critical care
OT  - *medical/nutrition ethics
OT  - *nutrition support practice
OT  - *personal equipoise
OT  - *standard of care
EDAT- 2020/04/30 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/05/24 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1002/ncp.10492 [doi]
PST - ppublish
SO  - Nutr Clin Pract. 2020 Jun;35(3):495-498. doi: 10.1002/ncp.10492. Epub 2020 Apr
      29.


PMID- 32347190
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Aug
TI  - Moral dilemmas involving anthropological and ethical dimensions in healthcare
      curriculum.
PG  - 1238-1249
LID - 10.1177/0969733020914382 [doi]
AB  - BACKGROUND: Currently a variety of novel scenarios have appeared within nursing
      practice such as confidentiality of a patient victim of abuse, justice in
      insolvent patients, poorly informed consent delivery, non-satisfactory medicine
      outputs, or the possibility to reject a recommended treatment. These scenarios
      presuppose skills that are not usually acquired during the degree. Thus, the
      implementation of teaching approaches that promote the acquisition of these
      skills in the nursing curriculum is increasingly relevant. OBJECTIVE: The article
      analyzes an academic model which integrates in the curriculum a series of
      specific theoretical concepts together with practical skills to acquire the basic
      ethic assessment competency. RESEARCH DESIGN: The project includes designing two 
      subjects, General Anthropology and Ethics-Bioethics, with an applied approach in 
      the nursing curriculum. The sequential structure of the curriculum in both
      subjects is constituted by three learning domains (theoretical, practical, and
      communicative) with different educational strategies. ETHICAL CONSIDERATIONS: No 
      significant ethical considerations as this is a discussion paper. FINDINGS: The
      model was structured from the anthropology's concepts and decision-making
      process, applied to real situations. The structure of the three domains
      theoretical-practical-communicative is present in each session. DISCUSSION: It is
      observed that theoretical domain fosters the capacity for critical analysis and
      subsequent ability to judge diverse situations. The practical domain reflected
      two significant difficulties: students' resistance to internalizing moral
      problems and the tendency to superficial criticism. The communicative domain has 
      frequently shown that the conflicting points are in the principles to be applied.
      CONCLUSION: We conclude that this design achieves its objectives and may provide 
      future nursing professionals with ethical competences especially useful in
      healthcare practice. The three domains of the presented scheme are associated
      with the same process used in decision making at individual levels, where the
      exercise of clinical prudence acquires particular relevance.
FAU - Macpherson, Ignacio
AU  - Macpherson I
AUID- ORCID: https://orcid.org/0000-0002-4231-4038
FAU - Roque, Maria Victoria
AU  - Roque MV
AD  - International University of Catalonia, Spain.
FAU - Segarra, Ignacio
AU  - Segarra I
AD  - Catholic University of Murcia (UCAM), Spain.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Anthropology/education
MH  - Curriculum/*standards/trends
MH  - Education, Nursing, Baccalaureate/*ethics/trends
MH  - *Ethics
MH  - Humans
MH  - Stress Disorders, Post-Traumatic/*etiology/psychology
MH  - Students, Nursing/*psychology/statistics & numerical data
OTO - NOTNLM
OT  - Case study methods
OT  - ethics education
OT  - moral dilemmas
OT  - moral sensitivity
OT  - moral/ethical climate of organizations
OT  - virtue ethics
EDAT- 2020/04/30 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1177/0969733020914382 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Aug;27(5):1238-1249. doi: 10.1177/0969733020914382. Epub 2020
      Apr 29.


PMID- 32347187
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Aug
TI  - Non-technical skills in operating room nursing: Ethical aspects.
PG  - 1364-1372
LID - 10.1177/0969733020914376 [doi]
AB  - BACKGROUND: Non-technical skills are cognitive and interpersonal skills
      underpinning technical proficiency. Ethical values and respect for human dignity 
      make operating room nurses responsible for nursing decisions that are clinically 
      and technically sound and morally appropriate. AIM: To learn what ethical issues 
      operating room nurses perceive as important regarding non-technical skills.
      RESEARCH DESIGN: Qualitative individual in-depth interviews were conducted. The
      interviews were analysed using Braun and Clarke's six phases for thematic
      analysis. PARTICIPANTS AND RESEARCH CONTEXT: Eleven experienced
      perioperative/operating room nurses working in an operating unit at a Norwegian
      university hospital. ETHICAL CONSIDERATIONS: Approval was given by The Norwegian 
      Social Science Data Service in care of the hospital's Data Protection Officer.
      FINDINGS: Three main themes were found: respect and care for the patient, making 
      the patient feel safe, and respect within the perioperative team. These features 
      or themes, which incorporate collaboration and communication, are closely
      connected to patient safety. DISCUSSION: Defending the patient's dignity is part 
      of caring for and respecting the patient. The manner in which the operating room 
      team collaborates is important for the patient to feel safe and secure. Poor
      teamwork may have dire consequences. Reciprocal respect within the team includes 
      respect for each other's tasks and responsibilities and to talk to one another in
      a friendly manner. CONCLUSION: Being respectful and contributing to a caring
      atmosphere are central ethical skills in the operating room. To patients,
      harmonious teamwork translates into a feeling of safety and being cared for. The 
      nurses see respect and patient safety, and respect and reciprocal politeness
      among the members of the perioperative team as central ethical non-technical
      skills. Lack of respect influences the team negatively and is detrimental for
      patient safety. Good communication is an important safety measure during surgery 
      and creates a feeling of good 'flow' within the operating room team.
FAU - Hanssen, Ingrid
AU  - Hanssen I
AUID- ORCID: https://orcid.org/0000-0002-1720-8911
AD  - Lovisenberg Diaconal University College, Norway.
FAU - Smith Jacobsen, Inger Lise
AU  - Smith Jacobsen IL
FAU - Skramm, Sisilie Havnas
AU  - Skramm SH
AD  - Akershus University Hospital, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200429
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - *Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Male
MH  - Middle Aged
MH  - Norway
MH  - Patient Safety/standards
MH  - Perioperative Nursing/ethics/standards
MH  - Professional Competence/*standards
MH  - Qualitative Research
OTO - NOTNLM
OT  - Non-technical skills
OT  - Scrub Practitioners List of Intraoperative Non-Technical Skills
OT  - nursing care
OT  - perioperative team
OT  - respect
EDAT- 2020/04/30 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1177/0969733020914376 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Aug;27(5):1364-1372. doi: 10.1177/0969733020914376. Epub 2020
      Apr 29.


PMID- 32347144
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20220129
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Jun 16
TI  - Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A
      White Paper by the JAHA Editors.
PG  - e017013
LID - 10.1161/JAHA.120.017013 [doi]
AB  - Coronavirus Disease 2019 (COVID-19) has infected more than 3.0 million people
      worldwide and killed more than 200,000 as of April 27, 2020. In this White Paper,
      we address the cardiovascular co-morbidities of COVID-19 infection; the diagnosis
      and treatment of standard cardiovascular conditions during the pandemic; and the 
      diagnosis and treatment of the cardiovascular consequences of COVID-19 infection.
      In addition, we will also address various issues related to the safety of
      healthcare workers and the ethical issues related to patient care in this
      pandemic.
FAU - Gupta, Ajay K
AU  - Gupta AK
AD  - William Harvey Research Institute Barts and the London School of Medicine and
      Dentistry Queen Mary University of London United Kingdom.
AD  - Barts BP Centre of Excellence Barts Heart Centre London United Kingdom.
AD  - Royal London and St Bartholomew's Hospital Barts Health NHS Trust London United
      Kingdom.
FAU - Jneid, Hani
AU  - Jneid H
AD  - Division of Cardiology Baylor College of Medicine Houston TX.
FAU - Addison, Daniel
AU  - Addison D
AD  - Division of Cardiovascular Medicine Department of Medicine The Ohio State
      University Columbus OH.
FAU - Ardehali, Hossein
AU  - Ardehali H
AD  - Feinberg Cardiovascular and Renal Research Institute Northwestern University
      Chicago IL.
FAU - Boehme, Amelia K
AU  - Boehme AK
AD  - Department of Neurology Vagelos College of Physicians and Surgeons Columbia
      University New York NY.
AD  - Department of Epidemiology Mailman School of Public Health Columbia University
      New York NY.
FAU - Borgaonkar, Sanket
AU  - Borgaonkar S
AD  - Division of Cardiology Baylor College of Medicine Houston TX.
FAU - Boulestreau, Romain
AU  - Boulestreau R
AD  - Department of Cardiology Pau Hospital Pau France.
FAU - Clerkin, Kevin
AU  - Clerkin K
AD  - Division of Cardiology Department of Medicine Vagelos College of Physicians and
      Surgeons Columbia University New York NY.
FAU - Delarche, Nicolas
AU  - Delarche N
AD  - Department of Cardiology Pau Hospital Pau France.
FAU - DeVon, Holli A
AU  - DeVon HA
AD  - University of California, Los Angeles, School of Nursing Los Angeles CA.
FAU - Grumbach, Isabella M
AU  - Grumbach IM
AD  - Division of Cardiovascular Medicine Department of Medicine University of Iowa
      Carver College of Medicine Iowa City IA.
FAU - Gutierrez, Jose
AU  - Gutierrez J
AD  - Department of Neurology Vagelos College of Physicians and Surgeons Columbia
      University New York NY.
FAU - Jones, Daniel A
AU  - Jones DA
AD  - William Harvey Research Institute Barts and the London School of Medicine and
      Dentistry Queen Mary University of London United Kingdom.
AD  - Royal London and St Bartholomew's Hospital Barts Health NHS Trust London United
      Kingdom.
FAU - Kapil, Vikas
AU  - Kapil V
AD  - William Harvey Research Institute Barts and the London School of Medicine and
      Dentistry Queen Mary University of London United Kingdom.
AD  - Barts BP Centre of Excellence Barts Heart Centre London United Kingdom.
FAU - Maniero, Carmela
AU  - Maniero C
AD  - William Harvey Research Institute Barts and the London School of Medicine and
      Dentistry Queen Mary University of London United Kingdom.
AD  - Barts BP Centre of Excellence Barts Heart Centre London United Kingdom.
FAU - Mentias, Amgad
AU  - Mentias A
AD  - Division of Cardiology Department of Internal Medicine University of Iowa Iowa
      City IA.
FAU - Miller, Pamela S
AU  - Miller PS
AD  - Center for Nursing Excellence UCLA Health Los Angeles CA.
FAU - Ng, Sher May
AU  - Ng SM
AD  - Royal London and St Bartholomew's Hospital Barts Health NHS Trust London United
      Kingdom.
FAU - Parekh, Jai D
AU  - Parekh JD
AD  - Division of Cardiovascular Medicine Department of Medicine University of Iowa
      Carver College of Medicine Iowa City IA.
FAU - Sanchez, Reynaldo H
AU  - Sanchez RH
AD  - Division of Cardiovascular Medicine Department of Medicine The Ohio State
      University Columbus OH.
FAU - Sawicki, Konrad Teodor
AU  - Sawicki KT
AD  - Feinberg Cardiovascular and Renal Research Institute Northwestern University
      Chicago IL.
FAU - Te Riele, Anneline S J M
AU  - Te Riele ASJM
AD  - Division of Heart and Lungs Department of Cardiology University Medical Center
      Utrecht Utrecht the Netherlands.
FAU - Remme, Carol Ann
AU  - Remme CA
AD  - Department of Clinical and Experimental Cardiology Heart Centre Amsterdam UMC
      Location Academic Medical Center Amsterdam the Netherlands.
FAU - London, Barry
AU  - London B
AD  - Division of Cardiovascular Medicine Department of Medicine University of Iowa
      Carver College of Medicine Iowa City IA.
LA  - eng
GR  - K23 HL148528/HL/NHLBI NIH HHS/United States
GR  - PB-PG-1216-20028/DH_/Department of Health/United Kingdom
GR  - R01 HL108932/HL/NHLBI NIH HHS/United States
GR  - K12 CA133250/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20200429
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiovascular Diseases/*epidemiology
MH  - Comorbidity
MH  - Coronavirus Infections/*epidemiology
MH  - Global Health
MH  - Humans
MH  - Incidence
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7429024
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *cardiovascular disease
OT  - *cardiovascular risk factors
OT  - *coronavirus disease 2019
OT  - *management
OT  - *treatment
EDAT- 2020/04/30 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1161/JAHA.120.017013 [doi]
PST - ppublish
SO  - J Am Heart Assoc. 2020 Jun 16;9(12):e017013. doi: 10.1161/JAHA.120.017013. Epub
      2020 Apr 29.


PMID- 32346979
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 1547-5069 (Electronic)
IS  - 1527-6546 (Linking)
VI  - 52
IP  - 3
DP  - 2020 May
TI  - Analysis of Citation Patterns and Impact of Predatory Sources in the Nursing
      Literature.
PG  - 311-319
LID - 10.1111/jnu.12557 [doi]
AB  - PURPOSE: This study was undertaken to learn how predatory journal articles were
      cited in articles published in legitimate (nonpredatory) nursing journals. The
      extent of citation and citation patterns were studied. DESIGN: A two-phase
      approach was used. METHODS: In Phase 1, 204 articles published in legitimate
      nursing journals that cited a predatory publication were randomly selected for
      analysis from a list of 814 articles with predatory journal citations. In Phase
      2, the four predatory journal articles that were cited most frequently were
      analyzed further to examine their citation patterns. FINDINGS: The majority (n = 
      148, 72.55%) of the articles that cited a predatory publication were research
      reports. Most commonly, the predatory article was only cited once (n = 117,
      61.58%). Most (n = 158, 82.72%) of the predatory articles, though, were used
      substantively, that is, to provide a basis for the study or methods, describe the
      results, or explain the findings. The four articles in Phase 2 generated 38
      citations in legitimate journals, published from 2011 to 2019, demonstrating
      persistence in citation. An evaluation of the quality of these articles was
      mixed. CONCLUSIONS: The results of this study provide an understanding of the use
      and patterns of citations to predatory articles in legitimate nursing journals.
      Authors who choose predatory journals as the channel to disseminate their
      publications devalue the work that publishers, editors, and peer reviewers play
      in scholarly dissemination. Likewise, those who cite these works are also
      contributing to the problem of predatory publishing in nursing. CLINICAL
      RELEVANCE: Nurse authors should not publish their work in predatory journals and 
      should avoid citing articles from these journals, which disseminates the content 
      through the scholarly nursing literature.
CI  - (c) 2020 Sigma Theta Tau International.
FAU - Oermann, Marilyn H
AU  - Oermann MH
AUID- ORCID: 0000-0002-4534-8962
AD  - Editor-in-Chief, Nurse Educator and Journal of Nursing Care Quality, Thelma M.
      Ingles Professor of Nursing, Duke University School of Nursing, Durham, North
      Carolina.
FAU - Nicoll, Leslie H
AU  - Nicoll LH
AD  - Editor-in-Chief, CIN: Computers, Informatics Nursing and Nurse Author & Editor,
      President and Owner, Maine Desk LLC, Portland, Maine.
FAU - Ashton, Kathleen S
AU  - Ashton KS
AD  - Consulting Associate, Duke University School of Nursing, Durham, North Carolina.
FAU - Edie, Alison H
AU  - Edie AH
AD  - Assistant Professor, Duke University School of Nursing, Durham, North Carolina.
FAU - Amarasekara, Sathya
AU  - Amarasekara S
AD  - Statistician III, Duke University School of Nursing, Durham, North Carolina.
FAU - Chinn, Peggy L
AU  - Chinn PL
AD  - Editor-in-Chief, Advances in Nursing Science, Professor Emerita, University of
      Connecticut School of Nursing, Storrs, Connecticut.
FAU - Carter-Templeton, Heather
AU  - Carter-Templeton H
AD  - Associate Professor, Capstone College of Nursing, The University of Alabama,
      Tuscaloosa, Alabama.
FAU - Ledbetter, Leila S
AU  - Ledbetter LS
AD  - Research and Education Librarian, Liaison to the School of Nursing, Duke
      University Medical Center Library, Durham, North Carolina.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - United States
TA  - J Nurs Scholarsh
JT  - Journal of nursing scholarship : an official publication of Sigma Theta Tau
      International Honor Society of Nursing
JID - 100911591
SB  - IM
MH  - Humans
MH  - *Nursing
MH  - *Periodicals as Topic
MH  - Publishing/*standards/*statistics & numerical data
OTO - NOTNLM
OT  - *Citation analysis
OT  - *editorial standards
OT  - *ethical issues
OT  - *nursing journals
OT  - *predatory journals
OT  - *publishing
EDAT- 2020/04/30 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1111/jnu.12557 [doi]
PST - ppublish
SO  - J Nurs Scholarsh. 2020 May;52(3):311-319. doi: 10.1111/jnu.12557. Epub 2020 Apr
      28.


PMID- 32346958
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20201218
IS  - 1471-8847 (Electronic)
IS  - 1471-8731 (Linking)
VI  - 20
IP  - 2
DP  - 2020 Jun
TI  - The ethical challenges of the SARS-CoV-2 pandemic in the global south and the
      global north - same and different.
PG  - 62-64
LID - 10.1111/dewb.12263 [doi]
FAU - Schuklenk, Udo
AU  - Schuklenk U
LA  - eng
PT  - Editorial
PL  - England
TA  - Dev World Bioeth
JT  - Developing world bioethics
JID - 101120122
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Economics
MH  - *Health Policy
MH  - Health Resources
MH  - Hospital Bed Capacity
MH  - Humans
MH  - Intensive Care Units/statistics & numerical data
MH  - Pandemics
MH  - Personal Protective Equipment/supply & distribution
MH  - Pneumonia, Viral/*epidemiology
MH  - Refusal to Treat/ethics
MH  - Resource Allocation
MH  - SARS-CoV-2
MH  - Triage
PMC - PMC7267380
EDAT- 2020/04/30 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1111/dewb.12263 [doi]
PST - ppublish
SO  - Dev World Bioeth. 2020 Jun;20(2):62-64. doi: 10.1111/dewb.12263.


PMID- 32346893
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1938-3703 (Electronic)
IS  - 0021-8855 (Linking)
VI  - 53
IP  - 3
DP  - 2020 Jul
TI  - Interventions for inappropriate sexual behavior in individuals with intellectual 
      and developmental disabilities: A brief review.
PG  - 1316-1320
LID - 10.1002/jaba.716 [doi]
AB  - Although prevalence rates vary, 6% to 28% of individuals with intellectual or
      developmental disabilities (IDDs) engage in inappropriate sexual behavior (ISB), 
      ranging from public masturbation to sexually aggressive behavior. Along with
      increased risk for contacting the criminal justice system, people with IDDs who
      display ISB may encounter negative social consequences, restricted community
      access and barriers to independence, and a variety of counter-therapeutic
      outcomes. The purpose of the present review is to highlight recent, efficacious
      behavior-analytic treatments for ISB in individuals with IDDs. Ethical
      considerations and areas for future research will be discussed.
CI  - (c) 2020 Society for the Experimental Analysis of Behavior.
FAU - Falligant, John Michael
AU  - Falligant JM
AD  - Department of Psychology, Auburn University.
FAU - Pence, Sacha T
AU  - Pence ST
AD  - Department of Psychology, Auburn University.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200428
PL  - United States
TA  - J Appl Behav Anal
JT  - Journal of applied behavior analysis
JID - 0174763
SB  - IM
MH  - Aggression
MH  - *Applied Behavior Analysis
MH  - Developmental Disabilities/psychology/*therapy
MH  - Humans
MH  - Intellectual Disability/psychology/*therapy
MH  - Problem Behavior/*psychology
MH  - Sexual Behavior/*psychology
OTO - NOTNLM
OT  - *behavioral interventions
OT  - *developmental disabilities
OT  - *reinforcement-based interventions
OT  - *self-management
OT  - *sexual behavior
EDAT- 2020/04/30 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/04/30 06:00
PHST- 2017/03/14 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1002/jaba.716 [doi]
PST - ppublish
SO  - J Appl Behav Anal. 2020 Jul;53(3):1316-1320. doi: 10.1002/jaba.716. Epub 2020 Apr
      28.


PMID- 32346726
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20210507
IS  - 1527-974X (Electronic)
IS  - 1067-5027 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Jun 1
TI  - Problems with the problem list: challenges of transparency in an era of patient
      curation.
PG  - 981-984
LID - 10.1093/jamia/ocaa040 [doi]
AB  - In recent years, the OpenNotes movement and other changes in healthcare have
      driven institutions to make medical records increasingly transparent. As patients
      have begun to question and request changes to their Problem Lists, clinicians
      have come to face the ever more frequent challenge of discerning which changes to
      make and which to refuse. Now clinicians and patients together choose the list of
      problems that represent the patient's current state of health and illness. As the
      physician's role slides closer to consultant and the medical paternalism of the
      twentieth century falls further into the background of our technology-infused
      present, who holds the power of delineating a patient's clinical identity? This
      paper examines the ethical and practical dimensions of this question and proposes
      a research agenda that aims to answer it. Such explorations are essential to
      ensuring that the physician remains relevant to patient's notions of health,
      illness, intervention, and healing.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      American Medical Informatics Association. All rights reserved. For permissions,
      please email: journals.permissions@oup.com.
FAU - Porter, Amy S
AU  - Porter AS
AD  - Center for Comprehensive Care, Rainbow Babies and Children's Hospital, Cleveland,
      Ohio, USA.
FAU - O'Callaghan, Jolene
AU  - O'Callaghan J
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Englund, Kristin A
AU  - Englund KA
AD  - Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio,
      USA.
FAU - Lorenz, Robert R
AU  - Lorenz RR
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Kodish, Eric
AU  - Kodish E
AD  - Pediatrics Institute, Cleveland Clinic Children's Hospital, Cleveland Clinic
      Lerner College of Medicine at Case Western Reserve University, Cleveland, Ohio,
      USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Med Inform Assoc
JT  - Journal of the American Medical Informatics Association : JAMIA
JID - 9430800
SB  - IM
MH  - *Electronic Health Records
MH  - *Ethics, Medical
MH  - Humans
MH  - Medical Records, Problem-Oriented
MH  - Patient Portals
MH  - *Personal Autonomy
MH  - Physician-Patient Relations
PMC - PMC7647313
OTO - NOTNLM
OT  - *OpenNotes
OT  - *ethics
OT  - *patient autonomy
OT  - *problem list
OT  - *shared decision-making
OT  - *transparency
EDAT- 2020/04/30 06:00
MHDA- 2021/03/13 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 5826469 [pii]
AID - 10.1093/jamia/ocaa040 [doi]
PST - ppublish
SO  - J Am Med Inform Assoc. 2020 Jun 1;27(6):981-984. doi: 10.1093/jamia/ocaa040.


PMID- 32346665
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 21
DP  - 2020
TI  - Intraoperative evaluation of hepatic artery blood flow during
      pancreatoduodenectomy (HEPARFLOW): Protocol of an exploratory study.
PG  - 21-26
LID - 10.1016/j.isjp.2020.03.003 [doi]
AB  - INTRODUCTION: Pancreatoduodenectomy is the treatment of choice for a range of
      benign and malignant diseases. The pancreatic head must be separated from its
      supplying vessels, especially the gastroduodenal artery, during this operation.
      However, dissection of the gastroduodenal artery can disturb blood supply to the 
      liver and result in liver ischemia. There is currently no well-established
      algorithm to evaluate and ensure sufficient blood flow in patients with altered
      hepatic artery blood flow. To address this important issue, this study aims to
      establish a basis for assessing liver blood supply during pancreatoduodenectomy. 
      Furthermore, factors influencing arterial blood flow and related postoperative
      complications will be evaluated. METHODS AND ANALYSIS: The HEPARFLOW study is a
      single institutional single-arm prospective exploratory observational clinical
      trial. All consecutive patients undergoing elective partial or total
      pancreatoduodenectomy will be screened for inclusion until 100 patients are
      enrolled. Blood flow in the proper hepatic artery, gastroduodenal artery, portal 
      vein, and additional vessels supplying the liver will be measured during
      pancreatoduodenectomy using Doppler flowmetry. All patients will be followed up
      for 90 days after surgery. At each visit, standard clinical data, postoperative
      complications and mortality will be recorded. DISCUSSION: This will be the first 
      study to prospectively assess intraoperative flow rates of the hepatic artery and
      portal vein to evaluate liver blood supply during pancreatoduodenectomy. The
      preoperative and intraoperative factors influencing blood flow in the hepatic
      arteries will be identified. This study may also reveal the hemodynamic and
      clinical relevance of a compression of the celiac axis during
      pancreatoduodenectomy. ETHICS AND DISSEMINATION: This study was approved by the
      Ethics Committee of the University of Heidelberg (S-073/2018). The results will
      be published in a peer-reviewed journal and will be presented at medical
      meetings.
CI  - (c) 2020 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.
FAU - Al-Saeedi, Mohammed
AU  - Al-Saeedi M
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
FAU - Frank-Moldzio, Leonie
AU  - Frank-Moldzio L
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
FAU - Klauss, Miriam
AU  - Klauss M
AD  - Department of Diagnostic and Interventional Radiology, University Hospital
      Heidelberg, Germany.
FAU - Mayer, Philipp
AU  - Mayer P
AD  - Department of Diagnostic and Interventional Radiology, University Hospital
      Heidelberg, Germany.
FAU - Bruckner, Tom
AU  - Bruckner T
AD  - Institute of Medical Biometry and Informatics, University of Heidelberg, Germany.
FAU - Khajeh, Elias
AU  - Khajeh E
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
FAU - Golriz, Mohammad
AU  - Golriz M
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
FAU - Mehrabi, Arianeb
AU  - Mehrabi A
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
FAU - Knebel, Phillip
AU  - Knebel P
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Germany.
FAU - Diener, Markus K
AU  - Diener MK
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
AD  - The Study Center of the German Surgical Society (SDGC), University of Heidelberg,
      Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
FAU - Strobel, Oliver
AU  - Strobel O
AD  - Department of General, Visceral and Transplant Surgery, University of Heidelberg,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200404
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7182758
OTO - NOTNLM
OT  - CRF, case report form
OT  - CT, computed tomography
OT  - Hepatic artery blood flow
OT  - ISGLS, International Study Group of Liver Surgery
OT  - Pancreatoduodenectomy
OT  - Study protocol
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
CRDT- 2020/04/30 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/03/15 00:00 [revised]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
AID - 10.1016/j.isjp.2020.03.003 [doi]
AID - S2468-3574(20)30010-3 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Apr 4;21:21-26. doi: 10.1016/j.isjp.2020.03.003.
      eCollection 2020.


PMID- 32346464
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2001-0370 (Print)
IS  - 2001-0370 (Linking)
VI  - 18
DP  - 2020
TI  - Dynamic-informed consent: A potential solution for ethical dilemmas in population
      sequencing initiatives.
PG  - 913-921
LID - 10.1016/j.csbj.2020.03.027 [doi]
AB  - While the majority of population-level genome sequencing initiatives claim to
      follow the principles of informed consent, the requirements for informed consent 
      have not been-well defined in this context. In fact, the implementation of
      informed consent differs greatly across these initiatives - spanning broad
      consent, blanket consent, and tiered consent among others. As such, this calls
      for an investigation into the requirements for consent to be "informed" in the
      context of population genomics. One particular strategy that claims to be fully
      informed and to continuously engage participants is called "dynamic consent".
      Dynamic consent is based on a personalised communication platform that aims to
      facilitate the consent process. It is oriented to support continuous two-way
      communication between researchers and participants. In this paper, we analyze the
      requirements of informed consent in the context of population genomics, review
      various current implementations of dynamic consent, assess whether they fulfill
      the requirement of informed consent, and, in turn, enable participants to make
      autonomous and informed choices on whether or not to participate in research
      projects.
CI  - (c) 2020 The Authors.
FAU - Dankar, Fida K
AU  - Dankar FK
AD  - College of Information Technology, UAEU, Al-Ain, United Arab Emirates.
FAU - Gergely, Marton
AU  - Gergely M
AD  - College of Information Technology, UAEU, Al-Ain, United Arab Emirates.
FAU - Malin, Bradley
AU  - Malin B
AD  - Department of Biomedical Informatics, Vanderbilt University Medical Center,
      Nashville, TN, United States.
AD  - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN,
      United States.
AD  - Department of Electrical Engineering and Computer Science, Vanderbilt University,
      Nashville, TN, United States.
FAU - Badji, Radja
AU  - Badji R
AD  - Independent Scientist, Lille, France.
FAU - Dankar, Samar K
AU  - Dankar SK
AD  - Independent Scientist, Ottawa, Canada.
FAU - Shuaib, Khaled
AU  - Shuaib K
AD  - College of Information Technology, UAEU, Al-Ain, United Arab Emirates.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200402
PL  - Netherlands
TA  - Comput Struct Biotechnol J
JT  - Computational and structural biotechnology journal
JID - 101585369
PMC - PMC7182686
OTO - NOTNLM
OT  - Data privacy
OT  - Dynamic consent
OT  - Informed consent
OT  - Population genomics
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
CRDT- 2020/04/30 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/03/29 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
AID - 10.1016/j.csbj.2020.03.027 [doi]
AID - S2001-0370(19)30496-9 [pii]
PST - epublish
SO  - Comput Struct Biotechnol J. 2020 Apr 2;18:913-921. doi:
      10.1016/j.csbj.2020.03.027. eCollection 2020.


PMID- 32346390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1754-6605 (Print)
IS  - 1754-6605 (Linking)
VI  - 14
DP  - 2020
TI  - Epidemiological and histopathological characteristics of head and neck cancers in
      Bhutan from 2011 to 2017: a retrospective descriptive study.
PG  - 1024
LID - 10.3332/ecancer.2020.1024 [doi]
AB  - BACKGROUND: Head and neck cancers are among the commonest cancers in the
      developing world. Personal habits, such as the use of tobacco, betel nut and
      alcohol are strongly associated with the development of head and neck cancers at 
      certain sites. Therefore, they are among the preventable cancers. In Bhutan,
      there has not yet been a study conducted on head and neck cancers. OBJECTIVE: To 
      describe baseline epidemiological and histopathological characteristics of head
      and neck cancers in Bhutan. METHODS: This is a 7-year descriptive study of all
      cases of head and neck cancers presented at the Jigme Dorji Wangchuk National
      Referral Hospital from 2011 to 2017. The data were collected from the hospital's 
      medical records section, histopathology records, patient referral unit and some
      treatment centres in India. Prior approval was sought from the Research and
      Ethics Board for Health, the Ministry of Health and the hospital management.
      RESULTS: There were a total of 515 cases of head and neck cancers from 2011 to
      2017. The crude incidence rate was 10 per 100,000 and the overall age adjusted
      rate was 12.3 (95% CI 9.5-15.1) per 100,000 population. The prevalence during
      this 7-year period was 69.1 per 100,000 population. The commonest cancers are
      thyroid, oral cavity, hypopharyngeal, laryngeal and nasopharyngeal cancer in
      decreasing order. Head and neck cancers are more common in males than females in 
      the majority of sites except thyroid, salivary gland and sinonasal malignancies. 
      Thyroid cancers and nasopharyngeal cancers are found to affect younger age
      groups. Tashigang (48) followed by Paro (43) recorded the highest number of
      cases. Squamous cell carcinoma is the commonest histopathology type in almost all
      the cases, while papillary carcinoma is the commonest among thyroid cancers.
      Personal habits, such as smoking, chewing tobacco, betel nut and alcohol
      consumption, were found to be more common among patients suffering from oral
      cavity, laryngeal, hypopharyngeal and oropharyngeal cancers. CONCLUSION: Head and
      neck cancers are the third most common cancer in Bhutan after stomach cancer and 
      cervical cancer. Thyroid, oral cavity and hypopharynx are the top three
      anatomical sites for head and neck cancers in Bhutan. The current epidemiological
      and histopathological profile of head and neck cancers will form a baseline of
      information and basis for further research on head and neck cancers in Bhutan.
CI  - (c) the authors; licensee ecancermedicalscience.
FAU - Tshering, Phub
AU  - Tshering P
AD  - Jigme Dorji Wangchuk National Referral Hospital, Thimphu, Bhutan.
FAU - Dorjee, Sithar
AU  - Dorjee S
AD  - Khesar Gyalpo University of Medical Sciences, Thimphu, Bhutan.
FAU - Dendup, Tshering
AU  - Dendup T
AD  - Policy and Planning Division, Ministry of Health, Bhutan.
FAU - Dorji, Thinley
AU  - Dorji T
AD  - His Majesty's Kidu Medical Unit, Thimphu, Bhutan.
FAU - Wangmo, Dechen
AU  - Wangmo D
AD  - Minister of Health, Royal Government of Bhutan, Thimphu, Bhutan.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - England
TA  - Ecancermedicalscience
JT  - Ecancermedicalscience
JID - 101392236
PMC - PMC7176063
OTO - NOTNLM
OT  - Bhutan
OT  - alcohol
OT  - betel nut
OT  - epidemiology
OT  - head and neck cancer
OT  - histopathology
OT  - hypopharyngeal cancer
OT  - laryngeal cancer
OT  - nasopharyngeal cancer
OT  - oral cancer
OT  - salivary gland neoplasm
OT  - sinonasal malignancy
OT  - thyroid cancer
OT  - tobacco
COIS- None declared.
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
CRDT- 2020/04/30 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
AID - 10.3332/ecancer.2020.1024 [doi]
AID - can-14-1024 [pii]
PST - epublish
SO  - Ecancermedicalscience. 2020 Apr 15;14:1024. doi: 10.3332/ecancer.2020.1024.
      eCollection 2020.


PMID- 32346320
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1179-7258 (Print)
IS  - 1179-7258 (Linking)
VI  - 11
DP  - 2020
TI  - Nurse Students' Thoughts on a Sustainable Professional Life as Nurses: A
      Qualitative Study.
PG  - 295-303
LID - 10.2147/AMEP.S245877 [doi]
AB  - INTRODUCTION: In a global context of an increasing and aging population, along
      with environmental changes, nurses play an important role in relieving suffering 
      among vulnerable people and groups in society. Sustainability in nursing
      contributes to sustainable development through providing an environment that is
      not detrimental to/protects present and future generations' opportunities for
      good health. There is a global shortage of nurses, and it has been shown that,
      locally, every fifth newly graduated nurse considers leaving their new profession
      five years after graduation. The aim was to describe how nursing students'
      thought about a sustainable professional life as nurses before their graduation. 
      MATERIALS AND METHODS: A qualitative design with a written data set was used, and
      a thematic analysis was performed. One hundred five students (80 women and 25
      men) in semester six out of six of the nursing education program participated.
      RESULTS: The analysis resulted in three themes: 1) to have an ethical foundation 
      that guides the individual nurse in protecting the nursing care and developing
      the nursing care for their patients; 2) to be in a listening, reflexive and
      supportive workplace enabling a professional nurse to continuously grow and learn
      and 3) to be a proud professional nurse with integrity, not risking with their
      own health or personal professional development. CONCLUSION: The nursing students
      describe their thoughts on the requirements for having a sustainable professional
      life as nurses as having a strong inner ethical compass to help guide, protect
      and develop the nursing care for the patients. In addition, it requires a
      workplace with a reflexive and supporting culture. However, the nursing students 
      also put their own health and the opportunities for professional growth at the
      top of their priorities, and if these conditions are lacking, they will switch to
      another workplace.
CI  - (c) 2020 Hagg-Martinell et al.
FAU - Hagg-Martinell, Ann
AU  - Hagg-Martinell A
AUID- ORCID: 0000-0001-6477-4441
AD  - Department of Health Sciences, Red Cross University College, Huddinge, Sweden.
AD  - Department of Clinical Sciences Danderyd Hospital, Karolinska Institute,
      Stockholm, Sweden.
FAU - Tegnestedt, Charlotta
AU  - Tegnestedt C
AUID- ORCID: 0000-0002-3748-899X
AD  - Department of Health Sciences, Red Cross University College, Huddinge, Sweden.
FAU - Larsen, Joacim
AU  - Larsen J
AUID- ORCID: 0000-0003-0622-7794
AD  - Department of Health Sciences, Red Cross University College, Huddinge, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - New Zealand
TA  - Adv Med Educ Pract
JT  - Advances in medical education and practice
JID - 101562700
PMC - PMC7167258
OTO - NOTNLM
OT  - nurse students
OT  - professional life
OT  - sustainability
OT  - thematic analysis
COIS- The authors declare no conflicts of interest.
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
CRDT- 2020/04/30 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
AID - 10.2147/AMEP.S245877 [doi]
AID - 245877 [pii]
PST - epublish
SO  - Adv Med Educ Pract. 2020 Apr 15;11:295-303. doi: 10.2147/AMEP.S245877.
      eCollection 2020.


PMID- 32346165
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0019-5049 (Print)
IS  - 0019-5049 (Linking)
VI  - 64
IP  - 3
DP  - 2020 Mar
TI  - A prospective, randomised, comparative study to evaluate long axis, short axis
      and medial oblique axis approach for ultrasound-guided internal jugular vein
      cannulation.
PG  - 193-198
LID - 10.4103/ija.IJA_785_19 [doi]
AB  - BACKGROUND AND AIMS: The Ultrasound (USG)-guided internal jugular vein (IJV)
      cannulation can be performed using different approaches like short axis (SAX),
      long axis (LAX), oblique axis (OAX) or medial oblique axis (M-OAX). We aimed to
      determine which view was optimal for IJV cannulation. METHODS: After ethical
      committee approval and written informed consent, this prospective, randomised,
      controlled trial was conducted on 108 patients. Patients were allocated into one 
      of the three groups: A (SAX), B (LAX) and C (M-OAX approach) for USG-guided IJV
      cannulation. The number of needle passes, the success of IJV cannulation and its 
      diameter, venous access time, guidewire time, catheterisation time and
      complications if any were recorded. Statistical analysis was performed by SPSS
      version 17.0. RESULTS: First needle pass success rate was highest in M-OAX
      (97.2%) followed by SAX (88.9%) and then LAX (77.8%) but it was statistically
      insignificant among the groups. Mean venous access, guidewire insertion and
      catheterisation time were shortest in M-OAX followed by SAX and then LAX
      approach. It was statistically significant between LAX and SAX and between LAX
      and M-OAX group. (P < 0.001). The carotid puncture was noticed in two patients in
      the LAX group. The overall success rate and the number of needle passes were
      comparable among the groups. CONCLUSION: The M-OAX approach is a safe and
      effective technique for USG-guided IJV cannulation when compared to SAX and LAX
      approaches.
CI  - Copyright: (c) 2020 Indian Journal of Anaesthesia.
FAU - Lal, Jatin
AU  - Lal J
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Bhardwaj, Mamta
AU  - Bhardwaj M
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Verma, Meenakshi
AU  - Verma M
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
FAU - Bansal, Teena
AU  - Bansal T
AD  - Department of Anaesthesiology and Critical Care, Pt. BD Sharma University of
      Health Sciences, Rohtak, Haryana, India.
LA  - eng
PT  - Journal Article
DEP - 20200311
PL  - India
TA  - Indian J Anaesth
JT  - Indian journal of anaesthesia
JID - 0013243
PMC - PMC7179781
OTO - NOTNLM
OT  - Internal jugular vein cannulation
OT  - long axis
OT  - medial oblique axis
OT  - short axis
OT  - ultrasound
COIS- There are no conflicts of interest.
EDAT- 2020/04/30 06:00
MHDA- 2020/04/30 06:01
CRDT- 2020/04/30 06:00
PHST- 2019/11/09 00:00 [received]
PHST- 2019/12/21 00:00 [revised]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2020/04/30 06:01 [medline]
AID - 10.4103/ija.IJA_785_19 [doi]
AID - IJA-64-193 [pii]
PST - ppublish
SO  - Indian J Anaesth. 2020 Mar;64(3):193-198. doi: 10.4103/ija.IJA_785_19. Epub 2020 
      Mar 11.


PMID- 32345799
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1550-5014 (Electronic)
IS  - 0161-9268 (Linking)
VI  - 43
IP  - 2
DP  - 2020 Apr/Jun
TI  - The Role of Nurses as Allies Against Racism and Discrimination: An Analysis of
      Key Resistance Movements of Our Time.
PG  - 102-113
LID - 10.1097/ANS.0000000000000290 [doi]
AB  - The remnants of colonialism manifesting as structural violence, racism, and
      oppression continue to plague our society as evidenced by the persistence of
      health inequities, particularly for minority populations in the United States. As
      a profession bound by moral and ethical mandates, nursing must resist and
      deconstruct oppression in all its forms. Nurses, informed by critical race
      theory, intersectionality, and historical trauma, can become formidable allies
      with marginalized populations in the fight for social justice and health equity.
FAU - Weitzel, Jennifer
AU  - Weitzel J
AD  - University of Wisconsin-Milwaukee.
FAU - Luebke, Jeneile
AU  - Luebke J
FAU - Wesp, Linda
AU  - Wesp L
FAU - Graf, Maria Del Carmen
AU  - Graf MDC
FAU - Ruiz, Ashley
AU  - Ruiz A
FAU - Dressel, Anne
AU  - Dressel A
FAU - Mkandawire-Valhmu, Lucy
AU  - Mkandawire-Valhmu L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - ANS Adv Nurs Sci
JT  - ANS. Advances in nursing science
JID - 7809992
SB  - IM
MH  - Colonialism
MH  - Cultural Competency/*psychology
MH  - Education, Nursing/*methods
MH  - Humans
MH  - *Leadership
MH  - *Nurse's Role
MH  - Racism/*psychology
MH  - Social Justice
MH  - United States
EDAT- 2020/04/30 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
AID - 10.1097/ANS.0000000000000290 [doi]
AID - 00012272-202004000-00002 [pii]
PST - ppublish
SO  - ANS Adv Nurs Sci. 2020 Apr/Jun;43(2):102-113. doi: 10.1097/ANS.0000000000000290.


PMID- 32345700
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 27
TI  - Investigating the effect of clinical pharmacist intervention in transitions of
      care on drug-related hospital readmissions among the elderly: study protocol for 
      a randomised controlled trial.
PG  - e036650
LID - 10.1136/bmjopen-2019-036650 [doi]
AB  - INTRODUCTION: Drug-related problems (DRPs) are a major cause of unplanned
      hospital admissions among elderly people, and transitions of care have been
      emphasised as a key area for improving patient safety. We have designed a complex
      clinical pharmacist intervention that targets people >/=75 years of age
      undergoing transitions of care from hospital to home and primary care. The main
      objective is to investigate if the intervention can reduce the risk of unplanned 
      drug-related readmission within the first 180 days after the person is discharged
      from hospital. METHODS AND ANALYSIS: This is a randomised, controlled,
      superiority trial with two parallel arms. A total of 700 people >/=75 years will 
      be assigned to either intervention or routine care (control). The intervention,
      which aims to find and manage DRPs, is initiated within a week of the person
      being discharged from hospital and combines repeated medical chart reviews, phone
      interviews and in some cases medication reviews. People in both study arms may
      have been the subject of a medication review during their ward stay. As the
      primary outcome, we will measure time until unplanned drug-related readmission
      within 180 days of leaving hospital and use log rank tests and Cox proportional
      hazard models to analyse differences between the groups. Further investigations
      of subgroup effects and adjustments of the regression models will be based on
      heart failure and cognitive impairment as prognostic factors. ETHICS AND
      DISSEMINATION: The study has been approved by the Regional Ethical Review Board
      in Umea (registration numbers 2017-69-31M, 2018-83-32M and 2018-254-32M). We
      intend to publish the results with open access in international peer-reviewed
      journals and present our findings at international conferences. The trial is
      expected to result in more than one published article and form part of two PhD
      theses. TRIAL REGISTRATION NUMBER: NCT03671629.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kindstedt, Jonas
AU  - Kindstedt J
AUID- ORCID: 0000-0002-9422-5125
AD  - Department of Integrative Medical Biology, Umea University, Umea, Sweden
      jonas.kindstedt@umu.se.
FAU - Svahn, Sofia
AU  - Svahn S
AUID- ORCID: 0000-0001-5229-5988
AD  - Department of Integrative Medical Biology, Umea University, Umea, Sweden.
FAU - Sjolander, Maria
AU  - Sjolander M
AUID- ORCID: 0000-0002-8364-6290
AD  - Department of Integrative Medical Biology, Umea University, Umea, Sweden.
FAU - Glader, Eva-Lotta
AU  - Glader EL
AUID- ORCID: 0000-0003-4095-6501
AD  - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
FAU - Lovheim, Hugo
AU  - Lovheim H
AUID- ORCID: 0000-0002-5271-4780
AD  - Department of Community Medicine and Rehabilitation, Umea University, Umea,
      Sweden.
FAU - Gustafsson, Maria
AU  - Gustafsson M
AUID- ORCID: 0000-0003-3615-4880
AD  - Department of Integrative Medical Biology, Umea University, Umea, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03671629
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200427
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Aged
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Medication Reconciliation
MH  - *Patient Readmission
MH  - *Pharmaceutical Preparations
MH  - *Pharmacists
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7213854
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *clinical trials
OT  - *geriatric medicine
EDAT- 2020/04/30 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036650 [pii]
AID - 10.1136/bmjopen-2019-036650 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 27;10(4):e036650. doi: 10.1136/bmjopen-2019-036650.


PMID- 32345699
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 27
TI  - Study protocol for optimising glycaemic control in type 1 diabetes treated with
      multiple daily insulin injections: intermittently scanned continuous glucose
      monitoring, carbohydrate counting with automated bolus calculation, or both? A
      randomised controlled trial.
PG  - e036474
LID - 10.1136/bmjopen-2019-036474 [doi]
AB  - INTRODUCTION: There are beneficial effects of advanced carbohydrate counting with
      an automatic bolus calculator (ABC) and intermittently scanned continuous glucose
      monitoring (isCGM) in persons with type 1 diabetes. We aim to compare the effects
      of isCGM, training in carbohydrate counting with ABC and the combination of the
      two concepts with standard care. METHODS AND ANALYSIS: A multi-centre randomised 
      controlled trial with inclusion criteria: >/=18 years, type 1 diabetes >/=1 year,
      injection therapy, HbA1c >53 mmol/mol, whereas daily use of carbohydrate counting
      and/or CGM/isCGM wear are exclusion criteria. Inclusion was initiated in October 
      2018 and is ongoing. Eligible persons are randomised into four groups: standard
      care, ABC, isCGM or ABC+isCGM. Devices used are FreeStyle Libre Flash and smart
      phone diabetes application mySugr. Participants attend group courses according to
      treatment allocation with different educational contents. Participants are
      followed for 26 weeks with clinical visits and telephone consultations. At
      baseline and at study end, participants wear blinded CGM, have blood samples
      performed and fill in questionnaires on person-related outcomes, and at baseline 
      also on personality traits and hypoglycaemia awareness. The primary outcome is
      the difference in time spent in normoglycaemia (4-10 mmol/L) at study end versus 
      baseline between the isCGM group and the standard care group. Secondary outcomes 
      will also be analysed. Results are expected in 2020. ETHICS AND DISSEMINATION:
      Regional Scientific Ethics Committee approval (H-17040573). Results will be
      sought disseminated at conferences and in high impact journals.Trial registration
      numberClinicalTrial.gov registry (NCT03682237).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Secher, Anna Lilja
AU  - Secher AL
AUID- ORCID: 0000-0003-2247-6213
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark
      anna.elisabet.lilja.secher@regionh.dk.
FAU - Pedersen-Bjergaard, Ulrik
AU  - Pedersen-Bjergaard U
AD  - Endocrine Section, Department of Endocrinology and Nephrology, Nordsjaellands
      Hospital, Hillerod, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Kobenhavn,
      Denmark.
FAU - Svendsen, Ole Lander
AU  - Svendsen OL
AD  - Department of Endocrinology I, Bispebjerg Hospital, Kobenhavn, Denmark.
FAU - Gade-Rasmussen, Birthe
AU  - Gade-Rasmussen B
AD  - Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
FAU - Almdal, Thomas P
AU  - Almdal TP
AD  - Department of Endocrinology, Rigshospitalet, Kobenhavn, Denmark.
FAU - Dorflinger, Liv
AU  - Dorflinger L
AD  - Administration, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Vistisen, Dorte
AU  - Vistisen D
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Norgaard, Kirsten
AU  - Norgaard K
AD  - Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT03682237
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200427
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Blood Glucose
MH  - *Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 1/drug therapy
MH  - Dietary Carbohydrates/*administration & dosage
MH  - Glycated Hemoglobin A/analysis
MH  - Glycemic Control
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
PMC - PMC7213884
OTO - NOTNLM
OT  - *biotechnology & bioinformatics
OT  - *general diabetes
OT  - *nutrition & dietetics
COIS- Competing interests: KN is a shareholder of Novo Nordisk; has received research
      support from Novo Nordisk, Roche Diagnostics, Dexcom and Zealand Pharma; has
      received lecture fees from Medtronic, Roche Diagnostics, Rubin Medical, Sanofi,
      Zealand Pharma, Novo Nordisk and Dexcom and has served on advisory panels for
      Medtronic, Abbott and Novo Nordisk. UP-B has served on advisory boards for
      AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Novo Nordisk and Zealand
      Pharma and has received lecture fees from AstraZeneca, Bristol-Myers Squibb,
      Sanofi-Aventis and Novo Nordisk. TPA holds stocks in Novo Nordisk. ALS, OLS,
      BG-R, LD and DV do not have any competing interests.
EDAT- 2020/04/30 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036474 [pii]
AID - 10.1136/bmjopen-2019-036474 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 27;10(4):e036474. doi: 10.1136/bmjopen-2019-036474.


PMID- 32345696
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 27
TI  - Influence of metabolic profiles on the safety of drug therapy in routine care in 
      Germany: protocol of the cohort study EMPAR.
PG  - e032624
LID - 10.1136/bmjopen-2019-032624 [doi]
AB  - INTRODUCTION: Pre-emptive testing of pharmacogenetically relevant
      single-nucleotide polymorphisms can be an effective tool in the prevention of
      adverse drug reactions and therapy resistance. However, most of the tests are not
      used as standard in routine care in Germany because of lacking evidence for the
      clinical and economical benefit and their impact on the usage of healthcare
      services. We address this issue by investigating the influence of pharmacogenetic
      profiles on the use of healthcare services over an extended period of several
      years using routine care data from a statutory health insurance company. The goal
      is to provide clinical evidence whether pre-emptive pharmacogenetic testing of
      metabolic profiles in routine care in Germany is beneficial and cost-effective.
      METHODS AND ANALYSIS: The EMPAR (Einfluss metabolischer Profile auf die
      Arzneimitteltherapiesicherheit in der Routineversorgung) study is a
      non-interventional cohort study conducted to analyse pharmacogenetic risk factors
      that are important for drug therapy by means of endpoints relevant for
      healthcare. The analysis is based on pharmacogenetic profiles and statutory
      health insurance data. We perform pharmacogenetic, pharmacoepidemiological and
      pharmacoeconomic analyses using health care utilisation scores and machine
      learning techniques. Therefore, we aim to include about 10 000 patients (>/=18
      years) insured by the health insurance provider Techniker Krankenkasse. The study
      focuses on patients with prescriptions of anticoagulants and prescriptions of
      cholesterol-lowering drugs. Also, a screening for special pharmacogenetic
      characteristics will be performed in patients with at least one Y57.9! diagnosis 
      (Complication of medical and surgical care: drug or medicament, unspecified).
      Outcomes include the utilisation of health insurance services, the incidence of
      incapacity for work and costs for drugs and treatment. ETHICS AND DISSEMINATION: 
      The protocol was approved by the Ethics Committee of the Medical Faculty,
      University of Bonn (Lfd. Nr. 339/17). The results of this research project will
      be published in scientific open access journals and at conferences. TRIAL
      REGISTRATION NUMBER: German Clinical Trials Register, DRKS00013909.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Huebner, Tatjana
AU  - Huebner T
AUID- ORCID: 0000-0003-4548-1234
AD  - Research Division, Federal Institute for Drugs and Medical Devices, Bonn, North
      Rhine-Westphalia, Germany.
FAU - Steffens, Michael
AU  - Steffens M
AD  - Research Division, Federal Institute for Drugs and Medical Devices, Bonn, North
      Rhine-Westphalia, Germany.
FAU - Linder, Roland
AU  - Linder R
AD  - Techniker Krankenkasse, Hamburg, Germany.
FAU - Fracowiak, Jochen
AU  - Fracowiak J
AD  - Research Division, Federal Institute for Drugs and Medical Devices, Bonn, North
      Rhine-Westphalia, Germany.
FAU - Langner, Daria
AU  - Langner D
AD  - Techniker Krankenkasse, Hamburg, Germany.
FAU - Garling, Marco
AU  - Garling M
AD  - Techniker Krankenkasse, Hamburg, Germany.
FAU - Falkenberg, Felix
AU  - Falkenberg F
AD  - Techniker Krankenkasse, Hamburg, Germany.
FAU - Roethlein, Christoph
AU  - Roethlein C
AD  - Population Health Sciences, German Centre for Neurodegenerative Diseases, Bonn,
      North Rhine-Westphalia, Germany.
FAU - Gomm, Willy
AU  - Gomm W
AD  - Population Health Sciences, German Centre for Neurodegenerative Diseases, Bonn,
      North Rhine-Westphalia, Germany.
FAU - Haenisch, Britta
AU  - Haenisch B
AD  - Research Division, Federal Institute for Drugs and Medical Devices, Bonn, North
      Rhine-Westphalia, Germany.
AD  - Population Health Sciences, German Centre for Neurodegenerative Diseases, Bonn,
      North Rhine-Westphalia, Germany.
AD  - Centre for Translational Medicine, University of Bonn, Bonn, North
      Rhine-Westphalia, Germany.
FAU - Stingl, Julia
AU  - Stingl J
AD  - Institute for Clinical Pharmacology, RWTH Aachen University, Aachen, North
      Rhine-Westphalia, Germany jstingl@ukaachen.de.
LA  - eng
SI  - DRKS/DRKS00013909
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200427
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anticoagulants)
RN  - 0 (Hypolipidemic Agents)
SB  - IM
MH  - Adult
MH  - Anticoagulants/adverse effects
MH  - Cohort Studies
MH  - Drug-Related Side Effects and Adverse
      Reactions/epidemiology/genetics/*metabolism/prevention & control
MH  - Germany/epidemiology
MH  - Health Services Needs and Demand/economics/*statistics & numerical data
MH  - Humans
MH  - Hypolipidemic Agents/adverse effects
MH  - Insurance, Health/*statistics & numerical data
MH  - Machine Learning
MH  - *Metabolome
MH  - Pharmacoepidemiology
MH  - Polymorphism, Single Nucleotide
PMC - PMC7213853
OTO - NOTNLM
OT  - *health care research
OT  - *health economics
OT  - *pharmacoepidemiology
OT  - *pharmacogenetics
OT  - *precision medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/30 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-032624 [pii]
AID - 10.1136/bmjopen-2019-032624 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 27;10(4):e032624. doi: 10.1136/bmjopen-2019-032624.


PMID- 32345582
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2059-7908 (Print)
IS  - 2059-7908 (Linking)
VI  - 5
IP  - 4
DP  - 2020 Apr
TI  - The promise and pitfalls of social science research in an emergency: lessons from
      studying the Zika epidemic in Brazil, 2015-2016.
LID - e002307 [pii]
LID - 10.1136/bmjgh-2020-002307 [doi]
AB  - Social science generates evidence necessary to control epidemics. It can help to 
      craft appropriate public health responses, develop solutions to the epidemic
      impacts and improve understanding of why the epidemic occurred. Yet, there are
      practical constraints in undertaking this international research in a way that
      produces quality, ethical and appropriate data, and that values all voices and
      experiences, especially those of local researchers and research participants. In 
      this paper, we reflected on the experience of undertaking social science research
      during the 2015/2016 Zika epidemic in Brazil. This experience was considered from
      the perspective of this paper's authors: three Brazilian academics, two UK
      academics and two mothers of children affected by congenital Zika syndrome. This 
      group came together through the conduct of the Social and Economic Impact of Zika
      study, a mixed-methods social science study. The key findings highlight practical
      issues in the achievement of three goals: the conduct of high-quality social
      science in emergencies and efforts towards the decolonisation of global health in
      terms of levelling the power between Brazilian and UK researchers and optimising 
      the role of patients within research. From our perspective, the information
      collected through social science was valuable, providing detailed insight into
      the programmatic needs of mothers and their affected children (eg, economic and
      social support and mental health services). Social science was considered a low
      priority within the Zika epidemic despite its potential importance. There were
      logistical challenges in conducting social science research, foremost of which
      are the difficulties in developing a trusting and balanced power relationship
      between the UK and Brazilian researchers in a short time frame. When these issues
      were overcome, each partner brought unique qualities, making the research
      stronger. The mothers of affected children expressed dissatisfaction with
      research, as they were involved in many studies which were not coordinated, and
      from which they did not see a benefit. In conclusion, the importance of social
      science in epidemics must continue to be promoted by funders. Funders can also
      set in place mechanisms to help equalise the power dynamics between foreign and
      local researchers, researchers and participants, both to promote justice and to
      create best quality data.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Passos, Maria Joana
AU  - Passos MJ
AD  - Abraco a microcefalia, Salvador, Brazil.
FAU - Matta, Gustavo
AU  - Matta G
AD  - Escola Nacional de Saude Publica, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
FAU - Lyra, Tereza Maciel
AU  - Lyra TM
AD  - Aggeu Magalhaes Institute, FIOCRUZ/PE, Recife, Brazil.
AD  - Faculty of Medicine, University of Pernambuco, Recife, Brazil.
FAU - Moreira, Maria Elisabeth Lopes
AU  - Moreira MEL
AD  - Fernando Figueira Maternal and Children's Institute, FIOCRUZ, Rio de Janeiro,
      Brazil.
FAU - Kuper, Hannah
AU  - Kuper H
AUID- ORCID: 0000-0002-8952-0023
AD  - International Centre for Evidence in Disability, London School of Hygiene and
      Tropical Medicine, London, UK Hannah.Kuper@lshtm.ac.uk.
FAU - Penn-Kekana, Loveday
AU  - Penn-Kekana L
AD  - Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, 
      London, UK.
FAU - Mendonca, Mila
AU  - Mendonca M
AD  - Abraco a microcefalia, Salvador, Brazil.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 205377/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - BMJ Glob Health
JT  - BMJ global health
JID - 101685275
SB  - IM
MH  - Brazil/epidemiology
MH  - Child
MH  - Emergencies
MH  - *Epidemics
MH  - Humans
MH  - Social Sciences
MH  - *Zika Virus
MH  - *Zika Virus Infection/epidemiology
PMC - PMC7213811
OTO - NOTNLM
OT  - *control strategies
OT  - *health policies and all other topics
OT  - *health services research
OT  - *prevention strategies
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/30 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/01/09 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - bmjgh-2020-002307 [pii]
AID - 10.1136/bmjgh-2020-002307 [doi]
PST - ppublish
SO  - BMJ Glob Health. 2020 Apr;5(4). pii: bmjgh-2020-002307. doi:
      10.1136/bmjgh-2020-002307.


PMID- 32345552
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1701-2163 (Print)
IS  - 1701-2163 (Linking)
VI  - 42
IP  - 8
DP  - 2020 Aug
TI  - Salpingectomie bilaterale aux fins de contraception permanente : serie de cas et 
      facteurs limitant le changement de pratique.
PG  - 948-952
LID - S1701-2163(20)30069-4 [pii]
LID - 10.1016/j.jogc.2020.02.004 [doi]
AB  - OBJECTIVE: The Society of Obstetricians and Gynaecologists of Canada (SOGC) and
      the Society of Gynaecologic Oncology of Canada (GOC) recommend complete removal
      of the fallopian tubes as a permanent contraceptive method because of its
      association with a reduced risk of ovarian cancer. Currently, many women are not 
      offered bilateral salpingectomy as an alternative to tubal ligation for permanent
      contraception. METHOD: As part of a quality improvement initiative, we reviewed
      all cases of sterilization performed at our university centre between 1 January
      and 31 December 2018. A literature review of the clinical and ethical
      considerations that prevent clinicians from offering bilateral salpingectomy as
      permanent contraception is also presented. RESULTS: The records of 111 women who 
      underwent tubal sterilization were reviewed. Of these, 31.5% underwent bilateral 
      salpingectomy; 46.8% underwent tubal fulguration; 12.6% underwent clip ligation; 
      and 9.1% underwent tubal implant ligation (Essure). According to the information 
      on file, only 36.3% of women were offered bilateral salpingectomy, and of these, 
      83.8% chose this method. CONCLUSION: Bilateral salpingectomy should be offered to
      all women seeking permanent contraception. The benefits and very low risks
      associated with this procedure should make it a first choice option.
CI  - Copyright (c) 2020 The Society of Obstetricians and Gynaecologists of Canada/La
      Societe des obstetriciens et gynecologues du Canada. Published by Elsevier Inc.
      All rights reserved.
FAU - Ruel-Laliberte, Jessica
AU  - Ruel-Laliberte J
AD  - Medecin residente, Service d'obstetrique-gynecologie generale, Departement
      d'obstetrique et gynecologie, Centre hospitalier universitaire de Sherbrooke.
      Electronic address: jessica.ruel-laliberte@usherbrooke.ca.
FAU - Binette, Audrey
AU  - Binette A
AD  - Obstetricienne-gynecologue, Service d'obstetrique et gynecologie, Hopital
      regional de Rimouski, Centre integre de sante et de services sociaux du
      Bas-St-Laurent.
FAU - Bertrand, Amelie
AU  - Bertrand A
AD  - Professeure adjointe, Service d'obstetrique-gynecologie generale, Departement
      d'obstetrique et gynecologie, Centre hospitalier universitaire de Sherbrooke.
LA  - eng
PT  - Journal Article
DEP - 20200425
PL  - Netherlands
TA  - J Obstet Gynaecol Can
JT  - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et
      gynecologie du Canada : JOGC
JID - 101126664
SB  - IM
MH  - Canada
MH  - Clinical Audit
MH  - Contraception
MH  - Female
MH  - Humans
MH  - Quality Improvement
MH  - *Salpingectomy
MH  - *Sterilization, Reproductive
MH  - *Sterilization, Tubal
OTO - NOTNLM
OT  - cancer ovaire
OT  - contraception permanente
OT  - ligature tubaire
OT  - planification familiale
OT  - salpingectomie
OT  - sterilisation
EDAT- 2020/04/30 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/02/01 00:00 [revised]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - S1701-2163(20)30069-4 [pii]
AID - 10.1016/j.jogc.2020.02.004 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Can. 2020 Aug;42(8):948-952. doi: 10.1016/j.jogc.2020.02.004.
      Epub 2020 Apr 25.


PMID- 32345438
OWN - NLM
STAT- MEDLINE
DCOM- 20210331
LR  - 20210331
IS  - 1365-229X (Electronic)
IS  - 0009-9260 (Linking)
VI  - 75
IP  - 8
DP  - 2020 Aug
TI  - Split bolus dual-energy CT urography after urine dilution: a one-stop shop for
      detection and characterisation of urolithiasis.
PG  - 643.e11-643.e18
LID - S0009-9260(20)30119-7 [pii]
LID - 10.1016/j.crad.2020.03.020 [doi]
AB  - AIM: To determine the diagnostic performance of split-bolus dual-energy computed 
      tomography (CT) urography (SBDECTU) in the detection and characterisation of
      urolithiasis. MATERIALS AND METHODS: This single-centre Institute Ethics
      Committee (IEC)-approved prospective study was conducted from April 2014 to
      November 2015. One hundred and thirty consenting adults with microscopic
      haematuria underwent dual-energy true non-enhanced CT (DETNE) of the whole
      abdomen followed by a SBDECTU. The SBDECTU protocol consisted of synchronous
      nephrogram-urogram acquisition following urine dilution by oral hydration and
      normal saline injection. Calculi were detected and characterised using virtual
      non-enhanced (VNE) images derived from SBDECT were compared with DETNE (the
      reference standard). The subjective image quality and radiation dose were
      compared. RESULTS: Twenty-six participants had one or more calculi (total 129
      calculi) detected on DETNE CT. The sensitivity and specificity of VNE on a
      per-patient basis were 100%. Of the 129 calculi, 118 were detected on VNE, with a
      sensitivity of 91.47% and an accuracy of 91.47%. Of the calculi, 83.9% (99/118)
      could be characterised on SBDECTU images. On VNE images, complete iodine
      subtraction was seen in 73.1% (19/26). By omitting DETNE CT, the mean dose-length
      product of 537.6+/-152.9 mGy and volume CT dose index of 10.9+/-2.9 mGy*cm(2)
      could have been saved. CONCLUSION: SBDECTU has high diagnostic accuracy in the
      detection and characterisation of clinically significant urinary calculi at
      potentially half the radiation dose.
CI  - Copyright (c) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. 
      All rights reserved.
FAU - Manoharan, D
AU  - Manoharan D
AD  - Department of Radiology, All India Institute of Medical Sciences, Ansari Nagar,
      New Delhi 110049, India.
FAU - Sharma, S
AU  - Sharma S
AD  - Department of Radiology, All India Institute of Medical Sciences, Ansari Nagar,
      New Delhi 110049, India. Electronic address: drssharma@hotmail.com.
FAU - Das, C J
AU  - Das CJ
AD  - Department of Radiology, All India Institute of Medical Sciences, Ansari Nagar,
      New Delhi 110049, India.
FAU - Kumar, R
AU  - Kumar R
AD  - Department of Urology, All India Institute of Medical Sciences, Ansari Nagar, New
      Delhi 110049, India.
FAU - Kumar, P
AU  - Kumar P
AD  - Department of Medical Physics, All India Institute of Medical Sciences, Ansari
      Nagar, New Delhi 110029, India.
LA  - eng
PT  - Journal Article
DEP - 20200425
PL  - England
TA  - Clin Radiol
JT  - Clinical radiology
JID - 1306016
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radiation Dosage
MH  - Radiography, Dual-Energy Scanned Projection/*methods
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed/*methods
MH  - Urography/*methods
MH  - Urolithiasis/*diagnosis
MH  - Young Adult
EDAT- 2020/04/30 06:00
MHDA- 2021/04/01 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/01 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - S0009-9260(20)30119-7 [pii]
AID - 10.1016/j.crad.2020.03.020 [doi]
PST - ppublish
SO  - Clin Radiol. 2020 Aug;75(8):643.e11-643.e18. doi: 10.1016/j.crad.2020.03.020.
      Epub 2020 Apr 25.


PMID- 32345425
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 4
DP  - 2020 Apr 1
TI  - Should Surgeons or Anesthesiologists Manage Perioperative Pain Protocols?
PG  - E319-324
LID - amajethics.2020.319 [pii]
LID - 10.1001/amajethics.2020.319 [doi]
AB  - Enhanced recovery after surgery (ERAS((R))) protocols vary by surgery type. This 
      article examines benefits of ERAS pathways, compares ERAS pathways to traditional
      protocols from clinical and ethical standpoints, and discusses formal
      recommendations of the American College of Surgeons, the American Society of
      Anesthesiologists, and other groups.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Doerr, Patricia
AU  - Doerr P
AD  - Fourth-year resident in the Department of Anesthesiology at the University of
      North Carolina at Chapel Hill.
FAU - Chidgey, Brooke
AU  - Chidgey B
AD  - Associate professor of anesthesiology with subspecialty certification in pain
      management at the University of North Carolina School of Medicine in Chapel Hill.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Anesthesiologists
MH  - Humans
MH  - Length of Stay
MH  - Pain
MH  - Perioperative Care
MH  - *Surgeons
EDAT- 2020/04/30 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.319 [pii]
AID - 10.1001/amajethics.2020.319 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Apr 1;22(4):E319-324. doi: 10.1001/amajethics.2020.319.


PMID- 32345421
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 4
DP  - 2020 Apr 1
TI  - How Should a Surgeon and Anesthesiologist Cooperate During Intraoperative Cardiac
      Arrest?
PG  - E291-297
LID - amajethics.2020.291 [pii]
LID - 10.1001/amajethics.2020.291 [doi]
AB  - Surgeons and anesthesiologists each have a unique sense of duty and
      responsibility to patients throughout all phases of perioperative care.
      Intraoperative cardiac arrest during elective, noncardiac surgery is rare, with
      an incidence between 0.8 to 4.3 per 10 000 cases. Fortunately, patients who
      suffer cardiac arrest during surgery are more likely to survive than patients who
      suffer cardiac arrest in other settings. This article considers factors that have
      been shown to influence outcomes after intraoperative cardiac arrest and offers a
      framework for analyzing and discussing these clinically, ethically, and
      emotionally complex cases.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Jolissaint, Joshua S
AU  - Jolissaint JS
AD  - General surgery resident at Brigham and Women's Hospital and a clinical fellow in
      surgery at Harvard Medical School in Boston.
FAU - Nehra, Deepika
AU  - Nehra D
AD  - Associate surgeon in the Division of Trauma, Burn, and Surgical Critical Care at 
      Brigham and Women's Hospital and an assistant professor of surgery at Harvard
      Medical School in Boston.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Anesthesia
MH  - Anesthesiologists
MH  - *Heart Arrest
MH  - Humans
MH  - Incidence
MH  - *Surgeons
EDAT- 2020/04/30 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.291 [pii]
AID - 10.1001/amajethics.2020.291 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Apr 1;22(4):E291-297. doi: 10.1001/amajethics.2020.291.


PMID- 32345418
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 4
DP  - 2020 Apr 1
TI  - How Should Trainees' Influences on Postoperative Outcomes Be Disclosed?
PG  - E267-275
LID - amajethics.2020.267 [pii]
LID - 10.1001/amajethics.2020.267 [doi]
AB  - Conflict arises when surgeons and anesthesiologists disagree about goals of care 
      in perioperative settings. Collaboration is essential for safe, efficient, and
      effective care. Drawing on 2 pediatric cases that highlight risks of anesthetic
      exposure, this article examines the influence of surgical training on outcomes,
      barriers to collaboration, and anesthesiologists' ethical obligations to educate 
      surgeons and parents about anesthesia-induced neurotoxicity risks. The article
      also discusses how to align surgical and anesthetic practice during surgeries
      with prolonged anesthetic use.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Ekeoduru, Rhashedah
AU  - Ekeoduru R
AD  - Institutional ethics committee at Memorial Hermann Hospital in Houston, Texas.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Child
MH  - Humans
MH  - *Neurotoxicity Syndromes
MH  - Parents
MH  - *Surgeons
EDAT- 2020/04/30 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - amajethics.2020.267 [pii]
AID - 10.1001/amajethics.2020.267 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Apr 1;22(4):E267-275. doi: 10.1001/amajethics.2020.267.


PMID- 32345414
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1472-1465 (Electronic)
IS  - 0007-1250 (Linking)
VI  - 216
IP  - 3
DP  - 2020 Mar
TI  - Moral injury in a context of trauma.
PG  - 127-128
LID - 10.1192/bjp.2020.46 [doi]
AB  - Moral injury, characterised by guilt, shame and self-condemnation, is
      conceptualised either as an adjunct to post-traumatic stress disorder or as a new
      syndrome. Studies of symptoms and potentially morally injurious events have
      produced a possible definition and informed the design of rating scales. The
      current challenge remains the design of effective interventions. Because moral
      injury relates to ethical behaviour, the meaning attached to events and
      perceptions of the self, moral philosophy and spirituality could contribute to
      the design of treatments.
FAU - Jones, Edgar
AU  - Jones E
AUID- ORCID: 0000-0002-4610-9584
AD  - Professor of the History of Medicine and Psychiatry, Institute of Psychiatry,
      Psychology and Neuroscience, King's College London, UK.
LA  - eng
PT  - Editorial
PL  - England
TA  - Br J Psychiatry
JT  - The British journal of psychiatry : the journal of mental science
JID - 0342367
SB  - IM
MH  - *Guilt
MH  - Humans
MH  - *Morals
MH  - *Shame
MH  - Spirituality
MH  - Stress Disorders, Post-Traumatic/*psychology
MH  - Veterans/psychology
OTO - NOTNLM
OT  - *Moral injury
OT  - *post-traumatic illness
OT  - *post-traumatic stress disorder
OT  - *transgressive acts
OT  - *veterans
EDAT- 2020/04/30 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - 10.1192/bjp.2020.46 [doi]
AID - S000712502000046X [pii]
PST - ppublish
SO  - Br J Psychiatry. 2020 Mar;216(3):127-128. doi: 10.1192/bjp.2020.46.


PMID- 32345367
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20210616
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Apr 28
TI  - Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is
      achievable and cost-effective in daily clinical practice: data from the Brussels 
      UCLouvain RA Cohort.
PG  - 96
LID - 10.1186/s13075-020-02165-4 [doi]
AB  - BACKGROUND/PURPOSE: Studies have demonstrated that rheumatoid arthritis (RA)
      patients who achieve low disease activity or remission are able to taper
      biological disease-modifying antirheumatic drugs (bDMARDs). The aim of this study
      was to evaluate the proportion of patients in whom bDMARDs can be tapered in
      daily practice and to analyse the characteristics of these patients. Other
      objectives were to analyse which bDMARDs are more suitable for dose reduction and
      the cost savings. RESULTS: Data from 332 eligible RA patients from our Brussels
      UCLouvain cohort were retrospectively analysed; 140 patients (42.1%) received a
      tapered regimen, and 192 received stable doses of bDMARDs. The age at diagnosis
      (43.1 vs 38.7 years, p = 0.04), health assessment questionnaire (HAQ) score (1.3 
      vs 1.5, p = 0.048), RF positivity rate (83.3 vs 72.9%, p = 0.04) and disease
      duration at the time of bDMARD introduction (9.7 vs 12.1 years, p = 0.034) were
      significantly different between the reduced-dose and stable-dose groups.
      Interestingly, relatively more patients receiving a tapered dose were treated
      with a combination of bDMARDs and methotrexate (MTX) (86.7% vs 73.8%, p = 0.005).
      In our cohort, anti-TNF agents were the most commonly prescribed medications
      (68%). Only 15 patients experienced a flare during follow-up. Adalimumab,
      etanercept and rituximab were the most common bDMARDs in the reduced-dose group
      and were associated with the most important reductions in annual cost.
      CONCLUSION: In daily practice, tapering bDMARDs in RA patients who have achieved 
      low disease activity or remission is an achievable goal in a large proportion of 
      patients, thereby reducing potential side effects and annual drug-associated
      costs. The combination of bDMARDs with MTX could improve the success of dose
      reduction attempts. TRIAL REGISTRATION: This retrospective non-interventional
      study was retrospectively registered with local ethics approval.
FAU - Dierckx, Stephanie
AU  - Dierckx S
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Sokolova, Tatiana
AU  - Sokolova T
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Lauwerys, Bernard R
AU  - Lauwerys BR
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Avramovska, Aleksandra
AU  - Avramovska A
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - de Bellefon, Laurent Meric
AU  - de Bellefon LM
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Toukap, Adrien Nzeusseu
AU  - Toukap AN
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Stoenoiu, Maria
AU  - Stoenoiu M
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Houssiau, Frederic A
AU  - Houssiau FA
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium.
FAU - Durez, Patrick
AU  - Durez P
AD  - Rheumatology, Cliniques universitaires Saint-Luc - Universite catholique de
      Louvain - Institut de Recherche Experimentale et Clinique (IREC), Brussels,
      Belgium. patrick.durez@uclouvain.be.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*administration & dosage
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Biological Products/*administration & dosage
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor Inhibitors
PMC - PMC7189594
OTO - NOTNLM
OT  - *Dose tapering
OT  - *Remission
OT  - *Rheumatoid arthritis
OT  - *bioDMARDs
EDAT- 2020/04/30 06:00
MHDA- 2021/06/17 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
AID - 10.1186/s13075-020-02165-4 [doi]
AID - 10.1186/s13075-020-02165-4 [pii]
PST - epublish
SO  - Arthritis Res Ther. 2020 Apr 28;22(1):96. doi: 10.1186/s13075-020-02165-4.


PMID- 32344847
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 12
IP  - 5
DP  - 2020 Apr 25
TI  - Analysis of Motor Neurons Differentiated from Human Induced Pluripotent Stem
      Cells for the Use in Cell-Based Botulinum Neurotoxin Activity Assays.
LID - E276 [pii]
LID - 10.3390/toxins12050276 [doi]
AB  - Botulinum neurotoxins (BoNTs) are potent neurotoxins produced by bacteria, which 
      inhibit neurotransmitter release, specifically in their physiological target
      known as motor neurons (MNs). For the potency assessment of BoNTs produced for
      treatment in traditional and aesthetic medicine, the mouse lethality assay is
      still used by the majority of manufacturers, which is ethically questionable in
      terms of the 3Rs principle. In this study, MNs were differentiated from human
      induced pluripotent stem cells based on three published protocols. The resulting 
      cell populations were analyzed for their MN yield and their suitability for the
      potency assessment of BoNTs. MNs produce specific gangliosides and synaptic
      proteins, which are bound by BoNTs in order to be taken up by receptor-mediated
      endocytosis, which is followed by cleavage of specific soluble
      N-ethylmaleimide-sensitive-factor attachment receptor (SNARE) proteins required
      for neurotransmitter release. The presence of receptors and substrates for all
      BoNT serotypes was demonstrated in MNs generated in vitro. In particular, the MN 
      differentiation protocol based on Du et al. yielded high numbers of MNs in a
      short amount of time with high expression of BoNT receptors and targets. The
      resulting cells are more sensitive to BoNT/A1 than the commonly used
      neuroblastoma cell line SiMa. MNs are, therefore, an ideal tool for being
      combined with already established detection methods.
FAU - Schenke, Maren
AU  - Schenke M
AUID- ORCID: 0000-0001-5649-591X
AD  - Institute for Food Toxicology, Department of Food Toxicology and
      Replacement/Complementary Methods to Animal Testing, University of Veterinary
      Medicine, 30173 Hannover, Germany.
FAU - Schjeide, Brit-Maren
AU  - Schjeide BM
AD  - Institute of Nutritional Science, Department of Nutritional Biochemistry,
      University of Potsdam, 14558 Nuthetal, Germany.
FAU - Puschel, Gerhard P
AU  - Puschel GP
AD  - Institute of Nutritional Science, Department of Nutritional Biochemistry,
      University of Potsdam, 14558 Nuthetal, Germany.
FAU - Seeger, Bettina
AU  - Seeger B
AUID- ORCID: 0000-0002-4653-2841
AD  - Institute for Food Toxicology, Department of Food Toxicology and
      Replacement/Complementary Methods to Animal Testing, University of Veterinary
      Medicine, 30173 Hannover, Germany.
LA  - eng
GR  - 031L0132A/B/Bundesministerium fur Bildung und Forschung/International
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200425
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 0 (Acetylcholine Release Inhibitors)
RN  - 0 (Neurotoxins)
RN  - EC 3.4.24.69 (Botulinum Toxins)
SB  - IM
MH  - Acetylcholine Release Inhibitors/*pharmacology/toxicity
MH  - Animal Testing Alternatives
MH  - Biological Assay
MH  - Botulinum Toxins/*pharmacology/toxicity
MH  - Cell Line
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*drug effects/metabolism
MH  - Motor Neurons/*drug effects/metabolism
MH  - Neural Stem Cells/*drug effects/metabolism
MH  - Neurogenesis/*drug effects
MH  - Neurotoxins/*pharmacology/toxicity
PMC - PMC7291138
OTO - NOTNLM
OT  - *Botulinum neurotoxin
OT  - *cell-based in vitro assay
OT  - *induced pluripotent stem cells
OT  - *motor neurons
OT  - *potency assessment
EDAT- 2020/04/30 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/04/30 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/04/12 00:00 [revised]
PHST- 2020/04/23 00:00 [accepted]
PHST- 2020/04/30 06:00 [entrez]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
AID - toxins12050276 [pii]
AID - 10.3390/toxins12050276 [doi]
PST - epublish
SO  - Toxins (Basel). 2020 Apr 25;12(5). pii: toxins12050276. doi:
      10.3390/toxins12050276.


PMID- 32344295
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 127
DP  - 2020 Jun
TI  - 3D-printed anatomic models of the knee for evaluation of patellofemoral dysplasia
      in comparison to standard radiographs and computed tomography.
PG  - 109011
LID - S0720-048X(20)30200-X [pii]
LID - 10.1016/j.ejrad.2020.109011 [doi]
AB  - PURPOSE: To evaluate 3D-printed anatomic models of the distal femur and patella
      for diagnosis and classification of patellofemoral dysplasia in comparison to
      conventional radiographs (CR) and CT. METHOD: Following local ethics committee
      approval, CT-datasets of 50 patients were segmented and 3D-anatomic models of the
      distal femur and patella were printed. An expert panel reviewed CR, CT, 3D-models
      and patient history and classified the femoral trochleas into normal or Dejour
      type A-D and the patellas into Wiberg type A-C, which served as the standard of
      reference. The same classifications were performed by two readers independently, 
      first based on 3D-models and after 3 weeks based on CR and CT. Descriptive
      statistics, ROC-analysis and inter-reader reliability were performed. RESULTS:
      Trochlear dysplasia was present in 28/50 patients. Evaluations of 3D-models vs.
      CR/CT for trochlear dysplasia showed a sensitivity/specificity of 89.3 %/100 %
      vs. 96.4 %/68.2 % for reader 1 and 96.4 %/100 % vs. 96.4 %/90.9 % for reader 2,
      and an area under the curve of 0.946 vs. 0.823 for reader 1 (p=0.029) and 0.982
      vs. 0.937 for reader 2 (p=0.147). Evaluations of 3D-models vs. CR/CT for the
      Dejour classification showed a sensitivity/specificity of 32.1 %/100 % vs. 57.1
      %/68.2 % for reader 1 and 46.4 %/100 % vs. 50 %/90.9 % for reader 2 without
      significant differences. No significant differences existed for
      Wiberg-classification (50-66 % exact matches) or inter-reader reliabilities
      between 3D-models and CR/CT for all assessments (Kappa 0.428-0.92). CONCLUSION:
      In comparison to radiographs and CT, 3D-models achieve similar diagnostic
      accuracy for detection of patellofemoral dysplasia and have the potential to
      improve diagnosis for less experienced physicians.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Fritz, Benjamin
AU  - Fritz B
AD  - Radiology, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich,
      Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
      Electronic address: benjamin.fritz@balgrist.ch.
FAU - Fucentese, Sandro F
AU  - Fucentese SF
AD  - Department of Orthopedic Surgery, Balgrist University Hospital, Forchstrasse 340,
      8008, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich,
      Switzerland.
FAU - Zimmermann, Stefan M
AU  - Zimmermann SM
AD  - Department of Orthopedic Surgery, Balgrist University Hospital, Forchstrasse 340,
      8008, Zurich, Switzerland; Faculty of Medicine, University of Zurich, Zurich,
      Switzerland.
FAU - Tscholl, Philippe M
AU  - Tscholl PM
AD  - Division of Orthopedics and Trauma Surgery, Geneva University Hospital, Rue
      Gabrielle-Perret-Gentil 4, University of Geneva, 1205, Geneva, Switzerland.
FAU - Sutter, Reto
AU  - Sutter R
AD  - Radiology, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich,
      Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
FAU - Pfirrmann, Christian W A
AU  - Pfirrmann CWA
AD  - Radiology, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich,
      Switzerland; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200418
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Joint Diseases/*diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - *Models, Anatomic
MH  - Patellofemoral Joint/*diagnostic imaging
MH  - *Printing, Three-Dimensional
MH  - Radiography/*methods
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Tomography, X-Ray Computed/methods
MH  - Young Adult
OTO - NOTNLM
OT  - 3D printing
OT  - Joint instability
OT  - Multidetector computed tomography
OT  - Patellofemoral joint
OT  - Radiography
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/29 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/04/29 06:00
PHST- 2019/12/24 00:00 [received]
PHST- 2020/02/21 00:00 [revised]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - S0720-048X(20)30200-X [pii]
AID - 10.1016/j.ejrad.2020.109011 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 Jun;127:109011. doi: 10.1016/j.ejrad.2020.109011. Epub 2020
      Apr 18.


PMID- 32343850
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20210429
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 4
DP  - 2020 Apr 28
TI  - Palliative drug treatments for breathlessness in cystic fibrosis.
PG  - CD011855
LID - 10.1002/14651858.CD011855.pub3 [doi]
AB  - BACKGROUND: Cystic fibrosis is a life-limiting autosomal recessive genetic
      illness. A feeling of shortness of breath is common in cystic fibrosis,
      especially as the disease progresses. Reversing the underlying cause is the
      priority when treating breathlessness (dyspnoea), but when it is not feasible,
      palliation (easing) becomes the primary goal to improve an individual's quality
      of life. A range of drugs administered by various routes have been used, but no
      definite guidelines are available. A systematic review is needed to evaluate such
      treatments. OBJECTIVES: To assess the efficacy and safety of drugs used to ease
      breathlessness in people with cystic fibrosis. SEARCH METHODS: We searched the
      Cochrane Cystic Fibrosis Trials Register, compiled from electronic database
      searches and handsearching of journals and conference abstract books. Date of
      last search: 18 November 2019. We searched databases (clinicaltrials.gov, the
      ISRCTN registry, the Clinical Trials Registry India and WHO ICTRP) for ongoing
      trials. These searches were last run on 06 March 2020. SELECTION CRITERIA: We
      planned to include randomised and quasi-randomised controlled trials in people
      with cystic fibrosis (diagnosed by a positive sweat chloride test or genetic
      testing) who have breathlessness. We considered studies comparing any drugs used 
      for easing breathlessness to another drug administered by any route (inhaled
      (nebulised), intravenous, oral, subcutaneous, transmucosal (including buccal,
      sublingual and intra-nasal) and transdermal). DATA COLLECTION AND ANALYSIS: The
      authors assessed the search results according to the pre-defined inclusion
      criteria. MAIN RESULTS: The new searches in 2020 yielded two ongoing studies that
      were not relevant to the review question. Previous searches had found only one
      study (cross-over in design), which did not fulfil the inclusion criteria as no
      data were available from the first treatment period alone. AUTHORS' CONCLUSIONS: 
      Due to the lack of available evidence, this review cannot provide any information
      for clinical practice. The authors call for specific research in this area after 
      taking into account relevant ethical considerations. The research should focus on
      the efficacy and safety of the drugs with efficacy being measured in terms of
      improvement in quality of life, dyspnoea scores and hospital stay.
CI  - Copyright (c) 2020 The Cochrane Collaboration. Published by John Wiley & Sons,
      Ltd.
FAU - Jaiswal, Nishant
AU  - Jaiswal N
AD  - ICMR Advanced Centre for Evidence-Based Child Health, Postgraduate Institute of
      Medical Education and Research, Chandigarh, India.
FAU - Singh, Meenu
AU  - Singh M
AD  - Department of Pediatrics, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Agarwal, Amit
AU  - Agarwal A
AD  - ICMR Advanced Centre for Evidence-Based Child Health, Postgraduate Institute of
      Medical Education and Research, Chandigarh, India.
FAU - Chauhan, Anil
AU  - Chauhan A
AD  - ICMR Advanced Centre for Evidence-Based Child Health, Postgraduate Institute of
      Medical Education and Research, Chandigarh, India.
FAU - Jaiswal, Nikita
AU  - Jaiswal N
AD  - Department of Microbiology, Maharishi Markandeshwar (Deemed to be University),
      Mullana-Ambala, India.
LA  - eng
GR  - National Institute for Health Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200428
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
SB  - IM
UOF - Cochrane Database Syst Rev. 2017 Aug 10;8:CD011855. PMID: 28795404
MH  - Cystic Fibrosis/*complications
MH  - Dyspnea/*drug therapy
MH  - Humans
MH  - Palliative Care/*methods
PMC - PMC7193675
EDAT- 2020/04/29 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 10.1002/14651858.CD011855.pub3 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2020 Apr 28;4:CD011855. doi:
      10.1002/14651858.CD011855.pub3.


PMID- 32343643
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20201218
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 38
IP  - 19
DP  - 2020 Jul 1
TI  - Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community
      During the COVID-19 Pandemic.
PG  - 2201-2205
LID - 10.1200/JCO.20.00960 [doi]
FAU - Marron, Jonathan M
AU  - Marron JM
AD  - Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical 
      School, Boston, MA.
FAU - Joffe, Steven
AU  - Joffe S
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
FAU - Jagsi, Reshma
AU  - Jagsi R
AD  - University of Michigan, Ann Arbor, MI.
FAU - Spence, Rebecca A
AU  - Spence RA
AD  - American Society of Clinical Oncology, Alexandria, VA.
FAU - Hlubocky, Fay J
AU  - Hlubocky FJ
AD  - The University of Chicago, Chicago, IL.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200428
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
SB  - IM
CON - JAMA. 2020 Mar 27;:null. PMID: 32219367
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Critical Care
MH  - Humans
MH  - Medical Oncology
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
EDAT- 2020/04/29 06:00
MHDA- 2020/07/04 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1200/JCO.20.00960 [doi]
PST - ppublish
SO  - J Clin Oncol. 2020 Jul 1;38(19):2201-2205. doi: 10.1200/JCO.20.00960. Epub 2020
      Apr 28.


PMID- 32342781
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20210315
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1
DP  - 2020 Mar
TI  - A Right to Privacy and Confidentiality: Ethical Medical Care for Patients in
      United States Immigration Detention.
PG  - 161-168
LID - 10.1177/1073110520917004 [doi]
AB  - Recently, John Doe, an undocumented immigrant who was detained by United States
      Immigration and Customs Enforcement (ICE), was admitted to a hospital off-site
      from a detention facility. Custodial officers accompanied Mr. Doe into the exam
      room and refused to leave as physicians examined him. In this analysis, we
      examine the ethical dilemmas this case brings to light concerning the treatment
      of patients in immigration detention and their rights to privacy. We analyze what
      US law and immigration detention standards allow regarding immigration
      enforcement or custodial officers' presence in medical exams and documentation of
      detainee health information. We describe the ethical implications of the presence
      of officers in medical exam rooms, including its effects on the quality of the
      patient-provider relationship, patient privacy and confidentiality, and
      provider's ability to provide ethical care. We conclude that the presence of
      immigration enforcement or custodial officers during medical examination of
      detainees is a breach of the right to privacy of detainees who are not an obvious
      threat to the public. We urge ICE and the US Department of Homeland Security to
      clarify standards for and tighten enforcement around when officers are legally
      allowed to be stationed in medical exam rooms and document detainees'
      information.
FAU - Gutierrez, Amanda M
AU  - Gutierrez AM
AD  - Amanda M. Gutierrez, M.P.H., is a Research Assistant at the Baylor College of
      Medicine Center for Medical Ethics and Health Policy in Houston, Texas. Jacob D. 
      Hofstetter, M.G.P.S., is a Research and Policy Associate at the Massachusetts
      Appleseed Center for Law and Justice in Boston, Massachusetts. Emma Dishner,
      M.D., M.P.H., recently graduated from her Infectious Diseases fellowship from
      Baylor College of Medicine in Houston, Texas and will soon begin working with
      North Texas Infectious Diseases Consultants. Elizabeth Chiao, M.D., M.P.H., is a 
      Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dilreet
      Rai, M.D., is a hospitalist at the Michael E. Debakey VA Medical Center in
      Houston, Texas. Amy L. McGuire, J.D., Ph.D., is the Leon Jaworski Professor of
      Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy
      at Baylor College of Medicine. Dr. McGuire serves on the program committee for
      the Greenwall Foundation Faculty Scholars Program in Bioethics and is immediate
      past president of the Association of Bioethics Program Directors.
FAU - Hofstetter, Jacob D
AU  - Hofstetter JD
AD  - Amanda M. Gutierrez, M.P.H., is a Research Assistant at the Baylor College of
      Medicine Center for Medical Ethics and Health Policy in Houston, Texas. Jacob D. 
      Hofstetter, M.G.P.S., is a Research and Policy Associate at the Massachusetts
      Appleseed Center for Law and Justice in Boston, Massachusetts. Emma Dishner,
      M.D., M.P.H., recently graduated from her Infectious Diseases fellowship from
      Baylor College of Medicine in Houston, Texas and will soon begin working with
      North Texas Infectious Diseases Consultants. Elizabeth Chiao, M.D., M.P.H., is a 
      Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dilreet
      Rai, M.D., is a hospitalist at the Michael E. Debakey VA Medical Center in
      Houston, Texas. Amy L. McGuire, J.D., Ph.D., is the Leon Jaworski Professor of
      Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy
      at Baylor College of Medicine. Dr. McGuire serves on the program committee for
      the Greenwall Foundation Faculty Scholars Program in Bioethics and is immediate
      past president of the Association of Bioethics Program Directors.
FAU - Dishner, Emma L
AU  - Dishner EL
AD  - Amanda M. Gutierrez, M.P.H., is a Research Assistant at the Baylor College of
      Medicine Center for Medical Ethics and Health Policy in Houston, Texas. Jacob D. 
      Hofstetter, M.G.P.S., is a Research and Policy Associate at the Massachusetts
      Appleseed Center for Law and Justice in Boston, Massachusetts. Emma Dishner,
      M.D., M.P.H., recently graduated from her Infectious Diseases fellowship from
      Baylor College of Medicine in Houston, Texas and will soon begin working with
      North Texas Infectious Diseases Consultants. Elizabeth Chiao, M.D., M.P.H., is a 
      Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dilreet
      Rai, M.D., is a hospitalist at the Michael E. Debakey VA Medical Center in
      Houston, Texas. Amy L. McGuire, J.D., Ph.D., is the Leon Jaworski Professor of
      Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy
      at Baylor College of Medicine. Dr. McGuire serves on the program committee for
      the Greenwall Foundation Faculty Scholars Program in Bioethics and is immediate
      past president of the Association of Bioethics Program Directors.
FAU - Chiao, Elizabeth
AU  - Chiao E
AD  - Amanda M. Gutierrez, M.P.H., is a Research Assistant at the Baylor College of
      Medicine Center for Medical Ethics and Health Policy in Houston, Texas. Jacob D. 
      Hofstetter, M.G.P.S., is a Research and Policy Associate at the Massachusetts
      Appleseed Center for Law and Justice in Boston, Massachusetts. Emma Dishner,
      M.D., M.P.H., recently graduated from her Infectious Diseases fellowship from
      Baylor College of Medicine in Houston, Texas and will soon begin working with
      North Texas Infectious Diseases Consultants. Elizabeth Chiao, M.D., M.P.H., is a 
      Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dilreet
      Rai, M.D., is a hospitalist at the Michael E. Debakey VA Medical Center in
      Houston, Texas. Amy L. McGuire, J.D., Ph.D., is the Leon Jaworski Professor of
      Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy
      at Baylor College of Medicine. Dr. McGuire serves on the program committee for
      the Greenwall Foundation Faculty Scholars Program in Bioethics and is immediate
      past president of the Association of Bioethics Program Directors.
FAU - Rai, Dilreet
AU  - Rai D
AD  - Amanda M. Gutierrez, M.P.H., is a Research Assistant at the Baylor College of
      Medicine Center for Medical Ethics and Health Policy in Houston, Texas. Jacob D. 
      Hofstetter, M.G.P.S., is a Research and Policy Associate at the Massachusetts
      Appleseed Center for Law and Justice in Boston, Massachusetts. Emma Dishner,
      M.D., M.P.H., recently graduated from her Infectious Diseases fellowship from
      Baylor College of Medicine in Houston, Texas and will soon begin working with
      North Texas Infectious Diseases Consultants. Elizabeth Chiao, M.D., M.P.H., is a 
      Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dilreet
      Rai, M.D., is a hospitalist at the Michael E. Debakey VA Medical Center in
      Houston, Texas. Amy L. McGuire, J.D., Ph.D., is the Leon Jaworski Professor of
      Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy
      at Baylor College of Medicine. Dr. McGuire serves on the program committee for
      the Greenwall Foundation Faculty Scholars Program in Bioethics and is immediate
      past president of the Association of Bioethics Program Directors.
FAU - McGuire, Amy L
AU  - McGuire AL
AD  - Amanda M. Gutierrez, M.P.H., is a Research Assistant at the Baylor College of
      Medicine Center for Medical Ethics and Health Policy in Houston, Texas. Jacob D. 
      Hofstetter, M.G.P.S., is a Research and Policy Associate at the Massachusetts
      Appleseed Center for Law and Justice in Boston, Massachusetts. Emma Dishner,
      M.D., M.P.H., recently graduated from her Infectious Diseases fellowship from
      Baylor College of Medicine in Houston, Texas and will soon begin working with
      North Texas Infectious Diseases Consultants. Elizabeth Chiao, M.D., M.P.H., is a 
      Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dilreet
      Rai, M.D., is a hospitalist at the Michael E. Debakey VA Medical Center in
      Houston, Texas. Amy L. McGuire, J.D., Ph.D., is the Leon Jaworski Professor of
      Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy
      at Baylor College of Medicine. Dr. McGuire serves on the program committee for
      the Greenwall Foundation Faculty Scholars Program in Bioethics and is immediate
      past president of the Association of Bioethics Program Directors.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
CIN - J Law Med Ethics. 2020 Mar;48(1):169-171. PMID: 32342784
MH  - Confidentiality/*legislation & jurisprudence
MH  - *Ethics, Medical
MH  - Humans
MH  - Jails
MH  - Law Enforcement
MH  - Male
MH  - Physical Examination/*ethics
MH  - Privacy/*legislation & jurisprudence
MH  - *Undocumented Immigrants
MH  - United States
EDAT- 2020/04/29 06:00
MHDA- 2021/03/13 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
AID - 10.1177/1073110520917004 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1):161-168. doi: 10.1177/1073110520917004.


PMID- 32342777
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20210312
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1
DP  - 2020 Mar
TI  - Australian Aboriginal and Torres Strait Islander Collections of Genetic Heritage:
      The Legal, Ethical and Practical Considerations of a Dynamic Consent Approach to 
      Decision Making.
PG  - 205-217
LID - 10.1177/1073110520917012 [doi]
AB  - Dynamic Consent (DC) is both a model and a specific web-based tool that enables
      clear, granular communication and recording of participant consent choices over
      time. The DC model enables individuals to know and to decide how personal
      research information is being used and provides a way in which to exercise legal 
      rights provided in privacy and data protection law. The DC tool is flexible and
      responsive, enabling legal and ethical requirements in research data sharing to
      be met and for online health information to be maintained. DC has been used in
      rare diseases and genomics, to enable people to control and express their
      preferences regarding their own data. However, DC has never been explored in
      relationship to historical collections of bioscientific and genetic heritage or
      to contexts involving Aboriginal and Torres Strait Islander people (First Peoples
      of Australia). In response to the growing interest by First Peoples throughout
      Australia in genetic and genomic research, and the increasing number of
      invitations from researchers to participate in community health and wellbeing
      projects, this article examines the legal and ethical attributes and challenges
      of DC in these contexts. It also explores opportunities for including First
      Peoples' cultural perspectives, governance, and leadership as a method for
      defining (or redefining) DC on cultural terms that engage best practice research 
      and data analysis as well as respect for meaningful and longitudinal individual
      and family participation.
FAU - Prictor, Megan
AU  - Prictor M
AD  - Megan Prictor, Ph.D., is a Research Fellow in health, law and emerging
      technologies at Melbourne Law School, the University of Melbourne, Australia. Her
      interdisciplinary research focuses on informed consent approaches, electronic
      health records and data privacy. Sharon Huebner, Ph.D., is a Research Fellow at
      the University of Melbourne's Indigenous Studies Unit and an honorary Research
      Fellow at the Monash Indigenous Studies Centre, Monash University. She has worked
      with Aboriginal and Torres Strait Islander families for the past two decades
      protecting and preserving intergenerational rights to cultural heritage,
      including the digital return of material culture from archives, libraries and
      museums. Harriet J.A. Teare, D.Phil. (Chemistry), is a researcher in healthcare
      and policy, and Deputy Director of the Centre for Health, Law and Emerging
      Technologies (HeLEX), the University of Oxford. Over the past 6 years she has
      been developing dynamic consent approaches, working with different patient groups
      and organisations to learn directly from potential users about how such a tool
      could benefit their research experience. Luke Burchill, Ph.D., is an Associate
      Professor of Medicine at the University of Melbourne, where he leads the
      Aboriginal cardiovascular health disparities program. Clinically he works as an
      Adult Congenital Heart Disease Specialist at Royal Melbourne Hospital. Associate 
      Professor Burchill is the first Aboriginal cardiologist in Australia. Jane Kaye, 
      D.Phil., is the Director of the Centre for Health, Law, and Emerging Technologies
      (HeLEX) at the University of Oxford and has a part-time Professorship at the
      University of Melbourne, Australia, where she also leads the HeLEX@Melbourne
      research team. The focus of Professor Kaye's research is on governance with an
      emphasis on personalised medicine, biobanks, privacy, data-sharing frameworks,
      international governance and translational research.
FAU - Huebner, Sharon
AU  - Huebner S
AD  - Megan Prictor, Ph.D., is a Research Fellow in health, law and emerging
      technologies at Melbourne Law School, the University of Melbourne, Australia. Her
      interdisciplinary research focuses on informed consent approaches, electronic
      health records and data privacy. Sharon Huebner, Ph.D., is a Research Fellow at
      the University of Melbourne's Indigenous Studies Unit and an honorary Research
      Fellow at the Monash Indigenous Studies Centre, Monash University. She has worked
      with Aboriginal and Torres Strait Islander families for the past two decades
      protecting and preserving intergenerational rights to cultural heritage,
      including the digital return of material culture from archives, libraries and
      museums. Harriet J.A. Teare, D.Phil. (Chemistry), is a researcher in healthcare
      and policy, and Deputy Director of the Centre for Health, Law and Emerging
      Technologies (HeLEX), the University of Oxford. Over the past 6 years she has
      been developing dynamic consent approaches, working with different patient groups
      and organisations to learn directly from potential users about how such a tool
      could benefit their research experience. Luke Burchill, Ph.D., is an Associate
      Professor of Medicine at the University of Melbourne, where he leads the
      Aboriginal cardiovascular health disparities program. Clinically he works as an
      Adult Congenital Heart Disease Specialist at Royal Melbourne Hospital. Associate 
      Professor Burchill is the first Aboriginal cardiologist in Australia. Jane Kaye, 
      D.Phil., is the Director of the Centre for Health, Law, and Emerging Technologies
      (HeLEX) at the University of Oxford and has a part-time Professorship at the
      University of Melbourne, Australia, where she also leads the HeLEX@Melbourne
      research team. The focus of Professor Kaye's research is on governance with an
      emphasis on personalised medicine, biobanks, privacy, data-sharing frameworks,
      international governance and translational research.
FAU - Teare, Harriet J A
AU  - Teare HJA
AD  - Megan Prictor, Ph.D., is a Research Fellow in health, law and emerging
      technologies at Melbourne Law School, the University of Melbourne, Australia. Her
      interdisciplinary research focuses on informed consent approaches, electronic
      health records and data privacy. Sharon Huebner, Ph.D., is a Research Fellow at
      the University of Melbourne's Indigenous Studies Unit and an honorary Research
      Fellow at the Monash Indigenous Studies Centre, Monash University. She has worked
      with Aboriginal and Torres Strait Islander families for the past two decades
      protecting and preserving intergenerational rights to cultural heritage,
      including the digital return of material culture from archives, libraries and
      museums. Harriet J.A. Teare, D.Phil. (Chemistry), is a researcher in healthcare
      and policy, and Deputy Director of the Centre for Health, Law and Emerging
      Technologies (HeLEX), the University of Oxford. Over the past 6 years she has
      been developing dynamic consent approaches, working with different patient groups
      and organisations to learn directly from potential users about how such a tool
      could benefit their research experience. Luke Burchill, Ph.D., is an Associate
      Professor of Medicine at the University of Melbourne, where he leads the
      Aboriginal cardiovascular health disparities program. Clinically he works as an
      Adult Congenital Heart Disease Specialist at Royal Melbourne Hospital. Associate 
      Professor Burchill is the first Aboriginal cardiologist in Australia. Jane Kaye, 
      D.Phil., is the Director of the Centre for Health, Law, and Emerging Technologies
      (HeLEX) at the University of Oxford and has a part-time Professorship at the
      University of Melbourne, Australia, where she also leads the HeLEX@Melbourne
      research team. The focus of Professor Kaye's research is on governance with an
      emphasis on personalised medicine, biobanks, privacy, data-sharing frameworks,
      international governance and translational research.
FAU - Burchill, Luke
AU  - Burchill L
AD  - Megan Prictor, Ph.D., is a Research Fellow in health, law and emerging
      technologies at Melbourne Law School, the University of Melbourne, Australia. Her
      interdisciplinary research focuses on informed consent approaches, electronic
      health records and data privacy. Sharon Huebner, Ph.D., is a Research Fellow at
      the University of Melbourne's Indigenous Studies Unit and an honorary Research
      Fellow at the Monash Indigenous Studies Centre, Monash University. She has worked
      with Aboriginal and Torres Strait Islander families for the past two decades
      protecting and preserving intergenerational rights to cultural heritage,
      including the digital return of material culture from archives, libraries and
      museums. Harriet J.A. Teare, D.Phil. (Chemistry), is a researcher in healthcare
      and policy, and Deputy Director of the Centre for Health, Law and Emerging
      Technologies (HeLEX), the University of Oxford. Over the past 6 years she has
      been developing dynamic consent approaches, working with different patient groups
      and organisations to learn directly from potential users about how such a tool
      could benefit their research experience. Luke Burchill, Ph.D., is an Associate
      Professor of Medicine at the University of Melbourne, where he leads the
      Aboriginal cardiovascular health disparities program. Clinically he works as an
      Adult Congenital Heart Disease Specialist at Royal Melbourne Hospital. Associate 
      Professor Burchill is the first Aboriginal cardiologist in Australia. Jane Kaye, 
      D.Phil., is the Director of the Centre for Health, Law, and Emerging Technologies
      (HeLEX) at the University of Oxford and has a part-time Professorship at the
      University of Melbourne, Australia, where she also leads the HeLEX@Melbourne
      research team. The focus of Professor Kaye's research is on governance with an
      emphasis on personalised medicine, biobanks, privacy, data-sharing frameworks,
      international governance and translational research.
FAU - Kaye, Jane
AU  - Kaye J
AD  - Megan Prictor, Ph.D., is a Research Fellow in health, law and emerging
      technologies at Melbourne Law School, the University of Melbourne, Australia. Her
      interdisciplinary research focuses on informed consent approaches, electronic
      health records and data privacy. Sharon Huebner, Ph.D., is a Research Fellow at
      the University of Melbourne's Indigenous Studies Unit and an honorary Research
      Fellow at the Monash Indigenous Studies Centre, Monash University. She has worked
      with Aboriginal and Torres Strait Islander families for the past two decades
      protecting and preserving intergenerational rights to cultural heritage,
      including the digital return of material culture from archives, libraries and
      museums. Harriet J.A. Teare, D.Phil. (Chemistry), is a researcher in healthcare
      and policy, and Deputy Director of the Centre for Health, Law and Emerging
      Technologies (HeLEX), the University of Oxford. Over the past 6 years she has
      been developing dynamic consent approaches, working with different patient groups
      and organisations to learn directly from potential users about how such a tool
      could benefit their research experience. Luke Burchill, Ph.D., is an Associate
      Professor of Medicine at the University of Melbourne, where he leads the
      Aboriginal cardiovascular health disparities program. Clinically he works as an
      Adult Congenital Heart Disease Specialist at Royal Melbourne Hospital. Associate 
      Professor Burchill is the first Aboriginal cardiologist in Australia. Jane Kaye, 
      D.Phil., is the Director of the Centre for Health, Law, and Emerging Technologies
      (HeLEX) at the University of Oxford and has a part-time Professorship at the
      University of Melbourne, Australia, where she also leads the HeLEX@Melbourne
      research team. The focus of Professor Kaye's research is on governance with an
      emphasis on personalised medicine, biobanks, privacy, data-sharing frameworks,
      international governance and translational research.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Australia/ethnology
MH  - Collections as Topic
MH  - Culture
MH  - *Decision Making
MH  - Genomics/*ethics
MH  - Human Rights
MH  - Humans
MH  - Indigenous Peoples/*genetics
MH  - Informed Consent/*ethics/*legislation & jurisprudence
MH  - Ownership
EDAT- 2020/04/29 06:00
MHDA- 2021/03/13 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
AID - 10.1177/1073110520917012 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1):205-217. doi: 10.1177/1073110520917012.


PMID- 32342775
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20210818
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1
DP  - 2020 Mar
TI  - Whether to Waive Parental Permission in HIV Prevention Research Among
      Adolescents: Ethical and Legal Considerations.
PG  - 188-201
LID - 10.1177/1073110520917010 [doi]
AB  - Critical ethical questions arise concerning whether studies among adolescents of 
      new behavioral and biomedical HIV preventive interventions such as Pre-Exposure
      Prophylaxis (PrEP) should obtain parental permission. This paper examines the
      relevant regulations and ethical guidance concerning waivers of parental
      permission, and arguments for and against such waivers. Opponents of such waivers
      may argue that adolescent decision-making is "too immature" and that parents
      always have rights to decide how to protect their children. Yet requiring
      parental permission may put adolescents at risk, and/or limit adolescent
      participation, jeopardizing study findings' validity. This paper presents
      recommendations on when researchers and Institutional Review Boards (IRB) should 
      waive parental permission, and what special protections should be adopted for
      adolescents who consent for themselves, e.g., assuring adolescent privacy and
      confidentiality, screening for capacity to consent, and identifying adolescents
      who are at elevated risk from study participation. We also present a series of
      specific areas for future research to design tools to help make these
      assessments, and to inform researcher and IRB decisions. These recommendations
      can help ensure that research is conducted that can aid adolescents at risk for
      HIV, while minimizing risks and protecting these individuals' rights as much as
      possible.
FAU - Bauman, Laurie J
AU  - Bauman LJ
AD  - Laurie J. Bauman, Ph.D., is Professor of Pediatrics and Psychiatry and Behavioral
      Sciences at the Albert Einstein College of Medicine, where she also serves as
      Director of the Preventive Intervention Research Center and of the Behavioral
      Science Core of the Einstein-Rockefeller-CUNY Center for AIDS Research. She is
      also Director of the Bio-Behavioral Core of the HIV Center for Clinical and
      Behavioral Studies. Her research addresses HIV prevention among adolescents,
      including behavioral interventions and adoption of PrEP. Claude Ann Mellins,
      Ph.D., is a clinical psychologist and Professor of Medical Psychology in
      Psychiatry and Sociomedical Sciences at the HIV Center for Clinical and
      Behavioral Studies at the New York State Psychiatric Institute and Columbia
      University. She is the co-director of the HIV Center with 28 years of clinical
      and research experience working globally with youth and families affected by HIV.
      Robert Klitzman, M.D., is a professor of psychiatry at the Vagelos College of
      Physicians and Surgeons and the Mailman School of Public Health, and the Director
      of the online and in-person Bioethics Masters and Certificate Programs at
      Columbia University. He has published over 150 scientific journal articles and
      nine books on ethical issues concerning HIV, genetics, research, and other areas.
FAU - Mellins, Claude Ann
AU  - Mellins CA
AD  - Laurie J. Bauman, Ph.D., is Professor of Pediatrics and Psychiatry and Behavioral
      Sciences at the Albert Einstein College of Medicine, where she also serves as
      Director of the Preventive Intervention Research Center and of the Behavioral
      Science Core of the Einstein-Rockefeller-CUNY Center for AIDS Research. She is
      also Director of the Bio-Behavioral Core of the HIV Center for Clinical and
      Behavioral Studies. Her research addresses HIV prevention among adolescents,
      including behavioral interventions and adoption of PrEP. Claude Ann Mellins,
      Ph.D., is a clinical psychologist and Professor of Medical Psychology in
      Psychiatry and Sociomedical Sciences at the HIV Center for Clinical and
      Behavioral Studies at the New York State Psychiatric Institute and Columbia
      University. She is the co-director of the HIV Center with 28 years of clinical
      and research experience working globally with youth and families affected by HIV.
      Robert Klitzman, M.D., is a professor of psychiatry at the Vagelos College of
      Physicians and Surgeons and the Mailman School of Public Health, and the Director
      of the online and in-person Bioethics Masters and Certificate Programs at
      Columbia University. He has published over 150 scientific journal articles and
      nine books on ethical issues concerning HIV, genetics, research, and other areas.
FAU - Klitzman, Robert
AU  - Klitzman R
AD  - Laurie J. Bauman, Ph.D., is Professor of Pediatrics and Psychiatry and Behavioral
      Sciences at the Albert Einstein College of Medicine, where she also serves as
      Director of the Preventive Intervention Research Center and of the Behavioral
      Science Core of the Einstein-Rockefeller-CUNY Center for AIDS Research. She is
      also Director of the Bio-Behavioral Core of the HIV Center for Clinical and
      Behavioral Studies. Her research addresses HIV prevention among adolescents,
      including behavioral interventions and adoption of PrEP. Claude Ann Mellins,
      Ph.D., is a clinical psychologist and Professor of Medical Psychology in
      Psychiatry and Sociomedical Sciences at the HIV Center for Clinical and
      Behavioral Studies at the New York State Psychiatric Institute and Columbia
      University. She is the co-director of the HIV Center with 28 years of clinical
      and research experience working globally with youth and families affected by HIV.
      Robert Klitzman, M.D., is a professor of psychiatry at the Vagelos College of
      Physicians and Surgeons and the Mailman School of Public Health, and the Director
      of the online and in-person Bioethics Masters and Certificate Programs at
      Columbia University. He has published over 150 scientific journal articles and
      nine books on ethical issues concerning HIV, genetics, research, and other areas.
LA  - eng
GR  - P30 MH043520/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Adolescent
MH  - Decision Making
MH  - Ethics Committees, Research
MH  - HIV Infections/*prevention & control
MH  - Humans
MH  - Informed Consent By Minors/*ethics/*legislation & jurisprudence
MH  - Parental Consent/*ethics/*legislation & jurisprudence
MH  - Pre-Exposure Prophylaxis
MH  - Research Personnel
MH  - *Research Subjects
MH  - United States
PMC - PMC8367279
MID - NIHMS1727000
EDAT- 2020/04/29 06:00
MHDA- 2021/03/13 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
AID - 10.1177/1073110520917010 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1):188-201. doi: 10.1177/1073110520917010.


PMID- 32342758
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1_suppl
DP  - 2020 Mar
TI  - mHealth Research Applied to Regulated and Unregulated Behavioral Health Sciences.
PG  - 49-59
LID - 10.1177/1073110520917029 [doi]
AB  - Behavioral scientists are developing new methods and frameworks that leverage
      mobile health technologies to optimize individual level behavior change.
      Pervasive sensors and mobile apps allow researchers to passively observe human
      behaviors "in the wild" 24/7 which supports delivery of personalized
      interventions in the real-world environment. This is all possible because these
      technologies contain an incredible array of sensors that allow applications to
      constantly record user location and can contextualize current environmental
      conditions through barometers, thermometers, and ambient light sensors and can
      also capture audio and video of the user and their surroundings through multiple 
      integrated high-definition cameras and microphones. These tools are a game
      changer in behavioral health research and, not surprisingly, introduce new
      ethical, regulatory/legal and social implications described in this article.
FAU - Nebeker, Camille
AU  - Nebeker C
AD  - Camille Nebeker, Ed.D, M.S., is an associate professor in the University of
      California, San Diego Department of Family Medicine and Public Health, with a
      primary appointment in Behavioral Medicine and a secondary appointment in Global 
      Health.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Behavioral Research/*methods/trends
MH  - Behavioral Sciences/*methods/trends
MH  - *Citizen Science
MH  - *Digital Technology
MH  - *Ethics, Research
MH  - Humans
MH  - *Telemedicine
EDAT- 2020/04/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1177/1073110520917029 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1_suppl):49-59. doi: 10.1177/1073110520917029.


PMID- 32342756
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1_suppl
DP  - 2020 Mar
TI  - Ethical Considerations in the Conduct of Unregulated mHealth Research: Expert
      Perspectives.
PG  - 9-36
LID - 10.1177/1073110520917027 [doi]
AB  - To assist in resolving ethical questions surrounding unregulated mHealth
      research, we conducted in-depth qualitative interviews with experts from four key
      stakeholder groups: patient/research advocates, researchers, regulatory
      professionals, and mobile app/device developers. They discussed challenges and
      potential solutions in the context of two hypothetical scenarios involving
      unregulated mHealth research, including notifications/permissions for research
      use of mHealth data, data access procedures, new primary data collection,
      offering individual research results, and data sharing and dissemination.
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Catherine M. Hammack-Aviran, M.A., J.D., is an Associate in Health Policy in the 
      Center for Biomedical Ethics and Society at Vanderbilt University Medical Center 
      (Nashville, TN). Kathleen M. Brelsford, M.P.H., Ph.D., is a Research Assistant
      Professor in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Laura M. Beskow, M.P.H., Ph.D., is a
      Professor and the Ann Geddes Stahlman Chair in Medical Ethics in the Center for
      Biomedical Ethics & Society at Vanderbilt University Medical Center (Nashville,
      TN).
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Catherine M. Hammack-Aviran, M.A., J.D., is an Associate in Health Policy in the 
      Center for Biomedical Ethics and Society at Vanderbilt University Medical Center 
      (Nashville, TN). Kathleen M. Brelsford, M.P.H., Ph.D., is a Research Assistant
      Professor in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Laura M. Beskow, M.P.H., Ph.D., is a
      Professor and the Ann Geddes Stahlman Chair in Medical Ethics in the Center for
      Biomedical Ethics & Society at Vanderbilt University Medical Center (Nashville,
      TN).
FAU - Beskow, Laura M
AU  - Beskow LM
AD  - Catherine M. Hammack-Aviran, M.A., J.D., is an Associate in Health Policy in the 
      Center for Biomedical Ethics and Society at Vanderbilt University Medical Center 
      (Nashville, TN). Kathleen M. Brelsford, M.P.H., Ph.D., is a Research Assistant
      Professor in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Laura M. Beskow, M.P.H., Ph.D., is a
      Professor and the Ann Geddes Stahlman Chair in Medical Ethics in the Center for
      Biomedical Ethics & Society at Vanderbilt University Medical Center (Nashville,
      TN).
LA  - eng
GR  - R01 CA207538/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Adult
MH  - Biomedical Research/*ethics
MH  - *Data Collection
MH  - Female
MH  - Humans
MH  - *Information Dissemination
MH  - Male
MH  - Middle Aged
MH  - *Mobile Applications
MH  - Qualitative Research
MH  - Research Personnel/*psychology
MH  - Telemedicine/*ethics
PMC - PMC7789882
MID - NIHMS1653590
EDAT- 2020/04/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1177/1073110520917027 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1_suppl):9-36. doi: 10.1177/1073110520917027.


PMID- 32342753
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1_suppl
DP  - 2020 Mar
TI  - Expert Perspectives on Oversight for Unregulated mHealth Research: Empirical Data
      and Commentary.
PG  - 138-146
LID - 10.1177/1073110520917039 [doi]
AB  - In qualitative interviews with a diverse group of experts, the vast majority
      believed unregulated researchers should seek out independent oversight. Reasons
      included the need for objectivity, protecting app users from research risks, and 
      consistency in standards for the ethical conduct of research. Concerns included
      burdening minimal risk research and limitations in current systems of oversight. 
      Literature and analysis supports the use of IRBs even when not required by
      regulations, and the need for evidence-based improvements in IRB processes.
FAU - Beskow, Laura M
AU  - Beskow LM
AD  - Laura M. Beskow, M.P.H., Ph.D., is a Professor and the Ann Geddes Stahlman Chair 
      in Medical Ethics in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Catherine M. Hammack-Aviran, M.A.,
      J.D., is an Associate in Health Policy in the Center for Biomedical Ethics and
      Society at Vanderbilt University Medical Center (Nashville, TN). Kathleen M.
      Brelsford, M.P.H., Ph.D., was a Research Assistant Professor in the Center for
      Biomedical Ethics and Society at Vanderbilt University Medical Center (Nashville,
      TN). P. Pearl O'Rourke, M.D., was the Director of Human Research Affairs at
      Partners HealthCare Systems in Boston and an Associate Professor of Pediatrics at
      Harvard Medical School (Somerville, MA).
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Laura M. Beskow, M.P.H., Ph.D., is a Professor and the Ann Geddes Stahlman Chair 
      in Medical Ethics in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Catherine M. Hammack-Aviran, M.A.,
      J.D., is an Associate in Health Policy in the Center for Biomedical Ethics and
      Society at Vanderbilt University Medical Center (Nashville, TN). Kathleen M.
      Brelsford, M.P.H., Ph.D., was a Research Assistant Professor in the Center for
      Biomedical Ethics and Society at Vanderbilt University Medical Center (Nashville,
      TN). P. Pearl O'Rourke, M.D., was the Director of Human Research Affairs at
      Partners HealthCare Systems in Boston and an Associate Professor of Pediatrics at
      Harvard Medical School (Somerville, MA).
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Laura M. Beskow, M.P.H., Ph.D., is a Professor and the Ann Geddes Stahlman Chair 
      in Medical Ethics in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Catherine M. Hammack-Aviran, M.A.,
      J.D., is an Associate in Health Policy in the Center for Biomedical Ethics and
      Society at Vanderbilt University Medical Center (Nashville, TN). Kathleen M.
      Brelsford, M.P.H., Ph.D., was a Research Assistant Professor in the Center for
      Biomedical Ethics and Society at Vanderbilt University Medical Center (Nashville,
      TN). P. Pearl O'Rourke, M.D., was the Director of Human Research Affairs at
      Partners HealthCare Systems in Boston and an Associate Professor of Pediatrics at
      Harvard Medical School (Somerville, MA).
FAU - O'Rourke, P Pearl
AU  - O'Rourke PP
AD  - Laura M. Beskow, M.P.H., Ph.D., is a Professor and the Ann Geddes Stahlman Chair 
      in Medical Ethics in the Center for Biomedical Ethics and Society at Vanderbilt
      University Medical Center (Nashville, TN). Catherine M. Hammack-Aviran, M.A.,
      J.D., is an Associate in Health Policy in the Center for Biomedical Ethics and
      Society at Vanderbilt University Medical Center (Nashville, TN). Kathleen M.
      Brelsford, M.P.H., Ph.D., was a Research Assistant Professor in the Center for
      Biomedical Ethics and Society at Vanderbilt University Medical Center (Nashville,
      TN). P. Pearl O'Rourke, M.D., was the Director of Human Research Affairs at
      Partners HealthCare Systems in Boston and an Associate Professor of Pediatrics at
      Harvard Medical School (Somerville, MA).
LA  - eng
GR  - R01 CA207538/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Biomedical Research/*ethics/*legislation & jurisprudence
MH  - Ethics Committees, Research
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - *Mobile Applications
MH  - Qualitative Research
MH  - Research Personnel/classification/*psychology
MH  - *Telemedicine
PMC - PMC7783510
MID - NIHMS1653589
EDAT- 2020/04/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1177/1073110520917039 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1_suppl):138-146. doi: 10.1177/1073110520917039.


PMID- 32342752
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210507
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1_suppl
DP  - 2020 Mar
TI  - Unregulated Health Research Using Mobile Devices: Ethical Considerations and
      Policy Recommendations.
PG  - 196-226
LID - 10.1177/1073110520917047 [doi]
AB  - Mobile devices with health apps, direct-to-consumer genetic testing,
      crowd-sourced information, and other data sources have enabled research by new
      classes of researchers. Independent researchers, citizen scientists,
      patient-directed researchers, self-experimenters, and others are not covered by
      federal research regulations because they are not recipients of federal financial
      assistance or conducting research in anticipation of a submission to the FDA for 
      approval of a new drug or medical device. This article addresses the difficult
      policy challenge of promoting the welfare and interests of research participants,
      as well as the public, in the absence of regulatory requirements and without
      discouraging independent, innovative scientific inquiry. The article recommends a
      series of measures, including education, consultation, transparency,
      self-governance, and regulation to strike the appropriate balance.
FAU - Rothstein, Mark A
AU  - Rothstein MA
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Wilbanks, John T
AU  - Wilbanks JT
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Beskow, Laura M
AU  - Beskow LM
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Brothers, Kyle B
AU  - Brothers KB
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Doerr, Megan
AU  - Doerr M
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Evans, Barbara J
AU  - Evans BJ
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - McGowan, Michelle L
AU  - McGowan ML
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
FAU - Tovino, Stacey A
AU  - Tovino SA
AD  - Mark A. Rothstein, J.D., is Herbert F. Boehl Chair of Law and Medicine and
      Director of the Institute for Bioethics, Health Policy and Law at the University 
      of Louisville School of Medicine. John T. Wilbanks is Chief Commons Officer of
      Sage Bionetworks. Laura M. Beskow, M.P.H., Ph.D., is Professor and Ann Geddes
      Stahlman Chair in Medical Ethics at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center Kathleen M. Brelsford, Ph.D., M.P.H., is
      Research Assistant Professor at the Center for Biomedical Ethics and Society,
      Vanderbilt University Medical Center. Kyle B. Brothers, M.D., Ph.D., is Endowed
      Chair of Pediatric Clinical and Translational Research, University of Louisville 
      School of Medicine. Megan Doerr, M.S., L.G.C., is Principal Scientist, Governance
      at Sage Bionetworks. Barbara J. Evans, J.D., Ph.D., is Mary Ann and Lawrence E.
      Faust Professor of Law, Professor of Electrical and Computer Engineering, and
      Director of the Center for Biotechnology and Law, University of Houston.
      Catherine M. Hammack-Aviran, M.A., J.D., is Associate in Health Policy at the
      Center for Biomedical Ethics and Society, Vanderbilt University Medical Center.
      Michelle L. McGowan, Ph.D., is Associate Professor, Department of Pediatrics and 
      Department of Women's, Gender, and Sexuality Studies, Cincinnati Children's
      Hospital Medical Center. Stacey A. Tovino, J.D., Ph.D., is Judge Jack and Lulu
      Lehman Professor of Law at the William S. Boyd School of Law, University of
      Nevada-Las Vegas.
LA  - eng
GR  - R01 CA207538/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Biomedical Research/*legislation & jurisprudence/trends
MH  - *Computers, Handheld
MH  - *Ethics, Research
MH  - Guidelines as Topic
MH  - Humans
MH  - *Mobile Applications
MH  - *Policy
MH  - Research Personnel/classification
MH  - *Telemedicine
MH  - United States
EDAT- 2020/04/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1177/1073110520917047 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1_suppl):196-226. doi: 10.1177/1073110520917047.


PMID- 32342743
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210528
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1_suppl
DP  - 2020 Mar
TI  - Data Sharing in the Context of Health-Related Citizen Science.
PG  - 167-177
LID - 10.1177/1073110520917044 [doi]
AB  - As citizen science expands, questions arise regarding the applicability of norms 
      and policies created in the context of conventional science. This article focuses
      on data sharing in the conduct of health-related citizen science, asking whether 
      citizen scientists have obligations to share data and publish findings on par
      with the obligations of professional scientists. We conclude that there are good 
      reasons for supporting citizen scientists in sharing data and publishing
      findings, and we applaud recent efforts to facilitate data sharing. At the same
      time, we believe it is problematic to treat data sharing and publication as
      ethical requirements for citizen scientists, especially where there is the
      potential for burden and harm without compensating benefit.
FAU - Majumder, Mary A
AU  - Majumder MA
AD  - Mary A. Majumder, J.D., Ph.D., is an Associate Professor of Medicine at the
      Center for Medical Ethics and Health Policy, Baylor College of Medicine. Amy L.
      McGuire, J.D., Ph.D., is the Leon Jaworski Professor of Biomedical Ethics and
      Director of the Center for Medical Ethics and Health Policy at Baylor College of 
      Medicine. Dr. McGuire serves on the program committee for the Greenwall
      Foundation Faculty Scholars Program in Bioethics and is immediate past president 
      of the Association of Bioethics Program Directors.
FAU - McGuire, Amy L
AU  - McGuire AL
AD  - Mary A. Majumder, J.D., Ph.D., is an Associate Professor of Medicine at the
      Center for Medical Ethics and Health Policy, Baylor College of Medicine. Amy L.
      McGuire, J.D., Ph.D., is the Leon Jaworski Professor of Biomedical Ethics and
      Director of the Center for Medical Ethics and Health Policy at Baylor College of 
      Medicine. Dr. McGuire serves on the program committee for the Greenwall
      Foundation Faculty Scholars Program in Bioethics and is immediate past president 
      of the Association of Bioethics Program Directors.
LA  - eng
GR  - R01 CA207538/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - *Citizen Science
MH  - Humans
MH  - *Information Dissemination
MH  - *Scholarly Communication
EDAT- 2020/04/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1177/1073110520917044 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1_suppl):167-177. doi: 10.1177/1073110520917044.


PMID- 32342738
OWN - NLM
STAT- MEDLINE
DCOM- 20210409
LR  - 20210409
IS  - 1748-720X (Electronic)
IS  - 1073-1105 (Linking)
VI  - 48
IP  - 1_suppl
DP  - 2020 Mar
TI  - The Perils of Parity: Should Citizen Science and Traditional Research Follow the 
      Same Ethical and Privacy Principles?
PG  - 74-81
LID - 10.1177/1073110520917031 [doi]
AB  - The individual right of access to one's own data is a crucial privacy protection 
      long recognized in U.S. federal privacy laws. Mobile health devices and research 
      software used in citizen science often fall outside the HIPAA Privacy Rule,
      leaving participants without HIPAA's right of access to one's own data. Absent
      state laws requiring access, the law of contract, as reflected in end-user
      agreements and terms of service, governs individuals' ability to find out how
      much data is being stored and how it might be shared with third parties. Efforts 
      to address this problem by establishing norms of individual access to data from
      mobile health research unfortunately can run afoul of the FDA's investigational
      device exemption requirements.
FAU - Evans, Barbara J
AU  - Evans BJ
AD  - Barbara J. Evans, Ph.D., J.D., LL.M., is the Mary Ann and Lawrence E. Faust
      Professor of Law, a Professor of Electrical and Computer Engineering, and the
      Director of the Center for Biotechnology & Law at the University of Houston.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - J Law Med Ethics
JT  - The Journal of law, medicine & ethics : a journal of the American Society of Law,
      Medicine & Ethics
JID - 9315583
MH  - Citizen Science/*ethics
MH  - Confidentiality/*legislation & jurisprudence
MH  - Equipment and Supplies
MH  - Health Insurance Portability and Accountability Act
MH  - Humans
MH  - Patient Access to Records/*legislation & jurisprudence
MH  - Privacy/*legislation & jurisprudence
MH  - Software/*legislation & jurisprudence
MH  - *Telemedicine
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2020/04/29 06:00
MHDA- 2021/04/10 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/10 06:00 [medline]
AID - 10.1177/1073110520917031 [doi]
PST - ppublish
SO  - J Law Med Ethics. 2020 Mar;48(1_suppl):74-81. doi: 10.1177/1073110520917031.


PMID- 32342574
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1099-0879 (Electronic)
IS  - 1063-3995 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Nov
TI  - Predicting boundary violation propensity among mental health professionals.
PG  - 814-825
LID - 10.1002/cpp.2465 [doi]
AB  - Despite its clear importance, there have been very few empirical investigations
      of boundary violation propensity among mental health professionals. The present
      study explored the relationships between self-reported propensity for boundary
      violations and predictors theorized to increase their likelihood. Australian
      mental health professionals (N = 275) completed an online questionnaire battery
      including demographics, the Sexual Boundary Violation Index, Boundaries In
      Practice Scale, Boundary Violations Propensity Questionnaire, Marlow-Crowne
      Social Desirability Scale, Circumplex of Interpersonal Problems, Brief Inventory 
      of Pathological Narcissism, Barratt Impulsiveness Scale Brief Version,
      Satisfaction with Life Scale, Brief Experiential Avoidance Questionnaire, Adverse
      Childhood Experiences Questionnaire, and the Interpersonal Reactivity Index.
      Regression analysis was used to identify unique predictors. Boundary violation
      propensity was associated with nurturant interpersonal styles in females and
      dominant interpersonal styles in males. In regression analysis, unique predictors
      for male boundary violation propensity were grandiose narcissism, vulnerable
      narcissism, self-centred interpersonal traits, and low levels of empathic
      concern. For females, unique predictors were impulsivity, childhood adversity,
      self-sacrificing interpersonal traits, and vulnerable narcissism. In addition to 
      informing theory about those at risk of perpetrating boundary violations, the
      identified predictors can inform those involved in selection for training
      programmes and staff appointments and serve as markers for providing closer
      supervision.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Dickeson, Edward
AU  - Dickeson E
AUID- ORCID: https://orcid.org/0000-0002-8452-2097
AD  - School of Psychology, University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Roberts, Rachel
AU  - Roberts R
AUID- ORCID: https://orcid.org/0000-0002-9547-9995
AD  - School of Psychology, University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Smout, Matthew F
AU  - Smout MF
AUID- ORCID: https://orcid.org/0000-0002-6952-6014
AD  - University of South Australia Magill Campus, Magill, South Australia, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - England
TA  - Clin Psychol Psychother
JT  - Clinical psychology & psychotherapy
JID - 9416196
SB  - IM
MH  - Australia
MH  - Empathy
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mental Health
MH  - *Narcissism
MH  - Social Behavior
OTO - NOTNLM
OT  - interpersonal circumplex
OT  - mental-health professionals
OT  - narcissism
OT  - professional ethics
OT  - therapeutic boundaries
EDAT- 2020/04/29 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/04/21 00:00 [revised]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1002/cpp.2465 [doi]
PST - ppublish
SO  - Clin Psychol Psychother. 2020 Nov;27(6):814-825. doi: 10.1002/cpp.2465. Epub 2020
      May 19.


PMID- 32342442
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 1
DP  - 2020 May
TI  - Vulnerability in human research.
PG  - 68-82
LID - 10.1007/s40592-020-00110-4 [doi]
AB  - The conduct of prior ethics review of human research projects helps to protect
      vulnerable groups or populations from potential negative impacts of research.
      Contemporary considerations in human research considers the concept of
      vulnerability in terms of access to research opportunities, impacts on the
      consenting process, selection bias, and the generalisability of results. Recent
      work questions the validity of using enumerated lists as a check box approach to 
      protect research participants from exploitation. Through the use of broad
      categories to treat cohorts of human research participants as homogenous classes 
      and label some participants as vulnerable merely because they are members of a
      particular class, some ethics reviewers have used the National Statement on
      Ethical Conduct in Human Research to strip individuals of their "ethical
      equality". Labelling people as vulnerable does not help researchers or human
      research ethics committee members develop an understanding of the complexities of
      applying the principles of respect and of justice in ethical decision-making.
      Conversely, defining specific cohorts of research participants as needing nuanced
      ethical consideration, due to their vulnerable nature, may imply that other
      population groups need not be considered vulnerable. We contend that this
      assumption is erroneous. This paper explores the way that human research ethics
      guidance documents treat vulnerability within the Australian context and draws on
      contemporary discussion to focus an alternative perspective based on the
      principles in the National Statement on Ethical Conduct in Human Research for
      researchers and human research ethics committee members to consider.
FAU - Pieper, Ian J
AU  - Pieper IJ
AUID- ORCID: http://orcid.org/0000-0003-4838-224X
AD  - Australian Centre for Health Law Research, Queensland University of Technology, 2
      George St., Brisbane, QLD, 4000, Australia. pieper@live.co.uk.
FAU - Thomson, Colin J H
AU  - Thomson CJH
AD  - Australasian Human Research Ethics Consultancy Services Pty Ltd, Brisbane,
      Australia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - Checklist
MH  - Comprehension
MH  - Decision Making
MH  - *Ethics Committees, Research
MH  - *Ethics, Research
MH  - Guidelines as Topic
MH  - *Human Experimentation
MH  - Humans
MH  - Informed Consent
MH  - *Personhood
MH  - *Research Design
MH  - Research Subjects
MH  - *Social Justice
MH  - *Vulnerable Populations
OTO - NOTNLM
OT  - Human Research Ethics
OT  - Human Research Ethics Committee (HREC)
OT  - IRB
OT  - Vulnerability
EDAT- 2020/04/29 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1007/s40592-020-00110-4 [doi]
AID - 10.1007/s40592-020-00110-4 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 May;38(1):68-82. doi: 10.1007/s40592-020-00110-4.


PMID- 32341729
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1935-7877 (Print)
IS  - 1935-7877 (Linking)
VI  - 21
IP  - 1
DP  - 2020
TI  - Using Student-Led Discussion and Reflection of a Public Health-Related Nonfiction
      Book as a Tool to Encourage Inclusive Pedagogy in an Undergraduate Classroom.
LID - 21.1.26 [pii]
LID - 10.1128/jmbe.v21i1.2069 [doi]
AB  - Educators realize the need to provide an inclusive, safe environment in a diverse
      classroom setting to encourage discussion of sensitive topics. However,
      descriptions of evidence-based approaches that may help us to meet inclusive
      pedagogy-related competencies are limited. Here, we describe a discussion format 
      that followed chapter readings from a nonfiction biographical book called
      Mountains beyond Mountains: The Quest of Dr. Paul Farmer, a Man Who Would Cure
      the World (2003), by Tracy Kidder. This semester-long effort allowed sufficient
      time for students to develop an understanding of global public health affairs and
      to reflect on their own role in this world as responsible citizens. A discussion 
      around several sensitive issues emerged, such as the extent of their belief in
      faith versus science, their opinion on providing financial aid to developing
      countries versus addressing public health issues in their home country,
      stereotypes and how that may spread panic during a public-health emergency. The
      student essays provided evidence that activities were successful in 1) drawing
      out students' voices about world affairs, 2) teaching students to empathize with 
      varied belief systems, 3) helping students develop a deeper appreciation of
      empirical and ethical factors that may affect such issues-all of which are key
      competencies for an inclusive classroom setting. We believe that the activities
      are flexible in structure and could be easily incorporated into a biology or
      liberal arts classroom setting to achieve inclusive pedagogy-related goals.
CI  - (c)2020 Author(s). Published by the American Society for Microbiology.
FAU - Pandey, Sumali
AU  - Pandey S
AD  - Biosciences Department, Minnesota State University Moorhead, Moorhead, MN 56563.
FAU - Wisenden, Patricia
AU  - Wisenden P
AD  - Biosciences Department, Minnesota State University Moorhead, Moorhead, MN 56563.
FAU - Shegrud, Whitney R
AU  - Shegrud WR
AD  - Biosciences Department, Minnesota State University Moorhead, Moorhead, MN 56563.
LA  - eng
PT  - Journal Article
DEP - 20200410
PL  - United States
TA  - J Microbiol Biol Educ
JT  - Journal of microbiology & biology education
JID - 101543341
PMC - PMC7173629
EDAT- 2020/04/29 06:00
MHDA- 2020/04/29 06:01
CRDT- 2020/04/29 06:00
PHST- 2019/09/29 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/04/29 06:01 [medline]
AID - 10.1128/jmbe.v21i1.2069 [doi]
AID - jmbe-21-26 [pii]
PST - epublish
SO  - J Microbiol Biol Educ. 2020 Apr 10;21(1). pii: jmbe-21-26. doi:
      10.1128/jmbe.v21i1.2069. eCollection 2020.


PMID- 32341719
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220209
IS  - 1878-5077 (Print)
IS  - 1878-5077 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Jun
TI  - Covid-19 pandemic by the "real-time" monitoring: the Tunisian case and lessons
      for global epidemics in the context of 3PM strategies.
PG  - 133-138
LID - 10.1007/s13167-020-00207-0 [doi]
AB  - Covid-19 is neither the first nor the last viral epidemic which societies around 
      the world are, were and will be affected by. Which lessons should be taken from
      the current pandemic situation? The Covid-19 disease is still not well
      characterised, and many research teams all over the world are working on
      prediction of the epidemic scenario, protective measures to populations and
      sub-populations, therapeutic and vaccination issues, amongst others.
      Contextually, countries with currently low numbers of Covid-19-infected
      individuals such as Tunisia are intended to take lessons from those countries
      which already reached the exponential phase of the infection distribution as well
      as from those which have the exponential phase behind them and record a minor
      number of new cases such as China. To this end, in Tunisia, the pandemic wave has
      started with a significant delay compared with Europe, the main economic partner 
      of the country. In this paper, we do analyse the current pandemic situation in
      this country by studying the infection evolution and considering potential
      protective strategies to prevent a pandemic scenario. The model is predictive
      based on a large number of undetected Covid-19 cases that is particularly true
      for some country regions such as Sfax. Infection distribution and mortality rate 
      analysis demonstrate a highly heterogeneous picture over the country. Qualitative
      and quantitative comparative analysis leads to a conclusion that the reliable
      "real-time" monitoring based on the randomised laboratory tests is the optimal
      predictive strategy to create the most effective evidence-based preventive
      measures. In contrast, lack of tests may lead to incorrect political decisions
      causing either unnecessary over-protection of the population that is risky for a 
      long-term economic recession, or under-protection of the population leading to a 
      post-containment pandemic rebound. Recommendations are provided in the context of
      advanced predictive, preventive and personalised (3P) medical approach.
CI  - (c) The Author(s) 2020.
FAU - Chaari, Lotfi
AU  - Chaari L
AD  - University of Toulouse, IRIT - INP-ENSEEIHT (UMR 5505), 2 rue Charles Camichel,
      BP 7122 Toulouse Cedex 7, France.grid.11417.320000 0001 2353 1689
FAU - Golubnitschaja, Olga
AU  - Golubnitschaja O
AD  - Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation
      Oncology, Friedrich-Wilhelms-University Bonn, Bonn, Germany.grid.10388.320000
      0001 2240 3300
LA  - eng
PT  - Journal Article
DEP - 20200425
PL  - Switzerland
TA  - EPMA J
JT  - The EPMA journal
JID - 101517307
PMC - PMC7182506
OTO - NOTNLM
OT  - Anti-body
OT  - Anti-gene
OT  - Bottle-neck
OT  - Comorbidities
OT  - Covid-19
OT  - Depression
OT  - Economy
OT  - Epidemics
OT  - Ethics
OT  - Home isolation
OT  - Individual outcomes
OT  - Infection
OT  - Laboratory medicine
OT  - Multi-professional expertise
OT  - Pandemic
OT  - Policymaking
OT  - Population screening
OT  - Predictive preventive personalised (3P) medicine
OT  - Psychotic attitude
OT  - Related mortality
OT  - SARS-CoV-2
OT  - Salami-tactic
OT  - Strategy
OT  - Suicide
OT  - Suppressed immune defence
OT  - Targeted protective measures
OT  - Test
OT  - Titanic
OT  - Triage
OT  - Violence
OT  - "Real-time" monitoring
COIS- Conflict of interestThe authors declare that they have no conflict of interest.
EDAT- 2020/04/29 06:00
MHDA- 2020/04/29 06:01
CRDT- 2020/04/29 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/04/29 06:01 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1007/s13167-020-00207-0 [doi]
AID - 207 [pii]
PST - epublish
SO  - EPMA J. 2020 Apr 25;11(2):133-138. doi: 10.1007/s13167-020-00207-0. eCollection
      2020 Jun.


PMID- 32341418
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210427
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Apr 27
TI  - Assessing TEG6S reliability between devices and across multiple time points: A
      prospective thromboelastography validation study.
PG  - 7045
LID - 10.1038/s41598-020-63964-y [doi]
AB  - The TEG6S is a novel haemostasis analyser utilising resonance technology. It
      offers potentially greater coagulation information and ease of use, however has
      not been independently validated in a clinical setting. We aimed to determine if 
      the TEG6S is reliable between devices and across time points. We performed a
      prospective observational study with ethical approval. For interdevice
      reliability, we performed simultaneous analysis on two TEG6S devices on 25 adult 
      ICU patients. For time point reliability, we performed repeated sampling across
      five different time points on 15 adult participants. Blood was collected with
      informed consent, or as standard care, before four-channel citrated kaolin
      analysis. We observed almost perfect interdevice reliability across all TEG
      parameters. The Lin's concordance correlation coefficients (95% CI, major axis
      regression slope, intercept) were R-time: 0.96 (0.92-0.99, 0.88, 0.57); K-time:
      0.93 (0.87-0.98, 1.07, 0.00); Alpha Angle: 0.87 (0.78-0.96, 1.20, -14.10);
      Maximum Amplitude: 0.99 (0.98-0.99, 1.02, -1.38); Clot Lysis: 0.89 (0.82-0.97,
      1.20, 0.07). Additionally, we observed moderate-to-high reliability across time
      points. Demonstrating almost perfect agreement across different devices and
      moderate-to-high reliability across multiple time points, suggests the TEG6S
      platform can be used with haemostatic accuracy and generalisability. This has
      potentially significant implications for clinical practice and multi-site
      research programs.
FAU - Lloyd-Donald, Patryck
AU  - Lloyd-Donald P
AD  - Department of Anaesthesia, Austin Hospital, 145 Studley Rd, Heidelberg, 3084,
      Victoria, Australia.
FAU - Churilov, Leonid
AU  - Churilov L
AD  - Department of Medicine, Austin Health, Melbourne Medical School, University of
      Melbourne, 245 Burgundy St, Heidelberg, 3084, Victoria, Australia.
FAU - Cheong, Brandon
AU  - Cheong B
AD  - Department of Anaesthesia, Austin Hospital, 145 Studley Rd, Heidelberg, 3084,
      Victoria, Australia.
FAU - Bellomo, Rinaldo
AU  - Bellomo R
AD  - Department of Intensive Care, Austin Hospital, 145 Studley Rd, Heidelberg, 3084, 
      Victoria, Australia.
FAU - McCall, Peter R
AU  - McCall PR
AD  - Department of Anaesthesia, Austin Hospital, 145 Studley Rd, Heidelberg, 3084,
      Victoria, Australia.
FAU - Martensson, Johan
AU  - Martensson J
AD  - Department of Perioperative Medicine and Intensive Care Medicine, Karolinska
      University Hospital, Solna, and Department of Physiology and Pharmacology,
      Karolinska Institutet, SE-171 77, Stockholm, Sweden.
FAU - Glassford, Neil
AU  - Glassford N
AD  - Department of Intensive Care, Austin Hospital, 145 Studley Rd, Heidelberg, 3084, 
      Victoria, Australia.
FAU - Weinberg, Laurence
AU  - Weinberg L
AUID- ORCID: http://orcid.org/0000-0001-7403-7680
AD  - Department of Anaesthesia, Austin Hospital, 145 Studley Rd, Heidelberg, 3084,
      Victoria, Australia. laurence.weinberg@austin.org.au.
AD  - Department of Surgery, Austin Health, University of Melbourne, 3010 Victoria,
      Australia. laurence.weinberg@austin.org.au.
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 24H4NWX5CO (Kaolin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Coagulation/physiology
MH  - Female
MH  - Hemostasis/physiology
MH  - Humans
MH  - Kaolin/chemistry
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Thrombelastography/*methods
MH  - Young Adult
PMC - PMC7184600
EDAT- 2020/04/29 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/29 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-63964-y [doi]
AID - 10.1038/s41598-020-63964-y [pii]
PST - epublish
SO  - Sci Rep. 2020 Apr 27;10(1):7045. doi: 10.1038/s41598-020-63964-y.


PMID- 32341186
OWN - NLM
STAT- Publisher
LR  - 20200428
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 27
TI  - Ethics of resuscitation for extremely premature infants: a systematic review of
      argument-based literature.
LID - medethics-2020-106102 [pii]
LID - 10.1136/medethics-2020-106102 [doi]
AB  - OBJECTIVE: To present (1) the ethical concepts related to the debate on
      resuscitation of extremely premature infants (EPIs) as they are described in the 
      ethical literature; and (2) the ethical arguments based on these concepts.
      DESIGN: We conducted a systematic review of the ethical literature. We selected
      articles based on the following predefined inclusion/exclusion criteria: (1)
      English language articles (2) presenting fully elaborated ethical arguments (3)
      on resuscitation (4) of EPIs, that is, infants born before 28 weeks of gestation.
      ANALYSIS: After repeated reading of articles, we developed individual summaries, 
      conceptual schemes and an overall conceptual scheme. Ethical arguments and
      concepts were identified and analysed. RESULTS: Forty articles were included out 
      of 4709 screened. Personhood, best interest, autonomy and justice were concepts
      grounding the various arguments. Regarding these concepts, included authors
      agreed that the best interest principle should guide resuscitation decisions,
      whereas justice seemed the least important concept. The arguments addressed two
      questions: Should we resuscitate EPIs? Who should decide? Included authors agreed
      that not all EPIs should be resuscitated but disagreed on what criteria should
      ground this decision. Overall, included authors agreed that both parents and
      physicians should contribute to the decision. CONCLUSIONS: The included
      publications suggest that while the best interest is the main concept guiding
      resuscitation decisions, justice is the least important. The included authors
      also agree that both parents and physicians should be actively involved in
      resuscitation decisions for EPIs. However, our results suggest that parents'
      decision should be over-ridden when in contrast with the EPI's best interest.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Cavolo, Alice
AU  - Cavolo A
AD  - Centre for Biomedical Ethics and Law, Department of Public Health and Primary
      Care, KU Leuven Biomedical Sciences Group, Leuven, Belgium
      alice.cavolo@kuleuven.be.
FAU - Dierckx de Casterle, Bernadette
AU  - Dierckx de Casterle B
AD  - Academic Centre for Nursing and Midwifery, Department of Public Health and
      Primary Care, KU Leuven Biomedical Sciences Group, Leuven, Belgium.
FAU - Naulaers, Gunnar
AU  - Naulaers G
AD  - Pregnancy, Fetus and Newborn, Department of Development and Regeneration, KU
      Leuven UZ Leuven, Leuven, Belgium.
FAU - Gastmans, Chris
AU  - Gastmans C
AD  - Centre for Biomedical Ethics and Law, Department of Public Health and Primary
      Care, KU Leuven Biomedical Sciences Group, Leuven, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - ethics
OT  - neonatology
OT  - newborns and minors
COIS- Competing interests: None declared.
EDAT- 2020/04/29 06:00
MHDA- 2020/04/29 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/04/29 06:00 [medline]
AID - medethics-2020-106102 [pii]
AID - 10.1136/medethics-2020-106102 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 27. pii: medethics-2020-106102. doi:
      10.1136/medethics-2020-106102.


PMID- 32341185
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 11
DP  - 2020 Nov
TI  - Three scenarios illustrating ethical concerns when considering bariatric surgery 
      in obese adolescents with Prader-Willi syndrome.
PG  - 738-742
LID - 10.1136/medethics-2019-106038 [doi]
AB  - Prader-Willi syndrome (PWS) is one of the 25 syndromic forms of obesity, in which
      patients present-in addition to different degrees of obesity-intellectual
      disability, endocrine disturbs, hyperphagia and/or other signs of hypothalamic
      dysfunction. In front of a severe/extreme obesity and the failure of non-invasive
      treatments, bariatric surgery is proposed as a therapeutic option. The complexity
      of the clinical condition, which could affect the long-term effects of bariatric 
      surgery, and the frequent association with a mild to severe intellectual
      disability raise some ethical concerns in the treatment of obese PWS adolescents.
      This article analyses these issues referring to the principles of healthcare
      ethics: beneficence/non-maleficence (proportionality of treatments; minimisation 
      of risks); respect of autonomy; justice. Based on these principles, three
      hypothetical scenarios are defined: (1) obese PWS adolescent, capable of making
      an autonomous decision; (2) obese PWS adolescent with a severe intellectual
      disability, whose parents agree with bariatric surgery; (3) obese PWS adolescent 
      with a life-threatening condition and a severe intellectual disability, whose
      parents do not agree with bariatric surgery. The currently available evidence on 
      efficacy and safety of bariatric surgery in PWS adolescents with extreme or
      severe obesity and the lack of adequate long-term follow-up suggests great
      caution even in a very life-threatening condition. Clinicians must always obtain 
      a full IQ assessment of patients by psychologists. A multidisciplinary team is
      needed to analyse the clinical, psychological, social and ethical aspects and
      organise support for patient and parents, involving also the hospital ethical
      committee or, if necessary, legal authorities.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Di Pietro, Maria Luisa
AU  - Di Pietro ML
AD  - Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanita
      Pubblica, Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Zace, Drieda
AU  - Zace D
AD  - Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanita
      Pubblica, Universita Cattolica del Sacro Cuore, Rome, Italy
      drieda.zace@unicatt.it.
LA  - eng
PT  - Journal Article
DEP - 20200427
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Adolescent
MH  - *Bariatric Surgery
MH  - Beneficence
MH  - Humans
MH  - Hyperphagia
MH  - *Pediatric Obesity/complications
MH  - *Prader-Willi Syndrome/complications
OTO - NOTNLM
OT  - *autonomy
OT  - *clinical ethics
OT  - *minors/parental consent
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/04/29 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/29 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - medethics-2019-106038 [pii]
AID - 10.1136/medethics-2019-106038 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Nov;46(11):738-742. doi: 10.1136/medethics-2019-106038. Epub
      2020 Apr 27.


PMID- 32341047
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 26
TI  - Text messages for primary prevention of cardiovascular disease: the TextMe2
      randomised controlled trial protocol.
PG  - e036767
LID - 10.1136/bmjopen-2020-036767 [doi]
AB  - INTRODUCTION: Mobile health may be an effective means of delivering customised
      individually directed health promotion interventions for cardiovascular disease
      (CVD) primary prevention. The aim of this study is to evaluate the effectiveness 
      of a lifestyle-focused text messaging programme for primary CVD prevention.
      METHODS AND ANALYSIS: Single-blind randomised controlled trial with 6 months'
      follow-up in 246 patients with moderate-high absolute cardiovascular risk and
      without coronary heart disease recruited from a rapid access cardiology clinic.
      Participants will be randomised to receive either usual care or TextMe2 (text
      message-based prevention programme). The TextMe2 programme provides support,
      motivation and education on five topics: diet, physical activity, smoking,
      general cardiovascular health and medication adherence, and is delivered in four 
      text messages per week over 6 months. The primary outcome is change in the
      proportion of patients who have three or more of five key modifiable risk factors
      that are uncontrolled (low-density lipoprotein >2.0 mmol/L, systolic blood
      pressure >140 mm Hg, body mass index >24.9 kg/m(2), physical activity (less than 
      the equivalent of 150 min of moderate intensity each week), current smoker).
      Secondary outcomes are changes in single biomedical risk factors, behavioural
      risk factors, quality of life, depression/anxiety scores, medication adherence,
      cardiovascular health literacy and hospital readmissions/representations.
      Analysis will be according to the intention-to-treat principle and full
      statistical analysis plan developed prior to data lock. ETHICS AND DISSEMINATION:
      This study has been approved by the Western Sydney Local Health District Human
      Research Ethics Committee at Westmead (AU/RED/HREC/17/WMEAD/186). Results will be
      presented at scientific meetings and published in peer-reviewed publications.
      TRIAL REGISTRATION NUMBER: ACTRN12618001153202.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Klimis, Harry
AU  - Klimis H
AUID- ORCID: 0000-0002-3635-421X
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Sydney, New South Wales, Australia harry.klimis@sydney.edu.au.
AD  - Department of Cardiology, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Thiagalingam, Aravinda
AU  - Thiagalingam A
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Sydney, New South Wales, Australia.
AD  - Department of Cardiology, Westmead Hospital, Westmead, New South Wales,
      Australia.
FAU - Chow, Clara K
AU  - Chow CK
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, The University 
      of Sydney, Sydney, New South Wales, Australia.
AD  - Department of Cardiology, Westmead Hospital, Westmead, New South Wales,
      Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200426
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Primary Prevention/*methods
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
MH  - *Text Messaging
PMC - PMC7204915
OTO - NOTNLM
OT  - *cardiology
OT  - *clinical trials
OT  - *medical education & training
OT  - *preventive medicine
OT  - *protocols & guidelines
OT  - *risk management
COIS- Competing interests: None declared.
EDAT- 2020/04/29 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2020-036767 [pii]
AID - 10.1136/bmjopen-2020-036767 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 26;10(4):e036767. doi: 10.1136/bmjopen-2020-036767.


PMID- 32341046
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 26
TI  - Protocol for a systematic review of health promotion interventions for African
      Americans delivered in US barbershops and hair salons.
PG  - e035940
LID - 10.1136/bmjopen-2019-035940 [doi]
AB  - INTRODUCTION: African American adults are disproportionately burdened by chronic 
      diseases, particularly at younger ages. Developing culturally appropriate
      interventions is paramount to closing the gap in these health inequities. The
      purpose of this systematic review is to critically evaluate health promotion
      interventions for African Americans delivered in two environments that are
      frequented by this population: barbershops and hair salons. Characteristics of
      effective interventions will be identified and evidence for the effectiveness of 
      these interventions will be provided. Results of this review will inform future
      health promotion efforts for African Americans particularly focused on the
      leading health inequities in obesity-related chronic diseases: cardiovascular
      disease, cancer and type 2 diabetes. METHODS AND ANALYSIS: Subject headings and
      keywords will be used to search for synonyms of 'barbershops,' 'hair salons' and 
      'African Americans' to identify all relevant articles (from inception onwards) in
      the following databases: Academic Search Ultimate, Cumulative Index of Nursing
      and Allied Health Literature, Embase, PsycINFO, PubMed, Web of Science (Science
      Citation Index and Social Sciences Citation Index) and ProQuest Dissertations.
      Experimental and quasi-experimental studies for adult (>18 years) African
      Americans delivered in barbershops and hair salons will be included. Eligible
      interventions will include risk reduction/management of obesity-related chronic
      disease: cardiovascular disease, cancer and type 2 diabetes. Two reviewers will
      independently screen, select and extract data and a third will mediate
      disagreements. The methodological quality (or risk of bias) of individual studies
      will be appraised using the Effective Public Health Practice Project Quality
      Assessment Tool. Quality and content of the evidence will be narratively
      synthesised. ETHICS AND DISSEMINATION: Since this is a protocol for a systematic 
      review, ethical approval is not required. Findings from the review will be widely
      disseminated through conference presentations, peer-reviewed publications and
      traditional and social media outlets.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Palmer, Kelly
AU  - Palmer K
AUID- ORCID: 0000-0002-4818-6030
AD  - Department of Health Promotion Sciences, College of Public Health, University of 
      Arizona, Tucson, Arizona, USA kpalmer1@email.arizona.edu.
FAU - Rivers, Patrick
AU  - Rivers P
AD  - Department of Health Promotion Sciences, College of Public Health, University of 
      Arizona, Tucson, Arizona, USA.
FAU - Melton, Forest
AU  - Melton F
AD  - Department of Health Promotion Sciences, College of Public Health, University of 
      Arizona, Tucson, Arizona, USA.
FAU - McClelland, Jean
AU  - McClelland J
AD  - Health Sciences Library, University of Arizona Arizona Health Sciences Center,
      Tucson, Arizona, USA.
FAU - Hatcher, Jennifer
AU  - Hatcher J
AD  - Division of Public Health Practice and Translational Research, University of
      Arizona, Phoenix, Arizona, USA.
FAU - Marrero, David G
AU  - Marrero DG
AD  - Department of Health Promotion Sciences, College of Public Health, University of 
      Arizona, Tucson, Arizona, USA.
FAU - Thomson, Cynthia
AU  - Thomson C
AD  - Department of Health Promotion Sciences, College of Public Health, University of 
      Arizona, Tucson, Arizona, USA.
FAU - Garcia, David O
AU  - Garcia DO
AD  - Department of Health Promotion Sciences, College of Public Health, University of 
      Arizona, Tucson, Arizona, USA.
LA  - eng
GR  - P30 DK111022/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20200426
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *African Americans
MH  - *Barbering
MH  - Cardiovascular Diseases/prevention & control
MH  - Chronic Disease/prevention & control
MH  - Diabetes Mellitus, Type 2/prevention & control
MH  - Health Promotion/*methods
MH  - Humans
MH  - Neoplasms/prevention & control
MH  - Obesity/*complications/prevention & control
MH  - Research Design
MH  - Risk Management
MH  - Risk Reduction Behavior
MH  - Systematic Reviews as Topic
PMC - PMC7204845
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *hypertension
OT  - *oncology
OT  - *preventive medicine
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/29 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-035940 [pii]
AID - 10.1136/bmjopen-2019-035940 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 26;10(4):e035940. doi: 10.1136/bmjopen-2019-035940.


PMID- 32341044
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 26
TI  - (Cost-)effectiveness of lower extremity nerve decompression surgery in subjects
      with diabetes: the DeCompression (DECO) trial-study protocol for a randomised
      controlled trial.
PG  - e035644
LID - 10.1136/bmjopen-2019-035644 [doi]
AB  - INTRODUCTION: The peripheral nerves of patients with diabetes are often
      pathologically swollen, which results in entrapment at places of anatomical
      narrowing. This results in nerve dysfunction. Surgical treatment of compression
      neuropathies in the lower extremities (lower extremity nerve decompression
      (LEND)) results in relief of symptoms and gain in peripheral nerve function,
      which may lead to less sensory loss (short term) and less associated detrimental 
      effects including foot ulceration and amputations, and lower costs (long term).
      The aim of the DeCompression trial is to evaluate the effectiveness and
      (cost-)effectiveness of surgical decompression of compressed lower extremity
      nerves (LEND surgery) compared with patients treated with conventional
      (non-surgical) care. METHODS AND ANALYSIS: A stratified randomised (1 to 1)
      controlled trial comparing LEND surgery (intervention) with conventional
      non-surgical care (control strategy) in subjects with diabetes with problems of
      neuropathy due to compression neuropathies in the lower extremity. Randomisation 
      is stratified for participating hospital (n=11) and gender. Patients and controls
      have the same follow-up at 1.5, 3, 6, 9, 12, 18, 24 and 48 months. Participants
      (n=344) will be recruited in 12 months and enrolled in all affiliated hospitals
      in which they receive both the intervention or conventional non-surgical care and
      follow-up. Outcome assessors are blinded to group assignment. PRIMARY OUTCOME:
      disease-specific quality of life (Norfolk Quality of Life Questionnaire-Diabetic 
      Neuropathy). SECONDARY OUTCOMES: health-related quality of life (EuroQoL
      5-dimension 5-level (EQ-5D5L), 36-item Short Form (SF-36)), plantar sensation
      (Rotterdam Diabetic Foot Test Battery), incidence of ulcerations/amputations,
      resource use and productivity loss (Medical Cost Questionnaire, Productivity Cost
      Questionnaire) during follow-up. The incremental cost-effectiveness ratio will be
      estimated on the basis of the collected empirical data and a cost-utility model. 
      ETHICS AND DISSEMINATION: Ethics approval has been granted by the Medical
      Research Ethics Committee of Utrecht University Medical Center (reference:
      NL68312.041.19v5, protocol number: 19-335/M). Dissemination of results will be
      via journal articles and presentations at national and international conferences.
      TRIAL REGISTRATION NUMBER: NetherlandsTrial Registry NL7664.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rinkel, Willem D
AU  - Rinkel WD
AUID- ORCID: 0000-0001-8137-3076
AD  - Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University
      Medical Center, Utrecht, The Netherlands w.d.rinkel@umcutrecht.nl.
FAU - Fakkel, Tirzah M
AU  - Fakkel TM
AD  - Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University
      Medical Center, Utrecht, The Netherlands.
FAU - Castro Cabezas, Manuel
AU  - Castro Cabezas M
AD  - Department of Internal Medicine, Franciscus Gasthuis en Vlietland, Rotterdam, The
      Netherlands.
FAU - Birnie, Erwin
AU  - Birnie E
AD  - Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University
      Medical Center, Utrecht, The Netherlands.
AD  - Department of Genetics, University Medical Center Groningen, Groningen, The
      Netherlands.
FAU - Coert, J Henk
AU  - Coert JH
AD  - Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University
      Medical Center, Utrecht, The Netherlands.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200426
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Amputation/statistics & numerical data
MH  - Cost-Benefit Analysis
MH  - Decompression, Surgical/*methods
MH  - Diabetic Foot/epidemiology
MH  - Diabetic Neuropathies/physiopathology/*surgery
MH  - Humans
MH  - Lower Extremity
MH  - Nerve Compression Syndromes/physiopathology/surgery
MH  - Peroneal Neuropathies/physiopathology/*surgery
MH  - Quality of Life
MH  - *Randomized Controlled Trials as Topic
MH  - Tarsal Tunnel Syndrome/physiopathology/*surgery
MH  - Treatment Outcome
PMC - PMC7204866
OTO - NOTNLM
OT  - *diabetic foot
OT  - *diabetic neuropathy
OT  - *neurosurgery
OT  - *plastic & reconstructive surgery
COIS- Competing interests: None declared.
EDAT- 2020/04/29 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035644 [pii]
AID - 10.1136/bmjopen-2019-035644 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 26;10(4):e035644. doi: 10.1136/bmjopen-2019-035644.


PMID- 32340647
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1471-6348 (Electronic)
IS  - 0266-4623 (Linking)
VI  - 36
IP  - 3
DP  - 2020 Jun
TI  - Physicians' perception toward non-invasive prenatal testing through the eye of
      the Rogers' diffusion of innovation theory in China.
PG  - 239-244
LID - 10.1017/S0266462320000136 [doi]
AB  - OBJECTIVE: Physicians' attitudes and adoption behavior toward the delivery of
      prenatal tests take vital significance for its influence on their professional
      practice and patient acceptance. This study aimed to identify how physicians have
      perceived the diffusion of non-invasive prenatal testing (NIPT) in China.
      METHODS: A cross-sectional study was conducted from July 2016 to October 2016 in 
      Shanghai, and Fujian and Sichuan Provinces in China. Physicians working on
      prenatal screening completed a self-report questionnaire. Following Roger's
      diffusion of innovation model, multivariable logistic regressions were performed 
      separately for the following key elements of the theory which influence
      diffusion: physician-perceived attributes of NIPT, communication channels, the
      nature of the social system, the extent of change agent (who introduces
      innovations into a society), promotion efforts, and physicians' benefits from
      adopting NIPT. RESULTS: Most specialists had a positive attitude (53.2 percent)
      toward NIPT, whereas 58.9 percent of physicians had already adopted NIPT in their
      clinical practice. Physician adoption of NIPT was positively associated with the 
      strength of HTA evidence (p = .03), perceived communication frequency with
      colleagues (p = .04), adoption by other physicians (p = .07), hospital
      competition (p = .06), hospital teaching status (p = .02), perceived for-profit
      genetic testing company's promotion (p < .001), and perceived clinical practice
      skill improvement (p = .02). However, the adoption behavior toward NIPT may be
      negatively associated with physician-perceived ethical concerns of NIPT (p =
      .06). CONCLUSION: Obstetricians and gynecologists' positive perceptions
      facilitate the adoption of NIPT. Combined with cost-effectiveness analysis of
      prenatal screening methods, health policy makers can promote the adoption of
      appropriate, cost-effective prenatal screening in pregnant women.
FAU - Wei, Yan
AU  - Wei Y
AD  - Key Lab of Health Technology Assessment (Ministry of Health), School of Public
      Health, Fudan University, Shanghai, China.
FAU - Shi, Lizheng
AU  - Shi L
AD  - School of Public Health and Tropical Medicine, Tulane University, New Orleans,
      USA.
FAU - Ming, Jian
AU  - Ming J
AD  - Key Lab of Health Technology Assessment (Ministry of Health), School of Public
      Health, Fudan University, Shanghai, China.
FAU - He, Luyang
AU  - He L
AD  - Key Lab of Health Technology Assessment (Ministry of Health), School of Public
      Health, Fudan University, Shanghai, China.
FAU - Xu, Yan
AU  - Xu Y
AD  - Key Lab of Health Technology Assessment (Ministry of Health), School of Public
      Health, Fudan University, Shanghai, China.
FAU - Chen, Yingyao
AU  - Chen Y
AUID- ORCID: https://orcid.org/0000-0002-3470-0748
AD  - Key Lab of Health Technology Assessment (Ministry of Health), School of Public
      Health, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - England
TA  - Int J Technol Assess Health Care
JT  - International journal of technology assessment in health care
JID - 8508113
SB  - IM
MH  - Adult
MH  - China
MH  - Cross-Sectional Studies
MH  - *Diffusion of Innovation
MH  - Female
MH  - Genetic Testing
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Models, Theoretical
MH  - Physicians/*psychology
MH  - Pregnancy
MH  - *Prenatal Diagnosis
MH  - Self Report
MH  - Young Adult
OTO - NOTNLM
OT  - Adoption
OT  - Non-invasive prenatal testing
OT  - Prenatal diagnosis
OT  - Prenatal screening
OT  - Roger's model
EDAT- 2020/04/29 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1017/S0266462320000136 [doi]
AID - S0266462320000136 [pii]
PST - ppublish
SO  - Int J Technol Assess Health Care. 2020 Jun;36(3):239-244. doi:
      10.1017/S0266462320000136. Epub 2020 Apr 28.


PMID- 32340500
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 37
IP  - 1
DP  - 2020
TI  - Efficacy and safety of ultrasonography-guided radiofrequency ablation for the
      treatment of T1bN0M0 papillary thyroid carcinoma: a retrospective study.
PG  - 392-398
LID - 10.1080/02656736.2020.1752945 [doi]
AB  - Purpose: To evaluate the efficacy and safety of ultrasonography (US)-guided
      radiofrequency ablation (RFA) for treating low-risk T1bN0M0 papillary thyroid
      cancer (PTC).Methods: This retrospective study was approved by the ethics
      committee of the Chinese People's Liberation Army General Hospital
      (S2019-211-01). Sixty-six patients with T1bN0M0 PTC (14 men and 52 women with a
      mean age of 41.0 +/- 9.2 years [range, 21-61 years]), who were not eligible for
      or refused surgery, were included in our study. RFA was performed with the
      moving-shot technique, and the ablation area exceeded the tumor edge by at least 
      3 mm. US (including contrast-enhanced) was performed before RFA; 1, 3, and 6
      months after RFA, and every 6 months thereafter. US-guided core-needle biopsy was
      performed 3 or 6 months after ablation to rule out recurrence.Results: The
      technical success rate was 100%, and there were no major complications. The tumor
      volume decreased significantly; the volume reduction rate (VRR) was 99.11 +/-
      2.44% (range, 92.62-100%) at the final follow-up with 38 tumors (57.6%)
      disappearing. Significant decreases in the VRR were found at every other
      follow-up visit before 18 months (p < .01). Technique efficacy was obtained in
      64/66 (97.0%) patients over 20.5 +/- 7.4 months follow-up. Malignant cells were
      confirmed in 2 ablation zones (3.0%), and cervical lymph node metastasis was
      detected in 1 patient (1.5%). These patients underwent additional RFA and
      achieved good results.Conclusion: RFA may be considered a safe and effective
      modality for the management of T1bN0M0 PTC in select patients.
FAU - Xiao, Jing
AU  - Xiao J
AUID- ORCID: 0000-0002-3298-3705
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Zhang, Mingbo
AU  - Zhang M
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Yan, Lin
AU  - Yan L
AUID- ORCID: 0000-0002-3338-3015
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Lan, Yu
AU  - Lan Y
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Zhu, Yaqiong
AU  - Zhu Y
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Lin, Lin
AU  - Lin L
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Tang, Jie
AU  - Tang J
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
FAU - Luo, Yukun
AU  - Luo Y
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Ultrasound, The First Medical Center of Chinese PLA General
      Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radiofrequency Ablation/*methods
MH  - Retrospective Studies
MH  - Thyroid Cancer, Papillary/diagnostic imaging/*therapy
MH  - Ultrasonography/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - *Thyroid
OT  - *papillary carcinoma
OT  - *radiofrequency
OT  - *thermal ablation
OT  - *ultrasonography
OT  - *volume reduction rate
EDAT- 2020/04/29 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1080/02656736.2020.1752945 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2020;37(1):392-398. doi: 10.1080/02656736.2020.1752945.


PMID- 32339894
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Linking)
VI  - 65
DP  - 2020 Aug
TI  - Technologies for assessing vaccine responses in the very young.
PG  - 28-31
LID - S0952-7915(20)30034-0 [pii]
LID - 10.1016/j.coi.2020.03.011 [doi]
AB  - Many vaccines are administered to young children in order to prevent infectious
      diseases early in life. At the same time, most of these vaccines are not
      developed specifically with the immune system of young children in mind and our
      understanding of how newborn immune systems differ from adult counterparts is
      incomplete. The main reason for this lack of understanding stems from the ethical
      and logistical difficulties in obtaining samples from young children as well as
      the challenges associated with the small volume samples available. Here I review 
      some recent developments made in this field and discuss their implications for
      studying vaccine responses in young children and developing better vaccines,
      tailored to this important population of susceptible individuals in the future.
CI  - Copyright (c) 2020 The Author. Published by Elsevier Ltd.. All rights reserved.
FAU - Brodin, Petter
AU  - Brodin P
AD  - Science for Life Laboratory, Department of Women's and Children's Health,
      Karolinska Institutet, SE-17121, Sweden; Unit of Pediatric Rheumatology,
      Karolinska University Hospital, SE-17176, Sweden. Electronic address:
      petter.brodin@ki.se.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200424
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
RN  - 0 (Vaccines)
SB  - IM
MH  - Child
MH  - Humans
MH  - Immune System/*immunology
MH  - Vaccines/*immunology
EDAT- 2020/04/28 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - S0952-7915(20)30034-0 [pii]
AID - 10.1016/j.coi.2020.03.011 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2020 Aug;65:28-31. doi: 10.1016/j.coi.2020.03.011. Epub 2020
      Apr 24.


PMID- 32339787
OWN - NLM
STAT- MEDLINE
DCOM- 20201027
LR  - 20210903
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 253
DP  - 2020 Sep
TI  - Intelligent, Autonomous Machines in Surgery.
PG  - 92-99
LID - S0022-4804(20)30178-5 [pii]
LID - 10.1016/j.jss.2020.03.046 [doi]
AB  - Surgeons perform two primary tasks: operating and engaging patients and
      caregivers in shared decision-making. Human dexterity and decision-making are
      biologically limited. Intelligent, autonomous machines have the potential to
      augment or replace surgeons. Rather than regarding this possibility with denial, 
      ire, or indifference, surgeons should understand and steer these technologies.
      Closer examination of surgical innovations and lessons learned from the
      automotive industry can inform this process. Innovations in minimally invasive
      surgery and surgical decision-making follow classic S-shaped curves with three
      phases: (1) introduction of a new technology, (2) achievement of a performance
      advantage relative to existing standards, and (3) arrival at a performance
      plateau, followed by replacement with an innovation featuring greater machine
      autonomy and less human influence. There is currently no level I evidence
      demonstrating improved patient outcomes using intelligent, autonomous machines
      for performing operations or surgical decision-making tasks. History suggests
      that if such evidence emerges and if the machines are cost effective, then they
      will augment or replace humans, initially for simple, common, rote tasks under
      close human supervision and later for complex tasks with minimal human
      supervision. This process poses ethical challenges in assigning liability for
      errors, matching decisions to patient values, and displacing human workers, but
      may allow surgeons to spend less time gathering and analyzing data and more time 
      interacting with patients and tending to urgent, critical-and potentially more
      valuable-aspects of patient care. Surgeons should steer these technologies toward
      optimal patient care and net social benefit using the uniquely human traits of
      creativity, altruism, and moral deliberation.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Loftus, Tyler J
AU  - Loftus TJ
AD  - Department of Surge ry, University of Florida Health, Gainesville, Florida.
FAU - Filiberto, Amanda C
AU  - Filiberto AC
AD  - Department of Surge ry, University of Florida Health, Gainesville, Florida.
FAU - Balch, Jeremy
AU  - Balch J
AD  - Department of Surge ry, University of Florida Health, Gainesville, Florida.
FAU - Ayzengart, Alexander L
AU  - Ayzengart AL
AD  - Department of Surge ry, University of Florida Health, Gainesville, Florida.
FAU - Tighe, Patrick J
AU  - Tighe PJ
AD  - Departments of Biomedical Engineering, Computer and Information Science and
      Engineering, and Electrical and Computer Engineering, University of Florida,
      Gainesville, Florida.
FAU - Rashidi, Parisa
AU  - Rashidi P
AD  - Departments of Anesthesiology, Orthopedics, and Information Systems/Operations
      Management, University of Florida Health, Gainesville, Florida.
FAU - Bihorac, Azra
AU  - Bihorac A
AD  - Department of Medicine, University of Florida Health, Gainesville, Florida.
FAU - Upchurch, Gilbert R Jr
AU  - Upchurch GR Jr
AD  - Department of Surge ry, University of Florida Health, Gainesville, Florida.
      Electronic address: gib.upchurch@surgery.ufl.edu.
LA  - eng
GR  - P50 GM111152/GM/NIGMS NIH HHS/United States
GR  - R01 GM110240/GM/NIGMS NIH HHS/United States
GR  - R01 GM114290/GM/NIGMS NIH HHS/United States
GR  - R21 EB027344/EB/NIBIB NIH HHS/United States
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200424
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
SB  - IM
MH  - Artificial Intelligence/ethics/history/*trends
MH  - Decision Support Systems, Clinical/ethics/history/*instrumentation
MH  - Diffusion of Innovation
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Inventions/ethics/history/*trends
MH  - Liability, Legal
MH  - Patient Participation
MH  - Robotic Surgical Procedures/ethics/history/*trends
MH  - Surgeons/*ethics/psychology
PMC - PMC7594619
MID - NIHMS1581017
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Automation
OT  - *Innovation
OT  - *Machine learning
OT  - *Surgery
EDAT- 2020/04/28 06:00
MHDA- 2020/10/28 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/02/22 00:00 [revised]
PHST- 2020/03/08 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/10/28 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - S0022-4804(20)30178-5 [pii]
AID - 10.1016/j.jss.2020.03.046 [doi]
PST - ppublish
SO  - J Surg Res. 2020 Sep;253:92-99. doi: 10.1016/j.jss.2020.03.046. Epub 2020 Apr 24.


PMID- 32339766
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1878-1632 (Electronic)
IS  - 1529-9430 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Degenerate-disc infection study with contaminant control (DISC): a multicenter
      prospective case-control trial.
PG  - 1544-1553
LID - S1529-9430(20)30106-6 [pii]
LID - 10.1016/j.spinee.2020.03.013 [doi]
AB  - BACKGROUND: A bacterial cause of disc degeneration has evoked several
      controversies and, if true, would lead to a major shift in treatment paradigm.
      Earlier studies analyzing the relationship of bacterial disc infection within a
      degenerative cohort featured prolonged cultures susceptible to contamination. The
      degenerate-disc infection study with contaminant control (DISC) trial aims to
      investigate this theory further by examining infection rates using a
      non-degenerative control cohort in comparison to a degenerative internal control 
      cohort and a sham cohort (sampling only sterile paraspinal tissue). To our
      knowledge, the current study is the largest evaluating the growth of organisms
      (or possible contamination rate) in paraspinal tissue if prolonged cultures are
      performed. Protocols on methodology have been previously published. PURPOSE: (1) 
      To investigate the infection rates across cohorts (degenerative vs.
      nondegenerative control; paraspinal and/or disc controls vs. combined sampling
      cohorts) using stringent standardized aseptic surgical technique and laboratory
      processing. (2) To compare our findings to that of the literature and make a
      statement in support and/or against a possible contamination theory to positive
      cultures. STUDY DESIGN: Multicenter, multisurgeon case-control trial. PATIENT
      SAMPLE: In all, 812 surgical samples were retrieved across a 3.5-year period
      (2013-2016) including 25 trauma controls (nondegenerative), 550 "disc and
      paraspinal" samples (degenerative cases with internal control), 190 disc-only
      samples (degenerative cases without internal control), and 46 paraspinal only
      controls (sham group). OUTCOME MEASURES: Growth and/or Contamination rate (%) per
      cohort. Chi-square of growth in disc versus paraspinal samples as a means of
      examining the distribution of false positive and contaminant growth. The impact
      of previous injections and/or surgery on positive disc or paraspinal growth.
      Correlation of Modic changes with positive growth rates analyzed with the
      Kruskal-Wallis Test. The distribution of species in positive samples were also
      analyzed. METHODS: The DISC trial is registered under Australian and New Zealand 
      clinical trials registry-ACTRN12616000541404. Institutional ethics review was
      obtained (HREC northern sector 13/218) at the primary center and further centers 
      (n=6) were recruited. Patients undergoing spinal surgery with discectomy were
      eligible for trial entry with tissue specimens obtained using strict aseptic
      technique for microbiological examination. All specimens were handled with
      sterile instruments only and by a fresh instrument to a sterile pot that was
      closed immediately. Separate pots were used for the disc and paraspinal tissue
      respectively with similar stringent processing during microbiological assessment.
      A cohort of the degenerative cases at one single institution also underwent an
      additional histopathological examination. RESULTS: There was an expected
      significant difference in gender and age associated with the non-degenerative
      control group (due to trauma patients) compared with other cohorts. There was a
      higher percentage of positive-growth in the control group in comparison to the
      disc and paraspinal and disc only groups across positive disc growth (48% vs. 27%
      vs. 17%, p<.001). A similar infection rate was observed in the paraspinal samples
      across the equivalent controls (44% vs. 36% vs. 37%, p=.739). There was a
      significant difference in the proportions of positive growth with a large
      proportion of false positives (growth in both disc and paraspinal samples;
      p<.001). There was no difference in true positive growth between the case and
      control groups (16.0 vs. 7.7%, p=.112). These trends were preserved across all
      cohorts and when stratifying by spinal segment (cervical or lumbar). There was no
      correlation between Modic changes and positive disc culture growth (p=.398, n=144
      samples). Cutibacterium (formerly Propionibacterium) acnes was the most dominant 
      pathogen isolated, representing between 50% and 70% of positive disc and
      paraspinal specimens, followed by staphylococcal species. CONCLUSIONS: Our study 
      failed to find a difference in true infection rates between the nondegenerative
      and degenerative disc populations. These findings are suggestive of a
      contamination theory and against a common infective etiology in the setting of
      discogenic back and neck pain. We believe the rationale for antibiotic therapy in
      the management of discogenic back pain warrants further evidence to establish
      efficacy.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Rao, Prashanth J
AU  - Rao PJ
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia;
      Neurosurgical Research Group (NSURG), Sydney, Australia.
FAU - Maharaj, Monish
AU  - Maharaj M
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia;
      Neurosurgical Research Group (NSURG), Sydney, Australia; Department of
      Neurosurgery, Prince of Wales Public and Private Hospitals, Suite 7, Level 7,
      Randwick 2031, Australia. Electronic address: monish.maharaj@gmail.com.
FAU - Chau, Christine
AU  - Chau C
AD  - Department of Pathology, Prince of Wales Hospital Randwick, Australia.
FAU - Taylor, Peter
AU  - Taylor P
AD  - Department of Neurosurgery, The Canberra Hospital, Canberra, Australia.
FAU - Phan, Kevin
AU  - Phan K
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia;
      Neurosurgical Research Group (NSURG), Sydney, Australia; Department of
      Neurosurgery, Prince of Wales Public and Private Hospitals, Suite 7, Level 7,
      Randwick 2031, Australia.
FAU - Choy, Wen Jie
AU  - Choy WJ
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia;
      Neurosurgical Research Group (NSURG), Sydney, Australia.
FAU - Scherman, Daniel
AU  - Scherman D
AD  - Department of Neurosurgery, Westmead Hospital, Sydney, Australia.
FAU - Mews, Peter
AU  - Mews P
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia;
      Dept Microbiology NSW Health Pathology, St George Hospital, Kogarah, Australia.
FAU - Scholsem, Martin
AU  - Scholsem M
AD  - Department of Neurosurgery, St George Hospital, Kogarah, Australia.
FAU - Coughlan, Marc
AU  - Coughlan M
AD  - Department of Neurosurgery, Prince of Wales Public and Private Hospitals, Suite
      7, Level 7, Randwick 2031, Australia.
FAU - Mobbs, Ralph
AU  - Mobbs R
AD  - School of Medical Sciences, University of New South Wales, Sydney, Australia;
      Neurosurgical Research Group (NSURG), Sydney, Australia; Department of
      Neurosurgery, Prince of Wales Public and Private Hospitals, Suite 7, Level 7,
      Randwick 2031, Australia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200425
PL  - United States
TA  - Spine J
JT  - The spine journal : official journal of the North American Spine Society
JID - 101130732
SB  - IM
CIN - Spine J. 2020 Dec;20(12):2044-2045. PMID: 33248502
CIN - Spine J. 2020 Dec;20(12):2046-2047. PMID: 33248503
MH  - Australia
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Intervertebral Disc
MH  - *Intervertebral Disc Degeneration/surgery
MH  - *Intervertebral Disc Displacement
MH  - Lumbar Vertebrae
MH  - New Zealand
MH  - Propionibacterium acnes
MH  - Prospective Studies
OTO - NOTNLM
OT  - *Cutibacterium
OT  - *Degenerative back pain
OT  - *Disc contamination
OT  - *Disc infection
OT  - *Discitis
OT  - *Osteomyelitis
OT  - *Spine infection
EDAT- 2020/04/28 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/28 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/03/14 00:00 [revised]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - S1529-9430(20)30106-6 [pii]
AID - 10.1016/j.spinee.2020.03.013 [doi]
PST - ppublish
SO  - Spine J. 2020 Oct;20(10):1544-1553. doi: 10.1016/j.spinee.2020.03.013. Epub 2020 
      Apr 25.


PMID- 32339709
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210224
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 83
IP  - 3
DP  - 2020 Sep
TI  - Morbidity and mortality for the dermatologist: Resident-led pilot project.
PG  - 972-973
LID - S0190-9622(20)30706-4 [pii]
LID - 10.1016/j.jaad.2020.04.090 [doi]
FAU - Cusick, Elizabeth H
AU  - Cusick EH
AD  - Department of Dermatology, University of Rochester, Rochester, New York.
      Electronic address: Elizabeth_Cusick@urmc.rochester.edu.
FAU - Mercurio, Mary Gail
AU  - Mercurio MG
AD  - Department of Dermatology, University of Rochester, Rochester, New York.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
SB  - IM
MH  - Curriculum
MH  - Dermatologists/*education/ethics
MH  - Ethics, Medical/education
MH  - Humans
MH  - Internship and Residency/ethics/*methods/organization & administration
MH  - Medical Errors/ethics/*prevention & control
MH  - Patient Safety
MH  - Pilot Projects
MH  - Professionalism/ethics
MH  - *Quality Improvement
MH  - Teaching Rounds/ethics/*methods/organization & administration
MH  - Truth Disclosure/ethics
OTO - NOTNLM
OT  - *education
OT  - *ethics
OT  - *medical error
OT  - *morbidity
OT  - *mortality
OT  - *patient safety
OT  - *reflection
OT  - *residency
EDAT- 2020/04/28 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/17 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - S0190-9622(20)30706-4 [pii]
AID - 10.1016/j.jaad.2020.04.090 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2020 Sep;83(3):972-973. doi: 10.1016/j.jaad.2020.04.090. Epub
      2020 Apr 24.


PMID- 32339614
OWN - NLM
STAT- Publisher
LR  - 20200427
IS  - 1532-2939 (Electronic)
IS  - 0195-6701 (Linking)
DP  - 2020 Apr 24
TI  - Pulmonary microbiome patterns correlate with the course of the disease in
      patients with sepsis-induced ARDS following major abdominal surgery.
LID - S0195-6701(20)30203-6 [pii]
LID - 10.1016/j.jhin.2020.04.028 [doi]
AB  - BACKGROUND: Patients with sepsis-induced Acute Respiratory Distress Syndrome
      (ARDS) are hallmarked by high mortality rates. Early, targeted antibiotic therapy
      is crucial for patients' survival. The clinical use of a Next Generation
      Sequencing (NGS)-based approach for pathogen identification may lead to an
      improved diagnostic performance. Therefore, the objective of this study was to
      examine changes in the pulmonary-microbiome and resulting influences on patients'
      outcome in septic ARDS, but also to compare NGS- and culture-based diagnostic
      methods for pathogen identification. METHODS: In total, 30 patients in two groups
      were enrolled in the study: (1) 15 septic ARDS patients following major abdominal
      surgery and (2) 15 patients undergoing oesophageal resection serving as controls.
      In the ARDS group, blood samples were collected at ARDS onset as well as 5 days
      and 10 days afterwards. At the same timepoints, bronchoalveolar lavages (BAL)
      were performed to collect epithelial lining fluid for culture-, as well as
      NGS-based analyses and to evaluate longitudinal changes in the pulmonary
      microbiome. In the control group, only one BAL and one blood sample were
      collected. RESULTS: ARDS patients showed a significantly reduced alpha-diversity 
      (p=0.007**) and an increased dominance (p=0.012*) in their pulmonary-microbiome. 
      The alpha-diversity-index correlated with the length of stay in the intensive
      care unit (p-value=0.015) and the need for mechanical ventilation
      (p-value=0.009). In 42.9% of all ARDS patients, culture-based results were
      negative, while NGS findings indicated bacterial colonization. CONCLUSION:
      Sepsis-induced ARDS is associated with a significant dysbiosis of patients'
      pulmonary-microbiome, which is closely correlated with the clinical course of the
      disease. TRIAL REGISTRATION: This prospective, observational pilot study was
      approved by the Ethics Committee of the Medical Faculty of Heidelberg (trial code
      no. S-063/2015) and was prospectively registered in the German clinical trials
      register (DRKS-ID: DRKS00008317 prospectively registered: 28.10.2015). All study 
      patients or their legal representatives signed written informed consent.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Schmitt, Felix C F
AU  - Schmitt FCF
AD  - Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg,
      Germany. Electronic address: Felix.Schmitt@med.uni-heidelberg.de.
FAU - Lipinski, Anna
AU  - Lipinski A
AD  - Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg,
      Germany.
FAU - Hofer, Stefan
AU  - Hofer S
AD  - Department of Anaesthesiology, Kaiserslautern Westpfalz Hospital, Kaiserslautern,
      Germany.
FAU - Uhle, Florian
AU  - Uhle F
AD  - Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg,
      Germany.
FAU - Nusshag, Christian
AU  - Nusshag C
AD  - Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
FAU - Hackert, Thilo
AU  - Hackert T
AD  - Department of General, Visceral and Transplant Surgery, Heidelberg University
      Hospital, Heidelberg, Germany.
FAU - Dalpke, Alexander H
AU  - Dalpke AH
AD  - Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg
      University Hospital, Heidelberg, Germany; Translational Lung Research Center
      Heidelberg (TLRC), German Center For Lung Research (DZL), Heidelberg, Germany;
      Institute of Medical Microbiology and Hygiene, Technical University Dresden,
      Dresden, Germany.
FAU - Weigand, Markus A
AU  - Weigand MA
AD  - Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg,
      Germany.
FAU - Brenner, Thorsten
AU  - Brenner T
AD  - Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg,
      Germany.
FAU - Boutin, Sebastien
AU  - Boutin S
AD  - Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg
      University Hospital, Heidelberg, Germany; Translational Lung Research Center
      Heidelberg (TLRC), German Center For Lung Research (DZL), Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - England
TA  - J Hosp Infect
JT  - The Journal of hospital infection
JID - 8007166
SB  - IM
OTO - NOTNLM
OT  - 16S RNA gene sequencing
OT  - acute respiratory distress syndrome
OT  - anti-infective therapy
OT  - inflammation
OT  - lung
OT  - microbiome
OT  - sepsis
COIS- Declaration of Competing Interest The authors declare that the research was
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2020/04/28 06:00
MHDA- 2020/04/28 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
AID - S0195-6701(20)30203-6 [pii]
AID - 10.1016/j.jhin.2020.04.028 [doi]
PST - aheadofprint
SO  - J Hosp Infect. 2020 Apr 24. pii: S0195-6701(20)30203-6. doi:
      10.1016/j.jhin.2020.04.028.


PMID- 32339510
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20210110
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 158
IP  - 2
DP  - 2020 Aug
TI  - Regional Planning for Extracorporeal Membrane Oxygenation Allocation During
      Coronavirus Disease 2019.
PG  - 603-607
LID - S0012-3692(20)30769-8 [pii]
LID - 10.1016/j.chest.2020.04.026 [doi]
AB  - Health systems confronting the coronavirus disease 2019 (COVID-19) pandemic must 
      plan for surges in ICU demand and equitably distribute resources to maximize
      benefit for critically ill patients and the public during periods of resource
      scarcity. For example, morbidity and mortality could be mitigated by a proactive 
      regional plan for the triage of mechanical ventilators. Extracorporeal membrane
      oxygenation (ECMO), a resource-intensive and potentially life-saving modality in 
      severe respiratory failure, has generally not been included in proactive disaster
      preparedness until recently. This paper explores underlying assumptions and
      triage principles that could guide the integration of ECMO resources into
      existing disaster planning. Drawing from a collaborative framework developed by
      one US metropolitan area with multiple adult and pediatric extracorporeal life
      support centers, this paper aims to inform decision-making around ECMO use during
      a pandemic such as COVID-19. It also addresses the ethical and practical aspects 
      of not continuing to offer ECMO during a disaster.
CI  - Copyright (c) 2020 American College of Chest Physicians. Published by Elsevier
      Inc. All rights reserved.
FAU - Prekker, Matthew E
AU  - Prekker ME
AD  - Department of Medicine, Division of Pulmonary & Critical Care, Hennepin
      Healthcare and the University of Minnesota Medical School, Minneapolis, MN;
      Department of Emergency Medicine, Hennepin Healthcare and the University of
      Minnesota Medical School, Minneapolis, MN. Electronic address:
      Matthew.Prekker@hcmed.org.
FAU - Brunsvold, Melissa E
AU  - Brunsvold ME
AD  - Department of Surgery, University of Minnesota Medical School, Minneapolis, MN.
FAU - Bohman, J Kyle
AU  - Bohman JK
AD  - Department of Anesthesiology, Mayo Clinic School of Medicine, Rochester, MN.
FAU - Fischer, Gwenyth
AU  - Fischer G
AD  - Department of Pediatrics, Division of Pediatric Critical Care, University of
      Minnesota Medical School, Minneapolis, MN.
FAU - Gram, Kendra L
AU  - Gram KL
AD  - Pediatric Critical Care, Children's Minnesota, Minneapolis, MN.
FAU - Litell, John M
AU  - Litell JM
AD  - Department of Critical Care, Allina Health, Minneapolis, MN; Department of
      Emergency Medicine, Hennepin Healthcare and the University of Minnesota Medical
      School, Minneapolis, MN.
FAU - Saavedra-Romero, Ramiro
AU  - Saavedra-Romero R
AD  - Department of Critical Care, Allina Health, Minneapolis, MN; Department of
      Medicine, the University of Minnesota Medical School, Minneapolis, MN.
FAU - Hick, John L
AU  - Hick JL
AD  - Department of Emergency Medicine, Hennepin Healthcare and the University of
      Minnesota Medical School, Minneapolis, MN.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200425
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Critical Illness/*therapy
MH  - Extracorporeal Membrane Oxygenation/*statistics & numerical data
MH  - Global Health
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - SARS-CoV-2
MH  - Triage/*organization & administration
MH  - Ventilators, Mechanical/*supply & distribution
PMC - PMC7182515
OTO - NOTNLM
OT  - *ECMO (extracorporeal membrane oxygenation)
OT  - *critical care
OT  - *disaster
EDAT- 2020/04/28 06:00
MHDA- 2020/08/26 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - S0012-3692(20)30769-8 [pii]
AID - 10.1016/j.chest.2020.04.026 [doi]
PST - ppublish
SO  - Chest. 2020 Aug;158(2):603-607. doi: 10.1016/j.chest.2020.04.026. Epub 2020 Apr
      25.


PMID- 32338855
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 2354-4716 (Electronic)
IS  - 0172-780X (Linking)
VI  - 41
IP  - 1
DP  - 2020 Apr
TI  - Thyroid dysfunction among adults in Bahrain: A hospital-based study.
PG  - 1-9
AB  - OBJECTIVE: Since thyroid dysfunction is a common disorder and affecting all
      populations regardless of iodine status, a comprehensive evaluation of thyroid
      dysfunction in Bahrain is essential to draw a national strategy, increase public 
      awareness, and recognize the role of ethnicity. METHODS: Following the approval
      of the Research Ethics Committee, the study was initiated by collecting
      laboratory and patient's data that have performed thyroid function tests (TFTs)
      during January 2018 till January 2019 at the Royal Services of Bahrain Defense
      Force (BDF) Military Hospital. TFTs data for 19,736 subjects were collected and
      analyzed using SPSS. RESULTS: Based on the TFTs measurements and including
      treated euthyroid, 44.9% of subjects had thyroid dysfunction categorized as
      treated euthyroid (15.1%), hypothyroid (20%), hyperthyroid (3.3%), and
      subclinical hypothyroid (6.5%). Females having thyroid dysfunction were 2.9 times
      more than males, and the most female age group affected was 20-<40 years old
      (14.1%). Furthermore, the frequency and the levels of thyroid peroxidase antibody
      (TPOAb) and thyroglobulin antibody (TGAb) were related to the TSH level above or 
      below 10 microIU/l. The frequencies of TPOAb and TGAb were 79% and 61%,
      respectively, in the treated hypothyroid group that have TSH>10 microIU/l and
      were significantly higher than the counterpart groups of TSH between 4-10
      microIU/l (44% and 40%, respectively) (p<0.001). Similarly, the mean values of
      TPOAb and TGAb were significantly different between TSH>10 microIU/l and the
      counterpart groups of TSH between 4-10 microIU/l (p<0.001). CONCLUSION: This
      study showed that hypothyroidism predominates in the Bahraini population, and
      most of the patients were females with an age group of 20-<40 years old. In
      addition, the thyroid dysfunctions were correlated with the high percentages of
      positive frequencies with TPOAb and TGAb, indicating the predomination of
      autoimmune thyroid diseases. Besides, the determination of risk factors in
      relation to hypothyroidism occurrence such as genetic predisposition and loci
      genetic variants is highly essential. Also, more national studies and public
      awareness are needed to reduce the potential illnesses of thyroid dysfunction.
FAU - Abdulla, Jehan
AU  - Abdulla J
AD  - Bahrain Defense Force Hospital, Royal Medical Services, Kingdom of Bahrain.
FAU - Abubaker, Fatema
AU  - Abubaker F
AD  - Bahrain Defense Force Hospital, Royal Medical Services, Kingdom of Bahrain.
FAU - Saber, Feryal Al
AU  - Saber FA
AD  - Bahrain Defense Force Hospital, Royal Medical Services, Kingdom of Bahrain.
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Neuro Endocrinol Lett
JT  - Neuro endocrinology letters
JID - 8008373
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bahrain/epidemiology
MH  - Female
MH  - Hospitals/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thyroid Diseases/blood/diagnosis/*epidemiology
MH  - Thyroid Function Tests
MH  - Young Adult
EDAT- 2020/04/28 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/01/17 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - NEL410120A03 [pii]
PST - ppublish
SO  - Neuro Endocrinol Lett. 2020 Apr;41(1):1-9.


PMID- 32338719
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20211204
IS  - 1532-4796 (Electronic)
IS  - 0883-6612 (Linking)
VI  - 54
IP  - 11
DP  - 2020 Nov 1
TI  - Precision Health: The Role of the Social and Behavioral Sciences in Advancing the
      Vision.
PG  - 805-826
LID - 10.1093/abm/kaaa018 [doi]
AB  - BACKGROUND: In 2015, Collins and Varmus articulated a vision for precision
      medicine emphasizing molecular characterization of illness to identify actionable
      biomarkers to support individualized treatment. Researchers have argued for a
      broader conceptualization, precision health. Precision health is an ambitious
      conceptualization of health, which includes dynamic linkages between research and
      practice as well as medicine, population health, and public health. The goal is a
      unified approach to match a full range of promotion, prevention, diagnostic, and 
      treatment interventions to fundamental and actionable determinants of health; to 
      not just address symptoms, but to directly target genetic, biological,
      environmental, and social and behavioral determinants of health. PURPOSE: The
      purpose of this paper is to elucidate the role of social and behavioral sciences 
      within precision health. MAIN BODY: Recent technologies, research frameworks, and
      methods are enabling new approaches to measure, intervene, and conduct social and
      behavioral science research. These approaches support three opportunities in
      precision health that the social and behavioral sciences could colead including: 
      (a) developing interventions that continuously "tune" to each person's evolving
      needs; (b) enhancing and accelerating links between research and practice; and
      (c) studying mechanisms of change in real-world contexts. There are three
      challenges for precision health: (a) methods of knowledge organization and
      curation; (b) ethical conduct of research; and (c) equitable implementation of
      precision health. CONCLUSIONS: Precision health requires active coleadership from
      social and behavioral scientists. Prior work and evidence firmly demonstrate why 
      the social and behavioral sciences should colead with regard to three opportunity
      and three challenge areas.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society of Behavioral Medicine.
FAU - Hekler, Eric
AU  - Hekler E
AD  - Department of Family Medicine and Public Health, School of Medicine, UC San
      Diego, La Jolla, CA, USA.
AD  - Center for Wireless and Population Health Systems, Qualcomm Institute, UC San
      Diego, La Jolla, CA, USA.
AD  - Design Lab, UC San Diego, La Jolla, CA, USA.
FAU - Tiro, Jasmin A
AU  - Tiro JA
AD  - Department of Population and Data Sciences, University of Texas Southwestern
      Medical Center, Dallas, TX, USA.
AD  - Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA.
FAU - Hunter, Christine M
AU  - Hunter CM
AD  - Office of Behavioral and Social Sciences Research, National Institutes of Health,
      Bethesda, MD, USA.
FAU - Nebeker, Camille
AU  - Nebeker C
AD  - Department of Family Medicine and Public Health, School of Medicine, UC San
      Diego, La Jolla, CA, USA.
AD  - Center for Wireless and Population Health Systems, Qualcomm Institute, UC San
      Diego, La Jolla, CA, USA.
AD  - Design Lab, UC San Diego, La Jolla, CA, USA.
LA  - eng
GR  - P30 CA142543/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Ann Behav Med
JT  - Annals of behavioral medicine : a publication of the Society of Behavioral
      Medicine
JID - 8510246
SB  - IM
MH  - *Behavioral Research
MH  - *Behavioral Sciences
MH  - Ethics, Research
MH  - Humans
MH  - Population Health
MH  - *Precision Medicine
MH  - Public Health
MH  - Research Design
MH  - *Social Sciences
MH  - Stakeholder Participation
MH  - Translational Research, Biomedical
PMC - PMC7646154
OTO - NOTNLM
OT  - *Implementation science
OT  - *Precision health
OT  - *Precision medicine
OT  - *Research ethics
OT  - *Research methods
OT  - *Social and behavioral sciences
EDAT- 2020/04/28 06:00
MHDA- 2021/09/22 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 5825668 [pii]
AID - 10.1093/abm/kaaa018 [doi]
PST - ppublish
SO  - Ann Behav Med. 2020 Nov 1;54(11):805-826. doi: 10.1093/abm/kaaa018.


PMID- 32338583
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1708-8283 (Electronic)
IS  - 0883-0738 (Linking)
VI  - 35
IP  - 8
DP  - 2020 Jul
TI  - Contextualized Autonomy in Transitional Care for Youth With Neurologic
      Conditions: The Role of the Pediatric Neurologist.
PG  - 536-542
LID - 10.1177/0883073820918454 [doi]
AB  - Youth with neurologic conditions experience multiple life transitions. The
      transfer from pediatric to adult health care systems exemplifies one such complex
      and multifaceted transition that occurs in parallel with developmental, legal,
      and social changes that may influence the roles and responsibilities of youth and
      their caregivers. As a result, ethical situations, questions, and challenges may 
      surface in transition care to which pediatric neurologists may be confronted. In 
      this article, we focus on the topic of autonomy and situations that may arise in 
      transition care in the context of pediatric neurology. Building from a clinical
      case, we present the concept of contextualized autonomy to work through the
      questions that arise in the case and propose ways of thinking through those
      challenging situations in transition care.
FAU - Bogossian, Aline
AU  - Bogossian A
AUID- ORCID: 0000-0002-9816-5887
AD  - School of Social Work, Faculty of Arts and Science, Universite de Montreal,
      Pavillon Lionel-Groulx, Montreal, Quebec, Canada.
FAU - Majnemer, Annette
AU  - Majnemer A
AD  - School of Physical & Occupational Therapy, McGill University, Montreal, Quebec,
      Canada.
AD  - Montreal Children's Hospital and RI-McGill University Health Centre & Centre for 
      Interdisciplinary Research in Rehabilitation, Montreal, Quebec, Canada.
FAU - Racine, Eric
AU  - Racine E
AD  - Pragmatic Health Ethics Research Unit, Institut de recherches cliniques de
      Montreal, Montreal, Quebec, Canada.
AD  - Department of Neurology and Neurosurgery, Biomedical Ethics Unit and Division of 
      Experimental Medicine, McGill University, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200426
PL  - United States
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
SB  - IM
MH  - Adolescent
MH  - Cerebral Palsy/psychology/*therapy
MH  - Epilepsy/psychology/*therapy
MH  - Humans
MH  - Neurologists
MH  - Neurology
MH  - Personal Autonomy
MH  - Transition to Adult Care
MH  - *Transitional Care
OTO - NOTNLM
OT  - *autonomy
OT  - *cerebral palsy
OT  - *health care transition
OT  - *pragmatic health ethics
OT  - *youth
EDAT- 2020/04/28 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.1177/0883073820918454 [doi]
PST - ppublish
SO  - J Child Neurol. 2020 Jul;35(8):536-542. doi: 10.1177/0883073820918454. Epub 2020 
      Apr 26.


PMID- 32338567
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210702
IS  - 2329-4523 (Electronic)
IS  - 2329-4515 (Linking)
VI  - 11
IP  - 3
DP  - 2020 Jul-Sep
TI  - Research Use of Electronic Health Records: Patients' Views on Alternative
      Approaches to Permission.
PG  - 172-186
LID - 10.1080/23294515.2020.1755383 [doi]
AB  - Background: The increased use of electronic health records (EHRs) has resulted in
      new opportunities for research, but also raises concerns regarding privacy,
      confidentiality, and patient awareness. Because public trust is essential to the 
      success of the research enterprise, patient perspectives are essential to the
      development and implementation of ethical approaches to the research use of EHRs.
      Yet, little is known about patients' views and expectations regarding various
      approaches to seeking permission for research use of their EHR data. Methods: We 
      conducted semi-structured interviews with 120 patients in four counties in
      diverse regions of the southeastern United States: Appalachia, the Mississippi
      Delta, and the Piedmont area of North Carolina. We asked participants to
      consider, from multiple stakeholder perspectives, the advantages and
      disadvantages of three approaches to notifying patients of, or obtaining
      permission for, research use of their EHR data; whether they believed it would be
      acceptable if their healthcare organization used each approach; and which
      approach would be most appropriate. Results: Nearly all participants said General
      Notification, Broad Permission, and Categorical Permission would each be
      acceptable approaches to notification of, or permission for, EHR research. Over
      half identified Broad Permission as the most appropriate approach. Across all of 
      these discussions, major themes included the importance of clarity, simplicity,
      and usability of patient-facing materials, as well as the level of transparency, 
      trustworthiness, and respect for patients the approach conveys. Conclusions: Our 
      findings help to inform the development and implementation of ethical approaches 
      to the research use of EHRs by identifying key patient considerations regarding
      various approaches to permission and suggesting potential actions for healthcare 
      organizations and researchers.
FAU - Hammack-Aviran, Catherine M
AU  - Hammack-Aviran CM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Brelsford, Kathleen M
AU  - Brelsford KM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - McKenna, Kevin C
AU  - McKenna KC
AD  - Department of Population Health Sciences, Duke University School of Medicine,
      Durham, North Carolina, USA.
FAU - Graham, Ross D
AU  - Graham RD
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Lampron, Zachary M
AU  - Lampron ZM
AD  - Department of Pragmatic Health Systems Research, Duke Clinical Research
      Institute, Durham, North Carolina, USA.
FAU - Beskow, Laura M
AU  - Beskow LM
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
LA  - eng
GR  - R01 LM012178/LM/NLM NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200427
PL  - United States
TA  - AJOB Empir Bioeth
JT  - AJOB empirical bioethics
JID - 101631047
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Appalachian Region
MH  - *Attitude
MH  - Awareness
MH  - *Confidentiality
MH  - Data Collection/*ethics
MH  - *Electronic Health Records
MH  - Ethics, Research
MH  - Female
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Male
MH  - Middle Aged
MH  - Mississippi
MH  - North Carolina
MH  - *Privacy
MH  - Qualitative Research
MH  - Research Design
MH  - Surveys and Questionnaires
MH  - Trust
MH  - Young Adult
PMC - PMC7384941
MID - NIHMS1598068
OTO - NOTNLM
OT  - *Electronic health records
OT  - *consent
OT  - *patient perspectives
OT  - *permission
OT  - *qualitative research
OT  - *research ethics
EDAT- 2020/04/28 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.1080/23294515.2020.1755383 [doi]
PST - ppublish
SO  - AJOB Empir Bioeth. 2020 Jul-Sep;11(3):172-186. doi:
      10.1080/23294515.2020.1755383. Epub 2020 Apr 27.


PMID- 32338566
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20210702
IS  - 1943-281X (Electronic)
IS  - 0033-2747 (Linking)
VI  - 83
IP  - 2
DP  - 2020 Summer
TI  - Experiences and Insights from the Early US COVID-19 Epicenter: A Rapid Assessment
      Procedure Informed Clinical Ethnography Case Series.
PG  - 115-127
LID - 10.1080/00332747.2020.1750214 [doi]
AB  - OBJECTIVE: The Coronavirus disease (COVID-19) outbreak has evolved into a
      pandemic crisis, with King County in Washington State emerging as the early US
      epicenter. A literature review revealed few reports providing front-line clinical
      and research teams guidance related to multilevel, rapidly evolving COVID-19
      directives. METHOD: The Rapid Assessment Procedure Informed Clinical Ethnography 
      (RAPICE) method was used to develop a clinical case series and conduct
      participant observation during an ongoing comparative effectiveness trial of
      peer-integrated, patient-centered interventions after traumatic injury.
      Participants were patients enrolled in the intervention arm of the ongoing trial,
      as well as front-line clinicians, patient peer interventionists, and clinical
      research team members implementing the trial. All participants were exposed to
      the Washington State COVID-19 outbreak. RESULTS: Primary and secondary COVID-19
      prevention strategies were feasibly integrated into ongoing care coordination and
      behavioral interventions for at-risk patients. Beyond the compilation of case
      studies, as an iterative method, RAPICE data collection naturalistically evolved 
      to include observations of intervention team activity occurring within the larger
      pandemic epicenter context. A daily clinical research team huddle that flexibly
      accommodated virtual participation was also feasibly implemented. CONCLUSIONS:
      Primary and secondary COVID-19 prevention strategies can be feasibly integrated
      into ongoing clinical interventions during the pandemic. Routine, proactive
      clinical and research team communication that transparently addresses ethical
      tensions and health-sustaining activities may promote well-being for providers
      grappling with rapidly evolving pandemic directives. Proactive assessments of
      individual provider vulnerabilities for severe COVID-19 related respiratory
      illness may also be a crucial element of the health care system pandemic
      responses.
FAU - Moloney, Kathleen
AU  - Moloney K
FAU - Scheuer, Hannah
AU  - Scheuer H
FAU - Engstrom, Allison
AU  - Engstrom A
FAU - Schreiber, Merritt
AU  - Schreiber M
FAU - Whiteside, Lauren
AU  - Whiteside L
AUID- ORCID: 0000-0002-0284-5336
FAU - Nehra, Deepika
AU  - Nehra D
FAU - Walen, Mary Lou
AU  - Walen ML
FAU - Rivara, Frederick
AU  - Rivara F
FAU - Zatzick, Douglas
AU  - Zatzick D
AUID- ORCID: 0000-0001-7339-1020
LA  - eng
GR  - U24 AT009676/AT/NCCIH NIH HHS/United States
GR  - UH2 MH106338/MH/NIMH NIH HHS/United States
GR  - UH3 MH106338/MH/NIMH NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200427
PL  - United States
TA  - Psychiatry
JT  - Psychiatry
JID - 0376470
SB  - IM
CIN - Psychiatry. 2020 Summer;83(2):143-148. PMID: 32338584
MH  - Accidents, Traffic
MH  - Adolescent
MH  - Aged, 80 and over
MH  - Anthropology, Cultural
MH  - Betacoronavirus
MH  - COVID-19
MH  - Community Health Services
MH  - Coronavirus Infections/*prevention & control
MH  - Female
MH  - Femoral Fractures
MH  - Fractures, Multiple
MH  - Humans
MH  - Infection Control/*methods
MH  - Male
MH  - Middle Aged
MH  - Pandemics/*prevention & control
MH  - *Patient Care Team
MH  - *Peer Group
MH  - Pneumonia, Viral/*prevention & control
MH  - Primary Health Care
MH  - Quadriplegia
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Spinal Cord Injuries
MH  - Washington
MH  - Wounds and Injuries/psychology/*therapy
MH  - Wounds, Gunshot
PMC - PMC7438236
MID - NIHMS1586315
EDAT- 2020/04/28 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.1080/00332747.2020.1750214 [doi]
PST - ppublish
SO  - Psychiatry. 2020 Summer;83(2):115-127. doi: 10.1080/00332747.2020.1750214. Epub
      2020 Apr 27.


PMID- 32337981
OWN - NLM
STAT- MEDLINE
DCOM- 20201009
LR  - 20201009
IS  - 1520-5851 (Electronic)
IS  - 0013-936X (Linking)
VI  - 54
IP  - 11
DP  - 2020 Jun 2
TI  - In Vitro Cytotoxicity and Risk Assessments of Environmental Pollutants Using
      Fibroblasts of a Stranded Finless Porpoise (Neophocaena asiaeorientalis).
PG  - 6832-6841
LID - 10.1021/acs.est.9b07471 [doi]
AB  - Cetaceans accumulate high levels of environmental pollutants, yet their
      toxicological studies have been difficult due to technical and ethical issues. It
      is essential to identify and fill the current knowledge gaps in the in vitro
      assays available for cetaceans. The present study establishes a novel in vitro
      assay that uses the fibroblasts of a finless porpoise (Neophocaena
      asiaeorientalis) (FF) stranded in the Seto Inland Sea (SIS) to answer questions
      about the cytotoxicity and risks of environmental pollutants. FF were treated
      with 17 compounds including polychlorinated biphenyls (PCBs) and
      dichlorodiphenyltrichloroethane and their metabolites (DDTs) and evaluated for
      cytotoxicity, viability, and apoptosis. The results of FF were compared with
      those of human fibroblasts (HF). The relative potencies of the test compounds
      were comparable between the two species, as EC50 of these compounds significantly
      correlated for FF and HF. Exposure-activity ratios (EARs) revealed that
      accumulation of PCBs and DDTs are likely to pose adverse effects at the cellular 
      level in the SIS finless porpoises, as their tissue concentrations exceeded EC50 
      values obtained in this study. This study successfully evaluated the risks of
      environmental pollutants using cetacean fibroblasts isolated by a non-invasive
      method that may be applied to various cetacean species and compounds.
FAU - Ochiai, Mari
AU  - Ochiai M
AUID- ORCID: 0000-0002-2510-870X
AD  - Center for Marine Environmental Studies (CMES), Ehime University, 2-5 Bunkyo-cho,
      Matsuyama City, Ehime 790-8577 Japan.
FAU - Kurihara, Nozomi
AU  - Kurihara N
AD  - Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1, Yoshida,
      Yamaguchi City, Yamaguchi 753-8515, Japan.
FAU - Hirano, Masashi
AU  - Hirano M
AD  - Center for Marine Environmental Studies (CMES), Ehime University, 2-5 Bunkyo-cho,
      Matsuyama City, Ehime 790-8577 Japan.
FAU - Nakata, Akifumi
AU  - Nakata A
AD  - Hokkaido University of Science, 7-Jo 15-4-1 Maeda, Teine, Sapporo, Hokkaido
      006-8585, Japan.
FAU - Iwata, Hisato
AU  - Iwata H
AUID- ORCID: 0000-0002-6867-0532
AD  - Center for Marine Environmental Studies (CMES), Ehime University, 2-5 Bunkyo-cho,
      Matsuyama City, Ehime 790-8577 Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - United States
TA  - Environ Sci Technol
JT  - Environmental science & technology
JID - 0213155
RN  - 0 (Environmental Pollutants)
RN  - 0 (Water Pollutants, Chemical)
SB  - IM
MH  - Animals
MH  - *Environmental Pollutants
MH  - Fibroblasts
MH  - *Porpoises
MH  - Risk Assessment
MH  - *Water Pollutants, Chemical/analysis/toxicity
EDAT- 2020/04/28 06:00
MHDA- 2020/10/10 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/10/10 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.1021/acs.est.9b07471 [doi]
PST - ppublish
SO  - Environ Sci Technol. 2020 Jun 2;54(11):6832-6841. doi: 10.1021/acs.est.9b07471.
      Epub 2020 May 12.


PMID- 32337825
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20201218
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - High-immunological risk living donor renal transplant during the COVID-19
      outbreak: Uncertainties and ethical dilemmas.
PG  - 1949-1951
LID - 10.1111/ajt.15949 [doi]
FAU - Ho, Quan Yao
AU  - Ho QY
AUID- ORCID: https://orcid.org/0000-0002-0884-7076
AD  - Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore.
AD  - SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
FAU - Chung, Shimin J
AU  - Chung SJ
AUID- ORCID: https://orcid.org/0000-0002-5174-7361
AD  - Department of Infectious Diseases, Singapore General Hospital, Singapore,
      Singapore.
AD  - SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
FAU - Gan, Valerie H L
AU  - Gan VHL
AD  - Department of Urology, Singapore General Hospital, Singapore, Singapore.
AD  - SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
FAU - Ng, Lay Guat
AU  - Ng LG
AD  - Department of Urology, Singapore General Hospital, Singapore, Singapore.
AD  - SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
FAU - Tan, Ban Hock
AU  - Tan BH
AD  - Department of Infectious Diseases, Singapore General Hospital, Singapore,
      Singapore.
AD  - SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
FAU - Kee, Terence Y S
AU  - Kee TYS
AD  - Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore.
AD  - SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
LA  - eng
PT  - Letter
DEP - 20200508
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - Adult
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control/*transmission
MH  - Ethics, Medical
MH  - Female
MH  - Health Services Accessibility
MH  - Humans
MH  - Kidney Failure, Chronic/*surgery
MH  - Kidney Transplantation/*ethics
MH  - *Living Donors
MH  - Lupus Nephritis/*surgery
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control/*transmission
MH  - Risk
MH  - SARS-CoV-2
MH  - Telemedicine
MH  - Tissue and Organ Procurement
MH  - Treatment Outcome
MH  - Uncertainty
PMC - PMC7267290
OTO - NOTNLM
OT  - clinical decision-making
OT  - clinical research/practice
OT  - ethics
OT  - ethics and public policy
OT  - infection and infectious agents - viral
OT  - infectious disease
OT  - kidney transplantation/nephrology
EDAT- 2020/04/28 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/04/17 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.1111/ajt.15949 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jul;20(7):1949-1951. doi: 10.1111/ajt.15949. Epub 2020 May 
      8.


PMID- 32337792
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20200615
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Reply to "Ethical principles governing organ transplantation apply to paired
      exchange programs".
PG  - 1758-1759
LID - 10.1111/ajt.15945 [doi]
FAU - Ladin, Keren
AU  - Ladin K
AUID- ORCID: 0000-0002-4310-8260
AD  - Departments of Community Health and Occupational Therapy, Tufts University,
      Medford, Massachusetts, USA.
FAU - Kulkarni, Sanjay
AU  - Kulkarni S
AUID- ORCID: 0000-0002-0835-7907
AD  - Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200516
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CON - Am J Transplant. 2020 May;20(5):1223-1224. PMID: 32022980
CON - Am J Transplant. 2020 Jun;20(6):1756-1757. PMID: 32277552
MH  - Humans
MH  - Living Donors
MH  - *Organ Transplantation
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *ethics
OT  - *paired exchange
OT  - *patient-centered care
EDAT- 2020/04/28 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 10.1111/ajt.15945 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jun;20(6):1758-1759. doi: 10.1111/ajt.15945. Epub 2020 May 
      16.


PMID- 32337371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210623
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Verification, analytical validation, and clinical validation (V3): the foundation
      of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs).
PG  - 55
LID - 10.1038/s41746-020-0260-4 [doi]
AB  - Digital medicine is an interdisciplinary field, drawing together stakeholders
      with expertize in engineering, manufacturing, clinical science, data science,
      biostatistics, regulatory science, ethics, patient advocacy, and healthcare
      policy, to name a few. Although this diversity is undoubtedly valuable, it can
      lead to confusion regarding terminology and best practices. There are many
      instances, as we detail in this paper, where a single term is used by different
      groups to mean different things, as well as cases where multiple terms are used
      to describe essentially the same concept. Our intent is to clarify core
      terminology and best practices for the evaluation of Biometric Monitoring
      Technologies (BioMeTs), without unnecessarily introducing new terms. We focus on 
      the evaluation of BioMeTs as fit-for-purpose for use in clinical trials. However,
      our intent is for this framework to be instructional to all users of digital
      measurement tools, regardless of setting or intended use. We propose and describe
      a three-component framework intended to provide a foundational evaluation
      framework for BioMeTs. This framework includes (1) verification, (2) analytical
      validation, and (3) clinical validation. We aim for this common vocabulary to
      enable more effective communication and collaboration, generate a common and
      meaningful evidence base for BioMeTs, and improve the accessibility of the
      digital medicine field.
CI  - (c) The Author(s) 2020.
FAU - Goldsack, Jennifer C
AU  - Goldsack JC
AD  - Digital Medicine Society (DiMe), Boston, MA USA.
FAU - Coravos, Andrea
AU  - Coravos A
AUID- ORCID: 0000-0001-5379-3540
AD  - Digital Medicine Society (DiMe), Boston, MA USA.
AD  - Elektra Labs, Boston, MA USA.
AD  - 3Harvard-MIT Center for Regulatory Science, Boston, MA USA.0000 0001 2341
      2786grid.116068.8
FAU - Bakker, Jessie P
AU  - Bakker JP
AD  - Digital Medicine Society (DiMe), Boston, MA USA.
AD  - 4Philips, Monroeville, PA USA.grid.417285.d
FAU - Bent, Brinnae
AU  - Bent B
AD  - 5Biomedical Engineering Department, Duke University, Durham, NC USA.0000 0004
      1936 7961grid.26009.3d
FAU - Dowling, Ariel V
AU  - Dowling AV
AUID- ORCID: 0000-0002-7889-4978
AD  - Takeda Pharmaceuticals, Cambridge, MA USA.
FAU - Fitzer-Attas, Cheryl
AU  - Fitzer-Attas C
AD  - ClinMed LLC, Dayton, NJ USA.
FAU - Godfrey, Alan
AU  - Godfrey A
AUID- ORCID: 0000-0003-4049-9291
AD  - 8Computer and Information Sciences Department, Northumbria University,
      Newcastle-upon-Tyne, UK.0000000121965555grid.42629.3b
FAU - Godino, Job G
AU  - Godino JG
AD  - 9Center for Wireless and Population Health Systems, University of California, San
      Diego, CA USA.0000 0001 2107 4242grid.266100.3
FAU - Gujar, Ninad
AU  - Gujar N
AUID- ORCID: 0000-0001-7901-308X
AD  - Samsung Neurologica, Danvers, MA USA.
AD  - Curis Advisors, Cambridge, MA USA.
FAU - Izmailova, Elena
AU  - Izmailova E
AD  - Digital Medicine Society (DiMe), Boston, MA USA.
AD  - Koneksa Health, New York, USA.
FAU - Manta, Christine
AU  - Manta C
AD  - Digital Medicine Society (DiMe), Boston, MA USA.
AD  - Elektra Labs, Boston, MA USA.
FAU - Peterson, Barry
AU  - Peterson B
AD  - Independent Consultant, Charlotte, NC USA.
FAU - Vandendriessche, Benjamin
AU  - Vandendriessche B
AUID- ORCID: 0000-0003-0672-0327
AD  - Byteflies, Antwerp, Belgium.
AD  - 15Department of Electrical, Computer and Systems Engineering, Case Western
      Reserve University, Cleveland, OH USA.0000 0001 2164 3847grid.67105.35
FAU - Wood, William A
AU  - Wood WA
AD  - 16Department of Medicine, University of North Carolina at Chapel Hill; Lineberger
      Comprehensive Cancer Center, Chapel Hill, NC USA.0000000122483208grid.10698.36
FAU - Wang, Ke Will
AU  - Wang KW
AD  - 5Biomedical Engineering Department, Duke University, Durham, NC USA.0000 0004
      1936 7961grid.26009.3d
FAU - Dunn, Jessilyn
AU  - Dunn J
AUID- ORCID: 0000-0002-3241-8183
AD  - 5Biomedical Engineering Department, Duke University, Durham, NC USA.0000 0004
      1936 7961grid.26009.3d
AD  - 17Department of Biostatistics & Bioinformatics, Duke University, Durham, NC
      USA.0000 0004 1936 7961grid.26009.3d
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200414
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7156507
OTO - NOTNLM
OT  - Research data
OT  - Scientific community
COIS- Competing interestsThis collaborative manuscript was developed as part of
      research initiatives led by the Digital Medicine Society (DiMe). All authors are 
      members of DiMe. DiMe is a Massachusetts non-profit corporation with 501(c)(3)
      application pending. J.C.G. is a part-time employee of HealthMode, Inc. A.C. is
      founder of Elektra Labs. E.I. is an executive of Koneksa Health. J.P.B. is a
      full-time employee of Philips.
EDAT- 2020/04/28 06:00
MHDA- 2020/04/28 06:01
CRDT- 2020/04/28 06:00
PHST- 2019/09/22 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/04/28 06:01 [medline]
AID - 10.1038/s41746-020-0260-4 [doi]
AID - 260 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Apr 14;3:55. doi: 10.1038/s41746-020-0260-4. eCollection
      2020.


PMID- 32337166
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2228-7523 (Print)
IS  - 2228-7523 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Feb
TI  - Comparing the Effect of Bupivacaine and Ropivacaine in Cesarean Delivery with
      Spinal Anesthesia.
PG  - e94155
LID - 10.5812/aapm.94155 [doi]
AB  - BACKGROUND: Spinal anesthesia is the most common technique used for cesarean
      delivery due to some advantages compared to regional anesthesia. It is easily
      performed and provides a rapid onset of block. Though bupivacaine is a generally 
      used long-acting amide type local anesthetic drug for spinal anesthesia,
      ropivacaine may sometimes be selected. OBJECTIVES: This prospective, randomized, 
      double-blinded study was aimed at comparing clinical efficacy and safety between 
      ropivacaine and bupivacaine during cesarean section. METHODS: After getting
      ethical committee approval and written informed consent, 65 women who referred to
      Imam Khomeini Hospital of Ahvaz, Iran in 2018 were chosen for elective cesarean
      delivery under spinal anesthesia. They were randomly allocated to receive either 
      ropivacaine 1% (n = 33) or bupivacaine 0.5% (n = 32). Afterwards, the differences
      in the anesthetic efficacy, vital signs, and hemodynamics of participants between
      the two groups were recorded. RESULTS: Duration of sensory block was shorter in
      the ropivacaine group than bupivacaine group (132.5 +/- 21.6 min vs. 175.8 +/-
      26.2 min; P < 0.001). Ropivacaine also produced a shorter duration of motor
      blockade than bupivacaine (124.8 +/- 20.2 min vs. 168.2 +/- 21.7 min; P < 0.001).
      There is no difference between the two groups in terms of systolic and diastolic 
      blood pressure, but the heart rate of patients in the bupivacaine group is
      significantly higher than the ropivacaine group. CONCLUSIONS: The results suggest
      that ropivacaine and bupivacaine are two efficient drugs in anesthesia in the
      cesarean section, ropivacaine is a better choice due to little influence on the
      hemodynamics and shorter duration of sensory block and motor block which are
      useful for the recovery and also safe to the patients.
CI  - Copyright (c) 2020, Author(s).
FAU - Olapour, Alireza
AU  - Olapour A
AD  - Department of Anesthesiology, Pain Research Center, Ahvaz Jundishapur University 
      of Medical Sciences, Ahvaz, Iran.
FAU - Akhondzadeh, Reza
AU  - Akhondzadeh R
AD  - Department of Anesthesiology, Pain Research Center, Ahvaz Jundishapur University 
      of Medical Sciences, Ahvaz, Iran.
FAU - Rashidi, Mahbobe
AU  - Rashidi M
AD  - Department of Anesthesiology, Pain Research Center, Ahvaz Jundishapur University 
      of Medical Sciences, Ahvaz, Iran.
FAU - Gousheh, Mohammadreza
AU  - Gousheh M
AD  - Department of Anesthesiology, Pain Research Center, Ahvaz Jundishapur University 
      of Medical Sciences, Ahvaz, Iran.
FAU - Homayoon, Raziyeh
AU  - Homayoon R
AD  - Department of Anesthesiology, Pain Research Center, Ahvaz Jundishapur University 
      of Medical Sciences, Ahvaz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200118
PL  - Netherlands
TA  - Anesth Pain Med
JT  - Anesthesiology and pain medicine
JID - 101585412
PMC - PMC7144247
OTO - NOTNLM
OT  - Bupivacaine
OT  - Caesarean Section
OT  - Motor Block
OT  - Ropivacaine
OT  - Sensory Block
OT  - Spinal Anesthesia
COIS- Conflict of Interests: The authors report no conflicts of interest in this work.
EDAT- 2020/04/28 06:00
MHDA- 2020/04/28 06:01
CRDT- 2020/04/28 06:00
PHST- 2019/05/20 00:00 [received]
PHST- 2019/12/11 00:00 [revised]
PHST- 2019/12/20 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/04/28 06:01 [medline]
AID - 10.5812/aapm.94155 [doi]
PST - epublish
SO  - Anesth Pain Med. 2020 Jan 18;10(1):e94155. doi: 10.5812/aapm.94155. eCollection
      2020 Feb.


PMID- 32336987
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1753-2000 (Print)
IS  - 1753-2000 (Linking)
VI  - 14
DP  - 2020
TI  - A 12-month follow-up of a transdiagnostic indicated prevention of internalizing
      symptoms in school-aged children: the results from the EMOTION study.
PG  - 15
LID - 10.1186/s13034-020-00322-w [doi]
AB  - BACKGROUND: Anxious and depressive symptoms in youth are highly prevalent, are
      often comorbid and have a high rate of relapse. Preventive interventions are
      promising, but follow-up results are lacking. The transdiagnostic EMOTION program
      is an indicated preventive cognitive behavioral therapy (CBT) intervention
      targeting children aged 8-12 years. METHODS: The present study investigates the
      12 months follow-up effects of the EMOTION intervention in a cluster randomized
      controlled trial (RCT) with 795 children that included both child self-reports
      and parental reports. RESULTS: Mixed model analyses showed a larger decrease of
      symptoms in the intervention group than in the control group for child
      self-reported anxious symptoms (The Multidimensional Anxiety Scale for Children
      (MASC) difference 4.56, CI 1.83 to 7.29, p = .001). Parental reports for both
      anxious (MASC difference 2.50, CI .26 to 4.74, p = .029) and depressive (The Mood
      and Feelings Questionnaire-short form (SMFQ) difference 1.55, CI .83 to 2.26, p
      </= .001) symptoms in children also showed a reduction. No statistically
      significant difference was found for child self-reported depressive symptoms
      (SMFQ difference .69, CI - .22 to 1.60, p = .139). CONCLUSION: The
      transdiagnostic EMOTION program has shown the potential for long-term reductions 
      in symptoms of both anxiety and depression in school-aged children. However,
      results regarding depressive symptoms must be considered preliminary as only
      parental report indicated effect.Trial registration The regional ethics committee
      (REC) of Norway approved the study. Registration number: 2013/1909; Project
      title: Coping Kids: a randomized controlled study of a new indicated preventive
      intervention for children with symptoms of anxiety and depression.
      ClinicalTrials.gov Identifier; NCT02340637.
CI  - (c) The Author(s) 2020.
FAU - Loevaas, M E S
AU  - Loevaas MES
AD  - 1Department of Psychology, NTNU, Norwegian University of Science and Technology, 
      Trondheim, Norway.grid.5947.f0000 0001 1516 2393
AD  - 2Department of Child and Adolescent Psychiatry, St. Olavs University Hospital,
      Trondheim, Norway.grid.52522.320000 0004 0627 3560
FAU - Lydersen, S
AU  - Lydersen S
AD  - 3Medical Faculty, Department of Mental Health, Regional Center for Child and
      Youth Mental Health and Child Welfare, NTNU Norwegian University of Science and
      Technology, Trondheim, Norway.grid.5947.f0000 0001 1516 2393
FAU - Sund, A M
AU  - Sund AM
AD  - 2Department of Child and Adolescent Psychiatry, St. Olavs University Hospital,
      Trondheim, Norway.grid.52522.320000 0004 0627 3560
AD  - 3Medical Faculty, Department of Mental Health, Regional Center for Child and
      Youth Mental Health and Child Welfare, NTNU Norwegian University of Science and
      Technology, Trondheim, Norway.grid.5947.f0000 0001 1516 2393
FAU - Neumer, S-P
AU  - Neumer SP
AD  - 4Centre for Child and Adolescent Mental Health, RBUP East and South, Oslo,
      Norway.grid.458806.7
FAU - Martinsen, K D
AU  - Martinsen KD
AD  - 4Centre for Child and Adolescent Mental Health, RBUP East and South, Oslo,
      Norway.grid.458806.7
FAU - Holen, S
AU  - Holen S
AD  - 4Centre for Child and Adolescent Mental Health, RBUP East and South, Oslo,
      Norway.grid.458806.7
FAU - Patras, J
AU  - Patras J
AD  - 5Regional Centre for Child and Youth Mental Health and Child Welfare, UiT Arctic 
      University of Norway, Tromso, Norway.grid.10919.300000000122595234
FAU - Adolfsen, F
AU  - Adolfsen F
AD  - 5Regional Centre for Child and Youth Mental Health and Child Welfare, UiT Arctic 
      University of Norway, Tromso, Norway.grid.10919.300000000122595234
FAU - Rasmussen, L-M P
AU  - Rasmussen LP
AD  - 5Regional Centre for Child and Youth Mental Health and Child Welfare, UiT Arctic 
      University of Norway, Tromso, Norway.grid.10919.300000000122595234
FAU - Reinfjell, T
AU  - Reinfjell T
AD  - 1Department of Psychology, NTNU, Norwegian University of Science and Technology, 
      Trondheim, Norway.grid.5947.f0000 0001 1516 2393
AD  - 2Department of Child and Adolescent Psychiatry, St. Olavs University Hospital,
      Trondheim, Norway.grid.52522.320000 0004 0627 3560
LA  - eng
SI  - ClinicalTrials.gov/NCT02340637
PT  - Journal Article
DEP - 20200422
PL  - England
TA  - Child Adolesc Psychiatry Ment Health
JT  - Child and adolescent psychiatry and mental health
JID - 101297974
PMC - PMC7178617
OTO - NOTNLM
OT  - Anxiety
OT  - Child
OT  - Depression
OT  - Follow-up
OT  - Transdiagnostic prevention
COIS- Competing interestsOne of the authors, Kristin Martinsen, receives royalties from
      the sale of EMOTION manuals in Norway. All the other authors declare that they
      have no competing interests. All authors approved the final manuscript before
      publication.
EDAT- 2020/04/28 06:00
MHDA- 2020/04/28 06:01
CRDT- 2020/04/28 06:00
PHST- 2019/10/05 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/04/28 06:01 [medline]
AID - 10.1186/s13034-020-00322-w [doi]
AID - 322 [pii]
PST - epublish
SO  - Child Adolesc Psychiatry Ment Health. 2020 Apr 22;14:15. doi:
      10.1186/s13034-020-00322-w. eCollection 2020.


PMID- 32336692
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1086-3249 (Electronic)
IS  - 1054-6863 (Linking)
VI  - 30
IP  - 1
DP  - 2020
TI  - Ethical Concerns with Applied Behavior Analysis for Autism Spectrum "Disorder".
PG  - 31-69
LID - 10.1353/ken.2020.0000 [doi]
AB  - This paper has both theoretical and practical ambitions. The theoretical
      ambitions are to explore what would constitute both effective and ethical
      treatment of Autism Spectrum Disorder (ASD). However, the practical ambition is
      perhaps more important: we argue that a dominant form of Applied Behavior
      Analysis (ABA), which is widely taken to be far-and-away the best "treatment" for
      ASD, manifests systematic violations of the fundamental tenets of bioethics.
      Moreover, the supposed benefits of the treatment not only fail to mitigate these 
      violations, but often exacerbate them. Warnings of the perils of ABA are not
      original to us-autism advocates have been ringing this bell for some years.
      However, their pleas have been largely unheeded, and ABA continues to be offered 
      to and quite frequently pushed upon parents as the appropriate treatment for
      autistic children. Our contribution is to argue that, from a bioethical
      perspective, autism advocates are fully justified in their concerns-the rights of
      autistic children and their parents are being regularly infringed upon.
      Specifically, we will argue that employing ABA violates the principles of justice
      and nonmaleficence and, most critically, infringes on the autonomy of children
      and (when pushed aggressively) of parents as well.
FAU - Wilkenfeld, Daniel A
AU  - Wilkenfeld DA
FAU - McCarthy, Allison M
AU  - McCarthy AM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kennedy Inst Ethics J
JT  - Kennedy Institute of Ethics journal
JID - 9109135
SB  - IM
MH  - Adult
MH  - Applied Behavior Analysis/*ethics
MH  - Autism Spectrum Disorder/*therapy
MH  - Beneficence
MH  - *Bioethical Issues
MH  - Child
MH  - Humans
MH  - Parents
MH  - Patients
MH  - *Personal Autonomy
MH  - Social Justice
EDAT- 2020/04/28 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
AID - S1086324920100002 [pii]
AID - 10.1353/ken.2020.0000 [doi]
PST - ppublish
SO  - Kennedy Inst Ethics J. 2020;30(1):31-69. doi: 10.1353/ken.2020.0000.


PMID- 32336457
OWN - NLM
STAT- MEDLINE
DCOM- 20210713
LR  - 20210713
IS  - 1877-1300 (Electronic)
IS  - 1877-1297 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May
TI  - Implementation of a modified multiple mini-interview method to assess
      non-cognitive qualities during resident candidate interviews.
PG  - 585-589
LID - S1877-1297(20)30010-1 [pii]
LID - 10.1016/j.cptl.2020.01.010 [doi]
AB  - BACKGROUND AND PURPOSE: Conventional onsite interview methods often make
      comparing applicants difficult. Literature has noted conventional interviews
      leave room for bias and high interrater variability, making non-cognitive
      attributes difficult to ascertain. In 2016, the residency committee of a small,
      multi-site, academic-based postgraduate year one residency program implemented a 
      modified multiple mini-interview (MMI) approach as a component of the residency
      interview process to better qualify candidate attributes. EDUCATIONAL ACTIVITY
      AND SETTING: A modified MMI was developed to address the non-cognitive
      attributes, ethical reasoning, communication, and professionalism. Scenarios,
      scripts, questions, and rubrics were developed by residency committee members.
      The author of the case was assigned to role play that scenario with candidates
      while other committee members silently observed. Candidates and residency
      committee members were surveyed to explore their perception of the MMI as a
      component of the residency interview process. FINDINGS: Thirty-one candidates
      have been interviewed since the incorporation of the modified MMI. Of those, 20
      completed the post-interview survey. The majority of resident candidates (55%)
      completing the survey felt they were able to portray strengths and abilities more
      effectively vs. a conventional interview. Of the five residency committee
      members, all (100%) completed the survey and all (100%) perceived implementation 
      of the modified MMI provided increased confidence in determining candidate
      ranking. SUMMARY: Implementation of a modified MMI approach to an onsite
      residency interview process assisted residency committee members in assessing
      non-cognitive attributes and contributed to greater confidence in determining
      resident candidate ranking.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Henneman, Amy
AU  - Henneman A
AD  - Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, 901 S.
      Flagler Dr., West Palm Beach, FL 33416, United States. Electronic address:
      amy_henneman@pba.edu.
FAU - Haines, Seena
AU  - Haines S
AD  - Department of Pharmacy Practice, The University of Mississippi School of
      Pharmacy, 2500 North State Street, Jackson, MS 39216, United States. Electronic
      address: shaines@umc.edu.
LA  - eng
PT  - Journal Article
DEP - 20200130
PL  - United States
TA  - Curr Pharm Teach Learn
JT  - Currents in pharmacy teaching & learning
JID - 101560815
SB  - IM
MH  - *Cognition
MH  - Humans
MH  - Internship and Residency/*methods/statistics & numerical data
MH  - Interviews as Topic/*methods/statistics & numerical data
MH  - Personnel Selection/*methods/statistics & numerical data
MH  - Psychological Tests/*standards/statistics & numerical data
MH  - School Admission Criteria/trends
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Multiple mini-interview
OT  - *Non-cognitive attributes
OT  - *Residency
COIS- Declaration of competing interest None.
EDAT- 2020/04/28 06:00
MHDA- 2021/07/14 06:00
CRDT- 2020/04/28 06:00
PHST- 2019/05/29 00:00 [received]
PHST- 2019/11/11 00:00 [revised]
PHST- 2020/01/12 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/07/14 06:00 [medline]
AID - S1877-1297(20)30010-1 [pii]
AID - 10.1016/j.cptl.2020.01.010 [doi]
PST - ppublish
SO  - Curr Pharm Teach Learn. 2020 May;12(5):585-589. doi: 10.1016/j.cptl.2020.01.010. 
      Epub 2020 Jan 30.


PMID- 32336391
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1932-2275 (Print)
IS  - 1932-2275 (Linking)
VI  - 38
IP  - 2
DP  - 2020 Jun
TI  - Ethical Issues Confronting Muslim Patients in Perioperative and Critical Care
      Environments: A Survey of Islamic Jurisprudence.
PG  - 379-401
LID - S1932-2275(20)30002-1 [pii]
LID - 10.1016/j.anclin.2020.01.002 [doi]
AB  - Ethical dilemmas may arise when medical management conflicts with a patient's
      values, culture, religion, or legal considerations. Many Muslims encounter
      ethical dilemmas as patients in perioperative and critical care settings. This
      article discusses the fundamentals of Islamic jurisprudence and how this may
      affect hospitalized patients in terms of cleanliness and prayer in the setting of
      stoma and urinary catheters, fasting, transfusion, transplants, xenografts and
      animal-based medications, do-not-resuscitate orders, and postmortem examinations.
      Provider familiarity with how such situations may affect Muslim patients is
      important to navigate potential conflict and to deliver competent care.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Miller, Andrew C
AU  - Miller AC
AD  - Department of Emergency Medicine, Vidant Medical Center, East Carolina University
      Brody School of Medicine, 600 Moye Boulevard, Mailstop 625, Greenville, NC 27834,
      USA; The MORZAK Collaborative, 600 Moye Boulevard, Mailstop 625, Greenville, NC
      27834, USA. Electronic address: Taqwa1@gmail.com.
FAU - Khan, Abbas M
AU  - Khan AM
AD  - The MORZAK Collaborative, 600 Moye Boulevard, Mailstop 625, Greenville, NC 27834,
      USA.
FAU - Hebishi, Karim
AU  - Hebishi K
AD  - Departments of Internal Medicine and Psychiatry, Vidant Medical Center, East
      Carolina University Brody School of Medicine, 600 Moye Boulevard, Mailstop 628,
      Greenville, NC 27834, USA.
FAU - Castro Bigalli, Alberto A
AU  - Castro Bigalli AA
AD  - East Carolina University Brody School of Medicine, 600 Moye Boulevard, Room
      2S-20, Greenville, NC 27834, USA.
FAU - Vahedian-Azimi, Amir
AU  - Vahedian-Azimi A
AD  - Trauma Research Center, Baqiyatallah University of Medical Sciences, P.O. Box
      19575-174, Sheykh bahayi Stress, Vanak Square, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200401
PL  - United States
TA  - Anesthesiol Clin
JT  - Anesthesiology clinics
JID - 101273663
SB  - IM
MH  - Critical Care/*ethics
MH  - Delivery of Health Care
MH  - Fasting
MH  - Humans
MH  - *Islam
MH  - Jurisprudence
MH  - Organ Transplantation
MH  - Perioperative Care/*ethics
MH  - Surveys and Questionnaires
MH  - Urinary Catheters
OTO - NOTNLM
OT  - Ethics
OT  - Intensive care unit
OT  - Islam
OT  - Perioperative
OT  - Religion
COIS- Conflicts of Interest None declared.
EDAT- 2020/04/28 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - S1932-2275(20)30002-1 [pii]
AID - 10.1016/j.anclin.2020.01.002 [doi]
PST - ppublish
SO  - Anesthesiol Clin. 2020 Jun;38(2):379-401. doi: 10.1016/j.anclin.2020.01.002. Epub
      2020 Apr 1.


PMID- 32336345
OWN - NLM
STAT- MEDLINE
DCOM- 20200428
LR  - 20200428
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 151
IP  - 5
DP  - 2020 May
TI  - Dentistry's social contract is at risk.
PG  - 334-339
LID - S0002-8177(20)30039-8 [pii]
LID - 10.1016/j.adaj.2020.01.022 [doi]
AB  - BACKGROUND: The implications of the social contract for medicine and those it
      serves has been debated by bioethicists, political scientists, and physicians.
      Far less attention, however, has been given to dentistry's social contract.
      METHODS: The existing literature from medicine is used to explore the social
      contract and the role of dentistry in today's society, focusing on several areas 
      of interest. RESULTS: The authors' analysis discusses the history of the social
      contract and its implications for professionalism. The authors examine the
      failure of the dental profession to adequately address population needs and
      inequities in oral health, situating this in the context of an increasingly
      commodified, commercialized, cosmetically oriented, and proprietary culture in
      the profession. The authors highlight the important role of organized dentistry
      in facilitating change and renewing the social contract. CONCLUSIONS: The authors
      conclude that reforms are necessary for dentistry to remain a profession.
      PRACTICAL IMPLICATIONS: The authors' findings may inform oral health policies and
      underscore the need for change among dental providers and organized dentistry to 
      maintain dentistry's professional status.
CI  - Copyright (c) 2020 American Dental Association. Published by Elsevier Inc. All
      rights reserved.
FAU - Moeller, Jamie
AU  - Moeller J
FAU - Quinonez, Carlos R
AU  - Quinonez CR
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - IM
CIN - J Am Dent Assoc. 2020 Sep;151(9):646. PMID: 32854865
MH  - *Dentistry
OTO - NOTNLM
OT  - *Dentistry
OT  - *ethics
OT  - *population health
OT  - *professionalism
OT  - *social contract
EDAT- 2020/04/28 06:00
MHDA- 2020/04/29 06:00
CRDT- 2020/04/28 06:00
PHST- 2019/09/16 00:00 [received]
PHST- 2019/12/29 00:00 [revised]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/04/28 06:00 [entrez]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2020/04/29 06:00 [medline]
AID - S0002-8177(20)30039-8 [pii]
AID - 10.1016/j.adaj.2020.01.022 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2020 May;151(5):334-339. doi: 10.1016/j.adaj.2020.01.022.


PMID- 32336318
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210702
IS  - 1976-670X (Electronic)
IS  - 1976-6696 (Linking)
VI  - 53
IP  - 9
DP  - 2020 Sep
TI  - Improved human hematopoietic reconstitution in HepaRG co-transplanted humanized
      NSG mice.
PG  - 466-471
AB  - Several humanized mouse models are being used to study humanspecific immune
      responses and diseases. However, the pivotal needs of fetal tissues for the
      humanized mice model have been huddled because of the demand for ethical and
      medical approval. Thus, we have verified the hematopoietic and immunomodulatory
      function of HepaRG and developed a new and easy humanized mouse model to replace 
      the use of fetal liver tissue. HepaRG co-transplanted Hu-NSG mice significantly
      increased CD45+ lymphocytes and CD19+ B cells and CD3+ T cells than normal
      Hu-NSG, suggesting enhanced reconstitution of the human immune system. These
      results have improved the applicability of humanized mice by developing new
      models easily accessible. [BMB Reports 2020; 53(9): 466-471].
FAU - Kim, Jin
AU  - Kim J
AD  - Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul
      National University, Seoul 08826, Korea.
FAU - Ryu, Bokyeong
AU  - Ryu B
AD  - Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul
      National University, Seoul 08826, Korea.
FAU - Kim, Ukjin
AU  - Kim U
AD  - Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul
      National University, Seoul 08826, Korea.
FAU - Kim, Chang-Hwan
AU  - Kim CH
AD  - The 4th R&D Institute-6, Agency for Defense Development, Daejeon 34186, Korea.
FAU - Hur, Gyeung-Haeng
AU  - Hur GH
AD  - The 4th R&D Institute-6, Agency for Defense Development, Daejeon 34186, Korea.
FAU - Kim, C-Yoon
AU  - Kim CY
AD  - Stem Cell Biology, School of Medicine, Konkuk University, Seoul 05030, Korea.
FAU - Park, Jae-Hak
AU  - Park JH
AD  - Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul
      National University, Seoul 08826, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - BMB Rep
JT  - BMB reports
JID - 101465334
RN  - 0 (Antigens, CD19)
RN  - 0 (CD19 antigen, mouse)
RN  - 0 (CD3 Complex)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.1.3.48 (Ptprc protein, mouse)
SB  - IM
MH  - Animals
MH  - Antigens, CD19/immunology
MH  - B-Lymphocytes/immunology
MH  - CD3 Complex/immunology
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukocyte Common Antigens/immunology
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - T-Lymphocytes/immunology
PMC - PMC7526976
EDAT- 2020/04/28 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/12/14 00:00 [received]
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 4868 [pii]
PST - ppublish
SO  - BMB Rep. 2020 Sep;53(9):466-471.


PMID- 34221416
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Dec
TI  - A critical examination of legal and ethical considerations for nutrigenetic
      testing with recommendations for improving regulation in Canada: from science to 
      consumer.
PG  - lsaa003
LID - 10.1093/jlb/lsaa003 [doi]
FAU - Horne, Justine
AU  - Horne J
AD  - Health and Rehabilitation Sciences, Western University, Canada.
AD  - East Elgin Family Health Team, Canada.
FAU - Gilliland, Jason
AU  - Gilliland J
AD  - School of Health Studies, Western University, Canada.
AD  - Department of Geography, Western University, Canada.
AD  - Department of Paediatrics, Western University, Canada.
AD  - Department of Epidemiology and Biostatistics, Western University, Canada.
FAU - Madill, Janet
AU  - Madill J
AD  - Department of Food and Nutritional Sciences, Western University, Canada.
FAU - Shelley, Jacob
AU  - Shelley J
AD  - School of Health Studies, Western University, Canada.
AD  - Faculty of Law, Western University, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200428
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC8249086
EDAT- 2020/04/28 00:00
MHDA- 2020/04/28 00:01
CRDT- 2021/07/05 10:07
PHST- 2019/02/06 00:00 [received]
PHST- 2019/12/13 00:00 [revised]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2021/07/05 10:07 [entrez]
PHST- 2020/04/28 00:00 [pubmed]
PHST- 2020/04/28 00:01 [medline]
AID - 10.1093/jlb/lsaa003 [doi]
AID - lsaa003 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Apr 28;7(1):lsaa003. doi: 10.1093/jlb/lsaa003. eCollection
      2020 Jan-Dec.


PMID- 32335917
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 107
IP  - 8
DP  - 2020 Jul
TI  - Neuroenhancement in surgeons: benefits, risks and ethical dilemmas.
PG  - 946-950
LID - 10.1002/bjs.11601 [doi]
AB  - BACKGROUND: Surgeons traditionally aim to reduce mistakes in healthcare through
      repeated training and advancement of surgical technology. Recently,
      performance-enhancing interventions such as neurostimulation are emerging which
      may offset errors in surgical practice. METHODS: Use of transcranial
      direct-current stimulation (tDCS), a novel neuroenhancement technique that has
      been applied to surgeons to improve surgical technical performance, was reviewed.
      Evidence supporting tDCS improvements in motor and cognitive performance outside 
      of the field of surgery was assessed and correlated with emerging research
      investigating tDCS in the surgical setting and potential applications to wider
      aspects of healthcare. Ethical considerations and future implications of using
      tDCS in surgical training and perioperatively are also discussed. RESULTS:
      Outside of surgery, tDCS studies demonstrate improved motor performance with
      regards to reaction time, task completion, strength and fatigue, while also
      suggesting enhanced cognitive function through multitasking, vigilance and
      attention assessments. In surgery, current research has demonstrated improved
      performance in open knot-tying, laparoscopic and robotic skills while also
      offsetting subjective temporal demands. However, a number of ethical issues arise
      from the potential application of tDCS in surgery in the form of safety,
      coercion, distributive justice and fairness, all of which must be considered
      prior to implementation. CONCLUSION: Neuroenhancement may improve motor and
      cognitive skills in healthcare professions with impact on patient safety.
      Implementation will require accurate protocols and regulations to balance
      benefits with the associated ethical dilemmas, and to direct safe use for
      clinicians and patients.
CI  - (c) 2020 The Authors. British Journal of Surgery published by John Wiley & Sons
      Ltd on behalf of BJS Society Ltd.
FAU - Patel, R
AU  - Patel R
AUID- ORCID: 0000-0003-2386-0102
AD  - Department of Surgery and Cancer, Imperial College London, St Mary's Hospital
      Campus, 10th Floor, Queen Elizabeth the Queen Mother Building, Praed Street,
      London, W2 1NY, UK.
FAU - Ashcroft, J
AU  - Ashcroft J
AUID- ORCID: 0000-0003-2964-5032
AD  - Department of Surgery and Cancer, Imperial College London, St Mary's Hospital
      Campus, 10th Floor, Queen Elizabeth the Queen Mother Building, Praed Street,
      London, W2 1NY, UK.
FAU - Darzi, A
AU  - Darzi A
AD  - Department of Surgery and Cancer, Imperial College London, St Mary's Hospital
      Campus, 10th Floor, Queen Elizabeth the Queen Mother Building, Praed Street,
      London, W2 1NY, UK.
FAU - Singh, H
AU  - Singh H
AD  - Department of Surgery and Cancer, Imperial College London, St Mary's Hospital
      Campus, 10th Floor, Queen Elizabeth the Queen Mother Building, Praed Street,
      London, W2 1NY, UK.
FAU - Leff, D R
AU  - Leff DR
AUID- ORCID: 0000-0002-5310-1046
AD  - Department of Surgery and Cancer, Imperial College London, St Mary's Hospital
      Campus, 10th Floor, Queen Elizabeth the Queen Mother Building, Praed Street,
      London, W2 1NY, UK.
LA  - eng
GR  - 1215-20013/NIHR Imperial Biomedical Research Centre/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200426
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - IM
MH  - Attention
MH  - *Clinical Competence
MH  - *Cognition
MH  - Fatigue/prevention & control/psychology
MH  - Humans
MH  - Medical Errors/ethics/*prevention & control/psychology
MH  - Multitasking Behavior
MH  - Muscle Strength
MH  - Patient Safety
MH  - *Psychomotor Performance
MH  - Reaction Time
MH  - Surgeons/ethics/*psychology
MH  - Surgical Procedures, Operative/ethics/*methods
MH  - *Transcranial Direct Current Stimulation/ethics/methods
EDAT- 2020/04/27 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/04/27 06:00 [entrez]
AID - 10.1002/bjs.11601 [doi]
PST - ppublish
SO  - Br J Surg. 2020 Jul;107(8):946-950. doi: 10.1002/bjs.11601. Epub 2020 Apr 26.


PMID- 32335863
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 1
DP  - 2020 May
TI  - DBS: a compelling example for ethical and legal reflection-a French perspective
      on ethical and legal concerns about DBS.
PG  - 15-34
LID - 10.1007/s40592-020-00111-3 [doi]
AB  - Deep brain stimulation (DBS) is an approved treatment for neurological diseases
      and a promising one for psychiatric conditions, which may produce spectacular
      results very quickly. It is also a powerful tool for brain research and
      exploration. Beyond an overview of the ethical and legal literature on this
      topic, this paper aims at showing that DBS is a compelling example for
      ethical-legal reflection, as it combines a highly technical surgical procedure, a
      complex active medical device and neuromodulation of the human brain to restore
      lost abilities caused by a chronic and evolving disease. Some of the ethical and 
      legal issues raised by DBS are not specific, but shed new light on medical ethics
      and law. Others are more DBS-specific, as they are linked to the intricacies of
      research and treatment, to the need to tune the device, to the patients' control 
      over the device and its effects and to the involvement of family caregivers.
FAU - Desmoulin-Canselier, Sonia
AU  - Desmoulin-Canselier S
AD  - NormaStim Program ANR14-CE30-0016, University of Nantes (UMR 6297 DCS), Nantes,
      France. Sonia.Desmoulin-Canselier@univ-nantes.fr.
AD  - Laboratoire Droit et Changement Social, UMR CNRS 6297: Faculte de Droit de
      Nantes, Chemin de la Censive du Tertre, BP 8130744 313, Nantes Cedex 3, France.
      Sonia.Desmoulin-Canselier@univ-nantes.fr.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - Brain
MH  - Deep Brain Stimulation/*ethics
MH  - *Ethics, Medical
MH  - France
MH  - Humans
MH  - *Legislation, Medical
MH  - Mental Disorders/*therapy
MH  - Nervous System Diseases/*therapy
OTO - NOTNLM
OT  - Autonomy
OT  - Control
OT  - Deep brain stimulation
OT  - Ethics
OT  - Family caregivers
OT  - Identity
OT  - Information
OT  - Liability
OT  - Medical law
OT  - Research
OT  - Treatment
EDAT- 2020/04/27 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/04/27 06:00 [entrez]
AID - 10.1007/s40592-020-00111-3 [doi]
AID - 10.1007/s40592-020-00111-3 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 May;38(1):15-34. doi: 10.1007/s40592-020-00111-3.


PMID- 32335796
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Ubuntu philosophy and the consensus regarding incidental findings in genomic
      research: a heuristic approach.
PG  - 433-444
LID - 10.1007/s11019-020-09953-4 [doi]
AB  - This study adopts a heuristic technique to argue the thesis that a set of norms
      rooted in the African philosophy of Ubuntu can usefully supplement current
      research guidelines for dealing with incidental findings discovered in genomic
      research. The consensus regarding incidental findings is that there is an ethical
      obligation to return individual genetic incidental findings that meet the
      threshold of analytic and clinical validity, have clinical utility, and are
      actionable, provided that research contributors have not opted out from receiving
      such information. This study outlines the hurdles that may hinder the integration
      of this consensus in mainstream clinical practice, and shows how an ethical
      theory from the global south may be used to address the same. This will advance
      the field of ethical, legal and social issues of personalized medicine by
      providing exposure to the under-represented African perspective on the ethical,
      legal, and social issues of genomics.
FAU - Ewuoso, Cornelius
AU  - Ewuoso C
AUID- ORCID: http://orcid.org/0000-0001-7219-5554
AD  - Department of Philosophy, University of Johannesburg, Johannesburg, South Africa.
      corneliusewuoso@bioethicscenter.net.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Consensus
MH  - *Ethical Theory
MH  - Genetic Counseling/ethics/methods
MH  - Genomics/*ethics/*legislation & jurisprudence
MH  - Guidelines as Topic
MH  - Heuristics
MH  - Humans
MH  - Incidental Findings
MH  - Moral Obligations
MH  - *Philosophy, Medical
OTO - NOTNLM
OT  - Ancillary obligations
OT  - Genomic research
OT  - Heuristic
OT  - Incidental findings
OT  - Ubuntu philosophy
EDAT- 2020/04/27 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/04/27 06:00 [entrez]
AID - 10.1007/s11019-020-09953-4 [doi]
AID - 10.1007/s11019-020-09953-4 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):433-444. doi: 10.1007/s11019-020-09953-4.


PMID- 32335639
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Transrectal Ultrasound Guided Prostatic Biopsy and its Complications: A
      Descriptive Cross-sectional Study.
PG  - 44-47
AB  - INTRODUCTION: Transrectal ultrasound of prostate provides better visual for
      biopsy. Transrectal ultrasound guided prostate biopsy is usually performed in men
      with an abnormal digital rectal examination, and elevated prostate specific
      antigen (>4ng/ml) or prostate specific antigen velocity (rate of prostate
      specific antigen change) i.e., >0.4-0.75ng/ml/year. The aim of the study is to
      find out the complications of transrectal ultrasound guided prostatic biopsies.
      METHODS: This descriptive cross-sectional study was done among 50 patients who
      transrectal ultrasound guided prostatic biopsies in a tertiary care hospital,
      from July 2017 to July 2019 after receiving ethical approval from the
      Institutional Review Committee of Kathmandu Medical College and teaching
      hospital. Convenient sampling was done. All patients were informed about the
      potential benefits and risks of the transrectal ultrasound guided prostate biopsy
      and patients signed an informed written consent form. Statistical analysis was
      done by using Statistical Package for Social Sciences version 16. RESULTS: Mean
      prostate specific antigen was 34.571 and mean weight of prostate was 44.6gm.
      Moderate to severe pain was experienced by 15 (30%), 2 (4%) had hematuria with
      fever accounting for 3 (6%) patients. All were managed conservatively with no
      mortality related to the procedure and complication. Three patients was positive 
      for malignancy on re-biopsy. CONCLUSIONS: Transrectal ultrasound guided biopsy of
      prostate is a pioneer experience in Nepal. It has proved to be an useful tool of 
      diagnosis of suspected carcinoma of Prostate. Use of neurovascular block may
      reduce the pain during the procedure.
FAU - Joshi, Robin
AU  - Joshi R
AD  - Department of Urology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Cross-Sectional Studies
MH  - Early Detection of Cancer/methods
MH  - *Hematuria/diagnosis/etiology
MH  - Humans
MH  - *Image-Guided Biopsy/adverse effects/methods
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - *Pain, Procedural/etiology/prevention & control
MH  - Prostate/*pathology
MH  - Prostate-Specific Antigen/blood
MH  - *Prostatic Diseases/blood/diagnosis/epidemiology
MH  - Rectum/diagnostic imaging
MH  - Reproducibility of Results
MH  - Ultrasonography, Interventional/*methods
PMC - PMC7580473
OTO - NOTNLM
OT  - biopsy; prostate-specific antigen; magnetic resonance imaging.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):44-47.


PMID- 32335638
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Health Seeking Behaviour among Medical Students in a Teaching Hospital of Nepal: 
      A Descriptive Cross-sectional Study.
PG  - 39-43
AB  - INTRODUCTION: Medical students are more prone to suffer from various
      physiological and psychological problems but rather than seeking for formal
      health care, they tend to do informal consultation and often practice self
      medication. Thus, this study aimed to find out the health seeking behavior of
      medical students. METHODS: This descriptive cross-sectional study was done among 
      first and second year medical students of a teaching hospital from September to
      November 2019 after taking ethical approval from Institutional Review Committe.
      Total of 235 students were included in the study and self administered
      questionnaire was used. Data entry and analysis was done using Statistical
      Package for Social Sciences version 20.0. RESULTS: Among 235 students who
      participated in the study, 172 (73%) reported having health problems in the last 
      12 months, and fever and headache were commonly reported by 21 (13%) and 18 (50%)
      students, respectively. Total of 112 (65%) students visited hospital/clinic for
      health problems and reason given for not visiting hospital/clinic was 12 (28%)
      thinking that the problem was minor. University hospital was the most preferred
      place 189 (80%) during health problem and parents were the first people for
      consultation 116 (49%). Mean duration of absenteeism was 2.17+/-4.1 days and 167 
      (88%) visited hospital more than five times. CONCLUSIONS: Health problems were
      common among students and most of them required multiple hospital visits. Many
      students seeked for health from hospital/ clinic but informal consultations were 
      also seen.
FAU - Bhandari, Mukta Singh
AU  - Bhandari MS
AD  - Department of Community Medicine, Kathmandu University School of Medical
      Sciences, Dhulikhel, Kavrepalanchok, Nepal.
FAU - Chataut, Jagdish
AU  - Chataut J
AD  - Department of Community Medicine, Kathmandu University School of Medical
      Sciences, Dhulikhel, Kavrepalanchok, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Absenteeism
MH  - Adult
MH  - *Attitude to Health
MH  - Cross-Sectional Studies
MH  - Education, Medical, Undergraduate
MH  - Female
MH  - Health Behavior
MH  - Hospitals, Teaching/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Nepal/epidemiology
MH  - *Patient Acceptance of Health Care/psychology/statistics & numerical data
MH  - *Self Medication/psychology/statistics & numerical data
MH  - *Students, Medical/psychology/statistics & numerical data
PMC - PMC7580474
OTO - NOTNLM
OT  - health care utilization; medical students; health behaviour.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):39-43.


PMID- 32335637
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Prevalence of Dental Fear among 6-15 Years Old School Children.
PG  - 33-38
AB  - INTRODUCTION: Odontophobia or dental fear is a "unique phobia with special
      psychosomatic components that impact on the dental health of the odontophobia
      persons". It is well documented that dental fear has a significant impact on
      dental care utilization behaviors. The objective of this study was to find out
      the level of dental fear among school children studying in government schools of 
      Dharan, Nepal. METHODS: A descriptive cross-sectional study was conducted from
      March to August 2017 among 215 school going children of Dharan of age group 6 to 
      15 years. Ethical approval was obtained. Children studying in six different
      government schools of Dharan were selected using two stage cluster sampling
      method. The Children's Fear Survey Schedule-Dental Subscale was used to measure
      dental fear among the study group. Data were entered in Microsoft Excel Sheet
      2007 and analyzed in Statistical Package of Social Sciences 11.5. RESULTS: This
      study showed that among the total study population, 96 (44.7%) had high fear, 62 
      (28.8%) had moderate fear and 57 (26.5%) had low dental fear. Among males, 29
      (34.5%) had high fear whereas more than half of the female respondents had high
      fear. CONCLUSIONS: The present study showed that most of the school going
      children had high fear of dental treatment. So, school health programs should be 
      planned to make the children familiar to dentistry and proper treatment
      modalities should be provided to make the child comfortable to seek dental care.
FAU - Dahal, Sirjana
AU  - Dahal S
AD  - Department of Community and Public Health Dentistry, Kathmandu Medical College
      Teaching Hospital, Duwakot, Bhaktapur, Nepal.
FAU - Shrestha, Ashish
AU  - Shrestha A
AD  - Department of Public Health Dentistry, B.P. Koirala Institute of Health Sciences,
      Dharan, Nepal.
FAU - Bhagat, Tarakant
AU  - Bhagat T
AD  - Department of Public Health Dentistry, B.P. Koirala Institute of Health Sciences,
      Dharan, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Child Behavior
MH  - Cross-Sectional Studies
MH  - *Dental Anxiety/diagnosis/psychology
MH  - Dental Care for Children/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Needs Assessment
MH  - *Patient Acceptance of Health Care/psychology/statistics & numerical data
MH  - Pediatric Dentistry/methods
MH  - Prevalence
MH  - School Health Services/organization & administration/standards
MH  - Sex Factors
PMC - PMC7580482
OTO - NOTNLM
OT  - children;dental fear; gender differences; Nepal.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):33-38.


PMID- 32335635
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Bacteriology of Sputum Samples: A Descriptive Cross-sectional Study in a Tertiary
      Care Hospital.
PG  - 24-28
AB  - INTRODUCTION: Lower respiratory tract infection is a common infection and
      accounts for a greater burden of disease worldwide. It is a great challenge to
      the clinician and still more, with increasing antimicrobial resistance. Its
      empirical treatment may vary according to the type of causative organisms. The
      objective of this study is to identify the pathogenic microorganisms and their
      antimicrobial susceptibility pattern from sputum sample. METHODS: This
      descriptive cross-sectional study was conducted in KIST Medical College and
      Teaching Hospital from February 2015 to January 2016. Ethical approval was taken 
      from institutional review committee prior to the study with reference no.
      0051/2014/15. Data on culture and sensitivity of isolates from sputum samples
      were collected from the records of the hospital. Sample collection, processing,
      identification of microorganisms and antimicrobial susceptibility tests were
      performed according to the Clinical and Laboratory Standards Institute
      guidelines. All the data were tabulated in an Excel sheet and analyzed using SPSS
      version 20. RESULTS: Out of 2318 samples, 694 (29.93%) sputum samples at 95%
      confidence interval (737.21- 650.79) were reported as culture positive.
      Klebsiella was the most common isolate followed by Pseudomonas, Escherichia coli,
      Acinetobacter, Staphylococcus aureus, Candida albicans, Streptococcus pneumoniae,
      Streptococcus pyogenes, and others. Imipenem and vancomycin showed the most
      sensitivity towards gram-negative and gram-positive bacteria respectively.
      CONCLUSIONS: Proper diagnosis, identification of causative agents and their
      antimicrobial susceptibility pattern are important steps to limit the irrational 
      use of antimicrobials. Prescribing antimicrobials empirically in the case of
      suspected lower respiratory tract infection is difficult.
FAU - Raghubanshi, Bijendra Raj
AU  - Raghubanshi BR
AD  - Department of Microbiology, KIST Medical College and Teaching Hospital, Gwarko,
      Lalitpur.
FAU - Karki, Bal Man Singh
AU  - Karki BMS
AD  - Department of Microbiology, KIST Medical College and Teaching Hospital, Gwarko,
      Lalitpur.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/classification/therapeutic use
MH  - Antimicrobial Stewardship
MH  - Bacteria/classification/isolation & purification
MH  - Bacteriological Techniques/methods/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Nepal/epidemiology
MH  - Practice Patterns, Physicians'
MH  - *Respiratory Tract Infections/epidemiology/microbiology/therapy
MH  - Sputum/*microbiology
MH  - Tertiary Care Centers/statistics & numerical data
PMC - PMC7580478
OTO - NOTNLM
OT  - antimicrobial drug resistance; culture; respiratory tract infections; sputum
      culture.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):24-28.


PMID- 32335634
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Prevalence of Self Medication Practice among Dental Undergraduates in a Dental
      college.
PG  - 20-23
AB  - INTRODUCTION: Self-medication practice among future prescribers can cause a
      serious threat to the health care profession. There has been an increasing trend 
      among medical and dental students for self-medication. The objective of our study
      was to find the prevalence and practice of self-medication among dental
      undergraduates in Kantipur Dental College and Teaching Hospital. METHODS: A
      descriptive cross-sectional study was conducted among all the dental
      undergraduate students of Kantipur Dental College, Kathmandu, from July to
      September 2018. Ethical clearance was obtained from the institutional review
      board. A convenience sampling method was used. A prevalidated questionnaire was
      handed to the students in their classroom to collect the data. The data were
      analyzed using Statistical Package for the Social Sciences version 16 and
      Microsoft Excel 2010 and presented as frequency and percentage. RESULTS: The
      prevalence of self-medication among dental undergraduates was found to be in 150 
      (83.3%) out of a total of 180 students who participated in the study.
      CONCLUSIONS: Self-medication was commonly practiced by dental students.
      Self-medication should be considered as a serious threat, especially among the
      students with inadequate knowledge of drug, dose, and duration of treatment.
FAU - Shrestha, Aastha
AU  - Shrestha A
AD  - Department of Pharmacology, Kantipur Dental College, Basundhara, Kathmandu,
      Nepal.
FAU - Madhikarmi, Nirjala Laxmi
AU  - Madhikarmi NL
AD  - Department of Biochemistry, Kantipur Dental College, Basundhara, Kathmandu,
      Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Education, Dental
MH  - *Education, Medical, Undergraduate
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Hospitals, Teaching/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Needs Assessment
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - *Self Medication/methods/statistics & numerical data
MH  - Students, Medical/*statistics & numerical data
MH  - Surveys and Questionnaires
PMC - PMC7580486
OTO - NOTNLM
OT  - dental students; prevalence; self medication; undergraduate.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):20-23.


PMID- 32335633
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Satisfaction Level among Patients Treated with Fixed Dental Prosthesis in a
      Tertiary Care Hospital: A Descriptive Cross-sectional Study.
PG  - 15-19
AB  - INTRODUCTION: Dental treatment aims at correction of existing disease; prevention
      of future disease with rehabilitation of patient's lost functional capacity and
      aesthetics. Fixed dental prosthesis is any prosthesis that is cemented to a
      natural tooth or dental implants abutments that cannot be removed by patient. The
      success of prosthodontic treatment is related to prosthesis survival, with its
      ability to fulfil biologic and patient-evaluated objectives with patient
      satisfaction. This study is aimed to find the patient satisfaction with fixed
      prosthodontic treatment. METHODS: This descriptive cross-sectional study was done
      in a tertiary care hospital among 102 patients rehabilitated with fixed dental
      prosthesis from August to September 2019 after taking ethical approval from
      Institutional Review Committee of Kathmandu Medical College. (IRC No.
      1207201918). Convenience sampling was done. The questionnaire assessed patient's 
      satisfaction of fixed prosthesis on the basis of appearance, chewing ability,
      cleansibility, speech and awareness of oral hygiene measures for cleaning of the 
      prosthesis. Data entry was done in Microsoft excel and analysed using Statistical
      Package for Social Sciences (SPSS)version 20.0, point estimate at 95% Confidence 
      Interval was calculated along with frequency and proportion for binary data.
      RESULTS: The majority of the patients 87 (85.3%) were satisfied with their fixed 
      prosthesis, at 95% confidence interval (93.5- 81%). Eighty one (79.4%) were
      satisfied with their chewing ability; 99 (97.1%) satisfied with their speech, 78 
      (76.4%) satisfied with appearance of fixed prosthesis. Ninety eight patients
      (96.1%) were aware of oral hygiene measures, out of which only 66 (67.3%) used
      interdental aids for cleaning of their fixed prosthesis. CONCLUSIONS: Several
      factors (chewing ability, appearance, speech, cleansibility of fixed prosthesis) 
      had positive impact on overall satisfaction in majority of the patients. Dentists
      should continue to emphasise on the significance of maintaining good oral hygiene
      and use of interdental aids for the longevity of fixed prosthesis.
FAU - Shrestha, Lajana
AU  - Shrestha L
AD  - Department of Prosthodontics and Maxillofacial Prosthetics, Kathmandu Medical
      College, Duwakot, Bhaktapur, Nepal.
FAU - Dahal, Sirjana
AU  - Dahal S
AD  - Department of Community and Public Health Dentistry, Kathmandu Medical College,
      Duwakot, Bhaktapur, Nepal.
FAU - Pradhan, Dilesh
AU  - Pradhan D
AD  - Department of Prosthodontics and Maxillofacial Prosthetics, Kathmandu Medical
      College, Duwakot, Bhaktapur, Nepal.
FAU - Lohani, Junu
AU  - Lohani J
AD  - Department of Prosthodontics and Maxillofacial Prosthetics, Kathmandu Medical
      College, Duwakot, Bhaktapur, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Dental Prosthesis/methods/psychology/standards
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Needs Assessment
MH  - Nepal/epidemiology
MH  - Oral Hygiene/*statistics & numerical data
MH  - Patient Satisfaction/*statistics & numerical data
MH  - Quality Improvement/organization & administration
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers/statistics & numerical data
PMC - PMC7580481
OTO - NOTNLM
OT  - dental prosthesis; interdental aids; satisfaction.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):15-19.


PMID- 32335631
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Prevalence of Operated Facial Injury in the Department of Oral and Maxillofacial 
      Surgery of a Tertiary Hospital.
PG  - 6-10
AB  - INTRODUCTION: Maxillofacial injury is one of the commonest causes of surgery
      performed by an oral and maxillofacial surgeon. Socioeconomic conditions,
      cultural variation, age, and gender affect the etiology of the injury. The study 
      is aimed to find the prevalence of facial injury that is operated by the oral and
      maxillofacial surgeons in the College of Medical Sciences and Teaching Hospital, 
      Bharatpur, Chitwan, a tertiary hospital. METHODS: A descriptive cross-sectional
      study was performed using the chart from the hospital registry for the patient
      being operated under general anesthesia from April 1, 2017, to March 2019. Simple
      random sampling was done using computer-generated random numbers. Ethical
      approval was received from the Institutional Review Committee of the hospital.
      The Data for the reason for surgery, age, age groups etiology, and tissue
      involvement were analyzed using Statistical Package for the Social Sciences
      version 20. RESULTS: Facial injury occupies 378 (71.59%) of the total operation
      performed by Oral and Maxillofacial surgeon in a tertiary hospital. Soft tissue
      196 (52.85%) and facial bone fracture 182 (48.15%) is distributed among the
      facial injuries. Young adults are commonly affected, and the road traffic
      accident is the major cause of facial trauma. CONCLUSIONS: Facial injury-related 
      surgeries are more prevalent in the tertiary hospital of Bharatpur.
FAU - Dhungel, Safal
AU  - Dhungel S
AD  - Department of Oral and Maxillofacial Surgery, College of Medical Sciences and
      Teaching Hospital, Bharatpur, Chitwan, Nepal.
FAU - Singh, Ashutosh Kumar
AU  - Singh AK
AD  - Department of Oral and Maxillofacial Surgery, College of Medical Sciences and
      Teaching Hospital, Bharatpur, Chitwan, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Accidents, Traffic/*statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - *Maxillofacial Injuries/epidemiology/etiology/surgery
MH  - Nepal/epidemiology
MH  - Prevalence
MH  - Skull Fractures/epidemiology/etiology/therapy
MH  - Soft Tissue Injuries/epidemiology/etiology/surgery
MH  - *Surgery, Oral/methods/statistics & numerical data
MH  - Tertiary Care Centers/statistics & numerical data
MH  - *Wounds and Injuries/epidemiology/etiology
MH  - Young Adult
PMC - PMC7580476
OTO - NOTNLM
OT  - facial injuries; maxillofacial injuries; prevalence; trauma.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):6-10.


PMID- 32335630
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 221
DP  - 2020 Jan
TI  - Prevalence of Postpartum Family Planning Service Coverage in Selected Referral
      Facilities of Nepal.
PG  - 1-5
AB  - INTRODUCTION: Nepal Society of Obstetricians and Gynecologists jointly with the
      Nepalese government and with the support from the International Federation of
      Obstetrics and Gynecology has implemented an initiative to institutionalize
      postpartum family planning services in selected major referral facilities of
      Nepal to address the gap of low uptake of postpartum family planning in Nepal.
      The aim of the study is to find the prevalence of the service coverage of
      postpartum contraception in the selected facilities. METHODS: A descriptive
      cross-sectional study was conducted in seven major referral facilities across
      Nepal. Data were collected from the hospital records of all women who delivered
      in these facilities between October 2018 and March 2019. Ethical approval for
      this study was obtained from Nepal Health Research Council. Data analysis was
      done with SPSS version 23. RESULTS: Among the 29,072 deliveries from all the
      facilities, postpartum family planning counseling coverage was 27,301 (93.9%).
      The prevalence of uptake of Postpartum Intrauterine Device is 1581 (5.4%) and
      female sterilization is 1830 (6.3%). In total 11387 mothers (52.2%) had the
      intention to choose a postpartum family planning method. However, 36% of mothers 
      neither used nor had the intention to choose a postpartum family planning method.
      CONCLUSIONS: The coverage of Postpartum Intrauterine Device counseling service
      coverage in Nepal is higher in 2018 as compared to 2016-2017 and in other
      countries implementing Postpartum Intrauterine Device initiatives. However, the
      prevalence of service coverage of immediate Postpartum Family Planning methods,
      mainly Postpartum Intrauterine Device in 2018 is lower in Nepal as compared to
      2016-2017, and other countries implementing Postpartum Intrauterine Device
      initiative. More efforts are needed to encourage mothers delivering in the
      facilities to use the postpartum family planning method.
FAU - Thapa, Kusum
AU  - Thapa K
AD  - Nepal Society of Obstetricians and Gynaecologists, Paropakar Maternity and
      Women's Hospital Thapathali, Kathmandu, Nepal.
FAU - Dhital, Rolina
AU  - Dhital R
AD  - Nepal Society of Obstetricians and Gynaecologists, Paropakar Maternity and
      Women's Hospital, Thapathali, Kathmandu, Nepal.
FAU - Rajbhandari, Sameena
AU  - Rajbhandari S
AD  - Nepal Society of Obstetricians and Gynaecologists, Paropakar Maternity and
      Women's Hospital Thapathali, Kathmandu, Nepal.
FAU - Thapa, Shikha
AU  - Thapa S
AD  - Nepal Society of Obstetricians and Gynaecologists, Paropakar Maternity and
      Women's Hospital Thapathali, Kathmandu, Nepal.
FAU - Pokhrel, Sabina
AU  - Pokhrel S
AD  - Nepal Society of Obstetricians and Gynaecologists, Paropakar Maternity and
      Women's Hospital Thapathali, Kathmandu, Nepal.
FAU - Mishra, Sangeeta
AU  - Mishra S
AD  - Koshi Zonal Hospital, Biratnagar Morang District, Province One, Nepal.
FAU - Subedi, Shanti
AU  - Subedi S
AD  - Nobel Medical College Teaching Hospital Biratnagar, Morang District, Province
      One, Nepal.
FAU - Singh, Dela
AU  - Singh D
AD  - Western Regional Hospital Pokhara, Nepal.
FAU - Acharya, Shreedhar
AU  - Acharya S
AD  - Lumbini Zonal Hospital, Butwal, Nepal.
FAU - Pokhrel, Sunil Mani
AU  - Pokhrel SM
AD  - Bharatpur Hospital Bharatpur, Nepal.
FAU - Thapa, Kalpana
AU  - Thapa K
AD  - Bheri Zonal Hospital, Nepalgunj, Nepal.
FAU - Poudel, Atit
AU  - Poudel A
AD  - Bhakatpur Hospital, Bhakatpur, Nepal.
FAU - Vaidya, Sapana
AU  - Vaidya S
AD  - Nepal Society of Obstetricians and Gynaecologists, Paropakar Maternity and
      Women's Hospital Thapathali, Kathmandu, Nepal.
FAU - Tunnacliffe, Emily-Anne
AU  - Tunnacliffe EA
AD  - International Federation of Obstetrics and Gynecology London, UK.
FAU - Makins, Anita
AU  - Makins A
AD  - International Federation of Obstetrics and Gynecology London, UK.
FAU - Arulkumaran, Sabaratnam
AU  - Arulkumaran S
AD  - International Federation of Obstetrics and Gynecology London, UK.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Contraception/*statistics & numerical data
MH  - *Counseling/methods/statistics & numerical data
MH  - Cross-Sectional Studies
MH  - *Family Planning Services/methods/standards
MH  - Female
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Intrauterine Devices/*statistics & numerical data
MH  - Nepal
MH  - *Postpartum Period
MH  - Pregnancy
MH  - Prevalence
MH  - *Professional Practice Gaps/methods/statistics & numerical data
MH  - Quality Improvement/organization & administration
PMC - PMC7580487
OTO - NOTNLM
OT  - family planning services; female sterilization; intrauterine devices; postpartum 
      period.
EDAT- 2020/04/27 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Jan;58(221):1-5.


PMID- 32335623
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Knowledge and Preventive Practices of Hepatitis B Transmission among Dental
      Students and Interns in a Tertiary Hospital: A Descriptive Cross-sectional Study.
PG  - 108-111
AB  - INTRODUCTION: Hepatitis B is one of the most common contagious diseases in Nepal 
      and is a signifi- cant public health issue. It is transmitted through contact
      with contaminated blood or other bodily fluids on broken skin or mucous
      membranes. Junior doctors and dentists are at particular risk of hepatitis B
      exposure. This study aims to find the level of knowledge of transmission and
      prevention of hepatitis B among the dental students. METHODS: This was a
      descriptive cross-sectional study conducted among dental students and interns at 
      Kantipur Dental College Teaching Hospital and Research Center, Kathamndu from
      January 2019 to February 2019 after ethical approval was provided by the
      Institutional Review Committee. The study included dental students and graduate
      intern doctors. Convenience sampling was done. Point estimate at 95% Confidence
      Interval was done along with frequency and proportion of binary data. RESULTS:
      Out of one hundred forty two students, 68 (48%) of participants had completed a
      full course of hepatitis B vaccine. Thirty seven (26%) had started but had less
      than three recommended shots and 37 (26%) had not received any vaccines for
      hepatitis B prevention. Only 14 (10%) of the study group had checked their
      hepatitis B titer prior to commencing medical education. CONCLUSIONS: There is
      also a lack of understanding of transmission, prevention and post exposure
      prophylaxis for hepatitis B infection among them among new health care providers 
      in Nepal. This puts both the practitioners and patients at risk of chronic
      hepatitis B infection, which is unnecessary given cheap and easy prevention
      strategies, can virtually eliminate the risk.
FAU - Bhandari, Durga
AU  - Bhandari D
AD  - Department of Internal Medicine, Kantipur Dental College Teaching Hospital and
      Research Center, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Health Knowledge, Attitudes, Practice
MH  - *Health Personnel
MH  - *Hepatitis B/epidemiology/prevention & control
MH  - Humans
MH  - Nepal/epidemiology
MH  - *Students, Dental
MH  - Tertiary Care Centers
MH  - Vaccination
PMC - PMC7654456
OTO - NOTNLM
OT  - Hepatitis B; dental students; vaccination.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):108-111.


PMID- 32335621
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Knowledge on Diet among the Hypertensive Patients in a Tertiary Care Center
      Nepal: A Descriptive Cross-sectional Study.
PG  - 98-101
AB  - INTRODUCTION: Hypertension is one of the leading causes of death and disability
      in both developed and developing countries. The prevalence of hypertension is
      increasing rapidly worldwide. The aim of the study was to determine the knowledge
      of diet and exercise among hypertensive patients. METHODS: This descriptive
      cross-sectional study was conducted using a structured questionnaire among 169
      hypertensive patients at Kathmandu diabetes and thyroid center from May 2017 to
      July 2017 after taking ethical clearance from Nepal Health Research Council,
      Nepal. A convenience sampling method was used. Data was collected and entry was
      done in Statistical Package for the Social Sciences version 16.0 point estimate
      at 95% confidence interval was calculated along with frequency and proportion for
      binary data. RESULTS: Out of total 169 participants enrolled in this study, only 
      79 (46.7%) had good knowledge and 90 (53.3%) had poor knowledge regarding diet
      and exercise. The mean age of participants was 54.68+/-13.91 years. CONCLUSIONS: 
      This study revealed that the knowledge about diet and exercise among hypertensive
      patients is poor and this study suggests the need for a proper educational
      intervention to improve awareness and to control hypertension effectively.
FAU - Maharjan, Nabina
AU  - Maharjan N
AD  - Department of Healthcare Management, School of Health Sciences, Wuhan University,
      Wuhan, China.
FAU - Maharjan, Narayani
AU  - Maharjan N
AD  - Department of Clinical Laboratory Science, Zhongnan Hospital of Wuhan University,
      Wuhan, Hubei, China.
FAU - Li, Rui
AU  - Li R
AD  - Department of Healthcare Management, School of Health Sciences, Wuhan University,
      Wuhan, China.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - *Diet
MH  - Exercise
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Hypertension/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Nepal/epidemiology
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
MH  - Young Adult
PMC - PMC7654453
OTO - NOTNLM
OT  - diet; exercise; hypertension; knowledge.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):98-101.


PMID- 32335620
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Study of Missing Clinical Details in Computed Tomography Radiology Request Forms:
      A Descriptive Cross-sectional Study.
PG  - 94-97
AB  - INTRODUCTION: Detailed clinical history through a properly filled requisition
      form can help a radiologist in making a diagnosis. The objective of this study
      was to observe the missing clinical details of Computed Tomography requisition
      forms at radiology department in tertiary care hospital. METHODS: This
      descriptive cross-sectional study was done in 196 Computed Tomography requisition
      forms in the department of radiology from September 2019 to October 2019. Ethical
      clearance from the Institutional Review Committee - Reference No. 120720194 was
      obtained. An informed consent from the participants was taken prior to the
      procedure. Convenient sampling was done. The data obtained were computed and
      analyzed using Statistical Package for Social Sciences to tabulate the results.
      The results were displayed in frequency and proportion of binary data. RESULTS:
      All the request forms had name filled, however date was filled in 183 (93.4%),
      age was filled in 195 (99.5%), sex was filled in 193 (98.5%) and address was only
      in 30 (15.3%) of the forms. Clinical history and provisional diagnosis were
      written in 179 (91.3%) forms. Signature was found in more than half of forms 135 
      (68.9%) whereas the department referring the patient was filled in 92 (46.9%) of 
      forms and the name of doctor referring the patient was not filled mostly. The
      handwriting was clear in 191 (97.4%) of cases and standard words were used. Use
      of non-standard abbreviation was found in only 2 (1%) forms. CONCLUSIONS:
      Clinical details were filled in most of the requisition forms however other
      parameters were still incompletely and inadequately filled.
FAU - Badu, Muna
AU  - Badu M
AD  - Department of Radiology, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Forms and Records Control
MH  - Humans
MH  - *Informed Consent
MH  - Physicians
MH  - *Radiology
MH  - *Tomography, X-Ray Computed
PMC - PMC7654455
OTO - NOTNLM
OT  - data; forms; missing; Tomography; radiology.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):94-97.


PMID- 32335619
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Knowledge and Attitude Regarding Patients Right among Nurses in a Teaching
      Hospital: A Descriptive Cross-sectional Study.
PG  - 88-93
AB  - INTRODUCTIONS: It is important to maintain trust and satisfaction among patients.
      The health personnel take an important role to overcome their right. The
      objective of this study was to find out knowledge and attitude regarding
      patients' rights among nurses in Teaching Hospital. METHODS: A descriptive cross 
      sectional study was conducted among 122 nurses in different wards of Teaching
      Hospital. Nurses were selected by using simple random sampling technique for data
      collection. Ethical clearance was taken from Chitwan Medical College
      institutional reviewers Committee (CMC-IRC) to conduct the study. A structured,
      self- administered questionnaire and five-point Likert scale were used to analyze
      the collected data. Data was collected from 27th Ashadh to 9th Shrawan 2075.
      RESULTS: This study revealed that out of 122 respondents, 30 (24.6%) of
      respondents have an adequate level of knowledge whereas about half 62 (50.8%) of 
      respondents had favorable and 60 (49.2%) had an unfavorable level of attitude
      regarding patients right. Sixty-one (50%) of the nurses were from the age group
      <22 years, 27 (77.9%) were unmarried, about 93 (76.2%) of nurses had completed
      Proficiency Certificate Level Nursing, 101 (82.2%) had work experience less than 
      24 months. CONCLUSIONS: According to the study, it concluded that one-fourth of
      the respondents have an adequate level of knowledge, one-half of the respondents 
      had a favorable attitude. Therefore, knowledge and attitude regarding patients'
      rights should be increase through in-service education and seminars should be
      organized by the administration to promote quality health care service.
FAU - Gurung, Tara
AU  - Gurung T
AD  - Department of Medicine, Chitwan Medical College and Teaching Hospital, Bharatpur,
      Chitwan, Nepal.
FAU - Neupane, Srijana
AU  - Neupane S
AD  - School of Nursing, Chitwan Medical College and Teaching Hospital, Kailashnagar,
      Chitwan, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - *Health Knowledge, Attitudes, Practice
MH  - Hospitals, Teaching
MH  - Humans
MH  - *Nurses
MH  - *Patient Rights
MH  - Surveys and Questionnaires
MH  - Young Adult
PMC - PMC7654450
OTO - NOTNLM
OT  - attitude; knowledge; patients right.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):88-93.


PMID- 32335618
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Emergency Stay Duration of Patients in Emergency Department of A Tertiary Care
      Hospital in Nepal: A Descriptive Cross-sectional Study.
PG  - 84-87
AB  - INTRODUCTION: Emergency department of a hospital is responsible for providing
      medical and surgical care to patients arriving at the hospital in need of
      immediate care. Emergency department is not staffed or equipped to provide
      prolonged care. Duration of stay in the Emergency department directly affects the
      quality of patient care. Longer length of stay is associated with Emergency
      department overcrowding, decline in patient care, increased mortality and
      decreased patients satisfaction. The main aim of this study is to find the mean
      stay duration of patients in the emergency department of a tertiary care hospital
      in Nepal. METHODS: This is a descriptive cross-sectional study which was
      conducted in a tertiary care teaching hospital from Jan 15,2019 to Jan 30, 2019. 
      Ethical clearance was obtained from Kathmandu Medical College- Instutional Review
      Committee. The calculated sample size was 587. Consecutive sampling technique was
      used. The data thus obtained was entered in SPSS version 20 and necessary
      calculations were done. RESULTS: The mean emergency stay duration was obtained to
      be 3.18 hours at 95% confidence interval (C.I and standard deviation was 2.51
      hours. Female had longer mean duration of stay (3.25 hours) compared to male
      (3.11 hours). The maximum length of stay was 15.3 hours. Most of the patients
      attending the emergency department were discharged right through the emergency
      department 398 ( 67.8%). Mean duration of stay was longest (5.06 hours) for the
      referral group. CONCLUSIONS: The mean stay duration in Emergency Department of
      tertiary care hospital in Nepal is getting shorter compared to similar study done
      previously.
FAU - Simkhada, Prashant
AU  - Simkhada P
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Acharya, Shradha
AU  - Acharya S
AD  - Tribhuban University Teaching Hospital, Maharajgunj, Kathmandu, Nepal.
FAU - Lama, Roshan
AU  - Lama R
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Dahal, Sujata
AU  - Dahal S
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
FAU - Lohola, Nita
AU  - Lohola N
AD  - Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
FAU - Thapa, Ashish
AU  - Thapa A
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Emergencies
MH  - *Emergency Service, Hospital
MH  - Female
MH  - Humans
MH  - *Length of Stay
MH  - Male
MH  - Nepal
MH  - Tertiary Care Centers
PMC - PMC7654449
OTO - NOTNLM
OT  - emergency; length of stay; Nepal.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):84-87.


PMID- 32335617
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Prevalence of Atrial Fibrillation in Obstructive Sleep Apnea Patients in a
      Tertiary Care Center.
PG  - 80-83
AB  - INTRODUCTION: Atrial fibrillation is the most common sustained
      arrhythmias.Recently there has been evidence of higher prevalence of atrial
      fibrillation in obstructive sleep apnea patients compared to the general
      population. The aim of this study was to find the prevalence of atrial
      fibrillation in patients of obstructive sleep apnea in a tertiary care center.
      METHODS: This descriptive cross-sectional study was done in Om Hospital and
      Research Centre from January 2016 to 2018 March after ethical clearance.
      Convenience sampling was done. Data was collected and entry was done in microsoft
      excel, point estimate at 95% Confidence Interval was calculated along with
      frequency and proportion for binary data. RESULTS: The prevalence of atrial
      fibrillation in patients with obstructive sleep apnea is 7 (10.44%) at 95%
      Confidence Interval (6.70-14.17%). Apnoea-Hypopnoea Index of more than 30was
      present in 3 (42.8%) patients of atrial fibrillation. Atrial fibrillation was
      seen highest, 3 (42.8%) in patients with BMI more than 30 and lowest, 1 (14.28%) 
      patients with BMI less than 23.5. Prevalence of atrial fibrillation was seen 5
      (71.4%) in male patients and 2 (28.57%) in female patients. Sixty seven (75.28%) 
      patients had obstructive sleep apnea in which male patients was predominant 48
      (71.64%). CONCLUSIONS: Prevalence ofatrial fibrillation in patients of
      obstructive sleep apnea was found to higher than the similar studies done. It is 
      important to obtain detail cardiac history in any patients with obstructive sleep
      apnea and look for arrhythmias speciallyatrial fibrillation.
FAU - Dhakal, Subodh Sagar
AU  - Dhakal SS
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathamndu, Nepal.
FAU - Neupane, Asmita
AU  - Neupane A
AD  - Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathamndu, Nepal.
FAU - Bhattarai, Mahesh
AU  - Bhattarai M
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathamandu, Nepal.
FAU - Karki, Dambar Bahadur
AU  - Karki DB
AD  - Department of Internal Medicine, Kathmandu Medical College and Teaching Hospital,
      Sinamangal, Kathamandu, Nepal.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Adult
MH  - *Atrial Fibrillation/epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Risk Factors
MH  - *Sleep Apnea, Obstructive/epidemiology
MH  - Tertiary Care Centers
PMC - PMC7654447
OTO - NOTNLM
OT  - atrial fibrillation; obstructive sleep apnea; prevalence.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):80-83.


PMID- 32335616
OWN - NLM
STAT- MEDLINE
DCOM- 20210503
LR  - 20210503
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 222
DP  - 2020 Feb
TI  - Sleep Quality among Medical Students of a Tertiary Care Hospital: A Descriptive
      Cross-sectional Study.
PG  - 76-79
AB  - INTRODUCTION: Medical students are under constant stress due to demanding
      academic load, fear of exam failure and hectic schedules. These factors can lead 
      to poor sleep quality among medical students. Sleep quality of medical students
      not only determine their academic performance but is also important in
      determining long term effect on cognitive, psychosocial, behavioural as well as
      physical health of individuals. Although there are not enough recent studies to
      assess sleep quality of students, it is necessary to evaluate the condition of
      sleep among students. This study aims to find out the prevalence of poor sleep
      quality among medical students. METHODS: This descriptive cross-sectional was
      conducted among undergraduate medical students of Kathmandu Medical College from 
      October to November 2019 after taking ethical clearance from Institutional Review
      Committee of a tertiary care hospital before collecting data from participants.
      Subjects were recruited by simple random sampling from students of first, second,
      third and final years and were asked to fill the self-reported questionnaires,
      using Pittsburgh Sleep Quality Index. Descriptive statistical analysis was done
      using Statistical Software for Social Sciences version 24. RESULTS: Out of 217
      selected medical students, 96 (44.23%) of students have poor sleep quality with
      prevalence among male and female students as 41 (39.8%) and 55 (48.2%)
      respectively. The mean duration of sleep among students was 6.7+/-1.6 hours.
      CONCLUSIONS: Significant numbers of medical students have poor sleep quality
      which may affect their academic performance and may have long term impact on
      their health. Efforts must be directed towards educating about the sleep hygiene 
      as well as proper time management skills.
FAU - Sundas, Nabin
AU  - Sundas N
AD  - Kathmandu Medical College, Sinamangal, Kathmandu.
FAU - Ghimire, Saransh
AU  - Ghimire S
AD  - Kathmandu Medical College, Sinamangal, Kathmandu.
FAU - Bhusal, Suzit
AU  - Bhusal S
AD  - Kathmandu Medical College, Sinamangal, Kathmandu.
FAU - Pandey, Rakshya
AU  - Pandey R
AD  - Kathmandu Medical College, Sinamangal, Kathmandu.
FAU - Rana, Krishna
AU  - Rana K
AD  - Deurali Primary Health center, Nuwakot, Nepal.
FAU - Dixit, Hemang
AU  - Dixit H
AD  - Kathmandu Medical College, Sinamangal, Kathmandu.
LA  - eng
PT  - Journal Article
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - *Sleep
MH  - *Students, Medical
MH  - Surveys and Questionnaires
MH  - Tertiary Care Centers
PMC - PMC7654448
OTO - NOTNLM
OT  - medical students; Pittsburgh sleep quality index; sleep quality.
EDAT- 2020/04/27 06:00
MHDA- 2021/05/04 06:00
CRDT- 2020/04/27 06:00
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/05/04 06:00 [medline]
PST - ppublish
SO  - JNMA J Nepal Med Assoc. 2020 Feb;58(222):76-79.


PMID- 32335032
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1701-2163 (Print)
IS  - 1701-2163 (Linking)
VI  - 42
IP  - 9
DP  - 2020 Sep
TI  - Bioethics of Translating Limited Evidence into Clinical Practice: Case Study of
      the Cerebroplacental Ratio.
PG  - 1154-1157
LID - S1701-2163(20)30221-8 [pii]
LID - 10.1016/j.jogc.2020.02.117 [doi]
AB  - Bioethics can help address the challenges of translating research into clinical
      practice in the twenty-first century. The cerebroplacental ratio in obstetrical
      ultrasound provides a case study of how bioethical principles can help advance
      practical approaches when evidence is limited. This can help clinicians use
      cerebroplacental ratio when additional risk factors are present in critical cases
      that warrant increased surveillance; disclose limited information appropriately; 
      allocate resources; and weigh benefits against risks. Balancing the key ethical
      principles of respect for autonomy, beneficence, non-maleficence, and justice
      within this context illuminates how bioethics can assist health care providers as
      well as help set a research agenda. Such analyses are essential to improving
      clinical care, given the rapid pace at which medicine is evolving.
CI  - Copyright (c) 2020 The Society of Obstetricians and Gynaecologists of Canada/La
      Societe des obstetriciens et gynecologues du Canada. Published by Elsevier Inc.
      All rights reserved.
FAU - Ramji, Naila
AU  - Ramji N
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and
      Newborn Care, The Ottawa Hospital, University of Ottawa, Ottawa, ON. Electronic
      address: naila.ramji@post.harvard.edu.
FAU - Klitzman, Robert
AU  - Klitzman R
AD  - Department of Psychiatry, College of Physicians & Surgeons, Columbia University, 
      New York, NY; Department of Bioethics, School of Professional Studies, Columbia
      University, New York, NY.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - Netherlands
TA  - J Obstet Gynaecol Can
JT  - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et
      gynecologie du Canada : JOGC
JID - 101126664
SB  - IM
MH  - Beneficence
MH  - *Bioethics
MH  - Fetal Growth Retardation/*diagnostic imaging
MH  - Fetus/*diagnostic imaging
MH  - Humans
MH  - Social Justice
MH  - Ultrasonography, Prenatal/*ethics
OTO - NOTNLM
OT  - *bioethics
OT  - *obstetrics
OT  - *translational medical research
OT  - *ultrasonography
EDAT- 2020/04/27 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/27 06:00
PHST- 2019/09/14 00:00 [received]
PHST- 2020/02/01 00:00 [revised]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/04/27 06:00 [entrez]
AID - S1701-2163(20)30221-8 [pii]
AID - 10.1016/j.jogc.2020.02.117 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Can. 2020 Sep;42(9):1154-1157. doi: 10.1016/j.jogc.2020.02.117.
      Epub 2020 Apr 22.


PMID- 32334575
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Apr 25
TI  - Autonomous decisions by couples in reproductive care.
PG  - 30
LID - 10.1186/s12910-020-00470-w [doi]
AB  - BACKGROUND: Preconception Expanded Carrier Screening (ECS) is a genetic test
      offered to a general population or to couples who have no known risk of recessive
      and X-linked genetic diseases and are interested in becoming parents. A test may 
      screen for carrier status of several autosomal recessive diseases at one go. Such
      a program has been piloted in the Netherlands and may become a reality in more
      European countries in the future. The ethical rationale for such tests is that
      they enhance reproductive autonomy. The dominant conception of autonomy is
      individual-based. However, at the clinic, people deciding on preconception ECS
      will be counselled together and are expected to make a joint decision, as a
      couple. The aim of the present study was to develop an understanding of
      autonomous decisions made by couples in the context of reproductive technologies 
      in general and of preconception ECS in particular. Further, to shed light on what
      occurs in reproductive clinics and suggest concrete implications for healthcare
      professionals. MAIN TEXT: Based on the shift in emphasis from individual autonomy
      to relational autonomy, a notion of couple autonomy was suggested and some
      features of this concept were outlined. First, that both partners are
      individually autonomous and that the decision is reached through a communicative 
      process. In this process each partner should feel free to express his or her
      concerns and preferences, so no one partner dominates the discussion. Further,
      there should be adequate time for the couple to negotiate possible differences
      and conclude that the decision is right for them. The final decision should be
      reached through consensus of both partners without coercion, manipulation or
      miscommunication. Through concrete examples, the suggested notion of couple
      autonomy was applied to diverse clinical situations. CONCLUSIONS: A notion of
      couple autonomy can be fruitful for healthcare professionals by structuring their
      attention to and support of a couple who is required to make an autonomous joint 
      decision concerning preconception ECS. A normative implication for healthcare
      staff is to allow the necessary time for decision-making and to promote a
      dialogue that can increase the power of the weaker part in a relationship.
FAU - Matar, Amal
AU  - Matar A
AD  - Centre for Research Ethics and Bioethics, Department of Public Health and Caring 
      Sciences, Uppsala University, Box 564, 751 22, Uppsala, Sweden.
FAU - Hoglund, Anna T
AU  - Hoglund AT
AD  - Centre for Research Ethics and Bioethics, Department of Public Health and Caring 
      Sciences, Uppsala University, Box 564, 751 22, Uppsala, Sweden.
      anna.hoglund@crb.uu.se.
FAU - Segerdahl, Par
AU  - Segerdahl P
AD  - Centre for Research Ethics and Bioethics, Department of Public Health and Caring 
      Sciences, Uppsala University, Box 564, 751 22, Uppsala, Sweden.
FAU - Kihlbom, Ulrik
AU  - Kihlbom U
AD  - Centre for Research Ethics and Bioethics, Department of Public Health and Caring 
      Sciences, Uppsala University, Box 564, 751 22, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200425
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Decision Making
MH  - Europe
MH  - Female
MH  - Genetic Carrier Screening
MH  - *Genetic Testing
MH  - Humans
MH  - Netherlands
MH  - *Parents
MH  - *Personal Autonomy
PMC - PMC7183638
OTO - NOTNLM
OT  - *Couple autonomy
OT  - *Expanded carrier screening
OT  - *Preconception
OT  - *Relational autonomy
OT  - *Reproductive autonomy
EDAT- 2020/04/27 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/04/27 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00470-w [doi]
AID - 10.1186/s12910-020-00470-w [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Apr 25;21(1):30. doi: 10.1186/s12910-020-00470-w.


PMID- 32333688
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 4
DP  - 2020 May
TI  - The ethics of ectogenesis.
PG  - 328-330
LID - 10.1111/bioe.12745 [doi]
FAU - Rasanen, Joona
AU  - Rasanen J
AD  - Department of Philosophy, Classics, History of Art and Ideas, University of Oslo,
      Oslo, Norway.
FAU - Smajdor, Anna
AU  - Smajdor A
AD  - Department of Philosophy, Classics, History of Art and Ideas, University of Oslo,
      Oslo, Norway.
LA  - eng
PT  - Editorial
PT  - Introductory Journal Article
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Ectogenesis/*ethics
MH  - Female
MH  - Fetus/embryology
MH  - Humans
MH  - Pregnancy
MH  - Uterus
EDAT- 2020/04/26 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.1111/bioe.12745 [doi]
PST - ppublish
SO  - Bioethics. 2020 May;34(4):328-330. doi: 10.1111/bioe.12745.


PMID- 32332651
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20210115
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 17
DP  - 2020 Apr
TI  - Electroacupuncture for lumbar disc herniation: A protocol for systematic review
      and meta-analysis.
PG  - e19867
LID - 10.1097/MD.0000000000019867 [doi]
AB  - BACKGROUND: This systematic review aims to evaluate the effectiveness of
      electroacupuncture in treatment of lumbar disc herniation (LDH). METHODS:
      Electronic databases of all electroacupuncture for LDH will be searched at
      PubMed, Cochrane Library, Springer, EMBASE, China National Knowledge
      Infrastructure (CNKI), Wan-Fang, and Chinese Biological Medical disc, (CBM) from 
      inception to February 29, 2020, with language restricted in Chinese and English. 
      The primary outcome is Japanese Orthopedic Association Scores, a quantification
      scale for a comprehensive assessment according to patients' subjects feeling and 
      objective function. Secondary outcomes included visual analogue scale (VAS),
      Oswestry dysfunction index (ODI), Pittsburgh sleep quality index (PSQI),
      Self-rating anxiety scale (SAS), self-depression rating scale (SDS), follow-up
      relapse rate. The systematic review and searches for randomized controlled trials
      of this therapy for LDH. The Cochrane RevMan V5.3 bias assessment tool is
      implemented to assess bias risk, data integration risk, meta-analysis risk, and
      subgroup analysis risk (if conditions are met). Mean difference (MD), standard
      mean deviation (SMD) and binary data will be used to represent continuous
      results. RESULTS: This study will provide a comprehensive review and evaluation
      of the available evidence for the treatment of LDH with this therapy. CONCLUSION:
      This study will provide new evidence to evaluate the effectiveness and side
      effects of electroacupuncture for LDH. Due to the data is not personalized, no
      formal ethical approval is required.
FAU - Shen, Yuquan
AU  - Shen Y
AD  - Affiliated to The First People's Hospital of Longquanyi District, Chengdu,
      Sichuan.
FAU - Zhou, Qun
AU  - Zhou Q
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Leixiao
AU  - Zhang L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine,
      Chengdu, Sichuan.
FAU - Gao, Liang
AU  - Gao L
AD  - Boai hospital affiliated to China rehabilitation research center, Beijing.
FAU - Zhang, Di
AU  - Zhang D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Wang, Xinling
AU  - Wang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Yu, Yang
AU  - Yu Y
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Zhang, Zhengsong
AU  - Zhang Z
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Liu, Jianjia
AU  - Liu J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
FAU - Liang, Shumi
AU  - Liang S
AD  - Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Guilong
AU  - Zhang G
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - Intervertebral disc disease
SB  - IM
MH  - Clinical Protocols
MH  - Electroacupuncture/methods/*standards
MH  - Humans
MH  - Intervertebral Disc Degeneration/physiopathology/*therapy
MH  - Intervertebral Disc Displacement/physiopathology/*therapy
MH  - Meta-Analysis as Topic
MH  - Review Literature as Topic
MH  - Treatment Outcome
PMC - PMC7440177
EDAT- 2020/04/26 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 10.1097/MD.0000000000019867 [doi]
AID - 00005792-202004240-00062 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(17):e19867. doi: 10.1097/MD.0000000000019867.


PMID- 32332616
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 17
DP  - 2020 Apr
TI  - Effects of angiotensin-converting enzyme inhibitors or angiotensin receptor
      blockers on all-cause mortality, cardiovascular death, and cardiovascular events 
      among peritoneal dialysis patients: A protocol for systematic review.
PG  - e19767
LID - 10.1097/MD.0000000000019767 [doi]
AB  - BACKGROUND: Based on the International Society for peritoneal dialysis (PD)
      recommendations, blockade of renin-angiotensin systems with an
      angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers
      (ARB) improves residual kidney function in PD patients. However, the long-term
      effectiveness of ACEI/ARB use in PD patients has not been fully elucidated. We,
      therefore, intend to perform a systematic review and meta-analysis to summarize
      the effects of ACEI/ARB use on long-term mortality, cardiovascular outcomes, and 
      adverse events among PD patients. METHODS: This systematic review will include
      both randomized controlled trials and non-randomized studies in adult PD
      patients. We also plan to incorporate data from our cohort study in Thai PD
      population into this review. We will search PubMed, Medline, EMBASE, Cochrane
      Library, Web of Science, Scopus, CINAHL, and grey literature from inception to
      February 29, 2019, with no language restrictions. The process of study screening,
      selection, data extraction, risk of bias assessment, and grading the strength of 
      evidence will be performed independently by a pair of reviewers. Any discrepancy 
      will be resolved through a team discussion and/or consultation with the third
      reviewer. The pooled effects estimate and 95% confidence intervals will be
      estimated using DerSimonian-Laird random-effects models. Heterogeneity will be
      assessed by the Cochran Q test, I index and tau-squared statistics. The funnel
      plots along with the Begg and Egger test and trim and fill method will be
      performed to investigate any evidence of publication bias. Preplanned subgroup
      analyses and random-effects univariate meta-regressions will be performed to
      quantify the potential sources of heterogeneity based on studies- and
      patient-characteristics. RESULTS: This will be the first systematic review and
      meta-analysis to summarize the long-term effectiveness of renin-angiotensin
      system inhibitors in PD populations. CONCLUSION: In summary, this systematic
      review and meta-analysis will summarize the effectiveness of ACEI/ARB on
      long-term mortality, cardiovascular outcomes, and adverse events among adult PD
      patients by integrated all available evidences. ETHICS AND DISSEMINATION: Based
      on the existing published data, an ethical approval is not required. The findings
      will be disseminated through scientific meetings and publications in
      peer-reviewed journals.PROSPERO registration number: CRD42019129492.
FAU - Nochaiwong, Surapon
AU  - Nochaiwong S
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
FAU - Ruengorn, Chidchanok
AU  - Ruengorn C
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
FAU - Mongkhon, Pajaree
AU  - Mongkhon P
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
AD  - Division of Pharmacy Practice, Department of Pharmaceutical Care, School of
      Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
FAU - Thavorn, Kednapa
AU  - Thavorn K
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
AD  - Ottawa Hospital Research Institute, Ottawa Hospital.
AD  - Institute of Clinical and Evaluative Sciences, ICES uOttawa.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Awiphan, Ratanaporn
AU  - Awiphan R
AD  - Department of Pharmaceutical Care.
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
FAU - Noppakun, Kajohnsak
AU  - Noppakun K
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
AD  - Department of Internal Medicine, Division of Nephrology.
FAU - Vongsanim, Surachet
AU  - Vongsanim S
AD  - Department of Internal Medicine, Division of Nephrology.
FAU - Chongruksut, Wilaiwan
AU  - Chongruksut W
AD  - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy,
      Chiang Mai University, Chiang Mai.
AD  - Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai,
      Thailand.
FAU - Hutton, Brian
AU  - Hutton B
AD  - Ottawa Hospital Research Institute, Ottawa Hospital.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Ontario, Canada.
FAU - Sood, Manish M
AU  - Sood MM
AD  - Ottawa Hospital Research Institute, Ottawa Hospital.
AD  - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa,
      Ontario, Canada.
FAU - Knoll, Greg A
AU  - Knoll GA
AD  - Ottawa Hospital Research Institute, Ottawa Hospital.
AD  - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa,
      Ontario, Canada.
CN  - Thai Renal Outcomes Research (THOR) Investigators
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Angiotensin Receptor Antagonists/*standards/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*standards/therapeutic use
MH  - Cardiovascular Diseases/epidemiology/mortality
MH  - *Clinical Protocols
MH  - Cohort Studies
MH  - Humans
MH  - Kidney Failure, Chronic/complications/mortality
MH  - *Mortality
MH  - Peritoneal Dialysis/*adverse effects/methods/trends
MH  - Retrospective Studies
PMC - PMC7220652
EDAT- 2020/04/26 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 10.1097/MD.0000000000019767 [doi]
AID - 00005792-202004240-00027 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(17):e19767. doi: 10.1097/MD.0000000000019767.


PMID- 32332559
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20210106
IS  - 1529-4242 (Electronic)
IS  - 0032-1052 (Linking)
VI  - 145
IP  - 5
DP  - 2020 May
TI  - The New 2019 Institutional Review Board Common Rule Update: Implications for
      Plastic Surgery Research.
PG  - 1323-1330
LID - 10.1097/PRS.0000000000006752 [doi]
AB  - Clinical research remains at the forefront of academic practice and
      evidence-based medicine. Unfortunately, history has shown that human subjects are
      vulnerable to experimentation without regard for their own dignity and informed
      decision-making. Subsequently, it is vital for research institutes to uphold
      safeguards and ethical conscientiousness toward human subjects. The establishment
      of federal regulations and the development of institutional review boards have
      set guidance on these processes. On January 21, 2019, final revisions to the
      Federal Policy for the Protection of Human Subjects (the "Common Rule") went into
      effect. The purpose of this article is to review changes to the Common Rule and
      discuss their impact on plastic surgery research.
FAU - Crystal, Dustin T
AU  - Crystal DT
AD  - From the Division of Plastic Surgery, Beth Israel Deaconess Medical Center,
      Harvard Medical School; the Division of Plastic Surgery, University of
      Washington; and the Department of Plastic Surgery, The Ohio State University.
FAU - Cuccolo, Nicholas G
AU  - Cuccolo NG
AD  - From the Division of Plastic Surgery, Beth Israel Deaconess Medical Center,
      Harvard Medical School; the Division of Plastic Surgery, University of
      Washington; and the Department of Plastic Surgery, The Ohio State University.
FAU - Ibrahim, Ahmed M S
AU  - Ibrahim AMS
AD  - From the Division of Plastic Surgery, Beth Israel Deaconess Medical Center,
      Harvard Medical School; the Division of Plastic Surgery, University of
      Washington; and the Department of Plastic Surgery, The Ohio State University.
FAU - Neligan, Peter C
AU  - Neligan PC
AD  - From the Division of Plastic Surgery, Beth Israel Deaconess Medical Center,
      Harvard Medical School; the Division of Plastic Surgery, University of
      Washington; and the Department of Plastic Surgery, The Ohio State University.
FAU - Janis, Jeffrey E
AU  - Janis JE
AD  - From the Division of Plastic Surgery, Beth Israel Deaconess Medical Center,
      Harvard Medical School; the Division of Plastic Surgery, University of
      Washington; and the Department of Plastic Surgery, The Ohio State University.
FAU - Lin, Samuel J
AU  - Lin SJ
AD  - From the Division of Plastic Surgery, Beth Israel Deaconess Medical Center,
      Harvard Medical School; the Division of Plastic Surgery, University of
      Washington; and the Department of Plastic Surgery, The Ohio State University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
SB  - IM
MH  - Academies and Institutes/ethics/standards
MH  - Biomedical Research/*ethics/standards
MH  - Ethics Committees, Research/*standards
MH  - Evidence-Based Medicine/ethics/standards
MH  - Human Experimentation/*ethics/standards
MH  - Informed Consent/ethics/standards
MH  - Research Design/*standards
MH  - Surgery, Plastic/*ethics/standards
MH  - United States
EDAT- 2020/04/26 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.1097/PRS.0000000000006752 [doi]
AID - 00006534-202005000-00038 [pii]
PST - ppublish
SO  - Plast Reconstr Surg. 2020 May;145(5):1323-1330. doi:
      10.1097/PRS.0000000000006752.


PMID- 32332557
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20210106
IS  - 1529-4242 (Electronic)
IS  - 0032-1052 (Linking)
VI  - 145
IP  - 5
DP  - 2020 May
TI  - Tips and Pearls on Social Media for the Plastic Surgeon.
PG  - 988e-996e
LID - 10.1097/PRS.0000000000006778 [doi]
AB  - LEARNING OBJECTIVES: After studying this article, the participant should be able 
      to: 1. Identify the key social media platforms to use. 2. Recall the primary
      components of the code of conduct when using social media. 3. Recognize how to
      build a social media presence and brand. 4. Summarize the primary applications of
      social media in plastic surgery. SUMMARY: Social media are a growing new tool
      that has emerged in recent years, with numerous applications that have allowed
      for an effective means to rapidly disseminate information. Plastic surgeons must 
      gain an understanding of the technology to both grow their practices and the
      specialty as a whole in an ethical and responsible way. The different platforms
      available; code of conduct; how to build a social media presence; and the main
      applications of advertising, education, and research, as based on evidence-based 
      recommendations, are presented.
FAU - Chen, Austin D
AU  - Chen AD
AD  - From the Division of Plastic and Reconstructive Surgery, Department of Surgery,
      Beth Israel Deaconess Medical Center, Harvard Medical School; and the Division of
      Plastic Surgery, Department of Surgery, Stanford University.
FAU - Furnas, Heather J
AU  - Furnas HJ
AD  - From the Division of Plastic and Reconstructive Surgery, Department of Surgery,
      Beth Israel Deaconess Medical Center, Harvard Medical School; and the Division of
      Plastic Surgery, Department of Surgery, Stanford University.
FAU - Lin, Samuel J
AU  - Lin SJ
AD  - From the Division of Plastic and Reconstructive Surgery, Department of Surgery,
      Beth Israel Deaconess Medical Center, Harvard Medical School; and the Division of
      Plastic Surgery, Department of Surgery, Stanford University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
SB  - IM
MH  - Codes of Ethics
MH  - *Communication
MH  - Humans
MH  - Marketing of Health Services/ethics/methods
MH  - Patient Education as Topic
MH  - Patient Selection
MH  - Research Design
MH  - *Social Media
MH  - Surgeons/economics/ethics/*psychology
MH  - Surgery, Plastic/economics/ethics/*methods/trends
EDAT- 2020/04/26 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.1097/PRS.0000000000006778 [doi]
AID - 00006534-202005000-00036 [pii]
PST - ppublish
SO  - Plast Reconstr Surg. 2020 May;145(5):988e-996e. doi:
      10.1097/PRS.0000000000006778.


PMID- 32332349
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1538-7488 (Electronic)
IS  - 0002-936X (Linking)
VI  - 120
IP  - 5
DP  - 2020 May
TI  - States Move to Ban Pelvic Exams on Unconscious Women.
PG  - 17
LID - 10.1097/01.NAJ.0000662748.74909.3e [doi]
AB  - Despite long-standing ethical concerns, the practice has persisted.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Nurs
JT  - The American journal of nursing
JID - 0372646
SB  - IM
MH  - Female
MH  - *Gynecological Examination/ethics
MH  - Gynecology/*education
MH  - Hospitals, Teaching/ethics
MH  - Human Rights/legislation & jurisprudence
MH  - Humans
MH  - Peripartum Period
MH  - Unconsciousness/*psychology
EDAT- 2020/04/26 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
AID - 10.1097/01.NAJ.0000662748.74909.3e [doi]
AID - 00000446-202005000-00010 [pii]
PST - ppublish
SO  - Am J Nurs. 2020 May;120(5):17. doi: 10.1097/01.NAJ.0000662748.74909.3e.


PMID- 32332329
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20210206
IS  - 1531-698X (Electronic)
IS  - 1040-8703 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Jun
TI  - Emerging issues in the ethical utilization of pediatric extracorporeal membrane
      oxygenation.
PG  - 411-415
LID - 10.1097/MOP.0000000000000901 [doi]
AB  - PURPOSE OF REVIEW: As we have refined our extracorporeal membrane oxygenation
      (ECMO) capabilities and enhanced our ability to care for children with illnesses 
      previously deemed lethal, the patient populations for whom ECMO is a medically
      appropriate intervention have expanded. Such expansion has prompted consideration
      of evolving ethical issues. In this review, we highlight several of the emerging 
      ethical issues in pediatric ECMO. RECENT FINDINGS: Expansion of ECMO into
      increasingly diverse pediatric populations has prompted several ethical
      questions. First, some have found that there are specific clinical settings in
      which ECMO ought to be obligatory. Second, expanded use of ECMO may prompt
      disagreements among healthcare providers or between providers and family members 
      regarding decisions about decannulation. Finally, analysis of the ethical
      challenges associated with integration of other disruptive healthcare modalities 
      into patient care, will allow us insight into how to assure ethical expansion of 
      pediatric ECMO. SUMMARY: Expansion of pediatric ECMO highlights several ethical
      issues including whether ECMO is ever ethically obligatory, how to ethically
      decannulate a patient when survival is deemed unlikely, and how to guide
      expansion of pediatric ECMO based upon lessons learned from the implementation of
      other disruptive healthcare interventions into practice.
FAU - Carlisle, Erica M
AU  - Carlisle EM
AD  - Division of Pediatric Surgery, Department of Surgery, University of Iowa Stead
      Family Children's Hospital, Iowa City, Iowa.
FAU - Loeff, Deborah S
AU  - Loeff DS
AD  - Division of Pediatric Surgery, Department of Surgery, University of Chicago Comer
      Children's Hospital, Chicago, Illinois, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Pediatr
JT  - Current opinion in pediatrics
JID - 9000850
SB  - IM
MH  - Child
MH  - *Critical Care
MH  - *Decision Making
MH  - Extracorporeal Membrane Oxygenation/*ethics/methods
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Pediatrics
EDAT- 2020/04/26 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - 10.1097/MOP.0000000000000901 [doi]
AID - 00008480-202006000-00014 [pii]
PST - ppublish
SO  - Curr Opin Pediatr. 2020 Jun;32(3):411-415. doi: 10.1097/MOP.0000000000000901.


PMID- 32332154
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20220323
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Balancing the duty to treat with the duty to family in the context of the
      COVID-19 pandemic.
PG  - 360-363
LID - 10.1136/medethics-2020-106250 [doi]
AB  - Healthcare systems around the world are struggling to maintain a sufficient
      workforce to provide adequate care during the COVID-19 pandemic. Staffing
      problems have been exacerbated by healthcare workers (HCWs) refusing to work out 
      of concern for their families. I sketch a deontological framework for assessing
      when it is morally permissible for HCWs to abstain from work to protect their
      families from infection and when it is a dereliction of duty to patients. I argue
      that it is morally permissible for HCWs to abstain from work when their duty to
      treat is outweighed by the combined risks and burdens of that work. For HCWs who 
      live with their families, the obligation to protect one's family from infection
      contributes significantly to those burdens. There are, however, a range of
      complicating factors including the strength of duty to treat which varies
      according to the HCW's role, the vulnerability of family members to the disease, 
      the willingness of family members to risk infection and the resources available
      to the HCW to protect their family. In many cases, HCWs in 'frontline' roles with
      a weak duty to treat and families at home will be morally permitted to abstain
      from work given the risks posed by COVID-19; therefore, society should provide
      additional incentives to maintain sufficient staff in these roles.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - McConnell, Doug
AU  - McConnell D
AUID- ORCID: 0000-0001-5813-0834
AD  - Philosophy, University of Oxford, Oxford 2678, UK doug.mcconnell@gmail.com.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 104848/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200424
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Age Factors
MH  - *Attitude of Health Personnel
MH  - Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - *Conflict, Psychological
MH  - Coronavirus Infections/*epidemiology
MH  - Family/*psychology
MH  - Health Personnel/*psychology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - Risk Factors
MH  - SARS-CoV-2
PMC - PMC7211094
OTO - NOTNLM
OT  - *family
OT  - *health workforce
OT  - *professional - professional relationship
OT  - *public health ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/26 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - medethics-2020-106250 [pii]
AID - 10.1136/medethics-2020-106250 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):360-363. doi: 10.1136/medethics-2020-106250. Epub
      2020 Apr 24.


PMID- 32332151
OWN - NLM
STAT- Publisher
LR  - 20200425
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 24
TI  - Ethical aspects of time in intensive care decision making.
LID - medethics-2019-105752 [pii]
LID - 10.1136/medethics-2019-105752 [doi]
AB  - The decision-making environment in intensive care units (ICUs) is influenced by
      the transformation of intensive care medicine, the staffing situation and the
      increasing importance of patient autonomy. Normative implications of time in
      intensive care, which affect all three areas, have so far barely been considered.
      The study explores patterns of decision making concerning the continuation,
      withdrawal and withholding of therapies in intensive care. A triangulation of
      qualitative data collection methods was chosen. Data were collected through
      non-participant observation on a surgical ICU at an academic medical centre
      followed by semi-structured interviews with nurses and physicians. The
      transcribed interviews and observation notes were coded and analysed using
      qualitative content analysis according to Mayring. Three themes related to time
      emerged regarding the escalation or de-escalation of therapies: influence of time
      on prognosis, time as a scarce resource and timing in regards to decision making.
      The study also reveals the ambivalence of time as a norm for decision making. The
      challenge of dealing with time-related efforts in ICU care results from the
      tension between the need to wait to optimise patient care, which must be balanced
      against the significant time pressure which is characteristic of the ICU setting.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Seidlein, Anna-Henrikje
AU  - Seidlein AH
AUID- ORCID: http://orcid.org/0000-0002-7690-567X
AD  - Institute of Ethics and History of Medicine, University Medicine Greifswald,
      Greifswald, Germany.
FAU - Hannich, Arne
AU  - Hannich A
AD  - Institute of Ethics and History of Medicine, University Medicine Greifswald,
      Greifswald, Germany.
FAU - Nowak, Andre
AU  - Nowak A
AD  - Institute for History and Ethics of Medicine, Martin Luther University
      Halle-Wittenberg, Halle(Saale), Germany.
FAU - Grundling, Matthias
AU  - Grundling M
AD  - Department of Anesthesiology and Intensive Care Medicine, Universitatsklinikum
      Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany.
FAU - Salloch, Sabine
AU  - Salloch S
AD  - Institute of Ethics and History of Medicine, University Medicine Greifswald,
      Greifswald, Germany sabine.salloch@med.uni-greifswald.de.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical Ethics
OT  - ethics
OT  - health personnel
OT  - philosophy of medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/26 06:00
MHDA- 2020/04/26 06:00
CRDT- 2020/04/26 06:00
PHST- 2019/08/07 00:00 [received]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/04/26 06:00 [medline]
AID - medethics-2019-105752 [pii]
AID - 10.1136/medethics-2019-105752 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 24. pii: medethics-2019-105752. doi:
      10.1136/medethics-2019-105752.


PMID- 32332148
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 12
DP  - 2020 Dec
TI  - In the name of science: animal appellations and best practice.
PG  - 840-843
LID - 10.1136/medethics-2020-106127 [doi]
AB  - BACKGROUND: The practice of giving animal research subjects proper names is
      frowned on by the academic scientific community. While researchers provide a
      number of reasons for desisting from giving their animal subjects proper names,
      the most common are that (1) naming leads to anthropomorphising which, in turn,
      leads to data and results that are unobjective and invalid; and (2) while naming 
      does not necessarily entail some mistake on the researcher's part, some feature
      of the research enterprise renders the practice impossible or ill-advised.
      OBJECTIVES: My aim is to assess whether the scientific community's attitude
      towards naming animal research subjects is justified. That is, I wish to consider
      whether the practice of naming animal research subjects is good or bad for the
      purposes of scientific research. METHOD: After reviewing the extant literature, I
      constructed a list of the main arguments researchers provide for desisting from
      naming their animal research subjects. I then analysed these arguments, with a
      view to determining whether they in fact provide good reasons to avoid naming
      animal research subjects. CONCLUSION: I argue that none of the aforementioned
      reasons usually provide good grounds for not naming animal research subjects.
      Moreover, there are usually powerful reasons in favour of researchers giving
      their research animals proper names. This is because the practice usually leads
      to greater empathy and so to improved animal well-being. This, in turn, leads to 
      better animal science. Thus, the scientific community's attitude towards naming
      animal research subjects is not justified.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - du Toit, Jessica
AU  - du Toit J
AD  - Philosophy, Western University, London, ON N6A 3K7, Canada jess.dutoit@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Animal Experimentation/*ethics
MH  - *Animal Rights
MH  - Animals
MH  - Attitude
MH  - Empathy
MH  - *Ethics, Research
MH  - Humans
MH  - Philosophy, Medical
MH  - *Research Personnel
OTO - NOTNLM
OT  - *animal experimentation
OT  - *ethics
OT  - *philosophical ethics
OT  - *research ethics
OT  - *speciesism
COIS- Competing interests: None declared.
EDAT- 2020/04/26 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - medethics-2020-106127 [pii]
AID - 10.1136/medethics-2020-106127 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Dec;46(12):840-843. doi: 10.1136/medethics-2020-106127. Epub
      2020 Apr 24.


PMID- 32332006
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 23
TI  - Effect of vitamin D supplementation on pain and physical function in patients
      with knee osteoarthritis (OA): an OA Trial Bank protocol for a systematic review 
      and individual patient data (IPD) meta-analysis.
PG  - e035302
LID - 10.1136/bmjopen-2019-035302 [doi]
AB  - INTRODUCTION: Observational data suggest that vitamin D deficiency is associated 
      with the onset and progression of knee osteoarthritis (OA). However, randomised
      controlled trials (RCTs) to date investigating the efficacy of vitamin D
      supplementation in knee OA have reported conflicting results. Further research is
      needed to clarify the effects of vitamin D on patient-reported outcomes and
      determine whether there are patient subgroups who may benefit from the
      supplementation. The aim of this individual patient data (IPD) meta-analysis is
      to identify patient-level predictors of treatment response to vitamin D
      supplementation on pain and physical function. METHODS AND ANALYSIS: A systematic
      literature search will be conducted for RCTs of vitamin D supplementation on knee
      OA. Authors of original RCTs will be contacted to obtain the IPD. The primary
      outcomes will include long-term (>/=12 months) pain and physical function.
      Secondary outcomes will include medium-term (>/=6 months and <12 months) and
      short-term (<6 months) pain and physical function, as well as patient global
      assessment, quality of life and adverse events. Potential treatment effect
      modifiers to be examined in the subgroup analyses include age, gender, body mass 
      index, baseline knee pain severity and physical function, baseline vitamin D
      level, radiographic stage, presence of bone marrow lesions on MRI, presence of
      clinical signs of local inflammation and concomitant depressive symptoms. Both
      one-step and two-step modelling methods will be used to determine the possible
      modifiable effect of each subgroup of interest. ETHICS AND DISSEMINATION:
      Research ethical or governance approval is exempt for this study as no new data
      are being collected. This study will be the first IPD meta-analysis to clarify
      the effect of vitamin D supplementation on clinical symptoms in different
      subgroups of patients with knee OA. The findings will be disseminated through
      peer-review publications and conference presentations. PROSPERO REGISTRATION
      NUMBER: CRD42018107740.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jin, Xingzhong
AU  - Jin X
AUID- ORCID: 0000-0003-4293-8665
AD  - Zhujiang Hospital, Southern Medical University, Guangzhou, China
      xingzhong.jin@unsw.edu.au Changhai.Ding@utas.edu.au.
AD  - Centre for Big Data Research in Health, University of New South Wales, Sydney,
      New South Wales, Australia.
AD  - Institute of Bone and Joint Research, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Antony, Benny
AU  - Antony B
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
      Australia.
FAU - Wang, Xia
AU  - Wang X
AD  - Institute of Bone and Joint Research, The University of Sydney, Sydney, New South
      Wales, Australia.
FAU - Persson, Monica Sm
AU  - Persson MS
AUID- ORCID: 0000-0002-8532-3006
AD  - Centre of Evidence Based Dermatology, University of Nottingham, Nottingham,
      United Kingdom.
FAU - McAlindon, Timothy
AU  - McAlindon T
AD  - Tufts Medical Center, Boston, Massachusetts, USA.
FAU - Arden, Nigel K
AU  - Arden NK
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
      University of Oxford, Oxford, United Kingdom.
AD  - MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of
      Shouthampton, Southampton, United Kingdom.
FAU - Srivastava, Sudeepti
AU  - Srivastava S
AD  - Department of Orthopaedic Surgery, King George's Medical University, Lucknow,
      India.
FAU - Srivastava, Rajeshwar
AU  - Srivastava R
AD  - Department of Orthopaedic Surgery, King George's Medical University, Lucknow,
      India.
FAU - Van Middelkoop, Marienke
AU  - Van Middelkoop M
AD  - Department of General Practice, Erasmus MC University Medical Center, Rotterdam, 
      The Netherlands.
FAU - Bierma-Zeinstra, Sita Ma
AU  - Bierma-Zeinstra SM
AD  - Department of General Practice, Erasmus MC University Medical Center, Rotterdam, 
      The Netherlands.
FAU - Zhang, Weiya
AU  - Zhang W
AD  - Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United
      Kingdom.
FAU - Cicuttini, Flavia
AU  - Cicuttini F
AD  - Department of Epidemiology and Preventative Medicine, Monash University,
      Melbourne, Victoria, Australia.
FAU - Ding, Changhai
AU  - Ding C
AD  - Zhujiang Hospital, Southern Medical University, Guangzhou, China
      xingzhong.jin@unsw.edu.au Changhai.Ding@utas.edu.au.
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
      Australia.
AD  - Department of Epidemiology and Preventative Medicine, Monash University,
      Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Vitamins)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Arthralgia/*drug therapy/physiopathology
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Osteoarthritis, Knee/complications/*drug therapy/physiopathology
MH  - Patient Reported Outcome Measures
MH  - *Systematic Reviews as Topic
MH  - Vitamin D/*therapeutic use
MH  - Vitamin D Deficiency/complications/*drug therapy/physiopathology
MH  - Vitamins/*therapeutic use
PMC - PMC7204938
OTO - NOTNLM
OT  - *general medicine (see internal medicine)
OT  - *preventive medicine
OT  - *rheumatology
COIS- Competing interests: None declared.
EDAT- 2020/04/26 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035302 [pii]
AID - 10.1136/bmjopen-2019-035302 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 23;10(4):e035302. doi: 10.1136/bmjopen-2019-035302.


PMID- 32331924
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20211021
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 43
IP  - 9
DP  - 2020 Nov
TI  - Tips and guidelines for being a successful researcher.
PG  - 540-550
LID - S0210-5705(20)30114-X [pii]
LID - 10.1016/j.gastrohep.2020.03.010 [doi]
AB  - This article aims to share our experience with those who consider dedicating
      themselves to research. In this way, the characteristics, qualities or
      competences that, in our opinion, a good researcher should fulfill are listed,
      and therefore the keys that can help you achieve a successful research career.
      The intention of this article is not to simply list a series of theoretical
      recommendations but to share some personal suggestions based on our experience
      and, therefore, of an eminently practical nature. The fundamental qualities to be
      discussed are: Ethics and honesty. Curiosity, passion, enthusiasm and motivation.
      Persistence, dedication and discipline. Ambition and leadership. Compromise and
      responsibility. Organization and planning. Acquire knowledge of research
      methodology. Critical and positive attitude towards difficulties and failure.
      Prioritization of objectives and time management. The importance of a good
      mentor. Establishment of a network of collaborators and teamwork. Maintain a
      balance between clinical and research activity. Combine public and private
      investigation. Balance between professional and personal life. And, finally,
      humility, generosity and thanks. Research represents a fundamental pillar of
      medical activity and it is evident that the highest quality of care arises from
      the integration of excellent clinical practice and research activity. With the
      philosophy that most of the qualities to develop an excellent research activity
      depend on attitude, and can be learned, developed and improved, in this
      manuscript we share with the reader a series of recommendations that we consider 
      essential to be a good researcher.
CI  - Copyright (c) 2020 Elsevier Espana, S.L.U. All rights reserved.
FAU - Gisbert, Javier P
AU  - Gisbert JP
AD  - Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto
      de Investigacion Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid,
      Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas
      (CIBEREHD), Madrid, Espana. Electronic address: javier.p.gisbert@gmail.com.
FAU - Chaparro, Maria
AU  - Chaparro M
AD  - Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto
      de Investigacion Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid,
      Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas
      (CIBEREHD), Madrid, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Reglas y consejos para ser un investigador de exito.
DEP - 20200421
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
SB  - IM
MH  - Biomedical Research/*methods/*standards
MH  - Guidelines as Topic
OTO - NOTNLM
OT  - Investigacion
OT  - Investigador
OT  - Investigation
OT  - Mentor
OT  - Researcher
OT  - Success
OT  - Successful
OT  - Exito: Exitoso
EDAT- 2020/04/26 06:00
MHDA- 2020/04/26 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/04/26 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - S0210-5705(20)30114-X [pii]
AID - 10.1016/j.gastrohep.2020.03.010 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2020 Nov;43(9):540-550. doi:
      10.1016/j.gastrohep.2020.03.010. Epub 2020 Apr 21.


PMID- 32331607
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20200520
IS  - 1268-6034 (Print)
IS  - 1268-6034 (Linking)
VI  - 25
IP  - 142
DP  - 2020 Mar - Apr
TI  - [Compassion fatigue and empathetic suffering].
PG  - 29-32
LID - S1268-6034(20)30008-6 [pii]
LID - 10.1016/j.sger.2020.01.008 [doi]
AB  - Compassion fatigue and empathetic suffering are terms generally applied to health
      care providers caring for elderly people. An exhaustion accompanied by acute
      emotional pain results of tension and preoccupation with the suffering of those
      being helped. Learning to recognize it and to manage its symptoms is the first
      step toward healing. Compassion is an important care index and a professionalism 
      marker.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Thomas, Philippe
AU  - Thomas P
AD  - Centre de recherches semiotiques (CeReS), EA 3648, Universite de Limoges, 39 rue 
      Camille-Guerin, 87000 Limoges, France. Electronic address:
      philippe.thomas.2008@orange.fr.
FAU - Hazif-Thomas, Cyril
AU  - Hazif-Thomas C
AD  - Service de psychiatrie du sujet age, SPURBO, EA 7479, CHRU de Brest, route de
      Ploudalmezeau, 29820 Bohars, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Souffrance compassionnelle et fatigue d'empathie.
DEP - 20200121
PL  - France
TA  - Soins Gerontol
JT  - Soins. Gerontologie
JID - 9616322
MH  - Aged
MH  - *Compassion Fatigue
MH  - *Empathy
MH  - Health Personnel/*psychology
MH  - Humans
OTO - NOTNLM
OT  - burn out
OT  - compassion
OT  - empathie
OT  - ethics
OT  - geriatrics
OT  - geriatrie
OT  - nursing
OT  - soins
OT  - ethique
EDAT- 2020/04/26 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
AID - S1268-6034(20)30008-6 [pii]
AID - 10.1016/j.sger.2020.01.008 [doi]
PST - ppublish
SO  - Soins Gerontol. 2020 Mar - Apr;25(142):29-32. doi: 10.1016/j.sger.2020.01.008.
      Epub 2020 Jan 21.


PMID- 32331498
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20210505
IS  - 2322-5939 (Electronic)
IS  - 2322-5939 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 1
TI  - Neoliberalism 4.0: The Rise of Illiberal Capitalism Comment on "How Neoliberalism
      Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD
      Prevention".
PG  - 175-178
LID - 10.15171/ijhpm.2019.111 [doi]
AB  - Neoliberal logic and institutional lethargy may well explain part of the reason
      why governments pay little attention to how their economic and development
      policies negatively affect health outcomes associated with the global diffusion
      of unhealthy commodities. In calling attention to this the authors encourage
      health advocates to consider strategies other than just regulation to curb both
      the supply and demand for these commodities, by better understanding how
      neoliberal logic suffuses institutional regimes, and how it might be coopted to
      alternative ends. The argument is compelling as possible mid-level reform, but it
      omits the history of the development of neoliberalism, from its founding in
      liberal philosophy and ethics in the transition from feudalism to capitalism, to 
      its hegemonic rise in global economics over the past four decades. This rise was 
      as much due to elites (the 1% and now 0.001%) wanting to reverse the progressive 
      compression in income and wealth distribution during the first three decades that
      followed World War Two. Through three phases of neoliberal policy (structural
      adjustment, financialization, austerity) wealth ceased trickling downwards, and
      spiralled upwards. Citizen discontent with stagnating or declining livelihoods
      became the fuel for illiberal leaders to take power in many countries, heralding 
      a new, autocratic and nationalistic form of neoliberalism. With climate crises
      mounting and ecological limits rendering mid-level reform of coopting the
      neoliberal logic to incentivize production of healthier commodities, health
      advocates need to consider more profound idea of how to tame or erode
      (increasingly predatory) capitalism itself.
CI  - (c) 2020 The Author(s); Published by Kerman University of Medical Sciences. This 
      is an open-access article distributed under the terms of the Creative Commons
      Attribution License (http://creativecommons.org/ licenses/by/4.0), which permits 
      unrestricted use, distribution, and reproduction in any medium, provided the
      original work is properly cited.
FAU - Labonte, Ronald
AU  - Labonte R
AUID- ORCID: 0000-0002-0615-740X
AD  - Globalization and Health Equity, Faculty of Medicine, School of Epidemiology and 
      Public Health, University of Ottawa, Ottawa, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200401
PL  - Iran
TA  - Int J Health Policy Manag
JT  - International journal of health policy and management
JID - 101619905
SB  - IM
CON - Int J Health Policy Manag. 2019 Sep 01;8(9):514-520. PMID: 31657174
CIN - Int J Health Policy Manag. 2020 Dec 01;9(12):539-541. PMID: 32610829
MH  - *Capitalism
MH  - Government
MH  - Humans
MH  - *Noncommunicable Diseases
MH  - Policy
MH  - Politics
PMC - PMC7182151
OTO - NOTNLM
OT  - *Capitalism
OT  - *Health Inequities
OT  - *Liberalism
OT  - *Neoliberalism
EDAT- 2020/04/26 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/04/26 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2019/11/03 00:00 [accepted]
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - 10.15171/ijhpm.2019.111 [doi]
PST - epublish
SO  - Int J Health Policy Manag. 2020 Apr 1;9(4):175-178. doi: 10.15171/ijhpm.2019.111.


PMID- 32330963
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220414
IS  - 1806-9339 (Electronic)
IS  - 0100-7203 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Apr
TI  - Quality of Life for Women with Human Papillomavirus-induced Lesions.
PG  - 211-217
LID - 10.1055/s-0040-1709192 [doi]
AB  - OBJECTIVE: To reveal the changes in the quality of life reported by women with
      Human papillomavirus (HPV)-induced lesions. METHODS: This is a cross-sectional,
      descriptive-exploratory study of a qualitative approach performed from June to
      August 2016. Semi-structured face-to-face interviews based on five questions on
      the concept of quality of life were used. The data were submitted to thematic
      analysis. All ethical aspects have been contemplated. RESULTS: A total of 20
      women aged between 25 and 59 years old were interviewed. From the analysis of the
      data, the following thematic units emerged: physical and emotional changes,
      especially complaints of pruritus, discharge and pain, worry, fear, shame and
      sadness; changes in sexual and affective relationships with decreased libido,
      dyspareunia and interruption of sexual activity; changes in social relationships 
      resulting in absenteeism at work. CONCLUSION: Human papillomavirus infection
      impairs the quality of life of women as it significantly affects sexual,
      affective, physical, emotional, and everyday habits. Therefore, HPV infection can
      lead to exponential changes in the quality of life of women, which can be
      mitigated by the availability of sources of support such as family, friends and
      the multi-professional team, helping to improve knowledge and cope with HPV.
CI  - Thieme Revinter Publicacoes Ltda Rio de Janeiro, Brazil.
FAU - Pereira-Caldeira, Natalia Maria Vieira
AU  - Pereira-Caldeira NMV
AUID- ORCID: 0000-0002-4231-7116
AD  - Department of General and Specialized Nursing, Programa Enfermagem Fundamental,
      Escola de Enfermagem de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao
      Preto, SP, Brazil.
FAU - Goes, Fernanda Garcia Bezerra
AU  - Goes FGB
AUID- ORCID: 0000-0003-3894-3998
AD  - Department of Nursing of Rio das Ostras, Universidade Federal Fluminense, Rio das
      Ostras, RJ, Brazil.
FAU - Almeida-Cruz, Maria Cristina Mendes de
AU  - Almeida-Cruz MCM
AUID- ORCID: 0000-0003-2615-3390
AD  - Department of General and Specialized Nursing, Programa Enfermagem Fundamental,
      Escola de Enfermagem de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao
      Preto, SP, Brazil.
FAU - Caliari, Juliano de Souza
AU  - Caliari JS
AUID- ORCID: 0000-0002-3021-1138
AD  - Department of Nursing, Instituto Federal de Educacao Ciencia e Tecnologia do
      Sudeste de Minas Gerais, Passos, MG, Brazil.
FAU - Pereira-Avila, Fernanda Maria Vieira
AU  - Pereira-Avila FMV
AUID- ORCID: 0000-0003-1060-6754
AD  - Department of Nursing of Rio das Ostras, Universidade Federal Fluminense, Rio das
      Ostras, RJ, Brazil.
FAU - Gir, Elucir
AU  - Gir E
AUID- ORCID: 0000-0002-3757-4900
AD  - Department of General and Specialized Nursing, Programa Enfermagem Fundamental,
      Escola de Enfermagem de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao
      Preto, SP, Brazil.
LA  - eng
PT  - Journal Article
TT  - Qualidade de vida de mulheres com lesoes induzidas Pelo Papilomavirus Humano.
DEP - 20200424
PL  - Brazil
TA  - Rev Bras Ginecol Obstet
JT  - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira
      das Sociedades de Ginecologia e Obstetricia
JID - 9214757
SB  - IM
MH  - Adult
MH  - Alphapapillomavirus
MH  - Anxiety
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Genital Diseases, Female/physiopathology/psychology
MH  - Humans
MH  - Middle Aged
MH  - *Papillomavirus Infections/physiopathology/psychology
MH  - *Quality of Life
MH  - Sexual Behavior
MH  - Women's Health
COIS- The authors have no conflict of interests to declare.
EDAT- 2020/04/25 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1055/s-0040-1709192 [doi]
PST - ppublish
SO  - Rev Bras Ginecol Obstet. 2020 Apr;42(4):211-217. doi: 10.1055/s-0040-1709192.
      Epub 2020 Apr 24.


PMID- 32330671
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 2468-7847 (Electronic)
IS  - 2468-7847 (Linking)
VI  - 49
IP  - 7
DP  - 2020 Sep
TI  - Impact of Hysteroscopic Metroplasty on Reproductive Outcomes of Women with a
      Dysmorphic Uterus and Recurrent Miscarriages: A Systematic Review and
      Meta-Analysis.
PG  - 101763
LID - S2468-7847(20)30106-9 [pii]
LID - 10.1016/j.jogoh.2020.101763 [doi]
AB  - The aim of this systematic literature review and meta-analysis is to assess the
      impact of hysteroscopic metroplasty for dysmorphic uteri on reproductive outcomes
      in women with recurrent miscarriages. Available studies were identified through a
      PubMed, Scopus, and Cochrane search until June 2019. Live-birth rate, clinical
      pregnancy and miscarriage rate after hysteroscopic metroplasty was evaluated.
      DerSimonian and Laird's random-effect model was used for relative risks,
      Freeman-Tukey Double Arcsine for pooled estimates and exact method to stabilize
      variances and CIs. Heterogeneity was quantified using I2-statistics. Six out of
      164 published studies met the inclusion criteria. All (n = 221) women underwent
      metroplasty, using 5Fr-hysteroscope with bipolar electrodes or
      26Fr/28Fr-resectoscope in outpatient or inpatient settings. After 6 to 60-month
      follow-up, reported live-birth rate was 50% (0.37-0.63 95% CI) from a clinical
      pregnancy rate of 73% (0.51-0.91 95% CI) and miscarriage rate was 23% (0.15-0.30 
      95% CI). Hysteroscopic metroplasty for dysmorphic uteri led half of the women who
      experienced recurrent miscarriages at least one live birth and is correlated to
      few surgical and obstetric complications. However, randomized clinical trials and
      case-control studies are unavailable due to ethical constrains; inhomogenity of
      follow-up durations and standardized protocols regarding preoperative diagnosis
      and post-surgical management resrict our conclusions.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - De Franciscis, Pasquale
AU  - De Franciscis P
AD  - Department of Woman, Child and General and Specialized Surgery, Obstetrics and
      Gynecology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
FAU - Riemma, Gaetano
AU  - Riemma G
AD  - Department of Woman, Child and General and Specialized Surgery, Obstetrics and
      Gynecology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
FAU - Schiattarella, Antonio
AU  - Schiattarella A
AD  - Department of Woman, Child and General and Specialized Surgery, Obstetrics and
      Gynecology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
FAU - Cobellis, Luigi
AU  - Cobellis L
AD  - Department of Woman, Child and General and Specialized Surgery, Obstetrics and
      Gynecology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
FAU - Colacurci, Nicola
AU  - Colacurci N
AD  - Department of Woman, Child and General and Specialized Surgery, Obstetrics and
      Gynecology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
FAU - Vitale, Salvatore Giovanni
AU  - Vitale SG
AD  - Obstetrics and Gynecology Unit, Department of General Surgery and Medical
      Surgical Specialties, University of Catania, 95123 Catania, Italy. Electronic
      address: sgvitale@unict.it.
FAU - Cianci, Antonio
AU  - Cianci A
AD  - Obstetrics and Gynecology Unit, Department of General Surgery and Medical
      Surgical Specialties, University of Catania, 95123 Catania, Italy.
FAU - Lohmeyer, Franziska Michaela
AU  - Lohmeyer FM
AD  - Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS,
      00168 Rome, Italy.
FAU - La Verde, Marco
AU  - La Verde M
AD  - Department of Woman, Child and General and Specialized Surgery, Obstetrics and
      Gynecology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200421
PL  - France
TA  - J Gynecol Obstet Hum Reprod
JT  - Journal of gynecology obstetrics and human reproduction
JID - 101701588
SB  - IM
MH  - Abortion, Habitual/*surgery
MH  - Adult
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Hysteroscopy/*methods
MH  - Live Birth
MH  - Pregnancy
MH  - Treatment Outcome
MH  - Uterus/*abnormalities/*surgery
OTO - NOTNLM
OT  - Dysmorphic uterus
OT  - Hysteroscopy
OT  - Recurrent miscarriages
OT  - Reproductive outcomes
COIS- Declaration of Competing Interest None.
EDAT- 2020/04/25 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - S2468-7847(20)30106-9 [pii]
AID - 10.1016/j.jogoh.2020.101763 [doi]
PST - ppublish
SO  - J Gynecol Obstet Hum Reprod. 2020 Sep;49(7):101763. doi:
      10.1016/j.jogoh.2020.101763. Epub 2020 Apr 21.


PMID- 32330635
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 83
IP  - 1
DP  - 2020 Jul
TI  - Applying the ethical principles of resource allocation to drugs in limited supply
      during a public health crisis.
PG  - 170-171
LID - S0190-9622(20)30693-9 [pii]
LID - 10.1016/j.jaad.2020.04.078 [doi]
FAU - Kong, Ha Eun
AU  - Kong HE
AD  - Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
      Electronic address: haeun.kong@emory.edu.
FAU - Grant-Kels, Jane M
AU  - Grant-Kels JM
AD  - Dermatology Department, University of Connecticut, Farmington, Connecticut;
      Dermatology Department, University of Florida, Gainesville, Florida.
FAU - Stoff, Benjamin K
AU  - Stoff BK
AD  - Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia;
      Emory Center for Ethics, Atlanta, Georgia.
LA  - eng
PT  - Editorial
DEP - 20200421
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
SB  - IM
MH  - *COVID-19
MH  - *Drug Prescriptions
MH  - Humans
MH  - *Public Health
MH  - Resource Allocation/*ethics
PMC - PMC7194708
EDAT- 2020/04/25 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - S0190-9622(20)30693-9 [pii]
AID - 10.1016/j.jaad.2020.04.078 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2020 Jul;83(1):170-171. doi: 10.1016/j.jaad.2020.04.078. Epub
      2020 Apr 21.


PMID- 32330258
OWN - NLM
STAT- MEDLINE
DCOM- 20210325
LR  - 20210424
IS  - 1527-974X (Electronic)
IS  - 1067-5027 (Linking)
VI  - 27
IP  - 5
DP  - 2020 May 1
TI  - How accurate is the medical record? A comparison of the physician's note with a
      concealed audio recording in unannounced standardized patient encounters.
PG  - 770-775
LID - 10.1093/jamia/ocaa027 [doi]
AB  - OBJECTIVES: Accurate documentation in the medical record is essential for quality
      care; extensive documentation is required for reimbursement. At times, these 2
      imperatives conflict. We explored the concordance of information documented in
      the medical record with a gold standard measure. MATERIALS AND METHODS: We
      compared 105 encounter notes to audio recordings covertly collected by
      unannounced standardized patients from 36 physicians, to identify discrepancies
      and estimate the reimbursement implications of billing the visit based on the
      note vs the care actually delivered. RESULTS: There were 636 documentation
      errors, including 181 charted findings that did not take place, and 455 findings 
      that were not charted. Ninety percent of notes contained at least 1 error. In 21 
      instances, the note justified a higher billing level than the gold standard audio
      recording, and in 4, it underrepresented the level of service (P = .005),
      resulting in 40 level 4 notes instead of the 23 justified based on the audio, a
      74% inflated misrepresentation. DISCUSSION: While one cannot generalize about
      specific error rates based on a relatively small sample of physicians exclusively
      within the Department of Veterans Affairs Health System, the magnitude of the
      findings raise fundamental concerns about the integrity of the current medical
      record documentation process as an actual representation of care, with
      implications for determining both quality and resource utilization. CONCLUSION:
      The medical record should not be assumed to reflect care delivered. Furthermore, 
      errors of commission-documentation of services not actually provided-may inflate 
      estimates of resource utilization.
CI  - Published by Oxford University Press on behalf of the American Medical
      Informatics Association 2020. This work is written by US Government employees and
      is in the public domain in the US.
FAU - Weiner, Saul J
AU  - Weiner SJ
AD  - Jesse Brown VA Medical Center, Center of Innovation for Complex Chronic
      Healthcare, Chicago, Illinois, USA.
AD  - Department of Medicine, College of Medicine, University of Illinois at Chicago,
      Chicago, Illinois, USA.
FAU - Wang, Shiyuan
AU  - Wang S
AD  - College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
FAU - Kelly, Brendan
AU  - Kelly B
AD  - Jesse Brown VA Medical Center, Center of Innovation for Complex Chronic
      Healthcare, Chicago, Illinois, USA.
FAU - Sharma, Gunjan
AU  - Sharma G
AD  - Jesse Brown VA Medical Center, Center of Innovation for Complex Chronic
      Healthcare, Chicago, Illinois, USA.
FAU - Schwartz, Alan
AU  - Schwartz A
AD  - Department of Medical Education, College of Medicine, University of Illinois at
      Chicago, Chicago, Illinois, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - J Am Med Inform Assoc
JT  - Journal of the American Medical Informatics Association : JAMIA
JID - 9430800
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Documentation
MH  - Electronic Health Records
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medical Audit
MH  - *Medical Errors
MH  - *Medical Records/standards
MH  - Middle Aged
MH  - Patient Simulation
MH  - Physicians
MH  - Quality of Health Care
MH  - United States
MH  - Veterans Health Services
PMC - PMC7647276
OTO - NOTNLM
OT  - *health care costs, unannounced standardized patients, medical ethics
OT  - *medical records
OT  - *quality of health care
EDAT- 2020/04/25 06:00
MHDA- 2021/03/26 06:00
CRDT- 2020/04/25 06:00
PHST- 2019/09/07 00:00 [received]
PHST- 2020/02/07 00:00 [revised]
PHST- 2020/02/29 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/03/26 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 5824779 [pii]
AID - 10.1093/jamia/ocaa027 [doi]
PST - ppublish
SO  - J Am Med Inform Assoc. 2020 May 1;27(5):770-775. doi: 10.1093/jamia/ocaa027.


PMID- 32330224
OWN - NLM
STAT- MEDLINE
DCOM- 20200812
LR  - 20210711
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 173
IP  - 3
DP  - 2020 Aug 4
TI  - Ventilator Triage Policies During the COVID-19 Pandemic at U.S. Hospitals
      Associated With Members of the Association of Bioethics Program Directors.
PG  - 188-194
LID - 10.7326/M20-1738 [doi]
AB  - BACKGROUND: The coronavirus disease 2019 pandemic has or threatens to overwhelm
      health care systems. Many institutions are developing ventilator triage policies.
      OBJECTIVE: To characterize the development of ventilator triage policies and
      compare policy content. DESIGN: Survey and mixed-methods content analysis.
      SETTING: North American hospitals associated with members of the Association of
      Bioethics Program Directors. PARTICIPANTS: Program directors. MEASUREMENTS:
      Characteristics of institutions and policies, including triage criteria and
      triage committee membership. RESULTS: Sixty-seven program directors responded
      (response rate, 91.8%); 36 (53.7%) hospitals did not yet have a policy, and 7
      (10.4%) hospitals' policies could not be shared. The 29 institutions providing
      policies were relatively evenly distributed among the 4 U.S. geographic regions
      (range, 5 to 9 policies per region). Among the 26 unique policies analyzed, 3
      (11.3%) were produced by state health departments. The most frequently cited
      triage criteria were benefit (25 policies [96.2%]), need (14 [53.8%]), age (13
      [50.0%]), conservation of resources (10 [38.5%]), and lottery (9 [34.6%]).
      Twenty-one (80.8%) policies use scoring systems, and 20 of these (95.2%) use a
      version of the Sequential Organ Failure Assessment score. Among the policies that
      specify the triage team's composition (23 [88.5%]), all require or recommend a
      physician member, 20 (87.0%) a nurse, 16 (69.6%) an ethicist, 8 (34.8%) a
      chaplain, and 8 (34.8%) a respiratory therapist. Thirteen (50.0% of all policies)
      require or recommend that those making triage decisions not be involved in direct
      patient care, but only 2 (7.7%) require that their decisions be blinded to
      ethically irrelevant considerations. LIMITATION: The results may not be
      generalizable to institutions without academic bioethics programs. CONCLUSION:
      Over one half of respondents did not have ventilator triage policies. Policies
      have substantial heterogeneity, and many omit guidance on fair implementation.
      PRIMARY FUNDING SOURCE: None.
FAU - Antommaria, Armand H Matheny
AU  - Antommaria AHM
AD  - Ethics Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio,
      University of Cincinnati School of Medicine, Cincinnati, Ohio (A.H.A.).
FAU - Gibb, Tyler S
AU  - Gibb TS
AD  - Program in Medical Ethics, Humanities & Law, Western Michigan University Homer
      Stryker M.D. School of Medicine, Kalamazoo, Michigan (T.S.G.).
FAU - McGuire, Amy L
AU  - McGuire AL
AD  - Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston,
      Texas (A.L.M.).
FAU - Wolpe, Paul Root
AU  - Wolpe PR
AD  - Center for Ethics and School of Medicine, Emory University, Atlanta, Georgia
      (P.R.W.).
FAU - Wynia, Matthew K
AU  - Wynia MK
AD  - University of Colorado Center for Bioethics and Humanities, Schools of Medicine
      and Public Health, and UC Health System, Aurora, Colorado (M.K.W.).
FAU - Applewhite, Megan K
AU  - Applewhite MK
AD  - Alden March Bioethics Institute and Department of Surgery, Albany Medical
      College, Albany, New York (M.K.A.).
FAU - Caplan, Arthur
AU  - Caplan A
AD  - Division of Medical Ethics, NYU Grossman School of Medicine, New York, New York
      (A.C., T.S.).
FAU - Diekema, Douglas S
AU  - Diekema DS
AD  - Departments of Pediatrics and Bioethics & Humanities, University of Washington
      School of Medicine, Seattle, Washington, Treuman Katz Center for Pediatric
      Bioethics, Seattle Children's Research Institute, Seattle, Washington (D.S.D.).
FAU - Hester, D Micah
AU  - Hester DM
AD  - Department of Medical Humanities & Bioethics, College of Medicine, University of 
      Arkansas for Medical Sciences, Little Rock, Arkansas (D.M.H.).
FAU - Lehmann, Lisa Soleymani
AU  - Lehmann LS
AD  - VA New England Healthcare System, Bedford, Massachusetts, Harvard Medical School 
      and Harvard T.H. Chan School of Public Health, Boston, Massachusetts (L.S.L.).
FAU - McLeod-Sordjan, Renee
AU  - McLeod-Sordjan R
AD  - Division of Medical Ethics, Department of Medicine, Northwell Health System, New 
      Hyde Park, New York, Hofstra Northwell School of Graduate Nursing and Physician
      Assistant Studies, Hofstra University, Hempstead, New York (R.M.).
FAU - Schiff, Tamar
AU  - Schiff T
AD  - Division of Medical Ethics, NYU Grossman School of Medicine, New York, New York
      (A.C., T.S.).
FAU - Tabor, Holly K
AU  - Tabor HK
AD  - Stanford Center for Biomedical Ethics, Stanford University School of Medicine,
      Stanford, California (H.K.T., S.E.W.).
FAU - Wieten, Sarah E
AU  - Wieten SE
AD  - Stanford Center for Biomedical Ethics, Stanford University School of Medicine,
      Stanford, California (H.K.T., S.E.W.).
FAU - Eberl, Jason T
AU  - Eberl JT
AD  - Albert Gnaegi Center for Health Care Ethics, Saint Louis University, St. Louis,
      Missouri (J.T.E.).
CN  - Task Force of the Association of Bioethics Program Directors
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
SB  - IM
MH  - Betacoronavirus
MH  - Bioethics
MH  - COVID-19
MH  - Coronavirus Infections/*therapy
MH  - Health Policy
MH  - Hospitals
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy
MH  - Respiration, Artificial/*ethics/*standards
MH  - SARS-CoV-2
MH  - Surveys and Questionnaires
MH  - Triage/*ethics/*standards
MH  - United States
MH  - Ventilators, Mechanical/supply & distribution
PMC - PMC7207244
IR  - Matheny Antommaria AH
FIR - Matheny Antommaria, Armand H
IR  - Gibb TS
FIR - Gibb, Tyler S
IR  - McGuire AL
FIR - McGuire, Amy L
IR  - Wolpe PR
FIR - Wolpe, Paul Root
IR  - Wynia MK
FIR - Wynia, Matthew K
IR  - Applewhite MK
FIR - Applewhite, Megan K
IR  - Caplan A
FIR - Caplan, Arthur
IR  - Diekema DS
FIR - Diekema, Douglas S
IR  - Hester DM
FIR - Hester, D Micah
IR  - Lehmann LS
FIR - Lehmann, Lisa Soleymani
IR  - McLeod-Sordjan R
FIR - McLeod-Sordjan, Renee
IR  - Schiff T
FIR - Schiff, Tamar
IR  - Tabor HK
FIR - Tabor, Holly K
IR  - Wieten S
FIR - Wieten, Sarah
IR  - Eberl JT
FIR - Eberl, Jason T
EDAT- 2020/04/25 06:00
MHDA- 2020/08/13 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/08/13 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 2765364 [pii]
AID - 10.7326/M20-1738 [doi]
PST - ppublish
SO  - Ann Intern Med. 2020 Aug 4;173(3):188-194. doi: 10.7326/M20-1738. Epub 2020 Apr
      24.


PMID- 32329948
OWN - NLM
STAT- MEDLINE
DCOM- 20200610
LR  - 20201218
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Jun
TI  - Ethical framework for head and neck cancer care impacted by COVID-19.
PG  - 1214-1217
LID - 10.1002/hed.26193 [doi]
AB  - The COVID-19 pandemic has upended head and neck cancer care delivery in ways
      unforeseen and unprecedented. The impact of these changes parallels other fields 
      in oncology, but is disproportionate due to protective measures and limitations
      on potentially aerosolizing procedures and related interventions specific to the 
      upper aerodigestive tract. The moral and professional dimensions of providing
      ethically appropriate and consistent care for our patients in the COVID-19 crisis
      are considered herein for head and neck oncology providers.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Shuman, Andrew G
AU  - Shuman AG
AUID- ORCID: 0000-0002-9305-7860
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan
      Medical School, Ann Arbor, Michigan, USA.
AD  - Department of Otolaryngology-Head & Neck Surgery, University of Michigan Medical 
      School, Ann Arbor, Michigan, USA.
FAU - Campbell, Bruce H
AU  - Campbell BH
AD  - Department of Otolaryngology and Communication Sciences, Medical College of
      Wisconsin, Milwaukee, Wisconsin, USA.
AD  - Center for Bioethics and Medical Humanities, Medical College of Wisconsin,
      Milwaukee, Wisconsin, USA.
CN  - AHNS Ethics & Professionalism Service
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200428
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/prevention & control
MH  - Disease Management
MH  - Female
MH  - Head and Neck Neoplasms/diagnosis/*therapy
MH  - Humans
MH  - Male
MH  - Medical Oncology/*ethics
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Patient Care Planning/*ethics
MH  - Pneumonia, Viral/*epidemiology/prevention & control
MH  - Risk Assessment
MH  - United States
PMC - PMC7264503
OTO - NOTNLM
OT  - *COVID-19
OT  - *cancer ethics
OT  - *head and neck cancer
OT  - *professional duty to treat
OT  - *public health ethics
EDAT- 2020/04/25 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1002/hed.26193 [doi]
PST - ppublish
SO  - Head Neck. 2020 Jun;42(6):1214-1217. doi: 10.1002/hed.26193. Epub 2020 Apr 28.


PMID- 32329902
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20200901
IS  - 1365-2044 (Electronic)
IS  - 0003-2409 (Linking)
VI  - 75
IP  - 9
DP  - 2020 Sep
TI  - Examining consent for interventional research in potential deceased organ donors:
      a narrative review.
PG  - 1229-1235
LID - 10.1111/anae.15039 [doi]
AB  - In the last decade, research in transplant medicine has focused on developing
      interventions in the management of the deceased organ donor to improve the
      quality and quantity of transplantable organs. Despite the promise of
      interventional donor research, there remain debates about the ethics of this
      research, specifically regarding gaining research consent. Here, we examine the
      concerns and ambiguities around consent for interventional donor research, which 
      incorporate questions about who should consent for interventional donor research 
      and what people are being asked to consent for. We highlight the US and UK policy
      responses to these concerns and argue that, whereas guidance in this area has
      done much to clarify these ambiguities, there is little consideration of the
      nature, practicalities and context around consent in this area, particularly
      regarding organ donors and their families. We review wider studies of consent in 
      critical care research and social science studies of consent in medical research,
      to gain a broader view of consent in this area as a relational and contextual
      process. We contend a lack of consideration has been given to: what it might mean
      to consent to interventional donor research; how families, patients and health
      professionals might experience providing and seeking this consent; who is best
      placed to have these discussions; and the socio-institutional contexts affecting 
      these processes. Further, empirical research is required to establish an ethical 
      and sensitive model for consent in interventional donor research, ensuring the
      principles enshrined in research ethics are met and public trust in organ
      donation is maintained.
CI  - (c) 2020 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of
      Association of Anaesthetists.
FAU - Cooper, J
AU  - Cooper J
AD  - School of Health Sciences, City, University of London, UK.
FAU - Harvey, D
AU  - Harvey D
AD  - Department of Intensive Care Medicine, Nottingham University NHS Trust,
      Nottingham, UK.
FAU - Gardiner, D
AU  - Gardiner D
AD  - Department of Intensive Care Medicine, Nottingham University NHS Trust,
      Nottingham, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200424
PL  - England
TA  - Anaesthesia
JT  - Anaesthesia
JID - 0370524
SB  - IM
MH  - Biomedical Research/*ethics/*legislation & jurisprudence
MH  - Humans
MH  - Informed Consent/*ethics/*legislation & jurisprudence
MH  - Tissue Donors/*ethics/*legislation & jurisprudence
MH  - United Kingdom
MH  - United States
OTO - NOTNLM
OT  - *consent
OT  - *ethics
OT  - *interventional research
OT  - *organ donation
EDAT- 2020/04/25 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1111/anae.15039 [doi]
PST - ppublish
SO  - Anaesthesia. 2020 Sep;75(9):1229-1235. doi: 10.1111/anae.15039. Epub 2020 Apr 24.


PMID- 32329884
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1551-7489 (Print)
IS  - 1551-7489 (Linking)
VI  - 16
IP  - 2
DP  - 2020 Mar/Apr
TI  - Can opioid vigilance and patient-centered care coexist? A qualitative study of
      communicative tensions encountered by surgical trainees.
PG  - 91-101
LID - jom.2020.0555 [pii]
LID - 10.5055/jom.2020.0555 [doi]
AB  - OBJECTIVE: The American health care system's adoption of the patient-centered
      care (PCC) model has transformed how medical pro-viders communicate with patients
      about prescription pain medication. Concomitantly, the nation's opioid epidemic
      has necessitated a proactive response from the medical profession, requiring
      providers who frequently dispense opioids for acute pain to exercise vigi-lance
      in monitoring and limiting outpatient prescriptions. This qualitative study
      explores how surgical trainees balance PCC directives, including shared decision 
      making, exchanging information with patients, and relationship maintenance, with 
      opioid prescribing vigi-lance. DESIGN: Investigators conducted interviews with 17
      surgical residents and fellows (trainees) who routinely prescribe opioids at an
      ac-ademic medical center. RESULTS: A qualitative descriptive analysis produced
      four codes, which were reduced to themes depicting problematic intersections
      between PCC imperatives and opioid vigilance during post-operative
      opioid-prescribing communication: (a) sharing the deci-sion-making process
      contended with exerting medical authority, (b) reciprocating information
      contended with negotiating opioid prescribing terms with patients, (c)
      maintaining symbiotic relationships contended with prescribing ethics, and (d)
      achieving patient satisfaction contended with safeguarding opioid medications.
      CONCLUSION: Surgical training programs must supply trainees with post-surgical
      prescribing guidelines and communication skills training. Training should
      emphasize how PCC directives may work in tandem with-not in opposition to-opioid 
      vigilance.
FAU - Troutman Adams, Elizabeth
AU  - Troutman Adams E
AD  - School of Media and Journalism, University of North Carolina at Chapel Hill,
      Chapel Hill, North Carolina.
FAU - Cohen, Elisia L
AU  - Cohen EL
AD  - Hubbard School of Journalism and Mass Communication, University of Minnesota,
      Minneapolis, Minnesota.
FAU - Bernard, Andrew
AU  - Bernard A
AD  - Department of Trauma and Surgery, College of Medicine, University of Kentucky,
      Lexington, Kentucky.
FAU - Darnell, Whittney H
AU  - Darnell WH
AD  - College of Communication and Information, University of Kentucky, Lexington,
      Kentucky.
FAU - Oyler, Douglas R
AU  - Oyler DR
AD  - Department of Pharmacy Practice and Science, University of Kentucky College of
      Pharmacy, Lexington, Kentucky.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Opioid Manag
JT  - Journal of opioid management
JID - 101234523
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - *Analgesics, Opioid/adverse effects/therapeutic use
MH  - *Drug Prescriptions
MH  - Humans
MH  - *Patient-Centered Care
MH  - *Practice Patterns, Physicians'
MH  - Qualitative Research
MH  - United States
EDAT- 2020/04/25 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
AID - jom.2020.0555 [pii]
AID - 10.5055/jom.2020.0555 [doi]
PST - ppublish
SO  - J Opioid Manag. 2020 Mar/Apr;16(2):91-101. doi: 10.5055/jom.2020.0555.


PMID- 32329530
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1099-1751 (Electronic)
IS  - 0749-6753 (Linking)
VI  - 35
IP  - 4
DP  - 2020 Jul
TI  - Patient safety attitudes among critical care nurses: A case study in North
      Cyprus.
PG  - 910-921
LID - 10.1002/hpm.2976 [doi]
AB  - INTRODUCTION: Patient safety has become a crucial priority in quality healthcare.
      Adverse events and serious errors involving critically ill patients are common
      and can be potentially life-threatening. Thus, this study aimed to examine
      patient safety attitudes among critical care nurses. METHODS: This
      cross-sectional study was conducted in two hospitals in North Cyprus. Eighty
      nurses working in critical care units participated in the study. Following
      ethical approval, data were collected between September and October 2018, using
      the Demographic Characteristics Questionnaire and Safety Attitudes Questionnaire.
      FINDINGS: Nurses' overall scores regarding patient safety attitudes were found to
      be negative. The highest positive rate was for safety climate, followed by
      perception of management, teamwork, working conditions, job satisfaction, and
      stress recognition, respectively. There were significant differences among
      working conditions, perception of management, and stress recognition based on
      participants' positions and event reporting. CONCLUSION: Our findings indicate
      safety culture needs to be improved in the hospitals included in the study.
      Healthcare managers and decision-makers should foster patient safety culture
      through in-service education, management support, institutional regulations, and 
      updated guidelines.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Al-Mugheed, Khalid
AU  - Al-Mugheed K
AUID- ORCID: https://orcid.org/0000-0002-8437-977X
AD  - Surgical Nursing Department, Near East University Faculty of Nursing, Nicosia,
      Cyprus.
FAU - Bayraktar, Nurhan
AU  - Bayraktar N
AD  - Surgical Nursing Department, Near East University Faculty of Nursing, Nicosia,
      Cyprus.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - England
TA  - Int J Health Plann Manage
JT  - The International journal of health planning and management
JID - 8605825
MH  - Adult
MH  - *Critical Care
MH  - Cross-Sectional Studies
MH  - Cyprus
MH  - Female
MH  - Health Care Surveys
MH  - Humans
MH  - Middle Aged
MH  - *Nursing Staff, Hospital
MH  - Organizational Case Studies
MH  - *Patient Safety
MH  - *Safety Management
MH  - Young Adult
OTO - NOTNLM
OT  - Cyprus
OT  - critical care
OT  - nursing
OT  - patient safety attitude
OT  - safety culture
EDAT- 2020/04/25 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/04/25 06:00
PHST- 2019/08/16 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1002/hpm.2976 [doi]
PST - ppublish
SO  - Int J Health Plann Manage. 2020 Jul;35(4):910-921. doi: 10.1002/hpm.2976. Epub
      2020 Apr 24.


PMID- 32329209
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1557-0681 (Electronic)
IS  - 1478-2189 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Sep
TI  - Rehabilitation following shoulder arthroplasty in the United Kingdom National
      Health Service: A survey of publicly facing information.
PG  - 359-364
LID - 10.1002/msc.1468 [doi]
AB  - INTRODUCTION: The prevalence of shoulder arthroplasty (SA) is rising, but there
      is limited research evaluating rehabilitation following SA and whether there is
      an optimal approach remains unknown. The aim of this study was to understand
      current National Health Service (NHS) practice for rehabilitation following SA as
      a platform for conducting much needed further research. METHODS: Two reviewers
      independently undertook electronic searches for publicly available information
      sheets (PIS) from websites of NHS Trusts that included detail about
      rehabilitation following SA, for example, duration of immobilisation. One
      reviewer extracted data, and a second reviewer verified this. ETHICAL APPROVAL:
      Not required. RESULTS: Forty-three PIS from 40 Trusts were identified.
      Twenty-four referred to more than one type of arthroplasty (anatomic, reverse and
      hemiarthroplasty) but did not describe different approaches to rehabilitation
      based on prosthesis type. Twenty-five PIS provided some instruction regarding
      movement restrictions, which varied considerably. All PIS referred to
      postoperative immobilisation, typically with a sling, with median duration of 4
      weeks (range 0 to 8). Thirty-four PIS reported commencing passive exercise
      immediately. Median time to commencing active exercise was 4 weeks (range 1 to 6)
      and 5 weeks (range 1 to 16) for resisted exercise. Median time expected to return
      to driving was 6 weeks (range 3 to 12) and general work 12 weeks (range 3 to 26).
      CONCLUSION: This study has highlighted significant heterogeneity between
      rehabilitation approaches following SA, not previously reported in the United
      Kingdom, with a lack of specific rehabilitation PIS for different prosthesis
      types. Our results will facilitate evaluation of rehabilitation strategies in
      future research.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Littlewood, Chris
AU  - Littlewood C
AUID- ORCID: 0000-0002-7703-727X
AD  - Department of Health Professions, Faculty of Health, Psychology and Social Care, 
      Manchester Metropolitan University, Manchester, UK.
FAU - Morgan, Marie
AU  - Morgan M
AD  - Derby Shoulder Unit, University Hospitals Derby and Burton NHS Foundation Trust, 
      Derby, UK.
FAU - Pitt, Lisa
AU  - Pitt L
AD  - Derby Shoulder Unit, University Hospitals Derby and Burton NHS Foundation Trust, 
      Derby, UK.
FAU - Moffatt, Maria
AU  - Moffatt M
AD  - Upper Limb Research Unit, Wrightington, Wigan and Leigh NHS Foundation Trust,
      Wigan, UK.
FAU - Edwards, Peter
AU  - Edwards P
AD  - School of Physiotherapy and Exercise Science, Curtin University, Perth, Western
      Australia, Australia.
FAU - Davies, Ronnie
AU  - Davies R
AD  - Shoulder and Elbow Service, Manchester University NHS Foundation Trust,
      Manchester, UK.
FAU - Peach, Chris
AU  - Peach C
AD  - Shoulder and Elbow Service, Manchester University NHS Foundation Trust,
      Manchester, UK.
LA  - eng
GR  - PDF-2018-11-ST2-005/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200423
PL  - England
TA  - Musculoskeletal Care
JT  - Musculoskeletal care
JID - 101181344
SB  - IM
MH  - Arthroplasty
MH  - *Arthroplasty, Replacement, Shoulder
MH  - Humans
MH  - Physical Therapy Modalities
MH  - *State Medicine
MH  - United Kingdom
OTO - NOTNLM
OT  - *protocol
OT  - *rehabilitation
OT  - *shoulder arthroplasty
OT  - *shoulder replacement
OT  - *survey
EDAT- 2020/04/25 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/03/22 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1002/msc.1468 [doi]
PST - ppublish
SO  - Musculoskeletal Care. 2020 Sep;18(3):359-364. doi: 10.1002/msc.1468. Epub 2020
      Apr 23.


PMID- 32329193
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 2324-9269 (Electronic)
IS  - 2324-9269 (Linking)
VI  - 8
IP  - 7
DP  - 2020 Jul
TI  - Patient perspectives on variant reclassification after cancer susceptibility
      testing.
PG  - e1275
LID - 10.1002/mgg3.1275 [doi]
AB  - BACKGROUND: Little is known about the impact of reclassification on patients'
      perception of medical uncertainty or trust in genetics-based clinical care.
      METHODS: Semistructured telephone interviews were conducted with 20 patients who 
      had received a reclassified genetic test result related to hereditary cancer. All
      participants had undergone genetic counseling and testing for cancer
      susceptibility at Vanderbilt-Ingram Cancer Center Hereditary Cancer Clinic within
      the last six years. RESULTS: Most of the participants did not express distress
      related to the variant reclassification and only a minority expressed a decrease 
      in trust in medical genetics. However, recall of the new interpretation was
      limited, even though all participants were recontacted by letter, phone, or
      clinic visit. CONCLUSION: Reclassification of genetic tests is an important issue
      in modern healthcare because changes in interpretation have the potential to
      alter previously recommended management. Participants in this study did not
      express strong feelings of mistrust or doubt about their genetic evaluation.
      However, there was a low level of comprehension and information retention related
      to the updated report. Future research can build on this study to improve
      communication with patients about their reclassified results.
CI  - (c) 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley
      Periodicals LLC.
FAU - Halverson, Colin M E
AU  - Halverson CME
AUID- ORCID: 0000-0002-4205-7860
AD  - Center for Bioethics, Indiana University School of Medicine, Indianapolis, IN,
      USA.
AD  - Regenstrief Institute, Indianapolis, IN, USA.
FAU - Connors, Laurie M
AU  - Connors LM
AD  - School of Nursing, Vanderbilt University, Nashville, TN, USA.
FAU - Wessinger, Bronson C
AU  - Wessinger BC
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
FAU - Clayton, Ellen W
AU  - Clayton EW
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN, USA.
AD  - Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN,
      USA.
AD  - School of Law, Vanderbilt University, Nashville, TN, USA.
FAU - Wiesner, Georgia L
AU  - Wiesner GL
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
AD  - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville,
      TN, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200424
PL  - United States
TA  - Mol Genet Genomic Med
JT  - Molecular genetics & genomic medicine
JID - 101603758
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Attitude
MH  - Comprehension
MH  - Female
MH  - Genetic Counseling/*psychology
MH  - Genetic Predisposition to Disease/*classification/psychology
MH  - Genetic Testing/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*genetics
MH  - Patients/*psychology
MH  - Surveys and Questionnaires
PMC - PMC7336756
OTO - NOTNLM
OT  - *ethics
OT  - *genetics
OT  - *reclassification
OT  - *recontact
OT  - *uncertainty
EDAT- 2020/04/25 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/04/25 06:00
PHST- 2019/11/27 00:00 [received]
PHST- 2020/01/17 00:00 [revised]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1002/mgg3.1275 [doi]
PST - ppublish
SO  - Mol Genet Genomic Med. 2020 Jul;8(7):e1275. doi: 10.1002/mgg3.1275. Epub 2020 Apr
      24.


PMID- 32329156
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1098-2353 (Electronic)
IS  - 0897-3806 (Linking)
VI  - 33
IP  - 6
DP  - 2020 Sep
TI  - The effect of positioning on maternal anatomy and hemodynamics during late
      pregnancy.
PG  - 943-949
LID - 10.1002/ca.23614 [doi]
AB  - INTRODUCTION: Supine positioning during late pregnancy causes dramatic
      compression of maternal abdominal vasculature and is a risk factor for
      stillbirth. The azygos vein has been shown to provide collateral circulation in
      this scenario. There are many well-known anatomical differences in abdominal
      vasculature between the left and right sides of the body. However, the effect of 
      left and right positioning in pregnancy has not been well studied. MATERIALS AND 
      METHODS: After obtaining ethics approval, 10 women with uncomplicated pregnancies
      between 34 and 38 weeks gestation underwent magnetic resonance imaging in the
      left and right lateral positions. Phase contrast images were evaluated to measure
      blood flow through the abdominal aorta, inferior vena cava, and azygos vein.
      RESULTS: No significant differences between left and right lateral positions were
      found in blood flow through the IVC at its formation (mean difference -0.15 L/min
      [CI -0.47, 0.18], p = .34) or through the azygos vein (mean difference 0.02 L/min
      [CI -0.22, 0.26], p = .87). Blood flow through the IVC just above the level of
      the renal veins was found to be reduced by 35% in the right lateral position when
      compared to the left (mean difference 1.01 L/min [CI 0.25, 1.43], p = .03). There
      were no significant differences in cardiac output or blood flow through the
      abdominal aorta. CONCLUSIONS: While it was noted that blood flow through the IVC 
      immediately above the level of the renal veins was reduced in the right lateral
      position, this did not appear to impact significantly on maternal cardiac output 
      or blood flow through the azygos vein.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Humphries, Aimee
AU  - Humphries A
AUID- ORCID: https://orcid.org/0000-0003-0747-0964
AD  - Department of Anatomy and Medical Imaging, The University of Auckland, Auckland, 
      New Zealand.
AD  - Department of Obstetrics and Gynaecology, The University of Auckland, Auckland,
      New Zealand.
FAU - Thompson, John M D
AU  - Thompson JMD
AUID- ORCID: https://orcid.org/0000-0001-6944-381X
AD  - Department of Obstetrics and Gynaecology, The University of Auckland, Auckland,
      New Zealand.
AD  - Department of Paediatrics: Child and Youth Health, The University of Auckland,
      Auckland, New Zealand.
FAU - Stone, Peter
AU  - Stone P
AUID- ORCID: https://orcid.org/0000-0003-1546-752X
AD  - Department of Obstetrics and Gynaecology, The University of Auckland, Auckland,
      New Zealand.
FAU - Mirjalili, Seyed Ali
AU  - Mirjalili SA
AUID- ORCID: https://orcid.org/0000-0002-1599-3573
AD  - Department of Anatomy and Medical Imaging, The University of Auckland, Auckland, 
      New Zealand.
LA  - eng
GR  - Auckland Academic Health Alliance, A+ Trust 6851
PT  - Journal Article
DEP - 20200511
PL  - United States
TA  - Clin Anat
JT  - Clinical anatomy (New York, N.Y.)
JID - 8809128
SB  - IM
MH  - Adult
MH  - Aorta, Abdominal/diagnostic imaging/*physiology
MH  - Azygos Vein/diagnostic imaging/*physiology
MH  - Female
MH  - Hemodynamics/*physiology
MH  - Humans
MH  - Patient Positioning/*methods
MH  - Pregnancy
MH  - Regional Blood Flow/*physiology
MH  - Vena Cava, Inferior/diagnostic imaging/*physiology
OTO - NOTNLM
OT  - aortocaval compression
OT  - azygos vein
OT  - hemodynamics
OT  - maternal
OT  - position
OT  - pregnancy
EDAT- 2020/04/25 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1002/ca.23614 [doi]
PST - ppublish
SO  - Clin Anat. 2020 Sep;33(6):943-949. doi: 10.1002/ca.23614. Epub 2020 May 11.


PMID- 32329032
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 1
DP  - 2020 May
TI  - Rethinking Health Care Ethics: A response to Professor Reis-Dennis.
PG  - 87-90
LID - 10.1007/s40592-020-00105-1 [doi]
FAU - Scher, Stephen
AU  - Scher S
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
      sscher@mclean.harvard.edu.
AD  - McLean Hospital, Belmont, MA, USA. sscher@mclean.harvard.edu.
AD  - Discipline of Psychiatry, University of Sydney Medical School, Sydney, Australia.
      sscher@mclean.harvard.edu.
AD  - , Cambridge, MA, USA. sscher@mclean.harvard.edu.
FAU - Kozlowska, Kasia
AU  - Kozlowska K
AD  - Discipline of Psychiatry and Discipline of Child & Adolescent Health, University 
      of Sydney Medical School, Sydney, Australia.
AD  - The Children's Hospital at Westmead, Westmead, NSW, Australia.
AD  - Westmead Institute for Medical Research, Westmead, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
CON - Monash Bioeth Rev. 2020 May;38(1):83-86. PMID: 32306202
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1007/s40592-020-00105-1 [doi]
AID - 10.1007/s40592-020-00105-1 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 May;38(1):87-90. doi: 10.1007/s40592-020-00105-1.


PMID- 32328679
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 1433-3023 (Electronic)
IS  - 0937-3462 (Linking)
VI  - 31
IP  - 7
DP  - 2020 Jul
TI  - The controversial Dr. J. Marion Sims (1813-1883).
PG  - 1299-1303
LID - 10.1007/s00192-020-04301-9 [doi]
AB  - J. Marion Sims (1813-1883) is often regarded as the founder of modern surgical
      gynecology. Widely known and respected during his lifetime, he was honored after 
      death with a statue erected in New York City's Bryant Park. It was later
      relocated to Central Park, where it remained until 2018, when it was removed
      after persistent public protests over its presence. The controversy arose over
      perceptions of Sims's most famous achievement: the development of the first
      reliable surgical cure for vesico-vaginal fistula, a catastrophic complication of
      prolonged obstructed labor, which was common in the nineteenth century. Sims
      developed his surgical technique by operating on a group of enslaved
      African-American women with fistulas between 1846 and 1849. Modern attacks on
      Sims are based more on a presentist revulsion over the institution of slavery
      than on a clear understanding of what Sims actually did within the context of his
      time and place. Modern critics attack his "experimental" surgeries, the patients'
      lack of "informed consent," and Sims's failure to use anesthesia during fistula
      surgery. None of these criticisms takes into consideration the appalling nature
      of the injuries these women had received, the suffering their condition caused
      them, the lack of any effective "standard-of-care" treatment for fistulas at that
      time, the social and legal constraints facing doctors who treated slaves, or the 
      uncertain and problematic early history of anesthesiology. Although
      "retrospective indignation" may be emotionally satisfying, it does not illuminate
      the past nor help us understand difficult decision-making in surgery, whatever
      the time or place.
FAU - Wall, L Lewis
AU  - Wall LL
AD  - Departments of Anthropology, Obstetrics & Gynecology, Washington University in
      St. Louis, Campus Box 1114, McMillan Hall 112, One Brookings Drive, St. Louis,
      MO, 63110, USA. WALLL@wustl.edu.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200423
PL  - England
TA  - Int Urogynecol J
JT  - International urogynecology journal
JID - 101567041
SB  - IM
MH  - Female
MH  - *Gynecology
MH  - History, 19th Century
MH  - Humans
MH  - Informed Consent
MH  - New York
MH  - Retrospective Studies
MH  - *Vesicovaginal Fistula
OTO - NOTNLM
OT  - *History of gynecology
OT  - *J. Marion Sims
OT  - *Medical ethics
OT  - *Presentism
OT  - *Vesico-vaginal fistula
EDAT- 2020/04/25 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/02/23 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1007/s00192-020-04301-9 [doi]
AID - 10.1007/s00192-020-04301-9 [pii]
PST - ppublish
SO  - Int Urogynecol J. 2020 Jul;31(7):1299-1303. doi: 10.1007/s00192-020-04301-9. Epub
      2020 Apr 23.


PMID- 32328358
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar 20
TI  - Evaluation of Oral Health Status Using the Geriatric Oral Health Assessment Index
      Among the Geriatric Population in India: A Pilot Study.
PG  - e7344
LID - 10.7759/cureus.7344 [doi]
AB  - Introduction and aim Clinical indicators alone are insufficient for evaluating
      oral health. In addition to health and disease, oral health includes socio-dental
      indicators of physical, psychological, and social aspects of well-being. The
      adaptive capacity of an individual influences the perception of oral
      health-related quality of life (OHRQoL). Indices such as the Oral Health Impact
      Profile, Oral Impacts on Daily Performances, and the Geriatric Oral Health
      Assessment Index (GOHAI) have been used to measure OHRQoL. This study was
      designed to assess OHRQoL in older individuals using the GOHAI. Methods Subjects 
      aged older than 65 years who visited our institution from January to March 2016
      were included. Subjects with cognitive behavior disorders were excluded. Subjects
      were assigned into three groups based on age: 65-69 years, 70-74 years, and 75
      years or older. The participants were asked 12 questions, and their responses
      were assessed by age group. Our Institutional Ethics Committee approved the study
      protocol. Results The 219 subjects recruited included 126 (57.5%) patients aged
      65-69 years, 57 (26.0%) patients aged 70-74 years, and 36 (16.4%) patients aged
      75 years or older. Several physical, physiological, and psychological aspects of 
      the GOHAI differed significantly among these three groups, with overall OHRQoL
      decreasing with age. Conclusion Although oral healthcare problems were widespread
      in the geriatric population, they were not a primary concern. Attitudes toward
      dentistry require improvement. However, further studies in larger populations are
      required to assess geriatric oral health.
CI  - Copyright (c) 2020, Venkatesan et al.
FAU - Venkatesan, Akshaya
AU  - Venkatesan A
AD  - Oral Pathology, Faculty of Dental Sciences, Sri Ramachandra Institution of Higher
      Education and Research, Chennai, IND.
FAU - V, Annie Sylvea
AU  - V AS
AD  - Oral Pathology, Faculty of Dental Sciences, Sri Ramachandra Institute of Higher
      Education and Research, Chennai, IND.
FAU - Ramalingam, Suganya
AU  - Ramalingam S
AD  - Oral Pathology, Sri Ramachandra Institute of Higher Education and Research,
      Chennai, IND.
FAU - Seenivasan, Madhan Kumar
AU  - Seenivasan MK
AD  - Prosthodontics, Sri Ramachandra Institute of Higher Education and Research,
      Chennai, IND.
FAU - Narasimhan, Malathi
AU  - Narasimhan M
AD  - Oral Pathology, Faculty of Dental Sciences, Sri Ramachandra Institute of Higher
      Education and Research, Chennai, IND.
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7170016
OTO - NOTNLM
OT  - assessment
OT  - geriatric
OT  - geriatric oral health assessment index
OT  - oral health
OT  - swallowing
OT  - xerostomia
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
AID - 10.7759/cureus.7344 [doi]
PST - epublish
SO  - Cureus. 2020 Mar 20;12(3):e7344. doi: 10.7759/cureus.7344.


PMID- 32328307
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2090-214X (Print)
VI  - 2020
DP  - 2020
TI  - Gum Arabic (Acacia Senegal) Augmented Total Antioxidant Capacity and Reduced
      C-Reactive Protein among Haemodialysis Patients in Phase II Trial.
PG  - 7214673
LID - 10.1155/2020/7214673 [doi]
AB  - BACKGROUND: Oxidative processes might increase in patients with end-stage renal
      disease (ESRD) according to the current literature. Oxidative stress (OS) is a
      risk factor of atherosclerosis and cardiovascular complications, which are major 
      causes of mortality among ESRD patients. Haemodialysis (HD) is life-saving
      procedure, nevertheless it is an active chronic inflammatory status that could
      augment cardiovascular disease and increase mortality. Gum Arabic (GA) has been
      claimed to act as an antioxidant and anti-inflammatory agent in experimental
      studies and clinical trials. Therefore, we assumed GA supplementation among
      haemodialysis patients would reduce oxidative stress and consequently reduce the 
      state of chronic inflammatory activation associated with haemodialysis. METHODS: 
      Forty end-stage renal failure (ESRF) patients aged 18-80 years who were on
      regular haemodialysis in Arif Renal Center, Omdurman, Sudan, were recruited. All 
      recruited patients met the inclusion criteria and signed informed consent prior
      to enrolment. The patients received 30 g/day of GA for 12 weeks. C-reactive
      protein (CRP) and complete blood count (CBC) were measured as baseline and
      monthly. Total antioxidant capacity (TAC) and oxidative stress marker
      malondialdehyde (MDA) levels were measured before and after GA intake. Ethical
      approval from the National Medicines and Poisons Board was obtained. RESULTS: Gum
      Arabic significantly augmented total antioxidant capacity level (P < 0.001) (95% 
      CI, 0.408-0.625) and also attenuated oxidative marker MDA and C-reactive protein 
      (P < 0.001). CONCLUSIONS: GA has revealed potent antioxidative and
      anti-inflammatory properties in haemodialysis patients. Oral digestion of GA (30 
      g/day) decreased oxidative stress and inflammatory markers among haemodialysis
      patients. Trial registration. ClinicalTrials.gov Identifier: NCT03214692,
      registered 11 July 2017 (prospective registration).
CI  - Copyright (c) 2020 Nour Elkhair Ali et al.
FAU - Ali, Nour Elkhair
AU  - Ali NE
AD  - Department of Physiology, Faculty of Medicine, Alneelain University, Khartoum,
      Sudan.
AD  - Nephrology Unit, Military Hospital Omdurman, Sudan.
FAU - Kaddam, Lamis AbdelGadir
AU  - Kaddam LA
AUID- ORCID: https://orcid.org/0000-0002-1083-4514
AD  - Department of Physiology, Faculty of Medicine, Alneelain University, Khartoum,
      Sudan.
FAU - Alkarib, Suad Yousif
AU  - Alkarib SY
AD  - Department of Pharmaceutics, College of Pharmacy, Karary University, Khartoum,
      Sudan.
FAU - Kaballo, Babikir Gabir
AU  - Kaballo BG
AD  - Nephrology Unit, Military Hospital Omdurman, Sudan.
AD  - Department of Medicine, Medicine & Surgery College, Karary University, Khartoum, 
      Sudan.
FAU - Khalid, Sami Ahmed
AU  - Khalid SA
AD  - Faculty of Pharmacy, University of Science & Technology, Omdurman, Sudan.
FAU - Higawee, Abdalazim
AU  - Higawee A
AD  - Nephrology Unit, Military Hospital Omdurman, Sudan.
FAU - AbdElhabib, Alaa
AU  - AbdElhabib A
AD  - Nephrology Unit, Military Hospital Omdurman, Sudan.
FAU - AlaaAldeen, Alaa
AU  - AlaaAldeen A
AD  - Nephrology Unit, Military Hospital Omdurman, Sudan.
FAU - Phillips, Aled O
AU  - Phillips AO
AD  - Institute of Nephrology, Cardiff University School of Medicine, Cardiff, UK.
FAU - Saeed, Amal Mahmoud
AU  - Saeed AM
AD  - Department of Physiology, Faculty of Medicine, University of Khartoum, Khartoum, 
      Sudan.
LA  - eng
SI  - ClinicalTrials.gov/NCT03214692
PT  - Journal Article
DEP - 20200409
PL  - United States
TA  - Int J Nephrol
JT  - International journal of nephrology
JID - 101546753
PMC - PMC7171621
COIS- The authors declare no conflicts of interest.
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
CRDT- 2020/04/25 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/01/27 00:00 [revised]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
AID - 10.1155/2020/7214673 [doi]
PST - epublish
SO  - Int J Nephrol. 2020 Apr 9;2020:7214673. doi: 10.1155/2020/7214673. eCollection
      2020.


PMID- 32328220
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220210
IS  - 1998-1929 (Print)
IS  - 1998-1929 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Jun
TI  - A Proposed Process for Risk Mitigation During the COVID-19 Pandemic.
PG  - 299-305
LID - 10.1007/s40617-020-00430-1 [doi]
AB  - Recent executive orders have led some applied behavior analysis (ABA) providers
      to interpret themselves as "essential personnel" during the COVID-19 pandemic. In
      this article, we argue against a blanket interpretation that being labeled
      "essential personnel" means that all in-person ABA services for all clients
      should continue during the COVID-19 pandemic. We believe this argument holds even
      if ABA providers are not in a jurisdiction currently under an active
      shelter-at-home or related order. First, we provide a brief description of risks 
      associated with continued in-person ABA service delivery, as well as risks
      associated with the temporary suspension of services or the transition to remote 
      ABA service delivery. For many clients, continued in-person service delivery
      carries a significant risk of severe harm to the client, family and caregivers,
      staff, and a currently overburdened health care system. In these situations, ABA 
      providers should temporarily suspend services or transition to telehealth or
      other forms of remote service delivery until information from federal, state, and
      local health care experts deems in-person contact safe. In rare cases, temporary 
      suspension of services or a transition to remote service delivery may place the
      client or others at risk of significant harm. In these situations, in-person
      services should likely continue, and ongoing assessment and risk mitigation are
      essential.
CI  - (c) Association for Behavior Analysis International 2020.
FAU - Cox, David J
AU  - Cox DJ
AD  - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School
      of Medicine, Baltimore, MD 21224 USA.grid.21107.350000 0001 2171 9311
FAU - Plavnick, Joshua B
AU  - Plavnick JB
AD  - Department of Counseling, Educational Psychology, and Special Education, College 
      of Education, Michigan State University, East Lansing, MI 48824
      USA.grid.17088.360000 0001 2150 1785
FAU - Brodhead, Matthew T
AU  - Brodhead MT
AD  - Department of Counseling, Educational Psychology, and Special Education, College 
      of Education, Michigan State University, East Lansing, MI 48824
      USA.grid.17088.360000 0001 2150 1785
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200423
PL  - Switzerland
TA  - Behav Anal Pract
JT  - Behavior analysis in practice
JID - 101515653
PMC - PMC7178923
OTO - NOTNLM
OT  - Autism
OT  - COVID-19
OT  - Decision making
OT  - Essential services
OT  - Ethics
OT  - pandemic
COIS- Conflict of InterestAll three authors declare they have no conflicts of interest.
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1007/s40617-020-00430-1 [doi]
AID - 430 [pii]
PST - epublish
SO  - Behav Anal Pract. 2020 Apr 23;13(2):299-305. doi: 10.1007/s40617-020-00430-1.
      eCollection 2020 Jun.


PMID- 32328000
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-042X (Print)
IS  - 1664-042X (Linking)
VI  - 11
DP  - 2020
TI  - Altered Sarcomeric Structure and Function in Woody Breast Myopathy of Avian
      Pectoralis Major Muscle.
PG  - 287
LID - 10.3389/fphys.2020.00287 [doi]
AB  - The "Woody" or "Wooden" breast disease is a severe myopathy of pectoralis major
      muscle recently identified within rapidly growing broiler lines all around the
      world with a prevalence rate around 20%, or even higher. Although of significant 
      ethical and economic impact, little is known regarding the structural and
      functional aspects of the contractile apparatus in the woody breast muscle. The
      aim of the present study was to determine physiological properties of the
      contractile system in the morphologically intact muscle fibers of focally damaged
      woody breast in comparison with normal muscle fibers to gain insight into the
      muscle function of the animal and possibly mechanisms involved in the disease
      development. Muscle samples were taken from woody breast (non-lesioned areas) and
      normal breast muscles from broilers. Length-tension curves, maximal active
      stress, maximal shortening velocity, calcium sensitivity, rate of tension
      development, lattice spacing and muscle biochemical composition were investigated
      on single skinned fibers. Sarcomeres of woody breast fibers were more compliant, 
      which is very likely related to the wider spacing (18% wider compared to
      controls) between thick and thin filament. No differences were found in optimal
      sarcomere length (2.68 +/- 0.04 vs. 2.65 +/- 0.05 mum) nor in maximal active
      stress (116 +/- 17 vs. 125 +/- 19 mN mm(-2)). However, woody breast fibers had
      less steep descending arm as shown in length-tension curve. Woody breast muscle
      fibers had 40% bigger sarcomeric volume compared to controls. Content of
      contractile proteins (myosin and actin), and maximal shortening velocity were
      unchanged indicating that the growth in woody breast muscle fiber was associated 
      with synthesis of new contractile units with unaltered kinetics. Calcium
      sensitivity was decreased in woody breast muscle fibers significantly. In
      conclusion, the results show that the rapid growth of muscle in woody breast
      disease is associated with significant structural and functional changes in the
      pectoralis major musculature, associated with alterations in the mechanical
      anchoring of contractile filaments.
CI  - Copyright (c) 2020 Liu, Puolanne, Schwartzkopf and Arner.
FAU - Liu, Jiao
AU  - Liu J
AD  - College of Life Sciences, South-Central University for Nationalities, Wuhan,
      China.
AD  - Thoracic Surgery, Department of Clinical Sciences, Lund, Faculty of Medicine,
      Lund University, Lund, Sweden.
FAU - Puolanne, Eero
AU  - Puolanne E
AD  - Department of Food and Nutrition, University of Helsinki, Helsinki, Finland.
FAU - Schwartzkopf, Matthias
AU  - Schwartzkopf M
AD  - Deutsches Elektronen-Synchrotron, Hamburg, Germany.
FAU - Arner, Anders
AU  - Arner A
AD  - Thoracic Surgery, Department of Clinical Sciences, Lund, Faculty of Medicine,
      Lund University, Lund, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC7160512
OTO - NOTNLM
OT  - avian muscle
OT  - hypertrophy
OT  - muscle disease
OT  - muscular dystrophy
OT  - sarcomere
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
CRDT- 2020/04/25 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
AID - 10.3389/fphys.2020.00287 [doi]
PST - epublish
SO  - Front Physiol. 2020 Apr 9;11:287. doi: 10.3389/fphys.2020.00287. eCollection
      2020.


PMID- 32327988
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Linking)
VI  - 14
DP  - 2020
TI  - Neurodiagnostics in Sports: Investigating the Athlete's Brain to Augment
      Performance and Sport-Specific Skills.
PG  - 133
LID - 10.3389/fnhum.2020.00133 [doi]
AB  - Enhancing performance levels of athletes during training and competition is a
      desired goal in sports. Quantifying training success is typically accompanied by 
      performance diagnostics including the assessment of sports-relevant behavioral
      and physiological parameters. Even though optimal brain processing is a key
      factor for augmented motor performance and skill learning, neurodiagnostics is
      typically not implemented in performance diagnostics of athletes. We propose,
      that neurodiagnostics via non-invasive brain imaging techniques such as
      functional near-infrared spectroscopy (fNIRS) will offer novel perspectives to
      quantify training-induced neuroplasticity and its relation to motor behavior. A
      better understanding of such a brain-behavior relationship during the execution
      of sport-specific movements might help to guide training processes and to
      optimize training outcomes. Furthermore, targeted non-invasive brain stimulation 
      such as transcranial direct current stimulation (tDCS) might help to further
      enhance training outcomes by modulating brain areas that show training-induced
      neuroplasticity. However, we strongly suggest that ethical aspects in the use of 
      non-invasive brain stimulation during training and/or competition need to be
      addressed before neuromodulation can be considered as a performance enhancer in
      sports.
CI  - Copyright (c) 2020 Seidel-Marzi and Ragert.
FAU - Seidel-Marzi, Oliver
AU  - Seidel-Marzi O
AD  - Institute for General Kinesiology and Exercise Science, Faculty of Sport Science,
      University of Leipzig, Leipzig, Germany.
AD  - Department of Neurology, Max Planck Institute for Human Cognitive and Brain
      Sciences, Leipzig, Germany.
FAU - Ragert, Patrick
AU  - Ragert P
AD  - Institute for General Kinesiology and Exercise Science, Faculty of Sport Science,
      University of Leipzig, Leipzig, Germany.
AD  - Department of Neurology, Max Planck Institute for Human Cognitive and Brain
      Sciences, Leipzig, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC7160821
OTO - NOTNLM
OT  - athletes
OT  - fNIRS
OT  - neurodiagnostic
OT  - neuromodulation
OT  - neuroplasticity
OT  - non-invasive brain stimulation
OT  - performance enhancement
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
CRDT- 2020/04/25 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
AID - 10.3389/fnhum.2020.00133 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2020 Apr 9;14:133. doi: 10.3389/fnhum.2020.00133. eCollection
      2020.


PMID- 32327482
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 22
TI  - Mapping the digital food environment: a scoping review protocol.
PG  - e036241
LID - 10.1136/bmjopen-2019-036241 [doi]
AB  - INTRODUCTION: Food environments are the interface through which people interact
      with the broader food system. They are a key determinant of healthy and
      sustainable diets. The widespread use of digital technology in late modernity and
      the shift towards a digital society have posed new challenges for nutrition and
      health, with a concomitant surge in research on social media, digital health
      promotion interventions, and more recently, increasing interest in digital food
      marketing. While the literature is abundant on studies linking food, nutrition
      and digital technology, the effort to conceptualise and describe the digital food
      environment is new. This scoping review aims to support the development of a
      definition of the digital food environment and characterise it, along with key
      thematic research trends on this topic and potential consequences for nutrition
      and health. METHODS AND ANALYSIS: The planned scoping review will be supported by
      the methodological framework proposed by Arksey and O'Malley and further
      developed by Levac et al. Development and reporting will follow the Preferred
      Reporting Items for Systematic Reviews and MetaAnalyses-Extension for Scoping
      Reviews (PRISMA-ScR) checklist and guidelines. The development of the search
      strategy was guided by the food environment conceptual framework developed by
      Turner et al. Four databases will be searched: MEDLINE, EMBASE, Scopus and Web of
      Science. Citation searching will be applied to identify additional studies,
      through checking of reference lists of primary studies and reviews. Studies in
      English, published from the year 2000 onwards, will be included. No geographical 
      or population limits will be applied. Data will be extracted and analysed using a
      standardised charting tool. ETHICS AND DISSEMINATION: No ethical approval is
      required for this study. The results will be submitted to an international
      peer-reviewed journal and scientific conferences. They will be disseminated
      through digital science communication platforms, including academic social media,
      to amplify its reach and usefulness.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Granheim, Sabrina Ionata
AU  - Granheim SI
AUID- ORCID: 0000-0003-4326-1772
AD  - Department of Public Health and Sport Sciences, Inland Norway University of
      Applied Sciences, Elverum, Norway sabrina.granheim@inn.no.
FAU - Opheim, Elin
AU  - Opheim E
AD  - Department of Research, University Library, Inland Norway University of Applied
      Sciences, Elverum, Norway.
FAU - Terragni, Laura
AU  - Terragni L
AD  - Department of Nursing and Health Promotion, OsloMet - Oslo Metropolitan
      University, Oslo, Norway.
FAU - Torheim, Liv Elin
AU  - Torheim LE
AD  - Department of Nursing and Health Promotion, OsloMet - Oslo Metropolitan
      University, Oslo, Norway.
FAU - Thurston, Miranda
AU  - Thurston M
AD  - Department of Public Health and Sport Sciences, Inland Norway University of
      Applied Sciences, Elverum, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200422
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Food
MH  - Humans
MH  - Peer Review
MH  - *Research Design
MH  - *Social Media
MH  - Systematic Reviews as Topic
PMC - PMC7204828
OTO - NOTNLM
OT  - *information technology
OT  - *nutrition & dietetics
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/25 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036241 [pii]
AID - 10.1136/bmjopen-2019-036241 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 22;10(4):e036241. doi: 10.1136/bmjopen-2019-036241.


PMID- 32327480
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 22
TI  - Effectiveness and feasibility of internet-based and mobile-based interventions
      for individuals experiencing bereavement: a systematic review protocol.
PG  - e036034
LID - 10.1136/bmjopen-2019-036034 [doi]
AB  - INTRODUCTION: Internet-based and mobile-based interventions (IMIs) provide an
      innovative and efficient self-management tool for mental health problems. This
      systematic review aims to summarise and critically evaluate studies addressing
      the effectiveness and feasibility of IMIs for normal and complicated grief in
      bereaved adults. METHODS AND ANALYSIS: The databases MEDLINE, Cochrane Library,
      PsycINFO, Embase and Web of Science and Google Scholar (for 'grey' literature)
      will be systematically searched for feasibility studies or randomised controlled 
      trials of IMIs for bereaved adults who were experiencing normal/complicated
      grief. Data will be extracted and evaluated independently by two reviewers from
      studies eligible for inclusion. Quality of evidence will be assessed, and results
      will be synthesised qualitatively and pooled meta-analytically, if sufficient
      outcome data are available. Preferred Reporting Items for Systematic Reviews and 
      Meta-Analyses standards and Grades of Recommendation, Assessment, Development and
      Evaluation methodology will be used. ETHICS AND DISSEMINATION: No primary data
      will be collected; thus, ethical approval is not required. The results will be
      disseminated through a peer-reviewed publication and conference presentations.
      TRIAL REGISTRATION NUMBER: CRD42019131428.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Luppa, Melanie
AU  - Luppa M
AUID- ORCID: 0000-0003-3927-6728
AD  - Institute of Social Medicine, Occupational Health and Public Health, University
      of Leipzig, Faculty of Medicine, Leipzig, Sachsen, Germany
      Melanie.Luppa@medizin.uni-leipzig.de.
FAU - Lobner, Margrit
AU  - Lobner M
AD  - Institute of Social Medicine, Occupational Health and Public Health, University
      of Leipzig, Faculty of Medicine, Leipzig, Sachsen, Germany.
FAU - Pabst, Alexander
AU  - Pabst A
AD  - Institute of Social Medicine, Occupational Health and Public Health, University
      of Leipzig, Faculty of Medicine, Leipzig, Sachsen, Germany.
FAU - Schlapke, Christine
AU  - Schlapke C
AD  - Institute of Social Medicine, Occupational Health and Public Health, University
      of Leipzig, Faculty of Medicine, Leipzig, Sachsen, Germany.
FAU - Stein, Janine
AU  - Stein J
AD  - Institute of Social Medicine, Occupational Health and Public Health, University
      of Leipzig, Faculty of Medicine, Leipzig, Sachsen, Germany.
FAU - Riedel-Heller, Steffi G
AU  - Riedel-Heller SG
AD  - Institute of Social Medicine, Occupational Health and Public Health, University
      of Leipzig, Faculty of Medicine, Leipzig, Sachsen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200422
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Bereavement
MH  - Feasibility Studies
MH  - Grief
MH  - Humans
MH  - *Internet
MH  - Mental Health
MH  - *Mobile Applications
MH  - *Psychotherapy, Psychodynamic
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - *Self-Management
MH  - Systematic Reviews as Topic
PMC - PMC7204864
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *mental health
OT  - *preventive medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/25 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036034 [pii]
AID - 10.1136/bmjopen-2019-036034 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 22;10(4):e036034. doi: 10.1136/bmjopen-2019-036034.


PMID- 32327479
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 22
TI  - [(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent
      prostate cancer state amenable for curative-intent ablative therapy: study
      protocol for a phase II trial.
PG  - e035959
LID - 10.1136/bmjopen-2019-035959 [doi]
AB  - INTRODUCTION: The oligometastatic (OM) disease hypothesis of an intermediate
      metastatic state with limited distant disease deposits amenable for curative
      therapies remains debatable. Over a third of prostate cancer (PCa) patients
      treated with radical prostatectomy and postoperative radiotherapy experience
      disease recurrence; these patients are considered incurable by current standards.
      Often the recurrence cannot be localised by conventional imaging (CT and bone
      scan). Combined anatomical imaging with CT and/or MR with positron emission
      tomography (PET) using a novel second-generation prostate-specific membrane
      antigen (PSMA) probe, [(18)F]DCFPyL, is a promising imaging modality to unveil
      disease deposits in these patients. A new and earlier molecularly defined
      oligorecurrent (OR) state may be amenable to focal-targeted ablative
      curative-intent therapies, such as stereotactic ablative radiotherapy (SABR) or
      surgery, thereby significantly delaying or completely avoiding the need for
      palliative therapies in men with recurrent PCa after maximal local treatments.
      METHODS AND ANALYSIS: This ongoing single-institution phase II study will enrol
      up to 75 patients total, to include up to 37 patients with response-evaluable
      disease, who have rising prostate-specific antigen (range 0.4-3.0 ng/mL)
      following maximal local therapies with no evidence of disease on conventional
      imaging. These patients will undergo [(18)F]DCFPyL PET-MR/CT imaging to detect
      disease deposits, which will then be treated with SABR or surgery. The primary
      endpoints are performance of [(18)F]DCFPyL PET-MR/CT, and treatment response
      rates following SABR or surgery. Demographics and disease characteristics will be
      summarised and analysed descriptively. Response rates will be described with
      waterfall plots and proportions. ETHICS AND DISSEMINATION: Ethics approval was
      obtained from the institutional Research Ethics Board. All patients will provide 
      written informed consent. [(18)F]DCFPyL has approval from Health Canada. The
      results of the study will be disseminated by the principal investigator. Patients
      will not be identifiable as individuals in any publication or presentation of
      this study. TRIAL REGISTRATION NUMBERS: NCT03160794.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Glicksman, Rachel M
AU  - Glicksman RM
AUID- ORCID: 0000-0002-0555-8754
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Metser, Ur
AU  - Metser U
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai
      Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Valliant, John
AU  - Valliant J
AD  - Centre for Probe Development and Commercialization, McMaster University,
      Hamilton, Ontario, Canada.
FAU - Chung, Peter W
AU  - Chung PW
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Fleshner, Neil E
AU  - Fleshner NE
AD  - Department of Surgical Oncology, Division of Urology, University Health Network, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Bristow, Robert G
AU  - Bristow RG
AD  - Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University 
      of Manchester; Cancer Research UK Manchester Institute and Manchester Cancer
      Research Centre; The Christie NHS Foundation Trust, Manchester, UK.
FAU - Green, David
AU  - Green D
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Finelli, Antonio
AU  - Finelli A
AD  - Department of Surgical Oncology, Division of Urology, University Health Network, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Hamilton, Robert
AU  - Hamilton R
AD  - Department of Surgical Oncology, Division of Urology, University Health Network, 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Stanescu, Teodor
AU  - Stanescu T
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Hussey, Douglas
AU  - Hussey D
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai
      Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Catton, Charles
AU  - Catton C
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Gospodarowicz, Mary
AU  - Gospodarowicz M
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Warde, Padraig
AU  - Warde P
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Bayley, Andrew
AU  - Bayley A
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Breen, Stephen
AU  - Breen S
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Department of Medical Physics, Odette Cancer Centre, Sunnybrook Health Sciences
      Centre, Toronto, Ontario, Canada.
FAU - Vines, Doug
AU  - Vines D
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario,
      Canada.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Jaffray, David A
AU  - Jaffray DA
AD  - Office of the Chief Technology and Digital Officer; Department of Radiation
      Physics; Department of Imaging Physics, University of Texas MD Anderson Cancer
      Center, Houston, Texas, USA.
FAU - Berlin, Alejando
AU  - Berlin A
AUID- ORCID: 0000-0002-1880-6905
AD  - Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
      alejandro.Berlin@rmp.uhn.ca.
AD  - Radiation Medicine Program, Princess Margaret Hospital Cancer Centre, University 
      Health Network, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03160794
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200422
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Canada
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Neoplasm Recurrence, Local/diagnostic imaging
MH  - *Positron Emission Tomography Computed Tomography
MH  - *Prostatic Neoplasms/diagnostic imaging/radiotherapy/surgery
PMC - PMC7204865
OTO - NOTNLM
OT  - *prostate disease
OT  - *radiation oncology
OT  - *radiology & imaging
COIS- Competing interests: UM declares a competing interest with Point Biopharm Inc. as
      a consultant.
EDAT- 2020/04/25 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-035959 [pii]
AID - 10.1136/bmjopen-2019-035959 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 22;10(4):e035959. doi: 10.1136/bmjopen-2019-035959.


PMID- 32327474
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 22
TI  - Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial:
      study protocol for a randomised controlled trial in residential aged-care
      facilities assessing frailty as the primary outcome.
PG  - e032851
LID - 10.1136/bmjopen-2019-032851 [doi]
AB  - INTRODUCTION: Many medicines have adverse effects which are difficult to detect
      and frequently go unrecognised. Pharmacist monitoring of changes in signs and
      symptoms of these adverse effects, which we describe as medicine-induced
      deterioration, may reduce the risk of developing frailty. The aim of this trial
      is to determine the effectiveness of a 12-month pharmacist service compared with 
      usual care in reducing medicine-induced deterioration, frailty and adverse
      reactions in older people living in aged-care facilities in Australia. METHODS
      AND ANALYSIS: The reducing medicine-induced deterioration and adverse reactions
      trial is a multicentre, open-label randomised controlled trial. Participants will
      be recruited from 39 facilities in South Australia and Tasmania. Residents will
      be included if they are using four or more medicines at the time of recruitment, 
      or taking more than one medicine with anticholinergic or sedative properties. The
      intervention group will receive a pharmacist assessment which occurs every 8
      weeks. The pharmacists will liaise with the participants' general practitioners
      when medicine-induced deterioration is evident or adverse events are considered
      serious. The primary outcome is a reduction in medicine-induced deterioration
      from baseline to 6 and 12 months, as measured by change in frailty index. The
      secondary outcomes are changes in cognition scores, 24-hour movement behaviour,
      grip strength, weight, percentage robust, pre-frail and frail classification,
      rate of adverse medicine events, health-related quality of life and health
      resource use. The statistical analysis will use mixed-models adjusted for
      baseline to account for repeated outcome measures. A health economic evaluation
      will be conducted following trial completion using data collected during the
      trial. ETHICS AND DISSEMINATION: Ethics approvals have been obtained from the
      Human Research Ethics Committee of University of South Australia (ID:0000036440) 
      and University of Tasmania (ID:H0017022). A copy of the final report will be
      provided to the Australian Government Department of Health. TRIAL REGISTRATION
      NUMBER: Australian and New Zealand Trials Registry ACTRN12618000766213.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lim, Renly
AU  - Lim R
AUID- ORCID: 0000-0003-4135-2523
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia
      renly.lim@unisa.edu.au.
FAU - Bereznicki, Luke
AU  - Bereznicki L
AD  - School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
FAU - Corlis, Megan
AU  - Corlis M
AD  - Helping Hand Aged Care, North Adelaide, South Australia, Australia.
FAU - Kalisch Ellett, Lisa M
AU  - Kalisch Ellett LM
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia.
FAU - Kang, Ai Choo
AU  - Kang AC
AD  - Southern Cross Care (SA&NT), Adelaide, South Australia, Australia.
FAU - Merlin, Tracy
AU  - Merlin T
AD  - Discipline of Public Health, University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Parfitt, Gaynor
AU  - Parfitt G
AD  - UniSA Allied Health and Human Performance, University of South Australia,
      Adelaide, South Australia, Australia.
FAU - Pratt, Nicole L
AU  - Pratt NL
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia.
FAU - Rowett, Debra
AU  - Rowett D
AD  - UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South 
      Australia, Australia.
FAU - Torode, Stacey
AU  - Torode S
AD  - Southern Cross Care (SA&NT), Adelaide, South Australia, Australia.
FAU - Whitehouse, Joseph
AU  - Whitehouse J
AD  - Pharmacy Improvement Centre Ltd, Welland, South Australia, Australia.
FAU - Andrade, Andre Q
AU  - Andrade AQ
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia.
FAU - Bilton, Rebecca
AU  - Bilton R
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia.
FAU - Cousins, Justin
AU  - Cousins J
AD  - School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
FAU - Kelly, Lan
AU  - Kelly L
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia.
FAU - Schubert, Camille
AU  - Schubert C
AD  - Discipline of Public Health, University of Adelaide, Adelaide, South Australia,
      Australia.
FAU - Williams, Mackenzie
AU  - Williams M
AD  - University of Tasmania, Hobart, Tasmania, Australia.
FAU - Roughead, Elizabeth Ellen
AU  - Roughead EE
AD  - Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health
      Sciences, University of South Australia, Adelaide, South Australia, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200422
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Body Weight
MH  - *Clinical Deterioration
MH  - Cognition
MH  - Drug-Related Side Effects and Adverse Reactions/*prevention & control
MH  - Frailty/chemically induced/*prevention & control
MH  - Hand Strength
MH  - Health Services Needs and Demand/statistics & numerical data
MH  - *Homes for the Aged
MH  - Humans
MH  - *Medication Therapy Management
MH  - Physical Functional Performance
MH  - Polypharmacy
MH  - Quality of Life
MH  - South Australia
MH  - Tasmania
MH  - Time Factors
PMC - PMC7204916
OTO - NOTNLM
OT  - *adverse drug events
OT  - *cognition
OT  - *nursing homes
OT  - *pharmacist
OT  - *physical activity
COIS- Competing interests: The reducing medicine-induced deterioration and adverse
      reactions (ReMInDAR) trial is by the Australian Government. ACK is employed as a 
      research assistant of the ReMInDAR trial. RB is employed as the ReMInDAR
      partnership engagement and trial manager to oversee the operations management for
      the trial.
EDAT- 2020/04/25 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-032851 [pii]
AID - 10.1136/bmjopen-2019-032851 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 22;10(4):e032851. doi: 10.1136/bmjopen-2019-032851.


PMID- 32327242
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 113
IP  - 5
DP  - 2020 May
TI  - Legal and ethical issues in cross-border gestational surrogacy.
PG  - 916-919
LID - S0015-0282(20)30248-X [pii]
LID - 10.1016/j.fertnstert.2020.03.003 [doi]
AB  - This article aims to identify the main legal and ethical issues around
      international surrogacy. Owing to the legal diversity and ethical background of
      such a globalized practice, a review of the key existing literature on these two 
      matters has been identified and analyzed. The article also identifies and
      analyzes the most significant legal solutions provided by supranational
      jurisdictions when dealing with cases of international surrogacy. The scope of
      the article includes the efforts to reach a minimum legal framework at the
      international level, with the aim not to standardize but to provide common legal 
      solutions to those travelling abroad to have a child by means of surrogacy.
CI  - Copyright (c) 2020 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
FAU - Igareda Gonzalez, Noelia
AU  - Igareda Gonzalez N
AD  - Autonomous University of Barcelona, Bellaterra, Barcelona, Spain. Electronic
      address: noelia.igareda@uab.cat.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200420
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
SB  - IM
MH  - Female
MH  - Humans
MH  - Internationality/legislation & jurisprudence
MH  - *Medical Tourism/ethics/legislation & jurisprudence
MH  - Policy Making
MH  - Pregnancy
MH  - *Reproductive Medicine/ethics/legislation & jurisprudence
MH  - Reproductive Techniques, Assisted/ethics/legislation & jurisprudence
MH  - *Surrogate Mothers/legislation & jurisprudence
OTO - NOTNLM
OT  - *cross-border gestational surrogacy
OT  - *ethics
OT  - *international surrogacy
OT  - *law
EDAT- 2020/04/25 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - S0015-0282(20)30248-X [pii]
AID - 10.1016/j.fertnstert.2020.03.003 [doi]
PST - ppublish
SO  - Fertil Steril. 2020 May;113(5):916-919. doi: 10.1016/j.fertnstert.2020.03.003.
      Epub 2020 Apr 20.


PMID- 32327056
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 1293-8505 (Print)
IS  - 1293-8505 (Linking)
VI  - 69
IP  - 258
DP  - 2020 Feb
TI  - [Refusal of care, a discriminatory act?]
PG  - 27-28
LID - S1293-8505(20)30007-5 [pii]
LID - 10.1016/j.revinf.2020.01.007 [doi]
AB  - If a patient can refuse care, health professionals may refuse to treat a person, 
      an act often considered discriminatory. Investigations have been carried out to
      shed light on this practice. This notion calls for a philosophical and ethical
      point of view.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Moutel, Gregoire
AU  - Moutel G
AD  - Equipe Anticipe Inserm U1086, Universite de Caen Normandie, esplanade de la Paix,
      14032 Caen cedex 5, France; Service de medecine legale et droit de sante, CHU
      Caen, avenue de la Cote-de-Nacre, CS 30001, 14033 Caen cedex 9, France; Espace
      regional de reflexion ethique de Normandie, avenue de la Cote-de-Nacre, CS 30001,
      14033 Caen cedex 9, France. Electronic address: gregoire.moutel@gmail.com.
FAU - Suzat, Bertille
AU  - Suzat B
AD  - Service de medecine legale et droit de sante, CHU Caen, avenue de la
      Cote-de-Nacre, CS 30001, 14033 Caen cedex 9, France.
FAU - Grandazzi, Guillaume
AU  - Grandazzi G
AD  - Espace regional de reflexion ethique de Normandie, avenue de la Cote-de-Nacre, CS
      30001, 14033 Caen cedex 9, France.
LA  - fre
PT  - Journal Article
TT  - Le refus de soins, un acte discriminatoire ?
DEP - 20200205
PL  - France
TA  - Rev Infirm
JT  - Revue de l'infirmiere
JID - 1267175
MH  - Ethics, Medical
MH  - Humans
MH  - Philosophy, Medical
MH  - *Prejudice
MH  - *Professional-Patient Relations
MH  - *Refusal to Treat
MH  - Treatment Refusal
OTO - NOTNLM
OT  - conscience
OT  - discrimination
OT  - ethics
OT  - philosophie
OT  - philosophy
OT  - refus de soins
OT  - refusal of care
OT  - ethique
EDAT- 2020/04/25 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
AID - S1293-8505(20)30007-5 [pii]
AID - 10.1016/j.revinf.2020.01.007 [doi]
PST - ppublish
SO  - Rev Infirm. 2020 Feb;69(258):27-28. doi: 10.1016/j.revinf.2020.01.007. Epub 2020 
      Feb 5.


PMID- 32326998
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20210110
IS  - 1481-8043 (Electronic)
IS  - 1481-8035 (Linking)
VI  - 22
IP  - 4
DP  - 2020 Jul
TI  - Ethical considerations of the duty to care and physician safety in the COVID-19
      pandemic.
PG  - 407-410
LID - 10.1017/cem.2020.376 [doi]
FAU - Bakewell, Francis
AU  - Bakewell F
AD  - Department of Emergency Medicine, The Ottawa Hospital, Ottawa, ON.
AD  - Medicine, Ethics, and Humanities Program, Department of Innovation in Medical
      Education, Faculty of Medicine, University of Ottawa, Ottawa, ON.
AD  - CAEP Bioethics Committee.
FAU - Pauls, Merril A
AU  - Pauls MA
AD  - CAEP Bioethics Committee.
AD  - Health Sciences Centre, Max Rady College of Medicine, Department of Emergency
      Medicine, University of Manitoba, Winnipeg, MB.
FAU - Migneault, David
AU  - Migneault D
AD  - CAEP Bioethics Committee.
AD  - Vancouver General Hospital, Vancouver, BC.
AD  - BC Children's Hospital, Vancouver, BC.
AD  - UBC Urgent Care Centre, Vancouver, BC.
AD  - Vancouver Coastal Health, Vancouver, BC.
AD  - UBC Department of Emergency Medicine, University of British Columbia, Vancouver, 
      BC.
LA  - eng
PT  - Journal Article
PL  - England
TA  - CJEM
JT  - CJEM
JID - 100893237
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Canada
MH  - Coronavirus Infections/*therapy
MH  - Delivery of Health Care/*ethics
MH  - Disease Outbreaks
MH  - *Ethics, Professional
MH  - Humans
MH  - Moral Obligations
MH  - Occupational Health/*ethics
MH  - Pandemics
MH  - Physicians/*ethics
MH  - Pneumonia, Viral/*therapy
MH  - Refusal to Treat/ethics
MH  - SARS-CoV-2
MH  - Triage
PMC - PMC7211799
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ethical obligations
OT  - *pandemic
OT  - *physician safety
EDAT- 2020/04/25 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1017/cem.2020.376 [doi]
AID - S1481803520003760 [pii]
PST - ppublish
SO  - CJEM. 2020 Jul;22(4):407-410. doi: 10.1017/cem.2020.376.


PMID- 32326934
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1472-684X (Electronic)
IS  - 1472-684X (Linking)
VI  - 19
IP  - 1
DP  - 2020 Apr 23
TI  - Social regulation activities in end-of-life: a qualitative study on completion of
      advance directives in Swiss nursing homes.
PG  - 57
LID - 10.1186/s12904-020-00562-9 [doi]
AB  - BACKGROUND: In Switzerland as in many countries, steady trend is observed in
      nursing homes to promote writing of advanced directives (ADs). Implementation of 
      ADs reflects the rise in public concern for the persons' right to
      self-determination and informed decision. The issue of end-of-life conditions is 
      particularly acute in situations with dementia. This article investigates how ADs
      interventions in nursing homes strive simultaneously to behave in line with the
      principles of care ethics and with the intention to respond to legally binding
      instructions. Healthcare to dying residents with dementia in nursing homes is
      interpreted in light of the Regulation theory. METHODS: Nursing home palliative
      care reference nurses were contacted through questionnaire. One hundred
      twenty-one addresses were reached, 69 responses were collected, giving a response
      rate of 57%. In order to deepen the understanding, 10 semi-directive interviews
      were conducted in 10 different nursing facilities with 12 palliative nurses.
      RESULTS: Presently, Swiss nursing homes are lacking a model of AD suitable to
      people with dementia. The study sheds light on dissimilarities in the purpose
      assigned to ADs' procedure in the different facilities. Discrepancies in
      end-of-life care practices reveal more the influence of structural and
      organisational devices specific to each setting than conflicting views on
      end-of-life care principles. We analyse the interpretation of the Law and its
      implementation in the participating NHs as compromises that could be accounted
      for as a form of social regulation. CONCLUSION: Dementia accentuates the
      uncertainty inherent to end-of-life trajectories. The implementation of
      standardised procedures aimed at collecting the wishes of the person deprived of 
      his or her discernment is source of dissonances with regard to the multiple
      interests involved in these care situations. In this context, the drafting of ADs
      during end-of-life care in NH correspond to new normative constraints requiring
      new collective regulation actions.
FAU - Droz Mendelzweig, M
AU  - Droz Mendelzweig M
AD  - Institut et Haute Ecole de la Sante La Source, Avenue Vinet 30, CH - 1004,
      Lausanne, Switzerland. m.droz@ecolelasource.ch.
LA  - eng
GR  - Kzs6/13/Schweizerische Akademie der Medizinischen Wissenschaften
PT  - Journal Article
DEP - 20200423
PL  - England
TA  - BMC Palliat Care
JT  - BMC palliative care
JID - 101088685
SB  - IM
MH  - Advance Directives/legislation & jurisprudence/*psychology/statistics & numerical
      data
MH  - Aged
MH  - Aged, 80 and over
MH  - *Death
MH  - Female
MH  - Humans
MH  - Male
MH  - Nursing Homes/organization & administration/statistics & numerical data
MH  - Qualitative Research
MH  - Surveys and Questionnaires
MH  - Switzerland
PMC - PMC7181527
OTO - NOTNLM
OT  - Advance directives, Nursing homes, End-of-life, Dementia, Regulation theory
EDAT- 2020/04/25 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/04/25 06:00
PHST- 2018/11/26 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1186/s12904-020-00562-9 [doi]
AID - 10.1186/s12904-020-00562-9 [pii]
PST - epublish
SO  - BMC Palliat Care. 2020 Apr 23;19(1):57. doi: 10.1186/s12904-020-00562-9.


PMID- 32326740
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210702
IS  - 1556-8342 (Electronic)
IS  - 1556-8253 (Linking)
VI  - 15
IP  - 7
DP  - 2020 Jul
TI  - Belimumab Concentrations in Maternal Serum and Breast Milk During Breastfeeding
      and the Safety Assessment of the Infant: A Case Study.
PG  - 475-477
LID - 10.1089/bfm.2020.0068 [doi]
AB  - Background: Belimumab is a recombinant human immunoglobulin G1 lambda monoclonal 
      antibody that binds soluble B lymphocyte stimulator protein with high affinity
      and inhibits its biological activity. Belimumab is not recommended for
      breastfeeding women due to insufficient data about its excretion into breast
      milk. In this study, we measured belimumab concentrations in the breast milk of
      one nursing mother diagnosed with mixed connective tissue disease (MCTD) and
      evaluated the health of her breastfed infant. Materials and Methods: Maternal
      serum and breast milk belimumab concentrations were collected three times (2
      weeks after the first dose, the day after the second dose, and 7 weeks after the 
      second dose) after ethical approval and informed consent. An enzyme-linked
      immunosorbent assay was used to detect belimumab in serum and breast milk
      samples. Case Report: A 39-year-old para 4 female was diagnosed with MCTD. The
      serum concentrations at three times were 29.45, 76.82, and 33.95 mcg/mL. The
      concentrations in breast milk were 0.12, 0.17, and 0.12 mcg/mL. The milk-to-serum
      concentration ratios at each sampling point were 0.0041, 0.0022, and 0.0035,
      respectively. Her infant experienced no health problems. Routine vaccinations
      were administered without any adverse effects such as infection or
      immunoreaction. Discussion and Conclusions: Breast milk levels of belimumab
      ranged from 1/200 to 1/500 of those in serum, and no harmful effect occurred in
      her infant. This is the first study reporting belimumab concentrations in human
      breast milk. Further studies are needed to elucidate the impact of exposure on
      breastfeeding infants.
FAU - Saito, Jumpei
AU  - Saito J
AD  - Department of Pharmacy, National Center for Child Health and Development, Tokyo, 
      Japan.
FAU - Yakuwa, Naho
AU  - Yakuwa N
AD  - Japan Drug Information Institute in Pregnancy, National Center for Child Health
      and Development, Tokyo, Japan.
FAU - Ishizuka, Tatsuo
AU  - Ishizuka T
AD  - Center of General Internal Medicine and Rheumatology, Gifu Municipal Hospital,
      Gifu, Japan.
FAU - Goto, Mikako
AU  - Goto M
AD  - Japan Drug Information Institute in Pregnancy, National Center for Child Health
      and Development, Tokyo, Japan.
FAU - Yamatani, Akimasa
AU  - Yamatani A
AD  - Department of Pharmacy, National Center for Child Health and Development, Tokyo, 
      Japan.
AD  - Japan Drug Information Institute in Pregnancy, National Center for Child Health
      and Development, Tokyo, Japan.
FAU - Murashima, Atsuko
AU  - Murashima A
AD  - Japan Drug Information Institute in Pregnancy, National Center for Child Health
      and Development, Tokyo, Japan.
AD  - Division of Maternal Medicine, Center of Maternal-Fetal, Neonatal and
      Reproductive Medicine, National Center for Child Health and Development, Tokyo,
      Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200423
PL  - United States
TA  - Breastfeed Med
JT  - Breastfeeding medicine : the official journal of the Academy of Breastfeeding
      Medicine
JID - 101260777
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunosuppressive Agents)
RN  - 73B0K5S26A (belimumab)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - Antibodies, Monoclonal, Humanized/*blood
MH  - *Breast Feeding
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*blood
MH  - Infant
MH  - Milk, Human/*chemistry
MH  - Mixed Connective Tissue Disease/*drug therapy
PMC - PMC7374635
OTO - NOTNLM
OT  - *belimumab
OT  - *breastfeeding
OT  - *mixed connective tissue disease
EDAT- 2020/04/25 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1089/bfm.2020.0068 [doi]
PST - ppublish
SO  - Breastfeed Med. 2020 Jul;15(7):475-477. doi: 10.1089/bfm.2020.0068. Epub 2020 Apr
      23.


PMID- 32325533
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20220418
IS  - 1439-3522 (Electronic)
IS  - 0720-4299 (Linking)
VI  - 88
IP  - 11
DP  - 2020 Nov
TI  - [The Erlangen Academic Psychiatry in Nationalsocialism.]
PG  - 713-721
LID - 10.1055/a-0893-6480 [doi]
AB  - INTRODUCTION: The 200th anniversary of the University Psychiatry Erlangen
      motivates a critical-historical analysis of the role of Friedrich Meggendorfer
      (1880-1953) as a psychiatrist under National Socialism. METHOD: A current
      evaluation of previously unconsidered sources made it possible to classify
      Friedrich Meggendorfer's role as a Nazi university psychiatrist in a
      differentiated way. RESULTS: Meggendorfer's expertise in hereditary psychiatry
      and forensic eugenics could be the decisive reason for his appointment as full
      professor of psychiatry to Erlangen in 1934. On 19.11.1945 Meggendorfer was
      supended by the military government. Although Meggendorfer was classified by the 
      court on 20.09.1946 as a "follower", he succeeded no reintegration into the
      faculty of the Friedrich-Alexander-University. DISCUSSION: Meggendorfer - among
      others through his explanations on the law for the prevention of hereditary
      diseases - allowed himself to be at least partially robbed of the freedom for
      independent intellectual creation as the core of academic self-understanding.
      CONCLUSION: The increased inclusion of ethical reflections in the psychiatric/
      psychosomatic specialist training can protect the "soul doctor" from being
      instrumentalized.
CI  - Thieme. All rights reserved.
FAU - Braun, Birgit
AU  - Braun B
AD  - Abteilung fur Psychosomatische Medizin und Psychotherapie, Universitatsklinikum
      Regensburg.
AD  - Klinik fur Psychiatrie und Psychotherapie, Universitatsklinikum Erlangen.
LA  - ger
PT  - Historical Article
PT  - Journal Article
TT  - Die Erlanger Universitatspsychiatrie im Nationalsozialismus.
DEP - 20200423
PL  - Germany
TA  - Fortschr Neurol Psychiatr
JT  - Fortschritte der Neurologie-Psychiatrie
JID - 8103137
SB  - IM
MH  - Eugenics
MH  - Germany
MH  - History, 20th Century
MH  - Humans
MH  - National Socialism
MH  - *Physicians
MH  - *Psychiatry
MH  - Psychophysiologic Disorders
COIS- Die Autorin arbeitete als Assistenz- und Facharztin an der Nachfolgeinstitution
      von Meggendorfers Klinik.
EDAT- 2020/04/24 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1055/a-0893-6480 [doi]
PST - ppublish
SO  - Fortschr Neurol Psychiatr. 2020 Nov;88(11):713-721. doi: 10.1055/a-0893-6480.
      Epub 2020 Apr 23.


PMID- 32325426
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20201218
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 5
DP  - 2020 May 5
TI  - Conversations and Medical News Frames on Twitter: Infodemiological Study on
      COVID-19 in South Korea.
PG  - e18897
LID - 10.2196/18897 [doi]
AB  - BACKGROUND: SARS-CoV-2 (severe acute respiratory coronavirus 2) was spreading
      rapidly in South Korea at the end of February 2020 following its initial outbreak
      in China, making Korea the new center of global attention. The role of social
      media amid the current coronavirus disease (COVID-19) pandemic has often been
      criticized, but little systematic research has been conducted on this issue.
      Social media functions as a convenient source of information in pandemic
      situations. OBJECTIVE: Few infodemiology studies have applied network analysis in
      conjunction with content analysis. This study investigates information
      transmission networks and news-sharing behaviors regarding COVID-19 on Twitter in
      Korea. The real time aggregation of social media data can serve as a starting
      point for designing strategic messages for health campaigns and establishing an
      effective communication system during this outbreak. METHODS: Korean
      COVID-19-related Twitter data were collected on February 29, 2020. Our final
      sample comprised of 43,832 users and 78,233 relationships on Twitter. We
      generated four networks in terms of key issues regarding COVID-19 in Korea. This 
      study comparatively investigates how COVID-19-related issues have circulated on
      Twitter through network analysis. Next, we classified top news channels shared
      via tweets. Lastly, we conducted a content analysis of news frames used in the
      top-shared sources. RESULTS: The network analysis suggests that the spread of
      information was faster in the Coronavirus network than in the other networks
      (Corona19, Shincheon, and Daegu). People who used the word "Coronavirus"
      communicated more frequently with each other. The spread of information was
      faster, and the diameter value was lower than for those who used other terms.
      Many of the news items highlighted the positive roles being played by individuals
      and groups, directing readers' attention to the crisis. Ethical issues such as
      deviant behavior among the population and an entertainment frame highlighting
      celebrity donations also emerged often. There was a significant difference in the
      use of nonportal (n=14) and portal news (n=26) sites between the four network
      types. The news frames used in the top sources were similar across the networks
      (P=.89, 95% CI 0.004-0.006). Tweets containing medically framed news articles
      (mean 7.571, SD 1.988) were found to be more popular than tweets that included
      news articles adopting nonmedical frames (mean 5.060, SD 2.904; N=40, P=.03, 95% 
      CI 0.169-4.852). CONCLUSIONS: Most of the popular news on Twitter had nonmedical 
      frames. Nevertheless, the spillover effect of the news articles that delivered
      medical information about COVID-19 was greater than that of news with nonmedical 
      frames. Social media network analytics cannot replace the work of public health
      officials; however, monitoring public conversations and media news that
      propagates rapidly can assist public health professionals in their complex and
      fast-paced decision-making processes.
CI  - (c)Han Woo Park, Sejung Park, Miyoung Chong. Originally published in the Journal 
      of Medical Internet Research (http://www.jmir.org), 05.05.2020.
FAU - Park, Han Woo
AU  - Park HW
AUID- ORCID: 0000-0002-1378-2473
AD  - Department of Media & Communication, Interdisciplinary Graduate Programs of
      Digital Convergence Business and East Asian Cultural Studies, Yeungnam
      University, Gyeongsan-si, Republic of Korea.
AD  - Cyber Emotions Research Institute, Gyeongsan-si, Republic of Korea.
FAU - Park, Sejung
AU  - Park S
AUID- ORCID: 0000-0001-9087-4075
AD  - Tim Russert Department of Communication, John Carroll University, Cleveland
      Heights, OH, United States.
FAU - Chong, Miyoung
AU  - Chong M
AUID- ORCID: 0000-0002-6760-6678
AD  - College of Information, University of North Texas, Denton, TX, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200505
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Communication
MH  - Coronavirus Infections/*epidemiology/virology
MH  - Health Education/*statistics & numerical data
MH  - Humans
MH  - Mass Media/*statistics & numerical data
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/virology
MH  - *Public Health
MH  - Republic of Korea/epidemiology
MH  - SARS-CoV-2
MH  - Social Media/*statistics & numerical data
PMC - PMC7202309
OTO - NOTNLM
OT  - *COVID-19
OT  - *SARS-CoV-2
OT  - *South Korea
OT  - *Twitter
OT  - *coronavirus
OT  - *infectious disease
OT  - *infodemiology
OT  - *medical news
OT  - *outbreak
OT  - *pandemic
OT  - *public health
OT  - *social media
EDAT- 2020/04/24 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/04/16 00:00 [revised]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - v22i5e18897 [pii]
AID - 10.2196/18897 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 May 5;22(5):e18897. doi: 10.2196/18897.


PMID- 32325058
OWN - NLM
STAT- MEDLINE
DCOM- 20200811
LR  - 20210422
IS  - 1097-4199 (Electronic)
IS  - 0896-6273 (Linking)
VI  - 106
IP  - 2
DP  - 2020 Apr 22
TI  - Modulation of Human Memory by Deep Brain Stimulation of the
      Entorhinal-Hippocampal Circuitry.
PG  - 218-235
LID - S0896-6273(20)30147-1 [pii]
LID - 10.1016/j.neuron.2020.02.024 [doi]
AB  - Neurological disorders affecting human memory present a major scientific,
      medical, and societal challenge. Direct or indirect deep brain stimulation (DBS) 
      of the entorhinal-hippocampal system, the brain's major memory hub, has been
      studied in people with epilepsy or Alzheimer's disease, intending to enhance
      memory performance or slow memory decline. Variability in the spatiotemporal
      parameters of stimulation employed to date notwithstanding, it is likely that
      future DBS for memory will employ closed-loop, nuanced approaches that are
      synergistic with native physiological processes. The potential for editing human 
      memory-decoding, enhancing, incepting, or deleting specific memories-suggests
      exciting therapeutic possibilities but also raises considerable ethical concerns.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Mankin, Emily A
AU  - Mankin EA
AD  - Department of Neurosurgery, University of California, Los Angeles, Los Angeles,
      CA 90095, USA.
FAU - Fried, Itzhak
AU  - Fried I
AD  - Department of Neurosurgery, University of California, Los Angeles, Los Angeles,
      CA 90095, USA; Department of Psychiatry and Biobehavioral Sciences, University of
      California, Los Angeles, Los Angeles, CA 90095, USA; Tel Aviv Medical Center and 
      Tel Aviv University, Tel Aviv, Israel. Electronic address:
      ifried@mednet.ucla.edu.
LA  - eng
GR  - R01 NS084017/NS/NINDS NIH HHS/United States
GR  - U01 NS108930/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - United States
TA  - Neuron
JT  - Neuron
JID - 8809320
SB  - IM
MH  - Alzheimer Disease/therapy
MH  - *Deep Brain Stimulation
MH  - Dementia/psychology/therapy
MH  - Entorhinal Cortex/*physiology
MH  - Hippocampus/*physiology
MH  - Humans
MH  - Memory/*physiology
MH  - Memory Disorders/psychology/therapy
MH  - Nerve Net/*physiology
PMC - PMC7347298
MID - NIHMS1568676
OTO - NOTNLM
OT  - *deep brain stimulation
OT  - *entorhinal cortex
OT  - *hippocampus
OT  - *memory
OT  - *neuromodulation
COIS- Declaration of Interests I.F. holds intellectual property in the field of deep
      brain stimulation assigned to the Regents of the University of California.
EDAT- 2020/04/24 06:00
MHDA- 2020/08/12 06:00
CRDT- 2020/04/24 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/27 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/08/12 06:00 [medline]
AID - S0896-6273(20)30147-1 [pii]
AID - 10.1016/j.neuron.2020.02.024 [doi]
PST - ppublish
SO  - Neuron. 2020 Apr 22;106(2):218-235. doi: 10.1016/j.neuron.2020.02.024.


PMID- 32324995
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210516
IS  - 2161-5063 (Electronic)
IS  - 2161-5063 (Linking)
VI  - 9
IP  - 5
DP  - 2020 May 15
TI  - Transcript Barcoding Illuminates the Expression Level of Synthetic Constructs in 
      E. coli Nissle Residing in the Mammalian Gut.
PG  - 1010-1021
LID - 10.1021/acssynbio.0c00040 [doi]
AB  - The development of robust engineered probiotic therapies demands accurate
      knowledge of genetic construct expression in the gut. However, the monetary and
      ethical costs of testing engineered strains in vertebrate hosts are incompatible 
      with current high-throughput design-build-test cycles. To enable parallel
      measurement of multiple construct designs, we placed unique DNA barcodes in
      engineered transcripts and measured barcode abundances via sequencing. In
      standard curve experiments, the barcode sequences exhibited consistent
      relationships between input and measured abundances, which allowed us to use
      transcript barcoding to measure expression levels of 30 GFP-expressing strains of
      E. coli Nissle in parallel. Applying this technology in culture and in the mouse 
      gut, we found that GFP expression in the gut could often be predicted from
      expression levels in culture, but several strains exhibited gut-specific
      expression. This work establishes the experimental design parameters and
      advantages of transcript barcoding to measure the performance of many engineered 
      probiotic designs in mammalian hosts.
FAU - Crook, Nathan
AU  - Crook N
AUID- ORCID: 0000-0001-6165-1972
AD  - Department of Chemical and Biomolecular Engineering, North Carolina State
      University, Raleigh, North Carolina 27606, United States.
FAU - Ferreiro, Aura
AU  - Ferreiro A
AD  - The Edison Family Center for Genome Sciences & Systems Biology, Washington
      University School of Medicine, St. Louis, Missouri 63110, United States.
AD  - Department of Biomedical Engineering, Washington University in St. Louis, St.
      Louis, Missouri 63130, United States.
FAU - Condiotte, Zevin
AU  - Condiotte Z
AD  - Department of Biomedical Engineering, Washington University in St. Louis, St.
      Louis, Missouri 63130, United States.
FAU - Dantas, Gautam
AU  - Dantas G
AUID- ORCID: 0000-0003-0455-8370
AD  - The Edison Family Center for Genome Sciences & Systems Biology, Washington
      University School of Medicine, St. Louis, Missouri 63110, United States.
AD  - Department of Biomedical Engineering, Washington University in St. Louis, St.
      Louis, Missouri 63130, United States.
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, Missouri 63110, United States.
AD  - Department of Molecular Microbiology, Washington University School of Medicine,
      St. Louis, Missouri 63110, United States.
LA  - eng
GR  - DP2 DK098089/DK/NIDDK NIH HHS/United States
GR  - R01 AT009741/AT/NCCIH NIH HHS/United States
GR  - R01 GM099538/GM/NIGMS NIH HHS/United States
GR  - T32 DK077653/DK/NIDDK NIH HHS/United States
GR  - R01 AI123394/AI/NIAID NIH HHS/United States
GR  - R01 HD092414/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200429
PL  - United States
TA  - ACS Synth Biol
JT  - ACS synthetic biology
JID - 101575075
RN  - 147336-22-9 (Green Fluorescent Proteins)
SB  - IM
MH  - Animals
MH  - DNA Barcoding, Taxonomic/*methods
MH  - Escherichia coli/genetics/*metabolism
MH  - *Gastrointestinal Microbiome
MH  - Green Fluorescent Proteins/genetics/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Probiotics
MH  - Promoter Regions, Genetic
PMC - PMC7293544
MID - NIHMS1587451
EDAT- 2020/04/24 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1021/acssynbio.0c00040 [doi]
PST - ppublish
SO  - ACS Synth Biol. 2020 May 15;9(5):1010-1021. doi: 10.1021/acssynbio.0c00040. Epub 
      2020 Apr 29.


PMID- 32324798
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20200720
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Methodological quality of cohort study on rheumatic diseases in China: A
      systematic review.
PG  - e0232020
LID - 10.1371/journal.pone.0232020 [doi]
AB  - OBJECTIVE: To evaluate systematically the quality of the cohort studies on
      rheumatic diseases in China. METHODS: Relevant databases were searched to find
      cohort studies on rheumatic diseases in China, and the basic information included
      in the literature was extracted and analyzed. Chinese and English literature were
      then compared with regard to methodological quality, according to the
      Newcastle-Ottawa Scale (NOS). RESULTS: In total, we included 46 cohort studies,
      with 19 studies published in English and 27 studies published in Chinese. With
      regard to the basic characteristics of the literature, 78.26% of the studies were
      published in the past four years; 16 studies were associated with hyperuricemia, 
      followed by eight studies involving systemic lupus erythematosus. The sample size
      of the studies in Chinese was lower than that in English studies (P< 0.05). The
      English literature was superior to the Chinese literature in terms of informed
      consent, ethical review and selection of statistical analysis methods. The
      methodology quality of the 46 included studies showed that the English and
      Chinese NOS scores were 5.59 +/- 1.25 and 6.06 +/- 1.11, respectively, and the
      difference was significant (P< 0.01). The "representativeness of the exposed
      group", "demonstration that outcome of interest was not present at start of
      study", and the "adequacy of follow up of cohorts" scores were relatively low in 
      Chinese and English studies. The score for "was follow-up long enough for
      outcomes to occur" item in English was higher than that in the Chinese studies;
      however, the "study controls for the most important factor" score for Chinese
      papers was better than that for the English papers. CONCLUSION: The Chinese
      rheumatic disease cohort studies started late, with a small sample size and fewer
      types of rheumatism. The quality of Chinese studies was better than English
      studies, and all reports were insufficient. In particular, "selecting exposed
      groups", "controlling the outcomes before study implementation" and "adequacy of 
      follow-up" needed improvement.
FAU - Zhang, Huan
AU  - Zhang H
AD  - Hunan University of Traditional Chinese Medicine, Changsha, China.
AD  - Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine,
      Chongqing, China.
FAU - Yi, Guoxiang
AU  - Yi G
AD  - Hunan University of Traditional Chinese Medicine, Changsha, China.
AD  - Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine,
      Chongqing, China.
FAU - Dai, Mingzhu
AU  - Dai M
AD  - Hunan University of Traditional Chinese Medicine, Changsha, China.
AD  - Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine,
      Chongqing, China.
FAU - Li, Yanping
AU  - Li Y
AD  - Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine,
      Chongqing, China.
FAU - Wu, Bin
AU  - Wu B
AUID- ORCID: 0000-0002-1882-3932
AD  - Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine,
      Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - China
MH  - Cohort Studies
MH  - Humans
MH  - Quality Control
MH  - Research Design/*standards
MH  - *Rheumatic Diseases
MH  - Sample Size
PMC - PMC7179908
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/24 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/04/24 06:00
PHST- 2019/09/23 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
AID - 10.1371/journal.pone.0232020 [doi]
AID - PONE-D-19-24922 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 23;15(4):e0232020. doi: 10.1371/journal.pone.0232020.
      eCollection 2020.


PMID- 32324769
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20200713
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Investigation of potential adverse central nervous system effects after long term
      oral administration of gadolinium in mice.
PG  - e0231495
LID - 10.1371/journal.pone.0231495 [doi]
AB  - OBJECTIVES: To examine potential gadolinium (Gd) accumulation in the brain of
      healthy mice after long-term oral administration of Gd-containing food pellets
      and to investigate whether Gd leads to adverse central nervous system (CNS)
      effects, specifically focussing on locomotor impairment in Gd exposed compared to
      control animals. MATERIALS AND METHODS: The local Animal Experimental Ethics
      Committee approved all procedures and applications. Fifteen female C57Bl/6 mice
      were orally exposed to a daily intake of 0.57 mmol Gd chloride/ kg body weight
      over a period of 90 weeks from the age of 4 weeks on. Gd-free, but otherwise
      equivalent experimental diets were given to the control group (N = 13). The
      animals were monitored daily by animal caretakers regarding any visible signs of 
      distress and evaluated clinically every four weeks for the first 60 weeks and
      afterwards every two weeks for a better temporal resolution of potential
      long-term effects regarding impairment of motor performance and loss of body
      weight. The individual Gd content was measured using mass spectrometry in a
      sub-cohort of N = 6 mice. RESULTS: The absolute brain Gd levels of the Gd-exposed
      mice were significantly increased compared to control mice (0.033+/- 0.009 vs.
      0.006+/- 0.002 nmol Gd/ g brain tissue). Long-term oral Gd exposure over almost
      the entire life-span did not lead to adverse CNS effects including locomotor
      changes (rotarod performance, p = 0.1467) in healthy mice throughout the study
      period. Gd-exposed mice showed less increased body weight compared to control
      mice during the study period (p = 0.0423). Histopathological alterations, such as
      hepatocellular vacuolization due to fatty change in the liver and a loss of
      nucleated cells in the red pulp of the spleen, were found in peripheral organs of
      both groups. CONCLUSIONS: Low levels of intracerebral Gd caused by chronic oral
      exposure over almost the entire life span of mice did not lead to alterations in 
      locomotor abilities in healthy mice throughout the normal aging process.
FAU - Norenberg, Dominik
AU  - Norenberg D
AUID- ORCID: 0000-0001-7726-9006
AD  - Department of Clinical Radiology and Nuclear Medicine, University Medical Center 
      Mannheim, Mannheim, Germany.
AD  - Department of Radiology, Munich University Hospitals, LMU, Munich, Germany.
FAU - Schmidt, Felix
AU  - Schmidt F
AD  - Munich Center for Neuropathology, Ludwig-Maximilians-University Munich, Munich,
      Germany.
AD  - Department of Neurology, Munich University Hospitals, LMU, Munich, Germany.
FAU - Schinke, Karin
AU  - Schinke K
AD  - Munich Center for Neuropathology, Ludwig-Maximilians-University Munich, Munich,
      Germany.
FAU - Frenzel, Thomas
AU  - Frenzel T
AD  - MR and CT Contrast Media Research, Bayer AG, Berlin, Germany.
FAU - Pietsch, Hubertus
AU  - Pietsch H
AD  - MR and CT Contrast Media Research, Bayer AG, Berlin, Germany.
FAU - Giese, Armin
AU  - Giese A
AD  - Munich Center for Neuropathology, Ludwig-Maximilians-University Munich, Munich,
      Germany.
FAU - Ertl-Wagner, Birgit
AU  - Ertl-Wagner B
AD  - Department of Radiology, Munich University Hospitals, LMU, Munich, Germany.
AD  - Department of Medical Imaging, The Hospital for Sick Children, University of
      Toronto, Toronto, Canada.
FAU - Levin, Johannes
AU  - Levin J
AD  - Department of Neurology, Munich University Hospitals, LMU, Munich, Germany.
AD  - German Center of Neurodegenerative Diseases (DZNE), Munich, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Central Nervous System/*drug effects
MH  - Female
MH  - Gadolinium/*administration & dosage/*adverse effects
MH  - Locomotion/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
PMC - PMC7179865
COIS- T.F. und H.P. are employees of Bayer AG and are currently conducting research
      sponsored by this company. For our study, T.F. and H.P. contributed primarily to 
      the methodology of intracerebral Gd measurements by ICP-MS. The research is,
      however, not financially supported by industry. The commercial affiliation to
      Bayer AG does not alter our adherence to PLOS ONE policies on sharing data and
      materials.
EDAT- 2020/04/24 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/04/24 06:00
PHST- 2019/11/12 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 10.1371/journal.pone.0231495 [doi]
AID - PONE-D-19-31486 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 23;15(4):e0231495. doi: 10.1371/journal.pone.0231495.
      eCollection 2020.


PMID- 32324658
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20210125
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
VI  - 33
IP  - 3
DP  - 2020 Jun
TI  - Augmented intelligence in pediatric anesthesia and pediatric critical care.
PG  - 404-410
LID - 10.1097/ACO.0000000000000845 [doi]
AB  - PURPOSE OF REVIEW: Acute care technologies, including novel monitoring devices,
      big data, increased computing capabilities, machine-learning algorithms and
      automation, are converging. This enables the application of augmented
      intelligence for improved outcome predictions, clinical decision-making, and
      offers unprecedented opportunities to improve patient outcomes, reduce costs, and
      improve clinician workflow. This article briefly explores recent work in the
      areas of automation, artificial intelligence and outcome prediction models in
      pediatric anesthesia and pediatric critical care. RECENT FINDINGS: Recent years
      have yielded little published research into pediatric physiological closed loop
      control (a type of automation) beyond studies focused on glycemic control for
      type 1 diabetes. However, there has been a greater range of research in augmented
      decision-making, leveraging artificial intelligence and machine-learning
      techniques, in particular, for pediatric ICU outcome prediction. SUMMARY: Most
      studies focusing on artificial intelligence demonstrate good performance on
      prediction or classification, whether they use traditional statistical tools or
      novel machine-learning approaches. Yet the challenges of implementation, user
      acceptance, ethics and regulation cannot be underestimated. Areas in which there 
      is easy access to routinely labeled data and robust outcomes, such as those
      collected through national networks and quality improvement programs, are likely 
      to be at the forefront of the adoption of these advances.
FAU - Gorges, Matthias
AU  - Gorges M
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia.
AD  - Research Institute, BC Children's Hospital, Vancouver, Canada.
FAU - Ansermino, J Mark
AU  - Ansermino JM
AD  - Department of Anesthesiology, Pharmacology & Therapeutics, University of British 
      Columbia.
AD  - Research Institute, BC Children's Hospital, Vancouver, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
SB  - IM
MH  - *Anesthesia/trends
MH  - *Artificial Intelligence
MH  - Child
MH  - *Critical Care/trends
MH  - Humans
MH  - Intelligence
MH  - Machine Learning
EDAT- 2020/04/24 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1097/ACO.0000000000000845 [doi]
AID - 00001503-202006000-00023 [pii]
PST - ppublish
SO  - Curr Opin Anaesthesiol. 2020 Jun;33(3):404-410. doi:
      10.1097/ACO.0000000000000845.


PMID- 32324070
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 2326-5108 (Electronic)
IS  - 2326-5094 (Linking)
VI  - 18
IP  - 2
DP  - 2020 Mar/Apr
TI  - Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases
      Intervention Clinical Capability Experience in Uganda.
PG  - 114-124
LID - 10.1089/hs.2019.0112 [doi]
AB  - The West Africa Ebola virus disease outbreak of 2014-2016 demonstrated that
      responses to viral hemorrhagic fever epidemics must go beyond emergency stopgap
      measures and should incorporate high-quality medical care and clinical research. 
      Optimal patient management is essential to improving outcomes, and it must be
      implemented regardless of geographical location or patient socioeconomic status. 
      Coupling clinical research with improved care has a significant added benefit:
      Improved data quality and management can guide the development of more effective 
      supportive care algorithms and can support regulatory approvals of
      investigational medical countermeasures (MCMs), which can alter the cycle of
      emergency response to reemerging pathogens. However, executing clinical research 
      during outbreaks of high-consequence pathogens is complicated and comes with
      ethical and research regulatory challenges. Aggressive care and excellent quality
      control must be balanced by the requirements of an appropriate infection
      prevention and control posture for healthcare workers and by overcoming the
      resource limitations inherent in many outbreak settings. The Joint Mobile
      Emerging Disease Intervention Clinical Capability was established in 2015 to
      develop a high-quality clinical trial capability in Uganda to support rigorous
      evaluation of MCMs targeting high-consequence pathogens like Ebola virus. This
      capability assembles clinicians, laboratorians, clinical researchers,
      logisticians, and regulatory professionals trained in infection prevention and
      control and in good clinical and good clinical laboratory practices. The
      resulting team is prepared to provide high-quality medical care and clinical
      research during high-consequence outbreaks.
FAU - Martins, Karen A
AU  - Martins KA
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Ayebare, Rodgers R
AU  - Ayebare RR
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Bhadelia, Nahid
AU  - Bhadelia N
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Kiweewa, Francis
AU  - Kiweewa F
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Waitt, Peter
AU  - Waitt P
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Mimbe, Derrick
AU  - Mimbe D
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Okello, Stephen
AU  - Okello S
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Naluyima, Prossy
AU  - Naluyima P
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Brett-Major, David M
AU  - Brett-Major DM
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Lawler, James V
AU  - Lawler JV
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Millard, Monica
AU  - Millard M
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Walwema, Richard
AU  - Walwema R
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Cardile, Anthony P
AU  - Cardile AP
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Ritchie, Chi
AU  - Ritchie C
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Kwiecien, Antonia
AU  - Kwiecien A
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Badu, Helen
AU  - Badu H
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Espinosa, Benjamin J
AU  - Espinosa BJ
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Beckett, Charmagne
AU  - Beckett C
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Bavari, Sina
AU  - Bavari S
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Zaman, Saima
AU  - Zaman S
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Christopher, George
AU  - Christopher G
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Clark, Danielle V
AU  - Clark DV
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Lamorde, Mohammed
AU  - Lamorde M
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
FAU - Kibuuka, Hannah
AU  - Kibuuka H
AD  - Karen A. Martins, PhD, is Research Health Science Program Manager, Medical
      Division; Chi Ritchie, MT, M(ASCP), is a Microbiologist; and Sina Bavari, PhD, is
      Science Director; all at the US Army Medical Research Institute of Infectious
      Diseases (USAMRIID), Fort Detrick, MD. Rodgers R. Ayebare, MB ChB, CIC, is Site
      Coordinator; and Peter Waitt, MD, is Clinical Lead, Joint Mobile Emerging Disease
      Intervention Clinical Capability (JMEDICC), Infectious Diseases Institute,
      College of Health Sciences, Makerere University, Kampala, Uganda. Nahid Bhadelia,
      MD, MA, is Associate Professor and Medical Director, Special Pathogens Unit,
      Section of Infectious Diseases, Boston University School of Medicine, Boston, MA.
      Francis Kiweewa, MD, is Head of Research and Scientific Affairs, Makerere
      University Walter Reed Project, and Strengthening Institutional Capacity for
      Research Administration (SICRA), Kampala, Uganda. Derrick Mimbe, MSC, and Stephen
      Okello, MD, are Program Managers, JMEDICC; Prossy Naluyima, PhD, is Laboratory
      Director; and Hannah Kibuuka, MD, is Executive Director, all in the Makerere
      University Walter Reed Project, Kampala, Uganda. David M. Brett-Major, MD, MPH,
      is a Professor, College of Public Health, and James V. Lawler, MD, MPH, is
      Executive Director, International Programs and Innovation, Global Center for
      Health Security and Division of Infectious Diseases; both at the University of
      Nebraska Medical Center, Omaha, NE. Monica Millard, MPH, is Country Program
      Director, US Army Medical Research Directorate-Africa/Uganda (MRD-A/U), Walter
      Reed Army Institute of Research (WRAIR), Kampala, Uganda. Richard Walwema is a
      Laboratorian, and Mohammed Lamorde, PhD, is Head of Global Health Security,
      Infectious Diseases Institute, College of Health Sciences, Makerere University,
      Kampala, Uganda. Anthony P. Cardile, DO, is at the Richard Barquist US Army
      Health Clinic, Ft. Detrick, MD. Antonia Kwiecien and Helen Badu are International
      Program Managers-Uganda, and Danielle V. Clark, PhD, is Director; all at Austere 
      environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson
      Foundation, Bethesda, MD. Benjamin J. Espinosa, PhD, is Deputy Director,
      Biological Defense Research Directorate, Naval Medical Research Center,
      Frederick, MD. Charmagne Beckett, MD MPH, is with the Infectious Diseases
      Directorate, Naval Medical Research Center, Silver Spring, MD. Saima Zaman, MPH, 
      is International Project Manager, Biological Threat Reduction Program, Defense
      Threat Reduction Agency, Fort Belvoir, VA. George Christopher, MD, is Joint
      Project Manager, Chemical, Biological, Radiological, and Nuclear Medical, Joint
      Program Executive Office for CBRN Defense, US Department of Defense, Fort
      Detrick, MD.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Health Secur
JT  - Health security
JID - 101654694
SB  - IM
MH  - Clinical Trials as Topic/methods/*organization & administration
MH  - Communicable Diseases, Emerging/prevention & control
MH  - Disease Outbreaks/*prevention & control
MH  - Disease Transmission, Infectious/prevention & control
MH  - Hemorrhagic Fevers, Viral/*prevention & control/therapy
MH  - Humans
MH  - Uganda/epidemiology
OTO - NOTNLM
OT  - Infectious diseases
OT  - Medical countermeasures
OT  - Outbreak response
OT  - Uganda
OT  - Viral hemorrhagic fevers
EDAT- 2020/04/24 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.1089/hs.2019.0112 [doi]
PST - ppublish
SO  - Health Secur. 2020 Mar/Apr;18(2):114-124. doi: 10.1089/hs.2019.0112.


PMID- 32324050
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Aug
TI  - Perceptions of occurrence of research misconduct and related factors among Kenyan
      investigators engaged in HIV research.
PG  - 372-389
LID - 10.1080/08989621.2020.1759425 [doi]
AB  - We report on occurrence and correlates of self-reported research misconduct (RM) 
      by 100 Kenyan researchers who had received ethics approval for an HIV research in
      the 5 years preceding the survey. The survey used the Scientific Misconduct
      Questionnaire-Revised tool uploaded on a Research Electronic Data Capture
      (REDCAP) platform. The response rate was low at 17.3% (100 out of 577) with 53.9%
      reporting awareness of an incident of RM in the preceding 5 years. Awareness was 
      associated with being in academia, perception of vulnerability to being caught,
      and the severity of possible punishment, if discovered. Two-thirds (68.3%)
      reported ever-involvement in any misconduct. Self-report of involvement in
      misconduct was associated with knowledge of rules and procedures on RM and a
      disposition to support such rules and regulations. Nearly 36% reported
      ever-involvement infabrication, falsification and/or plagiarism (FFP).
      Self-report of ever-involvement in FFP was associated with number of years in the
      academic position, perceived likelihood of being caught, and the perceived
      severity of the sanctions, if caught. We conclude that the occurrence of RM is
      not uncommon, and efforts to create awareness about RM as well as to establish
      institutional structures and policies on RM are needed.
FAU - Were, Edwin
AU  - Were E
AD  - Department of Reproductive Health, School of Medicine, College of Health
      Sciences, Moi University , Eldoret, Kenya.
FAU - Kaguiri, Eunice
AU  - Kaguiri E
AD  - Academic Model Providing Access to Healthcare , Eldoret, Kenya.
FAU - Kiplagat, Jepchirchir
AU  - Kiplagat J
AD  - Academic Model Providing Access to Healthcare , Eldoret, Kenya.
LA  - eng
GR  - G11 TW010554/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200513
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Awareness
MH  - Biomedical Research/ethics/standards/*statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/*epidemiology
MH  - Humans
MH  - Kenya
MH  - Male
MH  - Perception
MH  - Punishment
MH  - Research Personnel/ethics/*psychology/*statistics & numerical data
MH  - Scientific Misconduct/ethics/*statistics & numerical data
MH  - Self Report
OTO - NOTNLM
OT  - *HIV researchers
OT  - *Kenya
OT  - *research misconduct
EDAT- 2020/04/24 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1080/08989621.2020.1759425 [doi]
PST - ppublish
SO  - Account Res. 2020 Aug;27(6):372-389. doi: 10.1080/08989621.2020.1759425. Epub
      2020 May 13.


PMID- 32323918
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1557-0681 (Electronic)
IS  - 1478-2189 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Dec
TI  - Misconceived expectations: Patient reflections on the total knee replacement
      journey.
PG  - 415-424
LID - 10.1002/msc.1475 [doi]
AB  - INTRODUCTION: Fifty per cent of patients consent for total knee replacement (TKR)
      with unrealistic expectations about what it involves and can achieve. A framework
      is needed to help surgeons identify key knowledge gaps and misconceptions that
      can be targeted during the informed consent process. In this qualitative study,
      we explored knowledge gaps and misconceptions by asking patients to reflect on
      their expectations along the TKR journey. METHODS: Eligible adults were >/=18
      years, 12-month post-TKR and had completed a validated expectations questionnaire
      pre-TKR as part of a joint replacement registry. To capture a variety of
      perspectives, people with a range of pre-TKR expectation scores were invited. In 
      interviews, participants reflected on anticipated and actual experiences and
      unexpected experiences they had along the way. Transcripts were analysed through 
      inductive thematic analysis. Recruitment ceased when thematic saturation was
      reached. ETHICS APPROVAL: Ethical approval for this study was granted by the St
      Vincent's Hospital Melbourne Ethics Committee (LRR 077/18). RESULTS: In the final
      sample (n = 20; 50% female; median age = 72 years; contralateral TKR = 11), all
      participants described instances where their anticipated and actual experiences
      diverged, including high expectations of improvements in pain/function
      (pre-surgical optimism), lacking awareness about anaesthetic procedures
      (perioperative misunderstandings), feeling unprepared for the length of the
      recovery period (post-operative misestimations) and trying to make sense of
      ongoing functional limitations (long-term misattributions). DISCUSSION AND
      CONCLUSION: These findings are captured in a preliminary framework of therapeutic
      misconception. Although future research is needed to test this framework
      prospectively in larger, more generalisable samples, surgeons can consider these 
      key knowledge gaps and misconceptions when consenting for TKR.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Bunzli, Samantha
AU  - Bunzli S
AUID- ORCID: 0000-0002-5747-9361
AD  - Department of Surgery, St Vincent's Hospital Melbourne, The University of
      Melbourne, Melbourne, Victoria, Australia.
FAU - O'Brien, Penny
AU  - O'Brien P
AD  - Department of Surgery, St Vincent's Hospital Melbourne, The University of
      Melbourne, Melbourne, Victoria, Australia.
FAU - Klem, Nardia
AU  - Klem N
AD  - School of Physiotherapy and Exercise Science, Curtin University, Perth, Western
      Australia, Australia.
FAU - Incoll, Ian
AU  - Incoll I
AD  - Australian Orthopaedic Association, Sydney, New South Wales, Australia.
AD  - Faculty of Health and Medicine, University of Newcastle, Newcastle, New South
      Wales, Australia.
FAU - Singh, Jasvinder
AU  - Singh J
AD  - Medicine Service, VA Medical Center, Birmingham, Alabama, USA.
AD  - Department of Medicine at the School of Medicine, University of Alabama at
      Birmingham, Birmingham, Alabama, USA.
AD  - Department of Epidemiology, School of Public Health, University of Alabama at
      Birmingham, Birmingham, Alabama, USA.
FAU - Davaris, Myles
AU  - Davaris M
AD  - Department of Surgery, St Vincent's Hospital Melbourne, The University of
      Melbourne, Melbourne, Victoria, Australia.
FAU - Choong, Peter
AU  - Choong P
AD  - Department of Surgery, St Vincent's Hospital Melbourne, The University of
      Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Orthopaedics, St. Vincent's Hospital, Melbourne, Victoria,
      Australia.
FAU - Dowsey, Michelle
AU  - Dowsey M
AD  - Department of Surgery, St Vincent's Hospital Melbourne, The University of
      Melbourne, Melbourne, Victoria, Australia.
AD  - Department of Orthopaedics, St. Vincent's Hospital, Melbourne, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200423
PL  - England
TA  - Musculoskeletal Care
JT  - Musculoskeletal care
JID - 101181344
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Arthroplasty, Replacement, Knee
MH  - Female
MH  - Humans
MH  - Male
MH  - Motivation
MH  - *Osteoarthritis, Knee/surgery
MH  - Registries
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *informed consent
OT  - *knee arthroplasty
OT  - *patient expectations
OT  - *qualitative research
OT  - *total knee replacement
EDAT- 2020/04/24 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1002/msc.1475 [doi]
PST - ppublish
SO  - Musculoskeletal Care. 2020 Dec;18(4):415-424. doi: 10.1002/msc.1475. Epub 2020
      Apr 23.


PMID- 32323739
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 45
IP  - 5
DP  - 2020 May
TI  - The secretome of human dental pulp stem cells protects myoblasts from
      hypoxiainduced injury via the Wnt/betacatenin pathway.
PG  - 1501-1513
LID - 10.3892/ijmm.2020.4525 [doi]
AB  - Human dental pulp stem cells (hDPSCs) present several advantages, including their
      ability to be noninvasively harvested without ethical concern. The secretome of
      hDPSCs can promote the functional recovery of various tissue injuries. However,
      the protective effects on hypoxiainduced skeletal muscle injury remain to be
      explored. The present study demonstrated that C2C12 myoblast coculture with
      hDPSCs attenuated CoCl2induced hypoxic injury compared with C2C12 alone. The
      hDPSC secretome increased cell viability and differentiation and decreased G2/M
      cell cycle arrest under hypoxic conditions. These results were further verified
      using hDPSCconditioned medium (hDPSCCM). The present data revealed that the
      protective effects of hDPSCCM depend on the concentration ratio of the CM. In
      terms of the underlying molecular mechanism, hDPSCCM activated the
      Wnt/betacatenin pathway, which increased the protein levels of Wnt1,
      phosphorylatedglycogen synthase kinase3beta and betacatenin and the mRNA levels
      of Wnt target genes. By contrast, an inhibitor (XAV939) of Wnt/betacatenin
      diminished the protective effects of hDPSCCM. Taken together, the findings of the
      present study demonstrated that the hDPSC secretome alleviated the hypoxiainduced
      myoblast injury potentially through regulating the Wnt/betacatenin pathway. These
      findings may provide new insight into a therapeutic alternative using the hDPSC
      secretome in skeletal muscle hypoxiarelated diseases.
FAU - Zhang, Weihua
AU  - Zhang W
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Yu, Liming
AU  - Yu L
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Han, Xinxin
AU  - Han X
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Pan, Jie
AU  - Pan J
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Deng, Jiajia
AU  - Deng J
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Zhu, Luying
AU  - Zhu L
AD  - Oral Biomedical Engineering Laboratory, Shanghai Stomatological Hospital, Fudan
      University, Shanghai 200001, P.R. China.
FAU - Lu, Yun
AU  - Lu Y
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Liu, Shangfeng
AU  - Liu S
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Li, Qiang
AU  - Li Q
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
FAU - Liu, Yuehua
AU  - Liu Y
AD  - Department of Orthodontics, Shanghai Stomatological Hospital, Fudan University,
      Shanghai 200001, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200304
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Cell Cycle Checkpoints/physiology
MH  - Cell Differentiation/physiology
MH  - Cell Survival/physiology
MH  - Cells, Cultured
MH  - Dental Pulp/*metabolism
MH  - G2 Phase Cell Cycle Checkpoints/physiology
MH  - Humans
MH  - Hypoxia/*metabolism
MH  - Muscle, Skeletal/metabolism
MH  - Myoblasts/*metabolism
MH  - Stem Cells/metabolism
MH  - Wnt Signaling Pathway/*physiology
MH  - beta Catenin/*metabolism
PMC - PMC7138287
EDAT- 2020/04/24 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/04/24 06:00
PHST- 2019/08/18 00:00 [received]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.3892/ijmm.2020.4525 [doi]
PST - ppublish
SO  - Int J Mol Med. 2020 May;45(5):1501-1513. doi: 10.3892/ijmm.2020.4525. Epub 2020
      Mar 4.


PMID- 32323712
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20200731
IS  - 1972-6007 (Electronic)
IS  - 0009-9074 (Linking)
VI  - 171
IP  - 3
DP  - 2020 May-Jun
TI  - Emergency Contraception: are the rights to conscience and to reproductive freedom
      irreconcilable?
PG  - e237-e239
LID - 10.7417/CT.2020.2220 [doi]
AB  - Emergency Contraception (EC) has been gaining attention for its controversial
      nature, from the ethical, moral and religious perspectives. Objecting health
      professionals feel that the implementation of certain procedures or the
      prescription of some drugs would engender a conflict of conscience. That is also 
      true in the context of reproductive medicine and not only limited to EC, but
      including abortion and some medically-assisted procreation procedures; all such
      procedures have created a rift between sexuality and procreation that has
      substantial ethical complexities. Provided that respect for conscience is
      essential, and codified in many national and international statutes, any refusal 
      to provide services or medication should be limited if it might negatively affect
      a patient's health, is based on scientific misinformation, or could bring about
      inequalities of any kind. First and foremost, any imposition of religious or
      moral beliefs on patients should not be countenanced. In fact, any form of
      conscientious objection that could harm patient well-being should be allowed only
      if the fundamental duty towards patients can be effectively discharged. The right
      to thorough and unbiased information is crucial so as to enable patients to make 
      well-informed decisions. Moreover, as the WHO has remarked, access to safe and
      legal reproductive services should be fostered particularly in at-risk,
      resource-poor areas.
FAU - Signore, F
AU  - Signore F
AD  - Department of Obstetrics and Gynecology, Misericordia Hospital, Grosseto, Italy.
FAU - Baffa, A
AU  - Baffa A
AD  - Department of Obstetrics and Gynecology, Misericordia Hospital, Grosseto, Italy.
FAU - Votino, R
AU  - Votino R
AD  - Department of Obstetrics and Gynecology, Misericordia Hospital, Grosseto, Italy.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Ter
JT  - La Clinica terapeutica
JID - 0372604
SB  - IM
MH  - Access to Information
MH  - *Conscience
MH  - Contraception, Postcoital/*psychology
MH  - Female
MH  - Freedom
MH  - Health Personnel
MH  - Humans
MH  - Pregnancy
MH  - Reproductive Medicine
OTO - NOTNLM
OT  - Conscientious objection
OT  - Emergency contraception
OT  - Ethical aspects
EDAT- 2020/04/24 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
AID - 10.7417/CT.2020.2220 [doi]
PST - ppublish
SO  - Clin Ter. 2020 May-Jun;171(3):e237-e239. doi: 10.7417/CT.2020.2220.


PMID- 32323709
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20200731
IS  - 1972-6007 (Electronic)
IS  - 0009-9074 (Linking)
VI  - 171
IP  - 3
DP  - 2020 May-Jun
TI  - Advances in Medically-assisted procreation technologies: can malpractice claims
      and "reproductive damage" be identified.
PG  - e225-e228
LID - 10.7417/CT.2020.2217 [doi]
AB  - Medically assisted procreation and assisted reproductive techniques have made
      giant strides over the past decades, enabling countless couples to achieve
      parenthood. Still, the ethical and moral concerns that have come to the fore as a
      result of ART's rise pose a multi-faceted issue that lawmakers have struggled to 
      keep up with; procedures such as heterologous fertilization are strictly
      regulated, and even banned, in several nations around the globe, among which
      Italy, where a controversial piece of legislation was passed in 2004; such a
      reform has been partly nullified by court decisions, among which the Italian
      Constitutional Court and even the European Court of Human Rights. Relevant
      scientific articles were identified from Medline, Cochrane Central, Scopus, Web
      of Science, Science Direct, EMBASE and Google Scholar, through February 2020, by 
      using the following keywords: "assisted reproductive techniques", "heterologous
      fertilization", "European rulings on ART", "reproductive damages". The rise of
      ART has laid bare a shortage of adequate legal tools for the purpose of
      guaranteeing the exercise of reproductive rights for all. Hence, the
      harmonization of regulations, at least at the European level, is greatly needed
      in order to ensure equality of parental opportunities for all.
FAU - Negro, F
AU  - Negro F
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome.
FAU - Varone, M C
AU  - Varone MC
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome.
FAU - Del Rio, A
AU  - Del Rio A
AD  - Department of Anatomical, Histological, Forensic and Orthopedic Sciences,
      Sapienza University of Rome, Rome.
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Ter
JT  - La Clinica terapeutica
JID - 0372604
SB  - IM
MH  - Female
MH  - Human Rights/legislation & jurisprudence
MH  - Humans
MH  - Italy
MH  - Male
MH  - *Malpractice
MH  - Morals
MH  - Reproductive Techniques, Assisted/adverse effects/ethics/*legislation &
      jurisprudence
OTO - NOTNLM
OT  - Court rulings
OT  - Donor anonymity
OT  - Medically-assisted reproduction
OT  - Reproductive damage
EDAT- 2020/04/24 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
AID - 10.7417/CT.2020.2217 [doi]
PST - ppublish
SO  - Clin Ter. 2020 May-Jun;171(3):e225-e228. doi: 10.7417/CT.2020.2217.


PMID- 32323611
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Aug
TI  - The role of online ethics consultation on mental health.
PG  - 1261-1269
LID - 10.1177/0969733020906596 [doi]
AB  - BACKGROUND: Nurses experience moral distress when they cannot do what they
      believe is right or when they must do what they believe is wrong. Given the
      limited mechanisms for managing ethical issues for nurses in Japan, an Online
      Ethics Consultation on mental health (OEC) was established open to anyone seeking
      anonymous consultation on mental health practice. RESEARCH OBJECTIVE: To report
      the establishment of the Online Ethics Consultation and describe and evaluate its
      effectiveness. ETHICAL CONSIDERATIONS: The research was conducted in accordance
      with the Declaration of Helsinki. RESEARCH DESIGN: This evaluation describes the 
      outcomes of 5 years of operation of the Online Ethics Consultation on mental
      health in Japan. PARTICIPANTS: The Online Ethics Consultation received 12 emails 
      requesting consultation. Consultees included mental health nurses, psychiatrists,
      and service users. FINDINGS: The most common questions directed to the service
      were about seclusion and physical restraint. Response time from receipt of email 
      to sending a reply was between 1 and 14 days. Despite the disappointing number of
      consultations, feedback has been positive. DISCUSSION: The Online Ethics
      Consultation was established to assist morally sensitive nurses in resolving
      their ethical problems through provision of unbiased and encouraging advice.
      Mental health care in Japan has been less than ideal: long-term social
      hospitalization, seclusion, and restraint are common practices that often lead to
      moral distress in nurses and the questions received reflected this. The head of
      the Online Ethics Consultation sent a supportive, facilitative response
      summarizing the opinions of several consultants. CONCLUSION: This study provides 
      key information for the establishment of an online ethics resource the adoption
      of which has the potential to improve the experience of nurses, allied health and
      clients of mental health services. This paper has implications for services
      concerned with improving patient care, managing nurses' moral distress, building 
      ethics into decision-making.
FAU - Ohnishi, Kayoko
AU  - Ohnishi K
AUID- ORCID: https://orcid.org/0000-0002-6762-4788
AD  - Konan Women's University, Japan.
FAU - Stone, Teresa E
AU  - Stone TE
AD  - Chiang Mai University, Thailand; Yamaguchi University, Japan.
FAU - Yoshiike, Takashi
AU  - Yoshiike T
AD  - Osaka University of Human Sciences, Japan.
FAU - Kitaoka, Kazuyo
AU  - Kitaoka K
AD  - Komatsu University, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200423
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Ethics Consultation/*standards/statistics & numerical data
MH  - Female
MH  - Humans
MH  - *Internet-Based Intervention
MH  - Japan
MH  - Male
MH  - Mental Health/*standards/statistics & numerical data
MH  - Restraint, Physical/ethics
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Clinical ethics
OT  - ethics consultation
OT  - mental health/psychiatry
OT  - moral distress
OT  - nursing ethics
EDAT- 2020/04/24 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1177/0969733020906596 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Aug;27(5):1261-1269. doi: 10.1177/0969733020906596. Epub 2020
      Apr 23.


PMID- 32323066
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 37
IP  - 6
DP  - 2020 Apr 22
TI  - Artificial Intelligence in radiotherapy: state of the art and future directions.
PG  - 50
LID - 10.1007/s12032-020-01374-w [doi]
AB  - Recent advances in computing capability allowed the development of sophisticated 
      predictive models to assess complex relationships within observational data,
      described as Artificial Intelligence. Medicine is one of the several fields of
      application and Radiation oncology could benefit from these approaches,
      particularly in patients' medical records, imaging, baseline pathology, planning 
      or instrumental data. Artificial Intelligence systems could simplify many steps
      of the complex workflow of radiotherapy such as segmentation, planning or
      delivery. However, Artificial Intelligence could be considered as a "black box"
      in which human operator may only understand input and output predictions and its 
      application to the clinical practice remains a challenge. The low transparency of
      the overall system is questionable from manifold points of view (ethical
      included). Given the complexity of this issue, we collected the basic definitions
      to help the clinician to understand current literature, and overviewed
      experiences regarding implementation of AI within radiotherapy clinical workflow,
      aiming to describe this field from the clinician perspective.
FAU - Francolini, Giulio
AU  - Francolini G
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
FAU - Desideri, Isacco
AU  - Desideri I
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
      isacco.desideri@unifi.it.
AD  - Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero - Universitaria
      Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
      isacco.desideri@unifi.it.
FAU - Stocchi, Giulia
AU  - Stocchi G
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
FAU - Salvestrini, Viola
AU  - Salvestrini V
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
FAU - Ciccone, Lucia Pia
AU  - Ciccone LP
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
FAU - Garlatti, Pietro
AU  - Garlatti P
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
FAU - Loi, Mauro
AU  - Loi M
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
FAU - Livi, Lorenzo
AU  - Livi L
AD  - Radiotherapy Department, University of Florence, Florence, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200422
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
SB  - IM
MH  - *Algorithms
MH  - Animals
MH  - *Artificial Intelligence
MH  - Humans
MH  - Neoplasms/*radiotherapy
MH  - Radiotherapy/methods
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/*methods
OTO - NOTNLM
OT  - Artificial Intelligence
OT  - Autocontouring
OT  - Deep neural networks
OT  - Machine learning
EDAT- 2020/04/24 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
AID - 10.1007/s12032-020-01374-w [doi]
AID - 10.1007/s12032-020-01374-w [pii]
PST - epublish
SO  - Med Oncol. 2020 Apr 22;37(6):50. doi: 10.1007/s12032-020-01374-w.


PMID- 32322824
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2032-0418 (Print)
IS  - 2032-0418 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Mar 27
TI  - Recommendations for the surgical treatment of endometriosis Part 2: deep
      endometriosis daggerdouble dagger paragraph sign.
PG  - 269-297
AB  - STUDY QUESTION: How should surgery for endometriosis be performed? SUMMARY
      ANSWER: This document provides recommendations covering technical aspects of
      different methods of surgery for deep endometriosis in women of reproductive age.
      WHAT IS KNOWN ALREADY: Endometriosis is highly prevalent and often associated
      with severe symptoms. Yet compared to equally prevalent conditions it is poorly
      understood and a challenge to manage. Previously published guidelines have
      provided recommendations for (surgical) treatment of deep endometriosis, based on
      the best available evidence, but without technical information and details on how
      to best perform such treatment in order to be effective and safe. STUDY DESIGN
      SIZE DURATION: A working group of the European Society for Gynaecological
      Endoscopy (ESGE), European Society of Human Reproduction and Embryology (ESHRE)
      and the World Endometriosis Society (WES) collaborated on writing recommendations
      on the practical aspects of surgery for treatment of deep endometriosis.
      PARTICIPANTS MATERIALS SETTING METHODS: This document focused on surgery for deep
      endometriosis, and is complementary to a previous document in this series
      focusing on endometrioma surgery. MAIN RESULTS AND THE ROLE OF CHANCE: The
      document presents general recommendations for surgery for deep endometriosis,
      starting from preoperative assessments and first steps of surgery. Different
      approaches for surgical treatment are discussed and are respective of location
      and extent of disease; uterosacral ligaments and rectovaginal septum with or
      without involvement of the rectum, urinary tract or extrapelvic endometriosis. In
      addition, recommendations are provided on the treatment of frozen pelvis and on
      hysterectomy as a treatment for deep endometriosis. LIMITATIONS REASONS FOR
      CAUTION: Owing to the limited evidence available, recommendations are mostly
      based on clinical expertise. Where available, references of relevant studies were
      added. WIDER IMPLICATIONS OF THE FINDINGS: These recommendations complement
      previous guidelines on management of endometriosis and the recommendations for
      surgical treatment of ovarian endometrioma. STUDY FUNDING - COMPETING INTERESTS: 
      The meetings of the working group were funded by ESGE, ESHRE and WES.Dr. Roman
      reports personal fees from ETHICON, PLASMASURGICAL, OLYMPUS, and NORDIC PHARMA,
      outside the submitted work; Dr. Becker reports grants from Bayer AG, Volition Rx,
      MDNA Life Sciences, and Roche Diagnostics Inc, and other relationships or
      activities from AbbVie Inc, and Myriad Inc, during the conduct of the study; Dr. 
      Tomassetti reports non-financial support from ESHRE, during the conduct of the
      study; non-financial support and other from Lumenis, Gedeon-Richter, Ferring
      Pharmaceuticals, and Merck SA, outside the submitted work. The other authors had 
      nothing to disclose.
CI  - Copyright (c) 2019 Facts, Views & Vision.
CN  - Working group of ESGE, ESHRE and WES
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - Belgium
TA  - Facts Views Vis Obgyn
JT  - Facts, views & vision in ObGyn
JID - 101578773
PMC - PMC7162667
OTO - NOTNLM
OT  - deep endometriosis
OT  - endometriosis
OT  - extrapelvic
OT  - frozen pelvis
OT  - good practice recommendations
OT  - hysterectomy
OT  - laparoscopy
OT  - surgery
COIS- Conflict of interest Dr. Roman reports personal fees from ETHICON,
      PLASMASURGICAL, OLYMPUS, and NORDIC PHARMA, outside the submitted work; Dr.
      Becker reports grants from Bayer AG, Volition Rx, MDNA Life Sciences, and Roche
      Diagnostics Inc, and other relationships or activities from AbbVie Inc, and
      Myriad Inc, during the conduct of the study; Dr. Tomassetti reports non-financial
      support from ESHRE, during the conduct of the study; non-financial support and
      other from Lumenis, Gedeon-Richter, Ferring Pharmaceuticals, and Merck SA,
      outside the submitted work. The other authors had nothing to disclose.
IR  - Keckstein J
FIR - Keckstein, Joerg
IR  - Becker CM
FIR - Becker, Christian M
IR  - Canis M
FIR - Canis, Michel
IR  - Feki A
FIR - Feki, Anis
IR  - Grimbizis GF
FIR - Grimbizis, Grigoris F
IR  - Hummelshoj L
FIR - Hummelshoj, Lone
IR  - Nisolle M
FIR - Nisolle, Michelle
IR  - Roman H
FIR - Roman, Horace
IR  - Saridogan E
FIR - Saridogan, Ertan
IR  - Tanos V
FIR - Tanos, Vasilios
IR  - Tomassetti C
FIR - Tomassetti, Carla
IR  - Ulrich UA
FIR - Ulrich, Uwe A
IR  - Vermeulen N
FIR - Vermeulen, Nathalie
IR  - De Wilde RL
FIR - De Wilde, Rudy Leon
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:01
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:01 [medline]
PST - epublish
SO  - Facts Views Vis Obgyn. 2020 Mar 27;11(4):269-297.


PMID- 32322796
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2588-400X (Electronic)
IS  - 2588-400X (Linking)
VI  - 4
IP  - 2
DP  - 2020 Spring
TI  - A Review on the Etiology and Management of Pediatric Traumatic Spinal Cord
      Injuries.
PG  - e28
LID - 10.22114/ajem.v0i0.256 [doi]
AB  - CONTEXT: Pediatric traumatic spinal cord injury (SCI) is an uncommon presentation
      in the emergency department. Severe injuries are associated with devastating
      outcomes and complications, resulting in high costs to both the society and the
      economic system. EVIDENCE ACQUISITION: The data on pediatric traumatic spinal
      cord injuries has been narratively reviewed. RESULTS: Pediatric SCI is a
      life-threatening emergency leading to serious outcomes and high mortality in
      children if not managed promptly. Pediatric SCI can impose many challenges to
      neurosurgeons and caregivers because of the lack of large studies with high
      evidence level and specific guidelines in terms of diagnosis, initial management 
      and of in-hospital treatment options. Several novel potential treatment options
      for SCI have been developed and are currently under investigation. However,
      research studies into this field have been limited by the ethical and
      methodological challenges. CONCLUSION: Future research is needed to investigate
      the safety and efficacy of the recent uprising neurodegenerative techniques in
      SCI population. Owing to the current limitations, there is a need to develop
      novel trial methodologies that can overcome the current methodological and
      ethical limitations.
CI  - (c) 2020 Tehran University of Medical Sciences.
FAU - Benmelouka, Amira
AU  - Benmelouka A
AD  - Faculty of Medicine, University of Algiers, Algiers, Algeria.
FAU - Shamseldin, Laila Salah
AU  - Shamseldin LS
AD  - Faculty of Medicine, Tanta University, Tanta, Egypt.
FAU - Nourelden, Anas Zakarya
AU  - Nourelden AZ
AD  - Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
FAU - Negida, Ahmed
AU  - Negida A
AD  - Medical Research Group of Egypt, Egypt.
AD  - Faculty of Medicine, Zagazig University, Zagazig, Egypt.
AD  - Neurosurgery Department, Bahcesehir University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191010
PL  - Iran
TA  - Adv J Emerg Med
JT  - Advanced journal of emergency medicine
JID - 101745107
PMC - PMC7163256
OTO - NOTNLM
OT  - Child
OT  - Neurosurgery
OT  - Pediatrics
OT  - Spinal Cord Injuries
OT  - Trauma
COIS- Conflict of interest None to declare
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:01
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:01 [medline]
AID - 10.22114/ajem.v0i0.256 [doi]
AID - AJEM-4-e28 [pii]
PST - epublish
SO  - Adv J Emerg Med. 2019 Oct 10;4(2):e28. doi: 10.22114/ajem.v0i0.256. eCollection
      2020 Spring.


PMID- 32322370
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2001-0370 (Print)
IS  - 2001-0370 (Linking)
VI  - 18
DP  - 2020
TI  - Ethical issues related to research on genome editing in human embryos.
PG  - 887-896
LID - 10.1016/j.csbj.2020.03.014 [doi]
AB  - Although the potential advantages of clinical germline genome editing (GGE) over 
      currently available methods are limited, the implementation of GGE in the clinic 
      has been proposed and discussed. Ethical issues related to such an application
      have been extensively debated, meanwhile, seemingly less attention has been paid 
      to ethical implications of studies which would have to be conducted in order to
      evaluate potential clinical uses of GGE. In this article, we first provide an
      overview of the debate on potential clinical uses of GGE. Then, we discuss
      questions and ethical issues related to the studies relevant to evaluation of
      potential clinical uses of GGE. In particular, we describe the problems related
      to the acceptable safety threshold, current technical hurdles in human GGE, the
      destruction of human embryos used in the experiments, involvement of egg donors, 
      and genomic sequencing performed on the samples of the research participants. The
      technical and ethical problems related to studies on GGE should be acknowledged
      and carefully considered in the process of deciding to apply technology in such a
      way that will provide benefits and minimize harms.
CI  - (c) 2020 The Authors.
FAU - Niemiec, Emilia
AU  - Niemiec E
AD  - Centre for Research Ethics and Bioethics, Uppsala University, Box 564, 751 22
      Uppsala, Sweden.
FAU - Howard, Heidi Carmen
AU  - Howard HC
AD  - Centre for Research Ethics and Bioethics, Uppsala University, Box 564, 751 22
      Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200321
PL  - Netherlands
TA  - Comput Struct Biotechnol J
JT  - Computational and structural biotechnology journal
JID - 101585369
PMC - PMC7163211
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - Egg donation
OT  - Genome editing
OT  - Oocyte donation
OT  - Research ethics
OT  - Whole genome sequencing
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:01
CRDT- 2020/04/24 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:01 [medline]
AID - 10.1016/j.csbj.2020.03.014 [doi]
AID - S2001-0370(19)30517-3 [pii]
PST - epublish
SO  - Comput Struct Biotechnol J. 2020 Mar 21;18:887-896. doi:
      10.1016/j.csbj.2020.03.014. eCollection 2020.


PMID- 32322145
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1078-4497 (Print)
IS  - 1078-4497 (Linking)
VI  - 37
IP  - 4
DP  - 2020 Apr
TI  - The Return of the Plague: A Primer on Pandemic Ethics.
PG  - 158-159
FAU - Geppert, Cynthia M A
AU  - Geppert CMA
LA  - eng
PT  - Editorial
PL  - United States
TA  - Fed Pract
JT  - Federal practitioner : for the health care professionals of the VA, DoD, and PHS
JID - 9500574
PMC - PMC7173641
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:01
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:01 [medline]
PST - ppublish
SO  - Fed Pract. 2020 Apr;37(4):158-159.


PMID- 32322034
OWN - NLM
STAT- Publisher
LR  - 20210422
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2020 Apr 22
TI  - Hundreds of people volunteer to be infected with coronavirus.
LID - 10.1038/d41586-020-01179-x [doi]
FAU - Callaway, Ewen
AU  - Callaway E
LA  - eng
PT  - News
DEP - 20200422
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - Diseases
OT  - Ethics
OT  - Vaccines
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
AID - 10.1038/d41586-020-01179-x [doi]
AID - 10.1038/d41586-020-01179-x [pii]
PST - aheadofprint
SO  - Nature. 2020 Apr 22. pii: 10.1038/d41586-020-01179-x. doi:
      10.1038/d41586-020-01179-x.


PMID- 32321788
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1078-4535 (Print)
IS  - 1078-4535 (Linking)
VI  - 26
IP  - 2
DP  - 2020 May 1
TI  - Lesbian, Gay, Bisexual, and Transgender People, and the Nursing Imperative.
PG  - 81-82
LID - 10.1891/CRNR-D-20-00014 [doi]
AB  - This essay speaks to the legacy value of nurses' caring for all people, no matter
      how they feel about the person's values or lifestyle, including the current
      issues around gender identity and sexual orientation. This legacy is deeply
      imbedded in the moral ethics of nursing and supports the proposition that if
      there isn't caring, it isn't nursing.
CI  - (c) Copyright 2020 Creative Health Care Management.
FAU - Manthey, Marie
AU  - Manthey M
LA  - eng
PT  - Editorial
PL  - United States
TA  - Creat Nurs
JT  - Creative nursing
JID - 9505022
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Care/*ethics/*psychology
MH  - Nursing Staff, Hospital/*ethics/*psychology
MH  - Sexual and Gender Minorities/*psychology
MH  - Transgender Persons/*psychology
OTO - NOTNLM
OT  - LGBT persons
OT  - caring
OT  - definition of nursing
OT  - ethics
OT  - morality
OT  - nobility of nursing
EDAT- 2020/04/24 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
AID - 26/2/81 [pii]
AID - 10.1891/CRNR-D-20-00014 [doi]
PST - ppublish
SO  - Creat Nurs. 2020 May 1;26(2):81-82. doi: 10.1891/CRNR-D-20-00014.


PMID- 32321562
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20201218
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Apr 22
TI  - Clinical ethics recommendations for the allocation of intensive care treatments
      in exceptional, resource-limited circumstances: the Italian perspective during
      the COVID-19 epidemic.
PG  - 165
LID - 10.1186/s13054-020-02891-w [doi]
FAU - Vergano, Marco
AU  - Vergano M
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy. marco.vergano@aslcittaditorino.it.
FAU - Bertolini, Guido
AU  - Bertolini G
AD  - Laboratorio di Epidemiologia Clinica, Dipartimento di Salute Pubblica, Istituto
      di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
FAU - Giannini, Alberto
AU  - Giannini A
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy.
FAU - Gristina, Giuseppe R
AU  - Gristina GR
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy.
FAU - Livigni, Sergio
AU  - Livigni S
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy.
FAU - Mistraletti, Giovanni
AU  - Mistraletti G
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy.
FAU - Riccioni, Luigi
AU  - Riccioni L
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy.
FAU - Petrini, Flavia
AU  - Petrini F
AD  - Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva, Viale
      dell'Universita 11, 00185, Rome, Italy.
LA  - eng
PT  - Editorial
DEP - 20200422
PL  - England
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
SB  - IM
CIN - Respirology. 2020 Oct;25(10):1033-1034. PMID: 32761691
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*therapy
MH  - Critical Care/*ethics
MH  - *Epidemics
MH  - Health Care Rationing/*ethics
MH  - Health Resources/supply & distribution
MH  - Humans
MH  - Italy/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/epidemiology/*therapy
MH  - Practice Guidelines as Topic
MH  - Societies, Medical
PMC - PMC7175451
EDAT- 2020/04/24 06:00
MHDA- 2020/04/25 06:00
CRDT- 2020/04/24 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
AID - 10.1186/s13054-020-02891-w [doi]
AID - 10.1186/s13054-020-02891-w [pii]
PST - epublish
SO  - Crit Care. 2020 Apr 22;24(1):165. doi: 10.1186/s13054-020-02891-w.


PMID- 32321110
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 1806-9460 (Electronic)
IS  - 1516-3180 (Linking)
VI  - 138
IP  - 1
DP  - 2020 Jan-Feb
TI  - Use of smartphone-based instant messaging services in medical practice: a
      cross-sectional study.
PG  - 86-92
LID - S1516-31802020000100086 [pii]
LID - 10.1590/1516-3180.2020.0010.R1.28032020 [doi]
AB  - BACKGROUND: Instant messaging services (IMS) are widely used in medical practice.
      OBJECTIVE: To evaluate perceptions regarding use and usability of IMS within
      clinical practice and assess users' knowledge of the ethical and legal context
      involved in using IMS within medical practice. DESIGN AND SETTING:
      Cross-sectional study conducted in different hospitals and medical institutions
      in Minas Gerais, Brazil. METHODS: Medical students, medical residents, primary
      care physicians and specialist doctors answered an online questionnaire regarding
      epidemiological data, graduation level and use of IMS for medical communication. 
      Responses were collected over a five-month period and data were assessed using
      the IBM-SPSS software. RESULTS: 484 people answered the questionnaire: 97.0%
      declared that they were using IMS for medical-related purposes; 42.0%, to
      elucidate medical concerns every week; 75.0%, to share imaging or laboratory
      tests and patients' medical records; and 90.5%, to participate in clinical
      case-study private groups. Moreover, only 37.0% declared that they had knowledge 
      of the legislative aspects of use of smartphones within clinical practice.
      Differences in the frequency of discussion of medical concerns within the daily
      routine between student/residents and general practitioners/specialists, and in
      the frequency of image-sharing and patient-guiding/assistance between students
      and medical doctors, were observed. CONCLUSIONS: Our results provide reliable
      proof that medical doctors and students use IMS, as a tool for clinical case
      discussions, interactions between healthcare providers and patients, or
      dissemination of knowledge and information. Nonetheless, because of limitations
      to the ethical and legal regulations, evidence-based discussions between
      authorities, academics and medical institutions are needed in order to fully
      achieve positive outcomes from such platforms.
FAU - Nascimento, Israel Junior Borges do
AU  - Nascimento IJBD
AUID- ORCID: http://orcid.org/0000-0001-5240-0493
AD  - PharmB. Medical Research Specialist, Medical School and TeleHealth Center,
      University Hospital, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 
      (MG), Brazil; and Medical Research Specialist, Medical College of Wisconsin,
      Milwaukee, Wisconsin, United States.
FAU - Oliveira, Joao Antonio de Queiroz
AU  - Oliveira JAQ
AUID- ORCID: http://orcid.org/0000-0003-3116-4713
AD  - PharmD. MSc. Pharmacist, Medical School and TeleHealth Center, University
      Hospital, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG),
      Brazil.
FAU - Wolff, Iago Souza
AU  - Wolff IS
AUID- ORCID: http://orcid.org/0000-0003-0920-5814
AD  - MD. Physician, Medical School and TeleHealth Center, University Hospital,
      Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG), Brazil.
FAU - Ribeiro, Laura Defensor
AU  - Ribeiro LD
AUID- ORCID: http://orcid.org/0000-0003-0491-5411
AD  - MD. Physician, Medical School and TeleHealth Center, University Hospital,
      Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG), Brazil.
FAU - Silva, Maira Viana Rego Souza E
AU  - Silva MVRSE
AUID- ORCID: http://orcid.org/0000-0003-2079-7291
AD  - MD. Physician, Medical School and TeleHealth Center, University Hospital,
      Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG), Brazil.
FAU - Cardoso, Clareci Silva
AU  - Cardoso CS
AUID- ORCID: http://orcid.org/0000-0003-0689-1644
AD  - MD, MSc, PhD. Professor, Department of Public Health, Medical School and
      TeleHealth Center, Universidade Federal de Sao Joao del-Rei, Divinopolis, Brazil.
FAU - Mars, Maurice
AU  - Mars M
AUID- ORCID: http://orcid.org/0000-0001-8784-780X
AD  - MBChB, MD. Professor, Department of TeleHealth, Nelson R. Mandela School of
      Medicine, University of KwaZulu-Natal, Durban, South Africa.
FAU - Ribeiro, Antonio Luiz
AU  - Ribeiro AL
AUID- ORCID: http://orcid.org/0000-0002-2740-0042
AD  - MD, PhD. Professor, Medical School and TeleHealth Center, University Hospital,
      Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG), Brazil.
FAU - Marcolino, Milena Soriano
AU  - Marcolino MS
AUID- ORCID: http://orcid.org/0000-0003-4278-3771
AD  - MD, MSc, PhD. Professor, Medical School and TeleHealth Center, University
      Hospital, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte (MG),
      Brazil.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Sao Paulo Med J
JT  - Sao Paulo medical journal = Revista paulista de medicina
JID - 100897261
SB  - IM
CIN - Sao Paulo Med J. 2020 Jun;138(3):269-270. PMID: 32578746
MH  - Brazil
MH  - Cross-Sectional Studies
MH  - Humans
MH  - *Physicians
MH  - *Smartphone
MH  - *Students, Medical
EDAT- 2020/04/23 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - S1516-31802020000100086 [pii]
AID - 10.1590/1516-3180.2020.0010.R1.28032020 [doi]
PST - ppublish
SO  - Sao Paulo Med J. 2020 Jan-Feb;138(1):86-92. doi:
      10.1590/1516-3180.2020.0010.R1.28032020.


PMID- 32320846
OWN - NLM
STAT- MEDLINE
DCOM- 20210804
LR  - 20210804
IS  - 1559-2030 (Electronic)
IS  - 1551-7144 (Linking)
VI  - 93
DP  - 2020 Jun
TI  - Proactive health support (PaHS) - telephone-based self-management support for
      persons at risk of hospital admission: Study protocol for a randomized controlled
      trial.
PG  - 106004
LID - S1551-7144(20)30082-3 [pii]
LID - 10.1016/j.cct.2020.106004 [doi]
AB  - BACKGROUND: A small proportion of patients account for most of the healthcare
      costs. Previous studies of supportive interventions have several methodological
      limitations and results are mixed. This article describes the protocol for
      Proactive Health Support: a national randomized controlled trial of
      telephone-based self-management support (ClinicalTrials.gov, NCT03628469). The
      main aim of the intervention is to reduce hospital admissions and improve quality
      of life at six months. METHODS: A sample size of 4400 is needed and individuals
      with the highest risk of hospital admission in Denmark are invited by electronic 
      communication and telephone to participate in a 1:1 randomized controlled trial. 
      The intervention group receives one face-to-face start-up session followed by
      telephone sessions about individual goals regarding participants' knowledge,
      coping and need of healthcare. Quality of life was assessed with the mental
      health composite score of the SF-36v2 questionnaire. Primary analyses are done
      using the intention-to-treat principle. DISCUSSION: The trial has been approved
      by The Regional Committee on Health Research Ethics (SJ-677). Intervention nurses
      do not assume clinical responsibility for the participants and the intervention
      is an addition to the general healthcare services. The intervention is complex
      due to challenging skills and behaviors required by nurses, individual tailoring 
      of the intervention, and interacting intervention components. The study therefore
      includes process evaluation. The research program comprises: 1. Development
      initiation, 2. Intervention effect, 3. Cost-effectiveness, 4. Organizational
      implementation, and 5. Participants' experiences. Inclusion to the trial began
      April 9th, 2018, was completed July 1st, 2019 and follow-up will be completed
      February 1st, 2020.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Benthien, Kirstine Skov
AU  - Benthien KS
AD  - Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg
      Hospital, Copenhagen, Denmark. Electronic address:
      kirstine.skov.benthien@regionh.dk.
FAU - Rasmussen, Knud
AU  - Rasmussen K
AD  - Production, Research and Innovation, Region Zealand, Soro, Denmark. Electronic
      address: kra@regionsjaelland.dk.
FAU - Nielsen, Camilla Palmhoj
AU  - Nielsen CP
AD  - DEFACTUM - Social & Health Services and Labour Market, Aarhus, Denmark.
      Electronic address: camilla.palmhoj@rm.dk.
FAU - Hjarnaa, Louise
AU  - Hjarnaa L
AD  - Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg
      Hospital, Copenhagen, Denmark. Electronic address: louise.hjarnaa@regionh.dk.
FAU - Rasmussen, Maja Kjaer
AU  - Rasmussen MK
AD  - Centre for Innovative Medical Technology, Odense University Hospital, Odense,
      Denmark. Electronic address: maja.kjaer.rasmussen@rsyd.dk.
FAU - Kidholm, Kristian
AU  - Kidholm K
AD  - Centre for Innovative Medical Technology, Odense University Hospital, Odense,
      Denmark. Electronic address: kristian.kidholm@rsyd.dk.
FAU - Nielsen, Berit Kjaerside
AU  - Nielsen BK
AD  - DEFACTUM - Social & Health Services and Labour Market, Aarhus, Denmark.
      Electronic address: beritnie@rm.dk.
FAU - Nissen, Nina Konstantin
AU  - Nissen NK
AD  - DEFACTUM - Social & Health Services and Labour Market, Aarhus, Denmark.
      Electronic address: niniss@rm.dk.
FAU - Fredens, Mia
AU  - Fredens M
AD  - DEFACTUM - Social & Health Services and Labour Market, Aarhus, Denmark.
      Electronic address: mia.fredens@rm.dk.
FAU - Winther, Susanne
AU  - Winther S
AD  - Clinical Nursing Research Unit, Aalborg University Hospital, Aalborg, Denmark.
      Electronic address: susanne.winther@rn.dk.
FAU - Gronkjaer, Mette
AU  - Gronkjaer M
AD  - Clinical Nursing Research Unit, Aalborg University Hospital, Aalborg, Denmark;
      Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic
      address: mette.groenkjaer@rn.dk.
FAU - Toft, Ulla
AU  - Toft U
AD  - Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg
      Hospital, Copenhagen, Denmark. Electronic address: ulla.toft@regionh.dk.
LA  - eng
SI  - ClinicalTrials.gov/NCT03628469
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200419
PL  - United States
TA  - Contemp Clin Trials
JT  - Contemporary clinical trials
JID - 101242342
SB  - IM
MH  - Adaptation, Psychological
MH  - Cost-Benefit Analysis
MH  - Denmark
MH  - Female
MH  - Goals
MH  - Health Knowledge, Attitudes, Practice
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Mental Health
MH  - Patient Admission/*statistics & numerical data
MH  - Patient Satisfaction
MH  - Program Development
MH  - Program Evaluation
MH  - *Quality of Life
MH  - Research Design
MH  - Risk Factors
MH  - Self-Management/*methods
MH  - *Telephone
OTO - NOTNLM
OT  - *Health-related quality of life
OT  - *High-cost
OT  - *Hospital admissions
OT  - *Randomized controlled trial
COIS- Declaration of Competing interest The authors declare that they have no conflicts
      of interest.
EDAT- 2020/04/23 06:00
MHDA- 2021/08/05 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/08/05 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - S1551-7144(20)30082-3 [pii]
AID - 10.1016/j.cct.2020.106004 [doi]
PST - ppublish
SO  - Contemp Clin Trials. 2020 Jun;93:106004. doi: 10.1016/j.cct.2020.106004. Epub
      2020 Apr 19.


PMID- 32320722
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1873-5894 (Electronic)
IS  - 0730-725X (Linking)
VI  - 70
DP  - 2020 Jul
TI  - Assessment of biliary anatomy in potential living liver donors: Added value of
      gadoxetic acid-enhanced T1 MR Cholangiography (MRC) including utilization of
      controlled aliasing in parallel imaging results in higher acceleration
      (CAIPIRINHA) technique in comparison to T2W-MRC.
PG  - 64-72
LID - S0730-725X(20)30074-6 [pii]
LID - 10.1016/j.mri.2020.04.011 [doi]
AB  - OBJECTIVES: To assess the added value of gadoxetic-acid-enhanced T1-weighted
      magnetic resonance Cholangiography (T1W-MRC) including controlled aliasing in
      parallel imaging results in higher acceleration (CAIPIRINHA)-Volumetric
      Interpolated Breathhold (VIBE) technique compared to T2-weighted MR
      Cholangiography (T2W-MRC) in depicting biliary anatomy in potential living liver 
      donors. METHODS: Eighty-five potential donors including 34 men with a mean age of
      35.6 years (range, 18-55 years) and 51 women with a mean age of 36.7 years
      (range, 23-57 years), were enrolled in this ethics-approved retrospective study. 
      Image quality for depiction of bile ducts was evaluated by two readers in
      consensus in 3 separate reading sessions: 1) T2W-MRC alone, 2) T1W-MRC alone
      (including CAIPI-VIBE and generalized autocalibrating partially parallel
      acquisitions (GRAPPA)-VIBE techniques, and 3) combined T1W/T2W-MRC. Accuracy of
      T2W-MRC, T1W-MRC, and combined T1W/T2W-MRC for the identification/classification 
      of the biliary variants was calculated using intraoperative cholangiogram (IOC)
      as the reference standard. Image quality and reader diagnostic confidence
      provided by CAIPI-VIBE technique was compared with GRAPPA-VIBE technique.
      Datasets were compared using the Wilcoxon signed-rank test. RESULTS: Image
      quality for depiction of the bile ducts was significantly superior in the
      combined T1W/T2W-MRC group, when compared to each of T2W-MRC and T1W-MRC groups
      independently (P value = 0.001-0.034). The combination of CAIPI-VIBE and
      GRAPPA-VIBE was superior compared to each of the sequences individually. The
      accuracy of T2W-MRC and T1W-MRC was 93% and 91%, respectively. T1W-MRC depicted
      four biliary variants better than T2W-MRC. Two variants not well seen in T2W-MRC 
      were clearly shown on T1W-MRC. CONCLUSION: Gadoxetic-acid-enhanced T1W-MRC and
      conventional T2W-MRC techniques are complementary for depiction of biliary
      variants in potential liver donors and the combination of the two improves the
      results. The combination of CAIPI-VIBE and GRAPPA-VIBE techniques appear to be
      complementary for optimal diagnostic yield of T1W-MRC.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Guimaraes, Luis
AU  - Guimaraes L
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai
      Hospital and Women's College Hospital, University of Toronto, Toronto, ON,
      Canada.
FAU - Babaei Jandaghi, Ali
AU  - Babaei Jandaghi A
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai
      Hospital and Women's College Hospital, Toronto, ON, Canada.
FAU - Menezes, Ravi
AU  - Menezes R
AD  - Joint Department of Medical Imaging, University Health Network, Toronto, ON,
      Canada.
FAU - Grant, David
AU  - Grant D
AD  - Division of General Surgery, Toronto General Hospital, University of Toronto,
      Toronto, ON, Canada.
FAU - Cattral, Mark
AU  - Cattral M
AD  - Division of General Surgery, Toronto General Hospital, University of Toronto,
      Toronto, ON, Canada.
FAU - Jhaveri, Kartik S
AU  - Jhaveri KS
AD  - Joint Department of Medical Imaging, University Health Network, Mount Sinai
      Hospital and Women's College Hospital, University of Toronto, Toronto, ON,
      Canada. Electronic address: kartik.jhaveri@uhn.ca.
LA  - eng
PT  - Journal Article
DEP - 20200419
PL  - Netherlands
TA  - Magn Reson Imaging
JT  - Magnetic resonance imaging
JID - 8214883
RN  - 0 (Contrast Media)
RN  - 0 (gadolinium ethoxybenzyl DTPA)
RN  - K2I13DR72L (Gadolinium DTPA)
SB  - IM
MH  - Acceleration
MH  - Adolescent
MH  - Adult
MH  - Bile Ducts/*anatomy & histology/*diagnostic imaging
MH  - Breath Holding
MH  - Cholangiography/*methods
MH  - *Contrast Media
MH  - Female
MH  - *Gadolinium DTPA
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - *Liver
MH  - *Living Donors
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Young Adult
COIS- Declaration of competing interest None.
EDAT- 2020/04/23 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/02/11 00:00 [received]
PHST- 2020/04/02 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - S0730-725X(20)30074-6 [pii]
AID - 10.1016/j.mri.2020.04.011 [doi]
PST - ppublish
SO  - Magn Reson Imaging. 2020 Jul;70:64-72. doi: 10.1016/j.mri.2020.04.011. Epub 2020 
      Apr 19.


PMID- 32320622
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1558-9110 (Electronic)
IS  - 1058-0360 (Linking)
VI  - 29
IP  - 2
DP  - 2020 May 8
TI  - Knowledge, Training, and Attitudes of Students and Speech-Language Pathologists
      About Providing Communication Services to Individuals Who Are Transgender.
PG  - 597-610
LID - 10.1044/2020_AJSLP-19-00148 [doi]
AB  - Purpose Little is known about the professional knowledge, training, and attitudes
      of current and future speech-language pathologists (SLPs) toward serving people
      who are transgender. The purpose of this study was to understand the current
      climate of students and professionals in delivering voice and communications
      services to people who are transgender. An understanding of these areas is
      necessary to help practicing and aspiring SLPs work toward cultural competence in
      serving this population. Method A survey was completed by 386 speech-language
      pathology students and SLPs at three professional conferences. The survey
      assessed the professional and ethical knowledge, training experiences, and
      attitudes of the participants in relation to communication services for people
      who are transgender. Results In terms of professional knowledge, the majority of 
      students and experienced SLP respondents agreed or strongly agreed (77.8%) that
      treating clients who are transgender was within the SLP scope of practice and was
      their ethical responsibility (82.2%). Regarding training, approximately 20% of
      survey respondents received training for working with people who are transgender,
      whereas approximately 8% of survey respondents reported having experience working
      with clients who are transgender. With respect to attitude, approximately 54% of 
      survey respondents reported being comfortable treating clients who are
      transgender, and 37% of survey respondents reported they were likely to pursue
      training for treating clients who are transgender. Additional analyses were
      completed comparing students and experienced SLPs as well as the influence of
      geographic region. Discussion Students and SLPs were generally knowledgeable of
      professional guidelines and standards regarding serving people who are
      transgender. However, in this survey, very few clinicians indicated they had
      received training to serve this population. Recommendations to address this gap
      are discussed.
FAU - Matthews, Jairus-Joaquin
AU  - Matthews JJ
AD  - Department of Communication Sciences and Disorders, University of West Georgia,
      Carrollton.
FAU - Olszewski, Abbie
AU  - Olszewski A
AD  - Department of Speech Pathology and Audiology, University of Nevada, Reno.
FAU - Petereit, Juli
AU  - Petereit J
AD  - Nevada Center for Bioinformatics, University of Nevada, Reno.
LA  - eng
GR  - U54 GM104944/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200422
PL  - United States
TA  - Am J Speech Lang Pathol
JT  - American journal of speech-language pathology
JID - 9114726
SB  - IM
MH  - Attitude of Health Personnel
MH  - Humans
MH  - Pathologists
MH  - Speech
MH  - *Speech-Language Pathology
MH  - Students
MH  - Surveys and Questionnaires
MH  - *Transgender Persons
PMC - PMC7842867
EDAT- 2020/04/23 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1044/2020_AJSLP-19-00148 [doi]
PST - ppublish
SO  - Am J Speech Lang Pathol. 2020 May 8;29(2):597-610. doi:
      10.1044/2020_AJSLP-19-00148. Epub 2020 Apr 22.


PMID- 32320532
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Improving safety in organ recovery transportation: Report from the
      ASTS/UNOS/AST/AOPO transportation safety summit.
PG  - 2001-2008
LID - 10.1111/ajt.15930 [doi]
AB  - Despite the passage of a decade since the tragic loss of an organ recovery team
      from the University of Michigan, there are currently no national standards
      governing air and ground transportation of organ recovery personnel.
      Consequently, the American Society of Transplant Surgeons, the Association of
      Organ Procurement Organizations, and the United Network for Organ Sharing jointly
      convened a transportation summit to review and update recommendations for
      national transportation standards. Expanded air transport quality assurance
      protocols, including a requirement for two engine turbine-powered aircraft
      piloted by two qualified pilots certified through onsite inspections was
      recommended. Ground transportation providers must ensure adequate safety
      restraints are available, ambulance avoided if possible, and the use of lights
      and sirens minimized. Finally, adequate insurance coverage for all team members, 
      including trainees should be provided and should not rely on carrier liability
      insurance policies. The summit participants have committed the support of their
      organizations to promote and enact these regulations nationally.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Axelrod, David A
AU  - Axelrod DA
AUID- ORCID: 0000-0001-5684-0613
AD  - University of Iowa, Iowa City, Iowa, USA.
FAU - Shah, Shimul
AU  - Shah S
AD  - University of Cincinnati, Cincinnati, Ohio, USA.
FAU - Guarrera, James
AU  - Guarrera J
AD  - Rutgers University, Newark, New Jersey, USA.
FAU - Shepard, Brian
AU  - Shepard B
AD  - United Network for Organ Sharing, Richmond, Virginia, USA.
FAU - Scalea, Joseph
AU  - Scalea J
AUID- ORCID: 0000-0001-8278-2859
AD  - University of Maryland, Baltimore, Maryland, USA.
FAU - Cooper, Mathew
AU  - Cooper M
AD  - Medstar-Georgetown University, Washington, District of Columbia, USA.
FAU - Kandaswamy, Raja
AU  - Kandaswamy R
AD  - University of Minnesota, Minneapolis, Minnesota, USA.
LA  - eng
PT  - Journal Article
DEP - 20200517
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - Aircraft
MH  - Humans
MH  - *Organ Transplantation
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
MH  - Transportation
MH  - United States
OTO - NOTNLM
OT  - *Organ Procurement and Transplantation Network (OPTN)
OT  - *donors and donation: deceased
OT  - *editorial/personal viewpoint
OT  - *ethics and public policy
OT  - *insurance
OT  - *organ procurement
OT  - *organ procurement and allocation
OT  - *organ procurement organization
EDAT- 2020/04/23 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1111/ajt.15930 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Aug;20(8):2001-2008. doi: 10.1111/ajt.15930. Epub 2020 May 
      17.


PMID- 32320363
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210702
IS  - 2162-1918 (Print)
IS  - 2162-1918 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul
TI  - The Northwestern Abdominoplasty Scar Model: A Tool for High-Throughput Assessment
      of Scar Therapeutics.
PG  - 396-404
LID - 10.1089/wound.2018.0900 [doi]
AB  - Significance: Scar management is an important concern in plastic surgery. Scar
      models that best mimic in vivo human scarring are essential for understanding
      scar development and progression, assessing the efficacy of therapeutics, and
      providing reliable and valid research outcomes. Recent Advances: In 2016, Lanier 
      et al. proposed a new in vivo patient model, the Northwestern Abdominoplasty Scar
      Model, that overcomes the prior limitations of both animal and human models, with
      greater representativeness of the human scarring process, expedited recruitment, 
      smaller sample requirements, and greater flexibility in the types and number of
      interventions that can be studied simultaneously. Critical Issues: Existing
      animal models suffer from limitations that impede generalization to human scars. 
      Human scar studies are difficult to conduct and rarely used due to recruitment
      difficulties, ethical concerns regarding purposeful wounding, and inherent
      variability based on location, type of scar, and the heterogeneity of the host
      response between humans. Although overcoming many of these hurdles, the
      Northwestern Abdominoplasty Scar Model still has a few limitations. In addition, 
      there remains a need for further study of and comparison between the Northwestern
      Abdominoplasty Scar Model and existing human and animal models, to inspire more
      widespread acceptance of a standardized human scar model. Future Directions: The 
      Northwestern Abdominoplasty Scar Model is a critical stepping stone toward better
      human scar models. This model hopefully will inspire other in vivo patient models
      utilizing elective surgery to overcome recruitment and ethical concerns.
FAU - Hsieh, Ji-Cheng
AU  - Hsieh JC
AD  - Department of Plastic and Reconstructive Surgery, Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois.
FAU - Joshi, Chitang J
AU  - Joshi CJ
AD  - Department of Plastic and Reconstructive Surgery, Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois.
FAU - Wan, Rou
AU  - Wan R
AD  - Department of Plastic and Reconstructive Surgery, Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois.
FAU - Galiano, Robert D
AU  - Galiano RD
AD  - Department of Plastic and Reconstructive Surgery, Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200429
PL  - United States
TA  - Adv Wound Care (New Rochelle)
JT  - Advances in wound care
JID - 101590593
SB  - IM
MH  - Abdominoplasty/*adverse effects/ethics/methods
MH  - Animals
MH  - Cicatrix/etiology/physiopathology/*therapy
MH  - Clinical Trials as Topic/ethics/methods
MH  - Disease Models, Animal
MH  - Human Experimentation/*ethics
MH  - Humans
MH  - Informed Consent
MH  - Mice
MH  - Rabbits
MH  - *Skin Physiological Phenomena
MH  - Sus scrofa
MH  - Wound Healing/*physiology
PMC - PMC7307678
OTO - NOTNLM
OT  - *plastic surgery
OT  - *review
OT  - *scar models
OT  - *scars
OT  - *wound
OT  - *wound healing
EDAT- 2020/04/23 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1089/wound.2018.0900 [doi]
PST - ppublish
SO  - Adv Wound Care (New Rochelle). 2020 Jul;9(7):396-404. doi:
      10.1089/wound.2018.0900. Epub 2020 Apr 29.


PMID- 32320313
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 2156-535X (Electronic)
IS  - 2156-5333 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Oct
TI  - Exposing the Risks of Social Media Recruitment in Adolescents and Young Adults
      with Cancer: #Beware.
PG  - 601-607
LID - 10.1089/jayao.2020.0018 [doi]
AB  - Enrolling adolescents and young adults (AYAs) in psychosocial research studies
      during cancer treatment is challenging. Successful AYA study recruitment not
      specific to oncology patients supports social media network advertising and
      recruitment strategies. However, this brief report describes several challenges
      to recruiting an appropriate and credible anonymous sample while conducting
      Institutional Review Board-approved research using social media recruitment.
      Namely, ethical oversight impeded access to AYAs with cancer and monetary
      remuneration allured many noneligible AYA participants who accessed the online
      survey. Lessons learned from this study provide caution for researchers
      interested in a similar approach and illustrate ways to determine credibility of 
      findings.
FAU - Bell, Cynthia J
AU  - Bell CJ
AD  - College of Nursing, Wayne State University, Detroit, Michigan, USA.
FAU - Spruit, Jessica L
AU  - Spruit JL
AD  - College of Nursing, Wayne State University, Detroit, Michigan, USA.
FAU - Kavanaugh, Karen L
AU  - Kavanaugh KL
AD  - Department of Nursing Research and Evidence Based Practice, Children's Wisconsin,
      Milwaukee, Wisconsin, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200422
PL  - United States
TA  - J Adolesc Young Adult Oncol
JT  - Journal of adolescent and young adult oncology
JID - 101543508
SB  - IM
MH  - Adolescent
MH  - Humans
MH  - Risk Factors
MH  - Social Media/*standards
MH  - Young Adult
OTO - NOTNLM
OT  - *active cancer treatment
OT  - *adolescent young adult
OT  - *psychosocial research
OT  - *social media recruitment
EDAT- 2020/04/23 06:00
MHDA- 2021/08/04 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1089/jayao.2020.0018 [doi]
PST - ppublish
SO  - J Adolesc Young Adult Oncol. 2020 Oct;9(5):601-607. doi: 10.1089/jayao.2020.0018.
      Epub 2020 Apr 22.


PMID- 32319874
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1545-0864 (Electronic)
IS  - 0735-9683 (Linking)
VI  - 37
IP  - 2
DP  - 2020 Apr-Jun
TI  - Why the "sea of same"? A qualitative look at DTCA within the larger context of
      healthcare marketing.
PG  - 155-175
LID - 10.1080/07359683.2020.1754050 [doi]
AB  - After over two decades of direct-to-consumer pharmaceutical advertising (DTCA),
      the ads have changed very little, both within and over the years. One respondent 
      in this exploratory study called it the "sea of same." To better understand why
      agency professionals, their pharmaceutical clients, and consumers operate in a
      "sea of same," in-depth interviews were conducted with nine advertising agency
      professionals who work on DTCA and health-advertising accounts. Respondents
      discussed the research, planning, and insight process that informed the strategy 
      and subsequent DTCA tactics. Similar to students or coworkers who always sit in
      the same seat, DTCA ads exist in a defined comfort zone.
FAU - Macias, Wendy
AU  - Macias W
AD  - Department of Strategic Communication, Bob Schieffer College of Communication,
      Texas Christian University, Fort Worth, Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - England
TA  - Health Mark Q
JT  - Health marketing quarterly
JID - 8306485
MH  - *Direct-to-Consumer Advertising
MH  - Drug Industry/economics
MH  - Female
MH  - Grounded Theory
MH  - *Health Care Sector
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - *Marketing
OTO - NOTNLM
OT  - Advertising ethics
OT  - advertising practice
OT  - direct-to-consumer pharmaceutical advertising
OT  - health marketing
OT  - qualitative research
EDAT- 2020/04/23 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1080/07359683.2020.1754050 [doi]
PST - ppublish
SO  - Health Mark Q. 2020 Apr-Jun;37(2):155-175. doi: 10.1080/07359683.2020.1754050.
      Epub 2020 Apr 22.


PMID- 32319855
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210607
IS  - 1746-076X (Electronic)
IS  - 1746-0751 (Linking)
VI  - 15
IP  - 3
DP  - 2020 Mar
TI  - Challenging misinformation and engaging patients: characterizing a regenerative
      medicine consult service.
PG  - 1427-1440
LID - 10.2217/rme-2020-0018 [doi]
AB  - Aim: To address the unmet needs of patients interested in regenerative medicine, 
      Mayo Clinic created a Regenerative Medicine Consult Service (RMCS). We describe
      the service and patient satisfaction. Materials & methods: We analyzed RMCS
      databases through retrospective chart analysis and performed qualitative
      interviews with patients. Results: The average patient was older to elderly and
      seeking information about regenerative options for their condition. Patients
      reported various conditions with osteoarthritis being most common. Over a third
      of consults included discussions about unproven interventions. About a third of
      patients received a clinical or research referral. Patients reported the RMCS as 
      useful and the consultant as knowledgeable. Conclusion: An institutional RMCS can
      meet patients' informational needs and support the responsible translation of
      regenerative medicine.
FAU - Smith, Cambray
AU  - Smith C
AUID- ORCID: 0000-0001-9723-891X
AD  - Biomedical Ethics Research Program, Mayo Clinic, 200 First Street, SW, Rochester,
      MN 55905, USA.
FAU - Martin-Lillie, Charlene
AU  - Martin-Lillie C
AD  - Center for Regenerative Medicine, Mayo Clinic, 200 First Street, SW, Rochester,
      MN 55905, USA.
FAU - Higano, Jennifer Dens
AU  - Higano JD
AD  - Mayo Clinic Alix School of Medicine, 200 First Street, SW, Rochester, MN 55905,
      USA.
FAU - Turner, Leigh
AU  - Turner L
AUID- ORCID: 0000-0001-7283-6809
AD  - Center for Bioethics, School of Public Health & College of Pharmacy, University
      of Minnesota, N520 Boynton, 410 Church Street SE, Minneapolis, MN 55455, USA.
FAU - Phu, Sydney
AU  - Phu S
AD  - School of History, Philosophy & Religion, Oregon State University, 322 Milam
      Hall, 2520 SW Campus Way, Corvallis, OR 97331, USA.
FAU - Arthurs, Jennifer
AU  - Arthurs J
AD  - Center for Regenerative Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville,
      FL 32224, USA.
FAU - Nelson, Timothy J
AU  - Nelson TJ
AD  - Center for Regenerative Medicine, Mayo Clinic, 200 First Street, SW, Rochester,
      MN 55905, USA.
AD  - Department of General Internal Medicine, Mayo Clinic, 200 First Street, SW,
      Rochester, MN 55905, USA.
FAU - Shapiro, Shane
AU  - Shapiro S
AUID- ORCID: 0000-0001-5753-0625
AD  - Center for Regenerative Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville,
      FL 32224, USA.
AD  - Department of Orthopedic Surgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville,
      FL 32224, USA.
FAU - Master, Zubin
AU  - Master Z
AUID- ORCID: 0000-0002-3462-4546
AD  - Biomedical Ethics Research Program, Mayo Clinic, 200 First Street, SW, Rochester,
      MN 55905, USA.
AD  - Center for Regenerative Medicine, Mayo Clinic, 200 First Street, SW, Rochester,
      MN 55905, USA.
LA  - eng
GR  - UL1 TR002377/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200422
PL  - England
TA  - Regen Med
JT  - Regenerative medicine
JID - 101278116
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - *Communication
MH  - *Evidence-Based Medicine
MH  - Female
MH  - Humans
MH  - Infant
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Minnesota/epidemiology
MH  - Osteoarthritis/epidemiology/*therapy
MH  - Patient Navigation/*standards
MH  - Patient Participation/*statistics & numerical data
MH  - Referral and Consultation/*standards
MH  - *Regenerative Medicine
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC7466910
OTO - NOTNLM
OT  - *consultation service
OT  - *ethical
OT  - *evidence-based medicine
OT  - *information for patients
OT  - *patient education
OT  - *patient navigation
OT  - *regenerative medicine education
OT  - *responsible translation
OT  - *unproven stem cell therapies
EDAT- 2020/04/23 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.2217/rme-2020-0018 [doi]
PST - ppublish
SO  - Regen Med. 2020 Mar;15(3):1427-1440. doi: 10.2217/rme-2020-0018. Epub 2020 Apr
      22.


PMID- 32319444
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Apr
TI  - [Between intensive care and palliative care at the time of CoViD-19.]
PG  - 223-230
LID - 10.1701/3347.33185 [doi]
AB  - The pandemic infection caused by the virus SARS-CoV-2 has determined a severe
      imbalance between demand and actual supply of intensive care. The shortage of
      intensive care units (ICU) beds and ventilators for the treatment of patients
      with severe respiratory failure produced angst in the clinicians/intensivists who
      have to decide which patients admit to ICU and in which patients to implement
      palliative care. They have to apply specific clinical and ethical criteria, in
      emergency conditions. Proportionality and appropriateness criteria should be
      integrated with equity, equality, utility criteria, widening the distributive
      justice concept from the right of the patient to receive all available therapies 
      to a right resources allocation during shortage, guided by public health ethic.
      The clinical criteria should include the disease severity, the number and
      severity of comorbidities, frailty, the organ failures and their stage, the
      patient's age, the functional autonomy and cognitive status. Consequently the
      first come-first served rule to ICU admission should not be applied. The patients
      not admitted to ICU due to clinical reasons and advanced stage diseases should
      receive a high quality palliative care, to obtain a good symptoms control (mainly
      dyspnea, anxiety and delirium) and to implement palliative sedation at the end of
      life. Finally particular attention should be paid to the bereavement management
      of the family/caregivers and in the right approach of psychological problems and 
      Post-Traumatic Stress Disorder of health workers involved in the pandemia.
FAU - Romano, Massimo
AU  - Romano M
AD  - Cardiologo, Comitato Ordinatore Master di 2 degrees livello in Cure Palliative,
      Universita di Milano.
LA  - ita
PT  - Journal Article
TT  - Fra cure intensive e cure palliative ai tempi di CoViD-19.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - Bereavement
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/psychology/therapy
MH  - *Critical Care/ethics
MH  - *Decision Making
MH  - Family Health
MH  - Health Equity
MH  - Health Resources
MH  - Hospital Bed Capacity
MH  - Humans
MH  - Italy
MH  - *Palliative Care/ethics
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/psychology/therapy
MH  - *Resource Allocation
MH  - Respiration, Artificial
MH  - SARS-CoV-2
MH  - Severity of Illness Index
EDAT- 2020/04/23 06:00
MHDA- 2020/04/25 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
AID - 10.1701/3347.33185 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Apr;111(4):223-230. doi: 10.1701/3347.33185.


PMID- 32319443
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Apr
TI  - [Ethical, deontologic and legal considerations about SIAARTI Document "Clinical
      ethics recommendations for the allocation of intensive care treatments, in
      exceptional, resource-limited circumstances".]
PG  - 212-222
LID - 10.1701/3347.33184 [doi]
AB  - On 6 March 2020, the Italian Society of Anaesthesia Analgesia Resuscitation and
      Intensive care (SIAARTI) published the document "Clinical Ethics Recommendations 
      for Admission to and Suspension of Intensive Care in Exceptional Conditions of
      Imbalance between Needs and Available Resources". The document, which aims to
      propose treatment decision-making criteria in the face of exceptional imbalances 
      between health needs and available resources, has produced strong reactions,
      within the medical-scientific community, in the academic world, and in the media.
      In the current context of international public health emergency caused by the
      CoViD-19 epidemic, this work aims to explain the ethical, deontological and legal
      bases of the SIAARTI Document and to propose methodologic and argumentative
      integrations that are useful for understanding and placing in context the
      decision-making criteria proposed. The working group that contributed to the
      drafting of this paper agrees that it is appropriate that healthcare personnel,
      who is particularly committed to taking care of those who are currently in need
      of intensive or sub-intensive care, should benefit from clear operational
      indications that are useful to orient care and, at the same time, that the
      population should know in advance which criteria will guide the tragic choices
      that may fall on each one of us. This contribution therefore firstly reflects on 
      the appropriateness of the SIAARTI standpoint and the objectives of the SIAARTI
      Document. It then turns to demonstrate how the recommendations it proposes can be
      framed within a shared interdisciplinary, ethical, deontological and legal
      perspective.
FAU - Piccinni, Mariassunta
AU  - Piccinni M
AD  - Ricercatrice di diritto privato, Universita di Padova.
FAU - Aprile, Anna
AU  - Aprile A
AD  - Professoressa associata di medicina legale, Universita di Padova.
FAU - Benciolini, Paolo
AU  - Benciolini P
AD  - Professore ordinario di medicina legale i.q., Universita di Padova.
FAU - Busatta, Lucia
AU  - Busatta L
AD  - Docente a contratto, Universita di Padova.
FAU - Cadamuro, Elena
AU  - Cadamuro E
AD  - Assegnista di diritto penale, Universita di Padova.
FAU - Malacarne, Paolo
AU  - Malacarne P
AD  - Direttore UO Anestesia e Rianimazione, PS Azienda Ospedaliera Universitaria
      Pisana.
FAU - Marin, Francesca
AU  - Marin F
AD  - Ricercatrice di filosofia morale, Universita di Padova.
FAU - Orsi, Luciano
AU  - Orsi L
AD  - Medico palliativista, Crema, vicepresidente SICP, gia Direttore Dipartimento Cure
      Palliative, Mantova.
FAU - Palermo Fabris, Elisabetta
AU  - Palermo Fabris E
AD  - Professoressa associata di diritto penale i.q., Universita di Padova.
FAU - Pisu, Alessandra
AU  - Pisu A
AD  - Professoressa associata di diritto privato, Universita di Cagliari.
FAU - Provolo, Debora
AU  - Provolo D
AD  - Ricercatrice di diritto penale, Universita di Padova.
FAU - Scalera, Antonio
AU  - Scalera A
AD  - Consigliere, Corte di appello di Catanzaro.
FAU - Tomasi, Marta
AU  - Tomasi M
AD  - Collaboratrice di ricerca, Universita di Trento.
FAU - Zamperetti, Nereo
AU  - Zamperetti N
AD  - UOC Hospice e cure palliative, Ospedale di Bolzano.
FAU - Rodriguez, Daniele
AU  - Rodriguez D
AD  - Professore di medicina legale i.q., Universita di Padova.
LA  - ita
PT  - Journal Article
TT  - Considerazioni etiche, deontologiche e giuridiche sul Documento SIAARTI
      "Raccomandazioni di etica clinica per l'ammissione a trattamenti intensivi e per 
      la loro sospensione, in condizioni eccezionali di squilibrio tra necessita e
      risorse disponibili".
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - *Critical Care/ethics/legislation & jurisprudence
MH  - Health Resources
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Intensive Care Units
MH  - Interdisciplinary Communication
MH  - Italy
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/*ethics/legislation & jurisprudence
MH  - SARS-CoV-2
EDAT- 2020/04/23 06:00
MHDA- 2020/04/25 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
AID - 10.1701/3347.33184 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Apr;111(4):212-222. doi: 10.1701/3347.33184.


PMID- 32319442
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Apr
TI  - [Clinical ethics recommendations for the allocation of intensive care treatments,
      in exceptional, resource-limited circumstances.]
PG  - 207-211
LID - 10.1701/3347.33183 [doi]
AB  - On February 21st, 2020 the first case of severe acute respiratory syndrome due to
      the coronavirus 2 (SARS-CoV-2) causing the CoViD-19 disease, was identified in
      Italy. In the following days, despite the restrictive public health measures
      aimed to avoid the infection's spread, the number of cases increased. As of March
      8th, 2020, Italy is the 2nd most affected country in the world. As of March 6th, 
      2020, the Italian Society of Anesthesia Analgesia Resuscitation and Intensive
      Care (SIAARTI) published operational recommendations and ethical considerations
      to support the clinicians involved in the care of critically-ill CoViD-19
      patients, in regard a probable scenario where an imbalance between supply and
      demand of ICU beds, is put in place by a steadily rising number of these
      patients.
FAU - Riccioni, Luigi
AU  - Riccioni L
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Bertolini, Guido
AU  - Bertolini G
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Giannini, Alberto
AU  - Giannini A
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Vergano, Marco
AU  - Vergano M
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Gristina, Giuseppe
AU  - Gristina G
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Livigni, Sergio
AU  - Livigni S
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Mistraletti, Giovanni
AU  - Mistraletti G
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
FAU - Petrini Gruppo di Lavoro Siaarti-Societa Italiana di Anestesia Analgesia
      Rianimazione E Terapia Intensiva, Flavia
AU  - Petrini Gruppo di Lavoro Siaarti-Societa Italiana di Anestesia Analgesia
      Rianimazione E Terapia Intensiva F
AD  - 1Comitato Etico - SIAARTI; 4Presidente SIAARTI; 2Laboratorio di Epidemiologia
      Clinica, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche
      Mario Negri IRCCS; 3Gruppo di Studio per la Bioetica - SIAARTI.
LA  - ita
PT  - Journal Article
TT  - Raccomandazioni di etica clinica per l'ammissione a trattamenti intensivi e per
      la loro sospensione, in condizioni eccezionali di squilibrio tra necessita e
      risorse disponibili.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
CIN - Recenti Prog Med. 2020 Nov;111(11):697-698. PMID: 33205775
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology
MH  - *Critical Care/statistics & numerical data
MH  - Decision Making/*ethics
MH  - *Health Resources/ethics
MH  - *Hospital Bed Capacity
MH  - Humans
MH  - Italy
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology
MH  - *Resource Allocation/ethics
MH  - SARS-CoV-2
EDAT- 2020/04/23 06:00
MHDA- 2020/04/25 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
AID - 10.1701/3347.33183 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Apr;111(4):207-211. doi: 10.1701/3347.33183.


PMID- 32319438
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20201218
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Apr
TI  - [Facing Covid-19 in Italy: ethics, logistics, and therapeutics on the epidemic's 
      front line].
PG  - 192-197
LID - 10.1701/3347.33179 [doi]
FAU - Rosenbaum, Lisa
AU  - Rosenbaum L
AD  - National Correspondent. The New England Journal of Medicine.
LA  - ita
PT  - Journal Article
TT  - Epidemia di CoViD-19 in Italia: gli aspetti etici, logistici e clinici della
      risposta in prima linea.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/transmission
MH  - *Critical Care
MH  - Ethics, Medical
MH  - Health Resources
MH  - Hospital Bed Capacity
MH  - Humans
MH  - *Infection Control
MH  - Infectious Disease Transmission, Patient-to-Professional/*prevention & control
MH  - Italy
MH  - *Pandemics
MH  - *Personal Protective Equipment
MH  - *Personnel, Hospital
MH  - *Pneumonia, Viral/epidemiology/transmission
MH  - SARS-CoV-2
EDAT- 2020/04/23 06:00
MHDA- 2020/04/25 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
AID - 10.1701/3347.33179 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2020 Apr;111(4):192-197. doi: 10.1701/3347.33179.


PMID- 32319351
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 1533-1601 (Electronic)
IS  - 0192-6233 (Linking)
VI  - 48
IP  - 4
DP  - 2020 Jun
TI  - Predatory Journals: What They Are and How to Avoid Them.
PG  - 607-610
LID - 10.1177/0192623320920209 [doi]
AB  - Predatory journals-also called fraudulent, deceptive, or pseudo-journals-are
      publications that claim to be legitimate scholarly journals but misrepresent
      their publishing practices. Some common forms of predatory publishing practices
      include falsely claiming to provide peer review, hiding information about article
      processing charges, misrepresenting members of the journal's editorial board, and
      other violations of copyright or scholarly ethics. Because of their increasing
      prevalence, this article aims to provide helpful information for authors on how
      to identify and avoid predatory journals.
FAU - Elmore, Susan A
AU  - Elmore SA
AUID- ORCID: 0000-0002-1680-9176
AD  - National Institute of Environmental Health Sciences, Cellular and Molecular
      Pathology Branch, Research Triangle Park, NC, USA.
FAU - Weston, Eleanor H
AU  - Weston EH
AUID- ORCID: 0000-0002-9745-8397
AD  - Vista Technology Services Inc, Contractor for the NIEHS Library, National
      Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
LA  - eng
GR  - Z99 ES999999/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200422
PL  - United States
TA  - Toxicol Pathol
JT  - Toxicologic pathology
JID - 7905907
SB  - IM
MH  - Humans
MH  - Peer Review, Research
MH  - *Periodicals as Topic
MH  - Publishing
PMC - PMC7237319
MID - NIHMS1580666
OTO - NOTNLM
OT  - *deceptive journal
OT  - *fake peer review
OT  - *predatory journals
OT  - *predatory publishing
OT  - *publishing ethics
OT  - *scholarly communications
EDAT- 2020/04/23 06:00
MHDA- 2021/05/01 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1177/0192623320920209 [doi]
PST - ppublish
SO  - Toxicol Pathol. 2020 Jun;48(4):607-610. doi: 10.1177/0192623320920209. Epub 2020 
      Apr 22.


PMID- 32318667
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2576-2095 (Electronic)
IS  - 2576-2095 (Linking)
VI  - 3
IP  - 1
DP  - 2020 Mar
TI  - Guidelines for the ethical review of laboratory animal welfare People's Republic 
      of China National Standard GB/T 35892-2018 [Issued 6 February 2018 Effective from
      1 September 2018].
PG  - 103-113
LID - 10.1002/ame2.12111 [doi]
AB  - These Chinese National Guidelines (GB/T 35892-20181) were issued February 06,
      2018 and became effective September 01, 2018. The authors recognized the urgent
      need for an authentic English translation to inform the international community
      of the compliance requirements in China. It was appreciated that the final
      translation must reflect the specialist understanding of those working under the 
      Guideline whilst remaining faithful to the meaning of the original Chinese text. 
      A three-step translation process was therefore determined. Step 1: A professional
      interpretation service (KL Communications, UK) was commissioned to prepare a
      literal translation of the Chinese text. Supportive documents were provided which
      explained specialist terminology. This translation was checked by two bilingual
      experts. Step 2: A workshop was held in Nanjing in May 2019 to which were invited
      experts in laboratory animal welfare and ethical use. These included
      international native English-speaking and Chinese-speaking delegates. The
      delegates worked in multi-lingual teams to review sections of the literal
      translation ahead of the workshop, and to agree an authentic interpretation
      during the workshop. Step 3: Following the workshop, three bilingual experts (two
      native Chinese speakers and one native English speaker) reviewed the entire
      document to ensure consistency of terminology and general accuracy. This document
      is thus not a "literal translation" but an "accurate interpretation" of the
      original text. Any challenge of work being performed under these Guidelines
      should rely on the Chinese text in the first place. However, this translation may
      be used as mitigating evidence, especially where those performing the work are
      non-Chinese speakers.
CI  - (c) 2020 The Authors. Animal Models and Experimental Medicine published by John
      Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory
      Animal Sciences.
FAU - MacArthur Clark, Judy A
AU  - MacArthur Clark JA
AUID- ORCID: https://orcid.org/0000-0002-2183-2629
AD  - JMC Welfare International Sandwich, Kent UK.
FAU - Sun, Deming
AU  - Sun D
AD  - National Research Institute for Health & Welfare and Ethics Committee of Chinese 
      Association for Laboratory Animal Science Beijing China.
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - United States
TA  - Animal Model Exp Med
JT  - Animal models and experimental medicine
JID - 101726292
PMC - PMC7167230
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.1002/ame2.12111 [doi]
AID - AME212111 [pii]
PST - epublish
SO  - Animal Model Exp Med. 2020 Apr 14;3(1):103-113. doi: 10.1002/ame2.12111.
      eCollection 2020 Mar.


PMID- 32318611
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2277-9531 (Print)
IS  - 2277-9531 (Linking)
VI  - 9
DP  - 2020
TI  - Readiness of school teachers to accept notifications about causes and preventive 
      measures on food poisoning.
PG  - 43
LID - 10.4103/jehp.jehp_505_19 [doi]
AB  - INTRODUCTION: In this era of globalization, urbanization, and rapidly expanding
      unhygienic food corners across the globe, the incidence of food poisoning is very
      common nowadays. AIM: The aim of our study was to investigate the perceptions and
      readiness of schoolteachers to accept notifications on food poisoning as a part
      of education to the students. METHODOLOGY: A descriptive cross-sectional study
      was carried out with the help of a validated questionnaire for data collection.
      Our research involved schoolteachers from both primary and secondary schools in
      Muar. The questionnaire was pretested among the eligible trainee teachers and
      yielded an internal consistency reliability coefficient (c = Cronbach's alpha) of
      0.082. This study was conducted from October 29, 2017, to December 14, 2018, in
      Muar. Our sample size was 259. Ethical consent was obtained from the Institution 
      Ethical Committee. RESULTS: A total of 259 schoolteachers from both primary and
      secondary schools in Muar were included in this study. In our study, 81.1% of the
      teachers responded that they can easily educate their students about food
      poisoning. Most of them (93.1%) were ready to receive notifications on food
      poisoning in any mode, and about 72% of the teachers preferred WhatsApp as their 
      mode of receiving notification. The least (1.2%) preferred mode of notification
      was LINE (a social app). Teachers' willingness to disseminate the information
      regarding food poisoning was also higher (98.5%). CONCLUSIONS: We concluded that 
      majority of the schoolteachers had a good perception and were ready to receive
      the notifications on food poisoning through WhatsApp as a part of education to
      the students.
CI  - Copyright: (c) 2020 Journal of Education and Health Promotion.
FAU - Marzo, Roy Rillera
AU  - Marzo RR
AD  - Department of Community Medicine, Faculty of Medicine, Asia Metropolitan
      University, Cheras, Selangor, Malaysia.
FAU - Bhattacharya, Sudip
AU  - Bhattacharya S
AD  - Department of Community Medicine, Himalayan Institute of Medical Sciences,
      Dehradun, Uttarakhand, India.
FAU - Niranjan, Vikram
AU  - Niranjan V
AD  - Department of Health Sciences, University of Limerick, Limerick, Ireland.
FAU - Shagaran, Kauseliah
AU  - Shagaran K
AD  - Department of Community and Health, Asia Metropolitan University, Cheras,
      Selangor, Malaysia.
FAU - Mohd Idris, Muhammad Azmer Bin
AU  - Mohd Idris MAB
AD  - Department of Community and Health, Asia Metropolitan University, Cheras,
      Selangor, Malaysia.
FAU - Clement, Benjamin Jackson
AU  - Clement BJ
AD  - Department of Community and Health, Asia Metropolitan University, Cheras,
      Selangor, Malaysia.
FAU - Raman, Vanishree
AU  - Raman V
AD  - Department of Community and Health, Asia Metropolitan University, Cheras,
      Selangor, Malaysia.
FAU - Sinappanrajah, Shereen Anne A/P
AU  - Sinappanrajah SAA
AD  - Department of Community and Health, Asia Metropolitan University, Cheras,
      Selangor, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200228
PL  - India
TA  - J Educ Health Promot
JT  - Journal of education and health promotion
JID - 101593794
PMC - PMC7161664
OTO - NOTNLM
OT  - Food poisoning
OT  - notification
OT  - readiness
OT  - schoolteachers
COIS- There are no conflicts of interest.
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2019/12/02 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.4103/jehp.jehp_505_19 [doi]
AID - JEHP-9-43 [pii]
PST - epublish
SO  - J Educ Health Promot. 2020 Feb 28;9:43. doi: 10.4103/jehp.jehp_505_19.
      eCollection 2020.


PMID- 32318586
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2297-1769 (Print)
IS  - 2297-1769 (Linking)
VI  - 7
DP  - 2020
TI  - Ethical Considerations for Wildlife Reintroductions and Rewilding.
PG  - 163
LID - 10.3389/fvets.2020.00163 [doi]
AB  - The recovery of many populations of large carnivores and herbivores in major
      parts of Europe and North America offers ecosystem services and opportunities for
      sustainable utilization of wildlife. Examples of services are hunting, meat, and 
      skin, along with less invasive utilization such as ecotourism and wildlife
      spotting. An increasing number of studies also point out the ecosystem function, 
      landscape engineering, and cascading effects of wildlife as values for human
      existence, biodiversity conservation, and ecosystem resilience. Within this
      framework, the concept of rewilding has emerged as a means to add to the
      wilderness through either supplementary release of wildlife species already
      present or reintroduction of species formerly present in a certain area. The
      latter involves translocation of species from other geographical areas, releases 
      from captivity, feralization, retro-breeding, or de-domestication of breeds for
      which the wild ancestor is extinct. While all these initiatives aim to reverse
      some of the negative human impacts on life on earth, some pose challenges such as
      conflicts of interest between humans and wildlife in, for example, forestry,
      agriculture, traffic, or disease dynamics (e.g., zoonosis). There are also
      welfare aspects when managing wildlife populations with the purpose to serve
      humans or act as tools in landscape engineering. These welfare aspects are
      particularly apparent when it comes to releases of animals handled by humans,
      either from captivity or translocated from other geographical areas. An ethical
      values clash is that translocation can involve suffering of the actual
      individual, while also contributing to reintroduction of species and
      reestablishment of ecological functions. This paper describes wildlife recovery
      in Europe and North America and elaborates on ethical considerations raised by
      the use of wildlife for different purposes, in order to find ways forward that
      are acceptable to both the animals and humans involved. The reintroduction ethics
      aspects raised are finally formulated in 10 guidelines suggested for management
      efforts aimed at translocating wildlife or reestablishing wilderness areas.
CI  - Copyright (c) 2020 Thulin and Rocklinsberg.
FAU - Thulin, Carl-Gustaf
AU  - Thulin CG
AD  - Department of Anatomy, Physiology and Biochemistry, Swedish University of
      Agricultural Sciences, Uppsala, Sweden.
FAU - Rocklinsberg, Helena
AU  - Rocklinsberg H
AD  - Department of Animal Environment and Health, Swedish University of Agricultural
      Sciences, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200403
PL  - Switzerland
TA  - Front Vet Sci
JT  - Frontiers in veterinary science
JID - 101666658
PMC - PMC7146822
OTO - NOTNLM
OT  - animal welfare
OT  - conservation
OT  - ecosystem service
OT  - ethics
OT  - reintroduction
OT  - restoration
OT  - rewilding
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2018/08/23 00:00 [received]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.3389/fvets.2020.00163 [doi]
PST - epublish
SO  - Front Vet Sci. 2020 Apr 3;7:163. doi: 10.3389/fvets.2020.00163. eCollection 2020.


PMID- 32318524
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - DSD: A Discussion at the Crossroads of Medicine, Human Rights, and Politics.
PG  - 125
LID - 10.3389/fped.2020.00125 [doi]
AB  - Over the past years, the topic of "disorder/differences in sex development (DSD)"
      or "intersex" people has become subject of the international political agenda. In
      2017, a resolution of the Parliamentary Assembly of the Council of Europe argued 
      that the practice of surgically modifying intersex children's genitals without
      medical necessity and without consent of the person concerned is a human rights
      violation. This resolution and related statements might impact heavily on
      pediatric urologists and their practice. While this resolution concerns a form of
      soft law and is not directly enforceable in member states, it might impact the
      national debates concerning legislation and medical guidelines on DSD.
      Consequently, this article reflects on this discussion by elaborating on the
      importance of human rights in our evolving understanding and legislation on DSD
      and other gender and sexuality issues in general. It constitutes a plea for a
      dialogue between medical professionals, lawmakers and human rights scholars which
      would lead to legislation and medical guidelines that take a holistic and
      rights-based approach.
CI  - Copyright (c) 2020 De Sutter.
FAU - De Sutter, Petra
AU  - De Sutter P
AD  - Department for Reproductive Medicine, Ghent University, Ghent, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7147372
OTO - NOTNLM
OT  - Council of Europe
OT  - DSD
OT  - bio-ethics
OT  - human rights
OT  - intersex
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2019/12/22 00:00 [received]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.3389/fped.2020.00125 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Apr 3;8:125. doi: 10.3389/fped.2020.00125. eCollection 2020.


PMID- 32318365
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2249-4863 (Print)
IS  - 2249-4863 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Feb
TI  - How effective is the virtual primary healthcare centers? An experience from rural
      India.
PG  - 465-469
LID - 10.4103/jfmpc.jfmpc_1124_19 [doi]
AB  - INTRODUCTION: Virtual clinic is a new concept in India. This summary describes
      that how a virtual clinic is transforming the healthcare scenario in rural India.
      Virtual clinic is based on a social business model, which may involve diverse
      stakeholders to promote primary care. AIM: This virtual e-clinic aims to expand
      health outreach in rural and hard-to-reach areas of India and provide primary
      health care services by connecting local practitioners and health workers
      visiting patients with qualified allopathic doctors in city through video
      conferencing technologies. METHODOLOGY: This was a cross-sectional study
      evaluating the feasibility and acceptance of virtual primary care. A convenient
      sampling method was used. Data on demographic profiles, morbidity patterns, and
      referrals were collected with proper consent. This virtual clinic comprises of
      smartphones, monitors, and assistive devices so that patient can interact with
      the doctors through video-conferencing and can have authenticated prescriptions
      with standardized protocols. The private organization who initiated the virtual
      care program had two centers at the beginning and gradually expanded them to 20
      in Uttar Pradesh. Consultations charges were kept minimum to no-profit, no-loss. 
      Data were collected from January 2019 to June 2010. RESULTS: Total number of
      consultations made was 800. Out of 800 patients, 157 patients belonged to age
      group of >/=60 years. Mean age the patient was 56 +/- 1.56 years, among them 421 
      (52.62%) were male. The participants actively engaged in clinical interactions
      and completed full sessions of consultations, which highlight the acceptability
      of the virtual care system and feasibility of effective patient-provider
      communication and service delivery using digital technologies. CONCLUSION: The
      concept of virtual primary care is becoming very popular in rural region where no
      qualified doctors are available. The initial results of this technological
      startup appears to be promising; however, it is necessary to evaluate the quality
      of care, health outcomes, potentials to integrate such innovations in existing
      primary care, and the legal as well as ethical issues in the future research.
CI  - Copyright: (c) Journal of Family Medicine and Primary Care.
FAU - Angrish, Siddharth
AU  - Angrish S
AD  - Chief Executive Officer, Jiyyo Innovations, Chandigarh, India.
FAU - Sharma, Meghna
AU  - Sharma M
AD  - Vice President, Medical Affairs at Jiyyo, Chandigarh, India.
FAU - Bashar, Md Abu
AU  - Bashar MA
AD  - Department of Community Medicine, MM Institute of Medical Sciences and Research, 
      Mullana, Ambala, Haryana, India.
FAU - Tripathi, Shailesh
AU  - Tripathi S
AD  - Department of Health and Family Welfare, Uttarpradesh, India.
FAU - Hossain, Md Mahbub
AU  - Hossain MM
AD  - School of Public Health, Texas A & M University, College Station, TX, USA.
FAU - Bhattacharya, Sudip
AU  - Bhattacharya S
AD  - Department of Community Medicine, Himalayan Institute of Medical Sciences,
      Dehradun, India.
FAU - Singh, Amarjeet
AU  - Singh A
AD  - Department of Community Medicine, PGIMER, Chandigarh, India.
LA  - eng
PT  - Journal Article
DEP - 20200228
PL  - India
TA  - J Family Med Prim Care
JT  - Journal of family medicine and primary care
JID - 101610082
PMC - PMC7113938
OTO - NOTNLM
OT  - Digital health
OT  - e-clinic
OT  - e-referral
OT  - telehealth
OT  - telemedicine
OT  - virtual clinic
COIS- There are no conflicts of interest.
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/01/24 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.4103/jfmpc.jfmpc_1124_19 [doi]
AID - JFMPC-9-465 [pii]
PST - epublish
SO  - J Family Med Prim Care. 2020 Feb 28;9(2):465-469. doi:
      10.4103/jfmpc.jfmpc_1124_19. eCollection 2020 Feb.


PMID- 32317996
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Research on Supportive Psychosocial, Drug Treatment, and Health Education
      Intervention and Health Management Model of Community-Residing Elderly Adults
      With Late Life Depression in Liaoning Province: A Protocol.
PG  - 267
LID - 10.3389/fpsyt.2020.00267 [doi]
AB  - BACKGROUND: Late life depression (LLD), a common mental disorder, has become an
      increasingly acute public health concern with a quickly expanding geriatric
      population worldwide. To our knowledge, however, the incidence of LLD in northern
      cities in China has not been empirically investigated, and many elderly people
      with depressive moods and mild depressive symptoms have not been given sufficient
      attention. METHODS/DESIGN: This is a multi-stage and prospective study. The first
      stage is a cross-sectional study, investigating the epidemiological
      characteristics of LLD in northern China and exploring the biological,
      psychological, and social risk factors for developing LLD based on a set of
      questionnaires from 6,800 community-residing elderly adults. The second stage
      involves statistical analysis, by constructing a risk factor model for LLD and
      analyzing their direct and indirect functional routes on the basis of structural 
      equation modeling. The third stage is an experimental study a total of 60 elderly
      patients with LLD and their principle caregivers will be randomly assigned to
      control and trial groups. The trial group patients and caregivers will undergo
      supportive psychosocial, drug treatment, and health education (PDH) intervention,
      whereas the control group patients and caregivers will be treated routinely
      (treatment as routine, TAR, which includes drug treatment and health education). 
      At the end of the intervention, depressive symptoms, quality of life, and the
      social and cognitive functioning of the patients in the two groups will be
      respectively assessed at a baseline and after 6, 9, and 12 months
      post-intervention by employing scales and questionnaires to analyze the
      effectiveness of the supportive PDH intervention measures in comparison with TAR.
      Ultimately, a supportive PDH intervention and health management model will be
      obtained by combining PDH intervention with mental health institutions, community
      health services, and aging families as the main line. DISCUSSION: This study will
      provide strong and suitable evidence for enhancing the integrated supportive PDH 
      intervention and health management model of LLD patients among community-dwelling
      residents. ETHICS: This study has been approved by the Ethics and Research
      Committee of the First Affiliated Hospital of China Medical University (approval 
      No. [2019] 2019-312-2).
CI  - Copyright (c) 2020 Duan, Shao, Fu, Tian and Zhu.
FAU - Duan, Li
AU  - Duan L
AD  - Department of Psychiatry, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
FAU - Shao, Xiaojun
AU  - Shao X
AD  - Department of Psychiatry, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
FAU - Fu, Chunfeng
AU  - Fu C
AD  - Department of Psychiatry, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
FAU - Tian, Chunsheng
AU  - Tian C
AD  - Department of Psychiatry, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
FAU - Zhu, Gang
AU  - Zhu G
AD  - Department of Psychiatry, The First Affiliated Hospital of China Medical
      University, Shenyang, China.
AD  - Central Laboratory, The First Affiliated Hospital of China Medical University,
      Shenyang, China.
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7147631
OTO - NOTNLM
OT  - community
OT  - health management
OT  - late life depression
OT  - risk factor
OT  - supportive PDH intervention
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.3389/fpsyt.2020.00267 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Apr 3;11:267. doi: 10.3389/fpsyt.2020.00267. eCollection
      2020.


PMID- 32317925
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210317
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 14
DP  - 2020
TI  - Dopaminergic Progenitors Derived From Epiblast Stem Cells Function Similarly to
      Primary VM-Derived Progenitors When Transplanted Into a Parkinson's Disease
      Model.
PG  - 312
LID - 10.3389/fnins.2020.00312 [doi]
AB  - Neural transplantation in neurodegenerative diseases such as Parkinson's disease 
      (PD) offers to replace cells lost during the progression of the disease process. 
      Primary fetal ventral mesencephalon (VM), the origin of bona fide midbrain
      dopaminergic (DAergic) precursors, is currently the gold standard source of cells
      for transplantation in PD. However, the use of tissue from this source raises
      ethical and logistical constraints necessitating the need for alternative
      supplies of donor cells. The requirement of any alternative donor cell source is 
      to have the capability to generate authentic mature DAergic neurons, which could 
      be utilized in cell-replacement strategies. Mouse pluripotent stem cells can
      efficiently generate electrochemically mature midbrain DAergic precursors in
      vitro using a stepwise control of FGF signaling. Here, we have compared DAergic
      transplants derived from two progenitor cell sources in an allograft system:
      mouse epiblast stem cells (EpiSC) and primary fetal mouse VM tissue. Cells were
      transplanted into the striatum of 6-OHDA lesioned mice pre-treated with L-DOPA.
      Drug-induced rotations, a number of motor tests and drug-induced abnormal
      involuntary movements (AIMs) were assessed. Functional improvements were
      demonstrated post-transplantation in some behavioral tests, with no difference in
      graft volume or the number of TH immuno-positive cells in the grafts of the two
      transplant groups. L-DOPA-induced AIMs and amphetamine-induced AIMs were observed
      in both transplant groups, with no differences in rate or severity between the
      two groups. Collectively, in this mouse-to-mouse allograft system, we report no
      significant differences in the functional ability between the gold standard
      primary VM derived and pluripotent stem cell-derived DAergic transplants.
CI  - Copyright (c) 2020 Precious, Smith, Heuer, Jaeger, Lane, Dunnett, Li, Kelly and
      Rosser.
FAU - Precious, Sophie V
AU  - Precious SV
AD  - Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United
      Kingdom.
FAU - Smith, Gaynor A
AU  - Smith GA
AD  - School of Medicine, UK Dementia Research Institute, Cardiff University, Cardiff, 
      United Kingdom.
FAU - Heuer, Andreas
AU  - Heuer A
AD  - Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United
      Kingdom.
AD  - Behavioural Neuroscience Laboratory, Department of Experimental Medical Sciences,
      Lund University, Lund, Sweden.
FAU - Jaeger, Ines
AU  - Jaeger I
AD  - Stem Cell Neurogenesis Group, School of Medicine and Biosciences, Neuroscience
      and Mental Health Research Institute, Cardiff University, Cardiff, United
      Kingdom.
FAU - Lane, Emma L
AU  - Lane EL
AD  - School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff,
      United Kingdom.
FAU - Dunnett, Stephen B
AU  - Dunnett SB
AD  - Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United
      Kingdom.
FAU - Li, Meng
AU  - Li M
AD  - Stem Cell Neurogenesis Group, School of Medicine and Biosciences, Neuroscience
      and Mental Health Research Institute, Cardiff University, Cardiff, United
      Kingdom.
FAU - Kelly, Claire M
AU  - Kelly CM
AD  - School of Health Sciences, Cardiff Metropolitan University, Cardiff, United
      Kingdom.
FAU - Rosser, Anne E
AU  - Rosser AE
AD  - Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United
      Kingdom.
AD  - Wales Brain Repair and Intracranial Neurotherapeutics Unit, School of Medicine,
      Cardiff University, Cardiff, United Kingdom.
AD  - MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine,
      Cardiff University, Cardiff, United Kingdom.
LA  - eng
GR  - MC_PC_16030/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/L010305/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R022429/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200407
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC7154167
OTO - NOTNLM
OT  - Parkinson's disease
OT  - dopaminergic neurons
OT  - primary fetal ventral mesencephalon
OT  - stem cells
OT  - transplantation
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.3389/fnins.2020.00312 [doi]
PST - epublish
SO  - Front Neurosci. 2020 Apr 7;14:312. doi: 10.3389/fnins.2020.00312. eCollection
      2020.


PMID- 32317890
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1658-354X (Print)
VI  - 14
IP  - 2
DP  - 2020 Apr-Jun
TI  - Deliberate reattempts at blind double lumen tube placement: A grave ethical
      concern.
PG  - 261-262
LID - 10.4103/sja.SJA_538_19 [doi]
FAU - Kumar, Akhil
AU  - Kumar A
AD  - Department of Anaesthesiology, Sir Ganga Ram Hospital, New Delhi, India.
FAU - Dutta, Amitabh
AU  - Dutta A
AD  - Department of Anaesthesiology, Sir Ganga Ram Hospital, New Delhi, India.
FAU - Sharma, Shikha
AU  - Sharma S
AD  - Department of Anaesthesiology, Sir Ganga Ram Hospital, New Delhi, India.
FAU - Sood, Jayashree
AU  - Sood J
AD  - Department of Anaesthesiology, Sir Ganga Ram Hospital, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200305
PL  - India
TA  - Saudi J Anaesth
JT  - Saudi journal of anaesthesia
JID - 101500601
PMC - PMC7164468
COIS- There are no conflicts of interest.
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/08/23 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.4103/sja.SJA_538_19 [doi]
AID - SJA-14-261 [pii]
PST - ppublish
SO  - Saudi J Anaesth. 2020 Apr-Jun;14(2):261-262. doi: 10.4103/sja.SJA_538_19. Epub
      2020 Mar 5.


PMID- 32317845
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1078-4497 (Print)
IS  - 1078-4497 (Linking)
VI  - 37
IP  - 3
DP  - 2020 Mar
TI  - To Prevent Pernicious Political Activities: The Hatch Act and Government Ethics.
PG  - 105-107
FAU - Geppert, Cynthia M A
AU  - Geppert CMA
LA  - eng
PT  - Editorial
PL  - United States
TA  - Fed Pract
JT  - Federal practitioner : for the health care professionals of the VA, DoD, and PHS
JID - 9500574
PMC - PMC7170168
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
PST - ppublish
SO  - Fed Pract. 2020 Mar;37(3):105-107.


PMID- 32317815
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 0300-1652 (Print)
IS  - 0300-1652 (Linking)
VI  - 61
IP  - 1
DP  - 2020 Jan-Feb
TI  - A Comparison of Pain Scores in Neonatal Circumcision with or without Local
      Anesthesia in Jos, Nigeria.
PG  - 11-15
LID - 10.4103/nmj.NMJ_68_19 [doi]
AB  - INTRODUCTION: Neonatal circumcisions are commonly performed in Nigeria, most
      often without anesthesia. The aim of this study was to determine whether
      anesthesia was required for neonatal circumcision. MATERIALS AND METHODS: All
      new-born male neonates presenting for routine circumcision were considered for
      inclusion in the study. This was a randomized control study, comparing pain
      scores during circumcision with local anesthesia or without local anesthesia. A
      total of 72 neonates were randomly assigned to the two groups using
      computer-generated random numbers, with 36 in each group. The neonates were not
      matched for age or weight. All the anesthetic procedures and circumcisions were
      performed in identical manner by the principal investigators using the plastic
      bell technique. Approval for the study was obtained from the Research Ethics
      Committee of the hospital. Written voluntary informed consent was obtained from
      the parents of the neonates. RESULTS: The mean age and weight of the neonates in 
      the study were 17 +/- 2 days and 3.2 +/- 0.68 kg, respectively. The mean
      Neonatal/Infant pain score was 4.8 in the local anesthesia group and 6.0 in those
      without anesthesia. The mean transcutaneous PO2 was 90.47 +/- 7.53 in those with 
      anesthesia compared to 85.83 +/- 5.61 in those without anesthesia. The mean heart
      rate was 133.88 +/- 35.00 beats/min in the anesthesia group compared to 152.11
      +/- 79.80 in those without anesthesia. Neonates circumcised without local
      anesthesia had higher respiratory rate compared to those circumcised with local
      anesthesia. CONCLUSION: Neonates circumcised without local anesthesia had higher 
      mean pain scores, heart rate, lower oxygen saturation and increased mean
      respiratory rate than those that had local anesthesia. Local anesthesia should be
      routinely used during neonatal circumcision.
CI  - Copyright: (c) 2020 Nigerian Medical Journal.
FAU - Fikin, Aminu Gango
AU  - Fikin AG
AD  - Department of Family Medicine, Plateau State Specialist Hospital, Jos, Nigeria.
FAU - Yohanna, Stephen
AU  - Yohanna S
AD  - Department of Family Medicine, Bingham University Teaching Hospital, Jos,
      Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200302
PL  - Nigeria
TA  - Niger Med J
JT  - Nigerian medical journal : journal of the Nigeria Medical Association
JID - 0315137
PMC - PMC7113820
OTO - NOTNLM
OT  - Local anesthesia
OT  - neonatal circumcision
OT  - plateau specialist hospital
COIS- There are no conflicts of interest.
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/09/22 00:00 [revised]
PHST- 2019/11/17 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - 10.4103/nmj.NMJ_68_19 [doi]
AID - NMJ-61-11 [pii]
PST - ppublish
SO  - Niger Med J. 2020 Jan-Feb;61(1):11-15. doi: 10.4103/nmj.NMJ_68_19. Epub 2020 Mar 
      2.


PMID- 32317595
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1530-0293 (Electronic)
IS  - 0090-3493 (Linking)
VI  - 48
IP  - 6
DP  - 2020 Jun
TI  - Policies for Mandatory Ethics Consultations at U.S. Academic Teaching Hospitals: 
      A Multisite Survey Study.
PG  - 847-853
LID - 10.1097/CCM.0000000000004343 [doi]
AB  - OBJECTIVES: To determine the number of top-ranked U.S. academic institutions that
      require ethics consultation for specific adult clinical circumstances (e.g.,
      family requests for potentially inappropriate treatment) and to detail those
      circumstances and the specific clinical scenarios for which consultations are
      mandated. DESIGN: Cross-sectional survey study, conducted online or over the
      phone between July 2016 and October 2017. SETTING: We identified the top 50
      research medical schools through the 2016 U.S. News and World Report rankings.
      The primary teaching hospital for each medical school was included. SUBJECTS: The
      chair/director of each hospital's adult clinical ethics committee, or a suitable 
      alternate representative familiar with ethics consultation services, was
      identified for study recruitment. INTERVENTIONS: None. MEASUREMENTS AND MAIN
      RESULTS: A representative from the adult ethics consultation service at each of
      the 50 target hospitals was identified. Thirty-six of 50 sites (72%) consented to
      participate in the study, and 18 (50%) reported having at least one current
      mandatory consultation policy. Of the 17 sites that completed the survey and
      listed their triggers for mandatory ethics consultations, 20 trigger scenarios
      were provided, with three sites listing two distinct clinical situations. The
      majority of these triggers addressed family requests for potentially
      inappropriate treatment (9/20, 45%) or medical decision-making for unrepresented 
      patients lacking decision-making capacity (7/20, 35%). Other triggers included
      organ donation after circulatory death, initiation of extracorporeal membrane
      oxygenation, denial of valve replacement in patients with subacute bacterial
      endocarditis, and posthumous donation of sperm. Twelve (67%) of the 18 sites with
      mandatory policies reported that their protocol(s) was formally documented in
      writing. CONCLUSIONS: Among top-ranked academic medical centers, the existence
      and content of official policies regarding situations that mandate ethics
      consultations are variable. This finding suggests that, despite recent critical
      care consensus guidelines recommending institutional review as standard practice 
      in particular scenarios, formal adoption of such policies has yet to become
      widespread and uniform.
FAU - Neal, Jonathan B
AU  - Neal JB
AD  - University of Connecticut School of Medicine, Farmington, CT.
FAU - Pearlman, Robert A
AU  - Pearlman RA
AD  - National Center for Ethics in Health Care, Veterans Health Administration,
      Seattle, WA.
AD  - University of Washington School of Medicine, Seattle, WA.
FAU - White, Douglas B
AU  - White DB
AD  - Department of Critical Care Medicine, University of Pittsburgh School of
      Medicine, Pittsburgh, PA.
FAU - Tolchin, Benjamin
AU  - Tolchin B
AD  - Department of Neurology, Yale School of Medicine, New Haven, CT.
AD  - Center for Neuroepidemiology and Clinical Neurological Research, Yale School of
      Medicine, New Haven, CT.
FAU - Sheth, Kevin N
AU  - Sheth KN
AD  - Center for Neuroepidemiology and Clinical Neurological Research, Yale School of
      Medicine, New Haven, CT.
AD  - Division of Neurocritical Care and Emergency Neurology, Department of Neurology, 
      Yale School of Medicine, New Haven, CT.
FAU - Bernat, James L
AU  - Bernat JL
AD  - Dartmouth Geisel School of Medicine, Hanover, NH.
FAU - Hwang, David Y
AU  - Hwang DY
AD  - Center for Neuroepidemiology and Clinical Neurological Research, Yale School of
      Medicine, New Haven, CT.
AD  - Division of Neurocritical Care and Emergency Neurology, Department of Neurology, 
      Yale School of Medicine, New Haven, CT.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
SB  - IM
CIN - Crit Care Med. 2020 Jun;48(6):928-929. PMID: 32433083
MH  - Cross-Sectional Studies
MH  - Ethics Consultation/*organization & administration/standards
MH  - Health Services Misuse
MH  - Hospitals, Teaching/*ethics
MH  - Humans
MH  - United States
EDAT- 2020/04/23 06:00
MHDA- 2021/05/20 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1097/CCM.0000000000004343 [doi]
PST - ppublish
SO  - Crit Care Med. 2020 Jun;48(6):847-853. doi: 10.1097/CCM.0000000000004343.


PMID- 32317059
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Apr 1
TI  - ScreenTB: a tool for prioritising risk groups and selecting algorithms for
      screening for active tuberculosis.
PG  - 367-375
LID - 10.5588/ijtld.19.0284 [doi]
AB  - SETTING AND OBJECTIVES: There is an urgent need to improve tuberculosis (TB) case
      detection globally. This would require greater focus on the implementation of TB 
      screening programs. However, to be productive, cost-effective, and ethical, TB
      screening efforts should be tailored to their local context, targeted to the
      populations most likely to benefit and utilizing diagnostic tools with sufficient
      accuracy.DESIGN AND RESULTS: We have developed an online tool, ScreenTB to help
      National TB Programmes (NTPs) and their partners plan TB screening activities by 
      modeling the potential outcomes of screening programs, including yield of TB
      cases diagnosed (true- and false-positives), costs, and cost-effectiveness,
      specific to the populations screened and the diagnostic algorithms used. In
      Myanmar, ScreenTB was used to assist the NTP in prioritizing risk groups for
      screening efforts and selecting appropriate screening algorithms to maximize case
      detection and minimize false-positive diagnoses.CONCLUSION: The ScreenTB tool can
      help facilitate the prioritization of risk groups for screening and the selection
      of appropriate screening algorithms. This is useful when used as part of a larger
      planning process that considers feasibility of screening, vulnerability of risk
      groups, potential impact of screening on TB transmission, human rights
      implications of screening and equity in health care access.
FAU - Miller, C R
AU  - Miller CR
AD  - Global TB Programme, World Health Organization, Geneva, Switzerland.
FAU - Mitchell, E M H
AU  - Mitchell EMH
AD  - General Epidemiology and Disease Control, Department of Public Health, Institute 
      of Tropical Medicine, Antwerp, Belgium.
FAU - Nishikiori, N
AU  - Nishikiori N
AD  - Global TB Programme, World Health Organization, Geneva, Switzerland.
FAU - Zwerling, A
AU  - Zwerling A
AD  - University of Ottawa, School of Epidemiology & Public Health, Ottawa, ON, Canada.
FAU - Lonnroth, K
AU  - Lonnroth K
AD  - Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
SB  - IM
MH  - Algorithms
MH  - Humans
MH  - Mass Screening
MH  - Myanmar
MH  - Risk Factors
MH  - *Tuberculosis/diagnosis/epidemiology
EDAT- 2020/04/23 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - 10.5588/ijtld.19.0284 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2020 Apr 1;24(4):367-375. doi: 10.5588/ijtld.19.0284.


PMID- 32316980
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1757-7241 (Electronic)
IS  - 1757-7241 (Linking)
VI  - 28
IP  - 1
DP  - 2020 Apr 21
TI  - Therapeutic management of severe hypothermia with veno-arterial ECMO: where do we
      stand? Case report and review of the current literature.
PG  - 30
LID - 10.1186/s13049-020-00723-y [doi]
AB  - BACKGROUND: Severe accidental hypothermia is associated with high morbidity and
      mortality. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides
      an efficient rewarming method with complete cardiopulmonary support. The use of
      VA-ECMO for this indication has greatly improved the vital and functional
      prognosis of patients. CASE PRESENTATION: We report a case of a 46-year-old
      patient who was treated for severe hypothermia with a temperature of 22.4 degrees
      C along with initial cardiac arrest, whose progression was favorable after the
      implementation of VA-ECMO support. Two months after initial cardiac arrest, the
      patient was reassessed and showed signs of complete recovery with regard to his
      mental and physical capacities. CONCLUSIONS: The recent international
      publications and groups of experts recommend the use of VA ECMO as the gold
      standard therapy to treat severe hypothermia. Therefore, it seems suitable to
      update the current knowledge on the topic by analysing the latest international
      publications. The performance of this technique calls into question ethical and
      economic factors. Two distinct medical teams tried to identify and regroup
      prognosis factors in predictive survival scores. They raise the question of the
      utility of these scores in clinical practice. Indeed, according to which survival
      rate should we proceed to prolonged resuscitation and implement VA-ECMO?
      Additional studies will be needed for external approval of these survival scores,
      and additional reflection by experts will be required.
FAU - Ledoux, Aurelien
AU  - Ledoux A
AD  - Department of Intensive Care Medicine, General Hospital of Valenciennes,
      Valenciennes, France.
FAU - Saint Leger, Piehr
AU  - Saint Leger P
AD  - Department of Intensive Care Medicine, General Hospital of Valenciennes,
      Valenciennes, France. saintleger-p@ch-valenciennes.fr.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20200421
PL  - England
TA  - Scand J Trauma Resusc Emerg Med
JT  - Scandinavian journal of trauma, resuscitation and emergency medicine
JID - 101477511
SB  - IM
MH  - Extracorporeal Membrane Oxygenation/*methods
MH  - Heart Arrest/etiology/*therapy
MH  - Humans
MH  - Hypothermia/etiology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - *Resuscitation
MH  - Rewarming/*methods
PMC - PMC7175497
OTO - NOTNLM
OT  - Cardiac arrest
OT  - Extracorporeal membrane oxygenation
OT  - Hypothermia
OT  - Rewarming
EDAT- 2020/04/23 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/04/23 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1186/s13049-020-00723-y [doi]
AID - 10.1186/s13049-020-00723-y [pii]
PST - epublish
SO  - Scand J Trauma Resusc Emerg Med. 2020 Apr 21;28(1):30. doi:
      10.1186/s13049-020-00723-y.


PMID- 32316962
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 21
TI  - The understanding of research ethics at health sciences schools in Jordan: a
      cross-sectional study.
PG  - 121
LID - 10.1186/s12909-020-02040-5 [doi]
AB  - BACKGROUND: Research ethics is required for high-quality research that positively
      influences society. There is limited understanding of research ethics in Middle
      Eastern countries including Jordan. Here, we aim to investigate the level of
      understanding of research ethics principles among health sciences faculty members
      in Jordan. METHODS: This is a cross sectional study where faculty members from
      the University of Jordan were surveyed for their knowledge and, attitude of
      research ethics principles. The study was conducted in the period between July
      2016 to July 2017 using a customized-design questionnaire involving demographic
      data and participants' contributions toward research, and assessment of
      participants' knowledge, belief and attitude towards research ethics. Different
      question-formats have been used including multiple-choice, yes or no, and a four 
      point Likert-type questions. Obtained responses were tabulated according to
      gender, academic-rank, and knowledge about research ethics principles. RESULTS:
      The study had a response rate of 51%. Among the 137 participants of this study,
      most (96%) were involved in human and animal research, yet, only 2/3 had prior
      training in research ethics. Moreover, 91% believed that investigators should
      have training in research ethics and 87% believed that there should be a
      mandatory postgraduate course on that. The average correct scores for correct
      understanding of researchers towards research ethics was 62%. Yet, there were
      some misconceptions about the major ethical principles as only 43% identified
      them correctly. Additionally, the role of research ethics committees was not well
      understood by most of the respondents. CONCLUSIONS: Although there is acceptable 
      knowledge about research ethics, discrepancies in understanding in research
      ethics principles seems to exist. There is a large support for further training
      in responsible conduct of research by faculty in health sciences in Jordan. Thus,
      such training should be required by universities to address this knowledge gap in
      order to improve research quality and its impact on society.
FAU - Tarboush, Nafez Abu
AU  - Tarboush NA
AD  - Department of Biochemistry and Physiology, School of Medicine, The University of 
      Jordan, Amman, 11942, Jordan. natarboush@ju.edu.jo.
FAU - Alkayed, Zaid
AU  - Alkayed Z
AD  - Internal Medicine Unit, Psychiatry Division, Jordan University Hospital, Amman,
      Jordan.
FAU - Alzoubi, Karem H
AU  - Alzoubi KH
AD  - Department of Clinical Pharmacy, Jordan University of Science and Technology,
      Irbid, Jordan.
FAU - Al-Delaimy, Wael K
AU  - Al-Delaimy WK
AD  - Department of Family Medicine and Public Health, University of California San
      Diego, San Diego, CA, USA.
LA  - eng
GR  - 5R25TW010026-02/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200421
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Adult
MH  - *Allied Health Occupations
MH  - Authorship
MH  - Conflict of Interest
MH  - Cross-Sectional Studies
MH  - Ethics Committees, Research
MH  - *Ethics, Research
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Jordan
MH  - Male
MH  - Middle Aged
MH  - Ownership
MH  - Surveys and Questionnaires
PMC - PMC7175529
OTO - NOTNLM
OT  - Authorship
OT  - Awareness
OT  - Conflict of interest
OT  - Ethical principles
OT  - Informed consent
OT  - Ownership
OT  - Research ethics committees
EDAT- 2020/04/23 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/04/23 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1186/s12909-020-02040-5 [doi]
AID - 10.1186/s12909-020-02040-5 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Apr 21;20(1):121. doi: 10.1186/s12909-020-02040-5.


PMID- 32316753
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20200707
IS  - 0261-1929 (Print)
IS  - 0261-1929 (Linking)
VI  - 48
IP  - 1
DP  - 2020 Jan
TI  - It's Time to Reconsider The Principles of Humane Experimental Technique.
PG  - 40-46
LID - 10.1177/0261192920911339 [doi]
AB  - In the 60 years since the publication of The Principles of Humane Experimental
      Technique, the Three Rs (Reduction, Refinement, Replacement) proposed by William 
      Russell and Rex Burch have gradually been accepted throughout the world as ways
      of facing up to the ethical and scientific dilemmas involved in animal
      experimentation. However, the scale of animal use and the use of animals as
      models of humans has continued, seemingly almost unchallenged in much of the
      scientific community, despite the warnings about models, species differences and 
      human variation spelled out in the The Principles. In this Comment, it is
      proposed that it is time to move away from the animal welfare focus of the Three 
      Rs, in favour of a wider concept of humanity, which also embraces human welfare. 
      In addition, since less than 10% of new drugs successfully pass from preclinical 
      testing, which is highly reliant on animal procedures, to acceptance for clinical
      use, it is argued that the aim should not be to directly replace animal testing
      with non-animal methods with similar aims and which produce similar results, but 
      to take advantage of developments in cell and molecular biology and in computer
      science, to devise new, different, appropriate, specific and intelligent
      stand-alone preclinical testing strategies that are applicable to particular
      human situations.
FAU - Balls, Michael
AU  - Balls M
AD  - Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - England
TA  - Altern Lab Anim
JT  - Alternatives to laboratory animals : ATLA
JID - 8110074
SB  - IM
MH  - *Animal Experimentation/standards
MH  - *Animal Testing Alternatives/trends
MH  - *Animal Welfare/standards/trends
MH  - Animals
MH  - Humans
MH  - Publishing
MH  - *Research Design/trends
OTO - NOTNLM
OT  - Three Rs
OT  - alternatives
OT  - animal experiments
OT  - drug development
OT  - inhumanity
OT  - reduction
OT  - refinement
OT  - replacement
EDAT- 2020/04/23 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
AID - 10.1177/0261192920911339 [doi]
PST - ppublish
SO  - Altern Lab Anim. 2020 Jan;48(1):40-46. doi: 10.1177/0261192920911339. Epub 2020
      Apr 21.


PMID- 32316548
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 8
DP  - 2020 Apr 17
TI  - Emotional Complications in Midwives Participating in Pregnancy Termination
      Procedures-Polish Experience.
LID - E2776 [pii]
LID - 10.3390/ijerph17082776 [doi]
AB  - Background: Ethically controversial medical procedures, such as the termination
      of pregnancy, are frequently associated with a discrepancy between personal
      attitude and values versus requirements related to a professional situation. The 
      study aimed to assess emotional complications in midwives participating in
      pregnancy termination procedures. Methods: The study included 181 midwives
      working in state-governed healthcare facilities in central and eastern Poland.
      The Oldenburg Burnout Inventory (OLBI) and the present authors' own questionnaire
      were used in the study. The results indicating the level of occupational burnout 
      were presented in two scales: the exhaustion scale and the disengagement scale.
      Results: The study revealed that 48% of midwives had never participated in
      pregnancy termination procedures due to fetal defects. The level of occupational 
      burnout described with the exhaustion factor (t = 2.06; p < 0.041) and
      disengagement factor (t = 2.96; p < 0.003) was significantly higher in the group 
      of midwives participating in pregnancy termination procedures due to fetal
      defects than in the group of midwives who did not participate in pregnancy
      terminations. The most common factors contributing to burnout reported by
      midwives who participated in pregnancy terminations were: moral dilemmas (68%),
      seeing the aborted fetus (65%), anticipating the child's death in case it was
      born with signs of life (59%) and the lack of professional psychological support 
      for medical personnel (56%). Conclusions: Importantly, pregnancy termination
      should be performed by persons who find such procedures acceptable from the
      viewpoint of their value system. It is a protective factor in regards to work
      with women who undergo terminations. Moreover, developing a system of
      informational and psychological support for midwives participating in pregnancy
      termination procedures is also a significant aspect.
FAU - Zareba, Kornelia
AU  - Zareba K
AUID- ORCID: 0000-0002-8262-4380
AD  - First Department of Obstetrics and Gynecology, Center of Postgraduate Medical
      Education, 01-004 Warsaw, Poland.
FAU - Banasiewicz, Jolanta
AU  - Banasiewicz J
AD  - Department of Medical Psychology and Medical Communication, Medical University of
      Warsaw, 00-575 Warsaw, Poland.
FAU - Rozenek, Hanna
AU  - Rozenek H
AD  - Department of Medical Psychology and Medical Communication, Medical University of
      Warsaw, 00-575 Warsaw, Poland.
FAU - Ciebiera, Michal
AU  - Ciebiera M
AUID- ORCID: 0000-0001-5780-5983
AD  - Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical
      Education, 01-809 Warsaw, Poland.
FAU - Jakiel, Grzegorz
AU  - Jakiel G
AD  - First Department of Obstetrics and Gynecology, Center of Postgraduate Medical
      Education, 01-004 Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200417
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Abortion, Induced
MH  - Adult
MH  - *Burnout, Professional/epidemiology
MH  - *Emotions
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Midwifery
MH  - Poland
MH  - Pregnancy
MH  - Surveys and Questionnaires
PMC - PMC7216072
OTO - NOTNLM
OT  - *abortion
OT  - *burnout
OT  - *midwife
OT  - *occupational burnout
OT  - *stress
OT  - *termination of pregnancy
OT  - *workplace stress
EDAT- 2020/04/23 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/04/11 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - ijerph17082776 [pii]
AID - 10.3390/ijerph17082776 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Apr 17;17(8). pii: ijerph17082776. doi:
      10.3390/ijerph17082776.


PMID- 32316503
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 17
TI  - Artificial Intelligence in Radiology-Ethical Considerations.
LID - E231 [pii]
LID - 10.3390/diagnostics10040231 [doi]
AB  - Artificial intelligence (AI) is poised to change much about the way we practice
      radiology in the near future. The power of AI tools has the potential to offer
      substantial benefit to patients. Conversely, there are dangers inherent in the
      deployment of AI in radiology, if this is done without regard to possible ethical
      risks. Some ethical issues are obvious; others are less easily discerned, and
      less easily avoided. This paper explains some of the ethical difficulties of
      which we are presently aware, and some of the measures we may take to protect
      against misuse of AI.
FAU - Brady, Adrian P
AU  - Brady AP
AUID- ORCID: 0000-0003-3473-0282
AD  - Radiology Department, Mercy University Hospital, T12 WE28 Cork, Ireland.
AD  - European Society of Radiology (ESR), Am Gestade 1, 1010 Vienna, Austria.
FAU - Neri, Emanuele
AU  - Neri E
AUID- ORCID: 0000-0001-7950-4559
AD  - Diagnostic and Interventional Radiology, Department of Translational Research,
      University of Pisa, Via Roma, 67, 56126 Pisa, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7235856
OTO - NOTNLM
OT  - artificial intelligence
OT  - machine learning
OT  - radiology ethics
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - diagnostics10040231 [pii]
AID - 10.3390/diagnostics10040231 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2020 Apr 17;10(4). pii: diagnostics10040231. doi:
      10.3390/diagnostics10040231.


PMID- 32316371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Apr 16
TI  - Does the "Morning Morality Effect" Apply to Prehospital Anaesthesiologists? An
      Investigation into Diurnal Changes in Ethical Behaviour.
LID - E101 [pii]
LID - 10.3390/healthcare8020101 [doi]
AB  - The "morning morality effect"-the alleged phenomenon that people are more likely 
      to act in unethical ways in the afternoon when they are tired and have less
      self-control than in the morning-may well be expected to influence prehospital
      anaesthesiologist manning mobile emergency care units (MECUs). The working
      conditions of these units routinely entail fatigue, hunger, sleep deprivation and
      other physical or emotional conditions that might make prehospital units
      predisposed to exhibit the "morning morality effect". We investigated whether
      this is in fact the case by looking at the distribution of patient transports to 
      hospital with and without physician escort late at night at the end of the shift 
      as a surrogate marker for changing thresholds in ethical behaviour. All missions 
      over a period of 11 years in the MECU in Odense were reviewed. Physician-escorted
      transports to hospital were compared with non-physician-escorted transports
      during daytime, evening, and night-time (which correlates with time on the 24 h
      shifts). In total, 26,883 patients were transported to hospital following
      treatment by the MECU. Of these, 27.4% (26.9%-27.9%) were escorted to the
      hospital. The ratio of patient transports to hospital with and without physician 
      escort during the three periods of the day did not differ (p = 1.00). We found no
      evidence of changes in admission patterns over the day. Thus, no evidence of the 
      expected "morning morality effect" could be found in a prehospital
      physician-manned emergency care unit.
FAU - Brochner, Anne Craveiro
AU  - Brochner AC
AD  - Department of Anaesthesiology and Intensive Care Medicine V, Mobile Emergency
      Care Unit, Odense University Hospital, 5000 Odense, Denmark.
AD  - Department of Regional Health Research, University of Southern Denmark, 5000
      Odense, Denmark.
AD  - Department of Anaesthesiology, Kolding Hospital, a part of Hospital Lillebaelt,
      6000 Kolding, Denmark.
FAU - Binderup, Lars Grassme
AU  - Binderup LG
AD  - Philosophy, Department for the Study of Culture, University of Southern Denmark, 
      5230 Odense, Denmark.
FAU - Schaffalitzky de Muckadell, Caroline
AU  - Schaffalitzky de Muckadell C
AD  - Philosophy, Department for the Study of Culture, University of Southern Denmark, 
      5230 Odense, Denmark.
FAU - Mikkelsen, Soren
AU  - Mikkelsen S
AD  - Department of Anaesthesiology and Intensive Care Medicine V, Mobile Emergency
      Care Unit, Odense University Hospital, 5000 Odense, Denmark.
AD  - Department of Regional Health Research, University of Southern Denmark, 5000
      Odense, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7349197
OTO - NOTNLM
OT  - admission pattern
OT  - ethical correct behaviour
OT  - morning morality
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/23 06:00
MHDA- 2020/04/23 06:01
CRDT- 2020/04/23 06:00
PHST- 2020/04/07 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/23 06:01 [medline]
AID - healthcare8020101 [pii]
AID - 10.3390/healthcare8020101 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Apr 16;8(2). pii: healthcare8020101. doi:
      10.3390/healthcare8020101.


PMID- 32316270
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20201210
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 8
DP  - 2020 Apr 16
TI  - COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might
      Help.
LID - E1834 [pii]
LID - 10.3390/molecules25081834 [doi]
AB  - The desperate need to find drugs for COVID-19 has indicated repurposing
      strategies as our quickest way to obtain efficacious medicines. One of the
      options under investigation is the old antimalarial drug, chloroquine, and its
      analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona
      alkaloids, these chiral antimalarials are currently in use as the racemate.
      Besides the ethical concern related to accelerated large-scale clinical trials of
      drugs with unproven efficacy, the known potential detrimental cardiac effects of 
      these drugs should also be considered. In principle, the safety profile might be 
      ameliorated by using chloroquine/hydroxychloroquine single enantiomers in place
      of the racemate.
FAU - Lentini, Giovanni
AU  - Lentini G
AUID- ORCID: 0000-0001-7079-5994
AD  - Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, via
      E. Orabona, 4, I-70126 Bari, Italy.
FAU - Cavalluzzi, Maria Maddalena
AU  - Cavalluzzi MM
AD  - Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, via
      E. Orabona, 4, I-70126 Bari, Italy.
FAU - Habtemariam, Solomon
AU  - Habtemariam S
AUID- ORCID: 0000-0001-6743-2244
AD  - Pharmacognosy Research Laboratories & Herbal Analysis Services UK, University of 
      Greenwich, Chatham-Maritime, Kent ME4 4TB, UK.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antimalarials)
RN  - 0 (Antiviral Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 886U3H6UFF (Chloroquine)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Antimalarials
MH  - Antiviral Agents/adverse effects/chemistry/pharmacology/therapeutic use
MH  - Arrhythmias, Cardiac/chemically induced
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Cardiotoxicity
MH  - Chloroquine/*adverse effects/chemistry/pharmacology/*therapeutic use
MH  - Coronavirus Infections/*drug therapy
MH  - *Drug Repositioning
MH  - Humans
MH  - Hydroxychloroquine/adverse effects/chemistry/therapeutic use
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - SARS-CoV-2
MH  - Stereoisomerism
PMC - PMC7221598
OTO - NOTNLM
OT  - 2019-nCoV
OT  - COVID-19
OT  - Ebola
OT  - MERS
OT  - SARS
OT  - SARS-CoV-2
OT  - chiral switch
OT  - hydroxychloroquine
OT  - repositioning
EDAT- 2020/04/23 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/04/23 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/04/14 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
AID - molecules25081834 [pii]
AID - 10.3390/molecules25081834 [doi]
PST - epublish
SO  - Molecules. 2020 Apr 16;25(8). pii: molecules25081834. doi:
      10.3390/molecules25081834.


PMID- 32315260
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1544-0591 (Electronic)
IS  - 0022-0345 (Linking)
VI  - 99
IP  - 7
DP  - 2020 Jul
TI  - Artificial Intelligence in Dentistry: Chances and Challenges.
PG  - 769-774
LID - 10.1177/0022034520915714 [doi]
AB  - The term "artificial intelligence" (AI) refers to the idea of machines being
      capable of performing human tasks. A subdomain of AI is machine learning (ML),
      which "learns" intrinsic statistical patterns in data to eventually cast
      predictions on unseen data. Deep learning is a ML technique using multi-layer
      mathematical operations for learning and inferring on complex data like imagery. 
      This succinct narrative review describes the application, limitations and
      possible future of AI-based dental diagnostics, treatment planning, and conduct, 
      for example, image analysis, prediction making, record keeping, as well as dental
      research and discovery. AI-based applications will streamline care, relieving the
      dental workforce from laborious routine tasks, increasing health at lower costs
      for a broader population, and eventually facilitate personalized, predictive,
      preventive, and participatory dentistry. However, AI solutions have not by large 
      entered routine dental practice, mainly due to 1) limited data availability,
      accessibility, structure, and comprehensiveness, 2) lacking methodological rigor 
      and standards in their development, 3) and practical questions around the value
      and usefulness of these solutions, but also ethics and responsibility. Any AI
      application in dentistry should demonstrate tangible value by, for example,
      improving access to and quality of care, increasing efficiency and safety of
      services, empowering and enabling patients, supporting medical research, or
      increasing sustainability. Individual privacy, rights, and autonomy need to be
      put front and center; a shift from centralized to distributed/federated learning 
      may address this while improving scalability and robustness. Lastly,
      trustworthiness into, and generalizability of, dental AI solutions need to be
      guaranteed; the implementation of continuous human oversight and standards
      grounded in evidence-based dentistry should be expected. Methods to visualize,
      interpret, and explain the logic behind AI solutions will contribute
      ("explainable AI"). Dental education will need to accompany the introduction of
      clinical AI solutions by fostering digital literacy in the future dental
      workforce.
FAU - Schwendicke, F
AU  - Schwendicke F
AD  - Department of Operative and Preventive Dentistry, Charite - Universitatsmedizin
      Berlin, Berlin, Germany.
FAU - Samek, W
AU  - Samek W
AUID- ORCID: 0000-0002-6283-3265
AD  - Department of Video Coding and Analytics, Fraunhofer Heinrich Hertz Institute,
      Berlin, Germany.
FAU - Krois, J
AU  - Krois J
AD  - Department of Operative and Preventive Dentistry, Charite - Universitatsmedizin
      Berlin, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200421
PL  - United States
TA  - J Dent Res
JT  - Journal of dental research
JID - 0354343
SB  - IM
MH  - *Artificial Intelligence
MH  - Dentistry
MH  - Forecasting
MH  - Humans
MH  - Image Processing, Computer-Assisted
PMC - PMC7309354
OTO - NOTNLM
OT  - *decision-making
OT  - *deep learning
OT  - *dental
OT  - *diagnostic systems
OT  - *informatics
OT  - *machine learning
EDAT- 2020/04/22 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1177/0022034520915714 [doi]
PST - ppublish
SO  - J Dent Res. 2020 Jul;99(7):769-774. doi: 10.1177/0022034520915714. Epub 2020 Apr 
      21.


PMID- 32315224
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 2573-1602 (Electronic)
IS  - 2573-1599 (Linking)
VI  - 3
IP  - 2
DP  - 2020 Apr
TI  - Ethics and Global Governance of Human Germline Genome Editing: The Problem of
      Techno-Scientific Colonialist Paternalism.
PG  - 83-88
LID - 10.1089/crispr.2019.0045 [doi]
AB  - I want to enrich the debate about the ethics and governance of human germline
      editing (HGE) by emphasizing an underappreciated, yet important, set of concerns 
      regarding exclusionary practices, norms, and efforts that impede a broader
      discussion about the subject. The possibility for establishing a binding, global,
      regulatory framework is influenced by economic and geopolitical factors as well
      as historical processes and sociopolitical problems, such as anti-scientific
      social movements and the politicization of science. Likewise, it is influenced by
      different understanding, epistemic resources, and goals between the CRISPR/genome
      editing community and the rest of society. In this Perspective, I explain the
      concept of "techno-scientific colonialist paternalism" and why it negatively
      affects our discussion around HGE. I also discuss the pitfalls of scientific
      self-regulation, and finally, I advocate that the implementation of HGE should
      cease to allow time and care for a thoughtful global discussion to emerge.
FAU - Arguedas-Ramirez, Gabriela
AU  - Arguedas-Ramirez G
AD  - Escuela de Filosofia (School of Philosophy), Universidad de Costa Rica, San Jose,
      Costa Rica.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - CRISPR J
JT  - The CRISPR journal
JID - 101738191
SB  - IM
MH  - CRISPR-Cas Systems
MH  - Clustered Regularly Interspaced Short Palindromic Repeats/genetics
MH  - Gene Editing/*ethics/*legislation & jurisprudence
MH  - Genome, Human
MH  - Germ Cells
MH  - Germ-Line Mutation/*ethics/genetics
MH  - Government
MH  - Humans
MH  - Paternalism/ethics
EDAT- 2020/04/22 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
AID - 10.1089/crispr.2019.0045 [doi]
PST - ppublish
SO  - CRISPR J. 2020 Apr;3(2):83-88. doi: 10.1089/crispr.2019.0045.


PMID- 32314973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 21
TI  - Delayed Auditory Feedback and Transcranial Direct Current Stimulation Treatment
      for the Enhancement of Speech Fluency in Adults Who Stutter: Protocol for a
      Randomized Controlled Trial.
PG  - e16646
LID - 10.2196/16646 [doi]
AB  - BACKGROUND: Stuttering is a complex speech disorder that affects speech fluency. 
      Recently, it has been shown that noninvasive brain stimulation may be useful to
      enhance the results of fluency interventions in adults who stutter. Delayed
      auditory feedback (DAF) is a method to enhance speech fluency in individuals who 
      stutter. Adjunctive interventions are warranted to enhance the efficacy of this
      intervention. OBJECTIVE: Individuals who stutter have pathological activation
      patterns in the primary and secondary auditory areas. Consequently, in this
      study, we hypothesize that stimulation of these areas might be promising as an
      adjunctive method to fluency training via DAF to enhance speech therapy success
      in individuals with a stutter. We will systematically test this hypothesis in
      this study. METHODS: This study is designed as a randomized, double-blind,
      sham-controlled clinical trial. All participants will receive DAF. The
      intervention group will additionally receive real transcranial direct current
      stimulation, while the control group will be exposed to sham stimulation. The
      assignment of the participants to one of these groups will be randomized. Before 
      starting the treatment program, 2 preintervention assessments will be conducted
      to determine the severity of stuttering. Once these assessments are completed,
      each subject will participate in 6 intervention sessions. Postintervention
      assessments will be carried out immediately and 1 week after the last
      intervention session. Subsequently, to explore the long-term stability of the
      treatment results, the outcome parameters will be obtained in follow-up
      assessments 6 weeks after the treatment. The primary outcome measurement-the
      percentage of stuttered syllables-will be calculated in pre-, post-, and
      follow-up assessments; the secondary outcomes will be the scores of the following
      questionnaires: the Stuttering Severity Instrument-Fourth Edition and the Overall
      Assessment of the Speaker's Experience of Stuttering. RESULTS: This protocol was 
      funded in 2019 and approved by the Research Ethics Committee of the Iran
      University of Medical Sciences in June 2019. Data collection started in October
      2019. As of February 2020, we have enrolled 30 participants. We expect data
      analysis to be completed in April 2020, and results will be published in summer
      2020. CONCLUSIONS: We anticipate that this study will show an adjunctive effect
      of transcranial direct current stimulation, when combined with DAF, on
      stuttering. This should include not only a reduction in the percentage of
      stuttered syllables but also improved physical behavior and quality of life in
      adults who stutter. TRIAL REGISTRATION: ClinicalTrial.gov NCT03990168;
      https://clinicaltrials.gov/ct2/show/NCT03990168. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/16646.
CI  - (c)Narges Moein, Reyhane Mohamadi, Reza Rostami, Michael Nitsche, Reza Zomorrodi,
      Amir Ostadi, Abbasali Keshtkar. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 21.04.2020.
FAU - Moein, Narges
AU  - Moein N
AUID- ORCID: https://orcid.org/0000-0002-5102-5385
AD  - Department of Speech and Language Pathology, School of Rehabilitation Sciences,
      Iran University of Medical Sciences, Tehran, Iran.
FAU - Mohamadi, Reyhane
AU  - Mohamadi R
AUID- ORCID: https://orcid.org/0000-0003-2823-5197
AD  - Department of Speech and Language Pathology, School of Rehabilitation Sciences,
      Iran University of Medical Sciences, Tehran, Iran.
AD  - Rehabilitation Research Center, Iran University of Medical Sciences, Tehran,
      Iran.
FAU - Rostami, Reza
AU  - Rostami R
AUID- ORCID: https://orcid.org/0000-0001-9318-108X
AD  - Faculty of Psychology, University of Tehran, Tehran, Iran.
FAU - Nitsche, Michael
AU  - Nitsche M
AUID- ORCID: https://orcid.org/0000-0002-2207-5965
AD  - Department of Psychology and Neurosciences, Leibniz Research Centre for Working
      Environment and Human Factors, Dortmund, Germany.
FAU - Zomorrodi, Reza
AU  - Zomorrodi R
AUID- ORCID: https://orcid.org/0000-0002-1648-843X
AD  - Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and
      Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON,
      Canada.
FAU - Ostadi, Amir
AU  - Ostadi A
AUID- ORCID: https://orcid.org/0000-0003-1953-4507
AD  - Faculty of Science, University of Waterloo, Waterloo, ON, Canada.
FAU - Keshtkar, Abbasali
AU  - Keshtkar A
AUID- ORCID: https://orcid.org/0000-0002-7305-8639
AD  - Department of Health Sciences Education Development, School of Public Health,
      Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
SI  - ClinicalTrials.gov/NCT03990168
PT  - Journal Article
DEP - 20200421
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7201314
OTO - NOTNLM
OT  - delayed auditory feedback
OT  - speech fluency
OT  - stuttering
OT  - transcranial direct current stimulation
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - v9i4e16646 [pii]
AID - 10.2196/16646 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 21;9(4):e16646. doi: 10.2196/16646.


PMID- 32314663
OWN - NLM
STAT- MEDLINE
DCOM- 20201120
LR  - 20201120
IS  - 1533-0338 (Electronic)
IS  - 1533-0338 (Linking)
VI  - 19
DP  - 2020 Jan-Dec
TI  - Robust Optimization of SBRT Planning for Patients With Early Stage Non-Small Cell
      Lung Cancer.
PG  - 1533033820916505
LID - 10.1177/1533033820916505 [doi]
AB  - PURPOSE: Setup uncertainty is a known challenge for stereotactic body
      radiotherapy planning. Using the internal target volume-based robust optimization
      was proposed as a more accurate way than the conventional planning target
      volume-based optimization when considering the robustness criteria. In this
      study, we aim to investigate the feasibility of internal target volume-based
      robust optimization in stereotactic body radiotherapy planning using
      4-dimensional computed tomography and develop a novel dose-volume histogram band 
      width metric to quantitatively evaluate robustness. METHOD AND MATERIALS: A total
      of 50 patients with early stage non-small cell lung cancer, who underwent
      stereotactic body radiotherapy, were retrospectively selected. Each of the 50
      patients had 2 stereotactic body radiotherapy plans: one with the conventional
      planning target volume-based optimization and the other with patient-specific
      robustly optimized internal target volume and with a uniform 5 mm setup error.
      These were compared with the planning target volume-based optimization method
      based on both plan quality and robustness. The quality was evaluated using
      dosimetric parameters and radiobiology parameters, such as high-dose spillage (V 
      90%RX, conformity index), intermediate-dose spillage (dose falloff products),
      low-dose spillage (normal tissue: V 50%RX), and lung tissue complication
      probability. The robustness was evaluated under a uniform 3 to 5 mm setup errors 
      with a novel proposed metric: dose-volume histogram band width. RESULTS: When
      compared with planning target volume-based optimization plans, the internal
      target volume-based robust optimization plans have better conformity of internal 
      target volume coverage (conformity index: 1.17 vs 1.27, P < .001),
      intermediate-dose spillage (dose falloff product: 129 vs 167, P < .001), low-dose
      spillage in normal tissue (V 50%RX: 0.8% vs 1.5%, P < .05), and lower risk of
      radiation pneumonitis (lung tissue complication probability: 4.2% vs 5.5%, P <
      .001). For the robustness, dose-volume histogram band width analysis shows that
      the average values in internal target volume, D 95%, D 98%, and D 99%, of
      internal target volume-based robust optimization are smaller than that of
      planning target volume-based optimization (unit cGy) under 3-, 4-, and 5-mm setup
      uncertainties (3-mm setup uncertainty: 42 vs 73 cGy; 4-mm setup uncertainty: 88
      vs 176 cGy; 5-mm setup uncertainty: 229 vs 490 cGy), which might indicate that
      internal target volume-based robust optimization harbored a greater robustness
      regardless of the setup errors. CONCLUSIONS: Internal target volume-based robust 
      optimization may have clinical potential in offering better plan quality in both 
      target and organs at risk and lower risk of radiation pneumonitis. In addition,
      the proposed internal target volume-based robust optimization may demonstrate
      robustness regardless of different setup uncertainties in the stereotactic body
      radiotherapy planning. REGISTRATION: Retrospective study with local ethics
      committee approval.
FAU - Shang, Haijiao
AU  - Shang H
AUID- ORCID: 0000-0003-3977-1737
AD  - Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai,
      People's Republic of China.
AD  - University of Chinese Academy of Sciences, Beijing, People's Republic of China.
FAU - Pu, Yuehu
AU  - Pu Y
AD  - Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai,
      People's Republic of China.
AD  - University of Chinese Academy of Sciences, Beijing, People's Republic of China.
FAU - Wang, Yuenan
AU  - Wang Y
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical
      Research Center for Cancer/Cancer Hospital, Shenzhen Hospital, Chinese Academy of
      Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
SB  - IM
MH  - Algorithms
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/pathology/*radiotherapy
MH  - Four-Dimensional Computed Tomography/methods
MH  - Humans
MH  - Lung Neoplasms/diagnostic imaging/pathology/*radiotherapy
MH  - Neoplasm Staging
MH  - Organs at Risk/radiation effects
MH  - Prognosis
MH  - Radiosurgery/*methods/*standards
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/*methods/*standards
MH  - Radiotherapy, Intensity-Modulated/methods
MH  - Retrospective Studies
PMC - PMC7175055
OTO - NOTNLM
OT  - *dose volume histogram bands width (DVHBW)
OT  - *radiation pneumonitis (RP)
OT  - *robust optimization (RO)
OT  - *stereotactic body radiotherapy (SBRT)
EDAT- 2020/04/22 06:00
MHDA- 2020/11/21 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/11/21 06:00 [medline]
AID - 10.1177/1533033820916505 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820916505. doi:
      10.1177/1533033820916505.


PMID- 32314551
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20201218
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - Transplant programs during COVID-19: Unintended consequences for health
      inequality.
PG  - 1954-1955
LID - 10.1111/ajt.15931 [doi]
FAU - Sharma, Shivani
AU  - Sharma S
AUID- ORCID: https://orcid.org/0000-0002-7682-2858
AD  - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
FAU - Lawrence, Christopher
AU  - Lawrence C
AUID- ORCID: https://orcid.org/0000-0002-8159-0879
AD  - Spire Healthcare, London, UK.
FAU - Giovinazzo, Francesco
AU  - Giovinazzo F
AUID- ORCID: https://orcid.org/0000-0002-3392-9292
AD  - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
LA  - eng
PT  - Letter
DEP - 20200510
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communicable Disease Control
MH  - Coronavirus Infections/*prevention & control/transmission
MH  - Cultural Characteristics
MH  - Health Care Rationing
MH  - Health Equity
MH  - *Health Services Accessibility
MH  - *Health Status Disparities
MH  - Healthcare Disparities
MH  - Humans
MH  - Minority Groups
MH  - Organ Transplantation/*ethics/standards/*trends
MH  - Pandemics/*prevention & control
MH  - Patient Education as Topic
MH  - Patient Safety
MH  - Pneumonia, Viral/*prevention & control/transmission
MH  - Resource Allocation
MH  - Risk
MH  - SARS-CoV-2
MH  - *Socioeconomic Factors
OTO - NOTNLM
OT  - allied health/nursing
OT  - ethics and public policy
OT  - patient characteristics
OT  - patient safety
OT  - quality of care/care delivery
OT  - social sciences
EDAT- 2020/04/22 06:00
MHDA- 2020/07/21 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1111/ajt.15931 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jul;20(7):1954-1955. doi: 10.1111/ajt.15931. Epub 2020 May 
      10.


PMID- 32314549
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Jun
TI  - Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the
      "ideal" patient.
PG  - 4107-4113
LID - 10.1002/cam4.3031 [doi]
AB  - BACKGROUND: Perspectives of clinical trial (CT) personnel on accrual to oncology 
      CTs are relatively absent from the literature. This study explores CT personnel's
      experience recruiting patients to oncology CTs. METHODS: A qualitative study
      design was utilized. In-depth, individual interviews with 12 oncology CT
      personnel were conducted, including six CT nurses and six
      physician-investigators. Interviews were digitally recorded and transcribed
      verbatim. Data were subjected to thematic and ethical analysis to identify key
      concepts and themes. RESULTS: CT personnel reported considering two ethical
      commitments in CT recruitment: maintaining trial integrity and ensuring patient
      autonomy through obtaining informed consent. The process of gatekeeping emerged
      as a way to navigate these ethical commitments during CT accrual. Gatekeeping was
      influenced by: (a) perceptions of patients' personal suitability for a trial, and
      (b) healthcare resources and infrastructure. CT personnel's discernment of
      personal suitability was influenced by patients' cognitive and mental health
      status, language and cultural background, geographic location, family support,
      and disease status. Three structural factors impacted gatekeeping: complexity of 
      CTs, consent process, and time limitations in the healthcare system. CT personnel
      experienced most factors as constraints to accrual and gaining patients' informed
      consent. CONCLUSION: CT personnel discussed navigating ethical challenges in CT
      recruitment by offering enrollment to specific patient populations, exacerbating 
      other ethical tensions. Systems-level strategies are needed to address barriers
      to ethical CT recruitment. Future research should investigate the role of
      policies and/or tools (eg, decision aids) to support patients and CT personnel's 
      discussions about CT participation, promote more ethical recruitment, and
      potentially increase accrual.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Bell, Jennifer A H
AU  - Bell JAH
AUID- ORCID: 0000-0003-3617-6852
AD  - University of Toronto, Toronto, ON, Canada.
AD  - Princess Margaret Cancer Centre, Toronto, ON, Canada.
FAU - Kelly, Mary T
AU  - Kelly MT
AD  - University Health Network, Toronto, ON, Canada.
FAU - Gelmon, Karen
AU  - Gelmon K
AD  - University of British Columbia, Vancouver, BC, Canada.
FAU - Chi, Kim
AU  - Chi K
AD  - University of British Columbia, Vancouver, BC, Canada.
FAU - Ho, Anita
AU  - Ho A
AD  - University of British Columbia, Vancouver, BC, Canada.
AD  - University of California, Oakland, CA, USA.
AD  - Centre for Health Evaluation & Outcomes Sciences, University of British Columbia,
      Vancouver, BC, Canada.
FAU - Rodney, Patricia
AU  - Rodney P
AD  - University of British Columbia, Vancouver, BC, Canada.
FAU - Balneaves, Lynda G
AU  - Balneaves LG
AD  - University of Manitoba, Winnipeg, MB, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200420
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Biomedical Research/*ethics
MH  - Clinical Trials as Topic/*methods/psychology
MH  - Decision Making/*ethics
MH  - Female
MH  - Gatekeeping
MH  - Humans
MH  - Informed Consent/*ethics
MH  - Male
MH  - Neoplasms/*therapy
MH  - Patient Participation
MH  - Patient Selection/*ethics
MH  - Qualitative Research
MH  - Research Personnel/ethics/*psychology
MH  - Surveys and Questionnaires
PMC - PMC7300392
OTO - NOTNLM
OT  - *clinical trials
OT  - *oncology trials
OT  - *research ethics
OT  - *trial accrual
OT  - *trial participants
EDAT- 2020/04/22 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/01/06 00:00 [received]
PHST- 2020/02/28 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1002/cam4.3031 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Jun;9(12):4107-4113. doi: 10.1002/cam4.3031. Epub 2020 Apr 20.


PMID- 32314405
OWN - NLM
STAT- MEDLINE
DCOM- 20210101
LR  - 20210101
IS  - 1834-7819 (Electronic)
IS  - 0045-0421 (Linking)
VI  - 65
IP  - 4
DP  - 2020 Dec
TI  - The state of bariatric dental care in Australia: a silent disability crisis?
PG  - 313-315
LID - 10.1111/adj.12772 [doi]
AB  - In the absence of dental related guidelines available in Australia specific to
      obesity and minimal awareness of the clinical implications on local dental
      practice, bariatric dental care can be perceived as a 'silent disability crisis'.
      This opinion piece and brief clinical note aims to question and raise awareness
      amongst dental professionals surrounding the current limited availability of
      bariatric dental chairs, difficulties in access, the safety of dental care
      delivery and ethical considerations for the dental management of people with
      obesity.
CI  - (c) 2020 Australian Dental Association.
FAU - Malik, Z
AU  - Malik Z
AUID- ORCID: 0000-0003-2000-8029
AD  - Department of Oral Medicine, Oral Pathology and Special Needs Dentistry, Westmead
      Centre for Oral Health, Westmead Hospital, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200523
PL  - Australia
TA  - Aust Dent J
JT  - Australian dental journal
JID - 0370612
SB  - IM
MH  - Australia
MH  - *Bariatrics
MH  - Dental Care
MH  - Humans
MH  - Obesity/complications
OTO - NOTNLM
OT  - *Bariatric
OT  - *bariatric dental services
OT  - *crisis
OT  - *disability
OT  - *obesity
EDAT- 2020/04/22 06:00
MHDA- 2021/01/02 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/01/02 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1111/adj.12772 [doi]
PST - ppublish
SO  - Aust Dent J. 2020 Dec;65(4):313-315. doi: 10.1111/adj.12772. Epub 2020 May 23.


PMID- 32314398
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20210517
IS  - 1466-7657 (Electronic)
IS  - 0020-8132 (Linking)
VI  - 67
IP  - 2
DP  - 2020 Jun
TI  - Privacy, confidentiality, security and patient safety concerns about electronic
      health records.
PG  - 218-230
LID - 10.1111/inr.12585 [doi]
AB  - AIMS: This study explored concerns among nurses working in the United Arab
      Emirates associated with the use of electronic health records, including privacy,
      confidentiality, security and patient safety. BACKGROUND: Given the widespread
      implementation of electronic health records, there are concerns about data
      integrity that could jeopardize healthcare quality. Addressing nurses' concerns
      about data integrity and safety is critical to inform health policies and promote
      public trust. METHODS: Nurses working in healthcare settings in the United Arab
      Emirates (N = 562) were invited to share their concerns about data integrity and 
      patient safety using a mixed-method approach. Data were collected between January
      and June 2018 via questionnaires and focus group interviews. Following a survey
      of nurses' concerns about privacy, confidentiality, security and patient safety
      in electronic health records, six focus groups were held to gain deeper insights 
      about their concerns. Major themes that emerged from the focus groups were
      extracted to align with the main sections of the questionnaire. RESULTS: Nurses
      expressed concern over the security of electronic health records (n = 270, 48%). 
      Administrative-related security, inadequate training and access by unauthorized
      users were the most frequently reported concerns. The main patient safety
      concerns were associated with non-technological factors, including lack of audit 
      by staff, poor communication with technology vendors and length of time required 
      for documentation. The focus group results reflected similar issues, with an
      additional theme being inconsistency in data integrity policies. CONCLUSIONS AND 
      IMPLICATIONS FOR NURSING/HEALTH POLICY: Frontline nurse managers need to
      integrate pragmatic policies to support staff compliance with the code of ethics 
      when using online data. Nurses must follow workplace policies that foster
      reporting of risks to online incident systems to ensure data integrity. A unified
      health policy based on multidisciplinary partnership is critical to safeguard
      online data and promote public trust.
CI  - (c) 2020 International Council of Nurses.
FAU - Bani Issa, W
AU  - Bani Issa W
AUID- ORCID: https://orcid.org/0000-0001-8551-9052
AD  - Department of Nursing, College of Health Sciences, University of Sharjah,
      Sharjah, United Arab Emirates.
AD  - Research Institute of Medical and Health Sciences, University of Sharjah,
      Sharjah, United Arab Emirates.
FAU - Al Akour, I
AU  - Al Akour I
AD  - Department of Management Information System, University of Sharjah, Sharjah,
      United Arab Emirates.
FAU - Ibrahim, A
AU  - Ibrahim A
AD  - College of Business, American University in the Emirates, Dubai, United Arab
      Emirates.
FAU - Almarzouqi, A
AU  - Almarzouqi A
AD  - Health Services Administration, University of Sharjah, Sharjah, United Arab
      Emirates.
FAU - Abbas, S
AU  - Abbas S
AD  - Nursing Department - Hospitals Sector, Ministry of Health and Prevention,
      Sharjah, United Arab Emirates.
FAU - Hisham, F
AU  - Hisham F
AD  - Clinical Resource Nurse, Ministry of Health and Prevention, Sharjah, United Arab 
      Emirates.
FAU - Griffiths, J
AU  - Griffiths J
AD  - CEO Office, Dubai Healthcare Authority, Dubai, United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - England
TA  - Int Nurs Rev
JT  - International nursing review
JID - 7808754
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Confidentiality/*psychology/*standards
MH  - Electronic Health Records/*standards/statistics & numerical data
MH  - Female
MH  - Focus Groups
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nursing Staff, Hospital/*psychology
MH  - Patient Safety/*standards/statistics & numerical data
MH  - *Privacy
MH  - Surveys and Questionnaires
MH  - United Arab Emirates
OTO - NOTNLM
OT  - Code of ethics
OT  - Confidentiality
OT  - Data Integrity
OT  - Electronic Health Records
OT  - Health Policy
OT  - Nursing Policy
OT  - Patient Safety
OT  - Privacy
OT  - Security
OT  - United Arab Emirates
EDAT- 2020/04/22 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/09/22 00:00 [received]
PHST- 2020/02/16 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1111/inr.12585 [doi]
PST - ppublish
SO  - Int Nurs Rev. 2020 Jun;67(2):218-230. doi: 10.1111/inr.12585. Epub 2020 Apr 21.


PMID- 32314388
OWN - NLM
STAT- MEDLINE
DCOM- 20200422
LR  - 20200616
IS  - 1930-7837 (Electronic)
IS  - 0022-0337 (Linking)
VI  - 84
IP  - 4
DP  - 2020 Apr
TI  - What Is the Educational Value of a Student-Led Conference in Dental Education?
PG  - 449-457
LID - 10.21815/JDE.019.192 [doi]
AB  - Student-led conferences are a type of inquiry learning and student-led pedagogy. 
      They have the potential to foster learning across many of the domains required
      for professional dental practice including communication and interpersonal
      skills, adaptive capability, professional attitude and ethical judgment,
      entrepreneurship, and a social and community orientation. A student-led
      conference, which provided a framework for students studying oral biosciences to 
      create and host a conference focused on contemporary issues in oral biosciences, 
      was introduced into the Bachelor of Oral Health program at the University of
      Sydney in Australia in 2017 and 2018. The aim of this qualitative study was to
      examine the educational purposes that the student-led conference satisfied. Data 
      were collected from the 2017 cohort of students in the form of reflective essays.
      In 2018, students' experience of the conference was recorded from a focus group
      discussion. In both years, reflective accounts written by attendees were
      collected. The thematic analysis generated four themes: integration of learning, 
      personal learning, student resourcefulness through peer relationships, and deep
      commitment to delivering an excellent conference. The learning project served as 
      a platform for students to display their professionalism and skills gained in
      entrepreneurship, communication, and adaptive capability. This study provided an 
      example of a participatory curriculum approach with the potential to help
      students generate a working understanding of knowledge structures and how
      knowledge is created and circulates in the discipline.
CI  - (c) 2019 American Dental Education Association.
FAU - Leadbeatter, Delyse
AU  - Leadbeatter D
FAU - Gao, Jinlong
AU  - Gao J
FAU - Forsyth, Cathryn Jane
AU  - Forsyth CJ
FAU - Lansdown, Karen
AU  - Lansdown K
FAU - Wong, Grace
AU  - Wong G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Dent Educ
JT  - Journal of dental education
JID - 8000150
SB  - IM
MH  - Australia
MH  - *Curriculum
MH  - *Education, Dental
MH  - Humans
MH  - Learning
MH  - Students
OTO - NOTNLM
OT  - basic sciences
OT  - dental education
OT  - educational activities
OT  - educational methodology
OT  - oral biosciences
OT  - student-led pedagogy
OT  - teaching methods
OT  - teaching pedagogy
EDAT- 2020/04/22 06:00
MHDA- 2020/04/23 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/07/16 00:00 [received]
PHST- 2019/11/19 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/23 06:00 [medline]
AID - 10.21815/JDE.019.192 [doi]
PST - ppublish
SO  - J Dent Educ. 2020 Apr;84(4):449-457. doi: 10.21815/JDE.019.192.


PMID- 32314384
OWN - NLM
STAT- MEDLINE
DCOM- 20200422
LR  - 20200616
IS  - 1930-7837 (Electronic)
IS  - 0022-0337 (Linking)
VI  - 84
IP  - 4
DP  - 2020 Apr
TI  - Integrating Competency-Based Didactic and Experiential Global Health Learning for
      Dental Students: The Global Health Learning Helix Model.
PG  - 438-448
LID - 10.21815/JDE.019.186 [doi]
AB  - The aim of this study was to evaluate the feasibility and preliminary outcomes of
      immersive integrated experiential and didactic courses in strengthening
      competency-based global health learning in dental education. To address global
      inequities in oral health and student interest in global health, the Harvard
      School of Dental Medicine introduced two global health courses in 2017-18. The
      first was a didactic course in the core predoctoral curriculum, and the second,
      in collaboration with the Inter-American Center for Global Health, was a five-day
      elective experiential learning course in rural Costa Rica. The experiential
      course was an extension of the didactic course. All 33 second-year dental
      students completed the didactic course, and three of those students completed the
      experiential course. A pre-post survey and a six-month follow-up survey on
      self-reported knowledge based on course learning objectives were administered.
      The experiential course students also completed journals and interviews for
      qualitative analysis. Thirty-two students completed the pre-post didactic course 
      surveys, for a response rate of 94%. There was a 100% response rate on the
      pre-post didactic surveys by those students who participated in the experiential 
      learning course. While the experiential learning group scored similarly to the
      class average before the didactic course, they had higher scores than the class
      averages both immediately after and at the six-month follow-up. All three
      students reported that the experiential learning course was "extremely effective"
      in building on what they learned in the didactic course. Qualitative analysis of 
      the journals and interviews suggested enhanced learning from the combination of
      didactic and experiential methods. These preliminary results support the Global
      Health Learning Helix Model, a theoretical competency-based teaching model for
      ethical student global health engagement to better prepare the future generation 
      in tackling oral health disparities both locally and worldwide.
CI  - (c) 2019 American Dental Education Association.
FAU - Yu, Amy
AU  - Yu A
FAU - Lambert, R Frederick
AU  - Lambert RF
FAU - Alvarado, Jose A
AU  - Alvarado JA
FAU - Guzman, Carlos A Faerron
AU  - Guzman CAF
FAU - Seymour, Brittany
AU  - Seymour B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Dent Educ
JT  - Journal of dental education
JID - 8000150
SB  - IM
MH  - Curriculum
MH  - Education, Dental
MH  - Global Health
MH  - Humans
MH  - *Problem-Based Learning
MH  - *Students, Dental
OTO - NOTNLM
OT  - dental education
OT  - dental students
OT  - didactic learning
OT  - experiential learning
OT  - global health
OT  - teaching methodology
EDAT- 2020/04/22 06:00
MHDA- 2020/04/23 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/06/12 00:00 [received]
PHST- 2019/11/04 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/23 06:00 [medline]
AID - 10.21815/JDE.019.186 [doi]
PST - ppublish
SO  - J Dent Educ. 2020 Apr;84(4):438-448. doi: 10.21815/JDE.019.186.


PMID- 32314360
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210315
IS  - 1468-4446 (Electronic)
IS  - 0007-1315 (Linking)
VI  - 71
IP  - 3
DP  - 2020 Jun
TI  - What's on trial? The making of field experiments in international development.
PG  - 444-459
LID - 10.1111/1468-4446.12723 [doi]
AB  - In the last 20 years, the drive for evidence-based policymaking has been coupled 
      with a concurrent push for the use of randomized controlled trials (RCTs) as the 
      "gold-standard" for generating rigorous evidence on whether or not development
      interventions work. Drawing on content analysis of 63 development RCTs and 4
      years of participant observation, I provide a rich description of the diverse set
      of actors and the transnational organizational effort required to implement
      development RCTs and maintain their "scientific status." Particularly, I
      investigate the boundary work that proponents of RCTs-also known as
      randomistas-do to differentiate the purposes and merits of testing development
      projects from doing them, as a way to bypass the political and ethical problems
      presented by adopting the experimental method with foreign aid beneficiaries in
      poor countries. Although randomistas have been mostly successful in
      differentiating RCTs from the projects evaluated, I also examine cases where they
      were not able to do so, as a means to highlight the controversies associated with
      implementing RCTs in international development.
CI  - (c) 2019 London School of Economics and Political Science.
FAU - de Souza Leao, Luciana
AU  - de Souza Leao L
AD  - Department of Sociology, College of Literature, Science and the Arts, University 
      of Michigan, Ann Arbor, MI.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - England
TA  - Br J Sociol
JT  - The British journal of sociology
JID - 0373126
SB  - IM
MH  - Humans
MH  - *International Cooperation
MH  - Poverty
MH  - Randomized Controlled Trials as Topic/*standards
MH  - Research Design
OTO - NOTNLM
OT  - NGOs
OT  - economics
OT  - field experiments
OT  - global poverty
OT  - international development
EDAT- 2020/04/22 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/03/12 00:00 [received]
PHST- 2019/10/04 00:00 [revised]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1111/1468-4446.12723 [doi]
PST - ppublish
SO  - Br J Sociol. 2020 Jun;71(3):444-459. doi: 10.1111/1468-4446.12723. Epub 2020 Apr 
      21.


PMID- 32314277
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20220531
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 1
DP  - 2020 May
TI  - Review of Altered inheritance: CRISPR and the ethics of human genome editing by
      Francoise Baylis.
PG  - 91-93
LID - 10.1007/s40592-020-00106-0 [doi]
FAU - Sun, Bob Z
AU  - Sun BZ
AD  - Department of Pediatrics, University of Washington, 4800 Sand Point Way NE,
      OC.7.830, Seattle, WA, 98105, USA. bobzsun@uw.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - CRISPR-Cas Systems/genetics
MH  - *Clustered Regularly Interspaced Short Palindromic Repeats/genetics
MH  - Databases, Genetic
MH  - *Gene Editing
MH  - Genome, Human
MH  - Humans
EDAT- 2020/04/22 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1007/s40592-020-00106-0 [doi]
AID - 10.1007/s40592-020-00106-0 [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 May;38(1):91-93. doi: 10.1007/s40592-020-00106-0.


PMID- 32314205
OWN - NLM
STAT- MEDLINE
DCOM- 20210315
LR  - 20210629
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 2154
DP  - 2020
TI  - Isolation of Epidermal and Hair Follicle Melanocytes.
PG  - 23-32
LID - 10.1007/978-1-0716-0648-3_3 [doi]
AB  - Here we describe the isolation of epidermal melanocytes and hair follicle
      melanocytes from human skin tissue. Epidermal and hair follicle melanocytes are
      two distinct populations of melanocytes which are contained within the skin and
      the hair follicle, with differing yet overlapping roles. Epidermal melanocytes
      are normally isolated from the epidermis of vellus-haired skin tissue (e.g.,
      face, breast, abdomen), while hair follicle melanocytes are derived from the
      outer root sheath (ORS) of the middle/lower terminal anagen hair follicles of the
      scalp. These methods utilize ethically sourced human skin tissue obtained from
      donors undergoing plastic surgery.
FAU - Baker, Richard
AU  - Baker R
AD  - The Centre for Skin Sciences, Faculty of Life Sciences, University of Bradford,
      Bradford, UK. r.baker2@bradford.ac.uk.
FAU - Thornton, M Julie
AU  - Thornton MJ
AD  - The Centre for Skin Sciences, Faculty of Life Sciences, University of Bradford,
      Bradford, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Melanins)
SB  - IM
MH  - Cell Separation/*methods
MH  - Epidermal Cells/*cytology/*metabolism
MH  - Hair Follicle/*cytology
MH  - Humans
MH  - Melanins/metabolism
MH  - Melanocytes/*cytology/*metabolism
MH  - Skin Pigmentation
OTO - NOTNLM
OT  - *Cell culture
OT  - *Epidermis
OT  - *Hair follicle
OT  - *Hair follicle melanocyte
OT  - *Melanin
OT  - *Melanocyte
OT  - *Outer root sheath
OT  - *Pigment
EDAT- 2020/04/22 06:00
MHDA- 2021/03/16 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/03/16 06:00 [medline]
AID - 10.1007/978-1-0716-0648-3_3 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2020;2154:23-32. doi: 10.1007/978-1-0716-0648-3_3.


PMID- 32314114
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1573-6814 (Electronic)
IS  - 1389-9333 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Sep
TI  - Ethical and deontological aspects of pediatric biobanks: the situation in Italy.
PG  - 469-477
LID - 10.1007/s10561-020-09833-4 [doi]
AB  - While pediatric biobanks are a precious resource for scientific research to
      improve our understanding of genetic pathologies, the value of these studies
      should be considered together with the value of the privacy rights of pediatric
      donors, as they are particularly vulnerable and in many cases unable to discern
      the meaning of the donation of biological material and the related implications
      of the research. Thus this work calls for reflection on the numerous ethical and 
      legal issues involved in the development and regulation of these biobanks. In
      particular, it explores what form of consent best balances the intangible rights 
      of the minor, on the one hand, and the development of technological progress and 
      scientific research, on the other, and examines the implications of the
      collection of biological material of minors in biobanks. It focuses on solutions 
      to bridge the gaps in current Italian legislation, especially in light of the
      current lack of attention to the interests of fragile subjects. In addition, this
      work presents an overview of the pediatric biobanks in Italy.
FAU - Cannovo, Nunzia
AU  - Cannovo N
AD  - Ethics Committee of University of Naples 'Federico II', Via Sergio Pansini 5,
      Naples, Italy. nunzia.cannovo@gmail.com.
FAU - Guarino, Rosa
AU  - Guarino R
AD  - University of Naples 'Federico II', Naples, Italy.
FAU - Fedeli, Piergiorgio
AU  - Fedeli P
AD  - Law School, University of Camerino, Via A. D'Accorso 16, Camerino, MC, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - Netherlands
TA  - Cell Tissue Bank
JT  - Cell and tissue banking
JID - 100965121
SB  - IM
MH  - Biological Specimen Banks/*ethics
MH  - Child
MH  - Communication
MH  - *Ethical Theory
MH  - Humans
MH  - Informed Consent/ethics
MH  - Italy
PMC - PMC7452917
OTO - NOTNLM
OT  - Genetics research
OT  - Italy
OT  - Pediatric biobanks
OT  - Regulation
EDAT- 2020/04/22 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1007/s10561-020-09833-4 [doi]
AID - 10.1007/s10561-020-09833-4 [pii]
PST - ppublish
SO  - Cell Tissue Bank. 2020 Sep;21(3):469-477. doi: 10.1007/s10561-020-09833-4. Epub
      2020 Apr 20.


PMID- 32314102
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Aug
TI  - Bridging the Gap Between Ethical Theory and Practice in Medicine: A
      Constructivist Grounded Theory Study.
PG  - 2255-2275
LID - 10.1007/s11948-020-00217-1 [doi]
AB  - Physicians try hard to alleviate mental and physical ailments of their patients. 
      Thus, they are heavily burdened by observing ethics and staying well-informed
      while improving health of their patients. A major ethical concern or dilemma in
      medication is that some physicians know their behavior is unethical, yet act
      against their moral compass. This study develops models of theory-practice gap,
      offering optimal solutions for the gap. These solutions would enhance
      self-motivation or remove external obstacles to stimulate ethical practices in
      medicine. The Constructivist Grounded Theory Methodology is applied here where
      the participants and the main researcher mutually interacted with each other.
      Data collection was performed through qualitative methods including observation
      and semi-structured interviews with 21 physicians and medical students. Initial
      and focused coding was done, from which principal concepts were later extracted. 
      MAXQDA software was used for analyzing data. Analysis of twelve major concepts in
      the study resulted in two factors and solution groups, from which four general
      notions influencing the ethical theory and practice gap in medicine were
      extracted: (1) providing effective education to change attitude and behavior; (2)
      considering motivational and emotional factors; (3) reconstructing regulations
      and processes to facilitate ethical practice; (4) conducting comprehensive and
      systematic studies. The existing medical educational system needs to be
      reconsidered to add to individual internal motivation, including optimizing
      persuasion strategies, maximizing participation of students, adhering to virtuous
      ethical theories, and fostering emotions. Additionally, regulations and processes
      can be reconstructed to remove practical obstacles and promote ethical practice
      with insignificant damages to individual self-motivation.
FAU - Madani, Mansure
AU  - Madani M
AD  - Medical Ethics and History of Medicine Research Center, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Vedadhir, AbouAli
AU  - Vedadhir A
AD  - Department of Anthropology, University of Tehran, Tehran, 14117-13118, Iran.
      vedadha@ut.ac.ir.
AD  - Population Health Sciences, University of Bristol, Canynge Hall, Bristol, BS8
      2PS, UK. vedadha@ut.ac.ir.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Medical Ethics and History of Medicine Research Center, Endocrinology and
      Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences,
      Tehran, Iran.
FAU - Khazaei, Zahra
AU  - Khazaei Z
AD  - Department of Philosophy, University of Qom, Qom, Iran.
FAU - Gharamaleki, Ahad Faramarz
AU  - Gharamaleki AF
AD  - Department of Philosophy and Islamic Kalam, Faculty of Theology, University of
      Tehran, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Ethical Theory
MH  - *Grounded Theory
MH  - Humans
MH  - Motivation
MH  - *Physicians
MH  - *Students, Medical
OTO - NOTNLM
OT  - *Effective education of ethics
OT  - *Internalization
OT  - *Medical ethics
OT  - *Theory-practice gap
EDAT- 2020/04/22 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/04/22 06:00
PHST- 2018/02/17 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1007/s11948-020-00217-1 [doi]
AID - 10.1007/s11948-020-00217-1 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Aug;26(4):2255-2275. doi: 10.1007/s11948-020-00217-1. Epub
      2020 Apr 20.


PMID- 32313869
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2516-8657 (Electronic)
IS  - 2516-8657 (Linking)
VI  - 13
DP  - 2020
TI  - Ethical Issues in Research and Development of Epigenome-wide Technologies.
PG  - 2516865720913253
LID - 10.1177/2516865720913253 [doi]
AB  - To date, few scholarly discussions on ethical implications of epigenetics and
      epigenomics technologies have focused on the current phase of research and
      development, in which researchers are confronted with real and practical ethical 
      dilemmas. In this article, a responsible research and innovation approach, using 
      interviews and an expert meeting, is applied to a case of epigenomic test
      development for cervical cancer screening. This article provides an overview of
      ethical issues presently facing epigenomics researchers and test developers, and 
      discusses 3 sets of issues in depth: (1) informed consent; (2) communication with
      donors and/or research participants, and (3) privacy and publication of data and 
      research results. Although these issues are familiar to research ethics, some
      aspects are new and most require reinterpretation in the context of epigenomics
      technologies. With this article, we aim to start a discussion of the practical
      ethical issues rising in research and development of epigenomic technologies and 
      to offer guidance for researchers working in the field of epigenetic and
      epigenomic technology.
CI  - (c) The Author(s) 2020.
FAU - Bunnik, Eline M
AU  - Bunnik EM
AUID- ORCID: https://orcid.org/0000-0003-1481-6222
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands.
FAU - Timmers, Marjolein
AU  - Timmers M
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands.
FAU - Bolt, Ineke Lle
AU  - Bolt IL
AD  - Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC,
      Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200413
PL  - United States
TA  - Epigenet Insights
JT  - Epigenetics insights
JID - 101735398
PMC - PMC7154555
OTO - NOTNLM
OT  - Epigenomic technologies
OT  - informed consent
OT  - privacy
OT  - research ethics
OT  - responsible research and innovation
COIS- Declaration of conflicting interests:The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1177/2516865720913253 [doi]
AID - 10.1177_2516865720913253 [pii]
PST - epublish
SO  - Epigenet Insights. 2020 Apr 13;13:2516865720913253. doi:
      10.1177/2516865720913253. eCollection 2020.


PMID- 32313838
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2379-6146 (Electronic)
IS  - 2379-6146 (Linking)
VI  - 4
IP  - 2
DP  - 2020 Apr
TI  - The European medical information framework: A novel ecosystem for sharing
      healthcare data across Europe.
PG  - e10214
LID - 10.1002/lrh2.10214 [doi]
AB  - INTRODUCTION: The European medical information framework (EMIF) was an Innovative
      Medicines Initiative project jointly supported by the European Union and the
      European Federation of Pharmaceutical Industries and Associations, that generated
      a common technology and governance framework to identify, assess and (re)use
      healthcare data, to facilitate real-world data research. The objectives of EMIF
      included providing a unified platform to support a wide range of studies within
      two verification programmes-Alzheimer's disease (EMIF-AD), and metabolic
      consequences of obesity (EMIF-MET). METHODS: The EMIF platform was built around
      two main data-types: electronic health record data and research cohort data, and 
      the platform architecture composed of a set of tools designed to enable data
      discovery and characterisation. This included the EMIF catalogue, which allowed
      users to find relevant data sources, including the data-types collected. Data
      harmonisation via a common data model were central to the project especially for 
      population data sources. EMIF also developed an ethical code of practice to
      ensure data protection, patient confidentiality and compliance with the European 
      Data Protection Directive, and GDPR. RESULTS: Currently 18 population-based
      disease agnostic and 60 cohort-based Alzheimer's data partners from across 14
      countries are contained within the catalogue, and this will continue to expand.
      The work conducted in EMIF-AD and EMIF-MET includes standardizing cohorts,
      summarising baseline characteristics of patients, developing diagnostic
      algorithms, epidemiological studies, identifying and validating novel biomarkers 
      and selecting potential patient samples for pharmacological intervention.
      CONCLUSIONS: EMIF was designed to provide a sustainable model as demonstrated by 
      the sustainability plans for EMIF-AD. Although network-wide studies using EMIF
      were not conducted during this project to evaluate its sustainability, learning
      from EMIF will be used in the follow-on IMI-2 project, European Health Data and
      Evidence Network (EHDEN). Furthermore, EMIF has facilitated collaborations
      between partners and continues to promote a wider adoption of principles,
      technology and architecture through some of its continued work.
CI  - (c) 2019 The Authors. Learning Health Systems published by Wiley Periodicals,
      Inc. on behalf of the University of Michigan.
FAU - Lovestone, Simon
AU  - Lovestone S
AD  - Neurodegeneration, Janssen R&D, Janssen Pharmaceutica, Beerse, Belgium.
CN  - EMIF Consortium
LA  - eng
PT  - Journal Article
DEP - 20191225
PL  - United States
TA  - Learn Health Syst
JT  - Learning health systems
JID - 101708071
PMC - PMC7156868
OTO - NOTNLM
OT  - EMIF
OT  - EMIF-AD
OT  - EMIF-MET
OT  - catalogue
OT  - use case
COIS- The authors declare no conflict of interest in the publication of this
      manuscript.
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/06/19 00:00 [received]
PHST- 2019/11/27 00:00 [revised]
PHST- 2019/11/29 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1002/lrh2.10214 [doi]
AID - LRH210214 [pii]
PST - epublish
SO  - Learn Health Syst. 2019 Dec 25;4(2):e10214. doi: 10.1002/lrh2.10214. eCollection 
      2020 Apr.


PMID- 32313817
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210411
IS  - 2329-4302 (Print)
IS  - 2329-4302 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Jul
TI  - Virtual clinical trials in medical imaging: a review.
PG  - 042805
LID - 10.1117/1.JMI.7.4.042805 [doi]
AB  - The accelerating complexity and variety of medical imaging devices and methods
      have outpaced the ability to evaluate and optimize their design and clinical use.
      This is a significant and increasing challenge for both scientific investigations
      and clinical applications. Evaluations would ideally be done using clinical
      imaging trials. These experiments, however, are often not practical due to
      ethical limitations, expense, time requirements, or lack of ground truth. Virtual
      clinical trials (VCTs) (also known as in silico imaging trials or virtual imaging
      trials) offer an alternative means to efficiently evaluate medical imaging
      technologies virtually. They do so by simulating the patients, imaging systems,
      and interpreters. The field of VCTs has been constantly advanced over the past
      decades in multiple areas. We summarize the major developments and current status
      of the field of VCTs in medical imaging. We review the core components of a VCT: 
      computational phantoms, simulators of different imaging modalities, and
      interpretation models. We also highlight some of the applications of VCTs across 
      various imaging modalities.
CI  - (c) 2020 Society of Photo-Optical Instrumentation Engineers (SPIE).
FAU - Abadi, Ehsan
AU  - Abadi E
AUID- ORCID: https://orcid.org/0000-0002-9123-5854
AD  - Duke University, Department of Radiology, Durham, North Carolina, United States.
FAU - Segars, William P
AU  - Segars WP
AD  - Duke University, Department of Radiology, Durham, North Carolina, United States.
FAU - Tsui, Benjamin M W
AU  - Tsui BMW
AUID- ORCID: https://orcid.org/0000-0001-7928-5093
AD  - Johns Hopkins University, Department of Radiology, Baltimore, Maryland, United
      States.
FAU - Kinahan, Paul E
AU  - Kinahan PE
AUID- ORCID: https://orcid.org/0000-0001-6461-3306
AD  - University of Washington, Department of Radiology, Seattle, Washington, United
      States.
FAU - Bottenus, Nick
AU  - Bottenus N
AUID- ORCID: https://orcid.org/0000-0002-4080-2310
AD  - Duke University, Department of Biomedical Engineering, Durham, North Carolina,
      United States.
AD  - University of Colorado Boulder, Department of Mechanical Engineering, Boulder,
      Colorado, United States.
FAU - Frangi, Alejandro F
AU  - Frangi AF
AUID- ORCID: https://orcid.org/0000-0002-2675-528X
AD  - University of Leeds, School of Computing, Leeds, United Kingdom.
AD  - University of Leeds, School of Medicine, Leeds, United Kingdom.
FAU - Maidment, Andrew
AU  - Maidment A
AD  - University of Pennsylvania, Department of Radiology, Philadelphia, Pennsylvania, 
      United States.
FAU - Lo, Joseph
AU  - Lo J
AUID- ORCID: https://orcid.org/0000-0002-9540-5072
AD  - Duke University, Department of Radiology, Durham, North Carolina, United States.
FAU - Samei, Ehsan
AU  - Samei E
AD  - Duke University, Department of Radiology, Durham, North Carolina, United States.
LA  - eng
GR  - R01 EB001838/EB/NIBIB NIH HHS/United States
GR  - R01 HL131753/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20200411
PL  - United States
TA  - J Med Imaging (Bellingham)
JT  - Journal of medical imaging (Bellingham, Wash.)
JID - 101643461
PMC - PMC7148435
OTO - NOTNLM
OT  - computational phantoms
OT  - in silico imaging
OT  - medical imaging simulation
OT  - simulations
OT  - virtual clinical trials
OT  - virtual imaging trials
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1117/1.JMI.7.4.042805 [doi]
AID - 19247SSVR [pii]
PST - ppublish
SO  - J Med Imaging (Bellingham). 2020 Jul;7(4):042805. doi: 10.1117/1.JMI.7.4.042805. 
      Epub 2020 Apr 11.


PMID- 32313814
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2326-9901 (Electronic)
IS  - 2326-9901 (Linking)
VI  - 7
IP  - 1
DP  - 2020
TI  - A system for the high-throughput analysis of acute thermal avoidance and
      adaptation in C. elegans.
PG  - e129
LID - 10.14440/jbm.2020.324 [doi]
AB  - Nociception and its plasticity are essential biological processes controlling
      adaptive behavioral responses in animals. These processes are also linked to
      different pain conditions in human and have received considerable attention,
      notably via studies in rodent models and the use of heat-evoked withdrawal
      behavior assays as a readout of unpleasant experience. More recently,
      invertebrates have also emerged as useful complementary models, with their own
      set of advantages, including their amenability to genetic manipulations, the
      accessibility and relative simplicity of their nervous system and ethical
      concerns linked to animal suffering. Like humans, the nematode Caenorhabditis
      elegans (C. elegans) can detect noxious heat and produce avoidance responses such
      as reversals. Here, we present a methodology suitable for the high-throughput
      analysis of C. elegans heat-evoked reversals and the adaptation to repeated
      stimuli. We introduce two platforms: the INFERNO (for infrared-evoked reversal
      analysis platform), allowing the quantification of the thermal sensitivity in a
      petri dish containing a large population (> 100 animals), and the ThermINATOR
      (for thermal adaptation multiplexed induction platform), allowing the
      mass-adaptation of up to 18 worm populations at the same time. We show that wild 
      type animals progressively desensitize in response to repeated noxious heat
      pulses. Furthermore, analyzing the phenotype of mutant animals, we show that the 
      mechanisms underlying baseline sensitivity and adaptation, respectively, are
      supported by genetically separable molecular pathways. In conclusion, the
      presented method enables the high-throughput evaluation of thermal avoidance in
      C. elegans and will contribute to accelerate studies in the field with this
      invertebrate model.
CI  - (c) 2013-2020 The Journal of Biological Methods, All rights reserved.
FAU - Lia, Andrei-Stefan
AU  - Lia AS
AD  - Department of Biology, University of Fribourg, Fribourg, Switzerland.
FAU - Glauser, Dominique A
AU  - Glauser DA
AD  - Department of Biology, University of Fribourg, Fribourg, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200317
PL  - United States
TA  - J Biol Methods
JT  - Journal of biological methods
JID - 101639022
PMC - PMC7163209
OTO - NOTNLM
OT  - computer-assisted behavioral analysis
OT  - nematode
OT  - noxious heat avoidance
OT  - sensory plasticity
OT  - worm
COIS- Competing interests: The authors have declared that no competing interests exist.
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/02/13 00:00 [revised]
PHST- 2020/02/16 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.14440/jbm.2020.324 [doi]
PST - epublish
SO  - J Biol Methods. 2020 Mar 17;7(1):e129. doi: 10.14440/jbm.2020.324. eCollection
      2020.


PMID- 32313701
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2059-8661 (Electronic)
IS  - 2059-8661 (Linking)
VI  - 4
IP  - 2
DP  - 2020 Apr
TI  - Scientific Review Committees as part of institutional review of human participant
      research: Initial implementation at institutions with Clinical and Translational 
      Science Awards.
PG  - 115-124
LID - 10.1017/cts.2019.439 [doi]
AB  - INTRODUCTION: Scientific quality and feasibility are part of ethics review by
      Institutional Review Boards (IRBs). Scientific Review Committees (SRCs) were
      proposed to facilitate this assessment by the Clinical and Translational Science 
      Award (CTSA) SRC Consensus Group. This study assessed SRC feasibility and impact 
      at CTSA-affiliated academic health centers (AHCs). METHODS: SRC implementation at
      10 AHCs was assessed pre/post-intervention using quantitative and qualitative
      methods. Pre-intervention, four AHCs had no SRC, and six had at least one SRC
      needing modifications to better align with Consensus Group recommendations.
      RESULTS: Facilitators of successful SRC implementation included broad-based
      communication, an external motivator, senior-level support, and committed SRC
      reviewers. Barriers included limited resources and staffing, variable local
      mandates, limited SRC authority, lack of anticipated benefit, and operational
      challenges. Research protocol quality did not differ significantly between study 
      periods, but respondents suggested positive effects. During intervention, median 
      total review duration did not lengthen for the 40% of protocols approved within 3
      weeks. For the 60% under review after 3 weeks, review was lengthened primarily
      due to longer IRB review for SRC-reviewed protocols. Site interviews recommended 
      designing locally effective SRC processes, building buy-in by communication or by
      mandate, allowing time for planning and sharing best practices, and connecting
      SRC and IRB procedures. CONCLUSIONS: The CTSA SRC Consensus Group recommendations
      appear feasible. Although not conclusive in this relatively short initial
      implementation, sites perceived positive impact by SRCs on study quality. Optimal
      benefit will require local or federal mandate for implementation, adapting
      processes to local contexts, and employing SRC stipulations.
CI  - (c) The Association for Clinical and Translational Science 2020.
FAU - Selker, Harry P
AU  - Selker HP
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
AD  - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 
      Boston, MA, USA.
FAU - Welch, Lisa C
AU  - Welch LC
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
AD  - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 
      Boston, MA, USA.
FAU - Patchen-Fowler, Elizabeth
AU  - Patchen-Fowler E
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
FAU - Breeze, Janis L
AU  - Breeze JL
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
AD  - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 
      Boston, MA, USA.
FAU - Terrin, Norma
AU  - Terrin N
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
AD  - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 
      Boston, MA, USA.
FAU - Parajulee, Anshu
AU  - Parajulee A
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
FAU - LeClair, Amy
AU  - LeClair A
AD  - Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA,
      USA.
AD  - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 
      Boston, MA, USA.
FAU - Naeim, Arash
AU  - Naeim A
AD  - UCLA Clinical and Translational Science Institute, University of California, Los 
      Angeles (UCLA), Los Angeles, CA, USA.
FAU - Marnocha, Rebecca
AU  - Marnocha R
AD  - University of Wisconsin Institute for Clinical and Translational Research,
      University of Wisconsin-Madison, Madison, WI, USA.
FAU - Morelli Novak, Julie
AU  - Morelli Novak J
AD  - Tufts Health Sciences Institutional Review Board, Tufts University, Boston, MA,
      USA.
FAU - Caldwell, Christine Sego
AU  - Caldwell CS
AD  - Indiana Clinical and Translational Sciences Institute, Indiana University,
      Indianapolis, IN, USA.
FAU - Cola, Philip A
AU  - Cola PA
AD  - Clinical and Translational Science Collaborative (CTSC) of Cleveland, Case
      Western Reserve University, Cleveland, OH, USA.
FAU - Croker, Jennifer A
AU  - Croker JA
AD  - Center for Clinical and Translational Science, University of Alabama at
      Birmingham, Birmingham, AL, USA.
FAU - Cifu, David X
AU  - Cifu DX
AD  - VCU C. Kenneth and Dianne Wright Center for Clinical and Translational Research, 
      Virginia Commonwealth University, Richmond, VA, USA.
FAU - Williams, Kirsten M
AU  - Williams KM
AD  - Clinical and Translational Science Institute at Children's National, George
      Washington University, Washington, DC, USA.
FAU - Snyder, Denise C
AU  - Snyder DC
AD  - Duke Clinical and Translational Science Institute, Duke University School of
      Medicine, Durham, NC, USA.
FAU - Kitterman, Darlene
AU  - Kitterman D
AD  - Oregon Clinical and Translational Research Institute, Oregon Health and Science
      University, Portland, OR, USA.
LA  - eng
GR  - UL1 TR002649/TR/NCATS NIH HHS/United States
GR  - UL1 TR002548/TR/NCATS NIH HHS/United States
GR  - UL1 TR002529/TR/NCATS NIH HHS/United States
GR  - UL1 TR002369/TR/NCATS NIH HHS/United States
GR  - UL1 TR001876/TR/NCATS NIH HHS/United States
GR  - UL1 TR002553/TR/NCATS NIH HHS/United States
GR  - UL1 TR002373/TR/NCATS NIH HHS/United States
GR  - UL1 TR001417/TR/NCATS NIH HHS/United States
GR  - UL1 TR001881/TR/NCATS NIH HHS/United States
GR  - UL1 TR002544/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200127
PL  - England
TA  - J Clin Transl Sci
JT  - Journal of clinical and translational science
JID - 101689953
PMC - PMC7159811
OTO - NOTNLM
OT  - Ethics review
OT  - Scientific Review Committee
OT  - operational feasibility
OT  - quantitative and qualitative methods
OT  - scientific quality
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/08/28 00:00 [received]
PHST- 2019/11/14 00:00 [revised]
PHST- 2019/11/17 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1017/cts.2019.439 [doi]
PST - epublish
SO  - J Clin Transl Sci. 2020 Jan 27;4(2):115-124. doi: 10.1017/cts.2019.439.
      eCollection 2020 Apr.


PMID- 32313683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2055-5784 (Print)
IS  - 2055-5784 (Linking)
VI  - 6
DP  - 2020
TI  - A protocol for a pilot cluster randomized control trial of e-vouchers and mobile 
      phone application to enhance access to maternal health services in Cameroon.
PG  - 45
LID - 10.1186/s40814-020-00589-y [doi]
AB  - BACKGROUND: Cameroon still has relatively high maternal mortality rate (MMR) of
      596/100,000 live births. Approximately 40% of births are unattended by skilled
      healthcare personnel with high out-of-pocket expenditures. Poor resource
      allocation, poorly functioning referral systems, long trekking distances to
      health facilities, all of which lead to low rates of use of maternal health
      services. OBJECTIVES: The aim of this pilot study is to explore perception and
      acceptability of mobile health (mhealth) and e-voucher and to determine the
      feasibility of conducting a large cluster randomized trial to determine the
      effects of combining e-vouchers and a mobile application compared with usual care
      in improving access to and use of maternal health services. METHODS: This is a
      multimethod study that comprises two phases. The first phase is the development
      of the mobile phone app, which includes a qualitative formative study through
      in-depth key informant interviews and focus group discussions. The second phase
      is a cluster randomized control trial assessing the combination of e-vouchers and
      a mobile application compared with usual care in improving access to and use of
      maternal health services. Feasibility will be determined based on evaluating
      randomization, contamination, enrollment rate, complete follow up, compliance
      rate, success in matching data from different sources, and data completeness.
      ETHICS AND DISCUSSION: Ethics approval has been granted, and the trial has been
      registered in the Pan-African Clinical Trials Registry. We will disseminate our
      findings through peer-reviewed manuscripts and conference presentations. Findings
      from this study will inform the design and conduct of a larger randomized trial. 
      TRIAL REGISTRATION: PACTR201808703097367. The trial on the Pan African Clinical
      Trials Registry.
CI  - (c) The Author(s) 2020.
FAU - Nkangu, Miriam N
AU  - Nkangu MN
AD  - 1School of Epidemiology and Public Health, University of Ottawa, Ottawa,
      Canada.grid.28046.380000 0001 2182 2255
AD  - Health Promotion Alliance Cameroon (HPAC), Yaounde, Cameroon.
AD  - 9WHO Collaborating Center for Knowledge Translation and Health Technology
      Assessment in Health Equity, Ottawa University, Ottawa, Canada.grid.28046.380000 
      0001 2182 2255
AD  - 10Bruyere Research Institute, Ottawa, Canada.grid.418792.10000 0000 9064 3333
FAU - Okwen, Patrick M
AU  - Okwen PM
AD  - Effective Basic Services (eBASE) Africa, Bamenda, Cameroon.
FAU - Mbuagbaw, Lawrence
AU  - Mbuagbaw L
AD  - 3Department of Health Research Methods, Evidence and Impact, McMaster University,
      Hamilton, Canada.grid.25073.330000 0004 1936 8227
AD  - 4Biostatistics Unit, The Research Institute, St Joseph's Healthcare Hamilton,
      Hamilton, Canada.grid.416721.70000 0001 0742 7355
AD  - Centre for the Development of Best Practices in Health, Yaounde, Cameroon.
FAU - Weledji, Donald K
AU  - Weledji DK
AD  - SPRL Donwels System, Brussels, Belgium.
FAU - Roberts, Janet Hatcher
AU  - Roberts JH
AD  - 1School of Epidemiology and Public Health, University of Ottawa, Ottawa,
      Canada.grid.28046.380000 0001 2182 2255
AD  - 9WHO Collaborating Center for Knowledge Translation and Health Technology
      Assessment in Health Equity, Ottawa University, Ottawa, Canada.grid.28046.380000 
      0001 2182 2255
AD  - 10Bruyere Research Institute, Ottawa, Canada.grid.418792.10000 0000 9064 3333
FAU - Yaya, Sanni
AU  - Yaya S
AD  - 8School of International Development and Global Studies, University of Ottawa,
      Ottawa, Canada.grid.28046.380000 0001 2182 2255
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - England
TA  - Pilot Feasibility Stud
JT  - Pilot and feasibility studies
JID - 101676536
PMC - PMC7155248
OTO - NOTNLM
OT  - Cluster randomized control trials
OT  - Family planning
OT  - Feasibility
OT  - Geographic information system
OT  - Maternal mortality
OT  - Pilot
OT  - Qualitative research
OT  - Reproductive health
OT  - Vouchers
OT  - mHealth
COIS- Competing interestThe authors declare that they have no competing interest.
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/03/05 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1186/s40814-020-00589-y [doi]
AID - 589 [pii]
PST - epublish
SO  - Pilot Feasibility Stud. 2020 Apr 14;6:45. doi: 10.1186/s40814-020-00589-y.
      eCollection 2020.


PMID- 32313603
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1935-7877 (Print)
IS  - 1935-7877 (Linking)
VI  - 21
IP  - 1
DP  - 2020
TI  - An Undergraduate Elective Course That Introduces Topics of Diversity, Equity, and
      Inclusion into Discussions of Science.
LID - 21.1.10 [pii]
LID - 10.1128/jmbe.v21i1.1947 [doi]
AB  - In this Science, Ethics, and Society elective undergraduate course at the St.
      Louis College of Pharmacy, students consider topics that scientists face
      continuously, including human and animal subjects, science denial, treatment of
      scientists, who owns and funds science, personalized medicine and genetics,
      health disparities, and scientific integrity, all through lenses of inclusion and
      equity. Students read primary and secondary literature pertaining to each day's
      topic, upload reflections to a course management system, and engage in structured
      dialogue in a facilitated classroom environment. Overarching themes address how
      women and men and their scientific work have been treated or received
      differently, as well as particular challenges faced by people of color, members
      of the LGBTQIA+ community, and those with disabilities. This course helps
      students see how the culture of science has been created and sustained, how it
      has not encouraged equal participation, and how it could be shaped differently.
      Student responses to the course recognize that this approach to the scientific
      material is valuable and that it does not appear elsewhere in their curriculum.
CI  - (c)2020 Author(s). Published by the American Society for Microbiology.
FAU - Reese, Amy J
AU  - Reese AJ
AD  - Department of Basic Sciences, St. Louis College of Pharmacy, St. Louis, MO 63110.
LA  - eng
PT  - Journal Article
DEP - 20200410
PL  - United States
TA  - J Microbiol Biol Educ
JT  - Journal of microbiology & biology education
JID - 101543341
PMC - PMC7148155
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1128/jmbe.v21i1.1947 [doi]
AID - jmbe-21-10 [pii]
PST - epublish
SO  - J Microbiol Biol Educ. 2020 Apr 10;21(1). pii: jmbe-21-10. doi:
      10.1128/jmbe.v21i1.1947. eCollection 2020.


PMID- 32313495
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0899-8280 (Print)
IS  - 0899-8280 (Linking)
VI  - 33
IP  - 2
DP  - 2020 Apr
TI  - A fellowcraft's application of the plumb, the square, and the level in medical
      practice.
PG  - 302-304
LID - 10.1080/08998280.2020.1711683 [doi]
AB  - In Freemasonry, each degree represents the refining and transformation of the
      individual through a unique set of working tools that symbolize the progression
      of lessons from an entered apprentice to a master mason. For a fellowcraft, the
      lessons are represented by the tools of the square, level, and plumb. With these 
      tools, masons are reminded how to conduct themselves and interact with others.
      The application of the fellowcraft working tools to medical practice emphasizes
      aspects of the physician-patient relationship and the ethical treatment of
      patients.
CI  - Copyright (c) 2020 Baylor University Medical Center.
FAU - Kopel, Jonathan
AU  - Kopel J
AUID- ORCID: 0000-0001-5934-2695
AD  - School of Medicine, Texas Tech University Health Sciences CenterLubbockTexas.
LA  - eng
PT  - Journal Article
DEP - 20200113
PL  - United States
TA  - Proc (Bayl Univ Med Cent)
JT  - Proceedings (Baylor University. Medical Center)
JID - 9302033
PMC - PMC7156001
OTO - NOTNLM
OT  - Fellowcraft
OT  - Freemasonry
OT  - level
OT  - medical education
OT  - plumb
OT  - square
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2019/12/17 00:00 [revised]
PHST- 2019/12/30 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
AID - 10.1080/08998280.2020.1711683 [doi]
AID - 1711683 [pii]
PST - epublish
SO  - Proc (Bayl Univ Med Cent). 2020 Jan 13;33(2):302-304. doi:
      10.1080/08998280.2020.1711683. eCollection 2020 Apr.


PMID- 32313280
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 84
IP  - 3
DP  - 2020 Mar
TI  - The Impact of Pharmacy Student Participation in the White Coat Ceremony on
      Professionalization.
PG  - 7689
LID - 10.5688/ajpe7689 [doi]
AB  - Objective. To assess the impact of participation in a formal white coat ceremony 
      on Doctor of Pharmacy (PharmD) students' professionalization by analyzing
      students' reflective writing. Methods. First-year PharmD students participated in
      the college's white coat ceremony following orientation. During the Foundations
      of Pharmacy course in the first semester, students were instructed to reflect on 
      and write about the impact the white coat ceremony had on them as a graded
      assignment. A grading rubric was developed to standardize assessment of the
      reflections and to differentiate critical reflection (which cites future
      behavioral change) from other forms of reflection that are less impactful, such
      as non-critical reflection, general understanding, and non-reflection. Thematic
      analysis was conducted and prevalent themes were identified. Each reflection was 
      then reviewed to identify up to three themes. Results. Of the 225 students in the
      incoming class of 2020, 218 submitted valid reflection assignments. Of these, 92%
      met critical reflection criteria. Four percent offered "negative connotation,"
      while 75% described an eye-opening experience or realization. Of 483 thematic
      classifications, six student professionalization themes were identified, as
      follows: personal achievement (26%), professionalism (21%), welcome to pharmacy
      (18%), patient care (16.8%), life-long learning (12.8%), and code of ethics
      (5.2%). Conclusion. For the majority of PharmD students, the white coat ceremony 
      held during first-year orientation had a positive impact on their
      professionalization. All pharmacy schools should conduct a white coat ceremony
      that includes recitation of the Pledge of Professionalism as an impactful first
      step toward student professionalization.
CI  - (c) 2020 American Association of Colleges of Pharmacy.
FAU - Briceland, Laurie L
AU  - Briceland LL
AD  - Albany College of Pharmacy and Health Sciences, Albany, New York.
FAU - Brewer, Jeffrey M
AU  - Brewer JM
AD  - Albany College of Pharmacy and Health Sciences, Albany, New York.
FAU - Dominelli, Angela
AU  - Dominelli A
AD  - Albany College of Pharmacy and Health Sciences, Albany, New York.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
MH  - Ceremonial Behavior
MH  - Cohort Studies
MH  - Education, Pharmacy/*trends
MH  - Humans
MH  - Learning
MH  - Professionalism/*education
MH  - Students, Pharmacy/psychology
MH  - Writing
PMC - PMC7159004
OTO - NOTNLM
OT  - *professional identity formation
OT  - *reflective practitioner
OT  - *reflective writing
OT  - *student professional development
OT  - *white coat ceremony
EDAT- 2020/04/22 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.5688/ajpe7689 [doi]
AID - ajpe7689 [pii]
PST - ppublish
SO  - Am J Pharm Educ. 2020 Mar;84(3):7689. doi: 10.5688/ajpe7689.


PMID- 32313274
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 84
IP  - 3
DP  - 2020 Mar
TI  - Status of Pharmacy Ethics Education in Australia and New Zealand.
PG  - 7452
LID - 10.5688/ajpe7452 [doi]
AB  - Objective. To explore models of teaching in, resources available to, and delivery
      of a standardized course in pharmacy ethics. Methods. An email invitation was
      sent to the educator responsible for teaching pharmacy ethics at each of 19
      institutions in Australia and New Zealand. Over a six- to eight-week period,
      semi-structured interviews were conducted in person, by email, or by phone, and
      were audio-recorded where possible, transcribed verbatim, and entered into data
      analysis software. Using an inductive analysis approach, themes related to the
      topics and issues discussed in the interview process were identified. Results. Of
      the educators invited to participate, 17 completed an interview and were included
      in this study. Participants reported a paucity of resources available for
      teaching pharmacy ethics at schools in Australia and New Zealand. Compounding
      this issue was the lack of expertise and ad-hoc process educators used to create 
      their courses. Assessment methods varied between institutions. Participants felt 
      schools needed to move toward a more standardized pharmacy ethics course with
      clear and defined guidelines. Conclusion. This study identified many areas in
      pharmacy ethics that need improvement and revealed the need to develop resources 
      and course structure that adhere to the highest level of Miller's pyramid, while 
      using known frameworks to evaluate ethical competency.
CI  - (c) 2020 American Association of Colleges of Pharmacy.
FAU - Beshara, Stephanie
AU  - Beshara S
AD  - The University of Sydney, Sydney Pharmacy School, Sydney, Australia.
FAU - Herron, David
AU  - Herron D
AD  - James Cook University, College of Medicine and Dentistry, Queensland, Australia.
FAU - Moles, Rebekah J
AU  - Moles RJ
AD  - The University of Sydney, Sydney Pharmacy School, Sydney, Australia.
FAU - Chaar, Betty
AU  - Chaar B
AD  - The University of Sydney, Sydney Pharmacy School, Sydney, Australia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
MH  - Australia
MH  - Curriculum
MH  - Education, Pharmacy/methods
MH  - Ethics, Pharmacy/*education
MH  - Health Educators
MH  - Humans
MH  - Interviews as Topic
MH  - New Zealand
MH  - Program Development/methods
MH  - Students, Pharmacy
MH  - Teaching
PMC - PMC7159001
OTO - NOTNLM
OT  - *Miller's pyramid
OT  - *course structure
OT  - *ethics
OT  - *resources
OT  - *teaching
EDAT- 2020/04/22 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - 10.5688/ajpe7452 [doi]
AID - ajpe7452 [pii]
PST - ppublish
SO  - Am J Pharm Educ. 2020 Mar;84(3):7452. doi: 10.5688/ajpe7452.


PMID- 32313250
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20210123
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 26
IP  - 6
DP  - 2020 Jun
TI  - Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in
      rheumatology.
PG  - 974-980
LID - 10.1038/s41591-020-0833-4 [doi]
AB  - Phase 3 trials are the mainstay of drug development across medicine but have
      often not met expectations set by preceding phase 2 studies. A systematic
      meta-analysis evaluated all randomized controlled, double-blind trials
      investigating targeted disease-modifying anti-rheumatic drugs in rheumatoid and
      psoriatic arthritis. Primary outcomes of American College of Rheumatology (ACR)
      20 responses were compared by mixed-model logistic regression, including
      exploration of potential determinants of efficacy overestimation. In rheumatoid
      arthritis, phase 2 trial outcomes systematically overestimated subsequent phase 3
      results (odds ratio comparing ACR20 in phase 2 versus phase 3: 1.39, 95%
      confidence interval: 1.25-1.57, P < 0.001). Data for psoriatic arthritis trials
      were similar, but not statistically significant (odds ratio comparing ACR20 in
      phase 2 versus phase 3: 1.35, 95% confidence interval: 0.94-1.94, P = 0.09).
      Differences in inclusion criteria largely explained the observed differences in
      efficacy findings. Our findings have implications for all stakeholders in new
      therapeutic development and testing, as well as potential ethical implications.
FAU - Kerschbaumer, Andreas
AU  - Kerschbaumer A
AUID- ORCID: http://orcid.org/0000-0002-6685-8873
AD  - Division of Rheumatology, Department of Internal Medicine III, Medical University
      of Vienna, Vienna, Austria.
FAU - Smolen, Josef S
AU  - Smolen JS
AUID- ORCID: http://orcid.org/0000-0002-4302-8877
AD  - Division of Rheumatology, Department of Internal Medicine III, Medical University
      of Vienna, Vienna, Austria.
FAU - Herkner, Harald
AU  - Herkner H
AUID- ORCID: http://orcid.org/0000-0003-1329-6149
AD  - Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria.
FAU - Stefanova, Tijen
AU  - Stefanova T
AD  - Division of Rheumatology, Department of Internal Medicine III, Medical University
      of Vienna, Vienna, Austria.
FAU - Chwala, Eva
AU  - Chwala E
AUID- ORCID: http://orcid.org/0000-0001-7686-5535
AD  - University Library, Medical University of Vienna, Vienna, Austria.
FAU - Aletaha, Daniel
AU  - Aletaha D
AUID- ORCID: http://orcid.org/0000-0003-2108-0030
AD  - Division of Rheumatology, Department of Internal Medicine III, Medical University
      of Vienna, Vienna, Austria. daniel.aletaha@meduniwien.ac.at.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200420
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (Antirheumatic Agents)
SB  - IM
CIN - Nat Rev Rheumatol. 2020 Jul;16(7):359-360. PMID: 32504076
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - *Clinical Trials, Phase II as Topic
MH  - *Clinical Trials, Phase III as Topic
MH  - Drug Development
MH  - Humans
MH  - Logistic Models
MH  - Outcome Assessment, Health Care
MH  - *Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2020/04/22 06:00
MHDA- 2020/09/09 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/09/19 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1038/s41591-020-0833-4 [doi]
AID - 10.1038/s41591-020-0833-4 [pii]
PST - ppublish
SO  - Nat Med. 2020 Jun;26(6):974-980. doi: 10.1038/s41591-020-0833-4. Epub 2020 Apr
      20.


PMID- 32313152
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20220210
IS  - 1530-0366 (Electronic)
IS  - 1098-3600 (Linking)
VI  - 22
IP  - 7
DP  - 2020 Jul
TI  - Mainstreaming genetics and genomics: a systematic review of the barriers and
      facilitators for nurses and physicians in secondary and tertiary care.
PG  - 1149-1155
LID - 10.1038/s41436-020-0785-6 [doi]
AB  - PURPOSE: Genetic and genomic health information increasingly informs routine
      clinical care and treatment. This systematic review aimed to identify the
      barriers and facilitators to integrating genetics and genomics into nurses' and
      physicians' usual practice (mainstreaming). METHODS: A search of MEDLINE, EMBASE,
      CINAHL, and PsycINFO generated 7873 articles, of which 48 were included. Using
      narrative synthesis, barriers and facilitators were mapped to the Theoretical
      Domains Framework (TDF). RESULTS: Barriers were limitations to genetics knowledge
      and skill, low confidence initiating genetics discussions, lack of resources and 
      guidelines, and concerns about discrimination and psychological harm.
      Facilitators were positive attitudes toward genetics, willingness to participate 
      in discussions upon patient initiation, and intention to engage in genetics
      education. CONCLUSION: Nurses and physicians are largely underprepared to
      integrate genetic and genomic health information into routine clinical care.
      Ethical, legal, and psychological concerns surrounding genetic information can
      lead to avoidance of genetics discussions. The knowledge-practice gap could limit
      patients' and families' access to vital genetic information. Building the
      capacity of the current and next generation of nurses and physicians to integrate
      genetics and genomics into usual clinical practice is essential if opportunities 
      afforded by precision medicine are to be fully realized.
FAU - White, Stephanie
AU  - White S
AUID- ORCID: http://orcid.org/0000-0002-5550-6397
AD  - Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia.
      stephanie.a.white@student.uts.edu.au.
FAU - Jacobs, Chris
AU  - Jacobs C
AD  - Graduate School of Health, University of Technology Sydney, Ultimo, NSW,
      Australia.
FAU - Phillips, Jane
AU  - Phillips J
AD  - Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20200421
PL  - United States
TA  - Genet Med
JT  - Genetics in medicine : official journal of the American College of Medical
      Genetics
JID - 9815831
SB  - IM
MH  - *Genomics
MH  - Humans
MH  - *Physicians
MH  - Tertiary Healthcare
OTO - NOTNLM
OT  - *behavior change
OT  - *genetics
OT  - *genomics
OT  - *implementation science
OT  - *mainstreaming
EDAT- 2020/04/22 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/13 00:00 [accepted]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - 10.1038/s41436-020-0785-6 [doi]
AID - S1098-3600(21)01181-3 [pii]
PST - ppublish
SO  - Genet Med. 2020 Jul;22(7):1149-1155. doi: 10.1038/s41436-020-0785-6. Epub 2020
      Apr 21.


PMID- 32313041
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20210420
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Apr 20
TI  - Determining organ weight toxicity with Bayesian causal models: Improving on the
      analysis of relative organ weights.
PG  - 6625
LID - 10.1038/s41598-020-63465-y [doi]
AB  - Regulatory authorities require animal toxicity tests for new chemical entities.
      Organ weight changes are accepted as a sensitive indicator of chemically induced 
      organ damage, but can be difficult to interpret because changes in organ weight
      might reflect chemically-induced changes in overall body weight. A common
      solution is to calculate the relative organ weight (organ to body weight ratio), 
      but this inadequately controls for the dependence on body weight - a point made
      by statisticians for decades, but which has not been widely adopted. The
      recommended solution is an analysis of covariance (ANCOVA), but it is rarely
      used, possibly because both the method of statistical correction and the
      interpretation of the output may be unclear to those with minimal statistical
      training. Using relative organ weights can easily lead to incorrect conclusions, 
      resulting in poor decisions, wasted resources, and an ethically questionable use 
      of animals. We propose to cast the problem into a causal modelling framework as
      it directly assesses questions of scientific interest, the results are easy to
      interpret, and the analysis is simple to perform with freely available software. 
      Furthermore, by taking a Bayesian approach we can model unequal variances,
      control for multiple testing, and directly provide evidence of safety.
FAU - Lazic, Stanley E
AU  - Lazic SE
AD  - Data Sciences and Quantitative Biology, AstraZeneca, R&D, Cambridge, CB4 0WG, UK.
      stan.lazic@cantab.net.
AD  - Prioris.ai Inc., Suite 459, 207 Bank Street, Ottawa, K2P 2N2, Canada.
      stan.lazic@cantab.net.
FAU - Semenova, Elizaveta
AU  - Semenova E
AUID- ORCID: http://orcid.org/0000-0002-8271-2575
AD  - Data Sciences and Quantitative Biology, AstraZeneca, R&D, Cambridge, CB4 0WG, UK.
FAU - Williams, Dominic P
AU  - Williams DP
AD  - Functional and Mechanistic Safety, Clinical Pharmacology and Safety Sciences,
      AstraZeneca, R&D, Cambridge, CB4 0WG, UK.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Chromates)
RN  - C9G6VY6ZZ4 (sodium bichromate)
SB  - IM
MH  - Animals
MH  - Bayes Theorem
MH  - Body Weight
MH  - Chromates/toxicity
MH  - Computer Simulation
MH  - Female
MH  - Liver/pathology
MH  - *Models, Biological
MH  - Organ Size
MH  - Probability
MH  - Rats, Inbred F344
MH  - *Toxicity Tests
PMC - PMC7170916
EDAT- 2020/04/22 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/09/10 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
AID - 10.1038/s41598-020-63465-y [doi]
AID - 10.1038/s41598-020-63465-y [pii]
PST - epublish
SO  - Sci Rep. 2020 Apr 20;10(1):6625. doi: 10.1038/s41598-020-63465-y.


PMID- 32312798
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210919
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Jun
TI  - The Broader Sharing of Deceased Donor Kidneys Is an Ethical and Legal Imperative.
PG  - 1174-1176
LID - 10.1681/ASN.2020020121 [doi]
FAU - Klarman, Sharon E
AU  - Klarman SE
AD  - Department of Nursing, Yale-New Haven Hospital Transplantation Center, New Haven,
      Connecticut.
FAU - Formica, Richard N Jr
AU  - Formica RN Jr
AD  - Department of Medicine, Section of Nephrology, Yale University, New Haven,
      Connecticut richard.formica@yale.edu.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200420
PL  - United States
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
SB  - IM
MH  - Humans
MH  - *Kidney Transplantation
MH  - *Tissue Donors
MH  - Tissue and Organ Procurement/*ethics/*legislation & jurisprudence
PMC - PMC7269362
OTO - NOTNLM
OT  - *cadaver organ transplantation
OT  - *clinical nephrology
OT  - *kidney transplantation
EDAT- 2020/04/22 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - ASN.2020020121 [pii]
AID - 10.1681/ASN.2020020121 [doi]
PST - ppublish
SO  - J Am Soc Nephrol. 2020 Jun;31(6):1174-1176. doi: 10.1681/ASN.2020020121. Epub
      2020 Apr 20.


PMID- 32312756
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 2059-7029 (Electronic)
IS  - 2059-7029 (Linking)
VI  - 5
IP  - 2
DP  - 2020 Apr
TI  - Preferences to receive unsolicited findings of germline genome sequencing in a
      large population of patients with cancer.
LID - e000619 [pii]
LID - 10.1136/esmoopen-2019-000619 [doi]
AB  - BACKGROUND: In precision medicine, somatic and germline DNA sequencing are
      essential to make genome-guided treatment decisions in patients with cancer.
      However, it can also uncover unsolicited findings (UFs) in germline DNA that
      could have a substantial impact on the lives of patients and their relatives. It 
      is therefore critical to understand the preferences of patients with cancer
      concerning UFs derived from whole-exome (WES) or whole-genome sequencing (WGS).
      METHODS: In a quantitative multicentre study, adult patients with cancer (any
      stage and origin of disease) were surveyed through a digital questionnaire based 
      on previous semi-structured interviews. Background knowledge was provided by
      showing two videos, introducing basic concepts of genetics and general
      information about different categories of UFs (actionable, non-actionable,
      reproductive significance, unknown significance). RESULTS: In total 1072 patients
      were included of whom 701 participants completed the whole questionnaire.
      Overall, 686 (85.1%) participants wanted to be informed about UFs in general.
      After introduction of four UFs categories, 113 participants (14.8%) changed their
      answer: 718 (94.2%) participants opted for actionable variants, 537 (72.4%) for
      non-actionable variants, 635 (87.0%) participants for UFs of reproductive
      significance and 521 (71.8%) for UFs of unknown significance. Men were more
      interested in receiving certain UFs than women: non-actionable: OR 3.32; 95% CI
      2.05 to 5.37, reproductive significance: OR 1.97; 95% CI 1.05 to 3.67 and unknown
      significance: OR 2.00; 95% CI 1.25 to 3.21. In total, 244 (33%) participants
      conceded family members to have access to their UFs while still alive. 603 (82%) 
      participants agreed to information being shared with relatives, after they would 
      pass away. CONCLUSION: Our study showed that the vast majority of patients with
      cancer desires to receive all UFs of genome testing, although a substantial
      minority does not wish to receive non-actionable findings. Incorporation of
      categories in informed consent procedures supports patients in making informed
      decisions on UFs.
CI  - (c) Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. Published by BMJ on behalf of the European Society for Medical
      Oncology.
FAU - Bijlsma, Rhode
AU  - Bijlsma R
AUID- ORCID: 0000-0003-0980-6652
AD  - Department of Medical Oncology, University Medical Center Utrecht, Cancer Center,
      Utrecht, The Netherlands.
FAU - Wouters, Roel
AU  - Wouters R
AD  - Department of Medical Humanities, University Medical Center Utrecht, Julius
      Center, Utrecht, The Netherlands.
FAU - Wessels, Hester
AU  - Wessels H
AD  - Department of Corporate Communications, University Medical Center Utrecht,
      Utrecht, The Netherlands.
FAU - Sleijfer, Stefan
AU  - Sleijfer S
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The
      Netherlands.
AD  - Center for Personalized Cancer Treatment (CPCT), Rotterdam, The Netherlands.
FAU - Beerepoot, Laurens
AU  - Beerepoot L
AD  - Department of Medical Oncology, Elisabeth-Tweesteden Hospital, Tilburg, The
      Netherlands.
FAU - Ten Bokkel Huinink, Daan
AU  - Ten Bokkel Huinink D
AD  - Department of Medical Oncology, Diakonessenhuis, Utrecht, The Netherlands.
FAU - Cruijsen, Hester
AU  - Cruijsen H
AD  - Department of Medical Oncology, Antonius Hospital, Sneek, The Netherlands.
FAU - Heijns, Joan
AU  - Heijns J
AD  - Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands.
FAU - Lolkema, Martijn P
AU  - Lolkema MP
AD  - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The
      Netherlands.
FAU - Steeghs, Neeltje
AU  - Steeghs N
AD  - Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
FAU - van Voorthuizen, Theo
AU  - van Voorthuizen T
AD  - Department of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands.
FAU - Vulink, Annelie
AU  - Vulink A
AD  - Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, The
      Netherlands.
FAU - Witteveen, Els
AU  - Witteveen E
AD  - Department of Medical Oncology, University Medical Center Utrecht, Cancer Center,
      Utrecht, The Netherlands.
FAU - Ausems, Margreet
AU  - Ausems M
AD  - Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, 
      University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Bredenoord, Annelien
AU  - Bredenoord A
AD  - Department of Medical Humanities, University Medical Center Utrecht, Julius
      Center, Utrecht, The Netherlands.
FAU - May, Anne M
AU  - May AM
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Voest, Emile
AU  - Voest E
AUID- ORCID: 0000-0001-8249-9586
AD  - Center for Personalized Cancer Treatment (CPCT), Rotterdam, The Netherlands
      e.voest@nki.nl.
AD  - Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
SB  - IM
MH  - Female
MH  - Germ-Line Mutation/*genetics
MH  - Humans
MH  - Male
MH  - Neoplasms/*genetics
MH  - Whole Genome Sequencing/*methods
PMC - PMC7200077
OTO - NOTNLM
OT  - *cancer patients
OT  - *ethics
OT  - *genome sequencing
OT  - *preferences
OT  - *unsolicited finding
COIS- Competing interests: None declared.
EDAT- 2020/04/22 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2019/12/05 00:00 [revised]
PHST- 2019/12/29 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - S2059-7029(20)30053-3 [pii]
AID - 10.1136/esmoopen-2019-000619 [doi]
PST - ppublish
SO  - ESMO Open. 2020 Apr;5(2). pii: S2059-7029(20)30053-3. doi:
      10.1136/esmoopen-2019-000619.


PMID- 32312727
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210523
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 19
TI  - Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study
      protocol for a randomised controlled trial.
PG  - e035947
LID - 10.1136/bmjopen-2019-035947 [doi]
AB  - INTRODUCTION: Diabetes affects more than 425 million people worldwide with a
      lifetime risk of diabetic foot ulcer (DFU) of up to 25%. Management includes
      wound debridement, wound dressings, offloading, treatment of infection and
      ischaemia, optimising glycaemic control; use of advanced adjuvant therapies is
      limited by high cost and lack of robust evidence. METHODS AND ANALYSIS: A
      multicentre, seamless phase II/III, open, parallel group, multi-arm multi-stage
      randomised controlled trial in patients with a hard-to-heal DFU, with blinded
      outcome assessment. A maximum of 447 participants will be randomised (245
      participants in phase II and 202 participants in phase III). The phase II primary
      objective will determine the efficacy of treatment strategies including
      hydrosurgical debridement +/- decellularised dermal allograft, or the combination
      with negative pressure wound therapy, as an adjunct to treatment as usual (TAU), 
      compared with TAU alone, with patients randomised in a 1:1:1:2 allocation. The
      outcome is achieving at least 50% reduction in index ulcer area at 4 weeks post
      randomisation.The phase III primary objective will determine whether one
      treatment strategy, continued from phase II, reduces time to healing of the index
      ulcer compared with TAU alone, with participants randomised in a 1:1 allocation. 
      Secondary objectives will compare healing status of the index ulcer, infection
      rate, reulceration, quality of life, cost-effectiveness and incidence of adverse 
      events over 52 weeks post randomisation. Phase II and phase III primary endpoint 
      analysis will be conducted using a mixed-effects logistic regression model and
      Cox proportional hazards regression, respectively. A within-trial economic
      evaluation will be undertaken; the primary economic analysis will be a
      cost-utility analysis presenting ICERs for each treatment strategy in rank order 
      of effectiveness, with effects expressed as quality-adjusted life years.The trial
      has predefined progression criteria for the selection of one treatment strategy
      into phase III based on efficacy, safety and costs at 4 weeks. ETHICS AND
      DISSEMINATION: Ethics approval has been granted by the National Research Ethics
      Service (NRES) Committee Yorkshire and The Humber - Bradford Leeds Research
      Ethics Committee; approved 26 April 2017; (REC reference: 17/YH/0055). There is
      planned publication of a monograph in National Institute for Health Research
      journals and main trial results and associated papers in high-impact
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: ISRCTN64926597; registered on 
      6 June 2017.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brown, Sarah
AU  - Brown S
AUID- ORCID: 0000-0002-1840-3786
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK medsbro@leeds.ac.uk.
FAU - Nixon, Jane
AU  - Nixon J
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
FAU - Ransom, Myka
AU  - Ransom M
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
FAU - Gilberts, Rachael
AU  - Gilberts R
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
FAU - Dewhirst, Nikki
AU  - Dewhirst N
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
AD  - Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - McGinnis, Elizabeth
AU  - McGinnis E
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
AD  - Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Longo, Roberta
AU  - Longo R
AD  - Academic Unit of Health Economics, Leeds Institute of Health Sciences, University
      of Leeds, Leeds, UK.
FAU - Game, Frances
AU  - Game F
AD  - Derby Teaching Hospitals NHS Fundation Trust, Derby, UK.
FAU - Bojke, Chris
AU  - Bojke C
AD  - Academic Unit of Health Economics, Leeds Institute of Health Sciences, University
      of Leeds, Leeds, UK.
FAU - Chadwick, Paul
AU  - Chadwick P
AD  - College of Podiatry, London, UK.
FAU - Chandrasekar, Akila
AU  - Chandrasekar A
AD  - NHS Blood and Transplant, Liverpool, UK.
FAU - Chetter, Ian
AU  - Chetter I
AD  - University of Hull, Hull, UK.
FAU - Collier, Howard
AU  - Collier H
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
FAU - Fernandez, Catherine
AU  - Fernandez C
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
FAU - Homer-Vanniasinkam, Shervanthi
AU  - Homer-Vanniasinkam S
AD  - Leeds Teaching Hospitals NHS Trust, Leeds, UK.
FAU - Jude, Edward
AU  - Jude E
AD  - Tameside General Hospital, Manchester, UK.
FAU - Leigh, Richard
AU  - Leigh R
AD  - Royal Free London NHS Foundation Trust, London, UK.
FAU - Lomas, Richard
AU  - Lomas R
AD  - NHS Blood and Transplant, Liverpool, UK.
FAU - Vowden, Peter
AU  - Vowden P
AD  - Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
FAU - Wason, James
AU  - Wason J
AD  - MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
AD  - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
      UK.
FAU - Sharples, Linda
AU  - Sharples L
AD  - Department of Medical Statistics, London Schoool of Hygience and Tropical
      Medicine, London, UK.
FAU - Russell, David
AU  - Russell D
AD  - Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research,
      University of Leeds, Leeds, UK.
AD  - Leeds Teaching Hospitals NHS Trust, Leeds, UK.
LA  - eng
GR  - 15/08/77/DH_/Department of Health/United Kingdom
GR  - MC_UU_00002/6/MRC_/Medical Research Council/United Kingdom
GR  - MR/N028171/1/MRC_/Medical Research Council/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200419
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Acellular Dermis
MH  - Adult
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Cost-Benefit Analysis
MH  - *Debridement
MH  - Diabetes Mellitus
MH  - *Diabetic Foot/therapy
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Negative-Pressure Wound Therapy
MH  - Quality of Life
MH  - Quality-Adjusted Life Years
MH  - Randomized Controlled Trials as Topic
MH  - *Skin Transplantation
MH  - Wound Healing
PMC - PMC7245399
OTO - NOTNLM
OT  - *clinical trials
OT  - *diabetes & endocrinology
OT  - *diabetic foot
OT  - *statistics & research methods
OT  - *wound management
COIS- Competing interests: AC and RLom are employees of NHS Blood and Transplant who
      provide the DCD.
EDAT- 2020/04/22 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-035947 [pii]
AID - 10.1136/bmjopen-2019-035947 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 19;10(4):e035947. doi: 10.1136/bmjopen-2019-035947.


PMID- 32312723
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 19
TI  - Eversion technique versus conventional endarterectomy with patch angioplasty in
      carotid surgery: protocol for a systematic review with meta-analyses and trial
      sequential analysis of randomised clinical trials.
PG  - e030503
LID - 10.1136/bmjopen-2019-030503 [doi]
AB  - INTRODUCTION: Traditional carotid endarterectomy is considered to be the standard
      technique for prevention of a new stroke in patients with a symptomatic carotid
      stenosis. Use of patch angioplasty to restore the arterial wall after
      longitudinal endarterectomy is, to date, not unequivocally proven to be superior 
      to eversion technique. A systematic review is needed for evaluation of benefits
      and harms of the eversion technique versus the traditional endarterectomy with
      patch angioplasty in patients with symptomatic carotid stenosis. METHODS AND
      OUTCOMES: The review will be conducted according to this protocol following the
      recommendations of the 'Cochrane Handbook for Systematic Reviews' and reported
      according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 
      Randomised clinical trials comparing eversion technique versus endarterectomy
      with patch angioplasty in patients with a symptomatic stenosis of the internal
      carotid artery will be included. Primary outcomes are all-cause mortality rate,
      health-related quality of life and serious adverse events. Secondary outcomes are
      30-day stroke and mortality rate, symptomatic arterial restenosis or occlusion
      and non-serious adverse events. The databases Cochrane Central Register of
      Controlled Trials, PubMed/MEDLINE and EMBASE will be searched (November 2019). We
      will primarily base our conclusions on meta-analyses of trials with overall
      low-risk of bias. We will use trial sequential analysis to assist the evaluation 
      of imprecision in Grading of Recommendations, Assessment, Development and
      Evaluation. However, if pooled point estimates of all trials are similar to
      pooled point estimates of trials with overall low risk of bias and there is lack 
      of a statistical significant interaction between estimates from trials with
      overall high risk of bias and trials with overall low risk of bias we will
      consider the trial sequential analysis adjusted precision of the estimate
      achieved in all trials as the result of our meta-analyses. ETHICS AND
      DISSEMINATION: The proposed systematic review will collect and analyse data from 
      published studies, therefore, ethical approval is not required. The results of
      the review will be disseminated by publication in a peer-review journal and
      submitted for presentation at conferences. PROSPERO REGISTRATION NUMBER:
      CRD42019119361.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Marsman, Martijn S
AU  - Marsman MS
AUID- ORCID: 0000-0002-9819-8080
AD  - Department of Vascular Surgery, Rijnstate Hospital, Arnhem, The Netherlands
      mmarsman@rijnstate.nl.
FAU - Wetterslev, Jorn
AU  - Wetterslev J
AUID- ORCID: 0000-0001-7778-1771
AD  - Rigshospitalet, Copenhagen Trial Unit, Centre for Clinical Intervention Research,
      Copenhagen, Denmark.
FAU - Vriens, Patrick W H E
AU  - Vriens PWHE
AD  - Department of Vascular Surgery, Elisabeth-Tweesteden Hospital, Tilburg, The
      Netherlands.
FAU - Bleys, Ronald L A W
AU  - Bleys RLAW
AD  - Department of Anatomy, University Medical Center Utrecht, Utrecht, The
      Netherlands.
FAU - Jahrome, Abdelkarime Kh
AU  - Jahrome AK
AD  - Department of Vascular Surgery, HFG, Medical Center Leeuwarden, Leeuwarden, The
      Netherlands.
FAU - Moll, Frans L
AU  - Moll FL
AD  - Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The
      Netherlands.
FAU - Keus, Frederik
AU  - Keus F
AD  - Department of Critical Care, University of Groningen, University Medical Center
      Groningen, Groningen, The Netherlands.
FAU - Koning, Giel G
AU  - Koning GG
AD  - Department of Vascular Surgery, Ikazia Hospital, Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200419
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Angioplasty/*methods
MH  - Bias
MH  - Carotid Arteries/*surgery
MH  - Carotid Stenosis/*surgery
MH  - Data Collection/methods
MH  - Endarterectomy, Carotid/adverse effects/*methods
MH  - Humans
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7245381
OTO - NOTNLM
OT  - *head & neck surgery
OT  - *stroke
OT  - *surgery
OT  - *vascular surgery
COIS- Competing interests: JW is a member of the taskforce at Copenhagen Trial Unit to 
      develop theory and software doing TSA, presently available as freeware at
      www.ctu.dk/tsa.
EDAT- 2020/04/22 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-030503 [pii]
AID - 10.1136/bmjopen-2019-030503 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 19;10(4):e030503. doi: 10.1136/bmjopen-2019-030503.


PMID- 32312621
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20210119
IS  - 1879-730X (Electronic)
IS  - 1879-7296 (Linking)
VI  - 137
IP  - 3
DP  - 2020 May
TI  - Ethical questions related to Covid-19 and ENT practice.
PG  - 155-156
LID - S1879-7296(20)30099-5 [pii]
LID - 10.1016/j.anorl.2020.04.009 [doi]
FAU - Simon, F
AU  - Simon F
AD  - Service d'ORL et chirurgie cervico-faciale pediatrique, hopital Necker-enfants
      malades, AP-HP, 149, rue de Sevres, 75015 Paris, France. Electronic address:
      f.simon@aphp.fr.
LA  - eng
PT  - Editorial
DEP - 20200415
PL  - France
TA  - Eur Ann Otorhinolaryngol Head Neck Dis
JT  - European annals of otorhinolaryngology, head and neck diseases
JID - 101531465
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Disease Management
MH  - France
MH  - Humans
MH  - Otolaryngologists/*ethics
MH  - Pandemics/ethics
MH  - Pneumonia, Viral/*epidemiology
PMC - PMC7158828
EDAT- 2020/04/22 06:00
MHDA- 2020/05/26 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - S1879-7296(20)30099-5 [pii]
AID - 10.1016/j.anorl.2020.04.009 [doi]
PST - ppublish
SO  - Eur Ann Otorhinolaryngol Head Neck Dis. 2020 May;137(3):155-156. doi:
      10.1016/j.anorl.2020.04.009. Epub 2020 Apr 15.


PMID- 32312524
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210408
LR  - 20210408
IS  - 1545-7206 (Electronic)
IS  - 0033-3182 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Nov - Dec
TI  - "Reply: Methodological and Ethical Concerns in the Study of AntiNMDA Encephalitis
      With Positron Emission Tomography".
PG  - 863-864
LID - S0033-3182(20)30050-5 [pii]
LID - 10.1016/j.psym.2020.02.009 [doi]
FAU - Kerik-Rotenberg, Nora
AU  - Kerik-Rotenberg N
AD  - PET-CT Molecular Imaging Unit, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico. Electronic address: nora.kerik@hotmail.com.
FAU - Diaz-Meneses, Ivan
AU  - Diaz-Meneses I
AD  - PET-CT Molecular Imaging Unit, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
FAU - Hernandez-Ramirez, Rodrigo
AU  - Hernandez-Ramirez R
AD  - PET-CT Molecular Imaging Unit, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
FAU - Munoz-Casillas, Rodrigo
AU  - Munoz-Casillas R
AD  - PET-CT Molecular Imaging Unit, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
FAU - Reynoso-Mejia, Carlos
AU  - Reynoso-Mejia C
AD  - PET-CT Molecular Imaging Unit, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
FAU - Aguilar-Palomeque, Carlos
AU  - Aguilar-Palomeque C
AD  - PET-CT Molecular Imaging Unit, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
FAU - Flores-Rivera, Jose
AU  - Flores-Rivera J
AD  - Department of Neurology, National Institute of Neurology and Neurosurgery, Mexico
      City, Mexico.
FAU - Espinola-Nadurille, Mariana
AU  - Espinola-Nadurille M
AD  - Department of Neuropsychiatry, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
FAU - Ramirez-Bermudez, Jesus
AU  - Ramirez-Bermudez J
AD  - Department of Neuropsychiatry, National Institute of Neurology and Neurosurgery, 
      Mexico City, Mexico.
LA  - eng
PT  - Letter
DEP - 20200313
PL  - England
TA  - Psychosomatics
JT  - Psychosomatics
JID - 0376506
SB  - IM
EDAT- 2020/04/22 06:00
MHDA- 2020/04/22 06:01
CRDT- 2020/04/22 06:00
PHST- 2020/02/26 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/22 06:01 [medline]
PHST- 2020/04/22 06:00 [entrez]
AID - S0033-3182(20)30050-5 [pii]
AID - 10.1016/j.psym.2020.02.009 [doi]
PST - ppublish
SO  - Psychosomatics. 2020 Nov - Dec;61(6):863-864. doi: 10.1016/j.psym.2020.02.009.
      Epub 2020 Mar 13.


PMID- 32312314
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Apr 20
TI  - Health and well-being literacy initiatives focusing on immigrant communities: an 
      environmental scan protocol to identify "what works and what does not".
PG  - 84
LID - 10.1186/s13643-020-01340-7 [doi]
AB  - INTRODUCTION: Most of the major cities in the developed western countries are
      characterized by an increasing multiculturalism brought by the immigrant
      population. The immigrant communities face challenges in the new environment with
      their health and wellness related unmet needs. It is imperative to find
      sustainable ways to empower these diverse communities to champion their health
      and wellness. Community-based health and wellness literacy initiatives (CBHWLI)
      focusing on immigrant communities can be an important step towards citizen
      empowerment in this regard. The aim of the present environmental scan is to
      identify the key factors that might impact a CBHWLI in immigrant communities in
      Canada in order to facilitate the process in practice and identify the
      competencies and training required for its implementation. METHODS: This study
      will gather information from existing literature and online sources as well as
      will capture expert and lay perspectives on the factors that can impact the
      effectiveness and sustainability of CBHWLIs through conducting a comprehensive
      environmental scan: (i) a systematic scoping review of published literature and
      grey literature, (ii) a comprehensive Internet search, (iii) key informant
      interviews, and (iv) community consultation. Specific methodological and
      analytical frameworks will guide each step. ETHICS AND DISSEMINATION: This study 
      is the first step in establishing a practical base for developing CBHWLI
      implementation research. Once the initial findings have been generated, the
      second step will involve inviting experts to provide their input. We first plan
      to disseminate the results of our scoping review and Internet scan through
      meetings with key stakeholders, to be followed by journal publications and
      conference or workshop presentations. Ethical approval is not required for the
      scoping review or Internet scan; however, approval to conduct interviews with key
      informants and community consultations in the second stage of the study will be
      sought from the Conjoint Health Research Ethics Board.
FAU - Turin, Tanvir C
AU  - Turin TC
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      G012F, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1,
      Canada. turin.chowdhury@ucalgary.ca.
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
      turin.chowdhury@ucalgary.ca.
FAU - Chowdhury, Nashit
AU  - Chowdhury N
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      G012F, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1,
      Canada.
FAU - Ferdous, Mahzabin
AU  - Ferdous M
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      G012F, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1,
      Canada.
FAU - Vaska, Marcus
AU  - Vaska M
AD  - Knowledge Resource Service, Tom Baker Cancer Centre, Alberta Health Services,
      1331-29 St. NW, Calgary, AB, T2N 4N2, Canada.
FAU - Rumana, Nahid
AU  - Rumana N
AD  - Sleep Center, Foothills Medical Center, University of Calgary, 1403-29 St NW,
      Calgary, AB, T2N 2TN, Canada.
FAU - Dahal, Rudra
AU  - Dahal R
AD  - Community Based Citizen Researcher, Calgary, AB, Canada.
FAU - Rahman, Nafiza
AU  - Rahman N
AD  - Community Based Citizen Researcher, Calgary, AB, Canada.
FAU - Chowdhury, Mohammad Z I
AU  - Chowdhury MZI
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - Canada
MH  - *Emigrants and Immigrants
MH  - Humans
MH  - Public Health
MH  - Systematic Reviews as Topic
PMC - PMC7168966
EDAT- 2020/04/22 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01340-7 [doi]
AID - 10.1186/s13643-020-01340-7 [pii]
PST - epublish
SO  - Syst Rev. 2020 Apr 20;9(1):84. doi: 10.1186/s13643-020-01340-7.


PMID- 32312313
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Apr 21
TI  - Stress testing journals: a quasi-experimental study of rejection rates of a
      previously published paper.
PG  - 88
LID - 10.1186/s12916-020-01550-9 [doi]
AB  - BACKGROUND: When a journal receives a duplicate publication, the ability to
      identify the submitted work as previously published, and reject it, is an assay
      to publication ethics best practices. The aim of this study was to evaluate how
      three different types of journals, namely open access (OA) journals,
      subscription-based journals, and presumed predatory journals, responded to
      receiving a previously published manuscript for review. METHODS: We performed a
      quasi-experimental study in which we submitted a previously published article to 
      a random sample of 602 biomedical journals, roughly 200 journals from each
      journal type sampled: OA journals, subscription-based journals, and presumed
      predatory journals. Three hundred and three journals received a Word version in
      manuscript format, while 299 journals received the formatted publisher's PDF
      version of the published article. We then recorded responses to the submission
      received after approximately 1 month. Responses were reviewed, extracted, and
      coded in duplicate. Our primary outcome was the rate of rejection of the two
      types of submitted articles (PDF vs Word) within our three journal types.
      RESULTS: We received correspondence back from 308 (51.1%) journals within our
      study timeline (32 days); (N = 46 predatory journals, N = 127 OA journals, N =
      135 subscription-based journals). Of the journals that responded, 153 received
      the Word version of the paper, while 155 received the PDF version. Four journals 
      (1.3%) accepted our paper, 291 (94.5%) journals rejected the paper, and 13 (4.2%)
      requested a revision. A chi-square test looking at journal type, and submission
      type, was significant (chi(2) (4) = 23.50, p < 0.001). All four responses to
      accept our article came from presumed predatory journals, 3 of which received the
      Word format and 1 that received the PDF format. Less than half of journals that
      rejected our submissions did so because they identified ethical issues such as
      plagiarism with the manuscript (133 (45.7%)). CONCLUSION: Few journals accepted
      our submitted paper. However, our findings suggest that all three types of
      journals may not have adequate safeguards in place to recognize and act on
      plagiarism or duplicate submissions.
FAU - Cobey, Kelly D
AU  - Cobey KD
AD  - Centre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital
      Research Institute, Ottawa, Canada. kcobey@toh.on.ca.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Canada. kcobey@toh.on.ca.
FAU - Rice, Danielle B
AU  - Rice DB
AD  - Centre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital
      Research Institute, Ottawa, Canada.
AD  - Department of Psychology, McGill University, Montreal, Quebec, Canada.
FAU - Lalu, Manoj M
AU  - Lalu MM
AD  - Centre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital
      Research Institute, Ottawa, Canada.
AD  - Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University
      of Ottawa, Ottawa, Canada.
AD  - Regenerative Medicine Program, The Ottawa Hospital, Ottawa, Canada.
FAU - Abramowitz, Daniel
AU  - Abramowitz D
AD  - Division of General Surgery, University of Toronto, Toronto, Canada.
FAU - Ahmadzai, Nadera
AU  - Ahmadzai N
AD  - Centre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital
      Research Institute, Ottawa, Canada.
FAU - Cunningham, Heather
AU  - Cunningham H
AD  - Gerstein Science Information Centre, University of Toronto, Toronto, Canada.
FAU - Ayala, Ana Patricia
AU  - Ayala AP
AD  - Gerstein Science Information Centre, University of Toronto, Toronto, Canada.
FAU - Raffoul, Hana
AU  - Raffoul H
AD  - Faculty of Engineering, University of Waterloo, Waterloo, Canada.
FAU - Khan, Faizan
AU  - Khan F
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Canada.
FAU - Shamseer, Larissa
AU  - Shamseer L
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Canada.
FAU - Moher, David
AU  - Moher D
AD  - Centre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital
      Research Institute, Ottawa, Canada.
AD  - School of Epidemiology and Public Health, Faculty of Medicine, University of
      Ottawa, Ottawa, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200421
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
MH  - Humans
MH  - Non-Randomized Controlled Trials as Topic
MH  - Periodicals as Topic/*standards
MH  - Publications/*standards
MH  - Research Design
PMC - PMC7171725
OTO - NOTNLM
OT  - *Open access
OT  - *Plagiarism
OT  - *Predatory journals
OT  - *Scholarly publishing models
EDAT- 2020/04/22 06:00
MHDA- 2020/12/17 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
AID - 10.1186/s12916-020-01550-9 [doi]
AID - 10.1186/s12916-020-01550-9 [pii]
PST - epublish
SO  - BMC Med. 2020 Apr 21;18(1):88. doi: 10.1186/s12916-020-01550-9.


PMID- 32312238
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20210110
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 20
TI  - Informal payments for inpatient health care in post-health transformation plan
      period: evidence from Iran.
PG  - 539
LID - 10.1186/s12889-020-8432-3 [doi]
AB  - BACKGROUND: In 2014, a revision of the national medical tariffs for inpatient
      health care services took place in Iran, and a new hotline was set up to report
      informal payments. It was expected that such measures would eliminate or decrease
      informal payments prevalence. This study estimates the prevalence of informal
      payments for inpatient health care services in the post-reform period, explores
      factors associated with informal payments and examines patients' and healthcare
      providers' views regarding the causes of informal payments and possible practical
      solutions for their reduction. METHODS: We surveyed by phone patients who used
      inpatient health care services in seven Iranian hospitals in 2016. Descriptive
      and regression analyses were used to estimate the prevalence and determine
      factors associated with informal payments. We conducted a qualitative analysis
      through thematic analyses based on focus group discussions and in-depth
      interviews. RESULTS: Of 2696 respondents, 14% reported paying informally for
      inpatient services. Informal payments were reported more frequently among private
      hospital users, given more frequently to physicians in public teaching hospitals 
      and 'other staff' in private hospitals, in the form of cash and voluntary. Being 
      an adult, hospital or treatment type, being insured, and household head's
      education influenced the probability of paying informally. The amount paid
      informally was associated with being insured, the educational status of the
      household's head, household size, service, and hospital types. Based on
      qualitative findings, the leading causes of informal payments reported by
      patients and healthcare providers can be categorized into four groups - financing
      challenges; governance challenges; service delivery challenges; and actors and
      stakeholders. Modifying, adjusting and applying policy interventions;
      supervision, monitoring and evaluation; and actors and stakeholders were
      identified as possible solutions for tackling informal payment in the inpatient
      health care services. CONCLUSION: The prevalence of informal patient payments for
      inpatient services in the post-reform period seems to have reduced; however, they
      remain to be common. Regular monitoring, reviewing of payment policies to the
      physicians, informing patients, changing the behaviour of healthcare providers
      and patients, and developing ethical guidelines to prevent informal payments were
      suggested for reduction and elimination of informal payments in the Iranian
      healthcare sector.
FAU - Doshmangir, Leila
AU  - Doshmangir L
AD  - Social Determinants of Health Research Center, Tabriz Health Services Management 
      Research Center, Iranian Center of Excellence in Health Management, School of
      Management and Medical Informatics, Tabriz University of Medical Sciences,
      Tabriz, Iran.
FAU - Sajadi, Haniye Sadat
AU  - Sajadi HS
AD  - Knowledge Utilization Research Center, University Research and Development
      Center, Tehran University of Medical Sciences, Tehran, Iran. hsajjadi@tums.ac.ir.
FAU - Ghiasipour, Maryam
AU  - Ghiasipour M
AD  - Department of Health Management and Economics, School of Public Health, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Aboutorabi, Ali
AU  - Aboutorabi A
AD  - School of Management and Medical Informatics, Iran University of Medical
      Sciences, Tehran, Iran.
FAU - Gordeev, Vladimir Sergeevich
AU  - Gordeev VS
AD  - Department of Infectious Disease Epidemiology, The London School of Hygiene &
      Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
AD  - Institute of Population Health Sciences, Queen Mary University of London, Mile
      End Road, London, E1 4NS, UK.
LA  - eng
GR  - 241/M/93195/NIHR
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
EIN - BMC Public Health. 2020 May 25;20(1):781. PMID: 32450836
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Financing, Personal
MH  - Health Expenditures/*statistics & numerical data
MH  - Hospitalization/*economics
MH  - Humans
MH  - *Inpatients
MH  - Interviews as Topic
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
PMC - PMC7171751
OTO - NOTNLM
OT  - Health care reform
OT  - Health expenditures
OT  - Health policy
OT  - Health policy and systems research
OT  - Informal payments
OT  - Iran
EDAT- 2020/04/22 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/04/22 06:00
PHST- 2019/06/29 00:00 [received]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1186/s12889-020-8432-3 [doi]
AID - 10.1186/s12889-020-8432-3 [pii]
PST - epublish
SO  - BMC Public Health. 2020 Apr 20;20(1):539. doi: 10.1186/s12889-020-8432-3.


PMID- 32312201
OWN - NLM
STAT- MEDLINE
DCOM- 20201020
LR  - 20201020
IS  - 2424-8363 (Electronic)
VI  - 25
IP  - 2
DP  - 2020 Jun
TI  - Maintaining Effective Microsurgery Training with Reduced Utilisation of Live
      Rats.
PG  - 206-213
LID - 10.1142/S2424835520500241 [doi]
AB  - Background: Microvascular surgery is now an integral part of many surgical
      disciplines, and the success of these procedures relies on the technical skills
      of the surgeon. Although numerous training models and simulations have been
      developed, the living rat model is favoured for its high fidelity to clinical
      microsurgery. However, there are serious ethical concerns over the use of live
      models for training. The aim of this study was to demonstrate if effective skill 
      acquisition was possible with a reduction in the number of live rats. Methods:
      Two course structures were designed, that were implemented. Total training hours 
      remained the same in both the courses, but the number of rats used was reduced
      from conventional five rats per participant to four in group A and to three in
      group B while increasing the training time spent on synthetic and ex-vivo models.
      We assessed the effectiveness of the courses by comparing the patency rates, the 
      time taken per anastomosis and efficiency of the utilisation rate of rats.
      Results: There were 30 participants in Group A and 28 participants in group B. We
      observed that group B was able to perform anastomosis in a significantly shorter 
      time and with patency rates similar to group A in spite of a lesser number of
      rats used in the training. Conclusions: we were able to conclusively demonstrate 
      that it was possible to reduce live rat usage in microsurgical training without
      compromising on the quality of training.
FAU - Lahiri, Amitabha
AU  - Lahiri A
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Muttath, Sandeep Sebastin
AU  - Muttath SS
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Yusoff, Siti Khadijah
AU  - Yusoff SK
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
FAU - Chong, Alphonsus Ks
AU  - Chong AK
AD  - Department of Hand and Reconstructive Microsurgery, National University Hospital,
      Singapore.
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - J Hand Surg Asian Pac Vol
JT  - The journal of hand surgery Asian-Pacific volume
JID - 101688432
SB  - IM
MH  - Anastomosis, Surgical/education
MH  - Animals
MH  - Clinical Competence
MH  - Female
MH  - Humans
MH  - Male
MH  - Microsurgery/*education
MH  - *Models, Anatomic
MH  - *Models, Animal
MH  - Operative Time
MH  - Rats
OTO - NOTNLM
OT  - Anastomosis
OT  - Microsurgery training
OT  - Simulation model
OT  - Surgical curriculum
OT  - Surgical education
OT  - Surgical simulation
EDAT- 2020/04/22 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - 10.1142/S2424835520500241 [doi]
PST - ppublish
SO  - J Hand Surg Asian Pac Vol. 2020 Jun;25(2):206-213. doi:
      10.1142/S2424835520500241.


PMID- 32312018
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 16
DP  - 2020 Apr
TI  - Imaging features and mechanisms of novel coronavirus pneumonia (COVID-19): Study 
      Protocol Clinical Trial (SPIRIT Compliant).
PG  - e19900
LID - 10.1097/MD.0000000000019900 [doi]
AB  - INTRODUCTION: A novel coronavirus, tentatively designated as 2019 Novel
      Coronavirus (2019-nCoV), now called severe acute respiratory syndrome coronavirus
      2, emerged in Wuhan, China, at the end of 2019 and which continues to expand. On 
      February 11, 2020, the World Health Organization (WHO) named the disease
      coronavirus disease 2019 (COVID-19). On February 28, WHO increased our assessment
      of the risk of spread and the risk of impact of COVID-19 to very high at a global
      level. The COVID-19 poses significant threats to international health.Computed
      tomography (CT) has been an important imaging modality in assisting in the
      diagnosis and management of patients withCOVID-19. Some retrospective imaging
      studies have reported chest CT findings of COVID-19 in the past 2 months,
      suggesting that several CT findings may be characteristic. To our knowledge,
      there has been no prospective multicentre imaging study of COVID-19 to date.We
      proposed a hypothesis: There are some specific CT features on Chest CT of
      COVID-19 patients. And the mechanism of these CT features is explicable based on 
      pathological findings. OBJECTIVE: To investigate the specific CT features of
      COVID-19 and the formation mechanism of these CT features. METHOD: This study is 
      a prospective multicenter observational study. We will recruit 100 patients with 
      COVID-19 at 55 hospitals. All patients undergo chest CT examination with the same
      scan protocol. The distribution and morphology of lesions on chest CT, clinical
      data will be recorded. A number of patients will be pathologically examined after
      permission is granted. The data of these three aspects will be analyzed
      synthetically. DISCUSSION: This study will help us to identify the chest CT
      features of COVID-19 and its mechanism. ETHICS AND DISSEMINATION: This
      retrospective study was approved by the Biomedical Research Ethics Committee of
      West China Hospital of Sichuan University (No. 2020-140). Written informed
      consent will be obtained from all study participants prior to enrollment in the
      study. To protect privacy of participants, all private information were kept
      anonymous. The results will be published in a peer-reviewed journal and will be
      disseminated electronically and in print regardless of results.
FAU - Huang, Zixing
AU  - Huang Z
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu.
FAU - Zhao, Shuang
AU  - Zhao S
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu.
FAU - Xu, Lin
AU  - Xu L
AD  - Department of Radiology, Danzhou Central Hospital, Danzhou.
FAU - Chen, Jianxin
AU  - Chen J
AD  - Department of Radiology, West China-Guangan Hospital, Sichuan University,
      Guangan.
FAU - Lin, Wei
AU  - Lin W
AD  - Department of Radiology, First People's Hospital.
FAU - Zeng, Hanjiang
AU  - Zeng H
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu.
FAU - Chen, Zhixia
AU  - Chen Z
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu.
FAU - Du, Liang
AU  - Du L
AD  - Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University.
FAU - Shi, Yujun
AU  - Shi Y
AD  - Laboratory of Pathology, West China Hospital, Sichuan University.
FAU - Zhang, Na
AU  - Zhang N
AD  - Department of Radiology, Public Health Clinical Center, Chengdu, China.
FAU - Song, Bin
AU  - Song B
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Betacoronavirus/immunology/*isolation & purification
MH  - COVID-19
MH  - China/epidemiology
MH  - Coronavirus/immunology/isolation & purification
MH  - Coronavirus Infections/*diagnostic imaging/pathology
MH  - Global Health/statistics & numerical data
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Pandemics
MH  - Pneumonia, Viral/*diagnostic imaging/pathology
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - SARS-CoV-2
MH  - Tomography, X-Ray Computed/*methods/statistics & numerical data
MH  - World Health Organization/*organization & administration
PMC - PMC7220219
EDAT- 2020/04/22 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
AID - 10.1097/MD.0000000000019900 [doi]
AID - 00005792-202004170-00102 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(16):e19900. doi: 10.1097/MD.0000000000019900.


PMID- 32311955
OWN - NLM
STAT- MEDLINE
DCOM- 20200429
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 16
DP  - 2020 Apr
TI  - Electroacupuncture therapy for change of pain in classical trigeminal neuralgia.
PG  - e19710
LID - 10.1097/MD.0000000000019710 [doi]
AB  - INTRODUCTION: Classical trigeminal neuralgia (CTN) is a kind of trigeminal
      neuralgia which is due to neurovascular compression. The common neurological
      treatment CTN drug called carbamazepine is the main measure, although it usually 
      has side effects and a high-rate of relapse. As a critical alternative therapy,
      electroacupuncture (EA) has been shown to benefit for neuropathic pain. The aims 
      of this study are to observe the therapeutic effect and safety of EA for CTN, to 
      evaluate whether EA has the advantage over carbamazepine in the analgesia of CTN.
      Furthermore, we would to establish a standardized, effective, and convenient
      therapy program of EA. METHODS AND ANALYSIS: One hundred twenty patients
      diagnosed with CTN will be randomized for a 4-week intervention. The
      interventions will be different according to the four groups (EA + carbamazepine 
      group, sham EA + carbamazepine group, EA + placebo group and sham EA + placebo
      group). EA therapy will be performed in specific acupoints with a dilute wave
      (2/100 Hz) for 60 minutes. Carbamazepine tablets will be taken orally with 0.1 g 
      each time, thrice daily. Sham EA and placebo intervention will not receive EA and
      drug treatment. The main outcomes are the change from baseline intensity of pain 
      at 6 months (pain evaluation by visual analogue score) and the change from
      baseline brief introduction of 2-week pain to evaluate pain comprehensively. The 
      data management and statistical analysis will be conducted by third party
      statisticians. Incidence of adverse events will be investigated. ETHICS AND
      DISSEMINATION: Ethics approval was obtained from the Clinical Trial Ethics
      Committee of The Third Affiliated Hospital of Zhejiang Chinese Medical University
      (NO. ZSLL-KY-2017-033) and Jiaxing Hospital of Traditional Chinese Medicine (NO. 
      2018-JZLK-002). The results will be disseminated by presentation at peer-reviewed
      journals.
FAU - Sun, Jing
AU  - Sun J
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      Zhejiang, China.
FAU - Li, Rongrong
AU  - Li R
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
FAU - Li, Xiaoyu
AU  - Li X
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
FAU - Chen, Lifang
AU  - Chen L
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      Zhejiang, China.
FAU - Liang, Yi
AU  - Liang Y
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
FAU - Zhang, Qifei
AU  - Zhang Q
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
FAU - Sun, Ruohan
AU  - Sun R
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
FAU - Hu, Hantong
AU  - Hu H
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      Zhejiang, China.
FAU - Shao, Xiaomei
AU  - Shao X
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
      Zhejiang, China.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - The Third Clinical Medical College, Zhejiang Chinese Medical University, Key
      Laboratory of Acupuncture and Neurology of Zhejiang Province.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics, Non-Narcotic/therapeutic use
MH  - Carbamazepine/therapeutic use
MH  - Combined Modality Therapy
MH  - *Electroacupuncture/methods
MH  - Humans
MH  - Middle Aged
MH  - *Multicenter Studies as Topic
MH  - Nerve Compression Syndromes/complications/therapy
MH  - Patient Selection
MH  - *Randomized Controlled Trials as Topic
MH  - Trigeminal Neuralgia/etiology/*therapy
MH  - Young Adult
PMC - PMC7440061
EDAT- 2020/04/22 06:00
MHDA- 2020/04/30 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/04/30 06:00 [medline]
AID - 10.1097/MD.0000000000019710 [doi]
AID - 00005792-202004170-00039 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(16):e19710. doi: 10.1097/MD.0000000000019710.


PMID- 32311926
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 16
DP  - 2020 Apr
TI  - Impact of healthy diet and physical activity on metabolic health in men and
      women: Study Protocol Clinical Trial (SPIRIT Compliant).
PG  - e19584
LID - 10.1097/MD.0000000000019584 [doi]
AB  - INTRODUCTION: Healthy dietary patterns and physical activity (PA) represent
      important lifestyle behaviors with considerable potential to influence on
      age-related metabolic health. Yet, data on the combined effects of these
      lifestyle behaviors on metabolic health including low-grade systemic inflammation
      in aging populations remain scarce. Therefore, this protocol describes a
      randomized controlled trial aiming to examine the impacts of healthy dietary
      patterns alone or combined with PA on metabolic health in middle-aged and older
      men and women. MATERIAL AND METHODS: The ORUDIET study is a 3-arm randomized
      controlled 16-week trial: Healthy Diet (HD), Healthy diet plus PA (HD-PA), and
      control (CON). The trial is open label, randomized with allocation concealment,
      parallel groups with passive controls. Participants without overt disease aged
      between 55 and 70 years, with BMI below 35, a current intake of a maximum of 1
      serving of fruit and vegetable per day, and noncompliance to PA guidelines are
      eligible for inclusion. Participants in HD are instructed to increase fruit and
      vegetable intake to 5 servings per day (equivalent to 500 g). Participants in
      HD-PA receive the same dietary intervention as the HD and are additionally
      instructed to engage in moderate-to-vigorous physical activities for at least 150
      minutes per week. The primary study outcomes are changes in metabolic and
      inflammatory health biomarkers. Secondary outcomes are changes in body
      composition and perceived health. ETHICS AND DISSEMINATION: The study protocol
      has been approved by the ethical review board in Uppsala, Sweden. The results
      will be published in peer-reviewed journals and disseminated in national and
      international conferences. TRIAL REGISTRATION NUMBER: NCT04062682 Pre-results.
FAU - Bergens, Oscar
AU  - Bergens O
AD  - School of Health Sciences, Orebro University, Orebro, Sweden.
FAU - Veen, Jort
AU  - Veen J
FAU - Montiel-Rojas, Diego
AU  - Montiel-Rojas D
FAU - Edholm, Peter
AU  - Edholm P
FAU - Kadi, Fawzi
AU  - Kadi F
FAU - Nilsson, Andreas
AU  - Nilsson A
LA  - eng
SI  - ClinicalTrials.gov/NCT04062682
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (Interleukins)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Aged
MH  - Alanine Transaminase/blood
MH  - Aspartate Aminotransferases/blood
MH  - Blood Glucose/metabolism
MH  - Blood Pressure
MH  - Body Composition
MH  - C-Reactive Protein/metabolism
MH  - Cholesterol, HDL/blood
MH  - *Diet, Healthy
MH  - Exercise/*physiology
MH  - Female
MH  - Glycated Hemoglobin A/metabolism
MH  - Health Status
MH  - Humans
MH  - Inflammation/blood
MH  - Insulin/blood
MH  - Interleukins/*blood
MH  - Male
MH  - Metabolic Syndrome/blood/diagnosis
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Triglycerides/blood
PMC - PMC7220060
EDAT- 2020/04/22 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - 10.1097/MD.0000000000019584 [doi]
AID - 00005792-202004170-00010 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(16):e19584. doi: 10.1097/MD.0000000000019584.


PMID- 32311924
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20210101
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 16
DP  - 2020 Apr
TI  - Traditional Chinese medicine combined with western medicine for the treatment of 
      secondary pulmonary tuberculosis: A PRISMA-compliant meta-analysis.
PG  - e19567
LID - 10.1097/MD.0000000000019567 [doi]
AB  - OBJECTIVE: To evaluate the differences between traditional Chinese medicine
      combined with western medicine and western medicine alone for the treatment of
      secondary tuberculosis and its impact on the evaluation of clinical efficacy and 
      safety of patients in randomized controlled trials. METHODS: A literature search 
      of all major academic databases was conducted (PubMed, CNKI, Wanfang, VIP).
      Meta-analysis was conducted using RevMan 5.3 and Stata 12.0 software for those
      studies that satisfied the inclusion criteria. Ethical approval was not necessary
      because no people or animals were selected as subjects in this meta-analysis.
      RESULTS: Twenty-three randomized controlled trials were included in this
      meta-analysis. The following indicators in the treatment group (traditional
      Chinese medicine decoction combined with western medicine chemotherapy) improved 
      in comparison with those in the control group:focus absorption rate (RR:1.18; 95%
      CI: 1.15-1.22);sputum smear negative rate (RR: 1.17; 95% CI:
      1.09-1.27);comprehensive clinical effective rate (RR: 1.18; 95% CI:
      1.14-1.22);cavity closure rate (RR: 1.37; 95% CI: 1.12-1.67).The difference of
      Immune function indicator likes CD4+ level (SMD: 0.76; 95% CI: -0.25 to 1.76)
      between the treatment group and the control group was not significant. In
      addition, safety evaluation indicators like the decrease rate of white blood cell
      (WBC) and platelets (PLT) and the elevation rate of alanine aminotransferase
      (ALT) and uric acid (UA) in the treatment group were reduced compared with those 
      in the control group (P < .05). CONCLUSIONS: The curative effect of combining
      traditional Chinese and western medicine for the treatment of secondary
      tuberculosis is better than that of western medicine alone and is conducive to
      reducing the incidence of adverse reactions.
FAU - Li, Xiangwen
AU  - Li X
AD  - School of Public Health, Shaanxi University of Chinese Medicine, Xianyang, P.R.
      China.
FAU - Li, Xinghui
AU  - Li X
FAU - Liu, Qiling
AU  - Liu Q
FAU - Sun, Na
AU  - Sun N
FAU - Zhang, Bei
AU  - Zhang B
FAU - Shi, Chuandao
AU  - Shi C
FAU - Zhang, Rongqiang
AU  - Zhang R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antitubercular Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 268B43MJ25 (Uric Acid)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Alanine Transaminase/blood
MH  - Antitubercular Agents/adverse effects/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Humans
MH  - Phytotherapy
MH  - Platelet Count
MH  - Randomized Controlled Trials as Topic
MH  - Sputum/microbiology
MH  - Treatment Outcome
MH  - Tuberculosis, Pulmonary/diagnostic imaging/*drug therapy/immunology
MH  - Uric Acid/blood
PMC - PMC7220241
EDAT- 2020/04/22 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - 10.1097/MD.0000000000019567 [doi]
AID - 00005792-202004170-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(16):e19567. doi: 10.1097/MD.0000000000019567.


PMID- 32311921
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20220414
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 16
DP  - 2020 Apr
TI  - Study on urinary metabolomics of premenstrual dysphoric disorder patients with
      liver-qi depression syndrome treated with Xiaoyaosan: Study Protocol Clinical
      Trial (SPIRIT Compliant).
PG  - e19425
LID - 10.1097/MD.0000000000019425 [doi]
AB  - INTRODUCTION: Premenstrual dysphoric disorder (PMDD) is a serious form of
      premenstrual syndrome with mental symptoms as its main manifestation, which
      seriously affects women's health and daily life. Some basic research and clinical
      studies have shown that the Chinese herbal medicine of Xiaoyaosan can relieve the
      symptoms of mental disorders with few side effects. The aim of this study is to
      evaluate the clinical efficacy of Xiaoyaosan for treating PMDD with liver-qi
      depression syndrome. In addition, metabonomics and small molecular marker
      compounds closely related to the pathogenesis of PMDD are expected to be found,
      and mechanism of Xiaoyaosan is further explored from the metabolic level. METHODS
      AND ANALYSIS: This study is a clinical pilot trial. Thirty PMDD patients with
      liver-qi depression syndrome and thirty healthy participants will be recruited.
      Study participants will be assigned in a 1:1 ratio to 2 groups: a normal control 
      group and Xiaoyaosan treatment group. The treatment group will receive the
      Chinese patent medicine of Xiaoyaosan for 3 menstrual cycles. The primary outcome
      is the syndrome change in the Daily Record of Severity of Problems (DRSP). The
      secondary outcome is improvement in TCM syndrome, which will be measured with TCM
      symptom score scale. Urine metabolism profiles of participants by liquid
      chromatograph-mass spectrometer (LC-MS) method will be measured to explore the
      mechanism of PMDD pathogenesis and action of Xiaoyaosan on PMDD. DISCUSSION: This
      trial will evaluate the effectiveness and the therapeutic mechanism from the
      metabolomics level of Xiaoyaosan in individuals with PMDD. If successful, the
      outcome of this trial will provide a viable treatment option for PMDD patients
      and objective evidence on the efficacy of Xiaoyaosan for PMDD. ETHICS AND
      DISSEMINATION: The trial has been approved by the Institutional Ethics Committee 
      of Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (file
      number: DZMEC-KY-2019-73). Written informed consent will be obtained from all
      participants. The results of the study will be published in peer-reviewed
      journals or communicated via yearly reports to funding bodies. TRIAL
      REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1900026296.
FAU - Xu, Mengbai
AU  - Xu M
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
AD  - Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,
      Beijing.
FAU - Liu, Yanfeng
AU  - Liu Y
AD  - Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,
      Beijing.
FAU - Guo, Yu
AU  - Guo Y
AD  - School of Traditional Chinese Medicine, Jinan University, Guangzhou.
FAU - Liu, Chenyue
AU  - Liu C
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
FAU - Liu, Yueyun
AU  - Liu Y
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
FAU - Yan, Zhiyi
AU  - Yan Z
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
FAU - Hou, Yajing
AU  - Hou Y
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
FAU - Li, Xiaojuan
AU  - Li X
AD  - School of Traditional Chinese Medicine, Jinan University, Guangzhou.
FAU - Ma, Qingyu
AU  - Ma Q
AD  - School of Traditional Chinese Medicine, Jinan University, Guangzhou.
FAU - Zhou, Xuan
AU  - Zhou X
AD  - School of Traditional Chinese Medicine, Jinan University, Guangzhou.
FAU - Liu, Liuqing
AU  - Liu L
AD  - Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,
      Beijing.
FAU - Huang, Sheng
AU  - Huang S
AD  - Jiuzhitang Co., Ltd., Changsha, China.
FAU - Chen, Jiaxu
AU  - Chen J
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine.
AD  - School of Traditional Chinese Medicine, Jinan University, Guangzhou.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (xiaoyaosan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Controlled Clinical Trials as Topic
MH  - Depression/*drug therapy/etiology
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Liver
MH  - Metabolomics
MH  - Pilot Projects
MH  - Premenstrual Dysphoric Disorder/*drug therapy/psychology/*urine
MH  - Qi
MH  - Young Adult
PMC - PMC7220159
EDAT- 2020/04/22 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/04/22 06:00
PHST- 2020/04/22 06:00 [entrez]
PHST- 2020/04/22 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - 10.1097/MD.0000000000019425 [doi]
AID - 00005792-202004170-00005 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(16):e19425. doi: 10.1097/MD.0000000000019425.


PMID- 34457731
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2156-8650 (Electronic)
IS  - 2156-8650 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Jun
TI  - Active Learning to Promote Early and Effective Physician Interaction with
      Pharmaceutical Industry Marketing Practices.
PG  - 727-735
LID - 10.1007/s40670-020-00943-y [doi]
AB  - BACKGROUND: Interactions with pharmaceutical companies influence physicians'
      prescribing behavior. Less than half of US family medicine residency programs
      have educational curricula addressing their influence. However, medical students 
      have extensive exposure to pharmaceutical industry marketing during their early
      years of training. We developed a successful and required active learning
      curriculum for medical students during their first-year of medical school.
      METHODOLOGY: A philosopher bioethicist lectured to first-year medical students on
      the ethical issues surrounding the interactions with pharmaceutical
      representatives and outlined the three principles approach to clinical ethics as 
      presented in the American Board of Internal Medicine Physician Charter (2002).
      The lecture also described the eight physician types offered by Fugh-Berman et
      al. Students watched two fictitious physician-pharmaceutical representative
      interactions. To promote active learning, students were provided a 3 x 3 Bingo
      card with each physician type. The bioethicist facilitated a discussion
      addressing the interactions. RESULTS: Two hundred twenty-nine first-year medical 
      students participated in this required intervention. Fifty-two percent of
      first-year medical students had already interacted with pharmaceutical
      representatives. The session changed students' opinions of pharmaceutical
      representatives and their ability to identify strategies to mitigate their
      influence. Students articulated ethical issues involved in the interaction,
      techniques used by pharmaceutical representatives, and techniques that could be
      used by medical students or physicians. Ninety-one percent of students believed
      they could independently find reliable information about a drug. CONCLUSION: The 
      session was effective to start the conversation regarding the ethical issues
      involved with the interaction between medical students/physicians and
      pharmaceutical representatives in the first year of medical school.
CI  - (c) International Association of Medical Science Educators 2020.
FAU - Baskir, Elan
AU  - Baskir E
AD  - Herbert Wertheim College of Medicine (HWCOM), Florida International University,
      Miami, FL 33199 USA.grid.65456.340000 0001 2110 1845
FAU - Athauda, Gagani
AU  - Athauda G
AD  - Department of Cellular Biology and Pharmacology, Herbert Wertheim College of
      Medicine (HWCOM), Florida International University, Miami, FL 33199
      USA.grid.65456.340000 0001 2110 1845
FAU - Zeiarati, Golsheed N
AU  - Zeiarati GN
AD  - Department of Cellular Biology and Pharmacology, Herbert Wertheim College of
      Medicine (HWCOM), Florida International University, Miami, FL 33199
      USA.grid.65456.340000 0001 2110 1845
FAU - Kashan, Sanaz B
AU  - Kashan SB
AD  - Herbert Wertheim College of Medicine (HWCOM), Florida International University,
      Miami, FL 33199 USA.grid.65456.340000 0001 2110 1845
FAU - Camps-Romero, Eduardo
AU  - Camps-Romero E
AD  - Herbert Wertheim College of Medicine (HWCOM), Florida International University,
      Miami, FL 33199 USA.grid.65456.340000 0001 2110 1845
FAU - Gillis, Marin
AU  - Gillis M
AD  - Herbert Wertheim College of Medicine (HWCOM), Florida International University,
      Miami, FL 33199 USA.grid.65456.340000 0001 2110 1845
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - United States
TA  - Med Sci Educ
JT  - Medical science educator
JID - 101625548
PMC - PMC8368611
OTO - NOTNLM
OT  - Ethics
OT  - First-year medical students
OT  - Medical education
OT  - Pharmaceutical industry
COIS- Conflict of InterestThe authors declare that they have no conflict of interest.
EDAT- 2020/04/22 00:00
MHDA- 2020/04/22 00:01
CRDT- 2021/08/30 05:57
PHST- 2021/08/30 05:57 [entrez]
PHST- 2020/04/22 00:00 [pubmed]
PHST- 2020/04/22 00:01 [medline]
AID - 10.1007/s40670-020-00943-y [doi]
AID - 943 [pii]
PST - epublish
SO  - Med Sci Educ. 2020 Apr 22;30(2):727-735. doi: 10.1007/s40670-020-00943-y.
      eCollection 2020 Jun.


PMID- 32311783
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 0745-5194 (Print)
IS  - 0745-5194 (Linking)
VI  - 34
IP  - 1
DP  - 2020 Mar
TI  - The Global Psyche: Experiments in the Ethics and Politics of Mental Life.
PG  - 5-20
LID - 10.1111/maq.12570 [doi]
FAU - Behague, Dominique P
AU  - Behague DP
AD  - Center for Medicine, Health & Society, Vanderbilt University Nashville, USA.
AD  - Department of Global Health & Social Medicine, King's College London, London, UK.
FAU - MacLeish, Kenneth
AU  - MacLeish K
AD  - Center for Medicine, Health & Society, Vanderbilt University Nashville, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Anthropol Q
JT  - Medical anthropology quarterly
JID - 8405037
SB  - IM
MH  - *Anthropology, Medical
MH  - *Global Health/ethics/ethnology
MH  - Humans
MH  - *Mental Health/ethics/ethnology
MH  - Politics
MH  - Power, Psychological
EDAT- 2020/04/21 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/01/05 00:00 [received]
PHST- 2020/01/09 00:00 [revised]
PHST- 2020/01/10 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1111/maq.12570 [doi]
PST - ppublish
SO  - Med Anthropol Q. 2020 Mar;34(1):5-20. doi: 10.1111/maq.12570.


PMID- 32311781
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 0745-5194 (Print)
IS  - 0745-5194 (Linking)
VI  - 34
IP  - 1
DP  - 2020 Mar
TI  - "Making Patients" in Postwar and Resource-scarce Settings. Diagnosing and
      Treating Mental Illness in Postwar Kosovo.
PG  - 59-76
LID - 10.1111/maq.12554 [doi]
AB  - Postwar development contexts are increasingly sites of mental health and
      psychosocial interventions in which local health providers are trained by foreign
      experts in evidence-based diagnostic and treatment strategies. Underlying this
      course of action is a well-accepted biomedical logic that assumes symptoms can be
      identified and translated into mental disorders, and disorders into forms of
      treatment. I question this logic by investigating how patients are actually
      "made" in postwar and resource-scarce settings. Specifically, I focus on the
      tensions and ethical dilemmas with which practitioners in Kosovo grapple as they 
      navigate requirements of international standards, their own perception of good
      care, and the limited resources at their disposal. The resultant practice of
      "making patients" to fit diagnostic repertoires is a product of health
      practitioners' structural power, but also an ethical response to the materially
      untenable conditions that practitioners and their patients are confronting.
CI  - (c) 2019 by the American Anthropological Association.
FAU - Kienzler, Hanna
AU  - Kienzler H
AD  - Department of Global Health and Social Medicine, King's College London.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Anthropol Q
JT  - Medical anthropology quarterly
JID - 8405037
SB  - IM
MH  - Anthropology, Medical
MH  - Armed Conflicts/*ethnology
MH  - Female
MH  - Humans
MH  - Kosovo/ethnology
MH  - Male
MH  - *Mental Disorders/diagnosis/ethnology/therapy
MH  - Mental Health/ethnology
MH  - Relief Work
MH  - Women/psychology
OTO - NOTNLM
OT  - *Kosovo
OT  - *development
OT  - *humanitarian aid
OT  - *mental health
OT  - *war
EDAT- 2020/04/21 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/04/21 06:00
PHST- 2018/09/28 00:00 [received]
PHST- 2019/09/13 00:00 [revised]
PHST- 2019/09/23 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
AID - 10.1111/maq.12554 [doi]
PST - ppublish
SO  - Med Anthropol Q. 2020 Mar;34(1):59-76. doi: 10.1111/maq.12554.


PMID- 32311632
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 89
DP  - 2020 Jun
TI  - Perceptions of female Saudi undergraduate nursing students toward family-centered
      care.
PG  - 104421
LID - S0260-6917(19)31401-7 [pii]
LID - 10.1016/j.nedt.2020.104421 [doi]
AB  - BACKGROUND: While family-centered care is considered a vital part of nursing
      care, nursing students seem to struggle in incorporating family-centered care in 
      the clinical setting. Several factors such as minimal exposure in family
      interactions throughout their clinical practice, lack of experience in organizing
      family-centered clinical experiences, access to restricted clinical areas, and
      inadequate supervision from clinical instructors present as challenges among
      nursing students in practicing family-centered care. OBJECTIVES: This study
      explored the perceptions of nursing students toward family-centered care in Saudi
      Arabia. DESIGN: This study used the quantitative approach through the
      cross-sectional survey method. SETTINGS: The study was conducted in the Faculty
      of Nursing of a government university in Saudi Arabia. PARTICIPANTS: A total
      population sample comprising 232 female junior and student nurses participated in
      the study. METHODS: After the approval of the Ethical Board Committee had been
      secured, a survey containing a demographic information sheet and the
      Family-Centered Care Questionnaire was distributed to the students from June 2018
      to February 2019. RESULTS: The overall mean of the students' responses in the
      questionnaire was 3.76 (SD = 0.67, range = 3.40-4.08), indicating a modest
      perception toward family-centered care. The dimension "family is the constant"
      received the most positive response from the students (M = 3.90, SD = 0.77),
      whereas the dimension "parent-to-parent support" was rated the lowest with a mean
      of 3.64 (SD = 0.89). Junior nursing students had more positive perception toward 
      family-centered care than the seniors. Weak negative correlations were observed
      between students' age and family-centered care perception. CONCLUSIONS: This
      study provides insights into family-centered care, which could be used in
      crafting policies and interventions in various health care settings and nursing
      education in Saudi Arabia. Such insights could foster positive perceptions toward
      family-centered care among student nurses and guarantee excellent family-centered
      care nursing practice.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Alabdulaziz, Hawa
AU  - Alabdulaziz H
AD  - Faculty of Nursing, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic
      address: halabdulaziz@kau.edu.sa.
FAU - Cruz, Jonas Preposi
AU  - Cruz JP
AD  - Nursing Department, College of Applied Medical Sciences, Shaqra University, Al
      Dawdmi, Saudi Arabia. Electronic address: cruzjpc@su.edu.sa.
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Cross-Sectional Studies
MH  - Education, Nursing, Baccalaureate
MH  - Female
MH  - Humans
MH  - *Patient-Centered Care
MH  - *Perception
MH  - *Professional-Family Relations
MH  - Students, Nursing/*psychology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Family centered care
OT  - Nursing
OT  - Nursing education
OT  - Nursing students
OT  - Saudi Arabia
COIS- Declaration of competing interest The authors declare no conflict of interest.
EDAT- 2020/04/21 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/09/15 00:00 [received]
PHST- 2020/02/02 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - S0260-6917(19)31401-7 [pii]
AID - 10.1016/j.nedt.2020.104421 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Jun;89:104421. doi: 10.1016/j.nedt.2020.104421. Epub 2020 
      Apr 3.


PMID- 32311514
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 255
DP  - 2020 Jun
TI  - Writing to template: Researchers' negotiation of procedural research ethics.
PG  - 112980
LID - S0277-9536(20)30199-4 [pii]
LID - 10.1016/j.socscimed.2020.112980 [doi]
AB  - This qualitative study examines researchers' views of research ethics in everyday
      global mental health research practice. We present data from a multi-site study
      conducted in 2014-15 involving 35 individual in-depth interviews that explore
      researchers' perceptions of procedural ethics in research conducted in South
      Asia. We examine how researchers' negotiate ethical procedures, and consider the 
      impact this has on ethical practice. This study foregrounds researchers' pivotal 
      role in procedural research ethics: they produce ethical documents including
      research protocols and informed consent forms; engage in ethical review; and
      apply ethical documents to research practice. We apply the analytical framework
      of boundary objects to show the active work that ethical documents simultaneously
      enable and inhibit as researchers and ethical review boards apply these as
      templates for interaction. This analysis shows how the documents required by
      procedural ethics processes facilitate representations of research that are
      generalised, standardised, and abstracted from the situated context in which they
      are applied. Researchers' engagement with these standardised forms cannot prepare
      them for potential ethical issues in research practice. These templates therefore
      act as ideal constructions of what research ethics could be, documenting moral
      intent that researchers draw upon to translate into practice.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Chiumento, Anna
AU  - Chiumento A
AD  - Department of Psychological Sciences, University of Liverpool, United Kingdom.
      Electronic address: Anna.Chiumento@liverpool.ac.uk.
FAU - Rahman, Atif
AU  - Rahman A
AD  - Department of Psychological Sciences, University of Liverpool, United Kingdom.
FAU - Frith, Lucy
AU  - Frith L
AD  - Department of Health Services Research, University of Liverpool, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200411
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Asia
MH  - *Ethics, Research
MH  - Humans
MH  - Informed Consent
MH  - *Negotiating
MH  - Research Personnel
MH  - Writing
OTO - NOTNLM
OT  - *Boundary objects
OT  - *Empirical ethics
OT  - *Ethical review
OT  - *Global health research
OT  - *Qualitative
OT  - *Research ethics
OT  - *South Asia
EDAT- 2020/04/21 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/08/12 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - S0277-9536(20)30199-4 [pii]
AID - 10.1016/j.socscimed.2020.112980 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Jun;255:112980. doi: 10.1016/j.socscimed.2020.112980. Epub 2020
      Apr 11.


PMID- 32311136
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - All People.
PG  - 2
LID - 10.1002/hast.1092 [doi]
AB  - In early March 2020, the March-April Hastings Center Report was very nearly
      assembled and contained nothing about Covid-19, which was still just beginning to
      make itself publicly known in the United States. Two weeks later, the editorial
      line-up was undergoing a remix, and essays that lay out sweeping agendas for the 
      response to the worldwide crisis were in preparation. The central theme in the
      agenda that Lawrence O. Gostin and colleagues develop is that the pandemic
      requires a sharp break from usual ethical norms yet simultaneously demands a
      return to core ethical commitments. A similar theme is sounded by Mildred Z.
      Solomon and colleagues in a commentary calling for federal actions to keep the
      health care system functioning. Other essays in the issue take up an assortment
      of topical issues-including international patient dumping-that were simmering
      along prior to the pandemic, and the two articles take up foundational questions 
      about the nature of moral reasoning.
CI  - (c) 2020 The Hastings Center.
FAU - Kaebnick, Greg
AU  - Kaebnick G
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
CON - Hastings Cent Rep. 2020 Mar;50(2):3. PMID: 32311132
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Humans
MH  - Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United States
OTO - NOTNLM
OT  - *Covid-19
OT  - *moral reasoning
OT  - *novel coronavirus pandemic
OT  - *public health ethics
OT  - *reasonable person standard
EDAT- 2020/04/21 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
AID - 10.1002/hast.1092 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):2. doi: 10.1002/hast.1092.


PMID- 32311134
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - African Conceptions of Age-Based Moral Standing: Anchoring Values to Regional
      Realities.
PG  - 35-43
LID - 10.1002/hast.1100 [doi]
AB  - Is age discrimination ethically objectionable? One puzzle is that we sometimes
      assume that the target of both age discrimination and ageism must be older
      people, yet in poorer nations, older people are generally shown more respect.
      This article explores the ethical question. It looks first at ethical arguments
      favoring age discrimination toward younger people in low-income, less
      industrialized countries of the global South, using sub-Saharan Africa as an
      illustration. It contrasts these with arguments favoring age discrimination
      toward older people in high-income, more industrialized countries of the global
      North, particularly the United States and United Kingdom. Finally, it considers
      what role, if any, differences in life expectancy, infant and child mortality,
      and prospects for healthy lives should play in the moral embrace of a particular 
      view by a community. It argues that there can be reasons to favor different types
      of discrimination in different parts of the world.
CI  - (c) 2020 The Hastings Center.
FAU - Jecker, Nancy S
AU  - Jecker NS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Africa
MH  - Ageism/*ethics
MH  - Delivery of Health Care/ethics
MH  - Humans
MH  - *Morals
MH  - Resource Allocation/ethics/supply & distribution
OTO - NOTNLM
OT  - age discrimination
OT  - allocation of scarce resources
OT  - moral reasoning
OT  - moral standing
OT  - social determinants of health
EDAT- 2020/04/21 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1002/hast.1100 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):35-43. doi: 10.1002/hast.1100.


PMID- 32311128
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - Budgets versus Bans: How U.S. Law Restricts Germline Gene Editing.
PG  - 4-5
LID - 10.1002/hast.1094 [doi]
AB  - In late 2019, He Jiankui, the Chinese scientist who created the world's first
      gene-edited babies, and two embryologists were sentenced to prison and fined.
      Thirteen months earlier, when the world first learned about the experiment, He
      and his colleagues drew swift and nearly uniform international condemnation for
      prematurely moving to human trials, for the risks they took with the children's
      health, and for He's secrecy. The organizing committee for the second genome
      editing summit said the experiment failed to conform with international norms."
      In the United States, the legal picture is complex. No doubt the specific
      experiment He performed would have run afoul of long-standing research
      regulations due to its problems with informed consent and ethical review. But
      other laws also affect this kind of work, in particular, a budget rider that for 
      the past four years has been included in federal appropriations legislation.
CI  - (c) 2020 The Hastings Center.
FAU - Johnston, Josephine
AU  - Johnston J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Budgets/*legislation & jurisprudence
MH  - Gene Editing/ethics/*legislation & jurisprudence
MH  - *Germ Cells
MH  - United States
MH  - United States Food and Drug Administration
OTO - NOTNLM
OT  - *U.S. federal appropriations legislation
OT  - *budget rider
OT  - *germline editing
OT  - *human embryo research
OT  - *human gene editing
OT  - *research ethics
EDAT- 2020/04/21 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1002/hast.1094 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):4-5. doi: 10.1002/hast.1094.


PMID- 32311126
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20200716
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - A Demanding Ethics of Care.
PG  - 46
LID - 10.1002/hast.1102 [doi]
AB  - The writer responds to the book review essay "Caring for People with
      Disabilities: An Ethics of Respect," by Kevin Mintz and David Wasserman, in the
      January-February 2020 issue of the Hastings Center Report, which discusses her
      book Learning from My Daughter: The Value and Care of Disabled Minds.
CI  - (c) 2020 The Hastings Center.
FAU - Kittay, Eva Feder
AU  - Kittay EF
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
CON - Hastings Cent Rep. 2020 Jan;50(1):44-45. PMID: 32068283
CIN - Hastings Cent Rep. 2020 Mar;50(2):46-47. PMID: 32311123
MH  - *Disabled Persons
MH  - Humans
EDAT- 2020/04/21 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1002/hast.1102 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):46. doi: 10.1002/hast.1102.


PMID- 32311125
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - Reasonable Persons, Autonomous Persons, and Lady Hale: Determining a Standard for
      Risk Disclosure.
PG  - 25-34
LID - 10.1002/hast.1099 [doi]
AB  - Among various kinds of disclosures typically required in research as well as in
      clinical scenarios, risk information figures prominently. A key question is, what
      kinds of risk information would the reasonable person want to know? I will argue,
      however, that the reasonable person construct is and always has been incapable of
      settling this very question. After parsing the nebulous if not "contentless"
      character of the reasonable person, I will explain how Western courts have
      actually adjudicated cases of "negligent nondisclosure," that is, cases in which 
      patient-plaintiffs allege that their informed consent rights were violated by the
      failure of their health providers to inform them of reasonably foreseeable risks 
      that subsequently materialized. To support my argument, I will scrutinize the
      landmark decision by the United Kingdom's Supreme Court in Montgomery v.
      Lanarkshire Health Board and, in particular, Justice Brenda Hale's concurrence.
CI  - (c) 2020 The Hastings Center.
FAU - Banja, John
AU  - Banja J
LA  - eng
PT  - Journal Article
PT  - Legal Case
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Decision Making
MH  - Disclosure/*legislation & jurisprudence/*standards
MH  - Humans
MH  - Informed Consent
MH  - Patients
MH  - *Personal Autonomy
MH  - Risk Assessment
MH  - United States
OTO - NOTNLM
OT  - autonomy
OT  - health care decision-making
OT  - informed consent
OT  - medical ethics
OT  - reasonable person standard
OT  - research ethics
OT  - risk disclosure
EDAT- 2020/04/21 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1002/hast.1099 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):25-34. doi: 10.1002/hast.1099.


PMID- 32311124
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - Plus ca change: Renee Fox and the Sociology of Organ Replacement Therapy.
PG  - 6-7
LID - 10.1002/hast.1095 [doi]
AB  - Rereading Renee C. Fox's "A Sociological Perspective on Organ Transplantation and
      Hemodialysis," published in 1970, one is likely to be struck more by continuity
      than by change. The most pressing of the social, policy, and ethical concerns
      that Fox raised remain problematic fifty years later. We still struggle with
      scientific and clinical uncertainty, with the boundary between experimentation
      and therapy, and with the cost of organ replacement therapies and disparities in 
      how they are allocated. We still have an imperfect understanding of transplant
      immune responses. We still debate when a potential donor "actually" dies, and we 
      still seem to think better empirical criteria could harmonize the diverse
      religious, cultural, and socioeconomic values of patients, providers, third-party
      payers, and policy-makers. Organ transplantation was for Fox both a particular
      case unfolding in time and an entryway for discussing the difficult moral
      questions presented by many new medical technologies in a context of high demand 
      and limited resources.
CI  - (c) 2020 The Hastings Center.
FAU - Frader, Joel E
AU  - Frader JE
FAU - Bosk, Charles L
AU  - Bosk CL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Humans
MH  - *Organ Transplantation
MH  - *Sociology
PS  - Fox R
FPS - Fox, Renee
OTO - NOTNLM
OT  - determination of death
OT  - human values
OT  - organ transplantation
EDAT- 2020/04/21 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
AID - 10.1002/hast.1095 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):6-7. doi: 10.1002/hast.1095.


PMID- 32310690
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1538-957X (Electronic)
IS  - 1538-9588 (Linking)
VI  - 21
IP  - 4
DP  - 2020
TI  - Investigation of the instinctive reaction of human drivers in social dilemma
      based on the use of a driving simulator and a questionnaire survey.
PG  - 254-258
LID - 10.1080/15389588.2020.1739274 [doi]
AB  - ObjectiveThe moral and ethical issue is a great challenge to the development of
      autonomous vehicles. There may be distinctions between the choices made by an
      observer and a participant. The paper is designed to investigate whether drivers 
      will sacrifice the fewest people to save more people in social dilemma, and
      whether human drivers would give priority to protecting pedestrians or
      self-protection in an emergency.Methodology: The experiment was conducted with a 
      total of 50 participants assigned to three groups. Three experimental scenarios
      were designed and each of them contained a social dilemma. A driving simulator
      was used in this study to explore the choices of human drivers in social dilemma.
      In addition, the simulator results were compared with those of questionnaire
      survey.Result: In study 1, 73% of 22 participants swerved into the right lane to 
      hit only one pedestrian for the safety of other five. In study 2 and 3, more
      participants chose to hit the barrier to protect the pedestrian.Conclusion: A
      conclusion can be drawn from the second and third group of experiments that most 
      drivers consider not only their own safety, but the safety of pedestrians. Most
      of the participants intended to minimize the total amount of harm in social
      dilemma. The choice of crashing into barriers to protect a pedestrian can also be
      seen as a way to minimize the total amount of harm.
FAU - Gao, Zhenhai
AU  - Gao Z
AD  - State Key Laboratory of Automotive Simulation and Control, Jilin University,
      Changchun, China.
FAU - Sun, Yiteng
AU  - Sun Y
AD  - State Key Laboratory of Automotive Simulation and Control, Jilin University,
      Changchun, China.
FAU - Hu, Hongyu
AU  - Hu H
AD  - State Key Laboratory of Automotive Simulation and Control, Jilin University,
      Changchun, China.
FAU - Zhang, Tianyao
AU  - Zhang T
AD  - State Key Laboratory of Automotive Simulation and Control, Jilin University,
      Changchun, China.
FAU - Gao, Fei
AU  - Gao F
AUID- ORCID: 0000-0001-9020-6720
AD  - State Key Laboratory of Automotive Simulation and Control, Jilin University,
      Changchun, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200420
PL  - England
TA  - Traffic Inj Prev
JT  - Traffic injury prevention
JID - 101144385
SB  - IM
MH  - Adult
MH  - Automobile Driving/*psychology
MH  - Choice Behavior
MH  - Computer Simulation
MH  - *Conflict, Psychological
MH  - Female
MH  - Humans
MH  - *Instinct
MH  - Male
MH  - Pedestrians
MH  - Self Care
MH  - Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - *Driver behavior
OT  - *autonomous vehicles
OT  - *driving simulator
OT  - *instinctive reaction
OT  - *traffic psychology
EDAT- 2020/04/21 06:00
MHDA- 2020/11/24 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - 10.1080/15389588.2020.1739274 [doi]
PST - ppublish
SO  - Traffic Inj Prev. 2020;21(4):254-258. doi: 10.1080/15389588.2020.1739274. Epub
      2020 Apr 20.


PMID- 32309974
OWN - NLM
STAT- MEDLINE
DCOM- 20210616
LR  - 20210616
IS  - 1939-0025 (Electronic)
IS  - 0002-9432 (Linking)
VI  - 90
IP  - 5
DP  - 2020
TI  - Trialing the feasibility of a critical time intervention for youth transitioning 
      out of homelessness.
PG  - 535-545
LID - 10.1037/ort0000454 [doi]
AB  - Little is known regarding the specific types of service models and collaborations
      that are necessary to support diverse populations of youth in transition out of
      homelessness. Transitional supports addressing the complex needs of this
      population are needed to stabilize the array of housing arrangements that youth
      access. This study was a pilot randomized controlled trial of one such critical
      time intervention, called the Housing Outreach Program-Collaboration (HOP-C).
      HOP-C is a multicomponent, multidisciplinary intervention that provides 6 months 
      of mental health and peer support, along with transitional case management to
      youth who have transitioned into some form of stable housing out of homelessness.
      In this trial, 65 youth were randomized to receive HOP-C plus treatment as usual 
      or transitional case management plus treatment as usual. Outcome assessments were
      completed by 30 treatment and 28 control participants. The findings suggest that 
      this intervention is feasible with mental health, employment or education, and
      housing metrics favoring HOP-C with odds ratios ranging from 2.28 to 3.18 and
      better subjective housing stability. Other indicators showed less change. HOP-C
      appears feasible and should be tested in a fully powered trial, providing the
      intervention for a duration longer than 6 months. Overall, these data suggest the
      potential benefit in fostering city-level, multidisciplinary teams sourced from
      several organizations to support youth transitioning out of homelessness.
      Pragmatic trial method considerations for this population are also addressed as
      are the ethical considerations pertinent to engaging highly marginalized youth in
      clinical trials. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
FAU - Kidd, Sean A
AU  - Kidd SA
AUID- ORCID: 0000-0002-2435-786X
AD  - Department of Psychiatry.
FAU - Vitopoulos, Nina
AU  - Vitopoulos N
AD  - Centre for Addiction and Mental Health.
FAU - Frederick, Tyler
AU  - Frederick T
AUID- ORCID: 0000-0002-1277-907X
AD  - Faculty of Social Sciences and Humanities.
FAU - Leon, Scott
AU  - Leon S
AUID- ORCID: 0000-0002-6635-0228
AD  - Wellesley Institute.
FAU - Wang, Wei
AU  - Wang W
AUID- ORCID: 0000-0002-0336-506X
AD  - Centre for Addiction and Mental Health.
FAU - Mushquash, Christopher
AU  - Mushquash C
AD  - Department of Psychology.
FAU - McKenzie, Kwame
AU  - McKenzie K
AD  - Department of Psychiatry.
LA  - eng
SI  - ClinicalTrials.gov/NCT03277794
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200420
PL  - United States
TA  - Am J Orthopsychiatry
JT  - The American journal of orthopsychiatry
JID - 0400640
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Case Management
MH  - Employment
MH  - Feasibility Studies
MH  - Female
MH  - Homeless Youth/*psychology
MH  - *Housing
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - *Mental Health
MH  - Ontario
MH  - Quality of Life
MH  - Social Support
MH  - Tertiary Prevention/*methods
MH  - Young Adult
EDAT- 2020/04/21 06:00
MHDA- 2021/06/17 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/06/17 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - 2020-27094-001 [pii]
AID - 10.1037/ort0000454 [doi]
PST - ppublish
SO  - Am J Orthopsychiatry. 2020;90(5):535-545. doi: 10.1037/ort0000454. Epub 2020 Apr 
      20.


PMID- 32309917
OWN - NLM
STAT- Publisher
LR  - 20200420
IS  - 2047-9018 (Electronic)
IS  - 0029-6570 (Linking)
DP  - 2020 Apr 20
TI  - Exploring the experiences of domiciliary caregivers simulating the role of care
      recipients.
LID - 10.7748/ns.2020.e11382 [doi]
AB  - AIM: To find out if an immersive simulation intervention would be feasible in a
      domiciliary care context, and to explore what effect, if any, the intervention
      would have on the domiciliary caregivers who participated. METHOD: This was an
      immersive simulation pilot project in which six domiciliary caregivers
      (simulants) assumed the profile of people receiving domiciliary care. Second-year
      and third-year nursing students provided domiciliary care to the simulants, with 
      support from a registered nurse. Thematic analysis was used to identify themes
      from post-intervention semi-structured interviews and a focus group with the
      simulants. FINDINGS: Five main themes were identified: recognising the need for
      stimulation; reflecting on the importance of person-centred communication; the
      value of companionship and confidence in caregivers; understanding boundaries and
      vulnerabilities; and empathy and practice changes. Following the intervention,
      most of the simulants reported that they re-examined the care they provide from
      the care recipient's perspective, and were increasingly attuned to the wishes of 
      care recipients. CONCLUSION: The findings of this pilot project suggest that
      immersive simulation could be a valuable intervention in the domiciliary care
      context. The feedback from simulants suggests that it is beneficial to provide
      domiciliary caregivers with the opportunity to assume the role of care
      recipients, and enables them to reflect on the complexity and value of the care
      that they provide. The findings indicate that important elements of ethical care 
      include domiciliary caregivers having adequate time to deliver care and develop
      trust, which can assist in fostering effective caregiver-care recipient
      relationships.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Gallagher, Ann
AU  - Gallagher A
AD  - International Care Ethics Observatory, School of Health Sciences, Faculty of
      Health and Medical Sciences, University of Surrey, Surrey, England.
FAU - Peacock, Matthew
AU  - Peacock M
AD  - International Care Ethics Observatory, School of Health Sciences, Faculty of
      Health and Medical Sciences, University of Surrey, Surrey, England.
FAU - Cox, Anna
AU  - Cox A
AD  - International Care Ethics Observatory, School of Health Sciences, Faculty of
      Health and Medical Sciences, University of Surrey, Surrey, England.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Nurs Stand
JT  - Nursing standard (Royal College of Nursing (Great Britain) : 1987)
JID - 9012906
OTO - NOTNLM
OT  - carers
OT  - ethical issues
OT  - ethical practice
OT  - patient experience
OT  - patients
OT  - qualitative research
OT  - research
OT  - social care
COIS- This project was funded by The Ethox Foundation
EDAT- 2020/04/21 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/07/15 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - 10.7748/ns.2020.e11382 [doi]
AID - e11382 [pii]
PST - aheadofprint
SO  - Nurs Stand. 2020 Apr 20. pii: e11382. doi: 10.7748/ns.2020.e11382.


PMID- 32309637
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2398-385X (Electronic)
IS  - 2398-385X (Linking)
VI  - 5
DP  - 2020
TI  - Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision
      Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use 
      Disorder.
LID - e200003 [pii]
LID - 10.20900/jpbs.20200003 [doi]
AB  - Buprenorphine (BUP) can safely and effectively reduce craving, overdose, and
      mortality rates in people with opioid use disorder (OUD). However, adoption of
      ED-initiation of BUP has been slow partly due to physician perception this
      practice is too complex and disruptive. We report progress of the ongoing EMBED
      (EMergency department-initiated BuprenorphinE for opioid use Disorder) project.
      This project is a five-year collaboration across five healthcare systems with the
      goal to develop, integrate, study, and disseminate user-centered Clinical
      Decision Support (CDS) to promote the adoption of Emergency Department
      (ED)-initiation of buprenorphine/naloxone (BUP) into routine emergency care. Soon
      to enter its third year, the project has already completed multiple milestones to
      achieve its goals including (1) user-centered design of the CDS prototype, (2)
      integration of the CDS into an automated electronic health record (EHR) workflow,
      (3) data coordination including derivation and validation of an EHR-based
      computable phenotype, (4) meeting all ethical and regulatory requirements to
      achieve a waiver of informed consent, (5) pilot testing of the intervention at a 
      single site, and (6) launching a parallel group-randomized 18-month pragmatic
      trial in 20 EDs across 5 healthcare systems. Pilot testing of the intervention in
      a single ED was associated with increased rates of ED-initiated BUP and naloxone 
      prescribing and a doubling of the number of unique physicians adopting the
      practice. The ongoing multi-center pragmatic trial will assess the intervention's
      effectiveness, scalability, and generalizability with a goal to shift the
      emergency care paradigm for OUD towards early identification and treatment. TRIAL
      REGISTRATION: Clinicaltrials.gov # NCT03658642.
FAU - Melnick, Edward R
AU  - Melnick ER
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT 06519, USA.
FAU - Nath, Bidisha
AU  - Nath B
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT 06519, USA.
FAU - Ahmed, Osama M
AU  - Ahmed OM
AD  - Yale University School of Medicine, New Haven, CT 06510, USA.
FAU - Brandt, Cynthia
AU  - Brandt C
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT 06519, USA.
AD  - Yale University School of Medicine, New Haven, CT 06510, USA.
FAU - Chartash, David
AU  - Chartash D
AD  - Yale Center for Medical Informatics, Yale University School of Medicine, New
      Haven, CT 06511, USA.
FAU - Dziura, James D
AU  - Dziura JD
AD  - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 
      06520, USA.
FAU - Hess, Erik P
AU  - Hess EP
AD  - Department of Emergency Medicine, University of Alabama at Birmingham School of
      Medicine, Birmingham, AL 35233, USA.
FAU - Holland, Wesley C
AU  - Holland WC
AD  - Yale University School of Medicine, New Haven, CT 06510, USA.
FAU - Hoppe, Jason A
AU  - Hoppe JA
AD  - Department of Emergency Medicine, University of Colorado, Aurora, CO 80045, USA.
FAU - Jeffery, Molly M
AU  - Jeffery MM
AD  - Department of Emergency Medicine, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Katsovich, Liliya
AU  - Katsovich L
AD  - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 
      06520, USA.
FAU - Li, Fangyong
AU  - Li F
AD  - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 
      06520, USA.
FAU - Lu, Charles C
AU  - Lu CC
AD  - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 
      06520, USA.
FAU - Maciejewski, Kaitlin
AU  - Maciejewski K
AD  - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 
      06520, USA.
FAU - Maleska, Matthew
AU  - Maleska M
AD  - The Patient Revolution, New Haven, CT 06511, USA.
FAU - Mao, Jodi A
AU  - Mao JA
AD  - Yale University School of Medicine, New Haven, CT 06510, USA.
FAU - Martel, Shara
AU  - Martel S
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT 06519, USA.
FAU - Michael, Sean
AU  - Michael S
AD  - Department of Emergency Medicine, University of Colorado, Aurora, CO 80045, USA.
FAU - Paek, Hyung
AU  - Paek H
AD  - Information Technology Services, Yale New-Haven Health, New Haven, CT 06519, USA.
FAU - Patel, Mehul D
AU  - Patel MD
AD  - Department of Emergency Medicine, University of North Carolina School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Platts-Mills, Timothy F
AU  - Platts-Mills TF
AD  - Department of Emergency Medicine, University of North Carolina School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Rajeevan, Haseena
AU  - Rajeevan H
AD  - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 
      06520, USA.
FAU - Ray, Jessica M
AU  - Ray JM
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT 06519, USA.
FAU - Skains, Rachel M
AU  - Skains RM
AD  - Department of Emergency Medicine, University of Alabama at Birmingham School of
      Medicine, Birmingham, AL 35233, USA.
FAU - Soares, William E 3rd
AU  - Soares WE 3rd
AD  - Department of Emergency Medicine, University of Massachusetts Medical
      School-Baystate, Baystate, MA 01199, USA.
FAU - Deutsch, Ashley
AU  - Deutsch A
AD  - Department of Emergency Medicine, University of Massachusetts Medical
      School-Baystate, Baystate, MA 01199, USA.
FAU - Solad, Yauheni
AU  - Solad Y
AD  - Information Technology Services, Yale New-Haven Health, New Haven, CT 06519, USA.
FAU - D'Onofrio, Gail
AU  - D'Onofrio G
AD  - Department of Emergency Medicine, Yale University School of Medicine, New Haven, 
      CT 06519, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03658642
GR  - T15 LM007056/LM/NLM NIH HHS/United States
GR  - UG3 DA047003/DA/NIDA NIH HHS/United States
GR  - UH3 DA047003/DA/NIDA NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200221
PL  - England
TA  - J Psychiatr Brain Sci
JT  - Journal of psychiatry and brain science
JID - 101739159
PMC - PMC7164817
MID - NIHMS1564921
OTO - NOTNLM
OT  - buprenorphine
OT  - clinical decision support systems
OT  - electronic health records
OT  - health informatics
OT  - health information technology
OT  - medication for opioid use disorder (MOUD)
OT  - opioid use disorder
OT  - opioid-related disorders
OT  - quality improvement
OT  - user-centered design
COIS- CONFLICTS OF INTEREST The authors have no financial conflicts or competing
      interests to disclose.
EDAT- 2020/04/21 06:00
MHDA- 2020/04/21 06:01
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/04/21 06:01 [medline]
AID - 10.20900/jpbs.20200003 [doi]
PST - ppublish
SO  - J Psychiatr Brain Sci. 2020;5. doi: 10.20900/jpbs.20200003. Epub 2020 Feb 21.


PMID- 32308995
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20200803
IS  - 2090-2735 (Electronic)
IS  - 2090-2727 (Linking)
VI  - 2020
DP  - 2020
TI  - Physical Effects of Maternal Deaths on Midwives' Health: A Qualitative Approach.
PG  - 2606798
LID - 10.1155/2020/2606798 [doi]
AB  - Grief does not only affect human emotions but also impacts their physical health.
      Understanding physical grief of people can bring to bear the grip of its daunting
      nature, a situation where routines become challenging. A qualitative explorative 
      descriptive research method was used. A purposive sample of 18 ward supervisors
      and 39 ward midwives was used to ascertain the physical effects of maternal
      deaths on these caregivers in the Ashanti Region of Ghana. Data were collected
      through semistructured and focus group discussions. Data analysis was done
      parallel with data collection till saturation was reached. Ethics was obtained
      from the University of the Western Cape, South Africa, and Ghana Health Service. 
      The findings indicated that generally, as a result of grieving over the deaths of
      their patients, midwives experienced physical health sufferings. Therefore,
      reported depression is expressed as insomnia, appetite loss, exhaustion, and
      social isolation. There is the need to reduce the physical effects of patients'
      death on caregivers in Ghana and therefore, the study recommends that all
      hospitals in Ghana utilize employee assistance programmes, a workplace
      intervention programme designed for such purposes.
CI  - Copyright (c) 2020 Anita Fafa Dartey and Ellemes Phuma-Ngaiyaye.
FAU - Dartey, Anita Fafa
AU  - Dartey AF
AUID- ORCID: https://orcid.org/0000-0002-8263-4562
AD  - School of Nursing and Midwifery, University of Health and Allied Sciences, Ho,
      PMB 31, Volta Region, Ghana.
FAU - Phuma-Ngaiyaye, Ellemes
AU  - Phuma-Ngaiyaye E
AD  - Department of Nursing & Midwifery, Mzuzu University, Malawi.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - Egypt
TA  - J Pregnancy
JT  - Journal of pregnancy
JID - 101553823
SB  - IM
MH  - Female
MH  - Ghana
MH  - Humans
MH  - Maternal Death/*psychology
MH  - *Midwifery
MH  - Pregnancy
MH  - Qualitative Research
PMC - PMC7152977
COIS- The authors of the manuscript declare that no conflict of interest exists.
EDAT- 2020/04/21 06:00
MHDA- 2020/08/04 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
AID - 10.1155/2020/2606798 [doi]
PST - epublish
SO  - J Pregnancy. 2020 Apr 1;2020:2606798. doi: 10.1155/2020/2606798. eCollection
      2020.


PMID- 32308500
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1179-1411 (Print)
IS  - 1179-1411 (Linking)
VI  - 12
DP  - 2020
TI  - Pap Smear Ransom - Is It Ethical to Refuse to Refill a Patient's Birth Control
      Until They Come in for Their Annual Exam?
PG  - 265-267
LID - 10.2147/IJWH.S246220 [doi]
AB  - A review of the common but questionably ethical practice of refusing to refill a 
      patient's birth control prescription until they are seen in office for, and
      presumably pay for, a yearly examination. This forced decision between making
      time for the appointment or risking an unintended pregnancy is comically referred
      to as "Pap Smear Ransom." This short review examines the limited data to support 
      or decry this common practice.
CI  - (c) 2020 Marchand and Sainz.
FAU - Marchand, Greg J
AU  - Marchand GJ
AUID- ORCID: 0000-0003-4724-9148
AD  - The Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.
FAU - Sainz, Katelyn M
AU  - Sainz KM
AUID- ORCID: 0000-0002-0025-9755
AD  - The Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - New Zealand
TA  - Int J Womens Health
JT  - International journal of women's health
JID - 101531698
PMC - PMC7153914
OTO - NOTNLM
OT  - annual exam
OT  - birth control
OT  - contraception
OT  - office gynecology
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/04/21 06:00
MHDA- 2020/04/21 06:01
CRDT- 2020/04/21 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/04/21 06:01 [medline]
AID - 10.2147/IJWH.S246220 [doi]
AID - 246220 [pii]
PST - epublish
SO  - Int J Womens Health. 2020 Apr 8;12:265-267. doi: 10.2147/IJWH.S246220.
      eCollection 2020.


PMID- 32308213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200423
IS  - 0021-9584 (Print)
IS  - 0021-9584 (Linking)
VI  - 97
IP  - 4
DP  - 2020 Apr 14
TI  - Valorization of Sour Milk to Form Bioplastics: Friend or Foe?
PG  - 1073-1076
LID - 10.1021/acs.jchemed.9b00754 [doi]
AB  - A demonstration was developed to introduce students to waste valorization in
      order to form bioplastics. Waste valorization is the process of reusing,
      recycling, or composting, from waste, useful products or sources of energy. In
      this demonstration, waste valorization is introduced by converting sour milk into
      a bioplastic via the addition of lemon juice upon heating. Utilizing lemon juice 
      to perform the acidification offers a greener procedure than the traditional
      formaldehyde (used commercially to make galalith) and enhances the
      transferability in remote locations such as the Amazon Rainforest in comparison
      to vinegar. Students can establish connections to relevant United Nations
      Sustainable Development Goals (UN SDGs) by adopting a systems thinking approach. 
      However, through this, it is noteworthy that this process is also used
      (particularly in the Indian subcontinent) to make paneer, a farmer cheese. While 
      this also enables students to make a link to additional UN SDGs pertaining to
      "zero hunger", there is an ethical discussion to be had as to whether such a
      process that is utilized to feed malnourished citizens should be used to make a
      decorative bioplastic. As such, despite this demonstration being transferrable,
      instructors may consider carefully whether to utilize this resource, and, if so, 
      to use this as an opportunity to teach the importance of ethics in science.
CI  - Copyright (c) 2020 American Chemical Society and Division of Chemical Education, 
      Inc.
FAU - Jefferson, Mark T
AU  - Jefferson MT
AD  - Department of Chemistry, University of York, Heslington, York YO10 5DD, England, 
      United Kingdom.
FAU - Rutter, Connor
AU  - Rutter C
AD  - Department of Chemistry, University of York, Heslington, York YO10 5DD, England, 
      United Kingdom.
FAU - Fraine, Katherine
AU  - Fraine K
AD  - Department of Chemistry, University of York, Heslington, York YO10 5DD, England, 
      United Kingdom.
FAU - Borges, Gabriel V B
AU  - Borges GVB
AD  - Department of Natural Sciences, Escola SESC de Ensino Medio, Av Ayrton Senna
      5677, Rio de Janeiro, RJ, Brazil.
FAU - de Souza Santos, Gabriela M
AU  - de Souza Santos GM
AD  - Department of Natural Sciences, Escola SESC de Ensino Medio, Av Ayrton Senna
      5677, Rio de Janeiro, RJ, Brazil.
FAU - Schoene, Frederico A P
AU  - Schoene FAP
AD  - Department of Natural Sciences, Escola SESC de Ensino Medio, Av Ayrton Senna
      5677, Rio de Janeiro, RJ, Brazil.
FAU - Hurst, Glenn A
AU  - Hurst GA
AD  - Department of Chemistry, University of York, Heslington, York YO10 5DD, England, 
      United Kingdom.
AD  - Green Chemistry Centre of Excellence, Department of Chemistry, University of
      York, Heslington, York YO10 5DD, England, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200219
PL  - United States
TA  - J Chem Educ
JT  - Journal of chemical education
JID - 2985122R
PMC - PMC7161078
COIS- The authors declare no competing financial interest.
EDAT- 2020/04/21 06:00
MHDA- 2020/04/21 06:01
CRDT- 2020/04/21 06:00
PHST- 2019/08/12 00:00 [received]
PHST- 2020/01/15 00:00 [revised]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/04/21 06:01 [medline]
AID - 10.1021/acs.jchemed.9b00754 [doi]
PST - ppublish
SO  - J Chem Educ. 2020 Apr 14;97(4):1073-1076. doi: 10.1021/acs.jchemed.9b00754. Epub 
      2020 Feb 19.


PMID- 32307970
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20200710
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 4
DP  - 2020 Apr
TI  - ["WITNESS IN WHITE" SEMINAR TOURS ON MEDICINE AND PHYSICIANS IN THE HOLOCAUST].
PG  - 287-291
AB  - INTRODUCTION: The Holocaust represents a seminal event in the annals of medicine.
      For the first time in history, doctors played a prominent role in the extreme
      abuse of medical rights, violation of medical obligation to patients,
      infringement of patient autonomy, forced and unnecessary invasive and damaging
      procedures for political purposes and the ultimate injustice of involuntary
      euthanasia. Physicians provided the legitimacy, know-how and momentum that
      allowed these processes to take place in a symbiotic relationship with the
      political establishment during the Nazi era. It is critical that modern day
      physicians be aware of what transpired during this period. For that purpose, we
      describe a multiyear program bringing Israeli physicians on a learning mission to
      relevant sites of medical involvement and complicity in Nazi era crimes. These
      guided educational tours, under the auspices of the Israel Medical Association,
      originally took place in Poland and more recently, alternately visit Germany and 
      Poland. At all sites, background information on medical practice during the Nazi 
      era is provided, as well as ethical discussions on the merits (positive) or
      demerits (negative) of physicians who played a role at those particular
      locations. In addition to site visits, background discussions and lectures are
      provided to achieve a more comprehensive, deeper and more profound understanding 
      of the issues. Emphasis is placed on learning from examples with relevance to
      modern day medicine, thus providing the principles from which participants can
      grow to become more ethical, principled and sensitive physicians as well as
      individuals. The tour includes formal and emotional ceremonies when relevant at
      extermination sites where physicians were directly involved, as well as focus
      groups allowing and encouraging emotional expression and catharsis. The critical 
      role of personal growth during the tour is emphasized with both pre-tour and
      post-tour meetings providing buffering on both ends. Participants and staff, as
      well as documented feedback over the years, attest to the utility and profound
      value of these learning and growth-oriented medical missions.
FAU - Fox, Matthew A
AU  - Fox MA
AD  - Jakobovits Center for Jewish Medical Ethics, Faculty of Health Sciences, Ben
      Gurion University of the Negev.
FAU - Strous, Rael D
AU  - Strous RD
AD  - Department of Psychiatry, Maayenei Hayeshua Medical Center, Bnei Brak, Sackler
      Faculty of Medicine, Tel Aviv University.
LA  - heb
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - Germany
MH  - History, 20th Century
MH  - *Holocaust
MH  - Humans
MH  - Israel
MH  - National Socialism
MH  - *Physicians
EDAT- 2020/04/21 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Apr;159(4):287-291.


PMID- 32307963
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20200710
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 4
DP  - 2020 Apr
TI  - [Holocaust Doctors Survivors and Holocaust's memory].
PG  - 258-262
AB  - INTRODUCTION: The Eichmann Trial constituted a turning point in the collective
      consciousness of Israeli society and its treatment of the Holocaust and of
      Holocaust survivors. From an anonymous, unfathomable and incomprehensible on a
      personal level topic, it was personalized into the testimonies and personal
      stories of survivors who only then been understood and penetrated consciousness. 
      In the design of the memory of medicine during the Holocaust, as part of the
      design of the Holocaust's memory in general, are unique ethical, medical and
      social aspects. The purpose of this study was to examine the role of Holocaust
      surviving doctors in shaping the memory of medicine during the Holocaust.
      CONCLUSIONS: The surviving doctors were not silent. They have worked extensively 
      in shaping the memory of medicine during the Holocaust, and they have a crucial
      role in shaping memory of medicine during the Holocaust in Israeli society.
      DISCUSSION: Holocaust surviving doctors delivered their memories in writing and
      orally, first in medical journals and in front of a physician audience. Gradually
      their circle of communication channels expanded, especially after the Eichmann
      trial. The memory of medicine during the Holocaust has always been on the public 
      agenda, even if only several actions were taken. In October 1955, the Holocaust
      Surviving Doctors' Association was established, but the number of its members was
      limited and it was active for only seven years. From the 1990s onwards, we have
      witnessed an increase in organized activity to shape the memory of the Holocaust.
FAU - Herzog, Rachel
AU  - Herzog R
AD  - Clalit Health Services, Doctor's Organization.
LA  - heb
PT  - Journal Article
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - *Holocaust
MH  - Humans
MH  - Israel
MH  - Memory
MH  - Morals
MH  - *Physicians
MH  - Survivors
EDAT- 2020/04/21 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Apr;159(4):258-262.


PMID- 32307956
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20201218
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 159
IP  - 4
DP  - 2020 Apr
TI  - [Ethical decision-making framework for the allocation of scarce mechanical
      ventilators during the COVID-19 crisis].
PG  - 235-239
FAU - Peled Raz, Maya
AU  - Peled Raz M
AD  - Bnei Zion Medical Center; Senior Lecturer, the School of Public Health,
      University of Haifa.
LA  - heb
PT  - News
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Decision Making/*ethics
MH  - Humans
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Resource Allocation/*ethics
MH  - SARS-CoV-2
MH  - *Ventilators, Mechanical
EDAT- 2020/04/21 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2020 Apr;159(4):235-239.


PMID- 32307727
OWN - NLM
STAT- MEDLINE
DCOM- 20210702
LR  - 20210802
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 86
IP  - 8
DP  - 2020 Aug
TI  - Commentary on ICH guideline on genomic sampling and data management-enabling
      opportunities in drug development and patient treatment.
PG  - 1454-1464
LID - 10.1111/bcp.14305 [doi]
AB  - The ability to benefit from knowledge of human genomic data in medicine has been 
      anticipated since the sequencing of the human genome. That promise has
      experienced some degree of realization, particularly in oncology where
      biomarker-specific clinical trials and patient treatment specific to the genetics
      of their tumours now occur. With whole genome sequencing and related technologies
      becoming more affordable, and the generation and management of vast amounts of
      data and information, more capable, new opportunities to benefit from these
      developments lie ahead. Already emerging are many studies describing the
      association of genomic variation with molecular underpinnings of disease,
      association with patient response to drugs and informing the nomination of new
      drug targets. These developments are accompanied by some ethical, legal and
      regulatory challenges, which we discuss in this article.
CI  - (c) 2020 The British Pharmacological Society.
FAU - Ehmann, Falk
AU  - Ehmann F
AUID- ORCID: 0000-0001-9226-027X
AD  - European Medicines Agency, Domenico Scarlattilaan 6, 1083, HS, Amsterdam, The
      Netherlands.
FAU - Aerssens, Jeroen
AU  - Aerssens J
AD  - European Medicines Agency, Domenico Scarlattilaan 6, 1083, HS, Amsterdam, The
      Netherlands.
FAU - Blanchard, Rebecca
AU  - Blanchard R
AD  - European Medicines Agency, Domenico Scarlattilaan 6, 1083, HS, Amsterdam, The
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200518
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
SB  - IM
MH  - *Data Management
MH  - *Drug Development
MH  - Genome, Human
MH  - *Genomics
MH  - Guidelines as Topic
MH  - Humans
PMC - PMC7373702
OTO - NOTNLM
OT  - *ICH E18
OT  - *drug development
OT  - *genomic data management
OT  - *genomic sampling
EDAT- 2020/04/21 06:00
MHDA- 2021/07/03 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/11/28 00:00 [received]
PHST- 2020/01/04 00:00 [accepted]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/07/03 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - 10.1111/bcp.14305 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2020 Aug;86(8):1454-1464. doi: 10.1111/bcp.14305. Epub 2020 
      May 18.


PMID- 32307620
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - Embedding Ethics Education in Clinical Clerkships by Identifying Clinical Ethics 
      Competencies: The Vanderbilt Experience.
PG  - 163-174
LID - 10.1007/s10730-020-09410-y [doi]
AB  - The clinical clerkships in medical school are the first formal opportunity for
      trainees to apply bioethics concepts to clinical encounters. These clerkships are
      also typically trainees' first sustained exposure to the "reality" of working in 
      clinical teams and the full force of the challenges and ethical tensions of
      clinical care. We have developed a specialized, embedded ethics curriculum for
      Vanderbilt University medical students during their second (clerkship) year to
      address the unique experience of trainees' first exposure to clinical care. Our
      embedded curriculum is centered around core "ethics competencies" specific to the
      clerkship: for Medicine, advanced planning and end-of-life discussions; for
      Surgery, informed consent; for Pediatrics, the patient-family-provider triad; for
      Obstetrics and Gynecology, women's autonomy, unborn child's interests, and
      partner's rights; and for Neurology/Psychiatry, decision-making capacity. In this
      paper, we present the rationale for these competencies, how we integrated them
      into the clerkships, and how we assessed these competencies. We also review the
      additional ethical issues that have been identified by rotating students in each 
      clerkship and discuss our strategies for continued evolution of our ethics
      curriculum.
FAU - Langerman, Alexander
AU  - Langerman A
AUID- ORCID: http://orcid.org/0000-0003-0866-463X
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN, USA. Alexander.Langerman@vumc.org.
AD  - Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical
      Center, Nashville, TN, USA. Alexander.Langerman@vumc.org.
AD  - Department of Radiology and Radiological Sciences, Vanderbilt University Medical 
      Center, Nashville, TN, USA. Alexander.Langerman@vumc.org.
AD  - Vanderbilt University Medical Center, 1215 21st Avenue South, Suite 7209, Medical
      Center East, South Tower, Nashville, TN, 37215, USA.
      Alexander.Langerman@vumc.org.
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
      Alexander.Langerman@vumc.org.
FAU - Cutrer, William B
AU  - Cutrer WB
AD  - Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN,
      USA.
AD  - Department of Critical Care Medicine, Vanderbilt University Medical Center,
      Nashville, TN, USA.
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
FAU - Yakes, Elizabeth Ann
AU  - Yakes EA
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
FAU - Meador, Keith G
AU  - Meador KG
AD  - Center for Biomedical Ethics and Society, Vanderbilt University Medical Center,
      Nashville, TN, USA.
AD  - Department of Psychiatry and Health Policy, Vanderbilt University Medical Center,
      Nashville, TN, USA.
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Clinical Clerkship/*methods/trends
MH  - Curriculum/standards/trends
MH  - Ethics, Medical/*education
MH  - Female
MH  - Humans
MH  - Male
MH  - Professional Competence/*standards
OTO - NOTNLM
OT  - Clinical clerkships
OT  - Competency
OT  - Education
OT  - Ethics
OT  - Medical student
EDAT- 2020/04/21 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - 10.1007/s10730-020-09410-y [doi]
AID - 10.1007/s10730-020-09410-y [pii]
PST - ppublish
SO  - HEC Forum. 2020 Jun;32(2):163-174. doi: 10.1007/s10730-020-09410-y.


PMID- 32307052
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1558-1969 (Electronic)
IS  - 0749-0712 (Linking)
VI  - 36
IP  - 2
DP  - 2020 May
TI  - The Intersection of Hand Surgery Practice and Industry.
PG  - 215-219
LID - S0749-0712(20)30012-3 [pii]
LID - 10.1016/j.hcl.2020.01.012 [doi]
AB  - This article focuses on the working relationship between practicing hand surgeons
      and company representatives. The basic job of reps is to influence surgeon
      behavior to use their products. Surgeons must make certain that nothing of value 
      is received in a quid pro quo for using industry products. Physicians have an
      ethical obligation to only use industry devices that are in the best interests of
      their patients. Hand surgeons may become involved in product development and
      thereby come into contact with industry. Several key steps are required to
      protect any intellectual property surgeons develop in their interactions with
      industry.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Weiss, Arnold-Peter C
AU  - Weiss AC
AD  - Hand & Upper Extremity Surgery, Department of Orthopaedics, Alpert Medical School
      of Brown University, Providence, RI, USA; University Orthopedics, 1 Kettle Point 
      Avenue, East Providence, RI 02914, USA. Electronic address: apcweiss@brown.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hand Clin
JT  - Hand clinics
JID - 8510415
SB  - IM
MH  - Conflict of Interest
MH  - Hand/*surgery
MH  - Humans
MH  - Industry
MH  - *Interinstitutional Relations
MH  - Orthopedics/ethics/organization & administration/*standards
MH  - Patents as Topic
MH  - Technology Transfer
OTO - NOTNLM
OT  - *Commercialization
OT  - *Implants
OT  - *Industry
OT  - *Intellectual property
OT  - *Products
COIS- Disclosure The author has nothing to disclose.
EDAT- 2020/04/21 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
AID - S0749-0712(20)30012-3 [pii]
AID - 10.1016/j.hcl.2020.01.012 [doi]
PST - ppublish
SO  - Hand Clin. 2020 May;36(2):215-219. doi: 10.1016/j.hcl.2020.01.012.


PMID- 32307022
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 15
IP  - 1
DP  - 2020 Apr 19
TI  - Combined radiotherapy and concurrent tumor treating fields (TTFields) for
      glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results
      from a phase I trial.
PG  - 83
LID - 10.1186/s13014-020-01521-7 [doi]
AB  - BACKGROUND: Glioblastoma is a rapidly proliferating tumor. Patients bear an
      inferior prognosis with a median survival time of 14-16 months. Proliferation and
      repopulation are a major resistance promoting factor for conventionally
      fractionated radiotherapy. Tumor-Treating-Fields (TTFields) are an antimitotic
      modality applying low-intensity (1-3 V/cm), intermediate-frequency (100-300 kHz) 
      alternating electric-fields. More recently interference of TTFields with
      DNA-damage-repair and synergistic effects with radiotherapy were reported in the 
      preclinical setting. This study aims at examining the dosimetric consequences of 
      TTFields applied during the course of radiochemotherapy. METHODS:
      Cone-beam-computed-tomography (CBCT)-data from the first seven patients of the
      PriCoTTF-phase-I-trial were used in a predefined way for dosimetric verification 
      and dose-accumulation of the non-coplanar-intensity-modulated-radiotherapy
      (IMRT)-treatment-plans as well as geometric analysis of the transducer-arrays by 
      which TTFields are applied throughout the course of treatment.
      Transducer-array-position and contours were obtained from the low-dose CBCT's
      routinely made for image-guidance. Material-composition of the electrodes was
      determined and a respective Hounsfield-unit was assigned to the electrodes. After
      6D-fusion with the planning-CT, the dose-distribution was recalculated using a
      Boltzmann-equation-solver (Acuros XB) and a Monte-Carlo-dose-calculation-engine. 
      RESULTS: Overdosage in the scalp in comparison to the treatment plan without
      electrodes stayed below 8.5% of the prescribed dose in the first 2 mm below and
      also in deeper layers outside 1cm(2) at highest dose as obtained from
      dose-volume-histogram comparisons. In the clinical target volume (CTV),
      underdosage was limited to 2.0% due to dose attenuation by the electrodes in
      terms of D95 and the effective-uniform-dose. Principal-component-analysis (PCA)
      showed that the first principal-position-component of the variation of repeated
      array-placement in the direction of the largest variations and the perpendicular 
      second-component spanning a tangential plane on the skull had a standard
      deviation of 1.06 cm, 1.23 cm, 0.96 cm, and 1.11 cm for the frontal, occipital,
      left and right arrays for the first and 0.70 cm, 0.71 cm, 0.79 cm, and 0.68 cm,
      respectively for the second-principal-component. The variations did not differ
      from patient-to-patient (p > 0.8, Kruskal-Wallis-tests). This motion led to a
      diminution of the dosimetric effects of the electrodes. CONCLUSION: From a
      dosimetric point of view, dose deviations in the CTV due to transducer-arrays
      were not clinically significant in the first 7 patients and confirmed feasibility
      of combined adjuvant radiochemotherapy and concurrent TTFields. PriCoTTF Trial: A
      phase I/II trial of TTFields prior and concomitant to radiotherapy in newly
      diagnosed glioblastoma. DRKS-ID: DRKS00016667. Date of Registration in DRKS:
      2019/02/26. Investigator Sponsored/Initiated Trial (IST/IIT): yes. Ethics
      Approval/Approval of the Ethics Committee: Approved. (leading) Ethics Committee
      Nr.: 18-8316-MF, Ethik-Kommission der Medizinischen. Fakultat der Universitat
      Duisburg-Essen. EUDAMED-No. (for studies acc. to Medical Devices act):
      CIV-18-08-025247.
FAU - Guberina, N
AU  - Guberina N
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Pottgen, C
AU  - Pottgen C
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Kebir, S
AU  - Kebir S
AD  - Division of Clinical Neurooncology, Department of Neurology and West German
      Cancer Center, University Hospital Essen, University of Duisburg-Essen,
      Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Lazaridis, L
AU  - Lazaridis L
AD  - Division of Clinical Neurooncology, Department of Neurology and West German
      Cancer Center, University Hospital Essen, University of Duisburg-Essen,
      Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Scharmberg, C
AU  - Scharmberg C
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Lubcke, W
AU  - Lubcke W
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Niessen, M
AU  - Niessen M
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Guberina, M
AU  - Guberina M
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Scheffler, B
AU  - Scheffler B
AD  - DKFZ-Division Translational Neurooncology at the West German Cancer Centre (WTZ),
      German Cancer Consortium (DKTK), Partner Site University Hospital Essen,
      University of Duisburg-Essen, Duisburg, Germany.
AD  - German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen,
      Germany.
FAU - Jendrossek, V
AU  - Jendrossek V
AD  - Institute of Cell Biology (Cancer Research), University Hospital Essen, Essen,
      Germany.
FAU - Jabbarli, R
AU  - Jabbarli R
AD  - Department of Neurosurgery, University Hospital Essen, University of
      Duisburg-Essen, Essen, Germany.
FAU - Pierscianek, D
AU  - Pierscianek D
AD  - Department of Neurosurgery, University Hospital Essen, University of
      Duisburg-Essen, Essen, Germany.
FAU - Sure, U
AU  - Sure U
AD  - Department of Neurosurgery, University Hospital Essen, University of
      Duisburg-Essen, Essen, Germany.
FAU - Schmidt, T
AU  - Schmidt T
AD  - Division of Clinical Neurooncology, Department of Neurology and West German
      Cancer Center, University Hospital Essen, University of Duisburg-Essen,
      Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Oster, C
AU  - Oster C
AD  - Division of Clinical Neurooncology, Department of Neurology and West German
      Cancer Center, University Hospital Essen, University of Duisburg-Essen,
      Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Hau, P
AU  - Hau P
AD  - Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg
      University Hospital, Regensburg, Germany.
FAU - Grosu, A L
AU  - Grosu AL
AD  - Department of Radiation Oncology, University Hospital Freiburg, Freiburg im
      Breisgau, Germany.
AD  - German Cancer Consortium (DKTK) Partner Site University Hospital Freiburg,
      Heidelberg, Germany.
FAU - Stuschke, M
AU  - Stuschke M
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
      Martin.Stuschke@uk-essen.de.
AD  - German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen,
      Germany. Martin.Stuschke@uk-essen.de.
FAU - Glas, M
AU  - Glas M
AD  - Division of Clinical Neurooncology, Department of Neurology and West German
      Cancer Center, University Hospital Essen, University of Duisburg-Essen,
      Hufelandstrasse 55, 45147, Essen, Germany. Martin.Glas@uk-essen.de.
AD  - German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen,
      Germany. Martin.Glas@uk-essen.de.
FAU - Nour, Y
AU  - Nour Y
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
FAU - Ludemann, L
AU  - Ludemann L
AD  - Department of Radiotherapy, West German Cancer Center, University Hospital Essen,
      University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200419
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Brain Neoplasms/diagnostic imaging/drug therapy/radiotherapy/*therapy
MH  - Chemoradiotherapy
MH  - Combined Modality Therapy
MH  - Cone-Beam Computed Tomography
MH  - *Electric Stimulation Therapy
MH  - Glioblastoma/diagnostic imaging/drug therapy/radiotherapy/*therapy
MH  - Humans
MH  - Organs at Risk/radiation effects
MH  - *Radiometry
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted
MH  - *Radiotherapy, Intensity-Modulated
MH  - Scalp/radiation effects
MH  - Transducers/adverse effects
PMC - PMC7168823
OTO - NOTNLM
OT  - Dosimetry
OT  - Glioblastoma
OT  - Non-coplanar IMRT
OT  - TTFields
EDAT- 2020/04/21 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1186/s13014-020-01521-7 [doi]
AID - 10.1186/s13014-020-01521-7 [pii]
PST - epublish
SO  - Radiat Oncol. 2020 Apr 19;15(1):83. doi: 10.1186/s13014-020-01521-7.


PMID- 32306973
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 19
TI  - An integrated humanities-social sciences course in health sciences education:
      proposed design, effectiveness, and associated factors.
PG  - 117
LID - 10.1186/s12909-020-02022-7 [doi]
AB  - BACKGROUND: Previous research has not provided enough direction regarding
      effective content design of courses integrating the humanities and social
      sciences in medical and dental education. This study aims at exploring how an
      Integrated Medical/Dental Humanities-Social Medicine/Dentistry course may be
      designed; how effective it may be in terms of student growth in knowledge,
      attitudes, skills, and aspirations; and associated factors. METHODS: The course
      was designed by distilling commonalities in the international standards for
      medical/dental education proposed by seven major health organizations. This
      analysis resulted in a curriculum covering nine major topics: history,
      professionalism, communication, ethics, management, policy, insurance, law, and
      research methodology. During the 2017 calendar year, data was collected and
      statistically analyzed from 68 third-year pre-doctoral students enrolled in the
      resulting MDHS 13-week course. RESULTS: Participants showed growth in skills,
      aspirations, knowledge, and attitudes, with the greatest change occurring in
      skills, then aspirations, knowledge, and attitudes. Knowledge growth was the only
      variable significantly related to student achievement of course objectives (beta 
      = 0.635, t (63) = 3.394, p = 0.001). The topics that students perceived as most
      critical were insurance, policy, management, and law. The perceived importance of
      research was most common among participants and was significantly related to all 
      learning outcomes (For knowledge, beta = 0.213, t (63) = 2.203, p = 0.031; for
      attitudes, beta = 0.784, t (63) = 10.257, p = 0.000; for skills, beta = 0.769, t 
      (63) = 9.772, p = 0.000; and aspirations beta = 0.639, t (63) = 7.595, p =
      0.000). CONCLUSIONS: This study proposed a framework for humanities-social
      sciences education in health sciences education and analyzed its implementation. 
      The empirical evaluation of its effectiveness and factors related to successful
      outcomes found that students perceived gains in their knowledge, attitudes,
      skills, and aspirations for humanistic and social aspects of dentistry/medicine. 
      In addition, their recognition of the importance of research was associated with 
      the greatest growth in all four learning outcomes. This study may contribute to
      the improved design of integrated humanities-social sciences courses.
FAU - Lee, Jihyun
AU  - Lee J
AD  - Department of Dental Education, School of Dentistry, Seoul National University,
      Seoul, Republic of Korea. leeji1@snu.ac.kr.
FAU - Lee, Jueyeun
AU  - Lee J
AD  - Department of Preventive Dentistry, College of Dentistry, Yonsei University,
      Seoul, Republic of Korea.
FAU - Jung, Il Young
AU  - Jung IY
AD  - Department of Conservative Dentistry, College of Dentistry, Yonsei University,
      Seoul, Republic of Korea.
LA  - eng
GR  - NRF-2017R1C1B2010469/National Research Foundation of Korea
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200419
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Adult
MH  - *Curriculum
MH  - Education, Dental
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humanities/*education
MH  - Humans
MH  - Male
MH  - Professionalism
MH  - Program Development/*methods
MH  - Program Evaluation
MH  - Republic of Korea
MH  - Social Sciences/*education
MH  - Surveys and Questionnaires
PMC - PMC7168810
OTO - NOTNLM
OT  - Achievement
OT  - Curriculum
OT  - KASA (knowledge, attitudes, skills, and aspirations)
OT  - Medical/Dental humanities
OT  - Social medicine/dentistry
EDAT- 2020/04/21 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.1186/s12909-020-02022-7 [doi]
AID - 10.1186/s12909-020-02022-7 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Apr 19;20(1):117. doi: 10.1186/s12909-020-02022-7.


PMID- 32306967
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Apr 19
TI  - Altered muscle membrane potential and redox status differentiates two subgroups
      of patients with chronic fatigue syndrome.
PG  - 173
LID - 10.1186/s12967-020-02341-9 [doi]
AB  - BACKGROUND: In myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS),
      altered membrane excitability often occurs in exercising muscles demonstrating
      muscle dysfunction regardless of any psychiatric disorder. Increased oxidative
      stress is also present in many ME/CFS patients and could affect the membrane
      excitability of resting muscles. METHODS: Seventy-two patients were examined at
      rest, during an incremental cycling exercise and during a 10-min post-exercise
      recovery period. All patients had at least four criteria leading to a diagnosis
      of ME/CFS. To explore muscle membrane excitability, M-waves were recorded during 
      exercise (rectus femoris (RF) muscle) and at rest (flexor digitorum longus (FDL) 
      muscle). Two plasma markers of oxidative stress (thiobarbituric acid reactive
      substance (TBARS) and oxidation-reduction potential (ORP)) were measured. Plasma 
      potassium (K(+)) concentration was also measured at rest and at the end of
      exercise to explore K(+) outflow. RESULTS: Thirty-nine patients had marked M-wave
      alterations in both the RF and FDL muscles during and after exercise while the
      resting values of plasma TBARS and ORP were increased and exercise-induced K(+)
      outflow was decreased. In contrast, 33 other patients with a diagnosis of ME/CFS 
      had no M-wave alterations and had lower baseline levels of TBARS and ORP. M-wave 
      changes were inversely proportional to TBARS and ORP levels. CONCLUSIONS: Resting
      muscles of ME/CFS patients have altered muscle membrane excitability. However,
      our data reveal heterogeneity in some major biomarkers in ME/CFS patients.
      Measurement of ORP may help to improve the diagnosis of ME/CFS. Trial
      registration Ethics Committee "Ouest II" of Angers (May 17, 2019) RCB ID: number 
      2019-A00611-56.
FAU - Jammes, Yves
AU  - Jammes Y
AD  - UMR 1263 C2VN INRA INSERM, Faculty of Medicine, Aix Marseille University,
      Marseille, France.
AD  - Department of Internal Medicine, European Hospital, Marseille, France.
FAU - Adjriou, Nabil
AU  - Adjriou N
AD  - UMR 1263 C2VN INRA INSERM, Faculty of Medicine, Aix Marseille University,
      Marseille, France.
FAU - Kipson, Nathalie
AU  - Kipson N
AD  - UMR 1263 C2VN INRA INSERM, Faculty of Medicine, Aix Marseille University,
      Marseille, France.
FAU - Criado, Christine
AU  - Criado C
AD  - UMR 1263 C2VN INRA INSERM, Faculty of Medicine, Aix Marseille University,
      Marseille, France.
FAU - Charpin, Caroline
AU  - Charpin C
AD  - Department of Internal Medicine, European Hospital, Marseille, France.
FAU - Rebaudet, Stanislas
AU  - Rebaudet S
AD  - Department of Internal Medicine, European Hospital, Marseille, France.
FAU - Stavris, Chloe
AU  - Stavris C
AD  - Department of Internal Medicine, European Hospital, Marseille, France.
FAU - Guieu, Regis
AU  - Guieu R
AD  - UMR 1263 C2VN INRA INSERM, Faculty of Medicine, Aix Marseille University,
      Marseille, France.
FAU - Fenouillet, Emmanuel
AU  - Fenouillet E
AD  - UMR 1263 C2VN INRA INSERM, Faculty of Medicine, Aix Marseille University,
      Marseille, France.
AD  - Institut National des Sciences Biologiques, CNRS, Paris, France.
FAU - Retornaz, Frederique
AU  - Retornaz F
AD  - Department of Internal Medicine, European Hospital, Marseille, France.
      F.retornaz@hopital-europeen.fr.
LA  - eng
PT  - Journal Article
DEP - 20200419
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
SB  - IM
MH  - Exercise
MH  - *Fatigue Syndrome, Chronic
MH  - Humans
MH  - Membrane Potentials
MH  - Oxidation-Reduction
MH  - Oxidative Stress
PMC - PMC7168976
OTO - NOTNLM
OT  - *Muscle excitability
OT  - *Myalgic encephalomyelitis/chronic fatigue syndrome
OT  - *Oxidative stress
OT  - *Potassium outflow
EDAT- 2020/04/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/04/21 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/04/21 06:00 [entrez]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.1186/s12967-020-02341-9 [doi]
AID - 10.1186/s12967-020-02341-9 [pii]
PST - epublish
SO  - J Transl Med. 2020 Apr 19;18(1):173. doi: 10.1186/s12967-020-02341-9.


PMID- 32306403
OWN - NLM
STAT- MEDLINE
DCOM- 20200429
LR  - 20210914
IS  - 1098-240X (Electronic)
IS  - 0160-6891 (Linking)
VI  - 43
IP  - 3
DP  - 2020 Jun
TI  - How effective response to COVID-19 relies on nursing research.
PG  - 213-214
LID - 10.1002/nur.22025 [doi]
FAU - Lake, Eileen T
AU  - Lake ET
AUID- ORCID: 0000-0002-8823-3436
AD  - Center for Health Outcomes and Policy Research, University of Pennsylvania,
      Philadelphia, Pennsylvania.
LA  - eng
PT  - Editorial
DEP - 20200419
PL  - United States
TA  - Res Nurs Health
JT  - Research in nursing & health
JID - 7806136
SB  - IM
CIN - Res Nurs Health. 2020 Aug;43(4):306. PMID: 32557692
CIN - Res Nurs Health. 2021 Oct;44(5):743-745. PMID: 34365670
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Humans
MH  - *Nursing Research
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
PMC - PMC7264727
OTO - NOTNLM
OT  - *COVID-19
OT  - *ethics
OT  - *nurses
OT  - *nursing research
OT  - *pandemics
OT  - *telehealth
EDAT- 2020/04/20 06:00
MHDA- 2020/04/30 06:00
CRDT- 2020/04/20 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/20 06:00 [pubmed]
PHST- 2020/04/30 06:00 [medline]
PHST- 2020/04/20 06:00 [entrez]
AID - 10.1002/nur.22025 [doi]
PST - ppublish
SO  - Res Nurs Health. 2020 Jun;43(3):213-214. doi: 10.1002/nur.22025. Epub 2020 Apr
      19.


PMID- 32306202
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210325
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - 1
DP  - 2020 May
TI  - Review of Rethinking Health Care Ethics by Stephen Scher and Kasia Kozlowska :
      Palgrave Macmillan, available open access:
      https://link.springer.com/content/pdf/10.1007/978-981-13-0830-7.pdf.
PG  - 83-86
LID - 10.1007/s40592-020-00107-z [doi]
FAU - Reis-Dennis, Samuel
AU  - Reis-Dennis S
AD  - Alden March Bioethics Institute, Albany Medical College, Albany, USA.
      reisdes@amc.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
CIN - Monash Bioeth Rev. 2020 May;38(1):87-90. PMID: 32329032
EDAT- 2020/04/20 06:00
MHDA- 2020/04/20 06:01
CRDT- 2020/04/20 06:00
PHST- 2020/04/20 06:00 [pubmed]
PHST- 2020/04/20 06:01 [medline]
PHST- 2020/04/20 06:00 [entrez]
AID - 10.1007/s40592-020-00107-z [doi]
AID - 10.1007/s40592-020-00107-z [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 May;38(1):83-86. doi: 10.1007/s40592-020-00107-z.


PMID- 32304884
OWN - NLM
STAT- MEDLINE
DCOM- 20210224
LR  - 20210304
IS  - 1095-9572 (Electronic)
IS  - 1053-8119 (Linking)
VI  - 219
DP  - 2020 Oct 1
TI  - Neuroimaging young children and associations with neurocognitive development in a
      South African birth cohort study.
PG  - 116846
LID - S1053-8119(20)30333-5 [pii]
LID - 10.1016/j.neuroimage.2020.116846 [doi]
AB  - Magnetic resonance imaging (MRI) is an indispensable tool for investigating brain
      development in young children and the neurobiological mechanisms underlying
      developmental risk and resilience. Sub-Saharan Africa has the highest proportion 
      of children at risk of developmental delay worldwide, yet in this region there is
      very limited neuroimaging research focusing on the neurobiology of such
      impairment. Furthermore, paediatric MRI imaging is challenging in any setting due
      to motion sensitivity. Although sedation and anesthesia are routinely used in
      clinical practice to minimise movement in young children, this may not be ethical
      in the context of research. Our study aimed to investigate the feasibility of
      paediatric multimodal MRI at age 2-3 years without sedation, and to explore the
      relationship between cortical structure and neurocognitive development at this
      understudied age in a sub-Saharan African setting. A total of 239 children from
      the Drakenstein Child Health Study, a large observational South African birth
      cohort, were recruited for neuroimaging at 2-3 years of age. Scans were conducted
      during natural sleep utilising locally developed techniques. T1-MEMPRAGE and
      T2-weighted structural imaging, resting state functional MRI, diffusion tensor
      imaging and magnetic resonance spectroscopy sequences were included. Child
      neurodevelopment was assessed using the Bayley-III Scales of Infant and Toddler
      Development. Following 23 pilot scans, 216 children underwent scanning and
      T1-weighted images were obtained from 167/216 (77%) of children (median age 34.8 
      months). Furthermore, we found cortical surface area and thickness within frontal
      regions were associated with cognitive development, and in temporal and frontal
      regions with language development (beta coefficient >/=0.20). Overall, we
      demonstrate the feasibility of carrying out a neuroimaging study of young
      children during natural sleep in sub-Saharan Africa. Our findings indicate that
      dynamic morphological changes in heteromodal association regions are associated
      with cognitive and language development at this young age. These proof-of-concept
      analyses suggest similar links between the brain and cognition as prior
      literature from high income countries, enhancing understanding of the interplay
      between cortical structure and function during brain maturation.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Wedderburn, Catherine J
AU  - Wedderburn CJ
AD  - Department of Paediatrics and Child Health, Red Cross War Memorial Children's
      Hospital, University of Cape Town, South Africa; Department of Clinical Research,
      London School of Hygiene & Tropical Medicine, UK; Neuroscience Institute,
      University of Cape Town, South Africa. Electronic address:
      catherine.wedderburn@lshtm.ac.uk.
FAU - Subramoney, Sivenesi
AU  - Subramoney S
AD  - Department of Paediatrics and Child Health, Red Cross War Memorial Children's
      Hospital, University of Cape Town, South Africa.
FAU - Yeung, Shunmay
AU  - Yeung S
AD  - Department of Clinical Research, London School of Hygiene & Tropical Medicine,
      UK.
FAU - Fouche, Jean-Paul
AU  - Fouche JP
AD  - Department of Psychiatry, University of Cape Town, South Africa.
FAU - Joshi, Shantanu H
AU  - Joshi SH
AD  - Departments of Neurology, Psychiatry and Biobehavioral Sciences, University of
      California Los Angeles, CA, USA.
FAU - Narr, Katherine L
AU  - Narr KL
AD  - Departments of Neurology, Psychiatry and Biobehavioral Sciences, University of
      California Los Angeles, CA, USA.
FAU - Rehman, Andrea M
AU  - Rehman AM
AD  - MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine,
      London, UK.
FAU - Roos, Annerine
AU  - Roos A
AD  - Department of Paediatrics and Child Health, Red Cross War Memorial Children's
      Hospital, University of Cape Town, South Africa; Neuroscience Institute,
      University of Cape Town, South Africa; SU/UCT MRC Unit on Risk and Resilience in 
      Mental Disorders, Department of Psychiatry, Stellenbosch University, South
      Africa.
FAU - Ipser, Jonathan
AU  - Ipser J
AD  - Neuroscience Institute, University of Cape Town, South Africa; Department of
      Psychiatry, University of Cape Town, South Africa.
FAU - Robertson, Frances C
AU  - Robertson FC
AD  - Division of Biomedical Engineering, Department of Human Biology, University of
      Cape Town, South Africa; Cape Universities Brain Imaging Centre (CUBIC), Cape
      Town, South Africa.
FAU - Groenewold, Nynke A
AU  - Groenewold NA
AD  - Neuroscience Institute, University of Cape Town, South Africa; Department of
      Psychiatry, University of Cape Town, South Africa.
FAU - Gibb, Diana M
AU  - Gibb DM
AD  - MRC Clinical Trials Unit, University College, London, UK.
FAU - Zar, Heather J
AU  - Zar HJ
AD  - Department of Paediatrics and Child Health, Red Cross War Memorial Children's
      Hospital, University of Cape Town, South Africa; SAMRC Unit on Child & Adolescent
      Health, University of Cape Town, South Africa.
FAU - Stein, Dan J
AU  - Stein DJ
AD  - Neuroscience Institute, University of Cape Town, South Africa; Department of
      Psychiatry, University of Cape Town, South Africa; SU/UCT MRC Unit on Risk and
      Resilience in Mental Disorders, University of Cape Town, South Africa.
FAU - Donald, Kirsten A
AU  - Donald KA
AD  - Department of Paediatrics and Child Health, Red Cross War Memorial Children's
      Hospital, University of Cape Town, South Africa; Neuroscience Institute,
      University of Cape Town, South Africa.
LA  - eng
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
GR  - R01 AA026834/AA/NIAAA NIH HHS/United States
GR  - U24 AA014811/AA/NIAAA NIH HHS/United States
GR  - 203525/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - R21 AA023887/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - United States
TA  - Neuroimage
JT  - NeuroImage
JID - 9215515
SB  - IM
MH  - Brain/*diagnostic imaging/physiology
MH  - Child Development/*physiology
MH  - Child, Preschool
MH  - Cognition/*physiology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Neuroimaging
MH  - South Africa
PMC - PMC7443699
MID - NIHMS1593517
OTO - NOTNLM
OT  - *Africa
OT  - *Children
OT  - *Cognition
OT  - *Cortical surface area
OT  - *Cortical thickness
OT  - *Neuroimaging
COIS- Declaration of competing interest The authors report no conflicts of interest.
EDAT- 2020/04/19 06:00
MHDA- 2021/02/25 06:00
CRDT- 2020/04/19 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/02/25 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - S1053-8119(20)30333-5 [pii]
AID - 10.1016/j.neuroimage.2020.116846 [doi]
PST - ppublish
SO  - Neuroimage. 2020 Oct 1;219:116846. doi: 10.1016/j.neuroimage.2020.116846. Epub
      2020 Apr 15.


PMID- 32304822
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20201218
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 94
DP  - 2020 May
TI  - COVID-19: Four Paediatric Cases in Malaysia.
PG  - 125-127
LID - S1201-9712(20)30181-8 [pii]
LID - 10.1016/j.ijid.2020.03.049 [doi]
AB  - OBJECTIVE: This is a brief report of 4 paediatric cases of COVID-19 infection in 
      Malaysia BACKGROUND: COVID-19, a coronavirus, first detected in Wuhan, China has 
      now spread rapidly to over 60 countries and territories around the world,
      infecting more than 85000 individuals. As the case count amongst children is low,
      there is need to report COVID-19 in children to better understand the virus and
      the disease. CASES: In Malaysia, until end of February 2020, there were four
      COVID-19 paediatric cases with ages ranging from 20 months to 11 years. All four 
      cases were likely to have contracted the virus in China. The children had no
      symptoms or mild flu-like illness. The cases were managed symptomatically. None
      required antiviral therapy. DISCUSSION: There were 2 major issues regarding the
      care of infected children. Firstly, the quarantine of an infected child with a
      parent who tested negative was an ethical dilemma. Secondly, oropharyngeal and
      nasal swabs in children were at risk of false negative results. These issues have
      implications for infection control. Consequently, there is a need for clearer
      guidelines for child quarantine and testing methods in the management of COVID-19
      in children.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights
      reserved.
FAU - See, K C
AU  - See KC
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Liew, S M
AU  - Liew SM
AD  - Department of Primary Care Medicine, Faculty of Medicine, University of Malaya,
      Malaysia.
FAU - Ng, David C E
AU  - Ng DCE
AD  - Department of Paediatric, Hospital Tuanku Jaafar, Seremban, Ministry of Health,
      Malaysia.
FAU - Chew, E L
AU  - Chew EL
AD  - Department of Paediatric, Hospital Sultanah Maliha, Langkawi, Ministry of Health,
      Malaysia.
FAU - Khoo, E M
AU  - Khoo EM
AD  - Department of Primary Care Medicine, Faculty of Medicine, University of Malaya,
      Malaysia.
FAU - Sam, C H
AU  - Sam CH
AD  - Department of Paediatric, Hospital Sultanah Maliha, Langkawi, Ministry of Health,
      Malaysia.
FAU - Sheena, D
AU  - Sheena D
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Zahilah Filzah, Z
AU  - Zahilah Filzah Z
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Chin, S Y
AU  - Chin SY
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Lee, P Y
AU  - Lee PY
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Tan, L P
AU  - Tan LP
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Farah Najwa, Z
AU  - Farah Najwa Z
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Sabrina, S
AU  - Sabrina S
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Them, W W
AU  - Them WW
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Saipriya, T
AU  - Saipriya T
AD  - Department of Paediatric, Hospital Sungai Buloh, Ministry of Health, Malaysia.
FAU - Muhammad Zamakhshari, Z A
AU  - Muhammad Zamakhshari ZA
AD  - Department of Paediatric, Hospital Tuanku Jaafar, Seremban, Ministry of Health,
      Malaysia.
FAU - Cheah, W K
AU  - Cheah WK
AD  - Department of Medicine, Hospital Taiping, Ministry of Health, Malaysia.
FAU - Peariasamy, K
AU  - Peariasamy K
AD  - Institute for Clinical Research, Block B, National Institute of Health, Setia
      Alam, Ministry of Health, Malaysia.
FAU - Goh, P P
AU  - Goh PP
AD  - Institute for Clinical Research, Block B, National Institute of Health, Setia
      Alam, Ministry of Health, Malaysia. Electronic address: pikpin@gmail.com.
FAU - Ibrahim, H
AU  - Ibrahim H
AD  - Division for Research and Technical Support, Ministry of Health, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the
      International Society for Infectious Diseases
JID - 9610933
SB  - IM
MH  - *Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - Child
MH  - Child, Preschool
MH  - *Coronavirus Infections/virology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Malaysia
MH  - Male
MH  - *Pandemics
MH  - *Pneumonia, Viral/virology
MH  - SARS-CoV-2
PMC - PMC7158792
OTO - NOTNLM
OT  - COVID-19
OT  - Coronavirus
OT  - Epidemiology
OT  - Outbreak
OT  - Paediatric
OT  - epidemic
OT  - nCoV
EDAT- 2020/04/19 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/02/29 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - S1201-9712(20)30181-8 [pii]
AID - 10.1016/j.ijid.2020.03.049 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2020 May;94:125-127. doi: 10.1016/j.ijid.2020.03.049. Epub 2020
      Apr 15.


PMID- 32304304
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220615
IS  - 2191-0278 (Electronic)
IS  - 0334-0139 (Linking)
VI  - 34
IP  - 3
DP  - 2020 Apr 17
TI  - Study of epidemiological determinants of undernutrition among adolescent girls in
      urban slums of Berhampur, Odisha: a cross-sectional study.
LID - 10.1515/ijamh-2019-0208 [doi]
AB  - BACKGROUND: Adolescent girls are vulnerable to many problems, undernutrition
      being the most common. This results in growth restriction resulting in stunting, 
      wasting, underweight and last but not the least iron-deficiency anaemia.
      Nutritional needs are high during puberty which later leads to complications
      during pregnancy and its outcomes. MATERIALS AND METHODS: A field based
      cross-sectional study was carried out to assess the nutritional status of the
      girls and to determine the various factors responsible for undernutrition. After 
      clearance from the Institution Ethical Committee (IEC) and permission from Child 
      Development Programme Officer (CDPO), the study was conducted in the anganwadi
      centres (AWC) of urban slums in the field practice area of the Department of
      Community Medicine from the 1st October 2014 to the 31st October 2016. All the
      adolescent girls enlisted in the seven anganwadi centres were included as study
      subjects with their consent. A pre-designed, pre-tested and semi-structured
      questionnaire was used to collect data on following sections. (a)
      socio-demographic profile and (b) nutritional status. Dietary intake was taken
      using the 24-h recall method. Anthropometry was measured and haemoglobin (Hb) was
      estimated. SPSS version 21 was used for descriptive and analytic statistics.
      RESULTS: Among the 160 girls 98(61.3%), 69(43.1%), 53(33.1%) were underweight,
      stunted and wasted, respectively. Anaemia was present among 144(90%) of the
      girls. CONCLUSION: Strict monitoring of weekly iron and folic acid
      supplementation (WIFS) as well as nutrition education are essential measures to
      solve the problem of undernutrition among adolescent girls.
CI  - (c) 2020 Walter de Gruyter GmbH, Berlin/Boston.
FAU - Mohanty, Sambedana
AU  - Mohanty S
AUID- ORCID: https://orcid.org/0000-0002-3895-1042
AD  - Department of Community Medicine, IMS and SUM Hospital, Bhubaneswar, Odisha,
      India.
FAU - Panda, Manasee
AU  - Panda M
AD  - Department of Community Medicine, Bhima Bhoi Medical College, Balangir, Odisha,
      India.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Int J Adolesc Med Health
JT  - International journal of adolescent medicine and health
JID - 8506960
SB  - IM
OTO - NOTNLM
OT  - adolescent
OT  - anaemia
OT  - nutrition
OT  - stunting
OT  - teen
OT  - underweight
OT  - wasting
EDAT- 2020/04/19 06:00
MHDA- 2020/04/19 06:01
CRDT- 2020/04/19 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2020/01/05 00:00 [accepted]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/04/19 06:01 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1515/ijamh-2019-0208 [doi]
AID - /j/ijamh.ahead-of-print/ijamh-2019-0208/ijamh-2019-0208.xml [pii]
PST - epublish
SO  - Int J Adolesc Med Health. 2020 Apr 17;34(3). pii:
      /j/ijamh.ahead-of-print/ijamh-2019-0208/ijamh-2019-0208.xml. doi:
      10.1515/ijamh-2019-0208.


PMID- 32304263
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20200721
IS  - 1600-0579 (Electronic)
IS  - 1396-5883 (Linking)
VI  - 24
IP  - 3
DP  - 2020 Aug
TI  - Assessment of dentists' behaviour on the use of patients' images.
PG  - 513-517
LID - 10.1111/eje.12530 [doi]
AB  - BACKGROUND: Photographs and radiographs are indispensable resources for dental
      education, research and dissemination of clinical cases in scientific journals.
      The objective of this study was to evaluate the behaviour of dentists on the use 
      of patients' images. MATERIAL AND METHODS: Fifty-two dentists were interviewed
      using a semi-structured script containing open-ended questions on the use of
      patients' images. The answers were analysed using a qualitative-quantitative
      method of the discourse of the collective subject, and the distribution of the
      absolute and relative frequency of the answers was presented according to the
      central ideas obtained from the discourses. RESULTS: The following central ideas 
      on the use of patients' images were identified: (a) purpose: didactic and/or
      academic; (b) informed consent: verbal or absent when the patient cannot be
      identified; (c) discussion groups on social media contribute to learning; (d)
      most dentists would not appreciate and sue the author if they had their own
      photographs/imaging examinations posted on social media; 5. most dentists
      received some information on ethical regulations during dental school and state
      that images can be used with patient authorisation, without identification and
      for didactic/academic purposes. CONCLUSION: Dentists consider the use of
      patients' images for didactic and scientific purposes beneficial, request
      informed consent to share mainly images that reveal the identity and would not
      appreciate if their personal images were shared without consent.
CI  - (c) 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.
FAU - Costa, Eliana Dantas
AU  - Costa ED
AUID- ORCID: https://orcid.org/0000-0003-4463-7436
AD  - Division of Oral Radiology, Department of Oral Diagnosis, Piracicaba Dental
      School, University of Campinas, Piracicaba, Brazil.
FAU - Martins, Luciano Augusto Cano
AU  - Martins LAC
AUID- ORCID: https://orcid.org/0000-0001-5159-8645
AD  - Division of Oral Radiology, Department of Oral Diagnosis, Piracicaba Dental
      School, University of Campinas, Piracicaba, Brazil.
FAU - Cral, Wilson Gustavo
AU  - Cral WG
AUID- ORCID: https://orcid.org/0000-0002-2015-4934
AD  - Division of Oral Radiology, Department of Oral Diagnosis, Piracicaba Dental
      School, University of Campinas, Piracicaba, Brazil.
FAU - Peroni, Leonardo Vieira
AU  - Peroni LV
AUID- ORCID: https://orcid.org/0000-0002-1391-6216
AD  - Division of Oral Radiology, Department of Oral Diagnosis, Piracicaba Dental
      School, University of Campinas, Piracicaba, Brazil.
FAU - Freitas, Deborah Queiroz
AU  - Freitas DQ
AUID- ORCID: https://orcid.org/0000-0002-1425-5966
AD  - Division of Oral Radiology, Department of Oral Diagnosis, Piracicaba Dental
      School, University of Campinas, Piracicaba, Brazil.
FAU - Oliveira, Matheus Lima
AU  - Oliveira ML
AUID- ORCID: https://orcid.org/0000-0002-8054-8759
AD  - Division of Oral Radiology, Department of Oral Diagnosis, Piracicaba Dental
      School, University of Campinas, Piracicaba, Brazil.
LA  - eng
GR  - 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)
PT  - Journal Article
DEP - 20200523
PL  - England
TA  - Eur J Dent Educ
JT  - European journal of dental education : official journal of the Association for
      Dental Education in Europe
JID - 9712132
MH  - Attitude of Health Personnel
MH  - Communication
MH  - *Dentists
MH  - Education, Dental
MH  - Humans
MH  - *Social Media
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - bioethics
OT  - dentists
OT  - deontology
OT  - qualitative research
EDAT- 2020/04/19 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/04/19 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/02/22 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1111/eje.12530 [doi]
PST - ppublish
SO  - Eur J Dent Educ. 2020 Aug;24(3):513-517. doi: 10.1111/eje.12530. Epub 2020 May
      23.


PMID- 32304235
OWN - NLM
STAT- MEDLINE
DCOM- 20200827
LR  - 20200827
IS  - 1326-5377 (Electronic)
IS  - 0025-729X (Linking)
VI  - 212
IP  - 9
DP  - 2020 May
TI  - Teaching and learning in general practice: ethical and legal considerations for
      GP teachers and medical students.
PG  - 403-405.e1
LID - 10.5694/mja2.50593 [doi]
FAU - Kelly, Michaela
AU  - Kelly M
AD  - University of Queensland, Brisbane, QLD.
FAU - Sturman, Nancy
AU  - Sturman N
AD  - University of Queensland, Brisbane, QLD.
FAU - Pakchung, David
AU  - Pakchung D
AD  - Avant Mutual Group, Brisbane, QLD.
LA  - eng
PT  - Journal Article
DEP - 20200418
PL  - Australia
TA  - Med J Aust
JT  - The Medical journal of Australia
JID - 0400714
SB  - IM
MH  - Confidentiality/ethics
MH  - *Ethics, Medical
MH  - Family Practice/*education/ethics
MH  - General Practice/education/ethics
MH  - Humans
MH  - Interprofessional Relations
MH  - Physician-Patient Relations/*ethics
MH  - Students, Medical/statistics & numerical data
OTO - NOTNLM
OT  - *Confidentiality
OT  - *Ethics, professional
OT  - *General practice
OT  - *Informed consent
EDAT- 2020/04/19 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.5694/mja2.50593 [doi]
PST - ppublish
SO  - Med J Aust. 2020 May;212(9):403-405.e1. doi: 10.5694/mja2.50593. Epub 2020 Apr
      18.


PMID- 32304201
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 101
DP  - 2020 Jan-Apr
TI  - [Robots for care. The ethics of measured action in the face of uncertainty].
PG  - 87-100
AB  - Beyond the utopian or dystopian scenarios that accompany the progressive
      introduction of robots for care in daily environments, their use in the medical
      field entails controversies that require alternative forms of ethical
      responsibility. From this general objective, in this article we propose a series 
      of reflections to articulate an ethical framework capable of orienting the
      introduction and use of robots in the field of health. The presented proposal is 
      developed from a series of considerations about robots and care, as a starting
      point to develop an ethical framework based on the principle of precaution and
      measured action. It proposes a non-essentialist conceptualization of robots, that
      emphasizes their relational and contextual nature, understanding robots as
      heterogeneous artifacts that are constituted in a network of therapeutic
      relationships and that mediate our care relationships. This approach has a set of
      implications, which we articulate around measured action as an ethical proposal. 
      The measured action, in our interpretation, responds to the principle of
      precaution and is configured through four dimensions: (1) the institutional
      commitment, (2) which integrates the fears and hopes of all those concerned
      actors, (3) which is realized carrying out progressive and revocable actions,
      under continuous monitoring and evaluation, and (4) which incorporates into the
      design process those actors practicing ''good care''.
FAU - Valles-Peris, Nuria
AU  - Valles-Peris N
AD  - Barcelona Science and Technology Studies Group (STS-b), Departamento de
      Psicologia Social, Universitat Autonoma de Barcelona Campus de la UAB, 08193
      Bellaterra, Cerdanyola del Valles, Barcelona. nuria.valles@uab.cat.
FAU - Domenech, Miquel
AU  - Domenech M
AD  - Barcelona Science and Technology Studies Group (STS-b), Departamento de
      Psicologia Social, Universitat Autonoma de Barcelona. Campus de la UAB, 08193
      Bellaterra, Cerdanyola del Valles, Barcelona.
LA  - spa
PT  - Journal Article
TT  - Robots para los cuidados. La etica de la accion mesurada frente a la
      incertidumbre.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - *Bioethical Issues
MH  - Delivery of Health Care/*ethics
MH  - Humans
MH  - Morals
MH  - Robotics/*ethics
MH  - *Uncertainty
EDAT- 2020/04/19 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/04/19 06:00
PHST- 2019/03/25 00:00 [received]
PHST- 2019/12/30 00:00 [accepted]
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
PST - ppublish
SO  - Cuad Bioet. 2020 Jan-Apr;31(101):87-100.


PMID- 32304198
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 101
DP  - 2020 Jan-Apr
TI  - [Age limitation to lung transplant recipients. Ethical aspects].
PG  - 43-56
AB  - We present a review of bioethical aspects of limiting patients 65 years or older 
      to lung transplantation. Lung transplantation is a therapeutic option in patients
      with severe advanced respiratory diseases, progressive despite medical treatment 
      to prolong the expected survival. It is an aggressive surgical treatment, and the
      patient must complete a lifelong immunosuppressive treatment. Given the donor
      shortage, access to this treatment is regulated by organ transplant societies,
      which develop patient selection guidelines. One contraindication to
      transplantation has been the age of 65 years, sustained by the poor results of
      older patients and following utilitarian bioethics concept. For the time being
      there is no unified selection criteria to identify older patients susceptible to 
      have a worse outcome after transplantation. Applying a personalist bioethics, we 
      propose to use selection criteria based on frailty scales to identify those frail
      patients more likely to die after the transplant procedure.
FAU - Reig Mezquida, Juan Pablo
AU  - Reig Mezquida JP
AD  - Hospital Universitari i Politecnic La Fe, Valencia. Espana. C/ Sagunto 151 p/13
      Valencia. Espana. jpreig@comv.es.
FAU - Sales Badia, Gabriel
AU  - Sales Badia G
AD  - Hospital Universitari i Politecnic La Fe, Valencia. Espana. C/ Sagunto 151 p/13
      Valencia. Espana.
FAU - Tudela Cuenca, Julio
AU  - Tudela Cuenca J
AD  - Universidad Catolica de Valencia San Vicente Martir. Valencia. Espana.
      jpreig@comv.es.
LA  - spa
PT  - Journal Article
TT  - Limitacion por edad en trasplante de pulmon. Aspectos eticos.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Bioethical Issues
MH  - Humans
MH  - Lung Transplantation/*ethics/mortality/*standards
MH  - Patient Selection/*ethics
EDAT- 2020/04/19 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/04/19 06:00
PHST- 2018/10/14 00:00 [received]
PHST- 2019/05/03 00:00 [accepted]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
PST - ppublish
SO  - Cuad Bioet. 2020 Jan-Apr;31(101):43-56.


PMID- 32304196
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1132-1989 (Print)
IS  - 1132-1989 (Linking)
VI  - 31
IP  - 101
DP  - 2020 Jan-Apr
TI  - [Bioethics and spirituality at the end of life].
PG  - 13-18
AB  - Understanding suffering and hope with people - children, youth and adults who
      die! Being with so many people waited, despaired, cried the lives of parents,
      children and friends, we will better understand the pain and suffering and
      spirituality of those at the end of life. With this essay, we intend to raise the
      reflection of health professionals to experience spirituality in caring for the
      end-of-life person. Study and hermeneutic analysis based on texts by Daniel
      Serr)o, Walter Osswald and Filipe Almeida. Results. Medicine and nursing are
      aware of human finitude, but of a finitude that is not identified with
      nothingness, emptiness, absence, but an ethic of hope ''(Moltmann, 2012).
      Bioethics in clinical practice calls for the humanization and spirituality of the
      dying process. Each sick person calls for a therapeutic response on the horizon
      of friendship, which refuses, therefore, disagreements generated in the corridors
      inhabited by moral strangers. Spirituality is also the therapeutic window of a
      universe that awaits intensity of glances, cuddling with outstretched hands,
      respect in the dignity that is recognized.
FAU - Costa Gomes, Carlos
AU  - Costa Gomes C
AD  - Instituto de Bioetica, Universidade Catolica Portuguesa (IB-UCP).
      cgomes@porto.ucp.pt.
FAU - Borges Neto, Renato da Silveira
AU  - Borges Neto RDS
AD  - Departamento de Teologia/CRE da Pontificia Universidade Catolica do Rio de
      Janeiro (PUC-Rio).
LA  - spa
PT  - Journal Article
TT  - Bioetica y espiritualidad al final de la vida.
PL  - Spain
TA  - Cuad Bioet
JT  - Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y
      Etica Medica
JID - 101312976
SB  - IM
MH  - *Bioethical Issues
MH  - Humans
MH  - *Spirituality
MH  - Terminal Care/*ethics
EDAT- 2020/04/19 06:00
MHDA- 2021/04/30 06:00
CRDT- 2020/04/19 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
PST - ppublish
SO  - Cuad Bioet. 2020 Jan-Apr;31(101):13-18.


PMID- 32304014
OWN - NLM
STAT- In-Data-Review
LR  - 20200501
IS  - 1573-0980 (Electronic)
IS  - 1386-7415 (Linking)
VI  - 41
IP  - 1
DP  - 2020 Feb
TI  - Is skin bleaching a moral wrong? An African bioethical perspective.
PG  - 1-22
LID - 10.1007/s11017-020-09520-1 [doi]
AB  - Focusing on black communities in Africa, in this paper, I attempt an African
      bioethico-aesthetic deconstruction of the falsehood in colorist definitions of
      beauty purveyed by the migration of non-surgical cosmetics to Africa. I provide a
      novel ethical evaluation of the act of skin bleaching using principles of the
      African ethic of communion. I argue that skin bleaching is morally wrong to the
      extent that it promotes disharmonious relations and false identity in the beauty 
      industry in Africa. Drawing on scientific studies that link toxic ingredients in 
      many skin-bleaching products to adverse health effects, I discuss the public
      health impact of bleaching cosmetics and other problems occasioned by their
      strategic expansion into African markets. I propose that there is an urgent need 
      for a relational ethic of polycentric governance that would harmoniously regulate
      the production and distribution of cosmetic products across regions in order to
      avoid the exploitation of consumers in black African societies, while also
      protecting consumers' right to make informed choices through education.
FAU - Fayemi, Ademola Kazeem
AU  - Fayemi AK
AUID- ORCID: https://orcid.org/0000-0001-7589-8626
AD  - University of Johannesburg, Johannesburg, South Africa. kcaristotle@yahoo.com.
AD  - University of Lagos, Akoka, Nigeria. kcaristotle@yahoo.com.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Theor Med Bioeth
JT  - Theoretical medicine and bioethics
JID - 9805378
SB  - IM
OTO - NOTNLM
OT  - African bioethic of communion
OT  - Beauty ideals
OT  - Colorism
OT  - Skin-bleaching cosmetics
OT  - South Sahara
EDAT- 2020/04/19 06:00
MHDA- 2020/04/19 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/04/19 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1007/s11017-020-09520-1 [doi]
AID - 10.1007/s11017-020-09520-1 [pii]
PST - ppublish
SO  - Theor Med Bioeth. 2020 Feb;41(1):1-22. doi: 10.1007/s11017-020-09520-1.


PMID- 32303983
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Defensive practice is indefensible: how defensive medicine runs counter to the
      ethical and professional obligations of clinicians.
PG  - 413-420
LID - 10.1007/s11019-020-09950-7 [doi]
AB  - Defensive medicine has become pervasive. Defensive medicine is often thought of
      as a systems issue, the inevitable result of an adversarial malpractice
      environment, with consequent focus on system-responses and tort reform. But
      defensive medicine also has ethical and professionalism implications that should 
      be considered beyond the need for tort reform. This article examines defensive
      medicine from an ethics and professionalism perspective, showing how defensive
      medicine is deeply problematic. First, a definition of defensive medicine is
      offered that describes the essence of defensive practice: clinical actions with
      the goal of protecting the clinician against litigation or some adverse outcome. 
      Ethical arguments against defensive medicine are considered: (1) defensive
      medicine is deceptive and undermines patient autonomy; (2) defensive medicine
      subjugates patient interests to physician interests and violate fiduciary
      obligations; (3) defensive medicine exposes patients to harm without benefit; (4)
      defensive medicine undermines trust in the profession; and (5) defensive medicine
      violates obligations of justice. Possible arguments in favor of defensive
      medicine are considered and refuted. Defensive practice is therefore unethical
      and unprofessional, and should be viewed as a challenge for medical ethics and
      professionalism.
FAU - Bester, Johan Christiaan
AU  - Bester JC
AD  - University of Nevada Las Vegas, Las Vegas, NV, USA. jcbester@gmail.com.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Defensive Medicine/*ethics
MH  - Humans
MH  - Malpractice
MH  - Medical Overuse
MH  - *Moral Obligations
MH  - Personal Autonomy
MH  - Philosophy, Medical
MH  - Physician-Patient Relations
MH  - *Professionalism
MH  - Trust
OTO - NOTNLM
OT  - Clinical ethics
OT  - Defensive medicine
OT  - Fiduciary obligations
OT  - Medical ethics
OT  - Professionalism
EDAT- 2020/04/19 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1007/s11019-020-09950-7 [doi]
AID - 10.1007/s11019-020-09950-7 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):413-420. doi: 10.1007/s11019-020-09950-7.


PMID- 32303917
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2198-7793 (Print)
IS  - 2198-7793 (Linking)
VI  - 6
IP  - 1
DP  - 2020 Apr 17
TI  - Gastric volvulus with perforation 1 year after total pancreatectomy: a case
      report.
PG  - 74
LID - 10.1186/s40792-020-00840-x [doi]
AB  - BACKGROUND: Because of its rare indication and relatively simple reconstruction
      procedure (only choledochojejunostomy and gastrojejunostomy) compared to those
      for pancreatoduodenectomy, the technical tips and pitfalls of total
      pancreatectomy are rarely discussed. Herein, we discuss a rare case of gastric
      volvulus 1 year after total pancreatectomy and provide advice to prevent such
      cases. CASE PRESENTATION: A 66-year-old woman underwent total pancreatectomy with
      splenectomy for mixed-type intraductal papillary mucinous neoplasm of the
      pancreas. Choledochojejunostomy (retro-colic route) and gastrojejunostomy
      (ante-colic route, Billroth II method) were performed for reconstruction. The
      final diagnosis was mixed-type intraductal papillary mucinous adenoma of the
      pancreas without malignant neoplasm. She had no clinical symptoms, such as
      abdominal pain and fever, during postoperative follow-up. However, at 1 year
      postoperatively, she complained of abdominal pain. Contrast-enhanced abdominal
      computed tomography showed volvulus and perforation of the stomach. Emergent
      surgery was performed. The stomach fornix was located on the right side and was
      partly perforated. We resected the perforation site with a linear cutter(R) (New 
      Type Linear Cutter, Ethicon, USA) and released the gastric volvulus. Moreover, we
      fixed the stomach to the left abdominal wall using non-absorbable thread. The
      cause of the perforation was clinically and pathologically unclear. Her serum
      albumin and cholinesterase levels temporarily decreased postoperatively, but
      gradually increased. A recurrence of volvulus-related symptoms has not been
      observed. CONCLUSIONS: After total pancreatectomy with splenectomy, although the 
      stomach is connected with the jejunum, it is typically fixed only by the pedicle 
      of the left gastric artery and vein. In the present case, this anatomical change 
      may have been a cause of the gastric volvulus. Thus, it might be better to fix
      the remnant stomach in total pancreatectomy with splenectomy.
FAU - Takahashi, Yusuke
AU  - Takahashi Y
AD  - Department of Hepatobiliary Pancreatic Surgery, Nagano Municipal Hospital, 1333-1
      Tomitake, Nagano City, Nagano, 381-8551, Japan.
      yusuke_takahashi@hospital.nagano.nagano.jp.
FAU - Seki, Hitoshi
AU  - Seki H
AD  - Department of Hepatobiliary Pancreatic Surgery, Nagano Municipal Hospital, 1333-1
      Tomitake, Nagano City, Nagano, 381-8551, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Surg Case Rep
JT  - Surgical case reports
JID - 101662125
PMC - PMC7165202
OTO - NOTNLM
OT  - Pancreatectomy
OT  - Pancreatic intraductal neoplasms
OT  - Stomach volvulus
EDAT- 2020/04/19 06:00
MHDA- 2020/04/19 06:01
CRDT- 2020/04/19 06:00
PHST- 2020/03/05 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/04/19 06:01 [medline]
AID - 10.1186/s40792-020-00840-x [doi]
AID - 10.1186/s40792-020-00840-x [pii]
PST - epublish
SO  - Surg Case Rep. 2020 Apr 17;6(1):74. doi: 10.1186/s40792-020-00840-x.


PMID- 32303724
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20210417
IS  - 1471-0080 (Electronic)
IS  - 1471-0072 (Linking)
VI  - 21
IP  - 8
DP  - 2020 Aug
TI  - Biomedical ethics 2.0: redefining the meaning of disease, patient and treatment.
PG  - 417-418
LID - 10.1038/s41580-020-0247-7 [doi]
FAU - Grinnell, Frederick
AU  - Grinnell F
AUID- ORCID: http://orcid.org/0000-0001-5337-3087
AD  - Robert McLemore Professor of Medical Science. Department of Cell Biology Ethics
      in Science and Medicine Program UT Southwestern Med Ctr, Dallas, TX, USA.
      frederick.grinnell@utsouthwestern.edu.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - England
TA  - Nat Rev Mol Cell Biol
JT  - Nature reviews. Molecular cell biology
JID - 100962782
SB  - IM
MH  - Bioethics/*history/*trends
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
EDAT- 2020/04/19 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/04/19 06:00 [entrez]
AID - 10.1038/s41580-020-0247-7 [doi]
AID - 10.1038/s41580-020-0247-7 [pii]
PST - ppublish
SO  - Nat Rev Mol Cell Biol. 2020 Aug;21(8):417-418. doi: 10.1038/s41580-020-0247-7.


PMID- 32303517
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 16
TI  - Prospective observational study on the pharmacokinetic properties of the Irrua
      ribavirin regimen used in routine clinical practice in patients with Lassa fever 
      in Nigeria.
PG  - e036936
LID - 10.1136/bmjopen-2020-036936 [doi]
AB  - INTRODUCTION: Lassa fever (LF) is a severe and often fatal systemic disease in
      humans and affects a large number of countries in West Africa. Treatment options 
      are limited to supportive care and the broad-spectrum antiviral agent ribavirin. 
      However, evidence for ribavirin efficacy in patients with LF is poor and
      pharmacokinetic (PK) data are not available.Irrua Specialist Teaching Hospital
      (ISTH) developed an intravenous ribavirin regimen different to the WHO
      recommendation. Apart from a lower total daily dose the drug is usually
      administered once per day which reduces the exposure of personnel to patients
      with LF. The aim of this study is to characterise the PK of the Irrua ribavirin
      regimen. METHODS AND ANALYSIS: This prospective, observational clinical study
      will assess PK properties of the Irrua ribavirin regimen on routinely
      ribavirin-treated patients with LF at ISTH, a referral hospital serving 19 local 
      governmental areas in a LF endemic zone in Nigeria. Participants will be adults
      with PCR-confirmed LF. The primary objective is to describe classical PK
      parameters for ribavirin (maximum plasma drug concentration, time to maximum
      plasma drug concentration, area under the plasma drug concentration vs time
      curve, half-life time T1/2, volume of distribution). Blood samples will be
      collected at 0.5, 1, 3, 5, 8, 12 and 24 hours after doses on day 1, day 4 and day
      10 of ribavirin treatment. Ribavirin plasma concentrations will be determined
      using liquid chromatography coupled to tandem mass spectrometry. ETHICS AND
      DISSEMINATION: The study will be conducted in compliance with the protocol, the
      Declaration of Helsinki, Good Clinical Practice (GCP) and the Nigerian National
      Code for Health Research Ethics. The protocol has received approval by the Health
      Research Ethics Committee of ISTH. Results will be made available to LF
      survivors, their caregivers, the funders, LF research society and other
      researchers. REGISTRATION DETAILS: ISRCTN11104750.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Erameh, Cyril
AU  - Erameh C
AD  - Institute of Lassa Fever Research and Control, Irrua Specialist Teaching
      Hospital, Irrua, Nigeria.
AD  - Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
FAU - Edeawe, Osahogie
AU  - Edeawe O
AD  - Institute of Lassa Fever Research and Control, Irrua Specialist Teaching
      Hospital, Irrua, Nigeria.
FAU - Akhideno, Peter
AU  - Akhideno P
AD  - Institute of Lassa Fever Research and Control, Irrua Specialist Teaching
      Hospital, Irrua, Nigeria.
AD  - Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria.
FAU - Eifediyi, Gloria
AU  - Eifediyi G
AD  - Institute of Lassa Fever Research and Control, Irrua Specialist Teaching
      Hospital, Irrua, Nigeria.
FAU - Omansen, Till F
AU  - Omansen TF
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Wagner, Christine
AU  - Wagner C
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Sarpong, Francisca
AU  - Sarpong F
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Koch, Till
AU  - Koch T
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Wicha, Sebastian
AU  - Wicha S
AD  - Department of Clinical Pharmacology, University of Hamburg, Hamburg, Germany.
FAU - Kurth, Florian
AU  - Kurth F
AUID- ORCID: 0000-0002-3807-473X
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
AD  - Department of Infectious Diseases and Pulmonary Medicine, Charite
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Duraffour, Sophie
AU  - Duraffour S
AD  - Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg,
      Germany.
FAU - Oestereich, Lisa
AU  - Oestereich L
AD  - Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg,
      Germany.
FAU - Pahlmann, Meike
AU  - Pahlmann M
AD  - Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg,
      Germany.
FAU - Okogbenin, Sylvanus
AU  - Okogbenin S
AD  - Institute of Lassa Fever Research and Control, Irrua Specialist Teaching
      Hospital, Irrua, Nigeria.
AD  - Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital,
      Irrua, Nigeria.
FAU - Ogbaini-Emovon, Ephraim
AU  - Ogbaini-Emovon E
AD  - Institute of Lassa Fever Research and Control, Irrua Specialist Teaching
      Hospital, Irrua, Nigeria.
FAU - Gunther, Stephan
AU  - Gunther S
AUID- ORCID: 0000-0002-6562-0230
AD  - Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg,
      Germany.
FAU - Ramharter, Michael
AU  - Ramharter M
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany.
FAU - Groger, Mirjam
AU  - Groger M
AD  - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &
      I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany groger@bnitm.de.
LA  - eng
SI  - ISRCTN/ISRCTN11104750
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200416
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Lassa Fever/drug therapy
MH  - Nigeria
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - Research Design
MH  - Ribavirin/*pharmacokinetics
PMC - PMC7200043
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *infectious diseases
OT  - *virology
COIS- Competing interests: None declared.
EDAT- 2020/04/19 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2020-036936 [pii]
AID - 10.1136/bmjopen-2020-036936 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 16;10(4):e036936. doi: 10.1136/bmjopen-2020-036936.


PMID- 32303516
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 16
TI  - Obstetrical safety indicators for preventing hospital harms in low risk births: a
      scoping review protocol.
PG  - e036203
LID - 10.1136/bmjopen-2019-036203 [doi]
AB  - INTRODUCTION: Optimising the safety of obstetric patient care is a primary
      concern for many hospitals. Performance indicators measuring aspects of patient
      care processes can lead to improvements in health systems and the prevention of
      harm to the patient. We present our protocol for a scoping review to identify
      indicators for obstetric safety in low risk births. We aim to identify indicators
      addressing preventable hospital harms, to summarise the data and synthesise
      results. METHODS AND ANALYSIS: We will use methods described by Arksey and
      O'Malley and further expanded by Levac et al. We will search electronic databases
      such as Medline, Embase, CINAHL and the Cochrane Library, and websites from
      professional bodies and other organisations, using an iterative search
      strategy.Two reviewers will independently screen titles and abstracts of search
      results to determine eligibility for inclusion. If eligibility is not clear, the 
      reviewers will screen the full text version. If reviewers' decisions regarding
      eligibility differ, a third reviewer will review the record. Two reviewers will
      independently extract data from records that meet our inclusion criteria using a 
      standardised data collection form. We will narratively describe quantitative
      data, such as the frequency with which indicators are identified, and conduct a
      thematic analysis of the qualitative data. We will compile a comprehensive list
      of patient safety indicators and organise them according to concepts that best
      suit the data such as the Donabedian model or the Hospital Harm Framework. We
      will discuss the implications for future research, clinical practice and
      policy-making. We will report the conduct of the review using the Preferred
      Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping
      reviews checklist. ETHICS AND DISSEMINATION: The sources of information included 
      in this scoping review will be available to the public. Therefore, ethics
      approval is not warranted. We will disseminate results in a peer-reviewed
      publication, conference/event presentation(s) and stakeholder communications.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Conway, Aislinn
AU  - Conway A
AUID- ORCID: 0000-0002-7566-3138
AD  - Better Outcomes & Registry Network (BORN) Ontario, Children's Hospital of Eastern
      Ontario - Ottawa Children's Treatment Centre, Ottawa, Ontario, Canada
      aislinnconway@gmail.com.
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario,
      Canada.
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
FAU - Reszel, Jessica
AU  - Reszel J
AUID- ORCID: 0000-0003-1702-5629
AD  - Better Outcomes & Registry Network (BORN) Ontario, Children's Hospital of Eastern
      Ontario - Ottawa Children's Treatment Centre, Ottawa, Ontario, Canada.
AD  - Ottawa Health Research Institute, Ottawa, Ontario, Canada.
FAU - Walker, Mark C
AU  - Walker MC
AUID- ORCID: 0000-0001-8974-4548
AD  - Better Outcomes & Registry Network (BORN) Ontario, Children's Hospital of Eastern
      Ontario - Ottawa Children's Treatment Centre, Ottawa, Ontario, Canada.
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
AD  - Ottawa Health Research Institute, Ottawa, Ontario, Canada.
AD  - OMNI Research Group, Department of Obstetrics, Gynecology, and Newborn Care,
      University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada.
FAU - Grimshaw, Jeremy M
AU  - Grimshaw JM
AUID- ORCID: 0000-0001-8015-8243
AD  - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
AD  - Centre for Implementation Research, Ottawa Hospital Research Institute, Ottawa,
      Ontario, Canada.
FAU - Dunn, Sandra I
AU  - Dunn SI
AUID- ORCID: 0000-0003-4192-7884
AD  - Better Outcomes & Registry Network (BORN) Ontario, Children's Hospital of Eastern
      Ontario - Ottawa Children's Treatment Centre, Ottawa, Ontario, Canada.
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario,
      Canada.
AD  - Ottawa Health Research Institute, Ottawa, Ontario, Canada.
AD  - School of Nursing, University of Ottawa, Ottawa, Ontario, Canada.
LA  - eng
GR  - CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200416
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Female
MH  - Hospitals
MH  - Humans
MH  - Obstetrics/*standards
MH  - *Patient Safety
MH  - *Peer Review
MH  - *Policy Making
MH  - Pregnancy
MH  - Research Design
MH  - Review Literature as Topic
PMC - PMC7200041
OTO - NOTNLM
OT  - *audit
OT  - *health & safety
OT  - *obstetrics
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/04/19 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036203 [pii]
AID - 10.1136/bmjopen-2019-036203 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 16;10(4):e036203. doi: 10.1136/bmjopen-2019-036203.


PMID- 32303513
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 16
TI  - Prevalence and determinants of anaemia in children aged 6-59 months in Africa: a 
      protocol for systematic review and meta-analysis.
PG  - e032042
LID - 10.1136/bmjopen-2019-032042 [doi]
AB  - INTRODUCTION: Anaemia, especially in children aged <5 years, is a global health
      problem disproportionately affecting populations in low-income and middle-income 
      countries. It is associated with high disability and death rates and has a
      negative effect on development. This study seeks to evaluate the prevalence and
      determinants of anaemia in children aged 6-59 months residing in Africa. METHODS 
      AND ANALYSIS: This protocol was prepared using the 2015 Preferred Reporting Items
      for Systematic Reviews and Meta-analyses for Protocols guidelines. Relevant
      citations will be identified by searching EMBASE, Web of Science, PubMed, Global 
      Medicus Index and African Journals Online from inception to 30 September 2019
      with no language restrictions. Two authors will independently screen and select
      eligible studies for the review. Random-effect meta-analytic methods will be used
      to pool study-specific estimates and heterogeneity will be assessed and
      quantified using the chi(2) test on Cochrane's Q and I(2) statistics,
      respectively. Publication bias will be evaluated using funnel plots and Egger's
      test. Subgroup analysis and multiple meta-regression using backward elimination
      will be performed to investigate sources of substantial heterogeneity. ETHICS AND
      DISSEMINATION: No ethical approval is required for this study as it is based on
      already published data. The findings of the review will be published in a
      peer-reviewed journal and presented at conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Simo, Larissa Pone
AU  - Simo LP
AD  - Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon.
AD  - Clinical Research Education, Networking & Consultancy (CRENC), Douala, Cameroon.
FAU - Agbor, Valirie Ndip
AU  - Agbor VN
AUID- ORCID: 0000-0002-6708-6852
AD  - Nuffield Department of Population Health, University of Oxford, Oxford, UK
      nvagbor@gmail.com.
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
FAU - AgborNdip, Ettamba
AU  - AgborNdip E
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
AD  - Institute of Child Health, University College London, London, UK.
FAU - Ekaney, Domin Sone M
AU  - Ekaney DSM
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
AD  - Ecole de Sante Publique, Universite Libre de Bruxelles, Bruxelles, Belgium.
FAU - Mbeng, Emmanuel Njang
AU  - Mbeng EN
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
FAU - Etombi, Christie Linonge
AU  - Etombi CL
AD  - Clinical Research Education, Networking & Consultancy (CRENC), Douala, Cameroon.
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
FAU - Neba, Kilton Nforchu
AU  - Neba KN
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
FAU - Kemah, Ben-Lawrence Ayong
AU  - Kemah BA
AD  - Department of Clinical Research, Health Education and Research Organization
      (HERO), Buea, Cameroon.
FAU - Mbanya, Dora
AU  - Mbanya D
AD  - Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon.
AD  - Yaounde University Teaching Hospital (YUTH), Yaounde, Cameroon.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200416
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Africa/epidemiology
MH  - Anemia/*epidemiology
MH  - Case-Control Studies
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Infant
MH  - Prevalence
MH  - Publication Bias
MH  - Randomized Controlled Trials as Topic
PMC - PMC7199940
OTO - NOTNLM
OT  - *Africa
OT  - *anaemia
OT  - *child
OT  - *infant
COIS- Competing interests: None declared.
EDAT- 2020/04/19 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/04/19 06:00
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-032042 [pii]
AID - 10.1136/bmjopen-2019-032042 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 16;10(4):e032042. doi: 10.1136/bmjopen-2019-032042.


PMID- 32303273
OWN - NLM
STAT- MEDLINE
DCOM- 20210531
LR  - 20210531
IS  - 2051-5960 (Electronic)
IS  - 2051-5960 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Apr 17
TI  - Characterising cellular and molecular features of human peripheral nerve
      degeneration.
PG  - 51
LID - 10.1186/s40478-020-00921-w [doi]
AB  - Nerve regeneration is a key biological process in those recovering from neural
      trauma. From animal models it is known that the regenerative capacity of the
      peripheral nervous system (PNS) relies heavily on the remarkable ability of
      Schwann cells to undergo a phenotypic shift from a myelinating phenotype to one
      that is supportive of neural regeneration. In rodents, a great deal is known
      about the molecules that control this process, such as the transcription factors 
      c-Jun and early growth response protein 2 (EGR2/KROX20), or mark the cells and
      cellular changes involved, including SOX10 and P75 neurotrophin receptor
      (p75NTR). However, ethical and practical challenges associated with studying
      human nerve injury have meant that little is known about human nerve
      regeneration.The present study addresses this issue, analysing 34 denervated and 
      five healthy nerve samples from 27 patients retrieved during reconstructive nerve
      procedures. Using immunohistochemistry and Real-Time quantitative Polymerase
      Chain Reaction (RT-qPCR), the expression of SOX10, c-Jun, p75NTR and EGR2 was
      assessed in denervated samples and compared to healthy nerve. Nonparametric
      smoothing linear regression was implemented to better visualise trends in the
      expression of these markers across denervated samples.It was found, first, that
      two major genes associated with repair Schwann cells in rodents, c-Jun and
      p75NTR, are also up-regulated in acutely injured human nerves, while the myelin
      associated transcription factor EGR2 is down-regulated, observations that
      encourage the view that rodent models are relevant for learning about human nerve
      injury. Second, as in rodents, the expression of c-Jun and p75NTR declines during
      long-term denervation. In rodents, diminishing c-Jun and p75NTR levels mark the
      general deterioration of repair cells during chronic denervation, a process
      thought to be a major obstacle to effective nerve repair. The down-regulation of 
      c-Jun and p75NTR reported here provides the first molecular evidence that also in
      humans, repair cells deteriorate during chronic denervation.
FAU - Wilcox, Matthew B
AU  - Wilcox MB
AD  - Peripheral Nerve Injury Research Unit, Royal National Orthopaedic Hospital,
      Stanmore, UK.
AD  - Department of Pharmacology, UCL School of Pharmacy, University College London,
      London, WC1N 1AX, UK.
AD  - UCL Centre for Nerve Engineering, University College London, London, UK.
FAU - Laranjeira, Simao G
AU  - Laranjeira SG
AD  - UCL Centre for Nerve Engineering, University College London, London, UK.
AD  - Department of Mechanical Engineering, University College London, London, UK.
FAU - Eriksson, Tuula M
AU  - Eriksson TM
AD  - Department of Biomaterials and Tissue Engineering, Eastman Dental Institute,
      University College London, London, UK.
FAU - Jessen, Kristjan R
AU  - Jessen KR
AD  - UCL Centre for Nerve Engineering, University College London, London, UK.
AD  - Department of Cell and Developmental Biology, University College London, London, 
      UK.
FAU - Mirsky, Rhona
AU  - Mirsky R
AD  - UCL Centre for Nerve Engineering, University College London, London, UK.
AD  - Department of Cell and Developmental Biology, University College London, London, 
      UK.
FAU - Quick, Tom J
AU  - Quick TJ
AD  - Peripheral Nerve Injury Research Unit, Royal National Orthopaedic Hospital,
      Stanmore, UK.
AD  - UCL Centre for Nerve Engineering, University College London, London, UK.
FAU - Phillips, James B
AU  - Phillips JB
AD  - Department of Pharmacology, UCL School of Pharmacy, University College London,
      London, WC1N 1AX, UK. jb.phillips@ucl.ac.uk.
AD  - UCL Centre for Nerve Engineering, University College London, London, UK.
      jb.phillips@ucl.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200417
PL  - England
TA  - Acta Neuropathol Commun
JT  - Acta neuropathologica communications
JID - 101610673
RN  - 0 (NGFR protein, human)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Proto-Oncogene Proteins c-jun)
RN  - 0 (Receptors, Nerve Growth Factor)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nerve Degeneration/*metabolism
MH  - Nerve Regeneration/*physiology
MH  - Nerve Tissue Proteins/*metabolism
MH  - Peripheral Nerve Injuries/*metabolism
MH  - Proto-Oncogene Proteins c-jun/*metabolism
MH  - Receptors, Nerve Growth Factor/*metabolism
PMC - PMC7164159
OTO - NOTNLM
OT  - *Human tissue
OT  - *Muscle reinnervation
OT  - *Nerve transfer
OT  - *Peripheral nerve degeneration
OT  - *Schwann cells
EDAT- 2020/04/19 06:00
MHDA- 2021/06/01 06:00
CRDT- 2020/04/19 06:00
PHST- 2019/11/27 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2021/06/01 06:00 [medline]
AID - 10.1186/s40478-020-00921-w [doi]
AID - 10.1186/s40478-020-00921-w [pii]
PST - epublish
SO  - Acta Neuropathol Commun. 2020 Apr 17;8(1):51. doi: 10.1186/s40478-020-00921-w.


PMID- 32303101
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Ethical Considerations for Participatory Health through Social Media: Healthcare 
      Workforce and Policy Maker Perspectives.
PG  - 71-76
LID - 10.1055/s-0040-1701981 [doi]
AB  - OBJECTIVES: To identify the different ethical issues that should be considered in
      participatory health through social media from different stakeholder perspectives
      (i.e., patients/service users, health professionals, health information
      technology (If) professionals, and policy makers) in any healthcare context.
      METHODS: We implemented a two-round survey composed of open ended questions in
      the first round, aggregated into a list of ethical issues rated for importance by
      participants in the second round, to generate a ranked list of possible ethical
      issues in participatory health based on healthcare professionals' and policy
      makers' opinions on both their own point of view and their beliefs for other
      stakeholders' perspectives. RESULTS: Twenty-six individuals responded in the
      first round of the survey. Multiple ethical issues were identified for each
      perspective. Data privacy, data security, and digital literacy were common themes
      in all perspectives. Thirty-three individuals completed the second round of the
      survey. Data privacy and data security were ranked among the three most important
      ethical issues in all perspectives. Quality assurance was the most important
      issue from the healthcare professionals' perspective and the second most
      important issue from the patients' perspective. Data privacy was the most
      important consideration for patients/service users. Digital literacy was ranked
      as the fourth most important issue, except for policy makers' perspective.
      CONCLUSIONS: Different stakeholders' opinions fairly agreed that there are common
      ethical issues that should be considered across the four groups (patients,
      healthcare professionals, health IT professionals, policy makers) such as data
      privacy, security, and quality assurance.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Rivera-Romero, Octavio
AU  - Rivera-Romero O
AD  - Computer Engineering School, Universidad de Sevilla, Seville, Spain.
FAU - Konstantinidis, Stathis
AU  - Konstantinidis S
AD  - University of Nottingham, Nottingham, UK.
FAU - Denecke, Kerstin
AU  - Denecke K
AD  - Bern University of Applied Sciences, Bern, Switzerland.
FAU - Gabarron, Elia
AU  - Gabarron E
AD  - Norwegian Centre of E-Health Research, University Hospital North Norway, Norway.
FAU - Petersen, Carolyn
AU  - Petersen C
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,
      USA.
FAU - Househ, Mowafa
AU  - Househ M
AD  - College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar.
FAU - Merolli, Mark
AU  - Merolli M
AD  - Health and Biomedical Informatics Centre, Melbourne Medical School, University of
      Melbourne, Melbourne, Australia.
FAU - Mayer, Miguel Angel
AU  - Mayer MA
AD  - Research Programme on Biomedical Informatics, Hospital del Mar Medical Research
      Institute, Universitat Pompeu Fabra, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Computer Security
MH  - *Ethics, Clinical
MH  - *Health Personnel/ethics
MH  - Health Workforce
MH  - Humans
MH  - Privacy
MH  - Social Media/*ethics
MH  - Surveys and Questionnaires
PMC - PMC7442531
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1055/s-0040-1701981 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):71-76. doi: 10.1055/s-0040-1701981. Epub 2020
      Apr 17.


PMID- 32303100
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Challenges and Best Practices in Ethical Review of Human and Organizational
      Factors Studies in Health Technology: a Synthesis of Testimonies.
PG  - 58-70
LID - 10.1055/s-0040-1701979 [doi]
AB  - OBJECTIVE: Human and Organizational Factors (HOF) studies in health technology
      involve human beings and thus require Institutional Review Board (IRB) approval. 
      Yet HOF studies have specific constraints and methods that may not fit standard
      regulations and IRB practices. Gaining IRB approval may pose difficulties for HOF
      researchers. This paper aims to provide a first overview of HOF study challenges 
      to get IRB review by exploring differences and best practices across different
      countries. METHODS: HOF researchers were contacted by email to provide a
      testimony about their experience with IRB review and approval. Testimonies were
      thematically analyzed and synthesized to identify and discuss shared themes.
      RESULTS: Researchers from seven European countries, Argentina, Canada, Australia,
      and the United States answered the call. Four themes emerged that indicate shared
      challenges in legislation, IRB inefficiencies and inconsistencies, general
      regulation and costs, and lack of HOF study knowledge by IRB members. We propose 
      a model for IRB review of HOF studies based on best practices. CONCLUSION:
      International criteria are needed that define low and high-risk HOF studies, to
      allow identification of studies that can undergo an expedited (or exempted)
      process from those that need full IRB review. Enhancing IRB processes in such a
      way would be beneficial to the conduct of HOF studies. Greater knowledge and
      promotion of HOF methods and evidence-based HOF study designs may support the
      evolving discipline. Based on these insights, training and guidance to IRB
      members may be developed to support them in ensuring that appropriate ethical
      issues for HOF studies are considered.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Peute, Linda W
AU  - Peute LW
AD  - Centre for Human Factor Engineering of Health Information technology - Amsterdam 
      UMC, University of Amsterdam, department of Medical Informatics, Amsterdam, The
      Netherlands.
FAU - Lichtner, Valentina
AU  - Lichtner V
AD  - Centre for Medication Safety and Service Quality, UCL School of Pharmacy, UK.
FAU - Baysari, Melissa T
AU  - Baysari MT
AD  - The University of Sydney, Faculty of Medicine and Health, Sydney, Australia.
FAU - Hagglund, Maria
AU  - Hagglund M
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;
      Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
FAU - Homco, Juell
AU  - Homco J
AD  - Department of Medical Informatics, University of Oklahoma - Tulsa School of
      Community Medicine, USA.
FAU - Jansen-Kosterink, Stephanie
AU  - Jansen-Kosterink S
AD  - Roessingh Research and Development, eHealth group, Enschede, The Netherlands.
FAU - Jauregui, Ignacio
AU  - Jauregui I
AD  - Health Informatics Department, Hospital Italiano de Buenos Aires, Argentina.
FAU - Kaipio, Johanna
AU  - Kaipio J
AD  - Department of Computer Science, Aalto University, Finland.
FAU - Kuziemsky, Craig E
AU  - Kuziemsky CE
AD  - MacEwan University, Edmonton, AB, Canada.
FAU - Lehnbom, Elin Christina
AU  - Lehnbom EC
AD  - Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of 
      Norway, Norway; Department of Health and Caring Sciences, Faculty of Health and
      Life Sciences, Linnaeus University, Sweden.
FAU - Leite, Francisca
AU  - Leite F
AD  - Hospital da Luz Learning Health, Portugal.
FAU - Lesselroth, Blake
AU  - Lesselroth B
AD  - Department of Medical Informatics, University of Oklahoma - Tulsa School of
      Community Medicine, USA.
FAU - Luna, Daniel
AU  - Luna D
AD  - Health Informatics Department, Hospital Italiano de Buenos Aires, Argentina.
FAU - Otero, Carlos
AU  - Otero C
AD  - Health Informatics Department, Hospital Italiano de Buenos Aires, Argentina.
FAU - Pedersen, Rune
AU  - Pedersen R
AD  - Norwegian Centre for E-health Research, University Hospital of North Norway HF,
      Norway; Department of Clinical Medicine, Faculty of Health Sciences, UiT The
      Arctic University of Norway, Norway.
FAU - Pelayo, Sylvia
AU  - Pelayo S
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des technologies de sante 
      et des pratiques medicales, INSERM-CIC-IT 1403/Evalab, Lille, France.
FAU - Santos, Raquel
AU  - Santos R
AD  - Hospital da Luz Learning Health, Portugal.
FAU - Silva, Nuno-Andre
AU  - Silva NA
AD  - Hospital da Luz Learning Health, Portugal.
FAU - Tyllinen, Mari
AU  - Tyllinen M
AD  - Department of Computer Science, Aalto University, Finland.
FAU - Van Velsen, Lex
AU  - Van Velsen L
AD  - Roessingh Research and Development, eHealth group, Enschede, The Netherlands.
FAU - Zheng, Wu Yi
AU  - Zheng WY
AD  - The University of Sydney, Faculty of Medicine and Health, Sydney, Australia.
FAU - Jaspers, Monique
AU  - Jaspers M
AD  - Centre for Human Factor Engineering of Health Information technology - Amsterdam 
      UMC, University of Amsterdam, department of Medical Informatics, Amsterdam, The
      Netherlands.
FAU - Marcilly, Romaric
AU  - Marcilly R
AD  - Univ. Lille, CHU Lille, ULR 2694 - METRICS: Evaluation des technologies de sante 
      et des pratiques medicales, INSERM-CIC-IT 1403/Evalab, Lille, France.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Biomedical Technology/*ethics
MH  - Ethical Review/*standards
MH  - Ethics Committees, Research/*organization & administration/standards
MH  - Humans
MH  - Internationality
MH  - Public Policy
PMC - PMC7442520
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1055/s-0040-1701979 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):58-70. doi: 10.1055/s-0040-1701979. Epub 2020
      Apr 17.


PMID- 32303098
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Ethical Use of Electronic Health Record Data and Artificial Intelligence:
      Recommendations of the Primary Care Informatics Working Group of the
      International Medical Informatics Association.
PG  - 51-57
LID - 10.1055/s-0040-1701980 [doi]
AB  - OBJECTIVE: To create practical recommendations for the curation of routinely
      collected health data and artificial intelligence (AI) in primary care with a
      focus on ensuring their ethical use. METHODS: We defined data curation as the
      process of management of data throughout its lifecycle to ensure it can be used
      into the future. We used a literature review and Delphi exercises to capture
      insights from the Primary Care Informatics Working Group (PCIWG) of the
      International Medical Informatics Association (IMIA). RESULTS: We created six
      recommendations: (1) Ensure consent and formal process to govern access and
      sharing throughout the data life cycle; (2) Sustainable data creation/collection 
      requires trust and permission; (3) Pay attention to Extract-Transform-Load (ETL) 
      processes as they may have unrecognised risks; (4) Integrate data governance and 
      data quality management to support clinical practice in integrated care systems; 
      (5) Recognise the need for new processes to address the ethical issues arising
      from AI in primary care; (6) Apply an ethical framework mapped to the data life
      cycle, including an assessment of data quality to achieve effective data
      curation. CONCLUSIONS: The ethical use of data needs to be integrated within the 
      curation process, hence running throughout the data lifecycle. Current
      information systems may not fully detect the risks associated with ETL and AI;
      they need careful scrutiny. With distributed integrated care systems where data
      are often used remote from documentation, harmonised data quality assessment,
      management, and governance is important. These recommendations should help
      maintain trust and connectedness in contemporary information systems and planned 
      developments.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Liaw, Siaw-Teng
AU  - Liaw ST
AD  - WHO Collaborating Centre on eHealth, School of Public Health & Community
      Medicine, UNSW Sydney, Botany Road, Kensington, NSW 2033, Australia.
FAU - Liyanage, Harshana
AU  - Liyanage H
AD  - Clnical Informatics and Health Outcomes Research Group, Nuffield Department of
      Primary Care Health Sciences, University of Oxford, Eagle House, 7 Walton Well
      Road, Oxford, OX2 6ED, UK.
FAU - Kuziemsky, Craig
AU  - Kuziemsky C
AD  - Office of Research Services, MacEwan University, Edmonton, Alberta, Canada.
FAU - Terry, Amanda L
AU  - Terry AL
AD  - Centre for Studies in Family Medicine, Department of Family Medicine, Department 
      of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health, 
      Schulich School of Medicine & Dentistry, Western University, Canada.
FAU - Schreiber, Richard
AU  - Schreiber R
AD  - Internal Medicine and Informatics, Geisinger Health System and Geisinger
      Commonwealth School of Medicine, Camp Hill, PA, United States.
FAU - Jonnagaddala, Jitendra
AU  - Jonnagaddala J
AD  - WHO Collaborating Centre on eHealth, School of Public Health & Community
      Medicine, UNSW Sydney, Botany Road, Kensington, NSW 2033, Australia.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AD  - Clnical Informatics and Health Outcomes Research Group, Nuffield Department of
      Primary Care Health Sciences, University of Oxford, Eagle House, 7 Walton Well
      Road, Oxford, OX2 6ED, UK.
LA  - eng
PT  - Guideline
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Data Accuracy
MH  - Electronic Health Records/*ethics
MH  - Ethics, Medical
MH  - Humans
MH  - Information Dissemination/ethics
MH  - Medical Informatics/ethics
MH  - Medical Records Systems, Computerized/ethics/standards
MH  - Primary Health Care/*ethics
PMC - PMC7442527
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1055/s-0040-1701980 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):51-57. doi: 10.1055/s-0040-1701980. Epub 2020
      Apr 17.


PMID- 32303097
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Ethics in Telehealth: Comparison between Guidelines and Practice-based Experience
      -the Case for Learning Health Systems.
PG  - 44-50
LID - 10.1055/s-0040-1701976 [doi]
AB  - OBJECTIVES: To understand ethical issues within the tele-health domain,
      specifically how well established macro level telehealth guidelines map with
      micro level practitioner perspectives. METHODS: We developed four overarching
      issues to use as a starting point for developing an ethical framework for
      telehealth. We then reviewed telemedicine ethics guidelines elaborated by the
      American Medical Association (AMA), the World Medical Association (WMA), and the 
      telehealth component of the Health Professions council of South Africa (HPCSA).
      We then compared these guidelines with practitioner perspectives to identify the 
      similarities and differences between them. Finally, we generated suggestions to
      bridge the gap between ethics guidelines and the micro level use of telehealth.
      RESULTS: Clear differences emerged between the ethics guidelines and the
      practitioner perspectives. The main reason for the differences were the different
      contexts where telehealth was used, for example, variability in international
      practice and variations in the complexity of patient-provider interactions.
      Overall, published guidelines largely focus on macro level issues related to
      technology and maintaining data security in patient-provider interactions while
      practitioner concern is focused on applying the guidelines to specific micro
      level contexts. CONCLUSIONS: Ethics guidelines on telehealth have a macro level
      focus in contrast to the micro level needs of practitioners. Work is needed to
      close this gap. We recommend that both telehealth practitioners and ethics
      guideline developers better understand healthcare systems and adopt a learning
      health system approach that draws upon different contexts of clinical practice,
      innovative models of care delivery, emergent data and evidence-based outcomes.
      This would help develop a clearer set of priorities and guidelines for the
      ethical conduct of telehealth.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Kuziemsky, Craig E
AU  - Kuziemsky CE
AD  - Office of Research Services and School of Business, MacEwan University, Edmonton,
      Alberta, Canada.
FAU - Hunter, Inga
AU  - Hunter I
AD  - School of Management, Massey University, New Zealand.
FAU - Gogia, Shashi B
AU  - Gogia SB
AD  - Society for Administration of Telemedicine and Healthcare Informatics (SATHI),
      New Delhi, India.
FAU - Lyenger, Sriram
AU  - Lyenger S
AD  - University of Arizona College of Medicine, USA.
FAU - Kulatunga, Gumindu
AU  - Kulatunga G
AD  - Postgraduate Institute of Medicine, University of Colombo, Sri Lanka.
FAU - Rajput, Vije
AU  - Rajput V
AD  - General Practitioner, Stonydelph Health Centre, Tamworth, UK.
FAU - Subbian, Vignesh
AU  - Subbian V
AD  - College of Engineering, The University of Arizona, USA.
FAU - John, Oommen
AU  - John O
AD  - George Institute for Global Health, University of New South Wales, New Delhi,
      India.
FAU - Kleber, Araujo
AU  - Kleber A
AD  - NUTES Universidade Federal de Pernambuco, Brazil.
FAU - Mandirola, Humberto F
AU  - Mandirola HF
AD  - Hospital Italiano de Buenos Aires, Argentina.
FAU - Florez-Arango, Jose
AU  - Florez-Arango J
AD  - Texas A & M Health Sciences Center, USA.
FAU - Al-Shorbaji, Najeeb
AU  - Al-Shorbaji N
AD  - eHealth Development Association of Jordan, Jordan.
FAU - Meher, Sushil
AU  - Meher S
AD  - All India Institute of Medical Sciences, India.
FAU - Udayasankaran, Jai Ganesh
AU  - Udayasankaran JG
AD  - Sri Sathya Sai Central Trust, India.
FAU - Basu, Arindam
AU  - Basu A
AD  - School of Health Sciences, University of Canterbury, New Zealand.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - *Attitude of Health Personnel
MH  - *Bioethical Issues
MH  - Cross-Cultural Comparison
MH  - *Guidelines as Topic
MH  - Health Services for the Aged/ethics
MH  - Humans
MH  - Learning Health System
MH  - Physicians
MH  - Telemedicine/*ethics
PMC - PMC7442533
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1055/s-0040-1701976 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):44-50. doi: 10.1055/s-0040-1701976. Epub 2020
      Apr 17.


PMID- 32303095
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Ethics in Health Informatics.
PG  - 26-31
LID - 10.1055/s-0040-1701966 [doi]
AB  - Contemporary bioethics was fledged and is sustained by challenges posed by new
      technologies. These technologies have affected many lives. Yet health informatics
      affects more lives than any of them. The challenges include the development and
      the appropriate uses and users of machine learning software, the balancing of
      privacy rights against the needs of public health and clinical practice in a time
      of Big Data analytics, whether and how to use this technology, and the role of
      ethics and standards in health policy. Historical antecedents in statistics and
      evidence-based practice foreshadow some of the difficulties now faced, but the
      scope and scale of these challenges requires that ethics, too, be brought to
      scale in parallel, especially given the size of contemporary data sets and the
      processing power of new computers. Fortunately, applied ethics affords a variety 
      of tools to help identify and rank applicable values, support best practices, and
      contribute to standards. The bioethics community can in partnership with the
      informatics community arrive at policies that promote the health sciences while
      reaffirming the many and varied rights that patients expect will be honored.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Goodman, Kenneth W
AU  - Goodman KW
AD  - Institute for Bioethics and Health Policy, University of Miami Miller School of
      Medicine, Miami, USA.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Big Data
MH  - *Bioethical Issues
MH  - Confidentiality/ethics
MH  - Humans
MH  - Information Dissemination/ethics
MH  - Learning Health System/ethics
MH  - Medical Informatics/*ethics
MH  - Privacy
MH  - *Public Policy
PMC - PMC7442522
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1055/s-0040-1701966 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):26-31. doi: 10.1055/s-0040-1701966. Epub 2020
      Apr 17.


PMID- 32303093
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2364-0502 (Electronic)
IS  - 0943-4747 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Aug
TI  - Donald A. B. Lindberg: Inspiring Leader and Visionary in Biomedicine, Healthcare,
      and Informatics.
PG  - 253-258
LID - 10.1055/s-0040-1701972 [doi]
AB  - BACKGROUND: As Director of the US National Library of Medicine (NLM) for 30
      years, Dr. Donald A. B. Lindberg was instrumental in bringing biomedical research
      and healthcare worldwide into the age of genomic and translational medicine
      through the informatics systems developed by the NLM. Lindberg opened free access
      and worldwide public dissemination of all the NLM's biomedical literature and
      databases, thus helping transform not only biomedical research like the Human
      Genome Project and its successors, but also the practices of medicine and
      healthcare internationally. Guiding, leading, and teaching-by-example at
      national, regional, and global levels of biomedical and healthcare informatics,
      Lindberg helped coalesce a dynamic discipline that provides a foundation for the 
      human understanding which promotes the future health of our world. OBJECTIVES: To
      provide historical insight into the scientific, technological, and practical
      clinical accomplishments of Donald Lindberg, and to describe how this led to
      contributions in the worldwide interdisciplinary evolution of informatics, and
      its impact on the biosciences and practices of medicine, nursing, and other
      healthcare-related disciplines. METHODS: Review and comment on the publications, 
      scientific contributions, and leadership of Donald Lindberg in the evolution of
      biomedical and health informatics which anticipate the vision, scholarship,
      research in the field, and represent the deeply ethical humanism he exhibited
      throughout his life. These were essential in producing the informatics systems,
      such as the Unified Medical Language System (UMLS), MEDLINE, PubMed, PubMed
      Central, and ClinicalTrials.gov, which, together with NLM training programs and
      conferences, made possible the interactions among researchers and practitioners
      leading to the past quarter-century of rapid and dramatic advances in biomedical 
      scientific inquiry and clinical discoveries, openly shared across the globe.
      CONCLUSION: Dr. Lindberg was a uniquely talented physician and pioneering
      researcher in biomedical and health informatics. As the main leader in developing
      and funding innovative informatics research for more than 30 years as Director of
      the National Library of Medicine, he helped bring together the most creative
      interdisciplinary researchers to bridge the worlds of biomedical research,
      education, and clinical practice. Lindberg's emphasis on open-access to the
      biomedical literature through publicly shared computer-mediated methods of search
      and inquiry are seen as an example of ethical scientific openness.
CI  - Georg Thieme Verlag KG Stuttgart.
FAU - Kulikowski, Casimir A
AU  - Kulikowski CA
AD  - Department of Computer Science, Rutgers University, USA.
LA  - eng
PT  - Biography
PT  - Historical Article
PT  - Journal Article
PT  - Portrait
DEP - 20200417
PL  - Germany
TA  - Yearb Med Inform
JT  - Yearbook of medical informatics
JID - 9312666
SB  - IM
MH  - Biomedical Research/history
MH  - Decision Support Systems, Clinical/history
MH  - History, 20th Century
MH  - History, 21st Century
MH  - MEDLINE/history
MH  - Medical Informatics/*history
MH  - National Library of Medicine (U.S.)/*history/organization & administration
MH  - Societies, Medical/history
MH  - Unified Medical Language System/history
MH  - United States
PS  - Lindberg DAB
FPS - Lindberg, Donald A B
PMC - PMC7442506
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1055/s-0040-1701972 [doi]
PST - ppublish
SO  - Yearb Med Inform. 2020 Aug;29(1):253-258. doi: 10.1055/s-0040-1701972. Epub 2020 
      Apr 17.


PMID- 32302673
OWN - NLM
STAT- MEDLINE
DCOM- 20210714
LR  - 20210714
IS  - 1095-953X (Electronic)
IS  - 0969-9961 (Linking)
VI  - 141
DP  - 2020 Jul
TI  - Genetic testing for neurodegenerative diseases: Ethical and health communication 
      challenges.
PG  - 104871
LID - S0969-9961(20)30146-7 [pii]
LID - 10.1016/j.nbd.2020.104871 [doi]
AB  - Advances in genomic science are informing an expansion of genetic testing for
      neurodegenerative diseases, which can be used for diagnostic and predictive
      purposes and performed in both medical and consumer genomics settings. Such
      testing-which is often for severe and incurable conditions like Huntington's,
      Alzheimer's, and Parkinson's diseases-raises important ethical and health
      communication challenges. This review addresses such challenges in the contexts
      of clinical, research, and direct-to-consumer genetic testing; these include
      informed consent, risk estimation and communication, potential benefits and
      psychosocial harms of genetic information (e.g., genetic discrimination), access 
      to services, education and workforce needs, and health policies. The review also 
      highlights future areas of likely growth in the field, including polygenic risk
      scores, use of genetic testing in clinical trials, and return of individual
      research results.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Roberts, J Scott
AU  - Roberts JS
AD  - Department of Health Behavior & Health Education, University of Michigan School
      of Public Health, United States of America. Electronic address:
      jscottr@umich.edu.
FAU - Patterson, Anne K
AU  - Patterson AK
AD  - University of Michigan School of Public Health, United States of America.
FAU - Uhlmann, Wendy R
AU  - Uhlmann WR
AD  - Department of Internal Medicine, Division of Genetic Medicine, Department of
      Human Genetics, University of Michigan School of Medicine, United States of
      America.
LA  - eng
GR  - P30 AG053760/AG/NIA NIH HHS/United States
GR  - RF1 AG047866/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200414
PL  - United States
TA  - Neurobiol Dis
JT  - Neurobiology of disease
JID - 9500169
SB  - IM
MH  - Genetic Predisposition to Disease
MH  - *Genetic Testing/ethics
MH  - *Health Communication
MH  - Humans
MH  - Neurodegenerative Diseases/*diagnosis/*genetics
MH  - Risk Factors
PMC - PMC7311284
MID - NIHMS1590976
COIS- Declaration of Competing Interest The authors have no conflicts to report.
EDAT- 2020/04/18 06:00
MHDA- 2021/07/15 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/07/15 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - S0969-9961(20)30146-7 [pii]
AID - 10.1016/j.nbd.2020.104871 [doi]
PST - ppublish
SO  - Neurobiol Dis. 2020 Jul;141:104871. doi: 10.1016/j.nbd.2020.104871. Epub 2020 Apr
      14.


PMID- 32302503
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1947-5543 (Electronic)
IS  - 1947-5543 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Jun
TI  - Biobanking for Genomic and Personalized Health Research: Participant Perceptions 
      and Preferences.
PG  - 204-212
LID - 10.1089/bio.2019.0090 [doi]
AB  - Introduction: Biospecimens and associated data are invaluable tools in Genomics
      and Personalized Health (GAPH) research and can aid in the discovery of disease
      etiology and the development of therapeutics. Objective: To examine the
      experiences of patients invited to a particular GAPH study, Spectrometry in TIA
      Rapid Assessment (SpecTRA), and to explore broader biospecimen and data sharing
      preferences among a larger group of patients who had opted into a Permission to
      Contact for research program. Methods: An electronic survey was e-mailed to 515
      participants. The survey was completed by 38% of participants, an unspecified
      number of whom were also SpecTRA participants. Results: Of those respondents who 
      recalled participating in SpecTRA, 96% strongly agreed, agreed, or were neutral
      when asked if they received enough information to make an informed decision.
      Seventy-two percent agreed and 20% were neutral when asked if their study
      questions were addressed. Ninety-six percent of all respondents felt that
      SpecTRA's aim to develop a proteomic test for stroke was a worthwhile investment 
      for health care, 98% said they were willing to provide a sample and/or
      information to facilitate the project's goals, and 96% to health research in
      general. Fifty-three percent of all participants suggested they would be
      comfortable sharing health information collected during SpecTRA with for-profit
      organizations, 87% with nonprofit organizations, and 38% said it matters to them 
      where in the world their sample/information would be sent. Conclusions: Our
      results suggest that while there is room for improvement in providing adequate
      information to enable participants' understanding of the purpose of GAPH studies 
      such as SpecTRA, patients are supportive of GAPH in general. Results also suggest
      that willingness to participate would likely be impacted by factors such as the
      study's commercial and national affiliations. This study indicates that further
      work is required to guide improvements on how the GAPH research community
      describes studies to potential participants, and to enable participation options 
      that incorporate variable participant preferences.
FAU - Barnes, Rebecca
AU  - Barnes R
AD  - Department of Research and Capacity Building, Island Health, Victoria, Canada.
FAU - Votova, Kristine
AU  - Votova K
AD  - Department of Research and Capacity Building, Island Health, Victoria, Canada.
AD  - Division of Medical Sciences, University of Victoria, Victoria, Canada.
FAU - Rahimzadeh, Vasiliki
AU  - Rahimzadeh V
AD  - Department of Family Medicine, McGill University, Montreal, Canada.
AD  - Centre of Genomics and Policy, McGill University, Montreal, Canada.
FAU - Osman, Noura
AU  - Osman N
AD  - Department of Research and Capacity Building, Island Health, Victoria, Canada.
AD  - Department of Neurosciences, Stroke Rapid Assessment Unit, Island Health,
      Victoria, Canada.
FAU - Penn, Andrew M
AU  - Penn AM
AD  - Department of Neurosciences, Stroke Rapid Assessment Unit, Island Health,
      Victoria, Canada.
FAU - Zawati, Ma'n H
AU  - Zawati MH
AD  - Centre of Genomics and Policy, McGill University, Montreal, Canada.
FAU - Knoppers, Bartha M
AU  - Knoppers BM
AD  - Centre of Genomics and Policy, McGill University, Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - United States
TA  - Biopreserv Biobank
JT  - Biopreservation and biobanking
JID - 101507284
SB  - IM
MH  - *Blood Banks
MH  - Decision Making
MH  - Female
MH  - Genomics
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Information Dissemination
MH  - Informed Consent
MH  - Male
MH  - Precision Medicine
MH  - Stroke/*blood
MH  - Surveys and Questionnaires
MH  - Tissue Donors/*psychology
OTO - NOTNLM
OT  - REDCap
OT  - biobanking
OT  - ethics
OT  - personalized medicine
EDAT- 2020/04/18 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1089/bio.2019.0090 [doi]
PST - ppublish
SO  - Biopreserv Biobank. 2020 Jun;18(3):204-212. doi: 10.1089/bio.2019.0090. Epub 2020
      Apr 17.


PMID- 32302284
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20201218
IS  - 1936-9018 (Electronic)
IS  - 1936-900X (Linking)
VI  - 21
IP  - 3
DP  - 2020 Apr 13
TI  - Healthcare Ethics During a Pandemic.
PG  - 477-483
LID - 10.5811/westjem.2020.4.47549 [doi]
AB  - As clinicians and support personnel struggle with their responsibilities to treat
      during the current COVID-19 pandemic, several ethical issues have emerged. Will
      healthcare workers and support staff fulfill their duty to treat in the face of
      high risks? Will institutional and government leaders at all levels do the right 
      things to help alleviate healthcare workers risks and fears? Will physicians be
      willing to make hard, resource-allocation decisions if they cannot first husband 
      or improvise alternatives?With our healthcare facilities and governments
      unprepared for this inevitable disaster, front-line doctors, advanced providers, 
      nurses, EMS, and support personnel struggle with acute shortages of
      equipment-both to treat patients and protect themselves. With their personal and 
      possibly their family's lives and health at risk, they must weigh the option of
      continuing to work or retreat to safety. This decision, made daily, is based on
      professional and personal values, how they perceive existing risks-including
      available protective measures, and their perception of the level and transparency
      of information they receive. Often, while clinicians get this information,
      support personnel do not, leading to absenteeism and deteriorating healthcare
      services. Leadership can use good risk communication (complete, widely
      transmitted, and transparent) to align healthcare workers' risk perceptions with 
      reality. They also can address the common problems healthcare workers must
      overcome to continue working (ie, risk mitigation techniques). Physicians, if
      they cannot sufficiently husband or improvise lifesaving resources, will have to 
      face difficult triage decisions. Ideally, they will use a predetermined plan,
      probably based on the principles of Utilitarianism (maximizing the greatest good)
      and derived from professional and community input. Unfortunately, none of these
      plans is optimal.
FAU - Iserson, Kenneth V
AU  - Iserson KV
AD  - University of Arizona, Department of Emergency Medicine, Tucson, Arizona.
LA  - eng
PT  - Journal Article
DEP - 20200413
PL  - United States
TA  - West J Emerg Med
JT  - The western journal of emergency medicine
JID - 101476450
SB  - IM
MH  - Attitude of Health Personnel
MH  - Betacoronavirus
MH  - COVID-19
MH  - Communication
MH  - *Coronavirus Infections/epidemiology
MH  - *Decision Making/ethics
MH  - Disasters
MH  - Disease Outbreaks
MH  - Health Personnel
MH  - Humans
MH  - Leadership
MH  - *Pandemics
MH  - Physicians
MH  - *Pneumonia, Viral/epidemiology
MH  - *Resource Allocation/ethics
MH  - Risk
MH  - SARS-CoV-2
PMC - PMC7234717
EDAT- 2020/04/18 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/03 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - westjem.2020.4.47549 [pii]
AID - 10.5811/westjem.2020.4.47549 [doi]
PST - epublish
SO  - West J Emerg Med. 2020 Apr 13;21(3):477-483. doi: 10.5811/westjem.2020.4.47549.


PMID- 32302055
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1469-185X (Electronic)
IS  - 0006-3231 (Linking)
VI  - 95
IP  - 4
DP  - 2020 Aug
TI  - Minimizing animal welfare harms associated with predation management in
      agro-ecosystems.
PG  - 1097-1108
LID - 10.1111/brv.12601 [doi]
AB  - The impacts of wild predators on livestock are a common source of human-wildlife 
      conflict globally, and predators are subject to population control for this
      reason in many situations. Animal welfare is one of many important considerations
      affecting decisions about predation management. Recent studies discussing animal 
      welfare in this context have presented arguments emphasizing the importance of
      avoiding intentional harm to predators, but they have not usually considered
      harms imposed by predators on livestock and other animals. Efforts to mitigate
      predation impacts (including 'no control' approaches) cause a variety of harms to
      predators, livestock and other wildlife. Successfully minimizing the overall
      frequency and magnitude of harms requires consideration of the direct, indirect, 
      intentional and unintentional harms imposed on all animals inhabiting
      agricultural landscapes. We review the harms resulting from the management of
      dingoes and other wild dogs in the extensive beef cattle grazing systems of
      Australia to illustrate how these negative impacts can be minimized across both
      wild and domestic species present on a farm or in a free-ranging livestock
      grazing context. Similar to many other predator-livestock conflicts, wild dogs
      impose intermittent harms on beef cattle (especially calves) including fatal
      predation, non-fatal attack (mauling and biting), pathogen transmission, and
      fear- or stress-related effects. Wild dog control tools and strategies impose
      harms on dingoes and other wildlife including stress, pain and death as a
      consequence of both lethal and non-lethal control approaches. To balance these
      various sources of harm, we argue that the tactical use of lethal predator
      control approaches can result in harming the least number of individual animals, 
      given certain conditions. This conclusion conflicts with both traditional (e.g.
      continuous or ongoing lethal control) and contemporary (e.g. predator-friendly or
      no-control) predation management approaches. The general and transferable issues,
      approaches and principles we describe have broad applicability to many other
      human-wildlife conflicts around the world.
CI  - (c) 2020 Cambridge Philosophical Society.
FAU - Allen, Benjamin L
AU  - Allen BL
AUID- ORCID: 0000-0002-1533-0163
AD  - Institute for Life Sciences and the Environment, University of Southern
      Queensland, Toowoomba, Queensland, 4350, Australia.
AD  - Centre for African Conservation Ecology, Nelson Mandela University, Port
      Elizabeth, 6034, South Africa.
FAU - Hampton, Jordan O
AU  - Hampton JO
AD  - Murdoch University, Murdoch, Western Australia, 6150, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200417
PL  - England
TA  - Biol Rev Camb Philos Soc
JT  - Biological reviews of the Cambridge Philosophical Society
JID - 0414576
SB  - IM
MH  - *Agriculture
MH  - *Animal Welfare
MH  - Animals
MH  - Animals, Domestic
MH  - Animals, Wild
MH  - Australia
MH  - Canidae
MH  - Cattle
MH  - Dogs
MH  - *Ecosystem
MH  - Humans
MH  - *Predatory Behavior
OTO - NOTNLM
OT  - *agriculture
OT  - *animal ethics
OT  - *culling
OT  - *human-wildlife conflict
OT  - *humaneness
OT  - *predator control
OT  - *wildlife management
EDAT- 2020/04/18 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/04/18 06:00
PHST- 2019/11/05 00:00 [received]
PHST- 2020/03/24 00:00 [revised]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1111/brv.12601 [doi]
PST - ppublish
SO  - Biol Rev Camb Philos Soc. 2020 Aug;95(4):1097-1108. doi: 10.1111/brv.12601. Epub 
      2020 Apr 17.


PMID- 32302042
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1573-3599 (Electronic)
IS  - 1059-7700 (Linking)
VI  - 29
IP  - 6
DP  - 2020 Dec
TI  - Diagnostic uncertainties, ethical tensions, and accounts of role responsibilities
      in genetic counseling communication.
PG  - 1159-1172
LID - 10.1002/jgc4.1282 [doi]
AB  - Diagnostic uncertainties are intricately associated with genomic
      testing-especially concerning new technologies such as exome sequencing-with test
      results being either inconclusive or generating secondary findings or showing
      variants of uncertain significance. In the process of genetic counseling,
      diagnostic uncertainties have to be managed even when test results for an
      individual client are either positive or negative because of differential
      implications for family members. Previous studies have investigated diagnostic
      uncertainties in relation to clients wanting to know or not know the test
      results; here, we extend this line of research by addressing how genetic
      counselors and clients account for the management of diagnostic uncertainties
      vis-a-vis the attendant ethical tensions in the complex communicative environment
      in the clinic setting. Our dataset from the Norwegian context is longitudinal,
      consisting of ten audio-recorded pre-test genetic counseling sessions. It
      involves one extended family with a high burden of colorectal cancer. Through
      theme-oriented discourse analysis, we demonstrate how diagnostic uncertainties
      give rise to tensions concerning risks and benefits of knowing in both
      professional and familial spheres, which then map onto accounts of various role
      responsibilities. For instance, in looking for certainty via advanced genomic
      testing to reduce diagnostic uncertainty for clients, genetic counselors are
      confronted with tensions regarding what can be communicated and made known
      because of their role responsibilities toward what may be regarded as scientific 
      others and clinical others. Likewise, clients are faced with tensions concerning 
      wanting to know/not know, which invokes various familial others and may align or 
      not align with genetic counselors' preferences, especially relating to management
      of diagnostic uncertainties and secondary findings.
CI  - (c) 2020 The Authors. Journal of Genetic Counseling published by Wiley
      Periodicals, Inc. on behalf of National Society of Genetic Counselors.
FAU - Thomassen Hammerstad, Goril
AU  - Thomassen Hammerstad G
AUID- ORCID: 0000-0002-5336-9456
AD  - Department of Language and Literature, Norwegian University of Science and
      Technology (NTNU), Trondheim, Norway.
FAU - Sarangi, Srikant
AU  - Sarangi S
AD  - Danish Institute of Humanities and Medicine (DIHM), Aalborg University, Aalborg, 
      Denmark.
FAU - Bjornevoll, Inga
AU  - Bjornevoll I
AD  - Department of Pathology and Medical Genetics, Trondheim University Hospital,
      Trondheim, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - United States
TA  - J Genet Couns
JT  - Journal of genetic counseling
JID - 9206865
SB  - IM
MH  - *Communication
MH  - Counselors/*psychology
MH  - *Ethics, Professional
MH  - Family
MH  - Female
MH  - Genetic Counseling/*psychology
MH  - Genetic Testing
MH  - Humans
MH  - *Professional Role
MH  - Social Behavior
MH  - *Uncertainty
MH  - Whole Exome Sequencing
OTO - NOTNLM
OT  - *benefits and risks of knowing
OT  - *communication
OT  - *diagnostic uncertainty
OT  - *ethical tensions
OT  - *exome sequencing
OT  - *genetic counseling
OT  - *genomic testing
OT  - *role-responsibility
OT  - *wanting to know/not know
EDAT- 2020/04/18 06:00
MHDA- 2021/04/15 06:00
CRDT- 2020/04/18 06:00
PHST- 2019/08/02 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/03/01 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1002/jgc4.1282 [doi]
PST - ppublish
SO  - J Genet Couns. 2020 Dec;29(6):1159-1172. doi: 10.1002/jgc4.1282. Epub 2020 Apr
      17.


PMID- 32301862
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 1538-5159 (Electronic)
IS  - 0017-9078 (Linking)
VI  - 119
IP  - 1
DP  - 2020 Jul
TI  - Research on the Radiotoxicology of Plutonium Using Animals: Consideration of the 
      3Rs-Replace, Reduce, Refine.
PG  - 133-140
LID - 10.1097/HP.0000000000001258 [doi]
AB  - To characterize the health effects of incorporated plutonium, many experiments
      have been conducted using different animal models. These range from (1) applied
      (tissue uptake/retention determination, decorporation therapy efficacy), (2)
      fundamental (gene expression, cancer induction), and (3) dosimetry models. In
      recent years, the use of animals for scientific purposes has become a public
      concern. The application of the 3Rs - Replace (use of alternative methods or
      animals not considered capable of experiencing pain, suffering, and distress),
      Reduce (reduction in animal numbers), and Refine (better animal welfare and
      minimization of suffering, pain and distress) - has increased to address ethical 
      concerns and legislative requirements. The introduction of novel non-animal
      technologies is also an important factor as complementary options to animal
      experimentation. In radiotoxicology research, it seems there is a natural
      tendency to Replace given the possibility of data reuse obtained from
      contamination cases in man and animal studies. The creation of "registries" and
      "repositories" for nuclear industry workers (civil and military) is now a rich
      legacy for radiotoxicological measurements. Similarly, Reduction in animal
      numbers can be achieved by good experimental planning with prior statistical
      analyses of animal numbers required to obtain robust data. Multiple measurements 
      in the same animal over time (external body counting, excreta collection) with
      appropriate detection instruments also allow Reduction. In terms of Refinement,
      this has become "de rigueur" and a necessity given the societal and legal
      concerns for animal welfare. For research in radiotoxicology, particularly
      long-term studies, better housing conditions within the constraints of radiation 
      protection issues for research workers are an important concern. These are all
      pertinent considerations for the 3Rs remit and future research in
      radiotoxicology.
FAU - Griffiths, Nina M
AU  - Griffiths NM
AD  - Laboratoire de RadioToxicologie, CEA, Universite Paris-Saclay,
      Bruyeres-le-Chatel, 91297 ARPAJON, France.
FAU - Van der Meeren, Anne
AU  - Van der Meeren A
AD  - Laboratoire de RadioToxicologie, CEA, Universite Paris-Saclay,
      Bruyeres-le-Chatel, 91297 ARPAJON, France.
FAU - Angulo, Jaime F
AU  - Angulo JF
AD  - Laboratoire de RadioToxicologie, CEA, Universite Paris-Saclay,
      Bruyeres-le-Chatel, 91297 ARPAJON, France.
FAU - Vincent-Naulleau, Silvia
AU  - Vincent-Naulleau S
AD  - Bureau des Etudes Biomedicales chez l'Animal, CEA/DRF/D3P/BEBA, 92260
      FONTENAY-aux-ROSES, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Health Phys
JT  - Health physics
JID - 2985093R
RN  - 0 (Biomarkers)
RN  - 53023GN24M (Plutonium)
SB  - IM
MH  - Animal Experimentation
MH  - Animal Rights
MH  - Animal Testing Alternatives/*methods
MH  - Animal Welfare
MH  - Animals
MH  - Animals, Laboratory
MH  - Biomarkers
MH  - Gene Expression Regulation/radiation effects
MH  - Humans
MH  - Models, Statistical
MH  - Neoplasms/chemically induced
MH  - Plutonium/*adverse effects/*pharmacokinetics
MH  - Radiation Exposure/prevention & control
MH  - Radiometry
EDAT- 2020/04/18 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1097/HP.0000000000001258 [doi]
AID - 00004032-202007000-00017 [pii]
PST - ppublish
SO  - Health Phys. 2020 Jul;119(1):133-140. doi: 10.1097/HP.0000000000001258.


PMID- 32301737
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 17
TI  - Effectiveness and Cost-Effectiveness of Receiving a Hearing Dog on Mental
      Well-Being and Health in People With Hearing Loss: Protocol for a Randomized
      Controlled Trial.
PG  - e15452
LID - 10.2196/15452 [doi]
AB  - BACKGROUND: People with hearing loss, particularly those who lose their hearing
      in adulthood, are at an increased risk of social isolation, mental health
      difficulties, unemployment, loss of independence, risk of accidents, and impaired
      quality of life. In the United Kingdom, a single third-sector organization
      provides hearing dogs, a specific type of assistance dog trained to provide sound
      support to people with hearing loss. These dogs may also deliver numerous
      psychosocial benefits to recipients. This has not previously been fully
      investigated. OBJECTIVE: The study aims to evaluate the impact of a hearing dog
      partnership on the lives of individuals with severe or profound hearing loss.
      METHODS: A 2-arm, randomized controlled trial will be conducted within the United
      Kingdom with 162 hearing dog applicants, aged 18 years and older. Participants
      will be randomized 1:1 using a matched-pairs design to receive a hearing dog
      sooner than usual (intervention arm: arm B) or to receive a hearing dog within
      the usual timeframe (comparator arm: arm A). In the effectiveness analysis, the
      primary outcome is a comparison of mental well-being 6 months after participants 
      in arm B have received a hearing dog (arm A have not yet received a hearing dog),
      measured using the Short Warwick Edinburgh Mental Well-Being Scale. Secondary
      outcome measures include the Patient Health Questionnaire-9, Generalized Anxiety 
      Disorder-7, and Work and Social Adjustments Scale. An economic evaluation will
      assess the cost-effectiveness, including health-related quality-adjusted life
      years using the EuroQol 5 Dimensions and social care-related quality-adjusted
      life years. Participants will be followed up for up to 2 years. A nested
      qualitative study will investigate the impacts of having a hearing dog and how
      these impacts occur. RESULTS: The study is funded by the National Institute for
      Health Research's School for Social Care Research. Recruitment commenced in March
      2017 and is now complete. A total of 165 participants were randomized. Data
      collection will continue until January 2020. Results will be published in
      peer-reviewed journals and at conferences. A summary of the findings will be made
      available to participants. Ethical approval was received from the University of
      York's Department of Social Policy and Social Work Research Ethics Committee
      (reference SPSW/S/17/1). CONCLUSIONS: The findings from this study will provide, 
      for the first time, strong and reliable evidence on the impact of having a
      hearing dog on people's lives in terms of their quality of life, well-being, and 
      mental health. TRIAL REGISTRATION: International Standard Randomised Controlled
      Trial Number Registry ISRCTN36452009; http://www.isrctn.com/ISRCTN36452009.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15452.
CI  - (c)Lucy Stuttard, Catherine Hewitt, Caroline Fairhurst, Helen Weatherly, Simon
      Walker, Francesco Longo, Jane Maddison, Philip Boyle, Bryony Beresford.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 17.04.2020.
FAU - Stuttard, Lucy
AU  - Stuttard L
AUID- ORCID: https://orcid.org/0000-0001-7205-7151
AD  - Social Policy Research Unit, Department of Social Policy and Social Work, Alcuin 
      B Block, University of York, York, United Kingdom.
FAU - Hewitt, Catherine
AU  - Hewitt C
AUID- ORCID: https://orcid.org/0000-0002-0415-3536
AD  - York Trials Unit, Department of Health Sciences, University of York, York, United
      Kingdom.
FAU - Fairhurst, Caroline
AU  - Fairhurst C
AUID- ORCID: https://orcid.org/0000-0003-0547-462X
AD  - York Trials Unit, Department of Health Sciences, University of York, York, United
      Kingdom.
FAU - Weatherly, Helen
AU  - Weatherly H
AUID- ORCID: https://orcid.org/0000-0002-9117-6452
AD  - Centre for Health Economics, University of York, York, United Kingdom.
FAU - Walker, Simon
AU  - Walker S
AUID- ORCID: https://orcid.org/0000-0002-5750-3691
AD  - Centre for Health Economics, University of York, York, United Kingdom.
FAU - Longo, Francesco
AU  - Longo F
AUID- ORCID: https://orcid.org/0000-0002-1833-7328
AD  - Centre for Health Economics, University of York, York, United Kingdom.
FAU - Maddison, Jane
AU  - Maddison J
AUID- ORCID: https://orcid.org/0000-0002-7963-211X
AD  - Social Policy Research Unit, Department of Social Policy and Social Work, Alcuin 
      B Block, University of York, York, United Kingdom.
FAU - Boyle, Philip
AU  - Boyle P
AUID- ORCID: https://orcid.org/0000-0002-4233-8603
AD  - Social Policy Research Unit, Department of Social Policy and Social Work, Alcuin 
      B Block, University of York, York, United Kingdom.
FAU - Beresford, Bryony
AU  - Beresford B
AUID- ORCID: https://orcid.org/0000-0003-0716-2902
AD  - Social Policy Research Unit, Department of Social Policy and Social Work, Alcuin 
      B Block, University of York, York, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7195660
OTO - NOTNLM
OT  - assistance dog
OT  - economics
OT  - hearing loss
OT  - qualitative research
OT  - randomized controlled trial
EDAT- 2020/04/18 06:00
MHDA- 2020/04/18 06:01
CRDT- 2020/04/18 06:00
PHST- 2019/07/18 00:00 [received]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2019/12/05 00:00 [revised]
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/04/18 06:01 [medline]
AID - v9i4e15452 [pii]
AID - 10.2196/15452 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 17;9(4):e15452. doi: 10.2196/15452.


PMID- 32301736
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2291-9694 (Print)
VI  - 8
IP  - 4
DP  - 2020 Apr 17
TI  - Impact of the European General Data Protection Regulation (GDPR) on Health Data
      Management in a European Union Candidate Country: A Case Study of Serbia.
PG  - e14604
LID - 10.2196/14604 [doi]
AB  - As of May 2018, all relevant institutions within member countries of the European
      Economic Area are required to comply with the European General Data Protection
      Regulation (GDPR) or face significant fines. This regulation has also had a
      notable effect on the European Union (EU) candidate countries, which are
      undergoing the process of harmonizing their legislature with the EU as part of
      the accession process. The Republic of Serbia is an example of such a candidate
      country, and its 2018 Personal Data Protection Act mirrors the majority of
      provisions in the GDPR. This paper presents the impact of the GDPR on health data
      management and Serbia's capability to conduct international health data research 
      projects. Data protection incidents reported in Serbia are explored to identify
      common underlying causes using a novel taxonomy of contributing factors across
      aspects and health system levels. The GDPR has an extraterritorial application
      for the non-EU data controllers who process the data of EU citizens and
      residents, which mainly affects private practices used by medical tourists from
      the EU, public health care institutions frequented by foreigners, as well as
      expatriates, dual citizens, tourists, and other visitors. Serbia generally does
      not have well-established procedures to support international research
      collaborations around its health data. For smaller projects, contractual
      arrangements can be made with health data providers and their ethics committees. 
      Even then, organizations that have not previously participated in similar
      ventures may require approval or support from health authorities. Extensive
      studies that involve multisite data typically require the support of central
      health system institutions and relevant research data aggregators or electronic
      health record vendors. The lack of a framework for preparation, anonymization,
      and assurance of privacy preservation forces researchers to rely heavily on local
      expertise and support. Given the current limitation and potential issues with the
      legislation, it remains to be seen whether the move toward the GDPR will be
      beneficial for the Serbian health system, medical research, protection of
      personal data and privacy rights, and research capacity. Although significant
      progress has been made so far, a strategic approach is needed at the national
      level to address insufficient resources in the area of data protection and
      develop the personal data protection environment further. This will also require 
      a targeted educational effort among health workers and decision makers, aiming to
      improve awareness and develop skills and knowledge necessary for the workforce.
CI  - (c)Branko Marovic, Vasa Curcin. Originally published in JMIR Medical Informatics 
      (http://medinform.jmir.org), 17.04.2020.
FAU - Marovic, Branko
AU  - Marovic B
AUID- ORCID: https://orcid.org/0000-0002-6557-3913
AD  - Computer Centre, University of Belgrade, Belgrade, Serbia.
FAU - Curcin, Vasa
AU  - Curcin V
AUID- ORCID: https://orcid.org/0000-0002-8308-2886
AD  - School of Population Health and Environmental Sciences, King's College London,
      London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200417
PL  - Canada
TA  - JMIR Med Inform
JT  - JMIR medical informatics
JID - 101645109
PMC - PMC7195664
OTO - NOTNLM
OT  - data sharing
OT  - ethical issues
OT  - health care systems
OT  - information disclosure
OT  - international aspects
OT  - legal aspects
OT  - medical tourists
OT  - patient data privacy
OT  - policy compliance
OT  - privacy act
OT  - public policy
EDAT- 2020/04/18 06:00
MHDA- 2020/04/18 06:01
CRDT- 2020/04/18 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2019/10/06 00:00 [accepted]
PHST- 2019/09/27 00:00 [revised]
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/04/18 06:01 [medline]
AID - v8i4e14604 [pii]
AID - 10.2196/14604 [doi]
PST - epublish
SO  - JMIR Med Inform. 2020 Apr 17;8(4):e14604. doi: 10.2196/14604.


PMID- 32301262
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 10
DP  - 2020 Oct
TI  - Pig-to-human heart transplantation: Who goes first?
PG  - 2669-2674
LID - 10.1111/ajt.15916 [doi]
AB  - Cardiac xenotransplantation has recently taken an important step towards clinical
      reality. In anticipation of the "first-in-human" heart xenotransplantation trial,
      we propose a set of patient characteristics that define potential candidates. Our
      premise is that, to be ethically justified, the risks posed by current
      state-of-the-art options must outweigh the anticipated risks of a pioneering
      xenotransplant procedure. Suitable candidates include patients who are at high
      immunologic risk because of sensitization to alloantigens, including those who
      have exhibited early onset or accelerated cardiac allograft vasculopathy. In
      addition, patients should be considered (1) for whom mechanical circulatory
      support would be prohibitively risky due to a hypercoagulable state, a
      contraindication to anticoagulation, or restrictive physiology; (2) with severe
      biventricular dysfunction predicting unsuccessful univentricular left heart
      support; and (3) adults with complex congenital heart disease. In conclusion,
      because the published preclinical benchmark for clinical translation of heart
      xenotransplantation appears within reach, carefully and deliberately defining
      appropriate trial participants is timely as the basis for ethical clinical trial 
      design.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Pierson, Richard N 3rd
AU  - Pierson RN 3rd
AD  - Division of Cardiac Surgery, Massachusetts General Hospital, Harvard University, 
      Boston, Massachusetts, USA.
AD  - Center for Transplantation Sciences, Department of Surgery, Massachusetts General
      Hospital, Harvard University, Boston, Massachusetts, USA.
FAU - Burdorf, Lars
AU  - Burdorf L
AUID- ORCID: 0000-0001-8943-4750
AD  - Division of Cardiac Surgery, Massachusetts General Hospital, Harvard University, 
      Boston, Massachusetts, USA.
AD  - Center for Transplantation Sciences, Department of Surgery, Massachusetts General
      Hospital, Harvard University, Boston, Massachusetts, USA.
FAU - Madsen, Joren C
AU  - Madsen JC
AD  - Division of Cardiac Surgery, Massachusetts General Hospital, Harvard University, 
      Boston, Massachusetts, USA.
AD  - Center for Transplantation Sciences, Department of Surgery, Massachusetts General
      Hospital, Harvard University, Boston, Massachusetts, USA.
FAU - Lewis, Gregory D
AU  - Lewis GD
AD  - Division of Cardiology, Department of Medicine, Massachusetts General Hospital,
      Harvard University, Boston, Massachusetts, USA.
FAU - D'Alessandro, David A
AU  - D'Alessandro DA
AD  - Division of Cardiac Surgery, Massachusetts General Hospital, Harvard University, 
      Boston, Massachusetts, USA.
LA  - eng
GR  - U19 AI090959/GF/NIH HHS/United States
GR  - U01 AI066335/GF/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200525
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - Adult
MH  - Animals
MH  - Contraindications
MH  - *Heart Diseases
MH  - *Heart Transplantation
MH  - Humans
MH  - Postoperative Complications
MH  - Swine
MH  - Transplantation, Heterologous
OTO - NOTNLM
OT  - *alloantibody/allosensitization/alloimmunity
OT  - *cardiac allograft vasculopathy
OT  - *cardiac/heart transplant
OT  - *cardiac/heart transplant: alternatives
OT  - *chronic rejection
OT  - *ethics and public policy
OT  - *heart failure
OT  - *mechanical circulatory support
OT  - *mechanical circulatory support: alternatives
OT  - *translational research/science
OT  - *xenotransplantation
EDAT- 2020/04/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/04/05 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1111/ajt.15916 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Oct;20(10):2669-2674. doi: 10.1111/ajt.15916. Epub 2020 May
      25.


PMID- 32301260
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 27
IP  - 8
DP  - 2020 Aug
TI  - Advanced multiparametric magnetic resonance imaging of multinodular and
      vacuolating neuronal tumor.
PG  - 1561-1569
LID - 10.1111/ene.14264 [doi]
AB  - BACKGROUND AND PURPOSE: Multinodular and vacuolating neuronal tumor (MVNT) of the
      cerebrum is a rare brain lesion with suggestive imaging features. The aim of our 
      study was to report the largest series of MVNTs so far and to evaluate the
      utility of advanced multiparametric magnetic resonance (MR) techniques. METHODS: 
      This multicenter retrospective study was approved by our institutional research
      ethics board. From July 2014 to May 2019, two radiologists read in consensus the 
      MR examinations of patients presenting with a lesion suggestive of an MVNT. They 
      analyzed the lesions' MR characteristics on structural images and advanced
      multiparametric MR imaging. RESULTS: A total of 64 patients (29 women and 35 men,
      mean age 44.2 +/- 15.1 years) from 25 centers were included. Lesions were all
      hyperintense on fluid-attenuated inversion recovery and T2-weighted imaging
      without post-contrast enhancement. The median relative apparent diffusion
      coefficient on diffusion-weighted imaging was 1.13 [interquartile range (IQR),
      0.2]. Perfusion-weighted imaging showed no increase in perfusion, with a relative
      cerebral blood volume of 1.02 (IQR, 0.05) and a relative cerebral blood flow of
      1.01 (IQR, 0.08). MR spectroscopy showed no abnormal peaks. Median follow-up was 
      2 (IQR, 1.2) years, without any changes in size. CONCLUSIONS: A comprehensive
      characterization protocol including advanced multiparametric magnetic resonance
      imaging sequences showed no imaging patterns suggestive of malignancy in MVNTs.
      It might be useful to better characterize MVNTs.
CI  - (c) 2020 European Academy of Neurology.
FAU - Lecler, A
AU  - Lecler A
AUID- ORCID: 0000-0001-7869-1815
AD  - Department of Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, France.
FAU - Broquet, V
AU  - Broquet V
AD  - Department of Neuroradiology, CHU Lille, Lille, France.
FAU - Bailleux, J
AU  - Bailleux J
AD  - Department of Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, France.
FAU - Carsin, B
AU  - Carsin B
AD  - Department of Radiology, CHRU de Rennes, Rennes, France.
FAU - Adle-Biassette, H
AU  - Adle-Biassette H
AD  - Department of Pathology, Lariboisiere Hospital, Paris Diderot,
      Paris-Cite-Sorbonne University, Paris, France.
FAU - Baloglu, S
AU  - Baloglu S
AD  - Department of Radiology, University Hospital of Strasbourg, Strasbourg, France.
FAU - Forestier, G
AU  - Forestier G
AUID- ORCID: 0000-0003-4797-9693
AD  - Department of Neuroradiology, CHU Limoges, Limoges, France.
FAU - Bonneville, F
AU  - Bonneville F
AD  - Department of Neuroradiology, Hopital Pierre-Paul-Riquet, CHU Purpan, Toulouse,
      France.
FAU - Calvier, E
AU  - Calvier E
AD  - Neurology Department, Hopital Rene et Guillaume-Laennec, CHU de Nantes,
      Saint-Herblain, France.
FAU - Chauvet, D
AU  - Chauvet D
AD  - Department of Neurosurgery, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, France.
FAU - Comby, P O
AU  - Comby PO
AUID- ORCID: 0000-0002-6651-2784
AD  - Department of Vascular and Interventional Radiology, Image-Guided Therapy Center,
      Francois-Mitterrand University Hospital, Dijon, France.
FAU - Cottier, J P
AU  - Cottier JP
AD  - Department of Radiology, CHRU de Tours, Tours, France.
AD  - Brain and Imaging laboratory, UMR U930, INSERM, Francois-Rabelais University,
      Tours, France.
FAU - Cotton, F
AU  - Cotton F
AD  - Service de Radiologie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Benite, Hospices
      Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France.
FAU - Deschamps, R
AU  - Deschamps R
AD  - Department of Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, 
      France.
FAU - Diard-Detoeuf, C
AU  - Diard-Detoeuf C
AD  - Department of Neurology, CH Sainte-Perrine, Paris, France.
FAU - Ducray, F
AU  - Ducray F
AD  - Department of Neuro-oncology, Lyon French Reference Center of Paraneoplastic
      Neurological Syndrome, Hospices Civils de Lyon, Lyon, France.
FAU - Drissi, C
AU  - Drissi C
AUID- ORCID: 0000-0002-5684-6262
AD  - Faculte de Medecine de Tunis, Institut National de Neurologie, Service de
      Neuroradiologie, Universite de Tunis El Manar, Tunis, Tunisia.
FAU - Elmaleh, M
AU  - Elmaleh M
AD  - Pediatric Radiology Department, Robert Debre Hospital, Paris, France.
FAU - Farras, J
AU  - Farras J
AD  - Jordi Radiologia C/ de la Roda, Andorra la Vella, Andorra.
FAU - Aguilar Garcia, J
AU  - Aguilar Garcia J
AD  - Neurology Department, Hopital Rene et Guillaume-Laennec, CHU de Nantes,
      Saint-Herblain, France.
FAU - Gerardin, E
AU  - Gerardin E
AD  - Department of Neuroradiology and MRI, Rouen University Hospital, Rouen, France.
FAU - Grand, S
AU  - Grand S
AD  - Neuroradiologie diagnostique et interventionnelle et IRM Nord 'Centre Hospitalier
      et Universitaire de Alpes Grenoble', Grenoble, France.
FAU - Jianu, D C
AU  - Jianu DC
AD  - Department of Neurology, Victor Babes University of Medecine and Pharmacy,
      Timisoara, Romania.
FAU - Kremer, S
AU  - Kremer S
AD  - Department of Radiology, University Hospital of Strasbourg, Strasbourg, France.
FAU - Loiseau, H
AU  - Loiseau H
AD  - Service de Neurochirurgie, CHU de Bordeaux, Universite de Bordeaux, Bordeaux,
      France.
FAU - Magne, N
AU  - Magne N
AD  - Department of Neuroradiology and MRI, Rouen University Hospital, Rouen, France.
FAU - Mejdoubi, M
AU  - Mejdoubi M
AD  - Department of Neuroradiology, University Hospital of Martinique, Fort-de-France, 
      France.
FAU - Moulignier, A
AU  - Moulignier A
AUID- ORCID: 0000-0001-7566-0175
AD  - Department of Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, 
      France.
FAU - Ollivier, M
AU  - Ollivier M
AD  - Service de Radiologie, Groupe Hospitalier Pellegrin, Bordeaux, France.
FAU - Nagi, S
AU  - Nagi S
AD  - Faculte de Medecine de Tunis, Institut National de Neurologie, Service de
      Neuroradiologie, Universite de Tunis El Manar, Tunis, Tunisia.
AD  - Clinique les Berges du Lac, rue du Lac de Constance, Tunis, Tunisia.
FAU - Rodallec, M
AU  - Rodallec M
AD  - Centre d'Imagerie Centre Cardiologique du Nord, CCN, Saint-Denis, France.
FAU - Shor, N
AU  - Shor N
AUID- ORCID: 0000-0003-0693-1829
AD  - Department of Neuroradiology, Pitie-Salpetriere Hospital, Paris, France.
FAU - Tourdias, T
AU  - Tourdias T
AD  - Service de Neuroimagerie Diagnostique et Therapeutique, CHU de Bordeaux et INSERM
      U1215, Universite de Bordeaux, Bordeaux, France.
FAU - Vandendries, C
AU  - Vandendries C
AD  - Department of Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, France.
AD  - Centre d'Imagerie Medicale Paris 15eme, RMX, Paris, France.
FAU - Anxionnat, R
AU  - Anxionnat R
AD  - Service de Radiologie, CHU de Nancy, Nancy, France.
FAU - Duron, L
AU  - Duron L
AD  - Department of Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, France.
FAU - Savatovsky, J
AU  - Savatovsky J
AD  - Department of Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild,
      Paris, France.
AD  - Centre d'Imagerie Paris 13, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200522
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Adult
MH  - *Brain Neoplasms/diagnostic imaging
MH  - Diffusion Magnetic Resonance Imaging
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - *Multiparametric Magnetic Resonance Imaging
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *diagnosis
OT  - *diagnostic imaging
OT  - *magnetic resonance imaging
OT  - *multinodular and vacuolating neuronal tumor
OT  - *neoplasms
EDAT- 2020/04/18 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/01/23 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1111/ene.14264 [doi]
PST - ppublish
SO  - Eur J Neurol. 2020 Aug;27(8):1561-1569. doi: 10.1111/ene.14264. Epub 2020 May 22.


PMID- 32301051
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 2212-277X (Electronic)
IS  - 2212-2761 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Oct
TI  - Teaching health professionals how to tailor gender-affirming medicine protocols: 
      A design thinking project.
PG  - 324-328
LID - 10.1007/s40037-020-00581-5 [doi]
AB  - BACKGROUND: Content knowledge surrounding transgender (trans) medicine is
      currently lacking in the formal medical education curricula. Evidence indicates
      that the main protocols used to assess and refer trans patients for
      gender-affirming medicine are misunderstood by health professionals, and require 
      flexible adaptation to achieve health equity and patient-centred care. APPROACH: 
      A free online educational tool for gender-affirming medicine, The Path to
      Patient-Centred Care, was developed to teach learners how to adapt assessment
      protocols. Resource creation was supported by a knowledge translation grant that 
      endorsed design thinking, a human-centred and solutions-focused framework
      recommended for use in curriculum development. EVALUATION: The Path to
      Patient-Centred Care provides learners with information related to key principles
      of patient-centred care in gender-affirming medicine, including a guide on how to
      adapt the main assessment protocols to achieve equitable care. The curriculum
      also includes narratives from trans patients and health professionals that focus 
      on health equity, and a clinical vignette about a complex case, designed to
      foster critical thinking on medical ethics. Project future directions involve an 
      implementation and evaluation pilot study with a diverse group of continuing
      professional development medical learners using a mixed-methods program
      evaluation design. REFLECTION: The use of design thinking to develop this
      resource exemplifies a novel approach to curriculum development. By using
      pedagogical strategies that foster critical reflection, this innovative online
      education tool strives to teach self-directed learners how to provide care that
      emphasizes trans people's self-determination and autonomy in medical
      decision-making.
FAU - MacKinnon, Kinnon R
AU  - MacKinnon KR
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada. k.mackinnon@mail.utoronto.ca.
FAU - Ross, Lori E
AU  - Ross LE
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Rojas Gualdron, David
AU  - Rojas Gualdron D
AD  - The Wilson Centre, Faculty of Medicine at University Health Network, University
      of Toronto, Toronto, Ontario, Canada.
AD  - Centre for Ambulatory Care Education, Women's College Hospital, Toronto, Ontario,
      Canada.
FAU - Ng, Stella L
AU  - Ng SL
AD  - The Wilson Centre, Faculty of Medicine at University Health Network, University
      of Toronto, Toronto, Ontario, Canada.
AD  - Centre for Ambulatory Care Education, Women's College Hospital, Toronto, Ontario,
      Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Perspect Med Educ
JT  - Perspectives on medical education
JID - 101590643
SB  - IM
EIN - Perspect Med Educ. 2020 Jun;9(3):195. PMID: 32410079
MH  - Culturally Competent Care/*trends
MH  - Education, Medical/methods
MH  - Humans
MH  - Patient-Centered Care/*methods/trends
MH  - Transgender Persons/*psychology
PMC - PMC7550508
OTO - NOTNLM
OT  - *Continuing education
OT  - *Design thinking
OT  - *Gender-affirming medicine
OT  - *Protocols
EDAT- 2020/04/18 06:00
MHDA- 2021/07/08 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1007/s40037-020-00581-5 [doi]
AID - 10.1007/s40037-020-00581-5 [pii]
PST - ppublish
SO  - Perspect Med Educ. 2020 Oct;9(5):324-328. doi: 10.1007/s40037-020-00581-5.


PMID- 32301040
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - Medical conspiracy theories: cognitive science and implications for ethics.
PG  - 505-518
LID - 10.1007/s11019-020-09951-6 [doi]
AB  - Although recent trends in politics and media make it appear that conspiracy
      theories are on the rise, in fact they have always been present, probably because
      they are sustained by natural dispositions of the human brain. This is also the
      case with medical conspiracy theories. This article reviews some of the most
      notorious health-related conspiracy theories. It then approaches the reasons why 
      people believe these theories, using concepts from cognitive science. On the
      basis of that knowledge, the article makes normative proposals for public health 
      officials and health workers as a whole, to deal with conspiracy theories, in
      order to preserve some of the fundamental principles of medical ethics.
FAU - Andrade, Gabriel
AU  - Andrade G
AD  - Ajman University, Ajman, United Arab Emirates. Gabrielernesto2000@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Anti-Vaccination Movement/psychology
MH  - Cognitive Science/*ethics/standards
MH  - Drug Industry/ethics
MH  - Humans
MH  - Knowledge
MH  - Mass Media/*ethics/standards
MH  - *Politics
MH  - *Public Opinion
PMC - PMC7161434
OTO - NOTNLM
OT  - Cognitive science
OT  - Ethics
OT  - Human brain
OT  - Medical conspiracy theories
OT  - Public policy
EDAT- 2020/04/18 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1007/s11019-020-09951-6 [doi]
AID - 10.1007/s11019-020-09951-6 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):505-518. doi: 10.1007/s11019-020-09951-6.


PMID- 32300944
OWN - NLM
STAT- MEDLINE
DCOM- 20210809
LR  - 20210809
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Aug
TI  - Connecting to the Heart: Teaching Value-Based Professional Ethics.
PG  - 2235-2254
LID - 10.1007/s11948-020-00216-2 [doi]
AB  - Engineering programs in the United States have been experimenting with diverse
      pedagogical approaches to educate future professional engineers. However, a
      crucial dimension of ethics education that focuses on the values, personal
      commitments, and meaning of engineers has been missing in many of these
      pedagogical approaches. We argue that a value-based approach to professional
      ethics education is critically needed in engineering education, because such an
      approach is indispensable for cultivating self-reflective and socially engaged
      engineers. This paper starts by briefly comparing two prevalent approaches to
      ethics education in science and engineering: professional (teaching professional 
      ethical standards, including codes of ethics) and philosophical (teaching ethical
      theories and their applications in professional settings). While we acknowledge
      that both approaches help meet certain ethics education objectives, we also argue
      that neither of these is sufficient to personally engage students in authentic
      moral learning. We make the case that it is important to connect ethics education
      to the heart, which is extensively driven by values, and present a value-based
      approach to professional ethics education. We provide some classroom practices
      that cultivate a safe, diverse, and engaging learning environment. Finally, we
      discuss the implications of a value-based approach to professional ethics
      education for curriculum design and pedagogical practice, including opportunities
      and challenges for engineering faculty eager to incorporate value-based inquiry
      into their classrooms.
FAU - Snieder, Roel
AU  - Snieder R
AUID- ORCID: 0000-0003-1445-0857
AD  - Office of Academic Affairs, Colorado School of Mines, Hill Hall 206A, Golden, CO,
      80401, USA. rsnieder@mines.edu.
FAU - Zhu, Qin
AU  - Zhu Q
AUID- ORCID: 0000-0002-6673-1901
AD  - Division of Humanities, Arts, and Social Science, Colorado School of Mines,
      Stratton Hall 306, 1005 14th Street, Golden, CO, 80401, USA.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Curriculum
MH  - *Education, Professional
MH  - Engineering
MH  - *Ethics, Professional
MH  - Humans
MH  - Students
MH  - Teaching
MH  - United States
PMC - PMC7417392
OTO - NOTNLM
OT  - *Engineering education
OT  - *Personal ethics
OT  - *Professional ethics education
OT  - *Self-reflective pedagogies
OT  - *Value-based ethics
EDAT- 2020/04/18 06:00
MHDA- 2021/08/10 06:00
CRDT- 2020/04/18 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/08/10 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1007/s11948-020-00216-2 [doi]
AID - 10.1007/s11948-020-00216-2 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Aug;26(4):2235-2254. doi: 10.1007/s11948-020-00216-2. Epub
      2020 Apr 16.


PMID- 32300921
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20220216
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - Enlightened Self-interest in Altruism (ESIA).
PG  - 147-161
LID - 10.1007/s10730-020-09406-8 [doi]
AB  - Altruism and the medical profession have been linked throughout the history of
      medicine. Students are drawn to the calling of medicine because of altruistic
      values, dedication to service, and the desire to alleviate suffering and promote 
      healing. Despite a dedication to these values, altruism in medicine is threatened
      by empathy erosion that develops in the clinical years of medical school and an
      increasing rate of medical student burnout. Currently, there are two widespread
      movements in medicine aimed at addressing the dual loss of altruism and physician
      and student burnout-professionalism and wellness. Despite widespread recognition 
      of the problems and programs aimed at improving them, there has been little
      headway, and even calls to abandon altruism in the modern marketplace of
      medicine. What is needed is not an abandonment of a fundamental, defining value
      of the profession, but a re-evaluation of the meaning of altruism in medicine and
      a framework that allows for students and physicians to provide altruistic care
      for a sustainable, rewarding career in the healing profession. This paper
      proposes the Enlightened Self-Interest in Altruism (ESIA) model as an ethical
      framework to allow medical students to synergize the interests of the self with
      those they serve in a mutually beneficial relationship to improve patient care
      and the healthcare system at large. The ESIA model acknowledges that egoism and
      altruism are intertwined, dynamic motivators of behavior. In the enlightened
      self-interest approach, the interests of the group are also the interests of the 
      self. The physician-patient relationship is a dyad in which egoism and altruism
      may converge in an enlightened way that acknowledges that the interests of one
      are the interests of the whole. This is a paradigm shift from the historical view
      of egoism and altruism as opposing motivations. This paper will present the
      threats to altruism, explore the interface of egoism and altruism in a clinical
      vignette, and then present the ESIA framework as an educational approach to
      aligning the interests of providers and patients to prevent burnout and promote
      altruism.
FAU - Vearrier, Laura
AU  - Vearrier L
AD  - Department of Emergency Medicine, University of Mississippi Medical Center, 2500 
      North State Street, Jackson, MS, USA. lvearrier@umc.edu.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - *Altruism
MH  - Attitude of Health Personnel
MH  - Burnout, Professional/prevention & control/psychology
MH  - Empathy/ethics
MH  - Humans
MH  - Physician-Patient Relations
MH  - Physicians/*psychology
PMC - PMC7224037
OTO - NOTNLM
OT  - Altruism
OT  - Burn out
OT  - Education, medical
OT  - Empathy
OT  - Ethics
OT  - Professionalism
EDAT- 2020/04/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1007/s10730-020-09406-8 [doi]
AID - 10.1007/s10730-020-09406-8 [pii]
PST - ppublish
SO  - HEC Forum. 2020 Jun;32(2):147-161. doi: 10.1007/s10730-020-09406-8.


PMID- 32300891
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 41
IP  - 8
DP  - 2020 Aug
TI  - Conflicts of interest and Scientific Societies.
PG  - 2095-2102
LID - 10.1007/s10072-020-04330-8 [doi]
AB  - The purpose of this paper is to bring attention to the complex issue of conflicts
      of interest (COIs) from the point of view of Scientific Societies and their
      responsibility in managing secondary interests possibly undermining their
      activities such as improvement of professional quality, research promotion, and
      development of guidelines. The first publication on the issue of COIs dates back 
      to more than a century, but only in the last decades the related ethical and
      legal problems have received public and professional attention. The growing role 
      of industry in biomedical research, the significant decrease in public
      contributions to health, care, training, and research, and the involvement of
      physicians in industry-funded research have obliged to study how to identify and 
      manage COIs. The Bioethics and Palliative Care Study Group of the Italian
      Neurological Society addressed the issue with a specific focus on Scientific
      Societies that, in our opinion, should also set an example for individual
      practice, raising awareness among their associates on COIs and implementing
      strategies for their identification and management. The paper is focused on the
      nature of the COI, why and how it could be managed, which policies can be
      implemented, and which kind of action should be considered by Scientific
      Societies. We emphasize the role of Scientific Societies in fostering knowledge
      and awareness of conflicts of interest through training and continuing education.
FAU - Gasparini, Maddalena
AU  - Gasparini M
AD  - GdS Bioetica e Cure Palliative, Milan, Italy.
FAU - Tarquini, Daniela
AU  - Tarquini D
AD  - GdS Bioetica e Cure Palliative, Rome, Italy.
FAU - Pucci, Eugenio
AU  - Pucci E
AD  - UOC Neurologia, AV4-ASUR, Fermo, Marche, Italy.
FAU - Alberti, Francesco
AU  - Alberti F
AD  - GdS Bioetica e Cure Palliative, Sanremo, IM, Italy.
FAU - D'Alessandro, Roberto
AU  - D'Alessandro R
AD  - Servizio di Epidemiologia e Biostatistica, Istituto delle Scienze Neurologiche di
      Bologna, Bologna, Italy.
FAU - Marogna, Maura
AU  - Marogna M
AD  - SC Neurologia, Ospedale Villa Scassi ASL3, Genoa, Italy.
FAU - Veronese, Simone
AU  - Veronese S
AD  - Department of Palliative Care and Research, Fondazione FARO, Torino, Italy.
FAU - Porteri, Corinna
AU  - Porteri C
AD  - Bioethics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via
      Pilastroni 4, 25125, Brescia, Italy. cporteri@fatebenefratelli.eu.
CN  - Bioethics and Palliative Care Study Group of the Italian Neurological Society
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200416
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
SB  - IM
MH  - *Biomedical Research
MH  - Conflict of Interest
MH  - Humans
MH  - *Physicians
MH  - Societies, Medical
MH  - Societies, Scientific
OTO - NOTNLM
OT  - Biomedical research
OT  - Conflict of interest
OT  - Ethics
OT  - Pharmaceutical industry
OT  - Policy
OT  - Scientific Society
EDAT- 2020/04/18 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/04/18 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - 10.1007/s10072-020-04330-8 [doi]
AID - 10.1007/s10072-020-04330-8 [pii]
PST - ppublish
SO  - Neurol Sci. 2020 Aug;41(8):2095-2102. doi: 10.1007/s10072-020-04330-8. Epub 2020 
      Apr 16.


PMID- 32300671
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2451-8654 (Electronic)
IS  - 2451-8654 (Linking)
VI  - 18
DP  - 2020 Jun
TI  - Determining a Bayesian predictive power stopping rule for futility in a
      non-inferiority trial with binary outcomes.
PG  - 100561
LID - 10.1016/j.conctc.2020.100561 [doi]
AB  - BACKGROUND/AIMS: Non-inferiority trials investigate whether a novel intervention,
      which typically has other benefits (i.e., cheaper or safer), has similar clinical
      effectiveness to currently available treatments. In situations where interim
      evidence in a non-inferiority trial suggests that the novel treatment is truly
      inferior, ethical concerns with continuing randomisation to the "inferior"
      intervention are raised. Thus, if interim data indicate that concluding
      non-inferiority at the end of the trial is unlikely, stopping for futility should
      be considered. To date, limited examples are available to guide the development
      of stopping rules for non-inferiority trials. METHODS: We used a Bayesian
      predictive power approach to develop a stopping rule for futility for a trial
      collecting binary outcomes. We evaluated the frequentist operating
      characteristics of the stopping rule to ensure control of the Type I and Type II 
      error. Our case study is the Intranasal Ketamine for Procedural Sedation trial
      (INK trial), a non-inferiority trial designed to assess the sedative properties
      of ketamine administered using two alternative routes. RESULTS: We considered
      implementing our stopping rule after the INK trial enrols 140 patients out of
      560. The trial would be stopped if 12 more patients experience a failure on the
      novel treatment compared to standard care. This trial has a type I error rate of 
      2.2% and a power of 80%. CONCLUSIONS: Stopping for futility in non-inferiority
      trials reduces exposure to ineffective treatments and preserves resources for
      alternative research questions. Futility stopping rules based on Bayesian
      predictive power are easy to implement and align with trial aims. TRIAL
      REGISTRATION: ClinicalTrials.gov NCT02828566 July 11, 2016.
CI  - (c) 2020 The Authors.
FAU - Heath, Anna
AU  - Heath A
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Canada.
AD  - Division of Biostatistics, Dalla Lana School of Public Health, University of
      Toronto, Canada.
AD  - Department of Statistics, University College London, London, United Kingdom.
FAU - Offringa, Martin
AU  - Offringa M
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Canada.
AD  - Division of Neonatology, University of Toronto, Canada.
FAU - Pechlivanoglou, Petros
AU  - Pechlivanoglou P
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Canada.
FAU - Rios, Juan David
AU  - Rios JD
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Canada.
FAU - Klassen, Terry P
AU  - Klassen TP
AD  - University of Manitoba, Winnipeg, Canada.
AD  - Children's Hospital Research Institute of Manitoba, Winnipeg, Canada.
FAU - Poonai, Naveen
AU  - Poonai N
AD  - Departments of Paediatrics, Internal Medicine, Epidemiology & Biostatistics,
      Schulich School of Medicine & Dentistry, Western University, Canada.
AD  - Children's Health Research Institute, London, Ontario, Canada.
FAU - Pullenayegum, Eleanor
AU  - Pullenayegum E
AD  - Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,
      Canada.
AD  - Division of Biostatistics, Dalla Lana School of Public Health, University of
      Toronto, Canada.
CN  - KidsCAN PERC Innovative Paediatric Clinical Trials Team
LA  - eng
SI  - ClinicalTrials.gov/NCT02828566
PT  - Journal Article
DEP - 20200408
PL  - Netherlands
TA  - Contemp Clin Trials Commun
JT  - Contemporary clinical trials communications
JID - 101671157
PMC - PMC7153169
OTO - NOTNLM
OT  - Bayesian predictive power
OT  - DSMB, Data Safety Monitoring Board
OT  - IN, Intranasal
OT  - INK Trial, Intranasal Ketamine for Procedural Sedation trial
OT  - IV, Intravenous
OT  - Non-inferiority trial
OT  - Procedural sedation
OT  - Stopping rule
OT  - Trial design
COIS- We have no conflicting interests to declare.
EDAT- 2020/04/18 06:00
MHDA- 2020/04/18 06:01
CRDT- 2020/04/18 06:00
PHST- 2020/01/16 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/04/18 06:01 [medline]
AID - 10.1016/j.conctc.2020.100561 [doi]
AID - S2451-8654(20)30045-4 [pii]
AID - 100561 [pii]
PST - epublish
SO  - Contemp Clin Trials Commun. 2020 Apr 8;18:100561. doi:
      10.1016/j.conctc.2020.100561. eCollection 2020 Jun.


PMID- 32300318
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - An Evolutionary Point of View of Animal Ethics.
PG  - 403
LID - 10.3389/fpsyg.2020.00403 [doi]
FAU - Criscuolo, Francois
AU  - Criscuolo F
AD  - Universite de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
FAU - Sueur, Cedric
AU  - Sueur C
AD  - Universite de Strasbourg, CNRS, IPHC UMR 7178, Strasbourg, France.
AD  - Institut Universitaire de France, Paris, France.
AD  - CEERE, Centre Europeen d'Enseignement et de Recherche en Ethique, Universite de
      Strasbourg, Strasbourg, France.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7142228
OTO - NOTNLM
OT  - animal ethics
OT  - empathy
OT  - environmental ethics
OT  - evolutionary biology
OT  - human-animal relationships
OT  - one health
OT  - sentience
OT  - trade-offs
EDAT- 2020/04/18 06:00
MHDA- 2020/04/18 06:01
CRDT- 2020/04/18 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/04/18 06:01 [medline]
AID - 10.3389/fpsyg.2020.00403 [doi]
PST - epublish
SO  - Front Psychol. 2020 Apr 2;11:403. doi: 10.3389/fpsyg.2020.00403. eCollection
      2020.


PMID- 32300316
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - The Developmental Implications of the Use of Reproductive Technologies for
      Transgender People: A Comparative Cross-Section Protocol.
PG  - 243
LID - 10.3389/fpsyt.2020.00243 [doi]
AB  - BACKGROUND: Today, individuals and couples with fertility issues can use advances
      in biomedical technologies to conceive. Transgender persons also benefit from
      these advances and can not only actualize their self-identified gender identities
      but also experience parenthood. These strategies for persons to self-actualize
      and to access parenthood have improved the condition of transgender persons.
      However, some may question the welfare of the offspring because such transfamily 
      forms are often confusing to many. The sparse research on the psychological
      well-being of children of transgender people is reassuring. However, the limited 
      empirical research justifies more studies to be conducted with an evidence-based 
      methodology to assess whether these new methods of parenting have any adverse
      impact on children. AIMS: The current report details the protocol we built to
      compare cognitive development, mental health, gender identity, quality of life,
      and family dynamics in children of transgender fathers and donor sperm
      insemination (DSI) and two control groups matched for age and gende typically
      developing (TD) children and children from cisgender parents and DSI. HYPOTHESIS:
      To calculate sample sizes, we hypothesize no significant difference between
      groups. SUBJECTS AND METHODS: Since 2008, married couples that include a
      transgender father have been able to access DSI and have started conceiving
      children in France. They are always invited to participate in research to assess 
      their children's well-being. To date, the cohort includes 53 children in 37
      families. We propose to carry out a cross-sectional comparative study exploring
      cognitive development with the Brunet-Lezine Psychomotor Development Scale or
      Wechsler's Intelligence Scales according to age; mental health with the Child
      Behaviour Checklist; gender identity with the Gender Identity Interview for
      Children; quality of life with the KIDSCREEN and the Adolescent Coping
      Questionnaire; and family dynamics with the Parental Bonding Instrument, the
      Inventory of Parent and Peer Attachment, the Five-Minute Speech Sample, and
      Corman's Family Drawing Test. To assess possible subtle differences between
      children's family drawings, we will use a generalization of the
      "lady-tasting-tea" procedure to link qualitative and quantitative approaches in
      psychiatric research. Twenty raters [four child and family psychoanalysts
      (CHILDPSY), four adult psychiatrists (ADUPSY), four biologists working in
      assistive reproduction technology (BIOL), four endocrinologists working with
      transgender individuals (ENDOC), and four students (STUD)] will be randomly shown
      the drawings and asked to blindly classify them using a Likert scale according to
      whether the child has a transgender father. STATISTICAL ANALYSIS: After testing
      normality, comparisons between the three groups will be performed with
      appropriate statistical tests (Kruskal-Wallis, ANOVA, Chi2 or Fisher's exact
      test). For the "lady-tasting-tea" procedure, we will use a permutation test.
      ETHICS: The study protocol has been approved by the CERES (Comite d'Ethique de
      Recherche en Sante) of Paris 5 University. Registration number is 2015/31.
CI  - Copyright (c) 2020 Mamou, Lagrange, Mendes, Wielart, Poirier, Medjkane, Brunelle,
      Drouineaud, Rosenblum, Grundler, Ansermet, Falissard, Cohen and Condat.
FAU - Mamou, Gregor
AU  - Mamou G
AD  - Clinique Dupre, Fondation Sante des Etudiants de France, Sceaux, France.
FAU - Lagrange, Chrystelle
AU  - Lagrange C
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Mendes, Nicolas
AU  - Mendes N
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Wielart, Joy
AU  - Wielart J
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Poirier, Fanny
AU  - Poirier F
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Medjkane, Francois
AU  - Medjkane F
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Brunelle, Julie
AU  - Brunelle J
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Drouineaud, Veronique
AU  - Drouineaud V
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Rosenblum, Ouriel
AU  - Rosenblum O
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Grundler, Nouria
AU  - Grundler N
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
FAU - Ansermet, Francois
AU  - Ansermet F
AD  - Service de Psychiatrie de l'enfant et de l'adolescent, Departement de l'enfant et
      de l'adolescent, Hopitaux Universitaires de Geneve, Geneva, Switzerland.
FAU - Falissard, Bruno
AU  - Falissard B
AD  - Centre de recherche en Epidemiologie et Sante des Populations, INSERM, U1018,
      Paris, France.
FAU - Cohen, David
AU  - Cohen D
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
AD  - Institut des Systemes Intelligents et de Robotiques, Universite Pierre et Marie
      Curie, Paris, France.
FAU - Condat, Agnes
AU  - Condat A
AD  - Service de Psychiatrie de l'Enfant et de l'Adolescent, Hopital Pitie-Salpetriere,
      Paris, France.
AD  - CESP INSERM 1018, ED3C, Universite Paris Descartes, Paris, France.
AD  - CECOS Paris Cochin, Hopital Cochin, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7145385
OTO - NOTNLM
OT  - adolescent
OT  - child
OT  - psychological well-being
OT  - reproductive technologies
OT  - transgender
EDAT- 2020/04/18 06:00
MHDA- 2020/04/18 06:01
CRDT- 2020/04/18 06:00
PHST- 2019/04/18 00:00 [received]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/04/18 06:01 [medline]
AID - 10.3389/fpsyt.2020.00243 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Apr 1;11:243. doi: 10.3389/fpsyt.2020.00243. eCollection
      2020.


PMID- 32300002
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20211102
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 15
TI  - Cognitive-behavioral therapy-based intervention to treat symptoms of anxiety in
      pregnancy in a prenatal clinic using non-specialist providers in Pakistan: design
      of a randomised trial.
PG  - e037590
LID - 10.1136/bmjopen-2020-037590 [doi]
AB  - INTRODUCTION: Prenatal anxiety is a prevalent condition that is harmful for women
      and a strong predictor of postpartum depression. This trial assesses an
      intervention initiated in early pregnancy to mid pregnancy among women with
      clinical or subclinical symptoms of anxiety in Pakistan. METHODS AND ANALYSIS:
      Happy Mother, Healthy Baby (HMHB) is a phase three, two-arm, single-blind,
      individual randomised clinical trial conducted in the outpatient department of
      Holy Family Hospital, a large public tertiary care facility affiliated with
      Rawalpindi Medical University (RMU). Pregnant women (enrolled at </=22 weeks of
      gestation) receive six individual HMHB sessions based on cognitive-behavioral
      therapy (CBT) and relaxation techniques that are administered by non-specialist
      providers and tailored to address anxiety symptoms. Two to six booster sessions
      are given between the fifth consecutive weekly core session and the sixth core
      session that occurs in the third trimester. Apart from baseline data, data are
      collected in the third trimester, at birth and at 6-weeks postpartum. Primary
      outcomes include diagnoses of postpartum common mental disorders. Secondary
      outcomes include symptoms of anxiety and of depression, and birth outcomes
      including small-for-gestational age, low birth weight and preterm birth. An
      economic analysis will determine the cost effectiveness of the intervention.
      ETHICS: Ethics approval was obtained from the Johns Hopkins Bloomberg School of
      Health Institutional Review Board (Baltimore, USA), the Human Development
      Research Foundation Ethics Committee (Islamabad, Pakistan), the RMU Institutional
      Research Forum (Rawalpindi, Pakistan) and the National Institute of Mental
      Health-appointed Global Mental Health Data Safety and Monitoring Board.
      DISSEMINATION: Results from this trial will build evidence for the efficacy of a 
      CBT-based intervention for pregnant women delivered by non-specialised providers.
      Identification of an evidence-based intervention for anxiety starting in early
      pregnancy to mid pregnancy may be transferable for use and scale-up in other
      low-income and middle-income countries. TRIAL REGISTRATION NUMBER: NCT03880032.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Surkan, Pamela J
AU  - Surkan PJ
AUID- ORCID: 0000-0002-0334-5931
AD  - Department of International Health, Johns Hopkins University Bloomberg School of 
      Public Health, Baltimore, Maryland, USA psurkan@jhu.edu.
FAU - Hamdani, Syed Usman
AU  - Hamdani SU
AD  - Human Development Research Foundation, Rawalpindi, Pakistan.
AD  - Institute of Psychiatry, Rawalpindi Medical University, Rawalpindi, Pakistan.
FAU - Huma, Zill-E
AU  - Huma ZE
AD  - Human Development Research Foundation, Rawalpindi, Pakistan.
FAU - Nazir, Huma
AU  - Nazir H
AD  - Human Development Research Foundation, Rawalpindi, Pakistan.
FAU - Atif, Najia
AU  - Atif N
AD  - Human Development Research Foundation, Rawalpindi, Pakistan.
FAU - Rowther, Armaan A
AU  - Rowther AA
AD  - Department of International Health, Johns Hopkins University Bloomberg School of 
      Public Health, Baltimore, Maryland, USA.
FAU - Chaudhri, Rizwana
AU  - Chaudhri R
AD  - Department of Gynaecology and Obstetrics, Holy Family Hospital, Rawalpindi
      Medical University, Rawalpindi, Pakistan.
FAU - Zafar, Shamsa
AU  - Zafar S
AD  - Human Development Research Foundation, Rawalpindi, Pakistan.
AD  - Department of Obstetrics and Gynaecology, Air University, Islamabad, Pakistan.
FAU - Mullany, Luke C
AU  - Mullany LC
AD  - Department of International Health, Johns Hopkins University Bloomberg School of 
      Public Health, Baltimore, Maryland, USA.
FAU - Malik, Abid
AU  - Malik A
AD  - Human Development Research Foundation, Rawalpindi, Pakistan.
AD  - Institute of Psychiatry, Rawalpindi Medical University, Rawalpindi, Pakistan.
FAU - Rahman, Atif
AU  - Rahman A
AD  - Department of Psychological Sciences, University of Liverpool, Liverpool, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT03880032
GR  - R01 MH111859/MH/NIMH NIH HHS/United States
GR  - T32 GM136577/GM/NIGMS NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200415
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anxiety/*therapy
MH  - Clinical Trials, Phase III as Topic
MH  - *Cognitive Behavioral Therapy
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Pakistan
MH  - Pregnancy/*psychology
MH  - Premature Birth
MH  - Randomized Controlled Trials as Topic
MH  - Single-Blind Method
PMC - PMC7200036
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *depression & mood disorders
OT  - *prenatal diagnosis
OT  - *therapeutics
COIS- Competing interests: None declared.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2020-037590 [pii]
AID - 10.1136/bmjopen-2020-037590 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 15;10(4):e037590. doi: 10.1136/bmjopen-2020-037590.


PMID- 32299999
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 15
TI  - Effects of a traditional Chinese mind-body exercise, Baduanjin, on the physical
      and cognitive functions in the community of older adults with cognitive frailty: 
      study protocol for a randomised controlled trial.
PG  - e034965
LID - 10.1136/bmjopen-2019-034965 [doi]
AB  - INTRODUCTION: Cognitive frailty (CF) is a clinical manifestation characterised by
      the simultaneous presence of both physical frailty and cognitive impairment among
      older adults without dementia and has become a new target for healthy ageing.
      Increasing evidence shows that regular Baduanjin (a traditional Chinese mind-body
      exercise) training is beneficial in improving physical function and cognitive
      ability in the older adults. The primary aim of this trial is to observe the
      effect of Baduanjin on physical and cognitive functions in older adults with CF. 
      METHODS AND ANALYSIS: In this prospective, outcome assessor-blind, two-arm
      randomised controlled trial, a total of 102 participants with CF will be
      recruited and randomly allocated (1:1) into the Baduanjin training or usual
      physical activity control group. The control group will receive health education 
      for 30 min at least once a month. Based on health education, participants in the 
      Baduanjin exercise group will receive a 24-week Baduanjin training with 60 min
      per session and 3 sessions per week, while those in the usual physical activity
      control group will maintain their original lifestyle. Primary outcomes (frailty
      index and global cognitive ability), body composition, grip force, balance,
      fatigue, specific cognitive domain, including memory, execution and visual
      spatial abilities, and life quality of secondary outcomes will be measured at
      baseline, and at 13 and 25 weeks after randomisation, while the structural and
      functional MRI will be measured at baseline and 25 weeks after randomisation. The
      mixed linear model will be conducted to observe the intervention effects. ETHICS 
      AND DISSEMINATION: The study has been approved by the ethics committee of the
      second people's hospital of Fujian province (Approval no. 2018-KL015). Results
      will be submitted for publication in peer-reviewed journals and disseminated at
      scientific conferences. TRIAL REGISTRATION NUMBER: ChiCTR1800020341; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Xia, Rui
AU  - Xia R
AUID- ORCID: 0000-0002-5941-8263
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Wan, Mingyue
AU  - Wan M
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Lin, Huiying
AU  - Lin H
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Qiu, Pingting
AU  - Qiu P
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Ye, Yu
AU  - Ye Y
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - He, Jianquan
AU  - He J
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Yin, Lianhua
AU  - Yin L
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Tao, Jing
AU  - Tao J
AD  - Rehabilitation Medicine College, Fujian University of Traditional Chinese
      Medicine, Fuzhou, Fujian, China.
FAU - Chen, Lidian
AU  - Chen L
AD  - College of Rehabilitation Medicine, Fujian University of Traditional Chinese
      Medicine, Fuzhou, China.
FAU - Zheng, Guohua
AU  - Zheng G
AD  - College of Nursing and Health Management, Shanghai University of Medicine &
      Health Sciences, Shanghai, China zhenggh@sumhs.edu.cn.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - China
MH  - Cognition
MH  - *Exercise Therapy
MH  - *Frailty
MH  - Humans
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
PMC - PMC7201298
OTO - NOTNLM
OT  - *complementary medicine
OT  - *geriatric medicine
OT  - *rehabilitation medicine
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/18 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034965 [pii]
AID - 10.1136/bmjopen-2019-034965 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 15;10(4):e034965. doi: 10.1136/bmjopen-2019-034965.


PMID- 32299792
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 6
DP  - 2020 Jun 9
TI  - Teaching the National Institutes of Health Stroke Scale to Paramedics (E-Learning
      vs Video): Randomized Controlled Trial.
PG  - e18358
LID - 10.2196/18358 [doi]
AB  - BACKGROUND: Prompt and accurate identification of stroke victims is essential to 
      reduce time from symptom onset to adequate treatment and to improve neurological 
      outcomes. Most neurologists evaluate the extent of neurological deficit according
      to the National Institutes of Health Stroke Scale (NIHSS), but the use of this
      scale by paramedics, the first healthcare providers to usually take care of
      stroke victims, has proven unreliable. This might be, at least in part, due to
      the teaching method. The video used to teach NIHSS lacks interactivity, while
      more engaging electronic learning (e-learning) methods might improve knowledge
      acquisition. OBJECTIVE: This study was designed to evaluate whether a highly
      interactive e-learning module could enhance NIHSS knowledge acquisition in
      paramedics. METHODS: A randomized controlled trial comparing a specially designed
      e-learning module with the original NIHSS video was performed with paramedics
      working in Geneva, Switzerland. A registration number was not required as our
      study does not come into the scope of the Swiss federal law on human research.
      The protocol was nevertheless submitted to the local ethics committee (Project ID
      2017-00847), which issued a "Declaration of no objection." Paramedics were
      excluded if they had prior knowledge of or previous training in the NIHSS, or if 
      they had worked in a neurology or neurosurgery ward. The primary outcome was
      overall performance in the study quiz, which contained 50 questions. Secondary
      outcomes were performance by NIHSS item, time to course and quiz completion, user
      satisfaction regarding the learning method, user perception of the course
      duration, and probability the user would recommend the course to a colleague.
      RESULTS: The study was completed by 39 paramedics. There was a better overall
      median score (36/50 vs 33/50, P=.04) and a higher degree of satisfaction
      regarding the learning method in the e-learning group (90% vs 37%, P=.002). Users
      who had followed the e-learning module were more likely to recommend the course
      to a colleague (95% vs 63%, P=.02). Paramedics in the e-learning group took more 
      time to complete the course (93 vs 59 minutes, P<.001), but considered the
      duration to be more adequate (75% vs 32%, P=.01). Time to quiz completion was
      similar between groups (25 vs 38 minutes, P=.12). CONCLUSIONS: Use of an
      e-learning module shows promising results in teaching the NIHSS to paramedics.
CI  - (c)Avinash Koka, Laurent Suppan, Philippe Cottet, Emmanuel Carrera, Loric Stuby, 
      Melanie Suppan. Originally published in the Journal of Medical Internet Research 
      (http://www.jmir.org), 09.06.2020.
FAU - Koka, Avinash
AU  - Koka A
AUID- ORCID: 0000-0002-3911-0528
AD  - Division of Emergency Medicine, Department of Anaesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals,
      Geneva, Switzerland.
FAU - Suppan, Laurent
AU  - Suppan L
AUID- ORCID: 0000-0001-6989-6421
AD  - Division of Emergency Medicine, Department of Anaesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals,
      Geneva, Switzerland.
FAU - Cottet, Philippe
AU  - Cottet P
AUID- ORCID: 0000-0001-6029-8548
AD  - Division of Emergency Medicine, Department of Anaesthesiology, Clinical
      Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals,
      Geneva, Switzerland.
FAU - Carrera, Emmanuel
AU  - Carrera E
AUID- ORCID: 0000-0003-0045-5382
AD  - Stroke Center, Department of Neurology, Geneva University Hospitals, Geneva,
      Switzerland.
FAU - Stuby, Loric
AU  - Stuby L
AUID- ORCID: 0000-0003-1663-5249
AD  - Geneve TEAM Ambulances, Geneva, Switzerland.
FAU - Suppan, Melanie
AU  - Suppan M
AUID- ORCID: 0000-0002-8807-9619
AD  - Division of Anesthesiology, Department of Anaesthesiology, Clinical Pharmacology,
      Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva,
      Switzerland.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200609
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Allied Health Personnel/*education
MH  - Computer-Assisted Instruction/*methods
MH  - Education, Distance/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - National Institutes of Health (U.S.)
MH  - Stroke/*therapy
MH  - United States
MH  - Young Adult
PMC - PMC7312264
OTO - NOTNLM
OT  - *active learning
OT  - *e-learning
OT  - *electronic learning
OT  - *online learning
OT  - *stroke
OT  - *video
EDAT- 2020/04/18 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - v22i6e18358 [pii]
AID - 10.2196/18358 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Jun 9;22(6):e18358. doi: 10.2196/18358.


PMID- 32299771
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1878-7886 (Electronic)
IS  - 1878-7886 (Linking)
VI  - 157
IP  - 3 Suppl 2
DP  - 2020 Jun
TI  - Residency training in robotic surgery: The role of simulation.
PG  - S123-S129
LID - S1878-7886(20)30068-0 [pii]
LID - 10.1016/j.jviscsurg.2020.03.006 [doi]
AB  - Simulation has become increasingly important in surgical teaching in recent years
      and the French National Authority for Health (HAS) recently underlined the goal
      and ethical priority: "never the first time on the patient". Simulation programs 
      have been tested and validated for laparotomy and for laparoscopy, but there is
      not yet a validated program specific for robotic surgery. Due to substantial
      advances in this new technology, we have developed a program in Nancy dedicated
      to outside-the-operating room (OR) teaching of robotic surgery using the Da Vinci
      robot. This teaching is based on a combined program of theoretical teaching
      (e-learning) and learning of practical skills using virtual simulators
      (DV-Trainer(R), Robotic Mentor(R), DVSS(R)), mechanical simulators (Dome,
      Applied(R) abdominal simulators), microsurgery and wet lab using ex vivo animal
      organs, anesthetized animals, and cadavers. This program also emphasizes team
      training. The course is intended for residents in surgical training and is
      integrated into the specialized study diploma (DES) program for Visceral and
      Digestive Surgery; it also can be used by qualified surgeons who can integrate it
      with the Inter-University Diploma (DIU) in General Robotic Surgery for basic
      techniques and also for DIUs in other surgical specialties (digestive and
      gynecologic surgery) for robotic uses within their specialty. These courses are
      based on the concept of step-by-step skills acquisition and verification allowing
      a transition to safe clinical activity.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Bresler, L
AU  - Bresler L
AD  - General and digestive surgery, CHU Nancy, 54511 Vandoeuvre-les-Nancy, France.
      Electronic address: l.bresler@chru-nancy.fr.
FAU - Perez, M
AU  - Perez M
AD  - General and emergency surgery, CHU Nancy, 54511 Vandoeuvre-les-Nancy, France.
FAU - Hubert, J
AU  - Hubert J
AD  - Urology, CHU Nancy, 54511 Vandoeuvre-les-Nancy, France.
FAU - Henry, J P
AU  - Henry JP
AD  - Stan Institute Nancy, France.
FAU - Perrenot, C
AU  - Perrenot C
AD  - General and emergency surgery, CHU Nancy, 54511 Vandoeuvre-les-Nancy, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200413
PL  - France
TA  - J Visc Surg
JT  - Journal of visceral surgery
JID - 101532664
SB  - IM
MH  - *Clinical Competence
MH  - *Computer Simulation
MH  - Education, Medical, Graduate/*methods
MH  - General Surgery/*education
MH  - Humans
MH  - Internship and Residency/*methods
MH  - Robotic Surgical Procedures/*education
MH  - Simulation Training/*methods
OTO - NOTNLM
OT  - Robotic surgery
OT  - Simulation
OT  - Surgical education
EDAT- 2020/04/18 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - S1878-7886(20)30068-0 [pii]
AID - 10.1016/j.jviscsurg.2020.03.006 [doi]
PST - ppublish
SO  - J Visc Surg. 2020 Jun;157(3 Suppl 2):S123-S129. doi:
      10.1016/j.jviscsurg.2020.03.006. Epub 2020 Apr 13.


PMID- 32299678
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 2212-2672 (Print)
IS  - 2212-2672 (Linking)
VI  - 120
IP  - 6
DP  - 2020 Jun
TI  - Advancements in Personalized Nutrition Technologies: Guiding Principles for
      Registered Dietitian Nutritionists.
PG  - 1074-1085
LID - S2212-2672(20)30098-8 [pii]
LID - 10.1016/j.jand.2020.01.020 [doi]
AB  - Individualized nutrition counseling and care is a cornerstone of practice for
      registered dietitian nutritionists (RDNs). The term personalized nutrition (PN)
      refers to "individual-specific information founded in evidence-based science to
      promote dietary behavior change that may result in measurable health benefits."
      PN technologies, which include the "omics" approaches, may offer the potential to
      improve specificity of nutrition care through assessment of molecular-level data,
      such as genes or the microbiome, in order to determine the course for nutrition
      intervention. These technologies are evolving rapidly, and for many RDNs, it is
      unclear whether, when, or how these technologies should be incorporated into the 
      nutrition care process. In order to provide guidance in these developing PN
      fields, International Life Sciences Institute North America convened a
      multidisciplinary panel to develop guiding principles for PN approaches. The
      objective of this article is to inform RDN practice decisions related to the
      implementation of PN technologies by examining the alignment of proposed PN
      guiding principles with the Code of Ethics for the Nutrition and Dietetics
      Profession, as well as Scope and Standards of Practice. Guiding principles are
      described as they apply to each stage of the nutrition care process and include
      identifying potential beneficiaries, communicating effects transparently, and
      protecting individual privacy. Guiding principles for PN augment standard
      guidance for RDNs to pose relevant questions, raise potential concerns, and guide
      evaluation of supporting evidence for specific PN technologies. RDNs have a
      responsibility to think critically about the application of PN technologies,
      including appropriateness and potential effectiveness, for the individual served.
CI  - Copyright (c) 2020 Academy of Nutrition and Dietetics. Published by Elsevier Inc.
      All rights reserved.
FAU - Rozga, Mary
AU  - Rozga M
FAU - Latulippe, Marie E
AU  - Latulippe ME
FAU - Steiber, Alison
AU  - Steiber A
LA  - eng
PT  - Journal Article
DEP - 20200413
PL  - United States
TA  - J Acad Nutr Diet
JT  - Journal of the Academy of Nutrition and Dietetics
JID - 101573920
SB  - IM
MH  - Clinical Competence/standards
MH  - Diet
MH  - Dietetics/standards
MH  - Health Behavior
MH  - Humans
MH  - Nutrition Assessment
MH  - Nutrition Disorders/diagnosis
MH  - Nutrition Therapy/*methods
MH  - Nutritional Sciences
MH  - Nutritionists/*standards
MH  - Precision Medicine/*methods
EDAT- 2020/04/18 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/04/18 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2020/04/18 06:00 [entrez]
AID - S2212-2672(20)30098-8 [pii]
AID - 10.1016/j.jand.2020.01.020 [doi]
PST - ppublish
SO  - J Acad Nutr Diet. 2020 Jun;120(6):1074-1085. doi: 10.1016/j.jand.2020.01.020.
      Epub 2020 Apr 13.


PMID- 32298839
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 190
DP  - 2020 Jun
TI  - Progress of the ALIFE2 study: A dynamic road towards more evidence.
PG  - 39-44
LID - S0049-3848(20)30088-8 [pii]
LID - 10.1016/j.thromres.2020.03.015 [doi]
AB  - Investigator-initiated studies are invaluable, especially in fields that are not 
      particularly of interest for the pharmaceutical industry because they are either 
      less profitable or concern special patient groups such as pregnant women.
      However, designing, conducting, and completing an investigator-initiated
      randomised controlled trial is challenging. Patients and physicians' preferences,
      ethics requirements, (international) legislation and funding are all areas where 
      such challenges are encountered. The Anticoagulants for LIving FEtuses (ALIFE)2
      study (NTR3361) is an example of an investigator initiated international
      multicenter trial that progresses slowly, at least initially, as many challenges 
      had to be overcome. Here, we discuss the challenges we faced during the course of
      the ALIFE2 study up till now and we explain how some of these challenges can be
      tackled or even avoided.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Hamulyak, Eva N
AU  - Hamulyak EN
AD  - Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands. Electronic address: e.n.hamulyak@amsterdamumc.nl.
FAU - de Jong, Paulien G
AU  - de Jong PG
AD  - Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - Scheres, Luuk J J
AU  - Scheres LJJ
AD  - Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands; Department of Clinical Epidemiology, Leiden
      University Medical Center, Leiden, the Netherlands.
FAU - Ewington, Lauren J
AU  - Ewington LJ
AD  - Warwick Medical School, University Hospitals Coventry and Warwickshire NHS trust,
      Coventry, United Kingdom.
FAU - Middeldorp, Saskia
AU  - Middeldorp S
AD  - Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - Quenby, Siobhan
AU  - Quenby S
AD  - Warwick Medical School, University Hospitals Coventry and Warwickshire NHS trust,
      Coventry, United Kingdom.
FAU - Goddijn, Mariette
AU  - Goddijn M
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology,
      Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
LA  - eng
GR  - PB-PG-1013-32011/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200318
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
SB  - IM
MH  - *Anticoagulants
MH  - Female
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - *Physicians
MH  - Pregnancy
MH  - Research Personnel
OTO - NOTNLM
OT  - *Anticoagulants
OT  - *Clinical trial
OT  - *Design
OT  - *Investigator initiated
OT  - *Miscarriage
OT  - *Thrombophilia
EDAT- 2020/04/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/17 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/02/07 00:00 [revised]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - S0049-3848(20)30088-8 [pii]
AID - 10.1016/j.thromres.2020.03.015 [doi]
PST - ppublish
SO  - Thromb Res. 2020 Jun;190:39-44. doi: 10.1016/j.thromres.2020.03.015. Epub 2020
      Mar 18.


PMID- 32298146
OWN - NLM
STAT- MEDLINE
DCOM- 20200605
LR  - 20210421
IS  - 1535-4970 (Electronic)
IS  - 1073-449X (Linking)
VI  - 201
IP  - 11
DP  - 2020 Jun 1
TI  - Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care
      Perspective.
PG  - 1337-1344
LID - 10.1164/rccm.202004-1037CP [doi]
AB  - In response to the estimated potential impact of coronavirus disease (COVID-19)
      on New York City hospitals, our institution prepared for an influx of critically 
      ill patients. Multiple areas of surge planning progressed, simultaneously focused
      on infection control, clinical operational challenges, ICU surge capacity,
      staffing, ethics, and maintenance of staff wellness. The protocols developed
      focused on clinical decisions regarding intubation, the use of high-flow oxygen, 
      engagement with infectious disease consultants, and cardiac arrest. Mechanisms to
      increase bed capacity and increase efficiency in ICUs by outsourcing procedures
      were implemented. Novel uses of technology to minimize staff exposure to COVID-19
      as well as to facilitate family engagement and end-of-life discussions were
      encouraged. Education and communication remained key in our attempts to
      standardize care, stay apprised on emerging data, and review seminal literature
      on respiratory failure. Challenges were encountered and overcome through
      interdisciplinary collaboration and iterative surge planning as ICU admissions
      rose. Support was provided for both clinical and nonclinical staff affected by
      the profound impact COVID-19 had on our city. We describe in granular detail the 
      procedures and processes that were developed during a 1-month period while surge 
      planning was ongoing and the need for ICU capacity rose exponentially. The
      approaches described here provide a potential roadmap for centers that must
      rapidly adapt to the tremendous challenge posed by this and potential future
      pandemics.
FAU - Griffin, Kelly M
AU  - Griffin KM
AD  - Division of Pulmonary and Critical Care Medicine and.
FAU - Karas, Maria G
AU  - Karas MG
AD  - Division of Cardiology, Department of Medicine, and.
FAU - Ivascu, Natalia S
AU  - Ivascu NS
AD  - Department of Anesthesiology, Weill Cornell Medicine, New York Presbyterian
      Hospital, New York, New York.
FAU - Lief, Lindsay
AU  - Lief L
AD  - Division of Pulmonary and Critical Care Medicine and.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
SB  - IM
MH  - Airway Management
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Critical Illness
MH  - Health Resources/*supply & distribution
MH  - Hospitalization
MH  - *Hospitals
MH  - Humans
MH  - Infection Control/organization & administration
MH  - Intensive Care Units
MH  - New York City/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - *Surge Capacity
MH  - Workforce/organization & administration
PMC - PMC7258631
OTO - NOTNLM
OT  - *ICUs
OT  - *SARS virus
OT  - *pandemics
EDAT- 2020/04/17 06:00
MHDA- 2020/06/06 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/06/06 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1164/rccm.202004-1037CP [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2020 Jun 1;201(11):1337-1344. doi:
      10.1164/rccm.202004-1037CP.


PMID- 32297876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 16
TI  - Comparative Study of Postural Garment Versus Exercises for Patients With
      Nonspecific Cervical Pain: Protocol for a Randomized Crossover Trial.
PG  - e14807
LID - 10.2196/14807 [doi]
AB  - BACKGROUND: There is a high prevalence of work-related musculoskeletal disorders 
      among health care professionals. Posture is an essential point to be addressed
      for health care professionals with musculoskeletal disorders. Cervical pain can
      result from several conditions. Treatment should include posture modification and
      home exercise. OBJECTIVE: This study aims to compare a new postural garment
      (Posture Plus Force; Medi, Bayreuth, Germany) with exercises for women with
      nonspecific cervical pain. The investigators focus on nurses and allied health
      professionals due to the importance of posture in work-related musculoskeletal
      disorders. METHODS: This randomized crossover clinical trial has a 3-month
      treatment sequence and a 3-month washout period. Participants will include nurses
      and allied health professionals 21 to 55 years of age with cervical pain.
      Participants are allocated at random to two intervention groups: a postural
      garment (Posture Plus Force) to be worn for 2 to 4 hours per day for 90 days (P+ 
      group) and five physiotherapy sessions (20 minutes each) to learn stretching and 
      strengthening exercises with instructions to continue at home on a daily basis
      for 90 days (Ex group). The participants in each group will crossover
      interventions after a 3-month washout period. The primary outcomes are postural
      control and pain intensity. A static posturography will be performed with a scan 
      (SpinalMouse; Idiag AG, Fehraltorf, Switzerland). The visual analogue scale is a 
      psychometric measuring instrument designed to document cervical pain severity in 
      individual participants. The secondary outcomes are cervical pain-related
      disability, catastrophizing, the global perceived effect of treatment, and the
      evaluation of garment comfort. Physical activity is assessed with the
      International Physical Activity Questionnaire. Assessment of primary and
      secondary outcomes is performed at T0 (pre-intervention), T1 (immediately after
      garment fitting for P+ group), T30, T60, and T90. The same measurements are
      recorded after the washout period and during the second intervention following
      the same sequence. All patients are provided with a logbook for compliance
      recording, over the counter drug use, pain evaluation, and sick leave.
      Statistical analysis is conducted following intention-to-treat principles and the
      treatment effects calculated using linear mixed models. RESULTS: The study design
      has been approved by the Ethics Commission of Hospital N Sra de Meritxell,
      Andorra in March 2017. A total of 32 participants are already enrolled in the
      study. An extension of the study is planned in a Spanish university hospital to
      achieve a larger sample. Study results are expected to be published during 2020. 
      CONCLUSIONS: The Postural garment is expected to improve cervical pain by
      enhancing posture. TRIAL REGISTRATION: ClinicalTrials.gov NCT03560492;
      https://clinicaltrials.gov/ct2/show/NCT03560492. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): DERR1-10.2196/14807.
CI  - (c)Merce Avellanet, Anna Boada-Pladellorens, Jean-Claude Perrot, Laura Loro,
      Lidia Rodrigo Cansado, David Monterde, Josep Romagosa, Elvira Gea. Originally
      published in JMIR Research Protocols (http://www.researchprotocols.org),
      16.04.2020.
FAU - Avellanet, Merce
AU  - Avellanet M
AUID- ORCID: https://orcid.org/0000-0003-1574-9906
AD  - Rehabilitation Department, Hospital Nostra Senyora de Meritxell, Escaldes-
      Engordany, Andorra.
FAU - Boada-Pladellorens, Anna
AU  - Boada-Pladellorens A
AUID- ORCID: https://orcid.org/0000-0003-4048-3310
AD  - Rehabilitation Department, Hospital Nostra Senyora de Meritxell, Escaldes-
      Engordany, Andorra.
FAU - Perrot, Jean-Claude
AU  - Perrot JC
AUID- ORCID: https://orcid.org/0000-0002-4465-6533
AD  - Rehabilitation Department, Hospital Nostra Senyora de Meritxell, Escaldes-
      Engordany, Andorra.
FAU - Loro, Laura
AU  - Loro L
AUID- ORCID: https://orcid.org/0000-0001-6344-5144
AD  - Rehabilitation Department, Hospital Nostra Senyora de Meritxell, Escaldes-
      Engordany, Andorra.
FAU - Rodrigo Cansado, Lidia
AU  - Rodrigo Cansado L
AUID- ORCID: https://orcid.org/0000-0002-3848-5125
AD  - Rehabilitation Department, Hospital Nostra Senyora de Meritxell, Escaldes-
      Engordany, Andorra.
FAU - Monterde, David
AU  - Monterde D
AUID- ORCID: https://orcid.org/0000-0001-5362-0455
AD  - Department of Health, Catalan Health Institute, Govern de Catalunya, Barcelona,
      Spain.
FAU - Romagosa, Josep
AU  - Romagosa J
AUID- ORCID: https://orcid.org/0000-0002-6192-1888
AD  - Statistics Department, Govern d'Andorra, Andorra la Vella, Andorra.
FAU - Gea, Elvira
AU  - Gea E
AUID- ORCID: https://orcid.org/0000-0002-5694-5746
AD  - Pharmacy Department, Hospital Nostra Senyora de Meritxell, Escaldes- Engordany,
      Andorra.
LA  - eng
SI  - ClinicalTrials.gov/NCT03560492
PT  - Journal Article
DEP - 20200416
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7193442
OTO - NOTNLM
OT  - cervical exercises
OT  - cervical pain
OT  - musculoskeletal disorder
OT  - postural garment
OT  - posture
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:01
CRDT- 2020/04/17 06:00
PHST- 2019/05/29 00:00 [received]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2019/12/08 00:00 [revised]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:01 [medline]
AID - v9i4e14807 [pii]
AID - 10.2196/14807 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 16;9(4):e14807. doi: 10.2196/14807.


PMID- 32297834
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1552-5732 (Electronic)
IS  - 0890-3344 (Linking)
VI  - 36
IP  - 2
DP  - 2020 May
TI  - References From Predatory Publishers: Policy Statement for the Journal of Human
      Lactation.
PG  - 219-220
LID - 10.1177/0890334420912210 [doi]
CN  - JHL Editorial Team
AD  - Ethan Bamberger, BS, JHL Assistant Editor led the team in developing this policy.
      Other contributing team members were Kathleen Marinelli, MD, IBCLC, FABM, Sara
      Gill, PhD, RN, IBCLC, FAAN, Laura Duckett, PhD, MPH, RN, Azza Ahmed, DNSc, RN,
      IBCLC, CPNP, Cynthia Hoover, MA and Joan E. Dodgson, PhD, MPH, RN, FAAN.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - United States
TA  - J Hum Lact
JT  - Journal of human lactation : official journal of International Lactation
      Consultant Association
JID - 8709498
MH  - Breast Feeding/*trends
MH  - *Editorial Policies
MH  - Female
MH  - Humans
MH  - Publishing/economics/*standards/trends
OTO - NOTNLM
OT  - Journal of Human Lactation
OT  - breastfeeding
OT  - predatory publishing
OT  - publishing ethics
EDAT- 2020/04/17 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1177/0890334420912210 [doi]
PST - ppublish
SO  - J Hum Lact. 2020 May;36(2):219-220. doi: 10.1177/0890334420912210. Epub 2020 Apr 
      16.


PMID- 32297817
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 8
DP  - 2020 Aug
TI  - In-course and career outcomes predicted by medical school selection procedures
      based on personal qualities.
PG  - 944-946
LID - 10.1080/0142159X.2020.1747605 [doi]
AB  - This paper reports a 40-year follow-up of 57 graduates from the initial intake to
      an Australian medical school who were selected on the basis of either academic
      criteria alone or desirable personal qualities as assessed by non-cognitive tests
      and an interview (with a third small group satisfying both criteria). Both
      students and teaching staff have remained blind to the basis for selection until 
      the present day. Analysis of their under- and post-graduate careers indicates
      that 'academic' entrants were more likely to complete an intercalated BMedSci
      degree and to become specialists, while 'personal qualities' entrants were more
      likely to graduate with honours, become GPs, and win higher degrees after
      graduation. However, gender more significantly predicted these outcomes, with
      female results similar to 'personal qualities' entrants and males' similar to
      'academic.' The results are interpreted with reference to the aims and structure 
      of the Newcastle medicine curriculum.
FAU - Powis, David
AU  - Powis D
AUID- ORCID: 0000-0002-0494-0142
AD  - School of Psychology, The University of Newcastle, Callaghan, Australia.
FAU - Munro, Don
AU  - Munro D
AUID- ORCID: 0000-0001-8395-8692
AD  - School of Psychology, The University of Newcastle, Callaghan, Australia.
FAU - Bore, Miles
AU  - Bore M
AUID- ORCID: 0000-0002-9691-6851
AD  - School of Psychology, The University of Newcastle, Callaghan, Australia.
FAU - Burstal, Ann
AU  - Burstal A
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - Australia
MH  - Career Choice
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Female
MH  - Humans
MH  - Male
MH  - Schools, Medical
MH  - Specialization
MH  - *Students, Medical
OTO - NOTNLM
OT  - *Psychometrics
OT  - *education environment
OT  - *ethics/attitudes
OT  - *outcome-based
OT  - *professionalism
EDAT- 2020/04/17 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1080/0142159X.2020.1747605 [doi]
PST - ppublish
SO  - Med Teach. 2020 Aug;42(8):944-946. doi: 10.1080/0142159X.2020.1747605. Epub 2020 
      Apr 16.


PMID- 32297352
OWN - NLM
STAT- Publisher
LR  - 20211022
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
DP  - 2020 Apr 16
TI  - Palliative care for rare advanced lung diseases in underserved Appalachia: Study 
      protocol for a randomized controlled trial.
LID - 10.1111/jan.14395 [doi]
AB  - AIM: To pilot test a home end-of-life and palliative care intervention for family
      caregivers and patients with rare advanced lung diseases and to estimate
      effect-size for the power analysis in a future clinical trial. DESIGN: This study
      uses a parallel randomized control trial. Families are randomly assigned to the
      intervention group or the control group in a 1:1 fashion. METHODS: The study
      population includes patients with rare advanced lung diseases and their family
      caregivers who are involved in patients' home care. The control group receives
      standard care through their hospital or outpatient clinics. The intervention
      group receives standard care plus 2-weekly home end-of-life and palliative care
      coaching by experienced community nurses. Primary outcome is breathlessness
      measured by shortness of breath scale. Secondary outcomes are: (a) caregivers'
      anxiety and depression measures; (b) the presence of patient's signed advance
      directives in the medical record or not; and (c) Helpfulness of intervention
      measured by self-report Helpfulness scale. The study was funded in October 2018
      and received ethical Institutional Review Board approval in February 2019.
      DISCUSSION: West Virginia has one of the highest incidence rates of lung disease 
      deaths in the nation. However, there is inadequate home end-of-life and
      palliative care for this underserved population. This is an initial
      interventional study of nurse-led coaching home-based palliative care for rare
      advanced lung diseases in rural Appalachia. Developing research collaboration
      with clinicians is essential for enrolment. Enrolment was successful due to
      regular meetings with pulmonologists who screened patients per the study
      inclusion criteria in their specialty clinic and made direct referrals to the
      research assistants. Results of this study will be used in the future trial.
      IMPACT: The findings will contribute to the evidence-based home nursing care,
      planning for family/patient preferences and supportive end-of-life palliative
      care for managing advanced lung diseases at home. TRIAL REGISTRATION:
      ClinicalTrials.gov identifier NCT03813667; registered January 23, 2019.
      https://clinicaltrials.gov/ct2/show/NCT03813667.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Piamjariyakul, Ubolrat
AU  - Piamjariyakul U
AUID- ORCID: https://orcid.org/0000-0003-0310-3673
AD  - School of Nursing, West Virginia University, Morgantown, WV, USA.
FAU - Smothers, Angel
AU  - Smothers A
AD  - School of Nursing, West Virginia University, Morgantown, WV, USA.
FAU - Young, Stephanie
AU  - Young S
AD  - School of Nursing, West Virginia University, Morgantown, WV, USA.
FAU - Petitte, Trisha
AU  - Petitte T
AD  - School of Nursing, West Virginia University, Morgantown, WV, USA.
FAU - Wen, Sijin
AU  - Wen S
AD  - Department of Biostatistics School of Public Health, West Virginia University,
      Morgantown, WV, USA.
FAU - Morrissey, Elizabeth
AU  - Morrissey E
AD  - School of Nursing, West Virginia University, Morgantown, WV, USA.
FAU - Shafique, Saima
AU  - Shafique S
AD  - Department of Epidemiology School of Public Health, West Virginia University,
      Morgantown, WV, USA.
FAU - Zulfikar, Rafia
AU  - Zulfikar R
AD  - Section of Pulmonary, Critical Care, and Sleep Medicine, School of Medicine, West
      Virginia University, Morgantown, WV, USA.
FAU - Sangani, Rahul
AU  - Sangani R
AD  - Section of Pulmonary, Critical Care, and Sleep Medicine, School of Medicine, West
      Virginia University, Morgantown, WV, USA.
FAU - Smith, Carol E
AU  - Smith CE
AD  - School of Nursing and School of Preventive Medicine, University of Kansas Medical
      Center, Kansas City, KS, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03813667
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
GR  - 2U54GM104942-02/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20200416
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
PMC - PMC7572472
MID - NIHMS1584072
OTO - NOTNLM
OT  - advance directives
OT  - advanced lung diseases
OT  - end-of-life care
OT  - nursing intervention
OT  - palliative
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/03/27 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1111/jan.14395 [doi]
PST - aheadofprint
SO  - J Adv Nurs. 2020 Apr 16. doi: 10.1111/jan.14395.


PMID- 32297134
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210831
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Jun
TI  - Medical Students' Acquaintance with Core Concepts, Institutions and Guidelines on
      Good Scientific Practice: A Pre- and Post-questionnaire Survey.
PG  - 1827-1845
LID - 10.1007/s11948-020-00215-3 [doi]
AB  - German medical students are not sufficiently introduced to the ethical principles
      and pitfalls of scientific work. Therefore, a compulsory course on good
      scientific practice (GSP) has been developed and implemented into the curriculum 
      of medical students, with the goal to foster scientific integrity and prevent
      scientific misconduct. Students' knowledge and attitudes towards GSP were
      evaluated by a pre-post-teaching questionnaire survey (n = 239). Most
      participants initially had startling knowledge gaps in the field. Moreover, they 
      were not acquainted with core institutions on GSP, the office of ombudsperson and
      the nationally binding guidelines on GSP. The pre-post-teaching comparison showed
      statistically significant improvement in all areas tested; moreover, after the
      course participants confided more trust in GSP institutions. Applying ethical
      rules into practice can be challenging; therefore, students need to learn to work
      independently with guidelines on GSP and should be introduced to institutions
      providing further guidance. As our study has shown, students are very willing to 
      pursue a scientific career based on integrity and honesty, however, they lack the
      knowledge how to do so. In light of our results, we therefore recommend to
      integrate courses on GSP already at an early time into the mandatory curriculum
      of medical students.
FAU - Fuerholzer, Katharina
AU  - Fuerholzer K
AUID- ORCID: http://orcid.org/0000-0002-6586-5377
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University,
      Parkstrasse 11, 89073, Ulm, Germany. katharina.fuerholzer@alumni.uni-ulm.de.
FAU - Schochow, Maximilian
AU  - Schochow M
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University,
      Parkstrasse 11, 89073, Ulm, Germany.
FAU - Peter, Richard
AU  - Peter R
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University,
      Parkstrasse 11, 89073, Ulm, Germany.
FAU - Steger, Florian
AU  - Steger F
AD  - Institute of the History, Philosophy and Ethics of Medicine, Ulm University,
      Parkstrasse 11, 89073, Ulm, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
EIN - Sci Eng Ethics. 2021 Aug 10;27(4):54. PMID: 34374873
MH  - Curriculum
MH  - *Education, Medical, Undergraduate
MH  - Friends
MH  - Humans
MH  - Motivation
MH  - *Students, Medical
MH  - Surveys and Questionnaires
PMC - PMC8354979
OTO - NOTNLM
OT  - *Ethics
OT  - *Germany
OT  - *Medical education
OT  - *Medicine
OT  - *Questionnaire
OT  - *Scientific integrity
EDAT- 2020/04/17 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/17 06:00
PHST- 2019/05/28 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1007/s11948-020-00215-3 [doi]
AID - 10.1007/s11948-020-00215-3 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Jun;26(3):1827-1845. doi: 10.1007/s11948-020-00215-3. Epub
      2020 Apr 15.


PMID- 32297016
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 1176-7529 (Print)
IS  - 1176-7529 (Linking)
VI  - 17
IP  - 2
DP  - 2020 Jun
TI  - Ethical Reasoning and Moral Distress in Social Care Among Long-Term Care Staff.
PG  - 283-295
LID - 10.1007/s11673-020-09974-x [doi]
AB  - There are studies on the normative ethical frameworks used by long-term care
      staff and studies proposing how staff should reason, but few studies explore how 
      staff actually reason. This study reports on the ethical reasoning process and
      experiences of moral distress of long-term care staff in the provision of social 
      care. Seven interdisciplinary focus groups were conducted with twenty front-line 
      staff. Staff typically did not have difficulty determining the ethical decision
      and/or action; however, they frequently experience moral distress. To manage
      these experiences of moral distress in making ethical decisions, staff 1) comply 
      with being told what to do out of fear of consequences, 2) defer decisions to
      family, 3) "have a meeting," 4) socialization into and acceptance of workplace
      culture. Findings suggest that to better understand how and why staff make
      ethical decisions and improve quality and ethical care, we must explore the
      interaction between front-line practice and organizational and public policy.
FAU - Greason, Michelle
AU  - Greason M
AD  - St Thomas University, 51 Dineen Drive., BMH 309, Fredericton, New Brunswick, E3B 
      5G3, Canada. mgreason@stu.ca.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Netherlands
TA  - J Bioeth Inq
JT  - Journal of bioethical inquiry
JID - 101250741
SB  - IM
MH  - Decision Making
MH  - Focus Groups
MH  - Humans
MH  - *Long-Term Care
MH  - *Morals
MH  - Social Support
MH  - Stress, Psychological
OTO - NOTNLM
OT  - Empirical ethics
OT  - Ethical reasoning
OT  - Ethics policy
OT  - Long-term care
OT  - Moral distress
OT  - Quality care
EDAT- 2020/04/17 06:00
MHDA- 2021/09/14 06:00
CRDT- 2020/04/17 06:00
PHST- 2019/02/14 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1007/s11673-020-09974-x [doi]
AID - 10.1007/s11673-020-09974-x [pii]
PST - ppublish
SO  - J Bioeth Inq. 2020 Jun;17(2):283-295. doi: 10.1007/s11673-020-09974-x. Epub 2020 
      Apr 15.


PMID- 32296985
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20220208
IS  - 1435-5604 (Electronic)
IS  - 0914-8779 (Linking)
VI  - 38
IP  - 5
DP  - 2020 Sep
TI  - The old sheep: a convenient and suitable model for senile osteopenia.
PG  - 620-630
LID - 10.1007/s00774-020-01098-x [doi]
AB  - INTRODUCTION: Existing osteoporosis models in sheep exhibit some disadvantages,
      e.g., challenging surgical procedures, serious ethical concerns, failure of
      reliable induction of substantial bone loss, or lack of comparability to the
      human condition. This study aimed to compare bone morphological and mechanical
      properties of old and young sheep, and to evaluate the suitability of the old
      sheep as a model for senile osteopenia. MATERIALS AND METHODS: The lumbar
      vertebral body L3 of female merino sheep with two age ranges, i.e., old animals
      (6-10 years; n = 41) and young animals (2-4 years; n = 40), was analyzed
      concerning its morphological and mechanical properties by bone densitometry,
      quantitative histomorphometry, and biomechanical testing of the corticalis and/or
      central spongious region. RESULTS: In comparison with young sheep, old animals
      showed only marginally diminished bone mineral density of the vertebral bodies,
      but significantly decreased structural (bone volume, - 15.1%; ventral cortical
      thickness, - 11.8%; lateral cortical thickness, - 12.2%) and bone formation
      parameters (osteoid volume, osteoid surface, osteoid thickness, osteoblast
      surface, all - 100.0%), as well as significantly increased bone erosion (eroded
      surface, osteoclast surface). This resulted in numerically decreased
      biomechanical properties (compressive strength; - 6.4%). CONCLUSION: Old sheep
      may represent a suitable model of senile osteopenia with markedly diminished bone
      structure and formation, and substantially augmented bone erosion. The underlying
      physiological aging concept reduces challenging surgical procedures and ethical
      concerns and, due to complex alteration of different facets of bone turnover, may
      be well representative of the human condition.
FAU - Maenz, Stefan
AU  - Maenz S
AD  - Chair of Materials Science, Otto Schott Institute of Materials Research,
      Friedrich-Schiller-University Jena, Jena, Germany.
FAU - Brinkmann, Olaf
AU  - Brinkmann O
AD  - Chair of Orthopedics, Department of Orthopedics, Jena University Hospital,
      Waldkliniken Eisenberg GmbH, Eisenberg, Germany.
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Hasenbein, Ines
AU  - Hasenbein I
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Braun, Christina
AU  - Braun C
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Kunisch, Elke
AU  - Kunisch E
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Horbert, Victoria
AU  - Horbert V
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Gunnella, Francesca
AU  - Gunnella F
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Sachse, Andre
AU  - Sachse A
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
FAU - Bischoff, Sabine
AU  - Bischoff S
AD  - Institute of Laboratory Animal Sciences and Welfare, Jena University Hospital,
      Jena, Germany.
FAU - Schubert, Harald
AU  - Schubert H
AD  - Institute of Laboratory Animal Sciences and Welfare, Jena University Hospital,
      Jena, Germany.
FAU - Jandt, Klaus D
AU  - Jandt KD
AD  - Chair of Materials Science, Otto Schott Institute of Materials Research,
      Friedrich-Schiller-University Jena, Jena, Germany.
FAU - Bossert, Jorg
AU  - Bossert J
AD  - Chair of Materials Science, Otto Schott Institute of Materials Research,
      Friedrich-Schiller-University Jena, Jena, Germany.
FAU - Driesch, Dominik
AU  - Driesch D
AD  - BioControl Jena GmbH, Jena, Germany.
FAU - Kinne, Raimund W
AU  - Kinne RW
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany. raimund.w.kinne@med.uni-jena.de.
FAU - Bungartz, Matthias
AU  - Bungartz M
AD  - Chair of Orthopedics, Department of Orthopedics, Jena University Hospital,
      Waldkliniken Eisenberg GmbH, Eisenberg, Germany.
AD  - Experimental Rheumatology Unit, Department of Orthopedics, Jena University
      Hospital, Waldkliniken Eisenberg GmbH, Klosterlausnitzer Str. 81, 07607,
      Eisenberg, Germany.
LA  - eng
GR  - doctoral candidate scholarship/Carl-Zeiss-Stiftung
GR  - FKZ 0316205C/Bundesministerium fur Bildung und Forschung
GR  - FKZ 035577D/Bundesministerium fur Bildung und Forschung
GR  - FKZ 0316205B/Bundesministerium fur Bildung und Forschung
GR  - FKZ 13N12601/Bundesministerium fur Bildung und Forschung
PT  - Journal Article
DEP - 20200415
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
SB  - IM
MH  - Animals
MH  - Biomechanical Phenomena
MH  - Bone Density
MH  - Bone Diseases, Metabolic/*pathology/physiopathology
MH  - Cancellous Bone/pathology/physiopathology
MH  - Compressive Strength
MH  - *Disease Models, Animal
MH  - Elastic Modulus
MH  - Female
MH  - Lumbar Vertebrae/pathology/physiopathology
MH  - Osteogenesis
MH  - Sheep/*physiology
OTO - NOTNLM
OT  - Large animal model
OT  - Old sheep
OT  - Senile osteopenia
OT  - Senile osteoporosis
EDAT- 2020/04/17 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/04/17 06:00
PHST- 2019/06/15 00:00 [received]
PHST- 2020/03/08 00:00 [accepted]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1007/s00774-020-01098-x [doi]
AID - 10.1007/s00774-020-01098-x [pii]
PST - ppublish
SO  - J Bone Miner Metab. 2020 Sep;38(5):620-630. doi: 10.1007/s00774-020-01098-x. Epub
      2020 Apr 15.


PMID- 32296815
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 35
IP  - 4
DP  - 2020 Apr 28
TI  - An ethical perspective on 'Genes versus children'.
PG  - 1006-1007
LID - 10.1093/humrep/deaa023 [doi]
FAU - Segers, Seppe
AU  - Segers S
AD  - Bioethics Institute Ghent, Department of Philosophy and Moral Sciences, Ghent
      University, Ghent 9000, Belgium.
FAU - Pennings, Guido
AU  - Pennings G
AD  - Bioethics Institute Ghent, Department of Philosophy and Moral Sciences, Ghent
      University, Ghent 9000, Belgium.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
CON - Hum Reprod. 2020 Jan 1;35(1):5-11. PMID: 31916579
MH  - Child
MH  - *Goals
MH  - Humans
MH  - *Motivation
EDAT- 2020/04/17 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 5817893 [pii]
AID - 10.1093/humrep/deaa023 [doi]
PST - ppublish
SO  - Hum Reprod. 2020 Apr 28;35(4):1006-1007. doi: 10.1093/humrep/deaa023.


PMID- 32296808
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201218
IS  - 0304-4602 (Print)
IS  - 0304-4602 (Linking)
VI  - 49
IP  - 4
DP  - 2020 Apr
TI  - Extracorporeal Membrane Oxygenation for Severe Respiratory Failure During
      Respiratory Epidemics and Pandemics: A Narrative Review.
PG  - 199-214
AB  - INTRODUCTION: Epidemics and pandemics from zoonotic respiratory viruses, such as 
      the 2019 novel coronavirus, can lead to significant global intensive care burden 
      as patients progress to acute respiratory distress syndrome (ARDS). A subset of
      these patients developed refractory hypoxaemia despite maximal conventional
      mechanical ventilation and required extracorporeal membrane oxygenation (ECMO).
      This review focuses on considerations for ventilatory strategies, infection
      control and patient selection related to ECMO for ARDS in a pandemic. We also
      summarise the experiences with ECMO in previous respiratory pandemics. METHODS: A
      review of pertinent studies was conducted via a search using MEDLINE, EMBASE and 
      Google Scholar. References of articles were also examined to identify other
      relevant publications. RESULTS: Since the H1N1 Influenza pandemic in 2009, the
      use of ECMO for ARDS continues to grow despite limitations in evidence for
      survival benefit. There is emerging evidence to suggest that lung protective
      ventilation for ARDS can be further optimised while receiving ECMO so as to
      minimise ventilator-induced lung injury and subsequent contributions to
      multi-organ failure. Efforts to improve outcomes should also encompass
      appropriate infection control measures to reduce co-infections and prevent
      nosocomial transmission of novel respiratory viruses. Patient selection for ECMO 
      in a pandemic can be challenging. We discuss important ethical considerations and
      predictive scoring systems that may assist clinical decision-making to optimise
      resource allocation. CONCLUSION: The role of ECMO in managing ARDS during
      respiratory pandemics continues to grow. This is supported by efforts to redefine
      optimal ventilatory strategies, reinforce infection control measures and enhance 
      patient selection.
FAU - Lim, Joel Kian Boon
AU  - Lim JKB
AD  - Children's Intensive Care Unit, KK Women's and Children's Hospital, Singapore.
FAU - Qadri, Syeda Kashfi
AU  - Qadri SK
FAU - Toh, Theresa Shu Wen
AU  - Toh TSW
FAU - Lin, Cheryl Bin
AU  - Lin CB
FAU - Mok, Yee Hui
AU  - Mok YH
FAU - Lee, Jan Hau
AU  - Lee JH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Ann Acad Med Singap
JT  - Annals of the Academy of Medicine, Singapore
JID - 7503289
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/*therapy
MH  - *Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*complications/*therapy
MH  - Respiration, Artificial
MH  - Respiratory Distress Syndrome/*therapy/*virology
MH  - SARS-CoV-2
EDAT- 2020/04/17 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PST - ppublish
SO  - Ann Acad Med Singap. 2020 Apr;49(4):199-214.


PMID- 32296741
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2475-2991 (Electronic)
IS  - 2475-2991 (Linking)
VI  - 4
IP  - 4
DP  - 2020 Apr
TI  - Factors Affecting Food Security in Women Enrolled in a Program for Vulnerable
      Group Development.
PG  - nzaa037
LID - 10.1093/cdn/nzaa037 [doi]
AB  - BACKGROUND: Food security is defined as physical and economic access to
      sufficient food to meet the dietary requirements for a productive and healthy
      life. Evidence from the literature suggests that >800 million people worldwide
      are food insecure. Vulnerable Group Development (VGD) is the largest social
      safety net of the Government of Bangladesh targeting ultra-poor women to end
      hunger, achieve food security, improve nutrition, and promote sustainable
      agriculture. OBJECTIVES: The objective of this study is to explore the factors
      associated with food security among VGD women in Bangladesh. METHODS: A total of 
      870 women (435/group) participated in the baseline survey and another 800 women
      (400/group) participated in the endline survey. Participants in the intervention 
      group received monthly rations of 30 kg fortified rice (FFR) and the control
      group received 30 kg of non-FFR for 12 mo. Multiple logistic regression analysis 
      was used to establish both crude and confounder-adjusted relations between the
      primary outcome and response variables. Written consent was proved by study
      participants. This study (PR-14091) was approved by the Research Review Committee
      and Ethical Review Committee. RESULTS: Severe food insecurity in the endline
      survey decreased from approximately 50% to 6.3% in both groups. The hunger scale 
      also improved between the baseline and endline survey. More than 97% of
      respondents at endline reported no hunger compared with 80% at baseline; only 3% 
      of women in both groups reported moderate hunger at endline. Multivariable
      regression model showed that ownership of a house and land for agriculture,
      wealth index (richest quintile), and absence of fever were significantly
      associated with food security (P < 0.05). CONCLUSIONS: Our analysis shows that
      the VGD rice distribution program significantly improves the food security status
      of vulnerable women; however, ownership of a house and land for agriculture were 
      the most significant factors associated with household food security in VGD
      program areas of Bangladesh.
CI  - Copyright (c) The Author(s) 2020.
FAU - Khanam, Mansura
AU  - Khanam M
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Ara, Gulshan
AU  - Ara G
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Rahman, Ahmed Shafiqur
AU  - Rahman AS
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Islam, Zhahirul
AU  - Islam Z
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Farhad, Shahriar
AU  - Farhad S
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Khan, Sihan Sadat
AU  - Khan SS
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Sanin, Kazi Istiaque
AU  - Sanin KI
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
FAU - Rahman, Mohammad Mahbobor
AU  - Rahman MM
AD  - World Food Programme, IDB Bhaban, IDB Bhaban 14th, 16th and 17th Floor E/8-A,
      Rokeya Sharani Agargaon, Sher-e-Bangla Nagar, Dhaka-1207, Bangladesh.
FAU - Majoor, Herma
AU  - Majoor H
AD  - World Food Programme, IDB Bhaban, IDB Bhaban 14th, 16th and 17th Floor E/8-A,
      Rokeya Sharani Agargaon, Sher-e-Bangla Nagar, Dhaka-1207, Bangladesh.
FAU - Ahmed, Tahmeed
AU  - Ahmed T
AUID- ORCID: 0000-0002-4607-7439
AD  - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
      Dhaka, Bangladesh.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - United States
TA  - Curr Dev Nutr
JT  - Current developments in nutrition
JID - 101717957
PMC - PMC7144907
OTO - NOTNLM
OT  - assessment
OT  - food insecurity
OT  - food security
OT  - social safety net
OT  - women
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:01
CRDT- 2020/04/17 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:01 [medline]
AID - 10.1093/cdn/nzaa037 [doi]
AID - nzaa037 [pii]
PST - epublish
SO  - Curr Dev Nutr. 2020 Mar 19;4(4):nzaa037. doi: 10.1093/cdn/nzaa037. eCollection
      2020 Apr.


PMID- 32296660
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2251-9920 (Print)
IS  - 2251-9920 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Mar
TI  - Interpersonal Communication among Critical Care Nurses: an Ethnographic Study.
PG  - 57-64
LID - 10.34172/jcs.2020.009 [doi]
AB  - Introduction: Interpersonal communication in critical care units is one of the
      most important factors due to complicated and critical conditions of patients.
      Nurses' confrontation with ethical distresses and conflict resolution techniques 
      are often influenced by the culture governing these units. This study aimed to
      explore interpersonal communication culture among critical care nurses. Methods: 
      A focused ethnographic approach was used to conduct study in Iran. The research
      method was based on the research evolutionary cycle model recommended by Spradley
      (1980). Data were collected over six months through purposeful sampling and semi 
      structured interviews (n=18) and participation observation (n=43). The data were 
      obtained over six months of observation and interview with participants. Data
      analysis was done by Spradley method and was interpreted to discover the meaning 
      units from the obtained themes. MAXQDA10 was used to manage data. Results: Five
      major domains of observations and high-level consensus were extracted in this
      study, including grouping, work-life interaction, professionalism, organizational
      atmosphere and experience. Conclusion: Development of interpersonal communication
      culture is influenced by various factors. Besides, the working models and nurses'
      use of workspace are indispensable components of effective communication at
      workplace. The findings of this study can be helpful in determining appropriate
      strategies and practices to resolve communication problems among nurses by
      specifying challenges, thereby leading to proper communication among nurses,
      promoting this communication and finally providing high quality and more
      effective care.
CI  - (c) 2020 The Author(s).
FAU - Mahvar, Tayebeh
AU  - Mahvar T
AUID- ORCID: https://orcid.org/0000-0001-5524-0181
AD  - Department of Nursing, Nursing and Midwifery Faculty, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Mohammadi, Nooredin
AU  - Mohammadi N
AUID- ORCID: https://orcid.org/0000-0002-4790-6737
AD  - Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
FAU - Seyedfatemi, Naima
AU  - Seyedfatemi N
AUID- ORCID: https://orcid.org/0000-0002-5292-4219
AD  - Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
FAU - Vedadhir, AbouAli
AU  - Vedadhir A
AUID- ORCID: https://orcid.org/0000-0001-8620-1396
AD  - Department of Anthropology, Social Sciences Faculty, Tehran University of Medical
      Sciences, Tehran, Iran.
AD  - Honorary Senior Research Fellow, Population Health Sciences, University of
      Bristol, Bristol, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200301
PL  - Iran
TA  - J Caring Sci
JT  - Journal of caring sciences
JID - 101589637
PMC - PMC7146730
OTO - NOTNLM
OT  - Communications
OT  - Critical care
OT  - Ethnography
OT  - Nurses
OT  - Personal
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:01
CRDT- 2020/04/17 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2019/01/13 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:01 [medline]
AID - 10.34172/jcs.2020.009 [doi]
PST - epublish
SO  - J Caring Sci. 2020 Mar 1;9(1):57-64. doi: 10.34172/jcs.2020.009. eCollection 2020
      Mar.


PMID- 32296519
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2048-8505 (Print)
IS  - 2048-8505 (Linking)
VI  - 13
IP  - 2
DP  - 2020 Apr
TI  - Raising awareness of unspecified living kidney donation: an ELPAT view.
PG  - 159-165
LID - 10.1093/ckj/sfz067 [doi]
AB  - BACKGROUND: Living donor kidney transplantation (LDKT) is the preferred treatment
      for patients with end-stage renal disease and unspecified living kidney donation 
      is morally justified. Despite the excellent outcomes of LDKT, unspecified kidney 
      donation (UKD) is limited to a minority of European countries due to legal
      constraints and moral objections. Consequently, there are significant variations 
      in practice and approach between countries and the contribution of UKD is
      undervalued. Where UKD is accepted as routine, an increasing number of patients
      in the kidney exchange programme are successfully transplanted when a 'chain' of 
      transplants is triggered by a single unspecified donor. By expanding the shared
      living donor pool, the benefit of LDKT is extended to patients who do not have
      their own living donor because a recipient on the national transplant list always
      completes the chain. Is there a moral imperative to increase the scope of UKD and
      how could this be achieved? METHODS: An examination of the literature and
      individual country practices was performed to identify the limitations on UKD in 
      Europe and recommend strategies to increase transplant opportunities. RESULTS:
      Primary limitations to UKD, key players and their roles and responsibilities were
      identified. CONCLUSIONS: Raising awareness to encourage the public to volunteer
      to donate is appropriate and desirable to increase UKD. Recommendations are made 
      to provide a framework for increasing awareness and engagement in UKD. The
      public, healthcare professionals, policy makers and society and religious leaders
      have a role to play in creating an environment for change.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of
      ERA-EDTA.
FAU - Burnapp, Lisa
AU  - Burnapp L
AD  - Department of Transplantation and Nephrology, Guy's & St Thomas' NHS Foundation
      Trust, London, UK.
FAU - Van Assche, Kristof
AU  - Van Assche K
AD  - Faculty of Law, University of Antwerp, Antwerp, Belgium.
FAU - Lennerling, Annette
AU  - Lennerling A
AD  - Department of Transplantation, Sahlgrenska University Hospital, Gothenburg,
      Sweden.
FAU - Slaats, Dorthe
AU  - Slaats D
AD  - Department Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
FAU - Van Dellen, David
AU  - Van Dellen D
AD  - Department of Surgery, Manchester Royal Infirmary, Manchester, UK.
FAU - Mamode, Nizam
AU  - Mamode N
AD  - Department of Transplantation and Nephrology, Guy's & St Thomas' NHS Foundation
      Trust, London, UK.
FAU - Citterio, Franco
AU  - Citterio F
AD  - Renal Transplantation Unit, Catholic University, Rome, Italy.
FAU - Zuidema, Willij
AU  - Zuidema W
AD  - Department Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
FAU - Weimar, Willem
AU  - Weimar W
AD  - Department Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
FAU - Dor, Frank J M F
AU  - Dor FJMF
AD  - Imperial College Renal and Transplant Centre, Hammersmith Hospital, Imperial
      College, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20190615
PL  - England
TA  - Clin Kidney J
JT  - Clinical kidney journal
JID - 101579321
PMC - PMC7147300
OTO - NOTNLM
OT  - donation
OT  - ethics
OT  - kidney
OT  - living
OT  - unspecified
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:01
CRDT- 2020/04/17 06:00
PHST- 2018/11/18 00:00 [received]
PHST- 2019/04/08 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:01 [medline]
AID - 10.1093/ckj/sfz067 [doi]
AID - sfz067 [pii]
PST - epublish
SO  - Clin Kidney J. 2019 Jun 15;13(2):159-165. doi: 10.1093/ckj/sfz067. eCollection
      2020 Apr.


PMID- 32296196
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 0030-9982 (Print)
IS  - 0030-9982 (Linking)
VI  - 70
IP  - 4
DP  - 2020 Apr
TI  - The Quantum of Solace in Ethics Education.
PG  - 569-571
FAU - Shamim, Muhammad Shahid
AU  - Shamim MS
AD  - Dow University of Health Sciences. Karachi, Pakistan.
LA  - eng
PT  - Editorial
PL  - Pakistan
TA  - J Pak Med Assoc
JT  - JPMA. The Journal of the Pakistan Medical Association
JID - 7501162
SB  - IM
MH  - Curriculum
MH  - Ethics, Medical/*education
MH  - Faculty, Medical
MH  - Humans
MH  - Pakistan
MH  - Teaching Materials
EDAT- 2020/04/17 06:00
MHDA- 2021/03/20 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
AID - 9757 [pii]
PST - ppublish
SO  - J Pak Med Assoc. 2020 Apr;70(4):569-571.


PMID- 32295943
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20220414
IS  - 1117-1936 (Print)
VI  - 27
IP  - 2
DP  - 2020 Apr-Jun
TI  - Stage of chronic kidney disease and cochlear function: A cross-sectional survey.
PG  - 122-126
LID - 10.4103/npmj.npmj_148_19 [doi]
AB  - BACKGROUND: Studies have shown that hearing loss increases in patients with
      chronic kidney disease (CKD) with decreasing glomerular filtration rate. The
      hearing loss in CKD patients may worsen over time which in turn will negatively
      affect the patient's ability to effectively communicate with people, resulting in
      low self-esteem, social isolation, anger and depression. We aimed to assess the
      relationship between stage of CKD and hearing threshold in patients with CKD in
      Kaduna. PATIENTS AND METHODS: A cross-sectional study of patients with CKD in
      Kaduna. Individuals were selected consecutively using convenience sampling.
      Ethical approval and informed consent were obtained. The patients were grouped
      based on the stage of the disease. The pure tone audiometry was carried out using
      a Diagnostic Audiometer (Graphic Digi-IS, USA). The hearing threshold of the
      patients was then compared based on stage of the disease. The data collected was 
      analysed using Statistical Product and Service Solutions, version 20. RESULTS:
      Sixty CKD patients (120 ears) were assessed. Their mean age was 43.2 +/- 13.4
      years and 70% were males. Of the 120 ears studied, 51 (42.5%) had normal hearing 
      thresholds and 69 (57.5%) had hearing loss. Of the 69 ears with hearing loss, 11 
      (15.9%), 22 (31.9%) and 36 (52.2%) were in Stage III, IV and V, respectively, and
      the difference was statistically significant (P = 0.006). All those with Stage
      III CKD had mild hearing loss and the hearing loss worsen with advancing stage.
      Stage III CKD had significantly better hearing than those with stage IV and V (P 
      < 0.001). CONCLUSION: Our study showed a statistically significant relationship
      between advancing stage of CKD and hearing loss. The hearing loss worsen with
      advancing stage of CKD.
FAU - Fufore, Mohammed Bello
AU  - Fufore MB
AD  - Department of ENT, Federal Medical Centre, Yola, Adamawa State, Nigeria.
FAU - Kirfi, Abdullahi Musa
AU  - Kirfi AM
AD  - Department of ENT, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi,
      Bauchi State, Nigeria.
FAU - Salisu, Abubakar Danjuma
AU  - Salisu AD
AD  - Department of ENT, Aminu Kano Teaching Hospital, Kano, Kano State, Nigeria.
FAU - Samdi, Thomas Musa
AU  - Samdi TM
AD  - Department of Clinical Services, National Ear Care Centre, Kaduna, Nigeria.
FAU - Abubakar, Abdulhameed Bala
AU  - Abubakar AB
AD  - Department of Internal Medicine, Barau Dikko Teaching Hospital, Kaduna, Nigeria.
FAU - Onakoya, Paul Adekunle
AU  - Onakoya PA
AD  - Department of ENT, University College Hospital, Ibadan, Nigeria.
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Niger Postgrad Med J
JT  - The Nigerian postgraduate medical journal
JID - 9613595
SB  - IM
MH  - Adult
MH  - Aged
MH  - Audiometry, Pure-Tone
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Hearing Loss/diagnosis/*epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - Prevalence
MH  - Renal Insufficiency, Chronic/*complications/diagnosis/epidemiology
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - hearing loss
OT  - pure tone audiometry
OT  - stage
COIS- None
EDAT- 2020/04/17 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
AID - NigerPostgradMedJ_2020_27_2_122_282309 [pii]
AID - 10.4103/npmj.npmj_148_19 [doi]
PST - ppublish
SO  - Niger Postgrad Med J. 2020 Apr-Jun;27(2):122-126. doi: 10.4103/npmj.npmj_148_19.


PMID- 32295794
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20220415
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 13
IP  - 4
DP  - 2020 Apr 14
TI  - Hereditary angioedema: the challenges of cross-border family investigation and
      treatment.
LID - e231906 [pii]
LID - 10.1136/bcr-2019-231906 [doi]
AB  - Hereditary angioedema (HAE) is a rare genetic disorder characterised by recurrent
      swellings involving subcutaneous and submucosal tissue that can be potentially
      life threatening in cases involving the upper airway. In this case report, we
      present a Syrian refugee family with HAE who have lived in Denmark since 2014.
      The index patient is an 8-year-old girl diagnosed with HAE after being
      hospitalised in Denmark with an angioedema attack. Her younger sister and father 
      were diagnosed later, following investigation of the family. Exploring the family
      history, deaths due to suffocation were described in previous generations and
      other family members based in Sweden, Germany, Turkey, Saudi Arabia, USA and
      Syria could also potentially be affected. This highlights the need for a
      cross-border effort to diagnose and treat this inherited disorder.
CI  - (c) BMJ Publishing Group Limited 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Brix, Anna Trier Heiberg
AU  - Brix ATH
AUID- ORCID: http://orcid.org/0000-0002-5242-859X
AD  - Falculty of Health Science, University of Southern Denmark, Odense, Denmark.
AD  - Department of Dermatology and Allergy Center, Odense University Hospital, Odense,
      Denmark.
FAU - Svensson, Trine Mehlbye
AU  - Svensson TM
AD  - Falculty of Health Science, University of Southern Denmark, Odense, Denmark.
AD  - Department of Dermatology and Allergy Center, Odense University Hospital, Odense,
      Denmark.
FAU - Sandberg, Malin
AU  - Sandberg M
AD  - Department of Dermatology and Allergy Center, Odense University Hospital, Odense,
      Denmark.
FAU - Bygum, Anette
AU  - Bygum A
AD  - Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
      anette.bygum@rsyd.dk.
AD  - Clinical institute, University of Southern Denmark, Odense, Denmark.
LA  - eng
PT  - Case Reports
DEP - 20200414
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Complement C1 Inhibitor Protein)
RN  - 0 (SERPING1 protein, human)
SB  - IM
MH  - Angioedemas, Hereditary/*diagnosis/*genetics/*therapy
MH  - Child
MH  - Complement C1 Inhibitor Protein/genetics
MH  - Denmark/epidemiology
MH  - Family Health
MH  - Female
MH  - Humans
MH  - Mutation/genetics
MH  - Pedigree
MH  - Refugees
MH  - Syria/ethnology
MH  - Transients and Migrants
PMC - PMC7199096
OTO - NOTNLM
OT  - dermatology
OT  - ethics
OT  - ethnic studies
COIS- Competing interests: ATHB has been involved in teaching activities with CSL
      Behring. AB has been involved in research and teaching activities with CSL
      Behring, Shire and Biocryst. MS has received travel grants from CSL Behring.
EDAT- 2020/04/17 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - 13/4/e231906 [pii]
AID - 10.1136/bcr-2019-231906 [doi]
PST - epublish
SO  - BMJ Case Rep. 2020 Apr 14;13(4). pii: 13/4/e231906. doi: 10.1136/bcr-2019-231906.


PMID- 32295780
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Randomised controlled trial of a person-centred transition programme for
      adolescents with type 1 diabetes (STEPSTONES-DIAB): a study protocol.
PG  - e036496
LID - 10.1136/bmjopen-2019-036496 [doi]
AB  - INTRODUCTION: Adolescence is a critical period for youths with chronic
      conditions, when they are supposed to take over the responsibility for their
      health. Type 1 diabetes (T1D) is one of the most common chronic conditions in
      childhood and inadequate self-management increases the risk of short-term and
      long-term complications. There is a lack of evidence regarding the effectiveness 
      of transition programmes. As a part of the Swedish Transition Effects Project
      Supporting Teenagers with chrONic mEdical conditionS research programme, the
      objective of this study is to evaluate the effectiveness and experiences of
      different transitional care models, including a person-centred transition
      programme aiming to empower adolescents with T1D to become active partners in
      their health and care. METHODS AND ANALYSIS: In this randomised controlled trial,
      patients are recruited from two paediatric diabetes clinics at the age of 16
      years. Patients are randomly assigned to either the intervention group (n=70)
      where they will receive usual care plus the structured transition programme, or
      to the control group (n=70) where they will only receive usual care. Data will be
      collected at 16, 17 and 18.5 years of age. In a later stage, the intervention
      group will be compared with adolescents in a dedicated youth clinic in a third
      setting. The primary outcome is patient empowerment. Secondary outcomes include
      generic, diabetes-specific and transfer-specific variables. ETHICS AND
      DISSEMINATION: The study has been approved by the Ethical Review Board in
      Stockholm (Dnr 2018/1725-31). Findings will be reported following the
      Consolidated Standards of Reporting Trials statement and disseminated in
      peer-reviewed journals and at international conferences. TRIAL REGISTRATION
      NUMBER: NCT03994536.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Brorsson, Anna Lena
AU  - Brorsson AL
AUID- ORCID: 0000-0002-8136-6340
AD  - Department of Neurobiology, Care Sciences and Society, Karolinska Institutet,
      Stockholm, Sweden anna-lena.brorsson@ki.se.
AD  - Gothenburg Centre for Person-Centred Care (GPCC), University of Gothenburg,
      Gothenburg, Sweden.
FAU - Bratt, Ewa-Lena
AU  - Bratt EL
AD  - Institute of Health and Care Sciences, University of Gothenburg, Gothenburg,
      Sweden.
AD  - Department of Pediatric Cardiology, The Queen Silvia Children's Hospital,
      Gothenburg, Sweden.
FAU - Moons, Philip
AU  - Moons P
AD  - Institute of Health and Care Sciences, University of Gothenburg, Gothenburg,
      Sweden.
AD  - Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
FAU - Ek, Anna
AU  - Ek A
AD  - Division of Pediatrics, Department of Clinical Science, Intervention and
      Technology, Karolinska Institutet, Stockholm, Sweden.
AD  - Department of Paediatric Diabetes, Astrid Lindgren's Children's Hospital,
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Jelleryd, Elisabeth
AU  - Jelleryd E
AD  - Department of Paediatric Diabetes, Astrid Lindgren's Children's Hospital,
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Torbjornsdotter, Torun
AU  - Torbjornsdotter T
AD  - Department of Paediatric Diabetes, Astrid Lindgren's Children's Hospital,
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Sparud-Lundin, Carina
AU  - Sparud-Lundin C
AD  - Gothenburg Centre for Person-Centred Care (GPCC), University of Gothenburg,
      Gothenburg, Sweden.
AD  - Institute of Health and Care Sciences, University of Gothenburg, Gothenburg,
      Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03994536
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Chronic Disease
MH  - *Diabetes Mellitus, Type 1/therapy
MH  - Empowerment
MH  - Humans
MH  - *Patient Participation
MH  - *Patient-Centered Care
MH  - Randomized Controlled Trials as Topic
MH  - *Self-Management
MH  - Sweden
PMC - PMC7200039
OTO - NOTNLM
OT  - *diabetes & endocrinology
OT  - *medical education & training
OT  - *paediatrics
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036496 [pii]
AID - 10.1136/bmjopen-2019-036496 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e036496. doi: 10.1136/bmjopen-2019-036496.


PMID- 32295779
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - STEP.De study-a multicentre cluster-randomised effectiveness trial of exercise
      therapy for patients with depressive symptoms in healthcare services: study
      protocol.
PG  - e036287
LID - 10.1136/bmjopen-2019-036287 [doi]
AB  - INTRODUCTION: Although exercise therapy has widely been shown to be an
      efficacious treatment modality for depression, evidence for its effectiveness and
      cost efficiency is lacking. The Sport/Exercise Therapy for Depression study is a 
      multicentre cluster-randomised effectiveness trial that aims to compare the
      effectiveness and cost efficiency of exercise therapy and psychotherapy as
      antidepressant treatment. METHODS AND ANALYSIS: 480 patients (aged 18-65) with an
      International Classification of Diseases diagnosis associated with depressive
      symptoms are recruited. Up to 30 clusters (psychotherapists) are randomly
      assigned to allocate patients to either an exercise or a psychotherapy treatment 
      as usual in a 2:1 ratio. The primary outcome (depressive symptoms) and the
      secondary outcomes (work and social adjustment, quality of life) will be assessed
      at six measurement time points (t0: baseline, t1: 8 weeks after treatment
      initiation, t2: 16 weeks after treatment initiation, t3/4/5: 2, 6, 12 months
      after treatment). Linear regression analyses will be used for the primary
      endpoint data analysis. For the secondary endpoints, mixed linear and logistic
      regression models with fixed and random factors will be added. For the cost
      efficiency analysis, expenditures in the 12 months before and after the
      intervention and the outcome difference will be compared between groups in a
      multilevel model. Recruitment start date was 1 July 2018 and the planned
      recruitment end date is 31 December 2020. ETHICS AND DISSEMINATION: The study
      protocol was approved by the ethics committee of the University of Potsdam (No.
      17/2018) and the Freie Universitat Berlin (No. 206/2018) and registered in the
      ISRCTN registry. Informed written consent will be obtained from all participants.
      The study will be reported in accordance with the Consolidated Standards of
      Reporting Trials and the Recommendations for Interventional Trials statements.
      The results will be published in peer-reviewed academic journals and disseminated
      to the public. TRIAL REGISTRATION NUMBER: ISRCTN28972230.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Heissel, Andreas
AU  - Heissel A
AUID- ORCID: 0000-0001-9270-7027
AD  - Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of 
      Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany
      andreas.heissel@uni-potsdam.de.
FAU - Pietrek, Anou
AU  - Pietrek A
AD  - Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of 
      Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.
FAU - Schwefel, Melanie
AU  - Schwefel M
AD  - Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of 
      Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.
FAU - Abula, Kahar
AU  - Abula K
AD  - Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of 
      Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.
FAU - Wilbertz, Gregor
AU  - Wilbertz G
AD  - Department of Education and Psychology, Freie Universitat Berlin, Berlin,
      Germany.
FAU - Heinzel, Stephan
AU  - Heinzel S
AD  - Department of Education and Psychology, Freie Universitat Berlin, Berlin,
      Germany.
FAU - Rapp, Michael
AU  - Rapp M
AD  - Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of 
      Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.
LA  - eng
SI  - ISRCTN/ISRCTN28972230
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Berlin
MH  - *Depression/therapy
MH  - *Exercise Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Psychotherapy
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Social Adjustment
MH  - Young Adult
PMC - PMC7200038
OTO - NOTNLM
OT  - *depression & mood disorders
OT  - *health economics
OT  - *mental health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036287 [pii]
AID - 10.1136/bmjopen-2019-036287 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e036287. doi: 10.1136/bmjopen-2019-036287.


PMID- 32295778
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Live birth after in vitro maturation versus standard in vitro fertilisation for
      women with polycystic ovary syndrome: protocol for a non-inferiority randomised
      clinical trial.
PG  - e035334
LID - 10.1136/bmjopen-2019-035334 [doi]
AB  - INTRODUCTION: Polycystic ovary syndrome (PCOS) is the first common cause of
      anovulatory infertility. Currently, in vitro fertilisation (IVF) is recommended
      when conventional attempts have failed. In vitro maturation (IVM) of human
      oocytes is an emerging treatment option in infertile women with PCOS. It is a
      patient-friendly intervention, avoiding the risk of ovarian hyperstimulation
      syndrome, which is a serious complication of controlled ovarian stimulation in
      the standard IVF procedure. We plan a randomised controlled trial (RCT) to
      evaluate whether IVM is non-inferior to the standard IVF for live birth in women 
      with PCOS. METHODS AND ANALYSIS: This is a single-centre, open-label,
      non-inferiority RCT performed in a large reproductive medicine centre in China.
      Infertile women with PCOS will be randomised to receive either IVM or standard
      IVF in a 1:1 treatment ratio after informed consent. IVF procedures used in our
      study are all standard treatments and other standard-assisted reproductive
      technologies will be similar between the two groups. The primary outcome is
      ongoing pregnancy leading to live birth within 6 months of the first oocyte
      retrieval cycle after randomisation. Pregnancy outcome, maternal safety and
      obstetric and perinatal complications will be secondary outcomes. The planned
      sample size is 350 (175 per group). ETHICS AND DISSEMINATION: Ethical permission 
      was acquired from the Ethics Committee of Peking University Third Hospital. The
      results will be issued to publications through scientific journals and conference
      reports. TRIAL REGISTRATION NUMBER: NCT03463772.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zheng, Xiaoying
AU  - Zheng X
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Guo, Wei
AU  - Guo W
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Zeng, Lin
AU  - Zeng L
AUID- ORCID: 0000-0001-8707-5854
AD  - Research Center of Clinical Epidemiology, Peking University Third Hospital,
      Beijing, China.
FAU - Zheng, Danni
AU  - Zheng D
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Yang, Shuo
AU  - Yang S
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Wang, Lina
AU  - Wang L
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Wang, Rui
AU  - Wang R
AUID- ORCID: 0000-0002-6622-8134
AD  - OB/GYN, School of Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Mol, Ben W
AU  - Mol BW
AD  - OB/GYN, School of Medicine, Monash University, Melbourne, Victoria, Australia.
FAU - Li, Rong
AU  - Li R
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China.
FAU - Qiao, Jie
AU  - Qiao J
AUID- ORCID: 0000-0003-2126-1376
AD  - Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China Jie.qiao@263.net.
LA  - eng
SI  - ClinicalTrials.gov/NCT03463772
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - China
MH  - *Equivalence Trials as Topic
MH  - Female
MH  - Fertilization in Vitro/*methods
MH  - Humans
MH  - In Vitro Oocyte Maturation Techniques/*methods
MH  - Infertility, Female/etiology/*therapy
MH  - *Live Birth
MH  - Polycystic Ovary Syndrome/*complications
PMC - PMC7200037
OTO - NOTNLM
OT  - *gynaecology
OT  - *reproductive medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035334 [pii]
AID - 10.1136/bmjopen-2019-035334 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e035334. doi: 10.1136/bmjopen-2019-035334.


PMID- 32295777
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Strategies aimed at preventing chronic opioid use in trauma and acute care
      surgery: a scoping review protocol.
PG  - e035268
LID - 10.1136/bmjopen-2019-035268 [doi]
AB  - INTRODUCTION: Globally every year, millions of patients sustain traumatic
      injuries and require acute care surgeries. A high incidence of chronic opioid use
      (up to 58%) has been documented in these populations with significant negative
      individual and societal impacts. Despite the importance of this public health
      issue, optimal strategies to limit the chronic use of opioids after trauma and
      acute care surgery are not clear. We aim to identify existing strategies to
      prevent chronic opioid use in these populations. METHODS AND ANALYSIS: We will
      perform a scoping review of peer-reviewed and non-peer-reviewed literature to
      identify studies, reviews, recommendations and guidelines on strategies aimed at 
      preventing chronic opioid use in patients after trauma and acute care surgery. We
      will search MEDLINE, EMBASE, PsycINFO, CINHAL, Cochrane Central Register of
      Controlled Trials, Web of Science, ProQuest and websites of trauma and acute care
      surgery, pain, government and professional organisations. Databases will be
      searched for papers published from 1 January 2005 to a maximum of 6 months before
      submission of the final manuscript. Two reviewers will independently evaluate
      studies for eligibility and extract data from included studies using a
      standardised data abstraction form. Preventive strategies will be classified
      according to their types and targeted trauma populations and acute care surgery
      procedures. ETHICS AND DISSEMINATION: Research ethics approval is not required as
      this study is based on the secondary use of published data. This work will inform
      research and clinical stakeholders on the required next steps towards the uptake 
      of effective strategies aimed at preventing chronic opioid use in trauma and
      acute care surgery patients.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Berube, Melanie
AU  - Berube M
AUID- ORCID: 0000-0002-6657-3915
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec - Universite Laval
      (Hopital de l'Enfant-Jesus), Quebec, Quebec, Canada melanie.berube@fsi.ulaval.ca.
AD  - Faculty of Nursing, Universite Laval, Quebec, Quebec, Canada.
FAU - Moore, Lynne
AU  - Moore L
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec - Universite Laval
      (Hopital de l'Enfant-Jesus), Quebec, Quebec, Canada.
AD  - Department of Social and Preventative Medicine, Universite Laval, Quebec, Quebec,
      Canada.
FAU - Lauzier, Francois
AU  - Lauzier F
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec - Universite Laval
      (Hopital de l'Enfant-Jesus), Quebec, Quebec, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Universite Laval,
      Quebec, Quebec, Canada.
FAU - Cote, Caroline
AU  - Cote C
AD  - Faculty of Nursing, Universite Laval, Quebec, Quebec, Canada.
FAU - Vogt, Kelly
AU  - Vogt K
AD  - Department of Surgery, London Health Sciences Centre (Victoria Hospital), London,
      Ontario, Canada.
FAU - Tremblay, Lorraine
AU  - Tremblay L
AD  - Department of General Surgery, Sunnybrook Health Sciences Centre, Toronto,
      Ontario, Canada.
AD  - Departement of Surgery, University of Toronto, Toronto, Ontario, Canada.
FAU - Martel, Marc-Olivier
AU  - Martel MO
AD  - Faculty of Dentistry & Department of Anesthesia, McGill University, Montreal,
      Quebec, Canada.
FAU - Page, Gabrielle
AU  - Page G
AD  - Department of Anesthesiology and Pain Medicine, Universite de Montreal, Montreal,
      Quebec, Canada.
AD  - Research center of the Centre hospitalier de l'Universite de Montreal (CRCHUM),
      Universite de Montreal, Montreal, Quebec, Canada.
FAU - Tardif, Pier-Alexandre
AU  - Tardif PA
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec - Universite Laval
      (Hopital de l'Enfant-Jesus), Quebec, Quebec, Canada.
FAU - Pinard, Anne-Marie
AU  - Pinard AM
AD  - Department of Anesthesiology and Critical Care Medicine, Universite Laval,
      Quebec, Quebec, Canada.
FAU - Hameed, S Morad
AU  - Hameed SM
AD  - Department of Surgery, Vancouver Costal Health (Vancouver General Hospital),
      Vancouver, British Columbia, Canada.
FAU - Perreault, Kadija
AU  - Perreault K
AD  - Department of Social and Preventative Medicine, Universite Laval, Quebec, Quebec,
      Canada.
FAU - Sirois, Caroline
AU  - Sirois C
AD  - Department of Social and Preventative Medicine, Universite Laval, Quebec, Quebec,
      Canada.
FAU - Belanger, Carole
AU  - Belanger C
AD  - Faculty of Nursing, Universite Laval, Quebec, Quebec, Canada.
FAU - Turgeon, Alexis F
AU  - Turgeon AF
AUID- ORCID: 0000-0001-5675-8791
AD  - Population Health and Optimal Health Practices Research Unit, Trauma - Emergency 
      - Critical Care Medicine, Centre de Recherche du CHU de Quebec - Universite Laval
      (Hopital de l'Enfant-Jesus), Quebec, Quebec, Canada.
AD  - Department of Anesthesiology and Critical Care Medicine, Universite Laval,
      Quebec, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/*therapeutic use
MH  - Digestive System Diseases/*surgery
MH  - *Duration of Therapy
MH  - Emergencies
MH  - Humans
MH  - Opioid-Related Disorders/*prevention & control
MH  - Pain Management/*methods
MH  - Pain, Postoperative/*drug therapy
MH  - *Review Literature as Topic
MH  - Surgical Procedures, Operative
MH  - Wounds and Injuries/*surgery
PMC - PMC7200027
OTO - NOTNLM
OT  - *orthopaedic & trauma surgery
OT  - *pain management
OT  - *preventive medicine
OT  - *surgery
OT  - *trauma management
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035268 [pii]
AID - 10.1136/bmjopen-2019-035268 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e035268. doi: 10.1136/bmjopen-2019-035268.


PMID- 32295776
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210511
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Mobile technology intervention for weight loss in rural men: protocol for a pilot
      pragmatic randomised controlled trial.
PG  - e035089
LID - 10.1136/bmjopen-2019-035089 [doi]
AB  - INTRODUCTION: Men who are overweight or obese in the rural Midwestern USA are an 
      unrepresented, at-risk group exhibiting rising rates of cardiovascular disease,
      poor access to preventive care and poor lifestyle behaviours that contribute to
      sedentary lifestyle and unhealthy diet. Self-monitoring of eating and activity
      has demonstrated efficacy for weight loss. Use of mobile technologies for
      self-monitoring eating and activity may address rural men's access disparities to
      preventive health resources and support weight loss. Our pilot trial will assess 
      the feasibility and acceptability of two mobile applications for weight loss in
      rural men to inform a future, full-scale trial. METHODS AND ANALYSIS: A 6-month
      randomised controlled trial with contextual evaluation will randomise 80 men
      using a 1:1 ratio to either a Mobile Technology Plus (MT+) intervention or a
      basic Mobile Technology (MT) intervention in rural, midlife men (aged 40-69
      years). The MT+ intervention consists of a smartphone self-monitoring application
      enhanced with discussion group (Lose-It premium), short message service
      text-based support and Wi-Fi scale. The MT group will receive only a
      self-monitoring application (Lose-It basic). Feasibility and acceptability will
      be evaluated using number of men recruited and retained, and evaluative focus
      group feedback. We seek to determine point estimates and variability of outcome
      measures of weight loss (kg and % body weight) and improved dietary and physical 
      activity behaviours (Behavioral Risk Factor Surveillance System (BRFSS) physical 
      activity and fruit and vegetable consumption surveys, data from Lose-It!
      application (kcal/day, steps/day)). Community capacity will be assessed using
      standard best practice methods. Descriptive content analysis will evaluate
      intervention acceptability and contextual sensitivity. ETHICS AND DISSEMINATION: 
      This protocol was approved by the University of Nebraska Medical Center
      Institutional Review Board (IRB# 594-17-EP). Dissemination of findings will occur
      through ClinicalTrials.gov and publish pilot data to inform the design of a
      larger clinical trial. TRIAL REGISTRATION NUMBER: NCT03329079; preresults.
      Protocol V.10, study completion date 31 August 2020. Roles and responsibilities
      funder: NIH/NINR Health Disparities Section 1R15NR017522-01.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Eisenhauer, Christine M
AU  - Eisenhauer CM
AUID- ORCID: 0000-0002-8591-7162
AD  - College of Nursing- Northern Division, University of Nebraska Medical Center,
      Norfolk, Nebraska, USA ceisenhauer@unmc.edu.
FAU - Brito, Fabiana Almeida
AU  - Brito FA
AD  - College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska,
      USA.
FAU - Yoder, Aaron M
AU  - Yoder AM
AD  - College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska,
      USA.
FAU - Kupzyk, Kevin A
AU  - Kupzyk KA
AD  - College of Nursing, University of Nebraska Medical Center, Omaha, Nebraska, USA.
FAU - Pullen, Carol H
AU  - Pullen CH
AD  - College of Nursing, University of Nebraska Medical Center, Omaha, Nebraska, USA.
FAU - Salinas, Katherine E
AU  - Salinas KE
AD  - College of Nursing, University of Nebraska Medical Center, Omaha, Nebraska, USA.
FAU - Miller, Jessica
AU  - Miller J
AD  - College of Nursing- Northern Division, University of Nebraska Medical Center,
      Norfolk, Nebraska, USA.
FAU - Hageman, Patricia A
AU  - Hageman PA
AD  - College of Allied Health, University of Nebraska Medical Center, Omaha, Nebraska,
      USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT03329079
GR  - U54 OH010162/OH/NIOSH CDC HHS/United States
GR  - R15 NR017522/NR/NINR NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Overweight
MH  - Pilot Projects
MH  - Randomized Controlled Trials as Topic
MH  - Technology
MH  - *Weight Loss
PMC - PMC7200044
OTO - NOTNLM
OT  - *preventive medicine
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035089 [pii]
AID - 10.1136/bmjopen-2019-035089 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e035089. doi: 10.1136/bmjopen-2019-035089.


PMID- 32295775
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Collaborating with healthcare providers to understand their perspectives on a
      hospital-to-home warning signs intervention for rural transitional care: protocol
      of a multimethod descriptive study.
PG  - e034698
LID - 10.1136/bmjopen-2019-034698 [doi]
AB  - INTRODUCTION: This study builds on our prior research, which identified that
      older rural patients and families (1) view preparation for detecting and
      responding to worsening health conditions as their most pressing unmet
      transitional care (TC) need and (2) perceive an evidence-based intervention,
      preparing them to detect and respond to warning signs of worsening health
      conditions, as highly likely to meet this need. Yet, what healthcare providers
      need to implement a warning signs intervention in rural TC is unclear. The
      objectives of this study are (1) to examine healthcare providers' perspectives on
      the acceptability of a warning signs intervention and (2) to identify barriers
      and facilitators to healthcare providers' provision of the intervention in rural 
      communities. METHODS AND ANALYSIS: This multimethod descriptive study uses a
      community-based, participatory research approach. We will examine healthcare
      providers' perspectives on a warning signs intervention. A purposive,
      criterion-based sample of healthcare providers stratified by professional
      designation (three strata: nurses, physicians and allied healthcare
      professionals) in two regions (Southwestern and Northeastern Ontario, Canada)
      will (1) rate the acceptability of the intervention and (2) participate in small 
      (n=4-6 healthcare providers), semistructured telephone focus group discussions on
      barriers and facilitators to delivering the intervention in rural communities.
      Two to three focus groups per stratum will be held in each region for a total of 
      12-18 focus groups. Data will be analysed using conventional qualitative content 
      analysis and descriptive statistics. ETHICS AND DISSEMINATION: Ethics approval
      was obtained from the Office of Research Ethics at York University and the Health
      Sciences North Research Ethics Board. Findings will be communicated through plain
      language summary and policy briefs, press releases, manuscripts and conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fox, Mary T
AU  - Fox MT
AUID- ORCID: 0000-0003-0572-3892
AD  - School of Nursing, York University, Toronto, Ontario, Canada maryfox@yorku.ca.
FAU - Butler, Jeffrey I
AU  - Butler JI
AUID- ORCID: 0000-0003-2765-7208
AD  - School of Nursing, York University, Toronto, Ontario, Canada.
FAU - Sidani, Souraya
AU  - Sidani S
AUID- ORCID: 0000-0002-9115-2389
AD  - Daphne Cockwell School of Nursing, Ryerson University, Toronto, Ontario, Canada.
FAU - Durocher, Evelyne
AU  - Durocher E
AUID- ORCID: 0000-0002-2122-3997
AD  - School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.
FAU - Nowrouzi-Kia, Behdin
AU  - Nowrouzi-Kia B
AUID- ORCID: 0000-0002-5586-4282
AD  - Occupational Science and Occupational Therapy, University of Toronto, Toronto,
      Ontario, Canada.
FAU - Yamada, Janet
AU  - Yamada J
AD  - Daphne Cockwell School of Nursing, Ryerson University, Toronto, Ontario, Canada.
FAU - Dahlke, Sherry
AU  - Dahlke S
AUID- ORCID: 0000-0001-6599-3101
AD  - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
FAU - Skinner, Mark W
AU  - Skinner MW
AUID- ORCID: 0000-0001-7148-6827
AD  - Trent School of the Environment, Trent University, Peterborough, Ontario, Canada.
LA  - eng
GR  - 163072/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Health Personnel
MH  - Hospitals
MH  - Humans
MH  - Ontario
MH  - Qualitative Research
MH  - *Rural Population
MH  - *Transitional Care
PMC - PMC7200029
OTO - NOTNLM
OT  - *protocols & guidelines
OT  - *qualitative research
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034698 [pii]
AID - 10.1136/bmjopen-2019-034698 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e034698. doi: 10.1136/bmjopen-2019-034698.


PMID- 32295774
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Evaluating the Alimentary and Respiratory Tracts in Health and disease (EARTH)
      research programme: a protocol for prospective, longitudinal, controlled,
      observational studies in children with chronic disease at an Australian tertiary 
      paediatric hospital.
PG  - e033916
LID - 10.1136/bmjopen-2019-033916 [doi]
AB  - INTRODUCTION: Chronic gastrointestinal and respiratory conditions of childhood
      can have long-lasting physical, psychosocial and economic effects on children and
      their families. Alterations in diet and intestinal and respiratory microbiomes
      may have important implications for physical and psychosocial health. Diet
      influences the intestinal microbiome and should be considered when exploring
      disease-specific alterations. The concepts of gut-brain and gut-lung axes provide
      novel perspectives for examining chronic childhood disease(s). We established the
      'Evaluating the Alimentary and Respiratory Tracts in Health and disease' (EARTH) 
      research programme to provide a structured, holistic evaluation of children with 
      chronic gastrointestinal and/or respiratory conditions. METHODS AND ANALYSIS: The
      EARTH programme provides a framework for a series of prospective, longitudinal,
      controlled, observational studies (comprised of individual substudies), conducted
      at an Australian tertiary paediatric hospital (the methodology is applicable to
      other settings). Children with a chronic gastrointestinal and/or respiratory
      condition will be compared with age and gender matched healthy controls (HC)
      across a 12-month period. The following will be collected at baseline, 6 and 12
      months: (i) stool, (ii) oropharyngeal swab/sputum, (iii) semi-quantitative food
      frequency questionnaire, (iv) details of disease symptomatology, (v)
      health-related quality of life and (vi) psychosocial factors. Data on the
      intestinal and respiratory microbiomes and diet will be compared between children
      with a condition and HC. Correlations between dietary intake (energy,
      macro-nutrients and micro-nutrients), intestinal and respiratory microbiomes
      within each group will be explored. Data on disease symptomatology, quality of
      life and psychosocial factors will be compared between condition and HC
      cohorts.Results will be hypothesis-generating and direct future focussed studies.
      There is future potential for direct translation into clinical care, as diet is a
      highly modifiable factor. ETHICS AND DISSEMINATION: Ethics approval: Sydney
      Children's Hospitals Network Human Research Ethics Committee (HREC/18/SCHN/26).
      Results will be presented at international conferences and published in
      peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04071314.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Coffey, Michael J
AU  - Coffey MJ
AUID- ORCID: 0000-0002-5543-9438
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
FAU - McKay, Isabelle R
AU  - McKay IR
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
FAU - Doumit, Michael
AU  - Doumit M
AD  - Department of Physiotherapy, Sydney Children's Hospital Randwick, Sydney, New
      South Wales, Australia.
FAU - Chuang, Sandra
AU  - Chuang S
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
AD  - Department of Respiratory, Sydney Children's Hospital Randwick, Sydney, New South
      Wales, Australia.
FAU - Adams, Susan
AU  - Adams S
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
AD  - Department of Surgery, Sydney Children's Hospital Randwick & Neuroscience
      Research Australia (NeuRA), Sydney, New South Wales, Australia.
FAU - Stelzer-Braid, Sacha
AU  - Stelzer-Braid S
AD  - School of Medical Sciences, University of New South Wales, Sydney, New South
      Wales, Australia.
AD  - Virology Research Laboratory, Prince of Wales Hospital, Sydney, New South Wales, 
      Australia.
FAU - Waters, Shafagh A
AU  - Waters SA
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
AD  - Molecular and Integrative Cystic Fibrosis (miCF) Research Centre(R), Sydney, New 
      South Wales, Australia.
FAU - Kasparian, Nadine A
AU  - Kasparian NA
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
AD  - Cincinnati Children's Center for Heart Disease and the Developing Mind, Heart
      Institute and the Division of Behavioral Medicine and Clinical Psychology,
      Cincinnati Children's Hospital Medical Center & Department of Pediatrics,
      University of Cincinnati, Cincinnati, Ohio, USA.
FAU - Thomas, Torsten
AU  - Thomas T
AD  - Centre for Marine Science and Innovation, School of Biological, Earth and
      Environmental Sciences, University of New South Wales, Sydney, New South Wales,
      Australia.
FAU - Jaffe, Adam
AU  - Jaffe A
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia.
AD  - Molecular and Integrative Cystic Fibrosis (miCF) Research Centre & Department of 
      Respiratory, Sydney Children's Hospital Randwick, Randwick, New South Wales,
      Australia.
FAU - Katz, Tamarah
AU  - Katz T
AD  - Department of Nutrition and Dietetics, Sydney Children's Hospital Randwick,
      Sydney, New South Wales, Australia.
FAU - Ooi, Chee Y
AU  - Ooi CY
AD  - Discipline of Paediatrics, School of Women's and Children's Health, Faculty of
      Medicine, University of New South Wales, Sydney, New South Wales, Australia
      keith.ooi@unsw.edu.au.
AD  - Molecular and Integrative Cystic Fibrosis (miCF) Research Centre & Department of 
      Respiratory, Sydney Children's Hospital Randwick, Randwick, New South Wales,
      Australia.
LA  - eng
SI  - ClinicalTrials.gov/NCT04071314
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Chronic Disease
MH  - Cystic Fibrosis/complications/*microbiology
MH  - Diet Records
MH  - Feces/microbiology
MH  - Gastrointestinal Microbiome
MH  - Gastrointestinal Tract/microbiology
MH  - Hirschsprung Disease/complications/*microbiology
MH  - Hospitals, Pediatric
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Longitudinal Studies
MH  - *Microbiota
MH  - New South Wales
MH  - Oropharynx/microbiology
MH  - Outcome Assessment, Health Care
MH  - Prospective Studies
MH  - Quality of Life
MH  - Respiratory System/microbiology
MH  - Sex Factors
MH  - Sleep Apnea, Obstructive/complications/*microbiology
MH  - Sputum/microbiology
MH  - Symptom Assessment
MH  - Tertiary Care Centers
MH  - Virome
PMC - PMC7200033
OTO - NOTNLM
OT  - *gastroenterology
OT  - *nutrition & dietetics
OT  - *paediatrics
OT  - *respiratory medicine (see Thoracic Medicine)
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033916 [pii]
AID - 10.1136/bmjopen-2019-033916 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e033916. doi: 10.1136/bmjopen-2019-033916.


PMID- 32295773
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Family-based habit intervention to promote parent support for child physical
      activity in Canada: protocol for a randomised trial.
PG  - e033732
LID - 10.1136/bmjopen-2019-033732 [doi]
AB  - INTRODUCTION: Regular physical activity (PA) participation has many important
      physical and psychological health benefits, managing and preventing over 25
      chronic conditions. Being more physically active as a child is associated with
      being more active as an adult, but less than 10% of Canadian children are
      achieving the recommended PA guidelines of 60 minutes per day of moderate to
      vigorous PA. Parental support is a predictor of child PA, but parent intention to
      support child PA does not always predict enacted support. Targeting factors that 
      assist in the sustainability of parent support behaviour of child PA may have an 
      impact on child PA. The purpose of this study is to evaluate an intervention
      designed to promote habit formation of parental support (HABIT, independent
      variable) on child PA (dependant variable) compared with a planning and education
      group (PLANNING) and an education only group (EDUCATION). METHODS AND ANALYSIS:
      The three conditions will be compared using a 6-month longitudinal randomised
      trial. Eligible families have at least one child aged 6-12 years who is not
      meeting the 2011 Canadian PA Guidelines. Intervention materials are delivered at 
      baseline, with check-in sessions at 6 weeks and 3 months. Child's
      moderate-to-vigorous PA, measured by accelerometry, is assessed at baseline, 6
      weeks, 3 months and 6 months as the primary outcome. At baseline and 6 months,
      children perform fitness testing. Parents and children complete questionnaires at
      all timepoints. So far, 123 families have been recruited from the Greater
      Victoria and surrounding area. Recruitment will be continuing through 2020 with a
      target of 240 families. ETHICS AND DISSEMINATION: This protocol has been approved
      by the University of Victoria Human Research Ethics Board (Victoria, Canada).
      Results will be shared at conferences as presentations and as published
      manuscripts. Study findings will be made available to interested participants.
      TRIAL REGISTRATION NUMBER: NCT03145688; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Medd, Emily R
AU  - Medd ER
AUID- ORCID: 0000-0002-9270-9310
AD  - Behavioural Medicine Laboratory, School of Exercise Science, Physical and Health 
      Education, Faculty of Education, University of Victoria, Victoria, British
      Columbia, Canada ermedd@uvic.ca.
FAU - Beauchamp, Mark R
AU  - Beauchamp MR
AUID- ORCID: 0000-0001-8909-3896
AD  - School of Kinesiology, Faculty of Education, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Blanchard, Chris M
AU  - Blanchard CM
AUID- ORCID: 0000-0002-7780-6956
AD  - School of Health and Human Performance, Faculty of Health, Dalhousie University, 
      Halifax, Nova Scotia, Canada.
FAU - Carson, Valerie
AU  - Carson V
AUID- ORCID: 0000-0002-3009-3282
AD  - Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton,
      Alberta, Canada.
FAU - Gardner, Benjamin
AU  - Gardner B
AUID- ORCID: 0000-0003-1223-5934
AD  - Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience,
      King's College London, London, United Kingdom.
FAU - Warburton, Darren Er
AU  - Warburton DE
AUID- ORCID: 0000-0002-2842-9170
AD  - School of Kinesiology, Faculty of Education, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Rhodes, Ryan E
AU  - Rhodes RE
AUID- ORCID: 0000-0003-0940-9040
AD  - Behavioural Medicine Laboratory, School of Exercise Science, Physical and Health 
      Education, Faculty of Education, University of Victoria, Victoria, British
      Columbia, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03145688
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Canada
MH  - Child
MH  - Exercise/*psychology
MH  - *Family
MH  - Guideline Adherence/statistics & numerical data
MH  - *Habits
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - Parents/*psychology
MH  - Single-Blind Method
MH  - Time Factors
PMC - PMC7200035
OTO - NOTNLM
OT  - *preventive medicine
OT  - *public health
OT  - *sports medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033732 [pii]
AID - 10.1136/bmjopen-2019-033732 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e033732. doi: 10.1136/bmjopen-2019-033732.


PMID- 32295772
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 14
TI  - Applications of qualitative grounded theory methodology to investigate hearing
      loss: protocol for a qualitative systematic review.
PG  - e033537
LID - 10.1136/bmjopen-2019-033537 [doi]
AB  - INTRODUCTION: Hearing loss is a chronic condition affecting 12 million
      individuals in the UK. People with hearing loss regularly experience difficulties
      interacting in everyday conversations. These difficulties in communication can
      result in a person with hearing loss withdrawing from social situations and
      becoming isolated. While hearing loss research has largely deployed quantitative 
      methods to investigate various aspects of the condition, qualitative research is 
      becoming more widespread. Grounded theory is a specific qualitative methodology
      that has been used to establish novel theories on the experiences of living with 
      hearing loss. METHOD AND ANALYSIS: The aim of this systematic review is to
      establish how grounded theory has been applied to investigate the psychosocial
      aspects of hearing loss. Methods are reported according to the Preferred
      Reporting Items for Systematic Reviews and Meta-Analysis Protocols 2015
      checklist. Studies included in this review will have applied grounded theory as
      an overarching methodology or have grounded theory embedded among other
      methodologies. Studies included will have adult participants (>/=18 years) who
      are either people with an acquired hearing loss, their family and friends
      (communication partners), or healthcare practitioners including audiologists,
      general practitioners, ear, nose and throat specialists and hearing therapists.
      The quality of application of grounded theory in each study will be assessed
      using the Guideline for Reporting and Evaluating Grounded Theory Research
      Studies. ETHICS AND DISSEMINATION: As only secondary data will be used in this
      systematic review, ethical approval is not required. No other ethical issues are 
      foreseen. This review is registered with the International Prospective Register
      of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO). Findings will be
      disseminated via peer-reviewed publications and at relevant academic conferences.
      Findings may also be published in relevant professional and third sector
      newsletters and magazines as appropriate. Data will inform future research and
      guideline development. PROSPERO REGISTRATION NUMBER: CRD42019134197.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ali, Yasmin H K
AU  - Ali YHK
AUID- ORCID: 0000-0002-0228-6562
AD  - Hearing Sciences, National Institute of Health Research Nottingham Biomedical
      Research Centre, Nottingham, Nottinghamshire, UK yasmin.ali@nottingham.ac.uk.
AD  - School of Medicine, Clinical Neuroscience, Hearing Sciences, University of
      Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Wright, Nicola
AU  - Wright N
AD  - School of Health Sciences, Queen's Medical Centre, University of Nottingham,
      Nottingham, Nottinghamshire, UK.
FAU - Charnock, David
AU  - Charnock D
AD  - School of Health Sciences, Queen's Medical Centre, University of Nottingham,
      Nottingham, Nottinghamshire, UK.
FAU - Henshaw, Helen
AU  - Henshaw H
AUID- ORCID: 0000-0002-0547-4403
AD  - Hearing Sciences, National Institute of Health Research Nottingham Biomedical
      Research Centre, Nottingham, Nottinghamshire, UK.
AD  - School of Medicine, Clinical Neuroscience, Hearing Sciences, University of
      Nottingham, Nottingham, Nottinghamshire, UK.
FAU - Hoare, Derek
AU  - Hoare D
AUID- ORCID: 0000-0002-8768-1392
AD  - Hearing Sciences, National Institute of Health Research Nottingham Biomedical
      Research Centre, Nottingham, Nottinghamshire, UK.
AD  - School of Medicine, Clinical Neuroscience, Hearing Sciences, University of
      Nottingham, Nottingham, Nottinghamshire, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200414
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (BIA 10-2474)
RN  - 0 (Cyclic N-Oxides)
RN  - 0 (Pyridines)
SB  - IM
MH  - Adult
MH  - Checklist
MH  - Cyclic N-Oxides
MH  - Deafness
MH  - Family
MH  - Friends
MH  - *Grounded Theory
MH  - *Hearing Loss/classification/etiology/psychology
MH  - Humans
MH  - Pyridines
MH  - Qualitative Research
PMC - PMC7200034
OTO - NOTNLM
OT  - *grounded theory
OT  - *hearing loss
OT  - *qualitative research
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/04/17 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033537 [pii]
AID - 10.1136/bmjopen-2019-033537 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 14;10(4):e033537. doi: 10.1136/bmjopen-2019-033537.


PMID- 32295662
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210125
IS  - 1938-744X (Electronic)
IS  - 1935-7893 (Linking)
VI  - 14
IP  - 5
DP  - 2020 Oct
TI  - Allocation of Scarce Resources in a Pandemic: A Systematic Review of US State
      Crisis Standards of Care Documents.
PG  - 677-683
LID - 10.1017/dmp.2020.101 [doi]
AB  - The aim of this systematic review was to locate and analyze United States state
      crisis standards of care (CSC) documents to determine their prevalence and
      quality. Following PRISMA guidelines, Google search for "allocation of scarce
      resources" and "crisis standards of care (CSC)" for each state. We analyzed the
      plans based on the 2009 Institute of Medicine (IOM) report, which provided
      guidance for establishing CSC for use in disaster situations, as well as the 2014
      CHEST consensus statement's 11 core topic areas. The search yielded 42 state
      documents, and we excluded 11 that were not CSC plans. Of the 31 included plans, 
      13 plans were written for an "all hazards" approach, while 18 were pandemic
      influenza specific. Eighteen had strong ethical grounding. Twenty-one plans had
      integrated and ongoing community and provider engagement, education, and
      communication. Twenty-two had assurances regarding legal authority and
      environment. Sixteen plans had clear indicators, triggers, and lines of
      responsibility. Finally, 28 had evidence-based clinical processes and operations.
      Five plans contained all 5 IOM elements: Arizona, Colorado, Minnesota, Nevada,
      and Vermont. Colorado and Minnesota have all hazards documents and processes for 
      both adult and pediatric populations and could be considered exemplars for other 
      states.
FAU - Romney, Douglas
AU  - Romney D
AD  - OSU Wexner Medical Center Department of Emergency Medicine, Columbus, Ohio.
FAU - Fox, Hannah
AU  - Fox H
AD  - OSU Wexner Medical Center Department of Emergency Medicine, Columbus, Ohio.
FAU - Carlson, Stephanie
AU  - Carlson S
AD  - OSU Wexner Medical Center Department of Emergency Medicine, Columbus, Ohio.
FAU - Bachmann, Daniel
AU  - Bachmann D
AD  - OSU Wexner Medical Center Department of Emergency Medicine, Columbus, Ohio.
FAU - O'Mathuna, Donal
AU  - O'Mathuna D
AUID- ORCID: 0000-0001-5331-3340
AD  - OSU Wexner Medical Center Department of Emergency Medicine, Columbus, Ohio.
FAU - Kman, Nicholas
AU  - Kman N
AUID- ORCID: 0000-0002-4769-4658
AD  - OSU Wexner Medical Center Department of Emergency Medicine, Columbus, Ohio.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200416
PL  - United States
TA  - Disaster Med Public Health Prep
JT  - Disaster medicine and public health preparedness
JID - 101297401
SB  - IM
MH  - Disaster Planning/methods
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Resource Allocation/*methods/supply & distribution/trends
MH  - Standard of Care/ethics/standards
MH  - *State Government
MH  - United States
PMC - PMC7198465
OTO - NOTNLM
OT  - *allocation of resources
OT  - *coronavirus
OT  - *disaster planning
OT  - *pandemics
EDAT- 2020/04/17 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - S1935789320001019 [pii]
AID - 10.1017/dmp.2020.101 [doi]
PST - ppublish
SO  - Disaster Med Public Health Prep. 2020 Oct;14(5):677-683. doi:
      10.1017/dmp.2020.101. Epub 2020 Apr 16.


PMID- 32295607
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1747-5341 (Electronic)
IS  - 1747-5341 (Linking)
VI  - 15
IP  - 1
DP  - 2020 Apr 16
TI  - Normality in medicine: a critical review.
PG  - 3
LID - 10.1186/s13010-020-00087-2 [doi]
AB  - What is considered normal determines clinical practice in medicine and has
      implications at an individual level, doctor-patient relationship and health care 
      policies. With the increase in medical information and technical abilities it is 
      urgent to have a clear concept of normality in medicine so that crucial
      discussions can be held with unequivocal terms.The different meanings for
      normality were analyzed throughout the literature and grouped according to their 
      relevance in the academic community in models, namely the Biostatistical Theory
      (BST), Health, Ideal, Process and Biological advantage. The BST is the most
      established naturalistic approach, however normal variability can arguably
      constitute a problem. Health is similar and raises the question of setting the
      boundaries of pathology. Normality as an Ideal is an useful tool but is naturally
      unrealistic. As a Process it is comprehensible but is hard to frame for practical
      purposes. If considered as a Biological Advantage, seems intuitive but
      abnormality should tend to disappear.After, three examples were presented to
      discuss these models. They were Anemia, Psychiatric diseases and Psychopathy. In 
      the case of Anemia the BST was applied and the arbitrary boundaries but with
      social impact were exposed. Psychiatric diseases was discussed under the process 
      of self-organization and non-suffering ideal. With Psychopathy the boundaries of 
      biological advantage are questioned.This review appeals to the importance of
      redesigning of the concept of normality in medicine according to current times
      and stresses the importance of integrating concepts such as variability and
      autonomy.
FAU - Catita, Marisa
AU  - Catita M
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine,
      University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
AD  - ICBAS - Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto, 
      Porto, Portugal.
FAU - Aguas, Artur
AU  - Aguas A
AD  - ICBAS - Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto, 
      Porto, Portugal.
FAU - Morgado, Pedro
AU  - Morgado P
AD  - Life and Health Sciences Research Institute (ICVS), School of Medicine,
      University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
      pedromorgado@med.uminho.pt.
AD  - ICVS-3Bs PT Government Associate Laboratory, Braga/Guimaraes, Portugal.
      pedromorgado@med.uminho.pt.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200416
PL  - England
TA  - Philos Ethics Humanit Med
JT  - Philosophy, ethics, and humanities in medicine : PEHM
JID - 101258058
SB  - IM
MH  - Anemia
MH  - *Biostatistics
MH  - *Delivery of Health Care
MH  - Ethics, Medical
MH  - *Models, Statistical
MH  - Practice Patterns, Physicians'
MH  - Psychiatry
PMC - PMC7161186
OTO - NOTNLM
OT  - *Cultural medicine
OT  - *Medical ethics
OT  - *Normality
OT  - *Psychiatry
EDAT- 2020/04/17 06:00
MHDA- 2021/09/09 06:00
CRDT- 2020/04/17 06:00
PHST- 2019/12/12 00:00 [received]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.1186/s13010-020-00087-2 [doi]
AID - 10.1186/s13010-020-00087-2 [pii]
PST - epublish
SO  - Philos Ethics Humanit Med. 2020 Apr 16;15(1):3. doi: 10.1186/s13010-020-00087-2.


PMID- 32295604
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20220414
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 21
IP  - Suppl 1
DP  - 2020 Apr 16
TI  - Ethical issues in cluster randomized trials conducted in low- and middle-income
      countries: an analysis of two case studies.
PG  - 314
LID - 10.1186/s13063-020-04269-3 [doi]
AB  - BACKGROUND: Cluster randomized trials are common in health research in low- and
      middle-income countries raising issues that challenge interpretation of standard 
      ethical guidelines. While the Ottawa Statement on the ethical design and conduct 
      of cluster randomized trials provides guidance for researchers and research
      ethics committees, it does not explicitly focus on low- and middle-income
      settings. MAIN BODY: In this paper, we use the lens of the Ottawa Statement to
      analyze two cluster randomized trials conducted in low- and middle-income
      settings in order to identify gaps or ethical issues requiring further analysis
      and guidance. The PolyIran trial was a parallel-arm, cluster trial examining the 
      effectiveness of a polypill for prevention of cardiovascular disease in Golestan 
      province, Iran. The PASTAL trial was an adaptive, multistage, parallel-arm,
      cluster trial evaluating the effect of incentives for human immunodeficiency
      virus self-testing and follow-up on male partners of pregnant women in Malawi.
      Through an in-depth case analysis of these two studies we highlight several
      issues in need of further exploration. First, standards for verbal consent and
      waivers of consent require methods for operationalization if they are to be
      employed consistently. Second, the appropriate choice of a control arm remains
      contentious. Particularly in the case of implementation interventions, locally
      available care is required as the comparator to address questions of comparative 
      effectiveness. However, locally available care might be lower than standards set 
      out in national guidelines. Third, while the need for access to effective
      interventions post-trial is widely recognized, it is often not possible to
      guarantee this upfront. Clarity on what is required of researchers and sponsors
      is needed. Fourth, there is a pressing need for ethics education and capacity
      building regarding cluster randomized trials in these settings. CONCLUSION: We
      identify four issues in cluster randomized trials conducted in low- and
      middle-income countries for which further ethical analysis and guidance is
      required.
FAU - Choko, Augustine T
AU  - Choko AT
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Roshandel, Gholamreza
AU  - Roshandel G
AD  - Golestan Research Center of Gastroenterology and Hepatology, Golestan University 
      of Medical Sciences, Gorgan, Iran.
FAU - Conserve, Donaldson F
AU  - Conserve DF
AD  - Department of Health Promotion, Education and Behaviour, University of South
      Carolina, Columbia, USA.
FAU - Corbett, Elizabeth L
AU  - Corbett EL
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
AD  - Department of Clinical Research, London School of Hygiene and Tropical Medicine, 
      London, UK.
FAU - Fielding, Katherine
AU  - Fielding K
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
AD  - School of Public Health, University of the Witwatersrand, Johannesburg, South
      Africa.
FAU - Hemming, Karla
AU  - Hemming K
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Malekzadeh, Reza
AU  - Malekzadeh R
AD  - Digestive Disease Research Center, Digestive Diseases Research Institute, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Weijer, Charles
AU  - Weijer C
AD  - Rotman Institute of Philosophy, Western University, London, Canada.
      cweijer@uwo.ca.
LA  - eng
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
GR  - SRF-2017-10-002/DH_/Department of Health/United Kingdom
PT  - Journal Article
DEP - 20200416
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - Anti-HIV Agents/therapeutic use
MH  - Coronary Artery Disease/epidemiology/*prevention & control
MH  - *Developing Countries
MH  - Drug Combinations
MH  - *Ethics, Research
MH  - Female
MH  - HIV/*immunology
MH  - HIV Infections/*diagnosis/drug therapy/epidemiology
MH  - HIV Testing/methods
MH  - Humans
MH  - Informed Consent/ethics
MH  - Iran/epidemiology
MH  - Malawi/epidemiology
MH  - Male
MH  - Randomized Controlled Trials as Topic/*ethics
MH  - Treatment Outcome
PMC - PMC7161096
OTO - NOTNLM
OT  - Cluster randomized trial
OT  - Equipoise
OT  - Ethics
OT  - Informed consent
OT  - Low- and middle-income countries
OT  - Post-trial access
OT  - Research ethics
OT  - Research ethics committee
EDAT- 2020/04/17 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 10.1186/s13063-020-04269-3 [doi]
AID - 10.1186/s13063-020-04269-3 [pii]
PST - epublish
SO  - Trials. 2020 Apr 16;21(Suppl 1):314. doi: 10.1186/s13063-020-04269-3.


PMID- 32295426
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1754-9515 (Electronic)
IS  - 1754-9507 (Linking)
VI  - 22
IP  - 3
DP  - 2020 Jun
TI  - "Many wasted months": Stakeholders' perspectives about waiting for
      speech-language pathology services.
PG  - 313-326
LID - 10.1080/17549507.2020.1747541 [doi]
AB  - Purpose: High demand for speech-language pathology services is reflected in long 
      waiting lists. Waiting can be active or passive and has implications for
      stakeholders, including consumers, professionals, and organisations. The present 
      study explored experiences and perspectives regarding waiting for speech-language
      pathology services through analysis of stakeholders' written submissions to an
      Australian Government Senate Inquiry.Method: Written submissions (n = 337) were
      screened for terms related to waiting. Included submissions (n = 133) were
      written by organisations (36.8%), speech-language pathologists (29.3%), parents
      (27.8%), individuals with communication and/or swallowing difficulties (5.3%),
      and others.Result: Inductive thematic analysis identified three themes. (1)
      Duration. Consistently described as long. (2) Consequences. Consumers'
      consequences included: burden on physical health, finances, time, emotional
      wellbeing, and relationships, reduced continuity of care, and increased
      intervention needs. Professional consequences included: stress and burnout
      impacting job satisfaction, and reduced effectiveness. Societal consequences
      included: social and ethical burden, and a drain on health and legal systems. (3)
      Actions. Consumers advocated and sought alternatives (e.g. threats to harm their 
      child, relocation to a capital city), professionals implemented service delivery 
      and policy actions, and organisations lacked effective system-wide
      strategies.Conclusion: Existing services did not appear to meet stakeholders'
      needs. Action is needed to improve speech-language pathology waiting lists and
      access to services, and minimise possible consequences for stakeholders.
FAU - McGill, Nicole
AU  - McGill N
AUID- ORCID: 0000-0002-4150-6986
AD  - School of Teacher Education, Charles Sturt University, Bathurst, NSW, Australia.
FAU - Crowe, Kathryn
AU  - Crowe K
AUID- ORCID: 0000-0003-3496-5129
AD  - School of Teacher Education, Charles Sturt University, Bathurst, NSW, Australia.
AD  - School of Health Sciences, University of Iceland, Reykjavik, Iceland.
FAU - Mcleod, Sharynne
AU  - Mcleod S
AUID- ORCID: 0000-0002-7279-7851
AD  - School of Teacher Education, Charles Sturt University, Bathurst, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - England
TA  - Int J Speech Lang Pathol
JT  - International journal of speech-language pathology
JID - 101320232
SB  - IM
MH  - Australia
MH  - *Health Services Accessibility
MH  - Humans
MH  - *Speech-Language Pathology
MH  - *Waiting Lists
OTO - NOTNLM
OT  - *consumer
OT  - *government
OT  - *qualitative research
OT  - *retention
OT  - *service delivery
OT  - *speech-language pathology
OT  - *waiting list
OT  - *workforce issues
EDAT- 2020/04/17 06:00
MHDA- 2021/08/26 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2020/04/17 06:00 [entrez]
AID - 10.1080/17549507.2020.1747541 [doi]
PST - ppublish
SO  - Int J Speech Lang Pathol. 2020 Jun;22(3):313-326. doi:
      10.1080/17549507.2020.1747541. Epub 2020 Apr 15.


PMID- 32294825
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20200601
IS  - 0254-6450 (Print)
IS  - 0254-6450 (Linking)
VI  - 41
IP  - 3
DP  - 2020 Mar 10
TI  - [Experience and challenge on interoperability of big data in health care].
PG  - 303-309
LID - 10.3760/cma.j.issn.0254-6450.2020.03.005 [doi]
AB  - Problems in interoperability is the biggest barrier limiting the use of big data 
      in health care worldwide. Interoperability contains five dimensions: business,
      security, ethics, semantics and technology. Based on the comparison of the three 
      common interoperability models led by government, enterprise or research
      institution, and the current status of big data development in China, this paper 
      proposes a new operation model which can be led by university, aided by
      enterprise and supported by government, and summarizes the three major challenges
      in the development of big data interoperability in China: professional standard
      and specification, data security and ethics, incentive mechanism and assessment. 
      Only when a feasible model is adopted, technical difficulties are overcome and
      data are truly shared, we can achieve maximized integration of multi-source data,
      expanding its application fields and establish a multi-business mode to
      comprehensively improve the population based health decision-making and
      management.
FAU - Wang, S F
AU  - Wang SF
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University, Beijing 100191, China.
FAU - Ning, Y
AU  - Ning Y
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University, Beijing 100191, China.
FAU - Li, L M
AU  - Li LM
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking
      University, Beijing 100191, China.
LA  - chi
GR  - 91846303/National Natural Science Foundation of China
PT  - Journal Article
PL  - China
TA  - Zhonghua Liu Xing Bing Xue Za Zhi
JT  - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
JID - 8208604
SB  - IM
MH  - *Big Data
MH  - China
MH  - Delivery of Health Care/*organization & administration
MH  - Humans
OTO - NOTNLM
OT  - Big data in health care
OT  - Common data model
OT  - Distributed network
OT  - Interoperability
EDAT- 2020/04/17 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/17 06:00
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
AID - 10.3760/cma.j.issn.0254-6450.2020.03.005 [doi]
PST - ppublish
SO  - Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Mar 10;41(3):303-309. doi:
      10.3760/cma.j.issn.0254-6450.2020.03.005.


PMID- 32294810
OWN - NLM
STAT- Publisher
LR  - 20200728
IS  - 1441-2772 (Print)
IS  - 1441-2772 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Apr 15
TI  - ANZICS guiding principles for complex decision making during the COVID-19
      pandemic.
PG  - 98-102
AB  - The global 2019 coronavirus disease (COVID-19) pandemic has led to major
      challenges in clinical decision making when the demand for intensive care exceeds
      local capacity. In order to promote consistent, transparent, objective and
      ethical decision making, the Australian and New Zealand Intensive Care Society
      (ANZICS) formed a committee to urgently develop guidelines outlining key
      principles that should be utilised during the pandemic. This guidance is intended
      to support the practice of intensive care specialists during the COVID-19
      pandemic and to promote the development of local admission policies that should
      be endorsed by health care organisations and relevant local authorities.
FAU - Warrillow, Stephen
AU  - Warrillow S
AD  - Department of Intensive Care, Austin Health, Melbourne, VIC, Australia.
      Stephen.Warrillow@austin.org.au.
FAU - Austin, Danielle
AU  - Austin D
AD  - Intensive Care Unit, Liverpool Hospital, Sydney, NSW, Australia.
FAU - Cheung, Winston
AU  - Cheung W
AD  - Intensive Care Unit, Concord Repatriation General Hospital, Sydney, NSW,
      Australia.
FAU - Close, Eliana
AU  - Close E
AD  - Faculty of Law, Queensland University of Technology, Brisbane, QLD, Australia.
FAU - Holley, Anthony
AU  - Holley A
AD  - Department of Intensive Care, Royal Brisbane Hospital, Brisbane, QLD, Australia.
FAU - Horgan, Ben
AU  - Horgan B
AD  - Western Australian Health Translation Network, Perth, WA, Australia.
FAU - Jansen, Melanie
AU  - Jansen M
AD  - Department of Intensive Care, Children's Hospital at Westmead, Sydney, NSW,
      Australia.
FAU - Joynt, Gavin
AU  - Joynt G
AD  - Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Lister, Paula
AU  - Lister P
AD  - Department of Paediatric Critical Care, Sunshine Coast Hospital and Health
      Service, Sunshine Coast, QLD, Australia.
FAU - Moodie, Stewart
AU  - Moodie S
AD  - Department of Intensive Care, Royal Adelaide Hospital, Adelaide, SA, Australia.
FAU - Nichol, Alistair
AU  - Nichol A
AD  - Department of Intensive Care, Alfred Hospital, Melbourne, VIC, Australia.
FAU - Nicholls, Mark
AU  - Nicholls M
AD  - Department of Intensive Care, St Vincent's Hospital, Sydney, NSW, Australia.
FAU - Peake, Sandra
AU  - Peake S
AD  - Department of Intensive Care Medicine, Queen Elizabeth Hospital, Adelaide, SA,
      Australia.
FAU - Skowronski, George
AU  - Skowronski G
AD  - Department of Intensive Care Medicine, St George Hospital, Sydney, NSW,
      Australia.
FAU - Streat, Stephen
AU  - Streat S
AD  - Organ Donation New Zealand, Auckland, New Zealand.
FAU - White, Ben
AU  - White B
AD  - Faculty of Law, Queensland University of Technology, Brisbane, QLD, Australia.
FAU - Willmott, Lindy
AU  - Willmott L
AD  - Faculty of Law, Queensland University of Technology, Brisbane, QLD, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Australia
TA  - Crit Care Resusc
JT  - Critical care and resuscitation : journal of the Australasian Academy of Critical
      Care Medicine
JID - 100888170
SB  - IM
OTO - NOTNLM
OT  - *COVID-19
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
AID - Warrillow_2020/06_0107 [pii]
PST - aheadofprint
SO  - Crit Care Resusc. 2020 Apr 15;22(2):98-102.


PMID- 32294741
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20200616
IS  - 1678-4219 (Electronic)
IS  - 0004-2803 (Linking)
VI  - 57
IP  - 1
DP  - 2020 Jan-Mar
TI  - PLACEBO USE IN THE CONTEXT OF INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS.
PG  - 87-90
LID - S0004-28032020000100087 [pii]
LID - 10.1590/S0004-2803.202000000-15 [doi]
AB  - Inflammatory bowel disease comprises two distinct conditions - Crohn's disease
      and ulcerative colitis - which can be treated with immunomodulators. A
      non-neglectable proportion of these patients will need biologic therapy, and many
      patients under biologic treatment will experience either primary or secondary
      failure. As a consequence, clinical trials evaluating new therapeutic
      alternatives are being developed. These trials share common features, such as
      being controlled with placebo. Placebo use in clinical trials is a matter of
      intense debate. Those who support placebo use highlight the methodologic
      advantages placebo-controlled trials have. Those against placebo use argue that
      it would be against ethical principles in clinical research to expose a patient
      to placebo when a valid therapeutic alternative exists. In this review, we
      summarize the existing arguments for and against the use of placebo in the
      context of inflammatory bowel disease research. We finally suggest that it is
      very likely that in the near future inflammatory bowel disease trials will no
      longer be controlled with a placebo arm, but instead they will be non-inferiority
      trials with an active comparator.
FAU - Lasa, Juan Sebastian
AU  - Lasa JS
AUID- ORCID: http://orcid.org/0000-0002-8995-1659
AD  - Hospital Britanico de Buenos Aires, Gastroenterology Department, Argentina.
AD  - CEMIC, Gastroenterology Department, Buenos Aires, Argentina.
FAU - Zubiaurre, Ignacio
AU  - Zubiaurre I
AUID- ORCID: http://orcid.org/0000-0001-8334-9934
AD  - Hospital Britanico de Buenos Aires, Gastroenterology Department, Argentina.
FAU - Rausch, Astrid
AU  - Rausch A
AUID- ORCID: http://orcid.org/0000-0003-4969-7585
AD  - Hospital Britanico de Buenos Aires, Gastroenterology Department, Argentina.
FAU - Olivera, Pablo
AU  - Olivera P
AUID- ORCID: http://orcid.org/0000-0002-2740-6102
AD  - CEMIC, Gastroenterology Department, Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Brazil
TA  - Arq Gastroenterol
JT  - Arquivos de gastroenterologia
JID - 15310600R
RN  - 0 (Placebos)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Colitis, Ulcerative/*drug therapy
MH  - Crohn Disease/*drug therapy
MH  - Humans
MH  - Placebos
EDAT- 2020/04/16 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/08/21 00:00 [received]
PHST- 2019/10/22 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - S0004-28032020000100087 [pii]
AID - 10.1590/S0004-2803.202000000-15 [doi]
PST - ppublish
SO  - Arq Gastroenterol. 2020 Jan-Mar;57(1):87-90. doi:
      10.1590/S0004-2803.202000000-15.


PMID- 32294685
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 1983-1447 (Electronic)
IS  - 0102-6933 (Linking)
VI  - 41
IP  - spe
DP  - 2020
TI  - Spiritual care performed in a drug user clinic.
PG  - e20190121
LID - S1983-14472020000200413 [pii]
LID - 10.1590/1983-1447.2020.20190121 [doi]
AB  - OBJECTIVE: To know the spiritual care practices of health workers in the context 
      of an inpatient unit for the treatment of addictive disorders, aiming to
      incorporate an expanded care practice. METHOD: Qualitative study considering the 
      Convergent Care Research theoretical framework. The data collection occurred
      using semi-structured interviews, with three rounds of conversations and informal
      chats with 14 health professionals, from July to November 2017. The analysis
      followed the steps of apprehension, synthesis, theorization and transference.
      RESULTS: Four categories emerged: respect for user ethical values; addressing the
      beliefs and values of professionals; the health professional-user relationship;
      and collective spiritual care. The main actions highlighted were individual
      (relaxation and prayer) and collective (meditation, spirituality and the 12
      steps). CONCLUSION: The rounds of conversations carried out in this research
      allowed workers to talk about spiritual care in addiction, to better understand
      its relevance to meet the needs of the patient.
FAU - Oliveira, Charlise Pasuch de
AU  - Oliveira CP
AUID- ORCID: http://orcid.org/0000-0003-4191-6499
AD  - Hospital de Clinicas de Porto Alegre (HCPA), Servico de Enfermagem em Adicao.
      Porto Alegre, Rio Grande do Sul, Brasil.
FAU - Calixto, Alessandra Mendes
AU  - Calixto AM
AUID- ORCID: http://orcid.org/0000-0001-7620-178X
AD  - Hospital de Clinicas de Porto Alegre (HCPA), Servico de Enfermagem em Adicao.
      Porto Alegre, Rio Grande do Sul, Brasil.
FAU - Disconzi, Mitieli Vizcaychipi
AU  - Disconzi MV
AUID- ORCID: http://orcid.org/0000-0002-5875-0926
AD  - Hospital de Clinicas de Porto Alegre (HCPA), Servico de Enfermagem Ambulatorial. 
      Porto Alegre, Rio Grande do Sul, Brasil.
FAU - Pinho, Leandro Barbosa de
AU  - Pinho LB
AUID- ORCID: http://orcid.org/0000-0003-1434-3058
AD  - Universidade Federal do Rio Grande do Sul (UFRGS), Programa de Pos-Graduacao em
      Enfermagem, Porto Alegre, Rio Grande do Sul, Brasil.
FAU - Camatta, Marcio Wagner
AU  - Camatta MW
AUID- ORCID: http://orcid.org/0000-0002-4067-526X
AD  - Universidade Federal do Rio Grande do Sul (UFRGS), Programa de Pos-Graduacao em
      Enfermagem, Porto Alegre, Rio Grande do Sul, Brasil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20200409
PL  - Brazil
TA  - Rev Gaucha Enferm
JT  - Revista gaucha de enfermagem
JID - 8504882
MH  - Adult
MH  - Female
MH  - *Health Personnel/ethics/organization & administration/psychology
MH  - Humans
MH  - Male
MH  - Meditation
MH  - Middle Aged
MH  - Nursing Staff/psychology
MH  - Nutritionists/psychology
MH  - *Pastoral Care/ethics
MH  - Professional-Patient Relations
MH  - Psychology
MH  - Qualitative Research
MH  - Religion
MH  - Respect
MH  - *Spirituality
MH  - *Substance Abuse Treatment Centers
MH  - Substance-Related Disorders/psychology/*rehabilitation
EDAT- 2020/04/16 06:00
MHDA- 2020/06/03 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/04/10 00:00 [received]
PHST- 2019/09/06 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
AID - S1983-14472020000200413 [pii]
AID - 10.1590/1983-1447.2020.20190121 [doi]
PST - epublish
SO  - Rev Gaucha Enferm. 2020 Apr 9;41(spe):e20190121. doi:
      10.1590/1983-1447.2020.20190121. eCollection 2020.


PMID- 32294676
OWN - NLM
STAT- MEDLINE
DCOM- 20200507
LR  - 20200507
IS  - 1807-3107 (Electronic)
IS  - 1806-8324 (Linking)
VI  - 34
IP  - supp1 1
DP  - 2020
TI  - Periodontal disease and its impact on general health in Latin America. Section
      II: Introduction part II.
PG  - e023
LID - S1806-83242020000200601 [pii]
LID - 10.1590/1807-3107bor-2020.vol34.0023 [doi]
AB  - The epidemiological data on gingivitis and periodontitis in Latin America are
      scarce, as the majority of the Latin American studies have analyzed probing depth
      instead of clinical attachment loss. Reported data have shown high variations in 
      results between different Latin American countries, with the main causes of these
      differences being the clinical case definition and methodological strategies
      used. In general, data have revealed that the prevalence of periodontal disease
      is higher in Latin Americans than in populations in the USA or Europe. Regarding 
      its relations with other diseases and conditions, some Latin American studies
      have focused on the association between periodontitis and adverse pregnancy
      outcomes, or poor glycemic control in diabetic patients; however, these studies
      have reported controversial results. In Chile, reports have indicated that
      periodontal treatment significantly reduced the preterm birth rate; however, no
      association between periodontitis and perinatal outcome was found in Brazil. For 
      diabetes mellitus, Brazilian studies have reported controversial findings;
      however, a Chilean interventional study reported significant reductions in the
      glycosylated hemoglobin levels after periodontal treatment. Although
      epidemiological data for Latin America are scarce, the information available at
      present is useful for establishing national policies on health promotion,
      prevention, and treatment of periodontal disease. Therefore, dental schools must 
      play a key role in educating professionals who are highly trained in the
      promotion, prevention, early diagnosis and treatment of periodontal disease, with
      an approach to risk, and strong biopsychosocial and ethical components. Thus,
      future Latin American dentists would be able to face the challenge of decreasing 
      the prevalence of periodontal diseases by leading interdisciplinary health
      teamwork.
FAU - Carvajal, Paola
AU  - Carvajal P
AUID- ORCID: http://orcid.org/0000-0001-5045-4412
AD  - Universidad de Chile, Faculty of Dentistry, Department of Conservative Dentistry,
      Santiago, Chile.
AD  - Universidad de Chile, Faculty of Dentistry, Center for Surveillance and
      Epidemiology of Oral Diseases, Santiago, Chile.
FAU - Vernal, Rolando
AU  - Vernal R
AUID- ORCID: http://orcid.org/0000-0002-1391-320X
AD  - Universidad de Chile, Faculty of Dentistry, Department of Conservative Dentistry,
      Santiago, Chile.
AD  - Universidad de Chile, Faculty of Dentistry, Periodontal Biology Laboratory,
      Santiago, Chile.
FAU - Reinero, Daniela
AU  - Reinero D
AUID- ORCID: http://orcid.org/0000-0002-5577-7947
AD  - Universidad de Chile, Faculty of Dentistry, Department of Conservative Dentistry,
      Santiago, Chile.
FAU - Malheiros, Zilson
AU  - Malheiros Z
AUID- ORCID: http://orcid.org/0000-0003-0999-7217
AD  - Latin American Oral Health Association - LAOHA, Sao Paulo, SP, Brazil.
AD  - Colgate Palmolive Company, Global Technology Center, Piscataway, NJ, USA.
FAU - Stewart, Bernal
AU  - Stewart B
AUID- ORCID: http://orcid.org/0000-0002-3054-4098
AD  - Latin American Oral Health Association - LAOHA, Sao Paulo, SP, Brazil.
AD  - Colgate Palmolive Company, Global Technology Center, Piscataway, NJ, USA.
FAU - Pannuti, Claudio Mendes
AU  - Pannuti CM
AUID- ORCID: http://orcid.org/0000-0003-4181-3975
AD  - Latin American Oral Health Association - LAOHA, Sao Paulo, SP, Brazil.
AD  - Universidade de Sao Paulo - USP, School of Dentistry, Department of Stomatology, 
      Sao Paulo, SP, Brazil.
FAU - Romito, Giuseppe Alexandre
AU  - Romito GA
AUID- ORCID: http://orcid.org/0000-0001-5669-912X
AD  - Latin American Oral Health Association - LAOHA, Sao Paulo, SP, Brazil.
AD  - Universidade de Sao Paulo - USP, School of Dentistry, Department of Stomatology, 
      Sao Paulo, SP, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200409
PL  - Brazil
TA  - Braz Oral Res
JT  - Brazilian oral research
JID - 101307187
SB  - IM
MH  - Age Factors
MH  - Female
MH  - Gingivitis/epidemiology/etiology
MH  - Humans
MH  - Latin America/epidemiology
MH  - Male
MH  - Periodontal Attachment Loss
MH  - Periodontal Diseases/*epidemiology/*etiology
MH  - Prevalence
MH  - Risk Factors
EDAT- 2020/04/16 06:00
MHDA- 2020/05/08 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2019/10/14 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/05/08 06:00 [medline]
AID - S1806-83242020000200601 [pii]
AID - 10.1590/1807-3107bor-2020.vol34.0023 [doi]
PST - epublish
SO  - Braz Oral Res. 2020 Apr 9;34(supp1 1):e023. doi:
      10.1590/1807-3107bor-2020.vol34.0023. eCollection 2020.


PMID- 32294412
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 2213-6711 (Electronic)
IS  - 2213-6711 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Apr 14
TI  - Chimeric Humanized Vasculature and Blood: The Intersection of Science and Ethics.
PG  - 538-540
LID - S2213-6711(20)30106-5 [pii]
LID - 10.1016/j.stemcr.2020.03.016 [doi]
AB  - The only curative therapy for diseases such as organ failure is orthotopic organ 
      transplantation. Organ transplantation has been limited due to the shortage of
      donor organs. The huge disparity between those who need and those who receive
      transplantation therapy drives the pursuit of alternative treatments. Therefore, 
      novel therapies are warranted. Recent studies support the feasibility of
      generating human-porcine chimeras that one day would provide humanized
      vasculature and blood for transplantation and serve as important research models.
      The ethical issues they raise require open discussion and dialog lest promising
      lines of inquiry flounder due to unfounded fears or compromised public trust.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Garry, Daniel J
AU  - Garry DJ
AD  - Lillehei Heart Institute, Department of Medicine, University of Minnesota,
      Minneapolis, MN 55455, USA; Stem Cell Institute, University of Minnesota,
      Minneapolis, MN 55455, USA; Regenerative Medicine and Sciences Program, Paul and 
      Sheila Wellstone Muscular Dystrophy Center, University of Minnesota, 2231 6(th)
      Street SE (CCRB 4-146), Minneapolis, MN 55455, USA. Electronic address:
      garry@umn.edu.
FAU - Caplan, Arthur L
AU  - Caplan AL
AD  - Division of Medical Ethics, New York University Langone Medical Center, New York,
      NY 10016, USA.
FAU - Garry, Mary G
AU  - Garry MG
AD  - Lillehei Heart Institute, Department of Medicine, University of Minnesota,
      Minneapolis, MN 55455, USA; Stem Cell Institute, University of Minnesota,
      Minneapolis, MN 55455, USA; Regenerative Medicine and Sciences Program, Paul and 
      Sheila Wellstone Muscular Dystrophy Center, University of Minnesota, 2231 6(th)
      Street SE (CCRB 4-146), Minneapolis, MN 55455, USA.
LA  - eng
GR  - R01 HL144582/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Stem Cell Reports
JT  - Stem cell reports
JID - 101611300
SB  - IM
MH  - Animals
MH  - Blood/*metabolism
MH  - Blood Vessels/*physiology
MH  - Chimera/*physiology
MH  - *Ethics, Research
MH  - Genetic Engineering
MH  - Humans
MH  - *Science
PMC - PMC7160389
OTO - NOTNLM
OT  - *Etv2
OT  - *chimeras
OT  - *complementation
OT  - *ethics
OT  - *human
OT  - *pig
EDAT- 2020/04/16 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/03/17 00:00 [revised]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - S2213-6711(20)30106-5 [pii]
AID - 10.1016/j.stemcr.2020.03.016 [doi]
PST - ppublish
SO  - Stem Cell Reports. 2020 Apr 14;14(4):538-540. doi: 10.1016/j.stemcr.2020.03.016.


PMID- 32294411
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 2213-6711 (Electronic)
IS  - 2213-6711 (Linking)
VI  - 14
IP  - 4
DP  - 2020 Apr 14
TI  - Informed Consent for Human Embryo Genome Editing.
PG  - 530-537
LID - S2213-6711(20)30100-4 [pii]
LID - 10.1016/j.stemcr.2020.03.010 [doi]
AB  - In the event that human embryo genome editing is considered safe enough for the
      clinic, researchers will need to consider how to administer consent so that
      would-be recipients of edited embryos can make an informed decision. Informed
      consent will require truthfulness, sensitivity, regulatory compliance, and
      attention to the highest ethical standards.
CI  - Copyright (c) 2020 The Author. Published by Elsevier Inc. All rights reserved.
FAU - Jonlin, Erica C
AU  - Jonlin EC
AD  - University of Washington, Institute for Stem Cell and Regenerative Medicine, 850 
      Republican Street, Box 358056, Seattle, WA 98109, USA. Electronic address:
      ejonlin@uw.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Stem Cell Reports
JT  - Stem cell reports
JID - 101611300
SB  - IM
MH  - Embryo Research/ethics
MH  - Embryo, Mammalian/*metabolism
MH  - *Gene Editing/ethics
MH  - Humans
MH  - *Informed Consent/ethics
MH  - Therapeutic Misconception
PMC - PMC7160388
EDAT- 2020/04/16 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/03/02 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - S2213-6711(20)30100-4 [pii]
AID - 10.1016/j.stemcr.2020.03.010 [doi]
PST - ppublish
SO  - Stem Cell Reports. 2020 Apr 14;14(4):530-537. doi: 10.1016/j.stemcr.2020.03.010.


PMID- 32294094
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20200706
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Towards a fully automated surveillance of well-being status in laboratory mice
      using deep learning: Starting with facial expression analysis.
PG  - e0228059
LID - 10.1371/journal.pone.0228059 [doi]
AB  - Assessing the well-being of an animal is hindered by the limitations of efficient
      communication between humans and animals. Instead of direct communication, a
      variety of parameters are employed to evaluate the well-being of an animal.
      Especially in the field of biomedical research, scientifically sound tools to
      assess pain, suffering, and distress for experimental animals are highly demanded
      due to ethical and legal reasons. For mice, the most commonly used laboratory
      animals, a valuable tool is the Mouse Grimace Scale (MGS), a coding system for
      facial expressions of pain in mice. We aim to develop a fully automated system
      for the surveillance of post-surgical and post-anesthetic effects in mice. Our
      work introduces a semi-automated pipeline as a first step towards this goal. A
      new data set of images of black-furred laboratory mice that were moving freely is
      used and provided. Images were obtained after anesthesia (with isoflurane or
      ketamine/xylazine combination) and surgery (castration). We deploy two
      pre-trained state of the art deep convolutional neural network (CNN)
      architectures (ResNet50 and InceptionV3) and compare to a third CNN architecture 
      without pre-training. Depending on the particular treatment, we achieve an
      accuracy of up to 99% for the recognition of the absence or presence of
      post-surgical and/or post-anesthetic effects on the facial expression.
FAU - Andresen, Niek
AU  - Andresen N
AUID- ORCID: 0000-0002-3596-0795
AD  - Department of Computer Vision & Remote Sensing, Technische Universitat Berlin,
      Berlin, Germany.
FAU - Wollhaf, Manuel
AU  - Wollhaf M
AUID- ORCID: 0000-0002-8190-6503
AD  - Department of Computer Vision & Remote Sensing, Technische Universitat Berlin,
      Berlin, Germany.
FAU - Hohlbaum, Katharina
AU  - Hohlbaum K
AD  - Institute of Animal Welfare, Animal Behavior, and Laboratory Animal Science,
      Department of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany.
FAU - Lewejohann, Lars
AU  - Lewejohann L
AD  - Institute of Animal Welfare, Animal Behavior, and Laboratory Animal Science,
      Department of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany.
AD  - German Centre for the Protection of Laboratory Animals (Bf3R), German Federal
      Institute for Risk Assessment (BfR), Berlin, Germany.
FAU - Hellwich, Olaf
AU  - Hellwich O
AD  - Department of Computer Vision & Remote Sensing, Technische Universitat Berlin,
      Berlin, Germany.
FAU - Thone-Reineke, Christa
AU  - Thone-Reineke C
AD  - Institute of Animal Welfare, Animal Behavior, and Laboratory Animal Science,
      Department of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany.
FAU - Belik, Vitaly
AU  - Belik V
AUID- ORCID: 0000-0003-3748-0071
AD  - System Modeling Group, Institute for Veterinary Epidemiology and Biostatistics,
      Department of Veterinary Medicine, Freie Universitat Berlin, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anesthetics)
SB  - IM
MH  - Anesthetics/administration & dosage
MH  - *Animal Welfare
MH  - Animals
MH  - Animals, Laboratory/*physiology
MH  - Behavior, Animal/physiology
MH  - Castration/adverse effects
MH  - Datasets as Topic
MH  - *Deep Learning
MH  - Facial Expression
MH  - Female
MH  - Laboratory Animal Science/*methods
MH  - Male
MH  - Mice/physiology
MH  - Pain, Postoperative/*diagnosis/etiology
PMC - PMC7159220
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/16 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/08/08 00:00 [received]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
AID - 10.1371/journal.pone.0228059 [doi]
AID - PONE-D-19-22429 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 15;15(4):e0228059. doi: 10.1371/journal.pone.0228059.
      eCollection 2020.


PMID- 32293836
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1303-6165 (Electronic)
IS  - 1300-0144 (Linking)
VI  - 50
IP  - SI-1
DP  - 2020 Apr 21
TI  - Quarantine and its legal dimension
PG  - 544-548
LID - 10.3906/sag-2004-153 [doi]
AB  - Quarantine and isolation are public health measures used for centuries to prevent
      the spread of infectious diseases. Quarantine is separation of persons who have
      been exposed to an infection but asymptomatic, while isolation is separation of
      infected patients. Voluntary quarantine is preferred, but if necessary, it can be
      mandatory. These implementations can lead to restrictions on individual
      liberties, leading to ethical and legal problems. Isolation and quarantine
      enforcement are regulated by laws. Those who do not follow the quarantine rules
      could be punished. Isolation and quarantine practices in our country are
      described in General Hygiene Law. In this study the importance of quarantine,
      when and how it is applied, and its ethical and especially legal dimension are
      discussed.
CI  - This work is licensed under a Creative Commons Attribution 4.0 International
      License.
FAU - Kilic, Rahmi
AU  - Kilic R
AUID- ORCID: 0000-0002-9514-5485
AD  - Department of Ear Nose Throat Clinic, Ankara Training and Research
      Hospital,Health Sciences University, Ankara, Turkey
FAU - Ataman Hatipoglu, Cigdem
AU  - Ataman Hatipoglu C
AUID- ORCID: 0000-0002-1104-8232
AD  - Department of Infectious Diseases and Clinical Microbiology Clinic,Ankara
      Training and Research Hospital,Health Sciences University, Ankara, Turkey
FAU - Gunes, Cemil
AU  - Gunes C
AUID- ORCID: 0000-0001-6132-4373
AD  - Health Ministry, General Directorate of Legal Services, Ankara, Turkey
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200421
PL  - Turkey
TA  - Turk J Med Sci
JT  - Turkish journal of medical sciences
JID - 9441758
SB  - IM
MH  - Disease Outbreaks/*prevention & control
MH  - Humans
MH  - Public Health/*legislation & jurisprudence
MH  - Quarantine/*legislation & jurisprudence
PMC - PMC7195983
OTO - NOTNLM
OT  - *Quarantine
OT  - *isolation
OT  - *law
EDAT- 2020/04/16 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
AID - 10.3906/sag-2004-153 [doi]
PST - epublish
SO  - Turk J Med Sci. 2020 Apr 21;50(SI-1):544-548. doi: 10.3906/sag-2004-153.


PMID- 32293822
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1518-0557 (Electronic)
IS  - 1517-5693 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Oct 6
TI  - Genetics in human reproduction.
PG  - 480-491
LID - 10.5935/1518-0557.20200007 [doi]
AB  - Approximately 50% of the causes of infertility are of genetic origin. The
      objective of this study was to analyze the role of genetics in human reproduction
      by reviewing the main genetic causes of infertility and the use of
      preimplantation genetic testing in Brazil. This literature review comprised
      articles in English and Portuguese published on databases PubMed, Scielo, and
      Bireme from 1990 to 2019. Randomized clinical trials and specialized guidelines
      were given preference whenever possible. Genetic cause can be traced back to up
      to 20% of the cases of severe azoospermia or oligozoospermia. Subjects with these
      conditions are good candidates for genetic screening. In women, genetic causes of
      infertility (fragile X syndrome, X-trisomy, and Turner's syndrome, some of which 
      diagnosed with karyotyping) culminate with premature ovarian failure. Genetic
      screening helps advise couples of the risk of experiencing early reproductive
      capacity loss and of the chances of their offspring carrying genetic disorders.
      In addition to enhancing the prevention of serious diseases in the offspring of
      couples at increased risk of genetic diseases, preimplantation genetic screening 
      improves the success rates of assisted reproduction procedures by allowing the
      selection of euploid embryos for transfer. The interface between genetics and
      human reproduction has gained significant relevance, but discussions are still
      needed on which procedures are clinically and ethically acceptable and how they
      should be regulated.
FAU - Rodrigues, Vivian de Oliveira
AU  - Rodrigues VO
AD  - Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.
FAU - Polisseni, Fernanda
AU  - Polisseni F
AD  - Surgery Department, Medical School - Federal University of Juiz de Fora, Juiz de 
      Fora, MG, Brazil.
FAU - Pannain, Gabriel Duque
AU  - Pannain GD
AD  - Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.
FAU - Carvalho, Miralva Aurora Galvao
AU  - Carvalho MAG
AD  - Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201006
PL  - Brazil
TA  - JBRA Assist Reprod
JT  - JBRA assisted reproduction
JID - 101684552
SB  - IM
MH  - Female
MH  - Genetic Counseling
MH  - *Genetic Testing
MH  - Humans
MH  - Infertility/*genetics
MH  - Male
MH  - Pregnancy
MH  - *Preimplantation Diagnosis
MH  - *Reproductive Techniques, Assisted
PMC - PMC7558894
OTO - NOTNLM
OT  - *female infertility
OT  - *genetics
OT  - *male infertility
OT  - *preimplantation genetic diagnosis
OT  - *preimplantation genetic screening
EDAT- 2020/04/16 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.5935/1518-0557.20200007 [doi]
PST - epublish
SO  - JBRA Assist Reprod. 2020 Oct 6;24(4):480-491. doi: 10.5935/1518-0557.20200007.


PMID- 32293418
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Apr 15
TI  - Perspectives regarding privacy in clinical research among research professionals 
      from the Arab region: an exploratory qualitative study.
PG  - 27
LID - 10.1186/s12910-020-0456-9 [doi]
AB  - BACKGROUND: Protecting the privacy of research participants is widely recognized 
      as one of the standard ethical requirements for clinical research. It is unknown,
      however, how research professionals regard concepts of privacy as well as the
      situations in the research setting that require privacy protections. The aim of
      this study was to explore the views of research professionals from Arab countries
      regarding concepts and scope of privacy that occur in clinical research. METHODS:
      We adopted an exploratory qualitative approach by the use of focus group
      discussions. We recruited individuals involved in research from Egypt and
      Morocco. We analyzed focus group data via a constant comparison approach, which
      consisted of close reading of the transcribed interviews followed by coding and
      then determining themes and subthemes. RESULTS: Between August 2016 and July
      2018, we conducted nine focus group discussions. Respondents discussed several
      privacy issues that occurred before the research began (e.g., recruitment
      practices); during research (e.g., data collection and physical exams), and after
      the research (e.g., secondary use of data and data sharing). Respondents revealed
      their perspectives of patients towards privacy in the clinical and research
      settings and mentioned that patients are more likely to permit access to their
      privacy in the clinical setting compared with research setting due to the
      existence of benefits and trust in clinical care. Respondents also recommended
      training regarding data protections for individuals involved in research.
      CONCLUSIONS: Our study shows that research professionals discussed a range of
      privacy issues that are present during the different stages of research. We
      recommend 1) development of standards regarding privacy protections during
      recruitment efforts; 2) additional training for individuals involved in research 
      regarding best practices with data security in secondary research; 3) a
      quantitative study involving investigators and REC members to determine their
      knowledge, attitudes and practices regarding privacy issues that occur in
      research; and 4) a quantitative study involving patients to elicit their views
      regarding their privacy concerns in research.
FAU - Adarmouch, Latifa
AU  - Adarmouch L
AUID- ORCID: 0000-0002-9543-6899
AD  - Cadi Ayyad University School of Medicine Community Medicine and Public Health
      Department, Marrakech, Morocco. l.adarmouch@hotmail.com.
FAU - Felaefel, Marwan
AU  - Felaefel M
AD  - The American University in Cairo, Cairo, Egypt.
FAU - Wachbroit, Robert
AU  - Wachbroit R
AD  - University of Maryland School of Medicine, Baltimore, MD, USA.
FAU - Silverman, Henry
AU  - Silverman H
AD  - University of Maryland School of Medicine, Baltimore, MD, USA.
LA  - eng
GR  - R25 TW007090/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200415
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Arabs
MH  - *Computer Security
MH  - *Confidentiality
MH  - Egypt
MH  - Female
MH  - Humans
MH  - Male
MH  - *Privacy
MH  - Qualitative Research
PMC - PMC7158072
OTO - NOTNLM
OT  - *Clinical research
OT  - *Confidentiality
OT  - *Egypt
OT  - *Morocco
OT  - *Privacy
EDAT- 2020/04/16 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/04/25 00:00 [received]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-0456-9 [doi]
AID - 10.1186/s12910-020-0456-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Apr 15;21(1):27. doi: 10.1186/s12910-020-0456-9.


PMID- 32293411
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Mar 23
TI  - Ethical arguments concerning human-animal chimera research: a systematic review.
PG  - 24
LID - 10.1186/s12910-020-00465-7 [doi]
AB  - BACKGROUND: The burgeoning field of biomedical research involving the mixture of 
      human and animal materials has attracted significant ethical controversy. Due to 
      the many dimensions of potential ethical conflict involved in this type of
      research, and the wide variety of research projects under discussion, it is
      difficult to obtain an overview of the ethical debate. This paper attempts to
      remedy this by providing a systematic review of ethical reasons in academic
      publications on human-animal chimera research. METHODS: We conducted a systematic
      review of the ethical literature concerning human-animal chimeras based on the
      research question: "What ethical reasons have been given for or against
      conducting human-animal chimera research, and how have these reasons been treated
      in the ongoing debate?" Our search extends until the end of the year 2017,
      including MEDLINE, Embase, PhilPapers and EthxWeb databases, restricted to
      peer-reviewed journal publications in English. Papers containing ethical reasons 
      were analyzed, and the reasons were coded according to whether they were
      endorsed, mentioned or rejected. RESULTS: Four hundred thirty-one articles were
      retrieved by our search, and 88 were ultimately included and analyzed. Within
      these articles, we found 464 passages containing reasons for and against
      conducting human-animal chimera research. We classified these reasons into five
      categories and, within these, identified 12 broad and 31 narrow reason types. 15%
      of the retrieved passages contained reasons in favor of conducting chimera
      research (Category P), while 85% of the passages contained reasons against it.
      The reasons against conducting chimera research fell into four further
      categories: reasons concerning the creation of a chimera (Category A), its
      treatment (Category B), reasons referring to metaphysical or social issues
      resulting from its existence (Category C) and to potential downstream effects of 
      chimera research (Category D). A significant proportion of identified passages
      (46%) fell under Category C. CONCLUSIONS: We hope that our results, in revealing 
      the conceptual and argumentative structure of the debate and highlighting some
      its most notable tendencies and prominent positions, will facilitate continued
      discussion and provide a basis for the development of relevant policy and
      legislation.
FAU - Kwisda, Koko
AU  - Kwisda K
AD  - CELLS - Centre for Ethics and Law in the Life Sciences, Leibniz University
      Hannover, Otto-Brenner-Strasse 1, 30159, Hannover, Germany.
      koko.kwisda@cells.uni-hannover.de.
FAU - White, Lucie
AU  - White L
AD  - Institute of Philosophy, Leibniz University Hannover, Im Moore 21, 30167,
      Hannover, Germany.
FAU - Hubner, Dietmar
AU  - Hubner D
AD  - Institute of Philosophy, Leibniz University Hannover, Im Moore 21, 30167,
      Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200323
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - *Animal Experimentation/ethics
MH  - Animals
MH  - *Biomedical Research
MH  - *Chimera
MH  - Dissent and Disputes
MH  - Humans
MH  - Morals
PMC - PMC7092670
OTO - NOTNLM
OT  - *Chimera research
OT  - *Ethics
OT  - *Human-animal chimeras
OT  - *Systematic review
EDAT- 2020/04/16 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/03/17 00:00 [received]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00465-7 [doi]
AID - 10.1186/s12910-020-00465-7 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Mar 23;21(1):24. doi: 10.1186/s12910-020-00465-7.


PMID- 32293407
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Apr 15
TI  - Development and psychometric evaluation of a new tool for measuring the attitudes
      of patients with progressive neurological diseases to ethical aspects of
      end-of-life care.
PG  - 28
LID - 10.1186/s12910-020-00471-9 [doi]
AB  - BACKGROUND: Knowing the opinions of patients with Progressive Neurological
      Diseases (PNDs) and their family members on end-of-life care can help initiate
      communication and the drawing up of a care plan. The aim of this paper is to
      describe the creation and psychometric properties of the newly developed
      APND-EoLC questionnaire (the Attitudes of Patients with Progressive Neurological 
      Disease to End of Life Care questionnaire). METHODS: Following focus group
      discussion, four main areas of interest were identified: patients' and family
      members' attitudes towards end-of-life care, factors influencing decisions about 
      treatment to prolong patients' life, concerns and fears regarding dying, and
      opinions on the system of care. The created questions were divided into domains
      based on factor analysis and psychometric properties were evaluated by sample of 
      209 patients with PND and 118 their family members. RESULTS: The final version of
      the scale contains a total of 28 questions divided into six domains (end-of-life 
      control, keeping patients alive, trust in doctors/treatment, trust in social
      support, sense of suffering, and dependence/loss of control) and five individual 
      questions determining views of the care system with specified response options.
      Construct validity was verified by confirmatory factor analysis for each
      evaluated area individually. Appropriate psychometric properties were identified 
      in the questionnaire. CONCLUSIONS: The APND-EoLC questionnaire can be recommended
      for use in both research and clinical practice.
FAU - Buzgova, Radka
AU  - Buzgova R
AD  - Department of Nursing and Midwifery, Faculty of medicine, University of Ostrava, 
      Ostrava, Czech Republic. radka.buzgova@osu.cz.
FAU - Kozakova, Radka
AU  - Kozakova R
AD  - Department of Nursing and Midwifery, Faculty of medicine, University of Ostrava, 
      Ostrava, Czech Republic.
LA  - eng
GR  - AZV MZ CR no. 17-29447A/Ministerstvo Zdravotnictvi Ceske Republiky/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Attitude
MH  - *Attitude to Health
MH  - Family
MH  - Female
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - *Psychometrics
MH  - Reproducibility of Results
MH  - Surveys and Questionnaires
MH  - *Terminal Care
PMC - PMC7161107
OTO - NOTNLM
OT  - *Attitudes
OT  - *Care
OT  - *End of life
OT  - *Neurology
OT  - *Reliability
OT  - *Validity
EDAT- 2020/04/16 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/04/03 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00471-9 [doi]
AID - 10.1186/s12910-020-00471-9 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Apr 15;21(1):28. doi: 10.1186/s12910-020-00471-9.


PMID- 32293405
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 15
TI  - Patient perspectives of bedside teaching in an obstetrics, Gynaecology and
      neonatology hospital.
PG  - 111
LID - 10.1186/s12909-020-02016-5 [doi]
AB  - BACKGROUND: Osler taught doctors to "have no teaching without a patient for a
      text, and the best teaching is that taught by the patient himself". Bedside
      teaching (BST) facilitates clinical practice of skills, teaches empathy, instils 
      confidence and builds on patient-doctor relationships. However, its use has
      declined dramatically due to concerns regarding privacy and autonomy. Most of the
      research in this area concentrates on medical student or academic opinion of BST 
      using survey based methods. This qualitative study aimed to explore the patient's
      experiences and opinions of BST. METHODS: With ethical approval a qualitative
      study was conducted using semi-structured interviews which were examined using
      Thematic Analysis. Patients who had participated in a BST tutorial were invited
      to participate and gave written consent after discussion with a study researcher.
      RESULTS: Twenty-two patients were interviewed (obstetrics ante-natal [n = 10],
      obstetrics post-natal [n = 5] and gynaecology [n = 7]) ranging from ages 24-80
      yrs. Four major themes were identified, with 11 sub-themes. The major themes
      included (i) Professional Mannerisms (ii) Privacy and Personal Wellbeing (iii)
      Quality of Patient Experience of BST and (iv) Clinical Experience and Learning
      Importance. The reaction of patients toward teaching at the bedside was
      altruistic and positive, with importance placed on learning. CONCLUSION: This
      research supports the concept of patient focused learning, and can reassure
      faculty that patients largely support its continuation as an integral component
      in education. Future research aims to extend this assessment to other patient
      groups with the aim of learning from and improving their experience.
FAU - Carty, Michelle
AU  - Carty M
AD  - UCD School of Psychology, University College Dublin, Donnybrook, Dublin 4,
      Ireland.
FAU - O'Riordan, Nicola
AU  - O'Riordan N
AD  - Obstetrics and Gynaecology, National Maternity Hospital, Dublin 2, Ireland.
FAU - Ivers, Mary
AU  - Ivers M
AD  - UCD School of Psychology, University College Dublin, Donnybrook, Dublin 4,
      Ireland.
FAU - Higgins, Mary F
AU  - Higgins MF
AD  - UCD Perinatal Research Centre, UCD School of Medicine, Obstetrics and
      Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland.
      mary.higgins@ucd.ie.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Attitude of Health Personnel
MH  - Education, Medical, Undergraduate/methods
MH  - Female
MH  - Gynecology/*education
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neonatology/*education
MH  - Obstetrics/*education
MH  - Patient Participation/*statistics & numerical data
MH  - Patient Satisfaction/*statistics & numerical data
MH  - *Physician-Patient Relations
MH  - Young Adult
PMC - PMC7158153
OTO - NOTNLM
OT  - Bedside teaching - medical education
OT  - Medical student
EDAT- 2020/04/16 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/02/25 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1186/s12909-020-02016-5 [doi]
AID - 10.1186/s12909-020-02016-5 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Apr 15;20(1):111. doi: 10.1186/s12909-020-02016-5.


PMID- 32293007
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1464-3685 (Electronic)
IS  - 0300-5771 (Linking)
VI  - 49 Suppl 1
DP  - 2020 Apr 1
TI  - Availability, access, analysis and dissemination of small-area data.
PG  - i4-i14
LID - 10.1093/ije/dyz051 [doi]
AB  - In this era of 'big data', there is growing recognition of the value of
      environmental, health, social and demographic data for research. Open government 
      data initiatives are growing in number and in terms of content. Remote sensing
      data are finding widespread use in environmental research, including in low- and 
      middle-income settings. While our ability to study environment and health
      associations across countries and continents grows, data protection rules and
      greater patient control over the use of their data present new challenges to
      using health data in research. Innovative tools that circumvent the need for the 
      physical sharing of data by supporting non-disclosive sharing of information, or 
      that permit spatial analysis without researchers needing access to underlying
      patient data can be used to support analyses while protecting data
      confidentiality. User-friendly visualizations, allowing small-area data to be
      seen and understood by non-expert audiences, are revolutionizing public and
      researcher interactions with data. The UK Small Area Health Statistics Unit's
      Environment and Health Atlas for England and Wales, and the US National
      Environmental Public Health Tracking Network offer good examples. Open data
      facilitates user-generated outputs, and 'mash-ups', and user-generated inputs
      from social media, mobile devices and wearable tech are new data streams that
      will find utility in future studies, and bring novel dimensions with respect to
      ethical use of small-area data.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      International Epidemiological Association.
FAU - Hodgson, Susan
AU  - Hodgson S
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
FAU - Fecht, Daniela
AU  - Fecht D
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
AD  - UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, 
      Imperial College London, London, UK.
FAU - Gulliver, John
AU  - Gulliver J
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
FAU - Iyathooray Daby, Hima
AU  - Iyathooray Daby H
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
AD  - UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, 
      Imperial College London, London, UK.
FAU - Piel, Frederic B
AU  - Piel FB
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
AD  - UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, 
      Imperial College London, London, UK.
FAU - Yip, Fuyuen
AU  - Yip F
AD  - Environmental Health Tracking Section, National Center for Environmental Health, 
      Centers for Disease Control and Prevention, Atlanta, USA.
FAU - Strosnider, Heather
AU  - Strosnider H
AD  - Environmental Health Tracking Section, National Center for Environmental Health, 
      Centers for Disease Control and Prevention, Atlanta, USA.
FAU - Hansell, Anna
AU  - Hansell A
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
AD  - UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, 
      Imperial College London, London, UK.
FAU - Elliott, Paul
AU  - Elliott P
AD  - MRC-PHE Centre for Environment and Health, School of Public Health, Imperial
      College London, London, UK.
AD  - UK Small Area Health Statistics Unit, MRC-PHE Centre for Environment and Health, 
      Imperial College London, London, UK.
LA  - eng
GR  - MR/L01341X/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Epidemiol
JT  - International journal of epidemiology
JID - 7802871
SB  - IM
MH  - *Access to Information
MH  - Big Data
MH  - Confidentiality
MH  - *Data Analysis
MH  - England
MH  - Humans
MH  - *Information Dissemination
MH  - Public Health
MH  - *Small-Area Analysis
MH  - Wales
PMC - PMC7158061
OTO - NOTNLM
OT  - *Small-area studies
OT  - *environment and health
OT  - *open data
OT  - *remote sensing
EDAT- 2020/04/16 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/03/11 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - 5819944 [pii]
AID - 10.1093/ije/dyz051 [doi]
PST - ppublish
SO  - Int J Epidemiol. 2020 Apr 1;49 Suppl 1:i4-i14. doi: 10.1093/ije/dyz051.


PMID- 32292811
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - Human health versus human rights: An emerging ethical dilemma arising from
      coronavirus disease pandemic.
PG  - 100511
LID - 10.1016/j.jemep.2020.100511 [doi]
FAU - Chia, T
AU  - Chia T
AD  - Department of Anatomy, Faculty of Basic Medical Sciences, College of Health
      Sciences, Nile University of Nigeria, Abuja, Nigeria.
FAU - Oyeniran, O I
AU  - Oyeniran OI
AD  - Department of Physiology, Faculty of Basic Medical Sciences, College of Health
      Sciences, Nile University of Nigeria, Abuja, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7151279
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/04/03 00:00 [received]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.1016/j.jemep.2020.100511 [doi]
AID - S2352-5525(20)30049-9 [pii]
AID - 100511 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100511. doi:
      10.1016/j.jemep.2020.100511. Epub 2020 Apr 11.


PMID- 32292810
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-5525 (Print)
VI  - 14
DP  - 2020 Jul-Sep
TI  - [Covid-19 and some ethical issues in France].
PG  - 100510
LID - 10.1016/j.jemep.2020.100510 [doi]
FAU - Charlier, P
AU  - Charlier P
AD  - Laboratoire Anthropologie, Archeologie, Biologie (LAAB), Universite Paris-Saclay 
      (UVSQ), 2, avenue de la source de la Bievre, 78180 Montigny-Le-Bretonneux,
      France.
LA  - fre
PT  - Editorial
TT  - Covid-19 et quelques problematiques ethiques en France.
DEP - 20200404
PL  - France
TA  - Ethics Med Public Health
JT  - Ethics, medicine, and public health
JID - 101681177
PMC - PMC7128296
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.1016/j.jemep.2020.100510 [doi]
AID - S2352-5525(20)30048-7 [pii]
AID - 100510 [pii]
PST - ppublish
SO  - Ethics Med Public Health. 2020 Jul-Sep;14:100510. doi:
      10.1016/j.jemep.2020.100510. Epub 2020 Apr 4.


PMID- 32292675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar 13
TI  - Association of Zinc Transporter-8 Autoantibody (ZnT8A) with Type 1 Diabetes
      Mellitus.
PG  - e7263
LID - 10.7759/cureus.7263 [doi]
AB  - BACKGROUND: Zinc transporter 8 autoantibody (ZnT8A), discovered through
      bioinformatics, is identified as another major biomarker for type 1 diabetes
      mellitus (T1DM), expanding the panel of diagnostic autoantibodies. The absence of
      standard autoantibodies in T1DM patients and the presence of ZnT8A in individuals
      before disease development has led the researchers to evaluate ZnT8A to gather
      information about the frequency and its association. Therefore, we aim to find
      out the concentration of ZnT8A and its association with T1DM. METHODS: A
      case-control study with 25 type 1 diabetes mellitus patients and 25 first-degree 
      relatives of cases as controls was conducted at Ziauddin University in
      collaboration with the Baqai Institute of Diabetology and Endocrinology (BIDE),
      Karachi. Demographic data were collected from patients on a standard
      questionnaire. Blood samples were collected, after approval from Ziauddin Ethics 
      Review Committee, from subjects and serum was separated to estimate ZnT8A by
      using sandwich enzyme-linked immunosorbent assay (ELISA). RESULTS: The mean age
      at diagnosis of T1DM patients was 13.40+/-5.05 years, and the duration of
      diabetes was 7.74+/-5.85 years. The frequency of ZnT8A was found higher in cases 
      (19 (76%)) compared to controls (6 (24%)). ZnT8A concentrations were
      significantly higher in cases (13.82 ng/ml) compared to the controls (8.78 ng/ml;
      p= 0.024). The cut-off value of 9 ng/ml was selected for measuring sensitivity,
      specificity, and accuracy, which were determined as 76%, 76%, and 76%,
      respectively. CONCLUSIONS: ZnT8A was found significantly associated with T1DM.
      Subjects with ZnT8A values >/= 9 ng/ml are 10 times more at risk to develop T1DM 
      (p = 0.000).
CI  - Copyright (c) 2020, Bhatty et al.
FAU - Bhatty, Afreen
AU  - Bhatty A
AD  - Biochemistry, Ziauddin University, Karachi, PAK.
FAU - Baig, Saeeda
AU  - Baig S
AD  - Biochemistry, Ziauddin University, Karachi, PAK.
FAU - Fawwad, Asher
AU  - Fawwad A
AD  - Medicine, Baqai Institute of Diabetology and Endocrinology, Baqai Medical
      University, Karachi, PAK.
FAU - Rubab, Zil E
AU  - Rubab ZE
AD  - Biochemistry, Ziauddin University, Karachi, PAK.
FAU - Shahid, Moazzam A
AU  - Shahid MA
AD  - Biochemistry, Ziauddin University, Karachi, PAK.
FAU - Waris, Nazish
AU  - Waris N
AD  - Research, Baqai Institute of Diabetology and Endocrinology, Karachi, PAK.
LA  - eng
PT  - Journal Article
DEP - 20200313
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7153815
OTO - NOTNLM
OT  - autoantibodies
OT  - autoimmune disease
OT  - autoimmunity
OT  - diabetes mellitus
OT  - type 1
OT  - zinc transporter 8
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
AID - 10.7759/cureus.7263 [doi]
PST - epublish
SO  - Cureus. 2020 Mar 13;12(3):e7263. doi: 10.7759/cureus.7263.


PMID- 32292430
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1682-024X (Print)
IS  - 1681-715X (Linking)
VI  - 36
IP  - 3
DP  - 2020 Mar-Apr
TI  - Prognostic markers in Chronic Lymphocytic Leukaemia - A flow cytometric analysis.
PG  - 338-343
LID - 10.12669/pjms.36.3.541 [doi]
AB  - OBJECTIVE: To find out the frequency of ZAP-70, CD38 and CD49d in patients
      diagnosed with CLL in our population. METHODS: This is a cross sectional study
      conducted in Army Medical College in collaboration with Armed Forces Institute of
      Pathology and Military Hospital Rawalpindi from 1(st) January 2018 to 30(th)
      November 2018. Permission from Institutional Ethical Committee was obtained.
      Blood samples were collected by non-probability consecutive sampling technique
      and analyzed for blood counts and flow cytometry was done for ZAP-70, CD38 and
      CD49d. Manufacturer's instructions for the kits were strictly followed. RESULTS: 
      Fifty-one newly diagnosed patients with CLL were studied for the prognostic
      markers in CLL. CD 38 was expressed in 25(49%) and CD49d in 21(41.2%). ZAP-70
      expression was not detected in our series of patients. CONCLUSION: We conclude
      that CD38 and CD49d expression was detected in almost half of the patients of CLL
      in our series. CD49d showed statistically positive correlation with CD38, showing
      that it is a more pragmatic choice for reliable prognostication of CLL along with
      CD38.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Haq, Hala
AU  - Haq H
AD  - Dr. Hala Haq, MBBS, M.Phil (Hematology). Demonstrator Pathology, Fazaia Medical
      College, Islamabad, Pakistan.
FAU - Uddin, Nasir
AU  - Uddin N
AD  - Col. Nasir Uddin, MBBS, FCPS. Assistant Professor Pathology, Army Medical
      College, Rawalpindi, Pakistan.
FAU - Khan, Saleem Ahmed
AU  - Khan SA
AD  - Maj. Gen. Saleem Ahmed Khan, HI (M), MBBS, MCPS, FCPS, FRCP, PhD. Professor
      Pathology and Principal, Army Medical College, Rawalpindi, Pakistan.
FAU - Ghaffar, Sunia
AU  - Ghaffar S
AD  - Dr. Sunia Ghaffar, MBBS, M. Phil. Army Medical College, Rawalpindi, Pakistan.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC7150385
OTO - NOTNLM
OT  - CD39
OT  - CD49d
OT  - Chronic Lymphocytic Leukaemia
OT  - Immunophenotyping
OT  - Prognostic markers
OT  - ZAP-70
COIS- Conflict of interest: There is no conflict of interest among the authors.
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
AID - 10.12669/pjms.36.3.541 [doi]
AID - PJMS-39-338 [pii]
PST - ppublish
SO  - Pak J Med Sci. 2020 Mar-Apr;36(3):338-343. doi: 10.12669/pjms.36.3.541.


PMID- 32292333
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1662-5161 (Print)
IS  - 1662-5161 (Linking)
VI  - 14
DP  - 2020
TI  - Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in 
      Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology.
PG  - 54
LID - 10.3389/fnhum.2020.00054 [doi]
AB  - The Seventh Annual Deep Brain Stimulation (DBS) Think Tank held on September 8th 
      of 2019 addressed the most current: (1) use and utility of complex
      neurophysiological signals for development of adaptive neurostimulation to
      improve clinical outcomes; (2) Advancements in recent neuromodulation techniques 
      to treat neuropsychiatric disorders; (3) New developments in optogenetics and
      DBS; (4) The use of augmented Virtual reality (VR) and neuromodulation; (5)
      commercially available technologies; and (6) ethical issues arising in and from
      research and use of DBS. These advances serve as both "markers of progress" and
      challenges and opportunities for ongoing address, engagement, and deliberation as
      we move to improve the functional capabilities and translational value of DBS. It
      is in this light that these proceedings are presented to inform the field and
      initiate ongoing discourse. As consistent with the intent, and spirit of this,
      and prior DBS Think Tanks, the overarching goal is to continue to develop
      multidisciplinary collaborations to rapidly advance the field and ultimately
      improve patient outcomes.
CI  - Copyright (c) 2020 Ramirez-Zamora, Giordano, Gunduz, Alcantara, Cagle, Cernera,
      Difuntorum, Eisinger, Gomez, Long, Parks, Wong, Chiu, Patel, Grill, Walker,
      Little, Gilron, Tinkhauser, Thevathasan, Sinclair, Lozano, Foltynie, Fasano,
      Sheth, Scangos, Sanger, Miller, Brumback, Rajasethupathy, McIntyre, Schlachter,
      Suthana, Kubu, Sankary, Herrera-Ferra, Goetz, Cheeran, Steinke, Hess, Almeida,
      Deeb, Foote and Okun.
FAU - Ramirez-Zamora, Adolfo
AU  - Ramirez-Zamora A
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Giordano, James
AU  - Giordano J
AD  - Departments of Neurology and Biochemistry, and Neuroethics Studies
      Program-Pellegrino Center for Clinical Bioethics, Georgetown University Medical
      Center, Washington, DC, United States.
FAU - Gunduz, Aysegul
AU  - Gunduz A
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Alcantara, Jose
AU  - Alcantara J
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Cagle, Jackson N
AU  - Cagle JN
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Cernera, Stephanie
AU  - Cernera S
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Difuntorum, Parker
AU  - Difuntorum P
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Eisinger, Robert S
AU  - Eisinger RS
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Gomez, Julieth
AU  - Gomez J
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Long, Sarah
AU  - Long S
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Parks, Brandon
AU  - Parks B
AD  - J. Crayton Pruitt Family Department of Biomedical Engineering, Center for
      Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, 
      United States.
AD  - Department of Neurosurgery, Center for Movement Disorders and Neurorestoration,
      University of Florida, Gainesville, FL, United States.
FAU - Wong, Joshua K
AU  - Wong JK
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Chiu, Shannon
AU  - Chiu S
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Patel, Bhavana
AU  - Patel B
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Grill, Warren M
AU  - Grill WM
AD  - Department of Biomedical Engineering, Duke University, Durham, NC, United States.
FAU - Walker, Harrison C
AU  - Walker HC
AD  - Department of Neurology, University of Alabama at Birmingham, Birmingham, AL,
      United States.
AD  - Department of Biomedical Engineering, University of Alabama at Birmingham,
      Birmingham, AL, United States.
FAU - Little, Simon J
AU  - Little SJ
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      CA, United States.
FAU - Gilron, Ro'ee
AU  - Gilron R
AD  - Graduate Program in Neuroscience, Department of Neurological Surgery, Kavli
      Institute for Fundamental Neuroscience, University of California, San Francisco, 
      San Francisco, CA, United States.
FAU - Tinkhauser, Gerd
AU  - Tinkhauser G
AD  - Department of Neurology, Bern University Hospital and the University of Bern,
      Bern, Switzerland.
AD  - Medical Research Council Brain Network Dynamics Unit, University of Oxford,
      Oxford, United Kingdom.
FAU - Thevathasan, Wesley
AU  - Thevathasan W
AD  - Department of Neurology, The Royal Melbourne and Austin Hospitals, University of 
      Melbourne, Melbourne, VIC, Australia.
AD  - Medical Bionics Department, University of Melbourne, East Melbourne, VIC,
      Australia.
AD  - Bionics Institute, East Melbourne, VIC, Australia.
FAU - Sinclair, Nicholas C
AU  - Sinclair NC
AD  - Medical Bionics Department, University of Melbourne, East Melbourne, VIC,
      Australia.
AD  - Bionics Institute, East Melbourne, VIC, Australia.
FAU - Lozano, Andres M
AU  - Lozano AM
AD  - Department of Surgery, Division of Neurosurgery, University of Toronto, Toronto, 
      ON, Canada.
FAU - Foltynie, Thomas
AU  - Foltynie T
AD  - Institute of Neurology, University College London, London, United Kingdom.
FAU - Fasano, Alfonso
AU  - Fasano A
AD  - Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman
      Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON, Canada.
AD  - Division of Neurology, University of Toronto, Krembil Brain Institute, Center for
      Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, ON,
      Canada.
FAU - Sheth, Sameer A
AU  - Sheth SA
AD  - Department of Neurological Surgery, Baylor College of Medicine, Houston, TX,
      United States.
FAU - Scangos, Katherine
AU  - Scangos K
AD  - Department of Psychiatry, University of California, San Francisco, San Francisco,
      CA, United States.
FAU - Sanger, Terence D
AU  - Sanger TD
AD  - Department of Biomedical Engineering, Neurology, Biokinesiology, University of
      Southern California, Los Angeles, CA, United States.
FAU - Miller, Jonathan
AU  - Miller J
AD  - Case Western Reserve University School of Medicine, University Hospitals
      Cleveland Medical Center, Cleveland, OH, United States.
FAU - Brumback, Audrey C
AU  - Brumback AC
AD  - Departments of Neurology and Pediatrics at Dell Medical School and the Center for
      Learning and Memory, University of Texas at Austin, Austin, TX, United States.
FAU - Rajasethupathy, Priya
AU  - Rajasethupathy P
AD  - Laboratory for Neural Dynamics and Cognition, Rockefeller University, New York,
      NY, United States.
AD  - Department of Bioengineering, Stanford University, Stanford, CA, United States.
FAU - McIntyre, Cameron
AU  - McIntyre C
AD  - Department of Biomedical Engineering, Case Western Reserve University, Cleveland,
      OH, United States.
FAU - Schlachter, Leslie
AU  - Schlachter L
AD  - Department of Neurosurgery, Mount Sinai Health System, New York, NY, United
      States.
FAU - Suthana, Nanthia
AU  - Suthana N
AD  - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of
      Medicine at UCLA, Los Angeles, CA, United States.
FAU - Kubu, Cynthia
AU  - Kubu C
AD  - Department of Neurology, Cleveland Clinic, Cleveland, OH, United States.
FAU - Sankary, Lauren R
AU  - Sankary LR
AD  - Center for Bioethics, Cleveland Clinic, Cleveland, OH, United States.
FAU - Herrera-Ferra, Karen
AU  - Herrera-Ferra K
AD  - Asociacion Mexicana de Neuroetica, Mexico City, Mexico.
FAU - Goetz, Steven
AU  - Goetz S
AD  - Medtronic Neuromodulation, Minneapolis, MN, United States.
FAU - Cheeran, Binith
AU  - Cheeran B
AD  - Neuromodulation Division, Abbott, Plano, TX, United States.
FAU - Steinke, G Karl
AU  - Steinke GK
AD  - Boston Scientific Neuromodulation, Valencia, CA, United States.
FAU - Hess, Christopher
AU  - Hess C
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Almeida, Leonardo
AU  - Almeida L
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Deeb, Wissam
AU  - Deeb W
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Foote, Kelly D
AU  - Foote KD
AD  - Department of Neurosurgery, Norman Fixel Institute for Neurological Diseases,
      Center for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
FAU - Okun, Michael S
AU  - Okun MS
AD  - Department of Neurology, Norman Fixel Institute for Neurological Diseases,
      Program for Movement Disorders and Neurorestoration, University of Florida,
      Gainesville, FL, United States.
LA  - eng
GR  - UH3 NS103468/NS/NINDS NIH HHS/United States
GR  - UL1 TR001409/TR/NCATS NIH HHS/United States
GR  - R01 NS091236/NS/NINDS NIH HHS/United States
GR  - R00 MH109652/MH/NIMH NIH HHS/United States
GR  - U01 NS103802/NS/NINDS NIH HHS/United States
GR  - R01 NS040894/NS/NINDS NIH HHS/United States
GR  - R01 NS096008/NS/NINDS NIH HHS/United States
GR  - R01 MH114853/MH/NIMH NIH HHS/United States
GR  - R37 NS040894/NS/NINDS NIH HHS/United States
GR  - F32 MH115419/MH/NIMH NIH HHS/United States
GR  - K08 NS094643/NS/NINDS NIH HHS/United States
GR  - UH3 NS103549/NS/NINDS NIH HHS/United States
GR  - UH3 NS100553/NS/NINDS NIH HHS/United States
GR  - TL1 TR001428/TR/NCATS NIH HHS/United States
GR  - R01 NR014852/NR/NINR NIH HHS/United States
GR  - RC1 NS068086/NS/NINDS NIH HHS/United States
GR  - UH3 NS095553/NS/NINDS NIH HHS/United States
GR  - K23 NS110962/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20200327
PL  - Switzerland
TA  - Front Hum Neurosci
JT  - Frontiers in human neuroscience
JID - 101477954
PMC - PMC7134196
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *deep brain stimulation
OT  - *depression
OT  - *local field potentials
OT  - *neuroethics
OT  - *optogenetics
OT  - *stereoelectroencephalography
OT  - *tremor
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
AID - 10.3389/fnhum.2020.00054 [doi]
PST - epublish
SO  - Front Hum Neurosci. 2020 Mar 27;14:54. doi: 10.3389/fnhum.2020.00054. eCollection
      2020.


PMID- 32292235
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0377-1237 (Print)
IS  - 0377-1237 (Linking)
VI  - 76
IP  - 2
DP  - 2020 Apr
TI  - The missing pieces in the jigsaw and need for cohesive research amidst
      coronavirus infectious disease 2019 global response.
PG  - 132-135
LID - 10.1016/j.mjafi.2020.04.001 [doi]
AB  - Identifying the research needs and gaps amidst this COVID-19 travelling across
      the countries is absolutely important for finely improving on the way we think
      and act. The natural history of the disease as well as viral shedding in
      different stages of clinical illness needs to be known which helps in triaging
      the patients in hospital settings. Animal and environmental interface need to be 
      studied for defining the high-risk situations. Transmission dynamics in community
      or hospital and defining the laboratory criteria for the case confirmation will
      be most crucial. Gene sequencing and validation and, suitable use of molecular
      based tests such as real-time polymerase chain reaction (qRT-PCR) should be
      clearly evaluated for diagnosis and/ or surveillance. The movement control
      strategy must be defined to prevent secondary transmission in healthcare as well 
      as in community settings. Repurposing of drug molecules is an elegant strategy to
      develop therapeutics in the case of pandemics quickly. Unproven practices and
      treatment protocols should invite critical scrutiny on the basis of ethics.
      Socioeconomic status of the community is also an important determinant for the
      compliance and sustainable public health measures.
CI  - (c) 2020 Director General, Armed Forces Medical Services. Published by Elsevier, 
      a division of RELX India Pvt. Ltd.
FAU - Gupta, Naveen
AU  - Gupta N
AD  - Joint Director & Officer in Charge, Centre for Arboviral and Zoonotic Diseases,
      National Centre for Diseases Control, 22, Shamnath Marg, Civil Line, New Delhi,
      India.
FAU - Singhai, Monil
AU  - Singhai M
AD  - Deputy Director, Centre for Arboviral and Zoonotic Diseases, National Centre for 
      Diseases Control, 22, Shamnath Marg, Civil Line, New Delhi, India.
FAU - Garg, Shubha
AU  - Garg S
AD  - Assistant Director, Centre for Arboviral and Zoonotic Diseases, National Centre
      for Diseases Control, 22, Shamnath Marg, Civil Line, New Delhi, India.
FAU - Shah, Dhara
AU  - Shah D
AD  - Assistant Director, Centre for Arboviral and Zoonotic Diseases, National Centre
      for Diseases Control, 22, Shamnath Marg, Civil Line, New Delhi, India.
FAU - Sood, Vishesh
AU  - Sood V
AD  - Assistant Director, Centre for Arboviral and Zoonotic Diseases, National Centre
      for Diseases Control, 22, Shamnath Marg, Civil Line, New Delhi, India.
FAU - Singh, Sujeet Kumar
AU  - Singh SK
AD  - Director, National Centre for Diseases Control, 22, Shamnath Marg, Civil Line,
      New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - India
TA  - Med J Armed Forces India
JT  - Medical journal, Armed Forces India
JID - 7602492
PMC - PMC7141472
OTO - NOTNLM
OT  - Coronavirus infectious disease 2019
OT  - Knowledge gaps
OT  - Outbreak management
OT  - Pandemic
OT  - Research needs
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/03/31 00:00 [received]
PHST- 2020/04/05 00:00 [accepted]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.1016/j.mjafi.2020.04.001 [doi]
AID - S0377-1237(20)30062-9 [pii]
PST - ppublish
SO  - Med J Armed Forces India. 2020 Apr;76(2):132-135. doi:
      10.1016/j.mjafi.2020.04.001. Epub 2020 Apr 7.


PMID- 32292067
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20201223
IS  - 1526-2359 (Electronic)
IS  - 1073-2748 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Jan-Dec
TI  - Ethical Challenges of Pediatric Cancer Care: Interviews With Nurses in Saudi
      Arabia.
PG  - 1073274820917210
LID - 10.1177/1073274820917210 [doi]
AB  - Despite rapid and successful development in pediatric cancer treatment, many
      ethical challenges remain. These challenges have been, and continue to be, the
      subject of much research, but few qualitative studies have explored the views of 
      nurses, especially in the Middle East. This study, therefore, seeks to fill a
      knowledge gap in this area and to better understand the concerns of
      nurses-particularly those in Saudi Arabia and the Middle East. Face-to-face,
      in-depth interviews were conducted with 17 male and female nurses working in
      pediatric units at 2 hospitals in Saudi Arabia to explore their views on the
      ethical challenges in caring for children with cancer. All interviews were
      recorded and transcribed, then line-by-line encoded, merged, and categorized into
      themes. Our results show that pediatric cancer is perceived as being "different" 
      from other diseases, and from cancer in adults. Nurses are an integral part of
      the medical care team and are aware of the importance of their role, as well as
      the special relationships that they develop with the children. Consent is
      mandatory and necessary and can be signed by any parent. Assent is important when
      children become able to give it. Pediatric cancer is seen as a different disease 
      by nurses for various reasons. Their roles and relationships with children and
      families pose many challenges. Though parental consent and child assent are
      essential, nurses' collaboration is important for shared decision-making. Our
      study paves the way for broader studies to understand the concerns of nurses and 
      other health-care providers about treating children with pediatric cancer.
FAU - Alahmad, Ghiath
AU  - Alahmad G
AUID- ORCID: https://orcid.org/0000-0002-3331-4378
AD  - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi
      Arabia.
AD  - King Saud Bin Abdulaziz University of Health Sciences (KSAU-HS), Riyadh, Saudi
      Arabia.
FAU - Al-Kamli, Halah
AU  - Al-Kamli H
AD  - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi
      Arabia.
AD  - King Saud Bin Abdulaziz University of Health Sciences (KSAU-HS), Riyadh, Saudi
      Arabia.
FAU - Alzahrani, Haneen
AU  - Alzahrani H
AD  - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi
      Arabia.
AD  - King Saud Bin Abdulaziz University of Health Sciences (KSAU-HS), Riyadh, Saudi
      Arabia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Control
JT  - Cancer control : journal of the Moffitt Cancer Center
JID - 9438457
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Cooperative Behavior
MH  - Decision Making, Shared
MH  - *Ethics, Nursing
MH  - Female
MH  - Humans
MH  - Infant
MH  - Interviews as Topic
MH  - Male
MH  - Neoplasms/*nursing
MH  - Nurse's Role
MH  - Nurses/*psychology
MH  - Parents/*psychology
MH  - Qualitative Research
MH  - Saudi Arabia
PMC - PMC7160780
OTO - NOTNLM
OT  - bioethics
OT  - decision making
OT  - informed consent
OT  - nurses qualitative
OT  - pediatric cancer
EDAT- 2020/04/16 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - 10.1177/1073274820917210 [doi]
PST - ppublish
SO  - Cancer Control. 2020 Jan-Dec;27(1):1073274820917210. doi:
      10.1177/1073274820917210.


PMID- 32291790
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1467-9566 (Electronic)
IS  - 0141-9889 (Linking)
VI  - 42
IP  - 4
DP  - 2020 May
TI  - From more-than-human solidarity to multi-species biographical value: insights
      from a veterinary school about ethical dilemmas in One Health promotion.
PG  - 789-808
LID - 10.1111/1467-9566.13065 [doi]
AB  - This article features a partnership between a veterinary school and a charity
      that aims to enhance the wellbeing of low-income people. Through this
      partnership, the charity periodically hosts veterinary clinics for clients and
      their pets. Even as the veterinarians and veterinary students duly examine
      people's pets, these pop-up clinics aim to help people and their pets. Hence our 
      analysis revolves around the ethics of 'more-than-human solidarity'. By
      'more-than-human solidarity', we mean efforts to help others that either center
      on or that implicate non-human beings. To delve into the ethical and sociological
      implications of subsidised veterinary services, and to assist with program
      planning, we conducted several in-depth interviews with veterinarians. Most
      substantively, we found that the veterinary school's outreach clinics give rise
      to multi-species biographical value, which is prized as a pedagogical resource
      for veterinary students. The veterinarians whom we interviewed felt troubled by
      the extent to which the pop-up clinics ultimately benefited the veterinary
      school, but also by the shortage of subsidised veterinary services in the
      vicinity. Based on these interviews and our own reflections, we invite more
      scholarship on cultural, economic and political influences that shape the lives
      of human beings and non-human animals alike.
CI  - (c) 2020 Foundation for the Sociology of Health & Illness.
FAU - Rock, Melanie J
AU  - Rock MJ
AUID- ORCID: 0000-0003-2436-3159
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, Calgary, Canada.
FAU - Degeling, Chris
AU  - Degeling C
AD  - Australian Centre for Health Engagement, Evidence, and Values, University of
      Wollongong, Wollongong, Australia.
FAU - Adams, Cindy L
AU  - Adams CL
AD  - Department of Clinical and Diagnostic Sciences, Faculty of Veterinary Medicine,
      University of Calgary, Calgary, Canada.
LA  - eng
GR  - MOP-130569/CIHR/Canada
GR  - MOP-130569/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200415
PL  - England
TA  - Sociol Health Illn
JT  - Sociology of health & illness
JID - 8205036
SB  - IM
MH  - Animals
MH  - Health Promotion
MH  - Humans
MH  - Morals
MH  - *Schools, Veterinary
MH  - Sociology
MH  - *Veterinarians
OTO - NOTNLM
OT  - *animal welfare
OT  - *charities
OT  - *ethical analysis
OT  - *human-pet bonding
OT  - *poverty
OT  - *problem-based learning
OT  - *social determinants of health
OT  - *sociology, medical
OT  - *veterinary education
EDAT- 2020/04/16 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.1111/1467-9566.13065 [doi]
PST - ppublish
SO  - Sociol Health Illn. 2020 May;42(4):789-808. doi: 10.1111/1467-9566.13065. Epub
      2020 Apr 15.


PMID- 32291599
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 28
IP  - 12
DP  - 2020 Dec
TI  - Cancer patients, physicians, and nurses differ in their attitudes toward the
      decisional role in do-not-resuscitate decision-making.
PG  - 6057-6066
LID - 10.1007/s00520-020-05460-7 [doi]
AB  - PURPOSE: Do-not-resuscitate (DNR) decision-making in severely ill patients
      presents many difficult medical, ethical, and legal challenges. The primary aim
      of this study was to explore cancer patients' and health care professionals'
      attitudes regarding DNR decision-making authority and timing of the decision.
      METHODS: This study was a questionnaire survey among Danish cancer patients and
      their attending physicians and nurses in an oncology outpatient setting.
      Potential differences between patients', physicians', and nurses' answers to the 
      questionnaire were analyzed using Fisher's exact test. RESULTS: Responses from
      904 patients, 59 physicians, and 160 nurses were analyzed. The majority in all
      three groups agreed that DNR decisions should be made in collaboration between
      physician and patient. However, one-third of the patients answered that the
      patient alone should make the decision regarding DNR, which contrasts with the
      physicians' and nurses' attitudes, 0% and 6% pointing to the patient as sole
      decision-maker, respectively. In case of disagreement between patient and
      physician, a majority of both patients (66%) and physicians (86%) suggested
      themselves as the ultimate decision-maker. Additionally, 43% of patients but only
      19% of physicians preferred the DNR discussion being brought up early in the
      course of the disease. CONCLUSIONS: With regard to the decisional role of patient
      vs. physician and the timing of the DNR discussion, we found a substantial
      discrepancy between the attitudes of cancer patients and physicians. This
      discrepancy calls for a greater awareness and discussion of this sensitive topic 
      among both health care professionals and the public.
FAU - Saltbaek, Lena
AU  - Saltbaek L
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib
      Juuls Vej 7, DK-2730, Herlev, Denmark. lesa@cancer.dk.
AD  - Survivorship and Inequality in Cancer, Danish Cancer Society Research Center,
      Strandboulevarden 49, DK-2100, Copenhagen, Denmark. lesa@cancer.dk.
AD  - Department of Oncology, Zealand University Hospital, Ringstedgade 61, DK-4700,
      Naestved, Denmark. lesa@cancer.dk.
FAU - Michelsen, Hanne M
AU  - Michelsen HM
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib
      Juuls Vej 7, DK-2730, Herlev, Denmark.
FAU - Nelausen, Knud M
AU  - Nelausen KM
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib
      Juuls Vej 7, DK-2730, Herlev, Denmark.
FAU - Theile, Susann
AU  - Theile S
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib
      Juuls Vej 7, DK-2730, Herlev, Denmark.
FAU - Dehlendorff, Christian
AU  - Dehlendorff C
AD  - Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research
      Center, Strandboulevarden 49, DK-2100, Copenhagen, Denmark.
FAU - Dalton, Susanne O
AU  - Dalton SO
AD  - Survivorship and Inequality in Cancer, Danish Cancer Society Research Center,
      Strandboulevarden 49, DK-2100, Copenhagen, Denmark.
AD  - Department of Oncology, Zealand University Hospital, Ringstedgade 61, DK-4700,
      Naestved, Denmark.
FAU - Nielsen, Dorte L
AU  - Nielsen DL
AD  - Department of Oncology, Herlev and Gentofte University Hospital, Borgmester Ib
      Juuls Vej 7, DK-2730, Herlev, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Attitude of Health Personnel
MH  - Attitude to Death
MH  - *Decision Making
MH  - Denmark/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Medical Oncology
MH  - Medical Staff, Hospital/psychology
MH  - Middle Aged
MH  - Neoplasms/diagnosis/mortality/psychology/*therapy
MH  - *Nurses/psychology/statistics & numerical data
MH  - *Patients/psychology/statistics & numerical data
MH  - *Physicians/psychology/statistics & numerical data
MH  - Professional-Patient Relations
MH  - Resuscitation Orders/*psychology
MH  - Surveys and Questionnaires
MH  - Time Factors
OTO - NOTNLM
OT  - Cancer
OT  - Decision
OT  - Decisional role
OT  - Do-not-resuscitate
OT  - Resuscitation order
OT  - Timing
EDAT- 2020/04/16 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/06/17 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - 10.1007/s00520-020-05460-7 [doi]
AID - 10.1007/s00520-020-05460-7 [pii]
PST - ppublish
SO  - Support Care Cancer. 2020 Dec;28(12):6057-6066. doi: 10.1007/s00520-020-05460-7. 
      Epub 2020 Apr 15.


PMID- 32291432
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20210412
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 41
IP  - 4
DP  - 2020 Apr
TI  - The prevalence of hypocalcemia following total thyroidectomy. A retrospective
      study based at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
PG  - 431-434
LID - 10.15537/smj.2020.4.25045 [doi]
AB  - OBJECTIVES: To estimate the prevalence of hypocalcemia following total
      thyroidectomy (TT) at a tertiary center. METHODS: This retrospective study was
      conducted between 2014 and 2019 at King Abdulaziz University Hospital (KAUH),
      Jeddah, Saudi Arabia. The study was based at the Department of General Surgery
      and was approved by the Research Ethics Committee of KAUH. Medical records of 154
      patients who had undergone TT were reviewed. Data such as age, gender, level of
      postoperative calcium at 24 and 48 hours after surgery, parathyroid hormone (PTH)
      levels, central neck dissection (CCND), histological diagnosis were entered into 
      Microsoft Excel sheets. RESULTS: Hypocalcemia occurred more on the second day
      after surgery in 67.4% of patients. Among them, 83.9% were female and 16.1% were 
      male. The majority of patients were asymptomatic and benign thyroid disease was
      the most common. There was a significant association between hypocalcemia and the
      PTH level (p less than 0.001). CONCLUSION: There was a high prevalence of
      hypocalcemia on the second day after surgery. Presence of hypocalcemia
      association with the PTH level. Meticulous surgical technique and preservation of
      parathyroid vascularity are important in preventing postoperative hypocalcemia.
FAU - Althoubaity, Fatma K
AU  - Althoubaity FK
AD  - Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. 
      E-mail. sultanalmusallam1418@gmail.com.
FAU - Almusallam, Sultan A
AU  - Almusallam SA
FAU - Alghorair, Abdullah S
AU  - Alghorair AS
FAU - AlQahtani, Faisal S
AU  - AlQahtani FS
FAU - Khotani, Omar M
AU  - Khotani OM
FAU - Bamakhish, Naif F
AU  - Bamakhish NF
FAU - Alzriri, Ammar D
AU  - Alzriri AD
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - 0 (Parathyroid Hormone)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Calcium/metabolism
MH  - Female
MH  - Humans
MH  - Hypocalcemia/*epidemiology/etiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Parathyroid Hormone/metabolism
MH  - Postoperative Complications/*epidemiology/etiology/prevention & control
MH  - Prevalence
MH  - Retrospective Studies
MH  - Saudi Arabia/epidemiology
MH  - Sex Factors
MH  - *Thyroidectomy/adverse effects
PMC - PMC7841603
EDAT- 2020/04/16 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
AID - 10.15537/smj.2020.4.25045 [doi]
PST - ppublish
SO  - Saudi Med J. 2020 Apr;41(4):431-434. doi: 10.15537/smj.2020.4.25045.


PMID- 32291296
OWN - NLM
STAT- MEDLINE
DCOM- 20200904
LR  - 20200904
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 94
IP  - 19
DP  - 2020 May 12
TI  - Patients' views on the ethical challenges of early Parkinson disease detection.
PG  - e2037-e2044
LID - 10.1212/WNL.0000000000009400 [doi]
AB  - OBJECTIVE: To evaluate the point of view of patients with Parkinson disease (PD) 
      on early detection and risk disclosure in the prodromal phase of PD and to derive
      recommendations for an ethical framework for the recruitment of prodromal PD
      cohorts. METHODS: A standardized questionnaire to evaluate the patients'
      perception on early diagnosis in PD was designed by an interdisciplinary study
      group. After testing in a preliminary feasibility study (n = 20), the survey was 
      performed retrospectively with patients from our clinic. RESULTS: A total of 101 
      patients with PD answered the questions. The majority of patients reported that
      time from onset of motor symptoms to diagnosis was burdensome, including false
      diagnoses and many consultations of various medical specialists. However, most of
      the patients evaluated early risk disclosure with skepticism. Freedom of choice
      and the potential of changes in lifestyle were rated as important. CONCLUSION:
      Although patients with PD reported the time to diagnosis retrospectively as
      burdensome, the majority was skeptical regarding early disclosure of risk,
      especially with regard to the lack of pharmacologic options. Circumstances under 
      which early detection and disclosure would have been approved by the majority of 
      patients were (1) advice on lifestyle changes (exercise, nutrition) as
      potentially disease course-modifying therapy; (2) the establishment of an early
      diagnosis "culture," including early clarification of the patients' wish to know;
      and (3) regular support and follow-up of individuals after risk disclosure.
CI  - (c) 2020 American Academy of Neurology.
FAU - Schaeffer, Eva
AU  - Schaeffer E
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany. eva.schaeffer@uksh.de.
FAU - Rogge, Annette
AU  - Rogge A
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany.
FAU - Nieding, Katharina
AU  - Nieding K
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany.
FAU - Helmker, Vera
AU  - Helmker V
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany.
FAU - Letsch, Christa
AU  - Letsch C
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany.
FAU - Hauptmann, Bjorn
AU  - Hauptmann B
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany.
FAU - Berg, Daniela
AU  - Berg D
AD  - From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of
      Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of
      Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and
      Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience,
      Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of
      Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research,
      University of Tubingen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Attitude
MH  - Disclosure/*ethics
MH  - *Early Diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*diagnosis
MH  - Patients/*psychology
MH  - Surveys and Questionnaires/standards
EDAT- 2020/04/16 06:00
MHDA- 2020/09/05 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/11/19 00:00 [accepted]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/09/05 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - WNL.0000000000009400 [pii]
AID - 10.1212/WNL.0000000000009400 [doi]
PST - ppublish
SO  - Neurology. 2020 May 12;94(19):e2037-e2044. doi: 10.1212/WNL.0000000000009400.
      Epub 2020 Apr 14.


PMID- 32290863
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Apr 14
TI  - Principal component analysis of adipocytokines and insulin associate with risk
      factors of cardiovascular diseases.
PG  - 212
LID - 10.1186/s13104-020-04976-9 [doi]
AB  - OBJECTIVES: Obesity plays an important role in the development of chronic
      diseases like cardiovascular diseases and diabetes. The possible underlying
      mechanism for this connection is that adipose tissue secretes an array of
      chemical messenger adipokines proinflammatory cytokines (tumor necrosis
      factor-alpha, interleukin-6, and interleukin-1-beta). This study aimed to
      investigate the linkage between adipocytokines and insulin with the
      cardiovascular disease risk, with particular reference to the adipokines
      galectin-3, plasminogen activator inhibitor-1, and interleukin-1-beta, C-reactive
      protein, and monocyte chemoattractant protein. RESULT: Two patterns were
      identified. The first pattern was galectin-3, plasminogen activator inhibitor-1
      and interleukin-1-beta and the second one was C-reactive protein, insulin and
      monocyte chemoattractant protein-1. The second pattern was strongly associated
      with the higher scores for resting metabolic rate, diastolic blood pressure,
      homeostasis model insulin resistance index, lipid profile (except low density
      lipoprotein, total cholesterol), and body composition parameters (except fat free
      mass index and waist hip ratio), while negatively associated with age and high
      density lipoprotein level (all p < 0.05). The first pattern was, however,
      significantly associated with body fat mass, obesity degree percentage, waist
      circumference, fat mass index, and waist hip ratio (p < 0.05 for all). This is a 
      retrospective study. Ethics approval (IR.TUMS.VCR.REC.1395.1597).
FAU - Yarizadeh, Habib
AU  - Yarizadeh H
AD  - Students' Scientific Center, Tehran University of Medical Sciences, PO Box
      1417755331, Tehran, Iran.
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
FAU - Setayesh, Leila
AU  - Setayesh L
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
FAU - Askarpoor, Moein
AU  - Askarpoor M
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
FAU - Pooyan, Sara
AU  - Pooyan S
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
FAU - Sajjadi, Seyedeh Forough
AU  - Sajjadi SF
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
FAU - Badrooj, Negin
AU  - Badrooj N
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
FAU - Roberts, Caroline
AU  - Roberts C
AD  - Department of Nutritional Sciences, School of Life Course Sciences, Faculty of
      Life Sciences and Medicine, King's College London, London, UK.
FAU - Mirzaei, Khadijeh
AU  - Mirzaei K
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences (TUMS), P.O. Box: 14155-6117, Tehran, Iran.
      mirzaei_kh@tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Adipokines)
RN  - 0 (Insulin)
SB  - IM
MH  - Adipokines/*blood
MH  - Adolescent
MH  - Adult
MH  - Body Mass Index
MH  - Cardiovascular Diseases/*blood/*epidemiology
MH  - Female
MH  - Humans
MH  - Insulin/*blood
MH  - Iran/epidemiology
MH  - Middle Aged
MH  - Obesity/*epidemiology/*metabolism
MH  - Principal Component Analysis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Waist Circumference
MH  - Waist-Hip Ratio
MH  - Young Adult
PMC - PMC7157993
OTO - NOTNLM
OT  - Adipocytokines
OT  - Cardiovascular diseases
OT  - Obesity
EDAT- 2020/04/16 06:00
MHDA- 2021/01/12 06:00
CRDT- 2020/04/16 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
AID - 10.1186/s13104-020-04976-9 [doi]
AID - 10.1186/s13104-020-04976-9 [pii]
PST - epublish
SO  - BMC Res Notes. 2020 Apr 14;13(1):212. doi: 10.1186/s13104-020-04976-9.


PMID- 32290584
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 12
TI  - Human Wharton's Jelly-Cellular Specificity, Stemness Potency, Animal Models, and 
      Current Application in Human Clinical Trials.
LID - E1102 [pii]
LID - 10.3390/jcm9041102 [doi]
AB  - Stem cell therapies offer a great promise for regenerative and reconstructive
      medicine, due to their self-renewal and differentiation capacity. Although
      embryonic stem cells are pluripotent, their utilization involves embryo
      destruction and is ethically controversial. Therefore, adult tissues that have
      emerged as an alternative source of stem cells and perinatal tissues, such as the
      umbilical cord, appear to be particularly attractive. Wharton's jelly, a
      gelatinous connective tissue contained in the umbilical cord, is abundant in
      mesenchymal stem cells (MSCs) that express CD105, CD73, CD90, Oct-4, Sox-2, and
      Nanog among others, and have the ability to differentiate into osteogenic,
      adipogenic, chondrogenic, and other lineages. Moreover, Wharton's jelly-derived
      MSCs (WJ-MSCs) do not express MHC-II and exhibit immunomodulatory properties,
      which makes them a good alternative for allogeneic and xenogeneic
      transplantations in cellular therapies. Therefore, umbilical cord, especially
      Wharton's jelly, is a promising source of mesenchymal stem cells.
FAU - Stefanska, Katarzyna
AU  - Stefanska K
AUID- ORCID: 0000-0002-8814-4935
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
FAU - Ozegowska, Katarzyna
AU  - Ozegowska K
AD  - Department of Infertility and Reproductive Endocrinology, Poznan University of
      Medical Sciences, 60-535 Poznan, Poland.
FAU - Hutchings, Greg
AU  - Hutchings G
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
FAU - Popis, Malgorzata
AU  - Popis M
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
FAU - Moncrieff, Lisa
AU  - Moncrieff L
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
AD  - School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
FAU - Dompe, Claudia
AU  - Dompe C
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
AD  - School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
FAU - Janowicz, Krzysztof
AU  - Janowicz K
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Aberdeen AB25 2ZD, UK.
FAU - Pienkowski, Wojciech
AU  - Pienkowski W
AD  - Division of Perinatology and Women's Diseases, Poznan University of Medical
      Sciences, 60-535 Poznan, Poland.
FAU - Gutaj, Pawel
AU  - Gutaj P
AD  - Department of Obstetrics and Women's Diseases, Poznan University of Medical
      Sciences, 60-535 Poznan, Poland.
FAU - Shibli, Jamil A
AU  - Shibli JA
AUID- ORCID: 0000-0003-1971-0195
AD  - Department of Periodontology, Dental Research Division, Guarulhos University,
      Guarulhos, 07023-070 Sao Paulo, Brazil.
FAU - Prado, Walterson Mathias
AU  - Prado WM
AD  - Department of Periodontology, Dental Research Division, Guarulhos University,
      Guarulhos, 07023-070 Sao Paulo, Brazil.
FAU - Piotrowska-Kempisty, Hanna
AU  - Piotrowska-Kempisty H
AD  - Department of Toxicology, Poznan University of Medical Sciences, 61-631 Poznan,
      Poland.
FAU - Mozdziak, Paul
AU  - Mozdziak P
AUID- ORCID: 0000-0002-1575-3123
AD  - Physiology Graduate Program, North Carolina State University, Raleigh, NC 27695, 
      USA.
FAU - Bruska, Malgorzata
AU  - Bruska M
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
FAU - Zabel, Maciej
AU  - Zabel M
AD  - Division of Histology and Embryology, Department of Human Morphology and
      Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
AD  - Division of Anatomy and Histology, University of Zielona Gora, 65-046 Zielona
      Gora, Poland.
FAU - Kempisty, Bartosz
AU  - Kempisty B
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
AD  - Department of Anatomy, Poznan University of Medical Sciences, 60-781 Poznan,
      Poland.
AD  - Department of Obstetrics and Gynecology, University Hospital and Masaryk
      University, 602 00 Brno, Czech Republic.
AD  - Department of Veterinary Surgery, Institute of Veterinary Medicine, Nicolaus
      Copernicus University in Torun, 87-100 Torun, Poland.
FAU - Nowicki, Michal
AU  - Nowicki M
AD  - Department of Histology and Embryology, Poznan University of Medical Sciences,
      60-781 Poznan, Poland.
LA  - eng
GR  - 0070/DW/2018/02/Ministerstwo Nauki i Szkolnictwa Wyzszego
PT  - Journal Article
PT  - Review
DEP - 20200412
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7230974
OTO - NOTNLM
OT  - Wharton's jelly
OT  - stem cells
OT  - umbilical cord
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/03/30 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
AID - jcm9041102 [pii]
AID - 10.3390/jcm9041102 [doi]
PST - epublish
SO  - J Clin Med. 2020 Apr 12;9(4). pii: jcm9041102. doi: 10.3390/jcm9041102.


PMID- 32290432
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 11
TI  - Global Strategies for Population Management of Domestic Cats (Felis catus): A
      Systematic Review to Inform Best Practice Management for Remote Indigenous
      Communities in Australia.
LID - E663 [pii]
LID - 10.3390/ani10040663 [doi]
AB  - Pet domestic cat (Felis catus) populations are increasing all around the world,
      resulting in an increase in contact with humans and wildlife, potentially
      spreading zoonotic diseases and predating on wildlife. With the recently
      identified rise in cat populations in remote Indigenous communities in Australia,
      culturally appropriate cat population management strategies are required. A
      systematic review process was conducted to review the current global cat
      population management practices that are suitable for owned, free-roaming cat
      populations in these communities. Eight articles on in-situ field cat populations
      and five studies simulating computer modelled cat populations reported results of
      66 population management interventions. Surgical Sterilisation (SS) was used in
      all socialised owned cat articles. The trap-neuter-release (TNR) method was used 
      most frequently on unsocialised cats and gained the best results when the
      trap-remove (TR) method was used concurrently to adopt out unwanted social cats
      and euthanise ill or injured cats. The results of this review suggest that
      long-term TNR/SS programs supplemented with TR provide the current most ethically
      sound best practice, humane method of managing cat populations in remote
      Australian Indigenous communities. It is also recognised that no one plan will
      fit all, and that further research on the micro-level techniques used to deploy
      both TNR and TR needs to occur, and that culturally appropriate community
      consultation during all processes is vital in achieving a sustainable management 
      program.
FAU - Kennedy, Brooke P A
AU  - Kennedy BPA
AUID- ORCID: 0000-0002-1337-9705
AD  - AMRRIC-Animal Management in Rural and Remote Indigenous Communities, Winnellie,
      NT 0820, Australia.
AD  - School of Environmental and Rural Science, University of New England, Armidale
      NSW 2353, Australia.
FAU - Cumming, Bonny
AU  - Cumming B
AD  - AMRRIC-Animal Management in Rural and Remote Indigenous Communities, Winnellie,
      NT 0820, Australia.
FAU - Brown, Wendy Y
AU  - Brown WY
AUID- ORCID: 0000-0002-5309-3381
AD  - School of Environmental and Rural Science, University of New England, Armidale
      NSW 2353, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200411
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7222776
OTO - NOTNLM
OT  - Felis catus
OT  - aboriginal community
OT  - culturally appropriate
OT  - domestic cat
OT  - indigenous community
OT  - population management
EDAT- 2020/04/16 06:00
MHDA- 2020/04/16 06:01
CRDT- 2020/04/16 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/04/06 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/04/16 06:00 [entrez]
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2020/04/16 06:01 [medline]
AID - ani10040663 [pii]
AID - 10.3390/ani10040663 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Apr 11;10(4). pii: ani10040663. doi: 10.3390/ani10040663.


PMID- 32289696
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1876-4754 (Electronic)
IS  - 1876-4754 (Linking)
VI  - 13
IP  - 3
DP  - 2020 May - Jun
TI  - Effectiveness of cathodal tDCS of the primary motor or sensory cortex in
      migraine: A randomized controlled trial.
PG  - 675-682
LID - S1935-861X(20)30034-6 [pii]
LID - 10.1016/j.brs.2020.02.012 [doi]
AB  - OBJECTIVES: Transcranial Direct Current Stimulation (tDCS) is a new technology
      that is extensively used for migraine treatment. The present study aims to
      examine the effectiveness of cathodal-tDCS (c-tDCS) in decreasing migraine pain
      frequency, duration, and intensity at the right primary motor cortex (M1) or
      sensory cortex (S1) in individuals with episodic or chronic migraine. METHODS:
      The present study has a randomized, single-blind, and sham-controlled design. It 
      tests the effectiveness of 22 sessions of c-tDCS (20min/1000 muA) in 45 migraine 
      patients (episodic = 35; chronic = 10/with aura = 28; without aura = 17). Spread 
      over 10 consecutive weeks, the sessions started with three sessions per week and 
      ended with one session per week. Participants were tested at the baseline, at the
      end of intervention, and at 12-month follow-up. The migraine diagnosis was based 
      on criteria set by International Headache Society (IHS) and patients were
      allocated to two experimental (nm1 = 15; ns1 = 15) and a sham intervention group 
      (nc = 15). RESULTS: The results of a series of MANCOVAs showed a significant
      reduction (p < 0.05) in all hypothesized symptoms of migraine pain in both
      experimental groups compared to the sham intervention group at the posttest and
      follow-up. CONCLUSION: The application of c-tDCS to M1 or S1 can be used as a
      technological intervention for the prophylactic and therapeutic treatment of
      episodic or chronic migraine. ETHICAL COMMITTEE REGISTRATION NUMBER:
      Ir.mums.fm.rec.1396.362.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Rahimi, Mohammad Dawood
AU  - Rahimi MD
AD  - School of Education and Psychology, Ferdowsi University of Mashhad, Mashhad,
      Iran.
FAU - Fadardi, Javad Salehi
AU  - Fadardi JS
AD  - School of Education and Psychology, Ferdowsi University of Mashhad, Mashhad,
      Iran; School of Community and Global Health, Claremont Graduate University, USA; 
      School of Psychology, Bangor University, UK. Electronic address:
      j.s.fadardi@um.ac.ir.
FAU - Saeidi, Morteza
AU  - Saeidi M
AD  - Mashhad University of Medical Sciences, Mashhad, Iran.
FAU - Bigdeli, Imanolla
AU  - Bigdeli I
AD  - School of Education and Psychology, Ferdowsi University of Mashhad, Mashhad,
      Iran.
FAU - Kashiri, Rohollah
AU  - Kashiri R
AD  - Mashhad University of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200214
PL  - United States
TA  - Brain Stimul
JT  - Brain stimulation
JID - 101465726
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Electrodes
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*diagnosis/*therapy
MH  - Motor Cortex/*physiology
MH  - Pain/diagnosis
MH  - Pain Management/methods
MH  - Single-Blind Method
MH  - Somatosensory Cortex/*physiology
MH  - Transcranial Direct Current Stimulation/*methods
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - *Migraine treatment
OT  - *Primary motor or primary sensory cortex
OT  - *Transcranial direct current stimulation
OT  - *t-DCS
EDAT- 2020/04/15 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/07/28 00:00 [received]
PHST- 2020/02/06 00:00 [revised]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - S1935-861X(20)30034-6 [pii]
AID - 10.1016/j.brs.2020.02.012 [doi]
PST - ppublish
SO  - Brain Stimul. 2020 May - Jun;13(3):675-682. doi: 10.1016/j.brs.2020.02.012. Epub 
      2020 Feb 14.


PMID- 32289648
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 253
DP  - 2020 May
TI  - Social, ethical, and other value judgments in health economics modelling.
PG  - 112975
LID - S0277-9536(20)30194-5 [pii]
LID - 10.1016/j.socscimed.2020.112975 [doi]
AB  - Modelling is a major method of inquiry in health economics. In other
      modelling-intensive fields, such as climate science, recent scholarship has
      described how social and ethical values influence model development. However, no 
      similar work has been done in health economics. This study explored the role of
      social, ethical, and other values in health economics modelling using
      philosophical theory and qualitative interviews in British Columbia, Canada.
      Twenty-two professionals working in health economics modelling were interviewed
      between February and May, 2019. The study findings provide support for four
      philosophical arguments positing an essential role for social and ethical values 
      throughout scientific inquiry and demonstrate how these arguments apply to health
      economics modelling. It highlights the role of social values in informing early
      modelling decisions, shaping model assumptions, making trade-offs between
      desirable model features, and setting standards of evidence. These results point 
      to several decisions in the modelling process that warrant focus in future health
      economics research, particularly that which aims to incorporate patient and
      public values.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Harvard, Stephanie
AU  - Harvard S
AD  - Faculty of Health Sciences, Simon Fraser University, 8888 University
      Drive,Burnaby, British Columbia, V5A 1S6, Canada; Centre for Clinical
      Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 828
      West 10th Avenue, Vancouver, British Columbia, V5Z 1M9, Canada. Electronic
      address: harvards@mail.ubc.ca.
FAU - Werker, Gregory R
AU  - Werker GR
AD  - Sauder School of Business, University of British Columbia, Henry Angus Building
      2053 Main Mall, Vancouver, British Columbia, V6T 1Z2, Canada; Centre for Health
      Evaluation and Outcome Sciences, St. Paul's Hospital, 588 - 1081 Burrard Street, 
      Vancouver, British Columbia, V6Z 1Y6, Canada.
FAU - Silva, Diego S
AU  - Silva DS
AD  - Sydney Health Ethics, School of Public Health, University of Syeney, 92/94
      Parrammata Rd, Camperdown, NSW, 2050, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200402
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - British Columbia
MH  - Economics
MH  - *Economics, Medical
MH  - Humans
MH  - *Judgment
MH  - Morals
MH  - Social Values
OTO - NOTNLM
OT  - *Canada
OT  - *Health economics
OT  - *Modelling
OT  - *PPI
OT  - *Patient and public involvement
OT  - *Patient-oriented research
OT  - *Qualitative
OT  - *Values
EDAT- 2020/04/15 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - S0277-9536(20)30194-5 [pii]
AID - 10.1016/j.socscimed.2020.112975 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 May;253:112975. doi: 10.1016/j.socscimed.2020.112975. Epub 2020
      Apr 2.


PMID- 32289498
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 2468-7189 (Electronic)
IS  - 2468-7189 (Linking)
VI  - 48
IP  - 10
DP  - 2020 Oct
TI  - [Comparative survey of French oocyte donor's profile and motivations between
      nulliparous and multiparous donors, 2017-2018].
PG  - 736-745
LID - S2468-7189(20)30157-4 [pii]
LID - 10.1016/j.gofs.2020.04.004 [doi]
AB  - OBJECTIVES: Since the authorization of French nulliparous women to donate
      oocytes, who are the new donors? What are the similar and differential points
      with the initial donors who have already procreated? METHODS: Retrospective
      multicenter cohort study using a questionnaire. RESULTS: The return rate is 90.7%
      with 248 donor files from 5 French assisted reproductive technology (ART)
      centers, included between 1 January 2017 and 31 December 2018. The average age is
      31,0 years. More than two thirds of women have a higher educational level than
      the license. Donation is spontaneous or relational in 69% and 25% of cases,
      respectively. Among nulliparous donors, 37% don't know the possibility of
      self-preservation but after information, 80% wish to benefit from it versus 32%
      of multiparous women if they were given the opportunity. CONCLUSIONS: This study 
      by the Study Group for Egg Donation (GEDO) highlights the particularities of
      French oocytes donors. The 2015 decree allowed to diversify the origin of the
      donation, which remains mainly altruistic but the possibility of
      self-preservation for nulliparous donors also seems to motivate women. This link 
      between donation and self-preservation poses an ethical problem that needs to be 
      approached and resolved in the next Bioethics Law framing Assisted Reproductive
      Technologies (ART).
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Kretz, M
AU  - Kretz M
AD  - Service de Gynecologie, Hopitaux Universitaires de Strasbourg, avenue Moliere,
      67000 Strasbourg. Electronic address: mathilda.kretz@chru-strasbourg.fr.
FAU - Ohl, J
AU  - Ohl J
AD  - Service d'Assistance Medicale a la Procreation (CMCO), Hopitaux Universitaires de
      Strasbourg, rue Louis Pasteur, 67300 Schiltigheim. Electronic address:
      jeanine.ohl@chru-strasbourg.fr.
FAU - Letur, H
AU  - Letur H
AD  - Service d'Assistance Medicale a la Procreation - Preservation de la Fertilite,
      Polyclinique de Navarre, boulevard Haute rive, 64000 Pau. Electronic address:
      helene.letur@cliniquedenavarre.com.
FAU - Guivarch, A
AU  - Guivarch A
AD  - Clinique La Sagesse, 3, place Saint Guenole, 35000 Rennes. Electronic address:
      anne.guivarch@orange.fr.
FAU - Catteau-Jonard, S
AU  - Catteau-Jonard S
AD  - Universite. Lille, CHU Lille, 59000 Lille, France. Electronic address:
      sophie.catteau@chru-lille.fr.
FAU - De Mouzon, J
AU  - De Mouzon J
AD  - 15, rue Guilleminot, 75014 Paris, France. Electronic address:
      jacques.de.mouzon@gmail.com.
LA  - fre
PT  - Journal Article
PT  - Multicenter Study
TT  - Profils et motivations des donneuses d'ovocytes en France en 2017-2018 :
      comparaison entre les nullipares et celles qui ont deja procree.
DEP - 20200411
PL  - France
TA  - Gynecol Obstet Fertil Senol
JT  - Gynecologie, obstetrique, fertilite & senologie
JID - 101693805
SB  - IM
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - *Motivation
MH  - *Oocyte Donation
MH  - Oocytes
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Autoconservation
OT  - *Donneuses
OT  - *Donors
OT  - *Fertility preservation
OT  - *France
OT  - *Oocytes
OT  - *Ovocytes
EDAT- 2020/04/15 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - S2468-7189(20)30157-4 [pii]
AID - 10.1016/j.gofs.2020.04.004 [doi]
PST - ppublish
SO  - Gynecol Obstet Fertil Senol. 2020 Oct;48(10):736-745. doi:
      10.1016/j.gofs.2020.04.004. Epub 2020 Apr 11.


PMID- 32289282
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1558-349X (Electronic)
IS  - 1546-1440 (Linking)
VI  - 17
IP  - 8
DP  - 2020 Aug
TI  - Fortifying Our Teams to Best Serve Our Patients: A Report of the 2019 Summer
      Intersociety Meeting.
PG  - 1061-1067
LID - S1546-1440(20)30264-7 [pii]
LID - 10.1016/j.jacr.2020.03.007 [doi]
AB  - Continuing the thematic focus on fostering wellness and professional fulfillment 
      in our workplace, the 2019 Radiology Intersociety Committee Conference focused on
      understanding and leading multigenerational workforces and developing
      high-functioning teams. To lead a multigenerational workforce and to understand
      and embrace traditional versus emerging cultures in our workplace, effective
      leaders should foster diversity of their teams. Sustaining such teams requires an
      understanding of different styles and preferences for bidirectional communication
      and clarity of information sharing and learning; active efforts may be needed to 
      focus on practical approaches to succession planning, breaking down traditional
      hierarchies, clarifying role delineation, and managing authority gradients. An
      effective team requires attention to the well-being of team members and
      professional behavior in and out of the workplace. Conference participants
      unanimously endorsed multi-organizational support statements and activities
      assuring professional behavior of their members, along with the desire to explore
      codes of conduct and ethics.
CI  - Copyright (c) 2020 American College of Radiology. Published by Elsevier Inc. All 
      rights reserved.
FAU - Kruskal, Jonathan
AU  - Kruskal J
AD  - Chair, Department of Radiology, Beth Israel Deaconess Medical Center, Boston,
      Massachusetts. Electronic address: jkruskal@bidmc.harvard.edu.
FAU - Meltzer, Carolyn C
AU  - Meltzer CC
AD  - Department Chair, Institutional Dean, Emory University, Atlanta, Georgia.
FAU - Shanafelt, Tait
AU  - Shanafelt T
AD  - Director, WellMD Center, Stanford University, Stanford, California.
FAU - Gupta, Sonia
AU  - Gupta S
AD  - Department of Radiology, Beth Israel Deaconess Medical Center, Boston,
      Massachusetts.
FAU - Rawson, James
AU  - Rawson J
AD  - Vice Chair, Department of Radiology, Beth Israel Deaconess Medical Center,
      Boston, Massachusetts.
FAU - Deitte, Lori
AU  - Deitte L
AD  - Vice Chair of Education, Department of Radiology and Radiological Sciences,
      Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Gibbs, Iris
AU  - Gibbs I
AD  - Dean, Stanford University, Stanford, California.
FAU - Raybon, Courtney
AU  - Raybon C
AD  - Vanderbilt University, Nashville, Tennessee.
FAU - West, Derek
AU  - West D
AD  - Emory University, Atlanta, Georgia.
FAU - Canon, Cheri
AU  - Canon C
AD  - Chair, Department of Radiology, University of Alabama, Tuscaloosa, Alabama.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - United States
TA  - J Am Coll Radiol
JT  - Journal of the American College of Radiology : JACR
JID - 101190326
SB  - IM
MH  - Group Processes
MH  - Humans
MH  - *Leadership
MH  - Patient Care Team
MH  - *Radiology
MH  - Workplace
OTO - NOTNLM
OT  - Leadership
OT  - professional fulfillment
OT  - professionalism
OT  - team building
OT  - wellness
EDAT- 2020/04/15 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - S1546-1440(20)30264-7 [pii]
AID - 10.1016/j.jacr.2020.03.007 [doi]
PST - ppublish
SO  - J Am Coll Radiol. 2020 Aug;17(8):1061-1067. doi: 10.1016/j.jacr.2020.03.007. Epub
      2020 Apr 11.


PMID- 32289230
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1545-293X (Electronic)
IS  - 1527-8204 (Linking)
VI  - 21
DP  - 2020 Aug 31
TI  - Pedigrees and Perpetrators: Uses of DNA and Genealogy in Forensic Investigations.
PG  - 535-564
LID - 10.1146/annurev-genom-111819-084213 [doi]
AB  - In the past few years, cases with DNA evidence that could not be solved with
      direct matches in DNA databases have benefited from comparing single-nucleotide
      polymorphism data with private and public genomic databases. Using a combination 
      of genome comparisons and traditional genealogical research, investigators can
      triangulate distant relatives to the contributor of DNA data from a crime scene, 
      ultimately identifying perpetrators of violent crimes. This approach has also
      been successful in identifying unknown deceased persons and perpetrators of
      lesser crimes. Such advances are bringing into focus ethical questions on how
      much access to DNA databases should be granted to law enforcement and how best to
      empower public genome contributors with control over their data. The necessary
      policies will take time to develop but can be informed by reflection on the
      familial searching policies developed for searches of the federal DNA database
      and considerations of the anonymity and privacy interests of civilians.
FAU - Katsanis, Sara H
AU  - Katsanis SH
AD  - Mary Ann & J. Milburn Smith Child Health Research, Outreach, and Advocacy Center,
      Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois 60611,
      USA; email: skatsanis@luriechildrens.org.
AD  - Department of Pediatrics, Northwestern University, Chicago, Illinois 60611, USA.
LA  - eng
GR  - R01 HG009923/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20200414
PL  - United States
TA  - Annu Rev Genomics Hum Genet
JT  - Annual review of genomics and human genetics
JID - 100911346
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Crime/*statistics & numerical data
MH  - DNA/analysis/*genetics
MH  - DNA Fingerprinting/*ethics
MH  - Databases, Nucleic Acid/*statistics & numerical data
MH  - Forensic Genetics/*ethics
MH  - Humans
MH  - Pedigree
OTO - NOTNLM
OT  - *forensic DNA
OT  - *genetic genealogy
OT  - *kinship associations
EDAT- 2020/04/15 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1146/annurev-genom-111819-084213 [doi]
PST - ppublish
SO  - Annu Rev Genomics Hum Genet. 2020 Aug 31;21:535-564. doi:
      10.1146/annurev-genom-111819-084213. Epub 2020 Apr 14.


PMID- 32289072
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2352-8273 (Print)
IS  - 2352-8273 (Linking)
VI  - 11
DP  - 2020 Aug
TI  - Mitigating loss of health insurance and means tested benefits in an unconditional
      cash transfer experiment: Implementation lessons from Stockton's guaranteed
      income pilot.
PG  - 100578
LID - 10.1016/j.ssmph.2020.100578 [doi]
AB  - *Cash transfers, universal basic income, and guaranteed income have re-emerged as
      potential solutions to income volatility.*Methods used in Stockton's guaranteed
      income experiment, are testing how GI can exist alongside existing safety net
      benefits.*A multi-tiered approach to mitigating potential means tested benefits
      loss is both effective and ethically sound.
FAU - Baker, Amy Castro
AU  - Baker AC
AD  - University of Pennsylvania, School of Social Policy & Practice, USA.
FAU - Martin-West, Stacia
AU  - Martin-West S
AD  - University of Tennessee-Knoxville, College of Social Work, USA.
FAU - Samra, Sukhi
AU  - Samra S
AD  - Stockton Economic Empowerment Demonstration, USA.
FAU - Cusack, Meagan
AU  - Cusack M
AD  - University of Pennsylvania, School of Social Policy & Practice, USA.
AD  - US Department of Veterans Affairs, Center for Health Equity Research & Promotion,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - England
TA  - SSM Popul Health
JT  - SSM - population health
JID - 101678841
PMC - PMC7142678
COIS- The authors have no conflicts of interest or financial disclosures.
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.1016/j.ssmph.2020.100578 [doi]
AID - S2352-8273(19)30379-9 [pii]
AID - 100578 [pii]
PST - ppublish
SO  - SSM Popul Health. 2020 Aug;11:100578. doi: 10.1016/j.ssmph.2020.100578. Epub 2020
      Mar 31.


PMID- 32287130
OWN - NLM
STAT- MEDLINE
DCOM- 20200624
LR  - 20210929
IS  - 1526-7598 (Electronic)
IS  - 0003-2999 (Linking)
VI  - 130
IP  - 5
DP  - 2020 May
TI  - Science Without Conscience Is but the Ruin of the Soul: The Ethics of Big Data
      and Artificial Intelligence in Perioperative Medicine.
PG  - 1234-1243
LID - 10.1213/ANE.0000000000004728 [doi]
AB  - Artificial intelligence-driven anesthesiology and perioperative care may just be 
      around the corner. However, its promises of improved safety and patient outcomes 
      can only become a reality if we take the time to examine its technical, ethical, 
      and moral implications. The aim of perioperative medicine is to diagnose, treat, 
      and prevent disease. As we introduce new interventions or devices, we must take
      care to do so with a conscience, keeping patient care as the main objective, and 
      understanding that humanism is a core component of our practice. In our article, 
      we outline key principles of artificial intelligence for the perioperative
      physician and explore limitations and ethical challenges in the field.
FAU - Canales, Cecilia
AU  - Canales C
AD  - From the Department of Anesthesiology and Perioperative Medicine, University of
      California Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles,
      California.
FAU - Lee, Christine
AU  - Lee C
AD  - Department of Biomedical Engineering, University of California, Irvine, Irvine,
      California.
FAU - Cannesson, Maxime
AU  - Cannesson M
AD  - From the Department of Anesthesiology and Perioperative Medicine, University of
      California Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles,
      California.
LA  - eng
GR  - R01 EB029751/EB/NIBIB NIH HHS/United States
GR  - R01 HL144692/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
SB  - IM
MH  - *Algorithms
MH  - Artificial Intelligence/*ethics
MH  - *Big Data
MH  - *Conscience
MH  - Humans
MH  - Perioperative Medicine/*ethics/trends
MH  - Physicians/ethics
PMC - PMC7519874
MID - NIHMS1628914
EDAT- 2020/04/15 06:00
MHDA- 2020/06/25 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/06/25 06:00 [medline]
AID - 10.1213/ANE.0000000000004728 [doi]
AID - 00000539-202005000-00016 [pii]
PST - ppublish
SO  - Anesth Analg. 2020 May;130(5):1234-1243. doi: 10.1213/ANE.0000000000004728.


PMID- 32287086
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201218
IS  - 1940-5480 (Electronic)
IS  - 1067-151X (Linking)
VI  - 28
IP  - 11
DP  - 2020 Jun 1
TI  - Practice Management During the COVID-19 Pandemic.
PG  - 464-470
LID - 10.5435/JAAOS-D-20-00379 [doi]
AB  - On March 14, 2020, the Surgeon General of the United States urged a widespread
      cessation of all elective surgery across the country. The suddenness of this
      mandate and the concomitant spread of the COVID-19 virus left many hospital
      systems, orthopaedic practices, and patients with notable anxiety and confusion
      as to the near, intermediate, and long-term future of our healthcare system. As
      with most businesses in the United States during this time, many orthopaedic
      practices have been emotionally and fiscally devastated because of this crisis.
      Furthermore, this pandemic is occurring at a time where small and midsized
      orthopaedic groups are already struggling to cover practice overhead and to
      maintain autonomy from larger health systems. It is anticipated that many groups 
      will experience financial demise, leading to substantial global consolidation.
      Because the authors represent some of the larger musculoskeletal multispecialty
      groups in the country, we are uniquely positioned to provide a framework with
      recommendations to best weather the ensuing months. We think these
      recommendations will allow providers and their staff to return to an
      infrastructure that can adjust immediately to the pent-up healthcare demand that 
      may occur after the COVID-19 pandemic. In this editorial, we address practice
      finances, staffing, telehealth, operational plans after the crisis, and ethical
      considerations.
FAU - Vaccaro, Alexander R
AU  - Vaccaro AR
AD  - From the Department of Orthopaedic Surgery, Rothman Institute, Thomas Jefferson
      University, Philadelphia, PA (Dr. Vaccaro, Dr. Getz, and Dr. Donnally), the
      OrthoCarolina, Charlotte, NC (Dr. Cohen), and the Department of Orthopaedic
      Surgery, Midwest Orthopaedics at Rush, Chicago, IL (Dr. Cole).
FAU - Getz, Charles L
AU  - Getz CL
FAU - Cohen, Bruce E
AU  - Cohen BE
FAU - Cole, Brian J
AU  - Cole BJ
FAU - Donnally, Chester J 3rd
AU  - Donnally CJ 3rd
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Acad Orthop Surg
JT  - The Journal of the American Academy of Orthopaedic Surgeons
JID - 9417468
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Cost-Benefit Analysis
MH  - Delivery of Health Care/*organization & administration
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - Male
MH  - Orthopedic Procedures/*economics/methods
MH  - Outcome Assessment, Health Care
MH  - Pandemics/*prevention & control
MH  - *Pneumonia, Viral
MH  - Practice Management, Medical/*organization & administration
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7197337
EDAT- 2020/04/15 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.5435/JAAOS-D-20-00379 [doi]
PST - ppublish
SO  - J Am Acad Orthop Surg. 2020 Jun 1;28(11):464-470. doi: 10.5435/JAAOS-D-20-00379.


PMID- 32287038
OWN - NLM
STAT- MEDLINE
DCOM- 20200421
LR  - 20201218
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Apr 16
TI  - A Case for Participatory Disease Surveillance of the COVID-19 Pandemic in India.
PG  - e18795
LID - 10.2196/18795 [doi]
AB  - The coronavirus disease pandemic requires the deployment of novel surveillance
      strategies to curtail further spread of the disease in the community.
      Participatory disease surveillance mechanisms have already been adopted in
      countries for the current pandemic. India, with scarce resources, good telecom
      support, and a not-so-robust heath care system, makes a strong case for
      introducing participatory disease surveillance for the prevention and control of 
      the pandemic. India has just launched Aarogya Setu, which is a first-of-its-kind 
      participatory disease surveillance initiative in India. This will supplement the 
      existing Integrated Disease Surveillance Programme in India by finding missing
      cases and having faster aggregation, analysis of data, and prompt response
      measures. This newly created platform empowers communities with the right
      information and guidance, enabling protection from infection and reducing
      unnecessary contact with the overburdened health care system. However, caution
      needs to be exercised to address participation from digitally isolated
      populations, ensure the reliability of data, and consider ethical concerns such
      as maintaining individual privacy.
CI  - (c)Suneela Garg, Nidhi Bhatnagar, Navya Gangadharan. Originally published in JMIR
      Public Health and Surveillance (http://publichealth.jmir.org), 16.04.2020.
FAU - Garg, Suneela
AU  - Garg S
AUID- ORCID: 0000-0002-2196-1607
AD  - Maulana Azad Medical College, Delhi University, Delhi, India.
FAU - Bhatnagar, Nidhi
AU  - Bhatnagar N
AUID- ORCID: 0000-0003-0024-194X
AD  - Maulana Azad Medical College, Delhi University, Delhi, India.
FAU - Gangadharan, Navya
AU  - Gangadharan N
AUID- ORCID: 0000-0003-3892-544X
AD  - Maulana Azad Medical College, Delhi University, Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200416
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Community-Based Participatory Research
MH  - *Coronavirus
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Disease Outbreaks/*prevention & control
MH  - Humans
MH  - India/epidemiology
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Public Health
MH  - *Public Health Surveillance
MH  - SARS-CoV-2
PMC - PMC7164788
OTO - NOTNLM
OT  - *COVID-19
OT  - *India
OT  - *infectious disease
OT  - *outbreak
OT  - *pandemic
OT  - *participatory
OT  - *public health
OT  - *surveillance
EDAT- 2020/04/15 06:00
MHDA- 2020/04/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/22 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - v6i2e18795 [pii]
AID - 10.2196/18795 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 Apr 16;6(2):e18795. doi: 10.2196/18795.


PMID- 32286670
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1938-2464 (Electronic)
IS  - 1938-2464 (Linking)
VI  - 13
IP  - 5
DP  - 2020 Sep 1
TI  - Model of Empathic Pain Assessment and Treatment in Persons With Dementia.
PG  - 264-276
LID - 10.3928/19404921-20200402-01 [doi]
AB  - The current article presents an evidence-based model for understanding clinical
      empathy's relationship with the assessment and treatment of pain in persons with 
      advanced dementia. A literature review informed creation of an interdisciplinary 
      conceptual framework of clinician empathy in pain assessment and treatment among 
      persons with advanced dementia. Driven by observation of behaviors indicating
      pain in persons with dementia unable to self-report, the model represents the
      cognitive, affective, ethical, and behavioral components of clinical empathy
      involved in assessing and treating pain, relevant patient outcomes, and
      contextual factors influencing empathy and outcomes; and provides a framework for
      testing clinical empathy interventions to improve adverse outcomes in persons
      with advanced dementia. Understanding the relationship between clinician empathy 
      and the assessment and treatment of pain in persons with advanced dementia may
      improve care quality and help reduce pain behaviors in this patient population.
      This model may be used to inform pain research in persons with dementia and
      develop clinical interventions and clinician education programs. [Research in
      Gerontological Nursing, 13(5), 264-276.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Starr, Lauren T
AU  - Starr LT
FAU - Magan, Kristin Corey
AU  - Magan KC
LA  - eng
GR  - T32 NR009356/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - United States
TA  - Res Gerontol Nurs
JT  - Research in gerontological nursing
JID - 101392499
SB  - IM
MH  - Dementia/*nursing
MH  - *Empathy
MH  - Humans
MH  - *Models, Psychological
MH  - Pain/*diagnosis
MH  - *Pain Measurement
MH  - Quality of Health Care
MH  - *Severity of Illness Index
EDAT- 2020/04/15 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/04/15 06:00
PHST- 2018/07/30 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.3928/19404921-20200402-01 [doi]
PST - ppublish
SO  - Res Gerontol Nurs. 2020 Sep 1;13(5):264-276. doi: 10.3928/19404921-20200402-01.
      Epub 2020 Apr 14.


PMID- 32286554
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20220531
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 580
IP  - 7803
DP  - 2020 Apr
TI  - Coronavirus: a veterinary perspective.
PG  - 321
LID - 10.1038/d41586-020-01077-2 [doi]
FAU - da Hora, Aline Santana
AU  - da Hora AS
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CON - Science. 2020 Apr 8;:null. PMID: 32269068
MH  - Animals
MH  - Animals, Domestic
MH  - COVID-19
MH  - Cats
MH  - *Coronavirus
MH  - *Coronavirus Infections/transmission/veterinary
MH  - Dogs
MH  - Ferrets
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - Veterinary Medicine
OTO - NOTNLM
OT  - *Ethics
OT  - *Virology
EDAT- 2020/04/15 06:00
MHDA- 2020/05/12 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
AID - 10.1038/d41586-020-01077-2 [doi]
AID - 10.1038/d41586-020-01077-2 [pii]
PST - ppublish
SO  - Nature. 2020 Apr;580(7803):321. doi: 10.1038/d41586-020-01077-2.


PMID- 32286110
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 8
DP  - 2020 Aug
TI  - Rethinking health professions' education leadership: Developing 'eco-ethical'
      leaders for a more sustainable world and future.
PG  - 855-860
LID - 10.1080/0142159X.2020.1748877 [doi]
AB  - In this commentary, we discuss health professions' education (HPE) leadership in 
      relation to planetary health emergencies, suggesting that an 'eco-ethical
      leadership' approach is highly relevant. Building on both traditional and more
      contemporary leadership approaches and the need for HPE to be socially and
      environmentally accountable, we define the key features of eco-ethical leadership
      and its underpinning beliefs and values, then expand on these features in terms
      of leadership at intrapersonal, interpersonal, team, organisational and system
      levels. Eco-ethical leadership is needed to tackle a range of 'wicked' problems -
      a changing climate, environmental pollution, deforestation, all of which threaten
      global biodiversity and human civilisation. Such leadership requires passionate
      individuals to role model the behaviours and actions that are required to bring
      people along with them, not least the learners, many of whom are already
      concerned about their future. Eco-ethical leadership (and followership) offers an
      integrated approach for HPE, centred around sustainability, values,
      collaboration, justice, advocacy and, if need be, activism. The environment
      cannot not wait. Eco-ethical leaders already exist but their numbers are small.
      They are required in key positions in academia and healthcare to drive the agenda
      in partnership with learners, many of whom are already environmental advocates
      and activists.
FAU - McKimm, Judy
AU  - McKimm J
AUID- ORCID: 0000-0002-8949-5067
AD  - Strategic Educational Development, Swansea University Medical School, Swansea,
      UK.
FAU - McLean, Michelle
AU  - McLean M
AUID- ORCID: 0000-0002-9912-2483
AD  - Medical Education and Planetary Health, Bond University, Gold Coast, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
MH  - Delivery of Health Care
MH  - Health Occupations
MH  - Humans
MH  - *Leadership
MH  - *Morals
OTO - NOTNLM
OT  - *Leadership
OT  - *eco-ethical leadership
OT  - *environment
OT  - *ethical leadership
OT  - *followership
OT  - *health professions education
OT  - *planetary health
EDAT- 2020/04/15 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1080/0142159X.2020.1748877 [doi]
PST - ppublish
SO  - Med Teach. 2020 Aug;42(8):855-860. doi: 10.1080/0142159X.2020.1748877. Epub 2020 
      Apr 14.


PMID- 32286030
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20200420
IS  - 1565-1088 (Print)
VI  - 22
IP  - 4
DP  - 2020 Apr
TI  - Hippocratic Oath and Heart Failure Journey: An Update on Therapies.
PG  - 249-254
AB  - BACKGROUND: The innovation that has taken place in medicine, combined with
      state-of-the-art technological developments, provides therapeutic options for
      patients in conditions that were previously considered incurable. This promotion 
      at the same time presents us with new ethical challenges. In this article, we
      review the journey through life of an advanced heart failure patient, covering a 
      variety of potential clinical and ethics subjects in the field of heart failure
      treatment. We review the ethical principles of the Hippocratic Oath against the
      background of the realities of practicing medicine and of the enormous advances
      in therapeutics.
FAU - Peled, Yael
AU  - Peled Y
AD  - Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Hashomer,
      Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Ram, Eilon
AU  - Ram E
AD  - Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Hashomer,
      Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
AD  - Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel.
AD  - Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer,
      Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
SB  - IM
MH  - Cardiology/standards/*trends
MH  - Combined Modality Therapy
MH  - Echocardiography, Transesophageal/methods
MH  - Female
MH  - Forecasting
MH  - Heart Failure/*diagnostic imaging/*therapy
MH  - *Hippocratic Oath
MH  - Humans
MH  - Male
MH  - Practice Patterns, Physicians'/*ethics/trends
MH  - *Treatment Outcome
EDAT- 2020/04/15 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
PST - ppublish
SO  - Isr Med Assoc J. 2020 Apr;22(4):249-254.


PMID- 32285994
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1365-2524 (Electronic)
IS  - 0966-0410 (Linking)
VI  - 28
IP  - 5
DP  - 2020 Sep
TI  - Supporting patients with long-term conditions in the community: Evaluation of the
      Greater Manchester Community Pharmacy Care Plan Service.
PG  - 1671-1687
LID - 10.1111/hsc.12992 [doi]
AB  - The Greater Manchester Community Pharmacy Care Plan (GMCPCP) service provided
      tailored care plans to help adults with one or more qualifying long-term
      condition (hypertension, asthma, diabetes and COPD) to achieve health goals and
      better self-management of their long-term conditions. The service ran between
      February and December 2017. The aim of this study was to investigate the impact
      of the service on patient activation, as measured by the PAM measure (primary
      outcome). Secondary outcomes included quality of life (EQ-5D-5L, EQ-VAS),
      medication adherence (MARS-5), NHS resource use and costs, systolic and diastolic
      blood pressure, HDL cholesterol ratio levels and body mass index (BMI). A before 
      and after design was used, with follow-up at 6-months. A questionnaire was
      distributed at follow-up and telephone interviews with willing participants were 
      used to investigate patient satisfaction with the service. The study was approved
      by the University of Manchester Research Ethics Committee. Quantitative data were
      analysed in SPSS v22 (IBM). A total of 382 patients were recruited to the
      service; 280 (73%) remained at follow-up. Ten patients were interviewed and 43
      completed the questionnaire. A total of 613 goals were set; mean of 1.7 goals per
      patient. Fifty percent of goals were met at follow-up. There were significant
      improvements in PAM, EQ-5D-5L and EQ-VAS scores and significant reductions in
      systolic blood pressure, BMI and HDL cholesterol ratio at follow-up. Mean NHS
      service use costs were significantly lower at follow-up; with a mean decrease per
      patient of pound236.43 (+/-SD pound968.47). The mean cost per patient for
      providing the service was pound203.10, resulting in potential cost-savings of
      pound33.33 per patient (SD +/- 874.65). Questionnaire respondents reported high
      levels of satisfaction with the service. This study suggests that the service is 
      acceptable to patients and may lead to improvements in health outcomes and allows
      for modest cost savings. Limitations of the study included the low response rate 
      to the patient questionnaire.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Seston, Elizabeth M
AU  - Seston EM
AUID- ORCID: 0000-0002-6672-8622
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Magola, Esnath
AU  - Magola E
AUID- ORCID: 0000-0002-0584-2798
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Bower, Peter
AU  - Bower P
AUID- ORCID: 0000-0001-9558-3349
AD  - Division of Population Health, Health Services Research and Primary Care, Faculty
      of Biology, Medicine and Health, University of Manchester, Manchester Academic
      Health Science Centre, Manchester, UK.
FAU - Chen, Li-Chia
AU  - Chen LC
AUID- ORCID: 0000-0002-6158-6645
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Jacobs, Sally
AU  - Jacobs S
AUID- ORCID: 0000-0002-6199-5748
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Lewis, Penny J
AU  - Lewis PJ
AUID- ORCID: 0000-0002-3976-5807
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Steinke, Douglas
AU  - Steinke D
AUID- ORCID: 0000-0001-8917-2674
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Willis, Sarah C
AU  - Willis SC
AUID- ORCID: 0000-0002-0368-0684
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
FAU - Schafheutle, Ellen I
AU  - Schafheutle EI
AUID- ORCID: 0000-0001-7072-0888
AD  - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, 
      Medicine and Health, University of Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200414
PL  - England
TA  - Health Soc Care Community
JT  - Health & social care in the community
JID - 9306359
RN  - 0 (Lipids)
SB  - IM
MH  - Aged
MH  - Blood Pressure
MH  - Body Mass Index
MH  - Chronic Disease/economics/*therapy
MH  - Community Pharmacy Services/economics/*organization & administration
MH  - England
MH  - Female
MH  - Health Expenditures/statistics & numerical data
MH  - Health Resources/*statistics & numerical data
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Patient Participation/psychology
MH  - Patient Satisfaction
MH  - Quality of Life
MH  - Self-Management/economics/*methods
MH  - State Medicine
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *care planning and management
OT  - *chronic/long-term conditions
OT  - *community pharmacy
OT  - *patient activation
OT  - *pharmacy practice research
EDAT- 2020/04/15 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/08/16 00:00 [received]
PHST- 2020/02/13 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1111/hsc.12992 [doi]
PST - ppublish
SO  - Health Soc Care Community. 2020 Sep;28(5):1671-1687. doi: 10.1111/hsc.12992. Epub
      2020 Apr 14.


PMID- 32285853
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20211206
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 156
IP  - 2
DP  - 2020
TI  - Research and research ethics committees and the obligation for them to operate in
      accordance with the principle of the social covenant.
PG  - 138-141
LID - 10.24875/GMM.M20000355 [doi]
AB  - The relationship between the social covenant, ethics and scientific research is
      highly important for society. Economic prosperity and better health are two of
      the main reasons why society supports science, without society itself being able 
      to determine the nature of the research that is to be implemented; this is
      decided by Research Committees (RCs) and Research Ethics Committees (RECs). This 
      article analyzes how the work of RCs and RECs must have a social covenant and
      represent the interests of society in order to promote its trust in research.
CI  - Copyright: (c) 2020 Permanyer.
FAU - Valdez-Martinez, Edith
AU  - Valdez-Martinez E
AD  - Instituto Mexicano del Seguro Social, Health Research Coordination, Mexico City, 
      Mexico.
FAU - Bedolla, Miguel
AU  - Bedolla M
AD  - Nortwest Vista College, San Antonio, Texas, United States.
LA  - eng
PT  - Journal Article
TT  - Los comites de investigacion y etica en investigacion y la obligacion de que
      operen de acuerdo con el principio de la alianza social.
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
SB  - IM
CIN - Gac Med Mex. 2021;157(2):214. PMID: 34270539
MH  - *Ethics Committees, Research
MH  - Social Behavior
OTO - NOTNLM
OT  - Alianza social
OT  - Comites de investigacion
OT  - Comites de etica
OT  - Ethics
OT  - Ethics Committees
OT  - Mexico
OT  - Mexico
OT  - Research Committees
OT  - Social covenant
OT  - Etica
EDAT- 2020/04/15 06:00
MHDA- 2020/04/17 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
AID - j156/2/138 [pii]
AID - 10.24875/GMM.M20000355 [doi]
PST - ppublish
SO  - Gac Med Mex. 2020;156(2):138-141. doi: 10.24875/GMM.M20000355.


PMID- 32285803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 14
TI  - EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45
      Study): Protocol for an Australian Linked Cohort Study.
PG  - e15646
LID - 10.2196/15646 [doi]
AB  - BACKGROUND: Chronic kidney disease (CKD) and diabetes are the major causes of
      death and disability worldwide. They are associated with high health service
      utilization persisting over many years. Their slow progression and wide clinical 
      variation make them eminently suitable for study in population-based cohorts.
      However, current understanding of their prevalence, incidence, and progression is
      largely based on studies conducted in clinical populations. OBJECTIVE: This study
      aims to establish a novel link between an existing population-based cohort (the
      45 and Up Study) and routinely collected laboratory and administrative data to
      facilitate research across the full disease spectrum of CKD and diabetes.
      METHODS: In the EXTEND45 Study (EXamining OuTcomEs in chroNic Disease in the 45
      and Up Study), baseline questionnaire responses of over 260,000 participants of
      the 45 and Up Study aged >/=45 years living in New South Wales (NSW), collected
      between January 2006 and December 2009, are linked to data from laboratory
      service providers as well as national- and state-based administrative datasets
      via probabilistic linkage. Routinely collected data were obtained for
      participants who could be linked between January 2005 and July 2013. Laboratory
      data will enable the identification of early cases of chronic disease and the
      assessment of clinically relevant biochemical targets during the disease course. 
      Health administrative datasets will allow for the examination of health service
      use, pharmacological management, and clinical outcomes. RESULTS: The study
      received ethics approval from the NSW Population and Health Services Research
      Ethics Committee in February 2014. Data linkage for 267,153 of the 45 and Up
      Study participants was completed in June 2016, with congruent linkage achieved
      for 265,086 (99.23%) individuals. To date, the CKD and diabetes cohorts have been
      identified (published elsewhere), and a diverse portfolio of research projects
      relating to disease burden, risk factors, health outcomes, and health service
      utilization is in development. CONCLUSIONS: The EXTEND45 Study represents an
      unparalleled opportunity to perform extensive research into diseases of
      considerable public health and clinical importance. Strengths include the
      population-based nature of the cohort and the availability of longitudinal
      information on the complete disease pathway for affected individuals.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/15646.
CI  - (c)Celine Foote, Carinna Hockham, Louisa Sukkar, Anna Campain, Amy Kang, Tamara
      Young, Alan Cass, Clara K Chow, Elizabeth Comino, Martin Gallagher, Stephen Jan, 
      John Knight, Bette Liu, Martin McNamara, David Peiris, Carol Pollock, David
      Sullivan, Germaine Wong, Sophia Zoungas, Kris Rogers, Min Jun, Meg Jardine.
      Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 14.04.2020.
FAU - Foote, Celine
AU  - Foote C
AUID- ORCID: https://orcid.org/0000-0003-0203-3861
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Concord Repatriation General Hospital, Sydney, Australia.
FAU - Hockham, Carinna
AU  - Hockham C
AUID- ORCID: https://orcid.org/0000-0003-2126-5350
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Sukkar, Louisa
AU  - Sukkar L
AUID- ORCID: https://orcid.org/0000-0001-7409-2938
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - School of Public Health, University of Sydney, Sydney, Australia.
FAU - Campain, Anna
AU  - Campain A
AUID- ORCID: https://orcid.org/0000-0003-1057-0085
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Kang, Amy
AU  - Kang A
AUID- ORCID: https://orcid.org/0000-0002-0300-1282
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Young, Tamara
AU  - Young T
AUID- ORCID: https://orcid.org/0000-0003-2727-8347
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Cass, Alan
AU  - Cass A
AUID- ORCID: https://orcid.org/0000-0002-3923-3173
AD  - Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
FAU - Chow, Clara K
AU  - Chow CK
AUID- ORCID: https://orcid.org/0000-0003-4693-0038
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Westmead Applied Research Centre, Faculty of Medicine and Health, University of
      Sydney, Sydney, Australia.
AD  - Department of Cardiology, Westmead Hospital, Sydney, Australia.
FAU - Comino, Elizabeth
AU  - Comino E
AUID- ORCID: https://orcid.org/0000-0002-9459-6073
AD  - Centre for Primary Health Care and Equity, University of New South Wales, Sydney,
      Australia.
FAU - Gallagher, Martin
AU  - Gallagher M
AUID- ORCID: https://orcid.org/0000-0001-9187-6187
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Concord Repatriation General Hospital, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
AD  - Sydney Medical School, University of Sydney, Sydney, Australia.
FAU - Jan, Stephen
AU  - Jan S
AUID- ORCID: https://orcid.org/0000-0003-2839-1405
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
AD  - Sydney Medical School, University of Sydney, Sydney, Australia.
FAU - Knight, John
AU  - Knight J
AUID- ORCID: https://orcid.org/0000-0001-7298-5150
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Liu, Bette
AU  - Liu B
AUID- ORCID: https://orcid.org/0000-0002-0787-5825
AD  - School of Public Health and Community Medicine, University of New South Wales,
      Sydney, Australia.
FAU - McNamara, Martin
AU  - McNamara M
AUID- ORCID: https://orcid.org/0000-0002-4849-3313
AD  - The Sax Institute, Sydney, Australia.
FAU - Peiris, David
AU  - Peiris D
AUID- ORCID: https://orcid.org/0000-0002-6898-3870
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Pollock, Carol
AU  - Pollock C
AUID- ORCID: https://orcid.org/0000-0001-7167-6495
AD  - Renal Division, Kolling Institute for Medical Research, Sydney, Australia.
AD  - University of Sydney, Sydney, Australia.
FAU - Sullivan, David
AU  - Sullivan D
AUID- ORCID: https://orcid.org/0000-0003-3085-5627
AD  - Sydney Medical School, University of Sydney, Sydney, Australia.
AD  - Department of Chemical Pathology, Royal Prince Alfred Hospital, Sydney,
      Australia.
FAU - Wong, Germaine
AU  - Wong G
AUID- ORCID: https://orcid.org/0000-0001-8422-7269
AD  - School of Public Health, University of Sydney, Sydney, Australia.
AD  - Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia.
FAU - Zoungas, Sophia
AU  - Zoungas S
AUID- ORCID: https://orcid.org/0000-0003-2672-0949
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Australia.
FAU - Rogers, Kris
AU  - Rogers K
AUID- ORCID: https://orcid.org/0000-0001-5497-4298
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Graduate School of Health, University of Technology Sydney, Sydney, Australia.
FAU - Jun, Min
AU  - Jun M
AUID- ORCID: https://orcid.org/0000-0003-1460-7535
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Jardine, Meg
AU  - Jardine M
AUID- ORCID: https://orcid.org/0000-0002-0160-2375
AD  - The George Institute for Global Health, Sydney, Australia.
AD  - Concord Repatriation General Hospital, Sydney, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200414
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7189250
OTO - NOTNLM
OT  - biomarkers
OT  - cardiovascular disease
OT  - chronic kidney disease
OT  - data linkage
OT  - diabetes mellitus
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2019/07/28 00:00 [received]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2019/12/06 00:00 [revised]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - v9i4e15646 [pii]
AID - 10.2196/15646 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 14;9(4):e15646. doi: 10.2196/15646.


PMID- 32285798
OWN - NLM
STAT- MEDLINE
DCOM- 20201224
LR  - 20201224
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 67
IP  - 4
DP  - 2020 Apr
TI  - Medical students' perspectives on the ethics of clinical reality.
LID - A10190600 [pii]
AB  - INTRODUCTION: Medical ethicists have pointed out that a gap exists between
      classroom teaching of bioethical theory and the ethics of clinical reality.
      Studies recommend that the teaching of bioethics should focus on everyday
      dilemmas in the clinical setting instead of only dramatic dilemmas and have
      expressed the need for more studies of how medical students perceive ethical
      problems in the clinical setting. This study explored themes in and types of
      ethical dilemmas in medical students' reflective writing in their clinical
      rotations. METHODS: The study was a qualitative explorative analysis of group
      reflection texts from fourth-year medical students at Aarhus University, Denmark.
      RESULTS: The thematic analysis of 51 group reflection texts (n = 396) revealed
      four key themes in the material: 1) confidentiality issues, 2) treatment options 
      and side effects, 3) the students' role and responsibility and 4)
      information-giving and communication. The majority of the ethical dilemmas that
      the students identified were everyday dilemmas. Dramatic dilemmas were
      represented to a limited degree. CONCLUSIONS: Students' perspectives on ethical
      dilemmas in the clinical setting provide a unique opportunity to integrate a
      variety of ethical dimensions into bioethical education and draw attention to
      overlooked everyday ethical dilemmas. Thus, involving the students' perspectives 
      may be a way to bridge the gap between bioethical theory and the ethics of
      clinical reality. FUNDING: none. TRIAL REGISTRATION: not relevant.
CI  - Articles published in the DMJ are "open access". This means that the articles are
      distributed under the terms of the Creative Commons Attribution Non-commercial
      License, which permits any non-commercial use, distribution, and reproduction in 
      any medium, provided the original author(s) and source are credited.
FAU - Moller, Jane Ege
AU  - Moller JE
AD  - jane@cesu.au.dk.
FAU - Clemmensen, Charlotte Ronn
AU  - Clemmensen CR
FAU - Mohamed, Nasteha Abdullahi
AU  - Mohamed NA
FAU - Sondergaard, Sara
AU  - Sondergaard S
FAU - Saether, Solveig
AU  - Saether S
FAU - Andersen, Tine Hoffmann
AU  - Andersen TH
FAU - Gormsen, Line
AU  - Gormsen L
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Bioethics/*education
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Male
MH  - Qualitative Research
MH  - Students, Medical/*psychology
EDAT- 2020/04/15 06:00
MHDA- 2020/12/29 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
AID - A10190600 [pii]
PST - ppublish
SO  - Dan Med J. 2020 Apr;67(4). pii: A10190600.


PMID- 32285721
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 1466-187X (Electronic)
IS  - 0142-159X (Linking)
VI  - 42
IP  - 12
DP  - 2020 Dec
TI  - Improving ethical engagement on global health electives.
PG  - 1430-1431
LID - 10.1080/0142159X.2020.1751811 [doi]
FAU - Shiwani, Taha
AU  - Shiwani T
AD  - School of Medicine, Imperial College London, London.
FAU - Elghazaly, Hussein
AU  - Elghazaly H
AD  - School of Medicine, Imperial College London, London.
FAU - Sharif, Faraz
AU  - Sharif F
AD  - School of Medicine, Imperial College London, London.
FAU - Butt, Zain
AU  - Butt Z
AD  - School of Medicine, Imperial College London, London.
FAU - Mian, Areeb
AU  - Mian A
AD  - School of Medicine, Imperial College London, London.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200414
PL  - England
TA  - Med Teach
JT  - Medical teacher
JID - 7909593
SB  - IM
CON - Med Teach. 2020 Jun;42(6):628-635. PMID: 32083958
MH  - Curriculum
MH  - *Global Health
MH  - Humans
MH  - *Internship and Residency
EDAT- 2020/04/15 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1080/0142159X.2020.1751811 [doi]
PST - ppublish
SO  - Med Teach. 2020 Dec;42(12):1430-1431. doi: 10.1080/0142159X.2020.1751811. Epub
      2020 Apr 14.


PMID- 32285631
OWN - NLM
STAT- MEDLINE
DCOM- 20211005
LR  - 20211005
IS  - 1475-357X (Print)
IS  - 1475-357X (Linking)
VI  - 25
IP  - 1
DP  - 2020 Feb
TI  - Debate: You can't take politics out of the debate on gender-diverse children.
PG  - 40-42
LID - 10.1111/camh.12350 [doi]
AB  - The focus of concern in the public conversation about the care of gender-diverse 
      children and adolescents is to some degree a matter of politics: that is, the
      dynamics of power and 'voice' in our modern world. There are questions relating
      to child and parent autonomy in making identity-driven life decisions; the
      counterbalancing need to safeguard children when new technologies enable new life
      choices to be made; the role of professional 'experts' (e.g. in claiming to
      evaluate the 'authenticity' of a young person's gender identity); and the
      significance, and credibility, of different kinds of evidence in making treatment
      decisions. All these weighty and wide-ranging considerations come to the fore in 
      the United Kingdom and elsewhere when discussing what might be an ethical, safe
      and just response to gender-diverse children in our changing society.
CI  - (c) 2020 Association for Child and Adolescent Mental Health.
FAU - Wren, Bernadette
AU  - Wren B
AD  - Gender Identity Development Service, Tavistock & Portman NHS Foundation Trust,
      London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Child Adolesc Ment Health
JT  - Child and adolescent mental health
JID - 101142157
MH  - Adolescent
MH  - Child
MH  - Female
MH  - *Gender Identity
MH  - Humans
MH  - Male
MH  - *Politics
MH  - Transgender Persons/*legislation & jurisprudence/psychology
OTO - NOTNLM
OT  - *Gender identity
OT  - *children and adolescents
OT  - *ethics
OT  - *interventions
EDAT- 2020/04/15 06:00
MHDA- 2021/10/06 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/09/18 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/10/06 06:00 [medline]
AID - 10.1111/camh.12350 [doi]
PST - ppublish
SO  - Child Adolesc Ment Health. 2020 Feb;25(1):40-42. doi: 10.1111/camh.12350.


PMID- 32285341
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210702
IS  - 1573-9686 (Electronic)
IS  - 0090-6964 (Linking)
VI  - 48
IP  - 7
DP  - 2020 Jul
TI  - Biomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip 
      Models.
PG  - 2002-2027
LID - 10.1007/s10439-020-02498-w [doi]
AB  - The development of novel 3D tissue culture systems has enabled the in vitro study
      of in vivo processes, thereby overcoming many of the limitations of previous 2D
      tissue culture systems. Advances in biomaterials, including the discovery of
      novel synthetic polymers has allowed for the generation of physiologically
      relevant in vitro 3D culture models. A large number of 3D culture systems, aided 
      by novel organ-on-a-chip and bioreactor technologies have been developed to
      improve reproducibility and scalability of in vitro organ models. The discovery
      of induced pluripotent stem cells (iPSCs) and the increasing number of protocols 
      to generate iPSC-derived cell types has allowed for the generation of novel 3D
      models with minimal ethical limitations. The production of iPSC-derived 3D
      cultures has revolutionized the field of developmental biology and in particular,
      the study of fetal brain development. Furthermore, physiologically relevant 3D
      cultures generated from PSCs or adult stem cells (ASCs) have greatly advanced in 
      vitro disease modelling and drug discovery. This review focuses on advances in 3D
      culture systems over the past years to model fetal development, disease pathology
      and support drug discovery in vitro, with a specific focus on the enabling role
      of biomaterials.
FAU - D'Costa, Katya
AU  - D'Costa K
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Canada.
FAU - Kosic, Milena
AU  - Kosic M
AD  - Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University
      of Toronto, Toronto, Canada.
FAU - Lam, Angus
AU  - Lam A
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Canada.
FAU - Moradipour, Azeen
AU  - Moradipour A
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Canada.
FAU - Zhao, Yimu
AU  - Zhao Y
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Canada.
FAU - Radisic, Milica
AU  - Radisic M
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Canada. m.radisic@utoronto.ca.
AD  - Department of Chemical Engineering and Applied Chemistry, University of Toronto, 
      Toronto, ON, Canada. m.radisic@utoronto.ca.
AD  - Toronto General Research Institute, University Health Network, Toronto, ON,
      Canada. m.radisic@utoronto.ca.
LA  - eng
GR  - MOP-126027/CAPMC/ CIHR/Canada
GR  - RGPIN 326982-10/Natural Sciences and Engineering Research Council of Canada
GR  - CHRP 493737-16/NSERC-CIHR Collaborative Health Research Grant
GR  - R01 HL076485/HL/NHLBI NIH HHS/United States
GR  - 2R01 HL076485/NH/NIH HHS/United States
GR  - MOP-137107/CAPMC/ CIHR/Canada
PT  - Journal Article
PT  - Review
DEP - 20200413
PL  - United States
TA  - Ann Biomed Eng
JT  - Annals of biomedical engineering
JID - 0361512
RN  - 0 (Biocompatible Materials)
SB  - IM
MH  - Adult Stem Cells/cytology
MH  - Animals
MH  - *Biocompatible Materials
MH  - Bioreactors
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology
MH  - *Lab-On-A-Chip Devices
MH  - Microfluidics
MH  - *Organoids
MH  - *Tissue Culture Techniques
PMC - PMC7334104
MID - NIHMS1584317
EDAT- 2020/04/15 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1007/s10439-020-02498-w [doi]
AID - 10.1007/s10439-020-02498-w [pii]
PST - ppublish
SO  - Ann Biomed Eng. 2020 Jul;48(7):2002-2027. doi: 10.1007/s10439-020-02498-w. Epub
      2020 Apr 13.


PMID- 32285336
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1836-6716 (Electronic)
IS  - 1321-2753 (Linking)
VI  - 38
IP  - Suppl 1
DP  - 2020 Dec
TI  - Justice in control of methicillin-resistant Staphylococcus aureus transmission: a
      fair question to ask?
PG  - 56-71
LID - 10.1007/s40592-020-00109-x [doi]
AB  - Active surveillance cultures and contact precautions is a strategy to control the
      transmission of methicillin-resistant Staphylococcus aureus (MRSA) within
      healthcare facilities. Whether to implement this strategy to routinely screen and
      isolate inpatients with MRSA in non-outbreak (endemic) settings, or to remove it 
      and use standard infection control precautions only is scientifically and
      ethically controversial, in view of the potential adverse effects of contact
      precautions on patients. To support the use of standard precautions only, it has 
      been argued that active surveillance to identify patients who are
      asymptomatically colonised with MRSA to place them in contact precautions is
      unjust or unfair to these patients in various ways. This paper will unpack and
      examine four distinct arguments, which are advanced from a medical ethics or
      quality improvement ethical framework, for why this is so. Our analysis shows
      that while these arguments highlight the injustice of current practices, they do 
      not provide strong ethical reasons for justifying the removal of active
      surveillance and contact precautions to control MRSA transmission and infection. 
      An implication of our arguments is that the ethical frame for evaluating
      prevention and control strategies for MRSA, a multi-drug resistant bacteria,
      should shift from healthcare to primarily public health. From a public health
      ethics perspective, whether a strategy is unjust, or how ethically significant
      its lack of fairness is, depends on assessing the evidence for its public health 
      effectiveness and necessity in a given setting, and the extent of the harms and
      burdens patients with MRSA bear when they are on contact precautions, which
      remain matters of scientific debate or uncertainty. As an ethical consideration
      in the debate, the chief normative implication of justice is to provide us
      further reasons to revise current active surveillance-contact precautions
      practices, and for the need for research and interventions to minimise their
      potential adverse effects on patients.
FAU - Voo, Teck Chuan
AU  - Voo TC
AUID- ORCID: http://orcid.org/0000-0003-4757-7328
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Block MD11, #02-03, 10 Medical Drive, Singapore, 117597,
      Singapore. medvtc@nus.edu.sg.
FAU - Lederman, Zohar
AU  - Lederman Z
AD  - Emergency Medicine Department, Shamir Medical Center, Ashdod, Israel.
LA  - eng
GR  - R-171-000-060-133/National University of Singapore
PT  - Journal Article
PL  - United States
TA  - Monash Bioeth Rev
JT  - Monash bioethics review
JID - 100973394
SB  - IM
MH  - Carrier State
MH  - *Ethical Analysis
MH  - *Ethical Theory
MH  - Humans
MH  - Infection Control/*methods/*standards
MH  - *Methicillin-Resistant Staphylococcus aureus
MH  - Social Justice
MH  - Staphylococcal Infections/*prevention & control
OTO - NOTNLM
OT  - Active surveillance
OT  - Antibiotic resistance
OT  - Asymptomatic carriers
OT  - Contact precautions
OT  - Ethics
OT  - Infection control
OT  - Justice
OT  - MRSA
OT  - Methicillin-resistant Staphylococcus aureus
OT  - Public health
EDAT- 2020/04/15 06:00
MHDA- 2021/08/17 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1007/s40592-020-00109-x [doi]
AID - 10.1007/s40592-020-00109-x [pii]
PST - ppublish
SO  - Monash Bioeth Rev. 2020 Dec;38(Suppl 1):56-71. doi: 10.1007/s40592-020-00109-x.


PMID- 32285306
OWN - NLM
STAT- MEDLINE
DCOM- 20201111
LR  - 20201111
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 22
IP  - 5
DP  - 2020 Apr 13
TI  - Evaluating Change in Men Who Have Sexually Offended: Linkages to Risk Assessment 
      and Management.
PG  - 22
LID - 10.1007/s11920-020-01146-3 [doi]
AB  - PURPOSE OF REVIEW: We provide a review and synthesis of the sexual offense
      treatment change literature with implications for dynamic sexual violence risk
      assessment and management. An argument is presented for the need for a dynamic
      approach in research and practice, and that for change to be prognostic, such
      changes need to be risk relevant and to come from credible change agents. RECENT 
      FINDINGS: Extant research demonstrates that changes on psychologically meaningful
      dimensions of risk and need (e.g., sexual deviance; attitudes and cognitions;
      anger, aggression, and hostility) tend to be associated with reductions in sexual
      and other forms of recidivism; however, changes in domains less germane to risk
      and need tend not to be (e.g., empathy, mental health and well-being). Formalized
      dynamic sexual offense risk measures can be administered at multiple time points 
      to reliably measure changes in sexual violence risk. Change information can then 
      be used systematically to adjust risk appraisals. The extant literature supports 
      the dynamic nature of sexual violence risk. Working toward the routine assessment
      of change with psychometrically sound measures, and integrating this information 
      into risk management interventions, can not only improve lives and reduce sexual 
      violence but is an ethical and human responsibility.
FAU - Olver, Mark E
AU  - Olver ME
AD  - University of Saskatchewan, Saskatoon, SK, Canada. mark.olver@usask.ca.
FAU - Stockdale, Keira C
AU  - Stockdale KC
AD  - Saskatoon Police Service, Saskatoon, SK, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200413
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
SB  - IM
MH  - Aggression
MH  - Humans
MH  - Male
MH  - *Paraphilic Disorders
MH  - Risk Assessment
MH  - *Sex Offenses/prevention & control
MH  - Sexual Behavior
OTO - NOTNLM
OT  - *Dynamic risk factor
OT  - *Risk assessment
OT  - *Sexual offense treatment
OT  - *Sexual recidivism
OT  - *Treatment change
EDAT- 2020/04/15 06:00
MHDA- 2020/11/12 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/11/12 06:00 [medline]
AID - 10.1007/s11920-020-01146-3 [doi]
AID - 10.1007/s11920-020-01146-3 [pii]
PST - epublish
SO  - Curr Psychiatry Rep. 2020 Apr 13;22(5):22. doi: 10.1007/s11920-020-01146-3.


PMID- 32284930
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200416
IS  - 1016-1430 (Print)
IS  - 1016-1430 (Linking)
VI  - 34
DP  - 2020
TI  - Spirituality as a sociocultural determinant of health in the context of medical
      curriculum: A call for action.
PG  - 6
LID - 10.34171/mjiri.34.6 [doi]
AB  - Background: This study aimed to investigate the state of spirituality in the
      general medicine curricula in Iran. Methods: Reference books for general medicine
      were reviewed and data were analyzed according to the qualitative content
      analysis method. Results: After reviewing references, it was found that only 35
      paragraphs of the educational reference pages dealt with this subject. Related
      topics to spirituality had 2 major themes: (a) spirituality and care (assessment,
      treatment, palliative care, and bereavement); (b) spirituality and
      professionalism (considering culture and medical ethics). Conclusion: This study 
      showed that despite the importance of the subject and much evidence on
      spirituality and medicine, medical references have limitations. The authors
      suggested some strategies to develop a specific course and integrate all
      educational references with the objectives of the general medical education
      course in Iran.
CI  - (c) 2020 Iran University of Medical Sciences.
FAU - Seddigh, Ruohollah
AU  - Seddigh R
AD  - Spiritual Health Research Center, Iran University of Medical Sciences, Tehran,
      Iran.
FAU - Azarnik, Somayeh
AU  - Azarnik S
AD  - Spiritual Health Research Center, Iran University of Medical Sciences, Tehran,
      Iran.
FAU - Memaryan, Nadereh
AU  - Memaryan N
AD  - Spiritual Health Research Center, Iran University of Medical Sciences, Tehran,
      Iran.
AD  - Mental Health Department, School of Behavioral Sciences and Mental Health (Tehran
      Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran.
FAU - Hadi, Fatemeh
AU  - Hadi F
AUID- ORCID: https://orcid.org/0000-0002-0893-8699
AD  - Mental Health Research Center, Department of Psychiatry, School of Medicine, Iran
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200217
PL  - Iran
TA  - Med J Islam Repub Iran
JT  - Medical journal of the Islamic Republic of Iran
JID - 8910777
PMC - PMC7139262
OTO - NOTNLM
OT  - Iran
OT  - Medical curriculum
OT  - Sociocultural determinant of health
OT  - Spiritual health
OT  - Spiritual needs
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.34171/mjiri.34.6 [doi]
PST - epublish
SO  - Med J Islam Repub Iran. 2020 Feb 17;34:6. doi: 10.34171/mjiri.34.6. eCollection
      2020.


PMID- 32284910
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2164-957X (Print)
IS  - 2164-9561 (Linking)
VI  - 9
DP  - 2020
TI  - Difficulties Perceived by ICU Nurses Providing End-of-Life Care: A Qualitative
      Study.
PG  - 2164956120916176
LID - 10.1177/2164956120916176 [doi]
AB  - BACKGROUND: With advances in medicine and technology, intensive care units (ICUs)
      have the capacity to treat patients who would have previously not been expected
      to survive and would therefore not have been managed in ICUs. When an individual 
      is not expected to survive, doctors and nurses face the modern ethical dilemma of
      death associated with withdrawal of life-supporting strategies. The aim of this
      study was to identify difficulties perceived by ICU nurses providing end-of-life 
      care (EOLC) in Poland. METHODS: The qualitative study was designed to investigate
      the difficulties, and the related barriers, to EOLC provided in ICUs in Poland.
      We conducted individual telephone interviews with ICU nurses from across Poland. 
      RESULTS: The main issues raised during the interviews included (1) barriers
      attributable to the hospital, (2) barriers related to the patient's family, and
      (3) barriers related to the ICU personnel providing direct EOLC. The interviewed 
      nurses considered the lack of support from managers to be the main barrier. We
      found that ICU nurses in Poland dealt with end-of-life aspects that were
      emotionally and psychologically taxing. In addition, they lacked specialized
      training in this area, especially with regard to family care and care provision. 
      CONCLUSIONS: A pressing need exists to improve facilities and make equipment
      ensuring a desirable standard of care more available. Specialized palliative care
      training programs should be incorporated into compulsory nursing curricula for
      ICU nurses.
CI  - (c) The Author(s) 2020.
FAU - Ozga, Dorota
AU  - Ozga D
AUID- ORCID: https://orcid.org/0000-0002-9457-9388
AD  - Institute of Health Sciences, College of Medical Sciences of the University of
      Rzeszow, Rzeszow, Poland.
FAU - Wozniak, Krystyna
AU  - Wozniak K
AD  - Institute of Health Sciences, College of Medical Sciences of the University of
      Rzeszow, Rzeszow, Poland.
FAU - Gurowiec, Piotr Jerzy
AU  - Gurowiec PJ
AD  - Faculty of Medical Sciences, Public Higher Medical Professional School in Opole, 
      Opole, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - United States
TA  - Glob Adv Health Med
JT  - Global advances in health and medicine
JID - 101584936
PMC - PMC7139169
OTO - NOTNLM
OT  - critical care
OT  - end-of-life care
OT  - intensive care
OT  - nursing
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2019/10/11 00:00 [received]
PHST- 2020/03/07 00:00 [revised]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.1177/2164956120916176 [doi]
AID - 10.1177_2164956120916176 [pii]
PST - epublish
SO  - Glob Adv Health Med. 2020 Apr 7;9:2164956120916176. doi:
      10.1177/2164956120916176. eCollection 2020.


PMID- 32284707
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210428
IS  - 1591-7398 (Electronic)
IS  - 1128-7462 (Linking)
VI  - 31
IP  - 1
DP  - 2020
TI  - When can Muslims withdraw or withhold life support? A narrative review of Islamic
      juridical rulings.
PG  - 29-46
LID - 10.1080/11287462.2020.1736243 [doi]
AB  - When it is ethically justifiable to stop medical treatment? For many Muslim
      patients, families, and clinicians this ethical question remains a challenging
      one as Islamic ethico-legal guidance on such matters remains scattered and
      difficult to interpret. In light of this gap, we conducted a systematic
      literature review to aggregate rulings from Islamic jurists and juridical
      councils on whether, and when, it is permitted to withdraw and/or withhold
      life-sustaining care. A total of 16 fatwas were found, 8 of which were
      single-author rulings, and 8 represented the collective view of a juridical
      council. The fatwas are similar in that nearly all judge that Islamic law,
      provided certain conditions are met, permits abstaining from life-sustaining
      treatment. Notably, the justifying conditions appear to rely on physician
      assessment of the clinical prognosis. The fatwas differ when it comes to what
      conditions justify withdrawing or withholding life- sustaining care. Our analyses
      suggest that while notions of futility greatly impact the bioethical discourse
      regarding with holding and/or withdrawal of treatment, the conceptualization of
      futility lacks nuance. Therefore, clinicians, Islamic jurists, and bioethicists
      need to come together in order to unify a conception of medical futility and
      relate it to the ethics of withholding and/or withdrawal of treatment.
CI  - (c) 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &
      Francis Group.
FAU - Mohiuddin, Afshan
AU  - Mohiuddin A
AD  - Initiative on Islam and Medicine, Program on Medicine and Religion, The
      University of Chicago, Chicago, IL, USA.
AD  - Department of Internal Medicine, University Hospitals Regional Medical Center,
      Macomb Township, MI, USA.
FAU - Suleman, Mehrunisha
AU  - Suleman M
AD  - Centre of Islamic Studies, University of Cambridge, Cambridge, UK.
FAU - Rasheed, Shoaib
AU  - Rasheed S
AD  - Department of Internal Medicine, Henry Ford Macomb Hospital, Chicago, IL, USA.
FAU - Padela, Aasim I
AU  - Padela AI
AUID- ORCID: 0000-0003-4834-2889
AD  - Initiative on Islam and Medicine, Program on Medicine and Religion, The
      University of Chicago, Chicago, IL, USA.
AD  - Section of Emergency Medicine, Department of Medicine, The University of Chicago,
      Chicago, IL, USA.
AD  - MacLean Center for Clinical Medical Ethics, The University of Chicago, Chicago,
      IL, USA.
LA  - eng
PT  - Journal Article
DEP - 20200322
PL  - England
TA  - Glob Bioeth
JT  - Global bioethics = Problemi di bioetica
JID - 9425218
PMC - PMC7144300
OTO - NOTNLM
OT  - Fatwa
OT  - Islam Muslim
OT  - Withholding
OT  - end of life care
OT  - withdrawal
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2019/01/07 00:00 [received]
PHST- 2020/02/15 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.1080/11287462.2020.1736243 [doi]
AID - 1736243 [pii]
PST - epublish
SO  - Glob Bioeth. 2020 Mar 22;31(1):29-46. doi: 10.1080/11287462.2020.1736243.
      eCollection 2020.


PMID- 32284691
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Pitfalls and Safeguards in Industry-Funded Research.
PG  - 104-110
LID - 10.31486/toj.19.0093 [doi]
AB  - Background: Physicians should follow ethical principles in their relationships
      with industry and be mindful that such relationships-if they are perceived as
      conflicts of interest-can undermine trust in the patient-physician relationship. 
      Methods: By identifying potential pitfalls and safeguards that can help prevent
      problems, this article focuses on ensuring that physician-industry relationships 
      do not result in ethical transgressions or cause damage to doctor-patient
      relationships. Results: Patient trust in physicians can be undermined by the
      perception that a physician-investigator is operating in the best interest of the
      research rather than the best interest of the patient. Payments from the
      pharmaceutical industry to physician-investigators are transparent because of the
      Sunshine Act, and patients can easily determine if their personal physicians have
      received money from industry. Research subsidies from industry should represent
      fair market value for the work performed. Postmarketing trials with the primary
      goal of increasing familiarity with a drug and prescribing rates should be
      avoided. Medical societies play an important role in establishing standards for
      professional conduct. Conclusion: Ethically sound actions in physician
      relationships with industry should be guided by professional standards, medical
      society guidelines, and local institutional policies.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Breault, Joseph L
AU  - Breault JL
AD  - Former Chair, Institutional Review Board, and Senior Physician, Department of
      Family Medicine, Ochsner Clinic Foundation, New Orleans, LA.
AD  - The University of Queensland Faculty of Medicine, Ochsner Clinical School, New
      Orleans, LA.
FAU - Knafl, Emily
AU  - Knafl E
AD  - The University of Queensland Faculty of Medicine, Ochsner Clinical School, New
      Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122252
OTO - NOTNLM
OT  - Bias
OT  - conflict of interest
OT  - ethics
OT  - research
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0093 [doi]
AID - toj.19.0093 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):104-110. doi: 10.31486/toj.19.0093.


PMID- 32284690
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Precision Medicine and the Institutional Review Board: Ethics and the Genome.
PG  - 98-103
LID - 10.31486/toj.19.0098 [doi]
AB  - Background: Clinical research studies often integrate precision medicine
      technologies and techniques, offering novel treatment opportunities for patients 
      but also posing significant challenges for regulatory authorities and local
      institutional review boards (IRBs) as they attempt to protect patient safety and 
      privacy. Methods: We review the basics of precision medicine and discuss how IRBs
      are addressing new challenges associated with the era of precision medicine.
      Results: Precision medicine trials rely on genomic testing for inclusion criteria
      and investigational drug therapy choices. The vast amounts of complex information
      that can be obtained from basic genetic sequencing tests must be stored,
      analyzed, and interpreted, creating challenges for clinicians, researchers, and
      regulatory staff who are concerned with complex ethical, security, and legal
      issues surrounding patients' personal genetic data in the digital age. All
      members of the IRB face a rapidly changing environment. The traditional areas of 
      primary concern, such as patient privacy, terminology, and financial benefits,
      have been joined by issues associated with precision medicine, such as
      accelerated US Food and Drug Administration drug approval, multiple informed
      consent form modifications, increasing length and complexity of informed consent 
      forms, and participant genetic privacy. The challenge to the IRB is to remain
      focused on the prior areas of significance while also adapting the evaluation
      process to the novel science of precision medicine. Conclusion: In this era of
      exponentially increasing big data and easy-to-access genetic sequencing data,
      IRBs will be tasked with adapting their processes and adjusting to the new
      technology and its corresponding complexities. Such adaptation has always been
      required of IRBs, but now it will need to occur rapidly as technology and data
      analysis capabilities accelerate.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Matrana, Marc R
AU  - Matrana MR
AD  - Ochsner Cancer Institute, Ochsner Clinic Foundation, New Orleans, LA.
AD  - The University of Queensland Faculty of Medicine, Ochsner Clinical School, New
      Orleans, LA.
FAU - Campbell, Bob
AU  - Campbell B
AD  - Ochsner Institutional Review Board, Ochsner Clinic Foundation, New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122257
OTO - NOTNLM
OT  - Ethics
OT  - ethics committees
OT  - genetic privacy
OT  - genomics
OT  - precision medicine
OT  - research
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0098 [doi]
AID - toj.19.0098 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):98-103. doi: 10.31486/toj.19.0098.


PMID- 32284689
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Important Considerations for the Institutional Review Board When Granting Health 
      Insurance Portability and Accountability Act Authorization Waivers.
PG  - 95-97
LID - 10.31486/toj.19.0083 [doi]
AB  - Background: Privacy is recognized as a basic human right in the United States and
      has been identified as a core principle of ethics in clinical research. However, 
      changes in the regulations, changes in how research is conducted, and the
      availability of health data stored in electronic health record systems all pose
      risks to individuals' privacy. Methods: The Health Insurance Portability and
      Accountability Act (HIPAA) Privacy Rule addresses the use and disclosure of
      individuals' health information and sets standards for privacy rights so that
      individuals can understand and control how their health information is used.
      However, despite the significant increase in the complexity of the data privacy
      landscape, the HIPAA Privacy Rule has been largely unchanged since its enactment 
      in 1996. Results: Generally, healthcare entities may not use or disclose
      protected health information (PHI) for research without written authorization
      from each subject permitting that use or disclosure. However, the HIPAA Privacy
      Rule allows an institutional review board (IRB) to waive the need for such
      authorization if documentation is provided that the use or disclosure of PHI
      presents "no more than a minimal risk to the privacy" of the subjects. Because
      IRBs were one of the only bodies allowed to waive the need for authorizations in 
      the research context, they essentially served as the gatekeepers of privacy for
      human subjects. However, this situation changed with the 2018 revisions to 45 CFR
      section sign46-known as the Common Rule-that added new categories of exempt
      research. Under the new regulations, research administrative staff may review a
      submitted research study and determine that it is exempt without the IRB ever
      being involved and with no independent review of privacy considerations. This
      change lessens privacy protections for research subjects. Therefore, IRBs must be
      mindful of the relevant HIPAA guidance and carefully consider all facts and
      circumstances available when granting approvals of HIPAA authorization waiver
      requirements, especially in the content of exempt research, so that the IRB is
      confident that reasonable safeguards to protect patient privacy have been
      maintained. Research institutions should amend their processes to ensure that the
      appropriate level of privacy review is given to all studies, even those that are 
      exempt. Conclusion: Few concrete rules are applicable in the research context
      that ensure compliance with the HIPAA Privacy Rule. Ultimately, more definitive
      regulatory guidance integrating HIPAA and the revised Common Rule should be
      promulgated.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Williams, Kelsey
AU  - Williams K
AD  - Department of Compliance and Privacy, Ochsner Clinic Foundation, New Orleans, LA.
FAU - Colomb, Paul
AU  - Colomb P
AD  - Department of Compliance and Privacy, Ochsner Clinic Foundation, New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122251
OTO - NOTNLM
OT  - Ethics committees-research
OT  - Health Insurance Portability and Accountability Act
OT  - privacy
OT  - research
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0083 [doi]
AID - toj.19.0083 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):95-97. doi: 10.31486/toj.19.0083.


PMID- 32284688
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Exemptions and Limited Institutional Review Board Review: A Practical Look at the
      2018 Common Rule Requirements for Exempt Research.
PG  - 87-94
LID - 10.31486/toj.19.0095 [doi]
AB  - Background: The revised Common Rule sought to modernize an outdated regulatory
      framework, provide clarity to the research community about the application of
      regulations, and reduce regulatory burden. From the advance notice of proposed
      rulemaking in 2011 to the implementation of the Final Rule, a significant amount 
      of commentary and opinion was generated about the rules that govern most
      federally funded human subjects research. Methods: This article provides insight 
      into the changes to the regulatory framework for low-risk research, clarifies
      when exemptions can be applied, and explains the use of limited institutional
      review board (IRB) review. Results: In attempting to fulfill the objectives of
      reducing regulatory burden, freeing IRB administrative resources, and protecting 
      human subjects, the new regulations acknowledge low-risk research and privacy
      concerns, as well as the increased use of biospecimens. In the Final Rule, the
      Office for Human Research Protections updated the definition of human subject and
      expanded the exemption framework. The definition of human subject in the Final
      Rule includes biospecimens, and the new exemption framework includes expanded
      definitions, modifications to existing exemption categories, the creation of new 
      categories, and the creation of a new concept called limited IRB review. The
      expanded exemption framework was designed to help alleviate the regulatory
      burdens of low-risk research. Conclusion: Whether the revised regulations will
      meet the needs of the research community and human subject participants is
      unknown. While the revised Common Rule includes some welcome modifications and
      additions, the changes have also introduced new concepts that are not fully
      elucidated and have therefore introduced new ambiguities.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Walch-Patterson, Amelia
AU  - Walch-Patterson A
AD  - Human Research Protection Program, Ochsner Clinic Foundation, New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122256
OTO - NOTNLM
OT  - Clinical trials data monitoring committees
OT  - confidentiality
OT  - ethics committees-research
OT  - legislation
OT  - privacy
OT  - research subjects
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0095 [doi]
AID - toj.19.0095 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):87-94. doi: 10.31486/toj.19.0095.


PMID- 32284687
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Understanding Broad Consent.
PG  - 81-86
LID - 10.31486/toj.19.0088 [doi]
AB  - Background: The 2018 revisions to the Common Rule that were effective in January 
      2019 introduced a new category of informed consent: broad consent. Methods:
      Investigators and institutional review board (IRB) members need to understand (1)
      what broad consent is, (2) the role of broad consent under the revised Common
      Rule, (3) how and when broad consent can be used, (4) exempt research categories 
      that relate to broad consent, and (5) the scope of limited IRB review as it
      relates to broad consent. Results: Under the prior regulations, researchers had
      two consent options: obtain study-specific informed consent or request the IRB to
      waive the requirement to obtain informed consent. The revision to the Common Rule
      introduced the third option of broad consent, but its applicability is limited.
      Broad consent can only be used to obtain an individual's consent for the storage,
      maintenance, and secondary research use of identifiable private information or
      identifiable biospecimens. The regulatory authority for broad consent is at 45
      CFR section sign46.116(d). None of the required elements of broad consent can be 
      omitted or altered because each element is considered essential. Broad consent
      shares many of the requirements for study-specific informed consent, but several 
      elements are unique: a description of the types of secondary research that may be
      conducted; statements describing the private information or biospecimens that
      might be used in research, whether sharing of the information or biospecimens
      might occur, and the types of institutions or researchers that might conduct
      research with the information or biospecimens; information on how long the
      information or biospecimens may be stored, maintained, and used; a statement that
      subjects will or will not be informed of the details of any subsequent research; 
      a statement that research results will or will not be disclosed to subjects; and 
      contact information for obtaining answers to questions about the subjects' rights
      regarding storage and use of information or biospecimens and whom to contact
      regarding research-related harm. Conclusion: Broad consent provides flexibility
      that did not exist prior to the revision, giving researchers the option to obtain
      broad consent for the storage, maintenance, and secondary research use of
      identifiable private information or identifiable biospecimens. With an
      understanding of the regulations, an investigator can plan how best to organize
      his or her research plan and decide whether to obtain study-specific informed
      consent, to apply for a waiver of consent, or to obtain broad consent.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Maloy, John W
AU  - Maloy JW
AD  - Assistant Vice Chancellor for Research Management, Louisiana State University
      Health Sciences Center Shreveport, Shreveport, LA.
FAU - Bass, Pat F 3rd
AU  - Bass PF 3rd
AD  - Office of Research, Louisiana State University Health Sciences Center Shreveport,
      Shreveport, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122261
OTO - NOTNLM
OT  - Ethics committees-research
OT  - informed consent
OT  - research
OT  - research personnel
OT  - research subjects
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0088 [doi]
AID - toj.19.0088 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):81-86. doi: 10.31486/toj.19.0088.


PMID- 32284686
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Implementation of Common Rule Changes to the Informed Consent Form: A Research
      Staff and Institutional Review Board Collaboration.
PG  - 76-80
LID - 10.31486/toj.19.0080 [doi]
AB  - Background: The Common Rule, which governs federally funded clinical research
      involving human subjects, formally defines the requirements for institutional
      review board (IRB) membership, functions and operations, and review of research, 
      as well as the requirements for obtaining informed consent from research
      participants. The revisions to the Common Rule effective in January 2019 changed 
      some content requirements for informed consent forms. Methods: This article
      summarizes the history of informed consent requirements, the changes made to the 
      requirements by the revision to the Common Rule, and the ways in which IRBs and
      research staff work together to develop informed consent forms that comply with
      the regulations and provide all the information potential research subjects need 
      to decide whether to participate in a study. Results: Clinical research
      coordinators, under their investigators' supervision, are responsible for
      ensuring that research consent forms comply with the requirements of the federal 
      regulations and the institution. Many IRBs have provided education regarding
      these new requirements, as well as consent templates that contain all the
      required elements. To ensure that the Common Rule's requirements are met, the IRB
      reviews each study submission, including the consent form. The IRB panel makes
      revisions to the consent forms as needed and returns the approved consent form to
      the investigator and clinical research coordinator. Conclusion: Research
      coordinators play an essential role in developing consent forms and providing the
      required review information to the IRB. In turn, through optimizing and
      standardizing consent forms and ensuring that all requirements of the Common Rule
      are followed, IRBs ensure that the rights of participants are protected and
      upheld.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Gartel, Grace
AU  - Gartel G
AD  - Kayentis, Boston, MA.
FAU - Scuderi, Heather
AU  - Scuderi H
AD  - Ochsner Clinic Foundation Institutional Review Board and Clinical Trials
      Coordinator, Ochsner Clinic Foundation, New Orleans, LA.
FAU - Servay, Christine
AU  - Servay C
AD  - Ochsner Clinic Foundation Institutional Review Board, Ochsner Clinic Foundation, 
      New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122266
OTO - NOTNLM
OT  - Consent forms
OT  - ethics committees-research
OT  - research personnel
OT  - research subjects
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0080 [doi]
AID - toj.19.0080 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):76-80. doi: 10.31486/toj.19.0080.


PMID- 32284685
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Revised Common Rule Changes to the Consent Process and Consent Form.
PG  - 62-75
LID - 10.31486/toj.19.0055 [doi]
AB  - Background: The Federal Policy for the Protection of Human Subjects-the Common
      Rule-was revised in 2017 to reduce administrative burdens for low-risk research
      while enhancing protections for human subjects enrolled in
      greater-than-minimal-risk trials. These enhanced protections involve changes to
      the consent process. Methods: We review the general requirements applicable to
      the consent process, as well as the additional elements of consent mandated by
      the revisions to the Common Rule. The regulations apply to federally funded
      studies and are optional for non-federally funded studies. Results: Two new
      general requirements for the consent process, one basic required element for the 
      consent form, and three optional additional elements for the consent form were
      added in an effort to improve potential subjects' understanding of research
      studies and to facilitate the exchange of information between the research staff 
      and potential subjects. Important information about the study should be extracted
      into a concise key information section to help potential subjects make informed
      decisions regarding participation. Conclusion: The revisions to the Common Rule
      are intended to enhance human subject protection by providing more information in
      an understandable form during the consent process. The new consent elements aim
      to increase transparency and help improve clarity.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - LeCompte, Leah L
AU  - LeCompte LL
AD  - Department of Rehabilitation Services, Ochsner Clinic Foundation, New Orleans,
      LA.
FAU - Young, Sylvia J
AU  - Young SJ
AD  - Human Research Protection Program, Ochsner Clinic Foundation, New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122264
OTO - NOTNLM
OT  - Consent forms
OT  - ethics committees-research
OT  - informed consent
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0055 [doi]
AID - toj.19.0055 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):62-75. doi: 10.31486/toj.19.0055.


PMID- 32284683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Institutional Review Board Assessment-Balancing Efficiency and Quality.
PG  - 50-55
LID - 10.31486/toj.19.0075 [doi]
AB  - Background: Satisfactory measurements of the quality of institutional review
      board (IRB) reviews and services continue to be elusive. For evaluative purposes,
      the review process can be separated into two parts: the administrative functions 
      that support the review board and the review board's decisions. Methods:
      Administrative performance and board decision-making lend themselves to very
      different measures of quality. In particular, administrative performance is
      amenable to measures of process efficiency and correctness, while board decisions
      require a thoughtful consideration of the meaning of quality in the context of
      the ethical review of research. Discussion: In the evaluation of administrative
      process, simple numbers such as mean or median time from submission to
      determination allow for easy comparison between IRBs, but their use means
      foregoing the opportunity for nuanced assessment and continuous improvement. The 
      full distribution of measured values would indicate whether the IRB takes longer 
      with complex studies or with certain categories of studies. An analysis of
      outliers would give the IRB an opportunity to assess particularly problematic
      areas. While such measures and analyses are not easily standardized or shared,
      they would be useful within the IRB, and one measure of quality would be whether 
      an IRB had procedures in place for routinely conducting such analyses. In the
      evaluation of decision quality, at a minimum, IRBs should be held to a measure of
      the consistency of their decisions. Consistency should be used as an internal
      quality measure. A potential indicator of quality would be the existence of tools
      and processes for routinely monitoring the consistency of decisions and requiring
      clear rationale for inconsistencies. Conclusion: Ongoing quality assessment and
      continuous improvement in decision-making are likely to require committed
      resources, but such a commitment will be necessary to provide balance to the
      impetus to improve efficiency and administrative performance.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Rosenfeld, Stephen J
AU  - Rosenfeld SJ
AD  - Freeport Research Systems, LLC, Freeport, ME.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122259
OTO - NOTNLM
OT  - Decision making-organizational
OT  - ethics committees-research
OT  - ethics-research
OT  - process assessment-health care
OT  - quality improvement
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0075 [doi]
AID - toj.19.0075 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):50-55. doi: 10.31486/toj.19.0075.


PMID- 32284680
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Vulnerability in Research: Basic Ethical Concepts and General Approach to Review.
PG  - 34-38
LID - 10.31486/toj.19.0079 [doi]
AB  - Background: The concept of vulnerability is a cornerstone of the theoretical
      basis and practical application of ethics in human subjects research. Risks to
      humans participating in research must be minimized; that is, subjects must be
      offered protection from risks. Vulnerable subjects require additional
      protections. Methods: This paper reviews the ethical and conceptual basis of
      vulnerability within the context of human subjects research and suggests a basic 
      approach that institutional review boards (IRBs) can use when considering if the 
      research includes adequate safeguards to protect the rights and welfare of
      subjects who are likely to be vulnerable. Results: Two distinct approaches to
      describing the features that make a person vulnerable are the categorical
      approach and the contextual approach. The categorical approach considers certain 
      groups or populations as vulnerable. This approach is not optimal because it does
      not address persons with multiple vulnerabilities, does not account for variation
      in the degree of vulnerability within the group based on individual
      characteristics, and classifies certain persons as vulnerable rather than
      identifying situations in which individuals might be considered vulnerable. The
      alternate contextual approach allows for a more nuanced understanding of the
      nature of the vulnerability than the categorical approach and therefore a more
      focused approach to safeguards. The IRB is charged with ensuring that additional 
      safeguards to protect the rights and welfare of subjects who are likely to be
      vulnerable are included in the study under review. To make this determination,
      the IRB might be advised to consider two questions: (1) is inclusion necessary?
      and (2) if so, are safeguards adequate? Conclusion: Although vulnerability is
      often presented as a yes/no consequence related to some characteristic of a
      group, a more accurate approach is to consider vulnerability as occurring along a
      spectrum of seriousness and as a consequence of situations and context. With this
      idea in mind, investigators and IRBs are advised to take a stepwise approach to
      determining if the study meets the regulatory and ethical admonition to ensure
      that safeguards protect the rights and welfare of vulnerable subjects.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - Gordon, Bruce G
AU  - Gordon BG
AD  - Assistant Vice-Chancellor for Regulatory Affairs, Executive Chairman,
      Institutional Review Boards, and Professor, Department of Pediatrics, University 
      of Nebraska Medical Center, Omaha, NE.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122263
OTO - NOTNLM
OT  - Ethics committees-research
OT  - ethics-research
OT  - vulnerable populations
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.19.0079 [doi]
AID - toj.19.0079 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):34-38. doi: 10.31486/toj.19.0079.


PMID- 32284679
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1524-5012 (Print)
IS  - 1524-5012 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Spring
TI  - Why Human Subjects Research Protection Is Important.
PG  - 16-33
LID - 10.31486/toj.20.5012 [doi]
AB  - Background: Institutional review boards (IRBs), duly constituted under the Office
      of Human Research Protection, have the federally mandated responsibility of
      reviewing research involving human subjects to ensure that a proposed protocol
      meets the appropriate ethical guidelines before subjects may be enrolled in any
      study. The road leading to the current regulations and ethical considerations has
      been long and checkered. Methods: This paper reviews the history of human
      subjects participating in research, including examples of egregious events, and
      the ethical analyses that precipitated the evolution of the mandated protections 
      afforded participants in research under current federal regulations. Results: Key
      documents-from the Nuremberg Code in 1947 to the Belmont Report in 1978 to Moral 
      Science: Protecting Participants in Human Subjects Research in 2011-that have
      informed the ethics debate regarding human subjects protection in research
      activities are presented in light of their historic significance, highlighting
      the complexity of the issues surrounding protection of human subjects in
      research. Conclusion: The examples from history and the scarcity of contemporary 
      examples demonstrate that the regulations for the protection of humans
      participating in research have evolved in a way that minimizes the probability
      that subjects will be harmed when they choose to participate in research. The
      examples also reinforce the importance of individual responsibility. Failure of
      IRBs to provide appropriate review and oversight can lead to severe consequences,
      as can abrogation by the investigator to place the well-being of the subjects as 
      the primary responsibility in any research protocol. Understanding how we arrived
      at the current approach and some of the failures that directed this course can
      support efforts to continually reevaluate and improve the safety of subjects who 
      are willing to participate in research activities.
CI  - (c)2020 by the author(s); Creative Commons Attribution License (CC BY).
FAU - White, Michael G
AU  - White MG
AD  - Department of Pediatric Cardiology, Ochsner Clinic Foundation, New Orleans, LA
      and The University of Queensland Faculty of Medicine, Ochsner Clinical School,
      New Orleans, LA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ochsner J
JT  - The Ochsner journal
JID - 101125795
PMC - PMC7122250
OTO - NOTNLM
OT  - Ethics committees-research
OT  - ethics-research
OT  - research subjects
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - 10.31486/toj.20.5012 [doi]
AID - toj.20.5012 [pii]
PST - ppublish
SO  - Ochsner J. 2020 Spring;20(1):16-33. doi: 10.31486/toj.20.5012.


PMID- 32284657
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Ethical barriers to artificial intelligence in the national health service,
      United Kingdom of Great Britain and Northern Ireland.
PG  - 293-295
LID - 10.2471/BLT.19.237230 [doi]
FAU - Thompson, Claire Louise
AU  - Thompson CL
AD  - School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, Scotland.
FAU - Morgan, Heather May
AU  - Morgan HM
AD  - School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,
      Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, Scotland.
LA  - eng
PT  - Journal Article
DEP - 20200228
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - Algorithms
MH  - Artificial Intelligence/*ethics
MH  - *Diffusion of Innovation
MH  - Northern Ireland
MH  - Social Responsibility
MH  - *State Medicine
MH  - Trust
MH  - Truth Disclosure
MH  - United Kingdom
PMC - PMC7133482
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/12/23 00:00 [revised]
PHST- 2020/01/03 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237230 [doi]
AID - BLT.19.237230 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):293-295. doi: 10.2471/BLT.19.237230.
      Epub 2020 Feb 28.


PMID- 32284655
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Artificial intelligence, diagnostic imaging and neglected tropical diseases:
      ethical implications.
PG  - 288-289
LID - 10.2471/BLT.19.237560 [doi]
FAU - Vaisman, Alon
AU  - Vaisman A
AD  - Division Infectious Diseases, Toronto General Hospital, University of Toronto,
      14EN 209, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.
FAU - Linder, Nina
AU  - Linder N
AD  - Department of Women's and Children's Health, International Maternal and Child
      health, Uppsala University, Sweden.
FAU - Lundin, Johan
AU  - Lundin J
AD  - Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
FAU - Orchanian-Cheff, Ani
AU  - Orchanian-Cheff A
AD  - Health Sciences Library, University Health Network, Toronto, Canada.
FAU - Coulibaly, Jean T
AU  - Coulibaly JT
AD  - Unite de Formation et de Recherche Biosciences, Universite Felix
      Houphouet-Boigny, Abidjan, Cote d'Ivoire.
FAU - Ephraim, Richard Kd
AU  - Ephraim RK
AD  - Department of Medical Laboratory Sciences, University of Cape Coast, Cape Coast, 
      Ghana.
FAU - Bogoch, Isaac I
AU  - Bogoch II
AD  - Division Infectious Diseases, Toronto General Hospital, University of Toronto,
      14EN 209, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200303
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Diagnostic Imaging/*ethics
MH  - Humans
MH  - *Neglected Diseases
MH  - *Tropical Medicine
PMC - PMC7133484
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2019/12/16 00:00 [revised]
PHST- 2019/12/17 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237560 [doi]
AID - BLT.19.237560 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):288-289. doi: 10.2471/BLT.19.237560.
      Epub 2020 Mar 3.


PMID- 32284654
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Ethical implications of conversational agents in global public health.
PG  - 285-287
LID - 10.2471/BLT.19.237636 [doi]
FAU - Luxton, David D
AU  - Luxton DD
AD  - Department of Psychiatry & Behavioral Sciences, University of Washington School
      of Medicine, 1959 NE Pacific St, Seattle, Washington 98195-6560, United States of
      America.
LA  - eng
PT  - Journal Article
DEP - 20200127
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - Bias
MH  - *Communication
MH  - *Digital Technology
MH  - *Global Health
MH  - Health Services Accessibility
MH  - Humans
MH  - Mental Health Services/supply & distribution
MH  - Privacy
MH  - Public Health
PMC - PMC7133471
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2019/10/29 00:00 [revised]
PHST- 2019/12/06 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237636 [doi]
AID - BLT.19.237636 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):285-287. doi: 10.2471/BLT.19.237636.
      Epub 2020 Jan 27.


PMID- 32284652
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20220413
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Ethical challenges of digital health technologies: Aadhaar, India.
PG  - 277-281
LID - 10.2471/BLT.19.237123 [doi]
AB  - PROBLEM: The proliferation of information and communication technologies in India
      has enabled the emergence of health-related digital applications, from which
      important ethical issues arise. APPROACH: The Aadhaar identification system
      provides each resident in India with a 12-digit unique identification number,
      linked to demographic and biometric data. Identification by Aadhaar in welfare
      programmes has the important advantage of ensuring targeted benefits reach the
      intended recipients. LOCAL SETTING: Some of the major issues faced by the public 
      health sector in India are inadequate funding and inefficient utilization of the 
      funds allocated. The enhancement of currently available digital health records
      will greatly increase the efficiency of the health care services. RELEVANT
      CHANGES: The Aadhaar identification system has been linked to several health
      programmes since 2013. Success was achieved in a programme encouraging pregnant
      women to undergo delivery at a health facility, as use of Aadhaar number ensured 
      that cash incentives reached the correct recipient. However, interruptions in the
      treatment of patients with tuberculosis and acquired immunodeficiency syndrome
      have been reported in other health programmes, due to patients fearing a breach
      of their confidentiality. LESSONS LEARNT: Although the proposed merging of the
      Aadhaar identification system with digital health care records could enable
      greater efficiency in monitoring public health and welfare programmes, important 
      ethical issues of privacy and data ownership and use must be considered. In
      joining the digital revolution, low- and middle-income countries must also
      develop strict legal regulation to protect data and avoid information technology 
      companies exploiting such databases for profit.
CI  - (c) 2020 The authors; licensee World Health Organization.
FAU - Gopichandran, Vijayaprasad
AU  - Gopichandran V
AD  - Employees State Insurance Corporation Medical College and Post Graduate Institute
      of Medical Sciences and Research, Chennai, India.
FAU - Ganeshkumar, Parasuraman
AU  - Ganeshkumar P
AD  - Indian Council of Medical Research, National Institute of Epidemiology, Chennai, 
      India.
FAU - Dash, Sambit
AU  - Dash S
AD  - Department of Biochemistry, Melaka-Manipal Medical College, Manipal Academy of
      Higher Education, Karnataka, India.
FAU - Ramasamy, Aarthy
AU  - Ramasamy A
AD  - Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalapuram,
      Chennai, 600086, India.
LA  - eng
PT  - Journal Article
DEP - 20190117
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - Biometric Identification/ethics
MH  - Digital Technology/*ethics
MH  - Humans
MH  - India
MH  - Public Health
MH  - *Records
PMC - PMC7133485
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/09/30 00:00 [revised]
PHST- 2019/11/04 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237123 [doi]
AID - BLT.19.237123 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):277-281. doi: 10.2471/BLT.19.237123.
      Epub 2019 Jan 17.


PMID- 32284651
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Ethical dilemmas posed by mobile health and machine learning in psychiatry
      research.
PG  - 270-276
LID - 10.2471/BLT.19.237107 [doi]
AB  - The application of digital technology to psychiatry research is rapidly leading
      to new discoveries and capabilities in the field of mobile health. However, the
      increase in opportunities to passively collect vast amounts of detailed
      information on study participants coupled with advances in statistical techniques
      that enable machine learning models to process such information has raised novel 
      ethical dilemmas regarding researchers' duties to: (i) monitor adverse events and
      intervene accordingly; (ii) obtain fully informed, voluntary consent; (iii)
      protect the privacy of participants; and (iv) increase the transparency of
      powerful, machine learning models to ensure they can be applied ethically and
      fairly in psychiatric care. This review highlights emerging ethical challenges
      and unresolved ethical questions in mobile health research and provides
      recommendations on how mobile health researchers can address these issues in
      practice. Ultimately, the hope is that this review will facilitate continued
      discussion on how to achieve best practice in mobile health research within
      psychiatry.
CI  - (c) 2020 The authors; licensee World Health Organization.
FAU - Jacobson, Nicholas C
AU  - Jacobson NC
AD  - Department of Biomedical Data Science and Psychiatry, Geisel School of Medicine, 
      Dartmouth College, Suite 300, Office # 333S, 46 Centerra Parkway, Lebanon, NH
      03766, United States of America (USA).
FAU - Bentley, Kate H
AU  - Bentley KH
AD  - Department of Psychiatry, Massachusetts General Hospital-Harvard Medical School, 
      Cambridge, USA.
FAU - Walton, Ashley
AU  - Walton A
AD  - Department of Statistics, Harvard University, Cambridge, USA.
FAU - Wang, Shirley B
AU  - Wang SB
AD  - Department of Psychology, Harvard University, Cambridge, USA.
FAU - Fortgang, Rebecca G
AU  - Fortgang RG
AD  - Department of Psychology, Harvard University, Cambridge, USA.
FAU - Millner, Alexander J
AU  - Millner AJ
AD  - Department of Psychology, Harvard University, Cambridge, USA.
FAU - Coombs, Garth 3rd
AU  - Coombs G 3rd
AD  - Department of Psychology, Harvard University, Cambridge, USA.
FAU - Rodman, Alexandra M
AU  - Rodman AM
AD  - Department of Psychology, Harvard University, Cambridge, USA.
FAU - Coppersmith, Daniel D L
AU  - Coppersmith DDL
AD  - Department of Psychology, Harvard University, Cambridge, USA.
LA  - eng
GR  - P30 DA029926/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20200225
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - *Ethics, Research
MH  - Informed Consent
MH  - Machine Learning/*ethics
MH  - Privacy
MH  - *Psychiatry
MH  - Telemedicine/*ethics
PMC - PMC7133483
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2020/02/04 00:00 [revised]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237107 [doi]
AID - BLT.19.237107 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):270-276. doi: 10.2471/BLT.19.237107.
      Epub 2020 Feb 25.


PMID- 32284650
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Ensuring trustworthy use of artificial intelligence and big data analytics in
      health insurance.
PG  - 263-269
LID - 10.2471/BLT.19.234732 [doi]
AB  - Technological advances in big data (large amounts of highly varied data from many
      different sources that may be processed rapidly), data sciences and artificial
      intelligence can improve health-system functions and promote personalized care
      and public good. However, these technologies will not replace the fundamental
      components of the health system, such as ethical leadership and governance, or
      avoid the need for a robust ethical and regulatory environment. In this paper, we
      discuss what a robust ethical and regulatory environment might look like for big 
      data analytics in health insurance, and describe examples of safeguards and
      participatory mechanisms that should be established. First, a clear and effective
      data governance framework is critical. Legal standards need to be enacted and
      insurers should be encouraged and given incentives to adopt a human-centred
      approach in the design and use of big data analytics and artificial intelligence.
      Second, a clear and accountable process is necessary to explain what information 
      can be used and how it can be used. Third, people whose data may be used should
      be empowered through their active involvement in determining how their personal
      data may be managed and governed. Fourth, insurers and governance bodies,
      including regulators and policy-makers, need to work together to ensure that the 
      big data analytics based on artificial intelligence that are developed are
      transparent and accurate. Unless an enabling ethical environment is in place, the
      use of such analytics will likely contribute to the proliferation of unconnected 
      data systems, worsen existing inequalities, and erode trustworthiness and trust.
CI  - (c) 2020 The authors; licensee World Health Organization.
FAU - Ho, Calvin W L
AU  - Ho CWL
AD  - Faculty of Law, Cheng Yu Tung Tower, Centennial Campus, The University of Hong
      Kong, Pokfulam, Hong Kong Special Administrative Region, China.
FAU - Ali, Joseph
AU  - Ali J
AD  - Department of International Health, Johns Hopkins Bloomberg School of Public
      Health, Baltimore, United States of America.
FAU - Caals, Karel
AU  - Caals K
AD  - Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National
      University of Singapore, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20200225
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - *Artificial Intelligence/ethics
MH  - *Big Data
MH  - Data Science
MH  - *Insurance, Health
MH  - *Trust
PMC - PMC7133481
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/06/30 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.234732 [doi]
AID - BLT.19.234732 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):263-269. doi: 10.2471/BLT.19.234732.
      Epub 2020 Feb 25.


PMID- 32284649
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - How to achieve trustworthy artificial intelligence for health.
PG  - 257-262
LID - 10.2471/BLT.19.237289 [doi]
AB  - Artificial intelligence holds great promise in terms of beneficial, accurate and 
      effective preventive and curative interventions. At the same time, there is also 
      awareness of potential risks and harm that may be caused by unregulated
      developments of artificial intelligence. Guiding principles are being developed
      around the world to foster trustworthy development and application of artificial 
      intelligence systems. These guidelines can support developers and governing
      authorities when making decisions about the use of artificial intelligence. The
      High-Level Expert Group on Artificial Intelligence set up by the European
      Commission launched the report Ethical guidelines for trustworthy artificial
      intelligence in2019. The report aims to contribute to reflections and the
      discussion on the ethics of artificial intelligence technologies also beyond the 
      countries of the European Union (EU). In this paper, we use the global health
      sector as a case and argue that the EU's guidance leaves too much room for local,
      contextualized discretion for it to foster trustworthy artificial intelligence
      globally. We point to the urgency of shared globalized efforts to safeguard
      against the potential harms of artificial intelligence technologies in health
      care.
CI  - (c) 2020 The authors; licensee World Health Organization.
FAU - Baeroe, Kristine
AU  - Baeroe K
AD  - Department of Global Public Health and Primary Care, University of Bergen, PO Box
      7804, N-5020 Bergen, Norway.
FAU - Miyata-Sturm, Ainar
AU  - Miyata-Sturm A
AD  - Oslo Metropolitan University, Oslo, Norway.
FAU - Henden, Edmund
AU  - Henden E
AD  - Oslo Metropolitan University, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20200127
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - *Artificial Intelligence
MH  - *Delivery of Health Care
MH  - European Union
MH  - Goals
MH  - *Trust
PMC - PMC7133476
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/12/01 00:00 [revised]
PHST- 2020/01/10 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237289 [doi]
AID - BLT.19.237289 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):257-262. doi: 10.2471/BLT.19.237289.
      Epub 2020 Jan 27.


PMID- 32284646
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Linking)
VI  - 98
IP  - 4
DP  - 2020 Apr 1
TI  - Defining ethical standards for the application of digital tools to population
      health research.
PG  - 239-244
LID - 10.2471/BLT.19.237370 [doi]
AB  - There is growing interest in population health research, which uses methods based
      on artificial intelligence. Such research draws on a range of clinical and
      non-clinical data to make predictions about health risks, such as identifying
      epidemics and monitoring disease spread. Much of this research uses data from
      social media in the public domain or anonymous secondary health data and is
      therefore exempt from ethics committee scrutiny. While the ethical use and
      regulation of digital-based research has been discussed, little attention has
      been given to the ethics governance of such research in higher education
      institutions in the field of population health. Such governance is essential to
      how scholars make ethical decisions and provides assurance to the public that
      researchers are acting ethically. We propose a process of ethics governance for
      population health research in higher education institutions. The approach takes
      the form of review after the research has been completed, with particular focus
      on the role artificial intelligence algorithms play in augmenting
      decision-making. The first layer of review could be national, open-science
      repositories for open-source algorithms and affiliated data or information which 
      are developed during research. The second layer would be a sector-specific
      validation of the research processes and algorithms by a committee of academics
      and stakeholders with a wide range of expertise across disciplines. The committee
      could be created as an off-shoot of an already functioning national oversight
      body or health technology assessment organization. We use case studies of good
      practice to explore how this process might operate.
CI  - (c) 2020 The authors; licensee World Health Organization.
FAU - Samuel, Gabrielle
AU  - Samuel G
AD  - Department of Global Health and Social Medicine, King's College London, Bush
      House, North East Wing, The Strand, London, WC2R 2LS, England.
FAU - Derrick, Gemma
AU  - Derrick G
AD  - Department of Educational Research, Lancaster University, Lancaster, England.
LA  - eng
PT  - Journal Article
DEP - 20190117
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - *Ethics, Research
MH  - *Population Health
PMC - PMC7133469
EDAT- 2020/04/15 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2019/10/18 00:00 [revised]
PHST- 2019/10/25 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.2471/BLT.19.237370 [doi]
AID - BLT.19.237370 [pii]
PST - ppublish
SO  - Bull World Health Organ. 2020 Apr 1;98(4):239-244. doi: 10.2471/BLT.19.237370.
      Epub 2019 Jan 17.


PMID- 32284637
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20200520
IS  - 2048-8343 (Electronic)
IS  - 0025-7273 (Linking)
VI  - 64
IP  - 2
DP  - 2020 Apr
TI  - The 'Converted Unbelievers': Catholics in Family Planning in French-Speaking
      Belgium (1947-73).
PG  - 267-286
LID - 10.1017/mdh.2020.6 [doi]
AB  - This paper looks at the journey of eleven counsellors in marital counselling
      centres in French-speaking Belgium, from the creation of the centres in 1953, to 
      the 1970s, when contraception became legal, and abortion became a public issue.
      At the time of Humanae Vitae, groups of volunteers, working within Catholic
      organisations where counselling took place, began to structure their activity
      around Carl Rogers's ethics of client-centred therapy, placing their religious
      ideology in a secondary position to focus on the problems experienced by the
      couples and women they were receiving in the centres. These were often challenges
      they were experiencing themselves in their own lives. The reiteration of the
      Catholic orthodox view on contraception through Humanae Vitae marked a gap
      between the counsellors and the Church. This contribution questions the
      identity-related tension of Catholics working in conjugal counselling centres and
      the type of commitments they made to both the conjugal centres and the Church in 
      a moment where family planning was debated both in the Church and politically.
CI  - (c) The Author(s) 2020.
FAU - Crosetti, Anne-Sophie
AU  - Crosetti AS
AD  - Universite libre de Bruxelles, Avenue Jeanne 44, 1150 Ixelles, Belgium.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - England
TA  - Med Hist
JT  - Medical history
JID - 0401052
SB  - IM
MH  - Belgium
MH  - Catholicism/*history
MH  - Contraception/ethics/*history
MH  - Counseling/ethics/*history
MH  - Family Planning Services/ethics/*history
MH  - Female
MH  - History, 20th Century
MH  - Humans
MH  - Male
MH  - *Religion and Medicine
PMC - PMC7120260
OTO - NOTNLM
OT  - *Belgium
OT  - *Catholicism
OT  - *Church Norms
OT  - *Counselling
OT  - *Responsible Parenthood
OT  - *Rogerian Approach
EDAT- 2020/04/15 06:00
MHDA- 2020/05/21 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
AID - 10.1017/mdh.2020.6 [doi]
PST - ppublish
SO  - Med Hist. 2020 Apr;64(2):267-286. doi: 10.1017/mdh.2020.6.


PMID- 32284477
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 0974-7559 (Electronic)
IS  - 0019-6061 (Linking)
VI  - 57
IP  - 4
DP  - 2020 Apr 15
TI  - Global Strategy on Digital Health.
PG  - 356-358
AB  - Digital technology has been a revolutionary foray in education, industry,
      research and recently, healthcare. Digital health encompasses various aspects of 
      technology like information and communication, mobile health, data-recording and 
      telemedicine. There has been an exponential and unregulated increase in digital
      health services in last few years which have raised concerns over data privacy,
      ethical standards and quality of services. The World Health Organization recently
      released the global strategy on digital health as a visionary document that
      provides a framework for countries to implement and expand digital health
      services. The following update briefly highlights the salient features of the
      update.
FAU - Dhingra, Dhulika
AU  - Dhingra D
AD  - Department of Pediatrics, Chacha Nehru Bal Chikitsalaya, New Delhi, India.
FAU - Dabas, Aashima
AU  - Dabas A
AD  - Department of Pediatrics, Maulana Azad Medical College, New Delhi, India.
      Correspondence to: Dr Aashima Dabas, Associate Professor, Department of
      Pediatrics, Maulana Azad Medical College and associated Lok Nayak Hospital, New
      Delhi 110 002, India. dr.aashimagupta@gmail.com.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian Pediatr
JT  - Indian pediatrics
JID - 2985062R
SB  - IM
MH  - Communication
MH  - Delivery of Health Care
MH  - Humans
MH  - *Telemedicine
MH  - World Health Organization
EDAT- 2020/04/15 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PST - ppublish
SO  - Indian Pediatr. 2020 Apr 15;57(4):356-358.


PMID- 32284414
OWN - NLM
STAT- MEDLINE
DCOM- 20200731
LR  - 20200731
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 117
IP  - 15
DP  - 2020 Apr 14
TI  - Leveraging legacy archaeological collections as proxies for climate and
      environmental research.
PG  - 8287-8294
LID - 10.1073/pnas.1914154117 [doi]
AB  - Understanding the causes and consequences of previous climate changes is
      essential for testing present-day climate models and projections. Archaeological 
      sites are paleoenvironmental archives containing unique ecological baselines with
      data on paleoclimate transformations at a human timescale. Anthropogenic and
      nonanthropogenic forces have destroyed many sites, and others are under immediate
      threat. In the face of this loss, previously excavated collections from these
      sites-referred to as legacy collections-offer a source of climate and other
      paleoenvironmental information that may no longer exist elsewhere. Here, we 1)
      review obstacles to systematically using data from legacy archaeological
      collections, such as inconsistent or unreported field methods, inadequate
      records, unsatisfactory curation, and insufficient public knowledge of relevant
      collections; 2) suggest best practices for integrating archaeological data into
      climate and environmental research; and 3) summarize several studies to
      demonstrate the benefits and challenges of using legacy collections as archives
      of local and regional environmental proxies. Data from archaeological legacy
      collections contribute regional ecological baselines as well as serve to correct 
      shifting baselines. They also enable regional climate reconstructions at various 
      timescales and corroborate or refine radiocarbon dates. Such uses of legacy
      collections raise ethical concerns regarding ownership of and responsibility for 
      cultural resources and highlight the importance of Indigenous involvement in
      planning and executing fieldwork and stewardship of cultural heritage. Finally,
      we discuss methodologies, practices, and policies pertaining to archaeological
      legacy collections and support calls for discipline-wide shifts in collections
      management to ensure their long-term utility in multidisciplinary research and
      public engagement.
FAU - St Amand, Frankie
AU  - St Amand F
AUID- ORCID: 0000-0002-6264-8203
AD  - Climate Change Institute, University of Maine, Orono, ME 04469;
      anne.st@maine.edu.
AD  - Anthropology Department, University of Maine, Orono, ME 04469.
FAU - Childs, S Terry
AU  - Childs ST
AUID- ORCID: 0000-0002-3322-1155
AD  - Department of the Interior Museum Program, Washington, DC 20240.
FAU - Reitz, Elizabeth J
AU  - Reitz EJ
AUID- ORCID: 0000-0002-5119-2976
AD  - Georgia Museum of Natural History, University of Georgia, Athens, GA 30602.
FAU - Heller, Sky
AU  - Heller S
AUID- ORCID: 0000-0001-7150-014X
AD  - Climate Change Institute, University of Maine, Orono, ME 04469.
AD  - Anthropology Department, University of Maine, Orono, ME 04469.
FAU - Newsom, Bonnie
AU  - Newsom B
AUID- ORCID: 0000-0001-7240-9778
AD  - Climate Change Institute, University of Maine, Orono, ME 04469.
AD  - Anthropology Department, University of Maine, Orono, ME 04469.
FAU - Rick, Torben C
AU  - Rick TC
AUID- ORCID: 0000-0002-8254-5885
AD  - Department of Anthropology, National Museum of Natural History, Smithsonian
      Institution, Washington, DC 20013-7012.
FAU - Sandweiss, Daniel H
AU  - Sandweiss DH
AUID- ORCID: 0000-0002-9984-8831
AD  - Climate Change Institute, University of Maine, Orono, ME 04469.
AD  - Anthropology Department, University of Maine, Orono, ME 04469.
FAU - Wheeler, Ryan
AU  - Wheeler R
AUID- ORCID: 0000-0001-5479-1301
AD  - Robert S. Peabody Institute of Archaeology, Andover, MA 01810.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
MH  - Archaeology/*history
MH  - Climate Change/*history
MH  - Environment
MH  - Environmental Science/*history
MH  - History, Ancient
MH  - Humans
MH  - Research/*economics
PMC - PMC7165441
OTO - NOTNLM
OT  - *archaeology
OT  - *climate proxies
OT  - *climate research
OT  - *legacy archaeological collections
COIS- The authors declare no competing interest.
EDAT- 2020/04/15 06:00
MHDA- 2020/08/01 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/08/01 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 1914154117 [pii]
AID - 10.1073/pnas.1914154117 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8287-8294. doi:
      10.1073/pnas.1914154117.


PMID- 32284391
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 12
TI  - Evaluation of non-invasive continuous physiological monitoring devices for
      neonates in Nairobi, Kenya: a research protocol.
PG  - e035184
LID - 10.1136/bmjopen-2019-035184 [doi]
AB  - INTRODUCTION: Continuous physiological monitoring devices are often not available
      for monitoring high-risk neonates in low-resource settings. Easy-to-use,
      non-invasive, multiparameter, continuous physiological monitoring devices could
      be instrumental in providing appropriate care and improving outcomes for
      high-risk neonates in these low-resource settings. METHODS AND ANALYSIS: The
      purpose of this prospective, observational, facility-based evaluation is to
      provide evidence to establish whether two existing non-invasive, multiparameter, 
      continuous physiological monitoring devices developed by device developers,
      EarlySense and Sibel, can accurately and reliably measure vital signs in neonates
      (when compared with verified reference devices). We will also assess the
      feasibility, usability and acceptability of these devices for use in neonates in 
      low-resource settings in Africa. Up to 500 neonates are enrolled in two phases:
      (1) a verification and accuracy evaluation phase at Aga Khan University-Nairobi
      and (2) a clinical feasibility evaluation phase at Pumwani Maternity Hospital in 
      Nairobi, Kenya. Both quantitative and qualitative data are collected and
      analysed. Agreement between the investigational and reference devices is
      determined using a priori-defined accuracy thresholds. ETHICS AND DISSEMINATION: 
      This trial was approved by the Aga Khan University Nairobi Research Ethics
      Committee and the Western Institutional Review Board. We plan to disseminate
      research results in peer-reviewed journals and international conferences. TRIAL
      REGISTRATION NUMBER: NCT03920761.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ginsburg, Amy Sarah
AU  - Ginsburg AS
AUID- ORCID: 0000-0002-2291-2276
AD  - Clinical Trial Center, University of Washington, Seattle, Washington, United
      States messageforamy@gmail.com.
FAU - Nkwopara, Evangelyn
AU  - Nkwopara E
AD  - Children's Healthcare of Atlanta, Atlanta, Georgia, United States.
FAU - Macharia, William
AU  - Macharia W
AD  - Pediatrics, Aga Khan University, Nairobi, Kenya.
FAU - Ochieng, Roseline
AU  - Ochieng R
AD  - Pediatrics, Aga Khan University, Nairobi, Kenya.
FAU - Waiyego, Mary
AU  - Waiyego M
AD  - Pediatrics, Pumwani Maternity Hospital, Nairobi, Kenya.
FAU - Zhou, Guohai
AU  - Zhou G
AD  - Biostatistics, Brigham and Women's Hospital, Boston, Massachusetts, United
      States.
FAU - Karasik, Roman
AU  - Karasik R
AD  - EarlySense, Ramat Gan, Israel.
FAU - Xu, Shuai
AU  - Xu S
AD  - Sibel Inc, Evanston, Illinois, United States.
AD  - Dermatology, Northwestern University, Evanston, Illinois, USA.
FAU - Ansermino, J Mark
AU  - Ansermino JM
AD  - Anesthesiology, The University of British Columbia, Vancouver, British Columbia, 
      Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03920761
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200412
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Attitude of Health Personnel
MH  - Feasibility Studies
MH  - Heart Rate
MH  - Humans
MH  - Infant, Newborn
MH  - Kenya
MH  - Monitoring, Physiologic/*instrumentation
MH  - Movement
MH  - Nurseries, Hospital
MH  - Observational Studies as Topic
MH  - Oximetry
MH  - Patient Acceptance of Health Care
MH  - Qualitative Research
MH  - Remote Sensing Technology/*instrumentation
MH  - Respiratory Rate
MH  - Skin Temperature
MH  - Sleep
MH  - *Vital Signs
MH  - *Wearable Electronic Devices
PMC - PMC7200030
OTO - NOTNLM
OT  - *neonatology
OT  - *physiology
OT  - *quality in health care
COIS- Competing interests: RK is employed by EarlySense and SX is employed by Sibel.
EDAT- 2020/04/15 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035184 [pii]
AID - 10.1136/bmjopen-2019-035184 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 12;10(4):e035184. doi: 10.1136/bmjopen-2019-035184.


PMID- 32284387
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 12
TI  - Usual care and a self-management support programme versus usual care and a
      relaxation programme for people living with chronic headache disorders: a
      randomised controlled trial protocol (CHESS).
PG  - e033520
LID - 10.1136/bmjopen-2019-033520 [doi]
AB  - INTRODUCTION: Chronic headaches are poorly diagnosed and managed and can be
      exacerbated by medication overuse. There is insufficient evidence on the
      non-pharmacological approaches to helping people living with chronic headaches.
      METHODS AND ANALYSIS: Chronic Headache Education and Self-management Study is a
      pragmatic randomised controlled trial to test the effectiveness and
      cost-effectiveness of a self-management education support programme on top of
      usual care for patients with chronic headaches against a control of usual care
      and relaxation. The intervention is a 2-day group course based on education,
      personal reflection and a cognitive behavioural approach, plus a nurse-led
      one-to-one consultation and follow-up over 8 weeks. We aim to recruit 689
      participants (356 to the intervention arm and 333 to the control) from primary
      care and self-referral in London and the Midlands. The trial is powered to show a
      difference of 2.0 points on the Headache Impact Test, a patient-reported outcome 
      measure at 12 months post randomisation. Secondary outcomes include health
      related quality of life, self-efficacy, social activation and engagement, anxiety
      and depression and healthcare utilisation. Outcomes are being measured at 4, 8
      and 12 months. Cost-effectiveness will be expressed in terms of incremental cost 
      per quality-adjusted life year gained. ETHICS AND DISSEMINATION: This trial will 
      provide data on effectiveness and cost-effectiveness of a self-management support
      programme for chronic headaches. The results will inform commissioning of
      services and clinical practice. North West - Greater Manchester East Research
      Ethics Committee have approved the trial. The current protocol version is 3.6
      date 7 March 2019. TRIAL REGISTRATION NUMBER: ISRCTN79708100.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Patel, Shilpa
AU  - Patel S
AUID- ORCID: 0000-0003-0726-4888
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK
      shilpa.patel@warwick.ac.uk.
FAU - Achana, Felix
AU  - Achana F
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Carnes, Dawn
AU  - Carnes D
AUID- ORCID: 0000-0002-3152-3133
AD  - Centre for Primary Care and Public Health, Queen Mary University of London,
      London, UK.
FAU - Eldridge, Sandra
AU  - Eldridge S
AD  - Centre for Primary Care and Public Health, Queen Mary University of London,
      London, UK.
FAU - Ellard, David R
AU  - Ellard DR
AUID- ORCID: 0000-0002-2992-048X
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Griffiths, Frances
AU  - Griffiths F
AUID- ORCID: 0000-0002-4173-1438
AD  - Warwick Medical School, Division of Health Sciences, University of Warwick,
      Coventry, UK.
FAU - Haywood, Kirstie
AU  - Haywood K
AD  - Warwick Medical School, Division of Health Sciences, University of Warwick,
      Coventry, UK.
FAU - Hee, Siew Wan
AU  - Hee SW
AUID- ORCID: 0000-0002-0415-263X
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Mistry, Dipesh
AU  - Mistry D
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Mistry, Hema
AU  - Mistry H
AUID- ORCID: 0000-0002-5023-1160
AD  - Warwick Medical School, Warwick Evidence, University of Warwick, Coventry, UK.
FAU - Nichols, Vivien P
AU  - Nichols VP
AUID- ORCID: 0000-0002-3372-1395
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Petrou, Stavros
AU  - Petrou S
AUID- ORCID: 0000-0003-3121-6050
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Pincus, Tamar
AU  - Pincus T
AD  - Department of Psychology, Royal Holloway University of London, Egham, UK.
FAU - Potter, Rachel
AU  - Potter R
AUID- ORCID: 0000-0001-6655-8996
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Sandhu, Harbinder Kaur
AU  - Sandhu HK
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Stewart, Kimberley
AU  - Stewart K
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Taylor, Stephanie
AU  - Taylor S
AUID- ORCID: 0000-0001-7454-6354
AD  - Centre for Primary Care and Public Health, Queen Mary University of London,
      London, UK.
FAU - Underwood, Martin
AU  - Underwood M
AUID- ORCID: 0000-0002-0309-1708
AD  - Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry,
      UK.
FAU - Matharu, Manjit
AU  - Matharu M
AD  - University College London Queen Square Institute of Neurology and The National
      Hospital for Neurology and Neurosurgery, London, UK.
LA  - eng
SI  - ISRCTN/ISRCTN79708100
GR  - RP-PG-1212-20018/DH_/Department of Health/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200412
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Anxiety
MH  - Chronic Disease
MH  - Cognitive Behavioral Therapy
MH  - Depression
MH  - Follow-Up Studies
MH  - Headache Disorders/*therapy
MH  - Humans
MH  - Patient Acceptance of Health Care
MH  - Patient Education as Topic
MH  - Patient Reported Outcome Measures
MH  - Patient Selection
MH  - Practice Patterns, Nurses'
MH  - *Program Development
MH  - Quality of Life
MH  - *Relaxation Therapy
MH  - Sample Size
MH  - Self Efficacy
MH  - Self-Management/*methods
MH  - Social Participation
PMC - PMC7200026
OTO - NOTNLM
OT  - *chronic headache
OT  - *migraine
OT  - *primary care
OT  - *self-management
OT  - *study protocol
OT  - *tension type headache
COIS- Competing interests: MU is a director and shareholder of Clinvivo Ltd. Use of
      this company was specified in original application for funding to NIHR. MU has
      recused himself from all discussion regarding the use of the app in this study.
      All contracting processes have been in accord with University of Warwick
      financial regulations. MU was chair of the National Institute for Health and Care
      Excellence accreditation advisory committee until March 2017 for which he
      received a fee. He is chief investigator or coinvestigator on multiple previous
      and current research grants from the UK NIHR, Arthritis Research UK and is a
      coinvestigator on grants funded by Arthritis Australia and Australian NHMRC. He
      has received travel expenses for speaking at conferences from the professional
      organisations hosting the conferences. He is part of an academic partnership with
      Serco Ltd related to return to work initiatives. He is an editor of the NIHR
      journal series and a member of the NIHR Journal Editors group for which he
      receives a fee. He has published multiple papers on chronic pain some of which
      are referenced in this paper. MM serves on the advisory board for Allergan,
      Medtronic, Novartis and TEVA and has received payment for the development of
      educational presentations from Allergan, electroCore, Medtronic, Novartis and
      TEVA. ShP and HKS are directors of Health Psychology Services Ltd, which in part 
      provides psychological treatments for those with chronic pain.
EDAT- 2020/04/15 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033520 [pii]
AID - 10.1136/bmjopen-2019-033520 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 12;10(4):e033520. doi: 10.1136/bmjopen-2019-033520.


PMID- 32284311
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 2213-3348 (Electronic)
VI  - 8
IP  - 6
DP  - 2020 Nov
TI  - Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient
      technique for venous malformations.
PG  - 1066-1073
LID - S2213-333X(20)30101-3 [pii]
LID - 10.1016/j.jvsv.2019.11.022 [doi]
AB  - OBJECTIVE: The objective of this study was to retrospectively review the clinical
      and radiographic outcomes of patients with venous malformations (VMs) treated
      with bleomycin-polidocanol foam (BPF) sclerotherapy. METHODS: The Institutional
      Review Board waived ethical approval for this retrospective review in which 55
      patients (31 female and 24 male patients; mean age, 18.8 years; range, 2-60
      years) were treated with BPF sclerotherapy. The stability (half-life) of BPF
      compared with polidocanol foam was studied. Standard sclerotherapy techniques
      were used. A total of 111 sclerotherapy sessions were performed, with a mean of
      2.0 treatments per patient (range, 1-6). An average of 10 mL of BPF was used per 
      procedure, with the total amount ranging from 2.5 to 30 mL. Symptoms before and
      after treatment, follow-up time, complications, and volume reduction on magnetic 
      resonance imaging were recorded. RESULTS: The median half-lives of the BPF and
      polidocanol foam were 238.25 +/- 3.86 seconds and 194.33 +/- 3.5 seconds,
      respectively. A t-test indicated significant differences between the groups (P < 
      .01). The mean follow-up was 14 months (range, 6-24 months). All 55 patients
      (100%) reported improvement in symptoms. The total excellent and good response
      rate was 94.6%. An excellent response was achieved in 32 cases (58.2% [32/55]), a
      good response in 20 cases (36.4% [20/55]), and a poor response in 3 cases (5.4%
      [3/55]). Postprocedural magnetic resonance imaging demonstrated volume reduction 
      of treated lesions in 54 of 55 patients (98%), with a mean lesion volume
      reduction of 84.6%. Postprocedure complications were minor in 13 of 111
      procedures (12%) that were performed on 10 of 55 patients (18.2%), and no major
      complications occurred. CONCLUSIONS: BPF sclerotherapy of VMs is safe and
      effective. BPF sclerotherapy can be a promising first-line treatment of VMs.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Yang, Xi
AU  - Yang X
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Gu, Hao
AU  - Gu H
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Jin, Yunbo
AU  - Jin Y
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Hu, Li
AU  - Hu L
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Hua, Chen
AU  - Hua C
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Wang, Yungying
AU  - Wang Y
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Sun, Yi
AU  - Sun Y
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Yu, Wenxin
AU  - Yu W
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China.
FAU - Lin, Xiaoxi
AU  - Lin X
AD  - Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's
      Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
      Shanghai, China. Electronic address: linxiaoxi@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200410
PL  - United States
TA  - J Vasc Surg Venous Lymphat Disord
JT  - Journal of vascular surgery. Venous and lymphatic disorders
JID - 101607771
RN  - 0 (Sclerosing Solutions)
RN  - 0AWH8BFG9A (Polidocanol)
RN  - 11056-06-7 (Bleomycin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bleomycin/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Polidocanol/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Sclerosing Solutions/adverse effects/*therapeutic use
MH  - *Sclerotherapy/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vascular Malformations/diagnostic imaging/*therapy
MH  - Veins/*abnormalities/diagnostic imaging
MH  - Young Adult
OTO - NOTNLM
OT  - *Bleomycin
OT  - *Foam stability
OT  - *Polidocanol foam
OT  - *Sclerotherapy
OT  - *Venous malformation
EDAT- 2020/04/15 06:00
MHDA- 2021/04/29 06:00
CRDT- 2020/04/15 06:00
PHST- 2019/08/05 00:00 [received]
PHST- 2019/11/03 00:00 [accepted]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - S2213-333X(20)30101-3 [pii]
AID - 10.1016/j.jvsv.2019.11.022 [doi]
PST - ppublish
SO  - J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):1066-1073. doi:
      10.1016/j.jvsv.2019.11.022. Epub 2020 Apr 10.


PMID- 32284004
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20201218
IS  - 1097-6817 (Electronic)
IS  - 0194-5998 (Linking)
VI  - 162
IP  - 6
DP  - 2020 Jun
TI  - Navigating the Ethics of COVID-19 in Otolaryngology.
PG  - 811-812
LID - 10.1177/0194599820920850 [doi]
AB  - The COVID-19 pandemic has dramatically altered how otolaryngologists contemplate 
      and assume their roles in health care delivery. The ethical implications of this 
      pandemic upon our practice are formidable and distinct from other surgical
      fields. The salient ethical issues of public health stewardship and safety,
      distributive justice, and nonabandonment are distilled for the practicing
      otolaryngologist.
FAU - Shuman, Andrew G
AU  - Shuman AG
AD  - Center for Bioethics and Social Sciences in Medicine, University of Michigan
      Medical School, Ann Arbor, Michigan, USA.
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Michigan
      Medical School, Ann Arbor, Michigan, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200414
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of
      Otolaryngology-Head and Neck Surgery
JID - 8508176
SB  - IM
MH  - COVID-19
MH  - Communicable Disease Control/*organization & administration
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Delivery of Health Care/*ethics
MH  - Disease Transmission, Infectious/*ethics/prevention & control
MH  - Female
MH  - Humans
MH  - Male
MH  - Otolaryngologists/*ethics
MH  - Otolaryngology/ethics
MH  - Pandemics/*prevention & control/statistics & numerical data
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Practice Patterns, Physicians'/ethics
MH  - United States
OTO - NOTNLM
OT  - *COVID19
OT  - *pandemic response
OT  - *public health ethics
EDAT- 2020/04/15 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/15 06:00 [entrez]
AID - 10.1177/0194599820920850 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2020 Jun;162(6):811-812. doi:
      10.1177/0194599820920850. Epub 2020 Apr 14.


PMID- 32283812
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 9
TI  - Recalibrating Veterinary Medicine through Animal Welfare Science and Ethics for
      the 2020s.
LID - E654 [pii]
LID - 10.3390/ani10040654 [doi]
AB  - What should leading discourses and innovation regarding animal welfare look like 
      for the veterinary profession in the 2020s? This essay considers four main
      challenges into which veterinarians are increasingly being drawn, as they respond
      to increasing public expectation for them to be scientific and moral authorities 
      in animal welfare in addition to their traditional role as trusted health
      experts. They include: (1) to go beyond traditional conceptions of health by
      adopting a holistic view that also considers animal welfare, not only disease
      treatment; (2) to reimagine their professional duties when it comes to disease
      prevention at the intersection of animal-human-ecosystem health; (3) to develop
      core competencies/proficiency in animal welfare science and ethics in order to
      navigate discourses concerning competing priorities and socio-political
      ideologies and to provide professional leadership in animal welfare; (4) to
      provide feedback on novel networked devices, monitoring technologies and
      automated animal welfare solutions and their impact on animals' welfare. To
      competently navigate the intricacies of the socio-political and connected world
      as trusted authorities and conduits for innovation in and through animal welfare,
      veterinarians and veterinary students are encouraged to: (a) develop core
      competencies in veterinary ethics, animal welfare science and deliberative
      capacities that are well-informed by current multidisciplinary frameworks, such
      as One Health; (b) engage interested parties in more effective collaboration and 
      ethical decision-making in order to address animal welfare related concerns
      within their immediate sphere of influence (e.g., in a given community); and (c) 
      participate in the process of engineering and technological design that
      incorporates animals' welfare data (such as their preferences) for real-time
      animal monitoring through adding animal scientific and values-aware evidence in
      information technology systems. In order to tackle these challenges, four pillars
      are suggested to help guide veterinarians and the veterinary profession. They
      are: Collaboration, Critical Engagement, Centeredness on Research, and Continuous
      Self-Critique.
FAU - De Paula Vieira, Andreia
AU  - De Paula Vieira A
AD  - Faculty of Veterinary Medicine, School of Health Sciences, Universidade Positivo,
      R. Prof. Pedro V. P. De Souza, 5300, Curitiba 81280-330, Brazil.
FAU - Anthony, Raymond
AU  - Anthony R
AD  - Department of Philosophy, University of Alaska Anchorage, 3211 Providence Drive, 
      Anchorage, AK 99508, USA.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7223361
OTO - NOTNLM
OT  - One Health
OT  - animal health
OT  - animal welfare
OT  - veterinary education
OT  - veterinary ethics
OT  - welfare technology and systems
EDAT- 2020/04/15 06:00
MHDA- 2020/04/15 06:01
CRDT- 2020/04/15 06:00
PHST- 2019/12/01 00:00 [received]
PHST- 2020/03/29 00:00 [revised]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2020/04/15 06:01 [medline]
AID - ani10040654 [pii]
AID - 10.3390/ani10040654 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Apr 9;10(4). pii: ani10040654. doi: 10.3390/ani10040654.


PMID- 32283663
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20210316
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 9
TI  - Human Platelet Lysate Can Replace Fetal Calf Serum as a Protein Source to Promote
      Expansion and Osteogenic Differentiation of Human Bone-Marrow-Derived Mesenchymal
      Stromal Cells.
LID - E918 [pii]
LID - 10.3390/cells9040918 [doi]
AB  - Fetal calf serum (FCS) is frequently used as a growth factor and protein source
      in bone-marrow-derived mesenchymal stromal cell (BMSC) culture media, although it
      is a xenogenic product presenting multiple disadvantages including but not
      limited to ethical concerns. A promising alternative for FCS is human platelet
      lysate (hPL), which is produced out of human platelet concentrates and happens to
      be a stable and reliable protein source. In this study, we investigated the
      influence of hPL in an expansion medium (ESM) and an osteogenic differentiation
      medium (ODM) on the proliferation and osteogenic differentiation capacity of
      human BMSC. Therefore, we assessed population doublings during cell expansion,
      performed alizarin red staining to evaluate the calcium content in the
      extracellular matrix and determined the activity of alkaline phosphatase (ALP) as
      osteogenic differentiation correlates. The proliferation rate of BMSC cultured in
      ESM supplemented with hPL exceeded the proliferation rate of BMSC cultured in the
      presence of FCS. Furthermore, the calcium content and ALP activity was
      significantly higher in samples incubated in hPL-supplemented ODM, especially in 
      the early phases of differentiation. Our results show that hPL can replace FCS as
      a protein supplier in cell culture media and does not negatively affect the
      osteogenic differentiation capacity of BMSC.
FAU - Karadjian, Maria
AU  - Karadjian M
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Senger, Anne-Sophie
AU  - Senger AS
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Essers, Christopher
AU  - Essers C
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Wilkesmann, Sebastian
AU  - Wilkesmann S
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Heller, Raban
AU  - Heller R
AUID- ORCID: 0000-0001-8006-9742
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Fellenberg, Joerg
AU  - Fellenberg J
AUID- ORCID: 0000-0002-6187-6474
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Simon, Rolf
AU  - Simon R
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
FAU - Westhauser, Fabian
AU  - Westhauser F
AUID- ORCID: 0000-0001-9948-4209
AD  - Center of Orthopedics, Traumatology, and Spinal Cord Injury, Heidelberg
      University Hospital, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 27432CM55Q (Serum Albumin, Bovine)
SB  - IM
MH  - Animals
MH  - Blood Platelets/*metabolism
MH  - Bone Marrow Cells/*metabolism
MH  - Cattle
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Humans
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Osteogenesis/*genetics
MH  - Serum Albumin, Bovine/*metabolism
PMC - PMC7226817
OTO - NOTNLM
OT  - *fetal calf serum
OT  - *human mesenchymal stromal cells
OT  - *human platelet lysate
OT  - *osteogenic differentiation
OT  - *population doublings
EDAT- 2020/04/15 06:00
MHDA- 2021/03/17 06:00
CRDT- 2020/04/15 06:00
PHST- 2020/02/16 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/15 06:00 [entrez]
PHST- 2020/04/15 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
AID - cells9040918 [pii]
AID - 10.3390/cells9040918 [doi]
PST - epublish
SO  - Cells. 2020 Apr 9;9(4). pii: cells9040918. doi: 10.3390/cells9040918.


PMID- 32283270
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201218
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 230
IP  - 6
DP  - 2020 Jun
TI  - Surgeons, Ethics, and COVID-19: Early Lessons Learned.
PG  - 1119-1120
LID - S1072-7515(20)30301-X [pii]
LID - 10.1016/j.jamcollsurg.2020.03.028 [doi]
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery and MacLean Center for Clinical Medical Ethics, The
      University of Chicago, Chicago, IL. Electronic address:
      pangelos@surgery.bsd.uchicago.edu.
LA  - eng
PT  - Journal Article
DEP - 20200410
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - Humans
MH  - Pandemics/*ethics
MH  - Physician's Role
MH  - Pneumonia, Viral/epidemiology
MH  - Psychological Distress
MH  - SARS-CoV-2
MH  - Surgeons/*ethics/psychology
PMC - PMC7151452
EDAT- 2020/04/14 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/03/29 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - S1072-7515(20)30301-X [pii]
AID - 10.1016/j.jamcollsurg.2020.03.028 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Jun;230(6):1119-1120. doi:
      10.1016/j.jamcollsurg.2020.03.028. Epub 2020 Apr 10.


PMID- 32283077
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1531-5053 (Electronic)
IS  - 0278-2391 (Linking)
VI  - 78
IP  - 10
DP  - 2020 Oct
TI  - Do Speakers Fully Disclose Potential Conflicts of Interest in Oral and
      Maxillofacial Surgery?
PG  - 1669-1673
LID - S0278-2391(20)30236-6 [pii]
LID - 10.1016/j.joms.2020.03.010 [doi]
AB  - PURPOSE: The complete disclosure of conflicts of interest is critical to
      providing objective and ethical continuing education. The purpose of this study
      was to determine the accuracy of the disclosed financial relationships by
      speakers at an annual oral and maxillofacial surgery conference. MATERIALS AND
      METHODS: This retrospective cross-sectional study compared speakers' disclosures 
      on the American Association of Oral and Maxillofacial Surgery Dental Implant
      Conference 2018 website to the payments reported on the Center for Medicare and
      Medicaid Services Open Payments Database. The predictor variable was the number
      of companies reported by the speakers. The outcome variable was the number of
      relevant companies discovered on the Open Payments Database. Other variables
      evaluated included total dollar sum transferred and the type of speaker (oral and
      maxillofacial surgeon (OMS) vs non-OMS). Companies providing payments to speakers
      on the Open Payments Database were deemed relevant if they had provided goods or 
      services relevant to dental implants. Descriptive statistics were computed, and
      the Student t test was performed, with P < .05 considered to indicate statistical
      significance. RESULTS: A total of 43 speakers were included (32 OMSs; 74.4%). We 
      found that 35 of the 43 speakers (81.4%) had received payments relating to dental
      implants on the Open Payments Database that had not been disclosed on the
      conference website. On average, the speakers disclosed 0.65 +/- 1.04 companies;
      however, 2.51 +/- 1.32 relevant companies per speaker were reported on the Open
      Payments Database (P < .0001). The OMS speakersdisclosed 0.47 +/- 0.95 company on
      the conference site but had 2.47 +/- 1.32 companies reporting payments on the
      Open Payments Database (P < .0001). Non-OMS speakers disclosed 1.18 +/- 1.17
      companies, with 2.64 +/- 1.36 companies listed on the Open Payments Database (P =
      .0044). CONCLUSIONS: Continuing education conferences offer an avenue of
      knowledge transfer; however, the objectivity of the information presented could
      be affected by undisclosed conflicts of interest. The results from the present
      study have demonstrated that most speakers at an annual oral and maxillofacial
      surgery conference have underreported payments from companies relevant to the
      conference topic.
CI  - Copyright (c) 2020 American Association of Oral and Maxillofacial Surgeons.
      Published by Elsevier Inc. All rights reserved.
FAU - Durrani, Idrys
AU  - Durrani I
AD  - DMD Candidate, Harvard School of Dental Medicine, Boston, MA.
FAU - Ji, Yisi D
AU  - Ji YD
AD  - MD Candidate, Department of Oral and Maxillofacial Surgery, Massachusetts General
      Hospital, Harvard Medical School, Boston, MA.
FAU - Peacock, Zachary S
AU  - Peacock ZS
AD  - Assistant Professor, Department of Oral and Maxillofacial Surgery, Massachusetts 
      General Hospital, Harvard School of Dental Medicine, Boston, MA. Electronic
      address: zpeacock@partners.org.
LA  - eng
PT  - Journal Article
DEP - 20200318
PL  - United States
TA  - J Oral Maxillofac Surg
JT  - Journal of oral and maxillofacial surgery : official journal of the American
      Association of Oral and Maxillofacial Surgeons
JID - 8206428
SB  - IM
MH  - Aged
MH  - *Conflict of Interest
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Medicare
MH  - Retrospective Studies
MH  - *Surgery, Oral
MH  - United States
EDAT- 2020/04/14 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - S0278-2391(20)30236-6 [pii]
AID - 10.1016/j.joms.2020.03.010 [doi]
PST - ppublish
SO  - J Oral Maxillofac Surg. 2020 Oct;78(10):1669-1673. doi:
      10.1016/j.joms.2020.03.010. Epub 2020 Mar 18.


PMID- 32283043
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1557-7740 (Electronic)
IS  - 1557-7740 (Linking)
VI  - 23
IP  - 9
DP  - 2020 Sep
TI  - The Principles of Revised Clinical Guidelines about Palliative Sedation Therapy
      of the Japanese Society for Palliative Medicine.
PG  - 1184-1190
LID - 10.1089/jpm.2019.0626 [doi]
AB  - Background: When the suffering of a terminally ill patient is intolerable and
      refractory, sedatives are sometimes used for symptom relief. Objective: To
      describe the main principles of revised Japanese clinical guidelines about
      palliative sedation therapy. Design: Consensus methods using the Delphi technique
      were used. Results: The main principles of the guidelines that were newly defined
      or developed are as follows: (1) palliative sedation was defined as
      "administration of sedatives for the purpose of alleviating refractory suffering"
      (excluding the aim of reducing patient consciousness); (2) palliative sedation
      was classified according to the method of administration of sedatives: respite
      sedation versus continuous sedation (including (continuous) proportional sedation
      and continuous deep sedation); (3) a description of state-of-the-art recommended 
      treatments for difficult symptoms such as delirium, dyspnea, and pain before the 
      symptom was determined as refractory was included; (4) the principle of
      proportionality was newly defined from an ethical point of view; and (5)
      families' consent was regarded as being desirable (mandatory in the previous
      version). Conclusions: We described the main principles of revised Japanese
      clinical guidelines about palliative sedation therapy. Further consensus building
      is necessary.
FAU - Imai, Kengo
AU  - Imai K
AD  - Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
FAU - Morita, Tatsuya
AU  - Morita T
AD  - Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital,
      Hamamatsu, Japan.
FAU - Akechi, Tatsuo
AU  - Akechi T
AD  - Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City
      University Graduate School of Medical Sciences, Nagoya, Japan.
FAU - Baba, Mika
AU  - Baba M
AD  - Department of Palliative Medicine, Suita Tokushukai Hospital, Suita, Japan.
FAU - Yamaguchi, Takashi
AU  - Yamaguchi T
AD  - Division of Palliative Care, Konan Medical Center, Kobe, Japan.
FAU - Sumi, Hiroko
AU  - Sumi H
AD  - Nursing Department, Kyoto University Hospital, Kyoto, Japan.
FAU - Tashiro, Shimon
AU  - Tashiro S
AD  - Department of Sociology, Graduate School of Arts and Letters, Tohoku University, 
      Sendai, Japan.
FAU - Aita, Kaoruko
AU  - Aita K
AD  - Uehiro Division, The Center for Death and Life Studies and Practical Ethics,
      Graduate School of Humanities and Sociology, The University of Tokyo, Tokyo,
      Japan.
FAU - Shimizu, Tetsuro
AU  - Shimizu T
AD  - Iwate University of Health and Medical Sciences, Morioka, Japan.
FAU - Hamano, Jun
AU  - Hamano J
AD  - Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba,
      Tsukuba, Japan.
FAU - Sekimoto, Go
AU  - Sekimoto G
AD  - Home Palliative Care, Sekimoto Home Care Clinic, Kobe, Japan.
FAU - Maeda, Isseki
AU  - Maeda I
AD  - Department of Palliative Care, Senri-Chuo Hospital, Toyonaka, Japan.
FAU - Shinjo, Takuya
AU  - Shinjo T
AD  - Palliative Medicine, Shinjo Clinic, Kobe, Japan.
FAU - Nagayama, Jun
AU  - Nagayama J
AD  - Division of Palliative Medicine, Hamanomachi Hospital, Fukuoka, Japan.
FAU - Hayashi, Eriko
AU  - Hayashi E
AD  - Department of Nursing, Fujisawa Shounandai Hospital, Kanagawa, Japan.
FAU - Hisayama, Yukie
AU  - Hisayama Y
AD  - Patient Family Support Center, Shizuoka Cancer Center, Shizuoka, Japan.
FAU - Inaba, Kazuto
AU  - Inaba K
AD  - Law Institute, Chukyo University, Nagoya, Japan.
FAU - Abo, Hirofumi
AU  - Abo H
AD  - Department of Palliative Medicine, Rokko Hospital, Kobe, Japan.
FAU - Suga, Akihiko
AU  - Suga A
AD  - Nakanogo Clinic, Shizuoka, Japan.
FAU - Ikenaga, Masayuki
AU  - Ikenaga M
AD  - Department of Palliative Medicine, Yodogawa Christian Hospital, Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200413
PL  - United States
TA  - J Palliat Med
JT  - Journal of palliative medicine
JID - 9808462
RN  - 0 (Hypnotics and Sedatives)
SB  - IM
MH  - *Deep Sedation
MH  - Humans
MH  - Hypnotics and Sedatives
MH  - Japan
MH  - Palliative Care
MH  - *Palliative Medicine
MH  - *Terminal Care
MH  - Terminally Ill
OTO - NOTNLM
OT  - *continuous deep sedation
OT  - *definition
OT  - *guideline
OT  - *palliative sedation
OT  - *proportional sedation
OT  - *refractory suffering
EDAT- 2020/04/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1089/jpm.2019.0626 [doi]
PST - ppublish
SO  - J Palliat Med. 2020 Sep;23(9):1184-1190. doi: 10.1089/jpm.2019.0626. Epub 2020
      Apr 13.


PMID- 32282992
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20201218
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 9
DP  - 2020 Sep
TI  - Coronavirus disease 2019: Utilizing an ethical framework for rationing absolutely
      scarce health-care resources in transplant allocation decisions.
PG  - 2332-2336
LID - 10.1111/ajt.15914 [doi]
AB  - The novel coronavirus disease 2019 (COVID-19) is impacting transplant programs
      around the world, and, as the center of the pandemic shifts to the United States,
      we have to prepare to make decisions about which patients to transplant during
      times of constrained resources. In this paper, we discuss how to transition from 
      the traditional justice versus utility consideration in organ allocation to a
      more nuanced allocation scheme based on ethical values that drive decisions in
      times of absolute scarcity. We recognize that many decisions are made based on
      the practical limitations that transplant programs face, especially at the
      extremes. As programs make the transition from a standard approach to a
      resource-constrained approach to transplantation, we utilize a framework for
      ethical decisions in settings of absolutely scarce resources to help guide
      programs in deciding which patients to transplant, which donors to accept, how to
      minimize risk, and how to ensure the best utilization of transplant team members.
CI  - (c) 2020 The American Society of Transplantation and the American Society of
      Transplant Surgeons.
FAU - Wall, Anji E
AU  - Wall AE
AUID- ORCID: 0000-0002-7359-1337
AD  - Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical 
      Center, Dallas, Texas.
FAU - Pruett, Timothy
AU  - Pruett T
AUID- ORCID: 0000-0002-0715-8535
AD  - Division of Transplantation, University of Minnesota, Minneapolis, Minnesota.
FAU - Stock, Peter
AU  - Stock P
AUID- ORCID: 0000-0002-5806-0167
AD  - Division of Transplant Surgery, University of California San Francisco, San
      Francisco, California.
FAU - Testa, Giuliano
AU  - Testa G
AD  - Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical 
      Center, Dallas, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200426
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/*organization & administration
MH  - Health Resources/*statistics & numerical data
MH  - Humans
MH  - Organ Transplantation/*statistics & numerical data
MH  - Pandemics
MH  - Patient Selection
MH  - Pneumonia, Viral/*epidemiology
MH  - Resource Allocation/*methods
MH  - SARS-CoV-2
PMC - PMC7262060
OTO - NOTNLM
OT  - *editorial/personal viewpoint
OT  - *ethics
OT  - *ethics and public policy
OT  - *infection and infectious agents - viral
OT  - *infectious disease
OT  - *organ acceptance
OT  - *organ allocation
OT  - *organ procurement and allocation
OT  - *organ transplantation in general
OT  - *patient safety
EDAT- 2020/04/14 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/03/29 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1111/ajt.15914 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Sep;20(9):2332-2336. doi: 10.1111/ajt.15914. Epub 2020 Apr 
      26.


PMID- 32282974
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20201218
IS  - 1471-8847 (Electronic)
IS  - 1471-8731 (Linking)
VI  - 20
IP  - 2
DP  - 2020 Jun
TI  - Latin American healthcare systems in times of pandemic.
PG  - 69-73
LID - 10.1111/dewb.12262 [doi]
AB  - The COVID- 19 pandemic is a critical test for the already overburdened and mostly
      underfunded public healthcare systems of Latin America. In a region that suffers 
      from severe inequalities, public healthcare systems are the only source of
      medical care for a large sector of the population who work in the informal
      economy or are unemployed. State-run hospitals and clinics are already
      overstressed by continuous demand for treatment of vector-borne diseases and
      community-acquired infections as well as high rates of non-communicable diseases.
      Ideological misconceptions and denial among Latin America's political leaders
      prevented timely preparations for the pandemic and added to chronic governance
      problems. As ethical expertise in Latin America focuses on research ethics, few
      hospitals in the region have functioning clinical ethics committees or clinical
      ethics policy, forcing healthcare personnel to make excruciating treatment
      decisions in an environment dominated by material scarcity and public distrust.
      This essay examines the emergence of COVID-19 in Latin America and the serious
      challenge that it poses for Latin America's public healthcare systems.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Litewka, Sergio G
AU  - Litewka SG
AUID- ORCID: 0000-0002-4196-5998
FAU - Heitman, Elizabeth
AU  - Heitman E
AUID- ORCID: 0000-0002-4855-8551
LA  - eng
GR  - R25 TW009722/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Dev World Bioeth
JT  - Developing world bioethics
JID - 101120122
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/transmission
MH  - Health Policy
MH  - *Health Services Needs and Demand
MH  - Humans
MH  - Latin America/epidemiology
MH  - *National Health Programs
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/transmission
MH  - Public Health Administration
MH  - Quarantine
MH  - *Resource Allocation
MH  - SARS-CoV-2
PMC - PMC7262025
OTO - NOTNLM
OT  - *COVID-19
OT  - *Latin American public healthcare systems
OT  - *health care
OT  - *inequalities
OT  - *resource allocation
EDAT- 2020/04/14 06:00
MHDA- 2020/07/07 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/05 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1111/dewb.12262 [doi]
PST - ppublish
SO  - Dev World Bioeth. 2020 Jun;20(2):69-73. doi: 10.1111/dewb.12262. Epub 2020 Apr
      20.


PMID- 32282972
OWN - NLM
STAT- MEDLINE
DCOM- 20200708
LR  - 20201218
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 7
DP  - 2020 Jul
TI  - COVID-19: Thoughts and comments from a tertiary liver transplant center in
      France.
PG  - 1952-1953
LID - 10.1111/ajt.15918 [doi]
FAU - Tzedakis, Stylianos
AU  - Tzedakis S
AUID- ORCID: 0000-0002-5934-0320
AD  - Department of Hepatobiliary and Digestive Surgery, University Hospital
      Pontchaillou, Rennes 1 University, Rennes, France.
FAU - Jeddou, Heithem
AU  - Jeddou H
AD  - Department of Hepatobiliary and Digestive Surgery, University Hospital
      Pontchaillou, Rennes 1 University, Rennes, France.
FAU - Houssel-Debry, Pauline
AU  - Houssel-Debry P
AD  - Department of Gastroenterology and Hepatology, University Hospital Pontchaillou, 
      Rennes 1 University, Rennes, France.
FAU - Sulpice, Laurent
AU  - Sulpice L
AD  - Department of Hepatobiliary and Digestive Surgery, University Hospital
      Pontchaillou, Rennes 1 University, Rennes, France.
FAU - Boudjema, Karim
AU  - Boudjema K
AD  - Department of Hepatobiliary and Digestive Surgery, University Hospital
      Pontchaillou, Rennes 1 University, Rennes, France.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200426
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CON - Am J Transplant. 2020 Jul;20(7):1773-1779. PMID: 32202064
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - France
MH  - Humans
MH  - *Liver Transplantation
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Tissue and Organ Procurement
PMC - PMC7262076
OTO - NOTNLM
OT  - *clinical decision-making
OT  - *clinical research/practice
OT  - *editorial/personal viewpoint
OT  - *ethics
OT  - *guidelines
OT  - *infection and infectious agents - viral
OT  - *liver transplantation/hepatology
OT  - *organ procurement and allocation
OT  - *organ procurement organization
EDAT- 2020/04/14 06:00
MHDA- 2020/07/09 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1111/ajt.15918 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jul;20(7):1952-1953. doi: 10.1111/ajt.15918. Epub 2020 Apr 
      26.


PMID- 32282726
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 15
DP  - 2020 Apr
TI  - Prognostic significance of E-cadherin expression in prostatic carcinoma: A
      protocol for systematic review and meta-analysis.
PG  - e19707
LID - 10.1097/MD.0000000000019707 [doi]
AB  - BACKGROUND: Increasing studies were performed to explore the prognostic value of 
      E-cadherin in prostatic carcinoma, however, with inconsistent results. Hence,
      this systematic review is aimed to evaluate the prognostic role of E-cadherin in 
      patients with prostatic carcinoma (PCa). METHODS: A comprehensive literature
      search in all available databases will be conducted to identify eligible studies.
      We will employ hazard ratios (HRs) and 95% confidence intervals (95% CIs) to
      estimate the correlations between E-cadherin expression and overall survival
      (OS), disease-free survival (DFS), relapse-free survival (RFS), progression-free 
      survival (PFS) and clinicopathological features. Meta-analysis will be performed 
      using Review Manager (Revman) 5.3.5 software (Cochrane Community, London, United 
      Kingdom) and STATA 14 software (version 14.0; Stata Corp, College Station, TX).
      RESULTS: This study will provide a high-quality synthesis of current evidence of 
      the correlations between snail expression and OS, DFS/RFS, PFS and
      clinicopathological features. CONCLUSION: The study will provide updated evidence
      to assess whether the expression of E-cadherin is in association with poor
      prognosis in patients with PCa. ETHICS AND DISSEMINATION: It is not necessary for
      ethical approval because individuals cannot be identified. The protocol will be
      disseminated in a peer-reviewed journal or presented at a relevant conference.
      PROSPERO REGISTRATION NUMBER: This systematic review protocol has been registered
      in the PROSPERO network (No. CRD42019128353).
FAU - Zhang, Xiwen
AU  - Zhang X
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
FAU - Zhang, Zhenhua
AU  - Zhang Z
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Chen, Shuntai
AU  - Chen S
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
AD  - Beijing University of Chinese Medicine, Beijing.
FAU - Jiang, Juling
AU  - Jiang J
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
FAU - Qi, Runzhi
AU  - Qi R
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
FAU - Mi, Xue
AU  - Mi X
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
AD  - Shanxi University of Chinese Medicine, Xianyang, Shanxi Province, China.
FAU - Zhang, Xing
AU  - Zhang X
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
FAU - Xi, Yupeng
AU  - Xi Y
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
FAU - Zheng, Honggang
AU  - Zheng H
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
FAU - Hua, Baojin
AU  - Hua B
AD  - Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDH1 protein, human)
RN  - 0 (Cadherins)
SB  - IM
MH  - Antigens, CD/metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Cadherins/*metabolism
MH  - Carcinoma/*metabolism
MH  - Disease-Free Survival
MH  - Humans
MH  - Incidence
MH  - London/epidemiology
MH  - Male
MH  - Prognosis
MH  - Prostatic Neoplasms/epidemiology/mortality/*pathology
MH  - Sensitivity and Specificity
MH  - United Kingdom/epidemiology
PMC - PMC7220467
EDAT- 2020/04/14 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - 10.1097/MD.0000000000019707 [doi]
AID - 00005792-202004100-00035 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(15):e19707. doi: 10.1097/MD.0000000000019707.


PMID- 32282718
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 15
DP  - 2020 Apr
TI  - Traditional Chinese medicine Danggui Shaoyao San for the treatment of Alzheimer's
      disease: A Protocol for Systematic Review.
PG  - e19669
LID - 10.1097/MD.0000000000019669 [doi]
AB  - BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia.
      Traditional Chinese formula Danggui Shaoyao San (DSS) has been considered a
      potential therapeutic approach for AD. However, no systemic review regarding its 
      efficacy and safety has been conducted. Herein, we propose a protocol for the
      study that aims to evaluate the efficacy and safety of DSS in patients with AD.
      METHODS: Sixteen electronic databases including PubMed, EMBASE, Cochrane
      database, Web of science, Chinese National Knowledge Infrastructure, VIP, Wanfang
      database, China Biomedical Literature Database, Chinese Clinical Trial Registry
      System, Koreanstudies Information Service System, Oriental Medicine Advanced
      Searching Integrated System, Research Information Sharing Service, DBpia, Korean 
      Traditional Knowledge Portal, Japanese CiNii databases and J-STAGE databases will
      be searched from the inception up to February 29, 2020. Randomized controlled
      trials (RCTs) that meet the pre-specified eligibility criteria will be included. 
      RevMan software (V.5.3.5) will be used to perform data synthesis following data
      extraction and publication risk assessment. Subgroup and sensitivity analysis
      will be performed according to the condition of included RCTs. The primary
      outcomes include changes in the Mini-Mental State Examination (MMSE), Alzheimer's
      Disease Assessment Scale-cognitive subscale (ADAS-Cog), and Activities of Daily
      Living scale (ADL). Additional outcomes are clinical effective rate and adverse
      event rate. The Grading of Recommendations Assessment, Development and Evaluation
      system will be used to assess the strength of the evidence. RESULTS: This study
      will provide a well-reported and high-quality synthesis of RCTs on the efficacy
      and safety of DSS for the treatment of AD. CONCLUSION: This systematic review
      protocol will be helpful for providing evidence of whether DSS is an effective
      and safe therapeutic approach for patients with AD. ETHICS AND DISSEMINATION:
      Ethical approval is not necessary as this protocol is only for systematic review 
      and does not involve privacy data or conduct an animal experiment. This protocol 
      will be disseminated by a peer-review journal or conference presentation.
      SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020150450.
FAU - You, Yu
AU  - You Y
AD  - Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai Dadao Avenue,
      Wen Jiang District.
FAU - Liu, Xinglong
AU  - Liu X
AD  - Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai Dadao Avenue,
      Wen Jiang District.
FAU - You, Yanyan
AU  - You Y
AD  - West China Hospital, Sichuan University, Wu Hou District, Chengdu, Sichuan,
      China.
FAU - Liu, Dan
AU  - Liu D
AD  - West China Hospital, Sichuan University, Wu Hou District, Chengdu, Sichuan,
      China.
FAU - Zhang, Chunjiang
AU  - Zhang C
AD  - Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai Dadao Avenue,
      Wen Jiang District.
FAU - Chen, Yunhui
AU  - Chen Y
AD  - Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai Dadao Avenue,
      Wen Jiang District.
FAU - Zhang, Tiane
AU  - Zhang T
AD  - Chengdu University of Traditional Chinese Medicine, No. 1166 Liutai Dadao Avenue,
      Wen Jiang District.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (danggui-shaoyao-san)
SB  - IM
MH  - Activities of Daily Living
MH  - Alzheimer Disease/complications/diagnosis/*drug therapy
MH  - Dementia/epidemiology/etiology
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Medicine, Chinese Traditional/*methods
MH  - Mental Status and Dementia Tests/statistics & numerical data
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
PMC - PMC7220468
EDAT- 2020/04/14 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - 10.1097/MD.0000000000019669 [doi]
AID - 00005792-202004100-00027 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(15):e19669. doi: 10.1097/MD.0000000000019669.


PMID- 32282699
OWN - NLM
STAT- MEDLINE
DCOM- 20200417
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 15
DP  - 2020 Apr
TI  - Association of finasteride with prostate cancer: A systematic review and
      meta-analysis.
PG  - e19486
LID - 10.1097/MD.0000000000019486 [doi]
AB  - BACKGROUND: The Prostate Cancer Prevention Trial has shown a protective effect of
      finasteride on prostate cancer, but it also showed that finasteride can increase 
      the risk of high-grade prostate cancer. Several studies have investigated the
      relationship between finasteride and prostate cancer, but these studies have
      shown inconsistent results. ETHICS: The protocol was approved by the
      institutional review board of each study center. Written informed consent will be
      obtained from all patients before registration, in accordance with the
      Declaration of Helsinki. METHODS: We performed a systematic literature review and
      meta-analysis to assess the association between finasteride and prostate cancer. 
      Systematic literature searches were conducted using PubMed, EMBASE, Science
      Direct/Elsevier, MEDLINE, CNKI, and the Cochrane Library up to October 2018 to
      identify studies that involved the relationship between finasteride and prostate 
      cancer. Meta-analysis was performed using Review Manager and Stata software.
      Combined ORs were identified with 95% confidence intervals (95% CI) in a random
      or fixed effects model. RESULTS: Eight studies were identified, including 54,335 
      cases of patients that used finasteride and 9197 patients who served as placebo
      controls. Our results illustrate that there is a significant correlation between 
      finasteride use and prostate cancer with combined ORs of 0.70 [0.51, 0.96]. A
      significant correlation between finasteride use and high-grade prostate cancer
      was also observed with combined ORs of 2.10 [1.85, 2.38]. CONCLUSIONS: This study
      confirms that finasteride significantly reduced the risk of prostate cancer;
      however, the malignant degree of prostate cancer was increased. Studies with
      larger sample sizes are needed to better clarify the correlation between
      finasteride use and prostate cancer.
FAU - Wang, Lei
AU  - Wang L
AD  - Department of Urology, Tangdu Hospital, The Air Force Medical University, Xi'an, 
      Shaanxi, China.
FAU - Lei, Yonghua
AU  - Lei Y
FAU - Gao, Yanyao
AU  - Gao Y
FAU - Cui, Dong
AU  - Cui D
FAU - Tang, Qisheng
AU  - Tang Q
FAU - Li, Ruixiao
AU  - Li R
FAU - Wang, Dong
AU  - Wang D
FAU - Chen, Yu
AU  - Chen Y
FAU - Zhang, Bo
AU  - Zhang B
FAU - Wang, He
AU  - Wang H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (5-alpha Reductase Inhibitors)
RN  - 57GNO57U7G (Finasteride)
SB  - IM
MH  - 5-alpha Reductase Inhibitors/*adverse effects
MH  - Finasteride/*adverse effects
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*chemically induced
PMC - PMC7220188
EDAT- 2020/04/14 06:00
MHDA- 2020/04/18 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/04/18 06:00 [medline]
AID - 10.1097/MD.0000000000019486 [doi]
AID - 00005792-202004100-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(15):e19486. doi: 10.1097/MD.0000000000019486.


PMID- 32282559
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1539-0705 (Electronic)
IS  - 1522-2179 (Linking)
VI  - 22
IP  - 3
DP  - 2020 Jun
TI  - Pediatric Concurrent Hospice Care: A Scoping Review and Directions for Future
      Nursing Research.
PG  - 238-245
LID - 10.1097/NJH.0000000000000648 [doi]
AB  - In 2010, forgoing curative therapies were removed as a hospice eligibility
      criterion for children through section 2302 of the Patient Protection and
      Affordable Care Act called Concurrent Care for Children. Given that concurrent
      care is a federally mandated option for children and their families, no review of
      the science has been conducted. The purpose of this study was to systematically
      collect the evidence on concurrent hospice care, critically appraise the
      evidence, and identify areas for future nursing research. Of the 186 articles
      identified for review, 14 met the inclusion and exclusion criteria. Studies in
      this review described concurrent hospice care from a variety of perspectives:
      policy, legal, and ethics. However, only 1 article evaluated the impact of
      concurrent hospice care on outcomes, whereas several studies explained clinical
      and state-level implementation. There is a need for further studies that move
      beyond conceptualization and generate baseline and outcomes data. Understanding
      the effectiveness of concurrent hospice care might provide important information 
      for future nursing research. The approaches used to disseminate and implement
      concurrent hospice care at state, provider, and family levels should be explored.
FAU - Lindley, Lisa C
AU  - Lindley LC
FAU - Keim-Malpass, Jessica
AU  - Keim-Malpass J
FAU - Svynarenko, Radion
AU  - Svynarenko R
FAU - Cozad, Melanie J
AU  - Cozad MJ
FAU - Mack, Jennifer W
AU  - Mack JW
FAU - Hinds, Pamela S
AU  - Hinds PS
LA  - eng
GR  - R01 NR017848/NR/NINR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - J Hosp Palliat Nurs
JT  - Journal of hospice and palliative nursing : JHPN : the official journal of the
      Hospice and Palliative Nurses Association
JID - 100887419
SB  - IM
MH  - Forecasting/methods
MH  - Hospice Care/*methods/trends
MH  - Humans
MH  - Nursing Research/*trends
MH  - Pediatrics/*methods/trends
MH  - United States
PMC - PMC7716801
MID - NIHMS1650383
EDAT- 2020/04/14 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1097/NJH.0000000000000648 [doi]
AID - 00129191-202006000-00011 [pii]
PST - ppublish
SO  - J Hosp Palliat Nurs. 2020 Jun;22(3):238-245. doi: 10.1097/NJH.0000000000000648.


PMID- 32282442
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201218
IS  - 1940-5480 (Electronic)
IS  - 1067-151X (Linking)
VI  - 28
IP  - 11
DP  - 2020 Jun 1
TI  - A Bioethical Perspective for Navigating Moral Dilemmas Amidst the COVID-19
      Pandemic.
PG  - 471-476
LID - 10.5435/JAAOS-D-20-00371 [doi]
AB  - The Coronavirus disease 2019 pandemic has been an unprecedented challenge to
      healthcare systems and clinicians around the globe. As the virus has spread,
      critical questions arose about how to best deliver health care in emergency
      situations where material and personnel resources become scarce. Clinicians who
      excel at caring for the individual patient at the bedside are now being
      reoriented into a system where they are being asked to see the collective public 
      as their responsibility. As such, the clinical ethics that clinicians are
      accustomed to practicing are being modified by a framework of public health
      ethics defined by the presence of a global pandemic. There are many unknowns
      about Coronavirus disease 2019, which makes it difficult to provide consistent
      recommendations and guidelines that uniformly apply to all situations. This lack 
      of consensus leads to the clinicians' confusion and distress. Real-life dilemmas 
      about how to allocate resources and provide care in hotspot cities make explicit 
      the need for careful ethical analysis, but the need runs far deeper than that;
      even when not trading some lives against others, the responsibilities of both
      individual clinicians and the broader healthcare system are changing in the face 
      of this crisis.
FAU - Dunham, Alexandra M
AU  - Dunham AM
AD  - From the Department of Orthopaedic Surgery, The Johns Hopkins University School
      of Medicine (Dr. Dunham and Dr. Humbyrd), and The Johns Hopkins University,
      Berman Institute of Bioethics (Dr. Rieder and Dr. Humbyrd), Baltimore MD.
FAU - Rieder, Travis N
AU  - Rieder TN
FAU - Humbyrd, Casey J
AU  - Humbyrd CJ
LA  - eng
GR  - T32 AR067708/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Acad Orthop Surg
JT  - The Journal of the American Academy of Orthopaedic Surgeons
JID - 9417468
SB  - IM
MH  - *Betacoronavirus
MH  - Bioethical Issues
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Delivery of Health Care/*ethics
MH  - Female
MH  - Humans
MH  - Male
MH  - Orthopedic Procedures/*ethics
MH  - Outcome Assessment, Health Care
MH  - Pandemics/*ethics/prevention & control
MH  - *Pneumonia, Viral
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7197334
MID - NIHMS1583613
EDAT- 2020/04/14 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.5435/JAAOS-D-20-00371 [doi]
PST - ppublish
SO  - J Am Acad Orthop Surg. 2020 Jun 1;28(11):471-476. doi: 10.5435/JAAOS-D-20-00371.


PMID- 32281909
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 1089-4098 (Electronic)
IS  - 1073-8584 (Linking)
VI  - 26
IP  - 5-6
DP  - 2020 Oct-Dec
TI  - If Human Brain Organoids Are the Answer to Understanding Dementia, What Are the
      Questions?
PG  - 438-454
LID - 10.1177/1073858420912404 [doi]
AB  - Because our beliefs regarding our individuality, autonomy, and personhood are
      intimately bound up with our brains, there is a public fascination with cerebral 
      organoids, the "mini-brain," the "brain in a dish". At the same time, the ethical
      issues around organoids are only now being explored. What are the prospects of
      using human cerebral organoids to better understand, treat, or prevent dementia? 
      Will human organoids represent an improvement on the current,
      less-than-satisfactory, animal models? When considering these questions, two
      major issues arise. One is the general challenge associated with using any stem
      cell-generated preparation for in vitro modelling (challenges amplified when
      using organoids compared with simpler cell culture systems). The other relates to
      complexities associated with defining and understanding what we mean by the term 
      "dementia." We discuss 10 puzzles, issues, and stumbling blocks to watch for in
      the quest to model "dementia in a dish."
FAU - Ooi, Lezanne
AU  - Ooi L
AUID- ORCID: 0000-0001-9241-8268
AD  - Illawarra Health and Medical Research Institute, Wollongong, New South Wales,
      Australia.
AD  - School of Chemistry and Molecular Bioscience, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Dottori, Mirella
AU  - Dottori M
AD  - Illawarra Health and Medical Research Institute, Wollongong, New South Wales,
      Australia.
AD  - School of Medicine, University of Wollongong, Wollongong, New South Wales,
      Australia.
AD  - Department of Anatomy & Neuroscience, University of Melbourne, Parkville,
      Victoria, Australia.
AD  - Department of Biomedical Engineering, University of Melbourne, Parkville,
      Victoria, Australia.
FAU - Cook, Anthony L
AU  - Cook AL
AUID- ORCID: 0000-0003-1770-7910
AD  - Wicking Dementia Research and Education Centre, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Engel, Martin
AU  - Engel M
AUID- ORCID: 0000-0001-7602-1340
AD  - Illawarra Health and Medical Research Institute, Wollongong, New South Wales,
      Australia.
AD  - School of Chemistry and Molecular Bioscience, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Gautam, Vini
AU  - Gautam V
AD  - John Curtin School of Medical Research, Australian National University, Canberra,
      ACT, Australia.
FAU - Grubman, Alexandra
AU  - Grubman A
AD  - Department of Anatomy and Developmental Biology, Monash University, Clayton,
      Victoria, Australia.
AD  - Development and Stem Cells Program, Monash Biomedicine Discovery Institute,
      Clayton, Victoria, Australia.
AD  - Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria,
      Australia.
FAU - Hernandez, Damian
AU  - Hernandez D
AD  - Department of Anatomy & Neuroscience, University of Melbourne, Parkville,
      Victoria, Australia.
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
      University of Melbourne, East Melbourne, Victoria, Australia.
AD  - Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
FAU - King, Anna E
AU  - King AE
AUID- ORCID: 0000-0003-1792-0965
AD  - Wicking Dementia Research and Education Centre, College of Health and Medicine,
      University of Tasmania, Hobart, Tasmania, Australia.
FAU - Maksour, Simon
AU  - Maksour S
AD  - Illawarra Health and Medical Research Institute, Wollongong, New South Wales,
      Australia.
AD  - School of Medicine, University of Wollongong, Wollongong, New South Wales,
      Australia.
FAU - Targa Dias Anastacio, Helena
AU  - Targa Dias Anastacio H
AD  - Illawarra Health and Medical Research Institute, Wollongong, New South Wales,
      Australia.
AD  - School of Chemistry and Molecular Bioscience, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Balez, Rachelle
AU  - Balez R
AD  - Illawarra Health and Medical Research Institute, Wollongong, New South Wales,
      Australia.
AD  - School of Chemistry and Molecular Bioscience, University of Wollongong,
      Wollongong, New South Wales, Australia.
FAU - Pebay, Alice
AU  - Pebay A
AD  - Department of Anatomy & Neuroscience, University of Melbourne, Parkville,
      Victoria, Australia.
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
      University of Melbourne, East Melbourne, Victoria, Australia.
AD  - Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
FAU - Pouton, Colin
AU  - Pouton C
AD  - Monash Institute of Pharmaceutical Sciences, Monash University, Parkville,
      Victoria, Australia.
FAU - Valenzuela, Michael
AU  - Valenzuela M
AD  - Regenerative Neuroscience Group, Brain and Mind Centre and Sydney Medical School,
      University of Sydney, Sydney, New South Wales, Australia.
FAU - White, Anthony
AU  - White A
AD  - Queensland Institute of Medical Research Berghofer, Brisbane, Queensland,
      Australia.
FAU - Williamson, Robert
AU  - Williamson R
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
AD  - Department of Paediatrics, University of Melbourne, Parkville, Victoria,
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200413
PL  - United States
TA  - Neuroscientist
JT  - The Neuroscientist : a review journal bringing neurobiology, neurology and
      psychiatry
JID - 9504819
SB  - IM
MH  - Alzheimer Disease/*pathology
MH  - Animals
MH  - Brain/*pathology
MH  - Cell Differentiation/physiology
MH  - Dementia/*pathology/physiopathology
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology
MH  - Organoids/*cytology
PMC - PMC7539594
OTO - NOTNLM
OT  - *Alzheimer's disease
OT  - *cerebral
OT  - *cortical
OT  - *dementia
OT  - *disease model
OT  - *induced pluripotent stem cells
OT  - *neurodegeneration
OT  - *organoids
EDAT- 2020/04/14 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1177/1073858420912404 [doi]
PST - ppublish
SO  - Neuroscientist. 2020 Oct-Dec;26(5-6):438-454. doi: 10.1177/1073858420912404. Epub
      2020 Apr 13.


PMID- 32281647
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210205
IS  - 1687-1634 (Electronic)
IS  - 1020-3397 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Mar 24
TI  - Annual meeting of the Eastern Mediterranean Research Ethics Review Committee.
PG  - 365-366
LID - 10.26719/2020.26.3.365 [doi]
LA  - eng
PT  - News
DEP - 20200324
PL  - Egypt
TA  - East Mediterr Health J
JT  - Eastern Mediterranean health journal = La revue de sante de la Mediterranee
      orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
JID - 9608387
SB  - IM
MH  - Advisory Committees/*organization & administration
MH  - Artificial Intelligence
MH  - Cooperative Behavior
MH  - Disaster Planning/organization & administration
MH  - *Ethics, Research
MH  - Humans
MH  - World Health Organization/*organization & administration
EDAT- 2020/04/14 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
AID - 10.26719/2020.26.3.365 [doi]
PST - epublish
SO  - East Mediterr Health J. 2020 Mar 24;26(3):365-366. doi: 10.26719/2020.26.3.365.


PMID- 32281485
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20220415
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Aug
TI  - Spirituality in nursing: A concept analysis.
PG  - 1327-1343
LID - 10.1177/0969733020909534 [doi]
AB  - BACKGROUND: Spirituality has always been present in the history of nursing and
      continues to be a topic of nursing interest. Spirituality has ancient roots. The 
      term 'spirituality' is interpreted as spirit and is translated as breath and
      soul, whereas spirituality (immateriality) is spiritual nature. Historically, the
      term spirituality is associated with the term religiosity, a definition that
      persists today, and often the two terms are used interchangeably. In the
      healthcare context, the construct is still. OBJECTIVE: To clarify the concept of 
      spirituality in nursing. RESEARCH DESIGN: In this article spirituality was
      explored using Rodgers' evolutionary and inductive method of concept analysis.
      PARTICIPANTS AND RESEARCH CONTEXT: For this analysis, a sample of 71 articles
      published in English, from 2008 to 2018 from PubMed/Medline, CINAHL Plus with
      full text, PsycINFO, SciELO databases were retrieved. It was also accomplished an
      empirical search of dictionaries and e-books. ETHICAL CONSIDERATIONS: This study 
      was conducted according to good scientific practice. FINDINGS: It emerged that
      "spirituality" is a dynamic process and has a range of attributes. The cultural
      dimensions, the religious and spiritual traditions, the ethnic diversity and the 
      influence of the historical and social contexts represent the societal and
      historical conditions ingrained in the Western thought that influence the
      emergence of spirituality as a concept. Antecedents, attributes and onsequences
      appeared to inform and strengthen one another over time. Spirituality is a
      significant concept for the discipline of nursing with profound consequences for 
      caring patients and for work organizations.
FAU - Murgia, Carla
AU  - Murgia C
AUID- ORCID: https://orcid.org/0000-0003-2390-6385
AD  - University of Rome 'Tor Vergata', Italy.
AD  - Centre of Excellence for Nursing Scholarship OPI Rome Italy, Italy.
FAU - Notarnicola, Ippolito
AU  - Notarnicola I
AUID- ORCID: https://orcid.org/0000-0002-4828-8811
AD  - Centre of Excellence for Nursing Scholarship OPI Rome Italy, Italy.
FAU - Rocco, Gennaro
AU  - Rocco G
AD  - Centre of Excellence for Nursing Scholarship OPI Rome Italy, Italy.
FAU - Stievano, Alessandro
AU  - Stievano A
AD  - Centre of Excellence for Nursing Scholarship OPI Rome Italy, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200413
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - *Concept Formation
MH  - Humans
MH  - *Spirituality
OTO - NOTNLM
OT  - Concept analysis
OT  - ethics
OT  - nurse
OT  - nursing
OT  - sociology of religions
OT  - spirituality
EDAT- 2020/04/14 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1177/0969733020909534 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Aug;27(5):1327-1343. doi: 10.1177/0969733020909534. Epub 2020
      Apr 13.


PMID- 32281412
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20200707
IS  - 0261-1929 (Print)
IS  - 0261-1929 (Linking)
VI  - 48
IP  - 1
DP  - 2020 Jan
TI  - Factors Related to Animal Neglect in Brazilian Laboratories.
PG  - 29-39
LID - 10.1177/0261192920911341 [doi]
AB  - Our objectives were to identify the prevalence of negligence of laboratory
      animals in Brazil, to determine the primary factors associated with its
      occurrence and to suggest prevention strategies. A questionnaire was made
      available online between October 2015 and March 2016. A total of 116 respondents 
      with experience in the use of laboratory animals and/or the use of alternative
      methods answered the questionnaire. Most respondents were women (77 respondents, 
      66.4%), a significant proportion had a degree in Veterinary Medicine (31
      respondents, 27.2%), and a majority used animals in their work (88 respondents,
      75.9%). Of the 88 animal users, 23 supplied information on the numbers and
      species of animals they used. When asked whether they knew that Brazilian law
      forbade animal experimentation when alternative methods exist, seven (9.1%)
      respondents mentioned Act 9605/1998. Most, but not all, respondents (96
      respondents, 82.8%) submitted their projects to an Animal Use and Ethics
      Committee (AUEC), and many (65 respondents, 56%) reported their belief that
      animal neglect occurred at their institution. Negligence was found to be
      associated with: institutions where the numbers of animals used were not recorded
      (p = 0.008); institutions where respondents were unaware of the relevant
      legislation, that is, Act 9605/1998 (p = 0.042); or where there was evidence that
      not all project proposals were submitted to the AUEC or evidence of no
      submissions at all (p = 0.022). Negligence of animals was found to be highly
      prevalent. Prevention strategies might involve increased transparency to the
      general public, the empowerment of individuals that work with animals to report
      any concerns, optimised inspection of facilities where animal work is carried out
      and significant improvements to the role of AUECs.
FAU - Bones, Vanessa Carli
AU  - Bones VC
AD  - Regional Council of Veterinary Medicine of the State of Parana (CRMV-PR) and
      Animal Welfare Laboratory (LABEA), Agrarian Science Sector, Federal University of
      Parana (UFPR), Curitiba, Brazil.
FAU - Molento, Carla Forte Maiolino
AU  - Molento CFM
AUID- ORCID: https://orcid.org/0000-0003-1408-7891
AD  - Animal Welfare Laboratory (LABEA), Federal University of Parana (UFPR), Curitiba,
      Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - England
TA  - Altern Lab Anim
JT  - Alternatives to laboratory animals : ATLA
JID - 8110074
SB  - IM
MH  - Animal Experimentation/statistics & numerical data
MH  - *Animal Welfare/statistics & numerical data
MH  - Animals
MH  - Animals, Laboratory
MH  - Brazil
MH  - Female
MH  - Humans
MH  - *Laboratories/statistics & numerical data
MH  - Male
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Three Rs
OT  - animal welfare
OT  - crimes against animals
OT  - diagnosis of neglect
EDAT- 2020/04/14 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1177/0261192920911341 [doi]
PST - ppublish
SO  - Altern Lab Anim. 2020 Jan;48(1):29-39. doi: 10.1177/0261192920911341. Epub 2020
      Apr 11.


PMID- 32281330
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20201210
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 45
IP  - 6
DP  - 2020 Mar
TI  - [Analysis on clinical study protocols of traditional Chinese medicine for
      coronavirus disease 2019].
PG  - 1232-1241
LID - 10.19540/j.cnki.cjcmm.20200220.501 [doi]
AB  - To analyze the registered clinical trial protocols of traditional Chinese
      medicine(TCM) for the prevention and treatment of coronavirus disease
      2019(COVID-19), in order to provide information for improving the quality of
      research design. The website of the Chinese Clinical Trial
      Registry(www.chictr.org.cn) and the American Clinical Trial
      Registry(clinicaltrials.gov) were searched to collect protocols of TCM for
      COVID-19. Documents were screened following the inclusion criteria, and data were
      extracted in regard to registration date, study objective, type of design,
      sponsor, patient, sample size, intervention, and evaluation index. Descriptive
      analysis was conducted. A total of 49 clinical trial protocols of TCM for
      COVID-19 were included. Primary sponsors were mainly hospitals or universities in
      places like Hubei, Beijing, Zhejiang and other regions. The implementation units 
      are mainly in Hubei, Guangdong, Zhejiang, Henan and other regional hospitals. The
      types of study design were mainly experimental studies(40), including 30
      randomized parallel controlled trials, 7 non-randomized controlled trials, 2
      single arm trials and 1 consecutively recruited trial; besides, there were also 6
      observational studies, 2 health service studies and 1 preventive study. The
      sample size reached a total of 30 562 cases, with a maximum of 20 000 for a
      single study and a minimum of 30. The 49 trials subjects included healthy
      people(3), isolation and observation cases(1), suspected cases(10),confirmed
      COVID-19 patients(31) and COVID-19 recovery patients(4). Of the 31 trials planned
      to include confirmed COVID-19 patients, 16 protocols no definite disease
      classification, 3 with a clear exclusion of severe subjects, 4 with common
      subjects, 2 with light, common or severe subjects, 1 with light and common
      subjects, 1 with common or severe subjects, 3 with severe subjects, and 1 with
      severe or critical subjects. The experimental interventions included Chinese
      patent medicine(Lianhua Qingwen Capsules/Granules, Huoxiang Zhengqi Dropping
      Pills/Oral Liquid, Babao Dan, Gubiao Jiedu Ling, Jinhao Jiere Granules, Compound 
      Yu-xingcao Mixture, Jinye Baidu Granules, Shufeng Jiedu Capsuless,
      Shuanghuanglian Oral Liquid, Tanreqing Injection, Xuebijing Injection, Reduning
      Injection, Xiyanping Injection), Chinese medicinal decoction and taichi. The
      primary evaluation outcomes mainly included antipyretic time, clinical symptom
      relief, novel coronavirus nucleic acid turning to negative, conversion rate of
      severe cases and chest CT. There was a quick response of clinical research on the
      prevention and treatment of COVID-19 with TCM, with the current registered
      protocols covers the whole process of disease prevention, treatment and
      rehabilitation. However, issues need to be concerned, including unclear
      definition of patient's condition, unclear research objectives, unclear
      intervention process and inappropriate outcomes, etc. In addition, researchers
      should consider the actual difficulties and workload of doctors in epidemic
      response environment, and make effort to optimize the process and improve the
      operability of research protocols under the principle of medical ethics.
FAU - Wang, Hui
AU  - Wang H
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Jin, Xin-Yao
AU  - Jin XY
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Pang, Bo
AU  - Pang B
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Liu, Chun-Xiang
AU  - Liu CX
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Zheng, Wen-Ke
AU  - Zheng WK
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Yang, Feng-Wen
AU  - Yang FW
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Pang, Wen-Tai
AU  - Pang WT
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
FAU - Zhang, Jun-Hua
AU  - Zhang JH
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese
      Medicine Tianjin 301617, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese
      materia medica
JID - 8913656
RN  - 0 (Drugs, Chinese Herbal)
RN  - COVID-19 drug treatment
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - China
MH  - *Clinical Trial Protocols as Topic
MH  - Coronavirus Infections/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
OTO - NOTNLM
OT  - 2019-nCoV
OT  - COVID-19
OT  - clinical trials
OT  - protocol registration
OT  - traditional Chinese medicine
EDAT- 2020/04/14 06:00
MHDA- 2020/04/15 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20200220.501 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1232-1241. doi:
      10.19540/j.cnki.cjcmm.20200220.501.


PMID- 32281214
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20220720
IS  - 1540-8167 (Electronic)
IS  - 1045-3873 (Linking)
VI  - 31
IP  - 6
DP  - 2020 Jun
TI  - Performance of electrophysiology procedures at an academic medical center amidst 
      the 2020 coronavirus (COVID-19) pandemic.
PG  - 1249-1254
LID - 10.1111/jce.14493 [doi]
AB  - A global coronavirus (COVID-19) pandemic occurred at the start of 2020 and is
      already responsible for more than 74 000 deaths worldwide, just over 100 years
      after the influenza pandemic of 1918. At the center of the crisis is the highly
      infectious and deadly SARS-CoV-2, which has altered everything from individual
      daily lives to the global economy and our collective consciousness. Aside from
      the pulmonary manifestations of disease, there are likely to be several
      electrophysiologic (EP) sequelae of COVID-19 infection and its treatment, due to 
      consequences of myocarditis and the use of QT-prolonging drugs. Most crucially,
      the surge in COVID-19 positive patients that have already overwhelmed the New
      York City hospital system requires conservation of hospital resources including
      personal protective equipment (PPE), reassignment of personnel, and
      reorganization of institutions, including the EP laboratory. In this proposal, we
      detail the specific protocol changes that our EP department has adopted during
      the COVID-19 pandemic, including performance of only urgent/emergent procedures, 
      after hours/7-day per week laboratory operation, single attending-only cases to
      preserve PPE, appropriate use of PPE, telemedicine and video chat follow-up
      appointments, and daily conferences to collectively manage the clinical and
      ethical dilemmas to come. We discuss also discuss how we perform EP procedures on
      presumed COVID positive and COVID tested positive patients to highlight issues
      that others in the EP community may soon face in their own institution as the
      virus continues to spread nationally and internationally.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Rubin, Geoffrey A
AU  - Rubin GA
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Biviano, Angelo
AU  - Biviano A
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Dizon, Jose
AU  - Dizon J
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Yarmohammadi, Hirad
AU  - Yarmohammadi H
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Ehlert, Frederick
AU  - Ehlert F
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Saluja, Deepak
AU  - Saluja D
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Rubin, David A
AU  - Rubin DA
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Morrow, John P
AU  - Morrow JP
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Waase, Marc
AU  - Waase M
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Berman, Jeremy
AU  - Berman J
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Kushnir, Alexander
AU  - Kushnir A
AUID- ORCID: 0000-0003-1644-643X
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Abrams, Mark P
AU  - Abrams MP
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Garan, Hasan
AU  - Garan H
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
FAU - Wan, Elaine Y
AU  - Wan EY
AUID- ORCID: 0000-0002-5328-7282
AD  - Division of Cardiology, Department of Medicine, Vagelos College of Physicians and
      Surgeons, Columbia University, New York, New York.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200420
PL  - United States
TA  - J Cardiovasc Electrophysiol
JT  - Journal of cardiovascular electrophysiology
JID - 9010756
SB  - IM
CIN - J Cardiovasc Electrophysiol. 2020 Oct;31(10):2791-2792. PMID: 32876365
MH  - Academic Medical Centers/*supply & distribution
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*diagnosis
MH  - Electrophysiology/*methods
MH  - Humans
MH  - Pandemics
MH  - Personal Protective Equipment/*standards
MH  - Pneumonia, Viral/*diagnosis
MH  - SARS-CoV-2
PMC - PMC7262273
OTO - NOTNLM
OT  - *COVID-19
OT  - *coronavirus
OT  - *electrophysiology laboratory
OT  - *pandemic
EDAT- 2020/04/14 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/06 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1111/jce.14493 [doi]
PST - ppublish
SO  - J Cardiovasc Electrophysiol. 2020 Jun;31(6):1249-1254. doi: 10.1111/jce.14493.
      Epub 2020 Apr 20.


PMID- 32281144
OWN - NLM
STAT- Publisher
LR  - 20200603
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
DP  - 2020 Apr 12
TI  - Is it ethical to be a 'whistleblower' during COVID-19 pandemic? Ethical
      challenges confronted by health care workers in China.
LID - 10.1111/jan.14376 [doi]
FAU - Zhu, Junhong
AU  - Zhu J
AUID- ORCID: https://orcid.org/0000-0002-8217-4930
AD  - Nursing Studies, Zhejiang University School of Medicine, Hangzhou, Zhejiang,
      China.
LA  - eng
PT  - Editorial
DEP - 20200412
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
PMC - PMC7262094
EDAT- 2020/04/14 06:00
MHDA- 2020/04/14 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1111/jan.14376 [doi]
PST - aheadofprint
SO  - J Adv Nurs. 2020 Apr 12. doi: 10.1111/jan.14376.


PMID- 32280925
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2542-4548 (Electronic)
IS  - 2542-4548 (Linking)
VI  - 4
IP  - 2
DP  - 2020 Apr
TI  - Provider Knowledge and Support of Uterus Transplantation: Surveying
      Multidisciplinary Team Members.
PG  - 150-158
LID - 10.1016/j.mayocpiqo.2019.11.001 [doi]
AB  - OBJECTIVE: To determine relevant provider opinions on uterus transplantation
      (UTx). PATIENTS AND METHODS: We invited 1933 providers in obstetrics and
      gynecology, transplant surgery, transplant medicine, internal medicine, and
      family medicine at a large, integrated health care system to complete an online
      survey containing a series of questions on their attitudes about the ethics and
      clinical utility of UTx. The survey was open from June 4, 2018, through July 2,
      2018. We received 449 responses overall (23.2% response rate). RESULTS: Of 433
      physicians who responded, 195 (45.0%) believe that UTx is ethically justified,
      and just over a third (160 of 446 [35.9%]) would introduce the possibility of UTx
      to a patient with absolute uterine factor infertility (AUFI). Respondents
      indicated the risks to donor, recipient, and child carried the most weight in
      their ethical evaluation and were most supportive of UTx in a patient with
      congenital uterine absence (334 of 743 [45.0%]; participants were allowed to
      choose more than one answer). A majority stated that a living or cadaveric donor 
      would be an acceptable donor source (238 of 395 [60.3%]). CONCLUSION: Provider
      support for UTx is qualified by safety concerns and its expansion to patient
      populations other than women with AUFI. This survey suggests that most providers 
      limit their support of UTx to patients with the most demonstrated clinical need, 
      childless women with AUFI.
CI  - (c) 2019 Mayo Foundation for Medical Education and Research. Published by
      Elsevier Inc.
FAU - Riggan, Kirsten A
AU  - Riggan KA
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN.
FAU - Khan, Zaraq
AU  - Khan Z
AD  - Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN.
AD  - Division of Reproductive Endocrinology and Infertility, Mayo Clinic, Rochester,
      MN.
AD  - Division of Minimally Invasive Gynecologic Surgery, Mayo Clinic, Rochester, MN.
FAU - Langstraat, Carrie L
AU  - Langstraat CL
AD  - Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN.
AD  - Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN.
FAU - Allyse, Megan A
AU  - Allyse MA
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN.
AD  - Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN.
LA  - eng
GR  - UL1 TR002377/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200217
PL  - Netherlands
TA  - Mayo Clin Proc Innov Qual Outcomes
JT  - Mayo Clinic proceedings. Innovations, quality & outcomes
JID - 101728275
PMC - PMC7140015
OTO - NOTNLM
OT  - AUFI, absolute uterine factor infertility
OT  - MRKH, Mayer-Rokitansky-Kuster-Hauser syndrome
OT  - UTx, uterus transplant
OT  - VCA, vascular composite allograft
EDAT- 2020/04/14 06:00
MHDA- 2020/04/14 06:01
CRDT- 2020/04/14 06:00
PHST- 2019/10/10 00:00 [received]
PHST- 2019/10/21 00:00 [revised]
PHST- 2019/11/13 00:00 [accepted]
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/04/14 06:01 [medline]
AID - 10.1016/j.mayocpiqo.2019.11.001 [doi]
AID - S2542-4548(19)30174-2 [pii]
PST - epublish
SO  - Mayo Clin Proc Innov Qual Outcomes. 2020 Feb 17;4(2):150-158. doi:
      10.1016/j.mayocpiqo.2019.11.001. eCollection 2020 Apr.


PMID- 32280094
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 75
IP  - 1
DP  - 2020
TI  - What Could Be the Main Levers to Promote a Timely Diagnosis of Neurocognitive
      Disorders?
PG  - 201-210
LID - 10.3233/JAD-191253 [doi]
AB  - BACKGROUND: Neurocognitive disorders (NCD) are a growing health issue and the
      importance of diagnosis is still debated despite the benefits of making a
      diagnosis appearing to be greater than the risks. OBJECTIVE: The aim of the
      present study was to explore the perception of the main benefits and risks to
      perform a diagnosis workup of NCD in a population of general practitioners (GPs),
      specialized physicians (SPs), other healthcare professionals (OHPs), and informal
      caregivers (ICs), and to identify the lowest perceived benefits and the highest
      perceived risks that could be levers to promote a diagnosis of NCD. METHODS: A
      standardized questionnaire was submitted to GPs, SPs, OHPs, and ICs aiming to
      evaluate the importance of eight benefits and eight risks related to NCD
      diagnosis (selected from the literature) for four prototypical clinical cases at 
      different stages of the disease: subjective cognitive impairment/mild NCD, major 
      NCD at mild/moderate stage, moderate stage with behavioral and psychotic
      symptoms, and severe stage. RESULTS: The lowest perceived benefits of making an
      NCD diagnosis were "access to medical research", "patient's right to know", and
      "initiation of symptomatic drug treatment". The highest perceived risks of making
      an NCD diagnosis were "negative psychological impact for the patient", "absence
      of disease-modifying treatment", and "absence of suitable institution".
      CONCLUSION: This study highlights the lowest perceived benefits and the highest
      perceived risks of making an NCD diagnosis. These benefits and risks could be
      modified to become levers to promote a personalized diagnosis of NCD.
FAU - Garnier-Crussard, Antoine
AU  - Garnier-Crussard A
AD  - Centre Memoire Ressource et Recherche de Lyon (CMRR), Hopital des Charpennes,
      Hospices Civils de Lyon, Lyon, France.
AD  - Institut du Vieillissement I-Vie, Hospices Civils de Lyon, Lyon, France.
FAU - Vernaudon, Julien
AU  - Vernaudon J
AD  - Centre Memoire Ressource et Recherche de Lyon (CMRR), Hopital des Charpennes,
      Hospices Civils de Lyon, Lyon, France.
AD  - Institut du Vieillissement I-Vie, Hospices Civils de Lyon, Lyon, France.
AD  - Centre de Recherche Clinique CRC - VCF (Vieillissement - Cerveau - Fragilite),
      Hopital des Charpennes, Hospices Civils de Lyon, Lyon, France.
FAU - Auguste, Nicolas
AU  - Auguste N
AD  - Centre Mutualiste de Consultation Memoire, Saint-Etienne, France.
FAU - Dauphinot, Virginie
AU  - Dauphinot V
AD  - Centre Memoire Ressource et Recherche de Lyon (CMRR), Hopital des Charpennes,
      Hospices Civils de Lyon, Lyon, France.
AD  - Institut du Vieillissement I-Vie, Hospices Civils de Lyon, Lyon, France.
FAU - Krolak-Salmon, Pierre
AU  - Krolak-Salmon P
AD  - Centre Memoire Ressource et Recherche de Lyon (CMRR), Hopital des Charpennes,
      Hospices Civils de Lyon, Lyon, France.
AD  - Institut du Vieillissement I-Vie, Hospices Civils de Lyon, Lyon, France.
AD  - Centre de Recherche Clinique CRC - VCF (Vieillissement - Cerveau - Fragilite),
      Hopital des Charpennes, Hospices Civils de Lyon, Lyon, France.
AD  - INSERM, U1028; CNRS, UMR5292; Lyon Centre de Recherche en Neurosciences de Lyon, 
      Dynamique Cerebrale et Cognition, Lyon, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Caregivers/*psychology
MH  - Cognitive Dysfunction/diagnosis
MH  - *Health Personnel
MH  - Humans
MH  - Neurocognitive Disorders/*diagnosis
MH  - Neuropsychological Tests
MH  - Risk Factors
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Benefits and risks
OT  - *ethical issues
OT  - *neurocognitive disorders
OT  - *personalized diagnosis
OT  - *timely diagnosis
EDAT- 2020/04/14 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - JAD191253 [pii]
AID - 10.3233/JAD-191253 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;75(1):201-210. doi: 10.3233/JAD-191253.


PMID- 32280086
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 75
IP  - 2
DP  - 2020
TI  - A Prospective Longitudinal Study of Caregivers of Community Dwelling Persons with
      Severe Dementia (PISCES): Study Protocol.
PG  - 403-416
LID - 10.3233/JAD-190897 [doi]
AB  - Although many persons with severe dementia (PWSDs) are cared for at home by their
      family caregivers, few studies have assessed end of life (EOL) care experiences
      of PWSDs. We present the protocol for the PISCES study (Panel study Investigating
      Status of Cognitively impaired Elderly in Singapore) which aims to describe the
      clinical course, health care utilization, and expenditures for community-dwelling
      PWSDs; and perceived burden, coping, resilience, anticipatory and prolonged grief
      among their caregivers. This ongoing multi-center prospective longitudinal study 
      is recruiting primary informal caregivers of 250 PWSDs from major restructured
      public hospitals, community hospitals, home care foundations, and hospices in
      Singapore. Caregivers are surveyed every four months for two years or until the
      PWSD passes away and then at eight weeks and six months post-death to assess the 
      bereavement of the caregiver. Survey questionnaires included validated tools to
      assess PWSDs' quality of life, suffering, behaviors, functional status, resource 
      utilization; and caregiver's satisfaction with care, awareness of prognosis, care
      preferences, resilience, coping, perceived burden, distress, positive aspects of 
      caregiving, anticipatory grief, and bereavement adjustment. We also conduct
      qualitative in-depth interviews with a sub-sample of caregivers. The survey data 
      is being linked with medical and billing records of PWSDs. The study has been
      approved by an ethics board. Results from the study will be disseminated through 
      publications and presentations targeting researchers, policy makers and
      clinicians interested in understanding and improving EOL care for PWSDs and their
      caregivers.
FAU - Malhotra, Chetna
AU  - Malhotra C
AD  - Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.
AD  - Program in Health Services and Systems Research, Duke-NUS Medical School,
      Singapore.
FAU - Vishwanath, Padmini
AU  - Vishwanath P
AD  - Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.
FAU - Yong, Jing Rong
AU  - Yong JR
AD  - Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.
FAU - Ostbye, Truls
AU  - Ostbye T
AD  - Program in Health Services and Systems Research, Duke-NUS Medical School,
      Singapore.
FAU - Seow, Dennis
AU  - Seow D
AD  - Department of Geriatric Medicine, Singapore General Hospital, Singapore.
FAU - Yap, Phillip
AU  - Yap P
AD  - Geriatric Centre, Khoo Teck Puat Hospital, Singapore.
FAU - Tan, Lay Ling
AU  - Tan LL
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Tham, Weng Yew
AU  - Tham WY
AD  - Care for the Elderly Foundation, Singapore.
FAU - Vaingankar, Janhavi
AU  - Vaingankar J
AD  - Research Division, Institute of Mental Health, Singapore.
FAU - Foo, Jason
AU  - Foo J
AD  - Alzheimer's Disease Association, Singapore.
FAU - Tan, Boon Yeow
AU  - Tan BY
AD  - St. Luke's Hospital, Singapore.
FAU - Tong, Kamun
AU  - Tong K
AD  - Post-acute & Continuing Care, Jurong Community Hospital, Singapore.
FAU - Ng, Wai Chong
AU  - Ng WC
AD  - Hua Mei Centre for Successful Ageing, Tsao Foundation, Singapore.
FAU - Allen, John Carson Jr
AU  - Allen JC Jr
AD  - Centre of Quantitative Medicine, Duke-NUS Medical School, Singapore.
FAU - Malhotra, Rahul
AU  - Malhotra R
AD  - Program in Health Services and Systems Research, Duke-NUS Medical School,
      Singapore.
AD  - Centre for Ageing Research and Education (CARE), Duke-NUS Medical School,
      Singapore.
FAU - Tan, Weng Mooi
AU  - Tan WM
AD  - Agency for Integrated Care, Singapore.
FAU - Wee, Shiou Liang
AU  - Wee SL
AD  - Program in Health Services and Systems Research, Duke-NUS Medical School,
      Singapore.
AD  - Geriatric Education and Research Institute, Alexandra Health Pte Ltd, Singapore.
FAU - Ng, Li Ling
AU  - Ng LL
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Goveas, Richard
AU  - Goveas R
AD  - Department of Geriatric Psychiatry, Institute of Mental Health, Singapore.
FAU - Mok, Vanessa
AU  - Mok V
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Sim, Alisson
AU  - Sim A
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Ng, Wei Fern
AU  - Ng WF
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Wong, Hon Khuan
AU  - Wong HK
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Balasundaram, Bharathi
AU  - Balasundaram B
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Tan, Rui Qi
AU  - Tan RQ
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Ong, Pui Sim
AU  - Ong PS
AD  - Department of Psychological Medicine, Changi General Hospital, Singapore.
FAU - Cheong, Chin Yee
AU  - Cheong CY
AD  - Geriatric Centre, Khoo Teck Puat Hospital, Singapore.
FAU - Yee Chung Pheng, Alethea
AU  - Yee Chung Pheng A
AD  - Assisi Hospice, Singapore.
FAU - Tiong, Christina
AU  - Tiong C
AD  - Home Nursing Foundation, Singapore.
FAU - Hum, Allyn
AU  - Hum A
AD  - Dover Park Hospice, Singapore.
FAU - Lee, Angel
AU  - Lee A
AD  - St. Andrew's Community Hospital, Singapore.
FAU - Finkelstein, Eric A
AU  - Finkelstein EA
AD  - Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.
AD  - Program in Health Services and Systems Research, Duke-NUS Medical School,
      Singapore.
LA  - eng
SI  - ClinicalTrials.gov/NCT03382223
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
MH  - Adaptation, Psychological
MH  - Caregivers/*psychology
MH  - *Dementia
MH  - Female
MH  - Humans
MH  - *Independent Living
MH  - Male
MH  - Psychological Distress
MH  - Quality of Life/*psychology
MH  - *Research Design
MH  - Resilience, Psychological
MH  - *Terminal Care
OTO - NOTNLM
OT  - *Dementia
OT  - *Singapore
OT  - *end of life
OT  - *health care utilization
OT  - *palliative care
EDAT- 2020/04/14 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - JAD190897 [pii]
AID - 10.3233/JAD-190897 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;75(2):403-416. doi: 10.3233/JAD-190897.


PMID- 32280085
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201015
IS  - 1875-8622 (Electronic)
IS  - 1386-0291 (Linking)
VI  - 75
IP  - 3
DP  - 2020
TI  - The clinical value of Arrival-time Parametric Imaging using contrast-enhanced
      ultrasonography in differentiating benign and malignant breast lesions.
PG  - 369-382
LID - 10.3233/CH-200826 [doi]
AB  - OBJECTIVES: To evaluate the clinical value of Arrival-time Parametric Imaging
      (At-PI) in the differentiation of benign and malignant breast lesions. METHODS:
      For this ethics committee-approved retrospective study, a total of 184 breast
      lesions in 176 women were included and gray-scale ultrasound, contrast-enhanced
      ultrasound (CEUS) and At-PI were performed. In CEUS and At-PI, perfusion
      patterns, perfusion uniformity and color spatial distribution for lesions were
      analyzed qualitatively and the maximal diameter ratio of the lesion in
      accumulated parametric images and that in gray-scale images (MDRAI/GI) and area
      ratio of the lesion in accumuated parametric images and that in gray-scale images
      (ARAI/GI) were calculated quantitatively. Kappa and Intraclass Correlation
      Coefficient were used to evaluate the interobserver reproducibility for CEUS and 
      At-PI and the intraobserver reproducibility for At-PI, respectively. The area
      under receiver operating characteristic (AUC), sensitivity, specificity, accuracy
      and positive and negative likelihood ratios (PPV, NPV) were calculated for
      MDRAI/GI and ARAI/GI. RESULTS: Good interobserver and intraobserver
      reproducibility for At-PI were identified. In At-PI, there were statistically
      significant differences in perfusion patterns, color spatial distribution,
      MDRAI/GI and ARAI/GI between benign and malignant breast lesions (P < 0.05). The 
      AUCs of MDRAI/GI and ARAI/GI were 0.895 and 0.954, respectively, with no
      significant difference between them (Z = 1.84, P > 0.05). By using the thresholds
      of 1.125 for MDRAI/GI and 1.21 for ARAI/GI, the sensitivity, specificity,
      accuracy, PPV and NPV of At-PI were 84.48%, 88.24%, 85.57%, 92.45% and 76.92%,
      respectively, for MDRAI/GI and 93.10%, 91.18%, 92.39%, 94.74% and 88.57%,
      respectively, for ARAI/GI. CONCLUSIONS: At-PI is helpful to distinguish benign
      from malignant breast lesions. And MDRAI/GI and ARAI/GI are useful and efficient 
      features for differential diagnosis.
FAU - Hu, Wenjie
AU  - Hu W
AD  - Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong
      University School of Medicine, Shanghai, China.
FAU - Dong, Yi
AU  - Dong Y
AD  - Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Zhang, Xuemei
AU  - Zhang X
AD  - Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University
      School of Medicine, Shanghai, China.
FAU - Zhang, Huiping
AU  - Zhang H
AD  - Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong
      University School of Medicine, Shanghai, China.
FAU - Li, Fan
AU  - Li F
AD  - Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong
      University School of Medicine, Shanghai, China.
FAU - Bai, Min
AU  - Bai M
AD  - Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong
      University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Clin Hemorheol Microcirc
JT  - Clinical hemorheology and microcirculation
JID - 9709206
RN  - 0 (Contrast Media)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*diagnosis/*diagnostic imaging/pathology
MH  - Contrast Media/*therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Ultrasonography/*methods
MH  - Young Adult
OTO - NOTNLM
OT  - Arrival-time Parametric Imaging
OT  - Contrast-enhanced ultrasound
OT  - benign and malignant breast lesions
EDAT- 2020/04/14 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - CH200826 [pii]
AID - 10.3233/CH-200826 [doi]
PST - ppublish
SO  - Clin Hemorheol Microcirc. 2020;75(3):369-382. doi: 10.3233/CH-200826.


PMID- 32280047
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1769-664X (Electronic)
IS  - 0929-693X (Linking)
VI  - 27
IP  - 5
DP  - 2020 Jul
TI  - Tracheostomy, respiratory support, and developmental outcomes in neonates with
      severe lung diseases: Retrospective study in one center.
PG  - 270-274
LID - S0929-693X(20)30084-1 [pii]
LID - 10.1016/j.arcped.2020.03.011 [doi]
AB  - OBJECTIVES: Pediatric tracheostomy has evolved significantly in the past few
      decades and the optimal timing to perform it in children with respiratory
      assistance is still debated. The objective of this study was to describe the
      indications, timing, complications, and outcomes of infants on respiratory
      support who had a tracheostomy in a tertiary pediatric intensive care unit
      (PICU). METHODS: All children younger than 18 months of corrected age requiring
      respiratory support for at least 1 week and who had a tracheostomy between
      January 2005 and December 2015 were included. Their demographic and clinical data
      and their outcomes at 24 months of corrected age were collected and analyzed
      after approval from the CHU Sainte-Justine ethics committee. RESULTS: During the 
      study period, 18 children (14 preterm infants, 4 polymalformative syndromes, and 
      2 diaphragmatic hernias) were included. The median corrected age at tracheostomy 
      was 97 days (0-289 days) and 94.4% were elective. The indications for
      tracheostomy were ventilation for more than 7 days with (61.1%) or without
      (38.9%) orolaryngotracheal anomaly. The median number of consultants involved per
      patient was 16 consultants (10-23 consultants). The median hospital length of
      stay was 122 days (8-365 days) before tracheostomy and 235 days (22-891 days)
      after tracheostomy. The median invasive ventilation time was 68 days (8-168 days)
      before tracheostomy and 64 days (5-982 days) after tracheostomy. In terms of
      complications, there were nine cases of tracheitis and five cases of tracheal
      granulomas. At 24 months of corrected age, 17 of 18 children survived, one of/17 
      was still hospitalized, three of 17 were decannulated, three of 17 received
      respiratory support via their tracheostomy, 11 of 17 were fed with a gastrostomy,
      and all had neurodevelopmental delay. CONCLUSION: Tracheostomy in infants
      requiring at least 1 week of ventilation is performed for complex cases and is
      favored for orolaryngotracheal anomalies. Clinicians should anticipate the need
      for developmental care in this population.
CI  - Copyright (c) 2020 French Society of Pediatrics. Published by Elsevier Masson
      SAS. All rights reserved.
FAU - Bergeron Gallant, K
AU  - Bergeron Gallant K
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada.
FAU - Sauthier, M
AU  - Sauthier M
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada.
FAU - Kawaguchi, A
AU  - Kawaguchi A
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada; University of Ottawa, Children's Hospital of
      Eastern Ontario, Ottawa, Canada.
FAU - Essouri, S
AU  - Essouri S
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada.
FAU - Quintal, M C
AU  - Quintal MC
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada.
FAU - Emeriaud, G
AU  - Emeriaud G
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada.
FAU - Jouvet, P
AU  - Jouvet P
AD  - Pediatric Intensive Care Unit, CHU Sainte-Justine, Montreal, Canada; University
      of Montreal, Montreal, Canada. Electronic address: philippe.jouvet@umontreal.ca.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - France
TA  - Arch Pediatr
JT  - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
JID - 9421356
SB  - IM
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Intensive Care Units, Pediatric
MH  - Lung Diseases/complications/physiopathology/*therapy
MH  - Male
MH  - Neurodevelopmental Disorders/diagnosis/epidemiology/*etiology
MH  - *Respiration, Artificial
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Tertiary Care Centers
MH  - *Tracheostomy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Children
OT  - Developmental care
OT  - Intensive care
OT  - Mechanical ventilation
OT  - Neuropsychological stimulation
OT  - Tracheostomy
EDAT- 2020/04/14 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/04/14 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/12/27 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - S0929-693X(20)30084-1 [pii]
AID - 10.1016/j.arcped.2020.03.011 [doi]
PST - ppublish
SO  - Arch Pediatr. 2020 Jul;27(5):270-274. doi: 10.1016/j.arcped.2020.03.011. Epub
      2020 Apr 9.


PMID- 32279730
OWN - NLM
STAT- MEDLINE
DCOM- 20201209
LR  - 20201214
IS  - 1558-1381 (Electronic)
IS  - 1047-9651 (Linking)
VI  - 31
IP  - 2
DP  - 2020 May
TI  - Ethics and Regulation of Opioid Prescriptions for Management of Pain: The
      Washington State Experience.
PG  - 279-287
LID - S1047-9651(20)30004-8 [pii]
LID - 10.1016/j.pmr.2020.01.004 [doi]
AB  - Painful conditions affect a significant population in the United States. As the
      scientific understanding of the benefits and harms of opioid therapy has evolved,
      so too has the application of prescription opioid therapy for the treatment of
      pain. The rapid increase in the use of prescription and illicit opioids over the 
      past decade has contributed to a public health crisis commonly referred to as the
      "opioid crisis." In this article, the ethical approaches to treating patients
      with opioid pharmaceuticals as well as the development of regulation of opioid
      therapy in Washington State are reviewed.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Babington, James R
AU  - Babington JR
AD  - Swedish Pain Services, Swedish Medical Center, 21616 76th Avenue West, Suite 212,
      Edmonds, WA 98026, USA. Electronic address: James.babington@swedish.org.
FAU - Matthews, Micah
AU  - Matthews M
AD  - Washington Medical Commission, 111 Israel Road Southeast, Tumwater, WA 98501,
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200310
PL  - United States
TA  - Phys Med Rehabil Clin N Am
JT  - Physical medicine and rehabilitation clinics of North America
JID - 9102787
RN  - 0 (Analgesics, Opioid)
SB  - IM
MH  - Analgesics, Opioid/*therapeutic use
MH  - Chronic Pain/*drug therapy
MH  - Decision Making
MH  - *Health Policy
MH  - Humans
MH  - Opioid-Related Disorders/*prevention & control
MH  - Pain Management/*ethics
MH  - Practice Patterns, Physicians'/legislation & jurisprudence
MH  - Prescriptions/*standards
MH  - Washington
OTO - NOTNLM
OT  - *Chronic pain
OT  - *Ethics
OT  - *Health care regulation
OT  - *Opioid therapy
OT  - *Pain management
COIS- Disclosure Neither author has any commercial or financial conflicts of interest
      or any external funding sources.
EDAT- 2020/04/14 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - S1047-9651(20)30004-8 [pii]
AID - 10.1016/j.pmr.2020.01.004 [doi]
PST - ppublish
SO  - Phys Med Rehabil Clin N Am. 2020 May;31(2):279-287. doi:
      10.1016/j.pmr.2020.01.004. Epub 2020 Mar 10.


PMID- 32279538
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Oct
TI  - A comparative analysis of retracted papers in Health Sciences from China and
      India.
PG  - 401-416
LID - 10.1080/08989621.2020.1754804 [doi]
AB  - Academics are expected to publish their research work. Hence, during the past few
      years, the scientific community has witnessed an ever-increasing growth and
      output in scientific papers. However, a large number of authors have violated
      ethical norms of research leading to retractions of their research works as well.
      The article focuses on the scientific fraud emanating from China and India in
      Health Sciences for a period of three years i.e. 2015 to 2018. The present data
      were extracted from http://retractiondatabase.org/using a search filter term
      "Research Articles OR Articles in Press" on the subject category of Health
      Sciences (HSC). A total of 318 retracted papers were retrieved and the result of 
      the study indicated that majority (268 items) of the retracted papers in Health
      Science originated from China, whereas just 50 retracted papers originated from
      India as on 21-02-2019. While analyzing the data, 26 redundant articles from
      China have been removed that received retraction notices. Further, the results of
      the study suggest that there are several factors associated with retraction of
      scientific papers, which include unreliable results, duplication of results,
      plagiarism, forged authorship, error in the text, error in data and so on.
FAU - Palla, Ishfaq Ahmad
AU  - Palla IA
AD  - Department of Library and Infromation Science, Pondicherry University ,
      Puducherry, India.
FAU - Singson, Mangkhollen
AU  - Singson M
AD  - Department of Library and Infromation Science, Pondicherry University ,
      Puducherry, India.
FAU - Thiyagarajan, S
AU  - Thiyagarajan S
AD  - Department of International Business Pondicherry University, Puducherry, India.
LA  - eng
PT  - Journal Article
DEP - 20200418
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Authorship/standards
MH  - Biomedical Research/ethics/*statistics & numerical data
MH  - China
MH  - Humans
MH  - India
MH  - Journal Impact Factor
MH  - Plagiarism
MH  - *Retraction of Publication as Topic
MH  - Scientific Misconduct/statistics & numerical data
OTO - NOTNLM
OT  - *Health Science
OT  - *Research Misconduct
OT  - *journal impact factor
OT  - *plagiarism
OT  - *retractions
EDAT- 2020/04/14 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/04/14 06:00
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
AID - 10.1080/08989621.2020.1754804 [doi]
PST - ppublish
SO  - Account Res. 2020 Oct;27(7):401-416. doi: 10.1080/08989621.2020.1754804. Epub
      2020 Apr 18.


PMID- 32279318
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 3
DP  - 2020 May
TI  - Should Institutions Disclose the Names of Employees with Covid-19?
PG  - 25-27
LID - 10.1002/hast.1107 [doi]
AB  - Prestigious University is a large, private educational institution with a medical
      school, a university hospital, a law school, and graduate and undergraduate
      colleges all on a single campus. In the face of the Covid-19 pandemic, students
      were told during spring break to return to campus only briefly to retrieve their 
      belongings. Classes then went online. On March 23, 2020, the faculty, students,
      and staff were emailed the following by the university's director of infection
      control and public health: We have become aware that a Prestigious University
      staff member has tested positive for the virus that causes Covid-19. The
      individual, who was last on campus on March 16, is now in isolation at their
      permanent residence and is doing well clinically. The university has already
      identified those members of our community who may have been in close contact with
      this individual, and we are working to notify them. Further, this individual's
      local health department has a protocol for identifying people who have been in
      direct contact with anyone testing positive for Covid-19 (such as this
      Prestigious University staff member) so that they can self-quarantine and watch
      for COVID-19 symptoms for a period of 14 days from their last contact with the
      infected individual. A professor in the Philosophy Department has asked the
      ethicists at the medical school whether such contact tracing suffices. "Don't the
      members of the community deserve to know who this is? Isn't there a mandate to
      identify this person in order to maximize public health benefits and slow the
      spread of this deadly virus?"
CI  - (c) 2020 The Hastings Center.
FAU - Sulmasy, Daniel P
AU  - Sulmasy DP
FAU - Veatch, Robert M
AU  - Veatch RM
LA  - eng
PT  - Journal Article
DEP - 20200412
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Academic Medical Centers/organization & administration
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology
MH  - Disclosure/*ethics
MH  - Humans
MH  - Infection Control/*organization & administration/standards
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
PMC - PMC7262051
OTO - NOTNLM
OT  - *Covid-19
OT  - *confidentiality and privacy
OT  - *novel coronavirus SARS-CoV-2
OT  - *public health emergency
OT  - *public health ethics
EDAT- 2020/04/13 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/04/13 06:00
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
AID - 10.1002/hast.1107 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 May;50(3):25-27. doi: 10.1002/hast.1107. Epub 2020 Apr
      12.


PMID- 32278753
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20210725
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Linking)
VI  - 110
IP  - 2
DP  - 2020 Aug
TI  - Cardiothoracic Surgeons in Pandemics: Ethical Considerations.
PG  - 355-358
LID - S0003-4975(20)30500-2 [pii]
LID - 10.1016/j.athoracsur.2020.03.006 [doi]
FAU - Drake, Daniel
AU  - Drake D
AD  - Munson Healthcare, Department of Surgery, Traverse City, Michigan.
FAU - Morrow, Cynthia D
AU  - Morrow CD
AD  - Independent Researcher, Ann Arbor, Michigan.
FAU - Kinlaw, Kathleen
AU  - Kinlaw K
AD  - Emory Center for Ethics, Healthcare Ethics Consortium, Department of Pediatrics, 
      Emory University, Atlanta, Georgia.
FAU - De Bonis, Michele
AU  - De Bonis M
AD  - Department of Cardiac Surgery, IRCCS San Raffaele Scientific Institute,
      Vita-Salute San Raffaele University, Milan, Italy.
FAU - Zangrillo, Alberto
AU  - Zangrillo A
AD  - Anesthesia and Intensive Care Department, IRCCS San Raffaele Scientific
      Institute, Vita-Salute San Raffaele University, Milan, Italy.
FAU - Sade, Robert M
AU  - Sade RM
AD  - Medical University of South Carolina, Division of Cardiothoracic Surgery,
      Department of Surgery, Institute of Human Values in Health Care, Charleston,
      South Carolina. Electronic address: sader@musc.edu.
CN  - Cardiothoracic Ethics Forum
LA  - eng
GR  - UL1 TR001450/TR/NCATS NIH HHS/United States
PT  - Editorial
PT  - Research Support, N.I.H., Extramural
DEP - 20200409
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
SB  - IM
CIN - Ann Thorac Surg. 2021 Jul;112(1):342. PMID: 32511991
CIN - Ann Thorac Surg. 2021 Jul;112(1):342-343. PMID: 33038340
MH  - Humans
MH  - *Pandemics
MH  - Thoracic Surgery/*ethics
MH  - Thoracic Surgical Procedures/*ethics
PMC - PMC7146709
IR  - Blitzer D
FIR - Blitzer, David
IR  - Carpenter AJ
FIR - Carpenter, Andrea J
IR  - Ceppa DP
FIR - Ceppa, DuyKhanh P
IR  - Chen EP
FIR - Chen, Edward P
IR  - Cohen RG
FIR - Cohen, Robbin G
IR  - D'Amico TA
FIR - D'Amico, Thomas A
IR  - Drake DH
FIR - Drake, Daniel H
IR  - Entwistle JW 3rd
FIR - Entwistle, John W 3rd
IR  - Fedak PW
FIR - Fedak, Paul W
IR  - Fenton KN
FIR - Fenton, Kathleen N
IR  - Loebe M
FIR - Loebe, Matthias
IR  - Mayer JE
FIR - Mayer, John E
IR  - McKneally MF
FIR - McKneally, Martin F
IR  - Merrill WH
FIR - Merrill, Walter H
IR  - Millikan SJ
FIR - Millikan, Scott J
IR  - Moffatt-Bruce SD
FIR - Moffatt-Bruce, Susan D
IR  - Murthy SC
FIR - Murthy, Sudish C
IR  - Naunheim KS
FIR - Naunheim, Keith S
IR  - Orringer MB
FIR - Orringer, Mark B
IR  - Pickens A
FIR - Pickens, Allan
IR  - Ray S
FIR - Ray, Shuddhadeb
IR  - Romano JC
FIR - Romano, Jennifer C
IR  - Sade RM
FIR - Sade, Robert M
IR  - Starnes SL
FIR - Starnes, Sandra L
IR  - Swain JA
FIR - Swain, Julie A
IR  - Tweddell JS
FIR - Tweddell, James S
IR  - Whyte RI
FIR - Whyte, Richard I
IR  - Wood DD
FIR - Wood, Douglas D
IR  - Zwischenberger JB
FIR - Zwischenberger, Joseph B
EDAT- 2020/04/13 06:00
MHDA- 2020/09/01 06:00
CRDT- 2020/04/13 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
AID - S0003-4975(20)30500-2 [pii]
AID - 10.1016/j.athoracsur.2020.03.006 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2020 Aug;110(2):355-358. doi: 10.1016/j.athoracsur.2020.03.006. 
      Epub 2020 Apr 9.


PMID- 32278728
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201218
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 230
IP  - 6
DP  - 2020 Jun
TI  - Ethics in the Time of Coronavirus: Recommendations in the COVID-19 Pandemic.
PG  - 1114-1118
LID - S1072-7515(20)30309-4 [pii]
LID - 10.1016/j.jamcollsurg.2020.04.004 [doi]
FAU - Kramer, Jessica B
AU  - Kramer JB
AD  - Department of Surgery, Washington University in Saint Louis School of Medicine,
      St Louis, MO.
FAU - Brown, Douglas E
AU  - Brown DE
AD  - Department of Surgery, Washington University in Saint Louis School of Medicine,
      St Louis, MO.
FAU - Kopar, Piroska K
AU  - Kopar PK
AD  - Department of Surgery, Washington University in Saint Louis School of Medicine,
      St Louis, MO. Electronic address: pkopar@wustl.edu.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
CIN - J Am Coll Surg. 2020 Aug;231(2):301-302. PMID: 32487426
MH  - Betacoronavirus
MH  - Biomedical Research/ethics
MH  - COVID-19
MH  - Confidentiality/ethics
MH  - Coronavirus Infections/epidemiology
MH  - *Ethics, Medical
MH  - Health Resources/ethics/supply & distribution
MH  - Humans
MH  - Mass Screening/ethics
MH  - Pandemics/*ethics
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
MH  - Social Responsibility
MH  - Terminal Care/ethics
PMC - PMC7194670
EDAT- 2020/04/13 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/13 06:00
PHST- 2020/04/01 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
AID - S1072-7515(20)30309-4 [pii]
AID - 10.1016/j.jamcollsurg.2020.04.004 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Jun;230(6):1114-1118. doi:
      10.1016/j.jamcollsurg.2020.04.004. Epub 2020 Apr 9.


PMID- 32278727
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20201218
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 230
IP  - 6
DP  - 2020 Jun
TI  - Ethical Rationing of Personal Protective Equipment to Minimize Moral Residue
      During the COVID-19 Pandemic.
PG  - 1111-1113
LID - S1072-7515(20)30304-5 [pii]
LID - 10.1016/j.jamcollsurg.2020.03.031 [doi]
AB  - This article proposes systems for the fair distribution of scarce resources to
      healthcare providers. It builds on classic ethical structures and adapts them to 
      the equitable distribution of personal protective equipment (PPE) to clinicians
      at risk of contracting novel corona virus-19 (COVID-19). The article also defines
      systems of allocation that are generally considered unethical and are to be
      avoided. We emphasize that policies must be transparent, collaborative, applied
      equally, and have a system of accountability. It is recognized that unless the
      supply of PPE is quickly replenished, or viable alternatives to traditional
      equipment are devised in the coming days to weeks, hospitals and healthcare
      systems will face the difficult task of rationing PPE to at-risk clinicians. This
      paper suggests an ethical framework for that process.
CI  - Copyright (c) 2020 American College of Surgeons. Published by Elsevier Inc. All
      rights reserved.
FAU - Binkley, Charles E
AU  - Binkley CE
AD  - ProNobis Health, San Francisco, CA. Electronic address:
      binkley@pronobishealth.org.
FAU - Kemp, David S
AU  - Kemp DS
AD  - UC Berkeley School of Law, Berkeley, CA.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology
MH  - *Ethics, Medical
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Infection Control/instrumentation
MH  - Morals
MH  - Pandemics/*ethics
MH  - Personal Protective Equipment/ethics/*supply & distribution
MH  - Pneumonia, Viral/epidemiology
MH  - SARS-CoV-2
PMC - PMC7195046
EDAT- 2020/04/13 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/13 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
AID - S1072-7515(20)30304-5 [pii]
AID - 10.1016/j.jamcollsurg.2020.03.031 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Jun;230(6):1111-1113. doi:
      10.1016/j.jamcollsurg.2020.03.031. Epub 2020 Apr 9.


PMID- 32278725
OWN - NLM
STAT- MEDLINE
DCOM- 20200730
LR  - 20210316
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 231
IP  - 2
DP  - 2020 Aug
TI  - Medically Necessary, Time-Sensitive Procedures: Scoring System to Ethically and
      Efficiently Manage Resource Scarcity and Provider Risk During the COVID-19
      Pandemic.
PG  - 281-288
LID - S1072-7515(20)30317-3 [pii]
LID - 10.1016/j.jamcollsurg.2020.04.011 [doi]
AB  - Hospitals have severely curtailed the performance of nonurgent surgical
      procedures in anticipation of the need to redeploy healthcare resources to meet
      the projected massive medical needs of patients with coronavirus disease 2019
      (COVID-19). Surgical treatment of non-COVID-19 related disease during this
      period, however, still remains necessary. The decision to proceed with medically 
      necessary, time-sensitive (MeNTS) procedures in the setting of the COVID-19
      pandemic requires incorporation of factors (resource limitations, COVID-19
      transmission risk to providers and patients) heretofore not overtly considered by
      surgeons in the already complicated processes of clinical judgment and shared
      decision-making. We describe a scoring system that systematically integrates
      these factors to facilitate decision-making and triage for MeNTS procedures, and 
      appropriately weighs individual patient risks with the ethical necessity of
      optimizing public health concerns. This approach is applicable across a broad
      range of hospital settings (academic and community, urban and rural) in the midst
      of the pandemic and may be able to inform case triage as operating room capacity 
      resumes once the acute phase of the pandemic subsides.
CI  - Copyright (c) 2020 American College of Surgeons. Published by Elsevier Inc. All
      rights reserved.
FAU - Prachand, Vivek N
AU  - Prachand VN
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL. Electronic address: vprachan@uchicago.edu.
FAU - Milner, Ross
AU  - Milner R
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Angelos, Peter
AU  - Angelos P
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Posner, Mitchell C
AU  - Posner MC
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Fung, John J
AU  - Fung JJ
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Agrawal, Nishant
AU  - Agrawal N
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Jeevanandam, Valluvan
AU  - Jeevanandam V
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
FAU - Matthews, Jeffrey B
AU  - Matthews JB
AD  - Department of Surgery, University of Chicago Medicine and Biological Sciences,
      Chicago, IL.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
CIN - J Minim Invasive Gynecol. 2020 Jul - Aug;27(5):1188-1195. PMID: 32446972
CIN - J Am Coll Surg. 2020 Sep;231(3):406. PMID: 32593496
CIN - J Am Coll Surg. 2020 Sep;231(3):407. PMID: 32660734
CIN - J Am Coll Surg. 2020 Aug;231(2):288. PMID: 32684303
MH  - Betacoronavirus
MH  - COVID-19
MH  - Chicago/epidemiology
MH  - Coronavirus Infections/epidemiology/*prevention & control
MH  - Decision Making/*ethics
MH  - Disease Transmission, Infectious/*prevention & control
MH  - Efficiency, Organizational
MH  - Health Resources/*supply & distribution
MH  - Humans
MH  - Infection Control/*organization & administration
MH  - Pandemics/*prevention & control
MH  - Patient Selection/*ethics
MH  - Pneumonia, Viral/epidemiology/*prevention & control
MH  - Risk
MH  - SARS-CoV-2
MH  - Surgery Department, Hospital/*ethics
MH  - Triage/ethics
PMC - PMC7195575
EDAT- 2020/04/13 06:00
MHDA- 2020/07/31 06:00
CRDT- 2020/04/13 06:00
PHST- 2020/04/02 00:00 [received]
PHST- 2020/04/07 00:00 [revised]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/07/31 06:00 [medline]
PHST- 2020/04/13 06:00 [entrez]
AID - S1072-7515(20)30317-3 [pii]
AID - 10.1016/j.jamcollsurg.2020.04.011 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2020 Aug;231(2):281-288. doi: 10.1016/j.jamcollsurg.2020.04.011. 
      Epub 2020 Apr 9.


PMID- 32278314
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 1877-5764 (Electronic)
IS  - 1877-5756 (Linking)
VI  - 24
DP  - 2020 Jun
TI  - Sub-optimal use of ultrasound examinations may result in underperformance of
      Vietnamese maternity care - A qualitative study of midwives' experiences and
      views.
PG  - 100508
LID - S1877-5756(19)30084-9 [pii]
LID - 10.1016/j.srhc.2020.100508 [doi]
AB  - OBJECTIVE: To explore Vietnamese midwives' experiences and views on the role of
      obstetric ultrasound in relation to clinical management, including ethical
      aspects. METHODS: Using a qualitative design, content analysis of focus group
      discussions with midwives (N = 25) working at Departments of Obstetrics and
      Gynecology at three hospitals in urban, semi-urban and rural parts of Hanoi were 
      performed. RESULTS: Obstetric ultrasound was reported as being a highly valuable 
      tool, although replacing ordinary antenatal care surveillance with ultrasound
      examinations and misuse of ultrasound without medical indication was perceived as
      troubling. Participants generally viewed the fetus as a human being already at an
      early stage of pregnancy. However, when complications occurred, the pregnant
      woman's health was mostly prioritised. CONCLUSION: Although the use of ultrasound
      has many benefits during pregnancy, replacing ordinary antenatal care
      surveillance with ultrasound examinations and misuse of ultrasound without
      medical indication is concerning and needs to be addressed. There is also a need 
      to communicate the benefits of adequate antenatal care to pregnant women and
      caution about the non-beneficial use of repeated ultrasound examinations without 
      medical indication. Additionally, non-medical ultrasounds consume limited
      healthcare resources and its use needs to be better regulated in Vietnam.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Holmlund, Sophia
AU  - Holmlund S
AD  - Department of Clinical Sciences, Obstetrics and Gynecology, Umea University,
      Umea, Sweden. Electronic address: sofia.holmlund@umu.se.
FAU - Lan, Pham Thi
AU  - Lan PT
AD  - Department of Dermatology and Venereology, Hanoi Medical University, Hanoi, Viet 
      Nam. Electronic address: lanphamthi009@gmail.com.
FAU - Edvardsson, Kristina
AU  - Edvardsson K
AD  - Department of Clinical Sciences, Obstetrics and Gynecology, Umea University,
      Umea, Sweden; Judith Lumley Centre, School of Nursing and Midwifery, La Trobe
      University, Melbourne, Australia. Electronic address:
      k.edvardsson@latrobe.edu.au.
FAU - Ntaganira, Joseph
AU  - Ntaganira J
AD  - School of Public Health, College of Medicine and Health Sciences, University of
      Rwanda, Kigali, Rwanda. Electronic address: jntaganira@nursph.org.
FAU - Graner, Sofie
AU  - Graner S
AD  - Department of Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet,
      Stockholm, Sweden. Electronic address: sofie.graner@ki.se.
FAU - Small, Rhonda
AU  - Small R
AD  - Department of Women's and Children's and Reproductive Health, Karolinska
      Institutet, Stockholm, Sweden; Judith Lumley Centre, La Trobe University,
      Melbourne, Australia. Electronic address: r.small@latrobe.edu.au.
FAU - Mogren, Ingrid
AU  - Mogren I
AD  - Department of Clinical Sciences, Obstetrics and Gynecology, Umea University,
      Umea, Sweden; Judith Lumley Centre, La Trobe University, Melbourne, Australia.
      Electronic address: ingrid.mogren@umu.se.
LA  - eng
PT  - Journal Article
DEP - 20200317
PL  - Netherlands
TA  - Sex Reprod Healthc
JT  - Sexual & reproductive healthcare : official journal of the Swedish Association of
      Midwives
JID - 101530546
SB  - IM
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - Female
MH  - Focus Groups
MH  - Health Services Misuse/*prevention & control
MH  - Humans
MH  - Maternal Health Services/*standards
MH  - *Midwifery
MH  - Pregnancy
MH  - Prenatal Care/*standards
MH  - Qualitative Research
MH  - Ultrasonography, Prenatal/*psychology
MH  - Vietnam
OTO - NOTNLM
OT  - Antenatal care
OT  - Maternal health services
OT  - Midwives
OT  - Pregnant women
OT  - Ultrasonography prenatal
OT  - Vietnam
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/12 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/04/12 06:00
PHST- 2019/03/01 00:00 [received]
PHST- 2020/02/25 00:00 [revised]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S1877-5756(19)30084-9 [pii]
AID - 10.1016/j.srhc.2020.100508 [doi]
PST - ppublish
SO  - Sex Reprod Healthc. 2020 Jun;24:100508. doi: 10.1016/j.srhc.2020.100508. Epub
      2020 Mar 17.


PMID- 32278265
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1873-4758 (Electronic)
IS  - 0955-3959 (Linking)
VI  - 78
DP  - 2020 Apr
TI  - Problematizing the DSM-5 criteria for opioid use disorder: A qualitative
      analysis.
PG  - 102690
LID - S0955-3959(20)30031-1 [pii]
LID - 10.1016/j.drugpo.2020.102690 [doi]
AB  - BACKGROUND: This paper includes the voices of people who are members of a
      peer-led drug user group (SNAP) in Canada who are receiving heroin-assisted
      treatment (HAT) outside of a clinical trial. Drawing from critical drug studies, 
      we problematize the criteria for severe opioid use disorder (OUD) from the fifth 
      edition of the Diagnostic and Statistical Manual of Mental Disorders, by
      exploring SNAP members' experiences in relation to heroin-assisted treatment, and
      examining how SNAP participants' narratives challenge conventional notions of
      what constitutes severe opioid use disorder. METHOD: Drawing on critical analysis
      and research guidelines developed by drug user unions and organizations, and
      critical methodological frameworks on ethical community-based-and-responsive
      research for social justice, in this paper we focus on semi-structured interviews
      conducted with 36 SNAP members at the Vancouver Area Network of Drug Users site
      in the Downtown Eastside of Vancouver, Canada. We included opened ended questions
      about experiences prior to receiving HAT, experiences while receiving HAT,
      experiences of drug use and cessation, and future hopes. RESULTS: Although SNAP
      participants were diagnosed as suffering from OUD, the DSM-5 criteria for OUD
      fails to encompass their diverse experiences of opioid use. Nor does the DSM
      diagnosis capture the complexities of their lived experience. The DSM OUD
      constructs an idea of addiction and the addicted person based on a list of
      symptoms thought to be associated with extended use of opioids. The problem with 
      this is that many of these "symptoms" of drug use are, in the case of SNAP
      participants, tied to contextual issues of living in the DTES, experiencing
      structural vulnerability, and being the target of punitive drug policies and
      laws. CONCLUSION: To label someone as having a severe disorder shifts the focus
      from political and social issues, including the lived experiences of people who
      use heroin. The DSM-5 de-contextualizes drug use. How addiction and heroin are
      constituted has political implications that will determine what types of services
      and programs will be set up. Treating a disorder, or a person with a disorder,
      requires a much different approach than understanding heroin use as a habit.
      SNAP, and their allies, are rupturing conventional ideas about heroin and taken
      for granted assumptions about people who use heroin.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Boyd, Susan
AU  - Boyd S
AD  - Faculty of Human & Social Development, University of Victoria, Victoria, BC V8W
      2Y2, Canada. Electronic address: scboyd@uvic.ca.
FAU - Ivsins, Andrew
AU  - Ivsins A
AD  - Department of Medicine, University of British Columbia, British Columbia Centre
      on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada.
FAU - Murray, Dave
AU  - Murray D
AD  - SALOME/NAOMI Association of Patients (SNAP), C/O VANDU, 380 E. Hastings St.,
      Vancouver, BC V6A 1P4, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200408
PL  - Netherlands
TA  - Int J Drug Policy
JT  - The International journal on drug policy
JID - 9014759
RN  - 0 (Analgesics, Opioid)
RN  - 70D95007SX (Heroin)
SB  - IM
MH  - Analgesics, Opioid
MH  - Canada
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Heroin
MH  - Humans
MH  - *Opioid-Related Disorders/diagnosis
OTO - NOTNLM
OT  - *Canada
OT  - *Community-based research
OT  - *Critical drug studies
OT  - *DSM
OT  - *Heroin-assisted treatment
OT  - *Opioid Use Disorder
OT  - *Qualitative research
COIS- Conflict of Interest Statement The author(s) declared no potential conflicts of
      interest with respect to the research, authorship, and/or publication of this
      article.
EDAT- 2020/04/12 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/12 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S0955-3959(20)30031-1 [pii]
AID - 10.1016/j.drugpo.2020.102690 [doi]
PST - ppublish
SO  - Int J Drug Policy. 2020 Apr;78:102690. doi: 10.1016/j.drugpo.2020.102690. Epub
      2020 Apr 8.


PMID- 32278227
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1557-8615 (Electronic)
IS  - 0883-9441 (Linking)
VI  - 58
DP  - 2020 Aug
TI  - Ethical content of expert recommendations for end-of-life decision-making in
      intensive care units: A systematic review.
PG  - 10-19
LID - S0883-9441(20)30541-4 [pii]
LID - 10.1016/j.jcrc.2020.03.010 [doi]
AB  - PURPOSE: Intensive care unit health care professionals must be skilled in
      providing end-of-life care. Crucial in this kind of care is end-of-life
      decision-making, which is a complex process involving a variety of stakeholders
      and requiring adequate justification. The aim of this systematic review is to
      analyse papers tackling ethical issues in relation to end-of-life decision-making
      in intensive care units. It explores the ethical positions, arguments and
      principles. METHODS: A literature search was conducted in bibliographic databases
      and grey literature sources for the time period from 1990 to 2019. The constant
      comparative method was used for qualitative analysis of included papers in order 
      to identify ethical content including ethical positions, ethical arguments, and
      ethical principles used in decision-making process. RESULTS: In the 15 included
      papers we have identified a total of 43 ethical positions. Ten positions were
      identified as substantive, 33 as procedural. Twelve different ethical principles 
      emerged from the ethical arguments. The most frequently used principles are the
      principles of beneficence, autonomy and nonmaleficence. CONCLUSIONS: We have
      demonstrated that recommendations and guidelines designed specifically by
      intensive or critical care experts for intensive care units promote similar
      ethical positions, with minimal dissenting positions.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Spoljar, Diana
AU  - Spoljar D
AD  - University Hospital Dubrava, School of Medicine, University of Zagreb, Avenija
      Gojka Suska 6, 10000 Zagreb, Croatia. Electronic address: dspoljar@kbd.hr.
FAU - Curkovic, Marko
AU  - Curkovic M
AD  - University Psychiatric Hospital Vrapce, School of Medicine, University of Zagreb,
      Bolnicka Cesta 32, 10000 Zagreb, Croatia.
FAU - Gastmans, Chris
AU  - Gastmans C
AD  - Centre for Biomedical Ethics and Law, Faculty of Medicine, KU Leuven,
      Kapucijnenvoer 35, Box 7001, 3000 Leuven, Belgium. Electronic address:
      chris.gastmans@kuleuven.be.
FAU - Gordijn, Bert
AU  - Gordijn B
AD  - Institute of Ethics, School of Theology, Philosophy, and Music, Dublin City
      University, DCU All Hallows Campus, Dublin 9, Ireland. Electronic address:
      bert.gordijn@dcu.ie.
FAU - Vrkic, Dina
AU  - Vrkic D
AD  - Central Medical Library, School of Medicine, University of Zagreb, Salata ul. 2, 
      10000 Zagreb, Croatia. Electronic address: dina.vrkic@mef.hr.
FAU - Jozepovic, Ana
AU  - Jozepovic A
AD  - School of Medicine, University of Zagreb, Salata ul. 2, 10000 Zagreb, Croatia.
FAU - Vuletic, Suzana
AU  - Vuletic S
AD  - Catholic Faculty of Theology in Dakovo, University of Josip Juraj Strossmayer in 
      Osijek, Petra Preradovica 17, 31400 Dakovo, Croatia.
FAU - Tonkovic, Dinko
AU  - Tonkovic D
AD  - University Hospital Centre Zagreb, School of Medicine, University of Zagreb,
      Kispaticeva ul. 12, 10000 Zagreb, Croatia.
FAU - Borovecki, Ana
AU  - Borovecki A
AD  - Andrija Stampar School of Public Health, School of Medicine, University of
      Zagreb, Johna Davidsona Rockfellera 4, 10000 Zagreb, Croatia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200331
PL  - United States
TA  - J Crit Care
JT  - Journal of critical care
JID - 8610642
SB  - IM
MH  - *Critical Illness
MH  - Decision Making/*ethics
MH  - Expert Testimony
MH  - Humans
MH  - Intensive Care Units
MH  - Terminal Care/*ethics
OTO - NOTNLM
OT  - *End-of-life care
OT  - *End-of-life decision-making
OT  - *Ethics
OT  - *Intensive care units
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/04/12 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S0883-9441(20)30541-4 [pii]
AID - 10.1016/j.jcrc.2020.03.010 [doi]
PST - ppublish
SO  - J Crit Care. 2020 Aug;58:10-19. doi: 10.1016/j.jcrc.2020.03.010. Epub 2020 Mar
      31.


PMID- 32277645
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 1
DP  - 2020 Jan-Feb
TI  - Assessment of ex-vivo efficacy (oncogram) of immunotherapeutic and
      chemotherapeutic agents in bladder cancer: A pilot study of personalized
      treatment.
PG  - 295-301
AB  - PURPOSE: To investigate the ex-vivo efficacy of immunotherapeutics and
      chemotherapeutics in bladder cancer primary cell cultures, to assess the
      applicability of the method according to the results and to evaluate suitability 
      of the oncogram method for personalized treatment of bladder cancer. METHODS:
      After receiving ethics committee approval, tumor tissue was obtained from
      patients with transurethral resection performed due to bladder tumor from 2015 to
      2017. Primary culture was produced from the obtained fresh tissue. Each culture
      was divided into 6 groups. The control group had only medium applied, while the
      other groups had Bacillus Calmette Guerin (BCG), Interferon-alpha (IFN-alpha),
      Gemcitabine, BCG+IFN-alpha and BCG+Gemcitabine, respectively. Viability tests in 
      the 24th hour were performed on each culture. The results of all cases were
      compared with their own controls. Also, results of each case were compared
      between the cases with similar pathologic results. RESULTS: The study assessed 24
      bladder cancer cases. Mean patient age was 66.2+/-11.7 years (34-83), with 19
      male (79.5%) and 5 female patients (20.5%). When data were compared between the
      groups, viability percentages were 31.2%, 30.9%, 27.7%, 32.1% and 29.4% in the
      BCG, IFN-alpha, Gemcitabine, BCG+IFN-alpha and BCG+Gemcitabine groups compared
      with their own controls (73.1%), respectively (p<0.001). In addition, we found
      that viability results were not similar in all cases. CONCLUSIONS: Cell cultures 
      produced from bladder cancer tissue might help to determine sensitivity to
      treatment. This ex-vivo method (oncogram) is a simple and applicable method that 
      can be used for personalized treatment before intravesical or systemic therapy.
FAU - Celik, Serdar
AU  - Celik S
AD  - Health Sciences University, Izmir Bozyaka Training and Research Hospital,
      Department of Urology, Izmir, Turkey.
FAU - Sari, Hilmi
AU  - Sari H
FAU - Ugur Mungan, Mehmet
AU  - Ugur Mungan M
FAU - Yorukoglu, Kutsal
AU  - Yorukoglu K
FAU - Celebi, Ilhan
AU  - Celebi I
FAU - Aktas, Safiye
AU  - Aktas S
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Male
MH  - Pilot Projects
MH  - Precision Medicine/*methods
MH  - Urinary Bladder Neoplasms/*drug therapy/pathology
EDAT- 2020/04/12 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Jan-Feb;25(1):295-301.


PMID- 32277552
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20200615
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Ethical principles governing organ transplantation apply to paired exchange
      programs.
PG  - 1756-1757
LID - 10.1111/ajt.15906 [doi]
FAU - Flechner, Stuart M
AU  - Flechner SM
AUID- ORCID: 0000-0002-8172-3918
AD  - Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Cooper, Matthew
AU  - Cooper M
AD  - Medstar Georgetown Transplant Institute, Washington, District of Columbia, USA.
FAU - Waterman, Amy
AU  - Waterman A
AUID- ORCID: 0000-0002-7799-0060
AD  - Division of Nephrology, UCLA School of Medicine, Los Angeles, California, USA.
FAU - Kennealey, Peter
AU  - Kennealey P
AD  - Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora,
      California, USA.
FAU - Redfield, Robert
AU  - Redfield R
AD  - Department of Surgery, University of Wisconsin, Madison, Wisconsin, USA.
FAU - Verbesey, Jennifer
AU  - Verbesey J
AD  - Medstar Georgetown Transplant Institute, Washington, District of Columbia, USA.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200504
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CON - Am J Transplant. 2020 May;20(5):1223-1224. PMID: 32022980
CIN - Am J Transplant. 2020 Jun;20(6):1758-1759. PMID: 32337792
MH  - Humans
MH  - Living Donors
MH  - *Organ Transplantation
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *donors and donation: living
OT  - *ethics and public policy
OT  - *kidney transplantation/nephrology
OT  - *kidney transplantation: living donor
EDAT- 2020/04/12 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - 10.1111/ajt.15906 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Jun;20(6):1756-1757. doi: 10.1111/ajt.15906. Epub 2020 May 
      4.


PMID- 32277402
OWN - NLM
STAT- MEDLINE
DCOM- 20210205
LR  - 20210920
IS  - 2210-7711 (Electronic)
VI  - 42
IP  - 2
DP  - 2020 Apr
TI  - Exploring pharmacy ethics in developing countries: a scoping review.
PG  - 418-435
LID - 10.1007/s11096-020-01021-4 [doi]
AB  - Background Healthcare ethics have been profoundly influenced by principles of
      bioethics that emerged post-World War II in the Declaration of Geneva 1948.
      'Beneficence' (to do good), 'Non-Maleficence' (to do no harm), 'Justice'
      (fairness and justice in access) and 'Respect for Autonomy' (respect for patient 
      individuality, including decision making, privacy, and right to refuse), have
      become foundational principles of contemporary medical codes of ethics. These
      principles are well reflected in most professional pharmacy code of ethics
      globally. This domain remains relatively unexplored in most developing countries 
      and the majority of what has been published in this area relates to western
      cultures. There have been no attempts to pool findings from a similar scope of
      research emanating in developing countries. Aim of the review This study aims to 
      explore the scope of pharmacy ethics in the literature pertaining to developing
      countries. Methods An extensive search of three relevant (Scopus, CINAHL, IPA)
      databases was conducted from Jan 2000 to Feb 2020, in order to identify relevant 
      studies conducted in or focussed on ethics in pharmacy in developing countries. A
      separate Google Scholar search was carried out in an effort to locate
      supplementary articles, hand-searched articles were also included to achieve an
      exhaustive investigation of all current relevant studies. Results The full text
      of 20 relevant articles that met inclusion criteria were critically analysed and 
      qualitatively categorised into three emerging themes; Ethical challenges in
      pharmacy practice, Approaches used in teaching pharmacy ethics, and Code of
      ethics analysis and implementation. Conclusions: Findings of this literature
      review illuminated a gap in pharmacy ethics literacy in developing countries and 
      variances in pharmacists' ethical attitudes in handling ethical dilemmas, as well
      as a lack of familiarity with ethical principles and codes of ethics.
      Pharmacists' lack of respect for patients' autonomy and pharmacists being prone
      to financial pressure were found to have a significant impact on pharmacy
      practice in most of developing countries. However, attempts are being made to
      rectify this gap by efforts to incorporate ethical and professional education in 
      undergraduate curricula, and by studies in which new codes of ethics are being
      implemented.
FAU - Fino, Leen B
AU  - Fino LB
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia.
AD  - Faculty of Pharmacy, Applied Science Private University, Amman, 11931, Jordan.
FAU - Basheti, Iman A
AU  - Basheti IA
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia.
AD  - Faculty of Pharmacy, Applied Science Private University, Amman, 11931, Jordan.
FAU - Saini, Bandana
AU  - Saini B
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia.
FAU - Moles, Rebekah
AU  - Moles R
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia.
FAU - Chaar, Betty B
AU  - Chaar BB
AD  - School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
      Sydney, NSW, 2006, Australia. betty.chaar@sydney.edu.au.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200410
PL  - Netherlands
TA  - Int J Clin Pharm
JT  - International journal of clinical pharmacy
JID - 101554912
SB  - IM
MH  - Attitude of Health Personnel
MH  - Bioethical Issues
MH  - Codes of Ethics
MH  - *Developing Countries
MH  - *Ethics, Pharmacy
MH  - Humans
MH  - Pharmacists/*ethics
MH  - Teaching
OTO - NOTNLM
OT  - Developing countries
OT  - Literature review
OT  - Pharmacy ethics
OT  - Pharmacy ethics teaching
EDAT- 2020/04/12 06:00
MHDA- 2021/02/07 06:00
CRDT- 2020/04/12 06:00
PHST- 2019/10/22 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/02/07 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - 10.1007/s11096-020-01021-4 [doi]
AID - 10.1007/s11096-020-01021-4 [pii]
PST - ppublish
SO  - Int J Clin Pharm. 2020 Apr;42(2):418-435. doi: 10.1007/s11096-020-01021-4. Epub
      2020 Apr 10.


PMID- 32277323
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1573-2630 (Electronic)
IS  - 0165-5701 (Linking)
VI  - 40
IP  - 7
DP  - 2020 Jul
TI  - Protective effects of carnosic acid on retinal ganglion cells in acute ocular
      hypertension rats.
PG  - 1869-1878
LID - 10.1007/s10792-020-01359-8 [doi]
AB  - OBJECTIVE: To observe the protective effects of carnosic acid on rat retinal
      ganglion cells (RGCs) among acute ocular hypertension rats. METHODS: Sixty male
      SPF (specific-pathogen-free) SD rats (10 weeks) were randomly assigned to
      untreated group, carnosic-acid-treated group and hypertensive group with 20 rats 
      for each. The acute ocular hypertension animal model was induced by the perfusion
      of normal saline solution into anterior chamber of eyes to elevate the
      intraocular pressure (IOP) to 110 mmHg for 60 min in the rats of the
      carnosic-acid-treated group and hypertensive group. Then, the carnosic acid
      dissolving in dimethyl sulfoxide (DMSO) was intraperitoneally injected for
      consecutive 7 days in the carnosic-acid-treated group, and only DMSO was used in 
      the same way in the hypertensive group. The rats were killed 2 weeks after
      experiment, and retinal sections were prepared for histopathological and
      apoptotic retinal ganglion cells (RGCs) examination by hemotoxylin and eosin
      staining and TUNEL staining. Use immunofluorescence employed to examine the
      survival of RGCs. This study protocol was approved by the Ethic Committee for
      Experimental Animal of Three Gorges University. RESULTS: The retinal morphology
      and structure were clear in the untreated group. The edema of retinal tissue,
      loosely arranged RGCs and swollen nucleus were seen in the hypertensive group. In
      the carnosic-acid-treated group, the retinal morphology and structure were
      regular. The retinal nerve fiber layer (RNFL) thickness was (32.96 +/- 1.63),
      (58.96 +/- 1.57) and (50.11 +/- 2.37) mum, and the apoptotic cell number was
      (6.92 +/- 2.96), (29.85 +/- 6.40) and (14.69 +/- 2.98)/field, and the survived
      cell number was (2363.17 +/- 148.45), (1308.67 +/- 106.02) and (1614.17 +/-
      96.39)/0.235 mm(2) in the untreated group, hypertensive group and
      carnosic-acid-treated group, respectively, showing significant differences among 
      groups (F = 339.284, 81.583, 122.68, all at P < 0.01). Compared with the
      untreated group, the RNFL thickness was thickened, the number of apoptotic RGCs
      was much more, and the number of survived RGCs was decreased in the hypertensive 
      group. In the carnosic-acid-treated group, the RNFL thickness was thinner, the
      number of apoptotic RGCs was reduced, and the number of survived RGCs was
      increased in comparison with the untreated group (all at P < 0.01). CONCLUSIONS: 
      Carnosic acid plays a protective effect on RGCs by inhibiting the cell apoptosis 
      in acute ocular hypertension rats.
FAU - Liang, Liang
AU  - Liang L
AUID- ORCID: http://orcid.org/0000-0002-0082-5235
AD  - Department of Ophthalmology, Yichang Central People's Hospital, The First College
      of Clinical Medical Science, China Three Gorges University, Yichang, 443003,
      People's Republic of China. liangliang419519@163.com.
FAU - He, Liye
AU  - He L
AD  - Department of Ophthalmology, Yichang Central People's Hospital, The First College
      of Clinical Medical Science, China Three Gorges University, Yichang, 443003,
      People's Republic of China.
FAU - Zhu, Mengnan
AU  - Zhu M
AD  - Department of Ophthalmology, Yichang Central People's Hospital, The First College
      of Clinical Medical Science, China Three Gorges University, Yichang, 443003,
      People's Republic of China.
FAU - Chen, Baoji
AU  - Chen B
AD  - Department of Ophthalmology, Yichang Central People's Hospital, The First College
      of Clinical Medical Science, China Three Gorges University, Yichang, 443003,
      People's Republic of China.
FAU - Xiao, Changyi
AU  - Xiao C
AD  - Department of Ophthalmology, Yichang Central People's Hospital, The First College
      of Clinical Medical Science, China Three Gorges University, Yichang, 443003,
      People's Republic of China.
LA  - eng
GR  - 81770920/National Natural Science Foundation Program of China
GR  - WJ2017Q037/Hubei Health and Family Planning Commission Youth Talent Project
PT  - Journal Article
DEP - 20200410
PL  - Netherlands
TA  - Int Ophthalmol
JT  - International ophthalmology
JID - 7904294
RN  - 0 (Abietanes)
RN  - LI791SXT24 (salvin)
SB  - IM
MH  - Abietanes
MH  - Animals
MH  - Disease Models, Animal
MH  - *Glaucoma/drug therapy
MH  - Intraocular Pressure
MH  - Male
MH  - *Ocular Hypertension/drug therapy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Retinal Ganglion Cells
OTO - NOTNLM
OT  - Carnosic acid
OT  - Ocular hypertension
OT  - Rats
OT  - Retinal ganglion cells
EDAT- 2020/04/12 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/04/12 06:00
PHST- 2018/10/06 00:00 [received]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - 10.1007/s10792-020-01359-8 [doi]
AID - 10.1007/s10792-020-01359-8 [pii]
PST - ppublish
SO  - Int Ophthalmol. 2020 Jul;40(7):1869-1878. doi: 10.1007/s10792-020-01359-8. Epub
      2020 Apr 10.


PMID- 32277236
OWN - NLM
STAT- Publisher
LR  - 20210428
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
DP  - 2020 Apr 11
TI  - Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas 
      During the COVID-19 Pandemic.
LID - noaa090 [pii]
LID - 10.1093/neuonc/noaa090 [doi]
AB  - The COVID-19 outbreak is posing unprecedented risks and challenges for all
      communities and healthcare systems, worldwide. There are unique considerations
      for many adult patients with gliomas who are vulnerable to the novel coronavirus 
      due to older age and immunosuppression. As patients with terminal illnesses, they
      present ethical challenges for centers that may need to ration access to
      ventilator care due to insufficient critical care capacity. It is urgent for the 
      neuro-oncology community to develop a pro-active and coordinated approach to the 
      care of adults with gliomas in order to provide them with the best possible
      oncologic care while also reducing their risk of viral infection during times of 
      potential healthcare system failure. In this article, we present an approach
      developed by an international multi-disciplinary group to optimize the care of
      adults with gliomas during this pandemic. We recommend measures to promote strict
      social distancing and minimize exposures for patients, address risk and benefit
      of all therapeutic interventions, pro-actively develop end of life plans, educate
      patients and caregivers and ensure the health of the multi-disciplinary
      neuro-oncology workforce. This pandemic is already changing neuro-oncologic care 
      delivery around the globe. It is important to highlight opportunities to maximize
      the benefit and minimize the risk of glioma management during this pandemic and
      potentially, in the future.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Mohile, Nimish A
AU  - Mohile NA
AD  - Department of Neurology, University of Rochester Medical Center.
FAU - Blakeley, Jaishri O
AU  - Blakeley JO
AD  - Department of Neurology, Johns Hopkins University.
FAU - Gatson, Na Tosha N
AU  - Gatson NTN
AD  - Geisinger Health, Neuroscience and Cancer Institutes, and Geisinger Commonwealth 
      School of Medicine.
FAU - Hottinger, Andreas F
AU  - Hottinger AF
AD  - CHUV Lausanne University Hospital & University of Lausanne, Departments of
      Clinical Neurosciences & Oncology, Lausanne, Switzerland.
FAU - Lassman, Andrew B
AU  - Lassman AB
AD  - Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia
      University Irving Medical Center.
FAU - Ney, Douglas E
AU  - Ney DE
AD  - Departments of Neurology and Neurosurgery, University of Colorado School of
      Medicine; Aurora, CO.
FAU - Olar, Adriana
AU  - Olar A
AD  - Departments of Pathology and Neurosurgery, Medical University of South Carolina
      and Hollings Cancer Center, Charleston, SC.
FAU - Schiff, David
AU  - Schiff D
AD  - University of Virginia, Departments of Neurology, Neurological Surgery.
FAU - Shih, Helen A
AU  - Shih HA
AD  - Department of Radiation Oncology, Massachusetts General Hospital.
FAU - Strowd, Roy
AU  - Strowd R
AD  - Wake Forest School of Medicine, Department of Neurology, Internal Medicine,
      Section on Hematology and Oncology.
FAU - van den Bent, Martin J
AU  - van den Bent MJ
AD  - Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, the Netherlands.
FAU - Ziu, Mateo
AU  - Ziu M
AD  - Department of Neurosurgery, Inova Neuroscience and Spine Institute, Virginia
      Commonwealth University.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
SB  - IM
CIN - Neuro Oncol. 2020 Jul 7;22(7):1048-1049. PMID: 32343803
PMC - PMC7184330
OTO - NOTNLM
OT  - Adult glioma
OT  - COVID-19
OT  - Pandemic
EDAT- 2020/04/12 06:00
MHDA- 2020/04/12 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/03/27 00:00 [received]
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/04/12 06:00 [medline]
AID - 5818980 [pii]
AID - 10.1093/neuonc/noaa090 [doi]
PST - aheadofprint
SO  - Neuro Oncol. 2020 Apr 11. pii: 5818980. doi: 10.1093/neuonc/noaa090.


PMID- 32277079
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210410
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Apr 10
TI  - An Embodied Perspective as a Victim of Sexual Harassment in Virtual Reality
      Reduces Action Conformity in a Later Milgram Obedience Scenario.
PG  - 6207
LID - 10.1038/s41598-020-62932-w [doi]
AB  - Group pressure can often result in people carrying out harmful actions towards
      others that they would not normally carry out by themselves. However, few studies
      have manipulated factors that might overcome this. Here male participants (n =
      60) were in a virtual reality (VR) scenario of sexual harassment (SH) of a lone
      woman by a group of males in a bar. Participants were either only embodied as one
      of the males (Group, n = 20), or also as the woman (Woman, n = 20). A control
      group (n = 20) only experienced the empty bar, not the SH. One week later they
      were the Teacher in a VR version of Milgram's Obedience experiment where they
      were encouraged to give shocks to a female Learner by a group of 3 virtual males.
      Those who had been in the Woman condition gave about half the number of shocks of
      those in the Group condition, with the controls between these two. We explain the
      results through embodiment promoting identification with the woman or the group, 
      and delegitimization of the group for those in the Woman condition. The
      experiment raised important ethical issues, showing that a VR study with positive
      ethical intentions can sometimes produce unexpected and non-beneficent results.
FAU - Neyret, Solene
AU  - Neyret S
AUID- ORCID: http://orcid.org/0000-0001-5871-1305
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain.
FAU - Navarro, Xavi
AU  - Navarro X
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain.
FAU - Beacco, Alejandro
AU  - Beacco A
AUID- ORCID: http://orcid.org/0000-0001-8192-1431
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain.
FAU - Oliva, Ramon
AU  - Oliva R
AUID- ORCID: http://orcid.org/0000-0002-6472-8573
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain.
FAU - Bourdin, Pierre
AU  - Bourdin P
AUID- ORCID: http://orcid.org/0000-0002-8745-3787
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain.
AD  - Computer Science, Multimedia and Telecommunications Department, Universitat
      Oberta de Catalunya, Barcelona, Spain.
FAU - Valenzuela, Jose
AU  - Valenzuela J
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain.
FAU - Barberia, Itxaso
AU  - Barberia I
AUID- ORCID: http://orcid.org/0000-0003-3045-2289
AD  - Department of Cognition, Development and Educational Psychology, University of
      Barcelona, Barcelona, Spain.
FAU - Slater, Mel
AU  - Slater M
AUID- ORCID: http://orcid.org/0000-0002-6223-0050
AD  - Event Lab, Department of Clinical Psychology and Psychobiology, University of
      Barcelona, Barcelona, Spain. melslater@ub.edu.
AD  - Institute of Neurosciences of the University of Barcelona, Barcelona, Spain.
      melslater@ub.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200410
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Adult
MH  - Dominance-Subordination
MH  - Female
MH  - Humans
MH  - Male
MH  - Peer Influence
MH  - *Sexual Harassment
MH  - Virtual Reality
MH  - Young Adult
PMC - PMC7148366
EDAT- 2020/04/12 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/12 06:00
PHST- 2019/06/03 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-62932-w [doi]
AID - 10.1038/s41598-020-62932-w [pii]
PST - epublish
SO  - Sci Rep. 2020 Apr 10;10(1):6207. doi: 10.1038/s41598-020-62932-w.


PMID- 32277068
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20220418
IS  - 2239-253X (Electronic)
IS  - 0003-469X (Linking)
VI  - 91
DP  - 2020
TI  - Non-antibiotic prophylaxis in thyroid surgery. Experience of a single Institution
      and revision of literature.
PG  - 372-377
LID - S0003469X20032637 [pii]
AB  - AIM: To evaluate the incidence of SSI and systemic infectious complications in a 
      consecutive series of patients undergoing thyroid surgery in the absence of
      prophylactic antibiotic (NO-AP). METHODS: Prospective observational study
      including 77 patients who underwent total thyroidectomy and completion of
      previous hemithyroidectomy in NO-AP. The surgical intervention was performed by
      surgeons who were experienced in the procedure, and involved the use of Ligasure 
      Harmonic Ethicon(R), absorbable hemostat in oxidized regenerated cellulose
      (Tabotamp(R)), and skin incision suture device Skin Stapler(R). The following
      risk factors were assessed: gender, age, BMI, alcohol consumption, habitual
      smoking, co-morbidities, ASA score, indication to surgery, duration of anesthesia
      and procedure lenght, type of surgical procedure, fever, white blood cells count,
      dosage of the pre-operative C Reactive Protein in the five first post-operative
      day, and histological diagnosis. The data were collected and processed using IBM 
      SPSS software v.23.0. RESULTS: No factors of increased infectious risk have been 
      identified. No infectious surgical and systemic complications have been reported 
      causes of prolongation of the length of the hospital stay. CONCLUSIONS: Fever,
      neutrophilic leukocytosis and increased PCR cannot be assessed as predictive
      factors of infectious complication in thyroid surgery. The cutaneous antisepsis
      of the operative field with chlorhexidine gluconate, the improvement of the
      surgical technique, the protection of the cutaneous margins of incision, the use 
      of new devices, the accurate hemostasis and the reduction of surgery time lead to
      a lack of SSIs and systemic infection complications in all patients undergoing
      thyroid surgery in NO-AP. KEY WORDS: Antibiotic prophylaxis, Surgical site
      infections, Thyroid surgery, Thyroidectomy.
FAU - Spaziani, Erasmo
AU  - Spaziani E
FAU - Di Filippo, Annalisa Romina
AU  - Di Filippo AR
FAU - Di Cristofano, Claudio
AU  - Di Cristofano C
FAU - Caruso, Gianluca
AU  - Caruso G
FAU - Spaziani, Martina
AU  - Spaziani M
FAU - Orelli, Simone
AU  - Orelli S
FAU - Fiorini, Flavia
AU  - Fiorini F
FAU - Maragoni, Maurizio
AU  - Maragoni M
FAU - Facci, Giuliano
AU  - Facci G
FAU - Picchio, Marcello
AU  - Picchio M
FAU - De Cesare, Alessandro
AU  - De Cesare A
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Italy
TA  - Ann Ital Chir
JT  - Annali italiani di chirurgia
JID - 0372343
RN  - 0 (Anti-Infective Agents, Local)
SB  - IM
MH  - Anti-Infective Agents, Local/*therapeutic use
MH  - Antibiotic Prophylaxis
MH  - Hemostasis, Surgical
MH  - Humans
MH  - Prospective Studies
MH  - Surgical Wound Infection/prevention & control
MH  - *Thyroid Gland
MH  - *Thyroidectomy/adverse effects
EDAT- 2020/04/12 06:00
MHDA- 2021/08/14 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S0003469X20032637 [pii]
PST - ppublish
SO  - Ann Ital Chir. 2020;91:372-377.


PMID- 32277021
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20201218
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Allocation of scarce resources during the COVID-19 pandemic: a Jewish ethical
      perspective.
PG  - 444-446
LID - 10.1136/medethics-2020-106242 [doi]
AB  - The novel COVID-19 pandemic has placed medical triage decision-making in the
      spotlight. As life-saving ventilators become scarce, clinicians are being forced 
      to allocate scarce resources in even the wealthiest countries. The pervasiveness 
      of air travel and high rate of transmission has caused this pandemic to spread
      swiftly throughout the world. Ethical triage decisions are commonly based on the 
      utilitarian approach of maximising total benefits and life expectancy. We present
      triage guidelines from Italy, USA and the UK as well as the Jewish ethical
      prospective on medical triage. The Jewish tradition also recognises the
      utilitarian approach but there is disagreement between the rabbis whether human
      discretion has any role in the allocation of scarce resources and triage
      decision-making.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Solnica, Amy
AU  - Solnica A
AD  - Henrietta Szold School of Nursing, Faculty of Medicine, Hebrew University,
      Jerusalem, Israel amysolnica@gmail.com.
AD  - Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical
      Center, Jerusalem, Israel.
FAU - Barski, Leonid
AU  - Barski L
AD  - Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva,
      Israel.
AD  - Department of Medicine, Soroka University Medical Center, Beer Sheva, Israel.
FAU - Jotkowitz, Alan
AU  - Jotkowitz A
AD  - Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva,
      Israel.
AD  - Department of Medicine, Soroka University Medical Center, Beer Sheva, Israel.
LA  - eng
PT  - Journal Article
DEP - 20200410
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Clinical Protocols/standards
MH  - Coronavirus Infections/*epidemiology
MH  - Health Care Rationing/*ethics
MH  - Humans
MH  - Jews/*psychology
MH  - Judaism/*psychology
MH  - Morals
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology
MH  - SARS-CoV-2
MH  - Standard of Care/ethics
MH  - Triage/*ethics
MH  - Ventilators, Mechanical/supply & distribution
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *ethics
OT  - *religious ethics
OT  - *resource allocation
COIS- Competing interests: None declared.
EDAT- 2020/04/12 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - medethics-2020-106242 [pii]
AID - 10.1136/medethics-2020-106242 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):444-446. doi: 10.1136/medethics-2020-106242. Epub
      2020 Apr 10.


PMID- 32277020
OWN - NLM
STAT- Publisher
LR  - 20200411
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 10
TI  - Prepared for practice? UK Foundation doctors' confidence in dealing with ethical 
      issues in the workplace.
LID - medethics-2019-105961 [pii]
LID - 10.1136/medethics-2019-105961 [doi]
AB  - This paper investigates the medical law and ethics (MEL) learning needs of
      Foundation doctors (FYs) by means of a national survey developed in association
      with key stakeholders including the General Medical Council and Health Education 
      England. Four hundred sevnty-nine doctors completed the survey. The average
      self-reported level of preparation in MEL was 63%. When asked to rate how
      confident they felt in approaching three cases of increasing ethical complexity, 
      more FYs were fully confident in the more complex cases than in the more standard
      case. There was no apparent relationship with confidence and reported teaching at
      medical school. The less confident doctors were no more likely to ask for further
      teaching on the topic than the confident doctors. This suggests that FYs can be
      vulnerable when facing ethical decisions by being underprepared, not recognising 
      their lack of ability to make a reasoned decision or by being overconfident.
      Educators need to be aware of this and provide practical MEL training based on
      trainee experiences and real-world ethics and challenge learners' views. Given
      the complexities of many ethical decisions, preparedness should not be seen as
      the ability to make a difficult decision but rather a recognition that such cases
      are difficult, that doubt is permissible and the solution may well be beyond the 
      relatively inexperienced doctor. Educators and supervisors should therefore be
      ensuring that this is clear to their trainees. This necessitates an environment
      in which questions can be asked and uncertainty raised with the expectation of a 
      supportive response.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Corfield, Lorraine
AU  - Corfield L
AD  - Keele Medical School, Keele University, Keele, Staffordshire, UK
      lcorfield@doctors.org.uk.
FAU - Williams, Richard Alun
AU  - Williams RA
AUID- ORCID: http://orcid.org/0000-0001-6333-9448
AD  - Management School, Lancaster University, Lancaster, Lancashire, UK.
FAU - Lavelle, Claire
AU  - Lavelle C
AD  - GP Trainee, Wirral GP Specialty Training Scheme, Birkenhead, UK.
FAU - Latcham, Natalie
AU  - Latcham N
AD  - Department of Medicine, Morecambe Bay Hospitals NHS Trust, Kendal, Cumbria, UK.
FAU - Talash, Khojasta
AU  - Talash K
AD  - Academic Foundation Doctor, Morecambe Bay Hospitals NHS Trust, Kendal, Cumbria,
      UK.
FAU - Machin, Laura
AU  - Machin L
AD  - School of Health and Medicine, Lancaster University, Lancaster, Lancashire, UK.
LA  - eng
PT  - Journal Article
DEP - 20200410
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - decision-making
OT  - education for health care professionals
COIS- Competing interests: None declared.
EDAT- 2020/04/12 06:00
MHDA- 2020/04/12 06:00
CRDT- 2020/04/12 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/04/12 06:00 [medline]
AID - medethics-2019-105961 [pii]
AID - 10.1136/medethics-2019-105961 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 10. pii: medethics-2019-105961. doi:
      10.1136/medethics-2019-105961.


PMID- 32277018
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20210110
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Whose life to save? Scarce resources allocation in the COVID-19 outbreak.
PG  - 364-366
LID - 10.1136/medethics-2020-106227 [doi]
AB  - After initially emerging in China, the coronavirus (COVID-19) outbreak has
      advanced rapidly. The World Health Organization (WHO) has recently declared it a 
      pandemic, with Europe becoming its new epicentre. Italy has so far been the most 
      severely hit European country and demand for critical care in the northern region
      currently exceeds its supply. This raises significant ethical concerns, among
      which is the allocation of scarce resources. Professionals are considering the
      prioritisation of patients most likely to survive over those with remote chances,
      and this news has triggered an intense debate about the right of every individual
      to access healthcare. The proposed analysis suggests that the national emergency 
      framework in which prioritisation criteria are currently enforced should not lead
      us to perceive scarce resources allocation as something new. From an ethical
      perspective, the novelty of the current emergency is not grounded in the
      devastating effects of scarce resources allocation, which is rife in recent and
      present clinical practice. Rather, it has to do with the extraordinarily high
      number of people who find themselves personally affected by the implications of
      scarce resources allocation and who suddenly realise that the principle of
      'equals should be treated equally' may no longer be applicable. Along with the
      need to allocate appropriate additional financial resources to support the
      healthcare system, and thus to mitigate the scarcity of resources, the analysis
      insists on the relevance of a medical ethics perspective that does not place the 
      burden of care and choice solely on physicians.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Mannelli, Chiara
AU  - Mannelli C
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy chiara.mannelli@ircc.it.
AD  - University of Turin, Department of Philosophy and Education Science, Torino,
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*therapy
MH  - Health Care Rationing/ethics/*organization & administration
MH  - Humans
MH  - Italy/epidemiology
MH  - Pandemics
MH  - Pneumonia, Viral/*epidemiology/*therapy
MH  - SARS-CoV-2
MH  - Waiting Lists
PMC - PMC7242866
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *emergency medicine
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/12 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - medethics-2020-106227 [pii]
AID - 10.1136/medethics-2020-106227 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):364-366. doi: 10.1136/medethics-2020-106227. Epub
      2020 Apr 9.


PMID- 32276958
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 9
TI  - Summarising and synthesising regression coefficients through systematic review
      and meta-analysis for improving hypertension prediction using metamodelling:
      protocol.
PG  - e036388
LID - 10.1136/bmjopen-2019-036388 [doi]
AB  - INTRODUCTION: Hypertension is one of the most common medical conditions and
      represents a major risk factor for heart attack, stroke, kidney disease and
      mortality. The risk of progression to hypertension depends on several factors,
      and combining these risk factors into a multivariable model for risk
      stratification would help to identify high-risk individuals who should be
      targeted for healthy behavioural changes and/or medical treatment to prevent the 
      development of hypertension. The risk prediction models can be further improved
      in terms of accuracy by using a metamodel updating technique where existing
      hypertension prediction models can be updated by combining information available 
      in existing models with new data. A systematic review and meta-analysis will be
      performed of hypertension prediction models in order to identify known risk
      factors for high blood pressure and to summarise the magnitude of their
      association with hypertension. METHODS AND ANALYSIS: MEDLINE, Embase, Web of
      Science, Scopus and grey literature will be systematically searched for studies
      predicting the risk of hypertension among the general population. The search will
      be based on two key concepts: hypertension and risk prediction. The summary
      statistics from the individual studies will be the regression coefficients of the
      hypertension risk prediction models, and random-effect meta-analysis will be used
      to obtain pooled estimates. Heterogeneity and publication bias will be assessed, 
      along with study quality, which will be assessed using the Prediction Model Risk 
      of Bias Assessment Tool checklist. ETHICS AND DISSEMINATION: Ethics approval is
      not required for this systematic review and meta-analysis. We plan to disseminate
      the results of our review through journal publications and presentations at
      applicable platforms.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chowdhury, Mohammad Ziaul Islam
AU  - Chowdhury MZI
AUID- ORCID: 0000-0002-5397-2773
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada mohammad.chowdhury@ucalgary.ca.
FAU - Naeem, Iffat
AU  - Naeem I
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - Quan, Hude
AU  - Quan H
AD  - Department of Community Health Sciences, University of Calgary Cumming School of 
      Medicine, Calgary, Alberta, Canada.
FAU - Leung, Alexander A
AU  - Leung AA
AD  - Department of Medicine, University of Calgary Cumming School of Medicine,
      Calgary, Alberta, Canada.
FAU - Sikdar, Khokan C
AU  - Sikdar KC
AD  - Health Status Assessment, Surveillance and Reporting, Public Health Surveillance 
      and Infrastructure, Population, Public and Indigenous Health, Alberta Health
      Services, Calgary, Alberta, Canada.
FAU - O'Beirne, Maeve
AU  - O'Beirne M
AD  - Department of Family Medicine, University of Calgary Cumming School of Medicine, 
      Calgary, Alberta, Canada.
FAU - Turin, Tanvir C
AU  - Turin TC
AUID- ORCID: 0000-0002-7499-5050
AD  - Department of Family Medicine, University of Calgary Cumming School of Medicine, 
      Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Hypertension/*diagnosis
MH  - Meta-Analysis as Topic
MH  - *Models, Theoretical
MH  - *Research Design
MH  - Risk Factors
MH  - Systematic Reviews as Topic
PMC - PMC7170633
OTO - NOTNLM
OT  - *hypertension
OT  - *risk management
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/04/12 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036388 [pii]
AID - 10.1136/bmjopen-2019-036388 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 9;10(4):e036388. doi: 10.1136/bmjopen-2019-036388.


PMID- 32276955
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 9
TI  - Hypertensive disorders of pregnancy and risk of asthma in offspring: protocol for
      a systematic review and meta-analysis.
PG  - e035145
LID - 10.1136/bmjopen-2019-035145 [doi]
AB  - INTRODUCTION: Hypertensive disorders of pregnancy (HDP), one of the most common
      obstetrical complications, has been reported to have a controversial relationship
      with the increased risk of asthma in offspring. No systematic review of this
      topic has been performed. The aim of this systematic review will be to summarise 
      the available evidence examining the association between HDP and the risk of
      asthma in offspring. METHODS AND ANALYSIS: We will follow the Preferred Reporting
      Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational
      Studies in Epidemiology guidelines. A systematic search of the PubMed, Embase,
      Cochrane and Web of Science databases will be performed using a detailed search
      strategy from database inception through 31 December 2019. Cohort, case-control
      and cross-sectional studies that report a diagnosis of maternal HDP and asthma in
      offspring will be included. Studies will be limited to the English language and
      include only human participants. Two independent reviewers will conduct the study
      selection, data extraction and risk of bias assessments using a standardised data
      extraction form. A meta-analysis will be performed to calculate overall pooled
      estimates using the generic inverse variance method. The data will be synthesised
      by either fixed-effect or random effects models according to heterogeneity tests.
      All analyses will be performed in Stata 14 and RevMan 5.3. High-quality evidence 
      of the relationship between HDP and the risk of asthma in exposed offspring will 
      be identified through the synthesis of current studies. In addition, the results 
      of subgroup analyses and related secondary outcomes will be reported. The
      following will be concluded: (i) whether HDP increases the risk of asthma in
      offspring, (ii) whether HDP affects the severity of asthma in exposed offspring
      and (iii) whether possible differences in the risk of asthma among different HDP 
      subgroups exist. ETHICS AND DISSEMINATION: There is no requirement for ethics
      approval because the meta-analysis and systematic review will be based on
      published data. It is anticipated that the dissemination of results will take
      place at conferences and through publication in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Li, Ping
AU  - Li P
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Chengdu, China.
FAU - Xiong, Tao
AU  - Xiong T
AUID- ORCID: 0000-0001-5255-6324
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China tao_xiong@126.com.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Chengdu, China.
AD  - Deep Underground Space Medical Center, West China Hospital, Sichuan University,
      Chengdu, China.
FAU - Hu, Yong
AU  - Hu Y
AD  - Department of Pediatrics, West China Second University Hospital, Sichuan
      University, Chengdu, Sichuan, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children
      (Sichuan University) Ministry of Education, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200409
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Asthma/epidemiology
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Hypertension, Pregnancy-Induced/epidemiology
MH  - *Pre-Eclampsia
MH  - Pregnancy
MH  - Research Design
MH  - Systematic Reviews as Topic
PMC - PMC7170635
OTO - NOTNLM
OT  - *asthma
OT  - *community child health
OT  - *hypertension
OT  - *paediatrics
OT  - *perinatology
COIS- Competing interests: None declared.
EDAT- 2020/04/12 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-035145 [pii]
AID - 10.1136/bmjopen-2019-035145 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 9;10(4):e035145. doi: 10.1136/bmjopen-2019-035145.


PMID- 32276953
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 9
TI  - Effects of brief family psychoeducation for caregivers of people with
      schizophrenia in Japan provided by visiting nurses: protocol for a cluster
      randomised controlled trial.
PG  - e034425
LID - 10.1136/bmjopen-2019-034425 [doi]
AB  - INTRODUCTION: Development of a support system for families caring for people with
      schizophrenia in routine psychiatric care settings is an important issue
      worldwide. Regional mental health systems are inadequate for delivering effective
      services to such family members. Despite evidence that family psychoeducation
      (FPE) alleviates the burden of schizophrenia on families, its dissemination in
      routine clinical practice remains insufficient, suggesting the need for
      developing an effective and implementable intervention for family caregivers in
      the existing mental health system setting. In Japan, the visiting nurse service
      system would be a practical way of providing family services. Visiting nurses in 
      local communities are involved in the everyday lives of people with schizophrenia
      and their families. Accordingly, visiting nurses understand their needs and are
      able to provide family support as a service covered by national health insurance.
      The purpose of this study is to discover whether a brief FPE programme provided
      by visiting nurses caring for people with schizophrenia will alleviate family
      burden through a cluster randomised controlled trial (cRCT). METHODS AND
      ANALYSIS: The study will be a two-arm, parallel-group (visiting nurse agency)
      cRCT. Forty-seven visiting nurse agencies will be randomly allocated to the brief
      FPE group (intervention group) or treatment as usual group (control group).
      Caregivers of people with schizophrenia will be recruited by visiting nurses
      using a randomly ordered list. The primary outcome will be caregiver burden,
      measured using the Japanese version of Zarit Burden Interview. Outcome
      assessments will be conducted at baseline, 1-month follow-up and 6-month
      follow-up. Multiple levels of three-way interactions in mixed models will be used
      to examine whether the brief FPE programme will alleviate the burden on
      caregivers relative to treatment as usual. ETHICS AND DISSEMINATION: The Research
      Ethics Committee of the Graduate School of Medicine and Faculty of Medicine, The 
      University of Tokyo, Japan (No 2019065NI) approved this study. The results will
      be published in a scientific peer-reviewed journal. TRIAL REGISTRATION NUMBER:
      UMIN000038044.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yasuma, Naonori
AU  - Yasuma N
AUID- ORCID: 0000-0002-1216-7639
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Bunkyo-ku, Tokyo, Japan nnyy712@gmail.com.
AD  - Department of Community Mental Health and Law, National Institute of Mental
      Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Sato, Sayaka
AU  - Sato S
AD  - Department of Community Mental Health and Law, National Institute of Mental
      Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Yamaguchi, Sosei
AU  - Yamaguchi S
AUID- ORCID: 0000-0002-0579-4431
AD  - Department of Community Mental Health and Law, National Institute of Mental
      Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Matsunaga, Asami
AU  - Matsunaga A
AD  - Department of Community Mental Health and Law, National Institute of Mental
      Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Shiozawa, Takuma
AU  - Shiozawa T
AD  - Department of Community Mental Health and Law, National Institute of Mental
      Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Tachimori, Hisateru
AU  - Tachimori H
AD  - Department of Clinical Epidemiology, Translational Medical Center, National
      Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira,
      Tokyo, Japan.
FAU - Watanabe, Kazuhiro
AU  - Watanabe K
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - Imamura, Kotaro
AU  - Imamura K
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - Nishi, Daisuke
AU  - Nishi D
AUID- ORCID: 0000-0001-9349-3294
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Bunkyo-ku, Tokyo, Japan.
FAU - Fujii, Chiyo
AU  - Fujii C
AD  - Department of Community Mental Health and Law, National Institute of Mental
      Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
FAU - Kawakami, Norito
AU  - Kawakami N
AUID- ORCID: 0000-0003-1080-2720
AD  - Department of Mental Health, Graduate School of Medicine, The University of
      Tokyo, Bunkyo-ku, Tokyo, Japan.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200409
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Caregivers
MH  - Health Education/*methods
MH  - Humans
MH  - Japan
MH  - Mental Health
MH  - *Nurses, Community Health
MH  - Psychology/education
MH  - Randomized Controlled Trials as Topic
MH  - *Schizophrenia/therapy
PMC - PMC7170625
OTO - NOTNLM
OT  - *brief family psychoeducation
OT  - *caregivers
OT  - *schizophrenia
OT  - *visiting nurses
COIS- Competing interests: None declared.
EDAT- 2020/04/12 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034425 [pii]
AID - 10.1136/bmjopen-2019-034425 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 9;10(4):e034425. doi: 10.1136/bmjopen-2019-034425.


PMID- 32276886
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-4898 (Electronic)
IS  - 1477-5131 (Linking)
VI  - 16
IP  - 3
DP  - 2020 Jun
TI  - Effects of methylphenidate on the lower urinary tract in patients with attention 
      deficit hyperactivity disorder and without voiding dysfunction.
PG  - 351.e1-351.e6
LID - S1477-5131(20)30049-8 [pii]
LID - 10.1016/j.jpurol.2020.02.015 [doi]
AB  - BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is characterised by a
      range of symptoms, such as excessive mobility, difficulty in maintaining
      attention and inadequate impulse control. Methylphenidate (MPH) is widely
      prescribed as a treatment for ADHD. In the literature, studies investigating the 
      effects of MPH on the lower urinary tract (LUT) are limited. OBJECTIVE: The aim
      of the study was to evaluate MPH-induced LUT symptoms (LUTSs) in patients with
      ADHD without a diagnosis of voiding dysfunction (VD). STUDY DESIGN: After ethical
      committee approval, volunteers aged 7-17 y were divided into two groups, with
      group 1 composed of individuals diagnosed with ADHD but not VD and group 2
      (control) composed of healthy individuals. Lower urinary tract symptoms and
      quality of life, in addition to uroflowmetry test results and postvoiding
      residual volume (PVRV), were evaluated in both groups at baseline and again 4 wk 
      later. The individuals in group 1 were treated with MPH after baseline screening.
      The dysfunctional voiding scoring system questionnaire was used for scoring
      LUTSs. Postvoiding residual volume was measured by ultrasound. Bladder capacity
      (BC) was calculated as the sum of voided volume (VV) and PVRV. The means of the
      maximum flow rate (Q max), mean flow rate (Q mean), VV, PVRV and BC were
      recorded. RESULTS: After exclusions, there were 43 participants in group 1 and 39
      participants in group 2. There was no significant difference between the mean age
      of groups (p = 0.727). Compared with the baseline, VV and BC increased
      significantly in group 1 (p = 0.001 and p = 0.002, respectively) at the 4-wk
      follow-up. There was no significant difference in these parameters in group 2.
      DISCUSSION: This study demonstrated that VV and BC increased after MPH treatment 
      in patients with ADHD without a diagnosis of VD. The mechanism underlying this
      effect is unclear, but it may be associated with dopaminergic and noradrenergic
      effects. CONCLUSION: The findings of the present study can inform further studies
      on the mechanism underlying the effect of MPH on the LUT. In a future study, the 
      authors suggest evaluating the effects of MPH in a urodynamic study in patients
      with ADHD diagnosed with VD.
CI  - Copyright (c) 2020 Journal of Pediatric Urology Company. Published by Elsevier
      Ltd. All rights reserved.
FAU - Olcucu, Mahmut Taha
AU  - Olcucu MT
AD  - Agri State Hospital, Department of Urology, Agri, Turkey; University of Health
      Sciences, Antalya Training and Research Hospital, Department of Urology, Antalya,
      Turkey. Electronic address: matah_ol@hotmail.com.
FAU - Kilic, Hilal Tugba
AU  - Kilic HT
AD  - Agri State Hospital, Department of Child and Adolescent Psychiatry, Agri, Turkey.
FAU - Yildirim, Kadir
AU  - Yildirim K
AD  - Elazig Fethi Sekin City Hospital, Department of Urology, Elazig, Turkey.
FAU - Ates, Ferhat
AU  - Ates F
AD  - University of Health Sciences, Sultan Abdulhamid Han Training and Research
      Hospital, Department of Urology, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200303
PL  - England
TA  - J Pediatr Urol
JT  - Journal of pediatric urology
JID - 101233150
RN  - 0 (Central Nervous System Stimulants)
RN  - 207ZZ9QZ49 (Methylphenidate)
SB  - IM
MH  - *Attention Deficit Disorder with Hyperactivity/drug therapy
MH  - *Central Nervous System Stimulants/therapeutic use
MH  - Humans
MH  - *Methylphenidate/therapeutic use
MH  - Quality of Life
MH  - Urinary Bladder
OTO - NOTNLM
OT  - *Attention deficit hyperactivity disorder
OT  - *Bladder capacity
OT  - *Lower urinary tract
OT  - *Methylphenidate
OT  - *Voided volume
EDAT- 2020/04/12 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/12 06:00
PHST- 2019/09/16 00:00 [received]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S1477-5131(20)30049-8 [pii]
AID - 10.1016/j.jpurol.2020.02.015 [doi]
PST - ppublish
SO  - J Pediatr Urol. 2020 Jun;16(3):351.e1-351.e6. doi: 10.1016/j.jpurol.2020.02.015. 
      Epub 2020 Mar 3.


PMID- 32276834
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 5
DP  - 2020 Jun
TI  - Novel Technique in a Sheep Model of Uterine Transplantation.
PG  - 1399-1401
LID - S0041-1345(20)30310-9 [pii]
LID - 10.1016/j.transproceed.2020.02.040 [doi]
AB  - INTRODUCTION: Uterine transplantation (UTx) is a surgical therapeutic modality
      designed for the treatment of patients with exclusive uterine factor infertility.
      Experimental models are paramount to study this transplant modality, and as the
      ewes' uteri are very similar to that of humans, they are frequently used with
      this purpose. The aim of this study is to describe a novel technical variation
      for UTx in sheep. METHODS: This study was conducted at Laboratory of Medical
      Investigation 37 of the University of Sao Paulo School of Medicine in Sao Paulo, 
      Brazil, and was approved by the Ethics Committee of Animal Use of the university.
      We used 3 adult female sheep that weighed approximately 45 kg and were not
      pregnant. We performed the technique of uterine autotransplantation with a novel 
      technical variation that we called sequential vascularization: first, we
      performed the right uterine artery and vein anastomoses, after which the uterine 
      graft was vascularized, and then the contralateral vascular anastomoses were
      performed. CONCLUSION: We described 3 successful uterine autotransplants in sheep
      models with sequential vascularization. This variation technique will probably
      allow warm ischemia time in UTx to significantly decrease.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Arantes, Rubens Macedo
AU  - Arantes RM
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil. Electronic
      address: rmarantes@usp.br.
FAU - Nacif, Lucas Souto
AU  - Nacif LS
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Pinheiro, Rafael Soares
AU  - Pinheiro RS
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Rocha-Santos, Vinicius
AU  - Rocha-Santos V
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - de Martino, Rodrigo Bronze
AU  - de Martino RB
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Waisberg, Daniel Reis
AU  - Waisberg DR
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Pantanali, Carlos Andres Rodriguez
AU  - Pantanali CAR
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Fortunato, Allana
AU  - Fortunato A
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Lima, Marisa Rafaela
AU  - Lima MR
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Ducatti, Liliana
AU  - Ducatti L
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Haddad, Luciana Bertocco de Paiva
AU  - Haddad LBP
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Ejzenberg, Dani
AU  - Ejzenberg D
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Galvao, Flavio Henrique
AU  - Galvao FH
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Andraus, Wellington
AU  - Andraus W
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
FAU - Carneiro-D'Albuquerque, Luiz
AU  - Carneiro-D'Albuquerque L
AD  - Liver and Gastrointestinal Transplant Division, Department of Gastroenterology,
      University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Anastomosis, Surgical/methods
MH  - Animals
MH  - Brazil
MH  - Female
MH  - Humans
MH  - Infertility, Female/surgery
MH  - Sheep
MH  - Transplantation, Autologous
MH  - Uterine Artery/surgery
MH  - Uterus/*transplantation
EDAT- 2020/04/12 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/02/01 00:00 [received]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S0041-1345(20)30310-9 [pii]
AID - 10.1016/j.transproceed.2020.02.040 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Jun;52(5):1399-1401. doi:
      10.1016/j.transproceed.2020.02.040. Epub 2020 Apr 8.


PMID- 32276721
OWN - NLM
STAT- MEDLINE
DCOM- 20200428
LR  - 20220531
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 151
IP  - 5
DP  - 2020 May
TI  - Ethical practice during the COVID-19 pandemic.
PG  - 377-378
LID - S0002-8177(20)30225-7 [pii]
LID - 10.1016/j.adaj.2020.03.038 [doi]
CN  - Ethics Subcommittee of the Council on Ethics, Bylaws and Judicial Affairs
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - Dentistry/trends
MH  - *Ethics, Dental
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
PMC - PMC7141474
IR  - Cohen DF
FIR - Cohen, Donald F
IR  - Kurkowski MA
FIR - Kurkowski, Michael A
IR  - Wilson RJ Jr
FIR - Wilson, Robert J Jr
IR  - Jonke GJ
FIR - Jonke, Guenter J
IR  - Patel OR
FIR - Patel, Onika R
IR  - Pappas RP
FIR - Pappas, Renee P
IR  - Hall DW
FIR - Hall, Daniel W
IR  - Pandya A
FIR - Pandya, Anisha
EDAT- 2020/04/12 06:00
MHDA- 2020/04/29 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/04/29 06:00 [medline]
PHST- 2020/04/12 06:00 [entrez]
AID - S0002-8177(20)30225-7 [pii]
AID - 10.1016/j.adaj.2020.03.038 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2020 May;151(5):377-378. doi: 10.1016/j.adaj.2020.03.038. Epub
      2020 Apr 8.


PMID- 32276415
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20200430
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 7
DP  - 2020 Apr 8
TI  - Healthspan Maintenance and Prevention of Parkinson's-like Phenotypes with
      Hydroxytyrosol and Oleuropein Aglycone in C. elegans.
LID - E2588 [pii]
LID - 10.3390/ijms21072588 [doi]
AB  - Numerous studies highlighted the beneficial effects of the Mediterranean diet
      (MD) in maintaining health, especially during ageing. Even neurodegeneration,
      which is part of the natural ageing process, as well as the foundation of
      ageing-related neurodegenerative disorders like Alzheimer's and Parkinson's
      disease (PD), was successfully targeted by MD. In this regard, olive oil and its 
      polyphenolic constituents have received increasing attention in the last years.
      Thus, this study focuses on two main olive oil polyphenols, hydroxytyrosol (HT)
      and oleuropein aglycone (OLE), and their effects on ageing symptoms with special 
      attention to PD. In order to avoid long-lasting, expensive, and ethically
      controversial experiments, the established invertebrate model organism
      Caenorhabditis elegans was used to test HT and OLE treatments. Interestingly,
      both polyphenols were able to increase the survival after heat stress, but only
      HT could prolong the lifespan in unstressed conditions. Furthermore, in aged
      worms, HT and OLE caused improvements of locomotive behavior and the attenuation 
      of autofluorescence as a marker for ageing. In addition, by using three different
      C. elegans PD models, HT and OLE were shown i) to enhance locomotion in worms
      suffering from alpha-synuclein-expression in muscles or rotenone exposure, ii) to
      reduce alpha-synuclein accumulation in muscles cells, and iii) to prevent
      neurodegeneration in alpha-synuclein-containing dopaminergic neurons. Hormesis,
      antioxidative capacities and an activity-boost of the proteasome & phase II
      detoxifying enzymes are discussed as potential underlying causes for these
      beneficial effects. Further biological and medical trials are indicated to assess
      the full potential of HT and OLE and to uncover their mode of action.
FAU - Brunetti, Giovanni
AU  - Brunetti G
AD  - Department of Biomedical and Biotechnological Sciences, University of Catania,
      95125 Catania, Italy.
FAU - Di Rosa, Gabriele
AU  - Di Rosa G
AD  - Department of Biomedical and Biotechnological Sciences, University of Catania,
      95125 Catania, Italy.
FAU - Scuto, Maria
AU  - Scuto M
AUID- ORCID: 0000-0003-1019-5158
AD  - Department of Biomedical and Biotechnological Sciences, University of Catania,
      95125 Catania, Italy.
FAU - Leri, Manuela
AU  - Leri M
AD  - Department of Experimental and Clinical Biomedical Sciences "Mario Serio",
      University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
AD  - Department of Neuroscience, Psychology, Area of Medicine and Health of the Child 
      of the University of Florence, Viale Pieraccini, 6 - 50139 Florence, Italy.
FAU - Stefani, Massimo
AU  - Stefani M
AD  - Department of Experimental and Clinical Biomedical Sciences "Mario Serio",
      University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
FAU - Schmitz-Linneweber, Christian
AU  - Schmitz-Linneweber C
AD  - Humboldt University of Berlin, Faculty of Life Sciences, Institute of Biology,
      Molecular Genetics Group, Philippstr. 13, House 22, 10115 Berlin, Germany.
FAU - Calabrese, Vittorio
AU  - Calabrese V
AUID- ORCID: 0000-0002-0478-985X
AD  - Department of Biomedical and Biotechnological Sciences, University of Catania,
      95125 Catania, Italy.
FAU - Saul, Nadine
AU  - Saul N
AUID- ORCID: 0000-0002-6798-0918
AD  - Humboldt University of Berlin, Faculty of Life Sciences, Institute of Biology,
      Molecular Genetics Group, Philippstr. 13, House 22, 10115 Berlin, Germany.
LA  - eng
GR  - P40 OD010440/OD/NIH HHS/United States
GR  - No 633589 (Aging with Elegans)./Horizon 2020 Framework Programme
PT  - Journal Article
DEP - 20200408
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Acetates)
RN  - 0 (Cyclopentane Monoterpenes)
RN  - 0 (Polyphenols)
RN  - 0 (Pyrans)
RN  - 0 (alpha-Synuclein)
RN  - 0 (oleuropein aglycone)
RN  - 10597-60-1 (3,4-dihydroxyphenylethanol)
RN  - ML9LGA7468 (Phenylethyl Alcohol)
SB  - IM
MH  - Acetates/pharmacology/*therapeutic use
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Caenorhabditis elegans/drug effects
MH  - Cyclopentane Monoterpenes/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Dopaminergic Neurons/*metabolism/physiology
MH  - Parkinson Disease/*prevention & control
MH  - Phenylethyl Alcohol/*analogs & derivatives/pharmacology/therapeutic use
MH  - Polyphenols/pharmacology
MH  - Pyrans/pharmacology/*therapeutic use
MH  - Treatment Outcome
MH  - *alpha-Synuclein
PMC - PMC7178172
OTO - NOTNLM
OT  - C. elegans
OT  - Parkinson's disease
OT  - ageing
OT  - healthspan
OT  - lifespan
OT  - olive oil
OT  - polyphenols
EDAT- 2020/04/12 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/04/12 06:00
PHST- 2020/03/13 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/12 06:00 [entrez]
PHST- 2020/04/12 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
AID - ijms21072588 [pii]
AID - 10.3390/ijms21072588 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Apr 8;21(7). pii: ijms21072588. doi: 10.3390/ijms21072588.


PMID- 32276076
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1553-4669 (Electronic)
IS  - 1553-4650 (Linking)
VI  - 27
IP  - 7
DP  - 2020 Nov - Dec
TI  - Laparoscopic Cervical Encerclage in Pregnancy in 6 Steps.
PG  - 1478-1479
LID - S1553-4650(20)30138-2 [pii]
LID - 10.1016/j.jmig.2020.03.011 [doi]
AB  - STUDY OBJECTIVE: Cervical insufficiency occurs in 0.1% to 1 % of all pregnancies 
      and is associated with a high risk of second-trimester abortion and/or preterm
      delivery [1]. Laparoscopic encerclage is highly recommended for a previous failed
      vaginal encerclage and is superior to the laparotomy approach in terms of low
      morbidity and faster recovery [2]. Laparoscopic encerclage in pregnancy is more
      challenging than that in the nonpregnant state. This is because of the enlarged
      uterine size, engorged uterine vessels, and infeasibility of using a uterine
      manipulator. The standardization and description of the technique are the main
      objectives of this video (Video 1). We have described the surgery in 6 steps that
      could make this procedure easier and safer. DESIGN: A step-by-step video
      demonstration of the technique. SETTING: Paul's Hospital, Centre for Advanced
      Endoscopy & Infertility Treatment, Kochi, India. A 29-year-old pregnant woman,
      gravida 3 abortions 2, at 13 weeks period of gestation, with a history of 2
      second-trimester abortions owing to cervical insufficiency. The patient had a
      failed vaginal cervical encerclage at 18 weeks in the second pregnancy.
      INTERVENTIONS: This is a step-wise laparoscopic approach for successful cervical 
      encerclage in pregnancy. In this video, we demonstrate our technique for
      laparoscopic cervical encerclage in a pregnant woman's uterus in 6 steps using a 
      Mersilene tape (Ethicon US, LLC, Somerville, NJ) as follows: (1) Opening the
      uterovesical fold and dissecting the bladder, (2) opening the left broad ligament
      and creating a window, (3) opening the right broad ligament and creating a
      window, (4) placing the Mersilene tape on the left side medial to the uterine
      vessels at the cervicoisthmic junction, (5) placing the Mersilene tape on the
      right side medial to the uterine vessels at the cervicoisthmic junction, (6)
      tying the Mersilene tape anteriorly. CONCLUSION: The standardization of
      laparoscopic cervical encerclage in pregnancy using the above 6 steps could make 
      this procedure easier and safer to perform. Moreover, the standardization of the 
      surgical technique could shorten the learning curve.
CI  - Copyright (c) 2020 AAGL. Published by Elsevier Inc. All rights reserved.
FAU - Paul, P G
AU  - Paul PG
AD  - Department of Endoscopy, Paul's Hospital, Centre for Advanced Endoscopy &
      Infertility, Kochi, Kerala, India. Electronic address: drpaulpg@gmail.com.
FAU - Saherwala, Tasneem
AU  - Saherwala T
AD  - Department of Endoscopy, Paul's Hospital, Centre for Advanced Endoscopy &
      Infertility, Kochi, Kerala, India.
FAU - Barma, Poulami
AU  - Barma P
AD  - Department of Endoscopy, Paul's Hospital, Centre for Advanced Endoscopy &
      Infertility, Kochi, Kerala, India.
FAU - Paul, George
AU  - Paul G
AD  - Department of Endoscopy, Paul's Hospital, Centre for Advanced Endoscopy &
      Infertility, Kochi, Kerala, India.
FAU - Thakur, Sanghamitra
AU  - Thakur S
AD  - Department of Endoscopy, Paul's Hospital, Centre for Advanced Endoscopy &
      Infertility, Kochi, Kerala, India.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20200408
PL  - United States
TA  - J Minim Invasive Gynecol
JT  - Journal of minimally invasive gynecology
JID - 101235322
RN  - Uterine Anomalies
SB  - IM
MH  - Abortion, Habitual/therapy
MH  - Abortion, Spontaneous/prevention & control
MH  - Adult
MH  - Broad Ligament/surgery
MH  - Cerclage, Cervical/*methods
MH  - Female
MH  - Humans
MH  - India
MH  - Laparoscopy/*methods
MH  - Pregnancy
MH  - Urogenital Abnormalities/complications/surgery
MH  - Uterine Cervical Incompetence/etiology/*surgery
MH  - Uterus/abnormalities/surgery
OTO - NOTNLM
OT  - *Cervical insufficiency
OT  - *Laparoscopy in pregnancy
OT  - *Mersilene tape
EDAT- 2020/04/11 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - S1553-4650(20)30138-2 [pii]
AID - 10.1016/j.jmig.2020.03.011 [doi]
PST - ppublish
SO  - J Minim Invasive Gynecol. 2020 Nov - Dec;27(7):1478-1479. doi:
      10.1016/j.jmig.2020.03.011. Epub 2020 Apr 8.


PMID- 32275849
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Apr
TI  - Promoting Oncologist Well-Being to Foster Delivery of Ethical, High-Quality
      Cancer Care: Priorities for 2020 and Beyond.
PG  - 188-190
LID - 10.1200/OP.20.00069 [doi]
FAU - Shanafelt, Tait D
AU  - Shanafelt TD
AD  - Stanford Medicine, Stanford University, Stanford, CA.
FAU - Kamal, Arif H
AU  - Kamal AH
AD  - Duke Cancer Institute and Duke Fuqua School of Business, Durham, NC.
FAU - Hlubocky, Fay J
AU  - Hlubocky FJ
AD  - The University of Chicago Medicine, Department of Medicine, Section of
      Hematology/Oncology, MacLean Center for Clinical Medical Ethics, Cancer Research 
      Center, Supportive Oncology Program, Chicago, IL.
LA  - eng
PT  - Editorial
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
SB  - IM
MH  - Humans
MH  - *Neoplasms/therapy
MH  - *Oncologists
MH  - Quality of Health Care/ethics
EDAT- 2020/04/11 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
AID - 10.1200/OP.20.00069 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2020 Apr;16(4):188-190. doi: 10.1200/OP.20.00069.


PMID- 32275805
OWN - NLM
STAT- MEDLINE
DCOM- 20200526
LR  - 20201218
IS  - 1742-6723 (Electronic)
IS  - 1742-6723 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Jun
TI  - Clinical and ethical challenges for emergency departments during communicable
      disease outbreaks: Can lessons from Ebola Virus Disease be applied to the
      COVID-19 pandemic?
PG  - 520-524
LID - 10.1111/1742-6723.13514 [doi]
AB  - EDs fulfil a frontline function during public health emergencies (PHEs) and will 
      play a pivotal role during the COVID-19 pandemic. This perspective article draws 
      on qualitative data from a longitudinal, ethnographic study of an Australian
      tertiary ED to illustrate the clinical and ethical challenges faced by EDs during
      PHEs. Interview data collected during the 2014 Ebola Virus Disease PHE of
      International Concern suggest that ED clinicians have a strong sense of
      professional responsibility, but this can be compromised by increased visibility 
      of risk and sub-optimal engagement from hospital managers and public health
      authorities. The study exposes the tension between a healthcare worker's right to
      protection and a duty to provide treatment. Given the narrow window of
      opportunity to prepare for a surge of COVID-19 presentations, there is an
      immediate need to reflect and learn from previous experiences. To maintain the
      confidence of ED clinicians, and minimise the risk of moral injury, hospital and 
      public health authorities must urgently develop processes to support ethical
      healthcare delivery and ensure adequate resourcing of EDs.
CI  - (c) 2020 Australasian College for Emergency Medicine.
FAU - Markwell, Alexandra
AU  - Markwell A
AD  - Emergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane,
      Queensland, Australia.
AD  - Clinical Senate, Queensland Health, Brisbane, Queensland, Australia.
AD  - School of Medicine, The University of Queensland, Brisbane, Queensland,
      Australia.
FAU - Mitchell, Rob
AU  - Mitchell R
AUID- ORCID: 0000-0002-6422-3348
AD  - Emergency and Trauma Centre, Alfred Hospital, Melbourne, Victoria, Australia.
AD  - School of Public Health and Preventive Medicine, Monash University, Melbourne,
      Victoria, Australia.
FAU - Wright, April L
AU  - Wright AL
AD  - Business School, The University of Queensland, Brisbane, Queensland, Australia.
FAU - Brown, Anthony Ft
AU  - Brown AF
AD  - Emergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane,
      Queensland, Australia.
AD  - School of Medicine, The University of Queensland, Brisbane, Queensland,
      Australia.
LA  - eng
GR  - Linkage project grant LP0989662/Australian Research Council/International
PT  - Journal Article
DEP - 20200505
PL  - Australia
TA  - Emerg Med Australas
JT  - Emergency medicine Australasia : EMA
JID - 101199824
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus/isolation & purification
MH  - Coronavirus Infections/*diagnosis/epidemiology/therapy
MH  - Decision Making
MH  - Disease Outbreaks/*ethics/prevention & control
MH  - Emergency Medical Services
MH  - Emergency Medicine/*ethics
MH  - Emergency Service, Hospital/*ethics
MH  - Hemorrhagic Fever, Ebola/epidemiology
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/diagnosis/*epidemiology/therapy
MH  - Public Health
MH  - SARS-CoV-2
MH  - Ventilators, Mechanical/*ethics/statistics & numerical data
PMC - PMC7262026
OTO - NOTNLM
OT  - *COVID-19
OT  - *Ebola
OT  - *public health
EDAT- 2020/04/11 06:00
MHDA- 2020/05/27 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/05/27 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - 10.1111/1742-6723.13514 [doi]
PST - ppublish
SO  - Emerg Med Australas. 2020 Jun;32(3):520-524. doi: 10.1111/1742-6723.13514. Epub
      2020 May 5.


PMID- 32275263
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Linking)
VI  - 91
IP  - 3-S
DP  - 2020 Apr 10
TI  - New competences to manage urban health: Health City Manager core curriculum.
PG  - 21-28
LID - 10.23750/abm.v91i3-S.9430 [doi]
AB  - A core curriculum is an essential step in development knowledge, competences and 
      abilities and it defines educational content for the specialized area of practice
      in such a way that it can be delivered to new professional job. The Health City
      Manager core curriculum defines the strategic aspects of action to improve health
      in cities through a holistic approach, with regard to the individual, and a
      multi-sectoral approach, with regard to health promotion policies within the
      urban context. The Health City Manager core curriculum recognizes that the
      concept of health is an essential element for the well-being of a society, and
      this concept does not merely refer to physical survival or to the absence of
      disease, but includes psychological aspects, natural, environmental, climatic and
      housing conditions, working, economic, social and cultural life - as defined by
      the World Health Organization (WHO). The Health City Manager core curriculum
      considers health not as an "individual good" but as a "common good" that calls
      all citizens to ethics and to the observance of the rules of civil coexistence,
      to virtuous behaviours based on mutual respect. The common good is therefore an
      objective to be pursued by both citizens and mayors and local administrators who 
      must act as guarantors of equitable health ensuring, that the health of the
      community is considered as an investment and not just as a cost. The role of
      cities in health promotion in the coming decades will be magnified by the
      phenomenon of urbanization with a concentration of 70% of the global population
      on its territory.
FAU - Lenzi, Andrea
AU  - Lenzi A
AD  - University of Rome La Sapienza, Dept Experimental Medicine.
      andrea.lenzi@uniroma1.it.
FAU - Capolongo, Stefano
AU  - Capolongo S
AD  - Department of Architecture, Built environment and Construction engineering (ABC) 
      - Politecnico di Milano. stefano.capolongo@polimi.it.
FAU - Ricciardi, Gualtiero
AU  - Ricciardi G
AD  - Universita Cattolica del Sacro Cuore in Rome. Walter.Ricciardi@unicatt.it.
FAU - Signorelli, Carlo
AU  - Signorelli C
AD  - Universita Vita-Salute San Raffaele in Milan. signorelli.carlo@hsr.it.
FAU - Napier, David
AU  - Napier D
AD  - University College of London. d.napier@ucl.ac.uk.
FAU - Rebecchi, Andrea
AU  - Rebecchi A
AD  - Department of Architecture, Built environment and Construction engineering (ABC) 
      - Politecnico di Milano. andrea.rebecchi@polimi.it.
FAU - Spinato, Chiara
AU  - Spinato C
AD  - Array. chiara.spinato@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200410
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
SB  - IM
MH  - Cities
MH  - *Curriculum
MH  - Humans
MH  - *Public Health
MH  - Urban Health/*education
PMC - PMC7975917
EDAT- 2020/04/11 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - 10.23750/abm.v91i3-S.9430 [doi]
PST - epublish
SO  - Acta Biomed. 2020 Apr 10;91(3-S):21-28. doi: 10.23750/abm.v91i3-S.9430.


PMID- 32274626
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 34
IP  - 7
DP  - 2020 Jul
TI  - Could fluorescence-guided surgery be an efficient and sustainable option? A SICE 
      (Italian Society of Endoscopic Surgery) health technology assessment summary.
PG  - 3270-3284
LID - 10.1007/s00464-020-07542-3 [doi]
AB  - BACKGROUND: Indocyanine green fluorescence vision is an upcoming technology in
      surgery. It can be used in three ways: angiographic and biliary tree
      visualization and lymphatic spreading studies. The present paper shows the most
      outstanding results from an health technology assessment study design, conducted 
      on fluorescence-guided compared with standard vision surgery. METHODS: A health
      technology assessment approach was implemented to investigate the economic,
      social, ethical, and organizational implications related to the adoption of the
      innovative fluorescence-guided view, with a focus on minimally invasive approach.
      With the support of a multidisciplinary team, qualitative and quantitative data
      were collected, by means of literature evidence, validated questionnaires and
      self-reported interviews, considering the dimensions resulting from the EUnetHTA 
      Core Model. RESULTS: From a systematic search of literature, we retrieved the
      following studies: 6 on hepatic, 1 on pancreatic, 4 on biliary, 2 on bariatric, 4
      on endocrine, 2 on thoracic, 11 on colorectal, 7 on urology, 11 on gynecology, 2 
      on gastric surgery. Fluorescence guide has shown advantages on the length of
      hospitalization particularly in colorectal surgery, with a reduction of the rate 
      of leakages and re-do anastomoses, in spite of a slight increase in operating
      time, and is confirmed to be a safe, efficacious, and sustainable vision
      technology. Clinical applications are still presenting a low evidence in the
      literature. CONCLUSION: The present paper, under the patronage of Italian Society
      of Endoscopic Surgery, based on an HTA approach, sustains the use of
      fluorescence-guided vision in minimally invasive surgery, in the fields of
      general, gynecologic, urologic, and thoracic surgery, as an efficient and
      economically sustainable technology.
FAU - Vettoretto, N
AU  - Vettoretto N
AD  - Chirurgia Montichiari, Azienda Socio Sanitaria Territoriale Degli Spedali Civili,
      V.le Ciotti 154, Montichiari, 25018, Brescia, Italy. nereovet@gmail.com.
FAU - Foglia, E
AU  - Foglia E
AD  - LIUC - Universita Cattaneo, Castellanza, VA, Italy.
FAU - Ferrario, L
AU  - Ferrario L
AD  - LIUC - Universita Cattaneo, Castellanza, VA, Italy.
FAU - Gerardi, C
AU  - Gerardi C
AD  - Centro di Politiche Regolatorie, Istituto di Ricerche Farmacologiche "Mario
      Negri" IRCCS, Milan, Italy.
FAU - Molteni, B
AU  - Molteni B
AD  - Department of Clinical and Experimental Surgery, University of Brescia, Brescia, 
      Italy.
FAU - Nocco, U
AU  - Nocco U
AD  - Ingegneria Clinica, Azienda Socio Sanitaria Territoriale dei Sette Laghi, Varese,
      Italy.
FAU - Lettieri, E
AU  - Lettieri E
AD  - School of Management, Department of Management, Economics and Industrial
      Engineering, Politecnico, Milano, Italy.
FAU - Molfino, S
AU  - Molfino S
AD  - Department of Clinical and Experimental Surgery, University of Brescia, Brescia, 
      Italy.
FAU - Baiocchi, G L
AU  - Baiocchi GL
AD  - Department of Clinical and Experimental Surgery, University of Brescia, Brescia, 
      Italy.
FAU - Elmore, U
AU  - Elmore U
AD  - Department of Gastrointestinal Surgery, IRCCS San Raffaele Scientific Institute, 
      Vita-Salute San Raffaele University, Milan, Italy.
FAU - Rosati, R
AU  - Rosati R
AD  - Department of Gastrointestinal Surgery, IRCCS San Raffaele Scientific Institute, 
      Vita-Salute San Raffaele University, Milan, Italy.
FAU - Curro, G
AU  - Curro G
AD  - Department of Human Pathology of Adult and Evolutive Age, University Hospital of 
      Messina, Messina, Italy.
FAU - Cassinotti, E
AU  - Cassinotti E
AD  - Chirurgia Generale, Fondazione IRCCS - Ca' Granda - Ospedale Maggiore Policlinico
      - University of Milan, Milan, Italy.
FAU - Boni, L
AU  - Boni L
AD  - Chirurgia Generale, Fondazione IRCCS - Ca' Granda - Ospedale Maggiore Policlinico
      - University of Milan, Milan, Italy.
FAU - Cirocchi, R
AU  - Cirocchi R
AD  - Department of Surgical Sciences, University of Perugia, Perugia, Italy.
FAU - Marano, A
AU  - Marano A
AD  - Chirurgia Generale ed Oncologica, Azienda Ospedaliera S. Croce e Carle, Cuneo,
      Italy.
FAU - Petz, W L
AU  - Petz WL
AD  - Chirurgia, IEO, European Institute of Oncology IRCCS, Milan, Italy.
FAU - Arezzo, A
AU  - Arezzo A
AD  - Department of Surgical Sciences, University of Torino, Turin, Italy.
FAU - Bonino, M A
AU  - Bonino MA
AD  - Department of Surgical Sciences, University of Torino, Turin, Italy.
FAU - Davini, F
AU  - Davini F
AD  - Centro multidisciplinare Chirurgia Robotica, Chirurgia Toracica mini-invasiva e
      Robotica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
FAU - Biondi, A
AU  - Biondi A
AD  - Chirurgia Generale, Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, 
      Italy.
FAU - Anania, G
AU  - Anania G
AD  - Chirurgia Generale, University of Ferrara, Ferrara, Italy.
FAU - Agresta, F
AU  - Agresta F
AD  - Chirurgia Generale, Azienda ULSS 5 "Polesana", Hospital of Adria, Adria, RO,
      Italy.
FAU - Silecchia, G
AU  - Silecchia G
AD  - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome-Polo Pontino, Rome, Italy.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
RN  - IX6J1063HV (Indocyanine Green)
SB  - IM
MH  - *Efficiency, Organizational
MH  - Endoscopy/*methods
MH  - *Fluorescence
MH  - Humans
MH  - *Indocyanine Green
MH  - Italy
MH  - Operative Time
MH  - Qualitative Research
MH  - Societies, Medical
MH  - Surgery, Computer-Assisted/*methods
MH  - *Sustainable Development
MH  - Systematic Reviews as Topic
MH  - Technology Assessment, Biomedical
OTO - NOTNLM
OT  - *Fluorescence
OT  - *Indocyanine green
OT  - *Laparoscopy
OT  - *Surgery
EDAT- 2020/04/11 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - 10.1007/s00464-020-07542-3 [doi]
AID - 10.1007/s00464-020-07542-3 [pii]
PST - ppublish
SO  - Surg Endosc. 2020 Jul;34(7):3270-3284. doi: 10.1007/s00464-020-07542-3.


PMID- 32274371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2288-7970 (Print)
IS  - 2288-7970 (Linking)
VI  - 36
IP  - 1
DP  - 2020 Mar 31
TI  - Ethics of Live Surgery Demonstration or Broadcast: Is It Beneficial to the
      Patients?
PG  - 4-6
LID - 10.5758/vsi.2020.36.1.4 [doi]
FAU - Min, Seung-Kee
AU  - Min SK
AUID- ORCID: https://orcid.org/0000-0002-1433-2562
AD  - Division of Vascular Surgery, Department of Surgery, Seoul National University
      College of Medicine, Seoul, Korea.
LA  - eng
PT  - Editorial
PL  - Korea (South)
TA  - Vasc Specialist Int
JT  - Vascular specialist international
JID - 101633116
PMC - PMC7119144
COIS- CONFLICTS OF INTEREST Seung-Kee Min has been the editor-in-chief of Vasc
      Specialist Int since 2019.
EDAT- 2020/04/11 06:00
MHDA- 2020/04/11 06:01
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/04/11 06:01 [medline]
AID - 10.5758/vsi.2020.36.1.4 [doi]
AID - VSI-36-004 [pii]
PST - ppublish
SO  - Vasc Specialist Int. 2020 Mar 31;36(1):4-6. doi: 10.5758/vsi.2020.36.1.4.


PMID- 32274120
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220817
IS  - 2072-1439 (Print)
IS  - 2072-1439 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar
TI  - Detection of plasma T790M mutation after the first generation EGFR-TKI resistance
      of non-small cell lung cancer in the real world.
PG  - 550-557
LID - 10.21037/jtd.2019.12.122 [doi]
AB  - BACKGROUND: The epidermal growth factor receptor (EGFR) gene has been identified 
      as the driving gene of non-small cell lung cancer (NSCLC), and EGFR-tyrosine
      kinase inhibitor (TKI) has shown efficacy, but acquired resistance is inevitable.
      It has been confirmed that the secondary EGFR Thr790Met (T790M) mutation accounts
      for about 50% of the mechanisms of acquired resistance to EGFR-TKI. The
      third-generation of EGFR-TKI has significantly efficacy in advanced
      T790M-positive NSCLC patients. Therefore, it is necessary to detect the status of
      T790M in patients with acquired resistance after first generation EGFR-TKI. The
      objective of this study was to investigate the positive rate of plasma test T790M
      mutation and its relationship with different clinical characteristics, and the
      frequency of T790M mutation in advanced EGFR-mutant NSCLC patients with acquired 
      resistance after firstline EGFR-TKI treatment. METHODS: Patients from a single
      clinical center (Taizhou hospital) were recruited prospectively from September
      2017 to June 2018. The eligibility criteria of the trial included the following: 
      (I) aged 18 years or older, histologically confirmed NSCLC stage IIIB/st and EGFR
      mutation positive; (II) progressive disease (PD) after first generation EGFR-TKI 
      by RECIST v1.1, with PFS>3 months; (III) no third generation TKI treatment. All
      patients signed informed consent, had 10 mL of blood drawn, and were evaluated
      for the presence of T790M gene by amplification refractory mutation system
      (ARMS). The study was approved by the Ethics Committee of Taizhou Hospital
      (ethical batch number: 201637). RESULTS: A total of 189 patients were included in
      the analysis. The overall T790M mutation rate of plasma detection was 36.51%
      (69/189). The positive rate of T790M mutation after the failure of first
      generation EGFR-TKI treatment was not correlated with the patient's age, sex, and
      the type of first generation TKI drugs. However, it was related to the mutation
      type of EGFR in baseline and the mode of progression according to reports by Wu
      et al. The frequency of T790M mutation among patients with initial exon 19
      deletion mutation, exon 21 L858R point mutation, and other mutations were 45.45%,
      26.19% and 33.33%, respectively. The mutation rate of T790M in 19del mutant
      patients was higher than that of L858R mutation and other mutations (P=0.026).
      The frequency of T790M mutation in local progression patients was 50% after the
      first generation TKI was resistant to drug treatment: in gradual progression it
      was 26.92%, and in dramatic progression it was 38.10%. The frequency of T790M
      mutation of patients with local progression was significantly higher (P=0.031).
      CONCLUSIONS: The patients with EGFR mutations after the first generation of
      EGFR-TKI-acquired resistance of NSCLC were evaluated for their plasma EGFR
      mutation status, and the overall T790M mutation rate of was 36.51%. The frequency
      of T790M mutation with initial mutation of 19 del was higher than that of L858R
      mutation and other mutations, and local progression was higher than that in
      patients with gradual progression and dramatic progression.
CI  - 2020 Journal of Thoracic Disease. All rights reserved.
FAU - Li, Haiyan
AU  - Li H
AD  - Pulmonary Medicine, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou
      Medical University, Taizhou 317000, China.
FAU - Wang, Jinwei
AU  - Wang J
AD  - Functional Inspection Section, Affiliated Taizhou Hospital of Zhejiang Province
      of Wenzhou Medical University, Taizhou 317000, China.
FAU - Zhang, Guojing
AU  - Zhang G
AD  - Oncology Department, Wenzhou Geriatric Hospital, Wenzhou 325600, China.
FAU - Li, Yuping
AU  - Li Y
AD  - Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou 325000, China.
FAU - Lin, Ling
AU  - Lin L
AD  - Pulmonary Medicine, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou
      Medical University, Taizhou 317000, China.
FAU - Yang, Haihua
AU  - Yang H
AD  - Radiation Oncology, Laboratory of Cellular and Molecular Radiation Oncology,
      Radiation Oncology Institute of Enze Medical Health Academy, Affiliated Taizhou
      Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou 317000,
      China.
FAU - Zhou, Jingjing
AU  - Zhou J
AD  - Pathology Department, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou
      Medical University, Taizhou 317000, China.
FAU - Zhang, Lingna
AU  - Zhang L
AD  - Pathology Department, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou
      Medical University, Taizhou 317000, China.
FAU - Lv, Dongqing
AU  - Lv D
AD  - Pulmonary Medicine, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou
      Medical University, Taizhou 317000, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC7138969
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - T790M
OT  - cell-free DNA (cfDNA)
OT  - epidermal growth factor receptor (EGFR)
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/04/11 06:00
MHDA- 2020/04/11 06:01
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/04/11 06:01 [medline]
AID - 10.21037/jtd.2019.12.122 [doi]
AID - jtd-12-03-550 [pii]
PST - ppublish
SO  - J Thorac Dis. 2020 Mar;12(3):550-557. doi: 10.21037/jtd.2019.12.122.


PMID- 32273787
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1179-7258 (Print)
IS  - 1179-7258 (Linking)
VI  - 11
DP  - 2020
TI  - Using High-Fidelity Simulation to Teach Ethics Related Non-Technical Skills:
      Description of an Innovative Model.
PG  - 247-251
LID - 10.2147/AMEP.S247207 [doi]
AB  - This article describes a high-fidelity (Hi-Fi) simulation-based innovative
      educational strategy intended to introduce anesthesiology residents to key
      ethical considerations and how they apply to their practice. Three Hi-Fi
      simulation scenarios involving situations with various ethical issues are
      described with their debriefing objectives and the trainees' subjective feedback.
      Three high-fidelity simulation scenarios are described: (a) teaching critical
      incident disclosure, (b) disclosing and discussing patient awareness during
      general anesthesia, and (c) would physicians override a do-not-resuscitate (DNR) 
      order if the cause of a cardiac arrest is iatrogenic? We used Hi-Fi simulation in
      an innovative way to teach these principles of ethics. Simulation, through
      carefully crafted debriefing, can contribute to the acquisition of essential
      non-technical ethical skills. How best to integrate simulation in an existent
      ethics curriculum and how it compares with more traditional teaching methods are 
      questions that need to be addressed.
CI  - (c) 2020 Tanoubi et al.
FAU - Tanoubi, Issam
AU  - Tanoubi I
AUID- ORCID: 0000-0002-6123-0956
AD  - Department of Anesthesiology, Centre d'apprentissage des Attitudes et Habiletes
      Cliniques (CAAHC), Universite de Montreal, Faculty of Medicine, Montreal, Quebec,
      Canada.
FAU - Georgescu, L Mihai
AU  - Georgescu LM
AD  - Department of Anesthesiology, Centre d'apprentissage des Attitudes et Habiletes
      Cliniques (CAAHC), Universite de Montreal, Faculty of Medicine, Montreal, Quebec,
      Canada.
FAU - Robitaille, Arnaud
AU  - Robitaille A
AD  - Department of Anesthesiology, Centre d'apprentissage des Attitudes et Habiletes
      Cliniques (CAAHC), Universite de Montreal, Faculty of Medicine, Montreal, Quebec,
      Canada.
FAU - Drolet, Pierre
AU  - Drolet P
AD  - Department of Anesthesiology, Centre d'apprentissage des Attitudes et Habiletes
      Cliniques (CAAHC), Universite de Montreal, Faculty of Medicine, Montreal, Quebec,
      Canada.
FAU - Perron, Roger
AU  - Perron R
AD  - Department of Anesthesiology, Centre d'apprentissage des Attitudes et Habiletes
      Cliniques (CAAHC), Universite de Montreal, Faculty of Medicine, Montreal, Quebec,
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - New Zealand
TA  - Adv Med Educ Pract
JT  - Advances in medical education and practice
JID - 101562700
PMC - PMC7105365
OTO - NOTNLM
OT  - debriefing
OT  - ethic scenario
OT  - ethics principles education
OT  - high-fidelity simulation
COIS- None of the authors have any competing interests in this work.
EDAT- 2020/04/11 06:00
MHDA- 2020/04/11 06:01
CRDT- 2020/04/11 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/04/11 06:01 [medline]
AID - 10.2147/AMEP.S247207 [doi]
AID - 247207 [pii]
PST - epublish
SO  - Adv Med Educ Pract. 2020 Mar 26;11:247-251. doi: 10.2147/AMEP.S247207.
      eCollection 2020.


PMID- 32273322
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 8
TI  - Short-term PsychoEducation for Carers To Reduce Over Medication of people with
      intellectual disabilities (SPECTROM): study protocol.
PG  - e037912
LID - 10.1136/bmjopen-2020-037912 [doi]
AB  - INTRODUCTION: Psychotropic medications that are primarily licenced for the
      treatment of psychiatric disorders are used widely (32%-85%) among people with
      intellectual disabilities (ID) often for the management of problem (challenging) 
      behaviour in the absence of a psychiatric disorder. Care staff play a pivotal
      role in the prescribing process. Currently, no staff training programme exists to
      address the issue of overprescribing of psychotropic medication in people with
      ID, thus highlighting an urgent need for developing a psychoeducational programme
      (PEP) specifically designed to address this issue. We propose to develop a PEP
      for care staff using the methodology described in the UK Medical Research Council
      guide for complex interventions. METHODS AND ANALYSIS: The development of the PEP
      will involve (1) gathering information on available relevant training programmes,
      (2) running four focus groups with care staff and other professionals to
      establish the content and format of the PEP, and (3) organising a co-design event
      involving all relevant stakeholders to discuss the format of the PEP. A core
      project team will develop the PEP under guidance from the PEP Development Group
      which will consist of 10-12 relevant stakeholder representatives. Feedback from
      selected stakeholders on a draft PEP will allow us to refine the PEP before
      implementation. The PEP will have web-based modules supplemented by face to face 
      training sessions. When the final draft is ready, we will field test the PEP on
      six to eight care staff from community care homes for people with ID. After
      completing the field test, we will run a focus group involving participants in
      the PEP to get feedback on the PEP. ETHICS AND DISSEMINATION: Ethics approval for
      this study was waived by the UK Health Regulatory Authority as the study does not
      collect any patient related information and only include care staff outside the
      UK NHS. This will be the first ever such universally freely available PEP
      supported by training manual and slides.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Deb, Shoumitro
AU  - Deb S
AUID- ORCID: 0000-0002-1300-8103
AD  - Division of Psychiatry, Faculty of Medicine, Department of Brain Sciences,
      Imperial College London, London, UK s.deb@imperial.ac.uk.
FAU - Limbu, Bharati
AU  - Limbu B
AD  - Division of Psychiatry, Faculty of Medicine, Department of Brain Sciences,
      Imperial College London, London, UK.
FAU - Crawford, Mike
AU  - Crawford M
AD  - Division of Psychiatry, Faculty of Medicine, Department of Brain Sciences,
      Imperial College London, London, UK.
FAU - Weaver, Tim
AU  - Weaver T
AD  - Department of Mental Health Research, School of Health and Education, Middlesex
      University, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200408
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Caregivers/*education
MH  - Humans
MH  - *Intellectual Disability
MH  - Prescription Drug Overuse/*prevention & control
MH  - Program Development
MH  - Psychotropic Drugs/*administration & dosage
PMC - PMC7245413
OTO - NOTNLM
OT  - *clinical pharmacology
OT  - *psychiatry
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/04/11 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2020-037912 [pii]
AID - 10.1136/bmjopen-2020-037912 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 8;10(4):e037912. doi: 10.1136/bmjopen-2020-037912.


PMID- 32273320
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 8
TI  - Knowledge mobilisation in bridging community-practice-academia-policy through
      meaningful engagement: systematic integrative review protocol focusing on studies
      conducted on health and wellness among immigrant communities.
PG  - e036081
LID - 10.1136/bmjopen-2019-036081 [doi]
AB  - INTRODUCTION: Though the importance of knowledge mobilisation has been
      established globally in health and wellness research, a certain degree of
      ambiguity remains regarding the meaning and extent of knowledge mobilisation
      activities and how they have been implemented. In this study, we aim to explore
      the different descriptions of knowledge mobilisation and the diverse ways
      mobilisation activities have been realised by different researchers working for
      the betterment of health and wellness of immigrant communities in their host
      countries. METHODS AND ANALYSIS: We aimed to conduct an integrative review to
      organise the available literature describing knowledge mobilisation pertaining to
      health and wellness in immigrant communities. We will employ a comprehensive
      search, using appropriate search-terms, to identify relevant literature and will 
      qualitatively synthesise the information toward fulfilling our objectives.
      Specific methodological and analytical frameworks related to the integrative
      review process will guide each step of the process. A librarian designed the
      systematic search of the academic and grey literature from database inception to 
      December 2019. The databases include MEDLINE (Ovid), Embase, PsycINFO, PubMed,
      CINAHL and SocINDEX. For grey literature, we will conduct searches in AHS Insite,
      Google, Google Scholar, OAISter and government websites. A two-stage
      (title-abstract and full-text) screening will be conducted, including
      single-citation tracking and hand search of reference lists. ETHICS AND
      DISSEMINATION: Ethical approval is not required for this review. We first plan to
      disseminate the results of our systematic review protocol through meetings with
      key stakeholders, followed by appropriate publications and presentations at
      applicable platforms. We also have opted for an integrated knowledge translation 
      or community-engaged knowledge mobilisation approach where we have engaged with
      community-based citizen researchers from the inception of our research.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Turin, Tanvir C
AU  - Turin TC
AUID- ORCID: 0000-0002-7499-5050
AD  - Department of Family Medicine, Cumming School of Medicine, Universit of Calgary, 
      Calgary, Alberta, Canada turin.chowdhury@ucalgary.ca.
AD  - Department of Community Health Sciences, Cumming School of Medicine, Universit of
      Calgary, Calgary, Albert, Canada.
FAU - Chowdhury, Nashit
AU  - Chowdhury N
AD  - Department of Family Medicine, Cumming School of Medicine, Universit of Calgary, 
      Calgary, Alberta, Canada.
FAU - Vaska, Marcus
AU  - Vaska M
AD  - Knowledge Resource Service, Alberta Health Services, Calgary, Alberta, Canada.
FAU - Rumana, Nahid
AU  - Rumana N
AD  - Sleep Center, Fotthills Medical Center, University of Calgary, Calgary, Alberta, 
      Canada.
FAU - Lasker, Mohammad Ali Ashraf
AU  - Lasker MAA
AD  - Community Based Citizen Researcher, Calgary, Alberta, Canada.
FAU - Chowdhury, Mohammad Ziaul Islam
AU  - Chowdhury MZI
AUID- ORCID: 0000-0002-5397-2773
AD  - Department of Community Health Sciences, Cumming School of Medicine, Universit of
      Calgary, Calgary, Albert, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Community Health Services
MH  - *Emigrants and Immigrants
MH  - *Health Status
MH  - Humans
MH  - Organizations
MH  - Policy
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - *Translational Research, Biomedical
PMC - PMC7245397
OTO - NOTNLM
OT  - *primary care
OT  - *public health
OT  - *statistics & research methods
COIS- Competing interests: None declared.
EDAT- 2020/04/11 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036081 [pii]
AID - 10.1136/bmjopen-2019-036081 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 8;10(4):e036081. doi: 10.1136/bmjopen-2019-036081.


PMID- 32273317
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 8
TI  - Community-based weight loss programme targeting overweight Chinese adults with
      pre-diabetes: study protocol of a randomised controlled trial.
PG  - e035196
LID - 10.1136/bmjopen-2019-035196 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is one of the world's fastest
      growing health problems. Asians have a strong ethnic predisposition for T2DM,
      developing T2DM at a lower degree of obesity and at younger ages than other
      ethnic groups. T2DM has a gradual onset, with most individuals progressing
      through a pre-diabetic state, providing an opportunity to prevent T2DM and its
      complications. This study aims to evaluate the effectiveness of a community-based
      lifestyle intervention programme on weight loss and improvements in insulin
      sensitivity and cardiometabolic profiles in Chinese adults with pre-diabetes.
      METHODS AND ANALYSIS: This study is a 12-month, assessor-blinded randomised
      controlled trial. Adults with pre-diabetes (aged 40-64 years, n=180) with
      pre-diabetes are randomised into either an intervention group (receiving
      group-based lifestyle interventions) or a control group (receiving text messages 
      containing health information). The intervention programme targets a weight loss 
      of 5% during the first 6 months by restricting caloric intake and increasing
      physical activity. Participants in the intervention group will attend six group
      sessions and two individual face-to-face diet counselling sessions during the
      first 6 months, followed by monthly telephone support during the 6-month
      maintenance phase. Participants in the control group will receive monthly text
      messages containing general health information only. The primary outcome is
      weight loss (%). Secondary outcomes include insulin sensitivity (assessed using
      fasting insulin level and homeostatic model assessment of insulin resistance),
      glycaemic control (assessed using glycated haemoglobin level), lipid profile,
      blood pressure, carotid artery thickness, dietary intake and level of physical
      activity. Intention-to-treat analysis will be conducted using a generalised
      linear mixed effects model with a logit link and linear mixed models. ETHICS AND 
      DISSEMINATION: This study has been approved by the relevant research ethics
      committee. The results will be disseminated through peer-reviewed journals and
      scientific presentations. TRIAL REGISTRATION NUMBER: NCT03609697.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Ho, Mandy
AU  - Ho M
AUID- ORCID: 0000-0002-4460-7969
AD  - School of Nursing, University of Hong Kong Li Ka Shing Faculty of Medicine,
      Pokfulam, Hong Kong mandyho1@hku.hk.
FAU - Chau, Pui Hing
AU  - Chau PH
AD  - School of Nursing, University of Hong Kong Li Ka Shing Faculty of Medicine,
      Pokfulam, Hong Kong.
FAU - Yu, Esther Yee Tak
AU  - Yu EYT
AD  - Department of Family Medicine and Primary Care, University of Hong Kong Li Ka
      Shing Faculty of Medicine, Pokfulam, Hong Kong.
FAU - Ying, Michael Tin-Cheung
AU  - Ying MT
AD  - Department of Health Technology and Informatics, Hong Kong Polytechnic
      University, Kowloon, Hong Kong.
FAU - Lam, Cindy Lo Kuen
AU  - Lam CLK
AD  - Department of Family Medicine and Primary Care, University of Hong Kong Li Ka
      Shing Faculty of Medicine, Pokfulam, Hong Kong.
LA  - eng
SI  - ClinicalTrials.gov/NCT03609697
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200408
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Pressure
MH  - Carotid Intima-Media Thickness
MH  - China
MH  - Community Health Services
MH  - Diet, Reducing/*methods
MH  - *Exercise
MH  - Glycated Hemoglobin A/metabolism
MH  - Humans
MH  - Insulin/metabolism
MH  - Insulin Resistance
MH  - Lipid Metabolism
MH  - Middle Aged
MH  - Overweight/metabolism/*therapy
MH  - Prediabetic State/metabolism/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Weight Loss
MH  - Weight Reduction Programs/*methods
PMC - PMC7245377
OTO - NOTNLM
OT  - *general diabetes
OT  - *preventive medicine
OT  - *primary care
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/11 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035196 [pii]
AID - 10.1136/bmjopen-2019-035196 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 8;10(4):e035196. doi: 10.1136/bmjopen-2019-035196.


PMID- 32273315
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 8
TI  - Hospital-based sentinel surveillance for Streptococcus pneumoniae and other
      invasive bacterial diseases in India (HBSSPIBD): design and methodology.
PG  - e034663
LID - 10.1136/bmjopen-2019-034663 [doi]
AB  - INTRODUCTION: Streptococcus pneumoniae is one of the frequently isolated
      organisms and an important aetiological agent of invasive bacterial diseases
      (IBD) like pneumonia, meningitis and sepsis. As a measure to control the burden
      of IBD, the Government of India introduced Pneumoccocal Conjugate Vaccine-13
      (PCV-13) in the Universal Immunization Program in high burden districts of five
      states in a phased manner from 2017 onwards. It is essential to understand the
      trend of circulating pneumococcal serotypes associated with IBD in the
      prevaccination and postvaccination scenarios to decide on the expansion of
      vaccination programmes and PCV reformulation. This manuscript describes the
      protocol for hospital-based sentinel surveillance for S. pneumoniae and other
      organisms causing IBD across various geographical regions in India. METHODS AND
      ANALYSIS: Hospital-based surveillance is established in selected hospitals to
      recruit children aged 1-59 months with symptoms of pneumonia and other IBD.
      Diagnostic criteria were adapted from standard WHO case definitions. Case Report 
      Forms (CRFs) are used to collect data from the enrolled children. Blood,
      cerebrospinal fluid (CSF) and other normally sterile body fluids are collected
      and subjected to microscopy, cytology, latex agglutination, biochemistry,
      bacteriological culture and real-time PCR as applicable. Pneumococcal isolates
      are serotyped and tested for assessing antimicrobial resistance patterns. Data
      will be analysed by simple descriptive statistics to estimate the proportion of
      pneumonia and other IBD due to S. pneumoniae, Hemophilus influenzae type b and
      Neisseria meningitidis. Prevalence of bacterial infection, circulating
      pneumococcal serotypes, antibiotic resistance patterns, serotype variability
      across seasons and regions will be described in terms of percentage with 95%
      confidence interval. ETHICS AND DISSEMINATION: The institutional review boards of
      the coordinating centre, all sentinel sites, regional and national reference
      laboratories approved the project. The results will be published in peer-reviewed
      journals and shared with stakeholders for deciding on revising vaccination
      strategy appropriately.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rajkumar, Prabu
AU  - Rajkumar P
AUID- ORCID: 0000-0001-9839-800X
AD  - Health Systems Research, ICMR-National Institute of Epidemiology, Chennai, India.
FAU - Bharathy, Sukumar
AU  - Bharathy S
AD  - Health Systems Research, ICMR-National Institute of Epidemiology, Chennai, India.
FAU - Girish Kumar, C P
AU  - Girish Kumar CP
AD  - Laboratory Division, ICMR-National Institute of Epidemiology, Chennai, India.
FAU - Veeraraghavan, Balaji
AU  - Veeraraghavan B
AD  - Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil
      Nadu, India.
FAU - Verghese, Valsan
AU  - Verghese V
AD  - Department of Child Health, Christian Medical College and Hospital Vellore,
      Vellore, Tamil Nadu, India.
FAU - Gupta, Nivedita
AU  - Gupta N
AD  - Epidemiology and Communicable Diseases, Indian Council of Medical Research, New
      Delhi, India.
FAU - Kangusamy, Boopathi
AU  - Kangusamy B
AD  - Health Systems Research, ICMR-National Institute of Epidemiology, Chennai, India.
FAU - Ravi, Muthusamy
AU  - Ravi M
AD  - Computing and Information Science, ICMR-National Institute of Epidemiology,
      Chennai, India.
FAU - Jayaraman, Yuvaraj
AU  - Jayaraman Y
AUID- ORCID: 0000-0003-4017-8404
AD  - Health Systems Research, ICMR-National Institute of Epidemiology, Chennai, India 
      j_yuvan@yahoo.com.
CN  - HBSSPIBD network team
CN  - HBSSPIBD network team*
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200408
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Pneumococcal Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bacterial Infections/*epidemiology
MH  - Child
MH  - Child, Preschool
MH  - Hospitals
MH  - Humans
MH  - India/epidemiology
MH  - Infant
MH  - Middle Aged
MH  - *Pneumococcal Infections/epidemiology/prevention & control
MH  - Pneumococcal Vaccines
MH  - *Sentinel Surveillance
MH  - Serotyping
MH  - Streptococcus pneumoniae/immunology
MH  - Young Adult
PMC - PMC7245370
OTO - NOTNLM
OT  - *India
OT  - *children
OT  - *invasive bacterial diseases
OT  - *sentinel Surveillance
OT  - *streptococcus pneumoniae
COIS- Competing interests: None declared.
IR  - Malik S
FIR - Malik, Shikha
IR  - Biswas D
FIR - Biswas, Debasis
IR  - Kumar A
FIR - Kumar, Amber
IR  - Singh K
FIR - Singh, Kuldeep
IR  - Nag VL
FIR - Nag, Vijaya Lakshmi
IR  - Sharma A
FIR - Sharma, Anuradha
IR  - Kumar P
FIR - Kumar, Prawin
IR  - Varghese R
FIR - Varghese, Rosemol
IR  - Kumar D JL
FIR - Kumar D, Jones Lionel
IR  - Sharma M
FIR - Sharma, Milap
IR  - Jharyal SC
FIR - Jharyal, S C
IR  - Sreenivasan P
FIR - Sreenivasan, Priya
IR  - Sarada Devi KL
FIR - Sarada Devi, K L
IR  - Jyothi R
FIR - Jyothi, R
IR  - Poovazhagi V
FIR - Poovazhagi, V
IR  - Devasena NR
FIR - Devasena, N R
IR  - Benakappa N
FIR - Benakappa, Naveen
IR  - Sathenahalli VB
FIR - Sathenahalli, Veeraraja B
IR  - Bhavana J
FIR - Bhavana, J
IR  - Balasubramanian S
FIR - Balasubramanian, S
IR  - Bai Perumal SP
FIR - Bai Perumal, Sulochana Putli
IR  - Vijay Kumar G
FIR - Vijay Kumar, G
IR  - Padmaja G
FIR - Padmaja, G
IR  - Usha Rani P
FIR - Usha Rani, P
IR  - Baghel B
FIR - Baghel, Bhagat
IR  - Majumdar DJ
FIR - Majumdar, Dev Jyoti
IR  - Baveja S
FIR - Baveja, Sujata
IR  - Shinde A
FIR - Shinde, Alka
IR  - Karnik P
FIR - Karnik, Prachi
IR  - Jain H
FIR - Jain, Hemant
IR  - Mutha A
FIR - Mutha, Anitha
IR  - Mehta N
FIR - Mehta, Nirbhay
IR  - Vyas BR
FIR - Vyas, Bhadresh R
IR  - Mehta KD
FIR - Mehta, Krunal D
IR  - Chaudhry AK
FIR - Chaudhry, Anil Kumar
IR  - Kumar M
FIR - Kumar, Manoj
IR  - Malhotra B
FIR - Malhotra, Bharti
IR  - Saini GS
FIR - Saini, G S
IR  - Soodan S
FIR - Soodan, Shashi
IR  - Kour H
FIR - Kour, Harleen
EDAT- 2020/04/11 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034663 [pii]
AID - 10.1136/bmjopen-2019-034663 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 8;10(4):e034663. doi: 10.1136/bmjopen-2019-034663.


PMID- 32273308
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 4
DP  - 2020 Apr
TI  - Systems thinking in gender and medicine.
PG  - 225-226
LID - 10.1136/medethics-2020-106206 [doi]
FAU - Earp, Brian D
AU  - Earp BD
AD  - Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
      brian.earp@gmail.com.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Ethics, Medical
MH  - Gender Identity
MH  - Humans
MH  - *Medicine
MH  - Systems Analysis
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/11 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
AID - medethics-2020-106206 [pii]
AID - 10.1136/medethics-2020-106206 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Apr;46(4):225-226. doi: 10.1136/medethics-2020-106206.


PMID- 32273302
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1468-2052 (Electronic)
IS  - 1359-2998 (Linking)
VI  - 105
IP  - 6
DP  - 2020 Nov
TI  - How does the BAPM Framework for Practice on Perinatal Management of Extreme
      Preterm Birth Before 27 Weeks of Gestation impact delivery of Newborn Life
      Support? A Resuscitation Council UK response.
PG  - 672-674
LID - 10.1136/archdischild-2020-318927 [doi]
AB  - In October 2019, the British Association of Perinatal Medicine (BAPM) published a
      Framework1 and associated infographic2 for 'Practice on Perinatal Management of
      Extreme Preterm Birth Before 27 Weeks of Gestation' This outlined an approach,
      based on data from the UK and abroad, to assist clinicians in decision-making
      relating to perinatal care at </=26(+6) weeks gestation. Many frontline providers
      of delivery room care of extremely preterm infants will have completed a
      Resuscitation Council UK (RCUK) Newborn Life Support or Advanced Resuscitation of
      the Newborn Infant course. This RCUK response to the BAPM Framework highlights
      how this might impact on their approach.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Fawke, Joe
AU  - Fawke J
AD  - Neonatology, University Hospitals of Leicester NHS Trust, Leicester, UK
      joe.fawke@uhl-tr.nhs.uk.
AD  - Resuscitation Council (UK), London, UK.
FAU - Tinnion, Robert J
AU  - Tinnion RJ
AD  - Neonatal Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle upon 
      Tyne, UK.
FAU - Monnelly, Victoria
AU  - Monnelly V
AD  - Neonatology, Simpson Centre for Reproductive Health, Edinburgh, UK.
FAU - Ainsworth, Sean B
AU  - Ainsworth SB
AD  - Women and Children's Services, Victoria Hospital, Kirkcaldy, Fife, UK.
FAU - Cusack, Jonathan
AU  - Cusack J
AD  - Neonatology, University Hospitals of Leicester NHS Trust, Leicester, UK.
FAU - Wyllie, Jonathan
AU  - Wyllie J
AD  - Resuscitation Council (UK), London, UK.
AD  - Neonatology, James Cook University Hospital, Middlesbrough, Middlesbrough, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200409
PL  - England
TA  - Arch Dis Child Fetal Neonatal Ed
JT  - Archives of disease in childhood. Fetal and neonatal edition
JID - 9501297
SB  - IM
MH  - Clinical Decision-Making
MH  - Counseling
MH  - Gestational Age
MH  - *Guideline Adherence
MH  - Humans
MH  - *Infant, Extremely Premature
MH  - Infant, Newborn
MH  - Intensive Care, Neonatal
MH  - Palliative Care
MH  - Parents
MH  - *Perinatal Care
MH  - *Practice Guidelines as Topic
MH  - *Resuscitation
MH  - Risk Factors
OTO - NOTNLM
OT  - ethics
OT  - neonatology
OT  - outcomes research
OT  - resuscitation
COIS- Competing interests: None declared.
EDAT- 2020/04/11 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/01/26 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - archdischild-2020-318927 [pii]
AID - 10.1136/archdischild-2020-318927 [doi]
PST - ppublish
SO  - Arch Dis Child Fetal Neonatal Ed. 2020 Nov;105(6):672-674. doi:
      10.1136/archdischild-2020-318927. Epub 2020 Apr 9.


PMID- 32273295
OWN - NLM
STAT- Publisher
LR  - 20220323
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 9
TI  - Insight is a useful construct in clinical assessments if used wisely.
LID - medethics-2020-106128 [pii]
LID - 10.1136/medethics-2020-106128 [doi]
AB  - Medical ethicist, Guidry-Grimes has critically reviewed the concept of insight,
      voicing concerns that it lacks consensus as to its components and that it
      undermines patient perspectives. We respond by briefly summarising research over 
      the last 30 years that she overlooks which has helped establish the clinical
      validity of the construct. This includes the adoption of standardised assessment 
      tools-at least in research-and longitudinal and cross-sectional studies
      quantifying associations with psychopathological, clinical and cognitive
      measures. We also make the distinction between the current standards for
      assessing decision-making capacity leading to, where appropriate, involuntary
      treatment in clinical and medico-legal settings which in most legislations do not
      include insight assessments, and anecdotal reports of the use and misuse of 'lack
      of insight' as a proxy for more comprehensive evaluation. We conclude by
      encouraging a broader view of insight akin to self-knowledge.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - David, Anthony
AU  - David A
AUID- ORCID: http://orcid.org/0000-0003-0967-774X
AD  - Department of Psychiatry, UCL Institute of Mental Health, London, UK
      anthony.s.david@ucl.ac.uk.
FAU - Ariyo, Kevin
AU  - Ariyo K
AD  - Department of Psychological Medicine, Institute of Psychiatry Psychology and
      Neuroscience, London, UK.
LA  - eng
GR  - 203376/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20200409
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - capacity
OT  - decision-making
OT  - involuntary civil commitment
OT  - mentally ill and disabled persons
OT  - psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/04/11 06:00
MHDA- 2020/04/11 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/04/11 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - medethics-2020-106128 [pii]
AID - 10.1136/medethics-2020-106128 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 9. pii: medethics-2020-106128. doi:
      10.1136/medethics-2020-106128.


PMID- 32273074
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210505
IS  - 1877-1300 (Electronic)
IS  - 1877-1297 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar
TI  - An evaluation of virtual ethics discussion groups as a method of learning on a
      pharmacist Independent Prescribing (IP) programme.
PG  - 347-354
LID - S1877-1297(19)30332-6 [pii]
LID - 10.1016/j.cptl.2019.12.015 [doi]
AB  - BACKGROUND AND PURPOSE: A postgraduate body within Queen's University Belfast
      (QUB) has offered a pharmacist Independent Prescribing (IP) programme to
      pharmacists living locally in Northern Ireland (NI) since 2006. In 2016, this
      course was modified and delivered by the School of Pharmacy within QUB for a
      non-local population of pharmacists from Great Britain (GB). In order to
      substitute face-to-face, live training in NI, distance learning methods were
      employed for one of the modules that involved studying ethical dilemmas. The
      purpose of this study was to assess participant acceptance and perceived
      effectiveness of the utilized distance learning methods. EDUCATIONAL ACTIVITY AND
      SETTING: All participants within Cohort 2 of the IP programme offered to GB
      pharmacists viewed an online recorded lecture on dealing with ethical dilemmas.
      This involved being taught about a professional decision-making model.
      Participants then applied this model to four ethical case studies via virtual
      discussion groups and were invited to complete a questionnaire regarding their
      views on these teaching methods. FINDINGS: Twenty participants viewed the online 
      recorded lecture, and 19 attended the virtual discussion groups. Eighteen
      participants (90%) responded to the survey. Participants reacted positively to
      the e-learning format. Following the training, all participants felt confident
      applying the professional decision-making model and only one did not intend to
      apply the model to their practice. SUMMARY: The utilized e-learning format was
      well received and effective in producing pharmacists who felt confident
      approaching and resolving ethical dilemmas in their new roles as pharmacist
      prescribers.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - O'Hare, Conor
AU  - O'Hare C
AD  - School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast,
      Northern Ireland BT9 7BL, United Kingdom. Electronic address: cohare35@qub.ac.uk.
FAU - Haughey, Sharon
AU  - Haughey S
AD  - School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast,
      Northern Ireland BT9 7BL, United Kingdom. Electronic address:
      s.l.haughey@qub.ac.uk.
FAU - Lloyd, Frances
AU  - Lloyd F
AD  - Northern Ireland Centre for Pharmacy Teaching and Learning, Beechill House, 42
      Beechill Road, Belfast, Northern Ireland BT8 7RL, United Kingdom. Electronic
      address: f.lloyd@qub.ac.uk.
FAU - McCalmont, Mark
AU  - McCalmont M
AD  - School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast,
      Northern Ireland BT9 7BL, United Kingdom. Electronic address:
      m.mccalmont@qub.ac.uk.
FAU - Girvin, Briegeen
AU  - Girvin B
AD  - School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast,
      Northern Ireland BT9 7BL, United Kingdom. Electronic address: b.girvin@qub.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20191231
PL  - United States
TA  - Curr Pharm Teach Learn
JT  - Currents in pharmacy teaching & learning
JID - 101560815
SB  - IM
MH  - Drug Prescriptions/*standards/statistics & numerical data
MH  - Education, Distance/methods/*standards/statistics & numerical data
MH  - Education, Pharmacy, Continuing/methods/standards/statistics & numerical data
MH  - *Ethics
MH  - Humans
MH  - *Learning
MH  - Northern Ireland
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Distance learning
OT  - *Ethical dilemmas
OT  - *Online recorded lecture
OT  - *Pharmacist independent prescribing programme
OT  - *Synchronous virtual discussion groups
COIS- Declaration of competing interest None
EDAT- 2020/04/11 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/04/11 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2019/09/03 00:00 [revised]
PHST- 2019/12/05 00:00 [accepted]
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
AID - S1877-1297(19)30332-6 [pii]
AID - 10.1016/j.cptl.2019.12.015 [doi]
PST - ppublish
SO  - Curr Pharm Teach Learn. 2020 Mar;12(3):347-354. doi: 10.1016/j.cptl.2019.12.015. 
      Epub 2019 Dec 31.


PMID- 32272609
OWN - NLM
STAT- MEDLINE
DCOM- 20200925
LR  - 20200925
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 7
DP  - 2020 Apr 7
TI  - A Mixed-Method Modified Delphi Study toward Identifying Key Elements of
      Psychotherapy in Iran.
LID - E2514 [pii]
LID - 10.3390/ijerph17072514 [doi]
AB  - PURPOSE: In Iran, psychotherapy is regarded as an effective treatment for
      psychiatric disorders. However, no previous research has identified the key
      elements of psychotherapy that may be specific to Iranian society. The current
      study was conducted in an attempt to identify these elements. METHODS: A
      mixed-method modified Delphi approach was used, taking place over several stages 
      during 2017-2018. The first stage involved interviewing 12 experts in
      psychotherapy to identify key elements of psychotherapy in Iran by thematic
      analysis. Then, successive Delphi rounds were conducted to obtain consensus (75% 
      agreement) from 70 psychotherapy experts on these key elements. RESULTS: Key
      elements of psychotherapy were grouped into the following themes: (1) systematic 
      education/training; (2) psychotherapist competency; (3) psychotherapy reflective 
      of Iranian societal needs; and (4) the substrate (scientific/ethical principles) 
      of psychotherapy. Consensus was reached during two Delphi rounds. In Delphi round
      1, 52.8% of the statements reached consensus, and all remaining statements
      reached consensus in round 2. CONCLUSIONS: The key elements of psychotherapy in
      Iran are a set of conditions for the education and training of competent
      psychotherapists who can perform psychiatric interventions appropriate to Iranian
      society under supervised rules. These should serve as a framework for improving
      the current delivery of psychotherapy in Iran.
FAU - Rezaie, Leeba
AU  - Rezaie L
AD  - Sleep Disorders Research Center, Kermanshah University of Medical Sciences,
      Kermanshah 6719851115, Iran.
FAU - Heydari, Shima
AU  - Heydari S
AD  - Student Research Committee of Kermanshah University of Medical Sciences,
      Kermanshah 6719851115, Iran.
FAU - Paschall, Ethan
AU  - Paschall E
AUID- ORCID: 0000-0001-7031-4951
AD  - Clinical Psychology Doctoral Fellow, Eastern Michigan University, Ypsilanti, MI
      48197, USA.
FAU - Khazaie, Habibolah
AU  - Khazaie H
AD  - Sleep Disorders Research Center, Kermanshah University of Medical Sciences,
      Kermanshah 6719851115, Iran.
FAU - Sadeghi Bahmani, Dena
AU  - Sadeghi Bahmani D
AUID- ORCID: 0000-0002-1301-5522
AD  - Sleep Disorders Research Center, Kermanshah University of Medical Sciences,
      Kermanshah 6719851115, Iran.
AD  - Center of Affective, Stress and Sleep Disorders, Psychiatric Clinics, University 
      of Basel, 4001 Basel, Switzerland.
AD  - Departments of Physical Therapy, University of Alabama at Birmingham, Birmingham,
      AL 35209, USA.
FAU - Brand, Serge
AU  - Brand S
AUID- ORCID: 0000-0003-2175-2765
AD  - Sleep Disorders Research Center, Kermanshah University of Medical Sciences,
      Kermanshah 6719851115, Iran.
AD  - Center of Affective, Stress and Sleep Disorders, Psychiatric Clinics, University 
      of Basel, 4001 Basel, Switzerland.
AD  - Division of Sport Science and Psychosocial Health, Department of Sport, Exercise 
      and Health, Faculty of Medicine, University of Basel, 4001 Basel, Switzerland.
AD  - School of Medicine, Tehran University of Medical Sciences, Tehran 1416753955,
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Consensus
MH  - Delphi Technique
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - *Psychotherapy
MH  - *Research Design
PMC - PMC7178105
OTO - NOTNLM
OT  - *Iran
OT  - *key elements
OT  - *mixed-method Delphi study
OT  - *psychotherapy
EDAT- 2020/04/11 06:00
MHDA- 2020/09/26 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/02/29 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/04/02 00:00 [accepted]
PHST- 2020/04/11 06:00 [entrez]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2020/09/26 06:00 [medline]
AID - ijerph17072514 [pii]
AID - 10.3390/ijerph17072514 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Apr 7;17(7). pii: ijerph17072514. doi:
      10.3390/ijerph17072514.


PMID- 34221415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210706
IS  - 2053-9711 (Print)
IS  - 2053-9711 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan-Dec
TI  - Regulatory responses to medical machine learning.
PG  - lsaa002
LID - 10.1093/jlb/lsaa002 [doi]
AB  - Companies and healthcare providers are developing and implementing new
      applications of medical artificial intelligence, including the artificial
      intelligence sub-type of medical machine learning (MML). MML is based on the
      application of machine learning (ML) algorithms to automatically identify
      patterns and act on medical data to guide clinical decisions. MML poses
      challenges and raises important questions, including (1) How will regulators
      evaluate MML-based medical devices to ensure their safety and effectiveness? and 
      (2) What additional MML considerations should be taken into account in the
      international context? To address these questions, we analyze the current
      regulatory approaches to MML in the USA and Europe. We then examine international
      perspectives and broader implications, discussing considerations such as data
      privacy, exportation, explanation, training set bias, contextual bias, and trade 
      secrecy.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of Duke
      University School of Law, Harvard Law School, Oxford University Press, and
      Stanford Law School.
FAU - Minssen, Timo
AU  - Minssen T
AD  - Centre for Advanced Studies in Biomedical Innovation Law, Copenhagen, Denmark.
FAU - Gerke, Sara
AU  - Gerke S
AD  - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard
      Law School, Cambridge, USA.
FAU - Aboy, Mateo
AU  - Aboy M
AD  - Centre for Law, Medicine, and Life Sciences (LML), Faculty of Law, University of 
      Cambridge, Cambridge, UK.
FAU - Price, Nicholson
AU  - Price N
AD  - University of Michigan Law School, Ann Arbor, MI, USA.
FAU - Cohen, Glenn
AU  - Cohen G
AD  - Harvard Law School and Petrie-Flom Center for Health Law Policy, Biotechnology,
      and Bioethics at Harvard Law School, Cambridge, USA.
LA  - eng
PT  - Journal Article
DEP - 20200411
PL  - England
TA  - J Law Biosci
JT  - Journal of law and the biosciences
JID - 101633120
PMC - PMC8248979
OTO - NOTNLM
OT  - artificial intelligence
OT  - ethics
OT  - medical devices
OT  - medical machine learning
OT  - regulation
EDAT- 2020/04/11 00:00
MHDA- 2020/04/11 00:01
CRDT- 2021/07/05 10:07
PHST- 2019/10/02 00:00 [received]
PHST- 2021/07/05 10:07 [entrez]
PHST- 2020/04/11 00:00 [pubmed]
PHST- 2020/04/11 00:01 [medline]
AID - 10.1093/jlb/lsaa002 [doi]
AID - lsaa002 [pii]
PST - epublish
SO  - J Law Biosci. 2020 Apr 11;7(1):lsaa002. doi: 10.1093/jlb/lsaa002. eCollection
      2020 Jan-Dec.


PMID- 32272210
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20220531
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 31
IP  - 7
DP  - 2020 Jul
TI  - JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for
      tumour-agnostic treatments in patients with solid tumours with microsatellite
      instability or NTRK fusions.
PG  - 861-872
LID - S0923-7534(20)36386-9 [pii]
LID - 10.1016/j.annonc.2020.03.299 [doi]
AB  - A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in
      Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese
      Society of Medical Oncology (JSMO), the European Society for Medical Oncology
      (ESMO), the American Society of Clinical Oncology (ASCO), and the Taiwan Oncology
      Society (TOS). The purpose of the meeting was to focus on what we have learnt
      from both microsatellite instability (MSI)/deficient mismatch repair (dMMR)
      biomarkers in predicting the efficacy of anti-programmed death-1
      (PD-1)/programmed death ligand-1 (PD-L1) immunotherapy, and the neurotrophic
      tyrosine receptor kinase (NTRK) gene fusions in predicting the efficacy of
      inhibitors of the tropomyosin receptor kinase (TRK) proteins across a range of
      solid tumour types. The recent regulatory approvals of the anti-PD-1 antibody
      pembrolizumab and the TRK inhibitors larotrectinib and entrectinib, based on
      specific tumour biomarkers rather than specific tumour type, have heralded a
      paradigm shift in cancer treatment approaches. The purpose of the meeting was to 
      develop international expert consensus recommendations on the use of such
      tumour-agnostic treatments in patients with solid tumours. The aim was to
      generate a reference document for clinical practice, for pharmaceutical companies
      in the design of clinical trials, for ethics committees in the approval of
      clinical trial protocols and for regulatory authorities in relation to drug
      approvals, with a particular emphasis on diagnostic testing and patient
      selection.
CI  - Copyright (c) 2020 European Society for Medical Oncology. Published by Elsevier
      Ltd. All rights reserved.
FAU - Yoshino, T
AU  - Yoshino T
AD  - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer
      Center Hospital East, Kashiwa, Japan. Electronic address:
      tyoshino@east.ncc.go.jp.
FAU - Pentheroudakis, G
AU  - Pentheroudakis G
AD  - Department of Medical Oncology, University of Ioannina, Ioannina, Greece.
FAU - Mishima, S
AU  - Mishima S
AD  - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer
      Center Hospital East, Kashiwa, Japan.
FAU - Overman, M J
AU  - Overman MJ
AD  - Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The
      University of Texas MD Anderson Cancer Center, Houston, USA.
FAU - Yeh, K-H
AU  - Yeh KH
AD  - Department of Medical Oncology, National Taiwan University Cancer Center and
      Cancer Research Center, National Taiwan University College of Medicine, Taipei,
      Taiwan.
FAU - Baba, E
AU  - Baba E
AD  - Department of Oncology and Social Medicine, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Naito, Y
AU  - Naito Y
AD  - Department of Experimental Therapeutics/Breast and Medical Oncology, National
      Cancer Center Hospital East, Kashiwa, Japan.
FAU - Calvo, F
AU  - Calvo F
AD  - Department of Clinical Pharmacology, University of Paris and Institute Gustave
      Roussy, Villejuif, France.
FAU - Saxena, A
AU  - Saxena A
AD  - Department of Medicine, Division of Hematology & Medical Oncology, Thoracic
      Oncology Service, Weill Cornell Medicine, New York, USA.
FAU - Chen, L-T
AU  - Chen LT
AD  - National Institute of Cancer Research, National Health Research Institutes,
      Tainan, Taiwan.
FAU - Takeda, M
AU  - Takeda M
AD  - Department of Medical Oncology, Kindai University, Osaka, Japan.
FAU - Cervantes, A
AU  - Cervantes A
AD  - CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA,
      University of Valencia, Valencia, Spain.
FAU - Taniguchi, H
AU  - Taniguchi H
AD  - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer
      Center Hospital East, Kashiwa, Japan.
FAU - Yoshida, K
AU  - Yoshida K
AD  - Department of Surgical Oncology, Gifu University, Graduate School of Medicine,
      Gifu, Japan.
FAU - Kodera, Y
AU  - Kodera Y
AD  - Department of Gastrointestinal Surgery, Nagoya University, Nagoya, Japan.
FAU - Kitagawa, Y
AU  - Kitagawa Y
AD  - Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
FAU - Tabernero, J
AU  - Tabernero J
AD  - Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron
      Institute of Oncology (V.H.I.O.), Barcelona, Spain.
FAU - Burris, H
AU  - Burris H
AD  - The Sarah Cannon Research Institute, Nashville, USA.
FAU - Douillard, J-Y
AU  - Douillard JY
AD  - ESMO, Lugano, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical
      Oncology
JID - 9007735
SB  - IM
MH  - *Clinical Trials as Topic
MH  - Consensus
MH  - Humans
MH  - Japan
MH  - Medical Oncology
MH  - *Microsatellite Instability
MH  - *Neoplasms/drug therapy/genetics
MH  - Taiwan
OTO - NOTNLM
OT  - *NTRK
OT  - *microsatellite instability
OT  - *mismatch repair
OT  - *recommendations
OT  - *tumour-agnostic
COIS- Disclosure EB has received research funding from Taiho, Chugai, Astellas, Merck
      biopharma, Daiichi Sankyo, Ono, Kyowa-Kirin and Takeda; HB has received fees for 
      consultancy/advisory roles paid to his institution from Mersana, AstraZeneca,
      FORMA therapeutics, Janssen, Novartis, Roche/Genentech, MedImmune, BMS, Celgene, 
      Incyte, Boehringer Ingelheim, Eisai and Tolero Pharmaceuticals, and research
      funding paid to his institution from AstraZeneca, Novartis, MedImmune, BMS,
      Celgene, Incyte, Janssen, Roche/Genentech, MacroGenics, Boehringer Ingelheim,
      Lilly, Seattle Genetics, Merck, Agios, Jounce Therapeutics, Moderna Therapeutics,
      CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, Immunocore, Takeda,
      Millennium, Biomed Valley Discoveries, TG therapeutics, eFFECTOR Therapeutics,
      Gilead Sciences, BioAtla, CicloMed, Loxo, Vertex, Harpoon Therapeutics, Jiangsu
      Hengrui Medicine, Arch, Kyocera, Arvinas and Revolution Medicines; AC has
      received fees for consultancy/advisory roles from Merck Serono, Roche, BeiGene,
      Bayer, Servier, Eli Lilly, Novartis, Takeda, Astellas and Pierre Fabre and
      research funding from Genentech, Merck Serono, Roche, BeiGene, Bayer, Servier,
      Eli Lilly, Novartis, Takeda, Astellas, FibroGen, Amcure, Sierra Oncology,
      AstraZeneca, Medimmune, BMS and MSD; FC has received fees for
      consultancy/advisory roles from Phillips; L-TC has received research funding from
      Novartis, Merck Serono, TTY, Polaris, SyncorePharm, Pfizer, and BMS, honoraria
      from ONO, Eli Lilly, MSD, Pharma Engine, TTY, SyncorePharm, Novartis, AstraZeneca
      and Ipsen, patents and royalties for ENO-1 mAb from HuniLife, and is a Scientific
      Advisory Board member at Pharma Engine and a board member at Sinopharm Taiwan,
      Ltd; YK has received fees for consultancy/advisory roles from Ono Asahi Kasei and
      BMS research funding from Taiho, Chugai, Yakult, Daiichi-Sankyo, Merck Serono,
      Asahi Kasei, EA Pharma, Otsuka Pharmaceutical Co., Ltd, Otsuka Pharmaceutical
      Factory Inc., Takeda, Shionogi, Kaken Pharmaceuticals, Kowa Pharmaceuticals,
      Astellas, Medicon, Dainippon Sumitomo Pharmaceuticals, Taisho Toyama
      Pharmaceuticals, Kyowa Kirin, Pfizer Japan, Ono, NIHON, Japan Blood Products
      Organization, Medtronic Japan, Sanofi K.K., and grants from Eisai, Tsumura, KCI
      Licensing, Inc, Abbott Japan, Fuji Film and Toyama Chemical Co.; YKo has receive 
      research funding from Taiho, Chugai, Takeda, MSD, Nihon Kayaku, Yakult, Lilly
      Japan, Ono, EA Pharma, Novartis, Daiichi-Sankyo, BMS and Sanofi; YN has received 
      fees for consultancy/advisory roles from Eli Lilly, AstraZeneca, Chugai, Pfizer, 
      Novartis, Eisai, Bayer, Fuji Film Toyama Chemistry, Shionogi, Taiho, Ono,
      Guardent Health, Kyowa Kirin and Mundipharma; MJO has received fees for
      consultancy/advisory roles from Janssen Research and Development LLC, AgilVax,
      Takeda Pharmaceuticals (Japan), Acrotech Biopharma, Promega, Genentech Inc., and 
      Novartis Pharmaceuticals and research funding from Roche, BMS, Merck, AstraZeneca
      and Nouscom; GP has received fees for consultancy/advisory roles from Roche,
      Merck and Amgen and research funding from: Roche, Amgen, Novartis, MSD, BMS,
      Pfizer, Boehringer and Astra Zeneca; AS has received fees for consultancy from
      Genentech, AstraZeneca and Medtronic and for advisory boards from AstraZeneca and
      Takeda; JT has received fees for consultancy/advisory roles from Array Biopharma,
      AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Genmab A/S,
      Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, 
      Eli Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners,
      Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael
      Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics,
      Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine,
      HalioDx SAS and Roche Diagnostics; MT has received fees for consultancy/advisory 
      roles from Chugai; HT has received research funding from Sysmex, Takeda and
      Daiichi-Sankyo; KHY has received fees for consultancy/advisory roles from Amgen, 
      Boehringer Ingelheim, Bayer, BMS, MSD, Merck Serono, Eli Lilly, Ono and Takeda;
      KY has received fees for consultancy/advisory roles from Abbott, AbbVie, Asa hi
      Kasei Pharma, Astellas, Biogen Japan, Celgene, Chugai, Covidien Japan, Daiichi
      Sankyo, Eisai, Eli Lilly Japan, GlaxoSmithKline, Johnson & Johnson, KCI, Kyowa
      Kirin, Meiji Seika Pharma, Merck Serono, MSD, Nippon Kayaku, Novartis, Ono
      Pharm., Otsuka Pharm., Sanofi, Taiho Pharm., Toray Medical, Tsumura and Yakult
      Honsha; TY has received research funding from Novartis Pharma K.K., MSD K.K.,
      Sumitomo Dainippon Pharma Co., Ltd, Chugai, Sanofi K.K., Daiichi Sankyo, Parexel 
      International Inc., Ono, GlaxoSmithKline K.K. and Boehringer Ingelheim Japan. JYD
      and SM declare no conflicts of interests.
EDAT- 2020/04/10 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/01/28 00:00 [received]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
PHST- 2020/04/10 06:00 [entrez]
AID - S0923-7534(20)36386-9 [pii]
AID - 10.1016/j.annonc.2020.03.299 [doi]
PST - ppublish
SO  - Ann Oncol. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. Epub 2020
      Apr 6.


PMID- 32271968
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1467-7652 (Electronic)
IS  - 1467-7644 (Linking)
VI  - 18
IP  - 8
DP  - 2020 Aug
TI  - Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory
      perspective.
PG  - 1651-1669
LID - 10.1111/pbi.13383 [doi]
AB  - Over the last three decades, the development of new genome editing techniques,
      such as ODM, TALENs, ZFNs and the CRISPR-Cas system, has led to significant
      progress in the field of plant and animal breeding. The CRISPR-Cas system is the 
      most versatile genome editing tool discovered in the history of molecular biology
      because it can be used to alter diverse genomes (e.g. genomes from both plants
      and animals) including human genomes with unprecedented ease, accuracy and high
      efficiency. The recent development and scope of CRISPR-Cas system have raised new
      regulatory challenges around the world due to moral, ethical, safety and
      technical concerns associated with its applications in pre-clinical and clinical 
      research, biomedicine and agriculture. Here, we review the art, applications and 
      potential risks of CRISPR-Cas system in genome editing. We also highlight the
      patent and ethical issues of this technology along with regulatory frameworks
      established by various nations to regulate CRISPR-Cas-modified
      organisms/products.
CI  - (c) 2020 The Authors. Plant Biotechnology Journal published by Society for
      Experimental Biology and The Association of Applied Biologists and John Wiley &
      Sons Ltd.
FAU - Zhang, Debin
AU  - Zhang D
AD  - National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural
      University, Wuhan, China.
AD  - College of Public Administration, Huazhong Agricultural University, Wuhan, China.
FAU - Hussain, Amjad
AU  - Hussain A
AD  - National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural
      University, Wuhan, China.
FAU - Manghwar, Hakim
AU  - Manghwar H
AD  - National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural
      University, Wuhan, China.
FAU - Xie, Kabin
AU  - Xie K
AUID- ORCID: 0000-0003-0643-2456
AD  - National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural
      University, Wuhan, China.
FAU - Xie, Shengsong
AU  - Xie S
AD  - Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction,
      Ministry of Education, Wuhan, China.
FAU - Zhao, Shuhong
AU  - Zhao S
AD  - Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction,
      Ministry of Education, Wuhan, China.
FAU - Larkin, Robert M
AU  - Larkin RM
AD  - Key Laboratory of Horticultural Plant Biology, Ministry of Education, College of 
      Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan,
      China.
FAU - Qing, Ping
AU  - Qing P
AD  - College of Public Administration, Huazhong Agricultural University, Wuhan, China.
FAU - Jin, Shuangxia
AU  - Jin S
AUID- ORCID: 0000-0002-1495-9154
AD  - National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural
      University, Wuhan, China.
FAU - Ding, Fang
AU  - Ding F
AUID- ORCID: 0000-0002-9697-7179
AD  - Hubei Key Laboratory of Plant Pathology, College of Plant Sciences and
      Technology, Huazhong Agricultural University, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200430
PL  - England
TA  - Plant Biotechnol J
JT  - Plant biotechnology journal
JID - 101201889
SB  - IM
MH  - Agriculture
MH  - Animals
MH  - *CRISPR-Cas Systems/genetics
MH  - Clustered Regularly Interspaced Short Palindromic Repeats
MH  - *Gene Editing
MH  - Humans
MH  - Plants/genetics
PMC - PMC7336378
OTO - NOTNLM
OT  - *CRISPR-Cas system
OT  - *ethics
OT  - *genome editing
OT  - *regulations
OT  - *risks
EDAT- 2020/04/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/09/20 00:00 [received]
PHST- 2020/02/22 00:00 [revised]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
PHST- 2020/04/10 06:00 [entrez]
AID - 10.1111/pbi.13383 [doi]
PST - ppublish
SO  - Plant Biotechnol J. 2020 Aug;18(8):1651-1669. doi: 10.1111/pbi.13383. Epub 2020
      Apr 30.


PMID- 32271841
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20200713
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - The associations of palliative care experts regarding food refusal: A
      cross-sectional study with an open question evaluated by triangulation analysis.
PG  - e0231312
LID - 10.1371/journal.pone.0231312 [doi]
AB  - INTRODUCTION: Health professionals in oncologic and palliative care settings are 
      often faced with the problem that patients stop eating and drinking. While the
      causes of food refusal are very different, the result is often malnutrition,
      which is linked to health comorbidities and a high mortality rate. However, the
      professionals lack the time and knowledge to clarify the cause for each patient. 
      What associations do health professionals have when faced with food refusal?
      OBJECTIVE: To investigate the associations that health professionals in
      oncological and palliative settings have about denied eating behavior. METHODS: A
      cross-sectional study, starting with an open question focusing professionals'
      associations regarding food refusal. The results were inductively analyzed,
      whereby generic categories were developed. Subsequently, the categories were
      transformed into quantitative data to calculate the relationships between the
      categories. RESULTS: A total of 350 out of 2000 participants completed the
      survey, resulting in a response rate of 17.5%. Food refusal is primarily
      associated with physical and ethical aspects and with end-of-life. Half of the
      participants frequently find that patients refuse to eat. The attitudes show that
      the autonomy of the patient is the highest good and is to be respected. Even in
      the case of patients with limited decision-making capacity, the refusal to eat is
      acceptable. CONCLUSION: Clarifying the cause of food refusal requires a great
      deal of knowledge and is strongly influenced by the associations of health
      professionals. While the associations have very negative connotations,
      information and training is needed to make professionals aware of this and to
      change their associations. With this knowledge and in an interprofessional
      cooperation, mis-labelling of patient settings can be avoided and fears can be
      reduced.
FAU - Fringer, Andre
AU  - Fringer A
AUID- ORCID: 0000-0003-4950-7788
AD  - Institute of Nursing, School of Health Professionals, ZHAW University of Applied 
      Sciences, Winterthur, Switzerland.
AD  - Department of Nursing Science, Institute of Health, Witten/Herdecke University,
      Witten, Germany.
FAU - Stangle, Sabrina
AU  - Stangle S
AUID- ORCID: 0000-0003-1664-8824
AD  - Institute of Nursing, School of Health Professionals, ZHAW University of Applied 
      Sciences, Winterthur, Switzerland.
AD  - Department of Nursing Science, Institute of Health, Witten/Herdecke University,
      Witten, Germany.
FAU - Buche, Daniel
AU  - Buche D
AD  - Palliative Centre St.Gallen, Cantonal Hospital St.Gallen, St.Gallen, Switzerland.
FAU - Ott, Stefan Ch
AU  - Ott SC
AUID- ORCID: 0000-0002-8675-0376
AD  - Department of Economics, FHS St.Gallen University of Applied Sciences St.Gallen, 
      St.Gallen, Switzerland.
FAU - Schnepp, Wilfried
AU  - Schnepp W
AD  - Department of Nursing Science, Institute of Health, Witten/Herdecke University,
      Witten, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Adult
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Family
MH  - Female
MH  - *Food
MH  - *Health Personnel
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Palliative Care
PMC - PMC7145006
COIS- A.F. reports grant vom Hans Altschuler-Foundation, Switzerland. The authors A.F.,
      S.S., D.B., O.C.S. and W.S. have nothing to disclose.
EDAT- 2020/04/10 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 10.1371/journal.pone.0231312 [doi]
AID - PONE-D-19-21281 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 9;15(4):e0231312. doi: 10.1371/journal.pone.0231312.
      eCollection 2020.


PMID- 32271155
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210327
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 9
TI  - Reducing Salt Intake in China with "Action on Salt China" (ASC): Protocol for
      Campaigns and Randomized Controlled Trials.
PG  - e15933
LID - 10.2196/15933 [doi]
AB  - BACKGROUND: Salt intake in China is over twice the maximum recommendation of the 
      World Health Organization. Unlike most developed countries where salt intake is
      mainly derived from prepackaged foods, around 80% of the salt consumed in China
      is added during cooking. OBJECTIVE: Action on Salt China (ASC), initiated in
      2017, aims to develop, implement, and evaluate a comprehensive and tailored salt 
      reduction program for national scaling-up. METHODS: ASC consists of six programs 
      working in synergy to increase salt awareness and to reduce the amount of salt
      used during cooking at home and in restaurants, as well as in processed foods.
      Since September 2018, two health campaigns on health education and processed
      foods have respectively started, in parallel with four open-label cluster
      randomized controlled trials (RCTs) in six provinces across China: (1) app-based 
      intervention study (AIS), in which a mobile app is used to achieve and sustain
      salt reduction in school children and their families; (2) home cook-based
      intervention study (HIS), in which family cooks receive support in using less
      salt; (3) restaurant-based intervention study (RIS) targeting restaurant
      consumers, cooks, and managers; and (4) comprehensive intervention study (CIS),
      which is a real-world implementation and evaluation of all available
      interventions in the three other RCTs. To explore the barriers, facilitators, and
      effectiveness of delivering a comprehensive salt reduction intervention, these
      RCTs will last for 1 year (stage 1), followed by nationwide implementation (stage
      2). In AIS, HIS, and CIS, the primary outcome of salt reduction will be evaluated
      by 24-hour urinary sodium excretion in 6030 participants, including 5436 adults
      and 594 school children around 8-9 years old. In RIS, the salt content of meals
      will be measured by laboratory food analysis of the 5 best-selling dishes from
      192 restaurants. Secondary outcomes will include process evaluation; changes in
      knowledge, attitude, and practice on salt intake; and economic evaluation.
      RESULTS: All RCTs have been approved by Queen Mary Research Ethics Committee and 
      the Institutional Review Boards of leading institutes in China. The research
      started in June 2017 and is expected to be completed around March 2021. The
      baseline investigations of the four RCTs were completed in May 2019. CONCLUSIONS:
      The ASC project is progressing smoothly. The intervention packages and tailored
      components will be promoted for salt reduction in China, and could be adopted by 
      other countries. TRIAL REGISTRATION: Chinese Clinical Trial Registry. AIS:
      ChiCTR1800017553; https://tinyurl.com/vdr8rpr. HIS: ChiCTR1800016804;
      https://tinyurl.com/w8c7x3w. RIS: ChiCTR1800019694; https://tinyurl.com/uqkjgfw. 
      CIS: ChiCTR1800018119; https://tinyurl.com/s3ajldw. INTERNATIONAL REGISTERED
      REPORT IDENTIFIER (IRRID): DERR1-10.2196/15933.
CI  - (c)Puhong Zhang, Feng J He, Yuan Li, Changning Li, Jing Wu, Jixiang Ma, Bing
      Zhang, Huijun Wang, Yinghua Li, Junhua Han, Rong Luo, Jing He, Xian Li, Yu Liu,
      Changqiong Wang, Monique Tan, Graham A MacGregor, Xinhua Li. Originally published
      in JMIR Research Protocols (http://www.researchprotocols.org), 09.04.2020.
FAU - Zhang, Puhong
AU  - Zhang P
AUID- ORCID: https://orcid.org/0000-0003-4610-9848
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - He, Feng J
AU  - He FJ
AUID- ORCID: https://orcid.org/0000-0003-2807-4119
AD  - Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine
      & Dentistry, Queen Mary University of London, London, United Kingdom.
FAU - Li, Yuan
AU  - Li Y
AUID- ORCID: https://orcid.org/0000-0003-1887-7065
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Li, Changning
AU  - Li C
AUID- ORCID: https://orcid.org/0000-0003-1234-6423
AD  - Surveillance Department, Chinese Center for Health Education, Beijing, China.
FAU - Wu, Jing
AU  - Wu J
AUID- ORCID: https://orcid.org/0000-0003-3519-0839
AD  - The National Center for Chronic and Noncommunicable Disease Control and
      Prevention, The Chinese Center for Disease Control and Prevention, Beijing,
      China.
FAU - Ma, Jixiang
AU  - Ma J
AUID- ORCID: https://orcid.org/0000-0002-9649-0088
AD  - Chronic Diseases and Aging Health Management Division, The Chinese Center for
      Disease Control and Prevention, Beijing, China.
FAU - Zhang, Bing
AU  - Zhang B
AUID- ORCID: https://orcid.org/0000-0002-8399-9061
AD  - National Institute for Nutrition and Health, The Chinese Center for Disease
      Control and Prevention, Beijing, China.
FAU - Wang, Huijun
AU  - Wang H
AUID- ORCID: https://orcid.org/0000-0002-8064-4564
AD  - National Institute for Nutrition and Health, The Chinese Center for Disease
      Control and Prevention, Beijing, China.
FAU - Li, Yinghua
AU  - Li Y
AUID- ORCID: https://orcid.org/0000-0002-0371-8304
AD  - Surveillance Department, Chinese Center for Health Education, Beijing, China.
FAU - Han, Junhua
AU  - Han J
AUID- ORCID: https://orcid.org/0000-0002-5224-9292
AD  - Food Policy, China National Center for Food Safety Risk Assessment, Beijing,
      China.
FAU - Luo, Rong
AU  - Luo R
AUID- ORCID: https://orcid.org/0000-0003-2725-9939
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
FAU - He, Jing
AU  - He J
AUID- ORCID: https://orcid.org/0000-0002-0458-9276
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
FAU - Li, Xian
AU  - Li X
AUID- ORCID: https://orcid.org/0000-0001-5445-4022
AD  - The George Institute for Global Health at Peking University Health Science
      Center, Beijing, China.
AD  - Faculty of Medicine, University of New South Wales, Sydney, Australia.
FAU - Liu, Yu
AU  - Liu Y
AUID- ORCID: https://orcid.org/0000-0003-1497-3949
AD  - School of Computing, Beihang University, Beijing, China.
FAU - Wang, Changqiong
AU  - Wang C
AUID- ORCID: https://orcid.org/0000-0002-2971-4467
AD  - Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine
      & Dentistry, Queen Mary University of London, London, United Kingdom.
FAU - Tan, Monique
AU  - Tan M
AUID- ORCID: https://orcid.org/0000-0003-4287-5553
AD  - Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine
      & Dentistry, Queen Mary University of London, London, United Kingdom.
FAU - MacGregor, Graham A
AU  - MacGregor GA
AUID- ORCID: https://orcid.org/0000-0001-9206-4500
AD  - Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine
      & Dentistry, Queen Mary University of London, London, United Kingdom.
FAU - Li, Xinhua
AU  - Li X
AUID- ORCID: https://orcid.org/0000-0002-4701-3963
AD  - Chinese Center for Disease Control and Prevention, Beijing, China.
LA  - eng
GR  - 16/136/77/DH_/Department of Health/United Kingdom
GR  - MR/J015903/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20200409
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7180507
OTO - NOTNLM
OT  - 24-hour urinary sodium
OT  - China
OT  - dietary
OT  - randomized controlled trials
OT  - salt reduction
OT  - scaling-up
OT  - sodium
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
CRDT- 2020/04/10 06:00
PHST- 2019/08/21 00:00 [received]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2019/12/22 00:00 [revised]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
AID - v9i4e15933 [pii]
AID - 10.2196/15933 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 9;9(4):e15933. doi: 10.2196/15933.


PMID- 32270629
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 2046-2344 (Electronic)
IS  - 2046-2336 (Linking)
VI  - 32
IP  - 3
DP  - 2020 May 6
TI  - Biological basis of child health 2: introduction to fertilisation, prenatal
      development and birth.
PG  - 32-41
LID - 10.7748/ncyp.2020.e1245 [doi]
AB  - This article is the second in a series called the biological basis of child
      health. It considers the period of development from fertilisation to birth,
      outlining the three stages of prenatal development - the germinal, embryonic and 
      fetal stages. The article details how tissues and organs typically develop at
      each stage, and explains how and when deviations in development and congenital
      anomalies are likely to occur. It also describes some of the common congenital
      anomalies, their potential effects and their detection before or after birth.
      Information is also provided about the delivery of full-term infants, including
      the stages of labour.
CI  - (c) 2020 RCN Publishing Company Ltd. All rights reserved. Not to be copied,
      transmitted or recorded in any way, in whole or part, without prior permission of
      the publishers.
FAU - Crawford, Doreen
AU  - Crawford D
AD  - Crawford McKenzie consultancy, Colsterworth, England.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200409
PL  - England
TA  - Nurs Child Young People
JT  - Nursing children and young people
JID - 101554473
MH  - Child
MH  - *Child Health
MH  - Embryology/education
MH  - Female
MH  - *Fertilization
MH  - *Fetal Development
MH  - Humans
MH  - *Parturition
MH  - Pediatric Nursing/education
MH  - Pregnancy
OTO - NOTNLM
OT  - antenatal
OT  - child development
OT  - child health
OT  - childbirth
OT  - ethical issues
OT  - genetic disorders
OT  - genetics
OT  - intrapartum care
OT  - parents
OT  - professional
COIS- None declared
EDAT- 2020/04/10 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/11/12 00:00 [accepted]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/10 06:00 [entrez]
AID - 10.7748/ncyp.2020.e1245 [doi]
AID - 15 [pii]
PST - ppublish
SO  - Nurs Child Young People. 2020 May 6;32(3):32-41. doi: 10.7748/ncyp.2020.e1245.
      Epub 2020 Apr 9.


PMID- 32270353
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 37
IP  - 5
DP  - 2020 Apr 9
TI  - Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous
      irreversible electroporation: feasibility, safety and efficacy.
PG  - 45
LID - 10.1007/s12032-020-01360-2 [doi]
AB  - Cholangiocarcinoma (CC) accounts for about 3% of the gastrointestinal and 10-25% 
      of all hepatobiliary malignancies. It arises from the epithelium of the bile duct
      and it can be classified in intrahaepatic (ICC), perihilar (PCC) and distal (DCC)
      cholangiocarcinoma, depending on the anatomical location. About 50-60% of the
      cases are PCC. Early detection is very difficult for the lack of symptoms, and
      most of the patients are not resectable at the time of diagnosis. IRE is a
      non-thermal ablation technique that determines cellular apoptosis by electrical
      impulses without involving extracellular matrix like MW or RF ablation (MWA and
      RFA). The aim of our study is to demonstrate the safety, feasibility and efficacy
      of this procedure in the treatment of cholangiocarcinoma according to our
      experience. From 2015 to 2019, fifteen patients with unre-sectable perhilar and
      intrahepatic colangiocarcinoma (7 female and 8 male, mean age 69.2) were referred
      to our department to be enrolled in our prospective study that was approved by
      local Ethical Committee. Eight lesions were defined iCC and seven of them pCC.
      Six patients had biliary STENT and four external percutaneous transhepatic
      biliary drainage (PTBD). The IRE procedure was performed to expert radiologist
      (G.B.) under CT guidance using the Nanoknife IRE device (Angiodynamics,
      Queensbury, NY). The data before and after treatment were compared using Wilcoxon
      Rank Test and the survival outcome was evaluated using Kaplan Meyer Test. All
      procedures performed under CT guidance have been successfully completed. Treated 
      lesions were located seven perhilar and eight intrahepatic sites and showed a
      mean volume 66.3 (SD 70.9; IC ranged from 5.57 to 267.20 cm(3)). No major
      complications were observed. From 30 to 90 days, the mortality rate was around
      0%. Progression of the disease in all cases were not observed. Only one patient
      was reported increase of the Ca19-9 without sign of pancreatitis and bile
      obstruction. The imaging follow-up showed the local disease control with a
      decrease of the entire volume of the lesion and a further reduction of the
      densitometric values. From the comparison between the mean volumes for each group
      (before and after treatment), the Wilcoxon Rank test demonstrated the statistical
      significant difference with a p value < 0.01. On the contrary, it is believed
      that this results encouraging in considering the IRE procedure the safe, feasible
      and effective method in the treatment of the CC.
FAU - Belfiore, Maria Paola
AU  - Belfiore MP
AD  - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, 
      Naples, Italy.
FAU - Reginelli, Alfonso
AU  - Reginelli A
AUID- ORCID: http://orcid.org/0000-0003-4809-6235
AD  - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, 
      Naples, Italy. alfonso.reginelli@hotmail.com.
FAU - Maggialetti, Nicola
AU  - Maggialetti N
AD  - Department of Medicine and Health Sciences "V. Tiberio", University of Molise,
      Via Francesco De Sanctis 1, Campobasso, Italy.
FAU - Carbone, Mattia
AU  - Carbone M
AD  - Department of Radiology, San Giovanni E Ruggi D'Aragona Hospital, Ospedale, Via
      San Leonardo, Salerno, Italy.
FAU - Giovine, Sabrina
AU  - Giovine S
AD  - Department of Radiology, SG Moscati Hospital, ASL Caserta, Aversa, Italy.
FAU - Laporta, Antonella
AU  - Laporta A
AD  - Department of Radiology, Avellino, Italy.
FAU - Urraro, Fabrizio
AU  - Urraro F
AD  - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, 
      Naples, Italy.
FAU - Nardone, Valerio
AU  - Nardone V
AD  - Unit of Radiation Oncology, Ospedale del Mare, 80147, Naples, Italy.
FAU - Grassi, Roberta
AU  - Grassi R
AD  - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, 
      Naples, Italy.
FAU - Cappabianca, Salvatore
AU  - Cappabianca S
AD  - Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, 
      Naples, Italy.
FAU - Brunese, Luca
AU  - Brunese L
AD  - Department of Medicine and Health Sciences "V. Tiberio", University of Molise,
      Via Francesco De Sanctis 1, Campobasso, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200409
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
SB  - IM
MH  - Ablation Techniques/*methods
MH  - Aged
MH  - Bile Duct Neoplasms/diagnostic imaging/pathology/*surgery
MH  - Cholangiocarcinoma/diagnostic imaging/pathology/*surgery
MH  - *Electroporation
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Prospective Studies
MH  - Surgery, Computer-Assisted
MH  - *Tomography, X-Ray Computed
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cholangiocarcinoma
OT  - Cholangiography-MRI
OT  - IRE
OT  - Intrahepatic-CC
OT  - MWA
OT  - Perihepatic-CC
OT  - RFA
EDAT- 2020/04/10 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
AID - 10.1007/s12032-020-01360-2 [doi]
AID - 10.1007/s12032-020-01360-2 [pii]
PST - epublish
SO  - Med Oncol. 2020 Apr 9;37(5):45. doi: 10.1007/s12032-020-01360-2.


PMID- 32269881
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar 7
TI  - Ethical Artificial Intelligence for Digital Health Organizations.
PG  - e7202
LID - 10.7759/cureus.7202 [doi]
AB  - This technical report describes the methods undertaken by a US-based Digital
      Health company (X2AI or X2 for short) to develop an ethical code for startup
      environments and other organizations delivering emotional artificial intelligence
      (AI) services, especially for mental health support. With a growing demand
      worldwide for scalable, affordable, and accessible health care solutions, the use
      of AI offers tremendous potential to improve emotional well-being. To realize
      this potential, it is imperative that AI service providers prioritize clear and
      consistent ethical guidelines that align with global considerations regarding
      user safety and privacy. This report offers a template for an ethical code that
      can be implemented by other emotional AI services and their affiliates. It
      includes practical guidelines for integrating support from clients,
      collaborators, and research partners. It also shows how existing ethical systems 
      can inform the development of AI ethics.
CI  - Copyright (c) 2020, Joerin et al.
FAU - Joerin, Angela
AU  - Joerin A
AD  - Psychology, X2AI Inc., San Francisco, USA.
FAU - Rauws, Michiel
AU  - Rauws M
AD  - CEO & Founder, X2AI Inc., San Francisco, USA.
FAU - Fulmer, Russell
AU  - Fulmer R
AD  - Counseling, Northwestern University, Evanston, USA.
FAU - Black, Valerie
AU  - Black V
AD  - Anthropology, University of California, Berkeley, USA.
LA  - eng
PT  - Journal Article
DEP - 20200307
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7138421
OTO - NOTNLM
OT  - artificial intelligence
OT  - chatbot
OT  - codes of ethics
OT  - ethics
OT  - healthcare technology
OT  - mental health
COIS- The authors have declared financial relationships, which are detailed in the next
      section.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
CRDT- 2020/04/10 06:00
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
AID - 10.7759/cureus.7202 [doi]
PST - epublish
SO  - Cureus. 2020 Mar 7;12(3):e7202. doi: 10.7759/cureus.7202.


PMID- 32269779
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2054-5703 (Print)
IS  - 2054-5703 (Linking)
VI  - 7
IP  - 3
DP  - 2020 Mar
TI  - Risk communication in tables versus text: a registered report randomized trial on
      'fact boxes'.
PG  - 190876
LID - 10.1098/rsos.190876 [doi]
AB  - OBJECTIVES: identifying effective summary formats is fundamental to multiple
      fields including science communication, systematic reviews, evidence-based policy
      and medical decision-making. This study tested whether table or text-only formats
      lead to better comprehension of the potential harms and benefits of different
      options, here in a medical context. DESIGN: pre-registered, longitudinal
      experiment: between-subjects factorial 2 (message format) x 2 topic (therapeutic 
      or preventative intervention) on comprehension and later recall (CONSORT-SPI
      2018). SETTING: longitudinal online survey experiment. PARTICIPANTS: 2305
      census-matched UK residents recruited through the survey panel firm YouGov.
      PRIMARY OUTCOME MEASURE: comprehension of harms and benefits and knowledge recall
      after six weeks. RESULTS: fact boxes-simple tabular messages-led to more
      comprehension (d = 0.39) and slightly more knowledge recall after six weeks (d = 
      0.12) compared to the same information in text. These patterns of results were
      consistent between the two medical topics and across all levels of objective
      numeracy and education. Fact boxes were rated as more engaging than text, and
      there were no differences between formats in treatment decisions, feeling
      informed or trust. CONCLUSIONS: the brief table format of the fact box improved
      the comprehension of harms and benefits relative to the text-only control.
      Effective communication supports informed consent and decision-making and brings 
      ethical and practical advantages. Fact boxes and other summary formats may be
      effective in a wide range of communication contexts.
CI  - (c) 2020 The Authors.
FAU - Brick, Cameron
AU  - Brick C
AUID- ORCID: 0000-0002-7174-8193
AD  - Winton Centre for Risk and Evidence Communication, Centre for Mathematical
      Sciences, University of Cambridge, Wilberforce Road, Cambridge, CB3 0WA, UK.
AD  - Department of Psychology, University of Amsterdam, 1012 WX Amsterdam, The
      Netherlands.
FAU - McDowell, Michelle
AU  - McDowell M
AUID- ORCID: 0000-0002-1522-757X
AD  - Harding Center for Risk Literacy, University of Potsdam, 14469 Potsdam, Germany.
AD  - Max Planck Institute for Human Development, 14195 Berlin, Germany.
FAU - Freeman, Alexandra L J
AU  - Freeman ALJ
AUID- ORCID: 0000-0002-4115-161X
AD  - Winton Centre for Risk and Evidence Communication, Centre for Mathematical
      Sciences, University of Cambridge, Wilberforce Road, Cambridge, CB3 0WA, UK.
LA  - eng
SI  - figshare/10.6084/m9.figshare.c.4895250
PT  - Journal Article
DEP - 20200325
PL  - England
TA  - R Soc Open Sci
JT  - Royal Society open science
JID - 101647528
PMC - PMC7137953
OTO - NOTNLM
OT  - decision aid
OT  - decision-making
OT  - fact box
OT  - medical decision
OT  - risk communication
OT  - risk literacy
COIS- The authors declare no competing interests.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
CRDT- 2020/04/10 06:00
PHST- 2019/05/13 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
AID - 10.1098/rsos.190876 [doi]
AID - rsos190876 [pii]
PST - epublish
SO  - R Soc Open Sci. 2020 Mar 25;7(3):190876. doi: 10.1098/rsos.190876. eCollection
      2020 Mar.


PMID- 32269412
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210502
IS  - 0734-0451 (Print)
IS  - 0734-0451 (Linking)
VI  - 41
IP  - 2
DP  - 2020 May
TI  - Ethics and Etiquette in Humanitarian Engagement-101.
PG  - 83-91
LID - 10.1055/s-0040-1708526 [doi]
AB  - As the travel industry continues to grow, so does the creation and proliferation 
      of voluntourism opportunities offered to individuals who want to impact the lives
      of populations due to adversities or misfortunes of war, weather, or poverty. A
      more popular form of tourism for individuals to volunteer professional or
      personal expertise in a chartable manner is often termed "voluntourism."
      Unquestionably, there is a lure to volunteer for a short-term experience in
      exotic lands with the hopes of improving living conditions. This article aims to 
      identify how an individual can move from being a well-meaning voluntourist to an 
      engaged and dedicated humanitarian by following professional ethical principles
      and etiquette behavior.
CI  - (c) Thieme Medical Publishers.
FAU - Clark, Jackie L
AU  - Clark JL
AD  - Callier Center, University of Texas at Dallas, Dallas, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200407
PL  - United States
TA  - Semin Hear
JT  - Seminars in hearing
JID - 8413380
PMC - PMC7138635
OTO - NOTNLM
OT  - autonomy
OT  - beneficence
OT  - cultural differences
OT  - ethics
OT  - ethnocentrism
OT  - etiquette
OT  - justice
OT  - maleficence
OT  - voluntourism
COIS- Conflict of Interest The author is a co-founder and current volunteer co-director
      of the Coalition for Global Hearing Health and receives no financial support.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
CRDT- 2020/04/10 06:00
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
AID - 10.1055/s-0040-1708526 [doi]
AID - 00824 [pii]
PST - ppublish
SO  - Semin Hear. 2020 May;41(2):83-91. doi: 10.1055/s-0040-1708526. Epub 2020 Apr 7.


PMID- 32269028
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 7
TI  - Effectiveness of nicotine replacement therapy sample at outdoor smoking hotspots 
      for initiating quit attempts and use of smoking cessation services: a protocol
      for a cluster randomised controlled trial.
PG  - e036339
LID - 10.1136/bmjopen-2019-036339 [doi]
AB  - INTRODUCTION: More than half of the smoking population in Hong Kong are
      unmotivated to quit. Only about 2% of tobacco users in the territory have ever
      used cessation aids such as nicotine replacement therapy (NRT). The present study
      aims to assess the effectiveness of delivering 1-week free NRT sample plus brief 
      intervention to smokers at outdoor smoking hotspots on quit attempts and use of
      smoking cessation services. METHODS AND ANALYSIS: This is a two-arm, pragmatic,
      multisite, cluster randomised controlled trial (RCT) on the effectiveness of
      increasing quit attempts, use of cessation service and recruitment outcomes.
      Trained smoking cessation ambassadors will approach smokers at outdoor smoking
      hotspots, and deliver brief smoking cessation advice. Recruitment sessions are
      randomised to intervention or control group (allocation ratio 1:1). Participants 
      in the intervention group (n=550) will receive 1-week free NRT sample (either
      patch or gum), brief medication advice from an onsite nurse and cessation service
      referral, whereas participants in control group (n=275) will only receive the
      brief advice and service referral. The primary outcomes are the proportion of
      participants who enrol in any cessation service in Hong Kong within 1 month of
      the recruitment, and the proportion of participants who report quit attempts at
      1-month follow-up. Secondary outcomes include self-reported use of NRT,
      self-reported 7-day tobacco abstinence, 30-day abstinence at 3 months and 6
      months, biochemically validated abstinence at 6 months, perceived importance,
      difficulty and confidence to quit (scale 0-10), and Incremental Behavior Change
      towards Smoking Cessation. Process outcomes include number of smokers who will be
      approached, will accept the brief smoking cessation advice or be recruited to
      participate in the RCT. ETHICS AND DISSEMINATION: The Institutional Review Board 
      of the University of Hong Kong/Hospital Authority Hong Kong West Cluster approved
      the trial (UW 18-118). Findings will be disseminated through funding website,
      publication and conference presentations. TRIAL REGISTRATION NUMBER: NCT03717051.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cheung, Yee Tak Derek
AU  - Cheung YTD
AUID- ORCID: 0000-0002-5850-5349
AD  - School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong
      derekcheung@hku.hk.
FAU - Chan, Ching Han Helen
AU  - Chan CHH
AD  - Integrated Centre on Smoking Cessation, Tung Wah Group of Hospitals, Hong Kong,
      Hong Kong.
FAU - Ho, Kin Sang
AU  - Ho KS
AD  - Integrated Centre on Smoking Cessation, Tung Wah Group of Hospitals, Hong Kong,
      Hong Kong.
FAU - Tang, Celeste
AU  - Tang C
AD  - Integrated Centre on Smoking Cessation, Tung Wah Group of Hospitals, Hong Kong,
      Hong Kong.
FAU - Lau, Chloe Wing Hei
AU  - Lau CWH
AD  - School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong.
FAU - Li, William Ho Cheung
AU  - Li WHC
AUID- ORCID: 0000-0002-3195-7695
AD  - School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong.
FAU - Wang, Man Ping
AU  - Wang MP
AUID- ORCID: 0000-0003-4000-2388
AD  - School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong.
FAU - Lam, Tai Hing
AU  - Lam TH
AD  - School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong.
LA  - eng
SI  - ClinicalTrials.gov/NCT03717051
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200407
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Hong Kong
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Smokers
MH  - Smoking
MH  - Smoking Cessation/*methods
MH  - *Smoking Prevention
MH  - *Tobacco Use Cessation Devices
PMC - PMC7170641
OTO - NOTNLM
OT  - *brief intervention
OT  - *nicotine replacement therapy
OT  - *smoking cessation
OT  - *smoking hotpsots
COIS- Competing interests: THL is the principal investigator of two-family well-being
      projects, and MPW is the coinvestigator of one of the two projects funded by Hong
      Kong Jockey Club Charities Trust. All other authors have no connection with
      tobacco, alcohol, pharmaceutical or gaming industries or anybody substantially
      funded by these organisations.
EDAT- 2020/04/10 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
AID - bmjopen-2019-036339 [pii]
AID - 10.1136/bmjopen-2019-036339 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 7;10(4):e036339. doi: 10.1136/bmjopen-2019-036339.


PMID- 32269027
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 7
TI  - Prevalence and clinical implications of respiratory viruses in stable chronic
      obstructive pulmonary disease (COPD) and exacerbations: a systematic review and
      meta-analysis protocol.
PG  - e035640
LID - 10.1136/bmjopen-2019-035640 [doi]
AB  - INTRODUCTION: Both stable chronic obstructive pulmonary disease (COPD) and acute 
      exacerbations represent leading causes of death, disability and healthcare
      expenditure. They are complex, heterogeneous and their mechanisms are poorly
      understood. The role of respiratory viruses has been studied extensively but is
      still not adequately addressed clinically. Through a rigorous evidence update, we
      aim to define the prevalence and clinical burden of the different respiratory
      viruses in stable COPD and exacerbations, and to investigate whether viral load
      of usual respiratory viruses could be used for diagnosis of exacerbations
      triggered by viruses, which are currently not diagnosed or treated
      aetiologically. METHODS AND ANALYSIS: Based on a prospectively registered
      protocol, we will systematically review the literature using standard methods
      recommended by the Cochrane Collaboration and the Grading of Recommendations
      Assessment, Development and Evaluation working group. We will search
      Medline/PubMed, Excerpta Medica dataBASE (EMBASE), the Cochrane Library, the
      WHO's Clinical Trials Registry and the proceedings of relevant international
      conferences on 2 March 2020. We will evaluate: (A) the prevalence of respiratory 
      viruses in stable COPD and exacerbations, (B) differences in the viral loads of
      respiratory viruses in stable COPD vs exacerbations, to explore whether the viral
      load of prevalent respiratory viruses could be used as a diagnostic biomarker for
      exacerbations triggered by viruses and (C) the association between the presence
      of respiratory viruses and clinical outcomes in stable COPD and in exacerbations.
      ETHICS AND DISSEMINATION: Ethics approval is not required since no primary data
      will be collected. Our findings will be presented in national and international
      scientific conferences and will be published in peer reviewed journals.
      Respiratory viruses currently represent a lost opportunity to improve the
      outcomes of both stable COPD and exacerbations. Our work aspires to 'demystify'
      the prevalence and clinical burden of viruses in stable COPD and exacerbations
      and to promote clinical and translational research. PROSPERO REGISTRATION NUMBER:
      CRD42019147658.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Kefala, Anastasia M
AU  - Kefala AM
AD  - Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.
FAU - Fortescue, Rebecca
AU  - Fortescue R
AD  - Cochrane Airways, Population Health Research Institute, University of London
      Saint George's, London, UK.
FAU - Alimani, Gioulinta S
AU  - Alimani GS
AD  - Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.
AD  - Athens Breath Centre, Athens, Greece.
FAU - Kanavidis, Prodromos
AU  - Kanavidis P
AD  - First Department of Surgery, Laikon General Hospital, National and Kapodistrian
      University of Athens, Athens, Greece.
FAU - McDonnell, Melissa Jane
AU  - McDonnell MJ
AD  - Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland.
FAU - Magiorkinis, Emmanouil
AU  - Magiorkinis E
AD  - Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.
AD  - Department of Laboratory Haematology, Sotiria Regional Chest Disease Hospital of 
      Athens, Athens, Greece.
FAU - Megremis, Spyridon
AU  - Megremis S
AD  - Division of Evolution and Genomic Science, The University of Manchester,
      Manchester, UK.
FAU - Paraskevis, Dimitrios
AU  - Paraskevis D
AD  - Department of Hygiene, Epidemiology and Medical Statistics, National and
      Kapodistrian University of Athens, Athens, Greece.
FAU - Voyiatzaki, Chrysa
AU  - Voyiatzaki C
AD  - Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.
FAU - Mathioudakis, Georgios A
AU  - Mathioudakis GA
AD  - Athens Breath Centre, Athens, Greece.
FAU - Papageorgiou, Effie
AU  - Papageorgiou E
AD  - Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.
FAU - Papadopoulos, Nikolaos G
AU  - Papadopoulos NG
AD  - Division of Infection, Immunity and Respiratory Medicine, The University of
      Manchester, Manchester, UK.
AD  - Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University
      of Athens, Athens, Greece.
FAU - Vestbo, Jorgen
AU  - Vestbo J
AD  - Division of Infection, Immunity and Respiratory Medicine, The University of
      Manchester, Manchester, UK.
AD  - North West Lung Centre, Manchester University NHS Foundation Trust, Manchester
      Academic Health Science Centre, Manchester, UK.
FAU - Beloukas, Apostolos
AU  - Beloukas A
AUID- ORCID: 0000-0001-5639-0528
AD  - Department of Biomedical Sciences, University of West Attica, Egaleo, Greece.
AD  - Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
FAU - Mathioudakis, Alexander G
AU  - Mathioudakis AG
AUID- ORCID: 0000-0002-4675-9616
AD  - Division of Infection, Immunity and Respiratory Medicine, The University of
      Manchester, Manchester, UK alexander.mathioudakis@manchester.ac.uk.
AD  - North West Lung Centre, Manchester University NHS Foundation Trust, Manchester
      Academic Health Science Centre, Manchester, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200407
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Disease Progression
MH  - Humans
MH  - *Meta-Analysis as Topic
MH  - Prevalence
MH  - Pulmonary Disease, Chronic Obstructive/physiopathology/*virology
MH  - Respiratory Tract Infections/*epidemiology/physiopathology/virology
MH  - Spirometry
MH  - *Systematic Reviews as Topic
MH  - *Viral Load
MH  - Virus Diseases/*epidemiology/physiopathology/virology
PMC - PMC7170624
OTO - NOTNLM
OT  - *adult thoracic medicine
OT  - *chronic airways disease
OT  - *epidemiology
OT  - *respiratory infections
COIS- Competing interests: DP reports grants form Gilead Sciences, GSK, Janssen and
      MSD, outside the submitted work. NGP reports personal fees from Novartis,
      Nutricia, HAL, Menarini/Faes Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GSK,
      MSD, Asit Biotech, Boehringer Ingelheim and grans from Gerolymatos International 
      SA and Capricare, outside the submitted work. JV reports personal fees from
      Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis, AstraZeneca, GSK, outside
      the submitted work. AGM reports grants from Boehringer Ingelheim, outside the
      submitted work.
EDAT- 2020/04/10 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
AID - bmjopen-2019-035640 [pii]
AID - 10.1136/bmjopen-2019-035640 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 7;10(4):e035640. doi: 10.1136/bmjopen-2019-035640.


PMID- 32269026
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 7
TI  - Effect of a web drama video series on HIV and other sexually transmitted
      infection testing among gay, bisexual and queer men: study protocol for a
      community-based, pragmatic randomised controlled trial in Singapore: the People
      Like Us (PLU) Evaluation Study.
PG  - e033855
LID - 10.1136/bmjopen-2019-033855 [doi]
AB  - INTRODUCTION: Gay, bisexual and queer (GBQ) men are at disproportionately higher 
      risk of acquiring HIV and other sexually transmitted infections (STI). While
      HIV/STI testing rates among GBQ men are increasing worldwide, they remain
      suboptimal in a variety of settings. METHODS AND ANALYSIS: The study is a
      pragmatic randomised controlled trial designed to evaluate an online video series
      developed by a community-based organisation in Singapore for GBQ men. A total of 
      300 HIV-negative GBQ men in Singapore aged 18-29 years old will be recruited for 
      this study. Participants will subsequently be randomised into the intervention
      arm (n=150) and the control arm (n=150). The intervention arm (n=150) will be
      assigned the intervention along with sexual health information via a pamphlet,
      while the control group (n=150) will be assigned only the sexual health
      information via a pamphlet. Participants should also not have watched the video
      prior to their participation in this study, which will be ascertained through a
      questionnaire. Primary outcomes for this evaluation are changes in self-reported 
      intention to test for, actual testing for and regularity of testing for HIV,
      syphilis, chlamydia and gonorrhoea at the 3 and 6 months after intervention.
      Secondary outcomes include changes in self-reported risk perception for HIV and
      other STIs, knowledge of HIV, knowledge of risks associated with acquiring STIs, 
      knowledge of HIV pre-exposure prophylaxis, consistent condom use for anal sex
      with casual partners, incidence of STIs, connectedness to the lesbian, gay,
      bisexual and transgender community, self-concealment of sexual orientation,
      perceived homophobia, internalised homophobia, HIV testing self-efficacy and HIV 
      testing social norms. ETHICS AND DISSEMINATION: The study has been approved by
      the National University of Singapore Institutional Review Board (S-19-059) and
      registered at ClinicalTrials.gov. The results will be published in peer-reviewed 
      academic journals and disseminated to community-based organisations and
      policymakers. TRIAL REGISTRATION NUMBER: NCT04021953.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Tan, Rayner Kay Jin
AU  - Tan RKJ
AUID- ORCID: 0000-0002-9188-3368
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Singapore rayner.tan@u.nus.edu.
FAU - Koh, Wee Ling
AU  - Koh WL
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Singapore.
FAU - Le, Daniel
AU  - Le D
AD  - Action for AIDS Singapore, Singapore.
FAU - Tan, Avin
AU  - Tan A
AD  - Action for AIDS Singapore, Singapore.
FAU - Tyler, Adrian
AU  - Tyler A
AD  - Action for AIDS Singapore, Singapore.
FAU - Tan, Calvin
AU  - Tan C
AD  - Action for AIDS Singapore, Singapore.
FAU - Banerjee, Sumita
AU  - Banerjee S
AD  - Action for AIDS Singapore, Singapore.
FAU - Wong, Chen Seong
AU  - Wong CS
AD  - National Centre for Infectious Diseases, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Wong, Mee-Lian
AU  - Wong ML
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Singapore.
FAU - Chio, Martin Tze-Wei
AU  - Chio MT
AD  - Department of STI Control (DSC) Clinic, National Skin Centre, Singapore.
FAU - Chen, Mark I-Cheng
AU  - Chen MI
AD  - Saw Swee Hock School of Public Health, National University of Singapore and
      National University Health System, Singapore.
AD  - National Centre for Infectious Diseases, Singapore.
LA  - eng
SI  - ClinicalTrials.gov/NCT04021953
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200407
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Chlamydia Infections/diagnosis
MH  - Drama
MH  - Gonorrhea/diagnosis
MH  - HIV Infections/diagnosis/epidemiology
MH  - HIV Seronegativity
MH  - HIV Testing
MH  - Health Education/*methods
MH  - Homosexuality, Male
MH  - Humans
MH  - Intention
MH  - *Internet
MH  - Male
MH  - Motion Pictures
MH  - *Pamphlets
MH  - Sample Size
MH  - Self Report
MH  - *Sexual and Gender Minorities
MH  - Sexually Transmitted Diseases/*diagnosis
MH  - Singapore/epidemiology
MH  - Syphilis/diagnosis
MH  - *Video Recording
MH  - Young Adult
PMC - PMC7170638
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *infectious diseases
OT  - *public health
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/10 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-033855 [pii]
AID - 10.1136/bmjopen-2019-033855 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 7;10(4):e033855. doi: 10.1136/bmjopen-2019-033855.


PMID- 32268922
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Apr 8
TI  - Protocol for a scoping review of the current data practices in forensic medicine.
PG  - 76
LID - 10.1186/s13643-020-01308-7 [doi]
AB  - BACKGROUND: Data related to forensic postmortems or autopsies are still mainly
      captured in hard copy format and archived. This paper-based practice impacts on
      the practitioner's ability to report on incidence, prevalence, and statistical
      trends related to cases that are commonly seen in mortuaries in forensic
      medicine. An autopsy can be used to inform and provide evidence-based knowledge
      for further research about important issues, including social development and
      assist in providing statistics and data for public health initiatives for
      implementation and monitoring. Currently, in forensic medicine and pathology
      research developments are largely hampered by the inefficient data capturing
      system which only allows access to basic information while pertinent information 
      is largely recorded manually and is therefore difficult to obtain. There is thus 
      a need to improve the efficiency of the data capturing system in forensic
      pathology, and this review is intended to inform the choice and decisions of
      appropriate data capture practices and is being conducted to identify nationally 
      and internationally the current data mining and storage systems in place.
      METHODS: The methodology for this scoping review will be guided by the
      methodological framework for scoping review. The search strategy was developed by
      the authors, and we will conduct a search from 1 January 2008 of electronic
      databases (Cochrane Library, Scopus, Web of Science, and Science Direct) and
      search through WorldCat and PubMed for citations and literature using both
      keywords and the Medical Subject Headings (MeSH).The electronic search will be
      supplemented by hand searching references of the included studies and references 
      in journals and websites. All articles will be assessed for eligibility by two
      reviewers (the primary and secondary authors) and uploaded into EndNote Excel
      spreadsheet, and duplicates will be identified and removed. The two reviewers
      (primary and secondary authors) will screen the eligible abstracts and articles
      against the inclusion criteria, and selection will be on a minimum percentage
      agreement of 50%. The selection process will be documented by following and using
      a PRISMA flow diagram. The extracted data will be analyzed and reported in the
      form of a narrative review with descriptive analysis and text analysis once the
      data is summarized for description and characterization. DISCUSSION: The results 
      of this review will identify and describe data capturing, management, and storage
      practices for use in forensic medicine. It will also review the efficiency of the
      different data systems and report where possible on the uses of the data system
      within the forensic medicine and pathology field. ETHICS AND DISSEMINATION:
      Although research ethics approval is not required for this scoping review because
      the study will not include human or animal participants, the study was submitted 
      for approval to the University of Kwazulu Natal Biomedical Research Ethics
      Committee and obtained provisional approval. Data will be sourced only from
      published literature and gray literature. The results will be presented at
      relevant national and international conferences and published in a peer-reviewed 
      journal. All search results including excluded studies will be added into an
      addendum in the article and made available for public perusal to therefore ensure
      transparency and reproducibility.
FAU - Prahladh, Salona
AU  - Prahladh S
AD  - Department of Forensic Medicine, Inkosi Albert Luthuli Central Hospital, 800 Vusi
      Mzimela Rd, Umkumbaan, Durban, 4091, South Africa. sprahladh@gmail.com.
FAU - van Wyk, Jacqueline
AU  - van Wyk J
AD  - Discipline of Clinical and Professional Practice, College of Health Sciences,
      University of KwaZulu-Natal, Durban, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
MH  - *Delivery of Health Care
MH  - Forensic Medicine
MH  - Humans
MH  - Reproducibility of Results
MH  - *Research Design
MH  - Review Literature as Topic
MH  - Systematic Reviews as Topic
PMC - PMC7140479
OTO - NOTNLM
OT  - *Autopsy
OT  - *Data
OT  - *Database
OT  - *Forensic medicine
OT  - *Forensic pathology
OT  - *Postmortem examination
EDAT- 2020/04/10 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.1186/s13643-020-01308-7 [doi]
AID - 10.1186/s13643-020-01308-7 [pii]
PST - epublish
SO  - Syst Rev. 2020 Apr 8;9(1):76. doi: 10.1186/s13643-020-01308-7.


PMID- 32268908
OWN - NLM
STAT- MEDLINE
DCOM- 20201102
LR  - 20201102
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Apr 8
TI  - Medical education: an Italian contribution to the discussion on global health
      education.
PG  - 30
LID - 10.1186/s12992-020-00561-8 [doi]
AB  - BACKGROUND: In Italy an important contribution to the spread of global health
      education (GHE) grew from the establishment and work of the Italian Network for
      Global Health Education (INGHE). INGHE gave a national shared definition of
      global health (GH), grounded in the theory of determinants of health, inspired by
      a vision of social justice, and committed to reduce health inequities. The aim of
      this article is to share with the international community INGHE's point of view
      on Medical Education. METHODS: To express its view of medical education at the
      national level, INGHE established a dedicated commission, which elaborated a
      first draft of the document and then shared and discussed it with all other
      members. RESULTS: INGHE elaborated a paper where it explained the need to change 
      medical education in order to prepare future health professionals for the
      challenges of the globalized and unequal world. In this article the authors
      summarize the experience of INGHE and share with the international community its 
      document. CONCLUSIONS: The authors believe it is necessary now, more than ever,
      to insert this new approach to health at social and academic levels. Students
      should play a fundamental role in the spread of GHE, and activities related with 
      GHE could be considered an important part of the third mission of universities to
      promote social justice.
FAU - Civitelli, Giulia
AU  - Civitelli G
AD  - Public Health and Infectious Diseases Department, Sapienza University of Rome,
      Piazzale Aldo Moro 5, 00185, Rome, Italy. giulia.civitelli@uniroma1.it.
AD  - Italian Network for Global Health Education (INGHE), Rome, Italy.
      giulia.civitelli@uniroma1.it.
AD  - Italian Society of Migration Medicine (SIMM - Societa Italiana di Medicina delle 
      Migrazioni), Rome, Italy. giulia.civitelli@uniroma1.it.
AD  - Caritas Medical Area, Rome, Italy. giulia.civitelli@uniroma1.it.
FAU - Tarsitani, Gianfranco
AU  - Tarsitani G
AD  - Public Health and Infectious Diseases Department, Sapienza University of Rome,
      Piazzale Aldo Moro 5, 00185, Rome, Italy.
AD  - Italian Network for Global Health Education (INGHE), Rome, Italy.
FAU - Rinaldi, Alessandro
AU  - Rinaldi A
AD  - Public Health and Infectious Diseases Department, Sapienza University of Rome,
      Piazzale Aldo Moro 5, 00185, Rome, Italy.
AD  - Italian Network for Global Health Education (INGHE), Rome, Italy.
AD  - Italian Society of Migration Medicine (SIMM - Societa Italiana di Medicina delle 
      Migrazioni), Rome, Italy.
FAU - Marceca, Maurizio
AU  - Marceca M
AD  - Public Health and Infectious Diseases Department, Sapienza University of Rome,
      Piazzale Aldo Moro 5, 00185, Rome, Italy.
AD  - Italian Network for Global Health Education (INGHE), Rome, Italy.
AD  - Italian Society of Migration Medicine (SIMM - Societa Italiana di Medicina delle 
      Migrazioni), Rome, Italy.
AD  - Italian Society of Medical Education (SIPEM - Societa Italiana di Pedagogia
      Medica), Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
SB  - IM
MH  - Education, Medical/*standards/trends
MH  - Global Health/*trends
MH  - Humans
MH  - Italy
PMC - PMC7140347
OTO - NOTNLM
OT  - *Determinants of health
OT  - *Global health
OT  - *Inequities in health
OT  - *Medical education
OT  - *Medical ethics
OT  - *University's third mission
EDAT- 2020/04/10 06:00
MHDA- 2020/11/03 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/11/03 06:00 [medline]
AID - 10.1186/s12992-020-00561-8 [doi]
AID - 10.1186/s12992-020-00561-8 [pii]
PST - epublish
SO  - Global Health. 2020 Apr 8;16(1):30. doi: 10.1186/s12992-020-00561-8.


PMID- 32268890
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Apr 8
TI  - An interprofessional cohort analysis of student interest in medical ethics
      education: a survey-based quantitative study.
PG  - 26
LID - 10.1186/s12910-020-00468-4 [doi]
AB  - BACKGROUND: There is continued need for enhanced medical ethics education across 
      the United States. In an effort to guide medical ethics education reform, we
      report the first interprofessional survey of a cohort of graduate medical,
      nursing and allied health professional students that examined perceived student
      need for more formalized medical ethics education and assessed preferences for
      teaching methods in a graduate level medical ethics curriculum. METHODS: In
      January 2018, following the successful implementation of a peer-led, grassroots
      medical ethics curriculum, student leaders under faculty guidance conducted a
      cross-sectional survey with 562 of 1357 responses received (41% overall response 
      rate) among students enrolled in the School of Medicine, College of Nursing,
      Doctor of Physical Therapy and BS/(D) MD Professional Scholars programs at The
      Medical College of Georgia at Augusta University. An in person or web-based
      questionnaire was designed to measure perceived need for a more in-depth medical 
      ethics curriculum. RESULTS: The majority of respondents were female (333, 59.3%),
      white (326, 58.0%) and mid-20s in age (340, 60.5%). Almost half of respondents
      (47%) reported no prior medical ethics exposure or training in their previous
      educational experience, while 60% of students across all degree programs reported
      an interest in more medical ethics education and 92% noted that an understanding 
      of medical ethics was important to their future career. Over a quarter of
      students (28%) were interested in pursuing graduate-level training in medical
      ethics, with case-based discussions, small group peer settings and ethics guest
      lectures being the most desired teaching methods. CONCLUSIONS: The future
      physician, nursing and physical therapist workforce in our medical community
      demonstrated an unmet need and strong interest for more formal medical ethics
      education within their current coursework. Grassroots student-driven curricular
      development and leadership in medical ethics can positively impact medical
      education. Subsequent integration of interprofessional training in medical ethics
      may serve as a vital curricular approach to improving the training of ethically
      competent healthcare professionals and overcoming the current hierarchical
      clinical silos.
FAU - DeFoor, Mikalyn T
AU  - DeFoor MT
AUID- ORCID: 0000-0002-3164-1615
AD  - School of Medicine, Medical College of Georgia at Augusta University, Augusta,
      GA, 30909, USA. mdefoor@augusta.edu.
FAU - Chung, Yunmi
AU  - Chung Y
AD  - Institute of Public and Preventative Health, Augusta University, Augusta, GA,
      30909, USA.
FAU - Zadinsky, Julie K
AU  - Zadinsky JK
AD  - Augusta University College of Nursing, Augusta, GA, 30909, USA.
FAU - Dowling, Jeffrey
AU  - Dowling J
AD  - Augusta University Rehabilitation, Augusta, GA, 30909, USA.
AD  - Center for Bioethics and Health Policy, Medical College of Georgia at Augusta
      University, Augusta, GA, 30909, USA.
FAU - Sams, Richard W 2nd
AU  - Sams RW 2nd
AD  - Center for Bioethics and Health Policy, Medical College of Georgia at Augusta
      University, Augusta, GA, 30909, USA.
AD  - Department of Family Medicine, Medical College of Georgia at Augusta University, 
      Augusta, GA, 30909, USA.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Cross-Sectional Studies
MH  - Curriculum
MH  - *Education, Medical
MH  - *Ethics, Medical
MH  - Female
MH  - Humans
MH  - Interprofessional Relations
MH  - Male
MH  - Students
MH  - *Students, Medical
MH  - Surveys and Questionnaires
MH  - United States
PMC - PMC7140336
OTO - NOTNLM
OT  - *Curriculum
OT  - *Healthcare ethics
OT  - *Interprofessional education (IPE)
OT  - *Medical education
OT  - *Medical ethics
EDAT- 2020/04/10 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/08/07 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00468-4 [doi]
AID - 10.1186/s12910-020-00468-4 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Apr 8;21(1):26. doi: 10.1186/s12910-020-00468-4.


PMID- 32268869
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 2212-3946 (Electronic)
IS  - 1574-888X (Linking)
VI  - 15
IP  - 5
DP  - 2020
TI  - Bio-mimicking Shear Stress Environments for Enhancing Mesenchymal Stem Cell
      Differentiation.
PG  - 414-427
LID - 10.2174/1574888X15666200408113630 [doi]
AB  - Mesenchymal stem cells (MSCs) are multipotent stromal cells, with the ability to 
      differentiate into mesodermal (e.g., adipocyte, chondrocyte, hematopoietic,
      myocyte, osteoblast), ectodermal (e.g., epithelial, neural) and endodermal (e.g.,
      hepatocyte, islet cell) lineages based on the type of induction cues provided. As
      compared to embryonic stem cells, MSCs hold a multitude of advantages from a
      clinical translation perspective, including ease of isolation, low immunogenicity
      and limited ethical concerns. Therefore, MSCs are a promising stem cell source
      for different regenerative medicine applications. The in vitro differentiation of
      MSCs into different lineages relies on effective mimicking of the in vivo milieu,
      including both biochemical and mechanical stimuli. As compared to other
      biophysical cues, such as substrate stiffness and topography, the role of fluid
      shear stress (SS) in regulating MSC differentiation has been investigated to a
      lesser extent although the role of interstitial fluid and vascular flow in
      regulating the normal physiology of bone, muscle and cardiovascular tissues is
      well-known. This review aims to summarise the current state-of-the-art regarding 
      the role of SS in the differentiation of MSCs into osteogenic, cardiovascular,
      chondrogenic, adipogenic and neurogenic lineages. We will also highlight and
      discuss the potential of employing SS to augment the differentiation of MSCs to
      other lineages, where SS is known to play a role physiologically but has not yet 
      been successfully harnessed for in vitro differentiation, including liver, kidney
      and corneal tissue lineage cells. The incorporation of SS, in combination with
      biochemical and biophysical cues during MSC differentiation, may provide a
      promising avenue to improve the functionality of the differentiated cells by more
      closely mimicking the in vivo milieu.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Arora, Seep
AU  - Arora S
AD  - Department of Biomedical Engineering, National University of Singapore, 21 Lower 
      Kent Ridge Rd, 117583, Singapore.
FAU - Srinivasan, Akshaya
AU  - Srinivasan A
AD  - Department of Biomedical Engineering, National University of Singapore, 21 Lower 
      Kent Ridge Rd, 117583, Singapore.
FAU - Leung, Chak Ming
AU  - Leung CM
AD  - Department of Biomedical Engineering, National University of Singapore, 21 Lower 
      Kent Ridge Rd, 117583, Singapore.
FAU - Toh, Yi-Chin
AU  - Toh YC
AD  - Department of Biomedical Engineering, National University of Singapore, 21 Lower 
      Kent Ridge Rd, 117583, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Stem Cell Res Ther
JT  - Current stem cell research & therapy
JID - 101272517
SB  - IM
MH  - Animals
MH  - *Biomimetics
MH  - *Cell Differentiation
MH  - Cell Lineage
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology
MH  - *Shear Strength
MH  - *Stress, Mechanical
OTO - NOTNLM
OT  - Mesenchymal stem cells
OT  - biomimicking
OT  - differentiation
OT  - mechanical stimulus
OT  - microenvironmental cues
OT  - shear stress
EDAT- 2020/04/10 06:00
MHDA- 2021/05/28 06:00
CRDT- 2020/04/10 06:00
PHST- 2019/08/31 00:00 [received]
PHST- 2019/09/03 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/04/10 06:00 [entrez]
AID - CSCR-EPUB-105722 [pii]
AID - 10.2174/1574888X15666200408113630 [doi]
PST - ppublish
SO  - Curr Stem Cell Res Ther. 2020;15(5):414-427. doi:
      10.2174/1574888X15666200408113630.


PMID- 32268617
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2076-2615 (Print)
IS  - 2076-2615 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Animals in Moral Limbo: How Literary Pigs May Help Lab-Generated Ones.
LID - E629 [pii]
LID - 10.3390/ani10040629 [doi]
AB  - When considering that artistic and literary artifacts reflect the cultural views 
      and mores of a particular time period, there is a significant misalignment
      between stories depicting increased moral status of pigs (e.g., vis-a-vis
      human-porcine relationships) and ongoing practices of pig consumption,
      commodification, and medical experimentation. In fact, there has been increased
      industrial farm meat production and biotechnological experimentation.
      Xenotransplantation trials, for example, are being heralded "the answer" to organ
      shortages needed for human transplantation, while significant ethical concerns
      persist. In this paper, I posit that literary reflections add a valuable
      dimension to animal ethics deliberations, providing a meta-narrative against
      which to assess normative practices. Beginning with synopses of three books: E.B.
      White's Charlotte's Web (1952), Robert Newton Peck's A Day No Pigs Would Die
      (1972), and Paul Griffin's Saving Marty (2017), I illustrate a shifting moral
      status view of human-pig relationships. Next, I discuss personhood attributions
      through biological, philosophical, and legal frameworks; review benefits and
      risks of xenotransplantation; reflect on the moral status of non-human animals;
      and offer concluding thoughts.
FAU - Tuck, Nancy
AU  - Tuck N
AD  - Albany Medical College, Alden March Bioethics Institute, 43 New Scotland Avenue, 
      Albany, NY 12208, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200406
PL  - Switzerland
TA  - Animals (Basel)
JT  - Animals : an open access journal from MDPI
JID - 101635614
PMC - PMC7222736
OTO - NOTNLM
OT  - animal ethics
OT  - animal experimentation
OT  - animal moral status
OT  - animal welfare
COIS- This author has no conflicts of interest to declare.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
CRDT- 2020/04/10 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/03/29 00:00 [revised]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
AID - ani10040629 [pii]
AID - 10.3390/ani10040629 [doi]
PST - epublish
SO  - Animals (Basel). 2020 Apr 6;10(4). pii: ani10040629. doi: 10.3390/ani10040629.


PMID- 32268509
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201001
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 7
DP  - 2020 Apr 6
TI  - Big Data and Digitalization in Dentistry: A Systematic Review of the Ethical
      Issues.
LID - E2495 [pii]
LID - 10.3390/ijerph17072495 [doi]
AB  - Big Data and Internet and Communication Technologies (ICT) are being increasingly
      implemented in the healthcare sector. Similarly, research in the field of dental 
      medicine is exploring the potential beneficial uses of digital data both for
      dental practice and in research. As digitalization is raising numerous novel and 
      unpredictable ethical challenges in the biomedical context, our purpose in this
      study is to map the debate on the currently discussed ethical issues in digital
      dentistry through a systematic review of the literature. Four databases (Web of
      Science, Pub Med, Scopus, and Cinahl) were systematically searched. The study
      results highlight how most of the issues discussed by the retrieved literature
      are in line with the ethical challenges that digital technologies are introducing
      in healthcare such as privacy, anonymity, security, and informed consent. In
      addition, image forgery aimed at scientific misconduct and insurance fraud was
      frequently reported, together with issues of online professionalism and
      commercial interests sought through digital means.
FAU - Favaretto, Maddalena
AU  - Favaretto M
AD  - Institute for Biomedical Ethics, University of Basel, 4056 Basel, Switzerland.
FAU - Shaw, David
AU  - Shaw D
AD  - Institute for Biomedical Ethics, University of Basel, 4056 Basel, Switzerland.
FAU - De Clercq, Eva
AU  - De Clercq E
AD  - Institute for Biomedical Ethics, University of Basel, 4056 Basel, Switzerland.
FAU - Joda, Tim
AU  - Joda T
AD  - Department of Reconstructive Dentistry, University Center for Dental Medicine
      Basel, 4058 Basel, Switzerland.
FAU - Elger, Bernice Simone
AU  - Elger BS
AD  - Institute for Biomedical Ethics, University of Basel, 4056 Basel, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200406
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Big Data
MH  - *Dentistry
MH  - Humans
MH  - Informed Consent
MH  - *Physician-Patient Relations
MH  - Privacy
PMC - PMC7177351
OTO - NOTNLM
OT  - *Big Data
OT  - *digital dentistry
OT  - *ethical issues
OT  - *oral health
EDAT- 2020/04/10 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/04/10 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/04/03 00:00 [revised]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - ijerph17072495 [pii]
AID - 10.3390/ijerph17072495 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Apr 6;17(7). pii: ijerph17072495. doi:
      10.3390/ijerph17072495.


PMID- 32268023
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20200414
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 382
IP  - 15
DP  - 2020 Apr 9
TI  - Standing Up against Gender Bias and Harassment - A Matter of Professional Ethics.
PG  - 1385-1387
LID - 10.1056/NEJMp1915351 [doi]
FAU - Mello, Michelle M
AU  - Mello MM
AUID- ORCID: 0000-0003-2877-4270
AD  - From Stanford Law School and the Department of Medicine, Stanford University
      School of Medicine, Stanford, CA (M.M.M.); and the Department of Radiation
      Oncology and the Center for Bioethics and Social Sciences, University of Michigan
      Medical School, Ann Arbor (R.J.).
FAU - Jagsi, Reshma
AU  - Jagsi R
AD  - From Stanford Law School and the Department of Medicine, Stanford University
      School of Medicine, Stanford, CA (M.M.M.); and the Department of Radiation
      Oncology and the Center for Bioethics and Social Sciences, University of Michigan
      Medical School, Ann Arbor (R.J.).
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - IM
MH  - Codes of Ethics
MH  - *Ethics, Professional
MH  - Female
MH  - Humans
MH  - Interprofessional Relations/ethics
MH  - Male
MH  - Sexism/ethics/*prevention & control
MH  - Sexual Harassment/ethics/*prevention & control
EDAT- 2020/04/09 06:00
MHDA- 2020/04/15 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
AID - 10.1056/NEJMp1915351 [doi]
PST - ppublish
SO  - N Engl J Med. 2020 Apr 9;382(15):1385-1387. doi: 10.1056/NEJMp1915351.


PMID- 32267779
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20210223
IS  - 1939-6376 (Electronic)
IS  - 1939-6368 (Linking)
VI  - 66
IP  - 3
DP  - 2020 Jun
TI  - Flaws (and quality) in research today: can artificial intelligence intervene?
PG  - 170-175
LID - 10.1080/19396368.2020.1749727 [doi]
AB  - The existing flaws in both conducting and reporting of research have been
      outlined and criticized in the past. Weak research design, poor methodology, lack
      of fresh ideas and poor reporting are the main points to blame. Issues have been 
      continually raised on the types of results published, review process,
      sponsorship, notion, ethics, and incentives in publishing, the role of regulatory
      agencies and stakeholders, the role of funding, and the cooperation between
      funders and academic institutions and the training of both clinicians and
      methodologists or statisticians. As a result, there is loss of the utmost goal:
      the production of robust research to form recommendations to support pragmatic
      decision in a real-world context. We propose the construction of a model based on
      artificial intelligence that could assist stakeholders, clinicians, and patients 
      to guide conducting the best quality of research. We briefly describe the levels 
      of the workflow, including the input and output data collection, the feature
      extraction/selection, the architecture, and parameterization of the model, along 
      with its training, operation, and refinement.
FAU - Siristatidis, Charalampos
AU  - Siristatidis C
AD  - Assisted Reproduction Unit, Second Department of Obstetrics and Gynecology,
      Medical School, National and Kapodistrian University of Athens, Aretaieion
      Hospital , Athens, Greece.
FAU - Pouliakis, Abraham
AU  - Pouliakis A
AD  - Second Department of Pathology, Medical School, National and Kapodistrian
      University of Athens, Aretaieion Hospital , Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - England
TA  - Syst Biol Reprod Med
JT  - Systems biology in reproductive medicine
JID - 101464963
SB  - IM
MH  - *Artificial Intelligence
MH  - Biomedical Research/*standards/*trends
MH  - Humans
MH  - Models, Theoretical
MH  - Quality Control
OTO - NOTNLM
OT  - Artificial neural network
OT  - artificial intelligence
OT  - research
OT  - study design
EDAT- 2020/04/09 06:00
MHDA- 2021/02/24 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.1080/19396368.2020.1749727 [doi]
PST - ppublish
SO  - Syst Biol Reprod Med. 2020 Jun;66(3):170-175. doi: 10.1080/19396368.2020.1749727.
      Epub 2020 Apr 8.


PMID- 32267408
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20220413
IS  - 1984-0446 (Electronic)
IS  - 0034-7167 (Linking)
VI  - 73
IP  - 3
DP  - 2020
TI  - Nursing work in assisted human reproduction: between technology and humanization.
PG  - e20170919
LID - S0034-71672020000300151 [pii]
LID - 10.1590/0034-7167-2017-0919 [doi]
AB  - OBJECTIVES: To analyze the social representations of nurses who work with
      assisted human reproduction about the operation with reproductive
      biotechnologies. METHODS: Qualitative approach, supported by the Theory of Social
      Representations, with sixteen participants. Individual, semi-structured
      interviews, analyzed through the Alceste software. RESULTS: Pragmatic elements
      related to nurses' performance from a professional, institutional, and public
      policy perspective in reproductive biotechnologies emerged, demonstrating the
      practical dimension of these representations. The characteristics of the
      professional to act in this area were addressed, showing the lack of information 
      and search for scientificity; precarious perception of the organizational
      structure of health services; and attributions of nursing care arising from the
      health care practice in assisted human reproduction. FINAL CONSIDERATIONS: Social
      representation is anchored in the link between technology/medicalization and
      humanization/reception regarding reproductive biotechnologies. Working in
      assisted human reproduction involves a new and challenging nursing care,
      requiring specific and ethical knowledge.
FAU - Queiroz, Ana Beatriz Azevedo
AU  - Queiroz ABA
AUID- ORCID: http://orcid.org/0000-0003-2447-6137
AD  - Universidade Federal do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Mohamed, Renata Porto Dos Santos
AU  - Mohamed RPDS
AUID- ORCID: http://orcid.org/0000-0002-0536-9793
AD  - Universidade Federal do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Moura, Maria Aparecida Vasconcelos
AU  - Moura MAV
AUID- ORCID: http://orcid.org/0000-0001-9085-6897
AD  - Universidade Federal do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Souza, Ivis Emilia de Oliveira
AU  - Souza IEO
AUID- ORCID: http://orcid.org/0000-0002-5037-7821
AD  - Universidade Federal do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Carvalho, Maria Cristina de Melo Pessanha
AU  - Carvalho MCMP
AUID- ORCID: http://orcid.org/0000-0003-4009-0189
AD  - Universidade Federal do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Vieira, Bianca Dargam Gomes
AU  - Vieira BDG
AUID- ORCID: http://orcid.org/0000-0002-0734-3685
AD  - Universidade Federal do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20200403
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
MH  - Adult
MH  - Female
MH  - *Humanism
MH  - Humans
MH  - Inventions/*standards
MH  - Male
MH  - Middle Aged
MH  - Nurse-Patient Relations
MH  - Nursing Care/*methods/psychology
MH  - Reproductive Health Services/*trends
MH  - User-Computer Interface
EDAT- 2020/04/09 06:00
MHDA- 2020/11/25 06:00
CRDT- 2020/04/09 06:00
PHST- 2018/01/11 00:00 [received]
PHST- 2019/02/19 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
AID - S0034-71672020000300151 [pii]
AID - 10.1590/0034-7167-2017-0919 [doi]
PST - epublish
SO  - Rev Bras Enferm. 2020 Apr 3;73(3):e20170919. doi: 10.1590/0034-7167-2017-0919.
      eCollection 2020.


PMID- 32267391
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 1980-220X (Electronic)
IS  - 0080-6234 (Linking)
VI  - 54
DP  - 2020
TI  - Scientific integrity among nursing students participating in the Scientific
      Initiation Program: An exploratory study.
PG  - e03548
LID - S0080-62342020000100414 [pii]
LID - 10.1590/S1980-220X2018047703548 [doi]
AB  - OBJECTIVE: To know the positions and practices adopted by nursing students in
      scientific initiation programs about the principles of scientific integrity in
      the different stages of the process of doing science. METHOD: An exploratory
      study of a quantitative nature, in which nursing student participants of the
      Scientific Initiation Program from the Federal District were interviewed.
      RESULTS: Fifty (50) nursing students participated in the study. Most of the
      interviewed participants presented good notions about the process of conducting
      research in its different stages. Nevertheless, it was found that even though
      they were familiar with good scientific practices, students did not always behave
      in the most responsible manner. It was observed that the knowledge on topics
      related to the ethics of the scientific process was predominantly obtained
      through formal education, consisting of classes and courses. Nonetheless, the
      importance of complementary spaces such as research and research groups is
      recognized. Conclusion: Research experiences are important educational and
      vocational training spaces for students. Therefore, good research practices need 
      to be included early in the academic curriculum.
FAU - Silva, Natallia Rodrigues Araujo da
AU  - Silva NRAD
AUID- ORCID: http://orcid.org/0000-0002-1577-6907
AD  - Universidade de Brasilia, Faculdade de Ciencias da Saude, Programa de
      Pos-Graduacao em Ciencias da Saude, Brasilia, DF, Brazil.
FAU - Padua, Gabriela Cristina Cantisani
AU  - Padua GCC
AUID- ORCID: http://orcid.org/0000-0003-4473-4586
AD  - Universidade de Brasilia, Faculdade de Ciencias da Saude, Programa de
      Pos-Graduacao em Ciencias da Saude, Brasilia, DF, Brazil.
FAU - Novaes, Maria Rita Carvalho Garbi
AU  - Novaes MRCG
AUID- ORCID: http://orcid.org/0000-0002-9366-6017
AD  - Fundacao de Ensino e Pesquisa em Ciencias da Saude, Escola Superior de Ciencias
      da Saude, Brasilia, DF, Brazil.
FAU - Guilhem, Dirce Bellezi
AU  - Guilhem DB
AUID- ORCID: http://orcid.org/0000-0003-4569-9081
AD  - Universidade de Brasilia, Faculdade de Ciencias da Saude, Departamento de
      Enfermagem, Brasilia, DF, Brazil.
LA  - eng
LA  - por
GR  - R25 TW001605/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20200406
PL  - Brazil
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Curriculum
MH  - Education, Nursing/*methods
MH  - Female
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Nursing Research/*education/ethics
MH  - Students, Nursing/*psychology
MH  - Young Adult
PMC - PMC8054486
MID - NIHMS1692118
EDAT- 2020/04/09 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/04/09 06:00
PHST- 2018/10/29 00:00 [received]
PHST- 2019/04/23 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - S0080-62342020000100414 [pii]
AID - 10.1590/S1980-220X2018047703548 [doi]
PST - epublish
SO  - Rev Esc Enferm USP. 2020 Apr 6;54:e03548. doi: 10.1590/S1980-220X2018047703548.
      eCollection 2020.


PMID- 32267064
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 127
IP  - 2
DP  - 2020 Aug
TI  - Gonadal sex and animal experimentation: Perfection vs. 3R principle?
PG  - 111-119
LID - 10.1111/bcpt.13411 [doi]
AB  - Replicability of experimental results and optimal use of experimental animals are
      everybody's concern. Current efforts towards increased replicability include
      guidelines and checklists as tools for experimenters, referees, editors and
      publishers. Guidelines are also provided for appropriate use of animals. To
      ensure the quality of experimental results, the number of animals must be
      adequate, that is, sufficiently large, for the purpose of the given experiment.
      To comply with current ethical recommendations, the use of animals should be
      reduced as much as possible. Therefore, determination of the number of animals
      for a given scientific objective includes contrasting considerations. Current
      guidelines for animal experimentation, notably from the National Institute of
      Health, mandate (with very few exceptions) inclusion of animals of both sexes in 
      experimental designs statistically powered to address the difference between the 
      two groups. Notably, absence of evidence for sex differences between the organ or
      system functions under study does not qualify as an exception. Mandatory, equal
      representation of both sexes raises several questions including ethical ones.
      Other guidelines, by public regulators and major publishers, do not seem to have 
      a similar selective focus on sex differences. In summary, current concerns about 
      replicability of scientific results are justified. Concomitantly, the knowledge
      of sex differences also between non-reproductive, non-endocrine organ functions
      is increasing. In principle, sex matters in any experimental context. However, an
      indiscriminate demand for inclusion of both sexes in all experimental protocols
      seems a waste of animals, money and time, violating traditional principles of
      animal experimentation, particularly that of reduction.
CI  - (c) 2020 Nordic Association for the Publication of BCPT (former Nordic
      Pharmacological Society).
FAU - Bie, Peter
AU  - Bie P
AUID- ORCID: https://orcid.org/0000-0002-9091-0205
AD  - Department of Cardiovascular and Renal Research, Institute of Molecular Medicine,
      University of Southern Denmark, Odense, Denmark.
FAU - Debrabant, Birgit
AU  - Debrabant B
AUID- ORCID: https://orcid.org/0000-0002-1964-3204
AD  - Epidemiology, Biostatistics and Biodemography, Department of Public Health,
      University of Southern Denmark, Odense, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200421
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
SB  - IM
MH  - Animal Experimentation/ethics/*standards
MH  - Animal Rights
MH  - Animal Use Alternatives/ethics/methods/standards
MH  - Animals
MH  - *Animals, Laboratory
MH  - Female
MH  - Guidelines as Topic
MH  - Housing, Animal/organization & administration/standards
MH  - Male
MH  - Research Design/*standards
MH  - *Sex Characteristics
OTO - NOTNLM
OT  - animal experiments
OT  - ethics
OT  - female
OT  - male
OT  - preference
OT  - resources
EDAT- 2020/04/09 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/04/09 06:00
PHST- 2019/10/21 00:00 [received]
PHST- 2020/03/26 00:00 [revised]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.1111/bcpt.13411 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2020 Aug;127(2):111-119. doi: 10.1111/bcpt.13411.
      Epub 2020 Apr 21.


PMID- 32266947
OWN - NLM
STAT- MEDLINE
DCOM- 20200428
LR  - 20201218
IS  - 0098-9134 (Print)
IS  - 0098-9134 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May 1
TI  - Public Health and Ethics Intersect at New Levels With Gerontological Nursing in
      COVID-19 Pandemic.
PG  - 4-7
LID - 10.3928/00989134-20200403-01 [doi]
FAU - Young, Heather M
AU  - Young HM
FAU - Fick, Donna M
AU  - Fick DM
LA  - eng
PT  - Editorial
DEP - 20200408
PL  - United States
TA  - J Gerontol Nurs
JT  - Journal of gerontological nursing
JID - 7510258
MH  - Aged
MH  - COVID-19
MH  - Coronavirus Infections/*epidemiology/*nursing
MH  - Geriatric Nursing/*ethics
MH  - Health Care Rationing/ethics
MH  - Humans
MH  - *Pandemics
MH  - Pneumonia, Viral/*epidemiology/*nursing
MH  - Public Health/*ethics
MH  - United States/epidemiology
EDAT- 2020/04/09 06:00
MHDA- 2020/04/29 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/29 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.3928/00989134-20200403-01 [doi]
PST - ppublish
SO  - J Gerontol Nurs. 2020 May 1;46(5):4-7. doi: 10.3928/00989134-20200403-01. Epub
      2020 Apr 8.


PMID- 32266876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 8
TI  - Investigating Health Impacts of Natural Resource Extraction Projects in Burkina
      Faso, Ghana, Mozambique, and Tanzania: Protocol for a Mixed Methods Study.
PG  - e17138
LID - 10.2196/17138 [doi]
AB  - BACKGROUND: Natural resource extraction projects offer both opportunities and
      risks for sustainable development and health in host communities. Often, however,
      the health of the community suffers. Health impact assessment (HIA) can mitigate 
      the risks and promote the benefits of development but is not routinely done in
      the developing regions that could benefit the most. OBJECTIVE: Our study aims to 
      investigate health and health determinants in regions affected by extractive
      industries in Burkina Faso, Ghana, Mozambique, and Tanzania. The evidence
      generated in our study will inform a policy dialogue on how HIA can be promoted
      as a regulatory approach as part of the larger research initiative called the
      HIA4SD (Health impact assessment for sustainable development) project. METHODS:
      The study is a concurrent triangulation, mixed methods, multi-stage, multi-focus 
      project that specifically addresses the topics of governance and policy, social
      determinants of health, health economics, health systems, maternal and child
      health, morbidity and mortality, and environmental determinants, as well as the
      associated health outcomes in natural resource extraction project settings across
      four countries. To investigate each of these health topics, the project will (1) 
      use existing population-level databases to quantify incidence of disease and
      other health outcomes and determinants over time using time series analysis; (2) 
      conduct two quantitative surveys on mortality and cost of disease in producer
      regions; and (3) collect primary qualitative data using focus groups and key
      informant interviews describing community perceptions of the impacts of
      extraction projects on health and partnership arrangements between the projects
      and local and national governance. Differences in health outcomes and health
      determinants between districts with and without an extraction project will be
      analyzed using matched geographical analyses in quasi-Poisson regression models
      and binomial regression models. Costs to the health system and to the households 
      from diseases found to be associated with projects in each country will be
      estimated retrospectively. RESULTS: Fieldwork for the study began in February
      2019 and concluded in February 2020. At the time of submission, qualitative data 
      collection had been completed in all four study countries. In Burkina Faso, 36
      focus group discussions and 74 key informant interviews were conducted in three
      sites. In Ghana, 34 focus group discussions and 64 key informant interviews were 
      conducted in three sites. In Mozambique, 75 focus group discussions and 103 key
      informant interviews were conducted in four sites. In Tanzania, 36 focus group
      discussions and 84 key informant interviews were conducted in three sites.
      Quantitative data extraction and collection is ongoing in all four study
      countries. Ethical approval for the study was received in all four study
      countries prior to beginning the fieldwork. Data analyses are underway and
      results are expected to be published in 2020 and 2021. CONCLUSIONS: Disentangling
      the complex interactions of resource extraction projects with their host
      communities requires an integrative approach drawing on many methodologies under 
      the HIA umbrella. By using complementary data sources to address the question of 
      population health in project areas from several angles, bias and missing data
      will be reduced, generating high-quality evidence to aid countries in moving
      toward sustainable development. INTERNATIONAL REGISTERED REPORT IDENTIFIER
      (IRRID): DERR1-10.2196/17138.
CI  - (c)Andrea Farnham, Herminio Cossa, Dominik Dietler, Rebecca Engebretsen, Andrea
      Leuenberger, Isaac Lyatuu, Belinda Nimako, Hyacinthe R Zabre, Fritz Brugger,
      Mirko S Winkler. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 08.04.2020.
FAU - Farnham, Andrea
AU  - Farnham A
AUID- ORCID: https://orcid.org/0000-0002-0830-0927
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Cossa, Herminio
AU  - Cossa H
AUID- ORCID: https://orcid.org/0000-0002-5771-2637
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - Manhica Health Research Centre, Maputo, Mozambique.
FAU - Dietler, Dominik
AU  - Dietler D
AUID- ORCID: https://orcid.org/0000-0001-9629-125X
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Engebretsen, Rebecca
AU  - Engebretsen R
AUID- ORCID: https://orcid.org/0000-0002-2839-5986
AD  - Swiss Federal Institute of Technology, Zurich, Switzerland.
FAU - Leuenberger, Andrea
AU  - Leuenberger A
AUID- ORCID: https://orcid.org/0000-0001-6116-148X
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
FAU - Lyatuu, Isaac
AU  - Lyatuu I
AUID- ORCID: https://orcid.org/0000-0001-5694-7648
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
AD  - Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania.
FAU - Nimako, Belinda
AU  - Nimako B
AUID- ORCID: https://orcid.org/0000-0001-7538-4481
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
AD  - University of Health and Allied Sciences, Ho, Ghana.
FAU - Zabre, Hyacinthe R
AU  - Zabre HR
AUID- ORCID: https://orcid.org/0000-0001-8835-9680
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
AD  - Research Institute of Health Sciences, Ouagadougou, Burkina Faso.
FAU - Brugger, Fritz
AU  - Brugger F
AUID- ORCID: https://orcid.org/0000-0003-1992-4492
AD  - Swiss Federal Institute of Technology, Zurich, Switzerland.
FAU - Winkler, Mirko S
AU  - Winkler MS
AUID- ORCID: https://orcid.org/0000-0001-7387-3863
AD  - Swiss Tropical and Public Health Institute, Basel, Switzerland.
AD  - University of Basel, Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200408
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7177430
OTO - NOTNLM
OT  - DHIS2
OT  - DHS
OT  - GIS
OT  - cost-benefit
OT  - environmental health
OT  - extractive industry
OT  - health impact assessment
OT  - mixed methods
OT  - time series
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/11/20 00:00 [received]
PHST- 2020/02/22 00:00 [accepted]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - v9i4e17138 [pii]
AID - 10.2196/17138 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 8;9(4):e17138. doi: 10.2196/17138.


PMID- 32266732
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 9
DP  - 2020 Nov
TI  - Using, risking, and consent: Why risking harm to bystanders is morally different 
      from risking harm to research subjects.
PG  - 899-905
LID - 10.1111/bioe.12743 [doi]
AB  - Subjects in studies on humans are used as a means of conducting the research and 
      achieving whatever good would justify putting them at risk. Accordingly, consent 
      must normally be obtained before subjects are exposed to any substantial risks to
      their welfare. Bystanders are also often put at risk, but they are not used as a 
      means. Accordingly-or so I argue-consent is more often unnecessary before
      bystanders are exposed to similar substantial risks to their welfare.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Walen, Alec
AU  - Walen A
AUID- ORCID: 0000-0002-5828-6596
AD  - Rutgers University School of Law, Camden, NJ, 08102-1519, USA.
LA  - eng
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
GR  - 1 R01 AI114617-01A1/NH/NIH HHS/United States
GR  - 1 R01 AI114617-01A1/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20200407
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Humans
MH  - *Informed Consent
MH  - *Research Subjects
PMC - PMC7541549
MID - NIHMS1578643
OTO - NOTNLM
OT  - *Means principle
OT  - *bystanders
OT  - *human subjects research
OT  - *informed consent
OT  - *research ethics
OT  - *risk
EDAT- 2020/04/09 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/04/09 06:00
PHST- 2019/01/03 00:00 [received]
PHST- 2020/02/15 00:00 [revised]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.1111/bioe.12743 [doi]
PST - ppublish
SO  - Bioethics. 2020 Nov;34(9):899-905. doi: 10.1111/bioe.12743. Epub 2020 Apr 7.


PMID- 32266581
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Jun
TI  - The Integration and Harmonisation of Secular and Islamic Ethical Principles in
      Formulating Acceptable Ethical Guidelines for Modern Biotechnology in Malaysia.
PG  - 1797-1825
LID - 10.1007/s11948-020-00214-4 [doi]
AB  - The Malaysian government recognises the potential contribution of biotechnology
      to the national economy. However, ongoing controversy persists regarding its
      ethical status and no specific ethical guidelines have been published relating to
      its use. In developing such guidelines, it is important to identify the
      underlying principles that are acceptable to Malaysian society. This paper
      discusses the process of determining relevant secular and Islamic ethical
      principles and establishing their similarities before harmonising them. To
      achieve this, a series of focus group discussions were conducted with 23
      knowledge experts representing various stakeholders in the biotechnology
      community. Notably, several principles between the secular and Islamic
      perspectives are indirectly or directly similar. All the experts agreed with the 
      predominant six ethical principles of secular and Islamic philosophy and their
      importance and relevance in modern biotechnology. These are beneficence and
      non-maleficence as the main or overarching principles, the preservation of
      religious and moral values, the preservation of the intellect and the mind, the
      protection of human safety, the protection of future generations, and protection 
      of the environment and biological diversity. Several adjustments were made to the
      terminologies and definitions of these six principles to formulate acceptable
      guiding principles for the ethics of modern biotechnology in Malaysia. These can 
      then be adopted as core values to underpin future national guidelines on modern
      biotechnology ethics. These principles will be particularly important in guiding 
      the policy makers, enforcers, industries and researchers to streamline their
      activities. In so doing, modern biotechnology and its products can be properly
      managed without jeopardising the interests of the Muslim community as well as the
      general public. Importantly, they are expansive and inclusive enough to embrace
      the religious sensitivity of diverse quarters of Malaysia.
FAU - Hasim, Nur Asmadayana
AU  - Hasim NA
AD  - The Institute of Islam Hadhari, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
AD  - Pusat Citra Universiti, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
FAU - Amin, Latifah
AU  - Amin L
AUID- ORCID: http://orcid.org/0000-0002-8086-3329
AD  - The Institute of Islam Hadhari, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia. nilam@ukm.edu.my.
AD  - Pusat Citra Universiti, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia. nilam@ukm.edu.my.
FAU - Mahadi, Zurina
AU  - Mahadi Z
AD  - Pusat Citra Universiti, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
FAU - Yusof, Nor Ashikin Mohamed
AU  - Yusof NAM
AD  - Perdana School of Science, Technology and Innovation Policy (PERDANA School),
      Universiti Teknologi Malaysia, 54100, Kuala Lumpur, Malaysia.
FAU - Ngah, Anisah Che
AU  - Ngah AC
AD  - Taylor's Law School, Taylor's University Lakeside Campus, 47500, Subang,
      Selangor, Malaysia.
FAU - Yaacob, Mashitoh
AU  - Yaacob M
AD  - The Institute of Islam Hadhari, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
AD  - Pusat Citra Universiti, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
FAU - Olesen, Angelina Patrick
AU  - Olesen AP
AD  - Pusat Citra Universiti, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
FAU - Aziz, Azwira Abdul
AU  - Aziz AA
AD  - Pusat Citra Universiti, Universiti Kebangsaan Malaysia, 43600, UKM Bangi,
      Selangor, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200407
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - Biotechnology
MH  - Humans
MH  - *Islam
MH  - Malaysia
MH  - Moral Obligations
MH  - *Religion and Medicine
OTO - NOTNLM
OT  - *Ethical principles
OT  - *Islamic ethics
OT  - *Malaysia
OT  - *Modern biotechnology
OT  - *Secular ethics
EDAT- 2020/04/09 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/09 06:00
PHST- 2018/04/03 00:00 [received]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.1007/s11948-020-00214-4 [doi]
AID - 10.1007/s11948-020-00214-4 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Jun;26(3):1797-1825. doi: 10.1007/s11948-020-00214-4. Epub
      2020 Apr 7.


PMID- 32266365
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1120-9135 (Print)
IS  - 1120-9135 (Linking)
VI  - 32
IP  - 3
DP  - 2020 May-Jun
TI  - Nurses' and physicians' opinions on end-of-life: a secondary analysis from an
      Italian cross-sectional study.
PG  - 274-284
LID - 10.7416/ai.2020.2350 [doi]
AB  - BACKGROUND: In daily clinical practice, healthcare workers face end-of-life
      issues, such as futility, which is generally defined as the provision of
      treatments that do not produce any meaningful benefit for patients. STUDY DESIGN:
      To investigate the end-of-life issues according to Italian nurses' and
      physicians' opinions and to detect any differences between them, a secondary
      analysis of existing data from a cross-sectional study was conducted. METHODS: A 
      validated questionnaire was used involving 351 nurses and 128 physicians from
      four hospitals in Central Italy. RESULTS: Regarding the definition of futility,
      nurses mainly focused on agony, suffering, and risks, while physicians paid more 
      attention to the hope of healing. Nevertheless, both were distressed by different
      aspects of the treatments; in particular, nurses by the 'invasiveness of the
      treatments' and physicians by the 'over-medicalization of death'. Instead, nurses
      and physicians similarly recognized patients' right to seek to anticipate the end
      of life when they are terminally-ill and to express freely their desire not to be
      revived. CONCLUSIONS: The description of experiences and opinions of health
      professionals could represent a valid basis to develop a 'regulatory system'
      aimed to guide and support daily clinical and nursing activities.
FAU - Leuter, C
AU  - Leuter C
AD  - Departmental Faculty of Medicine and Surgery, Campus Bio-Medico University of
      Rome, Italy.
FAU - Petrucci, C
AU  - Petrucci C
AD  - Department of Health, Life and Environmental Sciences, University of L'Aquila,
      Italy.
FAU - La Cerra, C
AU  - La Cerra C
AD  - Department of Health, Life and Environmental Sciences, University of L'Aquila,
      Italy.
FAU - Dante, A
AU  - Dante A
AD  - Department of Health, Life and Environmental Sciences, University of L'Aquila,
      Italy.
FAU - Franconi, I
AU  - Franconi I
AD  - Department of Health, Life and Environmental Sciences, University of L'Aquila,
      Italy - Permanent address: Obstetrics, Gynaecology, and Paediatric Operating
      Room, Salesi Children's Hospital, AOU Ospedali Riuniti, Ancona, Italy.
FAU - Caponnetto, V
AU  - Caponnetto V
AD  - Department of Health, Life and Environmental Sciences, University of L'Aquila,
      Italy.
FAU - Lancia, L
AU  - Lancia L
AD  - Department of Health, Life and Environmental Sciences, University of L'Aquila,
      Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Italy
TA  - Ann Ig
JT  - Annali di igiene : medicina preventiva e di comunita
JID - 9002865
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Attitude of Health Personnel
MH  - *Attitude to Health
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Nurses/*psychology
MH  - Physicians/*psychology
MH  - *Terminal Care
MH  - Young Adult
OTO - NOTNLM
OT  - *End of life care
OT  - *Ethics
OT  - *Futility
OT  - *Nurses
OT  - *Physicians
OT  - *Terminal care
EDAT- 2020/04/09 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - 10.7416/ai.2020.2350 [doi]
PST - ppublish
SO  - Ann Ig. 2020 May-Jun;32(3):274-284. doi: 10.7416/ai.2020.2350.


PMID- 32266151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally 
      Advanced Cervical Cancer Patients.
PG  - 376
LID - 10.3389/fonc.2020.00376 [doi]
AB  - Background: A Phase III randomized controlled trial investigating the addition of
      modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced
      cervical cancer patients is being conducted in South Africa (Human Research
      Ethics Committee approval: M1704133; ClincialTrials.gov ID: NCT03332069). Two
      hundred and ten participants were randomized and 202 participants were eligible
      for six month local disease control evaluation. Screening (18)F-FDG PET/CT scans 
      were conducted and repeated at six months post-treatment. Significant improvement
      in local control was reported in the mEHT group and complete metabolic resolution
      (CMR) of extra-pelvic disease was noted in some participants. We report on an
      analysis of the participants with CMR of disease inside and outside the radiation
      field. Method: Participants were included in this analysis if nodes outside the
      treatment field (FDG-uptake SUV>2.5) were visualized on pre-treatment scans and
      if participants were evaluated by (18)F-FDG PET/CT scans at six months
      post-treatment. Results: One hundred and eight participants (mEHT: HIV-positive n
      = 25, HIV-negative n = 29; Control Group: HIV-positive n = 26, HIV-negative n =
      28) were eligible for analysis. There was a higher CMR of all disease inside and 
      outside the radiation field in the mEHT Group: n = 13 [24.1%] than the control
      group: n = 3 [5.6%] (Chi squared, Fisher's exact: p = 0.013) with no significant 
      difference in the extra-pelvic response to treatment between the HIV-positive and
      -negative participants of each group. Conclusion: The CMR of disease outside the 
      radiation field at six months post-treatment provides evidence of an abscopal
      effect which was significantly associated with the addition of mEHT to treatment 
      protocols. This finding is important as the combined synergistic use of
      radiotherapy with mEHT could broaden the scope of radiotherapy to include
      systemic disease.
CI  - Copyright (c) 2020 Minnaar, Kotzen, Ayeni, Vangu and Baeyens.
FAU - Minnaar, Carrie Anne
AU  - Minnaar CA
AD  - Radiobiology, Department of Radiation Sciences, University of the Witwatersrand, 
      Johannesburg, South Africa.
FAU - Kotzen, Jeffrey Allan
AU  - Kotzen JA
AD  - Radiation Oncology, Wits Donald Gordon Medical Centre, Johannesburg, South
      Africa.
FAU - Ayeni, Olusegun Akinwale
AU  - Ayeni OA
AD  - Nuclear Medicine, Department of Radiation Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
FAU - Vangu, Mboyo-Di-Tamba
AU  - Vangu MD
AD  - Nuclear Medicine, Department of Radiation Sciences, University of the
      Witwatersrand, Johannesburg, South Africa.
FAU - Baeyens, Ans
AU  - Baeyens A
AD  - Radiobiology, Department of Radiation Sciences, University of the Witwatersrand, 
      Johannesburg, South Africa.
AD  - Radiobiology, Department of Human Structure and Repair, Ghent University, Ghent, 
      Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200324
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7105641
OTO - NOTNLM
OT  - *abscopal effect
OT  - *cervical cancer
OT  - *immunomodulation
OT  - *modulated electro-hyperthermia
OT  - *radiotherapy
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - 10.3389/fonc.2020.00376 [doi]
PST - epublish
SO  - Front Oncol. 2020 Mar 24;10:376. doi: 10.3389/fonc.2020.00376. eCollection 2020.


PMID- 32266049
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1948-0210 (Print)
IS  - 1948-0210 (Linking)
VI  - 12
IP  - 3
DP  - 2020 Mar 26
TI  - Mesenchymal stem cells in neurodegenerative diseases: Opinion review on ethical
      dilemmas.
PG  - 168-177
LID - 10.4252/wjsc.v12.i3.168 [doi]
AB  - The treatment of neurodegenerative diseases presents a growing need for
      innovation in relation to recent evidence in the field of reconstructive therapy 
      using stem cells. Understanding the molecular mechanisms underlying
      neurodegenerative disorders, and the advent of methods able to induce neuronal
      stem cell differentiation allowed to develop innovative therapeutic approaches
      offering the prospect of healthy and perfectly functional cell transplants, able 
      to replace the sick ones. Hence the importance of deepening the state of the art 
      regarding the clinical applications of advanced cell therapy products for the
      regeneration of nerve tissue. Besides representing a promising area of tissue
      transplant surgery and a great achievement in the field of neurodegenerative
      disease, stem cell research presents certain critical issues that need to be
      carefully examined from the ethical perspective. In fact, a subject so complex
      and not entirely explored requires a detailed scientific and ethical evaluation
      aimed at avoiding improper and ineffective use, rather than incorrect
      indications, technical inadequacies, and incongruous expectations. In fact, the
      clinical usefulness of stem cells will only be certain if able to provide the
      patient with safe, long-term and substantially more effective strategies than any
      other treatment available. The present paper provides an ethical assessment of
      tissue regeneration through mesenchymal stem cells in neurodegenerative diseases 
      with the aim to rule out the fundamental issues related to research and clinical 
      translation.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights
      reserved.
FAU - Scopetti, Matteo
AU  - Scopetti M
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
FAU - Santurro, Alessandro
AU  - Santurro A
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
FAU - Gatto, Vittorio
AU  - Gatto V
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
FAU - La Russa, Raffaele
AU  - La Russa R
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
FAU - Manetti, Federico
AU  - Manetti F
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
FAU - D'Errico, Stefano
AU  - D'Errico S
AD  - UOC Risk Management, Quality and Accreditation, Sant'Andrea University Hospital
      of Rome, Rome 00189, Italy.
FAU - Frati, Paola
AU  - Frati P
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
FAU - Fineschi, Vittorio
AU  - Fineschi V
AD  - Department of Anatomical, Histological, Forensic and Orthopaedic Sciences,
      Sapienza University of Rome, Rome 00185, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Stem Cells
JT  - World journal of stem cells
JID - 101535826
PMC - PMC7118285
OTO - NOTNLM
OT  - Ethical principles
OT  - Mesenchymal stem cells
OT  - Neurodegenerative diseases
OT  - Patient safety
OT  - Stem cell research
OT  - Stem cell therapy
COIS- Conflict-of-interest statement: The authors declare no conflict of interest. This
      study received no external funding.
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/10/21 00:00 [received]
PHST- 2020/02/13 00:00 [revised]
PHST- 2020/03/01 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - 10.4252/wjsc.v12.i3.168 [doi]
PST - ppublish
SO  - World J Stem Cells. 2020 Mar 26;12(3):168-177. doi: 10.4252/wjsc.v12.i3.168.


PMID- 32265977
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - German and Italian Users of Web-Accessed Genetic Data: Attitudes on Personal
      Utility and Personal Sharing Preferences. Results of a Comparative Survey
      (n=192).
PG  - 102
LID - 10.3389/fgene.2020.00102 [doi]
AB  - Genetic information is increasingly provided outside of the traditional clinical 
      setting, allowing users to access it directly via specialized online platforms.
      This development is possibly resulting in changing ethical and social challenges 
      for users of predictive genetic tests. Little is known about the attitudes and
      experiences of users of web-accessed genetic information. This survey analyzes
      data from two European countries with regard to the utility of genetic
      information, the users' ways of making use of and dealing with information, and
      their sharing behavior. Particular focus is given to ethical and social questions
      regarding the motivation to share personal genetic results with others. Social
      factors tested for are national background, gender, and marital, parental, and
      educational status. This study will contribute to public discourse and offer
      ethical recommendations. The study will also serve to validate the developed
      questionnaire for use in population representative surveys.
CI  - Copyright (c) 2020 Wohlke, Schaper, Oliveri, Cutica, Spinella, Pravettoni,
      Steinberger and Schicktanz.
FAU - Wohlke, Sabine
AU  - Wohlke S
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Gottingen, Germany.
FAU - Schaper, Manuel
AU  - Schaper M
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Gottingen, Germany.
FAU - Oliveri, Serena
AU  - Oliveri S
AD  - Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, 
      University of Milan, Milan, Italy.
AD  - Applied Research Division for Cognitive and Psychological Science, European
      Institute of Oncology, Milan, Italy.
FAU - Cutica, Ilaria
AU  - Cutica I
AD  - Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, 
      University of Milan, Milan, Italy.
AD  - Applied Research Division for Cognitive and Psychological Science, European
      Institute of Oncology, Milan, Italy.
FAU - Spinella, Francesca
AU  - Spinella F
AD  - Laboratory GENOMA, Rome, Italy.
FAU - Pravettoni, Gabriella
AU  - Pravettoni G
AD  - Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, 
      University of Milan, Milan, Italy.
AD  - Applied Research Division for Cognitive and Psychological Science, European
      Institute of Oncology, Milan, Italy.
FAU - Steinberger, Daniela
AU  - Steinberger D
AD  - bio.logis Genetic Information Management GmbH, Frankfurt, Germany.
FAU - Schicktanz, Silke
AU  - Schicktanz S
AD  - Department of Medical Ethics and History of Medicine, University Medical Center
      Gottingen, Gottingen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200318
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7099127
OTO - NOTNLM
OT  - attitudes
OT  - experiences
OT  - genomics
OT  - health information
OT  - lay people
OT  - survey
OT  - utility
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/06/11 00:00 [received]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - 10.3389/fgene.2020.00102 [doi]
PST - epublish
SO  - Front Genet. 2020 Mar 18;11:102. doi: 10.3389/fgene.2020.00102. eCollection 2020.


PMID- 32265768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - What Makes Employees' Work So Stressful? Effects of Vertical Leadership and
      Horizontal Management on Employees' Stress.
PG  - 340
LID - 10.3389/fpsyg.2020.00340 [doi]
AB  - Work stress is a significant problem all over the world. In the present study,
      from the perspective of the combination of vertical and horizontal management, we
      investigated the relationships of managerial ethical leadership, mutual
      monitoring, and mutual support among employees' work stress levels. A total of
      307 white collar employees in Japan were asked to complete an online
      questionnaire on three separate occasions. The results showed that both ethical
      leadership and mutual support were negatively related to stress. In addition,
      mutual support mediated the relationship between ethical leadership and work
      stress. Further, mutual monitoring moderated the relationship between ethical
      leadership and work stress: when mutual monitoring was high, stress did not
      decline with more ethical leadership. These results may suggest that ethical
      leadership can reduce work stress both directly and through mutual support,
      indirectly. Additionally, the direct effect may be constrained under high
      monitoring situations. Practical implications and needed future research are also
      discussed.
CI  - Copyright (c) 2020 Wang, Sakata, Komiya and Li.
FAU - Wang, Wei
AU  - Wang W
AD  - Institute of Psychology and Behavior, Henan University, Kaifeng, China.
FAU - Sakata, Kiroko
AU  - Sakata K
AD  - Social Psychology Laboratory, Graduate School of Integrated Arts and Sciences,
      Hiroshima University, Hiroshima, Japan.
FAU - Komiya, Asuka
AU  - Komiya A
AD  - Social Psychology Laboratory, Graduate School of Integrated Arts and Sciences,
      Hiroshima University, Hiroshima, Japan.
FAU - Li, Yongxin
AU  - Li Y
AD  - Institute of Psychology and Behavior, Henan University, Kaifeng, China.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7096576
OTO - NOTNLM
OT  - Japanese sample
OT  - ethical leadership
OT  - mutual monitoring
OT  - mutual support
OT  - work stress
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/07/20 00:00 [received]
PHST- 2020/02/13 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - 10.3389/fpsyg.2020.00340 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 19;11:340. doi: 10.3389/fpsyg.2020.00340. eCollection
      2020.


PMID- 32265766
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - How Is Ethical Leadership Linked to Subordinate Taking Charge? A Moderated
      Mediation Model of Social Exchange and Power Distance.
PG  - 315
LID - 10.3389/fpsyg.2020.00315 [doi]
AB  - Extant literature has suggested that leadership styles have a significant impact 
      on subordinate taking charge. However, the effect of ethical leadership on
      subordinate taking charge is still insufficiently explored. Drawing on social
      exchange theory, we developed a moderated mediation model in which social
      exchange was theorized as a mediating mechanism underlining why subordinates feel
      motivated to take charge with the supervision of ethical leadership. Moreover,
      power distance was supposed to be a relevant boundary condition to moderate such 
      a relationship. Two hundred thirty-nine independent leader-subordinate dyads in
      China were used to test the model. Results showed that subordinates' social
      exchange mediates the relationship between ethical leadership and subordinate
      taking charge, and such a relationship was found to be stronger among
      subordinates who had lower levels of power distance rather than higher levels.
      Theoretical and practical implications concerning enhancement of subordinate
      taking charge in organizations where ethical leaderships exist are discussed.
CI  - Copyright (c) 2020 Wang, Zhou, Bao, Zhang and Ju.
FAU - Wang, Qiao
AU  - Wang Q
AD  - School of Economics and Management, Nanjing University of Science and Technology,
      Nanjing, China.
FAU - Zhou, Xiaohu
AU  - Zhou X
AD  - School of Economics and Management, Nanjing University of Science and Technology,
      Nanjing, China.
FAU - Bao, Jiani
AU  - Bao J
AD  - School of Business and Administration, Nanjing University of Finance and
      Economics, Nanjing, China.
FAU - Zhang, Xueyan
AU  - Zhang X
AD  - School of Economics and Management, Nanjing University of Science and Technology,
      Nanjing, China.
FAU - Ju, Wei
AU  - Ju W
AD  - School of Economics and Management, Nanjing University of Science and Technology,
      Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7101091
OTO - NOTNLM
OT  - ethical leadership
OT  - moderated mediation model
OT  - power distance
OT  - social exchange
OT  - subordinate taking charge
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/09/19 00:00 [received]
PHST- 2020/02/10 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - 10.3389/fpsyg.2020.00315 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 20;11:315. doi: 10.3389/fpsyg.2020.00315. eCollection
      2020.


PMID- 32265699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Evolution of the Development of Core Competencies in Pharmaceutical Medicine and 
      Their Potential Use in Education and Training.
PG  - 282
LID - 10.3389/fphar.2020.00282 [doi]
AB  - The evolution of postgraduate vocational education and training in pharmaceutical
      medicine is described alongside the growth of this scientific-medical discipline 
      and profession for the development of new medicines. Over the past 50 years,
      whilst the training of competent professionals for their work has been paramount,
      this has paralleled the need to engage with the rapid and complex changes in R&D 
      technologies, patient and healthcare system needs, and the ethical and regulatory
      obligations applied to the development of medicines throughout their lifecycle.
      The move from unstructured training to formal programs with syllabus, curricula
      and assessments for certification, has been accompanied by educational changes to
      outcomes-based, learner-centered, competency-based programs. The evolution of
      education and training along with the development of the set of 57 core
      competencies for professional practitioners in pharmaceutical medicine are
      described within the competence framework of seven domains: discovery of
      medicines and early development; clinical development and clinical trials;
      medicines regulation; drug safety and surveillance; ethics and subject
      protection; healthcare marketplace; communication and management. The application
      of the core competencies in a harmonized, international platform of education and
      training in medicines development at the undergraduate, postgraduate and
      continuing professional development levels would invigorate the potential for
      having a competent workforce with the intent to provide faster access to better
      and appropriate medicines for patients worldwide.
CI  - Copyright (c) 2020 Stonier, Silva, Boyd, Criscuolo, Gabbay, Imamura, Kesselring, 
      Kerpel-Fronius, Klech and Klingmann.
FAU - Stonier, Peter D
AU  - Stonier PD
AD  - Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, United
      Kingdom.
FAU - Silva, Honorio
AU  - Silva H
AD  - International Federation of Associations of Pharmaceutical Physicians and
      Pharmaceutical Medicine, Woerden, Netherlands.
FAU - Boyd, Alan
AU  - Boyd A
AD  - Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, United
      Kingdom.
FAU - Criscuolo, Domenico
AU  - Criscuolo D
AD  - International Federation of Associations of Pharmaceutical Physicians and
      Pharmaceutical Medicine, Woerden, Netherlands.
FAU - Gabbay, Felicity J
AU  - Gabbay FJ
AD  - Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, United
      Kingdom.
FAU - Imamura, Kyoko
AU  - Imamura K
AD  - International Federation of Associations of Pharmaceutical Physicians and
      Pharmaceutical Medicine, Woerden, Netherlands.
FAU - Kesselring, Gustavo
AU  - Kesselring G
AD  - International Federation of Associations of Pharmaceutical Physicians and
      Pharmaceutical Medicine, Woerden, Netherlands.
FAU - Kerpel-Fronius, Sandor
AU  - Kerpel-Fronius S
AD  - International Federation of Associations of Pharmaceutical Physicians and
      Pharmaceutical Medicine, Woerden, Netherlands.
FAU - Klech, Heinrich
AU  - Klech H
AD  - PharmaTrain Federation, Brussels, Belgium.
FAU - Klingmann, Ingrid
AU  - Klingmann I
AD  - PharmaTrain Federation, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7096542
OTO - NOTNLM
OT  - Faculty of pharmaceutical medicine
OT  - IFAPP
OT  - PharmaTrain
OT  - core competencies
OT  - curriculum
OT  - pharmaceutical medicine
OT  - syllabus
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - 10.3389/fphar.2020.00282 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Mar 19;11:282. doi: 10.3389/fphar.2020.00282. eCollection
      2020.


PMID- 32265570
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20200603
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 580
IP  - 7802
DP  - 2020 Apr
TI  - Inclusive science: ditch insensitive terminology.
PG  - 185
LID - 10.1038/d41586-020-01034-z [doi]
FAU - Baeckens, Simon
AU  - Baeckens S
FAU - Blomberg, Simone P
AU  - Blomberg SP
FAU - Shine, Richard
AU  - Shine R
LA  - eng
PT  - Letter
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
MH  - Animals
MH  - Biological Mimicry
MH  - Dwarfism
MH  - Female
MH  - Male
MH  - Sexual Behavior, Animal
MH  - Snakes
MH  - *Terminology as Topic
OTO - NOTNLM
OT  - *Ethics
OT  - *History
EDAT- 2020/04/09 06:00
MHDA- 2020/06/04 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
AID - 10.1038/d41586-020-01034-z [doi]
AID - 10.1038/d41586-020-01034-z [pii]
PST - ppublish
SO  - Nature. 2020 Apr;580(7802):185. doi: 10.1038/d41586-020-01034-z.


PMID- 32265467
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20210407
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Apr 7
TI  - Correlation of anorectal manometry measures to severity of fecal incontinence in 
      patients with anorectal malformations - a cross-sectional study.
PG  - 6016
LID - 10.1038/s41598-020-62908-w [doi]
AB  - Anorectal malformations (ARM) are a spectrum of anomalies of the rectum and anal 
      canal affecting 1 in 2500 to 5000 live births. Functional problems are common and
      related to the type of ARM and associated malformations. We aimed to evaluate the
      results of Three-dimensional High Resolution Anorectal Manometry (3D-HRAM) in
      long-term follow-up after surgical correction of ARM with special reference to
      fecal incontinence. Twenty-one patients with anorectal malformations and primary 
      repair at our center consented to participate in the study. Pressures of the anal
      sphincter muscles and defects were addressed by 3D-HRAM. Fecal incontinence and
      disease-specific quality of life were evaluated by the Fecal Incontinence Quality
      of Life score and Wexner incontinence score respectively. The study was approved 
      by the Committee in Health Research Ethics and the Danish Data Protection Agency.
      Median age was 22(12-31) years and 13(67%) participants were females. Sphincter
      defect was present in 48% (N = 10) of participants. Participants with sphincter
      defects had significant higher Wexner score and size of sphincter defects and
      mean anal squeeze pressure were correlated to Wexner score. Participants with or 
      without sphincter defects did not differ on manometry parameters including
      resting anal and squeeze pressure or disease-specific quality of life. In a study
      of the long-term outcome after repair of anorectal malformations we found a
      higher Wexner incontinence score in the presence of an anal sphincter defect and 
      the size of the defect and mean anal squeeze pressure were correlated to the
      Wexner incontinence score.
FAU - Bjorsum-Meyer, T
AU  - Bjorsum-Meyer T
AD  - Department of Surgery, Odense University Hospital, Odense C, 5000, Denmark.
      Thomas.bjoersum-meyer@rsyd.dk.
AD  - University of Southern Denmark, Faculty of Health Science, Department of Clinical
      research, Odense C, 5000, Denmark. Thomas.bjoersum-meyer@rsyd.dk.
FAU - Christensen, P
AU  - Christensen P
AD  - Department of Surgery, Aarhus University Hospital, Odense, 9000, Denmark.
FAU - Jakobsen, M S
AU  - Jakobsen MS
AD  - Department of Pediatrics, Odense University Hospital, Odense, 5000, Denmark.
FAU - Baatrup, G
AU  - Baatrup G
AD  - Department of Surgery, Odense University Hospital, Odense C, 5000, Denmark.
AD  - University of Southern Denmark, Faculty of Health Science, Department of Clinical
      research, Odense C, 5000, Denmark.
FAU - Qvist, N
AU  - Qvist N
AD  - Department of Surgery, Odense University Hospital, Odense C, 5000, Denmark.
AD  - University of Southern Denmark, Faculty of Health Science, Department of Clinical
      research, Odense C, 5000, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anal Canal/pathology
MH  - Anorectal Malformations/complications/*pathology
MH  - Child
MH  - Cross-Sectional Studies
MH  - Fecal Incontinence/complications/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Quality of Life
MH  - Rectum/pathology
MH  - Severity of Illness Index
MH  - Young Adult
PMC - PMC7138810
EDAT- 2020/04/09 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/09 06:00
PHST- 2019/05/24 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1038/s41598-020-62908-w [doi]
AID - 10.1038/s41598-020-62908-w [pii]
PST - epublish
SO  - Sci Rep. 2020 Apr 7;10(1):6016. doi: 10.1038/s41598-020-62908-w.


PMID- 32265253
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Developing a multivariable prediction model for functional outcome after
      reperfusion therapy for acute ischaemic stroke: study protocol for the Targeting 
      Optimal Thrombolysis Outcomes (TOTO) multicentre cohort study.
PG  - e038180
LID - 10.1136/bmjopen-2020-038180 [doi]
AB  - INTRODUCTION: Intravenous thrombolysis (IVT) with recombinant tissue plasminogen 
      activator (rt-PA) is the only approved pharmacological reperfusion therapy for
      acute ischaemic stroke. Despite population benefit, IVT is not equally effective 
      in all patients, nor is it without significant risk. Uncertain treatment outcome 
      prediction complicates patient treatment selection. This study will develop and
      validate predictive algorithms for IVT response, using clinical, radiological and
      blood-based biomarker measures. A secondary objective is to develop predictive
      algorithms for endovascular thrombectomy (EVT), which has been proven as an
      effective reperfusion therapy since study inception. METHODS AND ANALYSIS: The
      Targeting Optimal Thrombolysis Outcomes Study is a multicenter prospective cohort
      study of ischaemic stroke patients treated at participating Australian Stroke
      Centres with IVT and/or EVT. Patients undergo neuroimaging using multimodal CT or
      MRI at baseline with repeat neuroimaging 24 hours post-treatment. Baseline and
      follow-up blood samples are provided for research use. The primary outcome is
      good functional outcome at 90 days poststroke, defined as a modified Rankin Scale
      (mRS) Score of 0-2. Secondary outcomes are reperfusion, recanalisation, infarct
      core growth, change in stroke severity, poor functional outcome, excellent
      functional outcome and ordinal mRS at 90 days. Primary predictive models will be 
      developed and validated in patients treated only with rt-PA. Models will be built
      using regression methods and include clinical variables, radiological measures
      from multimodal neuroimaging and blood-based biomarkers measured by mass
      spectrometry. Predictive accuracy will be quantified using c-statistics and R(2).
      In secondary analyses, models will be developed in patients treated using EVT,
      with or without prior IVT, reflecting practice changes since original study
      design. ETHICS AND DISSEMINATION: Patients, or relatives when patients could not 
      consent, provide written informed consent to participate. This study received
      approval from the Hunter New England Local Health District Human Research Ethics 
      Committee (reference 14/10/15/4.02). Findings will be disseminated via
      peer-reviewed publications and conference presentations.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Holliday, Elizabeth
AU  - Holliday E
AUID- ORCID: 0000-0002-4066-6224
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan, New
      South Wales, Australia liz.holliday@newcastle.edu.au.
AD  - Hunter Medical Research Institute, The University of Newcastle, New Lambton, New 
      South Wales, Australia.
FAU - Lillicrap, Thomas
AU  - Lillicrap T
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan, New
      South Wales, Australia.
AD  - Hunter Medical Research Institute, The University of Newcastle, New Lambton, New 
      South Wales, Australia.
FAU - Kleinig, Timothy
AU  - Kleinig T
AD  - Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia,
      Australia.
AD  - The University of Adelaide, Adelaide, South Australia, Australia.
FAU - Choi, Philip M C
AU  - Choi PMC
AD  - Department of Neurosciences, Eastern Health, Melbourne, Victoria, Australia.
AD  - Eastern Health Clinical School, Faculty of Medicine, Nursing and Health Sciences,
      Monash University, Melbourne, Victoria, Australia.
FAU - Maguire, Jane
AU  - Maguire J
AUID- ORCID: 0000-0001-5722-8311
AD  - University of Technology Sydney, Sydney, New South Wales, Australia.
FAU - Bivard, Andrew
AU  - Bivard A
AD  - Melbourne Brain Centre, Parkville, Victoria, Australia.
FAU - Lincz, Lisa F
AU  - Lincz LF
AUID- ORCID: 0000-0002-1612-2382
AD  - School of Biomedical Sciences and Pharmacy, The University of Newcastle,
      Callaghan, New South Wales, Australia.
AD  - Haematology Department, Calvary Mater Newcastle, Waratah, New South Wales,
      Australia.
FAU - Hamilton-Bruce, Monica Anne
AU  - Hamilton-Bruce MA
AUID- ORCID: 0000-0002-5222-620X
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
AD  - Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
FAU - Rao, Sushma R
AU  - Rao SR
AUID- ORCID: 0000-0002-1773-9747
AD  - The University of Adelaide, Adelaide, South Australia, Australia.
AD  - South Australian Health and Medical Research Institute, Adelaide, South
      Australia, Australia.
FAU - Snel, Marten F
AU  - Snel MF
AUID- ORCID: 0000-0002-8502-7274
AD  - The University of Adelaide, Adelaide, South Australia, Australia.
AD  - South Australian Health and Medical Research Institute, Adelaide, South
      Australia, Australia.
FAU - Trim, Paul J
AU  - Trim PJ
AD  - The University of Adelaide, Adelaide, South Australia, Australia.
AD  - South Australian Health and Medical Research Institute, Adelaide, South
      Australia, Australia.
FAU - Lin, Longting
AU  - Lin L
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan, New
      South Wales, Australia.
FAU - Parsons, Mark W
AU  - Parsons MW
AD  - Melbourne Brain Centre, Parkville, Victoria, Australia.
AD  - Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria,
      Australia.
FAU - Worrall, Bradford B
AU  - Worrall BB
AD  - Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.
AD  - Department of Public Health Sciences, University of Virginia, Charlottesville,
      Virginia, USA.
FAU - Koblar, Simon
AU  - Koblar S
AUID- ORCID: 0000-0002-8667-203X
AD  - Adelaide Medical School, The University of Adelaide, Adelaide, South Australia,
      Australia.
AD  - Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
FAU - Attia, John
AU  - Attia J
AUID- ORCID: 0000-0001-9800-1308
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan, New
      South Wales, Australia.
AD  - John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
FAU - Levi, Chris
AU  - Levi C
AD  - The Sydney Partnership for Health, Education, Research & Enterprise (SPHERE),
      Sydney, New South Wales, Australia.
AD  - School of Medicine and Public Health (SMPH), University of Newcastle (UoN),
      Callaghan, New South Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Fibrinolytic Agents)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Australia
MH  - *Brain Ischemia/drug therapy
MH  - *Endovascular Procedures
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - *Ischemic Stroke
MH  - New England
MH  - Prospective Studies
MH  - Reperfusion
MH  - *Stroke/diagnostic imaging/drug therapy
MH  - Thrombectomy
MH  - Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/therapeutic use
MH  - Treatment Outcome
PMC - PMC7245375
OTO - NOTNLM
OT  - *epidemiology
OT  - *statistics & research methods
OT  - *stroke
OT  - *stroke medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/09 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-038180 [pii]
AID - 10.1136/bmjopen-2020-038180 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 6;10(4):e038180. doi: 10.1136/bmjopen-2020-038180.


PMID- 32265252
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Association between functional social support and cognitive function in
      middle-aged and older adults: a protocol for a systematic review.
PG  - e037301
LID - 10.1136/bmjopen-2020-037301 [doi]
AB  - INTRODUCTION: Maintenance of cognitive function into old age is important for
      ageing populations. Researchers seek to identify modifiable risk and protective
      factors for cognitive function. One such modifiable factor is functional social
      support, that is, one's perception of whether their social network can provide
      resources such as material help, companionship, information and emotional
      contact, if needed. While the literature generally reports positive associations 
      between functional social support and cognitive function, results vary according 
      to study methods such as the tool used to measure functional social support or
      the specific cognitive domain under investigation. Our review will summarise the 
      association between functional social support and cognitive function in
      middle-aged and older-aged adults who reside in any setting (eg, community
      dwelling, long-term care facilities). We will also identify sources of discrepant
      findings between studies. METHODS AND ANALYSIS: This protocol was reported
      according to the Preferred Reporting Items for Systematic Reviews and
      Meta-Analysis Protocols guideline. PubMed, PsycINFO, Sociological Abstracts,
      Cumulative Index of Nursing and Allied Health Literature (CINAHL) and Scopus will
      be searched from inception to the present using a search strategy developed with 
      a medical librarian's help. We will supplement the database searches with a grey 
      literature search. English-language or French-language studies with a comparison 
      group will be subject to inclusion, regardless of the measures used to assess
      functional social support or cognitive function. We will assess risk of bias with
      the Cochrane Risk of Bias Tool-Version 2 or the Newcastle-Ottawa Scale,
      narratively synthesise the extracted data and conduct a meta-analysis of studies 
      with similar characteristics (eg, sample age and sex, cognitive function
      outcomes). Two independent raters will screen articles and assess risk of bias.
      ETHICS AND DISSEMINATION: This review is timely given the push toward early
      diagnosis and treatment of dementia/major neurocognitive disorder and other types
      of cognitive impairment. This protocol does not require a formal ethics review.
      We will publish our findings in a peer-reviewed journal.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Rutter, Emily C
AU  - Rutter EC
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Tyas, Suzanne L
AU  - Tyas SL
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
FAU - Maxwell, Colleen J
AU  - Maxwell CJ
AUID- ORCID: 0000-0002-7988-2899
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
AD  - School of Pharmacy, University of Waterloo, Waterlo, Ontario, Canada.
FAU - Law, Jane
AU  - Law J
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada.
AD  - School of Planning, University of Waterloo, Waterloo, Ontario, Canada.
FAU - O'Connell, Megan E
AU  - O'Connell ME
AD  - Department of Psychology, University of Saskatchewan, Saskatoon, Saskatchewan,
      Canada.
FAU - Konnert, Candace A
AU  - Konnert CA
AD  - Department of Psychology, University of Calgary, Calgary, Alberta, Canada.
FAU - Oremus, Mark
AU  - Oremus M
AUID- ORCID: 0000-0001-8190-253X
AD  - School of Public Health and Health Systems, University of Waterloo, Waterloo,
      Ontario, Canada moremus@uwaterloo.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Aging
MH  - *Cognition
MH  - *Cognitive Dysfunction
MH  - Delivery of Health Care
MH  - Humans
MH  - Social Support
MH  - Systematic Reviews as Topic
PMC - PMC7245373
OTO - NOTNLM
OT  - *delirium & cognitive disorders
OT  - *dementia
OT  - *epidemiology
OT  - *old age psychiatry
COIS- Competing interests: None declared.
EDAT- 2020/04/09 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2020-037301 [pii]
AID - 10.1136/bmjopen-2020-037301 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 6;10(4):e037301. doi: 10.1136/bmjopen-2020-037301.


PMID- 32265248
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Community engagement with immigrant communities involving health and wellness
      research: a systematic review protocol towards developing a taxonomy of community
      engagement definitions, frameworks, and methods.
PG  - e035649
LID - 10.1136/bmjopen-2019-035649 [doi]
AB  - INTRODUCTION: The importance of community engagement has been established
      globally in health and wellness research. A certain degree of ambiguity remains, 
      however, regarding the meaning of community engagement, which term has been used 
      for various purposes and implemented in various forms. In this study, we aimed to
      explore the different definitions of community engagement, discuss the various
      objectives that have been proposed and uncover the diverse ways this concept has 
      been implemented among researchers working for the betterment of the health and
      wellness of immigrant communities in host countries. METHODS AND ANALYSIS:
      Taxonomy is a process for classifying complex and multifaceted matters using
      logical conceptual domains and dimensions for clearer way of contextualising. We 
      will develop a taxonomy to organise the available literature on community
      engagement in immigrant health and wellness research in a way that captures user 
      knowledge and understanding of its various meanings and processes. Specific
      methodological and analytical frameworks for systematic review and taxonomy
      development will guide each step. We will conduct a comprehensive systematic
      search in relevant databases, from inception to December 2019, using appropriate 
      keywords followed by snowball search (single-citation tracking, reference lists).
      Papers will be included if they fall within predefined inclusion criteria (seen
      as most likely informative on elements pertaining to community engagement) and
      are written in English, regardless of design (conceptual, qualitative and
      quantitative). Two reviewers will independently employ two-stage screening
      (title-abstract screening followed by screening of the full text to determine
      inclusion). Finally, information that helps to develop taxonomy of the concept
      and practice of community engagement will be abstracted and used towards taxonomy
      development, where different levels of stakeholder research team members will be 
      involved. ETHICS AND DISSEMINATION: Ethical approval is not required for this
      systematic review. We have opted for an integrated knowledge translation or a
      community-engaged knowledge mobilisation approach where we are engaged with
      community-based citizen researchers from the inception of our programme. We plan 
      to disseminate the results of our review through meetings with key stakeholders, 
      followed by journal publications and presentations at applicable platforms.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Turin, Tanvir C
AU  - Turin TC
AUID- ORCID: 0000-0002-7499-5050
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada turin.chowdhury@ucalgary.ca.
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, Calgary, Alberta, Canada.
FAU - Abedin, Tasnima
AU  - Abedin T
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Chowdhury, Nashit
AU  - Chowdhury N
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Ferdous, Mahzabin
AU  - Ferdous M
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Vaska, Marcus
AU  - Vaska M
AD  - Knowledge Resource Service, Alberta Health Services, Calgary, Alberta, Canada.
FAU - Rumana, Nahid
AU  - Rumana N
AD  - Foothills Medical Center, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Urrutia, Rossana
AU  - Urrutia R
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
FAU - Chowdhury, Mohammad Ziaul Islam
AU  - Chowdhury MZI
AUID- ORCID: 0000-0002-5397-2773
AD  - Department of Family Medicine, Cumming School of Medicine, University of Calgary,
      Calgary, Alberta, Canada.
AD  - Department of Community Health Sciences, Cumming School of Medicine, University
      of Calgary, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200406
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Emigrants and Immigrants
MH  - Humans
MH  - Research Personnel
MH  - *Translational Research, Biomedical
PMC - PMC7245376
OTO - NOTNLM
OT  - *preventive medicine
OT  - *public health
OT  - *social medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/09 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2019-035649 [pii]
AID - 10.1136/bmjopen-2019-035649 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 6;10(4):e035649. doi: 10.1136/bmjopen-2019-035649.


PMID- 32265243
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Investigating the critical elements and psychosocial outcomes of Youth Flexible
      Assertive Community Treatment: a study protocol for an observational prospective 
      cohort study.
PG  - e035146
LID - 10.1136/bmjopen-2019-035146 [doi]
AB  - INTRODUCTION: When adolescents experience complex psychiatric and social
      problems, numerous healthcare services usually become involved. In these cases,
      fragmentation of care services is a risk that often results in both ineffective
      care and in patients disengaging from care services. To address these issues,
      Youth Flexible Assertive Community Treatment (Youth Flexible ACT) was developed
      in the Netherlands. This client-centred service delivery model aims to tackle the
      fragmented care system by providing psychiatric treatment and support in a
      flexible and integrated manner. While Youth Flexible ACT is gaining in
      popularity, the effectiveness of the care model remains largely unexamined.
      METHODS AND ANALYSIS: Here, we present an observational prospective cohort
      (2017-2021) in which a broad range of treatment outcomes will be monitored. The
      primary aim of the study is to examine change in treatment outcomes over the
      course of the Flexible ACT care. The secondary aim is to examine the association 
      between (elements of) Youth Flexible ACT model fidelity and treatment outcomes.
      An estimated total number of 200 adolescents who receive care from one of the 16 
      participating Youth Flexible ACT teams will be included in the study.
      Participants will be asked to complete assessments at four time points in 6-month
      intervals, resulting in a study duration of 18 months. Latent growth curve
      analysis will be conducted to examine change in psychosocial functioning over
      time and its relation to model fidelity. ETHICS AND DISSEMINATION: This study
      received ethical approval from Trimbos Ethics Committee (201607_75-FACT2). This
      approval applies for all participating institutions. The results of the study
      will be reported in accordance with the Strengthening the Reporting of
      Observational Studies in Epidemiology statement. Results will be disseminated via
      peer-reviewed academic journals and presentations at conferences. In addition,
      results will be made available for participating sites, funders and researchers.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Broersen, Marieke
AU  - Broersen M
AUID- ORCID: 0000-0001-5218-4866
AD  - GGZ Oost Brabant, Oss, The Netherlands m.broersen@ggzoostbrabant.nl.
AD  - Tranzo - Tilburg School of Social and Behavioral Sciences, Tilburg University,
      Tilburg, The Netherlands.
FAU - Creemers, Daan H M
AU  - Creemers DHM
AD  - GGZ Oost Brabant, Oss, The Netherlands.
FAU - Frieswijk, Nynke
AU  - Frieswijk N
AD  - Accare, Groningen, The Netherlands.
FAU - Vermulst, Ad A
AU  - Vermulst AA
AD  - GGZ Oost Brabant, Oss, The Netherlands.
FAU - Kroon, Hans
AU  - Kroon H
AD  - Tranzo - Tilburg School of Social and Behavioral Sciences, Tilburg University,
      Tilburg, The Netherlands.
AD  - Trimbos Institute, Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - *Adolescent Health Services
MH  - *Community Mental Health Services
MH  - Humans
MH  - Netherlands
MH  - Prospective Studies
PMC - PMC7245379
OTO - NOTNLM
OT  - *child & adolescent psychiatry
OT  - *community child health
OT  - *public health
COIS- Competing interests: None declared.
EDAT- 2020/04/09 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2019-035146 [pii]
AID - 10.1136/bmjopen-2019-035146 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 6;10(4):e035146. doi: 10.1136/bmjopen-2019-035146.


PMID- 32265242
OWN - NLM
STAT- MEDLINE
DCOM- 20210303
LR  - 20210303
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Core outcome set in paediatric sepsis in low- and middle-income countries: a
      study protocol.
PG  - e034960
LID - 10.1136/bmjopen-2019-034960 [doi]
AB  - INTRODUCTION: Sepsis is the leading cause of death in children worldwide and has 
      recently been declared a major global health issue. New interventions and a
      concerted effort to enhance our understanding of sepsis are required to address
      the huge burden of disease, especially in low- and middle-income countries (LMIC)
      where it is highest. An opportunity therefore exists to ensure that ongoing
      research in this area is relevant to all stakeholders and is of consistently high
      quality. One method to address these issues is through the development of a core 
      outcome set (COS). METHODS AND ANALYSIS: This study protocol outlines the phases 
      in the development of a core outcome set for paediatric sepsis in LMIC. The first
      step involves performing a systematic review of all outcomes reported in the
      research of paediatric sepsis in low middle-income countries. A three-stage
      international Delphi process will then invite a broad range of participants to
      score each generated outcome for inclusion into the COS. This will include an
      initial two-step online survey and finally, a face-to-face consensus meeting
      where each outcome will be reviewed, voted on and ratified for inclusion into the
      COS. ETHICS AND DISSEMINATION: No core outcome sets exist for clinical trials in 
      paediatric sepsis. This COS will serve to not only highlight the heavy burden of 
      paediatric sepsis in this setting and aid collaboration and participation between
      all stakeholders, but to promote ongoing essential high quality and relevant
      research into the topic. A COS in paediatric sepsis in LMIC will advocate for a
      common language and facilitate interpretation of findings from a variety of
      settings. A waiver for ethics approval has been granted by University of British 
      Columbia Children's and Women's Research Ethics Board.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Wooldridge, Gavin
AU  - Wooldridge G
AUID- ORCID: 0000-0001-6806-9328
AD  - Pediatric Critical Care, BC Children's Hospital, Vancouver, British Columbia,
      Canada gfwooldridge@gmail.com.
FAU - Murthy, Srinivas
AU  - Murthy S
AD  - Department of Pediatrics, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Kissoon, Niranjan
AU  - Kissoon N
AD  - Department of Pediatrics, University of British Columbia, Vancouver, British
      Columbia, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Consensus
MH  - Delphi Technique
MH  - *Developing Countries
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Research Design
MH  - *Sepsis/epidemiology/therapy
PMC - PMC7245395
OTO - NOTNLM
OT  - *community child health
OT  - *neonatal intensive & critical care
OT  - *paediatric infectious disease & immunisation
OT  - *paediatric intensive & critical care
COIS- Competing interests: None declared.
EDAT- 2020/04/09 06:00
MHDA- 2021/03/04 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/03/04 06:00 [medline]
AID - bmjopen-2019-034960 [pii]
AID - 10.1136/bmjopen-2019-034960 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 6;10(4):e034960. doi: 10.1136/bmjopen-2019-034960.


PMID- 32265240
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 6
TI  - Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence 
      of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre):
      protocol for a multicentre, observational study followed by randomised controlled
      feasibility trial.
PG  - e034201
LID - 10.1136/bmjopen-2019-034201 [doi]
AB  - INTRODUCTION: Acute kidney injury (AKI) is a frequent complication after cardiac 
      surgery with adverse short-term and long-term outcomes. Although prevention of
      AKI (PrevAKI) is strongly recommended, the optimal strategy is uncertain. The
      Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommended a bundle 
      of supportive measures in high-risk patients. In a single-centre trial, we
      recently demonstrated that the strict implementation of the KDIGO bundle
      significantly reduced the occurrence of AKI after cardiac surgery. In this
      feasibility study, we aim to evaluate whether the study protocol can be
      implemented in a multicentre setting in preparation for a large multicentre
      trial. METHODS AND ANALYSIS: We plan to conduct a prospective, observational
      survey followed by a randomised controlled, multicentre, multinational clinical
      trial including 280 patients undergoing cardiac surgery with cardiopulmonary
      bypass. The purpose of the observational survey is to explore the adherence to
      the KDIGO recommendations in routine clinical practice. The second phase is a
      randomised controlled trial. The objective is to investigate whether the trial
      protocol is implementable in a large multicentre, multinational setting. The
      primary endpoint of the interventional part is the compliance rate with the
      protocol. Secondary endpoints include the occurrence of any AKI and
      moderate/severe AKI as defined by the KDIGO criteria within 72 hours after
      surgery, renal recovery at day 90, use of renal replacement therapy (RRT) and
      mortality at days 30, 60 and 90, the combined endpoint major adverse kidney
      events consisting of persistent renal dysfunction, RRT and mortality at day 90
      and safety outcomes. ETHICS AND DISSEMINATION: The PrevAKI multicentre study has 
      been approved by the leading Research Ethics Committee of the University of
      Munster and the respective Research Ethics Committee at each participating site. 
      The results will be used to design a large, definitive trial. TRIAL REGISTRATION 
      NUMBER: NCT03244514.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Kullmar, Mira
AU  - Kullmar M
AD  - Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster,
      Munster, Nordrhein-Westfalen, Germany.
FAU - Massoth, Christina
AU  - Massoth C
AD  - Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster,
      Munster, Nordrhein-Westfalen, Germany.
FAU - Ostermann, Marlies
AU  - Ostermann M
AD  - Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, 
      London, UK.
FAU - Campos, Sara
AU  - Campos S
AD  - Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, 
      London, UK.
FAU - Grau Novellas, Neus
AU  - Grau Novellas N
AD  - Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, 
      London, UK.
FAU - Thomson, Gary
AU  - Thomson G
AD  - Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, 
      London, UK.
FAU - Haffner, Michael
AU  - Haffner M
AD  - Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, 
      London, UK.
FAU - Arndt, Christian
AU  - Arndt C
AD  - Department of Anesthesiology and Operative Intensive Care, University Hospital
      Marburg, Marburg, UK.
FAU - Wulf, Hinnerk
AU  - Wulf H
AD  - Anesthesiology & Intensive Care Medicine, Philipps-Universitat Marburg
      Fachbereich Medizin, Marburg, Germany.
FAU - Irqsusi, Marc
AU  - Irqsusi M
AD  - Department of Cardiothoracic Surgery, Philipps-Universitat Marburg Fachbereich
      Medizin, Marburg, Germany.
FAU - Monaco, Fabrizio
AU  - Monaco F
AD  - Intensive Care and Anesthesia Unit, Scientific Institute San Raffaele, Milano,
      Italy.
FAU - Di Prima, Ambra
AU  - Di Prima A
AD  - Intensive Care and Anesthesia Unit, Scientific Institute San Raffaele, Milano,
      Italy.
FAU - Garcia Alvarez, Mercedes
AU  - Garcia Alvarez M
AD  - Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona,
      Catalunya, Spain.
FAU - Italiano, Stefano
AU  - Italiano S
AD  - Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona,
      Catalunya, Spain.
FAU - Cegarra SanMartin, Virginia
AU  - Cegarra SanMartin V
AD  - Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona,
      Catalunya, Spain.
FAU - Kunst, Gudrun
AU  - Kunst G
AD  - Department of Anesthesia, Critical Care and Pain, King's College London, London, 
      UK.
FAU - Nair, Shrijit
AU  - Nair S
AD  - Department of Anesthesia, Critical Care and Pain, King's College London, London, 
      UK.
FAU - L'Acqua, Camilla
AU  - L'Acqua C
AD  - Department of Anesthesia and Critical Care, Centro Cardiologico Monzino IRCCS,
      Milano, Lombardia, Italy.
FAU - Hoste, Eric A J
AU  - Hoste EAJ
AD  - ICU, Universiteit Gent, Gent, Belgium.
FAU - Vandenberghe, Wim
AU  - Vandenberghe W
AD  - ICU, Universiteit Gent, Gent, Belgium.
FAU - Honore, Patrick M
AU  - Honore PM
AD  - Department of Intensive Care, CHU Brugmann, Brussels, Belgium.
FAU - Kellum, John
AU  - Kellum J
AD  - Center for Critical Care Nephrology, Department of Critical Care Medicine,
      University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
FAU - Forni, Lui
AU  - Forni L
AD  - Department of Intensive Care Medicine, Royal Surrey County Hospital NHS Trust,
      Guildford, Surrey, UK.
FAU - Grieshaber, Philippe
AU  - Grieshaber P
AD  - Department of Cardiac Surgery, Justus Liebig Universitat Giessen Fachbereich
      Medizin, Giessen, Hessen, Germany.
FAU - Weiss, Raphael
AU  - Weiss R
AD  - Department of Anaesthesiology, University Hospital Munster, Munster, Germany.
FAU - Gerss, Joachim
AU  - Gerss J
AD  - Institute of Biostatistics and Clinical Research, Westfalische
      Wilhelms-Universitat Munster, Munster, Germany.
FAU - Wempe, Carola
AU  - Wempe C
AD  - Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster,
      Munster, Nordrhein-Westfalen, Germany.
FAU - Meersch, Melanie
AU  - Meersch M
AD  - Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster,
      Munster, Nordrhein-Westfalen, Germany.
FAU - Zarbock, Alexander
AU  - Zarbock A
AUID- ORCID: 0000-0002-2124-1714
AD  - Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster,
      Munster, Nordrhein-Westfalen, Germany zarbock@uni-muenster.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT03244514
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Biomarkers)
RN  - 0 (Tissue Extracts)
RN  - 0 (samprost)
SB  - IM
MH  - Acute Kidney Injury/epidemiology/*prevention & control
MH  - Biomarkers
MH  - Cardiac Surgical Procedures/*adverse effects
MH  - Feasibility Studies
MH  - *Guideline Adherence
MH  - Humans
MH  - International Cooperation
MH  - Patient Participation
MH  - Postoperative Complications/epidemiology/*prevention & control
MH  - *Practice Guidelines as Topic
MH  - Prospective Studies
MH  - Time Factors
MH  - Tissue Extracts
PMC - PMC7245412
OTO - NOTNLM
OT  - *acute renal failure
OT  - *adult intensive & critical care
OT  - *cardiac surgery
COIS- Competing interests: MM, JK and AZ have received lecture fees from Astute
      Medical, Fresenius and Baxter, unrelated to the current study. JK and AZ have
      received grant support from Astute Medical, unrelated to the current study. MO
      has received lecture fees from Biomerieux, Fresenius Medical and Baxter. CA has
      received lecture fees from Baxter. LF has received research funding from Baxter
      and Ortho Clinical Diagnostics, consultancy fees from Medibeacon/La Jolla
      Pharmaceuticals and honoraria from Biomerieux/Astute.
EDAT- 2020/04/09 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-034201 [pii]
AID - 10.1136/bmjopen-2019-034201 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 6;10(4):e034201. doi: 10.1136/bmjopen-2019-034201.


PMID- 32265232
OWN - NLM
STAT- Publisher
LR  - 20200408
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 7
TI  - Defending the distinction between pregnancy and parenthood.
LID - medethics-2020-106216 [pii]
LID - 10.1136/medethics-2020-106216 [doi]
AB  - In this paper, I respond to the criticisms towards my account of the difference
      in moral status between fetuses and newborns. I show my critics have not
      adequately argued for their view that pregnant women participate in a
      parent-child relationship. While an important counterexample is raised against my
      account, this counterexample had already been dealt with in my original paper.
      Because the criticisms against my account lack argumentative support, they do not
      pose a problem for my account. I conclude the raised criticisms do not amount to 
      a stron philosophical case against my account.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Singh, Prabhpal
AU  - Singh P
AUID- ORCID: http://orcid.org/0000-0003-3660-8563
AD  - University of Waterloo, Waterloo, Ontario, Canada p248singh@uwaterloo.ca.
AD  - Ronin Institute, Montclair, New Jersey, USA.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - abortion
OT  - embryos and fetuses
OT  - infanticide
OT  - moral status
OT  - philosophical ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - medethics-2020-106216 [pii]
AID - 10.1136/medethics-2020-106216 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 7. pii: medethics-2020-106216. doi:
      10.1136/medethics-2020-106216.


PMID- 32265167
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 1878-3449 (Electronic)
IS  - 0749-2081 (Linking)
VI  - 36
IP  - 2
DP  - 2020 Apr
TI  - Risks at the Intersection of Research and Oncology Nursing.
PG  - 151002
LID - S0749-2081(20)30017-6 [pii]
LID - 10.1016/j.soncn.2020.151002 [doi]
AB  - OBJECTIVES: To describe the increasing complexity and scope of clinical trials
      research, convergent research, and the clinical nurse roles and responsibilities 
      to ensure safe patient care and study data integrity. DATA SOURCES: Textbooks,
      journal publications, federal regulations, US Food and Drug Administration
      documents, clinical practice guidelines. CONCLUSION: The immune system, genetics,
      and molecular pathology are not new in the context of oncology treatments. The
      reliability and clinical validation of in vitro diagnostic medical devices is,
      however, becoming increasingly more important in the development of marker driven
      targeted therapies, immunotherapy, and adoptive T-cell transfer. Protecting
      patients and preserving the integrity of clinical trials is of utmost importance.
      IMPLICATIONS FOR NURSING PRACTICE: The role and scope of oncology and research
      nurses will intersect and shift as clinical care continues to involve high-acuity
      patients who participate in complex in vitro diagnostic and therapeutics clinical
      trials. The expertise of oncology nurses may vary in skills and knowledge domain;
      however, all scopes of practice are underpinned by the nursing code of ethics to 
      ensure accountability for all aspects of patient care.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Schroeder, Wendy
AU  - Schroeder W
AD  - Schroeder Clinical Research Consulting, LLC, Phoenix, AX. Electronic address:
      schroeder.wendy@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200404
PL  - United States
TA  - Semin Oncol Nurs
JT  - Seminars in oncology nursing
JID - 8504688
SB  - IM
MH  - Biomedical Research/*organization & administration
MH  - Clinical Trials as Topic/*organization & administration
MH  - Ethics, Nursing
MH  - Genetic Testing
MH  - Humans
MH  - Neoplasms/diagnosis/genetics/immunology
MH  - Oncology Nursing/*organization & administration
MH  - Research Personnel/organization & administration
OTO - NOTNLM
OT  - biomarkers
OT  - cell therapy
OT  - genetics
OT  - genomics
OT  - immunotherapy
OT  - oncology and research nurse
COIS- Declaration of Competing Interest The authors do not have any conflicts of
      interest to declare.
EDAT- 2020/04/09 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - S0749-2081(20)30017-6 [pii]
AID - 10.1016/j.soncn.2020.151002 [doi]
PST - ppublish
SO  - Semin Oncol Nurs. 2020 Apr;36(2):151002. doi: 10.1016/j.soncn.2020.151002. Epub
      2020 Apr 4.


PMID- 32264952
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20210225
IS  - 1916-0216 (Electronic)
IS  - 1916-0208 (Linking)
VI  - 49
IP  - 1
DP  - 2020 Apr 7
TI  - Assessment of a virtual reality temporal bone surgical simulator: a national face
      and content validity study.
PG  - 17
LID - 10.1186/s40463-020-00411-y [doi]
AB  - BACKGROUND: Trainees in Otolaryngology-Head and Neck Surgery must gain
      proficiency in a variety of challenging temporal bone surgical techniques.
      Traditional teaching has relied on the use of cadavers; however, this method is
      resource-intensive and does not allow for repeated practice. Virtual reality
      surgical training is a growing field that is increasingly being adopted in
      Otolaryngology. CardinalSim is a virtual reality temporal bone surgical simulator
      that offers a high-quality, inexpensive adjunct to traditional teaching methods. 
      The objective of this study was to establish the face and content validity of
      CardinalSim through a national study. METHODS: Otolaryngologists and resident
      trainees from across Canada were recruited to evaluate CardinalSim. Ethics
      approval and informed consent was obtained. A face and content validity
      questionnaire with questions categorized into 13 domains was distributed to
      participants following simulator use. Descriptive statistics were used to
      describe questionnaire results, and either Chi-square or Fishers exact tests were
      used to compare responses between junior residents, senior residents, and
      practising surgeons. RESULTS: Sixty-two participants from thirteen different
      Otolaryngology-Head and Neck Surgery programs were included in the study (32
      practicing surgeons; 30 resident trainees). Face validity was achieved for 5 out 
      of 7 domains, while content validity was achieved for 5 out of 6 domains.
      Significant differences between groups (p-value of < 0.05) were found for one
      face validity domain (realistic ergonomics, p = 0.002) and two content validity
      domains (teaching drilling technique, p = 0.011 and overall teaching utility, p =
      0.006). The assessment scores, global rating scores, and overall attitudes
      towards CardinalSim, were universally positive. Open-ended questions identified
      limitations of the simulator. CONCLUSION: CardinalSim met acceptable criteria for
      face and content validity. This temporal bone virtual reality surgical simulation
      platform may enhance surgical training and be suitable for patient-specific
      surgical rehearsal for practicing Otolaryngologists.
FAU - Compton, Evan C
AU  - Compton EC
AD  - Section of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cumming
      School of Medicine, University of Calgary, Calgary, Alberta, Canada.
FAU - Agrawal, Sumit K
AU  - Agrawal SK
AD  - Department of Otolaryngology-Head and Neck Surgery, Western University, London,
      Ontario, Canada.
AD  - Department of Electrical and Computer Engineering, Western University, London,
      Ontario, Canada.
FAU - Ladak, Hanif M
AU  - Ladak HM
AD  - Department of Otolaryngology-Head and Neck Surgery, Western University, London,
      Ontario, Canada.
AD  - Department of Electrical and Computer Engineering, Western University, London,
      Ontario, Canada.
AD  - Department of Medical Biophysics, Western University, London, Ontario, Canada.
FAU - Chan, Sonny
AU  - Chan S
AD  - Department of Computer Sciences, University of Calgary, Calgary, Alberta, Canada.
FAU - Hoy, Monica
AU  - Hoy M
AD  - Section of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cumming
      School of Medicine, University of Calgary, Calgary, Alberta, Canada.
FAU - Nakoneshny, Steven C
AU  - Nakoneshny SC
AD  - Ohlson Research Initiative, Arnie Charbonneau Cancer Institute, Cumming School of
      Medicine, University of Calgary, 3280 Hospital Dr. NW, Calgary, AB, T2N 4Z6,
      Canada.
FAU - Siegel, Lauren
AU  - Siegel L
AD  - Department of Otolaryngology-Head and Neck Surgery, Western University, London,
      Ontario, Canada.
FAU - Dort, Joseph C
AU  - Dort JC
AD  - Section of Otolaryngology-Head and Neck Surgery, Department of Surgery, Cumming
      School of Medicine, University of Calgary, Calgary, Alberta, Canada.
      jdort@ucalgary.ca.
AD  - Ohlson Research Initiative, Arnie Charbonneau Cancer Institute, Cumming School of
      Medicine, University of Calgary, 3280 Hospital Dr. NW, Calgary, AB, T2N 4Z6,
      Canada. jdort@ucalgary.ca.
FAU - Lui, Justin T
AU  - Lui JT
AD  - Department of Otolaryngology-Head and Neck Surgery, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
GR  - NA/Collaborative Health Research Projects via the Natural Sciences and
      Engineering Council of Canada
PT  - Journal Article
DEP - 20200407
PL  - England
TA  - J Otolaryngol Head Neck Surg
JT  - Journal of otolaryngology - head & neck surgery = Le Journal
      d'oto-rhino-laryngologie et de chirurgie cervico-faciale
JID - 101479544
SB  - IM
EIN - J Otolaryngol Head Neck Surg. 2020 Apr 22;49(1):20. PMID: 32321592
MH  - *Attitude of Health Personnel
MH  - Canada
MH  - Clinical Competence
MH  - Ergonomics
MH  - Humans
MH  - *Internship and Residency
MH  - Medical Staff, Hospital/education
MH  - Otolaryngology/*education
MH  - Otorhinolaryngologic Surgical Procedures/*education
MH  - Reproducibility of Results
MH  - Temporal Bone/*surgery
MH  - *Virtual Reality
PMC - PMC7137498
OTO - NOTNLM
OT  - Content validity
OT  - Dissection
OT  - Education
OT  - Face validity
OT  - Patient-specific
OT  - Surgical simulation
OT  - Temporal bone
OT  - Virtual reality
EDAT- 2020/04/09 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - 10.1186/s40463-020-00411-y [doi]
AID - 10.1186/s40463-020-00411-y [pii]
PST - epublish
SO  - J Otolaryngol Head Neck Surg. 2020 Apr 7;49(1):17. doi:
      10.1186/s40463-020-00411-y.


PMID- 32264865
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210120
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 7
TI  - 'I didn't know what to expect': Exploring patient perspectives to identify
      targets for change to improve telephone-delivered psychological interventions.
PG  - 156
LID - 10.1186/s12888-020-02564-6 [doi]
AB  - BACKGROUND: Remote delivery of psychological interventions to meet growing demand
      has been increasing worldwide. Telephone-delivered psychological treatment has
      been shown to be equally effective and as satisfactory to patients as
      face-to-face treatment. Despite robust research evidence, however, obstacles
      remain to the acceptance of telephone-delivered treatment in practice. This study
      aimed to explore those issues using a phenomenological approach from a patient
      perspective to identify areas for change in current provision through the use of 
      theoretically based acceptability and behaviour change frameworks. METHODS:
      Twenty-eight semi-structured interviews with patients experiencing symptoms of
      common mental health problems, waiting, receiving or having recently received
      telephone-delivered psychological treatment via the UK National Health Service's 
      Improving Access to Psychological Therapies (IAPT) programme. Interviews were
      recorded, transcribed verbatim, and analysed using the Theoretical Domains
      Framework (TDF) and Theoretical Framework of Acceptability (TFA). RESULTS: The
      majority of data clustered within five key domains of the TDF (knowledge, skills,
      cognitive and interpersonal, environmental context and resources, beliefs about
      capabilities, beliefs about consequences) and mapped to all constructs of the TFA
      (affective attitude, ethicality, intervention coherence, self-efficacy, burden,
      opportunity costs, and perceived effectiveness). Themes highlighted that early
      stages of treatment can be affected by lack of patient knowledge and
      understanding, reservations about treatment efficacy, and practical obstacles
      such as absent non-verbal communication, which is deemed important in the
      development of therapeutic alliance. Yet post-treatment, patients can reflect
      more positively, and report gaining benefit from treatment. However, despite
      this, many patients say that if they were to return for future treatment, they
      would choose to see a practitioner face-to-face. CONCLUSIONS: Using a combination
      of theoretically underpinned models has allowed the identification of key targets
      for change. Addressing knowledge deficits to shift attitudes, highlighting the
      merits of telephone delivered treatment and addressing skills and practical
      issues may increase acceptability of, and engagement with, telephone-delivered
      treatment.
FAU - Rushton, Kelly
AU  - Rushton K
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK. Kelly.Rushton@manchester.ac.uk.
FAU - Ardern, Kerry
AU  - Ardern K
AD  - Department of Psychology, University of Sheffield, Sheffield, UK.
FAU - Hopkin, Elinor
AU  - Hopkin E
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
FAU - Welsh, Charlotte
AU  - Welsh C
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
FAU - Gellatly, Judith
AU  - Gellatly J
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
FAU - Faija, Cintia
AU  - Faija C
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
FAU - Armitage, Christopher J
AU  - Armitage CJ
AD  - Manchester Centre for Health Psychology, School of Health Sciences, University of
      Manchester, United Kingdom; Manchester University NHS Foundation Trust,
      Manchester Academic Health Science Centre, Manchester, UK.
FAU - Lidbetter, Nicky
AU  - Lidbetter N
AD  - Anxiety UK, Manchester, UK.
FAU - Lovell, Karina
AU  - Lovell K
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
FAU - Bower, Peter
AU  - Bower P
AD  - NIHR School for Primary Care Research, Centre for Primary Care and Health
      Services Research, Manchester Academic Health Science Centre, University of
      Manchester, Manchester, UK.
FAU - Bee, Penny
AU  - Bee P
AD  - School of Health Sciences, Division of Nursing, Midwifery and Social Work,
      Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
LA  - eng
GR  - RP-PG-1016-20010/DH_/Department of Health/United Kingdom
GR  - RP-PG-1016-20010/Programme Grants for Applied Research/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200407
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
MH  - Humans
MH  - *Psychosocial Intervention
MH  - Self Efficacy
MH  - *State Medicine
MH  - Telephone
MH  - Treatment Outcome
PMC - PMC7137505
OTO - NOTNLM
OT  - *Anxiety
OT  - *Common mental health problems
OT  - *Depression
OT  - *Guided self-help
OT  - *IAPT
OT  - *Mental health
OT  - *Patient perspective
OT  - *Psychological wellbeing practitioner
OT  - *Telephone therapy
EDAT- 2020/04/09 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/09 06:00
PHST- 2019/12/17 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s12888-020-02564-6 [doi]
AID - 10.1186/s12888-020-02564-6 [pii]
PST - epublish
SO  - BMC Psychiatry. 2020 Apr 7;20(1):156. doi: 10.1186/s12888-020-02564-6.


PMID- 32264790
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Nurses' experience of providing ethical care following an earthquake: A
      phenomenological study.
PG  - 911-923
LID - 10.1177/0969733020907952 [doi]
AB  - BACKGROUND: Ethical care provided by nurses to earthquake victims is one of the
      main subjects in nursing profession. OBJECTIVES: Given the information gap in
      this field, the present study is an attempt to explore the nurses' experience of 
      ethical care provided to victims of an earthquake. RESEARCH DESIGN AND METHOD: A 
      hermeneutic phenomenological study was performed. The participants were 16 nurses
      involved in providing care to the injured in Kermanshah earthquake, Iran. They
      were selected using purposeful sampling, and in-depth and semi-structured
      interviews were carried out. The transcribed interviews were analyzed based on
      the hermeneutic approach using the analysis method proposed by Diekelmann et al. 
      ETHICAL CONSIDERATIONS: The study was approved by the Research Council and Ethics
      Committee of Urmia University of Medical Sciences, Iran. FINDINGS: Data analyses 
      revealed four themes and 10 sub-themes that illustrated nurses' experience of
      ethical care during earthquake. The themes were (1) Respecting humanistic values 
      (sacrifice, stepping beyond task description, and voluntary work), (2) Commitment
      to ethics (honesty, confidentiality, and trustworthiness), (3) Respecting dignity
      of victims (respecting cultural values, maintaining privacy, having humanistic
      perspective, and effective communication), and (4) Spiritual support (helping
      patients to do religious rituals Psychological support). CONCLUSION: The results 
      showed the nurses' experience with providing care to earthquake victims. The
      findings underlined ethics and ethical values in providing nursing care during
      disasters. It is suggested that special courses on the importance of nursing
      ethics in critical situations be incorporated into nursing curriculums and
      in-service educations.
FAU - Moradi, Khalil
AU  - Moradi K
AD  - School of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia,
      Iran.
FAU - Abdi, Alireza
AU  - Abdi A
AD  - Emergenecy and Critical Care Department, Nursing and Midwifery School, Kermanshah
      university of Medical Sciences, Kermanshah, Iran.
FAU - Valiee, Sina
AU  - Valiee S
AUID- ORCID: https://orcid.org/0000-0002-5419-1004
AD  - Tehran University of Medical Sciences, Iran.
FAU - Rezaei, Soheila Ahangarzadeh
AU  - Rezaei SA
AD  - Faculty of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia,
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - *Disaster Victims
MH  - *Earthquakes
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Nurses/*psychology
MH  - Nursing Care/*ethics
MH  - Nursing Staff, Hospital/*psychology
MH  - Qualitative Research
OTO - NOTNLM
OT  - Earthquake
OT  - ethical care
OT  - experiences
OT  - nurses
OT  - phenomenology
EDAT- 2020/04/09 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/04/09 06:00
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/04/09 06:00 [entrez]
AID - 10.1177/0969733020907952 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):911-923. doi: 10.1177/0969733020907952. Epub 2020 Apr
      7.


PMID- 32260061
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2304-8158 (Print)
IS  - 2304-8158 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 3
TI  - Development of Next-Generation Nutritionally Fortified Plant-Based Milk
      Substitutes: Structural Design Principles.
LID - E421 [pii]
LID - 10.3390/foods9040421 [doi]
AB  - Consumers are increasingly interested in decreasing their dietary intake of
      animal-based food products, due to health, sustainability, and ethical concerns. 
      For this reason, the food industry is creating new products from plant-based
      ingredients that simulate many of the physicochemical and sensory attributes
      associated with animal-derived foods, including milk, eggs, and meat. An
      understanding of how the ingredient type, amount, and organization influence the 
      desirable physicochemical, sensory, and nutritional attributes of these
      plant-based foods is required to achieve this goal. A potential problem with
      plant-based diets is that they lack key micronutrients, such as vitamin B12,
      vitamin D, calcium, and omega-3 fatty acids. The aim of this review is to present
      the science behind the creation of next-generation nutritionally fortified
      plant-based milk substitutes. These milk-like products may be formed by
      mechanically breaking down certain plant materials (including nuts, seeds, and
      legumes) to produce a dispersion of oil bodies and other colloidal matter in
      water, or by forming oil-in-water emulsions by homogenizing plant-based oils and 
      emulsifiers with water. A brief overview of the formulation and fabrication of
      plant-based milks is given. The relationship between the optical properties,
      rheology, and stability of plant-based milks and their composition and structure 
      is then covered. Approaches to fortify these products with micronutrients that
      may be missing from a plant-based diet are also highlighted. In conclusion, this 
      article highlights how the knowledge of structural design principles can be used 
      to facilitate the creation of higher quality and more sustainable plant-based
      food products.
FAU - McClements, David Julian
AU  - McClements DJ
AUID- ORCID: 0000-0002-9016-1291
AD  - Department of Food Science, University of Massachusetts Amherst, Amherst, MA
      01003, USA.
AD  - Department of Food Science & Bioengineering, Zhejiang Gongshang University, 18
      Xuezheng Street, Hangzhou 310018, China.
LA  - eng
GR  - MAS00491/U.S. Department of Agriculture
PT  - Journal Article
PT  - Review
DEP - 20200403
PL  - Switzerland
TA  - Foods
JT  - Foods (Basel, Switzerland)
JID - 101670569
PMC - PMC7231295
OTO - NOTNLM
OT  - emulsions
OT  - oil bodies
OT  - plant-based milks
OT  - proteins
OT  - sustainability
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
CRDT- 2020/04/09 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
AID - foods9040421 [pii]
AID - 10.3390/foods9040421 [doi]
PST - epublish
SO  - Foods. 2020 Apr 3;9(4). pii: foods9040421. doi: 10.3390/foods9040421.


PMID- 32255577
STAT- Publisher
DA  - 20200408
PB  - Agency for Healthcare Research and Quality (US)
CTI - AHRQ Comparative Effectiveness Technical Briefs
DP  - 2020 Mar
BTI - Impact of Community Health Worker Certification on Workforce and Service Delivery
      for Asthma and Other Selected Chronic Diseases
AB  - BACKGROUND: Community Health Worker (CHW) certification has been proposed to
      promote the diffusion of the CHW model in healthcare organizations. However, the 
      extent to which health outcomes vary as a function of CHW certification is
      unclear. There is also a need to clarify the landscape of CHW certification
      efforts in the United States. OBJECTIVES: The objectives were to (1) determine
      the effects of certification on CHW recruitment, retention, scope of practice,
      reimbursement or employer liability; (2) ascertain the effects of certification
      on quality or consistency of care, health outcomes, or patient/family acceptance,
      trust, and use of community health workers; (3) elucidate the context of
      certification requirements and implementation in the United States; (4) identify 
      potential positive and negative implications of requiring certification; and (5) 
      identify future research needs. METHODS: We searched PubMed and CINAHL through
      October 2019 and handsearched relevant reviews. Our grey literature search
      focused on reports and presentations by national organizations, foundations, and 
      institutes. We also reviewed the websites of State health departments which have 
      CHW certification programs. We conducted interviews with Key Informants
      representing stakeholders in the CHW certification enterprise. We used these
      interviews to identify themes to contextualize findings from the published and
      grey literature searches. RESULTS: The evidence base for community health worker 
      certification is sparse. Our published literature search identified a handful of 
      studies examining correlates of certification (i.e., training, recruitment, and
      scope of practice) with health outcomes, but these were not linked to the broader
      issue of certification (n=4, 0 about asthma). We did not find any studies that
      evaluated the relationship between CHW certification and CHW retention,
      reimbursement, employer liability, or patients' and families' trust in and
      receptivity to CHWs. We did not find any studies suggesting that patients'
      outcomes differ as a function of intervention from a certified versus
      non-certified CHW, or that certification influences the quality or consistency of
      CHW-delivered interventions. We identified 37 documents through our grey
      literature search. Interviews with Key Informants identified four overarching
      themes: (1) the perceived utility of certification, (2) the philosophical/ethical
      considerations influencing certification, (3) its potential effects, and (4)
      recommended components and approaches. The majority of participants asserted that
      certification does not affect health outcomes. There were diverging opinions
      about the perceived and actual impact of certification on the CHW workforce,
      including recruitment, retention, career advancement, composition, and the
      financial viability of the CHW model. CONCLUSIONS: In the absence of evaluations 
      of the relationship between certification and outcomes related to patients' and
      families' health, and dimensions of CHWs' workforce development, the impact of
      CHW certification is more speculative than conclusive. Further research is needed
      to determine if certification is linked to improved outcomes for people with
      asthma and other chronic illness outcomes.
FAU - Ibe, Chidinma A.
AU  - Ibe CA
FAU - Wilson, Lisa M.
AU  - Wilson LM
FAU - Brodine, Joseph
AU  - Brodine J
FAU - Monroe, Dwyan
AU  - Monroe D
FAU - Boonyasai, Romsai Tony
AU  - Boonyasai RT
FAU - Meza, Benjamin
AU  - Meza B
FAU - Tschudy, Megan M.
AU  - Tschudy MM
FAU - McArthur, Kristen
AU  - McArthur K
FAU - Robinson, Karen A.
AU  - Robinson KA
LA  - eng
PT  - Review
PT  - Book
PL  - Rockville (MD)
EDAT- 2020/04/08 06:01
MHDA- 2020/04/08 06:01
CDAT- 2020/04/08 06:01
AID - NBK555582 [bookaccession]


PMID- 32259866
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20211204
IS  - 1439-3980 (Electronic)
IS  - 0722-1819 (Linking)
VI  - 52
IP  - 4
DP  - 2020 Aug
TI  - [Stem cells in regenerative medicine - from bench to bedside].
PG  - 338-349
LID - 10.1055/a-1122-8916 [doi]
AB  - The use of mesenchymal stem cells for regenerative medicine is becoming more
      popular than ever before - even though their clinical usage is limited. Many
      ethical and translational questions, as well as legal aspects and uncertainty
      regarding safety inhibit the growth of appropriate therapies from promising
      scientific approaches.This paper demonstrates the main problems of the
      translation from stem cell based therapies from basic science towards their
      clinical use.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Klietz, Marie-Luise
AU  - Klietz ML
AD  - Abteilung fur Plastische-, Rekonstruktive und Asthetische Chirurgie,
      Handchirurgie, Fachklinik Hornheide, Munster.
AD  - Sektion Plastische Chirurgie an der Klinik fur Unfall-, Hand- und
      Wiederherstellungschirurgie, Universitatsklinikum Munster, Munster.
AD  - Abteilung fur Plastische und Rekonstruktive Chirurgie, Institut fur
      Muskuloskelettale Medizin, Westfalische Wilhelms-Universitat Munster.
FAU - Kuckelhaus, Maximilian
AU  - Kuckelhaus M
AD  - Abteilung fur Plastische-, Rekonstruktive und Asthetische Chirurgie,
      Handchirurgie, Fachklinik Hornheide, Munster.
AD  - Sektion Plastische Chirurgie an der Klinik fur Unfall-, Hand- und
      Wiederherstellungschirurgie, Universitatsklinikum Munster, Munster.
AD  - Abteilung fur Plastische und Rekonstruktive Chirurgie, Institut fur
      Muskuloskelettale Medizin, Westfalische Wilhelms-Universitat Munster.
FAU - Kaiser, Hans Wilhelm
AU  - Kaiser HW
AD  - Dermatologisches Zentrum am Tegernsee, Tegernsee am Tegernsee.
FAU - Raschke, Michael J
AU  - Raschke MJ
AD  - Klinik fur Unfall-, Hand- und Wiederherstellungschirurgie, Universitatsklinikum
      Munster, Munster.
FAU - Hirsch, Tobias
AU  - Hirsch T
AD  - Abteilung fur Plastische-, Rekonstruktive und Asthetische Chirurgie,
      Handchirurgie, Fachklinik Hornheide, Munster.
AD  - Sektion Plastische Chirurgie an der Klinik fur Unfall-, Hand- und
      Wiederherstellungschirurgie, Universitatsklinikum Munster, Munster.
AD  - Abteilung fur Plastische und Rekonstruktive Chirurgie, Institut fur
      Muskuloskelettale Medizin, Westfalische Wilhelms-Universitat Munster.
FAU - Aitzetmuller, Matthias
AU  - Aitzetmuller M
AD  - Sektion Plastische Chirurgie an der Klinik fur Unfall-, Hand- und
      Wiederherstellungschirurgie, Universitatsklinikum Munster, Munster.
AD  - Abteilung fur Plastische und Rekonstruktive Chirurgie, Institut fur
      Muskuloskelettale Medizin, Westfalische Wilhelms-Universitat Munster.
LA  - ger
PT  - Journal Article
TT  - Stammzellen in der Regenerativen Medizin - Translationale Hurden und
      Moglichkeiten zur Uberwindung.
DEP - 20200407
PL  - Germany
TA  - Handchir Mikrochir Plast Chir
JT  - Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen
      Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen
      Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ 
      der V...
JID - 8302815
SB  - IM
MH  - *Mesenchymal Stem Cells
MH  - *Regenerative Medicine
MH  - Stem Cell Transplantation
MH  - Translational Research, Biomedical
COIS- Die Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/04/08 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 10.1055/a-1122-8916 [doi]
PST - ppublish
SO  - Handchir Mikrochir Plast Chir. 2020 Aug;52(4):338-349. doi: 10.1055/a-1122-8916. 
      Epub 2020 Apr 7.


PMID- 32259770
OWN - NLM
STAT- Publisher
LR  - 20210502
IS  - 1873-4758 (Electronic)
IS  - 0955-3959 (Linking)
VI  - 79
DP  - 2020 Apr 4
TI  - Impacts of mandated data collection on syringe distribution programs in the
      United States.
PG  - 102725
LID - S0955-3959(20)30066-9 [pii]
LID - 10.1016/j.drugpo.2020.102725 [doi]
AB  - OBJECTIVES: Syringe Distribution Programs (SDPs) are a well-proven public health 
      response to the spread of HIV and other blood borne illnesses among people who
      inject drugs. Many SDPs in the United States are required to collect data from
      service users as a condition of either legal authorization to operate or as a
      condition of funding. We sought to describe the prevalence of such externally
      mandated data collection and impact on service delivery at syringe distribution
      programs (SDPs) in the United States via an online survey. METHODS: Online survey
      of SDPs in the US. RESULTS: 63 SDPs participated. 95*2% collected data about
      individual service users, with 76*7% being mandated to do so by an external
      entity as a condition of legal authorization, and/or as a condition of funding.
      Only 21*7% of mandated respondents received any report back on how data was used.
      60*0% reported that data collection acted as a barrier to providing syringes to
      people who use drugs due to service user fears about loss of anonymity and/or law
      enforcement. 33*3% reported that the computer literacy and language skills
      required to collect data meant otherwise appropriate members of the community
      could not he hired as staff or volunteers. CONCLUSIONS: Data collection at SDPs
      may act as a barrier to service provision to populations at high risk for HIV and
      other blood born viruses, and place considerable logistic burdens on often
      under-resourced public health programs. Further, it is often unclear to SDPs what
      purpose their data is being put to. We argue that to be ethical, the purpose of
      data collection should be carefully considered and regularly reviewed to ensure
      data is being put to meaningful purpose which is commensurate with impacts on
      service delivery.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Davidson, Peter
AU  - Davidson P
AD  - Department of Medicine, University of California, San Diego, La Jolla, CA, United
      States. Electronic address: pdavidson@ucsd.edu.
FAU - Chakrabarti, Priya
AU  - Chakrabarti P
AD  - Department of Obstetrics and Gynecology, Loma Linda University Health, Loma
      Linda, CA, United States.
FAU - Marquesen, Michael
AU  - Marquesen M
AD  - Los Angeles Community Health Project, Los Angeles, CA, United States.
LA  - eng
GR  - R21 DA039782/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20200404
PL  - Netherlands
TA  - Int J Drug Policy
JT  - The International journal on drug policy
JID - 9014759
SB  - IM
PMC - PMC7308185
MID - NIHMS1578411
OTO - NOTNLM
OT  - Data collection
OT  - Ethics
OT  - People who inject drugs
OT  - Syringe distribution
COIS- Declaration of Competing Interest Research reported in this publication was
      supported in part by the National Institute on Drug Abuse of the US National
      Institutes of Health under Award Number R21DA039782. The content is solely the
      responsibility of the authors and does not necessarily represent the official
      views of the National Institutes of Health. The authors have no other conflicts
      of interest to report.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2020/03/01 00:00 [revised]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - S0955-3959(20)30066-9 [pii]
AID - 10.1016/j.drugpo.2020.102725 [doi]
PST - aheadofprint
SO  - Int J Drug Policy. 2020 Apr 4;79:102725. doi: 10.1016/j.drugpo.2020.102725.


PMID- 32259243
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1464-3790 (Electronic)
IS  - 0967-0742 (Linking)
VI  - 28
IP  - 2
DP  - 2020 May 1
TI  - Advance Research Directives: Legal and Ethical Issues and Insights from a
      National Survey of Dementia Researchers in Australia.
PG  - 375-400
LID - 10.1093/medlaw/fwaa003 [doi]
AB  - Advance research directives (ARDs) are a means by which people can document their
      wishes about research participation in the event of future incapacity. ARDs have 
      been endorsed in some ethics guidelines and position statements, however, formal 
      legal recognition is limited. A few empirical studies have investigated the views
      of researchers and other stakeholders on ARDs and tested strategies to implement 
      such directives. To further knowledge in this area, we undertook a survey of
      dementia researchers in Australia (n= 63) to examine their views on ARDs. Most of
      the survey respondents (>80%) thought ARDs would promote autonomy in
      decision-making and enable opportunities for people with cognitive impairment to 
      be included in research. Respondents indicated concern about directives not being
      available when needed (71%) and that ethics committees would not accept ARDs
      (60%). Few respondents had used ARDs, but a majority (from 57-80%) would be
      willing to offer ARDs for a range of research activities, such as observing
      behaviour and taking measures, blood samples or scans. Nearly all respondents
      (92%) agreed that current dissent should override prior wishes stated in an ARD. 
      The survey findings are contextualised with attention to ethics guidelines, laws 
      and practices to support advance research planning.
CI  - (c) The Author(s) 2020. Published by Oxford University Press; All rights
      reserved. For permissions, please email: journals.permissions@oup.com.
FAU - Ries, Nola M
AU  - Ries NM
AD  - Faculty of Law, Law | Health | Justice Research Centre, University of Technology 
      Sydney, Sydney, Australia.
FAU - Mansfield, Elise
AU  - Mansfield E
AD  - Health Behaviour Research Collaborative, School of Medicine and Public Health,
      Faculty of Health and Medicine and Priority Research Centre for Health Behaviour,
      University of Newcastle, Australia; and Hunter Medical Research Institute,
      Newcastle, Australia.
FAU - Sanson-Fisher, Rob
AU  - Sanson-Fisher R
AD  - Health Behaviour Research Collaborative, School of Medicine and Public Health,
      Faculty of Health and Medicine and Priority Research Centre for Health Behaviour,
      University of Newcastle, Australia; and Hunter Medical Research Institute,
      Newcastle, Australia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Med Law Rev
JT  - Medical law review
JID - 9308945
SB  - IM
MH  - Advance Directives/*ethics/*legislation & jurisprudence/*trends
MH  - Australia
MH  - Cognitive Dysfunction/psychology
MH  - Decision Making
MH  - Dementia/psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Personal Autonomy
MH  - Research Personnel/*psychology
MH  - Research Subjects/legislation & jurisprudence
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Advance research directive
OT  - Advance research planning
OT  - Australia
OT  - Dementia
OT  - Research
OT  - Survey
EDAT- 2020/04/08 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 5817088 [pii]
AID - 10.1093/medlaw/fwaa003 [doi]
PST - ppublish
SO  - Med Law Rev. 2020 May 1;28(2):375-400. doi: 10.1093/medlaw/fwaa003.


PMID- 32259141
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2667-677X (Print)
IS  - 2149-276X (Linking)
VI  - 48
IP  - 2
DP  - 2020 Apr
TI  - Accuracy of Tuffier's Line Identification by Palpation Method: Cross-Sectional
      Comparative Study Among Obese, Pregnant and Control Groups.
PG  - 108-114
LID - 10.5152/TJAR.2019.82346 [doi]
AB  - OBJECTIVE: Performance of safe central neuraxial blocks requires identification
      of accurate vertebral interspace. This study aimed to evaluate the accuracy of
      palpation method by confirmation with ultrasound in high-risk groups like obesity
      and pregnancy. METHODS: This cross-sectional comparative study was conducted
      after approval from the hospital ethics committee and written informed consent
      from participants. Participants were enrolled into four groups: normal weight
      non-pregnant (N), full-term pregnant (P), obese (O) and obese full-term pregnant 
      (PO). Tuffier's line at L4-L5 interspace was determined by palpation method and
      marked as P-line. Another examiner blinded to the marking done by palpation
      method confirmed it by ultrasound. The primary endpoint was to determine the
      accuracy of the palpation method, defined as true identification of Tuffier's
      line at the L4-L5 interspace by confirming it with ultrasound among four groups. 
      Proportion and percentage were computed and analysed the true identification of
      Tuffier's line at L4-L5 by chi-square test at 0.008 adjusted level of
      significance for multiple comparisons. RESULTS: Tuffier's line identification by 
      palpation method was confirmed by ultrasound scanning at L4-L5 interspace in
      75.3% (226/300) of participants. Proportion difference of true identification of 
      Tuffier's line at L4-L5 by palpation and ultrasound was statistically significant
      among the groups (p=0.0005). True identification was significantly lower in group
      PO [36.4%; p=0.0005<0.008] and group O [34%; p=0.0005<0.008] as compared to that 
      in group N. CONCLUSION: Palpation method was found to be the inaccurate surrogate
      for the L4-L5 vertebral interspace for obesity with or without pregnancy.
CI  - (c) Copyright 2020 by Turkish Anaesthesiology and Intensive Care Society.
FAU - Malik, Mehreen
AU  - Malik M
AUID- ORCID: 0000-0003-2466-228X
AD  - Department of Anaesthesiology, Aga Khan University, Karachi, Pakistan.
FAU - Ismail, Samina
AU  - Ismail S
AUID- ORCID: 0000-0001-6138-1810
AD  - Department of Anaesthesiology, Aga Khan University, Karachi, Pakistan.
LA  - eng
PT  - Journal Article
DEP - 20191017
PL  - Turkey
TA  - Turk J Anaesthesiol Reanim
JT  - Turkish journal of anaesthesiology and reanimation
JID - 101680817
PMC - PMC7101188
OTO - NOTNLM
OT  - Obesity
OT  - Tuffier's line
OT  - palpation method
OT  - pregnancy
OT  - ultrasound
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/04/02 00:00 [received]
PHST- 2019/05/30 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.5152/TJAR.2019.82346 [doi]
AID - tard-48-2-108 [pii]
PST - ppublish
SO  - Turk J Anaesthesiol Reanim. 2020 Apr;48(2):108-114. doi: 10.5152/TJAR.2019.82346.
      Epub 2019 Oct 17.


PMID- 32258837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 21
DP  - 2020
TI  - Protocol for a modified vaginal pipe for total laparoscopic hysterectomies:
      Experimental research.
PG  - 5-7
LID - 10.1016/j.isjp.2020.02.003 [doi]
AB  - BACKGROUND: The Vagi-Pipe(R) is a useful device for performing a total
      laparoscopic hysterectomy. The conventional model of the Vagi-Pipe(R) is unable
      to grasp the uterus during colpotomy for recovery of the resected uterus.
      However, the modified C-Type Vagi-Pipe(R) model has a shape that allows insertion
      into the vagina without removing the uterus manipulator. In this study, we will
      prospectively investigate the safety and efficacy of the C-Type Vagi-Pipe(R) in
      total laparoscopic hysterectomies. MATERIALS AND METHODS: In total, 25 female
      subjects aged between 20 and 60 years with uterine fibroids or adenomyosis will
      be included. Patients with complications regarded as unsuitable for this study by
      the investigators will be excluded. The C-Type Vagi-Pipe(R) will be used rather
      than the conventional Vagi-Pipe(R) when performing a total laparoscopic
      hysterectomy. The primary endpoint will be safety and the secondary endpoints
      will be operation time, bleeding volume, and presence of complications. ETHICS
      AND DISSEMINATION: The protocol was approved by the institutional review boards. 
      Written informed consent will be obtained from all patients before registration
      in accordance with the Declaration of Helsinki. Results of the study will be
      disseminated via publications in peer-reviewed journals.
CI  - (c) 2020 The Authors.
FAU - Ito, Fumitake
AU  - Ito F
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Kokabu, Tetsuya
AU  - Kokabu T
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Matsushima, Hiroshi
AU  - Matsushima H
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Koshiba, Akemi
AU  - Koshiba A
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Mori, Taisuke
AU  - Mori T
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Kusuki, Izumi
AU  - Kusuki I
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
FAU - Kitawaki, Jo
AU  - Kitawaki J
AD  - Department of Obstetrics and Gynecology, Kyoto Prefectural University of
      Medicine, Graduate School of Medical Science, Kyoto, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200314
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7125346
OTO - NOTNLM
OT  - Laparoscopic hysterectomy
OT  - Uterus
OT  - Vagi-Pipe(R)
OT  - Vagina
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/02/29 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1016/j.isjp.2020.02.003 [doi]
AID - S2468-3574(20)30006-1 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Mar 14;21:5-7. doi: 10.1016/j.isjp.2020.02.003.
      eCollection 2020.


PMID- 32258836
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 21
DP  - 2020
TI  - Characteristics, results, and reporting of contemporary surgical trials: A
      systematic review and analysis.
PG  - 1-4
LID - 10.1016/j.isjp.2020.03.002 [doi]
AB  - INTRODUCTION: The complexities and risks inherent to the field of surgery and
      surgical interventions present unique challenges to the design and analysis of
      surgical randomized controlled trials (RCT). Prior studies have investigated the 
      practical and methodologic challenges posed by surgical RCTs. To date, however, a
      comprehensive analysis of the contemporary literature across multiple surgical
      subspecialties does not exist. In this descriptive analysis, we set out to
      characterize surgical RCTs over the past 10 years across six major surgical
      specialties. METHODS AND ANALYSIS: A literature search by a medical librarian
      will be performed to identify all surgical randomized clinical trials published
      between January 2009 and December 2019 in the two journals with the highest
      impact factor for six surgical specialties as well as two large general medicine 
      journals. Two reviewers will independently screen the citations retrieved from
      the literature search and extract data according to a previously described
      protocol via a pre-defined data collection form. Categorical variables will be
      reported as counts and percentages. Following assessment of normality, continuous
      variables will be reported as mean (standard deviation) or median (inter-quartile
      range). Based on normality of data, independent t-test or the Mann-Whitney U test
      will be used to compare continuous variables and chi-square and Fisher's exact
      tests to compare categorical variables. Comparisons across multiple sets will be 
      performed using ANOVA or Kruskak-Wallis tests. Two-sided significance testing
      will be used and a p-value <0.05 will be considered significant without
      adjustment for multiple testing. All analyses will be performed using SPSS
      version 24 and R within RStudio. PROSPERO (ID number: 162797). ETHICS AND
      DISSEMINATION: There are no ethical concerns directly pertinent to this
      systematic review. The retrieved data will be made available upon request. The
      study will be written in English and submitted for publication in a peer-reviewed
      journal.
CI  - (c) 2020 The Authors.
FAU - Bryce Robinson, N
AU  - Bryce Robinson N
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Naik, Ajita
AU  - Naik A
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Hameed, Irbaz
AU  - Hameed I
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Ruan, Yongle
AU  - Ruan Y
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Rahouma, Mohamed
AU  - Rahouma M
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Weidenmann, Viola
AU  - Weidenmann V
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Zenati, Marco A
AU  - Zenati MA
AD  - BHS Department of Cardiothoracic Surgery, West Roxbury, MA, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA,
      USA.
FAU - Girardi, Leonard N
AU  - Girardi LN
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
FAU - Kurlansky, Paul
AU  - Kurlansky P
AD  - Department of Surgery, Columbia University Medical Center, New York, NY, USA.
FAU - Raja, Shahzad G
AU  - Raja SG
AD  - Department of Cardiac Surgery, Harefield Hospital, London, UK.
FAU - Moher, David
AU  - Moher D
AD  - Ottawa Methods Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
FAU - Fremes, Stephen
AU  - Fremes S
AD  - Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, 
      Toronto, ON, Canada.
FAU - Chikwe, Joanna
AU  - Chikwe J
AD  - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Siani Medical
      Center, Los Angeles, CA, USA.
FAU - Gaudino, Mario
AU  - Gaudino M
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7125342
OTO - NOTNLM
OT  - Methodology
OT  - Outcomes
OT  - Randomized control trial
OT  - Spin
OT  - Surgery
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1016/j.isjp.2020.03.002 [doi]
AID - S2468-3574(20)30009-7 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Mar 19;21:1-4. doi: 10.1016/j.isjp.2020.03.002.
      eCollection 2020.


PMID- 32258835
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2468-3574 (Electronic)
IS  - 2468-3574 (Linking)
VI  - 20
DP  - 2020
TI  - Use of Wide-Awake Local Anaesthetic No Tourniquet (WALANT) in upper limb and hand
      surgery: A systematic review protocol.
PG  - 8-12
LID - 10.1016/j.isjp.2020.03.001 [doi]
AB  - INTRODUCTION: Wide Awake Local Anaesthetic No Tourniquet (WALANT) technique has
      been developed to eliminate tourniquet pain during upper limb and hand surgery
      whilst also improving utilisation of operating theatre time and inpatient stay,
      however inconclusive data still limits the techniques uptake. Here presents a
      protocol for a systematic review to collate findings to produce conclusive data
      on efficacy of WALANT. METHODS: This systematic review will be registered a
      priori. All study designs defined by the Oxford Centre for Evidence-Based
      Medicine will be included in the search. "WALANT" in "upper limb" and "hand"
      surgery will be investigated as per the devised search strategy. 18 electronic
      databases will be searched, including PubMed, Medline and Embase in addition to a
      Grey literature search. Two independent teams of 3 researchers will screen all
      relevant titles, abstracts and subsequent full texts for suitability. Data will
      be extrapolated and entered into a preformatted database for analysis. ETHICS AND
      DISSEMINATION: This systematic review will be published in a peer-reviewed
      journal and presented at both national and international conferences within the
      field of plastic and orthopaedic surgery. This review aims to inform surgical
      practice and policy.
CI  - (c) 2020 The Authors.
FAU - O'Neill, Niamh
AU  - O'Neill N
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Abdall-Razak, Ali
AU  - Abdall-Razak A
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Norton, Emma
AU  - Norton E
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Kumar, Aneeta
AU  - Kumar A
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Shah, Heer
AU  - Shah H
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Khatkar, Harman
AU  - Khatkar H
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Alsafi, Zaid
AU  - Alsafi Z
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
FAU - Agha, Riaz
AU  - Agha R
AD  - Bart's and the London School of Medicine and Dentistry, London, UK.
AD  - Imperial College School of Medicine, London, UK.
AD  - St George's University of London, London, UK.
AD  - University of Southampton, Southampton, UK.
AD  - Southend Hospital, Southend-On-Sea, UK.
AD  - Oxford University Hospital, Oxford, UK.
AD  - University College London Medical School, London, UK.
AD  - Royal London Hospital, London, UK.
LA  - eng
PT  - Journal Article
DEP - 20200313
PL  - England
TA  - Int J Surg Protoc
JT  - International journal of surgery protocols
JID - 101758186
PMC - PMC7125343
OTO - NOTNLM
OT  - Hand
OT  - Limb
OT  - Orthopaedic
OT  - Plastic
OT  - Surgery
OT  - WALANT
COIS- The authors declare that they have no known competing financial interests or
      personal relationships that could have appeared to influence the work reported in
      this paper.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1016/j.isjp.2020.03.001 [doi]
AID - S2468-3574(20)30007-3 [pii]
PST - epublish
SO  - Int J Surg Protoc. 2020 Mar 13;20:8-12. doi: 10.1016/j.isjp.2020.03.001.
      eCollection 2020.


PMID- 32258429
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210619
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Machine intelligence in healthcare-perspectives on trustworthiness,
      explainability, usability, and transparency.
PG  - 47
LID - 10.1038/s41746-020-0254-2 [doi]
AB  - Machine Intelligence (MI) is rapidly becoming an important approach across
      biomedical discovery, clinical research, medical diagnostics/devices, and
      precision medicine. Such tools can uncover new possibilities for researchers,
      physicians, and patients, allowing them to make more informed decisions and
      achieve better outcomes. When deployed in healthcare settings, these approaches
      have the potential to enhance efficiency and effectiveness of the health research
      and care ecosystem, and ultimately improve quality of patient care. In response
      to the increased use of MI in healthcare, and issues associated when applying
      such approaches to clinical care settings, the National Institutes of Health
      (NIH) and National Center for Advancing Translational Sciences (NCATS) co-hosted 
      a Machine Intelligence in Healthcare workshop with the National Cancer Institute 
      (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB)
      on 12 July 2019. Speakers and attendees included researchers, clinicians and
      patients/ patient advocates, with representation from industry, academia, and
      federal agencies. A number of issues were addressed, including: data quality and 
      quantity; access and use of electronic health records (EHRs); transparency and
      explainability of the system in contrast to the entire clinical workflow; and the
      impact of bias on system outputs, among other topics. This whitepaper reports on 
      key issues associated with MI specific to applications in the healthcare field,
      identifies areas of improvement for MI systems in the context of healthcare, and 
      proposes avenues and solutions for these issues, with the aim of surfacing key
      areas that, if appropriately addressed, could accelerate progress in the field
      effectively, transparently, and ethically.
CI  - (c) This is a U.S. government work and not under copyright protection in the
      U.S.; foreign copyright protection may apply 2020.
FAU - Cutillo, Christine M
AU  - Cutillo CM
AD  - 1National Center for Advancing Translational Sciences, National Institutes of
      Health, Bethesda, MD USA.0000 0004 3497 6087grid.429651.d
FAU - Sharma, Karlie R
AU  - Sharma KR
AUID- ORCID: 0000-0003-3435-7721
AD  - 1National Center for Advancing Translational Sciences, National Institutes of
      Health, Bethesda, MD USA.0000 0004 3497 6087grid.429651.d
FAU - Foschini, Luca
AU  - Foschini L
AUID- ORCID: 0000-0003-1409-3570
AD  - 2Evidation Health Inc., San Mateo, CA USA.grid.492625.e
FAU - Kundu, Shinjini
AU  - Kundu S
AD  - 3Department of Radiology, The Johns Hopkins Hospital, Baltimore, MD USA.0000 0001
      2192 2723grid.411935.b
FAU - Mackintosh, Maxine
AU  - Mackintosh M
AD  - 4University College London, London, UK.0000000121901201grid.83440.3b
AD  - 5Alan Turing Institute, London, UK.0000 0004 5903 3632grid.499548.d
FAU - Mandl, Kenneth D
AU  - Mandl KD
AD  - 6Computational Health Informatics Program, Boston Children's Hospital, Boston, MA
      USA.0000 0004 0378 8438grid.2515.3
AD  - 7Departments of Pediatrics and Biomedical Informatics, Harvard Medical School,
      Boston, MA USA.000000041936754Xgrid.38142.3c
CN  - MI in Healthcare Workshop Working Group
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7099019
OTO - NOTNLM
OT  - Diagnosis
OT  - Disease prevention
OT  - Medical imaging
OT  - Public health
OT  - Therapeutics
COIS- Competing interestsThe authors declare no competing interests.
IR  - Beck T
FIR - Beck, Tyler
IR  - Collier E
FIR - Collier, Elaine
IR  - Colvis C
FIR - Colvis, Christine
IR  - Gersing K
FIR - Gersing, Kenneth
IR  - Gordon V
FIR - Gordon, Valery
IR  - Jensen R
FIR - Jensen, Roxanne
IR  - Shabestari B
FIR - Shabestari, Behrouz
IR  - Southall N
FIR - Southall, Noel
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1038/s41746-020-0254-2 [doi]
AID - 254 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Mar 26;3:47. doi: 10.1038/s41746-020-0254-2. eCollection
      2020.


PMID- 32258411
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2378-5128 (Print)
IS  - 2378-5128 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Apr
TI  - Emergency TREPP for Strangulated Inguinal Hernia Repair: A Consecutive Case
      Series.
PG  - e62-e66
LID - 10.1055/s-0040-1705171 [doi]
AB  - Background Patients with strangulated inguinal hernia (SIH) require emergency
      surgical treatment. International guidelines do not specify the surgical
      technique of preference. Frequently, an open anterior approach such as the
      Lichtenstein technique is used. The TransREctus sheath Pre-Peritoneal (TREPP)
      technique is an alternative, open posterior approach, which has shown promising
      results in the elective treatment of inguinal hernias. This study aims to
      evaluate the feasibility and safety of the TREPP technique in the emergency
      setting of SIHs. Materials and Methods After medical ethical approval was
      warranted, all consecutive patients, who underwent emergency TREPP (e-TREPP) at a
      high-volume hernia institute, were retrospectively included from 2006 up to and
      including 2016. Data retrieved from the electronic patient files were combined
      with the findings during a long-term outcome physical investigation at an
      outpatient department visit. e-TREPP was, prior to the start of the study,
      defined as TREPP performed immediately at the operation room. Results
      Thirty-three patients underwent e-TREPP for SIH. Ten patients were clinically
      evaluated, ten patients were deceased, nine patients could not be contacted, and 
      four patients did not or could not consent. Of the ten deceased patients, one
      patient died perioperatively due to massive aspiration followed by cardiac
      arrest. Nine patients died due to other causes. Two patients developed a
      recurrence after (after 13 days and 16 months respectively). Two patients were
      surgically treated for a wound infection (mesh removal in one). No patient
      reported chronic postoperative inguinal pain. Conclusion e-TREPP in experienced
      hands seems feasible and safe (Level of Evidence 4) for the treatment of patients
      with strangulated inguinal hernia, with percentages of postoperative
      complications comparable to other techniques.
FAU - Zwols, T L R
AU  - Zwols TLR
AUID- ORCID: 0000-0002-9277-5975
AD  - Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
AD  - Department of Surgery, St Jansdal Hospital, Harderwijk, The Netherlands.
FAU - Akkersdijk, W L
AU  - Akkersdijk WL
AD  - Department of Surgery, St Jansdal Hospital, Harderwijk, The Netherlands.
FAU - Bokkerink, W J V
AU  - Bokkerink WJV
AUID- ORCID: 0000-0001-7855-938X
AD  - Department of Surgery, St Jansdal Hospital, Harderwijk, The Netherlands.
AD  - Department of Surgery, Gelderse Vallei Hospital, The Netherlands.
FAU - Andeweg, C S
AU  - Andeweg CS
AD  - Department of Surgery, St Jansdal Hospital, Harderwijk, The Netherlands.
FAU - Pierie, J P E N
AU  - Pierie JPEN
AD  - Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
AD  - Postgraduate School of Medicine, University Medical Centre Groningen, Groningen, 
      The Netherlands.
FAU - Koning, G G
AU  - Koning GG
AD  - Department of Surgery, Ikazia Hospital, Rotterdam, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - United States
TA  - Surg J (N Y)
JT  - Surgery journal (New York, N.Y.)
JID - 101695022
PMC - PMC7108950
OTO - NOTNLM
OT  - TREPP
OT  - emergency
OT  - extraperitoneal
OT  - incarcerated
OT  - open preperitoneal
OT  - strangulated inguinal hernia
COIS- Conflict of Interest All authors have declared to have no conflict of interest.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1055/s-0040-1705171 [doi]
AID - 1900061oa [pii]
PST - epublish
SO  - Surg J (N Y). 2020 Mar 31;6(2):e62-e66. doi: 10.1055/s-0040-1705171. eCollection 
      2020 Apr.


PMID- 32257982
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Linking)
VI  - 8
DP  - 2020
TI  - A Critical Review on the Relevance of Paracetamol for Procedural Pain Management 
      in Neonates.
PG  - 89
LID - 10.3389/fped.2020.00089 [doi]
AB  - Effective and safe pain relief in neonates matters. This is not only because of
      ethical constraints or human empathy, but even more because pain treatment is an 
      important and crucial part of contemporary medical, paramedical, and nursing care
      to improve the outcome in neonatal intensive care graduates. Paracetamol
      (acetaminophen) is likely one of the pharmacological tools to attain this, with
      data on prescription practices suggesting that paracetamol is somehow the "rising
      star" in neonatal pain management. Besides very rare topical clinical scenarios
      like peripartal asphyxia and subsequent whole body hypothermia or the use of
      cardiorespiratory support devices, data on paracetamol pharmacokinetics and
      metabolism were reported throughout neonatal age or weight ranges, and we have
      summarized these data. In this review, we subsequently aimed to provide the
      reader with the currently available observations on the use of paracetamol as
      analgesic for different pain syndromes (major surgery, minor surgery or trauma,
      and procedural pain), with focus on the limitations of paracetamol when
      prescribed for neonatal procedural pain management. We hereby intentionally will 
      not discuss other indications (patent ductus arteriosus and fever) for
      paracetamol administration in neonates. Based on the available evidence,
      paracetamol has opioid-sparing effects for major pain syndromes, is effective to 
      treat minor to moderate pain syndromes, but fails for effective procedural pain
      management in neonates. This efficacy failure for procedural pain management
      should stimulate us to continue to search for more effective interventions,
      including non-pharmacological interventions and preventive strategies.
      Furthermore, there are also upcoming association type of epidemiological studies 
      on the relation between exposure to analgesics-including paracetamol-and the
      negative short- or long-term outcome characteristics (neuro-behavioral, atopy,
      and fertility). Consequently and in addition to the search for effective
      alternatives to prevent or treat pain, studies on long-term outcome following
      paracetamol exposure are needed to inform all stakeholders on the full
      effect-side effect balance of the different strategies to treat pain.
CI  - Copyright (c) 2020 Allegaert.
FAU - Allegaert, Karel
AU  - Allegaert K
AD  - Development and Regeneration, KU Leuven, Leuven, Belgium.
AD  - Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
AD  - Clinical Pharmacy, Erasmus MC Rotterdam, Rotterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200318
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC7093493
OTO - NOTNLM
OT  - acetaminophen
OT  - infant
OT  - newborn
OT  - opioid sparing
OT  - pain prevention
OT  - pain treatment
OT  - paracetamol
OT  - procedural pain management
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/11/08 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.3389/fped.2020.00089 [doi]
PST - epublish
SO  - Front Pediatr. 2020 Mar 18;8:89. doi: 10.3389/fped.2020.00089. eCollection 2020.


PMID- 32257977
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2287-8882 (Print)
IS  - 2287-8882 (Linking)
VI  - 8
IP  - 1
DP  - 2020 Mar
TI  - Survey on the practice of active surveillance for prostate cancer from the Middle
      East.
PG  - 41-48
LID - 10.1016/j.prnil.2019.11.001 [doi]
AB  - BACKGROUND: Prostate cancer is the most common cancer among Lebanese men.
      Management of prostate cancer includes medical, radiological, and surgical
      intervention. In addition, active surveillance (AS) is proven as a valid option
      in patients with low-risk prostate cancer. Currently, data from the Middle East
      about AS are scarce. The aim of this study is to assess the rate of
      implementation of AS by physicians, determine the selection and follow-up
      criteria used by physicians, and identify potential barriers to its widespread
      adoption. METHODS: After receiving ethical approval, a LimeSurvey electronic
      questionnaire was mailed to 206 eligible urologists, oncologists, and radiation
      oncologists registered in the order of physicians in Lebanon. The questionnaire
      included dichotomous, multiple choice questions, and multiple answer questions.
      The 23 questions tackled sociodemographic information, physician's attitude
      toward AS, and their current practices. Predictors of AS use were identified
      using the chi-squared and Fisher's exact test. Then, multivariate logistic
      regression model for the predictors of AS practice was conducted. RESULTS: The
      response rate was 25%, and the analysis was run on 52 respondents. Although most 
      of the respondents agreed that AS is a valid modality for low-risk prostate
      cancer, only 34 (65.4%) of them had patients on active surveillance. The rate of 
      patients on AS was also very low. Urologists, physicians with >15 years of
      experience, and those who practiced in a university hospital were all predictors 
      of AS usage (p = 0.005; p = 0.002; p = 0.025, respectively). However, physicians 
      with fear of patient noncompliance had the odds of resorting to this modality
      [odds ratio (OR) = 0.07 (0.01 - 0.76)]. CONCLUSION: The main obstacles to
      implementing AS were fear of patient noncompliance and lack of national awareness
      as well as acceptance among the Lebanese uro-oncological body. Efforts to
      decentralize knowledge and expertize to new health-care practitioners and
      community hospitals would encourage its implementation.
CI  - (c) 2019 Asian Pacific Prostate Society, Published by Elsevier Korea LLC.
FAU - El Sebaaly, Ralph
AU  - El Sebaaly R
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Mansour, Mazen
AU  - Mansour M
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Labban, Muhieddine
AU  - Labban M
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Jaafar, Rola F
AU  - Jaafar RF
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Armache, Alexandre
AU  - Armache A
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Mukherji, Deborah
AU  - Mukherji D
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - El Hajj, Albert
AU  - El Hajj A
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
DEP - 20191130
PL  - Korea (South)
TA  - Prostate Int
JT  - Prostate international
JID - 101605566
PMC - PMC7125368
OTO - NOTNLM
OT  - Active surveillance
OT  - Middle East
OT  - Prostate cancer
COIS- Mukherji reports grants, personal fees, and nonfinancial support from Astellas
      and Janssen, outside the submitted work. All the other authors have nothing to
      disclose.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/08/28 00:00 [received]
PHST- 2019/11/10 00:00 [revised]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1016/j.prnil.2019.11.001 [doi]
AID - S2287-8882(19)30079-0 [pii]
PST - ppublish
SO  - Prostate Int. 2020 Mar;8(1):41-48. doi: 10.1016/j.prnil.2019.11.001. Epub 2019
      Nov 30.


PMID- 32257834
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2214-9996 (Electronic)
IS  - 2214-9996 (Linking)
VI  - 86
IP  - 1
DP  - 2020 Mar 26
TI  - Perspectives and Solutions from Clinical Trainees and Mentors Regarding Ethical
      Challenges During Global Health Experiences.
PG  - 34
LID - 10.5334/aogh.2721 [doi]
AB  - Background: Clinical trainees face challenges throughout short-term experiences
      in global health (STEGH) that are not routinely addressed. Objectives: Describe
      common professional and ethical dilemmas faced by clinical trainees and identify 
      gaps and solutions for pre, during, and post-STEGH training and mentoring.
      Methods: We conducted a mixed-methods study among trainees and mentors involved
      in global health. The study utilized focus groups with trainees
      (November-December 2015) and online surveys of trainees, in-country and stateside
      faculty mentors (October 2016-April 2017). Results: 85% (17/20) of students
      reported feeling prepared for their STEGH; however, 59% (23/39) of faculty felt
      students were unprepared. A majority of both students (90%) and faculty (77%)
      stated students would likely experience an ethical dilemma during STEGH. Major
      themes relating to meaningful global health work were elucidated: personal and
      inter-professional skills; interpersonal networks and collaboration; and
      awareness of power dynamics and bias. Conclusions: The most common challenges
      faced by trainees during STEGH related to leadership, bias, ethics and
      interprofessional collaboration. Redirecting trainee energies from a focus on
      'doing' and deliverables to attitudes (e.g., humility, professionalism) that
      cultivate personal and professional growth will help create lifelong global
      health learners and leaders.
CI  - Copyright: (c) 2020 The Author(s).
FAU - Kasper, Jennifer
AU  - Kasper J
AD  - Harvard Medical School, US.
FAU - Mulye, Anita
AU  - Mulye A
AD  - Northwestern Feinberg School of Medicine, US.
FAU - Doobay-Persaud, Ashti
AU  - Doobay-Persaud A
AD  - Northwestern Feinberg School of Medicine, US.
FAU - Seymour, Brittany
AU  - Seymour B
AD  - Harvard School of Dental Medicine, US.
FAU - Nelson, Brett D
AU  - Nelson BD
AD  - Harvard Medical School, US.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - United States
TA  - Ann Glob Health
JT  - Annals of global health
JID - 101620864
SB  - IM
MH  - *Clinical Clerkship
MH  - *Ethics, Medical
MH  - *Faculty, Medical
MH  - Female
MH  - Focus Groups
MH  - *Global Health
MH  - Humans
MH  - Male
MH  - Professionalism
MH  - Qualitative Research
MH  - Students, Dental
MH  - *Students, Medical
PMC - PMC7101005
COIS- The authors have no competing interests to declare.
EDAT- 2020/04/08 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
AID - 10.5334/aogh.2721 [doi]
PST - epublish
SO  - Ann Glob Health. 2020 Mar 26;86(1):34. doi: 10.5334/aogh.2721.


PMID- 32257497
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-6900 (Print)
VI  - 2020
DP  - 2020
TI  - Utilization of Vicryl Bridging Mesh in Orthotopic Liver Transplantation to
      Achieve Tension-Free Abdominal Wall Closure: A Case Series.
PG  - 4716415
LID - 10.1155/2020/4716415 [doi]
AB  - Difficulty in primary fascial closure of the abdomen in transplant patients is a 
      common challenge. Abdominal wall tension may have detrimental effects on the
      newly transplanted graft due to compression, and blood flow hindrance,
      potentially leading to ischemia or thrombosis and possibly graft failure.
      Furthermore, patients will be at risk of developing fascial ischemia and
      dehiscence. Myocutaneous flaps, temporary closure with silastic mesh, abdominal
      wall transplants, and even graft reduction, bowel resection, and splenectomies
      have been practiced with varying degrees of success. In this study, we present
      four cases of patients who underwent orthotopic liver transplantation (OLT) with 
      bridging Vicryl knitted mesh (ETHICON VKML VICRYL-Polyglactin 910-30 x 30 cm) to 
      relieve the tension during the closure. Our results show that these patients,
      despite having a high average Model End-Stage Liver Disease (MELD) score of 25,
      had a good liver function at the time of discharge and continue to upon
      follow-up. They had a relatively short length of stay (LOS) in both the intensive
      care unit (ICU) and in the hospital, an average of 3.5 days and 9 days,
      respectively. Our case series successfully show that utilizing a bridging Vicryl 
      knitted mesh is a reasonable approach to attain tension-free abdominal closure in
      OLT with satisfying results.
CI  - Copyright (c) 2020 Ea-sle Chang et al.
FAU - Chang, Ea-Sle
AU  - Chang ES
AUID- ORCID: https://orcid.org/0000-0002-1364-0897
AD  - Saint Louis University, Department of Surgery, Saint Louis, MO 63104, USA.
FAU - Martino, Alice
AU  - Martino A
AD  - Saint Louis University, Department of Surgery, Saint Louis, MO 63104, USA.
FAU - Welu, Adam
AU  - Welu A
AUID- ORCID: https://orcid.org/0000-0001-9192-5145
AD  - Saint Louis University, Department of Surgery, Saint Louis, MO 63104, USA.
FAU - Nazzal, Mustafa
AU  - Nazzal M
AUID- ORCID: https://orcid.org/0000-0002-8437-6085
AD  - Saint Louis University, Department of Surgery, Saint Louis, MO 63104, USA.
LA  - eng
PT  - Case Reports
DEP - 20200319
PL  - United States
TA  - Case Rep Surg
JT  - Case reports in surgery
JID - 101580191
PMC - PMC7106884
COIS- There are no conflicts of interest to declare.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/02/15 00:00 [revised]
PHST- 2020/02/27 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1155/2020/4716415 [doi]
PST - epublish
SO  - Case Rep Surg. 2020 Mar 19;2020:4716415. doi: 10.1155/2020/4716415. eCollection
      2020.


PMID- 32257339
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2054-5703 (Print)
IS  - 2054-5703 (Linking)
VI  - 7
IP  - 2
DP  - 2020 Feb
TI  - Urinary suPAR: a non-invasive biomarker of infection and tissue inflammation for 
      use in studies of large free-ranging mammals.
PG  - 191825
LID - 10.1098/rsos.191825 [doi]
AB  - Studies of large free-ranging mammals incorporating physiological measurements
      typically require the collection of urine or faecal samples, due to ethical and
      practical concerns over trapping or darting animals. However, there is a dearth
      of validated biomarkers of immune activation and inflammation that can be
      measured non-invasively. We here evaluate the utility of urinary measurements of 
      the soluble form of the urokinase plasminogen activator receptor (suPAR), for use
      as a health marker in studies of wild large mammals. We investigate how urinary
      suPAR concentrations change in response to viral infection and surgical trauma
      (inflammation), comparing it to the measurement of a marker of cellular immune
      activation, urinary neopterin (uNEO), in captive rhesus macaques. We then test
      the field utility of urinary suPAR, assessing the effects of soil and faecal
      contamination, sunlight, storage at different temperatures, freeze-thaw cycles,
      and lyophilization. We find that suPAR concentrations rise markedly in response
      to both infection and surgery-associated inflammation, unlike uNEO
      concentrations, which only rise in response to the former. Our field validation
      demonstrates that urinary suPAR is reasonably robust to many of the issues
      associated with field collection, sample processing, and storage, as long as
      samples can be stored in a freezer. Urinary suPAR is thus a promising biomarker
      applicable for monitoring various aspects of health in wild primates and
      potentially also other large mammals.
CI  - (c) 2020 The Authors.
FAU - Higham, James P
AU  - Higham JP
AUID- ORCID: 0000-0002-1133-2030
AD  - Department of Anthropology, New York University, 25 Waverly Place, New York, NY
      10003, USA.
FAU - Stahl-Hennig, Christiane
AU  - Stahl-Hennig C
AD  - Unit of Infection Models, German Primate Center, Leibniz Institute for Primate
      Research, Kellnerweg 4, Gottingen 37077, Germany.
FAU - Heistermann, Michael
AU  - Heistermann M
AD  - Endocrinology Laboratory, German Primate Center, Leibniz Institute for Primate
      Research, Kellnerweg 4, Gottingen 37077, Germany.
LA  - eng
SI  - Dryad/10.5061/dryad.59zw3r23v
PT  - Journal Article
DEP - 20200212
PL  - England
TA  - R Soc Open Sci
JT  - Royal Society open science
JID - 101647528
PMC - PMC7062102
OTO - NOTNLM
OT  - behaviour
OT  - field studies
OT  - inflammation
OT  - non-invasive
OT  - physiology
COIS- We declare we have no competing interests.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/10/17 00:00 [received]
PHST- 2020/01/17 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1098/rsos.191825 [doi]
AID - rsos191825 [pii]
PST - epublish
SO  - R Soc Open Sci. 2020 Feb 12;7(2):191825. doi: 10.1098/rsos.191825. eCollection
      2020 Feb.


PMID- 32257304
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2054-5703 (Print)
IS  - 2054-5703 (Linking)
VI  - 7
IP  - 2
DP  - 2020 Feb
TI  - Man's best friends: attitudes towards the use of different kinds of animal depend
      on belief in different species' mental capacities and purpose of use.
PG  - 191162
LID - 10.1098/rsos.191162 [doi]
AB  - The animal purpose questionnaire (APQ) is a new instrument to measure human
      attitudes to animal use systematically across both species and purpose of use.
      This offers a more fine-grained approach to our understanding of how the belief
      in a specific animal's mental capacities relates to (dis-)agreement with their
      use for different human purposes. In the present study, 317 participants
      completed an online survey containing the APQ and the belief in animal mind (BAM)
      scale in a species-specific format, to test the prediction that levels of
      (dis-)agreement with animal use should mirror participants' judgements of animal 
      sentience. The results obtained with the APQ confirmed that attitudes to animal
      use differed significantly across both purpose and species. Key findings included
      a relatively greater concern for dolphins and dogs over chimpanzees (suggesting
      that phylogenetic position is not the only determinant of attitudes to animal
      use). Across the purposes examined, respondents were largely negative about
      animal usage, with the exception that there was less disagreement if this was for
      medical research. Participants were also asked to provide demographic details
      such as gender and dietary preference. Regression analyses revealed high
      predictive power for species-specific BAM across five different kinds of animal
      use. General BAM scores, non-meat-eating and being female accounted for 31.5% of 
      the total variability in APQ scores. The results indicate that BAM is a strong
      predictor of self-reported attitudes for using particular animals. However, the
      results showed some exceptions in the case of culturally typical 'produce'
      animals.
CI  - (c) 2020 The Authors.
FAU - Higgs, Matthew J
AU  - Higgs MJ
AD  - School of Psychology, University of Nottingham, University Park, Nottingham NG7
      2RD, UK.
AD  - School of Medicine, Neuroscience and Mental Health Research Institute, Cardiff
      University, Cardiff, UK.
FAU - Bipin, Sasha
AU  - Bipin S
AD  - School of Psychology, University of Nottingham, University Park, Nottingham NG7
      2RD, UK.
FAU - Cassaday, Helen J
AU  - Cassaday HJ
AUID- ORCID: 0000-0002-9227-373X
AD  - School of Psychology, University of Nottingham, University Park, Nottingham NG7
      2RD, UK.
LA  - eng
PT  - Journal Article
DEP - 20200226
PL  - England
TA  - R Soc Open Sci
JT  - Royal Society open science
JID - 101647528
PMC - PMC7062065
OTO - NOTNLM
OT  - animal ethics
OT  - animal purpose questionnaire
OT  - animal use
OT  - belief in animal mind
OT  - mind denial
COIS- M.J.H., S.B. and H.J.C. have no competing interests.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/07/26 00:00 [received]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1098/rsos.191162 [doi]
AID - rsos191162 [pii]
PST - epublish
SO  - R Soc Open Sci. 2020 Feb 26;7(2):191162. doi: 10.1098/rsos.191162. eCollection
      2020 Feb.


PMID- 32257269
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 2054-1058 (Print)
IS  - 2054-1058 (Linking)
VI  - 7
IP  - 3
DP  - 2020 May
TI  - Perspectives of older patients on the qualities which define a "good family
      nurse": A qualitative study.
PG  - 814-821
LID - 10.1002/nop2.456 [doi]
AB  - Aim: To explore what the term "good family nurse" means to older patients.
      Design: A descriptive qualitative study design was used, and a purposive sampling
      method was adopted. Methods: Semi-structured interviews were conducted with 21
      patients aged 65 years and older who were receiving primary care in Bialystok
      (Poland). The interviews were recorded and then transcribed in verbatim. The data
      were analysed using content analysis. Data were collected between February 2017
      and December 2018. Results: We identified six main categories of qualities that
      define a "good family nurse". These are as follows: (a) personal traits and
      attributes (sex and individual characteristics and behaviours not directly
      related to nursing); (b) providing care (caring attitude and patient support);
      (c) communicating with the patient (the ability to listen and inform the
      patient); (d) professional competence (knowledge, professional experience and
      good technical skills); (e) ethical attitude (respect, patience and vocation);
      and (f) availability (the frequency and duration of home visits, organization of 
      the doctor's appointments).
CI  - (c) 2020 The Authors. Nursing Open published by John Wiley & Sons Ltd.
FAU - Marcinowicz, Ludmila
AU  - Marcinowicz L
AUID- ORCID: 0000-0003-0614-1093
AD  - Department of Primary Health Care Medical University of Bialystok Bialystok
      Poland.
FAU - Taranta, Ewa
AU  - Taranta E
AD  - Department of Primary Health Care Medical University of Bialystok Bialystok
      Poland.
LA  - eng
PT  - Journal Article
DEP - 20200214
PL  - United States
TA  - Nurs Open
JT  - Nursing open
JID - 101675107
MH  - Humans
MH  - Poland
MH  - Primary Health Care
MH  - *Professional Competence
MH  - Qualitative Research
MH  - *Respect
PMC - PMC7113527
OTO - NOTNLM
OT  - *family nurse
OT  - *good nurse
OT  - *nursing
OT  - *older people
OT  - *primary health care
COIS- No conflict of interest has been declared by the authors.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/01/13 00:00 [revised]
PHST- 2020/01/20 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1002/nop2.456 [doi]
AID - NOP2456 [pii]
PST - epublish
SO  - Nurs Open. 2020 Feb 14;7(3):814-821. doi: 10.1002/nop2.456. eCollection 2020 May.


PMID- 32257259
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20211217
IS  - 2054-1058 (Print)
IS  - 2054-1058 (Linking)
VI  - 7
IP  - 3
DP  - 2020 May
TI  - Newly graduated registered nurses' self-assessed clinical competence and their
      need for further training.
PG  - 720-730
LID - 10.1002/nop2.443 [doi]
AB  - Aim: To explore and describe changes in self-assessed clinical competence and the
      need for further training among newly graduated Registered Nurses during their
      first 15 months of professional work in acute care hospital settings. Design:
      Quantitative longitudinal design. Methods: The 50-item Professional Nurse
      Self-Assessment Scale of clinical core competencies II was used. A total of 45
      newly graduated Registered Nurses answered the questionnaire at four different
      occasions. Data were collected after 2, 5, 9 and 15 months of working experience.
      Result: The components "ethical decision-making," "cooperation and consultation" 
      and "clinical leadership" were rated highest in clinical competence and lowest in
      need for further training. The components "professional development" and
      "critical thinking" were rated lowest in clinical competence and "direct clinical
      practice" rated highest in need for further training. The clinical competence
      increased significant between 9-15 months, with the exception of "critical
      thinking" and need for further training decreased significantly between 9-15
      months, with the exception of "critical thinking."
CI  - (c) 2020 The Authors. Nursing Open published by John Wiley & Sons Ltd.
FAU - Willman, Anna
AU  - Willman A
AUID- ORCID: 0000-0001-5911-6743
AD  - Department of Health Sciences Faculty of Health, Science, and Technology Karlstad
      University Karlstad Sweden.
FAU - Bjuresater, Kaisa
AU  - Bjuresater K
AD  - Department of Health Sciences Faculty of Health, Science, and Technology Karlstad
      University Karlstad Sweden.
FAU - Nilsson, Jan
AU  - Nilsson J
AD  - Department of Health Sciences Faculty of Health, Science, and Technology Karlstad
      University Karlstad Sweden.
AD  - Department of Health Promotion Sciences Sophiahemmet University Stockholm Sweden.
AD  - Japanese Red Cross Institute for humanitarian Studies Tokyo Japan.
LA  - eng
PT  - Journal Article
DEP - 20200122
PL  - United States
TA  - Nurs Open
JT  - Nursing open
JID - 101675107
MH  - *Clinical Competence
MH  - Humans
MH  - *Nurses
MH  - Self-Assessment
MH  - Surveys and Questionnaires
MH  - Thinking
PMC - PMC7113520
OTO - NOTNLM
OT  - *acute care settings
OT  - *clinical competence
OT  - *competence development
OT  - *complex patient situations
OT  - *newly registered graduated nurses
OT  - *nurse competence
COIS- The authors have no conflict of interest to declare.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/11/23 00:00 [received]
PHST- 2019/12/15 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1002/nop2.443 [doi]
AID - NOP2443 [pii]
PST - epublish
SO  - Nurs Open. 2020 Jan 22;7(3):720-730. doi: 10.1002/nop2.443. eCollection 2020 May.


PMID- 32257106
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2045-3701 (Print)
IS  - 2045-3701 (Linking)
VI  - 10
DP  - 2020
TI  - CCR5-Delta32 biology, gene editing, and warnings for the future of CRISPR-Cas9 as
      a human and humane gene editing tool.
PG  - 48
LID - 10.1186/s13578-020-00410-6 [doi]
AB  - BACKGROUND: Biomedical technologies have not just improved human health but also 
      assisted in the creation of human life. Since the first birth of a healthy baby
      by in vitro fertilization (IVF) 40 years ago, IVF has been the mainstay treatment
      for couples struggling with infertility. This technology, in addition to
      increasingly accessible genetic testing, has made it possible for countless
      couples to have children. Since CRISPR-Cas9 gene editing was described in 2015,
      its potential for targeting genetic diseases has been much anticipated. However, 
      the potential of using CRISPR-Cas9 for human germline modification has led to
      many fears of "designer babies" and widespread concerns for the impact of this
      technology on human evolution and its implications in Social Darwinism. In
      addition to these ethical/moral concerns, there remain many unknowns about
      CRISPR-Cas9 technology and endless unanticipated consequence to gene editing.
      METHODS: In this paper, we analyze the current progresses of CRISPR-Cas9
      technology and discuss the theoretical advantages of certain allelic variances in
      the C-C chemokine receptor 5 gene (CCR5) in the setting of recent ethical/moral
      concerns regarding gene editing using the CRISPR-Cas9 system. RESULTS: These
      uncertainties have been highlighted recently by the birth of Chinese twins whose 
      C-C chemokine receptor 5 (CCR5) gene had been inactivated via CRISPR-Cas9 to be
      theoretically protective against HIV infection. CCR5 signaling is critical for
      the successful infection of human immunodeficiency virus (HIV) and people with
      homozygous inactivating CCR5-Delta32 mutations have been shown to be protected
      against HIV infection. Those with the CCR5-Delta32/Delta32 mutation also have
      greater neuroplasticity, allowing for improved recovery from neurological trauma,
      and decreased Chagas cardiomyopathy. However, the CCR5-Delta32/Delta32 mutation
      has also been associated with earlier clinical manifestations for West Nile
      infection, ambiguous effects on osteoclast function, and a four-fold increased
      mortality from influenza infection. These detrimental health impacts, in addition
      to the confounding factor that these CRISPR babies do not carry this exact
      CCR5-Delta32/Delta32 mutation, lead to many questions regarding the children's
      future health and the moral conundrum of their birth. The creation and birth of
      these babies was not completed with any scientific, ethical, or governmental
      oversight, which has spurned the acceleration of talks regarding global
      regulations for human genetic editing. CONCLUSIONS: Although we can try to
      regulate for ethical, health-related only use of this technology, moral and
      governmental oversights need to be supplemented by technical regulations. For
      instance, whole genome sequencing needs to be used to eliminate off-target
      mutations that could affect the health and safety of infants born to this
      process. Like Pandora's Box, we cannot pretend to forget CRISPR-Cas9 technology, 
      all we can do is ensure a safe, moral, and equitable used of this technology.
CI  - (c) The Author(s) 2020.
FAU - Xu, MengMeng
AU  - Xu M
AD  - Department of Pediatrics, Morgan Stanley Children's Hospital, Columbia
      University, 3959 Broadway, New York, NY 10032 USA.grid.21729.3f0000000419368729
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - England
TA  - Cell Biosci
JT  - Cell & bioscience
JID - 101561195
PMC - PMC7106751
OTO - NOTNLM
OT  - CCR5-Delta32
OT  - CRISPR-Cas
OT  - HIV infection
OT  - Human genome editing
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/03/14 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1186/s13578-020-00410-6 [doi]
AID - 410 [pii]
PST - epublish
SO  - Cell Biosci. 2020 Mar 30;10:48. doi: 10.1186/s13578-020-00410-6. eCollection
      2020.


PMID- 32257029
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 0019-5413 (Print)
IS  - 0019-5413 (Linking)
VI  - 54
IP  - 2
DP  - 2020 Apr
TI  - World-Class Tumor Knee Prosthesis: Made in India.
PG  - 130-140
LID - 10.1007/s43465-019-00033-1 [doi]
AB  - AIM: Mega-prostheses required for reconstructing large gaps in bone after
      limb-saving surgeries for osteo-sarcoma patients have a long development cycle.
      This includes design of prosthesis components and surgical armamentarium,
      followed by pilot batch production, lab testing, human clinical trials and
      regulatory approvals. Most manufacturers stay away due to small market size
      coupled with the difficulties and high costs involved. Prostheses developed in
      the West are often unsuitable and unaffordable for the majority of Indian
      patients. There is a need for high-quality yet low-cost prostheses that are
      compatible with the anatomy and functionality of local population. METHOD: An
      inter-disciplinary group comprising orthopedic oncologists, mechanical engineers 
      and materials scientists from three different organizations in India took up the 
      above challenge. They developed a novel modular tumour knee prosthesis with
      rotating hinge, as well as surgical armamentarium with femoral and tibial cutting
      jigs and other instruments. Knee simulator and testing machines were developed to
      test the prosthesis. A dedicated pilot production facility along with inspection 
      and quality management system was set up. RESULT: The new prosthesis provides
      flexion-extension up to 120 degrees and axial rotation of +/-5 degrees. It
      successfully completed ten million cycles of fatigue and wear testing. The
      regulatory body of the government and institutional ethical committees of
      hospitals approved the human clinical trials, which are currently in progress.
      CONCLUSION: The design, manufacturing and testing of the prosthesis components
      and armamentarium took more than a decade and presented many challenges. These
      were overcome by several technological innovations by the engineering team and
      continuous feedback from the surgeons. The experience is expected to be useful to
      all others interested in this field.
CI  - (c) Indian Orthopaedics Association 2020.
FAU - Panda, Nirmal
AU  - Panda N
AD  - 1Non-Ferrous Materials Technology Development Centre, Hyderabad,
      India.grid.500631.10000 0004 6085 4956
FAU - Krishnamurty, Balasubramanian
AU  - Krishnamurty B
AD  - 1Non-Ferrous Materials Technology Development Centre, Hyderabad,
      India.grid.500631.10000 0004 6085 4956
FAU - Agarwal, Manish
AU  - Agarwal M
AD  - 2P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India.grid.417189.2
FAU - Ravi, Bhallamudi
AU  - Ravi B
AUID- ORCID: 0000-0001-7558-0423
AD  - 3Indian Institute of Technology Bombay, Mumbai, India.grid.417971.d0000 0001 2198
      7527
LA  - eng
PT  - Journal Article
DEP - 20200124
PL  - Switzerland
TA  - Indian J Orthop
JT  - Indian journal of orthopaedics
JID - 0137736
PMC - PMC7096344
OTO - NOTNLM
OT  - Knee simulator and testing machine
OT  - Osteosarcoma
OT  - Surgical instruments
OT  - Tumor knee prosthesis
COIS- Conflict of interestThe authors declare that they have no conflict of interest.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/11/17 00:00 [received]
PHST- 2019/12/16 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1007/s43465-019-00033-1 [doi]
AID - 33 [pii]
PST - epublish
SO  - Indian J Orthop. 2020 Jan 24;54(2):130-140. doi: 10.1007/s43465-019-00033-1.
      eCollection 2020 Apr.


PMID- 32256832
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1809-9777 (Print)
IS  - 1809-4864 (Linking)
VI  - 24
IP  - 2
DP  - 2020 Apr
TI  - Behavioral and Electrophysiological Assessment of Adults Who Underwent Cochlear
      Implantation After Hearing Aid Experience.
PG  - e132-e139
LID - 10.1055/s-0039-1695022 [doi]
AB  - Introduction Cochlear implantation has been considered a viable option to restore
      hearing perception in adults with severe to profound postlingual hearing loss.
      Objectives To analyze behavioral hearing responses and P300 latency and amplitude
      measurements in adults with bilateral sensorineural hearing loss at two phases,
      first when they were using hearing aids (HAs) and, then, after 12 months of
      cochlear implant (CI) use. The association between behavioral and
      electrophysiological evaluations was explored, as it is believed that the study
      of auditory processing with different hearing devices can contribute to future CI
      adjustments and fittings, especially for patients who cannot give subjective
      feedback (such as small children and individuals with multiple disabilities).
      Methods Prospective comparative study (Ethical approval 11489/2014). Twelve
      adults were assessed, 7 males and 5 females, in the 22 to 76 years old age range,
      who had undergone CI surgery after HA experience. Results The analyses showed an 
      improvement of hearing thresholds when patients started using CIs. Comparing data
      from P300 latency measurements, there was an increase of the P300 wave post-CI at
      Cz and Fz. Regarding the amplitude, P300 mean values decreased at Cz, but
      increased at Fz. There was no significant correlation between behavioral and
      electrophysiological assessment and the variables age, gender, auditory
      deprivation, and electronic device used. Conclusion There was a significant
      improvement of hearing thresholds after twelve months of CI experience. The mean 
      latency values of P300 after 12 months of CI use increased at Cz and Fz, while
      mean amplitude values decreased at Cz and increased at Fz.
FAU - Calderaro, Victor Goiris
AU  - Calderaro VG
AUID- ORCID: 0000-0002-4531-8368
AD  - Department of Ophthalmology, Otolaryngology and Head and Neck
      Surgery/Speech-Language Pathology and Audiology Division, Faculdade de Medicina
      de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Amaral, Maria Stella Arantes do
AU  - Amaral MSAD
AD  - Hospital das Clinicas, Faculdade de Medicina de Ribeirao Preto, Universidade de
      Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Luz, Benedita Aparecida Borges da
AU  - Luz BABD
AD  - Hospital das Clinicas, Faculdade de Medicina de Ribeirao Preto, Universidade de
      Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Bernal, Sarah Carolina
AU  - Bernal SC
AD  - Department of Ophthalmology, Otolaryngology and Head and Neck
      Surgery/Speech-Language Pathology and Audiology Division, Faculdade de Medicina
      de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.
FAU - Hyppolito, Miguel Angelo
AU  - Hyppolito MA
AD  - Department of Ophthalmology, Otolaryngology and Head and Neck Surgery, Faculdade 
      de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP,
      Brazil.
FAU - Reis, Ana Claudia Mirandola Barbosa
AU  - Reis ACMB
AD  - Department of Ophthalmology, Otolaryngology and Head and Neck
      Surgery/Speech-Language Pathology and Audiology Division, Faculdade de Medicina
      de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20191104
PL  - Brazil
TA  - Int Arch Otorhinolaryngol
JT  - International archives of otorhinolaryngology
JID - 101637652
PMC - PMC6828573
OTO - NOTNLM
OT  - P300
OT  - adult
OT  - cochlear implantation
OT  - event-related potentials
OT  - hearing loss
COIS- Conflicts of Interest The authors have no conflicts of interest to declare.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/02/17 00:00 [received]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1055/s-0039-1695022 [doi]
AID - 0959or [pii]
PST - ppublish
SO  - Int Arch Otorhinolaryngol. 2020 Apr;24(2):e132-e139. doi: 10.1055/s-0039-1695022.
      Epub 2019 Nov 4.


PMID- 32256735
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - Fast-track extubation in patients after intracranial hematoma surgery.
PG  - 2563-2569
LID - 10.3892/etm.2020.8507 [doi]
AB  - Early extubation, also known as fast track, is desirable after intracranial
      hematoma surgery to avoid ventilator-associated complications associated with
      admission to an intensive care unit (ICU). The objective of the present study was
      to determine whether ICU stay and ventilator-associated complications are reduced
      in patients who received surgery for intracranial hematoma if they are extubated 
      early. A total of 17 patients were randomly assigned to two groups: In Group 1,
      patients were extubated early or using the fast track method, while those in
      Group 2 were conventionally extubated at a later stage and were managed at the
      ICU. Patients from both groups were assessed on admission to the operating room
      per the established standards and after the selection criteria had been
      confirmed, general anesthesia was applied. Extubation time and hemodynamic
      stability (number of anesthetic adjustments required to maintain hemodynamic
      parameters within 20% of the predicted values) were assessed post-operatively.
      Patients in the conventional group (n=10) were transferred to the ICU and
      extubated at 8 h post-operatively; hemodynamic stability and the presence of
      complications were evaluated. The fast track group had no complications
      associated with ventilation or any other parameter. All patients extubated in a
      conventional manner and who were transferred to the ICU presented with
      complications, including seizures, aspiration, atelectasis or failed extubation. 
      In the future, fast track should be regarded as a routine technique in patients
      who meet the required criteria, so that they may be discharged quickly and with
      fewer complications. The present study was authorized by the ethics committee of 
      the hospital and the research sub-directorate with the number AN14-003; it was
      submitted to and approved by the ISRCTN registry for clinical trials (ID,
      ISRCTN16924441).
CI  - Copyright: (c) Gonzalez-Cordero et al.
FAU - Gonzalez-Cordero, Gustavo
AU  - Gonzalez-Cordero G
AD  - Servicio de Anestesiologia, Universidad Autonoma de Nuevo Leon, Facultad de
      Medicina y Hospital Universitario 'Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo
      Leon 64460, Mexico.
FAU - Garduno-Chavez, Belia Ines
AU  - Garduno-Chavez BI
AD  - Servicio de Anestesiologia, Universidad Autonoma de Nuevo Leon, Facultad de
      Medicina y Hospital Universitario 'Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo
      Leon 64460, Mexico.
FAU - Palacios-Rios, Dionisio
AU  - Palacios-Rios D
AD  - Servicio de Anestesiologia, Universidad Autonoma de Nuevo Leon, Facultad de
      Medicina y Hospital Universitario 'Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo
      Leon 64460, Mexico.
FAU - Estrada-Solis, Yesenia Nohemi
AU  - Estrada-Solis YN
AD  - Servicio de Anestesiologia, Universidad Autonoma de Nuevo Leon, Facultad de
      Medicina y Hospital Universitario 'Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo
      Leon 64460, Mexico.
FAU - Rodriguez-Sanchez, Iram Pablo
AU  - Rodriguez-Sanchez IP
AD  - Laboratorio de Fisiologia Molecular y Estructural, Universidad Autonoma de Nuevo 
      Leon, Facultad de Ciencias Biologicas, San Nicolas de los Garza, Nuevo Leon
      66450, Mexico.
FAU - Martinez-Ponce-de-Leon, Angel Raymundo
AU  - Martinez-Ponce-de-Leon AR
AD  - Servicio de Neurocirugia, Universidad Autonoma de Nuevo Leon, Facultad de
      Medicina y Hospital Universitario 'Dr Jose Eleuterio Gonzalez', Monterrey, Nuevo 
      Leon 64460, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20200210
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7098210
OTO - NOTNLM
OT  - avoidance of complications
OT  - fast track
OT  - intensive care unit
OT  - intracranial hematoma
OT  - post-surgery patients
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2019/03/07 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.3892/etm.2020.8507 [doi]
AID - ETM-0-0-8507 [pii]
PST - ppublish
SO  - Exp Ther Med. 2020 Apr;19(4):2563-2569. doi: 10.3892/etm.2020.8507. Epub 2020 Feb
      10.


PMID- 32256688
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1752-4458 (Print)
IS  - 1752-4458 (Linking)
VI  - 14
DP  - 2020
TI  - The experience of long stay in high and medium secure psychiatric hospitals in
      England: qualitative study of the patient perspective.
PG  - 25
LID - 10.1186/s13033-020-00358-7 [doi]
AB  - BACKGROUND: Some forensic patients in England remain in secure care for long,
      possibly unnecessarily prolonged, periods, raising significant ethical and
      resource issues. Research focused on the patients in secure care has examined
      quality of life and service provision but not the perspectives of patients
      experiencing long stays. This study explored how long stay patients experience
      secure care, what factors they felt influenced long stay, and its impact upon
      treatment engagement and motivation to progress. METHODS: Embedded within a
      larger epidemiological study, we conducted semi-structured interviews with a
      purposive sample of forty long stay patients from two high and six medium secure 
      hospitals. Long stay was defined as a 5 years stay in medium secure care or 10
      years in high secure care, or 15 years in a combination of high and medium
      secure. Transcripts were subject to thematic analysis, and narrative analysis at 
      individual case level to explore the relationship between emergent themes.
      RESULTS: Four themes emerged illustrating participants' attribution, outlook,
      approach, and readiness for change. A typology of four long stay stances was
      developed (dynamic acceptance, dynamic resistance, static acceptance, static
      resistance). These illustrate differences in the extent to which participants
      believed being in secure care helped them to get better, and actively work
      towards progression and leaving secure care. There were considerable differences 
      in how patients adopting these stances attributed the reasons for their long
      stay, they viewed their future, and their motivation to progress. Negative
      perceptions arose from excessive restrictions, treatment repetition and changes
      in therapeutic relationships, leading some patients to exhibiting tokenistic
      engagement and low motivation to progress. CONCLUSIONS: Planning care for long
      stay patients in secure psychiatric settings should take account of the differing
      stances patient's adopt towards engagement and progression. Service providers
      should be mindful of these stances and provide patients with individualised
      opportunities to progress through the secure care treatment pathway, avoiding
      treatment repetition and maintaining continuity in key professional
      relationships. Refocusing on quality of life may be appropriate for some
      long-term patients who are unwilling or unable to move on. For some long-term
      patients, purpose designed long stay setting may be appropriate.
CI  - (c) The Author(s) 2020.
FAU - Holley, Jessica
AU  - Holley J
AD  - 1Research Fellow, Middlesex University, London, UK.grid.15822.3c0000 0001 0710
      330X
FAU - Weaver, Tim
AU  - Weaver T
AD  - 2Associate Professor of Mental Health Research, Middlesex University, London,
      UK.grid.15822.3c0000 0001 0710 330X
FAU - Vollm, Birgit
AU  - Vollm B
AD  - 3Professor in Forensic Psychiatry, University of Nottingham and Nottinghamshire
      Healthcare NHS Foundation Trust, Nottingham, UK.grid.439378.20000 0001 1514 761X
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - England
TA  - Int J Ment Health Syst
JT  - International journal of mental health systems
JID - 101294224
PMC - PMC7104497
OTO - NOTNLM
OT  - Forensic mental health
OT  - Length of stay
OT  - Long stay patients
OT  - Mentally disordered offenders
OT  - Narrative analysis
OT  - Qualitative interviews
OT  - Secure care
OT  - Thematic content analysis
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/09/11 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1186/s13033-020-00358-7 [doi]
AID - 358 [pii]
PST - epublish
SO  - Int J Ment Health Syst. 2020 Mar 30;14:25. doi: 10.1186/s13033-020-00358-7.
      eCollection 2020.


PMID- 32256614
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1687-9740 (Print)
IS  - 1687-9740 (Linking)
VI  - 2020
DP  - 2020
TI  - A Prospective Observational Study of Drug Therapy Problems in Pediatric Ward of a
      Referral Hospital, Northeastern Ethiopia.
PG  - 4323189
LID - 10.1155/2020/4323189 [doi]
AB  - BACKGROUND: A drug therapy problem is any undesirable event experienced by a
      patient during drug therapy that interferes with achieving the desired goals of
      therapy. It has been pointed out that hospitalized pediatric patients are
      particularly prone to drug-related problems. Identifying drug therapy problems
      enables risk quantification and determination of the potential impact of
      prevention strategies. The purpose of this study was to assess the drug therapy
      problems in a pediatric ward of Dessie Referral Hospital, northeast of Ethiopia, 
      and to identify associated factors for drug therapy problems. METHODS: A
      prospective observational study design was carried out to assess drug therapy
      problems in a pediatric ward of Dessie Referral Hospital from February 1, 2018,
      to May 30, 2018. Ethical approval was obtained, and informed consent was signed
      by each study participant's parent before the commencement of the study. All
      patients admitted to the ward during the study period were included in the study.
      Data was collected by trained pharmacy staffs through medical record reviews of
      patients using a prepared standard checklist and semistructured questionnaire.
      The collected data were cleared and checked every day for completeness and
      consistency before processing. Data were entered, and descriptive statistical
      analysis was done using SPSS Version 20 Software. A P value of less than 0.05 was
      considered significant. RESULTS: The participants' mean age was 2.32 years with
      the standard deviation (SD) of 0.76 years. Among 81 patients, 71 (87.7%) of them 
      had at least one drug therapy problem per patient which indicates that the
      prevalence of the drug therapy problem was substantially high. Needs additional
      drug was the most predominantly encountered drug therapy problem accounted (30
      (25.2%)). On the other hand, ineffective drug was the least (3 (2.5%)) drug
      therapy problem. Antibiotics (47 (39.5%)) followed by fluid and electrolyte (25
      (21%)) were classes of drugs mostly involved in the drug therapy problem. The
      main risk factors reported to the occurrence of the drug therapy problems were
      prescribing and dose calculation errors. CONCLUSION: The present study revealed
      that majority of the patients had at least one DTP per patient; this indicates
      that prevalence of DTP was very high in the study area. Needs additional drug
      therapy followed by noncompliance was the major cause of the occurrence of DTP.
      Antibiotics were the main class of drugs involved in the drug therapy problem,
      and among the risk factors assessed, prescribing and dose calculation errors
      showed statistical significance.
CI  - Copyright (c) 2020 Gizachew Kassahun Bizuneh et al.
FAU - Bizuneh, Gizachew Kassahun
AU  - Bizuneh GK
AUID- ORCID: https://orcid.org/0000-0002-5527-5955
AD  - Department of Pharmacognosy, School of Pharmacy, College of Medicine and Health
      Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.
FAU - Adamu, Betelhem Anteneh
AU  - Adamu BA
AD  - Department of Pharmacognosy, School of Pharmacy, College of Medicine and Health
      Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.
FAU - Bizuayehu, Getenet Tadege
AU  - Bizuayehu GT
AD  - Department of Pharmacognosy, School of Pharmacy, College of Medicine and Health
      Sciences, Mizan Tepi University, Mizan, Ethiopia.
FAU - Adane, Solomon Debebe
AU  - Adane SD
AD  - Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, 
      Wollo University, Dessie, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20200320
PL  - Egypt
TA  - Int J Pediatr
JT  - International journal of pediatrics
JID - 101517077
PMC - PMC7115047
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2019/12/21 00:00 [revised]
PHST- 2020/01/23 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.1155/2020/4323189 [doi]
PST - epublish
SO  - Int J Pediatr. 2020 Mar 20;2020:4323189. doi: 10.1155/2020/4323189. eCollection
      2020.


PMID- 32256422
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Neuroprediction and A.I. in Forensic Psychiatry and Criminal Justice: A Neurolaw 
      Perspective.
PG  - 220
LID - 10.3389/fpsyg.2020.00220 [doi]
AB  - Advances in the use of neuroimaging in combination with A.I., and specifically
      the use of machine learning techniques, have led to the development of
      brain-reading technologies which, in the nearby future, could have many
      applications, such as lie detection, neuromarketing or brain-computer interfaces.
      Some of these could, in principle, also be used in forensic psychiatry. The
      application of these methods in forensic psychiatry could, for instance, be
      helpful to increase the accuracy of risk assessment and to identify possible
      interventions. This technique could be referred to as 'A.I. neuroprediction,' and
      involves identifying potential neurocognitive markers for the prediction of
      recidivism. However, the future implications of this technique and the role of
      neuroscience and A.I. in violence risk assessment remain to be established. In
      this paper, we review and analyze the literature concerning the use of
      brain-reading A.I. for neuroprediction of violence and rearrest to identify
      possibilities and challenges in the future use of these techniques in the fields 
      of forensic psychiatry and criminal justice, considering legal implications and
      ethical issues. The analysis suggests that additional research is required on
      A.I. neuroprediction techniques, and there is still a great need to understand
      how they can be implemented in risk assessment in the field of forensic
      psychiatry. Besides the alluring potential of A.I. neuroprediction, we argue that
      its use in criminal justice and forensic psychiatry should be subjected to
      thorough harms/benefits analyses not only when these technologies will be fully
      available, but also while they are being researched and developed.
CI  - Copyright (c) 2020 Tortora, Meynen, Bijlsma, Tronci and Ferracuti.
FAU - Tortora, Leda
AU  - Tortora L
AD  - Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
FAU - Meynen, Gerben
AU  - Meynen G
AD  - Willem Pompe Institute for Criminal Law and Criminology/Utrecht Centre for
      Accountability and Liability Law (UCALL), Utrecht University, Utrecht,
      Netherlands.
AD  - Faculty of Humanities, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
FAU - Bijlsma, Johannes
AU  - Bijlsma J
AD  - Willem Pompe Institute for Criminal Law and Criminology/Utrecht Centre for
      Accountability and Liability Law (UCALL), Utrecht University, Utrecht,
      Netherlands.
FAU - Tronci, Enrico
AU  - Tronci E
AD  - Department of Computer Science, Sapienza University of Rome, Rome, Italy.
FAU - Ferracuti, Stefano
AU  - Ferracuti S
AD  - Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200317
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7090235
OTO - NOTNLM
OT  - artificial intelligence
OT  - forensic psychiatry
OT  - neurolaw
OT  - neuroprediction
OT  - recidivism
OT  - risk assessment
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/08/24 00:00 [received]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.3389/fpsyg.2020.00220 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 17;11:220. doi: 10.3389/fpsyg.2020.00220. eCollection
      2020.


PMID- 32256407
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - A Pilot Randomized Control Trial With the Probiotic Strain Lactobacillus
      rhamnosus GG (LGG) in ADHD: Children and Adolescents Report Better Health-Related
      Quality of Life.
PG  - 181
LID - 10.3389/fpsyt.2020.00181 [doi]
AB  - Objectives: This double-blind pilot randomized placebo-controlled trial examined 
      the possible effect of the probiotic strain Lactobacillus rhamnosus GG ATCC53103 
      (LGG) on symptoms of attention-deficit/hyperactivity disorder (ADHD),
      health-related quality of life (QoL), and serum levels of cytokines in children
      and adolescents with ADHD. Methods: This trial evaluated 32 drug-naive children
      and adolescents aged between four and 17 years with a diagnosis of ADHD. The
      study subjects were randomly assigned to either the group that received LGG or
      the group that received the placebo. Assessments, comprising the ADHD
      Parent-Report Rating Scale-IV: Home Version; the Child Self-Report and Parent
      Proxy-Report of the Pediatric Quality of Life Inventory (TM) (PedsQL (TM) ) 4.0
      Generic Core Scale; the Parent Form (CBCL/6-18) and the Teacher Report Form (TRF)
      of the Child Behavior Checklist (CBCL) for ages 6-18 of the Achenbach System of
      Empirically Based Assessment (ASEBA); and the serum cytokines; were compared
      between the groups at the baseline and after 3 months. Results: Thirty-five
      participants were randomized, with 32 completing the study (91.4% retention).
      There was a significant improvement in the PedsQL Child Self-Report Total Score
      after 3 months of treatment in the probiotic (p = 0.021, d = 0.53), whereas there
      was no significant improvement in the placebo group (p = 0.563, d = 0.04). The
      results of psychometric parameters assessed by parents and teachers were not so
      straightforward. There were statistically significant differences in the levels
      of serum cytokines between the groups after the 3-month treatment period: IL-6 in
      both the probiotic (p = 0.004, d = 0.73) and the placebo groups (p = 0.035, d =
      0.94); IL-10 (p = 0.035, d = 0.6); IL-12 p70 (p = 0.025, d = 0.89); and TNF-alpha
      (p = 0.046, d = 0.64) in the probiotic group only. Conclusions: Children and
      adolescents with ADHD who received LGG supplementation reported better
      health-related QoL compared to their peers who received the placebo. This
      suggests that LGG supplementation could be beneficial. But results with
      psychometric tests conducted by parents and teachers as well as differences in
      the levels of inflammatory cytokines were ambiguous. Based on these results, we
      propose some study modifications: a longer observation period (6-12 months);
      inclusion of more children's self-report assessments; recruitment of non-drug
      naive patients and the possible omission of serum cytokines measurements.
      Clinical Trial Registration: Medical Ethics Committee (UKC-MB-KME-19-06/16).
CI  - Copyright (c) 2020 Kumperscak, Gricar, Ulen and Micetic-Turk.
FAU - Kumperscak, Hojka Gregoric
AU  - Kumperscak HG
AD  - Pediatric Clinic, University Medical Center Maribor, Maribor, Slovenia.
AD  - Faculty of Medicine, University of Maribor, Maribor, Slovenia.
FAU - Gricar, Alja
AU  - Gricar A
AD  - Faculty of Medicine, University of Maribor, Maribor, Slovenia.
FAU - Ulen, Ina
AU  - Ulen I
AD  - Community Health Center Dr. Adolf Drolc, Maribor, Slovenia.
FAU - Micetic-Turk, Dusanka
AU  - Micetic-Turk D
AD  - Faculty of Medicine, University of Maribor, Maribor, Slovenia.
LA  - eng
PT  - Journal Article
DEP - 20200317
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7092625
OTO - NOTNLM
OT  - ADHD
OT  - LGG
OT  - Lactobacillus rhamnosus GG
OT  - adolescents
OT  - attention-deficit/hyperactivity disorder
OT  - children
OT  - health-related quality of life
OT  - probiotics
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2020/01/07 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.3389/fpsyt.2020.00181 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Mar 17;11:181. doi: 10.3389/fpsyt.2020.00181. eCollection 
      2020.


PMID- 32256147
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1303-6092 (Electronic)
IS  - 1300-0152 (Linking)
VI  - 44
IP  - 2
DP  - 2020
TI  - Bioethical issues in genome editing by CRISPR-Cas9 technology.
PG  - 110-120
LID - 10.3906/biy-1912-52 [doi]
AB  - Genome editing technologies have led to fundamental changes in genetic science.
      Among them, CRISPR-Cas9 technology particularly stands out due to its advantages 
      such as easy handling, high accuracy, and low cost. It has made a quick
      introduction in fields related to humans, animals, and the environment, while
      raising difficult questions, applications, concerns, and bioethical issues to be 
      discussed. Most concerns stem from the use of CRISPR-Cas9 to genetically alter
      human germline cells and embryos (called germline genome editing). Germline
      genome editing leads to serial bioethical issues, such as the occurrence of
      undesirable changes in the genome, from whom and how informed consent is
      obtained, and the breeding of the human species (eugenics). However, the
      bioethical issues that CRISPR-Cas9 technology could cause in the environment,
      agriculture and livestock should also not be forgotten. In order for CRISPR-Cas9 
      to be used safely in all areas and to solve potential issues, worldwide
      legislation should be prepared, taking into account the opinions of both life and
      social scientists, policy makers, and all other stakeholders of the sectors, and 
      CRISPR-Cas9 applications should be implemented according to such legislations.
      However, these controls should not restrict scientific freedom. Here, various
      applications of CRISPR-Cas9 technology, especially in medicine and agriculture,
      are described and ethical issues related to genome editing using CRISPR-Cas9
      technology are discussed. The social and bioethical concerns in relation to human
      beings, other organisms, and the environment are addressed.
CI  - Copyright (c) 2020 The Author(s).
FAU - Ayanoglu, Fatma Betul
AU  - Ayanoglu FB
AUID- ORCID: https://orcid.org/0000-0002-8994-9444
AD  - Tissue Engineering, Biomaterials and Nanobiotechnology Laboratory, Ankara
      University Faculty of Science,Ankara University Biotechnology Institute, Ankara
      University Stem Cell Institute, Ankara Turkey.
FAU - Elcin, Ayse Eser
AU  - Elcin AE
AUID- ORCID: https://orcid.org/0000-0003-4674-6556
AD  - Tissue Engineering, Biomaterials and Nanobiotechnology Laboratory, Ankara
      University Faculty of Science,Ankara University Biotechnology Institute, Ankara
      University Stem Cell Institute, Ankara Turkey.
FAU - Elcin, Yasar Murat
AU  - Elcin YM
AUID- ORCID: https://orcid.org/0000-0003-1037-0825
AD  - Tissue Engineering, Biomaterials and Nanobiotechnology Laboratory, Ankara
      University Faculty of Science,Ankara University Biotechnology Institute, Ankara
      University Stem Cell Institute, Ankara Turkey.
AD  - Biovalda Health Technologies, Inc., Ankara Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - Turkey
TA  - Turk J Biol
JT  - Turkish journal of biology = Turk biyoloji dergisi
JID - 9434434
PMC - PMC7129066
OTO - NOTNLM
OT  - CRISPR-Cas9 technology
OT  - Genome editing
OT  - bioethical issues
OT  - bioethics
COIS- CONFLICT OF INTEREST: The third author is the founder and shareholder of Biovalda
      Health Technologies, Inc. (Ankara, Turkey). The authors declare no competing
      financial interests in relation to this article. The authors alone are
      responsible for the content and writing of the paper.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.3906/biy-1912-52 [doi]
PST - epublish
SO  - Turk J Biol. 2020 Apr 2;44(2):110-120. doi: 10.3906/biy-1912-52. eCollection
      2020.


PMID- 32256078
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1178-2390 (Print)
IS  - 1178-2390 (Linking)
VI  - 13
DP  - 2020
TI  - Describing Complexity in Palliative Home Care Through HexCom: A Cross-Sectional, 
      Multicenter Study.
PG  - 297-308
LID - 10.2147/JMDH.S240835 [doi]
AB  - BACKGROUND: Complexity has become a core issue in caring for patients with
      advanced disease and/or at the end-of-life. The Hexagon of Complexity (HexCom) is
      a complexity assessment model in the process of validation in health-care
      settings. Our objective is to use the instrument to describe differences in
      complexity across disease groups in specific home care for advanced disease
      and/or at the end-of-life patients, both in general and as relates to each domain
      and subdomain. METHODS: Cross-sectional study of home care was conducted in
      Catalonia. The instrument includes 6 domains of needs (clinical,
      psychological/emotional, social/family, spiritual, ethical, and death-related), 4
      domains of resources (intrapersonal, interpersonal, transpersonal, and
      practical), and 3 levels of complexity (High (H), Moderate (M), and Low (L)).
      Interdisciplinary home care teams assessed and agreed on the level of complexity 
      for each patient. RESULTS: Forty-three teams participated (74.1% of those
      invited). A total of 832 patients were assessed, 61.4% of which were cancer
      patients. Moderate complexity was observed in 385 (47.0%) cases and high
      complexity in 347 (42.4%). The median complexity score was 51 for cancer patients
      and 23 for patients with dementia (p<0.001). We observed the highest level of
      complexity in the social/family domain. Patients/families most frequently used
      interpersonal resources (80.5%). CONCLUSIONS: This study sheds light on the
      high-intensity work of support teams, the importance of the social/family domain 
      and planning the place of death, substantial differences in needs and resources
      across disease groups, and the importance of relationship wellbeing at the
      end-of-life.
CI  - (c) 2020 Busquet-Duran et al.
FAU - Busquet-Duran, Xavier
AU  - Busquet-Duran X
AUID- ORCID: 0000-0003-2441-2651
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
AD  - Multidisciplinary Research Group on Health and Society (GREMSAS), Barcelona,
      Spain.
AD  - Department of Nursing, University Foundation of Bages (FUB), University of Vic.
      Central University of Catalunya, Barcelona, Spain.
FAU - Jimenez-Zafra, Eva Maria
AU  - Jimenez-Zafra EM
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Manresa-Dominguez, Josep Maria
AU  - Manresa-Dominguez JM
AUID- ORCID: 0000-0001-8306-5798
AD  - Multidisciplinary Research Group on Health and Society (GREMSAS), Barcelona,
      Spain.
AD  - Metropolitan Nord Unit of Research Support, University Institute of Research in
      Primary Care (IDIAP) Jordi Gol, Barcelona, Spain.
AD  - Department of Nursing, Autonomous University of Barcelona, Barcelona, Spain.
FAU - Tura-Poma, Magda
AU  - Tura-Poma M
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Bosch-delaRosa, Olga
AU  - Bosch-delaRosa O
AD  - Psychosocial Care Team (EAPS), Red Cross, Granollers, Barcelona, Spain.
FAU - Moragas-Roca, Anna
AU  - Moragas-Roca A
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Galera Padilla, Maria Concepcion
AU  - Galera Padilla MC
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Martin Moreno, Susana
AU  - Martin Moreno S
AUID- ORCID: 0000-0002-1288-7046
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Martinez-Losada, Emilio
AU  - Martinez-Losada E
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Crespo-Ramirez, Silvia
AU  - Crespo-Ramirez S
AD  - Psychosocial Care Team (EAPS), Red Cross, Granollers, Barcelona, Spain.
FAU - Lopez-Garcia, Ana Isabel
AU  - Lopez-Garcia AI
AD  - Home Care Program, Support Team, PADES Granollers, Valles Oriental Primary Health
      Care Services, Catalan Institute of Health, Barcelona, Spain.
FAU - Toran-Monserrat, Pere
AU  - Toran-Monserrat P
AUID- ORCID: 0000-0002-9865-7427
AD  - Multidisciplinary Research Group on Health and Society (GREMSAS), Barcelona,
      Spain.
AD  - Metropolitan Nord Unit of Research Support, University Institute of Research in
      Primary Care (IDIAP) Jordi Gol, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - New Zealand
TA  - J Multidiscip Healthc
JT  - Journal of multidisciplinary healthcare
JID - 101512691
PMC - PMC7090197
OTO - NOTNLM
OT  - complexity
OT  - home care services
OT  - interdisciplinary research
OT  - non-cancer patient
OT  - palliative care
OT  - terminal care
OT  - terminally ill
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
CRDT- 2020/04/08 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/02/18 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
AID - 10.2147/JMDH.S240835 [doi]
AID - 240835 [pii]
PST - epublish
SO  - J Multidiscip Healthc. 2020 Mar 19;13:297-308. doi: 10.2147/JMDH.S240835.
      eCollection 2020.


PMID- 32255820
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20201001
IS  - 0008-5286 (Print)
IS  - 0008-5286 (Linking)
VI  - 61
IP  - 4
DP  - 2020 Apr
TI  - Veterinary Medical Ethics.
PG  - 349-350
FAU - Rollin, Bernard E
AU  - Rollin BE
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Vet J
JT  - The Canadian veterinary journal = La revue veterinaire canadienne
JID - 0004653
SB  - IM
MH  - Animals
MH  - *Education, Veterinary
MH  - Ethics
MH  - Ethics, Medical
MH  - *Veterinary Medicine
PMC - PMC7074119
EDAT- 2020/04/08 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PST - ppublish
SO  - Can Vet J. 2020 Apr;61(4):349-350.


PMID- 32255661
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20210502
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Linking)
VI  - 13
IP  - 5
DP  - 2020 May
TI  - Code Blue During the COVID-19 Pandemic.
PG  - e006779
LID - 10.1161/CIRCOUTCOMES.120.006779 [doi]
FAU - Chan, Paul S
AU  - Chan PS
AD  - Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City 
      (P.S.C.).
FAU - Berg, Robert A
AU  - Berg RA
AD  - The Children's Hospital of Philadelphia, University of Pennsylvania Perelman
      School of Medicine, Philadelphia (R.A.B., V.M.N.).
FAU - Nadkarni, Vinay M
AU  - Nadkarni VM
AD  - The Children's Hospital of Philadelphia, University of Pennsylvania Perelman
      School of Medicine, Philadelphia (R.A.B., V.M.N.).
LA  - eng
GR  - R01 HL123980/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200407
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
SB  - IM
MH  - COVID-19
MH  - Coronavirus Infections/*complications/*epidemiology
MH  - Decision Making
MH  - Ethics, Medical
MH  - Health Care Rationing/*methods
MH  - Humans
MH  - Pandemics
MH  - Personal Protective Equipment
MH  - Pneumonia, Viral/*complications/*epidemiology
MH  - *Resource Allocation
MH  - Resuscitation Orders/ethics
MH  - United States/epidemiology
PMC - PMC7237295
MID - NIHMS1584557
OTO - NOTNLM
OT  - *emergency treatment
OT  - *ethics
OT  - *pandemic
OT  - *personal protective equipment
OT  - *resuscitation
EDAT- 2020/04/08 06:00
MHDA- 2020/05/22 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 10.1161/CIRCOUTCOMES.120.006779 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2020 May;13(5):e006779. doi:
      10.1161/CIRCOUTCOMES.120.006779. Epub 2020 Apr 7.


PMID- 32255438
OWN - NLM
STAT- MEDLINE
DCOM- 20200409
LR  - 20201218
IS  - 0717-6384 (Electronic)
IS  - 0717-6384 (Linking)
VI  - 20
IP  - 3
DP  - 2020 Apr 1
TI  - Evidence synthesis relevant to COVID-19: a protocol for multiple systematic
      reviews and overviews of systematic reviews.
PG  - e7868
LID - 10.5867/medwave.2020.03.7867 [doi]
AB  - Introduction: The evidence on COVID-19 is being produced at high speed, so it is 
      challenging for decision-makers to keep up. It seems appropriate, then, to put
      into practice a novel approach able to provide the scientific community and other
      interested parties with quality evidence that is actionable, and rapidly and
      efficiently produced. Methods and analysis: We designed a protocol for multiple
      parallel systematic reviews and overviews of systematic reviews in line with the 
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols
      (PRISMA-P). We will search for primary studies and systematic reviews that answer
      different questions related to COVID-19 using both a centralized repository
      (Epistemonikos database) and a manual search in MEDLINE/PubMed, EMBASE, and the
      Cochrane Central Register of Controlled Trials. We will also search for
      literature in several other sources. At least two researchers will independently 
      undertake the selection of studies, data extraction, and assessment of the
      quality of the included studies. We will synthesize data for each question using 
      meta-analysis, when possible, and we will prepare Summary of Findings tables
      according to the GRADE approach. All the evidence will be organized in an open
      platform (L.OVE - Living OVerview of Evidence) that will be continuously updated 
      using artificial intelligence and a broad network of experts. Ethics and
      dissemination: No ethics approval is considered necessary. The results of these
      articles will be widely disseminated via peer-reviewed publications, social
      networks, and traditional media, and will be sent to relevant international
      organizations discussing this topic.
FAU - Rada, Gabriel
AU  - Rada G
AD  - Epistemonikos Foundation, Santiago, Chile. Centro Evidencia UC, Cochrane Chile
      partner center, Pontificia Universidad Catolica de Chile, Santiago, Chile.
      Internal Medicine Department, Faculty of Medicine, Pontificia Universidad
      Catolica de Chile, Santiago, Chile. Email: radagabriel@epistemonikos.org. ORCID: 
      0000-0003-2435-0710.
FAU - Verdugo-Paiva, Francisca
AU  - Verdugo-Paiva F
AD  - Epistemonikos Foundation, Santiago, Chile. Centro Evidencia UC, Cochrane Chile
      partner center, Pontificia Universidad Catolica de Chile, Santiago, Chile. ORCID:
      0000-0003-0199-9744.
FAU - Avila, Camila
AU  - Avila C
AD  - Epistemonikos Foundation, Santiago, Chile. ORCID: 0000-0001-5348-6284.
FAU - Morel-Marambio, Macarena
AU  - Morel-Marambio M
AD  - Centro Evidencia UC, Cochrane Chile partner center, Pontificia Universidad
      Catolica de Chile, Santiago, Chile. ORCID: 0000-0003-3410-3131.
FAU - Bravo-Jeria, Rocio
AU  - Bravo-Jeria R
AD  - Centro Evidencia UC, Cochrane Chile partner center, Pontificia Universidad
      Catolica de Chile, Santiago, Chile. ORCID: 0000-0002-3744-5578.
FAU - Pesce, Franco
AU  - Pesce F
AD  - Living Knowledge, Santiago, Chile. ORCID: 0000-0002-9209-4109.
FAU - Madrid, Eva
AU  - Madrid E
AD  - Centro Interdisciplinario de Estudios en Salud (CIESAL), Escuela de Medicina,
      Universidad de Valparaiso, Vina del Mar, Chile. Cochrane Chile partner center,
      Universidad de Valparaiso, Valparaiso, Chile. ORCID: 0000-0002-8095-5549.
FAU - Izcovich, Ariel
AU  - Izcovich A
AD  - Servicio de Medicina Interna, Hospital Aleman, Buenos Aires, Argentina. ORCID:
      0000-0001-9053-4396.
CN  - COVID-19 L.OVE Working Group
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Sintesis de evidencia relevante para COVID-19: protocolo comun para multiples
      revisiones sistematicas y revisiones panoramicas.
DEP - 20200401
PL  - Chile
TA  - Medwave
JT  - Medwave
JID - 101581949
SB  - IM
EIN - Medwave. 2020 May 20;20(4):e7912. PMID: 32469851
MH  - Access to Information
MH  - Artificial Intelligence
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections
MH  - *Evidence-Based Medicine
MH  - Humans
MH  - *Information Storage and Retrieval
MH  - Meta-Analysis as Topic
MH  - *Pandemics
MH  - *Pneumonia, Viral
MH  - Research Design
MH  - SARS-CoV-2
MH  - *Systematic Reviews as Topic
OTO - NOTNLM
OT  - * Coronavirus Infections
OT  - * Systematic Review
OT  - *COVID-19
IR  - Almendra-Pegueros R
FIR - Almendra-Pegueros, Rafael
IR  - Alvares C
FIR - Alvares, Carlos
IR  - Araneda G
FIR - Araneda, Gabriel
IR  - Avila C
FIR - Avila, Camila
IR  - Baladia E
FIR - Baladia, Eduard
IR  - Bohorquez-Blanco S
FIR - Bohorquez-Blanco, Sandra
IR  - Bravo-Jeria R
FIR - Bravo-Jeria, Rocio
IR  - Buhring-Bonacich K
FIR - Buhring-Bonacich, Kristian
IR  - Carrasco-Carre C
FIR - Carrasco-Carre, Cynthia
IR  - Carvajal-Julia N
FIR - Carvajal-Julia, Natalia
IR  - Cuadrado C
FIR - Cuadrado, Cristobal
IR  - Ferrada C
FIR - Ferrada, Catalina
IR  - Flores I
FIR - Flores, Ivan
IR  - Franco JVA
FIR - Franco, Juan Victor Ariel
IR  - Garnham R
FIR - Garnham, Roberto
IR  - Garroz R
FIR - Garroz, Roland
IR  - Gempeler-Rojas A
FIR - Gempeler-Rojas, Andres
IR  - Goez-Mogollon L
FIR - Goez-Mogollon, Lina
IR  - Gonzalez-Alarcon C
FIR - Gonzalez-Alarcon, Cristian
IR  - Izcovich A
FIR - Izcovich, Ariel
IR  - Madrid E
FIR - Madrid, Eva
IR  - Marques M
FIR - Marques, Maria
IR  - Martinez P
FIR - Martinez, Patricia
IR  - Meza N
FIR - Meza, Nicolas
IR  - Morel-Marambio M
FIR - Morel-Marambio, Macarena
IR  - Neumann J
FIR - Neumann, Josefina
IR  - Ojeda P
FIR - Ojeda, Paulina
IR  - Olguin P
FIR - Olguin, Pablo
IR  - Ortiz-Munoz L
FIR - Ortiz-Munoz, Luis
IR  - Pesce F
FIR - Pesce, Franco
IR  - Pena E
FIR - Pena, Eduardo
IR  - Pizarro AB
FIR - Pizarro, Ana Beatriz
IR  - Poloni D
FIR - Poloni, Daniel
IR  - Prieto P
FIR - Prieto, Pablo
IR  - Perez M
FIR - Perez, Marcelo
IR  - Perez-Bracchiglione J
FIR - Perez-Bracchiglione, Javier
IR  - Perez-Gaxiola G
FIR - Perez-Gaxiola, Giordano
IR  - Rada G
FIR - Rada, Gabriel
IR  - Ragusa M
FIR - Ragusa, Martin
IR  - Rojas MX
FIR - Rojas, Maria Ximena
IR  - Santillan-Garcia A
FIR - Santillan-Garcia, Azucena
IR  - Sepulveda J
FIR - Sepulveda, Javiera
IR  - Torres-Lopez LA
FIR - Torres-Lopez, Luz Angela
IR  - Urrea G
FIR - Urrea, Gabriela
IR  - Vargas-Peirano M
FIR - Vargas-Peirano, Manuel
IR  - Verdejo C
FIR - Verdejo, Catalina
IR  - Verdugo-Paiva F
FIR - Verdugo-Paiva, Francisca
IR  - Vergara L
FIR - Vergara, Laura
IR  - Villar JC
FIR - Villar, Juan Carlos
EDAT- 2020/04/08 06:00
MHDA- 2020/04/10 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/03/26 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/10 06:00 [medline]
AID - e7868 [pii]
AID - 10.5867/medwave.2020.03.7867 [doi]
PST - epublish
SO  - Medwave. 2020 Apr 1;20(3):e7868. doi: 10.5867/medwave.2020.03.7867.


PMID- 32255223
OWN - NLM
STAT- MEDLINE
DCOM- 20210217
LR  - 20210217
IS  - 1365-2834 (Electronic)
IS  - 0966-0429 (Linking)
VI  - 28
IP  - 4
DP  - 2020 May
TI  - Nurses' views on workload, care rationing and work environments.
PG  - 912-918
LID - 10.1111/jonm.13019 [doi]
AB  - AIMS: The article examines nurses' experiences to institutionally enforced
      choices they must make regarding what patient care will be left undone. Cognitive
      dissonance theory is used to discuss how missed care is reconciled with the
      nurses' sense of professionalism and feelings of compassion. BACKGROUND: Research
      into missed nursing care and care rationing is increasing, with an awareness that
      it impacts on nurses' coping ability. METHODS: In-depth video and telephone
      interviews were conducted with four experienced nurses who were asked to describe
      how they made choices regarding required patient care and how they managed care
      under workload pressures. RESULTS: Thematic analysis of interview narratives
      revealed four key themes describing the experiences of nurses managing their
      work: compromising care; incongruity between professional standards and
      organisational resources; emotional exhaustion; and depersonalization.
      CONCLUSIONS: Nurses expressed concerns that their professional values regarding
      patient care are being lost in a quest to achieve financial targets. It raises
      questions regarding ethical and psychological dilemmas created for workers by
      work intensification. IMPLICATIONS FOR NURSING MANAGEMENT: Financial
      effectiveness negatively impacts on nurses' emotional and clinical well-being
      cannot be easily dismissed, given that cognitive dissonance arises from
      attempting to provide quality care of patients whilst meeting organisational
      financial targets.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Harvey, Clare
AU  - Harvey C
AUID- ORCID: https://orcid.org/0000-0001-9016-8840
AD  - School of Nursing, Midwifery and Social Sciences, Central Queensland University, 
      Rockhampton Campus, Townsville, Qld, Australia.
FAU - Thompson, Shona
AU  - Thompson S
AD  - Faculty of Health Sciences, Eastern Institute of Technology, Napier, New Zealand.
FAU - Otis, Edmond
AU  - Otis E
AD  - Faculty of Health Sciences, Eastern Institute of Technology, Napier, New Zealand.
FAU - Willis, Eileen
AU  - Willis E
AUID- ORCID: https://orcid.org/0000-0001-7576-971X
AD  - School of Nursing, Midwifery and Social Sciences, Central Queensland University, 
      Rockhampton Campus, Townsville, Qld, Australia.
LA  - eng
GR  - Internal grant/Eastern Institute of Technology
PT  - Journal Article
DEP - 20200428
PL  - England
TA  - J Nurs Manag
JT  - Journal of nursing management
JID - 9306050
MH  - *Adaptation, Psychological
MH  - Health Care Rationing/*methods/statistics & numerical data
MH  - Humans
MH  - Interviews as Topic/methods
MH  - Nurses/*psychology/statistics & numerical data
MH  - Qualitative Research
MH  - Workload/psychology/*standards/statistics & numerical data
OTO - NOTNLM
OT  - implicit care rationing
OT  - missed nursing care
OT  - rationed nursing care
OT  - work intensification
EDAT- 2020/04/08 06:00
MHDA- 2021/02/18 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/12/05 00:00 [received]
PHST- 2020/03/03 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/02/18 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 10.1111/jonm.13019 [doi]
PST - ppublish
SO  - J Nurs Manag. 2020 May;28(4):912-918. doi: 10.1111/jonm.13019. Epub 2020 Apr 28.


PMID- 32253975
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Ethical conflicts in patient relationships: Experiences of ambulance nursing
      students.
PG  - 946-959
LID - 10.1177/0969733020911077 [doi]
AB  - BACKGROUND: Working as an ambulance nurse involves facing ethically problematic
      situations with multi-dimensional suffering, requiring the ability to create a
      trustful relationship. This entails a need to be clinically trained in order to
      identify ethical conflicts. AIM: To describe ethical conflicts in patient
      relationships as experienced by ambulance nursing students during clinical
      studies. RESEARCH DESIGN: An exploratory and interpretative design was used to
      inductively analyse textual data from examinations in clinical placement courses.
      PARTICIPANTS: The 69 participants attended a 1-year educational programme for
      ambulance nurses at a Swedish university. ETHICAL CONSIDERATIONS: The research
      was conducted in accordance with the Declaration of Helsinki. Participants gave
      voluntary informed consent for this study. FINDINGS: The students encountered
      ethical conflicts in patient relationships when they had inadequate access to the
      patient's narrative. Doubts regarding patient autonomy were due to uncertainty
      regarding the patient's decision-making ability, which forced students to handle 
      patient autonomy. Conflicting assessments of the patient's best interest added to
      the conflicts and also meant a disruption in patient focus. The absence of
      trustful relationships reinforced the ethical conflicts, together with an
      inadequacy in meeting different needs, which limited the possibility of providing
      proper care. DISCUSSION: Contextual circumstances add complexity to ethical
      conflicts regarding patient autonomy, dependency and the patient's best interest.
      Students felt they were fluctuating between paternalism and letting the patient
      choose, and were challenged by considerations regarding the patient's
      communication and decision-making ability, the views of third parties, and the
      need for prioritisation. CONCLUSION: The essence of the patient relationship is a
      struggle to preserve autonomy while focusing on the patient's best interest.
      Hence, there is a need for education and training that promotes ethical knowledge
      and ethical reflection focusing on the core nursing and caring values of trust
      and autonomy, particularly in situations that affect the patient's
      decision-making ability.
FAU - Bremer, Anders
AU  - Bremer A
AUID- ORCID: https://orcid.org/0000-0001-7865-3480
AD  - Linnaeus University, Sweden; Region Kalmar County, Sweden; University of Boras,
      Sweden.
FAU - Holmberg, Mats
AU  - Holmberg M
AD  - Linnaeus University, Sweden; Uppsala University, Sweden; Region Sormland, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200407
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Ambulances
MH  - Communication
MH  - Decision Making/*ethics
MH  - Emergency Medical Services/*ethics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nurse-Patient Relations/*ethics
MH  - *Personal Autonomy
MH  - Qualitative Research
MH  - *Relational Autonomy
MH  - Students, Nursing/*psychology
MH  - Sweden
MH  - Trust
PMC - PMC7323741
OTO - NOTNLM
OT  - Ambulance service
OT  - clinical studies
OT  - ethical conflicts
OT  - nursing students
OT  - patient relationship
OT  - thematic analysis
EDAT- 2020/04/08 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 10.1177/0969733020911077 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):946-959. doi: 10.1177/0969733020911077. Epub 2020 Apr
      7.


PMID- 32253817
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1557-0681 (Electronic)
IS  - 1478-2189 (Linking)
VI  - 18
IP  - 3
DP  - 2020 Sep
TI  - Implementing clinical guidelines into practice: The Osteoarthritis
      Self-management and Independent-living Support (OASIS) group-A service
      evaluation.
PG  - 404-411
LID - 10.1002/msc.1471 [doi]
AB  - INTRODUCTION: Arthritis is a common diagnosis for people presenting to healthcare
      reporting joint pain and stiffness. It is estimated that around 10 million people
      in the United Kingdom are thought to have arthritis. National Guidance states
      that patients with osteoarthritis should be offered three core treatments:
      information, exercise and weight loss advice. The Osteoarthritis Self-management 
      and Independent-living Support (OASIS) group is a programme of progressive
      exercise and educational advice. METHODS: This service evaluation was to
      determine if the OASIS group was improving functional and reported pain-level
      outcomes of patients with lower limb osteoarthritis between 2016 and 2018.
      Routinely collected data were analysed to determine its effects on a number of
      functional and self-reported outcomes. Ethical approval was not required
      following local National Health Service (NHS) Trust approval (Reference
      e2020-08). RESULTS: During the 3-year period of the review between 2016 and 2018,
      a total of 339 patients were invited to attend the OASIS group. A total of 196
      (57.8%) patients improved their overall pain score. Of the patients who attended 
      all six sessions, 96.7% (174) improved in at least one of the functional outcome 
      measures, and 90% (162) improved in at least two functional outcomes. CONCLUSION:
      On evaluation of the OASIS group, it has shown to be effective at improving pain 
      and functional performance of patients with lower limb osteoarthritis, whilst
      remaining cost-effective. In comparison with other similar initiatives, the
      results are comparable, and it is implemented over a shorter time period,
      enhancing the cost-effectiveness for the NHS.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Roberts, Shaun
AU  - Roberts S
AUID- ORCID: 0000-0002-4796-2114
AD  - Integrated Physiotherapy, Orthopaedic and Pain Service, Sir Robert Peel Hospital,
      Tamworth, UK.
FAU - Busby, Emma
AU  - Busby E
AD  - Integrated Physiotherapy, Orthopaedic and Pain Service, Samuel Johnson Hospital, 
      Lichfield, UK.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - Musculoskeletal Care
JT  - Musculoskeletal care
JID - 101181344
SB  - IM
MH  - Arthralgia
MH  - Exercise Therapy
MH  - Humans
MH  - *Osteoarthritis, Knee
MH  - *Self-Management
MH  - State Medicine
OTO - NOTNLM
OT  - *NICE
OT  - *OASIS
OT  - *arthritis
OT  - *exercise
OT  - *osteoarthritis
OT  - *self-management
EDAT- 2020/04/08 06:00
MHDA- 2021/10/29 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/03/28 00:00 [revised]
PHST- 2020/03/29 00:00 [accepted]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 10.1002/msc.1471 [doi]
PST - ppublish
SO  - Musculoskeletal Care. 2020 Sep;18(3):404-411. doi: 10.1002/msc.1471. Epub 2020
      Apr 6.


PMID- 32253747
OWN - NLM
STAT- MEDLINE
DCOM- 20200810
LR  - 20200810
IS  - 1652-7518 (Electronic)
IS  - 0023-7205 (Linking)
VI  - 117
DP  - 2020 Mar 23
TI  - [Difficulties and shortcomings in decisions on treatment restrictions].
LID - FTSE [pii]
AB  - Using a questionnaire for doctors at the Central hospital in Kristianstad,
      Sweden, we have investigated how work on treatment restrictions is handled and
      documented, whether different circumstances affect the decisions taken, and what 
      support and training the doctors consider is needed. Far from all
      patients/relatives are informed about decisions regarding life support treatment,
      and compliance with applicable laws and directives is low. The propensity to
      inform tend to be lower when the decision is that no life-sustaining measures
      will be taken. The decisions also tend not to be affected by several factors
      related to the patient, doctor, or the circumstances in which the decision was
      taken. The self-perceived level of knowledge, especially about documentation
      routines and current guidelines, is low and there are also shortcomings in terms 
      of knowledge about palliative care, communication methodology and medical ethics.
FAU - Padoan, Sergio
AU  - Padoan S
AD  - dr med vet, cheflakare , Centralsjukhuset Kristianstad.
FAU - Olofsson, Asa
AU  - Olofsson A
AD  - forskningssjukskoterska, Centralsjukhuset Kristianstad.
FAU - Dybkowska, Krystyna
AU  - Dybkowska K
AD  - overlakare, anestesikliniken, Centralsjukhuset Kristianstad.
FAU - Pettersson, Thomas
AU  - Pettersson T
AD  - overlakare, medicinkliniken, Centralsjukhuset Kristianstad.
FAU - Svensson, Inga
AU  - Svensson I
AD  - overlakare;, medicinkliniken, samtliga Centralsjukhuset Kristianstad.
LA  - swe
PT  - Journal Article
TT  - Brister i beslut om att begransa livsuppehallande behandling.
DEP - 20200323
PL  - Sweden
TA  - Lakartidningen
JT  - Lakartidningen
JID - 0027707
SB  - IM
MH  - *Decision Making
MH  - Ethics, Medical
MH  - Humans
MH  - Palliative Care
MH  - *Physicians
MH  - Sweden
EDAT- 2020/04/08 06:00
MHDA- 2020/08/11 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/08/11 06:00 [medline]
AID - FTSE [pii]
PST - epublish
SO  - Lakartidningen. 2020 Mar 23;117. pii: FTSE.


PMID- 32253562
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Jun
TI  - MIEO: a micro-invasive endoscopic operation port system for transluminal
      interventions-an acute and survival porcine study.
PG  - 2814-2823
LID - 10.1007/s00464-020-07518-3 [doi]
AB  - BACKGROUND: A reliable and sterile access through the intestinal wall to ease
      flexible endoscopic transluminal interventions is still appealing but lacks a
      suitable port system. METHODS: In a granted industry cooperation, we developed
      the MIEO-Port, a flexible three components overtube system that provides a
      temporary hermetic sealing of the intestinal wall to allow endoscopic
      disinfection and manipulation to gain access to the abdominal cavity. The port
      features an innovative head part which allows for coupling the port to the
      intestinal wall by vacuum suction and for controlled jetting the isolated
      intestinal surface with a disinfectant. The device was tested in vivo in 6 pigs
      for acute and long-term usability. All animal tests were approved by the local
      ethics committee. RESULTS: In the acute experiment, the port system supported
      sealed endoscopic mucosa resection and transluminal cholecystectomy. In the
      survival study on 5 animals, the MIEO-Port proved its reliability after
      transcolonic peritoneoscopy. In one animal, a port dislocation occurred after
      extensive retroperitoneal preparation, one animal revealed bacterial
      contamination at necropsy; however, all animals showed a favourable course over
      ten days and offered no signs of peritonitis or abscedation during post-mortem
      examination. DISCUSSION: To the best of our knowledge, the MIEO-Port system is
      the first device to provide a reliable and sterile flexible access to the
      peritoneal cavity that can be used throughout the entire gastrointestinal tract
      regardless of the access route and which combines hermetic sealing with local
      sterilization. Further studies are warranted.
FAU - Wilhelm, D
AU  - Wilhelm D
AD  - Technische Universitat Munchen, Fakultat fur Medizin, Klinik Und Poliklinik fur
      Chirurgie, Klinikum Rechts Der Isar, Ismaningerstr. 22, Munchen, 81675, Germany. 
      dirk.wilhelm@tum.de.
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany. dirk.wilhelm@tum.de.
FAU - Vogel, T
AU  - Vogel T
AD  - Technische Universitat Munchen, Fakultat fur Medizin, Klinik Und Poliklinik fur
      Chirurgie, Klinikum Rechts Der Isar, Ismaningerstr. 22, Munchen, 81675, Germany.
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany.
FAU - Jell, A
AU  - Jell A
AD  - Technische Universitat Munchen, Fakultat fur Medizin, Klinik Und Poliklinik fur
      Chirurgie, Klinikum Rechts Der Isar, Ismaningerstr. 22, Munchen, 81675, Germany.
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany.
FAU - Brunner, S
AU  - Brunner S
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany.
FAU - Kranzfelder, M
AU  - Kranzfelder M
AD  - Technische Universitat Munchen, Fakultat fur Medizin, Klinik Und Poliklinik fur
      Chirurgie, Klinikum Rechts Der Isar, Ismaningerstr. 22, Munchen, 81675, Germany.
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany.
FAU - Wantia, N
AU  - Wantia N
AD  - Technische Universitat Munchen, Institut fur Virologie Und Bakteriologie,
      Klinikum Rechts Der Isar, Munchen, Germany.
FAU - Feussner, H
AU  - Feussner H
AD  - Technische Universitat Munchen, Fakultat fur Medizin, Klinik Und Poliklinik fur
      Chirurgie, Klinikum Rechts Der Isar, Ismaningerstr. 22, Munchen, 81675, Germany.
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany.
FAU - Ostler, D
AU  - Ostler D
AD  - Arbeitsgruppe fur Minimal-Invasive Technologie Und Intervention, Klinikum Rechts 
      Der Isar, Munchen, Germany.
FAU - Koller, S
AU  - Koller S
AD  - Rochling Medical Waldachtal AG, Waldachtal, Deutschland, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - Germany
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
SB  - IM
MH  - Animals
MH  - Cholecystectomy/adverse effects/instrumentation/methods
MH  - Endoscopic Mucosal Resection/adverse effects/*instrumentation/methods
MH  - Intestinal Mucosa/*surgery
MH  - Laparoscopy/adverse effects/*instrumentation/methods
MH  - Models, Animal
MH  - Peritoneal Cavity/*surgery
MH  - Peritonitis/etiology/*prevention & control
MH  - Surgical Instruments
MH  - Swine
PMC - PMC7214494
OTO - NOTNLM
OT  - *Infection
OT  - *NOTES
OT  - *Overtube
OT  - *Sealing
OT  - *Sterilization
OT  - *Transluminal surgery
EDAT- 2020/04/08 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - 10.1007/s00464-020-07518-3 [doi]
AID - 10.1007/s00464-020-07518-3 [pii]
PST - ppublish
SO  - Surg Endosc. 2020 Jun;34(6):2814-2823. doi: 10.1007/s00464-020-07518-3. Epub 2020
      Apr 6.


PMID- 32253365
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 9
DP  - 2020 Sep
TI  - Clinical ethics report on the resuscitation of a patient in the emergency
      department with an uncertain resuscitation status and an implantable cardiac
      defibrillator.
PG  - 581-583
LID - 10.1136/medethics-2019-105945 [doi]
AB  - Cardiopulmonary resuscitation of a patient with an uncertain resuscitation
      status, and a discharging implantable cardiac defibrillator, presents a
      significant ethical challenge to healthcare professionals in the emergency
      department. Presently, no literature discusses these challenges or their
      implications for ethical healthcare delivery. This report will discuss the issues
      that arose during the management of such a case and attempt to raise awareness
      among healthcare professionals to ensure better preparation for similar
      situations.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Neal-Smith, Gregory
AU  - Neal-Smith G
AUID- ORCID: 0000-0002-7907-4277
AD  - A&E, Oxford University Hospitals, Oxford, UK gregnealsmith@doctors.org.uk.
FAU - Crellin, Adam
AU  - Crellin A
AD  - Medical Sciences Division, Oxford University Medical School, Oxford, UK.
FAU - Caseley, Rebekah
AU  - Caseley R
AD  - A&E, Oxford University Hospitals, Oxford, UK.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - *Cardiopulmonary Resuscitation
MH  - *Defibrillators, Implantable
MH  - Emergency Service, Hospital
MH  - Ethics, Clinical
MH  - *Heart Arrest
MH  - Humans
OTO - NOTNLM
OT  - *clinical ethics
OT  - *death
OT  - *education for healthcare professionals
OT  - *emergency medicine
OT  - *end-of-life care
COIS- Competing interests: None declared.
EDAT- 2020/04/08 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/03/11 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - medethics-2019-105945 [pii]
AID - 10.1136/medethics-2019-105945 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Sep;46(9):581-583. doi: 10.1136/medethics-2019-105945. Epub
      2020 Apr 6.


PMID- 32253351
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210323
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 94
IP  - 23
DP  - 2020 Jun 9
TI  - Ethics in the time of COVID: What remains the same and what is different.
PG  - 1007-1008
LID - 10.1212/WNL.0000000000009520 [doi]
FAU - Kim, Scott Y H
AU  - Kim SYH
AD  - From the Department of Bioethics, Clinical Center, National Institutes of Health,
      Bethesda, MD. scott.kim@nih.gov.
FAU - Grady, Christine
AU  - Grady C
AD  - From the Department of Bioethics, Clinical Center, National Institutes of Health,
      Bethesda, MD.
LA  - eng
PT  - Editorial
PT  - Research Support, N.I.H., Intramural
DEP - 20200406
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - Advance Directives
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Comorbidity
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Dementia/epidemiology
MH  - Disabled Persons
MH  - *Ethics, Medical
MH  - Health Priorities
MH  - Health Resources/ethics/supply & distribution/trends
MH  - Humans
MH  - Neurodegenerative Diseases/epidemiology
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/ethics/trends
MH  - SARS-CoV-2
MH  - Social Stigma
MH  - Social Values
MH  - Triage/ethics/trends
MH  - Vulnerable Populations
PMC - PMC7455363
EDAT- 2020/04/08 06:00
MHDA- 2020/09/25 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - WNL.0000000000009520 [pii]
AID - 10.1212/WNL.0000000000009520 [doi]
PST - ppublish
SO  - Neurology. 2020 Jun 9;94(23):1007-1008. doi: 10.1212/WNL.0000000000009520. Epub
      2020 Apr 6.


PMID- 32253255
OWN - NLM
STAT- MEDLINE
DCOM- 20201028
LR  - 20201028
IS  - 1477-9129 (Electronic)
IS  - 0950-1991 (Linking)
VI  - 147
IP  - 7
DP  - 2020 Apr 6
TI  - Responsible use of organoids in precision medicine: the need for active
      participant involvement.
LID - dev177972 [pii]
LID - 10.1242/dev.177972 [doi]
AB  - Organoids are three-dimensional multicellular structures grown in vitro from stem
      cells and which recapitulate some organ function. They are derivatives of living 
      tissue that can be stored in biobanks for a multitude of research purposes.
      Biobank research on organoids derived from patients is highly promising for
      precision medicine, which aims to target treatment to individual patients. The
      dominant approach for protecting the interests of biobank participants emphasizes
      broad consent in combination with privacy protection and ex ante (predictive)
      ethics review. In this paradigm, participants are positioned as passive donors;
      however, organoid biobanking for precision medicine purposes raises challenges
      that we believe cannot be adequately addressed without more ongoing involvement
      of patient-participants. In this Spotlight, we argue why a shift from passive
      donation towards more active involvement is particularly crucial for biobank
      research on organoids aimed at precision medicine, and suggest some approaches
      appropriate to this context.
CI  - (c) 2020. Published by The Company of Biologists Ltd.
FAU - Lensink, Michael A
AU  - Lensink MA
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, PO Box 85500, 3508 GA Utrecht, The Netherlands.
FAU - Jongsma, Karin R
AU  - Jongsma KR
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, PO Box 85500, 3508 GA Utrecht, The Netherlands.
FAU - Boers, Sarah N
AU  - Boers SN
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, PO Box 85500, 3508 GA Utrecht, The Netherlands.
FAU - Noordhoek, Jacquelien J
AU  - Noordhoek JJ
AD  - Dutch Cystic Fibrosis Foundation (NCFS), Dr. A. Schweitzerweg 3A, 3744 MG Baarn, 
      The Netherlands.
FAU - Beekman, Jeffrey M
AU  - Beekman JM
AD  - Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Regenerative
      Medicine Center, University Medical Center, Internal post KH.01.419.0, P.O. Box
      85090, 3508 AB Utrecht, The Netherlands.
FAU - Bredenoord, Annelien L
AU  - Bredenoord AL
AUID- ORCID: 0000-0002-7542-8963
AD  - Department of Medical Humanities, University Medical Center Utrecht, Utrecht
      University, PO Box 85500, 3508 GA Utrecht, The Netherlands
      a.l.bredenoord@umcutrecht.nl.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - Development
JT  - Development (Cambridge, England)
JID - 8701744
SB  - IM
MH  - Biological Specimen Banks/ethics
MH  - Community Participation
MH  - Directed Tissue Donation/ethics/trends
MH  - Health Services Needs and Demand
MH  - Humans
MH  - Organoids/*cytology
MH  - Precision Medicine/*ethics/*methods
MH  - Tissue Culture Techniques/ethics/methods
OTO - NOTNLM
OT  - *Biobanking
OT  - *Ethics
OT  - *Governance
OT  - *Involvement
OT  - *Organoids
OT  - *Precision medicine
OT  - *Stem cells
COIS- Competing interestsThe authors declare no competing or financial interests.
EDAT- 2020/04/08 06:00
MHDA- 2020/10/29 06:00
CRDT- 2020/04/08 06:00
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/10/29 06:00 [medline]
AID - 147/7/dev177972 [pii]
AID - 10.1242/dev.177972 [doi]
PST - epublish
SO  - Development. 2020 Apr 6;147(7). pii: 147/7/dev177972. doi: 10.1242/dev.177972.


PMID- 32253038
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 1525-3198 (Electronic)
IS  - 0022-0302 (Linking)
VI  - 103
IP  - 6
DP  - 2020 Jun
TI  - Innovative cooling strategies: Dairy cow responses and water and energy use.
PG  - 5440-5454
LID - S0022-0302(20)30241-1 [pii]
LID - 10.3168/jds.2019-17351 [doi]
AB  - Producers in the western United States commonly use spray water at the feed bunk 
      and fans in the lying area to mitigate heat stress in dairy cows. Often, spray
      water cycles on and off with fans turning on when a preset air temperature is
      reached. Although this method can be effective, innovative strategies are needed 
      to reduce water and energy use. We evaluated the effectiveness and resource
      efficiency of 4 cooling treatments on behavioral and physiological responses in
      dairy cows housed in a freestall barn: (1) conductive cooling in which mats with 
      recirculating evaporatively cooled water were buried under sand bedding (Mat;
      activated at 18.9 degrees C); (2) targeted convective cooling in which
      evaporatively cooled air was directed toward the cows through fabric ducts with
      nozzles at both the feed bunk and lying areas (Targeted Air; activated at 22
      degrees C); (3) evaporative cooling, with spray water in the feed area and fan
      over the freestalls (Baseline; activated at 22 degrees C); and (4) evaporative
      cooling with half the amount of spray water used in the Baseline and the fan
      moved to the feed bunk (Optimized Baseline; activated at 22 degrees C). In a
      crossover design, 8 groups of cows (4/group) producing an average (+/- standard
      deviation) of 37.5 +/- 4.5 kg/d of milk were tested for 3 d per treatment. For
      ethical reasons, beginning at 30 degrees C, the Mat treatment was supplemented
      with Baseline cooling and the Targeted Air treatment had spray water at the
      Optimized Baseline rate. We recorded body temperature, posture, and location
      within the pen every 3 min for 24 h/d, and respiration rates every 30 min daily
      from 1000 to 1900 h. Daily air temperature averaged (+/-SD) 26.3 +/- 7.1 degrees 
      C during 24 h and 33.3 +/- 4 degrees C from 1000 to 1900 h. We used pairwise
      comparisons of each treatment to Baseline to evaluate response variables. Milk
      production did not differ across treatments, nor did time spent lying (51 +/-
      2%/d on average). Respiration rates did not differ across treatments overall (61 
      +/- 3 breaths/min), but on an hourly basis, cows in the Mat treatment had a
      significantly higher rate than those in Baseline, at h 10 and 11 (70 vs. 58-59
      breaths/min). Body temperature averaged 38.7 +/- 0.05 degrees C across treatments
      and was 0.2 to 0.3 degrees C higher in the Mat treatment than in Baseline at h
      10, 11, 20, 21, and 22. These results collectively indicate that the Mat
      treatment did not effectively reduce indicators of heat load compared with
      Baseline. In contrast, Targeted Air and Optimized Baseline were both effective
      but differed in aspects of efficiency. Targeted Air used the least amount of
      water but the most energy of all options tested. In conclusion, more efficient
      heat abatement options were identified, particularly an Optimized Baseline
      strategy, which cut water use in half, required the same amount of energy as the 
      Baseline, and maintained similar physiological and behavioral responses in cows.
CI  - Copyright (c) 2020 American Dairy Science Association. Published by Elsevier Inc.
      All rights reserved.
FAU - Drwencke, Alycia M
AU  - Drwencke AM
AD  - Center for Animal Welfare, Department of Animal Science, University of
      California, Davis 95616.
FAU - Tresoldi, Grazyne
AU  - Tresoldi G
AD  - Center for Animal Welfare, Department of Animal Science, University of
      California, Davis 95616; College of Agriculture, California State University,
      Chico 95929.
FAU - Stevens, Matthew M
AU  - Stevens MM
AD  - Western Cooling Efficiency Center, University of California, Davis 95616.
FAU - Narayanan, Vinod
AU  - Narayanan V
AD  - Western Cooling Efficiency Center, University of California, Davis 95616;
      Department of Mechanical and Aerospace Engineering, University of California,
      Davis 95616.
FAU - Carrazco, Angelica V
AU  - Carrazco AV
AD  - Department of Animal Science, University of California, Davis 95616.
FAU - Mitloehner, Frank M
AU  - Mitloehner FM
AD  - Department of Animal Science, University of California, Davis 95616.
FAU - Pistochini, Theresa E
AU  - Pistochini TE
AD  - Western Cooling Efficiency Center, University of California, Davis 95616.
FAU - Tucker, Cassandra B
AU  - Tucker CB
AD  - Center for Animal Welfare, Department of Animal Science, University of
      California, Davis 95616. Electronic address: cbtucker@ucdavis.edu.
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Evaluation Study
PT  - Journal Article
DEP - 20200403
PL  - United States
TA  - J Dairy Sci
JT  - Journal of dairy science
JID - 2985126R
RN  - 059QF0KO0R (Water)
SB  - IM
MH  - Animals
MH  - Bedding and Linens
MH  - *Body Temperature/physiology
MH  - Cattle
MH  - *Cold Temperature
MH  - Dairying/*methods
MH  - Female
MH  - Heat Stress Disorders/prevention & control/*veterinary
MH  - Lactation
MH  - Milk
MH  - Respiratory Rate
MH  - Water
OTO - NOTNLM
OT  - conductive cooling
OT  - heat load
OT  - heat stress
OT  - spray water
OT  - targeted convective cooling
EDAT- 2020/04/08 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/07/29 00:00 [received]
PHST- 2020/02/02 00:00 [accepted]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2020/04/08 06:00 [entrez]
AID - S0022-0302(20)30241-1 [pii]
AID - 10.3168/jds.2019-17351 [doi]
PST - ppublish
SO  - J Dairy Sci. 2020 Jun;103(6):5440-5454. doi: 10.3168/jds.2019-17351. Epub 2020
      Apr 3.


PMID- 32252822
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 2523-3106 (Electronic)
IS  - 2523-3106 (Linking)
VI  - 60
IP  - 1
DP  - 2020 Apr 6
TI  - Mat Pilates is as effective as aquatic aerobic exercise in treating women with
      fibromyalgia: a clinical, randomized and blind trial.
PG  - 21
LID - 10.1186/s42358-020-0124-2 [doi]
AB  - BACKGROUND: The mat Pilates method is the therapeutic modalities which can be
      used in fibromyalgia treatment. Although there are no well-designed studies that 
      prove the effectiveness of the mat Pilates method in this population. The
      objective was to evaluate the effectiveness of the mat Pilates method for
      improving symptoms in women with fibromyalgia. METHODS: A single blind randomized
      controlled trial in which 42 women with fibromyalgia were randomized into two
      groups: mat Pilates and aquatic aerobic exercise. The exercises were performed
      twice a week for 12 weeks. Two evaluations were performed: one at baseline (T0), 
      and another at 12 weeks after randomization (T12). The primary outcome was pain
      measured by the Visual Analogue Scale (VAS). Secondary outcomes were function
      (Fibromyalgia Impact Questionnaire), sleep (Pittsburgh Sleep Quality Index
      [PSQI]), quality of life (Short Form 36 [SF-36]), fear avoidance (Fear Avoidance 
      Beliefs Questionnaire [FABQ-BR]) and pain catastrophizing (Pain-Related
      Catastrophizing Thoughts Scale [PRCTS]). RESULTS: There was improvement in both
      groups in relation to pain and function (p < 0.05). The aspects related to
      quality of life and the FABQ questionnaire only showed improvement in the mat
      Pilates group (p < 0.05). There was improvement in the PSQI and PRCTS variables
      only in the aquatic aerobic exercise group (p < 0.05), but no differences were
      observed between the groups for any of the evaluated variables. CONCLUSION:
      Significant improvements were observed in the two groups in relation to the
      disease symptoms, and no differences were observed between mat Pilates and
      aquatic aerobic exercise in any of the measured variables. TRIAL REGISTRATION:
      ClinicalTrials.gov Identifier (NCT03149198), May 11, 2017. Approved by the Ethics
      Committee of FACISA/UFRN (Number: 2.116.314).
FAU - de Medeiros, Suzy Araujo
AU  - de Medeiros SA
AD  - Federal University of Rio Grande do Norte, Faculty of Health Sciences of Trairi -
      (UFRN/FACISA), Santa Cruz, RN, Brazil.
FAU - de Almeida Silva, Hugo Jario
AU  - de Almeida Silva HJ
AD  - Federal University of Rio Grande do Norte, Faculty of Health Sciences of Trairi -
      (UFRN/FACISA), Postgraduate Program in Rehabilitation Sciences, Vila Trairi st,
      S/N, Centro, Santa Cruz, RN, 59200-000, Brazil.
FAU - do Nascimento, Rayssa Maria
AU  - do Nascimento RM
AD  - Federal University of Rio Grande do Norte, Faculty of Health Sciences of Trairi -
      (UFRN/FACISA), Santa Cruz, RN, Brazil.
FAU - da Silva Maia, Jaely Beatriz
AU  - da Silva Maia JB
AD  - Federal University of Rio Grande do Norte, Faculty of Health Sciences of Trairi -
      (UFRN/FACISA), Santa Cruz, RN, Brazil.
FAU - de Almeida Lins, Caio Alano
AU  - de Almeida Lins CA
AD  - Federal University of Rio Grande do Norte, Faculty of Health Sciences of Trairi -
      (UFRN/FACISA), Postgraduate Program in Rehabilitation Sciences, Vila Trairi st,
      S/N, Centro, Santa Cruz, RN, 59200-000, Brazil.
FAU - de Souza, Marcelo Cardoso
AU  - de Souza MC
AUID- ORCID: 0000-0002-9268-8353
AD  - Federal University of Rio Grande do Norte, Faculty of Health Sciences of Trairi -
      (UFRN/FACISA), Postgraduate Program in Rehabilitation Sciences, Vila Trairi st,
      S/N, Centro, Santa Cruz, RN, 59200-000, Brazil. marcelocardoso@facisa.ufrn.br.
LA  - eng
SI  - ClinicalTrials.gov/NCT03149198
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - England
TA  - Adv Rheumatol
JT  - Advances in rheumatology (London, England)
JID - 101734172
SB  - IM
MH  - Adult
MH  - Catastrophization/psychology
MH  - *Exercise
MH  - Exercise Movement Techniques/*methods
MH  - Fear
MH  - Female
MH  - Fibromyalgia/*therapy
MH  - Humans
MH  - Middle Aged
MH  - Pain Measurement/methods
MH  - Quality of Life
MH  - Single-Blind Method
MH  - Sleep
MH  - Swimming Pools
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - *Aerobic exercise
OT  - *Chronic pain
OT  - *Physiotherapy
OT  - *Rheumatology
EDAT- 2020/04/08 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/11/15 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
AID - 10.1186/s42358-020-0124-2 [doi]
AID - 10.1186/s42358-020-0124-2 [pii]
PST - epublish
SO  - Adv Rheumatol. 2020 Apr 6;60(1):21. doi: 10.1186/s42358-020-0124-2.


PMID- 32252743
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1472-6920 (Electronic)
IS  - 1472-6920 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 6
TI  - Medical, pharmacy and nursing students in the Baltic countries: interactions with
      the pharmaceutical and medical device industries.
PG  - 105
LID - 10.1186/s12909-020-02008-5 [doi]
AB  - BACKGROUND: Interactions between pharmaceutical and medical device industries and
      students can lead to commercial influences on educational messages, with a
      potential to bias future treatment choice. This is the first study in the Baltic 
      countries describing exposure and attitudes of medical, pharmacy and nursing
      students towards cooperation with industry. METHODS: A cross-sectional on-line
      survey of current medical, pharmacy and nursing students (n = 918) in three
      Baltic countries was carried out. RESULTS: We found that most students
      participate in events organized or sponsored by industry and accept a range of
      gifts and benefits. Students in the Baltic countries consider cooperation with
      industry important; at the same time, most do not feel that they have sufficient 
      training on how to ethically interact with pharmaceutical and medical device
      companies and believe that these interactions can influence their prescribing or 
      dispensing patterns. There is a tendency to rationalize cooperation with industry
      by referring to the current economic situation and patient benefits. Pharmacy
      students have higher rates of participation and they accept gifts and other
      benefits more often than nursing or medical students; therefore, they are likely 
      to be more vulnerable to potential industry influence. CONCLUSIONS: The findings 
      highlight the need to include topics on ethics and conflicts of interests in
      cooperation with industry in curriculum of health care students in Baltic
      countries. Without proper training, students continue to be at risk to industry
      influence and may develop habits for their further practice differing from
      evidence-based practice in prescribing and dispensing of medicines, as well as
      use of medical devices.
FAU - Salmane-Kulikovska, Ieva
AU  - Salmane-Kulikovska I
AD  - Faculty of Pharmacy, Riga Stradins University, Dzirciema street 16, Riga, LV,
      1007, Latvia.
FAU - Poplavska, Elita
AU  - Poplavska E
AD  - Faculty of Pharmacy and Institute of Public Health, Riga Stradins University,
      Dzirciema street 16, Riga, LV, 1007, Latvia. elita.poplavska@rsu.lv.
FAU - Mezinska, Signe
AU  - Mezinska S
AD  - Faculty of Medicine and Institute of Clinical and Preventive medicine, University
      of Latvia, Raina blvd. 19, Riga, LV-1050, Latvia.
FAU - Dumpe, Vita
AU  - Dumpe V
AD  - Health Projects for Latvia, Baznicas street 5 - 2, Riga, LV, 1010, Latvia.
FAU - Dauvarte, Helena
AU  - Dauvarte H
AD  - Riga Stradins University, Dzirciema street 16, Riga, LV, 1007, Latvia.
FAU - Lazdina, Lina
AU  - Lazdina L
AD  - Pauls Stradins Clinical University Hospital, Pilsonu street 13, Riga, LV-1002,
      Latvia.
FAU - Marchockij, Aleksandr
AU  - Marchockij A
AD  - Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, Kaunas,
      Lithuania.
FAU - Varzinskas, Karolis
AU  - Varzinskas K
AD  - Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, Kaunas,
      Lithuania.
FAU - Mintzes, Barbara J
AU  - Mintzes BJ
AD  - Faculty of Pharmacy and Charles Perkins Centre, The University of Sydney, Room
      6W75, 6th Floor, The Hub, Charles Perkins Centre D17, Sydney, NSW, 2006,
      Australia.
LA  - eng
GR  - n/a/Health Action International
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - BMC Med Educ
JT  - BMC medical education
JID - 101088679
SB  - IM
EIN - BMC Med Educ. 2020 Apr 22;20(1):122. PMID: 32321504
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Curriculum
MH  - Drug Industry/*ethics
MH  - Equipment and Supplies/*ethics
MH  - Estonia
MH  - Humans
MH  - Interprofessional Relations/*ethics
MH  - Latvia
MH  - Lithuania
MH  - Students, Health Occupations/psychology/*statistics & numerical data
PMC - PMC7137495
OTO - NOTNLM
OT  - Education
OT  - Estonia
OT  - Latvia
OT  - Lithuania
OT  - Medical device industry
OT  - Medical students
OT  - Nursing students
OT  - Pharmaceutical industry
OT  - Pharmacy students
EDAT- 2020/04/08 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/04/08 06:00
PHST- 2019/09/10 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.1186/s12909-020-02008-5 [doi]
AID - 10.1186/s12909-020-02008-5 [pii]
PST - epublish
SO  - BMC Med Educ. 2020 Apr 6;20(1):105. doi: 10.1186/s12909-020-02008-5.


PMID- 32251919
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 1873-2550 (Electronic)
IS  - 0304-4017 (Linking)
VI  - 280
DP  - 2020 Apr
TI  - Clinical safety of lauric acid for cattle and its in vitro and in vivo efficacy
      against Rhipicephalus microplus.
PG  - 109095
LID - S0304-4017(20)30075-3 [pii]
LID - 10.1016/j.vetpar.2020.109095 [doi]
AB  - The aim of the present study was to test the in vitro acaricidal activity of
      saturated fatty acids (hexanoic, octanoic, decanoic, lauric, myristic, palmitic, 
      octadecanoic, eicosanoic, docosanoic and tetracosanoic) against Rhipicephalus
      microplus and select a candidate compound for the subsequent determination of its
      clinical safety for mice and bovines as well as its in vivo efficacy (ethical
      clearance number 507/2013). None of the compounds exhibited in vitro larvicidal
      effectiveness, but acaricidal effectiveness was greater than 95 % in the adult
      immersion test at 40mg/ml (hexanoic, octanoic, decanoic, lauric, myristic,
      palmitic and eicosanoic acids). After a second AIT evaluation of serial
      concentrations of the fatty acids, lauric and myristic acids were selected for
      the safety and in vivo efficacy assays. No adverse effect was found in the local 
      lymph node assay in mice treated with lauric or myristic acid. Moreover, no
      clinical signs of systemic poisoning or dermatological, hematological or
      biochemical abnormalities were found in cattle after the topical application of 1
      % lauric acid. In the dose determination test, the 1% solution of this compound
      exhibited 86% efficacy in cattle naturally infested by a field population of
      Rhipicephalus microplus susceptible to all chemical groups, except synthetic
      pyrethroids. The efficacy of 1 % lauric acid was 53.4 % in the dose confirmation 
      test performed on another herd with a field R. microplus population resistant to 
      all chemical groups of acaricides. In conclusion, fatty acids are potential
      bioactive compounds for the control of R. microplus. Topically applied lauric
      acid (C12) exhibits in vivo acaricide activity against adults, nymphs and larvae 
      of R. (B) microplus and is safe for cattle.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Dos Santos, Larissa Bezerra
AU  - Dos Santos LB
AD  - School of Veterinary Medicine and Animal Science, Federal University of Mato
      Grosso do Sul, Campo Grande, Brazil.
FAU - Favero, Flavia Carolina
AU  - Favero FC
AD  - School of Veterinary Medicine and Animal Science, Federal University of Mato
      Grosso do Sul, Campo Grande, Brazil.
FAU - Conde, Mario Henrique
AU  - Conde MH
AD  - School of Veterinary Medicine and Animal Science, Federal University of Mato
      Grosso do Sul, Campo Grande, Brazil.
FAU - Freitas, Mariana Green
AU  - Freitas MG
AD  - School of Veterinary Medicine and Animal Science, Federal University of Mato
      Grosso do Sul, Campo Grande, Brazil.
FAU - Santos-Zanuncio, Vanessa Samudio
AU  - Santos-Zanuncio VS
AD  - Laboratory of Natural Products and Mass Spectrometry (LaPNEM), School of
      Pharmaceutical, Food and Nutrition Sciences (FACFAN), Federal University of Mato 
      Grosso do Sul (UFMS), Campo Grande, Brazil.
FAU - Carollo, Carlos Alexandre
AU  - Carollo CA
AD  - Laboratory of Natural Products and Mass Spectrometry (LaPNEM), School of
      Pharmaceutical, Food and Nutrition Sciences (FACFAN), Federal University of Mato 
      Grosso do Sul (UFMS), Campo Grande, Brazil.
FAU - Borges, Fernando de Almeida
AU  - Borges FA
AD  - School of Veterinary Medicine and Animal Science, Federal University of Mato
      Grosso do Sul, Campo Grande, Brazil. Electronic address: fernando.borges@ufms.br.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - Netherlands
TA  - Vet Parasitol
JT  - Veterinary parasitology
JID - 7602745
RN  - 0 (Acaricides)
RN  - 0 (Lauric Acids)
RN  - 1160N9NU9U (lauric acid)
SB  - IM
MH  - *Acaricides/adverse effects
MH  - Animals
MH  - Cattle
MH  - Cattle Diseases/*prevention & control
MH  - Female
MH  - Larva/growth & development
MH  - *Lauric Acids/adverse effects
MH  - Nymph/growth & development
MH  - *Rhipicephalus/growth & development
MH  - Tick Infestations/prevention & control/*veterinary
OTO - NOTNLM
OT  - Carboxylic acid
OT  - Green chemistry
OT  - Lauric acid
OT  - Rhipicephalus microplus
COIS- Declaration of Competing Interest The authors declare that they have no known
      competing financial interests or personal relationships that could have influence
      the work reported in this paper.
EDAT- 2020/04/07 06:00
MHDA- 2020/11/04 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - S0304-4017(20)30075-3 [pii]
AID - 10.1016/j.vetpar.2020.109095 [doi]
PST - ppublish
SO  - Vet Parasitol. 2020 Apr;280:109095. doi: 10.1016/j.vetpar.2020.109095. Epub 2020 
      Mar 26.


PMID- 32251871
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 413
DP  - 2020 Jun 15
TI  - Public opinion and legislations related to brain death, circulatory death and
      organ donation.
PG  - 116800
LID - S0022-510X(20)30136-2 [pii]
LID - 10.1016/j.jns.2020.116800 [doi]
AB  - BACKGROUND: It is poorly understood how public perception of the difference
      between brain death and circulatory death may influence attitudes towards organ
      donation. We investigated the public opinion on brain death versus circulatory
      death and documented inconsistencies in the legislations of countries with
      different cultural and socioeconomic backgrounds. METHODS: Using a crowdsourcing 
      approach, we randomized 1072 participants from 30 countries to a case report of
      organ donation after brain death or to one following circulatory death. Further, 
      we sampled guidelines from 24 countries and 5 continents. RESULTS: Of all
      participants, 73% stated they would be willing to donate all organs, while 16%
      would want to donate some of their organs. To increase the rate of donations, 47%
      would agree with organ donation without family consent as the default. Exposure
      to "brain death" was not associated with a lesser likelihood of participants
      agreeing with organ donation (82.1%) compared to "circulatory death" (81.9%;
      relative risk 1.02, 95% CI 0.99 to 1.03; p=.11). However, participants exposed to
      "circulatory death" were more certain that the patient was truly dead
      (87.9%+/-19.7%) than participants exposed to "brain death" (84.1%+/-22.7%;
      Cohen's d 0.18; p=0:004). Sampling of guidelines revealed large differences
      between countries regarding procedures required to confirm brain death and
      circulatory death, respectively. CONCLUSIONS: Implementation of organ donation
      after circulatory death is unlikely to negatively influence the willingness to
      donate organs, but legislation is still brain death-based in most countries. The 
      time seems ripe to increase the rate of circulatory death-based organ donation.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Othman, Marwan H
AU  - Othman MH
AD  - Departments of Neurology, Rigshospitalet, Copenhagen University Hospital,
      Denmark.
FAU - Dutta, Anirban
AU  - Dutta A
AD  - Department of Biomedical Engineering, University at Buffalo, State University of 
      New York, NY, United States.
FAU - Kondziella, Daniel
AU  - Kondziella D
AD  - Departments of Neurology, Rigshospitalet, Copenhagen University Hospital,
      Denmark; Faculty of Health and Medical Sciences, University of Copenhagen,
      Copenhagen, Denmark. Electronic address: daniel.kondziella@regionh.dk.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20200330
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
SB  - IM
MH  - Brain Death
MH  - Humans
MH  - *Public Opinion
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *Cardiac death
OT  - *Coma
OT  - *Consciousness
OT  - *Critical care
OT  - *Death
OT  - *Electroencephalography
OT  - *Ethics
OT  - *Intensive care
COIS- Declaration of Competing Interest The authors declare no conflict of interests.
EDAT- 2020/04/07 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/12/10 00:00 [received]
PHST- 2020/03/12 00:00 [revised]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - S0022-510X(20)30136-2 [pii]
AID - 10.1016/j.jns.2020.116800 [doi]
PST - ppublish
SO  - J Neurol Sci. 2020 Jun 15;413:116800. doi: 10.1016/j.jns.2020.116800. Epub 2020
      Mar 30.


PMID- 32251418
OWN - NLM
STAT- MEDLINE
DCOM- 20200710
LR  - 20200710
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Probing lasting cryoinjuries to oocyte-embryo transcriptome.
PG  - e0231108
LID - 10.1371/journal.pone.0231108 [doi]
AB  - Clinical applications of oocytes cryopreservation include preservation of future 
      fertility of young cancer patients, substitution of embryo freezing to avoid
      associated legal and ethical issues, and delaying childbearing years. While the
      outcome of oocyte cryopreservation has recently been improved, currently used
      vitrification method still suffer from increased biosafety risk and handling
      issues while slow freezing techniques yield overall low success. Understanding
      better the mechanism of cryopreservation-induced injuries may lead to development
      of more reliable and safe methods for oocyte cryopreservation. Using the mouse
      model, a microarray study was conducted on oocyte cryopreservation to identify
      cryoinjuries to transcriptionally active genome. To this end, metaphase II (MII) 
      oocytes were subjected to standard slow freezing, and then analyzed at the
      four-cell stage after embryonic genome activation. Non-frozen four-cell embryos
      served as controls. Differentially expressed genes were identified and validated 
      using RT-PCR. Embryos produced from the cryopreserved oocytes displayed 200
      upregulated and 105 downregulated genes, associated with the regulation of
      mitochondrial function, protein ubiquitination and maintenance, cellular response
      to stress and oxidative states, fatty acid and lipid regulation/metabolism, and
      cell cycle maintenance. These findings reveal previously unrecognized effects of 
      standard slow oocyte freezing on embryonic gene expression, which can be used to 
      guide improvement of oocyte cryopreservation methods.
FAU - Eroglu, Binnur
AU  - Eroglu B
AD  - Department of Neuroscience and Regenerative Medicine, Medical College of
      Georgia/Augusta University, Augusta, GA, United States of America.
FAU - Szurek, Edyta A
AU  - Szurek EA
AD  - Department of Neuroscience and Regenerative Medicine, Medical College of
      Georgia/Augusta University, Augusta, GA, United States of America.
FAU - Schall, Peter
AU  - Schall P
AD  - Department of Obstetrics, Gynecology and Reproductive Biology, College of
      Agriculture & Natural Resources/Michigan State University, East Lansing, MI,
      United States of America.
FAU - Latham, Keith E
AU  - Latham KE
AD  - Department of Obstetrics, Gynecology and Reproductive Biology, College of
      Agriculture & Natural Resources/Michigan State University, East Lansing, MI,
      United States of America.
FAU - Eroglu, Ali
AU  - Eroglu A
AUID- ORCID: 0000-0002-1402-6143
AD  - Department of Neuroscience and Regenerative Medicine, Medical College of
      Georgia/Augusta University, Augusta, GA, United States of America.
AD  - Department of Obstetrics and Gynecology, Medical College of Georgia/Augusta
      University, Augusta, GA, United States of America.
LA  - eng
GR  - R01 EB027203/EB/NIBIB NIH HHS/United States
GR  - R21 EB018538/EB/NIBIB NIH HHS/United States
GR  - T32 HD087166/HD/NICHD NIH HHS/United States
GR  - R24 OD012221/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Animals
MH  - Cryopreservation/*standards
MH  - Embryo, Mammalian/*physiology
MH  - Embryonic Development/genetics
MH  - Female
MH  - Fertilization in Vitro/methods
MH  - Freezing/*adverse effects
MH  - Gene Expression Regulation, Developmental
MH  - Humans
MH  - Male
MH  - Metaphase/genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred DBA
MH  - Oocytes/*physiology
MH  - Protein Interaction Maps/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Transcriptome/*genetics
PMC - PMC7135251
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/07 06:00
MHDA- 2020/07/11 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/11/30 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/07/11 06:00 [medline]
AID - 10.1371/journal.pone.0231108 [doi]
AID - PONE-D-19-33230 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 6;15(4):e0231108. doi: 10.1371/journal.pone.0231108.
      eCollection 2020.


PMID- 32251336
OWN - NLM
STAT- MEDLINE
DCOM- 20201125
LR  - 20210323
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Mar 23
TI  - Comparison of the short-term outcomes of using DST and PPH staplers in the
      treatment of grade III and IV hemorrhoids.
PG  - 5189
LID - 10.1038/s41598-020-62141-5 [doi]
AB  - Stapled hemorrhoidopexy has a few advantages such as less postoperative pain and 
      faster recovery compared with conventional hemorrhoidectomy. There are two major 
      devices used for stapled hemorrhoidopexy, PPH stapler (Ethicon EndoSurgery) and
      DST stapler (Covidien). This study was conducted to investigate the postoperative
      outcomes among patients with grade III and IV hemorrhoids who underwent
      hemorrhoidopexy with either of these two devices. A total of 242 consecutive
      patients underwent stapled hemorrhoidopexy with either PPH stapler (110 patients)
      or DST stapler (132 patients) at a single center in 2017. We performed a
      retrospective case-control study to compare the short-term postoperative outcomes
      and the complications between these two groups. After matching the cases in terms
      of age, gender, and the grade of hemorrhoids, there were 100 patients in each
      group (PPH versus DST). There were no significant differences in the
      postoperative visual analog scale (VAS) score and analgesic usage. Among
      complications, the incidence of anorectal stricture was significantly higher in
      the DST group (p = 0.02). Evaluation of the mucosal specimen showed that the
      total surface area, the muscle/mucosa ratio and the surface area of the muscle
      were also significantly higher in the DST group (p = 0.03). Further analysis of
      the DST group demonstrated that patients with anorectal stricture after surgery
      are younger than patients without anorectal stricture, and higher muscle/mucosa
      ratio (p = 0.03) and a higher surface area of the muscle (p = 0.03) also measured
      in the surgical specimen. The two devices provide similar outcomes of
      postoperative recovery. Patients who underwent DST stapled hemorrhoidopexy had a 
      higher incidence rate of stricture, larger area of muscle excision, and higher
      muscle/mucosa ratio in the surgical specimen. Further investigation is warranted 
      for a better understanding of the correlation between muscle excision and
      anorectal stricture.
FAU - Wang, Tzu-Hsuan
AU  - Wang TH
AD  - Division of colorectal surgery, Department of surgery, Taipei Medical University 
      Shuang-Ho Hospital, Taipei City, Taiwan.
FAU - Kiu, Kee-Thai
AU  - Kiu KT
AD  - Division of colorectal surgery, Department of surgery, Taipei Medical University 
      Shuang-Ho Hospital, Taipei City, Taiwan.
FAU - Yen, Min-Hsuan
AU  - Yen MH
AD  - Division of colorectal surgery, Department of surgery, Taipei Medical University 
      Shuang-Ho Hospital, Taipei City, Taiwan.
FAU - Chang, Tung-Cheng
AU  - Chang TC
AUID- ORCID: http://orcid.org/0000-0003-2185-0832
AD  - Division of colorectal surgery, Department of surgery, Taipei Medical University 
      Shuang-Ho Hospital, Taipei City, Taiwan. rotring810@yahoo.com.tw.
AD  - Department of surgery, school of medicine, college of medicine, Taipei Medical
      University, Taipei City, Taiwan. rotring810@yahoo.com.tw.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200323
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Analgesics)
RN  - 0 (Isoxazoles)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 9TUW81Y3CE (parecoxib)
SB  - IM
MH  - Acetaminophen/therapeutic use
MH  - Anal Canal/pathology
MH  - Analgesics/therapeutic use
MH  - Anus Diseases/etiology
MH  - Constriction, Pathologic/etiology
MH  - Equipment Design
MH  - Female
MH  - Hemorrhage/etiology
MH  - Hemorrhoidectomy/*instrumentation
MH  - Hemorrhoids/*surgery
MH  - Humans
MH  - Intestinal Mucosa/pathology
MH  - Isoxazoles/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Organ Size
MH  - Pain, Postoperative/drug therapy/etiology/prevention & control
MH  - Postoperative Complications/etiology
MH  - Retrospective Studies
MH  - *Surgical Staplers
MH  - Treatment Outcome
MH  - Urinary Retention/etiology
PMC - PMC7089945
EDAT- 2020/04/07 06:00
MHDA- 2020/11/26 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/11/21 00:00 [received]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/11/26 06:00 [medline]
AID - 10.1038/s41598-020-62141-5 [doi]
AID - 10.1038/s41598-020-62141-5 [pii]
PST - epublish
SO  - Sci Rep. 2020 Mar 23;10(1):5189. doi: 10.1038/s41598-020-62141-5.


PMID- 32251156
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20210209
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Aug
TI  - Cardiac Iron Overload by MRI in Children With B-Thalassemia Major and its
      Correlation With Cardiac Function by Echocardiography.
PG  - 398-402
LID - 10.1097/MPH.0000000000001786 [doi]
AB  - BACKGROUND: Serial echocardiography is strongly recommended in asymptomatic
      B-thalassemia major (TM) patients for early detection of subtle cardiac
      dysfunction. T2*magnetic resonance imaging (MRI) is a noninvasive measurement of 
      myocardial iron burden. Yet, it is not always available in many centers. Our
      study aimed to evaluate the myocardial function in TM patients using different
      echocardiographic modalities and to correlate these findings with cardiac T2*MRI.
      PATIENTS AND METHODS: This is a cross-sectional study that was carried out on 140
      children with a mean age of 10.9+/-3.7 years. One hundred children with TM and 40
      healthy children were matched for age and sex as a control group. Serum ferritin,
      serum iron, and iron-binding capacity were measured. Cardiac iron overload was
      assessed by T2*MRI and cardiac function was assessed by echocardiography. The
      local ethics committee approved the study. RESULTS: Among 100 children with TM,
      only 32% had cardiac iron overload of 8.525+/-5.45 detected by cardiac T2*MRI.
      Iron deposition correlated significantly with age. Markers of iron overload were 
      significantly correlated with cardiac T2*MRI. There were significantly lower
      values of myocardial performance index, longitudinal strain, circumferential
      strain, area strain, and radial strain in TM patients compared with the controls 
      (P<0.001). Only the myocardial performance index was correlated with T2*MRI.
      CONCLUSIONS: This study confirms that some parameters measured by tissue Doppler 
      imaging such as the myocardial performance index could be useful for the early
      detection of cardiac impairment in asymptomatic TM patients when cardiac MRI is
      lacking. Further studies on a large scale to identify other parameters with high 
      sensitivity are recommended.
FAU - El-Shanshory, Mohammed
AU  - El-Shanshory M
AD  - Department of Pediatrics, Tanta University Hospital, Tanta, Egypt.
FAU - Tolba, Osama
AU  - Tolba O
FAU - El-Shafiey, Rasha
AU  - El-Shafiey R
FAU - Elgamasy, Mohamed
AU  - Elgamasy M
FAU - Hablas, Nahed
AU  - Hablas N
FAU - Mawlana, Wegdan
AU  - Mawlana W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
SB  - IM
MH  - Adolescent
MH  - Case-Control Studies
MH  - Child
MH  - Cross-Sectional Studies
MH  - Egypt/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Diseases/diagnostic imaging/*epidemiology/pathology
MH  - Humans
MH  - Incidence
MH  - Iron Overload/diagnostic imaging/*epidemiology/pathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Prognosis
MH  - Ventricular Dysfunction, Left/diagnostic imaging/*epidemiology/pathology
MH  - beta-Thalassemia/*physiopathology
EDAT- 2020/04/07 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1097/MPH.0000000000001786 [doi]
AID - 00043426-202008000-00005 [pii]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2020 Aug;42(6):398-402. doi:
      10.1097/MPH.0000000000001786.


PMID- 32251003
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20210125
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 133
IP  - 12
DP  - 2020 Jun 20
TI  - Lung transplantation as therapeutic option in acute respiratory distress syndrome
      for coronavirus disease 2019-related pulmonary fibrosis.
PG  - 1390-1396
LID - 10.1097/CM9.0000000000000839 [doi]
AB  - BACKGROUND: Critical patients with the coronavirus disease 2019 (COVID-19), even 
      those whose nucleic acid test results had turned negative and those receiving
      maximal medical support, have been noted to progress to irreversible fatal
      respiratory failure. Lung transplantation (LT) as the sole therapy for end-stage 
      pulmonary fibrosis related to acute respiratory distress syndrome has been
      considered as the ultimate rescue therapy for these patients. METHODS: From
      February 10 to March 10, 2020, three male patients were urgently assessed and
      listed for transplantation. After conducting a full ethical review and after
      obtaining assent from the family of the patients, we performed three LT
      procedures for COVID-19 patients with illness durations of more than one month
      and extremely high sequential organ failure assessment scores. RESULTS: Two of
      the three recipients survived post-LT and started participating in a
      rehabilitation program. Pearls of the LT team collaboration and perioperative
      logistics were summarized and continually improved. The pathological results of
      the explanted lungs were concordant with the critical clinical manifestation, and
      provided insight towards better understanding of the disease. Government health
      affair systems, virology detection tools, and modern communication technology all
      play key roles towards the survival of the patients and their rehabilitation.
      CONCLUSIONS: LT can be performed in end-stage patients with respiratory failure
      due to COVID-19-related pulmonary fibrosis. If confirmed positive-turned-negative
      virology status without organ dysfunction that could contraindicate LT, LT
      provided the final option for these patients to avoid certain death, with proper 
      protection of transplant surgeons and medical staffs. By ensuring instant
      seamless care for both patients and medical teams, the goal of reducing the
      mortality rate and salvaging the lives of patients with COVID-19 can be attained.
FAU - Chen, Jing-Yu
AU  - Chen JY
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Qiao, Kun
AU  - Qiao K
AD  - Department of Thoracic Surgery, Shenzhen Third People's Hospital, Shenzhen,
      Guangdong 518100, China.
FAU - Liu, Feng
AU  - Liu F
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Wu, Bo
AU  - Wu B
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Xu, Xin
AU  - Xu X
AD  - Department of Thoracic Surgery/Oncology, State Key Laboratory and National
      Clinical Research Center for Respiratory Disease, The First Affiliated Hospital
      of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
FAU - Jiao, Guo-Qing
AU  - Jiao GQ
AD  - Department of Cardiothoracic Surgery, Wuxi People's Hospital Affiliated to
      Nanjing Medical University, Wuxi, Jiangsu 214023, China.
FAU - Lu, Rong-Guo
AU  - Lu RG
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Li, Hui-Xing
AU  - Li HX
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Zhao, Jin
AU  - Zhao J
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Huang, Jian
AU  - Huang J
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Critical Care Medicine, Zhongda Hospital, School of Medicine,
      Southeast University, Nanjing, Jiangsu 210009, China.
FAU - Lu, Xiao-Jie
AU  - Lu XJ
AD  - Wuxi Fifth Hospital, Wuxi, Jiangsu 214000, China.
FAU - Li, Jia-Shu
AU  - Li JS
AD  - Department of Respiratory Medicine and Critical Care Medicine, The First People's
      Hospital of Lianyungang City, Lianyungang, Jiangsu 222061, China.
FAU - Jiang, Shu-Yun
AU  - Jiang SY
AD  - Department of Critical Care Medicine, Wuxi People's Hospital Affiliated to
      Nanjing Medical University, Wuxi, Jiangsu 214023, China.
FAU - Wang, Da-Peng
AU  - Wang DP
AD  - Department of Critical Care Medicine, Wuxi People's Hospital Affiliated to
      Nanjing Medical University, Wuxi, Jiangsu 214023, China.
FAU - Hu, Chun-Xiao
AU  - Hu CX
AD  - Department of Anesthesiology, Wuxi People's Hospital Affiliated to Nanjing
      Medical University, Wuxi, Jiangsu 214023, China.
FAU - Wang, Gui-Long
AU  - Wang GL
AD  - Department of Anesthesiology, Wuxi People's Hospital Affiliated to Nanjing
      Medical University, Wuxi, Jiangsu 214023, China.
FAU - Huang, Dong-Xiao
AU  - Huang DX
AD  - Department of Anesthesiology, Wuxi People's Hospital Affiliated to Nanjing
      Medical University, Wuxi, Jiangsu 214023, China.
FAU - Jiao, Guo-Hui
AU  - Jiao GH
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Wei, Dong
AU  - Wei D
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Ye, Shu-Gao
AU  - Ye SG
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Huang, Jian-An
AU  - Huang JA
AD  - Department of Respiratory Medicine, The First Affiliated Hospital of Soochow
      University, Suzhou, Jiangsu 215006, China.
FAU - Zhou, Li
AU  - Zhou L
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - Zhang, Xiao-Qin
AU  - Zhang XQ
AD  - Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical
      University, Wuxi, Jiangsu 214023, China.
FAU - He, Jian-Xing
AU  - He JX
AD  - Department of Thoracic Surgery/Oncology, State Key Laboratory and National
      Clinical Research Center for Respiratory Disease, The First Affiliated Hospital
      of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
CIN - Eur Respir J. 2020 Aug 27;56(2):. PMID: 32631838
CIN - J Heart Lung Transplant. 2020 Sep;39(9):983-985. PMID: 32718694
MH  - Aged
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*complications/mortality
MH  - Extracorporeal Membrane Oxygenation
MH  - Humans
MH  - Lung Transplantation/*methods
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*complications/mortality
MH  - Pulmonary Fibrosis/mortality/*surgery
MH  - Respiratory Distress Syndrome/mortality/*surgery
MH  - SARS-CoV-2
PMC - PMC7339336
EDAT- 2020/04/07 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1097/CM9.0000000000000839 [doi]
AID - 00029330-202006200-00002 [pii]
PST - ppublish
SO  - Chin Med J (Engl). 2020 Jun 20;133(12):1390-1396. doi:
      10.1097/CM9.0000000000000839.


PMID- 32250989
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200416
IS  - 1538-9782 (Electronic)
IS  - 0887-6274 (Linking)
VI  - 34
IP  - 3
DP  - 2020 May/Jun
TI  - Ethical Decision Making in Critical Care: Communication, Coordination of Care,
      and the Practice of the Clinical Nurse Specialist.
PG  - 93-95
LID - 10.1097/NUR.0000000000000520 [doi]
FAU - Buhagiar, Teresa M
AU  - Buhagiar TM
AD  - Author Affiliations: Inpatient Palliative Care (Ms Buhagiar), Kaiser Permanente
      Santa Rosa, California; Senior Nursing Student (Mr Schoenlein), Pacific Lutheran 
      University, Tacoma, Washington; and Inpatient Palliative Care Team (Ms Smith),
      Kaiser Permanente Redwood City, California.
FAU - Schoenlein, Malcolm H
AU  - Schoenlein MH
FAU - Smith, Deborah S
AU  - Smith DS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Nurse Spec
JT  - Clinical nurse specialist CNS
JID - 8709115
MH  - Communication
MH  - Critical Care/*ethics/organization & administration
MH  - Decision Making/*ethics
MH  - Humans
MH  - Nurse Clinicians/*psychology
MH  - Practice Patterns, Nurses'
EDAT- 2020/04/07 06:00
MHDA- 2020/04/17 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
AID - 10.1097/NUR.0000000000000520 [doi]
AID - 00002800-202005000-00003 [pii]
PST - ppublish
SO  - Clin Nurse Spec. 2020 May/Jun;34(3):93-95. doi: 10.1097/NUR.0000000000000520.


PMID- 32250961
OWN - NLM
STAT- Publisher
LR  - 20220413
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
DP  - 2020 Apr 5
TI  - COVID-19 Related Misinformation on Social Media: A Qualitative Study from Iran.
LID - 10.2196/18932 [doi]
AB  - BACKGROUND: Background: During outbreaks of diseases a great amount of health
      threatening misinformation is produced and released. In the web-2 era much of
      this misinformation is disseminated via social media where information could
      spread easily and quickly. Monitoring social media content provides crucial
      insights for health managers to manage the crisis. OBJECTIVE: Objective: Given
      the misinformation surrounding COVID-19 outbreak, this study was aimed to analyze
      contents of the most commonly used social networks in Iran that is among the
      affected countries. METHODS: Methods: A social media monitoring conducted through
      a qualitative design to analyze the discussions of social media users about the
      content related to COVID-19 transferred via Iranian medical faculty members`
      groups in Telegram and Whats App during Feb 20 to March 20, 2020 emphasizing the 
      misinformation. Discourse analysis was applied and the written dialogues and
      discussions regarding misinformation about different aspects of the outbreak
      between medical faculty members all over the country were analyzed. RESULTS:
      Results: Cultural factors, demand pressure for information during the crisis, the
      easiness of information dissemination via social networks, marketing incentives
      and the poor legal supervision of online contents are the main reasons of
      misinformation dissemination. Disease statistics; treatments, vaccines and
      medicines; prevention and protection methods; dietary recommendations and disease
      transmission ways are the main subjective categories of releasing misinformation 
      regarding novel coronavirus outbreak. Consequences of misinformation
      dissemination regarding disease include psychosocial; economic; health status;
      health system and ethical ones. Active and effective presence of health
      professionals and authorities on social media during the crisis and the
      improvement of public health literacy in the long term are the most recommended
      strategies for dealing with issues related to misinformation. CONCLUSIONS:
      Conclusion: This study contributes the management of COVID-19 outbreak trough
      providing applicable insights for health managers to manage public information in
      this challenging time. CLINICALTRIAL:
FAU - Bastani, Peivand
AU  - Bastani P
AD  - Shiraz university of medical sciences, Shiraz university of medical sciences,
      Shiraz, IR.
FAU - Bahrami, Mohammad Amin
AU  - Bahrami MA
AD  - Shiraz university of medical sciences, Shiraz university of medical sciences,
      Shiraz, IR.
LA  - eng
PT  - Journal Article
DEP - 20200405
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
EDAT- 2020/04/07 06:00
MHDA- 2020/04/07 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/04/07 06:00 [medline]
AID - 10.2196/18932 [doi]
PST - aheadofprint
SO  - J Med Internet Res. 2020 Apr 5. doi: 10.2196/18932.


PMID- 32250660
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20210502
IS  - 0250-832X (Print)
IS  - 0250-832X (Linking)
VI  - 49
IP  - 4
DP  - 2020 May 1
TI  - A comparative study on image quality of two digital intraoral
      sensors-methodological, ethical and statistical issues.
PG  - 20200054
LID - 10.1259/dmfr.20200054 [doi]
FAU - Coelho-Silva, Fernanda
AU  - Coelho-Silva F
AUID- ORCID: http://orcid.org/0000-0001-6107-647X
AD  - Department of Oral Diagnosis, Piracicaba Dental School, State University of
      Campinas, Piracicaba, SP, Brazil.
FAU - Fontenele, Rocharles Cavalcante
AU  - Fontenele RC
AD  - Department of Oral Diagnosis, Piracicaba Dental School, State University of
      Campinas, Piracicaba, SP, Brazil.
FAU - de-Azevedo-Vaz, Sergio Lins
AU  - de-Azevedo-Vaz SL
AD  - Department of Oral Diagnosis, Piracicaba Dental School, State University of
      Campinas, Piracicaba, SP, Brazil.
AD  - Department of Clinical Dentistry, Federal University of Espirito Santo, Vitoria, 
      ES, Brazil.
FAU - Freitas, Deborah Queiroz
AU  - Freitas DQ
AD  - Department of Clinical Dentistry, Federal University of Espirito Santo, Vitoria, 
      ES, Brazil.
LA  - eng
PT  - Letter
DEP - 20200406
PL  - England
TA  - Dentomaxillofac Radiol
JT  - Dento maxillo facial radiology
JID - 7609576
MH  - *Radiography, Dental, Digital
PMC - PMC7213525
EDAT- 2020/04/07 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1259/dmfr.20200054 [doi]
PST - ppublish
SO  - Dentomaxillofac Radiol. 2020 May 1;49(4):20200054. doi: 10.1259/dmfr.20200054.
      Epub 2020 Apr 6.


PMID- 32250354
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 157
DP  - 2020 Mar 18
TI  - Learning Modern Laryngeal Surgery in a Dissection Laboratory.
LID - 10.3791/60407 [doi]
AB  - Surgery for laryngeal malignancies requires millimetric accuracy from the
      different endoscopic and open techniques available. Practice of this surgery is
      almost completely reserved to a few referral centers that deal with a large
      proportion of this pathology. Practice on human specimens is not always possible 
      for ethical, economic, or availability reasons. The aim of this study is to
      provide a reproducible method for the organization of a laryngeal laboratory on
      ex vivo animal models where it is possible to approach, learn, and refine
      laryngeal techniques. Porcine and ovine larynges are ideal, affordable, models to
      simulate laryngeal surgery given their similarity to the human larynx in their
      anatomical layout and tissue composition. Herein, the surgical steps of transoral
      laser surgery, open partial horizontal laryngectomy, and total laryngectomy are
      reported. The merging of endoscopic and exoscopic views guarantees an inside-out 
      perspective, which is vital for the comprehension of the complex laryngeal
      anatomy. The method was successfully adopted during three sessions of a
      dissection course "Lary-Gym". Further perspectives on robotic surgical training
      are described.
FAU - Crosetti, Erika
AU  - Crosetti E
AD  - Head and Neck Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS.
FAU - Fantini, Marco
AU  - Fantini M
AD  - Head and Neck Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS.
FAU - Lancini, Davide
AU  - Lancini D
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, University of Brescia;
      lancinidavide@gmail.com.
FAU - Manca, Andrea
AU  - Manca A
AD  - Head and Neck Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS.
FAU - Succo, Giovanni
AU  - Succo G
AD  - Head and Neck Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS; Department of 
      Oncology, University of Turin.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
DEP - 20200318
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
SB  - IM
MH  - Animals
MH  - Dissection/*education/methods
MH  - Larynx/anatomy & histology/*surgery
MH  - Otorhinolaryngologic Surgical Procedures/*education/methods
MH  - Robotic Surgical Procedures/education
MH  - Sheep
MH  - Simulation Training
MH  - Swine
EDAT- 2020/04/07 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
AID - 10.3791/60407 [doi]
PST - epublish
SO  - J Vis Exp. 2020 Mar 18;(157). doi: 10.3791/60407.


PMID- 32250321
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1877-718X (Electronic)
IS  - 1877-7171 (Linking)
VI  - 10
IP  - 2
DP  - 2020
TI  - Innovative Recruitment Strategies to Increase Diversity of Participation in
      Parkinson's Disease Research: The Fox Insight Cohort Experience.
PG  - 665-675
LID - 10.3233/JPD-191901 [doi]
AB  - BACKGROUND: Clinical research in Parkinson's disease (PD) faces practical and
      ethical challenges due to two interrelated problems: participant
      under-recruitment and lack of diversity. Fox Insight (FI) is a web-based
      longitudinal study collecting patient-reported outcomes and genetic data
      worldwide to inform therapeutic studies. FI's online platform provides an
      opportunity to evaluate online strategies for recruiting large, diverse research 
      cohorts. OBJECTIVE: This project aimed to determine 1) whether FI's digital
      marketing was associated with increased enrollment overall and from
      under-represented patient groups, compared to traditional recruitment methods; 2)
      the clinical and demographic characteristics of samples recruited online, and 3) 
      the cost of this online recruitment. METHOD: FI recruitment during a 6-week
      baseline period without digital promotion was compared to recruitment during
      several periods of digital outreach. Separate online recruiting intervals
      included general online study promotion and unique Facebook and Google ad
      campaigns targeting under-represented subgroups: early PD, late/advanced PD, and 
      residents of underrepresented/rural geographic areas. RESULTS: Early PD, late PD,
      and geotargeting campaigns enrolled more individuals in their respective cohorts 
      compared to baseline. All online campaigns also yielded greater total FI
      enrollment, attracting more participants who were non-White, Hispanic, older,
      female, and had lower educational attainment and income, and more medical
      comorbidities. Cost per new participant ranged from $21 (Facebook) to $108
      (Google). CONCLUSION: Digital marketing may allow researchers to increase,
      accelerate, and diversify recruitment for PD clinical studies, by tailoring
      digital ads to target PD cohort characteristics.
FAU - Dobkin, Roseanne D
AU  - Dobkin RD
AD  - Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
FAU - Amondikar, Ninad
AU  - Amondikar N
AD  - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
FAU - Kopil, Catherine
AU  - Kopil C
AD  - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
FAU - Caspell-Garcia, Chelsea
AU  - Caspell-Garcia C
AD  - University of Iowa, Iowa City, IA, USA.
FAU - Brown, Ethan
AU  - Brown E
AD  - University of California, & San Francisco Veterans Affairs Medical Care Plan, San
      Francisco, San Francisco, CA, USA.
FAU - Chahine, Lana M
AU  - Chahine LM
AD  - University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Marras, Connie
AU  - Marras C
AD  - Toronto Western Hospital, Toronto, Canada.
FAU - Dahodwala, Nabila
AU  - Dahodwala N
AD  - University of Pennsylvania, Philadelphia PA, USA.
FAU - Mantri, Sneha
AU  - Mantri S
AD  - Duke University, Durham, NC, USA.
FAU - Standaert, David G
AU  - Standaert DG
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Dean, Marissa
AU  - Dean M
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Shoulson, Ira
AU  - Shoulson I
AD  - University of Rochester, Rochester, NY, USA.
FAU - Marek, Kenneth
AU  - Marek K
AD  - Institute for Neurodegenerative Disorders, New Haven, CT, USA.
FAU - Katz, Andrea
AU  - Katz A
AD  - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
FAU - Korell, Monica
AU  - Korell M
AD  - University of California, & San Francisco Veterans Affairs Medical Care Plan, San
      Francisco, San Francisco, CA, USA.
FAU - Riley, Lindsey
AU  - Riley L
AD  - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
FAU - Tanner, Caroline M
AU  - Tanner CM
AD  - University of California, & San Francisco Veterans Affairs Medical Care Plan, San
      Francisco, San Francisco, CA, USA.
CN  - Fox Insight Study
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Parkinsons Dis
JT  - Journal of Parkinson's disease
JID - 101567362
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Biomedical Research/economics/ethics/standards
MH  - *Cultural Diversity
MH  - Female
MH  - Humans
MH  - *Internet/economics
MH  - Longitudinal Studies
MH  - Male
MH  - *Marketing of Health Services/economics/standards
MH  - Middle Aged
MH  - *Minority Groups
MH  - *Parkinson Disease
MH  - Patient Reported Outcome Measures
MH  - *Patient Selection/ethics
MH  - *Social Media/economics
MH  - Young Adult
PMC - PMC7242847
OTO - NOTNLM
OT  - *Parkinson's disease
OT  - *clinical trial
OT  - *diversity
OT  - *recruitment
EDAT- 2020/04/07 06:00
MHDA- 2021/07/27 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - JPD191901 [pii]
AID - 10.3233/JPD-191901 [doi]
PST - ppublish
SO  - J Parkinsons Dis. 2020;10(2):665-675. doi: 10.3233/JPD-191901.


PMID- 32250295
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
VI  - 76
IP  - 2
DP  - 2020
TI  - Ethical Issues Raised by the Introduction of Artificial Companions to Older
      Adults with Cognitive Impairment: A Call for Interdisciplinary Collaborations.
PG  - 445-455
LID - 10.3233/JAD-190952 [doi]
AB  - Due to the high costs of providing long-term care to older adults with cognitive 
      impairment, artificial companions are increasingly considered as a cost-efficient
      way to provide support. Artificial companions can comfort, entertain, and inform,
      and even induce a sense of being in a close relationship. Sensors and algorithms 
      are increasingly leading to applications that exude a life-like feel. We focus on
      a case study of an artificial companion for people with cognitive impairment.
      This companion is an avatar on an electronic tablet that is displayed as a dog or
      a cat. Whereas artificial intelligence guides most artificial companions, this
      application also relies on technicians "behind" the on-screen avatar, who via
      surveillance, interact with users. This case is notable because it particularly
      illustrates the tension between the endless opportunities offered by technology
      and the ethical issues stemming from limited regulations. Reviewing the case
      through the lens of biomedical ethics, concerns of deception, monitoring and
      tracking, as well as informed consent and social isolation are raised by the
      introduction of this technology to users with cognitive impairment. We provide a 
      detailed description of the case, review the main ethical issues and present two 
      theoretical frameworks, the "human-driven technology" platform and the
      emancipatory gerontology framework, to inform the design of future applications.
FAU - Portacolone, Elena
AU  - Portacolone E
AD  - Institute for Health & Aging, University of California San Francisco, San
      Francisco, CA, USA.
FAU - Halpern, Jodi
AU  - Halpern J
AD  - School of Public Health, University of California Berkeley, Berkeley, CA, USA.
FAU - Luxenberg, Jay
AU  - Luxenberg J
AD  - On Lok Lifeways, San Francisco, CA, USA.
FAU - Harrison, Krista L
AU  - Harrison KL
AD  - Division of Geriatric Medicine, University of California San Francisco, San
      Francisco, CA, USA.
AD  - Philip R. Lee Institute for Health Policy Studies, University of California San
      Francisco, San Francisco, CA, USA.
FAU - Covinsky, Kenneth E
AU  - Covinsky KE
AD  - Division of Geriatric Medicine, University of California San Francisco, San
      Francisco, CA, USA.
LA  - eng
GR  - K01 AG059831/AG/NIA NIH HHS/United States
GR  - L30 AG060590/AG/NIA NIH HHS/United States
GR  - K01 AG049102/AG/NIA NIH HHS/United States
GR  - R56 AG062165/AG/NIA NIH HHS/United States
GR  - P30 AG044281/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
SB  - IM
CIN - J Alzheimers Dis. 2020;76(2):457-460. PMID: 32568199
MH  - Aged
MH  - Animals
MH  - Artificial Intelligence/*ethics/standards
MH  - Cats
MH  - Cognitive Dysfunction/psychology/*therapy
MH  - Dogs
MH  - *Friends/psychology
MH  - Humans
MH  - Patient Care Team/*ethics/standards
MH  - Robotics/*ethics/standards
PMC - PMC7437496
MID - NIHMS1617534
OTO - NOTNLM
OT  - *Dementia
OT  - *ethics
OT  - *robots
OT  - *technology
EDAT- 2020/04/07 06:00
MHDA- 2021/05/08 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - JAD190952 [pii]
AID - 10.3233/JAD-190952 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2020;76(2):445-455. doi: 10.3233/JAD-190952.


PMID- 32250281
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20210215
IS  - 2369-2960 (Electronic)
IS  - 2369-2960 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Apr 6
TI  - Conducting Clinical Research During the COVID-19 Pandemic: Investigator and
      Participant Perspectives.
PG  - e18887
LID - 10.2196/18887 [doi]
AB  - As the medical landscape changes daily with the coronavirus disease (COVID-19)
      pandemic, clinical researchers are caught off-guard and are forced to make
      decisions on research visits in their ongoing clinical trials. Although there is 
      some guidance from local and national organizations, the principal investigator
      (PI) is ultimately responsible for determining the risk-benefit ratio of
      conducting, rescheduling, or cancelling each research visit. The PI should take
      into consideration the ethical principles of research, local/national guidance,
      the community risk of the pandemic in their locale, staffing strain, and the risk
      involved to each participant, to ultimately decide on the course of action. While
      balancing the rights and protection of the human subject, we seldom examine
      patients' views and opinions about their scheduled research visit(s). This
      article discusses the ethical principles of beneficence and autonomy in helping
      the decision-making process. We discuss ways to weigh-in local and national
      guidance, staffing strain, and institutional support into the decision-making
      process and outline potential changes needed for regulatory bodies depending on
      the decision. Further, we discuss the need to weigh-in the individual
      risk-benefit ratio for each participant and present a decision tree to navigate
      this complex process. Finally, we examine participant and caregiver perspectives 
      on their fears, sense of preparedness, and factors that they consider before
      deciding whether to keep or postpone the research appointments. This entry also
      provides PIs ways to support their research participants in both scenarios,
      including provision of psychological support.
CI  - (c)Prasad R Padala, Ashlyn M Jendro, Kalpana P Padala. Originally published in
      JMIR Public Health and Surveillance (http://publichealth.jmir.org), 06.04.2020.
FAU - Padala, Prasad R
AU  - Padala PR
AUID- ORCID: 0000-0003-1921-9806
AD  - Geriatric Research Education and Clinical Center, Eugene J Towbin Healthcare
      Center, Central Arkansas Veterans Healthcare System, North Little Rock, AR,
      United States.
AD  - Department of Psychiatry, University of Arkansas for Medical Sciences, Little
      Rock, AR, United States.
AD  - Department of Geriatrics, University of Arkansas for Medical Sciences, Little
      Rock, AR, United States.
FAU - Jendro, Ashlyn M
AU  - Jendro AM
AUID- ORCID: 0000-0003-0059-6636
AD  - Geriatric Research Education and Clinical Center, Eugene J Towbin Healthcare
      Center, Central Arkansas Veterans Healthcare System, North Little Rock, AR,
      United States.
FAU - Padala, Kalpana P
AU  - Padala KP
AUID- ORCID: 0000-0001-6021-0593
AD  - Geriatric Research Education and Clinical Center, Eugene J Towbin Healthcare
      Center, Central Arkansas Veterans Healthcare System, North Little Rock, AR,
      United States.
AD  - Department of Geriatrics, University of Arkansas for Medical Sciences, Little
      Rock, AR, United States.
LA  - eng
GR  - I01 RX002638/RX/RRD VA/United States
GR  - I01 RX002961/RX/RRD VA/United States
PT  - Journal Article
DEP - 20200406
PL  - Canada
TA  - JMIR Public Health Surveill
JT  - JMIR public health and surveillance
JID - 101669345
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Caregivers/psychology
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - Humans
MH  - Medical Staff/psychology
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - Research Personnel
MH  - Risk Assessment
MH  - SARS-CoV-2
PMC - PMC7141248
OTO - NOTNLM
OT  - *COVID-19
OT  - *clinical research
OT  - *ethics
OT  - *infectious disease
OT  - *outbreak
OT  - *pandemic
OT  - *public health
EDAT- 2020/04/07 06:00
MHDA- 2020/04/15 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
AID - v6i2e18887 [pii]
AID - 10.2196/18887 [doi]
PST - epublish
SO  - JMIR Public Health Surveill. 2020 Apr 6;6(2):e18887. doi: 10.2196/18887.


PMID- 32250273
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2368-7959 (Print)
IS  - 2368-7959 (Linking)
VI  - 7
IP  - 4
DP  - 2020 Apr 6
TI  - Portuguese Psychologists' Attitudes Toward Internet Interventions: Exploratory
      Cross-Sectional Study.
PG  - e16817
LID - 10.2196/16817 [doi]
AB  - BACKGROUND: Despite the significant body of evidence on the efficacy and
      cost-effectiveness of internet interventions, the implementation of such programs
      in Portugal is virtually non-existent. In addition, Portuguese psychologists' use
      and their attitudes towards such interventions is largely unknown. OBJECTIVE: The
      aim of this study was to explore Portuguese psychologists' knowledge, training,
      use and attitudes towards internet interventions; to investigate perceived
      advantages and limitations of such interventions; identify potential drivers and 
      barriers impacting implementation; and study potential factors associated to
      previous use and attitudes towards internet interventions. METHODS: An online
      cross-sectional survey was developed by the authors and disseminated by the
      Portuguese Psychologists Association to its members. RESULTS: A total of 1077
      members of the Portuguese Psychologists Association responded to the
      questionnaire between November 2018 and February 2019. Of these, 37.2% (N=363)
      were familiar with internet interventions and 19.2% (N=188) considered having the
      necessary training to work within the field. 29.6% (N=319) of participants
      reported to have used some form of digital technology to deliver care in the
      past. Telephone (23.8%; N=256), e-mail (16.2%; N=175) and SMS (16.1%; N=173)
      services were among the most adopted forms of digital technology, while guided
      (1.3%; N=14) and unguided (1.5%; N=16) internet interventions were rarely used.
      Accessibility (79.9%; N=860), convenience (45.7%; N=492) and cost-effectiveness
      (45.5%; N=490) were considered the most important advantages of internet
      interventions. Conversely, ethical concerns (40.7%; N=438), client's ICT
      illiteracy (43.2%; N=465) and negative attitudes towards internet interventions
      (37%; N=398) were identified as the main limitations. An assessment of
      participants attitudes towards internet interventions revealed a slightly
      negative/neutral stance (Median=46.21; SD=15.06) and revealed greater
      acceptability towards blended treatment interventions (62.9%; N=615) when
      compared to standalone internet interventions (18.6%; N=181). Significant
      associations were found between knowledge (chi(2)4=90.4; P<.001), training
      (chi(2)4=94.6; P<.001), attitudes (chi(2)3=38.4; P<.001) and previous use of
      internet interventions and between knowledge (chi(2)12=109.7; P<.001), training
      (chi(2)12=64.7; P<.001) and attitudes towards such interventions, with
      psychologists reporting to be ignorant and not having adequate training in the
      field, being more likely to present more negative attitudes towards these
      interventions and not having prior experience in its implementation. CONCLUSIONS:
      This study revealed that most Portuguese psychologists are not familiar with and 
      have no training or prior experience using internet interventions and had a
      slightly negative/neutral attitude towards such interventions. There was greater 
      acceptability towards blended treatment interventions compared to standalone
      internet interventions. Lack of knowledge and training were identified as the
      main barriers to overcome, underlining the need of promoting awareness and
      training initiatives to ensure internet interventions successful implementation.
CI  - (c)Cristina Mendes-Santos, Elisabete Weiderpass, Rui Santana, Gerhard Andersson. 
      Originally published in JMIR Mental Health (http://mental.jmir.org), 06.04.2020.
FAU - Mendes-Santos, Cristina
AU  - Mendes-Santos C
AUID- ORCID: https://orcid.org/0000-0003-1437-9157
AD  - Department of Culture and Society, Linkoping University, Linkoping, Sweden.
AD  - NOVA National School of Public Health, Public Health Research Centre,
      Universidade Nova de Lisboa, Lisboa, Portugal.
FAU - Weiderpass, Elisabete
AU  - Weiderpass E
AUID- ORCID: https://orcid.org/0000-0003-2237-0128
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Santana, Rui
AU  - Santana R
AUID- ORCID: https://orcid.org/0000-0003-1370-3242
AD  - NOVA National School of Public Health, Public Health Research Centre,
      Universidade Nova de Lisboa, Lisboa, Portugal.
FAU - Andersson, Gerhard
AU  - Andersson G
AUID- ORCID: https://orcid.org/0000-0003-4753-6745
AD  - Department of Behavioural Sciences and Learning, Linkoping University, Linkoping,
      Sweden.
AD  - Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet,
      Stockholm, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - Canada
TA  - JMIR Ment Health
JT  - JMIR mental health
JID - 101658926
PMC - PMC7171568
OTO - NOTNLM
OT  - Attitudes Toward Internet Interventions Survey (ATIIS)
OT  - EU
OT  - Portugal
OT  - attitudes
OT  - e-mental health
OT  - internet interventions
OT  - psychologists
EDAT- 2020/04/07 06:00
MHDA- 2020/04/07 06:01
CRDT- 2020/04/07 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2019/12/10 00:00 [revised]
PHST- 2020/04/07 06:00 [entrez]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/04/07 06:01 [medline]
AID - v7i4e16817 [pii]
AID - 10.2196/16817 [doi]
PST - epublish
SO  - JMIR Ment Health. 2020 Apr 6;7(4):e16817. doi: 10.2196/16817.


PMID- 32250233
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 2212-3946 (Electronic)
IS  - 1574-888X (Linking)
VI  - 15
IP  - 6
DP  - 2020
TI  - Regulation of Stem Cell-Based Research in India in Comparison with the US, EU and
      other Asian Countries: Current Issues and Future Perspectives.
PG  - 492-508
LID - 10.2174/1574888X15666200402134750 [doi]
AB  - Stem cell therapy is applicable for repair and replacement of damaged cells and
      tissues. Apart from transplanting cells to the body, the stem cell therapy
      directs them to grow new and healthy tissues. Stem cells in the area of
      regenerative medicines hold tremendous promise that may help to regenerate the
      damaged tissues and heal various diseases like multiple sclerosis, heart
      diseases, Parkinson's disease, and so on. To prove the safety, efficacy, and for 
      the requirement of a licence for manufacturing and sale, all the stem cell
      therapies should pass the required criteria and undergo certain examinations of
      the regulatory agencies. The regulatory authorities review the manufacturing
      procedures of products to assure its purity and potency. This review summarizes
      the comparative critical evaluations of existing regulations and developments on 
      the stem cells research in India, USA, EU and Asian regions and also discusses
      the challenges that have to be overcome and the important points that should be
      understood to position India as a source of the perspective nation in stem cells 
      around the world.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at
      epub@benthamscience.net.
FAU - Jose, Jobin
AU  - Jose J
AD  - Department of Pharmaceutical Regulatory Affairs and Pharmaceutics, NGSM Institute
      of Pharmaceutical Sciences, NITTE Deemed to be University, Paneer, Mangalore
      575018, Karnataka, India.
FAU - George, Teena
AU  - George T
AD  - Department of Pharmaceutical Regulatory Affairs and Pharmaceutics, NGSM Institute
      of Pharmaceutical Sciences, NITTE Deemed to be University, Paneer, Mangalore
      575018, Karnataka, India.
FAU - Thomas, Aaron M
AU  - Thomas AM
AD  - Department of Pharmaceutical Regulatory Affairs and Pharmaceutics, NGSM Institute
      of Pharmaceutical Sciences, NITTE Deemed to be University, Paneer, Mangalore
      575018, Karnataka, India.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Stem Cell Res Ther
JT  - Current stem cell research & therapy
JID - 101272517
SB  - IM
MH  - *European Union
MH  - Humans
MH  - India
MH  - Marketing
MH  - National Institutes of Health (U.S.)
MH  - Stem Cell Research/ethics/*legislation & jurisprudence
MH  - United States
OTO - NOTNLM
OT  - Asia
OT  - EU
OT  - India
OT  - Stem cells
OT  - USA
OT  - ethical considerations
EDAT- 2020/04/07 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/10/11 00:00 [received]
PHST- 2019/11/20 00:00 [revised]
PHST- 2019/11/29 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - CSCR-EPUB-105619 [pii]
AID - 10.2174/1574888X15666200402134750 [doi]
PST - ppublish
SO  - Curr Stem Cell Res Ther. 2020;15(6):492-508. doi:
      10.2174/1574888X15666200402134750.


PMID- 32250204
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1464-505X (Electronic)
IS  - 0003-3790 (Linking)
VI  - 77
IP  - 1
DP  - 2020 Jan
TI  - Preludes to the Inquisition: self-censorship in medieval astrological discourse.
PG  - 10-25
LID - 10.1080/00033790.2020.1714283 [doi]
AB  - Astrologers have exercised self-censorship throughout the centuries in order to
      fend off criticism. This was largely for religious reasons, but social,
      political, and ethical motivations also have to be taken into account. This paper
      explores the main reasons that led astrologers to increase censorship in their
      writings in the decades that preceded the Church's regulations and offers some
      examples of this self-imposed restraint in astrological judgements.
FAU - Avelar de Carvalho, Helena
AU  - Avelar de Carvalho H
AUID- ORCID: https://orcid.org/0000-0003-0256-4144
AD  - Centro Interuniversitario de Historia das Ciencias e da Tecnologia, Faculdade de 
      Ciencias da Universidade de Lisboa, Lisboa, Portugal.
LA  - eng
PT  - Historical Article
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - Ann Sci
JT  - Annals of science
JID - 0372361
MH  - Astrology/*history
MH  - *Censorship, Research
MH  - Christianity/*history
MH  - Europe
MH  - History, 15th Century
MH  - History, Medieval
MH  - *Religion and Science
OTO - NOTNLM
OT  - Astrology
OT  - Index
OT  - Portuguese Inquisition
OT  - papal bulls
OT  - self-censorship
EDAT- 2020/04/07 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1080/00033790.2020.1714283 [doi]
PST - ppublish
SO  - Ann Sci. 2020 Jan;77(1):10-25. doi: 10.1080/00033790.2020.1714283. Epub 2020 Apr 
      6.


PMID- 32249968
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1097-0258 (Electronic)
IS  - 0277-6715 (Linking)
VI  - 39
IP  - 15
DP  - 2020 Jul 10
TI  - A new conditional performance score for the evaluation of adaptive group
      sequential designs with sample size recalculation.
PG  - 2067-2100
LID - 10.1002/sim.8534 [doi]
AB  - In standard clinical trial designs, the required sample size is fixed in the
      planning stage based on initial parameter assumptions. It is intuitive that the
      correct choice of the sample size is of major importance for an ethical
      justification of the trial. The required parameter assumptions should be based on
      previously published results from the literature. In clinical practice, however, 
      historical data often do not exist or show highly variable results. Adaptive
      group sequential designs allow a sample size recalculation after a planned
      unblinded interim analysis in order to adjust the sample size during the ongoing 
      trial. So far, there exist no unique standards to assess the performance of
      sample size recalculation rules. Single performance criteria commonly reported
      are given by the power and the average sample size; the variability of the
      recalculated sample size and the conditional power distribution are usually
      ignored. Therefore, the need for an adequate performance score combining these
      relevant performance criteria is evident. To judge the performance of an adaptive
      design, there exist two possible perspectives, which might also be combined:
      Either the global performance of the design can be addressed, which averages over
      all possible interim results, or the conditional performance is addressed, which 
      focuses on the remaining performance conditional on a specific interim result. In
      this work, we give a compact overview of sample size recalculation rules and
      performance measures. Moreover, we propose a new conditional performance score
      and apply it to various standard recalculation rules by means of Monte-Carlo
      simulations.
CI  - (c) 2020 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd.
FAU - Herrmann, Carolin
AU  - Herrmann C
AUID- ORCID: 0000-0003-2384-7303
AD  - Institute of Biometry and Clinical Epidemiology, Charite - Universitatsmedizin
      Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu
      Berlin, Berlin Institute of Health, Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Pilz, Maximilian
AU  - Pilz M
AUID- ORCID: 0000-0002-9685-1613
AD  - Institute of Medical Biometry and Informatics, University Medical Center
      Ruprechts-Karls University Heidelberg, Heidelberg, Germany.
FAU - Kieser, Meinhard
AU  - Kieser M
AUID- ORCID: 0000-0003-2402-4333
AD  - Institute of Medical Biometry and Informatics, University Medical Center
      Ruprechts-Karls University Heidelberg, Heidelberg, Germany.
FAU - Rauch, Geraldine
AU  - Rauch G
AUID- ORCID: 0000-0002-2451-1660
AD  - Institute of Biometry and Clinical Epidemiology, Charite - Universitatsmedizin
      Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu
      Berlin, Berlin Institute of Health, Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200406
PL  - England
TA  - Stat Med
JT  - Statistics in medicine
JID - 8215016
SB  - IM
MH  - Monte Carlo Method
MH  - *Research Design
MH  - Sample Size
OTO - NOTNLM
OT  - *adaptive group-sequential design
OT  - *clinical trial
OT  - *performance score
OT  - *sample size recalculation
EDAT- 2020/04/07 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/07 06:00
PHST- 2018/11/01 00:00 [received]
PHST- 2019/12/20 00:00 [revised]
PHST- 2020/03/04 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1002/sim.8534 [doi]
PST - ppublish
SO  - Stat Med. 2020 Jul 10;39(15):2067-2100. doi: 10.1002/sim.8534. Epub 2020 Apr 6.


PMID- 32249453
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1744-6198 (Electronic)
IS  - 0029-6473 (Linking)
VI  - 55
IP  - 3
DP  - 2020 Jul
TI  - Professional identity: A concept analysis.
PG  - 447-472
LID - 10.1111/nuf.12450 [doi]
AB  - The purpose of this study is to give clarity to the concept of professional
      identity, drawing from health-related fields to help provide a common language
      and understanding for research and practice. Professional identity,
      professionalism, professional socialization, and other related terms are often
      used without a clear definition or with conflicting definitions. This can lead to
      misunderstandings and assumptions that complicate research and confuse educators 
      and professionals in guiding novice members. Concept analysis. Initially, 737
      articles were identified by searching CINAHL, PubMed Central, Google Scholar,
      Academic Search Complete, PsyINFO, and SocINDEX for the period 2000 to 2019.
      Finally, 68 studies met the inclusion criteria, 60 of which are discussed in this
      concept analysis. This concept analysis uses the method described by Walker and
      Avant. This concept analysis clarifies the definition of professional identity,
      using literature from health and related professions, as containing the
      attributes: skills and functions; knowledge values and ethics; personal identity;
      group identity; and the influence of the context of care. A more clear definition
      of professional identity will help researchers to have more precision in their
      analyses and provide mentors and educators with a clear goal.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Fitzgerald, Anita
AU  - Fitzgerald A
AUID- ORCID: http://orcid.org/0000-0002-2057-6643
AD  - School of Nursing, California State University, Long Beach, California.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200406
PL  - United States
TA  - Nurs Forum
JT  - Nursing forum
JID - 0401006
MH  - *Concept Formation
MH  - Humans
MH  - *Professionalism
MH  - *Social Identification
OTO - NOTNLM
OT  - concept analysis
OT  - health professions
OT  - nursing
OT  - occupational therapy
OT  - pharmacy
OT  - physicians
OT  - professional identity
OT  - professional socialization
OT  - professionalism
OT  - social work
EDAT- 2020/04/07 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1111/nuf.12450 [doi]
PST - ppublish
SO  - Nurs Forum. 2020 Jul;55(3):447-472. doi: 10.1111/nuf.12450. Epub 2020 Apr 6.


PMID- 32249443
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1467-8519 (Electronic)
IS  - 0269-9702 (Linking)
VI  - 34
IP  - 4
DP  - 2020 May
TI  - Neonatal incubator or artificial womb? Distinguishing ectogestation and
      ectogenesis using the metaphysics of pregnancy.
PG  - 354-363
LID - 10.1111/bioe.12717 [doi]
AB  - A 2017 Nature report was widely touted as hailing the arrival of the artificial
      womb. But the scientists involved claim their technology is merely an improvement
      in neonatal care. This raises an under-considered question: what differentiates
      neonatal incubation from artificial womb technology? Considering the nature of
      gestation-or metaphysics of pregnancy-(a) identifies more profound differences
      between fetuses and neonates/babies than their location (in or outside the
      maternal body) alone: fetuses and neonates have different physiological and
      physical characteristics; (b) characterizes birth as a physiological,
      mereological and topological transformation as well as a (morally relevant)
      change of location; and (c) delivers a clear distinction between neonatal
      incubation and ectogestation: the former supports neonatal physiology; the latter
      preserves fetal physiology. This allows a detailed conceptual classification of
      ectogenetive and ectogestative technologies according to which the 2017 system is
      not just improved neonatal incubation, but genuine ectogestation. But it is not
      an artificial womb, which is a term that is better put to rest. The analysis
      reveals that any ethical discussion involving ectogestation must always involve
      considerations of possible risks to the mother as well as her autonomy and
      rights. It also adds a third and potentially important dimension to debates in
      reproductive ethics: the physiological transition from fetus/gestateling to
      baby/neonate.
CI  - (c) 2020 The Authors. Bioethics published by John Wiley & Sons Ltd.
FAU - Kingma, Elselijn
AU  - Kingma E
AUID- ORCID: 0000-0001-9787-3198
AD  - Faculty of Humanities, University of Southampton, Southampton, United Kingdom of 
      Great Britain and Northern Ireland.
FAU - Finn, Suki
AU  - Finn S
AUID- ORCID: 0000-0001-7319-9848
AD  - Faculty of Humanities, University of Southampton, Southampton, United Kingdom of 
      Great Britain and Northern Ireland.
LA  - eng
GR  - 679586/H2020 European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200405
PL  - England
TA  - Bioethics
JT  - Bioethics
JID - 8704792
SB  - IM
MH  - Artificial Organs
MH  - Ectogenesis/*ethics
MH  - Female
MH  - Fetus/*physiology
MH  - Humans
MH  - Incubators, Infant
MH  - Infant, Newborn/*physiology
MH  - *Metaphysics
MH  - *Pregnancy
MH  - Uterus
OTO - NOTNLM
OT  - *artificial womb
OT  - *ectogenesis
OT  - *ectogestation
OT  - *ethics
OT  - *fetus
OT  - *gestateling
OT  - *metaphysics
OT  - *pregnancy
EDAT- 2020/04/07 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/04/07 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2019/10/25 00:00 [revised]
PHST- 2019/11/08 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1111/bioe.12717 [doi]
PST - ppublish
SO  - Bioethics. 2020 May;34(4):354-363. doi: 10.1111/bioe.12717. Epub 2020 Apr 5.


PMID- 32248737
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1744-5086 (Electronic)
IS  - 0928-6586 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Oct
TI  - Assessing the Quality of Published Surveys in Ophthalmology.
PG  - 339-343
LID - 10.1080/09286586.2020.1746359 [doi]
AB  - PURPOSE: Surveys are an important research modality in ophthalmology, but their
      quality has not been rigorously assessed. This study evaluated the quality of
      published ophthalmic surveys. METHODS: Three survey methodologists, three senior 
      ophthalmologists, and two research assistants developed a survey evaluation
      instrument focused on survey development and testing; sampling frame; response
      bias; results reporting; and ethics. Two investigators used the instrument to
      assess the quality of all ophthalmic surveys that were published between January 
      1, 2018 and December 31, 2018; indexed in MEDLINE/PubMed, Embase, and/or Web of
      Science; contained the search terms "ophthalmology" and "survey" or
      "questionnaire" in the title and/or abstract; and were available in English.
      RESULTS: The search identified 626 articles; 60 met the eligibility criteria and 
      were assessed with the survey evaluation instrument. Most surveys (93%; 56/60)
      defined the study population; 48% (29/60) described how question items were
      chosen; 30% (18/60) provided the survey for review or described the questions in 
      sufficient detail; 30% (18/60) were pre-tested or piloted; 25% (15/60) reported
      validity/clinical sensibility testing; 15% (9/60) described techniques used to
      assess non-response bias; and 63% (38/60) documented review by an institutional
      review board (IRB). CONCLUSION: The quality of published ophthalmic surveys can
      be improved by focusing on survey development, pilot testing, non-response bias
      and institutional review board review. The survey evaluation instrument can help 
      guide researchers in conducting quality ophthalmic surveys and assist journal
      editors in evaluating surveys submitted for publication.
FAU - Tran, Elaine M
AU  - Tran EM
AD  - Division of Ophthalmology, Warren Alpert Medical School, Brown University ,
      Providence, Rhode Island, USA.
AD  - Section of Ophthalmology, Providence Veterans Affairs Medical Center ,
      Providence, Rhode Island, USA.
FAU - Tran, Megan M
AU  - Tran MM
AD  - Division of Ophthalmology, Warren Alpert Medical School, Brown University ,
      Providence, Rhode Island, USA.
AD  - Section of Ophthalmology, Providence Veterans Affairs Medical Center ,
      Providence, Rhode Island, USA.
FAU - Clark, Melissa A
AU  - Clark MA
AD  - Department of Health Services, School of Public Health, Brown University ,
      Providence, Rhode Island, USA.
FAU - Scott, Ingrid U
AU  - Scott IU
AD  - Departments of Ophthalmology and Public Health Sciences, Penn State College of
      Medicine , Hershey, Pennsylvania, USA.
FAU - Margo, Curtis E
AU  - Margo CE
AD  - Departments of Ophthalmology and Pathology and Cell Biology, Morsani College of
      Medicine, University of South Florida , Tampa, Florida, USA.
FAU - Cosenza, Carol
AU  - Cosenza C
AD  - Center for Survey Research, University of Massachusetts Boston , Boston,
      Massachusetts, USA.
FAU - Johnson, Timothy P
AU  - Johnson TP
AD  - Survey Research Laboratory, University of Illinois at Chicago , Chicago,
      Illinois, USA.
FAU - Greenberg, Paul B
AU  - Greenberg PB
AUID- ORCID: 0000-0002-2305-6766
AD  - Division of Ophthalmology, Warren Alpert Medical School, Brown University ,
      Providence, Rhode Island, USA.
AD  - Section of Ophthalmology, Providence Veterans Affairs Medical Center ,
      Providence, Rhode Island, USA.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - England
TA  - Ophthalmic Epidemiol
JT  - Ophthalmic epidemiology
JID - 9435674
SB  - IM
MH  - Humans
MH  - *Ophthalmology
MH  - Quality Control
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *Research quality
OT  - *clinical research
OT  - *ophthalmology survey
OT  - *survey development
OT  - *survey research
EDAT- 2020/04/07 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1080/09286586.2020.1746359 [doi]
PST - ppublish
SO  - Ophthalmic Epidemiol. 2020 Oct;27(5):339-343. doi: 10.1080/09286586.2020.1746359.
      Epub 2020 Apr 6.


PMID- 32248224
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1930-613X (Electronic)
IS  - 0026-4075 (Linking)
VI  - 185
IP  - 7-8
DP  - 2020 Aug 14
TI  - Physiological Factors of Importance for Load Carriage in Experienced and
      Inexperienced Men and Women.
PG  - e1168-e1174
LID - 10.1093/milmed/usaa050 [doi]
AB  - INTRODUCTION: The ability to carry heavy loads is an important and necessary task
      during numerous outdoor activities and especially in military operations. The aim
      of this study was to investigate factors associated with load-carrying ability in
      men and women with and without extensive load-carrying experience. MATERIALS AND 
      METHODS: The energy expenditure during carrying no load, 20, 35, and 50 kg at 2
      walking speeds, 3 and 5 km h-1, was studied in 36 healthy participants, 19 men
      (30 +/- 6 years, 82.5 +/- 7.0 kg) and 17 women (29 +/- 6 years, 66.1 +/- 8.9 kg),
      experienced (>5 years) in carrying heavy loads (n = 16, 8 women) or with minor or
      no such experience (n = 20, 9 women). A standard backpack filled with weights to 
      according carry load was used during the walks. Anthropometric data, leg muscle
      strength, as well as trunk muscle endurance and muscle fiber distribution of the 
      thigh, were also obtained. Extra Load Index (ELI)-the oxygen uptake (VO2) during 
      total load over unloaded walking-was used as a proxy for load-carrying ability at
      20, 35, and 50 kg (ELI20, ELI35, and ELI50, respectively). In addition to
      analyzing factors of importance for the ELI values, we also conducted mediator
      analyses using sex and long-term carrying experience as causal variables for ELI 
      as the outcome value. The study was approved by the Regional Ethics Committee in 
      Stockholm, Sweden. RESULTS: For the lowest load (20 kg), ELI20, was correlated
      with body mass but no other factors. Walking with 35 and 50 kg load at 5 km h-1
      body mass, body height, leg muscle strength, and absolute VO2max were correlated,
      while relative VO2max, trunk muscle endurance, and leg muscle fiber distribution 
      were not correlated to ELI35 and ELI50.ELI50 at 5 km h-1 differed between the
      sexes. This difference was only mediated by the difference in body mass. Neither 
      muscle fiber distribution, leg muscle strength, trunk muscle endurance, and body 
      height nor did absolute or relative VO2max explain the difference.Participants
      with long-term experience of heavy load carrying had significant lower ELI20 and 
      ELI50 values than those with minor or no experience, but none of the above
      studied factors could explain this difference. CONCLUSION: The study showed that 
      body mass, without sex differences, and experience of carrying heavy loads are
      the dominant factors for the ability to carry heavy loads. Even though the effect
      of experience alludes to the need for extensive carrying training, no causality
      can be proven. Load carry training intervention studies is suggested for future
      investigations.
CI  - (c) Association of Military Surgeons of the United States 2020. All rights
      reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Godhe, Manne
AU  - Godhe M
AD  - Astrand Laboratory of Work Physiology, The Swedish School of Sport and Health
      Sciences, P.O. Box 5626, SE-114 86 Stockholm, Sweden.
FAU - Helge, Torbjorn
AU  - Helge T
AD  - Astrand Laboratory of Work Physiology, The Swedish School of Sport and Health
      Sciences, P.O. Box 5626, SE-114 86 Stockholm, Sweden.
FAU - Mattsson, C Mikael
AU  - Mattsson CM
AD  - Astrand Laboratory of Work Physiology, The Swedish School of Sport and Health
      Sciences, P.O. Box 5626, SE-114 86 Stockholm, Sweden.
FAU - Ekblom, Orjan
AU  - Ekblom O
AD  - Astrand Laboratory of Work Physiology, The Swedish School of Sport and Health
      Sciences, P.O. Box 5626, SE-114 86 Stockholm, Sweden.
FAU - Ekblom, Bjorn
AU  - Ekblom B
AD  - Astrand Laboratory of Work Physiology, The Swedish School of Sport and Health
      Sciences, P.O. Box 5626, SE-114 86 Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
SB  - IM
MH  - Adult
MH  - Female
MH  - Heart Rate
MH  - Humans
MH  - Male
MH  - Muscle Strength
MH  - Oxygen Consumption
MH  - Sweden
MH  - *Walking
MH  - Weight-Bearing
MH  - Young Adult
EDAT- 2020/04/06 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/04/06 06:00
PHST- 2019/11/05 00:00 [received]
PHST- 2020/01/17 00:00 [revised]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/04/06 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/04/06 06:00 [entrez]
AID - 5816008 [pii]
AID - 10.1093/milmed/usaa050 [doi]
PST - ppublish
SO  - Mil Med. 2020 Aug 14;185(7-8):e1168-e1174. doi: 10.1093/milmed/usaa050.


PMID- 32247678
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1958-5578 (Electronic)
IS  - 0040-5957 (Linking)
VI  - 75
IP  - 2
DP  - 2020 Apr
TI  - Orphan drug clinical development.
PG  - 141-147
LID - S0040-5957(20)30009-3 [pii]
LID - 10.1016/j.therap.2020.02.004 [doi]
AB  - Clinical development for orphan drugs is extremely demanding but fascinating.
      There is no single aspect that is really specific to it but instead it gathers
      most of the hurdles: design, outcomes, recruitment, ethics, cost, probability and
      predictability for success. To overcome these difficulties, there has to be a
      great collaboration between academic centers, small and large pharma companies,
      patients' representatives as well as health authorities to provide support and
      innovative approaches. The ultimate goal is to give access to patients with unmet
      medical needs to drugs with a favorable benefit-risk ratio. We review and discuss
      here the pillars for a successful clinical development for orphan drugs.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Blin, Olivier
AU  - Blin O
AD  - Service de pharmacologie clinique et pharmacovigilance, Aix Marseille Univ,
      AP-HM, INSERM, Inst Neurosci Syst, 13005 Marseille, France; Orphandev-FCRIN,
      INSERM, 13005 Marseille, France. Electronic address: olivier.blin@ap-hm.fr.
FAU - Lefebvre, Marie-Noelle
AU  - Lefebvre MN
AD  - Service de pharmacologie clinique et pharmacovigilance, Aix Marseille Univ,
      AP-HM, INSERM, Inst Neurosci Syst, 13005 Marseille, France; Orphandev-FCRIN,
      INSERM, 13005 Marseille, France.
FAU - Rascol, Olivier
AU  - Rascol O
AD  - Services de pharmacologie clinique et neurosciences, centre d'investigation
      clinique CIC 1436, NS-Park/FCRIN network, NeuroToul COEN center, universite de
      Toulouse UPS, CHU de Toulouse, INSERM, 31000 Toulouse, France.
FAU - Micallef, Joelle
AU  - Micallef J
AD  - Service de pharmacologie clinique et pharmacovigilance, Aix Marseille Univ,
      AP-HM, INSERM, Inst Neurosci Syst, 13005 Marseille, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200213
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
SB  - IM
MH  - Clinical Trials as Topic
MH  - Cost-Benefit Analysis
MH  - Drug Approval
MH  - Humans
MH  - *Orphan Drug Production/economics
MH  - Rare Diseases/*drug therapy
OTO - NOTNLM
OT  - Clinical trial
OT  - Market authorization
OT  - Orphan drugs
OT  - Patient
OT  - Rare diseases
EDAT- 2020/04/06 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/04/06 06:00
PHST- 2019/09/16 00:00 [received]
PHST- 2019/10/15 00:00 [accepted]
PHST- 2020/04/06 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/04/06 06:00 [entrez]
AID - S0040-5957(20)30009-3 [pii]
AID - 10.1016/j.therap.2020.02.004 [doi]
PST - ppublish
SO  - Therapie. 2020 Apr;75(2):141-147. doi: 10.1016/j.therap.2020.02.004. Epub 2020
      Feb 13.


PMID- 32247626
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1873-5347 (Electronic)
IS  - 0277-9536 (Linking)
VI  - 262
DP  - 2020 Oct
TI  - Suicide prevention is everyone's business: Challenges and opportunities for
      Google.
PG  - 112691
LID - S0277-9536(19)30686-0 [pii]
LID - 10.1016/j.socscimed.2019.112691 [doi]
AB  - The internet has become a key frontier for large-scale, public health efforts in 
      suicide prevention. Market-leading technology companies, such as Google, are
      developing interventions to deliver support information to those experiencing
      suicidal distress, but the precise technology, i.e. algorithms, behind this are
      proprietary. This raises important ethical questions regarding whether such
      large-scale public health interventions for suicide prevention should be
      happening behind closed corporate doors when this makes the evaluation of such
      interventions extremely difficult. Furthermore, as illustrated by Arendt et al.
      (2019), initiatives such as Google's Suicide Prevention Result (SPR) appear not
      to work in circumstances in which they could be of significant potential benefit,
      such as when individuals are searching for details of celebrity suicides. In the 
      current commentary, we discuss ways in which the SPR can be optimized, based on
      existing evidence regarding suicide-related internet use. We go on to discuss the
      ethical issues of large technology companies becoming key players in suicide
      prevention and critically consider how online public health initiatives of this
      kind are able to be evaluated.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kirtley, Olivia J
AU  - Kirtley OJ
AD  - Center for Contextual Psychiatry, KU Leuven, Department of Neuroscience, Campus
      Sint-Rafael, Kapucijnenvoer 33, Bus 7001 (Blok H), 3000, Leuven, Belgium.
      Electronic address: olivia.kirtley@kuleuven.be.
FAU - O'Connor, Rory C
AU  - O'Connor RC
AD  - Suicidal Behaviour Research Laboratory, Institute of Health & Wellbeing,
      University of Glasgow, Mental Health & Wellbeing, Academic Centre, Gartnavel
      Royal Hospital, 1055 Great Western Road, Glasgow, G12 0XH, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200118
PL  - England
TA  - Soc Sci Med
JT  - Social science & medicine (1982)
JID - 8303205
SB  - IM
MH  - Commerce
MH  - *Famous Persons
MH  - Humans
MH  - Internet
MH  - Suicidal Ideation
MH  - *Suicide/prevention & control
OTO - NOTNLM
OT  - *Internet
OT  - *Intervention
OT  - *Public health
OT  - *Suicide prevention
EDAT- 2020/04/06 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/06 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2019/11/16 00:00 [accepted]
PHST- 2020/04/06 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/04/06 06:00 [entrez]
AID - S0277-9536(19)30686-0 [pii]
AID - 10.1016/j.socscimed.2019.112691 [doi]
PST - ppublish
SO  - Soc Sci Med. 2020 Oct;262:112691. doi: 10.1016/j.socscimed.2019.112691. Epub 2020
      Jan 18.


PMID- 32247550
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20210920
IS  - 1879-3592 (Electronic)
IS  - 1383-5718 (Linking)
VI  - 850-851
DP  - 2020 Feb - Mar
TI  - 50 years existence and active participation of EEMS (now EEMGS) in the scientific
      community: A driver of European and international scientific collaborations for
      the protection of the environment and human health from genome stressors.
PG  - 503132
LID - S1383-5718(20)30002-4 [pii]
LID - 10.1016/j.mrgentox.2020.503132 [doi]
AB  - EEMS and its successor Society EEMGS have provided a dynamic and successful
      platform to stimulate research and exchanges among the different actors involved 
      in the protection of the environment and of human health from exposure to genome 
      stressors. It includes basic, translational and applied research projects. This
      was possible due to the enthusiasm, creativity and support of scientists
      convinced of the importance of these issues. In the future young scientists will 
      take over with new questions, new challenges, new technologies, new discoveries
      and new applications. A major challenge is the ethical questions emerging from
      the impressive potential of present genetic technologies capable of impacting the
      evolution of nature and humankind. The EEMGS, where academics, regulators and
      industries meet, should play a central role in these aspects, in particular in
      support of primary prevention and the establishment of internationally recognized
      guidelines. Collaboration with colleagues and other teams are of great importance
      to establish a stimulating open dialogue on scientific questions. However the key
      issues remain to do careful and rigorous research; to use logic and background
      knowledge; to define adequate experimental designs; to provide transparency in
      the protocols; to check repeatability of the results and to combine several
      statistical approaches in the quest to get to the truth. Among the many
      challenges ahead, re-evaluation of some key fundamental questions is necessary,
      such as the interplay between genetics and epigenetics, the existence of specific
      germ cell mutagens or the identification of the mechanisms leading to mutagen
      induced diseases. Translational and applied research will further include the
      development of systemic biomonitoring protocols, if possible in a single
      biological sample, the redaction of internationally harmonized guidelines but
      also the organization of platforms between geneticists and physicians open to all
      actors in the field. The creation of an independent European center to assess
      risk from exposure to mutagens, in particular in the light of the problematic of 
      global warming might be very helpful.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Knudsen, Lisbeth E
AU  - Knudsen LE
AD  - Department of Public Health, University of Copenhagen, Denmark. Electronic
      address: liek@sund.ku.dk.
FAU - Phillips, David H
AU  - Phillips DH
AD  - Department of Analytical, Environmental & Forensic Sciences, MRC-PHE Centre for
      Environment & Health, King's College London, UK.
FAU - Kirsch-Volders, Micheline
AU  - Kirsch-Volders M
AD  - Laboratory for Cell Genetics, Department Biology, Faculty of Sciences and
      Bio-engineering Sciences, Vrije Universiteit Brussel, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20200128
PL  - Netherlands
TA  - Mutat Res Genet Toxicol Environ Mutagen
JT  - Mutation research. Genetic toxicology and environmental mutagenesis
JID - 101632149
SB  - IM
MH  - Biomedical Research/trends
MH  - *Environmental Monitoring
MH  - Europe
MH  - Genome, Human/*genetics
MH  - Humans
MH  - Metagenomics/*trends
MH  - Mutagenesis/*genetics
MH  - Societies, Scientific/trends
OTO - NOTNLM
OT  - *EEMGS
OT  - *EU
OT  - *History
OT  - *International
OT  - *Young researcher
COIS- Declaration of Competing Interest None.
EDAT- 2020/04/06 06:00
MHDA- 2020/04/25 06:00
CRDT- 2020/04/06 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/04/06 06:00 [entrez]
PHST- 2020/04/06 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
AID - S1383-5718(20)30002-4 [pii]
AID - 10.1016/j.mrgentox.2020.503132 [doi]
PST - ppublish
SO  - Mutat Res Genet Toxicol Environ Mutagen. 2020 Feb - Mar;850-851:503132. doi:
      10.1016/j.mrgentox.2020.503132. Epub 2020 Jan 28.


PMID- 32247339
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20210402
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 95
IP  - 4
DP  - 2020 Apr
TI  - Ethical Considerations About Clinician Reimbursement for Advance Care Planning.
PG  - 653-657
LID - S0025-6196(19)31110-3 [pii]
LID - 10.1016/j.mayocp.2019.12.017 [doi]
FAU - Barwise, Amelia K
AU  - Barwise AK
AD  - Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
      Electronic address: Barwise.Amelia@mayo.edu.
FAU - Wilson, Michael E
AU  - Wilson ME
AD  - Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN;
      Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,
      Mayo Clinic, Rochester, MN; Knowledge and Evaluation Research Unit, Mayo Clinic, 
      Rochester, MN.
FAU - Sharp, Richard R
AU  - Sharp RR
AD  - Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN.
FAU - DeMartino, Erin S
AU  - DeMartino ES
AD  - Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
LA  - eng
GR  - TL1 TR002380/TR/NCATS NIH HHS/United States
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
SB  - IM
MH  - Adult
MH  - Advance Care Planning/*ethics
MH  - Centers for Medicare and Medicaid Services, U.S./ethics
MH  - Conflict of Interest
MH  - Healthcare Disparities/ethics
MH  - Humans
MH  - Insurance, Health, Reimbursement/*ethics
MH  - Physician-Patient Relations/ethics
MH  - Physicians/*ethics
MH  - United States
PMC - PMC7709876
MID - NIHMS1569498
EDAT- 2020/04/06 06:00
MHDA- 2020/08/19 06:00
CRDT- 2020/04/06 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/11/19 00:00 [revised]
PHST- 2019/12/16 00:00 [accepted]
PHST- 2020/04/06 06:00 [entrez]
PHST- 2020/04/06 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
AID - S0025-6196(19)31110-3 [pii]
AID - 10.1016/j.mayocp.2019.12.017 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2020 Apr;95(4):653-657. doi: 10.1016/j.mayocp.2019.12.017.


PMID- 32246731
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20200916
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 29
IP  - 11-12
DP  - 2020 Jun
TI  - A contribution to the ontology of the Fundamentals of Care framework from a
      wonder-based approach.
PG  - 1797-1807
LID - 10.1111/jocn.15272 [doi]
AB  - AIM AND OBJECTIVES: To critically discuss the ontological framework of
      Fundamentals of Care (FoC), as developed by Uhrenfeldt, et al. (2018), Journal of
      Clinical Nursing, 27, 3197-3204; to suggest theoretical improvements by taking a 
      wonder-based approach; and to show how this approach can be applied in healthcare
      sectors. BACKGROUND: Based on a critical discussion of a discursive study on the 
      ontology of FoC, studies in phenomenology of wonder and two action research
      projects involving "Wonder Labs," this article discusses whether the ontology and
      reflective practices behind FoC can be qualified further by an existential
      phenomenology of wonder and with practices of "Wonder Labs." DESIGN: This is a
      discursive study critically discussing Uhrenfeldt et al.'s primary focus on
      dyadic and relational openness and person-oriented attentiveness in a
      nurse-patient relationship. This is done by unfolding the phenomenology of wonder
      and wonder experiences at a hospice and a hospital, and by critically examining
      the psychologically influenced interpretation of Heidegger. CONCLUSION: The first
      attempts by Uhrenfeldt et al. to identify the philosophical roots and ontology of
      FoC by pointing to existential phenomenology and philosophy are acknowledged.
      However, in this article, we further elaborate this attempt by focusing on the
      phenomenology of wonder. We show that Heidegger speaking about "existential
      homecoming" referred to a philosophical practice focusing on the resonance with
      being, rather than on interpersonal and psychological relations. In conclusion,
      the article recognises the importance of integrating these two approaches
      described on the one hand as a person-oriented and lifeworld-led approach, and on
      the other hand as a being- and phenomenon-oriented approach to the nurse-patient 
      relationship. RELEVANCE TO CLINICAL PRACTICE: To be open to the "musicality" of
      the being dimension, as the core values of FoC, a wonder-based approach to value 
      clarifications and phenomenological dialogues is pivotal for the presence of
      openness, trust and attentiveness of the nurse-patient relationship. The
      practices of the "Wonder Lab" may be an approach for training nurses in hearing
      the call of this "ontological resonance."
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Hansen, Finn Thorbjorn
AU  - Hansen FT
AUID- ORCID: https://orcid.org/0000-0002-2252-2059
AD  - Centre of Dialogue and Organization, Department of Communication, Aalborg
      University, Aalborg, Denmark.
FAU - Jorgensen, Lene Bastrup
AU  - Jorgensen LB
AUID- ORCID: https://orcid.org/0000-0001-7873-6139
AD  - Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark.
AD  - Elective Surgery Center, Silkeborg Regional Hospital, Silkeborg, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200430
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
MH  - Humans
MH  - Nurse's Role
MH  - *Nurse-Patient Relations
MH  - Nursing Methodology Research
MH  - Philosophy
OTO - NOTNLM
OT  - Philosophy
OT  - ethics
OT  - holistic care
OT  - nursing care
OT  - patient-centred care
OT  - phenomenological hermeneutics
OT  - reflection
OT  - spirituality
EDAT- 2020/04/05 06:00
MHDA- 2020/09/17 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/05/08 00:00 [received]
PHST- 2020/01/26 00:00 [revised]
PHST- 2020/03/13 00:00 [accepted]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - 10.1111/jocn.15272 [doi]
PST - ppublish
SO  - J Clin Nurs. 2020 Jun;29(11-12):1797-1807. doi: 10.1111/jocn.15272. Epub 2020 Apr
      30.


PMID- 32246674
OWN - NLM
STAT- MEDLINE
DCOM- 20200407
LR  - 20220413
IS  - 1998-3603 (Electronic)
IS  - 0970-9290 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Jan-Feb
TI  - Beak and bumper - Physics forceps: Evaluation of new technique in extraction.
PG  - 4-13
LID - 10.4103/ijdr.IJDR_433_18 [doi]
AB  - PURPOSE: The history of dentistry is not short; it started from ancient Egypt to 
      ancient Romans and ancient Greeks. When it comes to extraction, all of them have 
      made their own discoveries and progress. The progress they made also helped
      dentistry to move ahead in evolution of new extraction technique - the Physics
      Forceps. We have assessed the viability in using the Physics Forceps for routine 
      dental extraction in our study for a period of 1 year. MATERIALS AND METHODS: The
      study was conducted on 241 patients indicated for extraction based on our
      inclusion criteria using Physics Forceps after obtaining informed consent and
      University Ethics Committee approval. Tooth fracture, buccal alveolar bone
      fracture, and soft tissue injury around the tooth to be extracted were studied.
      RESULTS: In our present study of 241 patients, 57.67% were females and 42.32%
      were males, out of which 93.77% had no tooth fracture, 3.32% had crown fracture, 
      1.65% had root fracture, and 1.24% had apex fracture. Further, 85.47% had no
      buccal alveolar bone fracture and 14.53% had buccal alveolar bone fracture. Using
      proper technique, 96.26% of patients had no soft tissue damage, and minimal
      damage was seen in 3.73% of patients. DISCUSSION: Extraction by Physics Forceps
      is a very good technique of extraction. No or very minimal tooth fracture and
      soft tissue injury were noted. Though the forceps is costly, it represents a
      valuable addition to regular armamentarium for a general dentist for routine
      extraction. Physics Forceps is a dental extractor rather than a forceps.
FAU - Raghu, K
AU  - Raghu K
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
FAU - Selvakumar, S R
AU  - Selvakumar SR
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
FAU - Muthukumar, Ramsay
AU  - Muthukumar R
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
FAU - Thangavelu, A
AU  - Thangavelu A
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
FAU - Sathyanarayanan, R
AU  - Sathyanarayanan R
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
FAU - Mani, Murali
AU  - Mani M
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
FAU - Balasubramaniam, Murali
AU  - Balasubramaniam M
AD  - Department of Oral and Maxillofacial Surgery, Indira Gandhi Institute of Dental
      Science, Sri Balaji Vidyapeeth (Deemed To Be University), Puducherry, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dent Res
JT  - Indian journal of dental research : official publication of Indian Society for
      Dental Research
JID - 9202990
MH  - Animals
MH  - *Beak
MH  - Female
MH  - Humans
MH  - Male
MH  - Physics
MH  - Surgical Instruments
MH  - Tooth Extraction
MH  - *Tooth Fractures
MH  - Tooth Socket
OTO - NOTNLM
OT  - Dental
OT  - Physics Forceps
OT  - extraction
OT  - hyaluronidase
OT  - oral and maxillofacial surgery
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - IndianJDentRes_2020_31_1_4_274108 [pii]
AID - 10.4103/ijdr.IJDR_433_18 [doi]
PST - ppublish
SO  - Indian J Dent Res. 2020 Jan-Feb;31(1):4-13. doi: 10.4103/ijdr.IJDR_433_18.


PMID- 32246647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - Expression profiles of long noncoding RNAs in retinopathy of prematurity.
PG  - 1962-1968
LID - 10.4103/1673-5374.280328 [doi]
AB  - Long noncoding RNA (lncRNA) regulates the proliferation and migration of human
      retinal endothelial cells, as well as retinal neovascularization in diabetic
      retinopathy. Based on similarities between the pathogenesis of retinopathy of
      prematurity (ROP) and diabetic retinopathy, lncRNA may also play a role in ROP.
      Seven-day-old mice were administered 75 +/- 2% oxygen for 5 days and normoxic air
      for another 5 days to establish a ROP model. Expression of lncRNA and mRNA in the
      retinal tissue of mice was detected by high-throughput sequencing technology, and
      biological functions of the resulted differentially expressed RNAs were evaluated
      by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. The
      results showed that compared with the control group, 57 lncRNAs were
      differentially expressed, including 43 upregulated and 14 downregulated, in the
      retinal tissue of ROP mice. Compared with control mice, 42 mRNAs were
      differentially expressed in the retinal tissue of ROP mice, including 24
      upregulated and 18 downregulated mRNAs. Differentially expressed genes were
      involved in ocular development and related metabolic pathways. The differentially
      expressed lncRNAs may regulate ROP in mice via microRNAs and multiple signaling
      pathways. Our results revealed that these differentially expressed lncRNAs may be
      therapeutic targets for ROP treatment. This study was approved by the Medical
      Ethics Committee of Shengjing Hospital of China Medical University on February
      25, 2016 (approval No. 2016PS074K).
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Ophthalmology, Shengjing Hospital of China Medical University,
      Shenyang, Liaoning Province, China.
FAU - Wang, Xue
AU  - Wang X
AD  - Department of Ophthalmology, Shengjing Hospital of China Medical University,
      Shenyang, Liaoning Province, China.
FAU - Ma, Yuan
AU  - Ma Y
AD  - Department of Ophthalmology, Shengjing Hospital of China Medical University,
      Shenyang, Liaoning Province, China.
FAU - Wang, Yue-Xia
AU  - Wang YX
AD  - Department of Ophthalmology, Shengjing Hospital of China Medical University,
      Shenyang, Liaoning Province, China.
FAU - Di, Yu
AU  - Di Y
AD  - Department of Ophthalmology, Shengjing Hospital of China Medical University,
      Shenyang, Liaoning Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7513972
OTO - NOTNLM
OT  - bioinformatics
OT  - gene therapy
OT  - long noncoding RNA
OT  - microglial
OT  - neurovascular disease
OT  - optic neuropathy
OT  - retinal development
OT  - retinal neovascularization
OT  - retinopathy of prematurity
OT  - signaling pathways
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - NeuralRegenRes_2020_15_10_1962_280328 [pii]
AID - 10.4103/1673-5374.280328 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Oct;15(10):1962-1968. doi: 10.4103/1673-5374.280328.


PMID- 32246645
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - Lithium promotes proliferation and suppresses migration of Schwann cells.
PG  - 1955-1961
LID - 10.4103/1673-5374.280324 [doi]
AB  - Schwann cell proliferation, migration and remyelination of regenerating axons
      contribute to regeneration after peripheral nervous system injury. Lithium
      promotes remyelination by Schwann cells and improves peripheral nerve
      regeneration. However, whether lithium modulates other phenotypes of Schwann
      cells, especially their proliferation and migration remains elusive. In the
      current study, primary Schwann cells from rat sciatic nerve stumps were cultured 
      and exposed to 0, 5, 10, 15, or 30 mM lithium chloride (LiCl) for 24 hours. The
      effects of LiCl on Schwann cell proliferation and migration were examined using
      the Cell Counting Kit-8, 5-ethynyl-2'-deoxyuridine, Transwell and wound healing
      assays. Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine assays showed that 5,
      10, 15, and 30 mM LiCl significantly increased the viability and proliferation
      rate of Schwann cells. Transwell-based migration assays and wound healing assays 
      showed that 10, 15, and 30 mM LiCl suppressed the migratory ability of Schwann
      cells. Furthermore, the effects of LiCl on the proliferation and migration
      phenotypes of Schwann cells were mostly dose-dependent. These data indicate that 
      lithium treatment significantly promotes the proliferation and inhibits the
      migratory ability of Schwann cells. This conclusion will inform strategies to
      promote the repair and regeneration of peripheral nerves. All of the animal
      experiments in this study were ethically approved by the Administration Committee
      of Experimental Animal Center of Nantong University, China (approval No.
      20170320-017) on March 2, 2017.
FAU - Gu, Xiao-Kun
AU  - Gu XK
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-Innovation Center of Neuroregeneration, Nantong University; Department of Hand
      Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province,
      China.
FAU - Li, Xin-Rui
AU  - Li XR
AD  - State Key Laboratory of Natural Medicines, School of Life Science and Technology,
      China Pharmaceutical University, Nanjing, Jiangsu Province, China.
FAU - Lu, Mei-Ling
AU  - Lu ML
AD  - State Key Laboratory of Natural Medicines, School of Life Science and Technology,
      China Pharmaceutical University, Nanjing, Jiangsu Province, China.
FAU - Xu, Hui
AU  - Xu H
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,
      Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu
      Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7513976
OTO - NOTNLM
OT  - 5-ethynyl-2'-deoxyuridine
OT  - Cell Counting Kit-8
OT  - Schwann cell
OT  - cell viability
OT  - lithium
OT  - migration
OT  - peripheral nerve
OT  - proliferation
OT  - regeneration
OT  - wound healing assay
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - NeuralRegenRes_2020_15_10_1955_280324 [pii]
AID - 10.4103/1673-5374.280324 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Oct;15(10):1955-1961. doi: 10.4103/1673-5374.280324.


PMID- 32246644
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - An early neuroprotective effect of atorvastatin against subarachnoid hemorrhage.
PG  - 1947-1954
LID - 10.4103/1673-5374.280326 [doi]
AB  - Atorvastatin has been shown to reduce early brain edema and neuronal death after 
      subarachnoid hemorrhage, but its mechanism is not clear. In this study, rat
      models of subarachnoid hemorrhage were established by autologous blood injection 
      in the cisterna magna. Rat models were intragastrically administered 20 mg/kg
      atorvastatin 24 hours before subarachnoid hemorrhage, 12 and 36 hours after
      subarachnoid hemorrhage. Compared with the controls, atorvastatin treatment
      demonstrated that at 72 hours after subarachnoid hemorrhage, neurological
      function had clearly improved; brain edema was remarkably relieved; cell
      apoptosis was markedly reduced in the cerebral cortex of rats; the number of
      autophagy-related protein Beclin-1-positive cells and the expression levels of
      Beclin-1 and LC3 were increased compared with subarachnoid hemorrhage only. The
      ultrastructural damage of neurons in the temporal lobe was also noticeably
      alleviated. The similarities between the effects of atorvastatin and rapamycin
      were seen in all the measured outcomes of subarachnoid hemorrhage. However, these
      were contrary to the results of 3-methyladenine injection, which inhibits the
      signaling pathway of autophagy. These findings indicate that atorvastatin plays
      an early neuroprotective role in subarachnoid hemorrhage by activating autophagy.
      The experimental protocol was approved by the Animal Ethics Committee of Anhui
      Medical University, China (904 Hospital of Joint Logistic Support Force of PLA;
      approval No. YXLL-2017-09) on February 22, 2017.
FAU - Chen, Jun-Hui
AU  - Chen JH
AD  - Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei
      Province; Department of Neurosurgery, Wuxi Clinical College of Anhui Medical
      University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu
      Province, China.
FAU - Wu, Ting
AU  - Wu T
AD  - Department of Cardiology, Wuxi Clinical College of Anhui Medical University, 904 
      Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu Province, China.
FAU - Xia, Wen-Yuan
AU  - Xia WY
AD  - Department of Science and Education, Wuxi Clinical College of Anhui Medical
      University, 904 Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu
      Province, China.
FAU - Shi, Zhong-Hua
AU  - Shi ZH
AD  - Department of Neurosurgery, Wuxi Clinical College of Anhui Medical University,
      904 Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu Province,
      China.
FAU - Zhang, Chun-Lei
AU  - Zhang CL
AD  - Department of Neurosurgery, Wuxi Clinical College of Anhui Medical University,
      904 Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu Province,
      China.
FAU - Chen, Lei
AU  - Chen L
AD  - Department of Neurosurgery, Wuxi Clinical College of Anhui Medical University,
      904 Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu Province,
      China.
FAU - Chen, Qian-Xue
AU  - Chen QX
AD  - Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei
      Province, China.
FAU - Wang, Yu-Hai
AU  - Wang YH
AD  - Department of Neurosurgery, Wuxi Clinical College of Anhui Medical University,
      904 Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu Province,
      China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7513987
OTO - NOTNLM
OT  - 3-methyladenine
OT  - LC3
OT  - apoptosis
OT  - atorvastatin
OT  - autophagy
OT  - early brain injury
OT  - neuroprotection
OT  - rapamycin
OT  - subarachnoid hemorrhage
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - NeuralRegenRes_2020_15_10_1947_280326 [pii]
AID - 10.4103/1673-5374.280326 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Oct;15(10):1947-1954. doi: 10.4103/1673-5374.280326.


PMID- 32246641
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - Neuroprotective mechanism of L-cysteine after subarachnoid hemorrhage.
PG  - 1920-1930
LID - 10.4103/1673-5374.280321 [doi]
AB  - Hydrogen sulfide, which can be generated in the central nervous system from the
      sulfhydryl-containing amino acid, L-cysteine, by cystathionine-beta-synthase, may
      exert protective effects in experimental subarachnoid hemorrhage; however, the
      mechanism underlying this effect is unknown. This study explored the mechanism
      using a subarachnoid hemorrhage rat model induced by an endovascular perforation 
      technique. Rats were treated with an intraperitoneal injection of 100 mM
      L-cysteine (30 muL) 30 minutes after subarachnoid hemorrhage. At 48 hours after
      subarachnoid hemorrhage, hematoxylin-eosin staining was used to detect changes in
      prefrontal cortex cells. L-cysteine significantly reduced cell edema.
      Neurological function was assessed using a modified Garcia score. Brain water
      content was measured by the wet-dry method. L-cysteine significantly reduced
      neurological deficits and cerebral edema after subarachnoid hemorrhage.
      Immunofluorescence was used to detect the number of activated microglia. Reverse 
      transcription-polymerase chain reaction (RT-PCR) was used to detect the levels of
      interleukin 1beta and CD86 mRNA in the prefrontal cortex. L-cysteine inhibited
      microglial activation in the prefrontal cortex and reduced the mRNA levels of
      interleukin 1beta and CD86. RT-PCR and western blot analysis of the complement
      system showed that L-cysteine reduced expression of the complement factors, C1q, 
      C3alpha and its receptor C3aR1, and the deposition of C1q in the prefrontal
      cortex. Dihydroethidium staining was applied to detect changes in reactive oxygen
      species, and immunohistochemistry was used to detect the number of NRF2- and
      HO-1-positive cells. L-cysteine reduced the level of reactive oxygen species in
      the prefrontal cortex and the number of NRF2- and HO-1-positive cells. Western
      blot assays and immunohistochemistry were used to detect the protein levels of
      CHOP and GRP78 in the prefrontal cortex and the number of CHOP- and
      GRP78-positive cells. L-cysteine reduced CHOP and GRP78 levels and the number of 
      CHOP- and GRP78-positive cells. The cystathionine-beta-synthase inhibitor,
      aminooxyacetic acid, significantly reversed the above neuroprotective effects of 
      L-cysteine. Taken together, L-cysteine can play a neuroprotective role by
      regulating neuroinflammation, complement deposition, oxidative stress and
      endoplasmic reticulum stress. The study was approved by the Animals Ethics
      Committee of Shandong University, China on February 22, 2016 (approval No.
      LL-201602022).
FAU - Xiong, Ye
AU  - Xiong Y
AD  - Department of Physiology, School of Basic Medical Sciences; Department of
      Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research
      Institute, Shandong University, Jinan, Shandong Province, China.
FAU - Xin, Dan-Qing
AU  - Xin DQ
AD  - Department of Physiology, School of Basic Medical Sciences, Shandong University, 
      Jinan, Shandong Province, China.
FAU - Hu, Quan
AU  - Hu Q
AD  - Department of Physiology, School of Basic Medical Sciences, Shandong University, 
      Jinan; Department of Neurosurgery, Taian Central Hospital, Taian, Shandong
      Province, China.
FAU - Wang, Ling-Xiao
AU  - Wang LX
AD  - Department of Physiology, School of Basic Medical Sciences; Department of
      Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research
      Institute, Shandong University, Jinan, Shandong Province, China.
FAU - Qiu, Jie
AU  - Qiu J
AD  - Department of Physiology, School of Basic Medical Sciences, Shandong University, 
      Jinan, Shandong Province, China.
FAU - Yuan, Hong-Tao
AU  - Yuan HT
AD  - Department of Physiology, School of Basic Medical Sciences, Shandong University, 
      Jinan, Shandong Province, China.
FAU - Chu, Xi-Li
AU  - Chu XL
AD  - Department of Physiology, School of Basic Medical Sciences, Shandong University, 
      Jinan, Shandong Province, China.
FAU - Liu, De-Xiang
AU  - Liu DX
AD  - Department of Medical Psychology and Ethics, School of Basic Medicine Sciences,
      Shandong University, Jinan, Shandong Province, China.
FAU - Li, Gang
AU  - Li G
AD  - Department of Neurosurgery, Qilu Hospital of Shandong University and Brain
      Science Research Institute, Shandong University, Jinan, Shandong Province, China.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Department of Physiology, School of Basic Medical Sciences, Shandong University, 
      Jinan, Shandong Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7513988
OTO - NOTNLM
OT  - aminooxyacetic acid
OT  - central nervous system
OT  - complement deposition
OT  - cystathionine-beta-synthase
OT  - early brain injury
OT  - endoplasmic reticulum stress
OT  - hydrogen sulfide
OT  - neuroinflammation
OT  - oxidative stress
OT  - subarachnoid hemorrhage
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - NeuralRegenRes_2020_15_10_1920_280321 [pii]
AID - 10.4103/1673-5374.280321 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Oct;15(10):1920-1930. doi: 10.4103/1673-5374.280321.


PMID- 32246639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - Combination of olfactory ensheathing cells and human umbilical cord mesenchymal
      stem cell-derived exosomes promotes sciatic nerve regeneration.
PG  - 1903-1911
LID - 10.4103/1673-5374.280330 [doi]
AB  - Olfactory ensheathing cells (OECs) are promising seed cells for nerve
      regeneration. However, their application is limited by the hypoxic environment
      usually present at the site of injury. Exosomes derived from human umbilical cord
      mesenchymal stem cells have the potential to regulate the pathological processes 
      that occur in response to hypoxia. The ability of OECs to migrate is unknown,
      especially in hypoxic conditions, and the effect of OECs combined with exosomes
      on peripheral nerve repair is not clear. Better understanding of these issues
      will enable the potential of OECs for the treatment of nerve injury to be
      addressed. In this study, OECs were acquired from the olfactory bulb of Sprague
      Dawley rats. Human umbilical cord mesenchymal stem cell-derived exosomes (0-400
      mug/mL) were cultured with OECs for 12-48 hours. After culture with 400 mug/mL
      exosomes for 24 hours, the viability and proliferation of OECs were significantly
      increased. We observed changes to OECs subjected to hypoxia for 24 hours and
      treatment with exosomes. Exosomes significantly promoted the survival and
      migration of OECs in hypoxic conditions, and effectively increased brain-derived 
      neurotrophic factor gene expression, protein levels and secretion. Finally, using
      a 12 mm left sciatic nerve defect rat model, we confirmed that OECs and exosomes 
      can synergistically promote motor and sensory function of the injured sciatic
      nerve. These findings show that application of OECs and exosomes can promote
      nerve regeneration and functional recovery. This study was approved by the
      Institutional Ethical Committee of the Air Force Medical University, China
      (approval No. IACUC-20181004) on October 7, 2018; and collection and use of human
      umbilical cord specimens was approved by the Ethics Committee of the Linyi
      People's Hospital, China (approval No. 30054) on May 20, 2019.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, 
      Xi'an, Shaanxi Province, China.
FAU - Wang, Wen-Tao
AU  - Wang WT
AD  - Department of Orthopedics, Changhai Hospital, Naval Medical University, Shanghai,
      China.
FAU - Gong, Chun-Rong
AU  - Gong CR
AD  - Rehabilitation Center, North District Hospital of the People's Hospital of Lin Yi
      City, Linyi, Shandong Province, China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Orthopedics, The Eighth Medical Center of Chinese PLA general
      Hospital, Beijing, China.
FAU - Shi, Mei
AU  - Shi M
AD  - Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, 
      Xi'an, Shaanxi Province, China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7513967
OTO - NOTNLM
OT  - brain-derived neurotrophic factor
OT  - cell migration
OT  - cell viability
OT  - functional recovery
OT  - hypoxia
OT  - nerve regeneration
OT  - sciatic functional index
OT  - sciatic nerve injury
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - NeuralRegenRes_2020_15_10_1903_280330 [pii]
AID - 10.4103/1673-5374.280330 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Oct;15(10):1903-1911. doi: 10.4103/1673-5374.280330.


PMID- 32246635
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201009
IS  - 1673-5374 (Print)
IS  - 1673-5374 (Linking)
VI  - 15
IP  - 10
DP  - 2020 Oct
TI  - GFAP expression in the optic nerve and increased H2S generation in the
      integration centers of the rainbow trout (Oncorhynchus mykiss) brain after
      unilateral eye injury.
PG  - 1867-1886
LID - 10.4103/1673-5374.280320 [doi]
AB  - Hydrogen sulfide (H2S) is considered as a protective factor against
      cardiovascular disorders. However, there are few reports on the effects of H2S in
      the central nervous system during stress or injury. Previous studies on goldfish 
      have shown that astrocytic response occurs in the damaged and contralateral optic
      nerves. Glial fibrillary acidic protein (GFAP) concentration in the optic nerves 
      of rainbow trout has not been measured previously. This study further
      characterized the astrocytic response in the optic nerve and the brain of a
      rainbow trout (Oncorhynchus mykiss) after unilateral eye injury and estimated the
      amount of H2S-producing enzyme cystathionine beta-synthase (CBS) in the brain of 
      the rainbow trout. Within 1 week after unilateral eye injury, a protein band
      corresponding to a molecular weight of 50 kDa was identified in the ipsi- and
      contralateral optic nerves of the rainbow trout. The concentration of GFAP in the
      injured optic nerve increased compared to the protein concentration on the
      contralateral side. The results of a quantitative analysis of GFAP(+) cell
      distribution in the contralateral optic nerve showed the largest number of
      GFAP(+) cells and fibers in the optic nerve head. In the damaged optic nerve,
      patterns of GFAP(+) cell migration and large GFAP(+) bipolar activated astrocytes
      were detected at 1 week after unilateral eye injury. The study of H2S-producing
      system after unilateral eye injury in the rainbow trout was conducted using
      enzyme-linked immunosorbent assay, western blot analysis, and
      immunohistochemistry of polyclonal antibodies against CBS in the integrative
      centers of the brain: telencephalon, optic tectum, and cerebellum. Enzyme-linked 
      immunosorbent assay results showed a 1.7-fold increase in CBS expression in the
      rainbow trout brain at 1 week after unilateral eye injury compared with that in
      intact animals. In the ventricular and subventricular regions of the rainbow
      trout telencephalon, CBS(+) radial glia and neuroepithelial cells were
      identified. After unilateral eye injury, the number of CBS(+) neuroepithelial
      cells in the pallial and subpallial periventricular regions of the telencephalon 
      increased. In the optic tectum, unilateral eye injury led to an increase in CBS
      expression in radial glial cells; simultaneously, the number of CBS(+)
      neuroepithelial cells decreased in intact animals. In the cerebellum of the
      rainbow trout, neuroglial interrelationships were revealed, where H2S was
      released, apparently, from astrocyte-like cells. The organization of
      H2S-producing cell complexes suggests that, the amount of glutamate produced in
      the rainbow trout cerebellum and its reuptake was controlled by astrocyte-like
      cells, reducing its excitotoxicity. In the dorsal matrix zone and granular
      eminences of the rainbow trout cerebellum, CBS was expressed in neuroepithelial
      cells. After unilateral eye injury, the level of CBS activity increased in all
      parts of the cerebellum. An increase in the number of H2S-producing cells was a
      response to oxidative stress after unilateral eye injury, and the overproduction 
      of H2S in the cerebellum occurred to neutralize reactive oxygen species,
      providing the cells of the rainbow trout cerebellum with a protective effect. A
      structural reorganization in the dorsal matrix zone, associated with the
      appearance of an additional CBS(+) apical zone, and a decrease in the enzyme
      activity in the dorsal matrix zone, was revealed in the zones of constitutive
      neurogenesis. All experiments were approved by the Commission on Biomedical
      Ethics, A.V. Zhirmunsky National Scientific Center of Marine Biology (NSCMB), Far
      Eastern Branch, Russian Academy of Science (FEB RAS) (approval No. 1) on July 31,
      2019.
FAU - Pushchina, Evgeniya V
AU  - Pushchina EV
AD  - A.V. Zhirmunsky National Scientific Center of Marine Biology, Far Eastern Branch,
      Russian Academy of Sciences, Vladivostok, Russia; A.A. Bogomoletz Institute of
      Physiology, National Academy of Sciences of Ukraine, Kiev, Ukraine.
FAU - Varaksin, Anatoly A
AU  - Varaksin AA
AD  - A.V. Zhirmunsky National Scientific Center of Marine Biology, Far Eastern Branch,
      Russian Academy of Sciences, Vladivostok, Russia.
FAU - Obukhov, Dmitry K
AU  - Obukhov DK
AD  - St. Petersburg State University, St. Petersburg, Russia.
FAU - Prudnikov, Igor M
AU  - Prudnikov IM
AD  - A.A. Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine,
      Kiev, Ukraine.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC7513979
OTO - NOTNLM
OT  - astrocyte-like cells
OT  - glial fibrillary acidic protein
OT  - hydrogen sulfide
OT  - neuroepithelial cells
OT  - neuroprotection
OT  - radial glial cells
OT  - rainbow trout (Oncorhynchus mykiss)
OT  - reactive oxygen species
OT  - unilateral eye injury
COIS- None
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - NeuralRegenRes_2020_15_10_1867_280320 [pii]
AID - 10.4103/1673-5374.280320 [doi]
PST - ppublish
SO  - Neural Regen Res. 2020 Oct;15(10):1867-1886. doi: 10.4103/1673-5374.280320.


PMID- 32246246
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1573-076X (Electronic)
IS  - 0165-005X (Linking)
VI  - 44
IP  - 4
DP  - 2020 Dec
TI  - Working on and with Relationships: Relational Work and Spatial Understandings of 
      Good Care in Community Mental Healthcare in Trieste.
PG  - 544-564
LID - 10.1007/s11013-020-09672-8 [doi]
AB  - Deinstitutionalization is often described as an organizational shift of moving
      care from the psychiatric hospital towards the community. This paper analyses
      deinstitutionalization as a daily care practice by adopting an empirical ethics
      approach instead. Deinstitutionalization of mental healthcare is seen as an
      important way of improving the quality of lives of people suffering from severe
      mental illness. But how is this done in practice and which different goods are
      strived for by those involved? We examine these questions by giving an
      ethnographic description of community mental health care in Trieste, a city that 
      underwent a radical process of deinstitutionalization in the 1970s. We show that 
      paying attention to the spatial metaphors used in daily care direct us to
      different notions of good care in which relationships are central. Addressing the
      question of how daily care practices of mental healthcare outside the hospital
      may be constituted and the importance of spatial metaphors used may inform other 
      practices that want to shape community mental health care.
FAU - Muusse, Christien
AU  - Muusse C
AUID- ORCID: http://orcid.org/0000-0003-1746-1236
AD  - Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht,
      The Netherlands. cmuusse@trimbos.nl.
AD  - Section of Medical Ethics, Department of General Practice, UMC Amsterdam,
      Amsterdam, The Netherlands. cmuusse@trimbos.nl.
FAU - Kroon, Hans
AU  - Kroon H
AD  - Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht,
      The Netherlands.
AD  - Tranzo, School of Social and Behavioural Sciences, Tilburg University, Tilburg,
      The Netherlands.
FAU - Mulder, Cornelis L
AU  - Mulder CL
AD  - Erasmus MC, Rotterdam, The Netherlands.
AD  - Parnassia Psychiatric Institute, The Hague, The Netherlands.
FAU - Pols, Jeannette
AU  - Pols J
AUID- ORCID: http://orcid.org/0000-0003-0157-2388
AD  - Section of Medical Ethics, Department of General Practice, UMC Amsterdam,
      Amsterdam, The Netherlands.
AD  - Department of Anthropology, University of Amsterdam, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cult Med Psychiatry
JT  - Culture, medicine and psychiatry
JID - 7707467
SB  - IM
MH  - Anthropology, Cultural
MH  - *Community Mental Health Services
MH  - *Continuity of Patient Care
MH  - Crisis Intervention
MH  - *Deinstitutionalization
MH  - Health Services Accessibility
MH  - Humans
MH  - Italy
MH  - Mental Disorders/psychology/*rehabilitation
PMC - PMC7497456
OTO - NOTNLM
OT  - Care collectives
OT  - Community mental healthcare
OT  - Deinstitutionalization
OT  - Empirical ethics
OT  - Spatial metaphors
EDAT- 2020/04/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - 10.1007/s11013-020-09672-8 [doi]
AID - 10.1007/s11013-020-09672-8 [pii]
PST - ppublish
SO  - Cult Med Psychiatry. 2020 Dec;44(4):544-564. doi: 10.1007/s11013-020-09672-8.


PMID- 32246245
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Jun
TI  - How to Design AI for Social Good: Seven Essential Factors.
PG  - 1771-1796
LID - 10.1007/s11948-020-00213-5 [doi]
AB  - The idea of artificial intelligence for social good (henceforth AI4SG) is gaining
      traction within information societies in general and the AI community in
      particular. It has the potential to tackle social problems through the
      development of AI-based solutions. Yet, to date, there is only limited
      understanding of what makes AI socially good in theory, what counts as AI4SG in
      practice, and how to reproduce its initial successes in terms of policies. This
      article addresses this gap by identifying seven ethical factors that are
      essential for future AI4SG initiatives. The analysis is supported by 27 case
      examples of AI4SG projects. Some of these factors are almost entirely novel to
      AI, while the significance of other factors is heightened by the use of AI. From 
      each of these factors, corresponding best practices are formulated which, subject
      to context and balance, may serve as preliminary guidelines to ensure that
      well-designed AI is more likely to serve the social good.
FAU - Floridi, Luciano
AU  - Floridi L
AD  - Digital Ethics Lab, Oxford Internet Institute, University of Oxford, Oxford, UK.
AD  - The Alan Turing Institute, London, UK.
FAU - Cowls, Josh
AU  - Cowls J
AUID- ORCID: https://orcid.org/0000-0002-8545-5068
AD  - Digital Ethics Lab, Oxford Internet Institute, University of Oxford, Oxford, UK. 
      jcowls@turing.ac.uk.
AD  - The Alan Turing Institute, London, UK. jcowls@turing.ac.uk.
FAU - King, Thomas C
AU  - King TC
AD  - Digital Ethics Lab, Oxford Internet Institute, University of Oxford, Oxford, UK.
FAU - Taddeo, Mariarosaria
AU  - Taddeo M
AD  - Digital Ethics Lab, Oxford Internet Institute, University of Oxford, Oxford, UK.
AD  - The Alan Turing Institute, London, UK.
LA  - eng
GR  - Doctoral Studentship/The Alan Turing Institute/International
GR  - EP/N023013/1/Engineering and Physical Sciences Research Council/International
PT  - Journal Article
DEP - 20200403
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - *Morals
PMC - PMC7286860
OTO - NOTNLM
OT  - *AI4SG
OT  - *Artificial intelligence
OT  - *Ethics
OT  - *Privacy
OT  - *Safety
OT  - *Social good
OT  - *Transparency
EDAT- 2020/04/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - 10.1007/s11948-020-00213-5 [doi]
AID - 10.1007/s11948-020-00213-5 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Jun;26(3):1771-1796. doi: 10.1007/s11948-020-00213-5. Epub
      2020 Apr 3.


PMID- 32245804
OWN - NLM
STAT- Publisher
LR  - 20211216
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 3
TI  - Primer on an ethics of AI-based decision support systems in the clinic.
LID - medethics-2019-105860 [pii]
LID - 10.1136/medethics-2019-105860 [doi]
AB  - Making good decisions in extremely complex and difficult processes and situations
      has always been both a key task as well as a challenge in the clinic and has led 
      to a large amount of clinical, legal and ethical routines, protocols and
      reflections in order to guarantee fair, participatory and up-to-date pathways for
      clinical decision-making. Nevertheless, the complexity of processes and physical 
      phenomena, time as well as economic constraints and not least further endeavours 
      as well as achievements in medicine and healthcare continuously raise the need to
      evaluate and to improve clinical decision-making. This article scrutinises if and
      how clinical decision-making processes are challenged by the rise of so-called
      artificial intelligence-driven decision support systems (AI-DSS). In a first
      step, this article analyses how the rise of AI-DSS will affect and transform the 
      modes of interaction between different agents in the clinic. In a second step, we
      point out how these changing modes of interaction also imply shifts in the
      conditions of trustworthiness, epistemic challenges regarding transparency, the
      underlying normative concepts of agency and its embedding into concrete contexts 
      of deployment and, finally, the consequences for (possible) ascriptions of
      responsibility. Third, we draw first conclusions for further steps regarding a
      'meaningful human control' of clinical AI-DSS.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Braun, Matthias
AU  - Braun M
AUID- ORCID: http://orcid.org/0000-0002-6687-6027
AD  - Insitute for Systematic Theology, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany matthias.braun@fau.de.
FAU - Hummel, Patrik
AU  - Hummel P
AD  - Insitute for Systematic Theology, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany.
FAU - Beck, Susanne
AU  - Beck S
AD  - Institute for Criminal Law and Criminology, Leibniz University Hannover,
      Hannover, Germany.
FAU - Dabrock, Peter
AU  - Dabrock P
AD  - Insitute for Systematic Theology, Friedrich-Alexander University
      Erlangen-Nurnberg (FAU), Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
PMC - PMC8639945
OTO - NOTNLM
OT  - decision-making
OT  - ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/09/20 00:00 [received]
PHST- 2019/12/23 00:00 [revised]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:00 [medline]
AID - medethics-2019-105860 [pii]
AID - 10.1136/medethics-2019-105860 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 3. pii: medethics-2019-105860. doi:
      10.1136/medethics-2019-105860.


PMID- 32245769
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20200410
LR  - 20200410
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 Apr 3
TI  - Managing clinical trials for covid-19: the importance of ethics committees.
PG  - m1369
LID - 10.1136/bmj.m1369 [doi]
FAU - Luo, Qiankun
AU  - Luo Q
AD  - People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
FAU - Qin, Tao
AU  - Qin T
AD  - Department of Scientific Research and Discipline Construction, Department of
      Hepatobiliary Surgery, People's Hospital of Zhengzhou University, Henan
      Provincial People's Hospital, No 7, Weiwu Road, Zhengzhou 450003, China.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200403
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
CON - BMJ. 2020 Mar 16;368:m1071. PMID: 32179567
COIS- Competing interests: None declared.
EDAT- 2020/04/05 06:00
MHDA- 2020/04/05 06:01
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/05 06:01 [medline]
AID - 10.1136/bmj.m1369 [doi]
PST - epublish
SO  - BMJ. 2020 Apr 3;369:m1369. doi: 10.1136/bmj.m1369.


PMID- 32245717
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1878-7452 (Electronic)
IS  - 1878-7452 (Linking)
VI  - 77
IP  - 6
DP  - 2020 Nov - Dec
TI  - Surgical Inpatient's Attitudes Toward Resident Participation: All About
      Expectations.
PG  - e28-e33
LID - S1931-7204(20)30059-3 [pii]
LID - 10.1016/j.jsurg.2020.02.025 [doi]
AB  - OBJECTIVE: Determine whether an educational video can improve surgical
      inpatients' attitudes toward resident participation in their care. METHODS:
      Patients admitted to the Trauma/Emergency General Surgery Service at University
      Hospital (San Antonio, Texas) were randomly divided into control and intervention
      groups. Patients in the intervention group viewed a short educational video about
      the role and responsibilities of medical students, residents, and attending
      surgeons. All patients then completed a previously published survey. RESULTS: A
      total of 140 patients responded to the survey (control=81 and intervention=59
      patients). Overall, 86.4% of patients were welcoming of resident participation.
      Patients who were expecting residents to be involved in their care had attitudes 
      that are more favorable on almost all survey questions regardless of their study 
      condition. However, patients in the intervention group who expected resident
      involvement in their care had more favorable attitudes about senior residents
      (postgraduate year 3-5) assisting in routine or complicated surgery than those in
      the control group who were expecting resident involvement (both p </= 0.001).
      This same group of patients also had more favorable attitudes about surgical
      outcomes and overall surgical health when residents are involved (p=0.004,
      p=0.001, respectively). Most patients (79%) said they had no residents previously
      involved in their care, or they were unsure if residents were previously
      involved. CONCLUSIONS: Patient expectation of resident involvement is one of the 
      most important factors influencing perceptions of inpatients about resident
      participation in surgery. Our goal should be early and frequent discussion with
      patients about resident involvement in order to foster an atmosphere of trust,
      including full transparency regarding resident involvement in surgical
      procedures. An educational video may help introduce the roles of trainees and
      attending surgeons but should not be used in lieu of direct discussion with
      patients.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Beale, Katherine G
AU  - Beale KG
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Kempenich, Jason W
AU  - Kempenich JW
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
      Electronic address: kempenich@uthscsa.edu.
FAU - Willis, Ross E
AU  - Willis RE
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Al Fayyadh, Mohammed J
AU  - Al Fayyadh MJ
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Reed, Charles C
AU  - Reed CC
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Paccione, Carmen
AU  - Paccione C
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Ebeling, Peter A
AU  - Ebeling PA
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Dao Campi, Haisar E
AU  - Dao Campi HE
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Dent, Daniel L
AU  - Dent DL
AD  - University of Texas Health Science Center at San Antonio, San Antonio, Texas.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200401
PL  - United States
TA  - J Surg Educ
JT  - Journal of surgical education
JID - 101303204
SB  - IM
MH  - Attitude
MH  - Education, Medical, Graduate
MH  - *General Surgery/education
MH  - Humans
MH  - Inpatients
MH  - *Internship and Residency
MH  - Motivation
MH  - Texas
OTO - NOTNLM
OT  - Ethics
OT  - Graduate medical education
OT  - Program director
OT  - Resident training
OT  - Student education
COIS- Declarations of Competing Interest None.
EDAT- 2020/04/05 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/03/22 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - S1931-7204(20)30059-3 [pii]
AID - 10.1016/j.jsurg.2020.02.025 [doi]
PST - ppublish
SO  - J Surg Educ. 2020 Nov - Dec;77(6):e28-e33. doi: 10.1016/j.jsurg.2020.02.025. Epub
      2020 Apr 1.


PMID- 32245629
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20200601
IS  - 1532-1932 (Electronic)
IS  - 1521-6934 (Linking)
VI  - 65
DP  - 2020 May
TI  - Population-based genetic testing for Women's cancer prevention.
PG  - 139-153
LID - S1521-6934(20)30034-1 [pii]
LID - 10.1016/j.bpobgyn.2020.02.007 [doi]
AB  - Germline mutations in cancer-susceptibility-genes (CSG) can dramatically increase
      womens' lifetime risk of ovarian, endometrial, breast and bowel cancers.
      Identification of unaffected carriers is important to enable proactive engagement
      with highly effective screening and preventive options to minimise cancer risk.
      Currently, a family-history model is used to identify individuals with CSGs.
      Complex regional referral guidelines specify the family-history criteria required
      before an individual is eligible for genetic-testing. This model is ineffective, 
      resource intense, misses >50% CSG carriers, is associated with underutilisation
      of genetic-testing services and delays detection of mutation carriers. Although
      awareness and detection of CSG-carriers has improved, over 97% carriers remain
      unidentified. This reflects significant missed opportunities for
      precision-prevention. Population-based genetic-testing (PBGT) represents a novel 
      healthcare strategy with the potential to dramatically improve detection of
      unaffected CSG-carriers along with enabling population risk-stratification for
      cancer precision-prevention. Several research studies have assessed the impact,
      feasibility, acceptability, long-term psychological outcomes and
      cost-effectiveness of population-based BRCA-testing in the Ashkenazi-Jewish
      population. Initial data on PBGT in the general-population is beginning to emerge
      and large implementation studies investigating PBGT in the general-population are
      needed. This review will summarise the current research into the clinical,
      psycho-social, health-economic, societal and ethical consequences of a PBGT model
      for women's cancer precision-prevention.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Evans, Olivia
AU  - Evans O
AD  - Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary
      University of London, Charterhouse Square, London, EC1M 6BQ, UK; Department of
      Gynaecological Oncology, St Bartholomew's Hospital, EC1A 7BE, London, UK.
FAU - Gaba, Faiza
AU  - Gaba F
AD  - Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary
      University of London, Charterhouse Square, London, EC1M 6BQ, UK; Department of
      Gynaecological Oncology, St Bartholomew's Hospital, EC1A 7BE, London, UK.
FAU - Manchanda, Ranjit
AU  - Manchanda R
AD  - Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary
      University of London, Charterhouse Square, London, EC1M 6BQ, UK; Department of
      Gynaecological Oncology, St Bartholomew's Hospital, EC1A 7BE, London, UK.
      Electronic address: r.manchanda@qmul.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200302
PL  - Netherlands
TA  - Best Pract Res Clin Obstet Gynaecol
JT  - Best practice & research. Clinical obstetrics & gynaecology
JID - 101121582
SB  - IM
MH  - Breast Neoplasms/diagnosis/*genetics
MH  - Colorectal Neoplasms, Hereditary Nonpolyposis/ethnology/*genetics
MH  - Early Detection of Cancer
MH  - Female
MH  - Genes, BRCA1
MH  - Genes, BRCA2
MH  - Genetic Predisposition to Disease/*ethnology/genetics
MH  - Genetic Testing/*methods
MH  - *Genetics, Population
MH  - Hereditary Breast and Ovarian Cancer Syndrome/ethnology/*genetics
MH  - Humans
MH  - Mutation
MH  - Neoplasms
MH  - Ovarian Neoplasms/diagnosis/*genetics
OTO - NOTNLM
OT  - BRCA
OT  - Breast
OT  - Cancer
OT  - Lynch syndrome
OT  - Ovarian
OT  - Population-based genetic testing
COIS- Declaration of Competing Interest RM is supported by an NHS Innovation
      Accelerator (NIA) Fellowship and by The Eve Appeal. RM declares research funding 
      from Barts & the London Charity and Rosetrees Trust outside this work, an
      honorarium for grant review from Israel National Institute for Health Policy
      Research and honorarium for advisory board membership from Astrazeneca/MSD.
EDAT- 2020/04/05 06:00
MHDA- 2020/06/02 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/01/21 00:00 [received]
PHST- 2020/02/26 00:00 [accepted]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - S1521-6934(20)30034-1 [pii]
AID - 10.1016/j.bpobgyn.2020.02.007 [doi]
PST - ppublish
SO  - Best Pract Res Clin Obstet Gynaecol. 2020 May;65:139-153. doi:
      10.1016/j.bpobgyn.2020.02.007. Epub 2020 Mar 2.


PMID- 32245573
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20201013
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 107
DP  - 2020 Jun
TI  - Improving participation in research is first about truly informed consent.
PG  - 107042
LID - S1525-5050(20)30221-3 [pii]
LID - 10.1016/j.yebeh.2020.107042 [doi]
FAU - Braillon, Alain
AU  - Braillon A
AD  - University Hospital, 80000 Amiens, France. Electronic address:
      braillon.alain@gmail.com.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200401
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
SB  - IM
CON - Epilepsy Behav. 2020 Mar;104(Pt A):106907. PMID: 32000099
CIN - Epilepsy Behav. 2020 Jun;107:107049. PMID: 32253146
MH  - Anxiety
MH  - Anxiety Disorders
MH  - *Depression
MH  - *Epilepsy
MH  - Humans
MH  - Informed Consent
OTO - NOTNLM
OT  - *Communication
OT  - *Ethics
OT  - *Psychotherapy
OT  - *Quality of care
COIS- Declaration of competing interest The author reports no relationships that could 
      be construed as a conflict of interest.
EDAT- 2020/04/05 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/04/05 06:00 [entrez]
AID - S1525-5050(20)30221-3 [pii]
AID - 10.1016/j.yebeh.2020.107042 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2020 Jun;107:107042. doi: 10.1016/j.yebeh.2020.107042. Epub 2020 
      Apr 1.


PMID- 32245560
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20200420
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
VI  - 65
IP  - 842
DP  - 2020 Jan - Feb
PG  - 51-54
LID - S0038-0814(20)30013-X [pii]
LID - 10.1016/j.soin.2020.01.013 [doi]
AB  - When medicine and humanities are dissociated and then reconciled, what is the
      meaning of "medical humanities" today? What are the strengths and weaknesses of
      the French system? At a time when the link between the humanities and medicine
      seems more distended than ever, ten recommendations for developing and changing
      the way future doctors look at things are presented.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Fleury, Cynthia
AU  - Fleury C
AD  - 292 rue Saint-Martin, 75141 Paris cedex 03, France. Electronic address:
      cynthia.fleury-perkins@lecnam.net.
FAU - Berthelier, Benoit
AU  - Berthelier B
AD  - 45 rue d'Ulm, 75230 Paris cedex 05, France.
FAU - Nasr, Nathalie
AU  - Nasr N
AD  - Universite Toulouse III - Paul-Sabatier, 118 route de Narbonne, 31062 Toulouse
      cedex 9, France.
LA  - fre
PT  - Journal Article
TT  - L'enseignement des humanites dans les facultes de medecine francaises.
DEP - 20200128
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
MH  - Education, Medical/*organization & administration
MH  - France
MH  - Humanities/*education
MH  - Humans
MH  - Schools, Medical
OTO - NOTNLM
OT  - decision medicale
OT  - enseignement
OT  - ethics
OT  - faculte de medecine
OT  - formation
OT  - humanity
OT  - humanite
OT  - medical decision-making
OT  - medical faculty
OT  - medicine
OT  - medecine
OT  - teaching
OT  - training
OT  - ethique
EDAT- 2020/04/05 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - S0038-0814(20)30013-X [pii]
AID - 10.1016/j.soin.2020.01.013 [doi]
PST - ppublish
SO  - Soins. 2020 Jan - Feb;65(842):51-54. doi: 10.1016/j.soin.2020.01.013. Epub 2020
      Jan 28.


PMID- 32245558
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20200420
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
VI  - 65
IP  - 842
DP  - 2020 Jan - Feb
TI  - [Positive ethical regulation of digital technology in care plan].
PG  - 41-45
LID - S0038-0814(20)30008-6 [pii]
LID - 10.1016/j.soin.2020.01.008 [doi]
AB  - The shift in our healthcare system towards organisational models based on patient
      care management is one of the structural changes that have taken place in recent 
      years. Digital technology represents a major lever to support this
      transformation, which has high stakes for improving the quality and efficiency of
      patient care. Positive regulation of the associated ethical issues can be
      achieved through the principle of a human guarantee of digital technology and
      artificial intelligence in health care, which is currently being recognised in
      the framework of the revision of the bioethics law.
CI  - Copyright (c) 2020. Published by Elsevier Masson SAS.
FAU - Gruson, David
AU  - Gruson D
AD  - 13 rue de l'Universite, 75007 Paris, France; 11 boulevard de Sebastopol, 75001
      Paris, France. Electronic address: gruson.david@yahoo.fr.
LA  - fre
PT  - Journal Article
TT  - La regulation ethique positive du numerique dans les parcours de soins.
DEP - 20200124
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
MH  - Artificial Intelligence/ethics
MH  - Biomedical Technology/*ethics
MH  - Delivery of Health Care/*organization & administration
MH  - Humans
OTO - NOTNLM
OT  - Comite consultatif national d'ethique
OT  - National Consultative Ethics Committee
OT  - artificial intelligence
OT  - bioethics
OT  - bioethique
OT  - care plan
OT  - digital
OT  - garantie humaine
OT  - human guarantee
OT  - intelligence artificielle
OT  - numerique
OT  - parcours de soins
EDAT- 2020/04/05 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/05 06:00
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - S0038-0814(20)30008-6 [pii]
AID - 10.1016/j.soin.2020.01.008 [doi]
PST - ppublish
SO  - Soins. 2020 Jan - Feb;65(842):41-45. doi: 10.1016/j.soin.2020.01.008. Epub 2020
      Jan 24.


PMID- 32245465
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1472-6939 (Electronic)
IS  - 1472-6939 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Apr 3
TI  - Impact of legislation and public funding on oncofertility: a survey of Canadian, 
      French and Moroccan pediatric hematologists/oncologists.
PG  - 25
LID - 10.1186/s12910-020-00466-6 [doi]
AB  - BACKGROUND: Chemotherapy and/or radiotherapy treatments may cause premature
      ovarian failure and irreversible loss of fertility. In the context of childhood
      cancers, it is now acknowledged that possible negative effects of therapies on
      future reproductive autonomy are a major concern. While a few options are open to
      post-pubertal patients, the only immediate option currently open to pre-pubertal 
      girls is cryopreservation of ovarian tissue and subsequent transplantation. The
      aim of the study was to address a current gap in knowledge regarding the offer of
      fertility preservation by Ovarian Tissue Cryopreservation (OTC) for prepubescent 
      girls with cancer, and to explore current practices and attitudes of Canadian,
      French and Moroccan pediatric heme oncologists. The comparative perspective is
      relevant since legal frameworks surrounding fertility preservation and funding
      offered by the healthcare system vary greatly. METHODS: An online survey was sent
      to the 45 pediatric oncology centers in Canada, France and Morocco. RESULTS: A
      total of 39 centers responded (86.6%). OTC is offered by almost all pediatric
      heme oncologists in France (98%), very few in Canada (5%), and none in Morocco
      (0%). For pediatric hematologists/oncologists who do not propose fertility
      preservation in Canada, the reasons are: the technique is still experimental
      (54%), it is not available locally (26%) and cost of the technique for the family
      (14%). 97% of Canadian and 100% of Moroccan pediatric hematologists/oncologists
      think OTC should be funded by the healthcare system as it is in France and in the
      province of Quebec in Canada. CONCLUSIONS: The results of this study show
      tremendous diversity in the provision of OTC across countries, whereby its offer 
      is correlated with legislation and funding. We argue that the current reality, in
      which this technology is often not offered to families, raises ethical issues
      related to justice and equity of access, as well as informed consent and future
      reproductive autonomy.
FAU - Affdal, Aliya Oulaya
AU  - Affdal AO
AD  - Bioethics Program, Department of Social and Preventive Medicine, School of Public
      Health, University of Montreal, Montreal, Quebec, Canada. affdal-aliya@orange.fr.
AD  - Centre de Recherche en Sante Publique, Montreal, Quebec, Canada.
      affdal-aliya@orange.fr.
FAU - Grynberg, Michael
AU  - Grynberg M
AD  - Department of Reproductive Medicine & Fertility Preservation, Hopital Antoine
      Beclere, Clamart, France; Universite Paris Saclay, Clamart, France.
FAU - Hessissen, Laila
AU  - Hessissen L
AD  - Pediatric Hematology and Oncology Center, Mohamed V University, Rabat, Morocco.
FAU - Ravitsky, Vardit
AU  - Ravitsky V
AD  - Bioethics Program, Department of Social and Preventive Medicine, School of Public
      Health, University of Montreal, Montreal, Quebec, Canada.
AD  - Centre de Recherche en Sante Publique, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200403
PL  - England
TA  - BMC Med Ethics
JT  - BMC medical ethics
JID - 101088680
SB  - IM
MH  - Canada
MH  - Child
MH  - Female
MH  - *Fertility Preservation
MH  - France
MH  - Humans
MH  - Legislation as Topic
MH  - Male
MH  - *Neoplasms/therapy
MH  - *Oncologists
MH  - Quebec
PMC - PMC7118810
EDAT- 2020/04/05 06:00
MHDA- 2021/07/13 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/01/25 00:00 [received]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
AID - 10.1186/s12910-020-00466-6 [doi]
AID - 10.1186/s12910-020-00466-6 [pii]
PST - epublish
SO  - BMC Med Ethics. 2020 Apr 3;21(1):25. doi: 10.1186/s12910-020-00466-6.


PMID- 32244256
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1464-3685 (Electronic)
IS  - 0300-5771 (Linking)
VI  - 49
IP  - 1
DP  - 2020 Feb 1
TI  - Duplicate and salami publication: a prevalence study of journal policies.
PG  - 281-288
LID - 10.1093/ije/dyz187 [doi]
AB  - BACKGROUND: Duplicate and salami publication are unethical, but are common
      practices with substantial consequences for science and society at large.
      Scientific journals are the 'gatekeepers' of the publication process. We
      investigated journal policies on duplicate and salami publication. METHODS: In
      2018, we performed a content analysis of policies of journals in the disciplines 
      of 'epidemiology and public health' and 'general and internal medicine'. Journal 
      policies were searched, extracted, coded and cross-checked. The associations of
      disciplinary categories and journal impact factors with journal policies were
      examined using Poisson regression models with a robust error variance. RESULTS: A
      total of 209 journals, including 122 in epidemiology and public health and 87 in 
      general and internal medicine, were sampled and their policies investigated.
      Overall, 18% of journals did not have any policies on either practice, 33% only
      referred to a generic guideline or checklist without explicit mention about
      either practice, 36% included policies on duplicate publication and only 13%
      included policies on both duplicate and salami publication. Having explicit
      journal policies did not differ by journal disciplinary categories (epidemiology 
      and public health vs general and internal medicine) or impact factors. Further
      analysis of journals with explicit policies found that although duplicate
      publication is universally discouraged, policies on salami publication are
      inconsistent and lack specific definitions of inappropriate divisions of papers. 
      CONCLUSIONS: Gaps exist in journal policies on duplicate and salami publication, 
      characterized by an overall lack of explicit policies, inconsistency and
      confusion in definitions of bad practices, and lack of clearly defined
      consequences for non-compliance. Scientific publication and the academic reward
      systems must evolve to credit good research practice.
CI  - (c) The Author(s) 2019; all rights reserved. Published by Oxford University Press
      on behalf of the International Epidemiological Association.
FAU - Ding, Ding
AU  - Ding D
AD  - Prevention Research Collaboration, Sydney School of Public Health, Camperdown,
      NSW, Australia.
AD  - Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.
FAU - Nguyen, Binh
AU  - Nguyen B
AD  - Prevention Research Collaboration, Sydney School of Public Health, Camperdown,
      NSW, Australia.
AD  - Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.
FAU - Gebel, Klaus
AU  - Gebel K
AD  - Prevention Research Collaboration, Sydney School of Public Health, Camperdown,
      NSW, Australia.
AD  - Australian Centre for Public and Population Health Research, Faculty of Health,
      University of Technology Sydney, Ultimo, NSW, Australia.
AD  - Centre for Chronic Disease Prevention, College of Public Health, Medical and
      Veterinary Sciences, James Cook University, Smithfield, QLD, Australia.
FAU - Bauman, Adrian
AU  - Bauman A
AD  - Prevention Research Collaboration, Sydney School of Public Health, Camperdown,
      NSW, Australia.
AD  - Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.
FAU - Bero, Lisa
AU  - Bero L
AD  - Charles Perkins Centre, University of Sydney, Camperdown, NSW, Australia.
AD  - School of Pharmacy, Faculty of Medicine and Health, University of Sydney,
      Camperdown, NSW, Australia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Epidemiol
JT  - International journal of epidemiology
JID - 7802871
SB  - IM
MH  - Biomedical Research/*ethics
MH  - *Editorial Policies
MH  - Humans
MH  - Periodicals as Topic
MH  - Publishing/*ethics
MH  - *Scientific Misconduct
OTO - NOTNLM
OT  - *Publication ethics
OT  - *dual publication
OT  - *duplicate publication
OT  - *journal policies
OT  - *least publishable unit
OT  - *redundant publication
OT  - *salami publication
OT  - *salami slicing
OT  - *smallest publishable unit
EDAT- 2020/04/04 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/09/01 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
AID - 5570871 [pii]
AID - 10.1093/ije/dyz187 [doi]
PST - ppublish
SO  - Int J Epidemiol. 2020 Feb 1;49(1):281-288. doi: 10.1093/ije/dyz187.


PMID- 32243681
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 20
IP  - 8
DP  - 2020 Aug
TI  - Regulating the risk-reward trade-off in transplantation.
PG  - 2282-2283
LID - 10.1111/ajt.15882 [doi]
FAU - Sharif, Adnan
AU  - Sharif A
AUID- ORCID: 0000-0002-7586-9136
AD  - Department of Nephrology and Transplantation, Queen Elizabeth Hospital,
      University Hospitals Birmingham, Edgbaston, Birmingham, UK.
AD  - Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston,
      Birmingham, UK.
FAU - Montgomery, Robert A
AU  - Montgomery RA
AD  - NYU Langone Transplant Institute, New York, New York, USA.
LA  - eng
PT  - Letter
DEP - 20200415
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
CIN - Am J Transplant. 2020 Aug;20(8):2284. PMID: 32304176
MH  - Humans
MH  - *Organ Transplantation
MH  - Reward
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
OTO - NOTNLM
OT  - *clinical decision-making
OT  - *donors and donation
OT  - *ethics and public policy
OT  - *health services and outcomes research
OT  - *law/legislation
OT  - *organ procurement and allocation
OT  - *organ transplantation in general
OT  - *recipient selection
OT  - *risk assessment/risk stratification
OT  - *waitlist management
EDAT- 2020/04/04 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - 10.1111/ajt.15882 [doi]
PST - ppublish
SO  - Am J Transplant. 2020 Aug;20(8):2282-2283. doi: 10.1111/ajt.15882. Epub 2020 Apr 
      15.


PMID- 32243555
OWN - NLM
STAT- MEDLINE
DCOM- 20210127
LR  - 20210127
IS  - 1938-2421 (Electronic)
IS  - 0148-4834 (Linking)
VI  - 59
IP  - 4
DP  - 2020 Apr 1
TI  - A Simulation Experience for Preparing Nurses to Address Refusal of Childhood
      Vaccines.
PG  - 222-226
LID - 10.3928/01484834-20200323-09 [doi]
AB  - BACKGROUND: Parents' refusal of childhood immunizations presents a challenge to
      the provision of care to children. Nurses should be prepared for having difficult
      conversations with vaccine-refusing families and for contributing to discussions 
      with their colleagues regarding whether to continue to provide care to these
      families. METHOD: A novel high-fidelity ethics simulation experience was
      developed and implemented in the pediatrics course of a baccalaureate nursing
      program. The simulation experience involved a clinical scenario in which nurses
      encountered and addressed parental vaccine refusal and discussed options for
      addressing refusal with their physician colleagues. RESULTS: Three themes emerged
      from analysis of the students' evaluations of the simulation experience. Students
      reported feeling better prepared for addressing vaccine hesitancy, having greater
      awareness of their own biases toward vaccine-refusing families, and becoming
      newly acquainted with their potential role in enforcing practices' dismissal
      policies for vaccine-refusing families. CONCLUSION: Nurse educators should
      consider incorporating ethics simulation experiences into existing ethics
      instruction and clinical training. [J Nurs Educ. 2020;59(4):222-226.].
CI  - Copyright 2020, SLACK Incorporated.
FAU - Nold, Laura
AU  - Nold L
FAU - Deem, Michael J
AU  - Deem MJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nurs Educ
JT  - The Journal of nursing education
JID - 7705432
SB  - IM
MH  - Child
MH  - Clinical Competence/*standards
MH  - Education, Nursing, Baccalaureate/*methods
MH  - Evidence-Based Nursing/*methods
MH  - Humans
MH  - *Patient Simulation
MH  - Pediatric Nursing/*education
MH  - Students, Nursing/statistics & numerical data
MH  - Treatment Refusal/statistics & numerical data
EDAT- 2020/04/04 06:00
MHDA- 2021/01/28 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2019/11/25 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/01/28 06:00 [medline]
AID - 10.3928/01484834-20200323-09 [doi]
PST - ppublish
SO  - J Nurs Educ. 2020 Apr 1;59(4):222-226. doi: 10.3928/01484834-20200323-09.


PMID- 32243472
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20200713
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - Physicians' norms and attitudes towards substance use in colleague physicians: A 
      cross-sectional survey in the Netherlands.
PG  - e0231084
LID - 10.1371/journal.pone.0231084 [doi]
AB  - INTRODUCTION: Substance use disorders (SUD) in physicians often remain concealed 
      for a long time. Peer monitoring and open discussions with colleagues are
      essential for identifying SUD. However, physicians often feel uncomfortable
      discussing substance use with a colleague. We explored physicians' attitudes and 
      norms about substance use (disorders) and their (intended) approach upon a
      presumption of substance use in a colleague. MATERIALS AND METHODS: An online
      cross-sectional survey concerning "Addiction in physicians" was administered by
      the Royal Dutch Medical Association physician panel. Overall, 1685 physicians
      (47%) responded. Data were analyzed by logistic regression to explore factors
      associated with taking action upon a substance use presumption. RESULTS: Most
      physicians agreed that SUD can happen to anyone (67%), is not a sign of weakness 
      (78%) and that it is a disease that can be treated (83%). Substance use in a
      working context was perceived as unacceptable (alcohol at work: 99%, alcohol
      during a standby duty: 91%, alcohol in the eight hours before work: 77%, and
      illicit drugs in the eight hours before work: 97%). Almost all respondents (97%) 
      intend to act upon a substance use presumption in a colleague. Of the 29% who
      ever had this presumption, 65% took actual action. Actual action was associated
      with male gender and older age (OR = 1.81; 95% CI = 1.20-2.74 and OR = 1.03; 95% 
      CI = 1.01-1.05, respectively). CONCLUSIONS: About one-third of physicians
      reported experience with a presumption of substance use in a colleague. Whilst
      most physicians intend to take action upon such a presumption, two-thirds
      actually do act upon a presumption. To bridge this intention-behavior gap
      continued medical education on signs and symptoms of SUD and instructions on how 
      to enter a supportive dialogue with a colleague about personal issues, may
      enhance physicians' knowledge, confidence, and ethical responsibility to act upon
      a presumption of substance use or other concerns in a colleague.
FAU - Geuijen, Pauline
AU  - Geuijen P
AUID- ORCID: 0000-0001-9299-3860
AD  - Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour,
      Radboud University Medical Center, Nijmegen, the Netherlands.
AD  - Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen,
      the Netherlands.
AD  - Physician Health Program ABS-doctors, Royal Dutch Medical Association (RDMA),
      Utrecht, the Netherlands.
FAU - de Rond, Marlies
AU  - de Rond M
AD  - Physician Health Program ABS-doctors, Royal Dutch Medical Association (RDMA),
      Utrecht, the Netherlands.
FAU - Kuppens, Joanneke
AU  - Kuppens J
AD  - Physician Health Program ABS-doctors, Royal Dutch Medical Association (RDMA),
      Utrecht, the Netherlands.
FAU - Atsma, Femke
AU  - Atsma F
AD  - Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute
      for Health Sciences, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Schene, Aart
AU  - Schene A
AD  - Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour,
      Radboud University Medical Center, Nijmegen, the Netherlands.
FAU - de Haan, Hein
AU  - de Haan H
AD  - Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen,
      the Netherlands.
AD  - Tactus Addiction Treatment, Deventer, the Netherlands.
FAU - de Jong, Cornelis
AU  - de Jong C
AD  - Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen,
      the Netherlands.
AD  - Behavioral Science Institute, Radboud University, Nijmegen, the Netherlands.
FAU - Schellekens, Arnt
AU  - Schellekens A
AD  - Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour,
      Radboud University Medical Center, Nijmegen, the Netherlands.
AD  - Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Nijmegen,
      the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200403
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - *Physicians
MH  - Substance-Related Disorders/*epidemiology
PMC - PMC7122818
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/04 06:00
MHDA- 2020/07/14 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
AID - 10.1371/journal.pone.0231084 [doi]
AID - PONE-D-19-18507 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 3;15(4):e0231084. doi: 10.1371/journal.pone.0231084.
      eCollection 2020.


PMID- 32243442
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1545-7885 (Electronic)
IS  - 1544-9173 (Linking)
VI  - 18
IP  - 4
DP  - 2020 Apr
TI  - Every fifth published metagenome is not available to science.
PG  - e3000698
LID - 10.1371/journal.pbio.3000698 [doi]
AB  - Have you ever sought to use metagenomic DNA sequences reported in scientific
      publications? Were you successful? Here, we reveal that metagenomes from no fewer
      than 20% of the papers found in our literature search, published between 2016 and
      2019, were not deposited in a repository or were simply inaccessible. The
      proportion of inaccessible data within the literature has been increasing
      year-on-year. Noncompliance with Open Data is best predicted by the scientific
      discipline of the journal. The number of citations, journal type (e.g., Open
      Access or subscription journals), and publisher are not good predictors of data
      accessibility. However, many publications in high-impact factor journals do
      display a higher likelihood of accessible metagenomic data sets. Twenty-first
      century science demands compliance with the ethical standard of data sharing of
      metagenomes and DNA sequence data more broadly. Data accessibility must become
      one of the routine and mandatory components of manuscript submissions-a
      requirement that should be applicable across the increasing number of disciplines
      using metagenomics. Compliance must be ensured and reinforced by funders,
      publishers, editors, reviewers, and, ultimately, the authors.
FAU - Eckert, Ester M
AU  - Eckert EM
AUID- ORCID: 0000-0002-7314-1715
AD  - Molecular Ecology Group (MEG), Water Research Institute, National Research
      Council of Italy, Verbania Pallanza, Italy.
FAU - Di Cesare, Andrea
AU  - Di Cesare A
AD  - Molecular Ecology Group (MEG), Water Research Institute, National Research
      Council of Italy, Verbania Pallanza, Italy.
FAU - Fontaneto, Diego
AU  - Fontaneto D
AUID- ORCID: 0000-0002-5770-0353
AD  - Molecular Ecology Group (MEG), Water Research Institute, National Research
      Council of Italy, Verbania Pallanza, Italy.
FAU - Berendonk, Thomas U
AU  - Berendonk TU
AD  - Technische Universitat Dresden Institut fur Hydrobiologie, Dresden, Germany.
FAU - Burgmann, Helmut
AU  - Burgmann H
AUID- ORCID: 0000-0002-5651-5906
AD  - Eawag, Swiss Federal Institute of Aquatic Science and Technology, Kastanienbaum, 
      Switzerland.
FAU - Cytryn, Eddie
AU  - Cytryn E
AD  - Institute of Soil Water and Environmental Sciences, Volcani Center, Agricultural 
      Research Organization, Rishon Lezion, Israel.
FAU - Fatta-Kassinos, Despo
AU  - Fatta-Kassinos D
AD  - Department of Civil and Environmental Engineering and Nireas-International Water 
      Research Center, University of Cyprus, Nicosia, Cyprus.
FAU - Franzetti, Andrea
AU  - Franzetti A
AUID- ORCID: 0000-0003-1279-9940
AD  - University of Milano Bicocca, Milan, Italy.
FAU - Larsson, D G Joakim
AU  - Larsson DGJ
AUID- ORCID: 0000-0002-5496-0328
AD  - Centre for Antibiotic Resistance Research (CARe), University of Gothenburg,
      Gothenburg, Sweden.
AD  - Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy,
      University of Gothenburg, Gothenburg, Sweden.
FAU - Manaia, Celia M
AU  - Manaia CM
AD  - Universidade Catolica Portuguesa, CBQF-Centro de Biotecnologia e Quimica
      Fina-Laboratorio Associado, Escola Superior de Biotecnologia, Porto, Portugal.
FAU - Pruden, Amy
AU  - Pruden A
AUID- ORCID: 0000-0002-3191-6244
AD  - Department of Civil & Environmental Engineering, Blacksburg, Virginia, United
      States of America.
FAU - Singer, Andrew C
AU  - Singer AC
AUID- ORCID: 0000-0003-4705-6063
AD  - UK Centre for Ecology & Hydrology, Wallingford, United Kingdom.
FAU - Udikovic-Kolic, Nikolina
AU  - Udikovic-Kolic N
AD  - Division for Marine and Environmental Research, Rudjer Boskovic Institute,
      Zagreb, Croatia.
FAU - Corno, Gianluca
AU  - Corno G
AUID- ORCID: 0000-0002-7423-8797
AD  - Molecular Ecology Group (MEG), Water Research Institute, National Research
      Council of Italy, Verbania Pallanza, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200403
PL  - United States
TA  - PLoS Biol
JT  - PLoS biology
JID - 101183755
SB  - IM
MH  - *Access to Information
MH  - Bibliometrics
MH  - Journal Impact Factor
MH  - *Metagenome
MH  - Open Access Publishing
MH  - Publications/*statistics & numerical data
PMC - PMC7159239
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/04 06:00
MHDA- 2020/07/28 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - 10.1371/journal.pbio.3000698 [doi]
AID - PBIOLOGY-D-19-03403 [pii]
PST - epublish
SO  - PLoS Biol. 2020 Apr 3;18(4):e3000698. doi: 10.1371/journal.pbio.3000698.
      eCollection 2020 Apr.


PMID- 32243410
OWN - NLM
STAT- MEDLINE
DCOM- 20200408
LR  - 20210111
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - Effect of auriculotherapy on chronic low back pain: A protocol for systematic
      review and meta-analysis.
PG  - e19722
LID - 10.1097/MD.0000000000019722 [doi]
AB  - BACKGROUND: Chronic low back pain (CLBP) is a clinically common and recurrent
      disease. However, many trials have shown that auriculotherapy (AT) can
      effectively treat CLBP. There are currently no systematic reviews of this
      therapy. The plan aims to evaluate the effectiveness and safety of this treatment
      in patients with CLBP. METHODS: This systematic evaluation will entail an
      electronic and manual search of all AT for CLBP from inception to January 31,
      2020, regardless of the publication status or language. Databases include PubMed,
      Excerpt Medica Database, Springer, Web of Science, the Cochrane Library, the
      World Health Organization International Clinical Trial Registration Platform, the
      Chinese Medicine Database, the China National Knowledge Infrastructure, the
      Chinese Biomedical Literature Database, the China Science Journal Database, and
      the Wanfang Database. Other sources of information, including bibliographies and 
      meeting minutes for identified publications, will also be searched. A manual
      search for grey literature, including unpublished conference articles will be
      performed. Additionally, any clinical randomized controlled trials related to AT 
      for CLBP, regardless of the publication status and language limitations, will be 
      included in the study. Study selection, data extraction, and research quality
      assessments will be conducted independently by 2 researchers. The main result was
      the use of a visual analog scale, a short pain scale, or other effective scale.
      Secondary outcomes included effectiveness, Oswestry dysfunction index,
      self-rating anxiety scale, self-depression rating scale, Pittsburgh sleep quality
      index, follow-up relapse rate, and adverse events. The system searches for
      randomized controlled trials of this therapy for CLBP. Implement the Cochrane
      RevMan V5.3 bias assessment tool to assess bias risk, data integration risk,
      meta-analysis risk, and subgroup analysis risk (if conditions are met). Mean
      difference, standard mean deviation, and binary data will be used to represent
      continuous results. RESULTS: This study will provide a comprehensive review and
      evaluation of the available evidence for the treatment of CLBP using this
      therapy. CONCLUSION: This study will provide new evidence to evaluate the
      effectiveness and side effects of AT on CLBP. Because the data is not
      personalized, no formal ethical approval is required. PROSPERO REGISTRATION
      NUMBER: CRD42020151584.
FAU - Zhang, Guilong
AU  - Zhang G
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Zhang, Leixiao
AU  - Zhang L
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine.
FAU - Deng, Yanli
AU  - Deng Y
AD  - Sichuan Second Chinese Medicine Hospital.
FAU - Shen, Yuquan
AU  - Shen Y
AD  - The First People's Hospital of Longquanyi District, Chengdu, Sichuan, China.
FAU - Wang, Xinling
AU  - Wang X
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
FAU - Yu, Yang
AU  - Yu Y
AD  - Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Auriculotherapy/*methods
MH  - Chronic Pain/*therapy
MH  - Humans
MH  - Low Back Pain/*therapy
MH  - Meta-Analysis as Topic
MH  - Pain Measurement
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7440161
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1097/MD.0000000000019722 [doi]
AID - 00005792-202004030-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19722. doi: 10.1097/MD.0000000000019722.


PMID- 32243406
OWN - NLM
STAT- MEDLINE
DCOM- 20200408
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - Effect of changes in serum levels of endogenous hydrogen sulfide on fracture
      healing: Study protocol clinical trial (SPIRIT compliant).
PG  - e19684
LID - 10.1097/MD.0000000000019684 [doi]
AB  - BACKGROUND: Fracture is a common disease; many factors affect fracture healing.
      Recent studies have confirmed that hydrogen sulfide (H2S) plays an essential role
      in bone formation, but most of these studies are drawing conclusions based on
      animal experiment; whether H2S could promote fracture healing in patients is
      still unclear. We aim to investigate the change of serum H2S in fracture
      patients, and analyze its effort on fracture healing. METHODS: This is a
      single-center, prospective cohort study. Patients with spinal or limb fracture
      will be recruited. Patient's serum and urine will be collected at baseline for
      examination (serum H2S, beta-CTX, OC, PINP, 25-OH-VitD3, S-CTX, urinary calcium, 
      and urinary creatinine). All patients will be followed-up for 24 months in
      outpatients settings, the image of X-ray or CT will be reviewed and fracture
      healing will be judged by 2 experienced orthopedic physicians. The difference in 
      serum parameters especially H2S will be compared between patients with fracture
      healed within 9 months and those with fracture unhealed at 9 months. DISCUSSION: 
      Results of the trial could provide insight into influence of H2S on fracture
      healing. ETHICS AND DISSEMINATION: The study was approved by the ethics committee
      of School of Medicine UESTC & Sichuan Provincial People's Hospital Ethics
      Committee. All the participants will be asked to provide written informed consent
      before data collection. The findings of the study will be published in
      peer-reviewed journals and will be presented at national or international
      conferences.
FAU - Liao, Feng
AU  - Liao F
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Zhu, Zongdong
AU  - Zhu Z
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Xiao, Chengwei
AU  - Xiao C
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Tan, Bo
AU  - Tan B
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Tang, Xiaoming
AU  - Tang X
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Wei, Dan
AU  - Wei D
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Yuan, Jiabin
AU  - Yuan J
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
FAU - Xiang, Xuemei
AU  - Xiang X
AD  - Jane lab. Big Data Research Center, University of Electronic Science and
      Technology of China, Chengdu, China.
FAU - Hu, Jiang
AU  - Hu J
AD  - Department of Orthopaedics, Affiliated Hospital of University of Electronic
      Science and Technology & Sichuan Provincial People's Hospital.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - YY9FVM7NSN (Hydrogen Sulfide)
SB  - IM
MH  - Arm Injuries/blood
MH  - Fracture Healing/*physiology
MH  - Fractures, Bone/*blood/urine
MH  - Humans
MH  - Hydrogen Sulfide/*blood/urine
MH  - Leg Injuries/blood
MH  - Osteogenesis/physiology
MH  - Prospective Studies
MH  - Spinal Fractures/blood
PMC - PMC7440181
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1097/MD.0000000000019684 [doi]
AID - 00005792-202004030-00051 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19684. doi: 10.1097/MD.0000000000019684.


PMID- 32243401
OWN - NLM
STAT- MEDLINE
DCOM- 20200408
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - The effects of the wenyang huoxue method on coronary heart disease heart failure:
      A protocol for systematic review.
PG  - e19672
LID - 10.1097/MD.0000000000019672 [doi]
AB  - BACKGROUND: Coronary heart disease (CHD) has become the primary cause of heart
      failure (HF). Wenyang Huoxue method can significantly improve cardiac function in
      patients with CHD complicated with HF, but it has not been systematically
      evaluated for efficacy and safety. METHODS: We will search China National
      Knowledge Infrastructure Database, Wanfang database, China Biomedical Literature 
      Database, China Science Journal Database PubMed, Excerpt Medica Database, and
      Cochrane library. Clinical trial registrations, potential grey literature,
      related conference abstracts, and reference lists of identified studies will also
      be retrieved. The electronic database will be searched for literatures published 
      from January 2000 to September 2019. Based on the heterogeneity test, data
      integration is performed using a fixed effect model or a random effects model.
      Changes in total effective rate in cardiac function will be assessed as primary
      outcome. 6-minute walk test, left ventricular ejection fraction, and plasma brain
      natriuretic peptide will be assessed as secondary outcomes. RevMan 5.3.5 will be 
      used for meta-analysis. RESULTS: This study will provide a high-quality
      comprehensive evaluation of the efficacy and safety of Wenyang Huoxue method for 
      treating patients with CHD complicated with HF. CONCLUSIONS: This systematic
      review will determine whether Wenyang Huoxue method provides evidence for
      effective intervention in patients with CHD complicated with HF. ETHICS AND
      DISSEMINATION: This systematic review and meta-analysis of randomized controlled 
      trials does not require ethical recognition, and the results of this paper will
      be published in an open access, internationally influential academic journal.
      TRIAL REGISTRATION NUMBER: CRD42016025957.
FAU - Han, Wenbo
AU  - Han W
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
FAU - Zhao, Yong
AU  - Zhao Y
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
FAU - Wang, Yahong
AU  - Wang Y
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
FAU - Dai, Yanyan
AU  - Dai Y
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
FAU - Hao, Jinhong
AU  - Hao J
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
FAU - Li, Tianli
AU  - Li T
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
FAU - Wang, Xian
AU  - Wang X
AD  - Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese
      Medcine.
AD  - Institute of cardiovascular disease, Beijing University of Chinese Medicine,
      Beijing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Cardiovascular Physiological Phenomena/*drug effects
MH  - Coronary Disease/complications/*drug therapy/physiopathology
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Heart Failure/*drug therapy/etiology/physiopathology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7440105
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1097/MD.0000000000019672 [doi]
AID - 00005792-202004030-00046 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19672. doi: 10.1097/MD.0000000000019672.


PMID- 32243400
OWN - NLM
STAT- MEDLINE
DCOM- 20200408
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - Treatment for acute flares of gout: A protocol for systematic review.
PG  - e19668
LID - 10.1097/MD.0000000000019668 [doi]
AB  - INTRODUCTION: The current evidence confirms the effectiveness and safety of
      several drug interventions in the treatment of acute flares of gout, however, the
      most preferred drugs are still unclear. We, therefore, seek to conduct a network 
      meta-analysis that can systematically compare non-steroidal anti-inflammatory
      drugs (NSAIDs), COXIBs, colchicine, hormones, or IL-1 receptor antagonists, etc. 
      for acute gout based on the latest evidence. METHODS AND ANALYSIS: Nine online
      databases are searched with inception to September 1, 2019; there will be no
      language restrictions on the included trials. Randomized controlled trials that
      include patients with acute flares of gout receiving drug therapy versus a
      control group will be included. The selection of studies, risk of bias assessment
      and data extraction will be conducted by 2 independent researchers. Bayesian
      network meta-analysis is applied using the Markov chain Monte Carlo method with
      Stata or R. The dichotomous data will be presented as risk ratios with 95% CIs
      and the continuous data will be presented as weighted mean differences or
      standardized mean differences with 95% CIs. Evidence quality will be evaluated
      using the GRADE system. ETHICS AND DISSEMINATION: This network meta-analysis will
      not involve private information from personal or imperil their rights, so,
      ethical approval is not required. The results of this network meta-analysis may
      be published in a journal or publicized in concerned conferences.
FAU - Tang, Hongzhi
AU  - Tang H
AD  - Outpatient department of Sichuan orthopedic hospital.
FAU - Xu, Guixing
AU  - Xu G
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
FAU - Zheng, Qianhua
AU  - Zheng Q
AD  - The First Affiliated Hospital of Chengdu University of Chinese Medicine, Chengdu,
      Sichuan, China.
FAU - Cheng, Ying
AU  - Cheng Y
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
FAU - Zheng, Hui
AU  - Zheng H
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
FAU - Li, Juan
AU  - Li J
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
FAU - Yin, Zihan
AU  - Yin Z
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
FAU - Liang, Fanrong
AU  - Liang F
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
FAU - Chen, Jiao
AU  - Chen J
AD  - The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University
      of Traditional Chinese Medicine.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Gout Suppressants)
RN  - 0 (Receptors, Interleukin-1)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Bayes Theorem
MH  - Colchicine/*therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/*therapeutic use
MH  - Female
MH  - Gout/*drug therapy/pathology
MH  - Gout Suppressants/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Interleukin-1/antagonists & inhibitors
MH  - Research Design
MH  - Symptom Flare Up
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7440275
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1097/MD.0000000000019668 [doi]
AID - 00005792-202004030-00045 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19668. doi: 10.1097/MD.0000000000019668.


PMID- 32243379
OWN - NLM
STAT- MEDLINE
DCOM- 20200408
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - The microcirculatory characteristics of the heart and lung meridians: Study
      protocol clinical trial (SPIRIT Compliant).
PG  - e19594
LID - 10.1097/MD.0000000000019594 [doi]
AB  - INTRODUCTION: The aim of the present study is to compare the microcirculatory
      difference of different meridians by using laser doppler flowmetry and
      investigate the specificity for the meridian-visceral association and
      site-to-site association between 2 specific meridians. METHODS AND ANALYSIS: The 
      Lung and Heart meridians are chosen as 2 specific studied meridians. 120
      participants will be enrolled and divided into the healthy control group, chronic
      stable angina pectoris group and healthy intervention group. Laser doppler
      flowmetry will be used to assess the blood perfusion of the Heart and Lung
      meridians. The specificity for the meridian-visceral association will be
      investigated by comparing the microcirculatory difference between the Heart and
      Lung meridians in the healthy control group and chronic stable angina pectoris
      group. Besides, participants in the healthy intervention group will receive 2
      sessions of moxibustion in the Heart meridian and Lung meridian, respectively, to
      explore the specificity for the site-to-site association on the body surface.
      Primary outcomes will be blood flow curve and blood perfusion units of relevant
      sites along the Heart and Lung meridians. Statistical analysis will be conducted 
      by third party statisticians. ETHICS AND DISSEMINATION: Ethics approval (approval
      No: ZSLL-KY-2019-001A-01) has been obtained from the Ethics Committee of the
      Third Affiliated Hospital of Zhejiang Chinese Medical University. The study
      findings will be disseminated through presentation at peer-reviewed medical
      journals. TRIAL REGISTRATION: ClinicalTrials.gov NCT04244812.
FAU - Hu, Hantong
AU  - Hu H
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou
      City, Zhejiang Province.
FAU - Jiang, Yongliang
AU  - Jiang Y
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Li, Xiaoyu
AU  - Li X
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Lou, Jiali
AU  - Lou J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Zhang, Yajun
AU  - Zhang Y
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - He, Xiaofen
AU  - He X
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Fang, Junfan
AU  - Fang J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Wu, Yuanyuan
AU  - Wu Y
AD  - The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou
      City, Zhejiang Province.
FAU - Shao, Xiaomei
AU  - Shao X
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
FAU - Fang, Jianqiao
AU  - Fang J
AD  - Department of Neurobiology and Acupuncture Research, The Third Clinical Medical
      College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and
      Neurology of Zhejiang Province, Hangzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04244812
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adult
MH  - Angina, Stable/physiopathology
MH  - Female
MH  - Heart/*physiology
MH  - Hemodynamics
MH  - Humans
MH  - *Laser-Doppler Flowmetry
MH  - Lung/*physiology
MH  - Male
MH  - *Meridians
MH  - Microcirculation/*physiology
MH  - Middle Aged
MH  - Moxibustion
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Young Adult
PMC - PMC7220657
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1097/MD.0000000000019594 [doi]
AID - 00005792-202004030-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19594. doi: 10.1097/MD.0000000000019594.


PMID- 32243365
OWN - NLM
STAT- MEDLINE
DCOM- 20200420
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - Effects of anodal transcranial direct current stimulation over the contralesional
      hemisphere on motor recovery in subacute stroke patients with severe upper
      extremity hemiparesis: Study protocol for a randomized controlled trial.
PG  - e19495
LID - 10.1097/MD.0000000000019495 [doi]
AB  - INTRODUCTION: Upper extremity motor impairment is one of the major sequelae of
      stroke, resulting in limitations of activities of daily living. Recently,
      contralesional cortical activation has been reported to be important for motor
      recovery in stroke patients with severe upper extremity hemiparesis due to the
      extensive corticospinal tract involvement. We therefore designed this study to
      investigate the effects of contralesional anodal transcranial direct current
      stimulation (tDCS), which induces cortical activation, in stroke patients with
      severe upper extremity motor impairment. METHODS AND ANALYSIS: We will recruit
      patients with subacute stroke (<3 months after onset) with unilateral upper
      extremity weakness who meet the following criteria: Shoulder Abduction and Finger
      Extension (SAFE) score below 8, Fugl-Meyer Assessment for upper extremity
      (FMA-UE) score </=25, and absent motor evoked potential (MEP) response on the
      affected extensor carpi radialis muscle. Subjects will be randomly allocated to
      either the intervention (n = 18) or the control group (n = 18). The intervention 
      group will undergo 10 sessions of robotic arm rehabilitation with simultaneous
      anodal tDCS over the contralesional premotor area, whereas the control group will
      receive sham tDCS during the same sessions. One daily session consists of 25
      minutes.The primary outcome measure of this study is the Fugl-Meyer Assessment
      score of the upper extremity; the secondary outcome measures are the Korean
      version of the Modified Barthel Index, the Brunnstrom stage of the affected arm
      and hand, the Box and Block Test, the Modified Ashworth Scale, the Manual Muscle 
      Power Test, and the patient's encephalographic laterality index. DISCUSSION:
      Findings of this study will help to establish an individualized tDCS protocol
      according to the stroke severity and to find out the EEG parameters to predict
      the better recovery in subacute stroke patients with severe upper extremity
      hemiparesis. ETHICS AND DISSEMINATION: The study was approved by the Seoul
      National University Bundang Hospital Institutional Review Board (IRB No.
      B-1806-475-006) and will be carried out in accordance with the approved
      guidelines. The results of the trial will be submitted for publication in a
      peer-reviewed journal.
FAU - Lee, Stephanie Hyeyoung
AU  - Lee SH
AD  - Department of Rehabilitation Medicine, Seoul National University College of
      Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of
      Korea.
FAU - Kim, Won-Seok
AU  - Kim WS
FAU - Park, Jihong
AU  - Park J
FAU - Kim, Junsik
AU  - Kim J
FAU - Paik, Nam-Jong
AU  - Paik NJ
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Activities of Daily Living
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Double-Blind Method
MH  - Evoked Potentials, Motor
MH  - Female
MH  - Functional Laterality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Motor Cortex/physiopathology
MH  - Paresis/*rehabilitation
MH  - Recovery of Function
MH  - Stroke Rehabilitation/*methods
MH  - Transcranial Direct Current Stimulation/*methods
MH  - *Upper Extremity
MH  - Young Adult
PMC - PMC7220659
EDAT- 2020/04/04 06:00
MHDA- 2020/04/21 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/21 06:00 [medline]
AID - 10.1097/MD.0000000000019495 [doi]
AID - 00005792-202004030-00010 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19495. doi: 10.1097/MD.0000000000019495.


PMID- 32243214
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 5
DP  - 2020 Jul
TI  - A review of the literature on ethical issues related to scientific authorship.
PG  - 284-324
LID - 10.1080/08989621.2020.1750957 [doi]
AB  - The article at hand presents the results of a literature review on the ethical
      issues related to scientific authorship. These issues are understood as questions
      and/or concerns about obligations, values or virtues in relation to reporting,
      authorship and publication of research results. For this purpose, the Web of
      Science core collection was searched for English resources published between 1945
      and 2018, and a total of 324 items were analyzed. Based on the review of the
      documents, ten ethical themes have been identified, some of which entail several 
      ethical issues. Ranked on the basis of their frequency of occurrence these themes
      are: 1) attribution, 2) violations of the norms of authorship, 3) bias, 4)
      responsibility and accountability, 5) authorship order, 6) citations and
      referencing, 7) definition of authorship, 8) publication strategy, 9)
      originality, and 10) sanctions. In mapping these themes, the current article
      explores major ethical issue and provides a critical discussion about the
      application of codes of conduct, various understandings of culture, and
      contributing factors to unethical behavior.
FAU - Hosseini, Mohammad
AU  - Hosseini M
AUID- ORCID: 0000-0002-2385-985X
AD  - Institute of Ethics, School of Theology, Philosophy and Music, Dublin City
      University , Dublin, Ireland.
FAU - Gordijn, Bert
AU  - Gordijn B
AUID- ORCID: 0000-0002-3686-8659
AD  - Institute of Ethics, School of Theology, Philosophy and Music, Dublin City
      University , Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200416
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Authorship/standards
MH  - *Ethics, Research
MH  - Guidelines as Topic/standards
MH  - Humans
MH  - Periodicals as Topic/*standards
MH  - Plagiarism
MH  - Punishment
MH  - Scientific Misconduct/ethics
OTO - NOTNLM
OT  - *Scientific authorship
OT  - *ethical issues
OT  - *obligations
OT  - *responsibilities
OT  - *values
OT  - *virtues
EDAT- 2020/04/04 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - 10.1080/08989621.2020.1750957 [doi]
PST - ppublish
SO  - Account Res. 2020 Jul;27(5):284-324. doi: 10.1080/08989621.2020.1750957. Epub
      2020 Apr 16.


PMID- 32242971
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 43
IP  - 8
DP  - 2020 Aug
TI  - Cardiac evaluation of young athletes: Time for a risk-based approach?
PG  - 906-914
LID - 10.1002/clc.23364 [doi]
AB  - Pre-participation cardiovascular screening (PPCS) is recommended by several
      scientific and sporting organizations on the premise that early detection of
      cardiac disease provides a platform for individualized risk assessment and
      management; which has been proven to lower mortality rates for certain conditions
      associated with sudden cardiac arrest (SCA) and sudden cardiac death (SCD). What 
      constitutes the most effective strategy for PPCS of young athletes remains a
      topic of considerable debate. The addition of the electrocardiogram (ECG) to the 
      medical history and physical examination undoubtedly enhances early detection of 
      disease, which meets the primary objective of PPCS. The benefit of enhanced
      sensitivity must be carefully balanced against the risk of potential harm through
      increased false-positive findings, costly downstream investigations, and
      unnecessary restriction/disqualification from competitive sports. To mitigate
      this risk, it is essential that ECG-based PPCS programs are implemented by
      institutions with a strong infrastructure and by physicians appropriately trained
      in modern ECG standards with adequate cardiology resources to guide downstream
      investigations. While PPCS is compulsory for most competitive athletes, the
      current debate surrounding ECG-based programs exists in a binary form; whereby
      ECG screening is mandated for all competitive athletes or none at all. This
      polarized approach fails to consider individualized patient risk and the
      available sports cardiology resources. The limitations of a uniform approach are 
      highlighted by evolving data, which suggest that athletes display a differential 
      risk profile for SCA/SCD, which is influenced by age, sex, ethnicity, sporting
      discipline, and standard of play. Evaluation of the etiology of SCA/SCD within
      high-risk populations reveals a disproportionately higher prevalence of
      ECG-detectable conditions. Selective ECG screening using a risk-based approach
      may, therefore, offer a more cost-effective and feasible approach to PPCS in the 
      setting of limited sports cardiology resources, although this approach is not
      without important ethical considerations.
CI  - (c) 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
FAU - MacLachlan, Hamish
AU  - MacLachlan H
AUID- ORCID: https://orcid.org/0000-0001-8682-6193
AD  - Cardiovascular Sciences Research Centre, St Georges University of London, London,
      UK.
FAU - Drezner, Jonathan A
AU  - Drezner JA
AUID- ORCID: https://orcid.org/0000-0003-3519-9120
AD  - Department of Family Medicine and the Center for Sports Cardiology, University of
      Washington, Seattle, Washington, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200403
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
SB  - IM
MH  - *Athletes
MH  - *Early Diagnosis
MH  - Global Health
MH  - Heart Diseases/*diagnosis/epidemiology
MH  - Humans
MH  - Incidence
MH  - Risk Assessment/*methods
MH  - Risk Factors
PMC - PMC7403680
OTO - NOTNLM
OT  - ECG
OT  - athlete
OT  - risk
OT  - screening
OT  - sports cardiology
OT  - sudden cardiac death
EDAT- 2020/04/04 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/09/08 00:00 [received]
PHST- 2020/03/06 00:00 [revised]
PHST- 2020/03/13 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - 10.1002/clc.23364 [doi]
PST - ppublish
SO  - Clin Cardiol. 2020 Aug;43(8):906-914. doi: 10.1002/clc.23364. Epub 2020 Apr 3.


PMID- 32242823
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 2291-5222 (Electronic)
IS  - 2291-5222 (Linking)
VI  - 8
IP  - 4
DP  - 2020 Apr 3
TI  - Intervention and Evaluation of Mobile Health Technologies in Management of
      Patients Undergoing Chronic Dialysis: Scoping Review.
PG  - e15549
LID - 10.2196/15549 [doi]
AB  - BACKGROUND: Studies have shown the effectiveness and user acceptance of mobile
      health (mHealth) technologies in managing patients with chronic kidney disease
      (CKD). However, incorporating mHealth technology into the standard care of
      patients with CKD still faces many challenges. To our knowledge, there are no
      reviews on mHealth interventions and their assessments concerning the management 
      of patients undergoing dialysis. OBJECTIVE: This study provided a scoping review 
      on existing apps and interventions of mHealth technologies in adult patients
      undergoing chronic dialysis and identified the gaps in patient outcome assessment
      of mHealth technologies in the literature. METHODS: We systematically searched
      PubMed (MEDLINE), Scopus, and the Cumulative Index to Nursing and Allied Health
      Literature databases, as well as gray literature sources. Two keywords, "mHealth"
      and "dialysis," were combined to address the main concepts of the objectives.
      Inclusion criteria were as follows: (1) mHealth interventions, which are on a
      smartphone, tablet, or web-based portals that are accessible through mobile
      devices; and (2) adult patients (age >/=18 years) on chronic dialysis. Only
      English papers published from January 2008 to October 2018 were included. Studies
      with mHealth apps for other chronic conditions, based on e-consultation or
      videoconferencing, non-English publications, and review papers were excluded.
      RESULTS: Of the 1054 papers identified, 22 met the inclusion and exclusion
      criteria. Most studies (n=20) were randomized controlled trials and cohort
      studies. These studies were carried out in 7 countries. The main purposes of
      these mHealth interventions were as follows: nutrition or dietary self-monitoring
      (n=7), remote biometric monitoring (n=7), web-based portal (n=4), self-monitoring
      of in-session dialysis-specific information (n=3), and self-monitoring of
      lifestyle or behavioral change (n=1). The outcomes of the 22 included studies
      were organized into five categories: (1) patient satisfaction and acceptance, (2)
      clinical effectiveness, (3) economic assessment, (4) health-related quality of
      life, and (5) impact on lifestyle or behavioral change. The mHealth interventions
      showed neutral to positive results in chronic dialysis patient management,
      reporting no to significant improvement of dialysis-specific measurements and
      some components of the overall quality of life assessment. Evaluation of these
      mHealth interventions consistently demonstrated evidence in patients'
      satisfaction, high level of user acceptance, and reduced use of health resources 
      and cost savings to health care services. However, there is a lack of studies
      evaluating safety, organizational, sociocultural, ethical, and legal aspects of
      mHealth technologies. Furthermore, a comprehensive cost-effectiveness and
      cost-benefit analysis of adopting mHealth technologies was not found in the
      literature. CONCLUSIONS: The gaps identified in this study will inform the
      creation of health policies and organizational support for mHealth implementation
      in patients undergoing dialysis. The findings of this review will inform the
      development of a comprehensive service model that utilizes mHealth technologies
      for home monitoring and self-management of patients undergoing chronic dialysis.
CI  - (c)Yang Yang, Helen Chen, Hammad Qazi, Plinio P Morita. Originally published in
      JMIR mHealth and uHealth (http://mhealth.jmir.org), 03.04.2020.
FAU - Yang, Yang
AU  - Yang Y
AUID- ORCID: 0000-0001-7290-5851
AD  - School of Public Health and Health Systems, Faculty of Applied Health Sciences,
      University of Waterloo, Waterloo, ON, Canada.
FAU - Chen, Helen
AU  - Chen H
AUID- ORCID: 0000-0002-9401-7895
AD  - School of Public Health and Health Systems, Faculty of Applied Health Sciences,
      University of Waterloo, Waterloo, ON, Canada.
FAU - Qazi, Hammad
AU  - Qazi H
AUID- ORCID: 0000-0002-7160-2274
AD  - School of Public Health and Health Systems, Faculty of Applied Health Sciences,
      University of Waterloo, Waterloo, ON, Canada.
FAU - Morita, Plinio P
AU  - Morita PP
AUID- ORCID: 0000-0001-9515-6478
AD  - School of Public Health and Health Systems, Faculty of Applied Health Sciences,
      University of Waterloo, Waterloo, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200403
PL  - Canada
TA  - JMIR Mhealth Uhealth
JT  - JMIR mHealth and uHealth
JID - 101624439
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Humans
MH  - *Mobile Applications
MH  - Quality of Life
MH  - Renal Dialysis
MH  - Technology
MH  - *Telemedicine
PMC - PMC7165304
OTO - NOTNLM
OT  - *health technology assessment
OT  - *mobile health
OT  - *patient outcome assessment
OT  - *renal dialysis
EDAT- 2020/04/04 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2019/12/28 00:00 [revised]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
AID - v8i4e15549 [pii]
AID - 10.2196/15549 [doi]
PST - epublish
SO  - JMIR Mhealth Uhealth. 2020 Apr 3;8(4):e15549. doi: 10.2196/15549.


PMID- 32242770
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 30
IP  - 7
DP  - 2020 Jun
TI  - "I Look at You and See You Looking at Me": Role Boundaries in a Dynamic Research 
      Relationship in Qualitative Health Research With Refugees.
PG  - 1083-1100
LID - 10.1177/1049732320910411 [doi]
AB  - In institutional ethical and deontological guidelines, there is a prevailing,
      static understanding of the research partnership, with a clear boundary between
      researcher and participant. In this article, we argue that such a static
      understanding may run the risk of impeding the development of an enhanced
      contextual and dynamic intersubjective understanding of the research partnership 
      and its impact on the growing importance of role boundaries in qualitative
      research. Drawing from a refugee health study on trauma and forced migration, we 
      explore the different ways in which participants and the researcher engaged with 
      the researcher's multiple positions and role boundaries. In doing so, we aim to
      contribute to a reflective research practice by providing tools to recognize
      signs of potential harm and offer potential vehicles of reconstruction and agency
      within the intersubjective space of a dynamic research relationship, within a
      continuous, shared renegotiation process of role boundaries.
FAU - de Smet, Sofie
AU  - de Smet S
AUID- ORCID: 0000-0001-6747-2916
AD  - KU Leuven, Leuven, Belgium.
AD  - Universiteit Gent, Gent, Belgium.
FAU - Rousseau, Cecile
AU  - Rousseau C
AD  - McGill University, Montreal, Quebec, Canada.
FAU - Stalpaert, Christel
AU  - Stalpaert C
AD  - Universiteit Gent, Gent, Belgium.
FAU - De Haene, Lucia
AU  - De Haene L
AD  - KU Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200403
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
MH  - Humans
MH  - Qualitative Research
MH  - *Refugees
MH  - Research Personnel
OTO - NOTNLM
OT  - *Belgium
OT  - *case study
OT  - *ethics
OT  - *qualitative research
OT  - *refugees
OT  - *research partnerships
OT  - *role boudaries
OT  - *trauma
EDAT- 2020/04/04 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - 10.1177/1049732320910411 [doi]
PST - ppublish
SO  - Qual Health Res. 2020 Jun;30(7):1083-1100. doi: 10.1177/1049732320910411. Epub
      2020 Apr 3.


PMID- 32242398
OWN - NLM
STAT- MEDLINE
DCOM- 20210817
LR  - 20210817
IS  - 2589-451X (Electronic)
IS  - 0255-2922 (Linking)
VI  - 40
IP  - 2
DP  - 2020 Apr
TI  - "Efficacy and safety of the Qiguiyin formula in severe pneumonia: study protocol 
      for a randomized, double-blind, placebo-controlled clinical trial".
PG  - 317-323
AB  - OBJECTIVE: To evaluate the clinical efficacy and safety of Qiguiyin (QGY) formula
      in patients with severe pneumonia in China compared with a placebo. METHODS: This
      is a multicenter double-blind, placebo-controlled, randomized clinical trial with
      two parallel arms. There will be 530 patients enrolled and randomized into either
      the experimental group (QGY formula) or the control group (placebo). Therapies
      for patients in the two groups above will be based on the conventional therapy.
      The primary outcome is 28-day mortality. Secondary outcomes include: (a) duration
      of hospital stay; (b) duration of time in the intensive care unit (ICU) stays;
      (c) duration of mechanical ventilation; (d) antibiotic DDD value(which means the 
      doses of antibotics during the treatment period); (e) serum procalcitonin (PCT)
      level; (f) serum C-reactive protein (CRP) level; (g) Pneumonia severity index
      (PSI) score; (h) Sequential Organ Failure Assessment (SOFA) score; (i) sputum
      culture results; (j) blood routine examination results; (k) routine urine test
      results; (l) stool routine examination results; (m) electrocardiogram results;
      (n) alanine aminotransferase levels; (o) aspartate amino transferase levels; (p) 
      total bilirubin; (q) creatinine levels; (r) urea nitrogen levels; and (s) adverse
      events. ETHICS AND DISSEMINATION: The protocol has been approved by the Research 
      Ethics Committee of Beijing Hospital of Traditional Chinese Medicine, Affiliated 
      with Capital Medical University (2018BL- 053-02). This trial aims to provide
      evidence for QGY formula combined with conventional therapy in treating patients 
      with severe bacterial pneumonia, and to verify the clinical effectiveness and
      safety of QGY formula in China compared with placebo. Additionally, this trial
      will reveal the effect of QGY formula on delaying/reversing the characteristics
      of drug-resistant bacteria.
FAU - Huang, Po
AU  - Huang P
AD  - Department of Emergency Medicine, Beijing Hospital of Traditional Chinese
      Medicine, Clinical Medical College of Traditional Chinese Medicine, Capital
      Medical University, Beijing 100010, China.
FAU - Guo, Yuhong
AU  - Guo Y
AD  - Department of Emergency Medicine, Beijing Hospital of Traditional Chinese
      Medicine, Clinical Medical College of Traditional Chinese Medicine, Capital
      Medical University, Beijing 100010, China.
FAU - Zhao, Jingxia
AU  - Zhao J
AD  - Laboratory of Infection and Immunity, Beijing Institute of Traditional Chinese
      Medicine, Beijing 100010, China.
FAU - Li, Bo
AU  - Li B
AD  - Laboratory of Infection and Immunity, Beijing Institute of Traditional Chinese
      Medicine, Beijing 100010, China.
FAU - Wu, Yanqing
AU  - Wu Y
AD  - Department of Emergency Medicine, Beijing Hospital of Traditional Chinese
      Medicine, Clinical Medical College of Traditional Chinese Medicine, Capital
      Medical University, Beijing 100010, China.
FAU - Liu, Qingquan
AU  - Liu Q
AD  - Department of Emergency Medicine, Beijing Hospital of Traditional Chinese
      Medicine, Clinical Medical College of Traditional Chinese Medicine, Capital
      Medical University, Beijing 100010, China.
LA  - eng
SI  - ChiCTR/ChiCTR1800019785
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - J Tradit Chin Med
JT  - Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
JID - 8211546
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - China
MH  - Clinical Protocols
MH  - Double-Blind Method
MH  - Drugs, Chinese Herbal/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pneumonia/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - *Clinical protocol
OT  - *Drug resistance
OT  - *Pneumonia
OT  - *Pseudomonas aeruginosa
OT  - *Safety
OT  - *Treatment outcome
EDAT- 2020/04/04 06:00
MHDA- 2021/08/18 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/08/18 06:00 [medline]
AID - 3020 [pii]
PST - ppublish
SO  - J Tradit Chin Med. 2020 Apr;40(2):317-323.


PMID- 32242345
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200409
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 35
IP  - 13
DP  - 2020 Apr 6
TI  - Recent Decrease in Organ Donation from Brain-Dead Potential Organ Donors in Korea
      and Possible Causes.
PG  - e94
LID - 10.3346/jkms.2020.35.e94 [doi]
AB  - BACKGROUND: In 1999, the Organ Transplantation Act legalized organ donation from 
      brain-dead patients. As a result of the government's continued efforts, the
      number of brain-dead donors steadily increased from 2002 through 2016. However,
      the number has declined since 2017. This paper examined the possible reasons
      behind the decline in brain-dead organ donation. METHODS: This investigation was 
      an analysis of published data from the Korea Organ Donation Agency annual reports
      from 2013 to 2018. RESULTS: The number of brain-dead organ donors in Korea rose
      steadily until 2016, declined in 2017 for the first time since 2002, and then
      dropped sharply in 2018. Although the number of brain-dead potential organ donors
      increased between 2017 and 2018, the number of eligible donors decreased,
      suggesting that patient families rejected the brain-death determination process
      and brain-dead organ donation. Statistics gathered during identification of
      brain-dead potential donors and actual donations confirm that rejection or
      withdrawal of consent by the family has increased. During the same period when
      donation from brain- dead patients decreased, five events occurred: 1)
      compensation for donor families was abolished; 2) an incident of mistreatment of 
      a brain-dead donor's remains occurred; 3) the Life-Sustaining Treatment Act was
      enacted, providing a legal procedure whereby families of brain-dead patients
      could forgo life-sustaining treatment; 4) residents' work week was limited to 80 
      hours; and 5) the Labor Standards Law was amended. CONCLUSION: Fewer eligible
      donors in spite of an increase in brain-dead potential organ donors suggests that
      reduction in these donations resulted mainly from factors associated with family 
      consent. Among such factors, implementation of the Life-sustaining Treatment Act 
      appears to be most important. Abolition of family compensation and the incident
      in which a brain-dead donor's remains were mistreated may also have influenced
      family consent.
CI  - (c) 2020 The Korean Academy of Medical Sciences.
FAU - Park, Jin
AU  - Park J
AUID- ORCID: https://orcid.org/0000-0002-4597-6344
AD  - Department of Critical Care Medicine and Neurology, Ewha Womans University Seoul 
      Hospital, Seoul, Korea.
FAU - Kim, Claire Junga
AU  - Kim CJ
AUID- ORCID: https://orcid.org/0000-0001-6889-5478
AD  - Department of Medical Education, Ewha Womans University School of Medicine,
      Seoul, Korea. clairejungakim@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
SB  - IM
MH  - Brain Death
MH  - Eligibility Determination
MH  - *Family
MH  - Humans
MH  - *Informed Consent
MH  - *Organ Transplantation
MH  - Republic of Korea
MH  - *Tissue Donors
MH  - *Tissue and Organ Procurement/trends
PMC - PMC7131902
OTO - NOTNLM
OT  - Brain Death
OT  - Ethics
OT  - Family
OT  - Organ Donor
OT  - Organ Transplantation
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/09/26 00:00 [received]
PHST- 2020/02/10 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 35.e94 [pii]
AID - 10.3346/jkms.2020.35.e94 [doi]
PST - epublish
SO  - J Korean Med Sci. 2020 Apr 6;35(13):e94. doi: 10.3346/jkms.2020.35.e94.


PMID- 32242266
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210504
IS  - 2509-9280 (Electronic)
IS  - 2509-9280 (Linking)
VI  - 4
IP  - 1
DP  - 2020 Apr 3
TI  - Image quality of late gadolinium enhancement in cardiac magnetic resonance with
      different doses of contrast material in patients with chronic myocardial
      infarction.
PG  - 21
LID - 10.1186/s41747-020-00149-2 [doi]
AB  - BACKGROUND: Contrast-enhanced cardiac magnetic resonance (CMR) is pivotal for
      evaluating chronic myocardial infarction (CMI). Concerns about safety of
      gadolinium-based contrast agents favour dose reduction. We assessed image quality
      of scar tissue in CMRs performed with different doses of gadobutrol in CMI
      patients. METHODS: Informed consent was waived for this Ethics Committee-approved
      single-centre retrospective study. Consecutive contrast-enhanced CMRs from CMI
      patients were retrospectively analysed according to the administered gadobutrol
      dose (group A, 0.10 mmol/kg; group B, 0.15 mmol/kg; group C, 0.20 mmol/kg). We
      calculated the signal-to-noise ratio for scar tissue (SNRscar) and
      contrast-to-noise ratio between scar and either remote myocardium (CNRscar-rem)
      or blood (CNRscar-blood). RESULTS: Of 79 CMRs from 79 patients, 22 belonged to
      group A, 26 to group B, and 31 to group C. The groups were homogeneous for age,
      sex, left ventricular morpho-functional parameters, and percentage of scar tissue
      over whole myocardium (p >/= 0.300). SNRscar was lower in group A (46.4;
      40.3-65.1) than in group B (70.1; 52.2-111.5) (p = 0.013) and group C (72.1;
      59.4-100.0) (p = 0.002), CNRscar-rem was lower in group A (62.9; 52.2-87.4) than 
      in group B (96.5; 73.1-152.8) (p = 0.008) and in group C (103.9; 83.9-132.0) (p =
      0.001). No other significant differences were found (p >/= 0.335). CONCLUSIONS:
      Gadobutrol at 0.10 mmol/kg provides inferior scar image quality of CMI than 0.15 
      and 0.20 mmol/kg; the last two dosages seem to provide similar LGE. Thus, for CMR
      of CMI, 0.15 mmol/kg of gadobutrol can be suggested instead of 0.20 mmol/kg, with
      no hindrance to scar visualisation. Dose reduction would not impact on diagnostic
      utility of CMR examinations.
FAU - Monti, Caterina Beatrice
AU  - Monti CB
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133, Milano, Italy.
FAU - Codari, Marina
AU  - Codari M
AD  - Department of Electronics, Information and Bioengineering, Politecnico di Milano,
      Via Ponzio 34/5, 20133, Milano, Italy.
FAU - Cozzi, Andrea
AU  - Cozzi A
AUID- ORCID: http://orcid.org/0000-0003-4922-7065
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Mangiagalli 31, 20133, Milano, Italy. andrea.cozzi1@unimi.it.
FAU - Ali, Marco
AU  - Ali M
AD  - Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097, San
      Donato Milanese, Italy.
AD  - Unit of Diagnostic Imaging and Stereotactic Radiosurgery, C.D.I. Centro
      Diagnostico Italiano S.p.A., Via Saint Bon 20, 20147, Milano, Italy.
FAU - Saggiante, Lorenzo
AU  - Saggiante L
AD  - Postgraduate School in Radiodiagnostics, Universita degli Studi di Milano, Via
      Festa del Perdono 7, 20122, Milano, Italy.
FAU - Sardanelli, Francesco
AU  - Sardanelli F
AD  - Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097, San
      Donato Milanese, Italy.
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Morandi 30, 20097, San Donato Milanese, Italy.
FAU - Secchi, Francesco
AU  - Secchi F
AD  - Unit of Radiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097, San
      Donato Milanese, Italy.
AD  - Department of Biomedical Sciences for Health, Universita degli Studi di Milano,
      Via Morandi 30, 20097, San Donato Milanese, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200403
PL  - England
TA  - Eur Radiol Exp
JT  - European radiology experimental
JID - 101721752
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 1BJ477IO2L (gadobutrol)
SB  - IM
MH  - Aged
MH  - Chronic Disease
MH  - Cicatrix/*diagnostic imaging
MH  - Contrast Media/*administration & dosage
MH  - Female
MH  - Humans
MH  - Image Interpretation, Computer-Assisted
MH  - Magnetic Resonance Imaging, Cine/*methods
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*diagnostic imaging
MH  - Organometallic Compounds/*administration & dosage
MH  - Retrospective Studies
MH  - Signal-To-Noise Ratio
PMC - PMC7118177
OTO - NOTNLM
OT  - *Contrast media
OT  - *Gadobutrol
OT  - *Gadolinium
OT  - *Magnetic resonance imaging
OT  - *Myocardial infarction
EDAT- 2020/04/04 06:00
MHDA- 2021/05/05 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
AID - 10.1186/s41747-020-00149-2 [doi]
AID - 10.1186/s41747-020-00149-2 [pii]
PST - epublish
SO  - Eur Radiol Exp. 2020 Apr 3;4(1):21. doi: 10.1186/s41747-020-00149-2.


PMID- 32241824
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20200721
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
VI  - 145
IP  - 5
DP  - 2020 May
TI  - All for One and One Delivery Room Approach for All?
LID - e20192704 [pii]
LID - 10.1542/peds.2019-2704 [doi]
AB  - Multiple births are increasing in frequency related to advanced maternal age and 
      fertility treatments, and they have an increased risk for congenital anomalies
      compared to singleton births. However, twins have the same congenital anomalies
      <15% of the time. Thus, having multiple births with discordant anomalies is a
      growing challenge for neonatologists. Although external anomalies can often be
      spotted quickly at delivery or sex differences between multiples can rapidly
      identify those with internal anomalies described on prenatal ultrasound, we
      present a case of male multiples, who would optimally receive different initial
      resuscitation strategies on the basis of the presence or absence of an internal
      anomaly. The similar size of 4 extremely preterm quadruplets raises concern for
      whether accurate, immediate identification of 1 neonate with a congenital
      diaphragmatic hernia will be reliable in the delivery room. Clinicians discuss
      the ethical considerations of an "all for one" approach to this resuscitation.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Kiefer, Autumn
AU  - Kiefer A
AD  - Department of Pediatrics, School of Medicine, West Virginia University,
      Morgantown, West Virginia; askiefer@hsc.wvu.edu.
FAU - Johnson Rolfes, Julie
AU  - Johnson Rolfes J
AD  - Division of Neonatology, Department of Pediatrics, Medical School, University of 
      Minnesota, Minneapolis, Minnesota.
FAU - Barretto, Greg Jr
AU  - Barretto G Jr
AD  - Department of Pediatrics, School of Medicine, University of Pittsburgh,
      Pittsburgh, Pennsylvania; and.
FAU - Lantos, John D
AU  - Lantos JD
AD  - Bioethics Center, Children's Mercy Hospital, Kansas City, Missouri.
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20200402
PL  - United States
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
SB  - IM
MH  - Cesarean Section/*ethics/methods
MH  - Delivery Rooms/*ethics
MH  - Delivery, Obstetric/ethics/methods
MH  - Female
MH  - Fetal Membranes, Premature Rupture/*diagnosis/*therapy
MH  - Humans
MH  - *Infant, Extremely Premature/physiology
MH  - Infant, Newborn
MH  - Intubation, Intratracheal/ethics/methods
MH  - Pregnancy
MH  - *Pregnancy, Quadruplet/physiology
COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential
      conflicts of interest to disclose.
EDAT- 2020/04/04 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/09/23 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - peds.2019-2704 [pii]
AID - 10.1542/peds.2019-2704 [doi]
PST - ppublish
SO  - Pediatrics. 2020 May;145(5). pii: peds.2019-2704. doi: 10.1542/peds.2019-2704.
      Epub 2020 Apr 2.


PMID- 32241807
OWN - NLM
STAT- Publisher
LR  - 20200403
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Apr 2
TI  - Audio and panoramic video recording in the operating room: legal and ethical
      perspectives.
LID - medethics-2019-106056 [pii]
LID - 10.1136/medethics-2019-106056 [doi]
AB  - INTRODUCTION: The idea of video recording (VR) in the operating room (OR) with
      panoramic cameras and microphones is a new concept that is changing the approach 
      to medical activities in the OR. However, VR in the OR has brought up many
      concerns regarding patient privacy and has highlighted legal and ethical issues
      that were never previously exposed. AIM: To review the literature concerning
      these aspects and provide a better ethical and legal understanding of the new
      challenges concerning VR in the OR. CONCLUSIONS: There is a disparity between the
      two main legal models concerning VR in the OR, namely the European legal system
      (General Data Protection Regulation (GDPR)) and the American legal framework
      (Health Insurance Portability and Accountability Act (HIPAA)). This difference
      mainly deals with two distinct bioethical paradigms: GDPR places a strong
      emphasis on protecting patients' privacy to improve the public health system,
      whereas HIPAA indicates the need to generate protocols to safeguard the risks
      connected to medical activity and patient privacy. Following from this point, we 
      may argue that, at the ethical and bioethical level, GDPR and HIPAA depend mainly
      on two different ethical models: a perspective based on moral acquaintances and
      weak proceduralism, respectively. It is worth noting the importance of developing
      additional guidelines concerning different world regions to avoid the ethical
      problems that may emerge when simply applying a foreign paradigm to a very
      different culture.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Gabrielli, Mauricio
AU  - Gabrielli M
AD  - Department of Digestive Surgery, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Valera, Luca
AU  - Valera L
AD  - Department of Philosophy, Bioethics Centre, Pontificia Universidad Catolica de
      Chile, Santiago, Chile luvalera@uc.cl.
FAU - Barrientos, Marcelo
AU  - Barrientos M
AD  - Department of Law, Insurance Research Center, Pontificia Universidad Catolica de 
      Chile, Santiago, Chile.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - clinical ethics
OT  - informed consent
OT  - legal aspects
OT  - research ethics
OT  - surgery
COIS- Competing interests: None declared.
EDAT- 2020/04/04 06:00
MHDA- 2020/04/04 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/04 06:00 [medline]
AID - medethics-2019-106056 [pii]
AID - 10.1136/medethics-2019-106056 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Apr 2. pii: medethics-2019-106056. doi:
      10.1136/medethics-2019-106056.


PMID- 32241806
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 8
DP  - 2020 Aug
TI  - Hope or despair: a response to 'Do not despair about severity-yet'.
PG  - 559
LID - 10.1136/medethics-2020-106162 [doi]
AB  - This is a brief response to 'Do not despair about severity-yet' by Barra et al It
      argues that they have no serious criticisms of Daniel Hausman's essay, 'The
      Significance of Severity'" and that indeed their work lends further support to
      his view that there is no justification for prioritising severity. As
      policy-akers, Barra and his coauthors are more constrained by popular attitudes, 
      which apparently favour prioritising severity.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hausman, Daniel
AU  - Hausman D
AUID- ORCID: 0000-0003-0249-3518
AD  - Department of Philosophy, University of Wisconsin-Madison, Madison, WI 53711, USA
      dhausman@wisc.edu.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200402
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2019 Aug;45(8):545-551. PMID: 31249106
CON - J Med Ethics. 2020 Aug;46(8):557-558. PMID: 32098908
MH  - *Hope
MH  - Humans
OTO - NOTNLM
OT  - *allocation of health care resources
OT  - *ethics
OT  - *health care economics
OT  - *philosophy of medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/04 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - medethics-2020-106162 [pii]
AID - 10.1136/medethics-2020-106162 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Aug;46(8):559. doi: 10.1136/medethics-2020-106162. Epub 2020
      Apr 2.


PMID- 32241801
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20201218
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 47
IP  - 6
DP  - 2020 Jun 1
TI  - Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the
      COVID-19 Pandemic.
PG  - 783-786
LID - 10.3899/jrheum.200369 [doi]
FAU - Scuccimarri, Rosie
AU  - Scuccimarri R
AD  - Division of Pediatric Rheumatology, McGill University Health Centre, Montreal,
      Quebec, and Chair, Canadian Rheumatology Association (CRA) Therapeutics
      Committee.
FAU - Sutton, Evelyn
AU  - Sutton E
AD  - Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, and
      President, CRA.
FAU - Fitzcharles, Mary-Ann
AU  - Fitzcharles MA
AD  - Alan Edwards Pain Management Unit, Division of Rheumatology, McGill University
      Health Centre, Montreal, Quebec, Canada, and Past Chair, CRA Therapeutics
      Committee. mfitzcharles@sympatico.ca.
LA  - eng
PT  - Editorial
DEP - 20200402
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Antirheumatic Agents/*therapeutic use
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/diagnosis/*drug therapy
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Hydroxychloroquine/*therapeutic use
MH  - Male
MH  - Pandemics/prevention & control/*statistics & numerical data
MH  - Pneumonia, Viral/diagnosis/*drug therapy
MH  - Prognosis
MH  - Rheumatologists/*ethics
MH  - Risk Assessment
MH  - SARS-CoV-2
MH  - Treatment Outcome
EDAT- 2020/04/04 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - jrheum.200369 [pii]
AID - 10.3899/jrheum.200369 [doi]
PST - ppublish
SO  - J Rheumatol. 2020 Jun 1;47(6):783-786. doi: 10.3899/jrheum.200369. Epub 2020 Apr 
      2.


PMID- 32241789
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 1
TI  - Acupuncture for poststroke hemiplegia focusing on cerebral bilateral connections:
      study protocol for a randomised controlled neuroimaging trial.
PG  - e034548
LID - 10.1136/bmjopen-2019-034548 [doi]
AB  - INTRODUCTION: Acupuncture is safe and effective for improving the motor function 
      of poststroke hemiplegic patients, but there still exists a certain gap between
      clinical practice and understanding its neural mechanisms. The cerebral
      functional reconstruction after unilateral motor pathway injury exhibits a
      bilateral tendency, however current studies seldom pay attention to it. Hence,
      based on cerebral bilateral connections, the underlying mechanism of acupuncture 
      in stroke rehabilitation remains an area for further research. The results of
      this study will increase our understanding of acupuncture-induced motor recovery 
      in patients who had suffered a stroke and demonstrate the differences in brain
      response and clinical assessments. METHODS AND ANALYSIS: This is a single-centre,
      randomised controlled, paralleled neuroimaging trial, with patients and outcome
      assessors blinded. Thirty patients who had a stroke with motor dysfunction
      meeting the inclusion criteria will be randomly assigned (2:1) to receive either 
      10 sessions true or sham acupoints treatments (five sessions per week for 2
      weeks). All the participants will receive conventional standard medical care and 
      rehabilitation. Motor function assessments and neuroimaging scanning will be
      conducted before and after the entire acupuncture treatment. The clinical and
      neuroimaging data will be analysed, respectively. The voxel-mirrored homotopic
      connectivity will be the primary outcome and the primary effect indicator. The
      secondary outcomes comprise clinical evaluations and neuroimaging assessments,
      which include Fugl-Meyer Assessment, the National Institutes of Health Stroke
      Scale, fractional anisotropy and gray matter volume. The Needle Sensation
      Assessment Scale is an additional outcome. The correlation analysis will be
      explored between the neuroimaging indicators, clinical motor assessments and
      needle sensation. ETHICS AND DISSEMINATION: The protocol has been approved by the
      ethics committee of Dongzhimen Hospital affiliated to Beijing University of
      Chinese Medicine (DZMEC-KY-2018-04). The results of the neuroimaging trial will
      be disseminated through peer-reviewed publications and conferences. TRIAL
      REGISTRATION NUMBER: Chinese Clinical Trials Registry (ChiCTR 1800016263).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Jiang, Lan
AU  - Jiang L
AUID- ORCID: 0000-0002-2630-1966
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Geng, Hualei
AU  - Geng H
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Lu, Mengxin
AU  - Lu M
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Du, Zhongming
AU  - Du Z
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Chen, Pei
AU  - Chen P
AD  - The National Clinical Research Center for Mental Disorders & Beijing Key
      Laboratory of Mental Disorders, Beijing An Ding Hospital, Beijing, China.
FAU - Han, Xiao
AU  - Han X
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Tang, Lixin
AU  - Tang L
AD  - Department of Acupuncture, Dongzhimen Hospital, The First Affiliated Hospital of 
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Tan, Zhongjian
AU  - Tan Z
AD  - Department of Radiology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China.
FAU - Zou, Yihuai
AU  - Zou Y
AD  - Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of
      Beijing University of Chinese Medicine, Beijing, China zouyihuai2004@163.com.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200401
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Acupuncture Therapy
MH  - Hemiplegia/etiology/*therapy
MH  - Humans
MH  - Neuroimaging
MH  - Randomized Controlled Trials as Topic
MH  - *Stroke/complications
MH  - *Stroke Rehabilitation
MH  - Treatment Outcome
PMC - PMC7170640
OTO - NOTNLM
OT  - *complementary medicine
OT  - *rehabilitation medicine
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/04/04 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - bmjopen-2019-034548 [pii]
AID - 10.1136/bmjopen-2019-034548 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 1;10(4):e034548. doi: 10.1136/bmjopen-2019-034548.


PMID- 32241788
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 1
TI  - Outcome measures evaluating physical functioning and their measurement properties
      in adolescent idiopathic scoliosis: a protocol for a systematic review.
PG  - e034286
LID - 10.1136/bmjopen-2019-034286 [doi]
AB  - INTRODUCTION: Physical functioning (PF) is the ability to carry out the physical 
      activity of daily living. It is an important outcome that provides a meaningful
      evaluation of individuals' life. PF can be assessed using patient-reported
      outcome measures, performance-based outcome measures or body structure and
      function measure. Measures need to be valid, reliable and responsive to change to
      evaluate the effects of an intervention. Adolescent idiopathic scoliosis (AIS) is
      the most common deformity among the paediatric population and impacts on
      individuals' lives. This systematic review will appraise evidence on the
      measurement properties of PF tools in individuals with AIS. METHODS/ANALYSIS: A
      protocol for systematic review and meta-analysis informed by Cochrane guidelines 
      is reported in line with Preferred Reporting Items for Systematic Reviews and
      Meta-Analysis-P. MEDLINE, PsycINFO, EMBASE, CINAHL, SPORTdiscus, Web of Science
      and PubMed will be searched in two stages, from inception until December 2019.
      Search 1 will inventory all studies that assessed PF in participants with AIS,
      without any limitations. The search terms will be scoliosis, adolescent and
      PF-related terms. Search 2 will include studies which investigated instrument
      measurement properties in the same population for measures identified in search
      one. Two reviewers will independently perform study selection, data extraction,
      risk of bias and overall quality assessment. The COnsensus-based Standards for
      the selection of health Measurement INstruments (COSMIN) risk of bias and a
      modified Grading of Recommendations, Assessment, Development and Evaluation
      (GRADE) guidelines will be used. A meta-analysis will be conducted if possible,
      or the evidence will be synthesised and summarised per measurement property per
      outcome measure per measurement type. ETHICS AND DISSEMINATION: This review will 
      provide recommendations for practice and future research, considering
      psychometric properties of outcome measures of PF in AIS. The results of this
      study will be disseminated through a peer-reviewed publication and conference
      presentation. PROSPERO REGISTRATION NUMBER: CRD42019142335.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alamrani, Samia
AU  - Alamrani S
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise & Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
AD  - Physical Therapy Department, College of Applied Medical Science, University of
      Tabouk, Tabouk, Saudi Arabia.
FAU - Rushton, Alison
AU  - Rushton A
AUID- ORCID: 0000-0001-8114-7669
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise & Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Gardner, Adrian
AU  - Gardner A
AD  - Spine Unit, The Royal Orthopaedic Hospital Birmingham, Birmingham, UK.
FAU - Falla, Deborah
AU  - Falla D
AUID- ORCID: 0000-0003-1689-6190
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise & Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
FAU - Heneghan, Nicola R
AU  - Heneghan NR
AUID- ORCID: 0000-0001-7599-3674
AD  - Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, 
      Exercise & Rehabilitation Sciences, University of Birmingham, Birmingham, UK
      n.heneghan@bham.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200401
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Activities of Daily Living
MH  - Adolescent
MH  - Bias
MH  - Body Constitution
MH  - Child
MH  - Guideline Adherence
MH  - Humans
MH  - Outcome Assessment, Health Care
MH  - *Patient Reported Outcome Measures
MH  - *Physical Functional Performance
MH  - Psychometrics
MH  - Scoliosis/*physiopathology
PMC - PMC7170637
OTO - NOTNLM
OT  - *adolescent idiopathic scoliosis
OT  - *measurement properties
OT  - *physical function
OT  - *scoliosis
COIS- Competing interests: None declared.
EDAT- 2020/04/04 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-034286 [pii]
AID - 10.1136/bmjopen-2019-034286 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 1;10(4):e034286. doi: 10.1136/bmjopen-2019-034286.


PMID- 32241785
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 4
DP  - 2020 Apr 1
TI  - Longitudinal cohort of HIV-negative transgender women of colour in New York City:
      protocol for the TURNNT ('Trying to Understand Relationships, Networks and
      Neighbourhoods among Transgender women of colour') study.
PG  - e032876
LID - 10.1136/bmjopen-2019-032876 [doi]
AB  - INTRODUCTION: In the USA, transgender women are among the most vulnerable to HIV.
      In particular, transgender women of colour face high rates of infection and low
      uptake of important HIV prevention tools, including pre-exposure prophylaxis
      (PrEP). This paper describes the design, sampling methods, data collection and
      analyses of the TURNNT ('Trying to Understand Relationships, Networks and
      Neighbourhoods among Transgender women of colour') study. In collaboration with
      communities of transgender women of colour, TURNNT aims to explore the complex
      social and environmental (ie, neighbourhood) structures that affect HIV
      prevention and other aspects of health in order to identify avenues for
      intervention. METHODS AND ANALYSES: TURNNT is a prospective cohort study, which
      will recruit 300 transgender women of colour (150 Black/African American, 100
      Latina and 50 Asian/Pacific Islander participants) in New York City. There will
      be three waves of data collection separated by 6 months. At each wave,
      participants will provide information on their relationships, social and sexual
      networks, and neighbourhoods. Global position system technology will be used to
      generate individual daily path areas in order to estimate neighbourhood-level
      exposures. Multivariate analyses will be conducted to assess cross-sectional and 
      longitudinal, independent and synergistic associations of personal relationships 
      (notably individual social capital), social and sexual networks, and
      neighbourhood factors (notably neighbourhood-level social cohesion) with PrEP
      uptake and discontinuation. ETHICS AND DISSEMINATION: The TURNNT protocol was
      approved by the Columbia University Institutional Review Board (reference no.
      AAAS8164). This study will provide novel insights into the relationship, network 
      and neighbourhood factors that influence HIV prevention behaviours among
      transgender women of colour and facilitate exploration of this population's
      health and well-being more broadly. Through community-based dissemination events 
      and consultation with policy makers, this foundational work will be used to guide
      the development and implementation of future interventions with and for
      transgender women of colour.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Callander, Denton
AU  - Callander D
AUID- ORCID: 0000-0002-4116-4250
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA.
FAU - Schneider, John A
AU  - Schneider JA
AD  - Department of Public Health Sciences, University of Chicago School of Medicine,
      Chicago, Illinois, USA.
AD  - Howard Brown Health Center, Chicago, Illinois, USA.
FAU - Radix, Asa
AU  - Radix A
AD  - Callen-Lorde Community Health Center, New York, New York, USA.
FAU - Chaix, Basile
AU  - Chaix B
AD  - Institut Pierre Louis d'Epidemiologie et de Sante Publique, Sorbonne Universite, 
      Paris, Ile-de-France, France.
FAU - Scheinmann, Roberta
AU  - Scheinmann R
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA.
FAU - Love, Gia
AU  - Love G
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA.
FAU - Smith, Jordyn
AU  - Smith J
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA.
FAU - Regan, Seann D
AU  - Regan SD
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA.
FAU - Kawachi, Ichiro
AU  - Kawachi I
AD  - Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public
      Health, Boston, Massachusetts, USA.
FAU - St James, Kiara
AU  - St James K
AD  - New York Transgender Advocacy Group, New York, New York, USA.
FAU - Ransome, Yusuf
AU  - Ransome Y
AD  - Department of Social and Behavioral Sciences, Yale School of Public Health, New
      Haven, Connecticut, USA.
FAU - Herrera, Cristina
AU  - Herrera C
AD  - Translatinx Network, New York, New York, USA.
FAU - Reisner, Sari L
AU  - Reisner SL
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Fenway Institute, Boston, Massachusetts, USA.
FAU - Doroshow, Ceyenne
AU  - Doroshow C
AD  - Gay and Lesbians Living in a Transgender Society, New York, New York, USA.
FAU - Poteat, Tonia
AU  - Poteat T
AD  - Department of Social Medicine, University of North Carolina at Chapel Hill School
      of Medicine, Chapel Hill, North Carolina, USA.
FAU - Watson, Kim
AU  - Watson K
AD  - Community Kinship Life, New York, New York, USA.
FAU - Bluebond-Langner, Rachel
AU  - Bluebond-Langner R
AD  - Hansjorg Wyss Department of Plastic Surgery, New York University School of
      Medicine, New York, New York, USA.
FAU - Toussaint, Nala
AU  - Toussaint N
AD  - Callen-Lorde Community Health Center, New York, New York, USA.
FAU - Garofalo, Robert
AU  - Garofalo R
AD  - Department of Pediatrics & Preventive Medicine, Ann and Robert H Lurie Children's
      Hospital of Chicago, Chicago, Illinois, USA.
AD  - Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
FAU - Sevelius, Jae
AU  - Sevelius J
AD  - Center for Excellence for Transgender Health, University of California San
      Francisco School of Medicine, San Francisco, California, USA.
FAU - Duncan, Dustin T
AU  - Duncan DT
AUID- ORCID: 0000-0001-8586-8711
AD  - Department of Epidemiology, Columbia University Mailman School of Public Health, 
      New York, New York, USA dd3018@columbia.edu.
LA  - eng
GR  - P30 MH062246/MH/NIMH NIH HHS/United States
GR  - R01 MD013554/MD/NIMHD NIH HHS/United States
GR  - R25 MH083620/MH/NIMH NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200401
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - African Americans/statistics & numerical data
MH  - Asian Americans/statistics & numerical data
MH  - Asians/statistics & numerical data
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/*prevention & control
MH  - *HIV Seronegativity
MH  - Hispanic or Latino/statistics & numerical data
MH  - Humans
MH  - *Interpersonal Relations
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Native Hawaiian or Other Pacific Islander/statistics & numerical data
MH  - New York City/ethnology
MH  - Prospective Studies
MH  - *Residence Characteristics
MH  - Sexual Partners
MH  - *Social Networking
MH  - *Transgender Persons/statistics & numerical data
MH  - Young Adult
PMC - PMC7170618
OTO - NOTNLM
OT  - *HIV & AIDS
OT  - *epidemiology
OT  - *sexual medicine
COIS- Competing interests: None declared.
EDAT- 2020/04/04 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - bmjopen-2019-032876 [pii]
AID - 10.1136/bmjopen-2019-032876 [doi]
PST - epublish
SO  - BMJ Open. 2020 Apr 1;10(4):e032876. doi: 10.1136/bmjopen-2019-032876.


PMID- 32241762
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200406
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 Apr 2
TI  - Covid-19: Can France's ethical support units help doctors make challenging
      decisions?
PG  - m1291
LID - 10.1136/bmj.m1291 [doi]
FAU - Arie, Sophie
AU  - Arie S
AD  - London.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
COIS- Competing interests: I have read and understood BMJ policy on declaration of
      interests and have no relevant interests to declare.
EDAT- 2020/04/04 06:00
MHDA- 2020/04/04 06:01
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/04 06:01 [medline]
AID - 10.1136/bmj.m1291 [doi]
PST - epublish
SO  - BMJ. 2020 Apr 2;369:m1291. doi: 10.1136/bmj.m1291.


PMID- 32241733
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20210706
IS  - 1532-8635 (Electronic)
IS  - 1524-9042 (Linking)
VI  - 21
IP  - 5
DP  - 2020 Oct
TI  - Factors Influencing Pain Dimensions in Patients with Chronic Tension-Type
      Headache: An Exploratory Survey.
PG  - 441-448
LID - S1524-9042(20)30081-3 [pii]
LID - 10.1016/j.pmn.2020.02.066 [doi]
AB  - BACKGROUND: Chronic tension type headache (CTTH) is one of the common cause of
      hospital visits among adolescents and adults. Chronic tension type headache
      produces pain, sleep disturbances, and disability among patients leading to a
      poor quality of life. Knowledge pattern of headache and various associated
      factors will aid appropriate management. AIMS: To identify the headache
      dimensions and their various influencing factors among patients of chronic
      tension-type headache. METHODS: Using consecutive sampling techniques, 169
      patients with chronic tension-type headache were recruited in this
      cross-sectional survey. Approval was obtained from the Institute's Ethics
      Committee. The Wong-Baker Foundation Pain intensity scale was used to assess the 
      pain severity. RESULTS: A pain severity score of 6 out of 10 was reported by 56% 
      of the patients, and the mean pain score reported by the patients was 6.62 +/-
      1.16. The mean weekly headache frequency was 4.95 +/- 0.38, and the mean daily
      headache duration was 8.68 +/- 1.68 hours. Significantly more patients who are
      married, patients who had a duration of illness less than two years, and patients
      who were treated with only analgesics reported higher headache severity. Higher
      headache frequency was reported by significantly more patients who were male,
      married, from a nuclear family, educated, unskilled laborers or employed, urban
      inhabitants, or only on analgesics, or had illness duration less than two years. 
      Headache duration was significantly higher in patients who were unskilled
      laborers or only on analgesics, or had illness duration less than two years.
      CONCLUSIONS: Patients with chronic tension-type headache experience moderate to
      high severity of headache, along with substantial duration and frequency, an
      outcome that was associated with various lifestyle-related factors that can
      result in stress. Lifestyle modification and nonpharmacological management are
      thus essential to reduce the severity, frequency, and duration of headache in
      patients with a chronic tension-type headache and medication overuse.
CI  - Copyright (c) 2020 American Society for Pain Management Nursing. Published by
      Elsevier Inc. All rights reserved.
FAU - Gopichandran, Lakshmanan
AU  - Gopichandran L
AD  - College of Nursing, All India Institute of Medical Sciences (AIIMS), New Delhi,
      India. Electronic address: pravigopi@gmail.com.
FAU - C, Kanniammal
AU  - C K
AD  - College of Nursing, Sri Ramaswami Memorial (SRM) University, Chennai, India.
FAU - G, Valli
AU  - G V
AD  - Mednakshi Ammal Dental College, Meenakshi University, Chennai, India.
FAU - M, Jaideep
AU  - M J
AD  - Mednakshi Ammal Dental College, Meenakshi University, Chennai, India.
FAU - Srivastava, Achal
AU  - Srivastava A
AD  - Neurology Department, All India Institute of Medical Sciences (AIIMS), New Delhi,
      India.
FAU - Vanamail, P
AU  - Vanamail P
AD  - Obstetrics and Gynecology (OBG) Department, All India Institute of Medical
      Sciences (AIIMS), New Delhi, India.
FAU - Dhandapani, Manju
AU  - Dhandapani M
AD  - National Institute of Nursing Education (NINE), Post Graduate Institute of
      Medical Education and Research (PGIMER), Chandigarh, India. Electronic address:
      manjuseban@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - United States
TA  - Pain Manag Nurs
JT  - Pain management nursing : official journal of the American Society of Pain
      Management Nurses
JID - 100890606
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Chi-Square Distribution
MH  - Chronic Pain/*classification/etiology/psychology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement/methods
MH  - Quality of Life/psychology
MH  - Surveys and Questionnaires
MH  - Tension-Type Headache/*complications/psychology
EDAT- 2020/04/04 06:00
MHDA- 2021/07/07 06:00
CRDT- 2020/04/04 06:00
PHST- 2018/12/30 00:00 [received]
PHST- 2019/10/13 00:00 [revised]
PHST- 2020/02/15 00:00 [accepted]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - S1524-9042(20)30081-3 [pii]
AID - 10.1016/j.pmn.2020.02.066 [doi]
PST - ppublish
SO  - Pain Manag Nurs. 2020 Oct;21(5):441-448. doi: 10.1016/j.pmn.2020.02.066. Epub
      2020 Mar 30.


PMID- 32241458
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 1873-6386 (Electronic)
IS  - 0160-2527 (Linking)
VI  - 69
DP  - 2020 Mar - Apr
TI  - Grounding the right to live in the community (CRPD Article 19) in the
      capabilities approach to social justice.
PG  - 101551
LID - S0160-2527(19)30039-1 [pii]
LID - 10.1016/j.ijlp.2020.101551 [doi]
AB  - For advocates of the rights of persons with disabilities, particularly persons
      with mental disabilities, the human right to live in the community as an equal
      member is seen to be central and, often, even as the basis for all other human
      rights. Yet, despite its articulation in human rights law in the Convention on
      the Rights of People with Disabilities (CRPD), foundational issues about the
      right remain undertheorized and unclear. This paper brings to bear the
      capabilities approach, a normative framework about human well-being, social
      development and social justice, to this central concern in disability rights,
      mental health ethics, and international human rights law: protecting and
      respecting a person's right to live in a community as an equal. We argue that
      this human and moral right is best conceptualized as a capability to live in the 
      community as an equal member. The capabilities approach provides this capability 
      with a strong ethical framework and conceptual resources to guide reasoning and
      its practical realization.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Wynne Bannister, Emma
AU  - Wynne Bannister E
AD  - Department of Global Health and Social Medicine, King's College London, United
      Kingdom. Electronic address: emma.wynne_bannister@kcl.ac.uk.
FAU - Venkatapuram, Sridhar
AU  - Venkatapuram S
AD  - King's Global Health Institute, King's College London, Franklin-Wilkins Building,
      Stamford Street, London SE1 9NH, United Kingdom. Electronic address:
      sridhar.venkatapuram@kcl.ac.uk.
LA  - eng
GR  - 203376/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200304
PL  - Netherlands
TA  - Int J Law Psychiatry
JT  - International journal of law and psychiatry
JID - 7806862
SB  - IM
MH  - Disabled Persons/*legislation & jurisprudence
MH  - Human Rights/*ethics/*legislation & jurisprudence
MH  - Humans
MH  - Independent Living/*ethics/*legislation & jurisprudence
MH  - *Social Justice
PMC - PMC7166074
OTO - NOTNLM
OT  - *CRPD (Convention of the Rights of Persons with Disabilities)
OT  - *Capabilities approach
OT  - *Community
OT  - *Disability
OT  - *Human rights
EDAT- 2020/04/04 06:00
MHDA- 2021/03/31 06:00
CRDT- 2020/04/04 06:00
PHST- 2019/02/28 00:00 [received]
PHST- 2020/02/17 00:00 [revised]
PHST- 2020/02/20 00:00 [accepted]
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
AID - S0160-2527(19)30039-1 [pii]
AID - 10.1016/j.ijlp.2020.101551 [doi]
PST - ppublish
SO  - Int J Law Psychiatry. 2020 Mar - Apr;69:101551. doi: 10.1016/j.ijlp.2020.101551. 
      Epub 2020 Mar 4.


PMID- 32241320
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1472-1465 (Electronic)
IS  - 0007-1250 (Linking)
VI  - 217
IP  - 4
DP  - 2020 Oct
TI  - History of psychiatry in the curriculum? History is part of life and life is part
      of history: why psychiatrists need to understand it better.
PG  - 535-536
LID - 10.1192/bjp.2020.64 [doi]
AB  - The General Medical Council has introduced a generic professional capabilities
      framework. It includes the need to develop the professional values, actions and
      aspirations fundamental to becoming a 'dedicated doctor'. The history of
      psychiatry has potential to facilitate this learning, both by an understanding of
      content and the ability to think historically.
FAU - Ash, Graham
AU  - Ash G
AUID- ORCID: 0000-0001-9227-281X
AD  - Library and Information Services, Royal College of Psychiatrists; Whittingham
      Lives Association; and History of Psychiatry Special Interest Group, Royal
      College of Psychiatrists, UK.
FAU - Hilton, Claire
AU  - Hilton C
AD  - Library and Information Services, Royal College of Psychiatrists; and History of 
      Psychiatry Special Interest Group, Royal College of Psychiatrists, UK.
FAU - Freudenthal, Robert
AU  - Freudenthal R
AD  - Haringey Older Persons Community Mental Health Team, Barnet, Enfield and Haringey
      Mental Health NHS Trust; and History of Psychiatry Special Interest Group, Royal 
      College of Psychiatrists, UK.
FAU - Stephenson, Thomas
AU  - Stephenson T
AD  - Institute of Psychiatry, Psychology & Neuroscience, King's College, London and
      South London and Maudsley NHS Trust; and History of Psychiatry Special Interest
      Group, Royal College of Psychiatrists, UK.
FAU - Ikkos, George
AU  - Ikkos G
AUID- ORCID: 0000-0003-1496-1040
AD  - Psychiatry in Dialogue with Neuroscience Medicine and Society, Psychiatry
      Section, Royal Society of Medicine; and History of Psychiatry Special Interest
      Group, Royal College of Psychiatrists, UK.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Psychiatry
JT  - The British journal of psychiatry : the journal of mental science
JID - 0342367
SB  - IM
MH  - *Curriculum
MH  - History, 19th Century
MH  - History, 20th Century
MH  - Humans
MH  - Psychiatry/*education/*history
OTO - NOTNLM
OT  - *History of psychiatry
OT  - *autistic spectrum disorder
OT  - *clinical governance
OT  - *education and training
OT  - *ethics
EDAT- 2020/04/04 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/04/04 06:00 [entrez]
AID - 10.1192/bjp.2020.64 [doi]
AID - S0007125020000641 [pii]
PST - ppublish
SO  - Br J Psychiatry. 2020 Oct;217(4):535-536. doi: 10.1192/bjp.2020.64.


PMID- 32240494
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1471-5546 (Electronic)
IS  - 1353-3452 (Linking)
VI  - 26
IP  - 3
DP  - 2020 Jun
TI  - Guiding Engineering Student Teams' Ethics Discussions with Peer Advising.
PG  - 1743-1769
LID - 10.1007/s11948-020-00212-6 [doi]
AB  - This study explores how peer advising affects student project teams' discussions 
      of engineering ethics. Peer ethics advisors from non-engineering disciplines are 
      expected to provide diverse perspectives and to help engineering student teams
      engage and sustain ethics discussions. To investigate how peer advising helps
      engineering student teams' ethics discussions, three student teams in different
      peer advising conditions were closely observed: without any advisor, with a
      single volunteer advisor, and with an advising team working on the ethics
      advising project. Micro-scale discourse analysis based on cognitive ethnography
      was conducted to find each team's cultural model of understanding of engineering 
      ethics. Cultural-historical activity theory (CHAT) analysis was also conducted to
      see what influenced each team's cultural model. In cultural model, the
      engineering team with an ethics advising team showed broader understanding in
      social implications of engineering. The results of CHAT analysis indicated that
      differences in rules, community, and division of labor among three teams
      influenced the teams' cultural models. The CHAT analysis also indicated that the 
      peer advisors working on the ethics advising project and the engineering team
      working on engineering design project created a collaborative environment. The
      findings indicated that collaborative environment supported peer ethics advising 
      to facilitate team discussions of engineering ethics.
FAU - Lee, Eun Ah
AU  - Lee EA
AD  - The University of Texas at Dallas, 800 W. Campbell Road, Richardson, TX, 75080,
      USA. EunAh.Lee@utdallas.edu.
FAU - Gans, Nicholas
AU  - Gans N
AD  - The University of Texas at Arlington, 701 S Nedderman Dr, Arlington, TX, 76019,
      USA.
FAU - Grohman, Magdalena
AU  - Grohman M
AD  - The University of Texas at Dallas, 800 W. Campbell Road, Richardson, TX, 75080,
      USA.
FAU - Tacca, Marco
AU  - Tacca M
AD  - The University of Texas at Dallas, 800 W. Campbell Road, Richardson, TX, 75080,
      USA.
FAU - Brown, Matthew J
AU  - Brown MJ
AD  - The University of Texas at Dallas, 800 W. Campbell Road, Richardson, TX, 75080,
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200402
PL  - England
TA  - Sci Eng Ethics
JT  - Science and engineering ethics
JID - 9516228
SB  - IM
MH  - *Engineering
MH  - Humans
MH  - Peer Group
MH  - *Students
OTO - NOTNLM
OT  - *Cognitive ethnography
OT  - *Cultural-historical activity theory (CHAT)
OT  - *Engineering ethics
OT  - *Peer advising
EDAT- 2020/04/03 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/03 06:00
PHST- 2018/05/02 00:00 [received]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1007/s11948-020-00212-6 [doi]
AID - 10.1007/s11948-020-00212-6 [pii]
PST - ppublish
SO  - Sci Eng Ethics. 2020 Jun;26(3):1743-1769. doi: 10.1007/s11948-020-00212-6. Epub
      2020 Apr 2.


PMID- 32240442
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Sep
TI  - "Doc, I'm Going for a Walk": Liberalizing or Restricting the Movement of
      Hospitalized Patients-Ethical, Legal, and Clinical Considerations.
PG  - 253-267
LID - 10.1007/s10730-020-09398-5 [doi]
AB  - When patients are admitted to the hospital, they are generally expected to remain
      in or within close proximity to their assigned rooms in order to promote their
      safety and appropriate medical care. Although there are circumstances when
      patients may safely leave their hospital room or floor, guidance within the
      medical literature for the management of patient movement within the hospital are
      lacking. Excessive restrictions on patient movement may be seen as overly
      paternalistic, while lax requirements may interfere with high quality care,
      patient safety and efficient hospital practice. As a result, guidance in the form
      of institutional policy is warranted. Such policy development should take into
      consideration the potential clinical, legal, and ethical concerns in balancing
      the competing values of patients' preferences and respect for autonomy, while
      ensuring high quality, safe, and efficacious medical care. This paper will
      provide a framework for hospitals to create institution-specific patient movement
      policies that are fair, systematic, and transparent.
FAU - Alfandre, David
AU  - Alfandre D
AUID- ORCID: http://orcid.org/0000-0001-9778-7580
AD  - VA National Center for Ethics in Health Care, US Department of Veterans Affairs, 
      Washington, DC, USA. david.alfandre@va.gov.
AD  - New York University School of Medicine, 423 East 23rd St (10P6), New York, NY,
      10010, USA. david.alfandre@va.gov.
AD  - Department of Medicine, Section of Hospital Medicine, VA New York Harbor
      Healthcare System, New York, NY, USA. david.alfandre@va.gov.
FAU - Stream, Sara
AU  - Stream S
AD  - New York University School of Medicine, 423 East 23rd St (10P6), New York, NY,
      10010, USA.
AD  - Department of Medicine, Section of Hospital Medicine, VA New York Harbor
      Healthcare System, New York, NY, USA.
FAU - Geppert, Cynthia
AU  - Geppert C
AD  - VA National Center for Ethics in Health Care, US Department of Veterans Affairs, 
      Washington, DC, USA.
AD  - University of New Mexico School of Medicine, Albuquerque, NM, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Endocarditis/complications/psychology
MH  - Hospitalization/legislation & jurisprudence/*trends
MH  - Humans
MH  - Jurisprudence
MH  - Male
MH  - Middle Aged
MH  - Organizational Policy
MH  - Walking/*ethics/psychology
OTO - NOTNLM
OT  - Ethics
OT  - Hospitalization
OT  - Movement
OT  - Restriction
EDAT- 2020/04/03 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1007/s10730-020-09398-5 [doi]
AID - 10.1007/s10730-020-09398-5 [pii]
PST - ppublish
SO  - HEC Forum. 2020 Sep;32(3):253-267. doi: 10.1007/s10730-020-09398-5.


PMID- 32240212
OWN - NLM
STAT- MEDLINE
DCOM- 20200716
LR  - 20200716
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 4
DP  - 2020
TI  - What would you like to print? Students' opinions on the use of 3D printing
      technology in medicine.
PG  - e0230851
LID - 10.1371/journal.pone.0230851 [doi]
AB  - BACKGROUND: Recent advances in 3D printing technology, and biomaterials are
      revolutionizing medicine. The beneficiaries of this technology are primarily
      patients, but also students of medical faculties. Taking into account that not
      all students have full, direct access to the latest advances in additive
      technologies, we surveyed their opinion on 3D printing and education in this
      area. The research aimed to determine what knowledge about the use of 3D printing
      technology in medicine, do students of medical faculties have. METHODS: The
      research was carried out in the form of a questionnaire among 430 students of the
      Medical University of Silesia in Katowice (Poland) representing various fields of
      medicine and health sciences. The questions included in the survey analyzed the
      knowledge of the respondents for 3D printing technology and the opportunities it 
      creates in medicine. RESULTS: The results indicate that students do have
      knowledge about 3D printing obtained mainly from the internet. They would be
      happy to deepen their knowledge at specialized courses in this field. Students
      appreciated the value of 3D printing in order to obtain accurate anatomical
      models, helpful in learning. However, they do not consider the possibility of
      complete abandonment of human cadavers in the anatomy classes. Their knowledge
      includes basic information about current applications of 3D printing in medicine,
      but not in all areas. However, they have no ethical doubts regarding the use of
      3D printing in any form. The vast majority of students deemed it necessary to
      incorporate information regarding 3D printing technology into the curriculum of
      different medical majors. CONCLUSION: This research is the first of its kind,
      which allows for probing students' knowledge about the additive technologies in
      medicine. Medical education should be extended to include issues related to the
      use of 3D printing for medical applications.
FAU - Wilk, Renata
AU  - Wilk R
AD  - Department of Anatomy, School of Health Sciences in Katowice, Medical University 
      of Silesia, Katowice, Poland.
FAU - Likus, Wirginia
AU  - Likus W
AUID- ORCID: 0000-0002-4738-6102
AD  - Department of Anatomy, School of Health Sciences in Katowice, Medical University 
      of Silesia, Katowice, Poland.
FAU - Hudecki, Andrzej
AU  - Hudecki A
AD  - Lukasiewicz Research Network-Institute of Non-Ferrous Metals, Gliwice, Poland.
FAU - Sygula, Marita
AU  - Sygula M
AD  - Department of Anatomy, School of Health Sciences in Katowice, Medical University 
      of Silesia, Katowice, Poland.
FAU - Rozycka-Nechoritis, Aleksandra
AU  - Rozycka-Nechoritis A
AD  - Department of Anatomy, School of Health Sciences in Katowice, Medical University 
      of Silesia, Katowice, Poland.
FAU - Nechoritis, Konstantinos
AU  - Nechoritis K
AD  - Department of Anatomy, School of Health Sciences in Katowice, Medical University 
      of Silesia, Katowice, Poland.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Attitude
MH  - Curriculum/trends
MH  - Education, Medical/methods
MH  - Female
MH  - Humans
MH  - Learning
MH  - Male
MH  - Models, Anatomic
MH  - Poland
MH  - Printing, Three-Dimensional/*trends
MH  - Students, Medical/*psychology
MH  - Surveys and Questionnaires
MH  - Technology/methods/trends
MH  - Young Adult
PMC - PMC7117709
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/04/03 06:00
MHDA- 2020/07/17 06:00
CRDT- 2020/04/03 06:00
PHST- 2019/07/21 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/07/17 06:00 [medline]
AID - 10.1371/journal.pone.0230851 [doi]
AID - PONE-D-19-20549 [pii]
PST - epublish
SO  - PLoS One. 2020 Apr 2;15(4):e0230851. doi: 10.1371/journal.pone.0230851.
      eCollection 2020.


PMID- 32239663
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210703
IS  - 1742-481X (Electronic)
IS  - 1742-4801 (Linking)
VI  - 17
IP  - 4
DP  - 2020 Aug
TI  - Pressure injury development in critically ill patients with a cervical collar in 
      situ: A retrospective longitudinal study.
PG  - 944-956
LID - 10.1111/iwj.13363 [doi]
AB  - Trauma patients with a serious injury to the head or neck can remain immobilised 
      with a cervical collar (C-collar) device in situ and are subsequently exposed to 
      device-related skin integrity threats. This study aimed to determine the
      incidence and risk factors associated with the development of C-collar-related
      pressure injures (CRPIs) in an intensive care unit. This retrospective
      longitudinal cohort study was conducted in an Australian metropolitan intensive
      care unit. Following ethical approval, data from patients over 18 years, who
      received a C-collar were retrieved over a 9-year period. Chi square and t-tests
      were used to identify variables associated with CRPI development. A logistic
      regression model was employed to analyse the risk factors. Data from 906 patients
      were analysed. Nine-year pressure injury incidence was 16.9% (n = 154/906).
      Pressure injury development directly associated with a C-collar increased by 33% 
      with each repositioning episode (odds ratio 1.328, 95% confidence interval
      1.024-1.723, P = .033). Time in the C-collar (10.4 to 2.5 days, P = .002) and
      length of stay in intensive care unit (ICU) (20.1 to 16.1 days, P < .001) were
      associated with pressure injury development. Patients with C-collar devices are a
      vulnerable group at risk for pressure injury development because of their
      immobility and length of ICU stay.
CI  - (c) 2020 Medicalhelplines.com Inc and John Wiley & Sons Ltd.
FAU - Wang, Harn-Rong N
AU  - Wang HN
AD  - School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland,
      Australia.
FAU - Campbell, Jill
AU  - Campbell J
AD  - School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland,
      Australia.
AD  - Skin Integrity Services, Royal Brisbane and Women's Hospital, Herston,
      Queensland, Australia.
FAU - Doubrovsky, Anna
AU  - Doubrovsky A
AD  - School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland,
      Australia.
FAU - Singh, Veeranjit
AU  - Singh V
AD  - Ipswich Hospital, Ipswich, Queensland, Australia.
FAU - Collins, Johnathon
AU  - Collins J
AD  - Sinai-Grace Hospital, Detroit, Michigan, USA.
FAU - Coyer, Fiona
AU  - Coyer F
AD  - Joint appointment Intensive Care Services, Royal Brisbane and Women's Hospital
      and School of Nursing, Queensland University of Technology, Herston, Queensland, 
      Australia.
AD  - Institute of Skin Integrity and Infection Prevention, University of Huddersfield,
      Huddersfield, UK.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - England
TA  - Int Wound J
JT  - International wound journal
JID - 101230907
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Australia
MH  - Cervical Vertebrae/*injuries
MH  - Critical Illness/*therapy
MH  - Female
MH  - Humans
MH  - Immobilization/*instrumentation
MH  - Incidence
MH  - Intensive Care Units/statistics & numerical data
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Neck Injuries/*therapy
MH  - Pressure Ulcer/*etiology
MH  - Protective Devices/*adverse effects/*statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Young Adult
PMC - PMC7948998
OTO - NOTNLM
OT  - cervical collar
OT  - critically ill patients
OT  - incidence
OT  - intensive care
OT  - pressure injury
EDAT- 2020/04/03 06:00
MHDA- 2021/06/03 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/01/15 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1111/iwj.13363 [doi]
PST - ppublish
SO  - Int Wound J. 2020 Aug;17(4):944-956. doi: 10.1111/iwj.13363. Epub 2020 Apr 1.


PMID- 32239318
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20211204
IS  - 1437-1596 (Electronic)
IS  - 0937-9827 (Linking)
VI  - 134
IP  - 5
DP  - 2020 Sep
TI  - Allelic frequency database of 15 polymorphic autosomal STRs in the
      Malayalam-speaking population of Kerala, India.
PG  - 1679-1681
LID - 10.1007/s00414-020-02286-0 [doi]
AB  - In this study, we assessed and established an allelic frequency database of
      Malayalam-speaking population of south western Indian state Kerala, using 15
      polymorphic short tandem repeats (STRs) genetic markers. For this study, 464
      unrelated healthy individuals were randomly selected following the ethical
      standards. The most polymorphic and most discriminating locus was D2S1338, with a
      value of 0.860 and 0.968, respectively. The range of heterozygosity extended from
      a minimum of 0.668 (TH01) to a maximum of 0.847 (D2S1338). The combined
      discrimination power (CPD) and combined exclusion power (CPE) were 1 and
      0.999997861, respectively, for all 15 autosomal STR loci under study. The
      combined probability of match (CPM) and combined paternity index (CPI) for all 15
      autosomal STR loci were found to be 9.85 x 10(-19) and 4.18 x 10(5),
      respectively.
FAU - Sreekumar, R
AU  - Sreekumar R
AD  - State Forensic Science Laboratory, Thiruvananthapuram, Kerala, 695010, India.
FAU - Thekkatavan, Ajeesh
AU  - Thekkatavan A
AD  - Biology Division, Regional Forensic Science Laboratory, Kannur, Kerala, 670002,
      India.
FAU - Shrivastava, Pankaj
AU  - Shrivastava P
AD  - DNA Fingerprinting Unit, State Forensic Science Laboratory, Department of Home
      (Police), Government of MP, Sagar, 470001, India.
      pankaj.shrivastava@rediffmail.com.
FAU - Kumawat, R K
AU  - Kumawat RK
AD  - DNA Division, State Forensic Science Laboratory, Jaipur, Rajasthan, 302016,
      India.
FAU - Dixit, Shivani
AU  - Dixit S
AD  - DNA Fingerprinting Unit, State Forensic Science Laboratory, Department of Home
      (Police), Government of MP, Sagar, 470001, India.
FAU - Chaubey, Gyaneshwer
AU  - Chaubey G
AD  - Cytogenetics Laboratory, Department of Zoology, Banaras Hindu University,
      Varanasi, UP, India.
LA  - eng
PT  - Journal Article
DEP - 20200401
PL  - Germany
TA  - Int J Legal Med
JT  - International journal of legal medicine
JID - 9101456
SB  - IM
MH  - Adult
MH  - Databases, Genetic
MH  - Ethnicity/*genetics
MH  - Female
MH  - *Gene Frequency
MH  - Genetics, Population
MH  - Humans
MH  - India/ethnology
MH  - Male
MH  - *Microsatellite Repeats
MH  - *Polymorphism, Genetic
OTO - NOTNLM
OT  - Genetic diversity
OT  - Kerala
OT  - Malayalam-speaking population
OT  - Polymorphism
OT  - STRs
EDAT- 2020/04/03 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/04/03 06:00
PHST- 2019/12/24 00:00 [received]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1007/s00414-020-02286-0 [doi]
AID - 10.1007/s00414-020-02286-0 [pii]
PST - ppublish
SO  - Int J Legal Med. 2020 Sep;134(5):1679-1681. doi: 10.1007/s00414-020-02286-0. Epub
      2020 Apr 1.


PMID- 32238939
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20210731
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 580
IP  - 7801
DP  - 2020 Apr
TI  - Rebuilding marine life.
PG  - 39-51
LID - 10.1038/s41586-020-2146-7 [doi]
AB  - Sustainable Development Goal 14 of the United Nations aims to "conserve and
      sustainably use the oceans, seas and marine resources for sustainable
      development". Achieving this goal will require rebuilding the marine life-support
      systems that deliver the many benefits that society receives from a healthy
      ocean. Here we document the recovery of marine populations, habitats and
      ecosystems following past conservation interventions. Recovery rates across
      studies suggest that substantial recovery of the abundance, structure and
      function of marine life could be achieved by 2050, if major pressures-including
      climate change-are mitigated. Rebuilding marine life represents a doable Grand
      Challenge for humanity, an ethical obligation and a smart economic objective to
      achieve a sustainable future.
FAU - Duarte, Carlos M
AU  - Duarte CM
AUID- ORCID: http://orcid.org/0000-0002-1213-1361
AD  - Red Sea Research Center (RSRC), King Abdullah University of Science and
      Technology, Thuwal, Saudi Arabia. carlos.duarte@kaust.edu.sa.
AD  - Arctic Research Centre, Department of Biology, Aarhus University, Aarhus,
      Denmark. carlos.duarte@kaust.edu.sa.
AD  - Computational Bioscience Research Center (CBRC), King Abdullah University of
      Science and Technology, Thuwal, Saudi Arabia. carlos.duarte@kaust.edu.sa.
FAU - Agusti, Susana
AU  - Agusti S
AUID- ORCID: http://orcid.org/0000-0003-0536-7293
AD  - Red Sea Research Center (RSRC), King Abdullah University of Science and
      Technology, Thuwal, Saudi Arabia.
FAU - Barbier, Edward
AU  - Barbier E
AUID- ORCID: http://orcid.org/0000-0002-5354-3995
AD  - Department of Economics, Colorado State University, Fort Collins, CO, USA.
FAU - Britten, Gregory L
AU  - Britten GL
AD  - Department of Earth, Atmospheric, and Planetary Sciences, Massachusetts Institute
      of Technology, Cambridge, MA, USA.
FAU - Castilla, Juan Carlos
AU  - Castilla JC
AD  - Departamento de Ecologia, Facultad de Ciencias Biologicas and Centro
      Interdisciplinario de Cambio Global, Pontificia Universidad Catolica de Chile,
      Santiago, Chile.
FAU - Gattuso, Jean-Pierre
AU  - Gattuso JP
AUID- ORCID: http://orcid.org/0000-0002-4533-4114
AD  - Laboratoire d'Oceanographie de Villefranche, Sorbonne Universite, CNRS,
      Villefranche-sur-Mer, France.
AD  - Institute for Sustainable Development and International Relations, Sciences Po,
      Paris, France.
AD  - Monegasque Association on Ocean Acidification, Prince Albert II of Monaco
      Foundation, Monaco, Monaco.
FAU - Fulweiler, Robinson W
AU  - Fulweiler RW
AUID- ORCID: http://orcid.org/0000-0003-0871-4246
AD  - Department of Earth & Environment, Boston University, Boston, MA, USA.
AD  - Department of Biology, Boston University, Boston, MA, USA.
FAU - Hughes, Terry P
AU  - Hughes TP
AUID- ORCID: http://orcid.org/0000-0002-5257-5063
AD  - Australian Research Council Centre of Excellence for Coral Reef Studies, James
      Cook University, Townsville, Queensland, Australia.
FAU - Knowlton, Nancy
AU  - Knowlton N
AD  - National Museum of Natural History, Smithsonian Institution, Washington, DC, USA.
FAU - Lovelock, Catherine E
AU  - Lovelock CE
AUID- ORCID: http://orcid.org/0000-0002-2219-6855
AD  - School of Biological Sciences, The University of Queensland, St Lucia,
      Queensland, Australia.
FAU - Lotze, Heike K
AU  - Lotze HK
AUID- ORCID: http://orcid.org/0000-0001-6258-1304
AD  - Department of Biology, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Predragovic, Milica
AU  - Predragovic M
AD  - Red Sea Research Center (RSRC), King Abdullah University of Science and
      Technology, Thuwal, Saudi Arabia.
FAU - Poloczanska, Elvira
AU  - Poloczanska E
AD  - Alfred Wegener Institute, Integrative Ecophysiology, Bremerhaven, Germany.
FAU - Roberts, Callum
AU  - Roberts C
AUID- ORCID: http://orcid.org/0000-0003-2276-4258
AD  - Department of Environment and Geography, University of York, York, UK.
FAU - Worm, Boris
AU  - Worm B
AD  - Department of Biology, Dalhousie University, Halifax, Nova Scotia, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200401
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
EIN - Nature. 2021 May;593(7857):E1-E2. PMID: 33864053
MH  - Animals
MH  - *Ecosystem
MH  - Endangered Species/*statistics & numerical data
MH  - Environmental Restoration and Remediation/*trends
MH  - Extinction, Biological
MH  - Fishes
MH  - Global Warming/prevention & control
MH  - Human Activities
MH  - Humans
MH  - Marine Biology/*trends
EDAT- 2020/04/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2020/04/03 06:00
PHST- 2019/05/24 00:00 [received]
PHST- 2020/02/18 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1038/s41586-020-2146-7 [doi]
AID - 10.1038/s41586-020-2146-7 [pii]
PST - ppublish
SO  - Nature. 2020 Apr;580(7801):39-51. doi: 10.1038/s41586-020-2146-7. Epub 2020 Apr
      1.


PMID- 32238752
OWN - NLM
STAT- MEDLINE
DCOM- 20200819
LR  - 20200819
IS  - 0546-1766 (Print)
IS  - 0546-1766 (Linking)
VI  - 67
IP  - 3
DP  - 2020
TI  - [Conflicts of interest and the ethics of developing fee-charging questionnaires].
PG  - 167-170
LID - 10.11236/jph.67.3_167 [doi]
AB  - There are some fee-charged questionnaires in the social medicine field. If a
      questionnaire is fee-charged, the researcher developing it may have a financial
      incentive, and the existence of a conflict of interest should be considered.
      Therefore, when a manuscript reporting a fee-charged questionnaire is submitted, 
      future fee-charging and the institution managing the questionnaire should be
      described as potential conflicts of interest. They should also be so described in
      forms for ethical review and informed consent.
FAU - Saijo, Yasuaki
AU  - Saijo Y
AD  - Division of Public Health and Epidemiology, Department of Social Medicine,
      Asahikawa Medical University.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Koshu Eisei Zasshi
JT  - [Nihon koshu eisei zasshi] Japanese journal of public health
JID - 19130150R
SB  - IM
MH  - *Conflict of Interest
MH  - Fees and Charges/*ethics
MH  - Humans
MH  - Surveys and Questionnaires/*economics
OTO - NOTNLM
OT  - conflict of interest
OT  - ethics
OT  - fee-charged questionnaire
EDAT- 2020/04/03 06:00
MHDA- 2020/08/20 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/08/20 06:00 [medline]
AID - 10.11236/jph.67.3_167 [doi]
PST - ppublish
SO  - Nihon Koshu Eisei Zasshi. 2020;67(3):167-170. doi: 10.11236/jph.67.3_167.


PMID- 32238631
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 140
IP  - 4
DP  - 2020
TI  - [AI-based QSAR Modeling for Prediction of Active Compounds in MIE/AOP].
PG  - 499-505
LID - 10.1248/yakushi.19-00190-4 [doi]
AB  - Toxicity testing is critical for new drug and chemical development process. A
      clinical study, experimental animal models, and in vitro study are performed to
      evaluate the safety of a new drug. The limitations of these methods include
      extensive time for toxicity testing, an ethical problem, and high costs of
      experimentation. Therefore computational methods are considered useful for
      estimating chemical toxicity. In silico toxicity prediction is one of the
      toxicity assessments that uses computational methods to predict and stimulate the
      toxicity of chemicals. In silico study aims to contribute to effective
      development of new drug and chemical design. In this study, quantitative
      structure-activity relationship (QSAR) models will be used to predict toxicities 
      based on chemical structural parameters. Because toxicities are complicated
      physiological phenomena, a similar toxicity expression might cause a different
      pathway. Also, since many drugs with unknown mechanisms of actions are available,
      the application of artificial intelligence (AI)-which uses sophisticated
      algorithms- is increasingly used to predict toxicities. Recently, the QSAR model 
      was applied to determine complex relations between chemical structures and
      toxicities. However, accuracy of QSAR for toxicity prediction remains an
      important issue. International competitions funded by public institutions can
      address this issue. Two important toxicity challenges were organized in the past 
      decade; this article presents issues of toxicity based on these challenges.
FAU - Uesawa, Yoshihiro
AU  - Uesawa Y
AD  - Department of Medical Molecular Informatics, Meiji Pharmaceutical University.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
SB  - IM
MH  - *Adverse Outcome Pathways
MH  - Animal Testing Alternatives
MH  - Animals
MH  - *Artificial Intelligence
MH  - Computer Simulation
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Models, Animal
MH  - *Quantitative Structure-Activity Relationship
MH  - Toxicity Tests/methods
OTO - NOTNLM
OT  - adverse effect database
OT  - adverse outcome pathway
OT  - artificial intelligence
OT  - chemical structure
OT  - machine learning
OT  - quantitative structure-activity relationship
EDAT- 2020/04/03 06:00
MHDA- 2020/09/08 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
AID - 10.1248/yakushi.19-00190-4 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2020;140(4):499-505. doi: 10.1248/yakushi.19-00190-4.


PMID- 32238484
OWN - NLM
STAT- MEDLINE
DCOM- 20210115
LR  - 20210416
IS  - 1526-9906 (Electronic)
IS  - 1526-9906 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Apr
TI  - Historical Perspectives: Shared Decision Making in the NICU.
PG  - e217-e225
LID - 10.1542/neo.21-4-e217 [doi]
AB  - The ethical dilemmas and predominant frameworks surrounding decision making for
      critically ill newborns have evolved substantially over the last 40 years. A
      shared decision-making approach is now favored, involving an exchange of
      information between parents and clinicians that emphasizes parental values and
      preferences, resulting in a personalized approach to decision making. In this
      review, we summarize the history of clinical decision making with a focus on the 
      NICU, highlight different models of decision making, describe the advantages and 
      current limitations of shared decision making, and discuss the ongoing and future
      challenges of decision making in the NICU amidst medical innovations and emerging
      technologies.
CI  - Copyright (c) 2020 by the American Academy of Pediatrics.
FAU - Sullivan, Anne
AU  - Sullivan A
AD  - Department of Newborn Medicine, Boston Children's Hospital, Boston, MA.
FAU - Cummings, Christy
AU  - Cummings C
AD  - Department of Newborn Medicine, Boston Children's Hospital, Boston, MA.
LA  - eng
GR  - R01 HD094794/HD/NICHD NIH HHS/United States
GR  - T32 HD098061/HD/NICHD NIH HHS/United States
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Neoreviews
JT  - NeoReviews
JID - 101085360
SB  - IM
MH  - *Clinical Decision-Making/ethics
MH  - *Decision Making, Shared
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal
MH  - *Intensive Care, Neonatal/ethics/history
MH  - *Professional-Family Relations
PMC - PMC8049458
MID - NIHMS1676450
EDAT- 2020/04/03 06:00
MHDA- 2021/01/16 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/01/16 06:00 [medline]
AID - 21/4/e217 [pii]
AID - 10.1542/neo.21-4-e217 [doi]
PST - ppublish
SO  - Neoreviews. 2020 Apr;21(4):e217-e225. doi: 10.1542/neo.21-4-e217.


PMID- 32238441
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 5
DP  - 2020 May
TI  - ICU triage in an impending crisis: uncertainty, pre-emption and preparation.
PG  - 287-288
LID - 10.1136/medethics-2020-106226 [doi]
FAU - Wilkinson, Dominic
AU  - Wilkinson D
AUID- ORCID: 0000-0003-3958-8633
AD  - Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of
      Oxford, Oxford, UK dominic.wilkinson@philosophy.ox.ac.uk.
AD  - John Radcliffe Hospital, Oxford, South Australia, United Kingdom.
AD  - Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
LA  - eng
GR  - 203132/Z/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200401
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - Humans
MH  - *Intensive Care Units
MH  - *Triage
MH  - Uncertainty
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/03 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - medethics-2020-106226 [pii]
AID - 10.1136/medethics-2020-106226 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 May;46(5):287-288. doi: 10.1136/medethics-2020-106226. Epub
      2020 Apr 1.


PMID- 32238345
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200406
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 369
DP  - 2020 Apr 1
TI  - Machine learning and artificial intelligence research for patient benefit: 20
      critical questions on transparency, replicability, ethics, and effectiveness.
PG  - m1312
LID - 10.1136/bmj.m1312 [doi]
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20200401
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
EFR - BMJ. 2020 Mar 20;368:l6927. PMID: 32198138
EDAT- 2020/04/03 06:00
MHDA- 2020/04/03 06:01
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/04/03 06:01 [medline]
AID - 10.1136/bmj.m1312 [doi]
PST - epublish
SO  - BMJ. 2020 Apr 1;369:m1312. doi: 10.1136/bmj.m1312.


PMID- 32238343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Apr 2
TI  - A Smartphone App (mDASHNa-CC) to Support Healthy Diet and Hypertension Control
      for Chinese Canadian Seniors: Protocol for Design, Usability and Feasibility
      Testing.
PG  - e15545
LID - 10.2196/15545 [doi]
AB  - BACKGROUND: This proposed study aims to translate the Dietary Approach to Stop
      Hypertension with Sodium (Na) Reduction for Chinese Canadians (DASHNa-CC), a
      classroom-based, antihypertensive, dietary educational intervention, to an
      innovative smartphone app (mDASHNa-CC). This study will enable Chinese Canadian
      seniors to access antihypertensive dietary interventions anytime, regardless of
      where they are. It is hypothesized that senior Chinese Canadians will be
      satisfied with their experiences using the mDASHNa-CC app and that the use of
      this app could lead to a decrease in their blood pressure and improvement in
      their health-related quality of life. OBJECTIVE: The goal of this study is to
      design and test the usability and feasibility of a smartphone-based dietary
      educational app to support a healthy diet and hypertension control for Chinese
      Canadian seniors. METHODS: A mixed-method two-phase design will be used. The
      study will be conducted in a Chinese immigrant community in Toronto, Ontario,
      Canada. Chinese Canadian seniors, who are at least 65 years old, self-identified 
      as Chinese, living in Canada, and with elevated blood pressure, will be
      recruited. In Phase I, we will design and test the usability of the app using a
      user-centered approach. In Phase II, we will test the feasibility of the app,
      including implementation (primary outcomes of accrual and attrition rates,
      technical issues, acceptability of the app, and adherence to the intervention)
      and preliminary effectiveness (secondary outcomes of systolic and diastolic blood
      pressure, weight, waist circumference, health-related quality of life, and health
      service utilization), using a pilot, two-group, randomized controlled trial with 
      a sample size of 60 participants in a Chinese Canadian community. RESULTS: The
      study is supported by the Startup Research Grant from Nipissing University,
      Canada. The research ethics application is under review by a university research 
      ethics review board. CONCLUSIONS: The study results will make several
      contributions to the existing literature, including illustrating the rigorous
      design and testing of smartphone app technology for hypertension self-management 
      in the community, exploring an approach to incorporating traditional medicine
      into chronic illness management in minority communities and promoting equal
      access to current technology among minority immigrant senior groups. TRIAL
      REGISTRATION: Clinicaltrials.gov NCT03988894;
      https://clinicaltrials.gov/ct2/show/NCT03988894. INTERNATIONAL REGISTERED REPORT 
      IDENTIFIER (IRRID): PRR1-10.2196/15545.
CI  - (c)Ping Zou, Jennifer Stinson, Monica Parry, Cindy-Lee Dennis, Yeqin Yang,
      Zhongqiu Lu. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 02.04.2020.
FAU - Zou, Ping
AU  - Zou P
AUID- ORCID: https://orcid.org/0000-0002-3973-7830
AD  - School of Nursing, Nipissing University, Toronto, ON, Canada.
FAU - Stinson, Jennifer
AU  - Stinson J
AUID- ORCID: https://orcid.org/0000-0002-9969-8052
AD  - Lawrence Bloomberg Faculty of Nursing, University of Toronto, Hospital for Sick
      Children, Toronto, ON, Canada.
FAU - Parry, Monica
AU  - Parry M
AUID- ORCID: https://orcid.org/0000-0002-6941-1380
AD  - Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON,
      Canada.
FAU - Dennis, Cindy-Lee
AU  - Dennis CL
AUID- ORCID: https://orcid.org/0000-0002-0135-7242
AD  - Lawrence Bloomberg Faculty of Nursing and Department of Psychiatry, University of
      Toronto, Toronto, ON, Canada.
FAU - Yang, Yeqin
AU  - Yang Y
AUID- ORCID: https://orcid.org/0000-0003-1039-7219
AD  - School of Nursing, Wenzhou Medical University, Wenzhou, China.
FAU - Lu, Zhongqiu
AU  - Lu Z
AUID- ORCID: https://orcid.org/0000-0002-6807-6189
AD  - School of Nursing, Wenzhou Medical University, Wenzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03988894
PT  - Journal Article
DEP - 20200402
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7316441
OTO - NOTNLM
OT  - Canada
OT  - Chinese
OT  - diet
OT  - hypertension
OT  - senior
OT  - smartphone app
EDAT- 2020/04/03 06:00
MHDA- 2020/04/03 06:01
CRDT- 2020/04/03 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2019/12/09 00:00 [accepted]
PHST- 2019/11/12 00:00 [revised]
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/04/03 06:01 [medline]
AID - v9i4e15545 [pii]
AID - 10.2196/15545 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Apr 2;9(4):e15545. doi: 10.2196/15545.


PMID- 32238293
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20211123
IS  - 1532-9453 (Electronic)
IS  - 1055-8586 (Linking)
VI  - 29
IP  - 1
DP  - 2020 Feb
TI  - The role of ethics consultation in decision making for bariatric surgery in
      pediatrics.
PG  - 150884
LID - S1055-8586(20)30004-4 [pii]
LID - 10.1016/j.sempedsurg.2020.150884 [doi]
AB  - The decision to pursue metabolic and bariatric surgery (MBS) for pediatric
      patients has become increasingly accepted by patients and their families and by
      health care professionals. The advancement of pre- and post-operative MBS
      guidelines, based on accumulating evidence for safety, efficacy, and
      cost-effectiveness help to map the clinical pathway for MBS consideration.
      Ethical issues remain possible for each case, however, and consultation with
      ethical experts can provide clarity in the consideration of MBS. Specifically,
      ethical issues related to principles of autonomy, justice, beneficence, and
      non-maleficence may need to be resolved based on patient characteristics,
      including preadolescent patients and those who present with intellectual
      disabilities. Institutions that offer MBS for pediatric patients will benefit
      from collaborating with ethics consultants to develop a structured approach that 
      helps ensure that ethical principles have been adequately addressed for patients 
      presenting for MBS.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Boles, Richard E
AU  - Boles RE
AD  - University of Colorado Anschutz Medical Campus, Department of Pediatrics, Aurora,
      CO 80045, United States. Electronic address: RichardBoles@CUAnschutz.edu.
FAU - Moore, Jaime M
AU  - Moore JM
AD  - University of Colorado Anschutz Medical Campus, Department of Pediatrics, Aurora,
      CO 80045, United States.
FAU - Glover, Jacqueline J
AU  - Glover JJ
AD  - University of Colorado Anschutz Medical Campus, Department of Pediatrics and
      Center for Bioethics and Humanities, Aurora, CO 80045, United States.
LA  - eng
GR  - T32 DK007658/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20200118
PL  - United States
TA  - Semin Pediatr Surg
JT  - Seminars in pediatric surgery
JID - 9216162
SB  - IM
MH  - Adolescent
MH  - Bariatric Surgery/*ethics
MH  - Child
MH  - Clinical Decision-Making/*ethics
MH  - *Decision Making, Shared
MH  - *Ethics Consultation
MH  - Female
MH  - Humans
MH  - Male
MH  - Pediatric Obesity/*surgery
PMC - PMC8607297
MID - NIHMS1742396
OTO - NOTNLM
OT  - Autonomy
OT  - Beneficence
OT  - Ethics
OT  - Justice
OT  - Non-maleficence
EDAT- 2020/04/03 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
AID - S1055-8586(20)30004-4 [pii]
AID - 10.1016/j.sempedsurg.2020.150884 [doi]
PST - ppublish
SO  - Semin Pediatr Surg. 2020 Feb;29(1):150884. doi: 10.1016/j.sempedsurg.2020.150884.
      Epub 2020 Jan 18.


PMID- 32238158
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 1
TI  - Parents' and healthcare professionals' perceptions of the use of live video
      recording in neonatal units: a focus group study.
PG  - 143
LID - 10.1186/s12887-020-02041-9 [doi]
AB  - BACKGROUND: The emerging use of video in neonatology units raises ethical and
      practical questions. This study aims to gain a better understanding of the
      suitability, limitations and constraints concerning the use of live video as a
      tool in neonatal clinical practice. The perceptions of parents and healthcare
      professionals in regard to live video were examined. METHODS: Nine focus groups
      were conducted in four neonatal units involving 20 healthcare professionals and
      19 parents. Data were triangulated using transcripts and field notes and analyzed
      using inductive and semantic thematic analysis. RESULTS: The seven major themes
      that emerged from the healthcare professionals focus groups were (i) the impact
      of video recording on healthcare professionals' behavior; (ii) the impact on
      parents; (iii) forensic issues;(iv) guarantee of use; (v) benefits for the
      newborn; (vi) methodology of use; and (vii) technical considerations &
      feasibility. The five major themes that emerged from parents focus groups were
      (i) benefits for the newborn and care enhancement; (ii) impact on parents and
      potential benefits in case of newborn child/parent separation; (iii) informed
      consent and guarantee of use;(iv) concern about a possible disruptive impact on
      healthcare professionals; and (v) data protection. CONCLUSION: Both parents and
      healthcare professionals found video recording useful and acceptable if measures 
      were taken to protect the data and mitigate any negative impacts on healthcare
      professionals.
FAU - Le Bris, Aude
AU  - Le Bris A
AD  - Department of Neonatology, University Hospital of Rennes, 35000, Rennes, France. 
      aude.lebris@outlook.com.
FAU - Mazille-Orfanos, Nadia
AU  - Mazille-Orfanos N
AD  - Department of Neonatology, University Hospital of Rennes, 35000, Rennes, France.
FAU - Simonot, Pauline
AU  - Simonot P
AD  - Department of Neonatology, University Hospital of Caen, Caen, France.
FAU - Luherne, Maude
AU  - Luherne M
AD  - Research and Innovation Department, Paediatric Department, University Hospital of
      Rennes and GCS HUGO, Rennes, France.
FAU - Flamant, Cyril
AU  - Flamant C
AD  - Department of Neonatology, University Hospital of Nantes, Nantes, France.
FAU - Gascoin, Geraldine
AU  - Gascoin G
AD  - Department of Neonatology, University Hospital of Angers, Angers, France.
FAU - OLaighin, Gearoid
AU  - OLaighin G
AD  - CURAM, Human Movement Laboratory, NUI Galway, Galway, Ireland.
FAU - Harte, Richard
AU  - Harte R
AD  - CURAM, Human Movement Laboratory, NUI Galway, Galway, Ireland.
FAU - Pladys, Patrick
AU  - Pladys P
AD  - Department of Neonatology, University Hospital of Rennes, 35000, Rennes, France.
AD  - Research and Innovation Department, Paediatric Department, University Hospital of
      Rennes and GCS HUGO, Rennes, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200401
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
SB  - IM
MH  - Focus Groups
MH  - *Health Personnel
MH  - Humans
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal
MH  - *Parents
MH  - *Video Recording
PMC - PMC7110620
OTO - NOTNLM
OT  - *Focus groups
OT  - *Healthcare professionals
OT  - *Parents
OT  - *Perceptions
OT  - *Video
EDAT- 2020/04/03 06:00
MHDA- 2021/02/27 06:00
CRDT- 2020/04/03 06:00
PHST- 2019/11/08 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
AID - 10.1186/s12887-020-02041-9 [doi]
AID - 10.1186/s12887-020-02041-9 [pii]
PST - epublish
SO  - BMC Pediatr. 2020 Apr 1;20(1):143. doi: 10.1186/s12887-020-02041-9.


PMID- 32238039
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Systematic reviews of empirical literature on bioethical topics: Results from a
      meta-review.
PG  - 960-978
LID - 10.1177/0969733020907935 [doi]
AB  - BACKGROUND: In bioethics, especially nursing ethics, systematic reviews are
      increasingly popular. The overall aim of a systematic review is to provide an
      overview of the published discussions on a specific topic. While a meta-review on
      systematic reviews on normative bioethical literature has already been performed,
      there is no equivalent for systematic reviews of empirical literature on ethical 
      topics. OBJECTIVE: This meta-review aims to present the general trends and
      characteristics of systematic reviews of empirical bioethical literature and to
      evaluate their reporting quality. RESEARCH DESIGN: Literature search was
      performed on PubMed and Google Scholar. Qualitative content analysis and
      quantitative approaches were used to evaluate the systematic reviews.
      Characteristics of systematic reviews were extracted and quantitatively analyzed.
      The reporting quality was measured using an adapted PRISMA checklist. FINDINGS:
      Seventy-six reviews were selected for analysis. Most reviews came from the field 
      of nursing (next to bioethics and medicine). Selected systematic reviews
      investigated issues related to clinical ethics (50%), followed by research ethics
      (36%) and public health ethics or organizational ethics (14%). In all, 72% of the
      systematic reviews included authors' ethical reflections on the findings and 59% 
      provided ethical recommendations. Despite the heterogeneous reporting of the
      reviews, reviews using PRISMA tended to score better regarding reporting quality.
      DISCUSSION: The heterogeneity currently observed is due both to the
      interdisciplinary nature of nursing ethics and bioethics, and to the emerging
      nature of systematic review methods in these fields. These results confirm the
      findings of our previous review of systematic reviews on normative literature,
      thereby highlighting a recurring methodological gap in systematic reviews of
      bioethical literature. This also indicates the need to develop more robust
      methodological standards. CONCLUSION: Through its extensive overview of the
      characteristics of systematic reviews of empirical literature on ethical topics, 
      this meta-review is expected to inform further discussions on minimal standards
      and reporting guidelines.
FAU - Mertz, Marcel
AU  - Mertz M
AUID- ORCID: https://orcid.org/0000-0002-4871-4219
AD  - Hannover Medical School, Germany.
FAU - Nobile, Helene
AU  - Nobile H
AD  - Hannover Medical School, Germany.
FAU - Kahrass, Hannes
AU  - Kahrass H
AD  - Hannover Medical School, Germany.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200402
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - *Bioethical Issues
MH  - *Empirical Research
MH  - Ethics, Nursing
MH  - Humans
MH  - *Systematic Reviews as Topic
PMC - PMC7323745
OTO - NOTNLM
OT  - Bioethics
OT  - empirical ethics
OT  - empirical literature
OT  - knowledge syntheses
OT  - systematic review
EDAT- 2020/04/03 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1177/0969733020907935 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):960-978. doi: 10.1177/0969733020907935. Epub 2020 Apr
      2.


PMID- 32238031
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Moral distress: Developing strategies from experience.
PG  - 1147-1156
LID - 10.1177/0969733020906593 [doi]
AB  - BACKGROUND: Moral distress was first described by Jameton in 1984, and has been
      defined as distress experienced by an individual when they are unable to carry
      out what they believe to be the right course of action because of real or
      perceived constraints on that action. This complex phenomenon has been studied
      extensively among healthcare providers, and intensive care professionals in
      particular report high levels of moral distress. This distress has been
      associated with provider burnout and associated consequences such as job
      attrition, with potential impacts on patient and family care. There is a paucity 
      of literature exploring how middle and late career healthcare providers
      experience and cope with moral distress. OBJECTIVES: We explore the experience of
      moral distress and the strategies and resources invoked to mitigate that distress
      in mid- and late-career healthcare providers practicing in paediatric intensive
      care, in order to identify ways in which the work environment can build a culture
      of moral resilience. RESEARCH DESIGN: An exploratory, qualitative quality
      improvement project utilizing focus group and semi-structured interviews with
      pediatric intensive care front-line providers. PARTICIPANTS: Mid-and-later career
      (10 + years in practice) pediatric intensive care front line providers in a
      tertiary pediatric hospital. RESEARCH CONTEXT: This work focuses on paediatric
      intensive care providers in a single critical care unit, in order to explore the 
      site-specific perspectives of health care providers in that context with respect 
      to moral distress coping strategies. ETHICAL CONSIDERATIONS: The study was
      approved by the Quality Management Office at the institution; consent was
      obtained from participants, and no identifying data was included in this project.
      FINDINGS: Participants endorsed perspective-building and described strategies for
      positive adaptation including; active, reflective and structured supports.
      Participants articulated interest in enhanced and accessible formal supports.
      DISCUSSION: Findings in this study resonate with the current literature in
      healthcare provider moral distress, and exposed ways in which the work
      environment could support a culture of moral resilience. Avenues are described
      for the management and mitigation of moral distress in this setting. CONCLUSION: 
      This exploratory work lays the groundwork for interventions that facilitate
      personal growth and meaning in the midst of moral crises in critical care
      practice.
FAU - Helmers, Andrew
AU  - Helmers A
AUID- ORCID: https://orcid.org/0000-0002-2935-9522
FAU - Palmer, Karen Dryden
AU  - Palmer KD
AD  - The Hospital for Sick Children, Canada.
FAU - Greenberg, Rebecca A
AU  - Greenberg RA
AD  - Mount Sinai Hospital, Canada; University of Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200402
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - *Adaptation, Psychological
MH  - Adult
MH  - Canada
MH  - Female
MH  - Focus Groups
MH  - Health Personnel/*ethics/*psychology
MH  - Humans
MH  - *Intensive Care Units, Pediatric
MH  - Male
MH  - Middle Aged
MH  - *Morals
MH  - Qualitative Research
MH  - *Resilience, Psychological
MH  - *Stress, Psychological
OTO - NOTNLM
OT  - Intensive care
OT  - moral distress
OT  - moral/ethical climate of organizations
OT  - pediatric
OT  - resilience
EDAT- 2020/04/03 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1177/0969733020906593 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):1147-1156. doi: 10.1177/0969733020906593. Epub 2020
      Apr 2.


PMID- 32237466
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 45
IP  - 5
DP  - 2020 Mar
TI  - [Discussion on design of clinical trial scheme for doctor-patient co-construction
      of traditional Chinese medicine and Western medicine under concept of narrative
      medicine].
PG  - 1202-1208
LID - 10.19540/j.cnki.cjcmm.20190620.502 [doi]
AB  - With the continuous improvement of modern medical technology, medical practice
      has become more and more procedural. The medical process is often dominated by
      doctors, while the value orientation of patients is often ignored, lacking
      effective communication between doctors and patients. In response to this
      phenomenon, Charon R proposed the concept of narrative medicine, which has been
      recognized by all walks of life. In recent years, the value of medical humanism
      has attracted more attention, and the research on narrative medicine at home and 
      abroad is increasing gradually. But at present, most of the research on narrative
      medicine is in terms of theory, lacking clinical research. How to make narrative 
      medicine applied in the real world is the focus of current research. Following
      the concept of narrative medicine, and taking the study on doctor-patient
      parallel medical record to evaluate the real clinical efficacy of traditional
      Chinese medicine(TCM) and Western medicine(WM) in the treatment of digestive
      diseases as an example, this study is to explore the design contents and key
      points of the clinical trial scheme of doctor-patient co-construction of TCM and 
      WM under narrative medicine, and discuss the activity form and clinical efficacy 
      evaluation method under narrative medicine. Clinical trial design includes four
      aspects: medicine, ethics, statistics and trial management. This study explored
      the design of the doctor-patient co-construction clinical trial scheme under
      narrative medicine from both theoretical and practical aspects, providing
      reference for the design and research of future doctor-patient co-construction
      scheme, and expecting to establish a better efficacy evaluation method of TCM and
      WM.
FAU - Xin, Yu
AU  - Xin Y
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700,
      China.
FAU - Yang, Hao-Xin
AU  - Yang HX
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700,
      China.
FAU - Zhang, Xiu-Wen
AU  - Zhang XW
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700,
      China.
FAU - Zhao, Guo-Zhen
AU  - Zhao GZ
AD  - Beijing Institute of Traditional Chinese Medicine, Beijing Hospital of
      Traditional Chinese Medicine, Capital Medical University Beijing 100010, China.
FAU - Dai, Yan-Yan
AU  - Dai YY
AD  - Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700,
      China.
FAU - Li, Bo
AU  - Li B
AD  - Beijing Institute of Traditional Chinese Medicine, Beijing Hospital of
      Traditional Chinese Medicine, Capital Medical University Beijing 100010, China
      Yanqing Hospital, Beijing Hospital of Traditional Chinese Medicine, Capital
      Medical University Beijing 102100, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese
      materia medica
JID - 8913656
SB  - IM
MH  - *Clinical Trials as Topic
MH  - Humans
MH  - Medical Records
MH  - Medicine, Chinese Traditional
MH  - *Narrative Medicine
MH  - Patient Participation
MH  - *Research Design
OTO - NOTNLM
OT  - clinical trial
OT  - doctor-patient co-construction
OT  - narrative medicine
OT  - parallel medical record
OT  - project design
EDAT- 2020/04/03 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.19540/j.cnki.cjcmm.20190620.502 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(5):1202-1208. doi:
      10.19540/j.cnki.cjcmm.20190620.502.


PMID- 32236962
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1521-1878 (Electronic)
IS  - 0265-9247 (Linking)
VI  - 42
IP  - 6
DP  - 2020 Jun
TI  - The Study That Made Rats Jump for Joy, and Then Killed Them: The Gap between
      Knowledge and Practice Widens When Scientists Fail to Engage with the Ethical
      Implications of Their Own Work.
PG  - e2000030
LID - 10.1002/bies.202000030 [doi]
AB  - Much contemporary behavioral science stops short of considering the ethical
      implications of its own findings. This generates a contradiction between methods 
      and discoveries, and hinders translation between updated scientific evidence for 
      animal sentience and corresponding political and legal changes. A recent and
      particularly illustrative example in rodents is described here.
CI  - (c) 2020 WILEY Periodicals, Inc.
FAU - Webb, Christine E
AU  - Webb CE
AUID- ORCID: 0000-0002-9757-729X
AD  - Department of Human Evolutionary Biology, Harvard University, 11 Divinity Avenue,
      Cambridge, MA, 02138, USA.
FAU - Woodford, Peter
AU  - Woodford P
AD  - Centre for Research in Modern European Philosophy, Kingston University, Penrhyn
      Road, Kingston upon Thames, KT1 2EE, UK.
FAU - Huchard, Elise
AU  - Huchard E
AD  - Institut des Sciences de l'Evolution, Universite de Montpellier, CC 065,
      Montpellier 05, 34095, France.
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200401
PL  - United States
TA  - Bioessays
JT  - BioEssays : news and reviews in molecular, cellular and developmental biology
JID - 8510851
SB  - IM
MH  - Animals
MH  - *Knowledge
MH  - Rats
OTO - NOTNLM
OT  - *animal ethics
OT  - *rodents
OT  - *sacrifice
OT  - *science-to-policy
OT  - *sentience
EDAT- 2020/04/03 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1002/bies.202000030 [doi]
PST - ppublish
SO  - Bioessays. 2020 Jun;42(6):e2000030. doi: 10.1002/bies.202000030. Epub 2020 Apr 1.


PMID- 32236913
OWN - NLM
STAT- MEDLINE
DCOM- 20200522
LR  - 20201218
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 145
IP  - 10
DP  - 2020 May
TI  - [Legal Issues of Resource Allocation in the COVID-19 Pandemic - Between
      Utilitarianism and Life Value Indifference].
PG  - 687-692
LID - 10.1055/a-1146-1160 [doi]
AB  - The COVID-19 pandemic poses unprecedented challenges for the German health care
      system. What is already the case in some other countries, may occur in Germany in
      the near future also: Faced with limited ICU resources, doctors will be forced to
      decide which patients to treat and which to let die. This paper examines the
      legal implications of such decisions. It takes up arguments from the general
      discussion on prioritization in medicine. A constitutional hurdle for the
      application of utilitarian criteria (in particular patients' age or social role) 
      comes from the principle that every human life is of equal value and must not be 
      traded off against others ("life value indifference"). However, the limits that
      the Grundgesetz (German Basic Law) sets for state actions do not apply directly
      to doctors. According to the Musterberufsordnung (professional code of conduct), 
      doctors act based on their conscience and the requirements of medical ethics and 
      humanity. The implications of this normative standard for the prioritizing in an 
      exceptional situation as the COVID 19 pandemic have not been sufficiently
      clarified. This uncertainty leads to emotional and moral burdens for doctors. The
      authors conclude that the German law grants a limited freedom of choice that
      allows physicians to apply utilitarian criteria in addition to purely medical
      decision algorithms.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Hubner, Joachim
AU  - Hubner J
FAU - Schewe, Denis M
AU  - Schewe DM
FAU - Katalinic, Alexander
AU  - Katalinic A
FAU - Frielitz, Fabian-S
AU  - Frielitz FS
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Rechtsfragen der Ressourcenzuteilung in der COVID-19-Pandemie - Zwischen
      Utilitarismus und Lebenswertindifferenz.
DEP - 20200401
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*mortality/therapy
MH  - Cost of Illness
MH  - Decision Making/*ethics
MH  - Delivery of Health Care/legislation & jurisprudence
MH  - *Ethics, Medical
MH  - Germany
MH  - Humans
MH  - Legislation, Medical
MH  - Pandemics
MH  - Physicians/ethics/standards
MH  - Pneumonia, Viral/*mortality/therapy
MH  - Resource Allocation/*ethics/legislation & jurisprudence
MH  - SARS-CoV-2
MH  - Value of Life
PMC - PMC7295273
COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
EDAT- 2020/04/03 06:00
MHDA- 2020/05/23 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/05/23 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1055/a-1146-1160 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2020 May;145(10):687-692. doi: 10.1055/a-1146-1160. Epub
      2020 Apr 1.


PMID- 32236811
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1573-3688 (Electronic)
IS  - 1053-0487 (Linking)
VI  - 30
IP  - 3
DP  - 2020 Sep
TI  - Smart Work Injury Management (SWIM) System: Artificial Intelligence in Work
      Disability Management.
PG  - 354-361
LID - 10.1007/s10926-020-09886-y [doi]
AB  - PURPOSE: This paper aims to illustrate an example of how to set up a work injury 
      database: the Smart Work Injury Management (SWIM) system. It is a secure and
      centralized cloud platform containing a set of management tools for data storage,
      data analytics, and machine learning. It employs artificial intelligence to
      perform in-depth analysis via text-mining techniques in order to extract both
      dynamic and static data from work injury case files. When it is fully developed, 
      this system can provide a more accurate prediction model for cost of work
      injuries. It can also predict return-to-work (RTW) trajectory and provide advice 
      on medical care and RTW interventions to all RTW stakeholders. The project will
      comprise three stages. Stage one: to identify human factors in terms of both
      facilitators and barriers RTW through face-to-face interviews and focus group
      discussions with different RTW stakeholders in order to collect opinions related 
      to facilitators, barriers, and essential interventions for RTW of injured
      workers; Stage two: to develop a machine learning model which employs artificial 
      intelligence to perform in-depth analysis. The technologies used will include: 1.
      Text-mining techniques including English and Chinese work segmentation as well as
      N-Gram to extract both dynamic and static data from free-style text as well as
      sociodemographic information from work injury case files; 2. Principle
      component/independent component analysis to identify features of significant
      relationships with RTW outcomes or combine raw features into new features; 3. A
      machine learning model that combines Variational Autoencoder, Long and Short Term
      Memory, and Neural Turning Machines. Stage two will also include the development 
      of an interactive dashboard and website to query the trained machine learning
      model. Stage three: to field test the SWIM system. CONCLUSION: SWIM ia secure and
      centralized cloud platform containing a set of management tools for data storage,
      data analytics, and machine learning. When it is fully developed, SWIM can
      provide a more accurate prediction model for the cost of work injuries and advice
      on medical care and RTW interventions to all RTW stakeholders. ETHICS: The
      project has been approved by the Ethics Committee for Human Subjects at the Hong 
      Kong Polytechnic University and is funded by the Innovation and Technology
      Commission (Grant # ITS/249/18FX).
FAU - Cheng, Andy S K
AU  - Cheng ASK
AUID- ORCID: 0000-0001-7503-5273
AD  - Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung
      Hom, Kowloon, Hong Kong. andy.cheng@polyu.edu.hk.
FAU - Ng, Peter H F
AU  - Ng PHF
AD  - Department of Computing, The Hong Kong Polytechnic University, Hung Hom, Kowloon,
      Hong Kong.
FAU - Sin, Zackary P T
AU  - Sin ZPT
AD  - Department of Computing, The Hong Kong Polytechnic University, Hung Hom, Kowloon,
      Hong Kong.
FAU - Lai, Sun H S
AU  - Lai SHS
AD  - Total Rehabilitaton Management (HK) Limited, Wanchai Road, Wanchai, Hong Kong.
FAU - Law, S W
AU  - Law SW
AD  - Department of Orthopaedics & Traumatology, Alice Ho Miu Ling Nethersole
      Hospital/Tai Po Hospital, Tai Po, NT, Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Occup Rehabil
JT  - Journal of occupational rehabilitation
JID - 9202814
SB  - IM
MH  - *Artificial Intelligence
MH  - *Disability Evaluation
MH  - Employment
MH  - Focus Groups
MH  - Hong Kong
MH  - Humans
MH  - *Return to Work
OTO - NOTNLM
OT  - *Artificial intelligence
OT  - *Machine learning
OT  - *Prediction
OT  - *Return to work
OT  - *Work disability management
EDAT- 2020/04/03 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1007/s10926-020-09886-y [doi]
AID - 10.1007/s10926-020-09886-y [pii]
PST - ppublish
SO  - J Occup Rehabil. 2020 Sep;30(3):354-361. doi: 10.1007/s10926-020-09886-y.


PMID- 32236794
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 1572-8633 (Electronic)
IS  - 1386-7423 (Linking)
VI  - 23
IP  - 3
DP  - 2020 Sep
TI  - A critical perspective on guidelines for responsible and trustworthy artificial
      intelligence.
PG  - 387-399
LID - 10.1007/s11019-020-09948-1 [doi]
AB  - Artificial intelligence (AI) is among the fastest developing areas of advanced
      technology in medicine. The most important qualia of AI which makes it different 
      from other advanced technology products is its ability to improve its original
      program and decision-making algorithms via deep learning abilities. This
      difference is the reason that AI technology stands out from the ethical issues of
      other advanced technology artifacts. The ethical issues of AI technology vary
      from privacy and confidentiality of personal data to ethical status and value of 
      AI entities in a wide spectrum, depending on their capability of deep learning
      and scope of the domains in which they operate. Developing ethical norms and
      guidelines for planning, development, production, and usage of AI technology has 
      become an important issue to overcome these problems. In this respect three
      outstanding documents have been produced:1. The Montreal Declaration for
      Responsible Development of Artificial Intelligence2. Ethics Guidelines for
      Trustworthy AI3. Asilomar Artificial Intelligence PrinciplesIn this study, these 
      three documents will be analyzed with respect to the ethical principles and
      values they involve, their perspectives for approaching ethical issues, and their
      prospects for ethical reasoning when one or more of these values and principles
      are in conflict. Then, the sufficiency of these guidelines for addressing current
      or prospective ethical issues emerging from the existence of AI technology in
      medicine will be evaluated. The discussion will be pursued in terms of the
      ambiguity of interlocutors and efficiency for working out ethical dilemmas
      occurring in practical life.
FAU - Buruk, Banu
AU  - Buruk B
AUID- ORCID: http://orcid.org/0000-0003-2272-5865
AD  - Department of History of Medicine and Ethics, TOBB ETU University Medical School,
      Ankara, Turkey. banuburuk@gmail.com.
FAU - Ekmekci, Perihan Elif
AU  - Ekmekci PE
AUID- ORCID: http://orcid.org/0000-0002-0777-3861
AD  - Department of History of Medicine and Ethics, TOBB ETU University Medical School,
      Ankara, Turkey.
FAU - Arda, Berna
AU  - Arda B
AUID- ORCID: http://orcid.org/0000-0003-2043-2444
AD  - Department of History of Medicine and Ethics, Ankara University Medical School,
      Ankara, Turkey.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Health Care Philos
JT  - Medicine, health care, and philosophy
JID - 9815900
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - Confidentiality/ethics/standards
MH  - Guidelines as Topic/*standards
MH  - Humans
MH  - Philosophy, Medical
MH  - Privacy
OTO - NOTNLM
OT  - Artificial intelligence (AI)
OT  - Ethical values
OT  - Ethics guidelines
OT  - Technology ethics
EDAT- 2020/04/03 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1007/s11019-020-09948-1 [doi]
AID - 10.1007/s11019-020-09948-1 [pii]
PST - ppublish
SO  - Med Health Care Philos. 2020 Sep;23(3):387-399. doi: 10.1007/s11019-020-09948-1.


PMID- 32236394
OWN - NLM
STAT- MEDLINE
DCOM- 20210506
LR  - 20210506
IS  - 2426-0266 (Electronic)
IS  - 2274-5807 (Linking)
VI  - 7
IP  - 2
DP  - 2020
TI  - Integrated Care for Older People and the Implementation in the INSPIRE Care
      Cohort.
PG  - 70-74
LID - 10.14283/jpad.2020.8 [doi]
AB  - BACKGROUNDS: The World Health Organization has published the Integrated Care for 
      Older People, ICOPE handbook Guidance on person-centred assessment and pathways
      in primary care. This is an integrated individual care tool focused on the
      individual and healthy ageing. The ICOPE tool proposes step by step, a screening,
      a fine assessment, the development of a personalized care plan, its
      implementation and follow up and finally the consideration of the caregivers and 
      community. The new Geroscience field is focusing on preventing age-related
      diseases, and should now investigate with the ICOPE tool the optimal maintenance 
      of intrinsic capacity (IC) through mobility, cognition, psychology, vitality,
      hearing and vision. This article aims to present this new tool and to presents
      its innovative implementation at the Toulouse University Hospital through the
      INSPIRE study. We believe that the ICOPE integrated care program will also be a
      pragmatic way to maintain cognitive functions and detect early Alzheimer.
      OBJECTIVES: The main objective of the INSPIRE study is to build a Bio-resource
      Research Platform for Healthy Ageing gathering biological, clinical and digital
      resources in order to identify markers of ageing, age-related diseases and IC
      evolution. The study will be also testing the implementation and follow up of the
      ICOPE tool. METHODS: The Inspire Platform will gather clinical data and
      bio-specimens from 1000 subjects in the Occitania Region, of different ages (from
      30 years and over) over 10 years. Data will be collected annually. Using the
      ICOPE tool IC domains will be monitored every 4 months. Once IC decline is
      identified, participants will have a thorough clinical assessment and blood
      sampling to investigate the response of markers of ageing at the time of decline.
      The French ethic committee approved the study. RESULTS: The Inspire platform aims
      to develop an integrative approach to promote novel new technologies for the
      assessment and monitoring of functional capacities.
FAU - Takeda, C
AU  - Takeda C
AD  - C. Takeda, Gerontopole, CHU Toulouse, Cite de la Sante, Hopital La Grave, Place
      Lange, 31059 Toulouse cedex 9, France, Tel : +33.(0)5.17.77.70.28, Fax
      +33.(0)5.61.77.70.71, E-mail: takeda.c@chu-toulouse.fr.
FAU - Guyonnet, S
AU  - Guyonnet S
FAU - Sumi, Y
AU  - Sumi Y
FAU - Vellas, B
AU  - Vellas B
FAU - Araujo de Carvalho, I
AU  - Araujo de Carvalho I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Switzerland
TA  - J Prev Alzheimers Dis
JT  - The journal of prevention of Alzheimer's disease
JID - 101638820
SB  - IM
MH  - Aging/*physiology
MH  - Cohort Studies
MH  - Delivery of Health Care, Integrated/*organization & administration
MH  - Geriatrics/standards
MH  - Global Health
MH  - Humans
MH  - Patient-Centered Care/*organization & administration
MH  - Primary Health Care/*organization & administration
MH  - World Health Organization
OTO - NOTNLM
OT  - *Integrated care
OT  - *intrinsic capacity
OT  - *person-centred assessment
OT  - *primary care
COIS- The author declares no conflict of interest.
EDAT- 2020/04/03 06:00
MHDA- 2021/05/07 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/05/07 06:00 [medline]
AID - 10.14283/jpad.2020.8 [doi]
PST - ppublish
SO  - J Prev Alzheimers Dis. 2020;7(2):70-74. doi: 10.14283/jpad.2020.8.


PMID- 32235610
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 7
DP  - 2020 Mar 30
TI  - The Current Understanding of Autophagy in Nanomaterial Toxicity and Its
      Implementation in Safety Assessment-Related Alternative Testing Strategies.
LID - E2387 [pii]
LID - 10.3390/ijms21072387 [doi]
AB  - Nanotechnology has rapidly promoted the development of a new generation of
      industrial and commercial products; however, it has also raised some concerns
      about human health and safety. To evaluate the toxicity of the great diversity of
      nanomaterials (NMs) in the traditional manner, a tremendous number of safety
      assessments and a very large number of animals would be required. For this
      reason, it is necessary to consider the use of alternative testing strategies or 
      methods that reduce, refine, or replace (3Rs) the use of animals for assessing
      the toxicity of NMs. Autophagy is considered an early indicator of NM
      interactions with cells and has been recently recognized as an important form of 
      cell death in nanoparticle-induced toxicity. Impairment of autophagy is related
      to the accelerated pathogenesis of diseases. By using mechanism-based
      high-throughput screening in vitro, we can predict the NMs that may lead to the
      generation of disease outcomes in vivo. Thus, a tiered testing strategy is
      suggested that includes a set of standardized assays in relevant human cell lines
      followed by critical validation studies carried out in animals or whole organism 
      models such as C. elegans (Caenorhabditis elegans), zebrafish (Danio rerio), and 
      Drosophila (Drosophila melanogaster)for improved screening of NM safety. A
      thorough understanding of the mechanisms by which NMs perturb biological systems,
      including autophagy induction, is critical for a more comprehensive elucidation
      of nanotoxicity. A more profound understanding of toxicity mechanisms will also
      facilitate the development of prevention and intervention policies against
      adverse outcomes induced by NMs. The development of a tiered testing strategy for
      NM hazard assessment not only promotes a more widespread adoption of non-rodent
      or 3R principles but also makes nanotoxicology testing more ethical, relevant,
      and cost- and time-efficient.
FAU - Chen, Rong-Jane
AU  - Chen RJ
AD  - Department of Food Safety/Hygiene and Risk Management, College of Medicine,
      National Cheng Kung University, Tainan 704, Taiwan.
FAU - Chen, Yu-Ying
AU  - Chen YY
AD  - Department of Environmental and Occupational Health, College of Medicine,
      National Cheng Kung University, Tainan 704, Taiwan.
FAU - Liao, Mei-Yi
AU  - Liao MY
AD  - Department of Applied Chemistry, National Pingtung University, Pingtung 900,
      Taiwan.
FAU - Lee, Yu-Hsuan
AU  - Lee YH
AD  - Department of Cosmeceutics, China Medical University, Taichung 651, Taiwan.
FAU - Chen, Zi-Yu
AU  - Chen ZY
AD  - Department of Environmental and Occupational Health, College of Medicine,
      National Cheng Kung University, Tainan 704, Taiwan.
FAU - Yan, Shian-Jang
AU  - Yan SJ
AD  - Department of Physiology, College of Medicine, National Cheng Kung University,
      Tainan 701, Taiwan.
FAU - Yeh, Ya-Ling
AU  - Yeh YL
AD  - Department of Environmental and Occupational Health, College of Medicine,
      National Cheng Kung University, Tainan 704, Taiwan.
FAU - Yang, Li-Xing
AU  - Yang LX
AD  - Institute of Oral Medicine and Department of Stomatology, College of Medicine,
      National Cheng Kung University Hospital, National Cheng Kung University, Tainan
      701, Taiwan.
FAU - Lee, Yen-Ling
AU  - Lee YL
AD  - Department of Hematology/Oncology, Tainan Hospital of Health and Welfare, Tainan 
      700, Taiwan.
FAU - Wu, Yuan-Hua
AU  - Wu YH
AD  - Department of Radiation Oncology, National Cheng Kung University Hospital,
      College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
FAU - Wang, Ying-Jan
AU  - Wang YJ
AUID- ORCID: 0000-0003-3169-2495
AD  - Department of Environmental and Occupational Health, College of Medicine,
      National Cheng Kung University, Tainan 704, Taiwan.
AD  - Department of Medical Research, China Medical University Hospital, China Medical 
      University, Taichung 404, Taiwan.
LA  - eng
GR  - MOST 108-2314-B-006-057/Ministry of Science and Technology, Taiwan
GR  - MOST 106-2314-B-006-029-MY3/Ministry of Science and Technology, Taiwan
GR  - MOST 107-2311-B-006-004-MY3/Ministry of Science and Technology, Taiwan
GR  - MOST 108-2113-M-153-001/Ministry of Science and Technology, Taiwan
GR  - 107A024/Environmental Protection Administration, Executive Yuan, R.O.C. Taiwan
PT  - Journal Article
PT  - Review
DEP - 20200330
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - *Autophagy/drug effects
MH  - High-Throughput Screening Assays/methods
MH  - Humans
MH  - Nanostructures/*toxicity
MH  - Toxicity Tests/*methods
PMC - PMC7177614
OTO - NOTNLM
OT  - C. elegans
OT  - alternative testing strategy
OT  - autophagy
OT  - high throughput screening
OT  - nanomaterials
OT  - tiered testing strategy
OT  - zebrafish and Drosophila models
EDAT- 2020/04/03 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/02/21 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/03/28 00:00 [accepted]
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
AID - ijms21072387 [pii]
AID - 10.3390/ijms21072387 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Mar 30;21(7). pii: ijms21072387. doi: 10.3390/ijms21072387.


PMID- 32235273
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20211204
IS  - 1473-6543 (Electronic)
IS  - 1062-4821 (Linking)
VI  - 29
IP  - 3
DP  - 2020 May
TI  - Applications of machine learning methods in kidney disease: hope or hype?
PG  - 319-326
LID - 10.1097/MNH.0000000000000604 [doi]
AB  - PURPOSE OF REVIEW: The universal adoption of electronic health records,
      improvement in technology, and the availability of continuous monitoring has
      generated large quantities of healthcare data. Machine learning is increasingly
      adopted by nephrology researchers to analyze this data in order to improve the
      care of their patients. RECENT FINDINGS: In this review, we provide a broad
      overview of the different types of machine learning algorithms currently
      available and how researchers have applied these methods in nephrology research. 
      Current applications have included prediction of acute kidney injury and chronic 
      kidney disease along with progression of kidney disease. Researchers have
      demonstrated the ability of machine learning to read kidney biopsy samples,
      identify patient outcomes from unstructured data, and identify subtypes in
      complex diseases. We end with a discussion on the ethics and potential pitfalls
      of machine learning. SUMMARY: Machine learning provides researchers with the
      ability to analyze data that were previously inaccessible. While still
      burgeoning, several studies show promising results, which will enable researchers
      to perform larger scale studies and clinicians the ability to provide more
      personalized care. However, we must ensure that implementation aids providers and
      does not lead to harm to patients.
FAU - Chan, Lili
AU  - Chan L
AD  - Division of Nephrology, Department of Medicine The Charles Bronfman Institute of 
      Personalized Medicine The Hasso Plattner Institute for Digital Health The BioMe
      Phenomics Center, Icahn School of Medicine at Mount Sinai, New York, New York,
      USA.
FAU - Vaid, Akhil
AU  - Vaid A
FAU - Nadkarni, Girish N
AU  - Nadkarni GN
LA  - eng
GR  - R01 DK127139/DK/NIDDK NIH HHS/United States
GR  - U01 HG009610/HG/NHGRI NIH HHS/United States
GR  - U01 HG007278/HG/NHGRI NIH HHS/United States
GR  - R01 DK108803/DK/NIDDK NIH HHS/United States
GR  - K23 DK107908/DK/NIDDK NIH HHS/United States
GR  - R56 DK126930/DK/NIDDK NIH HHS/United States
GR  - U01 DK116100/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
SB  - IM
MH  - Algorithms
MH  - Humans
MH  - Kidney Diseases/*therapy
MH  - *Machine Learning
MH  - Natural Language Processing
MH  - Translational Research, Biomedical
PMC - PMC7770625
MID - NIHMS1651315
EDAT- 2020/04/03 06:00
MHDA- 2021/02/05 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
AID - 10.1097/MNH.0000000000000604 [doi]
AID - 00041552-202005000-00009 [pii]
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 2020 May;29(3):319-326. doi:
      10.1097/MNH.0000000000000604.


PMID- 32235194
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210213
IS  - 1932-8095 (Electronic)
IS  - 1932-8087 (Linking)
VI  - 25
IP  - 3
DP  - 2020 May/Jun
TI  - End of Life Care's Ongoing Evolution.
PG  - 111-131
LID - 10.1097/NCM.0000000000000417 [doi]
AB  - PURPOSE/OBJECTIVES: PRIMARY PRACTICE SETTINGS:: Applicable to all settings across
      the transitions of care where case management practice occurs.
      FINDINGS/CONCLUSIONS: Continuing shifts in society's cultural landscape, ongoing 
      emphasis on value versus volume, and other industry fiscal imperatives continue
      to evoke an evolution in end-of-life care. The attainment of successful outcomes 
      by professional case managers with those populations will be dependent on
      awareness and comprehension of regulations, legislation, and reimbursement; the
      influences of ongoing industry trends; availability of emerging resources; and
      ongoing technological advances. Ethical excellence remains at the core of case
      management across the interprofessional workforce and the transitions of care.
      IMPLICATIONS FOR CASE MANAGEMENT PRACTICE: The professional case management
      workforce is tasked to effectively intervene across diverse client populations,
      with their caregivers and support systems. This action spans every life stage and
      illness course. With end-of-life care treatment and processes continuing to
      receive prime industry attention, case managers must be knowledgeable of the
      moving parts of this arena. Awareness of the ethical edges of each professional's
      sandbox is essential to quality-driven case management practice.
FAU - Fink-Samnick, Ellen
AU  - Fink-Samnick E
AD  - Ellen Fink-Samnick, MSW, ACSW, LCSW, CCM, CRP, is an award winning, industry
      subject matter expert who empowers health care's transdisciplinary workforce
      through professional speaking, writing, mentoring, and consultation. Ellen is an 
      esteemed author with more than 100 publications to her credit. She has authored
      content for the industry's knowledge projects for case managers, including books,
      chapters, and articles on the Ethical Use of Case Management Technology,
      Workplace Bullying, Collaborative Care, and the Social Determinants of Health.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Prof Case Manag
JT  - Professional case management
JID - 101291585
MH  - Adult
MH  - *Advance Directives
MH  - Case Management/*organization & administration
MH  - Case Managers/*education
MH  - Curriculum
MH  - Education, Nursing, Continuing/*organization & administration
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Palliative Care/*organization & administration
MH  - *Right to Die
MH  - Terminal Care/*organization & administration
MH  - United States
EDAT- 2020/04/03 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
AID - 10.1097/NCM.0000000000000417 [doi]
AID - 01269241-202005000-00002 [pii]
PST - ppublish
SO  - Prof Case Manag. 2020 May/Jun;25(3):111-131. doi: 10.1097/NCM.0000000000000417.


PMID- 32234805
OWN - NLM
STAT- MEDLINE
DCOM- 20200512
LR  - 20220129
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 368
IP  - 6491
DP  - 2020 May 8
TI  - Quantifying SARS-CoV-2 transmission suggests epidemic control with digital
      contact tracing.
LID - eabb6936 [pii]
LID - 10.1126/science.abb6936 [doi]
AB  - The newly emergent human virus SARS-CoV-2 (severe acute respiratory
      syndrome-coronavirus 2) is resulting in high fatality rates and incapacitated
      health systems. Preventing further transmission is a priority. We analyzed key
      parameters of epidemic spread to estimate the contribution of different
      transmission routes and determine requirements for case isolation and contact
      tracing needed to stop the epidemic. Although SARS-CoV-2 is spreading too fast to
      be contained by manual contact tracing, it could be controlled if this process
      were faster, more efficient, and happened at scale. A contact-tracing app that
      builds a memory of proximity contacts and immediately notifies contacts of
      positive cases can achieve epidemic control if used by enough people. By
      targeting recommendations to only those at risk, epidemics could be contained
      without resorting to mass quarantines ("lockdowns") that are harmful to society. 
      We discuss the ethical requirements for an intervention of this kind.
CI  - Copyright (c) 2020 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Ferretti, Luca
AU  - Ferretti L
AUID- ORCID: 0000-0001-7578-7301
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
FAU - Wymant, Chris
AU  - Wymant C
AUID- ORCID: 0000-0002-9847-8226
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
FAU - Kendall, Michelle
AU  - Kendall M
AUID- ORCID: 0000-0001-7344-7071
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
FAU - Zhao, Lele
AU  - Zhao L
AUID- ORCID: 0000-0002-2807-1914
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
FAU - Nurtay, Anel
AU  - Nurtay A
AUID- ORCID: 0000-0001-7107-1656
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
FAU - Abeler-Dorner, Lucie
AU  - Abeler-Dorner L
AUID- ORCID: 0000-0003-3662-4192
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
FAU - Parker, Michael
AU  - Parker M
AD  - Wellcome Centre for Ethics and the Humanities and Ethox Centre, University of
      Oxford, Oxford, UK.
FAU - Bonsall, David
AU  - Bonsall D
AUID- ORCID: 0000-0003-2187-0550
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK.
AD  - Oxford University NHS Trust, University of Oxford, Oxford, UK.
FAU - Fraser, Christophe
AU  - Fraser C
AUID- ORCID: 0000-0003-2399-9657
AD  - Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,
      University of Oxford, Oxford, UK. christophe.fraser@bdi.ox.ac.uk.
AD  - Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - G0800596/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
SB  - IM
CIN - J Math Biol. 2021 Oct 2;83(5):46. PMID: 34599662
MH  - Algorithms
MH  - Asymptomatic Diseases
MH  - Basic Reproduction Number
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Cell Phone
MH  - China/epidemiology
MH  - Contact Tracing/ethics/*methods
MH  - Coronavirus Infections/epidemiology/*prevention & control/*transmission
MH  - Epidemics/prevention & control
MH  - Humans
MH  - Infection Control
MH  - *Mobile Applications/ethics
MH  - Models, Theoretical
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/epidemiology/*prevention & control/*transmission
MH  - Probability
MH  - Quarantine
MH  - SARS-CoV-2
MH  - Time Factors
PMC - PMC7164555
EDAT- 2020/04/03 06:00
MHDA- 2020/05/19 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - science.abb6936 [pii]
AID - 10.1126/science.abb6936 [doi]
PST - ppublish
SO  - Science. 2020 May 8;368(6491). pii: science.abb6936. doi:
      10.1126/science.abb6936. Epub 2020 Mar 31.


PMID- 32234747
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 31
TI  - Evaluating a group-based Yoga of Stress Resilience programme: a pragmatic
      before-after interventional study protocol.
PG  - e035862
LID - 10.1136/bmjopen-2019-035862 [doi]
AB  - INTRODUCTION: Rates of mental health illnesses and burnout are increasing
      internationally. Therapeutic yoga is increasingly used to improve and maintain
      physical, mental and emotional well-being and general health. This protocol
      describes a study to evaluate the effectiveness of an existing primary care
      group-based therapeutic yoga programme, the Yoga of Stress Resilience programme, 
      which combines yoga and psychotherapeutic techniques, in improving mental health 
      and decreasing burnout. Implementation factors will also be evaluated for
      potential scale-up. METHODS AND ANALYSIS: A pragmatic before-after interventional
      trial design will be used to study changes in occupational participation and
      mental health outcomes, including anxiety, depression, burnout, functional
      impairment, insomnia, perceived stress, loneliness, self-compassion and readiness
      for change in adults experiencing anxiety and burnout. Repeated measures analysis
      of variance will be used to determine changes in outcome measures over time.
      Regression and multivariate analyses will be conducted to examine relationships
      between participant characteristics and outcomes and among various outcomes. The 
      Reach, Effectiveness, Adoption, Implementation, and Maintenance framework will be
      used to guide the analyses. ETHICS AND DISSEMINATION: Approval from the Hamilton 
      Integrated Research Ethics Board has been waived: project number 7082 (full
      review waived). Informed consent will be obtained prior to enrolling any
      participant into the study. All data will be kept confidential. Peer-reviewed
      publications and presentations will target researchers and health professionals. 
      TRIAL REGISTRATION NUMBER: The ClinicalTrials.gov registry (NCT03973216).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Alvarez, Elizabeth
AU  - Alvarez E
AUID- ORCID: 0000-0003-2333-0144
AD  - Health Research Methods, Evidence and Impact, McMaster University, Hamilton,
      Ontario, Canada alvare@mcmaster.ca.
AD  - Centre for Health Economics and Policy Analysis, McMaster University, Hamilton,
      Ontario, Canada.
FAU - Sutton, Arielle
AU  - Sutton A
AD  - Health Research Methods, Evidence and Impact, McMaster University, Hamilton,
      Ontario, Canada.
FAU - Barton, Bria
AU  - Barton B
AD  - Ontario Network of Sexual Assault /Domestic Violence Treatment Centres, Women's
      College Hospital, Toronto, Ontario, Canada.
FAU - Vaidya, Shailla
AU  - Vaidya S
AD  - Clairhurst Medical Centre, Toronto, Ontario, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03973216
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Anxiety/therapy
MH  - Burnout, Professional/therapy
MH  - Depression/therapy
MH  - Humans
MH  - *Mental Health
MH  - Randomized Controlled Trials as Topic
MH  - Stress, Psychological/*therapy
MH  - *Yoga
PMC - PMC7170620
OTO - NOTNLM
OT  - *anxiety disorders
OT  - *mental health
OT  - *primary care
COIS- Competing interests: SV developed and runs the Yoga of Stress Resilience
      programme.
EDAT- 2020/04/03 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035862 [pii]
AID - 10.1136/bmjopen-2019-035862 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 31;10(3):e035862. doi: 10.1136/bmjopen-2019-035862.


PMID- 32234743
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 31
TI  - Video-based smartphone app ('VIDEA bewegt') for physical activity support in
      German adults: a study protocol for a single-armed observational study.
PG  - e034027
LID - 10.1136/bmjopen-2019-034027 [doi]
AB  - INTRODUCTION: Insufficient physical activity is one of the most important risk
      factors for non-communicable diseases. Physical activity should therefore be
      intensively promoted in all age groups. Several trials suggest that it can be
      effectively increased through smartphone interventions.However, few of the
      smartphone-interventions available on the market have been scientifically
      evaluated. Therefore, the described study aims to assess the short-term and
      long-term effects of the smartphone intervention 'VIDEA bewegt' to increase
      physical activity. The trial is designed as a single-armed observational trial to
      assess effects under real-life conditions. METHODS AND ANALYSIS: The intervention
      consists of the smartphone-application 'VIDEA bewegt', which is a video-based
      preventative programme to improve physical activity in everyday life. The
      application contains several features and components including educational
      videos, documentation of activity and motivational exercises. A sample size of at
      least 106 participants is aimed for.The primary objective of this study is to
      determine the effect of the application on physical activity in German adults.
      Secondary objectives are to evaluate the self-efficacy, health-related quality of
      life and usability of 'VIDEA bewegt'.Data collection is based on online
      questionnaires, as well as system-internal recorded data.Changes of outcomes from
      baseline to programme completion and follow-up will be calculated. ETHICS AND
      DISSEMINATION: The Ethics Committee of the Technical University Dresden approved 
      the study on 25 May 2019 (EK 272062019). All data are processed anonymously and
      stored on servers only accessible by authorised personnel. The results of the
      study and the results of the usability test are aimed to be published in a
      scientific journal. TRIAL REGISTRATION NUMBER: German Clinical Trials Registry
      (DRKS00017392).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Fischer, Tillmann
AU  - Fischer T
AUID- ORCID: 0000-0003-3411-9838
AD  - Department for Prevention and Care of Diabetes, Department of Medicine III,
      Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, Dresden,
      Germany tillmann.fischer@tu-dresden.de.
FAU - Stumpf, Paul
AU  - Stumpf P
AD  - Department for Prevention and Care of Diabetes, Department of Medicine III,
      Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, Dresden,
      Germany.
FAU - Reinhardt, Gesine
AU  - Reinhardt G
AD  - Department for Prevention and Care of Diabetes, Department of Medicine III,
      Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, Dresden,
      Germany.
FAU - Schwarz, Peter E H
AU  - Schwarz PEH
AD  - Department for Prevention and Care of Diabetes, Department of Medicine III,
      Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, Dresden,
      Germany.
AD  - Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University
      Hospital and Faculty of Medicine, Technische Universitat Dresden, Dresden,
      Germany.
FAU - Timpel, Patrick
AU  - Timpel P
AD  - Department for Prevention and Care of Diabetes, Department of Medicine III,
      Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, Dresden,
      Germany.
LA  - eng
SI  - DRKS/DRKS00017392
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Exercise
MH  - Germany
MH  - Health Promotion
MH  - Humans
MH  - *Mobile Applications
MH  - Observational Studies as Topic
MH  - Quality of Life
MH  - Research Design
MH  - *Smartphone
PMC - PMC7170646
OTO - NOTNLM
OT  - *application
OT  - *prevention
OT  - *preventive medicine
OT  - *self-efficacy
OT  - *smartphone
OT  - *study protocol
COIS- Competing interests: The principal investigator PEHS was involved in the
      development and implementation of the app 'VIDEA bewegt' as a medical expert. He 
      is responsible for the medical and theoretical background and is shown in the
      app's videos. He received no payment for his participation in the app.
EDAT- 2020/04/03 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2019-034027 [pii]
AID - 10.1136/bmjopen-2019-034027 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 31;10(3):e034027. doi: 10.1136/bmjopen-2019-034027.


PMID- 32234742
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 31
TI  - Preferences for end-of-life care: a study protocol for a cross-sectional survey
      of Chinese frail elderly home residents in Hong Kong.
PG  - e033862
LID - 10.1136/bmjopen-2019-033862 [doi]
AB  - INTRODUCTION: Existing literature on attitudes toward end-of-life care (EoLC)
      covers the general public but has little information on the frail elderly
      population. The aim of the current study is to investigate the preferences of
      Chinese frail elderly home residents with respect to EoLC by conducting
      cross-sectional surveys. METHODS AND ANALYSIS: Surveys, including resident and
      family versions, were developed based on the existing literature and our pilot
      interviews. The targeted participants were 400 frail elderly home residents (aged
      >/=65 years old) and 200 family caregivers. Purposive sampling will be used as
      each elderly home will help to recruit five to 15 elderly participants for the
      study. Descriptive analysis and modelling will be used to examine preferences on 
      EoLC and related factors, as well as to compare the responses of elderly home
      residents with those of their family caregivers. ETHICS AND DISSEMINATION: The
      cross-sectional survey has obtained approval from the Institutional Review Board.
      Confidentiality and safety issues will be carefully observed. The results of the 
      study will be disseminated through international conferences, peer-reviewed
      academic journal publications, and a report in plain language to be shared with
      elderly residential homes.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Yan, Bo
AU  - Yan B
AUID- ORCID: 0000-0002-9967-4122
AD  - School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
      SAR, China.
FAU - Xu, Xinyi
AU  - Xu X
AD  - School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
      SAR, China.
FAU - Chau, Patsy Ph
AU  - Chau PP
AD  - School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
      SAR, China.
FAU - Takemura, Naomi
AU  - Takemura N
AD  - School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
      SAR, China.
FAU - Cheung, Derek Yt
AU  - Cheung DY
AUID- ORCID: 0000-0002-5850-5349
AD  - School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
      SAR, China.
FAU - Chan, Felix Hw
AU  - Chan FH
AD  - Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong
      Kong SAR, China.
FAU - Lin, Chia-Chin
AU  - Lin CC
AD  - School of Nursing, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
      SAR, China cclin@hku.hk.
AD  - School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Aged
MH  - Caregivers
MH  - China
MH  - Cross-Sectional Studies
MH  - *Frail Elderly
MH  - Homes for the Aged
MH  - Hong Kong
MH  - Humans
MH  - Language
MH  - Nursing Homes
MH  - *Patient Preference
MH  - *Terminal Care
PMC - PMC7170557
OTO - NOTNLM
OT  - *Chinese
OT  - *advance care planning
OT  - *advance directive
OT  - *end-of-life care
OT  - *frail
OT  - *survey
COIS- Competing interests: None declared.
EDAT- 2020/04/03 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2019-033862 [pii]
AID - 10.1136/bmjopen-2019-033862 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 31;10(3):e033862. doi: 10.1136/bmjopen-2019-033862.


PMID- 32234741
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 31
TI  - Investigating the effectiveness of care delivery at an acute geriatric community 
      hospital for older adults in the Netherlands: a protocol for a prospective
      controlled observational study.
PG  - e033802
LID - 10.1136/bmjopen-2019-033802 [doi]
AB  - INTRODUCTION: Hospital admission in older adults with multiple chronic conditions
      is associated with unwanted outcomes like readmission, institutionalisation,
      functional decline and mortality. Providing acute care in the community and
      integrating effective components of care models might lead to a reduction in
      negative outcomes. Recently, the first geriatrician-led Acute Geriatric Community
      Hospital (AGCH) was introduced in the Netherlands. Care at the AGCH is focused on
      the treatment of acute diseases, comprehensive geriatric assessment, setting
      patient-led goals, early rehabilitation and streamlined transitions of care.
      METHODS AND ANALYSIS: This prospective cohort study will investigate the
      effectiveness of care delivery at the AGCH on patient outcomes by comparing AGCH 
      patients to two historic cohorts of hospitalised patients. Propensity score
      matching will correct for potential population differences. The primary outcome
      is the 3-month unplanned readmission rate. Secondary outcomes include functional 
      decline, institutionalisation, healthcare utilisation, occurrence of delirium or 
      falls, health-related quality of life, mortality and patient satisfaction.
      Measurements will be conducted at admission, discharge and 1, 3 and 6 months
      after discharge. Furthermore, an economic evaluation and qualitative process
      evaluation to assess facilitators and barriers to implementation are planned.
      ETHICS AND DISSEMINATION: The study will be conducted according to the
      Declaration of Helsinki. The Medical Ethics Research Committee confirmed that the
      Medical Research Involving Human Subjects Act did not apply to this research
      project and official approval was not required. The findings of this study will
      be disseminated through public lectures, scientific conferences and journal
      publications. Furthermore, the findings of this study will aid in the
      implementation and financing of this concept (inter)nationally. TRIAL
      REGISTRATION NUMBER: NL7896; Pre-results.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Ribbink, Marthe E
AU  - Ribbink ME
AUID- ORCID: 0000-0002-5314-0520
AD  - Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam
      University Medical Centres, Amsterdam, Noord-Holland, Netherlands
      m.e.ribbink@amsterdamumc.nl.
FAU - Macneil-Vroomen, Janet L
AU  - Macneil-Vroomen JL
AD  - Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam
      University Medical Centres, Amsterdam, Noord-Holland, Netherlands.
AD  - Department of Internal Medicine, Section of Geriatrics, Yale School of Medicine, 
      New Haven, Connecticut, USA.
FAU - van Seben, Rosanne
AU  - van Seben R
AD  - Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam
      University Medical Centres, Amsterdam, Noord-Holland, Netherlands.
FAU - Oudejans, Irene
AU  - Oudejans I
AD  - Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam
      University Medical Centres, Amsterdam, Noord-Holland, Netherlands.
FAU - Buurman, Bianca M
AU  - Buurman BM
AD  - Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam
      University Medical Centres, Amsterdam, Noord-Holland, Netherlands.
AD  - ACHIEVE-Centre of Applied Research, Faculty of Health, Amsterdam University of
      Applied Sciences, Amsterdam, Noord-Holland, Netherlands.
CN  - AGCH study group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Delivery of Health Care/*standards
MH  - Female
MH  - Geriatrics/*standards
MH  - *Hospitals, Community
MH  - Humans
MH  - Male
MH  - Netherlands
MH  - Observational Studies as Topic
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Research Design
PMC - PMC7170597
OTO - NOTNLM
OT  - *community hospital
OT  - *functional decline
OT  - *geriatric medicine
OT  - *intermediate care facilities
OT  - *older adults
OT  - *readmissions
COIS- Competing interests: None declared.
IR  - Franssen R
FIR - Franssen, R
IR  - Frenkel WJ
FIR - Frenkel, W J
IR  - Henstra MJ
FIR - Henstra, M J
IR  - van Maanen MA
FIR - van Maanen, M A
IR  - Parlevliet JL
FIR - Parlevliet, J L
IR  - van Poelgeest EP
FIR - van Poelgeest, E P
IR  - Resodikromo MN
FIR - Resodikromo, M N
IR  - Kaland KJ
FIR - Kaland, K J
IR  - van der Velde N
FIR - van der Velde, N
IR  - Visser ME
FIR - Visser, M E
IR  - Willems HC
FIR - Willems, H C
EDAT- 2020/04/03 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2019-033802 [pii]
AID - 10.1136/bmjopen-2019-033802 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 31;10(3):e033802. doi: 10.1136/bmjopen-2019-033802.


PMID- 32234739
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 30
TI  - Assessing efficacy of CytoSorb haemoadsorber for prevention of organ dysfunction 
      in cardiac surgery patients with infective endocarditis: REMOVE-protocol for
      randomised controlled trial.
PG  - e031912
LID - 10.1136/bmjopen-2019-031912 [doi]
AB  - INTRODUCTION: Infective endocarditis (IE) is associated with high mortality and
      morbidity. Multiple organ failure is the main cause of death after surgery for
      IE. Cardiopulmonary bypass (CPB) can cause a systemic inflammatory response. In a
      pilot study (REMOVE-pilot (Revealing mechanisms and investigating efficacy of
      hemoad-sorption for prevention of vasodilatory shock in cardiac surgery patients 
      with infective endocarditis - a multicentric randomized controlled group
      sequential trial)), we found that plasma profiles of cytokines during and after
      CPB were higher in patients with IE compared with patients with non-infectious
      valvular heart disease. Sequential Organ Failure Assessment (SOFA) scores on the 
      first and second postoperative days and in-hospital mortality were also higher in
      IE patients. This protocol describes the design of the REMOVE trial on
      cytokine-adsorbing columns, for example, CytoSorb, for non-selective removal of
      cytokines. The aim of the REMOVE study is to demonstrate efficacy of CytoSorb on 
      the prevention of multiorgan dysfunction in patients with IE undergoing cardiac
      surgery. METHODS AND ANALYSIS: The REMOVE study is an interventional randomised
      controlled multicenter trial with a group sequential (Pocock) design for
      assessing efficacy of CytoSorb in patients undergoing cardiac surgery for IE. The
      change in mean total SOFA ( SOFA) score between preoperative and postoperative
      care will be used as primary endpoint. Data on 30-day mortality, changes in
      cytokines levels, duration of mechanical ventilation, length of intensive care
      unit and hospital stay, and postoperative stroke will be collected as secondary
      endpoints. An interim analysis will be conducted after including 25 participating
      patients per study arm (with a focus on feasibility of the recruitment as well as
      differences in cytokines and cell-free DNA levels). ETHICS AND DISSEMINATION: The
      protocol was approved by the institutional review board and ethics committee of
      the University of Jena as well as by the corresponding ethics committee of each
      participating study centre. The results will be published in a renowned
      international medical journal, irrespective of the outcomes of the study. TRIAL
      REGISTRATION NUMBER: The ClinicalTrials.gov registry (NCT03266302).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Diab, Mahmoud
AU  - Diab M
AUID- ORCID: 0000-0003-1529-6046
AD  - Department of Cardiothoracic Surgery, Jena University Hospital - Friedrich
      Schiller University of Jena, Jena, Thuringia, Germany.
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
FAU - Platzer, Stephanie
AU  - Platzer S
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
FAU - Guenther, Albrecht
AU  - Guenther A
AD  - Department of Neurology, Jena University Hospital - Friedrich Schiller University
      of Jena, Jena, Thuringia, Germany.
FAU - Sponholz, Christoph
AU  - Sponholz C
AUID- ORCID: 0000-0002-1746-7024
AD  - Department of Anaesthesiology and Critical Care Medicine, Jena University
      Hospital - Friedrich Schiller University of Jena, Jena, Thuringia, Germany.
FAU - Scherag, Andre
AU  - Scherag A
AUID- ORCID: 0000-0002-9406-4704
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
AD  - Center of clinical studies, Jena University Hospital - Friedrich Schiller
      University of Jena, Jena, Thuringen, Germany.
AD  - Institute of Medical Statistics, Computer and Data Sciences, Jena University
      Hospital - Friedrich Schiller University, Jena, Thuringia, Germany.
FAU - Lehmann, Thomas
AU  - Lehmann T
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
FAU - Velichkov, Ilia
AU  - Velichkov I
AD  - Department of Cardiothoracic Surgery, Jena University Hospital - Friedrich
      Schiller University of Jena, Jena, Thuringia, Germany.
FAU - Hagel, Stefan
AU  - Hagel S
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
AD  - Center for Infectious Diseases and Infection Control, Jena University Hospital - 
      Friedrich Schiller University, Jena, Thuringia, Germany.
FAU - Bauer, Michael
AU  - Bauer M
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
AD  - Department of Anaesthesiology and Critical Care Medicine, Jena University
      Hospital - Friedrich Schiller University of Jena, Jena, Thuringia, Germany.
FAU - Brunkhorst, Frank M
AU  - Brunkhorst FM
AD  - Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller
      University, Jena, Thuringia, Germany.
AD  - Department of Anaesthesiology and Critical Care Medicine, Jena University
      Hospital - Friedrich Schiller University of Jena, Jena, Thuringia, Germany.
AD  - Center of clinical studies, Jena University Hospital - Friedrich Schiller
      University of Jena, Jena, Thuringen, Germany.
FAU - Doenst, Torsten
AU  - Doenst T
AD  - Department of Cardiothoracic Surgery, Jena University Hospital - Friedrich
      Schiller University of Jena, Jena, Thuringia, Germany Doenst@med.uni-jena.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT03266302
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200330
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cytokines)
SB  - IM
MH  - *Cardiac Surgical Procedures/adverse effects
MH  - Cardiopulmonary Bypass/adverse effects
MH  - Cytokines/blood
MH  - Endocarditis/*complications
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Multiple Organ Failure/etiology/*prevention & control
MH  - Randomized Controlled Trials as Topic
PMC - PMC7170567
OTO - NOTNLM
OT  - *cardiac surgery
OT  - *cytokines
OT  - *cytosorb(R)
OT  - *hemoadsorption
OT  - *infective endocarditis
OT  - *organ dysfunction
COIS- Competing interests: FMB reports grants and personal fees from CytoSorbents
      Europe,outside the submitted work.
EDAT- 2020/04/03 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - bmjopen-2019-031912 [pii]
AID - 10.1136/bmjopen-2019-031912 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 30;10(3):e031912. doi: 10.1136/bmjopen-2019-031912.


PMID- 32234738
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 31
TI  - Impact of electronic palliative care coordination systems (EPaCCS) on care at the
      end of life across multiple care sectors, in one clinical commissioning group
      area, in England: a realist evaluation protocol.
PG  - e031153
LID - 10.1136/bmjopen-2019-031153 [doi]
AB  - INTRODUCTION: Electronic palliative care coordination systems (EPaCCS) aim to
      support people approaching the end of life (EOL) to receive consistent care,
      according to their wishes, that is coordinated effectively across multiple care
      sectors. They are in use across the UK although empirical evidence into their
      effectiveness is poor. This paper presents a protocol of a mixed-methods study,
      to understand how, and by whom, EPaCCS are being used and whether EPaCCS are
      enabling Healthcare Professionals (HCPs) to coordinate patients' EOL care.
      METHODS AND ANALYSIS: This is a mixed-methods study, carried out within a realist
      paradigm, to evaluate the impact of an EPaCCS on EOL care as provided by a
      Clinical Commissioning Group (CCG) in England. This study has two aims: (1)
      Describe the socio-demographic characteristics of patients who die with an EPaCCS
      record, their underlying cause of death and place of death and compare these with
      patients who die without an EPaCCS record. (2) Explore the impact of an EPaCCS on
      the experience of receiving EOL care for patients and their carers, and
      understand HCPs' views and experiences of utilising an EPaCCS to coordinate care 
      for their patients. The study will be conducted in five phases: (1) development
      of the initial programme theory; (2) focus group with CCG stakeholder board; (3) 
      individual interviews with HCPs, patients, current and bereaved carers; (4)
      retrospective cohort study of routinely collected data on EPaCCS usage and (5)
      data analysis and synthesis of study findings. ETHICS AND DISSEMINATION: The
      study has been approved by National Health Service South West-Frenchay Research
      Ethics Committee (REC reference number: 18/SW/0198). Findings will be published
      in a wide range of outputs targeted at key audiences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Pocock, Lucy
AU  - Pocock L
AD  - Centre for Academic Primary Care, University of Bristol, Bristol, UK
      lucy.pocock@bristol.ac.uk.
FAU - French, Lydia
AU  - French L
AUID- ORCID: 0000-0002-8517-2148
AD  - Centre for Academic Primary Care, University of Bristol, Bristol, UK.
FAU - Farr, Michelle
AU  - Farr M
AD  - NIHR ARC West, Bristol, UK.
FAU - Morris, Richard
AU  - Morris R
AD  - Centre for Academic Primary Care, University of Bristol, Bristol, UK.
FAU - Purdy, Sarah
AU  - Purdy S
AD  - Centre for Academic Primary Care, University of Bristol, Bristol, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - *Computer Systems
MH  - Death
MH  - England
MH  - Humans
MH  - Palliative Care/*organization & administration
MH  - Retrospective Studies
MH  - State Medicine
MH  - Terminal Care/*organization & administration
PMC - PMC7170566
OTO - NOTNLM
OT  - *palliative care
OT  - *primary care
OT  - *qualitative research
OT  - *quality in health care
COIS- Competing interests: None declared.
EDAT- 2020/04/03 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - bmjopen-2019-031153 [pii]
AID - 10.1136/bmjopen-2019-031153 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 31;10(3):e031153. doi: 10.1136/bmjopen-2019-031153.


PMID- 32234736
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 31
TI  - Combating antibiotic resistance using guidelines and enhanced stewardship in
      Kenya: a protocol for an implementation science approach.
PG  - e030823
LID - 10.1136/bmjopen-2019-030823 [doi]
AB  - INTRODUCTION: Antimicrobial resistance (AMR) is a growing problem globally
      especially in Sub-Saharan Africa including Kenya. Without any intervention,
      lower/middle-income countries (LMICs) will be most affected due to already higher
      AMR levels compared with higher income countries and due to the far higher burden
      of diseases in the LMICs. Studies have consistently shown that inappropriate use 
      of antimicrobials is the major driver of AMR. To address this challenge,
      hospitals are now implementing antibiotic stewardship programmes (ASPs), which
      have been shown to achieve reduced antibiotic usage, to decrease the prevalence
      of resistance and lead to significant economic benefits. However, the
      implementation of the guideline is highly dependent on the settings in which they
      are rolled out. This study, employing an implementation science approach, aims to
      address the knowledge gap in this area and provide critical data as well as
      practical experiences when using antibiotic guidelines and stewardship programmes
      in the public health sector. This will provide evidence of ASP performance and
      potentially contribute to the county, national and regional policies on
      antibiotics use. METHODS AND ANALYSIS: The study will be conducted in three
      geographically diverse regions, each represented by two hospitals. A baseline
      study on antibiotic usage, resistance and de-escalation, duration of hospital
      stay, rates of readmission and costs will be carried out in the preimplementation
      phase. The intervention, that is, the use of antibiotic guidelines and ASPs will 
      be instituted for 18 months using a stepwise implementation strategy that will
      facilitate learning and continuous improvement of stewardship activities and
      updating of guidelines to reflect the evolving antibiotic needs. ETHICS AND
      DISSEMINATION: Approvals to carry out the study have been obtained from the
      National Commission for Science, Technology and Innovation and the Mount Kenya
      University Ethics Review Committee. The approvals from the two institutions were 
      used to obtain permission to conduct the study at each of the participating
      hospitals. Study findings will be presented to policy stakeholders and published 
      in peer-reviewed scientific journals. It is anticipated that the findings will
      inform the appropriate antibiotic use guidelines within our local context.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Gitaka, Jesse
AU  - Gitaka J
AD  - Research and Innovation, Mount Kenya University, Thika, Kenya jgitaka@mku.ac.ke.
FAU - Kamita, Moses
AU  - Kamita M
AUID- ORCID: 0000-0002-1756-932X
AD  - Research and Innovation, Mount Kenya University, Thika, Kenya.
FAU - Mureithi, Dominic
AU  - Mureithi D
AD  - Department of Animal Health and Production, Maasai Mara University, Narok, Kenya.
FAU - Ndegwa, Davies
AU  - Ndegwa D
AD  - Department of Medical Laboratory Sciences, Kenya Medical Training College,
      Nairobi, Kenya.
FAU - Masika, Moses
AU  - Masika M
AD  - Department of Medical Microbiology, University of Nairobi College of Health
      Sciences, Nairobi, Kenya.
FAU - Omuse, Geoffrey
AU  - Omuse G
AD  - Department of Pathology, Aga Khan University, Nairobi, Kenya.
FAU - Ngari, Moses
AU  - Ngari M
AD  - Clinical Trial Facility, KEMRI/Wellcome Trust, Kilifi, Kenya.
FAU - Makokha, Francis
AU  - Makokha F
AD  - Research and Innovation, Mount Kenya University, Thika, Kenya.
FAU - Mwaura, Peter
AU  - Mwaura P
AD  - Research and Innovation, Mount Kenya University, Thika, Kenya.
FAU - Mathai, Ronald
AU  - Mathai R
AD  - Research and Innovation, Mount Kenya University, Thika, Kenya.
FAU - Muregi, Francis
AU  - Muregi F
AD  - Research and Innovation, Mount Kenya University, Thika, Kenya.
FAU - Mwau, Matilu
AU  - Mwau M
AD  - Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical
      Research Institute, Nairobi, Kenya.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Antimicrobial Stewardship/methods/*organization & administration
MH  - Clinical Protocols
MH  - Developing Countries
MH  - *Drug Resistance, Microbial
MH  - Guideline Adherence/*organization & administration
MH  - Hospitals
MH  - Humans
MH  - *Implementation Science
MH  - Inappropriate Prescribing/*prevention & control
MH  - Kenya
MH  - Practice Guidelines as Topic
MH  - Research Design
PMC - PMC7170570
OTO - NOTNLM
OT  - *antimicrobial resistance
OT  - *antimicrobial stewardship
OT  - *implementation science
COIS- Competing interests: None declared.
EDAT- 2020/04/03 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2019-030823 [pii]
AID - 10.1136/bmjopen-2019-030823 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 31;10(3):e030823. doi: 10.1136/bmjopen-2019-030823.


PMID- 32234714
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 368
DP  - 2020 Mar 31
TI  - To maintain ethical medical practices, we must not underplay the vocational
      aspect of medicine.
PG  - m1266
LID - 10.1136/bmj.m1266 [doi]
FAU - DiLallo, John
AU  - DiLallo J
AD  - New York, NY 10010, USA.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200331
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - IM
CON - BMJ. 2020 Mar 3;368:m227. PMID: 32127358
COIS- Competing interests: None declared.
EDAT- 2020/04/03 06:00
MHDA- 2020/04/03 06:01
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [entrez]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/04/03 06:01 [medline]
AID - 10.1136/bmj.m1266 [doi]
PST - epublish
SO  - BMJ. 2020 Mar 31;368:m1266. doi: 10.1136/bmj.m1266.


PMID- 32234338
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20210324
IS  - 1090-2139 (Electronic)
IS  - 0889-1591 (Linking)
VI  - 87
DP  - 2020 Jul
TI  - Using psychoneuroimmunity against COVID-19.
PG  - 4-5
LID - S0889-1591(20)30391-3 [pii]
LID - 10.1016/j.bbi.2020.03.025 [doi]
AB  - The worldwide outbreak of coronavirus disease 2019 (COVID-19) raises concerns of 
      widespread panic and anxiety in individuals subjected to the real or perceived
      threat of the virus. Compared to general populations, patients who are
      institutionalized in a closed unit are also very vulnerable to COVID-19 infection
      and complications. This crisis touched on difficult issues of not only
      psychiatric care and ethics, but also psychological impacts to psychiatric care
      givers. In this Viewpoint, we address both physical and biopsychosocial aspects
      of this infection, as well as the psychoneuroimmunity of preventive strategies of
      healthy lifestyle, regular exercise, balanced nutrition, quality sleep and a
      strong connection with people. Social distancing and wearing masks might help us 
      from pathogen exposure, yet such these measures also prevent us from expressing
      compassion and friendliness. Therefore, all forms of psychological support should
      be routinely implemented not only to consider psychological resilience but also
      to enhance psychoneuroimmunity against COVID-19.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Kim, Sung-Wan
AU  - Kim SW
AD  - Department of Psychiatry, Chonnam National University Medical School; Mindlink,
      Gwangju Bukgu Community Mental Health Center, Gwangju, Republic of Korea.
FAU - Su, Kuan-Pin
AU  - Su KP
AD  - Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China
      Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical
      University, Taichung, Taiwan; An-Nan Hospital, China Medical University, Tainan, 
      Taiwan. Electronic address: cobolsu@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200329
PL  - Netherlands
TA  - Brain Behav Immun
JT  - Brain, behavior, and immunity
JID - 8800478
SB  - IM
CIN - Brain Behav Immun. 2020 Jul;87:170-171. PMID: 32405149
CIN - Schizophr Res. 2021 Feb;228:235-236. PMID: 33476952
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/epidemiology/prevention & control/*psychology
MH  - Diet, Healthy
MH  - Exercise
MH  - Healthy Lifestyle
MH  - Humans
MH  - Masks
MH  - Mental Disorders/epidemiology/*psychology
MH  - Pandemics/prevention & control
MH  - Pneumonia, Viral/epidemiology/prevention & control/*psychology
MH  - *Psychoneuroimmunology
MH  - Resilience, Psychological
MH  - SARS-CoV-2
MH  - Sleep
MH  - Social Behavior
MH  - Social Support
MH  - Stress, Psychological/epidemiology/*psychology
PMC - PMC7194899
EDAT- 2020/04/03 06:00
MHDA- 2020/07/03 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/03/23 00:00 [received]
PHST- 2020/03/25 00:00 [revised]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - S0889-1591(20)30391-3 [pii]
AID - 10.1016/j.bbi.2020.03.025 [doi]
PST - ppublish
SO  - Brain Behav Immun. 2020 Jul;87:4-5. doi: 10.1016/j.bbi.2020.03.025. Epub 2020 Mar
      29.


PMID- 32233729
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1556-2654 (Electronic)
IS  - 1556-2646 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Oct
TI  - Indigenous Research Ethics Requirements: An Examination of Six Tribal
      Institutional Review Board Applications and Processes in the United States.
PG  - 279-291
LID - 10.1177/1556264620912103 [doi]
AB  - Tribal Institutional Review Boards (TIRBs) in the United States assert their
      rights within sovereign nations by developing ethical research processes that
      align with tribal values to protect indigenous knowledge systems and their
      community from cultural appropriation, exploitation, misuse, and harm. We
      reviewed six TIRB applications and processes to gain a better understanding about
      their requirements and research ethics. We located 48 activated and deactivated
      TIRBs in a database, mapped them in relation to tribal reservation lands, and
      then conducted in-depth content analysis. Our analysis demonstrates the
      importance of building relationships, becoming fully acquainted with the TIRB's
      operating environment before seeking research approval, and issues related to
      tribal data management practices.
FAU - Kuhn, Nicole S
AU  - Kuhn NS
AD  - University of Washington, Seattle, USA.
FAU - Parker, Myra
AU  - Parker M
AD  - University of Washington, Seattle, USA.
FAU - Lefthand-Begay, Clarita
AU  - Lefthand-Begay C
AUID- ORCID: 0000-0001-5882-8108
AD  - University of Washington, Seattle, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200401
PL  - United States
TA  - J Empir Res Hum Res Ethics
JT  - Journal of empirical research on human research ethics : JERHRE
JID - 101273949
SB  - IM
MH  - *Ethics Committees, Research
MH  - Ethics, Research
MH  - Humans
MH  - *Indians, North American
MH  - United States
OTO - NOTNLM
OT  - *Alaskan Native
OT  - *American Indian
OT  - *IRB review
OT  - *Native American
OT  - *ethics
OT  - *human subjects' protections
OT  - *research review boards
OT  - *tribal IRBs
OT  - *tribes
EDAT- 2020/04/03 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/03 06:00
PHST- 2020/04/03 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/04/03 06:00 [entrez]
AID - 10.1177/1556264620912103 [doi]
PST - ppublish
SO  - J Empir Res Hum Res Ethics. 2020 Oct;15(4):279-291. doi:
      10.1177/1556264620912103. Epub 2020 Apr 1.


PMID- 32233117
OWN - NLM
STAT- MEDLINE
DCOM- 20201106
LR  - 20210302
IS  - 2578-2363 (Electronic)
IS  - 2578-2355 (Linking)
VI  - 42
IP  - 2
DP  - 2020 Mar
TI  - Research Participant Views regarding Qualitative Data Sharing.
PG  - 13-27
LID - 10.1002/eahr.500044 [doi]
AB  - We found no studies in the United States that explored research participants'
      perspectives about sharing their qualitative data. We present findings from
      interviews with 30 individuals who participated in sensitive qualitative studies 
      to explore their understanding and concerns regarding qualitative data sharing.
      The vast majority supported sharing qualitative data so long as their data were
      deidentified and shared only among researchers. However, they raised concerns
      about confidentiality if the data were not adequately deidentified and about
      misuse by secondary users if data were shared beyond the research community.
      These concerns, though, did not deter them from participating in research.
      Notably, participants hoped their data would be shared and may have expected or
      assumed this was already happening. While many could not recollect details about 
      data-sharing plans for studies in which they participated, they trusted
      researchers and institutions to appropriately handle data sharing. If individuals
      view data sharing as an extension or integral part of their participation in
      qualitative research, then researchers may have a stronger obligation to share
      qualitative data than previously thought. Guidelines and tools to assist
      researchers and institutional review board members in ethical and responsible
      qualitative data sharing are urgently needed.
CI  - (c) 2020 by The Hastings Center. All rights reserved.
FAU - Mozersky, Jessica
AU  - Mozersky J
AD  - Assistant professor of medicine at the Bioethics Research Center at Washington
      University School of Medicine.
FAU - Parsons, Meredith
AU  - Parsons M
AD  - Senior public health research technician at the Bioethics Research Center at
      Washington University School of Medicine.
FAU - Walsh, Heidi
AU  - Walsh H
AD  - Senior project manager at the Bioethics Research Center at Washington University 
      School of Medicine.
FAU - Baldwin, Kari
AU  - Baldwin K
AD  - Clinical research coordinator II at the Bioethics Research Center at Washington
      University School of Medicine.
FAU - McIntosh, Tristan
AU  - McIntosh T
AD  - Instructor at the Bioethics Research Center at Washington University School of
      Medicine.
FAU - DuBois, James M
AU  - DuBois JM
AD  - Steven J. Bander professor of medical ethics and directs the Bioethics Research
      Center at Washington University School of Medicine.
LA  - eng
GR  - R01 HG009351/HG/NHGRI NIH HHS/United States
GR  - UL1 TR002345/TR/NCATS NIH HHS/United States
GR  - UL1TR002345/GF/NIH HHS/United States
GR  - R01HG009351/GF/NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Ethics Hum Res
JT  - Ethics & human research
JID - 101738005
SB  - IM
MH  - Adult
MH  - Confidentiality/*ethics
MH  - Data Anonymization/*standards
MH  - Female
MH  - Humans
MH  - Information Dissemination/*ethics
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - Qualitative Research
MH  - Research Personnel/standards
MH  - Research Subjects/*psychology
MH  - Trust
MH  - United States
PMC - PMC7418215
MID - NIHMS1593608
OTO - NOTNLM
OT  - data sharing plans
OT  - human subjects research
OT  - qualitative data sharing
OT  - qualitative research
OT  - research ethics
EDAT- 2020/04/02 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.1002/eahr.500044 [doi]
PST - ppublish
SO  - Ethics Hum Res. 2020 Mar;42(2):13-27. doi: 10.1002/eahr.500044.


PMID- 32232765
OWN - NLM
STAT- MEDLINE
DCOM- 20201023
LR  - 20201023
IS  - 0724-6145 (Print)
IS  - 0724-6145 (Linking)
VI  - 173
DP  - 2020
TI  - The Sustainability and Life Cycle Assessments of Industrial Biotechnology: An
      Introduction.
PG  - 3-9
LID - 10.1007/10_2020_123 [doi]
AB  - Industrial biotechnology (IB) uses biological and biochemical processes in
      industrial production and is often regarded as an emerging key technology
      revolutionizing the production of many products while protecting resources and
      the environment and fostering economic development. This contribution describes
      the background and sketches the content of the volume 'Sustainability and Life
      Cycle Assessment of Industrial Biotechnology' in the Springer series 'Advances in
      Biochemical Engineering/Biotechnology'. The field of IB is introduced from
      different perspectives (milestones in IB history, economics of biotechnology
      industry, environmental and social as well as ethical issues and impacts, green
      chemistry) and in several applications fields (production of chemicals,
      geobiotechnology in mining).
FAU - Frohling, Magnus
AU  - Frohling M
AD  - Technical University of Munich (TUM), TUM Campus Straubing for Biotechnology and 
      Sustainability, Straubing, Germany. magnus.froehling@tum.de.
FAU - Hiete, Michael
AU  - Hiete M
AD  - Ulm University, Department of Business Chemistry, Ulm, Germany.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Adv Biochem Eng Biotechnol
JT  - Advances in biochemical engineering/biotechnology
JID - 8307733
SB  - IM
MH  - *Biotechnology
MH  - *Industry
MH  - Sustainable Development
OTO - NOTNLM
OT  - Application
OT  - Economy
OT  - History
OT  - Industrial biotechnology
OT  - LCA
OT  - Outline
OT  - Sustainability asessment
EDAT- 2020/04/02 06:00
MHDA- 2020/10/24 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/24 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1007/10_2020_123 [doi]
PST - ppublish
SO  - Adv Biochem Eng Biotechnol. 2020;173:3-9. doi: 10.1007/10_2020_123.


PMID- 32232611
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1573-3394 (Electronic)
IS  - 1065-3058 (Linking)
VI  - 28
IP  - 2
DP  - 2020 Jun
TI  - When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for
      Pharmaceutical Pricing.
PG  - 121-136
LID - 10.1007/s10728-020-00394-x [doi]
AB  - The most common solutions to the problem of high pharmaceutical prices have taken
      the form of regulations, price negotiations, or changes in drug coverage by
      insurers. These measures for the most part transfer the burden of drug
      expenditures between pharmaceutical companies and payers or between payers. The
      aim of this study is to propose an alternative model for the relationship between
      the main stakeholders (the pharmaceutical companies, third party payers, and the 
      public) involved in the price setting and purchasing of pharmaceuticals, one that
      encourages a more cooperative approach. We draw from principles of ethics and
      health economics and apply them to the context of the pharmaceutical industry.
      The model prioritises two objectives, (1) to make drugs financially accessible to
      the patients who need them, and (2) to keep pharmaceutical companies viable and
      profitable. It is centered around the sharing of financial risk between the main 
      stakeholders, which we describe as 'enlightened risk sharing'. After establishing
      the foundations of this model, we expand on the type of policies that can follow 
      these principles with current day examples.
FAU - Balderrama, Fanor
AU  - Balderrama F
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University 
      Faculty of Health Sciences, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
      balderrf@mcmaster.ca.
FAU - Schwartz, Lisa J
AU  - Schwartz LJ
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University 
      Faculty of Health Sciences, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
FAU - Longo, Christopher J
AU  - Longo CJ
AD  - Department of Health Research Methods, Evidence, and Impact, McMaster University 
      Faculty of Health Sciences, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
AD  - Department of Health Policy and Management, DeGroote School of Business, McMaster
      University, 4350 South Service Road, Burlington, ON, L7L 5R8, Canada.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Health Care Anal
JT  - Health care analysis : HCA : journal of health philosophy and policy
JID - 9432537
MH  - *Costs and Cost Analysis
MH  - *Drug Costs
MH  - Drug Industry/*economics
MH  - Government Regulation
MH  - Humans
MH  - Insurance, Health, Reimbursement/*economics
MH  - Models, Economic
MH  - *Risk Sharing, Financial
OTO - NOTNLM
OT  - Business ethics
OT  - Fair pricing
OT  - Health economics
OT  - Pharmaceutical pricing
OT  - Policy
EDAT- 2020/04/02 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1007/s10728-020-00394-x [doi]
AID - 10.1007/s10728-020-00394-x [pii]
PST - ppublish
SO  - Health Care Anal. 2020 Jun;28(2):121-136. doi: 10.1007/s10728-020-00394-x.


PMID- 32232474
OWN - NLM
STAT- MEDLINE
DCOM- 20200519
LR  - 20210910
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 221
IP  - 11
DP  - 2020 May 11
TI  - Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.
PG  - 1752-1756
LID - 10.1093/infdis/jiaa152 [doi]
AB  - Controlled human challenge trials of SARS-CoV-2 vaccine candidates could
      accelerate the testing and potential rollout of efficacious vaccines. By
      replacing conventional phase 3 testing of vaccine candidates, such trials may
      subtract many months from the licensure process, making efficacious vaccines
      available more quickly. Obviously, challenging volunteers with this live virus
      risks inducing severe disease and possibly even death. However, we argue that
      such studies, by accelerating vaccine evaluation, could reduce the global burden 
      of coronavirus-related mortality and morbidity. Volunteers in such studies could 
      autonomously authorize the risks to themselves, and their net risk could be
      acceptable if participants comprise healthy young adults, who are at relatively
      low risk of serious disease following natural infection, if they have a high
      baseline risk of natural infection, and if during the trial they receive frequent
      monitoring and, following any infection, the best available care.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious
      Diseases Society of America.
FAU - Eyal, Nir
AU  - Eyal N
AD  - Center for Population-Level Bioethics, Rutgers University, New Brunswick, New
      Jersey, USA.
AD  - Department of Philosophy, Rutgers University, New Brunswick, New Jersey, USA.
AD  - Department of Health Behavior, Society and Policy, Rutgers School of Public
      Health, Piscataway, New Jersey, USA.
FAU - Lipsitch, Marc
AU  - Lipsitch M
AD  - Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. 
      H. Chan School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of
      Public Health, Boston, Massachusetts, USA.
FAU - Smith, Peter G
AU  - Smith PG
AD  - MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine,
      London, UK.
LA  - eng
GR  - AI114617-01A1/AI/NIAID NIH HHS/United States
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
GR  - U54 GM088558/GM/NIGMS NIH HHS/United States
GR  - R01 AI114617/AI/NIAID NIH HHS/United States
GR  - R56 AI114617/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
SB  - IM
CIN - J Infect Dis. 2020 Jun 16;222(1):169. PMID: 32348489
CIN - J Infect Dis. 2020 Jun 16;222(1):169-170. PMID: 32348499
CIN - J Infect Dis. 2020 Jul 6;222(3):516-517. PMID: 32495823
CIN - J Infect Dis. 2020 Jul 6;222(3):514-516. PMID: 32496536
CIN - J Infect Dis. 2020 Oct 1;222(9):1572-1574. PMID: 32845303
CIN - J Infect Dis. 2020 Oct 1;222(9):1574-1575. PMID: 32845306
CIN - J Infect Dis. 2020 Oct 1;222(9):1571-1572. PMID: 32845317
MH  - Betacoronavirus/immunology
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Clinical Trials as Topic/*standards
MH  - Coronavirus Infections/*prevention & control
MH  - Drug Development/*trends
MH  - Humans
MH  - Licensure
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - SARS-CoV-2
MH  - Viral Vaccines/*standards
PMC - PMC7184325
OTO - NOTNLM
OT  - * coronavirus
OT  - *ethics
OT  - *human challenge studies
OT  - *randomized controlled trials
OT  - *risk-taking
OT  - *vaccines
EDAT- 2020/04/02 06:00
MHDA- 2020/05/20 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/03/22 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/05/20 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 5814216 [pii]
AID - 10.1093/infdis/jiaa152 [doi]
PST - ppublish
SO  - J Infect Dis. 2020 May 11;221(11):1752-1756. doi: 10.1093/infdis/jiaa152.


PMID- 32231786
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2054-3581 (Print)
IS  - 2054-3581 (Linking)
VI  - 7
DP  - 2020
TI  - Policy Challenges for Organ Allocation in an Era of "Precision Medicine".
PG  - 2054358120912655
LID - 10.1177/2054358120912655 [doi]
AB  - There is increasing interest in the use of precision medicine tools and
      evidence-based outcome measures for donor-recipient matching to optimize
      transplant outcomes. Although the shift toward greater precision can provide
      health and resource benefits, it may be perceived as conflicting with both
      established equity-focused organ allocation norms and the legal and ethical
      obligations of health care providers and related institutions. With increasing
      evidence that various forms of human leukocyte antigen (HLA) mismatch and/or
      prognostic biomarkers can affect outcomes, the tension between maximizing utility
      and ensuring equity seems likely to intensify. In Canada, health care providers
      are generally required by law to put the interests of their patient, such as
      access to an organ, above the needs of the health care system and other patients.
      In addition, transplantation right of access lawsuits, which have been successful
      in the past, could affect the implementation of precision approaches. These legal
      tensions could be further heightened by media representations, which have
      historically favored strong rights of access. When implementing new precision
      technologies in organ allocation, there will be a recurrent need for policymakers
      to revisit the balance of equity and utility and to assess how to craft rules
      that reflect our society's conception of a fair allocation system.
CI  - (c) The Author(s) 2020.
FAU - Caulfield, Timothy
AU  - Caulfield T
AUID- ORCID: https://orcid.org/0000-0001-5471-6184
AD  - Health Law Institute, Faculty of Law, University of Alberta, Edmonton, Canada.
FAU - Murdoch, Blake
AU  - Murdoch B
AD  - Health Law Institute, Faculty of Law, University of Alberta, Edmonton, Canada.
FAU - Sapir-Pichhadze, Ruth
AU  - Sapir-Pichhadze R
AUID- ORCID: https://orcid.org/0000-0003-0745-004X
AD  - Department of Medicine, McGill University, Montreal, Quebec, Canada.
FAU - Keown, Paul
AU  - Keown P
AD  - Faculty of Medicine, The University of British Columbia, Vancouver, Canada.
LA  - eng
PT  - Editorial
DEP - 20200320
PL  - England
TA  - Can J Kidney Health Dis
JT  - Canadian journal of kidney health and disease
JID - 101640242
PMC - PMC7088188
OTO - NOTNLM
OT  - allocation policy
OT  - organ allocation
OT  - precision medicine
OT  - professional obligations
OT  - public representations
OT  - right of access
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/04/02 06:00
MHDA- 2020/04/02 06:01
CRDT- 2020/04/02 06:00
PHST- 2019/10/23 00:00 [received]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/02 06:01 [medline]
AID - 10.1177/2054358120912655 [doi]
AID - 10.1177_2054358120912655 [pii]
PST - epublish
SO  - Can J Kidney Health Dis. 2020 Mar 20;7:2054358120912655. doi:
      10.1177/2054358120912655. eCollection 2020.


PMID- 32231682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - Pioneering Informed Consent for Return of Research Results to Breast Cancer
      Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan
      BRCA1/2 Testing Experience Using Whole Exome Sequencing.
PG  - 170
LID - 10.3389/fgene.2020.00170 [doi]
AB  - INTRODUCTION: Obtaining informed consent from study participants and
      disseminating the findings responsibly is a key principle required for ethically 
      conducted clinical and genetic research. Reports from African researchers
      providing feedback on insights gained during the return of whole exome sequencing
      (WES) results to breast cancer patients treated in resource-limited settings is
      lacking. AIM: The empirical process used to fill this gap in relation to BRCA1/2 
      variant detection using WES provided unique insights incorporated into a
      pathology-supported genetic testing algorithm for return of research results to
      Kenyan breast cancer patients. METHODS: The Informed consent form approved by the
      Moi Teaching and Referral Hospital in Kenya was adopted from a translational
      research study conducted in South Africa. Initially, the informed consent process
      was piloted in 16 Kenyan female patients referred for breast surgery, following a
      community-based awareness campaign. A total of 95 female and two male breast
      cancer patients were enrolled in the study from 2013 to 2016.
      Immunohistochemistry (IHC) results of estrogen receptor (ER), progesterone
      receptor (PR) and human epidermal growth factor receptor-2 (HER2) status were
      obtained from hospital records. DNA of patients with a family history of cancer
      was extracted from saliva and screened for pathogenic variants in the BRCA1/2
      genes as the first step using WES. RESULTS: Ten patients approached for
      participation in this study declined to sign the informed consent form. Data on
      IHC used as a proxy for molecular subtype were available in 8 of 13 breast cancer
      patients (62%) with a family history of cancer. Five BRCA1/2 variants of
      uncertain clinical significance were detected, as well as a pathogenic BRCA2
      variant (c.5159C > A; S1720( *)) in a female patient eligible for return of WES
      results. CONCLUSION: Experience gained during the qualitative pilot phase was
      essential to overcome challenges associated with the translation of sophisticated
      genetic terms into native African languages. Detection of a pathogenic BRCA2
      variant in a patient with familial breast cancer, frequently associated with
      hormone receptor-positive breast carcinoma as reported in this case, led to a
      high level of confidence on which to base risk management in future.
      Implementation of new technologies alongside standard pathology provides a
      practical approach to the application of genomic medicine in Africa.
CI  - Copyright (c) 2020 Torrorey-Sawe, van der Merwe, Mining and Kotze.
FAU - Torrorey-Sawe, Rispah
AU  - Torrorey-Sawe R
AD  - Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and 
      Health Sciences, Stellenbosch University, Tygerberg, South Africa.
AD  - Department of Immunology, School of Medicine, College of Health Sciences, Moi
      University, Eldoret, Kenya.
FAU - van der Merwe, Nicole
AU  - van der Merwe N
AD  - Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and 
      Health Sciences, Stellenbosch University, Tygerberg, South Africa.
FAU - Mining, Simeon Kipkoech
AU  - Mining SK
AD  - Department of Immunology, School of Medicine, College of Health Sciences, Moi
      University, Eldoret, Kenya.
FAU - Kotze, Maritha J
AU  - Kotze MJ
AD  - Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and 
      Health Sciences, Stellenbosch University, Tygerberg, South Africa.
AD  - National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20200306
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7089032
OTO - NOTNLM
OT  - Africa
OT  - genetics
OT  - genomics
OT  - informed consent
OT  - pathology
OT  - return of results
EDAT- 2020/04/02 06:00
MHDA- 2020/04/02 06:01
CRDT- 2020/04/02 06:00
PHST- 2019/09/10 00:00 [received]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/02 06:01 [medline]
AID - 10.3389/fgene.2020.00170 [doi]
PST - epublish
SO  - Front Genet. 2020 Mar 6;11:170. doi: 10.3389/fgene.2020.00170. eCollection 2020.


PMID- 32231621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Feeling at Home in the Wilderness: Environmental Conditions, Well-Being and
      Aesthetic Experience.
PG  - 402
LID - 10.3389/fpsyg.2020.00402 [doi]
AB  - Environmental conditions affect one's aesthetic experience in natural
      environments. Understanding that effect requires accounting for the conditions
      affecting one's attention and experience. Rather than attempt to reduce and
      control environmental factors, we compare two similar groups during naturally
      occurring, intense and overwhelming conditions and examine the relationship
      between common characteristics as well as environment and group differences.
      Participants undertook a 5-day, winter, wilderness adventure training course
      designed to challenge their considerable wilderness and leadership skills under
      two different extreme weather conditions but within the same wilderness area (n =
      47 full participation). In addition to pre- and post-adventure questionnaires,
      participants responded daily during the wilderness experience to briefly describe
      a self-selected, strong experience of nature; characterize its associated feeling
      states; and answer questions probing eight aesthetic aspects of the experience.
      Participant strong experience of nature related to hedonic and eudaimonic
      feelings in different ways depending upon environmental conditions. In
      particular, strong correlations occurred between agreement ratings with "I felt
      at home in nature" daily experience reports and satisfaction with life and
      personal growth trait measures, but primarily during sunny and cold conditions on
      a high plateau (PG: Pearson r = 0.51; SWL: r = 0.70) and not significantly in
      stormy and wet weather in a mountain forest. In addition, experience narratives
      that correspond to strongest agreement to feeling at home in nature were examined
      for shared themes and synthesized into six dimensions: focus on sensory
      experiences at a particular moment, self-reflection, wonder, appreciation of
      beauty, positive emotions, and insight of relation to nature. These findings
      actualize the notion of wonder, aroused by sudden feelings or by reflection, as a
      salient ingredient in feeling at home in wilderness. The finding of feeling at
      home in nature, as the most important feature relating to feelings and
      well-being, is discussed in relation to self-awareness, philosophical thinking,
      and potential ethical awareness.
CI  - Copyright (c) 2020 Lovoll, Saether and Graves.
FAU - Lovoll, Helga Synnevag
AU  - Lovoll HS
AD  - Department of Physical Education, Volda University College, Volda, Norway.
FAU - Saether, Knut-Willy
AU  - Saether KW
AD  - Department of Religious Studies, Volda University College, Volda, Norway.
FAU - Graves, Mark
AU  - Graves M
AD  - Graduate School of Psychology, Fuller Theological Seminary, Pasadena, CA, United 
      States.
LA  - eng
PT  - Journal Article
DEP - 20200313
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7082929
OTO - NOTNLM
OT  - aesthetic experience
OT  - awe
OT  - beauty
OT  - natural environment
OT  - sublime
OT  - well-being
OT  - wilderness
OT  - wonder
EDAT- 2020/04/02 06:00
MHDA- 2020/04/02 06:01
CRDT- 2020/04/02 06:00
PHST- 2019/09/30 00:00 [received]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/02 06:01 [medline]
AID - 10.3389/fpsyg.2020.00402 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 13;11:402. doi: 10.3389/fpsyg.2020.00402. eCollection
      2020.


PMID- 32231602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Clinical Ethics Support Services Are Not as Well-Established in Forensic
      Psychiatry as in General Psychiatry.
PG  - 186
LID - 10.3389/fpsyt.2020.00186 [doi]
AB  - Background: Mental health care professionals deal with complex ethical dilemmas
      that involve the principles of autonomy, justice, beneficence, and
      non-maleficence. Such dilemmas are even more prominent in forensic mental health 
      care, where the restriction of personal rights is legitimated not only by patient
      well-being but also by public safety interests. Little is known about either the 
      use of formal ethics support services or specific ethical needs in forensic
      mental health care. Knowledge about the current structures and how they compare
      with those in general psychiatry would help to identify the most important
      ethical issues and to analyze whether there are unmet needs that might require
      specific ethics support. Methods: We performed a survey study in all general
      psychiatric and forensic psychiatric inpatient departments in Germany. The aims
      were to compare the availability and functioning of clinical ethics structures
      and to identify specific ethical needs in inpatient forensic and general mental
      health care. Results: Clinical ethics support was available in 74% of general
      psychiatric hospitals but in only 43% of all forensic psychiatric hospitals and
      25% of those offering treatment for offenders with substance use disorders. Most 
      ethics support services were interdisciplinary. The most frequently requested
      retrospective and prospective ethics consultations were on issues of omission and
      termination of treatment, coercive measures, and advance directives. Among the
      hospitals without access to ethics support, 71% indicated a need for training in 
      ethics. Discussion: Our results show that ethics consultation is well established
      in general psychiatry, but less so in forensic psychiatry. Mental health care
      professionals in forensic psychiatry seem to have a need for ethics support and
      training in clinical ethics. We also found a difference in access to ethics
      structures between hospitals that treat mentally disordered offenders and those
      that treat offenders with substance use disorders. Further research should focus 
      on how ethics support can be comprehensively implemented in forensic mental
      health care and how this might improve treatment quality and patient and staff
      well-being.
CI  - Copyright (c) 2020 Franke, Speiser, Dudeck and Streb.
FAU - Franke, Irina
AU  - Franke I
AD  - Department of Forensic Psychiatry and Psychotherapy, Ulm University, Ulm,
      Germany.
AD  - Psychiatric Services Graubuenden, Department of Forensic Psychiatry, Cazis,
      Switzerland.
FAU - Speiser, Oskar
AU  - Speiser O
AD  - Department of Forensic Psychiatry and Psychotherapy, Ulm University, Ulm,
      Germany.
FAU - Dudeck, Manuela
AU  - Dudeck M
AD  - Department of Forensic Psychiatry and Psychotherapy, Ulm University, Ulm,
      Germany.
FAU - Streb, Judith
AU  - Streb J
AD  - Department of Forensic Psychiatry and Psychotherapy, Ulm University, Ulm,
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20200313
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7082354
OTO - NOTNLM
OT  - clinical ethics
OT  - clinical ethics support
OT  - ethics consultation
OT  - forensic mental health
OT  - forensic psychotherapy
EDAT- 2020/04/02 06:00
MHDA- 2020/04/02 06:01
CRDT- 2020/04/02 06:00
PHST- 2019/09/10 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/02 06:01 [medline]
AID - 10.3389/fpsyt.2020.00186 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Mar 13;11:186. doi: 10.3389/fpsyt.2020.00186. eCollection 
      2020.


PMID- 32231601
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Attitudes About Informed Consent: An Exploratory Qualitative Analysis of UK
      Psychotherapy Trainees.
PG  - 183
LID - 10.3389/fpsyt.2020.00183 [doi]
AB  - Background: Ethical informed consent to psychotherapy has recently been the
      subject of in-depth analysis among healthcare ethicists. Objective: This study
      aimed to explore counseling and psychotherapy students' views and understanding
      about informed consent to psychological treatments. Methods: Two focus groups
      were conducted with a total of 10 students enrolled in a Masters course in
      counseling and psychotherapy at a British university. Questions concerned
      participants' understanding of informed consent including judgments about client 
      capacity; the kinds of information that should be disclosed; how consent might be
      obtained; and their experiences of informed consent, both as a client and as a
      therapist. Focus groups were audio-recorded, transcribed, and analyzed using
      qualitative content analysis. Coding was conducted independently by three
      authors. Results: Comments were classified into three main themes: (1) the
      reasons and justifications for informed consent; (2) informed consent processes; 
      and (3) the hidden ethics curriculum. Some trainees expressed significant doubts 
      about the importance of informed consent. However, participants also identified
      the need to establish the clients' voluntariness and their right to be informed
      about confidentiality issues. In general, the format and processes pertaining to 
      informed consent raised considerable questions and uncertainties. Participants
      were unsure about rules surrounding client capacity; expressed misgivings about
      describing treatment techniques; and strikingly, most trainees were skeptical
      about the clinical relevance of the evidence-base in psychotherapy. Finally,
      trainees' experiences as clients within obligatory psychotherapy sessions were
      suggestive of a "hidden ethics curriculum"-referring to the unintended
      transmission of norms and practices within training that undermine the explicit
      guidance expressed in formal professional ethics codes. Some students felt
      coerced into therapy, and some reported not undergoing informed consent
      processes. Reflecting on work placements, trainees expressed mixed views, with
      some unclear about who was responsible for informed consent. Conclusions: This
      qualitative study presents timely information on psychotherapy students' views
      about informed consent to psychotherapy. Major gaps in students' ethical,
      conceptual, and procedural knowledge were identified, and comments suggested the 
      influence of a hidden curriculum in shaping norms of practice. Implications: This
      exploratory study raises important questions about the preparedness of
      psychotherapy students to fulfill their ethical obligations.
CI  - Copyright (c) 2020 Blease, Arnott, Kelley, Proctor, Kube, Gaab and Locher.
FAU - Blease, Charlotte R
AU  - Blease CR
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United 
      States.
AD  - School of Psychology, University College Dublin, Dublin, Ireland.
FAU - Arnott, Tim
AU  - Arnott T
AD  - School of Healthcare, University of Leeds, Leeds, United Kingdom.
FAU - Kelley, John M
AU  - Kelley JM
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United 
      States.
AD  - Department of Psychology, Endicott College, Beverly, MA, United States.
FAU - Proctor, Gillian
AU  - Proctor G
AD  - School of Healthcare, University of Leeds, Leeds, United Kingdom.
FAU - Kube, Tobias
AU  - Kube T
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United 
      States.
AD  - Pain and Psychotherapy Lab, University of Koblenz and Landau, Landau, Germany.
FAU - Gaab, Jens
AU  - Gaab J
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
FAU - Locher, Cosima
AU  - Locher C
AD  - Division of Clinical Psychology and Psychotherapy, Faculty of Psychology,
      University of Basel, Basel, Switzerland.
AD  - School of Psychology, University of Plymouth, Plymouth, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20200313
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7083167
OTO - NOTNLM
OT  - ethics-clinical
OT  - informed consent
OT  - opinions
OT  - psychotherapy
OT  - psychotherapy education
OT  - psychotherapy research
OT  - survey
EDAT- 2020/04/02 06:00
MHDA- 2020/04/02 06:01
CRDT- 2020/04/02 06:00
PHST- 2019/08/08 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/02 06:01 [medline]
AID - 10.3389/fpsyt.2020.00183 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Mar 13;11:183. doi: 10.3389/fpsyt.2020.00183. eCollection 
      2020.


PMID- 32231027
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2304-8158 (Print)
IS  - 2304-8158 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Mar 28
TI  - Food Preservation: Challenges and Efforts for the Future.
LID - E391 [pii]
LID - 10.3390/foods9040391 [doi]
AB  - Microbial hazards and food oxidation have acquired substantial economical,
      ethical and legal importance in the food industry [...].
FAU - Kourkoutas, Yiannis
AU  - Kourkoutas Y
AD  - Laboratory of Applied Microbiology & Biotechnology, Department of Molecular
      Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis,
      Greece.
FAU - Proestos, Charalampos
AU  - Proestos C
AUID- ORCID: 0000-0002-3450-5969
AD  - Laboratory of Food Chemistry, Department of Chemistry, National and Kapodistrian 
      University of Athens, 15771 Athens, Greece.
LA  - eng
PT  - Editorial
DEP - 20200328
PL  - Switzerland
TA  - Foods
JT  - Foods (Basel, Switzerland)
JID - 101670569
PMC - PMC7230679
EDAT- 2020/04/02 06:00
MHDA- 2020/04/02 06:01
CRDT- 2020/04/02 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/02 06:01 [medline]
AID - foods9040391 [pii]
AID - 10.3390/foods9040391 [doi]
PST - epublish
SO  - Foods. 2020 Mar 28;9(4). pii: foods9040391. doi: 10.3390/foods9040391.


PMID- 32230982
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 7
DP  - 2020 Mar 27
TI  - Enhanced Public Interest in Response to the Refugee and Healthcare Crises in
      Greece.
LID - E2272 [pii]
LID - 10.3390/ijerph17072272 [doi]
AB  - Background: The Greek National Health System (NHS) has been profoundly affected
      by the synergy of the economic and refugee crises. We aimed at evaluating the
      public interest regarding refugee and healthcare issues in Greece. Methods:
      Google Trends was employed to normalize traffic data on a scale from 0 to 100,
      presented as monthly relative search volume (RSV) for the search term queries:
      "refugees", "health", "diseases", "hospital", and "economic crisis" in Greece,
      from the period 2008 to 2020. Cross-country comparisons in selected European
      countries were made. Results: The analysis of RSV data showed an upward trend for
      the keyword "refugee", in Greece, in the last five years, with two remarkable
      peaks from 2015 to 2016 and from 2019 to the present. Interest regarding refugees
      was more prevalent in the Aegean islands compared to the mainland. The mass
      influx of refugees has been linked to disease-related concerns. The search terms 
      "hospital" and "health" have been the most popular and constantly quested topics 
      since the beginning of the economic crisis in Greece, in 2009. Similar trends
      existed across Europe. Conclusion: There is an urgent need for effective public
      awareness of current politico-ethical and social-economic conditions. The
      patterns of public interest can formulate public policy.
FAU - Kotsiou, Ourania S
AU  - Kotsiou OS
AUID- ORCID: 0000-0001-5219-6971
AD  - Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, 
      BIOPOLIS, 41110 Larissa, Greece.
FAU - Kotsios, Vaios S
AU  - Kotsios VS
AD  - Metsovion Interdisciplinary Research Center, National Technical University of
      Athens, 44200 Athens, Greece.
FAU - Gourgoulianis, Konstantinos I
AU  - Gourgoulianis KI
AD  - Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, 
      BIOPOLIS, 41110 Larissa, Greece.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - *Delivery of Health Care
MH  - Europe
MH  - Greece
MH  - Humans
MH  - *Public Opinion
MH  - Public Policy
MH  - *Refugees
PMC - PMC7177306
OTO - NOTNLM
OT  - *Google Trends
OT  - *Greece
OT  - *economic crisis
OT  - *health
OT  - *public interest
OT  - *refugee
EDAT- 2020/04/02 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/01/31 00:00 [received]
PHST- 2020/03/18 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - ijerph17072272 [pii]
AID - 10.3390/ijerph17072272 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Mar 27;17(7). pii: ijerph17072272. doi:
      10.3390/ijerph17072272.


PMID- 32230814
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 7
DP  - 2020 Mar 27
TI  - Lessons Learned from Somatic Cell Nuclear Transfer.
LID - E2314 [pii]
LID - 10.3390/ijms21072314 [doi]
AB  - Somatic cell nuclear transfer (SCNT) has been an area of interest in the field of
      stem cell research and regenerative medicine for the past 20 years. The main
      biological goal of SCNT is to reverse the differentiated state of a somatic cell,
      for the purpose of creating blastocysts from which embryonic stem cells (ESCs)
      can be derived for therapeutic cloning, or for the purpose of reproductive
      cloning. However, the consensus is that the low efficiency in creating normal
      viable offspring in animals by SCNT (1-5%) and the high number of abnormalities
      seen in these cloned animals is due to epigenetic reprogramming failure. In this 
      review we provide an overview of the current literature on SCNT, focusing on
      protocol development, which includes early SCNT protocol deficiencies and
      optimizations along with donor cell type and cell cycle synchrony; epigenetic
      reprogramming in SCNT; current protocol optimizations such as nuclear
      reprogramming strategies that can be applied to improve epigenetic reprogramming 
      by SCNT; applications of SCNT; the ethical and legal implications of SCNT in
      humans; and specific lessons learned for establishing an optimized SCNT protocol 
      using a mouse model.
FAU - Gouveia, Chantel
AU  - Gouveia C
AD  - Institute for Cellular and Molecular Medicine, Department of Immunology and South
      African Medical Research Council (SAMRC) Extramural Unit for Stem Cell Research
      and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0002,
      South Africa.
AD  - Department of Obstetrics and Gynaecology, Reproductive Biology Laboratory,
      University of Pretoria, Steve Biko Academic Hospital, Pretoria 0002, South
      Africa.
FAU - Huyser, Carin
AU  - Huyser C
AD  - Department of Obstetrics and Gynaecology, Reproductive Biology Laboratory,
      University of Pretoria, Steve Biko Academic Hospital, Pretoria 0002, South
      Africa.
FAU - Egli, Dieter
AU  - Egli D
AD  - Department of Obstetrics and Gynecology, Columbia University Medical Center, New 
      York, NY 10027, USA.
FAU - Pepper, Michael S
AU  - Pepper MS
AUID- ORCID: 0000-0001-6406-2380
AD  - Institute for Cellular and Molecular Medicine, Department of Immunology and South
      African Medical Research Council (SAMRC) Extramural Unit for Stem Cell Research
      and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria 0002,
      South Africa.
LA  - eng
GR  - Flagship Grant and Extramural Unit for Stem Cell Research and Therapy/South
      African Medical Research Council
PT  - Journal Article
PT  - Review
DEP - 20200327
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - Blastocyst/*cytology
MH  - Cell Differentiation
MH  - Cellular Reprogramming
MH  - Cloning, Organism/methods
MH  - Embryo, Mammalian/cytology
MH  - Embryonic Development
MH  - Embryonic Stem Cells/*cytology
MH  - Epigenomics
MH  - Eye Enucleation
MH  - Humans
MH  - *Nuclear Transfer Techniques
MH  - Oocytes/cytology
PMC - PMC7177533
OTO - NOTNLM
OT  - ESC
OT  - SCNT
OT  - cloning
OT  - enucleation
OT  - epigenetic reprogramming
OT  - nuclear reprogramming
OT  - nuclear transfer
OT  - oocyte
OT  - somatic cell
EDAT- 2020/04/02 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
AID - ijms21072314 [pii]
AID - 10.3390/ijms21072314 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Mar 27;21(7). pii: ijms21072314. doi: 10.3390/ijms21072314.


PMID- 32229596
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 4
DP  - 2020 Apr
TI  - Commentary on 'Four types of gender bias affecting women surgeons, and their
      cumulative impact' by Hutchison.
PG  - 242-243
LID - 10.1136/medethics-2019-106020 [doi]
FAU - McLeod, Carolyn
AU  - McLeod C
AD  - Philosophy, University of Western Ontario, London, ON N6A 5B8, Canada
      cmcleod2@uwo.ca.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200330
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Apr;46(4):236-241. PMID: 32229595
CIN - J Med Ethics. 2020 Apr;46(4):247-248. PMID: 32229594
MH  - Female
MH  - Humans
MH  - Male
MH  - *Sexism
MH  - *Surgeons
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - *applied and professional ethics
OT  - *sexuality/gender
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/01/24 00:00 [received]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - medethics-2019-106020 [pii]
AID - 10.1136/medethics-2019-106020 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Apr;46(4):242-243. doi: 10.1136/medethics-2019-106020. Epub
      2020 Mar 30.


PMID- 32229595
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 4
DP  - 2020 Apr
TI  - Four types of gender bias affecting women surgeons and their cumulative impact.
PG  - 236-241
LID - 10.1136/medethics-2019-105552 [doi]
AB  - Women are under-represented in surgery, especially in leadership and academic
      roles, and face a gender pay gap. There has been little work on the role of
      implicit biases in women's under-representation in surgery. Nor has the impact of
      epistemic injustice, whereby stereotyping influences knowledge or credibility
      judgements, been explored. This article reports findings of a qualitative
      in-depth interview study with women surgeons that investigates gender biases in
      surgery, including subtle types of bias. The study was conducted with 46 women
      surgeons and trainees of the Royal Australasian College of Surgeons. Maximum
      variance sampling strategies ensured a comprehensive set of perspectives. Data
      were analysed using iterative thematic analysis to document and classify forms of
      gender bias experienced by the participants, including implicit bias and
      epistemic injustice. It found four types of bias affecting women surgeons: (1)
      workplace factors such as access to parental leave and role models; (2) epistemic
      injustices-unfair assessments of women surgeons' credibility by patients and
      colleagues; (3) stereotyped expectations that they will carry out more of
      surgery's carework, such as meeting the emotional needs of patients and (4)
      objectification. Implicit biases arose in each category. Given that many of the
      biases identified in this study are small, are harmless on their own and are not 
      necessarily under anyone's conscious control, important questions arise regarding
      how they cause harm and how to address them. I draw on theoretical work on
      cumulative harm to answer these questions.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hutchison, Katrina
AU  - Hutchison K
AUID- ORCID: 0000-0002-5817-7488
AD  - Department of Philosophy, Macquarie University, Sydney, NSW 2109, Australia
      katrina.hutchison@mq.edu.au.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200330
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CIN - J Med Ethics. 2020 Apr;46(4):246. PMID: 32229592
CIN - J Med Ethics. 2020 Apr;46(4):244-245. PMID: 32229593
CIN - J Med Ethics. 2020 Apr;46(4):247-248. PMID: 32229594
CIN - J Med Ethics. 2020 Apr;46(4):242-243. PMID: 32229596
CIN - J Med Ethics. 2020 Nov;46(11):785-786. PMID: 32723762
MH  - Female
MH  - Humans
MH  - Leadership
MH  - Male
MH  - *Physicians, Women
MH  - Sexism
MH  - *Surgeons
MH  - Workplace
OTO - NOTNLM
OT  - *ethics
OT  - *health workforce
OT  - *surgery
OT  - *women
COIS- Competing interests: KH reports non-financial support (travel and conference
      registration) from the Royal Australasian College of Surgeons (RACS) to present a
      paper at the RACS Annual Scientific Congress in 2017.
EDAT- 2020/04/02 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/02 06:00
PHST- 2019/05/03 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2019/12/10 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - medethics-2019-105552 [pii]
AID - 10.1136/medethics-2019-105552 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Apr;46(4):236-241. doi: 10.1136/medethics-2019-105552. Epub
      2020 Mar 30.


PMID- 32229594
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 4
DP  - 2020 Apr
TI  - Wrongdoing and responsibility in the context of cumulative harms: a response to
      commentators.
PG  - 247-248
LID - 10.1136/medethics-2020-106194 [doi]
FAU - Hutchison, Katrina
AU  - Hutchison K
AUID- ORCID: 0000-0002-5817-7488
AD  - Department of Philosophy, Macquarie University, Sydney, NSW 2109, Australia
      katrina.hutchison@mq.edu.au.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200330
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Apr;46(4):246. PMID: 32229592
CON - J Med Ethics. 2020 Apr;46(4):244-245. PMID: 32229593
CON - J Med Ethics. 2020 Apr;46(4):236-241. PMID: 32229595
CON - J Med Ethics. 2020 Apr;46(4):242-243. PMID: 32229596
MH  - Female
MH  - Humans
MH  - Social Behavior
MH  - *Surgeons
OTO - NOTNLM
OT  - *ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/03/06 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - medethics-2020-106194 [pii]
AID - 10.1136/medethics-2020-106194 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Apr;46(4):247-248. doi: 10.1136/medethics-2020-106194. Epub
      2020 Mar 30.


PMID- 32229593
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 4
DP  - 2020 Apr
TI  - Stop the bleeding: we must combat explicit as well as implicit biases affecting
      women surgeons.
PG  - 244-245
LID - 10.1136/medethics-2020-106066 [doi]
FAU - Scully, Brandi Braud
AU  - Scully BB
AD  - The Johns Hopkins Medical Institutions, Johns Hopkins, JHU Berman Institute of
      Bioethics, Baltimore, Maryland, USA bscully4@jhmi.edu.
AD  - Cardiac Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20200330
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Apr;46(4):236-241. PMID: 32229595
CIN - J Med Ethics. 2020 Apr;46(4):247-248. PMID: 32229594
MH  - Bias
MH  - Female
MH  - Humans
MH  - Male
MH  - *Sexism
MH  - *Surgeons
OTO - NOTNLM
OT  - *ethics
OT  - *sexuality/gender
OT  - *surgery
OT  - *women
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/02/13 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - medethics-2020-106066 [pii]
AID - 10.1136/medethics-2020-106066 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Apr;46(4):244-245. doi: 10.1136/medethics-2020-106066. Epub
      2020 Mar 30.


PMID- 32229592
OWN - NLM
STAT- MEDLINE
DCOM- 20200828
LR  - 20200828
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 4
DP  - 2020 Apr
TI  - Implicit bias, women surgeons and institutional solutions: commentary.
PG  - 246
LID - 10.1136/medethics-2020-106158 [doi]
FAU - Brennan, Samantha
AU  - Brennan S
AD  - Philosophy, University of Guelph College of Arts, Guelph, Ontario, Canada
      samantha.brennan@uoguelph.ca.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200330
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
CON - J Med Ethics. 2020 Apr;46(4):236-241. PMID: 32229595
CIN - J Med Ethics. 2020 Apr;46(4):247-248. PMID: 32229594
MH  - Ethicists
MH  - Ethics Committees, Clinical
MH  - Female
MH  - Humans
MH  - Male
MH  - *Sexism
MH  - *Surgeons
OTO - NOTNLM
OT  - *ethics committees/consultation
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2020/08/29 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/08/29 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - medethics-2020-106158 [pii]
AID - 10.1136/medethics-2020-106158 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Apr;46(4):246. doi: 10.1136/medethics-2020-106158. Epub 2020
      Mar 30.


PMID- 32229591
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 6
DP  - 2020 Jun
TI  - Technological moral enhancement or traditional moral progress? Why not both?
PG  - 405-411
LID - 10.1136/medethics-2019-105915 [doi]
AB  - A new argument has been made against moral enhancement by authors who are
      otherwise in favour of human enhancement. Additionally, they share the same
      evolutionary toolkit for analysing human traits as well as the belief that our
      current morality is unfit to deal with modern problems, such as climate change
      and nuclear proliferation. The argument is put forward by Buchanan and Powell and
      states that other paths to moral progress are enough to deal with these problems.
      Given the likely costs and risks involved with developing moral enhancement, this
      argument implies moral enhancement is an unpromising enterprise. After mentioning
      proposed solutions to such modern problems, I will argue that moral enhancement
      would help implement any of them. I will then detail Buchanan and Powell's new
      argument disfavouring moral enhancement and argue that it makes too bold
      assumptions about the efficacy of traditional moral progress. For instance, it
      overlooks how that progress was to achieve even in relatively successful cases
      such as the abolition of slavery. Traditional moral progress is likely to require
      assistance from non-traditional means in order to face new challenges.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Fabiano, Joao
AU  - Fabiano J
AUID- ORCID: 0000-0002-4569-7353
AD  - Department of Philosophy, University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil
      jlafabiano@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - *Dissent and Disputes
MH  - Humans
MH  - *Morals
OTO - NOTNLM
OT  - *applied and professional ethics
OT  - *enhancement
OT  - *philosophical ethics
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/04/02 06:00
PHST- 2019/10/24 00:00 [received]
PHST- 2020/02/11 00:00 [revised]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - medethics-2019-105915 [pii]
AID - 10.1136/medethics-2019-105915 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jun;46(6):405-411. doi: 10.1136/medethics-2019-105915. Epub
      2020 Mar 30.


PMID- 32229527
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 29
TI  - Postsurgical rehabilitation for adults with low back pain with or without
      radiculopathy who were treated surgically: protocol for a mixed studies
      systematic review.
PG  - e036817
LID - 10.1136/bmjopen-2020-036817 [doi]
AB  - INTRODUCTION: Surgical rates for low back pain (LBP) have been increasing in
      Europe, North America and Asia. Many patients treated surgically will require
      postsurgical rehabilitation. Little is known about the effectiveness of
      postsurgical rehabilitation interventions on health outcomes or about patients'
      experiences with these interventions. OBJECTIVES: To conduct a mixed studies
      systematic review of quantitative and qualitative studies regarding: (1) the
      effectiveness and safety of postsurgical rehabilitation interventions for adults 
      with LBP treated surgically and (2) the experiences of patients, healthcare
      providers, caregivers or others involved with the rehabilitation. METHODS AND
      ANALYSIS: We will search MEDLINE, Embase, PsycINFO, CINAHL, the Index to
      Chiropractic Literature, the Cochrane Controlled Register of Trials and the
      Rehabilitation & Sports Medicine Source for peer-reviewed empirical studies
      published from inception in any language. Studies using quantitative, qualitative
      and mixed methodologies will be included. We will also search reference lists of 
      all eligible articles. Data extraction will include type of presurgical
      pathology, indication for surgery, surgical procedure, how the intervention was
      delivered and by whom, context and setting. We will conduct a quality assessment 
      of each study and consider study quality in our evidence synthesis. We will use a
      sequential approach at the review level to synthesise and integrate data. First, 
      we will synthesise the quantitative and qualitative studies independently,
      conducting a meta-analysis of the quantitative studies if appropriate and
      thematic synthesis of the qualitative studies. Then, we will integrate the
      quantitative and qualitative evidence by juxtaposing the findings in a matrix.
      ETHICS AND DISSEMINATION: Ethical approval is not required for this knowledge
      synthesis. Findings will be disseminated through knowledge translation activities
      including: (1) presentations at national and international conferences and
      scientific meetings; (2) presentations to local and international stakeholders;
      (3) publications in peer-reviewed journals and (4) posts on organisational
      websites. PROSPERO REGISTRATION NUMBER: CRD42019134607.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Cancelliere, Carol
AU  - Cancelliere C
AUID- ORCID: 0000-0003-1883-4970
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada
      carolina.cancelliere@uoit.ca.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
FAU - Wong, Jessica J
AU  - Wong JJ
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
AD  - Epidemiology Division, Dalla Lana School of Public Health, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Yu, Hainan
AU  - Yu H
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
FAU - Nordin, Margareta
AU  - Nordin M
AD  - Department of Orthopedic Surgery and Environmental Medicine, NYU School of
      Medicine, Occupational and Industrial Orthopedic Center, New York University, New
      York, New York, USA.
FAU - Mior, Silvano
AU  - Mior S
AUID- ORCID: 0000-0001-6575-2797
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
AD  - Research, Canadian Memorial Chiropractic College, Toronto, Ontario, Canada.
FAU - Pereira, Paulo
AU  - Pereira P
AD  - Spine Unit, Department of Neurosurgery, Centro Hospitalar Universitario Sao Joao,
      Porto, Portugal.
AD  - Faculty of Medicine, University of Porto, Porto, Portugal.
FAU - Brunton, Ginny
AU  - Brunton G
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - EPPI-Centre, UCL Institute of Education, University College London, London, UK.
FAU - Shearer, Heather
AU  - Shearer H
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Connell, Gaelan
AU  - Connell G
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
AD  - Rehabilitation Sciences, Faculty of Medicine, The University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Verville, Leslie
AU  - Verville L
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
FAU - Taylor-Vaisey, Anne
AU  - Taylor-Vaisey A
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
FAU - Cote, Pierre
AU  - Cote P
AD  - Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada.
AD  - Centre for Disability Prevention and Rehabilitation, Ontario Tech University and 
      Canadian Memorial Chiropractic College, Oshawa, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200329
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - *Low Back Pain/rehabilitation/surgery
MH  - Orthopedic Procedures
MH  - Postoperative Complications
MH  - *Radiculopathy/rehabilitation/surgery
MH  - Systematic Reviews as Topic
PMC - PMC7170616
OTO - NOTNLM
OT  - *low back pain
OT  - *lumbar radiculopathy
OT  - *post-surgical rehabilitation
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2020-036817 [pii]
AID - 10.1136/bmjopen-2020-036817 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 29;10(3):e036817. doi: 10.1136/bmjopen-2020-036817.


PMID- 32229524
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 29
TI  - A protocol for a systematic review and meta-analysis to identify measures of
      breakthrough pain and evaluate their psychometric properties.
PG  - e035541
LID - 10.1136/bmjopen-2019-035541 [doi]
AB  - INTRODUCTION: Breakthrough pain is common in children and adults with cancer and 
      other conditions, including those approaching end-of-life, although it is often
      poorly managed, possibly partly due to a lack of validated assessment tools. This
      review aims to (1) identify all available instruments measuring breakthrough pain
      in infants, children, adolescents or adults and (2) critically appraise, compare 
      and summarise the quality of the psychometric properties of the identified
      instruments using COnsensus-based Standards for the selection of health
      Measurement INstruments (COSMIN) criteria. METHODS AND ANALYSIS: Two searches
      will be carried out between October 2019 and January 2020, one for each aim of
      the review. The Cochrane Library, International Prospective Register of
      Systematic Reviews, Embase, Cumulative Index of Nursing and Allied Health
      Literature, Medical Literature Analysis and Retrieval System Online (MEDLINE),
      PsycINFO, Web of Science Core Collection, Google Scholar, the ProQuest
      Dissertations & Theses Database, Evidence Search and OpenGrey databases will be
      searched from database inception until the date the search is conducted.
      Reference lists of eligible articles will be screened and authors in the field
      contacted. For search 1, articles will be screened by two reviewers by abstract, 
      and full-text where necessary, to identify if a breakthrough pain assessment was 
      used. Search 2 will then be conducted to identify studies evaluating measurement 
      properties of these assessments. Two reviewers will screen articles from search 2
      by title and abstract. All potentially relevant studies will be screened by full 
      text by both reviewers. For search 2, data will be extracted in parallel with the
      quality assessment process, as recommended by COSMIN. Two reviewers will assess
      methodological quality using the COSMIN Risk of Bias checklist and the COSMIN
      updated criteria for good measurement properties. Findings will be summarised
      and, if possible, data will be pooled using meta-analysis. The quality of the
      evidence will be graded and summarised using the Grading of Recommendations,
      Assessment, Development and Evaluations (GRADE) guidelines. ETHICS AND
      DISSEMINATION: Results of this review will be submitted for publication in a peer
      review journal and presented at conferences. PROSPERO REGISTRATION NUMBER:
      CRD42019155583.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Greenfield, Katie
AU  - Greenfield K
AUID- ORCID: 0000-0001-8827-6543
AD  - School of Psychology, University of Southampton, Southampton, Hampshire, UK.
FAU - Holley, Simone
AU  - Holley S
AUID- ORCID: 0000-0003-4631-2862
AD  - School of Psychology, University of Southampton, Southampton, Hampshire, UK.
FAU - Schoth, Daniel Eric
AU  - Schoth DE
AUID- ORCID: 0000-0002-9144-8067
AD  - School of Psychology, University of Southampton, Southampton, Hampshire, UK.
FAU - Bayliss, Julie
AU  - Bayliss J
AD  - The Louis Dundas Centre, Great Ormond Street Hospital for Children NHS Foundation
      Trust, London, UK.
FAU - Anderson, Anna-Karenia
AU  - Anderson AK
AUID- ORCID: 0000-0001-8542-4942
AD  - Paediatric Palliative Care, Royal Marsden Hospital NHS Trust, London, UK.
FAU - Jassal, Satbir
AU  - Jassal S
AD  - Paediatric Palliative Care, Rainbows Hospice for Children and Young People,
      Loughborough, Leicestershire, UK.
FAU - Rajapakse, Dilini
AU  - Rajapakse D
AD  - The Louis Dundas Centre, Great Ormond Street Hospital for Children NHS Foundation
      Trust, London, UK.
FAU - Fraser, Lorna Katharine
AU  - Fraser LK
AUID- ORCID: 0000-0002-1360-4191
AD  - Martin House Research Centre, Department of Health Sciences, University of York, 
      York, UK.
FAU - Mott, Christine
AU  - Mott C
AD  - Paediatric Palliative Care, Hummingbird House Hospice, Brisbane, Queensland,
      Australia.
FAU - Johnson, Margaret
AU  - Johnson M
AD  - Patient & Pubic Representative c/o Public Health and Primary Care, University of 
      Cambridge, Cambridge, UK.
FAU - Wong, Ian
AU  - Wong I
AUID- ORCID: 0000-0001-8242-0014
AD  - School of Pharmacy, University College London, London, UK.
FAU - Howard, Richard
AU  - Howard R
AD  - Department of Anaesthesia and Pain Medicine, Great Ormond Street Hospital for
      Children NHS Foundation Trust, London, UK.
FAU - Harrop, Emily
AU  - Harrop E
AUID- ORCID: 0000-0002-2480-2062
AD  - Paediatric Palliative Care, Helen & Douglas House Hospice, Oxford, UK.
AD  - Paediatric Palliative Care, Oxford University Hospitals NHS Trust, Oxford, UK.
FAU - Liossi, Christina
AU  - Liossi C
AUID- ORCID: 0000-0003-0627-6377
AD  - School of Psychology, University of Southampton, Southampton, Hampshire, UK
      cliossi@soton.ac.uk.
AD  - Department of Anaesthesia and Pain Medicine, Great Ormond Street Hospital for
      Children NHS Foundation Trust, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200329
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Breakthrough Pain/diagnosis/psychology/therapy
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Pain Management
MH  - *Psychometrics
MH  - Systematic Reviews as Topic
PMC - PMC7170606
OTO - NOTNLM
OT  - *cancer pain
OT  - *neurological pain
OT  - *pain management
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035541 [pii]
AID - 10.1136/bmjopen-2019-035541 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 29;10(3):e035541. doi: 10.1136/bmjopen-2019-035541.


PMID- 32229523
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20211006
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 29
TI  - Accelerated partner therapy (APT) partner notification for people with Chlamydia 
      trachomatis: protocol for the Limiting Undetected Sexually Transmitted infections
      to RedUce Morbidity (LUSTRUM) APT cross-over cluster randomised controlled trial.
PG  - e034806
LID - 10.1136/bmjopen-2019-034806 [doi]
AB  - INTRODUCTION: Partner notification (PN) is a process aiming to identify, test and
      treat the sex partners of people (index patients) with sexually transmitted
      infections (STIs). Accelerated partner therapy (APT) is a PN method whereby
      healthcare professionals assess sex partners, by telephone consultation, before
      giving the index patient antibiotics and STI self-sampling kits to deliver to
      their sex partner(s). The Limiting Undetected Sexually Transmitted infections to 
      RedUce Morbidity programme aims to determine the effectiveness of APT in
      heterosexual women and men with chlamydia and determine whether APT could affect 
      Chlamydia trachomatis transmission at population level. METHODS AND ANALYSIS:
      This protocol describes a cross-over cluster randomised controlled trial of APT, 
      offered as an additional PN method, compared with standard PN. The trial is
      accompanied by an economic evaluation, transmission dynamic modelling and a
      qualitative process evaluation involving patients, partners and healthcare
      professionals. Clusters are 17 sexual health clinics in areas of England and
      Scotland with contrasting patient demographics. We will recruit 5440 heterosexual
      women and men with chlamydia, aged >/=16 years.The primary outcome is the
      proportion of index patients testing positive for C. trachomatis 12-16 weeks
      after the PN consultation. Secondary outcomes include: proportion of sex partners
      treated; cost effectiveness; model-predicted chlamydia prevalence; experiences of
      APT.The primary outcome analysis will be by intention-to-treat, fitting random
      effects logistic regression models that account for clustering of index patients 
      within clinics and trial periods. The transmission dynamic model will be used to 
      predict change in chlamydia prevalence following APT. The economic evaluation
      will use mathematical modelling outputs, taking a health service perspective.
      Qualitative data will be analysed using interpretative phenomenological analysis 
      and framework analysis. ETHICS AND DISSEMINATION: This protocol received ethical 
      approval from London-Chelsea Research Ethics Committee (18/LO/0773). Findings
      will be published with open access licences. TRIAL REGISTRATION NUMBER:
      ISRCTN15996256.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Estcourt, Claudia S
AU  - Estcourt CS
AUID- ORCID: 0000-0001-5523-5630
AD  - School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
      claudia.estcourt@gcu.ac.uk.
FAU - Howarth, Alison R
AU  - Howarth AR
AD  - Institute for Global Health, UCL, London, UK.
FAU - Copas, Andrew
AU  - Copas A
AD  - Institute for Global Health, UCL, London, UK.
FAU - Low, Nicola
AU  - Low N
AUID- ORCID: 0000-0003-4817-8986
AD  - Institute of Social and Preventive Medicine, University of Bern, Bern,
      Switzerland.
FAU - Mapp, Fiona
AU  - Mapp F
AUID- ORCID: 0000-0003-0733-6036
AD  - Institute for Global Health, UCL, London, UK.
FAU - Woode Owusu, Melvina
AU  - Woode Owusu M
AD  - Institute for Global Health, UCL, London, UK.
FAU - Flowers, Paul
AU  - Flowers P
AD  - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
FAU - Roberts, Tracy
AU  - Roberts T
AD  - Health Economics Unit, University of Birmingham, Birmingham, UK.
FAU - Mercer, Catherine H
AU  - Mercer CH
AD  - Institute for Global Health, UCL, London, UK.
FAU - Wayal, Sonali
AU  - Wayal S
AD  - Institute for Global Health, UCL, London, UK.
AD  - Development Media International CIC, London, Greater London, UK.
FAU - Symonds, Merle
AU  - Symonds M
AD  - Western Sussex Hospitals NHS Foundation Trust, Worthing, West Sussex, UK.
FAU - Nandwani, Rak
AU  - Nandwani R
AD  - NHS Greater Glasgow and Clyde, Glasgow, UK.
FAU - Saunders, John
AU  - Saunders J
AD  - Institute for Global Health, UCL, London, UK.
AD  - Public Health England, London, UK.
FAU - Johnson, Anne M
AU  - Johnson AM
AD  - Institute for Global Health, UCL, London, UK.
FAU - Pothoulaki, Maria
AU  - Pothoulaki M
AD  - School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
FAU - Althaus, Christian
AU  - Althaus C
AD  - Institute of Social and Preventive Medicine, University of Bern, Bern,
      Switzerland.
FAU - Pickering, Karen
AU  - Pickering K
AD  - Health Economics Unit, University of Birmingham, Birmingham, UK.
FAU - McKinnon, Tamsin
AU  - McKinnon T
AD  - Institute for Global Health, UCL, London, UK.
FAU - Brice, Susannah
AU  - Brice S
AD  - All East Sexual Health, Barts Health NHS Trust, London, UK.
FAU - Comer, Alex
AU  - Comer A
AD  - All East Sexual Health, Barts Health NHS Trust, London, UK.
FAU - Tostevin, Anna
AU  - Tostevin A
AD  - Institute for Global Health, UCL, London, UK.
FAU - Ogwulu, Chidubem Duby
AU  - Ogwulu CD
AD  - Health Economics Unit, University of Birmingham, Birmingham, UK.
FAU - Vojt, Gabriele
AU  - Vojt G
AD  - School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
FAU - Cassell, Jackie A
AU  - Cassell JA
AUID- ORCID: 0000-0003-0777-0385
AD  - Brighton and Sussex Medical School, East Sussex, UK.
LA  - eng
SI  - ISRCTN/ISRCTN15996256
GR  - RP-PG-0614-20009/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200329
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Chlamydia Infections/drug therapy/prevention & control/transmission
MH  - Chlamydia trachomatis
MH  - *Contact Tracing
MH  - Cross-Over Studies
MH  - England
MH  - Female
MH  - Humans
MH  - Male
MH  - Randomized Controlled Trials as Topic
MH  - Scotland
MH  - Sexual Partners
MH  - Sexually Transmitted Diseases/*prevention & control
MH  - *Time-to-Treatment
MH  - Young Adult
PMC - PMC7170609
OTO - NOTNLM
OT  - *RCT
OT  - *STIs
OT  - *accelerated partner therapy
OT  - *chlamydia
OT  - *partner notification
OT  - *transmission
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034806 [pii]
AID - 10.1136/bmjopen-2019-034806 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 29;10(3):e034806. doi: 10.1136/bmjopen-2019-034806.


PMID- 32229522
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 29
TI  - Systematic review and network meta-analysis with individual participant data on
      cord management at preterm birth (iCOMP): study protocol.
PG  - e034595
LID - 10.1136/bmjopen-2019-034595 [doi]
AB  - INTRODUCTION: Timing of cord clamping and other cord management strategies may
      improve outcomes at preterm birth. However, it is unclear whether benefits apply 
      to all preterm subgroups. Previous and current trials compare various policies,
      including time-based or physiology-based deferred cord clamping, and cord
      milking. Individual participant data (IPD) enable exploration of different
      strategies within subgroups. Network meta-analysis (NMA) enables comparison and
      ranking of all available interventions using a combination of direct and indirect
      comparisons. OBJECTIVES: (1) To evaluate the effectiveness of cord management
      strategies for preterm infants on neonatal mortality and morbidity overall and
      for different participant characteristics using IPD meta-analysis. (2) To
      evaluate and rank the effect of different cord management strategies for preterm 
      births on mortality and other key outcomes using NMA. METHODS AND ANALYSIS:
      Systematic searches of Medline, Embase, clinical trial registries, and other
      sources for all ongoing and completed randomised controlled trials comparing cord
      management strategies at preterm birth (before 37 weeks' gestation) have been
      completed up to 13 February 2019, but will be updated regularly to include
      additional trials. IPD will be sought for all trials; aggregate summary data will
      be included where IPD are unavailable. First, deferred clamping and cord milking 
      will be compared with immediate clamping in pairwise IPD meta-analyses. The
      primary outcome will be death prior to hospital discharge. Effect differences
      will be explored for prespecified participant subgroups. Second, all identified
      cord management strategies will be compared and ranked in an IPD NMA for the
      primary outcome and the key secondary outcomes. Treatment effect differences by
      participant characteristics will be identified. Inconsistency and heterogeneity
      will be explored. ETHICS AND DISSEMINATION: Ethics approval for this project has 
      been granted by the University of Sydney Human Research Ethics Committee
      (2018/886). Results will be relevant to clinicians, guideline developers and
      policy-makers, and will be disseminated via publications, presentations and media
      releases. REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry
      (ANZCTR) (ACTRN12619001305112) and International Prospective Register of
      Systematic Reviews (PROSPERO, CRD42019136640).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - Seidler, Anna Lene
AU  - Seidler AL
AUID- ORCID: 0000-0002-0027-1623
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, 
      Australia lene.seidler@ctc.usyd.edu.au.
FAU - Duley, Lelia
AU  - Duley L
AD  - Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
FAU - Katheria, Anup C
AU  - Katheria AC
AD  - Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San 
      Diego, California, USA.
FAU - De Paco Matallana, Catalina
AU  - De Paco Matallana C
AD  - Department of Obstetrics and Gynecology, Clinic University Hospital Virgen de la 
      Arrixaca, Murcia, Spain.
FAU - Dempsey, Eugene
AU  - Dempsey E
AD  - Department of Paediatrics and Child Health, Cork University Maternity Hospital,
      Cork, Ireland.
FAU - Rabe, Heike
AU  - Rabe H
AD  - Academic Department of Paediatrics, Brighton and Sussex University Hospitals,
      Brighton, UK.
FAU - Kattwinkel, John
AU  - Kattwinkel J
AD  - Department of Pediatrics and Medicine, University of Virginia, Charlottesville,
      Virginia, USA.
FAU - Mercer, Judith
AU  - Mercer J
AD  - College of Nursing, University of Rhode Island, Kingston, Rhode Island, USA.
FAU - Josephsen, Justin
AU  - Josephsen J
AD  - Department of Pediatrics, St Louis University School of Medicine, St Louis,
      Missouri, USA.
FAU - Fairchild, Karen
AU  - Fairchild K
AD  - Department of Pediatrics and Medicine, University of Virginia, Charlottesville,
      Virginia, USA.
FAU - Andersson, Ola
AU  - Andersson O
AD  - Department of Clinical Sciences Lund, Pediatrics/Neonatology, Skane University
      Hospital, Lund University, Lund, Sweden.
FAU - Hosono, Shigeharu
AU  - Hosono S
AD  - Department of Perinatal and Neonatal Medicine, Jichi Medical University Saitama
      Medical Center, Saitama, Japan.
FAU - Sundaram, Venkataseshan
AU  - Sundaram V
AUID- ORCID: 0000-0002-3135-8115
AD  - Newborn Unit, Department of Pediatrics, Postgraduate Institute of Medical
      Education and Research, Chandigarh, India.
FAU - Datta, Vikram
AU  - Datta V
AD  - Department of Neonatology, Lady Hardinge Medical College, New Delhi, India.
FAU - El-Naggar, Walid
AU  - El-Naggar W
AD  - Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Tarnow-Mordi, William
AU  - Tarnow-Mordi W
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Debray, Thomas
AU  - Debray T
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Hooper, Stuart B
AU  - Hooper SB
AD  - The Ritchie Centre, Obstetrics & Gynaecology, Monash University, Clayton,
      Victoria, Australia.
FAU - Kluckow, Martin
AU  - Kluckow M
AD  - Department of Neonatology, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Polglase, Graeme
AU  - Polglase G
AD  - The Ritchie Centre, Obstetrics & Gynaecology, Monash University, Clayton,
      Victoria, Australia.
FAU - Davis, Peter G
AU  - Davis PG
AUID- ORCID: 0000-0001-6742-7314
AD  - Newborn Research Centre, The Royal Women's Hospital, Melbourne, Victoria,
      Australia.
FAU - Montgomery, Alan
AU  - Montgomery A
AD  - Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
FAU - Hunter, Kylie E
AU  - Hunter KE
AUID- ORCID: 0000-0002-2796-9220
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Barba, Angie
AU  - Barba A
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Simes, John
AU  - Simes J
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Askie, Lisa
AU  - Askie L
AD  - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, 
      Australia.
CN  - iCOMP Collaboration
LA  - eng
SI  - ANZCTR/ACTRN12619001305112
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200329
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Constriction
MH  - Delivery, Obstetric
MH  - Female
MH  - Fetal Blood/*physiology
MH  - Humans
MH  - Infant, Newborn
MH  - Meta-Analysis as Topic
MH  - Network Meta-Analysis
MH  - Placenta/physiology
MH  - Pregnancy
MH  - *Premature Birth
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Umbilical Cord/*physiology
PMC - PMC7170588
OTO - NOTNLM
OT  - *individual participant data meta-analysis
OT  - *network meta-analysis
OT  - *placental transfusion
OT  - *preterm birth
OT  - *prospective meta-analysis
OT  - *umbilical cord clamping
OT  - *umbilical cord milking
COIS- Competing interests: LD, ACK, CDPM, ED, HR, JK, JM, JJ, KF, OA, SH, VS, VD, WE-N 
      and WT-M are Chief Investigators for potentially eligible trials.
IR  - Tan-Koay AG
FIR - Tan-Koay, Ava Grace
IR  - Kugelman A
FIR - Kugelman, Amir
IR  - George A
FIR - George, Anu
IR  - Sachdeva A
FIR - Sachdeva, Anu
IR  - Pas AT
FIR - Pas, Arjan Te
IR  - K C A
FIR - K C, Ashish
IR  - Kumar B
FIR - Kumar, Bimlesh
IR  - Backes C
FIR - Backes, Carl
IR  - Tanprasertkul C
FIR - Tanprasertkul, Chamnan
IR  - Ruangkit C
FIR - Ruangkit, Chayatat
IR  - Ram Mohan G
FIR - Ram Mohan, G
IR  - Gyte G
FIR - Gyte, Gillian
IR  - Carroli G
FIR - Carroli, Guillermo
IR  - Al-Wassia H
FIR - Al-Wassia, Heidi
IR  - Atia H
FIR - Atia, Hytham
IR  - Nour I
FIR - Nour, Islam
IR  - Liu J
FIR - Liu, Jiangqin
IR  - Bauer J
FIR - Bauer, John
IR  - Murphy K
FIR - Murphy, Kellie
IR  - Robledo K
FIR - Robledo, Kristy
IR  - Dhaliwal L
FIR - Dhaliwal, Lakhbir
IR  - Perretta L
FIR - Perretta, Laura
IR  - Ling L
FIR - Ling, Lin
IR  - Varanattu M
FIR - Varanattu, Manoj
IR  - Goya M
FIR - Goya, Maria
IR  - Meyer M
FIR - Meyer, Michael
IR  - Silahli M
FIR - Silahli, Musa
IR  - Kler N
FIR - Kler, Neelam
IR  - Finer N
FIR - Finer, Neil
IR  - Kamlin O
FIR - Kamlin, Omar
IR  - Giannone P
FIR - Giannone, Peter
IR  - Pongmee P
FIR - Pongmee, Pharuhad
IR  - Panichkul P
FIR - Panichkul, Prisana
IR  - Knol R
FIR - Knol, Ronny
IR  - Kadam S
FIR - Kadam, Sandeep
IR  - Chamnanvanakij S
FIR - Chamnanvanakij, Sangkae
IR  - Badurdeen S
FIR - Badurdeen, Shiraz
IR  - Pratesi S
FIR - Pratesi, Simone
IR  - Ranjit T
FIR - Ranjit, Thomas
IR  - Leal VL
FIR - Leal, Victor Lago
IR  - Carlo W
FIR - Carlo, Waldemar
EDAT- 2020/04/02 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034595 [pii]
AID - 10.1136/bmjopen-2019-034595 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 29;10(3):e034595. doi: 10.1136/bmjopen-2019-034595.


PMID- 32229520
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 29
TI  - Protocol for a randomised trial of an interprofessional team-delivered
      intervention to support surrogate decision-makers in ICUs.
PG  - e033521
LID - 10.1136/bmjopen-2019-033521 [doi]
AB  - INTRODUCTION: Although shortcomings in clinician-family communication and
      decision making for incapacitated, critically ill patients are common, there are 
      few rigorously tested interventions to improve outcomes. In this manuscript, we
      present our methodology for the Pairing Re-engineered Intensive Care Unit Teams
      with Nurse-Driven Emotional support and Relationship Building (PARTNER 2) trial, 
      and discuss design challenges and their resolution. METHODS AND ANALYSIS: This is
      a pragmatic, stepped-wedge, cluster randomised controlled trial comparing the
      PARTNER 2 intervention to usual care among 690 incapacitated, critically ill
      patients and their surrogates in five ICUs in Pennsylvania. Eligible subjects
      will include critically ill patients at high risk of death and/or severe
      long-term functional impairment, their main surrogate decision-maker and their
      clinicians. The PARTNER intervention is delivered by the interprofessional ICU
      team and overseen by 4-6 nurses from each ICU. It involves: (1) advanced
      communication skills training for nurses to deliver support to surrogates
      throughout the ICU stay; (2) deploying a structured family support pathway; (3)
      enacting strategies to foster collaboration between ICU and palliative care
      services and (4) providing intensive implementation support to each ICU to
      incorporate the family support pathway into clinicians' workflow. The primary
      outcome is surrogates' ratings of the quality of communication during the ICU
      stay as assessed by telephone at 6-month follow-up. Prespecified secondary
      outcomes include surrogates' scores on the Hospital Anxiety and Depression Scale,
      the Impact of Event Scale, the modified Patient Perception of Patient Centredness
      scale, the Decision Regret Scale, nurses' scores on the Maslach Burnout
      Inventory, and length of stay during and costs of the index hospitalisation.We
      also discuss key methodological challenges, including determining the optimal
      level of randomisation, using existing staff to deploy the intervention and
      maximising long-term follow-up of participants. ETHICS AND DISSEMINATION: We
      obtained ethics approval through the University of Pittsburgh, Human Research
      Protection Office. The findings will be published in peer-reviewed journals.
      TRIAL REGISTRATION NUMBER: NCT02445937.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lincoln, Taylor
AU  - Lincoln T
AUID- ORCID: 0000-0002-9327-0290
AD  - Department of General Internal Medicine, Section of Palliative Care and Medical
      Ethics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania,
      USA.
FAU - Shields, Anne-Marie
AU  - Shields AM
AD  - Department of Critical Care Medicine, The CRISMA Center, Program on Ethics and
      Decision Making, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Buddadhumaruk, Praewpannarai
AU  - Buddadhumaruk P
AD  - Department of Critical Care Medicine, The CRISMA Center, Program on Ethics and
      Decision Making, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Chang, Chung-Chou H
AU  - Chang CH
AD  - Department of Biostatistics, University of Pittsburgh Graduate School of Public
      Health, Pittsburgh, Pennsylvania, USA.
AD  - Department of Critical Care Medicine, The CRISMA Center, University of Pittsburgh
      School of Medicine, Pittsburgh, Pennsylvania, USA.
FAU - Pike, Francis
AU  - Pike F
AD  - Department of Neuroscience, Ely Lilly and Company, Indianapolis, Indiana, USA.
FAU - Chen, Hsiangyu
AU  - Chen H
AD  - Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
      Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
FAU - Brown, Elke
AU  - Brown E
AD  - Department of Critical Care Medicine, The CRISMA Center, Program on Ethics and
      Decision Making, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Kozar, Veronica
AU  - Kozar V
AD  - Department of Critical Care Medicine, The CRISMA Center, Program on Ethics and
      Decision Making, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Pidro, Caroline
AU  - Pidro C
AD  - Department of Critical Care Medicine, The CRISMA Center, University of Pittsburgh
      School of Medicine, Pittsburgh, Pennsylvania, USA.
FAU - Kahn, Jeremy M
AU  - Kahn JM
AD  - Department of Critical Care Medicine, The CRISMA Center, University of Pittsburgh
      School of Medicine, Pittsburgh, Pennsylvania, USA.
FAU - Darby, Joseph M
AU  - Darby JM
AD  - Department of Critical Care Medicine, The CRISMA Center, University of Pittsburgh
      School of Medicine, Pittsburgh, Pennsylvania, USA.
AD  - ICU Service Center, UPMC Health System, Pittsburgh, Pennsylvania, USA.
FAU - Martin, Susan
AU  - Martin S
AD  - Donald Wolff Center for Quality Improvement and Innovation, UPMC Health System,
      Pittsburgh, Pennsylvania, USA.
FAU - Angus, Derek C
AU  - Angus DC
AD  - Department of Critical Care Medicine, The CRISMA Center, University of Pittsburgh
      School of Medicine, Pittsburgh, Pennsylvania, USA.
AD  - ICU Service Center, UPMC Health System, Pittsburgh, Pennsylvania, USA.
FAU - Arnold, Robert M
AU  - Arnold RM
AD  - Department of General Internal Medicine, Section of Palliative Care and Medical
      Ethics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania,
      USA.
AD  - Palliative Support Institute, UPMC Health System, Pittsburgh, Pennsylvania, USA.
FAU - White, Douglas B
AU  - White DB
AD  - Department of Critical Care Medicine, The CRISMA Center, Program on Ethics and
      Decision Making, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA douglas.white@pitt.edu.
AD  - ICU Service Center, UPMC Health System, Pittsburgh, Pennsylvania, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02445937
GR  - K24 HL148314/HL/NHLBI NIH HHS/United States
GR  - R01 NR014663/NR/NINR NIH HHS/United States
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200329
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Communication
MH  - Critical Illness/*therapy
MH  - *Decision Making
MH  - Humans
MH  - *Intensive Care Units
MH  - Multicenter Studies as Topic
MH  - *Nurses
MH  - Pennsylvania
MH  - Professional-Family Relations
MH  - *Proxy
MH  - Randomized Controlled Trials as Topic
PMC - PMC7170558
OTO - NOTNLM
OT  - *adult intensive & critical care
OT  - *adult palliative care
OT  - *clinical trials
OT  - *communication
OT  - *nursing
OT  - *statistics and research methods
COIS- Competing interests: None declared.
EDAT- 2020/04/02 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2019-033521 [pii]
AID - 10.1136/bmjopen-2019-033521 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 29;10(3):e033521. doi: 10.1136/bmjopen-2019-033521.


PMID- 32229435
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20210112
IS  - 1440-6047 (Electronic)
IS  - 0964-7058 (Linking)
VI  - 29
IP  - 1
DP  - 2020
TI  - Benefit risk and cost ratios in sustainable food and health policy: Changing and 
      challenging trajectories.
PG  - 1-8
LID - 10.6133/apjcn.202003_29(1).0001 [doi]
AB  - There is benefit, risk and cost in all that we do, but when it comes to food, we 
      expect that it will benefit our health, be available, safe to eat and affordable.
      But as climate change and demographic shifts through displacement and ageing
      gather momentum, the emphases on each of benefit, risk and cost will alter. That 
      we are ecological beings whose health and wellbeing are ecosystem-dependent, must
      now be the underpinning framework for risk management. Loss of natural
      environment and biodiversity represents reduced nutritional and health
      resilience, which will need to be factored in to risk assessment and management
      with climate change. This is proving a problematic risk communication challenge. 
      Previously desirable food and food pattern recommendations will be tempered by
      substantial sustainability, availability, safety, affordability, equity and
      ethical considerations. Future workforces will need to ensure basic livelihoods
      (food, water, shelter, clothing, healthcare, education, communication, essential 
      transport, resource management and effective governance) and with risk
      minimisation. Cost appraisal will have less to do with monetisation and more to
      do with resource management in accordance with equity and ethical principles.
      Communities could adopt Liveability Units (LU) for traceability and
      community-based transactions, as a currency for a more sustainable future,
      encouraging and enabling food and health system viability. Open source food and
      health systems, supported by LU matrix (bar code or QR) scanning with smartphones
      could be widely available for individual, household and community benefit, risk
      and cost management. The risk is remoteness from food's origins and megadata
      commercialisation.
FAU - Wahlqvist, Mark L
AU  - Wahlqvist ML
AD  - Monash Asia institute, Monash University, Melbourne, Australia. Email:
      mark.wahlqvist@wgmail.com.
AD  - Institute for Population Health Sciences, National Health Research Institutes,
      Miaoli County, Taiwan, ROC.
AD  - Department of Nutrition, China Medical University, Taichung, Taiwan, ROC.
AD  - School of Public Health, National Defense Medical Center, Taiwan, ROC.
AD  - Institute of Nutrition and Health, Qingdao University, Qingdao, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Asia Pac J Clin Nutr
JT  - Asia Pacific journal of clinical nutrition
JID - 9440304
SB  - IM
MH  - Climate Change/*economics
MH  - Demography
MH  - Diet/trends
MH  - Food Supply/*economics
MH  - Health Policy/*economics/trends
MH  - Humans
MH  - Risk Assessment/economics
EDAT- 2020/04/02 06:00
MHDA- 2021/01/13 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
AID - 10.6133/apjcn.202003_29(1).0001 [doi]
PST - ppublish
SO  - Asia Pac J Clin Nutr. 2020;29(1):1-8. doi: 10.6133/apjcn.202003_29(1).0001.


PMID- 32229141
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20210308
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
VI  - 140
IP  - 8
DP  - 2020 Aug
TI  - Artificial Intelligence in Dermatology: A Primer.
PG  - 1504-1512
LID - S0022-202X(20)31201-X [pii]
LID - 10.1016/j.jid.2020.02.026 [doi]
AB  - Artificial intelligence is becoming increasingly important in dermatology, with
      studies reporting accuracy matching or exceeding dermatologists for the diagnosis
      of skin lesions from clinical and dermoscopic images. However, real-world
      clinical validation is currently lacking. We review dermatological applications
      of deep learning, the leading artificial intelligence technology for image
      analysis, and discuss its current capabilities, potential failure modes, and
      challenges surrounding performance assessment and interpretability. We address
      the following three primary applications: (i) teledermatology, including triage
      for referral to dermatologists; (ii) augmenting clinical assessment during
      face-to-face visits; and (iii) dermatopathology. We discuss equity and ethical
      issues related to future clinical adoption and recommend specific standardization
      of metrics for reporting model performance.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Young, Albert T
AU  - Young AT
AD  - Department of Dermatology, University of California, San Francisco, San
      Francisco, California, USA; Dermatology Service, San Francisco Veterans Affairs
      Medical Center, San Francisco, California, USA.
FAU - Xiong, Mulin
AU  - Xiong M
AD  - Michigan State University College of Human Medicine, East Lansing, Michigan, USA.
FAU - Pfau, Jacob
AU  - Pfau J
AD  - Department of Dermatology, University of California, San Francisco, San
      Francisco, California, USA; Dermatology Service, San Francisco Veterans Affairs
      Medical Center, San Francisco, California, USA.
FAU - Keiser, Michael J
AU  - Keiser MJ
AD  - Department of Pharmaceutical Chemistry, Department of Bioengineering and
      Therapeutic Sciences, Institute for Neurodegenerative Diseases, and Bakar
      Computational Health Sciences Institute, University of California, San Francisco,
      San Francisco, California, USA.
FAU - Wei, Maria L
AU  - Wei ML
AD  - Department of Dermatology, University of California, San Francisco, San
      Francisco, California, USA; Dermatology Service, San Francisco Veterans Affairs
      Medical Center, San Francisco, California, USA; Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco,
      California, USA. Electronic address: maria.wei@ucsf.edu.
LA  - eng
GR  - TL1 TR001871/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200327
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
SB  - IM
MH  - Deep Learning/*ethics
MH  - Dermatology/ethics/*methods
MH  - Humans
MH  - Image Processing, Computer-Assisted/ethics/*methods
MH  - Referral and Consultation
MH  - Skin/*diagnostic imaging/pathology
MH  - Skin Diseases/*diagnosis/pathology
MH  - Telemedicine/ethics/methods
MH  - Triage/ethics/methods
EDAT- 2020/04/02 06:00
MHDA- 2021/03/09 06:00
CRDT- 2020/04/02 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/02/22 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - S0022-202X(20)31201-X [pii]
AID - 10.1016/j.jid.2020.02.026 [doi]
PST - ppublish
SO  - J Invest Dermatol. 2020 Aug;140(8):1504-1512. doi: 10.1016/j.jid.2020.02.026.
      Epub 2020 Mar 27.


PMID- 32228853
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20200930
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 36
IP  - 3
DP  - 2020 Mar
TI  - [Polygenic scores: towards designer babies?]
PG  - 289-291
LID - 10.1051/medsci/2020028 [doi]
AB  - A new company is offering extensive genetic analysis of embryos during an in
      vitro fertilisation procedure, allowing the derivation of polygenic scores for
      several diseases and embryo choice based on these results. Polygenic scores, if
      properly implemented, can indeed have substantial predictive value, and the
      possibility of embryo choice based on these data has become real, raising a
      number of practical and ethical problems. double dagger.
CI  - (c) 2020 medecine/sciences - Inserm.
FAU - Jordan, Bertrand
AU  - Jordan B
AD  - UMR 7268 ADES, Aix-Marseille, Universite /EFS/CNRS ; CoReBio PACA, case 901, Parc
      scientifique de Luminy, 13288 Marseille Cedex 09, France.
LA  - fre
PT  - News
TT  - Scores polygeniques : vers l'embryon a la carte ? - Chroniques genomiques.
DEP - 20200331
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
MH  - Choice Behavior
MH  - DNA Mutational Analysis/ethics/methods
MH  - Embryo Research/*ethics
MH  - Fertilization in Vitro/*ethics/methods/trends
MH  - Genetic Engineering/ethics
MH  - Genetic Testing/*ethics/methods/standards
MH  - Humans
MH  - Multifactorial Inheritance/genetics
MH  - Preimplantation Diagnosis/*ethics/*methods/standards
MH  - Research Design
EDAT- 2020/04/02 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1051/medsci/2020028 [doi]
AID - msc200007 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2020 Mar;36(3):289-291. doi: 10.1051/medsci/2020028. Epub 2020
      Mar 31.


PMID- 32228850
OWN - NLM
STAT- MEDLINE
DCOM- 20201001
LR  - 20201001
IS  - 1958-5381 (Electronic)
IS  - 0767-0974 (Linking)
VI  - 36
IP  - 3
DP  - 2020 Mar
TI  - [Legal and ethical considerations for the use of biobanks].
PG  - 279-282
LID - 10.1051/medsci/2020042 [doi]
FAU - Messaoudi, Zeineb
AU  - Messaoudi Z
AD  - MSc Biobanks and complex data management, Universite Cote d'Azur, Centre
      hospitalier universitaire de Nice, Hopital Pasteur, Biobanque BB-0033-00025,
      Nice, France.
FAU - Soltani, Nisrine
AU  - Soltani N
AD  - MSc Biobanks and complex data management, Universite Cote d'Azur, Centre
      hospitalier universitaire de Nice, Hopital Pasteur, Biobanque BB-0033-00025,
      Nice, France.
FAU - Arrighi, Nicole
AU  - Arrighi N
AD  - MSc Biobanks and complex data management, Universite Cote d'Azur, Centre
      hospitalier universitaire de Nice, Hopital Pasteur, Biobanque BB-0033-00025,
      Nice, France.
LA  - fre
PT  - News
TT  - Bioethique - L'existence des contraintes legales et reglementaires des
      biobanques.
DEP - 20200331
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
MH  - Biological Specimen Banks/*ethics/*legislation & jurisprudence
MH  - Confidentiality/ethics/legislation & jurisprudence
MH  - Europe
MH  - France
MH  - Government Regulation
MH  - Humans
MH  - Iceland
MH  - Informed Consent/ethics/legislation & jurisprudence
MH  - Legislation as Topic/ethics/standards
MH  - Morals
MH  - Specimen Handling/*ethics/standards
EDAT- 2020/04/02 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1051/medsci/2020042 [doi]
AID - msc200050 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2020 Mar;36(3):279-282. doi: 10.1051/medsci/2020042. Epub 2020
      Mar 31.


PMID- 32228776
OWN - NLM
STAT- MEDLINE
DCOM- 20200901
LR  - 20220316
IS  - 1476-1645 (Electronic)
IS  - 0002-9637 (Linking)
VI  - 103
IP  - 1
DP  - 2020 Jul
TI  - Confronting the Multidimensional Challenges of Research in the Context of
      Emerging Infectious Diseases in Brazil: The Example of Yellow Fever.
PG  - 38-40
LID - 10.4269/ajtmh.19-0559 [doi]
LID - tpmd190559 [pii]
AB  - In the most recent Brazilian yellow fever (YF) outbreak, a group of clinicians
      and researchers initiated in mid-January 2018 a considerable effort to develop a 
      multicenter randomized controlled clinical trial to evaluate the effect of
      sofosbuvir on YF viremia and clinical outcomes (Brazilian Clinical Trials
      Registry: RBR-93dp9n). The approval of this protocol had urgency given the
      seasonal/short-lived pattern of YF transmission, large number of human cases, and
      epidemic transmission at the outskirts of a large urban center. However, many
      intricacies in the research regulatory and ethical submission systems in Brazil
      were indomitable even under such pressing conditions. By April 2018, we had
      enrolled 29 patients for a target sample size of 90 participants. Had enrollment 
      been initiated 3 weeks earlier, an additional 31 patients could have been
      enrolled, reaching the prespecified sample size for the interim analysis. This
      recent experience highlights the urgent need to improve local preparedness for
      research in the setting of explosive outbreaks, as has been seen in the last few 
      years in different countries.
FAU - Avelino-Silva, Vivian I
AU  - Avelino-Silva VI
AD  - 1Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Figueiredo-Mello, Claudia
AU  - Figueiredo-Mello C
AD  - 2Instituto de Infectologia Emilio Ribas, Faculdade de Medicina da Universidade de
      Sao Paulo, Sao Paulo, Brazil.
FAU - Casadio, Luciana V B
AU  - Casadio LVB
AD  - 1Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Nastri, Ana C S S
AU  - Nastri ACSS
AD  - 1Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Marcilio, Izabel
AU  - Marcilio I
AD  - 1Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Ribeiro, Ana F
AU  - Ribeiro AF
AD  - 3Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil.
FAU - Levin, Anna S
AU  - Levin AS
AD  - 4Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de Sao
      Paulo, Sao Paulo, Brazil.
FAU - Sabino, Ester C
AU  - Sabino EC
AD  - 4Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de Sao
      Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - United States
TA  - Am J Trop Med Hyg
JT  - The American journal of tropical medicine and hygiene
JID - 0370507
RN  - 0 (Antiviral Agents)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Aedes/virology
MH  - Animals
MH  - Antiviral Agents/therapeutic use
MH  - Biomedical Research/ethics/*legislation & jurisprudence
MH  - Brazil/epidemiology
MH  - Communicable Diseases, Emerging/drug therapy/*epidemiology/virology
MH  - *Disease Outbreaks
MH  - Government Regulation
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Mosquito Vectors/virology
MH  - Patient Selection/ethics
MH  - Randomized Controlled Trials as Topic/ethics/*legislation & jurisprudence
MH  - Sofosbuvir/therapeutic use
MH  - Viremia/drug therapy/*epidemiology
MH  - Yellow Fever/drug therapy/*epidemiology/virology
MH  - Yellow fever virus/drug effects/*pathogenicity/physiology
PMC - PMC7356477
EDAT- 2020/04/02 06:00
MHDA- 2020/09/02 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/09/02 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.4269/ajtmh.19-0559 [doi]
AID - tpmd190559 [pii]
PST - ppublish
SO  - Am J Trop Med Hyg. 2020 Jul;103(1):38-40. doi: 10.4269/ajtmh.19-0559. Epub 2020
      Mar 26.


PMID- 32228737
OWN - NLM
STAT- MEDLINE
DCOM- 20200421
LR  - 20210919
IS  - 2045-7979 (Electronic)
IS  - 2045-7960 (Linking)
VI  - 29
DP  - 2020 Mar 31
TI  - COVID-19 disease emergency operational instructions for Mental Health Departments
      issued by the Italian Society of Epidemiological Psychiatry.
PG  - e116
LID - 10.1017/S2045796020000372 [doi]
AB  - During the current COVID-19 disease emergency, it is not only an ethical
      imperative but also a public health responsibility to keep the network of
      community psychiatry services operational, particularly for the most vulnerable
      subjects (those with mental illness, disability, and chronic conditions). At the 
      same time, it is necessary to reduce the spread of the COVID-19 disease within
      the outpatient and inpatient services affiliated with Mental Health Departments. 
      These instructions, first published online on 16 March 2020 in their original
      Italian version, provide a detailed description of actions, proposed by the
      Italian Society of Epidemiological Psychiatry, addressed to Italian Mental Health
      Departments during the current COVID-19 pandemic. The overall goal of the
      operational instructions is to guarantee, during the current health emergency,
      the provision of the best health care possible, taking into account both public
      health necessities and the safety of procedures. These instructions could
      represent a useful resource to mental health providers, and stakeholders to face 
      the current pandemic for which most of Mental Health Departments worldwide are
      not prepared to. These instructions could provide guidance and offer practical
      tools which can enable professionals and decision makers to foresee challenges,
      like those already experienced in Italy, which in part can be avoided or
      minimised if timely planned. These strategies can be shared and adopted, with the
      appropriate adjustments, by Mental Health Departments in other countries.
FAU - Starace, Fabrizio
AU  - Starace F
AD  - Department of Mental Health and Drug Abuse, AUSL Modena, Modena, Italy.
AD  - Italian Society of Epidemiological Psychiatry (SIEP), Modena, Italy.
FAU - Ferrara, Maria
AU  - Ferrara M
AUID- ORCID: https://orcid.org/0000-0003-2143-1101
AD  - Department of Psychiatry, Yale University, School of Medicine, New Haven, CT,
      USA.
AD  - Program for Specialized Treatment Early in Psychosis, Connecticut Mental Health
      Center, New Haven, CT, USA.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20200331
PL  - England
TA  - Epidemiol Psychiatr Sci
JT  - Epidemiology and psychiatric sciences
JID - 101561091
SB  - IM
MH  - Ambulatory Care
MH  - Betacoronavirus
MH  - COVID-19
MH  - Community Mental Health Services/*organization & administration
MH  - *Coronavirus Infections/epidemiology/prevention & control
MH  - Emergency Service, Hospital/*organization & administration
MH  - Health Services Research
MH  - Humans
MH  - Italy/epidemiology
MH  - Mental Disorders/therapy
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/prevention & control
MH  - *Practice Guidelines as Topic
MH  - *Psychiatry
MH  - Public Health
MH  - Quality of Health Care
MH  - SARS-CoV-2
MH  - Societies, Medical
PMC - PMC7163186
OTO - NOTNLM
OT  - Community mental health
OT  - emergency psychiatry
OT  - health service research
OT  - mental health
OT  - quality of care
EDAT- 2020/04/02 06:00
MHDA- 2020/04/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/04/22 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1017/S2045796020000372 [doi]
AID - S2045796020000372 [pii]
PST - epublish
SO  - Epidemiol Psychiatr Sci. 2020 Mar 31;29:e116. doi: 10.1017/S2045796020000372.


PMID- 32228716
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 13
IP  - 1
DP  - 2020 Mar 30
TI  - Critical methodological considerations in recruiting and engaging non-native
      English speaking workers with a head injury: a Canadian perspective.
PG  - 184
LID - 10.1186/s13104-020-05028-y [doi]
AB  - OBJECTIVE: Non-native English speaking workers with a mild work-related traumatic
      brain and/or head injury are a vulnerable and underrepresented population in
      research studies. The researchers present their experiences with recruiting and
      performing qualitative interviews with non-native English speaking individuals
      with a work-related mild traumatic brain injury, and provide recommendations on
      how to better include this vulnerable population in future research studies. This
      paper presents considerations regarding ethics, recruitment challenges, interview
      preparation and debriefing, sex & gender and language and cultural issues must be
      made when working with this vulnerable population. RESULTS: The researchers
      discuss critical issues and provide recommendations in recruiting and engaging
      with non-native English language workers including ethics, recruitment
      challenges, interview preparation and debriefing, sex & gender and language, and 
      cultural considerations that must be made when working with this population. The 
      study recommendations advise investigators to spend more time to learn about the 
      non-native English participants in the mild wrTBI context, to be familiar with
      the vulnerabilities and specific circumstances that these workers experience. By 
      increasing their awareness of the challenging facing this vulnerable population, 
      the intention is to provide better care and treatment options through
      evidence-based research and practice.
FAU - Nowrouzi-Kia, B
AU  - Nowrouzi-Kia B
AD  - Centre for Research in Occupational Safety and Health, Laurentian University,
      Sudbury, Canada. behdin@yorku.ca.
AD  - Toronto Rehabilitation Institute-University Health Network, Toronto, Canada.
      behdin@yorku.ca.
AD  - Rehabilitation Science Institute, University of Toronto, Toronto, Canada.
      behdin@yorku.ca.
AD  - Department of Occupational Science and Occupational Therapy, Faculty of Medicine,
      University of Toronto, Toronto, Canada. behdin@yorku.ca.
AD  - School of Nursing, Faculty of Health, York University, Toronto, Canada.
      behdin@yorku.ca.
FAU - Sharma, B
AU  - Sharma B
AD  - Toronto Rehabilitation Institute-University Health Network, Toronto, Canada.
FAU - Lewko, J
AU  - Lewko J
AD  - Centre for Research in Human Development, Laurentian University, Sudbury, Canada.
FAU - Colantonio, A
AU  - Colantonio A
AD  - Rehabilitation Science Institute, University of Toronto, Toronto, Canada.
AD  - Department of Occupational Science and Occupational Therapy, Faculty of Medicine,
      University of Toronto, Toronto, Canada.
LA  - eng
GR  - CGW-126580/Canadian Institutes for Health Research
PT  - Journal Article
DEP - 20200330
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
SB  - IM
MH  - Adult
MH  - *Biomedical Research/ethics/standards
MH  - Canada
MH  - *Craniocerebral Trauma
MH  - Cross-Sectional Studies
MH  - *Cultural Competency
MH  - Female
MH  - Humans
MH  - *Interview, Psychological/methods/standards
MH  - Male
MH  - Middle Aged
MH  - *Occupational Injuries
MH  - Ontario
MH  - *Patient Selection/ethics
MH  - Qualitative Research
MH  - *Researcher-Subject Relations/ethics
MH  - Self Report
MH  - Vulnerable Populations
PMC - PMC7106822
OTO - NOTNLM
OT  - Head injury
OT  - Interviews
OT  - Methodological considerations
OT  - Occupational injury
OT  - Qualitative
OT  - Traumatic brain injury
EDAT- 2020/04/02 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
AID - 10.1186/s13104-020-05028-y [doi]
AID - 10.1186/s13104-020-05028-y [pii]
PST - epublish
SO  - BMC Res Notes. 2020 Mar 30;13(1):184. doi: 10.1186/s13104-020-05028-y.


PMID- 32228611
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Mar 30
TI  - Risk factors for limited improvement after total trapeziometacarpal joint
      arthroplasty.
PG  - 90
LID - 10.1186/s12955-020-01333-z [doi]
AB  - BACKGROUND: Trapeziometacarpal (TMC) osteoarthritis can be painful and cause
      disability for patients. Total joint replacement of the TMC joint provides a
      pseudo arthrosis with good restoration of the thumb motion and pain relief in
      most patients. But there is also a risk of no improvement following the
      operation. The purpose of this study was to identify patients at risk of no
      clinically important improvement following operative treatment of osteoarthritis 
      of the TMC joint. METHODS: We included 287 consecutive patients (225 women, 62
      men) treated with total joint replacement of the TMC joint due to osteoarthritis 
      with a mean age of 58.9 years (range 41-80) in a prospective cohort study. We
      collected information preoperatively and 12 months postoperatively on
      disabilities of the arm, shoulder and hand score (DASH), grip strength and pain
      at rest and activity on a visual analogue scale (VAS). RESULTS: We found a
      statistically significant improvement in DASH from 42.0 to 15.9 (p < 0.001), VAS 
      at rest from 3.5 to 0.6 (p < 0.001), VAS at activity from 7.9 to 2.5 (p < 0.001) 
      and grip strength from 21.6 kg to 27.6 kg (p < 0.001) 12 months after the
      operation, when analysed as a group. There was an increased risk of no clinically
      important improvement in hand function for patients with preoperative high
      preoperative grip strength. Also, we found an increased risk of no clinically
      important improvement in female patients when using VAS as outcome. CONCLUSION:
      However, we were unable to detect one isolated preoperative predictor as
      indicator of successful result after operative treatment of TMC osteoarthritis,
      and as so it was not possible to establish a clinical valid tool for patient
      selection before surgery. Informed consent was obtained from all patients for
      being included in the study. The study needed no approval from The Regional
      Committee of Biomedical Research Ethics as the data was collected, as part of our
      normal pre- and postoperative clinical pathway, but the study is part of an
      outcome study of the results after total joint arthroplasty (TJA) of the TMC
      joint registered in Clinicaltrials.gov (NCT01554748). TRIAL REGISTRATION:
      Clinicaltrials.gov (NCT01554748). Registered 15 March 2012.
FAU - Mosegaard, Sebastian Breddam
AU  - Mosegaard SB
AD  - University Clinic for Hand, Hip and Knee Surgery, Department of Orthopaedics,
      Laegardvej 12, 7500, Holstebro, Denmark. sebmos@rm.dk.
AD  - Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 
      99, Aarhus N, 8200, Denmark. sebmos@rm.dk.
FAU - Stilling, Maiken
AU  - Stilling M
AD  - University Clinic for Hand, Hip and Knee Surgery, Department of Orthopaedics,
      Laegardvej 12, 7500, Holstebro, Denmark.
AD  - Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 
      99, Aarhus N, 8200, Denmark.
FAU - Hansen, Torben Baek
AU  - Hansen TB
AD  - University Clinic for Hand, Hip and Knee Surgery, Department of Orthopaedics,
      Laegardvej 12, 7500, Holstebro, Denmark.
AD  - Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 
      99, Aarhus N, 8200, Denmark.
LA  - eng
SI  - ClinicalTrials.gov/NCT01554748
PT  - Journal Article
DEP - 20200330
PL  - England
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arthroplasty, Replacement, Finger/*psychology
MH  - Carpometacarpal Joints/*surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/psychology/*surgery
MH  - Prospective Studies
MH  - Quality of Life
MH  - Risk Factors
MH  - Sex Factors
MH  - Thumb/*surgery
MH  - *Treatment Failure
PMC - PMC7106898
OTO - NOTNLM
OT  - Functionality
OT  - Osteoarthritis
OT  - Postoperative improvement
OT  - Risk factors
OT  - Total joint replacement
OT  - Trapeziometacarpal joint
EDAT- 2020/04/02 06:00
MHDA- 2020/07/23 06:00
CRDT- 2020/04/02 06:00
PHST- 2018/12/17 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
AID - 10.1186/s12955-020-01333-z [doi]
AID - 10.1186/s12955-020-01333-z [pii]
PST - epublish
SO  - Health Qual Life Outcomes. 2020 Mar 30;18(1):90. doi: 10.1186/s12955-020-01333-z.


PMID- 32228388
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Anthropomorphism in AI.
PG  - 88-95
LID - 10.1080/21507740.2020.1740350 [doi]
AB  - AI research is growing rapidly raising various ethical issues related to safety, 
      risks, and other effects widely discussed in the literature. We believe that in
      order to adequately address those issues and engage in a productive normative
      discussion it is necessary to examine key concepts and categories. One such
      category is anthropomorphism. It is a well-known fact that AI's functionalities
      and innovations are often anthropomorphized (i.e., described and conceived as
      characterized by human traits). The general public's anthropomorphic attitudes
      and some of their ethical consequences (particularly in the context of social
      robots and their interaction with humans) have been widely discussed in the
      literature. However, how anthropomorphism permeates AI research itself (i.e., in 
      the very language of computer scientists, designers, and programmers), and what
      the epistemological and ethical consequences of this might be have received less 
      attention. In this paper we explore this issue. We first set the
      methodological/theoretical stage, making a distinction between a normative and a 
      conceptual approach to the issues. Next, after a brief analysis of
      anthropomorphism and its manifestations in the public, we explore its presence
      within AI research with a particular focus on brain-inspired AI. Finally, on the 
      basis of our analysis, we identify some potential epistemological and ethical
      consequences of the use of anthropomorphic language and discourse within the AI
      research community, thus reinforcing the need of complementing the practical with
      a conceptual analysis.
FAU - Salles, Arleen
AU  - Salles A
AD  - Uppsala University.
AD  - Centro de Investigaciones Filosoficas (CIF).
FAU - Evers, Kathinka
AU  - Evers K
AD  - Uppsala University.
FAU - Farisco, Michele
AU  - Farisco M
AD  - Uppsala University.
AD  - Biogem, Biology and Molecular Genetics Institute.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - *Artificial Intelligence
MH  - *Bioethics
MH  - *Brain
MH  - Humans
OTO - NOTNLM
OT  - *AI
OT  - *anthropomorphism
OT  - *brain
OT  - *conceptual
OT  - *ethics
OT  - *mind
EDAT- 2020/04/02 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1080/21507740.2020.1740350 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Apr-Jun;11(2):88-95. doi: 10.1080/21507740.2020.1740350.


PMID- 32228387
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Artificial Intelligence in Clinical Neuroscience: Methodological and Ethical
      Challenges.
PG  - 77-87
LID - 10.1080/21507740.2020.1740352 [doi]
AB  - Clinical neuroscience is increasingly relying on the collection of large volumes 
      of differently structured data and the use of intelligent algorithms for data
      analytics. In parallel, the ubiquitous collection of unconventional data sources 
      (e.g. mobile health, digital phenotyping, consumer neurotechnology) is increasing
      the variety of data points. Big data analytics and approaches to Artificial
      Intelligence (AI) such as advanced machine learning are showing great potential
      to make sense of these larger and heterogeneous data flows. AI provides great
      opportunities for making new discoveries about the brain, improving current
      preventative and diagnostic models in both neurology and psychiatry and
      developing more effective assistive neurotechnologies. Concurrently, it raises
      many new methodological and ethical challenges. Given their transformative
      nature, it is still largely unclear how AI-driven approaches to the study of the 
      human brain will meet adequate standards of scientific validity and affect
      normative instruments in neuroethics and research ethics. This manuscript
      provides an overview of current AI-driven approaches to clinical neuroscience and
      an assessment of the associated key methodological and ethical challenges. In
      particular, it will discuss what ethical principles are primarily affected by AI 
      approaches to human neuroscience, and what normative safeguards should be
      enforced in this domain.
FAU - Ienca, Marcello
AU  - Ienca M
AUID- ORCID: 0000-0001-8835-5444
AD  - Swiss Federal Institute of Technology, ETH Zurich, Department of Health Sciences 
      and Technology.
FAU - Ignatiadis, Karolina
AU  - Ignatiadis K
AD  - Swiss Federal Institute of Technology, ETH Zurich, Department of Health Sciences 
      and Technology.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - *Big Data
MH  - *Bioethics
MH  - Humans
MH  - Neurosciences/*ethics/*methods
OTO - NOTNLM
OT  - *Accountability
OT  - *artificial intelligence
OT  - *big data
OT  - *discrimination
OT  - *neuroethics
OT  - *neuroprivacy
OT  - *neuroscience
EDAT- 2020/04/02 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1080/21507740.2020.1740352 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Apr-Jun;11(2):77-87. doi: 10.1080/21507740.2020.1740352.


PMID- 32228386
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Deep Fakes and Memory Malleability: False Memories in the Service of Fake News.
PG  - 96-104
LID - 10.1080/21507740.2020.1740351 [doi]
AB  - Deep fakes have rapidly emerged as one of the most ominous concerns within modern
      society. The ability to easily and cheaply generate convincing images, audio, and
      video via artificial intelligence will have repercussions within politics,
      privacy, law, security, and broadly across all of society. In light of the
      widespread apprehension, numerous technological efforts aim to develop tools to
      distinguish between reliable audio/video and the fakes. These tools and
      strategies will be particularly effective for consumers when their guard is
      naturally up, for example during election cycles. However, recent research
      suggests that not only can deep fakes create credible representations of reality,
      but they can also be employed to create false memories. Memory malleability
      research has been around for some time, but it relied on doctored photographs or 
      text to generate fraudulent recollections. These recollected but fake memories
      take advantage of our cognitive miserliness that favors selecting those recalled 
      memories that evoke our preferred weltanschauung. Even responsible consumers can 
      be duped when false but belief-consistent memories, implanted when we are least
      vigilant can, like a Trojan horse, be later elicited at crucial dates to confirm 
      our pre-determined biases and influence us to accomplish nefarious goals. This
      paper seeks to understand the process of how such memories are created, and,
      based on that, proposing ethical and legal guidelines for the legitimate use of
      fake technologies.
FAU - Liv, Nadine
AU  - Liv N
AD  - Interdisciplinary Center Herzliya Israel.
FAU - Greenbaum, Dov
AU  - Greenbaum D
AD  - Interdisciplinary Center Herzliya Israel.
AD  - Zvi Meitar Institute for Legal Implications of Emerging Technologies.
AD  - Yale University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - *Bioethics
MH  - *Deception
MH  - Humans
MH  - *Mass Media
MH  - *Memory
MH  - *Theory of Mind
OTO - NOTNLM
OT  - *Bioethics
OT  - *law
OT  - *media
OT  - *mind-brain
OT  - *morality/ethics
OT  - *theory of mind
EDAT- 2020/04/02 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1080/21507740.2020.1740351 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Apr-Jun;11(2):96-104. doi: 10.1080/21507740.2020.1740351.


PMID- 32228385
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Artificial Intelligence in Service of Human Needs: Pragmatic First Steps Toward
      an Ethics for Semi-Autonomous Agents.
PG  - 120-127
LID - 10.1080/21507740.2020.1740354 [doi]
AB  - The ethics of robots and artificial intelligence (AI) typically centers on
      "giving ethics" to as-yet imaginary AI with human-levels of autonomy in order to 
      protect us from their potentially destructive power. It is often assumed that to 
      do that, we should program AI with the true moral theory (whatever that might
      be), much as we teach morality to our children. This paper argues that the focus 
      on AI with human-level autonomy is misguided. The robots and AI that we have now 
      and in the near future are "semi-autonomous" in that their ability to make
      choices and to act is limited across a number of dimensions. Further, it may be
      morally problematic to create AI with human-level autonomy, even if it becomes
      possible. As such, any useful approach to AI ethics should begin with a theory of
      giving ethics to semi-autonomous agents (SAAs). In this paper, we work toward
      such a theory by evaluating our obligations to and for "natural" SAAs, including 
      nonhuman animals and humans with developing and diminished capacities. Drawing on
      research in neuroscience, bioethics, and philosophy, we identify the ways in
      which AI semi-autonomy differs from semi-autonomy in humans and nonhuman animals.
      We conclude on the basis of these comparisons that when giving ethics to SAAs, we
      should focus on principles and restrictions that protect human interests, but
      that we can only permissibly maintain this approach so long as we do not aim at
      developing technology with human-level autonomy.
FAU - Rieder, Travis N
AU  - Rieder TN
AUID- ORCID: 0000-0002-2919-8634
AD  - Berman Institute of Bioethics, Johns Hopkins University.
FAU - Hutler, Brian
AU  - Hutler B
AUID- ORCID: 0000-0001-6225-8961
AD  - Berman Institute of Bioethics, Johns Hopkins University.
FAU - Mathews, Debra J H
AU  - Mathews DJH
AUID- ORCID: 0000-0002-4897-7617
AD  - Berman Institute of Bioethics, Johns Hopkins University.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - Animals
MH  - Artificial Intelligence/*ethics
MH  - *Bioethics
MH  - Humans
MH  - *Personal Autonomy
MH  - Robotics/ethics
OTO - NOTNLM
OT  - *AI
OT  - *Agency
OT  - *artificial intelligence
OT  - *autonomy
OT  - *machine ethics
OT  - *neuroethics
EDAT- 2020/04/02 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1080/21507740.2020.1740354 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Apr-Jun;11(2):120-127. doi: 10.1080/21507740.2020.1740354.


PMID- 32228384
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - Superethics Instead of Superintelligence: Know Thyself, and Apply Science
      Accordingly.
PG  - 113-119
LID - 10.1080/21507740.2020.1740353 [doi]
AB  - The human species is combining an increased understanding of our cognitive
      machinery with the development of a technology that can profoundly influence our 
      lives and our ways of living together. Our sciences enable us to see our
      strengths and weaknesses, and build technology accordingly. What would future
      historians think of our current attempts to build increasingly smart systems, the
      purposes for which we employ them, the almost unstoppable goldrush toward ever
      more commercially relevant implementations, and the risk of superintelligence? We
      need a more profound reflection on what our science shows us about ourselves,
      what our technology allows us to do with that, and what, apparently, we aim to do
      with those insights and applications. As the smartest species on the planet, we
      don't need more intelligence. Since we appear to possess an underdeveloped
      capacity to act ethically and empathically, we rather require the kind of
      technology that enables us to act more consistently upon ethical principles. The 
      problem is not to formulate ethical rules, it's to put them into practice.
      Cognitive neuroscience and AI provide the knowledge and the tools to develop the 
      moral crutches we so clearly require. Why aren't we building them? We don't need 
      superintelligence, we need superethics.
FAU - Haselager, Pim
AU  - Haselager P
AD  - Radboud University Nijmegen.
FAU - Mecacci, Giulio
AU  - Mecacci G
AD  - Radboud University Nijmegen.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - *Bioethics
MH  - Cognitive Neuroscience/*ethics
MH  - *Empathy
MH  - Humans
OTO - NOTNLM
OT  - *Brain
OT  - *cognition
OT  - *computers
OT  - *empathy
OT  - *morality/ethics
OT  - *superintelligence
EDAT- 2020/04/02 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1080/21507740.2020.1740353 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Apr-Jun;11(2):113-119. doi: 10.1080/21507740.2020.1740353.


PMID- 32228383
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 2150-7759 (Electronic)
IS  - 2150-7759 (Linking)
VI  - 11
IP  - 2
DP  - 2020 Apr-Jun
TI  - "Sorry I Didn't Hear You." The Ethics of Voice Computing and AI in High Risk
      Mental Health Populations.
PG  - 105-112
LID - 10.1080/21507740.2020.1740355 [doi]
AB  - This article examines the ethical and policy implications of using voice
      computing and artificial intelligence to screen for mental health conditions in
      low income and minority populations. Mental health is unequally distributed among
      these groups, which is further exacerbated by increased barriers to psychiatric
      care. Advancements in voice computing and artificial intelligence promise
      increased screening and more sensitive diagnostic assessments. Machine learning
      algorithms have the capacity to identify vocal features that can screen those
      with depression. However, in order to screen for mental health pathology,
      computer algorithms must first be able to account for the fundamental differences
      in vocal characteristics between low income minorities and those who are not.
      While researchers have envisioned this technology as a beneficent tool, this
      technology could be repurposed to scale up discrimination or exploitation.
      Studies on the use of big data and predictive analytics demonstrate that low
      income minority populations already face significant discrimination. This article
      urges researchers developing AI tools for vulnerable populations to consider the 
      full ethical, legal, and social impact of their work. Without a national,
      coherent framework of legal regulations and ethical guidelines to protect
      vulnerable populations, it will be difficult to limit AI applications to solely
      beneficial uses. Without such protections, vulnerable populations will rightfully
      be wary of participating in such studies which also will negatively impact the
      robustness of such tools. Thus, for research involving AI tools like voice
      computing, it is in the research community's interest to demand more guidance and
      regulatory oversight from the federal government.
FAU - Villongco, Christopher
AU  - Villongco C
AD  - Morehouse School of Medicine.
FAU - Khan, Fazal
AU  - Khan F
AD  - University of Georgia School of Law.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJOB Neurosci
JT  - AJOB neuroscience
JID - 101518076
SB  - IM
MH  - Artificial Intelligence/*ethics
MH  - *Bioethics
MH  - Humans
MH  - Mental Disorders/*diagnosis
MH  - *Mentally Ill Persons
MH  - *Minority Groups
MH  - *Poverty
MH  - Speech Recognition Software/*ethics
OTO - NOTNLM
OT  - *Computers
OT  - *mental health
OT  - *psychiatry
OT  - *representations
EDAT- 2020/04/02 06:00
MHDA- 2020/10/22 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
AID - 10.1080/21507740.2020.1740355 [doi]
PST - ppublish
SO  - AJOB Neurosci. 2020 Apr-Jun;11(2):105-112. doi: 10.1080/21507740.2020.1740355.


PMID- 32228373
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20201113
IS  - 1087-2981 (Electronic)
IS  - 1087-2981 (Linking)
VI  - 25
IP  - 1
DP  - 2020 Dec
TI  - Analysing synthesis of evidence in a systematic review in health professions
      education: observations on struggling beyond Kirkpatrick.
PG  - 1731278
LID - 10.1080/10872981.2020.1731278 [doi]
AB  - Background: Systematic reviews in health professions education may well
      under-report struggles to synthesize disparate evidence that defies standard
      quantitative approaches. This paper reports further process analysis in a
      previously reported systematic review about mobile devices on clinical
      placements.Objective: For a troublesome systematic review: (1) Analyse further
      the distribution and reliability of classifying the evidence to Maxwell quality
      dimensions (beyond 'Does it work?') and their overlap with Kirkpatrick K-levels. 
      (2) Analyse how the abstracts represented those dimensions of the evidence-base. 
      (3) Reflect on difficulties in synthesis and merits of Maxwell dimensions.Design:
      Following integrative synthesis of 45 K2-K4 primary studies (by combined
      content-thematic analysis in the pragmatism paradigm): (1) Hierarchical cluster
      analysis explored overlap between Maxwell dimensions and K-levels. Independent
      and consensus-coding to Maxwell dimensions compared (using: percentages; kappa;
      McNemar hypothesis-testing) pre- vs post-discussion and (2) article abstract vs
      main body. (3) Narrative summary captured process difficulties and
      merits.Results: (1) The largest cluster (five-cluster dendrogram) was
      acceptability-accessibility-K1-appropriateness-K3, with K1 and K4 widely
      separated. For article main bodies, independent coding agreed most for
      appropriateness (good; adjusted kappa = 0.78). Evidence increased significantly
      pre-post-discussion about acceptability (p = 0.008; 31/45-->39/45),
      accessibility, and equity-ethics-professionalism. (2) Abstracts suggested
      efficiency significantly less than main bodies evidenced: 31.1% vs 44.4%, p =
      0.031. 3) Challenges and merits emerged for before, during, and after the
      review.Conclusions: There should be more systematic reporting of process analysis
      about difficulties synthesizing suboptimal evidence-bases. In this example,
      Maxwell dimensions were a useful framework beyond K-levels for classifying and
      synthesizing the evidence-base.
FAU - Maudsley, Gillian
AU  - Maudsley G
AD  - Department of Public Health & Policy, The University of Liverpool, Liverpool, UK.
FAU - Taylor, David
AU  - Taylor D
AUID- ORCID: https://orcid.org/0000-0002-3296-2963
AD  - Department of Public Health & Policy, The University of Liverpool, Liverpool, UK.
AD  - Medical Education & Physiology, College of Medicine, Gulf Medical University,
      Ajman, United Arab Emirates.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Educ Online
JT  - Medical education online
JID - 9806550
SB  - IM
MH  - Data Interpretation, Statistical
MH  - Health Occupations/*education
MH  - Humans
MH  - Reproducibility of Results
MH  - Research Design
MH  - *Systematic Reviews as Topic
PMC - PMC7170338
OTO - NOTNLM
OT  - Best evidence
OT  - Kirkpatrick levels
OT  - Maxwell dimensions of quality
OT  - cluster analysis
OT  - epistemology
OT  - evidence synthesis
OT  - evidence-based education
OT  - medical education
OT  - process analysis
OT  - systematic review
EDAT- 2020/04/02 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [entrez]
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
AID - 10.1080/10872981.2020.1731278 [doi]
PST - ppublish
SO  - Med Educ Online. 2020 Dec;25(1):1731278. doi: 10.1080/10872981.2020.1731278.


PMID- 32228242
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 14
IP  - 5
DP  - 2020 May
TI  - Cytomegalovirus and inflammatory bowel disease; reconsidering a 'result or reason
      dilemma' in terms of viral pathogenesis and medical ethics.
PG  - 307-309
LID - 10.1080/17474124.2020.1745631 [doi]
FAU - Arslan, Ferhat
AU  - Arslan F
AD  - Department of Infectious Diseases and Clinical Microbiology, Istanbul Medeniyet
      University , Istanbul, Turkey.
FAU - Vahaboglu, Haluk
AU  - Vahaboglu H
AUID- ORCID: https://orcid.org/0000-0001-8217-1767
AD  - Department of Infectious Diseases and Clinical Microbiology, Istanbul Medeniyet
      University , Istanbul, Turkey.
LA  - eng
PT  - Editorial
PT  - Meta-Analysis
DEP - 20200505
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Antiviral Agents)
RN  - 0 (Glucocorticoids)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - IM
MH  - Antiviral Agents/*adverse effects/therapeutic use
MH  - Colon/pathology/virology
MH  - Cytomegalovirus/*isolation & purification
MH  - Cytomegalovirus Infections/complications/*drug therapy
MH  - *Ethics, Medical
MH  - Ganciclovir/*adverse effects/therapeutic use
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Inflammatory Bowel Diseases/drug therapy/etiology/pathology/*virology
MH  - Intestinal Mucosa/pathology/virology
OTO - NOTNLM
OT  - Cytomegalovirus
OT  - antiviral therapy
OT  - ganciclovir
OT  - inflammatory bowel disease
OT  - ulcerative colitis
EDAT- 2020/04/02 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1080/17474124.2020.1745631 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2020 May;14(5):307-309. doi:
      10.1080/17474124.2020.1745631. Epub 2020 May 5.


PMID- 32228209
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20201008
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - A nurses' ethical commitment to people with intellectual and developmental
      disabilities.
PG  - 1066-1076
LID - 10.1177/0969733019900310 [doi]
AB  - Aim: This article explores the issues of knowledge deficits of healthcare
      professionals in meeting the needs of people with IDD throughout the life span,
      and to identify factors that contribute to these deficits. Although statistics
      vary due to census results and the presence of a "hidden population,"
      approximately 1%-3% of the global population identify as living with an
      intellectual or developmental disability. People with intellectual or
      developmental disability experience health inequities and confront multiple
      barriers in society, often related to the stigma of intellectual or developmental
      disability. Disparities in care and service are attributed to a lack of knowledge
      and understanding among healthcare providers about people with intellectual or
      developmental disability, despite their increased risk for chronic health
      problems. The near absence of educational programs in nursing both nationally and
      internationally contributes to this significant knowledge deficit. In addition,
      ethical considerations between paternalistic beneficence and idealized autonomy
      have resulted in a lack of clear direction in working with a population that is
      often ignored or exploited. Nurses who view people with intellectual or
      developmental disability as vulnerable without assessing or acknowledging their
      capabilities may err toward paternalism in an effort to "first do no harm."
      Likewise, nurses who fail to recognize the challenges and limitations faced by
      people with intellectual or developmental disability may not provide sufficient
      protections for a vulnerable person. People with intellectual or developmental
      disability are not binary, but rather complex individuals with a myriad of
      presentations. This article seeks to encourage a well-informed model of nursing
      care. Through an ethical lens, this article explores the nurse's ethical
      commitments in cases of victimization, access to care, decision making, and the
      provision of optimal end-of-life care for people with intellectual or
      developmental disability.
FAU - Fisher, Kathleen
AU  - Fisher K
AD  - Drexel University, USA.
FAU - Robichaux, Catherine
AU  - Robichaux C
AD  - University of Texas Health Science Center at San Antonio, USA.
FAU - Sauerland, Jeanie
AU  - Sauerland J
AD  - University Health System, USA.
FAU - Stokes, Felicia
AU  - Stokes F
AUID- ORCID: https://orcid.org/0000-0001-7939-3078
AD  - American Nurses Association, USA.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Crime Victims
MH  - Decision Making/ethics
MH  - Developmental Disabilities/*nursing
MH  - *Disabled Persons
MH  - *Ethics, Nursing
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Intellectual Disability/*nursing
MH  - Male
MH  - Patient Advocacy
MH  - Personal Autonomy
MH  - Quality of Life
MH  - Terminal Care
OTO - NOTNLM
OT  - Autism spectrum disorder
OT  - developmental disability
OT  - ethics
OT  - intellectual disability
OT  - nurses
EDAT- 2020/04/02 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1177/0969733019900310 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):1066-1076. doi: 10.1177/0969733019900310. Epub 2020
      Mar 31.


PMID- 32228169
OWN - NLM
STAT- MEDLINE
DCOM- 20210903
LR  - 20210903
IS  - 1461-7471 (Electronic)
IS  - 1363-4615 (Linking)
VI  - 57
IP  - 5
DP  - 2020 Oct
TI  - Being unneeded in post-Soviet Russia: Lessons for an anthropology of loneliness.
PG  - 635-648
LID - 10.1177/1363461520909612 [doi]
AB  - The problem of loneliness is receiving increasing attention in the popular media 
      and among social scientists. Despite anthropology's rich engagement with emotions
      and experience, the anthropology of loneliness is still scant. In psychology,
      loneliness has been defined as relational lack. In this article, I reconsider one
      culturally specific form of relational lack-being unneeded among post-Soviet
      Muscovites. I draw on the anthropological literature on emotion, exchange, and
      morality to suggest that being unneeded is an ethical commentary on a lack of
      recognition. During Soviet times, recognition was secured through informal social
      exchange practices. Being unneeded among middle-aged and elderly post-Soviet
      Muscovites is therefore connected to a constricted ability to give and experience
      recognition. One avenue of analysis for an anthropology of loneliness is to
      consider social exchange practices and how these connect with societal and moral 
      dimensions of loneliness.
FAU - Parsons, Michelle Anne
AU  - Parsons MA
AUID- ORCID: 0000-0003-2858-1014
AD  - Department of Anthropology, Northern Arizona University, Flagstaff, AZ, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200330
PL  - England
TA  - Transcult Psychiatry
JT  - Transcultural psychiatry
JID - 9708119
SB  - IM
MH  - Aged
MH  - *Anthropology
MH  - Humans
MH  - Loneliness/*psychology
MH  - Middle Aged
MH  - Morals
MH  - Recognition, Psychology
MH  - Russia
OTO - NOTNLM
OT  - *Russia
OT  - *loneliness
OT  - *morality
OT  - *recognition
OT  - *unneeded
EDAT- 2020/04/02 06:00
MHDA- 2021/09/04 06:00
CRDT- 2020/04/02 06:00
PHST- 2020/04/02 06:00 [pubmed]
PHST- 2021/09/04 06:00 [medline]
PHST- 2020/04/02 06:00 [entrez]
AID - 10.1177/1363461520909612 [doi]
PST - ppublish
SO  - Transcult Psychiatry. 2020 Oct;57(5):635-648. doi: 10.1177/1363461520909612. Epub
      2020 Mar 30.


PMID- 32227595
OWN - NLM
STAT- MEDLINE
DCOM- 20210222
LR  - 20210414
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 107
IP  - 9
DP  - 2020 Aug
TI  - Surgical ethics during a pandemic: moving into the unknown?
PG  - 1089-1090
LID - 10.1002/bjs.11638 [doi]
FAU - Ives, J
AU  - Ives J
AD  - Centre for Ethics in Medicine, Medical School, University of Bristol, UK.
FAU - Huxtable, R
AU  - Huxtable R
AD  - Centre for Ethics in Medicine, Medical School, University of Bristol, UK.
LA  - eng
PT  - Journal Article
DEP - 20200420
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - IM
CIN - Br J Surg. 2020 Aug;107(9):e324. PMID: 32658319
CIN - Br J Surg. 2021 Jan 27;108(1):e38. PMID: 33640934
CIN - Br J Surg. 2021 Jan 27;108(1):e37. PMID: 33640952
MH  - COVID-19/*complications
MH  - Elective Surgical Procedures/ethics
MH  - Humans
MH  - Surgical Procedures, Operative/*ethics
EDAT- 2020/04/01 06:00
MHDA- 2021/02/23 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/03/30 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/02/23 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1002/bjs.11638 [doi]
PST - ppublish
SO  - Br J Surg. 2020 Aug;107(9):1089-1090. doi: 10.1002/bjs.11638. Epub 2020 Apr 20.


PMID- 32227551
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20210428
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Linking)
VI  - 25
IP  - 6
DP  - 2020 Jun
TI  - Cancer Research Ethics and COVID-19.
PG  - 458-459
LID - 10.1634/theoncologist.2020-0221 [doi]
FAU - Shuman, Andrew G
AU  - Shuman AG
AD  - Center for Bioethics & Social Sciences in Medicine, University of Michigan
      Medical School, Ann Arbor, Michigan, USA.
AD  - Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, 
      USA.
FAU - Pentz, Rebecca D
AU  - Pentz RD
AUID- ORCID: 0000-0003-4338-6663
AD  - Winship Cancer Institute, Emory School of Medicine, Atlanta, Georgia, USA.
LA  - eng
PT  - Editorial
PT  - Comment
DEP - 20200330
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
SB  - IM
CON - Lancet Oncol. 2020 Mar;21(3):335-337. PMID: 32066541
MH  - Betacoronavirus
MH  - COVID-19
MH  - China
MH  - Coronavirus Infections
MH  - Ethics, Research
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - *SARS Virus
MH  - SARS-CoV-2
PMC - PMC7228207
EDAT- 2020/04/01 06:00
MHDA- 2020/06/18 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1634/theoncologist.2020-0221 [doi]
PST - ppublish
SO  - Oncologist. 2020 Jun;25(6):458-459. doi: 10.1634/theoncologist.2020-0221. Epub
      2020 Mar 30.


PMID- 32227461
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20220413
IS  - 1365-2753 (Electronic)
IS  - 1356-1294 (Linking)
VI  - 26
IP  - 2
DP  - 2020 Apr
TI  - Barriers to establishing shared decision-making in childbirth: Unveiling
      epistemic stereotypes about women in labour.
PG  - 515-519
LID - 10.1111/jep.13375 [doi]
AB  - RATIONALE, AIMS, AND OBJECTIVES: The benefits for shared decision-making (SDM) in
      delivery of high-quality and personalized care are undisputed, but what is it
      about the dynamics of the delivery room that leads some to doubt that true SDM is
      possible? How difficult can it be to establish SDM as the norm when caring for a 
      woman in labour? The discussion around SDM, autonomy, and rationality is timely
      and highly relevant to wider practice. METHOD: The concept of a person's autonomy
      in decision-making about their body and health is generally accepted and is
      indeed enshrined in law in many countries. This ought to lay the foundation for
      SDM in obstetrics. Yet, women's experience speaks to an uncomfortable truth,
      namely, that it is far from commonplace. We are interested in exploring this
      tension between the law and the practice. RESULTS: We examine a theory of female 
      rationality and its application to women in labour, and juxtapose this with the
      view from the front line of care delivery. Is a woman in labour able to fully
      engage in an SDM process? In answering this question, associations in the
      discourses and practises around women's capacity during labour are revealed,
      which act as barriers, consciously or unconsciously, to establishing SDM as the
      norm in obstetrics and midwifery. CONCLUSION(S): The recent UN report advocating 
      a human rights-based approach to end mistreatment and violence against women in
      reproductive health services has a particular focus on childbirth and obstetric
      violence. This paper contributes to the recognition of obstetric violence as a
      human rights violation. It offers conceptual tools to diagnose the impact of
      gender stereotypes during childbirth and to eliminate women's discrimination in
      the field of reproductive health.
CI  - (c) 2020 John Wiley & Sons, Ltd.
FAU - Villarmea, Stella
AU  - Villarmea S
AUID- ORCID: https://orcid.org/0000-0001-8575-1839
AD  - Department of Philosophy, University of Oxford, Oxford, UK.
AD  - Department of Philosophy, University of Alcala, Madrid, Spain.
FAU - Kelly, Brenda
AU  - Kelly B
AUID- ORCID: https://orcid.org/0000-0001-6828-5661
AD  - Women's & Reproductive Health, University of Oxford, Oxford, UK.
LA  - eng
GR  - EC-H2020-MSCA-IF-2017/SEP-201456162/Marie S Curie Fellowship
PT  - Journal Article
PL  - England
TA  - J Eval Clin Pract
JT  - Journal of evaluation in clinical practice
JID - 9609066
SB  - IM
MH  - Decision Making
MH  - Decision Making, Shared
MH  - Female
MH  - Humans
MH  - *Labor, Obstetric
MH  - *Midwifery
MH  - *Obstetrics
MH  - Pregnancy
OTO - NOTNLM
OT  - epistemology
OT  - medical ethics
OT  - person-centred medicine
OT  - philosophy of medicine
OT  - value
EDAT- 2020/04/01 06:00
MHDA- 2021/07/29 06:00
CRDT- 2020/04/01 06:00
PHST- 2019/07/06 00:00 [received]
PHST- 2019/12/08 00:00 [revised]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
AID - 10.1111/jep.13375 [doi]
PST - ppublish
SO  - J Eval Clin Pract. 2020 Apr;26(2):515-519. doi: 10.1111/jep.13375.


PMID- 32227362
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1444-0938 (Electronic)
IS  - 0816-4622 (Linking)
VI  - 103
IP  - 6
DP  - 2020 Nov
TI  - Prevalence and seasonal variation of Acanthamoeba in domestic tap water in
      greater Sydney, Australia.
PG  - 782-786
LID - 10.1111/cxo.13065 [doi]
AB  - BACKGROUND: This study examined the prevalence of free-living Acanthamoeba in
      domestic tap water in the greater Sydney region, Australia, and determined any
      seasonal variation in prevalence. METHODS: Fifty-four participants were included 
      in this study following approval from an institutional human research ethics
      committee. Each participant self-collected two samples (one in summer and another
      in winter) from the surface of the drain of the bathroom sink using an
      instructional kit. The samples were cultured by inoculating onto a non-nutrient
      agar plate seeded with Escherichia coli and incubation at 32 degrees C for two
      weeks. The plates were microscopically examined for the presence of free-living
      amoeba. DNA was isolated from 20 samples and a polymerase chain reaction (PCR)
      assay was performed for amplification of the partial sequence of the 18S
      ribosomal RNA gene. The PCR amplified products were sequenced using Sanger
      sequencing and genotyping was performed based on the variation in nucleotide
      sequences. RESULTS: A total of 97 samples were collected over the two collection 
      periods, with 28.6 per cent of samples morphologically classified as
      Acanthamoeba. The summer period yielded 16 of 54 (29.6 per cent) samples
      classified as Acanthamoeba, while the winter period yielded 12 of 43 (27.9 per
      cent) samples classified as Acanthamoeba. There was no statistically significant 
      difference (p = 0.85) between the prevalence of free-living Acanthamoeba in
      summer compared to winter. Phylogenetic analysis showed that 15 of 20 (75 per
      cent) isolates belonged to genotype T4, the most frequent genotype isolated in
      Acanthamoeba keratitis. CONCLUSION: The prevalence of free-living Acanthamoeba
      characterised morphologically in domestic tap water of the greater Sydney region 
      was higher than expected, especially considering the low incidence of
      Acanthamoeba keratitis in Australia. However, this study did not find variation
      between seasons. As the T4 genotype was most common, Sydney-based practitioners
      must always consider Acanthamoeba as a possible causative organism in cases of
      microbial keratitis, regardless of the season.
CI  - (c) 2020 Optometry Australia.
FAU - Carnt, Nicole A
AU  - Carnt NA
AUID- ORCID: 0000-0002-5376-0885
AD  - School of Optometry and Vision Science, The University of New South Wales,
      Sydney, Australia.
AD  - Centre for Vision Research, Westmead Institute for Medical Research, The
      University of Sydney, Sydney, Australia.
AD  - Institute of Ophthalmology, University College London, London, UK.
FAU - Subedi, Dinesh
AU  - Subedi D
AUID- ORCID: 0000-0002-1357-9520
AD  - School of Optometry and Vision Science, The University of New South Wales,
      Sydney, Australia.
FAU - Lim, Ann W
AU  - Lim AW
AD  - School of Optometry and Vision Science, The University of New South Wales,
      Sydney, Australia.
FAU - Lee, Rebecca
AU  - Lee R
AD  - School of Optometry and Vision Science, The University of New South Wales,
      Sydney, Australia.
FAU - Mistry, Priyal
AU  - Mistry P
AD  - School of Optometry and Vision Science, The University of New South Wales,
      Sydney, Australia.
FAU - Badenoch, Paul R
AU  - Badenoch PR
AD  - Department of Ophthalmology, Flinders Medical Centre, Adelaide, Australia.
AD  - College of Medicine and Public Health, Flinders University, Adelaide, Australia.
FAU - Kilvington, Simon
AU  - Kilvington S
AD  - Department of Infection, Immunity and Inflammation, University of Leicester,
      Leicester, UK.
FAU - Dutta, Debarun
AU  - Dutta D
AD  - School of Optometry and Vision Science, The University of New South Wales,
      Sydney, Australia.
AD  - Optometry and Vision Science, Life and Health Sciences, Aston University,
      Birmingham, UK.
LA  - eng
PT  - Journal Article
DEP - 20200329
PL  - United States
TA  - Clin Exp Optom
JT  - Clinical & experimental optometry
JID - 8703442
RN  - 059QF0KO0R (Water)
SB  - IM
MH  - *Acanthamoeba/genetics
MH  - *Acanthamoeba Keratitis
MH  - Humans
MH  - Phylogeny
MH  - Prevalence
MH  - Seasons
MH  - Water
OTO - NOTNLM
OT  - *Acanthamoeba
OT  - *contact lens
OT  - *genotypes
OT  - *keratitis
OT  - *risk factors
EDAT- 2020/04/01 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/04/01 06:00
PHST- 2019/07/09 00:00 [received]
PHST- 2019/11/17 00:00 [revised]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1111/cxo.13065 [doi]
PST - ppublish
SO  - Clin Exp Optom. 2020 Nov;103(6):782-786. doi: 10.1111/cxo.13065. Epub 2020 Mar
      29.


PMID- 32226924
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2573-3370 (Electronic)
IS  - 2573-3370 (Linking)
VI  - 3
IP  - 1
DP  - 2020
TI  - Recent Advances in Systems and Network Medicine: Meeting Report from the First
      International Conference in Systems and Network Medicine.
PG  - 22-35
LID - 10.1089/sysm.2020.0001 [doi]
AB  - The First International Conference in Systems and Network Medicine gathered
      together 200 global thought leaders, scientists, clinicians, academicians,
      industry and government experts, medical and graduate students, postdoctoral
      scholars and policymakers. Held at Georgetown University Conference Center in
      Washington D.C. on September 11-13, 2019, the event featured a day of
      pre-conference lectures and hands-on bioinformatic computational workshops
      followed by two days of deep and diverse scientific talks, panel discussions with
      eminent thought leaders, and scientific poster presentations. Topics ranged from:
      Systems and Network Medicine in Clinical Practice; the role of -omics
      technologies in Health Care; the role of Education and Ethics in Clinical
      Practice, Systems Thinking, and Rare Diseases; and the role of Artificial
      Intelligence in Medicine. The conference served as a unique nexus for
      interdisciplinary discovery and dialogue and fostered formation of new insights
      and possibilities for health care systems advances.
CI  - (c) Emma Kurnat-Thoma et al. 2020 Published by Mary Ann Liebert, Inc.
FAU - Kurnat-Thoma, Emma
AU  - Kurnat-Thoma E
AD  - National Institutes of Health, National Institute of Nursing Research (NIH/NINR),
      Bethesda, Maryland.
AD  - Genetics and Genomics, Georgetown University School of Nursing and Health
      Studies, Washington, District of Columbia.
FAU - Baranova, Ancha
AU  - Baranova A
AD  - The Chronic Metabolic and Rare Diseases Systems Biology Initiative (ChroMe
      RaDSBIn), School of Systems Biology, George Mason University, Fairfax, Virginia.
FAU - Baird, Pat
AU  - Baird P
AD  - Global Software Standards, Philips, Pleasant Prairie, Wisconsin.
FAU - Brodsky, Elia
AU  - Brodsky E
AD  - Pine Biotech, New Orleans, Louisiana.
FAU - Butte, Atul J
AU  - Butte AJ
AD  - Bakar Computational Health Sciences Institute, University of California San
      Francisco (UCSF), San Fransisco, California.
FAU - Cheema, Amrita K
AU  - Cheema AK
AD  - Department of Biochemistry, Molecular and Cellular Biology, Georgetown University
      Medical Center, Washington, District of Columbia.
FAU - Cheng, Feixiong
AU  - Cheng F
AD  - Cleveland Clinic Lerner College of Medicine, Case Western Reserve University,
      Cleveland Clinic, Cleveland, Ohio.
FAU - Dutta, Shuchismita
AU  - Dutta S
AD  - Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB)
      and Institute for Quantitative Biomedicine, Rutgers University, The State
      University of New Jersey, Piscataway, New Jersey.
FAU - Grant, Christina
AU  - Grant C
AD  - Rare Disease Institute, Division of Genetics and Metabolism, Children's National 
      Medical Center, Washington, District of Columbia.
FAU - Giordano, James
AU  - Giordano J
AD  - Department of Neurology, Neuroethics Studies Program-Pellegrino Center for
      Clinical Bioethics, and O'Neill-Pellegrino Program in Brain Sciences and Global
      Law and Policy, Georgetown University Medical Center, Washington, District of
      Columbia.
AD  - Department of Biochemistry, Neuroethics Studies Program-Pellegrino Center for
      Clinical Bioethics, and O'Neill-Pellegrino Program in Brain Sciences and Global
      Law and Policy, Georgetown University Medical Center, Washington, District of
      Columbia.
FAU - Maitland-van der Zee, Anke H
AU  - Maitland-van der Zee AH
AD  - Department of Respiratory Medicine, Amsterdam University Medical Centers,
      University of Amsterdam, Amsterdam, The Netherlands.
FAU - Fridsma, Douglas B
AU  - Fridsma DB
AD  - American Medical Informatics Association, Washington, District of Columbia.
FAU - Jarrin, Robert
AU  - Jarrin R
AD  - Department of Biochemistry, Molecular and Cellular Biology, Georgetown University
      Medical Center, Washington, District of Columbia.
FAU - Kann, Maricel G
AU  - Kann MG
AD  - Department of Biological Sciences, University of Maryland Baltimore County,
      Baltimore, Maryland.
FAU - Keeney, Jonathon
AU  - Keeney J
AD  - Department of Biochemistry and Molecular Medicine, George Washington University, 
      Washington, District of Columbia.
FAU - Loscalzo, Joseph
AU  - Loscalzo J
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, Massachusetts.
FAU - Madhavan, Guru
AU  - Madhavan G
AD  - National Academy of Engineering, The National Academies of Sciences, Engineering,
      and Medicine, Washington, District of Columbia.
FAU - Maron, Bradley A
AU  - Maron BA
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, Massachusetts.
FAU - McBride, Dennis K
AU  - McBride DK
AD  - Center for Advanced Healthcare Learning and Simulation (CAHLS), Washington,
      District of Columbia.
FAU - McKean, Maeve
AU  - McKean M
AD  - Georgetown University Global Health Initiative, Georgetown University Medical
      Center, Washington, District of Columbia.
FAU - Mun, Seong K
AU  - Mun SK
AD  - Arlington Innovation Center, Health Research, Virginia Tech, Arlington, Virginia.
FAU - Palmer, James C
AU  - Palmer JC
AD  - Caldwell Palmer, Denver, Colorado.
FAU - Patel, Bakul
AU  - Patel B
AD  - Center for Devices and Radiological Health, Food and Drug Administration, White
      Oak, Maryland.
FAU - Parakh, Kapil
AU  - Parakh K
AD  - Yale School of Medicine, New Haven, Connecticut.
FAU - Pariser, Anne R
AU  - Pariser AR
AD  - National Institutes of Health, National Center for Advancing Translational
      Sciences (NIH/NCATS), Bethesda, Maryland.
FAU - Pristipino, Christian
AU  - Pristipino C
AD  - Interventional Cardiology Unit, San Filippo Neri ASL Roma 1 Hospital, Rome,
      Italy.
AD  - Italian Association for Systems Medicine and Healthcare (ASSIMSS), Rome, Italy.
FAU - Radstake, Timothy R D J
AU  - Radstake TRDJ
AD  - Department of Rheumatology, Clinical Immunology and Center of Translational
      Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Rajasimha, Harsha K
AU  - Rajasimha HK
AD  - The Chronic Metabolic and Rare Diseases Systems Biology Initiative (ChroMe
      RaDSBIn), School of Systems Biology, George Mason University, Fairfax, Virginia.
AD  - Jeeva Informatics Solutions, Inc., Reston, Virginia.
FAU - Rouse, William B
AU  - Rouse WB
AD  - McCourt School of Public Policy, Georgetown University, Washington, District of
      Columbia.
FAU - Rozman, Damjana
AU  - Rozman D
AD  - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Saleh, Alif
AU  - Saleh A
AD  - Scipher Medicine, Boston, Massachusetts.
FAU - Schmidt, Harald H H W
AU  - Schmidt HHHW
AD  - Department of Pharmacology & Personalized Medicine, Faculty of Health, Medicine &
      Life Sciences, Maastricht University, Maastricht, The Netherlands.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, New York.
FAU - Sethi, Tavpritesh
AU  - Sethi T
AD  - Department of Computational Biology, Indraprastha Institute of Information
      Technology Delhi (IIIT), Delhi, India.
FAU - Silverman, Edwin K
AU  - Silverman EK
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, Massachusetts.
FAU - Skopac, Jessica
AU  - Skopac J
AD  - MITRE Corporation, McLean, Virginia.
FAU - Svab, Igor
AU  - Svab I
AD  - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
FAU - Trujillo, Sylvia
AU  - Trujillo S
AD  - Life Sciences/Digital Medicine, American Medical Association, Washington,
      District of Columbia.
FAU - Valentine, James E
AU  - Valentine JE
AD  - Hyman, Phelps & McNamara PC, Washington, District of Columbia.
AD  - University of Maryland Carey School of Law, Baltimore Maryland.
FAU - Verma, Dinesh
AU  - Verma D
AD  - Systems Engineering Research Center (SERC), Stevens Institute of Technology, New 
      Jersey.
FAU - West, Bruce J
AU  - West BJ
AD  - Army Research Laboratory, Army Research Office, Durham, North Carolina.
FAU - Vasudevan, Sona
AU  - Vasudevan S
AD  - Department of Biochemistry, Molecular and Cellular Biology, Georgetown University
      Medical Center, Washington, District of Columbia.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200226
PL  - United States
TA  - Syst Med (New Rochelle)
JT  - Systems medicine (New Rochelle, N.Y.)
JID - 101747120
PMC - PMC7099876
OTO - NOTNLM
OT  - artificial intelligence
OT  - big data
OT  - ethical legal social implications (ELSI)
OT  - international conference
OT  - network medicine
OT  - regulatory and health policy
OT  - systems
COIS- No competing financial interests exist.
EDAT- 2020/04/01 06:00
MHDA- 2020/04/01 06:01
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/01 06:01 [medline]
AID - 10.1089/sysm.2020.0001 [doi]
AID - 10.1089/sysm.2020.0001 [pii]
PST - epublish
SO  - Syst Med (New Rochelle). 2020 Feb 26;3(1):22-35. doi: 10.1089/sysm.2020.0001.
      eCollection 2020.


PMID- 32226481
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1752-4458 (Print)
IS  - 1752-4458 (Linking)
VI  - 14
DP  - 2020
TI  - Prevention and early intervention in youth mental health: is it time for a
      multidisciplinary and trans-diagnostic model for care?
PG  - 23
LID - 10.1186/s13033-020-00356-9 [doi]
AB  - BACKGROUND: Similar to other health care sectors, mental health has moved towards
      the secondary prevention, with the effort to detect and treat mental disorders as
      early as possible. However, converging evidence sheds new light on the potential 
      of primary preventive and promotion strategies for mental health of young people.
      We aimed to reappraise such evidence. METHODS: We reviewed the current state of
      knowledge on delivering promotion and preventive interventions addressing youth
      mental health. RESULTS: Half of all mental disorders start by 14 years and are
      usually preceded by non-specific psychosocial disturbances potentially evolving
      in any major mental disorder and accounting for 45% of the global burden of
      disease across the 0-25 age span. While some action has been taken to promote the
      implementation of services dedicated to young people, mental health needs during 
      this critical period are still largely unmet. This urges redesigning preventive
      strategies in a youth-focused multidisciplinary and trans-diagnostic framework
      which might early modify possible psychopathological trajectories. CONCLUSIONS:
      Evidence suggests that it would be unrealistic to consider promotion and
      prevention in mental health responsibility of mental health professionals alone. 
      Integrated and multidisciplinary services are needed to increase the range of
      possible interventions and limit the risk of poor long-term outcome, with also
      potential benefits in terms of healthcare system costs. However, mental health
      professionals have the scientific, ethical, and moral responsibility to indicate 
      the direction to all social, political, and other health care bodies involved in 
      the process of meeting mental health needs during youth years.
CI  - (c) The Author(s) 2020.
FAU - Colizzi, Marco
AU  - Colizzi M
AD  - 1Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement
      Sciences, University of Verona, 37134 Verona, Italy.grid.5611.30000 0004 1763
      1124
AD  - 2Department of Psychosis Studies, Institute of Psychiatry, Psychology and
      Neuroscience, King's College London, London, SE5 8AF UK.grid.13097.3c0000 0001
      2322 6764
FAU - Lasalvia, Antonio
AU  - Lasalvia A
AD  - 1Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement
      Sciences, University of Verona, 37134 Verona, Italy.grid.5611.30000 0004 1763
      1124
FAU - Ruggeri, Mirella
AU  - Ruggeri M
AD  - 1Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement
      Sciences, University of Verona, 37134 Verona, Italy.grid.5611.30000 0004 1763
      1124
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200324
PL  - England
TA  - Int J Ment Health Syst
JT  - International journal of mental health systems
JID - 101294224
PMC - PMC7092613
OTO - NOTNLM
OT  - Early intervention
OT  - Multidisciplinary care
OT  - Prevention
OT  - Promotion
OT  - Trans-diagnostic model
OT  - Youth mental health
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/04/01 06:00
MHDA- 2020/04/01 06:01
CRDT- 2020/04/01 06:00
PHST- 2019/12/27 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/01 06:01 [medline]
AID - 10.1186/s13033-020-00356-9 [doi]
AID - 356 [pii]
PST - epublish
SO  - Int J Ment Health Syst. 2020 Mar 24;14:23. doi: 10.1186/s13033-020-00356-9.
      eCollection 2020.


PMID- 32226400
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Scales Used to Measure Job Stressors in Intensive Care Units: Are They Relevant
      and Reliable? A Systematic Review.
PG  - 245
LID - 10.3389/fpsyg.2020.00245 [doi]
AB  - Background: Many studies have been conducted in intensive care units (ICUs) to
      identify the stress factors involved in the health of professionals and the
      quality and safety of care. The objectives are to identify the psychometric
      scales used in these studies to measure stressors and to assess their relevance
      and validity/reliability. Methods: All peer-reviewed full-text articles published
      in English between 1997 and 2016 and focusing on an empirical quantitative study 
      of job stressors were identified through searches on seven databases and
      editorial portals. Results: From the 102 studies analyzed, we identified 59
      different scales: 17 "all settings scales" (16 validated scales), 20 "healthcare 
      settings scales" (13 validated scales), and 22 "ICU settings scales" (two
      validated scales). All these scales used measured stressors from at least one of 
      the following eight broad categories: High job demands, Problematic relationships
      with other professionals, Lack of control over work situations and career, Lack
      of organizational resources, Problematic situations with users and relatives,
      Dealing with ethical- and moral-related situations, Risk management issues, and
      Disadvantages in comparison to other occupational situations. The "all settings
      scales" and "healthcare settings scales," the most often validated, did not
      measure, or only slightly measured, the stressors most specific to ICUs. Where
      these were taken into account, the authors were forced to develop their own tools
      or modify existing scales without testing the validity of the tool used.
      Conclusions: This review highlights the lack of a tool that meets both the
      criteria of validity and relevance with regard to the specificity of work in
      ICUs. Future research must focus on developing reliable/valid tools covering all 
      types of relevant stressors to ensure the quality of the studies carried out in
      this field.
CI  - Copyright (c) 2020 Laurent, Lheureux, Genet, Martin Delgado, Bocci,
      Prestifilippo, Besch and Capellier.
FAU - Laurent, Alexandra
AU  - Laurent A
AD  - Le Laboratoire de Psychologie: Dynamiques Relationnelles Et Processus
      Identitaires (Psy DREPI), University of Bourgogne Franche-Comte, Dijon, France.
AD  - La Maison des Sciences de l'Homme et de l'Environnement (MSHE) C. N. Ledoux,
      University of Bourgogne Franche-Comte, Besancon, France.
FAU - Lheureux, Florent
AU  - Lheureux F
AD  - Laboratory of Psychology, University of Bourgogne Franche-Comte, Besancon,
      France.
FAU - Genet, Magali
AU  - Genet M
AD  - Laboratory of Psychology, University of Bourgogne Franche-Comte, Besancon,
      France.
FAU - Martin Delgado, Maria Cruz
AU  - Martin Delgado MC
AD  - Intensive Care Unit, Hospital Universitario de Torrejon, Madrid, Spain.
FAU - Bocci, Maria G
AU  - Bocci MG
AD  - Department of Anesthesiology and Intensive Care, Fondazione Policlinico
      Universitario Agostino Gemelli IRCCS, Rome, Italy.
FAU - Prestifilippo, Alessia
AU  - Prestifilippo A
AD  - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
FAU - Besch, Guillaume
AU  - Besch G
AD  - Department of Anesthesiology and Intensive Care Medicine, University Hospital of 
      Besancon, University of Bourgogne Franche-Comte, Besancon, France.
FAU - Capellier, Gilles
AU  - Capellier G
AD  - Medical Intensive Care Unit, University Hospital of Besancon, Besancon, France.
LA  - eng
PT  - Systematic Review
DEP - 20200312
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7080865
OTO - NOTNLM
OT  - intensive care unit (ICU)
OT  - job stress scales
OT  - job stressors
OT  - occupational stressors
OT  - psychometrics
OT  - systematic review
EDAT- 2020/04/01 06:00
MHDA- 2020/04/01 06:01
CRDT- 2020/04/01 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/01 06:01 [medline]
AID - 10.3389/fpsyg.2020.00245 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 12;11:245. doi: 10.3389/fpsyg.2020.00245. eCollection
      2020.


PMID- 32225119
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Mar 26
TI  - The Perceptions of Professional Values among Students at a Spanish Nursing
      School.
LID - E74 [pii]
LID - 10.3390/healthcare8020074 [doi]
AB  - (1) Background: This study aims to reflect student nurses' perceptions of
      professional values across the four training years. (2) Methods: This study was
      designed as a cross-sectional study; data were collected using the Nurses'
      Professional Values Scale-Revised, adapted by Basurto-Hoyuelos. A total of 315
      student nurses participated from a Nursing Faculty in Spain representing each of 
      the four academic years. (3) Results: Students' perceptions of professional
      values were significantly correlated with their academic year. Overall, students'
      scores were higher in the ethics dimension. The two highest scores were for
      Maintain patient confidentiality for years 1 and 2 (4.77 and 4.68, respectively) 
      and Safeguard patients' right to privacy for years 3 and 4 (4.95 and 4.98,
      respectively). Lower scores were observed in the professional expertise dimension
      across all years, and corresponded to a single item Participate in peer review
      (3.51, 3.38, 3.98, and 3.26, respectively). (4) Conclusions: This study is
      relevant as it highlights how nursing students' perceptions of professional
      values change overtime, even during the four years of their training. The ethics 
      dimension was the most highly regarded across all academic years. However, the
      professional expertise dimension requires greater attention throughout the degree
      as students regarded it as less important for their immediate future.
FAU - Bleda, Silvia
AU  - Bleda S
AUID- ORCID: 0000-0003-4105-2061
AD  - Nursing Faculty Gimbernat, Autonomous University of Barcelona, Sant Cugat del
      Valles 08174, Spain.
FAU - Alvarez, Isabel
AU  - Alvarez I
AUID- ORCID: 0000-0001-9488-9960
AD  - Department of Social and Systematic Pedagogy, Autonomous University of Barcelona,
      Bellaterra 08193, Spain.
FAU - Prat, Merce
AU  - Prat M
AUID- ORCID: 0000-0003-0328-8276
AD  - Nursing Faculty Gimbernat, Autonomous University of Barcelona, Sant Cugat del
      Valles 08174, Spain.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC7348720
OTO - NOTNLM
OT  - ethics dimension
OT  - faculty
OT  - nursing school
OT  - nursing students
OT  - perceptions
OT  - professional values
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/01 06:00
MHDA- 2020/04/01 06:01
CRDT- 2020/04/01 06:00
PHST- 2020/03/04 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/01 06:01 [medline]
AID - healthcare8020074 [pii]
AID - 10.3390/healthcare8020074 [doi]
PST - epublish
SO  - Healthcare (Basel). 2020 Mar 26;8(2). pii: healthcare8020074. doi:
      10.3390/healthcare8020074.


PMID- 32225027
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1660-4601 (Electronic)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 7
DP  - 2020 Mar 26
TI  - Effectiveness of a Multifactorial Intervention in the First 1000 Days of Life to 
      Prevent Obesity and Overweight in Childhood: Study Protocol.
LID - E2239 [pii]
LID - 10.3390/ijerph17072239 [doi]
AB  - (1) Background: Obesity is a global health problem, and its prevention must be a 
      priority goal of public health, especially considering the seriousness of the
      problem among children. It is known that fetal and early postnatal environments
      may favor the appearance of obesity in later life. In recent years, the impact of
      the programs to prevent obesity in childhood has been scarce. The aim of this
      research is to evaluate the effectiveness of an intervention based on the concept
      of early programming. (2) Methods: Non-randomized controlled trial design.
      Inclusion criteria are: two-year-old infants whose gestational period begins in
      the 14 months following the start of the intervention, and whose mothers have
      made the complete follow-up of their pregnancy in the same clinical unit of the
      study. The intervention will be developed over all the known factors that affect 
      early programming, during pregnancy up to 2 years of life. Data will be collected
      through a data collection sheet by the paediatricians. A unibivariate and
      multivariate analysis of the data will be carried out. (3) Ethics and
      dissemination: The trial does not involve any risk to participants and their
      offspring. Signed informed consent is obtained from all participants. Ethical
      approval has been obtained. (4) Results: It is expected that this study will
      provide evidence on the importance of the prevention of obesity from the critical
      period of the first 1000 days of life, being able to establish this as a standard
      intervention in primary care.
FAU - Diaz-Rodriguez, Mercedes
AU  - Diaz-Rodriguez M
AUID- ORCID: 0000-0002-2546-2848
AD  - Department of Nursing and Physiotherapy, University of Cadiz, 11009 Andalusia,
      Spain.
FAU - Perez-Munoz, Celia
AU  - Perez-Munoz C
AD  - Department of Nursing and Physiotherapy, University of Cadiz, 11009 Andalusia,
      Spain.
FAU - Lendinez-de la Cruz, Jose Manuel
AU  - Lendinez-de la Cruz JM
AUID- ORCID: 0000-0002-6868-0239
AD  - Ribera del Muelle Health Centre, Clinic Management Unit (CMU) Puerto Real, Cadiz,
      Andalusian Health System, 11510 Andalusia, Spain.
FAU - Fernandez-Gutierrez, Martina
AU  - Fernandez-Gutierrez M
AUID- ORCID: 0000-0003-3961-2250
AD  - Department of Nursing and Physiotherapy, University of Cadiz, 11009 Andalusia,
      Spain.
FAU - Bas-Sarmiento, Pilar
AU  - Bas-Sarmiento P
AUID- ORCID: 0000-0001-6309-4997
AD  - Department of Nursing and Physiotherapy, University of Cadiz, 11009 Andalusia,
      Spain.
FAU - Ferriz-Mas, Bernardo C
AU  - Ferriz-Mas BC
AD  - Rio San Pedro Health Centre, Clinic Management Unit (CMU) Puerto Real, Cadiz,
      Andalusian Health System, 11519 Andalusia, Spain.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200326
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Controlled Clinical Trials as Topic
MH  - Female
MH  - Health Promotion/*methods
MH  - Humans
MH  - Infant
MH  - Mothers
MH  - Overweight/*prevention & control
MH  - Pediatric Obesity/*prevention & control
MH  - Pregnancy
MH  - *Primary Health Care
PMC - PMC7177794
OTO - NOTNLM
OT  - *childhood
OT  - *early programming
OT  - *obesity
OT  - *prevention
OT  - *primary care
EDAT- 2020/04/01 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/03/24 00:00 [accepted]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
AID - ijerph17072239 [pii]
AID - 10.3390/ijerph17072239 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Mar 26;17(7). pii: ijerph17072239. doi:
      10.3390/ijerph17072239.


PMID- 32224730
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20210203
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 272
IP  - 1
DP  - 2020 Jul
TI  - Donating a Kidney to a Stranger: A Review of the Benefits and Controversies of
      Unspecified Kidney Donation.
PG  - 45-47
LID - 10.1097/SLA.0000000000003855 [doi]
AB  - OF BACKGROUND DATA: Unspecified kidney donation (UKD) describes living donation
      of a kidney to a stranger. The practice is playing an increasingly important role
      within the transplant programme in the United Kingdom, where these donors are
      commonly used to trigger a chain of transplants; thereby amplifying the benefit
      derived from their donation. The initial reluctance to accept UKD was in part due
      to uncertainty about donor motivations and whether the practice was morally and
      ethically acceptable. OBJECTIVES: This article provides an overview of UKD and
      answers common questions regarding the ethical considerations, clinical
      assessment, and how UKD kidneys are used to maximize utility. Existing literature
      on outcomes after UKD is also discussed, along with current controversies.
      CONCLUSIONS: We believe UKD is an ethically acceptable practice which should
      continue to grow, despite its controversies. In our experience, these donors are 
      primarily motivated by a desire to help others and utilization of their kidney as
      part of a sharing scheme means that many more people seek to benefit from their
      very generous donation.
FAU - Maple, Hannah
AU  - Maple H
AD  - Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust,
      Clinical Transplant Laboratory, 3rd Floor Borough Wing, Guy's Hospital, Great
      Maze Pond, London, UK.
FAU - Draper, Heather
AU  - Draper H
AD  - Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Gogalniceanu, Petrut
AU  - Gogalniceanu P
AD  - Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, London,
      UK.
FAU - Burnapp, Lisa
AU  - Burnapp L
AD  - Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, London,
      UK.
AD  - NHS Blood and Transplant, Bristol, UK.
FAU - Chilcot, Joseph
AU  - Chilcot J
AD  - Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience,
      King's College London, London, UK.
FAU - Mamode, Nizam
AU  - Mamode N
AD  - Department of Transplantation, Guy's and St Thomas' NHS Foundation Trust, London,
      UK.
LA  - eng
GR  - HS&DR/13/54/54/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
MH  - Humans
MH  - *Kidney Transplantation
MH  - *Living Donors
MH  - Motivation
MH  - Tissue and Organ Harvesting/*ethics
MH  - United Kingdom
EDAT- 2020/04/01 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1097/SLA.0000000000003855 [doi]
AID - 00000658-202007000-00025 [pii]
PST - ppublish
SO  - Ann Surg. 2020 Jul;272(1):45-47. doi: 10.1097/SLA.0000000000003855.


PMID- 32224493
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 3
DP  - 2020 Mar 30
TI  - Innovative Approaches to Obtain Minors' Consent for Biomedical HIV Prevention
      Trials: Multi-Site Quasi-Experimental Study of Adolescent and Parent
      Perspectives.
PG  - e16509
LID - 10.2196/16509 [doi]
AB  - BACKGROUND: Despite the high burden of new HIV infections in minor adolescents,
      they are often excluded from biomedical HIV prevention trials, largely owing to
      the ethical complexities of obtaining consent for enrollment. Researchers and
      ethics regulators have a duty to protect adolescents-as a special category of
      human subjects, they must have protection that extends beyond those afforded to
      all human subjects. Typically, additional protection includes parental consent
      for enrollment. However, parental consent can present a risk of harm for minor
      adolescents. Research involving minor adolescents indicate that they are
      unwilling to join biomedical trials for stigmatized health problems, such as HIV,
      when parental consent is required. This presents a significant barrier to
      progress in adolescent HIV prevention by creating delays in research and the
      translation of new scientific evidence generated in biomedical trials in adult
      populations. OBJECTIVE: This protocol aims to examine how parental involvement in
      the consent process affects the acceptability of hypothetical participation in
      biomedical HIV prevention trials from the perspectives of minor adolescents and
      parents of minor adolescents. METHODS: In this protocol, we use a
      quasi-experimental design that involves a simulated consent process for 2
      different HIV prevention trials. The first trial is modeled after an open-label
      study of the use of tenofovir disoproxil fumarate and emtricitabine as
      preexposure prophylaxis for HIV. The second trial is modeled after a phase IIa
      trial of an injectable HIV integrase inhibitor. There are 2 groups in the
      study-minor adolescents aged 14 to 17 years, inclusive, and parents of minor
      adolescents in the same age range. The adolescent participants are randomized to 
      1 of 3 consent conditions with varying degrees of parental involvement. After
      undergoing a simulated consent process, they rate their willingness to
      participate (WTP) in each of the 2 trials if offered the opportunity. The primary
      outcome is WTP, given the consent condition. Parents undergo a similar process
      but are asked to rate the acceptability of each of the 3 consent conditions. The 
      primary outcome is acceptability of the consent method for enrollment. The
      secondary outcomes include the following: capacity to consent among both
      participant groups, the prevalence of medical mistrust, and the effects of the
      study phase (eg, phase IIa vs the open-label study) and drug administration route
      (eg, oral vs injection) on WTP (adolescents) and acceptability (parents) of the
      consent method. RESULTS: Enrollment began in April 2018 and ended mid-September
      2019. Data are being analyzed and dissemination is expected in April 2020.
      CONCLUSIONS: The study will provide the needed empirical data about minor
      adolescents' and parents' perspectives on consent methods for minors. The
      evidence generated can be used to guide investigators and ethics regulators in
      the design of consent processes for biomedical HIV prevention trials.
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/16509.
CI  - (c)Amelia Knopf, Mary A Ott, Claire Burke Draucker, J Dennis Fortenberry, Daniel 
      H Reirden, Renata Arrington-Sanders, John Schneider, Diane Straub, Rebecca Baker,
      Giorgos Bakoyannis, Gregory D Zimet. Originally published in JMIR Research
      Protocols (http://www.researchprotocols.org), 30.03.2020.
FAU - Knopf, Amelia
AU  - Knopf A
AUID- ORCID: https://orcid.org/0000-0003-2557-4556
AD  - Department of Community & Health Services, School of Nursing, Indiana University,
      Indianapolis, IN, United States.
FAU - Ott, Mary A
AU  - Ott MA
AUID- ORCID: https://orcid.org/0000-0003-1347-2480
AD  - Department of Pediatrics, School of Medicine, Indiana University, Indianapolis,
      IN, United States.
FAU - Draucker, Claire Burke
AU  - Draucker CB
AUID- ORCID: https://orcid.org/0000-0001-9844-351X
AD  - Department of Community & Health Services, School of Nursing, Indiana University,
      Indianapolis, IN, United States.
FAU - Fortenberry, J Dennis
AU  - Fortenberry JD
AUID- ORCID: https://orcid.org/0000-0001-6612-176X
AD  - Department of Pediatrics, School of Medicine, Indiana University, Indianapolis,
      IN, United States.
FAU - Reirden, Daniel H
AU  - Reirden DH
AUID- ORCID: https://orcid.org/0000-0002-4391-2718
AD  - Children's Hospital Colorado, School of Medicine, The University of Colorado,
      Aurora, CO, United States.
FAU - Arrington-Sanders, Renata
AU  - Arrington-Sanders R
AUID- ORCID: https://orcid.org/0000-0002-3801-901X
AD  - Division of General Pediatrics & Adolescent Medicine, School of Medicine, Johns
      Hopkins University, Baltimore, MD, United States.
FAU - Schneider, John
AU  - Schneider J
AUID- ORCID: https://orcid.org/0000-0002-7870-5639
AD  - Department of Medicine, The University of Chicago, Chicago, IL, United States.
FAU - Straub, Diane
AU  - Straub D
AUID- ORCID: https://orcid.org/0000-0002-7661-7360
AD  - Morsani College of Medicine, University of South Florida, Tampa, FL, United
      States.
FAU - Baker, Rebecca
AU  - Baker R
AUID- ORCID: https://orcid.org/0000-0001-9436-7329
AD  - Department of Community & Health Services, School of Nursing, Indiana University,
      Indianapolis, IN, United States.
FAU - Bakoyannis, Giorgos
AU  - Bakoyannis G
AUID- ORCID: https://orcid.org/0000-0002-2789-2497
AD  - Department of Biostatistics, School of Medicine, Indiana University,
      Indianapolis, IN, United States.
FAU - Zimet, Gregory D
AU  - Zimet GD
AUID- ORCID: https://orcid.org/0000-0003-3835-937X
AD  - Department of Pediatrics, School of Medicine, Indiana University, Indianapolis,
      IN, United States.
LA  - eng
GR  - U24 HD089880/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200330
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7154935
OTO - NOTNLM
OT  - HIV
OT  - adolescence
OT  - biomedical ethics
OT  - parental consent
EDAT- 2020/04/01 06:00
MHDA- 2020/04/01 06:01
CRDT- 2020/04/01 06:00
PHST- 2019/10/04 00:00 [received]
PHST- 2020/01/09 00:00 [accepted]
PHST- 2020/01/08 00:00 [revised]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/01 06:01 [medline]
AID - v9i3e16509 [pii]
AID - 10.2196/16509 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Mar 30;9(3):e16509. doi: 10.2196/16509.


PMID- 32224492
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20201019
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 22
IP  - 3
DP  - 2020 Mar 30
TI  - Connected Medical Technology and Cybersecurity Informed Consent: A New Paradigm.
PG  - e17612
LID - 10.2196/17612 [doi]
AB  - BACKGROUND: Connected medical technology is increasingly prevalent and offers
      both a host of new therapeutic potentials and cybersecurity-related
      considerations. Current practice largely does not include discussions of
      cybersecurity issues when clinicians obtain informed consent. OBJECTIVE: This
      paper aims to raise awareness about cybersecurity considerations for connected
      medical technology as they relate to informed consent discussions between
      patients and clinicians. METHODS: Clinicians, health care cybersecurity
      researchers, and informed consent experts propose the concept of a cybersecurity 
      informed consent for connected medical technology. RESULTS: This viewpoint
      discusses concepts designed to facilitate further discussion on the need,
      development, and execution of cybersecurity informed consent. CONCLUSIONS:
      Cybersecurity informed consent may be a necessary component of informed consent
      practices, as connected medical technology proliferates in the health care
      environment.
CI  - (c)Jeffrey Tully, Andrea Coravos, Megan Doerr, Christian Dameff. Originally
      published in the Journal of Medical Internet Research (http://www.jmir.org),
      30.03.2020.
FAU - Tully, Jeffrey
AU  - Tully J
AUID- ORCID: 0000-0002-3537-6716
AD  - Department of Anesthesiology and Pain Medicine, UC Davis Medical Center,
      Sacramento, CA, United States.
FAU - Coravos, Andrea
AU  - Coravos A
AUID- ORCID: 0000-0001-5379-3540
AD  - Elektra Labs, Boston, MA, United States.
AD  - Digital Medicine Society, Boston, MA, United States.
AD  - Harvard-MIT Center for Regulatory Science, Boston, MA, United States.
AD  - Policy Innovation Lab of Tomorrow, Penn State University, State College, PA,
      United States.
FAU - Doerr, Megan
AU  - Doerr M
AUID- ORCID: 0000-0003-2383-5978
AD  - Sage Bionetworks, Seattle, WA, United States.
FAU - Dameff, Christian
AU  - Dameff C
AUID- ORCID: 0000-0001-9613-2603
AD  - Department of Emergency Medicine, University of California San Diego, La Jolla,
      CA, United States.
AD  - Department of Computer Science and Engineering, La Jolla, CA, United States.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
MH  - Computer Security/*standards
MH  - Humans
MH  - Informed Consent/*standards
PMC - PMC7154933
OTO - NOTNLM
OT  - *connected medical technology
OT  - *cybersecurity
OT  - *digital health
OT  - *ethics
OT  - *informed consent
OT  - *medical devices
OT  - *patient autonomy
OT  - *privacy
EDAT- 2020/04/01 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/04/01 06:00
PHST- 2019/12/26 00:00 [received]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/01/28 00:00 [revised]
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
AID - v22i3e17612 [pii]
AID - 10.2196/17612 [doi]
PST - epublish
SO  - J Med Internet Res. 2020 Mar 30;22(3):e17612. doi: 10.2196/17612.


PMID- 32224276
OWN - NLM
STAT- MEDLINE
DCOM- 20200428
LR  - 20201218
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 82
IP  - 5
DP  - 2020 May
TI  - Ethical outpatient dermatology care during the coronavirus (COVID-19) pandemic.
PG  - 1272-1273
LID - S0190-9622(20)30467-9 [pii]
LID - 10.1016/j.jaad.2020.03.047 [doi]
FAU - Pathoulas, James T
AU  - Pathoulas JT
AD  - University of Minnesota Medical School, Minneapolis, Minnesota.
FAU - Stoff, Benjamin K
AU  - Stoff BK
AD  - Department of Dermatology, Emory University School of Medicine and Emory Center
      for Ethics, Atlanta, Georgia.
FAU - Lee, Kachiu C
AU  - Lee KC
AD  - Main Line Center for Laser Surgery, Ardmore, Pennsylvania.
FAU - Farah, Ronda S
AU  - Farah RS
AD  - Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
      Electronic address: rfarah@umn.edu.
LA  - eng
PT  - Letter
DEP - 20200326
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
SB  - IM
MH  - *Ambulatory Care
MH  - Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus
MH  - Coronavirus Infections
MH  - Dermatology/*ethics
MH  - Humans
MH  - Outpatients
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - SARS-CoV-2
MH  - *Telemedicine
PMC - PMC7195559
EDAT- 2020/04/01 06:00
MHDA- 2020/04/29 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/29 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - S0190-9622(20)30467-9 [pii]
AID - 10.1016/j.jaad.2020.03.047 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2020 May;82(5):1272-1273. doi: 10.1016/j.jaad.2020.03.047.
      Epub 2020 Mar 26.


PMID- 32224092
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1873-5894 (Electronic)
IS  - 0730-725X (Linking)
VI  - 70
DP  - 2020 Jul
TI  - A comparison study of inhomogeneous magnetization transfer (ihMT) and
      magnetization transfer (MT) in multiple sclerosis based on whole brain
      acquisition at 3.0 T.
PG  - 43-49
LID - S0730-725X(19)30474-6 [pii]
LID - 10.1016/j.mri.2020.03.010 [doi]
AB  - INTRODUCTION: Multiple sclerosis (MS) is a central nervous system disorder that
      may eventually affect its function. The clinical standard for MS severity is
      based on a clinical scale, which lacks lesion specific information. Magnetic
      resonance imaging of MS faces the challenge of myelin specificity, and in this
      work a new method inhomogeneous magnetization transfer (ihMT) is investigated as 
      new biomarker of demyelination in MS. METHODS: Local ethics committee approved
      this study and written informed consents were obtained. Between Oct 2017 to May
      2018, eighteen patients with relapsing-remitting MS (RRMS) (6 males, 12 females, 
      mean age 31.2) and sixteen healthy volunteers (6 males, 10 females, mean age 30.4
      years) were enrolled in this prospective study. All subjects underwent MRI exams 
      including MT and ihMT imaging as well as the Expanded Disability Status Scale
      (EDSS) assessments. Independent sample t-test were used to compare the difference
      of ihMT parameters between healthy white matter (HWM) and normal appearing white 
      matter (NAWM) and between HWM and MS lesions, respectively. Spearman correlation 
      were used to analyze the correlation between ihMT parameters of MS lesions and
      EDSS score. RESULTS: The ihMTR and qihMT demonstrate significant differences
      between WHM and NAWM groups, while no significant differences are observed for
      MTR and qMT. All parameters show significant differences between HWM and MS
      groups (p < 0.05). There was moderate negative correlation between MTR, qMT and
      EDSS score (-0.440 and -0.572), while there was a strong negative correlation
      between ihMTR and qihMT and EDSS score (-0.704 and -0.739). CONCLUSION: Based on 
      whole brain analysis at 3.0 T, ihMT showed better correlation with EDSS compared 
      to magnetization transfer imaging, and may be a potentially valuable biomarker
      for demyelination in MS.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Wen, Baohong
AU  - Wen B
AD  - Department of Radiology, Zhengzhou Univerisity First Affilicated Hospital,
      Zhengzhou, Henan, People's Republic of China.
FAU - Chen, Tao
AU  - Chen T
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Tian, Hongzhe
AU  - Tian H
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Xue, Hongqiang
AU  - Xue H
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Ren, Huipeng
AU  - Ren H
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Li, Li
AU  - Li L
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Fan, Qing
AU  - Fan Q
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China.
FAU - Ren, Zhuanqin
AU  - Ren Z
AD  - Department of Radiology, Baoji Center Hospital, Baoji, Shaanxi, People's Republic
      of China; Department of Medical Techniques, Shaanxi University of Chinese
      Medicine, Xianyang, 712000, Shannxi, People's Republic of China. Electronic
      address: Zhuanqin_ren@163.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200326
PL  - Netherlands
TA  - Magn Reson Imaging
JT  - Magnetic resonance imaging
JID - 8214883
SB  - IM
MH  - Adult
MH  - Brain/*diagnostic imaging/pathology
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*diagnostic imaging/pathology
MH  - Myelin Sheath/metabolism
MH  - Prospective Studies
OTO - NOTNLM
OT  - *EDSS
OT  - *Magnetization transfer
OT  - *Multiple sclerosis
OT  - *ihMT
EDAT- 2020/04/01 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/04/01 06:00
PHST- 2019/07/29 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - S0730-725X(19)30474-6 [pii]
AID - 10.1016/j.mri.2020.03.010 [doi]
PST - ppublish
SO  - Magn Reson Imaging. 2020 Jul;70:43-49. doi: 10.1016/j.mri.2020.03.010. Epub 2020 
      Mar 26.


PMID- 32223783
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2056-4694 (Print)
IS  - 2056-4694 (Linking)
VI  - 44
IP  - 2
DP  - 2020 Apr
TI  - The place of free will and agency in psychiatric practice.
PG  - 57-60
LID - 10.1192/bjb.2019.89 [doi]
AB  - In psychiatric practice, professionals tend to split patients into those who are 
      responsible for their actions, and those who are not. This approach does a
      disservice to both groups. Patients assumed to retain agency may be blamed, and
      those assumed to lack agency are disempowered. Professionals should adopt a more 
      nuanced approach to agency and control, recognising that it is impaired in most
      psychiatric disorders, but absent in very few. This is possible without making
      stigma worse.
FAU - Pearce, Steve
AU  - Pearce S
AUID- ORCID: https://orcid.org/0000-0002-6975-085X
AD  - Oxfordshire Complex Needs Service, Oxford Health NHS Foundation Trust, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJPsych Bull
JT  - BJPsych bulletin
JID - 101650950
PMC - PMC7283129
OTO - NOTNLM
OT  - Ethics
OT  - consent and capacity
OT  - history of psychiatry
OT  - personality disorders
OT  - philosophy
EDAT- 2020/04/01 06:00
MHDA- 2020/04/01 06:01
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/01 06:01 [medline]
AID - 10.1192/bjb.2019.89 [doi]
AID - S2056469419000895 [pii]
PST - ppublish
SO  - BJPsych Bull. 2020 Apr;44(2):57-60. doi: 10.1192/bjb.2019.89.


PMID- 32223773
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1481-8043 (Electronic)
IS  - 1481-8035 (Linking)
VI  - 22
IP  - 4
DP  - 2020 Jul
TI  - Ethical considerations in the allocation of critical care resources when capacity
      is overwhelmed.
PG  - 404-406
LID - 10.1017/cem.2020.354 [doi]
FAU - Pauls, Merril A
AU  - Pauls MA
AD  - Health Sciences Centre, Max Rady College of Medicine, Department of Emergency
      Medicine, University of Manitoba, Winnipeg, MB; CAEP Bioethics Committee.
AD  - CAEP Bioethics Committee.
FAU - Migneault, David
AU  - Migneault D
AD  - Vancouver General Hospital, BC Children's Hospital, UBC Urgent Care Centre,
      Vancouver Coastal Health, UBC Department of Emergency Medicine, University of
      British Columbia, Vancouver, BC; CAEP Bioethics Committee.
AD  - CAEP Bioethics Committee.
FAU - Bakewell, Francis
AU  - Bakewell F
AD  - Medicine, Ethics, and Humanities Program, The Ottawa Hospital; Faculty of
      Medicine, University of Ottawa, Ottawa, ON.
AD  - CAEP Bioethics Committee.
LA  - eng
PT  - Journal Article
PL  - England
TA  - CJEM
JT  - CJEM
JID - 100893237
SB  - IM
MH  - *Critical Care
MH  - Humans
MH  - *Resource Allocation
PMC - PMC7156547
OTO - NOTNLM
OT  - *Critical care
OT  - *ethics
OT  - *pandemic
OT  - *resource allocation
EDAT- 2020/04/01 06:00
MHDA- 2021/08/19 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1017/cem.2020.354 [doi]
AID - S1481803520003541 [pii]
PST - ppublish
SO  - CJEM. 2020 Jul;22(4):404-406. doi: 10.1017/cem.2020.354.


PMID- 32223701
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20210622
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Linking)
VI  - 16
IP  - 4
DP  - 2020 Apr
TI  - A Call to Action: Ethics Committee Roundtable Recommendations for Addressing
      Burnout and Moral Distress in Oncology.
PG  - 191-199
LID - 10.1200/JOP.19.00806 [doi]
AB  - Oncologist well-being is critical to initiating and maintaining the
      physician-patient relationship, yet many oncologists suffer from symptoms of
      burnout. Burnout has been linked to poor physical and mental health, as well as
      increased medical errors, patient dissatisfaction, and workforce attrition. In
      this Call to Action article, we discuss causes of and interventions for burnout
      and moral distress in oncology, highlight existing interventions, and provide
      recommendations for addressing burnout and improving well-being at the individual
      and organizational levels to deliver ethical, quality cancer care.
FAU - Hlubocky, Fay J
AU  - Hlubocky FJ
AD  - University of Chicago Medicine, Chicago, IL.
FAU - Taylor, Lynne P
AU  - Taylor LP
AD  - University of Washington Medical Center, Seattle, WA.
FAU - Marron, Jonathan M
AU  - Marron JM
AD  - Dana-Farber/Boston Children's Hospital, Boston, MA.
FAU - Spence, Rebecca A
AU  - Spence RA
AD  - American Society of Clinical Oncology, Alexandria, VA.
FAU - McGinnis, Molly M
AU  - McGinnis MM
AD  - American Society of Clinical Oncology, Alexandria, VA.
FAU - Brown, Richard F
AU  - Brown RF
AD  - Virginia Commonwealth University, Richmond, VA.
FAU - McFarland, Daniel C
AU  - McFarland DC
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Tetzlaff, Eric D
AU  - Tetzlaff ED
AD  - Fox Chase Cancer Center, Philadelphia, PA.
FAU - Gallagher, Colleen M
AU  - Gallagher CM
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Rosenberg, Abby R
AU  - Rosenberg AR
AD  - University of Washington School of Medicine, Department of Pediatrics, Seattle,
      WA.
FAU - Popp, Beth
AU  - Popp B
AD  - Icahn School of Medicine at Mount Sinai, New York, NY.
FAU - Dragnev, Konstantin
AU  - Dragnev K
AD  - Dartmouth-Hitchcock Medical Center, Lebanon, NH.
FAU - Bosserman, Linda D
AU  - Bosserman LD
AD  - City of Hope, Duarte, CA.
FAU - Dudzinski, Denise M
AU  - Dudzinski DM
AD  - University of Washington, Seattle, WA.
FAU - Smith, Sonali
AU  - Smith S
AD  - University of Chicago Medicine, Chicago, IL.
FAU - Chatwal, Monica
AU  - Chatwal M
AD  - H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Patel, Manali I
AU  - Patel MI
AD  - Stanford University School of Medicine, Stanford, CA.
FAU - Markham, Merry J
AU  - Markham MJ
AD  - University of Florida, Gainesville, FL.
FAU - Levit, Kathryn
AU  - Levit K
AD  - Independent Consultant, Alexandria, VA.
FAU - Bruera, Eduardo
AU  - Bruera E
AD  - The University of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Epstein, Ronald M
AU  - Epstein RM
AD  - University of Rochester Medical Center, Rochester, NY.
FAU - Brown, Marie
AU  - Brown M
AD  - American Medical Association and Rush University, Chicago, IL.
FAU - Back, Anthony L
AU  - Back AL
AD  - University of Washington Medicine, Seattle, WA.
FAU - Shanafelt, Tait D
AU  - Shanafelt TD
AD  - Stanford Medicine, Stanford, CA.
FAU - Kamal, Arif H
AU  - Kamal AH
AD  - Duke Cancer Center, Durham, NC.
LA  - eng
GR  - L30 CA220778/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200330
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
SB  - IM
MH  - *Burnout, Professional
MH  - Ethics Committees
MH  - Humans
MH  - Medical Oncology
MH  - Morals
MH  - *Oncologists
PMC - PMC7351333
EDAT- 2020/04/01 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1200/JOP.19.00806 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2020 Apr;16(4):191-199. doi: 10.1200/JOP.19.00806. Epub 2020 Mar
      30.


PMID- 32223632
OWN - NLM
STAT- MEDLINE
DCOM- 20200401
LR  - 20200401
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 4
DP  - 2020 May
TI  - Ethical Representation by Patient Advocacy Organizations Also Requires
      Responsible Management of Potential Financial Conflicts of Interest.
PG  - 59-61
LID - 10.1080/15265161.2020.1730508 [doi]
FAU - Bruno, Bethany
AU  - Bruno B
AUID- ORCID: 0000-0003-0445-6876
AD  - Cleveland Clinic Lerner College of Medicine.
AD  - Case Western Reserve University.
FAU - Rose, Susannah
AU  - Rose S
AUID- ORCID: 0000-0001-5895-7460
AD  - Cleveland Clinic Lerner College of Medicine.
AD  - Case Western Reserve University.
AD  - Office of Patient Experience, Cleveland Clinic.
AD  - Center for Bioethics, Cleveland Clinic.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 May;20(4):13-24. PMID: 32208091
MH  - *Autistic Disorder
MH  - Conflict of Interest
MH  - Drug Industry
MH  - Humans
MH  - Morals
MH  - *Patient Advocacy
EDAT- 2020/04/01 06:00
MHDA- 2020/04/02 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/02 06:00 [medline]
AID - 10.1080/15265161.2020.1730508 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 May;20(4):59-61. doi: 10.1080/15265161.2020.1730508.


PMID- 32223625
OWN - NLM
STAT- MEDLINE
DCOM- 20200401
LR  - 20200401
IS  - 1536-0075 (Electronic)
IS  - 1526-5161 (Linking)
VI  - 20
IP  - 4
DP  - 2020 May
TI  - A Care Ethics Approach to Ethical Advocacy for Community Conditions.
PG  - 35-37
LID - 10.1080/15265161.2020.1730501 [doi]
FAU - Day, Philip G
AU  - Day PG
AUID- ORCID: 0000-0003-2713-0529
AD  - University of Texas Southwestern Medical Center.
FAU - Sanchack, Kristian E
AU  - Sanchack KE
AD  - Naval Hospital Jacksonville.
FAU - Lennon, Robert P
AU  - Lennon RP
AUID- ORCID: 0000-0003-0973-5890
AD  - Penn State College of Medicine.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Am J Bioeth
JT  - The American journal of bioethics : AJOB
JID - 100898738
SB  - IM
CON - Am J Bioeth. 2020 May;20(4):13-24. PMID: 32208091
MH  - *Autistic Disorder
MH  - Ethical Analysis
MH  - Humans
MH  - Morals
EDAT- 2020/04/01 06:00
MHDA- 2020/04/02 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/04/02 06:00 [medline]
AID - 10.1080/15265161.2020.1730501 [doi]
PST - ppublish
SO  - Am J Bioeth. 2020 May;20(4):35-37. doi: 10.1080/15265161.2020.1730501.


PMID- 32223495
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Nurses' tension-based ethical decision making in rural acute care settings.
PG  - 1032-1043
LID - 10.1177/0969733020906594 [doi]
AB  - BACKGROUND: Nurses in acute care are frequently involved in ethical decision
      making and experience a higher prevalence of ethical conflicts and dilemmas.
      Nurses in underresourced rural acute care settings also are likely to face unique
      ethical challenges. However, rarely have the particular contexts of these
      experiences in rural acute care settings been researched. A culture of silence
      and fear in small towns has made exploring these issues difficult. OBJECTIVES: To
      explore registered nurses' experiences of ethical issues and ethical decision
      making in rural acute care hospitals in northern Ontario, Canada. RESEARCH
      DESIGN: Guided by an interpretive descriptive approach, data were collected by
      two nurse researchers using in-depth, individual, and semistructured telephone
      interviews. Data were managed with NVivo v.11 and analyzed using inductive,
      comparative, thematic analyses. PARTICIPANTS AND RESEARCH CONTEXT: The
      participants were eight registered nurses working in two acute care hospitals in 
      northern Ontario. ETHICAL CONSIDERATIONS: Ethical protocols were followed in
      accordance with ethics approval from the researchers' university and the
      hospitals. FINDINGS: Results identified four themes that culminated in the
      development of a quadruple helix ethical decision-making framework of power,
      trust, care, and fear. DISCUSSION AND CONCLUSION: The participants described
      complex ethical conflicts and dilemmas in acute care settings that were
      influenced by the context of working and living in small rural communities in
      northern Ontario. Nurses described navigating ethics in practice using a
      tension-based approach to ethical decision making, needing to carry these issues 
      silently and often having no resolution to ethical challenges. These findings
      have important implications for nursing education, research, and practice. Nurses
      need safe spaces, formal ethics support, and improved access to resources.
      Additional ethics education and training specific to the unique contexts of rural
      settings are needed.
FAU - Alzghoul, Manal M
AU  - Alzghoul MM
AUID- ORCID: https://orcid.org/0000-0003-3280-783X
AD  - Lakehead University, School of Nursing, Canada.
FAU - Jones-Bonofiglio, Kristen
AU  - Jones-Bonofiglio K
AUID- ORCID: https://orcid.org/0000-0003-3483-9333
AD  - Lakehead University, School of Nursing, Canada.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - Critical Care/*ethics
MH  - Decision Making/*ethics
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Nurses/*psychology
MH  - Ontario
MH  - Qualitative Research
MH  - *Rural Health Services
MH  - *Rural Population
MH  - Sample Size
OTO - NOTNLM
OT  - Acute care
OT  - ethical decision making
OT  - nurses
OT  - qualitative
OT  - rural
EDAT- 2020/04/01 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1177/0969733020906594 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):1032-1043. doi: 10.1177/0969733020906594. Epub 2020
      Mar 30.


PMID- 32223368
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1552-4264 (Electronic)
IS  - 1552-4264 (Linking)
VI  - 16
IP  - 2
DP  - 2020 Apr-Jun
TI  - Considerations for Developing Online Bereavement Support Groups.
PG  - 99-115
LID - 10.1080/15524256.2020.1745727 [doi]
AB  - The loss of a family member or friend can have profound psychological and
      physical implications, particularly for individuals without bereavement support
      services. Online support groups can be an effective means of extending services
      beyond the traditional modes of delivery. This is especially true for populations
      that include isolated individuals and those with limited support networks,
      limited transportation, challenging time commitments, or reside in communities
      with limited services available. The literature over the last 10 years was
      reviewed to discern the potential opportunities and challenges of providing
      online bereavement support group services. Discussed are challenges for
      recruitment of participants, availability of technology resources, addressing
      privacy and confidentiality issues, participants' knowledge of technical
      equipment, legal considerations, ethical considerations, accessibility, and other
      best practices. Diverse populations such as adolescents, older adults, and rural 
      communities must be uniquely considered when using online support groups.
FAU - Gibson, Allison
AU  - Gibson A
AUID- ORCID: http://orcid.org/0000-0002-4116-9465
AD  - Social Work, University of Kentucky, Lexington, Kentucky, USA.
FAU - Wladkowski, Stephanie P
AU  - Wladkowski SP
AUID- ORCID: http://orcid.org/0000-0003-4697-1139
AD  - Social Work, Eastern Michigan University, School of Social Work, Ypsilanti,
      Michigan, USA.
FAU - Wallace, Cara L
AU  - Wallace CL
AUID- ORCID: http://orcid.org/0000-0002-6739-1910
AD  - Social Work, Saint Louis University, College for Public, Health and Social
      Justice, St. Louis, Missouri, USA.
FAU - Anderson, Keith A
AU  - Anderson KA
AUID- ORCID: http://orcid.org/0000-0001-9572-5677
AD  - Social Work, University of Texas at Arlington, School of Social Work, Arlington, 
      Texas, USA.
LA  - eng
PT  - Journal Article
DEP - 20200328
PL  - United States
TA  - J Soc Work End Life Palliat Care
JT  - Journal of social work in end-of-life & palliative care
JID - 101235219
SB  - IM
MH  - *Bereavement
MH  - Confidentiality
MH  - Culture
MH  - Health Services Accessibility/organization & administration
MH  - Humans
MH  - *Internet
MH  - Quality of Health Care/standards
MH  - Self-Help Groups/*organization & administration
MH  - Social Support
MH  - Terminal Care/*organization & administration
OTO - NOTNLM
OT  - Bereavement
OT  - ethics
OT  - grief/loss
OT  - online social work
OT  - support group
OT  - technology
EDAT- 2020/04/01 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1080/15524256.2020.1745727 [doi]
PST - ppublish
SO  - J Soc Work End Life Palliat Care. 2020 Apr-Jun;16(2):99-115. doi:
      10.1080/15524256.2020.1745727. Epub 2020 Mar 28.


PMID- 32223327
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20210721
IS  - 1545-5815 (Electronic)
IS  - 0898-9621 (Linking)
VI  - 27
IP  - 6
DP  - 2020 Aug
TI  - Toward global standardization of conducting fair investigations of allegations of
      research misconduct.
PG  - 327-346
LID - 10.1080/08989621.2020.1747019 [doi]
AB  - In the United States, through nation-wide discussions, the procedures for
      handling allegations of research misconduct are now well established. Procedures 
      are geared toward carefully treating both complainants and respondents fairly in 
      accordance with the US framework. Other countries, which have their own cultural 
      and legal framework, also need fair and legally compatible procedures for
      conducting investigations of allegations of research misconduct. Given the rapid 
      growth of international collaboration in research, it is desirable to have a
      global standard, or common ground, for misconduct investigations. Institutions
      need clear guidance on important subjects such as what information should be
      included in the investigation reports, how the investigation committee should be 
      organized once research misconduct allegation has been received, how to conduct
      the investigation, how the data and information obtained should be taken as
      evidence for vs. against misconduct, and what policies the investigation
      committee should follow. We explore these issues from the viewpoint of members of
      committees investigating accusations of research misconduct (hereafter referred
      to as "investigation committees") as well as persons overseeing the committees in
      Japan. We hope to engender productive discussions among experts in misconduct
      investigations, leading to a formulation of international standards for such
      investigation.
FAU - Nouchi, Rei
AU  - Nouchi R
AUID- ORCID: 0000-0002-3118-4151
AD  - Division of Research Integrity and Ethics, School of Medicine, Shinshu University
      , Matsumoto, Nagano, Japan.
FAU - Aihara, Hiroaki
AU  - Aihara H
AUID- ORCID: 0000-0002-1907-5964
AD  - School of Science, The University of Tokyo , Bunkyo-ku, Tokyo, Japan.
AD  - Director, Association for the Promotion of Research Integrity , Shinjuku-ku,
      Tokyo, Japan.
FAU - Arie, Fumie
AU  - Arie F
AD  - Translational Medical Center, National Center of Neurology and Psychiatry ,
      Kodaira, Tokyo, Japan.
FAU - Asashima, Makoto
AU  - Asashima M
AUID- ORCID: 0000-0002-0012-026X
AD  - President, Association for the Promotion of Research Integrity , Shinjuku-ku,
      Tokyo, Japan.
AD  - Strategic Innovation and Research Center, Teikyo University , Itabashi-ku, Tokyo,
      Japan.
FAU - Daida, Hiroyuki
AU  - Daida H
AD  - Faculty of Health Science, Juntendo University , Bunkyo-ku, Tokyo, Japan.
FAU - Fudano, Jun
AU  - Fudano J
AD  - Director, Association for the Promotion of Research Integrity , Shinjuku-ku,
      Tokyo, Japan.
AD  - Tokyo Tech Academy for Leadership, Tokyo Institute of Technology , Meguro-ku,
      Tokyo, Japan.
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
AD  - Chief Executive, Pharmaceuticals and Medical Devices Agency , Chiyoda-ku, Tokyo, 
      Japan.
FAU - Fushiki, Shinji
AU  - Fushiki S
AUID- ORCID: 0000-0002-0407-9954
AD  - The Center for Quality Assurance in Research, Kyoto Prefectural University of
      Medicine , Kamigyo-ku, Kyoto, Japan.
FAU - Geller, Robert J
AU  - Geller RJ
AUID- ORCID: 0000-0001-6628-9431
AD  - School of Science, The University of Tokyo , Bunkyo-ku, Tokyo, Japan.
FAU - Hatano, Kazuo
AU  - Hatano K
AD  - The Center for Quality Assurance in Research, Kyoto Prefectural University of
      Medicine , Kamigyo-ku, Kyoto, Japan.
AD  - Research Regulatory Management, Astellas Pharm. Inc ., Tsukuba, Ibaraki, Japan.
FAU - Homma, Toshio
AU  - Homma T
AD  - Visiting Researcher, Association for the Promotion of Research Integrity ,
      Shinjuku-ku, Tokyo, Japan.
FAU - Kimura, Minoru
AU  - Kimura M
AUID- ORCID: 0000-0001-7026-419X
AD  - Director, Association for the Promotion of Research Integrity , Shinjuku-ku,
      Tokyo, Japan.
AD  - The Institute of Medical, SciencesTokai University , Isehara, Kanagawa, Japan.
FAU - Kuroki, Toshio
AU  - Kuroki T
AUID- ORCID: 0000-0001-6369-4351
AD  - Research Center for Science Systems, Japan Society for the Promotion of Science ,
      Chiyoda-ku, Tokyo.
FAU - Miki, Koichi
AU  - Miki K
AD  - Law School, Keio University , Minato-ku, Tokyo, Japan.
FAU - Morita, Ikuo
AU  - Morita I
AD  - Director, Association for the Promotion of Research Integrity , Shinjuku-ku,
      Tokyo, Japan.
AD  - Trustee, Vice-President, Ochanomizu University , Bunkyo-ku, Japan.
FAU - Nitta, Kosaku
AU  - Nitta K
AD  - Department of Nephrology, Tokyo Women's Medical University , Shinjuku-ku, Tokyo, 
      Japan.
FAU - Shinohara, Akira
AU  - Shinohara A
AUID- ORCID: 0000-0003-4207-8247
AD  - Director, Association for the Promotion of Research Integrity , Shinjuku-ku,
      Tokyo, Japan.
AD  - Institute for Protein Research, Osaka University , Suita, Osaka, Japan.
FAU - Siomi, Mikiko C
AU  - Siomi MC
AD  - School of Science, The University of Tokyo , Bunkyo-ku, Tokyo, Japan.
FAU - Yoshida, Masayuki
AU  - Yoshida M
AUID- ORCID: 0000-0002-4600-4504
AD  - Bioethics Research Center, Tokyo Medical and Dental University , Bunkyo-ku,
      Tokyo, Japan.
FAU - Ichikawa, Iekuni
AU  - Ichikawa I
AD  - Division of Research Integrity and Ethics, School of Medicine, Shinshu University
      , Matsumoto, Nagano, Japan.
AD  - Executive Director, Association for the Promotion of Research Integrity ,
      Shinjuku-ku, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - United States
TA  - Account Res
JT  - Accountability in research
JID - 9100813
SB  - IM
MH  - Advisory Committees/organization & administration
MH  - Dissent and Disputes/legislation & jurisprudence
MH  - *Ethics, Research
MH  - Guidelines as Topic/standards
MH  - Humans
MH  - *International Cooperation
MH  - Japan
MH  - Scientific Misconduct/*legislation & jurisprudence
MH  - United States
MH  - United States Office of Research Integrity/organization & administration
OTO - NOTNLM
OT  - *Research integrity
OT  - *research ethics
OT  - *research misconduct
OT  - *responsible conduct of research
EDAT- 2020/04/01 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1080/08989621.2020.1747019 [doi]
PST - ppublish
SO  - Account Res. 2020 Aug;27(6):327-346. doi: 10.1080/08989621.2020.1747019. Epub
      2020 May 12.


PMID- 34908791
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 0974-8520 (Print)
IS  - 0974-8520 (Linking)
VI  - 41
IP  - 2
DP  - 2020 Apr-Jun
TI  - Patterns of concomitant use of Ayurveda and conventional anti-diabetic
      formulations - Experiences at a tertiary care Ayurveda hospital, India.
PG  - 72-78
LID - 10.4103/ayu.AYU_81_20 [doi]
AB  - BACKGROUND: Majority of the population relies on traditional medicines for many
      of their health related problems. Particularly individuals with chronic illness
      like diabetes mellitus (DM) are more likely to simultaneously use herbal
      medicines. Many of such users believe that traditional medicines are natural and 
      therefore safe, but this is a dangerous over simplification. Some herbal
      medicines may be associated with adverse effects, which include interactions with
      prescribed drugs. Information on such concomitant use of anti-diabetic drugs
      along with Ayurveda medicines is limited in Indian scenario. AIMS AND OBJECTIVES:
      To survey the patterns of concomitant use of Ayurveda and conventional
      anti-diabetic drugs by diabetic patients attending an out-patient department of a
      tertiary care teaching hospital in New Delhi, India through a validated
      questionnaire. MATERIALS AND METHODS: This is a questionnaire-based survey,
      carried out after the approval of the Institutional Ethics Committee,
      subsequently registered at CTRI. A questionnaire to assess the pattern of
      concomitant use was developed; content was validated and pre-tested by a pilot
      study in 40 patients, further refined and used in the survey. The data was
      analyzed to evaluate the patterns of concomitant use of Ayurvedic and
      conventional anti-diabetic drugs. RESULTS: About 95.9% of diabetic patients were 
      taking herbo-mineral formulations concomitantly with conventional anti-diabetic
      drugs. Although 45.3% of diabetics were using Ayurveda interventions under the
      supervision of qualified AYUSH physicians, remaining involved in procuring the
      drugs over the counter (OTC) or from the local vendors. In majority of these
      instances, the use of Ayurveda formulations was not communicated with their
      physicians. CONCLUSION: The observations reveal that a majority of the diabetics 
      (95.9%) were taking one or the other form of herbal preparations along with their
      conventional anti-diabetic drugs and about 44% among them were using these
      concomitantly. Thus, generating awareness on good practices of drug use seems to 
      be essential.
CI  - Copyright: (c) 2021 AYU (An international quarterly journal of research in
      Ayurveda).
FAU - Galib, R
AU  - Galib R
AD  - Department of Rasa Shastra and Bhaishajya Kalpana, All India Institute of
      Ayurveda, New Delhi, India.
FAU - Dang, Poonam
AU  - Dang P
AD  - Department of Rasa Shastra and Bhaishajya Kalpana, All India Institute of
      Ayurveda, New Delhi, India.
FAU - Kumar, Vijay
AU  - Kumar V
AD  - Department of Rasa Shastra and Bhaishajya Kalpana, All India Institute of
      Ayurveda, New Delhi, India.
FAU - Rana, Rakesh
AU  - Rana R
AD  - Statistics Section, Central Council for Research in Ayurvedic Sciences, New
      Delhi, India.
FAU - Yadav, Pramod
AU  - Yadav P
AD  - Department of Rasa Shastra and Bhaishajya Kalpana, All India Institute of
      Ayurveda, New Delhi, India.
FAU - Prajapati, P K
AU  - Prajapati PK
AD  - Department of Rasa Shastra and Bhaishajya Kalpana, All India Institute of
      Ayurveda, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20211023
PL  - India
TA  - Ayu
JT  - Ayu
JID - 7605807
PMC - PMC8614209
OTO - NOTNLM
OT  - Ayurveda
OT  - concomitant use
OT  - diabetes
OT  - herb-drug interactions
COIS- There are no conflicts of interest.
EDAT- 2020/04/01 00:00
MHDA- 2020/04/01 00:01
CRDT- 2021/12/15 12:24
PHST- 2020/04/15 00:00 [received]
PHST- 2020/12/30 00:00 [revised]
PHST- 2021/01/18 00:00 [accepted]
PHST- 2021/12/15 12:24 [entrez]
PHST- 2020/04/01 00:00 [pubmed]
PHST- 2020/04/01 00:01 [medline]
AID - 10.4103/ayu.AYU_81_20 [doi]
AID - AYU-41-72 [pii]
PST - ppublish
SO  - Ayu. 2020 Apr-Jun;41(2):72-78. doi: 10.4103/ayu.AYU_81_20. Epub 2021 Oct 23.


PMID- 34752531
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211111
IS  - 8755-1225 (Print)
IS  - 1549-4810 (Linking)
VI  - 36
IP  - 2
DP  - 2020 Apr
TI  - Parallel Assessment of Chemotherapy Adherence and Supportive Therapy Adherence on
      Occurrence and Minimization of Adverse Drug Reactions Among Cancer Patients: A
      Clinical-Based Observational Study.
PG  - 72-77
LID - 10.1177/8755122520901739 [doi]
AB  - Background: Cancer is a disease that is inevitably treated using chemotherapy,
      but the cytotoxic drugs used in the treatment have the potency to cause adverse
      drug reactions (ADRs). Thus, supportive therapy plays an essential role in
      managing the untoward effects of the cancer drugs in patients. This highlights
      the importance of medication adherence in managing the disease, mitigating and
      preventing the occurrence of chemotherapy-induced ADR without compromising the
      health status of the cancer population. Objective: To assess the adherence to
      chemotherapy and supportive therapy and to evaluate type and degree of causality 
      of ADRs observed in cancer patients. Methods: On ethics committee approval, a
      6-month observational study was conducted among recruited cancer patients
      undergoing chemotherapy in a tertiary care hospital. Morisky Medication Adherence
      Measurement Scale-8 was employed to assess the medication adherence, and ADR
      causality was determined using Naranjo ADR Probability Scale. Results: Ninety
      cancer patients participated in the study, out of which females were 61.11%.
      Chemotherapy adherence in comparison to supportive drugs was observed to be more 
      (21.11%). Twelve different combination of ADR were reported in the subjects with 
      variability in the degree of causality assessment. Conclusion and Relevance: The 
      distinction of adherence to the medication used in cancer management with marked 
      level of ADR was well depicted in the study, implicating the necessity of prudent
      symbiotic practice of an oncology pharmacist, patient, and physician relationship
      in optimizing the quality of life of cancer patients by imparting vigilant
      efforts in medication adherence.
CI  - (c) The Author(s) 2020.
FAU - Kumar, Jyoti
AU  - Kumar J
AD  - KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
FAU - Gudhoor, Manjula
AU  - Gudhoor M
AUID- ORCID: https://orcid.org/0000-0002-7173-6408
AD  - KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
FAU - Ganachari, Madiwalayya Shivakantayya
AU  - Ganachari MS
AD  - KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20200122
PL  - United States
TA  - J Pharm Technol
JT  - The Journal of pharmacy technology : jPT : official publication of the
      Association of Pharmacy Technicians
JID - 8504643
PMC - PMC7047245
OTO - NOTNLM
OT  - adherence
OT  - adverse drug reactions
OT  - cancer
OT  - chemotherapy
OT  - pharmaceutical care
OT  - supportive care
COIS- Declaration of Conflicting Interests: The author(s) declared no potential
      conflicts of interest with respect to the research, authorship, and/or
      publication of this article.
EDAT- 2020/04/01 00:00
MHDA- 2020/04/01 00:01
CRDT- 2021/11/09 17:30
PHST- 2021/11/09 17:30 [entrez]
PHST- 2020/04/01 00:00 [pubmed]
PHST- 2020/04/01 00:01 [medline]
AID - 10.1177/8755122520901739 [doi]
AID - 10.1177_8755122520901739 [pii]
PST - ppublish
SO  - J Pharm Technol. 2020 Apr;36(2):72-77. doi: 10.1177/8755122520901739. Epub 2020
      Jan 22.


PMID- 32222721
OWN - NLM
STAT- MEDLINE
DCOM- 20210106
LR  - 20210106
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 26
DP  - 2020 Mar 29
TI  - The Study of Subthalamic Deep Brain Stimulation for Parkinson Disease-Associated 
      Camptocormia.
PG  - e919682
LID - 10.12659/MSM.919682 [doi]
AB  - BACKGROUND Camptocormia is an axis symptom of Parkinson disease. It remains
      uncertain whether treatment with medications and surgery are effective. In this
      study, we assessed the efficacy of subthalamic nucleus deep brain stimulation
      (STN DBS) in Parkinson disease-associated camptocormia and explored some of its
      mechanisms. MATERIAL AND METHODS Parkinson disease-associated camptocormia was
      diagnosed by the following procedures. All patients underwent bilateral STN DBS. 
      The patents' camptocormia was rated by degree and MDS Unified Parkinson's Disease
      Rating Scale (UPDRS) item 3.13 before and after DBS surgery. Rehabilitation and
      psychological interventions were used after surgery, in addition to adjustments
      of medication and stimulus parameters. The treatment effects on camptocormia were
      assessed comparing medication-off (presurgery) versus stimulation-on
      (post-surgery). Ethical approval for this study was provided through the Center
      of Human Research Ethics Committee (No. 2019-35). This study trial was registered
      in Chinese Clinical Trial Registry (No. ChiCTR1900022655). All the participants
      provided written informed consent. RESULTS After DBS surgery, all of study
      patients' symptoms were improved, with different levels of improvement. The
      minimum and maximum improvement rates were 20% and 100% respectively. The score
      of item 3.13 of the MDS-UPDRS III and the degree of camptocormia were found to be
      obviously improved (P<0.05). CONCLUSIONS STN DBS can improve Parkinson
      disease-associated camptocormia; STN DBS assisted with rehabilitation and
      psychological intervention appears to be more effective.
FAU - Liang, Siquan
AU  - Liang S
AD  - Department of Neurosurgery, Tianjin Huanhu Hosptial, Tianjin, China (mainland).
FAU - Yu, Yang
AU  - Yu Y
AD  - Department of Neurological Rehabilitation, Tianjin Huanhu Hosptial, Tianjin,
      China (mainland).
FAU - Li, Haitao
AU  - Li H
AD  - Department of Neurosurgery, Tianjin Huanhu Hosptial, Tianjin, China (mainland).
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Neurological Rehabilitation, Tianjin Huanhu Hosptial, Tianjin,
      China (mainland).
FAU - Cheng, Yuanyuan
AU  - Cheng Y
AD  - Department of Neurological Rehabilitation, Tianjin Huanhu Hosptial, Tianjin,
      China (mainland).
FAU - Yang, Hechao
AU  - Yang H
AD  - Department of Psychology, Tianjin Huanhu Hosptial, Tianjin, China (mainland).
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200329
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
RN  - Camptocormia
SB  - IM
MH  - Aged
MH  - Deep Brain Stimulation/*methods
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Muscular Atrophy, Spinal/diagnosis/etiology/physiopathology/*therapy
MH  - Parkinson Disease/complications/physiopathology/*therapy
MH  - Spinal Curvatures/diagnosis/etiology/physiopathology/*therapy
MH  - Subthalamic Nucleus/*physiology
MH  - Treatment Outcome
PMC - PMC7139194
EDAT- 2020/03/31 06:00
MHDA- 2021/01/07 06:00
CRDT- 2020/03/31 06:00
PHST- 2020/03/31 06:00 [entrez]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2021/01/07 06:00 [medline]
AID - 919682 [pii]
AID - 10.12659/MSM.919682 [doi]
PST - epublish
SO  - Med Sci Monit. 2020 Mar 29;26:e919682. doi: 10.12659/MSM.919682.


PMID- 32222699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 2
TI  - Engaging Patients and Professionals to Evaluate the Seriousness of Maternal and
      Child Health Outcomes: Protocol for a Modified Delphi Study.
PG  - e16478
LID - 10.2196/16478 [doi]
AB  - BACKGROUND: Maternal weight gain during pregnancy is one of the few potentially
      modifiable risk factors for many adverse maternal and child health outcomes.
      Defining the optimal pregnancy weight gain range is difficult because, while
      lower weight gain may prevent some outcomes, such as maternal and child obesity, 
      it may increase the risk of others such as fetal growth restriction and infant
      death. These health outcomes vary in their seriousness to mothers and their
      health care providers, and these differences in seriousness should be taken into 
      account when determining optimal weight gain ranges. However, the relative
      seriousness that women and their care providers place on different health
      outcomes is unknown. OBJECTIVE: We will determine the seriousness of 11 maternal 
      and child health outcomes that have been consistently associated with pregnancy
      weight gain. We will achieve this by engaging patients and maternal and child
      health professionals using an online modified Delphi panel process. METHODS: We
      aim to recruit a racially/ethnically and geographically diverse group of 90 US
      maternal and child health professionals and 90 women who are pregnant or less
      than 2 years postpartum. We will conduct 3 concurrent panels using the ExpertLens
      system, a previously evaluated online modified Delphi system that combines 2
      rounds of rating with 1 round of feedback and moderated online discussion. In
      Round 1, panelists are asked to rate the seriousness of each health outcome on a 
      scale of 0-100 and to provide a rationale for their scores. In Round 2, panelists
      will review their responses relative to those of other panelists. They will
      discuss their seriousness ratings anonymously using a moderated online discussion
      board. In Round 3, participants will revise their Round 1 responses based on
      group feedback and discussion. Each round will be open for 1-2 weeks. RESULTS:
      The study protocol was reviewed by our ethics boards and did not require approval
      as human research. A pilot study of 6 professionals and 7 patients was completed 
      in December 2019. CONCLUSIONS: Our numeric estimates of the seriousness of
      maternal and child health outcomes will enable future studies to determine
      pregnancy weight gain ranges that balance the risks of low and high weight gain
      for mothers and children. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):
      DERR1-10.2196/16478.
CI  - (c)Lisa M Bodnar, Dmitry Khodyakov, Katherine P Himes, Jessica G Burke, Sara
      Parisi, Jennifer A Hutcheon. Originally published in JMIR Research Protocols
      (http://www.researchprotocols.org), 02.06.2020.
FAU - Bodnar, Lisa M
AU  - Bodnar LM
AUID- ORCID: https://orcid.org/0000-0001-9427-5467
AD  - Department of Epidemiology, University of Pittsburgh Graduate School of Public
      Health, Pittsburgh, PA, United States.
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, United States.
AD  - Magee-Womens Research Institute, Pittsburgh, PA, United States.
FAU - Khodyakov, Dmitry
AU  - Khodyakov D
AUID- ORCID: https://orcid.org/0000-0002-2818-6906
AD  - RAND Health Care, Santa Monica, CA, United States.
FAU - Himes, Katherine P
AU  - Himes KP
AUID- ORCID: https://orcid.org/0000-0002-4949-2929
AD  - Department of Obstetrics, Gynecology, and Reproductive Sciences, University of
      Pittsburgh School of Medicine, Pittsburgh, PA, United States.
AD  - Magee-Womens Research Institute, Pittsburgh, PA, United States.
FAU - Burke, Jessica G
AU  - Burke JG
AUID- ORCID: https://orcid.org/0000-0002-0439-7653
AD  - Department of Behavioral and Community Health Sciences, University of Pittsburgh 
      Graduate School of Public Health, Pittsburgh, PA, United States.
FAU - Parisi, Sara
AU  - Parisi S
AUID- ORCID: https://orcid.org/0000-0002-7094-2912
AD  - Department of Epidemiology, University of Pittsburgh Graduate School of Public
      Health, Pittsburgh, PA, United States.
FAU - Hutcheon, Jennifer A
AU  - Hutcheon JA
AUID- ORCID: https://orcid.org/0000-0002-6618-6018
AD  - Department of Obstetrics and Gynaecology, University of British Columbia,
      Vancouver, BC, Canada.
LA  - eng
GR  - R01 HD094777/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20200602
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC7298634
OTO - NOTNLM
OT  - Delphi method
OT  - ExpertLens
OT  - children
OT  - mothers
OT  - online stakeholder engagement panels
OT  - patient engagement
OT  - pregnancy
EDAT- 2020/03/31 06:00
MHDA- 2020/03/31 06:01
CRDT- 2020/03/31 06:00
PHST- 2019/10/03 00:00 [received]
PHST- 2020/03/21 00:00 [accepted]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2020/03/31 06:01 [medline]
PHST- 2020/03/31 06:00 [entrez]
AID - v9i6e16478 [pii]
AID - 10.2196/16478 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2020 Jun 2;9(6):e16478. doi: 10.2196/16478.


PMID- 32222653
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 194
DP  - 2020 Jul
TI  - Ethical and medicolegal aspects in the management of neurosurgical emergencies
      among Jehovah's Witnesses: Clinical implications and review.
PG  - 105798
LID - S0303-8467(20)30141-4 [pii]
LID - 10.1016/j.clineuro.2020.105798 [doi]
AB  - When an incapacitated Jehovah's Witness neurologically deteriorates and requires 
      immediate craniectomy, institutional protocols may delay surgery if the patient's
      refusal of blood products is ambiguous. We are among the first to describe such
      an ethically contentious case in emergency neurosurgery, review the morbidity of 
      operative delays, discuss medicolegal concerns raised, and provide a detailed
      guide to hemostasis in patients who refuse blood products. We discuss the case of
      a 46-year-old woman presented with nausea, vomiting, and right-sided weakness,
      progressing to stupor over several hours. When an initial Computed Tomography
      (CT) scan showed a large, left-sided intraparenchymal hematoma with significant
      midline shift, she was booked for an emergency hemicraniectomy. According to the 
      family, she was a Jehovah's Witness and would have refused blood consent, but was
      without the proper documentation. Despite her worsening neurological status, an
      indeterminate blood consent delayed surgery for more than two hours. Her
      neurological exam did not improve postoperatively, and she later expired. The
      ethical, legal, and operative concerns that arise in the emergency neurosurgical 
      treatment of Jehovah's Witness patients pose unique management challenges. Since 
      operative delay is a preventable cause of mortality in patients requiring urgent 
      craniectomy, and the likelihood of requiring a transfusion from hemorrhage is
      minimal, an ambiguous blood consent should not postpone a potentially life-saving
      treatment. For the beneficence and autonomy of Jehovah's Witness patients,
      institutional policies should respect the family's wishes in order to expedite
      surgical decompression. In addition to discussing the nuances of such ethical
      considerations, we also provide a detailed list of commonly used, topical and
      parenteral hemostatic agents from the neurosurgical operating room which,
      depending on whether they are blood-derived, either should or should not be used 
      when treating a Jehovah's Witness.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Taylor, Blake E S
AU  - Taylor BES
AD  - Department of Neurosurgery, Rutgers- New Jersey Medical School, Newark, NJ, USA.
FAU - Narayan, Vinayak
AU  - Narayan V
AD  - Department of Neurosurgery, Rutgers- Robert Wood Johnson Medical School, New
      Brunswick, NJ, USA.
FAU - Jumah, Fareed
AU  - Jumah F
AD  - Department of Neurosurgery, Rutgers- Robert Wood Johnson Medical School, New
      Brunswick, NJ, USA.
FAU - Al-Mufti, Fawaz
AU  - Al-Mufti F
AD  - Department of Neurology and Neurosurgery, Westchester Medical Center, Valhalla,
      NY, USA.
FAU - Nosko, Michael
AU  - Nosko M
AD  - Department of Neurosurgery, Rutgers- Robert Wood Johnson Medical School, New
      Brunswick, NJ, USA.
FAU - Roychowdhury, Sudipta
AU  - Roychowdhury S
AD  - Department of Radiology, Rutgers- Robert Wood Johnson Medical School, New
      Brunswick, NJ, USA; Department of Neurology, Rutgers- Robert Wood Johnson Medical
      School, New Brunswick, NJ, USA.
FAU - Nanda, Anil
AU  - Nanda A
AD  - Department of Neurosurgery, Rutgers- New Jersey Medical School, Newark, NJ, USA; 
      Department of Neurosurgery, Rutgers- Robert Wood Johnson Medical School, New
      Brunswick, NJ, USA.
FAU - Gupta, Gaurav
AU  - Gupta G
AD  - Department of Neurosurgery, Rutgers- Robert Wood Johnson Medical School, New
      Brunswick, NJ, USA. Electronic address: guptaga@rwjms.rutgers.eu.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20200319
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
SB  - IM
MH  - Blood Loss, Surgical
MH  - Blood Transfusion/*ethics
MH  - Decompression, Surgical/ethics
MH  - Emergency Medical Services/*ethics
MH  - Female
MH  - Hemostasis
MH  - Humans
MH  - Intracranial Hemorrhages/diagnostic imaging/surgery
MH  - *Jehovah's Witnesses
MH  - Middle Aged
MH  - Neurologic Examination
MH  - Neurosurgery/*ethics
MH  - Neurosurgical Procedures/*ethics
MH  - Time-to-Treatment
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - *Blood loss
OT  - *Emergency neurosurgery
OT  - *Ethics
OT  - *Jehovah Witness
OT  - *Medicolegal
OT  - *Operative delay
COIS- Declaration of Competing Interest None.
EDAT- 2020/03/31 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/03/31 06:00
PHST- 2019/10/04 00:00 [received]
PHST- 2020/03/16 00:00 [revised]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
PHST- 2020/03/31 06:00 [entrez]
AID - S0303-8467(20)30141-4 [pii]
AID - 10.1016/j.clineuro.2020.105798 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2020 Jul;194:105798. doi: 10.1016/j.clineuro.2020.105798. 
      Epub 2020 Mar 19.


PMID- 32222570
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1532-2793 (Electronic)
IS  - 0260-6917 (Linking)
VI  - 89
DP  - 2020 Jun
TI  - Teaching about globalization for nursing practice: Medical tourism as an
      exemplar.
PG  - 104403
LID - S0260-6917(19)31147-5 [pii]
LID - 10.1016/j.nedt.2020.104403 [doi]
FAU - Camargo-Plazas, Pilar
AU  - Camargo-Plazas P
AD  - School of Nursing, Queen's University, Room 203, Cataraqui Building, 92 Barrie
      Street, Kingston, Ontario K7L 3N6, Canada. Electronic address: mdpc@queensu.ca.
FAU - Silva E Silva, Vanessa
AU  - Silva E Silva V
AD  - School of Nursing, Queen's University, Cataraqui Building, 92 Barrie Street,
      Kingston, Ontario K7L 3N6, Canada. Electronic address: 14vses@queensu.ca.
FAU - Duhn, Lenora
AU  - Duhn L
AD  - School of Nursing, Queen's University, Room 227, Cataraqui Building, 92 Barrie
      Street, Kingston, Ontario K7L 3N6, Canada. Electronic address: duhnl@queensu.ca.
FAU - Tregunno, Deborah
AU  - Tregunno D
AD  - School of Nursing, Queen's University, Room 236, Cataraqui Building, 92 Barrie
      Street, Kingston, Ontario K7L 3N6, Canada. Electronic address:
      tregunno@queensu.ca.
LA  - eng
PT  - Editorial
DEP - 20200319
PL  - Scotland
TA  - Nurse Educ Today
JT  - Nurse education today
JID - 8511379
MH  - Humans
MH  - *Internationality
MH  - Medical Tourism/*ethics/*legislation & jurisprudence
MH  - *Nurse's Role
MH  - Risk Factors
MH  - *Teaching
MH  - Tissue and Organ Procurement/ethics
OTO - NOTNLM
OT  - *Critical pedagogy
OT  - *Ethics
OT  - *Globalization
OT  - *Nursing undergraduate education
OT  - *Organ donation
OT  - *Organ tourism
OT  - *Transplant tourism
EDAT- 2020/03/31 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/03/31 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2019/11/02 00:00 [revised]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
PHST- 2020/03/31 06:00 [entrez]
AID - S0260-6917(19)31147-5 [pii]
AID - 10.1016/j.nedt.2020.104403 [doi]
PST - ppublish
SO  - Nurse Educ Today. 2020 Jun;89:104403. doi: 10.1016/j.nedt.2020.104403. Epub 2020 
      Mar 19.


PMID- 32222392
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20201112
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 52
IP  - 5
DP  - 2020 Jun
TI  - Anonymity and Organ Donation: Ethical and Policy Implications After the Opinion
      Released by the Italian Committee for Bioethics.
PG  - 1525-1527
LID - S0041-1345(19)31592-1 [pii]
LID - 10.1016/j.transproceed.2020.01.079 [doi]
AB  - According to Law 91/1999, art. 18, in Italy, health care professionals and
      administrative staff involved in the process of organ collection and
      transplantation are required to ensure anonymity of both the donor and the
      recipient. Against this backdrop, in 2018, the Italian Committee for Bioethics
      (ICB) released an official opinion titled "Opinion on the preservation of the
      anonymity of donor and receiver in the transplantation of organs" that offers a
      new perspective on the topic, effectively opening the possibility of anonymity
      ending at certain conditions. The relevance of anonymity within the transplant
      network is a globally recognized principle with a strong ethical value. In this
      article, based on the experience of one author directly involved in the ICB
      opinion drafting, we examine the document and discuss how such a proposal could
      be implemented at the legislative level.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Petrini, Carlo
AU  - Petrini C
AD  - Bioethics Unit, Italian National Institue of Health, Rome, Italy; Italian
      Committee for Bioethics, Rome, Italy. Electronic address: carlo.petrini@iss.it.
FAU - Riva, Luciana
AU  - Riva L
AD  - Bioethics Unit, Italian National Institue of Health, Rome, Italy.
FAU - Floridia, Giovanna
AU  - Floridia G
AD  - Bioethics Unit, Italian National Institue of Health, Rome, Italy.
FAU - Mannelli, Chiara
AU  - Mannelli C
AD  - Candiolo Cancer Istitute, FPO-IRCCS, Candiolo, (TO), Italy; Italian Ministry of
      Health, Rome, Italy; Department of Philosophy and Educational Sciences,
      University of Turin, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200325
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Attitude
MH  - *Bioethical Issues
MH  - Data Anonymization/*ethics
MH  - Humans
MH  - Italy
MH  - Organ Transplantation/*ethics/legislation & jurisprudence
MH  - Tissue Donors/*ethics/legislation & jurisprudence
MH  - Tissue and Organ Procurement/*ethics/legislation & jurisprudence
MH  - Transplant Recipients/legislation & jurisprudence
EDAT- 2020/03/31 06:00
MHDA- 2020/11/13 06:00
CRDT- 2020/03/31 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/01/02 00:00 [accepted]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2020/03/31 06:00 [entrez]
AID - S0041-1345(19)31592-1 [pii]
AID - 10.1016/j.transproceed.2020.01.079 [doi]
PST - ppublish
SO  - Transplant Proc. 2020 Jun;52(5):1525-1527. doi:
      10.1016/j.transproceed.2020.01.079. Epub 2020 Mar 25.


PMID- 32222342
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 1557-9816 (Electronic)
IS  - 0955-470X (Linking)
VI  - 34
IP  - 3
DP  - 2020 Jul
TI  - The ethical debate over child priority in post-mortem organ allocation: A scoping
      review and practical-ethical outlook.
PG  - 100543
LID - S0955-470X(20)30016-1 [pii]
LID - 10.1016/j.trre.2020.100543 [doi]
AB  - BACKGROUND: Organ allocation guidelines in many countries give children relative 
      priority, but the normative justification of child priority is seldom
      articulated. METHODOLOGY: We conducted a scoping review of the recent
      international literature (2013-2019) to identify moral positions and normative
      frameworks to justify or criticize pediatric priority in all kind of organ
      allocation. We identified 11 relevant papers. RESULTS: Our analysis revealed a
      complex juxtaposition of pro and contra argumentations along three main normative
      lines: a) equal treatment of each individual, b) individual benefit, and c)
      social benefit and the public good. The general type of argument can be found
      independent of the organ allocated. For each of these three lines we identified
      and categorized two types of argumentations: those in favor and those critical of
      the priority rule. Additionally, we discuss a problematic issue that has not yet 
      been mentioned in the literature, namely the effects of age thresholds related to
      child-priority rules in organ allocation. We illustrate this problem with an
      analysis of selected German data with allocated postmortal kidneys and livers.
      These data show non-normal distributions of organ transplantations and waiting
      times for patients between the ages of 16 and 19. DISCUSSION: Our overview serves
      as a matrix to reconsider existing guideline policy. The review can assist policy
      makers or experts on organ allocation committees in increasing the transparency
      of child priority rules, in explaining their justifications, and in reforming
      existing guidelines.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Schicktanz, Silke
AU  - Schicktanz S
AD  - Institute for Medical Ethics and History of Medicine, University Medical Center
      Gottingen, 37073 Gottingen, Germany. Electronic address:
      silke.schicktanz@medizin.uni-goettingen.de.
FAU - Simon, Alfred
AU  - Simon A
AD  - Institute for Medical Ethics and History of Medicine, University Medical Center
      Gottingen, 37073 Gottingen, Germany; German Academy of Medical Ethics, 37073
      Gottingen, Germany. Electronic address: simon@aem-online.de.
FAU - Raphael, Susanne
AU  - Raphael S
AD  - Institute for Medical Ethics and History of Medicine, University Medical Center
      Gottingen, 37073 Gottingen, Germany. Electronic address:
      Susanne.raphael@medizin.uni-goettingen.de.
FAU - Ahlert, Marlies
AU  - Ahlert M
AD  - Department of Law and Economics, Martin-Luther University Halle-Wittenberg,
      D-06099 Halle (Saale), Germany. Electronic address:
      marlies.ahlert@wiwi.uni-halle.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200317
PL  - United States
TA  - Transplant Rev (Orlando)
JT  - Transplantation reviews (Orlando, Fla.)
JID - 8804364
SB  - IM
MH  - Child
MH  - Humans
MH  - Morals
MH  - Organ Transplantation/*ethics
MH  - Practice Guidelines as Topic
MH  - Resource Allocation/*ethics
MH  - *Transplant Recipients
MH  - Waiting Lists
OTO - NOTNLM
OT  - *Child priority
OT  - *Ethics
OT  - *Organ allocation
OT  - *Policy
OT  - *Scoping review
OT  - *Transplantation
EDAT- 2020/03/31 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/03/31 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
PHST- 2020/03/31 06:00 [entrez]
AID - S0955-470X(20)30016-1 [pii]
AID - 10.1016/j.trre.2020.100543 [doi]
PST - ppublish
SO  - Transplant Rev (Orlando). 2020 Jul;34(3):100543. doi: 10.1016/j.trre.2020.100543.
      Epub 2020 Mar 17.


PMID- 32222179
OWN - NLM
STAT- MEDLINE
DCOM- 20200410
LR  - 20220531
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 151
IP  - 4
DP  - 2020 Apr
TI  - Ethical issues when a dentist with an active practice dies.
PG  - 305-306
LID - S0002-8177(20)30111-2 [pii]
LID - 10.1016/j.adaj.2020.02.009 [doi]
FAU - Burns, Jill M
AU  - Burns JM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - IM
CIN - J Am Dent Assoc. 2020 Aug;151(8):555-556. PMID: 32718479
MH  - *Dentists
MH  - *Ethics, Dental
MH  - Humans
EDAT- 2020/03/31 06:00
MHDA- 2020/04/11 06:00
CRDT- 2020/03/31 06:00
PHST- 2019/12/13 00:00 [received]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/02/09 00:00 [accepted]
PHST- 2020/03/31 06:00 [entrez]
PHST- 2020/03/31 06:00 [pubmed]
PHST- 2020/04/11 06:00 [medline]
AID - S0002-8177(20)30111-2 [pii]
AID - 10.1016/j.adaj.2020.02.009 [doi]
PST - ppublish
SO  - J Am Dent Assoc. 2020 Apr;151(4):305-306. doi: 10.1016/j.adaj.2020.02.009.


PMID- 35770263
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2671-8790 (Print)
IS  - 2671-8790 (Linking)
VI  - 34
IP  - 1
DP  - 2020 Mar 31
TI  - The effect of a mandatory choice systemfor organ donation after brain death
      onethical legitimacy and potential efficacyin a mathematical model.
PG  - 2-7
LID - 10.4285/kjt.2020.34.1.2 [doi]
AB  - Background: The "mandatory choice" system is an organ donation system that forces
      individuals to clearly express their choice about organ donation. Although this
      system is widely practiced in western countries, it has not yet been implemented 
      in many Asian countries. This study aimed to compare the possible outcomes of a
      mandatory choice system and the current system in Korea. Methods: A mathematical 
      model was used to predict outcomes under each system. A structured questionnaire 
      assuming two systems (current opt-in and mandatory choice) was developed to
      investigate participants' decisions on organ donation and the family's consent
      after brain death in each system. Participants who enrolled in this survey were
      100 couples (200 people). Results: The total number of donors decreased slightly 
      from 102 (51.0%) in the current opt-in system to 93 (46.5%) in the mandatory
      choice system. The rate of achieving autonomy was increased from 62.5% (125/200) 
      in the current system to 68.0% (136/200) in the mandatory choice system. The
      achievement of negative autonomy was relatively higher in the mandatory choice
      system (73.6% [67/91] vs. 63.2% [55/87]). Conclusions: The mandatory choice
      system can supplement the weak ethical point of the current system by increasing 
      the achievement of autonomy.
CI  - Copyright: (c) 2020 The Korean Society for Transplantation.
FAU - Cho, In Soo
AU  - Cho IS
AUID- ORCID: https://orcid.org/0000-0002-0086-3493
AD  - Department of Surgery, Dongsan Medical Center, Keimyung University School of
      Medicine, Daegu, Korea.
FAU - Lee, Hyun Yong
AU  - Lee HY
AUID- ORCID: https://orcid.org/0000-0002-9814-1412
AD  - Division of Transplantation and Vascular Surgery, Department of Surgery, Dongsan 
      Medical Center, Keimyung University School of Medicine, Daegu, Korea.
FAU - Park, Ui Jun
AU  - Park UJ
AUID- ORCID: https://orcid.org/0000-0002-5203-4216
AD  - Division of Transplantation and Vascular Surgery, Department of Surgery, Dongsan 
      Medical Center, Keimyung University School of Medicine, Daegu, Korea.
FAU - Kim, Hyoung Tae
AU  - Kim HT
AUID- ORCID: https://orcid.org/0000-0002-9714-8778
AD  - Division of Transplantation and Vascular Surgery, Department of Surgery, Dongsan 
      Medical Center, Keimyung University School of Medicine, Daegu, Korea.
FAU - Roh, Young-Nam
AU  - Roh YN
AUID- ORCID: https://orcid.org/0000-0002-0799-1578
AD  - Division of Transplantation and Vascular Surgery, Department of Surgery, Dongsan 
      Medical Center, Keimyung University School of Medicine, Daegu, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Transplant
JT  - Korean journal of transplantation
JID - 101775609
PMC - PMC9188930
OTO - NOTNLM
OT  - Autonomy
OT  - Mandatory choice system
OT  - Organ donation
EDAT- 2020/03/31 00:00
MHDA- 2020/03/31 00:01
CRDT- 2022/06/30 02:54
PHST- 2019/11/26 00:00 [received]
PHST- 2020/01/27 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2022/06/30 02:54 [entrez]
PHST- 2020/03/31 00:00 [pubmed]
PHST- 2020/03/31 00:01 [medline]
AID - 10.4285/kjt.2020.34.1.2 [doi]
AID - KJT-34-1-002 [pii]
PST - ppublish
SO  - Korean J Transplant. 2020 Mar 31;34(1):2-7. doi: 10.4285/kjt.2020.34.1.2.


PMID- 32222138
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1851-8265 (Electronic)
IS  - 1669-2381 (Linking)
VI  - 16
DP  - 2020 Mar 5
TI  - [Rationalism and the disembodiment of modern childbirth: the case for an ecology 
      of childbirth].
PG  - e2548
LID - 10.18294/sc.2020.2548 [doi]
AB  - The paper proposes a genealogy of the biomedical paradigm surrounding childbirth,
      with the aim of deconstructing the principles of rationalism that led to the
      objectification of the body and to the consequent commodification of birth. We
      intend to demonstrate how such a conception of the body and of sensibility
      determines the birth process, which leads us to consider it an event that is
      relational in nature. Methodologically, this deconstruction is carried out
      through a critical-descriptive genealogy of the theoretical assumptions of the
      rationalist conception of the body. By developing the concept of ecology of
      childbirth, we intend to call into question this relational nature of the body
      and to recover the value of corporeality and embodiment as a language of
      proximity, within a theoretical framework of the ethics of difference. This
      vindication of the ecological-relational nature of sensibility has the potential 
      to establish a dynamic of responsibility and cooperation capable of subverting
      the rationalist logic of control and the dominion of the current biomedical
      paradigm.
FAU - Viola, Federico Ignacio
AU  - Viola FI
AD  - Doctor en Filosofia. Investigador Asistente, Instituto de Filosofia, Universidad 
      Catolica de Santa Fe; Consejo Nacional de Investigaciones Cientificas y Tecnicas,
      Santa Fe, Argentina. fviola@ucsf.edu.ar.
FAU - Bonet de Viola, Ana Maria
AU  - Bonet de Viola AM
AD  - Doctora en Derecho. Docente Investigadora, Universidad Catolica de Santa Fe,
      Consejo Nacional de Investigaciones Cientificas y Tecnicas, Santa Fe, Argentina. 
      abonet@ucsf.edu.ar.
FAU - Espinoza, Marisa
AU  - Espinoza M
AD  - Medica Tocoginecologa. Docente Investigadora, Universidad Catolica de Santa Fe,
      Universidad Nacional del Litoral. Santa Fe, Argentina. mespinoza@ucsf.edu.ar.
LA  - spa
PT  - Journal Article
TT  - El racionalismo y la descorporalizacion moderna del parto: por una ecologia del
      nacimiento.
DEP - 20200305
PL  - Argentina
TA  - Salud Colect
JT  - Salud colectiva
JID - 101276038
SB  - IM
MH  - *Commodification
MH  - Female
MH  - *Human Body
MH  - Humans
MH  - *Medicalization
MH  - Obstetrics
MH  - *Parturition/physiology
MH  - *Philosophy
MH  - Pleasure
MH  - Pregnancy
MH  - Sensation
MH  - Social Control, Informal
OTO - NOTNLM
OT  - Birth
OT  - Commodification
OT  - Medicalization
OT  - Obstetrics
OT  - Social Control
EDAT- 2020/03/30 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/03/30 06:00
PHST- 2019/09/11 00:00 [received]
PHST- 2020/01/03 00:00 [accepted]
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
AID - 10.18294/sc.2020.2548 [doi]
PST - epublish
SO  - Salud Colect. 2020 Mar 5;16:e2548. doi: 10.18294/sc.2020.2548.


PMID- 32222125
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210929
IS  - 1303-6165 (Electronic)
IS  - 1300-0144 (Linking)
VI  - 50
IP  - SI-2
DP  - 2020 Nov 3
TI  - Update on liver transplantation-newer aspects
PG  - 1642-1650
LID - 10.3906/sag-2002-17 [doi]
AB  - Liver transplantation (LT) remains the only therapeutic option offering gold
      standard treatment for end-stage liver disease (ESLD) and acute liver failure
      (ALF), as well as for certain early-stage liver tumors. Currently, the greatest
      challenge facing LT is the simple fact that there are not enough adequate livers 
      for all the potential patients that could benefit from LT. Despite efforts to
      expand the donor pool to include living and deceased donors, organ shortage is
      still a major problem in many countries. To solve this problem, the use of
      marginal liver grafts has become an inevitable choice. Although the definition of
      marginal grafts or criteria for expanded donor selection has not been clarified
      yet, they are usually defined as grafts that may potentially cause primary
      nonfunction, impaired function, or late loss of function. These include steatotic
      livers, older donors, donors with positive viral serology, split livers, and
      donation after cardiac death (DCD). Therefore, to get the best outcome from these
      liver grafts, donor-recipient selection should be vigilant. Alcohol- related
      liver disease (ALD) is one of the most common indications for LT in Europe and
      North America. Traditionally, LT for alcoholic liver disease was kept limited for
      patients who have achieved 6 months of abstinence, in part due to social and
      ethical concerns regarding the use of a limited resource. However, the majority
      of patients with severe alcoholic hepatitis who fail medical therapy will not
      live long enough to meet this requirement. Besides, the initial results of early 
      liver transplantation (ELT) without waiting for 6 months of abstinence period are
      satisfactory in severe alcoholic hepatitis (SAH). It will be important to take
      care of these patients from a newer perspective.
CI  - This work is licensed under a Creative Commons Attribution 4.0 International
      License.
FAU - Metin, Olga
AU  - Metin O
AUID- ORCID: 0000-0003-4673-5099
AD  - Department of Internal Medicine, Okmeydani Training and Research Hospital,
      Istanbul, Turkey
FAU - Simsek, Cem
AU  - Simsek C
AUID- ORCID: 0000-0002-7037-5233
AD  - Department of Gastroenterology, School of Medicine, Hacettepe University, Ankara,
      Turkey
FAU - Gurakar, Ahmet
AU  - Gurakar A
AUID- ORCID: 0000-0002-2221-9148
AD  - Division of Gastroenterology and Hepatology, Johns Hopkins University School of
      Medicine Liver Transplant Program Baltimore, Maryland, USA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201103
PL  - Turkey
TA  - Turk J Med Sci
JT  - Turkish journal of medical sciences
JID - 9441758
SB  - IM
MH  - Age Factors
MH  - End Stage Liver Disease/*surgery
MH  - HIV Infections
MH  - Hepatitis, Alcoholic
MH  - Humans
MH  - *Liver Transplantation
MH  - Obesity
MH  - Tissue Donors
MH  - *Tissue and Organ Procurement
PMC - PMC7672347
OTO - NOTNLM
OT  - *extended criteria donor
OT  - *liver transplantation
OT  - *marginal liver grafts
OT  - *severe alcoholic hepatitis
EDAT- 2020/03/30 06:00
MHDA- 2021/08/21 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/03/22 00:00 [accepted]
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
AID - 10.3906/sag-2002-17 [doi]
PST - epublish
SO  - Turk J Med Sci. 2020 Nov 3;50(SI-2):1642-1650. doi: 10.3906/sag-2002-17.


PMID- 32221818
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20201214
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 2
DP  - 2020 Jun
TI  - Creating Space for Feminist Ethics in Medical School.
PG  - 111-124
LID - 10.1007/s10730-020-09403-x [doi]
AB  - Alongside clinical practice, medical schools now confront mounting reasons to
      examine nontraditional approaches to ethics. Increasing awareness of systems of
      oppression and their effects on the experiences of trainees, patients,
      professionals, and generally on medical care, is pushing medical curriculum into 
      an unfamiliar territory. While there is room throughout medical school to take up
      these concerns, ethics curricula are well-positioned to explore new pedagogical
      approaches. Feminist ethics has long addressed systems of oppression and broader 
      structures of power. Some of its established concepts can offer distinct value as
      medical climates change and adapt in response to increased awareness of the
      experiences of marginalized individuals and populations. In this essay, we offer 
      a set of concepts from feminist ethics that have a fundamental role to play in
      medical school curriculum: relationality, relational autonomy, and epistemic
      justice. Though these concepts are not exhaustive, they can be taught in tandem
      with the concepts that have historically grounded ethics education in medical
      school, such as autonomy and beneficence. Ultimately, we contend that these
      concepts hold particular value in ethics curriculum insofar as they diversify
      mainstream ethical approaches, directly address the pervasiveness of systems of
      oppression in medicine, and recognize the voices and concerns that may be
      marginalized in standard approaches.
FAU - Campelia, Georgina D
AU  - Campelia GD
AD  - University of Washington School of Medicine, & UW Medicine Ethics Consultation
      Service, Seattle, USA. gdcamp@uw.edu.
FAU - Feinsinger, Ashley
AU  - Feinsinger A
AD  - David Geffen School of Medicine and the Department of Philosophy at UCLA, Los
      Angeles, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Education, Medical, Undergraduate/methods
MH  - Ethics, Medical/*education
MH  - *Feminism
MH  - Humans
MH  - Schools, Medical/organization & administration/trends
EDAT- 2020/03/30 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - 10.1007/s10730-020-09403-x [doi]
AID - 10.1007/s10730-020-09403-x [pii]
PST - ppublish
SO  - HEC Forum. 2020 Jun;32(2):111-124. doi: 10.1007/s10730-020-09403-x.


PMID- 32221816
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 1572-8498 (Electronic)
IS  - 0956-2737 (Linking)
VI  - 32
IP  - 3
DP  - 2020 Sep
TI  - Physicians' End of Life Discussions with Patients: Is There an Ethical Obligation
      to Discuss Aid in Dying?
PG  - 227-238
LID - 10.1007/s10730-020-09402-y [doi]
AB  - Since Oregon implemented its Death with Dignity Act, many additional states have 
      followed suit demonstrating a growing understanding and acceptance of aid in
      dying (AID) processes. Traditionally, the patient has been the one to request and
      seek this option out. However, as Death with Dignity acts continue to expand, it 
      will impact the role of physicians and bring up questions over whether physicians
      have the ethical obligation to facilitate a conversation about AID with patients 
      during end of life discussions. Patients have the right to make informed
      decisions about their health, which implies that physicians have an obligation to
      discuss with and inform patients of the options that will accomplish the
      patients' goals of care. We will argue that physicians have an ethical obligation
      to inform certain patients about AID (in qualifying states) during end of life
      care discussions. We will also address what this obligation encompasses and
      explore guidelines of when and how these conversations should occur and proceed. 
      Earlier guidelines, presented by various palliative care and ethics experts, for 
      proceeding with such conversations have mostly agreed that the discussion of
      hospice and end of life care with patients should be initiated early and that the
      individual goals of a patient during the remaining duration of life should be
      thoroughly examined before discussion of appropriate options. In discussing AID, 
      physicians should never recommend but inform patients about the basics so that
      they can make an informed decision. If patients express further interest in AID, 
      the physician should open up the dialogue to address the reasoning behind this
      decision versus other possible treatments to ensure that patients clearly
      comprehend the process and implications of their decision. Ultimately, any end of
      life choice should be made by patients with the full capacity to express what
      they envision for the remaining duration of life and to comprehend the advantages
      and disadvantages of all the possible options.
FAU - Zhou, Yan Ming Jane
AU  - Zhou YMJ
AUID- ORCID: https://orcid.org/0000-0001-5428-9207
AD  - Alden March Bioethics Institute, Albany Medical College, Albany, NY, USA.
      yanming.jzhou@gmail.com.
FAU - Shelton, Wayne
AU  - Shelton W
AUID- ORCID: https://orcid.org/0000-0002-4346-963X
AD  - Alden March Bioethics Institute, Albany Medical College, Albany, NY, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - HEC Forum
JT  - HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues
JID - 8917455
MH  - Euthanasia/*ethics/psychology
MH  - Humans
MH  - *Physician-Patient Relations
MH  - Terminal Care/*ethics/methods
OTO - NOTNLM
OT  - Aid in dying
OT  - Death with dignity
OT  - End of life
OT  - Hospice
OT  - Informed consent
OT  - Palliative care
EDAT- 2020/03/30 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - 10.1007/s10730-020-09402-y [doi]
AID - 10.1007/s10730-020-09402-y [pii]
PST - ppublish
SO  - HEC Forum. 2020 Sep;32(3):227-238. doi: 10.1007/s10730-020-09402-y.


PMID- 32221596
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220113
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 41
IP  - 25
DP  - 2020 Jul 1
TI  - A putative placebo analysis of the effects of sacubitril/valsartan in heart
      failure across the full range of ejection fraction.
PG  - 2356-2362
LID - 10.1093/eurheartj/ehaa184 [doi]
AB  - AIMS: The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against
      active controls given renin-angiotensin system inhibitors (RASi) are ethically
      mandated in heart failure (HF) with reduced ejection fraction and are used in the
      vast majority of patients with HF with preserved ejection fraction. To estimate
      the effects of sacubitril/valsartan had it been tested against a placebo control,
      we made indirect comparisons of the effects of sacubitril/valsartan with putative
      placebos in HF across the full range of left ventricular ejection fraction
      (LVEF). METHODS AND RESULTS: We analysed patient-level data from the PARADIGM-HF 
      and PARAGON-HF trials (n = 13 194) and the CHARM-Alternative and CHARM-Preserved 
      trials (n = 5050, candesartan vs. placebo). The rate ratio (RR) of
      sacubitril/valsartan vs. putative placebo was estimated by the product of the RR 
      for sacubitril/valsartan vs. RASi and the RR for RASi vs. placebo. Total HF
      hospitalizations and cardiovascular death were analysed using the negative
      binomial method. Treatment effects were estimated using cubic spline methods by
      ejection fraction as a continuous measure. Across the range of LVEF,
      sacubitril/valsartan was associated with a RR 0.54 [95% confidence interval (CI) 
      0.45-0.65] for the recurrent primary endpoint compared with putative placebo (P <
      0.001). Treatment benefits of sacubitril/valsartan vs. putative placebo varied
      non-linearly with LVEF with attenuation of effects observed at LVEF above 60%.
      When analyzing data from PARADIGM-HF and CHARM-Alternative, the estimated risk
      reduction of sacubitril/valsartan vs. putative placebo was 48% (95% CI 35-58%); P
      < 0.001. When analyzing data from PARAGON-HF and CHARM-Preserved (with LVEF >/=
      45%), the estimated risk reduction of sacubitril/valsartan vs. putative placebo
      was 29% (95% CI 7-46%); P = 0.013. Across the full range of LVEF, consistent
      effects were observed for time-to-first endpoints: first primary endpoint (RR
      0.72, 95% CI 0.64-0.82), first HF hospitalization (RR 0.67, 95% CI 0.58-0.78),
      cardiovascular death (RR 0.76, 95% CI 0.64-0.89), and all-cause death (RR 0.83,
      95% CI 0.71-0.96); all P < 0.02. CONCLUSION: This putative placebo analysis
      reinforces the treatment benefits of sacubitril/valsartan on risk of adverse
      cardiovascular events across the full range of LVEF, with most pronounced effects
      observed at a LVEF up to 60%.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the
      European Society of Cardiology.
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75
      Francis St, Boston, MA 02115, USA.
FAU - Jhund, Pardeep S
AU  - Jhund PS
AD  - British Heart Foundation Cardiovascular Research Centre, Institute of
      Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place,
      Glasgow G12 8TA, UK.
FAU - Claggett, Brian L
AU  - Claggett BL
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75
      Francis St, Boston, MA 02115, USA.
FAU - Packer, Milton
AU  - Packer M
AD  - Baylor Heart and Vascular Institute, Baylor University Medical Center, 3500
      Gaston Avenue, Dallas, TX 75246, USA.
AD  - National Heart and Lung Institute, Imperial College, Royal Brompton Hospital,
      Dovehouse Street, London SW3 6LY, UK.
FAU - Widimsky, Jiri
AU  - Widimsky J
AD  - Department of Medicine III, Charles University in Prague, First Faculty of
      Medicine, Katerinska 32, CZ-121 08 Prague 2, Czech Republic.
FAU - Seferovic, Petar
AU  - Seferovic P
AD  - Heart Failure Center, Faculty of Medicine, University of Belgrade, 8 Koste
      Todorovica, Belgrade 11000, Serbia.
FAU - Rizkala, Adel
AU  - Rizkala A
AD  - Global Drug Development, Novartis Pharmaceuticals, 1 Health Plaza, East Hanover, 
      NJ 07936, USA.
FAU - Lefkowitz, Martin
AU  - Lefkowitz M
AD  - Global Drug Development, Novartis Pharmaceuticals, 1 Health Plaza, East Hanover, 
      NJ 07936, USA.
FAU - Shi, Victor
AU  - Shi V
AD  - Global Drug Development, Novartis Pharmaceuticals, 1 Health Plaza, East Hanover, 
      NJ 07936, USA.
FAU - McMurray, John J V
AU  - McMurray JJV
AD  - British Heart Foundation Cardiovascular Research Centre, Institute of
      Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place,
      Glasgow G12 8TA, UK.
FAU - Solomon, Scott D
AU  - Solomon SD
AD  - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75
      Francis St, Boston, MA 02115, USA.
LA  - eng
GR  - UL1 TR002541/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
CIN - Eur Heart J. 2020 Jul 1;41(25):2363-2365. PMID: 32350518
MH  - Aminobutyrates/therapeutic use
MH  - *Angiotensin Receptor Antagonists/therapeutic use
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Stroke Volume
MH  - Tetrazoles/therapeutic use
MH  - Valsartan
MH  - Ventricular Function, Left
PMC - PMC7327532
OTO - NOTNLM
OT  - *Placebo
OT  - *Sacubitril/valsartan
OT  - *Statistics
OT  - *Trials
EDAT- 2020/03/30 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/01/25 00:00 [received]
PHST- 2020/02/07 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - 5813082 [pii]
AID - 10.1093/eurheartj/ehaa184 [doi]
PST - ppublish
SO  - Eur Heart J. 2020 Jul 1;41(25):2356-2362. doi: 10.1093/eurheartj/ehaa184.


PMID- 32221489
OWN - NLM
STAT- MEDLINE
DCOM- 20200608
LR  - 20210327
IS  - 1476-5446 (Electronic)
IS  - 1462-0049 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Mar
TI  - How should we anaesthetise painful mandibular premolars?
PG  - 20-21
LID - 10.1038/s41432-020-0080-z [doi]
AB  - Design Randomised clinical trialStudy population The present study evaluated
      patients of different genders aged between 18-65 years old. The study design and 
      the language of the consent form were approved by the Ethics Committee at Tehran 
      University of Medical Sciences (TUMS) (approval code: IR.TUMS.REC.1394.1906). The
      study was registered in the Iranian Registry of Clinical Trials.Data Analysis The
      evaluation was performed using the Heft-Parker Visual Analog Scale (HP VAS) and
      complemented with the electrical pulp test accuracy to determine the success of
      anaesthesia Results In this study, the success rate was 93.8% (95% CI
      79.19-99.23) for mental/incisive nerve block (MINB), and 81.2% (95% CI
      63.56-92.79) for inferior alveolar nerve block (IANB). The difference was not
      significant (p = 0.26). An interesting result was the combination of both
      techniques was 100% successful in the failed cases (2 in MINB group; 6 in IANB
      group).Conclusions In conclusion, MINB using 4% Articaine showed a similar
      success rate as IANB using 4% Articaine in local anaesthesia for mandibular
      premolars with irreversible pulpitis. The beginning of anaesthesia was faster for
      MINB, and the injection was painless. The post-injection pain for MINB was higher
      than for IANB. Both techniques showed similar efficacy.
FAU - de Almeida Barros Mourao, Carlos Fernando
AU  - de Almeida Barros Mourao CF
AD  - Department of Oral Surgery, Dentistry School, Fluminense Federal University,
      Niteroi, Rio de Janeiro, Brazil; South Bay Dental Institute, California, USA.
FAU - Javid, Kayvon
AU  - Javid K
AD  - South Bay Dental Institute, California, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - England
TA  - Evid Based Dent
JT  - Evidence-based dentistry
JID - 100883603
RN  - 0 (Anesthetics, Local)
RN  - D3SQ406G9X (Carticaine)
SB  - IM
CON - Clin Oral Investig. 2019 Feb;23(2):839-845. PMID: 29882110
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anesthetics, Local
MH  - Bicuspid
MH  - Carticaine
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - Mandibular Nerve
MH  - Middle Aged
MH  - *Nerve Block
MH  - Pain
MH  - *Pulpitis
MH  - Young Adult
EDAT- 2020/03/30 06:00
MHDA- 2020/06/09 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/06/09 06:00 [medline]
AID - 10.1038/s41432-020-0080-z [doi]
AID - 10.1038/s41432-020-0080-z [pii]
PST - ppublish
SO  - Evid Based Dent. 2020 Mar;21(1):20-21. doi: 10.1038/s41432-020-0080-z.


PMID- 32221445
OWN - NLM
STAT- MEDLINE
DCOM- 20200721
LR  - 20210327
IS  - 1476-5373 (Electronic)
IS  - 0007-0610 (Linking)
VI  - 228
IP  - 6
DP  - 2020 Mar
TI  - Evaluation of the assessment of tooth wear by general dental practitioners.
PG  - 423-428
LID - 10.1038/s41415-020-1314-3 [doi]
AB  - Aim To evaluate currently available methods for assessing and monitoring tooth
      wear in a general dental practice environment.Method A questionnaire was
      developed and used to obtain data. Models were used to test the dentists'
      assessment of tooth wear. Ethical permission was obtained.Results Twenty general 
      dental practitioners were interviewed and 100% were aware of the use of study
      models, 50% about the use of photographs and 45% of the BEWE. Methods used to
      assess and monitor tooth wear were study models (75%), photographs (65%), BEWE
      (10%), Smith & Knight index (0%) and no method (15%). Sixty-five percent of
      dentists were unaware of any guidelines on monitoring tooth wear. In comparing
      serial photographs, no participant correctly identified all the wear changes and 
      25% thought a change had occurred when one hadn't. Statistical analysis showed a 
      sensitivity of only 73% with a specificity of 75%. In comparing serial study
      models (same cases as used in the photographs), 55% of participants identified a 
      change when no change occurred and 50-60% of participants were able to correctly 
      identify if wear had or had not occurred. Participants graded the models
      according to BEWE. Statistical analysis of these results shows a sensitivity of
      just 69% with a specificity of only 55%. The inter-operator agreement (Fliess'
      Kappa) showed an even lower degree of agreement was found with only 0.12, which
      suggests only a slight level of agreement, less than that with
      photographs.Conclusion Dentists do not seem to be aware of the current guidelines
      but do make reasonable attempts to monitor tooth wear. None of the currently
      available methods are ideal and even the use of serial study models is open to
      much inter-operator variability.
FAU - O'Hara, Mark
AU  - O'Hara M
AD  - Senior Clinical Teacher, Deputy Team Lead, Faculty of Dentistry, Oral &
      Craniofacial Sciences, King's College London, London, UK.
FAU - Millar, Brian J
AU  - Millar BJ
AD  - Professor, Consultant in Restorative Dentistry, Faculty of Dentistry, Oral &
      Craniofacial Sciences, King's College London, London, UK. brian.millar@kcl.ac.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br Dent J
JT  - British dental journal
JID - 7513219
SB  - IM
MH  - Dentists
MH  - Humans
MH  - Professional Role
MH  - *Tooth Attrition
MH  - *Tooth Erosion
MH  - *Tooth Wear
EDAT- 2020/03/30 06:00
MHDA- 2020/07/22 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/07/22 06:00 [medline]
AID - 10.1038/s41415-020-1314-3 [doi]
AID - 10.1038/s41415-020-1314-3 [pii]
PST - ppublish
SO  - Br Dent J. 2020 Mar;228(6):423-428. doi: 10.1038/s41415-020-1314-3.


PMID- 32221067
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 13
DP  - 2020 Mar
TI  - Evaluation of the effects of photobiomodulation on orthodontic movement of molar 
      verticalization with mini-implant: A randomized double-blind protocol study.
PG  - e19430
LID - 10.1097/MD.0000000000019430 [doi]
AB  - INTRODUCTION: Loss of a dental element can generate several repercussions in the 
      stomatognathic system. According to the latest survey by the Ministry of Health, 
      in 2010, Brazilian adults had, on average, 7 missing teeth. This loss may lead to
      movement of the adjacent teeth and the antagonist, which would make prosthetic
      rehabilitation harder to do. Anchoring systems, such as mini-implants, have been 
      increasingly used as a treatment option because they act with heavy but
      controlled forces and without side effects. Recent studies have shown that
      photobiomodulation (PBM) can accelerate orthodontic movement in molar intrusion. 
      The objective of this study will be to evaluate the effect of PBM on the
      acceleration of the orthodontic movement of molar verticalization and its effect 
      on pain and inflammation of the periodontal tissues. PATIENT CONCERNS:: the
      concerns assessments will be done over the study using anamnesis interviews and
      specific questionnaire. DIAGNOSIS: verticalization will be evaluated by clinical 
      and radiographic analysis. INTERVENTIONS: Thirty four healthy patients aged 30 to
      60 years, who need to recover the prosthetic space for oral rehabilitation after 
      loss of the posterior inferior dental elements and inclination of the adjacent
      element, will be randomly divided into 2 groups: G1 (control group) -
      verticalization by mini-implant + PBM simulation (placebo); G2 (experimental
      group) - verticalization by mini-implant + PBM. The movements will occur with the
      aid of mini-implants and elastomeric chains ligatures. The PBM will occur with
      diode laser application, 808 nm, 100 mW, receiving 1J per point, 10 seconds, 10
      points (5 per buccal and 5 per lingual) and radiant exposure of 25 J/cm. The
      orthodontic forces of verticalization (corresponding to any exchange of
      elastomeric ligation) will be applied every 30 days and the PBM will be applied
      immediately, 3 and 7 days of each month, for a period of 3 months. The crevicular
      gingival fluid (CGF) will be collected on the 1st, 3rd, and 7th days after the
      first activation, and then on the 3rd day of the following 2 months. OUTCOMES:
      Interleukins IL1beta, IL-6, IL-8, IL-10, and TNF-alpha will be analyzed by ELISA.
      Panoramic radiography will be performed at baseline and 90 afterwards to
      ascertain the amount (in degrees) of verticalization. To evaluate the pain, the
      Visual Analog Scale (VAS) will be used in all the consultations, and to evaluate 
      the quality of life, the Oral Health Impact Profile (OHIP-14) questionnaire will 
      be applied. Analgesics will be given and the quantity of drugs will be counted.
      If the data are normal, they will be submitted to Student t test. The data will
      be presented as means +/- SD and the value of p will be defined as <0.05.
      DISCUSSION: This protocol will determine the effectiveness of photobiomoduation
      regarding the orthodontic movement of molar verticalization. ETHICS AND
      DISSEMINATION: This protocol received approval from the Human Research Ethics
      Committee of Universidade Nove de Julho (certificate number: 3 533 219). The data
      will be published in a peer-reviewed periodical.
FAU - Murakami-Malaquias-Silva, Felipe
AU  - Murakami-Malaquias-Silva F
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Rosa, Ellen Perim
AU  - Rosa EP
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Almeida, Paulo Andre
AU  - Almeida PA
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Schalch, Tania Oppido
AU  - Schalch TO
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Tenis, Carlos Alberto
AU  - Tenis CA
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Negreiros, Renata Matalon
AU  - Negreiros RM
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Horliana, Ricardo Fidos
AU  - Horliana RF
AD  - Academic specialization student in Temporomandibular Disorder and Orofacial pain,
      Universidade Nove de Julho, UNINOVE.
FAU - Garcez, Aguinaldo Silva
AU  - Garcez AS
AD  - Sao Leopoldo Mandic, School of Dentistry, Campinas.
FAU - Fernandes, Marcella Ueda R
AU  - Fernandes MUR
AD  - Sao Leopoldo Mandic, School of Dentistry, Campinas.
FAU - Tortamano, Andre
AU  - Tortamano A
AD  - Coordinator of Graduation course.
AD  - Department of Orthodontics, School of Dentistry, University of Sao Paulo, Sao
      Paulo, Brazil.
FAU - Motta, Lara Jansiski
AU  - Motta LJ
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Bussadori, Sandra Kalil
AU  - Bussadori SK
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
FAU - Horliana, Anna Carolina Ratto Tempestini
AU  - Horliana ACRT
AD  - Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade
      Nove de Julho, UNINOVE.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Interleukins)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Brazil
MH  - Double-Blind Method
MH  - Female
MH  - Gingival Crevicular Fluid
MH  - Humans
MH  - Interleukins/*biosynthesis
MH  - Lasers, Semiconductor
MH  - Low-Level Light Therapy/*methods
MH  - Male
MH  - Middle Aged
MH  - Molar/*radiation effects
MH  - Pain/etiology
MH  - Pain Measurement
MH  - Quality of Life
MH  - Tooth Movement Techniques/adverse effects/*methods
MH  - Tumor Necrosis Factor-alpha/biosynthesis
PMC - PMC7220149
EDAT- 2020/03/30 06:00
MHDA- 2020/04/14 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
AID - 10.1097/MD.0000000000019430 [doi]
AID - 00005792-202003270-00008 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Mar;99(13):e19430. doi: 10.1097/MD.0000000000019430.


PMID- 32221063
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20220413
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 13
DP  - 2020 Mar
TI  - Taohong Siwu decoction for femoral head necrosis: A protocol for systematic
      review.
PG  - e19368
LID - 10.1097/MD.0000000000019368 [doi]
AB  - BACKGROUNDS: Femoral head necrosis is one of the most common orthopedic diseases 
      which can be diagnosed in all ages with different reasons. Taohong Siwu decoction
      (TSD) has been widely used in the treatment of femoral head necrosis. However, as
      far as we know, there is still a lack of supporting evidence regarding the
      efficacy of TSD for femoral head necrosis. Therefore, this protocol aims to
      evaluate the effectiveness and safety of TSD for femoral head necrosis. METHODS: 
      Eight electronic databases, including PubMed, the Cochrane Central Register of
      Controlled Trials, EMBASE, Web of Science, Chinese Biomedical Literature
      Database, China National Knowledge Infrastructure, Technology Periodical
      database, (Chinese Scientific Journal Database) and Wanfang Database will be
      searched from the time when the respective databases were established to January 
      2020. Randomized controlled trials of TSD in the treatment of femoral head
      necrosis will be collected. After evaluating the quality of methodology and
      extracting valid data, the final meta-analysis will be carried out with software 
      Revman 5.3. ETHICS AND DISSEMINATION: The results of this systematic review will 
      offer implications of the use of TSD treatment for Femoral Head Necrosis. It uses
      aggregated published data instead of individual patient data and does not require
      an ethical board review and approval. The findings will be published in a
      peer-reviewed journal and disseminated in conference presentations. RESULTS: The 
      results of this study will offer implications of the use of TSD treatment for FHN
      with this meta-analysis. CONCLUSION: The conclusion of this study will provide
      recent evidence to assess whether TSD is effective and safe in the treatment of
      FHN.
FAU - Chen, Guoming
AU  - Chen G
AD  - Guangzhou University of Chinese Medicine.
FAU - Xie, Yaying
AU  - Xie Y
AD  - Guangzhou University of Chinese Medicine.
FAU - Liu, Yunyun
AU  - Liu Y
AD  - Guangzhou University of Chinese Medicine.
FAU - Jin, Shanmi
AU  - Jin S
AD  - Guangzhou University of Chinese Medicine.
FAU - Chen, Ziyin
AU  - Chen Z
AD  - Guangzhou University of Chinese Medicine.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Guangzhou University of Chinese Medicine.
FAU - Shi, Peiyu
AU  - Shi P
AD  - Guangzhou University of Chinese Medicine.
FAU - Zhu, Junxia
AU  - Zhu J
AD  - Guangzhou University of Chinese Medicine.
FAU - Deng, Jieyi
AU  - Deng J
AD  - Guangzhou University of Chinese Medicine.
FAU - Liang, Haorui
AU  - Liang H
AD  - Guangzhou University of Chinese Medicine.
FAU - Zhou, Chi
AU  - Zhou C
AD  - Department of Orthopedics, First Affiliated Hospital of Guangzhou University of
      Chinese Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Taohong Siwu decoction II)
SB  - IM
MH  - China
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Femur Head Necrosis/*drug therapy
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
PMC - PMC7220747
EDAT- 2020/03/30 06:00
MHDA- 2020/04/14 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
AID - 10.1097/MD.0000000000019368 [doi]
AID - 00005792-202003270-00004 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Mar;99(13):e19368. doi: 10.1097/MD.0000000000019368.


PMID- 32221022
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20201222
IS  - 1525-1438 (Electronic)
IS  - 1048-891X (Linking)
VI  - 30
IP  - 5
DP  - 2020 May
TI  - Effectiveness of CO2 laser on urogenital syndrome in women with a previous
      gynecological neoplasia: a multicentric study.
PG  - 590-595
LID - 10.1136/ijgc-2019-001028 [doi]
AB  - BACKGROUND: Many women diagnosed with gynecological cancers undergo adjuvant
      therapy, which may lead to transient or permanent menopause that ultimately leads
      to urogenital syndrome and vulvovaginal atrophy. Studies advise against the use
      of estrogen in women with a history of hormone-dependent cancer. One alternative 
      is vaginal microablative fractional CO2 laser, which promotes tissue regeneration
      through the production of collagen and elastic fibers. OBJECTIVE: To evaluate the
      effectiveness of CO2 laser in the treatment of urogenital syndrome-in particular,
      symptomatic vulvovaginal atrophy in women who have survived gynecological
      cancers. METHODS: A retrospective study was carried out, including all patients
      with a history of gynecological cancers and vulvovaginal atrophy who underwent
      CO2 laser treatment between November 2012 and February 2018 in four Italian
      centers. The study was approved by the local ethics committee of each
      participating institution. The inclusion criteria were women aged between 18 and 
      75; Eastern Cooperative Oncology Group performance status <2; and history of
      breast, ovarian, cervical, or uterus cancer. Patients had to have vulvovaginal
      atrophy and at least one of the following symptoms of urogenital syndrome:
      vaginal dryness, dyspareunia, vaginal introitus pain, burning, or itching. Three 
      applications were administered at baseline, 30 days, and 60 days. All patients
      were evaluated before the first laser session, at each session, and 4 weeks after
      the last session. In particular, patients were asked to indicate the intensity of
      symptoms before the first session and 4 weeks after the last session, using
      Visual Analog Scale (VAS) scoring from 0 ('no discomfort') to 10 ('maximum
      discomfort'). RESULTS: A total of 1213 patients underwent CO2 laser treatment and
      of these, 1048 were excluded because they did not meet the inclusion criteria in 
      the analysis. Finally, a total of 165 patients were included in the study. The
      mean age at the time of treatment was 53 years (range 31-73). Dryness improved by
      66%, dyspareunia improved by 59%, burning improved by 66%, pain at introitus
      improved by 54%, and itching improved by 54%. The side effects were evaluated as 
      pain greater than VAS score 6 during and after the treatment period. No side
      effects were seen in any sessions. CONCLUSIONS: Fractional microablative CO2
      laser therapy offers an effective strategy in the management of the symptoms of
      genitourinary syndrome in post-menopausal women and in survivors of gynecological
      cancer.
CI  - (c) IGCS and ESGO 2020. No commercial re-use. See rights and permissions.
      Published by BMJ.
FAU - Angioli, Roberto
AU  - Angioli R
AD  - Department of Gynecology, University Campus Biomedico, Rome, Italy.
FAU - Stefano, Salvatore
AU  - Stefano S
AD  - Department of Obstetrics and Ginecology, IRCCS San Raffaele Hospital, Milan,
      Lombardia, Italy.
FAU - Filippini, Maurizio
AU  - Filippini M
AD  - Department of Ostetrics and Gynecology, Hospital State of Republic of San Marino,
      San Marino, Republic of San Marino.
FAU - Pieralli, Annalisa
AU  - Pieralli A
AD  - Department of Women and Child Health, Careggi University Hospital, Florence,
      Toscana, Italy.
FAU - Montera, Roberto
AU  - Montera R
AD  - Department of Gynecology, University Campus Biomedico, Rome, Italy.
FAU - Plotti, Francesco
AU  - Plotti F
AD  - Department of Gynecology, University Campus Biomedico, Rome, Italy.
FAU - Gatti, Alessandra
AU  - Gatti A
AD  - Department of Gynecology, University Campus Biomedico, Rome, Italy.
FAU - Bartolone, Martina
AU  - Bartolone M
AD  - Department of Gynecology, University Campus Biomedico, Rome, Italy.
FAU - Luvero, Daniela
AU  - Luvero D
AD  - Department of Gynecology, University Campus Biomedico, Rome, Italy
      d.luvero@unicampus.it.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200327
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the
      International Gynecological Cancer Society
JID - 9111626
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atrophy
MH  - Breast Neoplasms/*pathology/therapy
MH  - Female
MH  - Female Urogenital Diseases/pathology/*surgery
MH  - Genital Neoplasms, Female/*pathology/therapy
MH  - Humans
MH  - Laser Therapy/*methods
MH  - Lasers, Gas
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Syndrome
MH  - Vagina/pathology
MH  - Vulva/pathology
OTO - NOTNLM
OT  - *genitalia, female
OT  - *gynecology
OT  - *postoperative care
OT  - *quality of life (PRO)/palliative care
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2020/12/23 06:00
CRDT- 2020/03/30 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2019/12/06 00:00 [revised]
PHST- 2019/12/10 00:00 [accepted]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - ijgc-2019-001028 [pii]
AID - 10.1136/ijgc-2019-001028 [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2020 May;30(5):590-595. doi: 10.1136/ijgc-2019-001028. Epub
      2020 Mar 27.


PMID- 32220915
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 26
TI  - Exploration of stress management interventions to address psychological stress in
      stroke survivors: a protocol for a scoping review.
PG  - e035592
LID - 10.1136/bmjopen-2019-035592 [doi]
AB  - INTRODUCTION: Several studies have shown that stroke survivors report
      experiencing high and unremitting levels of stress, which can negatively affect
      brain repair processes and psychological outcomes and thereby compromise
      recovery. However, it is presently unclear which interventions have been trialled
      to manage stress in stroke survivors and whether they translate to clinically
      relevant outcomes. The aim of this scoping review will be to examine stress
      management interventions in stroke survivors in order to map the types of
      interventions trialled, commonly reported stress outcome measures and whether a
      reduction in stress contributes to reductions in relevant clinical outcomes.
      METHODS AND ANALYSIS: The methodological framework described in Arksey and
      O'Malley will be applied to this review. A draft search strategy was developed in
      collaboration with an experienced senior health research librarian. A systematic 
      search of Medline, Embase, CINAHL, Cochrane library, PsycInfo and
      Clinicaltrials.gov as well as hand searching of reference lists and reviews will 
      identify relevant studies for inclusion. To be eligible for inclusion, studies
      must report on the outcomes of an intervention targeting stress management and
      resilience in stroke survivors. Study selection and critical appraisal of
      selected studies will be carried out independently by two authors, with
      discrepancies resolved by consensus. Data will be charted using a standard
      extraction form. Results will be tabulated and narratively summarised to
      highlight findings relevant to our research questions and to inform
      recommendations for future research. ETHICS AND DISSEMINATION: This study does
      not require ethics approval. This scoping review will provide a synthesis of
      evidence for stress management interventions in stroke survivors. It will
      identify and clarify the gaps in stress research specific to stroke pathologies
      and highlight promising interventions for future research. Findings will be
      relevant to researchers and healthcare workers and will be disseminated via
      publications in peer-reviewed journals and presented at conferences.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hinwood, Madeleine
AU  - Hinwood M
AUID- ORCID: 0000-0002-2225-973X
AD  - School of Medicine and Public Health, The University of Newcastle, Callaghan, New
      South Wales, Australia Madeleine.Hinwood@newcastle.edu.au.
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
FAU - Ilicic, Marina
AU  - Ilicic M
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
AD  - School of Biomedical Sciences and Pharmacy and Priority Research Centre for
      Stroke and Brain Injury, The University of Newcastle, Callaghan, New South Wales,
      Australia.
FAU - Gyawali, Prajwal
AU  - Gyawali P
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
AD  - School of Biomedical Sciences and Pharmacy and Priority Research Centre for
      Stroke and Brain Injury, The University of Newcastle, Callaghan, New South Wales,
      Australia.
AD  - NHMRC Centre for Research Excellence in Stroke Rehabilitation and Brain Recovery,
      Heidelberg, Victoria, Australia.
FAU - Kluge, Murielle Gabriela
AU  - Kluge MG
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
AD  - School of Biomedical Sciences and Pharmacy and Priority Research Centre for
      Stroke and Brain Injury, The University of Newcastle, Callaghan, New South Wales,
      Australia.
FAU - Coupland, Kirsten
AU  - Coupland K
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
AD  - School of Biomedical Sciences and Pharmacy and Priority Research Centre for
      Stroke and Brain Injury, The University of Newcastle, Callaghan, New South Wales,
      Australia.
AD  - Department of Neurobiology, Care Sciences and Society, Karolinska Institute,
      Stockholm, Stockholm County, Sweden.
FAU - Smith, Angela
AU  - Smith A
AD  - HNEHealth Libraries, Hunter New England Local Health District, New Lambton, New
      South Wales, Australia.
FAU - Nilsson, Michael
AU  - Nilsson M
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
AD  - School of Biomedical Sciences and Pharmacy and Priority Research Centre for
      Stroke and Brain Injury, The University of Newcastle, Callaghan, New South Wales,
      Australia.
AD  - NHMRC Centre for Research Excellence in Stroke Rehabilitation and Brain Recovery,
      Heidelberg, Victoria, Australia.
AD  - Centre for Rehab Innovations, The University of Newcastle, Callaghan, New South
      Wales, Australia.
FAU - Walker, Frederick Rohan
AU  - Walker FR
AD  - Hunter Medical Research Institute, New Lambton Heights, New South Wales,
      Australia.
AD  - School of Biomedical Sciences and Pharmacy and Priority Research Centre for
      Stroke and Brain Injury, The University of Newcastle, Callaghan, New South Wales,
      Australia.
AD  - NHMRC Centre for Research Excellence in Stroke Rehabilitation and Brain Recovery,
      Heidelberg, Victoria, Australia.
AD  - Centre for Rehab Innovations, The University of Newcastle, Callaghan, New South
      Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Humans
MH  - Review Literature as Topic
MH  - Stress, Psychological/*therapy
MH  - Stroke/*psychology/*therapy
MH  - Survivors/*psychology
PMC - PMC7170611
OTO - NOTNLM
OT  - *epidemiology
OT  - *mental health
OT  - *rehabilitation medicine
OT  - *stroke
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035592 [pii]
AID - 10.1136/bmjopen-2019-035592 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 26;10(3):e035592. doi: 10.1136/bmjopen-2019-035592.


PMID- 32220914
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 26
TI  - Protocol for a cross-sectional study measuring person-centredness among
      healthcare providers in Malaysian primary care clinics: the adaptation and
      validation of the Person-Centred Practice Inventory-Staff (PCPI-S) Questionnaire.
PG  - e034128
LID - 10.1136/bmjopen-2019-034128 [doi]
AB  - INTRODUCTION: Person-centred care (PCC) has become a global movement in
      healthcare. Despite this, the level of PCC is not routinely assessed in clinical 
      practice. This protocol describes the adaptation and validation of the
      Person-Centred Practice Inventory-Staff (PCPI-S) tool that will be used to assess
      person-centred practices of primary healthcare providers in Malaysia. METHODS AND
      ANALYSIS: To ensure conceptual and item equivalence, the original version of the 
      PCPI-S will be reviewed and adapted for cultural context by an expert committee. 
      The instrument will subsequently be translated into Malay language using the
      forward-backward translation method by two independent bilingual speaking
      individuals. This will be pretested in four primary care clinics and refined
      accordingly. The instrument will be assessed for its psychometric properties,
      such as test-retest reliability, construct and internal validity, using
      exploratory and confirmatory factor analysis. ETHICS AND DISSEMINATION: Study
      findings will be disseminated to healthcare professionals and academicians in the
      field through publication in peer-reviewed journals and conference presentations,
      as well as at managerial clinic sites for practice improvement. The study was
      approved by the Medical Research and Ethics Committee (MREC), Ministry of Health 
      Malaysia (KKM/NIHSEC/ P18-766 (14) and Monash University Human Research Ethics
      Committee (2018-14363-19627).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Balqis-Ali, Nur Zahirah
AU  - Balqis-Ali NZ
AD  - Institute for Health Systems Research, National Institutes of Health, Shah Alam, 
      Malaysia.
FAU - Saw, Pui San
AU  - Saw PS
AUID- ORCID: 0000-0001-8042-4353
AD  - School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia
      saw.pui.san@monash.edu.
AD  - Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia,
      Bandar Sunway, Malaysia.
FAU - Jailani, Anis Syakira
AU  - Jailani AS
AD  - Institute for Health Systems Research, National Institutes of Health, Shah Alam, 
      Malaysia.
FAU - Yeoh, Tze Wei
AU  - Yeoh TW
AD  - Institute for Health Systems Research, National Institutes of Health, Shah Alam, 
      Malaysia.
FAU - Fun, Weng Hong
AU  - Fun WH
AD  - Institute for Health Systems Research, National Institutes of Health, Shah Alam, 
      Malaysia.
FAU - Mohd-Salleh, Noridah
AU  - Mohd-Salleh N
AD  - Family Health Development Division, Ministry Of Health Malaysia, Putrajaya,
      Malaysia.
FAU - Tengku Bahanuddin, Tengku Putri Zaharah
AU  - Tengku Bahanuddin TPZ
AD  - Family Health Development Division, Ministry Of Health Malaysia, Putrajaya,
      Malaysia.
FAU - Medan, Catherine Anak
AU  - Medan CA
AD  - Family Health Development Division, Ministry Of Health Malaysia, Putrajaya,
      Malaysia.
FAU - Lee, Shaun Wen Huey
AU  - Lee SWH
AUID- ORCID: 0000-0001-7361-6576
AD  - School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia.
AD  - School of Pharmacy, Taylor's University Lakeside Campus, Subang Jaya, Malaysia.
FAU - Sararaks, Sondi
AU  - Sararaks S
AD  - Institute for Health Systems Research, National Institutes of Health, Shah Alam, 
      Malaysia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200326
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Health Personnel
MH  - Humans
MH  - Malaysia
MH  - *Patient-Centered Care
MH  - Primary Health Care
MH  - Psychometrics
MH  - Reproducibility of Results
MH  - Research Design
MH  - *Surveys and Questionnaires
PMC - PMC7170592
OTO - NOTNLM
OT  - *Malaysia
OT  - *PCPI-S
OT  - *cultural adaptation
OT  - *healthcare provider
OT  - *person-centred
OT  - *primary care
OT  - *study protocol
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
AID - bmjopen-2019-034128 [pii]
AID - 10.1136/bmjopen-2019-034128 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 26;10(3):e034128. doi: 10.1136/bmjopen-2019-034128.


PMID- 32220874
OWN - NLM
STAT- Publisher
LR  - 20200329
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Mar 27
TI  - Balancing professional obligations and risks to providers in learning healthcare 
      systems.
LID - medethics-2019-105658 [pii]
LID - 10.1136/medethics-2019-105658 [doi]
AB  - Clinicians and administrators have a professional obligation to contribute (OTC) 
      to improvement of healthcare quality. At the same time, participation in embedded
      research poses risks to healthcare institutions. Disclosure of an institution's
      sensitive information could endanger relationships with patients and undermine
      its reputation. The existing ethical framework (EF) for learning healthcare
      systems (LHSs) does not address the conflict between the OTC and institutional
      interests. Ethical guidance and policy regulation are needed to create a safe
      environment for embedded research. In this article we analyse the EF for LHSs and
      the concept of professionalism. We suggest that the EF should be supplemented
      with an obligation to protect provider's legitimate interests. We define
      legitimate interests as those that enable providers to discharge their primary
      duties. We argue that both the OTC and the obligation to protect legitimate
      interests are grounded in the concept of medical professionalism and can be
      understood as a matter of contract between a democratic society and medical
      professionals. The proposed supplemented EF can be implemented into a regulatory 
      system in three different ways: the self-regulating: where providers decide
      themselves how to balance the ethical claims, the centralised: where a
      governmental institution decides the right balance between providers' interests
      and interests of a health system; and the mediating: where medical professionals,
      the state and patients negotiate their interests. Our article contributes to the 
      discussion on ethical relevance of providers' interests and the regulatory model 
      for weighing opposite interests in LHSs.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Piasecki, Jan
AU  - Piasecki J
AUID- ORCID: http://orcid.org/0000-0003-1298-736X
AD  - Department of Philosophy and Bioethics, Faculty of Health Sciences, Jagiellonian 
      University Medical College, Krakow, Poland jan.piasecki@uj.edu.pl.
FAU - Dranseika, Vilius
AU  - Dranseika V
AD  - Department of Philosophy and Bioethics, Faculty of Health Sciences, Jagiellonian 
      University Medical College, Krakow, Poland.
AD  - Institute of Philosophy, Vilnius University, Vilnius, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - applied and professional ethics
OT  - interests of health personnel/institutions
OT  - public health ethics
OT  - quality of healthcare
OT  - research ethics
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2020/03/30 06:00
CRDT- 2020/03/30 06:00
PHST- 2019/06/27 00:00 [received]
PHST- 2020/01/28 00:00 [revised]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/03/30 06:00 [medline]
AID - medethics-2019-105658 [pii]
AID - 10.1136/medethics-2019-105658 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Mar 27. pii: medethics-2019-105658. doi:
      10.1136/medethics-2019-105658.


PMID- 32220873
OWN - NLM
STAT- Publisher
LR  - 20200329
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Mar 27
TI  - Embracing slippery slope on physician-assisted suicide and euthanasia could have 
      significant unintended consequences.
LID - medethics-2020-106089 [pii]
LID - 10.1136/medethics-2020-106089 [doi]
AB  - In a recent article Joshua James Hatherley argues that, if physician-assisted
      suicide (PAS) is morally permissible for patients suffering from somatic
      illnesses, it should be permissible for psychiatric patients as well. He argues
      that psychiatric disorders do not necessarily impair decision-making ability,
      that they are not necessarily treatable and that legalising PAS for psychiatric
      patients would not diminish research and therapeutic interest in psychiatric
      treatments or impair their recovery through loss of hope. However, by erasing
      distinction between somatic and psychiatric disorders on those grounds, he also
      erases distinction between healthy adults and patients (whether somatic or
      psychiatric) essentially implying that PAS should be available to all, for all
      reasons or, ultimately no reason. Furthermore, as psychiatric patients are much
      more likely to be a source of usable organs for transplantation, their broad
      inclusion would strengthen the link between PAS/euthanasia and organ donation,
      potentially undermining both as well as diminishing already declining general
      trust in medical authorities and professionals and public health authorities and 
      activists.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Buturovic, Zeljka
AU  - Buturovic Z
AUID- ORCID: http://orcid.org/0000-0002-1826-2362
AD  - Institute for Social Sciences, Belgrade 11000, Serbia zbuturovic@idn.org.rs.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - dead donor rule
OT  - euthanasia
OT  - public health ethics
OT  - suicide/assisted suicide
OT  - transplantation
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2020/03/30 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/01/22 00:00 [received]
PHST- 2020/03/13 00:00 [revised]
PHST- 2020/03/20 00:00 [accepted]
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/03/30 06:00 [medline]
AID - medethics-2020-106089 [pii]
AID - 10.1136/medethics-2020-106089 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Mar 27. pii: medethics-2020-106089. doi:
      10.1136/medethics-2020-106089.


PMID- 32220870
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
VI  - 46
IP  - 7
DP  - 2020 Jul
TI  - Limits of trust in medical AI.
PG  - 478-481
LID - 10.1136/medethics-2019-105935 [doi]
AB  - Artificial intelligence (AI) is expected to revolutionise the practice of
      medicine. Recent advancements in the field of deep learning have demonstrated
      success in variety of clinical tasks: detecting diabetic retinopathy from images,
      predicting hospital readmissions, aiding in the discovery of new drugs, etc. AI's
      progress in medicine, however, has led to concerns regarding the potential
      effects of this technology on relationships of trust in clinical practice. In
      this paper, I will argue that there is merit to these concerns, since AI systems 
      can be relied on, and are capable of reliability, but cannot be trusted, and are 
      not capable of trustworthiness. Insofar as patients are required to rely on AI
      systems for their medical decision-making, there is potential for this to produce
      a deficit of trust in relationships in clinical practice.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Hatherley, Joshua James
AU  - Hatherley JJ
AUID- ORCID: 0000-0002-8581-9669
AD  - School of Historical, Philosophical, and International Studies, Monash
      University, Clayton, VIC 3194, Australia joshua.hatherley@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200327
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
MH  - *Artificial Intelligence
MH  - Humans
MH  - Reproducibility of Results
MH  - *Trust
OTO - NOTNLM
OT  - *ethics
OT  - *information technology
OT  - *quality of health care
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/03/30 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - medethics-2019-105935 [pii]
AID - 10.1136/medethics-2019-105935 [doi]
PST - ppublish
SO  - J Med Ethics. 2020 Jul;46(7):478-481. doi: 10.1136/medethics-2019-105935. Epub
      2020 Mar 27.


PMID- 32220869
OWN - NLM
STAT- Publisher
LR  - 20200521
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Mar 27
TI  - Can bioethics be an honest way of making a living? A reflection on normativity,
      governance and expertise.
LID - medethics-2019-105954 [pii]
LID - 10.1136/medethics-2019-105954 [doi]
AB  - The authority of bioethics as a field of inquiry and of bioethicists as scholars 
      with a distinctive expertise is being questioned on various fronts. Sarah
      Franklin's 2019 Nature commentary 'Ethical research - the long and bumpy road
      from shirked to shared' is the latest example . In this paper, we respond to
      these challenges by focusing on two key issues. First, we discuss the theory and 
      practice of bioethics. We argue that both of these endeavours are fundamental
      components of this field of inquiry and that bioethics cannot be reduced to the
      contribution that it makes to the production of biopolicy, as Franklin suggests. 
      Second, we contend that bioethicists have distinctive skills and knowledge that
      place them at an epistemic advantage in discussing normative questions. Hence, we
      reject views that deny the specific contribution that bioethicists can bring to
      assessing the ethics and governance of science and technology. We conclude by
      arguing that-despite formal and substantive differences between
      disciplines-philosophers, social scientists and other scholars should join forces
      and engage in critical friendships rather than turf wars to move towards the just
      governance of science and technology.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Camporesi, Silvia
AU  - Camporesi S
AUID- ORCID: http://orcid.org/0000-0003-4135-1723
AD  - Global Health & Social Medicine, King's College London, London, UK.
FAU - Cavaliere, Giulia
AU  - Cavaliere G
AUID- ORCID: http://orcid.org/0000-0001-8703-1499
AD  - Medical School, Lancaster University, Lancaster, UK g.cavaliere@lancaster.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - philosophical ethics
OT  - public policy
OT  - sociology
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2020/03/30 06:00
CRDT- 2020/03/30 06:00
PHST- 2019/11/11 00:00 [received]
PHST- 2020/03/08 00:00 [revised]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/03/30 06:00 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - medethics-2019-105954 [pii]
AID - 10.1136/medethics-2019-105954 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Mar 27. pii: medethics-2019-105954. doi:
      10.1136/medethics-2019-105954.


PMID- 32220868
OWN - NLM
STAT- Publisher
LR  - 20200329
IS  - 1473-4257 (Electronic)
IS  - 0306-6800 (Linking)
DP  - 2020 Mar 27
TI  - Assessing data protection and governance in health information systems: a novel
      methodology of Privacy and Ethics Impact and Performance Assessment (PEIPA).
LID - medethics-2019-105948 [pii]
LID - 10.1136/medethics-2019-105948 [doi]
AB  - BACKGROUND: Data processing of health research databases often requires a Data
      Protection Impact Assessment to evaluate the severity of the risk and the
      appropriateness of measures taken to comply with the European Union (EU) General 
      Data Protection Regulation (GDPR). We aimed to define and apply a comprehensive
      method for the evaluation of privacy, data governance and ethics among research
      networks involved in the EU Project Bridge Health. METHODS: Computerised survey
      among associated partners of main EU Consortia, using a targeted instrument
      designed by the principal investigator and progressively refined in collaboration
      with an international advisory panel. Descriptive measures using the percentage
      of adoption of privacy, data governance and ethical principles as main endpoints 
      were used for the analysis and interpretation of the results. RESULTS: A total of
      15 centres provided relevant information on the processing of sensitive data from
      10 European countries. Major areas of concern were noted for: data linkage
      (median, range of adoption: 45%, 30%-80%), access and accuracy of personal data
      (50%, 0%-100%) and anonymisation procedures (56%, 11%-100%). A high variability
      was noted in the application of privacy principles. CONCLUSIONS: A comprehensive 
      methodology of Privacy and Ethics Impact and Performance Assessment was
      successfully applied at international level. The method can help implementing the
      GDPR and expanding the scope of Data Protection Impact Assessment, so that the
      public benefit of the secondary use of health data could be well balanced with
      the respect of personal privacy.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Di Iorio, Concetta Tania
AU  - Di Iorio CT
AUID- ORCID: http://orcid.org/0000-0003-3105-3423
AD  - Executive Office, Legal, Serectrix snc, Pescara, Italy ct.diiorio@serectrix.eu.
FAU - Carinci, Fabrizio
AU  - Carinci F
AD  - Department of Statistical Sciences, University of Bologna, Bologna, Italy.
FAU - Oderkirk, Jillian
AU  - Oderkirk J
AD  - Health Division, Directorate for Employment, Labour and Social Affairs,
      Organisation for Economic Co-operation and Development (OECD), Paris, France.
FAU - Smith, David
AU  - Smith D
AD  - Former Deputy Commissioner, Information Commissioner's Office (ICO), Wilmslow,
      UK.
FAU - Siano, Manuela
AU  - Siano M
AD  - Department of International and EU Relations Services, Department of Digital
      Technologies and Information Security, Data Protection Authority, Rome, Italy.
FAU - de Marco, Dorotea Alessandra
AU  - de Marco DA
AD  - Department of International and EU Relations Services, Department of Digital
      Technologies and Information Security, Data Protection Authority, Rome, Italy.
FAU - de Lusignan, Simon
AU  - de Lusignan S
AD  - Nuffield Department of Primary Care and Health Sciences, University of Oxford,
      Oxford, UK.
AD  - Department of Clinical and Experimental Medicine, University of Surrey,
      Guildford, UK.
FAU - Hamalainen, Paivi
AU  - Hamalainen P
AD  - National Institute of Health and Welfare (THL), Helsinki, Finland.
FAU - Benedetti, Massimo Massi
AU  - Benedetti MM
AD  - Executive Office, Hub for International Health Research (HIRS), Perugia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - England
TA  - J Med Ethics
JT  - Journal of medical ethics
JID - 7513619
SB  - IM
OTO - NOTNLM
OT  - confidentiality/privacy
OT  - regulation
OT  - right to healthcare
OT  - technology/risk assessment
COIS- Competing interests: None declared.
EDAT- 2020/03/30 06:00
MHDA- 2020/03/30 06:00
CRDT- 2020/03/30 06:00
PHST- 2019/11/08 00:00 [received]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/03/12 00:00 [accepted]
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/03/30 06:00 [medline]
AID - medethics-2019-105948 [pii]
AID - 10.1136/medethics-2019-105948 [doi]
PST - aheadofprint
SO  - J Med Ethics. 2020 Mar 27. pii: medethics-2019-105948. doi:
      10.1136/medethics-2019-105948.


PMID- 32220418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200904
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 721
DP  - 2020 Jun 15
TI  - Corrigendum to "Climate change communication by the local digital press in
      northeastern Argentina: An ethical analysis" [Sci. Total Environ. 707 (2020),
      1-7/135737].
PG  - 137855
LID - S0048-9697(20)31368-1 [pii]
LID - 10.1016/j.scitotenv.2020.137855 [doi]
FAU - Lopez, Maria Soledad
AU  - Lopez MS
AD  - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Argentina; 
      Centro de Estudios de Variabilidad y Cambio Climatico (CEVARCAM), Facultad de
      Ingenieria y Ciencias Hidricas, Universidad Nacional del Litoral, Santa Fe,
      Argentina. Electronic address: mlopez@fbcb.unl.edu.ar.
FAU - Santi, Maria Florencia
AU  - Santi MF
AD  - Facultad Latinoamericana de Ciencias Sociales, Universidad Nacional de La
      Matanza, Buenos Aires, Argentina; Facultad de Ciencias de la Salud, Universidad
      Nacional de Entre Rios, Entre Rios, Argentina.
FAU - Muller, Gabriela Viviana
AU  - Muller GV
AD  - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Argentina; 
      Centro de Estudios de Variabilidad y Cambio Climatico (CEVARCAM), Facultad de
      Ingenieria y Ciencias Hidricas, Universidad Nacional del Litoral, Santa Fe,
      Argentina.
FAU - Gomez, Andrea Alejandra
AU  - Gomez AA
AD  - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Argentina; 
      Centro de Estudios de Variabilidad y Cambio Climatico (CEVARCAM), Facultad de
      Ingenieria y Ciencias Hidricas, Universidad Nacional del Litoral, Santa Fe,
      Argentina.
FAU - Staffolani, Claudio
AU  - Staffolani C
AD  - Facultad de Ciencias Medicas, Centro de Estudios Interdisciplinarios, Universidad
      Nacional de Rosario, Argentina.
FAU - Pomares, Luis Aragones
AU  - Pomares LA
AD  - Universidad de Alicante, Carretera San Vicente del Raspeig s/n. 03690 San Vicente
      del Raspeig, Alicante, Spain.
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20200324
PL  - Netherlands
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
SB  - IM
EFR - Sci Total Environ. 2020 Mar 10;707:135737. PMID: 31864007
EDAT- 2020/03/30 06:00
MHDA- 2020/03/30 06:01
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2020/03/30 06:01 [medline]
PHST- 2020/03/30 06:00 [entrez]
AID - S0048-9697(20)31368-1 [pii]
AID - 10.1016/j.scitotenv.2020.137855 [doi]
PST - ppublish
SO  - Sci Total Environ. 2020 Jun 15;721:137855. doi: 10.1016/j.scitotenv.2020.137855. 
      Epub 2020 Mar 24.


PMID- 32220271
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 3
DP  - 2020 Mar 1
TI  - How Should We Judge Whether and When Mission Statements Are Ethically Deployed?
PG  - E239-247
LID - amajethics.2020.239 [pii]
LID - 10.1001/amajethics.2020.239 [doi]
AB  - Mission statements communicate health care organizations' fundamental purposes
      and can help potential patients choose where to seek care and employees where to 
      seek employment. They offer limited benefit, however, when patients do not have
      meaningful choices about where to seek care, and they can be misused. Ethical
      implementation of mission statements requires health care organizations to be
      truthful and transparent about how their mission influences patient care, to
      create environments that help clinicians execute their professional obligations
      to patients, and to amplify their obligations to communities.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Schueler, Kellie E
AU  - Schueler KE
AD  - Fourth-year medical student at the University of Chicago Pritzker School of
      Medicine in Chicago, Illinois.
FAU - Stulberg, Debra B
AU  - Stulberg DB
AD  - Associate professor and interim chair in the Department of Family Medicine at the
      University of Chicago in Chicago, Illinois.
LA  - eng
PT  - Journal Article
DEP - 20200301
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - Delivery of Health Care/*ethics
MH  - Disclosure
MH  - Humans
MH  - *Organizational Policy
MH  - Organizations/*ethics
MH  - Patient Care/ethics
MH  - Physicians/ethics
MH  - *Social Responsibility
EDAT- 2020/03/30 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - amajethics.2020.239 [pii]
AID - 10.1001/amajethics.2020.239 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Mar 1;22(3):E239-247. doi: 10.1001/amajethics.2020.239.


PMID- 32220268
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 3
DP  - 2020 Mar 1
TI  - AMA Code of Medical Ethics' Opinions Related to Organizational Influence in
      Health Care.
PG  - E217-220
LID - amajethics.2020.217 [pii]
LID - 10.1001/amajethics.2020.217 [doi]
AB  - In recent decades, organized health care has displaced some traditional
      solo-practitioner physician roles. As larger organizations become more
      influential in the health care sector, American Medical Association (AMA)
      positions on professionalism and organizational development, as outlined in the
      Code of Medical Ethics, can help physicians navigate organizations' influence on 
      practice.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Scheper, Abigail
AU  - Scheper A
AD  - Fourth-year undergraduate student at North Carolina State University in Raleigh.
LA  - eng
PT  - Journal Article
DEP - 20200301
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - American Medical Association
MH  - Attitude
MH  - *Codes of Ethics
MH  - Delivery of Health Care/*ethics
MH  - Employment
MH  - Ethics, Medical
MH  - Humans
MH  - Organizations/*ethics
MH  - Physicians/*ethics
MH  - Practice Patterns, Physicians'/ethics
MH  - Professional Role
MH  - *Professionalism
MH  - United States
EDAT- 2020/03/30 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - amajethics.2020.217 [pii]
AID - 10.1001/amajethics.2020.217 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Mar 1;22(3):E217-220. doi: 10.1001/amajethics.2020.217.


PMID- 32220265
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 2376-6980 (Electronic)
VI  - 22
IP  - 3
DP  - 2020 Mar 1
TI  - What Should Physicians Consider Prior to Unionizing?
PG  - E193-200
LID - amajethics.2020.193 [pii]
LID - 10.1001/amajethics.2020.193 [doi]
AB  - Physicians considering unionization face many practical, emotional, and moral
      obstacles. Even some who feel that a collective bargaining unit is necessary
      remain concerned that patient care could suffer if physicians unionize. This
      article discusses unionized physicians' moral obligations to patient populations 
      and health care systems' share in this responsibility. It argues that
      unionization can be done ethically as long as union actions are focused on
      improving patient care.
CI  - (c) 2020 American Medical Association. All Rights Reserved.
FAU - Howard, Danielle
AU  - Howard D
AD  - Third-year neurology resident at Duke University Hospital in Durham, North
      Carolina.
LA  - eng
PT  - Journal Article
DEP - 20200301
PL  - United States
TA  - AMA J Ethics
JT  - AMA journal of ethics
JID - 101649265
SB  - IM
MH  - *Collective Bargaining
MH  - Employment/*ethics
MH  - Ethics, Medical
MH  - Humans
MH  - Labor Unions/*ethics
MH  - *Moral Obligations
MH  - Organizations
MH  - Physicians/*ethics
MH  - *Quality of Health Care
EDAT- 2020/03/30 06:00
MHDA- 2021/04/20 06:00
CRDT- 2020/03/30 06:00
PHST- 2020/03/30 06:00 [entrez]
PHST- 2020/03/30 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
AID - amajethics.2020.193 [pii]
AID - 10.1001/amajethics.2020.193 [doi]
PST - epublish
SO  - AMA J Ethics. 2020 Mar 1;22(3):E193-200. doi: 10.1001/amajethics.2020.193.


PMID- 34499053
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210910
IS  - 1815-672X (Electronic)
IS  - 0028-2715 (Linking)
VI  - 58
IP  - 223
DP  - 2020 Mar 30
TI  - Medical Thoracoscopy for Undiagnosed Exudative Pleural Effusion: A Descriptive
      Cross-sectional Study.
PG  - 158-164
LID - 10.31729/jnma.4873 [doi]
AB  - INTRODUCTION: Medical thoracoscopy has recently gained renewed interest due to
      its minimal invasive nature and high yield diagnostic outcome. This study aims to
      observe diagnostic yield and safety of medical thoracoscopy in undiagnosed
      exudative pleural effusion. METHODS: This is a descriptive cross-sectional study 
      conducted in two tertiary care hospitals in Chitwan from March 2018 to May 2018. 
      Ethical approval from the Institutional Review Board was obtained. Convenient
      sampling was done that included all the patients who met criteria for undiagnosed
      exudative pleural effusion after diagnostic thoracocentesis. Patients having
      contraindication to procedure and who refused consent were excluded. Statistical 
      analysis was performed using IBM SPSS Statistics 20 and data are presented as
      mean+/-SD and frequency (percentage). RESULTS: A total of 14 patients underwent
      rigid medical thoracoscopy. All 14 patients had unilateral pleural effusion. The 
      overall diagnostic yield was 100%. Malignancy was the most frequent
      histopathology diagnosis seen in 11 (78.57%) patients, the commonest being
      metastatic adenocarcinoma in 8 (57.1%). Pleural tuberculosis and acute-on-chronic
      pleuritis were seen in 2 (14.3%) and 1 (7.1%) patients, respectively. Pleural
      deposits and hemorrhagic pleural fluid were the two commonest findings, seen in
      10 (70.1%) and 9 (64.3%) patients, respectively. Two (14.3%) patients clinically 
      treated as tuberculous pleural effusion was re-diagnosed to have metastatic
      adenocarcinoma. Common procedure-related minor complications observed were mild
      to moderate pain and mild bleeding, observed in 3 (21.4%) and 2 (14.3%) patients,
      respectively. CONCLUSIONS: Medical thoracoscopy is a safe, well-tolerated and
      high yield procedure in undiagnosed exudative pleural effusion. This art of
      medicine should be promoted in daily medical practice.
FAU - Shrestha, Bishow Kumar
AU  - Shrestha BK
AD  - Pulmonary, Critical Care and Sleep Medicine Unit, Chitwan Medical College
      Teaching Hospital, Chitwan, Nepal.
FAU - Adhikari, Shital
AU  - Adhikari S
AD  - Pulmonary, Critical Care and Sleep Medicine Unit, Chitwan Medical College
      Teaching Hospital, Chitwan, Nepal.
FAU - Thakur, Binay Kumar
AU  - Thakur BK
AD  - Department of Thoracic Surgery, B P Koirala Memorial Cancer Hospital, Chitwan,
      Nepal.
FAU - Kadaria, Dipen
AU  - Kadaria D
AD  - Division of Pulmonary, Critical Care and Sleep Medicine, University of Tennessee 
      HSC, Memphis, TN, USA.
FAU - Tamrakar, Kishor Kumar
AU  - Tamrakar KK
AD  - Department of Surgery, Chitwan Medical College Teaching Hospital, Chitwan, Nepal.
FAU - Devkota, Mukti
AU  - Devkota M
AD  - Department of Thoracic Surgery, B P Koirala Memorial Cancer Hospital, Chitwan,
      Nepal.
LA  - eng
PT  - Journal Article
DEP - 20200330
PL  - Nepal
TA  - JNMA J Nepal Med Assoc
JT  - JNMA; journal of the Nepal Medical Association
JID - 0045233
SB  - IM
EDAT- 2020/03/30 00:00
MHDA- 2020/03/30 00:01
CRDT- 2021/09/09 12:20
PHST- 2020/03/11 00:00 [received]
PHST- 2021/09/09 12:20 [entrez]
PHST- 2020/03/30 00:00 [pubmed]
PHST- 2020/03/30 00:01 [medline]
AID - 10.31729/jnma.4873 [doi]
PST - epublish
SO  - JNMA J Nepal Med Assoc. 2020 Mar 30;58(223):158-164. doi: 10.31729/jnma.4873.


PMID- 32219845
OWN - NLM
STAT- MEDLINE
DCOM- 20200423
LR  - 20220716
IS  - 1552-146X (Electronic)
IS  - 0093-0334 (Linking)
VI  - 50
IP  - 2
DP  - 2020 Mar
TI  - Responding to Covid-19: How to Navigate a Public Health Emergency Legally and
      Ethically.
PG  - 8-12
LID - 10.1002/hast.1090 [doi]
AB  - Few novel or emerging infectious diseases have posed such vital ethical
      challenges so quickly and dramatically as the novel coronavirus SARS-CoV-2. The
      World Health Organization declared a public health emergency of international
      concern and recently classified Covid-19 as a worldwide pandemic. As of this
      writing, the epidemic has not yet peaked in the United States, but community
      transmission is widespread. President Trump declared a national emergency as
      fifty governors declared state emergencies. In the coming weeks, hospitals will
      become overrun, stretched to their capacities. When the health system becomes
      stretched beyond capacity, how can we ethically allocate scarce health goods and 
      services? How can we ensure that marginalized populations can access the care
      they need? What ethical duties do we owe to vulnerable people separated from
      their families and communities? And how do we ethically and legally balance
      public health with civil liberties?
CI  - (c) 2020 The Hastings Center.
FAU - Gostin, Lawrence O
AU  - Gostin LO
FAU - Friedman, Eric A
AU  - Friedman EA
FAU - Wetter, Sarah A
AU  - Wetter SA
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - United States
TA  - Hastings Cent Rep
JT  - The Hastings Center report
JID - 0410447
SB  - IM
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*prevention & control
MH  - Emergencies
MH  - Humans
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/*prevention & control
MH  - Public Health/*ethics/*legislation & jurisprudence
MH  - SARS-CoV-2
MH  - United States
PMC - PMC7228225
OTO - NOTNLM
OT  - *Covid-19
OT  - *allocation of scarce resources
OT  - *civil liberties
OT  - *crisis standards of care
OT  - *novel coronavirus SARS-CoV-2
OT  - *public health emergency
OT  - *public health ethics
EDAT- 2020/03/29 06:00
MHDA- 2020/04/24 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/04/24 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 10.1002/hast.1090 [doi]
PST - ppublish
SO  - Hastings Cent Rep. 2020 Mar;50(2):8-12. doi: 10.1002/hast.1090. Epub 2020 Mar 26.


PMID- 32219825
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20211204
IS  - 1003-9406 (Print)
IS  - 1003-9406 (Linking)
VI  - 37
IP  - 4
DP  - 2020 Apr 10
TI  - [Detection of a BRCA1 c.2013_2014ins GT variant an ethnic Han Chinese pedigree
      affected with breast cancer].
PG  - 415-418
LID - 10.3760/cma.j.issn.1003-9406.2020.04.012 [doi]
AB  - OBJECTIVE: To detect potential variant in an ethical Han Chinese pedigree
      affected with breast cancer. METHODS: The proband and her relatives were
      subjected to next-generation sequencing using a target capture sequencing kit
      containing 121 cancer-related genes. Candidate variants were selected by analysis
      of their type, frequency in population, and segregation with the phenotype.
      Candidate variant was verified by Sanger sequencing and TA cloning. RESULTS: A
      c.2013_2014ins GT variant was detected in the BRCA1 gene among all breast cancer 
      patients from this pedigree but not among healthy females. The variant was not
      recorded in the 1000 Genome Project database or the Exome Aggregation Consortium 
      (ExAC) database. The frameshifting insertion was predicted to form an premature
      stop codon in gene transcript and can give rise to a truncated protein.
      CONCLUSION: The BRCA1 c.2013_2014ins GT variant probably underlies the
      pathogenesis of breast cancer in this Chinese pedigree.
FAU - Qi, Pan
AU  - Qi P
AD  - Department of Head, Neck and Breast Surgery, Xinxiang Central Hospital, Henan
      453000, China. huqingtao@nibs.ac.cn.
FAU - Gao, Linlin
AU  - Gao L
FAU - He, Xiaoying
AU  - He X
FAU - Ni, Yuehan
AU  - Ni Y
FAU - Xu, Sheng
AU  - Xu S
FAU - Mai, Xueying
AU  - Mai X
FAU - Zhang, Guiling
AU  - Zhang G
FAU - Liu, Yuxia
AU  - Liu Y
FAU - Guo, Yu
AU  - Guo Y
FAU - Zhou, Yong
AU  - Zhou Y
FAU - Hu, Qingtao
AU  - Hu Q
LA  - chi
PT  - Case Reports
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Yi Chuan Xue Za Zhi
JT  - Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese
      journal of medical genetics
JID - 9425197
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
SB  - IM
MH  - Asians
MH  - BRCA1 Protein/*genetics
MH  - Breast Neoplasms/*genetics
MH  - Exome
MH  - Female
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Pedigree
MH  - Phenotype
EDAT- 2020/03/29 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 940637080 [pii]
AID - 10.3760/cma.j.issn.1003-9406.2020.04.012 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020 Apr 10;37(4):415-418. doi:
      10.3760/cma.j.issn.1003-9406.2020.04.012.


PMID- 32219193
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2473-1242 (Electronic)
IS  - 2473-1242 (Linking)
VI  - 4
IP  - 1
DP  - 2020
TI  - First, Do No Harm: Why Philanthropy Needs to Re-Examine Its Role in Reproductive 
      Equity and Racial Justice.
PG  - 17-22
LID - 10.1089/heq.2019.0094 [doi]
AB  - The philanthropic-industrial complex fosters the belief that the most
      marginalized communities lack an existing repository of historical and
      contemporary knowledge to address social and health inequities. In so doing,
      philanthropy has contributed to the diminishing political power, legitimacy, and 
      effectiveness of community voices and leadership in reproductive equity through
      research injustice, cultural arrogance, philanthropic redlining, and community
      harm. Black Feminism and Reproductive Justice, as mutually aligned theories and
      praxes, are described as new ethical standards for philanthropic accountability. 
      Funders must embody the equity they aspire to see and build through the
      operationalization of cultural rigor to advance structural equity and racial
      justice and to sustain community engagement in research.
CI  - (c) Karen A. Scott et al. 2020; Published by Mary Ann Liebert, Inc.
FAU - Scott, Karen A
AU  - Scott KA
AD  - Obstetrics, Gynecology, and Reproductive Sciences Department, School of Medicine,
      University of California, San Francisco, San Francisco, California.
FAU - Bray, Stephanie
AU  - Bray S
AD  - United Way California Capital Region, Sacramento, California.
FAU - McLemore, Monica R
AU  - McLemore MR
AD  - Family Health Care Nursing Department, School of Nursing, University of
      California, San Francisco, San Francisco, California.
LA  - eng
PT  - Journal Article
DEP - 20200312
PL  - United States
TA  - Health Equity
JT  - Health equity
JID - 101708316
PMC - PMC7097698
OTO - NOTNLM
OT  - cultural rigor
OT  - philanthropy
OT  - racial justice
OT  - reproductive equity
COIS- All authors have disclosed that that they have no significant relationships with,
      or financial interest in, any commercial companies pertaining to this article.
      All authors have participated in the perspective conception and design; data
      analysis and interpretation; critical development and revision of the article for
      significant intellectual content; and approval of the final version.
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
AID - 10.1089/heq.2019.0094 [doi]
AID - 10.1089/heq.2019.0094 [pii]
PST - epublish
SO  - Health Equity. 2020 Mar 12;4(1):17-22. doi: 10.1089/heq.2019.0094. eCollection
      2020.


PMID- 32219186
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220112
IS  - 2398-6352 (Electronic)
IS  - 2398-6352 (Linking)
VI  - 3
DP  - 2020
TI  - Digital phenotyping, behavioral sensing, or personal sensing: names and
      transparency in the digital age.
PG  - 45
LID - 10.1038/s41746-020-0251-5 [doi]
AB  - Data from networked sensors, such as those in our phones, are increasingly being 
      explored and used to identify behaviors related to health and mental health.
      While computer scientists have referred to this field as context sensing,
      personal sensing, or mobile sensing, medicine has more recently adopted the term 
      digital phenotyping. This paper discusses the implications of these labels in
      light of privacy concerns, arguing language that is transparent and meaningful to
      the people whose data we are acquiring.
CI  - (c) The Author(s) 2020.
FAU - Mohr, David C
AU  - Mohr DC
AUID- ORCID: 0000-0002-5443-7596
AD  - 1Center for Behavioral Intervention Technologies, Department of Preventive
      Medicine, Northwestern University, Chicago, IL USA.0000 0001 2299
      3507grid.16753.36
FAU - Shilton, Katie
AU  - Shilton K
AD  - 2College of Information Studies, University of Maryland, College Park, College
      Park, MD USA.0000 0001 0941 7177grid.164295.d
FAU - Hotopf, Matthew
AU  - Hotopf M
AD  - 3King's College London, Institute of Psychiatry, Psychology and Neuroscience,
      London, UK.0000 0001 2322 6764grid.13097.3c
LA  - eng
GR  - R01 MH111610/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20200325
PL  - England
TA  - NPJ Digit Med
JT  - NPJ digital medicine
JID - 101731738
PMC - PMC7096455
OTO - NOTNLM
OT  - Ethics
OT  - Medical research
COIS- Competing interestsDr. Mohr has accepted honoraria and consulting fees from Apple
      Inc., Otsuka America Pharmaceutical Inc., and has an ownership interest in
      Adaptive Health, Inc. Dr. Hotopf is the principal investigator of the RADAR-CNS
      consortium-a precompetitive public-private partnership jointly funded by the
      Innovative Medicines Initiative and European Federation of Pharmaceutical
      Industries and Associations. As such, he receives research funding and in kind
      contributions from five pharmaceutical companies-Janssen, Biogen, UCB, Lundbeck, 
      and Merck Sharp & Dohme. Dr. Shilton has no competing interests.
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2019/12/15 00:00 [received]
PHST- 2020/02/28 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
AID - 10.1038/s41746-020-0251-5 [doi]
AID - 251 [pii]
PST - epublish
SO  - NPJ Digit Med. 2020 Mar 25;3:45. doi: 10.1038/s41746-020-0251-5. eCollection
      2020.


PMID- 32218821
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - The pathological complete response and secreted protein acidic and rich in
      cysteine expression in patients with breast cancer receiving neoadjuvant
      nab-paclitaxel chemotherapy.
PG  - 2705-2712
LID - 10.3892/ol.2020.11354 [doi]
AB  - Biomarkers that can accurately predict treatment response are required for
      indicating optimal neoadjuvant treatments. The current study assessed the
      predictive value of secreted protein acidic and rich in cysteine (SPARC) mRNA
      expression for the response to neoadjuvant nab-paclitaxel (nab-PTX) therapy in
      patients with breast cancer. It was hypothesized that SPARC expression can affect
      the response to albumin-bound taxanes, including nab-PTX since SPARC binds
      albumin with a high affinity. Pre-therapeutic specimens of core needle biopsies
      were analyzed from 50 patients in a phase II trial of neoadjuvant nab-PTX and the
      factors that were associated with a pathological complete response (pCR) were
      assessed. The pre-therapeutic tumor mRNA levels of chemotherapy-related proteins 
      were quantified, including SPARC, and the correlations with post-therapeutic
      clinicopathological factors were assessed, including with pCR. The results
      demonstrated that pre-therapeutic SPARC mRNA expression was significantly higher 
      in non-pCR patients compared with patients with pCR (92.37+/-55.33 vs.
      56.53+/-30.19; P=0.027). A cutoff point of 48.5 was determined using receiver
      operating characteristic (ROC) curve analysis (sensitivity, 83.3%; specificity,
      50.0%), and patients were classified into low and high SPARC expression groups.
      High SPARC expression was associated with histological grade (P=0.035), estrogen 
      receptor expression (P=0.037), and progesterone receptor expression (P=0.002) but
      not with HER2 (P=0.895), and Ki-67 LI (P=0.743) expression. The results of the
      current study indicated that a high SPARC mRNA expression was a negative
      predictor of pCR following neoadjuvant nab-PTX therapy regardless of breast
      cancer subtype. The phase II study was conducted in accordance with the
      Declaration of Helsinki, and the protocol was approved by the Ethics Committee of
      the National Hospital Organization Takasaki General Medical Center (Registration 
      nos. H23-9 and H23-33).
CI  - Copyright: (c) Nakazawa et al.
FAU - Nakazawa, Yuko
AU  - Nakazawa Y
AD  - Department of General Surgical Science, Gunma University Graduate School of
      Medicine, Maebashi, Gunma 371-8511, Japan.
AD  - Department of Breast and Endocrine Surgery, National Hospital Organization
      Takasaki General Medical Center, Takasaki, Gunma 370-0829, Japan.
AD  - Department of Diagnostic Pathology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma 371-8511, Japan.
FAU - Nakazawa, Seshiru
AU  - Nakazawa S
AD  - Department of General Surgical Science, Gunma University Graduate School of
      Medicine, Maebashi, Gunma 371-8511, Japan.
FAU - Kurozumi, Sasagu
AU  - Kurozumi S
AD  - Department of General Surgical Science, Gunma University Graduate School of
      Medicine, Maebashi, Gunma 371-8511, Japan.
FAU - Ogino, Misato
AU  - Ogino M
AD  - Department of General Surgical Science, Gunma University Graduate School of
      Medicine, Maebashi, Gunma 371-8511, Japan.
AD  - Department of Breast and Endocrine Surgery, National Hospital Organization
      Takasaki General Medical Center, Takasaki, Gunma 370-0829, Japan.
FAU - Koibuchi, Yukio
AU  - Koibuchi Y
AD  - Department of Breast and Endocrine Surgery, National Hospital Organization
      Takasaki General Medical Center, Takasaki, Gunma 370-0829, Japan.
FAU - Odawara, Hiroki
AU  - Odawara H
AD  - Department of Surgery, Toho Hospital, Midori, Gunma 376-0121, Japan.
FAU - Oyama, Tetsunari
AU  - Oyama T
AD  - Department of Diagnostic Pathology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma 371-8511, Japan.
FAU - Horiguchi, Jun
AU  - Horiguchi J
AD  - Department of Breast Surgery, International University of Health and Welfare,
      Chiba 286-8686, Japan.
FAU - Fujii, Takaaki
AU  - Fujii T
AD  - Department of General Surgical Science, Gunma University Graduate School of
      Medicine, Maebashi, Gunma 371-8511, Japan.
FAU - Shirabe, Ken
AU  - Shirabe K
AD  - Department of General Surgical Science, Gunma University Graduate School of
      Medicine, Maebashi, Gunma 371-8511, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200127
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7068243
OTO - NOTNLM
OT  - breast cancer
OT  - nab-paclitaxel
OT  - neoadjuvant therapy
OT  - pathological complete response
OT  - secreted protein acidic and rich in cysteine
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2019/07/21 00:00 [received]
PHST- 2019/12/03 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
AID - 10.3892/ol.2020.11354 [doi]
AID - OL-0-0-11354 [pii]
PST - ppublish
SO  - Oncol Lett. 2020 Apr;19(4):2705-2712. doi: 10.3892/ol.2020.11354. Epub 2020 Jan
      27.


PMID- 32218761
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Editorial: Epistemological and Ethical Aspects of Research in the Social
      Sciences.
PG  - 428
LID - 10.3389/fpsyg.2020.00428 [doi]
FAU - Dettweiler, Ulrich
AU  - Dettweiler U
AD  - Department of Cultural Studies and Languages, Faculty of Arts and Education,
      University of Stavanger, Stavanger, Norway.
FAU - Hanfstingl, Barbara
AU  - Hanfstingl B
AD  - Faculty of Interdisciplinary Studies, Institute of Instructional and School
      Development, Alpen-Adria-Universitat Klagenfurt, Klagenfurt, Austria.
FAU - Schroter, Hannes
AU  - Schroter H
AD  - Department "Teaching, Learning, Counselling", German Institute for Adult
      Education - Leibniz Centre for Lifelong Learning, Bonn, Germany.
LA  - eng
PT  - Editorial
DEP - 20200311
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7078353
OTO - NOTNLM
OT  - Bayesian approach
OT  - data science
OT  - epistemology
OT  - implementation science
OT  - methodology
OT  - replicability
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2020/02/06 00:00 [received]
PHST- 2020/02/24 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
AID - 10.3389/fpsyg.2020.00428 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 11;11:428. doi: 10.3389/fpsyg.2020.00428. eCollection
      2020.


PMID- 32218755
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-1078 (Print)
IS  - 1664-1078 (Linking)
VI  - 11
DP  - 2020
TI  - Non-Clinical Autistic Traits Correlate With Social and Ethical but Not With
      Financial and Recreational Risk-Taking.
PG  - 360
LID - 10.3389/fpsyg.2020.00360 [doi]
AB  - Previous research into uncertain and risky decision-making in autism spectrum
      disorder (ASD) has been inconclusive, with some studies reporting less uncertain 
      and risky decisions by persons with ASD compared to neurotypicals, but other
      studies failing to find such effects. A possible explanation for these
      inconsistent findings is that aberrant decision-making in ASD is domain-specific,
      and only manifests itself in domains related to autism symptomatology. The
      present study examines this premise by correlating self-reported autistic traits 
      to individuals' intention to engage in risky behaviours, their perception of how 
      risky these behaviours are, and the amount of benefit they expect to obtain from 
      engaging in them; all for five separate domains of decision-making: social,
      ethical, recreational, health/safety, and financial. In line with the hypotheses,
      persons with higher autistic traits reported reduced intention to engage in risky
      social behaviours and increased intention to engage in risky ethical behaviours. 
      Furthermore, a positive correlation was found between autistic traits and risk
      perception in the social domain, indicating that persons with higher autistic
      traits perceive social behaviours as riskier than do persons with lower autistic 
      traits. Correlations between autistic traits and individuals' intention to engage
      in risky recreational and financial behaviours were small, and supported the null
      hypothesis (as shown by Bayes Factors). Given that most studies on uncertain and 
      risky decision-making take place in a financial context, the present results
      could explain previous inconsistent findings on decision-making in ASD.
      Therefore, future studies should also examine decision-making outside the
      financial realm.
CI  - Copyright (c) 2020 De Groot.
FAU - De Groot, Kristel
AU  - De Groot K
AD  - Institute of Psychology, Erasmus School of Social and Behavioural Sciences,
      Erasmus University Rotterdam, Rotterdam, Netherlands.
AD  - Department of Applied Economics, Erasmus School of Economics, Erasmus University 
      Rotterdam, Rotterdam, Netherlands.
AD  - Erasmus University Rotterdam Institute for Behaviour and Biology, Erasmus
      University Rotterdam, Rotterdam, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20200311
PL  - Switzerland
TA  - Front Psychol
JT  - Frontiers in psychology
JID - 101550902
PMC - PMC7078360
OTO - NOTNLM
OT  - Autism-Spectrum Quotient
OT  - Domain-Specific Risk-Taking scale
OT  - autism spectrum disorder
OT  - risk
OT  - uncertainty
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2019/04/01 00:00 [received]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
AID - 10.3389/fpsyg.2020.00360 [doi]
PST - epublish
SO  - Front Psychol. 2020 Mar 11;11:360. doi: 10.3389/fpsyg.2020.00360. eCollection
      2020.


PMID- 32218658
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Feb
TI  - Analyzing the effect of physician assignment in the survival of patients with
      advanced non-small-cell lung cancer.
PG  - 34-38
LID - 10.3747/co.27.5291 [doi]
AB  - Background: Non-small-cell lung cancer (nsclc) is the most common cause of cancer
      deaths worldwide, with a 5-year survival of 17%. The low survival rate observed
      in patients with nsclc is primarily attributable to advanced stage of disease at 
      diagnosis, with more than 50% of cases being stage iv at presentation. For
      patients with advanced disease, palliative systemic therapy can improve overall
      survival (os); however, a recent review at our institution of more than 500
      consecutive cases of advanced nsclc demonstrated that only 55% of the patients
      received palliative systemic therapy. What is unknown to date is whether that
      observed low rate of systemic therapy in our previous study is uniform across
      oncologists. Methods: With ethics approval, we performed a retrospective analysis
      of newly diagnosed patients with stage iv nsclc seen as outpatients at our
      institution between 2009 and 2012 by 4 different oncologists. Demographics,
      treatment, and survival data were collected and compared for the 4 oncologists.
      Results: The 4 oncologists saw 528 patients overall, with D seeing 115; L, 158;
      R, 137; and M, 118. Significant variation was observed in the proportion
      receiving 1 line or more of chemotherapy: D, 60%; L, 65%; R, 43%; and M, 52%.
      Physician assignment was not associated with a difference in median os, with D's 
      cohort having a median os of 6.8 months; L, 8.4 months; R, 7.0 months; and M, 7.0
      months. Conclusions: Practice size and proportion of patients treated varied
      between oncologists, but those differences did not translate into significantly
      different survival outcomes for patients.
CI  - 2020 Multimed Inc.
FAU - Wheatley-Price, P
AU  - Wheatley-Price P
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa.
AD  - The Ottawa Hospital, Ottawa.
FAU - Jonker, H
AU  - Jonker H
AD  - McMaster University, Hamilton, ON.
FAU - Al-Baimani, K
AU  - Al-Baimani K
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa.
FAU - Mhang, T
AU  - Mhang T
AD  - The Ottawa Hospital, Ottawa.
FAU - Nicholas, G
AU  - Nicholas G
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa.
AD  - The Ottawa Hospital, Ottawa.
FAU - Goss, G
AU  - Goss G
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa.
AD  - The Ottawa Hospital, Ottawa.
FAU - Laurie, S A
AU  - Laurie SA
AD  - Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa,
      Ottawa.
AD  - The Ottawa Hospital, Ottawa.
LA  - eng
PT  - Journal Article
DEP - 20200201
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*mortality/pathology/*therapy
MH  - Humans
MH  - Lung Neoplasms/*mortality/pathology/*therapy
MH  - Middle Aged
MH  - Oncologists/*standards
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC7096204
OTO - NOTNLM
OT  - *Physician effect
OT  - *chemotherapy
OT  - *non-small-cell lung cancer
COIS- CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology's
      policy on disclosing conflicts of interest, and we declare that we have none.
EDAT- 2020/03/29 06:00
MHDA- 2021/03/25 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
AID - 10.3747/co.27.5291 [doi]
AID - conc-27-34 [pii]
PST - ppublish
SO  - Curr Oncol. 2020 Feb;27(1):34-38. doi: 10.3747/co.27.5291. Epub 2020 Feb 1.


PMID- 32218647
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 0951-5666 (Print)
IS  - 0951-5666 (Linking)
VI  - 35
IP  - 4
DP  - 2020
TI  - Big tech and societal sustainability: an ethical framework.
PG  - 829-840
LID - 10.1007/s00146-020-00956-6 [doi]
AB  - Sustainability is typically viewed as consisting of three forces, economic,
      social, and ecological, in tension with one another. In this paper, we address
      the dangers posed to societal sustainability. The concern being addressed is the 
      very survival of societies where the rights of individuals, personal and
      collective freedoms, an independent judiciary and media, and democracy, despite
      its messiness, are highly valued. We argue that, as a result of various
      technological innovations, a range of dysfunctional impacts are threatening
      social and political stability. For instance, robotics and automation are
      replacing human labor and decision-making in a range of industries; search
      engines, monetized through advertising, have access to, and track, our interests 
      and preferences; social media, in connecting us to one another often know more
      about us than we ourselves do, enabling them to profit in ways which may not
      coincide with our well-being; online retailers have not only acquired the ability
      to track and predict our buying choices, but also they can squeeze vendors based 
      on their outsize bargaining power; and, in general, virtual technologies have
      changed both the way we think and our sense of self. With the rising deployment
      of the Internet of Things, and developments in machine learning and artificial
      intelligence, the threats to individual freedoms and rights, societal cohesion
      and harmony, employment and economic well-being, and trust in democracy are being
      ratcheted up. This paper lauds the benefits and addresses the harm wrought by the
      high tech giants in Information and Communication Technologies (ICTs). The search
      for rapidly growing revenues (and shareholder returns and stock prices) drives
      firms to accelerate product innovation without fully investigating the entire
      gamut of their impacts. As greater wealth accrues to the leaders of tech firms,
      inequalities within firms and societies are widening, creating social tensions
      and political ferment. We explore the ethical nature of the challenge employing a
      simple utilitarian calculus, complemented by approaches rooted in rights,
      justice, and the common good. Various options to address the challenges posed by 
      ICTs are considered and evaluated. We argue that regulation may do little more
      than slow down the damage to society, particularly since societal values and
      political preferences vary internationally. Firms need to establish ethical
      standards, imbuing the upholders of these standards with sufficient authority,
      while creating a culture of morality. User involvement and activism, and
      shareholders' concerns for the sustainability of societies on whose continued
      prosperity they depend, are imperative to humanity's ability to decide the future
      direction of technology.
CI  - (c) Springer-Verlag London Ltd., part of Springer Nature 2020.
FAU - Arogyaswamy, Bernard
AU  - Arogyaswamy B
AD  - Madden School of Business, LeMoyne College, Syracuse, NY USA.
LA  - eng
PT  - Journal Article
DEP - 20200319
PL  - Germany
TA  - AI Soc
JT  - AI & society
JID - 9883157
PMC - PMC7095243
OTO - NOTNLM
OT  - Big tech
OT  - Centralized power
OT  - Cognition
OT  - Ethical criteria
OT  - Social impacts
OT  - User activism
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2019/11/02 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 10.1007/s00146-020-00956-6 [doi]
AID - 956 [pii]
PST - ppublish
SO  - AI Soc. 2020;35(4):829-840. doi: 10.1007/s00146-020-00956-6. Epub 2020 Mar 19.


PMID- 32218603
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 3
DP  - 2020
TI  - A multi-state model analysis of the time from ethical approval to publication of 
      clinical research studies.
PG  - e0230797
LID - 10.1371/journal.pone.0230797 [doi]
AB  - BACKGROUND: Results of medical research should be made publicly available in a
      timely manner to enable patients and health professionals to make informed
      decisions about health issues. We aimed to apply a multi-state model to analyze
      the overall time needed to publish study results, and to examine predictors of
      the timing of transitions within the research process from study initiation
      through completion/discontinuation to eventual publication. METHODS: Using a
      newly developed multi-state model approach, we analysed the effect of different
      study-related factors on each of the transitions from study approval to eventual 
      publication, using a data set of clinical studies approved by a German research
      ethics committee between 2000 and 2002. RESULTS: Of 917 approved studies, 806
      were included in our analyses. About half of the clinical studies which began
      were subsequently published as full articles, and the median time from study
      approval to publication was 10 years. Differences across model states were
      apparent; several factors were predictive of the transition from study approval
      to completion, while funding source and collaboration were predictive of the
      transition from completion to publication. CONCLUSIONS: The proposed multi-state 
      model approach permits a more comprehensive analysis of time to publication than 
      a simple examination of the transition from approval to publication, and thus the
      findings represent an advance on previous studies of this aspect of the research 
      process.
FAU - Blumle, Anette
AU  - Blumle A
AUID- ORCID: 0000-0003-2877-1029
AD  - Institute for Evidence in Medicine (for Cochrane Germany Foundation), Faculty of 
      Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
FAU - Haag, Tobias
AU  - Haag T
AD  - Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical
      Center, University of Freiburg, Freiburg, Germany.
FAU - Balmford, James
AU  - Balmford J
AD  - Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical
      Center, University of Freiburg, Freiburg, Germany.
AD  - Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical
      Center, University of Freiburg, Freiburg, Germany.
FAU - Rucker, Gerta
AU  - Rucker G
AD  - Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical
      Center, University of Freiburg, Freiburg, Germany.
FAU - Schumacher, Martin
AU  - Schumacher M
AD  - Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical
      Center, University of Freiburg, Freiburg, Germany.
FAU - Binder, Nadine
AU  - Binder N
AD  - Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical
      Center, University of Freiburg, Freiburg, Germany.
AD  - Institute of Digitalization in Medicine, Faculty of Medicine and Medical Center, 
      University of Freiburg, Freiburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200327
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Ethics Committees, Research
MH  - *Models, Statistical
MH  - Time Factors
PMC - PMC7100954
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/03/29 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/03/29 06:00
PHST- 2019/06/06 00:00 [received]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1371/journal.pone.0230797 [doi]
AID - PONE-D-19-16086 [pii]
PST - epublish
SO  - PLoS One. 2020 Mar 27;15(3):e0230797. doi: 10.1371/journal.pone.0230797.
      eCollection 2020.


PMID- 32218549
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210107
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 580
IP  - 7801
DP  - 2020 Apr
TI  - Should scientists infect healthy people with the coronavirus to test vaccines?
PG  - 17
LID - 10.1038/d41586-020-00927-3 [doi]
FAU - Callaway, Ewen
AU  - Callaway E
LA  - eng
PT  - News
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
OTO - NOTNLM
OT  - *Diseases
OT  - *Ethics
OT  - *Infection
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 10.1038/d41586-020-00927-3 [doi]
AID - 10.1038/d41586-020-00927-3 [pii]
PST - ppublish
SO  - Nature. 2020 Apr;580(7801):17. doi: 10.1038/d41586-020-00927-3.


PMID- 32217687
OWN - NLM
STAT- Publisher
LR  - 20200328
IS  - 2633-3775 (Electronic)
IS  - 2633-3767 (Linking)
DP  - 2020 Mar 26
TI  - Comparison between Defence Healthcare Engagement and humanitarian assistance.
LID - bmjmilitary-2020-001437 [pii]
LID - 10.1136/bmjmilitary-2020-001437 [doi]
AB  - Humanitarian assistance and Defence Healthcare Engagement have traditionally both
      been taught on the Medical Humanitarian Stabilisation Operations Course. However,
      the two activities are distinct. This paper outlines the critical differences
      between them, focusing on their specific purposes, scope, timescales and ethics. 
      Humanitarian assistance will remain a distinct activity with a focus on the
      relief of suffering, guided by international norms, while Defence Healthcare
      Engagement will encompass a broader range of activities, less constrained by
      internationally agreed principles. This presents an opportunity for the Defence
      Medical Services to directly contribute to projecting UK influence, preventing
      conflict and building stability. However, it requires the Defence Medical
      Services to take responsibility for the ethical issues that Defence Healthcare
      Engagement raises. This paper recommends the development of an ethical framework 
      that reconciles the strategic aims of Defence Healthcare Engagement with
      maximising patient welfare at the tactical level. This is a paper commissioned as
      a part of the Humanitarian and Disaster Relief Operations special issue of BMJ
      Military Health.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and
      permissions. Published by BMJ.
FAU - Falconer Hall, Thomas
AU  - Falconer Hall T
AD  - Army Medical Services, Camberley, UK tomfalconerhall@gmail.com.
FAU - Horne, S
AU  - Horne S
AD  - Academic Department of Military Emergency Medicine, Royal Centre for Defence
      Medicine, Birmingham, UK.
FAU - Ross, D
AU  - Ross D
AD  - Robertson House, Camberley, Surrey, UK.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - England
TA  - BMJ Mil Health
JT  - BMJ military health
JID - 101761581
SB  - IM
OTO - NOTNLM
OT  - International health services
OT  - health policy
OT  - medical ethics
COIS- Competing interests: None declared.
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:00 [medline]
AID - bmjmilitary-2020-001437 [pii]
AID - 10.1136/bmjmilitary-2020-001437 [doi]
PST - aheadofprint
SO  - BMJ Mil Health. 2020 Mar 26. pii: bmjmilitary-2020-001437. doi:
      10.1136/bmjmilitary-2020-001437.


PMID- 32217561
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Accuracy and consequences of using trial-of-antibiotics for TB diagnosis (ACT-TB 
      study): protocol for a randomised controlled clinical trial.
PG  - e033999
LID - 10.1136/bmjopen-2019-033999 [doi]
AB  - INTRODUCTION: Over 40% of global tuberculosis case notifications are diagnosed
      clinically without mycobacteriological confirmation. Standard diagnostic
      algorithms include 'trial-of-antibiotics'-empirical antibiotic treatment given to
      mycobacteriology-negative individuals to treat infectious causes of symptoms
      other than tuberculosis, as a 'rule-out' diagnostic test for tuberculosis.
      Potentially 26.5 million such antibiotic courses/year are prescribed globally for
      the 5.3 million/year mycobacteriology-negative patients, making
      trial-of-antibiotics the most common tuberculosis diagnostic, and a global-scale 
      risk for antimicrobial resistance (AMR). Our systematic review found no
      randomised controlled trial (RCT) to support use of trial-of-antibiotic. The RCT 
      aims to determine the diagnostic and clinical value and AMR consequences of
      trial-of-antibiotics. METHODS AND ANALYSIS: A three-arm, open-label, RCT
      randomising (1:1:1) Malawian adults (>/=18 years) seeking primary care for cough 
      into: (a) azithromycin 500 mg one time per day for 3 days or (b) amoxicillin 1 g 
      three times per day for 5 days or (c) standard-of-care (no immediate antibiotic).
      We will perform mycobacteriology tests (microscopy, Xpert MTB/RIF (Mycobacterium 
      tuberculosis/rifampicin) and Mycobacterium tuberculosis culture) at baseline. We 
      will use audiocomputer-assisted self-interview to assess clinical improvement at 
      day 8. First primary outcome will be proportion of patients reporting day 8
      improvement out of those with negative mycobacteriology (specificity). Second
      primary outcome will be day 29 incidence of a composite endpoint of either death 
      or hospitalisation or missed tuberculosis diagnosis. To determine AMR impact we
      compare proportion of resistant nasopharyngeal Streptococcus pneumoniae isolates 
      on day 29. 400 mycobacteriology-negative participants/arm will be required to
      detect a >/=10% absolute difference in diagnostic specificity with 80% power. We 
      will estimate measures of effect by comparing outcomes in antibiotic arms
      (combined and individually) to standard-of-care. ETHICS AND DISSEMINATION: The
      study has been reviewed and approved by Malawi College of Medicine Research and
      Ethics Committee, London School of Hygiene & Tropical Medicine (LSHTM) Research
      Ethics Committee and Regional Committee for Health and Research Ethics - Norway, 
      and Malawi Pharmacy, Medicines and Poisons Board. We will present abstracts at
      relevant conferences, and prepare a manuscript for publication in a peer-reviewed
      journal. TRIAL REGISTRATION NUMBER: The clinical trial is registered with
      ClinicalTrials.gov, NCT03545373.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Divala, Titus Henry
AU  - Divala TH
AUID- ORCID: 0000-0003-3029-9579
AD  - TB Centre, London School of Hygiene and Tropical Medicine, London, UK
      titus.divala@lshtm.ac.uk.
AD  - Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
      Blantyre, Malawi.
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
FAU - Fielding, Katherine L
AU  - Fielding KL
AD  - TB Centre, London School of Hygiene and Tropical Medicine, London, UK.
AD  - School of Public Health, University of the Witwatersrand,
      Johannesburg-Braamfontein, Gauteng, South Africa.
FAU - Sloan, Derek J
AU  - Sloan DJ
AD  - School of Medicine, University of Saint Andrews, Saint Andrews, Fife, UK.
FAU - French, Neil
AU  - French N
AD  - Institute of Infection and Global Health, University of Liverpool Faculty of
      Health and Life Sciences, Liverpool, UK.
FAU - Nliwasa, Marriott
AU  - Nliwasa M
AD  - TB Centre, London School of Hygiene and Tropical Medicine, London, UK.
AD  - Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
      Blantyre, Malawi.
FAU - MacPherson, Peter
AU  - MacPherson P
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
AD  - Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
FAU - Kandulu, Chikondi Charity
AU  - Kandulu CC
AD  - Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
      Blantyre, Malawi.
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
FAU - Chiume, Lingstone
AU  - Chiume L
AD  - Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
      Blantyre, Malawi.
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
FAU - Chilanga, Sanderson
AU  - Chilanga S
AD  - Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
      Blantyre, Malawi.
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
FAU - Ndaferankhande, Masiye John
AU  - Ndaferankhande MJ
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
FAU - Corbett, Elizabeth L
AU  - Corbett EL
AD  - TB Centre, London School of Hygiene and Tropical Medicine, London, UK.
AD  - Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
      Blantyre, Malawi.
AD  - Malawi-Liverpool Wellcome Trust Clinical Research Programme, University of Malawi
      College of Medicine, Blantyre, Malawi.
LA  - eng
SI  - ClinicalTrials.gov/NCT03545373
GR  - 200901/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
GR  - WT200901/WT_/Wellcome Trust/United Kingdom
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Anti-Bacterial Agents)
RN  - 804826J2HU (Amoxicillin)
RN  - 83905-01-5 (Azithromycin)
SB  - IM
MH  - Amoxicillin/*administration & dosage
MH  - Anti-Bacterial Agents/*administration & dosage/therapeutic use
MH  - Azithromycin/*administration & dosage
MH  - Drug Resistance, Bacterial
MH  - Humans
MH  - Malawi
MH  - Mycobacterium tuberculosis/*isolation & purification
MH  - Sensitivity and Specificity
MH  - Streptococcus pneumoniae/drug effects/isolation & purification
MH  - Tuberculosis/*diagnosis
PMC - PMC7170647
OTO - NOTNLM
OT  - *TB
OT  - *antibiotics
OT  - *antimicrobial resistance
OT  - *diagnostic performance
OT  - *trial-of-antibiotics
OT  - *tuberculosis
COIS- Competing interests: None declared.
EDAT- 2020/03/29 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-033999 [pii]
AID - 10.1136/bmjopen-2019-033999 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e033999. doi: 10.1136/bmjopen-2019-033999.


PMID- 32217560
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Rationale and protocol for the 7- and 8-year longitudinal assessments of eye
      health in a cohort of young adults in the Raine Study.
PG  - e033440
LID - 10.1136/bmjopen-2019-033440 [doi]
AB  - INTRODUCTION: Eye diseases and visual impairment more commonly affect elderly
      adults, thus, the majority of ophthalmic cohort studies have focused on older
      adults. Cohort studies on the ocular health of younger adults, on the other hand,
      have been few. The Raine Study is a longitudinal study that has been following a 
      cohort since their birth in 1989-1991. As part of the 20-year follow-up of the
      Raine Study, participants underwent a comprehensive eye examination. As part of
      the 27- and 28-year follow-ups, eye assessments are being conducted and the data 
      collected will be compared with those of the 20-year follow-up. This will provide
      an estimate of population incidence and updated prevalence of ocular conditions
      such as myopia and keratoconus, as well as longitudinal change in ocular
      parameters in young Australian adults. Additionally, the data will allow
      exploration of the environmental, health and genetic factors underlying
      inter-subject differential long-term ocular changes. METHODS AND ANALYSIS:
      Participants are being contacted via telephone, email and/or social media and
      invited to participate in the eye examination. At the 27-year follow-up,
      participants completed a follow-up eye screening, which assessed visual acuity,
      autorefraction, ocular biometry and ocular sun exposure. Currently, at the
      28-year follow-up, a comprehensive eye examination is being conducted which, in
      addition to all the eye tests performed at the 27-year follow-up visit, includes 
      tonometry, optical coherence tomography, funduscopy and anterior segment
      topography, among others. Outcome measures include the incidence of refractive
      error and pterygium, an updated prevalence of these conditions, and the 8-year
      change in ocular parameters. ETHICS AND DISSEMINATION: The Raine Study is
      registered in the Australian New Zealand Clinical Trials Registry. The Gen2
      20-year, 27-year and 28-year follow-ups are approved by the Human Research Ethics
      Committee of the University of Western Australia. Findings resulting from the
      study will be published in health or medical journals and presented at
      conferences. TRIAL REGISTRATION NUMBER: ACTRN12617001599369; Active, not
      recruiting.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lee, Samantha Sze-Yee
AU  - Lee SS
AUID- ORCID: 0000-0001-6635-1098
AD  - Centre for Ophthalmology and Visual Science, University of Western Australia,
      Nedlands, Western Australia, Australia samantha.sy.lee29@gmail.com.
FAU - Lingham, Gareth
AU  - Lingham G
AUID- ORCID: 0000-0002-8957-0733
AD  - Lions Eye Institute, Nedlands, Western Australia, Australia.
FAU - Yazar, Seyhan
AU  - Yazar S
AD  - Centre for Ophthalmology and Visual Science, University of Western Australia,
      Nedlands, Western Australia, Australia.
AD  - Single Cell and Computational Genomics Lab, Garvan Institute of Medical Research,
      Darlinghurst, New South Wales, Australia.
FAU - Sanfilippo, Paul G
AU  - Sanfilippo PG
AD  - Centre for Eye Research Australia Ltd, University of Melbourne, Royal Victorian
      Eye and Ear Hospital, East Melbourne, Victoria, Australia.
FAU - Charng, Jason
AU  - Charng J
AD  - Centre for Ophthalmology and Visual Science, University of Western Australia,
      Nedlands, Western Australia, Australia.
FAU - Chen, Fred K
AU  - Chen FK
AD  - Centre for Ophthalmology and Visual Science, University of Western Australia,
      Nedlands, Western Australia, Australia.
AD  - Department of Ophthalmology, Royal Perth Hospital, Perth, Western Australia,
      Australia.
FAU - Hewitt, Alex W
AU  - Hewitt AW
AD  - Centre for Eye Research Australia Ltd, University of Melbourne, Royal Victorian
      Eye and Ear Hospital, East Melbourne, Victoria, Australia.
AD  - School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, 
      Hobart, Tasmania, Australia.
FAU - Ng, Fletcher
AU  - Ng F
AD  - Lions Eye Institute, Nedlands, Western Australia, Australia.
FAU - Hammond, Christopher
AU  - Hammond C
AD  - Department of Twin Research & Genetic Epidemiology, King's College London,
      London, UK.
FAU - Straker, Leon M
AU  - Straker LM
AD  - School of Physiotherapy and Exercise Science, Curtin University, Perth, Western
      Australia, Australia.
FAU - Eastwood, Peter R
AU  - Eastwood PR
AD  - Centre for Sleep Science, School of Human Sciences, University of Western
      Australia, Crawley, Western Australia, Australia.
AD  - Sir Charles Gairdner Hospital, West Australian Sleep Disorders Research
      Institute, Nedlands, Western Australia, Australia.
FAU - MacGregor, Stuart
AU  - MacGregor S
AD  - Genetics and Population Health, Queensland Institute of Medical Research - QIMR, 
      Brisbane, Queensland, Australia.
FAU - Rose, Kathryn A
AU  - Rose KA
AD  - University of Sydney, Sydney, New South Wales, Australia.
FAU - Lucas, Robyn M
AU  - Lucas RM
AUID- ORCID: 0000-0003-2736-3541
AD  - Australian National University, Research School of Population Health, College of 
      Health and Medicine, Canberra, Australian Capital Territory, Australia.
FAU - Guggenheim, Jeremy A
AU  - Guggenheim JA
AUID- ORCID: 0000-0001-5164-340X
AD  - School of Optometry and Vision Science, Cardiff University, Cardiff, South
      Glamorgan, UK.
FAU - Saw, Seang-Mei
AU  - Saw SM
AD  - Singapore Eye Research Institute, Singapore.
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
FAU - Coroneo, Minas T
AU  - Coroneo MT
AD  - Department of Ophthalmology, University of New South Wales, Sydney, New South
      Wales, Australia.
FAU - He, Mingguang
AU  - He M
AD  - Centre for Eye Research Australia Ltd, University of Melbourne, Royal Victorian
      Eye and Ear Hospital, East Melbourne, Victoria, Australia.
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen
      University, Guangzhou, China.
FAU - Mackey, David A
AU  - Mackey DA
AD  - Centre for Ophthalmology and Visual Science, University of Western Australia,
      Nedlands, Western Australia, Australia.
AD  - Centre for Eye Research Australia Ltd, University of Melbourne, Royal Victorian
      Eye and Ear Hospital, East Melbourne, Victoria, Australia.
LA  - eng
SI  - ANZCTR/ACTRN12617001599369
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adult
MH  - Australia
MH  - Biometry
MH  - Child
MH  - Diagnostic Techniques, Ophthalmological
MH  - Eye Diseases/*epidemiology
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Optic Disk/pathology
MH  - Prevalence
MH  - Refractive Errors/epidemiology
MH  - Research Design
MH  - Retina/pathology
MH  - Risk Factors
MH  - Visual Acuity
PMC - PMC7170556
OTO - NOTNLM
OT  - *Raine Study
OT  - *cohort study
OT  - *myopia
OT  - *ocular measures
OT  - *young adults
COIS- Competing interests: None declared.
EDAT- 2020/03/29 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-033440 [pii]
AID - 10.1136/bmjopen-2019-033440 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e033440. doi: 10.1136/bmjopen-2019-033440.


PMID- 32217559
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Physical prognostic factors predicting outcome following anterior cruciate
      ligament reconstruction: protocol for a systematic review.
PG  - e033429
LID - 10.1136/bmjopen-2019-033429 [doi]
AB  - INTRODUCTION: Injuries of the anterior cruciate ligament (ACL) are a common
      musculoskeletal complication and can cause significant reduction in patient
      function and quality of life. Many undergo ACL reconstruction, with high-quality 
      rehabilitation key to successful outcome. Knowledge of physical prognostic
      factors, such as quadriceps strength, is crucial to inform rehabilitation and has
      important implications for outcome following ACL reconstruction. However, these
      factors predicting outcome are poorly defined. Therefore, the aim of this
      systematic review is to establish physical prognostic factors predictive of
      outcome in adults following ACL reconstruction. Outcome will be subdivided into
      two groups of outcome measures, patient-reported and performance-based. Physical 
      prognostic factors of interest will reflect a range of domains and may be
      modifiable/non-modifiable. Results will help decide most appropriate management
      and assist in planning and tailoring preoperative and postoperative
      rehabilitation. METHODS AND ANALYSIS: This systematic review protocol is reported
      according to the Preferred Reporting Items for Systematic Review and
      Meta-Analysis Protocols. MEDLINE, CINAHL and EMBASE databases, key journals and
      grey literature will be searched from inception to July 2019. Prospective cohort 
      studies including participants aged >/=16 years who have undergone ACL
      reconstruction will be included, with articles focusing on multi-ligament
      reconstructions and ACL repair surgery, or not published in English excluded. Two
      independent reviewers will conduct searches, assess study eligibility, extract
      data, assess risk of bias (Quality in Prognostic Studies tool) and quantify
      overall quality of evidence (modified Grading of Recommendations, Assessment,
      Development and Evaluation guidelines). If possible, a meta-analysis will be
      conducted, otherwise a narrative synthesis will ensue focusing on prognostic
      factors, risk of bias of included studies and strength of association with
      outcomes. ETHICS AND DISSEMINATION: Findings will be published in a peer-reviewed
      journal, presented at conferences and locally to physiotherapy departments.
      Ethical approval is not required for this systematic review. PROSPERO
      REGISTRATION NUMBER: CRD42019127732.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Middlebrook, Andrew
AU  - Middlebrook A
AUID- ORCID: 0000-0002-2254-0783
AD  - Department of Health, University of Bath, Bath, UK midd84@hotmail.com.
FAU - Bekker, Sheree
AU  - Bekker S
AUID- ORCID: 0000-0003-0161-6280
AD  - Department of Health, University of Bath, Bath, UK.
FAU - Middlebrook, Nicola
AU  - Middlebrook N
AUID- ORCID: 0000-0003-2154-5723
AD  - Centre of Precision Rehabilitation for Spinal Pain, University of Birmingham,
      Birmingham, UK.
FAU - Rushton, Alison B
AU  - Rushton AB
AUID- ORCID: 0000-0001-8114-7669
AD  - Centre of Precision Rehabilitation for Spinal Pain, University of Birmingham,
      Birmingham, UK.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Age Factors
MH  - Anterior Cruciate Ligament Reconstruction/*statistics & numerical data
MH  - Body Mass Index
MH  - Humans
MH  - Muscle Strength/physiology
MH  - Pain Measurement
MH  - Prognosis
MH  - Prospective Studies
MH  - Quadriceps Muscle/physiology
MH  - Quality of Life
MH  - Range of Motion, Articular
MH  - Research Design
MH  - Sex Factors
MH  - Time-to-Treatment
PMC - PMC7170562
OTO - NOTNLM
OT  - *anterior cruciate ligament
OT  - *injury
OT  - *outcomes
OT  - *prognostic factors
OT  - *systematic review
COIS- Competing interests: None declared.
EDAT- 2020/03/29 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-033429 [pii]
AID - 10.1136/bmjopen-2019-033429 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e033429. doi: 10.1136/bmjopen-2019-033429.


PMID- 32217558
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - International mixed methods study protocol to develop a patient-reported outcome 
      measure for all types of chronic wounds (the WOUND-Q).
PG  - e032332
LID - 10.1136/bmjopen-2019-032332 [doi]
AB  - INTRODUCTION: Most patient-reported outcome measures (PROM) for chronic wounds
      are specific to a single wound type (eg, pressure ulcer) or part of the body. A
      barrier to outcome assessment in wound care and research is the lack of a
      rigorously designed PROM that can be used across wound types and locations. This 
      mixed method study describes the protocol for an international collaboration to
      develop and validate a new PROM called the WOUND-Q for adults with chronic
      wounds. METHODS AND ANALYSIS: In phase I, the qualitative approach of
      interpretive description is used to elicit concepts important to people with
      wounds regarding outcome. Participants from Canada, Denmark, the Netherlands, and
      the USA are aged 18 years and older and have a wound that has lasted 3 months or 
      longer. Interviews are digitally recorded, transcribed and coded. A conceptual
      framework and preliminary item pool are developed from the qualitative dataset.
      Draft scales are formed to cover important themes in the conceptual framework.
      These scales are refined using feedback from people with chronic wounds and wound
      care experts. After refinement, the scales are translated into Danish and Dutch, 
      following rigorous methods, to prepare for an international field-test study. In 
      phase II, data are collected in Canada, Denmark, the Netherlands, and the USA. An
      international sample of people with a large variety of chronic wounds complete
      the WOUND-Q. Rasch Measurement Theory analysis is used to identify the best
      subset of items to retain for each scale and to examine reliability and validity.
      ETHICS AND DISSEMINATION: This study is coordinated at Brigham and Women's
      Hospital (Boston, USA). Ethics board approval was received at each participating 
      site for both study phases. Findings will be published in peer-reviewed journals 
      and presented at national and international conferences and meetings.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Klassen, Anne
AU  - Klassen A
AUID- ORCID: 0000-0003-4720-0096
AD  - Pediatrics, McMaster University, Hamilton, Ontario, Canada.
FAU - van Haren, Emiel Lwg
AU  - van Haren EL
AD  - Plastic and Reconstructive Surgery, Catharina Ziekenhuis, Eindhoven, The
      Netherlands.
FAU - Cross, Karen
AU  - Cross K
AD  - Plastic Surgery, St Michael's Hospital, Toronto, Ontario, Canada.
FAU - Fan, Kenneth L
AU  - Fan KL
AD  - Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital,
      Washington, DC, USA.
FAU - Gibbons, Chris
AU  - Gibbons C
AD  - Department of Surgery, Patient Reported Outcome, Value, and Experience (PROVE)
      Center, Harvard Medical School, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
FAU - Hoogbergen, Maarten M
AU  - Hoogbergen MM
AD  - Plastic and Reconstructive Surgery, Catharina Ziekenhuis, Eindhoven, The
      Netherlands.
FAU - Longmire, Natasha M
AU  - Longmire NM
AD  - Pediatrics, McMaster University, Hamilton, Ontario, Canada.
FAU - Poulsen, Lotte
AU  - Poulsen L
AD  - Department of Plastic Surgery, University of Southern Denmark, Odense, Denmark.
FAU - Sorensen, Jens Ahm
AU  - Sorensen JA
AD  - Department of Plastic Surgery, Odense University Hospital, Odense, Denmark.
FAU - Squitieri, Lee
AU  - Squitieri L
AD  - Division of Plastic and Reconstructive Surgery, University of Southern
      California, Los Angeles, California, USA.
FAU - Tsangaris, Elena
AU  - Tsangaris E
AD  - Department of Surgery, Patient Reported Outcome, Value, and Experience (PROVE)
      Center, Harvard Medical School, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
FAU - van Alphen, Tert C
AU  - van Alphen TC
AD  - Plastic and Reconstructive Surgery, Catharina Ziekenhuis, Eindhoven, The
      Netherlands.
FAU - van Dishoeck, Anne-Margreet
AU  - van Dishoeck AM
AD  - Plastic and Reconstructive Surgery, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Vasilic, Dali
AU  - Vasilic D
AD  - Plastic and Reconstructive Surgery, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Pusic, Andrea L
AU  - Pusic AL
AD  - Department of Surgery, Patient Reported Outcome, Value, and Experience (PROVE)
      Center, Harvard Medical School, Brigham and Women's Hospital, Boston,
      Massachusetts, USA apusic@bwh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Chronic Disease/psychology/therapy
MH  - Humans
MH  - *Patient Reported Outcome Measures
MH  - *Pressure Ulcer/psychology/therapy
MH  - Psychometrics
MH  - Quality of Life
MH  - *Wounds and Injuries/psychology/therapy
PMC - PMC7170563
OTO - NOTNLM
OT  - *patient-reported outcome
OT  - *plastic and reconstructive surgery
OT  - *psychometrics
OT  - *quality of life
OT  - *rasch
OT  - *wound management
COIS- Competing interests: The WOUND-Q will be owned by Memorial Sloan-Kettering Cancer
      Center. Drs ALP and AK are codevelopers of other Q-Portfolio instruments and
      receive a share of any license revenue on the inventor sharing policies of the
      institutions that own them.
EDAT- 2020/03/29 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-032332 [pii]
AID - 10.1136/bmjopen-2019-032332 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e032332. doi: 10.1136/bmjopen-2019-032332.


PMID- 32217557
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20211204
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre
      randomised double-blinded, placebo controlled trial.
PG  - e028514
LID - 10.1136/bmjopen-2018-028514 [doi]
AB  - INTRODUCTION: Subarachnoid haemorrhage (SAH) from a ruptured cerebral aneurysm
      carries high morbidity and mortality. Despite huge advances in techniques to
      secure the aneurysm, there has been little progress in the treatment of the
      deleterious effects of the haemorrhage.Sulforaphane is an Nrf2 inducer with
      anti-oxidant and anti-inflammatory properties. It has been shown to improve
      clinical outcome in experimental models of SAH, but is unstable. SFX-01 (Evgen
      Pharma) is a novel composition comprised of synthetic sulforaphane stabilised
      within an alpha-cyclodextrin complex. On ingestion, the complex releases
      sulforaphane making SFX-01 an ideal vehicle for delivery of sulforaphane. METHODS
      AND ANALYSIS: The objective of the study is to assess the safety,
      pharmacokinetics and efficacy of SFX-01. This is a prospective, multicentre,
      randomised, double-blind placebo-controlled trial in patients aged 18-80 years
      with aneurysmal subarachnoid haemorrhage in the previous 48 hours. 90 patients
      will be randomised to receive SFX-01 (300 mg) or placebo two times per day for up
      to 28 days.Safety will be assessed using blood tests and adverse event
      reporting.Pharmacokinetics will be assessed based on paired blood and
      cerebrospinal fluid (CSF) sulforaphane levels on day 7. A subgroup will have
      hourly samples taken during 6 hours post-dosing on days 1 and 7. Pharmacodynamics
      will be assessed by haptoglobin and malondialdehyde levels, and maximum flow
      velocity of middle cerebral artery will be measured by transcranial Doppler
      ultrasound.Clinical outcomes will be assessed at days 28, 90 and 180 with
      modified Rankin Scale, Glasgow Outcome Score, SAH Outcome Tool, Short Form-36,
      Brain Injury Community Rehabilitation Outcome Scales and Check List for Cognitive
      and Emotional consequences following stroke. MRI at 6 months including
      quantitative susceptibility mapping and volumetric T1 will measure iron
      deposition and cortical volume.Safety, CSF sulforaphane concentration and middle 
      cerebral artery flow velocity will be primary outcomes and all others secondary. 
      ETHICS AND DISSEMINATION: Ethical approval was obtained from South Central
      Hampshire A committee. Outcomes of the trial will be submitted for publication in
      a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT02614742.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zolnourian, Ardalan H
AU  - Zolnourian AH
AUID- ORCID: 0000-0002-0428-179X
AD  - Department of Clinical Neurosciences, University of Southampton, Southampton, UK 
      a.zolnourian@soton.ac.uk.
AD  - Department of Neurosurgery, University Hospital Southampton NHS Foundation Trust,
      Southampton, UK.
FAU - Franklin, Stephen
AU  - Franklin S
AD  - Evgen Pharma, Liverpool, UK.
FAU - Galea, Ian
AU  - Galea I
AD  - Department of Clinical Neurosciences, University of Southampton, Southampton, UK.
AD  - Department of Experimental Neurology, Faculty of Medicine, University of
      Southampton, Southampton, UK.
FAU - Bulters, Diederik Oliver
AU  - Bulters DO
AD  - Department of Clinical Neurosciences, University of Southampton, Southampton, UK.
AD  - Department of Neurosurgery, University Hospital Southampton NHS Foundation Trust,
      Southampton, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02614742
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Dosage Forms)
RN  - 0 (Isothiocyanates)
RN  - 0 (Sulfoxides)
RN  - 0 (alpha-Cyclodextrins)
RN  - GA49J4310U (sulforaphane)
RN  - Z1LH97KTRM (alpha-cyclodextrin)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiovascular Agents/*administration & dosage/pharmacokinetics/therapeutic use
MH  - Clinical Protocols
MH  - Dosage Forms
MH  - Double-Blind Method
MH  - Drug Delivery Systems
MH  - Drug Stability
MH  - Female
MH  - Humans
MH  - Isothiocyanates/*administration & dosage/pharmacokinetics/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Subarachnoid Hemorrhage/*drug therapy
MH  - Sulfoxides
MH  - Treatment Outcome
MH  - Young Adult
MH  - alpha-Cyclodextrins/administration & dosage
PMC - PMC7170552
OTO - NOTNLM
OT  - *Nrf2
OT  - *delayed cerebral ischaemia
OT  - *randomised controlled trial
OT  - *subarachnoid haemorrhage
OT  - *sulforaphane
COIS- Competing interests: SF is the chief executive officer of Evgen Pharma plc. All
      the other authors have no financial or non-financial interest in Evgen Pharma
      plc.
EDAT- 2020/03/29 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
AID - bmjopen-2018-028514 [pii]
AID - 10.1136/bmjopen-2018-028514 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e028514. doi: 10.1136/bmjopen-2018-028514.


PMID- 32217535
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Mar
TI  - Utility and validity of dynamic chest radiography in cystic fibrosis (dynamic
      CF): an observational, non-controlled, non-randomised, single-centre, prospective
      study.
LID - e000569 [pii]
LID - 10.1136/bmjresp-2020-000569 [doi]
AB  - INTRODUCTION: Dynamic chest radiography (DCR) uses novel, low-dose radiographic
      technology to capture images of the thoracic cavity while in motion. Pulmonary
      function testing is important in cystic fibrosis (CF). The tolerability, rapid
      acquisition and lower radiation and cost compared with CT imaging may make DCR a 
      useful adjunct to current standards of care. METHODS AND ANALYSIS: This is an
      observational, non-controlled, non-randomised, single-centre, prospective study. 
      This study is conducted at the Liverpool Heart and Chest Hospital (LHCH) adult CF
      unit. Participants are adults with CF. This study reviews DCR taken during
      routine CF Annual Review (n=150), validates DCR-derived lung volumes against
      whole body plethysmography (n=20) and examines DCR at the start and end of
      pulmonary exacerbations of CF (n=20). The primary objectives of this study are to
      examine if DCR provides lung function information that correlates with PFT, and
      lung volumes that correlate whole body plethysmography. ETHICS AND DISSEMINATION:
      This study has received the following approvals: HRA REC (11 December 2019) and
      LHCH R&I (11 October 2019). Results are made available to people with CF, the
      funders and other researchers. Processed, anonymised data are available from the 
      research team on request. TRIAL REGISTRATION NUMBER: ISRCTN 64994816.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY.
      Published by BMJ.
FAU - FitzMaurice, Thomas Simon
AU  - FitzMaurice TS
AUID- ORCID: http://orcid.org/0000-0002-9334-486X
AD  - Adult CF Unit, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK
      thomas.fitzmaurice@lhch.nhs.uk.
AD  - Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
FAU - McNamara, Paul Stephen
AU  - McNamara PS
AD  - Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
AD  - Institute in the Park, Alder Hey Children's Hospital, Liverpool, UK.
FAU - Nazareth, Dilip
AU  - Nazareth D
AD  - Adult CF Unit, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK.
AD  - Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
FAU - McCann, Caroline
AU  - McCann C
AD  - Department of Radiology, Liverpool Heart and Chest Hospital NHS Trust, Liverpool,
      UK.
FAU - Bedi, Ram
AU  - Bedi R
AD  - Department of Bioengineering, University of Washington, Seattle, Washington, USA.
FAU - Shaw, Matthew
AU  - Shaw M
AD  - Research Department, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK.
FAU - Walshaw, Martin
AU  - Walshaw M
AD  - Adult CF Unit, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK.
AD  - Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
LA  - eng
SI  - ISRCTN/ISRCTN64994816
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
SB  - IM
MH  - Cystic Fibrosis/*diagnostic imaging/physiopathology
MH  - Humans
MH  - Lung/*diagnostic imaging/physiopathology
MH  - Prospective Studies
MH  - Radiography, Thoracic/economics/instrumentation/*methods
MH  - Respiratory Function Tests
PMC - PMC7206905
OTO - NOTNLM
OT  - *cystic fibrosis
OT  - *lung physiology
OT  - *respiratory infection
OT  - *respiratory muscles
COIS- Competing interests: RB reports personal fees from PHC Corporation of North
      America, Konica Minolta and Nihon Kohden Innovation Center outside the submitted 
      work. None of the other authors declare any competing interests.
EDAT- 2020/03/29 06:00
MHDA- 2021/06/11 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/02/19 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
AID - 7/1/e000569 [pii]
AID - 10.1136/bmjresp-2020-000569 [doi]
PST - ppublish
SO  - BMJ Open Respir Res. 2020 Mar;7(1). pii: 7/1/e000569. doi:
      10.1136/bmjresp-2020-000569.


PMID- 32217426
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
VI  - 126
DP  - 2020 May
TI  - Tumour subregion analysis of colorectal liver metastases using semi-automated
      clustering based on DCE-MRI: Comparison with histological subregions and impact
      on pharmacokinetic parameter analysis.
PG  - 108934
LID - S0720-048X(20)30123-6 [pii]
LID - 10.1016/j.ejrad.2020.108934 [doi]
AB  - PURPOSE: To use a novel segmentation methodology based on dynamic
      contrast-enhanced magnetic resonance imaging (DCE-MRI) to define tumour
      subregions of liver metastases from colorectal cancer (CRC), to compare these
      with histology, and to use these to compare extracted pharmacokinetic (PK)
      parameters between tumour subregions. MATERIALS AND METHODS: This
      ethically-approved prospective study recruited patients with CRC and >/=1 hepatic
      metastases scheduled for hepatic resection. Patients underwent DCE-MRI
      pre-metastasectomy. Histological sections of resection specimens were spatially
      matched to DCE-MRI acquisitions and used to define histological subregions of
      viable and non-viable tumour. A semi-automated voxel-wise image segmentation
      algorithm based on the DCE-MRI contrast-uptake curves was used to define imaging 
      subregions of viable and non-viable tumour. Overlap of histologically-defined and
      imaging subregions was compared using the Dice similarity coefficient (DSC).
      DCE-MRI PK parameters were compared for the whole tumour and histology-defined
      and imaging-derived subregions. RESULTS: Fourteen patients were included in the
      analysis. Direct histological comparison with imaging was possible in nine
      patients. Mean DSC for viable tumour subregions defined by imaging and histology 
      was 0.738 (range 0.540-0.930). There were significant differences between
      K(trans) and kep for viable and non-viable subregions (p < 0.001) and between
      whole lesions and viable subregions (p < 0.001). CONCLUSION: We demonstrate good 
      concordance of viable tumour segmentation based on pre-operative DCE-MRI with a
      post-operative histological gold-standard. This can be used to extract viable
      tumour-specific values from quantitative image analysis, and could improve
      treatment response assessment in clinical practice.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Franklin, James M
AU  - Franklin JM
AD  - Institute of Medical Imaging and Visualisation, Bournemouth University, UK;
      Radiology Department, Royal Bournemouth and Christchurch Hospitals NS Foundation 
      Trust, UK. Electronic address: jfranklin@bournemouth.ac.uk.
FAU - Irving, Benjamin
AU  - Irving B
AD  - Institute of Biomedical Engineering (Department of Engineering Science),
      University of Oxford, UK.
FAU - Papiez, Bartlomiej W
AU  - Papiez BW
AD  - Institute of Biomedical Engineering (Department of Engineering Science),
      University of Oxford, UK.
FAU - Kallehauge, Jesper F
AU  - Kallehauge JF
AD  - Institute of Biomedical Engineering (Department of Engineering Science),
      University of Oxford, UK.
FAU - Wang, Lai Mun
AU  - Wang LM
AD  - Department of Cellular Pathology, Oxford University Hospitals NHS Foundation
      Trust, UK.
FAU - Goldin, Robert D
AU  - Goldin RD
AD  - Centre for Pathology, Imperial College, London, UK.
FAU - Harris, Adrian L
AU  - Harris AL
AD  - Department of Oncology, University of Oxford, UK.
FAU - Anderson, Ewan M
AU  - Anderson EM
AD  - Radiology Department, Churchill Hospital, Oxford University Hospitals NHS
      Foundation Trust, UK.
FAU - Schnabel, Julia A
AU  - Schnabel JA
AD  - Institute of Biomedical Engineering (Department of Engineering Science),
      University of Oxford, UK; School of Biomedical Engineering and Imaging Sciences, 
      King's College London, UK.
FAU - Chappell, Michael A
AU  - Chappell MA
AD  - Institute of Biomedical Engineering (Department of Engineering Science),
      University of Oxford, UK.
FAU - Brady, Michael
AU  - Brady M
AD  - Department of Oncology, University of Oxford, UK.
FAU - Sharma, Ricky A
AU  - Sharma RA
AD  - NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer
      Institute, University College London, 72 Huntley Street, London, WC1E 6DD, UK.
FAU - Gleeson, Fergus V
AU  - Gleeson FV
AD  - Radiology Department, Churchill Hospital, Oxford University Hospitals NHS
      Foundation Trust, UK.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20200306
PL  - Ireland
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
RN  - 0 (Contrast Media)
SB  - IM
MH  - Algorithms
MH  - Cluster Analysis
MH  - Colorectal Neoplasms/*pathology
MH  - Contrast Media/*pharmacokinetics
MH  - Humans
MH  - Image Enhancement/*methods
MH  - Liver/diagnostic imaging/metabolism
MH  - Liver Neoplasms/*diagnostic imaging/metabolism/*secondary
MH  - Magnetic Resonance Imaging/*methods
MH  - Prospective Studies
OTO - NOTNLM
OT  - Colorectal neoplasm
OT  - Liver neoplasm
OT  - MRI
OT  - Perfusion imaging
EDAT- 2020/03/29 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/03/29 06:00
PHST- 2019/07/17 00:00 [received]
PHST- 2020/01/21 00:00 [revised]
PHST- 2020/03/01 00:00 [accepted]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - S0720-048X(20)30123-6 [pii]
AID - 10.1016/j.ejrad.2020.108934 [doi]
PST - ppublish
SO  - Eur J Radiol. 2020 May;126:108934. doi: 10.1016/j.ejrad.2020.108934. Epub 2020
      Mar 6.


PMID- 32217164
OWN - NLM
STAT- MEDLINE
DCOM- 20210215
LR  - 20210215
IS  - 1095-9572 (Electronic)
IS  - 1053-8119 (Linking)
VI  - 214
DP  - 2020 Jul 1
TI  - In vivo-assessment of the human temporal network: Evidence for asymmetrical
      effective connectivity.
PG  - 116769
LID - S1053-8119(20)30256-1 [pii]
LID - 10.1016/j.neuroimage.2020.116769 [doi]
AB  - The human temporal lobe is a multimodal association area which plays a key role
      in various aspects of cognition, particularly in memory formation and spatial
      navigation. Functional and anatomical connectivity of temporal structures is thus
      a subject of intense research, yet by far underexplored in humans due to ethical 
      and technical limitations. We assessed intratemporal cortico-cortical
      interactions in the living human brain by means of single pulse electrical
      stimulation, an invasive method allowing mapping effective intracortical
      connectivity with a high spatiotemporal resolution. Eighteen subjects with normal
      anterior-mesial temporal MR imaging undergoing intracranial presurgical epilepsy 
      diagnostics with multiple depth electrodes were included. The investigated
      structures were temporal pole, hippocampus, amygdala and parahippocampal gyrus.
      Intratemporal cortical connectivity was assessed as a function of amplitude of
      the early component of the cortico-cortical evoked potentials (CCEP). While the
      analysis revealed robust interconnectivity between all explored structures, a
      clear asymmetry in bidirectional connectivity was detected for the hippocampal
      network and for the connections between the temporal pole and parahippocampal
      gyrus. The amygdala showed bidirectional asymmetry only to the hippocampus. The
      provided evidence of asymmetrically weighed intratemporal effective connectivity 
      in humans in vivo is important for understanding of functional interactions
      within the temporal lobe since asymmetries in the brain connectivity define
      hierarchies in information processing. The findings are in exact accord with the 
      anatomical tracing studies in non-human primates and open a translational route
      for interventions employing modulation of temporal lobe function.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Novitskaya, Yulia
AU  - Novitskaya Y
AD  - Epilepsy Center, Department of Neurosurgery, Faculty of Medicine, University of
      Freiburg, Breisacher Strasse 64, 79106, Freiburg, Germany. Electronic address:
      yuliya.novitskaya@gmail.com.
FAU - Dumpelmann, Matthias
AU  - Dumpelmann M
AD  - Epilepsy Center, Department of Neurosurgery, Faculty of Medicine, University of
      Freiburg, Breisacher Strasse 64, 79106, Freiburg, Germany.
FAU - Vlachos, Andreas
AU  - Vlachos A
AD  - Department of Neuroanatomy, Institute of Anatomy and Cell Biology, Faculty of
      Medicine, University of Freiburg, Albert Strasse 17, 79104, Freiburg, Germany;
      Center for Basics in NeuroModulation, Faculty of Medicine, University of
      Freiburg, Breisacher Strasse 64, 79106, Freiburg, Germany.
FAU - Reinacher, Peter Christoph
AU  - Reinacher PC
AD  - Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine,
      University of Freiburg, Breisacher Strasse 64, 79106, Freiburg, Germany.
FAU - Schulze-Bonhage, Andreas
AU  - Schulze-Bonhage A
AD  - Epilepsy Center, Department of Neurosurgery, Faculty of Medicine, University of
      Freiburg, Breisacher Strasse 64, 79106, Freiburg, Germany; Center for Basics in
      NeuroModulation, Faculty of Medicine, University of Freiburg, Breisacher Strasse 
      64, 79106, Freiburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200323
PL  - United States
TA  - Neuroimage
JT  - NeuroImage
JID - 9215515
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brain/*physiology
MH  - Brain Mapping/methods
MH  - Electric Stimulation
MH  - Electrocorticography
MH  - Evoked Potentials, Somatosensory/physiology
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Nerve Net/*physiology
MH  - Young Adult
OTO - NOTNLM
OT  - *Asymmetry
OT  - *CCEP
OT  - *Effective connectivity
OT  - *Human temporal lobe
OT  - *Reciprocal connectivity
EDAT- 2020/03/29 06:00
MHDA- 2021/02/16 06:00
CRDT- 2020/03/29 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/02/22 00:00 [revised]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/02/16 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - S1053-8119(20)30256-1 [pii]
AID - 10.1016/j.neuroimage.2020.116769 [doi]
PST - ppublish
SO  - Neuroimage. 2020 Jul 1;214:116769. doi: 10.1016/j.neuroimage.2020.116769. Epub
      2020 Mar 23.


PMID- 32216574
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Student nurses' ethical views on responses to the severe acute respiratory
      syndrome outbreak.
PG  - 924-934
LID - 10.1177/0969733019895804 [doi]
AB  - BACKGROUND: Fifteen years have passed since the outbreak of severe acute
      respiratory syndrome in Hong Kong. At that time, there were reports of heroic
      acts among professionals who cared for these patients, whose bravery and
      professionalism were highly praised. However, there are concerns about changes in
      new generation of nursing professionals. OBJECTIVE: We aimed to examine the
      attitude of nursing students, should they be faced with severe acute respiratory 
      syndrome patients during their future work. RESEARCH DESIGN: A questionnaire
      survey was carried out to examine the attitude among final-year nursing students 
      to three ethical areas, namely, duty of care, resource allocation, and collateral
      damage. ETHICAL CONSIDERATIONS: This study was carried out in accordance with the
      requirements and recommendations of the Central Research and Ethics Committee,
      School of Health Sciences at Caritas Institute of Higher Education. FINDINGS:
      Complete responses from 102 subjects were analyzed. The overwhelming majority
      (96.1%) did not agree to participate in the intubation of severe acute
      respiratory syndrome patients if protective measures, that is, N95 mask and gown,
      were not available. If there were insufficient N95 masks for all the medical,
      nursing, and allied health workers in the hospital (resource allocation), 37.3%
      felt that the distribution of N95 masks should be by casting lot, while the rest 
      disagreed. When asked about collateral damage, more than three-quarters (77.5%)
      said that severe acute respiratory syndrome patients should be admitted to
      intensive care unit. There was sex difference in nursing students' attitude
      toward severe acute respiratory syndrome care during pregnancy and influence of
      age in understanding intensive care unit care for these patients. Interestingly, 
      94.1% felt that there should be a separate intensive care unit for severe acute
      respiratory syndrome patients. CONCLUSION: As infection control practice and
      isolation facilities improved over the years, relevant knowledge and nursing
      ethical issues related to infectious diseases should become part of nursing
      education and training programs, especially in preparation for outbreaks of
      infectious diseases or distress.
FAU - Kam, Joseph Km
AU  - Kam JK
AUID- ORCID: https://orcid.org/0000-0003-0579-0307
AD  - The Chinese University of Hong Kong, Hong Kong.
FAU - Chan, Eric
AU  - Chan E
AD  - Caritas Institute of Higher Education, Hong Kong.
FAU - Lee, Albert
AU  - Lee A
FAU - Wei, Vivian Wi
AU  - Wei VW
FAU - Kwok, Kin On
AU  - Kwok KO
AD  - The Chinese University of Hong Kong, Hong Kong.
FAU - Lui, Dominic
AU  - Lui D
FAU - Yuen, Robert Kn
AU  - Yuen RK
AD  - Holy Spirit Seminary College of Theology and Philosophy, Hong Kong.
LA  - eng
PT  - Journal Article
DEP - 20200327
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adult
MH  - *Attitude of Health Personnel
MH  - *Disease Outbreaks
MH  - *Ethics, Nursing
MH  - Female
MH  - Health Care Rationing
MH  - Hong Kong
MH  - Humans
MH  - Intensive Care Units
MH  - Male
MH  - Patient Admission
MH  - Severe Acute Respiratory Syndrome/*epidemiology
MH  - Standard of Care
MH  - Students, Nursing/*psychology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Collateral damage
OT  - Hong Kong
OT  - SARS
OT  - duty of care
OT  - nursing students
OT  - resource allocation
EDAT- 2020/03/29 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 10.1177/0969733019895804 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):924-934. doi: 10.1177/0969733019895804. Epub 2020 Mar
      27.


PMID- 32216570
OWN - NLM
STAT- MEDLINE
DCOM- 20201008
LR  - 20220414
IS  - 1477-0989 (Electronic)
IS  - 0969-7330 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jun
TI  - Value discrepancies between nurses and patients: A survey study.
PG  - 1044-1055
LID - 10.1177/0969733020906595 [doi]
AB  - BACKGROUND: Patient-centeredness, respect for patient autonomy, and shared
      decision-making have now made it to center stage in discussions on quality of
      care. Knowing what actually counts in care and how it should be accomplished from
      the patients' and nurses' perspective seems crucial. AIM: To explore how patients
      and their nurses perceive the importance and enactment of values in their
      healthcare. RESEARCH DESIGN: An observational, cross-sectional study using a
      self-developed questionnaire, consisting of 15 items related to seven values
      (e.g. uniqueness, autonomy, professionalism, compassion, responsiveness,
      partnership, and empowerment) as described in the taxonomy of Bastemeijer et al. 
      PARTICIPANTS AND RESEARCH CONTEXT: The survey was completed by 384 patients and
      81 nurses. Participants were recruited on eight internal medicine wards of a
      1000-bed university hospital in Belgium. ETHICAL CONSIDERATIONS: This study was
      approved by the ethical committee of the Ghent University Hospital
      (B670201836799). FINDINGS: (1) Patients and nurses prioritize values of care
      differently; (2) nurses report not being able to enact the values they prioritize
      in actual practice as much as one would like to; and (3) there is a gap in
      experienced delivery of a comprehensible explanation of all treatment options, a 
      conversation based on equality, making shared decisions, and being non-judgmental
      between nurses and patients. DISCUSSION: Our findings challenge nurses'
      overemphasis on professional compassion and uniqueness while arguing for
      increased attention on authentic shared decision-making and empowerment. The
      first step to a patient-centered culture truly involving patients in their
      healthcare is communication and information provision, rather than focusing on
      tangible and normative constructs. CONCLUSION: Our findings revealed differences 
      in prioritization and actual enactment of values in care between patients and
      nurses. This was especially so for values related to communication, provision of 
      complete unbiased information, and shared decision-making. Nurses should
      prioritize providing comprehensible information and using conversations based on 
      equality to make decision together with patients.
FAU - Van Humbeeck, Liesbeth
AU  - Van Humbeeck L
AUID- ORCID: https://orcid.org/0000-0002-8321-5001
AD  - Ghent University Hospital, Belgium.
FAU - Malfait, Simon
AU  - Malfait S
AUID- ORCID: https://orcid.org/0000-0001-7287-6034
AD  - Ghent University Hospital, Belgium.
FAU - Holvoet, Els
AU  - Holvoet E
AD  - Ghent University Hospital, Belgium.
FAU - Vogelaers, Dirk
AU  - Vogelaers D
AD  - Ghent University Hospital, Belgium.
FAU - De Pauw, Michel
AU  - De Pauw M
AD  - Ghent University Hospital, Belgium.
FAU - Van Den Noortgate, Nele
AU  - Van Den Noortgate N
AD  - Ghent University Hospital, Belgium.
FAU - Van Biesen, Wim
AU  - Van Biesen W
AD  - Ghent University Hospital, Belgium.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200327
PL  - England
TA  - Nurs Ethics
JT  - Nursing ethics
JID - 9433357
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Belgium
MH  - *Communication
MH  - Cross-Sectional Studies
MH  - *Decision Making, Shared
MH  - Female
MH  - Hospitals, University
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nurses/*psychology
MH  - Patient Participation/*psychology
MH  - Patient-Centered Care/*standards
MH  - Patients/*psychology
MH  - Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - Hospital
OT  - nurses
OT  - patient-centered care
OT  - patients
OT  - prioritization
OT  - quantitative
OT  - survey
OT  - values
EDAT- 2020/03/29 06:00
MHDA- 2020/10/09 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/10/09 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 10.1177/0969733020906595 [doi]
PST - ppublish
SO  - Nurs Ethics. 2020 Jun;27(4):1044-1055. doi: 10.1177/0969733020906595. Epub 2020
      Mar 27.


PMID- 32216534
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1758-1117 (Electronic)
IS  - 0023-6772 (Linking)
VI  - 54
IP  - 4
DP  - 2020 Aug
TI  - Use of high frequency jet ventilation as a refinement for imaging macaques with
      respiratory disease.
PG  - 386-390
LID - 10.1177/0023677220913328 [doi]
AB  - Imaging is used in human medicine to diagnose disease and monitor treatment
      efficacy. Computed tomography (CT) positron emission tomography (PET) and
      magnetic resonance (MR) are applied to animal models of infectious diseases to
      increase data quality, enhance their relevance to the clinical situation, and to 
      address ethical issues through reduction of numbers and refinement of study
      designs. The time required for collection of MR and PET-CT scans means that
      normal breathing produces motion artefacts that can render images unacceptable.
      We report, for the first time, the use of high frequency jet ventilation (HFJV)
      for respiratory management during imaging of macaques. HFJV enables continuous
      gaseous exchange, resulting in cessation of spontaneous breathing motion thus
      providing a motionless field without the potential stresses induced by repeated
      breath-hold strategies.
FAU - Sharpe, Sally A
AU  - Sharpe SA
AUID- ORCID: https://orcid.org/0000-0002-7014-7660
AD  - Public Health England, National Infection Service, Porton Down, Salisbury, SP4
      0JG, UK.
FAU - Scott, Shaun
AU  - Scott S
AD  - The Churchill Hospital, Headington, Oxford, UK.
FAU - Taylor, Irene
AU  - Taylor I
AD  - Public Health England, National Infection Service, Porton Down, Salisbury, SP4
      0JG, UK.
FAU - Skinner, Oliver
AU  - Skinner O
AD  - Public Health England, National Infection Service, Porton Down, Salisbury, SP4
      0JG, UK.
FAU - Clark, Simon O
AU  - Clark SO
AD  - Public Health England, National Infection Service, Porton Down, Salisbury, SP4
      0JG, UK.
FAU - Smyth, Donna
AU  - Smyth D
AD  - Public Health England, National Infection Service, Porton Down, Salisbury, SP4
      0JG, UK.
FAU - McIntyre, Anthony
AU  - McIntyre A
AD  - The Churchill Hospital, Headington, Oxford, UK.
FAU - Gleeson, Fergus V
AU  - Gleeson FV
AD  - The Churchill Hospital, Headington, Oxford, UK.
FAU - Dennis, Mike J
AU  - Dennis MJ
AD  - Public Health England, National Infection Service, Porton Down, Salisbury, SP4
      0JG, UK.
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - England
TA  - Lab Anim
JT  - Laboratory animals
JID - 0112725
SB  - IM
MH  - Animals
MH  - Female
MH  - High-Frequency Jet Ventilation/*methods
MH  - *Macaca fascicularis
MH  - *Macaca mulatta
MH  - Respiratory Tract Diseases/*diagnostic imaging
OTO - NOTNLM
OT  - PET-CT imaging
OT  - jet ventilation
OT  - non-human primate
OT  - respiratory management
EDAT- 2020/03/29 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/03/29 06:00
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/03/29 06:00 [entrez]
AID - 10.1177/0023677220913328 [doi]
PST - ppublish
SO  - Lab Anim. 2020 Aug;54(4):386-390. doi: 10.1177/0023677220913328. Epub 2020 Mar
      26.


PMID- 32216157
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20201005
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1469
IP  - 1
DP  - 2020 Jun
TI  - Citizen science in ecology: a place for humans in nature.
PG  - 52-64
LID - 10.1111/nyas.14340 [doi]
AB  - By involving the public, citizen science runs against the grain of an idealized
      science that leaves out the human element, and thus provides new opportunities
      for ecological research and society. We classify the goals of citizen science in 
      ecology and environment into four broad categories: (1) scientific, (2)
      participant benefits, (3) community, and (4) policy. Although none of these goals
      have been well studied, we review the literature showing that these projects are 
      most effective in tracking ecological trends over large swaths of space and time,
      and discuss the challenges of recruiting, training, retaining, and educating
      participants, maintaining and disseminating high-quality data, and connecting
      with the larger community and policy. Biomedical studies, where patients
      participate in their own treatment in randomized trials, provide an interesting
      comparison with citizen science in ecology, sharing challenges in recruitment and
      involvement of nonscientists and ethical conduct of research. Future study will
      help address the ethical difficulties and enhance ways for citizen science in
      ecology and the environment to complement scientific discovery, involve and
      educate the public, and guide policy founded in science and the local community.
CI  - (c) 2020 New York Academy of Sciences.
FAU - Adler, Frederick R
AU  - Adler FR
AUID- ORCID: 0000-0002-9022-3157
AD  - School of Biological Sciences, University of Utah, Salt Lake City, Utah.
AD  - Department of Mathematics, University of Utah, Salt Lake City, Utah.
FAU - Green, Austin M
AU  - Green AM
AD  - School of Biological Sciences, University of Utah, Salt Lake City, Utah.
FAU - Sekercioglu, Cagan H
AU  - Sekercioglu CH
AD  - School of Biological Sciences, University of Utah, Salt Lake City, Utah.
AD  - Conservation Science Group, Department of Zoology, Cambridge University,
      Cambridge, United Kingdom.
AD  - Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200326
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
SB  - IM
MH  - *Citizen Science
MH  - *Ecology
MH  - Humans
OTO - NOTNLM
OT  - *biomedical science
OT  - *citizen science
OT  - *ecology
OT  - *environment
EDAT- 2020/03/28 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/03/28 06:00
PHST- 2019/10/16 00:00 [received]
PHST- 2020/02/18 00:00 [revised]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - 10.1111/nyas.14340 [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2020 Jun;1469(1):52-64. doi: 10.1111/nyas.14340. Epub 2020 Mar 
      26.


PMID- 32216036
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1527-6473 (Electronic)
IS  - 1527-6465 (Linking)
VI  - 26
IP  - 8
DP  - 2020 Aug
TI  - Living Donor Liver Transplantation When Deceased Donor Is Not Possible or Timely:
      Case Examples and Ethical Perspectives.
PG  - 1066-1067
LID - 10.1002/lt.25765 [doi]
FAU - Shingina, Alexandra
AU  - Shingina A
AD  - Division of Gastroenterology and Hepatology, Vanderbilt University Medical
      Center, Nashville, TN.
FAU - Montenovo, Martin
AU  - Montenovo M
AD  - Division of Liver Transplantation and Hepatobiliary Surgery, Vanderbilt
      University Medical Center, Nashville, TN.
LA  - eng
PT  - Letter
PT  - Comment
DEP - 20200502
PL  - United States
TA  - Liver Transpl
JT  - Liver transplantation : official publication of the American Association for the 
      Study of Liver Diseases and the International Liver Transplantation Society
JID - 100909185
SB  - IM
CON - Liver Transpl. 2020 Mar;26(3):431-436. PMID: 31872945
CIN - Liver Transpl. 2020 Aug;26(8):1068. PMID: 32170994
MH  - Humans
MH  - *Liver Transplantation
MH  - *Living Donors
EDAT- 2020/03/28 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/02/25 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - 10.1002/lt.25765 [doi]
PST - ppublish
SO  - Liver Transpl. 2020 Aug;26(8):1066-1067. doi: 10.1002/lt.25765. Epub 2020 May 2.


PMID- 32215940
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
VI  - 76
IP  - 7
DP  - 2020 Jul
TI  - Does ethical leadership boost nurses' patient-oriented organizational citizenship
      behaviours? A cross-sectional study.
PG  - 1603-1613
LID - 10.1111/jan.14366 [doi]
AB  - AIMS: To examine the relationships between perceived ethical leadership,
      perceived interactional justice climate, and patient-oriented organizational
      citizenship behaviour. DESIGN: A cross-sectional non-experimental design was
      employed. METHODS: The convenience sampling was adopted. Data were collected in
      July and August 2018. A total of 738 nurses were recruited from eight Chinese
      hospitals. The survey included instrument scales of ethical leadership,
      interactional justice climate, and patient-oriented organizational citizenship
      behaviour. SPSS version 22 was used to compute means, standard deviations, and
      intercorrelations. The partial least squares structural equation modelling was
      chosen to estimate the path coefficients of the relationships. RESULTS:
      Relationships among perceived ethical leadership, perceived interactional justice
      climate, and organizational citizenship behaviours were statistically
      significant. Perceived interactional justice climate mediated the relationship
      between perceived ethical leadership and nurses' organizational citizenship
      behaviours. CONCLUSIONS: Ethical leadership is related to interactional justice
      climate, which, in turn, increases nurses' organizational citizenship behaviour. 
      Nurse leaders are encouraged to exhibit ethical behaviours and to create justice 
      climate. Ethical leadership scale can be used to select, train, and evaluate the 
      nurse supervisors and managers. IMPACT: Hospital administrators are encouraged to
      recruit and promote those with both moral compass and leadership potential to
      nursing leadership positions. Nursing managers should create a justice climate in
      their hospitals. Hospital administrators could use ethical leadership scale to
      develop ethical leadership training programmes.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Qiu, Shaoping
AU  - Qiu S
AUID- ORCID: https://orcid.org/0000-0002-2857-4415
AD  - The Department of Engineering Technology and Industrial Distribution, Texas A& M 
      University, College Station, TX, USA.
FAU - Dooley, Larry M
AU  - Dooley LM
AD  - The Department of Educational Administration and Human Resource Development,
      Texas A& M University, College Station, TX, USA.
FAU - Deng, Ruidi
AU  - Deng R
AD  - Hunan Anhua County Hospital of Traditional Chinese Medicine, Dongping, Hunan
      Province, China.
FAU - Li, Liqiong
AU  - Li L
AD  - The 2nd Department of Critical Care Medicine, The First Affiliated Hospital, Sun 
      Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - England
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
SB  - IM
MH  - Attitude of Health Personnel
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Job Satisfaction
MH  - Leadership
MH  - Morals
MH  - *Nurse Administrators
MH  - *Nursing Staff, Hospital
MH  - Organizational Culture
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Chinese hospitals
OT  - ethical leadership
OT  - interactional justice climate
OT  - nurse/nursing
OT  - organizational citizenship behaviour
EDAT- 2020/03/28 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/03/28 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2020/02/24 00:00 [revised]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - 10.1111/jan.14366 [doi]
PST - ppublish
SO  - J Adv Nurs. 2020 Jul;76(7):1603-1613. doi: 10.1111/jan.14366. Epub 2020 Apr 24.


PMID- 32215784
OWN - NLM
STAT- MEDLINE
DCOM- 20210108
LR  - 20210108
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Linking)
VI  - 59
IP  - 1
DP  - 2020 Aug
TI  - New Concepts and Technological Resources in Patient Education and Asthma
      Self-Management.
PG  - 19-37
LID - 10.1007/s12016-020-08782-w [doi]
AB  - Asthma is a chronic disease that is associated with significant morbidity and
      mortality. In general, the use of technology resources or electronic health
      (e-health) has been shown to have beneficial effects on patients with asthma.
      E-health can impact a broad section of patients and can be cost-effective and
      associated with high patient satisfaction. E-health may enable remote delivery of
      care, as well as timely access to health care, which are some of the common
      challenges faced by patients with asthma. Web-based asthma self-management
      systems have been found to improve quality of life, self-reported asthma
      symptoms, lung function, reduction in asthma symptoms/exacerbations, and
      self-reported adherence for adults. Social media is commonly being used as a
      platform to disseminate information on asthma to increase public awareness. It
      can facilitate asthma self-management in a patient friendly manner and has shown 
      to improve asthma control test scores as well as self-esteem. Text massages
      reminders can increase awareness regarding asthma treatment and control, thus
      potentially can improve adherence to medications and asthma outcome. Mobile
      health applications can support asthma self-management, improve a patient's
      quality of life, promote medication adherence, and potentially reduce the overall
      costs for asthma care. Inhaler trackers have shown to be beneficial to asthma
      outcome in various populations by improving adherence to asthma medications.
      Barriers such as physician financial reimbursement as well as licensing for
      rendering tele-healthcare services are important concerns. Other limitations of
      using technology resources in health care are related to liability,
      professionalism, and ethical issues such as breach of patient confidentiality and
      privacy. Additionally, there may be less face-to-face interaction and care of the
      patient when e-health is used.
FAU - Poowuttikul, Pavadee
AU  - Poowuttikul P
AD  - Department of Pediatrics, Division of Allergy/Immunology, Children's Hospital of 
      Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor,
      Pediatric Specialty Building, Detroit, MI, 48201, USA. ppoowutt@med.wayne.edu.
FAU - Seth, Divya
AU  - Seth D
AD  - Department of Pediatrics, Division of Allergy/Immunology, Children's Hospital of 
      Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor,
      Pediatric Specialty Building, Detroit, MI, 48201, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Anti-Asthmatic Agents)
SB  - IM
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Humans
MH  - Medication Adherence
MH  - Mobile Applications
MH  - Nebulizers and Vaporizers
MH  - Patient Education as Topic
MH  - Quality of Life
MH  - Self-Management
MH  - Telemedicine/*methods
OTO - NOTNLM
OT  - Asthma medication adherence
OT  - Asthma self-management
OT  - Electronic health
OT  - Inhaler trackers
OT  - Mobile health applications
OT  - Technology tools for asthma education
OT  - Telemedicine
OT  - Web-based asthma self-management systems
EDAT- 2020/03/28 06:00
MHDA- 2021/01/09 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/01/09 06:00 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - 10.1007/s12016-020-08782-w [doi]
AID - 10.1007/s12016-020-08782-w [pii]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2020 Aug;59(1):19-37. doi: 10.1007/s12016-020-08782-w.


PMID- 32215524
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1678-4758 (Electronic)
IS  - 0104-5970 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Jan-Mar
TI  - [Ethics and social medicine: Michel Foucault's perspective].
PG  - 171-180
LID - S0104-59702020000100171 [pii]
LID - 10.1590/S0104-59702020000100010 [doi]
AB  - Michel Foucault's preoccupation with medicine, its history and its impact on
      society, is a constant in his work. The goal of this study is to contrast the
      content of the lectures Foucault gave in Rio de Janeiro, in October 1974, with
      the preparatory notes for them which are part of the archival holdings acquired
      by the National Library of France. One of the key questions in those lectures is 
      the relationship between ethics and contemporary social medicine. This question, 
      analyzed from Foucault's point of view, constitutes the background and ultimate
      interest of this article.
FAU - Fernandez Agis, Domingo
AU  - Fernandez Agis D
AUID- ORCID: http://orcid.org/0000-0002-0702-1125
AD  - Profesor, Facultad de Humanidades, Seccion de Filosofia/ Universidad de La
      Laguna. San Cristobal de la Laguna - Espana. dferagi@ull.edu.es.
LA  - spa
PT  - Historical Article
PT  - Journal Article
TT  - La etica y la medicina social: la perspectiva de Michel Foucault.
PL  - Brazil
TA  - Hist Cienc Saude Manguinhos
JT  - Historia, ciencias, saude--Manguinhos
JID - 9513999
MH  - Brazil
MH  - Congresses as Topic/history
MH  - Ethics, Medical/*history
MH  - Health Policy/economics/history
MH  - History, 20th Century
MH  - Humans
MH  - Hygiene/history
MH  - Right to Health/history
MH  - Social Medicine/ethics/*history
PS  - Foucault M
FPS - Foucault, Michel
EDAT- 2020/03/28 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/03/28 06:00
PHST- 2018/04/10 00:00 [received]
PHST- 2018/06/23 00:00 [accepted]
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
AID - S0104-59702020000100171 [pii]
AID - 10.1590/S0104-59702020000100010 [doi]
PST - ppublish
SO  - Hist Cienc Saude Manguinhos. 2020 Jan-Mar;27(1):171-180. doi:
      10.1590/S0104-59702020000100010.


PMID- 32214357
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20200630
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 3
DP  - 2020
TI  - Relationships between objective structured clinical examination, computer-based
      testing, and clinical clerkship performance in Japanese medical students.
PG  - e0230792
LID - 10.1371/journal.pone.0230792 [doi]
AB  - BACKGROUND: It is unclear how comprehensive evaluations conducted prior to
      clinical clerkships (CC), such as the objective structured clinical examination
      (OSCE) and computer-based testing (CBT), reflect the performance of medical
      students in CC. Here we retrospectively analyzed correlations between OSCE and
      CBT scores and CC performance. METHODS: Ethical approval was obtained from our
      institutional review board. We analyzed correlations between OSCE and CBT scores 
      and CC performance in 94 medical students who took the OSCE and CBT in 2017 when 
      they were 4th year students, and who participated in the basic CC in 2018 when
      they were 5th year students. RESULTS: Total scores for OSCE and CBT were
      significantly correlated with CC performance (P<0.001, each). More specifically, 
      medical interview and chest examination components of the OSCE were significantly
      correlated with CC performance (P = 0.001, each), while the remaining five
      components of the OSCE were not. CONCLUSION: Our findings suggest that the OSCE
      and CBT play important roles in predicting CC performance in Japanese medical
      education context. Among OSCE components, medical interview and chest examination
      were suggested to be important for predicting CC performance.
FAU - Komasawa, Nobuyasu
AU  - Komasawa N
AUID- ORCID: 0000-0002-0607-3310
AD  - Medical Education Center, Osaka Medical College, Takatsuki, Japan.
FAU - Terasaki, Fumio
AU  - Terasaki F
AD  - Medical Education Center, Osaka Medical College, Takatsuki, Japan.
FAU - Nakano, Takashi
AU  - Nakano T
AD  - Medical Education Center, Osaka Medical College, Takatsuki, Japan.
FAU - Kawata, Ryo
AU  - Kawata R
AD  - Medical Education Center, Osaka Medical College, Takatsuki, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200326
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Clinical Clerkship
MH  - Clinical Competence
MH  - Educational Measurement/*methods
MH  - Humans
MH  - Japan
MH  - *Students, Medical
PMC - PMC7098585
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/03/28 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/03/28 06:00
PHST- 2019/10/23 00:00 [received]
PHST- 2020/03/08 00:00 [accepted]
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.1371/journal.pone.0230792 [doi]
AID - PONE-D-19-29629 [pii]
PST - epublish
SO  - PLoS One. 2020 Mar 26;15(3):e0230792. doi: 10.1371/journal.pone.0230792.
      eCollection 2020.


PMID- 32214285
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 2038-8306 (Electronic)
IS  - 1121-760X (Linking)
VI  - 64
IP  - 2
DP  - 2020 Mar 26
TI  - Isolation of rat hepatocytes for pharmacological studies on metabotropic
      glutamate receptor (mGluR) subtype 5: a comparison between collagenase I versus
      collagenase IV.
LID - 10.4081/ejh.2020.3123 [doi]
AB  - Isolated hepatocytes can be obtained from the liver by collagenase infusion, a
      procedure that could affect cell isolation as well as the integrity of membrane
      receptors. In this respect we compared metabotropic glutamate subtype 5 receptor 
      (mGluR5) protein expression and activity in rat hepatocytes isolated by two
      collagenases, type I and type IV. Hepatocytes were isolated from male Wistar rats
      (200-250 g) using collagenase I or collagenase IV and after isolation, viability 
      and morphology of rat hepatocytes were assessed measuring mGluR5 protein
      expression by Western blot analyses. mGluR5 activation was evaluated by
      inositol-1-phosphate (IP-1) accumulation after treatment with the mGluR5
      orthosteric agonist ACPD or the selective antagonist MPEP. No difference in
      cellular viability and morphology was observed using collagenase I when compared 
      with collagenase IV. An increase in mGluR5 protein expression was observed in
      hepatocytes isolated using collagenase IV with respect to collagenase I.
      Moreover, hepatocytes treated with ACPD and with MPEP presented higher levels of 
      IP-1 when isolated using collagenase IV compared to collagenase I. These results 
      indicate that collagenase IV better preserves the activity of surface proteins
      such as mGluR5 in isolated rat hepatocytes, an in vitro model useful to reduce
      the use of experimental animals, in line with the 3R ethical framework.
FAU - Berardo, Clarissa
AU  - Berardo C
AD  - Department of Internal Medicine and Therapeutics, University of Pavia.
      clarissa.berardo01@universitadipavia.it.
FAU - Ferrigno, Andrea
AU  - Ferrigno A
FAU - Siciliano, Veronica
AU  - Siciliano V
FAU - Richelmi, Plinio
AU  - Richelmi P
FAU - Vairetti, Mariapia
AU  - Vairetti M
FAU - Di Pasqua, Laura Giuseppina
AU  - Di Pasqua LG
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - Italy
TA  - Eur J Histochem
JT  - European journal of histochemistry : EJH
JID - 9207930
RN  - 0 (Grm5 protein, rat)
RN  - 0 (Receptor, Metabotropic Glutamate 5)
RN  - EC 3.4.24.- (Collagenases)
RN  - EC 3.4.24.- (collagenase 1)
SB  - IM
MH  - Animals
MH  - Cell Separation/*methods
MH  - Collagenases/*metabolism
MH  - Hepatocytes/cytology/*metabolism
MH  - Liver/cytology
MH  - Male
MH  - Rats, Wistar
MH  - Receptor, Metabotropic Glutamate 5/*metabolism
PMC - PMC7118438
EDAT- 2020/03/28 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/02/27 00:00 [received]
PHST- 2020/03/17 00:00 [accepted]
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
AID - 10.4081/ejh.2020.3123 [doi]
PST - epublish
SO  - Eur J Histochem. 2020 Mar 26;64(2). doi: 10.4081/ejh.2020.3123.


PMID- 32214061
OWN - NLM
STAT- MEDLINE
DCOM- 20201218
LR  - 20201218
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 26
DP  - 2020 Mar 26
TI  - An Animal Study of Implantation of an Esophageal Pacemaker Based on Per-Oral
      Endoscopic Myotomy Approach for Alleviation of Esophageal Peristalsis Disorders.
PG  - e920637
LID - 10.12659/MSM.920637 [doi]
AB  - BACKGROUND To restore esophageal peristalsis of achalasia patients by sequenced
      electric stimulation, an appropriate method must be established to implant the
      electrodes and pacemaker safely and effectively. We combined POEM (per-oral
      endoscopic myotomy) and abdominal wall puncture in pigs in order to explore a
      feasible procedure for the implantation. MATERIAL AND METHODS Five healthy male
      pigs were used in the present study with the permission of the Ethics Committee
      of Tianjin Medical University General Hospital. The electrodes were implanted in 
      esophageal submucosal tunnel by POEM with the end of the electrode deposited in
      the abdominal cavity using NOTES technique. A pacemaker was then positioned under
      the skin of the abdomen. Finally, the electrodes were connected with the
      pacemaker with the help of endoscopy in the abdominal cavity. Esophageal
      peristalsis of these pigs after implantation was monitored for esophageal
      intraluminal pressure changes using electronic gastroscopy and a high-resolution 
      manometry (HRM). The observation lasted for 6 h. RESULTS The procedure was
      effective to implant the electrode and the pacemaker using POEM and NOTES
      techniques. The connection of the 2 devices was also successful. Esophageal
      intraluminal pressure changes after electrical stimulation were recorded using
      HRM. Vital signs of the pigs were stable during the 6-h follow-up. CONCLUSIONS
      From this small-sample, short follow-up animal study, it was found that the
      implantation of esophageal electrodes and pacemaker based on POEM and NOTES is
      feasible, safe, and effective. Nevertheless, there is urgent need for long-term
      follow-up to confirm or disprove the safety of the procedure.
FAU - Chen, Qiuyu
AU  - Chen Q
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General
      Hospital, Tianjin, China (mainland).
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General
      Hospital, Tianjin, China (mainland).
FAU - Zhang, Lili
AU  - Zhang L
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General
      Hospital, Tianjin, China (mainland).
FAU - Zheng, Zhongqing
AU  - Zheng Z
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General
      Hospital, Tianjin, China (mainland).
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General
      Hospital, Tianjin, China (mainland).
FAU - Wang, Bangmao
AU  - Wang B
AD  - Department of Gastroenterology and Hepatology, Tianjin Medical University General
      Hospital, Tianjin, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20200326
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
SB  - IM
MH  - Animals
MH  - Electrodes
MH  - *Endoscopy
MH  - Esophageal Diseases/*physiopathology/*surgery
MH  - Male
MH  - Mucous Membrane/surgery
MH  - *Myotomy
MH  - *Pacemaker, Artificial
MH  - *Peristalsis
MH  - Pressure
MH  - *Prosthesis Implantation
MH  - Swine
PMC - PMC7119446
EDAT- 2020/03/28 06:00
MHDA- 2020/12/19 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/12/19 06:00 [medline]
AID - 920637 [pii]
AID - 10.12659/MSM.920637 [doi]
PST - epublish
SO  - Med Sci Monit. 2020 Mar 26;26:e920637. doi: 10.12659/MSM.920637.


PMID- 32213700
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20201218
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - Italy in a Time of Emergency and Scarce Resources: The Need for Embedding Ethical
      Reflection in Social and Clinical Settings.
PG  - 92-94
LID - 2020311092 [pii]
AB  - The COVID-19 virus is severely testing the Italian healthcare system, as the
      requests for intensive treatment are greater than the real capacity of the system
      to receive patients. Given this emergency situation, it follows that citizens are
      limited in their freedom of movement in order to limit infection, and that in
      hospitals a significant number of critical situations must be faced. This brief
      contribution aims to offer a reflection on the public and clinical role of the
      bioethicist: a figure able to promote dialogue between the world of medicine and 
      the community, and to face ethical dilemmas even in emergent clinical settings.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Nicoli, Federico
AU  - Nicoli F
AD  - Member, Center for Clinical Ethics, Biotechnology, and Life Sciences Department, 
      Insubria University, Varese Italy; responsible Clinical Ethics Service, Domus
      Salutis Clinic, Teresa Camplani Foundation, Brescia, Italy.
      federiconicoli82@gmail.com.
FAU - Gasparetto, Alessandra
AU  - Gasparetto A
AD  - Member, Center for Clinical Ethics, Biotechnology, and Life Sciences Department, 
      Insubria University, Varese Italy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Betacoronavirus
MH  - COVID-19
MH  - *Coronavirus Infections/epidemiology/prevention & control/transmission
MH  - Critical Care
MH  - Decision Making/*ethics
MH  - *Delivery of Health Care/ethics
MH  - *Ethicists
MH  - Humans
MH  - Italy
MH  - *Morals
MH  - *Pandemics/prevention & control
MH  - *Pneumonia, Viral/epidemiology/prevention & control/transmission
MH  - *Professional Role
MH  - SARS-CoV-2
MH  - Surge Capacity
EDAT- 2020/03/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 2020311092 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Spring;31(1):92-94.


PMID- 32213698
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - When Push Comes to Shove-How Should Physicians Respond to Magical Thinking?
PG  - 86-88
LID - 2020311086 [pii]
AB  - Should doctors shove their patients to choose in ways that are aligned with the
      patients' desired goals, when the patients' choices go wrong because of magical
      beliefs? I argue that doctors should not shove their patients in this way, but
      push them towards better and more reflective decision making. We can do this by
      nudging techniques or by more direct advice giving. If patients still choose
      wrongly, it is their choice, and doctors have fulfilled their professional,
      ethical duties.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Holm, Soren
AU  - Holm S
AD  - Professor of Bioethics, University of Manchester, Manchester UK; Professor of
      Medical Ethics (part-time), University of Oslo, Oslo Norway.
      soren.holm@manchester.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Decision Making
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Personal Autonomy
MH  - *Physician-Patient Relations
MH  - *Physicians
MH  - *Thinking
EDAT- 2020/03/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 2020311086 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Spring;31(1):86-88.


PMID- 32213694
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - Roles of the Ethics Consultant: A Response to Vaughan and Colleagues and De
      Renzo.
PG  - 74-75
LID - 2020311074 [pii]
AB  - We respond to commentaries on our article, "The Clinician as Clinical Ethics
      Consultant: An Empirical Method of Study," that appeared in the summer 2019 issue
      of The Journal of Clinical Ethics.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Kornfeld, Donald S
AU  - Kornfeld DS
AD  - Professor Emeritus of Psychiatry, Columbia University College of Physicians and
      Surgeons, New York, New York USA. dsk3@cumc.columbia.edu.
FAU - Prager, Kenneth
AU  - Prager K
AD  - Professor of Medicine, Columbia University Vangelos College of Physicians and
      Surgeons; Attending Physician, New York Presbyterian Hospital (Columbia);
      Director of Clinical Ethics, New York Presbyterian Hospital (Columbia), New York,
      New York USA. kmp1@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Ethicists
MH  - *Ethics, Clinical
MH  - Humans
MH  - Research Design
EDAT- 2020/03/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 2020311074 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Spring;31(1):74-75.


PMID- 32213691
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20200707
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Fall
TI  - The Role of Self-Care in Clinical Ethics Consultation: Clinical Ethicists' Risk
      for Burnout, Potential Harms, and What Ethicists Can Do.
PG  - 48-59
LID - 2020311048 [pii]
AB  - Clinical ethics consultants are inevitably called to participate in and bear
      witness to emotionally challenging cases. With the move toward the
      professionalization of ethics consultants, the responsibility to respond to and
      address difficult ethical dilemmas is likely to fall to a small set of people or 
      a single clinical ethicist. Combined with time constraints, the urgent nature of 
      these cases, and the moral distress of clinicians and staff encountered during
      consultation, like other healthcare professionals such as physicians and nurses, 
      clinical ethics consultants could risk burnout. If it is true that clinical
      ethicists are at risk for burnout, an important strategy to avoid burnout is to
      develop sound self-care practices. This article reviews the goals and skills of
      ethics consultation and the role-specific reasons that clinical ethicists may be 
      at risk for burnout, and argues that clinical ethicists may need to engage in
      self-care practices. Strategies to address burnout are reviewed and opportunities
      for future research are identified.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Firn, Janice
AU  - Firn J
AD  - Clinical Assistant Professor, University of Michigan Medical School, Department
      of Learning Health Sciences, and Center for Bioethics and Social Sciences in
      Medicine, Ann Arbor, Michigan USA. jfirn@ med.umich. edu.
FAU - O'Neil, Thomas
AU  - O'Neil T
AD  - Assistant Professor of Family Medicine, Department of Family Medicine, University
      of Michigan Medical School; Medical Director of Arbor Hospice in Ann Arbor,
      Michigan USA. toneil@arbor hospice.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Burnout, Psychological
MH  - *Ethicists/psychology
MH  - *Ethics Consultation
MH  - *Ethics, Clinical
MH  - Ethics, Medical
MH  - Humans
MH  - Self Care
EDAT- 2020/03/28 06:00
MHDA- 2020/07/08 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
AID - 2020311048 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Fall;31(1):48-59.


PMID- 32213690
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - Physician Burnout and Ethics Committees.
PG  - 42-47
LID - 2020311042 [pii]
AB  - This article provides a brief background of key issues in physician burnout, a
      significant problem in the healthcare industry. The extent and severity of
      burnout are not well understood; and those seeking help are often stigmatized. A 
      number of different approaches to alleviating burnout have been suggested, but
      the problem lacks any single or simple solution. We posit that an ethics
      committee may be well positioned to help address this issue because of its unique
      position within an institution. An ethics committee serves the entire hospital
      staff regardless of department. As such it may be able to identify common
      elements in the development of burnout, and can serve as a conduit to
      administration in identifying these. An ethics committee can obtain information
      about the extent of burnout by conducting surveys to assess the extent and
      severity of burnout in aninstitution, and serve as a central resource to help
      address and alleviate it. Finally, an ethics committee may be able to act as an
      intermediary between practitioners and the administration, in advising the
      administration of the extent of the problem and offer suggestions for alleviating
      it.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Edwards, Kristin
AU  - Edwards K
AD  - Yale New Haven Health System-Bridgeport Hospital, Bridgeport, Connecticut USA.
FAU - Newman, Richard L
AU  - Newman RL
AD  - Bridgeport Hospital, Bridgeport, Connecticut; Fairfield University, Fairfield,
      Connecticut USA. r.newman@snet.net.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Burnout, Professional
MH  - Ethics Committees
MH  - *Ethics Committees, Clinical
MH  - Humans
MH  - *Physicians
EDAT- 2020/03/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 2020311042 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Spring;31(1):42-47.


PMID- 32213689
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - A Listening Tour: Pediatric Clinical Ethics Rounds.
PG  - 27-41
LID - 2020311027 [pii]
AB  - A two-year rounding program was initiated by the clinical ethics consult service 
      (CECS) to improve ethics program integration and utilization at our 323-bed
      tertiary care pediatric hospital. Two critical variables were identified for
      improvement. One: identification of cases in which an ethics consult would have
      benefited clinical care but was not requested. Two: earlier detection of cases
      for which the medical team and/or family eventually sought ethics consultation
      but that worsened during the delay. Improvement relied on eliciting dialogue with
      the CECS by the medical team and/or patients and families, when it had either not
      occurred before or had not occurred when it would have been most beneficial. The 
      indirect nature of the improvements sought posed a specific challenge: how does
      one elicit such action from others? How does a small program with less than one
      full-time equivalent position that is dedicated to clinical ethics, and little
      funding, effect such a process change across an organization with more than 600
      physicians, 2,000 nurses, 600 medical students, and thousands of other clinicians
      and staff? The following accounts such an effort and the accompanying two-year
      study undertaken to document the results. The data presented demonstrate
      improvement in both identified variables: increased overall utilization of the
      CECS and earlier detection of cases in which the CECS is typically engaged.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Teti, Stowe Locke
AU  - Teti SL
AD  - Core Faculty and Lecturer on Global Health and Social Medicine; Director of the
      Writing Support Program; Executive Editor of the Harvard Medical School Bioethics
      Journal; and Executive Editor of Pediatric Ethicscope at the Center for
      Bioethics, Harvard Medical School, Boston, Massachusetts USA.
      Stowe_Teti@hms.harvard.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - Child
MH  - *Ethics Consultation
MH  - *Ethics, Clinical
MH  - Humans
MH  - *Pediatrics/ethics
MH  - Physicians
EDAT- 2020/03/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 2020311027 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Spring;31(1):27-41.


PMID- 32213688
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1046-7890 (Print)
IS  - 1046-7890 (Linking)
VI  - 31
IP  - 1
DP  - 2020 Spring
TI  - On Transference in Clinical Ethics Consultation: Recognizing and Working through 
      the Past in Surrogate Decision Making.
PG  - 17-26
LID - 2020311017 [pii]
AB  - Clinical ethics consultants often confront the most difficult clinical
      encounters, typically in the setting of chronically critically ill patients and
      surrogate decision makers. These encounters require not only analytical skills
      but interpersonal skills as well. In this article, I focus on an interpersonal
      skill absent from the American Society for Bioethics and the Humanities Task
      Force's Core Competencies for Healthcare Ethics Consultation. I introduce the
      psychoanalytic concept of transference and argue that knowledge and use of
      transference phenomena are sometimes indispensable for ethics consultation with
      surrogate decision makers. For solicitation of moral views, disclosure of
      relevant beliefs and values, and identification of the central ethical
      question-essential to assessment and analysis-cannot at times begin without
      recognition and working through of transference.
CI  - Copyright 2020 The Journal of Clinical Ethics. All rights reserved.
FAU - Guerin, Robert M
AU  - Guerin RM
AD  - University Hospitals Cleveland Medical Center, Cleveland, Ohio USA.
      Robert.Guerin@UHhospitals.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Ethics
JT  - The Journal of clinical ethics
JID - 9114645
SB  - IM
MH  - *Bioethics
MH  - Decision Making
MH  - Ethicists
MH  - *Ethics Consultation
MH  - *Ethics, Clinical
MH  - Humans
MH  - United States
EDAT- 2020/03/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - 2020311017 [pii]
PST - ppublish
SO  - J Clin Ethics. 2020 Spring;31(1):17-26.


PMID- 32213652
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20220414
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 182
IP  - 6
DP  - 2020 Jun
TI  - Carotid body chemosensitivity: early biomarker of dysmetabolism in humans.
PG  - 549-557
LID - 10.1530/EJE-19-0976 [doi]
LID - EJE-19-0976 [pii]
AB  - OBJECTIVE: The carotid bodies (CBs) are peripheral chemoreceptor organs
      classically described as being O2 sensors, which are increasingly emerging as
      core players in metabolic control. Herein we evaluated CB activity in prediabetes
      patients and determined its correlation with dysmetabolism clinical features.
      DESIGN AND METHODS: Prediabetes patients were recruited at the Cardiology
      Service, Hospital Santa Marta, Centro Hospitalar Lisboa Central, EPE (CHLC-EPE). 
      The study was approved by CHLC-EPE and NOVA Medical School Ethics Committee.
      Thirty-three prediabetic and 14 age-matched, non-prediabetic, volunteers had
      their peripheral chemosensitivity evaluated by the Dejours test. Serum biomarkers
      of metabolic disease, insulin sensitivity (HOMA-IR), blood pressure, carotid
      intima-media thickness (cIMT) and glucose tolerance were assessed. RESULTS: CB
      chemosensitivity was significantly increased in prediabetic group (P < 0.01).
      Fasting blood, glucose intolerance, fasting insulin and HOMA-IR were
      significantly higher in prediabetes patients. Insulin resistance correlated both 
      with peripheral chemosensitivity, assessed by the Dejours test (P < 0.05) and
      with abdominal circumference (P < 0.01). HbA1c correlated with HOMA-IR (P < 0.05)
      and left cIMT (P < 0.05) in prediabetes patients. CONCLUSIONS: We conclude that
      CB is overactive in prediabetes subjects and that peripheral chemosensitivity
      correlates with fasting insulin and insulin resistance representing a novel
      non-invasive functional biomarker to forecast early metabolic disease.
FAU - Cunha-Guimaraes, Joao P
AU  - Cunha-Guimaraes JP
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
FAU - Guarino, Maria P
AU  - Guarino MP
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
AD  - ciTechCare, Escola Superior de Saude de Leiria, Instituto Politecnico de Leiria, 
      Leiria, Portugal.
FAU - Timoteo, Ana T
AU  - Timoteo AT
AD  - Servico de Cardiologia, Hospital Santa Marta, Centro Hospital Lisboa Central,
      EPE, Lisbon, Portugal.
FAU - Caires, Iolanda
AU  - Caires I
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
FAU - Sacramento, Joana F
AU  - Sacramento JF
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
FAU - Ribeiro, Maria J
AU  - Ribeiro MJ
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
FAU - Selas, Mafalda
AU  - Selas M
AD  - Servico de Cardiologia, Hospital Santa Marta, Centro Hospital Lisboa Central,
      EPE, Lisbon, Portugal.
FAU - Santiago, Joao C P
AU  - Santiago JCP
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
FAU - Mota-Carmo, Miguel
AU  - Mota-Carmo M
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
AD  - Servico de Cardiologia, Hospital Santa Marta, Centro Hospital Lisboa Central,
      EPE, Lisbon, Portugal.
FAU - Conde, Silvia V
AU  - Conde SV
AUID- ORCID: 0000-0002-5920-5700
AD  - CEDOC, NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de
      Lisboa, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
SB  - IM
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Blood Glucose
MH  - Carotid Body/*metabolism/physiopathology
MH  - Female
MH  - Humans
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Prediabetic State/*blood/*diagnosis
EDAT- 2020/03/28 06:00
MHDA- 2020/05/06 06:00
CRDT- 2020/03/28 06:00
PHST- 2019/12/01 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - 10.1530/EJE-19-0976 [doi]
AID - EJE-19-0976 [pii]
PST - ppublish
SO  - Eur J Endocrinol. 2020 Jun;182(6):549-557. doi: 10.1530/EJE-19-0976.


PMID- 32213537
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 2052-4439 (Electronic)
IS  - 2052-4439 (Linking)
VI  - 7
IP  - 1
DP  - 2020 Mar
TI  - Randomised placebo-controlled cross-over study examining the role of anamorelin
      in mesothelioma (The ANTHEM study): rationale and protocol.
LID - e000551 [pii]
LID - 10.1136/bmjresp-2019-000551 [doi]
AB  - INTRODUCTION: Cachexia is common in malignant mesothelioma (MM); half of patients
      have malnutrition and low skeletal muscle mass. Malnourished patients have worse 
      quality of life (QoL). Weight loss is strongly associated with poor survival.
      Anamorelin is an oral ghrelin receptor agonist that improves appetite, body
      weight and QoL in advanced cancer. The aim of this study is to examine the
      efficacy of anamorelin in improving appendicular skeletal muscle mass (ASM) and
      patient-reported outcomes in patients with MM with cachexia. METHODS AND
      ANALYSIS: A single-centre, phase II, randomised, placebo-controlled cross-over
      pilot study with 28-day treatment periods and 3-day washout. Forty patients will 
      be randomised. Primary outcome is change in ASM relative to height measured by
      dual energy X-ray absorptiometry at end of period 1. Secondary outcomes include
      cancer-specific and cachexia-related QoL, objective physical activity, dietary
      intake and adverse events. Eligible patients will have confirmed MM, Eastern
      Cooperative Oncology Group 0-2, expected survival >3 months and cachexia (defined
      as >5% weight loss in 6 months or body mass index <20 kg/m(2) with weight loss
      >2%). ETHICS AND DISSEMINATION: Ethical approval has been granted. Results will
      be reported in peer-reviewed publications. TRIAL REGISTRATION NUMBER: Australian 
      New Zealand Clinical Trials Registry (U1111-1240-6828).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hoon, Siao Nge
AU  - Hoon SN
AD  - Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia,
      Australia.
AD  - Curtin Medical School, Curtin University, Perth, Western Australia, Australia.
FAU - Fyfe, Katrina
AU  - Fyfe K
AD  - Curtin Medical School, Curtin University, Perth, Western Australia, Australia.
AD  - Institute of Respiratory Health, Nedlands, Western Australia, Australia.
FAU - Peddle-McIntyre, Carolyn J
AU  - Peddle-McIntyre CJ
AD  - Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia,
      Australia.
AD  - Institute of Respiratory Health, Nedlands, Western Australia, Australia.
AD  - Exercise Medicine Research Institute, Edith Cowan University-Joondalup Campus,
      Joondalup, Western Australia, Australia.
FAU - Bowyer, Samantha
AU  - Bowyer S
AD  - Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia,
      Australia.
FAU - Hawkins, Felicity
AU  - Hawkins F
AD  - Palliative Care, Sir Charles Gairdner Hospital, Nedlands, Western Australia,
      Australia.
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Jeffery, Emily
AU  - Jeffery E
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Chih, Hui Jun
AU  - Chih HJ
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Creaney, Jenette
AU  - Creaney J
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Nowak, Anna
AU  - Nowak A
AD  - Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia,
      Australia.
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Brims, Fraser
AU  - Brims F
AD  - Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia,
      Australia fraser.brims@curtin.edu.au.
AD  - Curtin Medical School, Curtin University, Perth, Western Australia, Australia.
AD  - Institute of Respiratory Health, Nedlands, Western Australia, Australia.
LA  - eng
PT  - Clinical Trial Protocol
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Respir Res
JT  - BMJ open respiratory research
JID - 101638061
RN  - 0 (Appetite Stimulants)
RN  - 0 (Hydrazines)
RN  - 0 (Oligopeptides)
RN  - DD5RBA1NKF (anamorelin)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Appetite Stimulants/adverse effects/*therapeutic use
MH  - Australia
MH  - Body Composition/drug effects
MH  - Cachexia/*complications/*drug therapy/etiology/physiopathology
MH  - Clinical Trials, Phase II as Topic
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Humans
MH  - Hydrazines/adverse effects/*therapeutic use
MH  - Linear Models
MH  - Mesothelioma, Malignant/*complications
MH  - Muscle Strength/drug effects
MH  - Oligopeptides/adverse effects/*therapeutic use
MH  - Pilot Projects
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Weight Gain/drug effects
PMC - PMC7173983
OTO - NOTNLM
OT  - *asbestos induced lung disease
OT  - *mesothelioma
OT  - *palliative care
OT  - *pleural disease
COIS- Competing interests: None declared.
EDAT- 2020/03/28 06:00
MHDA- 2021/06/11 06:00
CRDT- 2020/03/28 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/01/31 00:00 [revised]
PHST- 2020/02/09 00:00 [accepted]
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
AID - 7/1/e000551 [pii]
AID - 10.1136/bmjresp-2019-000551 [doi]
PST - ppublish
SO  - BMJ Open Respir Res. 2020 Mar;7(1). pii: 7/1/e000551. doi:
      10.1136/bmjresp-2019-000551.


PMID- 32213527
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20220129
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Investigation of an extensive outbreak of HIV infection among children in Sindh, 
      Pakistan: protocol for a matched case-control study.
PG  - e036723
LID - 10.1136/bmjopen-2019-036723 [doi]
AB  - INTRODUCTION: In April 2019, 14 children were diagnosed with HIV infection by a
      private healthcare provider in Larkana district, Sindh province, Pakistan. Over
      the next 3 months, 930 individuals were diagnosed with HIV, >80% below 16 years, 
      the largest ever outbreak of HIV in children in Pakistan. In this protocol paper,
      we describe research methods for assessing likely modes of HIV transmission in
      this outbreak and investigate spatial and molecular epidemiology. METHODS AND
      ANALYSIS: A matched case-control study will be conducted with 406 cases
      recruited. Cases will be children aged below 16 years registered for care at the 
      HIV treatment centre at Shaikh Zayed Children Hospital in Larkana City. Controls 
      will be children who are HIV-uninfected (confirmed by a rapid HIV test) matched
      1:1 by age (within 1 year), sex and neighbourhood. Following written informed
      consent from the guardian, a structured questionnaire will be administered to
      collect data on sociodemographic indices and exposure to risk factors for
      parenteral, vertical and sexual (only among those aged above 10 years) HIV
      transmission. A blood sample will be collected for hepatitis B and C serology
      (cases and controls) and HIV lineage studies (cases only). Mothers of
      participants will be tested for HIV to investigate the possibility of
      mother-to-child transmission. Conditional logistic regression will be used to
      investigate the association of a priori defined risk factors with HIV infection. 
      Phylogenetic analyses will be conducted. Global positioning system coordinates of
      participants' addresses will be collected to investigate concordance between the 
      genetic and spatial epidemiology. ETHICS AND DISSEMINATION: Ethical approval was 
      granted by the Ethics Review Committee of the Aga Khan University, Karachi. Study
      results will be shared with Sindh and National AIDS Control Programs, relevant
      governmental and non-governmental organisations, presented at national and
      international research conferences and published in international peer-reviewed
      scientific journals.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Siddiqui, Amna R
AU  - Siddiqui AR
AD  - Department of Community Health Sciences, Aga Khan University, Karachi, Sindh,
      Pakistan.
FAU - Ali Nathwani, Apsara
AU  - Ali Nathwani A
AUID- ORCID: 0000-0002-2899-1577
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Abidi, Syed H
AU  - Abidi SH
AD  - Department of Biological and Biomedical Sciences, Aga Khan University, Karachi,
      Sindh, Pakistan.
FAU - Mahmood, Syed Faisal
AU  - Mahmood SF
AD  - Section of Infectious Disease, Department of Internal Medicine, the Aga Khan
      University, Karachi, Sindh, Pakistan.
FAU - Azam, Iqbal
AU  - Azam I
AD  - Department of Community Health Sciences, Aga Khan University, Karachi, Sindh,
      Pakistan.
FAU - Sawani, Sobiya
AU  - Sawani S
AD  - Department of Community Health Sciences, Aga Khan University, Karachi, Sindh,
      Pakistan.
FAU - Kazi, Abdul M
AU  - Kazi AM
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
FAU - Hotwani, Aneeta
AU  - Hotwani A
AD  - Infectious Disease Research Laboratory, Department of Pediatrics and Child
      Health, the Aga Khan University, Karachi, Sindh, Pakistan.
FAU - Memon, Sikander Ali
AU  - Memon SA
AD  - Sindh AIDS Control Program, Ministry of Health, Karachi, Sindh, Pakistan.
FAU - Soomro, Jamila
AU  - Soomro J
AD  - Public Health Wing, Ministry of Health, Karachi, Sindh, Pakistan.
FAU - Shaikh, Saqib Ali
AU  - Shaikh SA
AD  - Sindh AIDS Control Program, Ministry of Health, Karachi, Sindh, Pakistan.
FAU - Achakzai, Baseer
AU  - Achakzai B
AD  - National AIDS Control Program, Islamabad, Pakistan.
FAU - Saeed, Quaid
AU  - Saeed Q
AUID- ORCID: 0000-0001-6736-4253
AD  - National AIDS Control Program, Islamabad, Pakistan.
FAU - Simms, Victoria
AU  - Simms V
AD  - Department of Infectious Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, United Kingdom.
FAU - Khan, Palwasha
AU  - Khan P
AD  - Department of Clinical Research, London School of Hygiene and Tropical Medicine, 
      London, UK.
FAU - Ferrand, Rashida
AU  - Ferrand R
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi,
      Pakistan.
AD  - Department of Clinical Research, London School of Hygiene and Tropical Medicine, 
      London, UK.
FAU - Mir, Fatima
AU  - Mir F
AUID- ORCID: 0000-0001-8602-5353
AD  - Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
      fatima.mir@aku.edu.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - MR/R010161/1/MRC_/Medical Research Council/United Kingdom
GR  - 206316/Z/17/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Disease Outbreaks
MH  - *Epidemiologic Methods
MH  - Female
MH  - HIV Infections/*epidemiology/*transmission
MH  - Hepatitis B/epidemiology
MH  - Hepatitis C/epidemiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/statistics & numerical data
MH  - Male
MH  - Pakistan/epidemiology
MH  - Residence Characteristics
MH  - Sexual Behavior/statistics & numerical data
MH  - Socioeconomic Factors
MH  - Spatial Analysis
PMC - PMC7170612
OTO - NOTNLM
OT  - *HIV
OT  - *Pakistan
OT  - *case-control study
OT  - *children
OT  - *outbreak
COIS- Competing interests: None declared.
EDAT- 2020/03/28 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-036723 [pii]
AID - 10.1136/bmjopen-2019-036723 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e036723. doi: 10.1136/bmjopen-2019-036723.


PMID- 32213525
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Mixed-methods approach to understanding clinician macrocognition in the design of
      a clinical decision support tool: a study protocol.
PG  - e035313
LID - 10.1136/bmjopen-2019-035313 [doi]
AB  - INTRODUCTION: The anatomic variants of congenital heart disease (CHD) are
      multiple. The increased survival of these patients and disposition into
      communities has led to an increase in their acute presentation to non-CHD experts
      in primary care clinics and emergency departments. Given the vulnerability and
      fragility of these patients in the face of acute illness, new clinical decision
      support systems (CDSS) are urgently needed to better translate the best practice 
      recommendations for the care of these patients. This study aims to understand the
      perceived confidence and macrocognitive processes of non-CHD experts (emergency
      medicine physicians) and CHD experts (paediatric cardiac intensivists) when
      treating children with CHD during acute illness and apply this to optimise the
      design of a CDSS (MyHeartPass()) for these patients. METHODS AND ANALYSIS: The
      first phase of the study involves a survey of non-CHD experts and CHD experts to 
      understand their perceived confidence as it relates to treating acutely ill
      patients with CHD. The second phase is a qualitative cognitive task analysis
      using critical decision method to characterise and compare the macrocognitive
      processes used by non-CHD experts and CHD experts during the critical decision
      making. In phases 3 and 4, heuristic evaluation and usability testing of the CDSS
      will be completed. These results will be used to inform design changes to the
      chosen CDSS (MyHeartPass()). In the final phase, a within-participant simulation 
      design will be used to study the effect of the CDSS on clinical decision making
      compared with baseline (without use of CDSS). ETHICS AND DISSEMINATION: Ethics
      approval from The Hospital for Sick Children in Toronto, Ontario, Canada has been
      obtained for all phases. Results will be published in peer-reviewed journals and 
      presented at relevant conferences. On successful completion of these studies, it 
      is anticipated that there will be a controlled implementation of the redesigned
      CDSS.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Assadi, Azadeh
AU  - Assadi A
AUID- ORCID: 0000-0001-8156-6396
AD  - Department of Critical Care Medicine, Hospital for Sick Children, Toronto,
      Ontario, Canada az.assadi@mail.utoronto.ca.
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto
      Faculty of Applied Science and Engineering, Toronto, Ontario, Canada.
FAU - Laussen, Peter
AU  - Laussen P
AD  - Department of Critical Care Medicine, Hospital for Sick Children, Toronto,
      Ontario, Canada.
AD  - Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
FAU - Trbovich, Patricia
AU  - Trbovich P
AD  - Human Era, Department of Research and Innovation, North York General Hospital,
      Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management, and Evaluation, University of Toronto,
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Cardiologists/*psychology
MH  - Clinical Competence
MH  - Clinical Decision-Making/*methods
MH  - Cognition
MH  - Decision Support Systems, Clinical/*organization & administration
MH  - *Emergency Medicine
MH  - Heart Defects, Congenital/*therapy
MH  - Hospitals, Pediatric
MH  - Humans
MH  - Research Design
MH  - Self Concept
MH  - Severity of Illness Index
MH  - User-Computer Interface
PMC - PMC7170622
OTO - NOTNLM
OT  - *accident & emergency medicine
OT  - *congenital heart disease
OT  - *health informatics
OT  - *paediatrics
COIS- Competing interests: AA and PL are codesigners of the prototype MyHeartPass(TM)
      decision support tool. All work has been funded through the endowed David and
      Stacey Cynamon Chair in Pediatric Critical Care, The Hospital for Sick Children, 
      Toronto, Ontario, Canada. The CDSS is not available commercially, and there has
      been no extramural or private funding. None of the authors have received
      compensation for work undertaken.
EDAT- 2020/03/28 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035313 [pii]
AID - 10.1136/bmjopen-2019-035313 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e035313. doi: 10.1136/bmjopen-2019-035313.


PMID- 32213524
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Management of haemorrhoids: protocol of an umbrella review of systematic reviews 
      and meta-analyses.
PG  - e035287
LID - 10.1136/bmjopen-2019-035287 [doi]
AB  - INTRODUCTION: The prevalence of haemorrhoidal diseases was high in general
      population, and many treatments are proposed for the management of haemorrhoids. 
      The treatments include conservative and surgical interventions; the credibility
      and strength of current evidence of their effectiveness are not comprehensively
      evaluated. We aim to evaluate the credibility of systematic reviews and
      meta-analyses that assess the effectiveness of the treatments for haemorrhoidal
      diseases through an umbrella review. METHODS AND ANALYSIS: We will search Ovid
      Medline, Embase, Cochrane library and Web of Science from inception to March 2020
      without any language restriction. We will include meta-analyses that examine the 
      effectiveness of treatments in the management of haemorrhoids. Two reviewers will
      independently screen the titles and abstracts of retrieved articles, and they
      will extract data from the included meta-analyses. For each meta-analysis, we
      will estimate the effect size of a treatment through the random-effect model and 
      the fixed-effect model, and we will evaluate between-study heterogeneity
      (Cochrane's Q and I(2) statistics) and small-study effect (Egger's test); we will
      also estimate the evidence of excess significance bias. Evidence of each
      treatment will be graded according to prespecified criteria. Methodological
      quality of each meta-analysis will be evaluated by using Assessment of Multiple
      Systematic Reviews 2. The corrected cover area method will be used to assess the 
      impact of overlap in reviews on the findings of the umbrella review. ETHICS AND
      DISSEMINATION: We will present the results of the umbrella review at conferences 
      and publish the final report in a peer-reviewed journal. The umbrella review does
      not require ethical approval. PROSPERO REGISTRATION NUMBER: CRD42019140702.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Chen, Min
AU  - Chen M
AD  - Colorectal disease department, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - Tang, Tai-Chun
AU  - Tang TC
AD  - Colorectal disease department, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - He, Tao-Hong
AU  - He TH
AD  - Colorectal disease department, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - Du, Yong-Jun
AU  - Du YJ
AD  - Colorectal disease department, Hospital of Chengdu University of Traditional
      Chinese Medicine, Chengdu, China.
FAU - Qin, Di
AU  - Qin D
AD  - The Third Hospital/Acupuncture and Tuina School, Chengdu University of
      Traditional Chinese Medicine, Chengdu, China.
FAU - Zheng, Hui
AU  - Zheng H
AUID- ORCID: 0000-0002-0494-1217
AD  - The Third Hospital/Acupuncture and Tuina School, Chengdu University of
      Traditional Chinese Medicine, Chengdu, China zhenghui@cdutcm.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Hemorrhoids/surgery/*therapy
MH  - Life Style
MH  - Meta-Analysis as Topic
MH  - Pain Measurement
MH  - Patient Satisfaction
MH  - Research Design
MH  - Severity of Illness Index
MH  - Systematic Reviews as Topic
PMC - PMC7170589
OTO - NOTNLM
OT  - *gastroenterology
OT  - *general medicine (see internal medicine)
OT  - *primary care
OT  - *surgery
COIS- Competing interests: None declared.
EDAT- 2020/03/28 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-035287 [pii]
AID - 10.1136/bmjopen-2019-035287 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e035287. doi: 10.1136/bmjopen-2019-035287.


PMID- 32213522
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Built environment changes and active transport to school among adolescents: BEATS
      Natural Experiment Study protocol.
PG  - e034899
LID - 10.1136/bmjopen-2019-034899 [doi]
AB  - INTRODUCTION: Natural experiments are considered a priority for examining causal 
      associations between the built environment (BE) and physical activity (PA)
      because the randomised controlled trial design is rarely feasible. Few natural
      experiments have examined the effects of walking and cycling infrastructure on PA
      and active transport in adults, and none have examined the effects of such
      changes on PA and active transport to school among adolescents. We conducted the 
      Built Environment and Active Transport to School (BEATS) Study in Dunedin city,
      New Zealand, in 2014-2017. Since 2014, on-road and off-road cycling
      infrastructure construction has occurred in some Dunedin neighbourhoods,
      including the neighbourhoods of 6 out of 12 secondary schools. Pedestrian-related
      infrastructure changes began in 2018. As an extension of the BEATS Study, the
      BEATS Natural Experiment (BEATS-NE) (2019-2022) will examine the effects of BE
      changes on adolescents' active transport to school in Dunedin, New Zealand.
      METHODS AND ANALYSIS: The BEATS-NE Study will employ contemporary ecological
      models for active transport that account for individual, social, environmental
      and policy factors. The published BEATS Study methodology (surveys,
      accelerometers, mapping, Geographic Information Science analysis and focus
      groups) and novel methods (environmental scan of school neighbourhoods and
      participatory mapping) will be used. A core component continues to be the
      community-based participatory approach with the sustained involvement of key
      stakeholders to generate locally relevant data, and facilitate knowledge
      translation into evidence-based policy and planning. ETHICS AND DISSEMINATION:
      The BEATS-NE Study has been approved by the University of Otago Ethics Committee 
      (reference: 17/188). The results will be disseminated through scientific
      publications and symposia, and reports and presentations to stakeholders. TRIAL
      REGISTRATION NUMBER: ACTRN12619001335189.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Mandic, Sandra
AU  - Mandic S
AUID- ORCID: 0000-0003-4126-8874
AD  - Active Living Laboratory, School of Physical Education, Sport and Exercise
      Sciences, University of Otago, Dunedin, New Zealand sandra.mandic@otago.ac.nz.
AD  - Centre for Sustainability, University of Otago, Dunedin, New Zealand.
FAU - Hopkins, Debbie
AU  - Hopkins D
AD  - Transport Study Unit, School of Geography and the Environment, University of
      Oxford, Oxford, Oxfordshire, UK.
FAU - Garcia Bengoechea, Enrique
AU  - Garcia Bengoechea E
AD  - Health Research Institute, Department of Physical Education and Sport Sciences,
      Faculty of Education and Health Sciences, University of Limerick, Limerick,
      Ireland.
FAU - Moore, Antoni
AU  - Moore A
AD  - School of Surveying, University of Otago, Dunedin, New Zealand.
FAU - Sandretto, Susan
AU  - Sandretto S
AD  - College of Education, University of Otago, Dunedin, New Zealand.
FAU - Coppell, Kirsten
AU  - Coppell K
AUID- ORCID: 0000-0003-0996-2874
AD  - Department of Medicine, University of Otago, Dunedin, New Zealand.
FAU - Ergler, Christina
AU  - Ergler C
AD  - School of Geography, University of Otago, Dunedin, New Zealand.
FAU - Keall, Michael
AU  - Keall M
AD  - Department of Public Health, University of Otago, Wellington, New Zealand.
FAU - Rolleston, Anna
AU  - Rolleston A
AD  - Faculty of Health, Sport and Human Performance, University of Waikato, Hamilton, 
      Waikato, New Zealand.
FAU - Kidd, Gavin
AU  - Kidd G
AD  - Dunedin Secondary Schools' Partnership, Dunedin, New Zealand.
FAU - Wilson, Gordon
AU  - Wilson G
AD  - Dunedin Secondary Schools' Partnership, Dunedin, New Zealand.
FAU - Spence, John C
AU  - Spence JC
AD  - Faculty of Kinesiology, Sport and Recreation, University of Alberta, Alberta,
      Edmonton, Canada.
LA  - eng
SI  - ANZCTR/ACTRN12619001335189
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Bicycling/physiology
MH  - Body Weights and Measures
MH  - Built Environment/*statistics & numerical data
MH  - Exercise/*physiology
MH  - Female
MH  - Geographic Information Systems
MH  - Health Behavior
MH  - Humans
MH  - Interinstitutional Relations
MH  - Male
MH  - New Zealand
MH  - *Research Design
MH  - Residence Characteristics
MH  - Safety
MH  - Schools/statistics & numerical data
MH  - Social Support
MH  - Socioeconomic Factors
MH  - Transportation/*methods
MH  - Walking/physiology
PMC - PMC7170613
OTO - NOTNLM
OT  - *active transport
OT  - *adolescents
OT  - *built environment
OT  - *natural experiment
OT  - *physical activity
COIS- Competing interests: None declared.
EDAT- 2020/03/28 06:00
MHDA- 2021/02/17 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
AID - bmjopen-2019-034899 [pii]
AID - 10.1136/bmjopen-2019-034899 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e034899. doi: 10.1136/bmjopen-2019-034899.


PMID- 32213517
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Cognitive-behavioural group therapy for adolescents with ADHD: study protocol for
      a randomised controlled trial.
PG  - e032839
LID - 10.1136/bmjopen-2019-032839 [doi]
AB  - INTRODUCTION: Persistence of attention deficit hyperactivity disorder (ADHD) into
      adolescence is a significant burden to patients. Clinical guidelines recommend
      non-pharmacological therapies, but the evidence to support this recommendation is
      sparse. This study aims to evaluate the effect of a 12-week group
      cognitive-behavioural therapy (CBT) programme for adolescents with ADHD aged
      14-18 years, who still have impairing symptoms after treatment with medication.
      We will study the effect of the treatment on ADHD symptoms and examine moderators
      and mediators of the effect of the treatment on ADHD. METHODS AND ANALYSIS: We
      conduct a randomised controlled trial of CBT group therapy in adolescents with
      ADHD recruited from child psychiatric outpatient units in Mid-Norway. 99
      adolescents who met inclusion criteria and consented to participation have been
      randomised to a 12-week group intervention or to a control group receiving
      treatment as usual. Assessments are made at admission to the clinic,
      preintervention, postintervention and at a 9-month follow-up, obtaining
      adolescent, parent and teacher reports. Clinicians blinded to group allocation
      rate all participants as to their functioning preintervention and at the two
      postintervention assessment points. The primary outcome is change in symptom
      scores on the ADHD Rating Scale-IV. ETHICS AND DISSEMINATION: The Regional
      Committee for Medical and Health Research Ethics in South East Norway approved
      the study protocol (2015/2115). We will disseminate the findings in peer-reviewed
      publications and conference presentations, to user organisations and at courses
      attended by families and professionals. Two PhD students will publish and defend 
      dissertations relating to the study. Planned publications include primary and
      secondary outcomes and patient satisfaction with the treatment. Furthermore, we
      plan to publish a manual of CBT group therapy in adolescent ADHD to benefit
      treatment of patients in Norway and elsewhere. TRIAL REGISTRATION NUMBER:
      NCT02937142.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Novik, Torunn Stene
AU  - Novik TS
AUID- ORCID: 0000-0003-1179-5649
AD  - Department of Child and Adolescent Psychiatry, St Olav University Hospital,
      Trondheim, Norway torunn.stene.novik@stolav.no.
AD  - Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian
      University of Science and Technology, Trondheim, Norway.
FAU - Haugan, Anne-Lise Juul
AU  - Haugan AJ
AD  - Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian
      University of Science and Technology, Trondheim, Norway.
FAU - Lydersen, Stian
AU  - Lydersen S
AD  - Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian
      University of Science and Technology, Trondheim, Norway.
FAU - Thomsen, Per Hove
AU  - Thomsen PH
AD  - Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian
      University of Science and Technology, Trondheim, Norway.
AD  - Department of Child and Adolescent Psychiatry, Aarhus University Hospital,
      Aarhus, Denmark.
FAU - Young, Susan
AU  - Young S
AD  - Psychology Services Limited, London, UK.
AD  - Department of Psychology, University of Reykjavik, Reykjavik, Iceland.
FAU - Sund, Anne Mari
AU  - Sund AM
AD  - Department of Child and Adolescent Psychiatry, St Olav University Hospital,
      Trondheim, Norway.
AD  - Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian
      University of Science and Technology, Trondheim, Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT02937142
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - Adolescent
MH  - Attention Deficit Disorder with Hyperactivity/*therapy
MH  - *Cognitive Behavioral Therapy
MH  - Humans
MH  - *Psychotherapy, Group
MH  - *Randomized Controlled Trials as Topic
PMC - PMC7170565
OTO - NOTNLM
OT  - *ADHD
OT  - *child & adolescent psychiatry
OT  - *clinical trials
OT  - *cognitive behavioural therapy
COIS- Competing interests: TSN has received a speaker's fee from Medice in the last
      year. PHT has received speaker's fees from MEDICE and Shire in the last 3 years. 
      SY has received honoraria for consultation and/or educational talks in the last 5
      years from Janssen, HB Pharma and/or Shire. She is author of the 'ADHD Child
      Evaluation (ACE) and ACE+ (for adults)' and lead author of 'R&R2 for ADHD Youths 
      and Adults'. AMS has received travel support and congress fee from MEDICE in the 
      last year.
EDAT- 2020/03/28 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
AID - bmjopen-2019-032839 [pii]
AID - 10.1136/bmjopen-2019-032839 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e032839. doi: 10.1136/bmjopen-2019-032839.


PMID- 32213516
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20210413
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 3
DP  - 2020 Mar 25
TI  - Effect of peer support on patient anxiety during the coronary angiography or
      percutaneous coronary intervention perioperative period: a protocol for a
      systematic review and meta-analysis of randomised controlled trials.
PG  - e031952
LID - 10.1136/bmjopen-2019-031952 [doi]
AB  - INTRODUCTION: The purpose of this study is to investigate the effect of peer
      support on patient anxiety during the perioperative period of coronary
      angiography or percutaneous coronary intervention (PCI). METHODS AND ANALYSIS: We
      will search the following databases (PubMed, Web of Science, EMBASE, Cochrane
      Library, CINAHL, Clinicaltrials.gov, WHO International Clinical Trials Registry
      Platform, Google Scholar, Chinese National Knowledge Infrastructure, Chinese
      Science and Technology Periodicals Database, Chinese BioMedical Database and
      Wanfang Data) from the date of database inception to January 2019. Only
      randomised controlled trials will be included. For the data analysis, we will use
      RevMan V.5.3.5 software to evaluate the risk of bias, and the heterogeneity will 
      be investigated using the Q statistic and P index. Additionally, the Grading of
      Recommendations Assessment, Development and Evaluation system will be used to
      assess the quality of evidence. ETHICS AND DISSEMINATION: No ethics approval will
      be required since this is a systematic review of published studies. We aim to
      report information regarding the effects of peer support on patient anxiety
      during the perioperative period of coronary angiography or PCI. This systematic
      review and meta-analysis will be submitted to a peer-reviewed journal for
      publication. PROSPERO REGISTRATION NUMBER: CRD42019123290.
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Qin, Shuo
AU  - Qin S
AUID- ORCID: 0000-0002-2505-4211
AD  - College of Nursing, Hebei University of Chinese Medicine, Shijiazhuang, Hebei,
      China.
FAU - Gu, Yanmei
AU  - Gu Y
AD  - College of Nursing, Hebei University of Chinese Medicine, Shijiazhuang, Hebei,
      China yanmei.gu@mail.utoronto.ca.
FAU - Song, Tianyu
AU  - Song T
AD  - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide,
      South Australia, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200325
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
SB  - IM
MH  - *Anxiety
MH  - Coronary Angiography/*psychology
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Peer Group
MH  - Percutaneous Coronary Intervention/*psychology
MH  - Perioperative Period
MH  - *Social Support
MH  - Systematic Reviews as Topic
PMC - PMC7170568
OTO - NOTNLM
OT  - *anxiety
OT  - *cardiac surgery
OT  - *coronary heart disease
OT  - *peer support
OT  - *protocol
COIS- Competing interests: None declared.
EDAT- 2020/03/28 06:00
MHDA- 2021/04/14 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
AID - bmjopen-2019-031952 [pii]
AID - 10.1136/bmjopen-2019-031952 [doi]
PST - epublish
SO  - BMJ Open. 2020 Mar 25;10(3):e031952. doi: 10.1136/bmjopen-2019-031952.


PMID- 32213329
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20210110
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Scientific and ethical basis for social-distancing interventions against
      COVID-19.
PG  - 631-633
LID - S1473-3099(20)30190-0 [pii]
LID - 10.1016/S1473-3099(20)30190-0 [doi]
FAU - Lewnard, Joseph A
AU  - Lewnard JA
AD  - Division of Epidemiology, School of Public Health and Center for Computational
      Biology, College of Engineering, University of California, Berkeley, CA 94720,
      USA. Electronic address: jlewnard@berkeley.edu.
FAU - Lo, Nathan C
AU  - Lo NC
AD  - Department of Medicine, University of California, San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20200323
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
SB  - IM
CON - Lancet Infect Dis. 2020 Jun;20(6):678-688. PMID: 32213332
CIN - J Rehabil Med. 2020 Sep 8;52(9):jrm00099. PMID: 32896864
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections
MH  - Pandemics
MH  - Pneumonia, Viral
MH  - *SARS Virus
MH  - SARS-CoV-2
MH  - Singapore
PMC - PMC7118670
EDAT- 2020/03/28 06:00
MHDA- 2020/06/04 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/03/09 00:00 [accepted]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - S1473-3099(20)30190-0 [pii]
AID - 10.1016/S1473-3099(20)30190-0 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2020 Jun;20(6):631-633. doi: 10.1016/S1473-3099(20)30190-0.
      Epub 2020 Mar 23.


PMID- 32213279
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 2076-9172 (Print)
IS  - 2076-9172 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Oct 14
TI  - The Maimonides Model for a Regimen of Health: A Comparison with the Contemporary 
      Scenario.
LID - 10.5041/RMMJ.10396 [doi]
AB  - Rabbi Moses Ben Maimon, known as Maimonides, or The "Rambam" (a Hebrew acronym
      for his name), was one of the greatest arbiters of all times on matters of Jewish
      law, one of the greatest philosophers of the Middle Ages, a scientist, and a
      researcher. In addition, he was a court physician to the Egyptian Sultan. In
      addition to his monumental work on Jewish law and ethics, his writings on
      medicine have been considered classics over the generations. The aim of this
      paper is to assess Maimonides' health regimen and to compare his dietary
      recommendations with contemporary dietary regimens. To this end, Maimonides'
      recommendations were compared to the modern guidelines of the United States, the 
      Netherlands, and the World Health Organization (WHO), as well as to the
      Mediterranean diet, which is popular worldwide. Both marked similarities and
      contrasts were noted between Maimonides' and modern recommendations. Most of
      Maimonides' medical recommendations remain relevant more than 800 years later.
FAU - Segal, Isidor
AU  - Segal I
AD  - Emeritus Professor, Consulting Physician, Retired: "GIT Unit" Prince of Wales
      Hospital, Sydney, Australia.
FAU - Blazer, Shraga
AU  - Blazer S
AD  - Editor-in-Chief, Rambam Maimonides Medical Journal, Rambam Health Care Campus,
      Haifa, Israel.
LA  - eng
PT  - Journal Article
DEP - 20201014
PL  - Israel
TA  - Rambam Maimonides Med J
JT  - Rambam Maimonides medical journal
JID - 101538065
PMC - PMC7571434
EDAT- 2020/03/28 06:00
MHDA- 2020/03/28 06:01
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2020/03/28 06:01 [medline]
PHST- 2020/03/28 06:00 [entrez]
AID - RMMJ.10396 [pii]
AID - 10.5041/RMMJ.10396 [doi]
PST - epublish
SO  - Rambam Maimonides Med J. 2020 Oct 14;11(4). pii: RMMJ.10396. doi:
      10.5041/RMMJ.10396.


PMID- 32213235
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 75
IP  - 2
DP  - 2020 Mar 20
TI  - Community pharmacist's' knowledge and practice toward oral isotretinoin
      prescription: a systemic review.
PG  - 56-60
LID - 10.1691/ph.2020.9891 [doi]
AB  - Background: Although oral isotretinoin capsules are widely dispensed in
      pharmacies due to their effectiveness in clearing acne, the legal, ethical and
      practice responsibilities of community pharmacist regarding this medicine have
      not been well evaluated. This systematic review of community pharmacist's role
      and professional practice toward oral isotretinoin is significant to help
      pharmacy regulators and educator's making decisions to improve therapy outcomes. 
      Review methods: Eligible studies covering the period between 2009 and 2019 were
      identified by searching: Cochrane, PubMed and Google Scholar databases. Results: 
      A total of 56 studies were reviewed. It showed that pharmacy professionals
      exhibited a very low level of medication knowledge and an unsatisfactory level of
      practice regarding isotretinoin. Most studies showed that women of childbearing
      age were unnecessarily exposed to isotretinoin. These results indicate poor
      compliance of community pharmacists with risk minimization programs such as
      pregnancy prevention program (PPP) in Europe and iPLEDGE in USA. Conclusion:
      Community pharmacists need additional education, training and awareness in the
      area of oral isotretinoin to evaluate its use and patient's eligibility
      especially for female patients of childbearing age. This review results are
      critical to pharmacy educators worldwide who are concerned in implementing and
      developing professional practice standards for community pharmacists regarding
      oral isotretinoin.
FAU - Rashid, Z A
AU  - Rashid ZA
AD  - College of Pharmacy and Health Sciences. Ajman University, Ajman Al Jurf Area,
      United Arab Emirates.
FAU - Al-Tabakha, M M
AU  - Al-Tabakha MM
AD  - College of Pharmacy and Health Sciences. Ajman University, Ajman Al Jurf Area,
      United Arab Emirates;, Email: m.altabakha@ajman.ac.ae.
FAU - Alomar, M J
AU  - Alomar MJ
AD  - College of Pharmacy and Health Sciences. Ajman University, Ajman Al Jurf Area,
      United Arab Emirates.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - EH28UP18IF (Isotretinoin)
SB  - IM
MH  - Adult
MH  - Community Pharmacy Services
MH  - Education, Pharmacy, Continuing
MH  - Female
MH  - Humans
MH  - Isotretinoin/*therapeutic use
MH  - Middle Aged
MH  - Pharmacies
MH  - Pharmacists/*standards
MH  - Pregnancy
MH  - Professional Role
MH  - Surveys and Questionnaires
EDAT- 2020/03/28 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
AID - 10.1691/ph.2020.9891 [doi]
PST - ppublish
SO  - Pharmazie. 2020 Mar 20;75(2):56-60. doi: 10.1691/ph.2020.9891.


PMID- 32213113
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210721
IS  - 1522-1601 (Electronic)
IS  - 0161-7567 (Linking)
VI  - 128
IP  - 5
DP  - 2020 May 1
TI  - Performance evaluation of a portable bioimpedance cardiac output monitor for
      measuring hemodynamic changes in athletes during a head-up tilt test.
PG  - 1146-1152
LID - 10.1152/japplphysiol.00822.2019 [doi]
AB  - Cardiac output (CO) monitoring is useful for sports performance training, but
      most methods are unsuitable as they are invasive or hinder performance. The
      performance of PhysioFlow (PF), a portable noninvasive transthoracic bioimpedance
      CO monitor, was evaluated and compared with a reference Doppler CO monitor,
      USCOM, using a head-up tilt (HUT) test. With ethics committee approval, 20
      healthy well-trained athletes were subjected to HUT in a fixed order of 0 degrees
      , 70 degrees , 30 degrees , and 0 degrees for 3 min each. Simultaneous
      hemodynamic measurements using PF and USCOM were made 30 s after a change in HUT 
      and analyzed using t tests, ANOVA, and mountain plots. Heart rate (HR) and stroke
      volume (SV) from both monitors changed according to physiological expectation of 
      tilt, but PF measurements of SV were higher with a positive bias (PF vs. USCOM, 0
      degrees : 87.3 vs. 54.0 mL, P < 0.001; 70 degrees : 76.5 vs. 39.5 mL, P < 0.001; 
      30 degrees : 81.4 vs. 50.1 mL, P < 0.001; 0 degrees : 88.3 vs. 57.1 mL, P <
      0.001). Relative changes in SV (SV) after each tilt measured using PF were lower 
      with a negative bias (PF vs. USCOM, 0 degrees to 70 degrees : -12.3% vs. -26.3%, 
      P = 0.002; 70 degrees to 30 degrees : +6.4% vs. +31.2%, P < 0.001; 30 degrees to 
      0 degrees : +9.2% vs. +15.8%, P = 0.280). CO measurements using PF at 70 degrees 
      were erroneous. Compared with USCOM, PF overestimated SV measurements but
      underestimated the SV between HUT. Accuracy of the PF deteriorated at 70 degrees 
      , implying a gravitational influence on its performance. These findings suggested
      t